<SEC-DOCUMENT>0001628908-22-000027.txt : 20220224
<SEC-HEADER>0001628908-22-000027.hdr.sgml : 20220224
<ACCEPTANCE-DATETIME>20220223175714
ACCESSION NUMBER:		0001628908-22-000027
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		157
CONFORMED PERIOD OF REPORT:	20211231
FILED AS OF DATE:		20220224
DATE AS OF CHANGE:		20220223

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Evolent Health, Inc.
		CENTRAL INDEX KEY:			0001628908
		STANDARD INDUSTRIAL CLASSIFICATION:	SERVICES-MANAGEMENT SERVICES [8741]
		IRS NUMBER:				320454912
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-37415
		FILM NUMBER:		22665360

	BUSINESS ADDRESS:	
		STREET 1:		800 NORTH GLEBE RD, SUITE 500
		CITY:			ARLINGTON
		STATE:			VA
		ZIP:			22203
		BUSINESS PHONE:		571-389-6000

	MAIL ADDRESS:	
		STREET 1:		800 NORTH GLEBE RD, SUITE 500
		CITY:			ARLINGTON
		STATE:			VA
		ZIP:			22203
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>evh-20211231.htm
<DESCRIPTION>10-K
<TEXT>
<XBRL>
<?xml version="1.0" ?><!--XBRL Document Created with Wdesk from Workiva--><!--Copyright 2022 Workiva--><!--r:cffd2bd6-4cc3-4881-a14e-c3c94aea5d0e,g:f4f494d2-75b7-48aa-a2de-31bddada82ae,d:9aaa2fddc97e482da5dbe37ac85ae703--><html xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:srt="http://fasb.org/srt/2021-01-31" xmlns:country="http://xbrl.sec.gov/country/2021" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:evh="http://www.evolenthealth.com/20211231" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31" xmlns:stpr="http://xbrl.sec.gov/stpr/2021" xmlns:dei="http://xbrl.sec.gov/dei/2021q4" xmlns="http://www.w3.org/1999/xhtml" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrli="http://www.xbrl.org/2003/instance" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>evh-20211231</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231" name="dei:EntityCentralIndexKey" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM183L2ZyYWc6MzY5Y2U1M2FlMWViNGI5Yjg2NzUxYjA3NmU0MGNkYzYvdGFibGU6YzJhMDcxY2NhYWI1NDE5ZjhiYTFjZmRhNjMzYTdiYWYvdGFibGVyYW5nZTpjMmEwNzFjY2FhYjU0MTlmOGJhMWNmZGE2MzNhN2JhZl8xLTEtMS0xLTE3Nzc1_c2c90a9b-81c5-41d1-867c-97e2f3a6061b">0001628908</ix:nonNumeric><ix:nonNumeric contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231" name="dei:AmendmentFlag" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM183L2ZyYWc6MzY5Y2U1M2FlMWViNGI5Yjg2NzUxYjA3NmU0MGNkYzYvdGFibGU6YzJhMDcxY2NhYWI1NDE5ZjhiYTFjZmRhNjMzYTdiYWYvdGFibGVyYW5nZTpjMmEwNzFjY2FhYjU0MTlmOGJhMWNmZGE2MzNhN2JhZl8yLTEtMS0xLTE3Nzc1_0c4d1383-c945-45fd-81ff-d6d41b8b7f5b">false</ix:nonNumeric><ix:nonNumeric contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231" name="dei:DocumentFiscalYearFocus" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM183L2ZyYWc6MzY5Y2U1M2FlMWViNGI5Yjg2NzUxYjA3NmU0MGNkYzYvdGFibGU6YzJhMDcxY2NhYWI1NDE5ZjhiYTFjZmRhNjMzYTdiYWYvdGFibGVyYW5nZTpjMmEwNzFjY2FhYjU0MTlmOGJhMWNmZGE2MzNhN2JhZl80LTEtMS0xLTE3Nzc1_424c98f8-e3ae-4896-a6f5-fbca9820647b">2021</ix:nonNumeric><ix:nonNumeric contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231" name="dei:DocumentFiscalPeriodFocus" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM183L2ZyYWc6MzY5Y2U1M2FlMWViNGI5Yjg2NzUxYjA3NmU0MGNkYzYvdGFibGU6YzJhMDcxY2NhYWI1NDE5ZjhiYTFjZmRhNjMzYTdiYWYvdGFibGVyYW5nZTpjMmEwNzFjY2FhYjU0MTlmOGJhMWNmZGE2MzNhN2JhZl81LTEtMS0xLTE3Nzc1_2e11bbc1-31bb-4b00-a977-5d7e3618921c">FY</ix:nonNumeric><ix:nonNumeric contextRef="i3e21049ffc224cacb8134d73c9bb5b38_D20190101-20191231" name="us-gaap:AccountingStandardsUpdateExtensibleList" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yOC9mcmFnOjVjZWM5NGI5MzY4ODQyMTA5NWE3OThhZmFiNjljNDYwL3RhYmxlOjQzNDA0NmE1MTY4ODQzZDg5M2IxNTEyZjYxODkzYmU4L3RhYmxlcmFuZ2U6NDM0MDQ2YTUxNjg4NDNkODkzYjE1MTJmNjE4OTNiZThfMzMtMC0xLTEtMTc3NzU_a9886287-d75e-4db9-aa6f-bc3365fc9d17">http://fasb.org/us-gaap/2021-01-31#AccountingStandardsUpdate201613Member</ix:nonNumeric><ix:nonNumeric contextRef="iddbf996a3b1a4aeda47f1e8169c69262_D20200101-20200331" name="us-gaap:AccountingStandardsUpdateExtensibleList" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM180Ni9mcmFnOjhkNTIzNGI1NjdkZjRiMThiNjM1NmFmN2Q4OWQ4MDE3L3RleHRyZWdpb246OGQ1MjM0YjU2N2RmNGIxOGI2MzU2YWY3ZDg5ZDgwMTdfMzI1Ng_c324734f-03c4-4b52-af23-6ac596334a4b">http://fasb.org/us-gaap/2021-01-31#AccountingStandardsUpdate201613Member</ix:nonNumeric><ix:nonNumeric contextRef="if14fbffaf3854b8c835ade571c3cc193_I20211231" name="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" format="ixt-sec:durmonth" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM182MS9mcmFnOjAwMTYzM2MzZWYyYzQ1NWU4NGYzOGRkNTA0MGQ4Nzg4L3RhYmxlOjQzYWMxYWY0YWRhMDQ5YzRhMDQ0ZDJiNjlhZTk5ZWY4L3RhYmxlcmFuZ2U6NDNhYzFhZjRhZGEwNDljNGEwNDRkMmI2OWFlOTllZjhfMi0xLTEtMS0xNzc3NQ_18bc9a30-a2fc-4c2a-8643-5d59b08e0d5b">12</ix:nonNumeric><ix:nonNumeric contextRef="i8959430f12264863ae6656497c8cbe17_I20211231" name="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" format="ixt-sec:durmonth" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM182MS9mcmFnOjAwMTYzM2MzZWYyYzQ1NWU4NGYzOGRkNTA0MGQ4Nzg4L3RhYmxlOjQzYWMxYWY0YWRhMDQ5YzRhMDQ0ZDJiNjlhZTk5ZWY4L3RhYmxlcmFuZ2U6NDNhYzFhZjRhZGEwNDljNGEwNDRkMmI2OWFlOTllZjhfMy0xLTEtMS0xNzc3NQ_a25881b4-0037-445a-a6b8-da595d527c9e">12</ix:nonNumeric><ix:nonNumeric contextRef="i25cd20be19e940cf94f2ba0eef170452_I20211231" name="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" format="ixt-sec:durmonth" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM182MS9mcmFnOjAwMTYzM2MzZWYyYzQ1NWU4NGYzOGRkNTA0MGQ4Nzg4L3RhYmxlOjQzYWMxYWY0YWRhMDQ5YzRhMDQ0ZDJiNjlhZTk5ZWY4L3RhYmxlcmFuZ2U6NDNhYzFhZjRhZGEwNDljNGEwNDRkMmI2OWFlOTllZjhfNC0xLTEtMS0xNzc3NQ_e19f29ab-79b2-43f8-8e63-b93f1cb41c2e">12</ix:nonNumeric><ix:nonFraction unitRef="number" contextRef="i085a0d0eb6ed47f3bad60b4c05e2a3bd_D20200801-20200831" decimals="7" name="us-gaap:DebtInstrumentConvertibleConversionRatio1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM183Ni9mcmFnOjUwOWMxYThiMjdmYzRhNGZhZDEwMmY3MmE1MDQ1Mjc3L3RleHRyZWdpb246NTA5YzFhOGIyN2ZjNGE0ZmFkMTAyZjcyYTUwNDUyNzdfNQ_7bccba39-41a6-4558-a42b-4bc189ef459a">.0548667</ix:nonFraction><ix:nonFraction unitRef="number" contextRef="i744bd02bcde94561abd08918f859a83e_D20181001-20181031" decimals="7" name="us-gaap:DebtInstrumentConvertibleConversionRatio1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM183Ni9mcmFnOjUwOWMxYThiMjdmYzRhNGZhZDEwMmY3MmE1MDQ1Mjc3L3RleHRyZWdpb246NTA5YzFhOGIyN2ZjNGE0ZmFkMTAyZjcyYTUwNDUyNzdfMjE1_1d922635-0798-4711-ad46-33653e9d05d9">.0299135</ix:nonFraction><ix:nonFraction unitRef="number" contextRef="i8391049cde8843bea2025728f80db282_D20161201-20161231" decimals="7" name="us-gaap:DebtInstrumentConvertibleConversionRatio1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM183Ni9mcmFnOjUwOWMxYThiMjdmYzRhNGZhZDEwMmY3MmE1MDQ1Mjc3L3RleHRyZWdpb246NTA5YzFhOGIyN2ZjNGE0ZmFkMTAyZjcyYTUwNDUyNzdfMzkw_9ba0435e-defd-46f5-9c2b-98d60c17b71b">.0416082</ix:nonFraction><ix:nonNumeric contextRef="i0b413462d6244d118fb2d0156e9029e7_D20160301-20160331" name="evh:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsStockPriceTriggerConsecutiveTerm" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185MS9mcmFnOjlmMTJhYjBlYWNjMTQ1OTU5ZDhhNjcyY2JmZjdkYjZkL3RleHRyZWdpb246OWYxMmFiMGVhY2MxNDU5NTlkOGE2NzJjYmZmN2RiNmRfNTEyNA_e4d931ff-6eba-4d04-bddc-9b3b4429017b">P90D</ix:nonNumeric><ix:nonNumeric contextRef="ib4a9daf686984e69b26b36bbc92ff33d_D20160301-20160331" name="evh:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsStockPriceTriggerConsecutiveTerm" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185MS9mcmFnOjlmMTJhYjBlYWNjMTQ1OTU5ZDhhNjcyY2JmZjdkYjZkL3RleHRyZWdpb246OWYxMmFiMGVhY2MxNDU5NTlkOGE2NzJjYmZmN2RiNmRfNTMzOA_19dbae44-014f-4a37-a3b0-0e16f19819c4">P90D</ix:nonNumeric><ix:nonNumeric contextRef="i4902163dcfd64aac93ef32c5d4cb51e2_D20210101-20211231" name="evh:EarningsBeforeInterestTaxesDepreciationAndAmortizationGoalPeriod" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185MS9mcmFnOjlmMTJhYjBlYWNjMTQ1OTU5ZDhhNjcyY2JmZjdkYjZkL3RleHRyZWdpb246OWYxMmFiMGVhY2MxNDU5NTlkOGE2NzJjYmZmN2RiNmRfMzI5ODUzNDkxMDU4Mg_a8edff10-eb5c-4745-9477-bbe219e0ae2c">P2Y</ix:nonNumeric><ix:nonNumeric contextRef="i4902163dcfd64aac93ef32c5d4cb51e2_D20210101-20211231" name="evh:EarningsBeforeInterestTaxesDepreciationAndAmortizationGoalPeriod" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185MS9mcmFnOjlmMTJhYjBlYWNjMTQ1OTU5ZDhhNjcyY2JmZjdkYjZkL3RleHRyZWdpb246OWYxMmFiMGVhY2MxNDU5NTlkOGE2NzJjYmZmN2RiNmRfMzI5ODUzNDkxMDYwMA_5c625e05-1161-4caa-b418-357677b81681">P2Y</ix:nonNumeric><ix:nonFraction unitRef="number" contextRef="i4339469160624451b2787c8a94183aef_D20160301-20160331" decimals="4" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185NC9mcmFnOjQ0NzYzZTZmODRkZjRiOGE5OTNhMjMxZGYyZGE5NzE4L3RhYmxlOmRhYTQ3NzY5NjMyNzQ3M2E4ZWQxYmI0YjU3N2FhY2VlL3RhYmxlcmFuZ2U6ZGFhNDc3Njk2MzI3NDczYThlZDFiYjRiNTc3YWFjZWVfMS0xLTEtMS0xNzc3NQ_5540e65b-e091-4e8f-9fab-5d4432c77071">0.3333</ix:nonFraction><ix:nonFraction unitRef="number" contextRef="i0b413462d6244d118fb2d0156e9029e7_D20160301-20160331" decimals="4" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185NC9mcmFnOjQ0NzYzZTZmODRkZjRiOGE5OTNhMjMxZGYyZGE5NzE4L3RhYmxlOmRhYTQ3NzY5NjMyNzQ3M2E4ZWQxYmI0YjU3N2FhY2VlL3RhYmxlcmFuZ2U6ZGFhNDc3Njk2MzI3NDczYThlZDFiYjRiNTc3YWFjZWVfMi0xLTEtMS0xNzc3NQ_cc65a794-25f3-469b-b497-065b8ba103ae">0.3333</ix:nonFraction><ix:nonFraction unitRef="number" contextRef="ib4a9daf686984e69b26b36bbc92ff33d_D20160301-20160331" decimals="4" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185NC9mcmFnOjQ0NzYzZTZmODRkZjRiOGE5OTNhMjMxZGYyZGE5NzE4L3RhYmxlOmRhYTQ3NzY5NjMyNzQ3M2E4ZWQxYmI0YjU3N2FhY2VlL3RhYmxlcmFuZ2U6ZGFhNDc3Njk2MzI3NDczYThlZDFiYjRiNTc3YWFjZWVfMy0xLTEtMS0xNzc3NQ_d63520d4-a1a0-4ba2-b826-8f2d68dfb036">0.3333</ix:nonFraction></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="evh-20211231.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="idc0db51272c94df1839131500195947e_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7db6c6f189754c32a62fbe5b49259ed8_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:context id="ibc44c5b5f9be42eaa992bbd65360561b_I20220218"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-02-18</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:context id="i8daff60be410426d8f7bd49343c1ec0c_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibc0c0c2b8dc04c5698ca0577a54b2e03_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usdPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:context id="iba00e3572dc24848afe0d13147ef9951_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">evh:TransformationServicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib585ca9afa9b4d02874ade8f146f75cd_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">evh:TransformationServicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia6ba1f43ec4147adbafcb4a00fc450a2_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">evh:TransformationServicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic852ce517768443a8289b4dcbd762e47_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">evh:PlatformsAndOperationsServicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i971b8dd0fb5d4b10b55f27371adadaa7_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">evh:PlatformsAndOperationsServicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie0aa3b0e3e5a4d54a32e0a4b60149c35_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">evh:PlatformsAndOperationsServicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i12a6d1161de54547bd29f8efccd4c9b0_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3e21049ffc224cacb8134d73c9bb5b38_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i997aac773ca7467b9a246f3420865489_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5942ca937104445b92561d87e62b671c_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i235a50d4f95f4fe4ad003b456bd4d032_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie607b868cccf4190b29e8a645f1622cd_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifd10e063c50d49fd882ffd6694d2abea_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idecb0ab9f980489d88090494dd10781e_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia7bd0a6ac576439fb579120cf0ef0c48_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7130cb432c4b4fe7a260e8a3beeb35d8_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib3d180dea9514da28352fbc693ab84a5_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iff47976e029948eca0df0ec3f59e7929_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if9d18c41b2a74719afa2195476af7f6b_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i55a4ede774484bd8b99ec882803a31ae_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i07635cd96da44df8aeca179d3ffeeb6d_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id72c42fac3684e24b4ca0bf829d0e596_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i87534e1639d049319065f8650fc0c762_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i132368a16db343cdb75b4cc5b6d3c936_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6583965c38874fd5b1853fe21a37624d_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iea51ead9d5cc49309a974f68850d9313_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4b90c5fc5160471aba2652f11f6bb706_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie8e5b6e19bcc4d6aa9434387b2fd038c_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if4420575740f4afca80c3afb49e6e79e_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id4af8e59d8e745af8ddd5b829f03f70a_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2d2497909b9e4097b418e747f13bfc16_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icba6e493923b449aa57c46a563760234_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i86eec55ebc424a56b5b5394b8b2b2423_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i67b404347634468496e5eb9d721d74b6_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6464dcea2322451dbc03ac39361c75b9_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ieb0b713eae1b4f908dc2c23586d77948_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i911a108ecf12460193d53b0e6b24331f_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifead6db34ce543e2beca6b5c57feaf4e_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i843130db221949f4a5068562633a2182_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic8a05c8bd28c42f4918205dc608cf2de_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ide6ed4433a164b08bcb555a8e1f7a38c_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i88dcc077f08e4577b7b60dca2d354693_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iaf96f04b17974a2f8e19df7a883c4734_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1425ebfe96904025b4f40a30737efd06_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8f416a598c52444597bd56910cd0efbb_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7de15b24843f43e1bf1e49503dff1359_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idb7d2cb4638a4234b2407c840694aea3_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i88eadc89dc9a4d4aab536db563f563d5_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5724ef529cea411aadb2b6f086af09f1_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8a0a16beae314535bccd01c31668c8fd_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5f242398851f435581586484404b0dfb_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8a70782136dc46eb8037c247f5e1694a_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1bcca85fbf4c425299cf11a4c6626357_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i75b369d853b249f9a6495524752f5913_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2177056c167d473399f65b5105c9a7f2_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i109ffa352e8c4ce0b59170cf60e46101_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7fd6de5224704d7187b37d35a519cbfa_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i17d17fcbd53245e7981e707f61c46f1a_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2c95448403fa4d3b8d864ca25a132fb8_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8be054225f004416b985533cd8b4d2a6_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i733ca541299f4839bead39679b082534_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9632fb5d42444a5984c0033bf16be6f0_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5f1b61732fb142fc9539a36365f230ee_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="segment"><xbrli:measure>evh:segment</xbrli:measure></xbrli:unit><xbrli:context id="ibd159a0a266f484882b88b46c1b83d3f_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis">evh:RestrictedCashforLettersofCreditforFacilityLeasesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3a313b63f9a34c26b2a361281eca58df_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis">evh:RestrictedCashforLettersofCreditforFacilityLeasesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia9df011f1efd436cbcdff5e8bfdd9e5a_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis">evh:CollateralwithFinancialInstitutionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib52a820bc1fa4880b75c578ff17dda8d_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis">evh:CollateralwithFinancialInstitutionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic5164e2908114e21b24e2e1681c5dcba_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis">evh:RestrictedCashforBenefitManagementServicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i83fc6159c69f43e5822b38e95a2a3b46_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis">evh:RestrictedCashforBenefitManagementServicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i58c2398f3ddb4809a3cb1af5b5c34db8_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis">evh:RestrictedCashforOtherContractualCommitmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i58e611a688d54093ac555cb27c5810ec_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis">evh:RestrictedCashforOtherContractualCommitmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i98364cf4ba3e41af868d701b4c668283_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">evh:TrueHealthMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DiscontinuedOperationsDisposedOfBySaleMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id8e4ad0aaaf14d2e8309a07fe17aa411_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis">us-gaap:BankTimeDepositsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2a39d28f60a44d6bb41fe546afc858b2_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis">us-gaap:BankTimeDepositsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if8e7fd6ca1724c74bd0f4e3ca2947419_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i703e3ae1f15f4420b40ff930efbc9f87_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareAndSoftwareDevelopmentCostsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibc96172fcef14618a2c513b85e88be97_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i53d4b22f661d41dbb61ff5dcf8f75f50_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia186bface90a4c4098c96c8567d34124_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="unit"><xbrli:measure>evh:unit</xbrli:measure></xbrli:unit><xbrli:context id="ibff83f3576fa462088fb611595ae2107_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TradeNamesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie3bf7bed53b145e699f90d4132648c21_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TradeNamesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3ca5e8fff37648578ddcb5915d42bd23_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4cff67909d644529824bdb1faef1b019_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i701391050b2e43d082d405d3d16746d2_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6d3cdc666422461398b727dbf8a5d16e_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:ContractBasedIntangibleAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i80595e56a7a74f699957bf0f9a4173ce_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:ContractBasedIntangibleAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="number"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:context id="i532d2c0bf63243e999d48341920b6775_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iddbf996a3b1a4aeda47f1e8169c69262_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i70301f61588141189fb4444297fae8bd_I20211001"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">evh:VitalDecisionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-10-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icc3dde603e5f449c9078821a3218c74e_D20211001-20211001"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">evh:VitalDecisionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-01</xbrli:startDate><xbrli:endDate>2021-10-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i499adfced3fe4274a3f2ca19bf418044_I20211001"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">evh:VitalDecisionsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-10-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6f5e720f7a9e4b0d9114b35d5878bf70_I20211001"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">evh:VitalDecisionsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-10-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i393b8dc21e5b45e585a40c88e5f9cd40_I20211001"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">evh:VitalDecisionsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TradeNamesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-10-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i93823d3451b643ba8bd3aefc9d052c7c_D20211001-20211001"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">evh:VitalDecisionsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-01</xbrli:startDate><xbrli:endDate>2021-10-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i631f51b734d24d66935095cad71b62c0_D20211001-20211001"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">evh:VitalDecisionsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-01</xbrli:startDate><xbrli:endDate>2021-10-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i942460901cce441cba62f7e178ca70fd_D20211001-20211001"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">evh:VitalDecisionsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TradeNamesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-01</xbrli:startDate><xbrli:endDate>2021-10-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iba85fb86cb9c459986593ba474a68022_D20190528-20190528"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">evh:UniversityHealthCaredbaPassportHealthPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">us-gaap:VariableInterestEntityNotPrimaryBeneficiaryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-05-28</xbrli:startDate><xbrli:endDate>2019-05-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5aae66b17cd7411eb3d40e1f98e41587_I20190618"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:PassportNoteMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">us-gaap:NotesReceivableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-06-18</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i374acc0d61704b06a1daddce75dda523_I20190618"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:PassportNoteMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-06-18</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i458a8dd8fe1447e983bf102015ceb976_D20190606-20190606"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">evh:UniversityHealthCaredbaPassportHealthPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">us-gaap:VariableInterestEntityNotPrimaryBeneficiaryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-06-06</xbrli:startDate><xbrli:endDate>2019-06-06</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i50b57c8ae3af4f4d87078314e47600cb_I20191230"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">evh:UniversityHealthCaredbaPassportHealthPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">us-gaap:VariableInterestEntityNotPrimaryBeneficiaryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3f3edd8173b642a0af571267b2125442_D20210101-20210131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">evh:MolinaHealthcareIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i410c11618d854c73bc5727ec26d5ac44_D20200901-20200901"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">evh:MolinaHealthcareIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-09-01</xbrli:startDate><xbrli:endDate>2020-09-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i553144e874d7414ab395f79f6424736f_D20201116-20201116"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">evh:UniversityHealthCaredbaPassportHealthPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">us-gaap:VariableInterestEntityNotPrimaryBeneficiaryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-11-16</xbrli:startDate><xbrli:endDate>2020-11-16</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i24eda106b1dc4387aebfe529942c3586_D20200901-20200901"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">evh:PassportAssetAcquisitionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-09-01</xbrli:startDate><xbrli:endDate>2020-09-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8d16ce5f96ed484ea0bd662e9a0da3ec_D20201231-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:PassportNoteMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-12-31</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i660e59a50fb74adf8c9b97dba279e217_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">evh:UniversityHealthCaredbaPassportHealthPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">us-gaap:VariableInterestEntityNotPrimaryBeneficiaryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib292e37ea5764045b08aaf86b4bf8282_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">evh:UniversityHealthCaredbaPassportHealthPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">us-gaap:VariableInterestEntityNotPrimaryBeneficiaryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1857a80445fe4ba78e6b1cd41cf5528f_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">evh:UniversityHealthCaredbaPassportHealthPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">us-gaap:VariableInterestEntityNotPrimaryBeneficiaryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia321bb1b6e6b403aa6a27cd32dbe25f8_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">evh:VivantHealthMSOLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1c4a293e5ce54724af5effd8253d4d89_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">evh:TrueHealthMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DiscontinuedOperationsDisposedOfBySaleMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id9938925ae68403cbd1e3633d8c2af7a_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">evh:PlatformsAndOperationsServicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">evh:TrueHealthMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DiscontinuedOperationsDisposedOfBySaleMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i62b6ff0a18e64449a282407a6971fe18_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">evh:PlatformsAndOperationsServicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">evh:TrueHealthMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DiscontinuedOperationsDisposedOfBySaleMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic1ed065f23364faeb485521f6be7f439_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">evh:PlatformsAndOperationsServicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">evh:TrueHealthMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DiscontinuedOperationsDisposedOfBySaleMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i15f03ee2332146e4a7e0d5b5717bea28_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">evh:TrueHealthMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">evh:PremiumsRevenueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DiscontinuedOperationsDisposedOfBySaleMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6eca3f13863a45c481c07e49e9f434fe_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">evh:TrueHealthMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">evh:PremiumsRevenueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DiscontinuedOperationsDisposedOfBySaleMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iae64c322a5eb4929bc01485807d92b3a_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">evh:TrueHealthMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">evh:PremiumsRevenueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DiscontinuedOperationsDisposedOfBySaleMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if7ba948ef00b4ddeabe73338f1155e8b_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">evh:TrueHealthMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DiscontinuedOperationsDisposedOfBySaleMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iae6c9a536db44d69b64c473850d09499_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">evh:TrueHealthMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DiscontinuedOperationsDisposedOfBySaleMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib1b709ded692440f9e0b6b584a8c0080_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">evh:ServicesAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">evh:TrueHealthMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DiscontinuedOperationsDisposedOfBySaleMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i93a7fe07dcb74ecba6ec18daa2afd21d_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">evh:ServicesAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">evh:TrueHealthMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DiscontinuedOperationsDisposedOfBySaleMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0725607f45d24e7096771c6e0b9f7133_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">evh:ServicesAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">evh:TrueHealthMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DiscontinuedOperationsDisposedOfBySaleMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6ea3e63701234a91a969d79c7385efdc_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">evh:ServicesAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">evh:TrueHealthMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DiscontinuedOperationsDisposedOfBySaleMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic43c6cb369be49d49265e63f4d9abe41_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">evh:MedicaidCustomersMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">evh:EvolentHealthServicesSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i535e9398f53d482399e3acaf85d05d83_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">evh:MedicaidCustomersMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">evh:EvolentHealthServicesSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id2bc3ff361f24fefa6cc02e574174d0d_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">evh:MedicaidCustomersMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">evh:EvolentHealthServicesSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id9db9ac43e544bf2a8a53256e34c582f_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">evh:ClinicalSolutionsSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">evh:MedicaidCustomersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i79967d3cee0e4773a3e643d202cac1e7_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">evh:ClinicalSolutionsSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">evh:MedicaidCustomersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iceaed1bf0ba14aeabbd5e7c285fadb74_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">evh:ClinicalSolutionsSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">evh:MedicaidCustomersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icb83054796ca43aabbc5e7c5bcd8f242_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">evh:MedicareCustomersMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">evh:EvolentHealthServicesSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ide7e8d10e8754aeb98428c460346c2e6_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">evh:MedicareCustomersMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">evh:EvolentHealthServicesSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9dc8f259d0954c4790aef4d1cda35290_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">evh:MedicareCustomersMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">evh:EvolentHealthServicesSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id1eb1d14b8034af8af9fcc8ff413f4a8_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">evh:ClinicalSolutionsSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">evh:MedicareCustomersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i99e6ebd37717409cadbd8a0e52f302d8_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">evh:ClinicalSolutionsSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">evh:MedicareCustomersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibe57bae9f0e94d19b338958e93a6d9a0_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">evh:ClinicalSolutionsSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">evh:MedicareCustomersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i05cdaab0e8a9475391be6c9bb0290a02_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">evh:CommercialAndOtherCustomersMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">evh:EvolentHealthServicesSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i70c4c918cacd44ceb89f531391a51f89_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">evh:CommercialAndOtherCustomersMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">evh:EvolentHealthServicesSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7ae80f06fd7241178ec3bcbf2b433c78_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">evh:CommercialAndOtherCustomersMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">evh:EvolentHealthServicesSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i615c66ad61b84863b2bbc22a537fd294_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">evh:ClinicalSolutionsSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">evh:CommercialAndOtherCustomersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6c3248cb38b348cc83404e78b286c508_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">evh:ClinicalSolutionsSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">evh:CommercialAndOtherCustomersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i62d3399ff7cf4122b4eb5165603a12e2_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">evh:ClinicalSolutionsSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">evh:CommercialAndOtherCustomersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i98988f30813349e1a5594e72b40af5b1_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">evh:EvolentHealthServicesSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i00a9fb2f3f914116b87f14e146d04507_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">evh:EvolentHealthServicesSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i26a4f846df6445f78bba31f5ba0edcdd_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">evh:EvolentHealthServicesSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6d991ef4e2e0416f8c7aaaa6175cf843_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">evh:ClinicalSolutionsSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i73877656554945338d08c1e8006fc13a_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">evh:ClinicalSolutionsSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if6faab8365e548b981e0edaddae65523_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">evh:ClinicalSolutionsSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if14fbffaf3854b8c835ade571c3cc193_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:typedMember dimension="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis"><us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>2022-01-01</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain></xbrldi:typedMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8959430f12264863ae6656497c8cbe17_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:typedMember dimension="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis"><us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>2023-01-01</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain></xbrldi:typedMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i25cd20be19e940cf94f2ba0eef170452_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:typedMember dimension="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis"><us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>2024-01-01</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain></xbrldi:typedMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i546c40c371924532a3d2ed0ace7d354b_D20211001-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i54aba1ec35ba4673abba7abb46f76ef5_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CapitalizedContractCostAxis">evh:BonusesAndCommissionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i44f063f12cc04f629ffbb5c7712fd0f2_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CapitalizedContractCostAxis">evh:BonusesAndCommissionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icfdf7dc68ad9407fb6453da7eb51ff1e_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CapitalizedContractCostAxis">evh:BonusesAndCommissionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i32c4356526e94c2a842b0638c13e0da0_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CapitalizedContractCostAxis">evh:BonusesAndCommissionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i781700715d804fefb7f495ca8b0f9e4a_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CapitalizedContractCostAxis">evh:BonusesAndCommissionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1e5e51907f2d489ab6121950881bf006_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CapitalizedContractCostAxis">evh:ContractFulfillmentCostsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icf374646ef6b49209d89a39117fda72a_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CapitalizedContractCostAxis">evh:ContractFulfillmentCostsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8b41623f6b924d1986071e4349ac5013_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CapitalizedContractCostAxis">evh:ContractFulfillmentCostsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i764aef4cc3ae4cc1bcebb290a4525192_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CapitalizedContractCostAxis">evh:ContractFulfillmentCostsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i914217ccb9dc458290c3558593f0487c_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CapitalizedContractCostAxis">evh:ContractFulfillmentCostsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i409817ab2c13478f8041e2ff229d0614_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancingReceivablesPeriodPastDueAxis">evh:FInancialAssetLessThan60DaysMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iafc89cf729024311ade0aeb8068cb56d_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancingReceivablesPeriodPastDueAxis">evh:FInancialAssetLessThan120DaysPastDueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icc5d957904904562b11eb24c12475bd1_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancingReceivablesPeriodPastDueAxis">evh:FInancialAssetLessThan60DaysMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i23f9ca4a3b134c3cb50b438855efd900_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancingReceivablesPeriodPastDueAxis">evh:FInancialAssetLessThan120DaysPastDueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia1b27c6b1ce44bb4a7d45377795c832d_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3065c5c08a124284884a61ee233f4e16_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie08f3e6fd0bf42cf818c1f564fa39108_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia55f03733cd945fe9d885896e547d383_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia95d0a4759a840c0a34e767cc306a57e_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i370ec8ac69f6453daffb02508aef709b_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icd3eb9c2b2874ea99e8f34f94952be94_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3873f51f572a46ae8f17531700510927_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0b599414417745fdb6c3cddde5001d4b_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8c359ea835e64a39b5cab25a3948e3b7_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3a8f822ce668416caf0bf1e2f7037e11_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="reportingunit"><xbrli:measure>evh:reportingUnit</xbrli:measure></xbrli:unit><xbrli:context id="i113b515f40aa4b3e9afd7361c65483dc_D20200501-20200531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-05-01</xbrli:startDate><xbrli:endDate>2020-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i62320e40739f4842b8ffb078d42fa029_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibd34af6251294e159e55819cc46cbbb6_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id2d85a5202f44415bdbcb9412ab08509_D20191001-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-10-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id586f68951304ab3ac3fd84a42cb5e48_D20201031-20201031"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-10-31</xbrli:startDate><xbrli:endDate>2020-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ida02b25c4b5e464a9545df19946134c1_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">evh:EvolentHealthServicesSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i14e6a440f7dc431a9e1c85272b43d276_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">evh:ClinicalSolutionsSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if8fd35766cfc4fa8b1cbf4f3cd8a8dfc_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">evh:EvolentHealthServicesSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5f5145421bc94a90bb8982e11bb80abb_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">evh:ClinicalSolutionsSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icdbca3fab4684e269937d4a61379d67f_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">evh:EvolentHealthServicesSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie09b385083554dfe92dc601254dfdda8_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">evh:ClinicalSolutionsSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie58c5dcefe64400fa99a44a4db35e02d_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TradeNamesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if54550ac07374463b0640b875a8f1164_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TradeNamesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie1ed53b5943b4889b309941737607d78_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TradeNamesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if0eedc514d0a4637960f12892dff3179_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TradeNamesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i202c773f013e42dbaf2ed35f08ba74e4_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i71517c3f53a942378a08da469cfdd069_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8af88df592574869bf4e7732fd88234d_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i562af9019b024a169c81d1f41361d631_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9872c8fc2e2849be9d4b8a5ca7abe3dc_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i538bb825405f46a9ad4766eb47fd09f0_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if49e52c6692f4f418b64ecce40eae504_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idbec42c300ba44c8b821ff3fa0e1a438_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">evh:BelowMarketLeasesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i77a25d5d9d13456bafdeb192f90dc6dd_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">evh:BelowMarketLeasesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id03edbc8f3a0467fb3003d024d0d20bf_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">evh:BelowMarketLeasesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5b2c8aeaa33341d0b0241d264ebd0409_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">evh:BelowMarketLeasesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5bc515c9cd944501946244b550d6dea8_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:ContractBasedIntangibleAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i73d07853890d4173bfcafe5a74c9aedf_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:ContractBasedIntangibleAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4865a0a60cf141238d2403348647421d_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:ContractBasedIntangibleAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2916f379be034a929416cb11c770e888_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:ContractBasedIntangibleAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie6213ed773f940469197c948c85ce078_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">evh:TrueHealthMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DiscontinuedOperationsDisposedOfBySaleMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i886c543278f24614931e52b2326361a9_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:ContractBasedIntangibleAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">evh:TrueHealthMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DiscontinuedOperationsDisposedOfBySaleMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i83a4805b397642c7825f71f6f96da143_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">evh:TrueHealthMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DiscontinuedOperationsDisposedOfBySaleMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib096ee77af354199bc615f81ee527eaa_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:ContractBasedIntangibleAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">evh:TrueHealthMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DiscontinuedOperationsDisposedOfBySaleMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i04c13e91bd034f30a0f4a7c989fc5940_I20200831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:SeniorConvertibleNotesDue2024Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-08-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i788309cbaf3c49228dff05dacf3204c0_D20200801-20200831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:SeniorConvertibleNotesDue2024Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-08-01</xbrli:startDate><xbrli:endDate>2020-08-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i79f0de790533434b998387bf6c4ab709_D20200801-20200831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:ConvertibleSeniorNotesdue2021Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-08-01</xbrli:startDate><xbrli:endDate>2020-08-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8584b8487d5e4d7ca2a029dd1993309b_D20200801-20200831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-08-01</xbrli:startDate><xbrli:endDate>2020-08-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9b76113417844ee8a46162426a4ed221_D20200801-20200831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:NewNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-08-01</xbrli:startDate><xbrli:endDate>2020-08-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifef2fd52529f408dbb3bcb2d3f4ae616_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:SeniorConvertibleNotesDue2024Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2f7a8968a0e74fcfa7af898dd2afb7a6_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:SeniorConvertibleNotesDue2024Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2d6ffa68994846c2afc0f59e2f092900_D20200801-20200831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:SeniorConvertibleNotesDue2024Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-08-01</xbrli:startDate><xbrli:endDate>2020-08-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i440e2756c3e94ec7abffeb1fc8c10ab1_I20200831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:SeniorConvertibleNotesDue2024Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-08-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic9f911355bb8445c908c1c5b6b982236_I20191230"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:InitialTermLoanFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i792aeba7f36b437d85bdf7da6230451c_I20191230"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:CreditAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">evh:DelayedDrawTermLoanFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ife61530204fd4e7bbf85f09284f83168_I20191230"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:ConvertibleSeniorNotesdue2021Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i96e7c8227b2041f28199b45cd6df39d8_D20191230-20191230"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:SeniorCreditFacilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2019-12-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ieb668099634e44209035f0f361a970a7_D20191230-20191230"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:SeniorCreditFacilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:EurodollarMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2019-12-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icc5f3f563c8f4128a7d55ea114d571c7_D20191230-20191230"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:BaseRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:SeniorCreditFacilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2019-12-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i17e802ca9a354f61a67b176d11db40d2_D20191230-20191230"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:CreditAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">evh:DelayedDrawTermLoanFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2019-12-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib97b2b6f4e114116bcd48ecd930fff77_D20191230-20191230"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:SeniorCreditFacilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2019-12-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ida54e6975d324252aa18539914addfb0_D20191230-20191230"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:SeniorCreditFacilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2019-12-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibfa29a18103548678c4142edda54a480_D20191230-20191230"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodThreeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:SeniorCreditFacilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2019-12-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5e8884745c8748e9ac6420974639bd12_I20191230"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:SeniorCreditFacilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iab036707b4a24de2813c8c6ec050b319_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:SeniorCreditFacilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iadba955835944b7293cfc1935e0382e4_D20210108-20210108"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:SeniorCreditFacilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-08</xbrli:startDate><xbrli:endDate>2021-01-08</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i037876d85b5c4bea9f8460cdbf527197_D20210108-20210108"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:CreditAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-08</xbrli:startDate><xbrli:endDate>2021-01-08</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i88843d45ac464699a3408ba52bbc2f63_I20191230"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id418eef5065f4bf698e75757a9120794_D20191230-20191230"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2019-12-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0b6779acaae746b9a02d20842b794089_D20210108-20210108"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-08</xbrli:startDate><xbrli:endDate>2021-01-08</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i00584134c5844a27a4303a31c0b5f1f3_I20181031"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:SeniorConvertibleNotesDue2025Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i339c055665e9485da5895fb20444a7a8_D20181001-20181031"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:SeniorConvertibleNotesDue2025Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-10-01</xbrli:startDate><xbrli:endDate>2018-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i39addcd35f11436480a83296fb4dc83a_I20181031"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:SeniorConvertibleNotesDue2025Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic55a278f0f0c48b3bdd614bbb0a7eded_I20181022"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:SeniorConvertibleNotesDue2025Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-10-22</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic290bfcf094543248295da9fb01e4c88_I20181024"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:SeniorConvertibleNotesDue2025Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-10-24</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i48ca8bc8e051466a9a37e1e1da6febc3_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:SeniorConvertibleNotesDue2025Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idd22b7a2c5194e22908f4f8bfed93408_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:SeniorConvertibleNotesDue2025Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i36270cc40db54c1cbe5d5fe12dba090b_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:SeniorConvertibleNotesDue2025Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i69e9a51f20134473a4650107c879ce03_D20181001-20181031"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:SeniorConvertibleNotesDue2025Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-10-01</xbrli:startDate><xbrli:endDate>2018-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib49940b904c04bd784180584b89ab5bf_I20181031"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:SeniorConvertibleNotesDue2025Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4f7fefe0fb434989bf906e20f2422c6b_I20161231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:ConvertibleSeniorNotesdue2021Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2016-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i54bf54f1a88044bab71a8867d4a0c31f_D20161201-20161231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:ConvertibleSeniorNotesdue2021Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2016-12-01</xbrli:startDate><xbrli:endDate>2016-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7e9e77d057aa4381855c6fd7a1d6f4ea_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:ConvertibleSeniorNotesdue2021Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i087fe618f5364968ac66e7869d1caad5_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:ConvertibleSeniorNotesdue2021Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4d8110dbf411438a8a00e05653b625c8_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:ConvertibleSeniorNotesdue2021Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9a2926d0e711448fa37fb03edf2470a1_D20211201-20211201"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:ConvertibleSeniorNotesdue2021Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-12-01</xbrli:startDate><xbrli:endDate>2021-12-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie511597b55e24e0b9a57496e5718443a_I20211201"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:ConvertibleSeniorNotesdue2021Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id7ce03f7e23c4e8982556c1c3936f37c_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:SeniorConvertibleNotesDue2024Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2aac0290566244888dfc87dd98ff26b6_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:SeniorConvertibleNotesDue2024Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0f822324d7204951a08832492a541883_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:SeniorConvertibleNotesDue2024Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i40eea1e73a0a4178ad8f4535f4a3950e_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:SeniorConvertibleNotesDue2024Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i974ce0eee5ff4e6280561dba5e0ac368_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:SeniorConvertibleNotesDue2025Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i50fb6ca1635f4d128f6a1d489565ad0b_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:SeniorConvertibleNotesDue2025Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7f0d332f713a4f89bb808c44e818aea3_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:SeniorConvertibleNotesDue2025Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ica31b1dea8e04139a2223a01fd1e7439_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:SeniorConvertibleNotesDue2025Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id04e184022df4434b775ae12babcdd7d_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:ConvertibleSeniorNotesdue2021Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5f1ed0aa6efc4adda8d9ddf826e7eb41_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:ConvertibleSeniorNotesdue2021Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id11648efb5084baf81bbd2896c0fcdac_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:ConvertibleSeniorNotesdue2021Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icd0c2590d98d4a87a8626e624f822e5f_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:ConvertibleSeniorNotesdue2021Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i085a0d0eb6ed47f3bad60b4c05e2a3bd_D20200801-20200831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:SeniorConvertibleNotesDue2024Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-08-01</xbrli:startDate><xbrli:endDate>2020-08-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i744bd02bcde94561abd08918f859a83e_D20181001-20181031"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:SeniorConvertibleNotesDue2025Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-10-01</xbrli:startDate><xbrli:endDate>2018-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8391049cde8843bea2025728f80db282_D20161201-20161231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:ConvertibleSeniorNotesdue2021Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2016-12-01</xbrli:startDate><xbrli:endDate>2016-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia9961196998042f89c9a61f119c53f5e_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LetterOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iede64ab75aa34060b8b77784840d5794_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LetterOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i16c94c74682c4658bb289affc41db310_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LetterOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis">evh:RestrictedCashForLettersOfCreditForLetterOfCreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1ceb37a7eda64dfab33aaf8b47cbcf60_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LetterOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis">evh:CollateralwithFinancialInstitutionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1f3461e188de4f5c80fc4743b6823420_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LetterOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis">evh:CollateralwithFinancialInstitutionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iffcd0f576b5c4f27b02cf64ca97d07d5_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LetterOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis">evh:RestrictedCashForLettersOfCreditForLetterOfCreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id08281884be844d0a19d848a335a5a80_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">us-gaap:FinanceReceivablesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">evh:CookCountyHealthAndHospitalsSystemMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie20505dffcf4431286b007c0fcf4ab14_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">us-gaap:FinanceReceivablesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">evh:FloridaBlueMedicareIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib97fa9c20ea54ca1841b4c9b1f4ea27c_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">us-gaap:FinanceReceivablesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">evh:MolinaHealthcareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9f2a3a14183a4b9c91ebd0c42eb5510d_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">evh:CookCountyHealthAndHospitalsSystemMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4c5eb31ee1104de8a5635eca675175eb_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">evh:CookCountyHealthAndHospitalsSystemMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id0f333276f5e44b698dd6e5f92a87479_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">evh:CookCountyHealthAndHospitalsSystemMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iadb6308217bb4ce7bab0e77352bbe86e_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">evh:NewMexicoHealthConnectionsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idd6b43aa37f24ee4a2d07a9f35c9f6ce_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">evh:FloridaBlueMedicareIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i244051775e1e4019948fa2ba32e4ab27_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">evh:UniversityHealthCaredbaPassportHealthPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id221ab9a660d422d8841139a66fe1f9d_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">evh:UniversityHealthCaredbaPassportHealthPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8a931688112a4cc6bf3323cb239d7e4d_D20201001-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">evh:TrueHealthMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">evh:PremiumsRevenueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DiscontinuedOperationsDisposedOfBySaleMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-10-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8404c3b22073440a9f092260f57c4d0a_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">evh:MolinaHealthcareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1a21d5a158854825a4cb4f9e1b2d4103_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">us-gaap:LeaseAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic979e1a0ada24d7da7646f2ccae478c7_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">us-gaap:LeaseAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie94dd6f6dead455b8b597165bc5ec9ff_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:VA</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9a6c9ce1bc6a4595b939e65f2d38f28e_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:IL</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i16fcb9584de04a43bbe15a5b9cef1417_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:NJ</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic6005d9a695a4ec39b064ccaceff712d_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:IN</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic293662ed0144555ad060c822d4249ce_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:CA</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifdfd40d05cad486f8f8a1d4f5c27aedc_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i52b87d0e43a34ffc9389f5e532dad861_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7d76227fd72340699f3b20cadd0ca448_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i201d78ce09254edeb74a5d8656d986e3_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">evh:RestrictedStockUnitsRSUsPerformanceBasedRestrictedStockUnitsPBRSUsAndLeveragedStockUnitsLSUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia51882bd916343be8688568234c45e7d_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">evh:RestrictedStockUnitsRSUsPerformanceBasedRestrictedStockUnitsPBRSUsAndLeveragedStockUnitsLSUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic6ab9363606041b5b1b0664ec16f77e3_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">evh:RestrictedStockUnitsRSUsPerformanceBasedRestrictedStockUnitsPBRSUsAndLeveragedStockUnitsLSUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia6e4317e0fe84f639d451026ec4811f7_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iebc1de752eaa4389a6a51366f6e15efc_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7adc7fd9e069474b9522f7f84242457e_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icbc3599f42a84566bfd33e73e504c17e_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id074b4bed7284281bb2163f48f76bf03_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib784df78539b41c494661a446433f01c_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie27c749af3f640e6b503c30b7017a0cb_I20130923"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">evh:TwoThousandElevenEquityIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2013-09-23</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1d4614ce073d4c1dbaf45d31f2350ff7_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">evh:TwoThousandElevenEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i96a77abfddf84842a980b801febda12d_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">evh:TwoThousandElevenEquityIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie6ac3c72c3d048a79d7e7fab6a952c8d_I20150501"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">evh:TwoThousandFifteenEvolentHealthInc.OmnibusIncentiveCompensationPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2015-05-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i24c60745c92845f2979175286f6cfdb2_I20180613"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">evh:TwoThousandFifteenEvolentHealthInc.OmnibusIncentiveCompensationPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-06-13</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifd8fb1ee9c5446a8804b4991f663185d_I20210415"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">evh:TwoThousandFifteenEvolentHealthInc.OmnibusIncentiveCompensationPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-15</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib2892fd727a044ae9ebfd0032f5bc139_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">evh:TwoThousandFifteenEvolentHealthInc.OmnibusIncentiveCompensationPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4266034771344505a1b7761cd97832a1_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">evh:TwoThousandFifteenEvolentHealthInc.OmnibusIncentiveCompensationPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0017a1e05fa1452c857571fdbc23fd69_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">evh:LeveragedStockUnitsLSUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">evh:TwoThousandFifteenEvolentHealthInc.OmnibusIncentiveCompensationPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic48b20a77e2d4ff0bffc7a7d61a66f9c_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">evh:PerformanceBasedRestrictedStockUnitsPSUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">evh:TwoThousandFifteenEvolentHealthInc.OmnibusIncentiveCompensationPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0486c1cd30d84075a90f947bf2f00d37_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">evh:TwoThousandFifteenEvolentHealthInc.OmnibusIncentiveCompensationPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9057bdb4a3f7459a99f31c6dcfaf93e8_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">evh:TwoThousandFifteenEvolentHealthInc.OmnibusIncentiveCompensationPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i144feb14f3894f2a93baecbdbd67f999_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">evh:LeveragedStockUnitsLSUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">evh:TwoThousandFifteenEvolentHealthInc.OmnibusIncentiveCompensationPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3462813a792a43bdb0cd92a0d3fc4085_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id4cdbac3ed5841318a01e98ea7bb7cb3_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i45606ce9dfa74fc7bd724460f67189ab_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2ef2d194cc634bb5a3f24f06d02c7f5b_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i98059f1600aa412c87f3adc6788eb8b5_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i903fc0912d4e492c95e3ce815e897489_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i117e325270bf4054b07c98692139814a_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4ad066769cd0464cbcbcf7d1ec4ce0ad_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i91de07e5bb1e422aa1d46986a0b1006f_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">evh:PerformanceBasedRestrictedStockUnitsPSUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ief3bd4a971ea460990e3d8fb590be11d_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">evh:PerformanceBasedRestrictedStockUnitsPSUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i460ef5cbfd2c49989b7ae61f7d7e59b2_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">evh:PerformanceBasedRestrictedStockUnitsPSUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if0b01289c86a4176ab75517bdfe4ec1f_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">evh:LeveragedStockUnitsLSUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i824c4e26d9414a59ad8f2d73e36714d0_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">evh:LeveragedStockUnitsLSUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i89ff4001d069448c9d4b0758b35fcfdb_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">evh:LeveragedStockUnitsLSUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1d8c81c79de743e8be167a4c88ad5716_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3bb865fc0dda42bb8bbc52f03a761729_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5542e161a27e454bb0a6172a44d18515_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic2fe85c2e61b4a82aefe1b1a25d6bef0_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i686054032b8e4393aca78c7d43aa5ebd_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8b9330154a17434f90687e31afeba60a_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i532ccc69d7f7466ba58c97c04ba645e1_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0a2bd98f25e64cac9d230b30c39fd652_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i33d73ea883764a2dafec5a1252f33aef_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">evh:LeveragedStockUnitsLSUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ife9a61a44ecc47e88bb29426256eba9d_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">evh:PerformanceBasedRestrictedStockUnitsPSUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i686710b185af449cbe0de18d10c30d28_D20160301-20160331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2016-03-01</xbrli:startDate><xbrli:endDate>2016-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if1cf72bda2494db39c586d33c79355d7_I20160331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2016-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4339469160624451b2787c8a94183aef_D20160301-20160331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2016-03-01</xbrli:startDate><xbrli:endDate>2016-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i42f9f4a544794563bbd3b640b97627eb_I20160331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2016-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0b413462d6244d118fb2d0156e9029e7_D20160301-20160331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2016-03-01</xbrli:startDate><xbrli:endDate>2016-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i77ef8b91efad4f9c96efe1dd800f23a2_I20160331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheThreeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2016-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib4a9daf686984e69b26b36bbc92ff33d_D20160301-20160331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheThreeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2016-03-01</xbrli:startDate><xbrli:endDate>2016-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6df38813e0b146839515ddf8e5497101_D20160301-20160331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VestingAxis">evh:SharebasedCompensationAwardSubTrancheOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2016-03-01</xbrli:startDate><xbrli:endDate>2016-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie92afa03287e4824b694b978705b0da6_D20160301-20160331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VestingAxis">evh:SharebasedCompensationAwardSubTrancheTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2016-03-01</xbrli:startDate><xbrli:endDate>2016-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5f4625a059aa4800b22d29c186dc894c_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib4707869ee56405ab1f2a9c58e43b761_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i643136e202254be08774a096650b7946_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">evh:NonEmployeeDirectorsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i53ca92671b00498d832fcdf0ccb439b2_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">evh:NewCenturyHealthMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia60cbf2c61674250a7870e50684977b4_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i74fbd0cbfcb8404bbbc19a496f94e90d_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">evh:LeveragedStockUnitsLSUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i08583f7a5ec342338d4ec3de61aff226_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">evh:LeveragedStockUnitsLSUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4b299843c6624a0b86491cf8ede39655_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">evh:LeveragedStockUnitsLSUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheThreeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i04a926a87abf4421b1ca0ae299f722a6_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VestingAxis">evh:SharebasedPaymentArrangementTrancheFourMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">evh:LeveragedStockUnitsLSUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4902163dcfd64aac93ef32c5d4cb51e2_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">evh:PerformanceBasedRestrictedStockUnitsPSUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3c5f476b4e1249a08e8202ae0113bf9a_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">evh:PerformanceBasedRestrictedStockUnitsPSUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if24975b6c6fc46f2956741e09150759a_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i32a9b997fd964b44a992bdf9b2104f0e_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie5209e47858942b8a833f9d575b7d37c_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">evh:PerformanceBasedRestrictedStockUnitsPSUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1c1d55717222438abb87e60bcf9b59b9_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">evh:PerformanceBasedRestrictedStockUnitsPSUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6126841a44cb4c478fc23b6132251176_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4d7d673b0fbf48deaa07f821e1025d2e_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6b9dc5b6709f4577a0325ffd62a07675_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie8b8af0c663c4c6f8a82f961045e3772_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i39aaea1673c24c3e943c58e39738d3e1_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8104bf341ae243818cdc049157ebf28d_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">evh:FinitelivedTaxCreditCarryforwardMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i44a7d440fd3546178704d37b7cd7f209_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">evh:FinitelivedTaxCreditCarryforwardMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i598bb297864842fe8780e1b67c9dd1d8_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">evh:IndefinitelivedTaxCreditCarryforwardMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifd7da24ee1294bf3afc9c7ca2280330f_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">evh:IndefinitelivedTaxCreditCarryforwardMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i898c9db01cf04be08210dc1be3090eca_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibfe040616b3542e3a1e0d4d16022974d_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib0a5f68e764e419481a0d19e2432cafe_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">evh:PeriodsPriortoJune2015Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1cb7bef7317f4d90afc92b9268a6542c_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i871d99d3c60b41dea330fb287058c6b9_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7521b01c889643c9931e6cd5cbaf2b96_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9f8d5e268f3d4eb697463d42a1cc1553_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id48b2d5a479f4ab58afeb508e8f9bc7c_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:EquityMethodInvesteeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">evh:ServicesAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i441f674d44a64d47a96c0c85ef92310d_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:EquityMethodInvesteeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">evh:ServicesAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i28a8f36df87345df9d28593e38c0563c_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:EquityMethodInvesteeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">evh:ServicesAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibca1768da73d4a4188df3e08ee08a9ce_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">evh:GlobalHealthMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">us-gaap:VariableInterestEntityNotPrimaryBeneficiaryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib755be34efd8414388d2ce5ca242428f_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">evh:GlobalHealthMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">us-gaap:VariableInterestEntityNotPrimaryBeneficiaryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibde52dbc2c2c4cbda03403d89ddcaca6_I20150531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:OwnershipAxis">evh:EvolentHealthLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2015-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i02e542a70a5046e396e8cd9126fefd99_D20200901-20200901"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">evh:UniversityHealthCaredbaPassportHealthPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">us-gaap:VariableInterestEntityNotPrimaryBeneficiaryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-09-01</xbrli:startDate><xbrli:endDate>2020-09-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia11440f2d2cf4758bb0c9e18c239042c_I20200901"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">evh:UniversityHealthCaredbaPassportHealthPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">us-gaap:VariableInterestEntityNotPrimaryBeneficiaryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i299a8d5a546040409468f7f7fabc44c0_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">evh:UniversityHealthCaredbaPassportHealthPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">us-gaap:VariableInterestEntityNotPrimaryBeneficiaryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0abaa0eac87f4791aa3fc322969844f0_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8b0421b968754a01b6e430b519919d13_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2b88f3addfe64f84a6303a37b589e8f5_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib92fc8f3c5774739b4687eddbea853f3_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib80e545347c046f081508ec064bed62f_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i445dcacffbec464ebce55777f4c8895b_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i44e95c772e54413fb8612a96b7f4dd16_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0c4bfc6064ec4f93a8c1502ece6eaeae_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icb9299fd51a347b9a7a46a5d71c01525_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">evh:MeasurementInputRiskNeutralExpectedEarnoutConsiderationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1fec5420a1ee45fd97f27bb260399220_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4e9639a5adcd411a8b02679081819ef5_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i38e7d4598fcf4220b68ea93547e1d444_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic0d050fa1a3e4a2cb801e14c4a7886a2_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5798a2aee885432aa6df470400a67a94_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7b9f0cfef2b641acb147ef3af438fe7e_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">evh:TransformationServicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib3fa08547d374130bb63c1e8f0b2c225_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">evh:TransformationServicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6759af249ec643ef9a412f313e3297e3_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">evh:TransformationServicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i64859199d5a842baaab416b161ae29c9_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">evh:PlatformsAndOperationsServicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ica89d567d5bb41858b442d7b0d52a944_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">evh:PlatformsAndOperationsServicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibe63fb63b6ff4113a876f8b68f82e70a_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">evh:PlatformsAndOperationsServicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2f7f912d67eb4dc4be805fbdba0a463f_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifdb175ec1f9e4b0eb8e3f71649541a13_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie285ae7136404d0386bf1d58aebb605f_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia2137cc736cb46c28970ad4c0df7a021_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">evh:EmployeeSeveranceAndTerminationBenefitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic842aeb816144721bb643e4517b1fffb_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">evh:EmployeeSeveranceAndTerminationBenefitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id2b0eba26c804a30b8e75757e49f5f5d_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">evh:EmployeeSeveranceAndTerminationBenefitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i044e3156b9ce469fa3a7efb6527ef6c1_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:FacilityClosingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i40374039e5cf443a857163fd2a9b2b45_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:FacilityClosingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3e648308269a4bea807ba0b660a48b7c_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:FacilityClosingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i27138185aa744ae99ce808c1685e2fee_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">evh:ProfessionalServicesRestructuringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if18eac1cd66a4b9b9bcc87d4d6fe437c_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">evh:ProfessionalServicesRestructuringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i03de94c17d4149bbb0bf7a3e528d5f89_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">evh:ProfessionalServicesRestructuringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i41b92360defc47ba8a58871111248034_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">evh:EvolentHealthServicesSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">evh:TransformationServicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic42eb62d04fb4a118704b67ffb9fd515_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">evh:ClinicalSolutionsSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">evh:TransformationServicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iaf678763d1004f0e9876b94f94d0a5a6_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:IntersegmentEliminationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">evh:TransformationServicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i468f13cceecc41368537f1bf4d3bc06e_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">evh:TransformationServicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i57ed24791b0544679bd4b966e3ad6122_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">evh:TransformationServicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5f219d5f567141958f242abd7cb9efea_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">evh:PlatformsAndOperationsServicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">evh:EvolentHealthServicesSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia00ff8c8432c4957b4aef14482bbb1ca_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">evh:ClinicalSolutionsSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">evh:PlatformsAndOperationsServicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iac839f1f097a424c99205c02214639ed_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">evh:PlatformsAndOperationsServicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:IntersegmentEliminationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id762405c08c64368824019f2ec90b437_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">evh:PlatformsAndOperationsServicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie91abff3ebd24744803f889983e86d61_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">evh:PlatformsAndOperationsServicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i160f9ff72a8f428db94184c59ffafc47_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:IntersegmentEliminationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6750aca4d3ec49afaa3b71a05c995e4e_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2a43cc2e9054466a9f76a89472b3e611_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6e3a96f5efe64f78b6f207c1f9ccaadf_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">evh:EvolentHealthServicesSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">evh:TransformationServicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i04129486c45c47ce9cc1fa8184882c54_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">evh:ClinicalSolutionsSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">evh:TransformationServicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i755b7b89c5764b53aede85f57d5ac9de_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:IntersegmentEliminationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">evh:TransformationServicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i51b664fb7925436f8af4dc7608707edc_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">evh:TransformationServicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3c1ca3f52cf44a48a6eb1c640364e98d_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">evh:TransformationServicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ief95fd4bd2a9417aa7c0a210852e8203_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">evh:PlatformsAndOperationsServicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">evh:EvolentHealthServicesSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i77015663db9441cd9c37ef54417768be_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">evh:ClinicalSolutionsSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">evh:PlatformsAndOperationsServicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iccbcddcfb8ea4a728d495edce2f63324_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">evh:PlatformsAndOperationsServicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:IntersegmentEliminationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5f1fd6df16314fac900d170f76611052_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">evh:PlatformsAndOperationsServicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i05ee1fcfda47445a8c730b607300bcd3_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">evh:PlatformsAndOperationsServicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iea90da90740c47ea8a58199dbc28a879_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:IntersegmentEliminationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if1e0588b36354ec4ad0fe9d8b69a9b09_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0de9d5a3b6224de8a58bd015afb42ce0_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1b52f1300eeb41f7927ec4e356b5e849_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">evh:EvolentHealthServicesSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">evh:TransformationServicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5a806984574d41c5a8b3b5e54ae8b937_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">evh:ClinicalSolutionsSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">evh:TransformationServicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie7a1104b23254e04ac79b4e5e6c03ca1_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:IntersegmentEliminationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">evh:TransformationServicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8b652a3d61824fc79322c57e9476af89_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">evh:TransformationServicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5276f3d92d824c07b982e9971e0a15e8_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">evh:TransformationServicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0aa78e50814f49e9ad96c352399da780_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">evh:PlatformsAndOperationsServicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">evh:EvolentHealthServicesSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic29edb3405614f9a9149c89d25008350_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">evh:ClinicalSolutionsSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">evh:PlatformsAndOperationsServicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i424e54d030c64f9c9b3a971c4a6c858d_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">evh:PlatformsAndOperationsServicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:IntersegmentEliminationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i585a3b5e60524401a57bad2ad2ffe307_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">evh:PlatformsAndOperationsServicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifb609f7da9704b688626efcd5acd234c_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">evh:PlatformsAndOperationsServicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icb97bc4a90264c0aa3a7d497791a321c_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:IntersegmentEliminationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ice1bdb7b2e1c43bbbb3687fa61bb7bfc_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie97138a13af04a0ebbec53523bd2a882_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i973a81e9b0924e4e86048dc6df6379d0_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8b76d915d864443fbfe177d29bc9e4e4_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i035c62f748c14287b929adf98e0b2fbb_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6d3bee5994474a229055f5b47133978b_D20201001-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-10-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i03844ec391854836b0d4437e624d231c_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18zNC9mcmFnOjI3Y2IxNjhkZTFhNTRhNGQ5MGNkYTNlODdlZDg5N2RlL3RhYmxlOmE4OWNjMDNlN2U2MDQyMjY5NTA4MWU1MTFkYTU1MTkwL3RhYmxlcmFuZ2U6YTg5Y2MwM2U3ZTYwNDIyNjk1MDgxZTUxMWRhNTUxOTBfNTUtMS0xLTEtMTc3NzU_dc843966-7f80-4efe-b679-574368ea9780 id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18zNC9mcmFnOjI3Y2IxNjhkZTFhNTRhNGQ5MGNkYTNlODdlZDg5N2RlL3RhYmxlOmE4OWNjMDNlN2U2MDQyMjY5NTA4MWU1MTFkYTU1MTkwL3RhYmxlcmFuZ2U6YTg5Y2MwM2U3ZTYwNDIyNjk1MDgxZTUxMWRhNTUxOTBfNTUtNS0xLTEtMTk3MDg_6223642a-5e62-4a5b-967f-f9e515b1dca7 id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18zNC9mcmFnOjI3Y2IxNjhkZTFhNTRhNGQ5MGNkYTNlODdlZDg5N2RlL3RhYmxlOmE4OWNjMDNlN2U2MDQyMjY5NTA4MWU1MTFkYTU1MTkwL3RhYmxlcmFuZ2U6YTg5Y2MwM2U3ZTYwNDIyNjk1MDgxZTUxMWRhNTUxOTBfNTYtMy0xLTEtMTc3NzU_4f6ad754-8af7-4679-92ee-c45d9fc9dbf3 id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18zNC9mcmFnOjI3Y2IxNjhkZTFhNTRhNGQ5MGNkYTNlODdlZDg5N2RlL3RhYmxlOmE4OWNjMDNlN2U2MDQyMjY5NTA4MWU1MTFkYTU1MTkwL3RhYmxlcmFuZ2U6YTg5Y2MwM2U3ZTYwNDIyNjk1MDgxZTUxMWRhNTUxOTBfNTUtMy0xLTEtMTc3NzU_0dbfcc48-1d01-4540-ab2b-aa7e32633e3b id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18zNC9mcmFnOjI3Y2IxNjhkZTFhNTRhNGQ5MGNkYTNlODdlZDg5N2RlL3RhYmxlOmE4OWNjMDNlN2U2MDQyMjY5NTA4MWU1MTFkYTU1MTkwL3RhYmxlcmFuZ2U6YTg5Y2MwM2U3ZTYwNDIyNjk1MDgxZTUxMWRhNTUxOTBfNTYtMS0xLTEtMTc3NzU_ffc6fbc1-32e0-4d84-81d2-24061d12a248 id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18zNC9mcmFnOjI3Y2IxNjhkZTFhNTRhNGQ5MGNkYTNlODdlZDg5N2RlL3RhYmxlOmE4OWNjMDNlN2U2MDQyMjY5NTA4MWU1MTFkYTU1MTkwL3RhYmxlcmFuZ2U6YTg5Y2MwM2U3ZTYwNDIyNjk1MDgxZTUxMWRhNTUxOTBfNTYtNS0xLTEtMTk3MDg_209232cd-73f4-4e84-8252-0b6a41a6baaa" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18zNC9mcmFnOjI3Y2IxNjhkZTFhNTRhNGQ5MGNkYTNlODdlZDg5N2RlL3RleHRyZWdpb246MjdjYjE2OGRlMWE1NGE0ZDkwY2RhM2U4N2VkODk3ZGVfNjE0_407cd0f7-2686-4510-bcd4-91690222a249" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yNS9mcmFnOmM5ZGJiZjkwNWNkYjRhM2Y5NGMxZDk0YTNmMjcyZGM2L3RhYmxlOmI3MTFhYTE1OTNiOTQzZWRhOGQ2ZDQyN2QxNTZkOGFjL3RhYmxlcmFuZ2U6YjcxMWFhMTU5M2I5NDNlZGE4ZDZkNDI3ZDE1NmQ4YWNfMy01LTEtMS0xNzc3NQ_46c2cc00-d98a-4db8-8abe-548c1179f2d3 id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yNS9mcmFnOmM5ZGJiZjkwNWNkYjRhM2Y5NGMxZDk0YTNmMjcyZGM2L3RhYmxlOmI3MTFhYTE1OTNiOTQzZWRhOGQ2ZDQyN2QxNTZkOGFjL3RhYmxlcmFuZ2U6YjcxMWFhMTU5M2I5NDNlZGE4ZDZkNDI3ZDE1NmQ4YWNfOS01LTEtMS0xNzc3NQ_ffcafb22-b8f3-4ddb-b38a-5a09c149759c id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yNS9mcmFnOmM5ZGJiZjkwNWNkYjRhM2Y5NGMxZDk0YTNmMjcyZGM2L3RhYmxlOmI3MTFhYTE1OTNiOTQzZWRhOGQ2ZDQyN2QxNTZkOGFjL3RhYmxlcmFuZ2U6YjcxMWFhMTU5M2I5NDNlZGE4ZDZkNDI3ZDE1NmQ4YWNfMy01LTEtMS0xOTE3OA_3c9095fd-21fc-41c2-9170-ae15b4f36761 id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yNS9mcmFnOmM5ZGJiZjkwNWNkYjRhM2Y5NGMxZDk0YTNmMjcyZGM2L3RhYmxlOmI3MTFhYTE1OTNiOTQzZWRhOGQ2ZDQyN2QxNTZkOGFjL3RhYmxlcmFuZ2U6YjcxMWFhMTU5M2I5NDNlZGE4ZDZkNDI3ZDE1NmQ4YWNfOC01LTEtMS0xNzc3NQ_1ad8948c-28b0-4494-8a69-63b5046a268c id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yNS9mcmFnOmM5ZGJiZjkwNWNkYjRhM2Y5NGMxZDk0YTNmMjcyZGM2L3RhYmxlOmI3MTFhYTE1OTNiOTQzZWRhOGQ2ZDQyN2QxNTZkOGFjL3RhYmxlcmFuZ2U6YjcxMWFhMTU5M2I5NDNlZGE4ZDZkNDI3ZDE1NmQ4YWNfMy03LTEtMS0xNzc3NQ_a3433453-2481-4ae7-be53-93f804bda331 id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yNS9mcmFnOmM5ZGJiZjkwNWNkYjRhM2Y5NGMxZDk0YTNmMjcyZGM2L3RhYmxlOmI3MTFhYTE1OTNiOTQzZWRhOGQ2ZDQyN2QxNTZkOGFjL3RhYmxlcmFuZ2U6YjcxMWFhMTU5M2I5NDNlZGE4ZDZkNDI3ZDE1NmQ4YWNfOS01LTEtMS0xOTE5NA_260357c9-44f5-47eb-8910-fe9f9be2c529 id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yNS9mcmFnOmM5ZGJiZjkwNWNkYjRhM2Y5NGMxZDk0YTNmMjcyZGM2L3RhYmxlOmI3MTFhYTE1OTNiOTQzZWRhOGQ2ZDQyN2QxNTZkOGFjL3RhYmxlcmFuZ2U6YjcxMWFhMTU5M2I5NDNlZGE4ZDZkNDI3ZDE1NmQ4YWNfOC03LTEtMS0xNzc3NQ_943a5b31-2cfc-4168-b222-5a303f55b5aa id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yNS9mcmFnOmM5ZGJiZjkwNWNkYjRhM2Y5NGMxZDk0YTNmMjcyZGM2L3RhYmxlOmI3MTFhYTE1OTNiOTQzZWRhOGQ2ZDQyN2QxNTZkOGFjL3RhYmxlcmFuZ2U6YjcxMWFhMTU5M2I5NDNlZGE4ZDZkNDI3ZDE1NmQ4YWNfNC01LTEtMS0xOTE3OA_241368f3-5677-4baa-ba4b-666e2870cf8b id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yNS9mcmFnOmM5ZGJiZjkwNWNkYjRhM2Y5NGMxZDk0YTNmMjcyZGM2L3RhYmxlOmI3MTFhYTE1OTNiOTQzZWRhOGQ2ZDQyN2QxNTZkOGFjL3RhYmxlcmFuZ2U6YjcxMWFhMTU5M2I5NDNlZGE4ZDZkNDI3ZDE1NmQ4YWNfNC03LTEtMS0xNzc3NQ_acbcefc9-f3d5-494d-a386-35f27c437a74 id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yNS9mcmFnOmM5ZGJiZjkwNWNkYjRhM2Y5NGMxZDk0YTNmMjcyZGM2L3RhYmxlOmI3MTFhYTE1OTNiOTQzZWRhOGQ2ZDQyN2QxNTZkOGFjL3RhYmxlcmFuZ2U6YjcxMWFhMTU5M2I5NDNlZGE4ZDZkNDI3ZDE1NmQ4YWNfOC01LTEtMS0xOTE4Nw_0a57bcb2-3df7-4503-81cc-cba32b4b23a5 id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yNS9mcmFnOmM5ZGJiZjkwNWNkYjRhM2Y5NGMxZDk0YTNmMjcyZGM2L3RhYmxlOmI3MTFhYTE1OTNiOTQzZWRhOGQ2ZDQyN2QxNTZkOGFjL3RhYmxlcmFuZ2U6YjcxMWFhMTU5M2I5NDNlZGE4ZDZkNDI3ZDE1NmQ4YWNfNC01LTEtMS0xNzc3NQ_644b3506-ee17-40d9-933c-67a7ebbab750 id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yNS9mcmFnOmM5ZGJiZjkwNWNkYjRhM2Y5NGMxZDk0YTNmMjcyZGM2L3RhYmxlOmI3MTFhYTE1OTNiOTQzZWRhOGQ2ZDQyN2QxNTZkOGFjL3RhYmxlcmFuZ2U6YjcxMWFhMTU5M2I5NDNlZGE4ZDZkNDI3ZDE1NmQ4YWNfOS03LTEtMS0xNzc3NQ_2a40fbef-ea9c-434a-9dd7-fb55df812da8" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yNS9mcmFnOmM5ZGJiZjkwNWNkYjRhM2Y5NGMxZDk0YTNmMjcyZGM2L3RleHRyZWdpb246YzlkYmJmOTA1Y2RiNGEzZjk0YzFkOTRhM2YyNzJkYzZfMzI2_1383af2f-4f0a-411f-acf7-955e4538706b" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yMi9mcmFnOjJiM2Y4ODE3NTVhYTQ5ODk5MzI2NThlODM2YmIyNGI2L3RhYmxlOjQ1MmFlOGFkMjMxZjQ4MWQ4Njg3MGU5MDYxNWI3NTkxL3RhYmxlcmFuZ2U6NDUyYWU4YWQyMzFmNDgxZDg2ODcwZTkwNjE1Yjc1OTFfMjItMS0xLTEtMTc3NzU_de2bfa85-6392-4aa3-9252-cf468f01146c id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yMi9mcmFnOjJiM2Y4ODE3NTVhYTQ5ODk5MzI2NThlODM2YmIyNGI2L3RhYmxlOjQ1MmFlOGFkMjMxZjQ4MWQ4Njg3MGU5MDYxNWI3NTkxL3RhYmxlcmFuZ2U6NDUyYWU4YWQyMzFmNDgxZDg2ODcwZTkwNjE1Yjc1OTFfNi0zLTEtMS0xNzc3NQ_ac001ac4-a8c8-46b0-876f-5bb35a584888 id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yMi9mcmFnOjJiM2Y4ODE3NTVhYTQ5ODk5MzI2NThlODM2YmIyNGI2L3RhYmxlOjQ1MmFlOGFkMjMxZjQ4MWQ4Njg3MGU5MDYxNWI3NTkxL3RhYmxlcmFuZ2U6NDUyYWU4YWQyMzFmNDgxZDg2ODcwZTkwNjE1Yjc1OTFfMjMtMS0xLTEtMTc3NzU_0c4a3b28-a401-4580-bd6d-913e346e7efe id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yMi9mcmFnOjJiM2Y4ODE3NTVhYTQ5ODk5MzI2NThlODM2YmIyNGI2L3RhYmxlOjQ1MmFlOGFkMjMxZjQ4MWQ4Njg3MGU5MDYxNWI3NTkxL3RhYmxlcmFuZ2U6NDUyYWU4YWQyMzFmNDgxZDg2ODcwZTkwNjE1Yjc1OTFfMjItMy0xLTEtMTc3NzU_7665c1f5-8c13-4d79-9699-c169f3c45c6b id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yMi9mcmFnOjJiM2Y4ODE3NTVhYTQ5ODk5MzI2NThlODM2YmIyNGI2L3RhYmxlOjQ1MmFlOGFkMjMxZjQ4MWQ4Njg3MGU5MDYxNWI3NTkxL3RhYmxlcmFuZ2U6NDUyYWU4YWQyMzFmNDgxZDg2ODcwZTkwNjE1Yjc1OTFfMTMtMy0xLTEtMTc3NzU_46840606-41ef-48ee-84bf-1505ddaef468 id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yMi9mcmFnOjJiM2Y4ODE3NTVhYTQ5ODk5MzI2NThlODM2YmIyNGI2L3RhYmxlOjQ1MmFlOGFkMjMxZjQ4MWQ4Njg3MGU5MDYxNWI3NTkxL3RhYmxlcmFuZ2U6NDUyYWU4YWQyMzFmNDgxZDg2ODcwZTkwNjE1Yjc1OTFfNS0xLTEtMS0xNzc3NQ_f8d025b8-3255-478d-83d3-8aecd42fa11b id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yMi9mcmFnOjJiM2Y4ODE3NTVhYTQ5ODk5MzI2NThlODM2YmIyNGI2L3RhYmxlOjQ1MmFlOGFkMjMxZjQ4MWQ4Njg3MGU5MDYxNWI3NTkxL3RhYmxlcmFuZ2U6NDUyYWU4YWQyMzFmNDgxZDg2ODcwZTkwNjE1Yjc1OTFfMjgtMS0xLTEtMTc3NzU_03f34cbc-a6ef-428a-8ea2-e2626cbf946a id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yMi9mcmFnOjJiM2Y4ODE3NTVhYTQ5ODk5MzI2NThlODM2YmIyNGI2L3RhYmxlOjQ1MmFlOGFkMjMxZjQ4MWQ4Njg3MGU5MDYxNWI3NTkxL3RhYmxlcmFuZ2U6NDUyYWU4YWQyMzFmNDgxZDg2ODcwZTkwNjE1Yjc1OTFfNi0xLTEtMS0xNzc3NQ_469a4400-c2b4-4cf4-8445-c96411a59e90 id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yMi9mcmFnOjJiM2Y4ODE3NTVhYTQ5ODk5MzI2NThlODM2YmIyNGI2L3RhYmxlOjQ1MmFlOGFkMjMxZjQ4MWQ4Njg3MGU5MDYxNWI3NTkxL3RhYmxlcmFuZ2U6NDUyYWU4YWQyMzFmNDgxZDg2ODcwZTkwNjE1Yjc1OTFfMTMtMS0xLTEtMTc3NzU_00d8e9df-b51a-4134-ae28-46cb41ed669a id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yMi9mcmFnOjJiM2Y4ODE3NTVhYTQ5ODk5MzI2NThlODM2YmIyNGI2L3RhYmxlOjQ1MmFlOGFkMjMxZjQ4MWQ4Njg3MGU5MDYxNWI3NTkxL3RhYmxlcmFuZ2U6NDUyYWU4YWQyMzFmNDgxZDg2ODcwZTkwNjE1Yjc1OTFfMjMtMy0xLTEtMTc3NzU_0c7e2696-05ec-4e48-a7ec-d18b99a2d593 id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yMi9mcmFnOjJiM2Y4ODE3NTVhYTQ5ODk5MzI2NThlODM2YmIyNGI2L3RhYmxlOjQ1MmFlOGFkMjMxZjQ4MWQ4Njg3MGU5MDYxNWI3NTkxL3RhYmxlcmFuZ2U6NDUyYWU4YWQyMzFmNDgxZDg2ODcwZTkwNjE1Yjc1OTFfNS0zLTEtMS0xNzc3NQ_1aab1e38-d520-4d8e-a626-6f7e2520afce id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yMi9mcmFnOjJiM2Y4ODE3NTVhYTQ5ODk5MzI2NThlODM2YmIyNGI2L3RhYmxlOjQ1MmFlOGFkMjMxZjQ4MWQ4Njg3MGU5MDYxNWI3NTkxL3RhYmxlcmFuZ2U6NDUyYWU4YWQyMzFmNDgxZDg2ODcwZTkwNjE1Yjc1OTFfMjgtMy0xLTEtMTc3NzU_4b6e6c26-f2b8-4e61-8c51-c6866fd17f9b" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yMi9mcmFnOjJiM2Y4ODE3NTVhYTQ5ODk5MzI2NThlODM2YmIyNGI2L3RleHRyZWdpb246MmIzZjg4MTc1NWFhNDk4OTkzMjY1OGU4MzZiYjI0YjZfMjA1_0cf9d253-8d73-4596-9d10-31e28ee4f8d6" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM184NS9mcmFnOjdhMDNjNzc3NWZjNDRmMzlhZmY3NjkyYjY5NGQ5YzM3L3RhYmxlOjhhNDlhNzA4NDcxMDQwZTk4MzBiMDg2ZTIxMzRlYTk1L3RhYmxlcmFuZ2U6OGE0OWE3MDg0NzEwNDBlOTgzMGIwODZlMjEzNGVhOTVfMy01LTEtMS0xNzc3NQ_3a7f9340-a2d9-4068-b095-f659267e962c id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yNS9mcmFnOmM5ZGJiZjkwNWNkYjRhM2Y5NGMxZDk0YTNmMjcyZGM2L3RhYmxlOmI3MTFhYTE1OTNiOTQzZWRhOGQ2ZDQyN2QxNTZkOGFjL3RhYmxlcmFuZ2U6YjcxMWFhMTU5M2I5NDNlZGE4ZDZkNDI3ZDE1NmQ4YWNfMjctNy0xLTEtMTc3NzU_6123f20d-b2da-4983-8481-3001d793c73d id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM184NS9mcmFnOjdhMDNjNzc3NWZjNDRmMzlhZmY3NjkyYjY5NGQ5YzM3L3RhYmxlOjhhNDlhNzA4NDcxMDQwZTk4MzBiMDg2ZTIxMzRlYTk1L3RhYmxlcmFuZ2U6OGE0OWE3MDg0NzEwNDBlOTgzMGIwODZlMjEzNGVhOTVfMy01LTEtMS0yMTkzMQ_cd15aa32-72bb-4df8-a330-8fac8ecbd8bb id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM184NS9mcmFnOjdhMDNjNzc3NWZjNDRmMzlhZmY3NjkyYjY5NGQ5YzM3L3RhYmxlOjhhNDlhNzA4NDcxMDQwZTk4MzBiMDg2ZTIxMzRlYTk1L3RhYmxlcmFuZ2U6OGE0OWE3MDg0NzEwNDBlOTgzMGIwODZlMjEzNGVhOTVfMy03LTEtMS0xNzc3NQ_6123f20d-b2da-4983-8481-3001d793c73d id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMzAvZnJhZzo3NGIwMjA4NWYwNjY0MjYyOGY3OWUzMTNlNjFkZmI3Yy90YWJsZTpmYTRmNTRhZWVjNTg0NDBiYmYyYTcwYWUxMDNkNDVlNy90YWJsZXJhbmdlOmZhNGY1NGFlZWM1ODQ0MGJiZjJhNzBhZTEwM2Q0NWU3XzYtMS0xLTEtMzMwOTg_2d028ee7-25e5-43aa-a188-cea5ec2afbd1 id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yNS9mcmFnOmM5ZGJiZjkwNWNkYjRhM2Y5NGMxZDk0YTNmMjcyZGM2L3RhYmxlOmI3MTFhYTE1OTNiOTQzZWRhOGQ2ZDQyN2QxNTZkOGFjL3RhYmxlcmFuZ2U6YjcxMWFhMTU5M2I5NDNlZGE4ZDZkNDI3ZDE1NmQ4YWNfMjctNS0xLTEtMTkyNTY_cd15aa32-72bb-4df8-a330-8fac8ecbd8bb id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yNS9mcmFnOmM5ZGJiZjkwNWNkYjRhM2Y5NGMxZDk0YTNmMjcyZGM2L3RhYmxlOmI3MTFhYTE1OTNiOTQzZWRhOGQ2ZDQyN2QxNTZkOGFjL3RhYmxlcmFuZ2U6YjcxMWFhMTU5M2I5NDNlZGE4ZDZkNDI3ZDE1NmQ4YWNfMjctNS0xLTEtMTc3NzU_3a7f9340-a2d9-4068-b095-f659267e962c" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yNS9mcmFnOmM5ZGJiZjkwNWNkYjRhM2Y5NGMxZDk0YTNmMjcyZGM2L3RleHRyZWdpb246YzlkYmJmOTA1Y2RiNGEzZjk0YzFkOTRhM2YyNzJkYzZfMzIy_8cef74d3-e3cd-4cfd-a2b6-5f17f7e0cd7f" order="1"></ix:relationship></ix:resources></ix:header></div><div id="i9aaa2fddc97e482da5dbe37ac85ae703_4"></div><div style="min-height:27pt;width:100%"><div><span><br/></span></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:100%">UNITED STATES</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:38.25pt;padding-right:38.25pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:100%">SECURITIES AND EXCHANGE COMMISSION</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:38.25pt;padding-right:38.25pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">WASHINGTON, D.C. 20549</span></div></td></tr></table></div><div style="padding-left:38.25pt;padding-right:38.25pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">_________________________</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:120%">FORM <ix:nonNumeric contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231" name="dei:DocumentType" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM180L2ZyYWc6OTQ1NzYzOGM4N2Q2NGFkYThlMmYzZGZkMmMwNzJiYmUvdGV4dHJlZ2lvbjo5NDU3NjM4Yzg3ZDY0YWRhOGUyZjNkZmQyYzA3MmJiZV8zNzUz_6e89b1d6-7d34-46a6-aadb-178834c248fc">10-K</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">_________________________</span></div><div style="text-align:center"><span><br/></span></div><div style="padding-right:38.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">(Mark One)</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Wingdings 2',sans-serif;font-size:12pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231" name="dei:DocumentAnnualReport" format="ixt:fixed-true" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM180L2ZyYWc6OTQ1NzYzOGM4N2Q2NGFkYThlMmYzZGZkMmMwNzJiYmUvdGV4dHJlZ2lvbjo5NDU3NjM4Yzg3ZDY0YWRhOGUyZjNkZmQyYzA3MmJiZV8zNzY5_90b253c0-0e6e-4508-97f0-85417635c227">S</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">For the fiscal year ended <ix:nonNumeric contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM180L2ZyYWc6OTQ1NzYzOGM4N2Q2NGFkYThlMmYzZGZkMmMwNzJiYmUvdGV4dHJlZ2lvbjo5NDU3NjM4Yzg3ZDY0YWRhOGUyZjNkZmQyYzA3MmJiZV8xOTY_4cfa1ff6-b9d5-422c-a35f-9a16c9aa6cbe"><ix:nonNumeric contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231" name="dei:CurrentFiscalYearEndDate" format="ixt:date-monthname-day-en" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM180L2ZyYWc6OTQ1NzYzOGM4N2Q2NGFkYThlMmYzZGZkMmMwNzJiYmUvdGV4dHJlZ2lvbjo5NDU3NjM4Yzg3ZDY0YWRhOGUyZjNkZmQyYzA3MmJiZV8xOTY_ae3577d8-b587-4c78-8d2c-fe86c7d45ed8">December&#160;31</ix:nonNumeric>, 2021</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"> </span></div><div style="padding-left:19.12pt;padding-right:19.12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">OR</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#160;</span></div><div style="padding-left:19.12pt;padding-right:19.12pt;text-align:center"><span><br/></span></div><div style="padding-left:18pt;padding-right:38.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:12pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231" name="dei:DocumentTransitionReport" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM180L2ZyYWc6OTQ1NzYzOGM4N2Q2NGFkYThlMmYzZGZkMmMwNzJiYmUvdGV4dHJlZ2lvbjo5NDU3NjM4Yzg3ZDY0YWRhOGUyZjNkZmQyYzA3MmJiZV8zNzY1_a5a76b5a-d053-4715-b5fa-3713a24bf667">&#9744;</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">For the transition period from</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%;text-decoration:underline">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">to</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%;text-decoration:underline">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">&#160;</span></div><div style="padding-left:38.25pt;padding-right:38.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">Commission File Number:&#160;&#160;<ix:nonNumeric contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231" name="dei:EntityFileNumber" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM180L2ZyYWc6OTQ1NzYzOGM4N2Q2NGFkYThlMmYzZGZkMmMwNzJiYmUvdGV4dHJlZ2lvbjo5NDU3NjM4Yzg3ZDY0YWRhOGUyZjNkZmQyYzA3MmJiZV8zNzYw_06815ecc-200a-42fa-b918-1d22f26ef7d6">001-37415</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">_________________________</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231" name="dei:EntityRegistrantName" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM180L2ZyYWc6OTQ1NzYzOGM4N2Q2NGFkYThlMmYzZGZkMmMwNzJiYmUvdGV4dHJlZ2lvbjo5NDU3NjM4Yzg3ZDY0YWRhOGUyZjNkZmQyYzA3MmJiZV8zNzYx_a84c5af3-1ee7-4da4-b967-0790014ffab7">Evolent Health, Inc.</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">(Exact name of registrant as specified in its charter)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">_________________________</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:349.50pt"><tr><td style="width:1.0pt"></td><td style="width:102.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:7.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:42.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:7.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:46.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:7.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:37.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:7.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:75.25pt"></td><td style="width:1.0pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM180L2ZyYWc6OTQ1NzYzOGM4N2Q2NGFkYThlMmYzZGZkMmMwNzJiYmUvdGFibGU6NjcyYTc3Mjc1M2JkNDA5OWI2ZGMyNDk4ZDE2NmRmYjEvdGFibGVyYW5nZTo2NzJhNzcyNzUzYmQ0MDk5YjZkYzI0OThkMTY2ZGZiMV8wLTAtMS0xLTE3Nzc1_1675a454-48fe-4bb8-94a4-7ad9993c19fd">Delaware</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231" name="dei:EntityTaxIdentificationNumber" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM180L2ZyYWc6OTQ1NzYzOGM4N2Q2NGFkYThlMmYzZGZkMmMwNzJiYmUvdGFibGU6NjcyYTc3Mjc1M2JkNDA5OWI2ZGMyNDk4ZDE2NmRmYjEvdGFibGVyYW5nZTo2NzJhNzcyNzUzYmQ0MDk5YjZkYzI0OThkMTY2ZGZiMV8wLTgtMS0xLTE3Nzc1_1e877802-bcea-4baf-8eb7-172101c52883">32-0454912</ix:nonNumeric></span></td></tr><tr style="height:20pt"><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(State or other jurisdiction of<br/>incorporation or organization)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(I.R.S. Employer<br/>Identification No.)</span></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:24pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231" name="dei:EntityAddressAddressLine1" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM180L2ZyYWc6OTQ1NzYzOGM4N2Q2NGFkYThlMmYzZGZkMmMwNzJiYmUvdGFibGU6NjcyYTc3Mjc1M2JkNDA5OWI2ZGMyNDk4ZDE2NmRmYjEvdGFibGVyYW5nZTo2NzJhNzcyNzUzYmQ0MDk5YjZkYzI0OThkMTY2ZGZiMV8zLTAtMS0xLTE3Nzc1_d8a01fcb-ff0d-45da-89a3-55cb04f4bcc9">800 N. Glebe Road</ix:nonNumeric></span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">,</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231" name="dei:EntityAddressAddressLine2" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM180L2ZyYWc6OTQ1NzYzOGM4N2Q2NGFkYThlMmYzZGZkMmMwNzJiYmUvdGFibGU6NjcyYTc3Mjc1M2JkNDA5OWI2ZGMyNDk4ZDE2NmRmYjEvdGFibGVyYW5nZTo2NzJhNzcyNzUzYmQ0MDk5YjZkYzI0OThkMTY2ZGZiMV8zLTItMS0xLTE3Nzc1_57ecba0f-9ed1-48f9-867c-e93279162d9f">Suite 500</ix:nonNumeric></span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">,</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231" name="dei:EntityAddressCityOrTown" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM180L2ZyYWc6OTQ1NzYzOGM4N2Q2NGFkYThlMmYzZGZkMmMwNzJiYmUvdGFibGU6NjcyYTc3Mjc1M2JkNDA5OWI2ZGMyNDk4ZDE2NmRmYjEvdGFibGVyYW5nZTo2NzJhNzcyNzUzYmQ0MDk5YjZkYzI0OThkMTY2ZGZiMV8zLTQtMS0xLTE3Nzc1_038ae9c0-ac0b-4620-87f7-c92f8619b1e1">Arlington</ix:nonNumeric></span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">,</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231" name="dei:EntityAddressStateOrProvince" format="ixt-sec:stateprovnameen" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM180L2ZyYWc6OTQ1NzYzOGM4N2Q2NGFkYThlMmYzZGZkMmMwNzJiYmUvdGFibGU6NjcyYTc3Mjc1M2JkNDA5OWI2ZGMyNDk4ZDE2NmRmYjEvdGFibGVyYW5nZTo2NzJhNzcyNzUzYmQ0MDk5YjZkYzI0OThkMTY2ZGZiMV8zLTYtMS0xLTE3Nzc1_8fbbe55e-1cbc-4f7e-aef3-861b8ad570bb">Virginia</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231" name="dei:EntityAddressPostalZipCode" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM180L2ZyYWc6OTQ1NzYzOGM4N2Q2NGFkYThlMmYzZGZkMmMwNzJiYmUvdGFibGU6NjcyYTc3Mjc1M2JkNDA5OWI2ZGMyNDk4ZDE2NmRmYjEvdGFibGVyYW5nZTo2NzJhNzcyNzUzYmQ0MDk5YjZkYzI0OThkMTY2ZGZiMV8zLTgtMS0xLTE3Nzc1_9ab09a36-9991-4284-8b18-7087cde731c7">22203</ix:nonNumeric></span></td></tr><tr style="height:11pt"><td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(Address of principal executive offices)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(Zip Code)</span></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;           </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">(<ix:nonNumeric contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231" name="dei:CityAreaCode" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM180L2ZyYWc6OTQ1NzYzOGM4N2Q2NGFkYThlMmYzZGZkMmMwNzJiYmUvdGV4dHJlZ2lvbjo5NDU3NjM4Yzg3ZDY0YWRhOGUyZjNkZmQyYzA3MmJiZV8zNzY2_fa8eedb2-169a-4d20-8893-647a6bee13e8">571</ix:nonNumeric>) <ix:nonNumeric contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231" name="dei:LocalPhoneNumber" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM180L2ZyYWc6OTQ1NzYzOGM4N2Q2NGFkYThlMmYzZGZkMmMwNzJiYmUvdGV4dHJlZ2lvbjo5NDU3NjM4Yzg3ZDY0YWRhOGUyZjNkZmQyYzA3MmJiZV8zNzU0_b1c1a395-a44d-46cd-93cf-281d5525e51a">389-6000</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">Registrant&#8217;s telephone number, including area code</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">_________________________</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Securities registered pursuant to Section 12(b) of the Act:</span></div><div style="text-align:center;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:522.00pt"><tr><td style="width:1.0pt"></td><td style="width:238.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:88.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:190.00pt"></td><td style="width:1.0pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Title of each class</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Trading Symbol(s)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Name of each exchange on which registered</span></td></tr><tr style="height:24pt"><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM180L2ZyYWc6OTQ1NzYzOGM4N2Q2NGFkYThlMmYzZGZkMmMwNzJiYmUvdGFibGU6ZWRjNTdiNTljNDRiNDQ0ZmE5ZGNhNmE0MmY1OThiNTMvdGFibGVyYW5nZTplZGM1N2I1OWM0NGI0NDRmYTlkY2E2YTQyZjU5OGI1M18xLTAtMS0xLTE3Nzc1_e82c1638-de12-45f9-bb1b-4c0f111f7eeb">Class A Common Stock of Evolent Health, Inc., par value $0.01 per share</ix:nonNumeric></span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM180L2ZyYWc6OTQ1NzYzOGM4N2Q2NGFkYThlMmYzZGZkMmMwNzJiYmUvdGFibGU6ZWRjNTdiNTljNDRiNDQ0ZmE5ZGNhNmE0MmY1OThiNTMvdGFibGVyYW5nZTplZGM1N2I1OWM0NGI0NDRmYTlkY2E2YTQyZjU5OGI1M18xLTEtMS0xLTE3Nzc1_75b8a9a7-9c7f-48ae-8b30-5d484ac70a61">EVH</ix:nonNumeric></span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM180L2ZyYWc6OTQ1NzYzOGM4N2Q2NGFkYThlMmYzZGZkMmMwNzJiYmUvdGFibGU6ZWRjNTdiNTljNDRiNDQ0ZmE5ZGNhNmE0MmY1OThiNTMvdGFibGVyYW5nZTplZGM1N2I1OWM0NGI0NDRmYTlkY2E2YTQyZjU5OGI1M18xLTItMS0xLTE3Nzc1_46ca054f-b912-4427-ac1b-d5421465f393">New York Stock Exchange</ix:nonNumeric></span></td></tr></table></div><div style="text-indent:18pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Securities registered pursuant to section 12(g) of the Act: None</span></div><div style="text-indent:18pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. <ix:nonNumeric contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231" name="dei:EntityWellKnownSeasonedIssuer" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM180L2ZyYWc6OTQ1NzYzOGM4N2Q2NGFkYThlMmYzZGZkMmMwNzJiYmUvdGV4dHJlZ2lvbjo5NDU3NjM4Yzg3ZDY0YWRhOGUyZjNkZmQyYzA3MmJiZV8zNzY3_1a596c36-4309-4adb-b5c1-7d981d006d46">Yes</ix:nonNumeric> </span><span style="color:#000000;font-family:'Wingdings 2',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">S </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">No &#9744;</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act. Yes &#9744;  <ix:nonNumeric contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231" name="dei:EntityVoluntaryFilers" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM180L2ZyYWc6OTQ1NzYzOGM4N2Q2NGFkYThlMmYzZGZkMmMwNzJiYmUvdGV4dHJlZ2lvbjo5NDU3NjM4Yzg3ZDY0YWRhOGUyZjNkZmQyYzA3MmJiZV8zNzU1_2528efb1-a19f-4ed6-b163-31c43b8c805c">No</ix:nonNumeric> </span><span style="color:#000000;font-family:'Wingdings 2',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">S</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.  <ix:nonNumeric contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231" name="dei:EntityCurrentReportingStatus" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM180L2ZyYWc6OTQ1NzYzOGM4N2Q2NGFkYThlMmYzZGZkMmMwNzJiYmUvdGV4dHJlZ2lvbjo5NDU3NjM4Yzg3ZDY0YWRhOGUyZjNkZmQyYzA3MmJiZV8zNzU2_ebe71ba9-c002-44d8-81ef-4981247c98f6">Yes</ix:nonNumeric> </span><span style="color:#000000;font-family:'Wingdings 2',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">S</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">  No &#9744;</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&#167;232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).  <ix:nonNumeric contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231" name="dei:EntityInteractiveDataCurrent" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM180L2ZyYWc6OTQ1NzYzOGM4N2Q2NGFkYThlMmYzZGZkMmMwNzJiYmUvdGV4dHJlZ2lvbjo5NDU3NjM4Yzg3ZDY0YWRhOGUyZjNkZmQyYzA3MmJiZV8zNzcw_2f47ccfe-893f-47dd-ba1c-57dee85c1998">Yes</ix:nonNumeric>  </span><span style="color:#000000;font-family:'Wingdings 2',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">S</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">  No  &#9744;</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company.&#160;&#160;See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221;  &#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act.  </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231" name="dei:EntityFilerCategory" format="ixt-sec:entityfilercategoryen" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM180L2ZyYWc6OTQ1NzYzOGM4N2Q2NGFkYThlMmYzZGZkMmMwNzJiYmUvdGV4dHJlZ2lvbjo5NDU3NjM4Yzg3ZDY0YWRhOGUyZjNkZmQyYzA3MmJiZV8zNzU3_12ee84bf-2cd1-4e18-b9c3-90b4fa776bb2">Large accelerated filer</ix:nonNumeric>  </span><span style="color:#000000;font-family:'Wingdings 2',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">S</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">  Accelerated filer  &#9744;  Non-accelerated filer &#9744;  Smaller reporting company  </span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231" name="dei:EntitySmallBusiness" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM180L2ZyYWc6OTQ1NzYzOGM4N2Q2NGFkYThlMmYzZGZkMmMwNzJiYmUvdGV4dHJlZ2lvbjo5NDU3NjM4Yzg3ZDY0YWRhOGUyZjNkZmQyYzA3MmJiZV8zNzYy_0c3143bd-5310-49ec-9647-8948fd4f54b9">&#9744;</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Emerging growth company  </span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231" name="dei:EntityEmergingGrowthCompany" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM180L2ZyYWc6OTQ1NzYzOGM4N2Q2NGFkYThlMmYzZGZkMmMwNzJiYmUvdGV4dHJlZ2lvbjo5NDU3NjM4Yzg3ZDY0YWRhOGUyZjNkZmQyYzA3MmJiZV8zNzU4_f720f2cf-f883-41da-8fc4-1761f7d04e46">&#9744;</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13 (a) of the Exchange Act.  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#9744;</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="height:22.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:27pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has filed a report on and attestation to its management&#8217;s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report. </span><span style="color:#000000;font-family:'Wingdings 2',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231" name="dei:IcfrAuditorAttestationFlag" format="ixt:fixed-true" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM180L2ZyYWc6OTQ1NzYzOGM4N2Q2NGFkYThlMmYzZGZkMmMwNzJiYmUvdGV4dHJlZ2lvbjo5NDU3NjM4Yzg3ZDY0YWRhOGUyZjNkZmQyYzA3MmJiZV8zNzU5_533f6a14-61cd-4c8b-b954-c6be1e097ee1">S</ix:nonNumeric></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).&#160;Yes </span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231" name="dei:EntityShellCompany" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM180L2ZyYWc6OTQ1NzYzOGM4N2Q2NGFkYThlMmYzZGZkMmMwNzJiYmUvdGV4dHJlZ2lvbjo5NDU3NjM4Yzg3ZDY0YWRhOGUyZjNkZmQyYzA3MmJiZV8zNzY4_3eeb1f50-0436-428a-8394-93fb1ed96184">&#9744;</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"> No&#160; </span><span style="color:#000000;font-family:'Wingdings 2',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">S</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The aggregate market value of the voting and non-voting common equity held by non-affiliates of the registrant (based on the closing price of the shares on the New York Stock Exchange on such date) as of the last business day of the registrant&#8217;s most recently completed second fiscal quarter was $<ix:nonFraction unitRef="usd" contextRef="i7db6c6f189754c32a62fbe5b49259ed8_I20210630" decimals="-5" name="dei:EntityPublicFloat" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM180L2ZyYWc6OTQ1NzYzOGM4N2Q2NGFkYThlMmYzZGZkMmMwNzJiYmUvdGV4dHJlZ2lvbjo5NDU3NjM4Yzg3ZDY0YWRhOGUyZjNkZmQyYzA3MmJiZV8zMjM2_85563606-c8c3-4e73-b86c-c978c57ca85c">1.6</ix:nonFraction> billion. </span></div><div style="text-indent:22.5pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">As of February&#160;18, 2022, there were <ix:nonFraction unitRef="shares" contextRef="ibc44c5b5f9be42eaa992bbd65360561b_I20220218" decimals="INF" name="dei:EntityCommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM180L2ZyYWc6OTQ1NzYzOGM4N2Q2NGFkYThlMmYzZGZkMmMwNzJiYmUvdGV4dHJlZ2lvbjo5NDU3NjM4Yzg3ZDY0YWRhOGUyZjNkZmQyYzA3MmJiZV8zMjYz_c5e08724-5f7c-471b-83d6-bcb59c719ab0">90,827,306</ix:nonFraction> shares of the registrant&#8217;s Class A common stock outstanding.</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">Documents Incorporated by Reference</span></div><div style="text-align:center"><span><br/></span></div><div><ix:nonNumeric contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231" name="dei:DocumentsIncorporatedByReferenceTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM180L2ZyYWc6OTQ1NzYzOGM4N2Q2NGFkYThlMmYzZGZkMmMwNzJiYmUvdGV4dHJlZ2lvbjo5NDU3NjM4Yzg3ZDY0YWRhOGUyZjNkZmQyYzA3MmJiZV8zNzYz_a24ff7cd-4afc-4dcf-b411-99f076955a76" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Selected portions of the Proxy Statement for the Annual Meeting of Shareholders, scheduled for</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> June&#160;9, 2022, hav</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">e been incorporated by reference into Part III of this Form 10-K to the extent stated herein. Such proxy statement will be filed with the Securities and Exchange Commission within 120 days of the registrant&#8217;s fiscal year ended December&#160;31, 2021.</span></ix:nonNumeric></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;</span></div><div style="height:22.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div></div></div><div id="i9aaa2fddc97e482da5dbe37ac85ae703_244"></div><hr style="page-break-after:always"/><div style="min-height:18pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Evolent Health, Inc.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Table of Contents</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:4.455%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:87.927%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.318%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Item</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Page</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#i9aaa2fddc97e482da5dbe37ac85ae703_16">PART I</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i9aaa2fddc97e482da5dbe37ac85ae703_250">Business</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i9aaa2fddc97e482da5dbe37ac85ae703_250">1</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1A.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i9aaa2fddc97e482da5dbe37ac85ae703_181">Risk Factors</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i9aaa2fddc97e482da5dbe37ac85ae703_181">18</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1B. </span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i9aaa2fddc97e482da5dbe37ac85ae703_268">Unresolved Staff Comments</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i9aaa2fddc97e482da5dbe37ac85ae703_268">41</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i9aaa2fddc97e482da5dbe37ac85ae703_247">Properties</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i9aaa2fddc97e482da5dbe37ac85ae703_247">41</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i9aaa2fddc97e482da5dbe37ac85ae703_175">Legal Proceedings</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i9aaa2fddc97e482da5dbe37ac85ae703_175">41</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i9aaa2fddc97e482da5dbe37ac85ae703_205">Mine Safety Disclosures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i9aaa2fddc97e482da5dbe37ac85ae703_205">41</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:5.62pt;padding-right:5.62pt;text-align:center;text-indent:-9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#i9aaa2fddc97e482da5dbe37ac85ae703_172">PART II</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i9aaa2fddc97e482da5dbe37ac85ae703_262">Market for Registrant's Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i9aaa2fddc97e482da5dbe37ac85ae703_262">42</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i9aaa2fddc97e482da5dbe37ac85ae703_256">Reserved</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i9aaa2fddc97e482da5dbe37ac85ae703_256">43</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i9aaa2fddc97e482da5dbe37ac85ae703_139">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i9aaa2fddc97e482da5dbe37ac85ae703_139">43</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;padding-right:2.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7A.</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;padding-right:2.25pt;text-indent:-9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i9aaa2fddc97e482da5dbe37ac85ae703_166">Quantitative and Qualitative Disclosures About Market Risk</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i9aaa2fddc97e482da5dbe37ac85ae703_166">63</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;padding-right:2.25pt;text-indent:-9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i9aaa2fddc97e482da5dbe37ac85ae703_19">Financial Statements and Supplementary Data</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i9aaa2fddc97e482da5dbe37ac85ae703_19">65</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;padding-right:2.25pt;text-indent:-9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i9aaa2fddc97e482da5dbe37ac85ae703_271">Changes in and Disagreements With Accountants on Accounting and Financial Disclosure</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i9aaa2fddc97e482da5dbe37ac85ae703_271">121</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;padding-right:2.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9A.</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;padding-right:2.25pt;text-indent:-9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i9aaa2fddc97e482da5dbe37ac85ae703_169">Controls and Procedures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i9aaa2fddc97e482da5dbe37ac85ae703_169">121</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;padding-right:2.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9B.</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;padding-right:2.25pt;text-indent:-9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i9aaa2fddc97e482da5dbe37ac85ae703_208">Other Information</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i9aaa2fddc97e482da5dbe37ac85ae703_208">122</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9C.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i9aaa2fddc97e482da5dbe37ac85ae703_2529">Disclosure Regarding Foreign Jurisdictions that Prevent Inspections</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i9aaa2fddc97e482da5dbe37ac85ae703_2529">123</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6.75pt;padding-right:6.75pt;text-align:center;text-indent:-9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#i9aaa2fddc97e482da5dbe37ac85ae703_220">PART III</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;padding-right:2.25pt;text-indent:-9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i9aaa2fddc97e482da5dbe37ac85ae703_223">Directors, Executive Officers and Corporate Governance</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i9aaa2fddc97e482da5dbe37ac85ae703_223">124</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i9aaa2fddc97e482da5dbe37ac85ae703_226">Executive Compensation</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i9aaa2fddc97e482da5dbe37ac85ae703_226">124</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;padding-right:2.25pt;text-indent:-9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i9aaa2fddc97e482da5dbe37ac85ae703_229">Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i9aaa2fddc97e482da5dbe37ac85ae703_229">124</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;padding-right:2.25pt;text-indent:-9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i9aaa2fddc97e482da5dbe37ac85ae703_232">Certain Relationships and Related Transactions, and Director Independence</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i9aaa2fddc97e482da5dbe37ac85ae703_232">124</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;padding-right:2.25pt;text-indent:-9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i9aaa2fddc97e482da5dbe37ac85ae703_235">Principal Accounting Fees and Services</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i9aaa2fddc97e482da5dbe37ac85ae703_235">124</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#i9aaa2fddc97e482da5dbe37ac85ae703_238">PART IV</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i9aaa2fddc97e482da5dbe37ac85ae703_211">Exhibits, Financial Statement Schedules</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i9aaa2fddc97e482da5dbe37ac85ae703_211">125</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;padding-right:2.25pt;text-indent:-9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i9aaa2fddc97e482da5dbe37ac85ae703_259">Form 10-K Summary</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i9aaa2fddc97e482da5dbe37ac85ae703_259">129</a></span></div></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt;padding-right:2.25pt;text-indent:-9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i9aaa2fddc97e482da5dbe37ac85ae703_253">Signatures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i9aaa2fddc97e482da5dbe37ac85ae703_253">130</a></span></div></td></tr></table></div><div><span><br/></span></div><div style="height:18pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div></div></div><div id="i9aaa2fddc97e482da5dbe37ac85ae703_13"></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Explanatory Note</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In this Annual Report on 10-K, unless the context otherwise requires, &#8220;Evolent,&#8221; the &#8220;Company,&#8221; &#8220;we,&#8221; &#8220;our&#8221; and &#8220;us&#8221; refer to Evolent Health, Inc. and its consolidated subsidiaries. Evolent Health LLC, a subsidiary of Evolent Health, Inc. through which we conduct our operations, has owned all of our operating assets and substantially all of our business since inception. Evolent Health, Inc. is a holding company.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As used in this Annual Report on Form 10-K:</span></div><div><span><br/></span></div><div style="padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">&#8220;ACA&#8221; means the Patient Protection and Affordable Care Act;</span></div><div style="padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">&#8220;Accordion&#8221; means Accordion Health, Inc.;</span></div><div style="padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">&#8220;accountable care organizations,&#8221; or &#8220;ACOs,&#8221; means organizations of groups of doctors, hospitals and other health care providers which have come together voluntarily to provide coordinated care to their Medicare patients;</span></div><div style="padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">&#8220;Aldera&#8221; means Aldera Holdings, Inc.;</span></div><div style="padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">&#8220;capitated arrangements&#8221; means health care payment arrangements whereby providers are paid a fixed amount of money per patient during a given period of time rather than on a per-service or per-procedure basis;</span></div><div style="padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">&#8220;CMS&#8221; means the Centers for Medicare and Medicaid Services;</span></div><div style="padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">&#8220;DGCL&#8221; means General Corporation Law of the State of Delaware;</span></div><div style="padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">&#8220;EMR&#8221; means electronic medical records;</span></div><div style="padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">&#8220;Evolent Health Holdings&#8221; means Evolent Health Holdings, Inc., the predecessor to Evolent Health, Inc.;</span></div><div style="padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">&#8220;EVH Passport&#8221; means Justify Holdings, Inc., a wholly-owned subsidiary of the Company;</span></div><div style="padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:32.5pt">&#8220;Evolent Care Partners&#8221; means Evolent Care Partners (&#8220;ECP&#8221;), a wholly-owned subsidiary of the Company;</span></div><div style="padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">&#8220;Exchange Act&#8221; means the Securities Exchange Act of 1934, as amended;</span></div><div style="padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">&#8220;founders&#8221; means the Advisory Board Company (&#8220;The Advisory Board&#8221;), and the University of Pittsburgh Medical Center (&#8220;UPMC&#8221;);</span></div><div style="padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">&#8220;FTC&#8221; means the United States Federal Trade Commission;</span></div><div style="padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">&#8220;GAAP&#8221; means United States of America generally accepted accounting principles;</span></div><div style="padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">&#8220;health insurance exchanges&#8221; means organizations that provide a marketplace for individuals to purchase standardized and government regulated health insurance policies;</span></div><div style="padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">&#8220;HIPAA&#8221; means The Health Insurance Portability and Accountability Act;</span></div><div style="padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">&#8220;HITECH Act&#8221; means The Health Information Technology for Economic and Clinical Health Act;</span></div><div style="padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">&#8220;IPO&#8221; means our initial public offering of 13.2 million shares of our Class A common stock at a public offering price of $17.00 per share in June 2015;</span></div><div style="padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">&#8220;New Century Health&#8221; means NCIS Holdings, Inc., a wholly-owned subsidiary of the Company;</span></div><div style="padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">&#8220;NYSE&#8221; means the New York Stock Exchange;</span></div><div style="padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">&#8220;Offering Reorganization&#8221; means the reorganization undertaken in 2015 prior to our IPO where our predecessor, Evolent Health Holdings, Inc. merged with and into Evolent Health, Inc.;</span></div><div style="padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">&#8220;partners&#8221; means our customers, unless we indicate otherwise or the context otherwise implies;</span></div><div style="padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">&#8220;performance-based&#8221; means risk-based contracts with our partners wherein Evolent assumes financial responsibility for the cost of care, which may range from upside and downside gain share to all, or substantially all, of the responsibility for the cost of care within a defined scope subject to Evolent management controls and contractual protections;</span></div><div style="padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">&#8220;pharmacy benefit management,&#8221; or &#8220;PBM,&#8221; means the administration of prescription drug programs, including developing and maintaining a list of medications that are approved to be prescribed, contracting with pharmacies, negotiating discounts and rebates with drug manufacturers and processing prescription drug claim payments;</span></div><div style="padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">&#8220;population health&#8221; means an approach to health care that seeks to improve the health of an entire human population;</span></div><div style="padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">&#8220;SEC&#8221; means the Securities and Exchange Commission;</span></div><div style="padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">&#8220;Securities Act&#8221; means the Securities Act of 1933, as amended;</span></div><div style="padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">&#8220;third-party administration,&#8221; or &#8220;TPA,&#8221; means the processing of insurance claims or the administration of certain aspects of employee benefit plans for a separate entity;</span></div><div style="padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">&#8220;True Health&#8221; means True Health New Mexico, Inc., a previously wholly-owned subsidiary of Evolent Health, Inc.;</span></div><div style="padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">&#8220;TPG&#8221; means TPG Global, LLC and its affiliates including one or both of TPG Growth II BDH, LP and TPG Eagle Holdings, L.P.;</span></div><div style="padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">&#8220;TRA&#8221; means the Income Tax Receivables Agreement. See &#8220;Part II &#8211; Item 8. Financial Statements and Supplementary Data - Note 15&#8221; for further details of the Tax Receivables Agreement;</span></div><div style="padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">&#8220;UHC&#8221; means University Health Care, Inc d/b/a Passport Health Plan;</span></div><div style="padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">&#8220;UR&#8221; means utilization review;</span></div><div style="padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">&#8220;Valence Health&#8221; means Valence Health, Inc., excluding Cicerone Health Solutions, Inc.;</span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">i</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">&#8220;value-based care&#8221; means a health care management strategy that is focused on high-quality and cost-effective care with the goals of promoting a healthy lifestyle, enhancing the patient experience and reducing preventable hospital admissions and emergency visits; </span></div><div style="padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">&#8220;VIE&#8221; means variable interest entities; and</span></div><div style="padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">&#8220;Vital Decisions&#8221; means Vital Decisions, LLC, a wholly-owned subsidiary of the Company.</span></div><div><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ii</span></div></div></div><div id="i9aaa2fddc97e482da5dbe37ac85ae703_2497"></div><hr style="page-break-after:always"/><div style="min-height:18pt;width:100%"><div><span><br/></span></div></div><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">FORWARD-LOOKING STATEMENTS - CAUTIONARY LANGUAGE</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#160;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain statements made in this report and in other written or oral statements made by us or on our behalf are &#8220;forward-looking statements&#8221; within the meaning of the Private Securities Litigation Reform Act of 1995 (&#8220;PSLRA&#8221;).&#160;A forward-looking statement is a statement that is not a historical fact and, without limitation, includes any statement that may predict, forecast, indicate or imply future results, performance or achievements, and may contain words like:&#160;&#8220;believe,&#8221; &#8220;anticipate,&#8221; &#8220;expect,&#8221; &#8220;estimate,&#8221; &#8220;aim,&#8221; &#8220;predict,&#8221; &#8220;potential,&#8221; &#8220;continue,&#8221; &#8220;plan,&#8221; &#8220;project,&#8221; &#8220;will,&#8221; &#8220;should,&#8221; &#8220;shall,&#8221; &#8220;may,&#8221; &#8220;might&#8221; and other words or phrases with similar meaning in connection with a discussion of future operating or financial performance.&#160;In particular, these include statements relating to future actions, trends in our businesses, prospective services, future performance or financial results and the closing of pending transactions and the outcome of contingencies, such as legal proceedings.&#160;We claim the protection afforded by the safe harbor for forward-looking statements provided by the PSLRA.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These statements are only predictions based on our current expectations and projections about future events. Forward-looking statements involve risks and uncertainties that may cause actual results, level of activity, performance or achievements to differ materially from the results contained in the forward-looking statements.&#160;Risks and uncertainties that may cause actual results to vary materially, some of which are described within the forward-looking statements, include, among others:</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the significant portion of revenue we derive from our largest partners, and the potential loss, non-renewal, termination or renegotiation of our relationship or contract with any significant partner, or multiple partners in the aggregate;</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">evolution in the market for value-based care;</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">uncertainty in the health care regulatory framework, including the potential impact of policy changes;</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">our ability to offer new and innovative products and services;</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">risks related to completed and future acquisitions, investments, alliances and joint ventures, divert management resources, or result in unanticipated costs or dilute our stockholders;</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the financial benefits we expect to receive as a result of the sale of certain assets of Passport may not be realized;</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the growth and success of our partners, which is difficult to predict and is subject to factors outside of our control, including governmental funding reductions and other policy changes, enrollment numbers for our partners&#8217; plans, premium pricing reductions, selection bias in at-risk membership and the ability to control and, if necessary, reduce health care costs;</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">risks relating to our ability to maintain profitability for our total cost of care and New Century Health&#8217;s performance-based contracts and products, including capitation and risk-bearing contracts;</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">our ability to effectively manage our growth and maintain an efficient cost structure, and to successfully implement cost cutting measures;</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the potential negative impact of the COVID-19 pandemic and other public health emergencies;</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">our ability to recover the significant upfront costs in our partner relationships;</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">our ability to attract new partners and successfully capture new growth opportunities;</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the increasing number of risk-sharing arrangements we enter into with our partners;</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">our ability to estimate the size of our target markets;</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">our ability to maintain and enhance our reputation and brand recognition;</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">consolidation in the health care industry;</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">competition which could limit our ability to maintain or expand market share within our industry;</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">risks related to governmental payer audits and actions, including whistleblower claims;</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">our ability to partner with providers due to exclusivity provisions in our contracts;</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">risks related to our offshore operations;</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">our ability to contain health care costs, implement increases in premium rates on a timely basis, maintain adequate reserves for policy benefits or maintain cost effective provider agreements;</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">our dependency on our key personnel, and our ability to attract, hire, integrate and retain key personnel;</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the impact of additional goodwill and intangible asset impairments on our results of operations;</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">our indebtedness, our ability to service our indebtedness, and our ability to obtain additional financing;</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">our ability to achieve profitability in the future;</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the impact of litigation, including the ongoing class action lawsuit;</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">material weaknesses in the future may impact our ability to conclude that our internal control over financial reporting is not effective and we may be unable to produce timely and accurate financial statements;</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">restrictions and penalties as a result of privacy and data protection laws;</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">data loss or corruption due to failures or errors in our systems and service disruptions at our data centers;</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">restrictions and penalties as a result of privacy and data protection laws;</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">adequate protection of our intellectual property, including trademarks;</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">any alleged infringement, misappropriation or violation of third-party proprietary rights;</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">our use of &#8220;open source&#8221; software;</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">our ability to protect the confidentiality of our trade secrets, know-how and other proprietary information;</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">our reliance on third parties and licensed technologies;</span></div><div style="height:18pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">iii</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:18pt;width:100%"><div><span><br/></span></div></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">our ability to use, disclose, de-identify or license data and to integrate third-party technologies;</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">our reliance on Internet infrastructure, bandwidth providers, data center providers, other third parties and our own systems for providing services to our partners;</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">our reliance on third-party vendors to host and maintain our technology platform;</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">our obligations to make payments to certain of our pre-IPO investors for certain tax benefits we may claim in the future;</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">our ability to utilize benefits under the tax receivables agreement described herein;</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">our obligations to make payments under the tax receivables agreement that may be accelerated or may exceed the tax benefits we realize;</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the terms of agreements between us and certain of our pre-IPO investors;</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the conditional conversion features of the 2024 and 2025 convertible notes, which, if triggered, could require us to settle the 2024 or 2025 convertible notes in cash;</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the impact of the accounting method for convertible debt securities that may be settled in cash;</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the potential volatility of our Class A common stock price;</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the potential impact of our securities class action litigation;</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the potential decline of our Class A common stock price if a substantial number of shares are sold or become available for sale;</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">provisions in our second amended and restated certificate of incorporation and third amended and restated by-laws and provisions of Delaware law that discourage or prevent strategic transactions, including a takeover of us;</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the ability of certain of our investors to compete with us without restrictions;</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">provisions in our second amended and restated certificate of incorporation which could limit our stockholders&#8217; ability to obtain a favorable judicial forum for disputes with us or our directors, officers or employees; and</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">our intention not to pay cash dividends on our Class A common stock.</span></div><div style="padding-left:18pt;text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The risks included here are not exhaustive. Although we believe the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, level of activity, performance or achievements. More information on potential factors that could affect our businesses and financial performance is included in &#8220;Forward Looking Statements - Cautionary Language,&#8221; &#8220;Risk Factors&#8221; and &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; or similarly captioned sections of this Annual Report and the other period and current filings we make from time to time with the SEC. Moreover, we operate in a rapidly changing and competitive environment. New risk factors emerge from time to time, and it is not possible for management to predict all such risk factors.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further, it is not possible to assess the effect of all risk factors on our businesses or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements. Given these risks and uncertainties, investors should not place undue reliance on forward-looking statements as a prediction of actual results. In addition, we undertake no obligation to publicly update any forward-looking statements to reflect events or circumstances that occur after the date of this report.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Market Data and Industry Forecasts and Projections</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We use market data and industry forecasts and projections throughout this Annual Report on Form 10-K, and in particular in &#8220;Part I - Item 1. - Business.&#8221; We have obtained the market data from certain publicly available sources of information, including publicly available independent industry publications and other third-party sources. Unless otherwise indicated, statements in this Annual Report on Form 10-K concerning our industry and the markets in which we operate, including our general expectations and competitive position, business opportunity and market size, growth and share, are based on information from independent industry organizations and other third-party sources (including industry publications, surveys and forecasts), data from our internal research and management estimates. We believe the data that third parties have compiled is reliable, but we have not independently verified the accuracy of this information and there is no assurance that any of the forecasted amounts will be achieved. Any forecasts are based on data (including third-party data), models and experience of various professionals and are based on various assumptions, all of which are subject to change without notice. While we are not aware of any misstatements regarding the industry data presented herein, forecasts, assumptions, expectations, beliefs, estimates and projections involve risks and uncertainties and are subject to change based on various factors, including those described under the heading &#8220;Forward-Looking Statements - Cautionary Language&#8221; and in &#8220;Part I - Item 1A. Risk Factors.&#8221;</span></div><div style="height:18pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">iv</span></div></div></div><div id="i9aaa2fddc97e482da5dbe37ac85ae703_16"></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART I - FINANCIAL INFORMATION</span></div><div><span><br/></span></div><div id="i9aaa2fddc97e482da5dbe37ac85ae703_250"></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 1.  Business</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Market Opportunity</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a market leader in the new era of value-based care, in which leading health systems and physician organizations, which we refer to as providers, as well as health plans, which we refer to as payers, are moving their business models from traditional fee-for-service (&#8220;FFS&#8221;) reimbursement to an increasingly integrated clinical and financial responsibility for populations. We refer to our provider and payer customers as partners. We consider this integration of health care delivery and financial responsibility with the aim of lowering cost, enhancing quality, and improving satisfaction, to be the core of value-based care. We believe the pace of this integration is accelerating, driven by price pressure in traditional FFS health care, a market environment that is incentivizing value-based care models, growth in consumer-focused insurance programs, such as Medicare Advantage and innovation in data and technology.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The U.S. health care market was $4.1 trillion in spending during 2020, with approximately 20% of payments tied to performance or value-based care models. We believe the shift to value-based care is accelerating, driven by price pressure in traditional FFS health care, a policy and market environment that is incentivizing value-based care models and innovation in data and technology. We believe that the transition to value-based care is impacting the business models of both providers and payers in all segments of the market, including Medicare, Medicaid, and Commercial lines of business.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We believe there is a significant opportunity to improve the cost and quality of care by realigning the business between payers and providers. Providers are well-positioned to lead this transition to value-based care because of their control over large portions of health care delivery costs, their primary position with consumers, and their strong local brands. Providers operating successfully in value-based arrangements can diversify their revenue streams, capture superior economics, and improve the quality of care they provide.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also believe payers who successfully evolve their business model from that of FFS reimbursement towards value-based care can gain meaningful competitive advantages. Payers who successfully integrate care delivery and financing with providers stand to gain market advantage as medical expenses for their populations are lowered while quality of care is also improved. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The transformation of provider and payer business models from FFS to value-based care requires infrastructure that performs two functions: (i) the ability to create clinical value, which is typically defined as lowering the cost of care while maintaining or improving quality, that is superior to FFS, and (ii) an administrative platform on which to operate the value-based business. In addition to this infrastructure, we believe that participants in value-based arrangements also need sustainable contractual mechanisms to enable each party to capture clinical value that is created and sufficient lives in value-based arrangements to provide a return on infrastructure investments. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Our Business</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Our History</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Evolent was founded in 2011 by members of our management team, UPMC, an integrated delivery system in Pittsburgh, Pennsylvania, and The Advisory Board Company, to enable providers to pursue a value-based business model and evolve their competitive position and market opportunity. Since that time, we have grown both organically and through acquisitions. On February 1, 2016, the Company entered into a strategic alliance with UHC. In October 2016, we acquired Valence Health. Valence Health, based in Chicago, Illinois, was founded in 1996 and provides TPA services, value-based administration, population health and advisory services with a particular focus on the Medicaid and pediatric markets. On November 1, 2016, the Company completed the acquisition of Aldera, a key vendor and the primary software provider for the Valence Health TPA platform. In January 2018, we acquired a commercial health plan in New Mexico that focuses on small and large businesses, True Health. In October 2018, we acquired New Century Health, a national population health leader in managing specialty care for Medicare, commercial and Medicaid members under performance-based arrangements, focused primarily on oncology and cardiovascular care. In October 2021, we acquired Vital Decisions, a leading provider of technology-enabled advance care planning services.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 11, 2021, Evolent Health LLC, EH Holdings and True Health, each wholly owned subsidiaries of the Company, entered into a Stock Purchase Agreement (the &#8220;True Health SPA&#8221;) with Bright Health Management, Inc. (&#8220;Bright HealthCare&#8221;), pursuant to which EH Holdings agreed to sell all of its equity interests in True Health to Bright HealthCare. Closing of the transactions contemplated by the True Health SPA occurred on March 31, 2021 (the &#8220;True Health Closing&#8221;) and the Company has had no continuing involvement with True Health subsequent to the closing except a pre-existing services agreement for claims processing and other health plan administrative functions.</span></div><div style="text-align:justify"><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of the first quarter of 2021, the Company determined that True Health met the discontinued operations criteria and as such, True Health assets and liabilities as of December 31, 2020, and the results of operations for the years ended December 31, 2021, 2020 and 2019 are not included in continuing operations in the consolidated financial statements.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company made organizational changes, including re-evaluating its reportable segments, as a result of the entry into the agreement to sell True Health on January 11, 2021. Effective during the first quarter of 2021, the Company manages its operations and allocates resources across two reportable segments as follows:</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">Evolent Health Services, which houses our administrative simplification solution and certain supporting population health infrastructure; and</span></div><div style="padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:32.5pt">Clinical Solutions, which includes our specialty care management and physician-oriented total cost of care solutions, along with the New Century Health, Vital Decisions and Evolent Care Partners brands. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Evolent Health Services Overview</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Evolent Health Services segment includes our integrated value based care platform designed to help our customers manage and administer patient health in a more cost-effective manner. Upon the acquisitions in 2016 of Valence Health and Aldera, we have invested to upgrade the platform and integrate it with Identifi</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and our clinical solutions to create an integrated value-based care platform.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our comprehensive health plan administration services help regional and national payers and providers assemble the infrastructure required to operate, manage and capitalize on a variety of financial and administrative management services, such as health plan services, risk management, analytics and reporting and leadership and management. The economic model of this solution is primarily fee-based with defined service-level agreements around key operating metrics. The services provided by Evolent Health Services include:</span></div><div style="padding-left:18pt;text-align:justify"><span><br/></span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:32.5pt">Health plan services</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: Health plan services is a comprehensive suite of services including third-party administration, enrollment and billing support, medical and utilization management, third-party payment and program integrity support and provider network contracting services. Other health plan related services include sales and marketing, product development, actuarial, and regulatory and compliance.</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:32.5pt">Pharmacy benefit management</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our team of professionals support the prescription drug component of providers&#8217; plan offerings and bring national buying power and dedicated resources that are tightly integrated with the care delivery model. Differentiated from what we consider to be traditional PBMs, our solution is integrated into patient care and engages population health levers including generic utilization, provider management, and utilization management to reduce pharmacy costs.</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:32.5pt">Risk management</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Our risk management services provide the capabilities needed to successfully manage risk for payers, including analysis, data and operational integration with payer processes, and ongoing performance management.</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:32.5pt">Analytics and reporting</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: Our analytics and reporting services provide the ongoing and ad hoc analytic teams and reports required to measure, inform and improve performance, including population health analytics, market analytics, network evaluation, staffing models, physician effectiveness, clinical delivery optimization and patient engagement.</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:32.5pt">Leadership and management</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: Our local and national talent assist our partners in effectively managing the performance of their value-based operations.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Identifi</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> is our proprietary technology system that aggregates and analyzes data, manages care workflows and engages patients. Identifi</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> links our processes with those of our partners and other third parties to create a connected clinical delivery ecosystem, stratify patient populations, standardize clinical work flows and enable high-quality, cost-effective care. The configurable nature and broad capabilities of Identifi&#174; help enhance the benefits our partners receive from our services and increase the effectiveness of our partners&#8217; existing technology architecture. Highlights of the capabilities of Identifi</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> include the following:</span></div><div style="padding-left:36pt;text-align:justify"><span><br/></span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:32.5pt">Data and integration services: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Data from disparate sources, such as EMRs, and lab and pharmacy data, is collected, assembled, integrated and maintained to provide health care professionals with a holistic view of the patient.</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:32.5pt">Clinical and business content: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Clinical and business content is applied to the integrated data to create actionable information to optimize clinical and financial performance.</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:32.5pt">EMR integration: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Data and clinical insights from Identifi&#174; are fed back into partner EMRs to improve both provider and patient satisfaction, create workflow efficiencies, promote clinical documentation and coding and provide clinical support at the point-of-care.</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:32.5pt">Applications: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A suite of cloud-based applications manages the clinical, financial and operational aspects of the value-based model. Our applications scale with the clinical, financial and administrative needs of our provider </span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="padding-left:72pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">partners. As additional capabilities are required by our partners, they are often deployed as applications through Identifi&#174;.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Clinical Solutions</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Clinical Solutions segment has two primary solutions: (i) specialty care management services, and (ii) total cost of care management. From time to time, we package our solutions under various go-to-market brand names to create product differentiation. Our partners may engage us to provide one type of solution, or multiple types of solutions, depending on specific needs.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Core elements of our total cost of care management services include: (i) population health performance, which supports the delivery of patient-centric cost effective care and (ii) delivery network alignment, comprising the development of high performance delivery networks. Our total cost of care solution focuses on primary care providers, who serve as the primary point of contact for populations accessing medical care.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our specialty care management services support a broad range of specialty care delivery stakeholders during their transition from fee-for-service to value-based care, independent of their stage of maturation and specific market dynamics. We focus on the oncology and cardiology markets with the objective of helping providers and payers deliver higher quality, more affordable care and we provide comprehensive quality management for oncology and cardiology patients from diagnosis through advance care planning services.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Specialty Care Management Services Solution</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The foundation for our specialty care management services solution was derived through our acquisition in 2018 of New Century Health, a national population health leader in managing specialty care for Medicare, commercial and Medicaid members under performance-based and technology and services arrangements. Since then, we have continued to invest in the solution to broaden, deepen, and scale its capabilities. We have invested in internal capabilities as well as the acquisition of assets that expand our ability to provide more value for our clients and align with the evolution of our strategic approach to Clinical Solutions. For example, on October 1, 2021, we completed the acquisition of Vital Decisions, a leading provider of technology-enabled advance care planning services. The addition of Vital Decisions' specialized patient engagement services is intended to help enhance our solutions impact within our specialty care management services solution by improving patient care quality and by adding capabilities in patient engagement, telehealth and end-of-life management. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since its founding in 2002, New Century Health has focused on the oncology and cardiology markets, which are the two largest specialties in Medicare Advantage by total expenditures. Using clinical data analytics, predictive modeling and decision support tools, New Century Health has developed proprietary clinical pathways in these markets. Managed through its proprietary specialty care management platform, New Century Health combines high performance networks of specialists and enhanced clinical pathways to deliver higher quality and more affordable care, which we consider to be hallmarks of value-based care, to patients, providers and payers. Historically, New Century Health focused on the Medicare market and offered performance-based contracts, as well as technology and services arrangements, primarily to payers in the Medicare HMO segment of the overall Medicare market. More recently, New Century Health has entered into performance-based contracts with Medicaid health plans. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">New Century Health provides a differentiated approach designed to meet market challenges based on (i) networks of high-performance providers, (ii) design of evidence-based clinical pathways and (iii) leveraging our proprietary specialty care management technology.</span></div><div style="padding-left:54pt;text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(i)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:8.57pt;text-decoration:underline">High performance provider networks</span></div><div style="padding-left:36pt;text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We develop high-performance provider networks with tools, capabilities and incentives to align and support physicians. We develop and manage comprehensive specialty networks, provide physician engagement and support and identify provider financial incentive alignment. Key features include:</span></div><div style="padding-left:36pt;text-align:justify"><span><br/></span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:32.5pt">Direct contracts with specialists </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">facilitate ease of care.</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:32.5pt">Comprehensive specialty networks</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> include multiple downstream subspecialists.</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:32.5pt">Incentivizes financial payment</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for quality and cost efficient utilization.</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:32.5pt">Minimizes &#8220;buy and bill&#8221; incentives</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> through shared savings methodologies.</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:32.5pt">Dedicated provider operations</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> provide staff to support practices.</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:32.5pt">Clinical response team</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> provides clinical education on-site to practice staff.</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:32.5pt">Dedicated central call center</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> facilitates referrals and helps to resolve claims issues.</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:32.5pt">Provides established system</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of ongoing provider education and training.</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:32.5pt">Increases the frequency of utilization and value</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of advance care planning.</span></div><div style="text-align:justify;text-indent:-18pt"><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">(ii)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.8pt;text-decoration:underline">Design evidence-based clinical pathways</span></div><div style="padding-left:18pt;text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We design high-quality evidence-based clinical pathways to drive provider behavior towards improved quality of care at a lower cost. The transparent pathway development process for our specialty population health focal areas, oncology and cardiology, is designed to achieve the following objectives:</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:32.5pt">Reduce</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> unnecessary clinical variation.</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:32.5pt">Support</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> physician clinical decision making of evidence-based therapies.</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:32.5pt">Increase</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> patient engagement.</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:32.5pt">Facilitate</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> total cost-of-care management.</span></div><div style="padding-left:18pt;text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our clinical pathways are based on national guidelines with independent scientific advisory boards, in-house clinical expertise with original publications and presentations at national congress. We employ a collaborative review process that is not based on denials, which includes customized clinical review based on tier 1-5 drugs and proactive monitoring response to therapy. We employ quality metrics and clinical benchmarking to continually improve our pathways. We incentivize financial payment for quality by minimizing &#8220;buy and bill&#8221; incentives and through a shared savings methodology.</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(iii)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:3.03pt;text-decoration:underline">Leverage proprietary specialty care management technology</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We leverage a custom specialty care management workflow platform, CarePro</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">TM</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to provide clinical decision support and manage providers to high-quality care, while aiming to achieve significant cost savings. Our technology consists of a clinical decision support portal that provides oversight of individual treatment plans for pathway adherence. Our platform integrates clinical analytics and protocols, pharmacy management, physician engagement, network management and claims payment to drive improved outcomes for partners. Key attributes include:</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:32.5pt">Decision support portal</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> delivers specialty specific clinical experience based on assigned roles (e.g., cardiologist vs. oncologist).</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:32.5pt">Custom-built rules engine</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> allows flexibility for multiple specialties and automated decisions based on clinical relevance, considering, for example, rigor levels based on specified payers and providers.</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:32.5pt">Workflow capability</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> facilitates a seamless collaboration within and across organizations, connecting payers and clearing houses for systematic data exchange.</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:32.5pt">Nurse triage</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">system</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> leverages proprietary technology infrastructure.</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:32.5pt">Overall flexibility</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> enables a new business launch of existing specialty within 60 days.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total Cost of Care Management Solution</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our total cost of care management solution was developed based on the intellectual property contributions of UPMC at our founding. Since then, we have continued to invest in the solution to broaden, deepen and scale its capabilities.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our total cost of care management solution enables providers to manage populations they may be accountable for under value-based contracts with payers or ACO contracts with CMS. This solution seeks to reduce the total cost of care for a given population by identifying and managing high-cost patients with targeted interventions managed and coordinated through primary care physicians. The economic model of our total cost of care management solution is primarily performance-based, which we believe enhances our ability to influence provider behavior by aligning our incentives with our partners. We use, and may continue to use, different go-to-market brand names for various solution packages, depending on the markets we seek to address. These go-to-market brand names include: (i) Value Based Services, wherein we support primarily health systems in their value-based operations, and (ii) Evolent Care Partners, wherein we offer physicians the opportunity to join Evolent&#8217;s proprietary payer contracting vehicles, scaled risk pools, and operating model. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We refer to the offerings within this solution as value-based care services. Core elements of our value-based care services include: (i) population health performance, which supports the delivery of patient-centric cost effective care and (ii) delivery network alignment, comprising the development of high performance delivery networks. We integrate change management processes and ongoing physician-led transformation into all value-based services to build engagement, integration and alignment within our partners to successfully deliver value-based care and sustain performance. We have standardized the processes described below and are able to leverage our expertise across our partner base. Through the technological and clinical integration we achieve, our solutions are delivered as engrained components of our partners&#8217; core operations rather than as add-on solutions.</span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="padding-left:36pt;text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(i)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:8.57pt;text-decoration:underline">Population Health Performance</span></div><div style="padding-left:36pt;text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Population Health Performance is an integrated suite of technology-enabled solutions that supports the delivery of quality care in an environment where a provider&#8217;s need to manage health has significantly expanded. These solutions include:</span></div><div style="padding-left:36pt;text-align:justify"><span><br/></span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:32.5pt">Clinical programs</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: Care processes and ongoing clinical innovation that enables providers to target the right intervention at the right time for a given patient.</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:32.5pt">Specialized care team</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: Multi-disciplinary team that is deployed telephonically from a centralized location or throughout a local market to operate clinical programs, engage patients and support physicians.</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:32.5pt">Patient engagement</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: Integrated technologies and processes that enable outreach to engage patients in their own care process.</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:32.5pt">Quality and risk coding</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: Engagement of physicians to identify opportunities to close gaps in care and improve clinical documentation efforts.</span></div><div style="padding-left:36pt;text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(ii)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.8pt;text-decoration:underline">Delivery Network Alignment</span></div><div style="padding-left:36pt;text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We help our partners build the capabilities that are required to develop and maintain a coordinated and financially-aligned provider network that can deliver high-quality care necessary for value-based contracts. These capabilities include:</span></div><div style="padding-left:36pt;text-align:justify"><span><br/></span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:32.5pt">High-performance network</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: Supporting the capabilities needed to build, maintain and optimize provider- and clinically-integrated networks.</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:32.5pt">Value compensation models</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: Developing and supporting physician incentive payment programs that are linked to quality outcomes, payer shared savings arrangements and health plan performance.</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:32.5pt">Integrated specialty partnerships</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: Supporting the technology-enabled strategies, analytics and staff needed to optimize network referral patterns.</span></div><div style="padding-left:18pt;text-align:justify"><span><br/></span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Sources of Revenue</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The majority of our revenue is derived from recurring multi-year contracts, which we refer to as platform and operations. Platform and operations services accounted for 98.8%, 98.7% and 97.8% of our consolidated revenue for the years ended December 31, 2021, 2020 and 2019, respectively. We believe the recurring, multi-year nature of our platform and operations contracts enables us to have strong visibility into future revenue. The amount of revenue in a given platform and operations contract is typically driven by: (i) the number of members that Evolent is contracted to manage, (ii) the population types being served (e.g., Medicare, Medicaid, Commercial), and (iii) the depth and breadth of the services and technology applications that our partners utilize from us. In situations involving clinical solutions, we typically elect to: (iv) participate alongside or co-own risk-sharing arrangements with our partners whereby we share in a portion of the upside and downside clinical performance, or by owning a portion of the underwriting results through capitation. We believe performance-based contracts align our partners&#8217; incentives with our own and enables us to capture greater value from our contracts. We believe we are in the early stages of capitalizing on these aligned operating partnerships. We believe the current value-based care arrangements of our payer and provider partners represent a relatively small portion of their overall total opportunity.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our business model benefits from scale, as we leverage our purpose-built technology-enabled solutions and centralized resources in conjunction with the growth of our partners&#8217; membership base. While our absolute investment in our centralized resources and technologies may increase over time, we expect it will decrease as a percentage of revenue as we are able to scale this investment across a broader group of partners. We expect to grow with current partners as they increase membership in their existing operations, through expanding the number of services we provide to our existing partners, by adding new partners and by capturing value through risk-sharing arrangements.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The other portion of our revenue, which we call transformation, is typically composed of implementation services associated with our recurring revenue relationships. Due to the nature of recurring multi-year contracts, as we have added additional partners, transformation revenue has decreased to approximately 1% of total revenues for the year ended December 31, 2021. </span></div><div style="padding-left:36pt;text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Significant Activities</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 2, 2021, Evolent Health LLC and EV Thunder Merger Sub, LLC, each wholly owned subsidiaries of the Company, and the Company entered into a definitive agreement for the Company to acquire Vital Decisions. On October 1, 2021, we consummated the acquisition of Vital Decisions for $46.5 million in cash and the issuance of 1.8 million shares of Class A common stock. Vital Decisions reports into Evolent&#8217;s specialty care management offering, New Century Health, and is consolidated into the Company&#8217;s Clinical Solutions segment. </span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Competitive Strengths</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe we are well-positioned to benefit from the transformations occurring in health care payment and delivery described above. We believe this environment that rewards the better use of information to drive patient outcomes aligns with our business model, recent investments and other competitive strengths.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Early Innovator</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe we are an innovator in the delivery of comprehensive value-based care solutions. We were founded in 2011, ahead of the implementation of the ACA and before the rapid expansion of programs, such as Medicare ACOs or Medicare Bundled Payment Initiatives. Since our inception, we have invested a significant amount in expanding our offerings.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Differentiated Offering in High Cost Oncology and Cardiology Markets</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Cardiovascular disease and cancer accounted for approximately 15% of total U.S. health expenditures in 2016 to 2017. One of the major cost drivers is spending on oncology drugs which rose 60% from $45 billion in 2016 to $72 billion in 2020. We offer a comprehensive performance based solution that we believe delivers meaningful savings to customers relative to historical spend while at the same time improving the quality of care. Our specialty care management solution covered approximately 18.4 million lives in Medicare, Medicaid and Commercial markets through our Performance suite and New Century Health Technology and Services suite as of December&#160;31, 2021 and we believe our solution is one of the most comprehensive in the market today.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Comprehensive End-to-End Solutions</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We provide end-to-end, built-for-purpose, technology-enabled solutions for our partners to succeed in value-based payment models. We believe that offering comprehensive and integrated solutions which bring together clinical and administrative management allows payers and providers to accelerate their path to adoption of value-based care.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Depth of Market Experience</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">With experience across Medicare, Medicaid and commercial markets, our depth and variety of expertise allows us to serve a variety of customer types in the broad health care marketplace including health systems, providers, physicians, health plans, ACOs, delegated arrangements and other payers.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Proprietary Technology</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our integrated proprietary technology, Identifi&#174;, allows us to deliver a connected delivery ecosystem, implement replicable clinical processes, scale our value-based services and capitalize on multiple types of value-based payment relationships.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We leverage a custom specialty care management workflow platform, CarePro</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">TM</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">, to provide clinical decision support and manage providers to high-quality care, while aiming to achieve significant cost savings. Our technology consists of a clinical decision support portal that provides oversight of individual treatment plans for pathway adherence. Our platform integrates clinical analytics and protocols, pharmacy management, physician engagement, network management and claims payment to drive improved outcomes for partners.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We believe we are creating scaled benefits for our partners in areas such as data analytics, administrative services and care management. We expect Identifi&#174; and CarePro</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">TM</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> to enable us to deliver increasing levels of efficiency to our partners.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Provider-Heritage Brand Identity</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We believe our provider-heritage brand identity and origins differentiate us from our competitors in the value-based care services area. We believe our solutions resonate with potential partners seeking proven solutions that work with providers in a manner that attempts to minimize friction and foster a care team approach. Our analytical and clinical solutions are rooted in UPMC&#8217;s experience in growing a provider-led, integrated delivery network over the 15-years prior to the founding of Evolent Health, Inc., and growing to become one of the largest provider-owned health plans in the country. Our unique position allows for the sharing of data across multiple payers and care delivery integration regardless of payer, which we believe is not possible with traditional, payer-siloed solutions.</span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Partnership-Driven Business Model</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our business model is predicated on strategic partnerships with leading providers and payers that are attempting to evolve two of their most critical business functions: how they deliver care and how they are compensated for it. The partnership model enables cultural alignment, integration into the provider care delivery and payment work-flow, contractual relationships and a cycle of clinical and cost improvement with shared financial benefit. In certain cases, we also agree to participate alongside our partners in risk-sharing or other support arrangements to increase our alignment of interests via performance-based relationships.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Proven Leadership Team</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have made a significant investment in building an industry-leading management team. Our senior leadership team has extensive experience in the health care industry and a track record of delivering measurable clinical, financial and operational improvement for health care providers and payers. Our Chief Executive Officer, Seth Blackley, had served as our President since August 2011. Prior to co-founding the company, Mr. Blackley was the Executive Director of Corporate Development and Strategic Planning at The Advisory Board from June 2007 to August 2011.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Growth Opportunities</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Multiple Avenues for Growth with Our Existing, Embedded Partner Base</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have established a multi-year partnership model with multiple drivers of embedded growth through the following avenues:</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">growth in lives in existing covered populations;</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">partners expanding into new lines of value-based care to capture growth in new profit pools; </span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">cross-selling additional solutions to existing partners; and</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">capturing value created through a variety of value-based arrangements by participating alongside our partners in upside risk sharing arrangements. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Early Stages of a Rapidly Growing Transformational Addressable Market</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe that our existing partners represent a small fraction of providers and payers that could benefit from our solutions. The transformation of the care delivery and payment model in the United States has been rapid, but it is still in the early stages. Approximately 20% of health care payments were paid through performance or value-based care programs in 2020 and it is estimated that this number will continue to grow.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe there is significant market opportunity in our total cost of care solution. As of December&#160;31, 2021, our solution served less than 1% of the Medicare Shared Savings Program ACO-assignable population. Furthermore, we believe that populations covered by CMS ACOs will continue to grow, and also that the solution will be relevant to private payer value-based arrangements. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe there is a significant market opportunity in our specialty care management services solution. As of December&#160;31, 2021, New Century Health served approximately 1.4 million Medicaid Managed Care and Medicare HMO patients out of total population of approximately 70 million. This represents a market share of roughly 2% of this total population. We believe that the adoption of this solution in oncology and cardiology by payers serving the Medicare HMO market is very low but is likely to increase as the growth in spending in these specialties is higher than the growth in overall health care spending. Furthermore, we believe that our specialty care management solution is scalable to Medicaid and other lines of business.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Capitalize on Growth in Select Government-Driven Programs</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The number of people managed by government-driven programs in the United States has seen significant growth since 2016. Specifically, the number of Medicare beneficiaries reached 62 million in 2021, an 11% increase from 2016. The nature of our variable fee economic model enables us to benefit from this growth in government-managed lives. A significant portion of our revenues are attributable to government-driven programs, primarily comprised of Medicaid and, to a less significant extent, Medicare.</span></div><div style="text-align:justify"><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Ability to Capture Additional Value through Delivering Clinical Results</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We are capturing only a portion of the addressable clinical and administrative dollars in the market through our current solutions. We believe there is a significant opportunity to capture an increasing portion of the medical dollar over time, namely the remainder of the premium dollar which goes to medical expenses, and we have begun to do so in certain performance-based relationships. We believe business models that allow us to participate in the medical savings through a variety of risk-sharing arrangements that align incentives to reduce costs and improve quality outcomes will enable us to grow and differentiate ourselves from other vendors. We anticipate the manner with which we partner and share in risk with health care providers will likely continue to evolve over time given the still nascent and fragmented nature of value-based care.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Expand Offerings to Meet Evolving Market Needs</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There are multiple business offerings that our partners may require to operate in a value-based care environment that we do not currently provide, including but not limited to:</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">physician employment;</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">PBM expansion to include additional specialty pharmacy management capabilities;</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">additional specialty lines of business beyond oncology and cardiology, including kidney, musculoskeletal and fetal-maternal medicine care;</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">on-site or specialty clinic services; and</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">consumer engagement and digital outreach.</span></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Selectively Pursue Strategic Acquisitions and Investments</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe that the nature of our competitive landscape provides meaningful acquisition and investment opportunities. Our industry is in the early stages of its life cycle and there are multiple firms attempting to capitalize on the transformation of the care delivery model and the various forms of new profit pools. We believe that our partners will require an end-to-end solution and we believe we are well positioned to meet this demand by expanding the breadth of our offerings through not only organic growth, but also the acquisition of niche vendors and non-core portions of larger enterprises. From time to time, we may also pursue acquisition and investment opportunities of businesses related to services we currently provide or that are complementary to our technical capabilities. As an example of executing on our strategy, on October 1, 2021, we completed the acquisition of Vital Decisions, a leading provider of technology-enabled advance care planning services. The acquisition of Vital Decisions is expected to deepen capabilities of both organizations, allowing cross-sell, an enhanced value proposition to partners and an opportunity to increase the margin profile of the combined organization.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Sales and Marketing</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We market and sell our services to payers and providers throughout the United States. Our sales team works closely with our leadership team and subject matter experts to foster long-term relationships with our partners&#8217; leadership and board of directors given the nature of our partnerships. Our dedicated business development team works closely with our partners to identify additional service opportunities on a continuous basis.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Partner Relationships</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our business is predicated on strategic partnerships with leading payers and providers that are attempting to evolve two of their most critical business functions: how they deliver care and how they are compensated for it. The partnership model enables cultural alignment, integration into the care delivery and payment work flow, contractual relationships and a cycle of clinical and cost improvement with shared financial benefit.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have sought to partner with leading payers and providers in sizable markets, which we believe creates a growth cycle that benefits from the secular transition to value-based care.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2021, we had contractual relationships with 44 operating partners. We define an operating partner as an individual health plan or provider entity under contract with the Company based on a specific state-level geography and whether a relationship is based on fees for covered lives or capitation per life under management. Certain of our partners operate in a local and highly decentralized manner, requiring negotiation and contracting at a local level to expand into new arrangements and thus may be considered multiple entities under this definition, depending on partner business requirements.</span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes those partners who represented at least 10.0% of our consolidated revenue for the years ended December 31, 2021, 2020 or 2019:</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"></td><td style="width:380.50pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:48.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:48.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:48.25pt"></td><td style="width:1.0pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Year Ended December 31,</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cook County Health and Hospitals Systems </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Florida Blue Medicare, Inc. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">N/A</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Passport </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(4)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">New Mexico Health Connections</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt">The denominator excludes $44.8&#160;million, $117.4&#160;million and $171.7&#160;million of True Health premium revenue reclassified to discontinued operations for the years ended December 31, 2021, 2020 and 2019, respectively.</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt">Cook County Health and Hospital Systems utilizes both our administrative simplification solutions provided by Evolent Health Services, which accounted for 9.0% of our consolidated revenue for the year ended December 31, 2021 and our specialty care management solutions provided by New Century Health which accounted for 19.0% of our consolidated revenue for the year ended December 31, 2021. </span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt">Customer added during the year ended December 31, 2021. Florida Blue Medicare, Inc. utilizes our specialty care management solutions provided by New Century Health.</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(4)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt">Represents revenues from EVH Passport/UHC through the Molina Closing. Subsequent to the Molina Closing on September 1, 2020, the Company has not received any material revenue from EVH Passport. However, as part of the Molina Closing, we entered into a new contract with Molina on similar terms to our prior services contract with EVH Passport through December 31, 2020 which accounted for approximately 9.7% of our consolidated revenues for the year ended December 31, 2020.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">* &#160;&#160;&#160;&#160;Represents less than 10.0% of the respective balance</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2021, our average contractual relationship with our operating partners was approximately 5.2 years, with an average of 0.8 years of performance remaining per contract. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our contracts governing the relationships with our operating partners include key terms which may include the period of performance, revenue rates, advanced billing terms, service level agreements, termination clauses, exclusivity clauses and right of first refusal clauses. Typically, these contracts provide for a monthly payment calculated based on a specified rate multiplied by the number of members that our partners are managing. The specified rate varies depending on which market-facing solutions the partner has adopted and the number of services and technology applications they are utilizing. In some cases, we are responsible for paying for all, or substantially all, of the cost of care for a defined scope of health care services out of the revenue we receive. Some of our contracts allow for advance billing of our partners. In some of our contracts, a defined portion of the revenue is at risk and can be refunded to the partner if certain service levels are not attained. We monitor our compliance with the service levels to determine whether a refund will be provided and record an estimate of these refunds. In addition, certain of our contracts provide that if we fail to meet specified implementation targets, the contracts will terminate and we will be subject to financial penalties. Separately, the contracts of New Century Health typically run for one-year terms. While they typically contain year-to-year renewal provisions, we cannot assure you any or all of these contracts will be renewed in any particular year.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although the revenue from our contracts is not guaranteed because certain of our contracts are terminable for convenience by our partners after a notice period has passed, certain partners would be required to pay us a termination fee in certain circumstances. Termination fees and the related notice period in certain of our contracts are determined based on the scope of the market-facing solutions that the partner has adopted and the duration of the contract. Most of our contracts include cure periods for certain breaches, during which time we may attempt to resolve any issues that would trigger a partner&#8217;s ability to terminate the contract. However, certain of our contracts are also terminable immediately on the occurrence of certain events. For example, some of our contracts may be terminated by the partner if we fail to achieve target performance metrics over a specified period. Certain of our contracts may be terminated by the partner immediately following repeated failures by us to provide specified levels of service over periods ranging from six months to more than a year. Certain of our contracts may be terminated immediately by the partner if we lose applicable licenses, go bankrupt, lose our liability insurance, become insolvent, file for bankruptcy or receive an exclusion, suspension or debarment from state or federal government authorities. Additionally, if a partner were to lose applicable licenses, go bankrupt, lose liability insurance, become insolvent, file for bankruptcy or receive an exclusion, suspension or debarment from state or federal government authorities, our contract with such partner could in effect be terminated. The loss, termination or renegotiation of any contract could negatively impact our results. In addition, as our partners&#8217; businesses respond to market dynamics and financial pressures, and as our partners make strategic business decisions in respect of the lines of business they pursue and programs in which they participate, we expect that certain of our partners will, from time to time, seek to restructure their agreements with us.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The contracts often contain exclusivity or other restrictive provisions, which may limit our ability to partner with or provide services to other providers or purchase services from other vendors within certain time periods and in certain geographic areas. The exclusivity and other restrictive provisions are negotiated on an individual basis and vary depending on many factors, including the term and scope of the contract. The time limit on these exclusivity and other restrictive provisions typically corresponds to the term of the </span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">contract. These exclusivity or other restrictive provisions often apply to specific competitors of our health system partners or specific geographic areas within a particular state or an entire state, subject to certain exceptions, including, for example, exceptions for employer plan entities that have operations in the restricted geographic areas but that are headquartered elsewhere. Accordingly, these exclusivity clauses may prevent us from entering into relationships with certain potential partners.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The contracts with our partners impose other obligations on us. For example, we typically agree that all services provided under the partner contract and all employees providing such services will comply with our partner&#8217;s policies and procedures. In addition, in most instances, we have agreed to indemnify our partners against certain third-party claims, which may include claims that our services infringe the intellectual property rights of such third parties.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Competition</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The market for our solutions is fragmented, competitive and characterized by rapidly evolving technology standards, customer needs and the frequent introduction of new products and services. Our competitors range from smaller niche companies to large, well-financed and technologically-sophisticated entities. Our partners may also choose to insource solution functions from us in part or in whole. Our services solutions compete based on several factors, including breadth, depth and quality of product and service offerings, ability to deliver clinical, financial and operational performance improvement using products and services, quality and reliability of services, ease of use and convenience, brand recognition and the ability to integrate services with existing technology. We also compete based on price and aligned performance relationships.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Government Regulation</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our business is subject to extensive, complex and rapidly changing federal and state laws and regulations. Various federal and state agencies have discretion to issue regulations and interpret and enforce health care laws. While we believe we comply in all material respects with applicable health care and insurance laws and regulations, these regulations can vary significantly from jurisdiction to jurisdiction, and interpretation of existing laws and regulations may change periodically. Federal and state legislatures also may enact various legislative proposals that could materially impact certain aspects of our business. The following are summaries of key federal and state laws and regulations that impact our operations:</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Health Care Reform</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2010, the ACA and the Health Care and Education Reconciliation Act of 2010, which we refer to, collectively, as health care reform, was signed into law. Health care reform contains provisions that have changed and will continue to change the health insurance industry in substantial ways. For example, health care reform includes a mandate that employers with over 50 employees offer their employees group health insurance coverage or face tax penalties; prohibitions against insurance companies that offer individual major medical plans using pre-existing health conditions as a reason to deny an application for health insurance; medical loss ratio requirements that require each health insurance carrier to spend a certain percentage of their premium revenue on reimbursement for clinical services and activities that improve health care quality; establishment of health insurance exchanges to facilitate access to, and the purchase of, health insurance; and subsidies and cost-sharing credits to make health insurance more affordable for those below certain income levels.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Health care reform amended various provisions in many federal laws, including the Code, the Employee Retirement Income Security Act of 1974 and the Public Health Services Act. Health care reform is being implemented by the Department of Health and Human Services, the Department of Labor and the Department of Treasury. Most of the ACA regulations became effective on January 1, 2014. Since its enactment, the ACA has faced multiple congressional repeal and replace efforts, multiple challenges before the Supreme Court, and dozens of amendments including repeal of the tax penalty associated with the individual mandate to purchase coverage, plus three other taxes originally imposed by the ACA (on certain on employer-sponsored coverage, health insurers, and medical device companies). Separately, in December 2020 the U.S. Court of Appeals for the Fifth Circuit ruled that the ACA&#8217;s individual mandate is unconstitutional but did not invalidate the rest of the law; while in June 2021 the Supreme Court ruled that the plaintiffs (two individuals and several states) lacked standing challenge the constitutionality of the ACA&#8217;s individual mandate, leaving the merit questions of the case unresolved.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In his first year of office, the Biden Administration overturned several Trump Administration Executive Orders related to the ACA &#8211; for example, one directing federal agencies to modify how the ACA is implemented and two that previously cut funding for ACA marketplace outreach and enrollment. It is not known what other changes the new administration will implement through regulations or future executive orders, and how those may impact our partners and our business. It is also not known what legislation will advance in Congress &#8211; for example in the current Congress, we have seen proposals ranging from modest expansions of Medicare benefits (hearing, dental, vision) and drug pricing reforms to broad-scale reforms such as &#8220;Medicare for All&#8221; and others in between. Because of the continued uncertainty about the ACA and health care law more broadly, we cannot quantify or predict with any certainty their likely impact on our business, financial condition, operating results, and prospects.</span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, Congress, state legislatures and third-party payers may continue to review and assess alternative health care delivery and payment systems and may in the future propose and adopt legislation or policy changes or implementations effecting additional fundamental changes in the health care delivery system, including with respect to Medicare and Medicaid programs. We cannot assure you as to the ultimate content, timing, or effect of any changes, nor is it possible at this time to estimate the impact of any such potential legislation or changes. Health care reform has resulted in profound changes to the individual health insurance market and our business, and we expect these changes to continue.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Stark Law</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are subject to federal and state &#8220;self-referral&#8221; laws. The Stark Law is a federal statute that prohibits physicians from referring patients for items covered by Medicare or Medicaid to entities with which the physician has a financial relationship, unless that relationship falls within a specified exception. The Stark Law is a strict liability statute and is violated even if the parties did not have an improper intent to induce physician referrals. The Stark Law is relevant to our business because we frequently organize arrangements of various kinds under which (a) physicians and hospitals jointly invest in and own ACOs, clinically integrated networks and other entities that engage in value-based contracting with third-party payers or (b) physicians are paid by hospitals or hospital affiliates for care management, medical or other services related to value-based contracts. We evaluate when these investment and compensation arrangements create financial relationships under the Stark Law and design structures that are intended to satisfy exceptions under the Stark Law or Medicare Shared Savings Program waiver.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Anti-kickback Laws</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the United States, there are federal and state anti-kickback laws that generally prohibit the payment or receipt of kickbacks, bribes or other remuneration in exchange for the referral of patients or other health-related business. The United States federal health care programs&#8217; Anti-Kickback Statute makes it unlawful for individuals or entities knowingly and willfully to solicit, offer, receive or pay any kickback, bribe or other remuneration, directly or indirectly, in exchange for or to induce the referral of an individual to a person for the furnishing or arranging for the furnishing of any item or service for which payment may be made in whole or in part under a federal health care program or the purchase, lease or order, or arranging for or recommending purchasing, leasing or ordering, any good, facility, service, or item for which payment may be made in whole or in part under a federal health care program. Penalties for violations include criminal penalties and civil sanctions such as fines, imprisonment and possible exclusion from federal health care programs. The Anti-Kickback Statute raises similar compliance issues as the Stark Law. While there are safe harbors under the Anti-Kickback Statute, they differ from the Stark Law exceptions in that compliance with a safe harbor is not mandatory. If an arrangement falls outside the safe harbors, it must be evaluated on its specific facts to assess whether regulatory authorities might take the position that one purpose of the arrangement is to induce referrals of federal health care program business. Our business arrangements implicate the Anti-Kickback Statute for the same reasons they raise Stark Law issues. We evaluate whether investment and compensation arrangements being developed by us on behalf of hospital partners fall within one of the safe harbors or Medicare Shared Savings Program waiver. If not, we consider the factors that regulatory authorities are likely to consider in attempting to identify the intent behind such arrangements. We also design business models that reduce the risk that any such arrangements might be viewed as abusive and trigger Anti-Kickback Statute claims.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Antitrust Laws</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The antitrust laws are designed to prevent competitors from jointly fixing prices. However, competitors often work collaboratively to reduce the cost of health care and improve quality. To balance these competing goals, antitrust enforcement agencies have established a regulatory framework under which claims of per se price fixing can be avoided if a network of competitors (such as an ACO or clinically integrated network) is financially or clinically integrated. In this context, we evaluate the tests for financial and clinical integration that would be applied to the provider networks that we are helping to create and support, including the nature and extent of any financial risk that must be assumed to be deemed financially integrated and the types of programs that must be implemented to achieve clinical integration. However, even if a network is integrated, it is still subject to a &#8220;rule of reason&#8221; test to determine whether its activities are, on balance, pro-competitive. The key factors in the rule of reason analysis are market share and exclusivity. We focus on network size, composition and contracting policies to strengthen our partners&#8217; position that their networks meet the rule of reason test.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Federal Civil False Claims Act and State False Claims Laws</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The federal civil False Claims Act imposes liability on any person or entity who, among other things, knowingly presents, or causes to be presented, a false or fraudulent claim for payment by a federal health care program. The &#8220;qui tam&#8221; or &#8220;whistleblower&#8221; provisions of the False Claims Act allow a private individual to bring actions on behalf of the federal government alleging that the defendant has submitted a false claim to the federal government, and to share in any monetary recovery. Our activities relating to the way we sell and market our services, including our provider-led risk adjustment solution, may be subject to scrutiny under these laws.</span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">HIPAA, Privacy and Data Security Regulations</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">By processing data on behalf of our partners, we are subject to specific compliance obligations under privacy and data security-related laws, including HIPAA, the HITECH Act and related state laws. We are also subject to federal and state security breach notification laws, as well as state laws regulating the processing of protected personal information, including laws governing the collection, use and disclosure of social security numbers and related identifiers.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The regulations that implement HIPAA and the HITECH Act establish uniform standards governing the conduct of certain electronic health care transactions and protecting the security and privacy of individually identifiable health information maintained or transmitted by health care providers, health plans and health care clearinghouses, all of which are referred to as &#8220;covered entities,&#8221; and their &#8220;business associates&#8221; (which includes anyone who performs a service on behalf of a covered entity involving the use or disclosure of protected health information and is not a member of the covered entity&#8217;s workforce). Our partners&#8217; health plans generally will be covered entities, and, as their business associate, they may ask us to contractually comply with certain aspects of these standards by entering into requisite business associate agreements.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">HIPAA Health Care Fraud Standards</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The HIPAA health care fraud statute created a class of federal crimes, including health care fraud and false statements relating to health care matters, known as the &#8220;federal health care offenses.&#8221; The HIPAA health care fraud statute prohibits, among other things, executing a scheme to defraud any health care benefit program, while the HIPAA false statements statute prohibits, among other things, concealing a material fact or making a materially false statement in connection with the payment for health care benefits, items or services. Entities that are found to have aided or abetted in a violation of the HIPAA federal health care offenses are deemed by statute to have committed the offense and are punishable as a principal.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Medicare and Medicaid</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Medicare&#160;is a federal program that provides hospital and medical insurance benefits to persons age 65 and over, as well as certain other individuals. Medicaid&#160;programs are jointly funded by federal and state governments and are administered by states under an approved plan that provides hospital and other health care benefits to qualifying individuals. As we increase our exposure to Medicare and Medicaid businesses through new and existing partners, we increase our exposure to changes in government policy with respect to and regulation of the Medicaid and Medicare programs in which we and our partners participate. We are subject to regulation by both CMS and state agencies in respect of certain services we provide relating to Medicaid and Medicare programs.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because some of our partners are participants in governmental programs, our services have in the past and may again in the future be subject to periodic surveys and audits by governmental entities or contractors for compliance with Medicare and other standards and requirements. As a result of surveys or audits, CMS may seek premium and other refunds, prohibit us from continuing to market or enroll members in plans, exclude us from participating in one or more programs or institute other sanctions against us if we fail to comply with CMS regulations or Medicare contractual requirements.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The regulations and requirements applicable to us and other participants in Medicaid and Medicare programs are complex and subject to change. In October 2021, the CMS Center for Medicare and Medicaid Innovation (CMMI) published a white paper outlining its new strategic direction. Key themes include an increased focus on health equity, on streamlining the CMMI model portfolio, and on advancing new goals to get &#8220;all Medicare beneficiaries&#8221; and &#8220;the vast majority of Medicaid beneficiaries&#8221; into care relationships with accountability for quality and total cost of care by 2030. We cannot quantify or predict with any certainty the likely impact of this new strategic direction on availability or functioning of CMMI models, participation in CMS programs or modification to their rules and regulations, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">changes in the law or new interpretations of existing laws on our business, financial condition, operating results and prospects.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Following recent elections, Congress and state and local legislatures may propose and adopt legislation or policy changes or implementations effecting additional fundamental changes with respect to Medicare and Medicaid programs. Such changes in the law, or new interpretations of existing laws, may have a significant impact on our methods and costs of doing business. Additionally, expansion of enforcement activity could adversely affect our business and financial condition. Going forward, we expect CMS and Congress to continue to closely scrutinize each component of the Medicare program as well as modify the terms and requirements of the program. It is not possible to predict the outcome of this congressional or regulatory activity, either of which could adversely affect us. Similarly, we cannot predict whether pending or future federal or state legislation or court proceedings will change various aspects of the Medicaid and Medicare programs, nor can we predict the impact those changes will have on our business operations or financial results, but the effects could be materially adverse.</span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Consumer Protection Laws</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Federal and state consumer protection laws are being applied increasingly by the FTC, Federal Communications Commission and states&#8217; attorneys general to regulate the collection, use, storage and disclosure of personal or patient information, through websites or otherwise, and to regulate the presentation of website content and to regulate direct marketing, including telemarketing and telephonic communication. Courts may also adopt the standards for fair information practices promulgated by the FTC, which concern consumer notice, choice, security and access.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">State Privacy Laws</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to federal regulations issued under HIPAA, some states have enacted privacy and security statutes or regulations, which we refer to as state privacy laws, that govern the use and disclosure of a person&#8217;s medical information or records and, in some cases, are more stringent than those issued under HIPAA. These state privacy laws include regulation of health insurance providers and agents, regulation of organizations that perform certain administrative functions, such as UR, or TPA, issuance of notices of privacy practices and reporting and providing access to law enforcement authorities. In those cases, it may be necessary to modify our operations and procedures to comply with these more stringent state privacy laws. If we fail to comply with applicable state privacy laws, we could be subject to additional sanctions.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other State Laws</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">State insurance laws require licenses for certain health plan administrative activities, including TPA licenses for the processing, handling and adjudication of health insurance claims and UR agent licenses for providing medical management services. Given the nature and scope of services that we provide to certain partners, we are required to maintain TPA and UR agent licenses and ensure that such licenses are in good standing on an annual basis. In addition, laws in many states govern prompt payment obligations for health care services. These laws generally define claims payment processes and set specific time frames for submission, payment, and appeal steps. Failure to meet these requirements and time frames may result in rejection, delay of claims and possible interest and regulatory penalties. The Company has also established a captive insurance company under the laws of the State of Vermont and is subject to the captive insurance laws of that state.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Insurance subsidiaries and investees must be licensed by and are subject to the regulations of the jurisdictions in which they conduct business. For example, EVH Passport is regulated under specific Kentucky laws and regulations and indirectly affected by other health care-related laws and regulations. State regulations mandate minimum capital or restricted cash reserve requirements.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Intellectual Property</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our continued growth and success depend, in part, on our ability to protect our intellectual property and proprietary technology, including our Identifi&#174; software and CarePro</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">TM</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> platform. We primarily protect our intellectual property through a combination of copyrights, trademarks and trade secrets, intellectual property licenses and other contractual rights (including confidentiality, non-disclosure and assignment-of-invention agreements with our employees, independent contractors, consultants and companies with which we conduct business).</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">However, these intellectual property rights and procedures may not prevent others from creating a competitive online presence or otherwise competing with us. We may be unable to obtain, maintain and enforce the intellectual property rights on which our business depends, and assertions by third parties that we violate their intellectual property rights could have a material adverse effect on our business, financial condition and results of operations. For additional information related to our intellectual property position see &#8220;Part I - Item 1A. Risk Factors - Risks relating to our business and industry.&#8221;</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Research and Development</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Our research and development expenditures primarily consist of our strategic investment in enhancing the functionality and usability of our software, Identifi&#174; and developing programs and processes to maximize care delivery efficiency and effectiveness. We also capitalize software development costs related to Identifi&#174; and CarePro TM. Our research and development expenditures and capitalized software development costs also include the suite of products developed by New Century Health, Accordion, Valence Health and Aldera.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Environmental Focus</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe we have an important role to pay in society as an industry leader and partner. Though our environmental footprint is modest, environmental sustainability and responsible resource use are important for the Company now and in the future. We continue </span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to assess our physical office footprint and prioritize energy efficiency and environmental design in the buildings we occupy. As of December 31, 2021, our offices in Arlington, VA and Chicago are LEED Gold Certified and our regional office in Pune, India has achieved the rating of iNFHRA Excellence in Sustainability.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Human Capital Management</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We believe our commitment to and investment in human capital enables our continued efforts to dramatically reduce the total cost of care, improve clinical quality and simplify administration. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As of December&#160;31, 2021, we had approximately 3,500 global employees. None of our employees are represented by a labor union, and we are not a party to any collective bargaining agreements. We focus on the following key measures and objectives in managing our business in order to deploy and develop our human capital strategy:</span></div><div><span><br/></span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">Employee Compensation and Incentives</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">Employee Training and Career Development</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">Employee Well Being </span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">Diversity, Equity and Inclusion</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Employee Compensation and Incentives</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We aim to attract and retain the highest caliber of health care talent. We believe in pay for performance and structure our compensation to annually incent &amp; reward exceptional performance at all levels in the organization. Ensuring that our employees are compensated fairly and have the appropriate incentives in place to meet and exceed their potential is an integral part of our human capital management. We annually conduct market pay equity assessments and compensation reviews, and we continue to actively work to reduce unconscious bias in our sourcing, hiring practices, performance reviews and promotion opportunities that may contribute to pay inequities.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Employee Training and Career Development</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe that the continued edification and development of our talent is important in continuing to maintain growth as a company as well as the growth of our individual talent. Training programs are available to all employees through our company portal that is managed by our learning and development team. Our learning and development portal enables employees to find on-demand content, view and attend live learning sessions. Additionally, during 2020 we launched our internal mobility initiative. The initiative gives employees the visibility and opportunity to apply for positions within their current teams as well as company-wide. In 2021, we offered Talent profiles within our human capital management system to continue to support this initiative. We believe this initiative will continue to help with transparency of opportunities and talent across the organization, enables employees to develop in areas that align to their career goals as well as focus on increasing the diversity of our senior levels within the company over time. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Employee Well-Being</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe that we have a responsibility to help maintain the health and well-being of our employees. We provide our employees with comprehensive benefits including: medical insurance, dental, vision, PTO and 401k plan. In addition, we offer 100% paid maternity leave, parental leave, fertility support, diabetes and hypertension program offerings. With the on-going COVID-19 pandemic impacting our employees, we have continued to support work from home across our employee population. We continue to offer additional mental health offerings through our insurance provider and TalkSpace, work from home office set-up support, regular employee feedback surveys, personal impact days to promote social improvement engagement, an employee crisis fund, holistic wellness initiatives during the year that include yoga, cooking sessions, meditation and wellness challenges.</span></div><div style="text-align:justify"><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Diversity, Equity and Inclusion</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe that Evolent is a stronger company with diverse employees and encourage hiring and retention practices that focus on top performing talent regardless of gender, national origin, ethnicity or other protected class. In 2021, we continue to build on established diversity, equity and inclusion initiatives to continue to create a more equitable workspace. This initiative included additional training for leadership in diversity, equity and inclusion throughout the organization and the hiring of a Head of Diversity, Equity and Inclusion to focus on diversity as well as an internal organization review that focused around pay, job descriptions, recruiting, career pathing and development. In 2021, we introduced a new development program focused on top diverse employees across the business. We believe our continued commitment to diversity, equity and inclusion enables us to attract, develop and retain the highest caliber talent in health care. The table below demonstrates our progress on numerous diversity, equity and inclusion objectives based on our latest engagement surveys for each of the respective years below (results are based on self-identification):</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:80.150%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.872%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.872%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.596%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gender (global representation)</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Women</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Men</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Racial and ethnic minorities (U.S. representation)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Black or African American</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asian</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Hispanic or Latino</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Two or more races</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">American Indian or Alaska Native</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Native Hawaiian or Other Pacific Islander</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leadership Representation (Managing Director level or above)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Women</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Minorities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employee self-identification (U.S. representation)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">LGBTQ+</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Veteran</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Disabled Individual</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, our supplier diversity mission is to proactively identify, build relationships with, and purchase goods and services from certified small businesses as well as enterprises owned by minorities, women, veterans, LGTBQ+, and disabled persons that can help the Company achieve its corporate objectives.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Overall, we believe our culture, along with our internal programs and initiatives, allow us to effectively execute our human capital strategy. </span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Information about our Executive Officers</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our executive officers as of February&#160;23, 2022, were as follows:</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:539.25pt"><tr><td style="width:1.0pt"></td><td style="width:118.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:73.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:334.00pt"></td><td style="width:1.0pt"></td></tr><tr style="height:15pt"><td colspan="3" style="border-top:2pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Name</span></td><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Age</span></td><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Position</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Seth Blackley</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Executive Officer </span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">John Johnson</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Financial Officer</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Steve Tutewohl</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Operating Officer</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Jonathan Weinberg</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General Counsel</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Aammaad Shams</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate Controller</span></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Seth Blackley </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">is our co-founder and has served as our Chief Executive Officer since October 2020 and served as our President from August 2011 until his promotion. Prior to co-founding the company, Mr. Blackley was the Executive Director of Corporate Development and Strategic Planning at The Advisory Board from June 2007 to August 2011. Mr. Blackley began his career as an analyst in the Washington, D.C. office of McKinsey &amp; Company. Mr. Blackley holds a Bachelor of Arts degree in business from The University of North Carolina at Chapel Hill, and a master of business administration from Harvard Business School.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">John Johnson </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">has served as our Chief Financial Officer since July 2019. Prior to his role as Chief Financial Officer, Mr. Johnson was acting Chief Financial Officer for New Century Health from March 2019 to June 2019. Prior to his New Century Health role, Mr. Johnson was Senior Vice President, Corporate Performance at Evolent Health from January 2018 to March 2019 and Vice President, Corporate Performance at Evolent Health from April 2016 to December 2017. Prior to joining the Company, Mr. Johnson was the Managing Partner at Riverbend Analytics, LLC from December 2015 until April 2016 and the Vice President of Strategy at PSA Healthcare from February 2013 until November 2015. Mr. Johnson holds a Bachelor of Arts degree in Physics from Cornell University.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Steve Tutewohl </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">has served as our Chief Operating Officer since June 2020. Mr. Tutewohl has also served as the Chief Executive Officer of Evolent Health Services, since January 2018. Mr. Tutewohl previously served as the Chief Actuary of the Company from January 2017 until December 2017. Prior to the Company&#8217;s acquisition of Valence Health, Mr. Tutewohl was the Strategic Accounts Officer of Valence Health from October 1996 - January 2017. Mr. Tutewohl received his B.S. in risk management, math and actuarial science from the University of Wisconsin.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Jonathan Weinberg </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">has served as our General Counsel since January 2014. Prior to joining Evolent, Mr. Weinberg was a Senior Vice President and Deputy General Counsel for Coventry Health Care, Inc. (Aetna Inc.) from 1999 to 2013, and oversaw the day-to-day management of the legal department as well as the company&#8217;s risk management department. Prior to joining Coventry, Mr. Weinberg was an associate and then partner at Epstein Becker and Green, P.C. in the firm&#8217;s health care practice, specializing in managed care issues from 1992 to 2002. Mr. Weinberg received his Bachelor of Arts in history and political science from the University of Wisconsin-Madison and his juris doctorate from the Catholic University of America.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Aammaad Shams</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> has served as our Controller since June 2020. Prior to his role as Controller, Mr. Shams was the Company&#8217;s Assistant Corporate Controller from January 2020 to June 2020. Mr. Shams also served as Senior Director of Technical Accounting from April 2018 to June 2019 and Senior Director of Accounting from July 2019 until December 2019. Prior to joining the Company, Mr. Shams was a Director in KPMG, LLP&#8217;s Accounting Advisory Services practice from June 2015 until March 2018. Mr. Shams is a Certified Public Accountant in the Commonwealth of Virginia.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Corporate Information</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Evolent began business operations in August 2011. Evolent Health, Inc., the registrant, was incorporated in the State of Delaware in December 2014. We completed our IPO in June 2015 and our Class A common stock is listed on the NYSE under the symbol &#8220;EVH.&#8221; Evolent Health, Inc. is a holding company whose principal asset is all of the Class A common units it holds in Evolent Health LLC, and its only business is to act as sole managing member of Evolent Health LLC. Substantially all of our operations are conducted through Evolent Health LLC and its consolidated subsidiaries and the financial results of Evolent Health LLC are consolidated in the financial statements of Evolent Health, Inc.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Website to Access Our Reports</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our internet website address is www.evolenthealth.com. In addition to the information about us and our subsidiaries contained in this Annual Report on Form 10-K, information about us can be found on our website including information on our corporate governance </span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">principles and practices. Our Investor Relations website at ir.evolenthealth.com contains a significant amount of information about us, including financial and other information for investors. We encourage investors to visit our website, as we frequently update and post new information about our company on our website and it is possible that this information could be deemed to be material information. Our website and information included in or linked to our website are not part of this Annual Report on Form 10-K.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We make available, free of charge, on or through our website our Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K and amendments to those reports filed or furnished pursuant to Section 13(a) or 15(d) of the Exchange Act as soon as reasonably practicable after we electronically file such material with, or furnish it to, the SEC.</span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span><br/></span></div><div id="i9aaa2fddc97e482da5dbe37ac85ae703_181"></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 1A. Risk Factors</span></div><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following summary highlights some of the principal risks that could adversely affect our business, financial condition or results of operations. This summary is not complete and the risks summarized below are not the only risks we face. These risks are discussed more fully further below. These risks include, but are not limited to, the following:</span></div><div><span><br/></span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:32.5pt">We derive a significant portion of our revenues from our largest partners.</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:32.5pt">The market for value-based health care in the United States is rapidly evolving. </span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:32.5pt">The health care regulatory and political framework is uncertain and evolving.</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:32.5pt">If we are unable to offer new and innovative products and services or our products and services fail to keep pace with advances in industry standards, technology and our partners&#8217; needs, our partners may terminate or fail to renew their relationships with us and our revenue and results of operations may suffer.</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:32.5pt">We have made and entered, and may in the future make and enter acquisitions, investments and alliances and joint ventures, which may be difficult to integrate, divert management resources, result in unanticipated costs or dilute our stockholders.</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:32.5pt">The financial benefits we expect to receive as a result of our sale of certain assets of Passport to Molina may not be realized.</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:32.5pt">Our revenues and the growth of our business rely, in part, on the growth and success of our partners and certain revenues from our engagements, which are difficult to predict and are subject to factors outside of our control, including governmental funding reductions and other policy changes.</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:32.5pt">Failure to accurately underwrite performance-based contracts could result in a reduction in profitability for our Specialty Care Management solution.</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:32.5pt">If we fail to effectively manage our growth and cost structure, our business and results of operations could be harmed.</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:32.5pt">Public health emergencies such as the COVID-19 pandemic have adversely affected, and could in the future, adversely affect our business and the business of our customers and suppliers.</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:32.5pt">Our offshore support and professional services may prove difficult to manage or may not allow us to realize our cost reduction goals.</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:32.5pt">If we lose key members of our management team or employees or are unable to attract and retain the employees we need, our compensation costs will increase and our business and operating results will be adversely affected.</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:32.5pt">We have recorded a significant amount of goodwill, and we may never realize the full value of our intangible assets, causing us to record impairments that may negatively affect our results of operations.</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:32.5pt">We may need to obtain additional financing which may not be available or, if it is available, may result in a reduction in the ownership of our stockholders.</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:32.5pt">We have experienced net losses in the past and we may not achieve profitability in the future.</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:32.5pt">We are and may become subject to litigation, proceedings, government inquiries, reviews, audits or investigations which could have a material adverse effect on our business, financial condition and results of operations.</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:32.5pt">We typically incur significant upfront costs in our partner relationships, and if we are unable to develop or grow these partner relationships over time, we are unlikely to recover these costs and our operating results may suffer.</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:32.5pt">If we do not continue to attract new partners and successfully capture new opportunities, we may not achieve our financial projections, and our results of operations would be harmed.</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:32.5pt">As we enter into an increasing number and variety of risk sharing arrangements with partners, our revenues and profitability could be limited and negatively impacted.</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:32.5pt">If the estimates and assumptions we use to determine the size of the target markets for our services are inaccurate, our future growth rate may be impacted and our business would be harmed.</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:32.5pt">If we are not able to maintain and enhance our reputation and brand recognition, our business and results of operations will be harmed.</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:32.5pt">Consolidation in the health care industry could have a material adverse effect on our business, financial condition and results of operations.</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:32.5pt">We face intense competition, which could limit our ability to maintain or expand market share within our industry, and if we do not maintain or expand our market share our business and operating results will be harmed.</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:32.5pt">Our offerings could be subject to audits by CMS and other governmental payers and whistleblower claims under the False Claims Act.</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:32.5pt">Exclusivity and right of first refusal clauses in some of our partner and founder contracts may prohibit us from partnering with certain other providers in the future, and as a result may limit our growth.</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:32.5pt">We are subject to privacy and data protection laws.</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:32.5pt">Data loss or corruption may adversely affect our reputation and relationships.</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:32.5pt">Our business is subject to online security risks, and if we are unable to safeguard the security and privacy of confidential data, we may face significant liabilities and our reputation and business will be harmed.</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:32.5pt">If we are unable to obtain, maintain and enforce intellectual property protection for our technology and products or if the scope of our intellectual property protection is not sufficiently broad, others may be able to develop and </span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="padding-left:72pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">commercialize technology and products substantially similar to ours, and our ability to successfully commercialize our technology and products may be adversely affected.</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:32.5pt">If our trademarks and trade names are not adequately protected, we may not be able to build name recognition in our markets of interest and our business may be adversely affected.</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:32.5pt">Third parties may initiate proceedings alleging that we are violating their intellectual property rights.</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:32.5pt">Open source software could adversely affect our ability to offer our services and subject us to possible litigation.</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:32.5pt">If we are unable to protect the confidentiality of our trade secrets, know-how and other proprietary information, the value of our technology and products could be adversely affected.</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:32.5pt">We depend on certain technologies that are licensed to us. We do not control the intellectual property rights covering these technologies and any loss of our rights to these technologies or the rights licensed to us could prevent us from developing and/or commercializing our products.</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:32.5pt">Any restrictions on our use of, or ability to license, data, or our failure to license data and integrate third-party technologies, could have a material adverse effect on our business, financial condition and results of operations.</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:32.5pt">We rely on Internet infrastructure, bandwidth providers, data center providers, other third parties and our own systems for providing services to our partners, and any failure or interruption in the services provided by these third parties or our own systems could expose us to litigation and negatively impact our relationships with partners, adversely affecting our brand and our business.</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:32.5pt">We rely on third-party vendors to host and maintain our technology platform.</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:32.5pt">We have previously identified material weaknesses in our internal control over financial reporting. Although the material weaknesses were remediated, if we identify additional material weaknesses in the future, we and our auditor may conclude that our internal control over financial reporting is not effective and we may be unable to produce timely and accurate financial statements, any of which could adversely impact our investors&#8217; confidence and our stock price.</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:32.5pt">We will not be reimbursed for any payments made under the TRA in the event that any tax benefits are disallowed.</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:32.5pt">We are required to pay certain of our pre-IPO investors for certain tax benefits we may claim in the future, and these amounts are expected to be material.</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:32.5pt">We may not be able to realize all or a portion of the tax benefits that resulted from the exchanges of Class B common units for our Class A common stock or from the utilization of NOLs previously held by Evolent Health Holdings and an affiliate of TPG and from payments made under the TRA.</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:32.5pt">In certain cases, payments by us under the TRA may be accelerated or significantly exceed the tax benefits we realize in respect of the tax attributes subject to the TRA.</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:32.5pt">The agreements between us and certain of our pre-IPO investors were made in the context of an affiliated relationship and may contain different terms than comparable agreements with unaffiliated third parties.</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:32.5pt">The conditional conversion feature of the 2025 Notes, if triggered, may adversely affect our financial condition and operating results.</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:32.5pt">The accounting method for convertible debt securities that may be settled in cash, such as the 2024 Notes and the 2025 Notes, could have a material effect on our reported financial results.</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:32.5pt">We expect that our stock price will be volatile and may fluctuate or decline significantly.</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:32.5pt">We are subject to securities class action litigation and an adverse outcome in such litigation could have an adverse effect on our financial condition.</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:32.5pt">The market price of our Class A common stock could decline due to the large number of shares of Class A common stock issuable upon conversion of our convertible notes, or by sales or issuances of substantial amounts of our Class A common stock.</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:32.5pt">Some provisions of Delaware law, our second amended and restated certificate of incorporation and our third amended and restated by-laws and certain of our contracts may deter third parties from acquiring us.</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:32.5pt">Our second amended and restated certificate of incorporation and stockholders&#8217; agreement contain provisions renouncing our interest and expectation to participate in certain corporate opportunities identified by or presented to certain of our pre-IPO investors.</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:32.5pt">Our second amended and restated certificate of incorporation designates courts in the State of Delaware as the sole and exclusive forum for certain types of actions and proceedings that may be initiated by our stockholders, which could limit our stockholders&#8217; ability to obtain a favorable judicial forum for disputes with us or our directors, officers or employees.</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:32.5pt">We do not anticipate paying any cash dividends in the foreseeable future.</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Our business, operations and financial position are subject to various risks. You should carefully consider the risks and uncertainties described below, together with all of the other information in this Annual Report on Form 10-K, including the audited annual financial statements and notes thereto included elsewhere in this Form 10-K, when evaluating your investment in our securities. The risks and uncertainties described below are those that we currently believe may materially affect the Company. Additional risks and uncertainties of which we are unaware or that we currently deem immaterial also may become important factors that affect the Company. If any of the following risks are realized, our business, financial condition, operating results and prospects could be materially and adversely affected. In that event, the price of our securities could decline, and you could lose part or all of your investment. Some statements in this Form 10-K, including statements in the following risk factors, constitute forward-looking statements. Please refer to the section entitled &#8220;Forward-Looking Statements - Cautionary Language.&#8221;</span></div><div style="text-align:justify"><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19</span></div></div></div><div id="i9aaa2fddc97e482da5dbe37ac85ae703_184"></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks relating to our business and industry</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">We derive a significant portion of our revenues from our largest partners. The loss, termination or renegotiation of our relationship or contract with a significant partner, or multiple partners in the aggregate, could negatively impact our results.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Historically, we have relied on a limited number of partners for a substantial portion of our total revenue. Our largest partner in terms of revenue, Cook County Health and Hospitals System, comprised 28.0% of our revenue for the year ended December 31, 2021. The loss of Cook County Health and Hospitals System, which is currently conducting an request for proposal (&#8220;RFP&#8221;) for certain health plan services, or any other significant partner, pursuant to a reprocurement process or otherwise, or the non-renewal or renegotiation of any of our significant partner contracts, could adversely affect our results. In May 2020, Passport, our largest partner at the time, was not awarded a Kentucky managed Medicaid contract for the next contract period, which adversely affected our results. We cannot assure you that similar facts will not occur with a different partner in the future as often our customers who are county or municipal run bodies have requirements to run public procurement processes for renewals.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the ordinary course of business, we engage in active discussions and renegotiations, and at times we are required to participate in reprocurement or other RFP exercises with our partners in respect of the services we provide and the terms of our partner agreements, including our fees. As our partners&#8217; businesses respond to market dynamics and financial pressures, and as our partners make strategic business decisions in respect of the lines of business they pursue and programs in which they participate, certain of our partners have renegotiated or terminated, or not renewed, and we expect that in the future additional partners will, from time to time, seek to renegotiate or terminate or not renew their agreements with us. These discussions and future discussions have resulted and could result in reductions to the fees and changes to the scope of services contemplated by our original partner contracts and consequently have and could negatively impact our revenues, business and prospects. In addition, we may not successfully win new contracts or renewals of existing contracts through competitive market standard reprocurement or RFP processes.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because we rely on a limited number of partners for a significant portion of our revenues, we depend on the creditworthiness of these partners. Our partners are subject to a number of risks including reductions in payment rates from governmental payers, higher than expected health care costs and lack of predictability of financial results when entering new lines of business, particularly with high-risk populations, such as plans established under the ACA and Aged, Blind and Disabled Medicaid. If the financial condition of our partners declines, our credit risk could increase. Should one or more of our significant partners (including Cook County) declare bankruptcy, be declared insolvent or otherwise be restricted by state or federal laws or regulation from continuing in some or all of their operations, this could adversely affect our ongoing revenues, the collectability of our accounts receivable and affect our bad debt reserves and net income (loss).</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although we have long-term contracts with many partners, these contracts may be terminated before their term expires for various reasons, such as changes in the regulatory landscape and poor performance by us, subject to certain conditions. For example, after a specified period, certain of these contracts are terminable for convenience by our partners after a notice period has passed and the partner has paid a termination fee. Certain of our contracts are terminable immediately upon the occurrence of certain events. For example, some of our contracts may be terminated by the partner if we fail to achieve target performance metrics over a specified period. Certain of our contracts may be terminated by the partner immediately following repeated failures by us to provide specified levels of service over periods ranging from six months to more than a year. Certain of our contracts may be terminated immediately by the partner if we lose applicable licenses, go bankrupt, lose our liability insurance or receive an exclusion, suspension or debarment from state or federal government authorities. Additionally, if a partner were to lose applicable licenses, go bankrupt, lose liability insurance, become insolvent, file for bankruptcy or receive an exclusion, suspension or debarment from state or federal government authorities, our contract with such partner could in effect be terminated. In addition, certain of our contracts may be terminated immediately if we become insolvent or file for bankruptcy. If any of our contracts with our partners is terminated, we may not be able to recover all fees due under the terminated contract, which may adversely affect our operating results. In addition, certain of our contracts provide that if we fail to meet specified implementation targets, the contracts will terminate and we will be subject to financial penalties. Separately, the contracts of New Century Health, including Vital Decisions, typically run for one-year terms. While they typically contain year-to-year renewal provisions, we cannot assure that any or all of these contracts will be renewed in any particular year. We expect that future contracts will contain similar provisions to those described in this paragraph. The market for value-based health care in the United States continues to evolve, which makes it difficult to forecast demand for our products and services.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">The market for value-based health care in the United States is rapidly evolving. Our future financial performance will depend in part on growth in this market and on our ability to adapt to emerging demands of this market. It is difficult to predict with any precision the future growth rate and size of our target markets.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The rapidly evolving nature of the markets in which we operate, as well as other factors that are beyond our control, reduce our ability to accurately evaluate our long-term outlook and forecast annual performance. We believe that demand for our products and services has been driven in large part by price pressure in traditional FFS health care, a regulatory environment that is incentivizing value-</span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">based care models, a rapid expansion of retail insurance, broader use of the Internet and advances in technology. Widespread acceptance of the value-based care model is critical to our future growth and success. A reduction in demand for our products and services caused by lack of acceptance, technological challenges, competing offerings or other factors would result in a lower revenue growth rate or decreased revenue, either of which could negatively impact our business and results of operations. For example, a large portion of New Century Health&#8217;s revenue is derived from customers in the managed care industry, including risk bearing providers and national and regional managed care companies. Changes in this industry&#8217;s business practices could negatively impact New Century Health. For example, if New Century Health&#8217;s managed care customers seek to provide services directly to their subscribers instead of contracting with New Century Health for such services, New Century Health could be adversely affected.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The health care regulatory and political framework is uncertain and evolving.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Health care laws and regulations are rapidly evolving and may change significantly in the future, including as a result of the new Biden administration, which could adversely affect our financial condition and results of operations. For example, in March 2010, the ACA was adopted, which is a health care reform measure that aims to increase the number of Americans with health insurance and reduce health care related costs. The ACA includes a variety of health care reform provisions and requirements, which substantially changed the way health care is financed by both governmental and private insurers. Since its enactment, the ACA has faced multiple congressional repeal and replace efforts, multiple challenges before the Supreme Court, and dozens of amendments including repeal of the tax penalty associated with the individual mandate to purchase coverage, plus three other taxes originally imposed by the ACA (on certain on employer-sponsored coverage, health insurers, and medical device companies). Separately, in December 2020 the U.S. Court of Appeals for the Fifth Circuit ruled that the ACA&#8217;s individual mandate is unconstitutional but did not invalidate the rest of the law; while in June 2021 the Supreme Court ruled that the plaintiffs (two individuals and several states) lacked standing challenge the constitutionality of the ACA&#8217;s individual mandate, leaving the merit questions of the case unresolved. </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In his first year of office, the Biden Administration overturned several Trump Administration Executive Orders related to the ACA &#8211; for example, one directing federal agencies to modify how the ACA is implemented and two that previously cut funding for ACA marketplace outreach and enrollment. It is not known what other changes the new administration will implement through regulations or future executive orders, and how those may impact our partners and our business. It is also not known what legislation will advance in Congress &#8211; for example in the current Congress, we have seen proposals ranging from modest expansions of Medicare benefits (hearing, dental, vision) and drug pricing reforms to broad-scale reforms such as &#8220;Medicare for All&#8221; and others in between. Because of the continued uncertainty about the ACA and health care law more broadly, we cannot quantify or predict with any certainty their likely impact on our business, financial condition, operating results, and prospects.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, CMS, Congress, state legislatures and third-party payers may continue to review and assess alternative health care delivery and payment systems and may in the future propose and adopt legislation or policy changes or implementations effecting additional fundamental changes in the health care delivery system, including with respect to Medicare and Medicaid programs. In October 2021, the CMS Center for Medicare and Medicaid Innovation (CMMI) published a white paper outlining its new strategic direction. Key themes include an increased focus on health equity, on streamlining the CMMI model portfolio, and on advancing new goals to get &#8220;all Medicare beneficiaries&#8221; and &#8220;the vast majority of Medicaid beneficiaries&#8221; into care relationships with accountability for quality and total cost of care by 2030. We cannot quantify or predict with any certainty the likely impact of this new strategic direction on the availability or functioning of CMMI models, participation in CMS programs or modifications to their rules and regulations, changes in the law, or new interpretations of existing laws, on our methods and costs of doing business.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, expansion of enforcement activity could adversely affect our business and financial condition. Going forward, we expect CMS and Congress to continue to closely scrutinize each component of the Medicare program as well as modify the terms and requirements of the program. It is not possible to predict the outcome of this congressional or regulatory activity, either of which could adversely affect us. Similarly, we cannot predict whether pending or future federal or state legislation or court proceedings will change various aspects of the health care delivery system, including Medicaid and Medicare programs, nor can we predict the impact those changes will have on our business operations or financial results, but the effects could be materially adverse.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As another example of recent health care legislative changes, the Consolidated Appropriations Act (the &#8220;CAA&#8221;), enacted on December 27, 2020, contain provisions impacting group health plans, including protections for plan participants from surprise medical bills and ensuring health plan price transparency. The CAA prohibits plans from entering into services agreements that directly or indirectly restrict the plans from disclosing provider-specific costs and quality of care information. The CAA will also require certain service providers for health plans to comply with certain ERISA fee disclosure rules. In addition, effective January 1, 2022, the No Surprises Act (enacted as part of the CAA) provides protection against surprise medical bills by prohibiting plans and providers from balance billing patients for emergency care performed by out-of-network providers as well as non-emergency and ancillary services performed by out-of-network providers at in-network facilities, subject to certain notice and consent exceptions for non-emergency and ancillary services. The new law also grants additional patient protections, including requiring providers to send a good faith estimate of the expected charges for furnishing items or services to an insured patient&#8217;s health plan (or directly to an uninsured patient) before such items or services are delivered (including items or services reasonably expected to be provided in conjunction with scheduled items or </span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">services or that are reasonably expected to be delivered by another provider). The No Surprises Act also provides a dispute resolution process in the event the actual charges for such items and services are substantially higher than the plan&#8217;s estimate and will prohibit providers from charging patients an amount beyond the in-network cost sharing amount for services rendered by out-of-network providers, subject to certain exceptions. Several states have also enacted comprehensive surprise billing laws and the CAA defers to existing state requirements with respect to state-established payment amounts.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are unable to predict how these changes to the ACA and other health care reform initiatives from new legislation, regulation, judicial action and/or executive action, including the CAA and No Surprises Act and state laws, will ultimately impact the health care industry and what the potential impact may be on our business, financial condition, operating results and prospects.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to these health care laws and regulations, we are subject to various other laws and regulations, including, among others, other aspects of state insurance laws, the Stark Law relating to self-referrals, the whistleblower provisions of the False Claims Act, anti-kickback laws, antitrust laws and the privacy and data protection laws. We have identified instances of noncompliance in the past and cannot guarantee that we will not identify other instances in the future, or the outcome of any regulatory investigation into any non-compliance. See &#8220;Part I-Item 1. Business-Health Care Laws and Regulations&#8221; for additional information. If we were to become subject to litigation, liabilities or penalties under these or other laws or as part of a governmental review or audit, our business could be adversely affected.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">If we are unable to offer new and innovative products and services or our products and services fail to keep pace with advances in industry standards, technology and our partners&#8217; needs, our partners may terminate or fail to renew their relationships with us and our revenue and results of operations may suffer.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our success depends on providing high-quality products and services that health care providers use to improve clinical, financial and operational performance. If we cannot adapt to rapidly evolving industry standards, technology and increasingly sophisticated and varied partner needs, our existing technology could become undesirable or obsolete, which could harm our reputation. We must continue to invest significant resources in our personnel and technology in a timely and cost-effective manner in order to enhance our existing products and services and introduce new high-quality products and services that existing partners and potential new partners will want. Our operating results would also suffer if our innovations are not responsive to the needs of our existing partners or potential new partners, are not appropriately timed with market opportunity, are not effectively brought to market or significantly increase our operating costs. If our new or modified product and service innovations are not responsive to partner preferences, emerging industry standards or regulatory changes, are not appropriately timed with market opportunity or are not effectively brought to market, we may lose existing partners or be unable to obtain new partners and our results of operations may suffer. In addition, should any of our partners terminate their relationship with us after implementation has begun, we would not only lose our time, effort and resources invested in that implementation, but we would also have lost the opportunity to leverage those resources to build a relationship with other partners over that same period of time. In some cases, we price our services based on expectations of long-term relationships and when the partner terminates the relationship earlier than we had expected, we lose the resources invested in that relationship as well as the upside benefits we had anticipated.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also engage third-party vendors to develop, maintain and enhance our technology solutions, and our ability to develop and implement new technologies is therefore dependent on our ability to engage suitable vendors. We may also need to license software or technology from third parties in order to maintain, expand or modify our technology-enabled services platform. However, there is no guarantee we will be able to enter into such agreements on acceptable terms or at all. The functionality of our services platforms depend, in part, on our ability to integrate with third-party applications and data management systems that our partners use and from which they obtain data. These third parties may terminate their relationships with us, change the features of their applications and platforms, restrict our access to their applications and platforms or alter the terms governing use of their applications, data management systems and application programming interfaces and access to those applications and platforms in an adverse manner.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">We have made and entered, and may in the future make and enter acquisitions, investments and alliances and joint ventures, which may be difficult to integrate, divert management resources, result in unanticipated costs or dilute our stockholders.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As our business continues to grow, we may continue to acquire or invest in companies, businesses, products or technologies that complement our current products and services, enhance our market coverage or technical capabilities or offer growth opportunities. This may include acquiring or investing in companies, businesses, products or technologies that are tangential to our current business and in which we have limited or no prior operating experience. That and other acquisitions, investments, alliances or joint ventures, have resulted and could result in new, material risks to our results of operations, financial condition, business and prospects. These new risks could include increased variability in revenues and prospects associated with various risk sharing arrangements. In addition, the market price for our Class A common stock could also be affected, following the consummation of any other transaction, by factors that have not historically affected the market price for our Class A common stock.</span></div><div><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We continuously evaluate potential acquisition targets and investments. However, there can be no assurance that any of these potential acquisitions or investments will be consummated. Acquisitions, investments and alliances, including our recent acquisition of Vital Decisions, LLC, could result in numerous risks to our business which could negatively impact and our financial condition and results of operations, including:</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">difficulty converting platforms or integrating the purchased operations, products or technologies;</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">substantial unanticipated integration costs, delays and challenges that may arise in integration;</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the loss of key customers who are in turn subject to risks and financial dislocation in their businesses;</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the loss of key employees, particularly those of the acquired operations;</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">difficulty retaining or developing the acquired business&#8217; customers;</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">adverse effects on our existing business relationships with customers, suppliers, other partners, standing with regulators;</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">challenges related to the integration and operation of businesses that operate in new geographic areas and new markets or lines of business;</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">unanticipated financial losses in the acquired business, including the risk of higher than expected health care costs;</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">failure to realize the potential cost savings or other financial benefits or the strategic benefits of the acquisitions, including failure to consummate any proposed or contemplated transaction; and</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">liabilities, including acquired litigation, and expenses from the acquired businesses for contractual disputes with customers and other third parties, infringement of intellectual property rights, data privacy violations or other claims and failure to obtain indemnification for such liabilities or claims, and distraction of our personnel in connection with any related proceedings.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may be unable to integrate the operations, products, technologies or personnel gained through acquisitions or investments or integrate or complete any other such transaction without a material adverse effect on our business, financial condition and results of operations. Transaction agreements may impose limitations on our ability, or the ability of the business to be acquired, to conduct business. Events outside our control, including operating changes or regulatory changes, could also adversely affect our ability to realize anticipated revenues, synergies, benefits and cost savings. In addition, revenues of acquired businesses or companies, prior to and after consummation of a transaction, may be less than expected. Counterparties in transactions may have contracts with customers and other business partners which may require consents from these parties in connection with a transaction. If these consents cannot be obtained, the Company may suffer a loss of potential future revenue and may lose rights that are material to its business and the business of any combined company. Any such disruptions could limit our ability to achieve the anticipated benefits of the transaction. Any integration may be unpredictable, or subject to delays or changed circumstances, and we and any targets may not perform in accordance with our expectations.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have also entered into a number of joint ventures. Conflicts or disagreements between us and any joint venture partner may negatively impact the benefits expected to be achieved by the joint venture or may ultimately threaten the ability of such joint venture to continue. We are also subject to additional risks and uncertainties because we may be dependent upon and subject to the liability, losses or reputational damage relating to joint venture partners that are not entirely under our control.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with these acquisitions, investments, alliances or joint ventures, we could incur significant costs, debt, amortization expenses related to intangible assets or large and immediate write-offs or other impairments or charges (as was the case with the $47.1 million impairment charge we incurred in connection with our investment in GlobalHealth during the year ended December 31, 2020, which represented the total value of our investment), assume liabilities or issue stock (as we have done in prior transactions) that would dilute our current stockholders&#8217; ownership.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The financial benefits we expect to receive as a result of our sale of certain assets of Passport to Molina may not be realized.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 1, 2020, EVH Passport and Molina consummated the Molina Closing and the Passport Medicaid Contract was novated to Molina. In the event certain conditions are not fulfilled, we may not realize the economic benefits we expect to derive from the transaction. The amount of cash we ultimately receive in connection with the transactions consummated by the Molina APA, the wind down of EVH Passport and related transactions could be adversely affected by a number of factors including litigation from third parties, the outcome of ongoing protests against the Kentucky Medicaid awards for 2021 and the results of litigation related thereto, the performance of Passport through 2020 and the results of Medicaid open enrollment in the Commonwealth of Kentucky. In addition, at the time of the transaction the Company estimated a return of capital from EVH Passport between $130 million and $170 million in total. The Company now expects, given certain outcomes an estimated return of capital between $170 million and $190 million in total, subject to regulatory approval from the Kentucky Department of Insurance, and we cannot control or predict the timing of such capital return.</span></div><div><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Our revenues and the growth of our business rely, in part, on the growth and success of our partners and certain revenues from our engagements, which are difficult to predict and are subject to factors outside of our control, including governmental funding reductions and other policy changes.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We enter into agreements with our partners under which a significant portion of our fees are variable, including fees which are dependent upon the number of members that are covered by our partners&#8217; health care plans each month, expansion of our partners and the services that we provide, as well as performance-based metrics. The number of members covered by a partner&#8217;s health care plan is often impacted by factors outside of our control, such as the actions of our partner or third parties. In addition, ongoing payment of fees by our partners could be negatively impacted by the general financial condition of our partners. Accordingly, revenue under these agreements is unpredictable. If the number of members covered by one or more of our partners&#8217; plans were to be reduced by a material amount, or if member enrollment numbers in new plans are lower than expected, which was the case with our Florida Medicaid partners, such decrease would lead to a decrease in our expected revenue, which could harm our business, financial condition and results of operations. In addition, growth forecasts of our partners are subject to significant uncertainty and are based on assumptions and estimates that may prove to be inaccurate. Even if the markets in which our partners compete meet the size estimates and growth forecasted, their health plan membership could fail to grow at similar rates, if at all. In addition, a portion of the revenue under certain of our service contracts is tied to the partners&#8217; continued participation in specified payer programs over which we have no control. If a partner ceases to participate or is disqualified from participation in any such program, this would lead to a decrease in our expected revenue under the relevant contract.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the transition to value-based care may be challenging for our partners. For example, fully capitated or other provider risk arrangements have had a history of financial challenges for providers. Our partners may also have difficulty in value-based care if premium pricing is under pressure or if they incur selection bias in the health plans under which they assume risk and in so doing the premium, capitation amount or other risk-sharing arrangement they undertake does not adequately reflect the health status of the membership. Our partners may choose not to continue to capitalize affiliated health plans or subsidize losses to their reimbursement rates. Furthermore, revenue under our partner contracts may differ from our projections because of the termination of the contract for cause or at specified life cycle events, or because of fee reductions that are occasionally agreed to after the contract is initially signed.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our partners derive a substantial portion of their revenue from third-party private and federal and state governmental payers, including Medicaid programs. Revenue under certain of our agreements could be negatively impacted as a result of governmental funding reductions impacting government-sponsored programs, changes in reimbursement rates, and premium pricing reductions, as well as the inability of our partners to control and, if necessary, reduce health care costs, all of which are out of our control. Because certain of our partners&#8217; revenues are highly reliant on third-party payer reimbursement funding rates and mechanisms, overall reductions of rates from such payers could adversely impact the liquidity of our partners, resulting in their inability to make payments to us on agreed payment terms. These risks may be heightened by the COVID-19 pandemic. See &#8220;Risk factors-The health care regulatory and political framework is uncertain and evolving&#8221; for additional information.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Failure to accurately underwrite performance-based contracts could result in a reduction in profitability for our Specialty Care Management solution.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">New Century Health, the brand name we use for our specialty care management solution, derives a portion of its revenue from arrangements under which it assumes responsibility for a portion of the total cost of treatments (for oncology and cardiology patients) in exchange for a fixed fee. These are typically referred to as &#8220;performance-based contracts&#8221;. If the Company is unable to accurately underwrite the health care cost risk for New Century Health and control associated costs, the Company&#8217;s profitability could decline. Moreover, costs of providing cancer care are very hard to predict, in part as a result of rapidly changing utilization of new and existing drugs and changing diagnostic and therapeutic protocols. The competitive environment for New Century Health&#8217;s performance-based products could result in pricing pressures which could cause New Century Health to reduce its rates. In addition, customer demands or expectations as to margin levels could cause New Century Health to reduce its rates. A reduction in performance-based contract rates which are not accompanied by a reduction in covered services or expected underlying care trend could result in a decrease of New Century Health&#8217;s operating margins.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">If we fail to effectively manage our growth and cost structure, our business and results of operations could be harmed.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have expanded our operations significantly since our inception, organically as well as through acquisitions. If we do not effectively manage our growth and maintain an efficient cost structure as we continue to expand, the quality of our products and services could suffer. Our growth to date has increased the significant demands on our management, our operational and financial systems and infrastructure and other resources. We must also continue to improve our existing systems for operational and financial management, including our reporting systems, procedures and controls. These improvements require significant capital expenditures and place increasing demands on our management. We may not be successful in managing or expanding our operations or in </span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">maintaining adequate financial and operating systems and controls. If we do not successfully manage these processes, including the timely processing of claims on behalf of our partners, our business and results of operations could be harmed.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Public health emergencies such as the COVID-19 pandemic have adversely affected, and could in the future, adversely affect our business and the business of our customers and suppliers.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">An epidemic, pandemic or similar serious public health issue, and the measures undertaken by governmental authorities to address it, could significantly disrupt or prevent us from operating our business in the ordinary course for an extended period, and thereby, and/or along with any associated economic and/or social instability or distress, have a material adverse impact on our results of operations, cash flows and financial condition.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To date, due to the nature of the services we provide, market dynamics in our end markets and with our significant customers, our operations have not been materially affected by the ongoing global COVID-19 pandemic and the resulting volatility and uncertainty it has caused in the U.S. and international markets. The extent to which COVID-19 ultimately impacts our business will depend on future developments, which are highly uncertain and cannot be predicted with confidence. Factors that may determine the severity of the impact include the scope, severity and duration of the pandemic, including resurgence of COVID-19 cases due to more contagious variants such as Omicron, employee mobility and productivity and actions to contain COVID-19 or treat its impact (including federal, state and local directives to remain at home or forced business closures and the effectiveness of vaccines), among others. A prolonged economic downturn or recession resulting from the pandemic could adversely affect many of our partners which could, in turn, adversely impact our business, financial condition and results of operations.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The COVID-19 pandemic has impacted and may impact our business, financial condition, cash flows, or results of operations in a number of ways, including the following:</span></div><div><span><br/></span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">State Medicaid agencies may experience budget pressures as a result of the pandemic which could negatively impact payments to certain of our Medicaid health plan customers and potentially cause us to incur additional bad debt expense.</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">The impact of the pandemic on certain partners could result in delayed or reduced payments to us.</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">As our employees and our partners&#8217; employees work from home and access our system remotely, we may be subject to heightened security and privacy risks, including the risks of cyberattacks and privacy incidents.</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">Volatility in the capital markets could have a negative impact on our ability to access those markets on acceptable terms, or at all.</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">Any benefits to our business as a result of increased Medicaid membership or lower utilization may not be sustained in or through future periods.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The inherent uncertainty surrounding COVID-19, due in part to rapidly changing governmental directives, public health challenges and progress, and market reactions thereto, also makes it more challenging for our management to estimate the potential impact and the future performance of our business. We cannot predict the ultimate impact of the COVID-19 pandemic, but it could materially adversely affect our business, including our financial position, results of operations and/or cash flows.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Our offshore support and professional services may prove difficult to manage or may not allow us to realize our cost reduction goals.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We use certain offshore resources to provide certain support and professional services, which requires technical and logistical coordination. If we are unable to maintain acceptable standards of quality in support and professional services, our attempts to reduce costs and drive growth through margin improvements in technical support and professional services may be negatively impacted, which would adversely affect our results of operations. Our offshore resources, and their ability to provide support and professional services to our domestic operations, are subject to domestic regulation at the federal, state and local levels. In certain cases, those regulations restrict or prohibit us from using our offshore resources. As a result, we may not be able to reduce costs for our domestic operations or fully realize our margin improvement goals.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">If we lose key members of our management team or employees or are unable to attract and retain the employees we need, our compensation costs will increase and our business and operating results will be adversely affected.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our success depends largely upon the continued services of our key executive officers and recruitment of additional highly skilled employees. From time to time, there may be changes in our senior management team resulting from the hiring or departure of executives, which could disrupt our business. Hiring executives with needed skills or the replacement of one or more of our executive officers or other key employees would likely involve significant time and costs and may significantly delay or prevent the achievement of our business objectives.</span></div><div style="text-align:justify"><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">25</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, competition for qualified talent in our industry is intense, particularly in the last several months. In 2021, there has been a dramatic increase in workers leaving their positions throughout our industry that is being referred to as the &#8220;great resignation,&#8221; and the market to build, retain and replace talent has become even more highly competitive. Many of the companies with which we compete for personnel have greater financial and other resources than we do. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have faced and may continue to face difficulties attracting, hiring and retaining highly-skilled personnel and with appropriate qualifications and may not be able to fill positions. To attract top talent, we have had to offer, and believe we will need to continue to offer, competitive compensation and benefits packages before we can validate the productivity of those employees. We have increased, and expect to continue to increase, our employee compensation levels in response to competition, as necessary. In addition, the pressures of inflation have increased our costs of labor, and may continue to do so.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, we believe our corporate culture has been a key contributor to our success to date. However, in this period of the "great resignation," we have and may continue to face higher employee turnover rates. With many of our employees working remotely, we may find it difficult to maintain important aspects of our culture, which could negatively affect our ability to retain and recruit personnel who are essential to our future success and could ultimately have a negative impact on our business and our ability to execute on our strategy. In order to successfully expand our business, we must effectively recruit, integrate and motivate new and retain existing employees, while maintaining the beneficial aspects of our corporate culture. All of our employees are &#8220;at-will&#8221; employees, and their employment can be terminated by us or them at any time, for any reason and without notice. We may not be able to hire new employees quickly enough to meet our needs. If we fail to effectively manage our hiring needs and successfully integrate new employees, our efficiency and ability to meet our forecasts and our employee morale, productivity and retention could suffer, and our business and results of operations could be harmed. In addition, volatility or lack of performance in our stock price may affect our ability to attract replacements should key personnel depart.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">We have recorded a significant amount of goodwill, and we may never realize the full value of our intangible assets, causing us to record impairments that may negatively affect our results of operations.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has three reporting units. Our total assets include substantial goodwill. On December&#160;31, 2021, we had $426.3 million of goodwill on our consolidated balance sheet. Goodwill is not amortized, but is reviewed at least annually for indications of impairment, with consideration given to financial performance and other relevant factors.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While our annual goodwill impairment test is conducted on October 31, we have processes to monitor for interim triggering events. Under GAAP, we review our goodwill for impairment when events or changes in circumstances indicate the carrying value may not be recoverable. Factors that may be considered a change in circumstances indicating that the carrying value of our goodwill may not be recoverable include macroeconomic conditions, industry and market considerations, our overall financial performance including an analysis of our current and projected cash flows, revenue and earnings, a sustained decrease in our share price and other relevant entity-specific events including changes in strategy, customers or litigation. A detailed discussion of our impairment testing is included in &#8220;Part II - Item 8. Financial Statements and Supplementary Data - Note 9.&#8221;</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recorded impairment charges of $199.8 million and $215.1 million during the three months ended December 31, 2019 and June 30, 2020, respectively, as a result of the Kentucky Cabinet for Health and Family Services announcing that EVH Passport was not awarded a Kentucky managed Medicaid contract for the next contract period. When other indications of goodwill impairment exist, we may be required to recognize additional impairments in the future as a result of market conditions or other factors related to our performance, including changes in our forecasted results, investment strategy, interest rates or assumptions used as part of the goodwill impairment analysis. Any further impairment charges that we may record in the future could be material to our results of operations.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">We may need to obtain additional financing which may not be available or, if it is available, may result in a reduction in the ownership of our stockholders.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may need to raise additional funds in order to:</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">finance unanticipated working capital requirements;</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">develop or enhance our technological infrastructure and our existing products and services;</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">fund strategic relationships, including joint ventures and co-investments;</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">fund additional implementation engagements; and</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">acquire complementary businesses, technologies, products or services.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additional financing may not be available on terms favorable to us, or at all. If adequate funds are unavailable or are unavailable on acceptable terms, our ability to fund our expansion strategy, take advantage of unanticipated opportunities, develop or enhance technology or services or otherwise respond to competitive pressures could be significantly limited. If we raise additional funds by </span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">issuing equity or convertible debt securities, the ownership of our then-existing stockholders may be reduced, and holders of these securities may have rights, preferences or privileges senior to those of our then-existing stockholders. In addition, any indebtedness we incur and restrictive covenants contained in the agreements related thereto could:</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">make it difficult for us to satisfy our obligations, including interest payments on any debt obligations;</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">limit our ability to obtain additional financing to operate our business;</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">require us to dedicate a substantial portion of our cash flow to payments on our debt, reducing our ability to use our cash flow to fund capital expenditures and working capital and other general operational requirements;</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">limit our flexibility to plan for and react to changes in our business and the health care industry;</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">place us at a competitive disadvantage relative to our competitors;</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">limit our ability to pursue acquisitions; and</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">increase our vulnerability to general adverse economic and industry conditions, including changes in interest rates or a downturn in our business or the economy.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The occurrence of any one of these events could cause a significant decrease in our liquidity and impair our ability to pay amounts due on any indebtedness, and could have a material adverse effect on our business, financial condition and results of operations.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">We have experienced net losses in the past and we may not achieve profitability in the future.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have incurred significant net losses in the past and our operating expenses may increase in the future as we continue to invest to grow our business and build relationships with partners, develop our platforms and develop new solutions. These efforts may prove to be more expensive than we currently anticipate, and we may not succeed in increasing our revenue sufficiently to offset these higher expenses. In addition, as we continue to increase our partner base, we could incur increased losses due to mis-forecasted underwriting in performance-based contracts or because significant costs associated with entering into partner agreements are generally incurred upfront, while revenue under certain of our partner agreements is recognized each period in the month in which the services are delivered. As a result, we may need to raise additional capital through equity and debt financings in order to fund our operations. We may also fail to improve the gross margins of our business as anticipated. If we are unable to effectively manage these risks and difficulties as we encounter them, our business, financial condition and results of operations may suffer.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">We are and may become subject to litigation, proceedings, government inquiries, reviews, audits or investigations which could have a material adverse effect on our business, financial condition and results of operations.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are and may become subject to litigation, proceedings, government inquiries, reviews, audits or investigations in the future, including potential claims against us by our partners, with or without merit. For example, on August 8, 2019, a shareholder of the Company filed a class action complaint against the Company, asserting claims under Section 10(b) and 20(a) of the Securities Exchange Act of 1934. Some of these matters and claims may result in significant defense costs and potentially significant judgments against us, some of which we are not, or cannot be, insured against. We generally intend to defend ourselves vigorously; however, we cannot be certain of the ultimate outcomes of any claims or other matters that may arise in the future. Resolution of these types of matters against us may result in our having to pay significant fines, judgments or settlements, which, if uninsured, or if the fines, judgments and settlements exceed insured levels, could adversely impact our earnings and cash flows, thereby having a material adverse effect on our business, financial condition, results of operations, cash flow and per share trading price of our Class A common stock. Certain litigation, proceedings, government inquiries, reviews, audits or investigations or the resolution of such matters may affect the availability or cost of some of our insurance coverage, which could adversely impact our results of operations and cash flows, expose us to increased risks that would be uninsured and adversely impact our ability to attract directors and officers.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">We typically incur significant upfront costs in our partner relationships, and if we are unable to develop or grow these partner relationships over time, we are unlikely to recover these costs and our operating results may suffer.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We devote significant resources to establish relationships with our partners. Some of our partners undertake a significant and prolonged evaluation process, often to determine whether our products and services meet their unique health system needs, which has in the past resulted in extended periods of time to establish a partner relationship. Our efforts involve educating our partners about the use, technical capabilities and benefits of our products and services. Accordingly, our operating results will depend in substantial part on our ability to deliver a successful partner experience and persuade our partners to grow their relationship with us over time. There is no guarantee that we will be able to successfully convert a customer of our transformation services into a partner of our platform and operations services. If we are unable to sell additional products and services to existing partners, enter into and maintain favorable relationships with new partners or sufficiently grow our partners&#8217; lives on platform, it could have a material adverse effect on our business, financial condition and results of operations. As we grow, our customer acquisition costs could outpace our build-up of recurring revenue, and we may be unable to reduce our total operating costs through economies of scale such that we are unable to achieve profitability. For example, some of our partnerships require significant upfront investment including, in the case of new markets, investments in infrastructure to meet readiness and operating requirements which have outpaced our revenue growth. Under </span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">27</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the ASC 606 revenue standard, certain set up costs we incur during the implementation phase may be deferred into the P&amp;O phase, potentially along with associated revenues. If the economics of a partnership change such that we are unlikely to fully recover those costs, we may be required to write off a portion or all of those deferred costs and revenues and our operating results may suffer. In addition, we estimate the costs and timing for completing the transformation phase of relevant partner relationships. These estimates reflect our best judgment. Any increased or unexpected costs or unanticipated delays, including delays caused by factors outside our control, could cause our operating results to suffer.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">If we do not continue to attract new partners and successfully capture new opportunities, we may not achieve our financial projections, and our results of operations would be harmed.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In order to grow our business, we must continually attract new partners and successfully capture new opportunities. Our ability to do so depends in large part on the success of our sales and marketing efforts. Potential partners may seek out other options. Therefore, we must demonstrate that our products and services provide a viable solution for potential partners. If we fail to provide high-quality solutions and convince individual partners of our value proposition, we may not be able to retain existing partners or attract new partners. In addition, there may be a limited-time opportunity to achieve and maintain a significant share of the market for our products and services due in part to the rapidly evolving nature of the health care and technology industries and the substantial resources available to our existing and potential competitors. If the market for our products and services declines or grows more slowly than we expect, if we fail to successfully convert new growth opportunities or if the number of individual partners that use our solutions declines or fails to increase as we expect, our revenue, results of operations, financial condition, business and prospects could be harmed.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">As we enter into an increasing number and variety of risk sharing arrangements with partners, our revenues and profitability could be limited and negatively impacted.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We incorporate certain risk sharing arrangements as part of our contractual arrangements with certain partners, and we expect to enter an increasing number and variety of risk sharing arrangements in the future. As an example, as part of our strategy to support certain partners, we entered into upside and downside risk-sharing arrangements. Through our specialty care management services, we take on members from payers through performance-based arrangements where we assume risks related to pricing of contracts for the provision of oncology and cardiology services. We may incur losses under these arrangements if we are unable to adjust our rates if faced with increased costs related to patient care or pharmaceutical products.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As the market evolves, we expect to engage in similar and new risk sharing strategies with our partners. As of December 31, 2021, Evolent had approximately $11.7 million of restricted cash and restricted investments related to risk-sharing arrangements. These arrangements have included and may include provision of letters of credit, loans, reinsurance arrangements, equity investments and other extensions of capital, where we are and may be at risk of not recovering all or a portion of any such loan or other extension of capital. These and any other potential risk sharing arrangements could limit and negatively impact our revenue, results of operations, financial condition, business and prospects.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, our failure to agree on satisfactory risk sharing solutions with potential partners could negatively impact our ability to attract new partners. We may also be required to make additional capital contributions as we invest and enter into new joint ventures and strategic alliances.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">If the estimates and assumptions we use to determine the size of the target markets for our services are inaccurate, our future growth rate may be impacted and our business would be harmed.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Market opportunity estimates and growth forecasts are subject to significant uncertainty and are based on assumptions and estimates that may not prove to be accurate. Our estimates and forecasts relating to the size and expected growth of the markets for our services may prove to be inaccurate. Even if the markets in which we compete meet our size estimates and forecasted growth, our business could fail to grow at similar rates, if at all.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our estimates of the market opportunities for our services are based on the assumption that the strategic approaches we offer will be attractive to potential partners. Potential partners may pursue different strategic options, or none at all. In addition, our assumptions could be impacted by changes to health care laws and regulations. If our assumptions prove inaccurate, our business, financial condition and results of operations could be adversely affected.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">If we are not able to maintain and enhance our reputation and brand recognition, our business and results of operations will be harmed.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe that maintaining and enhancing our reputation and brand recognition is critical to our relationships with existing partners and to our ability to attract new partners. The promotion of our brands may require us to make substantial investments and we </span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">anticipate that, as our market becomes increasingly competitive, these marketing initiatives may become increasingly difficult and expensive. Our marketing activities may not be successful or yield increased revenue, and to the extent that these activities yield increased revenue, the increased revenue may not offset the expenses we incur and our results of operations could be harmed. In addition, any factor that diminishes our reputation or that of our management, including failing to meet the expectations of our partners, or any adverse publicity or litigation involving or surrounding the Company or one of our joint venture partners, investors or strategic alliance partners could make it substantially more difficult for us to attract new partners. Similarly, because our existing partners often act as references for us with prospective new partners, any existing partner that questions the quality of our work or that of our employees could impair our ability to secure additional new partners. Therefore, financial adversity of our partners&#8217; affiliated health plans may adversely affect our reputation. In addition, negative publicity resulting from any adverse government payer audit could injure our reputation. If we do not successfully maintain and enhance our reputation and brand recognition, our business may not grow and we could lose our relationships with partners, which would harm our business, results of operations and financial condition.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Consolidation in the health care industry could have a material adverse effect on our business, financial condition and results of operations.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Many health care industry participants and payers are consolidating to create larger and more integrated health care delivery systems with greater market power. We expect regulatory and economic conditions to result in additional consolidation in the health care industry in the future. As consolidation accelerates, the economies of scale of our partners&#8217; organizations may grow. If a partner experiences sizable growth following consolidation, it may determine that it no longer needs to rely on us and may reduce its demand for our products and services. In addition, as health care providers consolidate to create larger and more integrated health care delivery systems with greater market power, these providers may try to use their market power to negotiate fee reductions for our products and services. Consolidation may also result in the acquisition or future development by our partners of products and services that compete with our products and services. Finally, if any of our partners were to be acquired or otherwise change ownership, we cannot assure you that the new owner would not seek to renegotiate or terminate their agreements with us. Any of these potential results of consolidation could have a material adverse effect on our business, financial condition and results of operations.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">We face intense competition, which could limit our ability to maintain or expand market share within our industry, and if we do not maintain or expand our market share our business and operating results will be harmed.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The market for our products and services is fragmented, competitive and characterized by rapidly evolving technology standards, customer needs and the frequent introduction of new products and services. Our competitors range from smaller niche companies to large, well-financed and technologically-sophisticated entities.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We compete on the basis of several factors, including breadth, depth and quality of product and service offerings, ability to deliver clinical, financial and operational performance improvement through the use of products and services, quality and reliability of services, ease of use and convenience, brand recognition and the ability to integrate services with existing technology. Some of our competitors are more established, benefit from greater brand recognition, have larger client bases and have substantially greater financial, technical and marketing resources. Other competitors have proprietary technology that differentiates their product and service offerings from ours. Our competitors are constantly developing products and services that may become more efficient or appealing to our existing partners and potential partners. Additionally, some health care information technology providers have begun to incorporate enhanced analytical tools and functionality into their core product and service offerings used by health care providers. As a result of these competitive advantages, our competitors and potential competitors may be able to respond more quickly to market forces, undertake more extensive marketing campaigns for their brands, products and services and make more attractive offers to our existing partners and potential partners.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also compete on the basis of price. We are subject to pricing pressures as a result of, among other things, competition within the industry, consolidation of health care industry participants, practices of managed care organizations, government action and financial stress experienced by our partners. If our pricing experiences significant downward pressure, our business will be less profitable and our results of operations will be adversely affected.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We cannot be certain that we will be able to retain our current partners or expand our partner base in this competitive environment. If we do not retain current partners or expand our partner base, or if we have to renegotiate existing contracts, our business, financial condition and results of operations will be harmed. Moreover, we expect that competition will continue to increase as a result of consolidation in both the health care information technology and health care industries. If one or more of our competitors or potential competitors were to merge or partner with another of our competitors, the change in the competitive landscape could also adversely affect our ability to compete effectively and could harm our business, financial condition and results of operations.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Our offerings could be subject to audits by CMS and other governmental payers and whistleblower claims under the False Claims Act.</span></div><div style="text-align:justify"><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">29</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We support provider-sponsored health plans with Medicare Advantage, Medicaid and Exchange products, as well as health systems and physician groups participating in payer-delegated risk arrangements or in the CMS Next Generation ACO Model. We anticipate that CMS and other governmental payers will continue to review and audit the results of our services including risk adjustment offerings, with a focus on identifying possible false claims.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, aspects of our review process and coding procedures could be subject to claims under the False Claims Act or Anti-Kickback Statute. Negative results of any such audit or claim could have a material adverse effect on our business, financial condition, results of operations or prospects and could damage our reputation.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Exclusivity and right of first refusal clauses in some of our partner and founder contracts may prohibit us from partnering with certain other providers in the future, and as a result may limit our growth.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Some of our partner and founder contracts include exclusivity and right of first refusal clauses. Any founder contracts with exclusivity, right of first refusal or other restrictive provisions may limit our ability to conduct business with certain potential partners, including competitors of our founders. For example, under the UPMC IP Agreement, if we were to conduct business with certain precluded providers, it would result in the loss of the license thereunder. Partner contracts with exclusivity or other restrictive provisions may limit our ability to partner with or provide services to other providers or purchase services from other vendors within certain time periods. These exclusivity or other restrictive provisions often apply to specific competitors of our health system partners or specific geographic areas within a particular state or an entire state. Accordingly, these exclusivity clauses may prevent us from entering into relationships with potential partners and could cause our business, financial condition and results of operations to be harmed.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have also entered into a reseller, services and non-competition agreement with an affiliate of UPMC, pursuant to which we are prohibited from providing products or services to certain third parties and in certain territories. These restrictions could cause our business, financial condition and results of operations to be harmed if we found it advantageous to provide products or services to such third parties or in such territories during the restricted period.</span></div><div style="text-align:justify"><span><br/></span></div><div id="i9aaa2fddc97e482da5dbe37ac85ae703_187"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Data Protection Privacy, Cybersecurity, Intellectual Property and Technology</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">We are subject to privacy and data protection laws governing the transmission, security and privacy of health information, which may impose restrictions on the manner in which we access personal data and subject us to penalties if we are unable to fully comply with such laws.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As described below, we are required to comply with numerous federal and state laws and regulations governing the collection, use, disclosure, storage and transmission of individually identifiable health information that we may obtain or have access to in connection with the provision of our services. These laws and regulations, including their interpretation by governmental agencies, are subject to frequent change and could have a negative impact on our business.</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">HIPAA expanded protection of the privacy and security of personal health information and required the adoption of standards for the exchange of electronic health information. Among the standards that the Department of Health and Human Services has adopted pursuant to HIPAA are standards for electronic transactions and code sets, unique identifiers for providers, employers, health plans and individuals, security, electronic signatures, privacy and enforcement. Privacy regulations under HIPAA also provide patients with rights related to understanding and controlling how their protected health information is used and disclosed. As a provider of services to entities subject to HIPAA, we are directly subject to certain provisions of the regulations as a &#8220;Business Associate.&#8221;. If we are unable to properly protect the privacy and security of protected health information entrusted to us, we could be found to have breached our contracts with our customers and be subject to investigation by the U.S. Department of Health and Human Services Office for Civil Rights (&#8220;OCR&#8221;). In the event the OCR finds that we have failed to comply with applicable HIPAA privacy and security standards, we could face civil and criminal penalties that could have a material adverse effect on us. In addition, OCR performs compliance audits of Business Associates in order to proactively enforce the HIPAA privacy and security standards. OCR has become an increasingly active regulator and has signaled its intention to continue this trend. OCR has the discretion to impose penalties without being required to attempt to resolve violations through informal means; further, OCR may require companies to enter into resolution agreements and corrective action plans which impose ongoing compliance requirements. OCR enforcement activity can result in financial liability and reputational harm, and responses to such enforcement activity can consume significant internal resources.</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">The HITECH Act, enacted as part of the American Recovery and Reinvestment Act of 2009, also known as the &#8220;Stimulus Bill,&#8221; effective February 22, 2010, set forth health information security breach notification requirements and increased penalties for violation of HIPAA. The HITECH Act requires individual notification for all breaches, media notification of breaches for over 500 individuals and at least annual reporting of all breaches to the </span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">30</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="padding-left:72pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Department of Health and Human Services. Failure to comply with the HITECH Act could result in fines and penalties that could have a material adverse effect on us.</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">Numerous other federal and state laws may apply that restrict the use and protect the privacy and security of individually identifiable information, as well as employee personal information. These include state medical privacy laws, state social security number protection laws and federal and state consumer protection laws. These various laws in many cases are not preempted by HIPAA and may be subject to varying interpretations by the courts and government agencies, creating complex compliance issues for us and our partners and potentially exposing us to additional expense, adverse publicity and liability, any of which could adversely affect our business.</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">Federal and state consumer protection laws are increasingly being applied by the FTC and states&#8217; attorneys general to regulate the collection, use, storage and disclosure of personal or individually identifiable information, through websites or otherwise, and to regulate the presentation of website content.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There is ongoing concern from privacy advocates, regulators and others regarding data protection and privacy issues, and the number of jurisdictions with data protection and privacy laws have been increasing. Also, there are ongoing public policy discussions regarding whether the standards for de-identified, anonymous or pseudonymized health information are sufficient, and the risk of re-identification sufficiently small, to adequately protect patient privacy. These discussions may lead to further restrictions on the use of such information. There can be no assurance that these initiatives or future initiatives will not adversely affect our ability to access and use data or to develop or market current or future services.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The security measures that we and our third-party vendors and subcontractors have in place to ensure compliance with privacy and data protection laws may not protect our facilities and systems from security breaches, acts of vandalism or theft, computer viruses, misplaced or lost data, programming and human errors or other similar events. Under the HITECH Act, as a business associate we may also be liable for privacy and security breaches and failures of our subcontractors. Even though we provide for appropriate protections through our agreements with our subcontractors, we still have limited control over their actions and practices. A breach of privacy or security of individually identifiable health information by a subcontractor may result in an enforcement action, including criminal and civil liability, against us. Our failure to comply may result in criminal and civil liability because the potential for enforcement action against business associates is now greater. Enforcement actions against us could be costly and could interrupt regular operations, which may adversely affect our business. </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Data loss or corruption due to failures or errors in our systems or service disruptions at our data centers may adversely affect our reputation and relationships with existing partners, which could have a negative impact on our business, financial condition and results of operations.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because of the large amount of data that we collect and manage, it is possible that hardware failures or errors in our systems could result in data loss or corruption or cause the information that we collect to be incomplete or contain inaccuracies that our partners regard as significant. Complex software such as ours may contain errors or failures that are not detected until after the software is introduced or updates and new versions are released. We continually introduce new software and updates and enhancements to our existing software. Despite testing by us, we may discover defects or errors in our software. In addition, we may encounter defects or errors in connection with the integration of software and technology we acquire. Any defects or errors could expose us to risk of liability to partners and the government and could cause delays in the introduction of new products and services, result in increased costs and diversion of development resources, require design modifications, decrease market acceptance or partner satisfaction with our products and services or cause harm to our reputation.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Furthermore, our partners might use our software together with products from other companies. As a result, when problems occur, it might be difficult to identify the source of the problem. Even when our software does not cause these problems, the existence of these errors might cause us to incur significant costs, divert the attention of our technical personnel from our product development efforts, impact our reputation and lead to significant partner relations problems.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Our business is subject to online security risks, and if we are unable to safeguard the security and privacy of confidential data, we may face significant liabilities and our reputation and business will be harmed.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our services involve the collection, storage and analysis of confidential information, including intellectual property and personal information of employees, health providers and others, as well as protected health information of our partners&#8217; patients. Because of the extreme sensitivity of this information, the security features of our computer, network, and communications systems infrastructure are very important. In certain cases, we provide such information to third parties, for example, to the service providers who provide hosting services for our technology platform, and we may be unable to control the use of such information or the security protections employed by such third parties. We may be required to expend significant capital and other resources to protect against security breaches or to alleviate problems caused by security breaches. Despite our implementation of security measures designed to help ensure data security and compliance with applicable laws and rules, our facilities and systems, and those of our third-party providers, are vulnerable to cyber-attacks, security breaches, acts of vandalism or theft (including by employees), computer viruses, misplaced or </span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">lost data, programming and/or human errors, power outages, hardware failures or other similar events. Furthermore, our increased use of mobile and cloud technologies, including as a result of the shift to work-from-home arrangements as a result of the COVID-19 pandemic, has heightened these cybersecurity and privacy risks, including risks from cyber-attacks such as phishing, spam emails, hacking, social engineering, and malicious software. If an actual or perceived breach of our security occurs, or if we are unable to effectively resolve such breaches in a timely manner, the market perception of the effectiveness of our security measures could be harmed and we could lose sales and partners, which could have a material adverse effect on our business, operations, and financial results.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A cyber-attack that bypasses our, or our third-party providers&#8217;, security systems successfully could require us to expend significant resources to remediate any damage, and prevent future occurrences, interrupt our operations, damage our reputation and our relationship with our partners, expose us or other third parties to a risk of loss or misuse of confidential information, reduce demand for our products and services or subject us to significant liability through litigation as well as regulatory action. While we maintain insurance covering certain security and privacy damages and claim expenses, we may not carry insurance or maintain coverage sufficient to compensate for all liability and such insurance may not be available for renewal on acceptable terms or at all, and in any event, insurance coverage would not address the reputational damage that could result from a security incident.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cyber attacks continue to evolve in sophistication and volume and may remain undetected for an extended period. In addition, techniques used to obtain unauthorized access to information or to sabotage information technology systems change frequently. We have seen, and will continue to see, industry-wide vulnerabilities, such as the Log4j vulnerability reported in December 2021, which could in the future affect our or other parties&#8217; systems. We expect to continue to experience such vulnerabilities in the future. The costs of attempting to protect against cybersecurity risks and the costs of responding to cyber-attacks are significant. This could require us to expend significant resources to continue to modify or enhance our protective measures and to remediate any damage.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">New data security laws and regulations are being implemented rapidly and are evolving, and we may not be able to timely comply with such requirements, and such requirements may not be compatible with our current processes. Changing our processes could be time consuming and expensive, and failure to timely implement required changes could subject us to liability for non-compliance.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">If we are unable to obtain, maintain and enforce intellectual property protection for our technology and products or if the scope of our intellectual property protection is not sufficiently broad, others may be able to develop and commercialize technology and products substantially similar to ours, and our ability to successfully commercialize our technology and products may be adversely affected.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our business depends on proprietary technology and content, including software, databases, confidential information and know-how, the protection of which is crucial to the success of our business. We rely on a combination of trademark, trade-secret and copyright laws and confidentiality procedures and contractual provisions to protect our intellectual property rights in our proprietary technology and content. We may, over time, increase our investment in protecting our intellectual property through additional trademark, patent and other intellectual property filings that could be expensive and time-consuming. Effective trademark, trade-secret and copyright protection is expensive to develop and maintain, both in terms of initial and ongoing registration requirements and the costs of defending our rights. These measures, however, may not be sufficient to offer us meaningful protection. If we are unable to protect our intellectual property and other proprietary rights, our competitive position and our business could be harmed, as third parties may be able to commercialize and use technologies and software products that are substantially the same as ours without incurring the development and licensing costs that we have incurred. Any of our owned or licensed intellectual property rights could be challenged, invalidated, circumvented, infringed or misappropriated, our trade secrets and other confidential information could be disclosed in an unauthorized manner to third parties, or our intellectual property rights may not be sufficient to permit us to take advantage of current market trends or otherwise to provide us with competitive advantages, which could result in costly redesign efforts, discontinuance of certain offerings or other competitive harm.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Monitoring unauthorized use of our intellectual property is difficult and costly. From time to time, we seek to analyze our competitors&#8217; products and services, and may in the future seek to enforce our rights against potential infringement. However, the steps we have taken to protect our proprietary rights may not be adequate to prevent infringement or misappropriation of our intellectual property. We may not be able to detect unauthorized use of, or take appropriate steps to enforce, our intellectual property rights. Any inability to meaningfully protect our intellectual property rights could result in harm to our ability to compete and reduce demand for our technology and products. Moreover, our failure to develop and properly manage new intellectual property could adversely affect our market positions and business opportunities. Also, some of our products and services rely on technologies and software developed by or licensed from third parties, and we may not be able to maintain our relationships with such third parties or enter into similar relationships in the future on reasonable terms or at all.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may also be required to protect our proprietary technology and content in an increasing number of jurisdictions, a process that is expensive and may not be successful, or which we may not pursue in every location. In addition, effective intellectual property protection may not be available to us in every country, and the laws of some foreign countries may not be as protective of intellectual property rights as those in the United States. Additional uncertainty may result from changes to intellectual property legislation </span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">32</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">enacted in the United States and elsewhere, and from interpretations of intellectual property laws by applicable courts and agencies. Accordingly, despite our efforts, we may be unable to obtain and maintain the intellectual property rights necessary to provide us with a competitive advantage. Our failure to obtain, maintain and enforce our intellectual property rights could therefore have a material adverse effect on our business, financial condition and results of operations.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">If our trademarks and trade names are not adequately protected, we may not be able to build name recognition in our markets of interest and our business may be adversely affected.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The registered or unregistered trademarks or trade names that we own or license may be challenged, infringed, circumvented, declared generic, lapsed or determined to be infringing on or dilutive of other marks. We may not be able to protect our rights in these trademarks and trade names, which we need in order to build name recognition with potential partners. In addition, third parties may in the future file for registration of trademarks similar or identical to our trademarks. If they succeed in registering or developing common law rights in such trademarks, and if we are not successful in challenging such third-party rights, we may not be able to use these trademarks to commercialize our technologies or products in certain relevant countries. If we are unable to establish name recognition based on our trademarks and trade names, we may not be able to compete effectively and our business may be adversely affected.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Third parties may initiate legal proceedings alleging that we are infringing or otherwise violating their intellectual property rights, the outcome of which would be uncertain and could have a material adverse effect on our business, financial condition and results of operations.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our commercial success depends on our ability to develop and commercialize our services and use our proprietary technology without infringing the intellectual property or proprietary rights of third parties. Intellectual property disputes can be costly to defend and may cause our business, operating results and financial condition to suffer. As the market for health care in the United States expands and more patents are issued, the risk increases that there may be patents issued to third parties that relate to our products and technology of which we are not aware or that we must challenge to continue our operations as currently contemplated. Whether merited or not, we may face allegations that we, our partners, our licensees or parties indemnified by us have infringed or otherwise violated the patents, trademarks, copyrights or other intellectual property rights of third parties. Such claims may be made by competitors seeking to obtain a competitive advantage or by other parties. Additionally, in recent years, individuals and groups have begun purchasing intellectual property assets for the purpose of making claims of infringement and attempting to extract settlements from companies like ours. We may also face allegations that our employees have misappropriated the intellectual property or proprietary rights of their former employers or other third parties. It may be necessary for us to initiate litigation to defend ourselves in order to determine the scope, enforceability and validity of third-party intellectual property or proprietary rights, or to establish our respective rights. Regardless of whether claims that we are infringing patents or other intellectual property rights have merit, such claims can be time-consuming, divert management&#8217;s attention and financial resources and can be costly to evaluate and defend. Results of any such litigation are difficult to predict and may require us to stop commercializing or using our products or technology, obtain licenses, modify our services and technology while we develop non-infringing substitutes or incur substantial damages, settlement costs or face a temporary or permanent injunction prohibiting us from marketing or providing the affected products and services. If we require a third-party license, it may not be available on reasonable terms or at all, and we may have to pay substantial royalties, upfront fees or grant cross-licenses to intellectual property rights for our products and services. We may also have to redesign our products or services so they do not infringe third-party intellectual property rights, which may not be possible or may require substantial monetary expenditures and time, during which our technology and products may not be available for commercialization or use. Even if we have an agreement to indemnify us against such costs, the indemnifying party may be unable to uphold its contractual obligations. If we cannot or do not obtain a third-party license to the infringed technology on reasonable terms or at all, or obtain similar technology from another source, our revenue and earnings could be adversely impacted.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, we have been and may be subject to legal proceedings and claims in the ordinary course of business with respect to intellectual property. We are not currently subject to any claims from third parties asserting infringement of their intellectual property rights. Some third parties may be able to sustain the costs of complex litigation more effectively than we can because they have substantially greater resources. Even if resolved in our favor, litigation or other legal proceedings relating to intellectual property claims may cause us to incur significant expenses and could distract our technical and management personnel from their normal responsibilities. In addition, there could be public announcements of the results of hearings, motions or other interim proceedings or developments, and if securities analysts or investors perceive these results to be negative, it could have a material adverse effect on the price of our Class A common stock. Moreover, any uncertainties resulting from the initiation and continuation of any legal proceedings could have a material adverse effect on our ability to raise the funds necessary to continue our operations. Assertions by third parties that we violate their intellectual property rights could therefore have a material adverse effect on our business, financial condition and results of operations.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Our use of &#8220;open source&#8221; software could adversely affect our ability to offer our services and subject us to possible litigation.</span></div><div style="text-align:justify"><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">33</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We use open source software in connection with our products and services. Companies that incorporate open source software into their products have, from time to time, faced claims challenging the use of open source software and/or compliance with open source license terms. As a result, we could be subject to suits by parties claiming ownership of what we believe to be open source software or claiming noncompliance with open source licensing terms. Some open source software licenses require users who distribute software containing open source software to publicly disclose all or part of the source code to such software and/or make available any derivative works of the open source code, which could include valuable proprietary code of the user, on unfavorable terms or at no cost. While we monitor the use of open source software and try to ensure that none is used in a manner that would require us to disclose our proprietary source code or that would otherwise breach the terms of an open source agreement, such use could inadvertently occur, in part because open source license terms are often ambiguous. Any requirement to disclose our proprietary source code or pay damages for breach of contract could have a material adverse effect on our business, financial condition and results of operations and could help our competitors develop products and services that are similar to or better than ours.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">If we are unable to protect the confidentiality of our trade secrets, know-how and other proprietary information, the value of our technology and products could be adversely affected.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may not be able to protect our trade secrets, know-how and other proprietary information adequately. Although we use reasonable efforts to protect this proprietary information and technology, our employees, consultants and other parties may unintentionally or willfully disclose our information or technology to competitors. Enforcing a claim that a third-party illegally obtained and is using any of our proprietary information or technology is expensive and time-consuming, and the outcome is unpredictable. In addition, courts outside the United States are sometimes less willing to protect trade secrets, know-how and other proprietary information. We rely, in part, on non-disclosure, confidentiality and invention assignment agreements with our employees, consultants and other parties to protect our trade secrets, know-how and other intellectual property and proprietary information. These agreements may not be self-executing, or they may be breached and we may not have adequate remedies for such breach. Moreover, third parties may independently develop similar or equivalent proprietary information or otherwise gain access to our trade secrets, know-how and other proprietary information.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">We depend on certain technologies that are licensed to us. We do not control the intellectual property rights covering these technologies and any loss of our rights to these technologies or the rights licensed to us could prevent us from developing and/or commercializing our products.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a party to a number of license agreements under which we are granted rights to intellectual property that is important to our business, and we expect that we may need to enter into additional license agreements in the future. We rely on these licenses to use various proprietary technologies that may be material to our business, including without limitation those technologies licensed under an intellectual property and development services license agreement between us and UPMC, or the UPMC IP Agreement, and a technology license agreement between us and UPMC, or the UPMC Technology Agreement. Under the UPMC IP Agreement, certain of UPMC&#8217;s proprietary analytics models and know-how are licensed to us on a nonexclusive basis from UPMC; pursuant to the UPMC Technology Agreement, UPMC&#8217;s proprietary technology platform, associated know-how and the Identifi&#174; trademark are licensed to us on an irrevocable, non-exclusive basis from UPMC; in each case, subject to certain ongoing territorial, time and use restrictions. Our rights to use these technologies and know-how and employ the software claimed in the licensed technologies are subject to the continuation of and our compliance with the terms of those licenses. Our existing license agreements impose, and we expect that future license agreements will impose on us, various exclusivity obligations. If we fail to comply with our obligations under these agreements, the applicable licensor may have the right to terminate our license, in which case we may not be able to develop or commercialize the products or technologies covered by the license.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Disputes may arise between us and our licensors regarding intellectual property rights subject to a license agreement, including:</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the scope of rights granted under the license agreement and other interpretation-related issues;</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">whether and the extent to which our technology and processes infringe on intellectual property of the licensor that is not subject to the license agreement;</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">our obligations with respect to the use of the licensed technology in relation to our services and technologies, and which activities satisfy those obligations;</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">whether our activities are in compliance with the restrictions placed upon our rights to use the licensed technology by our licensors; and</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the ownership of inventions and know-how resulting from the joint creation or use of intellectual property by our licensors and us and our partners.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If disputes over intellectual property rights that we have licensed prevent or impair our ability to maintain our current licensing arrangements on acceptable terms, we may be unable to obtain equivalent replacement licensing arrangements or to successfully develop and commercialize the affected products and technologies.</span></div><div style="text-align:justify"><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">34</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The risks described elsewhere pertaining to our intellectual property rights also apply to the intellectual property rights that we license, and any failure by us or our licensors to obtain, maintain and enforce these rights could have a material adverse effect on our business. In some cases, we do not have control over the prosecution, maintenance or enforcement of the intellectual property rights that we license, and may not have sufficient ability to consult and input into the prosecution and maintenance process with respect to such intellectual property, and our licensors may fail to take the steps we feel are necessary or desirable in order to obtain, maintain and enforce the licensed intellectual property rights and, as a result, our ability to retain our competitive advantage with respect to our products and technologies may be materially affected.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Any restrictions on our use of, or ability to license, data, or our failure to license data and integrate third-party technologies, could have a material adverse effect on our business, financial condition and results of operations.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We depend upon licenses from third parties for some of the technology and data used in our applications, and for some of the technology platforms upon which these applications are built and operate, including under the UPMC IP Agreement and the UPMC Technology Agreement. We expect that we may need to obtain additional licenses from third parties in the future in connection with the development of our products and services. In addition, we obtain a portion of the data that we use from government entities, public records and from our partners for specific partner engagements. We believe that we have all rights necessary to use the data that is incorporated into our products and services. However, we cannot assure you that our licenses for information will allow us to use that information for all potential or contemplated applications and products. In addition, certain of our products depend on maintaining our data and analytics platform, which is populated with data disclosed to us by our partners with their consent. If these partners revoke their consent for us to maintain, use, de-identify and share this data, consistent with applicable law, our data assets could be degraded.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the future, data providers could withdraw their data from us or restrict our usage for any reason, including if there is a competitive reason to do so, if legislation is passed restricting the use of the data or if judicial interpretations are issued restricting use of the data that we currently use in our products and services. In addition, data providers could fail to adhere to our quality control standards in the future, causing us to incur additional expense to appropriately utilize the data. If a substantial number of data providers were to withdraw or restrict their data, or if they fail to adhere to our quality control standards, and if we are unable to identify and contract with suitable alternative data suppliers and integrate these data sources into our service offerings, our ability to provide products and services to our partners would be materially adversely impacted, which could have a material adverse effect on our business, financial condition and results of operations.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also integrate into our proprietary applications and use third-party software to maintain and enhance, among other things, content generation and delivery, and to support our technology infrastructure. Some of this software is proprietary and some is open source software. These technologies may not be available to us in the future on commercially reasonable terms or at all and could be difficult to replace once integrated into our own proprietary applications. Most of these licenses can be renewed only by mutual consent and may be terminated if we breach the terms of the license and fail to cure the breach within a specified period of time. Our inability to obtain, maintain or comply with any of these licenses could delay development until equivalent technology can be identified, licensed and integrated, which would harm our business, financial condition and results of operations.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Most of our third-party licenses are non-exclusive and our competitors may obtain the right to use any of the technology covered by these licenses to compete directly with us. Our use of third-party technologies exposes us to increased risks, including, but not limited to, risks associated with the integration of new technology into our solutions, the diversion of our resources from development of our own proprietary technology and our inability to generate revenue from licensed technology sufficient to offset associated acquisition and maintenance costs. In addition, if our data suppliers choose to discontinue support of the licensed technology in the future, we might not be able to modify or adapt our own solutions.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">We rely on Internet infrastructure, bandwidth providers, data center providers, other third parties and our own systems for providing services to our partners, and any failure or interruption in the services provided by these third parties or our own systems could expose us to litigation and negatively impact our relationships with partners, adversely affecting our brand and our business.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our ability to deliver our products and services, particularly our cloud-based solutions, is dependent on the development and maintenance of the infrastructure of the Internet and other telecommunications services by third parties. This includes maintenance of a reliable network connection with the necessary speed, data capacity and security for providing reliable Internet access and services and reliable telephone and facsimile services. As a result, our information systems require an ongoing commitment of significant resources to maintain and enhance existing systems and develop new systems in order to keep pace with continuing changes in information technology, emerging cybersecurity risks and threats, evolving industry and regulatory standards and changing preferences of our partners.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our services are designed to operate without interruption in accordance with our service level commitments. However, we have experienced limited interruptions in these systems in the past, including server failures that temporarily slow down the performance of our services, and we may experience more significant interruptions in the future. We rely on internal systems as well as third-party </span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">35</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">suppliers, including bandwidth and telecommunications equipment providers, to provide our services. We do not maintain redundant systems or facilities for some of these services. Interruptions in these systems, whether due to system failures, computer viruses, physical or electronic break-ins or other catastrophic events, could affect the security or availability of our services and prevent or inhibit the ability of our partners to access our services. These systems may be at greater risk of interruption as a result of increased use of mobile and cloud technologies, including as a result of the shift to work-from-home arrangements as a result of the COVID-19 pandemic.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the event of a catastrophic event with respect to one or more of these systems or facilities, we may experience an extended period of system unavailability, which could result in substantial costs to remedy those problems or negatively impact our relationship with our partners, our business, results of operations and financial condition. To operate without interruption, both we and our service providers must guard against:</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">damage from fire, power loss and other natural disasters;</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">telecommunications failures;</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">software and hardware errors, failures and crashes;</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">security breaches, computer viruses and similar disruptive problems; and</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">other potential interruptions.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any disruption in the network access, telecommunications or co-location services provided by third-party providers or any failure of or by third-party providers&#8217; systems or our own systems to handle current or higher volume of use could significantly harm our business. We exercise limited control over our third-party suppliers, which increases our vulnerability to problems with services they provide. Any errors, failures, interruptions or delays experienced in connection with these third-party technologies and information services or our own systems could negatively impact our relationships with partners and adversely affect our business and could expose us to third-party liabilities. Although we maintain insurance for our business, the coverage under our policies may not be adequate to compensate us for all losses that may occur. In addition, we cannot provide assurance that we will continue to be able to obtain adequate insurance coverage at an acceptable cost.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The reliability and performance of our Internet connection may be harmed by increased usage or by denial-of-service attacks. The Internet has experienced a variety of outages and other delays as a result of damages to portions of its infrastructure, and it could face outages and delays in the future. These outages and delays could reduce the level of Internet usage as well as the availability of the Internet to us for delivery of our Internet-based services.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">We rely on third-party vendors to host and maintain our technology platform.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We rely on third-party vendors to host and maintain our technology platform, including Identifi&#174;. Our ability to offer our services and operate our business is therefore dependent on maintaining our relationships with third-party vendors and entering into new relationships to meet the changing needs of our business. Any deterioration in our relationships with such vendors or our failure to enter into agreements with vendors in the future could harm our business, results of operations and financial condition. Despite precautions taken at our vendors&#8217; facilities, the occurrence of a natural disaster, a decision to close the facilities without adequate notice or other unanticipated problems, including relating to the COVID-19 pandemic, could result in lengthy interruptions in our service. These service interruption events could cause our platform to be unavailable to our partners and impair our ability to deliver services and to manage our relationships with new and existing partners, which in turn could materially affect our results of operations.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If our vendors are unable or unwilling to provide the services necessary to support our business, or if our agreements with such vendors are terminated, our operations could be significantly disrupted. Certain vendor agreements may be unilaterally terminated by the licensor for convenience, and if such agreements are terminated, we may not be able to enter into similar relationships in the future on reasonable terms or at all. We may also incur substantial costs, delays and disruptions to our business in transitioning such services to ourselves or other third-party vendors. In addition, third-party vendors may not be able to provide the services required in order to meet the changing needs of our business.</span></div><div style="text-align:justify"><span><br/></span></div><div id="i9aaa2fddc97e482da5dbe37ac85ae703_2537"></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks relating to internal control over financial reporting </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">We have previously identified material weaknesses in our internal control over financial reporting. Although the material weaknesses were remediated, if we identify additional material weaknesses in the future, we and our auditor may conclude that our internal control over financial reporting is not effective and we may be unable to produce timely and accurate financial statements, any of which could adversely impact our investors&#8217; confidence and our stock price.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our management is responsible for establishing and maintaining adequate internal control over financial reporting. The Company&#8217;s internal control over financial reporting includes policies and procedures that provide reasonable assurance regarding the reliability of </span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">36</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">financial reporting and the preparation of financial statements for external reporting purposes in accordance with U.S. generally accepted accounting principles.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A material weakness is a deficiency, or a combination of deficiencies, in internal control over financial reporting, such that a reasonable possibility exists that a material misstatement of our annual or interim financial statements would not be prevented or detected on a timely basis.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our efforts to design and implement an effective control environment may not be sufficient to identify or prevent future material weaknesses or significant deficiencies from occurring. Any newly identified material weakness could result in a misstatement of our financial statements or disclosures that would result in a material misstatement of our annual or interim consolidated financial statements that would not be prevented or detected. A control system, no matter how well designed and operated, can provide only reasonable assurance that the control system&#8217;s objectives will be met. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that misstatements due to error or fraud will not occur or that all control issues and all instances of fraud will be detected. In addition, if we identify future material weaknesses in our internal controls over financial reporting or if we are unable to comply with the demands that are placed upon us as a public company, including the requirements of Section 404 of the Sarbanes-Oxley Act, in a timely manner, we may be unable to accurately report our financial results, or report them within the timeframes required by the SEC. We also could become subject to investigations by the NYSE, the SEC or other regulatory authorities.</span></div><div style="text-align:justify"><span><br/></span></div><div id="i9aaa2fddc97e482da5dbe37ac85ae703_190"></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks relating to our structure </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">We are required to pay certain of our pre-IPO investors for certain tax benefits we may claim in the future, and these amounts are expected to be material.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under an exchange agreement we entered into at the time of our IPO, we granted TPG, The Advisory Board and Ptolemy Capital (together, the &#8220;Investor Stockholders&#8221;) an exchange right that allowed for receipt of newly-issued shares of the Company&#8217;s Class A common stock in exchange (a &#8220;Class B Exchange&#8221;) for an equal number of shares of the Company&#8217;s Class B common stock (which were subsequently canceled) and an equal number of Evolent Health LLC&#8217;s Class B common units. Class B common units received by the Company from relevant Investor Stockholders were simultaneously exchanged for an equivalent number of Class A units of Evolent Health LLC, and Evolent Health LLC cancelled the Class B common units it received in the Class B Exchanges, resulting in an increase in the Company&#8217;s economic interest in Evolent Health LLC.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2019, all of the Class B common units held by the Investor Stockholders and certain other stockholders had been exchanged (together with an equal number of shares) for our Class A common stock. These exchanges resulted in increases in the tax basis of our share of the assets of Evolent Health LLC that otherwise would not have been available to the Company. In addition, we expect that certain NOLs will be available to us as a result of the transactions as described in &#8220;Part II - Item 8. Financial Statements and Supplementary Data - Note 15 - &#8220;Tax Receivables Agreement.&#8221; These increases in tax basis and NOLs may reduce the amount of tax that we may otherwise be required to pay in the future, although the Internal Revenue Service (&#8220;IRS&#8221;) may challenge all or a part of the tax basis increases and NOLs, and a court could sustain such a challenge.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have entered into the TRA, related to the tax basis step-up of the assets of Evolent Health LLC and certain NOLs of the former members of Evolent Health LLC, with the Investor Stockholders and certain of our other investors (the &#8220;TRA Holders&#8221;). Pursuant to the TRA, we will pay the TRA Holders 85% of the amount of the cash savings, if any, in U.S. federal, state and local and non-U.S. income tax that we realize as a result of increases in tax basis resulting from exchanges of Class B common units for shares of our Class A common stock (calculated assuming that any post-IPO transfer of Class B common units (other than the exchanges) had not occurred) as well as certain other benefits attributable to payments under the TRA itself.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The TRA also requires us to pay 85% of the amount of the cash savings, if any, in U.S. federal, state and local and non-U.S. income tax that we realize as a result of the utilization of the NOLs of Evolent Health Holdings and an affiliate of TPG attributable to periods prior to our IPO and the deduction of any imputed interest attributable to our payment obligations under the TRA.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The payments that we make under the TRA could be substantial. Assuming no material changes in relevant tax law and based on our current operating plan and other assumptions, including our estimate of the tax basis of our assets as of the date of the Offering Reorganization and the estimated tax basis step-ups resulting from each completed exchange, we estimate that the total amount that we would be required to pay under the TRA could be approximately $109.8 million. This estimated amount includes approximately $17.2 million of potential future payments under the TRA related to the future utilization of the pre-IPO NOLs described above and approximately $92.6 million of potential future payments related to the tax basis step-up of the assets of Evolent Health LLC in connection with the exchanges that occurred in connection with our completed secondary offerings and private sales. The actual amount we will be required to pay under the TRA may be materially greater than these hypothetical amounts, as potential future payments will vary as a consequence of our tax position, the relevant tax basis analysis, our ability to generate sufficient future taxable </span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">37</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">income in order to be able to benefit from the aforementioned tax attributes, the character and timing of our taxable income and the income tax rates applicable at the time we realize cash savings attributable to our recognition and utilization of the aforementioned tax attributes. Payments under the TRA are not conditioned on our existing investors&#8217; continued ownership of any of our equity.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">We will not be reimbursed for any payments made under the TRA in the event that any tax benefits are disallowed.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the IRS successfully challenges the tax basis increases resulting from the Class B Exchanges or the existence or amount of the pre-IPO NOLs at any point in the future after payments are made under the TRA, we will not be reimbursed for any payments we had made under the TRA (although future payments under the TRA, if any, would be netted against any unreimbursed payments to reflect the result of any such successful challenge by the IRS). As a result, in certain circumstances, we could be required to make payments under the TRA in excess of our cash tax savings.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">We may not be able to realize all or a portion of the tax benefits that resulted from the exchanges of Class B common units for our Class A common stock or from the utilization of NOLs previously held by Evolent Health Holdings and an affiliate of TPG and from payments made under the TRA.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our ability to realize the tax benefits that we expect to be available as a result of the increases in tax basis created by the Class B Exchanges and by the payments made pursuant to the TRA, and our ability to utilize the pre-IPO NOLs of Evolent Health Holdings and an affiliate of TPG and the interest deductions imputed under the TRA all depend on a number of assumptions, including that we earn sufficient taxable income each year during the period over which such deductions are available and that there are no adverse changes in applicable law or regulations. If our actual taxable income is insufficient or there are adverse changes in applicable law or regulations, we may be unable to realize all or a portion of these expected benefits and our cash flows and stockholders&#8217; equity could be negatively affected. Please refer to the discussion in &#8220;Part II - Item 8. Financial Statements and Supplementary Data - Note 15 - Tax Receivables Agreement&#8221; for additional information.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">In certain cases, payments by us under the TRA may be accelerated or significantly exceed the tax benefits we realize in respect of the tax attributes subject to the TRA.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The TRA provides that upon certain changes of control, or if, at any time, we elect an early termination of the TRA or are in material breach of our obligations under the TRA, we would be required to make an immediate payment equal to the present value of the anticipated future tax benefits to certain current or former shareholders. Such payment would be based on certain valuation assumptions and deemed events set forth in the TRA, including the assumption that we have sufficient taxable income to fully utilize such tax benefits. The benefits would be payable even though, in certain circumstances, no tax basis step-up deductions and no NOLs are actually used at the time of the accelerated payment under the TRA. Accordingly, payments under the TRA may be made years in advance of the actual realization, if any, of the anticipated future tax benefits and may be significantly greater than the benefits we realize in respect of the tax attributes subject to the TRA. In these situations, our obligations under the TRA could have a substantial negative impact on our liquidity. We may not be able to finance our obligations under the TRA and any indebtedness we incur may limit our subsidiaries&#8217; ability to make distributions to us to pay these obligations. In addition, our obligations under the TRA could have the effect of delaying, deferring or preventing certain mergers, asset sales, other forms of business combinations or other changes of control that could be in the best interests of holders of our Class A common stock.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The agreements between us and certain of our pre-IPO investors were made in the context of an affiliated relationship and may contain different terms than comparable agreements with unaffiliated third parties.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The contractual agreements that we have with certain of our pre-IPO investors were negotiated in the context of an affiliated relationship in which representatives of such pre-IPO investors and their affiliates comprised a significant portion of our board of directors. As a result, the financial provisions, and the other terms of these agreements, such as covenants, contractual obligations on our part and on the part of such pre-IPO investors and termination and default provisions, may be less favorable to us than terms that we might have obtained in negotiations with unaffiliated third parties in similar circumstances, which could have a material adverse effect on our business, financial condition and results of operations.</span></div><div><span><br/></span></div><div id="i9aaa2fddc97e482da5dbe37ac85ae703_193"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Relating to Our Convertible Notes</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The conditional conversion feature of the 2025 Notes, if triggered, may adversely affect our financial condition and operating results.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the event the conditional conversion feature of the 2025 Notes is triggered, holders of such notes will be entitled to convert such notes at any time during specified periods at their option. If one or more holders elect to convert their 2025 Notes, unless we elect to satisfy our conversion obligation by delivering solely shares of our Class A common stock (other than paying cash in lieu of delivering any fractional share), we would be required to settle a portion or all of our conversion obligation through the payment of cash, which could adversely affect our liquidity. In addition, even if holders do not elect to convert their notes, we could be required under </span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">38</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">applicable accounting rules to reclassify all or a portion of the outstanding principal of the 2025 Notes, as applicable, as a current rather than long-term liability, which would result in a material reduction of our net working capital.</span></div><div style="text-align:justify"><span><br/></span></div><div id="i9aaa2fddc97e482da5dbe37ac85ae703_196"></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks relating to ownership of our Class A common stock</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">We expect that our stock price will be volatile and may fluctuate or decline significantly.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The trading price of our Class A common stock has been and may continue to be volatile and subject to wide price fluctuations in response to various factors, including:</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">economic and political conditions or events;</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">market conditions in the broader stock market in general, or in our industry in particular, including as a result of COVID-19 related impacts;</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">actual or anticipated fluctuations in our quarterly financial reports and results of operations;</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">our ability to satisfy our ongoing capital needs and unanticipated cash requirements;</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">indebtedness incurred in the future;</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">introduction of new products and services by us or our competitors;</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">business developments of our partners;</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">issuance of new or changed securities analysts&#8217; reports or recommendations;</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">sales of large blocks of our stock;</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">additions or departures of key personnel;</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">regulatory developments; and</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">litigation and governmental investigations.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">These and other factors may cause the market price and demand for our Class A common stock to fluctuate substantially, which may limit or prevent investors from readily selling their shares of Class A common stock, including any shares of Class A common stock they receive upon conversion of our convertible notes, and may otherwise negatively affect the liquidity of our Class A common stock. In addition, in the past, when the market price of a stock has been volatile, holders of that stock have instituted securities class action litigation against the company that issued the stock. We are, and from time to time may become, subject to such litigation, and we could incur substantial costs defending a lawsuit. Such a lawsuit could also divert the time and attention of our management from our business.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The trading market for our Class A common stock will also be influenced by the research and reports that industry or securities analysts publish about us or our business. If one or more of the analysts who cover us downgrades our stock, or if our results of operations do not meet their expectations, our stock price could decline.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">We are subject to securities class action litigation and an adverse outcome in such litigation could have an adverse effect on our financial condition.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On August 8, 2019, a shareholder of the Company filed a class action complaint against the Company, asserting claims under Section 10(b) and 20(a) of the Securities Exchange Act of 1934.  An amended complaint was filed on January 10, 2020, a second amended complaint was filed on June 8, 2020, and a third amended complaint, now titled</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%"> Plymouth County Retirement System v. Evolent Health, Inc., Frank Williams, Nicholas McGrane, Seth Blackley,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> was filed on December 2, 2021. The case, alleges that the Company&#8217;s executives made false or misleading statements regarding its business with Passport. The Company filed a motion to dismiss the second amended complaint, and the Eastern District of Virginia granted in part and denied in part the motion on March 24, 2021. The case entered the discovery phase, but discovery is again stayed pending a decision on the company&#8217;s third motion to dismiss, which was filed December 17, 2021. Briefing on the motion to dismiss was completed on February 10, 2022, and oral argument will be held on March 11, 2022. We and the individuals dispute these claims and intend to defend the matter vigorously. This litigation could result in substantial costs and have and may continue to result in a diversion of management&#8217;s resources and attention, which could harm our business and the value of our common stock.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">The market price of our Class A common stock could decline due to the large number of shares of Class A common stock issuable upon conversion of our convertible notes, or by sales or issuances of substantial amounts of our Class A common stock.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The market price of our Class A common stock could decline as a result of sales of a large number of the shares of our Class A common stock issuable upon the conversion of our convertible notes, or the perception that such sales could occur. These sales, or the possibility that these sales may occur, may also make it more difficult for us to raise additional capital by selling equity or equity-linked securities in the future, at a time and price that we deem appropriate. As of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:112%">February&#160;18, 2022</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:112%">90,827,306</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> shares of our Class A common stock were outstanding. Up to a maximum of 13.3 million shares of our Class A common stock is reserved for issuance upon the conversion of our convertible notes. Similarly, sales or issuances of substantial amounts of our Class A common stock in the public market by us or by our stockholders into the public market could cause the market price of our Class A common stock to decrease significantly.</span></div><div style="text-align:justify"><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">39</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Some provisions of Delaware law, our second amended and restated certificate of incorporation and our third amended and restated by-laws and certain of our contracts may deter third parties from acquiring us.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Among other things, our second amended and restated certificate of incorporation and our third amended and restated by-laws:</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">prohibit stockholder action by written consent;</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">authorize the issuance of &#8220;blank check&#8221; preferred stock that could be issued by our board of directors to increase the number of outstanding shares of capital stock, making a takeover more difficult and expensive;</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">prohibit cumulative voting in the election of directors, which would otherwise allow less than a majority of stockholders to elect director candidates;</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">provide that special meetings of the stockholders may be called only by or at the direction of the board of directors, the chairman of our board or the chief executive officer; and</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">require advance notice to be given by stockholders for any stockholder proposals or director nominees.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, Section 203 of the DGCL may affect the ability of an &#8220;interested stockholder&#8221; to engage in certain business combinations, for a period of three years following the time that the stockholder becomes an &#8220;interested stockholder.&#8221; We have elected in our second amended and restated certificate of incorporation not to be subject to Section 203 of the DGCL. Nevertheless, our second amended and restated certificate of incorporation contains provisions that have the same effect as Section 203 of the DGCL, except that they provide that each of TPG, UPMC and The Advisory Board and their transferees will not be deemed to be &#8220;interested stockholders,&#8221; and accordingly are not subject to such restrictions.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These and other provisions could have the effect of discouraging, delaying or preventing a transaction involving a change in control of our company or could make it more difficult for stockholders to elect directors of their choosing or to cause us to take other corporate actions that they desire. Provisions in certain of our contracts may also deter third parties from acquiring us. In addition, certain partners would have the right to terminate if we are acquired by certain competitors.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Our second amended and restated certificate of incorporation and stockholders&#8217; agreement contain provisions renouncing our interest and expectation to participate in certain corporate opportunities identified by or presented to certain of our pre-IPO investors.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">UPMC and its affiliates may engage in activities similar to ours or lines of business or have an interest in the same areas of corporate opportunities as we do. Our second amended and restated certificate of incorporation and stockholders&#8217; agreement provide that UPMC and its affiliates do not have any duty to refrain from (1) engaging, directly or indirectly, in the same or similar business activities or lines of business as us, including those business activities or lines of business deemed to be competing with us, or (2) doing business with any of our clients, customers or vendors. In the event that UPMC or any of its affiliates acquires knowledge of a potential business opportunity which may be a corporate opportunity for us, they have no duty to communicate or offer such corporate opportunity to us. Our second amended and restated certificate of incorporation and stockholders&#8217; agreement also provide that, to the fullest extent permitted by law, UPMC and its affiliates will not be liable to us for breach of any fiduciary duty or otherwise, by reason of directing such corporate opportunity to another person, or otherwise not communicating information regarding such corporate opportunity to us, and we have waived and renounced any claim that such business opportunity constituted a corporate opportunity that should have been presented to us. These potential conflicts of interest could have a material adverse effect on our business, financial condition, results of operations or prospects if attractive business opportunities are allocated by UPMC to itself or its affiliates instead of to us.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Our second amended and restated certificate of incorporation designates courts in the State of Delaware as the sole and exclusive forum for certain types of actions and proceedings that may be initiated by our stockholders, which could limit our stockholders&#8217; ability to obtain a favorable judicial forum for disputes with us or our directors, officers or employees.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our second amended and restated certificate of incorporation provides that, subject to limited exceptions, the Court of Chancery of the State of Delaware is the sole and exclusive forum for (a) any derivative action or proceeding brought on our behalf, (b) any action asserting a claim of breach of a fiduciary duty owed by any of our directors, officers or other employees to us or our stockholders, (c) any action asserting a claim against us arising pursuant to any provision of the DGCL, our second amended and restated certificate of incorporation or our third amended and restated by-laws, (d) any action to interpret, apply, enforce or determine the validity of our second amended and restated certificate of incorporation or third amended and restated by-laws or (e) any other action asserting a claim against us that is governed by the internal affairs doctrine. We refer to each of these proceedings as a covered proceeding. In addition, our second amended and restated certificate of incorporation provides that if any action the subject matter of which is a covered proceeding is filed in a court other than the specified Delaware courts without the approval of our board of directors, which we refer to as a foreign action, the claiming party will be deemed to have consented to (1) the personal jurisdiction of the specified Delaware courts in connection with any action brought in any such courts to enforce the exclusive forum provision described above and (2) having service of process made upon such claiming party in any such enforcement action by service upon such claiming </span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">40</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">party&#8217;s counsel in the foreign action as agent for such claiming party. Any person or entity purchasing or otherwise acquiring any interest in shares of our capital stock will be deemed to have notice of and to have consented to these provisions. These provisions may limit a stockholder&#8217;s ability to bring a claim in a judicial forum that it finds favorable for disputes with us or our directors, officers or other employees, which may discourage such lawsuits against us and our directors, officers and employees. Alternatively, if a court were to find these provisions of our second amended and restated certificate of incorporation inapplicable to, or unenforceable in respect of, one or more of the specified types of actions or proceedings, we may incur additional costs associated with resolving such matters in other jurisdictions, which could adversely affect our business and financial condition.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">We do not anticipate paying any cash dividends in the foreseeable future.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We currently intend to retain our future earnings, if any, for the foreseeable future to fund the development and growth of our business. We do not intend to pay any dividends to holders of our Class A common stock. As a result, capital appreciation in the price of our Class A common stock, if any, will be your only source of gain on an investment in our Class A common stock. See &#8220;Part II - Item 5. Market for Registrant&#8217;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities - Dividends&#8221; for a discussion of our dividend policy.</span></div><div style="text-align:justify"><span><br/></span></div><div id="i9aaa2fddc97e482da5dbe37ac85ae703_268"></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 1B. Unresolved Staff Comments</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div style="text-align:justify"><span><br/></span></div><div id="i9aaa2fddc97e482da5dbe37ac85ae703_247"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 2. Properties</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our corporate headquarters and executive officers are located in Arlington, Virginia, where we occupy approximately 29,000 square feet of office space. We also lease offices throughout the United States and in Pune, India. We lease all of our facilities and we do not own any real property. As provided in &#8220;Part II &#8211; Item 8. Financial Statements and Supplementary Data - Note 12 - Leases,&#8221; the total rental expense on operating leases, net of sublease income, was $18.0 million for the year ended December 31, 2021.</span></div><div style="text-align:justify"><span><br/></span></div><div id="i9aaa2fddc97e482da5dbe37ac85ae703_175"></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 3. Legal Proceedings</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The discussion in &#8220;Part II &#8211; Item 8. Financial Statements and Supplementary Data - Note 11 - Commitments and Contingencies - Litigation Matters&#8221; is incorporated by reference into this Part II, Item 1.</span></div><div style="text-align:justify"><span><br/></span></div><div id="i9aaa2fddc97e482da5dbe37ac85ae703_205"></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 4.  Mine Safety Disclosures</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div style="text-align:justify"><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">41</span></div></div></div><div id="i9aaa2fddc97e482da5dbe37ac85ae703_172"></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART II</span></div><div style="text-align:center"><span><br/></span></div><div id="i9aaa2fddc97e482da5dbe37ac85ae703_262"></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 5.  Market for Registrant&#8217;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Market and Dividend Information</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Market Information</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Class A common stock is traded on the New York Stock Exchange under the symbol &#8220;EVH.&#8221; </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Holders</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of February&#160;18, 2022, there were 50 holders of record of our Class A common stock. The number of record holders does not include individuals or entities who beneficially own shares and whose shares are held of record by a broker, bank, or other nominee, but does include each such broker, bank, or other nominee as one record holder.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Dividends</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have not declared or paid any cash dividends on our common stock. We do not anticipate paying any cash dividends on our Class A common stock for the foreseeable future. The timing and amount of future cash dividends, if any, is periodically evaluated by our board of directors and would depend on, among other factors, our current and expected earnings, financial condition, projected cash flows and anticipated financing needs.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Performance Graph</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following graph compares the cumulative total stockholder return on our Class A common stock for the last 5 years ended December&#160;31, 2021, to the cumulative total returns of the NASDAQ Health Care Index and the NYSE Composite Index over the same period. This graph assumes an investment of $100 at the closing price of the markets on December 31, 2016, in our Class A common stock, the NASDAQ Health Care Index and the NYSE Composite Index, and assumes the reinvestment of dividends, if any. </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The comparisons shown in the following graph are based upon historical data. We caution that the stock price performance shown in the graph below is not necessarily indicative of, nor is it intended to forecast, the potential future performance of our Class A common stock.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><img src="evh-20211231_g1.jpg" alt="evh-20211231_g1.jpg" style="height:333px;margin-bottom:5pt;vertical-align:text-bottom;width:694px"/></div><div style="text-align:justify"><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">42</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recent Sales of Unregistered Securities, Purchases of Equity Securities by the Issuer or Affiliated Purchases or Other Stockholder Matters</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November 15, 2021, we issued 15,642 shares of our Class A common stock in connection with a contingent consideration earn-out provision pursuant to the terms of an agreement between the Company and The Accountable Care Organization, Ltd. The issuance was exempt from registration under the Securities Act in reliance upon Section 4(a)(2) and Rule 506(b) of the Securities Act as a transaction by an issuer not involving a public offering. We determined that the purchasers of shares of Class A common stock in the transaction were accredited investors. The Company did not engage in a general solicitation or advertising with regard to the issuance and contribution of the Class A common stock issued in connection with the transaction.</span></div><div><span><br/></span></div><div id="i9aaa2fddc97e482da5dbe37ac85ae703_256"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 6.  Reserved</span></div><div style="text-align:justify"><span><br/></span></div><div id="i9aaa2fddc97e482da5dbe37ac85ae703_139"></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 7.  Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations (&#8220;MD&amp;A&#8221;) is intended to help the reader understand the Company&#8217;s financial condition and results of operations. The MD&amp;A is provided as a supplement to, and should be read in conjunction with, our consolidated financial statements and the accompanying notes to consolidated financial statements presented in &#8220;Part II &#8211; Item 8. Financial Statements and Supplementary Data&#8221; as well as &#8220;Part I - Item 1A. Risk Factors.&#8221;</span></div><div style="text-align:justify"><span><br/></span></div><div id="i9aaa2fddc97e482da5dbe37ac85ae703_142"></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">INTRODUCTION</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div id="i9aaa2fddc97e482da5dbe37ac85ae703_145"></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Background</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Evolent Health, Inc. is a holding company whose principal asset is all of the Class A common units it holds in Evolent Health LLC, and its only business is to act as sole managing member of Evolent Health LLC. Substantially all of our operations are conducted through Evolent Health LLC and its consolidated subsidiaries. The financial results of Evolent Health LLC are consolidated in the financial statements of Evolent Health, Inc.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Business Overview</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a market leader in the new era of value-based care, in which the delivery of health care is increasingly funded by at-risk payment models.  We provide integrated solutions to both health care providers, including independent physicians and health systems, as well as payers, including health plans and other risk-bearing organizations, with a common end: to improve health care quality and outcomes while reducing cost. We consider value-based care to be the necessary convergence of health care payment and delivery. We believe the pace of this convergence is accelerating, driven by price pressure in traditional FFS health care, a market environment that is incentivizing value-based care models, growth in consumer-focused insurance programs, such as Medicare Advantage and managed Medicaid, and innovation in data and technology. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We were an early innovator in Value-Based Care, founded in 2011 by members of our management team, UPMC, an integrated delivery system based in Pittsburgh, Pennsylvania, and The Advisory Board Company. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Today we manage our operations and allocate resources across two reportable segments: Evolent Health Services and Clinical Solutions. The Company&#8217;s EHS segment provides an integrated administrative and clinical platform for health plan administration and population health management. Our Clinical Solutions segment addresses a broad spectrum of clinical needs, with tailored solutions for Specialty Care Management in Oncology and Cardiology and holistic Total Cost of Care improvement. Our economic opportunity in the Clinical Solutions segment, which we believe to be significant, is largely based on (a) the total amount of medical expenses under management, and (b) the amount of savings we are able to generate relative to a benchmark or target. These partnerships, which we refer to as performance-based arrangements, include both capitation and shared savings arrangements. We also generate Clinical Solutions revenue by providing our technology and services platform on a fee basis.  We go to market for our Specialty Care Management under the brand name New Century Health, and for our Total Cost of Care solution under the brand name Evolent Care Partners.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All of our revenue is recognized in the United States and substantially all of our long-lived assets are located in the United States.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have incurred operating losses since our inception, in part because we have invested heavily in resources to support our growth. We intend to invest aggressively in the success of our partners, expand our geographic footprint and further develop our capabilities. We also expect to continue to incur operating losses for the foreseeable future and if we are unable to achieve our revenue growth and cost management objectives, we may not be able to achieve profitability. </span></div><div style="text-align:justify"><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">43</span></div></div></div><div id="i9aaa2fddc97e482da5dbe37ac85ae703_148"></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recent Events</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Evolent Health&#8217;s Response to COVID-19</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 11, 2020, the World Health Organization (the &#8220;WHO&#8221;) declared the novel strain of coronavirus (COVID-19) a global pandemic and recommended containment and mitigation measures worldwide. While response to the COVID-19 outbreak, including the emergence of variant strains of the virus, continues to rapidly evolve, it has led to aggressive actions to reduce the spread of the disease that seriously disrupted activities in large segments of the economy. We are continuing to monitor the COVID-19 outbreak and its impact on our business.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because of the nature of the services we provide and market dynamics in our end markets and with our significant customers, to date the COVID-19 pandemic has not materially impacted our financial condition or results of operations or our outlook. As of December&#160;31, 2021, we had cash and cash equivalents of $266.3 million and as of the date the financial statements were available to be issued, we believe our current cash balance is sufficient to meet our liquidity needs for the next twelve months. The COVID-19 crisis has also affected global access to capital and caused significant volatility in financial markets. Significant deterioration of the U.S. and global economies could have a significant adverse impact on our future liquidity needs. Although the impact of the COVID-19 pandemic on our business has not been severe to date, the long-term impact of the pandemic on our partners and the global economy is uncertain and will depend on various factors, including the scope, severity and duration of the pandemic, including resurgence of COVID-19 cases due to more contagious variants such as Omicron and the effectiveness of vaccines. A prolonged economic downturn or recession resulting from the pandemic could adversely affect many of our partners which could, in turn, adversely impact our business, financial condition and results of operations.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Evolent&#8217;s focus throughout this pandemic has been the health and safety of its employees and their families, as well as ensuring that we continue to furnish uninterrupted high-quality service to our partners.  Evolent has deployed a multi-faceted response to COVID-19, overseen by its Emergency Preparedness Team, led by the General Counsel, Chief Compliance Officer, and Chief Talent Officer, that focuses on maintaining its workforce in a manner that does not disrupt service delivery or operations. Evolent is closely monitoring and overseeing any issues of noncompliance or deficiencies with client operational service level agreements and continuing to review contractual business requirements in light of state and federal mandates, emergency laws and orders, and available financial support opportunities.  Evolent is also mindful of the impact COVID-19 has on its vendors and subcontractors, and we will continue to work with them regarding our collective obligations to Evolent&#8217;s customers. We require a COVID-19 Business Continuity Attestation from subcontractors and vendors, confirming that operational and financial obligations will be met and aiming to ensure that privacy and security risks or incidents can be mitigated and disclosed in a timely manner. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Evolent has instituted a voluntary return to the office. Fully vaccinated employees and those who have provided an approved religious or medical exemption are permitted to return to the Company&#8217;s offices in-person.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Summary of Impact of COVID-19</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In evaluating the impact of COVID-19 on our business, we considered, among other factors, the nature of the services we provide, end market trends and outlook and customer-specific trends.  In evaluating our health plan partners, we focused on possible changes in membership and medical utilization trends.  </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our two most significant service offerings in terms of revenue are specialty care management and administrative simplification services.&#160; Because both of these services offerings provide critical services to our clients and their members and have relatively long lead times to implement such services, we currently do not anticipate any material near-term disruption to the relevant contracts as a result of the pandemic.  </span></div><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The three key end-markets we serve are Medicaid, Medicare and Commercial.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Across 2020 and 2021, we saw changes in membership and medical utilization in our end-markets as a result of the COVID-19 pandemic. The pandemic initially resulted in a significant increase in unemployment in the United States through July 2020 but has since steadily decreased to pre-pandemic levels in December 2021. Historically, Medicaid enrollment has increased during periods of rising unemployment as individuals lose access to employer sponsored health care and turn to government sponsored health care. In addition, with respect to Medicaid, many states (including Illinois and Maryland) put in place new rules during the pandemic eliminating the ability of Medicaid health plans to dis-enroll non-paying members, as well as waiving certain eligibility requirements, which together contributed to an increase in membership during the period of the pandemic. In aggregate, as more than 50% of our lives on platform as of December&#160;31, 2021, are in Medicaid and we generally earn revenue with respect to those lives based on a per member per month model, we have experienced a modest net benefit in our business from increased membership in that market. We cannot predict the magnitude of this potential benefit, or how long it will last.  </span></div><div style="text-align:justify"><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">44</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">With respect to medical utilization, following the declaration of the pandemic by the WHO, many state-wide mandates deferred non-essential medical procedures to allow hospitals to focus on providing care to COVID-19 patients. Across all markets, our partners  experienced declines in non-essential care throughout the years ended December 31, 2020 and 2021, offset in part by increased costs for care of COVID-19 patients. We continue to monitor medical utilization trends closely as the pandemic progresses. Beginning late in the first quarter of 2020 after declaration of the pandemic and continuing through 2021, we have seen a modest benefit in our business from lower utilization trends. However, we cannot predict with any certainty the net impact of lower utilization on our business, as it is possible we will experience a surge in utilization as consumer behavior changes (for example if the novel coronavirus is controlled by the available vaccines or other measures).  </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Overall, we are unable to determine or predict the nature, duration, or scope of the overall impact the COVID-19 pandemic will have on our business, results of operations, liquidity, or capital resources. We are actively monitoring the ongoing situation and may take further actions that change our operations if required by law or that we determine are in the best interests of our employees or partners.  </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Customers</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The following table summarizes those partners who represented at least 10.0% of our consolidated revenue for the years ended December 31, 2021, 2020 and 2019:</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"></td><td style="width:380.50pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:48.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:48.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:48.25pt"></td><td style="width:1.0pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Year Ended December 31,</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cook County Health and Hospitals Systems </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">New Mexico Health Connections</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Florida Blue Medicare, Inc. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">N/A</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Passport </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(4)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt">The denominator excludes $44.8&#160;million, $117.4&#160;million and $171.7&#160;million of True Health premium revenue reclassified to discontinued operations for the years ended December 31, 2021, 2020 and 2019, respectively.</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt">Cook County Health and Hospital Systems utilizes both our administrative simplification solutions provided by Evolent Health Services, which accounted for 9.0% of our consolidated revenue for the year ended December 31, 2021 and our specialty care management solutions provided by New Century Health which accounted for 19.0% of our consolidated revenue for the year ended December 31, 2021. </span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt">Customer added during the year ended December 31, 2021. Florida Blue Medicare, Inc. utilizes our specialty care management solutions provided by New Century Health.</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(4)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt">Represents revenues from EVH Passport/UHC through the Molina Closing. Subsequent to the Molina Closing on September 1, 2020, the Company has not received any material revenue from EVH Passport. However, as part of the Molina Closing, we entered into a new contract with Molina on similar terms to our prior services contract with EVH Passport through December 31, 2020 which accounted for approximately 9.7% of our consolidated revenues for the year ended December 31, 2020.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">* &#160;&#160;&#160;&#160;Represents less than 10.0% of the respective balance</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Transactions</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has undertaken several transactions, some of which may impact year-to-year comparisons. The following is a discussion of certain of those transactions.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Acquisition of Vital Decisions</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On August 2, 2021, Evolent Health LLC and EV Thunder Merger Sub, LLC, each wholly owned subsidiaries of the Company, and the Company entered into a definitive agreement for the Company to acquire Vital Decisions. On October 1, 2021, we consummated the acquisition of Vital Decisions for $46.5 million in cash and the issuance of 1.8 million shares of Class A common stock. Vital Decisions reports into Evolent&#8217;s specialty care management offering, New Century Health, and is consolidated into the Company&#8217;s Clinical Solutions segment. The transaction closed on October 1, 2021. Refer to &#8220;Part II - Item 8. Financial Statements - Note 4&#8221; for additional discussion regarding the Vital Decisions transactions.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Conversion and Repayment of 2021 Notes</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Upon maturity of the 2021 Notes on December 1, 2021, outstanding 2021 Notes with a principal amount of $26.7&#160;million were settled, at the option of the holders, by converting $26.3&#160;million aggregate principal amount of 2021 Notes to common shares and cash repayment of $0.4&#160;million aggregate principal amount of 2021 Notes. Shares issued were valued based on the quoted trading prices on the conversion date for a total fair value of $28.5&#160;million resulting in a loss on debt extinguishment of $2.2&#160;million which was recorded in loss on repayment of debt on our consolidated statements of operations and comprehensive income (loss). Refer to &#8220;Part II - Item 8. Financial Statements - Note 10&#8221; for additional discussion regarding conversion and repayment of our 2021 Notes.  </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Sale of True Health New Mexico</span></div><div style="text-align:justify"><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">45</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On January 11, 2021, Evolent LLC, EH Holdings and True Health, each wholly owned subsidiaries of the Company, entered into the SPA with Bright HealthCare, pursuant to which EH Holdings agreed to sell all of its equity interest in True Health to Bright HealthCare for a purchase price of $22.0 million plus excess risk based capital, subject to satisfaction of customary closing conditions, including regulatory approvals. The purchase price is subject to a customary purchase price adjustment following the one-year anniversary of the True Health Closing based in part on actual medical claims experience. The True Health Closing occurred on March 31, 2021 and the Company has had no continuing involvement with True Health subsequent to the Closing except a pre-existing services agreement for claims processing and other health plan administrative functions. As of the first quarter of 2021, the Company determined that True Health met the discontinued operations criteria under ASC 205, and as such, True Health assets and liabilities as of December 31, 2020, and the results of operations for all periods presented are classified as discontinued operations and are not included in continuing operations in the consolidated financial statements.  Refer to &#8220;Part II - Item 8. Financial Statements - Note 5&#8221; for additional discussion regarding the True Health sale. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, in conjunction with the sale of True Health, the Company made organizational changes, including re-evaluating its reportable segments. Effective during the first quarter of 2021, the Company bifurcated its previous Services segment into two segments. The Company&#8217;s Evolent Health Services segment (&#8220;EHS&#8221;) includes our administrative simplification solution and certain supporting population health infrastructure. Our Clinical Solutions segment includes our specialty care management and physician-oriented total cost of care solutions, along with the New Century Health and Evolent Care Partners brands. Refer to &#8220;Part II - Item 8. Financial Statements - Note 22 for a further discussion of our operating results by segment.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Passport</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 30, 2019, UHC, Passport Health Solutions, LLC (&#8220;PHS I&#8221;), the Company and EVH Passport, closed a transaction whereby EVH Passport acquired substantially all of the assets and assumed substantially all of the liabilities of UHC, including the Passport Medicaid Contract.  The purchase price paid by EVH Passport consisted of $70.0 million in cash and a 30% equity interest in EVH Passport issued to the Sponsors; however, $16.2 million of the foregoing cash purchase price was held back until such time as PHS I delivers to EVH Passport certain owned real property and improvements.  </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 1, 2020, EVH Passport and Molina completed the Molina Closing and the Passport Medicaid Contract was novated to Molina. As a result, EVH Passport began to wind down its business. In connection with the Molina Closing, Molina deposited $20.0 million in cash in escrow, which was subsequently released to EVH Passport in January 2021. Prior to the Molina Closing, the Company accounted for its investment in EVH Passport as an unconsolidated variable interest entity under the equity method of accounting.  As a result of the Molina Closing, the Company concluded that a reconsideration event occurred whereby EVH Passport was determined to be a voting interest entity and that Evolent had a controlling financial interest in EVH Passport; accordingly, the Company consolidated EVH Passport as of September 1, 2020 in its consolidated financial statements. The Company accounted for the consolidation as an asset acquisition, as the Company concluded that assets acquired as a result of the consolidation did not meet the criteria to be classified as a business under GAAP. Following the Molina Closing and consolidation of EVH Passport in the Company&#8217;s consolidated financials, EVH Passport redeemed the Sponsors&#8217; equity interests in EVH Passport in accordance with the terms of EVH Passport's Stockholders' Agreement, and, as a result, EVH Passport became a wholly owned subsidiary of the Company. At the time of the transaction, the Company estimated a return of capital from EVH Passport between $130 million to $170 million. The Company now expects, given certain outcomes, an estimated return of capital between $170 million and $190 million, subject to regulatory approval from the Kentucky Department of Insurance. Refer to &#8220;Part II - Item 8. Financial Statements - Note 4&#8221; for additional discussion regarding the Passport transactions.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Repayment and Termination of Existing Credit Agreement</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 8, 2021, the Company repaid all outstanding amounts owed under, and terminated, the Credit Agreement with Ares Capital Corporation. The total amount paid to Ares Capital Corporation under the Credit Agreement in connection with the prepayment was $98.6 million, which included $9.7 million for the make-whole premium as well as $0.2 million in accrued interest. In addition to the payment of the Credit Agreement, the Company settled the outstanding warrants associated with the debt for $13.7 million. Refer to &#8220;Part II - Item 8. Financial Statements - Note 10&#8221; for additional discussion relating to the repayment of the Credit Agreement.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Repositioning Plan</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We continually assess opportunities to improve operational effectiveness and efficiency to better align our expenses with revenues, while continuing to make investments in our solutions, systems and people that we believe are important to our long-term goals. Across 2020, we divested or agreed to divest a majority of our health plan assets, including the assets of EVH Passport, which represented a significant revenue stream for the Company. In parallel with these divestitures, we contracted with a third-party vendor </span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">46</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to review our operating model and organizational design in order to improve our profitability, create value through our solutions and invest in strategic opportunities in future periods.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the fourth quarter of 2020, we committed to certain operational efficiency and profitability actions that we are taking in order to accomplish these objectives (&#8220;Repositioning Plan&#8221;). These actions included making organizational changes across our business as well as other profitability initiatives expected to result in reductions in force, re-aligning of resources as well as other potential operational efficiency and cost-reduction initiatives that will provide future benefit to the Company. The Repositioning Plan concluded in the fourth quarter of 2021.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides a summary of our total costs associated with the Repositioning Plan for the years ended December 31, 2021 and 2020, by major type of cost (in thousands):</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.066%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.761%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.761%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.902%"></td><td style="width:0.1%"></td></tr><tr style="height:23pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Year Ended December 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cumulative Amount Incurred through December 31, 2021</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Severance and termination benefits</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">185&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">185&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Office space consolidation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,742&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,742&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Professional services</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,391&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,275&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,666&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,318&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,275&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,593&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div id="i9aaa2fddc97e482da5dbe37ac85ae703_151"></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Critical Accounting Policies and Estimates</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have identified the accounting policies below as critical to the understanding of our results of operations and our financial condition. In applying these critical accounting policies in preparing our financial statements, management must use critical assumptions, estimates and judgments concerning future results or other developments, including the likelihood, timing or amount of one or more future events. Actual results may differ from these estimates under different assumptions or conditions. On an ongoing basis, we evaluate our assumptions, estimates and judgments based upon historical experience and various other information that we believe to be reasonable under the circumstances. For a detailed discussion of other significant accounting policies, see &#8220;Part II - Item 8. Financial Statements and Supplementary Data - Note 2.&#8221;</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Goodwill</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize the excess of the purchase price, plus the fair value of any non-controlling interests in the acquiree, over the fair value of identifiable net assets acquired as goodwill. Goodwill is not amortized, but is reviewed at least annually for indications of impairment, with consideration given to financial performance and other relevant factors. We perform impairment tests of goodwill at a reporting unit level. The Company has three reporting units and our annual goodwill impairment review occurs during the fourth quarter of each year. We perform impairment tests between annual tests if an event occurs, or circumstances change, that we believe would more likely than not reduce the fair value of a reporting unit below its carrying amount.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our goodwill impairment analysis first assesses qualitative factors to determine whether events or circumstances existed that would lead the Company to conclude it is more likely than not that the fair value of a reporting unit is below its carrying amount. Qualitative factors include macroeconomic, industry and market considerations, overall financial performance, industry, legal and other relevant events and factors affecting the reporting unit. Additionally, as part of this assessment, we may perform a quantitative analysis to support the qualitative factors above by applying sensitivities to assumptions and inputs used in measuring a reporting unit&#8217;s fair value. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">If the Company determines that it is more likely than not that the fair value of a reporting unit is below the carrying amount, a quantitative goodwill assessment is required. In the quantitative evaluation, the fair value of the relevant reporting unit is determined and compared to the carrying value. If the fair value is greater than the carrying value, then the carrying value is deemed to be recoverable and no further action is required. If the fair value estimate is less than the carrying value, goodwill is considered impaired for the amount by which the carrying amount exceeds the reporting unit&#8217;s fair value and a charge is reported in goodwill impairment on our consolidated statements of operations and comprehensive income (loss). We use discounted cash flow analyses and market multiple analyses in order to estimate reporting unit fair values. Discounted cash flow analyses rely on significant judgement and assumptions about expected future cash flows, weighted-average cost of capital, discount rates, expected long-term growth rates and operating margins. These assumptions are based on estimates of future revenue and earnings after considering such factors as general economic and market conditions which drive key assumptions of revenue growth rates, operating margins, capital expenditures and working capital requirements. The weighted average cost of capital is based on market-based factors/inputs but also considers the specific risk characteristics of the reporting unit&#8217;s cash flow forecast. A significant change to these estimates and assumptions could cause the estimated fair values of our reporting units and intangible assets to decline and increase the risk of an impairment charge to </span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">47</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">earnings. Intangible assets with finite lives are assessed for impairment whenever events or changes in circumstances indicate that the carrying value may not be recoverable.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On October 31, 2021, the Company performed its annual goodwill impairment review for fiscal year 2021. Based on our qualitative assessment, we did not identify sufficient indicators of impairment that would suggest fair value of our single reporting unit was below the carrying value. As a result, a quantitative goodwill impairment analysis was not required.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue Recognition</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Contracts with Multiple Performance Obligations</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our contracts with customers may contain multiple performance obligations, primarily when the customer has requested both transformation services and platform and operations services as these services are distinct from one another. When a contract has multiple performance obligations, we allocate the transaction price to each performance obligation based on the relative standalone selling price using the expected cost margin approach. This approach requires estimates regarding both the level of effort it will take to satisfy the performance obligation as well as fees that will be received under the variable pricing model. We also take into consideration customer demographics, current market conditions, the scope of services and our overall pricing strategy and objectives when determining the standalone selling price.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Principal vs Agent</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We use third parties to assist in satisfying our performance obligations. In order to determine whether we are the principal or agent in the arrangement, we review each third-party relationship on a contract-by-contract basis. We are an agent when our role is to arrange for another entity to provide the services to the customer. In these instances, we do not control the service before it is provided and recognize revenue on a net basis. We are the principal when we control the good or service prior to transferring control to the customer. We recognize revenue on a gross basis when we are the principal in the arrangement.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Taxes</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Significant management judgment is required in determining our provision for income taxes, our deferred tax assets and liabilities and any valuation allowance recorded against our net deferred tax assets. We estimate our actual current tax expense, including permanent charges and benefits, and temporary differences resulting from differing treatment of items, such as deferred revenue for tax and book accounting purposes. These temporary differences result in deferred tax assets and liabilities, which are included within our consolidated balance sheets.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We assess the likelihood that our deferred tax assets will be recovered from future taxable income by considering both positive and negative evidence relating to their recoverability. If we believe that recovery of these deferred tax assets is not more likely than not, we establish a valuation allowance. To the extent that we increase a valuation allowance in a period, we include an expense in the consolidated statement of operations in the period in which such determination is made.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In assessing the need for a valuation allowance, we considered all available evidence, including recent operating results, projections of future taxable income, our ability to utilize loss and credit carryforwards, and the feasibility of tax planning strategies. A significant piece of objective positive evidence evaluated for jurisdictions in a net deferred tax asset position was cumulative pre-tax income over the three years ended December 31, 2021. In addition, we considered that loss and credit carryforwards have not expired unused and the majority of our loss and credit carryforwards will not expire prior to 2032.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2021, we have determined that it is more likely than not that we will realize the benefit related to our deferred tax assets, except for a valuation allowance related to the realization of existing US deferred tax assets.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred tax liabilities, net of deferred tax assets, as of December 31, 2021, were $0.7 million, net of our valuation allowance of $101.3 million.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We account for uncertainty in income taxes by recognizing a tax position only when it is more likely than not that the tax position, based on its technical merits, will be sustained upon ultimate settlement with the applicable tax authority. The tax benefit to be recognized is the largest amount of tax benefit that is greater than fifty percent likely of being realized upon ultimate settlement with the applicable tax authority that has full knowledge of all relevant information.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our gross unrecognized benefits are $0.6 million as of December 31, 2021. Our evaluation of uncertain tax positions is based on factors including, but not limited to, changes in facts or circumstances, changes in tax law, effectively settled issues under audit, and </span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">48</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">new audit activity. If actual settlements differ from these estimates, or we adjust these estimates in future periods, we may need to recognize additional tax benefits or charges that could materially impact our financial position and results of operations.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a holding company and our assets consist of our direct ownership in Evolent Health LLC, for which we are the managing member. Taxable income or loss generated by Evolent Health LLC was allocated to holders of its units, including us, on a pro rata basis. Accordingly, we were subject to U.S. federal, state and local income taxes with respect to our allocable share of any taxable income of Evolent Health LLC. As a result of the 2019 Class B units exchanges, we became the sole owner of Evolent Health LLC and its entity classification changed from a partnership to an entity disregarded as separate from its owner for U.S. federal, state and local income tax purposes. Following the Class B units exchanges, any taxable income or loss generated by Evolent Health LLC is reportable and taxable on the Company&#8217;s federal, state and local income tax returns. Evolent Health LLC has direct ownership in corporate subsidiaries, which were subject to U.S. and foreign taxes with respect to their own operations during 2019.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Reserve for Claims and Performance-based Arrangements</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Reserves for performance-based arrangements and claims reflect actual payments under performance-based arrangements and the ultimate cost of claims that have been incurred but not reported, including expected development on reported claims, those that have been reported but not yet paid (reported claims in process), and other medical care expenses and services payable that are primarily composed of accruals for incentives and other amounts payable to health care professionals and facilities. The Company uses actuarial principles and assumptions that are consistently applied in each reporting period and recognizes the actuarial best estimate of the ultimate liability along with a margin for adverse deviation. This approach is consistent with actuarial standards of practice that the liabilities be adequate under moderately adverse conditions.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The process of estimating reserves involves a considerable degree of judgment by the Company and, as of any given date, is inherently uncertain. The methods for making such estimates and for establishing the resulting liability are continually reviewed, and adjustments are reflected in current results of operations in the period in which they are identified as experience develops or new information becomes known.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Business Combinations</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Companies acquired during each reporting period are reflected in the results of the Company effective from their respective dates of </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">acquisition through the end of the reporting period. The Company allocates the fair value of purchase consideration to the assets acquired and liabilities assumed based on their estimated fair values at the acquisition date. Our estimates of fair value are based upon assumptions believed to be reasonable but which are inherently uncertain and unpredictable and, as a result, actual results may differ from estimates. Critical estimates used to value certain identifiable assets include, but are not limited to, expected long-term revenues, future expected operating expenses, cost of capital, and appropriate discount rates.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The excess of the fair value of purchase consideration over the fair value of the assets acquired and liabilities assumed in the acquired entity is recorded as goodwill. Goodwill is assigned to the reporting unit that benefits from the synergies arising from the business combination. If the Company obtains new information about facts and circumstances that existed as of the acquisition date during the measurement period, which may be up to one year from the acquisition date, the Company may record adjustments to the assets acquired and liabilities assumed, with the corresponding offset to goodwill. Upon the conclusion of the measurement period or final determination of the values of assets acquired or liabilities assumed, whichever comes first, any subsequent adjustments are recorded to the Company's consolidated statements of operations and comprehensive income (loss).</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For contingent consideration recorded as a liability, the Company initially measures the amount at fair value as of the acquisition date and adjusts the liability, if needed, to fair value each reporting period. Changes in the fair value of contingent consideration, other than measurement period adjustments, are recognized as a change in fair value of contingent consideration and indemnification asset on the Company's consolidated statements of operations and comprehensive income (loss). Acquisition-related expenses and post-acquisition restructuring costs are recognized separately from the business combination and are expensed as incurred.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Adoption of New Accounting Standards</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2016, the FASB issued ASU 2016-13, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financial Instruments-Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and subsequently issued additional guidance that modified ASU 2016-13. The standard requires an entity to change its accounting approach for measuring and recognizing credit losses on certain financial assets measured at amortized cost, including trade receivables, certain non-trade receivables, customer advances and certain off-balance sheet credit exposures, by replacing the existing &#8220;incurred loss&#8221; framework with an expected credit loss recognition model.&#160; The new standard results in earlier recognition of credit losses based on past events, current conditions, and reasonable and supportable forecasts.&#160; The standard is effective for entities with fiscal years beginning after December 15, 2019, including interim periods within such fiscal years. We adopted the requirements of this standard effective January 1, 2020 using the modified retrospective approach and recorded a </span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">49</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">cumulative effect adjustment of $3.0 million to January 1, 2020 retained earnings (accumulated deficit).&#160;In our previous accounting policy for trade receivables and non-trade receivables, we maintained an allowance for doubtful accounts based on specific identification. Under the new accounting standard, we utilize several factors to develop historical losses, including aging schedules, customer creditworthiness, and historical payment experience, which are then adjusted for current conditions and reasonable and supportable forecasts in measurement of the allowance. In addition, for customer advances and certain off-balance sheet credit exposures, we evaluate the allowance through a discounted cash flow approach.&#160;Refer to Note 7 for additional disclosures related to current expected credit losses.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2019, the FASB issued ASU No. 2019-12, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Simplifying the Accounting for Income Taxes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The amendments in the ASU remove certain exceptions to the intraperiod tax allocation of losses and gains from different financial statement components and to the method of recognizing income taxes on interim period losses and the recognition of deferred tax liabilities for outside basis differences. In addition, the new guidance simplifies aspects of the accounting for franchise taxes and clarifies the accounting for transactions that result in a step-up in the tax basis of goodwill. The Company adopted this standard starting in the first quarter of 2021, which did not have a material impact on our consolidated financial statements.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2020, the FASB issued ASU 2020-06, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Accounting for Convertible Instruments and Contracts in an Entity&#8217;s Own Equity</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The ASU simplifies the accounting for certain financial instruments with characteristics of liabilities and equity, including convertible instruments and contracts in an entity&#8217;s own equity. Specifically, the ASU removes the separation models for convertible debt with a cash conversion feature or convertible instruments with a beneficial conversion feature and no longer permits the use of the treasury stock method from calculating earnings per share. As a result, after adopting the ASU&#8217;s guidance, we will not separately present in equity an embedded conversion feature of such debt. Instead, we will account for a convertible debt instrument wholly as debt unless (i) a convertible instrument contains features that require bifurcation as a derivative or (ii) a convertible debt instrument was issued at a substantial premium. Additionally, the ASU removes certain conditions for equity classification related to contracts in an entity&#8217;s own equity (e.g., warrants) and amends certain guidance related to the computation of earnings per share for convertible instruments and contracts on an entity&#8217;s own equity. The guidance in this ASU can be adopted using either a full or modified retrospective approach and becomes effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2021. We will adopt the ASU in the first quarter of fiscal 2022 and expect to use modified retrospective approach. The Company is currently assessing the impact, if any, that ASU 2020-06 would have on its financial position, results of operations or cash flows, however, the inability to use the treasury stock method in accounting for the shares issuable upon conversion of the 2024 Notes and the 2025 Notes will adversely affect our diluted earnings per share.</span></div><div style="text-align:justify"><span><br/></span></div><div id="i9aaa2fddc97e482da5dbe37ac85ae703_154"></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">RESULTS OF OPERATIONS</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Evolent Health, Inc. is a holding company and its principal asset is all of the Class&#160;A common units in Evolent Health LLC, which has owned all of our operating assets and substantially all of our business since inception. The financial results of Evolent Health LLC are consolidated in the financial statements of Evolent Health, Inc.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Key Components of our Results of Operations</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We derive revenue primarily from transformation services and platform and operations services.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Transformation Services Revenue</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Transformation services consist of implementation services whereby we assist the customer in launching its population health or health plan programs. In certain cases, transformation services can also include revenue associated with our support of certain one-time wind-down activities for clients who are exiting a line of business or population. The transformation services are usually completed within 12 months. We generally receive a fixed fee for transformation services and recognize revenue over time using an input method based on hours incurred compared to the total estimated hours required to satisfy our performance obligation.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Platform and Operations Services Revenue</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Platform and operations services are typically multi-year arrangements with customers to provide various clinical and administrative solutions. In our Clinical Solutions segment, our solutions are designed to lower the medical expenses of our partners and include our total cost of care and specialty care management services. In our Evolent Health Services segment, our solutions are designed to provide comprehensive health plan operations and claims processing services, and also include transition or run-out services to customers receiving primarily TPA services.  </span></div><div style="text-align:justify"><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">50</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our performance obligation in these arrangements is to provide an integrated suite of services, including access to our platform that is customized to meet the specialized needs of our customers and members. Generally, we will apply the series guidance to the performance obligation as we have determined that each time increment is distinct. We primarily utilize a variable fee structure for these services that typically includes a monthly payment that is calculated based on a specified per member per month rate, multiplied by the number of members that our partners are managing under a value-based care arrangement or a percentage of plan premiums. Our arrangements may also include other variable fees related to service level agreements, shared medical savings arrangements and other performance measures. Variable consideration is estimated using the most likely amount based on our historical experience and best judgment at the time. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In our Clinical Solutions segment, we enter into capitation arrangements that may include performance-based arrangements and/or gainshare features. We recognize capitation revenue on a gross basis when we have established control over the services within our scope and recognize capitation revenue on a net basis when we do not have control over the services within our scope. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Due to the nature of our arrangements, certain estimates may be constrained if it is probable that a significant reversal of revenue will occur when the uncertainty is resolved. We recognize revenue from platform and operations services over time using the time elapsed output method. Fixed consideration is recognized ratably over the contract term. In accordance with the series guidance, we allocate variable consideration to the period to which the fees relate.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contracts with Multiple Performance Obligations</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our contracts with customers may contain multiple performance obligations, primarily when the customer has requested both transformation services and platform and operations services as these services are distinct from one another. When a contract has multiple performance obligations, we allocate the transaction price to each performance obligation based on the relative standalone selling price using the expected cost margin approach. This approach requires estimates regarding both the level of effort it will take to satisfy the performance obligation as well as fees that will be received under the variable pricing model. We also take into consideration customer demographics, current market conditions, the scope of services and our overall pricing strategy and objectives when determining the standalone selling price.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the ordinary course of business, our reportable segments enter into transactions with one another. While intersegment transactions are treated like third-party transactions to determine segment performance, the revenues and expenses recognized by the segment that is the counterparty to the transaction are eliminated in consolidation and do not affect consolidated results.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cost of Revenue (exclusive of depreciation and amortization)</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our cost of revenue includes direct expenses and shared resources that perform services in direct support of clients. Costs consist primarily of employee-related expenses (including compensation, benefits and stock-based compensation), expenses for TPA support and other services, as well as other professional fees. In certain cases, our cost of revenue also includes claims and capitation payments to providers and payments for pharmaceutical treatments and other health care expenditures through performance-based arrangements.  Subsequent to the consolidation of EVH Passport on September 1, 2020, our cost of revenue includes the consolidated impact of the run out of EVH Passport&#8217;s operations, consisting principally of updates to EVH Passport&#8217;s claims reserve based on actual claims payments. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Selling, General and Administrative Expenses</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our selling, general and administrative expenses consist of employee-related expenses (including compensation, benefits and stock-based compensation) for selling and marketing, corporate development, finance, legal, human resources, corporate information technology, professional fees and other corporate expenses associated with these functional areas. Selling, general and administrative expenses also include costs associated with our centralized infrastructure and research and development activities to support our network development capabilities, claims processing services, including PBM administration, technology infrastructure, clinical program development and data analytics.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Depreciation and Amortization Expense</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation and amortization expenses consist of the amortization of intangible assets associated with the step up in fair value of Evolent Health LLC&#8217;s assets and liabilities for the Offering Reorganization, amortization of intangible assets recorded as part of our various business combinations and asset acquisitions and depreciation of property and equipment, including the amortization of capitalized software.</span></div><div style="text-align:justify"><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">51</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Lives on Platform and PMPM Fees</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Evolent Health Services Lives on Platform are calculated by summing members on our value-based care and comprehensive health plan administrative platform. Clinical Solutions Lives on Platform are calculated by summing the Clinical Solutions Lives on Platform in our Performance suite and New Century Health Technology and Services suite Lives on Platform. Clinical Solutions Lives on Platform in our Performance suite are calculated by summing members covered for oncology specialty care services and members covered for cardiology specialty care services for contracts not under ASO arrangements. New Century Health Technology and Services suite Lives on Platform are calculated by summing members covered for oncology specialty care services, members covered for cardiology specialty care services and members covered for advance care planning services for contracts under ASO arrangements. Members covered for more than one category are counted in each category. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Evolent Health Services average per member per month (&#8220;PMPM&#8221;) fee is defined as platform and operations revenue pertaining to the Evolent Health Services segment during the period reported divided by the average of the beginning and ending Evolent Health Services segment membership during the period reported divided by the number of months in the period. Clinical Solutions Performance suite Average PMPM fee is defined as platform and operations services revenue pertaining to our Clinical Solutions Performance suite during the period reported divided by the average of the beginning and ending Clinical Solutions Performance suite membership during the period reported divided by the number of months in the period. New Century Health Technology and Services suite Average PMPM fee is defined as platform and operations revenue pertaining to the New Century Health Technology and Services suite during the period reported divided by the average of the beginning and ending New Century Heath Technology and Services Suite membership during the period reported divided by the number of months in the period.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Management uses lives on platform and PMPM fees because we believe that they provide insight into the unit economics of our services. We believe that these measures are also useful to investors because they allow further insight into the period over period operational performance. We believe that these measures are also useful to investors because they allow further insight into the period over period operational performance.</span></div><div style="text-align:justify"><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">52</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Evolent Health, Inc. Consolidated Results</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"></td><td style="width:120.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:51.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:43.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:42.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:48.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:48.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:48.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:48.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:48.25pt"></td><td style="width:1.0pt"></td></tr><tr style="height:21pt"><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(in thousands, except percentages)</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">For the Year Ended December 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Change Over Prior Period</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">For the Year Ended December 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Change Over Prior Period</span></td></tr><tr style="height:14pt"><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Revenue</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Transformation services</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11,204&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11,990&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(786)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(6.6)%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11,990&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15,203&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3,213)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(21.1)%</span></td></tr><tr style="height:21pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Platform and operations services</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">896,753&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">912,649&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(15,896)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1.7)%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">912,649&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">671,919&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">240,730&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">35.8%</span></td></tr><tr style="height:21pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total revenue</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">907,957&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">924,639&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(16,682)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1.8)%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">924,639&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">687,122&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">237,517&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">34.6%</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Expenses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr style="height:39pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cost of revenue (exclusive of depreciation and amortization expenses presented separately below)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">657,551&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">696,581&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(39,030)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(5.6)%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">696,581&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">513,033&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">183,548&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">35.8%</span></td></tr><tr style="height:21pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Selling, general and administrative expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">219,499&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">210,412&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,087&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.3%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">210,412&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">236,448&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(26,036)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(11.0)%</span></td></tr><tr style="height:21pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Depreciation and amortization expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">60,037&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">60,835&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(798)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1.3)%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">60,835&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">60,323&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">512&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.8%</span></td></tr><tr style="height:21pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Loss (gain) on disposal of assets and consolidation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">698&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(698)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(100.0)%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">698&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(9,600)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10,298&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(107.3)%</span></td></tr><tr style="height:21pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Loss on extinguishment of debt, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,789&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4,789)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(100.0)%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,789&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,789&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">100.0%</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Goodwill impairment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">215,100&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(215,100)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(100.0)%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">215,100&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">199,800&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15,300&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7.7%</span></td></tr><tr style="height:30pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Change in fair value of contingent consideration and indemnification asset</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13,281&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,860&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,421&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">244.1%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,860&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3,997)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,857&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(196.6)%</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total operating expenses</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">950,368&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,192,275&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(241,907)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(20.3)%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,192,275&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">996,007&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">196,268&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">19.7%</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating loss</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(42,411)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(267,636)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">225,225&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">84.2%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(267,636)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(308,885)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">41,249&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(13.4)%</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr style="height:30pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Transformation services revenue as a % of total revenue</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr style="height:30pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Platform and operations services revenue as a % of total revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">98.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">98.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">98.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">97.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr style="height:21pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cost of revenue as a % of revenue</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">72.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">75.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">75.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">74.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr style="height:30pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Selling, general and administrative expenses as a % of total revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">24.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">22.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">22.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">34.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Comparison of the Results for the Year Ended December 31, 2021 to 2020 </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total revenue decreased by $16.7 million, or 1.8%, to $908.0 million for the year ended December 31, 2021, as compared to 2020.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Transformation services revenue decreased by $0.8 million, or 6.6%, to $11.2 million for the year ended December 31, 2021, as compared to 2020, due primarily to the timing and volume of implementation activities. Transformation services revenue accounted for 1.2% and 1.3% of our total revenue for the years ended December 31, 2021 and 2020, respectively. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Platform and operations services revenue decreased by $15.9 million, or 1.7%, to $896.8 million for the year ended December 31, 2021, as compared to 2020. This decrease is primarily due to the runout of EVH Passport&#8217;s operations compared to 2020 mostly offset by the addition of new partners and expansion with other existing partners. Platform and operations services revenue accounted for 98.8% and 98.7% of our total revenue for the years ended December 31, 2021 and 2020, respectively.</span></div><div style="text-align:justify"><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">53</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The following table represents Evolent&#8217;s revenue disaggregated by segment and end-market for the years ended December 31, 2021 and 2020 (in thousands):</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"></td><td style="width:327.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:48.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:48.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:48.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:48.25pt"></td><td style="width:1.0pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Year Ended December 31,</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr style="height:23pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Evolent Health Services</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Clinical Solutions</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicaid</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">215,236&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">236,634&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">205,833&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">274,028&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicare</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,358&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68,505&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">363,053&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">257,092&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial and other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68,219&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77,221&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,258&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,159&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">309,813&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">382,360&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">598,144&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">542,279&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Revenue from our Evolent Health Services segment decreased by $72.5 million for the year ended December 31, 2021, as compared to 2020 due to the consolidation and runout of services for EVH Passport, partially offset by new partner additions. Revenue from our Clinical Solutions segment increased by $55.9 million for the year ended December 31, 2021 as compared to 2020 due to new partner additions including Florida Blue Medicare, Inc., as well as expansion into new markets within current New Century Health Technology and Services Suite partners. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The following table represents the Company&#8217;s lives on platform as of December&#160;31, 2021 and 2020 and PMPM fees for the years ended December 31, 2021 and 2020 (Lives on Platform in thousands):</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:60.011%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.205%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.205%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.205%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.209%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Lives on Platform</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Average PMPM Fees</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Evolent Health Services</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,586&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,898&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17.25&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17.63&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Clinical Solutions</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Performance suite</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,502&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,602&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.33&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28.55&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">New Century Health Technology and Services suite</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,894&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,286&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.39&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.43&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> We had 44 and 37 operating partners as of December&#160;31, 2021 and 2020, respectively.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cost of Revenue</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides a summary of our total cost of revenue by segment for the year ended December 31, 2021, as compared to 2020 (amounts in thousands):</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.861%"><tr><td style="width:1.0%"></td><td style="width:29.358%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.105%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.356%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.105%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.356%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.105%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.356%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.105%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.356%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.105%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.356%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.105%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.356%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.105%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.356%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.115%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="45" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Evolent Health Services</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Clinical Solutions</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Corporate</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">198,190&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">216,004&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">456,912&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">474,803&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,449&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,774&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">657,551&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">696,581&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of revenue decreased by $39.0 million, or 5.6%, to $657.6 million for the year ended December 31, 2021, as compared to 2020. Cost of revenue decreased by approximately $23.2 million due to lower personnel costs, $8.4 million due to lower claims activity in our Clinical Solutions segment, $4.0 million in lower professional fees and $4.1 million in our technology services, TPA fees, brokerage fees and other costs. The principal driver of these decreases was the wind-down of EVH Passport relative to 2020. Cost of revenue for the year ended December 31, 2021 includes approximately $(0.5) million associated with the wind-down of EVH Passport, inclusive of a reduction in Passport&#8217;s claims reserve. Approximately $2.3 million and $1.8 million of total personnel costs was attributable to stock-based compensation expense for the years ended December 31, 2021 and 2020, respectively. Cost of revenue represented 72.4% and 75.3% of total services revenue for the years ended December 31, 2021 and 2020, respectively. Our cost of revenue decreased as a percentage of our total services revenue due to a change in the mix of our service offerings towards higher gross margin services with divestiture of our health plans combined with our Repositioning Plan. We expect our cost of revenue to decrease as a percentage of total services revenue over the longer-term subject to the composition of our growth.</span></div><div style="text-align:justify"><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">54</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Selling, General and Administrative Expenses</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides a summary of our total selling, general and administrative by segment for the year ended December 31, 2021, as compared to 2020 (amounts in thousands):</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.861%"><tr><td style="width:1.0%"></td><td style="width:29.358%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.105%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.356%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.105%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.356%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.105%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.356%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.105%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.356%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.105%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.356%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.105%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.356%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.105%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.356%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.115%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="45" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Evolent Health Services</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Clinical Solutions</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Corporate</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">86,480&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81,778&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,696&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,033&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">98,323&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104,601&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">219,499&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">210,412&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Selling, general, and administrative expenses increased by $9.1 million, or 4.3%, to $219.5 million for the year ended December 31, 2021, as compared to 2020. Professional fees increased by $14.8 million for the year ended December 31, 2021, as compared to 2020, respectively, primarily due to the Repositioning Plan and shareholder advisory services. During the year ended December 31, 2021, personnel costs decreased by $1.3&#160;million period over period due to a reduction in employee headcount, other expenses decreased by $2.8 million due to the termination of leases at EVH Passport during the third quarter of 2020 and legal fees decreased $2.1 million due to the timing and volume of transactions. Approximately $14.4 million and $12.8 million of total personnel costs were attributable to stock-based compensation expense for the year ended December 31, 2021 and 2020, respectively. Acquisition and severance costs accounted for approximately $4.4&#160;million and $9.2&#160;million of total selling, general and administrative expenses for the year ended December 31, 2021 and 2020, respectively. Selling, general and administrative expenses represented 24.2% and 22.8% of total revenue for the year ended December 31, 2021, as compared to 2020, respectively. While our selling, general and administrative expenses are expected to grow as our business grows, we expect them to decrease as a percentage of our total revenue over the long term due to cost saving initiatives introduced in the fourth quarter of 2020.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Depreciation and Amortization Expenses</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation and amortization expenses decreased $0.8 million, or 1.3%, to $60.0 million for the year ended December 31, 2021, as compared to 2020. The decrease was due primarily to lower amortization on existing technology intangibles of $3.9 million, offset, in part by, an increase in amortization expense for internal-use software of $2.6 million and customer relationships of $0.6 million. We expect depreciation and amortization expenses to increase in future periods as we continue to capitalize internal-use software and amortize intangible assets resulting from asset acquisitions and business combinations.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Loss on Extinguishment of Debt, net</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2020, as part of the issuance of the 2024 Notes, the Company issued $84.2 million aggregate principal amount of the 2024 Notes in exchange for $84.2 million aggregate principal of its 2021 Notes. These exchanges were accounted for as an extinguishment resulting in a net loss on extinguishment of debt of $4.8 million, including an aggregate cash payment to noteholders of $2.5 million, which is included in loss on extinguishment of debt, net on the consolidated statement of operations. </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Loss (Gain) on Disposal of Assets and Consolidation</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">During 2019, the Company, through a non-wholly owned consolidated subsidiary, entered into an agreement with an unrelated party to provide services and support to providers, independent physician associations, and other provider groups. During the year ended December 31, 2020, the Company sold its interest in the subsidiary and recorded a $6.4 million loss in loss (gain) on disposal of assets and consolidation on the consolidated statements of operations. The Company did not have any continuing involvement with the entity after the consummation of this transaction.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 1, 2020, EVH Passport and Molina consummated the Molina Closing, and the Passport Medicaid Contract was novated to Molina. As a result, the Company concluded that a reconsideration event occurred whereby EVH Passport was determined to be a voting interest entity and that Evolent had a controlling financial interest in EVH Passport; accordingly, the Company consolidated EVH Passport as of September 1, 2020 and recorded a $5.7 million bargain purchase gain in gain (loss) on disposal of assets and consolidation in its consolidated financial statements.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Goodwill Impairment</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December 31, 2020, we recorded a non-cash impairment charge of $215.1 million on our consolidated statements of operations as we determined that the implied fair value of goodwill of one of the two reporting units in the EHS segment was less than the carrying amount. See &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Part II - Item 8.</span><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Financial Statements - Note 9&#8221; for further details of the impairment charge to goodwill.</span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">55</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Change in Fair Value of Contingent Consideration and Indemnification Asset</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We recorded a gain on change in fair value of contingent consideration and indemnification asset of&#160;$13.3 million&#160;and&#160;$3.9 million for the year ended December 31, 2021 and 2020, respectively. This variance is the result of changes in the fair values of contingent liabilities incurred from entering into the warrant agreements compared to the liabilities acquired as a result of the acquisition of Vital Decisions in 2021.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Comparison of the Results for the Year Ended December 31, 2020 to 2019 </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total revenue increased by $238.4 million, or 34.6%, to $924.6 million for the year ended December 31, 2020 as compared to 2019.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Transformation services revenue decreased by $3.2 million, or 21.1%, to $12.0 million for year ended December 31, 2020, as compared to 2019, due primarily to the timing of implementation activities. Transformation services revenue accounted for 1.3% and 2.2% of our total revenue for the years ended December 31, 2020 and 2019, respectively. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Platform and operations services revenue increased by $241.6 million, or 36.0%, to $912.6 million for the year ended December 31, 2020, as compared to 2019 primarily as a result of membership growth with existing partners, cross-sell of new services to existing partners and new partner additions. Platform and operations services revenue accounted for 98.7% and 97.8% of our total revenue for years ended December 31, 2020 and 2019, respectively.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The following table represents Evolent&#8217;s revenue disaggregated by segment and end-market for the years ended December 31, 2020 and 2019 (in thousands):</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"></td><td style="width:327.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:48.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:48.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:48.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:48.25pt"></td><td style="width:1.0pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Year Ended December 31,</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr style="height:23pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Evolent Health Services</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Clinical Solutions</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicaid</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">236,634&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">267,222&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">274,028&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75,675&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicare</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68,505&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73,671&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">257,092&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">199,817&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial and other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77,221&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68,012&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,159&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,725&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">382,360&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">408,905&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">542,279&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">278,217&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Revenue from our Evolent Health Services segment decreased by $26.5 million for the year ended December 31, 2020 as compared to 2019 due to the disposal of non-strategic assets offset by higher revenue from Passport. Revenue from our Clinical Solutions segment increased by $264.1 million for the year ended December 31, 2020 as compared to 2019 due to new partner additions including Florida Blue Medicare, Inc., as well as expansion into new markets within current New Century Health Technology and Services Suite partners. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We had 37 and 39 operating partners as of December 31, 2020 and 2019, respectively.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cost of Revenue</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The following table provides a summary of our total cost of revenue by segment for the year ended December 31, 2020, as compared to 2019 (amounts in thousands):</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.861%"><tr><td style="width:1.0%"></td><td style="width:29.358%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.105%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.356%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.105%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.356%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.105%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.356%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.105%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.356%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.105%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.356%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.105%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.356%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.105%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.356%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.115%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="45" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Evolent Health Services</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Clinical Solutions</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Corporate</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">216,004&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">257,409&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">474,803&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">246,843&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,774&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,781&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">696,581&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">513,033&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of revenue increased by $183.5, or 35.8%, to $696.6 million for the year ended December 31, 2020, as compared to the year ended December 31, 2019. Cost of revenue increased by approximately $187.1 million period over period as a result of growth of our revenue generating services and additional payments related to performance-based arrangements, an increase of $5.4 million in professional fees due to the nature and timing of our projects, offset, in part by a decrease of $8.1 million if personnel costs period </span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">56</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">over period. Cost of revenue for the year ended December 31, 2020 includes approximately $(11.9) million associated with the wind-down of EVH Passport, inclusive of a reduction in Passport&#8217;s claims reserve. Approximately $1.8 million and $2.7 million of total personnel costs was attributable to stock-based compensation expense for the years ended December 31, 2020 and 2019, respectively. Cost of revenue represented 75.3% and 74.7% of total services revenue for the years ended December 31, 2020 and 2019, respectively. Our cost of revenue increased as a percentage of our total services revenue due to a change in the mix of our service offerings towards lower gross margin services, principally New Century Health, during 2020.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Selling, General and Administrative Expenses</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides a summary of our total selling, general and administrative by segment for the year ended December 31, 2020, as compared to 2019 (amounts in thousands):</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.861%"><tr><td style="width:1.0%"></td><td style="width:29.358%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.105%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.356%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.105%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.356%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.105%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.356%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.105%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.356%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.105%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.356%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.105%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.356%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.105%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.356%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.115%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="45" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Evolent Health Services</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Clinical Solutions</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Corporate</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81,778&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">127,608&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,033&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,178&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104,601&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">91,662&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">210,412&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">236,448&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Selling, general, and administrative expenses decreased by $26.0 million, or 11.0%, to $210.4 million for the year ended December 31, 2020, as compared to the year ended December 31, 2019. During the year ended December 31, 2020, personnel costs decreased by $33.7&#160;million period over period due to a reduction in employee headcount, offset, in part by an increase of $6.1 million in legal and professional fees due to the timing of our projects and an increase of $3.0 million in leasing costs due primarily to our consolidation of Passport. Approximately $12.8 million and $12.9 million of total personnel costs were attributable to stock-based compensation expense for the years ended December 31, 2020 and 2019, respectively. Ceded expenses under the reinsurance agreement were $14.0 million for the year ended December 31, 2019. Acquisition and severance costs accounted for approximately $9.2&#160;million and $27.9 million of total selling, general and administrative expenses for the years ended December 31, 2020 and 2019, respectively. Selling, general and administrative expenses represented 22.8% and 34.4% of total revenue for the year ended December 31, 2020, as compared to 2019, respectively.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Depreciation and Amortization Expenses</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation and amortization expenses increased $0.5 million, or 0.8%, to $60.8 million for the year ended December 31, 2020, as compared to 2019. The increase was due primarily to higher amortization expense for internal-use software of $5.6 million, offset in part by lower amortization on existing technology intangibles of $4.3 million as a result of the change in assets acquired through business combinations and asset acquisitions during 2019.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Loss on Extinguishment of Debt, net</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2020, as part of the issuance of the 2024 Notes, the Company issued $84.2 million aggregate principal amount of the 2024 Notes in exchange for $84.2 million aggregate principal of its 2021 Notes. These exchanges were accounted for as an extinguishment resulting in a net loss on extinguishment of debt of $4.8 million, including an aggregate cash payment to noteholders of $2.5 million, which is included in loss on extinguishment of debt, net on the consolidated statement of operations.</span></div><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2020, we also repurchased $14.0 million of the 2021 Notes with $13.9 million of cash and recorded an immaterial gain on extinguishment of debt.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Loss (Gain) on Disposal of Assets and Consolidation</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">During 2019, the Company, through a non-wholly owned consolidated subsidiary, entered into an agreement with an unrelated party to provide services and support to providers, independent physician associations, and other provider groups. During the year ended December 31, 2020, the Company sold its interest in the subsidiary and recorded a $6.4 million loss in loss (gain) on disposal of assets and consolidation on the consolidated statements of operations. The Company did not have any continuing involvement with the entity after the consummation of this transaction.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 1, 2020, EVH Passport and Molina consummated the Molina Closing, and the Passport Medicaid Contract was novated to Molina. As a result, the Company concluded that a reconsideration event occurred whereby EVH Passport was determined to be a voting interest entity and that Evolent had a controlling financial interest in EVH Passport; accordingly, the Company consolidated EVH Passport as of September 1, 2020 and recorded a $5.7 million bargain purchase gain in gain (loss) on disposal of assets and consolidation in its consolidated financial statements.</span></div><div style="text-align:justify"><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">57</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 24, 2019, the Company entered into a joint venture arrangement in respect of GlobalHealth. The Company determined that it had significant influence over the entity, but that it did not have control over the entity. Accordingly, the investment was accounted for under the equity method of accounting and the Company was allocated its proportional share of the entity&#8217;s earnings and losses for each reporting period. During the year ended December 31, 2019, we recorded a non-cash gain on disposal of assets of $9.6 million upon the consummation of the GlobalHealth transaction.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Goodwill Impairment</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December 31, 2020, we recorded a non-cash impairment charge of $215.1 million on our consolidated statements of operations as we determined that the implied fair value of goodwill of one of the three reporting units in the Services segment was less than the carrying amount. During the year ended December 31, 2019, we recorded a non-cash impairment charge of $199.8 million in the same reporting unit. Both of these charges related to the value of our investment in EVH Passport. See &#8220;Part II - Item 8. Financial Statements - Note 9&#8221; for further details of the impairment charge to goodwill.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Change in Fair Value of Contingent Consideration and Indemnification Asset</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recorded a (gain) loss on change in fair value of contingent consideration and indemnification asset of&#160;$3.9 million&#160;and&#160;$(4.0) million for the years December 31, 2020 as compared to 2019, respectively. This variance is the result of changes in the fair values of contingent liabilities incurred from entering in the warrant agreements compared to the liabilities acquired as a result of business combinations and asset acquisitions during 2016, 2018 and 2019. See &#8220;Part II - Item 8.  Financial Statements - Note 19&#8221; in this Form 10-K for the information related to the fair value of our warrant agreements.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Discussion of Non-Operating Results</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Interest Income</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest income consists of interest from investing cash in money market funds and interest from both our short-term and long-term investments. We recorded interest income of $0.4 million, $2.6 million and $3.4 million for the years ended December 31, 2021, 2020 and 2019, respectively. Interest income decreased during 2021 as a result of the repayment of the $40.0 million Passport Note on November 24, 2020. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Interest Expense</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Our interest expense is primarily attributable to our 2021 Notes, 2024 Notes, 2025 Notes and Credit Agreement with Ares Capital Corporation. We recorded interest expense (including amortization of deferred financing costs) of approximately $25.4 million, $28.3 million and $14.6 million for the years ended December 31, 2021, 2020 and 2019, respectively. The decrease in interest expense during the year ended December 31, 2021 compared to 2020 is driven primarily by the termination of the Ares Credit Agreement in January 2021, offset, in part by, the issuance of the 2024 Notes in August 2020. The increase in interest expense during the year ended December 31, 2020 compared to 2019 is driven primarily by the commencement of the Ares Credit Agreement in December 2019. See &#8220;Part II - Item 8.  Financial Statements - Note 10&#8221; in this Form 10-K for the information related to interest expense.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Impairment of Equity Method Investments</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June 30, 2020, the Oklahoma Insurance Division (&#8220;OID&#8221;) informed GlobalHealth, Inc. that in response to the COVID-19 pandemic, the OID required GlobalHealth, Inc. to increase its regulatory capital surplus by May 15, 2020. It would otherwise be placed into receivership if additional financing could not be secured. Certain investors agreed to provide liquidity as necessary to increase statutory capital reserves to no lower than 300%. In connection with the investment, GlobalHealth, Inc. transferred 100% of the equity interests in GlobalHealth, Inc. to the new investors for no consideration. Closing of this transaction occurred on May 13, 2020. As a result of this transaction, we have recorded a non-cash impairment charge of approximately $47.1 million, representing the total value of our investment, in impairment of equity method investments on the consolidated statements of operations for the year ended December 31, 2020.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Gain (Loss) from Equity Method Investees</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company allocated its proportional share of the investees&#8217; earnings and losses each reporting period. The Company&#8217;s proportional share of the gains (loss) from its equity method investments was approximately $13.2 million, $10.0 million and $(9.5) million for the years ended December 31, 2021, 2020 and 2019, respectively. The change in gain from equity method investees for the year ended December 31, 2021 compared to 2020 is driven primarily by the Company&#8217;s investment in Passport during 2020 combined with gains on the sale of our Florida equity investee&#8217;s membership during 2021. The change in gain (loss) from equity method investees for the </span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">58</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">year ended December 31, 2020 compared to 2019 is driven primarily by the Company&#8217;s investment in Passport during 2020 combined with income from our investment in Global Health, Inc.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Gain from Transfer of Membership</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December 31, 2021, EVH Passport earned a cash payment from Molina in the amount of $46.0 million based on the number of enrollees above a certain threshold in the D-SNP Business and Molina's Medicaid plan following the open enrollment period for plan year 2021. 50% of the payment was received during the year ended December 31, 2021, and the remaining 50% was received in the first quarter of 2022.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Loss on Repayment of Debt</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 8, 2021, the Company repaid all outstanding amounts owed under, and terminated, the Credit Agreement with Ares Capital Corporation. The total amount paid to Ares Capital Corporation under the Credit Agreement in connection with the prepayment was $98.6&#160;million, which included $9.7&#160;million for the make-whole premium as well as $0.2&#160;million in accrued interest. As a result of this transaction, the Company recorded loss on the repayment of debt of $19.2&#160;million, representing the remaining unamortized debt issuance costs of $9.5&#160;million, the make-whole premium and legal expenses.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Upon maturity of the 2021 Notes on December 1, 2021, outstanding 2021 Notes with a principal amount of $26.7&#160;million were settled, at the option of the holders, by converting $26.3&#160;million aggregate principal amount of 2021 Notes to common shares and cash repayment of $0.4&#160;million aggregate principal amount of 2021 Notes. Shares issued were valued based on the quoted trading prices on the conversion date for a total fair value of $28.5&#160;million resulting in a loss on debt extinguishment of $2.2&#160;million which was recorded in loss on repayment of debt on our consolidated statements of operations and comprehensive income (loss).</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Provision (Benefit) for Income Taxes</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recorded $0.5 million, $(2.4) million and $(22.8) million in income tax expense (benefit) the years ended December 31, 2021, 2020 and 2019, respectively, which resulted in effective tax rates of (1.6)%, 0.7% and 6.9%, respectively. The difference between our effective tax rate and our statutory rate is due primarily to the fact that the Company maintains a full valuation allowance recorded against its net deferred tax assets, with the exception of certain indefinite-lived components.</span></div><div><span><br/></span></div><div><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Loss from Discontinued Operations, Net of Tax</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">As of December&#160;31, 2021, the Company determined that True Health met the held for sale criteria under ASC 205, and as such, True Health assets and liabilities as of December 31, 2020, and the results of operations for all periods presented are classified as discontinued operations and are not included in continuing operations in the consolidated financial statements. The True Health Closing occurred on March 31, 2021.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">During the year ended December 31, 2021, the Company recorded purchase prices adjustments of $8.7&#160;million which are included in loss from discontinued operations on the consolidated statements of operations and comprehensive income (loss).</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the results of operations of the Company&#8217;s True Health business, which are included in the loss from discontinued operations in the consolidated statements of operations for the years ended December 31, 2021, 2020 and 2019.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:69.872%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.205%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.205%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.208%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Revenue</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Platform and operations</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">356&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">145&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Premiums</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,795&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">117,377&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">171,742&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenue</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,833&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">117,733&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">171,887&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Expenses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of revenue (exclusive of depreciation and amortization expenses presented separately below) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,885&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,343&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,633&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Claims expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,954&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87,951&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">135,774&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative expenses </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,764&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,576&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,617&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">59</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:69.872%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.205%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.205%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.208%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">160&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">640&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">590&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating expenses</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45,763&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">125,510&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">169,614&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating income (loss)</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(930)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,777)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,273&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">112&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">531&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">581&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(25)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income (loss) before income taxes and non-controlling interests</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(847)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,259)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,872&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Benefit (provision) for income taxes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(326)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,185)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,259&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(521)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,074)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,613&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt">Cost of revenue includes intercompany expenses between the Company and True Health that are recorded in income from continuing operations on the consolidated statements of operations related to an existing services agreement for claims processing and other health plan administrative functions of $2.8&#160;million, $13.6&#160;million and $6.6&#160;million for the years ended December 31, 2021, 2020 and 2019, respectively.</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt">Selling, general and administrative expenses include intercompany expenses between the Company and True Health that are recorded in income from continuing operations on the consolidated statements of operations related to an existing services agreement for claims processing and other health plan administrative functions of $1.1 million, $6.4 million and $6.0&#160;million for the years ended December 31 2021, 2020 and 2019, respectively. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div id="i9aaa2fddc97e482da5dbe37ac85ae703_157"></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">REVIEW OF CONSOLIDATED FINANCIAL CONDITION</span></div><div style="text-align:center"><span><br/></span></div><div id="i9aaa2fddc97e482da5dbe37ac85ae703_160"></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Liquidity and Capital Resources</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since its inception, the Company has incurred operating losses and net cash outflows from operations. The Company incurred operating losses of $42.4 million, $267.6 million and $308.9 million for the years ended December 31, 2021, 2020 and 2019, respectively. Net cash and restricted cash provided by (used in) operating activities was $38.7 million, $(16.2) million and $(42.6) million for the years ended December 31, 2021, 2020 and 2019, respectively.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2021, the Company had $266.3 million of cash and cash equivalents and $88.7 million in restricted cash and restricted investments. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe our current cash and cash equivalents will be sufficient to meet our working capital and capital expenditure requirements for the next twelve months. Our future capital requirements will depend on many factors, including our rate of revenue growth, the expansion of our sales and marketing activities and the timing and extent of our spending to support our investment efforts and expansion into other markets. We may also seek to invest in, or acquire complementary businesses, applications or technologies.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cash Flows</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following summary of cash flows for the years ended December 31, 2021, 2020 and 2019</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(in thousands) has been derived from our financial statements included in &#8220;Part II - Item 8.  Financial Statements - Consolidated Statements of Cash Flows:&#8221;</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"></td><td style="width:380.50pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:48.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:48.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:48.25pt"></td><td style="width:1.0pt"></td></tr><tr style="height:24pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Year Ended December 31,</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash and restricted cash provided by (used in) operating activities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38,747&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16,225)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(42,645)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash and restricted cash (used in) provided by investing activities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15,786)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">261,072&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(181,634)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash and restricted cash used in financing activities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(29,548)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11,862)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(35,545)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating Activities</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash flows from operating activities of $38.7 million for the year ended December 31, 2021 were primarily due to our net loss of $37.6 million, a loss on the repayment and termination of our Credit Agreement and 2021 Notes of $21.3 million, a gain on the disposal of assets of $6.8 million, gain on the transfer of memberships of $45.9 million, and non-cash items including depreciation and amortization expenses of $60.0 million, stock-based compensation expense of $16.7 million and change in fair value of contingent consideration and indemnification asset of $13.3 million. Our operating cash inflows were affected by the timing of our customer and vendor payments. In addition to these non-cash items, increases in accounts receivables and contract cost assets and reductions in reserves for claims and performance-based arrangements contributed and accrued liabilities approximately $28.9 million to our cash outflows. Those cash outflows were offset, in part by higher accounts payable and accrued compensation and employee benefits of approximately $10.8 million.</span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">60</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash flows used in operating activities of $16.2 million in the year ended December 31, 2020 were due primarily to our net loss of $334.2 million, partially offset by non-cash items, including an impairment of goodwill of $215.1 million, an impairment of an equity method investment of $47.1 million, depreciation and amortization expenses of $61.5 million, stock-based compensation expense of $14.6 million and a loss on the disposal of assets and consolidation of $0.7 million. Our operating cash inflows were affected by the timing of our customer and vendor payments. In addition to these non-cash items, increases in accounts receivables and contract cost assets and decreases in claims reserves contributed approximately $94.5 million to our cash outflows. Those cash outflows were partially offset by an increase in accounts payable, accrued expenses and accrued compensation and employee benefits contributed  approximately $23.5 million.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash flows used in operating activities of $42.6 million in the year ended December 31, 2019 were due primarily to our net loss of $305.6 million, partially offset by non-cash items, including goodwill impairment of $199.8 million, depreciation and amortization expenses of $60.9 million, stock-based compensation expense of $15.6 million and a decrease in deferred tax liability of $23.1 million. Our operating cash outflows were affected by the timing of our customer and vendor payments. An increase in contract cost assets combined with accounts payable and accrued liabilities contributed approximately $50.4 million to our cash outflows. Those cash outflows were partially offset by decreases in accounts receivable combined with increases in accrued compensation and employee benefits and claims reserves of approximately $49.1 million.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Investing Activities</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash flows used in investing activities of $15.8 million in the year ended December 31, 2021 were primarily attributable to cash flows of $46.5 million for the acquisition of Vital Decisions and $25.0 million of investments in internal-use software and purchases of property and equipment offset, in part by, $43.0 million from the transfer of membership and release of Passport escrow and returns of investment on equity method investments of $14.2 million. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash flows from investing activities of $261.1 million in the year ended December 31, 2020 were primarily attributable to cash flows from the impact of the initial consolidation of EVH Passport of $159.8 million, maturities and sales of investments primarily held by EVH Passport of $143.4 million, offset, in part by investments in internal-use software and purchases of property and equipment of $29.5 million, disposal of non-strategic assets of $2.3 million and purchases of investments of $11.2 million.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash flows used in investing activities of $181.6 million in the year ended December 31, 2019 were primarily attributable to purchases of property and equipment of $35.5 million, cash paid for asset acquisitions, business combinations and equity method investments of $96.1 million, amounts advanced to satisfy regulatory capital requirements of $46.4 million and purchases of investments of $11.1 million, partially offset by a customer&#8217;s repayment of advance to satisfy regulatory capital requirements of $5.4 million.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financing Activities </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash flows used in financing activities of $29.5 million in the year ended December 31, 2021 were primarily related to the repayment and termination of our Credit Agreement and settlement of our outstanding warrant agreements with Ares Capital Corporation of $98.4 million, offset, in part, by a $61.2 million increase in net working capital balances held on behalf of our partners for claims processing services and a $13.3 million increase from cash proceeds from stock option exercises. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash flows used in financing activities of $11.9 million in the year ended December 31, 2020 were primarily related to a $20.0 million redemption of the Sponsors equity in EVH Passport in accordance with the terms of EVH Passport&#8217;s Stockholders&#8217; Agreement as part of the EVH Passport wind-down and repurchase of our 2021 Notes of $16.6 million, $1.9 million of taxes withheld and paid for vests of restricted stock units and a $6.0 million decrease in working capital balances held on behalf of our partners for claims processing services offset, in part by $30.1 million from proceeds of convertible debt. The change in working capital balances held on behalf of partners for claims processing are pass-through amounts and can fluctuate materially from period to period depending on the timing of when the claims are processed.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash flows used in financing activities of $35.5 million in the year ended December 31, 2019 were primarily related to a $104.3 million increase in working capital balances held on behalf of our partners for claims processing as well as $2.6 million of taxes withheld and paid for vests of restricted stock units, offset, in part by net proceeds of $62.6 million from borrowings under the credit agreement.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cash flows from Discontinued Operations</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The consolidated statements of cash flows for all periods have not been adjusted to separately disclose cash flows related to discontinued operations. Cash flows related to the True Health business during the year ended December 31, 2021, 2020 and 2019 were as follows:</span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">61</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:69.872%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.205%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.205%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.208%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash flows provided by (used in) operating activities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,002&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,852&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,642)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash flows (used in) provided by investing activities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,494)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,636&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,172)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash flows used in financing activities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,500)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Contractual Obligations</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We believe that the amount of cash and cash equivalents on hand and cash flows from operations will be adequate for us to execute our business strategy and meet anticipated requirements for lease obligations, capital expenditures working capital and debt service for 2022. Our estimated contractual obligations (in thousands) as of December&#160;31, 2021, were as follows:</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"></td><td style="width:268.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:48.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:48.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:48.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:51.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:48.25pt"></td><td style="width:1.0pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023-2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2025-2026</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2027+</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating leases for facilities </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,950&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,221&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,493&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,225&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">86,889&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchase obligations related to vendor contracts</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,466&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,554&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,020&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Debt interest and termination payments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,684&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,376&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,588&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,648&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Debt principal repayment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">117,051&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">172,500&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">289,551&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total contractual obligations</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,100&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">152,202&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">192,581&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,225&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">409,108&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt">Operating leases for facilities includes $1.1 million due for leases that have not yet commenced.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">During the year ended December 31, 2021, the only material change from December 31, 2020 outside the ordinary course of business in the contractual obligations set forth above was the repayment and termination of our Credit Agreement and settlement of our warrant agreements with Ares Capital Corporation and the conversion and repayment of our 2021 Notes. Refer to the discussion in &#8220;Part II - Item 8. Financial Statements - Note 10&#8221; for additional information on our long-term debt.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Accounts Receivable, net</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounts receivable are recorded and carried at the original invoiced amount less an allowance for any potential uncollectible amounts. During the year ended December 31, 2021, accounts receivable, net, increased due to the impact of new customers of $71.3 million, offset, in part, by the timing of cash receipts from existing customers.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Restricted Cash and Restricted Investments</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restricted cash and restricted investments of $88.7 million is carried at cost and includes cash held on behalf of other entities for pharmacy and claims management services of $73.2 million, collateral for letters of credit required as security deposits for facility leases of $3.8 million, amounts held with financial institutions for risk-sharing arrangements of $11.7 million as of December&#160;31, 2021. See &#8220;Part II - Item 8. Financial Statements - Note 2&#8221; for further details of the Company&#8217;s restricted cash balances.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Goodwill and Intangible Assets</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize the excess of the purchase price, plus the fair value of any non-controlling interests in the acquiree, over the fair value of identifiable net assets acquired as goodwill. Identified intangible assets are recorded at their estimated fair values at the date of acquisition and are amortized over their respective estimated useful lives using a method of amortization that reflects the pattern in which the economic benefits of the intangible assets are used. The gross carrying value increases of $77.3 million in goodwill and $44.3&#160;million in intangibles is driven primarily by the October 2021 acquisition of Vital Decisions. See &#8220;Part II - Item 8. Financial Statements - Note 9&#8221; for further details of the Company&#8217;s restricted cash balances.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Uses of Capital</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our principal uses of cash are in the operation and expansion of our business. The Company does not anticipate paying a cash dividend on our Class A common stock in the foreseeable future.</span></div><div style="text-align:justify"><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">62</span></div></div></div><div id="i9aaa2fddc97e482da5dbe37ac85ae703_166"></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 7A.  Quantitative and Qualitative Disclosures About Market Risk</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are exposed to market risks in the ordinary course of our business. Market risk represents the risk of loss that may impact our financial position due to adverse changes in financial market prices and rates.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Interest Rate Risk</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2021, the Company had cash and cash equivalents and restricted cash and restricted investments of $354.9 million, which consisted of bank deposits with FDIC participating banks of $352.8 million, bank deposits in international banks of $2.2 million. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes in interest rates affect the interest earned on our cash and cash equivalents (including restricted cash). Our investments (including restricted investments) are classified as held-to-maturity and therefore are not subject to interest rate risk. We do not enter into investments for trading or speculative purposes and have not used any derivative financial instruments to manage our interest rate risk exposure.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2021, we had $289.6 million of aggregate principal amount of convertible notes outstanding, which are fixed rate instruments and not subject to fluctuations in interest rates. Refer to the discussion in &#8220;Part II - Item 8.  Financial Statements - Note 10&#8221; for additional information on our long-term debt.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Foreign Currency Exchange Risk</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Beginning in 2018, we have foreign currency risks related to our revenue and operating expenses denominated in currencies other than the U.S. dollar, primarily the Indian Rupee. In general, we are a net payor of currencies other than the U.S. dollar. Accordingly, changes in exchange rates, and in particular a strengthening of the U.S. dollar, may, in the future, negatively affect our operating results as expressed in U.S. dollars. At this time, we have not entered into, but in the future, we may enter into, derivatives or other financial instruments in an attempt to hedge our foreign currency exchange risk. It is difficult to predict the effect hedging activities would have on our results of operations. We recognized a foreign currency translation loss of $84 thousand, $44 thousand and $52 thousand for the years ended December 31, 2021, 2020 and 2019, respectively.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">63</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">64</span></div></div></div><div id="i9aaa2fddc97e482da5dbe37ac85ae703_19"></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 8.  Financial Statements and Supplementary Data</span></div><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">INDEX TO CONSOLIDATED FINANCIAL STATEMENTS</span></div><div><span><br/></span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:86.816%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.984%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Page</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i9aaa2fddc97e482da5dbe37ac85ae703_241">Report</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i9aaa2fddc97e482da5dbe37ac85ae703_241"> of Independent Registered Public Accounting Firm</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i9aaa2fddc97e482da5dbe37ac85ae703_241"> (PCAOB ID No. </a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231" name="dei:AuditorFirmId" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xOS9mcmFnOjk5ZDUzNzAxOWNjZTRjMjk4NDQ2M2U4OGI0ZWFlZThkL3RhYmxlOjBjOWI5YTY5OThmYTQ3NWE5MjgwYzUzN2Y1ZGZkYmYzL3RhYmxlcmFuZ2U6MGM5YjlhNjk5OGZhNDc1YTkyODBjNTM3ZjVkZmRiZjNfMS0wLTEtMS0zNTg3OS90ZXh0cmVnaW9uOjc1YmQ4OTk5MDU0OTQ3MTA5NDNiM2ViMGVjOWI0ZTE4XzIxOTkwMjMyNTU4MDU_07bc8f31-6c65-43f4-917d-4687f19c166d">34</ix:nonNumeric></span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i9aaa2fddc97e482da5dbe37ac85ae703_241">)</a></span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i9aaa2fddc97e482da5dbe37ac85ae703_241">66</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i9aaa2fddc97e482da5dbe37ac85ae703_22">Consolidated Balance Sheets</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i9aaa2fddc97e482da5dbe37ac85ae703_22">68</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i9aaa2fddc97e482da5dbe37ac85ae703_25">Consolidated Statements of Operations and Comprehensive Income (Loss)</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i9aaa2fddc97e482da5dbe37ac85ae703_25">69</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i9aaa2fddc97e482da5dbe37ac85ae703_28">Consolidated Statements of Changes in Shareholders&#8217; Equity</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i9aaa2fddc97e482da5dbe37ac85ae703_28">71</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i9aaa2fddc97e482da5dbe37ac85ae703_34">Consolidated Statements of Cash Flows</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i9aaa2fddc97e482da5dbe37ac85ae703_34">73</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i9aaa2fddc97e482da5dbe37ac85ae703_37">Notes to Consolidated Financial Statements</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i9aaa2fddc97e482da5dbe37ac85ae703_37">75</a></span></div></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span></div><div><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">65</span></div></div></div><div id="i9aaa2fddc97e482da5dbe37ac85ae703_241"></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">To the shareholders and the Board of Directors of Evolent Health, Inc. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Opinion on the Financial Statements</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have audited the accompanying consolidated balance sheets of Evolent Health, Inc. and subsidiaries (the "Company") as of December 31, 2021 and 2020, the related consolidated statements of operations and comprehensive income (loss), changes in shareholders' equity (deficit), and cash flows, for each of the three years in the period ended December 31, 2021, and the related notes (collectively referred to as the "financial statements"). In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2021 and 2020, and the results of its operations and its cash flows for each of the three years in the period ended December 31, 2021, in conformity with accounting principles generally accepted in the United States of America.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have also audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the Company's internal control over financial reporting as of December 31, 2021, based on criteria established in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Internal Control &#8212; Integrated Framework (2013)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> issued by the Committee of Sponsoring Organizations of the Treadway Commission and our report dated February 23, 2022, expressed an unqualified opinion on the Company's internal control over financial reporting. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Basis for Opinion</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These financial statements are the responsibility of the Company's management. Our responsibility is to express an opinion on the Company's financial statements based on our audits. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Emphasis of Matter</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As discussed in Note 5 to the financial statements, the accompanying consolidated financial statements have been retrospectively adjusted for discontinued operations. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Critical Audit Matter</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The critical audit matter communicated below is a matter arising from the current-period audit of the financial statements that was communicated or required to be communicated to the audit committee and that (1) relates to accounts or disclosures that are material to the financial statements and (2) involved our especially challenging, subjective, or complex judgments. The communication of critical audit matters does not alter in any way our opinion on the financial statements, taken as a whole, and we are not, by communicating the critical audit matter below, providing a separate opinion on the critical audit matter or on the accounts or disclosures to which it relates.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Reserve for Claims &#8212; Refer to Note 23 to the financial statements</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Critical Audit Matter Description</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company records reserves for the ultimate cost of claims that have been incurred but not reported (IBNR), including expected development on reported claims, those that have been reported but not yet paid (reported claims in process), and other medical care expenses and services payable. The Company uses actuarial principles and assumptions that are consistently applied in each reporting period and recognizes the actuarial best estimate of the ultimate liability along with a margin for adverse deviation. The liability is primarily calculated using completion factors developed by comparing the claim incurred date to the date claims were paid. Key assumptions include current payment experience, trend factors, and completion factors. Completion factors are impacted by several key items including changes in 1) electronic (auto-adjudication) versus manual claim processing, 2) provider claims submission rates, 3) membership, and 4) the mix of products. The Company uses historical completion factors combined with an analysis of current trends and operational factors to develop current estimates of completion factors. The Company estimates the liability for claims incurred in each month by applying the current estimates of completion factors to the current paid claims data. This approach implicitly assumes that historical completion rates will be a useful indicator for the current period.</span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">66</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For more recent months, and for newer lines of business where there is insufficient paid claims history to develop completion factors, the Company expects to rely more heavily on medical cost trend and expected loss ratio analysis that reflect expected claim payment patterns and other relevant operational considerations or authorization analysis. For each reporting period, the Company compares key assumptions used to establish the reserves for claims to actual experience. When actual experience differs from these assumptions, reserves for claims are adjusted through current period net income. Additionally, the Company evaluates expected future developments and emerging trends that may impact key assumptions. The process used to determine this liability requires the Company to make critical accounting estimates that involve considerable judgment, reflecting the variability inherent in forecasting future claim payments. These estimates are highly sensitive to changes in the Company's key assumptions, specifically completion factors and medical cost trends. The reserve for claims as of December 31, 2021 was $171.3 million.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We identified the IBNR reserve as a critical audit matter because the development of the IBNR reserve involves significant estimation by management. This required a high degree of auditor judgment and an increased extent of effort, including the need to involve our actuarial specialists.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">How the Critical Audit Matter Was Addressed in the Audit</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our audit procedures related to the reserve for claims included the following, among others: </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">We tested the effectiveness of controls related to the reserve for claims, including management&#8217;s controls over the development and reporting of the IBNR reserve.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">We tested the underlying data that served as the basis for the actuarial analysis, including claims lag triangles and membership data, to test that the inputs to the actuarial estimate were complete and accurate.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">With the assistance of our actuarial specialists, we evaluated the reasonableness of the actuarial methods and assumptions used by management to estimate the IBNR reserve by:</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8211;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:31pt">Developing an independent estimate of the IBNR reserve and comparing our estimate to management&#8217;s estimates.</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8211;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:31pt">Comparing management&#8217;s September 30, 2021 assumptions of expected development and ultimate cost of claims to actuals incurred during the fourth quarter of 2021 to identify potential bias in the determination of the reserve for claims.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ <ix:nonNumeric contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231" name="dei:AuditorName" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yNDEvZnJhZzo1MjI4ODI3YjVkY2Q0Mjg2YjA2YjYxMWNhNjQ4ZTdkYS90ZXh0cmVnaW9uOjUyMjg4MjdiNWRjZDQyODZiMDZiNjExY2E2NDhlN2RhXzMyOTg1MzQ5Mzg3OTg_a33c1eef-a7c3-431b-b840-b324013b0bc7">Deloitte &amp; Touche LLP</ix:nonNumeric></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231" name="dei:AuditorLocation" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yNDEvZnJhZzo1MjI4ODI3YjVkY2Q0Mjg2YjA2YjYxMWNhNjQ4ZTdkYS90ZXh0cmVnaW9uOjUyMjg4MjdiNWRjZDQyODZiMDZiNjExY2E2NDhlN2RhXzMyOTg1MzQ5Mzg3OTk_bf12f897-ae6e-4713-b7ec-b573589cc5de">McLean, Virginia</ix:nonNumeric>  </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 23, 2022 </span></div><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">We have served as the Company's auditor since 2019.</span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">67</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:9pt;margin-top:9pt;text-align:center"><span><br/></span></div><div id="i9aaa2fddc97e482da5dbe37ac85ae703_22"></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EVOLENT HEALTH, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONSOLIDATED BALANCE SHEETS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(in thousands, except share data)</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"></td><td style="width:409.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:63.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:58.00pt"></td><td style="width:1.0pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">ASSETS</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8daff60be410426d8f7bd49343c1ec0c_I20211231" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yMi9mcmFnOjJiM2Y4ODE3NTVhYTQ5ODk5MzI2NThlODM2YmIyNGI2L3RhYmxlOjQ1MmFlOGFkMjMxZjQ4MWQ4Njg3MGU5MDYxNWI3NTkxL3RhYmxlcmFuZ2U6NDUyYWU4YWQyMzFmNDgxZDg2ODcwZTkwNjE1Yjc1OTFfMy0xLTEtMS0xNzc3NQ_9fd365f1-934d-43ea-b134-3f32d27e9505">266,280</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc0c0c2b8dc04c5698ca0577a54b2e03_I20201231" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yMi9mcmFnOjJiM2Y4ODE3NTVhYTQ5ODk5MzI2NThlODM2YmIyNGI2L3RhYmxlOjQ1MmFlOGFkMjMxZjQ4MWQ4Njg3MGU5MDYxNWI3NTkxL3RhYmxlcmFuZ2U6NDUyYWU4YWQyMzFmNDgxZDg2ODcwZTkwNjE1Yjc1OTFfMy0zLTEtMS0xNzc3NQ_e64c5520-cb42-49eb-b96e-daf88adbe308">319,002</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash and restricted investments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8daff60be410426d8f7bd49343c1ec0c_I20211231" decimals="-3" name="us-gaap:RestrictedCashAndInvestmentsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yMi9mcmFnOjJiM2Y4ODE3NTVhYTQ5ODk5MzI2NThlODM2YmIyNGI2L3RhYmxlOjQ1MmFlOGFkMjMxZjQ4MWQ4Njg3MGU5MDYxNWI3NTkxL3RhYmxlcmFuZ2U6NDUyYWU4YWQyMzFmNDgxZDg2ODcwZTkwNjE1Yjc1OTFfNC0xLTEtMS0xNzc3NQ_b6a4a6c5-78fd-439f-83a3-08492feb5ba8">75,685</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc0c0c2b8dc04c5698ca0577a54b2e03_I20201231" decimals="-3" name="us-gaap:RestrictedCashAndInvestmentsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yMi9mcmFnOjJiM2Y4ODE3NTVhYTQ5ODk5MzI2NThlODM2YmIyNGI2L3RhYmxlOjQ1MmFlOGFkMjMxZjQ4MWQ4Njg3MGU5MDYxNWI3NTkxL3RhYmxlcmFuZ2U6NDUyYWU4YWQyMzFmNDgxZDg2ODcwZTkwNjE1Yjc1OTFfNC0zLTEtMS0xNzc3NQ_f0652a2c-16e5-46e3-92fa-70da1cdc5238">14,374</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable, net </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8daff60be410426d8f7bd49343c1ec0c_I20211231" decimals="-3" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yMi9mcmFnOjJiM2Y4ODE3NTVhYTQ5ODk5MzI2NThlODM2YmIyNGI2L3RhYmxlOjQ1MmFlOGFkMjMxZjQ4MWQ4Njg3MGU5MDYxNWI3NTkxL3RhYmxlcmFuZ2U6NDUyYWU4YWQyMzFmNDgxZDg2ODcwZTkwNjE1Yjc1OTFfNS0xLTEtMS0xNzc3NQ_f8d025b8-3255-478d-83d3-8aecd42fa11b">130,604</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc0c0c2b8dc04c5698ca0577a54b2e03_I20201231" decimals="-3" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yMi9mcmFnOjJiM2Y4ODE3NTVhYTQ5ODk5MzI2NThlODM2YmIyNGI2L3RhYmxlOjQ1MmFlOGFkMjMxZjQ4MWQ4Njg3MGU5MDYxNWI3NTkxL3RhYmxlcmFuZ2U6NDUyYWU4YWQyMzFmNDgxZDg2ODcwZTkwNjE1Yjc1OTFfNS0zLTEtMS0xNzc3NQ_1aab1e38-d520-4d8e-a626-6f7e2520afce">124,064</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8daff60be410426d8f7bd49343c1ec0c_I20211231" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yMi9mcmFnOjJiM2Y4ODE3NTVhYTQ5ODk5MzI2NThlODM2YmIyNGI2L3RhYmxlOjQ1MmFlOGFkMjMxZjQ4MWQ4Njg3MGU5MDYxNWI3NTkxL3RhYmxlcmFuZ2U6NDUyYWU4YWQyMzFmNDgxZDg2ODcwZTkwNjE1Yjc1OTFfNi0xLTEtMS0xNzc3NQ_469a4400-c2b4-4cf4-8445-c96411a59e90">51,391</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc0c0c2b8dc04c5698ca0577a54b2e03_I20201231" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yMi9mcmFnOjJiM2Y4ODE3NTVhYTQ5ODk5MzI2NThlODM2YmIyNGI2L3RhYmxlOjQ1MmFlOGFkMjMxZjQ4MWQ4Njg3MGU5MDYxNWI3NTkxL3RhYmxlcmFuZ2U6NDUyYWU4YWQyMzFmNDgxZDg2ODcwZTkwNjE1Yjc1OTFfNi0zLTEtMS0xNzc3NQ_ac001ac4-a8c8-46b0-876f-5bb35a584888">56,295</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current assets of discontinued operations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8daff60be410426d8f7bd49343c1ec0c_I20211231" decimals="-3" name="us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yMi9mcmFnOjJiM2Y4ODE3NTVhYTQ5ODk5MzI2NThlODM2YmIyNGI2L3RhYmxlOjQ1MmFlOGFkMjMxZjQ4MWQ4Njg3MGU5MDYxNWI3NTkxL3RhYmxlcmFuZ2U6NDUyYWU4YWQyMzFmNDgxZDg2ODcwZTkwNjE1Yjc1OTFfNy0xLTEtMS0xNzc3NQ_4fc41f59-a447-4c53-8774-15338c0f0f74">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc0c0c2b8dc04c5698ca0577a54b2e03_I20201231" decimals="-3" name="us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yMi9mcmFnOjJiM2Y4ODE3NTVhYTQ5ODk5MzI2NThlODM2YmIyNGI2L3RhYmxlOjQ1MmFlOGFkMjMxZjQ4MWQ4Njg3MGU5MDYxNWI3NTkxL3RhYmxlcmFuZ2U6NDUyYWU4YWQyMzFmNDgxZDg2ODcwZTkwNjE1Yjc1OTFfNy0zLTEtMS0xNzc3NQ_4b42b99f-52bc-4694-bd5e-33dbc281a7da">33,914</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current assets</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8daff60be410426d8f7bd49343c1ec0c_I20211231" decimals="-3" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yMi9mcmFnOjJiM2Y4ODE3NTVhYTQ5ODk5MzI2NThlODM2YmIyNGI2L3RhYmxlOjQ1MmFlOGFkMjMxZjQ4MWQ4Njg3MGU5MDYxNWI3NTkxL3RhYmxlcmFuZ2U6NDUyYWU4YWQyMzFmNDgxZDg2ODcwZTkwNjE1Yjc1OTFfOC0xLTEtMS0xNzc3NQ_d299786d-12af-42b6-bdb2-44f9b5c2cf6a">523,960</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc0c0c2b8dc04c5698ca0577a54b2e03_I20201231" decimals="-3" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yMi9mcmFnOjJiM2Y4ODE3NTVhYTQ5ODk5MzI2NThlODM2YmIyNGI2L3RhYmxlOjQ1MmFlOGFkMjMxZjQ4MWQ4Njg3MGU5MDYxNWI3NTkxL3RhYmxlcmFuZ2U6NDUyYWU4YWQyMzFmNDgxZDg2ODcwZTkwNjE1Yjc1OTFfOC0zLTEtMS0xNzc3NQ_21a9d3d3-e398-4311-9ade-11ce49d81ab0">547,649</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash and restricted investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8daff60be410426d8f7bd49343c1ec0c_I20211231" decimals="-3" name="us-gaap:RestrictedCashAndInvestmentsNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yMi9mcmFnOjJiM2Y4ODE3NTVhYTQ5ODk5MzI2NThlODM2YmIyNGI2L3RhYmxlOjQ1MmFlOGFkMjMxZjQ4MWQ4Njg3MGU5MDYxNWI3NTkxL3RhYmxlcmFuZ2U6NDUyYWU4YWQyMzFmNDgxZDg2ODcwZTkwNjE1Yjc1OTFfOS0xLTEtMS0xNzc3NQ_618c6504-c568-4188-984b-505490148702">12,977</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc0c0c2b8dc04c5698ca0577a54b2e03_I20201231" decimals="-3" name="us-gaap:RestrictedCashAndInvestmentsNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yMi9mcmFnOjJiM2Y4ODE3NTVhYTQ5ODk5MzI2NThlODM2YmIyNGI2L3RhYmxlOjQ1MmFlOGFkMjMxZjQ4MWQ4Njg3MGU5MDYxNWI3NTkxL3RhYmxlcmFuZ2U6NDUyYWU4YWQyMzFmNDgxZDg2ODcwZTkwNjE1Yjc1OTFfOS0zLTEtMS0xNzc3NQ_b3f97063-3040-4aac-bd50-850696b9dce4">6,654</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investments in equity method investees</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8daff60be410426d8f7bd49343c1ec0c_I20211231" decimals="-3" name="us-gaap:InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yMi9mcmFnOjJiM2Y4ODE3NTVhYTQ5ODk5MzI2NThlODM2YmIyNGI2L3RhYmxlOjQ1MmFlOGFkMjMxZjQ4MWQ4Njg3MGU5MDYxNWI3NTkxL3RhYmxlcmFuZ2U6NDUyYWU4YWQyMzFmNDgxZDg2ODcwZTkwNjE1Yjc1OTFfMTAtMS0xLTEtMTc3NzU_d29af860-00d5-4a5d-9262-6c381a5f521f">5,458</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc0c0c2b8dc04c5698ca0577a54b2e03_I20201231" decimals="-3" name="us-gaap:InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yMi9mcmFnOjJiM2Y4ODE3NTVhYTQ5ODk5MzI2NThlODM2YmIyNGI2L3RhYmxlOjQ1MmFlOGFkMjMxZjQ4MWQ4Njg3MGU5MDYxNWI3NTkxL3RhYmxlcmFuZ2U6NDUyYWU4YWQyMzFmNDgxZDg2ODcwZTkwNjE1Yjc1OTFfMTAtMy0xLTEtMTc3NzU_1ea5ab44-5315-446c-9df3-ebd90f777e53">6,498</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8daff60be410426d8f7bd49343c1ec0c_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yMi9mcmFnOjJiM2Y4ODE3NTVhYTQ5ODk5MzI2NThlODM2YmIyNGI2L3RhYmxlOjQ1MmFlOGFkMjMxZjQ4MWQ4Njg3MGU5MDYxNWI3NTkxL3RhYmxlcmFuZ2U6NDUyYWU4YWQyMzFmNDgxZDg2ODcwZTkwNjE1Yjc1OTFfMTEtMS0xLTEtMTc3NzU_886389cf-fdc3-401b-b1b0-ef5448561f70">81,365</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc0c0c2b8dc04c5698ca0577a54b2e03_I20201231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yMi9mcmFnOjJiM2Y4ODE3NTVhYTQ5ODk5MzI2NThlODM2YmIyNGI2L3RhYmxlOjQ1MmFlOGFkMjMxZjQ4MWQ4Njg3MGU5MDYxNWI3NTkxL3RhYmxlcmFuZ2U6NDUyYWU4YWQyMzFmNDgxZDg2ODcwZTkwNjE1Yjc1OTFfMTEtMy0xLTEtMTc3NzU_8d125e24-2593-4bb6-b42d-825d73239376">86,240</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use assets - operating</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8daff60be410426d8f7bd49343c1ec0c_I20211231" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yMi9mcmFnOjJiM2Y4ODE3NTVhYTQ5ODk5MzI2NThlODM2YmIyNGI2L3RhYmxlOjQ1MmFlOGFkMjMxZjQ4MWQ4Njg3MGU5MDYxNWI3NTkxL3RhYmxlcmFuZ2U6NDUyYWU4YWQyMzFmNDgxZDg2ODcwZTkwNjE1Yjc1OTFfMTItMS0xLTEtMTc3NzU_bcb38a9a-b016-4ecf-b0f0-cceffc4cc9e8">50,203</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc0c0c2b8dc04c5698ca0577a54b2e03_I20201231" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yMi9mcmFnOjJiM2Y4ODE3NTVhYTQ5ODk5MzI2NThlODM2YmIyNGI2L3RhYmxlOjQ1MmFlOGFkMjMxZjQ4MWQ4Njg3MGU5MDYxNWI3NTkxL3RhYmxlcmFuZ2U6NDUyYWU4YWQyMzFmNDgxZDg2ODcwZTkwNjE1Yjc1OTFfMTItMy0xLTEtMTc3NzU_ccf5bef2-7d83-4e03-a304-56cd52a3fec5">57,799</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other noncurrent assets </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8daff60be410426d8f7bd49343c1ec0c_I20211231" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yMi9mcmFnOjJiM2Y4ODE3NTVhYTQ5ODk5MzI2NThlODM2YmIyNGI2L3RhYmxlOjQ1MmFlOGFkMjMxZjQ4MWQ4Njg3MGU5MDYxNWI3NTkxL3RhYmxlcmFuZ2U6NDUyYWU4YWQyMzFmNDgxZDg2ODcwZTkwNjE1Yjc1OTFfMTMtMS0xLTEtMTc3NzU_00d8e9df-b51a-4134-ae28-46cb41ed669a">6,790</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc0c0c2b8dc04c5698ca0577a54b2e03_I20201231" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yMi9mcmFnOjJiM2Y4ODE3NTVhYTQ5ODk5MzI2NThlODM2YmIyNGI2L3RhYmxlOjQ1MmFlOGFkMjMxZjQ4MWQ4Njg3MGU5MDYxNWI3NTkxL3RhYmxlcmFuZ2U6NDUyYWU4YWQyMzFmNDgxZDg2ODcwZTkwNjE1Yjc1OTFfMTMtMy0xLTEtMTc3NzU_46840606-41ef-48ee-84bf-1505ddaef468">5,773</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contract cost assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8daff60be410426d8f7bd49343c1ec0c_I20211231" decimals="-3" name="us-gaap:CapitalizedContractCostNetNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yMi9mcmFnOjJiM2Y4ODE3NTVhYTQ5ODk5MzI2NThlODM2YmIyNGI2L3RhYmxlOjQ1MmFlOGFkMjMxZjQ4MWQ4Njg3MGU5MDYxNWI3NTkxL3RhYmxlcmFuZ2U6NDUyYWU4YWQyMzFmNDgxZDg2ODcwZTkwNjE1Yjc1OTFfMTQtMS0xLTEtMTc3NzU_788d837d-0914-4c63-ba66-75f3c0058ab4">32,624</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc0c0c2b8dc04c5698ca0577a54b2e03_I20201231" decimals="-3" name="us-gaap:CapitalizedContractCostNetNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yMi9mcmFnOjJiM2Y4ODE3NTVhYTQ5ODk5MzI2NThlODM2YmIyNGI2L3RhYmxlOjQ1MmFlOGFkMjMxZjQ4MWQ4Njg3MGU5MDYxNWI3NTkxL3RhYmxlcmFuZ2U6NDUyYWU4YWQyMzFmNDgxZDg2ODcwZTkwNjE1Yjc1OTFfMTQtMy0xLTEtMTc3NzU_ba348ed5-eb6f-45d1-91f4-e6fe1dc68424">26,687</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible assets, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8daff60be410426d8f7bd49343c1ec0c_I20211231" decimals="-3" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yMi9mcmFnOjJiM2Y4ODE3NTVhYTQ5ODk5MzI2NThlODM2YmIyNGI2L3RhYmxlOjQ1MmFlOGFkMjMxZjQ4MWQ4Njg3MGU5MDYxNWI3NTkxL3RhYmxlcmFuZ2U6NDUyYWU4YWQyMzFmNDgxZDg2ODcwZTkwNjE1Yjc1OTFfMTUtMS0xLTEtMTc3NzU_5d2f7d16-37e3-4d32-add6-eab2555c57ba">279,784</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc0c0c2b8dc04c5698ca0577a54b2e03_I20201231" decimals="-3" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yMi9mcmFnOjJiM2Y4ODE3NTVhYTQ5ODk5MzI2NThlODM2YmIyNGI2L3RhYmxlOjQ1MmFlOGFkMjMxZjQ4MWQ4Njg3MGU5MDYxNWI3NTkxL3RhYmxlcmFuZ2U6NDUyYWU4YWQyMzFmNDgxZDg2ODcwZTkwNjE1Yjc1OTFfMTUtMy0xLTEtMTc3NzU_d464e961-0388-459c-93a7-2eddb6227a7e">264,992</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8daff60be410426d8f7bd49343c1ec0c_I20211231" decimals="-3" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yMi9mcmFnOjJiM2Y4ODE3NTVhYTQ5ODk5MzI2NThlODM2YmIyNGI2L3RhYmxlOjQ1MmFlOGFkMjMxZjQ4MWQ4Njg3MGU5MDYxNWI3NTkxL3RhYmxlcmFuZ2U6NDUyYWU4YWQyMzFmNDgxZDg2ODcwZTkwNjE1Yjc1OTFfMTYtMS0xLTEtMTc3NzU_7cc889ab-d84b-4e25-a489-d23d04331678">426,297</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc0c0c2b8dc04c5698ca0577a54b2e03_I20201231" decimals="-3" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yMi9mcmFnOjJiM2Y4ODE3NTVhYTQ5ODk5MzI2NThlODM2YmIyNGI2L3RhYmxlOjQ1MmFlOGFkMjMxZjQ4MWQ4Njg3MGU5MDYxNWI3NTkxL3RhYmxlcmFuZ2U6NDUyYWU4YWQyMzFmNDgxZDg2ODcwZTkwNjE1Yjc1OTFfMTYtMy0xLTEtMTc3NzU_79eb79de-1574-40ad-a72c-6affdfb3a25b">349,029</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-current assets of discontinued operations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8daff60be410426d8f7bd49343c1ec0c_I20211231" decimals="-3" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yMi9mcmFnOjJiM2Y4ODE3NTVhYTQ5ODk5MzI2NThlODM2YmIyNGI2L3RhYmxlOjQ1MmFlOGFkMjMxZjQ4MWQ4Njg3MGU5MDYxNWI3NTkxL3RhYmxlcmFuZ2U6NDUyYWU4YWQyMzFmNDgxZDg2ODcwZTkwNjE1Yjc1OTFfMTctMS0xLTEtMTc3NzU_15012c48-18a7-4a99-a2a1-f42320ddbe5a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc0c0c2b8dc04c5698ca0577a54b2e03_I20201231" decimals="-3" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yMi9mcmFnOjJiM2Y4ODE3NTVhYTQ5ODk5MzI2NThlODM2YmIyNGI2L3RhYmxlOjQ1MmFlOGFkMjMxZjQ4MWQ4Njg3MGU5MDYxNWI3NTkxL3RhYmxlcmFuZ2U6NDUyYWU4YWQyMzFmNDgxZDg2ODcwZTkwNjE1Yjc1OTFfMTctMy0xLTEtMTc3NzU_876b3921-4f72-4421-b965-db4fd443d841">20,379</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8daff60be410426d8f7bd49343c1ec0c_I20211231" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yMi9mcmFnOjJiM2Y4ODE3NTVhYTQ5ODk5MzI2NThlODM2YmIyNGI2L3RhYmxlOjQ1MmFlOGFkMjMxZjQ4MWQ4Njg3MGU5MDYxNWI3NTkxL3RhYmxlcmFuZ2U6NDUyYWU4YWQyMzFmNDgxZDg2ODcwZTkwNjE1Yjc1OTFfMTgtMS0xLTEtMTc3NzU_0004fa08-53d8-4fe1-ab96-52155a6f13b6">1,419,458</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc0c0c2b8dc04c5698ca0577a54b2e03_I20201231" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yMi9mcmFnOjJiM2Y4ODE3NTVhYTQ5ODk5MzI2NThlODM2YmIyNGI2L3RhYmxlOjQ1MmFlOGFkMjMxZjQ4MWQ4Njg3MGU5MDYxNWI3NTkxL3RhYmxlcmFuZ2U6NDUyYWU4YWQyMzFmNDgxZDg2ODcwZTkwNjE1Yjc1OTFfMTgtMy0xLTEtMTc3NzU_9d949807-537b-4ce7-be17-531b01c00033">1,371,700</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">LIABILITIES AND SHAREHOLDERS&#8217; EQUITY</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr style="height:11pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8daff60be410426d8f7bd49343c1ec0c_I20211231" decimals="-3" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yMi9mcmFnOjJiM2Y4ODE3NTVhYTQ5ODk5MzI2NThlODM2YmIyNGI2L3RhYmxlOjQ1MmFlOGFkMjMxZjQ4MWQ4Njg3MGU5MDYxNWI3NTkxL3RhYmxlcmFuZ2U6NDUyYWU4YWQyMzFmNDgxZDg2ODcwZTkwNjE1Yjc1OTFfMjItMS0xLTEtMTc3NzU_de2bfa85-6392-4aa3-9252-cf468f01146c">96,084</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc0c0c2b8dc04c5698ca0577a54b2e03_I20201231" decimals="-3" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yMi9mcmFnOjJiM2Y4ODE3NTVhYTQ5ODk5MzI2NThlODM2YmIyNGI2L3RhYmxlOjQ1MmFlOGFkMjMxZjQ4MWQ4Njg3MGU5MDYxNWI3NTkxL3RhYmxlcmFuZ2U6NDUyYWU4YWQyMzFmNDgxZDg2ODcwZTkwNjE1Yjc1OTFfMjItMy0xLTEtMTc3NzU_7665c1f5-8c13-4d79-9699-c169f3c45c6b">31,975</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued liabilities </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8daff60be410426d8f7bd49343c1ec0c_I20211231" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yMi9mcmFnOjJiM2Y4ODE3NTVhYTQ5ODk5MzI2NThlODM2YmIyNGI2L3RhYmxlOjQ1MmFlOGFkMjMxZjQ4MWQ4Njg3MGU5MDYxNWI3NTkxL3RhYmxlcmFuZ2U6NDUyYWU4YWQyMzFmNDgxZDg2ODcwZTkwNjE1Yjc1OTFfMjMtMS0xLTEtMTc3NzU_0c4a3b28-a401-4580-bd6d-913e346e7efe">107,241</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc0c0c2b8dc04c5698ca0577a54b2e03_I20201231" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yMi9mcmFnOjJiM2Y4ODE3NTVhYTQ5ODk5MzI2NThlODM2YmIyNGI2L3RhYmxlOjQ1MmFlOGFkMjMxZjQ4MWQ4Njg3MGU5MDYxNWI3NTkxL3RhYmxlcmFuZ2U6NDUyYWU4YWQyMzFmNDgxZDg2ODcwZTkwNjE1Yjc1OTFfMjMtMy0xLTEtMTc3NzU_0c7e2696-05ec-4e48-a7ec-d18b99a2d593">73,242</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term debt, net of discount</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8daff60be410426d8f7bd49343c1ec0c_I20211231" decimals="-3" name="us-gaap:LongTermDebtCurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yMi9mcmFnOjJiM2Y4ODE3NTVhYTQ5ODk5MzI2NThlODM2YmIyNGI2L3RhYmxlOjQ1MmFlOGFkMjMxZjQ4MWQ4Njg3MGU5MDYxNWI3NTkxL3RhYmxlcmFuZ2U6NDUyYWU4YWQyMzFmNDgxZDg2ODcwZTkwNjE1Yjc1OTFfMjQtMS0xLTEtMTc3NzU_cf7c7622-7169-4db3-accb-aad376f4fc81">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc0c0c2b8dc04c5698ca0577a54b2e03_I20201231" decimals="-3" name="us-gaap:LongTermDebtCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yMi9mcmFnOjJiM2Y4ODE3NTVhYTQ5ODk5MzI2NThlODM2YmIyNGI2L3RhYmxlOjQ1MmFlOGFkMjMxZjQ4MWQ4Njg3MGU5MDYxNWI3NTkxL3RhYmxlcmFuZ2U6NDUyYWU4YWQyMzFmNDgxZDg2ODcwZTkwNjE1Yjc1OTFfMjQtMy0xLTEtMTc3NzU_23dcc40c-aa13-49f4-a200-680f9e477be6">26,557</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liability - current</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8daff60be410426d8f7bd49343c1ec0c_I20211231" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yMi9mcmFnOjJiM2Y4ODE3NTVhYTQ5ODk5MzI2NThlODM2YmIyNGI2L3RhYmxlOjQ1MmFlOGFkMjMxZjQ4MWQ4Njg3MGU5MDYxNWI3NTkxL3RhYmxlcmFuZ2U6NDUyYWU4YWQyMzFmNDgxZDg2ODcwZTkwNjE1Yjc1OTFfMjUtMS0xLTEtMTc3NzU_a98a6adb-ca21-42c0-a4d7-25c6c7aba16b">7,069</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc0c0c2b8dc04c5698ca0577a54b2e03_I20201231" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yMi9mcmFnOjJiM2Y4ODE3NTVhYTQ5ODk5MzI2NThlODM2YmIyNGI2L3RhYmxlOjQ1MmFlOGFkMjMxZjQ4MWQ4Njg3MGU5MDYxNWI3NTkxL3RhYmxlcmFuZ2U6NDUyYWU4YWQyMzFmNDgxZDg2ODcwZTkwNjE1Yjc1OTFfMjUtMy0xLTEtMTc3NzU_8cc1761c-6f36-42e9-99d1-954826577076">7,357</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued compensation and employee benefits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8daff60be410426d8f7bd49343c1ec0c_I20211231" decimals="-3" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yMi9mcmFnOjJiM2Y4ODE3NTVhYTQ5ODk5MzI2NThlODM2YmIyNGI2L3RhYmxlOjQ1MmFlOGFkMjMxZjQ4MWQ4Njg3MGU5MDYxNWI3NTkxL3RhYmxlcmFuZ2U6NDUyYWU4YWQyMzFmNDgxZDg2ODcwZTkwNjE1Yjc1OTFfMjYtMS0xLTEtMTc3NzU_4ba8002c-d261-45af-9339-5891b5510b73">51,861</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc0c0c2b8dc04c5698ca0577a54b2e03_I20201231" decimals="-3" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yMi9mcmFnOjJiM2Y4ODE3NTVhYTQ5ODk5MzI2NThlODM2YmIyNGI2L3RhYmxlOjQ1MmFlOGFkMjMxZjQ4MWQ4Njg3MGU5MDYxNWI3NTkxL3RhYmxlcmFuZ2U6NDUyYWU4YWQyMzFmNDgxZDg2ODcwZTkwNjE1Yjc1OTFfMjYtMy0xLTEtMTc3NzU_721d1fab-7a2d-4a0d-aa91-28e0fc200537">47,163</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8daff60be410426d8f7bd49343c1ec0c_I20211231" decimals="-3" name="us-gaap:ContractWithCustomerLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yMi9mcmFnOjJiM2Y4ODE3NTVhYTQ5ODk5MzI2NThlODM2YmIyNGI2L3RhYmxlOjQ1MmFlOGFkMjMxZjQ4MWQ4Njg3MGU5MDYxNWI3NTkxL3RhYmxlcmFuZ2U6NDUyYWU4YWQyMzFmNDgxZDg2ODcwZTkwNjE1Yjc1OTFfMjctMS0xLTEtMTc3NzU_86546b72-411a-4ec1-95d4-5eaf20208163">11,944</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc0c0c2b8dc04c5698ca0577a54b2e03_I20201231" decimals="-3" name="us-gaap:ContractWithCustomerLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yMi9mcmFnOjJiM2Y4ODE3NTVhYTQ5ODk5MzI2NThlODM2YmIyNGI2L3RhYmxlOjQ1MmFlOGFkMjMxZjQ4MWQ4Njg3MGU5MDYxNWI3NTkxL3RhYmxlcmFuZ2U6NDUyYWU4YWQyMzFmNDgxZDg2ODcwZTkwNjE1Yjc1OTFfMjctMy0xLTEtMTc3NzU_e2188d40-2eb6-40ca-b2bf-4c3c857a7073">10,187</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reserve for claims and performance - based arrangements </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8daff60be410426d8f7bd49343c1ec0c_I20211231" decimals="-3" name="evh:LiabilityForFuturePolicyBenefitsAndUnpaidClaimsAndClaimsAdjustmentExpenseAndPerformanceBasedArrangements" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yMi9mcmFnOjJiM2Y4ODE3NTVhYTQ5ODk5MzI2NThlODM2YmIyNGI2L3RhYmxlOjQ1MmFlOGFkMjMxZjQ4MWQ4Njg3MGU5MDYxNWI3NTkxL3RhYmxlcmFuZ2U6NDUyYWU4YWQyMzFmNDgxZDg2ODcwZTkwNjE1Yjc1OTFfMjgtMS0xLTEtMTc3NzU_03f34cbc-a6ef-428a-8ea2-e2626cbf946a">171,294</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc0c0c2b8dc04c5698ca0577a54b2e03_I20201231" decimals="-3" name="evh:LiabilityForFuturePolicyBenefitsAndUnpaidClaimsAndClaimsAdjustmentExpenseAndPerformanceBasedArrangements" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yMi9mcmFnOjJiM2Y4ODE3NTVhYTQ5ODk5MzI2NThlODM2YmIyNGI2L3RhYmxlOjQ1MmFlOGFkMjMxZjQ4MWQ4Njg3MGU5MDYxNWI3NTkxL3RhYmxlcmFuZ2U6NDUyYWU4YWQyMzFmNDgxZDg2ODcwZTkwNjE1Yjc1OTFfMjgtMy0xLTEtMTc3NzU_4b6e6c26-f2b8-4e61-8c51-c6866fd17f9b">178,827</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current liabilities of discontinued operations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8daff60be410426d8f7bd49343c1ec0c_I20211231" decimals="-3" name="us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yMi9mcmFnOjJiM2Y4ODE3NTVhYTQ5ODk5MzI2NThlODM2YmIyNGI2L3RhYmxlOjQ1MmFlOGFkMjMxZjQ4MWQ4Njg3MGU5MDYxNWI3NTkxL3RhYmxlcmFuZ2U6NDUyYWU4YWQyMzFmNDgxZDg2ODcwZTkwNjE1Yjc1OTFfMjktMS0xLTEtMTc3NzU_c9537b3e-06b0-4877-998a-b363a380fde6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc0c0c2b8dc04c5698ca0577a54b2e03_I20201231" decimals="-3" name="us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yMi9mcmFnOjJiM2Y4ODE3NTVhYTQ5ODk5MzI2NThlODM2YmIyNGI2L3RhYmxlOjQ1MmFlOGFkMjMxZjQ4MWQ4Njg3MGU5MDYxNWI3NTkxL3RhYmxlcmFuZ2U6NDUyYWU4YWQyMzFmNDgxZDg2ODcwZTkwNjE1Yjc1OTFfMjktMy0xLTEtMTc3NzU_2375d355-de18-4287-a40d-6b23d1e87621">27,986</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8daff60be410426d8f7bd49343c1ec0c_I20211231" decimals="-3" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yMi9mcmFnOjJiM2Y4ODE3NTVhYTQ5ODk5MzI2NThlODM2YmIyNGI2L3RhYmxlOjQ1MmFlOGFkMjMxZjQ4MWQ4Njg3MGU5MDYxNWI3NTkxL3RhYmxlcmFuZ2U6NDUyYWU4YWQyMzFmNDgxZDg2ODcwZTkwNjE1Yjc1OTFfMzAtMS0xLTEtMTc3NzU_65fcd4a2-c153-42ff-88a5-fc6824d958d4">445,493</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc0c0c2b8dc04c5698ca0577a54b2e03_I20201231" decimals="-3" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yMi9mcmFnOjJiM2Y4ODE3NTVhYTQ5ODk5MzI2NThlODM2YmIyNGI2L3RhYmxlOjQ1MmFlOGFkMjMxZjQ4MWQ4Njg3MGU5MDYxNWI3NTkxL3RhYmxlcmFuZ2U6NDUyYWU4YWQyMzFmNDgxZDg2ODcwZTkwNjE1Yjc1OTFfMzAtMy0xLTEtMTc3NzU_0b3c4412-f231-43ac-a92b-f65148cdfec9">403,294</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term debt, net of discount</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8daff60be410426d8f7bd49343c1ec0c_I20211231" decimals="-3" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yMi9mcmFnOjJiM2Y4ODE3NTVhYTQ5ODk5MzI2NThlODM2YmIyNGI2L3RhYmxlOjQ1MmFlOGFkMjMxZjQ4MWQ4Njg3MGU5MDYxNWI3NTkxL3RhYmxlcmFuZ2U6NDUyYWU4YWQyMzFmNDgxZDg2ODcwZTkwNjE1Yjc1OTFfMzEtMS0xLTEtMTc3NzU_ef15f993-8d97-491b-b049-d15839e35121">215,676</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc0c0c2b8dc04c5698ca0577a54b2e03_I20201231" decimals="-3" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yMi9mcmFnOjJiM2Y4ODE3NTVhYTQ5ODk5MzI2NThlODM2YmIyNGI2L3RhYmxlOjQ1MmFlOGFkMjMxZjQ4MWQ4Njg3MGU5MDYxNWI3NTkxL3RhYmxlcmFuZ2U6NDUyYWU4YWQyMzFmNDgxZDg2ODcwZTkwNjE1Yjc1OTFfMzEtMy0xLTEtMTc3NzU_0f23d363-7ebb-49d8-a628-bfb41fe2415a">263,343</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other long-term liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8daff60be410426d8f7bd49343c1ec0c_I20211231" decimals="-3" name="us-gaap:OtherLiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yMi9mcmFnOjJiM2Y4ODE3NTVhYTQ5ODk5MzI2NThlODM2YmIyNGI2L3RhYmxlOjQ1MmFlOGFkMjMxZjQ4MWQ4Njg3MGU5MDYxNWI3NTkxL3RhYmxlcmFuZ2U6NDUyYWU4YWQyMzFmNDgxZDg2ODcwZTkwNjE1Yjc1OTFfMzItMS0xLTEtMTc3NzU_eda2d901-66bd-43a2-995d-bdac1b81213d">5,531</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc0c0c2b8dc04c5698ca0577a54b2e03_I20201231" decimals="-3" name="us-gaap:OtherLiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yMi9mcmFnOjJiM2Y4ODE3NTVhYTQ5ODk5MzI2NThlODM2YmIyNGI2L3RhYmxlOjQ1MmFlOGFkMjMxZjQ4MWQ4Njg3MGU5MDYxNWI3NTkxL3RhYmxlcmFuZ2U6NDUyYWU4YWQyMzFmNDgxZDg2ODcwZTkwNjE1Yjc1OTFfMzItMy0xLTEtMTc3NzU_1fd26956-3a3b-4eda-93fb-98642dc74790">22,081</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities - noncurrent</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8daff60be410426d8f7bd49343c1ec0c_I20211231" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yMi9mcmFnOjJiM2Y4ODE3NTVhYTQ5ODk5MzI2NThlODM2YmIyNGI2L3RhYmxlOjQ1MmFlOGFkMjMxZjQ4MWQ4Njg3MGU5MDYxNWI3NTkxL3RhYmxlcmFuZ2U6NDUyYWU4YWQyMzFmNDgxZDg2ODcwZTkwNjE1Yjc1OTFfMzMtMS0xLTEtMTc3NzU_2b5d2c4f-b3ff-4a00-8a44-b6e69ea0f9fa">57,722</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc0c0c2b8dc04c5698ca0577a54b2e03_I20201231" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yMi9mcmFnOjJiM2Y4ODE3NTVhYTQ5ODk5MzI2NThlODM2YmIyNGI2L3RhYmxlOjQ1MmFlOGFkMjMxZjQ4MWQ4Njg3MGU5MDYxNWI3NTkxL3RhYmxlcmFuZ2U6NDUyYWU4YWQyMzFmNDgxZDg2ODcwZTkwNjE1Yjc1OTFfMzMtMy0xLTEtMTc3NzU_c35da98e-2761-4aec-ae5c-a54a04a0780f">62,526</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax liabilities, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8daff60be410426d8f7bd49343c1ec0c_I20211231" decimals="-3" name="us-gaap:DeferredIncomeTaxLiabilitiesNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yMi9mcmFnOjJiM2Y4ODE3NTVhYTQ5ODk5MzI2NThlODM2YmIyNGI2L3RhYmxlOjQ1MmFlOGFkMjMxZjQ4MWQ4Njg3MGU5MDYxNWI3NTkxL3RhYmxlcmFuZ2U6NDUyYWU4YWQyMzFmNDgxZDg2ODcwZTkwNjE1Yjc1OTFfMzQtMS0xLTEtMTc3NzU_4b390abf-a9da-4951-832a-5b11d40968ea">1,403</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc0c0c2b8dc04c5698ca0577a54b2e03_I20201231" decimals="-3" name="us-gaap:DeferredIncomeTaxLiabilitiesNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yMi9mcmFnOjJiM2Y4ODE3NTVhYTQ5ODk5MzI2NThlODM2YmIyNGI2L3RhYmxlOjQ1MmFlOGFkMjMxZjQ4MWQ4Njg3MGU5MDYxNWI3NTkxL3RhYmxlcmFuZ2U6NDUyYWU4YWQyMzFmNDgxZDg2ODcwZTkwNjE1Yjc1OTFfMzQtMy0xLTEtMTc3NzU_56e0b43f-f9ca-4699-a958-007eced58f6b">679</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-current liabilities from discontinued operations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8daff60be410426d8f7bd49343c1ec0c_I20211231" decimals="-3" name="us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yMi9mcmFnOjJiM2Y4ODE3NTVhYTQ5ODk5MzI2NThlODM2YmIyNGI2L3RhYmxlOjQ1MmFlOGFkMjMxZjQ4MWQ4Njg3MGU5MDYxNWI3NTkxL3RhYmxlcmFuZ2U6NDUyYWU4YWQyMzFmNDgxZDg2ODcwZTkwNjE1Yjc1OTFfMzUtMS0xLTEtMTc3NzU_e630f844-bd1f-4f52-b1d7-4a685d97a3d8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc0c0c2b8dc04c5698ca0577a54b2e03_I20201231" decimals="-3" name="us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yMi9mcmFnOjJiM2Y4ODE3NTVhYTQ5ODk5MzI2NThlODM2YmIyNGI2L3RhYmxlOjQ1MmFlOGFkMjMxZjQ4MWQ4Njg3MGU5MDYxNWI3NTkxL3RhYmxlcmFuZ2U6NDUyYWU4YWQyMzFmNDgxZDg2ODcwZTkwNjE1Yjc1OTFfMzUtMy0xLTEtMTc3NzU_4773c39d-24f3-44f3-b97e-b07ec8e1194a">177</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8daff60be410426d8f7bd49343c1ec0c_I20211231" decimals="-3" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yMi9mcmFnOjJiM2Y4ODE3NTVhYTQ5ODk5MzI2NThlODM2YmIyNGI2L3RhYmxlOjQ1MmFlOGFkMjMxZjQ4MWQ4Njg3MGU5MDYxNWI3NTkxL3RhYmxlcmFuZ2U6NDUyYWU4YWQyMzFmNDgxZDg2ODcwZTkwNjE1Yjc1OTFfMzYtMS0xLTEtMTc3NzU_4b1fe76e-0839-409f-91b4-23ad461e6fa5">725,825</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc0c0c2b8dc04c5698ca0577a54b2e03_I20201231" decimals="-3" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yMi9mcmFnOjJiM2Y4ODE3NTVhYTQ5ODk5MzI2NThlODM2YmIyNGI2L3RhYmxlOjQ1MmFlOGFkMjMxZjQ4MWQ4Njg3MGU5MDYxNWI3NTkxL3RhYmxlcmFuZ2U6NDUyYWU4YWQyMzFmNDgxZDg2ODcwZTkwNjE1Yjc1OTFfMzYtMy0xLTEtMTc3NzU_3eac2086-5df3-4156-9d54-a76791b55e5c">752,100</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Commitments and Contingencies (See Note 11)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="i8daff60be410426d8f7bd49343c1ec0c_I20211231" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yMi9mcmFnOjJiM2Y4ODE3NTVhYTQ5ODk5MzI2NThlODM2YmIyNGI2L3RhYmxlOjQ1MmFlOGFkMjMxZjQ4MWQ4Njg3MGU5MDYxNWI3NTkxL3RhYmxlcmFuZ2U6NDUyYWU4YWQyMzFmNDgxZDg2ODcwZTkwNjE1Yjc1OTFfMzctMS0xLTEtMTc3NzU_a6b56c85-7293-4041-ab11-e5cf7dc36d51"></ix:nonFraction></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="ibc0c0c2b8dc04c5698ca0577a54b2e03_I20201231" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yMi9mcmFnOjJiM2Y4ODE3NTVhYTQ5ODk5MzI2NThlODM2YmIyNGI2L3RhYmxlOjQ1MmFlOGFkMjMxZjQ4MWQ4Njg3MGU5MDYxNWI3NTkxL3RhYmxlcmFuZ2U6NDUyYWU4YWQyMzFmNDgxZDg2ODcwZTkwNjE1Yjc1OTFfMzctMy0xLTEtMTc3NzU_ffffb78e-b10d-43bc-852b-7cd3b86674a7"></ix:nonFraction></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Shareholders' Equity</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr style="height:23pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Class A common stock - $<ix:nonFraction unitRef="usdPerShare" contextRef="ibc0c0c2b8dc04c5698ca0577a54b2e03_I20201231" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yMi9mcmFnOjJiM2Y4ODE3NTVhYTQ5ODk5MzI2NThlODM2YmIyNGI2L3RhYmxlOjQ1MmFlOGFkMjMxZjQ4MWQ4Njg3MGU5MDYxNWI3NTkxL3RhYmxlcmFuZ2U6NDUyYWU4YWQyMzFmNDgxZDg2ODcwZTkwNjE1Yjc1OTFfMzktMC0xLTEtMTc3NzUvdGV4dHJlZ2lvbjpiYWIxOTVjODAyMWM0MmQ0OTM2M2JmMGQwMGRlY2E5OV8yNw_7c48e5e0-e958-4387-aff8-bc1cfcdb96ea"><ix:nonFraction unitRef="usdPerShare" contextRef="i8daff60be410426d8f7bd49343c1ec0c_I20211231" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yMi9mcmFnOjJiM2Y4ODE3NTVhYTQ5ODk5MzI2NThlODM2YmIyNGI2L3RhYmxlOjQ1MmFlOGFkMjMxZjQ4MWQ4Njg3MGU5MDYxNWI3NTkxL3RhYmxlcmFuZ2U6NDUyYWU4YWQyMzFmNDgxZDg2ODcwZTkwNjE1Yjc1OTFfMzktMC0xLTEtMTc3NzUvdGV4dHJlZ2lvbjpiYWIxOTVjODAyMWM0MmQ0OTM2M2JmMGQwMGRlY2E5OV8yNw_d79892af-82cd-4a20-ac90-08b9bf6a0440">0.01</ix:nonFraction></ix:nonFraction> par value; <ix:nonFraction unitRef="shares" contextRef="i8daff60be410426d8f7bd49343c1ec0c_I20211231" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yMi9mcmFnOjJiM2Y4ODE3NTVhYTQ5ODk5MzI2NThlODM2YmIyNGI2L3RhYmxlOjQ1MmFlOGFkMjMxZjQ4MWQ4Njg3MGU5MDYxNWI3NTkxL3RhYmxlcmFuZ2U6NDUyYWU4YWQyMzFmNDgxZDg2ODcwZTkwNjE1Yjc1OTFfMzktMC0xLTEtMTc3NzUvdGV4dHJlZ2lvbjpiYWIxOTVjODAyMWM0MmQ0OTM2M2JmMGQwMGRlY2E5OV80MQ_0d12a619-7a36-4917-a19f-0461f22a28bb"><ix:nonFraction unitRef="shares" contextRef="ibc0c0c2b8dc04c5698ca0577a54b2e03_I20201231" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yMi9mcmFnOjJiM2Y4ODE3NTVhYTQ5ODk5MzI2NThlODM2YmIyNGI2L3RhYmxlOjQ1MmFlOGFkMjMxZjQ4MWQ4Njg3MGU5MDYxNWI3NTkxL3RhYmxlcmFuZ2U6NDUyYWU4YWQyMzFmNDgxZDg2ODcwZTkwNjE1Yjc1OTFfMzktMC0xLTEtMTc3NzUvdGV4dHJlZ2lvbjpiYWIxOTVjODAyMWM0MmQ0OTM2M2JmMGQwMGRlY2E5OV80MQ_aabbf32e-f678-4fa5-834f-809ac75d7311">750,000,000</ix:nonFraction></ix:nonFraction> shares authorized; <ix:nonFraction unitRef="shares" contextRef="i8daff60be410426d8f7bd49343c1ec0c_I20211231" decimals="INF" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yMi9mcmFnOjJiM2Y4ODE3NTVhYTQ5ODk5MzI2NThlODM2YmIyNGI2L3RhYmxlOjQ1MmFlOGFkMjMxZjQ4MWQ4Njg3MGU5MDYxNWI3NTkxL3RhYmxlcmFuZ2U6NDUyYWU4YWQyMzFmNDgxZDg2ODcwZTkwNjE1Yjc1OTFfMzktMC0xLTEtMTc3NzUvdGV4dHJlZ2lvbjpiYWIxOTVjODAyMWM0MmQ0OTM2M2JmMGQwMGRlY2E5OV82Mw_0e44f980-18d8-41cf-a305-7f2c06217a7c">90,758,318</ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="ibc0c0c2b8dc04c5698ca0577a54b2e03_I20201231" decimals="INF" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yMi9mcmFnOjJiM2Y4ODE3NTVhYTQ5ODk5MzI2NThlODM2YmIyNGI2L3RhYmxlOjQ1MmFlOGFkMjMxZjQ4MWQ4Njg3MGU5MDYxNWI3NTkxL3RhYmxlcmFuZ2U6NDUyYWU4YWQyMzFmNDgxZDg2ODcwZTkwNjE1Yjc1OTFfMzktMC0xLTEtMTc3NzUvdGV4dHJlZ2lvbjpiYWIxOTVjODAyMWM0MmQ0OTM2M2JmMGQwMGRlY2E5OV83MA_a4bc4d8a-0a09-441c-a355-6ba22dbb50e4">85,894,450</ix:nonFraction> shares issued, respectively</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8daff60be410426d8f7bd49343c1ec0c_I20211231" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yMi9mcmFnOjJiM2Y4ODE3NTVhYTQ5ODk5MzI2NThlODM2YmIyNGI2L3RhYmxlOjQ1MmFlOGFkMjMxZjQ4MWQ4Njg3MGU5MDYxNWI3NTkxL3RhYmxlcmFuZ2U6NDUyYWU4YWQyMzFmNDgxZDg2ODcwZTkwNjE1Yjc1OTFfMzktMS0xLTEtMTc3NzU_5c4a1679-a643-4570-bd30-d661e97c1be9">908</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc0c0c2b8dc04c5698ca0577a54b2e03_I20201231" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yMi9mcmFnOjJiM2Y4ODE3NTVhYTQ5ODk5MzI2NThlODM2YmIyNGI2L3RhYmxlOjQ1MmFlOGFkMjMxZjQ4MWQ4Njg3MGU5MDYxNWI3NTkxL3RhYmxlcmFuZ2U6NDUyYWU4YWQyMzFmNDgxZDg2ODcwZTkwNjE1Yjc1OTFfMzktMy0xLTEtMTc3NzU_7eb8acc8-6db0-4887-99f3-4bcd89d4884e">859</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additional paid-in-capital</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8daff60be410426d8f7bd49343c1ec0c_I20211231" decimals="-3" name="us-gaap:AdditionalPaidInCapital" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yMi9mcmFnOjJiM2Y4ODE3NTVhYTQ5ODk5MzI2NThlODM2YmIyNGI2L3RhYmxlOjQ1MmFlOGFkMjMxZjQ4MWQ4Njg3MGU5MDYxNWI3NTkxL3RhYmxlcmFuZ2U6NDUyYWU4YWQyMzFmNDgxZDg2ODcwZTkwNjE1Yjc1OTFfNDAtMS0xLTEtMTc3NzU_c811eb22-d37d-4b7c-ac30-55eef77f97c8">1,340,989</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc0c0c2b8dc04c5698ca0577a54b2e03_I20201231" decimals="-3" name="us-gaap:AdditionalPaidInCapital" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yMi9mcmFnOjJiM2Y4ODE3NTVhYTQ5ODk5MzI2NThlODM2YmIyNGI2L3RhYmxlOjQ1MmFlOGFkMjMxZjQ4MWQ4Njg3MGU5MDYxNWI3NTkxL3RhYmxlcmFuZ2U6NDUyYWU4YWQyMzFmNDgxZDg2ODcwZTkwNjE1Yjc1OTFfNDAtMy0xLTEtMTc3NzU_9e2ffa35-9edf-440f-8e7b-ef23e9d47688">1,229,320</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated other comprehensive income (loss)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8daff60be410426d8f7bd49343c1ec0c_I20211231" decimals="-3" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yMi9mcmFnOjJiM2Y4ODE3NTVhYTQ5ODk5MzI2NThlODM2YmIyNGI2L3RhYmxlOjQ1MmFlOGFkMjMxZjQ4MWQ4Njg3MGU5MDYxNWI3NTkxL3RhYmxlcmFuZ2U6NDUyYWU4YWQyMzFmNDgxZDg2ODcwZTkwNjE1Yjc1OTFfNDEtMS0xLTEtMTc3NzU_6ea35a3d-87d9-4d01-9033-52c5cc04366d">362</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibc0c0c2b8dc04c5698ca0577a54b2e03_I20201231" decimals="-3" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yMi9mcmFnOjJiM2Y4ODE3NTVhYTQ5ODk5MzI2NThlODM2YmIyNGI2L3RhYmxlOjQ1MmFlOGFkMjMxZjQ4MWQ4Njg3MGU5MDYxNWI3NTkxL3RhYmxlcmFuZ2U6NDUyYWU4YWQyMzFmNDgxZDg2ODcwZTkwNjE1Yjc1OTFfNDEtMy0xLTEtMTc3NzU_c6e4db3f-bea2-41d7-b411-ff3c8bebc7d2">278</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Retained earnings (accumulated deficit)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8daff60be410426d8f7bd49343c1ec0c_I20211231" decimals="-3" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yMi9mcmFnOjJiM2Y4ODE3NTVhYTQ5ODk5MzI2NThlODM2YmIyNGI2L3RhYmxlOjQ1MmFlOGFkMjMxZjQ4MWQ4Njg3MGU5MDYxNWI3NTkxL3RhYmxlcmFuZ2U6NDUyYWU4YWQyMzFmNDgxZDg2ODcwZTkwNjE1Yjc1OTFfNDItMS0xLTEtMTc3NzU_5435f53f-69e9-4988-9623-02747495a78f">626,779</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibc0c0c2b8dc04c5698ca0577a54b2e03_I20201231" decimals="-3" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yMi9mcmFnOjJiM2Y4ODE3NTVhYTQ5ODk5MzI2NThlODM2YmIyNGI2L3RhYmxlOjQ1MmFlOGFkMjMxZjQ4MWQ4Njg3MGU5MDYxNWI3NTkxL3RhYmxlcmFuZ2U6NDUyYWU4YWQyMzFmNDgxZDg2ODcwZTkwNjE1Yjc1OTFfNDItMy0xLTEtMTc3NzU_2aae0786-0ce1-4421-bd9a-2516e7203a1b">589,178</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Treasury stock, at cost; <ix:nonFraction unitRef="shares" contextRef="ibc0c0c2b8dc04c5698ca0577a54b2e03_I20201231" decimals="INF" name="us-gaap:TreasuryStockShares" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yMi9mcmFnOjJiM2Y4ODE3NTVhYTQ5ODk5MzI2NThlODM2YmIyNGI2L3RhYmxlOjQ1MmFlOGFkMjMxZjQ4MWQ4Njg3MGU5MDYxNWI3NTkxL3RhYmxlcmFuZ2U6NDUyYWU4YWQyMzFmNDgxZDg2ODcwZTkwNjE1Yjc1OTFfNDMtMC0xLTEtMTc3NzUvdGV4dHJlZ2lvbjo4ZTBjYWU0ZDM1MjM0MmY5OGFhZWEyZjU1OWViZmU1NF8yOQ_ce9f4ead-b9b7-4704-9ed3-26192a1f5a0c"><ix:nonFraction unitRef="shares" contextRef="i8daff60be410426d8f7bd49343c1ec0c_I20211231" decimals="INF" name="us-gaap:TreasuryStockShares" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yMi9mcmFnOjJiM2Y4ODE3NTVhYTQ5ODk5MzI2NThlODM2YmIyNGI2L3RhYmxlOjQ1MmFlOGFkMjMxZjQ4MWQ4Njg3MGU5MDYxNWI3NTkxL3RhYmxlcmFuZ2U6NDUyYWU4YWQyMzFmNDgxZDg2ODcwZTkwNjE1Yjc1OTFfNDMtMC0xLTEtMTc3NzUvdGV4dHJlZ2lvbjo4ZTBjYWU0ZDM1MjM0MmY5OGFhZWEyZjU1OWViZmU1NF8yOQ_ceb6030b-adc9-4cc4-873d-667de68ba82e">1,537,582</ix:nonFraction></ix:nonFraction> shares issued, respectively</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8daff60be410426d8f7bd49343c1ec0c_I20211231" decimals="-3" name="us-gaap:TreasuryStockValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yMi9mcmFnOjJiM2Y4ODE3NTVhYTQ5ODk5MzI2NThlODM2YmIyNGI2L3RhYmxlOjQ1MmFlOGFkMjMxZjQ4MWQ4Njg3MGU5MDYxNWI3NTkxL3RhYmxlcmFuZ2U6NDUyYWU4YWQyMzFmNDgxZDg2ODcwZTkwNjE1Yjc1OTFfNDMtMS0xLTEtMTc3NzU_70be0207-646e-4132-aa59-bd8d4b63bd10">21,123</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibc0c0c2b8dc04c5698ca0577a54b2e03_I20201231" decimals="-3" name="us-gaap:TreasuryStockValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yMi9mcmFnOjJiM2Y4ODE3NTVhYTQ5ODk5MzI2NThlODM2YmIyNGI2L3RhYmxlOjQ1MmFlOGFkMjMxZjQ4MWQ4Njg3MGU5MDYxNWI3NTkxL3RhYmxlcmFuZ2U6NDUyYWU4YWQyMzFmNDgxZDg2ODcwZTkwNjE1Yjc1OTFfNDMtMy0xLTEtMTc3NzU_b123bea9-35ba-4b4f-9d40-400c5ba24410">21,123</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total shareholders' equity</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8daff60be410426d8f7bd49343c1ec0c_I20211231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yMi9mcmFnOjJiM2Y4ODE3NTVhYTQ5ODk5MzI2NThlODM2YmIyNGI2L3RhYmxlOjQ1MmFlOGFkMjMxZjQ4MWQ4Njg3MGU5MDYxNWI3NTkxL3RhYmxlcmFuZ2U6NDUyYWU4YWQyMzFmNDgxZDg2ODcwZTkwNjE1Yjc1OTFfNDQtMS0xLTEtMTc3NzU_622f204d-2184-4115-bf69-5466710c54ff">693,633</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc0c0c2b8dc04c5698ca0577a54b2e03_I20201231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yMi9mcmFnOjJiM2Y4ODE3NTVhYTQ5ODk5MzI2NThlODM2YmIyNGI2L3RhYmxlOjQ1MmFlOGFkMjMxZjQ4MWQ4Njg3MGU5MDYxNWI3NTkxL3RhYmxlcmFuZ2U6NDUyYWU4YWQyMzFmNDgxZDg2ODcwZTkwNjE1Yjc1OTFfNDQtMy0xLTEtMTc3NzU_d633142b-d641-44bf-94a3-205aef009850">619,600</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities and shareholders' equity</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8daff60be410426d8f7bd49343c1ec0c_I20211231" decimals="-3" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yMi9mcmFnOjJiM2Y4ODE3NTVhYTQ5ODk5MzI2NThlODM2YmIyNGI2L3RhYmxlOjQ1MmFlOGFkMjMxZjQ4MWQ4Njg3MGU5MDYxNWI3NTkxL3RhYmxlcmFuZ2U6NDUyYWU4YWQyMzFmNDgxZDg2ODcwZTkwNjE1Yjc1OTFfNDUtMS0xLTEtMTc3NzU_3aa18918-c15b-42b5-84fb-5fa784804293">1,419,458</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc0c0c2b8dc04c5698ca0577a54b2e03_I20201231" decimals="-3" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yMi9mcmFnOjJiM2Y4ODE3NTVhYTQ5ODk5MzI2NThlODM2YmIyNGI2L3RhYmxlOjQ1MmFlOGFkMjMxZjQ4MWQ4Njg3MGU5MDYxNWI3NTkxL3RhYmxlcmFuZ2U6NDUyYWU4YWQyMzFmNDgxZDg2ODcwZTkwNjE1Yjc1OTFfNDUtMy0xLTEtMTc3NzU_9784c573-3207-4375-95b3-4a42be410fec">1,371,700</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> <ix:footnote id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yMi9mcmFnOjJiM2Y4ODE3NTVhYTQ5ODk5MzI2NThlODM2YmIyNGI2L3RleHRyZWdpb246MmIzZjg4MTc1NWFhNDk4OTkzMjY1OGU4MzZiYjI0YjZfMjA1_0cf9d253-8d73-4596-9d10-31e28ee4f8d6" footnoteRole="http://www.xbrl.org/2003/role/footnote">See Note 20 for amounts attributable to related parties included in these line items.</ix:footnote></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">68</span></div></div></div><div id="i9aaa2fddc97e482da5dbe37ac85ae703_25"></div><hr style="page-break-after:always"/><div style="min-height:18pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EVOLENT HEALTH, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (LOSS) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> <br/>(in thousands, except per share data)</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:480.00pt"><tr><td style="width:1.0pt"></td><td style="width:301.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:55.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:55.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:55.00pt"></td><td style="width:1.0pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Year Ended December 31,</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Revenue</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Transformation services </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iba00e3572dc24848afe0d13147ef9951_D20210101-20211231" decimals="-3" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yNS9mcmFnOmM5ZGJiZjkwNWNkYjRhM2Y5NGMxZDk0YTNmMjcyZGM2L3RhYmxlOmI3MTFhYTE1OTNiOTQzZWRhOGQ2ZDQyN2QxNTZkOGFjL3RhYmxlcmFuZ2U6YjcxMWFhMTU5M2I5NDNlZGE4ZDZkNDI3ZDE1NmQ4YWNfMy01LTEtMS0xNzc3NQ_46c2cc00-d98a-4db8-8abe-548c1179f2d3">11,204</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib585ca9afa9b4d02874ade8f146f75cd_D20200101-20201231" decimals="-3" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yNS9mcmFnOmM5ZGJiZjkwNWNkYjRhM2Y5NGMxZDk0YTNmMjcyZGM2L3RhYmxlOmI3MTFhYTE1OTNiOTQzZWRhOGQ2ZDQyN2QxNTZkOGFjL3RhYmxlcmFuZ2U6YjcxMWFhMTU5M2I5NDNlZGE4ZDZkNDI3ZDE1NmQ4YWNfMy03LTEtMS0xNzc3NQ_a3433453-2481-4ae7-be53-93f804bda331">11,990</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia6ba1f43ec4147adbafcb4a00fc450a2_D20190101-20191231" decimals="-3" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yNS9mcmFnOmM5ZGJiZjkwNWNkYjRhM2Y5NGMxZDk0YTNmMjcyZGM2L3RhYmxlOmI3MTFhYTE1OTNiOTQzZWRhOGQ2ZDQyN2QxNTZkOGFjL3RhYmxlcmFuZ2U6YjcxMWFhMTU5M2I5NDNlZGE4ZDZkNDI3ZDE1NmQ4YWNfMy01LTEtMS0xOTE3OA_3c9095fd-21fc-41c2-9170-ae15b4f36761">15,203</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Platform and operations services </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic852ce517768443a8289b4dcbd762e47_D20210101-20211231" decimals="-3" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yNS9mcmFnOmM5ZGJiZjkwNWNkYjRhM2Y5NGMxZDk0YTNmMjcyZGM2L3RhYmxlOmI3MTFhYTE1OTNiOTQzZWRhOGQ2ZDQyN2QxNTZkOGFjL3RhYmxlcmFuZ2U6YjcxMWFhMTU5M2I5NDNlZGE4ZDZkNDI3ZDE1NmQ4YWNfNC01LTEtMS0xNzc3NQ_644b3506-ee17-40d9-933c-67a7ebbab750">896,753</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i971b8dd0fb5d4b10b55f27371adadaa7_D20200101-20201231" decimals="-3" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yNS9mcmFnOmM5ZGJiZjkwNWNkYjRhM2Y5NGMxZDk0YTNmMjcyZGM2L3RhYmxlOmI3MTFhYTE1OTNiOTQzZWRhOGQ2ZDQyN2QxNTZkOGFjL3RhYmxlcmFuZ2U6YjcxMWFhMTU5M2I5NDNlZGE4ZDZkNDI3ZDE1NmQ4YWNfNC03LTEtMS0xNzc3NQ_acbcefc9-f3d5-494d-a386-35f27c437a74">912,649</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie0aa3b0e3e5a4d54a32e0a4b60149c35_D20190101-20191231" decimals="-3" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yNS9mcmFnOmM5ZGJiZjkwNWNkYjRhM2Y5NGMxZDk0YTNmMjcyZGM2L3RhYmxlOmI3MTFhYTE1OTNiOTQzZWRhOGQ2ZDQyN2QxNTZkOGFjL3RhYmxlcmFuZ2U6YjcxMWFhMTU5M2I5NDNlZGE4ZDZkNDI3ZDE1NmQ4YWNfNC01LTEtMS0xOTE3OA_241368f3-5677-4baa-ba4b-666e2870cf8b">671,919</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenue</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231" decimals="-3" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yNS9mcmFnOmM5ZGJiZjkwNWNkYjRhM2Y5NGMxZDk0YTNmMjcyZGM2L3RhYmxlOmI3MTFhYTE1OTNiOTQzZWRhOGQ2ZDQyN2QxNTZkOGFjL3RhYmxlcmFuZ2U6YjcxMWFhMTU5M2I5NDNlZGE4ZDZkNDI3ZDE1NmQ4YWNfNS01LTEtMS0xNzc3NQ_92b2259e-d020-49ee-889b-bff94edfa911">907,957</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i12a6d1161de54547bd29f8efccd4c9b0_D20200101-20201231" decimals="-3" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yNS9mcmFnOmM5ZGJiZjkwNWNkYjRhM2Y5NGMxZDk0YTNmMjcyZGM2L3RhYmxlOmI3MTFhYTE1OTNiOTQzZWRhOGQ2ZDQyN2QxNTZkOGFjL3RhYmxlcmFuZ2U6YjcxMWFhMTU5M2I5NDNlZGE4ZDZkNDI3ZDE1NmQ4YWNfNS03LTEtMS0xNzc3NQ_0c5c9222-0bd3-4a3c-91e3-abce33ecf611">924,639</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e21049ffc224cacb8134d73c9bb5b38_D20190101-20191231" decimals="-3" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yNS9mcmFnOmM5ZGJiZjkwNWNkYjRhM2Y5NGMxZDk0YTNmMjcyZGM2L3RhYmxlOmI3MTFhYTE1OTNiOTQzZWRhOGQ2ZDQyN2QxNTZkOGFjL3RhYmxlcmFuZ2U6YjcxMWFhMTU5M2I5NDNlZGE4ZDZkNDI3ZDE1NmQ4YWNfNS01LTEtMS0yMzU3MA_b53eacd3-b461-4ad0-b71e-9be60f83aa6b">687,122</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:5pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Expenses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr style="height:23pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of revenue (exclusive of depreciation and amortization expenses presented separately below)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"> (1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231" decimals="-3" name="evh:CostofGoodsandServicesSoldExcludingDepreciationandAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yNS9mcmFnOmM5ZGJiZjkwNWNkYjRhM2Y5NGMxZDk0YTNmMjcyZGM2L3RhYmxlOmI3MTFhYTE1OTNiOTQzZWRhOGQ2ZDQyN2QxNTZkOGFjL3RhYmxlcmFuZ2U6YjcxMWFhMTU5M2I5NDNlZGE4ZDZkNDI3ZDE1NmQ4YWNfOC01LTEtMS0xNzc3NQ_1ad8948c-28b0-4494-8a69-63b5046a268c">657,551</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i12a6d1161de54547bd29f8efccd4c9b0_D20200101-20201231" decimals="-3" name="evh:CostofGoodsandServicesSoldExcludingDepreciationandAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yNS9mcmFnOmM5ZGJiZjkwNWNkYjRhM2Y5NGMxZDk0YTNmMjcyZGM2L3RhYmxlOmI3MTFhYTE1OTNiOTQzZWRhOGQ2ZDQyN2QxNTZkOGFjL3RhYmxlcmFuZ2U6YjcxMWFhMTU5M2I5NDNlZGE4ZDZkNDI3ZDE1NmQ4YWNfOC03LTEtMS0xNzc3NQ_943a5b31-2cfc-4168-b222-5a303f55b5aa">696,581</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e21049ffc224cacb8134d73c9bb5b38_D20190101-20191231" decimals="-3" name="evh:CostofGoodsandServicesSoldExcludingDepreciationandAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yNS9mcmFnOmM5ZGJiZjkwNWNkYjRhM2Y5NGMxZDk0YTNmMjcyZGM2L3RhYmxlOmI3MTFhYTE1OTNiOTQzZWRhOGQ2ZDQyN2QxNTZkOGFjL3RhYmxlcmFuZ2U6YjcxMWFhMTU5M2I5NDNlZGE4ZDZkNDI3ZDE1NmQ4YWNfOC01LTEtMS0xOTE4Nw_0a57bcb2-3df7-4503-81cc-cba32b4b23a5">513,033</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative expenses </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231" decimals="-3" name="us-gaap:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yNS9mcmFnOmM5ZGJiZjkwNWNkYjRhM2Y5NGMxZDk0YTNmMjcyZGM2L3RhYmxlOmI3MTFhYTE1OTNiOTQzZWRhOGQ2ZDQyN2QxNTZkOGFjL3RhYmxlcmFuZ2U6YjcxMWFhMTU5M2I5NDNlZGE4ZDZkNDI3ZDE1NmQ4YWNfOS01LTEtMS0xNzc3NQ_ffcafb22-b8f3-4ddb-b38a-5a09c149759c">219,499</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i12a6d1161de54547bd29f8efccd4c9b0_D20200101-20201231" decimals="-3" name="us-gaap:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yNS9mcmFnOmM5ZGJiZjkwNWNkYjRhM2Y5NGMxZDk0YTNmMjcyZGM2L3RhYmxlOmI3MTFhYTE1OTNiOTQzZWRhOGQ2ZDQyN2QxNTZkOGFjL3RhYmxlcmFuZ2U6YjcxMWFhMTU5M2I5NDNlZGE4ZDZkNDI3ZDE1NmQ4YWNfOS03LTEtMS0xNzc3NQ_2a40fbef-ea9c-434a-9dd7-fb55df812da8">210,412</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e21049ffc224cacb8134d73c9bb5b38_D20190101-20191231" decimals="-3" name="us-gaap:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yNS9mcmFnOmM5ZGJiZjkwNWNkYjRhM2Y5NGMxZDk0YTNmMjcyZGM2L3RhYmxlOmI3MTFhYTE1OTNiOTQzZWRhOGQ2ZDQyN2QxNTZkOGFjL3RhYmxlcmFuZ2U6YjcxMWFhMTU5M2I5NDNlZGE4ZDZkNDI3ZDE1NmQ4YWNfOS01LTEtMS0xOTE5NA_260357c9-44f5-47eb-8910-fe9f9be2c529">236,448</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231" decimals="-3" name="us-gaap:DepreciationAndAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yNS9mcmFnOmM5ZGJiZjkwNWNkYjRhM2Y5NGMxZDk0YTNmMjcyZGM2L3RhYmxlOmI3MTFhYTE1OTNiOTQzZWRhOGQ2ZDQyN2QxNTZkOGFjL3RhYmxlcmFuZ2U6YjcxMWFhMTU5M2I5NDNlZGE4ZDZkNDI3ZDE1NmQ4YWNfMTAtNS0xLTEtMTc3NzU_0357594c-325b-4aa3-8bd6-3a454899014c">60,037</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i12a6d1161de54547bd29f8efccd4c9b0_D20200101-20201231" decimals="-3" name="us-gaap:DepreciationAndAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yNS9mcmFnOmM5ZGJiZjkwNWNkYjRhM2Y5NGMxZDk0YTNmMjcyZGM2L3RhYmxlOmI3MTFhYTE1OTNiOTQzZWRhOGQ2ZDQyN2QxNTZkOGFjL3RhYmxlcmFuZ2U6YjcxMWFhMTU5M2I5NDNlZGE4ZDZkNDI3ZDE1NmQ4YWNfMTAtNy0xLTEtMTc3NzU_3698bf6c-728e-4fb0-9326-3be7d69ce16d">60,835</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e21049ffc224cacb8134d73c9bb5b38_D20190101-20191231" decimals="-3" name="us-gaap:DepreciationAndAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yNS9mcmFnOmM5ZGJiZjkwNWNkYjRhM2Y5NGMxZDk0YTNmMjcyZGM2L3RhYmxlOmI3MTFhYTE1OTNiOTQzZWRhOGQ2ZDQyN2QxNTZkOGFjL3RhYmxlcmFuZ2U6YjcxMWFhMTU5M2I5NDNlZGE4ZDZkNDI3ZDE1NmQ4YWNfMTAtNS0xLTEtMTkxOTQ_116164ee-d7ed-4efa-a55c-9f885f52e6d3">60,323</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss (gain) on disposal of assets and consolidation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231" decimals="-3" name="us-gaap:GainLossOnDispositionOfAssets1" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yNS9mcmFnOmM5ZGJiZjkwNWNkYjRhM2Y5NGMxZDk0YTNmMjcyZGM2L3RhYmxlOmI3MTFhYTE1OTNiOTQzZWRhOGQ2ZDQyN2QxNTZkOGFjL3RhYmxlcmFuZ2U6YjcxMWFhMTU5M2I5NDNlZGE4ZDZkNDI3ZDE1NmQ4YWNfMTEtNS0xLTEtMTc3NzU_d8f01148-9c70-4aa0-bf27-8476ae51c59d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i12a6d1161de54547bd29f8efccd4c9b0_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:GainLossOnDispositionOfAssets1" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yNS9mcmFnOmM5ZGJiZjkwNWNkYjRhM2Y5NGMxZDk0YTNmMjcyZGM2L3RhYmxlOmI3MTFhYTE1OTNiOTQzZWRhOGQ2ZDQyN2QxNTZkOGFjL3RhYmxlcmFuZ2U6YjcxMWFhMTU5M2I5NDNlZGE4ZDZkNDI3ZDE1NmQ4YWNfMTEtNy0xLTEtMTc3NzU_3c503b77-91c5-4b7d-8c43-768d2c6a0714">698</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3e21049ffc224cacb8134d73c9bb5b38_D20190101-20191231" decimals="-3" name="us-gaap:GainLossOnDispositionOfAssets1" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yNS9mcmFnOmM5ZGJiZjkwNWNkYjRhM2Y5NGMxZDk0YTNmMjcyZGM2L3RhYmxlOmI3MTFhYTE1OTNiOTQzZWRhOGQ2ZDQyN2QxNTZkOGFjL3RhYmxlcmFuZ2U6YjcxMWFhMTU5M2I5NDNlZGE4ZDZkNDI3ZDE1NmQ4YWNfMTEtNS0xLTEtMTkxOTQ_027077f6-dbbd-487f-afe6-785813b33185">9,600</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss on extinguishment of debt, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231" decimals="-3" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yNS9mcmFnOmM5ZGJiZjkwNWNkYjRhM2Y5NGMxZDk0YTNmMjcyZGM2L3RhYmxlOmI3MTFhYTE1OTNiOTQzZWRhOGQ2ZDQyN2QxNTZkOGFjL3RhYmxlcmFuZ2U6YjcxMWFhMTU5M2I5NDNlZGE4ZDZkNDI3ZDE1NmQ4YWNfMTItNS0xLTEtMTc3NzU_a8c9970a-8e07-49b9-896b-f39467decb53">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i12a6d1161de54547bd29f8efccd4c9b0_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yNS9mcmFnOmM5ZGJiZjkwNWNkYjRhM2Y5NGMxZDk0YTNmMjcyZGM2L3RhYmxlOmI3MTFhYTE1OTNiOTQzZWRhOGQ2ZDQyN2QxNTZkOGFjL3RhYmxlcmFuZ2U6YjcxMWFhMTU5M2I5NDNlZGE4ZDZkNDI3ZDE1NmQ4YWNfMTItNy0xLTEtMTc3NzU_288fc4b3-6a7c-4898-95e8-38528f8a2227">4,789</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e21049ffc224cacb8134d73c9bb5b38_D20190101-20191231" decimals="-3" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yNS9mcmFnOmM5ZGJiZjkwNWNkYjRhM2Y5NGMxZDk0YTNmMjcyZGM2L3RhYmxlOmI3MTFhYTE1OTNiOTQzZWRhOGQ2ZDQyN2QxNTZkOGFjL3RhYmxlcmFuZ2U6YjcxMWFhMTU5M2I5NDNlZGE4ZDZkNDI3ZDE1NmQ4YWNfMTItNS0xLTEtMTkyMDI_552c3561-6c2b-4ebf-8dc3-afaa7c08f663">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill impairment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231" decimals="-3" name="us-gaap:GoodwillImpairmentLoss" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yNS9mcmFnOmM5ZGJiZjkwNWNkYjRhM2Y5NGMxZDk0YTNmMjcyZGM2L3RhYmxlOmI3MTFhYTE1OTNiOTQzZWRhOGQ2ZDQyN2QxNTZkOGFjL3RhYmxlcmFuZ2U6YjcxMWFhMTU5M2I5NDNlZGE4ZDZkNDI3ZDE1NmQ4YWNfMTMtNS0xLTEtMTc3NzU_80c82eff-d414-4c4f-aa27-679d77cbc4a5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i12a6d1161de54547bd29f8efccd4c9b0_D20200101-20201231" decimals="-3" name="us-gaap:GoodwillImpairmentLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yNS9mcmFnOmM5ZGJiZjkwNWNkYjRhM2Y5NGMxZDk0YTNmMjcyZGM2L3RhYmxlOmI3MTFhYTE1OTNiOTQzZWRhOGQ2ZDQyN2QxNTZkOGFjL3RhYmxlcmFuZ2U6YjcxMWFhMTU5M2I5NDNlZGE4ZDZkNDI3ZDE1NmQ4YWNfMTMtNy0xLTEtMTc3NzU_49dc0f5d-bc2d-4491-8ca2-1c167853b9ca">215,100</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e21049ffc224cacb8134d73c9bb5b38_D20190101-20191231" decimals="-3" name="us-gaap:GoodwillImpairmentLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yNS9mcmFnOmM5ZGJiZjkwNWNkYjRhM2Y5NGMxZDk0YTNmMjcyZGM2L3RhYmxlOmI3MTFhYTE1OTNiOTQzZWRhOGQ2ZDQyN2QxNTZkOGFjL3RhYmxlcmFuZ2U6YjcxMWFhMTU5M2I5NDNlZGE4ZDZkNDI3ZDE1NmQ4YWNfMTMtNS0xLTEtMTkyMDI_c0975c81-d5ff-4b9c-8c73-e9cba8c13460">199,800</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value of contingent consideration and indemnification asset</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yNS9mcmFnOmM5ZGJiZjkwNWNkYjRhM2Y5NGMxZDk0YTNmMjcyZGM2L3RhYmxlOmI3MTFhYTE1OTNiOTQzZWRhOGQ2ZDQyN2QxNTZkOGFjL3RhYmxlcmFuZ2U6YjcxMWFhMTU5M2I5NDNlZGE4ZDZkNDI3ZDE1NmQ4YWNfMTQtNS0xLTEtMTc3NzU_4e2e85b9-06a6-4b27-9f5d-2a84797355a0">13,281</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i12a6d1161de54547bd29f8efccd4c9b0_D20200101-20201231" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yNS9mcmFnOmM5ZGJiZjkwNWNkYjRhM2Y5NGMxZDk0YTNmMjcyZGM2L3RhYmxlOmI3MTFhYTE1OTNiOTQzZWRhOGQ2ZDQyN2QxNTZkOGFjL3RhYmxlcmFuZ2U6YjcxMWFhMTU5M2I5NDNlZGE4ZDZkNDI3ZDE1NmQ4YWNfMTQtNy0xLTEtMTc3NzU_c488d7c2-3696-4200-bb0b-a696f7d48699">3,860</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3e21049ffc224cacb8134d73c9bb5b38_D20190101-20191231" decimals="-3" sign="-" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yNS9mcmFnOmM5ZGJiZjkwNWNkYjRhM2Y5NGMxZDk0YTNmMjcyZGM2L3RhYmxlOmI3MTFhYTE1OTNiOTQzZWRhOGQ2ZDQyN2QxNTZkOGFjL3RhYmxlcmFuZ2U6YjcxMWFhMTU5M2I5NDNlZGE4ZDZkNDI3ZDE1NmQ4YWNfMTQtNS0xLTEtMTkyMDI_0e2f194b-5e96-485a-ab6b-24e8299a6428">3,997</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating expenses</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231" decimals="-3" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yNS9mcmFnOmM5ZGJiZjkwNWNkYjRhM2Y5NGMxZDk0YTNmMjcyZGM2L3RhYmxlOmI3MTFhYTE1OTNiOTQzZWRhOGQ2ZDQyN2QxNTZkOGFjL3RhYmxlcmFuZ2U6YjcxMWFhMTU5M2I5NDNlZGE4ZDZkNDI3ZDE1NmQ4YWNfMTUtNS0xLTEtMTc3NzU_a00d0f8e-7cc7-4923-ad6a-6f344ca790ba">950,368</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i12a6d1161de54547bd29f8efccd4c9b0_D20200101-20201231" decimals="-3" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yNS9mcmFnOmM5ZGJiZjkwNWNkYjRhM2Y5NGMxZDk0YTNmMjcyZGM2L3RhYmxlOmI3MTFhYTE1OTNiOTQzZWRhOGQ2ZDQyN2QxNTZkOGFjL3RhYmxlcmFuZ2U6YjcxMWFhMTU5M2I5NDNlZGE4ZDZkNDI3ZDE1NmQ4YWNfMTUtNy0xLTEtMTc3NzU_5bd4d51d-bda6-48d8-ab16-e3d0bffe94f3">1,192,275</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e21049ffc224cacb8134d73c9bb5b38_D20190101-20191231" decimals="-3" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yNS9mcmFnOmM5ZGJiZjkwNWNkYjRhM2Y5NGMxZDk0YTNmMjcyZGM2L3RhYmxlOmI3MTFhYTE1OTNiOTQzZWRhOGQ2ZDQyN2QxNTZkOGFjL3RhYmxlcmFuZ2U6YjcxMWFhMTU5M2I5NDNlZGE4ZDZkNDI3ZDE1NmQ4YWNfMTUtNS0xLTEtMTkyMDI_92ab6dce-bce4-4135-8b60-f3dd13d49c50">996,007</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating loss</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yNS9mcmFnOmM5ZGJiZjkwNWNkYjRhM2Y5NGMxZDk0YTNmMjcyZGM2L3RhYmxlOmI3MTFhYTE1OTNiOTQzZWRhOGQ2ZDQyN2QxNTZkOGFjL3RhYmxlcmFuZ2U6YjcxMWFhMTU5M2I5NDNlZGE4ZDZkNDI3ZDE1NmQ4YWNfMTYtNS0xLTEtMTc3NzU_5a9e3c8b-5326-48e4-a504-4963dc49f4ea">42,411</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i12a6d1161de54547bd29f8efccd4c9b0_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yNS9mcmFnOmM5ZGJiZjkwNWNkYjRhM2Y5NGMxZDk0YTNmMjcyZGM2L3RhYmxlOmI3MTFhYTE1OTNiOTQzZWRhOGQ2ZDQyN2QxNTZkOGFjL3RhYmxlcmFuZ2U6YjcxMWFhMTU5M2I5NDNlZGE4ZDZkNDI3ZDE1NmQ4YWNfMTYtNy0xLTEtMTc3NzU_177902cf-abf1-49d7-8d84-69cac6134564">267,636</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3e21049ffc224cacb8134d73c9bb5b38_D20190101-20191231" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yNS9mcmFnOmM5ZGJiZjkwNWNkYjRhM2Y5NGMxZDk0YTNmMjcyZGM2L3RhYmxlOmI3MTFhYTE1OTNiOTQzZWRhOGQ2ZDQyN2QxNTZkOGFjL3RhYmxlcmFuZ2U6YjcxMWFhMTU5M2I5NDNlZGE4ZDZkNDI3ZDE1NmQ4YWNfMTYtNS0xLTEtMTkyMDI_b8dd709a-9991-431b-8085-5676c5ff9c6a">308,885</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231" decimals="-3" name="us-gaap:InvestmentIncomeInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yNS9mcmFnOmM5ZGJiZjkwNWNkYjRhM2Y5NGMxZDk0YTNmMjcyZGM2L3RhYmxlOmI3MTFhYTE1OTNiOTQzZWRhOGQ2ZDQyN2QxNTZkOGFjL3RhYmxlcmFuZ2U6YjcxMWFhMTU5M2I5NDNlZGE4ZDZkNDI3ZDE1NmQ4YWNfMTctNS0xLTEtMTc3NzU_ed8e7c16-ab33-49de-b138-dcd1658371e1">407</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i12a6d1161de54547bd29f8efccd4c9b0_D20200101-20201231" decimals="-3" name="us-gaap:InvestmentIncomeInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yNS9mcmFnOmM5ZGJiZjkwNWNkYjRhM2Y5NGMxZDk0YTNmMjcyZGM2L3RhYmxlOmI3MTFhYTE1OTNiOTQzZWRhOGQ2ZDQyN2QxNTZkOGFjL3RhYmxlcmFuZ2U6YjcxMWFhMTU5M2I5NDNlZGE4ZDZkNDI3ZDE1NmQ4YWNfMTctNy0xLTEtMTc3NzU_5fa1f4cc-ec24-4b32-b3bf-a9470d8699ef">2,633</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e21049ffc224cacb8134d73c9bb5b38_D20190101-20191231" decimals="-3" name="us-gaap:InvestmentIncomeInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yNS9mcmFnOmM5ZGJiZjkwNWNkYjRhM2Y5NGMxZDk0YTNmMjcyZGM2L3RhYmxlOmI3MTFhYTE1OTNiOTQzZWRhOGQ2ZDQyN2QxNTZkOGFjL3RhYmxlcmFuZ2U6YjcxMWFhMTU5M2I5NDNlZGE4ZDZkNDI3ZDE1NmQ4YWNfMTctNS0xLTEtMTkyMDk_02a2ab01-df64-405a-8e99-e04063811304">3,406</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231" decimals="-3" name="us-gaap:InterestExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yNS9mcmFnOmM5ZGJiZjkwNWNkYjRhM2Y5NGMxZDk0YTNmMjcyZGM2L3RhYmxlOmI3MTFhYTE1OTNiOTQzZWRhOGQ2ZDQyN2QxNTZkOGFjL3RhYmxlcmFuZ2U6YjcxMWFhMTU5M2I5NDNlZGE4ZDZkNDI3ZDE1NmQ4YWNfMTgtNS0xLTEtMTc3NzU_6a78d6c2-1102-41af-9956-e43dca7ba453">25,425</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i12a6d1161de54547bd29f8efccd4c9b0_D20200101-20201231" decimals="-3" name="us-gaap:InterestExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yNS9mcmFnOmM5ZGJiZjkwNWNkYjRhM2Y5NGMxZDk0YTNmMjcyZGM2L3RhYmxlOmI3MTFhYTE1OTNiOTQzZWRhOGQ2ZDQyN2QxNTZkOGFjL3RhYmxlcmFuZ2U6YjcxMWFhMTU5M2I5NDNlZGE4ZDZkNDI3ZDE1NmQ4YWNfMTgtNy0xLTEtMTc3NzU_99ca1463-f660-4524-8ecc-51938d108e3d">28,325</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3e21049ffc224cacb8134d73c9bb5b38_D20190101-20191231" decimals="-3" name="us-gaap:InterestExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yNS9mcmFnOmM5ZGJiZjkwNWNkYjRhM2Y5NGMxZDk0YTNmMjcyZGM2L3RhYmxlOmI3MTFhYTE1OTNiOTQzZWRhOGQ2ZDQyN2QxNTZkOGFjL3RhYmxlcmFuZ2U6YjcxMWFhMTU5M2I5NDNlZGE4ZDZkNDI3ZDE1NmQ4YWNfMTgtNS0xLTEtMTkyMDk_7c53cd4e-aeb0-46af-90bb-c9b0f542fead">14,555</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Impairment of equity method investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231" decimals="-3" name="us-gaap:EquityMethodInvestmentOtherThanTemporaryImpairment" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yNS9mcmFnOmM5ZGJiZjkwNWNkYjRhM2Y5NGMxZDk0YTNmMjcyZGM2L3RhYmxlOmI3MTFhYTE1OTNiOTQzZWRhOGQ2ZDQyN2QxNTZkOGFjL3RhYmxlcmFuZ2U6YjcxMWFhMTU5M2I5NDNlZGE4ZDZkNDI3ZDE1NmQ4YWNfMTktNS0xLTEtMTc3NzU_f623abc1-715a-4242-bdf3-2cb73a19f981">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i12a6d1161de54547bd29f8efccd4c9b0_D20200101-20201231" decimals="-3" name="us-gaap:EquityMethodInvestmentOtherThanTemporaryImpairment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yNS9mcmFnOmM5ZGJiZjkwNWNkYjRhM2Y5NGMxZDk0YTNmMjcyZGM2L3RhYmxlOmI3MTFhYTE1OTNiOTQzZWRhOGQ2ZDQyN2QxNTZkOGFjL3RhYmxlcmFuZ2U6YjcxMWFhMTU5M2I5NDNlZGE4ZDZkNDI3ZDE1NmQ4YWNfMTktNy0xLTEtMTc3NzU_6b50cf8a-2ad6-42c5-a4ec-1c5bbca0c14b">47,133</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e21049ffc224cacb8134d73c9bb5b38_D20190101-20191231" decimals="-3" name="us-gaap:EquityMethodInvestmentOtherThanTemporaryImpairment" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yNS9mcmFnOmM5ZGJiZjkwNWNkYjRhM2Y5NGMxZDk0YTNmMjcyZGM2L3RhYmxlOmI3MTFhYTE1OTNiOTQzZWRhOGQ2ZDQyN2QxNTZkOGFjL3RhYmxlcmFuZ2U6YjcxMWFhMTU5M2I5NDNlZGE4ZDZkNDI3ZDE1NmQ4YWNfMTktNS0xLTEtMTkyMDk_adf0b0ad-6da5-4047-bd24-49ea7a1947e6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain (loss) from equity method investees</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231" decimals="-3" name="us-gaap:IncomeLossFromEquityMethodInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yNS9mcmFnOmM5ZGJiZjkwNWNkYjRhM2Y5NGMxZDk0YTNmMjcyZGM2L3RhYmxlOmI3MTFhYTE1OTNiOTQzZWRhOGQ2ZDQyN2QxNTZkOGFjL3RhYmxlcmFuZ2U6YjcxMWFhMTU5M2I5NDNlZGE4ZDZkNDI3ZDE1NmQ4YWNfMjAtNS0xLTEtMTc3NzU_513dd88f-3329-4fab-bb44-62cfdb086baf">13,179</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i12a6d1161de54547bd29f8efccd4c9b0_D20200101-20201231" decimals="-3" name="us-gaap:IncomeLossFromEquityMethodInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yNS9mcmFnOmM5ZGJiZjkwNWNkYjRhM2Y5NGMxZDk0YTNmMjcyZGM2L3RhYmxlOmI3MTFhYTE1OTNiOTQzZWRhOGQ2ZDQyN2QxNTZkOGFjL3RhYmxlcmFuZ2U6YjcxMWFhMTU5M2I5NDNlZGE4ZDZkNDI3ZDE1NmQ4YWNfMjAtNy0xLTEtMTc3NzU_3a7067e2-b4dd-4080-acac-eecaaedd5656">10,039</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3e21049ffc224cacb8134d73c9bb5b38_D20190101-20191231" decimals="-3" sign="-" name="us-gaap:IncomeLossFromEquityMethodInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yNS9mcmFnOmM5ZGJiZjkwNWNkYjRhM2Y5NGMxZDk0YTNmMjcyZGM2L3RhYmxlOmI3MTFhYTE1OTNiOTQzZWRhOGQ2ZDQyN2QxNTZkOGFjL3RhYmxlcmFuZ2U6YjcxMWFhMTU5M2I5NDNlZGE4ZDZkNDI3ZDE1NmQ4YWNfMjAtNS0xLTEtMTkyMDk_a4aa33ae-b62f-45ef-841c-965aac144139">9,465</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain on transfer of membership</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231" decimals="-3" name="evh:GainOnTransferOfMembership" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yNS9mcmFnOmM5ZGJiZjkwNWNkYjRhM2Y5NGMxZDk0YTNmMjcyZGM2L3RhYmxlOmI3MTFhYTE1OTNiOTQzZWRhOGQ2ZDQyN2QxNTZkOGFjL3RhYmxlcmFuZ2U6YjcxMWFhMTU5M2I5NDNlZGE4ZDZkNDI3ZDE1NmQ4YWNfMjEtNS0xLTEtMTc3NzU_2189a2b7-76ab-4792-bdd1-8a29f3c4f5fb">45,938</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i12a6d1161de54547bd29f8efccd4c9b0_D20200101-20201231" decimals="-3" name="evh:GainOnTransferOfMembership" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yNS9mcmFnOmM5ZGJiZjkwNWNkYjRhM2Y5NGMxZDk0YTNmMjcyZGM2L3RhYmxlOmI3MTFhYTE1OTNiOTQzZWRhOGQ2ZDQyN2QxNTZkOGFjL3RhYmxlcmFuZ2U6YjcxMWFhMTU5M2I5NDNlZGE4ZDZkNDI3ZDE1NmQ4YWNfMjEtNy0xLTEtMTc3NzU_7b9abb88-eef2-4628-a46a-c03d5bbcc3a4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e21049ffc224cacb8134d73c9bb5b38_D20190101-20191231" decimals="-3" name="evh:GainOnTransferOfMembership" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yNS9mcmFnOmM5ZGJiZjkwNWNkYjRhM2Y5NGMxZDk0YTNmMjcyZGM2L3RhYmxlOmI3MTFhYTE1OTNiOTQzZWRhOGQ2ZDQyN2QxNTZkOGFjL3RhYmxlcmFuZ2U6YjcxMWFhMTU5M2I5NDNlZGE4ZDZkNDI3ZDE1NmQ4YWNfMjEtNS0xLTEtMTkyNDU_054e8a73-ab2f-4fc9-8104-50197adfd3ae">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss on repayment of debt</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231" decimals="-3" sign="-" name="evh:GainLossOnRepaymentOfDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yNS9mcmFnOmM5ZGJiZjkwNWNkYjRhM2Y5NGMxZDk0YTNmMjcyZGM2L3RhYmxlOmI3MTFhYTE1OTNiOTQzZWRhOGQ2ZDQyN2QxNTZkOGFjL3RhYmxlcmFuZ2U6YjcxMWFhMTU5M2I5NDNlZGE4ZDZkNDI3ZDE1NmQ4YWNfMjItNS0xLTEtMTc3NzU_84fe278a-0a04-48d8-8928-fdb3b9d5c81e">21,343</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i12a6d1161de54547bd29f8efccd4c9b0_D20200101-20201231" decimals="-3" name="evh:GainLossOnRepaymentOfDebt" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yNS9mcmFnOmM5ZGJiZjkwNWNkYjRhM2Y5NGMxZDk0YTNmMjcyZGM2L3RhYmxlOmI3MTFhYTE1OTNiOTQzZWRhOGQ2ZDQyN2QxNTZkOGFjL3RhYmxlcmFuZ2U6YjcxMWFhMTU5M2I5NDNlZGE4ZDZkNDI3ZDE1NmQ4YWNfMjItNy0xLTEtMTc3NzU_9810b448-5082-441f-a337-1478828e290d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e21049ffc224cacb8134d73c9bb5b38_D20190101-20191231" decimals="-3" name="evh:GainLossOnRepaymentOfDebt" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yNS9mcmFnOmM5ZGJiZjkwNWNkYjRhM2Y5NGMxZDk0YTNmMjcyZGM2L3RhYmxlOmI3MTFhYTE1OTNiOTQzZWRhOGQ2ZDQyN2QxNTZkOGFjL3RhYmxlcmFuZ2U6YjcxMWFhMTU5M2I5NDNlZGE4ZDZkNDI3ZDE1NmQ4YWNfMjItNS0xLTEtMTkyNTY_42d6422f-f6fc-425a-bd2d-69d7f733c03e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other expense, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:OtherOperatingIncomeExpenseNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yNS9mcmFnOmM5ZGJiZjkwNWNkYjRhM2Y5NGMxZDk0YTNmMjcyZGM2L3RhYmxlOmI3MTFhYTE1OTNiOTQzZWRhOGQ2ZDQyN2QxNTZkOGFjL3RhYmxlcmFuZ2U6YjcxMWFhMTU5M2I5NDNlZGE4ZDZkNDI3ZDE1NmQ4YWNfMjMtNS0xLTEtMTc3NzU_a4c56d1f-7b46-4aa4-bae4-6102339358fc">146</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i12a6d1161de54547bd29f8efccd4c9b0_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:OtherOperatingIncomeExpenseNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yNS9mcmFnOmM5ZGJiZjkwNWNkYjRhM2Y5NGMxZDk0YTNmMjcyZGM2L3RhYmxlOmI3MTFhYTE1OTNiOTQzZWRhOGQ2ZDQyN2QxNTZkOGFjL3RhYmxlcmFuZ2U6YjcxMWFhMTU5M2I5NDNlZGE4ZDZkNDI3ZDE1NmQ4YWNfMjMtNy0xLTEtMTc3NzU_83e1e614-ddc5-4c90-87f7-5e94810cc873">118</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3e21049ffc224cacb8134d73c9bb5b38_D20190101-20191231" decimals="-3" sign="-" name="us-gaap:OtherOperatingIncomeExpenseNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yNS9mcmFnOmM5ZGJiZjkwNWNkYjRhM2Y5NGMxZDk0YTNmMjcyZGM2L3RhYmxlOmI3MTFhYTE1OTNiOTQzZWRhOGQ2ZDQyN2QxNTZkOGFjL3RhYmxlcmFuZ2U6YjcxMWFhMTU5M2I5NDNlZGE4ZDZkNDI3ZDE1NmQ4YWNfMjMtNS0xLTEtMTkyNTY_2fce15e8-3942-40d1-ab33-248f86e35123">489</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss from continuing operations before income taxes</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yNS9mcmFnOmM5ZGJiZjkwNWNkYjRhM2Y5NGMxZDk0YTNmMjcyZGM2L3RhYmxlOmI3MTFhYTE1OTNiOTQzZWRhOGQ2ZDQyN2QxNTZkOGFjL3RhYmxlcmFuZ2U6YjcxMWFhMTU5M2I5NDNlZGE4ZDZkNDI3ZDE1NmQ4YWNfMjQtNS0xLTEtMTc3NzU_5e6b7864-2dc1-4a33-861e-24d2b5b993d1">29,801</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i12a6d1161de54547bd29f8efccd4c9b0_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yNS9mcmFnOmM5ZGJiZjkwNWNkYjRhM2Y5NGMxZDk0YTNmMjcyZGM2L3RhYmxlOmI3MTFhYTE1OTNiOTQzZWRhOGQ2ZDQyN2QxNTZkOGFjL3RhYmxlcmFuZ2U6YjcxMWFhMTU5M2I5NDNlZGE4ZDZkNDI3ZDE1NmQ4YWNfMjQtNy0xLTEtMTc3NzU_8c28df32-8e64-4612-a55c-a3ec6ac15298">330,540</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3e21049ffc224cacb8134d73c9bb5b38_D20190101-20191231" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yNS9mcmFnOmM5ZGJiZjkwNWNkYjRhM2Y5NGMxZDk0YTNmMjcyZGM2L3RhYmxlOmI3MTFhYTE1OTNiOTQzZWRhOGQ2ZDQyN2QxNTZkOGFjL3RhYmxlcmFuZ2U6YjcxMWFhMTU5M2I5NDNlZGE4ZDZkNDI3ZDE1NmQ4YWNfMjQtNS0xLTEtMTkyNTY_32509e42-1c58-47aa-a766-3ae60096c836">329,988</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provision (benefit) for income taxes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yNS9mcmFnOmM5ZGJiZjkwNWNkYjRhM2Y5NGMxZDk0YTNmMjcyZGM2L3RhYmxlOmI3MTFhYTE1OTNiOTQzZWRhOGQ2ZDQyN2QxNTZkOGFjL3RhYmxlcmFuZ2U6YjcxMWFhMTU5M2I5NDNlZGE4ZDZkNDI3ZDE1NmQ4YWNfMjUtNS0xLTEtMTc3NzU_1f00f303-89f9-4899-a27f-5daa78e5cccf">483</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i12a6d1161de54547bd29f8efccd4c9b0_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yNS9mcmFnOmM5ZGJiZjkwNWNkYjRhM2Y5NGMxZDk0YTNmMjcyZGM2L3RhYmxlOmI3MTFhYTE1OTNiOTQzZWRhOGQ2ZDQyN2QxNTZkOGFjL3RhYmxlcmFuZ2U6YjcxMWFhMTU5M2I5NDNlZGE4ZDZkNDI3ZDE1NmQ4YWNfMjUtNy0xLTEtMTc3NzU_ff1e4f9d-543d-4224-9369-edd44021901f">2,368</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3e21049ffc224cacb8134d73c9bb5b38_D20190101-20191231" decimals="-3" sign="-" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yNS9mcmFnOmM5ZGJiZjkwNWNkYjRhM2Y5NGMxZDk0YTNmMjcyZGM2L3RhYmxlOmI3MTFhYTE1OTNiOTQzZWRhOGQ2ZDQyN2QxNTZkOGFjL3RhYmxlcmFuZ2U6YjcxMWFhMTU5M2I5NDNlZGE4ZDZkNDI3ZDE1NmQ4YWNfMjUtNS0xLTEtMTkyNTY_e81e073e-fd96-466f-a7bc-e276283a5f2e">22,795</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 24.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss from continuing operations</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yNS9mcmFnOmM5ZGJiZjkwNWNkYjRhM2Y5NGMxZDk0YTNmMjcyZGM2L3RhYmxlOmI3MTFhYTE1OTNiOTQzZWRhOGQ2ZDQyN2QxNTZkOGFjL3RhYmxlcmFuZ2U6YjcxMWFhMTU5M2I5NDNlZGE4ZDZkNDI3ZDE1NmQ4YWNfMjYtNS0xLTEtMTc3NzU_d76450ef-cfe7-4881-b23e-9a162abc49db">30,284</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i12a6d1161de54547bd29f8efccd4c9b0_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yNS9mcmFnOmM5ZGJiZjkwNWNkYjRhM2Y5NGMxZDk0YTNmMjcyZGM2L3RhYmxlOmI3MTFhYTE1OTNiOTQzZWRhOGQ2ZDQyN2QxNTZkOGFjL3RhYmxlcmFuZ2U6YjcxMWFhMTU5M2I5NDNlZGE4ZDZkNDI3ZDE1NmQ4YWNfMjYtNy0xLTEtMTc3NzU_46bcd607-6919-41ba-bd7e-9e6da2dfd783">328,172</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3e21049ffc224cacb8134d73c9bb5b38_D20190101-20191231" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yNS9mcmFnOmM5ZGJiZjkwNWNkYjRhM2Y5NGMxZDk0YTNmMjcyZGM2L3RhYmxlOmI3MTFhYTE1OTNiOTQzZWRhOGQ2ZDQyN2QxNTZkOGFjL3RhYmxlcmFuZ2U6YjcxMWFhMTU5M2I5NDNlZGE4ZDZkNDI3ZDE1NmQ4YWNfMjYtNS0xLTEtMTkyNTY_7cd677f7-562c-4cff-afb6-94eb73d0af25">307,193</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:17.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income (loss) from discontinued operations, net of tax </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yNS9mcmFnOmM5ZGJiZjkwNWNkYjRhM2Y5NGMxZDk0YTNmMjcyZGM2L3RhYmxlOmI3MTFhYTE1OTNiOTQzZWRhOGQ2ZDQyN2QxNTZkOGFjL3RhYmxlcmFuZ2U6YjcxMWFhMTU5M2I5NDNlZGE4ZDZkNDI3ZDE1NmQ4YWNfMjctNS0xLTEtMTc3NzU_3a7f9340-a2d9-4068-b095-f659267e962c">7,317</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i12a6d1161de54547bd29f8efccd4c9b0_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yNS9mcmFnOmM5ZGJiZjkwNWNkYjRhM2Y5NGMxZDk0YTNmMjcyZGM2L3RhYmxlOmI3MTFhYTE1OTNiOTQzZWRhOGQ2ZDQyN2QxNTZkOGFjL3RhYmxlcmFuZ2U6YjcxMWFhMTU5M2I5NDNlZGE4ZDZkNDI3ZDE1NmQ4YWNfMjctNy0xLTEtMTc3NzU_6123f20d-b2da-4983-8481-3001d793c73d">6,074</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e21049ffc224cacb8134d73c9bb5b38_D20190101-20191231" decimals="-3" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yNS9mcmFnOmM5ZGJiZjkwNWNkYjRhM2Y5NGMxZDk0YTNmMjcyZGM2L3RhYmxlOmI3MTFhYTE1OTNiOTQzZWRhOGQ2ZDQyN2QxNTZkOGFjL3RhYmxlcmFuZ2U6YjcxMWFhMTU5M2I5NDNlZGE4ZDZkNDI3ZDE1NmQ4YWNfMjctNS0xLTEtMTkyNTY_cd15aa32-72bb-4df8-a330-8fac8ecbd8bb">1,613</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 24.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yNS9mcmFnOmM5ZGJiZjkwNWNkYjRhM2Y5NGMxZDk0YTNmMjcyZGM2L3RhYmxlOmI3MTFhYTE1OTNiOTQzZWRhOGQ2ZDQyN2QxNTZkOGFjL3RhYmxlcmFuZ2U6YjcxMWFhMTU5M2I5NDNlZGE4ZDZkNDI3ZDE1NmQ4YWNfMjgtNS0xLTEtMTc3NzU_c49b99c2-1aef-4003-806b-11d043c6a947">37,601</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i12a6d1161de54547bd29f8efccd4c9b0_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yNS9mcmFnOmM5ZGJiZjkwNWNkYjRhM2Y5NGMxZDk0YTNmMjcyZGM2L3RhYmxlOmI3MTFhYTE1OTNiOTQzZWRhOGQ2ZDQyN2QxNTZkOGFjL3RhYmxlcmFuZ2U6YjcxMWFhMTU5M2I5NDNlZGE4ZDZkNDI3ZDE1NmQ4YWNfMjgtNy0xLTEtMTc3NzU_059445f8-3794-4af1-abe2-9f2515cac297">334,246</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3e21049ffc224cacb8134d73c9bb5b38_D20190101-20191231" decimals="-3" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yNS9mcmFnOmM5ZGJiZjkwNWNkYjRhM2Y5NGMxZDk0YTNmMjcyZGM2L3RhYmxlOmI3MTFhYTE1OTNiOTQzZWRhOGQ2ZDQyN2QxNTZkOGFjL3RhYmxlcmFuZ2U6YjcxMWFhMTU5M2I5NDNlZGE4ZDZkNDI3ZDE1NmQ4YWNfMjgtNS0xLTEtMTkyNTY_29de1fd1-21e6-4603-8e1d-b3241b370b6f">305,580</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss attributable to non-controlling interests</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231" decimals="-3" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yNS9mcmFnOmM5ZGJiZjkwNWNkYjRhM2Y5NGMxZDk0YTNmMjcyZGM2L3RhYmxlOmI3MTFhYTE1OTNiOTQzZWRhOGQ2ZDQyN2QxNTZkOGFjL3RhYmxlcmFuZ2U6YjcxMWFhMTU5M2I5NDNlZGE4ZDZkNDI3ZDE1NmQ4YWNfMjktNS0xLTEtMTc3NzU_a10ceaab-8664-4942-a66d-497e3968da6b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i12a6d1161de54547bd29f8efccd4c9b0_D20200101-20201231" decimals="-3" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yNS9mcmFnOmM5ZGJiZjkwNWNkYjRhM2Y5NGMxZDk0YTNmMjcyZGM2L3RhYmxlOmI3MTFhYTE1OTNiOTQzZWRhOGQ2ZDQyN2QxNTZkOGFjL3RhYmxlcmFuZ2U6YjcxMWFhMTU5M2I5NDNlZGE4ZDZkNDI3ZDE1NmQ4YWNfMjktNy0xLTEtMTc3NzU_1026adc1-b9ab-4994-88ed-075d8f12b561">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3e21049ffc224cacb8134d73c9bb5b38_D20190101-20191231" decimals="-3" sign="-" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yNS9mcmFnOmM5ZGJiZjkwNWNkYjRhM2Y5NGMxZDk0YTNmMjcyZGM2L3RhYmxlOmI3MTFhYTE1OTNiOTQzZWRhOGQ2ZDQyN2QxNTZkOGFjL3RhYmxlcmFuZ2U6YjcxMWFhMTU5M2I5NDNlZGE4ZDZkNDI3ZDE1NmQ4YWNfMjktNS0xLTEtMTkyNTY_786f1d03-94cb-48e8-ad31-9c0764623193">3,609</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:23pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 31pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss attributable to common shareholders of Evolent Health, Inc.</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yNS9mcmFnOmM5ZGJiZjkwNWNkYjRhM2Y5NGMxZDk0YTNmMjcyZGM2L3RhYmxlOmI3MTFhYTE1OTNiOTQzZWRhOGQ2ZDQyN2QxNTZkOGFjL3RhYmxlcmFuZ2U6YjcxMWFhMTU5M2I5NDNlZGE4ZDZkNDI3ZDE1NmQ4YWNfMzAtNS0xLTEtMTc3NzU_19b0e485-6260-41f1-b4e9-3c97c234c728"><ix:nonFraction unitRef="usd" contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yNS9mcmFnOmM5ZGJiZjkwNWNkYjRhM2Y5NGMxZDk0YTNmMjcyZGM2L3RhYmxlOmI3MTFhYTE1OTNiOTQzZWRhOGQ2ZDQyN2QxNTZkOGFjL3RhYmxlcmFuZ2U6YjcxMWFhMTU5M2I5NDNlZGE4ZDZkNDI3ZDE1NmQ4YWNfMzAtNS0xLTEtMTc3NzU_34c1e7e0-fc69-4bdc-be43-ddb3ef807107">37,601</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i12a6d1161de54547bd29f8efccd4c9b0_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yNS9mcmFnOmM5ZGJiZjkwNWNkYjRhM2Y5NGMxZDk0YTNmMjcyZGM2L3RhYmxlOmI3MTFhYTE1OTNiOTQzZWRhOGQ2ZDQyN2QxNTZkOGFjL3RhYmxlcmFuZ2U6YjcxMWFhMTU5M2I5NDNlZGE4ZDZkNDI3ZDE1NmQ4YWNfMzAtNy0xLTEtMTc3NzU_47276093-49df-42a8-9bbd-a4f0df34d037"><ix:nonFraction unitRef="usd" contextRef="i12a6d1161de54547bd29f8efccd4c9b0_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yNS9mcmFnOmM5ZGJiZjkwNWNkYjRhM2Y5NGMxZDk0YTNmMjcyZGM2L3RhYmxlOmI3MTFhYTE1OTNiOTQzZWRhOGQ2ZDQyN2QxNTZkOGFjL3RhYmxlcmFuZ2U6YjcxMWFhMTU5M2I5NDNlZGE4ZDZkNDI3ZDE1NmQ4YWNfMzAtNy0xLTEtMTc3NzU_e8f68bad-99dd-4b99-9acb-741a4f5652df">334,246</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3e21049ffc224cacb8134d73c9bb5b38_D20190101-20191231" decimals="-3" sign="-" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yNS9mcmFnOmM5ZGJiZjkwNWNkYjRhM2Y5NGMxZDk0YTNmMjcyZGM2L3RhYmxlOmI3MTFhYTE1OTNiOTQzZWRhOGQ2ZDQyN2QxNTZkOGFjL3RhYmxlcmFuZ2U6YjcxMWFhMTU5M2I5NDNlZGE4ZDZkNDI3ZDE1NmQ4YWNfMzAtNS0xLTEtMTkyNTY_436a8d3c-073f-4296-af03-689f7e52133b"><ix:nonFraction unitRef="usd" contextRef="i3e21049ffc224cacb8134d73c9bb5b38_D20190101-20191231" decimals="-3" sign="-" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yNS9mcmFnOmM5ZGJiZjkwNWNkYjRhM2Y5NGMxZDk0YTNmMjcyZGM2L3RhYmxlOmI3MTFhYTE1OTNiOTQzZWRhOGQ2ZDQyN2QxNTZkOGFjL3RhYmxlcmFuZ2U6YjcxMWFhMTU5M2I5NDNlZGE4ZDZkNDI3ZDE1NmQ4YWNfMzAtNS0xLTEtMTkyNTY_a8db8b9f-7556-4b88-8d4a-6b128c94ac69">301,971</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:5pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Loss per common share</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic and diluted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Continuing operations</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231" decimals="2" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yNS9mcmFnOmM5ZGJiZjkwNWNkYjRhM2Y5NGMxZDk0YTNmMjcyZGM2L3RhYmxlOmI3MTFhYTE1OTNiOTQzZWRhOGQ2ZDQyN2QxNTZkOGFjL3RhYmxlcmFuZ2U6YjcxMWFhMTU5M2I5NDNlZGE4ZDZkNDI3ZDE1NmQ4YWNfMzQtNS0xLTEtMTc3NzU_1be0d8aa-7784-4a8d-b716-b5e8a6f955e8"><ix:nonFraction unitRef="usdPerShare" contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231" decimals="2" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsPerBasicShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yNS9mcmFnOmM5ZGJiZjkwNWNkYjRhM2Y5NGMxZDk0YTNmMjcyZGM2L3RhYmxlOmI3MTFhYTE1OTNiOTQzZWRhOGQ2ZDQyN2QxNTZkOGFjL3RhYmxlcmFuZ2U6YjcxMWFhMTU5M2I5NDNlZGE4ZDZkNDI3ZDE1NmQ4YWNfMzQtNS0xLTEtMTc3NzU_e035674e-3c54-4da7-a44d-68e94785e880">0.35</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i12a6d1161de54547bd29f8efccd4c9b0_D20200101-20201231" decimals="2" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsPerBasicShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yNS9mcmFnOmM5ZGJiZjkwNWNkYjRhM2Y5NGMxZDk0YTNmMjcyZGM2L3RhYmxlOmI3MTFhYTE1OTNiOTQzZWRhOGQ2ZDQyN2QxNTZkOGFjL3RhYmxlcmFuZ2U6YjcxMWFhMTU5M2I5NDNlZGE4ZDZkNDI3ZDE1NmQ4YWNfMzQtNy0xLTEtMTc3NzU_47ab00f1-b3ad-4d5b-8c18-b329fbbc06ba"><ix:nonFraction unitRef="usdPerShare" contextRef="i12a6d1161de54547bd29f8efccd4c9b0_D20200101-20201231" decimals="2" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yNS9mcmFnOmM5ZGJiZjkwNWNkYjRhM2Y5NGMxZDk0YTNmMjcyZGM2L3RhYmxlOmI3MTFhYTE1OTNiOTQzZWRhOGQ2ZDQyN2QxNTZkOGFjL3RhYmxlcmFuZ2U6YjcxMWFhMTU5M2I5NDNlZGE4ZDZkNDI3ZDE1NmQ4YWNfMzQtNy0xLTEtMTc3NzU_c1dc9607-9bf5-4cf1-a3d2-b0db3afb1c8d">3.86</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i3e21049ffc224cacb8134d73c9bb5b38_D20190101-20191231" decimals="2" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yNS9mcmFnOmM5ZGJiZjkwNWNkYjRhM2Y5NGMxZDk0YTNmMjcyZGM2L3RhYmxlOmI3MTFhYTE1OTNiOTQzZWRhOGQ2ZDQyN2QxNTZkOGFjL3RhYmxlcmFuZ2U6YjcxMWFhMTU5M2I5NDNlZGE4ZDZkNDI3ZDE1NmQ4YWNfMzQtNS0xLTEtMTkyNjg_297fced9-7321-4394-9d35-8f3d7ae6d0e4"><ix:nonFraction unitRef="usdPerShare" contextRef="i3e21049ffc224cacb8134d73c9bb5b38_D20190101-20191231" decimals="2" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsPerBasicShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yNS9mcmFnOmM5ZGJiZjkwNWNkYjRhM2Y5NGMxZDk0YTNmMjcyZGM2L3RhYmxlOmI3MTFhYTE1OTNiOTQzZWRhOGQ2ZDQyN2QxNTZkOGFjL3RhYmxlcmFuZ2U6YjcxMWFhMTU5M2I5NDNlZGE4ZDZkNDI3ZDE1NmQ4YWNfMzQtNS0xLTEtMTkyNjg_d87662c3-104c-4c72-8c1f-7e928653cdf7">3.73</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discontinued operations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231" decimals="2" sign="-" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yNS9mcmFnOmM5ZGJiZjkwNWNkYjRhM2Y5NGMxZDk0YTNmMjcyZGM2L3RhYmxlOmI3MTFhYTE1OTNiOTQzZWRhOGQ2ZDQyN2QxNTZkOGFjL3RhYmxlcmFuZ2U6YjcxMWFhMTU5M2I5NDNlZGE4ZDZkNDI3ZDE1NmQ4YWNfMzUtNS0xLTEtMTc3NzU_3cbafcdb-0f82-465e-b519-e19d64aa375c"><ix:nonFraction unitRef="usdPerShare" contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231" decimals="2" sign="-" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yNS9mcmFnOmM5ZGJiZjkwNWNkYjRhM2Y5NGMxZDk0YTNmMjcyZGM2L3RhYmxlOmI3MTFhYTE1OTNiOTQzZWRhOGQ2ZDQyN2QxNTZkOGFjL3RhYmxlcmFuZ2U6YjcxMWFhMTU5M2I5NDNlZGE4ZDZkNDI3ZDE1NmQ4YWNfMzUtNS0xLTEtMTc3NzU_697a90c3-40a0-4d50-b5ad-b2ef2b6a2202">0.09</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i12a6d1161de54547bd29f8efccd4c9b0_D20200101-20201231" decimals="2" sign="-" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yNS9mcmFnOmM5ZGJiZjkwNWNkYjRhM2Y5NGMxZDk0YTNmMjcyZGM2L3RhYmxlOmI3MTFhYTE1OTNiOTQzZWRhOGQ2ZDQyN2QxNTZkOGFjL3RhYmxlcmFuZ2U6YjcxMWFhMTU5M2I5NDNlZGE4ZDZkNDI3ZDE1NmQ4YWNfMzUtNy0xLTEtMTc3NzU_614d8f41-3c14-4669-9dc3-7aef83745f39"><ix:nonFraction unitRef="usdPerShare" contextRef="i12a6d1161de54547bd29f8efccd4c9b0_D20200101-20201231" decimals="2" sign="-" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yNS9mcmFnOmM5ZGJiZjkwNWNkYjRhM2Y5NGMxZDk0YTNmMjcyZGM2L3RhYmxlOmI3MTFhYTE1OTNiOTQzZWRhOGQ2ZDQyN2QxNTZkOGFjL3RhYmxlcmFuZ2U6YjcxMWFhMTU5M2I5NDNlZGE4ZDZkNDI3ZDE1NmQ4YWNfMzUtNy0xLTEtMTc3NzU_f821a2c7-e60f-4775-af30-3571e62c8d7b">0.08</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i3e21049ffc224cacb8134d73c9bb5b38_D20190101-20191231" decimals="2" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yNS9mcmFnOmM5ZGJiZjkwNWNkYjRhM2Y5NGMxZDk0YTNmMjcyZGM2L3RhYmxlOmI3MTFhYTE1OTNiOTQzZWRhOGQ2ZDQyN2QxNTZkOGFjL3RhYmxlcmFuZ2U6YjcxMWFhMTU5M2I5NDNlZGE4ZDZkNDI3ZDE1NmQ4YWNfMzUtNS0xLTEtMTkyNjg_65c2769c-8bf5-4a69-9670-8d84e869f596"><ix:nonFraction unitRef="usdPerShare" contextRef="i3e21049ffc224cacb8134d73c9bb5b38_D20190101-20191231" decimals="2" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yNS9mcmFnOmM5ZGJiZjkwNWNkYjRhM2Y5NGMxZDk0YTNmMjcyZGM2L3RhYmxlOmI3MTFhYTE1OTNiOTQzZWRhOGQ2ZDQyN2QxNTZkOGFjL3RhYmxlcmFuZ2U6YjcxMWFhMTU5M2I5NDNlZGE4ZDZkNDI3ZDE1NmQ4YWNfMzUtNS0xLTEtMTkyNjg_d3da87c4-e160-4bb7-b042-19a87036320a">0.02</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-controlling interests</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231" decimals="2" name="evh:EarningsPerSharePortionAttributableToNoncontrollingInterestDiluted" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yNS9mcmFnOmM5ZGJiZjkwNWNkYjRhM2Y5NGMxZDk0YTNmMjcyZGM2L3RhYmxlOmI3MTFhYTE1OTNiOTQzZWRhOGQ2ZDQyN2QxNTZkOGFjL3RhYmxlcmFuZ2U6YjcxMWFhMTU5M2I5NDNlZGE4ZDZkNDI3ZDE1NmQ4YWNfMzYtMS0xLTEtMjU2MTE_b50e84b8-a45a-41d3-9af3-908304b36487"><ix:nonFraction unitRef="usdPerShare" contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231" decimals="2" name="evh:EarningsPerSharePortionAttributableToNoncontrollingInterestBasic" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yNS9mcmFnOmM5ZGJiZjkwNWNkYjRhM2Y5NGMxZDk0YTNmMjcyZGM2L3RhYmxlOmI3MTFhYTE1OTNiOTQzZWRhOGQ2ZDQyN2QxNTZkOGFjL3RhYmxlcmFuZ2U6YjcxMWFhMTU5M2I5NDNlZGE4ZDZkNDI3ZDE1NmQ4YWNfMzYtMS0xLTEtMjU2MTE_ee4b7836-0c1c-4e91-a00a-f4f08b39f581">&#8212;</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i12a6d1161de54547bd29f8efccd4c9b0_D20200101-20201231" decimals="2" name="evh:EarningsPerSharePortionAttributableToNoncontrollingInterestBasic" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yNS9mcmFnOmM5ZGJiZjkwNWNkYjRhM2Y5NGMxZDk0YTNmMjcyZGM2L3RhYmxlOmI3MTFhYTE1OTNiOTQzZWRhOGQ2ZDQyN2QxNTZkOGFjL3RhYmxlcmFuZ2U6YjcxMWFhMTU5M2I5NDNlZGE4ZDZkNDI3ZDE1NmQ4YWNfMzYtMy0xLTEtMjU2MTE_cebaab0d-cb9a-4d96-96cf-e73e49782c92"><ix:nonFraction unitRef="usdPerShare" contextRef="i12a6d1161de54547bd29f8efccd4c9b0_D20200101-20201231" decimals="2" name="evh:EarningsPerSharePortionAttributableToNoncontrollingInterestDiluted" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yNS9mcmFnOmM5ZGJiZjkwNWNkYjRhM2Y5NGMxZDk0YTNmMjcyZGM2L3RhYmxlOmI3MTFhYTE1OTNiOTQzZWRhOGQ2ZDQyN2QxNTZkOGFjL3RhYmxlcmFuZ2U6YjcxMWFhMTU5M2I5NDNlZGE4ZDZkNDI3ZDE1NmQ4YWNfMzYtMy0xLTEtMjU2MTE_f7665397-906b-4348-84a7-07254c898be6">&#8212;</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i3e21049ffc224cacb8134d73c9bb5b38_D20190101-20191231" decimals="2" name="evh:EarningsPerSharePortionAttributableToNoncontrollingInterestBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yNS9mcmFnOmM5ZGJiZjkwNWNkYjRhM2Y5NGMxZDk0YTNmMjcyZGM2L3RhYmxlOmI3MTFhYTE1OTNiOTQzZWRhOGQ2ZDQyN2QxNTZkOGFjL3RhYmxlcmFuZ2U6YjcxMWFhMTU5M2I5NDNlZGE4ZDZkNDI3ZDE1NmQ4YWNfMzYtNS0xLTEtMjU2MTE_0d37b9ed-1132-4390-9d72-4c8dc81e16e0"><ix:nonFraction unitRef="usdPerShare" contextRef="i3e21049ffc224cacb8134d73c9bb5b38_D20190101-20191231" decimals="2" name="evh:EarningsPerSharePortionAttributableToNoncontrollingInterestDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yNS9mcmFnOmM5ZGJiZjkwNWNkYjRhM2Y5NGMxZDk0YTNmMjcyZGM2L3RhYmxlOmI3MTFhYTE1OTNiOTQzZWRhOGQ2ZDQyN2QxNTZkOGFjL3RhYmxlcmFuZ2U6YjcxMWFhMTU5M2I5NDNlZGE4ZDZkNDI3ZDE1NmQ4YWNfMzYtNS0xLTEtMjU2MTE_38addc30-6b9a-49e7-9ecf-74d51ec59ed6">0.04</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:23pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic and diluted loss per share attributable to common shareholders of Evolent Health, Inc.</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yNS9mcmFnOmM5ZGJiZjkwNWNkYjRhM2Y5NGMxZDk0YTNmMjcyZGM2L3RhYmxlOmI3MTFhYTE1OTNiOTQzZWRhOGQ2ZDQyN2QxNTZkOGFjL3RhYmxlcmFuZ2U6YjcxMWFhMTU5M2I5NDNlZGE4ZDZkNDI3ZDE1NmQ4YWNfMzYtNS0xLTEtMTc3NzU_1dc36fb6-30b6-45f5-a0d7-06d7a9e9335f"><ix:nonFraction unitRef="usdPerShare" contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yNS9mcmFnOmM5ZGJiZjkwNWNkYjRhM2Y5NGMxZDk0YTNmMjcyZGM2L3RhYmxlOmI3MTFhYTE1OTNiOTQzZWRhOGQ2ZDQyN2QxNTZkOGFjL3RhYmxlcmFuZ2U6YjcxMWFhMTU5M2I5NDNlZGE4ZDZkNDI3ZDE1NmQ4YWNfMzYtNS0xLTEtMTc3NzU_f8b4468e-36ed-4cf2-b7f3-455155f62856">0.44</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i12a6d1161de54547bd29f8efccd4c9b0_D20200101-20201231" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yNS9mcmFnOmM5ZGJiZjkwNWNkYjRhM2Y5NGMxZDk0YTNmMjcyZGM2L3RhYmxlOmI3MTFhYTE1OTNiOTQzZWRhOGQ2ZDQyN2QxNTZkOGFjL3RhYmxlcmFuZ2U6YjcxMWFhMTU5M2I5NDNlZGE4ZDZkNDI3ZDE1NmQ4YWNfMzYtNy0xLTEtMTc3NzU_1354653c-22c3-4b3a-bf59-2975c6a7d95b"><ix:nonFraction unitRef="usdPerShare" contextRef="i12a6d1161de54547bd29f8efccd4c9b0_D20200101-20201231" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yNS9mcmFnOmM5ZGJiZjkwNWNkYjRhM2Y5NGMxZDk0YTNmMjcyZGM2L3RhYmxlOmI3MTFhYTE1OTNiOTQzZWRhOGQ2ZDQyN2QxNTZkOGFjL3RhYmxlcmFuZ2U6YjcxMWFhMTU5M2I5NDNlZGE4ZDZkNDI3ZDE1NmQ4YWNfMzYtNy0xLTEtMTc3NzU_6a13b863-a134-4ff7-b9ae-26c31fbc200f">3.94</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i3e21049ffc224cacb8134d73c9bb5b38_D20190101-20191231" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yNS9mcmFnOmM5ZGJiZjkwNWNkYjRhM2Y5NGMxZDk0YTNmMjcyZGM2L3RhYmxlOmI3MTFhYTE1OTNiOTQzZWRhOGQ2ZDQyN2QxNTZkOGFjL3RhYmxlcmFuZ2U6YjcxMWFhMTU5M2I5NDNlZGE4ZDZkNDI3ZDE1NmQ4YWNfMzYtNS0xLTEtMTkyNjg_71979723-6e39-4211-8a6d-eaf820918e5d"><ix:nonFraction unitRef="usdPerShare" contextRef="i3e21049ffc224cacb8134d73c9bb5b38_D20190101-20191231" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yNS9mcmFnOmM5ZGJiZjkwNWNkYjRhM2Y5NGMxZDk0YTNmMjcyZGM2L3RhYmxlOmI3MTFhYTE1OTNiOTQzZWRhOGQ2ZDQyN2QxNTZkOGFjL3RhYmxlcmFuZ2U6YjcxMWFhMTU5M2I5NDNlZGE4ZDZkNDI3ZDE1NmQ4YWNfMzYtNS0xLTEtMTkyNjg_fe462964-8e16-4239-9bc7-5853f6b65425">3.67</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:5pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted-average common shares outstanding</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic and diluted</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yNS9mcmFnOmM5ZGJiZjkwNWNkYjRhM2Y5NGMxZDk0YTNmMjcyZGM2L3RhYmxlOmI3MTFhYTE1OTNiOTQzZWRhOGQ2ZDQyN2QxNTZkOGFjL3RhYmxlcmFuZ2U6YjcxMWFhMTU5M2I5NDNlZGE4ZDZkNDI3ZDE1NmQ4YWNfMzktNS0xLTEtMTc3NzU_4d2bf937-f10f-4d10-9f93-6566eaee8855"><ix:nonFraction unitRef="shares" contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yNS9mcmFnOmM5ZGJiZjkwNWNkYjRhM2Y5NGMxZDk0YTNmMjcyZGM2L3RhYmxlOmI3MTFhYTE1OTNiOTQzZWRhOGQ2ZDQyN2QxNTZkOGFjL3RhYmxlcmFuZ2U6YjcxMWFhMTU5M2I5NDNlZGE4ZDZkNDI3ZDE1NmQ4YWNfMzktNS0xLTEtMTc3NzU_e2c93d99-4d5a-42af-aa15-b4f7a2aa8373">86,067</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i12a6d1161de54547bd29f8efccd4c9b0_D20200101-20201231" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yNS9mcmFnOmM5ZGJiZjkwNWNkYjRhM2Y5NGMxZDk0YTNmMjcyZGM2L3RhYmxlOmI3MTFhYTE1OTNiOTQzZWRhOGQ2ZDQyN2QxNTZkOGFjL3RhYmxlcmFuZ2U6YjcxMWFhMTU5M2I5NDNlZGE4ZDZkNDI3ZDE1NmQ4YWNfMzktNy0xLTEtMTc3NzU_43f0e345-3af0-4b74-93ae-34e196683016"><ix:nonFraction unitRef="shares" contextRef="i12a6d1161de54547bd29f8efccd4c9b0_D20200101-20201231" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yNS9mcmFnOmM5ZGJiZjkwNWNkYjRhM2Y5NGMxZDk0YTNmMjcyZGM2L3RhYmxlOmI3MTFhYTE1OTNiOTQzZWRhOGQ2ZDQyN2QxNTZkOGFjL3RhYmxlcmFuZ2U6YjcxMWFhMTU5M2I5NDNlZGE4ZDZkNDI3ZDE1NmQ4YWNfMzktNy0xLTEtMTc3NzU_efcdf457-3aed-4d57-9eff-1d019a73ef97">84,928</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i3e21049ffc224cacb8134d73c9bb5b38_D20190101-20191231" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yNS9mcmFnOmM5ZGJiZjkwNWNkYjRhM2Y5NGMxZDk0YTNmMjcyZGM2L3RhYmxlOmI3MTFhYTE1OTNiOTQzZWRhOGQ2ZDQyN2QxNTZkOGFjL3RhYmxlcmFuZ2U6YjcxMWFhMTU5M2I5NDNlZGE4ZDZkNDI3ZDE1NmQ4YWNfMzktNS0xLTEtMTkyNzU_17b3a8da-cd42-48cf-b771-14854ba34a55"><ix:nonFraction unitRef="shares" contextRef="i3e21049ffc224cacb8134d73c9bb5b38_D20190101-20191231" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yNS9mcmFnOmM5ZGJiZjkwNWNkYjRhM2Y5NGMxZDk0YTNmMjcyZGM2L3RhYmxlOmI3MTFhYTE1OTNiOTQzZWRhOGQ2ZDQyN2QxNTZkOGFjL3RhYmxlcmFuZ2U6YjcxMWFhMTU5M2I5NDNlZGE4ZDZkNDI3ZDE1NmQ4YWNfMzktNS0xLTEtMTkyNzU_d4138463-e018-4b8c-b6bd-c98de3be60c7">82,364</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Comprehensive loss</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yNS9mcmFnOmM5ZGJiZjkwNWNkYjRhM2Y5NGMxZDk0YTNmMjcyZGM2L3RhYmxlOmI3MTFhYTE1OTNiOTQzZWRhOGQ2ZDQyN2QxNTZkOGFjL3RhYmxlcmFuZ2U6YjcxMWFhMTU5M2I5NDNlZGE4ZDZkNDI3ZDE1NmQ4YWNfNDItNS0xLTEtMTc3NzU_d602765a-8408-4f07-91d2-6cc1d0ec20f5">37,601</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i12a6d1161de54547bd29f8efccd4c9b0_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yNS9mcmFnOmM5ZGJiZjkwNWNkYjRhM2Y5NGMxZDk0YTNmMjcyZGM2L3RhYmxlOmI3MTFhYTE1OTNiOTQzZWRhOGQ2ZDQyN2QxNTZkOGFjL3RhYmxlcmFuZ2U6YjcxMWFhMTU5M2I5NDNlZGE4ZDZkNDI3ZDE1NmQ4YWNfNDItNy0xLTEtMTc3NzU_b3ab09a1-d157-4806-977d-c453a053058a">334,246</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3e21049ffc224cacb8134d73c9bb5b38_D20190101-20191231" decimals="-3" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yNS9mcmFnOmM5ZGJiZjkwNWNkYjRhM2Y5NGMxZDk0YTNmMjcyZGM2L3RhYmxlOmI3MTFhYTE1OTNiOTQzZWRhOGQ2ZDQyN2QxNTZkOGFjL3RhYmxlcmFuZ2U6YjcxMWFhMTU5M2I5NDNlZGE4ZDZkNDI3ZDE1NmQ4YWNfNDItNS0xLTEtMTkyODI_6d262eba-5c2a-4faa-8da8-8c4c8a3478f8">305,580</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive loss, net of taxes, related to:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency translation adjustment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yNS9mcmFnOmM5ZGJiZjkwNWNkYjRhM2Y5NGMxZDk0YTNmMjcyZGM2L3RhYmxlOmI3MTFhYTE1OTNiOTQzZWRhOGQ2ZDQyN2QxNTZkOGFjL3RhYmxlcmFuZ2U6YjcxMWFhMTU5M2I5NDNlZGE4ZDZkNDI3ZDE1NmQ4YWNfNDQtNS0xLTEtMTc3NzU_ca75e441-0511-4f4b-8784-e16de76c2e93">84</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i12a6d1161de54547bd29f8efccd4c9b0_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yNS9mcmFnOmM5ZGJiZjkwNWNkYjRhM2Y5NGMxZDk0YTNmMjcyZGM2L3RhYmxlOmI3MTFhYTE1OTNiOTQzZWRhOGQ2ZDQyN2QxNTZkOGFjL3RhYmxlcmFuZ2U6YjcxMWFhMTU5M2I5NDNlZGE4ZDZkNDI3ZDE1NmQ4YWNfNDQtNy0xLTEtMTc3NzU_35d2ea27-b7a8-4983-89f1-02aa4c82befd">44</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3e21049ffc224cacb8134d73c9bb5b38_D20190101-20191231" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yNS9mcmFnOmM5ZGJiZjkwNWNkYjRhM2Y5NGMxZDk0YTNmMjcyZGM2L3RhYmxlOmI3MTFhYTE1OTNiOTQzZWRhOGQ2ZDQyN2QxNTZkOGFjL3RhYmxlcmFuZ2U6YjcxMWFhMTU5M2I5NDNlZGE4ZDZkNDI3ZDE1NmQ4YWNfNDQtNS0xLTEtMTkyODI_f00d44f4-49d9-4c7c-828f-c2680f04f436">52</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total comprehensive loss</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yNS9mcmFnOmM5ZGJiZjkwNWNkYjRhM2Y5NGMxZDk0YTNmMjcyZGM2L3RhYmxlOmI3MTFhYTE1OTNiOTQzZWRhOGQ2ZDQyN2QxNTZkOGFjL3RhYmxlcmFuZ2U6YjcxMWFhMTU5M2I5NDNlZGE4ZDZkNDI3ZDE1NmQ4YWNfNDUtNS0xLTEtMTc3NzU_ac920c19-ad66-45fe-921e-ffda5a6b44ba">37,685</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i12a6d1161de54547bd29f8efccd4c9b0_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yNS9mcmFnOmM5ZGJiZjkwNWNkYjRhM2Y5NGMxZDk0YTNmMjcyZGM2L3RhYmxlOmI3MTFhYTE1OTNiOTQzZWRhOGQ2ZDQyN2QxNTZkOGFjL3RhYmxlcmFuZ2U6YjcxMWFhMTU5M2I5NDNlZGE4ZDZkNDI3ZDE1NmQ4YWNfNDUtNy0xLTEtMTc3NzU_74fe0cb0-13ed-4246-988e-201aaca5bd16">334,290</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3e21049ffc224cacb8134d73c9bb5b38_D20190101-20191231" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yNS9mcmFnOmM5ZGJiZjkwNWNkYjRhM2Y5NGMxZDk0YTNmMjcyZGM2L3RhYmxlOmI3MTFhYTE1OTNiOTQzZWRhOGQ2ZDQyN2QxNTZkOGFjL3RhYmxlcmFuZ2U6YjcxMWFhMTU5M2I5NDNlZGE4ZDZkNDI3ZDE1NmQ4YWNfNDUtNS0xLTEtMTkyODI_4db18ffb-b824-4b0c-90fe-54f4afa61392">305,632</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total comprehensive loss attributable to non-controlling interests</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231" decimals="-3" name="us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yNS9mcmFnOmM5ZGJiZjkwNWNkYjRhM2Y5NGMxZDk0YTNmMjcyZGM2L3RhYmxlOmI3MTFhYTE1OTNiOTQzZWRhOGQ2ZDQyN2QxNTZkOGFjL3RhYmxlcmFuZ2U6YjcxMWFhMTU5M2I5NDNlZGE4ZDZkNDI3ZDE1NmQ4YWNfNDYtNS0xLTEtMTc3NzU_0346c921-27f0-4f47-af85-83bfd26acea1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i12a6d1161de54547bd29f8efccd4c9b0_D20200101-20201231" decimals="-3" name="us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yNS9mcmFnOmM5ZGJiZjkwNWNkYjRhM2Y5NGMxZDk0YTNmMjcyZGM2L3RhYmxlOmI3MTFhYTE1OTNiOTQzZWRhOGQ2ZDQyN2QxNTZkOGFjL3RhYmxlcmFuZ2U6YjcxMWFhMTU5M2I5NDNlZGE4ZDZkNDI3ZDE1NmQ4YWNfNDYtNy0xLTEtMTc3NzU_e497689d-657b-4aad-9ce2-a8d0ba646143">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3e21049ffc224cacb8134d73c9bb5b38_D20190101-20191231" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yNS9mcmFnOmM5ZGJiZjkwNWNkYjRhM2Y5NGMxZDk0YTNmMjcyZGM2L3RhYmxlOmI3MTFhYTE1OTNiOTQzZWRhOGQ2ZDQyN2QxNTZkOGFjL3RhYmxlcmFuZ2U6YjcxMWFhMTU5M2I5NDNlZGE4ZDZkNDI3ZDE1NmQ4YWNfNDYtNS0xLTEtMTkyODI_d5b0de02-2d3f-45cf-8c70-28ec4aa6aa76">3,609</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:23pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total comprehensive loss attributable to common shareholders of Evolent Health, Inc.</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yNS9mcmFnOmM5ZGJiZjkwNWNkYjRhM2Y5NGMxZDk0YTNmMjcyZGM2L3RhYmxlOmI3MTFhYTE1OTNiOTQzZWRhOGQ2ZDQyN2QxNTZkOGFjL3RhYmxlcmFuZ2U6YjcxMWFhMTU5M2I5NDNlZGE4ZDZkNDI3ZDE1NmQ4YWNfNDctNS0xLTEtMTc3NzU_6b3b57be-3454-4345-9f50-dd1c7ebdb83d">37,685</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i12a6d1161de54547bd29f8efccd4c9b0_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yNS9mcmFnOmM5ZGJiZjkwNWNkYjRhM2Y5NGMxZDk0YTNmMjcyZGM2L3RhYmxlOmI3MTFhYTE1OTNiOTQzZWRhOGQ2ZDQyN2QxNTZkOGFjL3RhYmxlcmFuZ2U6YjcxMWFhMTU5M2I5NDNlZGE4ZDZkNDI3ZDE1NmQ4YWNfNDctNy0xLTEtMTc3NzU_8ba1bc09-a75f-4ba2-9aba-00f801f27ba9">334,290</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3e21049ffc224cacb8134d73c9bb5b38_D20190101-20191231" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yNS9mcmFnOmM5ZGJiZjkwNWNkYjRhM2Y5NGMxZDk0YTNmMjcyZGM2L3RhYmxlOmI3MTFhYTE1OTNiOTQzZWRhOGQ2ZDQyN2QxNTZkOGFjL3RhYmxlcmFuZ2U6YjcxMWFhMTU5M2I5NDNlZGE4ZDZkNDI3ZDE1NmQ4YWNfNDctNS0xLTEtMTkyODI_998cfdb4-b259-48be-b5b7-b6903e3a2dc9">302,023</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="height:40.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">See accompanying Notes to Consolidated Financial Statements</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">69</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:18pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt"><ix:footnote id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yNS9mcmFnOmM5ZGJiZjkwNWNkYjRhM2Y5NGMxZDk0YTNmMjcyZGM2L3RleHRyZWdpb246YzlkYmJmOTA1Y2RiNGEzZjk0YzFkOTRhM2YyNzJkYzZfMzI2_1383af2f-4f0a-411f-acf7-955e4538706b" footnoteRole="http://www.xbrl.org/2003/role/footnote">See Note 20 for amounts attributable to unconsolidated related parties included in these line items.</ix:footnote></span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt"><ix:footnote id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yNS9mcmFnOmM5ZGJiZjkwNWNkYjRhM2Y5NGMxZDk0YTNmMjcyZGM2L3RleHRyZWdpb246YzlkYmJmOTA1Y2RiNGEzZjk0YzFkOTRhM2YyNzJkYzZfMzIy_8cef74d3-e3cd-4cfd-a2b6-5f17f7e0cd7f" footnoteRole="http://www.xbrl.org/2003/role/footnote">Includes $<ix:nonFraction unitRef="usd" contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231" decimals="-5" name="us-gaap:DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yNS9mcmFnOmM5ZGJiZjkwNWNkYjRhM2Y5NGMxZDk0YTNmMjcyZGM2L3RleHRyZWdpb246YzlkYmJmOTA1Y2RiNGEzZjk0YzFkOTRhM2YyNzJkYzZfMjY5_1c53a8ed-a6e9-479b-a61d-3b91b1e95ba4">6.8</ix:nonFraction>&#160;million loss on disposal of discontinued operations for the year ended December 31, 2021</ix:footnote>.</span></div><div style="height:40.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">See accompanying Notes to Consolidated Financial Statements</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">70</span></div></div></div><div id="i9aaa2fddc97e482da5dbe37ac85ae703_28"></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:19.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.058%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.455%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.356%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.356%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.150%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.523%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.058%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.042%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.142%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.556%"></td><td style="width:0.1%"></td></tr><tr><td colspan="66" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">EVOLENT HEALTH, INC.</span></td></tr><tr><td colspan="66" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS&#8217; EQUITY</span></td></tr><tr><td colspan="66" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:39pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Class A Common Stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Class B Common Stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Additional Paid-In Capital</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Accumulated Other Comprehensive Income (Loss)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Retained Earnings (Accumulated Deficit)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Treasury Stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total Shareholders' Equity<br/>Attributable to Evolent Health, Inc.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Non-controlling Interests</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total Equity (Deficit)</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance as of December 31, 2018</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i997aac773ca7467b9a246f3420865489_I20181231" decimals="-3" name="us-gaap:SharesIssued" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yOC9mcmFnOjVjZWM5NGI5MzY4ODQyMTA5NWE3OThhZmFiNjljNDYwL3RhYmxlOjQzNDA0NmE1MTY4ODQzZDg5M2IxNTEyZjYxODkzYmU4L3RhYmxlcmFuZ2U6NDM0MDQ2YTUxNjg4NDNkODkzYjE1MTJmNjE4OTNiZThfMTktMS0xLTEtMTc3NzU_493e21ae-423f-4406-ae99-5d4959ce3275">79,172</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i997aac773ca7467b9a246f3420865489_I20181231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yOC9mcmFnOjVjZWM5NGI5MzY4ODQyMTA5NWE3OThhZmFiNjljNDYwL3RhYmxlOjQzNDA0NmE1MTY4ODQzZDg5M2IxNTEyZjYxODkzYmU4L3RhYmxlcmFuZ2U6NDM0MDQ2YTUxNjg4NDNkODkzYjE1MTJmNjE4OTNiZThfMTktMy0xLTEtMTc3NzU_118d1a1a-dc50-42f6-b4fc-1ef7ee484080">792</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i5942ca937104445b92561d87e62b671c_I20181231" decimals="-3" name="us-gaap:SharesIssued" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yOC9mcmFnOjVjZWM5NGI5MzY4ODQyMTA5NWE3OThhZmFiNjljNDYwL3RhYmxlOjQzNDA0NmE1MTY4ODQzZDg5M2IxNTEyZjYxODkzYmU4L3RhYmxlcmFuZ2U6NDM0MDQ2YTUxNjg4NDNkODkzYjE1MTJmNjE4OTNiZThfMTktNS0xLTEtMTc3NzU_0161ebda-c3b3-40f7-97ba-599f25475e57">3,190</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5942ca937104445b92561d87e62b671c_I20181231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yOC9mcmFnOjVjZWM5NGI5MzY4ODQyMTA5NWE3OThhZmFiNjljNDYwL3RhYmxlOjQzNDA0NmE1MTY4ODQzZDg5M2IxNTEyZjYxODkzYmU4L3RhYmxlcmFuZ2U6NDM0MDQ2YTUxNjg4NDNkODkzYjE1MTJmNjE4OTNiZThfMTktNy0xLTEtMTc3NzU_a13ec87d-9490-4300-ab46-55ef88990909">31</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i235a50d4f95f4fe4ad003b456bd4d032_I20181231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yOC9mcmFnOjVjZWM5NGI5MzY4ODQyMTA5NWE3OThhZmFiNjljNDYwL3RhYmxlOjQzNDA0NmE1MTY4ODQzZDg5M2IxNTEyZjYxODkzYmU4L3RhYmxlcmFuZ2U6NDM0MDQ2YTUxNjg4NDNkODkzYjE1MTJmNjE4OTNiZThfMTktOS0xLTEtMTc3NzU_fe5f3080-c5cd-4b3a-a162-1acfd5257083">1,093,174</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie607b868cccf4190b29e8a645f1622cd_I20181231" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yOC9mcmFnOjVjZWM5NGI5MzY4ODQyMTA5NWE3OThhZmFiNjljNDYwL3RhYmxlOjQzNDA0NmE1MTY4ODQzZDg5M2IxNTEyZjYxODkzYmU4L3RhYmxlcmFuZ2U6NDM0MDQ2YTUxNjg4NDNkODkzYjE1MTJmNjE4OTNiZThfMTktMTEtMS0xLTE3Nzc1_f4644828-25b3-468e-8adc-62f0baa871b2">182</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifd10e063c50d49fd882ffd6694d2abea_I20181231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yOC9mcmFnOjVjZWM5NGI5MzY4ODQyMTA5NWE3OThhZmFiNjljNDYwL3RhYmxlOjQzNDA0NmE1MTY4ODQzZDg5M2IxNTEyZjYxODkzYmU4L3RhYmxlcmFuZ2U6NDM0MDQ2YTUxNjg4NDNkODkzYjE1MTJmNjE4OTNiZThfMTktMTMtMS0xLTE3Nzc1_4348e11d-b4ed-45ce-a7ae-93c8903694d1">50,009</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idecb0ab9f980489d88090494dd10781e_I20181231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yOC9mcmFnOjVjZWM5NGI5MzY4ODQyMTA5NWE3OThhZmFiNjljNDYwL3RhYmxlOjQzNDA0NmE1MTY4ODQzZDg5M2IxNTEyZjYxODkzYmU4L3RhYmxlcmFuZ2U6NDM0MDQ2YTUxNjg4NDNkODkzYjE1MTJmNjE4OTNiZThfMTktMTctMS0xLTE3Nzc1_19e5a6e5-bd73-4dcd-a6b8-d222bbd88f1b">1,143,824</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia7bd0a6ac576439fb579120cf0ef0c48_I20181231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yOC9mcmFnOjVjZWM5NGI5MzY4ODQyMTA5NWE3OThhZmFiNjljNDYwL3RhYmxlOjQzNDA0NmE1MTY4ODQzZDg5M2IxNTEyZjYxODkzYmU4L3RhYmxlcmFuZ2U6NDM0MDQ2YTUxNjg4NDNkODkzYjE1MTJmNjE4OTNiZThfMTktMTktMS0xLTE3Nzc1_e185a2d7-d365-4589-95a5-e1e9fe0fe6f8">45,532</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7130cb432c4b4fe7a260e8a3beeb35d8_I20181231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yOC9mcmFnOjVjZWM5NGI5MzY4ODQyMTA5NWE3OThhZmFiNjljNDYwL3RhYmxlOjQzNDA0NmE1MTY4ODQzZDg5M2IxNTEyZjYxODkzYmU4L3RhYmxlcmFuZ2U6NDM0MDQ2YTUxNjg4NDNkODkzYjE1MTJmNjE4OTNiZThfMTktMjEtMS0xLTE3Nzc1_a8ec487b-a02f-48b9-8294-a15dc1273e61">1,189,356</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stock-based compensation expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib3d180dea9514da28352fbc693ab84a5_D20190101-20191231" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yOC9mcmFnOjVjZWM5NGI5MzY4ODQyMTA5NWE3OThhZmFiNjljNDYwL3RhYmxlOjQzNDA0NmE1MTY4ODQzZDg5M2IxNTEyZjYxODkzYmU4L3RhYmxlcmFuZ2U6NDM0MDQ2YTUxNjg4NDNkODkzYjE1MTJmNjE4OTNiZThfMjAtOS0xLTEtMTc3NzU_ac09f50b-c3da-4474-89e2-69e955395137">16,006</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iff47976e029948eca0df0ec3f59e7929_D20190101-20191231" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yOC9mcmFnOjVjZWM5NGI5MzY4ODQyMTA5NWE3OThhZmFiNjljNDYwL3RhYmxlOjQzNDA0NmE1MTY4ODQzZDg5M2IxNTEyZjYxODkzYmU4L3RhYmxlcmFuZ2U6NDM0MDQ2YTUxNjg4NDNkODkzYjE1MTJmNjE4OTNiZThfMjAtMTctMS0xLTE3Nzc1_9fb5e63d-9993-4c43-aa65-da96cd5ebadc">16,006</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e21049ffc224cacb8134d73c9bb5b38_D20190101-20191231" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yOC9mcmFnOjVjZWM5NGI5MzY4ODQyMTA5NWE3OThhZmFiNjljNDYwL3RhYmxlOjQzNDA0NmE1MTY4ODQzZDg5M2IxNTEyZjYxODkzYmU4L3RhYmxlcmFuZ2U6NDM0MDQ2YTUxNjg4NDNkODkzYjE1MTJmNjE4OTNiZThfMjAtMjEtMS0xLTE3Nzc1_87e213e8-02ce-4786-99e9-8371a8568848">16,006</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Exercise of stock options</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="if9d18c41b2a74719afa2195476af7f6b_D20190101-20191231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yOC9mcmFnOjVjZWM5NGI5MzY4ODQyMTA5NWE3OThhZmFiNjljNDYwL3RhYmxlOjQzNDA0NmE1MTY4ODQzZDg5M2IxNTEyZjYxODkzYmU4L3RhYmxlcmFuZ2U6NDM0MDQ2YTUxNjg4NDNkODkzYjE1MTJmNjE4OTNiZThfMjEtMS0xLTEtMTc3NzU_faaf30cd-b01d-46cf-a140-3455b23d9d9f">138</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if9d18c41b2a74719afa2195476af7f6b_D20190101-20191231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yOC9mcmFnOjVjZWM5NGI5MzY4ODQyMTA5NWE3OThhZmFiNjljNDYwL3RhYmxlOjQzNDA0NmE1MTY4ODQzZDg5M2IxNTEyZjYxODkzYmU4L3RhYmxlcmFuZ2U6NDM0MDQ2YTUxNjg4NDNkODkzYjE1MTJmNjE4OTNiZThfMjEtMy0xLTEtMTc3NzU_cae2d2c1-3608-430c-afd5-24595957ceaf">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib3d180dea9514da28352fbc693ab84a5_D20190101-20191231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yOC9mcmFnOjVjZWM5NGI5MzY4ODQyMTA5NWE3OThhZmFiNjljNDYwL3RhYmxlOjQzNDA0NmE1MTY4ODQzZDg5M2IxNTEyZjYxODkzYmU4L3RhYmxlcmFuZ2U6NDM0MDQ2YTUxNjg4NDNkODkzYjE1MTJmNjE4OTNiZThfMjEtOS0xLTEtMTc3NzU_1d47e53f-743b-4bcf-8561-f65cd0695fcc">1,091</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iff47976e029948eca0df0ec3f59e7929_D20190101-20191231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yOC9mcmFnOjVjZWM5NGI5MzY4ODQyMTA5NWE3OThhZmFiNjljNDYwL3RhYmxlOjQzNDA0NmE1MTY4ODQzZDg5M2IxNTEyZjYxODkzYmU4L3RhYmxlcmFuZ2U6NDM0MDQ2YTUxNjg4NDNkODkzYjE1MTJmNjE4OTNiZThfMjEtMTctMS0xLTE3Nzc1_1e3c8a31-10b1-411c-9f0f-b9621b376c69">1,092</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e21049ffc224cacb8134d73c9bb5b38_D20190101-20191231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yOC9mcmFnOjVjZWM5NGI5MzY4ODQyMTA5NWE3OThhZmFiNjljNDYwL3RhYmxlOjQzNDA0NmE1MTY4ODQzZDg5M2IxNTEyZjYxODkzYmU4L3RhYmxlcmFuZ2U6NDM0MDQ2YTUxNjg4NDNkODkzYjE1MTJmNjE4OTNiZThfMjEtMjEtMS0xLTE3Nzc1_f4f051f1-a778-4b83-906e-c9ecd785b020">1,092</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Restricted stock units vested, net of shares withheld for taxes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="if9d18c41b2a74719afa2195476af7f6b_D20190101-20191231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yOC9mcmFnOjVjZWM5NGI5MzY4ODQyMTA5NWE3OThhZmFiNjljNDYwL3RhYmxlOjQzNDA0NmE1MTY4ODQzZDg5M2IxNTEyZjYxODkzYmU4L3RhYmxlcmFuZ2U6NDM0MDQ2YTUxNjg4NDNkODkzYjE1MTJmNjE4OTNiZThfMjItMS0xLTEtMTc3NzU_f4042f8c-d051-4df0-a54c-d793bbeb1785">363</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if9d18c41b2a74719afa2195476af7f6b_D20190101-20191231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yOC9mcmFnOjVjZWM5NGI5MzY4ODQyMTA5NWE3OThhZmFiNjljNDYwL3RhYmxlOjQzNDA0NmE1MTY4ODQzZDg5M2IxNTEyZjYxODkzYmU4L3RhYmxlcmFuZ2U6NDM0MDQ2YTUxNjg4NDNkODkzYjE1MTJmNjE4OTNiZThfMjItMy0xLTEtMTc3NzU_b07c58ee-990f-41f6-9afa-e986c990615a">4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib3d180dea9514da28352fbc693ab84a5_D20190101-20191231" decimals="-3" sign="-" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yOC9mcmFnOjVjZWM5NGI5MzY4ODQyMTA5NWE3OThhZmFiNjljNDYwL3RhYmxlOjQzNDA0NmE1MTY4ODQzZDg5M2IxNTEyZjYxODkzYmU4L3RhYmxlcmFuZ2U6NDM0MDQ2YTUxNjg4NDNkODkzYjE1MTJmNjE4OTNiZThfMjItOS0xLTEtMTc3NzU_0b97840c-8bb0-4c36-b5eb-957465b17b6a">2,613</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iff47976e029948eca0df0ec3f59e7929_D20190101-20191231" decimals="-3" sign="-" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yOC9mcmFnOjVjZWM5NGI5MzY4ODQyMTA5NWE3OThhZmFiNjljNDYwL3RhYmxlOjQzNDA0NmE1MTY4ODQzZDg5M2IxNTEyZjYxODkzYmU4L3RhYmxlcmFuZ2U6NDM0MDQ2YTUxNjg4NDNkODkzYjE1MTJmNjE4OTNiZThfMjItMTctMS0xLTE3Nzc1_ffcbb0e2-b536-42d9-a662-645c331b02b6">2,609</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3e21049ffc224cacb8134d73c9bb5b38_D20190101-20191231" decimals="-3" sign="-" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yOC9mcmFnOjVjZWM5NGI5MzY4ODQyMTA5NWE3OThhZmFiNjljNDYwL3RhYmxlOjQzNDA0NmE1MTY4ODQzZDg5M2IxNTEyZjYxODkzYmU4L3RhYmxlcmFuZ2U6NDM0MDQ2YTUxNjg4NDNkODkzYjE1MTJmNjE4OTNiZThfMjItMjEtMS0xLTE3Nzc1_0f30651b-c62f-4b43-9610-5415df47ea99">2,609</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Share retirement</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="if9d18c41b2a74719afa2195476af7f6b_D20190101-20191231" decimals="-3" name="evh:StockVestedAndRetiredDuringPeriodShares" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yOC9mcmFnOjVjZWM5NGI5MzY4ODQyMTA5NWE3OThhZmFiNjljNDYwL3RhYmxlOjQzNDA0NmE1MTY4ODQzZDg5M2IxNTEyZjYxODkzYmU4L3RhYmxlcmFuZ2U6NDM0MDQ2YTUxNjg4NDNkODkzYjE1MTJmNjE4OTNiZThfMjMtMS0xLTEtMTc3NzU_2aa2d7ae-b353-46f3-b16e-2c3be2ca8654">5</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i55a4ede774484bd8b99ec882803a31ae_D20190101-20191231" decimals="-3" name="evh:StockVestedAndRetiredDuringPeriodValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yOC9mcmFnOjVjZWM5NGI5MzY4ODQyMTA5NWE3OThhZmFiNjljNDYwL3RhYmxlOjQzNDA0NmE1MTY4ODQzZDg5M2IxNTEyZjYxODkzYmU4L3RhYmxlcmFuZ2U6NDM0MDQ2YTUxNjg4NDNkODkzYjE1MTJmNjE4OTNiZThfMjMtNS0xLTEtMTc3NzU_e9a84ff6-c101-4737-b7b3-04338713caf1">44</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Class A common stock issued for Passport earn-out</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="if9d18c41b2a74719afa2195476af7f6b_D20190101-20191231" decimals="-3" name="evh:StockIssuedDuringPeriodSharesEarnOuts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yOC9mcmFnOjVjZWM5NGI5MzY4ODQyMTA5NWE3OThhZmFiNjljNDYwL3RhYmxlOjQzNDA0NmE1MTY4ODQzZDg5M2IxNTEyZjYxODkzYmU4L3RhYmxlcmFuZ2U6NDM0MDQ2YTUxNjg4NDNkODkzYjE1MTJmNjE4OTNiZThfMjQtMS0xLTEtMTc3NzU_4710e2d9-7ec2-4db2-ab38-5958bc200d1f">43</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib3d180dea9514da28352fbc693ab84a5_D20190101-20191231" decimals="-3" name="evh:StockIssuedDuringPeriodValueEarnOuts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yOC9mcmFnOjVjZWM5NGI5MzY4ODQyMTA5NWE3OThhZmFiNjljNDYwL3RhYmxlOjQzNDA0NmE1MTY4ODQzZDg5M2IxNTEyZjYxODkzYmU4L3RhYmxlcmFuZ2U6NDM0MDQ2YTUxNjg4NDNkODkzYjE1MTJmNjE4OTNiZThfMjQtOS0xLTEtMTc3NzU_63ed1033-684e-4a09-8304-3a56a782b220">800</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iff47976e029948eca0df0ec3f59e7929_D20190101-20191231" decimals="-3" name="evh:StockIssuedDuringPeriodValueEarnOuts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yOC9mcmFnOjVjZWM5NGI5MzY4ODQyMTA5NWE3OThhZmFiNjljNDYwL3RhYmxlOjQzNDA0NmE1MTY4ODQzZDg5M2IxNTEyZjYxODkzYmU4L3RhYmxlcmFuZ2U6NDM0MDQ2YTUxNjg4NDNkODkzYjE1MTJmNjE4OTNiZThfMjQtMTctMS0xLTE3Nzc1_02551075-a3eb-4fd7-9745-6fc5b6e5dd17">800</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e21049ffc224cacb8134d73c9bb5b38_D20190101-20191231" decimals="-3" name="evh:StockIssuedDuringPeriodValueEarnOuts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yOC9mcmFnOjVjZWM5NGI5MzY4ODQyMTA5NWE3OThhZmFiNjljNDYwL3RhYmxlOjQzNDA0NmE1MTY4ODQzZDg5M2IxNTEyZjYxODkzYmU4L3RhYmxlcmFuZ2U6NDM0MDQ2YTUxNjg4NDNkODkzYjE1MTJmNjE4OTNiZThfMjQtMjEtMS0xLTE3Nzc1_6687c960-b5de-4af1-8f25-4a14380a0466">800</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Amount attributable to NCI from business combination</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i07635cd96da44df8aeca179d3ffeeb6d_D20190101-20191231" decimals="-3" name="evh:AdjustmentsToAdditionalPaidInCapitalAcquisitions" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yOC9mcmFnOjVjZWM5NGI5MzY4ODQyMTA5NWE3OThhZmFiNjljNDYwL3RhYmxlOjQzNDA0NmE1MTY4ODQzZDg5M2IxNTEyZjYxODkzYmU4L3RhYmxlcmFuZ2U6NDM0MDQ2YTUxNjg4NDNkODkzYjE1MTJmNjE4OTNiZThfMjUtMTktMS0xLTE3Nzc1_1c2d4423-d246-46d0-85f3-6c0bf79d904d">6,500</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e21049ffc224cacb8134d73c9bb5b38_D20190101-20191231" decimals="-3" name="evh:AdjustmentsToAdditionalPaidInCapitalAcquisitions" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yOC9mcmFnOjVjZWM5NGI5MzY4ODQyMTA5NWE3OThhZmFiNjljNDYwL3RhYmxlOjQzNDA0NmE1MTY4ODQzZDg5M2IxNTEyZjYxODkzYmU4L3RhYmxlcmFuZ2U6NDM0MDQ2YTUxNjg4NDNkODkzYjE1MTJmNjE4OTNiZThfMjUtMjEtMS0xLTE3Nzc1_45897c5e-0599-47fb-b3ec-d6eb669a6ca0">6,500</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Shares issued for equity-method investments and asset acquisitions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="if9d18c41b2a74719afa2195476af7f6b_D20190101-20191231" decimals="-3" name="evh:StockIssuedDuringPeriodSharesEquityMethodInvestmentsAndAssetAcquisitions" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yOC9mcmFnOjVjZWM5NGI5MzY4ODQyMTA5NWE3OThhZmFiNjljNDYwL3RhYmxlOjQzNDA0NmE1MTY4ODQzZDg5M2IxNTEyZjYxODkzYmU4L3RhYmxlcmFuZ2U6NDM0MDQ2YTUxNjg4NDNkODkzYjE1MTJmNjE4OTNiZThfMjYtMS0xLTEtMTc3NzU_8537960b-4955-4289-bc12-13b265d69c25">1,732</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if9d18c41b2a74719afa2195476af7f6b_D20190101-20191231" decimals="-3" name="evh:StockIssuedDuringPeriodValueEquityMethodInvestmentsAndAssetAcquisitions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yOC9mcmFnOjVjZWM5NGI5MzY4ODQyMTA5NWE3OThhZmFiNjljNDYwL3RhYmxlOjQzNDA0NmE1MTY4ODQzZDg5M2IxNTEyZjYxODkzYmU4L3RhYmxlcmFuZ2U6NDM0MDQ2YTUxNjg4NDNkODkzYjE1MTJmNjE4OTNiZThfMjYtMy0xLTEtMTc3NzU_65f98229-f6a1-4c93-92f1-3d1ee80cd9f2">18</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib3d180dea9514da28352fbc693ab84a5_D20190101-20191231" decimals="-3" name="evh:StockIssuedDuringPeriodValueEquityMethodInvestmentsAndAssetAcquisitions" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yOC9mcmFnOjVjZWM5NGI5MzY4ODQyMTA5NWE3OThhZmFiNjljNDYwL3RhYmxlOjQzNDA0NmE1MTY4ODQzZDg5M2IxNTEyZjYxODkzYmU4L3RhYmxlcmFuZ2U6NDM0MDQ2YTUxNjg4NDNkODkzYjE1MTJmNjE4OTNiZThfMjYtOS0xLTEtMTc3NzU_9a7209ba-4ab7-436c-9f51-9ccfb2b4109c">23,538</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iff47976e029948eca0df0ec3f59e7929_D20190101-20191231" decimals="-3" name="evh:StockIssuedDuringPeriodValueEquityMethodInvestmentsAndAssetAcquisitions" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yOC9mcmFnOjVjZWM5NGI5MzY4ODQyMTA5NWE3OThhZmFiNjljNDYwL3RhYmxlOjQzNDA0NmE1MTY4ODQzZDg5M2IxNTEyZjYxODkzYmU4L3RhYmxlcmFuZ2U6NDM0MDQ2YTUxNjg4NDNkODkzYjE1MTJmNjE4OTNiZThfMjYtMTctMS0xLTE3Nzc1_2f77e2aa-d72e-4f54-bf86-89b437d759cc">23,556</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e21049ffc224cacb8134d73c9bb5b38_D20190101-20191231" decimals="-3" name="evh:StockIssuedDuringPeriodValueEquityMethodInvestmentsAndAssetAcquisitions" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yOC9mcmFnOjVjZWM5NGI5MzY4ODQyMTA5NWE3OThhZmFiNjljNDYwL3RhYmxlOjQzNDA0NmE1MTY4ODQzZDg5M2IxNTEyZjYxODkzYmU4L3RhYmxlcmFuZ2U6NDM0MDQ2YTUxNjg4NDNkODkzYjE1MTJmNjE4OTNiZThfMjYtMjEtMS0xLTE3Nzc1_d0a4af4a-c652-44ca-a756-47add201c06a">23,556</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Exchange of Class B common stock</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="if9d18c41b2a74719afa2195476af7f6b_D20190101-20191231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yOC9mcmFnOjVjZWM5NGI5MzY4ODQyMTA5NWE3OThhZmFiNjljNDYwL3RhYmxlOjQzNDA0NmE1MTY4ODQzZDg5M2IxNTEyZjYxODkzYmU4L3RhYmxlcmFuZ2U6NDM0MDQ2YTUxNjg4NDNkODkzYjE1MTJmNjE4OTNiZThfMjctMS0xLTEtMTc3NzU_f45456f6-d3e2-4920-9b44-928420e08a69">3,146</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if9d18c41b2a74719afa2195476af7f6b_D20190101-20191231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yOC9mcmFnOjVjZWM5NGI5MzY4ODQyMTA5NWE3OThhZmFiNjljNDYwL3RhYmxlOjQzNDA0NmE1MTY4ODQzZDg5M2IxNTEyZjYxODkzYmU4L3RhYmxlcmFuZ2U6NDM0MDQ2YTUxNjg4NDNkODkzYjE1MTJmNjE4OTNiZThfMjctMy0xLTEtMTc3NzU_bd73a683-d95a-4553-9950-f755b25c6aee">31</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i55a4ede774484bd8b99ec882803a31ae_D20190101-20191231" decimals="-3" sign="-" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yOC9mcmFnOjVjZWM5NGI5MzY4ODQyMTA5NWE3OThhZmFiNjljNDYwL3RhYmxlOjQzNDA0NmE1MTY4ODQzZDg5M2IxNTEyZjYxODkzYmU4L3RhYmxlcmFuZ2U6NDM0MDQ2YTUxNjg4NDNkODkzYjE1MTJmNjE4OTNiZThfMjctNS0xLTEtMTc3NzU_2ca06a4d-e287-496d-b2e1-642c83b68524">3,146</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i55a4ede774484bd8b99ec882803a31ae_D20190101-20191231" decimals="-3" sign="-" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yOC9mcmFnOjVjZWM5NGI5MzY4ODQyMTA5NWE3OThhZmFiNjljNDYwL3RhYmxlOjQzNDA0NmE1MTY4ODQzZDg5M2IxNTEyZjYxODkzYmU4L3RhYmxlcmFuZ2U6NDM0MDQ2YTUxNjg4NDNkODkzYjE1MTJmNjE4OTNiZThfMjctNy0xLTEtMTc3NzU_94a122be-64dc-4b8a-8feb-2f5e74c58b8f">31</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib3d180dea9514da28352fbc693ab84a5_D20190101-20191231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yOC9mcmFnOjVjZWM5NGI5MzY4ODQyMTA5NWE3OThhZmFiNjljNDYwL3RhYmxlOjQzNDA0NmE1MTY4ODQzZDg5M2IxNTEyZjYxODkzYmU4L3RhYmxlcmFuZ2U6NDM0MDQ2YTUxNjg4NDNkODkzYjE1MTJmNjE4OTNiZThfMjctOS0xLTEtMTc3NzU_3a846c74-a423-4b50-a905-bf3d8fa337b0">42,377</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iff47976e029948eca0df0ec3f59e7929_D20190101-20191231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yOC9mcmFnOjVjZWM5NGI5MzY4ODQyMTA5NWE3OThhZmFiNjljNDYwL3RhYmxlOjQzNDA0NmE1MTY4ODQzZDg5M2IxNTEyZjYxODkzYmU4L3RhYmxlcmFuZ2U6NDM0MDQ2YTUxNjg4NDNkODkzYjE1MTJmNjE4OTNiZThfMjctMTctMS0xLTE3Nzc1_84f1f88e-cfa8-4cfb-9120-3283631b4c92">42,377</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i07635cd96da44df8aeca179d3ffeeb6d_D20190101-20191231" decimals="-3" sign="-" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yOC9mcmFnOjVjZWM5NGI5MzY4ODQyMTA5NWE3OThhZmFiNjljNDYwL3RhYmxlOjQzNDA0NmE1MTY4ODQzZDg5M2IxNTEyZjYxODkzYmU4L3RhYmxlcmFuZ2U6NDM0MDQ2YTUxNjg4NDNkODkzYjE1MTJmNjE4OTNiZThfMjctMTktMS0xLTE3Nzc1_e44b80a2-3acd-4e3e-8864-51b8f0f204e7">42,377</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Tax impact of Class B exchange</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib3d180dea9514da28352fbc693ab84a5_D20190101-20191231" decimals="-3" sign="-" name="evh:StockIssuedDuringPeriodSharesConversionofConvertibleSecuritiesTaxImpact" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yOC9mcmFnOjVjZWM5NGI5MzY4ODQyMTA5NWE3OThhZmFiNjljNDYwL3RhYmxlOjQzNDA0NmE1MTY4ODQzZDg5M2IxNTEyZjYxODkzYmU4L3RhYmxlcmFuZ2U6NDM0MDQ2YTUxNjg4NDNkODkzYjE1MTJmNjE4OTNiZThfMjgtOS0xLTEtMTc3NzU_85d6193a-4ddf-4e8c-86f2-588f2b9233bb">22</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iff47976e029948eca0df0ec3f59e7929_D20190101-20191231" decimals="-3" sign="-" name="evh:StockIssuedDuringPeriodSharesConversionofConvertibleSecuritiesTaxImpact" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yOC9mcmFnOjVjZWM5NGI5MzY4ODQyMTA5NWE3OThhZmFiNjljNDYwL3RhYmxlOjQzNDA0NmE1MTY4ODQzZDg5M2IxNTEyZjYxODkzYmU4L3RhYmxlcmFuZ2U6NDM0MDQ2YTUxNjg4NDNkODkzYjE1MTJmNjE4OTNiZThfMjgtMTctMS0xLTE3Nzc1_c5797f71-dcea-4c07-a4a1-6e8bc8ec0cbf">22</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3e21049ffc224cacb8134d73c9bb5b38_D20190101-20191231" decimals="-3" sign="-" name="evh:StockIssuedDuringPeriodSharesConversionofConvertibleSecuritiesTaxImpact" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yOC9mcmFnOjVjZWM5NGI5MzY4ODQyMTA5NWE3OThhZmFiNjljNDYwL3RhYmxlOjQzNDA0NmE1MTY4ODQzZDg5M2IxNTEyZjYxODkzYmU4L3RhYmxlcmFuZ2U6NDM0MDQ2YTUxNjg4NDNkODkzYjE1MTJmNjE4OTNiZThfMjgtMjEtMS0xLTE3Nzc1_b762c9d0-c84c-4f09-95df-e03c40e1fbc4">22</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Foreign currency translation adjustment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id72c42fac3684e24b4ca0bf829d0e596_D20190101-20191231" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yOC9mcmFnOjVjZWM5NGI5MzY4ODQyMTA5NWE3OThhZmFiNjljNDYwL3RhYmxlOjQzNDA0NmE1MTY4ODQzZDg5M2IxNTEyZjYxODkzYmU4L3RhYmxlcmFuZ2U6NDM0MDQ2YTUxNjg4NDNkODkzYjE1MTJmNjE4OTNiZThfMjktMTEtMS0xLTE3Nzc1_aa9ac33b-bd0a-4e10-b529-a07156d2ee11">52</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iff47976e029948eca0df0ec3f59e7929_D20190101-20191231" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yOC9mcmFnOjVjZWM5NGI5MzY4ODQyMTA5NWE3OThhZmFiNjljNDYwL3RhYmxlOjQzNDA0NmE1MTY4ODQzZDg5M2IxNTEyZjYxODkzYmU4L3RhYmxlcmFuZ2U6NDM0MDQ2YTUxNjg4NDNkODkzYjE1MTJmNjE4OTNiZThfMjktMTctMS0xLTE3Nzc1_1486874d-80db-416d-973e-3e3db84d4e9e">52</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3e21049ffc224cacb8134d73c9bb5b38_D20190101-20191231" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yOC9mcmFnOjVjZWM5NGI5MzY4ODQyMTA5NWE3OThhZmFiNjljNDYwL3RhYmxlOjQzNDA0NmE1MTY4ODQzZDg5M2IxNTEyZjYxODkzYmU4L3RhYmxlcmFuZ2U6NDM0MDQ2YTUxNjg4NDNkODkzYjE1MTJmNjE4OTNiZThfMjktMjEtMS0xLTE3Nzc1_2a8b7ec7-d23e-41ed-a95a-6385fb864802">52</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i87534e1639d049319065f8650fc0c762_D20190101-20191231" decimals="-3" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yOC9mcmFnOjVjZWM5NGI5MzY4ODQyMTA5NWE3OThhZmFiNjljNDYwL3RhYmxlOjQzNDA0NmE1MTY4ODQzZDg5M2IxNTEyZjYxODkzYmU4L3RhYmxlcmFuZ2U6NDM0MDQ2YTUxNjg4NDNkODkzYjE1MTJmNjE4OTNiZThfMzAtMTMtMS0xLTE3Nzc1_2a7c4584-44ba-4ee9-8195-a5431ca397fa">301,971</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iff47976e029948eca0df0ec3f59e7929_D20190101-20191231" decimals="-3" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yOC9mcmFnOjVjZWM5NGI5MzY4ODQyMTA5NWE3OThhZmFiNjljNDYwL3RhYmxlOjQzNDA0NmE1MTY4ODQzZDg5M2IxNTEyZjYxODkzYmU4L3RhYmxlcmFuZ2U6NDM0MDQ2YTUxNjg4NDNkODkzYjE1MTJmNjE4OTNiZThfMzAtMTctMS0xLTE3Nzc1_ad8cba7d-df93-4c8c-be84-f0e1a9e70657">301,971</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i07635cd96da44df8aeca179d3ffeeb6d_D20190101-20191231" decimals="-3" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yOC9mcmFnOjVjZWM5NGI5MzY4ODQyMTA5NWE3OThhZmFiNjljNDYwL3RhYmxlOjQzNDA0NmE1MTY4ODQzZDg5M2IxNTEyZjYxODkzYmU4L3RhYmxlcmFuZ2U6NDM0MDQ2YTUxNjg4NDNkODkzYjE1MTJmNjE4OTNiZThfMzAtMTktMS0xLTE3Nzc1_1015ac99-e35d-4fa5-a587-8f33833eb183">3,609</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3e21049ffc224cacb8134d73c9bb5b38_D20190101-20191231" decimals="-3" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yOC9mcmFnOjVjZWM5NGI5MzY4ODQyMTA5NWE3OThhZmFiNjljNDYwL3RhYmxlOjQzNDA0NmE1MTY4ODQzZDg5M2IxNTEyZjYxODkzYmU4L3RhYmxlcmFuZ2U6NDM0MDQ2YTUxNjg4NDNkODkzYjE1MTJmNjE4OTNiZThfMzAtMjEtMS0xLTE3Nzc1_651e1dd2-4023-446b-8f92-3325773b87a7">305,580</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Reclassification of non-controlling interests</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib3d180dea9514da28352fbc693ab84a5_D20190101-20191231" decimals="-3" sign="-" name="us-gaap:NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yOC9mcmFnOjVjZWM5NGI5MzY4ODQyMTA5NWE3OThhZmFiNjljNDYwL3RhYmxlOjQzNDA0NmE1MTY4ODQzZDg5M2IxNTEyZjYxODkzYmU4L3RhYmxlcmFuZ2U6NDM0MDQ2YTUxNjg4NDNkODkzYjE1MTJmNjE4OTNiZThfMzEtOS0xLTEtMTc3NzU_77ee7e05-7e2a-4c0e-8464-7ce6c0957a3c">643</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iff47976e029948eca0df0ec3f59e7929_D20190101-20191231" decimals="-3" sign="-" name="us-gaap:NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yOC9mcmFnOjVjZWM5NGI5MzY4ODQyMTA5NWE3OThhZmFiNjljNDYwL3RhYmxlOjQzNDA0NmE1MTY4ODQzZDg5M2IxNTEyZjYxODkzYmU4L3RhYmxlcmFuZ2U6NDM0MDQ2YTUxNjg4NDNkODkzYjE1MTJmNjE4OTNiZThfMzEtMTctMS0xLTE3Nzc1_80b9be17-3079-41a6-92b4-9c98f2b493cd">643</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i07635cd96da44df8aeca179d3ffeeb6d_D20190101-20191231" decimals="-3" name="us-gaap:NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yOC9mcmFnOjVjZWM5NGI5MzY4ODQyMTA5NWE3OThhZmFiNjljNDYwL3RhYmxlOjQzNDA0NmE1MTY4ODQzZDg5M2IxNTEyZjYxODkzYmU4L3RhYmxlcmFuZ2U6NDM0MDQ2YTUxNjg4NDNkODkzYjE1MTJmNjE4OTNiZThfMzEtMTktMS0xLTE3Nzc1_8d86f9f0-e046-4890-b574-9920391ad9eb">643</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance as of December 31, 2019</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i132368a16db343cdb75b4cc5b6d3c936_I20191231" decimals="-3" name="us-gaap:SharesIssued" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yOC9mcmFnOjVjZWM5NGI5MzY4ODQyMTA5NWE3OThhZmFiNjljNDYwL3RhYmxlOjQzNDA0NmE1MTY4ODQzZDg5M2IxNTEyZjYxODkzYmU4L3RhYmxlcmFuZ2U6NDM0MDQ2YTUxNjg4NDNkODkzYjE1MTJmNjE4OTNiZThfMzItMS0xLTEtMTc3NzU_13dc261d-5631-4289-816c-b4ec7aec587b">84,589</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i132368a16db343cdb75b4cc5b6d3c936_I20191231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yOC9mcmFnOjVjZWM5NGI5MzY4ODQyMTA5NWE3OThhZmFiNjljNDYwL3RhYmxlOjQzNDA0NmE1MTY4ODQzZDg5M2IxNTEyZjYxODkzYmU4L3RhYmxlcmFuZ2U6NDM0MDQ2YTUxNjg4NDNkODkzYjE1MTJmNjE4OTNiZThfMzItMy0xLTEtMTc3NzU_031a8ff4-2ecf-49cd-a11d-6f34e8ae9502">846</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i6583965c38874fd5b1853fe21a37624d_I20191231" decimals="-3" name="us-gaap:SharesIssued" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yOC9mcmFnOjVjZWM5NGI5MzY4ODQyMTA5NWE3OThhZmFiNjljNDYwL3RhYmxlOjQzNDA0NmE1MTY4ODQzZDg5M2IxNTEyZjYxODkzYmU4L3RhYmxlcmFuZ2U6NDM0MDQ2YTUxNjg4NDNkODkzYjE1MTJmNjE4OTNiZThfMzItNS0xLTEtMTc3NzU_779ca2e6-dcba-4a9e-a8cc-356e55713ec7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6583965c38874fd5b1853fe21a37624d_I20191231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yOC9mcmFnOjVjZWM5NGI5MzY4ODQyMTA5NWE3OThhZmFiNjljNDYwL3RhYmxlOjQzNDA0NmE1MTY4ODQzZDg5M2IxNTEyZjYxODkzYmU4L3RhYmxlcmFuZ2U6NDM0MDQ2YTUxNjg4NDNkODkzYjE1MTJmNjE4OTNiZThfMzItNy0xLTEtMTc3NzU_e2659435-add9-44a3-a49c-3f536a381482">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iea51ead9d5cc49309a974f68850d9313_I20191231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yOC9mcmFnOjVjZWM5NGI5MzY4ODQyMTA5NWE3OThhZmFiNjljNDYwL3RhYmxlOjQzNDA0NmE1MTY4ODQzZDg5M2IxNTEyZjYxODkzYmU4L3RhYmxlcmFuZ2U6NDM0MDQ2YTUxNjg4NDNkODkzYjE1MTJmNjE4OTNiZThfMzItOS0xLTEtMTc3NzU_060321d7-3894-4601-8a67-d12ae2045315">1,173,708</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4b90c5fc5160471aba2652f11f6bb706_I20191231" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yOC9mcmFnOjVjZWM5NGI5MzY4ODQyMTA5NWE3OThhZmFiNjljNDYwL3RhYmxlOjQzNDA0NmE1MTY4ODQzZDg5M2IxNTEyZjYxODkzYmU4L3RhYmxlcmFuZ2U6NDM0MDQ2YTUxNjg4NDNkODkzYjE1MTJmNjE4OTNiZThfMzItMTEtMS0xLTE3Nzc1_c7eeb083-1aaf-4276-b8f3-050ddd16dc30">234</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie8e5b6e19bcc4d6aa9434387b2fd038c_I20191231" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yOC9mcmFnOjVjZWM5NGI5MzY4ODQyMTA5NWE3OThhZmFiNjljNDYwL3RhYmxlOjQzNDA0NmE1MTY4ODQzZDg5M2IxNTEyZjYxODkzYmU4L3RhYmxlcmFuZ2U6NDM0MDQ2YTUxNjg4NDNkODkzYjE1MTJmNjE4OTNiZThfMzItMTMtMS0xLTE3Nzc1_c335462a-6fe9-4276-903f-0c5ff2fe35ca">251,962</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if4420575740f4afca80c3afb49e6e79e_I20191231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yOC9mcmFnOjVjZWM5NGI5MzY4ODQyMTA5NWE3OThhZmFiNjljNDYwL3RhYmxlOjQzNDA0NmE1MTY4ODQzZDg5M2IxNTEyZjYxODkzYmU4L3RhYmxlcmFuZ2U6NDM0MDQ2YTUxNjg4NDNkODkzYjE1MTJmNjE4OTNiZThfMzItMTUtMS0xLTE3Nzc1_15285529-adc8-4388-8f0f-a9453a2a77d4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id4af8e59d8e745af8ddd5b829f03f70a_I20191231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yOC9mcmFnOjVjZWM5NGI5MzY4ODQyMTA5NWE3OThhZmFiNjljNDYwL3RhYmxlOjQzNDA0NmE1MTY4ODQzZDg5M2IxNTEyZjYxODkzYmU4L3RhYmxlcmFuZ2U6NDM0MDQ2YTUxNjg4NDNkODkzYjE1MTJmNjE4OTNiZThfMzItMTctMS0xLTE3Nzc1_0556e15f-a6cb-41b3-be5e-a35b939850f6">922,358</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2d2497909b9e4097b418e747f13bfc16_I20191231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yOC9mcmFnOjVjZWM5NGI5MzY4ODQyMTA5NWE3OThhZmFiNjljNDYwL3RhYmxlOjQzNDA0NmE1MTY4ODQzZDg5M2IxNTEyZjYxODkzYmU4L3RhYmxlcmFuZ2U6NDM0MDQ2YTUxNjg4NDNkODkzYjE1MTJmNjE4OTNiZThfMzItMTktMS0xLTE3Nzc1_802fa539-54b2-4da0-95fd-ef3d6bcee62e">6,689</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icba6e493923b449aa57c46a563760234_I20191231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yOC9mcmFnOjVjZWM5NGI5MzY4ODQyMTA5NWE3OThhZmFiNjljNDYwL3RhYmxlOjQzNDA0NmE1MTY4ODQzZDg5M2IxNTEyZjYxODkzYmU4L3RhYmxlcmFuZ2U6NDM0MDQ2YTUxNjg4NDNkODkzYjE1MTJmNjE4OTNiZThfMzItMjEtMS0xLTE3Nzc1_3691a4ee-ef7f-4665-b6f9-8d4d080bca5a">929,047</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yOC9mcmFnOjVjZWM5NGI5MzY4ODQyMTA5NWE3OThhZmFiNjljNDYwL3RhYmxlOjQzNDA0NmE1MTY4ODQzZDg5M2IxNTEyZjYxODkzYmU4L3RhYmxlcmFuZ2U6NDM0MDQ2YTUxNjg4NDNkODkzYjE1MTJmNjE4OTNiZThfMzMtMC0xLTEtMTc3NzU_a9886287-d75e-4db9-aa6f-bc3365fc9d17">Cumulative-effect adjustment from adoption of ASU 2016-03</span></span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i86eec55ebc424a56b5b5394b8b2b2423_I20191231" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yOC9mcmFnOjVjZWM5NGI5MzY4ODQyMTA5NWE3OThhZmFiNjljNDYwL3RhYmxlOjQzNDA0NmE1MTY4ODQzZDg5M2IxNTEyZjYxODkzYmU4L3RhYmxlcmFuZ2U6NDM0MDQ2YTUxNjg4NDNkODkzYjE1MTJmNjE4OTNiZThfMzMtMTMtMS0xLTE3Nzc1_1366957d-c460-4358-8001-987a3dd760e8">2,970</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i67b404347634468496e5eb9d721d74b6_I20191231" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yOC9mcmFnOjVjZWM5NGI5MzY4ODQyMTA5NWE3OThhZmFiNjljNDYwL3RhYmxlOjQzNDA0NmE1MTY4ODQzZDg5M2IxNTEyZjYxODkzYmU4L3RhYmxlcmFuZ2U6NDM0MDQ2YTUxNjg4NDNkODkzYjE1MTJmNjE4OTNiZThfMzMtMTctMS0xLTE3Nzc1_5bd08e2f-1931-4272-8426-3aefc2d2724d">2,970</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6464dcea2322451dbc03ac39361c75b9_I20191231" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yOC9mcmFnOjVjZWM5NGI5MzY4ODQyMTA5NWE3OThhZmFiNjljNDYwL3RhYmxlOjQzNDA0NmE1MTY4ODQzZDg5M2IxNTEyZjYxODkzYmU4L3RhYmxlcmFuZ2U6NDM0MDQ2YTUxNjg4NDNkODkzYjE1MTJmNjE4OTNiZThfMzMtMjEtMS0xLTE3Nzc1_9f5eac6d-6640-43d6-8b74-b9ab2d497866">2,970</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stock-based compensation expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieb0b713eae1b4f908dc2c23586d77948_D20200101-20201231" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yOC9mcmFnOjVjZWM5NGI5MzY4ODQyMTA5NWE3OThhZmFiNjljNDYwL3RhYmxlOjQzNDA0NmE1MTY4ODQzZDg5M2IxNTEyZjYxODkzYmU4L3RhYmxlcmFuZ2U6NDM0MDQ2YTUxNjg4NDNkODkzYjE1MTJmNjE4OTNiZThfMzQtOS0xLTEtMTc3NzU_706b32b9-c915-41ca-adc3-579bc03512e4">14,606</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i911a108ecf12460193d53b0e6b24331f_D20200101-20201231" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yOC9mcmFnOjVjZWM5NGI5MzY4ODQyMTA5NWE3OThhZmFiNjljNDYwL3RhYmxlOjQzNDA0NmE1MTY4ODQzZDg5M2IxNTEyZjYxODkzYmU4L3RhYmxlcmFuZ2U6NDM0MDQ2YTUxNjg4NDNkODkzYjE1MTJmNjE4OTNiZThfMzQtMTctMS0xLTE3Nzc1_b729d47c-d68e-439d-8f5f-974ea9688b1a">14,606</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i12a6d1161de54547bd29f8efccd4c9b0_D20200101-20201231" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yOC9mcmFnOjVjZWM5NGI5MzY4ODQyMTA5NWE3OThhZmFiNjljNDYwL3RhYmxlOjQzNDA0NmE1MTY4ODQzZDg5M2IxNTEyZjYxODkzYmU4L3RhYmxlcmFuZ2U6NDM0MDQ2YTUxNjg4NDNkODkzYjE1MTJmNjE4OTNiZThfMzQtMjEtMS0xLTE3Nzc1_2b61eca8-23c3-4b4d-bad8-9750a0e1cdde">14,606</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Exercise of stock options</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ifead6db34ce543e2beca6b5c57feaf4e_D20200101-20201231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yOC9mcmFnOjVjZWM5NGI5MzY4ODQyMTA5NWE3OThhZmFiNjljNDYwL3RhYmxlOjQzNDA0NmE1MTY4ODQzZDg5M2IxNTEyZjYxODkzYmU4L3RhYmxlcmFuZ2U6NDM0MDQ2YTUxNjg4NDNkODkzYjE1MTJmNjE4OTNiZThfMzUtMS0xLTEtMTc3NzU_dab72ed9-8b06-4d0e-950c-aa625ab02331">416</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifead6db34ce543e2beca6b5c57feaf4e_D20200101-20201231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yOC9mcmFnOjVjZWM5NGI5MzY4ODQyMTA5NWE3OThhZmFiNjljNDYwL3RhYmxlOjQzNDA0NmE1MTY4ODQzZDg5M2IxNTEyZjYxODkzYmU4L3RhYmxlcmFuZ2U6NDM0MDQ2YTUxNjg4NDNkODkzYjE1MTJmNjE4OTNiZThfMzUtMy0xLTEtMTc3NzU_f9cbdffa-c209-4233-85b2-f85508c2cb6b">4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieb0b713eae1b4f908dc2c23586d77948_D20200101-20201231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yOC9mcmFnOjVjZWM5NGI5MzY4ODQyMTA5NWE3OThhZmFiNjljNDYwL3RhYmxlOjQzNDA0NmE1MTY4ODQzZDg5M2IxNTEyZjYxODkzYmU4L3RhYmxlcmFuZ2U6NDM0MDQ2YTUxNjg4NDNkODkzYjE1MTJmNjE4OTNiZThfMzUtOS0xLTEtMTc3NzU_7a361db1-50e9-48b0-a08a-8235113d5a86">2,573</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i911a108ecf12460193d53b0e6b24331f_D20200101-20201231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yOC9mcmFnOjVjZWM5NGI5MzY4ODQyMTA5NWE3OThhZmFiNjljNDYwL3RhYmxlOjQzNDA0NmE1MTY4ODQzZDg5M2IxNTEyZjYxODkzYmU4L3RhYmxlcmFuZ2U6NDM0MDQ2YTUxNjg4NDNkODkzYjE1MTJmNjE4OTNiZThfMzUtMTctMS0xLTE3Nzc1_4a8768bd-ed90-4091-aec6-facd107db807">2,577</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i12a6d1161de54547bd29f8efccd4c9b0_D20200101-20201231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yOC9mcmFnOjVjZWM5NGI5MzY4ODQyMTA5NWE3OThhZmFiNjljNDYwL3RhYmxlOjQzNDA0NmE1MTY4ODQzZDg5M2IxNTEyZjYxODkzYmU4L3RhYmxlcmFuZ2U6NDM0MDQ2YTUxNjg4NDNkODkzYjE1MTJmNjE4OTNiZThfMzUtMjEtMS0xLTE3Nzc1_0f32cf30-efb0-4f26-8426-e2e99d4b65c0">2,577</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Restricted stock units vested, net of shares withheld for taxes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ifead6db34ce543e2beca6b5c57feaf4e_D20200101-20201231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yOC9mcmFnOjVjZWM5NGI5MzY4ODQyMTA5NWE3OThhZmFiNjljNDYwL3RhYmxlOjQzNDA0NmE1MTY4ODQzZDg5M2IxNTEyZjYxODkzYmU4L3RhYmxlcmFuZ2U6NDM0MDQ2YTUxNjg4NDNkODkzYjE1MTJmNjE4OTNiZThfMzYtMS0xLTEtMTc3NzU_5662fa61-2676-4ea5-8e02-c0f361cd05c0">462</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifead6db34ce543e2beca6b5c57feaf4e_D20200101-20201231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yOC9mcmFnOjVjZWM5NGI5MzY4ODQyMTA5NWE3OThhZmFiNjljNDYwL3RhYmxlOjQzNDA0NmE1MTY4ODQzZDg5M2IxNTEyZjYxODkzYmU4L3RhYmxlcmFuZ2U6NDM0MDQ2YTUxNjg4NDNkODkzYjE1MTJmNjE4OTNiZThfMzYtMy0xLTEtMTc3NzU_995c09cd-527e-40ef-888a-a08a55f82bb5">5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ieb0b713eae1b4f908dc2c23586d77948_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yOC9mcmFnOjVjZWM5NGI5MzY4ODQyMTA5NWE3OThhZmFiNjljNDYwL3RhYmxlOjQzNDA0NmE1MTY4ODQzZDg5M2IxNTEyZjYxODkzYmU4L3RhYmxlcmFuZ2U6NDM0MDQ2YTUxNjg4NDNkODkzYjE1MTJmNjE4OTNiZThfMzYtOS0xLTEtMTc3NzU_0bec4a2c-8a6c-4a5d-95b6-7b9bf75e28ce">1,856</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i911a108ecf12460193d53b0e6b24331f_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yOC9mcmFnOjVjZWM5NGI5MzY4ODQyMTA5NWE3OThhZmFiNjljNDYwL3RhYmxlOjQzNDA0NmE1MTY4ODQzZDg5M2IxNTEyZjYxODkzYmU4L3RhYmxlcmFuZ2U6NDM0MDQ2YTUxNjg4NDNkODkzYjE1MTJmNjE4OTNiZThfMzYtMTctMS0xLTE3Nzc1_57fea2d4-9ea0-4ad7-982f-28cc07cb77f9">1,851</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i12a6d1161de54547bd29f8efccd4c9b0_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yOC9mcmFnOjVjZWM5NGI5MzY4ODQyMTA5NWE3OThhZmFiNjljNDYwL3RhYmxlOjQzNDA0NmE1MTY4ODQzZDg5M2IxNTEyZjYxODkzYmU4L3RhYmxlcmFuZ2U6NDM0MDQ2YTUxNjg4NDNkODkzYjE1MTJmNjE4OTNiZThfMzYtMjEtMS0xLTE3Nzc1_9d2cdc88-98ef-48bc-9228-930db1346b5a">1,851</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Consolidation of equity method investment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i843130db221949f4a5068562633a2182_D20200101-20201231" decimals="-3" name="us-gaap:TreasuryStockRetiredCostMethodAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yOC9mcmFnOjVjZWM5NGI5MzY4ODQyMTA5NWE3OThhZmFiNjljNDYwL3RhYmxlOjQzNDA0NmE1MTY4ODQzZDg5M2IxNTEyZjYxODkzYmU4L3RhYmxlcmFuZ2U6NDM0MDQ2YTUxNjg4NDNkODkzYjE1MTJmNjE4OTNiZThfMzctMTUtMS0xLTE3Nzc1_cf46b2a8-ec63-474f-a30c-6664379cd322">21,123</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i911a108ecf12460193d53b0e6b24331f_D20200101-20201231" decimals="-3" name="us-gaap:TreasuryStockRetiredCostMethodAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yOC9mcmFnOjVjZWM5NGI5MzY4ODQyMTA5NWE3OThhZmFiNjljNDYwL3RhYmxlOjQzNDA0NmE1MTY4ODQzZDg5M2IxNTEyZjYxODkzYmU4L3RhYmxlcmFuZ2U6NDM0MDQ2YTUxNjg4NDNkODkzYjE1MTJmNjE4OTNiZThfMzctMTctMS0xLTE3Nzc1_ffffdac0-9db8-4638-b4a6-f62efe1916af">21,123</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i12a6d1161de54547bd29f8efccd4c9b0_D20200101-20201231" decimals="-3" name="us-gaap:TreasuryStockRetiredCostMethodAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yOC9mcmFnOjVjZWM5NGI5MzY4ODQyMTA5NWE3OThhZmFiNjljNDYwL3RhYmxlOjQzNDA0NmE1MTY4ODQzZDg5M2IxNTEyZjYxODkzYmU4L3RhYmxlcmFuZ2U6NDM0MDQ2YTUxNjg4NDNkODkzYjE1MTJmNjE4OTNiZThfMzctMjEtMS0xLTE3Nzc1_3f2a4a57-2370-4f79-a405-61b3ba7bb4f0">21,123</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Share retirement</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="ifead6db34ce543e2beca6b5c57feaf4e_D20200101-20201231" decimals="-3" name="evh:StockVestedAndRetiredDuringPeriodShares" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yOC9mcmFnOjVjZWM5NGI5MzY4ODQyMTA5NWE3OThhZmFiNjljNDYwL3RhYmxlOjQzNDA0NmE1MTY4ODQzZDg5M2IxNTEyZjYxODkzYmU4L3RhYmxlcmFuZ2U6NDM0MDQ2YTUxNjg4NDNkODkzYjE1MTJmNjE4OTNiZThfMzgtMS0xLTEtMTc3NzU_46acda9e-e44a-44cc-ba4c-f54e3ba73457">188</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifead6db34ce543e2beca6b5c57feaf4e_D20200101-20201231" decimals="-3" name="evh:StockVestedAndRetiredDuringPeriodValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yOC9mcmFnOjVjZWM5NGI5MzY4ODQyMTA5NWE3OThhZmFiNjljNDYwL3RhYmxlOjQzNDA0NmE1MTY4ODQzZDg5M2IxNTEyZjYxODkzYmU4L3RhYmxlcmFuZ2U6NDM0MDQ2YTUxNjg4NDNkODkzYjE1MTJmNjE4OTNiZThfMzgtMy0xLTEtMTc3NzU_dcc8f2e6-cb28-4af5-aa4f-526fd13df037">2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ieb0b713eae1b4f908dc2c23586d77948_D20200101-20201231" decimals="-3" name="evh:StockVestedAndRetiredDuringPeriodValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yOC9mcmFnOjVjZWM5NGI5MzY4ODQyMTA5NWE3OThhZmFiNjljNDYwL3RhYmxlOjQzNDA0NmE1MTY4ODQzZDg5M2IxNTEyZjYxODkzYmU4L3RhYmxlcmFuZ2U6NDM0MDQ2YTUxNjg4NDNkODkzYjE1MTJmNjE4OTNiZThfMzgtOS0xLTEtMTc3NzU_58ad43ab-56d1-4dc6-84ec-53f76459b10e">683</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i911a108ecf12460193d53b0e6b24331f_D20200101-20201231" decimals="-3" name="evh:StockVestedAndRetiredDuringPeriodValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yOC9mcmFnOjVjZWM5NGI5MzY4ODQyMTA5NWE3OThhZmFiNjljNDYwL3RhYmxlOjQzNDA0NmE1MTY4ODQzZDg5M2IxNTEyZjYxODkzYmU4L3RhYmxlcmFuZ2U6NDM0MDQ2YTUxNjg4NDNkODkzYjE1MTJmNjE4OTNiZThfMzgtMTctMS0xLTE3Nzc1_6e98ec20-e4b0-4b4b-861f-03f49a33e0d6">685</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i12a6d1161de54547bd29f8efccd4c9b0_D20200101-20201231" decimals="-3" name="evh:StockVestedAndRetiredDuringPeriodValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yOC9mcmFnOjVjZWM5NGI5MzY4ODQyMTA5NWE3OThhZmFiNjljNDYwL3RhYmxlOjQzNDA0NmE1MTY4ODQzZDg5M2IxNTEyZjYxODkzYmU4L3RhYmxlcmFuZ2U6NDM0MDQ2YTUxNjg4NDNkODkzYjE1MTJmNjE4OTNiZThfMzgtMjEtMS0xLTE3Nzc1_59d032ec-4c6d-42e0-b01e-b4574d0ac543">685</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Class A common stock issued for payment of earn-outs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ifead6db34ce543e2beca6b5c57feaf4e_D20200101-20201231" decimals="-3" name="evh:StockIssuedDuringPeriodSharesEarnOuts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yOC9mcmFnOjVjZWM5NGI5MzY4ODQyMTA5NWE3OThhZmFiNjljNDYwL3RhYmxlOjQzNDA0NmE1MTY4ODQzZDg5M2IxNTEyZjYxODkzYmU4L3RhYmxlcmFuZ2U6NDM0MDQ2YTUxNjg4NDNkODkzYjE1MTJmNjE4OTNiZThfMzktMS0xLTEtMTc3NzU_7fd6a355-9fe2-4a2c-9c9a-5368b69dd5d2">616</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifead6db34ce543e2beca6b5c57feaf4e_D20200101-20201231" decimals="-3" name="evh:StockIssuedDuringPeriodValueEarnOuts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yOC9mcmFnOjVjZWM5NGI5MzY4ODQyMTA5NWE3OThhZmFiNjljNDYwL3RhYmxlOjQzNDA0NmE1MTY4ODQzZDg5M2IxNTEyZjYxODkzYmU4L3RhYmxlcmFuZ2U6NDM0MDQ2YTUxNjg4NDNkODkzYjE1MTJmNjE4OTNiZThfMzktMy0xLTEtMTc3NzU_dba75782-45fc-41f1-911d-e2bbfe3ed515">6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieb0b713eae1b4f908dc2c23586d77948_D20200101-20201231" decimals="-3" name="evh:StockIssuedDuringPeriodValueEarnOuts" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yOC9mcmFnOjVjZWM5NGI5MzY4ODQyMTA5NWE3OThhZmFiNjljNDYwL3RhYmxlOjQzNDA0NmE1MTY4ODQzZDg5M2IxNTEyZjYxODkzYmU4L3RhYmxlcmFuZ2U6NDM0MDQ2YTUxNjg4NDNkODkzYjE1MTJmNjE4OTNiZThfMzktOS0xLTEtMTc3NzU_499c0765-e616-4061-a1ed-bc88b0f03850">4,179</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i911a108ecf12460193d53b0e6b24331f_D20200101-20201231" decimals="-3" name="evh:StockIssuedDuringPeriodValueEarnOuts" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yOC9mcmFnOjVjZWM5NGI5MzY4ODQyMTA5NWE3OThhZmFiNjljNDYwL3RhYmxlOjQzNDA0NmE1MTY4ODQzZDg5M2IxNTEyZjYxODkzYmU4L3RhYmxlcmFuZ2U6NDM0MDQ2YTUxNjg4NDNkODkzYjE1MTJmNjE4OTNiZThfMzktMTctMS0xLTE3Nzc1_3c3061f2-79bf-40b3-af23-bd491c38428e">4,185</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i12a6d1161de54547bd29f8efccd4c9b0_D20200101-20201231" decimals="-3" name="evh:StockIssuedDuringPeriodValueEarnOuts" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yOC9mcmFnOjVjZWM5NGI5MzY4ODQyMTA5NWE3OThhZmFiNjljNDYwL3RhYmxlOjQzNDA0NmE1MTY4ODQzZDg5M2IxNTEyZjYxODkzYmU4L3RhYmxlcmFuZ2U6NDM0MDQ2YTUxNjg4NDNkODkzYjE1MTJmNjE4OTNiZThfMzktMjEtMS0xLTE3Nzc1_dc309e90-9735-4822-80a8-6570c05111a4">4,185</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Equity component of 2024 Notes, net of issuance costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieb0b713eae1b4f908dc2c23586d77948_D20200101-20201231" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yOC9mcmFnOjVjZWM5NGI5MzY4ODQyMTA5NWE3OThhZmFiNjljNDYwL3RhYmxlOjQzNDA0NmE1MTY4ODQzZDg5M2IxNTEyZjYxODkzYmU4L3RhYmxlcmFuZ2U6NDM0MDQ2YTUxNjg4NDNkODkzYjE1MTJmNjE4OTNiZThfNDAtOS0xLTEtMTc3NzU_8d714747-1ec8-40b8-b170-948f233f43a0">36,793</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i911a108ecf12460193d53b0e6b24331f_D20200101-20201231" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yOC9mcmFnOjVjZWM5NGI5MzY4ODQyMTA5NWE3OThhZmFiNjljNDYwL3RhYmxlOjQzNDA0NmE1MTY4ODQzZDg5M2IxNTEyZjYxODkzYmU4L3RhYmxlcmFuZ2U6NDM0MDQ2YTUxNjg4NDNkODkzYjE1MTJmNjE4OTNiZThfNDAtMTctMS0xLTE3Nzc1_8b8a8a73-55fe-4114-b480-daf344f6e581">36,793</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i12a6d1161de54547bd29f8efccd4c9b0_D20200101-20201231" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yOC9mcmFnOjVjZWM5NGI5MzY4ODQyMTA5NWE3OThhZmFiNjljNDYwL3RhYmxlOjQzNDA0NmE1MTY4ODQzZDg5M2IxNTEyZjYxODkzYmU4L3RhYmxlcmFuZ2U6NDM0MDQ2YTUxNjg4NDNkODkzYjE1MTJmNjE4OTNiZThfNDAtMjEtMS0xLTE3Nzc1_53f3b0aa-917e-4840-a2bd-1b618ceef2d9">36,793</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Disposal of assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic8a05c8bd28c42f4918205dc608cf2de_D20200101-20201231" decimals="-3" name="us-gaap:NoncontrollingInterestDecreaseFromDeconsolidation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yOC9mcmFnOjVjZWM5NGI5MzY4ODQyMTA5NWE3OThhZmFiNjljNDYwL3RhYmxlOjQzNDA0NmE1MTY4ODQzZDg5M2IxNTEyZjYxODkzYmU4L3RhYmxlcmFuZ2U6NDM0MDQ2YTUxNjg4NDNkODkzYjE1MTJmNjE4OTNiZThfNDEtMTktMS0xLTE3Nzc1_b9c7b64d-08d8-4e3b-b0a5-916710ba4a59">6,689</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i12a6d1161de54547bd29f8efccd4c9b0_D20200101-20201231" decimals="-3" name="us-gaap:NoncontrollingInterestDecreaseFromDeconsolidation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yOC9mcmFnOjVjZWM5NGI5MzY4ODQyMTA5NWE3OThhZmFiNjljNDYwL3RhYmxlOjQzNDA0NmE1MTY4ODQzZDg5M2IxNTEyZjYxODkzYmU4L3RhYmxlcmFuZ2U6NDM0MDQ2YTUxNjg4NDNkODkzYjE1MTJmNjE4OTNiZThfNDEtMjEtMS0xLTE3Nzc1_438cc8d7-7fac-4265-b0d4-73de2722c948">6,689</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Foreign currency translation adjustment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ide6ed4433a164b08bcb555a8e1f7a38c_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yOC9mcmFnOjVjZWM5NGI5MzY4ODQyMTA5NWE3OThhZmFiNjljNDYwL3RhYmxlOjQzNDA0NmE1MTY4ODQzZDg5M2IxNTEyZjYxODkzYmU4L3RhYmxlcmFuZ2U6NDM0MDQ2YTUxNjg4NDNkODkzYjE1MTJmNjE4OTNiZThfNDItMTEtMS0xLTE3Nzc1_70553822-bd1e-4b8d-b4bd-3ef2cd689e56">44</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i911a108ecf12460193d53b0e6b24331f_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yOC9mcmFnOjVjZWM5NGI5MzY4ODQyMTA5NWE3OThhZmFiNjljNDYwL3RhYmxlOjQzNDA0NmE1MTY4ODQzZDg5M2IxNTEyZjYxODkzYmU4L3RhYmxlcmFuZ2U6NDM0MDQ2YTUxNjg4NDNkODkzYjE1MTJmNjE4OTNiZThfNDItMTctMS0xLTE3Nzc1_8f0e1b27-5e95-4059-9825-53f6342d9d4f">44</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i12a6d1161de54547bd29f8efccd4c9b0_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yOC9mcmFnOjVjZWM5NGI5MzY4ODQyMTA5NWE3OThhZmFiNjljNDYwL3RhYmxlOjQzNDA0NmE1MTY4ODQzZDg5M2IxNTEyZjYxODkzYmU4L3RhYmxlcmFuZ2U6NDM0MDQ2YTUxNjg4NDNkODkzYjE1MTJmNjE4OTNiZThfNDItMjEtMS0xLTE3Nzc1_17da6005-e318-4a9f-b4f8-677c2b2565ef">44</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i88dcc077f08e4577b7b60dca2d354693_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yOC9mcmFnOjVjZWM5NGI5MzY4ODQyMTA5NWE3OThhZmFiNjljNDYwL3RhYmxlOjQzNDA0NmE1MTY4ODQzZDg5M2IxNTEyZjYxODkzYmU4L3RhYmxlcmFuZ2U6NDM0MDQ2YTUxNjg4NDNkODkzYjE1MTJmNjE4OTNiZThfNDMtMTMtMS0xLTE3Nzc1_93e1ac6a-1fd4-4f5c-aae2-4a6771211c60">334,246</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i911a108ecf12460193d53b0e6b24331f_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yOC9mcmFnOjVjZWM5NGI5MzY4ODQyMTA5NWE3OThhZmFiNjljNDYwL3RhYmxlOjQzNDA0NmE1MTY4ODQzZDg5M2IxNTEyZjYxODkzYmU4L3RhYmxlcmFuZ2U6NDM0MDQ2YTUxNjg4NDNkODkzYjE1MTJmNjE4OTNiZThfNDMtMTctMS0xLTE3Nzc1_ba79e546-8882-4e1c-92e9-471a4bf18320">334,246</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i12a6d1161de54547bd29f8efccd4c9b0_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yOC9mcmFnOjVjZWM5NGI5MzY4ODQyMTA5NWE3OThhZmFiNjljNDYwL3RhYmxlOjQzNDA0NmE1MTY4ODQzZDg5M2IxNTEyZjYxODkzYmU4L3RhYmxlcmFuZ2U6NDM0MDQ2YTUxNjg4NDNkODkzYjE1MTJmNjE4OTNiZThfNDMtMjEtMS0xLTE3Nzc1_a1eb5d34-d272-40e1-80e6-4d11d1621c89">334,246</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">See accompanying Notes to Consolidated Financial Statements</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">71</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:19.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.058%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.455%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.356%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.356%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.150%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.523%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.058%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.042%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.142%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.556%"></td><td style="width:0.1%"></td></tr><tr><td colspan="66" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">EVOLENT HEALTH, INC.</span></td></tr><tr><td colspan="66" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS&#8217; EQUITY</span></td></tr><tr><td colspan="66" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:39pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Class A Common Stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Class B Common Stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Additional Paid-In Capital</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Accumulated Other Comprehensive Income (Loss)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Retained Earnings (Accumulated Deficit)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Treasury Stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total Shareholders' Equity<br/>Attributable to Evolent Health, Inc.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Non-controlling Interests</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total Equity (Deficit)</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance as of December 31, 2020</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iaf96f04b17974a2f8e19df7a883c4734_I20201231" decimals="-3" name="us-gaap:SharesIssued" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yOC9mcmFnOjVjZWM5NGI5MzY4ODQyMTA5NWE3OThhZmFiNjljNDYwL3RhYmxlOjQzNDA0NmE1MTY4ODQzZDg5M2IxNTEyZjYxODkzYmU4L3RhYmxlcmFuZ2U6NDM0MDQ2YTUxNjg4NDNkODkzYjE1MTJmNjE4OTNiZThfNDQtMS0xLTEtMTc3NzU_7a868ca8-f47d-4d97-930b-665d404cc448">85,895</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaf96f04b17974a2f8e19df7a883c4734_I20201231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yOC9mcmFnOjVjZWM5NGI5MzY4ODQyMTA5NWE3OThhZmFiNjljNDYwL3RhYmxlOjQzNDA0NmE1MTY4ODQzZDg5M2IxNTEyZjYxODkzYmU4L3RhYmxlcmFuZ2U6NDM0MDQ2YTUxNjg4NDNkODkzYjE1MTJmNjE4OTNiZThfNDQtMy0xLTEtMTc3NzU_8f52aae6-c9c9-4c61-9a82-74909959912b">859</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1425ebfe96904025b4f40a30737efd06_I20201231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yOC9mcmFnOjVjZWM5NGI5MzY4ODQyMTA5NWE3OThhZmFiNjljNDYwL3RhYmxlOjQzNDA0NmE1MTY4ODQzZDg5M2IxNTEyZjYxODkzYmU4L3RhYmxlcmFuZ2U6NDM0MDQ2YTUxNjg4NDNkODkzYjE1MTJmNjE4OTNiZThfNDQtOS0xLTEtMTc3NzU_cf3632e9-c682-4105-a3d7-3a90f0fc0e8b">1,229,320</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8f416a598c52444597bd56910cd0efbb_I20201231" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yOC9mcmFnOjVjZWM5NGI5MzY4ODQyMTA5NWE3OThhZmFiNjljNDYwL3RhYmxlOjQzNDA0NmE1MTY4ODQzZDg5M2IxNTEyZjYxODkzYmU4L3RhYmxlcmFuZ2U6NDM0MDQ2YTUxNjg4NDNkODkzYjE1MTJmNjE4OTNiZThfNDQtMTEtMS0xLTE3Nzc1_2ac7708e-98d4-426f-b7f9-46768ac24ca2">278</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7de15b24843f43e1bf1e49503dff1359_I20201231" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yOC9mcmFnOjVjZWM5NGI5MzY4ODQyMTA5NWE3OThhZmFiNjljNDYwL3RhYmxlOjQzNDA0NmE1MTY4ODQzZDg5M2IxNTEyZjYxODkzYmU4L3RhYmxlcmFuZ2U6NDM0MDQ2YTUxNjg4NDNkODkzYjE1MTJmNjE4OTNiZThfNDQtMTMtMS0xLTE3Nzc1_852eb8fc-5b51-4d9c-aece-c1887ca00a51">589,178</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idb7d2cb4638a4234b2407c840694aea3_I20201231" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yOC9mcmFnOjVjZWM5NGI5MzY4ODQyMTA5NWE3OThhZmFiNjljNDYwL3RhYmxlOjQzNDA0NmE1MTY4ODQzZDg5M2IxNTEyZjYxODkzYmU4L3RhYmxlcmFuZ2U6NDM0MDQ2YTUxNjg4NDNkODkzYjE1MTJmNjE4OTNiZThfNDQtMTUtMS0xLTE3Nzc1_25134528-2bc3-4929-98a2-f6f3a59e50d9">21,123</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88eadc89dc9a4d4aab536db563f563d5_I20201231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yOC9mcmFnOjVjZWM5NGI5MzY4ODQyMTA5NWE3OThhZmFiNjljNDYwL3RhYmxlOjQzNDA0NmE1MTY4ODQzZDg5M2IxNTEyZjYxODkzYmU4L3RhYmxlcmFuZ2U6NDM0MDQ2YTUxNjg4NDNkODkzYjE1MTJmNjE4OTNiZThfNDQtMTctMS0xLTE3Nzc1_f0c4411a-9f50-4f0a-b86c-277432113ea4">619,600</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5724ef529cea411aadb2b6f086af09f1_I20201231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yOC9mcmFnOjVjZWM5NGI5MzY4ODQyMTA5NWE3OThhZmFiNjljNDYwL3RhYmxlOjQzNDA0NmE1MTY4ODQzZDg5M2IxNTEyZjYxODkzYmU4L3RhYmxlcmFuZ2U6NDM0MDQ2YTUxNjg4NDNkODkzYjE1MTJmNjE4OTNiZThfNDQtMTktMS0xLTE3Nzc1_4d978b7f-b0e2-44f9-87b3-f3e867899c99">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc0c0c2b8dc04c5698ca0577a54b2e03_I20201231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yOC9mcmFnOjVjZWM5NGI5MzY4ODQyMTA5NWE3OThhZmFiNjljNDYwL3RhYmxlOjQzNDA0NmE1MTY4ODQzZDg5M2IxNTEyZjYxODkzYmU4L3RhYmxlcmFuZ2U6NDM0MDQ2YTUxNjg4NDNkODkzYjE1MTJmNjE4OTNiZThfNDQtMjEtMS0xLTE3Nzc1_8c58ed7d-daca-4be3-aabe-17ef1aff0891">619,600</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stock-based compensation expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8a0a16beae314535bccd01c31668c8fd_D20210101-20211231" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yOC9mcmFnOjVjZWM5NGI5MzY4ODQyMTA5NWE3OThhZmFiNjljNDYwL3RhYmxlOjQzNDA0NmE1MTY4ODQzZDg5M2IxNTEyZjYxODkzYmU4L3RhYmxlcmFuZ2U6NDM0MDQ2YTUxNjg4NDNkODkzYjE1MTJmNjE4OTNiZThfMzItOS0xLTEtMTkzMTk_ce295e66-b901-4729-9ce8-aaef00d991cd">16,711</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5f242398851f435581586484404b0dfb_D20210101-20211231" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yOC9mcmFnOjVjZWM5NGI5MzY4ODQyMTA5NWE3OThhZmFiNjljNDYwL3RhYmxlOjQzNDA0NmE1MTY4ODQzZDg5M2IxNTEyZjYxODkzYmU4L3RhYmxlcmFuZ2U6NDM0MDQ2YTUxNjg4NDNkODkzYjE1MTJmNjE4OTNiZThfMzItMTctMS0xLTE5MzE5_c1c33bc6-12ef-41f9-9bb9-792b2d5f03ae">16,711</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yOC9mcmFnOjVjZWM5NGI5MzY4ODQyMTA5NWE3OThhZmFiNjljNDYwL3RhYmxlOjQzNDA0NmE1MTY4ODQzZDg5M2IxNTEyZjYxODkzYmU4L3RhYmxlcmFuZ2U6NDM0MDQ2YTUxNjg4NDNkODkzYjE1MTJmNjE4OTNiZThfMzItMjEtMS0xLTE5MzE5_eea8a8ce-24c7-421c-bfd7-1278dc45f045">16,711</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Exercise of stock options</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i8a70782136dc46eb8037c247f5e1694a_D20210101-20211231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yOC9mcmFnOjVjZWM5NGI5MzY4ODQyMTA5NWE3OThhZmFiNjljNDYwL3RhYmxlOjQzNDA0NmE1MTY4ODQzZDg5M2IxNTEyZjYxODkzYmU4L3RhYmxlcmFuZ2U6NDM0MDQ2YTUxNjg4NDNkODkzYjE1MTJmNjE4OTNiZThfMzMtMS0xLTEtMTkzMTk_f83ec2bc-fc66-49ff-be65-6d0bbaff525c">1,490</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8a70782136dc46eb8037c247f5e1694a_D20210101-20211231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yOC9mcmFnOjVjZWM5NGI5MzY4ODQyMTA5NWE3OThhZmFiNjljNDYwL3RhYmxlOjQzNDA0NmE1MTY4ODQzZDg5M2IxNTEyZjYxODkzYmU4L3RhYmxlcmFuZ2U6NDM0MDQ2YTUxNjg4NDNkODkzYjE1MTJmNjE4OTNiZThfMzMtMy0xLTEtMTkzMTk_f2b3a1c6-6476-491c-ae5d-b96bbc72db90">15</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8a0a16beae314535bccd01c31668c8fd_D20210101-20211231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yOC9mcmFnOjVjZWM5NGI5MzY4ODQyMTA5NWE3OThhZmFiNjljNDYwL3RhYmxlOjQzNDA0NmE1MTY4ODQzZDg5M2IxNTEyZjYxODkzYmU4L3RhYmxlcmFuZ2U6NDM0MDQ2YTUxNjg4NDNkODkzYjE1MTJmNjE4OTNiZThfMzMtOS0xLTEtMTkzMTk_390f6ffd-2b8b-480e-983b-b77c0118d7a3">13,274</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5f242398851f435581586484404b0dfb_D20210101-20211231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yOC9mcmFnOjVjZWM5NGI5MzY4ODQyMTA5NWE3OThhZmFiNjljNDYwL3RhYmxlOjQzNDA0NmE1MTY4ODQzZDg5M2IxNTEyZjYxODkzYmU4L3RhYmxlcmFuZ2U6NDM0MDQ2YTUxNjg4NDNkODkzYjE1MTJmNjE4OTNiZThfMzMtMTctMS0xLTE5MzE5_9ba403ba-5b29-4ad5-81e0-897aa8ab6d10">13,289</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yOC9mcmFnOjVjZWM5NGI5MzY4ODQyMTA5NWE3OThhZmFiNjljNDYwL3RhYmxlOjQzNDA0NmE1MTY4ODQzZDg5M2IxNTEyZjYxODkzYmU4L3RhYmxlcmFuZ2U6NDM0MDQ2YTUxNjg4NDNkODkzYjE1MTJmNjE4OTNiZThfMzMtMjEtMS0xLTE5MzE5_b937bbd9-3174-4880-be82-bf0b6fcc7711">13,289</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Restricted stock units vested, net of shares withheld for taxes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i8a70782136dc46eb8037c247f5e1694a_D20210101-20211231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yOC9mcmFnOjVjZWM5NGI5MzY4ODQyMTA5NWE3OThhZmFiNjljNDYwL3RhYmxlOjQzNDA0NmE1MTY4ODQzZDg5M2IxNTEyZjYxODkzYmU4L3RhYmxlcmFuZ2U6NDM0MDQ2YTUxNjg4NDNkODkzYjE1MTJmNjE4OTNiZThfMzQtMS0xLTEtMTkzMTk_88540ee9-fa4e-4d5a-8bb1-59fe94e85239">492</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8a70782136dc46eb8037c247f5e1694a_D20210101-20211231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yOC9mcmFnOjVjZWM5NGI5MzY4ODQyMTA5NWE3OThhZmFiNjljNDYwL3RhYmxlOjQzNDA0NmE1MTY4ODQzZDg5M2IxNTEyZjYxODkzYmU4L3RhYmxlcmFuZ2U6NDM0MDQ2YTUxNjg4NDNkODkzYjE1MTJmNjE4OTNiZThfMzQtMy0xLTEtMTkzMTk_34f94842-38c0-49e7-89fa-de0cd4c52bab">5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8a0a16beae314535bccd01c31668c8fd_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yOC9mcmFnOjVjZWM5NGI5MzY4ODQyMTA5NWE3OThhZmFiNjljNDYwL3RhYmxlOjQzNDA0NmE1MTY4ODQzZDg5M2IxNTEyZjYxODkzYmU4L3RhYmxlcmFuZ2U6NDM0MDQ2YTUxNjg4NDNkODkzYjE1MTJmNjE4OTNiZThfMzQtOS0xLTEtMTkzMTk_8615ce7e-c8b1-41da-b61a-9eeecf95c199">3,855</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5f242398851f435581586484404b0dfb_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yOC9mcmFnOjVjZWM5NGI5MzY4ODQyMTA5NWE3OThhZmFiNjljNDYwL3RhYmxlOjQzNDA0NmE1MTY4ODQzZDg5M2IxNTEyZjYxODkzYmU4L3RhYmxlcmFuZ2U6NDM0MDQ2YTUxNjg4NDNkODkzYjE1MTJmNjE4OTNiZThfMzQtMTctMS0xLTE5MzE5_1ba22cf7-9b13-48e0-a898-1973665e3454">3,850</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yOC9mcmFnOjVjZWM5NGI5MzY4ODQyMTA5NWE3OThhZmFiNjljNDYwL3RhYmxlOjQzNDA0NmE1MTY4ODQzZDg5M2IxNTEyZjYxODkzYmU4L3RhYmxlcmFuZ2U6NDM0MDQ2YTUxNjg4NDNkODkzYjE1MTJmNjE4OTNiZThfMzQtMjEtMS0xLTE5MzE5_5f93955d-da8b-4b86-a234-4d81bd65b0a7">3,850</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Shares issued for acquisition</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i8a70782136dc46eb8037c247f5e1694a_D20210101-20211231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesAcquisitions" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yOC9mcmFnOjVjZWM5NGI5MzY4ODQyMTA5NWE3OThhZmFiNjljNDYwL3RhYmxlOjQzNDA0NmE1MTY4ODQzZDg5M2IxNTEyZjYxODkzYmU4L3RhYmxlcmFuZ2U6NDM0MDQ2YTUxNjg4NDNkODkzYjE1MTJmNjE4OTNiZThfMzUtMS0xLTEtMTkzMTk_df88fedd-f8a0-40a2-b7ee-abcac4a73d45">1,771</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8a70782136dc46eb8037c247f5e1694a_D20210101-20211231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueAcquisitions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yOC9mcmFnOjVjZWM5NGI5MzY4ODQyMTA5NWE3OThhZmFiNjljNDYwL3RhYmxlOjQzNDA0NmE1MTY4ODQzZDg5M2IxNTEyZjYxODkzYmU4L3RhYmxlcmFuZ2U6NDM0MDQ2YTUxNjg4NDNkODkzYjE1MTJmNjE4OTNiZThfMzUtMy0xLTEtMTkzMTk_15275e53-10b1-4287-bb21-94e7593145f2">18</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8a0a16beae314535bccd01c31668c8fd_D20210101-20211231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueAcquisitions" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yOC9mcmFnOjVjZWM5NGI5MzY4ODQyMTA5NWE3OThhZmFiNjljNDYwL3RhYmxlOjQzNDA0NmE1MTY4ODQzZDg5M2IxNTEyZjYxODkzYmU4L3RhYmxlcmFuZ2U6NDM0MDQ2YTUxNjg4NDNkODkzYjE1MTJmNjE4OTNiZThfMzUtOS0xLTEtMTkzMTk_98e2979a-48a7-4cb2-a089-822b84b2608d">56,608</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5f242398851f435581586484404b0dfb_D20210101-20211231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueAcquisitions" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yOC9mcmFnOjVjZWM5NGI5MzY4ODQyMTA5NWE3OThhZmFiNjljNDYwL3RhYmxlOjQzNDA0NmE1MTY4ODQzZDg5M2IxNTEyZjYxODkzYmU4L3RhYmxlcmFuZ2U6NDM0MDQ2YTUxNjg4NDNkODkzYjE1MTJmNjE4OTNiZThfMzUtMTctMS0xLTE5MzE5_33671f22-f521-4533-9a52-ec2ad415d69d">56,626</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueAcquisitions" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yOC9mcmFnOjVjZWM5NGI5MzY4ODQyMTA5NWE3OThhZmFiNjljNDYwL3RhYmxlOjQzNDA0NmE1MTY4ODQzZDg5M2IxNTEyZjYxODkzYmU4L3RhYmxlcmFuZ2U6NDM0MDQ2YTUxNjg4NDNkODkzYjE1MTJmNjE4OTNiZThfMzUtMjEtMS0xLTE5MzE5_3ecf56fe-7b2d-4f64-b915-662e2d07392a">56,626</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Conversion of 2021 Notes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i8a70782136dc46eb8037c247f5e1694a_D20210101-20211231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yOC9mcmFnOjVjZWM5NGI5MzY4ODQyMTA5NWE3OThhZmFiNjljNDYwL3RhYmxlOjQzNDA0NmE1MTY4ODQzZDg5M2IxNTEyZjYxODkzYmU4L3RhYmxlcmFuZ2U6NDM0MDQ2YTUxNjg4NDNkODkzYjE1MTJmNjE4OTNiZThfMzYtMS0xLTEtMjMzNTQ_7f65750b-18ee-473d-b97c-b72f5de8b6bf">1,095</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8a70782136dc46eb8037c247f5e1694a_D20210101-20211231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yOC9mcmFnOjVjZWM5NGI5MzY4ODQyMTA5NWE3OThhZmFiNjljNDYwL3RhYmxlOjQzNDA0NmE1MTY4ODQzZDg5M2IxNTEyZjYxODkzYmU4L3RhYmxlcmFuZ2U6NDM0MDQ2YTUxNjg4NDNkODkzYjE1MTJmNjE4OTNiZThfMzYtMy0xLTEtMjMzNTQ_9fceaaf7-3fef-4855-8644-c2288c6ed58c">11</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8a0a16beae314535bccd01c31668c8fd_D20210101-20211231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yOC9mcmFnOjVjZWM5NGI5MzY4ODQyMTA5NWE3OThhZmFiNjljNDYwL3RhYmxlOjQzNDA0NmE1MTY4ODQzZDg5M2IxNTEyZjYxODkzYmU4L3RhYmxlcmFuZ2U6NDM0MDQ2YTUxNjg4NDNkODkzYjE1MTJmNjE4OTNiZThfMzYtOS0xLTEtMjMzNTQ_72eae4a3-98d1-4b58-9346-a59d84a0e72c">28,481</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5f242398851f435581586484404b0dfb_D20210101-20211231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yOC9mcmFnOjVjZWM5NGI5MzY4ODQyMTA5NWE3OThhZmFiNjljNDYwL3RhYmxlOjQzNDA0NmE1MTY4ODQzZDg5M2IxNTEyZjYxODkzYmU4L3RhYmxlcmFuZ2U6NDM0MDQ2YTUxNjg4NDNkODkzYjE1MTJmNjE4OTNiZThfMzYtMTctMS0xLTIzMzU0_022856f5-437a-4cf1-958d-3744ef1ecf60">28,492</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yOC9mcmFnOjVjZWM5NGI5MzY4ODQyMTA5NWE3OThhZmFiNjljNDYwL3RhYmxlOjQzNDA0NmE1MTY4ODQzZDg5M2IxNTEyZjYxODkzYmU4L3RhYmxlcmFuZ2U6NDM0MDQ2YTUxNjg4NDNkODkzYjE1MTJmNjE4OTNiZThfMzYtMjEtMS0xLTIzMzU0_895f72f8-c0a9-4abb-8850-bd28b3d09beb">28,492</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Class A common stock issued for payment of earn-outs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i8a70782136dc46eb8037c247f5e1694a_D20210101-20211231" decimals="-3" name="evh:StockIssuedDuringPeriodSharesEarnOuts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yOC9mcmFnOjVjZWM5NGI5MzY4ODQyMTA5NWE3OThhZmFiNjljNDYwL3RhYmxlOjQzNDA0NmE1MTY4ODQzZDg5M2IxNTEyZjYxODkzYmU4L3RhYmxlcmFuZ2U6NDM0MDQ2YTUxNjg4NDNkODkzYjE1MTJmNjE4OTNiZThfMzctMS0xLTEtMjMzNTQ_5ec46929-da5b-4358-8386-5347329ce519">16</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8a0a16beae314535bccd01c31668c8fd_D20210101-20211231" decimals="-3" name="evh:StockIssuedDuringPeriodValueEarnOuts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yOC9mcmFnOjVjZWM5NGI5MzY4ODQyMTA5NWE3OThhZmFiNjljNDYwL3RhYmxlOjQzNDA0NmE1MTY4ODQzZDg5M2IxNTEyZjYxODkzYmU4L3RhYmxlcmFuZ2U6NDM0MDQ2YTUxNjg4NDNkODkzYjE1MTJmNjE4OTNiZThfMzctOS0xLTEtMjMzNTQ_2ee1cb17-779e-49d6-ad2e-7acac1a9fe1a">450</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5f242398851f435581586484404b0dfb_D20210101-20211231" decimals="-3" name="evh:StockIssuedDuringPeriodValueEarnOuts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yOC9mcmFnOjVjZWM5NGI5MzY4ODQyMTA5NWE3OThhZmFiNjljNDYwL3RhYmxlOjQzNDA0NmE1MTY4ODQzZDg5M2IxNTEyZjYxODkzYmU4L3RhYmxlcmFuZ2U6NDM0MDQ2YTUxNjg4NDNkODkzYjE1MTJmNjE4OTNiZThfMzctMTctMS0xLTIzMzU0_b23f9ed9-a11c-4ebe-9e68-904babe69fd2">450</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231" decimals="-3" name="evh:StockIssuedDuringPeriodValueEarnOuts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yOC9mcmFnOjVjZWM5NGI5MzY4ODQyMTA5NWE3OThhZmFiNjljNDYwL3RhYmxlOjQzNDA0NmE1MTY4ODQzZDg5M2IxNTEyZjYxODkzYmU4L3RhYmxlcmFuZ2U6NDM0MDQ2YTUxNjg4NDNkODkzYjE1MTJmNjE4OTNiZThfMzctMjEtMS0xLTIzMzU0_e9d8300a-49bb-42de-88b5-3deb098fee1a">450</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Foreign currency translation adjustment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1bcca85fbf4c425299cf11a4c6626357_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yOC9mcmFnOjVjZWM5NGI5MzY4ODQyMTA5NWE3OThhZmFiNjljNDYwL3RhYmxlOjQzNDA0NmE1MTY4ODQzZDg5M2IxNTEyZjYxODkzYmU4L3RhYmxlcmFuZ2U6NDM0MDQ2YTUxNjg4NDNkODkzYjE1MTJmNjE4OTNiZThfMzYtMTEtMS0xLTE5MzE5_30e1f232-5857-4ba3-a6ba-ae6a55728993">84</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5f242398851f435581586484404b0dfb_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yOC9mcmFnOjVjZWM5NGI5MzY4ODQyMTA5NWE3OThhZmFiNjljNDYwL3RhYmxlOjQzNDA0NmE1MTY4ODQzZDg5M2IxNTEyZjYxODkzYmU4L3RhYmxlcmFuZ2U6NDM0MDQ2YTUxNjg4NDNkODkzYjE1MTJmNjE4OTNiZThfMzYtMTctMS0xLTE5MzE5_f0c20374-90b2-4e94-89d8-4f589db4b600">84</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yOC9mcmFnOjVjZWM5NGI5MzY4ODQyMTA5NWE3OThhZmFiNjljNDYwL3RhYmxlOjQzNDA0NmE1MTY4ODQzZDg5M2IxNTEyZjYxODkzYmU4L3RhYmxlcmFuZ2U6NDM0MDQ2YTUxNjg4NDNkODkzYjE1MTJmNjE4OTNiZThfMzYtMjEtMS0xLTE5MzE5_6a4138b7-4016-4a72-861e-ede8023d9b2e">84</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i75b369d853b249f9a6495524752f5913_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yOC9mcmFnOjVjZWM5NGI5MzY4ODQyMTA5NWE3OThhZmFiNjljNDYwL3RhYmxlOjQzNDA0NmE1MTY4ODQzZDg5M2IxNTEyZjYxODkzYmU4L3RhYmxlcmFuZ2U6NDM0MDQ2YTUxNjg4NDNkODkzYjE1MTJmNjE4OTNiZThfMzctMTMtMS0xLTE5MzE5_d1914d39-5c6f-453b-977d-0b3803568b36">37,601</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5f242398851f435581586484404b0dfb_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yOC9mcmFnOjVjZWM5NGI5MzY4ODQyMTA5NWE3OThhZmFiNjljNDYwL3RhYmxlOjQzNDA0NmE1MTY4ODQzZDg5M2IxNTEyZjYxODkzYmU4L3RhYmxlcmFuZ2U6NDM0MDQ2YTUxNjg4NDNkODkzYjE1MTJmNjE4OTNiZThfMzctMTctMS0xLTE5MzE5_2c081a5d-095a-48c1-a8c7-90788af74f34">37,601</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yOC9mcmFnOjVjZWM5NGI5MzY4ODQyMTA5NWE3OThhZmFiNjljNDYwL3RhYmxlOjQzNDA0NmE1MTY4ODQzZDg5M2IxNTEyZjYxODkzYmU4L3RhYmxlcmFuZ2U6NDM0MDQ2YTUxNjg4NDNkODkzYjE1MTJmNjE4OTNiZThfMzctMjEtMS0xLTE5MzE5_74335710-25b2-4ebf-93b0-0e4945c5ef45">37,601</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance as of December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i2177056c167d473399f65b5105c9a7f2_I20211231" decimals="-3" name="us-gaap:SharesIssued" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yOC9mcmFnOjVjZWM5NGI5MzY4ODQyMTA5NWE3OThhZmFiNjljNDYwL3RhYmxlOjQzNDA0NmE1MTY4ODQzZDg5M2IxNTEyZjYxODkzYmU4L3RhYmxlcmFuZ2U6NDM0MDQ2YTUxNjg4NDNkODkzYjE1MTJmNjE4OTNiZThfMzgtMS0xLTEtMTkzMTk_f2060742-74cd-4a88-9cb0-f8a02e84cad4">90,759</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2177056c167d473399f65b5105c9a7f2_I20211231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yOC9mcmFnOjVjZWM5NGI5MzY4ODQyMTA5NWE3OThhZmFiNjljNDYwL3RhYmxlOjQzNDA0NmE1MTY4ODQzZDg5M2IxNTEyZjYxODkzYmU4L3RhYmxlcmFuZ2U6NDM0MDQ2YTUxNjg4NDNkODkzYjE1MTJmNjE4OTNiZThfMzgtMy0xLTEtMTkzMTk_a96d8026-323e-4fd4-9fc8-0b860fb3cc8f">908</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i109ffa352e8c4ce0b59170cf60e46101_I20211231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yOC9mcmFnOjVjZWM5NGI5MzY4ODQyMTA5NWE3OThhZmFiNjljNDYwL3RhYmxlOjQzNDA0NmE1MTY4ODQzZDg5M2IxNTEyZjYxODkzYmU4L3RhYmxlcmFuZ2U6NDM0MDQ2YTUxNjg4NDNkODkzYjE1MTJmNjE4OTNiZThfMzgtOS0xLTEtMTkzMTk_8a770b7d-5034-473a-98f3-ecd96f41967c">1,340,989</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7fd6de5224704d7187b37d35a519cbfa_I20211231" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yOC9mcmFnOjVjZWM5NGI5MzY4ODQyMTA5NWE3OThhZmFiNjljNDYwL3RhYmxlOjQzNDA0NmE1MTY4ODQzZDg5M2IxNTEyZjYxODkzYmU4L3RhYmxlcmFuZ2U6NDM0MDQ2YTUxNjg4NDNkODkzYjE1MTJmNjE4OTNiZThfMzgtMTEtMS0xLTE5MzE5_df7ea04d-5e41-4777-b9bc-154977b6050f">362</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i17d17fcbd53245e7981e707f61c46f1a_I20211231" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yOC9mcmFnOjVjZWM5NGI5MzY4ODQyMTA5NWE3OThhZmFiNjljNDYwL3RhYmxlOjQzNDA0NmE1MTY4ODQzZDg5M2IxNTEyZjYxODkzYmU4L3RhYmxlcmFuZ2U6NDM0MDQ2YTUxNjg4NDNkODkzYjE1MTJmNjE4OTNiZThfMzgtMTMtMS0xLTE5MzE5_cff0568c-d39f-4078-8648-04a551ffdf05">626,779</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2c95448403fa4d3b8d864ca25a132fb8_I20211231" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yOC9mcmFnOjVjZWM5NGI5MzY4ODQyMTA5NWE3OThhZmFiNjljNDYwL3RhYmxlOjQzNDA0NmE1MTY4ODQzZDg5M2IxNTEyZjYxODkzYmU4L3RhYmxlcmFuZ2U6NDM0MDQ2YTUxNjg4NDNkODkzYjE1MTJmNjE4OTNiZThfMzgtMTUtMS0xLTE5MzE5_772a06ab-88a7-498b-8b02-94d14c6b233b">21,123</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8be054225f004416b985533cd8b4d2a6_I20211231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yOC9mcmFnOjVjZWM5NGI5MzY4ODQyMTA5NWE3OThhZmFiNjljNDYwL3RhYmxlOjQzNDA0NmE1MTY4ODQzZDg5M2IxNTEyZjYxODkzYmU4L3RhYmxlcmFuZ2U6NDM0MDQ2YTUxNjg4NDNkODkzYjE1MTJmNjE4OTNiZThfMzgtMTctMS0xLTE5MzE5_61e1a331-3a75-46cc-9d81-031e61f4bc4f">693,633</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i733ca541299f4839bead39679b082534_I20211231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yOC9mcmFnOjVjZWM5NGI5MzY4ODQyMTA5NWE3OThhZmFiNjljNDYwL3RhYmxlOjQzNDA0NmE1MTY4ODQzZDg5M2IxNTEyZjYxODkzYmU4L3RhYmxlcmFuZ2U6NDM0MDQ2YTUxNjg4NDNkODkzYjE1MTJmNjE4OTNiZThfMzgtMTktMS0xLTE5MzE5_ba1c1546-e5fa-40a8-a23c-5618b862db36">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8daff60be410426d8f7bd49343c1ec0c_I20211231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yOC9mcmFnOjVjZWM5NGI5MzY4ODQyMTA5NWE3OThhZmFiNjljNDYwL3RhYmxlOjQzNDA0NmE1MTY4ODQzZDg5M2IxNTEyZjYxODkzYmU4L3RhYmxlcmFuZ2U6NDM0MDQ2YTUxNjg4NDNkODkzYjE1MTJmNjE4OTNiZThfMzgtMjEtMS0xLTE5MzE5_1066aa92-4101-4539-8063-ddaeb979b4ba">693,633</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">See accompanying Notes to Consolidated Financial Statements</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">72</span></div></div></div><div id="i9aaa2fddc97e482da5dbe37ac85ae703_34"></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EVOLENT HEALTH, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONSOLIDATED STATEMENTS OF CASH FLOWS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(in thousands)</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"></td><td style="width:326.50pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:66.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:66.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:66.25pt"></td><td style="width:1.0pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Year Ended December 31,</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash Flows Provided by (Used In) Operating Activities</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18zNC9mcmFnOjI3Y2IxNjhkZTFhNTRhNGQ5MGNkYTNlODdlZDg5N2RlL3RhYmxlOmE4OWNjMDNlN2U2MDQyMjY5NTA4MWU1MTFkYTU1MTkwL3RhYmxlcmFuZ2U6YTg5Y2MwM2U3ZTYwNDIyNjk1MDgxZTUxMWRhNTUxOTBfMy0xLTEtMS0xNzc3NQ_c49b99c2-1aef-4003-806b-11d043c6a947">37,601</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i12a6d1161de54547bd29f8efccd4c9b0_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18zNC9mcmFnOjI3Y2IxNjhkZTFhNTRhNGQ5MGNkYTNlODdlZDg5N2RlL3RhYmxlOmE4OWNjMDNlN2U2MDQyMjY5NTA4MWU1MTFkYTU1MTkwL3RhYmxlcmFuZ2U6YTg5Y2MwM2U3ZTYwNDIyNjk1MDgxZTUxMWRhNTUxOTBfMy0zLTEtMS0xNzc3NQ_059445f8-3794-4af1-abe2-9f2515cac297">334,246</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3e21049ffc224cacb8134d73c9bb5b38_D20190101-20191231" decimals="-3" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18zNC9mcmFnOjI3Y2IxNjhkZTFhNTRhNGQ5MGNkYTNlODdlZDg5N2RlL3RhYmxlOmE4OWNjMDNlN2U2MDQyMjY5NTA4MWU1MTFkYTU1MTkwL3RhYmxlcmFuZ2U6YTg5Y2MwM2U3ZTYwNDIyNjk1MDgxZTUxMWRhNTUxOTBfMy01LTEtMS0xOTUwNA_c9da1e92-d0a1-4f34-9937-22bf91507069">305,580</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:23pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjustments to reconcile net loss to net cash and restricted cash used in operating activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value of contingent consideration and indemnification asset</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18zNC9mcmFnOjI3Y2IxNjhkZTFhNTRhNGQ5MGNkYTNlODdlZDg5N2RlL3RhYmxlOmE4OWNjMDNlN2U2MDQyMjY5NTA4MWU1MTFkYTU1MTkwL3RhYmxlcmFuZ2U6YTg5Y2MwM2U3ZTYwNDIyNjk1MDgxZTUxMWRhNTUxOTBfNS0xLTEtMS0xNzc3NQ_c7998437-f8da-4c5f-aa80-cf3cf5643967">13,281</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i12a6d1161de54547bd29f8efccd4c9b0_D20200101-20201231" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18zNC9mcmFnOjI3Y2IxNjhkZTFhNTRhNGQ5MGNkYTNlODdlZDg5N2RlL3RhYmxlOmE4OWNjMDNlN2U2MDQyMjY5NTA4MWU1MTFkYTU1MTkwL3RhYmxlcmFuZ2U6YTg5Y2MwM2U3ZTYwNDIyNjk1MDgxZTUxMWRhNTUxOTBfNS0zLTEtMS0xNzc3NQ_33f80b68-1de6-4fcd-b0b0-a8b614075eb1">3,860</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3e21049ffc224cacb8134d73c9bb5b38_D20190101-20191231" decimals="-3" sign="-" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18zNC9mcmFnOjI3Y2IxNjhkZTFhNTRhNGQ5MGNkYTNlODdlZDg5N2RlL3RhYmxlOmE4OWNjMDNlN2U2MDQyMjY5NTA4MWU1MTFkYTU1MTkwL3RhYmxlcmFuZ2U6YTg5Y2MwM2U3ZTYwNDIyNjk1MDgxZTUxMWRhNTUxOTBfNS01LTEtMS0xOTUwNA_f932c57c-f9c3-4f92-9b07-2dcf30fafc2b">3,997</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Gain) loss on disposal of assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231" decimals="-3" sign="-" name="evh:GainLossOnDispositionOfAssetsOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18zNC9mcmFnOjI3Y2IxNjhkZTFhNTRhNGQ5MGNkYTNlODdlZDg5N2RlL3RhYmxlOmE4OWNjMDNlN2U2MDQyMjY5NTA4MWU1MTFkYTU1MTkwL3RhYmxlcmFuZ2U6YTg5Y2MwM2U3ZTYwNDIyNjk1MDgxZTUxMWRhNTUxOTBfNi0xLTEtMS0xNzc3NQ_cf075745-e9c5-4cf0-a8c1-49d85f9882f3">6,786</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i12a6d1161de54547bd29f8efccd4c9b0_D20200101-20201231" decimals="-3" sign="-" name="evh:GainLossOnDispositionOfAssetsOperatingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18zNC9mcmFnOjI3Y2IxNjhkZTFhNTRhNGQ5MGNkYTNlODdlZDg5N2RlL3RhYmxlOmE4OWNjMDNlN2U2MDQyMjY5NTA4MWU1MTFkYTU1MTkwL3RhYmxlcmFuZ2U6YTg5Y2MwM2U3ZTYwNDIyNjk1MDgxZTUxMWRhNTUxOTBfNi0zLTEtMS0xNzc3NQ_cf1ce36d-b295-4516-8dc2-fca35d5e3b99">698</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3e21049ffc224cacb8134d73c9bb5b38_D20190101-20191231" decimals="-3" name="evh:GainLossOnDispositionOfAssetsOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18zNC9mcmFnOjI3Y2IxNjhkZTFhNTRhNGQ5MGNkYTNlODdlZDg5N2RlL3RhYmxlOmE4OWNjMDNlN2U2MDQyMjY5NTA4MWU1MTFkYTU1MTkwL3RhYmxlcmFuZ2U6YTg5Y2MwM2U3ZTYwNDIyNjk1MDgxZTUxMWRhNTUxOTBfNi01LTEtMS0xOTUwNA_400327a2-18d9-4e26-a77f-2808d8896975">9,600</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Gain) loss from equity method investees</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231" decimals="-3" name="us-gaap:IncomeLossFromEquityMethodInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18zNC9mcmFnOjI3Y2IxNjhkZTFhNTRhNGQ5MGNkYTNlODdlZDg5N2RlL3RhYmxlOmE4OWNjMDNlN2U2MDQyMjY5NTA4MWU1MTFkYTU1MTkwL3RhYmxlcmFuZ2U6YTg5Y2MwM2U3ZTYwNDIyNjk1MDgxZTUxMWRhNTUxOTBfNy0xLTEtMS0xNzc3NQ_1e765135-12c9-4108-aa47-dd0f3a7c0981">13,179</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i12a6d1161de54547bd29f8efccd4c9b0_D20200101-20201231" decimals="-3" name="us-gaap:IncomeLossFromEquityMethodInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18zNC9mcmFnOjI3Y2IxNjhkZTFhNTRhNGQ5MGNkYTNlODdlZDg5N2RlL3RhYmxlOmE4OWNjMDNlN2U2MDQyMjY5NTA4MWU1MTFkYTU1MTkwL3RhYmxlcmFuZ2U6YTg5Y2MwM2U3ZTYwNDIyNjk1MDgxZTUxMWRhNTUxOTBfNy0zLTEtMS0xNzc3NQ_612fcbd7-e1f4-42f7-8a20-913f78fa731e">10,039</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e21049ffc224cacb8134d73c9bb5b38_D20190101-20191231" decimals="-3" sign="-" name="us-gaap:IncomeLossFromEquityMethodInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18zNC9mcmFnOjI3Y2IxNjhkZTFhNTRhNGQ5MGNkYTNlODdlZDg5N2RlL3RhYmxlOmE4OWNjMDNlN2U2MDQyMjY5NTA4MWU1MTFkYTU1MTkwL3RhYmxlcmFuZ2U6YTg5Y2MwM2U3ZTYwNDIyNjk1MDgxZTUxMWRhNTUxOTBfNy01LTEtMS0xOTUwNA_cc8c717d-0758-48ab-8feb-699ef9e8da2c">9,465</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231" decimals="-3" name="us-gaap:DepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18zNC9mcmFnOjI3Y2IxNjhkZTFhNTRhNGQ5MGNkYTNlODdlZDg5N2RlL3RhYmxlOmE4OWNjMDNlN2U2MDQyMjY5NTA4MWU1MTFkYTU1MTkwL3RhYmxlcmFuZ2U6YTg5Y2MwM2U3ZTYwNDIyNjk1MDgxZTUxMWRhNTUxOTBfOC0xLTEtMS0xNzc3NQ_1838664f-6107-4739-bd3a-6957978dc208">60,037</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i12a6d1161de54547bd29f8efccd4c9b0_D20200101-20201231" decimals="-3" name="us-gaap:DepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18zNC9mcmFnOjI3Y2IxNjhkZTFhNTRhNGQ5MGNkYTNlODdlZDg5N2RlL3RhYmxlOmE4OWNjMDNlN2U2MDQyMjY5NTA4MWU1MTFkYTU1MTkwL3RhYmxlcmFuZ2U6YTg5Y2MwM2U3ZTYwNDIyNjk1MDgxZTUxMWRhNTUxOTBfOC0zLTEtMS0xNzc3NQ_76086d71-1ab2-4754-b7a3-c5075938b0ff">61,475</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e21049ffc224cacb8134d73c9bb5b38_D20190101-20191231" decimals="-3" name="us-gaap:DepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18zNC9mcmFnOjI3Y2IxNjhkZTFhNTRhNGQ5MGNkYTNlODdlZDg5N2RlL3RhYmxlOmE4OWNjMDNlN2U2MDQyMjY5NTA4MWU1MTFkYTU1MTkwL3RhYmxlcmFuZ2U6YTg5Y2MwM2U3ZTYwNDIyNjk1MDgxZTUxMWRhNTUxOTBfOC01LTEtMS0xOTUxMQ_13ae42d3-4cd6-4264-b5db-54a2590f3bf3">60,913</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Impairment of equity method investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231" decimals="-3" name="us-gaap:EquityMethodInvestmentOtherThanTemporaryImpairment" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18zNC9mcmFnOjI3Y2IxNjhkZTFhNTRhNGQ5MGNkYTNlODdlZDg5N2RlL3RhYmxlOmE4OWNjMDNlN2U2MDQyMjY5NTA4MWU1MTFkYTU1MTkwL3RhYmxlcmFuZ2U6YTg5Y2MwM2U3ZTYwNDIyNjk1MDgxZTUxMWRhNTUxOTBfOS0xLTEtMS0xNzc3NQ_67e64a2a-f40c-409f-8bc8-de9cf08b92df">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i12a6d1161de54547bd29f8efccd4c9b0_D20200101-20201231" decimals="-3" name="us-gaap:EquityMethodInvestmentOtherThanTemporaryImpairment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18zNC9mcmFnOjI3Y2IxNjhkZTFhNTRhNGQ5MGNkYTNlODdlZDg5N2RlL3RhYmxlOmE4OWNjMDNlN2U2MDQyMjY5NTA4MWU1MTFkYTU1MTkwL3RhYmxlcmFuZ2U6YTg5Y2MwM2U3ZTYwNDIyNjk1MDgxZTUxMWRhNTUxOTBfOS0zLTEtMS0xNzc3NQ_a1ebe7e4-c0f6-41e5-9a83-36f311feac54">47,133</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e21049ffc224cacb8134d73c9bb5b38_D20190101-20191231" decimals="-3" name="us-gaap:EquityMethodInvestmentOtherThanTemporaryImpairment" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18zNC9mcmFnOjI3Y2IxNjhkZTFhNTRhNGQ5MGNkYTNlODdlZDg5N2RlL3RhYmxlOmE4OWNjMDNlN2U2MDQyMjY5NTA4MWU1MTFkYTU1MTkwL3RhYmxlcmFuZ2U6YTg5Y2MwM2U3ZTYwNDIyNjk1MDgxZTUxMWRhNTUxOTBfOS01LTEtMS0xOTUxMQ_d8c21d96-8755-48c3-85e1-3a9c57a5de14">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18zNC9mcmFnOjI3Y2IxNjhkZTFhNTRhNGQ5MGNkYTNlODdlZDg5N2RlL3RhYmxlOmE4OWNjMDNlN2U2MDQyMjY5NTA4MWU1MTFkYTU1MTkwL3RhYmxlcmFuZ2U6YTg5Y2MwM2U3ZTYwNDIyNjk1MDgxZTUxMWRhNTUxOTBfMTAtMS0xLTEtMTc3NzU_21fad1be-f4ee-4a44-b7db-7453afb1b067">16,711</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i12a6d1161de54547bd29f8efccd4c9b0_D20200101-20201231" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18zNC9mcmFnOjI3Y2IxNjhkZTFhNTRhNGQ5MGNkYTNlODdlZDg5N2RlL3RhYmxlOmE4OWNjMDNlN2U2MDQyMjY5NTA4MWU1MTFkYTU1MTkwL3RhYmxlcmFuZ2U6YTg5Y2MwM2U3ZTYwNDIyNjk1MDgxZTUxMWRhNTUxOTBfMTAtMy0xLTEtMTc3NzU_a7be215c-2f15-4733-9b4f-8cd2dbaad197">14,606</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e21049ffc224cacb8134d73c9bb5b38_D20190101-20191231" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18zNC9mcmFnOjI3Y2IxNjhkZTFhNTRhNGQ5MGNkYTNlODdlZDg5N2RlL3RhYmxlOmE4OWNjMDNlN2U2MDQyMjY5NTA4MWU1MTFkYTU1MTkwL3RhYmxlcmFuZ2U6YTg5Y2MwM2U3ZTYwNDIyNjk1MDgxZTUxMWRhNTUxOTBfMTAtNS0xLTEtMTk1MzA_deaf12dc-3b99-468d-b04c-e21155086faa">15,618</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax benefit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:DeferredIncomeTaxesAndTaxCredits" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18zNC9mcmFnOjI3Y2IxNjhkZTFhNTRhNGQ5MGNkYTNlODdlZDg5N2RlL3RhYmxlOmE4OWNjMDNlN2U2MDQyMjY5NTA4MWU1MTFkYTU1MTkwL3RhYmxlcmFuZ2U6YTg5Y2MwM2U3ZTYwNDIyNjk1MDgxZTUxMWRhNTUxOTBfMTEtMS0xLTEtMTc3NzU_c5210a4d-2ce3-48a8-accf-afd8cfab3498">526</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i12a6d1161de54547bd29f8efccd4c9b0_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:DeferredIncomeTaxesAndTaxCredits" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18zNC9mcmFnOjI3Y2IxNjhkZTFhNTRhNGQ5MGNkYTNlODdlZDg5N2RlL3RhYmxlOmE4OWNjMDNlN2U2MDQyMjY5NTA4MWU1MTFkYTU1MTkwL3RhYmxlcmFuZ2U6YTg5Y2MwM2U3ZTYwNDIyNjk1MDgxZTUxMWRhNTUxOTBfMTEtMy0xLTEtMTc3NzU_ccf6a8cb-157e-49f1-b26b-304b87199e59">1,132</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3e21049ffc224cacb8134d73c9bb5b38_D20190101-20191231" decimals="-3" sign="-" name="us-gaap:DeferredIncomeTaxesAndTaxCredits" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18zNC9mcmFnOjI3Y2IxNjhkZTFhNTRhNGQ5MGNkYTNlODdlZDg5N2RlL3RhYmxlOmE4OWNjMDNlN2U2MDQyMjY5NTA4MWU1MTFkYTU1MTkwL3RhYmxlcmFuZ2U6YTg5Y2MwM2U3ZTYwNDIyNjk1MDgxZTUxMWRhNTUxOTBfMTEtNS0xLTEtMTk1MzA_bf27282e-d186-4792-ba1b-765680c5f7c4">23,124</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of contract cost assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231" decimals="-3" name="us-gaap:CapitalizedContractCostAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18zNC9mcmFnOjI3Y2IxNjhkZTFhNTRhNGQ5MGNkYTNlODdlZDg5N2RlL3RhYmxlOmE4OWNjMDNlN2U2MDQyMjY5NTA4MWU1MTFkYTU1MTkwL3RhYmxlcmFuZ2U6YTg5Y2MwM2U3ZTYwNDIyNjk1MDgxZTUxMWRhNTUxOTBfMTItMS0xLTEtMTc3NzU_23e7d887-b201-431d-9881-da6b0eec1a84">13,041</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i12a6d1161de54547bd29f8efccd4c9b0_D20200101-20201231" decimals="-3" name="us-gaap:CapitalizedContractCostAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18zNC9mcmFnOjI3Y2IxNjhkZTFhNTRhNGQ5MGNkYTNlODdlZDg5N2RlL3RhYmxlOmE4OWNjMDNlN2U2MDQyMjY5NTA4MWU1MTFkYTU1MTkwL3RhYmxlcmFuZ2U6YTg5Y2MwM2U3ZTYwNDIyNjk1MDgxZTUxMWRhNTUxOTBfMTItMy0xLTEtMTc3NzU_92068114-9f3d-4829-848d-ebba563336cf">21,195</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e21049ffc224cacb8134d73c9bb5b38_D20190101-20191231" decimals="-3" name="us-gaap:CapitalizedContractCostAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18zNC9mcmFnOjI3Y2IxNjhkZTFhNTRhNGQ5MGNkYTNlODdlZDg5N2RlL3RhYmxlOmE4OWNjMDNlN2U2MDQyMjY5NTA4MWU1MTFkYTU1MTkwL3RhYmxlcmFuZ2U6YTg5Y2MwM2U3ZTYwNDIyNjk1MDgxZTUxMWRhNTUxOTBfMTItNS0xLTEtMTk1MzA_bd212332-47ac-4667-9303-38c08e37a2fb">5,723</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of deferred financing costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231" decimals="-3" name="us-gaap:AmortizationOfFinancingCosts" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18zNC9mcmFnOjI3Y2IxNjhkZTFhNTRhNGQ5MGNkYTNlODdlZDg5N2RlL3RhYmxlOmE4OWNjMDNlN2U2MDQyMjY5NTA4MWU1MTFkYTU1MTkwL3RhYmxlcmFuZ2U6YTg5Y2MwM2U3ZTYwNDIyNjk1MDgxZTUxMWRhNTUxOTBfMTMtMS0xLTEtMTc3NzU_7c348443-6446-494b-97c3-bfd7de0a37ef">18,045</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i12a6d1161de54547bd29f8efccd4c9b0_D20200101-20201231" decimals="-3" name="us-gaap:AmortizationOfFinancingCosts" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18zNC9mcmFnOjI3Y2IxNjhkZTFhNTRhNGQ5MGNkYTNlODdlZDg5N2RlL3RhYmxlOmE4OWNjMDNlN2U2MDQyMjY5NTA4MWU1MTFkYTU1MTkwL3RhYmxlcmFuZ2U6YTg5Y2MwM2U3ZTYwNDIyNjk1MDgxZTUxMWRhNTUxOTBfMTMtMy0xLTEtMTc3NzU_ba49e390-17fa-4127-9ce7-d76d74bfe9c6">14,780</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e21049ffc224cacb8134d73c9bb5b38_D20190101-20191231" decimals="-3" name="us-gaap:AmortizationOfFinancingCosts" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18zNC9mcmFnOjI3Y2IxNjhkZTFhNTRhNGQ5MGNkYTNlODdlZDg5N2RlL3RhYmxlOmE4OWNjMDNlN2U2MDQyMjY5NTA4MWU1MTFkYTU1MTkwL3RhYmxlcmFuZ2U6YTg5Y2MwM2U3ZTYwNDIyNjk1MDgxZTUxMWRhNTUxOTBfMTMtNS0xLTEtMTk1MzA_e26a880e-6481-4579-b231-bc10f1f1f901">9,370</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest from customer advance for regulatory capital requirements</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231" decimals="-3" name="evh:PaidinKindInterestIncome" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18zNC9mcmFnOjI3Y2IxNjhkZTFhNTRhNGQ5MGNkYTNlODdlZDg5N2RlL3RhYmxlOmE4OWNjMDNlN2U2MDQyMjY5NTA4MWU1MTFkYTU1MTkwL3RhYmxlcmFuZ2U6YTg5Y2MwM2U3ZTYwNDIyNjk1MDgxZTUxMWRhNTUxOTBfMTQtMS0xLTEtMTc3NzU_2ca21444-a365-46da-a777-1f0cea566c47">323</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i12a6d1161de54547bd29f8efccd4c9b0_D20200101-20201231" decimals="-3" name="evh:PaidinKindInterestIncome" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18zNC9mcmFnOjI3Y2IxNjhkZTFhNTRhNGQ5MGNkYTNlODdlZDg5N2RlL3RhYmxlOmE4OWNjMDNlN2U2MDQyMjY5NTA4MWU1MTFkYTU1MTkwL3RhYmxlcmFuZ2U6YTg5Y2MwM2U3ZTYwNDIyNjk1MDgxZTUxMWRhNTUxOTBfMTQtMy0xLTEtMTc3NzU_2edf0e77-71ff-4c62-855d-c10909cd5a6d">1,869</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3e21049ffc224cacb8134d73c9bb5b38_D20190101-20191231" decimals="-3" name="evh:PaidinKindInterestIncome" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18zNC9mcmFnOjI3Y2IxNjhkZTFhNTRhNGQ5MGNkYTNlODdlZDg5N2RlL3RhYmxlOmE4OWNjMDNlN2U2MDQyMjY5NTA4MWU1MTFkYTU1MTkwL3RhYmxlcmFuZ2U6YTg5Y2MwM2U3ZTYwNDIyNjk1MDgxZTUxMWRhNTUxOTBfMTQtNS0xLTEtMTk1Mzk_0a214c28-1e2c-4d51-b7fe-b56521e95683">1,300</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain on transfer of membership</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231" decimals="-3" name="evh:GainOnTransferOfMembership" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18zNC9mcmFnOjI3Y2IxNjhkZTFhNTRhNGQ5MGNkYTNlODdlZDg5N2RlL3RhYmxlOmE4OWNjMDNlN2U2MDQyMjY5NTA4MWU1MTFkYTU1MTkwL3RhYmxlcmFuZ2U6YTg5Y2MwM2U3ZTYwNDIyNjk1MDgxZTUxMWRhNTUxOTBfMTUtMS0xLTEtMTc3NzU_bd5cd449-fe6d-441c-b953-4fc4e48800fd">45,938</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i12a6d1161de54547bd29f8efccd4c9b0_D20200101-20201231" decimals="-3" name="evh:GainOnTransferOfMembership" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18zNC9mcmFnOjI3Y2IxNjhkZTFhNTRhNGQ5MGNkYTNlODdlZDg5N2RlL3RhYmxlOmE4OWNjMDNlN2U2MDQyMjY5NTA4MWU1MTFkYTU1MTkwL3RhYmxlcmFuZ2U6YTg5Y2MwM2U3ZTYwNDIyNjk1MDgxZTUxMWRhNTUxOTBfMTUtMy0xLTEtMTc3NzU_6a0406af-60ed-4d96-a54d-f687412571d4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e21049ffc224cacb8134d73c9bb5b38_D20190101-20191231" decimals="-3" name="evh:GainOnTransferOfMembership" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18zNC9mcmFnOjI3Y2IxNjhkZTFhNTRhNGQ5MGNkYTNlODdlZDg5N2RlL3RhYmxlOmE4OWNjMDNlN2U2MDQyMjY5NTA4MWU1MTFkYTU1MTkwL3RhYmxlcmFuZ2U6YTg5Y2MwM2U3ZTYwNDIyNjk1MDgxZTUxMWRhNTUxOTBfMTUtNS0xLTEtMTk1NDY_741ee6cd-a268-41f3-94d4-b95a29941e32">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill impairment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231" decimals="-3" name="us-gaap:GoodwillImpairmentLoss" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18zNC9mcmFnOjI3Y2IxNjhkZTFhNTRhNGQ5MGNkYTNlODdlZDg5N2RlL3RhYmxlOmE4OWNjMDNlN2U2MDQyMjY5NTA4MWU1MTFkYTU1MTkwL3RhYmxlcmFuZ2U6YTg5Y2MwM2U3ZTYwNDIyNjk1MDgxZTUxMWRhNTUxOTBfMTYtMS0xLTEtMTc3NzU_e21e10cc-b7e5-4f69-adea-ab6a3dddeec0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i12a6d1161de54547bd29f8efccd4c9b0_D20200101-20201231" decimals="-3" name="us-gaap:GoodwillImpairmentLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18zNC9mcmFnOjI3Y2IxNjhkZTFhNTRhNGQ5MGNkYTNlODdlZDg5N2RlL3RhYmxlOmE4OWNjMDNlN2U2MDQyMjY5NTA4MWU1MTFkYTU1MTkwL3RhYmxlcmFuZ2U6YTg5Y2MwM2U3ZTYwNDIyNjk1MDgxZTUxMWRhNTUxOTBfMTYtMy0xLTEtMTc3NzU_fb8d3561-41d9-4fcf-9f1c-50f257cae9cb">215,100</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e21049ffc224cacb8134d73c9bb5b38_D20190101-20191231" decimals="-3" name="us-gaap:GoodwillImpairmentLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18zNC9mcmFnOjI3Y2IxNjhkZTFhNTRhNGQ5MGNkYTNlODdlZDg5N2RlL3RhYmxlOmE4OWNjMDNlN2U2MDQyMjY5NTA4MWU1MTFkYTU1MTkwL3RhYmxlcmFuZ2U6YTg5Y2MwM2U3ZTYwNDIyNjk1MDgxZTUxMWRhNTUxOTBfMTYtNS0xLTEtMTk1NTM_74f1d035-de96-4370-88a3-b039d2cc8a8c">199,800</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss on repayment of debt</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231" decimals="-3" sign="-" name="evh:GainLossOnRepaymentOfDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18zNC9mcmFnOjI3Y2IxNjhkZTFhNTRhNGQ5MGNkYTNlODdlZDg5N2RlL3RhYmxlOmE4OWNjMDNlN2U2MDQyMjY5NTA4MWU1MTFkYTU1MTkwL3RhYmxlcmFuZ2U6YTg5Y2MwM2U3ZTYwNDIyNjk1MDgxZTUxMWRhNTUxOTBfMTctMS0xLTEtMTc3NzU_e47c17f3-b24c-4425-b0d9-6f68fbc218d8">21,343</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i12a6d1161de54547bd29f8efccd4c9b0_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18zNC9mcmFnOjI3Y2IxNjhkZTFhNTRhNGQ5MGNkYTNlODdlZDg5N2RlL3RhYmxlOmE4OWNjMDNlN2U2MDQyMjY5NTA4MWU1MTFkYTU1MTkwL3RhYmxlcmFuZ2U6YTg5Y2MwM2U3ZTYwNDIyNjk1MDgxZTUxMWRhNTUxOTBfMTctMy0xLTEtMTc3NzU_7e625875-fc60-4f0b-bae1-c38161fa4b1f">4,789</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e21049ffc224cacb8134d73c9bb5b38_D20190101-20191231" decimals="-3" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18zNC9mcmFnOjI3Y2IxNjhkZTFhNTRhNGQ5MGNkYTNlODdlZDg5N2RlL3RhYmxlOmE4OWNjMDNlN2U2MDQyMjY5NTA4MWU1MTFkYTU1MTkwL3RhYmxlcmFuZ2U6YTg5Y2MwM2U3ZTYwNDIyNjk1MDgxZTUxMWRhNTUxOTBfMTctNS0xLTEtMTk1NTg_358996c7-16a3-479f-9de3-fd8450690449">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current operating cash inflows (outflows), net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:OtherNoncashIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18zNC9mcmFnOjI3Y2IxNjhkZTFhNTRhNGQ5MGNkYTNlODdlZDg5N2RlL3RhYmxlOmE4OWNjMDNlN2U2MDQyMjY5NTA4MWU1MTFkYTU1MTkwL3RhYmxlcmFuZ2U6YTg5Y2MwM2U3ZTYwNDIyNjk1MDgxZTUxMWRhNTUxOTBfMTgtMS0xLTEtMTc3NzU_2b1f6b93-5e50-4499-a2c4-1314a3e5f31b">715</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i12a6d1161de54547bd29f8efccd4c9b0_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:OtherNoncashIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18zNC9mcmFnOjI3Y2IxNjhkZTFhNTRhNGQ5MGNkYTNlODdlZDg5N2RlL3RhYmxlOmE4OWNjMDNlN2U2MDQyMjY5NTA4MWU1MTFkYTU1MTkwL3RhYmxlcmFuZ2U6YTg5Y2MwM2U3ZTYwNDIyNjk1MDgxZTUxMWRhNTUxOTBfMTgtMy0xLTEtMTc3NzU_aaa59f77-dee1-4a91-9182-25a107630b45">2,744</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3e21049ffc224cacb8134d73c9bb5b38_D20190101-20191231" decimals="-3" name="us-gaap:OtherNoncashIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18zNC9mcmFnOjI3Y2IxNjhkZTFhNTRhNGQ5MGNkYTNlODdlZDg5N2RlL3RhYmxlOmE4OWNjMDNlN2U2MDQyMjY5NTA4MWU1MTFkYTU1MTkwL3RhYmxlcmFuZ2U6YTg5Y2MwM2U3ZTYwNDIyNjk1MDgxZTUxMWRhNTUxOTBfMTgtNS0xLTEtMTk1NjU_d61c7c11-fb86-4995-a2a6-ef9d045810a6">264</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Changes in assets and liabilities, net of acquisitions:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable, net and contract assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231" decimals="-3" name="evh:IncreaseDecreaseInAccountsReceivableAndContractWithCustomerAsset" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18zNC9mcmFnOjI3Y2IxNjhkZTFhNTRhNGQ5MGNkYTNlODdlZDg5N2RlL3RhYmxlOmE4OWNjMDNlN2U2MDQyMjY5NTA4MWU1MTFkYTU1MTkwL3RhYmxlcmFuZ2U6YTg5Y2MwM2U3ZTYwNDIyNjk1MDgxZTUxMWRhNTUxOTBfMjAtMS0xLTEtMTc3NzU_3f03d1eb-d749-460d-a942-ecb63553ffd4">5,779</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i12a6d1161de54547bd29f8efccd4c9b0_D20200101-20201231" decimals="-3" name="evh:IncreaseDecreaseInAccountsReceivableAndContractWithCustomerAsset" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18zNC9mcmFnOjI3Y2IxNjhkZTFhNTRhNGQ5MGNkYTNlODdlZDg5N2RlL3RhYmxlOmE4OWNjMDNlN2U2MDQyMjY5NTA4MWU1MTFkYTU1MTkwL3RhYmxlcmFuZ2U6YTg5Y2MwM2U3ZTYwNDIyNjk1MDgxZTUxMWRhNTUxOTBfMjAtMy0xLTEtMTc3NzU_0a460cf3-2c31-4a03-8aac-c945728e0942">47,017</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e21049ffc224cacb8134d73c9bb5b38_D20190101-20191231" decimals="-3" sign="-" name="evh:IncreaseDecreaseInAccountsReceivableAndContractWithCustomerAsset" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18zNC9mcmFnOjI3Y2IxNjhkZTFhNTRhNGQ5MGNkYTNlODdlZDg5N2RlL3RhYmxlOmE4OWNjMDNlN2U2MDQyMjY5NTA4MWU1MTFkYTU1MTkwL3RhYmxlcmFuZ2U6YTg5Y2MwM2U3ZTYwNDIyNjk1MDgxZTUxMWRhNTUxOTBfMjAtNS0xLTEtMTk1NzI_0afe8dd3-32c9-4172-b19c-61a83ea98122">6,326</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current and non-current assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18zNC9mcmFnOjI3Y2IxNjhkZTFhNTRhNGQ5MGNkYTNlODdlZDg5N2RlL3RhYmxlOmE4OWNjMDNlN2U2MDQyMjY5NTA4MWU1MTFkYTU1MTkwL3RhYmxlcmFuZ2U6YTg5Y2MwM2U3ZTYwNDIyNjk1MDgxZTUxMWRhNTUxOTBfMjEtMS0xLTEtMTc3NzU_54c913f3-965c-46e5-a007-4de80972af02">5,599</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i12a6d1161de54547bd29f8efccd4c9b0_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18zNC9mcmFnOjI3Y2IxNjhkZTFhNTRhNGQ5MGNkYTNlODdlZDg5N2RlL3RhYmxlOmE4OWNjMDNlN2U2MDQyMjY5NTA4MWU1MTFkYTU1MTkwL3RhYmxlcmFuZ2U6YTg5Y2MwM2U3ZTYwNDIyNjk1MDgxZTUxMWRhNTUxOTBfMjEtMy0xLTEtMTc3NzU_e7ec1856-e0bc-4029-aeb4-4608c2f5d0bb">7,340</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e21049ffc224cacb8134d73c9bb5b38_D20190101-20191231" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18zNC9mcmFnOjI3Y2IxNjhkZTFhNTRhNGQ5MGNkYTNlODdlZDg5N2RlL3RhYmxlOmE4OWNjMDNlN2U2MDQyMjY5NTA4MWU1MTFkYTU1MTkwL3RhYmxlcmFuZ2U6YTg5Y2MwM2U3ZTYwNDIyNjk1MDgxZTUxMWRhNTUxOTBfMjEtNS0xLTEtMTk1NzI_9b27e22b-2a2e-436f-b45d-dcb9988ae5f4">791</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contract cost assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231" decimals="-3" name="evh:IncreaseDecreaseInCapitalizedContractCostNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18zNC9mcmFnOjI3Y2IxNjhkZTFhNTRhNGQ5MGNkYTNlODdlZDg5N2RlL3RhYmxlOmE4OWNjMDNlN2U2MDQyMjY5NTA4MWU1MTFkYTU1MTkwL3RhYmxlcmFuZ2U6YTg5Y2MwM2U3ZTYwNDIyNjk1MDgxZTUxMWRhNTUxOTBfMjItMS0xLTEtMTc3NzU_38d7d599-15f5-4e38-a6cd-6c91ea1a9e2c">18,979</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i12a6d1161de54547bd29f8efccd4c9b0_D20200101-20201231" decimals="-3" name="evh:IncreaseDecreaseInCapitalizedContractCostNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18zNC9mcmFnOjI3Y2IxNjhkZTFhNTRhNGQ5MGNkYTNlODdlZDg5N2RlL3RhYmxlOmE4OWNjMDNlN2U2MDQyMjY5NTA4MWU1MTFkYTU1MTkwL3RhYmxlcmFuZ2U6YTg5Y2MwM2U3ZTYwNDIyNjk1MDgxZTUxMWRhNTUxOTBfMjItMy0xLTEtMTc3NzU_5dd74f33-3484-4267-961e-ce05795915ca">11,400</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3e21049ffc224cacb8134d73c9bb5b38_D20190101-20191231" decimals="-3" name="evh:IncreaseDecreaseInCapitalizedContractCostNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18zNC9mcmFnOjI3Y2IxNjhkZTFhNTRhNGQ5MGNkYTNlODdlZDg5N2RlL3RhYmxlOmE4OWNjMDNlN2U2MDQyMjY5NTA4MWU1MTFkYTU1MTkwL3RhYmxlcmFuZ2U6YTg5Y2MwM2U3ZTYwNDIyNjk1MDgxZTUxMWRhNTUxOTBfMjItNS0xLTEtMTk1NzI_a22e0534-0af1-4b78-9cfe-80b0a7ae7291">23,057</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsPayable" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18zNC9mcmFnOjI3Y2IxNjhkZTFhNTRhNGQ5MGNkYTNlODdlZDg5N2RlL3RhYmxlOmE4OWNjMDNlN2U2MDQyMjY5NTA4MWU1MTFkYTU1MTkwL3RhYmxlcmFuZ2U6YTg5Y2MwM2U3ZTYwNDIyNjk1MDgxZTUxMWRhNTUxOTBfMjMtMS0xLTEtMTc3NzU_2d23c40d-20c4-4396-85b5-5848d1ff55d1">7,250</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i12a6d1161de54547bd29f8efccd4c9b0_D20200101-20201231" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsPayable" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18zNC9mcmFnOjI3Y2IxNjhkZTFhNTRhNGQ5MGNkYTNlODdlZDg5N2RlL3RhYmxlOmE4OWNjMDNlN2U2MDQyMjY5NTA4MWU1MTFkYTU1MTkwL3RhYmxlcmFuZ2U6YTg5Y2MwM2U3ZTYwNDIyNjk1MDgxZTUxMWRhNTUxOTBfMjMtMy0xLTEtMTc3NzU_46459d7c-3c46-43b5-8262-ef6668e71fd0">3,547</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3e21049ffc224cacb8134d73c9bb5b38_D20190101-20191231" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccountsPayable" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18zNC9mcmFnOjI3Y2IxNjhkZTFhNTRhNGQ5MGNkYTNlODdlZDg5N2RlL3RhYmxlOmE4OWNjMDNlN2U2MDQyMjY5NTA4MWU1MTFkYTU1MTkwL3RhYmxlcmFuZ2U6YTg5Y2MwM2U3ZTYwNDIyNjk1MDgxZTUxMWRhNTUxOTBfMjMtNS0xLTEtMTk1Nzk_b9638903-6fae-4ba4-9fce-1c6c72165b2c">5,480</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18zNC9mcmFnOjI3Y2IxNjhkZTFhNTRhNGQ5MGNkYTNlODdlZDg5N2RlL3RhYmxlOmE4OWNjMDNlN2U2MDQyMjY5NTA4MWU1MTFkYTU1MTkwL3RhYmxlcmFuZ2U6YTg5Y2MwM2U3ZTYwNDIyNjk1MDgxZTUxMWRhNTUxOTBfMjQtMS0xLTEtMTc3NzU_62cbab05-3415-42fd-bccd-c9ee532fa075">324</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i12a6d1161de54547bd29f8efccd4c9b0_D20200101-20201231" decimals="-3" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18zNC9mcmFnOjI3Y2IxNjhkZTFhNTRhNGQ5MGNkYTNlODdlZDg5N2RlL3RhYmxlOmE4OWNjMDNlN2U2MDQyMjY5NTA4MWU1MTFkYTU1MTkwL3RhYmxlcmFuZ2U6YTg5Y2MwM2U3ZTYwNDIyNjk1MDgxZTUxMWRhNTUxOTBfMjQtMy0xLTEtMTc3NzU_8b4d9e0b-2a8e-4d41-bbea-9c29b1ac98db">8,801</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3e21049ffc224cacb8134d73c9bb5b38_D20190101-20191231" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18zNC9mcmFnOjI3Y2IxNjhkZTFhNTRhNGQ5MGNkYTNlODdlZDg5N2RlL3RhYmxlOmE4OWNjMDNlN2U2MDQyMjY5NTA4MWU1MTFkYTU1MTkwL3RhYmxlcmFuZ2U6YTg5Y2MwM2U3ZTYwNDIyNjk1MDgxZTUxMWRhNTUxOTBfMjQtNS0xLTEtMTk1Nzk_d6c8b7c3-69c2-41b6-be62-987f5ca5b4aa">21,852</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued compensation and employee benefits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231" decimals="-3" name="us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18zNC9mcmFnOjI3Y2IxNjhkZTFhNTRhNGQ5MGNkYTNlODdlZDg5N2RlL3RhYmxlOmE4OWNjMDNlN2U2MDQyMjY5NTA4MWU1MTFkYTU1MTkwL3RhYmxlcmFuZ2U6YTg5Y2MwM2U3ZTYwNDIyNjk1MDgxZTUxMWRhNTUxOTBfMjUtMS0xLTEtMTc3NzU_47ceb3b0-7c10-4455-aa95-37d6315b032a">3,538</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i12a6d1161de54547bd29f8efccd4c9b0_D20200101-20201231" decimals="-3" name="us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18zNC9mcmFnOjI3Y2IxNjhkZTFhNTRhNGQ5MGNkYTNlODdlZDg5N2RlL3RhYmxlOmE4OWNjMDNlN2U2MDQyMjY5NTA4MWU1MTFkYTU1MTkwL3RhYmxlcmFuZ2U6YTg5Y2MwM2U3ZTYwNDIyNjk1MDgxZTUxMWRhNTUxOTBfMjUtMy0xLTEtMTc3NzU_12b5d259-432c-48ae-a42f-a47b3a2327c0">11,143</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e21049ffc224cacb8134d73c9bb5b38_D20190101-20191231" decimals="-3" name="us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18zNC9mcmFnOjI3Y2IxNjhkZTFhNTRhNGQ5MGNkYTNlODdlZDg5N2RlL3RhYmxlOmE4OWNjMDNlN2U2MDQyMjY5NTA4MWU1MTFkYTU1MTkwL3RhYmxlcmFuZ2U6YTg5Y2MwM2U3ZTYwNDIyNjk1MDgxZTUxMWRhNTUxOTBfMjUtNS0xLTEtMTk1Nzk_d6206bf9-777c-4ec7-875b-ff2de95decd3">9,246</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18zNC9mcmFnOjI3Y2IxNjhkZTFhNTRhNGQ5MGNkYTNlODdlZDg5N2RlL3RhYmxlOmE4OWNjMDNlN2U2MDQyMjY5NTA4MWU1MTFkYTU1MTkwL3RhYmxlcmFuZ2U6YTg5Y2MwM2U3ZTYwNDIyNjk1MDgxZTUxMWRhNTUxOTBfMjYtMS0xLTEtMTc3NzU_ba67d881-c63d-48e6-b8fa-0d41eac8f948">739</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i12a6d1161de54547bd29f8efccd4c9b0_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18zNC9mcmFnOjI3Y2IxNjhkZTFhNTRhNGQ5MGNkYTNlODdlZDg5N2RlL3RhYmxlOmE4OWNjMDNlN2U2MDQyMjY5NTA4MWU1MTFkYTU1MTkwL3RhYmxlcmFuZ2U6YTg5Y2MwM2U3ZTYwNDIyNjk1MDgxZTUxMWRhNTUxOTBfMjYtMy0xLTEtMTc3NzU_07a71f91-f149-45dc-b640-1a6435681d2b">8,943</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3e21049ffc224cacb8134d73c9bb5b38_D20190101-20191231" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18zNC9mcmFnOjI3Y2IxNjhkZTFhNTRhNGQ5MGNkYTNlODdlZDg5N2RlL3RhYmxlOmE4OWNjMDNlN2U2MDQyMjY5NTA4MWU1MTFkYTU1MTkwL3RhYmxlcmFuZ2U6YTg5Y2MwM2U3ZTYwNDIyNjk1MDgxZTUxMWRhNTUxOTBfMjYtNS0xLTEtMTk1ODY_b0f2e60b-806a-4726-a746-3325c424448d">756</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reserve for claims and performance-based arrangements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231" decimals="-3" sign="-" name="evh:IncreaseDecreaseInInsuranceAndPerformanceBasedArrangementsLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18zNC9mcmFnOjI3Y2IxNjhkZTFhNTRhNGQ5MGNkYTNlODdlZDg5N2RlL3RhYmxlOmE4OWNjMDNlN2U2MDQyMjY5NTA4MWU1MTFkYTU1MTkwL3RhYmxlcmFuZ2U6YTg5Y2MwM2U3ZTYwNDIyNjk1MDgxZTUxMWRhNTUxOTBfMjctMS0xLTEtMTc3NzU_9b31b02d-4674-4256-9a68-dc5c5c74bf6b">3,799</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i12a6d1161de54547bd29f8efccd4c9b0_D20200101-20201231" decimals="-3" sign="-" name="evh:IncreaseDecreaseInInsuranceAndPerformanceBasedArrangementsLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18zNC9mcmFnOjI3Y2IxNjhkZTFhNTRhNGQ5MGNkYTNlODdlZDg5N2RlL3RhYmxlOmE4OWNjMDNlN2U2MDQyMjY5NTA4MWU1MTFkYTU1MTkwL3RhYmxlcmFuZ2U6YTg5Y2MwM2U3ZTYwNDIyNjk1MDgxZTUxMWRhNTUxOTBfMjctMy0xLTEtMTc3NzU_d7ffca92-a61c-48e5-93ed-47325ffc5447">36,108</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e21049ffc224cacb8134d73c9bb5b38_D20190101-20191231" decimals="-3" name="evh:IncreaseDecreaseInInsuranceAndPerformanceBasedArrangementsLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18zNC9mcmFnOjI3Y2IxNjhkZTFhNTRhNGQ5MGNkYTNlODdlZDg5N2RlL3RhYmxlOmE4OWNjMDNlN2U2MDQyMjY5NTA4MWU1MTFkYTU1MTkwL3RhYmxlcmFuZ2U6YTg5Y2MwM2U3ZTYwNDIyNjk1MDgxZTUxMWRhNTUxOTBfMjctNS0xLTEtMTk1ODY_a9260591-b637-41d0-bbee-1f42849ad250">33,555</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use operating assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231" decimals="-3" sign="-" name="evh:IncreaseDecreaseInOperatingLeaseRightofUseAsset" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18zNC9mcmFnOjI3Y2IxNjhkZTFhNTRhNGQ5MGNkYTNlODdlZDg5N2RlL3RhYmxlOmE4OWNjMDNlN2U2MDQyMjY5NTA4MWU1MTFkYTU1MTkwL3RhYmxlcmFuZ2U6YTg5Y2MwM2U3ZTYwNDIyNjk1MDgxZTUxMWRhNTUxOTBfMjgtMS0xLTEtMTc3NzU_ea0c3354-f7ca-4575-b29c-ff18014c6bb8">8,844</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i12a6d1161de54547bd29f8efccd4c9b0_D20200101-20201231" decimals="-3" sign="-" name="evh:IncreaseDecreaseInOperatingLeaseRightofUseAsset" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18zNC9mcmFnOjI3Y2IxNjhkZTFhNTRhNGQ5MGNkYTNlODdlZDg5N2RlL3RhYmxlOmE4OWNjMDNlN2U2MDQyMjY5NTA4MWU1MTFkYTU1MTkwL3RhYmxlcmFuZ2U6YTg5Y2MwM2U3ZTYwNDIyNjk1MDgxZTUxMWRhNTUxOTBfMjgtMy0xLTEtMTc3NzU_3a7559ee-7c21-4472-911b-6a271ee9d640">11,934</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3e21049ffc224cacb8134d73c9bb5b38_D20190101-20191231" decimals="-3" name="evh:IncreaseDecreaseInOperatingLeaseRightofUseAsset" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18zNC9mcmFnOjI3Y2IxNjhkZTFhNTRhNGQ5MGNkYTNlODdlZDg5N2RlL3RhYmxlOmE4OWNjMDNlN2U2MDQyMjY5NTA4MWU1MTFkYTU1MTkwL3RhYmxlcmFuZ2U6YTg5Y2MwM2U3ZTYwNDIyNjk1MDgxZTUxMWRhNTUxOTBfMjgtNS0xLTEtMTk1ODY_b69a0177-7b6a-41cd-9751-36cb5477e915">20,811</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18zNC9mcmFnOjI3Y2IxNjhkZTFhNTRhNGQ5MGNkYTNlODdlZDg5N2RlL3RhYmxlOmE4OWNjMDNlN2U2MDQyMjY5NTA4MWU1MTFkYTU1MTkwL3RhYmxlcmFuZ2U6YTg5Y2MwM2U3ZTYwNDIyNjk1MDgxZTUxMWRhNTUxOTBfMjktMS0xLTEtMTc3NzU_29906912-17bf-45de-ad62-dc153091d8bf">6,522</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i12a6d1161de54547bd29f8efccd4c9b0_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18zNC9mcmFnOjI3Y2IxNjhkZTFhNTRhNGQ5MGNkYTNlODdlZDg5N2RlL3RhYmxlOmE4OWNjMDNlN2U2MDQyMjY5NTA4MWU1MTFkYTU1MTkwL3RhYmxlcmFuZ2U6YTg5Y2MwM2U3ZTYwNDIyNjk1MDgxZTUxMWRhNTUxOTBfMjktMy0xLTEtMTc3NzU_870c762a-29d5-4eff-8659-6a43366c72fa">2,782</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e21049ffc224cacb8134d73c9bb5b38_D20190101-20191231" decimals="-3" name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18zNC9mcmFnOjI3Y2IxNjhkZTFhNTRhNGQ5MGNkYTNlODdlZDg5N2RlL3RhYmxlOmE4OWNjMDNlN2U2MDQyMjY5NTA4MWU1MTFkYTU1MTkwL3RhYmxlcmFuZ2U6YTg5Y2MwM2U3ZTYwNDIyNjk1MDgxZTUxMWRhNTUxOTBfMjktNS0xLTEtMTk1ODY_c1bf7f56-b69c-49c3-bfa5-8fa72db0112a">27,724</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other long-term liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18zNC9mcmFnOjI3Y2IxNjhkZTFhNTRhNGQ5MGNkYTNlODdlZDg5N2RlL3RhYmxlOmE4OWNjMDNlN2U2MDQyMjY5NTA4MWU1MTFkYTU1MTkwL3RhYmxlcmFuZ2U6YTg5Y2MwM2U3ZTYwNDIyNjk1MDgxZTUxMWRhNTUxOTBfMzAtMS0xLTEtMTc3NzU_61ed1312-dea9-441e-8fe3-adfe5551da18">2,734</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i12a6d1161de54547bd29f8efccd4c9b0_D20200101-20201231" decimals="-3" name="us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18zNC9mcmFnOjI3Y2IxNjhkZTFhNTRhNGQ5MGNkYTNlODdlZDg5N2RlL3RhYmxlOmE4OWNjMDNlN2U2MDQyMjY5NTA4MWU1MTFkYTU1MTkwL3RhYmxlcmFuZ2U6YTg5Y2MwM2U3ZTYwNDIyNjk1MDgxZTUxMWRhNTUxOTBfMzAtMy0xLTEtMTc3NzU_38b4cf34-6148-40d2-bbc7-0890327956e8">8,166</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3e21049ffc224cacb8134d73c9bb5b38_D20190101-20191231" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18zNC9mcmFnOjI3Y2IxNjhkZTFhNTRhNGQ5MGNkYTNlODdlZDg5N2RlL3RhYmxlOmE4OWNjMDNlN2U2MDQyMjY5NTA4MWU1MTFkYTU1MTkwL3RhYmxlcmFuZ2U6YTg5Y2MwM2U3ZTYwNDIyNjk1MDgxZTUxMWRhNTUxOTBfMzAtNS0xLTEtMTk1ODY_773b919b-9762-462b-b785-a85992c55558">5,355</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash and restricted cash provided by (used in) operating activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231" decimals="-3" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18zNC9mcmFnOjI3Y2IxNjhkZTFhNTRhNGQ5MGNkYTNlODdlZDg5N2RlL3RhYmxlOmE4OWNjMDNlN2U2MDQyMjY5NTA4MWU1MTFkYTU1MTkwL3RhYmxlcmFuZ2U6YTg5Y2MwM2U3ZTYwNDIyNjk1MDgxZTUxMWRhNTUxOTBfMzEtMS0xLTEtMTc3NzU_cc93b6f8-da1d-4ce4-a903-c454433c831b">38,747</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i12a6d1161de54547bd29f8efccd4c9b0_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18zNC9mcmFnOjI3Y2IxNjhkZTFhNTRhNGQ5MGNkYTNlODdlZDg5N2RlL3RhYmxlOmE4OWNjMDNlN2U2MDQyMjY5NTA4MWU1MTFkYTU1MTkwL3RhYmxlcmFuZ2U6YTg5Y2MwM2U3ZTYwNDIyNjk1MDgxZTUxMWRhNTUxOTBfMzEtMy0xLTEtMTc3NzU_62702cbd-3beb-4879-b893-a7468f3f80b7">16,225</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3e21049ffc224cacb8134d73c9bb5b38_D20190101-20191231" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18zNC9mcmFnOjI3Y2IxNjhkZTFhNTRhNGQ5MGNkYTNlODdlZDg5N2RlL3RhYmxlOmE4OWNjMDNlN2U2MDQyMjY5NTA4MWU1MTFkYTU1MTkwL3RhYmxlcmFuZ2U6YTg5Y2MwM2U3ZTYwNDIyNjk1MDgxZTUxMWRhNTUxOTBfMzEtNS0xLTEtMTk1ODY_f0798002-74b1-4795-9f3b-988b476791a0">42,645</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash Flows Provided by (Used In) Investing Activities</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid for asset acquisitions and business combinations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231" decimals="-3" name="us-gaap:PaymentsToAcquireBusinessesGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18zNC9mcmFnOjI3Y2IxNjhkZTFhNTRhNGQ5MGNkYTNlODdlZDg5N2RlL3RhYmxlOmE4OWNjMDNlN2U2MDQyMjY5NTA4MWU1MTFkYTU1MTkwL3RhYmxlcmFuZ2U6YTg5Y2MwM2U3ZTYwNDIyNjk1MDgxZTUxMWRhNTUxOTBfMzMtMS0xLTEtMTc3NzU_bec21ee8-37b2-4cd2-b9b2-a8a32e25a2a0">49,012</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i12a6d1161de54547bd29f8efccd4c9b0_D20200101-20201231" decimals="-3" name="us-gaap:PaymentsToAcquireBusinessesGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18zNC9mcmFnOjI3Y2IxNjhkZTFhNTRhNGQ5MGNkYTNlODdlZDg5N2RlL3RhYmxlOmE4OWNjMDNlN2U2MDQyMjY5NTA4MWU1MTFkYTU1MTkwL3RhYmxlcmFuZ2U6YTg5Y2MwM2U3ZTYwNDIyNjk1MDgxZTUxMWRhNTUxOTBfMzMtMy0xLTEtMTc3NzU_77c6e1e3-0eb6-48eb-8381-43982ed8d293">300</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3e21049ffc224cacb8134d73c9bb5b38_D20190101-20191231" decimals="-3" name="us-gaap:PaymentsToAcquireBusinessesGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18zNC9mcmFnOjI3Y2IxNjhkZTFhNTRhNGQ5MGNkYTNlODdlZDg5N2RlL3RhYmxlOmE4OWNjMDNlN2U2MDQyMjY5NTA4MWU1MTFkYTU1MTkwL3RhYmxlcmFuZ2U6YTg5Y2MwM2U3ZTYwNDIyNjk1MDgxZTUxMWRhNTUxOTBfMzMtNS0xLTEtMTk1OTU_9cf224e6-28e4-4bd2-a780-2c4f338632f7">8,575</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from transfer of membership and release of Passport escrow</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231" decimals="-3" name="us-gaap:ProceedsFromDivestitureOfInterestInSubsidiariesAndAffiliates" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18zNC9mcmFnOjI3Y2IxNjhkZTFhNTRhNGQ5MGNkYTNlODdlZDg5N2RlL3RhYmxlOmE4OWNjMDNlN2U2MDQyMjY5NTA4MWU1MTFkYTU1MTkwL3RhYmxlcmFuZ2U6YTg5Y2MwM2U3ZTYwNDIyNjk1MDgxZTUxMWRhNTUxOTBfMzQtMS0xLTEtMTc3NzU_c0d72b8c-b580-48d6-815b-a06fbbe466c4">42,996</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i12a6d1161de54547bd29f8efccd4c9b0_D20200101-20201231" decimals="-3" name="us-gaap:ProceedsFromDivestitureOfInterestInSubsidiariesAndAffiliates" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18zNC9mcmFnOjI3Y2IxNjhkZTFhNTRhNGQ5MGNkYTNlODdlZDg5N2RlL3RhYmxlOmE4OWNjMDNlN2U2MDQyMjY5NTA4MWU1MTFkYTU1MTkwL3RhYmxlcmFuZ2U6YTg5Y2MwM2U3ZTYwNDIyNjk1MDgxZTUxMWRhNTUxOTBfMzQtMy0xLTEtMTc3NzU_b691db35-3a7e-4237-9d6c-09c22ba97f8b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e21049ffc224cacb8134d73c9bb5b38_D20190101-20191231" decimals="-3" name="us-gaap:ProceedsFromDivestitureOfInterestInSubsidiariesAndAffiliates" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18zNC9mcmFnOjI3Y2IxNjhkZTFhNTRhNGQ5MGNkYTNlODdlZDg5N2RlL3RhYmxlOmE4OWNjMDNlN2U2MDQyMjY5NTA4MWU1MTFkYTU1MTkwL3RhYmxlcmFuZ2U6YTg5Y2MwM2U3ZTYwNDIyNjk1MDgxZTUxMWRhNTUxOTBfMzQtNS0xLTEtMTk2MTg_aeeecebc-6855-49af-a128-453f9e01e822">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loan for implementation funding</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231" decimals="-3" name="us-gaap:PaymentsForProceedsFromLoansReceivable" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18zNC9mcmFnOjI3Y2IxNjhkZTFhNTRhNGQ5MGNkYTNlODdlZDg5N2RlL3RhYmxlOmE4OWNjMDNlN2U2MDQyMjY5NTA4MWU1MTFkYTU1MTkwL3RhYmxlcmFuZ2U6YTg5Y2MwM2U3ZTYwNDIyNjk1MDgxZTUxMWRhNTUxOTBfMzUtMS0xLTEtMTc3NzU_16e08adb-2fc7-401c-a324-207ccb46cfcc">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i12a6d1161de54547bd29f8efccd4c9b0_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:PaymentsForProceedsFromLoansReceivable" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18zNC9mcmFnOjI3Y2IxNjhkZTFhNTRhNGQ5MGNkYTNlODdlZDg5N2RlL3RhYmxlOmE4OWNjMDNlN2U2MDQyMjY5NTA4MWU1MTFkYTU1MTkwL3RhYmxlcmFuZ2U6YTg5Y2MwM2U3ZTYwNDIyNjk1MDgxZTUxMWRhNTUxOTBfMzUtMy0xLTEtMTc3NzU_b99c0ff1-b19a-425e-8af5-3cf374708984">1,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e21049ffc224cacb8134d73c9bb5b38_D20190101-20191231" decimals="-3" sign="-" name="us-gaap:PaymentsForProceedsFromLoansReceivable" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18zNC9mcmFnOjI3Y2IxNjhkZTFhNTRhNGQ5MGNkYTNlODdlZDg5N2RlL3RhYmxlOmE4OWNjMDNlN2U2MDQyMjY5NTA4MWU1MTFkYTU1MTkwL3RhYmxlcmFuZ2U6YTg5Y2MwM2U3ZTYwNDIyNjk1MDgxZTUxMWRhNTUxOTBfMzUtNS0xLTEtMTk2MjU_2556bc4c-14d5-45fd-9840-80e93b397a84">5,400</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Disposal of non-strategic assets and divestiture of discontinued operations, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231" decimals="-3" sign="-" name="evh:PaymentsForProceedsFromDisposalOfNonStrategicAssetsAndDivestitureOfDiscontinuedOperationsNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18zNC9mcmFnOjI3Y2IxNjhkZTFhNTRhNGQ5MGNkYTNlODdlZDg5N2RlL3RhYmxlOmE4OWNjMDNlN2U2MDQyMjY5NTA4MWU1MTFkYTU1MTkwL3RhYmxlcmFuZ2U6YTg5Y2MwM2U3ZTYwNDIyNjk1MDgxZTUxMWRhNTUxOTBfMzYtMS0xLTEtMTc3NzU_d98f11a0-f147-47a2-82f9-f6a8ff10d11f">3,490</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i12a6d1161de54547bd29f8efccd4c9b0_D20200101-20201231" decimals="-3" name="evh:PaymentsForProceedsFromDisposalOfNonStrategicAssetsAndDivestitureOfDiscontinuedOperationsNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18zNC9mcmFnOjI3Y2IxNjhkZTFhNTRhNGQ5MGNkYTNlODdlZDg5N2RlL3RhYmxlOmE4OWNjMDNlN2U2MDQyMjY5NTA4MWU1MTFkYTU1MTkwL3RhYmxlcmFuZ2U6YTg5Y2MwM2U3ZTYwNDIyNjk1MDgxZTUxMWRhNTUxOTBfMzYtMy0xLTEtMTc3NzU_4308a274-b602-492b-b580-447d4fe8fcee">2,287</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e21049ffc224cacb8134d73c9bb5b38_D20190101-20191231" decimals="-3" name="evh:PaymentsForProceedsFromDisposalOfNonStrategicAssetsAndDivestitureOfDiscontinuedOperationsNet" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18zNC9mcmFnOjI3Y2IxNjhkZTFhNTRhNGQ5MGNkYTNlODdlZDg5N2RlL3RhYmxlOmE4OWNjMDNlN2U2MDQyMjY5NTA4MWU1MTFkYTU1MTkwL3RhYmxlcmFuZ2U6YTg5Y2MwM2U3ZTYwNDIyNjk1MDgxZTUxMWRhNTUxOTBfMzYtNS0xLTEtMTk2MzM_0b4d6453-0828-4c8d-9eb4-caeb54143ef4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Return of equity method investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231" decimals="-3" name="us-gaap:ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18zNC9mcmFnOjI3Y2IxNjhkZTFhNTRhNGQ5MGNkYTNlODdlZDg5N2RlL3RhYmxlOmE4OWNjMDNlN2U2MDQyMjY5NTA4MWU1MTFkYTU1MTkwL3RhYmxlcmFuZ2U6YTg5Y2MwM2U3ZTYwNDIyNjk1MDgxZTUxMWRhNTUxOTBfMzctMS0xLTEtMTc3NzU_045e0655-3492-407c-9bf2-296604d02c7b">14,218</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i12a6d1161de54547bd29f8efccd4c9b0_D20200101-20201231" decimals="-3" name="us-gaap:ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18zNC9mcmFnOjI3Y2IxNjhkZTFhNTRhNGQ5MGNkYTNlODdlZDg5N2RlL3RhYmxlOmE4OWNjMDNlN2U2MDQyMjY5NTA4MWU1MTFkYTU1MTkwL3RhYmxlcmFuZ2U6YTg5Y2MwM2U3ZTYwNDIyNjk1MDgxZTUxMWRhNTUxOTBfMzctMy0xLTEtMTc3NzU_41d90fd4-e9f6-4f27-9505-1a5072eba29e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e21049ffc224cacb8134d73c9bb5b38_D20190101-20191231" decimals="-3" name="us-gaap:ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18zNC9mcmFnOjI3Y2IxNjhkZTFhNTRhNGQ5MGNkYTNlODdlZDg5N2RlL3RhYmxlOmE4OWNjMDNlN2U2MDQyMjY5NTA4MWU1MTFkYTU1MTkwL3RhYmxlcmFuZ2U6YTg5Y2MwM2U3ZTYwNDIyNjk1MDgxZTUxMWRhNTUxOTBfMzctNS0xLTEtMTk2NDA_530af99a-40cf-4226-a420-c5ed24138cc4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer advance for regulatory capital requirements</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231" decimals="-3" name="evh:PaymentsForCustomerAdvanceForRegulatoryCapitalRequirements" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18zNC9mcmFnOjI3Y2IxNjhkZTFhNTRhNGQ5MGNkYTNlODdlZDg5N2RlL3RhYmxlOmE4OWNjMDNlN2U2MDQyMjY5NTA4MWU1MTFkYTU1MTkwL3RhYmxlcmFuZ2U6YTg5Y2MwM2U3ZTYwNDIyNjk1MDgxZTUxMWRhNTUxOTBfMzgtMS0xLTEtMTk3MzM_2bb6edf6-63c5-42f5-aae3-012444441523">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i12a6d1161de54547bd29f8efccd4c9b0_D20200101-20201231" decimals="-3" name="evh:PaymentsForCustomerAdvanceForRegulatoryCapitalRequirements" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18zNC9mcmFnOjI3Y2IxNjhkZTFhNTRhNGQ5MGNkYTNlODdlZDg5N2RlL3RhYmxlOmE4OWNjMDNlN2U2MDQyMjY5NTA4MWU1MTFkYTU1MTkwL3RhYmxlcmFuZ2U6YTg5Y2MwM2U3ZTYwNDIyNjk1MDgxZTUxMWRhNTUxOTBfMzgtMy0xLTEtMTk3MzM_b19f24e1-e830-4fa3-bbf4-ae96ec91279c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3e21049ffc224cacb8134d73c9bb5b38_D20190101-20191231" decimals="-3" name="evh:PaymentsForCustomerAdvanceForRegulatoryCapitalRequirements" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18zNC9mcmFnOjI3Y2IxNjhkZTFhNTRhNGQ5MGNkYTNlODdlZDg5N2RlL3RhYmxlOmE4OWNjMDNlN2U2MDQyMjY5NTA4MWU1MTFkYTU1MTkwL3RhYmxlcmFuZ2U6YTg5Y2MwM2U3ZTYwNDIyNjk1MDgxZTUxMWRhNTUxOTBfMzgtNS0xLTEtMTk3MzM_46947d28-6a5d-4359-8397-3b67d2b7e354">46,400</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investments in equity method investees</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231" decimals="-3" name="us-gaap:PaymentsToAcquireInterestInSubsidiariesAndAffiliates" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18zNC9mcmFnOjI3Y2IxNjhkZTFhNTRhNGQ5MGNkYTNlODdlZDg5N2RlL3RhYmxlOmE4OWNjMDNlN2U2MDQyMjY5NTA4MWU1MTFkYTU1MTkwL3RhYmxlcmFuZ2U6YTg5Y2MwM2U3ZTYwNDIyNjk1MDgxZTUxMWRhNTUxOTBfMzktMS0xLTEtMTk3NDI_c121b317-0c36-40d2-bdaf-08d5d56e8872">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i12a6d1161de54547bd29f8efccd4c9b0_D20200101-20201231" decimals="-3" name="us-gaap:PaymentsToAcquireInterestInSubsidiariesAndAffiliates" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18zNC9mcmFnOjI3Y2IxNjhkZTFhNTRhNGQ5MGNkYTNlODdlZDg5N2RlL3RhYmxlOmE4OWNjMDNlN2U2MDQyMjY5NTA4MWU1MTFkYTU1MTkwL3RhYmxlcmFuZ2U6YTg5Y2MwM2U3ZTYwNDIyNjk1MDgxZTUxMWRhNTUxOTBfMzktMy0xLTEtMTk3NDI_445881b6-a01b-4ffa-af12-ed354d18ff2f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3e21049ffc224cacb8134d73c9bb5b38_D20190101-20191231" decimals="-3" name="us-gaap:PaymentsToAcquireInterestInSubsidiariesAndAffiliates" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18zNC9mcmFnOjI3Y2IxNjhkZTFhNTRhNGQ5MGNkYTNlODdlZDg5N2RlL3RhYmxlOmE4OWNjMDNlN2U2MDQyMjY5NTA4MWU1MTFkYTU1MTkwL3RhYmxlcmFuZ2U6YTg5Y2MwM2U3ZTYwNDIyNjk1MDgxZTUxMWRhNTUxOTBfMzktNS0xLTEtMTk3NDI_ec1c8995-fc70-4874-bbc7-351c073f008a">87,480</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:23pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Impact to cash and cash equivalents and restricted cash from initial consolidation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231" decimals="-3" name="us-gaap:CashAcquiredFromAcquisition" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18zNC9mcmFnOjI3Y2IxNjhkZTFhNTRhNGQ5MGNkYTNlODdlZDg5N2RlL3RhYmxlOmE4OWNjMDNlN2U2MDQyMjY5NTA4MWU1MTFkYTU1MTkwL3RhYmxlcmFuZ2U6YTg5Y2MwM2U3ZTYwNDIyNjk1MDgxZTUxMWRhNTUxOTBfMzgtMS0xLTEtMTc3NzU_dcbc266e-6ae0-4b86-9241-86ea2b3d336c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i12a6d1161de54547bd29f8efccd4c9b0_D20200101-20201231" decimals="-3" name="us-gaap:CashAcquiredFromAcquisition" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18zNC9mcmFnOjI3Y2IxNjhkZTFhNTRhNGQ5MGNkYTNlODdlZDg5N2RlL3RhYmxlOmE4OWNjMDNlN2U2MDQyMjY5NTA4MWU1MTFkYTU1MTkwL3RhYmxlcmFuZ2U6YTg5Y2MwM2U3ZTYwNDIyNjk1MDgxZTUxMWRhNTUxOTBfMzgtMy0xLTEtMTc3NzU_5cc122a0-56e7-4556-a411-f71feccd3889">159,755</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e21049ffc224cacb8134d73c9bb5b38_D20190101-20191231" decimals="-3" name="us-gaap:CashAcquiredFromAcquisition" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18zNC9mcmFnOjI3Y2IxNjhkZTFhNTRhNGQ5MGNkYTNlODdlZDg5N2RlL3RhYmxlOmE4OWNjMDNlN2U2MDQyMjY5NTA4MWU1MTFkYTU1MTkwL3RhYmxlcmFuZ2U6YTg5Y2MwM2U3ZTYwNDIyNjk1MDgxZTUxMWRhNTUxOTBfMzgtNS0xLTEtMTk2NDc_d93b67cd-fb8c-45a2-a85e-9157f34c0d94">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchases of investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231" decimals="-3" name="us-gaap:PaymentsToAcquireHeldToMaturitySecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18zNC9mcmFnOjI3Y2IxNjhkZTFhNTRhNGQ5MGNkYTNlODdlZDg5N2RlL3RhYmxlOmE4OWNjMDNlN2U2MDQyMjY5NTA4MWU1MTFkYTU1MTkwL3RhYmxlcmFuZ2U6YTg5Y2MwM2U3ZTYwNDIyNjk1MDgxZTUxMWRhNTUxOTBfMzktMS0xLTEtMTc3NzU_b1884f30-d681-4e48-9074-9f30d1d48ff6">2,995</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i12a6d1161de54547bd29f8efccd4c9b0_D20200101-20201231" decimals="-3" name="us-gaap:PaymentsToAcquireHeldToMaturitySecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18zNC9mcmFnOjI3Y2IxNjhkZTFhNTRhNGQ5MGNkYTNlODdlZDg5N2RlL3RhYmxlOmE4OWNjMDNlN2U2MDQyMjY5NTA4MWU1MTFkYTU1MTkwL3RhYmxlcmFuZ2U6YTg5Y2MwM2U3ZTYwNDIyNjk1MDgxZTUxMWRhNTUxOTBfMzktMy0xLTEtMTc3NzU_7b188519-ea00-4d7d-af29-54831c09cc9d">11,170</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3e21049ffc224cacb8134d73c9bb5b38_D20190101-20191231" decimals="-3" name="us-gaap:PaymentsToAcquireHeldToMaturitySecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18zNC9mcmFnOjI3Y2IxNjhkZTFhNTRhNGQ5MGNkYTNlODdlZDg5N2RlL3RhYmxlOmE4OWNjMDNlN2U2MDQyMjY5NTA4MWU1MTFkYTU1MTkwL3RhYmxlcmFuZ2U6YTg5Y2MwM2U3ZTYwNDIyNjk1MDgxZTUxMWRhNTUxOTBfMzktNS0xLTEtMTk2NTQ_375a6cd8-c7a4-4ab0-94fc-7c4221932a7f">11,125</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Maturities and sales of investments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231" decimals="-3" name="evh:ProceedsFromMaturityOfInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18zNC9mcmFnOjI3Y2IxNjhkZTFhNTRhNGQ5MGNkYTNlODdlZDg5N2RlL3RhYmxlOmE4OWNjMDNlN2U2MDQyMjY5NTA4MWU1MTFkYTU1MTkwL3RhYmxlcmFuZ2U6YTg5Y2MwM2U3ZTYwNDIyNjk1MDgxZTUxMWRhNTUxOTBfNDAtMS0xLTEtMTc3NzU_59e1b907-efed-41ef-a731-a3c1ca766d70">500</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i12a6d1161de54547bd29f8efccd4c9b0_D20200101-20201231" decimals="-3" name="evh:ProceedsFromMaturityOfInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18zNC9mcmFnOjI3Y2IxNjhkZTFhNTRhNGQ5MGNkYTNlODdlZDg5N2RlL3RhYmxlOmE4OWNjMDNlN2U2MDQyMjY5NTA4MWU1MTFkYTU1MTkwL3RhYmxlcmFuZ2U6YTg5Y2MwM2U3ZTYwNDIyNjk1MDgxZTUxMWRhNTUxOTBfNDAtMy0xLTEtMTc3NzU_b3c637c8-409f-4c46-8d35-81aad55c489e">143,441</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e21049ffc224cacb8134d73c9bb5b38_D20190101-20191231" decimals="-3" name="evh:ProceedsFromMaturityOfInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18zNC9mcmFnOjI3Y2IxNjhkZTFhNTRhNGQ5MGNkYTNlODdlZDg5N2RlL3RhYmxlOmE4OWNjMDNlN2U2MDQyMjY5NTA4MWU1MTFkYTU1MTkwL3RhYmxlcmFuZ2U6YTg5Y2MwM2U3ZTYwNDIyNjk1MDgxZTUxMWRhNTUxOTBfNDAtNS0xLTEtMTk2NTQ_6dea82b2-87de-40ed-9240-de4f70cbea16">2,575</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investments in internal-use software and purchases of property and equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231" decimals="-3" name="us-gaap:PaymentsToAcquireOtherProductiveAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18zNC9mcmFnOjI3Y2IxNjhkZTFhNTRhNGQ5MGNkYTNlODdlZDg5N2RlL3RhYmxlOmE4OWNjMDNlN2U2MDQyMjY5NTA4MWU1MTFkYTU1MTkwL3RhYmxlcmFuZ2U6YTg5Y2MwM2U3ZTYwNDIyNjk1MDgxZTUxMWRhNTUxOTBfNDEtMS0xLTEtMTc3NzU_a5b98bcc-f28d-463d-9d49-ccf97b774d10">24,983</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i12a6d1161de54547bd29f8efccd4c9b0_D20200101-20201231" decimals="-3" name="us-gaap:PaymentsToAcquireOtherProductiveAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18zNC9mcmFnOjI3Y2IxNjhkZTFhNTRhNGQ5MGNkYTNlODdlZDg5N2RlL3RhYmxlOmE4OWNjMDNlN2U2MDQyMjY5NTA4MWU1MTFkYTU1MTkwL3RhYmxlcmFuZ2U6YTg5Y2MwM2U3ZTYwNDIyNjk1MDgxZTUxMWRhNTUxOTBfNDEtMy0xLTEtMTc3NzU_1f51ba99-872b-4a78-8e7a-f9ba2b717de9">29,473</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3e21049ffc224cacb8134d73c9bb5b38_D20190101-20191231" decimals="-3" name="us-gaap:PaymentsToAcquireOtherProductiveAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18zNC9mcmFnOjI3Y2IxNjhkZTFhNTRhNGQ5MGNkYTNlODdlZDg5N2RlL3RhYmxlOmE4OWNjMDNlN2U2MDQyMjY5NTA4MWU1MTFkYTU1MTkwL3RhYmxlcmFuZ2U6YTg5Y2MwM2U3ZTYwNDIyNjk1MDgxZTUxMWRhNTUxOTBfNDEtNS0xLTEtMTk2MDk_80ce6bc9-1261-4904-a110-e7d14dc424b0">35,534</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other investing activities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231" decimals="-3" name="us-gaap:PaymentsForProceedsFromOtherInvestingActivities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18zNC9mcmFnOjI3Y2IxNjhkZTFhNTRhNGQ5MGNkYTNlODdlZDg5N2RlL3RhYmxlOmE4OWNjMDNlN2U2MDQyMjY5NTA4MWU1MTFkYTU1MTkwL3RhYmxlcmFuZ2U6YTg5Y2MwM2U3ZTYwNDIyNjk1MDgxZTUxMWRhNTUxOTBfNDItMS0xLTEtMTc3NzU_7bef6996-8ff9-4021-a1fc-c4bdfbb5cabb">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i12a6d1161de54547bd29f8efccd4c9b0_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:PaymentsForProceedsFromOtherInvestingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18zNC9mcmFnOjI3Y2IxNjhkZTFhNTRhNGQ5MGNkYTNlODdlZDg5N2RlL3RhYmxlOmE4OWNjMDNlN2U2MDQyMjY5NTA4MWU1MTFkYTU1MTkwL3RhYmxlcmFuZ2U6YTg5Y2MwM2U3ZTYwNDIyNjk1MDgxZTUxMWRhNTUxOTBfNDItMy0xLTEtMTc3NzU_bea70a93-b391-4b02-9fff-594cb57aeeec">106</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3e21049ffc224cacb8134d73c9bb5b38_D20190101-20191231" decimals="-3" name="us-gaap:PaymentsForProceedsFromOtherInvestingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18zNC9mcmFnOjI3Y2IxNjhkZTFhNTRhNGQ5MGNkYTNlODdlZDg5N2RlL3RhYmxlOmE4OWNjMDNlN2U2MDQyMjY5NTA4MWU1MTFkYTU1MTkwL3RhYmxlcmFuZ2U6YTg5Y2MwM2U3ZTYwNDIyNjk1MDgxZTUxMWRhNTUxOTBfNDItNS0xLTEtMTk2MDk_cab917c4-8936-4df8-aa9f-6f980ab435b9">495</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash and restricted cash (used in) provided by investing activities</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18zNC9mcmFnOjI3Y2IxNjhkZTFhNTRhNGQ5MGNkYTNlODdlZDg5N2RlL3RhYmxlOmE4OWNjMDNlN2U2MDQyMjY5NTA4MWU1MTFkYTU1MTkwL3RhYmxlcmFuZ2U6YTg5Y2MwM2U3ZTYwNDIyNjk1MDgxZTUxMWRhNTUxOTBfNDMtMS0xLTEtMTc3NzU_10dcb15e-7b1c-49b3-96f5-78c72394e607">15,786</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i12a6d1161de54547bd29f8efccd4c9b0_D20200101-20201231" decimals="-3" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18zNC9mcmFnOjI3Y2IxNjhkZTFhNTRhNGQ5MGNkYTNlODdlZDg5N2RlL3RhYmxlOmE4OWNjMDNlN2U2MDQyMjY5NTA4MWU1MTFkYTU1MTkwL3RhYmxlcmFuZ2U6YTg5Y2MwM2U3ZTYwNDIyNjk1MDgxZTUxMWRhNTUxOTBfNDMtMy0xLTEtMTc3NzU_9d7b55a4-6a9c-4513-be03-7188d6fa3757">261,072</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3e21049ffc224cacb8134d73c9bb5b38_D20190101-20191231" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18zNC9mcmFnOjI3Y2IxNjhkZTFhNTRhNGQ5MGNkYTNlODdlZDg5N2RlL3RhYmxlOmE4OWNjMDNlN2U2MDQyMjY5NTA4MWU1MTFkYTU1MTkwL3RhYmxlcmFuZ2U6YTg5Y2MwM2U3ZTYwNDIyNjk1MDgxZTUxMWRhNTUxOTBfNDMtNS0xLTEtMTk2MDI_9c1a19e9-72d2-4904-b3a0-a29e6954c284">181,634</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">See accompanying Notes to Consolidated Financial Statements</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">73</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"></td><td style="width:326.50pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:66.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:66.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:66.25pt"></td><td style="width:1.0pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Year Ended December 31,</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash Flows Used In Financing Activities</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr style="height:23pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Changes in working capital balances related to claims processing on behalf of partners</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231" decimals="-3" sign="-" name="evh:PaymentsForProceedsFromClaimsProcessingFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18zNC9mcmFnOjI3Y2IxNjhkZTFhNTRhNGQ5MGNkYTNlODdlZDg5N2RlL3RhYmxlOmE4OWNjMDNlN2U2MDQyMjY5NTA4MWU1MTFkYTU1MTkwL3RhYmxlcmFuZ2U6YTg5Y2MwM2U3ZTYwNDIyNjk1MDgxZTUxMWRhNTUxOTBfNDUtMS0xLTEtMTc3NzU_f21672d0-12d2-4348-85ff-60769531ee29">61,162</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i12a6d1161de54547bd29f8efccd4c9b0_D20200101-20201231" decimals="-3" name="evh:PaymentsForProceedsFromClaimsProcessingFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18zNC9mcmFnOjI3Y2IxNjhkZTFhNTRhNGQ5MGNkYTNlODdlZDg5N2RlL3RhYmxlOmE4OWNjMDNlN2U2MDQyMjY5NTA4MWU1MTFkYTU1MTkwL3RhYmxlcmFuZ2U6YTg5Y2MwM2U3ZTYwNDIyNjk1MDgxZTUxMWRhNTUxOTBfNDUtMy0xLTEtMTc3NzU_efce9c15-e85b-4970-b6f2-4fd8b29edae6">6,044</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3e21049ffc224cacb8134d73c9bb5b38_D20190101-20191231" decimals="-3" name="evh:PaymentsForProceedsFromClaimsProcessingFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18zNC9mcmFnOjI3Y2IxNjhkZTFhNTRhNGQ5MGNkYTNlODdlZDg5N2RlL3RhYmxlOmE4OWNjMDNlN2U2MDQyMjY5NTA4MWU1MTFkYTU1MTkwL3RhYmxlcmFuZ2U6YTg5Y2MwM2U3ZTYwNDIyNjk1MDgxZTUxMWRhNTUxOTBfNDUtNS0xLTEtMTk2NjE_22b96416-ee33-4ce6-b881-956c824dd2a9">104,268</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amount received from escrow in asset acquisition</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231" decimals="-3" name="evh:ProceedsFromAssetAcquisitionEscrow" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18zNC9mcmFnOjI3Y2IxNjhkZTFhNTRhNGQ5MGNkYTNlODdlZDg5N2RlL3RhYmxlOmE4OWNjMDNlN2U2MDQyMjY5NTA4MWU1MTFkYTU1MTkwL3RhYmxlcmFuZ2U6YTg5Y2MwM2U3ZTYwNDIyNjk1MDgxZTUxMWRhNTUxOTBfNDgtMS0xLTEtMTk3NjQ_e396c866-a9e9-46a7-977f-abca37418a4e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i12a6d1161de54547bd29f8efccd4c9b0_D20200101-20201231" decimals="-3" name="evh:ProceedsFromAssetAcquisitionEscrow" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18zNC9mcmFnOjI3Y2IxNjhkZTFhNTRhNGQ5MGNkYTNlODdlZDg5N2RlL3RhYmxlOmE4OWNjMDNlN2U2MDQyMjY5NTA4MWU1MTFkYTU1MTkwL3RhYmxlcmFuZ2U6YTg5Y2MwM2U3ZTYwNDIyNjk1MDgxZTUxMWRhNTUxOTBfNDgtMy0xLTEtMTk3NjQ_4693581c-340c-4e12-bb4b-3151fc5c8253">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e21049ffc224cacb8134d73c9bb5b38_D20190101-20191231" decimals="-3" name="evh:ProceedsFromAssetAcquisitionEscrow" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18zNC9mcmFnOjI3Y2IxNjhkZTFhNTRhNGQ5MGNkYTNlODdlZDg5N2RlL3RhYmxlOmE4OWNjMDNlN2U2MDQyMjY5NTA4MWU1MTFkYTU1MTkwL3RhYmxlcmFuZ2U6YTg5Y2MwM2U3ZTYwNDIyNjk1MDgxZTUxMWRhNTUxOTBfNDgtNS0xLTEtMTk3NjQ_4976dc79-2ec7-4763-9c32-06d1f991e0eb">500</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:23pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Repayment and termination of Credit Agreement including settlement of warrants</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231" decimals="-3" name="us-gaap:PaymentsOfDebtExtinguishmentCosts" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18zNC9mcmFnOjI3Y2IxNjhkZTFhNTRhNGQ5MGNkYTNlODdlZDg5N2RlL3RhYmxlOmE4OWNjMDNlN2U2MDQyMjY5NTA4MWU1MTFkYTU1MTkwL3RhYmxlcmFuZ2U6YTg5Y2MwM2U3ZTYwNDIyNjk1MDgxZTUxMWRhNTUxOTBfNDYtMS0xLTEtMTc3NzU_e10a4dea-c689-4d4c-836e-dfec5a79b22d">98,420</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i12a6d1161de54547bd29f8efccd4c9b0_D20200101-20201231" decimals="-3" name="us-gaap:PaymentsOfDebtExtinguishmentCosts" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18zNC9mcmFnOjI3Y2IxNjhkZTFhNTRhNGQ5MGNkYTNlODdlZDg5N2RlL3RhYmxlOmE4OWNjMDNlN2U2MDQyMjY5NTA4MWU1MTFkYTU1MTkwL3RhYmxlcmFuZ2U6YTg5Y2MwM2U3ZTYwNDIyNjk1MDgxZTUxMWRhNTUxOTBfNDYtMy0xLTEtMTc3NzU_9219efdc-5555-4c52-9d27-08d8d2d8034e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e21049ffc224cacb8134d73c9bb5b38_D20190101-20191231" decimals="-3" name="us-gaap:PaymentsOfDebtExtinguishmentCosts" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18zNC9mcmFnOjI3Y2IxNjhkZTFhNTRhNGQ5MGNkYTNlODdlZDg5N2RlL3RhYmxlOmE4OWNjMDNlN2U2MDQyMjY5NTA4MWU1MTFkYTU1MTkwL3RhYmxlcmFuZ2U6YTg5Y2MwM2U3ZTYwNDIyNjk1MDgxZTUxMWRhNTUxOTBfNDYtNS0xLTEtMTk2Nzg_d7d9c023-d548-4a13-aea6-94d797d7652b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from issuance of long term debt, net of offering costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231" decimals="-3" name="us-gaap:ProceedsFromConvertibleDebt" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18zNC9mcmFnOjI3Y2IxNjhkZTFhNTRhNGQ5MGNkYTNlODdlZDg5N2RlL3RhYmxlOmE4OWNjMDNlN2U2MDQyMjY5NTA4MWU1MTFkYTU1MTkwL3RhYmxlcmFuZ2U6YTg5Y2MwM2U3ZTYwNDIyNjk1MDgxZTUxMWRhNTUxOTBfNDctMS0xLTEtMTc3NzU_d7835603-64d3-44c1-8635-b5709a624dd9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i12a6d1161de54547bd29f8efccd4c9b0_D20200101-20201231" decimals="-3" name="us-gaap:ProceedsFromConvertibleDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18zNC9mcmFnOjI3Y2IxNjhkZTFhNTRhNGQ5MGNkYTNlODdlZDg5N2RlL3RhYmxlOmE4OWNjMDNlN2U2MDQyMjY5NTA4MWU1MTFkYTU1MTkwL3RhYmxlcmFuZ2U6YTg5Y2MwM2U3ZTYwNDIyNjk1MDgxZTUxMWRhNTUxOTBfNDctMy0xLTEtMTc3NzU_a3599f55-8a1f-4a19-b4ed-c260dc42d73c">30,062</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e21049ffc224cacb8134d73c9bb5b38_D20190101-20191231" decimals="-3" name="us-gaap:ProceedsFromConvertibleDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18zNC9mcmFnOjI3Y2IxNjhkZTFhNTRhNGQ5MGNkYTNlODdlZDg5N2RlL3RhYmxlOmE4OWNjMDNlN2U2MDQyMjY5NTA4MWU1MTFkYTU1MTkwL3RhYmxlcmFuZ2U6YTg5Y2MwM2U3ZTYwNDIyNjk1MDgxZTUxMWRhNTUxOTBfNDctNS0xLTEtMTk2OTU_a5302128-a26f-43ae-bdd8-9a1e0bb595fb">62,648</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issuance of warrant liability</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231" decimals="-3" name="us-gaap:ProceedsFromHedgeFinancingActivities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18zNC9mcmFnOjI3Y2IxNjhkZTFhNTRhNGQ5MGNkYTNlODdlZDg5N2RlL3RhYmxlOmE4OWNjMDNlN2U2MDQyMjY5NTA4MWU1MTFkYTU1MTkwL3RhYmxlcmFuZ2U6YTg5Y2MwM2U3ZTYwNDIyNjk1MDgxZTUxMWRhNTUxOTBfNTAtMS0xLTEtMTk3NTE_db8549ca-e6b8-4c4d-aa24-bae475f8616b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i12a6d1161de54547bd29f8efccd4c9b0_D20200101-20201231" decimals="-3" name="us-gaap:ProceedsFromHedgeFinancingActivities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18zNC9mcmFnOjI3Y2IxNjhkZTFhNTRhNGQ5MGNkYTNlODdlZDg5N2RlL3RhYmxlOmE4OWNjMDNlN2U2MDQyMjY5NTA4MWU1MTFkYTU1MTkwL3RhYmxlcmFuZ2U6YTg5Y2MwM2U3ZTYwNDIyNjk1MDgxZTUxMWRhNTUxOTBfNTAtMy0xLTEtMTk3NTE_aa19a600-b9b7-48ee-ae03-2ce676a835a5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e21049ffc224cacb8134d73c9bb5b38_D20190101-20191231" decimals="-3" name="us-gaap:ProceedsFromHedgeFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18zNC9mcmFnOjI3Y2IxNjhkZTFhNTRhNGQ5MGNkYTNlODdlZDg5N2RlL3RhYmxlOmE4OWNjMDNlN2U2MDQyMjY5NTA4MWU1MTFkYTU1MTkwL3RhYmxlcmFuZ2U6YTg5Y2MwM2U3ZTYwNDIyNjk1MDgxZTUxMWRhNTUxOTBfNTAtNS0xLTEtMTk3NTE_19c9b1af-95b5-4842-9c65-82ec16c88f24">7,092</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Repayment and repurchase of 2021 Notes and financing fees</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231" decimals="-3" name="us-gaap:RepaymentsOfSeniorDebt" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18zNC9mcmFnOjI3Y2IxNjhkZTFhNTRhNGQ5MGNkYTNlODdlZDg5N2RlL3RhYmxlOmE4OWNjMDNlN2U2MDQyMjY5NTA4MWU1MTFkYTU1MTkwL3RhYmxlcmFuZ2U6YTg5Y2MwM2U3ZTYwNDIyNjk1MDgxZTUxMWRhNTUxOTBfNDgtMS0xLTEtMTc3NzU_b39db2d6-46e7-43ef-b1a9-01057464eebe">429</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i12a6d1161de54547bd29f8efccd4c9b0_D20200101-20201231" decimals="-3" name="us-gaap:RepaymentsOfSeniorDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18zNC9mcmFnOjI3Y2IxNjhkZTFhNTRhNGQ5MGNkYTNlODdlZDg5N2RlL3RhYmxlOmE4OWNjMDNlN2U2MDQyMjY5NTA4MWU1MTFkYTU1MTkwL3RhYmxlcmFuZ2U6YTg5Y2MwM2U3ZTYwNDIyNjk1MDgxZTUxMWRhNTUxOTBfNDgtMy0xLTEtMTc3NzU_8966e74c-440f-477c-8349-a44d4fe641b9">16,606</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e21049ffc224cacb8134d73c9bb5b38_D20190101-20191231" decimals="-3" name="us-gaap:RepaymentsOfSeniorDebt" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18zNC9mcmFnOjI3Y2IxNjhkZTFhNTRhNGQ5MGNkYTNlODdlZDg5N2RlL3RhYmxlOmE4OWNjMDNlN2U2MDQyMjY5NTA4MWU1MTFkYTU1MTkwL3RhYmxlcmFuZ2U6YTg5Y2MwM2U3ZTYwNDIyNjk1MDgxZTUxMWRhNTUxOTBfNDgtNS0xLTEtMTk3MDE_72cc4254-0efc-4f4b-9ea9-b7d9795d2f5d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from stock option exercises</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231" decimals="-3" name="us-gaap:ProceedsFromStockOptionsExercised" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18zNC9mcmFnOjI3Y2IxNjhkZTFhNTRhNGQ5MGNkYTNlODdlZDg5N2RlL3RhYmxlOmE4OWNjMDNlN2U2MDQyMjY5NTA4MWU1MTFkYTU1MTkwL3RhYmxlcmFuZ2U6YTg5Y2MwM2U3ZTYwNDIyNjk1MDgxZTUxMWRhNTUxOTBfNDktMS0xLTEtMTc3NzU_0e2d9276-f673-4fdd-b1c5-277cd0b1e2e4">13,289</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i12a6d1161de54547bd29f8efccd4c9b0_D20200101-20201231" decimals="-3" name="us-gaap:ProceedsFromStockOptionsExercised" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18zNC9mcmFnOjI3Y2IxNjhkZTFhNTRhNGQ5MGNkYTNlODdlZDg5N2RlL3RhYmxlOmE4OWNjMDNlN2U2MDQyMjY5NTA4MWU1MTFkYTU1MTkwL3RhYmxlcmFuZ2U6YTg5Y2MwM2U3ZTYwNDIyNjk1MDgxZTUxMWRhNTUxOTBfNDktMy0xLTEtMTc3NzU_c92efb4b-5532-4272-a61d-5f4714e42306">2,577</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e21049ffc224cacb8134d73c9bb5b38_D20190101-20191231" decimals="-3" name="us-gaap:ProceedsFromStockOptionsExercised" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18zNC9mcmFnOjI3Y2IxNjhkZTFhNTRhNGQ5MGNkYTNlODdlZDg5N2RlL3RhYmxlOmE4OWNjMDNlN2U2MDQyMjY5NTA4MWU1MTFkYTU1MTkwL3RhYmxlcmFuZ2U6YTg5Y2MwM2U3ZTYwNDIyNjk1MDgxZTUxMWRhNTUxOTBfNDktNS0xLTEtMTk3MTY_1b67000c-8e9e-4738-83b0-ef05776ad12d">1,092</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Distributions to Sponsors</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231" decimals="-3" name="us-gaap:PaymentsToMinorityShareholders" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18zNC9mcmFnOjI3Y2IxNjhkZTFhNTRhNGQ5MGNkYTNlODdlZDg5N2RlL3RhYmxlOmE4OWNjMDNlN2U2MDQyMjY5NTA4MWU1MTFkYTU1MTkwL3RhYmxlcmFuZ2U6YTg5Y2MwM2U3ZTYwNDIyNjk1MDgxZTUxMWRhNTUxOTBfNTAtMS0xLTEtMTc3NzU_e7ab7c41-6fc3-4e7d-80ad-c00fb32e9979">1,300</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i12a6d1161de54547bd29f8efccd4c9b0_D20200101-20201231" decimals="-3" name="us-gaap:PaymentsToMinorityShareholders" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18zNC9mcmFnOjI3Y2IxNjhkZTFhNTRhNGQ5MGNkYTNlODdlZDg5N2RlL3RhYmxlOmE4OWNjMDNlN2U2MDQyMjY5NTA4MWU1MTFkYTU1MTkwL3RhYmxlcmFuZ2U6YTg5Y2MwM2U3ZTYwNDIyNjk1MDgxZTUxMWRhNTUxOTBfNTAtMy0xLTEtMTc3NzU_02d4d729-ab5c-4a61-ac9b-d0ca700f48d4">20,000</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e21049ffc224cacb8134d73c9bb5b38_D20190101-20191231" decimals="-3" name="us-gaap:PaymentsToMinorityShareholders" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18zNC9mcmFnOjI3Y2IxNjhkZTFhNTRhNGQ5MGNkYTNlODdlZDg5N2RlL3RhYmxlOmE4OWNjMDNlN2U2MDQyMjY5NTA4MWU1MTFkYTU1MTkwL3RhYmxlcmFuZ2U6YTg5Y2MwM2U3ZTYwNDIyNjk1MDgxZTUxMWRhNTUxOTBfNTAtNS0xLTEtMTk3MTY_736a1e87-7e6e-4a11-8583-418f4532111c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Taxes withheld and paid for vesting of restricted stock units</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231" decimals="-3" name="us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18zNC9mcmFnOjI3Y2IxNjhkZTFhNTRhNGQ5MGNkYTNlODdlZDg5N2RlL3RhYmxlOmE4OWNjMDNlN2U2MDQyMjY5NTA4MWU1MTFkYTU1MTkwL3RhYmxlcmFuZ2U6YTg5Y2MwM2U3ZTYwNDIyNjk1MDgxZTUxMWRhNTUxOTBfNTEtMS0xLTEtMTc3NzU_34f73386-b587-4c3f-8bf1-37cf4e1a98a8">3,850</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i12a6d1161de54547bd29f8efccd4c9b0_D20200101-20201231" decimals="-3" name="us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18zNC9mcmFnOjI3Y2IxNjhkZTFhNTRhNGQ5MGNkYTNlODdlZDg5N2RlL3RhYmxlOmE4OWNjMDNlN2U2MDQyMjY5NTA4MWU1MTFkYTU1MTkwL3RhYmxlcmFuZ2U6YTg5Y2MwM2U3ZTYwNDIyNjk1MDgxZTUxMWRhNTUxOTBfNTEtMy0xLTEtMTc3NzU_7330dda8-55e2-42d3-ad4f-ad93078d1f05">1,851</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3e21049ffc224cacb8134d73c9bb5b38_D20190101-20191231" decimals="-3" name="us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18zNC9mcmFnOjI3Y2IxNjhkZTFhNTRhNGQ5MGNkYTNlODdlZDg5N2RlL3RhYmxlOmE4OWNjMDNlN2U2MDQyMjY5NTA4MWU1MTFkYTU1MTkwL3RhYmxlcmFuZ2U6YTg5Y2MwM2U3ZTYwNDIyNjk1MDgxZTUxMWRhNTUxOTBfNTEtNS0xLTEtMTk3MDg_a95029f1-3d2b-47ad-81d1-ba39fbcbe05f">2,609</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash and restricted cash used in financing activities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18zNC9mcmFnOjI3Y2IxNjhkZTFhNTRhNGQ5MGNkYTNlODdlZDg5N2RlL3RhYmxlOmE4OWNjMDNlN2U2MDQyMjY5NTA4MWU1MTFkYTU1MTkwL3RhYmxlcmFuZ2U6YTg5Y2MwM2U3ZTYwNDIyNjk1MDgxZTUxMWRhNTUxOTBfNTItMS0xLTEtMTc3NzU_3c1d4988-14f1-4c04-9b4c-2a385e3d230c">29,548</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i12a6d1161de54547bd29f8efccd4c9b0_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18zNC9mcmFnOjI3Y2IxNjhkZTFhNTRhNGQ5MGNkYTNlODdlZDg5N2RlL3RhYmxlOmE4OWNjMDNlN2U2MDQyMjY5NTA4MWU1MTFkYTU1MTkwL3RhYmxlcmFuZ2U6YTg5Y2MwM2U3ZTYwNDIyNjk1MDgxZTUxMWRhNTUxOTBfNTItMy0xLTEtMTc3NzU_553b3c63-2e57-46c9-ac37-ba25bf8726fc">11,862</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3e21049ffc224cacb8134d73c9bb5b38_D20190101-20191231" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18zNC9mcmFnOjI3Y2IxNjhkZTFhNTRhNGQ5MGNkYTNlODdlZDg5N2RlL3RhYmxlOmE4OWNjMDNlN2U2MDQyMjY5NTA4MWU1MTFkYTU1MTkwL3RhYmxlcmFuZ2U6YTg5Y2MwM2U3ZTYwNDIyNjk1MDgxZTUxMWRhNTUxOTBfNTItNS0xLTEtMTk3MDg_b23c69b1-23a9-47cf-a69a-b9f2bb3c5ba4">35,545</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effect of exchange rate on cash and cash equivalents and restricted cash</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18zNC9mcmFnOjI3Y2IxNjhkZTFhNTRhNGQ5MGNkYTNlODdlZDg5N2RlL3RhYmxlOmE4OWNjMDNlN2U2MDQyMjY5NTA4MWU1MTFkYTU1MTkwL3RhYmxlcmFuZ2U6YTg5Y2MwM2U3ZTYwNDIyNjk1MDgxZTUxMWRhNTUxOTBfNTMtMS0xLTEtMTc3NzU_439e0807-6662-4266-86a7-17c9edf96341">52</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i12a6d1161de54547bd29f8efccd4c9b0_D20200101-20201231" decimals="-3" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18zNC9mcmFnOjI3Y2IxNjhkZTFhNTRhNGQ5MGNkYTNlODdlZDg5N2RlL3RhYmxlOmE4OWNjMDNlN2U2MDQyMjY5NTA4MWU1MTFkYTU1MTkwL3RhYmxlcmFuZ2U6YTg5Y2MwM2U3ZTYwNDIyNjk1MDgxZTUxMWRhNTUxOTBfNTMtMy0xLTEtMTc3NzU_60f826f3-d376-4db8-898e-512cbc57392a">65</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e21049ffc224cacb8134d73c9bb5b38_D20190101-20191231" decimals="-3" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18zNC9mcmFnOjI3Y2IxNjhkZTFhNTRhNGQ5MGNkYTNlODdlZDg5N2RlL3RhYmxlOmE4OWNjMDNlN2U2MDQyMjY5NTA4MWU1MTFkYTU1MTkwL3RhYmxlcmFuZ2U6YTg5Y2MwM2U3ZTYwNDIyNjk1MDgxZTUxMWRhNTUxOTBfNTMtNS0xLTEtMTk3MDg_11c0acf1-ef7a-4920-bee0-56a3066a0294">30</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net increase (decrease) in cash and cash equivalents and restricted cash</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18zNC9mcmFnOjI3Y2IxNjhkZTFhNTRhNGQ5MGNkYTNlODdlZDg5N2RlL3RhYmxlOmE4OWNjMDNlN2U2MDQyMjY5NTA4MWU1MTFkYTU1MTkwL3RhYmxlcmFuZ2U6YTg5Y2MwM2U3ZTYwNDIyNjk1MDgxZTUxMWRhNTUxOTBfNTQtMS0xLTEtMTc3NzU_50417f69-cfa7-413a-941c-1da812d20d57">6,639</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i12a6d1161de54547bd29f8efccd4c9b0_D20200101-20201231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18zNC9mcmFnOjI3Y2IxNjhkZTFhNTRhNGQ5MGNkYTNlODdlZDg5N2RlL3RhYmxlOmE4OWNjMDNlN2U2MDQyMjY5NTA4MWU1MTFkYTU1MTkwL3RhYmxlcmFuZ2U6YTg5Y2MwM2U3ZTYwNDIyNjk1MDgxZTUxMWRhNTUxOTBfNTQtMy0xLTEtMTc3NzU_95ebe89b-a6b1-47e7-91d5-ead0ffba898c">233,050</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3e21049ffc224cacb8134d73c9bb5b38_D20190101-20191231" decimals="-3" sign="-" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18zNC9mcmFnOjI3Y2IxNjhkZTFhNTRhNGQ5MGNkYTNlODdlZDg5N2RlL3RhYmxlOmE4OWNjMDNlN2U2MDQyMjY5NTA4MWU1MTFkYTU1MTkwL3RhYmxlcmFuZ2U6YTg5Y2MwM2U3ZTYwNDIyNjk1MDgxZTUxMWRhNTUxOTBfNTQtNS0xLTEtMTk3MDg_e5718c4b-ef9f-4d33-87ad-85fc21d25a3b">259,794</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents and restricted cash as of beginning-of-period </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc0c0c2b8dc04c5698ca0577a54b2e03_I20201231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18zNC9mcmFnOjI3Y2IxNjhkZTFhNTRhNGQ5MGNkYTNlODdlZDg5N2RlL3RhYmxlOmE4OWNjMDNlN2U2MDQyMjY5NTA4MWU1MTFkYTU1MTkwL3RhYmxlcmFuZ2U6YTg5Y2MwM2U3ZTYwNDIyNjk1MDgxZTUxMWRhNTUxOTBfNTUtMS0xLTEtMTc3NzU_dc843966-7f80-4efe-b679-574368ea9780">361,581</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icba6e493923b449aa57c46a563760234_I20191231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18zNC9mcmFnOjI3Y2IxNjhkZTFhNTRhNGQ5MGNkYTNlODdlZDg5N2RlL3RhYmxlOmE4OWNjMDNlN2U2MDQyMjY5NTA4MWU1MTFkYTU1MTkwL3RhYmxlcmFuZ2U6YTg5Y2MwM2U3ZTYwNDIyNjk1MDgxZTUxMWRhNTUxOTBfNTUtMy0xLTEtMTc3NzU_0dbfcc48-1d01-4540-ab2b-aa7e32633e3b">128,531</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7130cb432c4b4fe7a260e8a3beeb35d8_I20181231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18zNC9mcmFnOjI3Y2IxNjhkZTFhNTRhNGQ5MGNkYTNlODdlZDg5N2RlL3RhYmxlOmE4OWNjMDNlN2U2MDQyMjY5NTA4MWU1MTFkYTU1MTkwL3RhYmxlcmFuZ2U6YTg5Y2MwM2U3ZTYwNDIyNjk1MDgxZTUxMWRhNTUxOTBfNTUtNS0xLTEtMTk3MDg_6223642a-5e62-4a5b-967f-f9e515b1dca7">388,325</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents and restricted cash as of end-of-period </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8daff60be410426d8f7bd49343c1ec0c_I20211231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18zNC9mcmFnOjI3Y2IxNjhkZTFhNTRhNGQ5MGNkYTNlODdlZDg5N2RlL3RhYmxlOmE4OWNjMDNlN2U2MDQyMjY5NTA4MWU1MTFkYTU1MTkwL3RhYmxlcmFuZ2U6YTg5Y2MwM2U3ZTYwNDIyNjk1MDgxZTUxMWRhNTUxOTBfNTYtMS0xLTEtMTc3NzU_ffc6fbc1-32e0-4d84-81d2-24061d12a248">354,942</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc0c0c2b8dc04c5698ca0577a54b2e03_I20201231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18zNC9mcmFnOjI3Y2IxNjhkZTFhNTRhNGQ5MGNkYTNlODdlZDg5N2RlL3RhYmxlOmE4OWNjMDNlN2U2MDQyMjY5NTA4MWU1MTFkYTU1MTkwL3RhYmxlcmFuZ2U6YTg5Y2MwM2U3ZTYwNDIyNjk1MDgxZTUxMWRhNTUxOTBfNTYtMy0xLTEtMTc3NzU_4f6ad754-8af7-4679-92ee-c45d9fc9dbf3">361,581</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icba6e493923b449aa57c46a563760234_I20191231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18zNC9mcmFnOjI3Y2IxNjhkZTFhNTRhNGQ5MGNkYTNlODdlZDg5N2RlL3RhYmxlOmE4OWNjMDNlN2U2MDQyMjY5NTA4MWU1MTFkYTU1MTkwL3RhYmxlcmFuZ2U6YTg5Y2MwM2U3ZTYwNDIyNjk1MDgxZTUxMWRhNTUxOTBfNTYtNS0xLTEtMTk3MDg_209232cd-73f4-4e84-8252-0b6a41a6baaa">128,531</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt">As a result of the closing of the sale of True Health during the first quarter of 2021, the consolidated statements of operations, consolidated balance sheets, and related financial information reflect the Company&#8217;s operations and assets and liabilities of True Health as discontinued operations for all periods presented. Cash flows and comprehensive income have not been adjusted and are included in the consolidated statements of cash flows and consolidated statements of comprehensive income (loss) for all periods presented. <ix:footnote id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18zNC9mcmFnOjI3Y2IxNjhkZTFhNTRhNGQ5MGNkYTNlODdlZDg5N2RlL3RleHRyZWdpb246MjdjYjE2OGRlMWE1NGE0ZDkwY2RhM2U4N2VkODk3ZGVfNjE0_407cd0f7-2686-4510-bcd4-91690222a249" footnoteRole="http://www.xbrl.org/2003/role/footnote">See Note 5.</ix:footnote></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">See accompanying Notes to Consolidated Financial Statements</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">74</span></div></div></div><div id="i9aaa2fddc97e482da5dbe37ac85ae703_37"></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">EVOLENT HEALTH, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS </span></div><div id="i9aaa2fddc97e482da5dbe37ac85ae703_40"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 1.  <ix:nonNumeric contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231" name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM180MC9mcmFnOjhlMmVhMTYxYjgzZTRjMTk5ZjU4ZTNiZTY3Mzg5ODBiL3RleHRyZWdpb246OGUyZWExNjFiODNlNGMxOTlmNThlM2JlNjczODk4MGJfMjA1Nw_e1226a8a-038b-4777-8c8c-114e9901cf3c" continuedAt="i69aab908e1504af4a07b0bc573455c16" escape="true">Organization </ix:nonNumeric></span></div><div><span><br/></span></div><ix:continuation id="i69aab908e1504af4a07b0bc573455c16"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Evolent Health, Inc. was incorporated in December 2014 in the state of Delaware and through its subsidiaries supports leading health systems and physician organizations to move their business models from traditional fee for service reimbursement to value-based care, which we consider to be an integrated clinical and financial responsibility for populations. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since its inception, the Company has incurred losses from operations. As of December&#160;31, 2021, the Company had unrestricted cash and cash equivalents of $<ix:nonFraction unitRef="usd" contextRef="i8daff60be410426d8f7bd49343c1ec0c_I20211231" decimals="-5" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM180MC9mcmFnOjhlMmVhMTYxYjgzZTRjMTk5ZjU4ZTNiZTY3Mzg5ODBiL3RleHRyZWdpb246OGUyZWExNjFiODNlNGMxOTlmNThlM2JlNjczODk4MGJfMTI3OA_2b7bc196-9fbd-44fd-816e-4d64f8861057">266.3</ix:nonFraction> million. The Company believes it has sufficient liquidity for the next twelve months as of the date the financial statements were available to be issued.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s headquarters is located in Arlington, Virginia.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Evolent Health LLC Governance</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our operations are conducted through Evolent Health LLC. Evolent Health, Inc. is a holding company whose only business is to act as the sole managing member of Evolent Health LLC. As such, it controls Evolent Health LLC&#8217;s business and affairs and is responsible for the management of its business. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Issuances of Common Units</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Evolent Health LLC may only issue Class A common units to us, as the sole managing member of Evolent Health LLC. Class B common units may be issued only to persons or entities we permit. Such issuances of Class B common units shall be made in exchange for cash or other consideration. Class B common units may not be transferred as Class B common units except to certain permitted transferees and in accordance with the restrictions on transfer set forth in the third amended and restated operating agreement of Evolent Health LLC. Any such transfer must be accompanied by the transfer of an equal number of shares of our Class B common stock. As of December 31, 2021 and 2020, there are <ix:nonFraction unitRef="shares" contextRef="i9632fb5d42444a5984c0033bf16be6f0_I20201231" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM180MC9mcmFnOjhlMmVhMTYxYjgzZTRjMTk5ZjU4ZTNiZTY3Mzg5ODBiL3RleHRyZWdpb246OGUyZWExNjFiODNlNGMxOTlmNThlM2JlNjczODk4MGJfMzI5ODUzNDg4ODYxNw_d7b7e4da-b651-4cc7-a60d-8fbb4b98a704"><ix:nonFraction unitRef="shares" contextRef="i5f1b61732fb142fc9539a36365f230ee_I20211231" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM180MC9mcmFnOjhlMmVhMTYxYjgzZTRjMTk5ZjU4ZTNiZTY3Mzg5ODBiL3RleHRyZWdpb246OGUyZWExNjFiODNlNGMxOTlmNThlM2JlNjczODk4MGJfMzI5ODUzNDg4ODYxNw_fa7356df-d3f8-4d1e-a83d-8182870de8c6">no</ix:nonFraction></ix:nonFraction> Class B common units outstanding.</span></div></ix:continuation><div style="text-align:justify"><span><br/></span></div><div id="i9aaa2fddc97e482da5dbe37ac85ae703_43"></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 2.  <ix:nonNumeric contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231" name="us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM180My9mcmFnOjM1ZWJlNTMyYTAzYjQ3MzhiMzdiNGEzNWFjNmNlNzZkL3RleHRyZWdpb246MzVlYmU1MzJhMDNiNDczOGIzN2I0YTM1YWM2Y2U3NmRfMTU3Mjc_422c4c35-dafc-4271-a9f0-772279582c75" continuedAt="ia4aaf2754b3c4026bbe69c4840323f65" escape="true">Basis of Presentation, Summary of Significant Accounting Policies and Change in Accounting Principles</ix:nonNumeric></span></div><div style="text-align:justify"><span><br/></span></div><ix:continuation id="ia4aaf2754b3c4026bbe69c4840323f65" continuedAt="i6d254276861d4eed84fd0427c737c4ff"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM180My9mcmFnOjM1ZWJlNTMyYTAzYjQ3MzhiMzdiNGEzNWFjNmNlNzZkL3RleHRyZWdpb246MzVlYmU1MzJhMDNiNDczOGIzN2I0YTM1YWM2Y2U3NmRfMTU3NDE_7de823bf-ac93-4557-89ae-d7bb20877132" continuedAt="ie51f73fffa8e49998add9ec4bf96fb4b" escape="true">Basis of Presentation</ix:nonNumeric></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ie51f73fffa8e49998add9ec4bf96fb4b">The consolidated financial statements of the Company are prepared in accordance with U.S. GAAP. Our consolidated financial statements include the accounts of all subsidiaries. All intercompany accounts and transactions are eliminated in consolidation. The consolidated balance sheet as of December 31, 2020, has been derived from audited financial statements as of that date and reflects the impact of the sale of True Health. See Note 5 for a complete summary of this transaction.</ix:continuation> </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Summary of Significant Accounting Policies</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain GAAP policies that significantly affect the determination of our financial position, results of operations and cash flows, are summarized below.</span></div><div style="text-align:justify"><span><br/></span></div><ix:nonNumeric contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231" name="us-gaap:UseOfEstimates" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM180My9mcmFnOjM1ZWJlNTMyYTAzYjQ3MzhiMzdiNGEzNWFjNmNlNzZkL3RleHRyZWdpb246MzVlYmU1MzJhMDNiNDczOGIzN2I0YTM1YWM2Y2U3NmRfMTU3MzU_a12fd2c0-f195-4ae0-81ac-8588863f3e6b" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Accounting Estimates and Assumptions</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions affecting the reported amounts of assets and liabilities and the disclosures of contingent assets and liabilities as of the date of the financial statements and the reported amounts of revenue and expenses for the reporting period. Those estimates are inherently subject to change and actual results could differ from those estimates. In the accompanying consolidated financial statements, estimates are used for, but not limited to, the valuation of assets (including intangibles assets, goodwill and long-lived assets), liabilities, consideration related to business combinations and asset acquisitions, revenue recognition (including variable consideration), estimated selling prices for performance obligations in contracts with multiple performance obligations, reserves for claims and performance-based arrangements, credit losses, depreciable lives of assets, impairment of long-lived assets, stock-based compensation, deferred income taxes and valuation allowance, contingent liabilities, purchase price allocation in taxable stock transactions and useful lives of intangible assets.</span></div></ix:nonNumeric><div style="text-align:justify"><span><br/></span></div><ix:nonNumeric contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231" name="us-gaap:SegmentReportingPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM180My9mcmFnOjM1ZWJlNTMyYTAzYjQ3MzhiMzdiNGEzNWFjNmNlNzZkL3RleHRyZWdpb246MzVlYmU1MzJhMDNiNDczOGIzN2I0YTM1YWM2Y2U3NmRfMTU3NDM_4cd5d968-a641-4631-a393-ab5b7be26ec2" continuedAt="i053ce77a58cd428c91e3d50af7c53d0b" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Operating Segments</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating segments are defined as components of a business that may recognize revenue and incur expenses for which discrete financial information is available that is evaluated, on a regular basis, by the chief operating decision maker (&#8220;CODM&#8221;) to decide how </span></div></ix:nonNumeric></ix:continuation><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">75</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i6d254276861d4eed84fd0427c737c4ff" continuedAt="id0dd4b8188b948af80ad9b0c398759c5"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i053ce77a58cd428c91e3d50af7c53d0b">to allocate resources and assess performance. The Company made organizational changes, including re-evaluating its reportable segments, as a result of the entry into the agreement to sell True Health on January 11, 2021. Effective during the first quarter of 2021, the Company bifurcated its previous Services segment into <ix:nonFraction unitRef="segment" contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231" decimals="INF" name="us-gaap:NumberOfOperatingSegments" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM180My9mcmFnOjM1ZWJlNTMyYTAzYjQ3MzhiMzdiNGEzNWFjNmNlNzZkL3RleHRyZWdpb246MzVlYmU1MzJhMDNiNDczOGIzN2I0YTM1YWM2Y2U3NmRfMjE5OTAyMzI5NDc2MQ_36996c95-6a0f-49a8-9f69-e7b417168391">two</ix:nonFraction> segments. The Company&#8217;s Evolent Health Services segment (&#8220;EHS&#8221;) includes our administrative simplification solution and supporting population health infrastructure. Our Clinical Solutions segment includes our specialty care management and physician-oriented total cost of care solutions, along with the New Century Health and Evolent Care Partners brands. Refer to Note 22 for a further discussion of our operating results by segment.</ix:continuation></span></div><div style="text-align:justify"><span><br/></span></div><ix:nonNumeric contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231" name="us-gaap:CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM180My9mcmFnOjM1ZWJlNTMyYTAzYjQ3MzhiMzdiNGEzNWFjNmNlNzZkL3RleHRyZWdpb246MzVlYmU1MzJhMDNiNDczOGIzN2I0YTM1YWM2Y2U3NmRfMTU3MTE_63b02c16-0ade-4a8e-9f4a-450ddfbec365" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cash and Cash Equivalents</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We consider all highly liquid instruments with original maturities of three months or less to be cash equivalents. The Company holds materially all of our cash in bank deposits with FDIC participating banks, at cost, which approximates fair value. Cash and cash equivalents held in money market funds are carried at fair value, which approximates cost.</span></div></ix:nonNumeric><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Restricted Cash and Restricted Investments</span></div><div style="text-align:justify"><span><br/></span></div><ix:nonNumeric contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231" name="us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM180My9mcmFnOjM1ZWJlNTMyYTAzYjQ3MzhiMzdiNGEzNWFjNmNlNzZkL3RleHRyZWdpb246MzVlYmU1MzJhMDNiNDczOGIzN2I0YTM1YWM2Y2U3NmRfMTU3MTY_cebe285d-4d06-4ace-be90-598c28dab2b7" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restricted cash and restricted investments include cash and investments used to collateralize various contractual obligations as of December&#160;31, 2021 and 2020 (in thousands) as follows:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"></td><td style="width:421.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:54.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:54.25pt"></td><td style="width:1.0pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Collateral for letters of credit for facility leases </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibd159a0a266f484882b88b46c1b83d3f_I20211231" decimals="-3" name="us-gaap:RestrictedCashAndCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM180My9mcmFnOjM1ZWJlNTMyYTAzYjQ3MzhiMzdiNGEzNWFjNmNlNzZkL3RhYmxlOjgzYzE1OWRlMDNkNjRjYzE4NWFmMmUzODVmNTk2MmY1L3RhYmxlcmFuZ2U6ODNjMTU5ZGUwM2Q2NGNjMTg1YWYyZTM4NWY1OTYyZjVfMS0xLTEtMS0xNzc3NQ_6e56af00-f15b-4b02-b9d3-fd356a107df3">3,769</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3a313b63f9a34c26b2a361281eca58df_I20201231" decimals="-3" name="us-gaap:RestrictedCashAndCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM180My9mcmFnOjM1ZWJlNTMyYTAzYjQ3MzhiMzdiNGEzNWFjNmNlNzZkL3RhYmxlOjgzYzE1OWRlMDNkNjRjYzE4NWFmMmUzODVmNTk2MmY1L3RhYmxlcmFuZ2U6ODNjMTU5ZGUwM2Q2NGNjMTg1YWYyZTM4NWY1OTYyZjVfMS0zLTEtMS0xNzc3NQ_3e6c5f96-021f-4b71-991f-688075e47b8f">3,510</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Collateral with financial institutions </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia9df011f1efd436cbcdff5e8bfdd9e5a_I20211231" decimals="-3" name="us-gaap:RestrictedCashAndCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM180My9mcmFnOjM1ZWJlNTMyYTAzYjQ3MzhiMzdiNGEzNWFjNmNlNzZkL3RhYmxlOjgzYzE1OWRlMDNkNjRjYzE4NWFmMmUzODVmNTk2MmY1L3RhYmxlcmFuZ2U6ODNjMTU5ZGUwM2Q2NGNjMTg1YWYyZTM4NWY1OTYyZjVfMi0xLTEtMS0xNzc3NQ_5b97a3d6-0426-410b-876e-7b4307a8c657">11,662</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib52a820bc1fa4880b75c578ff17dda8d_I20201231" decimals="-3" name="us-gaap:RestrictedCashAndCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM180My9mcmFnOjM1ZWJlNTMyYTAzYjQ3MzhiMzdiNGEzNWFjNmNlNzZkL3RhYmxlOjgzYzE1OWRlMDNkNjRjYzE4NWFmMmUzODVmNTk2MmY1L3RhYmxlcmFuZ2U6ODNjMTU5ZGUwM2Q2NGNjMTg1YWYyZTM4NWY1OTYyZjVfMi0zLTEtMS0xNzc3NQ_52e2b1b6-713a-47b0-b710-9698b8cbda5b">4,743</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Claims processing services </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(4)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic5164e2908114e21b24e2e1681c5dcba_I20211231" decimals="-3" name="us-gaap:RestrictedCashAndCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM180My9mcmFnOjM1ZWJlNTMyYTAzYjQ3MzhiMzdiNGEzNWFjNmNlNzZkL3RhYmxlOjgzYzE1OWRlMDNkNjRjYzE4NWFmMmUzODVmNTk2MmY1L3RhYmxlcmFuZ2U6ODNjMTU5ZGUwM2Q2NGNjMTg1YWYyZTM4NWY1OTYyZjVfMy0xLTEtMS0xNzc3NQ_8f8f8398-bac5-4882-823c-343938a82bb6">73,226</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i83fc6159c69f43e5822b38e95a2a3b46_I20201231" decimals="-3" name="us-gaap:RestrictedCashAndCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM180My9mcmFnOjM1ZWJlNTMyYTAzYjQ3MzhiMzdiNGEzNWFjNmNlNzZkL3RhYmxlOjgzYzE1OWRlMDNkNjRjYzE4NWFmMmUzODVmNTk2MmY1L3RhYmxlcmFuZ2U6ODNjMTU5ZGUwM2Q2NGNjMTg1YWYyZTM4NWY1OTYyZjVfMy0zLTEtMS0xNzc3NQ_ee7d3c9d-2e21-4b4c-8b17-f05f2cd03eab">12,064</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i58c2398f3ddb4809a3cb1af5b5c34db8_I20211231" decimals="-3" name="us-gaap:RestrictedCashAndCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM180My9mcmFnOjM1ZWJlNTMyYTAzYjQ3MzhiMzdiNGEzNWFjNmNlNzZkL3RhYmxlOjgzYzE1OWRlMDNkNjRjYzE4NWFmMmUzODVmNTk2MmY1L3RhYmxlcmFuZ2U6ODNjMTU5ZGUwM2Q2NGNjMTg1YWYyZTM4NWY1OTYyZjVfNC0xLTEtMS0xNzc3NQ_2eb4d5c0-1634-4ece-baa4-e59bd8f147c0">5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i58e611a688d54093ac555cb27c5810ec_I20201231" decimals="-3" name="us-gaap:RestrictedCashAndCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM180My9mcmFnOjM1ZWJlNTMyYTAzYjQ3MzhiMzdiNGEzNWFjNmNlNzZkL3RhYmxlOjgzYzE1OWRlMDNkNjRjYzE4NWFmMmUzODVmNTk2MmY1L3RhYmxlcmFuZ2U6ODNjMTU5ZGUwM2Q2NGNjMTg1YWYyZTM4NWY1OTYyZjVfNC0zLTEtMS0xNzc3NQ_58ee5451-a672-4c79-8a4a-fd87eae02c97">711</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total restricted cash and restricted investments</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8daff60be410426d8f7bd49343c1ec0c_I20211231" decimals="-3" name="us-gaap:RestrictedCashAndInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM180My9mcmFnOjM1ZWJlNTMyYTAzYjQ3MzhiMzdiNGEzNWFjNmNlNzZkL3RhYmxlOjgzYzE1OWRlMDNkNjRjYzE4NWFmMmUzODVmNTk2MmY1L3RhYmxlcmFuZ2U6ODNjMTU5ZGUwM2Q2NGNjMTg1YWYyZTM4NWY1OTYyZjVfNS0xLTEtMS0xNzc3NQ_50e888ff-6074-4576-9815-500ec6808775">88,662</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc0c0c2b8dc04c5698ca0577a54b2e03_I20201231" decimals="-3" name="us-gaap:RestrictedCashAndCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM180My9mcmFnOjM1ZWJlNTMyYTAzYjQ3MzhiMzdiNGEzNWFjNmNlNzZkL3RhYmxlOjgzYzE1OWRlMDNkNjRjYzE4NWFmMmUzODVmNTk2MmY1L3RhYmxlcmFuZ2U6ODNjMTU5ZGUwM2Q2NGNjMTg1YWYyZTM4NWY1OTYyZjVfNS0zLTEtMS0xNzc3NQ_9581c207-ba6c-42d0-a7c6-a1dcf65708c0">21,028</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current restricted cash</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8daff60be410426d8f7bd49343c1ec0c_I20211231" decimals="-3" name="us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM180My9mcmFnOjM1ZWJlNTMyYTAzYjQ3MzhiMzdiNGEzNWFjNmNlNzZkL3RhYmxlOjgzYzE1OWRlMDNkNjRjYzE4NWFmMmUzODVmNTk2MmY1L3RhYmxlcmFuZ2U6ODNjMTU5ZGUwM2Q2NGNjMTg1YWYyZTM4NWY1OTYyZjVfNy0xLTEtMS0xNzc3NQ_e862900b-883e-4d7e-aa91-68aa85fa46a5">75,685</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc0c0c2b8dc04c5698ca0577a54b2e03_I20201231" decimals="-3" name="us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM180My9mcmFnOjM1ZWJlNTMyYTAzYjQ3MzhiMzdiNGEzNWFjNmNlNzZkL3RhYmxlOjgzYzE1OWRlMDNkNjRjYzE4NWFmMmUzODVmNTk2MmY1L3RhYmxlcmFuZ2U6ODNjMTU5ZGUwM2Q2NGNjMTg1YWYyZTM4NWY1OTYyZjVfNy0zLTEtMS0xNzc3NQ_ce9c8095-1b0c-48a8-b531-74ef1253e0c9">14,374</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current restricted cash and restricted investments</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8daff60be410426d8f7bd49343c1ec0c_I20211231" decimals="-3" name="us-gaap:RestrictedCashAndInvestmentsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM180My9mcmFnOjM1ZWJlNTMyYTAzYjQ3MzhiMzdiNGEzNWFjNmNlNzZkL3RhYmxlOjgzYzE1OWRlMDNkNjRjYzE4NWFmMmUzODVmNTk2MmY1L3RhYmxlcmFuZ2U6ODNjMTU5ZGUwM2Q2NGNjMTg1YWYyZTM4NWY1OTYyZjVfOC0xLTEtMS0xNzc3NQ_5b7f4023-896e-4357-993e-1df54930a12e">75,685</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc0c0c2b8dc04c5698ca0577a54b2e03_I20201231" decimals="-3" name="us-gaap:RestrictedCashAndInvestmentsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM180My9mcmFnOjM1ZWJlNTMyYTAzYjQ3MzhiMzdiNGEzNWFjNmNlNzZkL3RhYmxlOjgzYzE1OWRlMDNkNjRjYzE4NWFmMmUzODVmNTk2MmY1L3RhYmxlcmFuZ2U6ODNjMTU5ZGUwM2Q2NGNjMTg1YWYyZTM4NWY1OTYyZjVfOC0zLTEtMS0xNzc3NQ_2a2576c0-859b-41f8-a394-2ce1ef531d12">14,374</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-current restricted cash</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8daff60be410426d8f7bd49343c1ec0c_I20211231" decimals="-3" name="us-gaap:RestrictedCashAndCashEquivalentsNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM180My9mcmFnOjM1ZWJlNTMyYTAzYjQ3MzhiMzdiNGEzNWFjNmNlNzZkL3RhYmxlOjgzYzE1OWRlMDNkNjRjYzE4NWFmMmUzODVmNTk2MmY1L3RhYmxlcmFuZ2U6ODNjMTU5ZGUwM2Q2NGNjMTg1YWYyZTM4NWY1OTYyZjVfMTAtMS0xLTEtMTc3NzU_222be19c-b208-491c-b173-51723b0abc2c">12,977</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc0c0c2b8dc04c5698ca0577a54b2e03_I20201231" decimals="-3" name="us-gaap:RestrictedCashAndCashEquivalentsNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM180My9mcmFnOjM1ZWJlNTMyYTAzYjQ3MzhiMzdiNGEzNWFjNmNlNzZkL3RhYmxlOjgzYzE1OWRlMDNkNjRjYzE4NWFmMmUzODVmNTk2MmY1L3RhYmxlcmFuZ2U6ODNjMTU5ZGUwM2Q2NGNjMTg1YWYyZTM4NWY1OTYyZjVfMTAtMy0xLTEtMTc3NzU_06950652-354c-44bc-89f7-d5b24f095ee9">6,654</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total non-current restricted cash and restricted investments</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8daff60be410426d8f7bd49343c1ec0c_I20211231" decimals="-3" name="us-gaap:RestrictedCashAndInvestmentsNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM180My9mcmFnOjM1ZWJlNTMyYTAzYjQ3MzhiMzdiNGEzNWFjNmNlNzZkL3RhYmxlOjgzYzE1OWRlMDNkNjRjYzE4NWFmMmUzODVmNTk2MmY1L3RhYmxlcmFuZ2U6ODNjMTU5ZGUwM2Q2NGNjMTg1YWYyZTM4NWY1OTYyZjVfMTEtMS0xLTEtMTc3NzU_bf8df12c-e4a6-4ec5-89b6-740e4290ec60">12,977</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc0c0c2b8dc04c5698ca0577a54b2e03_I20201231" decimals="-3" name="us-gaap:RestrictedCashAndInvestmentsNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM180My9mcmFnOjM1ZWJlNTMyYTAzYjQ3MzhiMzdiNGEzNWFjNmNlNzZkL3RhYmxlOjgzYzE1OWRlMDNkNjRjYzE4NWFmMmUzODVmNTk2MmY1L3RhYmxlcmFuZ2U6ODNjMTU5ZGUwM2Q2NGNjMTg1YWYyZTM4NWY1OTYyZjVfMTEtMy0xLTEtMTc3NzU_a3921f95-aab5-4ef7-8eb4-bf54b688882a">6,654</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt">Amounts exclude $<ix:nonFraction unitRef="usd" contextRef="i98364cf4ba3e41af868d701b4c668283_I20201231" decimals="-5" name="evh:DisposalGroupIncludingDiscontinuedOperationRestrictedInvestmentsNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM180My9mcmFnOjM1ZWJlNTMyYTAzYjQ3MzhiMzdiNGEzNWFjNmNlNzZkL3RleHRyZWdpb246MzVlYmU1MzJhMDNiNDczOGIzN2I0YTM1YWM2Y2U3NmRfMzY2OA_63ea49a7-2067-4824-9096-fce9ac7c9f5c">0.6</ix:nonFraction> million of non-current restricted investments and $<ix:nonFraction unitRef="usd" contextRef="i98364cf4ba3e41af868d701b4c668283_I20201231" decimals="-5" name="evh:DisposalGroupIncludingDiscontinuedOperationRestrictedCashCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM180My9mcmFnOjM1ZWJlNTMyYTAzYjQ3MzhiMzdiNGEzNWFjNmNlNzZkL3RleHRyZWdpb246MzVlYmU1MzJhMDNiNDczOGIzN2I0YTM1YWM2Y2U3NmRfMzcxMw_9dcc1748-6652-4903-8f39-c29ece9cbc15">0.1</ix:nonFraction>&#160;million of current restricted cash from claims processing services reclassified to discontinued operations as of December&#160;31, 2020.</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt">Represents restricted cash related to collateral for letters of credit required in conjunction with lease agreements. See Note 12 for further discussion of our lease commitments. </span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt">Represents collateral held with financial institutions for risk-sharing and other arrangements. As of December&#160;31, 2021 and 2020, approximately $<ix:nonFraction unitRef="usd" contextRef="id8e4ad0aaaf14d2e8309a07fe17aa411_I20211231" decimals="-5" name="us-gaap:RestrictedCashAndCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM180My9mcmFnOjM1ZWJlNTMyYTAzYjQ3MzhiMzdiNGEzNWFjNmNlNzZkL3RleHRyZWdpb246MzVlYmU1MzJhMDNiNDczOGIzN2I0YTM1YWM2Y2U3NmRfNDEzMg_f9c63c32-0905-411e-89f4-537783525aac">11.7</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i2a39d28f60a44d6bb41fe546afc858b2_I20201231" decimals="-5" name="us-gaap:RestrictedCashAndCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM180My9mcmFnOjM1ZWJlNTMyYTAzYjQ3MzhiMzdiNGEzNWFjNmNlNzZkL3RleHRyZWdpb246MzVlYmU1MzJhMDNiNDczOGIzN2I0YTM1YWM2Y2U3NmRfNDEzOQ_4782f41b-88f4-4af1-b767-48af2fdfe277">4.7</ix:nonFraction> million, respectively, of the collateral amounts were held in a FDIC participating bank account. See Note 19 for discussion of fair value measurement and Note 11 for discussion of our risk-sharing arrangements. </span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(4)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt">Represents cash held by the Company related to claims processing services on behalf of partners. These are pass-through amounts and can fluctuate materially from period to period depending on the timing of when the claims are processed.</span></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides a reconciliation of cash and cash equivalents and restricted cash reported within the consolidated balance sheets that sum to the total of the same amounts shown in the consolidated statements of cash flows as of December&#160;31, 2021 and 2020 (in thousands).</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"></td><td style="width:433.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:48.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:48.25pt"></td><td style="width:1.0pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8daff60be410426d8f7bd49343c1ec0c_I20211231" decimals="-3" name="evh:CashAndCashEquivalentsAtCarryingValueExcludingDiscontinuedOperations" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM180My9mcmFnOjM1ZWJlNTMyYTAzYjQ3MzhiMzdiNGEzNWFjNmNlNzZkL3RhYmxlOjVmZjFiNzM5NjAzNzQ5NmZiYjVmZGU2YWI2ZmY0YTM4L3RhYmxlcmFuZ2U6NWZmMWI3Mzk2MDM3NDk2ZmJiNWZkZTZhYjZmZjRhMzhfMi0xLTEtMS0xNzc3NQ_e543631e-625f-470c-b1d5-0a5c6b9ffd61">266,280</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc0c0c2b8dc04c5698ca0577a54b2e03_I20201231" decimals="-3" name="evh:CashAndCashEquivalentsAtCarryingValueExcludingDiscontinuedOperations" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM180My9mcmFnOjM1ZWJlNTMyYTAzYjQ3MzhiMzdiNGEzNWFjNmNlNzZkL3RhYmxlOjVmZjFiNzM5NjAzNzQ5NmZiYjVmZGU2YWI2ZmY0YTM4L3RhYmxlcmFuZ2U6NWZmMWI3Mzk2MDM3NDk2ZmJiNWZkZTZhYjZmZjRhMzhfMi0zLTEtMS0xNzc3NQ_36ebdfef-0850-418c-8f2a-75f62fb682fb">340,490</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash and restricted investments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8daff60be410426d8f7bd49343c1ec0c_I20211231" decimals="-3" name="us-gaap:RestrictedCashAndInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM180My9mcmFnOjM1ZWJlNTMyYTAzYjQ3MzhiMzdiNGEzNWFjNmNlNzZkL3RhYmxlOjVmZjFiNzM5NjAzNzQ5NmZiYjVmZGU2YWI2ZmY0YTM4L3RhYmxlcmFuZ2U6NWZmMWI3Mzk2MDM3NDk2ZmJiNWZkZTZhYjZmZjRhMzhfMy0xLTEtMS0xNzc3NQ_457391b8-0225-4315-819d-7cca30db68f9">88,662</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc0c0c2b8dc04c5698ca0577a54b2e03_I20201231" decimals="-3" name="us-gaap:RestrictedCashAndInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM180My9mcmFnOjM1ZWJlNTMyYTAzYjQ3MzhiMzdiNGEzNWFjNmNlNzZkL3RhYmxlOjVmZjFiNzM5NjAzNzQ5NmZiYjVmZGU2YWI2ZmY0YTM4L3RhYmxlcmFuZ2U6NWZmMWI3Mzk2MDM3NDk2ZmJiNWZkZTZhYjZmZjRhMzhfMy0zLTEtMS0xNzc3NQ_fcbe51ce-7276-428d-9e0b-2dafb1c72b22">21,707</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted investments included in restricted cash and restricted investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8daff60be410426d8f7bd49343c1ec0c_I20211231" decimals="-3" name="us-gaap:RestrictedInvestments" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM180My9mcmFnOjM1ZWJlNTMyYTAzYjQ3MzhiMzdiNGEzNWFjNmNlNzZkL3RhYmxlOjVmZjFiNzM5NjAzNzQ5NmZiYjVmZGU2YWI2ZmY0YTM4L3RhYmxlcmFuZ2U6NWZmMWI3Mzk2MDM3NDk2ZmJiNWZkZTZhYjZmZjRhMzhfNC0xLTEtMS0xNzc3NQ_98d77601-4ad0-4c46-b3ef-0938bcf0cc7b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibc0c0c2b8dc04c5698ca0577a54b2e03_I20201231" decimals="-3" name="us-gaap:RestrictedInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM180My9mcmFnOjM1ZWJlNTMyYTAzYjQ3MzhiMzdiNGEzNWFjNmNlNzZkL3RhYmxlOjVmZjFiNzM5NjAzNzQ5NmZiYjVmZGU2YWI2ZmY0YTM4L3RhYmxlcmFuZ2U6NWZmMWI3Mzk2MDM3NDk2ZmJiNWZkZTZhYjZmZjRhMzhfNC0zLTEtMS0xNzc3NQ_caa0d8d9-5677-4cab-b95e-862fcda05712">616</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:5.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash and cash equivalents and restricted cash shown in the consolidated statements of cash flows </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8daff60be410426d8f7bd49343c1ec0c_I20211231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM180My9mcmFnOjM1ZWJlNTMyYTAzYjQ3MzhiMzdiNGEzNWFjNmNlNzZkL3RhYmxlOjVmZjFiNzM5NjAzNzQ5NmZiYjVmZGU2YWI2ZmY0YTM4L3RhYmxlcmFuZ2U6NWZmMWI3Mzk2MDM3NDk2ZmJiNWZkZTZhYjZmZjRhMzhfNS0xLTEtMS0xNzc3NQ_c3287692-dacc-4544-b15c-bc9b9a0803e3">354,942</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc0c0c2b8dc04c5698ca0577a54b2e03_I20201231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM180My9mcmFnOjM1ZWJlNTMyYTAzYjQ3MzhiMzdiNGEzNWFjNmNlNzZkL3RhYmxlOjVmZjFiNzM5NjAzNzQ5NmZiYjVmZGU2YWI2ZmY0YTM4L3RhYmxlcmFuZ2U6NWZmMWI3Mzk2MDM3NDk2ZmJiNWZkZTZhYjZmZjRhMzhfNS0zLTEtMS0xNzc3NQ_d826fd2d-b0b8-48cc-a16f-35f524ae3b3a">361,581</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt">As a result of the closing of the sale of True Health, the consolidated statements of operations, consolidated balance sheets and related financial information reflect the Company&#8217;s operations and assets and liabilities of True Health as discontinued operations for all periods presented. Cash flows and comprehensive income have not been adjusted and are included in the consolidated statements of cash flows and consolidated statements of comprehensive income (loss) for all periods presented. See Note 5.</span></div></ix:nonNumeric></ix:continuation><div style="text-align:justify"><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">76</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="id0dd4b8188b948af80ad9b0c398759c5" continuedAt="i5a242be18295407eab79721e8085f6fb"><ix:nonNumeric contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231" name="us-gaap:ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM180My9mcmFnOjM1ZWJlNTMyYTAzYjQ3MzhiMzdiNGEzNWFjNmNlNzZkL3RleHRyZWdpb246MzVlYmU1MzJhMDNiNDczOGIzN2I0YTM1YWM2Y2U3NmRfMzI5ODUzNDkyNzIyNA_d0245fa4-b636-442b-afd5-d6c20a5bcc6d" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Accounts Receivable and Allowances</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounts receivable are recorded and carried at the original invoiced amount less an allowance for any potential uncollectible amounts. We make estimates for the allowance for doubtful accounts and allowance for unbilled receivables based upon our assessment of various factors, including historical experience, the age of the accounts receivable balances, credit quality of our customers, current economic conditions, and other factors that may affect our ability to collect from customers.</span></div></ix:nonNumeric><div style="text-align:justify"><span><br/></span></div><ix:nonNumeric contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231" name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM180My9mcmFnOjM1ZWJlNTMyYTAzYjQ3MzhiMzdiNGEzNWFjNmNlNzZkL3RleHRyZWdpb246MzVlYmU1MzJhMDNiNDczOGIzN2I0YTM1YWM2Y2U3NmRfMzI5ODUzNDkyNzIyNQ_2eff441d-02fd-451e-88c8-eaf14667b9ee" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Property and Equipment, Net</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment are carried at cost less accumulated depreciation and amortization. Depreciation and amortization of property and equipment are computed using the straight-line method over the shorter of the estimated useful lives of the assets or the lease term. <ix:nonNumeric contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231" name="us-gaap:PropertyPlantAndEquipmentTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM180My9mcmFnOjM1ZWJlNTMyYTAzYjQ3MzhiMzdiNGEzNWFjNmNlNzZkL3RleHRyZWdpb246MzVlYmU1MzJhMDNiNDczOGIzN2I0YTM1YWM2Y2U3NmRfMzI5ODUzNDkyNzIyNg_09c7d2f1-b2d5-4467-96bc-103e7017b4d1" continuedAt="i9f3cdd4103ac4ed7a0436b1b17b38279" escape="true">The following summarizes the estimated useful lives by asset classification:</ix:nonNumeric></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><ix:continuation id="i9f3cdd4103ac4ed7a0436b1b17b38279" continuedAt="i9da33d1f222844ecbc1531d1013ee3de"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:63.066%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:34.040%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer hardware</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="if8e7fd6ca1724c74bd0f4e3ca2947419_D20210101-20211231" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM180My9mcmFnOjM1ZWJlNTMyYTAzYjQ3MzhiMzdiNGEzNWFjNmNlNzZkL3RhYmxlOmRiYTVlMDFlNzIxNDRkNWU4ZGVkMTk5ODhiYjU2OWMyL3RhYmxlcmFuZ2U6ZGJhNWUwMWU3MjE0NGQ1ZThkZWQxOTk4OGJiNTY5YzJfMC0yLTEtMS0xOTkxNQ_6d3b409c-6055-40d2-a72a-0c2a5175925f">3</ix:nonNumeric> years</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer software</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i703e3ae1f15f4420b40ff930efbc9f87_D20210101-20211231" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM180My9mcmFnOjM1ZWJlNTMyYTAzYjQ3MzhiMzdiNGEzNWFjNmNlNzZkL3RhYmxlOmRiYTVlMDFlNzIxNDRkNWU4ZGVkMTk5ODhiYjU2OWMyL3RhYmxlcmFuZ2U6ZGJhNWUwMWU3MjE0NGQ1ZThkZWQxOTk4OGJiNTY5YzJfMS0yLTEtMS0xOTkxNQ_9a5879bd-bb18-4bbc-97e8-bf95ef090cba">1</ix:nonNumeric> year</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture and equipment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ibc96172fcef14618a2c513b85e88be97_D20210101-20211231" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM180My9mcmFnOjM1ZWJlNTMyYTAzYjQ3MzhiMzdiNGEzNWFjNmNlNzZkL3RhYmxlOmRiYTVlMDFlNzIxNDRkNWU4ZGVkMTk5ODhiYjU2OWMyL3RhYmxlcmFuZ2U6ZGJhNWUwMWU3MjE0NGQ1ZThkZWQxOTk4OGJiNTY5YzJfMi0yLTEtMS0xOTkxNS90ZXh0cmVnaW9uOjBkMDQwM2ZlZjQ2YTQ2MzZiYjhlNDVkYTljMjZiY2YzXzIxOTkwMjMyNTU1Njg_28bbe26f-e125-4ad4-a2eb-e5ae50634313">3</ix:nonNumeric> - <ix:nonNumeric contextRef="i53d4b22f661d41dbb61ff5dcf8f75f50_D20210101-20211231" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM180My9mcmFnOjM1ZWJlNTMyYTAzYjQ3MzhiMzdiNGEzNWFjNmNlNzZkL3RhYmxlOmRiYTVlMDFlNzIxNDRkNWU4ZGVkMTk5ODhiYjU2OWMyL3RhYmxlcmFuZ2U6ZGJhNWUwMWU3MjE0NGQ1ZThkZWQxOTk4OGJiNTY5YzJfMi0yLTEtMS0xOTkxNS90ZXh0cmVnaW9uOjBkMDQwM2ZlZjQ2YTQ2MzZiYjhlNDVkYTljMjZiY2YzXzIxOTkwMjMyNTU1NzI_125668fa-060d-4dc9-9987-546e3f202010">7</ix:nonNumeric> years</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Internal-use software development costs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ia186bface90a4c4098c96c8567d34124_D20210101-20211231" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM180My9mcmFnOjM1ZWJlNTMyYTAzYjQ3MzhiMzdiNGEzNWFjNmNlNzZkL3RhYmxlOmRiYTVlMDFlNzIxNDRkNWU4ZGVkMTk5ODhiYjU2OWMyL3RhYmxlcmFuZ2U6ZGJhNWUwMWU3MjE0NGQ1ZThkZWQxOTk4OGJiNTY5YzJfMy0yLTEtMS0xOTkxNQ_5b4bfbb4-d4ec-4f13-a2b3-6c8befb9f330">5</ix:nonNumeric> years</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shorter of useful life or remaining lease term</span></td></tr></table></ix:continuation></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">When an item is sold or retired, the cost and related accumulated depreciation or amortization is eliminated and the resulting gain or loss, if any, is recorded in gain (loss) on disposal of assets and consolidation on our consolidated statements of operations and comprehensive income (loss).</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We periodically review the carrying value of our long-lived assets, including property and equipment, for impairment whenever events or circumstances indicate that the carrying amount of such assets may not be fully recoverable. For long-lived assets to be held and used, impairments are recognized when the carrying amount of a long-lived asset group is not recoverable and exceeds fair value. The carrying amount of a long-lived asset group is not recoverable if it exceeds the sum of the undiscounted cash flows expected to result from the use and eventual disposition of the asset group. An impairment loss is measured as the amount by which the carrying amount of a long-lived asset group exceeds its fair value.</span></div></ix:nonNumeric><div style="text-align:justify"><span><br/></span></div><ix:nonNumeric contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231" name="us-gaap:InternalUseSoftwarePolicy" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM180My9mcmFnOjM1ZWJlNTMyYTAzYjQ3MzhiMzdiNGEzNWFjNmNlNzZkL3RleHRyZWdpb246MzVlYmU1MzJhMDNiNDczOGIzN2I0YTM1YWM2Y2U3NmRfMzI5ODUzNDkyNzIyNw_64b720ae-b587-4045-8809-ef3c8614f21b" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Software Development Costs</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company capitalizes the cost of developing internal-use software, consisting primarily of personnel and related expenses (including stock-based compensation and employee taxes and benefits) for employees and third parties who devote time to their respective projects. Internal-use software costs are capitalized during the application development stage &#8211; when the research stage is complete and management has committed to a project to develop software that will be used for its intended purpose. Any costs incurred during subsequent efforts to significantly upgrade and enhance the functionality of the software are also capitalized. Capitalized software costs are included in property and equipment, net on our consolidated balance sheets. Amortization of internal-use software costs are recorded on a straight-line basis over their estimated useful life and begin once the project is substantially complete and the software is ready for its intended purpose.</span></div></ix:nonNumeric><div style="text-align:justify"><span><br/></span></div><ix:nonNumeric contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231" name="us-gaap:ResearchAndDevelopmentExpensePolicy" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM180My9mcmFnOjM1ZWJlNTMyYTAzYjQ3MzhiMzdiNGEzNWFjNmNlNzZkL3RleHRyZWdpb246MzVlYmU1MzJhMDNiNDczOGIzN2I0YTM1YWM2Y2U3NmRfMzI5ODUzNDkyNzIyOA_5104750a-44f9-4dfc-a87f-42a0341ce72d" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and Development Costs</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development costs consist primarily of personnel and related expenses (including stock-based compensation and employee taxes and benefits) for employees engaged in research and development activities as well as third-party fees. All such costs are expensed as incurred. We focus our research and development efforts on activities that support our technology infrastructure, clinical program development, data analytics and network development capabilities. Research and development costs are recorded within selling, general and administrative expenses on our consolidated statements of operations and comprehensive income (loss) and were $<ix:nonFraction unitRef="usd" contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231" decimals="-5" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM180My9mcmFnOjM1ZWJlNTMyYTAzYjQ3MzhiMzdiNGEzNWFjNmNlNzZkL3RleHRyZWdpb246MzVlYmU1MzJhMDNiNDczOGIzN2I0YTM1YWM2Y2U3NmRfMTA5OTUxMTY1NzU1Nw_1c01de54-e546-42c2-8a09-eef9a6486985">15.5</ix:nonFraction>&#160;million, $<ix:nonFraction unitRef="usd" contextRef="i12a6d1161de54547bd29f8efccd4c9b0_D20200101-20201231" decimals="-5" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM180My9mcmFnOjM1ZWJlNTMyYTAzYjQ3MzhiMzdiNGEzNWFjNmNlNzZkL3RleHRyZWdpb246MzVlYmU1MzJhMDNiNDczOGIzN2I0YTM1YWM2Y2U3NmRfMTA5OTUxMTY1NzUyNw_753d9ca8-60cf-4c45-baab-28b5afb34634">15.1</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i3e21049ffc224cacb8134d73c9bb5b38_D20190101-20191231" decimals="-5" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM180My9mcmFnOjM1ZWJlNTMyYTAzYjQ3MzhiMzdiNGEzNWFjNmNlNzZkL3RleHRyZWdpb246MzVlYmU1MzJhMDNiNDczOGIzN2I0YTM1YWM2Y2U3NmRfMTA5OTUxMTY1NzU0Mg_964905bf-d0d8-4329-82b5-63f3f974ff22">19.8</ix:nonFraction>&#160;million for the years ended December 31, 2021, 2020 and 2019, respectively.</span></div></ix:nonNumeric><div style="text-align:justify"><span><br/></span></div><ix:nonNumeric contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231" name="us-gaap:BusinessCombinationsPolicy" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM180My9mcmFnOjM1ZWJlNTMyYTAzYjQ3MzhiMzdiNGEzNWFjNmNlNzZkL3RleHRyZWdpb246MzVlYmU1MzJhMDNiNDczOGIzN2I0YTM1YWM2Y2U3NmRfMTU3MTI_2678520d-5511-4c93-ba73-e11e12a4388a" continuedAt="i4b54501ad53b4c29a1e5f02a70ed3b4e" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Business Combinations</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Companies acquired during each reporting period are reflected in the results of the Company effective from their respective dates of acquisition through the end of the reporting period. The Company allocates the fair value of purchase consideration to the assets acquired and liabilities assumed based on their estimated fair values at the acquisition date. Our estimates of fair value are based upon assumptions believed to be reasonable, but which are inherently uncertain and unpredictable and, as a result, actual results may differ </span></div></ix:nonNumeric></ix:continuation><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">77</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i5a242be18295407eab79721e8085f6fb" continuedAt="i180a7393c90f49e59ca8eae45864d268"><ix:continuation id="i4b54501ad53b4c29a1e5f02a70ed3b4e"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">from estimates. Critical estimates used to value certain identifiable assets include, but are not limited to, expected long-term revenues, future expected operating expenses, cost of capital and appropriate discount rates. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The excess of the fair value of purchase consideration over the fair value of the assets acquired and liabilities assumed in the acquired entity is recorded as goodwill. Goodwill is assigned to the reporting unit that benefits from the synergies arising from the business combination. If the Company obtains new information about facts and circumstances that existed as of the acquisition date during the measurement period, which may be up to one year from the acquisition date, the Company may record adjustments to the assets acquired and liabilities assumed, with the corresponding offset to goodwill. Upon the conclusion of the measurement period or final determination of the values of assets acquired or liabilities assumed, whichever comes first, any subsequent adjustments are recorded on the Company's consolidated statements of operations and comprehensive income (loss). </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For contingent consideration recorded as a liability, the Company initially measures the amount at fair value as of the acquisition date and adjusts the liability, if needed, to fair value at each reporting period. Changes in the fair value of contingent consideration, other than measurement period adjustments, are recognized as operating income or expense. Acquisition-related expenses are recognized separately from the business combination and are expensed as incurred.</span></div></ix:continuation><div style="text-align:justify"><span><br/></span></div><ix:nonNumeric contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231" name="us-gaap:EquityMethodInvestmentsPolicy" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM180My9mcmFnOjM1ZWJlNTMyYTAzYjQ3MzhiMzdiNGEzNWFjNmNlNzZkL3RleHRyZWdpb246MzVlYmU1MzJhMDNiNDczOGIzN2I0YTM1YWM2Y2U3NmRfMzI5ODUzNDkyNzIyOQ_25b4dfe5-e591-47d4-8d13-94fedf64c564" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Equity Method Investments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For entities that are not consolidated, but where the Company has significant influence over the operating or financial decisions of the entity, the Company accounts for the investment under the equity method of accounting. In accordance with the equity method of accounting, the Company will recognize its share of earnings or losses of the investee in the period in which they are reported by the investee. The Company also considers whether there are any indicators of other-than-temporary impairment of its investments accounted for under the equity method. These investments are included in investments in equity method investees on the consolidated balance sheets with income or loss included in gain (loss) from equity method investees on the consolidated statements of operations and comprehensive income (loss).</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Impairment of Equity Method Investments</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company considers certain factors to determine if there is a decrease in its investment fair value for its equity method investments that is other than temporary. The equity method investments will be written down to fair value if there is evidence of a loss in value which is other-than-temporary. The Company may estimate the fair value of its equity method investments by considering recent investee equity transactions, discounted cash flow analysis and recent operating results. If the fair value of the investment is below the carrying amount, management considers several factors when determining whether other-than-temporary impairment has occurred. The estimation of fair value and whether other-than-temporary impairment has occurred requires the application of significant judgment and future results may vary from current assumptions. Refer to Note 17 for additional discussion regarding impairments on equity method investments.</span></div></ix:nonNumeric><div><span><br/></span></div><ix:nonNumeric contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231" name="us-gaap:GoodwillAndIntangibleAssetsGoodwillPolicy" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM180My9mcmFnOjM1ZWJlNTMyYTAzYjQ3MzhiMzdiNGEzNWFjNmNlNzZkL3RleHRyZWdpb246MzVlYmU1MzJhMDNiNDczOGIzN2I0YTM1YWM2Y2U3NmRfMTU3MjI_aef6fdfe-96b4-4d8b-bd92-8fcfc41a42f2" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Goodwill</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize the excess of the purchase price, plus the fair value of any non-controlling interests in the acquiree, over the fair value of identifiable net assets acquired as goodwill. Goodwill is not amortized, but is reviewed at least annually for indications of impairment, with consideration given to financial performance and other relevant factors. We perform impairment tests of goodwill at a reporting unit level. Following the sale of True Health, the Company has <ix:nonFraction unitRef="unit" contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231" decimals="INF" name="us-gaap:NumberOfReportingUnits" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM180My9mcmFnOjM1ZWJlNTMyYTAzYjQ3MzhiMzdiNGEzNWFjNmNlNzZkL3RleHRyZWdpb246MzVlYmU1MzJhMDNiNDczOGIzN2I0YTM1YWM2Y2U3NmRfODA0OQ_369d52b2-e96e-40fb-b338-7a284aa52c23">three</ix:nonFraction> reporting units and our annual goodwill impairment review occurs during the fourth quarter of each year. We perform impairment tests between annual tests if an event occurs, or circumstances change, that we believe would more likely than not reduce the fair value of a reporting unit below its carrying amount. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our goodwill impairment analysis first assesses qualitative factors to determine whether events or circumstances existed that would lead the Company to conclude it is more likely than not that the fair value of a reporting unit is below its carrying amount. If the Company determines that it is more likely than not that the fair value of a reporting unit is below the carrying amount, a quantitative goodwill assessment is required. In the quantitative evaluation, the fair value of the relevant reporting unit is determined and compared to the carrying value. If the fair value is greater than the carrying value, then the carrying value is deemed to be recoverable and no further action is required. If the fair value estimate is less than the carrying value, goodwill is considered impaired for the amount by which the carrying amount exceeds the reporting unit&#8217;s fair value and a charge is reported in goodwill impairment on our consolidated statements of operations and comprehensive income (loss). See Note 9 for additional discussion regarding the goodwill impairment tests conducted during 2021 and 2020.</span></div></ix:nonNumeric></ix:continuation><div style="text-align:justify"><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">78</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i180a7393c90f49e59ca8eae45864d268" continuedAt="ib39c093caa7f429ea7b5913ecd04265a"><ix:nonNumeric contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231" name="us-gaap:IntangibleAssetsFiniteLivedPolicy" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM180My9mcmFnOjM1ZWJlNTMyYTAzYjQ3MzhiMzdiNGEzNWFjNmNlNzZkL3RleHRyZWdpb246MzVlYmU1MzJhMDNiNDczOGIzN2I0YTM1YWM2Y2U3NmRfMTU3NjE_f429d292-7193-4d9e-8668-9537eaef5469" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Intangible Assets, Net </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Identified intangible assets are recorded at their estimated fair values at the date of acquisition and are amortized over their respective estimated useful lives using a method of amortization that reflects the pattern in which the economic benefits of the intangible assets are used. </span></div><div style="text-align:justify"><span><br/></span></div><ix:nonNumeric contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231" name="us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM180My9mcmFnOjM1ZWJlNTMyYTAzYjQ3MzhiMzdiNGEzNWFjNmNlNzZkL3RleHRyZWdpb246MzVlYmU1MzJhMDNiNDczOGIzN2I0YTM1YWM2Y2U3NmRfMTU3Mjg_9ee25e6e-93c9-4f2d-bf08-a149ddda1f92" continuedAt="if729c6e414c04966af3dc51a5112f71b" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following summarizes the estimated useful lives by asset classification:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"></td><td style="width:438.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:97.75pt"></td><td style="width:1.0pt"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate trade name</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ibff83f3576fa462088fb611595ae2107_D20210101-20211231" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM180My9mcmFnOjM1ZWJlNTMyYTAzYjQ3MzhiMzdiNGEzNWFjNmNlNzZkL3RhYmxlOmNiNDQzOTY5NjgzYzQ4NThhNDJmYjg0MTI4ZTViMTE2L3RhYmxlcmFuZ2U6Y2I0NDM5Njk2ODNjNDg1OGE0MmZiODQxMjhlNWIxMTZfMC0xLTEtMS0xNzc3NS90ZXh0cmVnaW9uOjMwMWQwMGQxYTQzMDQwMDQ4ZjM0MmNkZWZjYWE3Yjc3XzQ_ffb16074-a85f-4f3f-93a1-de9e296bdf07">10</ix:nonNumeric> - <ix:nonNumeric contextRef="ie3bf7bed53b145e699f90d4132648c21_D20210101-20211231" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM180My9mcmFnOjM1ZWJlNTMyYTAzYjQ3MzhiMzdiNGEzNWFjNmNlNzZkL3RhYmxlOmNiNDQzOTY5NjgzYzQ4NThhNDJmYjg0MTI4ZTViMTE2L3RhYmxlcmFuZ2U6Y2I0NDM5Njk2ODNjNDg1OGE0MmZiODQxMjhlNWIxMTZfMC0xLTEtMS0xNzc3NS90ZXh0cmVnaW9uOjMwMWQwMGQxYTQzMDQwMDQ4ZjM0MmNkZWZjYWE3Yjc3Xzk_ffc6009b-8a5b-4d6d-a494-9f7eaa84de9d">20</ix:nonNumeric> years</span></div></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer relationships</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i3ca5e8fff37648578ddcb5915d42bd23_D20210101-20211231" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM180My9mcmFnOjM1ZWJlNTMyYTAzYjQ3MzhiMzdiNGEzNWFjNmNlNzZkL3RhYmxlOmNiNDQzOTY5NjgzYzQ4NThhNDJmYjg0MTI4ZTViMTE2L3RhYmxlcmFuZ2U6Y2I0NDM5Njk2ODNjNDg1OGE0MmZiODQxMjhlNWIxMTZfMS0xLTEtMS0xNzc3NS90ZXh0cmVnaW9uOjk1YzJlMzVlNmFiYzRhN2I4OWE5OTZiMTJmZjEzZGEyXzQ_23e9e49e-5186-467d-b55e-a311b9a92e35">10</ix:nonNumeric> - <ix:nonNumeric contextRef="i4cff67909d644529824bdb1faef1b019_D20210101-20211231" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM180My9mcmFnOjM1ZWJlNTMyYTAzYjQ3MzhiMzdiNGEzNWFjNmNlNzZkL3RhYmxlOmNiNDQzOTY5NjgzYzQ4NThhNDJmYjg0MTI4ZTViMTE2L3RhYmxlcmFuZ2U6Y2I0NDM5Njk2ODNjNDg1OGE0MmZiODQxMjhlNWIxMTZfMS0xLTEtMS0xNzc3NS90ZXh0cmVnaW9uOjk1YzJlMzVlNmFiYzRhN2I4OWE5OTZiMTJmZjEzZGEyXzk_7a6d5078-ec48-4803-a08a-43e5d7caff77">25</ix:nonNumeric> years</span></div></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Technology</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i701391050b2e43d082d405d3d16746d2_D20210101-20211231" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM180My9mcmFnOjM1ZWJlNTMyYTAzYjQ3MzhiMzdiNGEzNWFjNmNlNzZkL3RhYmxlOmNiNDQzOTY5NjgzYzQ4NThhNDJmYjg0MTI4ZTViMTE2L3RhYmxlcmFuZ2U6Y2I0NDM5Njk2ODNjNDg1OGE0MmZiODQxMjhlNWIxMTZfMi0xLTEtMS0xNzc3NQ_2f86b2be-0027-4fb4-ba98-bb258fd6f0da">5</ix:nonNumeric> years</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provider network contracts</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i6d3cdc666422461398b727dbf8a5d16e_D20210101-20211231" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM180My9mcmFnOjM1ZWJlNTMyYTAzYjQ3MzhiMzdiNGEzNWFjNmNlNzZkL3RhYmxlOmNiNDQzOTY5NjgzYzQ4NThhNDJmYjg0MTI4ZTViMTE2L3RhYmxlcmFuZ2U6Y2I0NDM5Njk2ODNjNDg1OGE0MmZiODQxMjhlNWIxMTZfMy0xLTEtMS0xNzc3NS90ZXh0cmVnaW9uOjNiMjEzMTYwNWQyNjQ0NTNiM2ZkZWMzY2Q4NGE0NGJmXzQ_1834ad11-72b1-4a35-8632-97b5b45a3951">3</ix:nonNumeric> - <ix:nonNumeric contextRef="i80595e56a7a74f699957bf0f9a4173ce_D20210101-20211231" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM180My9mcmFnOjM1ZWJlNTMyYTAzYjQ3MzhiMzdiNGEzNWFjNmNlNzZkL3RhYmxlOmNiNDQzOTY5NjgzYzQ4NThhNDJmYjg0MTI4ZTViMTE2L3RhYmxlcmFuZ2U6Y2I0NDM5Njk2ODNjNDg1OGE0MmZiODQxMjhlNWIxMTZfMy0xLTEtMS0xNzc3NS90ZXh0cmVnaW9uOjNiMjEzMTYwNWQyNjQ0NTNiM2ZkZWMzY2Q4NGE0NGJmXzk_87d2a928-cf0e-4531-87d3-4e2baf17f7a7">5</ix:nonNumeric> years</span></div></td></tr></table></div></ix:nonNumeric><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets are reviewed for impairment if circumstances indicate the Company may not be able to recover the asset&#8217;s carrying value. The Company evaluates recoverability by determining whether the undiscounted cash flows expected to result from the use and eventual disposition of that asset or group exceed the carrying value at the evaluation date. If the undiscounted cash flows are not sufficient to cover the carrying value, the Company measures an impairment loss as the excess of the carrying amount of the long-lived asset or group over its fair value. See Note 9 for additional discussion regarding our intangible assets.</span></div></ix:nonNumeric><div style="text-align:justify"><span><br/></span></div><ix:nonNumeric contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231" name="us-gaap:LiabilityReserveEstimatePolicy" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM180My9mcmFnOjM1ZWJlNTMyYTAzYjQ3MzhiMzdiNGEzNWFjNmNlNzZkL3RleHRyZWdpb246MzVlYmU1MzJhMDNiNDczOGIzN2I0YTM1YWM2Y2U3NmRfMTU3NzI_3199dda7-a656-4043-9fd2-388d217d151d" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Reserves for Claims and Performance-based Arrangements</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Reserves for claims and performance-based arrangements reflect estimates of payments under performance-based arrangements and the ultimate cost of claims that have been incurred but not reported, including expected development on reported claims, those that have been reported but not yet paid (reported claims in process) and other medical care expenses and services payable that are primarily composed of accruals for incentives and other amounts payable to health care professionals and facilities. The Company uses actuarial principles and assumptions that are consistently applied in each reporting period and recognizes the actuarial best estimate of the ultimate liability along with a margin for adverse deviation. This approach is consistent with actuarial standards of practice that the liabilities be adequate under moderately adverse conditions. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The process of estimating reserves involves a considerable degree of judgment by the Company and, as of any given date, is inherently uncertain. The methods for making such estimates and for establishing the resulting liability are continually reviewed and adjustments are reflected in current results of operations in the period in which they are identified as experience develops or new information becomes known. See Note 23 for additional discussion regarding our reserves for claims and performance-based arrangements.</span></div></ix:nonNumeric><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231" name="evh:RightOfOffsetPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM180My9mcmFnOjM1ZWJlNTMyYTAzYjQ3MzhiMzdiNGEzNWFjNmNlNzZkL3RleHRyZWdpb246MzVlYmU1MzJhMDNiNDczOGIzN2I0YTM1YWM2Y2U3NmRfMzg0ODI5MDc0MzYxOA_4c35f945-774d-4b38-b2a2-be1ff089ec6b" continuedAt="i10d23c5225364e729bb28cc66566a50f" escape="true">Right of Offset</ix:nonNumeric></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i10d23c5225364e729bb28cc66566a50f">Certain customer arrangements give the Company the legal right to net payment for amounts due from customers and claims payable.</ix:continuation> As of December 31, 2021 and 2020, approximately <ix:nonFraction unitRef="number" contextRef="i8daff60be410426d8f7bd49343c1ec0c_I20211231" decimals="2" name="evh:RightOfOffsetPercentageOfAccountsReceivableNettedAgainstClaimsPayable" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM180My9mcmFnOjM1ZWJlNTMyYTAzYjQ3MzhiMzdiNGEzNWFjNmNlNzZkL3RleHRyZWdpb246MzVlYmU1MzJhMDNiNDczOGIzN2I0YTM1YWM2Y2U3NmRfMjc0ODc3OTExNjAyMg_9a3ab4fb-cbe2-4a22-8f0c-c70e665c54af">42</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="ibc0c0c2b8dc04c5698ca0577a54b2e03_I20201231" decimals="INF" name="evh:RightOfOffsetPercentageOfAccountsReceivableNettedAgainstClaimsPayable" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM180My9mcmFnOjM1ZWJlNTMyYTAzYjQ3MzhiMzdiNGEzNWFjNmNlNzZkL3RleHRyZWdpb246MzVlYmU1MzJhMDNiNDczOGIzN2I0YTM1YWM2Y2U3NmRfMjc0ODc3OTExNjAyNw_0f5f2fa4-0af4-4568-a856-01d55b4d2feb">&#8212;</ix:nonFraction>% of gross accounts receivable have been netted against claims payable. Furthermore, as of December 31, 2021, approximately <ix:nonFraction unitRef="number" contextRef="i8daff60be410426d8f7bd49343c1ec0c_I20211231" decimals="2" name="evh:RightOfOffsetPercentageOfAccountsReceivableNetEligibleForNetBasisSettlement" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM180My9mcmFnOjM1ZWJlNTMyYTAzYjQ3MzhiMzdiNGEzNWFjNmNlNzZkL3RleHRyZWdpb246MzVlYmU1MzJhMDNiNDczOGIzN2I0YTM1YWM2Y2U3NmRfMzg0ODI5MDc0MzYxNA_d0667495-3a79-4e7c-8490-5648a87418ee">55</ix:nonFraction>% of our accounts receivable, net could ultimately be settled on a net basis, once the criteria for netting have been met.</span></div><div style="text-align:justify"><span><br/></span></div><ix:nonNumeric contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231" name="us-gaap:DebtPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM180My9mcmFnOjM1ZWJlNTMyYTAzYjQ3MzhiMzdiNGEzNWFjNmNlNzZkL3RleHRyZWdpb246MzVlYmU1MzJhMDNiNDczOGIzN2I0YTM1YWM2Y2U3NmRfMzI5ODUzNDkyNzIzMA_05421567-51fc-413f-9891-d847c5a069f3" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Long-term Debt</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Convertible notes and amounts borrowed under our credit agreement are carried at cost, net of debt discounts and issuance costs, as long-term debt on the consolidated balance sheets. The debt discounts and issuance costs are amortized to interest expense on the consolidated statements of operations and comprehensive income (loss) using the straight-line method over the contractual term of the note if that method is not materially different from the effective interest rate method. Cash interest payments are due either quarterly or semi-annually in arrears and we accrue interest expense monthly based on the annual coupon rate. See Note 10 for further discussion regarding our convertible notes and credit agreement.</span></div></ix:nonNumeric><div style="text-align:justify"><span><br/></span></div><ix:nonNumeric contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231" name="us-gaap:LesseeLeasesPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM180My9mcmFnOjM1ZWJlNTMyYTAzYjQ3MzhiMzdiNGEzNWFjNmNlNzZkL3RleHRyZWdpb246MzVlYmU1MzJhMDNiNDczOGIzN2I0YTM1YWM2Y2U3NmRfMTU3NDk_579805a1-24fa-4be6-a5c4-a877829d26c6" continuedAt="iec942cf0164a46fb986b7d7b6ccefb7f" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Leases</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company enters into various office space, data center and equipment lease agreements in conducting its normal business operations. At the inception of any contract, the Company evaluates the agreement to determine whether the contract contains a lease. If the contract contains a lease, the Company then evaluates the term and whether the lease is an operating or finance lease. Most leases include one or more options to renew or may have a termination option. The Company determines whether these options are reasonably certain to be exercised at the inception of the lease. The rent expense is recognized on a straight-line basis in the consolidated statements of operations and comprehensive income (loss) over the terms of the respective leases. Leases with an initial term of 12 months or less are not recorded on the consolidated balance sheets.</span></div></ix:nonNumeric></ix:continuation><div style="text-align:justify"><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">79</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="ib39c093caa7f429ea7b5913ecd04265a" continuedAt="ice4e786545984affb5172c062f66298d"><ix:continuation id="iec942cf0164a46fb986b7d7b6ccefb7f"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As most of our leases do not provide an implicit rate, we use our incremental borrowing rate based on the information available at commencement date in determining the present value of lease payments. We use the implicit rate when readily determinable. Further, the Company treats all lease and non-lease components as a single combined lease component for all classes of underlying assets.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company also enters into sublease agreements for some of its leased office space. Rental income attributable to subleases is immaterial and is offset against rent expense over the terms of the respective leases.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Refer to Note 12 for additional lease disclosures.</span></div></ix:continuation><div style="text-align:justify"><span><br/></span></div><ix:nonNumeric contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231" name="us-gaap:RevenueFromContractWithCustomerPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM180My9mcmFnOjM1ZWJlNTMyYTAzYjQ3MzhiMzdiNGEzNWFjNmNlNzZkL3RleHRyZWdpb246MzVlYmU1MzJhMDNiNDczOGIzN2I0YTM1YWM2Y2U3NmRfMTU3ODM_64f13be4-2989-4748-af49-5666bfb45f3e" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue Recognition</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We derive revenue from two sources: (1) transformation services and (2) platform and operations services. Transformation services consist of implementation services whereby we assist the customer in launching its population health or health plan programs, or implement certain platform and operations services. In certain cases, transformation services can also include revenue associated with our support of certain one-time wind-down activities for clients who are exiting a line of business or population. Platform and operations services generally include multi-year arrangements with customers to provide various population health, health plan operations, specialty care management and claims processing services on an ongoing basis, as well as transition or run-out services to customers receiving primarily TPA services. Revenue is recognized when control of the services is transferred to our customers.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We use the following 5-step model, outlined in Accounting Standards Codification (&#8220;ASC&#8221;) Topic 606, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue from Contracts with Customers</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (&#8220;ASC 606&#8221;), to determine revenue recognition from our contracts with customers:</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"> Identify the contract(s) with a customer</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"> Identify the performance obligations in the contract</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"> Determine the transaction price</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"> Allocate the transaction price to performance obligations</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"> Recognize revenue when (or as) the entity satisfies a performance obligation</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Note 6 for further discussion of our policies related to revenue recognition. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cost of Revenue (Exclusive of Depreciation and Amortization)</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our cost of revenue includes direct expenses and shared resources that perform services in direct support of clients. Costs consist primarily of employee-related expenses (including compensation, benefits and stock-based compensation), expenses for TPA support and other services, as well as other professional fees. In certain cases, our cost of revenue also includes claims and capitation payments to providers and payments for pharmaceutical treatments and other health care expenditures through capitated arrangements.</span></div></ix:nonNumeric><div style="text-align:justify"><span><br/></span></div><ix:nonNumeric contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231" name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM180My9mcmFnOjM1ZWJlNTMyYTAzYjQ3MzhiMzdiNGEzNWFjNmNlNzZkL3RleHRyZWdpb246MzVlYmU1MzJhMDNiNDczOGIzN2I0YTM1YWM2Y2U3NmRfMzI5ODUzNDkyNzIzMg_e85c8950-7fab-47ce-b91a-fa497083973a" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Stock-based Compensation</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company sponsors a stock-based incentive plan that provides for the issuance of stock-based awards to employees, vendors and non-employee directors of the Company or its consolidated subsidiaries. Our stock-based awards generally vest over a <ix:nonNumeric contextRef="i532d2c0bf63243e999d48341920b6775_D20210101-20211231" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM180My9mcmFnOjM1ZWJlNTMyYTAzYjQ3MzhiMzdiNGEzNWFjNmNlNzZkL3RleHRyZWdpb246MzVlYmU1MzJhMDNiNDczOGIzN2I0YTM1YWM2Y2U3NmRfMzg0ODI5MDc0MTEzNA_d4494652-32d7-49d7-8853-12a923bc9643">four-year</ix:nonNumeric> period and stock options expire <ix:nonNumeric contextRef="i532d2c0bf63243e999d48341920b6775_D20210101-20211231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM180My9mcmFnOjM1ZWJlNTMyYTAzYjQ3MzhiMzdiNGEzNWFjNmNlNzZkL3RleHRyZWdpb246MzVlYmU1MzJhMDNiNDczOGIzN2I0YTM1YWM2Y2U3NmRfMzg0ODI5MDc0MTEzNg_5fd38458-7d35-4a5a-94f2-c0d7e5204f18">10</ix:nonNumeric> years from the date of grant.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expense the fair value of stock-based awards granted under our incentive compensation plans. Fair value of stock options is determined using a Black-Scholes options valuation methodology. The fair value of the awards is expensed over the performance or service period, which generally corresponds to the vesting period, on a straight-line basis and is recognized as an increase to additional paid-in capital. Stock-based compensation expense is reflected in cost of revenue and selling, general and administrative expenses in our consolidated statements of operations and comprehensive income (loss). Additionally, and if applicable, we capitalize personnel expenses attributable to the development of internal-use software, which include stock-based compensation costs. We recognize share-based award forfeitures as they occur.</span></div></ix:nonNumeric><div style="text-align:justify"><span><br/></span></div><ix:nonNumeric contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231" name="us-gaap:IncomeTaxPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM180My9mcmFnOjM1ZWJlNTMyYTAzYjQ3MzhiMzdiNGEzNWFjNmNlNzZkL3RleHRyZWdpb246MzVlYmU1MzJhMDNiNDczOGIzN2I0YTM1YWM2Y2U3NmRfMzI5ODUzNDkyNzIzMw_3d57bda3-3d01-4962-98ad-036fb128a5c7" continuedAt="ic95cd71e6b974c8b81ed7a1f3acbe3d3" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Taxes</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred income taxes are recognized, based on enacted rates, when assets and liabilities have different values for financial statement and tax reporting purposes. A valuation allowance is recorded to the extent required. Considerable judgment and the use of estimates are required in determining whether a valuation allowance is necessary and, if so, the amount of such valuation allowance. In evaluating the need for a valuation allowance, we consider many factors, including: the nature and character of the deferred tax assets and liabilities; taxable income in prior carryback years; future reversals of temporary differences; the length of time carryovers can be utilized; and any tax planning strategies we would employ to avoid a tax benefit from expiring unused.</span></div></ix:nonNumeric></ix:continuation><div style="text-align:justify"><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">80</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="ice4e786545984affb5172c062f66298d"><ix:continuation id="ic95cd71e6b974c8b81ed7a1f3acbe3d3"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We use a recognition threshold and a measurement attribute for the financial statement recognition and measurement of uncertain tax positions taken or expected to be taken in a tax return. For those benefits to be recognized, a tax position must be more-likely-than-not to be sustained upon examination by taxing authorities. We recognize interest and penalties accrued on any unrecognized tax exposures as a component of income tax expense, when applicable. As of December 31, 2021 and 2020, our identified balance of uncertain income tax positions would not have a material impact to the consolidated financial statements. We are subject to taxation in various jurisdictions in the U.S. and India and remain subject to examination by taxing jurisdictions for the year 2011 and all subsequent periods due to the availability of NOL carryforwards.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a holding company and our assets consist of our direct ownership in Evolent Health LLC, for which we are the managing member. Prior to the Class B unit exchanges on December 26, 2019, Evolent Health LLC was classified as a partnership for U.S. federal and applicable state and local income tax purposes and, as such, was not subject to U.S. federal, state and local income taxes. Taxable income or loss generated by Evolent Health LLC was allocated to holders of its units, including us, on a pro rata basis. Accordingly, we were subject to U.S. federal, state and local income taxes with respect to our allocable share of any taxable income of Evolent Health LLC. As a result of the 2019 Class B units exchanges, we became the sole owner of Evolent Health LLC and its entity classification changed from a partnership to an entity disregarded as separate from its owner for U.S. federal, state and local income tax purposes. Following the Class B units exchanges, any taxable income or loss generated by Evolent Health LLC is reportable and taxable only on the Company&#8217;s federal, state and local income tax returns. Evolent Health LLC has direct ownership in corporate subsidiaries, which were subject to U.S. and foreign taxes with respect to their own operations during 2019.</span></div></ix:continuation><div><span><br/></span></div><ix:nonNumeric contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231" name="us-gaap:EarningsPerSharePolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM180My9mcmFnOjM1ZWJlNTMyYTAzYjQ3MzhiMzdiNGEzNWFjNmNlNzZkL3RleHRyZWdpb246MzVlYmU1MzJhMDNiNDczOGIzN2I0YTM1YWM2Y2U3NmRfMzI5ODUzNDkyNzIzNA_fa83dabe-1371-4bee-8b53-be3658e204ea" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Earnings (Loss) per Share</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic earnings (loss) per share is computed by dividing net income (loss) available to Class A common shareholders by the weighted-average number of Class A common shares outstanding.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For periods of net income, and when the effects are not anti-dilutive, we calculate diluted earnings per share by dividing net income available to Class A common shareholders by the weighted average number of Class A common shares plus the weighted average number of Class A common shares assuming the conversion of our convertible notes, as well as the impact of all potential dilutive common shares, consisting primarily of common stock options and unvested restricted stock awards using the treasury stock method and our exchangeable Class B common stock. For periods of net loss, shares used in the diluted earnings (loss) per share calculation represent basic shares as using potentially dilutive shares would be anti-dilutive.</span></div></ix:nonNumeric><div><span><br/></span></div><ix:nonNumeric contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231" name="us-gaap:FairValueMeasurementPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM180My9mcmFnOjM1ZWJlNTMyYTAzYjQ3MzhiMzdiNGEzNWFjNmNlNzZkL3RleHRyZWdpb246MzVlYmU1MzJhMDNiNDczOGIzN2I0YTM1YWM2Y2U3NmRfMzI5ODUzNDkyNzIzNQ_4d429f21-2f85-483e-be24-d34e1d2a4a83" continuedAt="i7623edd0172b4b279ee25421e8a9a7d1" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fair Value Measurement</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fair value is the price that would be received from the sale of an asset or paid to transfer a liability assuming an orderly transaction in the most advantageous market at the measurement date. Our consolidated balance sheets include various financial instruments (primarily cash not held in money-market funds, restricted cash, accounts receivable, accounts payable, accrued expenses and other liabilities) that are carried at cost and that approximate fair value.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Note 19 for further discussion regarding fair value measurement.</span></div></ix:nonNumeric></ix:continuation><div><span><br/></span></div><div id="i9aaa2fddc97e482da5dbe37ac85ae703_46"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 3.  <ix:nonNumeric contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231" name="us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM180Ni9mcmFnOjhkNTIzNGI1NjdkZjRiMThiNjM1NmFmN2Q4OWQ4MDE3L3RleHRyZWdpb246OGQ1MjM0YjU2N2RmNGIxOGI2MzU2YWY3ZDg5ZDgwMTdfMzI1MQ_8eac6c15-ccb7-4661-b943-77271c40d263" continuedAt="icf1c197c79c743cb886e1613e89d8adc" escape="true">Recently Issued Accounting Standards</ix:nonNumeric></span></div><div><span><br/></span></div><ix:continuation id="icf1c197c79c743cb886e1613e89d8adc" continuedAt="i06e9f27ecccd484795b7689c773bbc39"><ix:nonNumeric contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM180Ni9mcmFnOjhkNTIzNGI1NjdkZjRiMThiNjM1NmFmN2Q4OWQ4MDE3L3RleHRyZWdpb246OGQ1MjM0YjU2N2RmNGIxOGI2MzU2YWY3ZDg5ZDgwMTdfMzI1OA_37d6f2b0-c14d-4240-b146-49442d63621f" continuedAt="i7c9267bdf605470992e465cdf73b15e7" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Adoption of New Accounting Standards</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2016, the FASB issued ASU 2016-13, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financial Instruments-Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and subsequently issued additional guidance that modified ASU 2016-13. The standard requires an entity to change its accounting approach for measuring and recognizing credit losses on certain financial assets measured at amortized cost, including trade receivables, certain non-trade receivables, contract assets, held-to-maturity securities, customer advances and certain off-balance sheet credit exposures, by replacing the existing &#8220;incurred loss&#8221; framework with an expected credit loss recognition model.&#160; The new standard results in earlier recognition of credit losses based on past events, current conditions and reasonable and supportable forecasts.&#160;We adopted the requirements of this standard effective January 1, 2020 using the modified retrospective approach and recorded a cumulative effect adjustment of $<ix:nonFraction unitRef="usd" contextRef="i86eec55ebc424a56b5b5394b8b2b2423_I20191231" decimals="-5" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM180Ni9mcmFnOjhkNTIzNGI1NjdkZjRiMThiNjM1NmFmN2Q4OWQ4MDE3L3RleHRyZWdpb246OGQ1MjM0YjU2N2RmNGIxOGI2MzU2YWY3ZDg5ZDgwMTdfMTIwMA_61779148-74c7-47d4-add9-d77a7dad7e40">3.0</ix:nonFraction> million to January 1, 2020 retained earnings (accumulated deficit). Results for reporting periods beginning January 1, 2020 reflect the adoption of <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM180Ni9mcmFnOjhkNTIzNGI1NjdkZjRiMThiNjM1NmFmN2Q4OWQ4MDE3L3RleHRyZWdpb246OGQ1MjM0YjU2N2RmNGIxOGI2MzU2YWY3ZDg5ZDgwMTdfMzI1Ng_c324734f-03c4-4b52-af23-6ac596334a4b">ASU 2016-13</span>, while prior period amounts were not adjusted and continue to be reported in accordance with our historical accounting practices. Refer to Note 7 for additional disclosures related to current expected credit losses.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2019, the FASB issued ASU No. 2019-12,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Simplifying the Accounting for Income Taxes.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The amendments in the ASU remove certain exceptions to the intraperiod tax allocation of losses and gains from different financial statement components and to the method of recognizing income taxes on interim period losses and the recognition of deferred tax liabilities for outside basis differences. In addition, the new guidance simplifies aspects of the accounting for franchise taxes and clarifies the accounting for </span></div></ix:nonNumeric></ix:continuation><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">81</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i06e9f27ecccd484795b7689c773bbc39"><ix:continuation id="i7c9267bdf605470992e465cdf73b15e7"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">transactions that result in a step-up in the tax basis of goodwill. The Company adopted this standard starting in the first quarter of 2021, which did not have a material impact on our consolidated financial statements.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2020, the FASB issued ASU 2020-06, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Accounting for Convertible Instruments and Contracts in an Entity&#8217;s Own Equity</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The ASU simplifies the accounting for certain financial instruments with characteristics of liabilities and equity, including convertible instruments and contracts in an entity&#8217;s own equity. Specifically, the ASU removes the separation models for convertible debt with a cash conversion feature or convertible instruments with a beneficial conversion feature and no longer permits the use of the treasury stock method from calculating earnings per share. As a result, after adopting the ASU&#8217;s guidance, we will not separately present in equity an embedded conversion feature of such debt. Instead, we will account for a convertible debt instrument wholly as debt unless (i) a convertible instrument contains features that require bifurcation as a derivative or (ii) a convertible debt instrument was issued at a substantial premium. Additionally, the ASU removes certain conditions for equity classification related to contracts in an entity&#8217;s own equity (e.g., warrants) and amends certain guidance related to the computation of earnings per share for convertible instruments and contracts on an entity&#8217;s own equity. The guidance in this ASU can be adopted using either a full or modified retrospective approach and becomes effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2021. We will adopt the ASU in the first quarter of fiscal 2022, and expect to use modified retrospective approach. The Company is currently assessing the impact, if any, that ASU 2020-06 would have on its financial position, results of operations or cash flows, however, the inability to use the treasury stock method in accounting for the shares issuable upon conversion of the 2024 Notes and the 2025 Notes will adversely affect our diluted earnings per share.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recent Accounting Pronouncements Not Yet Effective</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2021, the FASB issued ASU 2021-08, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Business Combinations (Topic 805): Accounting for Contract Assets and Contract Liabilities from Contracts with Customers</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which requires contract assets and contract liabilities acquired in a business combination to be recognized and measured by the acquirer on the acquisition date in accordance with ASC 606, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue from Contracts with Customers.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> This approach differs from the current requirement to measure contract assets and contract liabilities acquired in a business combination at fair value. This new standard is effective for our interim and annual periods beginning after December 15, 2022, with early adoption permitted. We are currently evaluating the adoption impacts on our consolidated financial statements.</span></div></ix:continuation></ix:continuation><div style="text-align:justify"><span><br/></span></div><div id="i9aaa2fddc97e482da5dbe37ac85ae703_52"></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 4.  <ix:nonNumeric contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231" name="us-gaap:BusinessCombinationDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM181Mi9mcmFnOmJiYjIzMTBlOTRkMjQ4NzFhNjRjNTllMTk2ZDJiZDBmL3RleHRyZWdpb246YmJiMjMxMGU5NGQyNDg3MWE2NGM1OWUxOTZkMmJkMGZfNjU2NQ_6edfe19f-8b57-4708-9f6a-84526c99cf9a" continuedAt="id511c7cbdf894a7b894093921cf25c87" escape="true">Transactions</ix:nonNumeric></span></div><div style="text-align:justify"><span><br/></span></div><ix:continuation id="id511c7cbdf894a7b894093921cf25c87" continuedAt="i79aa1800a18240079549baec5bc69943"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Business Combinations</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Vital Decisions</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> </span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October 1, 2021, the Company completed its acquisition of Vital Decisions, including <ix:nonFraction unitRef="number" contextRef="i70301f61588141189fb4444297fae8bd_I20211001" decimals="INF" name="us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM181Mi9mcmFnOmJiYjIzMTBlOTRkMjQ4NzFhNjRjNTllMTk2ZDJiZDBmL3RleHRyZWdpb246YmJiMjMxMGU5NGQyNDg3MWE2NGM1OWUxOTZkMmJkMGZfMTA0NDUzNjA1MTc3NTg_dbd20f6a-b410-4e25-b1f8-c01c2034c6f1">100</ix:nonFraction>% of the voting equity interests. Vital Decisions is a leading provider of technology-enabled advance care planning services, ensuring that the care of individuals with serious illness aligns with their values and changing preferences throughout their health journey and, in particular, as they approach  end-of-life decisions. The transaction is expected to deepen our capabilities, allowing us to cross-sell across customers and enhance our value proposition to partners. </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total merger consideration, net of cash on hand and certain closing adjustments, was $<ix:nonFraction unitRef="usd" contextRef="icc3dde603e5f449c9078821a3218c74e_D20211001-20211001" decimals="-5" name="us-gaap:BusinessCombinationConsiderationTransferred1" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM181Mi9mcmFnOmJiYjIzMTBlOTRkMjQ4NzFhNjRjNTllMTk2ZDJiZDBmL3RleHRyZWdpb246YmJiMjMxMGU5NGQyNDg3MWE2NGM1OWUxOTZkMmJkMGZfMjE5OTAyMzMwOTY1Mw_0781d6e4-6a44-4edb-afef-40dec9031e30">117.7</ix:nonFraction> million, based on the closing price of the Company&#8217;s Class A common stock on the NYSE on October 1, 2021. The merger consideration consisted of $<ix:nonFraction unitRef="usd" contextRef="icc3dde603e5f449c9078821a3218c74e_D20211001-20211001" decimals="-5" name="us-gaap:PaymentsToAcquireBusinessesGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM181Mi9mcmFnOmJiYjIzMTBlOTRkMjQ4NzFhNjRjNTllMTk2ZDJiZDBmL3RleHRyZWdpb246YmJiMjMxMGU5NGQyNDg3MWE2NGM1OWUxOTZkMmJkMGZfMjE5OTAyMzMwOTU0MQ_5dd3d400-5f6b-4015-8fc9-a08c2d00ffff">46.5</ix:nonFraction> million of cash consideration, <ix:nonFraction unitRef="shares" contextRef="icc3dde603e5f449c9078821a3218c74e_D20211001-20211001" decimals="-5" name="us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM181Mi9mcmFnOmJiYjIzMTBlOTRkMjQ4NzFhNjRjNTllMTk2ZDJiZDBmL3RleHRyZWdpb246YmJiMjMxMGU5NGQyNDg3MWE2NGM1OWUxOTZkMmJkMGZfMzg0ODI5MDc1MTEyNA_e6947cd3-790a-44b5-9e69-de7d4b7f52b8">1.8</ix:nonFraction>&#160;million shares of Class A common stock, fair valued at $<ix:nonFraction unitRef="usd" contextRef="icc3dde603e5f449c9078821a3218c74e_D20211001-20211001" decimals="-5" name="us-gaap:BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM181Mi9mcmFnOmJiYjIzMTBlOTRkMjQ4NzFhNjRjNTllMTk2ZDJiZDBmL3RleHRyZWdpb246YmJiMjMxMGU5NGQyNDg3MWE2NGM1OWUxOTZkMmJkMGZfMjE5OTAyMzMwOTU4NA_f4020e29-197c-423e-8cdf-dda02974bb2b">56.6</ix:nonFraction> million as of October 1, 2021, and an earn-out of up to $<ix:nonFraction unitRef="usd" contextRef="i70301f61588141189fb4444297fae8bd_I20211001" decimals="-5" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM181Mi9mcmFnOmJiYjIzMTBlOTRkMjQ4NzFhNjRjNTllMTk2ZDJiZDBmL3RleHRyZWdpb246YmJiMjMxMGU5NGQyNDg3MWE2NGM1OWUxOTZkMmJkMGZfMzg0ODI5MDc1MTEwOQ_75859655-4725-49fd-98e6-b578f13347fd">45.0</ix:nonFraction>&#160;million, fair valued at $<ix:nonFraction unitRef="usd" contextRef="i70301f61588141189fb4444297fae8bd_I20211001" decimals="-5" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM181Mi9mcmFnOmJiYjIzMTBlOTRkMjQ4NzFhNjRjNTllMTk2ZDJiZDBmL3RleHRyZWdpb246YmJiMjMxMGU5NGQyNDg3MWE2NGM1OWUxOTZkMmJkMGZfMjE5OTAyMzMwOTYxOA_12729a9a-ab6f-4252-9a36-164ef6765061">14.6</ix:nonFraction> million as of October 1, 2021. See Note 18 for additional information regarding the fair value determination of the earn-out consideration.</span></div><div style="text-align:justify"><span><br/></span></div><ix:nonNumeric contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231" name="us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM181Mi9mcmFnOmJiYjIzMTBlOTRkMjQ4NzFhNjRjNTllMTk2ZDJiZDBmL3RleHRyZWdpb246YmJiMjMxMGU5NGQyNDg3MWE2NGM1OWUxOTZkMmJkMGZfMzI5ODUzNDkzNjI0Mw_d097634a-3f79-4fe5-8b11-eeeb7f316adf" continuedAt="i23cf6df7d19b4e7c92c69bfa10f29164" escape="true"><ix:nonNumeric contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231" name="us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM181Mi9mcmFnOmJiYjIzMTBlOTRkMjQ4NzFhNjRjNTllMTk2ZDJiZDBmL3RleHRyZWdpb246YmJiMjMxMGU5NGQyNDg3MWE2NGM1OWUxOTZkMmJkMGZfMzI5ODUzNDkzNjI0Mg_4dbbee18-b16a-42eb-a11e-b30dd4cc68cb" continuedAt="i320d682803664300ac8560184c91c814" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The purchase price was allocated to the assets acquired and liabilities assumed based on their estimated fair values as of October 1, 2021, as follows (in thousands):</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:87.372%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.428%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Purchase consideration:</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icc3dde603e5f449c9078821a3218c74e_D20211001-20211001" decimals="-3" name="us-gaap:PaymentsToAcquireBusinessesGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM181Mi9mcmFnOmJiYjIzMTBlOTRkMjQ4NzFhNjRjNTllMTk2ZDJiZDBmL3RhYmxlOjRhYzE5YzhjN2Q1MTRhZTViZjMwYTBmMmI5MWVkMjQxL3RhYmxlcmFuZ2U6NGFjMTljOGM3ZDUxNGFlNWJmMzBhMGYyYjkxZWQyNDFfMS0xLTEtMS0yOTE3OQ_0fe3a0cb-e9b7-4d10-99f5-230dde376804">46,500</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of Class A common stock issued</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icc3dde603e5f449c9078821a3218c74e_D20211001-20211001" decimals="-3" name="us-gaap:BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM181Mi9mcmFnOmJiYjIzMTBlOTRkMjQ4NzFhNjRjNTllMTk2ZDJiZDBmL3RhYmxlOjRhYzE5YzhjN2Q1MTRhZTViZjMwYTBmMmI5MWVkMjQxL3RhYmxlcmFuZ2U6NGFjMTljOGM3ZDUxNGFlNWJmMzBhMGYyYjkxZWQyNDFfMi0xLTEtMS0yOTgxMA_0430d8a2-81ec-4c5a-a11a-1f8bd1107a16">56,626</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of contingent consideration</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i70301f61588141189fb4444297fae8bd_I20211001" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM181Mi9mcmFnOmJiYjIzMTBlOTRkMjQ4NzFhNjRjNTllMTk2ZDJiZDBmL3RhYmxlOjRhYzE5YzhjN2Q1MTRhZTViZjMwYTBmMmI5MWVkMjQxL3RhYmxlcmFuZ2U6NGFjMTljOGM3ZDUxNGFlNWJmMzBhMGYyYjkxZWQyNDFfMy0xLTEtMS0yODcwMQ_868e5de0-b29a-4c5f-8d4b-8df671ce1821">14,600</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total consideration</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icc3dde603e5f449c9078821a3218c74e_D20211001-20211001" decimals="-3" name="us-gaap:BusinessCombinationConsiderationTransferred1" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM181Mi9mcmFnOmJiYjIzMTBlOTRkMjQ4NzFhNjRjNTllMTk2ZDJiZDBmL3RhYmxlOjRhYzE5YzhjN2Q1MTRhZTViZjMwYTBmMmI5MWVkMjQxL3RhYmxlcmFuZ2U6NGFjMTljOGM3ZDUxNGFlNWJmMzBhMGYyYjkxZWQyNDFfNC0xLTEtMS0yOTE2OQ_ce01334c-b8c0-4883-9b93-90c91630fa1c">117,726</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Tangible assets acquired:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i70301f61588141189fb4444297fae8bd_I20211001" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM181Mi9mcmFnOmJiYjIzMTBlOTRkMjQ4NzFhNjRjNTllMTk2ZDJiZDBmL3RhYmxlOjRhYzE5YzhjN2Q1MTRhZTViZjMwYTBmMmI5MWVkMjQxL3RhYmxlcmFuZ2U6NGFjMTljOGM3ZDUxNGFlNWJmMzBhMGYyYjkxZWQyNDFfNy0xLTEtMS0zNjYzNg_66914969-7977-4c9c-a3ac-5bf2b2cf21ef">1,430</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i70301f61588141189fb4444297fae8bd_I20211001" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM181Mi9mcmFnOmJiYjIzMTBlOTRkMjQ4NzFhNjRjNTllMTk2ZDJiZDBmL3RhYmxlOjRhYzE5YzhjN2Q1MTRhZTViZjMwYTBmMmI5MWVkMjQxL3RhYmxlcmFuZ2U6NGFjMTljOGM3ZDUxNGFlNWJmMzBhMGYyYjkxZWQyNDFfOC0xLTEtMS0zNjYzOA_05314b17-3e78-4dbd-b938-6a9d677f8f99">3,301</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:nonNumeric></ix:continuation><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">82</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i79aa1800a18240079549baec5bc69943" continuedAt="i6b9c842414014d44b8bb2d0e9388f769"><div><ix:continuation id="i23cf6df7d19b4e7c92c69bfa10f29164"><ix:continuation id="i320d682803664300ac8560184c91c814"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:87.372%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.428%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i70301f61588141189fb4444297fae8bd_I20211001" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM181Mi9mcmFnOmJiYjIzMTBlOTRkMjQ4NzFhNjRjNTllMTk2ZDJiZDBmL3RhYmxlOjRhYzE5YzhjN2Q1MTRhZTViZjMwYTBmMmI5MWVkMjQxL3RhYmxlcmFuZ2U6NGFjMTljOGM3ZDUxNGFlNWJmMzBhMGYyYjkxZWQyNDFfOS0xLTEtMS0zNjYzOA_922529b9-0346-4f6a-a967-bbe4dc4919eb">78</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other non-current assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i70301f61588141189fb4444297fae8bd_I20211001" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM181Mi9mcmFnOmJiYjIzMTBlOTRkMjQ4NzFhNjRjNTllMTk2ZDJiZDBmL3RhYmxlOjRhYzE5YzhjN2Q1MTRhZTViZjMwYTBmMmI5MWVkMjQxL3RhYmxlcmFuZ2U6NGFjMTljOGM3ZDUxNGFlNWJmMzBhMGYyYjkxZWQyNDFfMTAtMS0xLTEtMzY2Mzg_b7da90e7-aff2-42a7-8e81-74f5a5d48737">2,564</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total tangible assets acquired</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i70301f61588141189fb4444297fae8bd_I20211001" decimals="-3" name="evh:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedTangibleAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM181Mi9mcmFnOmJiYjIzMTBlOTRkMjQ4NzFhNjRjNTllMTk2ZDJiZDBmL3RhYmxlOjRhYzE5YzhjN2Q1MTRhZTViZjMwYTBmMmI5MWVkMjQxL3RhYmxlcmFuZ2U6NGFjMTljOGM3ZDUxNGFlNWJmMzBhMGYyYjkxZWQyNDFfMTEtMS0xLTEtMzY2Mzg_929ac431-3019-4054-b857-7c0f7c6ceccc">7,373</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Identifiable intangible assets acquired:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer relationships</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i499adfced3fe4274a3f2ca19bf418044_I20211001" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM181Mi9mcmFnOmJiYjIzMTBlOTRkMjQ4NzFhNjRjNTllMTk2ZDJiZDBmL3RhYmxlOjRhYzE5YzhjN2Q1MTRhZTViZjMwYTBmMmI5MWVkMjQxL3RhYmxlcmFuZ2U6NGFjMTljOGM3ZDUxNGFlNWJmMzBhMGYyYjkxZWQyNDFfMTQtMS0xLTEtMzY2NTI_053b8b64-7ce1-4af9-852c-c6a82044cc44">32,500</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Technology</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6f5e720f7a9e4b0d9114b35d5878bf70_I20211001" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM181Mi9mcmFnOmJiYjIzMTBlOTRkMjQ4NzFhNjRjNTllMTk2ZDJiZDBmL3RhYmxlOjRhYzE5YzhjN2Q1MTRhZTViZjMwYTBmMmI5MWVkMjQxL3RhYmxlcmFuZ2U6NGFjMTljOGM3ZDUxNGFlNWJmMzBhMGYyYjkxZWQyNDFfMTUtMS0xLTEtMzY2NTI_6e2c0fa8-d52c-4703-8418-cb4587f2366a">5,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate trade name</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i393b8dc21e5b45e585a40c88e5f9cd40_I20211001" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM181Mi9mcmFnOmJiYjIzMTBlOTRkMjQ4NzFhNjRjNTllMTk2ZDJiZDBmL3RhYmxlOjRhYzE5YzhjN2Q1MTRhZTViZjMwYTBmMmI5MWVkMjQxL3RhYmxlcmFuZ2U6NGFjMTljOGM3ZDUxNGFlNWJmMzBhMGYyYjkxZWQyNDFfMTYtMS0xLTEtMzY2NTI_3fa892a9-af2b-4858-863c-55d193c243ed">2,500</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total identifiable intangible assets acquired</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i70301f61588141189fb4444297fae8bd_I20211001" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM181Mi9mcmFnOmJiYjIzMTBlOTRkMjQ4NzFhNjRjNTllMTk2ZDJiZDBmL3RhYmxlOjRhYzE5YzhjN2Q1MTRhZTViZjMwYTBmMmI5MWVkMjQxL3RhYmxlcmFuZ2U6NGFjMTljOGM3ZDUxNGFlNWJmMzBhMGYyYjkxZWQyNDFfMTctMS0xLTEtMzY2NTI_b261ae49-8b9c-48b0-bd49-894db6cc02a3">40,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities assumed:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i70301f61588141189fb4444297fae8bd_I20211001" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM181Mi9mcmFnOmJiYjIzMTBlOTRkMjQ4NzFhNjRjNTllMTk2ZDJiZDBmL3RhYmxlOjRhYzE5YzhjN2Q1MTRhZTViZjMwYTBmMmI5MWVkMjQxL3RhYmxlcmFuZ2U6NGFjMTljOGM3ZDUxNGFlNWJmMzBhMGYyYjkxZWQyNDFfMjAtMS0xLTEtMzY2NTY_eb1587f3-2941-4d15-8dd4-92b0e02e6806">93</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued liabilities </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i70301f61588141189fb4444297fae8bd_I20211001" decimals="-3" name="evh:BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesAccruedLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM181Mi9mcmFnOmJiYjIzMTBlOTRkMjQ4NzFhNjRjNTllMTk2ZDJiZDBmL3RhYmxlOjRhYzE5YzhjN2Q1MTRhZTViZjMwYTBmMmI5MWVkMjQxL3RhYmxlcmFuZ2U6NGFjMTljOGM3ZDUxNGFlNWJmMzBhMGYyYjkxZWQyNDFfMjEtMS0xLTEtMzY2NTY_4b828a83-1517-47f1-a469-ee67a39ee69e">661</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued compensation and employee benefits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i70301f61588141189fb4444297fae8bd_I20211001" decimals="-3" name="evh:BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesAccruedCompensationAndEmployeeBenefits" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM181Mi9mcmFnOmJiYjIzMTBlOTRkMjQ4NzFhNjRjNTllMTk2ZDJiZDBmL3RhYmxlOjRhYzE5YzhjN2Q1MTRhZTViZjMwYTBmMmI5MWVkMjQxL3RhYmxlcmFuZ2U6NGFjMTljOGM3ZDUxNGFlNWJmMzBhMGYyYjkxZWQyNDFfMjItMS0xLTEtMzY2NTY_54785064-4233-459b-afd3-0351fce1f701">970</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax liabilities, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i70301f61588141189fb4444297fae8bd_I20211001" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM181Mi9mcmFnOmJiYjIzMTBlOTRkMjQ4NzFhNjRjNTllMTk2ZDJiZDBmL3RhYmxlOjRhYzE5YzhjN2Q1MTRhZTViZjMwYTBmMmI5MWVkMjQxL3RhYmxlcmFuZ2U6NGFjMTljOGM3ZDUxNGFlNWJmMzBhMGYyYjkxZWQyNDFfMjMtMS0xLTEtMzY2NTY_3bb09c74-55fe-448b-923a-11e580f6a546">499</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i70301f61588141189fb4444297fae8bd_I20211001" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM181Mi9mcmFnOmJiYjIzMTBlOTRkMjQ4NzFhNjRjNTllMTk2ZDJiZDBmL3RhYmxlOjRhYzE5YzhjN2Q1MTRhZTViZjMwYTBmMmI5MWVkMjQxL3RhYmxlcmFuZ2U6NGFjMTljOGM3ZDUxNGFlNWJmMzBhMGYyYjkxZWQyNDFfMjQtMS0xLTEtMzY2NTY_8b0005da-660f-4e8b-be0d-caad7216a62d">2,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i70301f61588141189fb4444297fae8bd_I20211001" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCapitalLeaseObligation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM181Mi9mcmFnOmJiYjIzMTBlOTRkMjQ4NzFhNjRjNTllMTk2ZDJiZDBmL3RhYmxlOjRhYzE5YzhjN2Q1MTRhZTViZjMwYTBmMmI5MWVkMjQxL3RhYmxlcmFuZ2U6NGFjMTljOGM3ZDUxNGFlNWJmMzBhMGYyYjkxZWQyNDFfMjUtMS0xLTEtMzY2NTY_34be5355-049c-47b5-8b00-bf757da58db6">2,712</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities assumed</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i70301f61588141189fb4444297fae8bd_I20211001" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM181Mi9mcmFnOmJiYjIzMTBlOTRkMjQ4NzFhNjRjNTllMTk2ZDJiZDBmL3RhYmxlOjRhYzE5YzhjN2Q1MTRhZTViZjMwYTBmMmI5MWVkMjQxL3RhYmxlcmFuZ2U6NGFjMTljOGM3ZDUxNGFlNWJmMzBhMGYyYjkxZWQyNDFfMjYtMS0xLTEtMzY2NTY_64dbb1d9-fc2d-4ee4-9511-5d97ddd31432">6,935</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i70301f61588141189fb4444297fae8bd_I20211001" decimals="-3" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM181Mi9mcmFnOmJiYjIzMTBlOTRkMjQ4NzFhNjRjNTllMTk2ZDJiZDBmL3RhYmxlOjRhYzE5YzhjN2Q1MTRhZTViZjMwYTBmMmI5MWVkMjQxL3RhYmxlcmFuZ2U6NGFjMTljOGM3ZDUxNGFlNWJmMzBhMGYyYjkxZWQyNDFfMjgtMS0xLTEtMzY2NzQ_dc534251-11f8-44ab-ab20-ee3d07cb6964">77,288</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net assets acquired</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i70301f61588141189fb4444297fae8bd_I20211001" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM181Mi9mcmFnOmJiYjIzMTBlOTRkMjQ4NzFhNjRjNTllMTk2ZDJiZDBmL3RhYmxlOjRhYzE5YzhjN2Q1MTRhZTViZjMwYTBmMmI5MWVkMjQxL3RhYmxlcmFuZ2U6NGFjMTljOGM3ZDUxNGFlNWJmMzBhMGYyYjkxZWQyNDFfMjktMS0xLTEtMzY2NzQ_8540945c-8872-4b83-8e8d-67425c7fc7ca">117,726</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></ix:continuation></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The fair value of the receivables acquired, as shown in the table above, approximates the gross contractual amounts and is expected to be collectible in full. Identifiable intangible assets associated with customer relationships, technology and corporate trade names will be amortized on a straight-line basis over their preliminary estimated useful lives of <ix:nonNumeric contextRef="i93823d3451b643ba8bd3aefc9d052c7c_D20211001-20211001" name="us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM181Mi9mcmFnOmJiYjIzMTBlOTRkMjQ4NzFhNjRjNTllMTk2ZDJiZDBmL3RleHRyZWdpb246YmJiMjMxMGU5NGQyNDg3MWE2NGM1OWUxOTZkMmJkMGZfMzg0ODI5MDc1MTEzNg_f8394840-05a5-4221-8fbd-7fba26eaa442">13</ix:nonNumeric> years, <ix:nonNumeric contextRef="i631f51b734d24d66935095cad71b62c0_D20211001-20211001" name="us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM181Mi9mcmFnOmJiYjIzMTBlOTRkMjQ4NzFhNjRjNTllMTk2ZDJiZDBmL3RleHRyZWdpb246YmJiMjMxMGU5NGQyNDg3MWE2NGM1OWUxOTZkMmJkMGZfMzg0ODI5MDc1MTE0OQ_a24aac1c-cf5e-4990-982f-43073226619b">5</ix:nonNumeric> years, and <ix:nonNumeric contextRef="i942460901cce441cba62f7e178ca70fd_D20211001-20211001" name="us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM181Mi9mcmFnOmJiYjIzMTBlOTRkMjQ4NzFhNjRjNTllMTk2ZDJiZDBmL3RleHRyZWdpb246YmJiMjMxMGU5NGQyNDg3MWE2NGM1OWUxOTZkMmJkMGZfMzg0ODI5MDc1MTE2MQ_b75e1e22-9dd5-402c-99f7-c58582d1a8b4">15</ix:nonNumeric> years, respectively. The customer relationships are primarily attributable to existing contracts with current customers. The technology consists primarily of a proprietary advance care planning documentation portal where patients can input information, and doctor/patient conversations are populated for later reference. The corporate trade name reflects the value that we believe the Vital Decisions brand name carries in the market. The fair value of the intangible assets was determined using the income approach and the relief from royalty approach. The income approach estimates fair value for an asset based on the present value of cash flows projected to be generated by the asset. Projected cash flows are discounted at a required rate of return that reflects the relative risk of achieving the cash flows and the time value of money. The relief from royalty approach estimates the fair value of an asset by calculating how much an entity would have to spend to lease a similar asset. Goodwill is calculated as the difference between the acquisition date fair value of the total consideration and the fair value of the net assets acquired and represents the future economic benefits that we expect to achieve as a result of the acquisition. The goodwill is attributable primarily to cross-selling opportunities and the acquired assembled workforce and was all allocated to the Clinical Solutions segment. Goodwill is considered to be an indefinite lived asset. $<ix:nonFraction unitRef="usd" contextRef="i70301f61588141189fb4444297fae8bd_I20211001" decimals="-5" name="us-gaap:BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM181Mi9mcmFnOmJiYjIzMTBlOTRkMjQ4NzFhNjRjNTllMTk2ZDJiZDBmL3RleHRyZWdpb246YmJiMjMxMGU5NGQyNDg3MWE2NGM1OWUxOTZkMmJkMGZfMzg0ODI5MDc1MTE3Ng_d0906338-15e5-4d69-af77-49f3a9341004">69.6</ix:nonFraction>&#160;million of the goodwill recorded on the transaction is deductible for tax purposes.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The amounts above reflect management&#8217;s estimate of the fair value of the tangible and intangible assets acquired and liabilities assumed. Any necessary adjustments will be finalized within one year from the date of acquisition.</span></div><div style="text-align:justify"><span><br/></span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Equity Investments</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Passport</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 28, 2019, UHC, Passport Health Solutions, LLC (&#8220;PHS I&#8221;), the Company and EVH Passport entered into an Asset Purchase Agreement (the &#8220;Passport APA&#8221;), which provided for the sale of substantially all of the assets of UHC and PHS I, including UHC&#8217;s Kentucky Medicaid contract (the &#8220;Passport Medicaid Contract&#8221;), to EVH Passport for a purchase price of $<ix:nonFraction unitRef="usd" contextRef="iba85fb86cb9c459986593ba474a68022_D20190528-20190528" decimals="-5" name="us-gaap:PaymentsToAcquireEquityMethodInvestments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM181Mi9mcmFnOmJiYjIzMTBlOTRkMjQ4NzFhNjRjNTllMTk2ZDJiZDBmL3RleHRyZWdpb246YmJiMjMxMGU5NGQyNDg3MWE2NGM1OWUxOTZkMmJkMGZfMzk0_526475b8-a550-4d0f-84e3-74a3c86c9251">70.0</ix:nonFraction> million in cash and the issuance of a <ix:nonFraction unitRef="number" contextRef="iba85fb86cb9c459986593ba474a68022_D20190528-20190528" decimals="2" name="us-gaap:VariableInterestEntityOwnershipPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM181Mi9mcmFnOmJiYjIzMTBlOTRkMjQ4NzFhNjRjNTllMTk2ZDJiZDBmL3RleHRyZWdpb246YmJiMjMxMGU5NGQyNDg3MWE2NGM1OWUxOTZkMmJkMGZfNDI3_a7351fbc-3dbf-4109-9f45-e274509e451a">30</ix:nonFraction>% interest in EVH Passport (the &#8220;Passport Purchase Price&#8221;) to The University of Louisville, the University of Louisville Physicians, University Medical Center, the Jewish Heritage Fund for Excellence, Norton Healthcare, Inc. and the Louisville/Jefferson County Primary Care Association (collectively, the &#8220;Sponsors&#8221;). </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 18, 2019, the Company contributed $<ix:nonFraction unitRef="usd" contextRef="i5aae66b17cd7411eb3d40e1f98e41587_I20190618" decimals="-5" name="us-gaap:NotesReceivableNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM181Mi9mcmFnOmJiYjIzMTBlOTRkMjQ4NzFhNjRjNTllMTk2ZDJiZDBmL3RleHRyZWdpb246YmJiMjMxMGU5NGQyNDg3MWE2NGM1OWUxOTZkMmJkMGZfNzkw_4716399f-b538-49c9-b2fd-b94f7ca49951">40.0</ix:nonFraction> million to UHC in the form of an advance for regulatory capital requirements under an agreement with UHC (the &#8220;Passport Note&#8221;). The Passport Note carried a fixed interest rate of <ix:nonFraction unitRef="number" contextRef="i374acc0d61704b06a1daddce75dda523_I20190618" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM181Mi9mcmFnOmJiYjIzMTBlOTRkMjQ4NzFhNjRjNTllMTk2ZDJiZDBmL3RleHRyZWdpb246YmJiMjMxMGU5NGQyNDg3MWE2NGM1OWUxOTZkMmJkMGZfOTY0_c8f34cfc-751c-4f98-b6b9-6d143dc761ed">6.5</ix:nonFraction>% per annum. Additionally, on </span></div></ix:continuation><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">83</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i6b9c842414014d44b8bb2d0e9388f769" continuedAt="i5f5de3f38ab54e35956775cacc5284d0"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">June 6, 2019, the Company and UHC entered into an Indemnity Agreement (the &#8220;Indemnity Agreement&#8221;), with an insurance company (the &#8220;Surety&#8221;). The Surety issued a performance bond in the amount of $<ix:nonFraction unitRef="usd" contextRef="i458a8dd8fe1447e983bf102015ceb976_D20190606-20190606" decimals="-5" name="us-gaap:VariableInterestEntityFinancialOrOtherSupportAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM181Mi9mcmFnOmJiYjIzMTBlOTRkMjQ4NzFhNjRjNTllMTk2ZDJiZDBmL3RleHRyZWdpb246YmJiMjMxMGU5NGQyNDg3MWE2NGM1OWUxOTZkMmJkMGZfMTE5MQ_fceb1ef1-47a2-413d-b0c6-3047deb2fcb0">25.0</ix:nonFraction> million to secure UHC&#8217;s performance under its Medicaid Contract. Pursuant to the Indemnity Agreement, the Company and UHC were jointly and severally liable to the Surety in the maximum amount of the bond, plus certain costs of the Surety, in the event of losses arising under the bond. The bond&#8217;s original expiry date was June 30, 2020 and during the three months ended June 30, 2020, was extended to December 31, 2020. The bond was released in October 2020. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 30, 2019, UHC, PHS I, the Company and EVH Passport consummated the transactions contemplated by the Passport APA (the &#8220;Passport Closing&#8221;).  At the Passport Closing, $<ix:nonFraction unitRef="usd" contextRef="i50b57c8ae3af4f4d87078314e47600cb_I20191230" decimals="-5" name="evh:PaymentsToAcquireEquityMethodInvestmentsAmountHeldBack" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM181Mi9mcmFnOmJiYjIzMTBlOTRkMjQ4NzFhNjRjNTllMTk2ZDJiZDBmL3RleHRyZWdpb246YmJiMjMxMGU5NGQyNDg3MWE2NGM1OWUxOTZkMmJkMGZfMTgyNA_4582d01d-2190-450b-931e-b65bbd34ed15">16.2</ix:nonFraction> million of the cash Passport Purchase Price was held back until such time as PHS I delivers to EVH Passport certain owned real property and improvements free and clear of all encumbrances. In addition, at the Passport Closing, EVH Passport and UHC entered into an agreement that provided for the administration and assumption of the financial risks by EVH Passport of UHC&#8217;s dual eligible special needs business (the &#8220;DNP Business&#8221;) until such time as EVH Passport became certified as a Medicare Advantage Organization and the D-SNP Business could be transferred to EVH Passport.  On October 1, 2020, the D-SNP Business was transferred from UHC to EVH Passport. At the Passport Closing, EVH Passport assumed UHC&#8217;s obligations under the Passport Note and the Indemnity Agreement. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 16, 2020, EVH Passport, Evolent Health LLC and Molina Healthcare, Inc. (&#8220;Molina&#8221;) entered into an Asset Purchase Agreement (the &#8220;Molina APA&#8221;), which contemplated the sale by EVH Passport to Molina of certain assets, including certain intellectual property rights of EVH Passport and EVH Passport&#8217;s rights under the Passport Medicaid Contract.  On September 1, 2020, EVH Passport and Molina consummated the transactions contemplated by the Molina APA (the &#8220;Molina Closing&#8221;) and the Passport Medicaid Contract was novated to Molina.  As a result, EVH Passport began to wind down its business.  In connection with the Molina Closing, Molina deposited $<ix:nonFraction unitRef="usd" contextRef="i3f3edd8173b642a0af571267b2125442_D20210101-20210131" decimals="-5" name="evh:CashReleasedFromEscrow" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM181Mi9mcmFnOmJiYjIzMTBlOTRkMjQ4NzFhNjRjNTllMTk2ZDJiZDBmL3RleHRyZWdpb246YmJiMjMxMGU5NGQyNDg3MWE2NGM1OWUxOTZkMmJkMGZfMzI1Ng_296ed786-8e93-4144-a110-44548996b7fb"><ix:nonFraction unitRef="usd" contextRef="i410c11618d854c73bc5727ec26d5ac44_D20200901-20200901" decimals="-5" name="evh:AssetPurchaseAgreementEscrowPayments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM181Mi9mcmFnOmJiYjIzMTBlOTRkMjQ4NzFhNjRjNTllMTk2ZDJiZDBmL3RleHRyZWdpb246YmJiMjMxMGU5NGQyNDg3MWE2NGM1OWUxOTZkMmJkMGZfMzI1Ng_96c71c80-edb0-4c5a-a12f-845c52411a51">20.0</ix:nonFraction></ix:nonFraction>&#160;million in cash in escrow, which was subsequently released to EVH Passport in January 2021.  In addition, at the Molina Closing, Molina and EVH Passport entered into an agreement that provided for the assumption of the financial risks by Molina of the D-SNP Business until such time as Molina&#8217;s Kentucky health plan becomes certified as a Medicare Advantage Organization and the D-SNP Business is transferred Molina.  The Company and EVH Passport continued to administer the D-SNP Business until January 1, 2021, at which time Molina became responsible for its administration until the D-SNP Business was officially transferred to Molina effective September 1, 2021.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prior to the Molina Closing, the Company accounted for its investment in EVH Passport as an unconsolidated variable interest entity under the equity method of accounting.  As a result of the transaction, the Company concluded that a reconsideration event occurred whereby EVH Passport was determined to be a voting interest entity and that Evolent had a controlling financial interest in EVH Passport; accordingly, the Company consolidated EVH Passport as of September 1, 2020 in its consolidated financial statements. The Company accounted for the transaction as an asset acquisition, as the Company concluded that assets acquired as a result of the consolidation did not meet the criteria to be classified as a business under GAAP.  Following the Molina Closing and consolidation of EVH Passport in the Company&#8217;s consolidated financials, on November 16, 2020, EVH Passport redeemed the Sponsors&#8217; equity interests in EVH Passport for $<ix:nonFraction unitRef="usd" contextRef="i553144e874d7414ab395f79f6424736f_D20201116-20201116" decimals="-5" name="us-gaap:PaymentsToMinorityShareholders" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM181Mi9mcmFnOmJiYjIzMTBlOTRkMjQ4NzFhNjRjNTllMTk2ZDJiZDBmL3RleHRyZWdpb246YmJiMjMxMGU5NGQyNDg3MWE2NGM1OWUxOTZkMmJkMGZfNDg1Mw_914e9020-eff1-4695-a589-f3e6728da0be">20.0</ix:nonFraction>&#160;million in cash in accordance with the terms of EVH Passport&#8217;s Stockholders&#8217; Agreement, and, as a result, EVH Passport became a wholly owned subsidiary of the Company.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of the consolidation, the Company recorded assets primarily consisting of cash and cash equivalents and restricted cash and cash equivalents of $<ix:nonFraction unitRef="usd" contextRef="i24eda106b1dc4387aebfe529942c3586_D20200901-20200901" decimals="-5" name="evh:AssetAcquisitionCashAndEquivalents" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM181Mi9mcmFnOmJiYjIzMTBlOTRkMjQ4NzFhNjRjNTllMTk2ZDJiZDBmL3RleHRyZWdpb246YmJiMjMxMGU5NGQyNDg3MWE2NGM1OWUxOTZkMmJkMGZfNTE2OQ_eadc1049-72c9-498a-95c0-cec01eb4a089">159.8</ix:nonFraction>&#160;million, available for sale securities of $<ix:nonFraction unitRef="usd" contextRef="i24eda106b1dc4387aebfe529942c3586_D20200901-20200901" decimals="-5" name="evh:AssetAcquisitionDebtSecuritiesAvailableForSale" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM181Mi9mcmFnOmJiYjIzMTBlOTRkMjQ4NzFhNjRjNTllMTk2ZDJiZDBmL3RleHRyZWdpb246YmJiMjMxMGU5NGQyNDg3MWE2NGM1OWUxOTZkMmJkMGZfNTIwNg_2ffa8448-a3e6-494a-b6d0-8d4b869aca76">88.6</ix:nonFraction>&#160;million, receivables related to unsettled sales of securities of $<ix:nonFraction unitRef="usd" contextRef="i24eda106b1dc4387aebfe529942c3586_D20200901-20200901" decimals="-5" name="evh:AssetAcquisitionDebtSecuritiesAvailableForSaleUnsettledSalesReceivables" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM181Mi9mcmFnOmJiYjIzMTBlOTRkMjQ4NzFhNjRjNTllMTk2ZDJiZDBmL3RleHRyZWdpb246YmJiMjMxMGU5NGQyNDg3MWE2NGM1OWUxOTZkMmJkMGZfNTI2Ng_231a5b8e-c071-4449-8338-5cc61d6011ae">43.0</ix:nonFraction>&#160;million and other assets of $<ix:nonFraction unitRef="usd" contextRef="i24eda106b1dc4387aebfe529942c3586_D20200901-20200901" decimals="-5" name="evh:AssetAcquisitionOtherAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM181Mi9mcmFnOmJiYjIzMTBlOTRkMjQ4NzFhNjRjNTllMTk2ZDJiZDBmL3RleHRyZWdpb246YmJiMjMxMGU5NGQyNDg3MWE2NGM1OWUxOTZkMmJkMGZfNTI4OQ_0f0baf49-9e45-4188-89f5-5ccb7317febf">50.2</ix:nonFraction>&#160;million and total liabilities primarily comprised of reserve for claims and performance-based arrangements of $<ix:nonFraction unitRef="usd" contextRef="i24eda106b1dc4387aebfe529942c3586_D20200901-20200901" decimals="-5" name="evh:AssetAcquisitionAccruedMedicalExpenses" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM181Mi9mcmFnOmJiYjIzMTBlOTRkMjQ4NzFhNjRjNTllMTk2ZDJiZDBmL3RleHRyZWdpb246YmJiMjMxMGU5NGQyNDg3MWE2NGM1OWUxOTZkMmJkMGZfNTM5NA_4a5d76dd-24be-463a-901d-61ce63c3591e">164.8</ix:nonFraction>&#160;million and accrued liabilities of $<ix:nonFraction unitRef="usd" contextRef="i24eda106b1dc4387aebfe529942c3586_D20200901-20200901" decimals="-5" name="evh:AssetAcquisitionAccruedLiabilities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM181Mi9mcmFnOmJiYjIzMTBlOTRkMjQ4NzFhNjRjNTllMTk2ZDJiZDBmL3RleHRyZWdpb246YmJiMjMxMGU5NGQyNDg3MWE2NGM1OWUxOTZkMmJkMGZfNTQyNA_5592f0b1-efdb-4054-8e62-8a97d29775af">50.0</ix:nonFraction>&#160;million. Subsequent to winddown activities, any remaining capital will be distributed to the Company subject to regulatory approval from the Kentucky Department of Insurance.  In addition, the Passport Note was eliminated upon consolidation, and as of December 31, 2020, the outstanding principal balance of the $<ix:nonFraction unitRef="usd" contextRef="i8d16ce5f96ed484ea0bd662e9a0da3ec_D20201231-20201231" decimals="-5" name="us-gaap:ProceedsFromCollectionOfNotesReceivable" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM181Mi9mcmFnOmJiYjIzMTBlOTRkMjQ4NzFhNjRjNTllMTk2ZDJiZDBmL3RleHRyZWdpb246YmJiMjMxMGU5NGQyNDg3MWE2NGM1OWUxOTZkMmJkMGZfNTczMQ_ee169de5-f1b0-4710-93af-fe7eecd8009d">40.0</ix:nonFraction>&#160;million Passport Note was repaid in full by EVH Passport including approximately $<ix:nonFraction unitRef="usd" contextRef="i8d16ce5f96ed484ea0bd662e9a0da3ec_D20201231-20201231" decimals="-5" name="us-gaap:ProceedsFromInterestReceived" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM181Mi9mcmFnOmJiYjIzMTBlOTRkMjQ4NzFhNjRjNTllMTk2ZDJiZDBmL3RleHRyZWdpb246YmJiMjMxMGU5NGQyNDg3MWE2NGM1OWUxOTZkMmJkMGZfNTgwNw_7bfa2bf6-3172-4218-afd2-c45a7ad656f5">3.6</ix:nonFraction>&#160;million of accrued interest.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the first quarter of 2021, pursuant to the terms of the Molina APA, EVH Passport received a cash payment from Molina in the amount of $<ix:nonFraction unitRef="usd" contextRef="i660e59a50fb74adf8c9b97dba279e217_D20210101-20210331" decimals="-5" name="evh:ProceedsFromTransferOfMembership" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM181Mi9mcmFnOmJiYjIzMTBlOTRkMjQ4NzFhNjRjNTllMTk2ZDJiZDBmL3RleHRyZWdpb246YmJiMjMxMGU5NGQyNDg3MWE2NGM1OWUxOTZkMmJkMGZfNTk3Mw_d7d3a9be-a3d2-4cb5-b59e-9677b7ab7310">23.0</ix:nonFraction>&#160;million based on the number of enrollees above a certain threshold in the D-SNP Business and Molina's Medicaid plan following the open enrollment period for plan year 2021. The payment is recorded in gain on transfer of membership on the consolidated statement of operations and comprehensive income (loss). The foregoing amount represents <ix:nonFraction unitRef="number" contextRef="ib292e37ea5764045b08aaf86b4bf8282_I20210331" decimals="INF" name="evh:TransferOfMembershipPercentageOfPaymentBasedOnNumberOfEnrollees" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM181Mi9mcmFnOmJiYjIzMTBlOTRkMjQ4NzFhNjRjNTllMTk2ZDJiZDBmL3RleHRyZWdpb246YmJiMjMxMGU5NGQyNDg3MWE2NGM1OWUxOTZkMmJkMGZfNjMwOA_72e003f6-0741-4226-8a0f-42d0409a34b7">50</ix:nonFraction>% of the payment that EVH Passport is eligible to receive pursuant to the terms of the Molina APA based on the number of such enrollees. The remaining <ix:nonFraction unitRef="number" contextRef="i1857a80445fe4ba78e6b1cd41cf5528f_I20211231" decimals="INF" name="evh:TransferOfMembershipPercentageOfPaymentSubjectToSatisfactionOfContingencies" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM181Mi9mcmFnOmJiYjIzMTBlOTRkMjQ4NzFhNjRjNTllMTk2ZDJiZDBmL3RleHRyZWdpb246YmJiMjMxMGU5NGQyNDg3MWE2NGM1OWUxOTZkMmJkMGZfNjQ2MA_b386d4c4-9e83-4ce4-8dd4-1497077d0923">50</ix:nonFraction>% was received in the first quarter of 2022 and was recorded as a receivable on our consolidated balance sheet and a gain on transfer of membership on the consolidated statement of operations and comprehensive income (loss) during the year ended December 31, 2021 as there were no remaining uncertainties related to realization.</span></div></ix:continuation><div style="text-align:justify"><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">84</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i5f5de3f38ab54e35956775cacc5284d0"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Loss on Disposal of Assets</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During 2019, the Company, through a consolidated subsidiary, entered into an agreement with an unrelated party to provide services and support to providers, independent physician associations, and other provider groups. During the first quarter of 2020, the Company sold its interest in the subsidiary and recorded a loss on disposal of assets of $<ix:nonFraction unitRef="usd" contextRef="ia321bb1b6e6b403aa6a27cd32dbe25f8_D20200101-20200331" decimals="-5" sign="-" name="us-gaap:GainLossOnDispositionOfAssets1" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM181Mi9mcmFnOmJiYjIzMTBlOTRkMjQ4NzFhNjRjNTllMTk2ZDJiZDBmL3RleHRyZWdpb246YmJiMjMxMGU5NGQyNDg3MWE2NGM1OWUxOTZkMmJkMGZfMTA5OTUxMTYzNDc0OQ_22670ac8-6fb0-46b3-8784-98117c18e4e4">6.4</ix:nonFraction> million in the consolidated statements of operations and comprehensive income (loss). The Company did not have any continuing involvement with the subsidiary after the consummation of this transaction.</span></div></ix:continuation><div style="text-align:justify"><span><br/></span></div><div id="i9aaa2fddc97e482da5dbe37ac85ae703_55"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 5.  <ix:nonNumeric contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231" name="us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM181NS9mcmFnOmNmZTY4OTBkMjFiYTQxZjE5OTA1MWYzYTFkMzI4MjZiL3RleHRyZWdpb246Y2ZlNjg5MGQyMWJhNDFmMTk5MDUxZjNhMWQzMjgyNmJfMjcyMQ_3c2cd643-68d6-491b-a602-5cbeeb31c11a" continuedAt="i5e14a57c487c41468142e85a44bd7e1b" escape="true">Discontinued Operations</ix:nonNumeric></span></div><div><span><br/></span></div><ix:continuation id="i5e14a57c487c41468142e85a44bd7e1b" continuedAt="iec427cf2209c473cb50fcbfd03a4af6e"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 11, 2021, Evolent Health LLC, EH Holdings and True Health, each wholly owned subsidiaries of the Company, entered into a Stock Purchase Agreement (the &#8220;True Health SPA&#8221;) with Bright Health Management, Inc. (&#8220;Bright HealthCare&#8221;), pursuant to which EH Holdings agreed to sell all of its equity interests in True Health to Bright HealthCare. Closing of the transactions contemplated by the True Health SPA occurred on March 31, 2021 (the &#8220;True Health Closing&#8221;) and the Company has had no continuing involvement with True Health subsequent to the closing except a pre-existing services agreement for claims processing and other health plan administrative functions.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of the first quarter of 2021, the Company determined that True Health met the discontinued operations criteria under ASC 205, and as such, True Health assets and liabilities as of December 31, 2020, and the results of operations for all periods presented are classified as discontinued operations and are not included in continuing operations in the consolidated financial statements.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December 31, 2021, the Company recorded purchase prices adjustments to the True Health Closing of $<ix:nonFraction unitRef="usd" contextRef="i1c4a293e5ce54724af5effd8253d4d89_D20210101-20211231" decimals="-5" sign="-" name="evh:DiscontinuedOperationGainLossOnPurchasePriceAdjustmentsNetOfTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM181NS9mcmFnOmNmZTY4OTBkMjFiYTQxZjE5OTA1MWYzYTFkMzI4MjZiL3RleHRyZWdpb246Y2ZlNjg5MGQyMWJhNDFmMTk5MDUxZjNhMWQzMjgyNmJfMjE5OTAyMzI1ODg4NA_37906391-e19a-4062-b493-e2fc5d54d217">8.7</ix:nonFraction>&#160;million which are included in loss from discontinued operations on the consolidated statements of operations and comprehensive income (loss).</span></div><div style="text-align:justify"><span><br/></span></div><ix:nonNumeric contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231" name="us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM181NS9mcmFnOmNmZTY4OTBkMjFiYTQxZjE5OTA1MWYzYTFkMzI4MjZiL3RleHRyZWdpb246Y2ZlNjg5MGQyMWJhNDFmMTk5MDUxZjNhMWQzMjgyNmJfMjcyMg_7e1c4ddc-a82a-42cc-8295-c655c3b84c53" continuedAt="i4ca79154b7c94bfd8108a16b2f43af6b" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the results of operations of the Company&#8217;s True Health business, which are included in loss from discontinued operations in the consolidated statements of operations and comprehensive income (loss) for the years ended December 31, 2021, 2020 and 2019:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:69.872%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.205%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.205%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.208%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Revenue</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Platform and operations</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id9938925ae68403cbd1e3633d8c2af7a_D20210101-20211231" decimals="-3" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM181NS9mcmFnOmNmZTY4OTBkMjFiYTQxZjE5OTA1MWYzYTFkMzI4MjZiL3RhYmxlOmIwOTBmOWQ1ZjljZDQxMDI5Y2ZhZGU2ZTMyOTIyMTE0L3RhYmxlcmFuZ2U6YjA5MGY5ZDVmOWNkNDEwMjljZmFkZTZlMzI5MjIxMTRfMy01LTEtMS0xNzc3NQ_0869a7cf-9ebc-4ad2-88d1-d6ed083dafa9">38</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i62b6ff0a18e64449a282407a6971fe18_D20200101-20201231" decimals="-3" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM181NS9mcmFnOmNmZTY4OTBkMjFiYTQxZjE5OTA1MWYzYTFkMzI4MjZiL3RhYmxlOmIwOTBmOWQ1ZjljZDQxMDI5Y2ZhZGU2ZTMyOTIyMTE0L3RhYmxlcmFuZ2U6YjA5MGY5ZDVmOWNkNDEwMjljZmFkZTZlMzI5MjIxMTRfMy03LTEtMS0xNzc3NQ_e6f92011-a02c-45ce-98cd-8248666b4c20">356</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic1ed065f23364faeb485521f6be7f439_D20190101-20191231" decimals="-3" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM181NS9mcmFnOmNmZTY4OTBkMjFiYTQxZjE5OTA1MWYzYTFkMzI4MjZiL3RhYmxlOmIwOTBmOWQ1ZjljZDQxMDI5Y2ZhZGU2ZTMyOTIyMTE0L3RhYmxlcmFuZ2U6YjA5MGY5ZDVmOWNkNDEwMjljZmFkZTZlMzI5MjIxMTRfMy01LTEtMS0xOTk2OA_b9d90580-6d5b-41dd-afed-79bbd6df44a4">145</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Premiums</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i15f03ee2332146e4a7e0d5b5717bea28_D20210101-20211231" decimals="-3" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM181NS9mcmFnOmNmZTY4OTBkMjFiYTQxZjE5OTA1MWYzYTFkMzI4MjZiL3RhYmxlOmIwOTBmOWQ1ZjljZDQxMDI5Y2ZhZGU2ZTMyOTIyMTE0L3RhYmxlcmFuZ2U6YjA5MGY5ZDVmOWNkNDEwMjljZmFkZTZlMzI5MjIxMTRfNC01LTEtMS0xNzc3NQ_122c5c50-a033-43eb-bfe7-8c5aad88d1e5">44,795</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6eca3f13863a45c481c07e49e9f434fe_D20200101-20201231" decimals="-3" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM181NS9mcmFnOmNmZTY4OTBkMjFiYTQxZjE5OTA1MWYzYTFkMzI4MjZiL3RhYmxlOmIwOTBmOWQ1ZjljZDQxMDI5Y2ZhZGU2ZTMyOTIyMTE0L3RhYmxlcmFuZ2U6YjA5MGY5ZDVmOWNkNDEwMjljZmFkZTZlMzI5MjIxMTRfNC03LTEtMS0xNzc3NQ_0fb0b667-2b01-46b8-ab54-5d88059b56b1">117,377</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iae64c322a5eb4929bc01485807d92b3a_D20190101-20191231" decimals="-3" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM181NS9mcmFnOmNmZTY4OTBkMjFiYTQxZjE5OTA1MWYzYTFkMzI4MjZiL3RhYmxlOmIwOTBmOWQ1ZjljZDQxMDI5Y2ZhZGU2ZTMyOTIyMTE0L3RhYmxlcmFuZ2U6YjA5MGY5ZDVmOWNkNDEwMjljZmFkZTZlMzI5MjIxMTRfNC01LTEtMS0xOTk2OA_5ddf2948-9982-4f8d-bcce-2b996430ff71">171,742</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenue</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1c4a293e5ce54724af5effd8253d4d89_D20210101-20211231" decimals="-3" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM181NS9mcmFnOmNmZTY4OTBkMjFiYTQxZjE5OTA1MWYzYTFkMzI4MjZiL3RhYmxlOmIwOTBmOWQ1ZjljZDQxMDI5Y2ZhZGU2ZTMyOTIyMTE0L3RhYmxlcmFuZ2U6YjA5MGY5ZDVmOWNkNDEwMjljZmFkZTZlMzI5MjIxMTRfNS01LTEtMS0xNzc3NQ_19a45f0e-9a28-4435-8dea-a917177f49aa">44,833</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if7ba948ef00b4ddeabe73338f1155e8b_D20200101-20201231" decimals="-3" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM181NS9mcmFnOmNmZTY4OTBkMjFiYTQxZjE5OTA1MWYzYTFkMzI4MjZiL3RhYmxlOmIwOTBmOWQ1ZjljZDQxMDI5Y2ZhZGU2ZTMyOTIyMTE0L3RhYmxlcmFuZ2U6YjA5MGY5ZDVmOWNkNDEwMjljZmFkZTZlMzI5MjIxMTRfNS03LTEtMS0xNzc3NQ_2632799e-76ac-4963-bfb2-7f86f67a12a3">117,733</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iae6c9a536db44d69b64c473850d09499_D20190101-20191231" decimals="-3" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM181NS9mcmFnOmNmZTY4OTBkMjFiYTQxZjE5OTA1MWYzYTFkMzI4MjZiL3RhYmxlOmIwOTBmOWQ1ZjljZDQxMDI5Y2ZhZGU2ZTMyOTIyMTE0L3RhYmxlcmFuZ2U6YjA5MGY5ZDVmOWNkNDEwMjljZmFkZTZlMzI5MjIxMTRfNS01LTEtMS0xOTk2OA_1335472f-8c2b-4211-a572-e08e96400074">171,887</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Expenses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of revenue (exclusive of depreciation and amortization expenses presented separately below) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1c4a293e5ce54724af5effd8253d4d89_D20210101-20211231" decimals="-3" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM181NS9mcmFnOmNmZTY4OTBkMjFiYTQxZjE5OTA1MWYzYTFkMzI4MjZiL3RhYmxlOmIwOTBmOWQ1ZjljZDQxMDI5Y2ZhZGU2ZTMyOTIyMTE0L3RhYmxlcmFuZ2U6YjA5MGY5ZDVmOWNkNDEwMjljZmFkZTZlMzI5MjIxMTRfOC01LTEtMS0xNzc3NQ_728c7882-60f2-4755-8765-f83c000d4c83">5,885</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if7ba948ef00b4ddeabe73338f1155e8b_D20200101-20201231" decimals="-3" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM181NS9mcmFnOmNmZTY4OTBkMjFiYTQxZjE5OTA1MWYzYTFkMzI4MjZiL3RhYmxlOmIwOTBmOWQ1ZjljZDQxMDI5Y2ZhZGU2ZTMyOTIyMTE0L3RhYmxlcmFuZ2U6YjA5MGY5ZDVmOWNkNDEwMjljZmFkZTZlMzI5MjIxMTRfOC03LTEtMS0xNzc3NQ_a1e19b8e-95dc-4085-a076-e8f8bdad4c8a">18,343</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iae6c9a536db44d69b64c473850d09499_D20190101-20191231" decimals="-3" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM181NS9mcmFnOmNmZTY4OTBkMjFiYTQxZjE5OTA1MWYzYTFkMzI4MjZiL3RhYmxlOmIwOTBmOWQ1ZjljZDQxMDI5Y2ZhZGU2ZTMyOTIyMTE0L3RhYmxlcmFuZ2U6YjA5MGY5ZDVmOWNkNDEwMjljZmFkZTZlMzI5MjIxMTRfOC01LTEtMS0xOTk3NQ_a3de4705-6c7a-4506-9bfe-467136a573e5">6,633</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Claims expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1c4a293e5ce54724af5effd8253d4d89_D20210101-20211231" decimals="-3" name="evh:DisposalGroupIncludingDiscontinuedOperationClaimsExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM181NS9mcmFnOmNmZTY4OTBkMjFiYTQxZjE5OTA1MWYzYTFkMzI4MjZiL3RhYmxlOmIwOTBmOWQ1ZjljZDQxMDI5Y2ZhZGU2ZTMyOTIyMTE0L3RhYmxlcmFuZ2U6YjA5MGY5ZDVmOWNkNDEwMjljZmFkZTZlMzI5MjIxMTRfOS01LTEtMS0xNzc3NQ_67cf4722-de0b-44c3-b3d3-4f13120d4ed3">33,954</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if7ba948ef00b4ddeabe73338f1155e8b_D20200101-20201231" decimals="-3" name="evh:DisposalGroupIncludingDiscontinuedOperationClaimsExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM181NS9mcmFnOmNmZTY4OTBkMjFiYTQxZjE5OTA1MWYzYTFkMzI4MjZiL3RhYmxlOmIwOTBmOWQ1ZjljZDQxMDI5Y2ZhZGU2ZTMyOTIyMTE0L3RhYmxlcmFuZ2U6YjA5MGY5ZDVmOWNkNDEwMjljZmFkZTZlMzI5MjIxMTRfOS03LTEtMS0xNzc3NQ_a5689e8d-5a1b-4ee5-9964-4a23459fc9a0">87,951</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iae6c9a536db44d69b64c473850d09499_D20190101-20191231" decimals="-3" name="evh:DisposalGroupIncludingDiscontinuedOperationClaimsExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM181NS9mcmFnOmNmZTY4OTBkMjFiYTQxZjE5OTA1MWYzYTFkMzI4MjZiL3RhYmxlOmIwOTBmOWQ1ZjljZDQxMDI5Y2ZhZGU2ZTMyOTIyMTE0L3RhYmxlcmFuZ2U6YjA5MGY5ZDVmOWNkNDEwMjljZmFkZTZlMzI5MjIxMTRfOS01LTEtMS0xOTk3NQ_915f8fb2-5df5-44ee-be63-c48292fe0103">135,774</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative expenses </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1c4a293e5ce54724af5effd8253d4d89_D20210101-20211231" decimals="-3" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM181NS9mcmFnOmNmZTY4OTBkMjFiYTQxZjE5OTA1MWYzYTFkMzI4MjZiL3RhYmxlOmIwOTBmOWQ1ZjljZDQxMDI5Y2ZhZGU2ZTMyOTIyMTE0L3RhYmxlcmFuZ2U6YjA5MGY5ZDVmOWNkNDEwMjljZmFkZTZlMzI5MjIxMTRfMTAtNS0xLTEtMTc3NzU_e8f7a524-6d7b-4a4d-ab77-10dc03016b7c">5,764</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if7ba948ef00b4ddeabe73338f1155e8b_D20200101-20201231" decimals="-3" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM181NS9mcmFnOmNmZTY4OTBkMjFiYTQxZjE5OTA1MWYzYTFkMzI4MjZiL3RhYmxlOmIwOTBmOWQ1ZjljZDQxMDI5Y2ZhZGU2ZTMyOTIyMTE0L3RhYmxlcmFuZ2U6YjA5MGY5ZDVmOWNkNDEwMjljZmFkZTZlMzI5MjIxMTRfMTAtNy0xLTEtMTc3NzU_0cc8c709-bd86-4e45-b501-3fc1290140f6">18,576</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iae6c9a536db44d69b64c473850d09499_D20190101-20191231" decimals="-3" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM181NS9mcmFnOmNmZTY4OTBkMjFiYTQxZjE5OTA1MWYzYTFkMzI4MjZiL3RhYmxlOmIwOTBmOWQ1ZjljZDQxMDI5Y2ZhZGU2ZTMyOTIyMTE0L3RhYmxlcmFuZ2U6YjA5MGY5ZDVmOWNkNDEwMjljZmFkZTZlMzI5MjIxMTRfMTAtNS0xLTEtMTk5NzU_7f5b6b68-0de8-4330-ba9b-cdf45bcbcd3a">26,617</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1c4a293e5ce54724af5effd8253d4d89_D20210101-20211231" decimals="-3" name="us-gaap:DepreciationAndAmortizationDiscontinuedOperations" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM181NS9mcmFnOmNmZTY4OTBkMjFiYTQxZjE5OTA1MWYzYTFkMzI4MjZiL3RhYmxlOmIwOTBmOWQ1ZjljZDQxMDI5Y2ZhZGU2ZTMyOTIyMTE0L3RhYmxlcmFuZ2U6YjA5MGY5ZDVmOWNkNDEwMjljZmFkZTZlMzI5MjIxMTRfMTEtNS0xLTEtMTc3NzU_fc7502a5-14e6-4c9f-a577-06e7c8e2c087">160</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if7ba948ef00b4ddeabe73338f1155e8b_D20200101-20201231" decimals="-3" name="us-gaap:DepreciationAndAmortizationDiscontinuedOperations" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM181NS9mcmFnOmNmZTY4OTBkMjFiYTQxZjE5OTA1MWYzYTFkMzI4MjZiL3RhYmxlOmIwOTBmOWQ1ZjljZDQxMDI5Y2ZhZGU2ZTMyOTIyMTE0L3RhYmxlcmFuZ2U6YjA5MGY5ZDVmOWNkNDEwMjljZmFkZTZlMzI5MjIxMTRfMTEtNy0xLTEtMTc3NzU_e150b216-d697-4dbd-9716-a10d5b78e82a">640</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iae6c9a536db44d69b64c473850d09499_D20190101-20191231" decimals="-3" name="us-gaap:DepreciationAndAmortizationDiscontinuedOperations" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM181NS9mcmFnOmNmZTY4OTBkMjFiYTQxZjE5OTA1MWYzYTFkMzI4MjZiL3RhYmxlOmIwOTBmOWQ1ZjljZDQxMDI5Y2ZhZGU2ZTMyOTIyMTE0L3RhYmxlcmFuZ2U6YjA5MGY5ZDVmOWNkNDEwMjljZmFkZTZlMzI5MjIxMTRfMTEtNS0xLTEtMTk5NzU_6e816e99-9bbc-4084-bad6-97d62b8379d7">590</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating expenses</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1c4a293e5ce54724af5effd8253d4d89_D20210101-20211231" decimals="-3" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM181NS9mcmFnOmNmZTY4OTBkMjFiYTQxZjE5OTA1MWYzYTFkMzI4MjZiL3RhYmxlOmIwOTBmOWQ1ZjljZDQxMDI5Y2ZhZGU2ZTMyOTIyMTE0L3RhYmxlcmFuZ2U6YjA5MGY5ZDVmOWNkNDEwMjljZmFkZTZlMzI5MjIxMTRfMTItNS0xLTEtMTc3NzU_7c56ed0c-4f99-4d47-94b9-f6e3af61da89">45,763</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if7ba948ef00b4ddeabe73338f1155e8b_D20200101-20201231" decimals="-3" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM181NS9mcmFnOmNmZTY4OTBkMjFiYTQxZjE5OTA1MWYzYTFkMzI4MjZiL3RhYmxlOmIwOTBmOWQ1ZjljZDQxMDI5Y2ZhZGU2ZTMyOTIyMTE0L3RhYmxlcmFuZ2U6YjA5MGY5ZDVmOWNkNDEwMjljZmFkZTZlMzI5MjIxMTRfMTItNy0xLTEtMTc3NzU_90ef6432-64b7-4d6b-83ca-f92e6a996d05">125,510</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iae6c9a536db44d69b64c473850d09499_D20190101-20191231" decimals="-3" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM181NS9mcmFnOmNmZTY4OTBkMjFiYTQxZjE5OTA1MWYzYTFkMzI4MjZiL3RhYmxlOmIwOTBmOWQ1ZjljZDQxMDI5Y2ZhZGU2ZTMyOTIyMTE0L3RhYmxlcmFuZ2U6YjA5MGY5ZDVmOWNkNDEwMjljZmFkZTZlMzI5MjIxMTRfMTItNS0xLTEtMTk5NzU_7e30c4e6-2a59-4f99-9987-fde335d1e298">169,614</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating income (loss)</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1c4a293e5ce54724af5effd8253d4d89_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM181NS9mcmFnOmNmZTY4OTBkMjFiYTQxZjE5OTA1MWYzYTFkMzI4MjZiL3RhYmxlOmIwOTBmOWQ1ZjljZDQxMDI5Y2ZhZGU2ZTMyOTIyMTE0L3RhYmxlcmFuZ2U6YjA5MGY5ZDVmOWNkNDEwMjljZmFkZTZlMzI5MjIxMTRfMTMtNS0xLTEtMTc3NzU_77bf358e-f420-4451-8a80-7df5d156e27b">930</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if7ba948ef00b4ddeabe73338f1155e8b_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM181NS9mcmFnOmNmZTY4OTBkMjFiYTQxZjE5OTA1MWYzYTFkMzI4MjZiL3RhYmxlOmIwOTBmOWQ1ZjljZDQxMDI5Y2ZhZGU2ZTMyOTIyMTE0L3RhYmxlcmFuZ2U6YjA5MGY5ZDVmOWNkNDEwMjljZmFkZTZlMzI5MjIxMTRfMTMtNy0xLTEtMTc3NzU_300cc81d-2c8f-4f5b-9f4b-3241c92d58da">7,777</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iae6c9a536db44d69b64c473850d09499_D20190101-20191231" decimals="-3" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM181NS9mcmFnOmNmZTY4OTBkMjFiYTQxZjE5OTA1MWYzYTFkMzI4MjZiL3RhYmxlOmIwOTBmOWQ1ZjljZDQxMDI5Y2ZhZGU2ZTMyOTIyMTE0L3RhYmxlcmFuZ2U6YjA5MGY5ZDVmOWNkNDEwMjljZmFkZTZlMzI5MjIxMTRfMTMtNS0xLTEtMTk5NzU_f82dba4a-fa4e-4d43-bd0a-2b9dbf92a7bb">2,273</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1c4a293e5ce54724af5effd8253d4d89_D20210101-20211231" decimals="-3" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationInterestIncome" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM181NS9mcmFnOmNmZTY4OTBkMjFiYTQxZjE5OTA1MWYzYTFkMzI4MjZiL3RhYmxlOmIwOTBmOWQ1ZjljZDQxMDI5Y2ZhZGU2ZTMyOTIyMTE0L3RhYmxlcmFuZ2U6YjA5MGY5ZDVmOWNkNDEwMjljZmFkZTZlMzI5MjIxMTRfMTQtNS0xLTEtMTc3NzU_fa86cc48-66b3-45e2-a16b-ee6a0aeee684">112</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if7ba948ef00b4ddeabe73338f1155e8b_D20200101-20201231" decimals="-3" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationInterestIncome" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM181NS9mcmFnOmNmZTY4OTBkMjFiYTQxZjE5OTA1MWYzYTFkMzI4MjZiL3RhYmxlOmIwOTBmOWQ1ZjljZDQxMDI5Y2ZhZGU2ZTMyOTIyMTE0L3RhYmxlcmFuZ2U6YjA5MGY5ZDVmOWNkNDEwMjljZmFkZTZlMzI5MjIxMTRfMTQtNy0xLTEtMTc3NzU_3385302c-d4c2-4408-baf8-da64df6ff9a6">531</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iae6c9a536db44d69b64c473850d09499_D20190101-20191231" decimals="-3" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationInterestIncome" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM181NS9mcmFnOmNmZTY4OTBkMjFiYTQxZjE5OTA1MWYzYTFkMzI4MjZiL3RhYmxlOmIwOTBmOWQ1ZjljZDQxMDI5Y2ZhZGU2ZTMyOTIyMTE0L3RhYmxlcmFuZ2U6YjA5MGY5ZDVmOWNkNDEwMjljZmFkZTZlMzI5MjIxMTRfMTQtNS0xLTEtMTk5NzU_3d1129d2-aca1-4b8d-aa60-3d8db973323c">581</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1c4a293e5ce54724af5effd8253d4d89_D20210101-20211231" decimals="-3" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationInterestExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM181NS9mcmFnOmNmZTY4OTBkMjFiYTQxZjE5OTA1MWYzYTFkMzI4MjZiL3RhYmxlOmIwOTBmOWQ1ZjljZDQxMDI5Y2ZhZGU2ZTMyOTIyMTE0L3RhYmxlcmFuZ2U6YjA5MGY5ZDVmOWNkNDEwMjljZmFkZTZlMzI5MjIxMTRfMTUtNS0xLTEtMTc3NzU_ddbb686d-21f9-4db6-8907-6d729580f2a7">4</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if7ba948ef00b4ddeabe73338f1155e8b_D20200101-20201231" decimals="-3" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationInterestExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM181NS9mcmFnOmNmZTY4OTBkMjFiYTQxZjE5OTA1MWYzYTFkMzI4MjZiL3RhYmxlOmIwOTBmOWQ1ZjljZDQxMDI5Y2ZhZGU2ZTMyOTIyMTE0L3RhYmxlcmFuZ2U6YjA5MGY5ZDVmOWNkNDEwMjljZmFkZTZlMzI5MjIxMTRfMTUtNy0xLTEtMTc3NzU_37da96e5-3ffd-4eaf-b509-26302b763417">12</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iae6c9a536db44d69b64c473850d09499_D20190101-20191231" decimals="-3" sign="-" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationInterestExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM181NS9mcmFnOmNmZTY4OTBkMjFiYTQxZjE5OTA1MWYzYTFkMzI4MjZiL3RhYmxlOmIwOTBmOWQ1ZjljZDQxMDI5Y2ZhZGU2ZTMyOTIyMTE0L3RhYmxlcmFuZ2U6YjA5MGY5ZDVmOWNkNDEwMjljZmFkZTZlMzI5MjIxMTRfMTUtNS0xLTEtMTk5NzU_db9549b2-eb3e-43ce-8232-30344c3540b1">21</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1c4a293e5ce54724af5effd8253d4d89_D20210101-20211231" decimals="-3" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationOtherExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM181NS9mcmFnOmNmZTY4OTBkMjFiYTQxZjE5OTA1MWYzYTFkMzI4MjZiL3RhYmxlOmIwOTBmOWQ1ZjljZDQxMDI5Y2ZhZGU2ZTMyOTIyMTE0L3RhYmxlcmFuZ2U6YjA5MGY5ZDVmOWNkNDEwMjljZmFkZTZlMzI5MjIxMTRfMTYtNS0xLTEtMTc3NzU_12dd6c5c-5a26-4368-bafa-0ba88167337b">25</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if7ba948ef00b4ddeabe73338f1155e8b_D20200101-20201231" decimals="-3" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationOtherExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM181NS9mcmFnOmNmZTY4OTBkMjFiYTQxZjE5OTA1MWYzYTFkMzI4MjZiL3RhYmxlOmIwOTBmOWQ1ZjljZDQxMDI5Y2ZhZGU2ZTMyOTIyMTE0L3RhYmxlcmFuZ2U6YjA5MGY5ZDVmOWNkNDEwMjljZmFkZTZlMzI5MjIxMTRfMTYtNy0xLTEtMTc3NzU_0bc545cb-4d5c-4931-85e9-dc5ea65e56d5">1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iae6c9a536db44d69b64c473850d09499_D20190101-20191231" decimals="-3" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationOtherExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM181NS9mcmFnOmNmZTY4OTBkMjFiYTQxZjE5OTA1MWYzYTFkMzI4MjZiL3RhYmxlOmIwOTBmOWQ1ZjljZDQxMDI5Y2ZhZGU2ZTMyOTIyMTE0L3RhYmxlcmFuZ2U6YjA5MGY5ZDVmOWNkNDEwMjljZmFkZTZlMzI5MjIxMTRfMTYtNS0xLTEtMTk5NzU_2df149dc-3ac2-4585-b776-199cd9c0e188">3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income (loss) before income taxes and non-controlling interests</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1c4a293e5ce54724af5effd8253d4d89_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM181NS9mcmFnOmNmZTY4OTBkMjFiYTQxZjE5OTA1MWYzYTFkMzI4MjZiL3RhYmxlOmIwOTBmOWQ1ZjljZDQxMDI5Y2ZhZGU2ZTMyOTIyMTE0L3RhYmxlcmFuZ2U6YjA5MGY5ZDVmOWNkNDEwMjljZmFkZTZlMzI5MjIxMTRfMTctNS0xLTEtMTc3NzU_1316f185-a286-4eb7-95a0-171bc64706d1">847</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if7ba948ef00b4ddeabe73338f1155e8b_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM181NS9mcmFnOmNmZTY4OTBkMjFiYTQxZjE5OTA1MWYzYTFkMzI4MjZiL3RhYmxlOmIwOTBmOWQ1ZjljZDQxMDI5Y2ZhZGU2ZTMyOTIyMTE0L3RhYmxlcmFuZ2U6YjA5MGY5ZDVmOWNkNDEwMjljZmFkZTZlMzI5MjIxMTRfMTctNy0xLTEtMTc3NzU_7a8d8716-5756-4564-801b-ab868cb6cfee">7,259</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iae6c9a536db44d69b64c473850d09499_D20190101-20191231" decimals="-3" name="us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM181NS9mcmFnOmNmZTY4OTBkMjFiYTQxZjE5OTA1MWYzYTFkMzI4MjZiL3RhYmxlOmIwOTBmOWQ1ZjljZDQxMDI5Y2ZhZGU2ZTMyOTIyMTE0L3RhYmxlcmFuZ2U6YjA5MGY5ZDVmOWNkNDEwMjljZmFkZTZlMzI5MjIxMTRfMTctNS0xLTEtMTk5NzU_c2d0f499-ecb1-4641-b1e3-e34ed36576ce">2,872</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">85</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="iec427cf2209c473cb50fcbfd03a4af6e" continuedAt="ic49dc11e3d2648328937f061208108ac"><ix:continuation id="i4ca79154b7c94bfd8108a16b2f43af6b" continuedAt="id8b7d92aadc2401fbf22b40cefed203c"><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:69.872%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.205%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.205%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.208%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Benefit (provision) for income taxes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1c4a293e5ce54724af5effd8253d4d89_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:DiscontinuedOperationTaxEffectOfDiscontinuedOperation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM181NS9mcmFnOmNmZTY4OTBkMjFiYTQxZjE5OTA1MWYzYTFkMzI4MjZiL3RhYmxlOmIwOTBmOWQ1ZjljZDQxMDI5Y2ZhZGU2ZTMyOTIyMTE0L3RhYmxlcmFuZ2U6YjA5MGY5ZDVmOWNkNDEwMjljZmFkZTZlMzI5MjIxMTRfMTgtNS0xLTEtMTc3NzU_7c143a07-316c-466f-956c-17506c1537b5">326</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if7ba948ef00b4ddeabe73338f1155e8b_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:DiscontinuedOperationTaxEffectOfDiscontinuedOperation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM181NS9mcmFnOmNmZTY4OTBkMjFiYTQxZjE5OTA1MWYzYTFkMzI4MjZiL3RhYmxlOmIwOTBmOWQ1ZjljZDQxMDI5Y2ZhZGU2ZTMyOTIyMTE0L3RhYmxlcmFuZ2U6YjA5MGY5ZDVmOWNkNDEwMjljZmFkZTZlMzI5MjIxMTRfMTgtNy0xLTEtMTc3NzU_106c3902-c690-4b4b-a258-2efff2f8547c">1,185</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iae6c9a536db44d69b64c473850d09499_D20190101-20191231" decimals="-3" name="us-gaap:DiscontinuedOperationTaxEffectOfDiscontinuedOperation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM181NS9mcmFnOmNmZTY4OTBkMjFiYTQxZjE5OTA1MWYzYTFkMzI4MjZiL3RhYmxlOmIwOTBmOWQ1ZjljZDQxMDI5Y2ZhZGU2ZTMyOTIyMTE0L3RhYmxlcmFuZ2U6YjA5MGY5ZDVmOWNkNDEwMjljZmFkZTZlMzI5MjIxMTRfMTgtNS0xLTEtMTk5NzU_de379250-e2a8-442b-804e-9bd3294a1a8c">1,259</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1c4a293e5ce54724af5effd8253d4d89_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM181NS9mcmFnOmNmZTY4OTBkMjFiYTQxZjE5OTA1MWYzYTFkMzI4MjZiL3RhYmxlOmIwOTBmOWQ1ZjljZDQxMDI5Y2ZhZGU2ZTMyOTIyMTE0L3RhYmxlcmFuZ2U6YjA5MGY5ZDVmOWNkNDEwMjljZmFkZTZlMzI5MjIxMTRfMTktNS0xLTEtMTc3NzU_ffe52d6e-5582-488c-8ca2-74fa0de34439">521</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if7ba948ef00b4ddeabe73338f1155e8b_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM181NS9mcmFnOmNmZTY4OTBkMjFiYTQxZjE5OTA1MWYzYTFkMzI4MjZiL3RhYmxlOmIwOTBmOWQ1ZjljZDQxMDI5Y2ZhZGU2ZTMyOTIyMTE0L3RhYmxlcmFuZ2U6YjA5MGY5ZDVmOWNkNDEwMjljZmFkZTZlMzI5MjIxMTRfMTktNy0xLTEtMTc3NzU_b2b99bf1-5b4a-4963-bf0c-45941b96654b">6,074</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iae6c9a536db44d69b64c473850d09499_D20190101-20191231" decimals="-3" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM181NS9mcmFnOmNmZTY4OTBkMjFiYTQxZjE5OTA1MWYzYTFkMzI4MjZiL3RhYmxlOmIwOTBmOWQ1ZjljZDQxMDI5Y2ZhZGU2ZTMyOTIyMTE0L3RhYmxlcmFuZ2U6YjA5MGY5ZDVmOWNkNDEwMjljZmFkZTZlMzI5MjIxMTRfMTktNS0xLTEtMTk5NzU_afc0fa76-6f38-4640-9a01-437f756ff6dd">1,613</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt">Cost of revenue includes intercompany expenses between the Company and True Health that are recorded in income from continuing operations in the consolidated statements of operations and comprehensive income (loss) related to an existing services agreement for claims processing and other health plan administrative functions of $<ix:nonFraction unitRef="usd" contextRef="ib1b709ded692440f9e0b6b584a8c0080_D20210101-20211231" decimals="-5" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM181NS9mcmFnOmNmZTY4OTBkMjFiYTQxZjE5OTA1MWYzYTFkMzI4MjZiL3RleHRyZWdpb246Y2ZlNjg5MGQyMWJhNDFmMTk5MDUxZjNhMWQzMjgyNmJfMTY1OA_6c5b4578-fdba-463b-85ac-45bb101c65ab">2.8</ix:nonFraction>&#160;million, $<ix:nonFraction unitRef="usd" contextRef="i93a7fe07dcb74ecba6ec18daa2afd21d_D20200101-20201231" decimals="-5" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM181NS9mcmFnOmNmZTY4OTBkMjFiYTQxZjE5OTA1MWYzYTFkMzI4MjZiL3RleHRyZWdpb246Y2ZlNjg5MGQyMWJhNDFmMTk5MDUxZjNhMWQzMjgyNmJfMTY2NQ_375b88e2-9c7b-47f6-96a8-b6ce0b859bfa">13.6</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i0725607f45d24e7096771c6e0b9f7133_D20190101-20191231" decimals="-5" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM181NS9mcmFnOmNmZTY4OTBkMjFiYTQxZjE5OTA1MWYzYTFkMzI4MjZiL3RleHRyZWdpb246Y2ZlNjg5MGQyMWJhNDFmMTk5MDUxZjNhMWQzMjgyNmJfMTA5OTUxMTYzMDY5OA_2a2b60c5-60cf-438b-8459-0329367a2ec1">6.6</ix:nonFraction>&#160;million for the years ended December 31, 2021, 2020 and 2019, respectively.</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt">Selling, general and administrative expenses includes intercompany expenses between the Company and True Health that are recorded in income from continuing operations on the consolidated statements of operations and comprehensive income (loss) related to an existing services agreement for claims processing and other health plan administrative functions of $<ix:nonFraction unitRef="usd" contextRef="ib1b709ded692440f9e0b6b584a8c0080_D20210101-20211231" decimals="-5" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM181NS9mcmFnOmNmZTY4OTBkMjFiYTQxZjE5OTA1MWYzYTFkMzI4MjZiL3RleHRyZWdpb246Y2ZlNjg5MGQyMWJhNDFmMTk5MDUxZjNhMWQzMjgyNmJfMjA2OQ_50ab129b-0bf1-400c-ab51-676f20d7265e">1.1</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="i93a7fe07dcb74ecba6ec18daa2afd21d_D20200101-20201231" decimals="-5" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM181NS9mcmFnOmNmZTY4OTBkMjFiYTQxZjE5OTA1MWYzYTFkMzI4MjZiL3RleHRyZWdpb246Y2ZlNjg5MGQyMWJhNDFmMTk5MDUxZjNhMWQzMjgyNmJfMjA3Ng_f904a473-edb4-42a2-bba2-5a3245bb5d41">6.4</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i0725607f45d24e7096771c6e0b9f7133_D20190101-20191231" decimals="-5" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM181NS9mcmFnOmNmZTY4OTBkMjFiYTQxZjE5OTA1MWYzYTFkMzI4MjZiL3RleHRyZWdpb246Y2ZlNjg5MGQyMWJhNDFmMTk5MDUxZjNhMWQzMjgyNmJfMTA5OTUxMTYzMDc4OA_c73509cb-ecdc-454d-b9d7-579ba4814115">6.0</ix:nonFraction>&#160;million for the years ended December 31, 2021, 2020 and 2019, respectively. </span></div></ix:continuation><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The consolidated statements of cash flows for all periods have not been adjusted to separately disclose cash flows related to discontinued operations. <ix:continuation id="id8b7d92aadc2401fbf22b40cefed203c" continuedAt="i4c89e441918740d391bf764985407a0d">Cash flows related to the True Health business during the year ended December 31, 2021, 2020 and 2019 were as follows:</ix:continuation></span></div><div style="text-align:justify"><span><br/></span></div><ix:continuation id="i4c89e441918740d391bf764985407a0d" continuedAt="i26cb1e40a51f4d2f92fb138cb668de11"><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:69.872%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.205%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.205%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.208%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash flows provided by (used in) operating activities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1c4a293e5ce54724af5effd8253d4d89_D20210101-20211231" decimals="-3" name="us-gaap:CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM181NS9mcmFnOmNmZTY4OTBkMjFiYTQxZjE5OTA1MWYzYTFkMzI4MjZiL3RhYmxlOjQyNjgyYTc0MDg3NTQ5M2M5MjNhZWE3ZWI5YmIzMGRhL3RhYmxlcmFuZ2U6NDI2ODJhNzQwODc1NDkzYzkyM2FlYTdlYjliYjMwZGFfMi0xLTEtMS0xNzc3NQ_5e249f92-6cb9-4d0b-9388-7d26475844ac">5,002</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if7ba948ef00b4ddeabe73338f1155e8b_D20200101-20201231" decimals="-3" name="us-gaap:CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM181NS9mcmFnOmNmZTY4OTBkMjFiYTQxZjE5OTA1MWYzYTFkMzI4MjZiL3RhYmxlOjQyNjgyYTc0MDg3NTQ5M2M5MjNhZWE3ZWI5YmIzMGRhL3RhYmxlcmFuZ2U6NDI2ODJhNzQwODc1NDkzYzkyM2FlYTdlYjliYjMwZGFfMi0zLTEtMS0xNzc3NQ_cbc4096e-9fdb-4e9d-ad44-7d048937f593">6,852</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iae6c9a536db44d69b64c473850d09499_D20190101-20191231" decimals="-3" sign="-" name="us-gaap:CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM181NS9mcmFnOmNmZTY4OTBkMjFiYTQxZjE5OTA1MWYzYTFkMzI4MjZiL3RhYmxlOjQyNjgyYTc0MDg3NTQ5M2M5MjNhZWE3ZWI5YmIzMGRhL3RhYmxlcmFuZ2U6NDI2ODJhNzQwODc1NDkzYzkyM2FlYTdlYjliYjMwZGFfMi01LTEtMS0yNzA0OQ_7815f47c-2799-4a3b-825f-fdcee94bfe71">6,642</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash flows (used in) provided by investing activities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1c4a293e5ce54724af5effd8253d4d89_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM181NS9mcmFnOmNmZTY4OTBkMjFiYTQxZjE5OTA1MWYzYTFkMzI4MjZiL3RhYmxlOjQyNjgyYTc0MDg3NTQ5M2M5MjNhZWE3ZWI5YmIzMGRhL3RhYmxlcmFuZ2U6NDI2ODJhNzQwODc1NDkzYzkyM2FlYTdlYjliYjMwZGFfMy0xLTEtMS0xNzc3NQ_f596583e-17af-4794-b817-90a88cc117a4">2,494</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if7ba948ef00b4ddeabe73338f1155e8b_D20200101-20201231" decimals="-3" name="us-gaap:CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM181NS9mcmFnOmNmZTY4OTBkMjFiYTQxZjE5OTA1MWYzYTFkMzI4MjZiL3RhYmxlOjQyNjgyYTc0MDg3NTQ5M2M5MjNhZWE3ZWI5YmIzMGRhL3RhYmxlcmFuZ2U6NDI2ODJhNzQwODc1NDkzYzkyM2FlYTdlYjliYjMwZGFfMy0zLTEtMS0xNzc3NQ_77e1747c-92c8-4eb5-8a46-fcaea34b73ff">2,636</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iae6c9a536db44d69b64c473850d09499_D20190101-20191231" decimals="-3" sign="-" name="us-gaap:CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM181NS9mcmFnOmNmZTY4OTBkMjFiYTQxZjE5OTA1MWYzYTFkMzI4MjZiL3RhYmxlOjQyNjgyYTc0MDg3NTQ5M2M5MjNhZWE3ZWI5YmIzMGRhL3RhYmxlcmFuZ2U6NDI2ODJhNzQwODc1NDkzYzkyM2FlYTdlYjliYjMwZGFfMy01LTEtMS0yNzA0OQ_bce50828-92e5-4cac-8509-4715d13840a0">7,172</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash flows used in financing activities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1c4a293e5ce54724af5effd8253d4d89_D20210101-20211231" decimals="-3" name="us-gaap:CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM181NS9mcmFnOmNmZTY4OTBkMjFiYTQxZjE5OTA1MWYzYTFkMzI4MjZiL3RhYmxlOjQyNjgyYTc0MDg3NTQ5M2M5MjNhZWE3ZWI5YmIzMGRhL3RhYmxlcmFuZ2U6NDI2ODJhNzQwODc1NDkzYzkyM2FlYTdlYjliYjMwZGFfNC0xLTEtMS0yNzA2NA_c6096468-ec6a-4bcf-b98b-4f1def1f1eb0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if7ba948ef00b4ddeabe73338f1155e8b_D20200101-20201231" decimals="-3" name="us-gaap:CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM181NS9mcmFnOmNmZTY4OTBkMjFiYTQxZjE5OTA1MWYzYTFkMzI4MjZiL3RhYmxlOjQyNjgyYTc0MDg3NTQ5M2M5MjNhZWE3ZWI5YmIzMGRhL3RhYmxlcmFuZ2U6NDI2ODJhNzQwODc1NDkzYzkyM2FlYTdlYjliYjMwZGFfNC0zLTEtMS0yNzA2NA_b471dfc3-b326-4a9d-ab7f-22312a2c16ca">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iae6c9a536db44d69b64c473850d09499_D20190101-20191231" decimals="-3" sign="-" name="us-gaap:CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM181NS9mcmFnOmNmZTY4OTBkMjFiYTQxZjE5OTA1MWYzYTFkMzI4MjZiL3RhYmxlOjQyNjgyYTc0MDg3NTQ5M2M5MjNhZWE3ZWI5YmIzMGRhL3RhYmxlcmFuZ2U6NDI2ODJhNzQwODc1NDkzYzkyM2FlYTdlYjliYjMwZGFfNC01LTEtMS0yNzA2NA_3e2a8096-bbef-4041-b661-e577d9ab5501">2,500</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the current and long-term assets and liabilities of the discontinued True Health business in the consolidated balance sheets as of December&#160;31, 2020:</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:82.927%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.873%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">ASSETS</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i98364cf4ba3e41af868d701b4c668283_I20201231" decimals="-3" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM181NS9mcmFnOmNmZTY4OTBkMjFiYTQxZjE5OTA1MWYzYTFkMzI4MjZiL3RhYmxlOmRmNTY5NGIzNmMxYjQwY2U5NzlkOTAzYjI0YWM0NGY4L3RhYmxlcmFuZ2U6ZGY1Njk0YjM2YzFiNDBjZTk3OWQ5MDNiMjRhYzQ0ZjhfMy0xLTEtMS0xNzc3NQ_7cc467bd-27a8-4ac0-b420-f8a5b10f3d68">21,488</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash and restricted investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i98364cf4ba3e41af868d701b4c668283_I20201231" decimals="-3" name="evh:DisposalGroupIncludingDiscontinuedOperationRestrictedCashAndRestrictedInvestmentsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM181NS9mcmFnOmNmZTY4OTBkMjFiYTQxZjE5OTA1MWYzYTFkMzI4MjZiL3RhYmxlOmRmNTY5NGIzNmMxYjQwY2U5NzlkOTAzYjI0YWM0NGY4L3RhYmxlcmFuZ2U6ZGY1Njk0YjM2YzFiNDBjZTk3OWQ5MDNiMjRhYzQ0ZjhfNC0xLTEtMS0xNzc3NQ_e44e8a62-6a48-4e4d-8727-663018619f7f">63</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i98364cf4ba3e41af868d701b4c668283_I20201231" decimals="-3" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM181NS9mcmFnOmNmZTY4OTBkMjFiYTQxZjE5OTA1MWYzYTFkMzI4MjZiL3RhYmxlOmRmNTY5NGIzNmMxYjQwY2U5NzlkOTAzYjI0YWM0NGY4L3RhYmxlcmFuZ2U6ZGY1Njk0YjM2YzFiNDBjZTk3OWQ5MDNiMjRhYzQ0ZjhfNS0xLTEtMS0xNzc3NQ_b6751419-5506-49c0-9e68-8831d01fa211">3,437</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i98364cf4ba3e41af868d701b4c668283_I20201231" decimals="-3" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM181NS9mcmFnOmNmZTY4OTBkMjFiYTQxZjE5OTA1MWYzYTFkMzI4MjZiL3RhYmxlOmRmNTY5NGIzNmMxYjQwY2U5NzlkOTAzYjI0YWM0NGY4L3RhYmxlcmFuZ2U6ZGY1Njk0YjM2YzFiNDBjZTk3OWQ5MDNiMjRhYzQ0ZjhfNi0xLTEtMS0xNzc3NQ_486e3e34-bc19-460d-90f3-549c733d77fb">5,198</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investments, at amortized cost</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i98364cf4ba3e41af868d701b4c668283_I20201231" decimals="-3" name="evh:DisposalGroupIncludingDiscontinuedOperationInvestmentsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM181NS9mcmFnOmNmZTY4OTBkMjFiYTQxZjE5OTA1MWYzYTFkMzI4MjZiL3RhYmxlOmRmNTY5NGIzNmMxYjQwY2U5NzlkOTAzYjI0YWM0NGY4L3RhYmxlcmFuZ2U6ZGY1Njk0YjM2YzFiNDBjZTk3OWQ5MDNiMjRhYzQ0ZjhfNy0xLTEtMS0xNzc3NQ_aac02375-a946-41ea-b0ef-a9f93e2004db">3,728</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i98364cf4ba3e41af868d701b4c668283_I20201231" decimals="-3" name="us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM181NS9mcmFnOmNmZTY4OTBkMjFiYTQxZjE5OTA1MWYzYTFkMzI4MjZiL3RhYmxlOmRmNTY5NGIzNmMxYjQwY2U5NzlkOTAzYjI0YWM0NGY4L3RhYmxlcmFuZ2U6ZGY1Njk0YjM2YzFiNDBjZTk3OWQ5MDNiMjRhYzQ0ZjhfOC0xLTEtMS0xNzc3NQ_7361fea5-01bf-461b-bf09-0ed38d8e33e9">33,914</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash and restricted investments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i98364cf4ba3e41af868d701b4c668283_I20201231" decimals="-3" name="evh:DisposalGroupIncludingDiscontinuedOperationRestrictedCashAndRestrictedInvestmentsNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM181NS9mcmFnOmNmZTY4OTBkMjFiYTQxZjE5OTA1MWYzYTFkMzI4MjZiL3RhYmxlOmRmNTY5NGIzNmMxYjQwY2U5NzlkOTAzYjI0YWM0NGY4L3RhYmxlcmFuZ2U6ZGY1Njk0YjM2YzFiNDBjZTk3OWQ5MDNiMjRhYzQ0ZjhfOS0xLTEtMS0xNzc3NQ_ee999fe7-272e-489e-9e97-b52253720d4c">616</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investments, at amortized cost</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i98364cf4ba3e41af868d701b4c668283_I20201231" decimals="-3" name="evh:DisposalGroupIncludingDiscontinuedOperationInvestmentsNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM181NS9mcmFnOmNmZTY4OTBkMjFiYTQxZjE5OTA1MWYzYTFkMzI4MjZiL3RhYmxlOmRmNTY5NGIzNmMxYjQwY2U5NzlkOTAzYjI0YWM0NGY4L3RhYmxlcmFuZ2U6ZGY1Njk0YjM2YzFiNDBjZTk3OWQ5MDNiMjRhYzQ0ZjhfMTAtMS0xLTEtMTc3NzU_8af7b227-c8b4-4b23-8dc6-e7229fd9c413">10,919</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other noncurrent assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i98364cf4ba3e41af868d701b4c668283_I20201231" decimals="-3" name="evh:DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM181NS9mcmFnOmNmZTY4OTBkMjFiYTQxZjE5OTA1MWYzYTFkMzI4MjZiL3RhYmxlOmRmNTY5NGIzNmMxYjQwY2U5NzlkOTAzYjI0YWM0NGY4L3RhYmxlcmFuZ2U6ZGY1Njk0YjM2YzFiNDBjZTk3OWQ5MDNiMjRhYzQ0ZjhfMTEtMS0xLTEtMTc3NzU_f2636dbb-df86-4db8-806f-d8d31daff131">59</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible assets, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i98364cf4ba3e41af868d701b4c668283_I20201231" decimals="-3" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM181NS9mcmFnOmNmZTY4OTBkMjFiYTQxZjE5OTA1MWYzYTFkMzI4MjZiL3RhYmxlOmRmNTY5NGIzNmMxYjQwY2U5NzlkOTAzYjI0YWM0NGY4L3RhYmxlcmFuZ2U6ZGY1Njk0YjM2YzFiNDBjZTk3OWQ5MDNiMjRhYzQ0ZjhfMTItMS0xLTEtMTc3NzU_44ae2047-63f2-4113-9b41-afea98f233ed">3,080</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i98364cf4ba3e41af868d701b4c668283_I20201231" decimals="-3" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationGoodwillNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM181NS9mcmFnOmNmZTY4OTBkMjFiYTQxZjE5OTA1MWYzYTFkMzI4MjZiL3RhYmxlOmRmNTY5NGIzNmMxYjQwY2U5NzlkOTAzYjI0YWM0NGY4L3RhYmxlcmFuZ2U6ZGY1Njk0YjM2YzFiNDBjZTk3OWQ5MDNiMjRhYzQ0ZjhfMTMtMS0xLTEtMTc3NzU_23406174-29a0-4731-a0cf-fc486f305972">5,705</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i98364cf4ba3e41af868d701b4c668283_I20201231" decimals="-3" name="us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM181NS9mcmFnOmNmZTY4OTBkMjFiYTQxZjE5OTA1MWYzYTFkMzI4MjZiL3RhYmxlOmRmNTY5NGIzNmMxYjQwY2U5NzlkOTAzYjI0YWM0NGY4L3RhYmxlcmFuZ2U6ZGY1Njk0YjM2YzFiNDBjZTk3OWQ5MDNiMjRhYzQ0ZjhfMTQtMS0xLTEtMTc3NzU_43bb81f7-0462-4aba-a8c1-98862ecfc10e">54,293</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">LIABILITIES</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i98364cf4ba3e41af868d701b4c668283_I20201231" decimals="-3" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationAccountsPayableCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM181NS9mcmFnOmNmZTY4OTBkMjFiYTQxZjE5OTA1MWYzYTFkMzI4MjZiL3RhYmxlOmRmNTY5NGIzNmMxYjQwY2U5NzlkOTAzYjI0YWM0NGY4L3RhYmxlcmFuZ2U6ZGY1Njk0YjM2YzFiNDBjZTk3OWQ5MDNiMjRhYzQ0ZjhfMTgtMS0xLTEtMTc3NzU_c53c9254-a2f9-4d67-8241-2b0f869d2384">93</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i98364cf4ba3e41af868d701b4c668283_I20201231" decimals="-3" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationAccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM181NS9mcmFnOmNmZTY4OTBkMjFiYTQxZjE5OTA1MWYzYTFkMzI4MjZiL3RhYmxlOmRmNTY5NGIzNmMxYjQwY2U5NzlkOTAzYjI0YWM0NGY4L3RhYmxlcmFuZ2U6ZGY1Njk0YjM2YzFiNDBjZTk3OWQ5MDNiMjRhYzQ0ZjhfMTktMS0xLTEtMTc3NzU_339e114c-9201-434e-a3f5-04a79735b5c7">11,265</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued compensation and employee benefits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i98364cf4ba3e41af868d701b4c668283_I20201231" decimals="-3" name="evh:DisposalGroupIncludingDiscontinuedOperationAccruedCompensationAndEmployeeBenefitsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM181NS9mcmFnOmNmZTY4OTBkMjFiYTQxZjE5OTA1MWYzYTFkMzI4MjZiL3RhYmxlOmRmNTY5NGIzNmMxYjQwY2U5NzlkOTAzYjI0YWM0NGY4L3RhYmxlcmFuZ2U6ZGY1Njk0YjM2YzFiNDBjZTk3OWQ5MDNiMjRhYzQ0ZjhfMjAtMS0xLTEtMTc3NzU_9d2f5763-08fe-4013-b863-bb7a8d2cf72f">1,115</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i98364cf4ba3e41af868d701b4c668283_I20201231" decimals="-3" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationDeferredRevenueCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM181NS9mcmFnOmNmZTY4OTBkMjFiYTQxZjE5OTA1MWYzYTFkMzI4MjZiL3RhYmxlOmRmNTY5NGIzNmMxYjQwY2U5NzlkOTAzYjI0YWM0NGY4L3RhYmxlcmFuZ2U6ZGY1Njk0YjM2YzFiNDBjZTk3OWQ5MDNiMjRhYzQ0ZjhfMjEtMS0xLTEtMTc3NzU_7d697d4e-4866-41d0-8fb6-bb8129bd8786">4,140</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reserve for claims and performance-based arrangements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i98364cf4ba3e41af868d701b4c668283_I20201231" decimals="-3" name="evh:DisposalGroupIncludingDiscontinuedOperationLiabilityForFuturePolicyBenefitsAndUnpaidClaimsAndClaimsAdjustmentExpenseAndPerformanceBasedArrangementsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM181NS9mcmFnOmNmZTY4OTBkMjFiYTQxZjE5OTA1MWYzYTFkMzI4MjZiL3RhYmxlOmRmNTY5NGIzNmMxYjQwY2U5NzlkOTAzYjI0YWM0NGY4L3RhYmxlcmFuZ2U6ZGY1Njk0YjM2YzFiNDBjZTk3OWQ5MDNiMjRhYzQ0ZjhfMjItMS0xLTEtMTc3NzU_366a4d58-0b2b-482d-8c0e-46a72b238186">9,858</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i98364cf4ba3e41af868d701b4c668283_I20201231" decimals="-3" name="us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM181NS9mcmFnOmNmZTY4OTBkMjFiYTQxZjE5OTA1MWYzYTFkMzI4MjZiL3RhYmxlOmRmNTY5NGIzNmMxYjQwY2U5NzlkOTAzYjI0YWM0NGY4L3RhYmxlcmFuZ2U6ZGY1Njk0YjM2YzFiNDBjZTk3OWQ5MDNiMjRhYzQ0ZjhfMjMtMS0xLTEtMTc3NzU_148e40ec-7977-4937-8d77-97eed0ccf2ce">26,471</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other long-term liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i98364cf4ba3e41af868d701b4c668283_I20201231" decimals="-3" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM181NS9mcmFnOmNmZTY4OTBkMjFiYTQxZjE5OTA1MWYzYTFkMzI4MjZiL3RhYmxlOmRmNTY5NGIzNmMxYjQwY2U5NzlkOTAzYjI0YWM0NGY4L3RhYmxlcmFuZ2U6ZGY1Njk0YjM2YzFiNDBjZTk3OWQ5MDNiMjRhYzQ0ZjhfMjQtMS0xLTEtMTc3NzU_89cbe27b-c63b-4d13-bc21-ef03eb4284a8">128</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:continuation></ix:continuation><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">86</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="ic49dc11e3d2648328937f061208108ac"><ix:continuation id="i26cb1e40a51f4d2f92fb138cb668de11"><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:82.927%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.873%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax liabilities, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i98364cf4ba3e41af868d701b4c668283_I20201231" decimals="-3" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationDeferredTaxLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM181NS9mcmFnOmNmZTY4OTBkMjFiYTQxZjE5OTA1MWYzYTFkMzI4MjZiL3RhYmxlOmRmNTY5NGIzNmMxYjQwY2U5NzlkOTAzYjI0YWM0NGY4L3RhYmxlcmFuZ2U6ZGY1Njk0YjM2YzFiNDBjZTk3OWQ5MDNiMjRhYzQ0ZjhfMjUtMS0xLTEtMTc3NzU_758dfbcc-7076-4a9f-88e2-2070a87f3b1e">49</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i98364cf4ba3e41af868d701b4c668283_I20201231" decimals="-3" name="us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM181NS9mcmFnOmNmZTY4OTBkMjFiYTQxZjE5OTA1MWYzYTFkMzI4MjZiL3RhYmxlOmRmNTY5NGIzNmMxYjQwY2U5NzlkOTAzYjI0YWM0NGY4L3RhYmxlcmFuZ2U6ZGY1Njk0YjM2YzFiNDBjZTk3OWQ5MDNiMjRhYzQ0ZjhfMjYtMS0xLTEtMTc3NzU_2ddddd50-0a46-47c8-924f-c6a897f7d66c">26,648</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt">Accounts payable excludes $<ix:nonFraction unitRef="usd" contextRef="i6ea3e63701234a91a969d79c7385efdc_I20201231" decimals="-5" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationAccountsPayableCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM181NS9mcmFnOmNmZTY4OTBkMjFiYTQxZjE5OTA1MWYzYTFkMzI4MjZiL3RleHRyZWdpb246Y2ZlNjg5MGQyMWJhNDFmMTk5MDUxZjNhMWQzMjgyNmJfMjU0NQ_462ed816-eda3-4efc-ba58-f4f70bf326a9"><ix:nonFraction unitRef="usd" contextRef="i6ea3e63701234a91a969d79c7385efdc_I20201231" decimals="-5" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM181NS9mcmFnOmNmZTY4OTBkMjFiYTQxZjE5OTA1MWYzYTFkMzI4MjZiL3RleHRyZWdpb246Y2ZlNjg5MGQyMWJhNDFmMTk5MDUxZjNhMWQzMjgyNmJfMjU0NQ_e61df0f7-7174-46f1-a2d0-578fb44b4b77">1.5</ix:nonFraction></ix:nonFraction>&#160;million between the Company and True Health related to an existing services agreement for claims processing and other health plan administrative functions as of December 31, 2020.</span></div></ix:continuation></ix:continuation><div style="text-align:justify"><span><br/></span></div><div id="i9aaa2fddc97e482da5dbe37ac85ae703_58"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 6.  <ix:nonNumeric contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231" name="us-gaap:RevenueFromContractWithCustomerTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM181OC9mcmFnOjdkZGUxNTIxODMxMzQ3YThhZTFjZmNjNDcyNGZlNmFlL3RleHRyZWdpb246N2RkZTE1MjE4MzEzNDdhOGFlMWNmY2M0NzI0ZmU2YWVfMTAyMTQ_d4b14138-16b1-426e-a0a5-1212a2187358" continuedAt="ie60e6ec05d3d4da491d635cb54ae563a" escape="true">Revenue Recognition</ix:nonNumeric></span></div><div><span><br/></span></div><ix:continuation id="ie60e6ec05d3d4da491d635cb54ae563a" continuedAt="i4ea3f7d93af54abc93df8e5bbd02421e"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We derive revenue from two sources: (1) transformation services and (2) platform and operations services.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Transformation Services Revenue</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Transformation services consist of implementation services whereby we assist the customer in launching its population health or health plan programs. In certain cases, transformation services can also include revenue associated with our support of certain one-time wind-down activities for clients who are exiting a line of business or population. The transformation services are usually completed within 12 months. We generally receive a fixed fee for transformation services and recognize revenue over time using an input method based on hours incurred compared to the total estimated hours required to satisfy our performance obligation.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Platform and Operations Services Revenue</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Platform and operations services are typically multi-year arrangements with customers to provide various clinical and administrative solutions. In our Clinical Solutions segment, our solutions are designed to lower the medical expenses of our partners and include our total cost of care and specialty care management services.  In our Evolent Health Services segment, our solutions are designed to provide comprehensive health plan operations and claims processing services, and also include transition or run-out services to customers receiving primarily third-party administration (&#8220;TPA&#8221;) services.  </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our performance obligation in these arrangements is to provide an integrated suite of services, including access to our platform that is customized to meet the specialized needs of our customers and members. Generally, we will apply the series guidance to the performance obligation as we have determined that each time increment is distinct. We primarily utilize a variable fee structure for these services that typically includes a monthly payment that is calculated based on a specified per member per month rate, multiplied by the number of members that our partners are managing under a value-based care arrangement or a percentage of plan premiums. Our arrangements may also include other variable fees related to service level agreements, shared medical savings arrangements and other performance measures. Variable consideration is estimated using the most likely amount based on our historical experience and best judgment at the time. Due to the nature of our arrangements, certain estimates may be constrained if it is probable that a significant reversal of revenue will occur when the uncertainty is resolved. We recognize revenue from platform and operations services over time using the time elapsed output method. Fixed consideration is recognized ratably over the contract term. In accordance with the series guidance, we allocate variable consideration to the period to which the fees relate.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In our Clinical Solutions segment, we enter into capitation arrangements that may include performance-based arrangements and/or gainshare features. We recognize capitation revenue on a gross basis when we have established control over the services within our scope and recognize capitation revenue on a net basis when we do not have control over the services within our scope. </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Contracts with Multiple Performance Obligations</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our contracts with customers may contain multiple performance obligations, primarily when the customer has requested both transformation services and platform and operations services as these services are distinct from one another. When a contract has multiple performance obligations, we allocate the transaction price to each performance obligation based on the relative standalone selling price using the expected cost margin approach. This approach requires estimates regarding both the level of effort it will take to satisfy the performance obligation as well as fees that will be received under the variable pricing model. We also take into consideration customer demographics, current market conditions, the scope of services and our overall pricing strategy and objectives when determining the standalone selling price.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Principal vs. Agent</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We occasionally use third parties to assist in satisfying our performance obligations. In order to determine whether we are the principal or agent in the arrangement, we review each third-party relationship on a contract by contract basis. As we integrate goods and services provided by third parties into our overall service, we control the goods and services provided to the customer prior to its delivery. As such, we are the principal and we will recognize revenue on a gross basis. In certain cases, we act as an agent and do not control the services from third parties before it is delivered to the customer thereby recognizing revenue on a net basis.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div></ix:continuation><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">87</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i4ea3f7d93af54abc93df8e5bbd02421e" continuedAt="i190828d5bd1c4326a2d5a5cf0b8a308f"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Disaggregation of Revenue</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span></div><ix:nonNumeric contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231" name="us-gaap:DisaggregationOfRevenueTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM181OC9mcmFnOjdkZGUxNTIxODMxMzQ3YThhZTFjZmNjNDcyNGZlNmFlL3RleHRyZWdpb246N2RkZTE1MjE4MzEzNDdhOGFlMWNmY2M0NzI0ZmU2YWVfMTAyMTU_b83b9a25-c0bb-456c-bc5b-c2ae84adda36" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table represents Evolent&#8217;s revenue disaggregated by segment and end-market for the years ended December 31, 2021, 2020 and 2019 (in thousands):</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"></td><td style="width:220.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:48.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:48.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:48.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:48.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:48.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:48.25pt"></td><td style="width:1.0pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="33" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Year Ended December 31,</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Evolent Health Services</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Clinical Solutions</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicaid</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic43c6cb369be49d49265e63f4d9abe41_D20210101-20211231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM181OC9mcmFnOjdkZGUxNTIxODMxMzQ3YThhZTFjZmNjNDcyNGZlNmFlL3RhYmxlOjFhM2IwOTk4MjA3ZDQzYTZhNzdhOGViZmM4OWMxMWEzL3RhYmxlcmFuZ2U6MWEzYjA5OTgyMDdkNDNhNmE3N2E4ZWJmYzg5YzExYTNfMy05LTEtMS0xNzc3NQ_69001b6a-af70-4404-b19d-e55f392cfee2">215,236</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i535e9398f53d482399e3acaf85d05d83_D20200101-20201231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM181OC9mcmFnOjdkZGUxNTIxODMxMzQ3YThhZTFjZmNjNDcyNGZlNmFlL3RhYmxlOjFhM2IwOTk4MjA3ZDQzYTZhNzdhOGViZmM4OWMxMWEzL3RhYmxlcmFuZ2U6MWEzYjA5OTgyMDdkNDNhNmE3N2E4ZWJmYzg5YzExYTNfMy0xMS0xLTEtMTc3NzU_4cf4fd4d-0b20-4c73-ba1e-1437f2f516cd">236,634</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id2bc3ff361f24fefa6cc02e574174d0d_D20190101-20191231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM181OC9mcmFnOjdkZGUxNTIxODMxMzQ3YThhZTFjZmNjNDcyNGZlNmFlL3RhYmxlOjFhM2IwOTk4MjA3ZDQzYTZhNzdhOGViZmM4OWMxMWEzL3RhYmxlcmFuZ2U6MWEzYjA5OTgyMDdkNDNhNmE3N2E4ZWJmYzg5YzExYTNfMy01LTEtMS0yNzkzNw_7be15cdf-22dc-4990-bb20-51deb55c7434">267,222</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id9db9ac43e544bf2a8a53256e34c582f_D20210101-20211231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM181OC9mcmFnOjdkZGUxNTIxODMxMzQ3YThhZTFjZmNjNDcyNGZlNmFlL3RhYmxlOjFhM2IwOTk4MjA3ZDQzYTZhNzdhOGViZmM4OWMxMWEzL3RhYmxlcmFuZ2U6MWEzYjA5OTgyMDdkNDNhNmE3N2E4ZWJmYzg5YzExYTNfMy0xMy0xLTEtMTc3NzU_70ee04d2-a19e-4c17-bb2f-0f9c25d62b49">205,833</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i79967d3cee0e4773a3e643d202cac1e7_D20200101-20201231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM181OC9mcmFnOjdkZGUxNTIxODMxMzQ3YThhZTFjZmNjNDcyNGZlNmFlL3RhYmxlOjFhM2IwOTk4MjA3ZDQzYTZhNzdhOGViZmM4OWMxMWEzL3RhYmxlcmFuZ2U6MWEzYjA5OTgyMDdkNDNhNmE3N2E4ZWJmYzg5YzExYTNfMy0xNS0xLTEtMTc3NzU_e4705806-9d23-4448-8051-f4ff8de6858d">274,028</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iceaed1bf0ba14aeabbd5e7c285fadb74_D20190101-20191231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM181OC9mcmFnOjdkZGUxNTIxODMxMzQ3YThhZTFjZmNjNDcyNGZlNmFlL3RhYmxlOjFhM2IwOTk4MjA3ZDQzYTZhNzdhOGViZmM4OWMxMWEzL3RhYmxlcmFuZ2U6MWEzYjA5OTgyMDdkNDNhNmE3N2E4ZWJmYzg5YzExYTNfMy0xMS0xLTEtMjc5NDk_7ef439bd-b212-4a5b-a77b-0e0c5f75a7bd">75,675</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicare</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb83054796ca43aabbc5e7c5bcd8f242_D20210101-20211231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM181OC9mcmFnOjdkZGUxNTIxODMxMzQ3YThhZTFjZmNjNDcyNGZlNmFlL3RhYmxlOjFhM2IwOTk4MjA3ZDQzYTZhNzdhOGViZmM4OWMxMWEzL3RhYmxlcmFuZ2U6MWEzYjA5OTgyMDdkNDNhNmE3N2E4ZWJmYzg5YzExYTNfNC05LTEtMS0xNzc3NQ_a79d0139-1d1c-4202-a24e-bfdc9fd51a6a">26,358</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide7e8d10e8754aeb98428c460346c2e6_D20200101-20201231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM181OC9mcmFnOjdkZGUxNTIxODMxMzQ3YThhZTFjZmNjNDcyNGZlNmFlL3RhYmxlOjFhM2IwOTk4MjA3ZDQzYTZhNzdhOGViZmM4OWMxMWEzL3RhYmxlcmFuZ2U6MWEzYjA5OTgyMDdkNDNhNmE3N2E4ZWJmYzg5YzExYTNfNC0xMS0xLTEtMTc3NzU_07c63450-21b9-42e7-a3f3-42f13d0e118d">68,505</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9dc8f259d0954c4790aef4d1cda35290_D20190101-20191231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM181OC9mcmFnOjdkZGUxNTIxODMxMzQ3YThhZTFjZmNjNDcyNGZlNmFlL3RhYmxlOjFhM2IwOTk4MjA3ZDQzYTZhNzdhOGViZmM4OWMxMWEzL3RhYmxlcmFuZ2U6MWEzYjA5OTgyMDdkNDNhNmE3N2E4ZWJmYzg5YzExYTNfNC01LTEtMS0yNzkzNw_fac91037-3af4-46ac-82db-aa3e6b5f4b5a">73,671</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1eb1d14b8034af8af9fcc8ff413f4a8_D20210101-20211231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM181OC9mcmFnOjdkZGUxNTIxODMxMzQ3YThhZTFjZmNjNDcyNGZlNmFlL3RhYmxlOjFhM2IwOTk4MjA3ZDQzYTZhNzdhOGViZmM4OWMxMWEzL3RhYmxlcmFuZ2U6MWEzYjA5OTgyMDdkNDNhNmE3N2E4ZWJmYzg5YzExYTNfNC0xMy0xLTEtMTc3NzU_0b99259d-bade-477a-9936-518817e365f0">363,053</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i99e6ebd37717409cadbd8a0e52f302d8_D20200101-20201231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM181OC9mcmFnOjdkZGUxNTIxODMxMzQ3YThhZTFjZmNjNDcyNGZlNmFlL3RhYmxlOjFhM2IwOTk4MjA3ZDQzYTZhNzdhOGViZmM4OWMxMWEzL3RhYmxlcmFuZ2U6MWEzYjA5OTgyMDdkNDNhNmE3N2E4ZWJmYzg5YzExYTNfNC0xNS0xLTEtMTc3NzU_bd5d5f9e-2871-402b-8adb-519e5f1766e1">257,092</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibe57bae9f0e94d19b338958e93a6d9a0_D20190101-20191231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM181OC9mcmFnOjdkZGUxNTIxODMxMzQ3YThhZTFjZmNjNDcyNGZlNmFlL3RhYmxlOjFhM2IwOTk4MjA3ZDQzYTZhNzdhOGViZmM4OWMxMWEzL3RhYmxlcmFuZ2U6MWEzYjA5OTgyMDdkNDNhNmE3N2E4ZWJmYzg5YzExYTNfNC0xMS0xLTEtMjc5NDk_ca2fb73f-e7ee-41c2-a163-1a9939b66fc3">199,817</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial and other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i05cdaab0e8a9475391be6c9bb0290a02_D20210101-20211231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM181OC9mcmFnOjdkZGUxNTIxODMxMzQ3YThhZTFjZmNjNDcyNGZlNmFlL3RhYmxlOjFhM2IwOTk4MjA3ZDQzYTZhNzdhOGViZmM4OWMxMWEzL3RhYmxlcmFuZ2U6MWEzYjA5OTgyMDdkNDNhNmE3N2E4ZWJmYzg5YzExYTNfNS05LTEtMS0xNzc3NQ_69f819c9-3bc0-49c2-9945-ade65fa594f8">68,219</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i70c4c918cacd44ceb89f531391a51f89_D20200101-20201231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM181OC9mcmFnOjdkZGUxNTIxODMxMzQ3YThhZTFjZmNjNDcyNGZlNmFlL3RhYmxlOjFhM2IwOTk4MjA3ZDQzYTZhNzdhOGViZmM4OWMxMWEzL3RhYmxlcmFuZ2U6MWEzYjA5OTgyMDdkNDNhNmE3N2E4ZWJmYzg5YzExYTNfNS0xMS0xLTEtMTc3NzU_ba5bfc25-6bb0-4a64-aebb-451a67ee1ea3">77,221</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7ae80f06fd7241178ec3bcbf2b433c78_D20190101-20191231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM181OC9mcmFnOjdkZGUxNTIxODMxMzQ3YThhZTFjZmNjNDcyNGZlNmFlL3RhYmxlOjFhM2IwOTk4MjA3ZDQzYTZhNzdhOGViZmM4OWMxMWEzL3RhYmxlcmFuZ2U6MWEzYjA5OTgyMDdkNDNhNmE3N2E4ZWJmYzg5YzExYTNfNS01LTEtMS0yNzkzNw_47796c13-8ea8-4b1e-93c4-2a954b355507">68,012</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i615c66ad61b84863b2bbc22a537fd294_D20210101-20211231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM181OC9mcmFnOjdkZGUxNTIxODMxMzQ3YThhZTFjZmNjNDcyNGZlNmFlL3RhYmxlOjFhM2IwOTk4MjA3ZDQzYTZhNzdhOGViZmM4OWMxMWEzL3RhYmxlcmFuZ2U6MWEzYjA5OTgyMDdkNDNhNmE3N2E4ZWJmYzg5YzExYTNfNS0xMy0xLTEtMTc3NzU_825ab137-14ce-4d3b-8152-7218c6129bfb">29,258</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6c3248cb38b348cc83404e78b286c508_D20200101-20201231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM181OC9mcmFnOjdkZGUxNTIxODMxMzQ3YThhZTFjZmNjNDcyNGZlNmFlL3RhYmxlOjFhM2IwOTk4MjA3ZDQzYTZhNzdhOGViZmM4OWMxMWEzL3RhYmxlcmFuZ2U6MWEzYjA5OTgyMDdkNDNhNmE3N2E4ZWJmYzg5YzExYTNfNS0xNS0xLTEtMTc3NzU_ec425148-a045-4a7f-84f5-f0e4f729b78d">11,159</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i62d3399ff7cf4122b4eb5165603a12e2_D20190101-20191231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM181OC9mcmFnOjdkZGUxNTIxODMxMzQ3YThhZTFjZmNjNDcyNGZlNmFlL3RhYmxlOjFhM2IwOTk4MjA3ZDQzYTZhNzdhOGViZmM4OWMxMWEzL3RhYmxlcmFuZ2U6MWEzYjA5OTgyMDdkNDNhNmE3N2E4ZWJmYzg5YzExYTNfNS0xMS0xLTEtMjc5NDk_753836f3-c39e-4ca1-957f-2761ed4e61cd">2,725</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i98988f30813349e1a5594e72b40af5b1_D20210101-20211231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM181OC9mcmFnOjdkZGUxNTIxODMxMzQ3YThhZTFjZmNjNDcyNGZlNmFlL3RhYmxlOjFhM2IwOTk4MjA3ZDQzYTZhNzdhOGViZmM4OWMxMWEzL3RhYmxlcmFuZ2U6MWEzYjA5OTgyMDdkNDNhNmE3N2E4ZWJmYzg5YzExYTNfNi05LTEtMS0xNzc3NQ_1fa1e5b6-1a4d-4267-8d4e-ccf9b9c6a78e">309,813</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i00a9fb2f3f914116b87f14e146d04507_D20200101-20201231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM181OC9mcmFnOjdkZGUxNTIxODMxMzQ3YThhZTFjZmNjNDcyNGZlNmFlL3RhYmxlOjFhM2IwOTk4MjA3ZDQzYTZhNzdhOGViZmM4OWMxMWEzL3RhYmxlcmFuZ2U6MWEzYjA5OTgyMDdkNDNhNmE3N2E4ZWJmYzg5YzExYTNfNi0xMS0xLTEtMTc3NzU_90f9a9c5-db84-47e4-9acc-6a9fd87ae52e">382,360</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i26a4f846df6445f78bba31f5ba0edcdd_D20190101-20191231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM181OC9mcmFnOjdkZGUxNTIxODMxMzQ3YThhZTFjZmNjNDcyNGZlNmFlL3RhYmxlOjFhM2IwOTk4MjA3ZDQzYTZhNzdhOGViZmM4OWMxMWEzL3RhYmxlcmFuZ2U6MWEzYjA5OTgyMDdkNDNhNmE3N2E4ZWJmYzg5YzExYTNfNi01LTEtMS0yNzkzNw_76c00934-f5c0-4166-92e6-4dedb4747d92">408,905</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6d991ef4e2e0416f8c7aaaa6175cf843_D20210101-20211231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM181OC9mcmFnOjdkZGUxNTIxODMxMzQ3YThhZTFjZmNjNDcyNGZlNmFlL3RhYmxlOjFhM2IwOTk4MjA3ZDQzYTZhNzdhOGViZmM4OWMxMWEzL3RhYmxlcmFuZ2U6MWEzYjA5OTgyMDdkNDNhNmE3N2E4ZWJmYzg5YzExYTNfNi0xMy0xLTEtMTc3NzU_2d88272c-67c6-4f8d-bb54-8ce9ed31637b">598,144</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i73877656554945338d08c1e8006fc13a_D20200101-20201231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM181OC9mcmFnOjdkZGUxNTIxODMxMzQ3YThhZTFjZmNjNDcyNGZlNmFlL3RhYmxlOjFhM2IwOTk4MjA3ZDQzYTZhNzdhOGViZmM4OWMxMWEzL3RhYmxlcmFuZ2U6MWEzYjA5OTgyMDdkNDNhNmE3N2E4ZWJmYzg5YzExYTNfNi0xNS0xLTEtMTc3NzU_752706fd-3843-4a5a-a30f-ef7e6b782c35">542,279</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if6faab8365e548b981e0edaddae65523_D20190101-20191231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM181OC9mcmFnOjdkZGUxNTIxODMxMzQ3YThhZTFjZmNjNDcyNGZlNmFlL3RhYmxlOjFhM2IwOTk4MjA3ZDQzYTZhNzdhOGViZmM4OWMxMWEzL3RhYmxlcmFuZ2U6MWEzYjA5OTgyMDdkNDNhNmE3N2E4ZWJmYzg5YzExYTNfNi0xMS0xLTEtMjc5NDk_eba868c8-563c-4b70-ac7f-6be4f8eaee1c">278,217</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Transaction Price Allocated to the Remaining Performance Obligations</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For contracts with a term greater than one year, we have allocated approximately $<ix:nonFraction unitRef="usd" contextRef="i8daff60be410426d8f7bd49343c1ec0c_I20211231" decimals="-5" name="us-gaap:RevenueRemainingPerformanceObligation" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM181OC9mcmFnOjdkZGUxNTIxODMxMzQ3YThhZTFjZmNjNDcyNGZlNmFlL3RleHRyZWdpb246N2RkZTE1MjE4MzEzNDdhOGFlMWNmY2M0NzI0ZmU2YWVfNTA5OA_34e97489-3ff7-4378-a40d-26accb3bef2d">178.8</ix:nonFraction> million of transaction price to performance obligations that are unsatisfied as of December&#160;31, 2021. We do not include variable consideration that is allocated entirely to a wholly unsatisfied performance obligation accounted for under the series guidance in the calculation. As a result, the balance represents the value of the fixed consideration in our long-term contracts that we expect will be recognized as revenue in a future period and excludes the majority of our platform and operations revenue, which is primarily derived based on variable consideration as discussed in Note 2. We expect to recognize revenue on approximately <ix:nonFraction unitRef="number" contextRef="if14fbffaf3854b8c835ade571c3cc193_I20211231" decimals="2" name="us-gaap:RevenueRemainingPerformanceObligationPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM181OC9mcmFnOjdkZGUxNTIxODMxMzQ3YThhZTFjZmNjNDcyNGZlNmFlL3RleHRyZWdpb246N2RkZTE1MjE4MzEzNDdhOGFlMWNmY2M0NzI0ZmU2YWVfNTcxNw_a1d99de6-2165-4119-aaaa-88b7fc644797">45</ix:nonFraction>%, <ix:nonFraction unitRef="number" contextRef="i8959430f12264863ae6656497c8cbe17_I20211231" decimals="2" name="us-gaap:RevenueRemainingPerformanceObligationPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM181OC9mcmFnOjdkZGUxNTIxODMxMzQ3YThhZTFjZmNjNDcyNGZlNmFlL3RleHRyZWdpb246N2RkZTE1MjE4MzEzNDdhOGFlMWNmY2M0NzI0ZmU2YWVfNTcyMQ_8732b237-f7aa-4e10-b82f-a4b67eec151d">70</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="i25cd20be19e940cf94f2ba0eef170452_I20211231" decimals="2" name="us-gaap:RevenueRemainingPerformanceObligationPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM181OC9mcmFnOjdkZGUxNTIxODMxMzQ3YThhZTFjZmNjNDcyNGZlNmFlL3RleHRyZWdpb246N2RkZTE1MjE4MzEzNDdhOGFlMWNmY2M0NzI0ZmU2YWVfNTcyOA_925caa09-4802-4b61-8b54-76aad6a46165">86</ix:nonFraction>% of these remaining performance obligations by December 31, 2022, 2023 and 2024, respectively, with the remaining balance to be recognized thereafter. However, because our existing contracts may be canceled or renegotiated including for reasons outside our control, the amount of revenue that we actually receive may be less or greater than this estimate and the timing of recognition may not be as expected.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Contract Balances</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contract balances consist of accounts receivable, contract assets and deferred revenue. Contract assets are recorded when the right to consideration for services is conditional on something other than the passage of time. Contract assets relating to unbilled receivables are transferred to accounts receivable when the right to consideration becomes unconditional. We classify contract assets as current or non-current based on the timing of our rights to the unconditional payments. Our contract assets are generally classified as current and recorded within prepaid expenses and other current assets on our consolidated balance sheets. Our current accounts receivables are classified within accounts receivable, net on our consolidated balance sheets and our non-current accounts receivable are classified within prepaid expenses and other non-current assets on our consolidated balance sheets.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred revenue includes advance customer payments and billings in excess of revenue recognized. We classify deferred revenue as current or non-current based on the timing of when we expect to recognize revenue. Our current deferred revenue is recorded within deferred revenue on our consolidated balance sheets and non-current deferred revenue is recorded within other long-term liabilities on our consolidated balance sheets.</span></div><div style="text-align:justify"><span><br/></span></div><ix:nonNumeric contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231" name="us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM181OC9mcmFnOjdkZGUxNTIxODMxMzQ3YThhZTFjZmNjNDcyNGZlNmFlL3RleHRyZWdpb246N2RkZTE1MjE4MzEzNDdhOGFlMWNmY2M0NzI0ZmU2YWVfMTAyMTg_01db16d2-409e-431e-9360-27d31dd3343a" continuedAt="i5a3cea5ba2f34b16b47dfd4b764db8cc" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides information about receivables, contract assets and deferred revenue from contracts with customers as of December&#160;31, 2021 and 2020 (in thousands):</span></div><div style="margin-top:5pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"></td><td style="width:403.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:58.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:67.75pt"></td><td style="width:1.0pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term receivables </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8daff60be410426d8f7bd49343c1ec0c_I20211231" decimals="-3" name="us-gaap:AccountsNotesAndLoansReceivableNetCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM181OC9mcmFnOjdkZGUxNTIxODMxMzQ3YThhZTFjZmNjNDcyNGZlNmFlL3RhYmxlOmFkMmJhNWVlN2E5ODRhNzM5ZTEzNzAxZjA4Y2IyMzE4L3RhYmxlcmFuZ2U6YWQyYmE1ZWU3YTk4NGE3MzllMTM3MDFmMDhjYjIzMThfMS0xLTEtMS0xNzc3NQ_04d3789c-3d5d-4ffa-b9d5-5245ea64589c">129,012</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc0c0c2b8dc04c5698ca0577a54b2e03_I20201231" decimals="-3" name="us-gaap:AccountsNotesAndLoansReceivableNetCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM181OC9mcmFnOjdkZGUxNTIxODMxMzQ3YThhZTFjZmNjNDcyNGZlNmFlL3RhYmxlOmFkMmJhNWVlN2E5ODRhNzM5ZTEzNzAxZjA4Y2IyMzE4L3RhYmxlcmFuZ2U6YWQyYmE1ZWU3YTk4NGE3MzllMTM3MDFmMDhjYjIzMThfMS0zLTEtMS0xNzc3NQ_8ce8808f-600c-458c-82e0-fabccce1c1eb">118,730</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term receivables </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8daff60be410426d8f7bd49343c1ec0c_I20211231" decimals="-3" name="us-gaap:LongTermAccountsNotesAndLoansReceivableNetNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM181OC9mcmFnOjdkZGUxNTIxODMxMzQ3YThhZTFjZmNjNDcyNGZlNmFlL3RhYmxlOmFkMmJhNWVlN2E5ODRhNzM5ZTEzNzAxZjA4Y2IyMzE4L3RhYmxlcmFuZ2U6YWQyYmE1ZWU3YTk4NGE3MzllMTM3MDFmMDhjYjIzMThfMi0xLTEtMS0xNzc3NQ_767ab6fe-dc65-4552-ab7d-b2ab84137f8d">4,877</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc0c0c2b8dc04c5698ca0577a54b2e03_I20201231" decimals="-3" name="us-gaap:LongTermAccountsNotesAndLoansReceivableNetNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM181OC9mcmFnOjdkZGUxNTIxODMxMzQ3YThhZTFjZmNjNDcyNGZlNmFlL3RhYmxlOmFkMmJhNWVlN2E5ODRhNzM5ZTEzNzAxZjA4Y2IyMzE4L3RhYmxlcmFuZ2U6YWQyYmE1ZWU3YTk4NGE3MzllMTM3MDFmMDhjYjIzMThfMi0zLTEtMS0xNzc3NQ_408c7757-8bc5-436b-9c0d-d51c3b7c4f39">4,554</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term contract assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8daff60be410426d8f7bd49343c1ec0c_I20211231" decimals="-3" name="us-gaap:ContractWithCustomerAssetNetCurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM181OC9mcmFnOjdkZGUxNTIxODMxMzQ3YThhZTFjZmNjNDcyNGZlNmFlL3RhYmxlOmFkMmJhNWVlN2E5ODRhNzM5ZTEzNzAxZjA4Y2IyMzE4L3RhYmxlcmFuZ2U6YWQyYmE1ZWU3YTk4NGE3MzllMTM3MDFmMDhjYjIzMThfMy0xLTEtMS0xNzc3NQ_4f1d190a-5b81-40bb-86bd-da0cc9ca0406">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc0c0c2b8dc04c5698ca0577a54b2e03_I20201231" decimals="-3" name="us-gaap:ContractWithCustomerAssetNetCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM181OC9mcmFnOjdkZGUxNTIxODMxMzQ3YThhZTFjZmNjNDcyNGZlNmFlL3RhYmxlOmFkMmJhNWVlN2E5ODRhNzM5ZTEzNzAxZjA4Y2IyMzE4L3RhYmxlcmFuZ2U6YWQyYmE1ZWU3YTk4NGE3MzllMTM3MDFmMDhjYjIzMThfMy0zLTEtMS0xNzc3NQ_4407aa62-ffee-46d4-b5f4-075f713420d9">329</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term deferred revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8daff60be410426d8f7bd49343c1ec0c_I20211231" decimals="-3" name="us-gaap:ContractWithCustomerLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM181OC9mcmFnOjdkZGUxNTIxODMxMzQ3YThhZTFjZmNjNDcyNGZlNmFlL3RhYmxlOmFkMmJhNWVlN2E5ODRhNzM5ZTEzNzAxZjA4Y2IyMzE4L3RhYmxlcmFuZ2U6YWQyYmE1ZWU3YTk4NGE3MzllMTM3MDFmMDhjYjIzMThfNC0xLTEtMS0xNzc3NQ_23dbb1c2-9608-4772-b14d-146215857653">11,944</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc0c0c2b8dc04c5698ca0577a54b2e03_I20201231" decimals="-3" name="us-gaap:ContractWithCustomerLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM181OC9mcmFnOjdkZGUxNTIxODMxMzQ3YThhZTFjZmNjNDcyNGZlNmFlL3RhYmxlOmFkMmJhNWVlN2E5ODRhNzM5ZTEzNzAxZjA4Y2IyMzE4L3RhYmxlcmFuZ2U6YWQyYmE1ZWU3YTk4NGE3MzllMTM3MDFmMDhjYjIzMThfNC0zLTEtMS0xNzc3NQ_58672868-e761-441f-b226-b4d217556462">10,187</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term deferred revenue</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8daff60be410426d8f7bd49343c1ec0c_I20211231" decimals="-3" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM181OC9mcmFnOjdkZGUxNTIxODMxMzQ3YThhZTFjZmNjNDcyNGZlNmFlL3RhYmxlOmFkMmJhNWVlN2E5ODRhNzM5ZTEzNzAxZjA4Y2IyMzE4L3RhYmxlcmFuZ2U6YWQyYmE1ZWU3YTk4NGE3MzllMTM3MDFmMDhjYjIzMThfNS0xLTEtMS0xNzc3NQ_9ca78e6c-00e8-4643-866f-7acb76ed7a61">4,437</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc0c0c2b8dc04c5698ca0577a54b2e03_I20201231" decimals="-3" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM181OC9mcmFnOjdkZGUxNTIxODMxMzQ3YThhZTFjZmNjNDcyNGZlNmFlL3RhYmxlOmFkMmJhNWVlN2E5ODRhNzM5ZTEzNzAxZjA4Y2IyMzE4L3RhYmxlcmFuZ2U6YWQyYmE1ZWU3YTk4NGE3MzllMTM3MDFmMDhjYjIzMThfNS0zLTEtMS0xNzc3NQ_391cee09-d295-48f6-948f-fc847210e0f0">3,593</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt">Amounts exclude $<ix:nonFraction unitRef="usd" contextRef="i98364cf4ba3e41af868d701b4c668283_I20201231" decimals="-5" name="evh:DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNetAfterGrossUp" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM181OC9mcmFnOjdkZGUxNTIxODMxMzQ3YThhZTFjZmNjNDcyNGZlNmFlL3RleHRyZWdpb246N2RkZTE1MjE4MzEzNDdhOGFlMWNmY2M0NzI0ZmU2YWVfNzY3NA_b5e621bd-0acd-4853-b186-0498553542bc">3.4</ix:nonFraction>&#160;million of short-term receivables and $<ix:nonFraction unitRef="usd" contextRef="i98364cf4ba3e41af868d701b4c668283_I20201231" decimals="-5" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationDeferredRevenueCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM181OC9mcmFnOjdkZGUxNTIxODMxMzQ3YThhZTFjZmNjNDcyNGZlNmFlL3RleHRyZWdpb246N2RkZTE1MjE4MzEzNDdhOGFlMWNmY2M0NzI0ZmU2YWVfNzcwNw_c00a39c9-b104-40b0-bce9-5e0e18b77d94">4.1</ix:nonFraction>&#160;million of short-term deferred revenue reclassified to discontinued operations as of December&#160;31, 2020.</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt">Excludes pharmacy claims receivable and premiums receivable.</span></div></ix:nonNumeric></ix:continuation><div style="text-align:justify"><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">88</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i190828d5bd1c4326a2d5a5cf0b8a308f"><ix:continuation id="i5a3cea5ba2f34b16b47dfd4b764db8cc"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes in deferred revenue for the year ended December 31, 2021 are as follows (in thousands):</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"></td><td style="width:433.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:102.25pt"></td><td style="width:1.0pt"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Deferred revenue</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of beginning-of-period</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc0c0c2b8dc04c5698ca0577a54b2e03_I20201231" decimals="-3" name="us-gaap:ContractWithCustomerLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM181OC9mcmFnOjdkZGUxNTIxODMxMzQ3YThhZTFjZmNjNDcyNGZlNmFlL3RhYmxlOmZkMmFmYWZkNmRjYzQyMmRhODU1NGNlNzYzOTIxYjQxL3RhYmxlcmFuZ2U6ZmQyYWZhZmQ2ZGNjNDIyZGE4NTU0Y2U3NjM5MjFiNDFfMS0xLTEtMS0xNzc3NQ_300d74d4-7bff-4dfd-aa9c-e40e66afeb4a">13,780</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reclassification to revenue, as a result of performance obligations satisfied</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231" decimals="-3" name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM181OC9mcmFnOjdkZGUxNTIxODMxMzQ3YThhZTFjZmNjNDcyNGZlNmFlL3RhYmxlOmZkMmFmYWZkNmRjYzQyMmRhODU1NGNlNzYzOTIxYjQxL3RhYmxlcmFuZ2U6ZmQyYWZhZmQ2ZGNjNDIyZGE4NTU0Y2U3NjM5MjFiNDFfMi0xLTEtMS0xNzc3NQ_a0313c38-4f7c-4fe4-b6de-b5b43fd0697f">10,175</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash received in advance of satisfaction of performance obligations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231" decimals="-3" name="evh:ContractWithCustomerLiabilityCashReceivedInAdvanceOfSatisfactionOfPerformanceObligations" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM181OC9mcmFnOjdkZGUxNTIxODMxMzQ3YThhZTFjZmNjNDcyNGZlNmFlL3RhYmxlOmZkMmFmYWZkNmRjYzQyMmRhODU1NGNlNzYzOTIxYjQxL3RhYmxlcmFuZ2U6ZmQyYWZhZmQ2ZGNjNDIyZGE4NTU0Y2U3NjM5MjFiNDFfMy0xLTEtMS0xNzc3NQ_82171695-50bc-48cd-af8e-02e281f4dbc2">12,776</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of end of period</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8daff60be410426d8f7bd49343c1ec0c_I20211231" decimals="-3" name="us-gaap:ContractWithCustomerLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM181OC9mcmFnOjdkZGUxNTIxODMxMzQ3YThhZTFjZmNjNDcyNGZlNmFlL3RhYmxlOmZkMmFmYWZkNmRjYzQyMmRhODU1NGNlNzYzOTIxYjQxL3RhYmxlcmFuZ2U6ZmQyYWZhZmQ2ZGNjNDIyZGE4NTU0Y2U3NjM5MjFiNDFfNC0xLTEtMS0xNzc3NQ_b5ce2a20-e98f-4ac3-95a4-eb506ed4f895">16,381</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:continuation><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The amount of revenue recognized from performance obligations satisfied (or partially satisfied) in a previous period was $<ix:nonFraction unitRef="usd" contextRef="i546c40c371924532a3d2ed0ace7d354b_D20211001-20211231" decimals="-5" name="us-gaap:ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM181OC9mcmFnOjdkZGUxNTIxODMxMzQ3YThhZTFjZmNjNDcyNGZlNmFlL3RleHRyZWdpb246N2RkZTE1MjE4MzEzNDdhOGFlMWNmY2M0NzI0ZmU2YWVfODA0MQ_81716abb-8956-4292-8547-8c65f02d1965">28.3</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i12a6d1161de54547bd29f8efccd4c9b0_D20200101-20201231" decimals="-5" name="us-gaap:ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM181OC9mcmFnOjdkZGUxNTIxODMxMzQ3YThhZTFjZmNjNDcyNGZlNmFlL3RleHRyZWdpb246N2RkZTE1MjE4MzEzNDdhOGFlMWNmY2M0NzI0ZmU2YWVfODA0OA_d3f8c792-bb35-4578-8066-b621bf606c6b">12.1</ix:nonFraction> million for the years ended December 31, 2021 and 2020, respectively, due primarily to net gain share as well as changes in other estimates.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Contract Cost Assets</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain bonuses and commissions earned by our sales team are considered incremental costs of obtaining a contract with a customer that we expect to be recoverable. The capitalized contract acquisition costs are classified as non-current assets and recorded within contract cost assets on our consolidated balance sheets. Amortization expense is recorded within selling, general and administrative expenses on the accompanying consolidated statements of operations and comprehensive income (loss). As of December&#160;31, 2021 and 2020, the Company had $<ix:nonFraction unitRef="usd" contextRef="i54aba1ec35ba4673abba7abb46f76ef5_I20211231" decimals="-5" name="us-gaap:CapitalizedContractCostNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM181OC9mcmFnOjdkZGUxNTIxODMxMzQ3YThhZTFjZmNjNDcyNGZlNmFlL3RleHRyZWdpb246N2RkZTE1MjE4MzEzNDdhOGFlMWNmY2M0NzI0ZmU2YWVfMTA5OTUxMTYzODI5Mw_d55c2735-07e1-4f2d-8e34-cbf30537a595">5.2</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i44f063f12cc04f629ffbb5c7712fd0f2_I20201231" decimals="-5" name="us-gaap:CapitalizedContractCostNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM181OC9mcmFnOjdkZGUxNTIxODMxMzQ3YThhZTFjZmNjNDcyNGZlNmFlL3RleHRyZWdpb246N2RkZTE1MjE4MzEzNDdhOGFlMWNmY2M0NzI0ZmU2YWVfODY5OA_30bf530d-13d4-4dd5-a628-2f8f81b5a01e">3.3</ix:nonFraction> million, respectively, of contract acquisition cost assets, net of accumulated amortization recorded in contract cost assets on the consolidated balance sheets. In addition, the Company recorded </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">amortiza</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">tion expense of  $<ix:nonFraction unitRef="usd" contextRef="icfdf7dc68ad9407fb6453da7eb51ff1e_D20210101-20211231" decimals="-5" name="us-gaap:CapitalizedContractCostAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM181OC9mcmFnOjdkZGUxNTIxODMxMzQ3YThhZTFjZmNjNDcyNGZlNmFlL3RleHRyZWdpb246N2RkZTE1MjE4MzEzNDdhOGFlMWNmY2M0NzI0ZmU2YWVfODkwNg_483e5190-9336-4903-99b6-9bf3b181a9f3">1.9</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="i32c4356526e94c2a842b0638c13e0da0_D20200101-20201231" decimals="-5" name="us-gaap:CapitalizedContractCostAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM181OC9mcmFnOjdkZGUxNTIxODMxMzQ3YThhZTFjZmNjNDcyNGZlNmFlL3RleHRyZWdpb246N2RkZTE1MjE4MzEzNDdhOGFlMWNmY2M0NzI0ZmU2YWVfODkzNw_1415429b-43f8-4d2c-803c-04574544b0ea">1.9</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i781700715d804fefb7f495ca8b0f9e4a_D20190101-20191231" decimals="-5" name="us-gaap:CapitalizedContractCostAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM181OC9mcmFnOjdkZGUxNTIxODMxMzQ3YThhZTFjZmNjNDcyNGZlNmFlL3RleHRyZWdpb246N2RkZTE1MjE4MzEzNDdhOGFlMWNmY2M0NzI0ZmU2YWVfMTA5OTUxMTYzODA5Ng_33f6d24c-9891-4aeb-9be8-9c598a8c204e">1.0</ix:nonFraction> million for the years ended December 31, 2021, 2020 and 2019, respectively.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In our platforms and operations arrangements, we incur certain costs related to the implementation of our platform before we begin to satisfy our performance obligation to the customer. The costs, which we expect to recover, are considered costs to fulfill a contract. Our contract fulfillment costs primarily include our employee labor costs and third-party vendor costs. The capitalized contract fulfillment costs are classified as non-current and recorded within contract cost assets on our consolidated balance sheets. Amortization expense is recorded within cost of revenue on the accompanying consolidated statements of operations and comprehensive income (loss). As of December&#160;31, 2021 and 2020, the Company had $<ix:nonFraction unitRef="usd" contextRef="i1e5e51907f2d489ab6121950881bf006_I20211231" decimals="-5" name="us-gaap:CapitalizedContractCostNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM181OC9mcmFnOjdkZGUxNTIxODMxMzQ3YThhZTFjZmNjNDcyNGZlNmFlL3RleHRyZWdpb246N2RkZTE1MjE4MzEzNDdhOGFlMWNmY2M0NzI0ZmU2YWVfOTY2Mg_d2069cac-782b-4b05-a4b2-353aadbe6037">27.4</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="icf374646ef6b49209d89a39117fda72a_I20201231" decimals="-5" name="us-gaap:CapitalizedContractCostNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM181OC9mcmFnOjdkZGUxNTIxODMxMzQ3YThhZTFjZmNjNDcyNGZlNmFlL3RleHRyZWdpb246N2RkZTE1MjE4MzEzNDdhOGFlMWNmY2M0NzI0ZmU2YWVfOTY2OQ_37c3b32f-8d61-41f6-9941-98e6e5ef9e03">23.4</ix:nonFraction> million, respectively, of contract fulfillment cost assets, net of accumulated amortization recorded in contract cost assets on the consolidated balance sheets. In addition, the Company recorded amortization expense of $<ix:nonFraction unitRef="usd" contextRef="i8b41623f6b924d1986071e4349ac5013_D20210101-20211231" decimals="-5" name="us-gaap:CapitalizedContractCostAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM181OC9mcmFnOjdkZGUxNTIxODMxMzQ3YThhZTFjZmNjNDcyNGZlNmFlL3RleHRyZWdpb246N2RkZTE1MjE4MzEzNDdhOGFlMWNmY2M0NzI0ZmU2YWVfOTg5MA_f8ac4179-f495-4bd7-ae5b-6cccc99093eb">11.1</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="i764aef4cc3ae4cc1bcebb290a4525192_D20200101-20201231" decimals="-5" name="us-gaap:CapitalizedContractCostAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM181OC9mcmFnOjdkZGUxNTIxODMxMzQ3YThhZTFjZmNjNDcyNGZlNmFlL3RleHRyZWdpb246N2RkZTE1MjE4MzEzNDdhOGFlMWNmY2M0NzI0ZmU2YWVfOTkxOA_86636262-085c-4fe4-a064-ae260f508e18">13.0</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i914217ccb9dc458290c3558593f0487c_D20190101-20191231" decimals="-5" name="us-gaap:CapitalizedContractCostAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM181OC9mcmFnOjdkZGUxNTIxODMxMzQ3YThhZTFjZmNjNDcyNGZlNmFlL3RleHRyZWdpb246N2RkZTE1MjE4MzEzNDdhOGFlMWNmY2M0NzI0ZmU2YWVfMTA5OTUxMTYzODI3OQ_11ef14dd-1afd-44f5-a3c3-98db61b542b7">4.7</ix:nonFraction> million, for the years ended December 31, 2021, 2020 and 2019, respectively.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These costs are deferred and then amortized on a straight-line basis over a period of benefit that we have determined to be the shorter of the contract term or <ix:nonNumeric contextRef="i8daff60be410426d8f7bd49343c1ec0c_I20211231" name="us-gaap:CapitalizedContractCostAmortizationPeriod" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM181OC9mcmFnOjdkZGUxNTIxODMxMzQ3YThhZTFjZmNjNDcyNGZlNmFlL3RleHRyZWdpb246N2RkZTE1MjE4MzEzNDdhOGFlMWNmY2M0NzI0ZmU2YWVfMTAxMDA_1c5aa8fa-76e8-48fa-bc03-f50a0a8425c3">five years</ix:nonNumeric>. The period of benefit was based on our technology, the nature of our customer arrangements and other factors.</span></div></ix:continuation><div style="text-align:justify"><span><br/></span></div><div id="i9aaa2fddc97e482da5dbe37ac85ae703_64"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 7. <ix:nonNumeric contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231" name="us-gaap:CreditLossFinancialInstrumentTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM182NC9mcmFnOjVmZDYzMzVhZDUyYjRiMGM5MjRmODY5Mzg3MzViZTdhL3RleHRyZWdpb246NWZkNjMzNWFkNTJiNGIwYzkyNGY4NjkzODczNWJlN2FfMzAwNQ_7ff2d314-9337-4c28-8e26-ed3af5f6b17c" continuedAt="i695cd37ec41f4842b0ee099eebf9a214" escape="true">Credit Losses </ix:nonNumeric></span></div><div><span><br/></span></div><ix:continuation id="i695cd37ec41f4842b0ee099eebf9a214" continuedAt="ib2a754dc24c543bdbd51a4091430f810"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are exposed to credit losses primarily through our accounts receivable from revenue transactions, investments held at amortized cost and customer advances for regulatory capital and other notes receivable. We estimate expected credit losses based on past events, current conditions and reasonable and supportable forecasts. Expected credit losses are measured over the remaining contractual life of these assets. As part of our consideration of current and forward-looking economic conditions, we considered the impact of the COVID-19 pandemic on our customers&#8217; and other third parties&#8217; ability to pay. We did not observe notable increases in delinquencies during the year ended December 31, 2021. Given the nature of our business, our past collection experience during recessionary and pre-recessionary periods and our forecasted impact of the COVID-19 pandemic on our business, we did not record material changes in our allowances due to the COVID-19 pandemic during the year ended December 31, 2021.</span></div><div><span><br/></span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Accounts Receivable from Revenue Transactions</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounts receivable represent the amounts owed to the Company for goods or services provided to customers or third parties. Current accounts receivables are classified within accounts receivable, net on the Company&#8217;s consolidated balance sheets, while non-current accounts receivables are classified within prepaid expenses and other noncurrent assets on the Company&#8217;s consolidated balance sheets. </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We monitor our ongoing credit exposure through active review of counterparty balances against contract terms, due dates and business strategy. Our activities include timely account reconciliation, dispute resolution and payment confirmation. We may employ legal counsel to pursue recovery of defaulted receivables. In addition, the Company will establish a general reserve based on delinquency rates. Historical loss rates are determined for each delinquency bucket in 30-day past-due intervals and then applied to the composition of the reporting date balance based on delinquency. The allowance implied from application of the historical loss rates is then adjusted, as necessary, for current conditions and reasonable and supportable forecasts.</span></div></ix:continuation><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">89</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span><br/></span></div><ix:continuation id="ib2a754dc24c543bdbd51a4091430f810"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Based on an aging analysis of our trade accounts receivable, non-trade accounts receivable and contract assets as of&#160;December&#160;31, 2021,&#160;<ix:nonFraction unitRef="number" contextRef="i8daff60be410426d8f7bd49343c1ec0c_I20211231" decimals="2" name="evh:FinancingReceivablePercentNotPastDue" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM182NC9mcmFnOjVmZDYzMzVhZDUyYjRiMGM5MjRmODY5Mzg3MzViZTdhL3RleHRyZWdpb246NWZkNjMzNWFkNTJiNGIwYzkyNGY4NjkzODczNWJlN2FfMjM4NQ_51822d52-d22c-4fce-8503-1df7a04f93f2">90</ix:nonFraction>% were current, <ix:nonFraction unitRef="number" contextRef="i409817ab2c13478f8041e2ff229d0614_I20211231" decimals="2" name="us-gaap:FinancingReceivablePercentPastDue1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM182NC9mcmFnOjVmZDYzMzVhZDUyYjRiMGM5MjRmODY5Mzg3MzViZTdhL3RleHRyZWdpb246NWZkNjMzNWFkNTJiNGIwYzkyNGY4NjkzODczNWJlN2FfMjQwMg_dd8eed4e-bff3-48e2-a459-d052a40a0111">2</ix:nonFraction>%&#160;were past due less than 60 days, with <ix:nonFraction unitRef="number" contextRef="iafc89cf729024311ade0aeb8068cb56d_I20211231" decimals="2" name="us-gaap:FinancingReceivablePercentPastDue1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM182NC9mcmFnOjVmZDYzMzVhZDUyYjRiMGM5MjRmODY5Mzg3MzViZTdhL3RleHRyZWdpb246NWZkNjMzNWFkNTJiNGIwYzkyNGY4NjkzODczNWJlN2FfMjQ0Mw_996f9edf-703a-41db-9f9e-5713978de60b">3</ix:nonFraction>% past due less than 120 days and at December 31, 2020, <ix:nonFraction unitRef="number" contextRef="ibc0c0c2b8dc04c5698ca0577a54b2e03_I20201231" decimals="2" name="evh:FinancingReceivablePercentNotPastDue" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM182NC9mcmFnOjVmZDYzMzVhZDUyYjRiMGM5MjRmODY5Mzg3MzViZTdhL3RleHRyZWdpb246NWZkNjMzNWFkNTJiNGIwYzkyNGY4NjkzODczNWJlN2FfMzI5ODUzNDg4NjcxNw_7dd9b4f2-684d-44c7-9ef2-21f7ce138007">59</ix:nonFraction>% were current, <ix:nonFraction unitRef="number" contextRef="icc5d957904904562b11eb24c12475bd1_I20201231" decimals="2" name="us-gaap:FinancingReceivablePercentPastDue1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM182NC9mcmFnOjVmZDYzMzVhZDUyYjRiMGM5MjRmODY5Mzg3MzViZTdhL3RleHRyZWdpb246NWZkNjMzNWFkNTJiNGIwYzkyNGY4NjkzODczNWJlN2FfMzI5ODUzNDg4NjcyMg_12e37e76-53dc-4182-a49d-9eae0998010f">24</ix:nonFraction>% were past due less than 60 days, with <ix:nonFraction unitRef="number" contextRef="i23f9ca4a3b134c3cb50b438855efd900_I20201231" decimals="2" name="us-gaap:FinancingReceivablePercentPastDue1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM182NC9mcmFnOjVmZDYzMzVhZDUyYjRiMGM5MjRmODY5Mzg3MzViZTdhL3RleHRyZWdpb246NWZkNjMzNWFkNTJiNGIwYzkyNGY4NjkzODczNWJlN2FfMzI5ODUzNDg4NjcyNw_c5b5d5a2-80ce-4364-8c32-9ea6dd4d936c">37</ix:nonFraction>% past due less than 120 days. As of&#160;December&#160;31, 2021 and 2020, in total we reported on the consolidated balance sheet&#160;$<ix:nonFraction unitRef="usd" contextRef="i8daff60be410426d8f7bd49343c1ec0c_I20211231" decimals="-5" name="us-gaap:AccountsReceivableNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM182NC9mcmFnOjVmZDYzMzVhZDUyYjRiMGM5MjRmODY5Mzg3MzViZTdhL3RleHRyZWdpb246NWZkNjMzNWFkNTJiNGIwYzkyNGY4NjkzODczNWJlN2FfMjQ5NA_2f96a278-8841-449b-b7fe-6ca2dfe2ad9a">171.5</ix:nonFraction> million&#160;and $<ix:nonFraction unitRef="usd" contextRef="ibc0c0c2b8dc04c5698ca0577a54b2e03_I20201231" decimals="-5" name="us-gaap:AccountsReceivableNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM182NC9mcmFnOjVmZDYzMzVhZDUyYjRiMGM5MjRmODY5Mzg3MzViZTdhL3RleHRyZWdpb246NWZkNjMzNWFkNTJiNGIwYzkyNGY4NjkzODczNWJlN2FfMzI5ODUzNDg4NjczMg_7f382ce6-5ca6-4add-a48e-b6716173e312">173.7</ix:nonFraction>&#160;million of accounts receivable, certain non-trade accounts receivable included in prepaid expenses and other assets, net of allowances of&#160;$<ix:nonFraction unitRef="usd" contextRef="i8daff60be410426d8f7bd49343c1ec0c_I20211231" decimals="-5" name="us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM182NC9mcmFnOjVmZDYzMzVhZDUyYjRiMGM5MjRmODY5Mzg3MzViZTdhL3RleHRyZWdpb246NWZkNjMzNWFkNTJiNGIwYzkyNGY4NjkzODczNWJlN2FfMjY4MQ_ec84ddad-86c6-4557-9879-0c1563bc6888">3.4</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ibc0c0c2b8dc04c5698ca0577a54b2e03_I20201231" decimals="-5" name="us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM182NC9mcmFnOjVmZDYzMzVhZDUyYjRiMGM5MjRmODY5Mzg3MzViZTdhL3RleHRyZWdpb246NWZkNjMzNWFkNTJiNGIwYzkyNGY4NjkzODczNWJlN2FfMzI5ODUzNDg4Njc0OA_0f1682e4-c0a9-4364-9fdd-1f95f04e5d18">7.1</ix:nonFraction>&#160;million, respectively. <ix:nonNumeric contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231" name="us-gaap:AccountsReceivableAllowanceForCreditLossTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM182NC9mcmFnOjVmZDYzMzVhZDUyYjRiMGM5MjRmODY5Mzg3MzViZTdhL3RleHRyZWdpb246NWZkNjMzNWFkNTJiNGIwYzkyNGY4NjkzODczNWJlN2FfMzAwNg_0ba67b3d-0fa7-4665-b0fe-66d91709e716" continuedAt="i0314371b9210439d90ff5414192c12d5" escape="true">The following table summarizes the changes in allowance for credit losses on our accounts receivables, certain non-trade accounts receivable and contract assets for the year ended December 31, 2021 and 2020 (in thousands):</ix:nonNumeric></span></div><ix:continuation id="i0314371b9210439d90ff5414192c12d5"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:76.816%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.594%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.596%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of beginning of period</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibc0c0c2b8dc04c5698ca0577a54b2e03_I20201231" decimals="-3" name="us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM182NC9mcmFnOjVmZDYzMzVhZDUyYjRiMGM5MjRmODY5Mzg3MzViZTdhL3RhYmxlOjZiOGIxZmE4ZDk0NTRhMWQ4OTdmYjYxNzU2ZmUzYjQ3L3RhYmxlcmFuZ2U6NmI4YjFmYThkOTQ1NGExZDg5N2ZiNjE3NTZmZTNiNDdfMi0xLTEtMS0xNzc3NQ_feb05c87-a09b-48ee-a7e8-29f3d84b2e05">7,056</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icba6e493923b449aa57c46a563760234_I20191231" decimals="-3" name="us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM182NC9mcmFnOjVmZDYzMzVhZDUyYjRiMGM5MjRmODY5Mzg3MzViZTdhL3RhYmxlOjZiOGIxZmE4ZDk0NTRhMWQ4OTdmYjYxNzU2ZmUzYjQ3L3RhYmxlcmFuZ2U6NmI4YjFmYThkOTQ1NGExZDg5N2ZiNjE3NTZmZTNiNDdfMi0zLTEtMS0xNzc3NQ_7c11150c-bf6f-4b26-99a4-ac8fb029d4b7">41</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Passport acquisition</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231" decimals="-3" name="evh:AccountsReceivableAllowanceForCreditLossAcquiredDuringPeriod" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM182NC9mcmFnOjVmZDYzMzVhZDUyYjRiMGM5MjRmODY5Mzg3MzViZTdhL3RhYmxlOjZiOGIxZmE4ZDk0NTRhMWQ4OTdmYjYxNzU2ZmUzYjQ3L3RhYmxlcmFuZ2U6NmI4YjFmYThkOTQ1NGExZDg5N2ZiNjE3NTZmZTNiNDdfMy0xLTEtMS0xNzc3NQ_c0103e75-99be-4bcf-bc54-d69b487a04e9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i12a6d1161de54547bd29f8efccd4c9b0_D20200101-20201231" decimals="-3" name="evh:AccountsReceivableAllowanceForCreditLossAcquiredDuringPeriod" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM182NC9mcmFnOjVmZDYzMzVhZDUyYjRiMGM5MjRmODY5Mzg3MzViZTdhL3RhYmxlOjZiOGIxZmE4ZDk0NTRhMWQ4OTdmYjYxNzU2ZmUzYjQ3L3RhYmxlcmFuZ2U6NmI4YjFmYThkOTQ1NGExZDg5N2ZiNjE3NTZmZTNiNDdfMy0zLTEtMS0xNzc3NQ_68c1acfe-7933-4c49-8352-5e2cfea66520">2,582</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cumulative transition adjustment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia1b27c6b1ce44bb4a7d45377795c832d_I20201231" decimals="-3" name="us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM182NC9mcmFnOjVmZDYzMzVhZDUyYjRiMGM5MjRmODY5Mzg3MzViZTdhL3RhYmxlOjZiOGIxZmE4ZDk0NTRhMWQ4OTdmYjYxNzU2ZmUzYjQ3L3RhYmxlcmFuZ2U6NmI4YjFmYThkOTQ1NGExZDg5N2ZiNjE3NTZmZTNiNDdfNC0xLTEtMS0xNzc3NQ_d8abb709-ec26-4d6b-99dc-0196a61c5bdb">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6464dcea2322451dbc03ac39361c75b9_I20191231" decimals="-3" name="us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM182NC9mcmFnOjVmZDYzMzVhZDUyYjRiMGM5MjRmODY5Mzg3MzViZTdhL3RhYmxlOjZiOGIxZmE4ZDk0NTRhMWQ4OTdmYjYxNzU2ZmUzYjQ3L3RhYmxlcmFuZ2U6NmI4YjFmYThkOTQ1NGExZDg5N2ZiNjE3NTZmZTNiNDdfNC0zLTEtMS0xNzc3NQ_c3462162-c76e-4f82-9d06-cce6f148c253">2,815</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provision for credit losses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231" decimals="-3" name="us-gaap:ProvisionForDoubtfulAccounts" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM182NC9mcmFnOjVmZDYzMzVhZDUyYjRiMGM5MjRmODY5Mzg3MzViZTdhL3RhYmxlOjZiOGIxZmE4ZDk0NTRhMWQ4OTdmYjYxNzU2ZmUzYjQ3L3RhYmxlcmFuZ2U6NmI4YjFmYThkOTQ1NGExZDg5N2ZiNjE3NTZmZTNiNDdfNS0xLTEtMS0xNzc3NQ_816ee80b-08b0-4f9d-b328-2e6d0bd5fc01">2,411</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i12a6d1161de54547bd29f8efccd4c9b0_D20200101-20201231" decimals="-3" name="us-gaap:ProvisionForDoubtfulAccounts" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM182NC9mcmFnOjVmZDYzMzVhZDUyYjRiMGM5MjRmODY5Mzg3MzViZTdhL3RhYmxlOjZiOGIxZmE4ZDk0NTRhMWQ4OTdmYjYxNzU2ZmUzYjQ3L3RhYmxlcmFuZ2U6NmI4YjFmYThkOTQ1NGExZDg5N2ZiNjE3NTZmZTNiNDdfNS0zLTEtMS0xNzc3NQ_74b4252d-81af-494d-86a5-8bd909eb0277">3,283</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Charge-offs</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231" decimals="-3" name="us-gaap:AllowanceForDoubtfulAccountsReceivableWriteOffs" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM182NC9mcmFnOjVmZDYzMzVhZDUyYjRiMGM5MjRmODY5Mzg3MzViZTdhL3RhYmxlOjZiOGIxZmE4ZDk0NTRhMWQ4OTdmYjYxNzU2ZmUzYjQ3L3RhYmxlcmFuZ2U6NmI4YjFmYThkOTQ1NGExZDg5N2ZiNjE3NTZmZTNiNDdfNi0xLTEtMS0xNzc3NQ_b67be07b-9fba-45e6-bf88-0da6c3fdb1a4">6,093</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i12a6d1161de54547bd29f8efccd4c9b0_D20200101-20201231" decimals="-3" name="us-gaap:AllowanceForDoubtfulAccountsReceivableWriteOffs" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM182NC9mcmFnOjVmZDYzMzVhZDUyYjRiMGM5MjRmODY5Mzg3MzViZTdhL3RhYmxlOjZiOGIxZmE4ZDk0NTRhMWQ4OTdmYjYxNzU2ZmUzYjQ3L3RhYmxlcmFuZ2U6NmI4YjFmYThkOTQ1NGExZDg5N2ZiNjE3NTZmZTNiNDdfNi0zLTEtMS0xNzc3NQ_e456afa9-cea5-430f-a4f4-eda6d0aa7349">1,665</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of end of period</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8daff60be410426d8f7bd49343c1ec0c_I20211231" decimals="-3" name="us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM182NC9mcmFnOjVmZDYzMzVhZDUyYjRiMGM5MjRmODY5Mzg3MzViZTdhL3RhYmxlOjZiOGIxZmE4ZDk0NTRhMWQ4OTdmYjYxNzU2ZmUzYjQ3L3RhYmxlcmFuZ2U6NmI4YjFmYThkOTQ1NGExZDg5N2ZiNjE3NTZmZTNiNDdfNy0xLTEtMS0xNzc3NQ_40e9b127-7a9c-42fb-ab3f-9585f4f34292">3,374</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibc0c0c2b8dc04c5698ca0577a54b2e03_I20201231" decimals="-3" name="us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM182NC9mcmFnOjVmZDYzMzVhZDUyYjRiMGM5MjRmODY5Mzg3MzViZTdhL3RhYmxlOjZiOGIxZmE4ZDk0NTRhMWQ4OTdmYjYxNzU2ZmUzYjQ3L3RhYmxlcmFuZ2U6NmI4YjFmYThkOTQ1NGExZDg5N2ZiNjE3NTZmZTNiNDdfNy0zLTEtMS0xNzc3NQ_373439e8-1931-420b-a0de-2c40f7ba7c7e">7,056</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt">Charge offs for the year ended December 31, 2021, are primarily due to balances written-off that were previously fully reserved as part of the Passport transaction.</span></div></ix:continuation></ix:continuation><div><span><br/></span></div><div id="i9aaa2fddc97e482da5dbe37ac85ae703_67"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 8.  <ix:nonNumeric contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231" name="us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM182Ny9mcmFnOjk0OWExZWFiYjQwNTQ1MmZhNDdhZTI4NjMyNDliOTZiL3RleHRyZWdpb246OTQ5YTFlYWJiNDA1NDUyZmE0N2FlMjg2MzI0OWI5NmJfNjYy_28bffe8d-e7bd-4e46-98a8-18283077e5db" continuedAt="ic8794775fd6b49e8b066f75ce9eadbe0" escape="true">Property and Equipment, Net</ix:nonNumeric></span></div><div><span><br/></span></div><ix:continuation id="ic8794775fd6b49e8b066f75ce9eadbe0"><ix:continuation id="i9da33d1f222844ecbc1531d1013ee3de"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following summarizes our property and equipment (in thousands):</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"></td><td style="width:408.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:54.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:67.75pt"></td><td style="width:1.0pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer hardware</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3065c5c08a124284884a61ee233f4e16_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM182Ny9mcmFnOjk0OWExZWFiYjQwNTQ1MmZhNDdhZTI4NjMyNDliOTZiL3RhYmxlOjE3OTQwMmM0YjIzNjQxMGJiZDk1NjFkZDc5YzM2MzUwL3RhYmxlcmFuZ2U6MTc5NDAyYzRiMjM2NDEwYmJkOTU2MWRkNzljMzYzNTBfMS0xLTEtMS0xNzc3NQ_ecaf647d-3273-4867-b2a2-599878304387">21,970</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie08f3e6fd0bf42cf818c1f564fa39108_I20201231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM182Ny9mcmFnOjk0OWExZWFiYjQwNTQ1MmZhNDdhZTI4NjMyNDliOTZiL3RhYmxlOjE3OTQwMmM0YjIzNjQxMGJiZDk1NjFkZDc5YzM2MzUwL3RhYmxlcmFuZ2U6MTc5NDAyYzRiMjM2NDEwYmJkOTU2MWRkNzljMzYzNTBfMS0zLTEtMS0xNzc3NQ_490164d0-c71d-4e59-ac42-8139ee786a5c">18,866</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture and equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia55f03733cd945fe9d885896e547d383_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM182Ny9mcmFnOjk0OWExZWFiYjQwNTQ1MmZhNDdhZTI4NjMyNDliOTZiL3RhYmxlOjE3OTQwMmM0YjIzNjQxMGJiZDk1NjFkZDc5YzM2MzUwL3RhYmxlcmFuZ2U6MTc5NDAyYzRiMjM2NDEwYmJkOTU2MWRkNzljMzYzNTBfMi0xLTEtMS0xNzc3NQ_90891177-ead0-420e-8c70-bf12f147b32e">3,581</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia95d0a4759a840c0a34e767cc306a57e_I20201231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM182Ny9mcmFnOjk0OWExZWFiYjQwNTQ1MmZhNDdhZTI4NjMyNDliOTZiL3RhYmxlOjE3OTQwMmM0YjIzNjQxMGJiZDk1NjFkZDc5YzM2MzUwL3RhYmxlcmFuZ2U6MTc5NDAyYzRiMjM2NDEwYmJkOTU2MWRkNzljMzYzNTBfMi0zLTEtMS0xNzc3NQ_6e8858f6-0a1f-4c75-8ede-c1eb1520092a">3,559</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Internal-use software development costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i370ec8ac69f6453daffb02508aef709b_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM182Ny9mcmFnOjk0OWExZWFiYjQwNTQ1MmZhNDdhZTI4NjMyNDliOTZiL3RhYmxlOjE3OTQwMmM0YjIzNjQxMGJiZDk1NjFkZDc5YzM2MzUwL3RhYmxlcmFuZ2U6MTc5NDAyYzRiMjM2NDEwYmJkOTU2MWRkNzljMzYzNTBfMy0xLTEtMS0xNzc3NQ_ad41c4b0-d01e-48f7-9d21-99ba6e90ce2c">159,587</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icd3eb9c2b2874ea99e8f34f94952be94_I20201231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM182Ny9mcmFnOjk0OWExZWFiYjQwNTQ1MmZhNDdhZTI4NjMyNDliOTZiL3RhYmxlOjE3OTQwMmM0YjIzNjQxMGJiZDk1NjFkZDc5YzM2MzUwL3RhYmxlcmFuZ2U6MTc5NDAyYzRiMjM2NDEwYmJkOTU2MWRkNzljMzYzNTBfMy0zLTEtMS0xNzc3NQ_8591bc18-be11-4d50-8908-237f60844c65">137,085</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3873f51f572a46ae8f17531700510927_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM182Ny9mcmFnOjk0OWExZWFiYjQwNTQ1MmZhNDdhZTI4NjMyNDliOTZiL3RhYmxlOjE3OTQwMmM0YjIzNjQxMGJiZDk1NjFkZDc5YzM2MzUwL3RhYmxlcmFuZ2U6MTc5NDAyYzRiMjM2NDEwYmJkOTU2MWRkNzljMzYzNTBfNC0xLTEtMS0xNzc3NQ_e6953dbd-f5b9-4cba-886e-613622fd0f60">15,325</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0b599414417745fdb6c3cddde5001d4b_I20201231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM182Ny9mcmFnOjk0OWExZWFiYjQwNTQ1MmZhNDdhZTI4NjMyNDliOTZiL3RhYmxlOjE3OTQwMmM0YjIzNjQxMGJiZDk1NjFkZDc5YzM2MzUwL3RhYmxlcmFuZ2U6MTc5NDAyYzRiMjM2NDEwYmJkOTU2MWRkNzljMzYzNTBfNC0zLTEtMS0xNzc3NQ_394d3d17-211f-4a01-a7e0-bef36f771342">15,586</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total property and equipment</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8daff60be410426d8f7bd49343c1ec0c_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM182Ny9mcmFnOjk0OWExZWFiYjQwNTQ1MmZhNDdhZTI4NjMyNDliOTZiL3RhYmxlOjE3OTQwMmM0YjIzNjQxMGJiZDk1NjFkZDc5YzM2MzUwL3RhYmxlcmFuZ2U6MTc5NDAyYzRiMjM2NDEwYmJkOTU2MWRkNzljMzYzNTBfNS0xLTEtMS0xNzc3NQ_6bb41cc0-613c-4ec3-b434-bc9d244b41bb">200,463</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc0c0c2b8dc04c5698ca0577a54b2e03_I20201231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM182Ny9mcmFnOjk0OWExZWFiYjQwNTQ1MmZhNDdhZTI4NjMyNDliOTZiL3RhYmxlOjE3OTQwMmM0YjIzNjQxMGJiZDk1NjFkZDc5YzM2MzUwL3RhYmxlcmFuZ2U6MTc5NDAyYzRiMjM2NDEwYmJkOTU2MWRkNzljMzYzNTBfNS0zLTEtMS0xNzc3NQ_11eb0ad5-6d58-42fa-bf32-6843e68facd6">175,096</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated depreciation and amortization expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8daff60be410426d8f7bd49343c1ec0c_I20211231" decimals="-3" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM182Ny9mcmFnOjk0OWExZWFiYjQwNTQ1MmZhNDdhZTI4NjMyNDliOTZiL3RhYmxlOjE3OTQwMmM0YjIzNjQxMGJiZDk1NjFkZDc5YzM2MzUwL3RhYmxlcmFuZ2U6MTc5NDAyYzRiMjM2NDEwYmJkOTU2MWRkNzljMzYzNTBfNi0xLTEtMS0xNzc3NQ_f52e0746-7282-4955-8a27-beffbc206dc2">119,098</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibc0c0c2b8dc04c5698ca0577a54b2e03_I20201231" decimals="-3" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM182Ny9mcmFnOjk0OWExZWFiYjQwNTQ1MmZhNDdhZTI4NjMyNDliOTZiL3RhYmxlOjE3OTQwMmM0YjIzNjQxMGJiZDk1NjFkZDc5YzM2MzUwL3RhYmxlcmFuZ2U6MTc5NDAyYzRiMjM2NDEwYmJkOTU2MWRkNzljMzYzNTBfNi0zLTEtMS0xNzc3NQ_c559e04b-4b1f-4ef6-a01b-0335b8f39b40">88,856</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total property and equipment, net</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8daff60be410426d8f7bd49343c1ec0c_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM182Ny9mcmFnOjk0OWExZWFiYjQwNTQ1MmZhNDdhZTI4NjMyNDliOTZiL3RhYmxlOjE3OTQwMmM0YjIzNjQxMGJiZDk1NjFkZDc5YzM2MzUwL3RhYmxlcmFuZ2U6MTc5NDAyYzRiMjM2NDEwYmJkOTU2MWRkNzljMzYzNTBfNy0xLTEtMS0xNzc3NQ_c2f10906-3c57-4f81-8135-445aeec89128">81,365</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc0c0c2b8dc04c5698ca0577a54b2e03_I20201231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM182Ny9mcmFnOjk0OWExZWFiYjQwNTQ1MmZhNDdhZTI4NjMyNDliOTZiL3RhYmxlOjE3OTQwMmM0YjIzNjQxMGJiZDk1NjFkZDc5YzM2MzUwL3RhYmxlcmFuZ2U6MTc5NDAyYzRiMjM2NDEwYmJkOTU2MWRkNzljMzYzNTBfNy0zLTEtMS0xNzc3NQ_b4698117-19d3-4fc9-9968-7c2de2c33d85">86,240</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:continuation><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company capitalized $<ix:nonFraction unitRef="usd" contextRef="ia186bface90a4c4098c96c8567d34124_D20210101-20211231" decimals="-5" name="us-gaap:CapitalizedComputerSoftwareAdditions" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM182Ny9mcmFnOjk0OWExZWFiYjQwNTQ1MmZhNDdhZTI4NjMyNDliOTZiL3RleHRyZWdpb246OTQ5YTFlYWJiNDA1NDUyZmE0N2FlMjg2MzI0OWI5NmJfMTYy_d6955ec8-f453-4a71-baa3-5d636c1a1023">22.5</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="i8c359ea835e64a39b5cab25a3948e3b7_D20200101-20201231" decimals="-5" name="us-gaap:CapitalizedComputerSoftwareAdditions" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM182Ny9mcmFnOjk0OWExZWFiYjQwNTQ1MmZhNDdhZTI4NjMyNDliOTZiL3RleHRyZWdpb246OTQ5YTFlYWJiNDA1NDUyZmE0N2FlMjg2MzI0OWI5NmJfMjM4_2df21e0f-7a5b-46e1-ba50-3133a4bfa6f9">24.6</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i3a8f822ce668416caf0bf1e2f7037e11_D20190101-20191231" decimals="-5" name="us-gaap:CapitalizedComputerSoftwareAdditions" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM182Ny9mcmFnOjk0OWExZWFiYjQwNTQ1MmZhNDdhZTI4NjMyNDliOTZiL3RleHRyZWdpb246OTQ5YTFlYWJiNDA1NDUyZmE0N2FlMjg2MzI0OWI5NmJfMTA5OTUxMTYyODU4Mw_b313d975-d7d5-437f-8891-7994ee742adf">30.9</ix:nonFraction> million of internal-use software development costs for the years ended December 31, 2021, 2020 and 2019, respectively. The net book value of capitalized internal-use software development costs was $<ix:nonFraction unitRef="usd" contextRef="i370ec8ac69f6453daffb02508aef709b_I20211231" decimals="-5" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM182Ny9mcmFnOjk0OWExZWFiYjQwNTQ1MmZhNDdhZTI4NjMyNDliOTZiL3RleHRyZWdpb246OTQ5YTFlYWJiNDA1NDUyZmE0N2FlMjg2MzI0OWI5NmJfMzM3_b42b6e46-d8e2-4a40-a1a7-5c26932f4117">71.2</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="icd3eb9c2b2874ea99e8f34f94952be94_I20201231" decimals="-5" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM182Ny9mcmFnOjk0OWExZWFiYjQwNTQ1MmZhNDdhZTI4NjMyNDliOTZiL3RleHRyZWdpb246OTQ5YTFlYWJiNDA1NDUyZmE0N2FlMjg2MzI0OWI5NmJfMzQ0_93925f9d-2d74-4f37-9890-80886b0b8640">75.3</ix:nonFraction> million as of December&#160;31, 2021 and 2020, respectively. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation expense related to property and equipment was $<ix:nonFraction unitRef="usd" contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231" decimals="-5" name="us-gaap:Depreciation" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM182Ny9mcmFnOjk0OWExZWFiYjQwNTQ1MmZhNDdhZTI4NjMyNDliOTZiL3RleHRyZWdpb246OTQ5YTFlYWJiNDA1NDUyZmE0N2FlMjg2MzI0OWI5NmJfNDQ2_787a09fb-b541-4334-9f9e-8b7abc6769b2">30.6</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="i12a6d1161de54547bd29f8efccd4c9b0_D20200101-20201231" decimals="-5" name="us-gaap:Depreciation" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM182Ny9mcmFnOjk0OWExZWFiYjQwNTQ1MmZhNDdhZTI4NjMyNDliOTZiL3RleHRyZWdpb246OTQ5YTFlYWJiNDA1NDUyZmE0N2FlMjg2MzI0OWI5NmJfNDc4_3ba29408-9860-4b08-b24f-08fb4b76a172">28.3</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i3e21049ffc224cacb8134d73c9bb5b38_D20190101-20191231" decimals="-5" name="us-gaap:Depreciation" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM182Ny9mcmFnOjk0OWExZWFiYjQwNTQ1MmZhNDdhZTI4NjMyNDliOTZiL3RleHRyZWdpb246OTQ5YTFlYWJiNDA1NDUyZmE0N2FlMjg2MzI0OWI5NmJfMTA5OTUxMTYyODc3MQ_b8b47505-eea3-4903-ad3a-90e55b6a49ae">23.3</ix:nonFraction> million, for the years ended December 31, 2021, 2020 and 2019, respectively, of which amortization expense related to capitalized internal-use software development costs was $<ix:nonFraction unitRef="usd" contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231" decimals="-5" name="us-gaap:CapitalizedComputerSoftwareAmortization1" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM182Ny9mcmFnOjk0OWExZWFiYjQwNTQ1MmZhNDdhZTI4NjMyNDliOTZiL3RleHRyZWdpb246OTQ5YTFlYWJiNDA1NDUyZmE0N2FlMjg2MzI0OWI5NmJfNjAz_c28efbd5-65b9-40b7-83e0-a8b77aba9b11">26.5</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="i12a6d1161de54547bd29f8efccd4c9b0_D20200101-20201231" decimals="-5" name="us-gaap:CapitalizedComputerSoftwareAmortization1" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM182Ny9mcmFnOjk0OWExZWFiYjQwNTQ1MmZhNDdhZTI4NjMyNDliOTZiL3RleHRyZWdpb246OTQ5YTFlYWJiNDA1NDUyZmE0N2FlMjg2MzI0OWI5NmJfNjM1_f1738cf3-8317-4f2c-8f4f-0b0bf2f80b96">24.3</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i3e21049ffc224cacb8134d73c9bb5b38_D20190101-20191231" decimals="-5" name="us-gaap:CapitalizedComputerSoftwareAmortization1" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM182Ny9mcmFnOjk0OWExZWFiYjQwNTQ1MmZhNDdhZTI4NjMyNDliOTZiL3RleHRyZWdpb246OTQ5YTFlYWJiNDA1NDUyZmE0N2FlMjg2MzI0OWI5NmJfMTA5OTUxMTYyODg4Mg_d9037ad2-e0a1-4ec5-bfc4-eb101df7331d">18.7</ix:nonFraction> million, respectively.</span></div></ix:continuation><div style="text-align:justify"><span><br/></span></div><div id="i9aaa2fddc97e482da5dbe37ac85ae703_70"></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 9.  <ix:nonNumeric contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231" name="us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM183MC9mcmFnOmIxYjdhNmFmNjEzYzQ3NWM5ZGI4Y2JlNmQzNTE1NDk3L3RleHRyZWdpb246YjFiN2E2YWY2MTNjNDc1YzlkYjhjYmU2ZDM1MTU0OTdfODYwMg_1a0abe50-36b7-4bf6-90d8-5ceb9bebf69a" continuedAt="i9f6bd395afca4d4a85d9f6a7caac1554" escape="true">Goodwill and Intangible Assets, Net</ix:nonNumeric></span></div><div style="text-align:justify"><span><br/></span></div><ix:continuation id="i9f6bd395afca4d4a85d9f6a7caac1554" continuedAt="i827a08372ae44b13b641e88cc6a62619"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Goodwill</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Goodwill has an estimated indefinite life and is not amortized; rather, it is reviewed for impairment at least annually or whenever events or changes in circumstances indicate that the carrying amount of the asset may not be recoverable.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Subsequent to the sale of True Health, the Company has <ix:nonFraction unitRef="reportingunit" contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231" decimals="INF" name="us-gaap:NumberOfReportingUnits" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM183MC9mcmFnOmIxYjdhNmFmNjEzYzQ3NWM5ZGI4Y2JlNmQzNTE1NDk3L3RleHRyZWdpb246YjFiN2E2YWY2MTNjNDc1YzlkYjhjYmU2ZDM1MTU0OTdfMzU2_c8cafdff-4a85-4bce-a4fd-4fd28f16f87f">three</ix:nonFraction> reporting units, each with </span><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">discrete financial information. Our assets and liabilities are employed in and relate to the operations of our reporting units. Therefore, the equity carrying value and future cash flows must be estimated each time a&#160;goodwill impairment&#160;analysis is performed on a reporting unit. As a result, our assets, liabilities and cash flows are assigned to reporting units using reasonable and consistent allocation methodologies. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our annual goodwill impairment review occurs on October 31 of each fiscal </span><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">year. We evaluate qualitative factors that could cause us to believe the estimated fair value of each of our reporting units may be lower than the carrying value and trigger a quantitative assessment, including, but not limited to (i) macroeconomic conditions, (ii) industry and market considerations, (iii) our overall financial performance, including an analysis of our current and projected cash flows, revenues and earnings, (iv) a sustained decrease in share price and (v) other relevant entity-specific events including changes in management, strategy, partners, or litigation.</span></div></ix:continuation><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">90</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span><br/></span></div><ix:continuation id="i827a08372ae44b13b641e88cc6a62619" continuedAt="i35cd26e0012642b5a6abf57011d53899"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2021 Goodwill Impairment Test</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October 31, 2021, the Company performed its annual goodwill impairment review for fiscal year 2021. Based on our qualitative assessment, we did not identify sufficient indicators of impairment that would suggest the fair value of any of our three reporting units was below their respective carrying values. As a result, a quantitative goodwill impairment analysis was not required.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2020 Goodwill Impairment Test</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March 31, 2020, the Company assessed whether there were additional events or changes in circumstances since its 2019 annual goodwill impairment test that would indicate that it was more likely than not that the fair values of the reporting units were less than the reporting units&#8217; carrying amounts that would require an additional interim impairment assessment after October 31, 2019. Considering the sharp decrease in the share price of the Company&#8217;s Class A common stock during the three months ended March 31, 2020, the Company determined indicators of an impairment were present and we performed an interim goodwill impairment assessment as of March 31, 2020. As a result of this test, the Company determined that there was <ix:nonFraction unitRef="usd" contextRef="iddbf996a3b1a4aeda47f1e8169c69262_D20200101-20200331" decimals="INF" name="us-gaap:GoodwillImpairmentLoss" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM183MC9mcmFnOmIxYjdhNmFmNjEzYzQ3NWM5ZGI4Y2JlNmQzNTE1NDk3L3RleHRyZWdpb246YjFiN2E2YWY2MTNjNDc1YzlkYjhjYmU2ZDM1MTU0OTdfMjUwOA_d8ae2c21-cb0d-4657-924a-15e980c0fc9d">no</ix:nonFraction> goodwill impairment of the reporting unit which recognized an impairment in the year ended December 31, 2019. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During May 2020, the Kentucky Cabinet for Health and Family Services (&#8220;CHFS&#8221;) announced that EVH Passport was not awarded a Kentucky managed Medicaid contract for the next contract period and the Passport Medicaid Contract would expire on December 31, 2020. As a result of this announcement, the Company determined there were events or changes in circumstances since its 2019 annual goodwill impairment test that indicated it was more likely than not that the fair value of <ix:nonFraction unitRef="reportingunit" contextRef="i113b515f40aa4b3e9afd7361c65483dc_D20200501-20200531" decimals="INF" name="evh:NumberOfReportingUnitsFairValueInExcessOfCarryingAmount" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM183MC9mcmFnOmIxYjdhNmFmNjEzYzQ3NWM5ZGI4Y2JlNmQzNTE1NDk3L3RleHRyZWdpb246YjFiN2E2YWY2MTNjNDc1YzlkYjhjYmU2ZDM1MTU0OTdfMzA5Nw_d9f61b8a-15f8-411d-903d-7837e874889f">one</ix:nonFraction> of its <ix:nonFraction unitRef="reportingunit" contextRef="i113b515f40aa4b3e9afd7361c65483dc_D20200501-20200531" decimals="INF" name="us-gaap:NumberOfReportingUnits" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM183MC9mcmFnOmIxYjdhNmFmNjEzYzQ3NWM5ZGI4Y2JlNmQzNTE1NDk3L3RleHRyZWdpb246YjFiN2E2YWY2MTNjNDc1YzlkYjhjYmU2ZDM1MTU0OTdfMzEwNw_0f6f319a-4d15-4ba1-a647-7f737906b142">two</ix:nonFraction> reporting units in the EHS segment was less than the reporting unit&#8217;s carrying amount triggering an interim quantitative assessment.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In performing this interim quantitative assessment, we estimated the fair value of the reporting unit by considering a discounted cash flow valuation approach (&#8220;income approach&#8221;). In determining the estimated fair value in a quantitative analysis, we projected future cash flows based on management&#8217;s estimates and long-term plans and applied a discount rate based on the Company&#8217;s weighted average cost of capital. This analysis required us to make judgments about revenues, expenses, fixed asset and working capital requirements, capital market assumptions, cash flows and discount rates.  </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of May 31, 2020, we determined that the reporting unit under review had an estimated fair value less than its carrying value.  As a result, we recorded a non-cash goodwill impairment charge of $<ix:nonFraction unitRef="usd" contextRef="i62320e40739f4842b8ffb078d42fa029_D20200401-20200630" decimals="-5" name="us-gaap:GoodwillImpairmentLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM183MC9mcmFnOmIxYjdhNmFmNjEzYzQ3NWM5ZGI4Y2JlNmQzNTE1NDk3L3RleHRyZWdpb246YjFiN2E2YWY2MTNjNDc1YzlkYjhjYmU2ZDM1MTU0OTdfNDAzNA_2ce57fc7-de9d-4a63-a2c6-d7c202b860d9"><ix:nonFraction unitRef="usd" contextRef="ibd34af6251294e159e55819cc46cbbb6_D20200101-20200630" decimals="-5" name="us-gaap:GoodwillImpairmentLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM183MC9mcmFnOmIxYjdhNmFmNjEzYzQ3NWM5ZGI4Y2JlNmQzNTE1NDk3L3RleHRyZWdpb246YjFiN2E2YWY2MTNjNDc1YzlkYjhjYmU2ZDM1MTU0OTdfNDAzNA_a5cac6a5-ef5f-4be2-987d-01d10e187357">215.1</ix:nonFraction></ix:nonFraction>&#160;million on our consolidated statements of operations and comprehensive income (loss) for the three and six months ended June 30, 2020. In addition, the Company reviewed its interim goodwill impairment analysis as of June 30, 2020 and did not identify any additional information or events that would contradict or change the conclusion reached by the Company as of May 31, 2020. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended September 30, 2020, we evaluated qualitative factors that could indicate the fair value of each of our reporting units may be lower than the carrying value. We did not identify any qualitative factors that would trigger a quantitative goodwill impairment test during the three months ended September 30, 2020. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the Company&#8217;s annual impairment analysis as of October 31, 2020, the Company concluded that previous impairment charges of $<ix:nonFraction unitRef="usd" contextRef="id2d85a5202f44415bdbcb9412ab08509_D20191001-20191231" decimals="-5" name="us-gaap:GoodwillImpairmentLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM183MC9mcmFnOmIxYjdhNmFmNjEzYzQ3NWM5ZGI4Y2JlNmQzNTE1NDk3L3RleHRyZWdpb246YjFiN2E2YWY2MTNjNDc1YzlkYjhjYmU2ZDM1MTU0OTdfNDg4MQ_34006fbc-07a3-4662-a1df-e350fe012bc3">199.8</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i62320e40739f4842b8ffb078d42fa029_D20200401-20200630" decimals="-5" name="us-gaap:GoodwillImpairmentLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM183MC9mcmFnOmIxYjdhNmFmNjEzYzQ3NWM5ZGI4Y2JlNmQzNTE1NDk3L3RleHRyZWdpb246YjFiN2E2YWY2MTNjNDc1YzlkYjhjYmU2ZDM1MTU0OTdfNDg4OA_32d62e43-8aff-49b9-89f7-ac2d6b86ff33">215.1</ix:nonFraction>&#160;million recorded during the three months ended December 31, 2019 and June 30, 2020, respectively, in <ix:nonFraction unitRef="reportingunit" contextRef="id586f68951304ab3ac3fd84a42cb5e48_D20201031-20201031" decimals="INF" name="evh:NumberOfReportingUnitsFairValueInExcessOfCarryingAmount" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM183MC9mcmFnOmIxYjdhNmFmNjEzYzQ3NWM5ZGI4Y2JlNmQzNTE1NDk3L3RleHRyZWdpb246YjFiN2E2YWY2MTNjNDc1YzlkYjhjYmU2ZDM1MTU0OTdfNDk4NA_2533f69b-16ce-41cd-bd9a-581a81d3b8db">one</ix:nonFraction> of our <ix:nonFraction unitRef="reportingunit" contextRef="id586f68951304ab3ac3fd84a42cb5e48_D20201031-20201031" decimals="INF" name="us-gaap:NumberOfReportingUnits" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM183MC9mcmFnOmIxYjdhNmFmNjEzYzQ3NWM5ZGI4Y2JlNmQzNTE1NDk3L3RleHRyZWdpb246YjFiN2E2YWY2MTNjNDc1YzlkYjhjYmU2ZDM1MTU0OTdfNDk5NA_0b209d7a-c8d2-49b5-903d-c7ac6766c703">two</ix:nonFraction> reporting units in the EHS segment left that specific reporting unit with a limited fair value cushion. Therefore, the Company elected to forego the qualitative assessment and proceed directly to the quantitative assessment of the goodwill impairment test for that specific reporting unit. This election does not preclude management from performing the qualitative assessment in any subsequent period. For the remaining reporting units, after assessing the totality of events and circumstances including the results of our previous valuations, the minimal impacts of the Passport loss and COVID-19, the Company does not believe that an event occurred or circumstances changed during the period under consideration that would, more likely than not, reduce the fair value of any reporting unit below their carrying amount. Therefore, the Company concluded that the quantitative assessment was not required. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In performing our October 31, 2020 impairment test for <ix:nonFraction unitRef="reportingunit" contextRef="id586f68951304ab3ac3fd84a42cb5e48_D20201031-20201031" decimals="INF" name="evh:NumberOfReportingUnitsFairValueInExcessOfCarryingAmount" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM183MC9mcmFnOmIxYjdhNmFmNjEzYzQ3NWM5ZGI4Y2JlNmQzNTE1NDk3L3RleHRyZWdpb246YjFiN2E2YWY2MTNjNDc1YzlkYjhjYmU2ZDM1MTU0OTdfNTk1OQ_5015ca66-91d2-4ed9-aa2d-a2c4c4c29b81">one</ix:nonFraction> of the specific reporting units referenced above, we estimated the fair value of our reporting units by considering a discounted cash flow valuation approach (&#8220;income approach&#8221;). In determining the estimated fair value using the income approach, we projected future cash flows based on management&#8217;s estimates and long-term plans and applied a discount rate based on the Company&#8217;s weighted average cost of capital. This analysis required us to make judgments about revenues, expenses, fixed asset and working capital requirements, capital market assumptions, cash flows and discount rates. As of October 31, 2020, we determined that the specific reporting unit had an estimated fair value greater than its carrying value and as a result, goodwill is not impaired.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2020, the Company assessed whether there were additional events or changes in circumstances since its annual goodwill impairment test that would indicate that it was more likely than not that the fair value of the reporting unit was less than the reporting unit&#8217;s carrying amounts that would require an interim impairment assessment after October 31, 2020. The Company </span></div></ix:continuation><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">91</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i35cd26e0012642b5a6abf57011d53899" continuedAt="ic424e6b6eb214a6f9322a4103d405483"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">determined there had been no such indicators, therefore, we did not perform an interim goodwill impairment assessment as of December 31, 2020. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Change in Goodwill</span></div><div style="text-align:justify"><span><br/></span></div><ix:nonNumeric contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231" name="us-gaap:ScheduleOfGoodwillTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM183MC9mcmFnOmIxYjdhNmFmNjEzYzQ3NWM5ZGI4Y2JlNmQzNTE1NDk3L3RleHRyZWdpb246YjFiN2E2YWY2MTNjNDc1YzlkYjhjYmU2ZDM1MTU0OTdfODYxMQ_fce16faa-7fae-4173-96fb-73dc4d19971d" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the changes in the carrying amount of goodwill, by reportable segment, for the periods presented (in thousands):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:60.705%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.983%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.772%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.983%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.772%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.985%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">EHS</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Clinical Solutions</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Consolidated</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of December 31, 2019 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ida02b25c4b5e464a9545df19946134c1_I20191231" decimals="-3" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM183MC9mcmFnOmIxYjdhNmFmNjEzYzQ3NWM5ZGI4Y2JlNmQzNTE1NDk3L3RhYmxlOjU0MjkzMDQ2ZWJiMjRjNjdhZWI0NmZhZmM1ZjNjNTdhL3RhYmxlcmFuZ2U6NTQyOTMwNDZlYmIyNGM2N2FlYjQ2ZmFmYzVmM2M1N2FfMS0xLTEtMS0xNzc3NQ_07ac5111-4bfa-4f4b-b8ab-7ea55ed767a3">431,684</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i14e6a440f7dc431a9e1c85272b43d276_I20191231" decimals="-3" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM183MC9mcmFnOmIxYjdhNmFmNjEzYzQ3NWM5ZGI4Y2JlNmQzNTE1NDk3L3RhYmxlOjU0MjkzMDQ2ZWJiMjRjNjdhZWI0NmZhZmM1ZjNjNTdhL3RhYmxlcmFuZ2U6NTQyOTMwNDZlYmIyNGM2N2FlYjQ2ZmFmYzVmM2M1N2FfMS0zLTEtMS0xNzc3NQ_cf640a78-0ac5-4114-a47d-b03173de4cf5">134,675</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icba6e493923b449aa57c46a563760234_I20191231" decimals="-3" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM183MC9mcmFnOmIxYjdhNmFmNjEzYzQ3NWM5ZGI4Y2JlNmQzNTE1NDk3L3RhYmxlOjU0MjkzMDQ2ZWJiMjRjNjdhZWI0NmZhZmM1ZjNjNTdhL3RhYmxlcmFuZ2U6NTQyOTMwNDZlYmIyNGM2N2FlYjQ2ZmFmYzVmM2M1N2FfMS01LTEtMS0xNzc3NQ_de7f0beb-c6e0-43c6-84c6-95c0f1efe680">566,359</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill disposal </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i00a9fb2f3f914116b87f14e146d04507_D20200101-20201231" decimals="-3" name="us-gaap:GoodwillWrittenOffRelatedToSaleOfBusinessUnit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM183MC9mcmFnOmIxYjdhNmFmNjEzYzQ3NWM5ZGI4Y2JlNmQzNTE1NDk3L3RhYmxlOjU0MjkzMDQ2ZWJiMjRjNjdhZWI0NmZhZmM1ZjNjNTdhL3RhYmxlcmFuZ2U6NTQyOTMwNDZlYmIyNGM2N2FlYjQ2ZmFmYzVmM2M1N2FfMi0xLTEtMS0xNzc3NQ_456d1861-a3b5-418b-b9d3-62639e9949de">2,200</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i73877656554945338d08c1e8006fc13a_D20200101-20201231" decimals="-3" name="us-gaap:GoodwillWrittenOffRelatedToSaleOfBusinessUnit" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM183MC9mcmFnOmIxYjdhNmFmNjEzYzQ3NWM5ZGI4Y2JlNmQzNTE1NDk3L3RhYmxlOjU0MjkzMDQ2ZWJiMjRjNjdhZWI0NmZhZmM1ZjNjNTdhL3RhYmxlcmFuZ2U6NTQyOTMwNDZlYmIyNGM2N2FlYjQ2ZmFmYzVmM2M1N2FfMi0zLTEtMS0xNzc3NQ_ec861440-832d-4dce-bad9-0d4a8a0d6274">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i12a6d1161de54547bd29f8efccd4c9b0_D20200101-20201231" decimals="-3" name="us-gaap:GoodwillWrittenOffRelatedToSaleOfBusinessUnit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM183MC9mcmFnOmIxYjdhNmFmNjEzYzQ3NWM5ZGI4Y2JlNmQzNTE1NDk3L3RhYmxlOjU0MjkzMDQ2ZWJiMjRjNjdhZWI0NmZhZmM1ZjNjNTdhL3RhYmxlcmFuZ2U6NTQyOTMwNDZlYmIyNGM2N2FlYjQ2ZmFmYzVmM2M1N2FfMi01LTEtMS0xNzc3NQ_8b524ecc-9b7a-4dad-8e7c-4cf0a45e7d99">2,200</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Impairment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i00a9fb2f3f914116b87f14e146d04507_D20200101-20201231" decimals="-3" name="us-gaap:GoodwillImpairmentLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM183MC9mcmFnOmIxYjdhNmFmNjEzYzQ3NWM5ZGI4Y2JlNmQzNTE1NDk3L3RhYmxlOjU0MjkzMDQ2ZWJiMjRjNjdhZWI0NmZhZmM1ZjNjNTdhL3RhYmxlcmFuZ2U6NTQyOTMwNDZlYmIyNGM2N2FlYjQ2ZmFmYzVmM2M1N2FfMy0xLTEtMS0xNzc3NQ_99234612-db50-402c-92c3-095db58d8143">215,100</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i73877656554945338d08c1e8006fc13a_D20200101-20201231" decimals="-3" name="us-gaap:GoodwillImpairmentLoss" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM183MC9mcmFnOmIxYjdhNmFmNjEzYzQ3NWM5ZGI4Y2JlNmQzNTE1NDk3L3RhYmxlOjU0MjkzMDQ2ZWJiMjRjNjdhZWI0NmZhZmM1ZjNjNTdhL3RhYmxlcmFuZ2U6NTQyOTMwNDZlYmIyNGM2N2FlYjQ2ZmFmYzVmM2M1N2FfMy0zLTEtMS0xNzc3NQ_7ac790ab-5cb6-4565-83d6-bdc0c0870487">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i12a6d1161de54547bd29f8efccd4c9b0_D20200101-20201231" decimals="-3" name="us-gaap:GoodwillImpairmentLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM183MC9mcmFnOmIxYjdhNmFmNjEzYzQ3NWM5ZGI4Y2JlNmQzNTE1NDk3L3RhYmxlOjU0MjkzMDQ2ZWJiMjRjNjdhZWI0NmZhZmM1ZjNjNTdhL3RhYmxlcmFuZ2U6NTQyOTMwNDZlYmIyNGM2N2FlYjQ2ZmFmYzVmM2M1N2FfMy01LTEtMS0xNzc3NQ_49e92921-1b25-4a23-a354-86b06907ab25">215,100</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency translation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i00a9fb2f3f914116b87f14e146d04507_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:GoodwillForeignCurrencyTranslationGainLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM183MC9mcmFnOmIxYjdhNmFmNjEzYzQ3NWM5ZGI4Y2JlNmQzNTE1NDk3L3RhYmxlOjU0MjkzMDQ2ZWJiMjRjNjdhZWI0NmZhZmM1ZjNjNTdhL3RhYmxlcmFuZ2U6NTQyOTMwNDZlYmIyNGM2N2FlYjQ2ZmFmYzVmM2M1N2FfNC0xLTEtMS0xNzc3NQ_56161dc0-d27e-4b57-816c-f0fc0aeb794b">30</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i73877656554945338d08c1e8006fc13a_D20200101-20201231" decimals="-3" name="us-gaap:GoodwillForeignCurrencyTranslationGainLoss" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM183MC9mcmFnOmIxYjdhNmFmNjEzYzQ3NWM5ZGI4Y2JlNmQzNTE1NDk3L3RhYmxlOjU0MjkzMDQ2ZWJiMjRjNjdhZWI0NmZhZmM1ZjNjNTdhL3RhYmxlcmFuZ2U6NTQyOTMwNDZlYmIyNGM2N2FlYjQ2ZmFmYzVmM2M1N2FfNC0zLTEtMS0xNzc3NQ_123439d1-27b4-4379-b488-96e80975db29">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i12a6d1161de54547bd29f8efccd4c9b0_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:GoodwillForeignCurrencyTranslationGainLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM183MC9mcmFnOmIxYjdhNmFmNjEzYzQ3NWM5ZGI4Y2JlNmQzNTE1NDk3L3RhYmxlOjU0MjkzMDQ2ZWJiMjRjNjdhZWI0NmZhZmM1ZjNjNTdhL3RhYmxlcmFuZ2U6NTQyOTMwNDZlYmIyNGM2N2FlYjQ2ZmFmYzVmM2M1N2FfNC01LTEtMS0xNzc3NQ_3753f51d-32ef-4a88-a49f-585a4d7046f5">30</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of December 31, 2020</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if8fd35766cfc4fa8b1cbf4f3cd8a8dfc_I20201231" decimals="-3" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM183MC9mcmFnOmIxYjdhNmFmNjEzYzQ3NWM5ZGI4Y2JlNmQzNTE1NDk3L3RhYmxlOjU0MjkzMDQ2ZWJiMjRjNjdhZWI0NmZhZmM1ZjNjNTdhL3RhYmxlcmFuZ2U6NTQyOTMwNDZlYmIyNGM2N2FlYjQ2ZmFmYzVmM2M1N2FfNS0xLTEtMS0xNzc3NQ_5d158e10-52fa-4a08-a9d0-ba2e01ca899d">214,354</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5f5145421bc94a90bb8982e11bb80abb_I20201231" decimals="-3" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM183MC9mcmFnOmIxYjdhNmFmNjEzYzQ3NWM5ZGI4Y2JlNmQzNTE1NDk3L3RhYmxlOjU0MjkzMDQ2ZWJiMjRjNjdhZWI0NmZhZmM1ZjNjNTdhL3RhYmxlcmFuZ2U6NTQyOTMwNDZlYmIyNGM2N2FlYjQ2ZmFmYzVmM2M1N2FfNS0zLTEtMS0xNzc3NQ_65c3c627-30ae-48fa-8880-dc2a804712bc">134,675</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc0c0c2b8dc04c5698ca0577a54b2e03_I20201231" decimals="-3" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM183MC9mcmFnOmIxYjdhNmFmNjEzYzQ3NWM5ZGI4Y2JlNmQzNTE1NDk3L3RhYmxlOjU0MjkzMDQ2ZWJiMjRjNjdhZWI0NmZhZmM1ZjNjNTdhL3RhYmxlcmFuZ2U6NTQyOTMwNDZlYmIyNGM2N2FlYjQ2ZmFmYzVmM2M1N2FfNS01LTEtMS0xNzc3NQ_e43cc33e-39a2-4309-93f4-3e431362c727">349,029</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill acquired</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i98988f30813349e1a5594e72b40af5b1_D20210101-20211231" decimals="-3" name="us-gaap:GoodwillAcquiredDuringPeriod" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM183MC9mcmFnOmIxYjdhNmFmNjEzYzQ3NWM5ZGI4Y2JlNmQzNTE1NDk3L3RhYmxlOjU0MjkzMDQ2ZWJiMjRjNjdhZWI0NmZhZmM1ZjNjNTdhL3RhYmxlcmFuZ2U6NTQyOTMwNDZlYmIyNGM2N2FlYjQ2ZmFmYzVmM2M1N2FfNi0xLTEtMS0yMTE4NA_87b8353a-d6d7-4f20-b863-3e6a73b644ce">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6d991ef4e2e0416f8c7aaaa6175cf843_D20210101-20211231" decimals="-3" name="us-gaap:GoodwillAcquiredDuringPeriod" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM183MC9mcmFnOmIxYjdhNmFmNjEzYzQ3NWM5ZGI4Y2JlNmQzNTE1NDk3L3RhYmxlOjU0MjkzMDQ2ZWJiMjRjNjdhZWI0NmZhZmM1ZjNjNTdhL3RhYmxlcmFuZ2U6NTQyOTMwNDZlYmIyNGM2N2FlYjQ2ZmFmYzVmM2M1N2FfNi0zLTEtMS0yMTE5MQ_f3527def-6ae5-47d6-86dd-5d026cc04ac7">77,288</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231" decimals="-3" name="us-gaap:GoodwillAcquiredDuringPeriod" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM183MC9mcmFnOmIxYjdhNmFmNjEzYzQ3NWM5ZGI4Y2JlNmQzNTE1NDk3L3RhYmxlOjU0MjkzMDQ2ZWJiMjRjNjdhZWI0NmZhZmM1ZjNjNTdhL3RhYmxlcmFuZ2U6NTQyOTMwNDZlYmIyNGM2N2FlYjQ2ZmFmYzVmM2M1N2FfNi01LTEtMS0yMTE5OQ_907d03a3-cce2-4dec-9e6d-581662916ec3">77,288</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency translation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i98988f30813349e1a5594e72b40af5b1_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:GoodwillForeignCurrencyTranslationGainLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM183MC9mcmFnOmIxYjdhNmFmNjEzYzQ3NWM5ZGI4Y2JlNmQzNTE1NDk3L3RhYmxlOjU0MjkzMDQ2ZWJiMjRjNjdhZWI0NmZhZmM1ZjNjNTdhL3RhYmxlcmFuZ2U6NTQyOTMwNDZlYmIyNGM2N2FlYjQ2ZmFmYzVmM2M1N2FfNy0xLTEtMS0yMTIwOQ_75b9c87b-df99-405c-a74e-90dd6ad5e146">20</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6d991ef4e2e0416f8c7aaaa6175cf843_D20210101-20211231" decimals="-3" name="us-gaap:GoodwillForeignCurrencyTranslationGainLoss" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM183MC9mcmFnOmIxYjdhNmFmNjEzYzQ3NWM5ZGI4Y2JlNmQzNTE1NDk3L3RhYmxlOjU0MjkzMDQ2ZWJiMjRjNjdhZWI0NmZhZmM1ZjNjNTdhL3RhYmxlcmFuZ2U6NTQyOTMwNDZlYmIyNGM2N2FlYjQ2ZmFmYzVmM2M1N2FfNy0zLTEtMS0yMTIxNA_41ab3ca8-90a2-4caf-ba2d-01105f3da480">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:GoodwillForeignCurrencyTranslationGainLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM183MC9mcmFnOmIxYjdhNmFmNjEzYzQ3NWM5ZGI4Y2JlNmQzNTE1NDk3L3RhYmxlOjU0MjkzMDQ2ZWJiMjRjNjdhZWI0NmZhZmM1ZjNjNTdhL3RhYmxlcmFuZ2U6NTQyOTMwNDZlYmIyNGM2N2FlYjQ2ZmFmYzVmM2M1N2FfNy01LTEtMS0yMTIyMg_cf56fd3f-1448-49d2-82fa-1d4a5f775de6">20</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of December 31, 2021</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icdbca3fab4684e269937d4a61379d67f_I20211231" decimals="-3" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM183MC9mcmFnOmIxYjdhNmFmNjEzYzQ3NWM5ZGI4Y2JlNmQzNTE1NDk3L3RhYmxlOjU0MjkzMDQ2ZWJiMjRjNjdhZWI0NmZhZmM1ZjNjNTdhL3RhYmxlcmFuZ2U6NTQyOTMwNDZlYmIyNGM2N2FlYjQ2ZmFmYzVmM2M1N2FfOC0xLTEtMS0yMTIyNw_4c644c9c-861a-40cf-9d43-88a5b25d7996">214,334</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie09b385083554dfe92dc601254dfdda8_I20211231" decimals="-3" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM183MC9mcmFnOmIxYjdhNmFmNjEzYzQ3NWM5ZGI4Y2JlNmQzNTE1NDk3L3RhYmxlOjU0MjkzMDQ2ZWJiMjRjNjdhZWI0NmZhZmM1ZjNjNTdhL3RhYmxlcmFuZ2U6NTQyOTMwNDZlYmIyNGM2N2FlYjQ2ZmFmYzVmM2M1N2FfOC0zLTEtMS0yMTIzMg_1976e705-df90-4e8a-b9c0-d27ec32c3670">211,963</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8daff60be410426d8f7bd49343c1ec0c_I20211231" decimals="-3" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM183MC9mcmFnOmIxYjdhNmFmNjEzYzQ3NWM5ZGI4Y2JlNmQzNTE1NDk3L3RhYmxlOjU0MjkzMDQ2ZWJiMjRjNjdhZWI0NmZhZmM1ZjNjNTdhL3RhYmxlcmFuZ2U6NTQyOTMwNDZlYmIyNGM2N2FlYjQ2ZmFmYzVmM2M1N2FfOC01LTEtMS0yMTI0MA_d8560f96-329b-472d-ad51-6fc4c5d38bb3">426,297</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt">Net of cumulative inception to date impairment of $<ix:nonFraction unitRef="usd" contextRef="ibc0c0c2b8dc04c5698ca0577a54b2e03_I20201231" decimals="-5" name="us-gaap:GoodwillImpairedAccumulatedImpairmentLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM183MC9mcmFnOmIxYjdhNmFmNjEzYzQ3NWM5ZGI4Y2JlNmQzNTE1NDk3L3RleHRyZWdpb246YjFiN2E2YWY2MTNjNDc1YzlkYjhjYmU2ZDM1MTU0OTdfNzQ1MA_01412ce1-c4a1-47d6-bf76-e901dff2b712">575.5</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="icba6e493923b449aa57c46a563760234_I20191231" decimals="-5" name="us-gaap:GoodwillImpairedAccumulatedImpairmentLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM183MC9mcmFnOmIxYjdhNmFmNjEzYzQ3NWM5ZGI4Y2JlNmQzNTE1NDk3L3RleHRyZWdpb246YjFiN2E2YWY2MTNjNDc1YzlkYjhjYmU2ZDM1MTU0OTdfNzQ1Nw_8247f5c6-6406-47b5-b300-496348082a89">360.4</ix:nonFraction> million as of December 31, 2020 and 2019, respectively.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt">Goodwill written-off upon disposal of a consolidated subsidiary.</span></div></ix:nonNumeric><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Intangible Assets, Net</span></div><div style="text-align:justify"><span><br/></span></div><ix:continuation id="if729c6e414c04966af3dc51a5112f71b"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Details of our intangible assets (in thousands, except weighted-average useful lives) as of December&#160;31, 2021 and December&#160;31, 2020  are presented below:</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"></td><td style="width:72.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:54.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:48.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:63.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:46.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:54.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:48.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:63.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:45.25pt"></td><td style="width:1.0pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr style="height:44pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted- Average Remaining Useful Life</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross Carrying Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Accumulated Amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net Carrying Value</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted- Average Remaining Useful Life</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross Carrying Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Accumulated Amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net Carrying Value</span></td></tr><tr style="height:24pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate trade name</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ie58c5dcefe64400fa99a44a4db35e02d_D20210101-20211231" name="us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM183MC9mcmFnOmIxYjdhNmFmNjEzYzQ3NWM5ZGI4Y2JlNmQzNTE1NDk3L3RhYmxlOmM0ZGIzYWY3Y2RlYTQ3MTQ5Y2ZhYzhiZmJmNmQ1NDViL3RhYmxlcmFuZ2U6YzRkYjNhZjdjZGVhNDcxNDljZmFjOGJmYmY2ZDU0NWJfMi0xLTEtMS0xNzc3NQ_73a528b9-8b0e-4207-ad6d-a9f9e7b17955">12.4</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if54550ac07374463b0640b875a8f1164_I20211231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM183MC9mcmFnOmIxYjdhNmFmNjEzYzQ3NWM5ZGI4Y2JlNmQzNTE1NDk3L3RhYmxlOmM0ZGIzYWY3Y2RlYTQ3MTQ5Y2ZhYzhiZmJmNmQ1NDViL3RhYmxlcmFuZ2U6YzRkYjNhZjdjZGVhNDcxNDljZmFjOGJmYmY2ZDU0NWJfMi0zLTEtMS0xNzc3NQ_426546ce-30cd-4423-85c5-802f099397de">25,800</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if54550ac07374463b0640b875a8f1164_I20211231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM183MC9mcmFnOmIxYjdhNmFmNjEzYzQ3NWM5ZGI4Y2JlNmQzNTE1NDk3L3RhYmxlOmM0ZGIzYWY3Y2RlYTQ3MTQ5Y2ZhYzhiZmJmNmQ1NDViL3RhYmxlcmFuZ2U6YzRkYjNhZjdjZGVhNDcxNDljZmFjOGJmYmY2ZDU0NWJfMi01LTEtMS0xNzc3NQ_5ec0de42-7697-468f-a613-f15eca6580f5">7,693</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if54550ac07374463b0640b875a8f1164_I20211231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM183MC9mcmFnOmIxYjdhNmFmNjEzYzQ3NWM5ZGI4Y2JlNmQzNTE1NDk3L3RhYmxlOmM0ZGIzYWY3Y2RlYTQ3MTQ5Y2ZhYzhiZmJmNmQ1NDViL3RhYmxlcmFuZ2U6YzRkYjNhZjdjZGVhNDcxNDljZmFjOGJmYmY2ZDU0NWJfMi03LTEtMS0xNzc3NQ_11c468e8-1c06-4762-90c0-8d52d183ecab">18,107</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ie1ed53b5943b4889b309941737607d78_D20200101-20201231" name="us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM183MC9mcmFnOmIxYjdhNmFmNjEzYzQ3NWM5ZGI4Y2JlNmQzNTE1NDk3L3RhYmxlOmM0ZGIzYWY3Y2RlYTQ3MTQ5Y2ZhYzhiZmJmNmQ1NDViL3RhYmxlcmFuZ2U6YzRkYjNhZjdjZGVhNDcxNDljZmFjOGJmYmY2ZDU0NWJfMi05LTEtMS0xNzc3NQ_f76130c4-d061-4f52-8aa6-9e261933b426">13.2</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if0eedc514d0a4637960f12892dff3179_I20201231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM183MC9mcmFnOmIxYjdhNmFmNjEzYzQ3NWM5ZGI4Y2JlNmQzNTE1NDk3L3RhYmxlOmM0ZGIzYWY3Y2RlYTQ3MTQ5Y2ZhYzhiZmJmNmQ1NDViL3RhYmxlcmFuZ2U6YzRkYjNhZjdjZGVhNDcxNDljZmFjOGJmYmY2ZDU0NWJfMi0xMS0xLTEtMTc3NzU_9b8eb0cd-3f6b-420e-be9a-349b1b09d770">23,300</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if0eedc514d0a4637960f12892dff3179_I20201231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM183MC9mcmFnOmIxYjdhNmFmNjEzYzQ3NWM5ZGI4Y2JlNmQzNTE1NDk3L3RhYmxlOmM0ZGIzYWY3Y2RlYTQ3MTQ5Y2ZhYzhiZmJmNmQ1NDViL3RhYmxlcmFuZ2U6YzRkYjNhZjdjZGVhNDcxNDljZmFjOGJmYmY2ZDU0NWJfMi0xMy0xLTEtMTc3NzU_47899088-cb1a-4f60-b0e6-577163db53e4">6,271</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if0eedc514d0a4637960f12892dff3179_I20201231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM183MC9mcmFnOmIxYjdhNmFmNjEzYzQ3NWM5ZGI4Y2JlNmQzNTE1NDk3L3RhYmxlOmM0ZGIzYWY3Y2RlYTQ3MTQ5Y2ZhYzhiZmJmNmQ1NDViL3RhYmxlcmFuZ2U6YzRkYjNhZjdjZGVhNDcxNDljZmFjOGJmYmY2ZDU0NWJfMi0xNS0xLTEtMTc3NzU_cfa97264-d497-4422-a9f5-529096de20f7">17,029</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:24pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer relationships </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i202c773f013e42dbaf2ed35f08ba74e4_D20210101-20211231" name="us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM183MC9mcmFnOmIxYjdhNmFmNjEzYzQ3NWM5ZGI4Y2JlNmQzNTE1NDk3L3RhYmxlOmM0ZGIzYWY3Y2RlYTQ3MTQ5Y2ZhYzhiZmJmNmQ1NDViL3RhYmxlcmFuZ2U6YzRkYjNhZjdjZGVhNDcxNDljZmFjOGJmYmY2ZDU0NWJfMy0xLTEtMS0xNzc3NQ_2636f3af-635e-4dd9-a8d8-b4fc11d470ee">14.9</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i71517c3f53a942378a08da469cfdd069_I20211231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM183MC9mcmFnOmIxYjdhNmFmNjEzYzQ3NWM5ZGI4Y2JlNmQzNTE1NDk3L3RhYmxlOmM0ZGIzYWY3Y2RlYTQ3MTQ5Y2ZhYzhiZmJmNmQ1NDViL3RhYmxlcmFuZ2U6YzRkYjNhZjdjZGVhNDcxNDljZmFjOGJmYmY2ZDU0NWJfMy0zLTEtMS0xNzc3NQ_9462cc40-c872-4243-8e9a-8dea1ac6d3bd">311,019</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i71517c3f53a942378a08da469cfdd069_I20211231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM183MC9mcmFnOmIxYjdhNmFmNjEzYzQ3NWM5ZGI4Y2JlNmQzNTE1NDk3L3RhYmxlOmM0ZGIzYWY3Y2RlYTQ3MTQ5Y2ZhYzhiZmJmNmQ1NDViL3RhYmxlcmFuZ2U6YzRkYjNhZjdjZGVhNDcxNDljZmFjOGJmYmY2ZDU0NWJfMy01LTEtMS0xNzc3NQ_0382f102-a2fa-4b9b-a50b-52c911b2f335">72,697</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i71517c3f53a942378a08da469cfdd069_I20211231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM183MC9mcmFnOmIxYjdhNmFmNjEzYzQ3NWM5ZGI4Y2JlNmQzNTE1NDk3L3RhYmxlOmM0ZGIzYWY3Y2RlYTQ3MTQ5Y2ZhYzhiZmJmNmQ1NDViL3RhYmxlcmFuZ2U6YzRkYjNhZjdjZGVhNDcxNDljZmFjOGJmYmY2ZDU0NWJfMy03LTEtMS0xNzc3NQ_33bb2216-34d9-48df-aab9-73ab8011aa2c">238,322</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i8af88df592574869bf4e7732fd88234d_D20200101-20201231" name="us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM183MC9mcmFnOmIxYjdhNmFmNjEzYzQ3NWM5ZGI4Y2JlNmQzNTE1NDk3L3RhYmxlOmM0ZGIzYWY3Y2RlYTQ3MTQ5Y2ZhYzhiZmJmNmQ1NDViL3RhYmxlcmFuZ2U6YzRkYjNhZjdjZGVhNDcxNDljZmFjOGJmYmY2ZDU0NWJfMy05LTEtMS0xNzc3NQ_2dbda7e4-ef6b-405a-9986-eab7dea4973b">16.2</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i562af9019b024a169c81d1f41361d631_I20201231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM183MC9mcmFnOmIxYjdhNmFmNjEzYzQ3NWM5ZGI4Y2JlNmQzNTE1NDk3L3RhYmxlOmM0ZGIzYWY3Y2RlYTQ3MTQ5Y2ZhYzhiZmJmNmQ1NDViL3RhYmxlcmFuZ2U6YzRkYjNhZjdjZGVhNDcxNDljZmFjOGJmYmY2ZDU0NWJfMy0xMS0xLTEtMTc3NzU_bf048af1-86bf-473b-a99a-87b6249a2b85">278,519</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i562af9019b024a169c81d1f41361d631_I20201231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM183MC9mcmFnOmIxYjdhNmFmNjEzYzQ3NWM5ZGI4Y2JlNmQzNTE1NDk3L3RhYmxlOmM0ZGIzYWY3Y2RlYTQ3MTQ5Y2ZhYzhiZmJmNmQ1NDViL3RhYmxlcmFuZ2U6YzRkYjNhZjdjZGVhNDcxNDljZmFjOGJmYmY2ZDU0NWJfMy0xMy0xLTEtMTc3NzU_dde09662-a87e-4f85-b07e-61fd713019b4">57,716</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i562af9019b024a169c81d1f41361d631_I20201231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM183MC9mcmFnOmIxYjdhNmFmNjEzYzQ3NWM5ZGI4Y2JlNmQzNTE1NDk3L3RhYmxlOmM0ZGIzYWY3Y2RlYTQ3MTQ5Y2ZhYzhiZmJmNmQ1NDViL3RhYmxlcmFuZ2U6YzRkYjNhZjdjZGVhNDcxNDljZmFjOGJmYmY2ZDU0NWJfMy0xNS0xLTEtMTc3NzU_8dd8beb6-d364-4275-8045-33be27011e35">220,803</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Technology</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i701391050b2e43d082d405d3d16746d2_D20210101-20211231" name="us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM183MC9mcmFnOmIxYjdhNmFmNjEzYzQ3NWM5ZGI4Y2JlNmQzNTE1NDk3L3RhYmxlOmM0ZGIzYWY3Y2RlYTQ3MTQ5Y2ZhYzhiZmJmNmQ1NDViL3RhYmxlcmFuZ2U6YzRkYjNhZjdjZGVhNDcxNDljZmFjOGJmYmY2ZDU0NWJfNC0xLTEtMS0xNzc3NQ_00f7bcbf-845e-40dd-bc92-360e40eb1773">2.0</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9872c8fc2e2849be9d4b8a5ca7abe3dc_I20211231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM183MC9mcmFnOmIxYjdhNmFmNjEzYzQ3NWM5ZGI4Y2JlNmQzNTE1NDk3L3RhYmxlOmM0ZGIzYWY3Y2RlYTQ3MTQ5Y2ZhYzhiZmJmNmQ1NDViL3RhYmxlcmFuZ2U6YzRkYjNhZjdjZGVhNDcxNDljZmFjOGJmYmY2ZDU0NWJfNC0zLTEtMS0xNzc3NQ_d70aad25-d4ec-4959-a25c-69a8e0a3c01e">87,922</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9872c8fc2e2849be9d4b8a5ca7abe3dc_I20211231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM183MC9mcmFnOmIxYjdhNmFmNjEzYzQ3NWM5ZGI4Y2JlNmQzNTE1NDk3L3RhYmxlOmM0ZGIzYWY3Y2RlYTQ3MTQ5Y2ZhYzhiZmJmNmQ1NDViL3RhYmxlcmFuZ2U6YzRkYjNhZjdjZGVhNDcxNDljZmFjOGJmYmY2ZDU0NWJfNC01LTEtMS0xNzc3NQ_cceb6844-dd61-4b46-a5e3-d2000a3bbc5b">73,378</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9872c8fc2e2849be9d4b8a5ca7abe3dc_I20211231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM183MC9mcmFnOmIxYjdhNmFmNjEzYzQ3NWM5ZGI4Y2JlNmQzNTE1NDk3L3RhYmxlOmM0ZGIzYWY3Y2RlYTQ3MTQ5Y2ZhYzhiZmJmNmQ1NDViL3RhYmxlcmFuZ2U6YzRkYjNhZjdjZGVhNDcxNDljZmFjOGJmYmY2ZDU0NWJfNC03LTEtMS0xNzc3NQ_3299c27f-cca3-48a0-9e68-959f95c3ea87">14,544</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i538bb825405f46a9ad4766eb47fd09f0_D20200101-20201231" name="us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM183MC9mcmFnOmIxYjdhNmFmNjEzYzQ3NWM5ZGI4Y2JlNmQzNTE1NDk3L3RhYmxlOmM0ZGIzYWY3Y2RlYTQ3MTQ5Y2ZhYzhiZmJmNmQ1NDViL3RhYmxlcmFuZ2U6YzRkYjNhZjdjZGVhNDcxNDljZmFjOGJmYmY2ZDU0NWJfNC05LTEtMS0xNzc3NQ_9194bbb7-22ff-4160-9ac7-5e3b5c488be0">1.8</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if49e52c6692f4f418b64ecce40eae504_I20201231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM183MC9mcmFnOmIxYjdhNmFmNjEzYzQ3NWM5ZGI4Y2JlNmQzNTE1NDk3L3RhYmxlOmM0ZGIzYWY3Y2RlYTQ3MTQ5Y2ZhYzhiZmJmNmQ1NDViL3RhYmxlcmFuZ2U6YzRkYjNhZjdjZGVhNDcxNDljZmFjOGJmYmY2ZDU0NWJfNC0xMS0xLTEtMTc3NzU_c519bbfb-c23f-4c1d-9f7b-9e1a6ec34b17">82,922</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if49e52c6692f4f418b64ecce40eae504_I20201231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM183MC9mcmFnOmIxYjdhNmFmNjEzYzQ3NWM5ZGI4Y2JlNmQzNTE1NDk3L3RhYmxlOmM0ZGIzYWY3Y2RlYTQ3MTQ5Y2ZhYzhiZmJmNmQ1NDViL3RhYmxlcmFuZ2U6YzRkYjNhZjdjZGVhNDcxNDljZmFjOGJmYmY2ZDU0NWJfNC0xMy0xLTEtMTc3NzU_881d2173-4b13-4d40-afd1-2cd222ea410a">63,507</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if49e52c6692f4f418b64ecce40eae504_I20201231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM183MC9mcmFnOmIxYjdhNmFmNjEzYzQ3NWM5ZGI4Y2JlNmQzNTE1NDk3L3RhYmxlOmM0ZGIzYWY3Y2RlYTQ3MTQ5Y2ZhYzhiZmJmNmQ1NDViL3RhYmxlcmFuZ2U6YzRkYjNhZjdjZGVhNDcxNDljZmFjOGJmYmY2ZDU0NWJfNC0xNS0xLTEtMTc3NzU_765096f2-6593-41c0-aaf9-70778e16465d">19,415</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:24pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Below market lease, net</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="idbec42c300ba44c8b821ff3fa0e1a438_D20210101-20211231" name="us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM183MC9mcmFnOmIxYjdhNmFmNjEzYzQ3NWM5ZGI4Y2JlNmQzNTE1NDk3L3RhYmxlOmM0ZGIzYWY3Y2RlYTQ3MTQ5Y2ZhYzhiZmJmNmQ1NDViL3RhYmxlcmFuZ2U6YzRkYjNhZjdjZGVhNDcxNDljZmFjOGJmYmY2ZDU0NWJfNS0xLTEtMS0xNzc3NQ_80a46397-e879-4d39-9348-669601b224d5">1.3</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i77a25d5d9d13456bafdeb192f90dc6dd_I20211231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM183MC9mcmFnOmIxYjdhNmFmNjEzYzQ3NWM5ZGI4Y2JlNmQzNTE1NDk3L3RhYmxlOmM0ZGIzYWY3Y2RlYTQ3MTQ5Y2ZhYzhiZmJmNmQ1NDViL3RhYmxlcmFuZ2U6YzRkYjNhZjdjZGVhNDcxNDljZmFjOGJmYmY2ZDU0NWJfNS0zLTEtMS0xNzc3NQ_c0d7b370-f296-48f7-a55d-7aa3d5f1aef0">1,218</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i77a25d5d9d13456bafdeb192f90dc6dd_I20211231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM183MC9mcmFnOmIxYjdhNmFmNjEzYzQ3NWM5ZGI4Y2JlNmQzNTE1NDk3L3RhYmxlOmM0ZGIzYWY3Y2RlYTQ3MTQ5Y2ZhYzhiZmJmNmQ1NDViL3RhYmxlcmFuZ2U6YzRkYjNhZjdjZGVhNDcxNDljZmFjOGJmYmY2ZDU0NWJfNS01LTEtMS0xNzc3NQ_2c651885-94d1-4e79-8bed-1cf74e340d04">950</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i77a25d5d9d13456bafdeb192f90dc6dd_I20211231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM183MC9mcmFnOmIxYjdhNmFmNjEzYzQ3NWM5ZGI4Y2JlNmQzNTE1NDk3L3RhYmxlOmM0ZGIzYWY3Y2RlYTQ3MTQ5Y2ZhYzhiZmJmNmQ1NDViL3RhYmxlcmFuZ2U6YzRkYjNhZjdjZGVhNDcxNDljZmFjOGJmYmY2ZDU0NWJfNS03LTEtMS0xNzc3NQ_12a21485-9f96-4c49-b37b-f6adfc182d6c">268</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="id03edbc8f3a0467fb3003d024d0d20bf_D20200101-20201231" name="us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM183MC9mcmFnOmIxYjdhNmFmNjEzYzQ3NWM5ZGI4Y2JlNmQzNTE1NDk3L3RhYmxlOmM0ZGIzYWY3Y2RlYTQ3MTQ5Y2ZhYzhiZmJmNmQ1NDViL3RhYmxlcmFuZ2U6YzRkYjNhZjdjZGVhNDcxNDljZmFjOGJmYmY2ZDU0NWJfNS05LTEtMS0xNzc3NQ_a804101a-b221-4a47-84f2-837721367f8f">2.3</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5b2c8aeaa33341d0b0241d264ebd0409_I20201231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM183MC9mcmFnOmIxYjdhNmFmNjEzYzQ3NWM5ZGI4Y2JlNmQzNTE1NDk3L3RhYmxlOmM0ZGIzYWY3Y2RlYTQ3MTQ5Y2ZhYzhiZmJmNmQ1NDViL3RhYmxlcmFuZ2U6YzRkYjNhZjdjZGVhNDcxNDljZmFjOGJmYmY2ZDU0NWJfNS0xMS0xLTEtMTc3NzU_3a803c6d-fc9a-48d9-83af-36e6f83c139f">1,118</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5b2c8aeaa33341d0b0241d264ebd0409_I20201231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM183MC9mcmFnOmIxYjdhNmFmNjEzYzQ3NWM5ZGI4Y2JlNmQzNTE1NDk3L3RhYmxlOmM0ZGIzYWY3Y2RlYTQ3MTQ5Y2ZhYzhiZmJmNmQ1NDViL3RhYmxlcmFuZ2U6YzRkYjNhZjdjZGVhNDcxNDljZmFjOGJmYmY2ZDU0NWJfNS0xMy0xLTEtMTc3NzU_cf114ad2-a172-4947-b1bd-abc365e34043">648</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5b2c8aeaa33341d0b0241d264ebd0409_I20201231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM183MC9mcmFnOmIxYjdhNmFmNjEzYzQ3NWM5ZGI4Y2JlNmQzNTE1NDk3L3RhYmxlOmM0ZGIzYWY3Y2RlYTQ3MTQ5Y2ZhYzhiZmJmNmQ1NDViL3RhYmxlcmFuZ2U6YzRkYjNhZjdjZGVhNDcxNDljZmFjOGJmYmY2ZDU0NWJfNS0xNS0xLTEtMTc3NzU_31f09b62-676c-47f1-9bec-751c11867f82">470</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:35pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provider network contracts </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i5bc515c9cd944501946244b550d6dea8_D20210101-20211231" name="us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM183MC9mcmFnOmIxYjdhNmFmNjEzYzQ3NWM5ZGI4Y2JlNmQzNTE1NDk3L3RhYmxlOmM0ZGIzYWY3Y2RlYTQ3MTQ5Y2ZhYzhiZmJmNmQ1NDViL3RhYmxlcmFuZ2U6YzRkYjNhZjdjZGVhNDcxNDljZmFjOGJmYmY2ZDU0NWJfNi0xLTEtMS0xNzc3NQ_7cbacfa8-b523-4b80-bbcc-ec8afc0cddff">2.2</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i73d07853890d4173bfcafe5a74c9aedf_I20211231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM183MC9mcmFnOmIxYjdhNmFmNjEzYzQ3NWM5ZGI4Y2JlNmQzNTE1NDk3L3RhYmxlOmM0ZGIzYWY3Y2RlYTQ3MTQ5Y2ZhYzhiZmJmNmQ1NDViL3RhYmxlcmFuZ2U6YzRkYjNhZjdjZGVhNDcxNDljZmFjOGJmYmY2ZDU0NWJfNi0zLTEtMS0xNzc3NQ_521ab21e-1656-4a7c-bd21-466a847010bd">16,417</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i73d07853890d4173bfcafe5a74c9aedf_I20211231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM183MC9mcmFnOmIxYjdhNmFmNjEzYzQ3NWM5ZGI4Y2JlNmQzNTE1NDk3L3RhYmxlOmM0ZGIzYWY3Y2RlYTQ3MTQ5Y2ZhYzhiZmJmNmQ1NDViL3RhYmxlcmFuZ2U6YzRkYjNhZjdjZGVhNDcxNDljZmFjOGJmYmY2ZDU0NWJfNi01LTEtMS0xNzc3NQ_0135a807-9c4a-4aa3-beca-656aa905f404">7,874</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i73d07853890d4173bfcafe5a74c9aedf_I20211231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM183MC9mcmFnOmIxYjdhNmFmNjEzYzQ3NWM5ZGI4Y2JlNmQzNTE1NDk3L3RhYmxlOmM0ZGIzYWY3Y2RlYTQ3MTQ5Y2ZhYzhiZmJmNmQ1NDViL3RhYmxlcmFuZ2U6YzRkYjNhZjdjZGVhNDcxNDljZmFjOGJmYmY2ZDU0NWJfNi03LTEtMS0xNzc3NQ_f342b040-31a6-470f-91ef-f6ce519ffc04">8,543</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i4865a0a60cf141238d2403348647421d_D20200101-20201231" name="us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM183MC9mcmFnOmIxYjdhNmFmNjEzYzQ3NWM5ZGI4Y2JlNmQzNTE1NDk3L3RhYmxlOmM0ZGIzYWY3Y2RlYTQ3MTQ5Y2ZhYzhiZmJmNmQ1NDViL3RhYmxlcmFuZ2U6YzRkYjNhZjdjZGVhNDcxNDljZmFjOGJmYmY2ZDU0NWJfNi05LTEtMS0xNzc3NQ_53a0927c-6eef-482b-91ab-df0758b04c43">2.9</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2916f379be034a929416cb11c770e888_I20201231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM183MC9mcmFnOmIxYjdhNmFmNjEzYzQ3NWM5ZGI4Y2JlNmQzNTE1NDk3L3RhYmxlOmM0ZGIzYWY3Y2RlYTQ3MTQ5Y2ZhYzhiZmJmNmQ1NDViL3RhYmxlcmFuZ2U6YzRkYjNhZjdjZGVhNDcxNDljZmFjOGJmYmY2ZDU0NWJfNi0xMS0xLTEtMTc3NzU_e3bbf0d0-3f11-478b-985c-e9622546815b">12,175</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2916f379be034a929416cb11c770e888_I20201231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM183MC9mcmFnOmIxYjdhNmFmNjEzYzQ3NWM5ZGI4Y2JlNmQzNTE1NDk3L3RhYmxlOmM0ZGIzYWY3Y2RlYTQ3MTQ5Y2ZhYzhiZmJmNmQ1NDViL3RhYmxlcmFuZ2U6YzRkYjNhZjdjZGVhNDcxNDljZmFjOGJmYmY2ZDU0NWJfNi0xMy0xLTEtMTc3NzU_0da4681d-9570-48cf-b335-d938319eaaad">4,900</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2916f379be034a929416cb11c770e888_I20201231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM183MC9mcmFnOmIxYjdhNmFmNjEzYzQ3NWM5ZGI4Y2JlNmQzNTE1NDk3L3RhYmxlOmM0ZGIzYWY3Y2RlYTQ3MTQ5Y2ZhYzhiZmJmNmQ1NDViL3RhYmxlcmFuZ2U6YzRkYjNhZjdjZGVhNDcxNDljZmFjOGJmYmY2ZDU0NWJfNi0xNS0xLTEtMTc3NzU_495c92d4-230a-4ffc-aeac-4ad52553f945">7,275</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:35pt"><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total intangible assets, net</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8daff60be410426d8f7bd49343c1ec0c_I20211231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM183MC9mcmFnOmIxYjdhNmFmNjEzYzQ3NWM5ZGI4Y2JlNmQzNTE1NDk3L3RhYmxlOmM0ZGIzYWY3Y2RlYTQ3MTQ5Y2ZhYzhiZmJmNmQ1NDViL3RhYmxlcmFuZ2U6YzRkYjNhZjdjZGVhNDcxNDljZmFjOGJmYmY2ZDU0NWJfNy0zLTEtMS0xNzc3NQ_8c97145a-2f6c-48a1-92f1-4639efd8c5ed">442,376</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8daff60be410426d8f7bd49343c1ec0c_I20211231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM183MC9mcmFnOmIxYjdhNmFmNjEzYzQ3NWM5ZGI4Y2JlNmQzNTE1NDk3L3RhYmxlOmM0ZGIzYWY3Y2RlYTQ3MTQ5Y2ZhYzhiZmJmNmQ1NDViL3RhYmxlcmFuZ2U6YzRkYjNhZjdjZGVhNDcxNDljZmFjOGJmYmY2ZDU0NWJfNy01LTEtMS0xNzc3NQ_105abf74-b3bb-480a-9e19-db5f1646868c">162,592</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8daff60be410426d8f7bd49343c1ec0c_I20211231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM183MC9mcmFnOmIxYjdhNmFmNjEzYzQ3NWM5ZGI4Y2JlNmQzNTE1NDk3L3RhYmxlOmM0ZGIzYWY3Y2RlYTQ3MTQ5Y2ZhYzhiZmJmNmQ1NDViL3RhYmxlcmFuZ2U6YzRkYjNhZjdjZGVhNDcxNDljZmFjOGJmYmY2ZDU0NWJfNy03LTEtMS0xNzc3NQ_23b890fc-9d77-41b9-8586-dc1d876eac8b">279,784</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc0c0c2b8dc04c5698ca0577a54b2e03_I20201231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM183MC9mcmFnOmIxYjdhNmFmNjEzYzQ3NWM5ZGI4Y2JlNmQzNTE1NDk3L3RhYmxlOmM0ZGIzYWY3Y2RlYTQ3MTQ5Y2ZhYzhiZmJmNmQ1NDViL3RhYmxlcmFuZ2U6YzRkYjNhZjdjZGVhNDcxNDljZmFjOGJmYmY2ZDU0NWJfNy0xMS0xLTEtMTc3NzU_f2d8f16b-6365-42b3-aa89-642fd8e2f7e6">398,034</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc0c0c2b8dc04c5698ca0577a54b2e03_I20201231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM183MC9mcmFnOmIxYjdhNmFmNjEzYzQ3NWM5ZGI4Y2JlNmQzNTE1NDk3L3RhYmxlOmM0ZGIzYWY3Y2RlYTQ3MTQ5Y2ZhYzhiZmJmNmQ1NDViL3RhYmxlcmFuZ2U6YzRkYjNhZjdjZGVhNDcxNDljZmFjOGJmYmY2ZDU0NWJfNy0xMy0xLTEtMTc3NzU_e24c16ab-42f8-4494-bdb0-c215aa0bb0ff">133,042</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc0c0c2b8dc04c5698ca0577a54b2e03_I20201231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM183MC9mcmFnOmIxYjdhNmFmNjEzYzQ3NWM5ZGI4Y2JlNmQzNTE1NDk3L3RhYmxlOmM0ZGIzYWY3Y2RlYTQ3MTQ5Y2ZhYzhiZmJmNmQ1NDViL3RhYmxlcmFuZ2U6YzRkYjNhZjdjZGVhNDcxNDljZmFjOGJmYmY2ZDU0NWJfNy0xNS0xLTEtMTc3NzU_b82032d1-1541-41e8-b086-4ef6dab04f97">264,992</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt">Amounts exclude $<ix:nonFraction unitRef="usd" contextRef="ie6213ed773f940469197c948c85ce078_I20201231" decimals="-5" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM183MC9mcmFnOmIxYjdhNmFmNjEzYzQ3NWM5ZGI4Y2JlNmQzNTE1NDk3L3RleHRyZWdpb246YjFiN2E2YWY2MTNjNDc1YzlkYjhjYmU2ZDM1MTU0OTdfNzc1MQ_f2c31656-8f0b-44ed-95b9-dddc85d472aa">2.2</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i886c543278f24614931e52b2326361a9_I20201231" decimals="-5" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM183MC9mcmFnOmIxYjdhNmFmNjEzYzQ3NWM5ZGI4Y2JlNmQzNTE1NDk3L3RleHRyZWdpb246YjFiN2E2YWY2MTNjNDc1YzlkYjhjYmU2ZDM1MTU0OTdfNzc1OA_4a4f88cd-a300-4d38-bb2e-15742f1b9172">0.9</ix:nonFraction>&#160;million of customer relationships and provider network contracts, respectively, net of accumulated amortization, with weighted average remaining useful lives of <ix:nonNumeric contextRef="i83a4805b397642c7825f71f6f96da143_D20200101-20201231" name="us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM183MC9mcmFnOmIxYjdhNmFmNjEzYzQ3NWM5ZGI4Y2JlNmQzNTE1NDk3L3RleHRyZWdpb246YjFiN2E2YWY2MTNjNDc1YzlkYjhjYmU2ZDM1MTU0OTdfNzkxNA_3070ca93-72f2-4d62-80f0-fbb9b1ec8dbe">15</ix:nonNumeric> years and <ix:nonNumeric contextRef="ib096ee77af354199bc615f81ee527eaa_D20200101-20201231" name="us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" format="ixt-sec:durmonth" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM183MC9mcmFnOmIxYjdhNmFmNjEzYzQ3NWM5ZGI4Y2JlNmQzNTE1NDk3L3RleHRyZWdpb246YjFiN2E2YWY2MTNjNDc1YzlkYjhjYmU2ZDM1MTU0OTdfNzkyMQ_eb6d0ce2-3123-4369-95f4-591fbd4e93b1">10</ix:nonNumeric> months reclassified to discontinued operations as of December&#160;31, 2020.</span></div></ix:continuation><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amortization expense related to intangible assets for the years ended December 31, 2021, 2020 and 2019, was $<ix:nonFraction unitRef="usd" contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231" decimals="-5" name="us-gaap:AmortizationOfIntangibleAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM183MC9mcmFnOmIxYjdhNmFmNjEzYzQ3NWM5ZGI4Y2JlNmQzNTE1NDk3L3RleHRyZWdpb246YjFiN2E2YWY2MTNjNDc1YzlkYjhjYmU2ZDM1MTU0OTdfODA0MA_4f627e2e-339a-4685-9e79-cd4c5983e125">29.4</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="i12a6d1161de54547bd29f8efccd4c9b0_D20200101-20201231" decimals="-5" name="us-gaap:AmortizationOfIntangibleAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM183MC9mcmFnOmIxYjdhNmFmNjEzYzQ3NWM5ZGI4Y2JlNmQzNTE1NDk3L3RleHRyZWdpb246YjFiN2E2YWY2MTNjNDc1YzlkYjhjYmU2ZDM1MTU0OTdfODEyMg_73e3a2ad-94b9-4ad0-ae6f-176770b62d55">32.3</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i3e21049ffc224cacb8134d73c9bb5b38_D20190101-20191231" decimals="-5" name="us-gaap:AmortizationOfIntangibleAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM183MC9mcmFnOmIxYjdhNmFmNjEzYzQ3NWM5ZGI4Y2JlNmQzNTE1NDk3L3RleHRyZWdpb246YjFiN2E2YWY2MTNjNDc1YzlkYjhjYmU2ZDM1MTU0OTdfMTA5OTUxMTYzNzE2OQ_3b3bbb50-d88b-473d-99aa-6d0b114448ae">37.1</ix:nonFraction> million respectively, excluding $<ix:nonFraction unitRef="usd" contextRef="i1c4a293e5ce54724af5effd8253d4d89_D20210101-20211231" decimals="-5" name="us-gaap:AmortizationOfIntangibleAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM183MC9mcmFnOmIxYjdhNmFmNjEzYzQ3NWM5ZGI4Y2JlNmQzNTE1NDk3L3RleHRyZWdpb246YjFiN2E2YWY2MTNjNDc1YzlkYjhjYmU2ZDM1MTU0OTdfMjE5OTAyMzI2ODEyNA_28f8b05a-268d-4fc6-b8dc-015b4dfd891a">0.2</ix:nonFraction>&#160;million, $<ix:nonFraction unitRef="usd" contextRef="if7ba948ef00b4ddeabe73338f1155e8b_D20200101-20201231" decimals="-5" name="us-gaap:AmortizationOfIntangibleAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM183MC9mcmFnOmIxYjdhNmFmNjEzYzQ3NWM5ZGI4Y2JlNmQzNTE1NDk3L3RleHRyZWdpb246YjFiN2E2YWY2MTNjNDc1YzlkYjhjYmU2ZDM1MTU0OTdfODE1Nw_cdd78c6c-b488-4351-adc5-5bf73d469b9e">0.6</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="iae6c9a536db44d69b64c473850d09499_D20190101-20191231" decimals="-5" name="us-gaap:AmortizationOfIntangibleAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM183MC9mcmFnOmIxYjdhNmFmNjEzYzQ3NWM5ZGI4Y2JlNmQzNTE1NDk3L3RleHRyZWdpb246YjFiN2E2YWY2MTNjNDc1YzlkYjhjYmU2ZDM1MTU0OTdfMTA5OTUxMTYzNzAwOA_a75a2702-2419-4431-8f45-70b6c4a1ba1b">0.6</ix:nonFraction>&#160;million of amortization expense related to discontinued operations for the years ended December 31, 2021, 2020 and 2019, respectively.</span></div></ix:continuation><div style="text-align:justify"><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">92</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="ic424e6b6eb214a6f9322a4103d405483"><ix:nonNumeric contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231" name="us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM183MC9mcmFnOmIxYjdhNmFmNjEzYzQ3NWM5ZGI4Y2JlNmQzNTE1NDk3L3RleHRyZWdpb246YjFiN2E2YWY2MTNjNDc1YzlkYjhjYmU2ZDM1MTU0OTdfODYyMw_8b53952d-abb5-45fa-a816-9ae6b01745f4" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Future estimated amortization of intangible assets (in thousands) as of December&#160;31, 2021, is as follows:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"></td><td style="width:478.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:58.00pt"></td><td style="width:1.0pt"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8daff60be410426d8f7bd49343c1ec0c_I20211231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM183MC9mcmFnOmIxYjdhNmFmNjEzYzQ3NWM5ZGI4Y2JlNmQzNTE1NDk3L3RhYmxlOjVhZGViNTY2ZGFlNzQ0MjA4NTM2Njc3NWU5ZDE1MzMzL3RhYmxlcmFuZ2U6NWFkZWI1NjZkYWU3NDQyMDg1MzY2Nzc1ZTlkMTUzMzNfMC0xLTEtMS0xNzc3NQ_181bf812-2381-4fe8-b98e-66ce43e597a5">29,102</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8daff60be410426d8f7bd49343c1ec0c_I20211231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM183MC9mcmFnOmIxYjdhNmFmNjEzYzQ3NWM5ZGI4Y2JlNmQzNTE1NDk3L3RhYmxlOjVhZGViNTY2ZGFlNzQ0MjA4NTM2Njc3NWU5ZDE1MzMzL3RhYmxlcmFuZ2U6NWFkZWI1NjZkYWU3NDQyMDg1MzY2Nzc1ZTlkMTUzMzNfMS0xLTEtMS0xNzc3NQ_f00e23bf-4218-4d98-859c-3fe89ad78c2c">26,798</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8daff60be410426d8f7bd49343c1ec0c_I20211231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM183MC9mcmFnOmIxYjdhNmFmNjEzYzQ3NWM5ZGI4Y2JlNmQzNTE1NDk3L3RhYmxlOjVhZGViNTY2ZGFlNzQ0MjA4NTM2Njc3NWU5ZDE1MzMzL3RhYmxlcmFuZ2U6NWFkZWI1NjZkYWU3NDQyMDg1MzY2Nzc1ZTlkMTUzMzNfMi0xLTEtMS0xNzc3NQ_9653138d-56d7-4cb7-97fc-fb530852ae32">20,913</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8daff60be410426d8f7bd49343c1ec0c_I20211231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM183MC9mcmFnOmIxYjdhNmFmNjEzYzQ3NWM5ZGI4Y2JlNmQzNTE1NDk3L3RhYmxlOjVhZGViNTY2ZGFlNzQ0MjA4NTM2Njc3NWU5ZDE1MzMzL3RhYmxlcmFuZ2U6NWFkZWI1NjZkYWU3NDQyMDg1MzY2Nzc1ZTlkMTUzMzNfMy0xLTEtMS0xNzc3NQ_39fdfa66-b09a-4dc5-922b-0ffae57b58a1">19,403</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8daff60be410426d8f7bd49343c1ec0c_I20211231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM183MC9mcmFnOmIxYjdhNmFmNjEzYzQ3NWM5ZGI4Y2JlNmQzNTE1NDk3L3RhYmxlOjVhZGViNTY2ZGFlNzQ0MjA4NTM2Njc3NWU5ZDE1MzMzL3RhYmxlcmFuZ2U6NWFkZWI1NjZkYWU3NDQyMDg1MzY2Nzc1ZTlkMTUzMzNfNC0xLTEtMS0xNzc3NQ_cf9193a3-891c-43a7-8efb-485030a4ba83">19,153</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8daff60be410426d8f7bd49343c1ec0c_I20211231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM183MC9mcmFnOmIxYjdhNmFmNjEzYzQ3NWM5ZGI4Y2JlNmQzNTE1NDk3L3RhYmxlOjVhZGViNTY2ZGFlNzQ0MjA4NTM2Njc3NWU5ZDE1MzMzL3RhYmxlcmFuZ2U6NWFkZWI1NjZkYWU3NDQyMDg1MzY2Nzc1ZTlkMTUzMzNfNS0xLTEtMS0xNzc3NQ_e3395371-2799-48a3-b732-23ba24a8e524">164,415</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total future amortization of intangible assets</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8daff60be410426d8f7bd49343c1ec0c_I20211231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM183MC9mcmFnOmIxYjdhNmFmNjEzYzQ3NWM5ZGI4Y2JlNmQzNTE1NDk3L3RhYmxlOjVhZGViNTY2ZGFlNzQ0MjA4NTM2Njc3NWU5ZDE1MzMzL3RhYmxlcmFuZ2U6NWFkZWI1NjZkYWU3NDQyMDg1MzY2Nzc1ZTlkMTUzMzNfNi0xLTEtMS0xNzc3NQ_6f04266a-f2e8-4f1e-8e38-10502a130397">279,784</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets are reviewed for impairment if circumstances indicate the Company may not be able to recover the assets&#8217; carrying value. We did not identify any circumstances during&#160;the year ended December 31, 2021, that would require an impairment test for our intangible assets.</span></div></ix:continuation><div style="text-align:justify"><span><br/></span></div><div id="i9aaa2fddc97e482da5dbe37ac85ae703_73"></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 10.  <ix:nonNumeric contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231" name="us-gaap:DebtDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM183My9mcmFnOjU3M2ZmODBkMmIzNDQ0MTlhMzdlOTRhZjRhNjk0MTBkL3RleHRyZWdpb246NTczZmY4MGQyYjM0NDQxOWEzN2U5NGFmNGE2OTQxMGRfMjExMjM_5613be9e-9566-4711-b469-db5ea6bf73e2" continuedAt="ida7a0e1696404d3bb22c16e7f1ebfec0" escape="true">Long-term Debt</ix:nonNumeric></span></div><div style="text-align:justify"><span><br/></span></div><ix:continuation id="ida7a0e1696404d3bb22c16e7f1ebfec0" continuedAt="id0a7ae7407e74dd4ad63a45e3fa9e72f"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2024 Notes</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2020, the Company issued $<ix:nonFraction unitRef="usd" contextRef="i04c13e91bd034f30a0f4a7c989fc5940_I20200831" decimals="INF" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM183My9mcmFnOjU3M2ZmODBkMmIzNDQ0MTlhMzdlOTRhZjRhNjk0MTBkL3RleHRyZWdpb246NTczZmY4MGQyYjM0NDQxOWEzN2U5NGFmNGE2OTQxMGRfNzg_574bcff7-500c-4499-9d34-8c27e733a868">117.1</ix:nonFraction>&#160;million aggregate principal amount of its <ix:nonFraction unitRef="number" contextRef="i04c13e91bd034f30a0f4a7c989fc5940_I20200831" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM183My9mcmFnOjU3M2ZmODBkMmIzNDQ0MTlhMzdlOTRhZjRhNjk0MTBkL3RleHRyZWdpb246NTczZmY4MGQyYjM0NDQxOWEzN2U5NGFmNGE2OTQxMGRfMTE1_ea74df94-0dfd-4346-bbd3-e26875bd87db">3.50</ix:nonFraction>% Convertible Senior Notes due 2024 (the &#8220;2024 Notes&#8221;) in privately negotiated exchange and/or subscription agreements, with certain holders of its outstanding 2021 Notes and certain new investors. The Company issued $<ix:nonFraction unitRef="usd" contextRef="i788309cbaf3c49228dff05dacf3204c0_D20200801-20200831" decimals="-5" name="us-gaap:DebtConversionConvertedInstrumentAmount1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM183My9mcmFnOjU3M2ZmODBkMmIzNDQ0MTlhMzdlOTRhZjRhNjk0MTBkL3RleHRyZWdpb246NTczZmY4MGQyYjM0NDQxOWEzN2U5NGFmNGE2OTQxMGRfMzMz_4a58f4eb-8046-49a6-850b-9b240847a1ea">84.2</ix:nonFraction> million aggregate principal amount of 2024 Notes in exchange for $<ix:nonFraction unitRef="usd" contextRef="i79f0de790533434b998387bf6c4ab709_D20200801-20200831" decimals="-5" name="us-gaap:DebtConversionOriginalDebtAmount1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM183My9mcmFnOjU3M2ZmODBkMmIzNDQ0MTlhMzdlOTRhZjRhNjk0MTBkL3RleHRyZWdpb246NTczZmY4MGQyYjM0NDQxOWEzN2U5NGFmNGE2OTQxMGRfNDAx_c364fe2d-7281-41db-b945-3adb48b8ed9d">84.2</ix:nonFraction> million aggregate principal amount of the 2021 Notes and an aggregate cash payment of $<ix:nonFraction unitRef="usd" contextRef="i8584b8487d5e4d7ca2a029dd1993309b_D20200801-20200831" decimals="-5" name="us-gaap:PaymentsOfDebtIssuanceCosts" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM183My9mcmFnOjU3M2ZmODBkMmIzNDQ0MTlhMzdlOTRhZjRhNjk0MTBkL3RleHRyZWdpb246NTczZmY4MGQyYjM0NDQxOWEzN2U5NGFmNGE2OTQxMGRfNDkw_8384681f-e453-4c80-9523-8d742f175c06">2.5</ix:nonFraction>&#160;million, and issued $<ix:nonFraction unitRef="usd" contextRef="i9b76113417844ee8a46162426a4ed221_D20200801-20200831" decimals="-5" name="us-gaap:DebtConversionConvertedInstrumentAmount1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM183My9mcmFnOjU3M2ZmODBkMmIzNDQ0MTlhMzdlOTRhZjRhNjk0MTBkL3RleHRyZWdpb246NTczZmY4MGQyYjM0NDQxOWEzN2U5NGFmNGE2OTQxMGRfNTA1_be91ef5c-1807-488d-b099-5c6dcd0c0cba">32.8</ix:nonFraction> million aggregate principal amount of New Notes for cash at par. We incurred $<ix:nonFraction unitRef="usd" contextRef="i04c13e91bd034f30a0f4a7c989fc5940_I20200831" decimals="-5" name="us-gaap:DeferredFinanceCostsNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM183My9mcmFnOjU3M2ZmODBkMmIzNDQ0MTlhMzdlOTRhZjRhNjk0MTBkL3RleHRyZWdpb246NTczZmY4MGQyYjM0NDQxOWEzN2U5NGFmNGE2OTQxMGRfNTg1_46775315-edfb-4dc4-a155-a22e886c78e7">3.0</ix:nonFraction>&#160;million of debt issuance costs in connection with the 2024 Notes, which we are amortizing to non-cash interest expense using the straight-line method over the contractual term of the 2024 Notes. The closing of the private placement of the 2024 Notes occurred on August 19, 2020.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Holders of the 2024 Notes are entitled to cash interest payments, which are payable semiannually in arrears on June 1 and December 1 of each year, beginning on December 1, 2020, at a rate equal to <ix:nonFraction unitRef="number" contextRef="i04c13e91bd034f30a0f4a7c989fc5940_I20200831" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM183My9mcmFnOjU3M2ZmODBkMmIzNDQ0MTlhMzdlOTRhZjRhNjk0MTBkL3RleHRyZWdpb246NTczZmY4MGQyYjM0NDQxOWEzN2U5NGFmNGE2OTQxMGRfMTA1Nw_141f9ca7-b3c8-4255-99e4-55cbf0abf8a6">3.50</ix:nonFraction>% per annum. The 2024 Notes will mature on December 1, 2024, unless earlier repurchased, redeemed or converted in accordance with their terms prior to such date. Upon maturity the principal amount of the notes may be settled via shares of the Company&#8217;s Class A common stock. We recorded interest expense of $<ix:nonFraction unitRef="usd" contextRef="ifef2fd52529f408dbb3bcb2d3f4ae616_D20210101-20211231" decimals="-5" name="us-gaap:InterestExpenseDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM183My9mcmFnOjU3M2ZmODBkMmIzNDQ0MTlhMzdlOTRhZjRhNjk0MTBkL3RleHRyZWdpb246NTczZmY4MGQyYjM0NDQxOWEzN2U5NGFmNGE2OTQxMGRfMTM3Mg_543bbfd6-c76e-48d5-974e-ed1787a36922">4.1</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i2f7a8968a0e74fcfa7af898dd2afb7a6_D20200101-20201231" decimals="-5" name="us-gaap:InterestExpenseDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM183My9mcmFnOjU3M2ZmODBkMmIzNDQ0MTlhMzdlOTRhZjRhNjk0MTBkL3RleHRyZWdpb246NTczZmY4MGQyYjM0NDQxOWEzN2U5NGFmNGE2OTQxMGRfMTA5OTUxMTY0OTAwMQ_e3744a74-8f99-49dd-80fa-621092978621">1.5</ix:nonFraction> million for the years ended December 31, 2021 and 2020, respectively.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2024 Notes are convertible into cash, shares of the Company's Class A common stock, or a combination of cash and shares of the Company's Class A common stock, at the Company's election, based on an initial conversion rate of 54.8667 shares of Class A common stock per $1,000 principal amount of the 2024 Notes, which is equivalent to an initial conversion price of approximately $<ix:nonFraction unitRef="usdPerShare" contextRef="i04c13e91bd034f30a0f4a7c989fc5940_I20200831" decimals="2" name="us-gaap:DebtInstrumentConvertibleConversionPrice1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM183My9mcmFnOjU3M2ZmODBkMmIzNDQ0MTlhMzdlOTRhZjRhNjk0MTBkL3RleHRyZWdpb246NTczZmY4MGQyYjM0NDQxOWEzN2U5NGFmNGE2OTQxMGRfMTc2Mw_7e0c908c-5913-41e3-bb21-3f0418bbc1fa">18.23</ix:nonFraction> per share of the Company&#8217;s Class A common stock. In the aggregate, the 2024 Notes are initially convertible into <ix:nonFraction unitRef="shares" contextRef="i788309cbaf3c49228dff05dacf3204c0_D20200801-20200831" decimals="-5" name="us-gaap:DebtInstrumentConvertibleNumberOfEquityInstruments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM183My9mcmFnOjU3M2ZmODBkMmIzNDQ0MTlhMzdlOTRhZjRhNjk0MTBkL3RleHRyZWdpb246NTczZmY4MGQyYjM0NDQxOWEzN2U5NGFmNGE2OTQxMGRfMTg3OQ_06ab1b0d-5746-4296-bc42-6bcdccda02ff">6.4</ix:nonFraction>&#160;million shares of the Company&#8217;s Class A common stock (excluding any shares issuable by the Company upon a conversion in connection with a make-whole provision upon a fundamental change or a notice of redemption under the governing indenture). The conversion rate may be adjusted under certain circumstances. Upon conversion, the Company will pay or deliver, as the case may be, cash or shares of the Company&#8217;s Class A common stock, or a combination of cash and shares of the Company&#8217;s Class A common stock, at the Company&#8217;s election.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The option to settle the 2024 Notes in cash or shares of the Company&#8217;s Class A common stock, or a combination of cash and shares of the Company&#8217;s Class A common stock, at the Company&#8217;s election, resulted in a bifurcation of the carrying value of the 2024 Notes into a debt component and an equity component. The debt component was determined to be $<ix:nonFraction unitRef="usd" contextRef="i04c13e91bd034f30a0f4a7c989fc5940_I20200831" decimals="-5" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM183My9mcmFnOjU3M2ZmODBkMmIzNDQ0MTlhMzdlOTRhZjRhNjk0MTBkL3RleHRyZWdpb246NTczZmY4MGQyYjM0NDQxOWEzN2U5NGFmNGE2OTQxMGRfMjc1Nw_47429047-fe29-4c8e-a8ee-e49e11af9658">78.9</ix:nonFraction>&#160;million, before issuance costs, based on the fair value of a nonconvertible debt instrument with the same term. The equity component was determined to be $<ix:nonFraction unitRef="usd" contextRef="i2d6ffa68994846c2afc0f59e2f092900_D20200801-20200831" decimals="-5" name="us-gaap:ProceedsFromIssuanceOfDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM183My9mcmFnOjU3M2ZmODBkMmIzNDQ0MTlhMzdlOTRhZjRhNjk0MTBkL3RleHRyZWdpb246NTczZmY4MGQyYjM0NDQxOWEzN2U5NGFmNGE2OTQxMGRfMjkwNg_0987102c-c5b2-47f0-ad17-64ef397edef1">38.1</ix:nonFraction>&#160;million before issuance costs and was recorded within additional paid-in capital. The equity component is the difference between the aggregate principal amount of the debt and the fair value of the debt component. Issuance costs of $<ix:nonFraction unitRef="usd" contextRef="i04c13e91bd034f30a0f4a7c989fc5940_I20200831" decimals="-5" name="evh:DebtIssuanceCostsNetDebtComponent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM183My9mcmFnOjU3M2ZmODBkMmIzNDQ0MTlhMzdlOTRhZjRhNjk0MTBkL3RleHRyZWdpb246NTczZmY4MGQyYjM0NDQxOWEzN2U5NGFmNGE2OTQxMGRfMzEzMw_d633f0b4-100d-4a24-8448-e3be0e8b3661">1.7</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i440e2756c3e94ec7abffeb1fc8c10ab1_I20200831" decimals="-5" name="us-gaap:DeferredFinanceCostsNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM183My9mcmFnOjU3M2ZmODBkMmIzNDQ0MTlhMzdlOTRhZjRhNjk0MTBkL3RleHRyZWdpb246NTczZmY4MGQyYjM0NDQxOWEzN2U5NGFmNGE2OTQxMGRfMzE0MA_539bc1c6-1bb9-46c6-a809-aebadf54830d">1.3</ix:nonFraction>&#160;million are allocated to the debt and equity components in proportion to the allocation of proceeds. Along with the equity component of $<ix:nonFraction unitRef="usd" contextRef="i2d6ffa68994846c2afc0f59e2f092900_D20200801-20200831" decimals="-5" name="us-gaap:ProceedsFromIssuanceOfDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM183My9mcmFnOjU3M2ZmODBkMmIzNDQ0MTlhMzdlOTRhZjRhNjk0MTBkL3RleHRyZWdpb246NTczZmY4MGQyYjM0NDQxOWEzN2U5NGFmNGE2OTQxMGRfMzI3MQ_7d892bad-7156-4226-bdb2-5e5772771f60">38.1</ix:nonFraction>&#160;million, $<ix:nonFraction unitRef="usd" contextRef="i04c13e91bd034f30a0f4a7c989fc5940_I20200831" decimals="-5" name="evh:DebtIssuanceCostsNetDebtComponent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM183My9mcmFnOjU3M2ZmODBkMmIzNDQ0MTlhMzdlOTRhZjRhNjk0MTBkL3RleHRyZWdpb246NTczZmY4MGQyYjM0NDQxOWEzN2U5NGFmNGE2OTQxMGRfMzI3NQ_f823aa0f-d7c9-4bd6-aef1-64c21a65a779">1.7</ix:nonFraction>&#160;million of issuance costs will be amortized to interest expense on the consolidated statements of operations and comprehensive income (loss) using the effective interest method over the contractual term of the 2024 Notes. The equity component recorded within additional paid-in capital will not be remeasured as long as it meets the conditions for equity classification. The Company recorded $<ix:nonFraction unitRef="usd" contextRef="ifef2fd52529f408dbb3bcb2d3f4ae616_D20210101-20211231" decimals="-5" name="evh:AmortizationOfDebtDiscountAndDebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM183My9mcmFnOjU3M2ZmODBkMmIzNDQ0MTlhMzdlOTRhZjRhNjk0MTBkL3RleHRyZWdpb246NTczZmY4MGQyYjM0NDQxOWEzN2U5NGFmNGE2OTQxMGRfMzY2OQ_c9ab91b6-8fb3-4e8c-8cc1-8102429a869e">7.9</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i2f7a8968a0e74fcfa7af898dd2afb7a6_D20200101-20201231" decimals="-5" name="evh:AmortizationOfDebtDiscountAndDebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM183My9mcmFnOjU3M2ZmODBkMmIzNDQ0MTlhMzdlOTRhZjRhNjk0MTBkL3RleHRyZWdpb246NTczZmY4MGQyYjM0NDQxOWEzN2U5NGFmNGE2OTQxMGRfMTA5OTUxMTY0OTAxOQ_adc8ee10-108d-4643-97c8-cc13db6596ed">2.7</ix:nonFraction> million of interest expense related to the amortization of the debt discount and the issuance costs allocated to the debt component for the years ended December 31, 2021 and 2020, respectively.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Holders of the 2024 Notes may require the Company to repurchase all or part of their notes upon the occurrence of a fundamental change at a price equal to <ix:nonFraction unitRef="number" contextRef="i788309cbaf3c49228dff05dacf3204c0_D20200801-20200831" decimals="INF" name="evh:DebtInstrumentRepurchasePriceDueToFundamentalChangeAsPercentageOfPrincipalAmount" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM183My9mcmFnOjU3M2ZmODBkMmIzNDQ0MTlhMzdlOTRhZjRhNjk0MTBkL3RleHRyZWdpb246NTczZmY4MGQyYjM0NDQxOWEzN2U5NGFmNGE2OTQxMGRfMzk1Ng_b67246ee-c079-481a-9b53-3f1020376d40">100.0</ix:nonFraction>% of the principal amount of the notes being repurchased, plus any accrued and unpaid interest to, but excluding, the fundamental change repurchase date. The Company may not redeem the 2024 Notes prior to March 1, 2023. The Company may redeem for cash all or any portion of the 2024 Notes, at its option, on or after March 1, 2023, if the last reported sale price of the Company&#8217;s Class A common stock has been at least <ix:nonFraction unitRef="number" contextRef="i788309cbaf3c49228dff05dacf3204c0_D20200801-20200831" decimals="INF" name="evh:DebtInstrumentRepurchaseCovenantSalePriceAsAPercentageOfConversionPrice" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM183My9mcmFnOjU3M2ZmODBkMmIzNDQ0MTlhMzdlOTRhZjRhNjk0MTBkL3RleHRyZWdpb246NTczZmY4MGQyYjM0NDQxOWEzN2U5NGFmNGE2OTQxMGRfNDM3Nw_9ddc6c48-14af-48ae-86b8-8d0f11a3a047">130.0</ix:nonFraction>% of the conversion price then in effect for at least <ix:nonNumeric contextRef="i788309cbaf3c49228dff05dacf3204c0_D20200801-20200831" name="evh:DebtInstrumentRepurchaseCovenantTradingDaysMinimum" format="ixt-sec:durday" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM183My9mcmFnOjU3M2ZmODBkMmIzNDQ0MTlhMzdlOTRhZjRhNjk0MTBkL3RleHRyZWdpb246NTczZmY4MGQyYjM0NDQxOWEzN2U5NGFmNGE2OTQxMGRfNDQzMg_73f5af25-2787-43bb-8a93-eb065a6f46b3">20</ix:nonNumeric> trading </span></div></ix:continuation><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">93</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="id0a7ae7407e74dd4ad63a45e3fa9e72f" continuedAt="ib3793730af1f4504928a5d99fd538797"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">days (whether or not consecutive) during any <ix:nonNumeric contextRef="i788309cbaf3c49228dff05dacf3204c0_D20200801-20200831" name="evh:DebtInstrumentRepurchaseCovenantConsecutiveTradingDaysMinimum" format="ixt-sec:durday" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM183My9mcmFnOjU3M2ZmODBkMmIzNDQ0MTlhMzdlOTRhZjRhNjk0MTBkL3RleHRyZWdpb246NTczZmY4MGQyYjM0NDQxOWEzN2U5NGFmNGE2OTQxMGRfNDQ4OA_9a6edacf-c498-4a92-adb4-75b3571253a0">30</ix:nonNumeric> consecutive trading day period (including the last trading day of such period) ending on, and including, the trading day immediately preceding the date on which the Company provides notice of redemption, at a redemption price equal to <ix:nonFraction unitRef="number" contextRef="i788309cbaf3c49228dff05dacf3204c0_D20200801-20200831" decimals="INF" name="evh:DebtInstrumentRepurchasePriceDueToChangeInSalePriceAsPercentageOfConversionPrice" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM183My9mcmFnOjU3M2ZmODBkMmIzNDQ0MTlhMzdlOTRhZjRhNjk0MTBkL3RleHRyZWdpb246NTczZmY4MGQyYjM0NDQxOWEzN2U5NGFmNGE2OTQxMGRfNDcyNg_bf569a9c-4465-4821-accd-ecb5cfa5340a">100.0</ix:nonFraction>% of the principal amount of the notes to be redeemed, plus accrued and unpaid interest to, but excluding, the redemption date.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Credit Agreement</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 30, 2019, the Company entered into a credit agreement, by and among the Company, Evolent Health LLC, as the borrower (the &#8220;Borrower&#8221;), certain subsidiaries of the Company, as guarantors, the lenders from time to time party thereto, and Ares Capital Corporation, as administrative agent and collateral agent, together with the Company (the &#8220;Credit Agreement&#8221;), pursuant to which the lenders agreed to extend credit to the Borrower in the form of (i) an initial secured term loan in the aggregate principal amount of $<ix:nonFraction unitRef="usd" contextRef="ic9f911355bb8445c908c1c5b6b982236_I20191230" decimals="INF" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM183My9mcmFnOjU3M2ZmODBkMmIzNDQ0MTlhMzdlOTRhZjRhNjk0MTBkL3RleHRyZWdpb246NTczZmY4MGQyYjM0NDQxOWEzN2U5NGFmNGE2OTQxMGRfNTQwMQ_f9cae012-89bf-4612-b6b9-bc539ae18ad2">75.0</ix:nonFraction> million (the &#8220;Initial Term Loan Facility&#8221;) and (ii) a delayed draw secured term loan facility in the aggregate principal amount of up to $<ix:nonFraction unitRef="usd" contextRef="i792aeba7f36b437d85bdf7da6230451c_I20191230" decimals="INF" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM183My9mcmFnOjU3M2ZmODBkMmIzNDQ0MTlhMzdlOTRhZjRhNjk0MTBkL3RleHRyZWdpb246NTczZmY4MGQyYjM0NDQxOWEzN2U5NGFmNGE2OTQxMGRfNTUzMw_341b191c-90c7-4c37-bd94-5006989ec3ad">50.0</ix:nonFraction> million (the &#8220;DDTL Facility&#8221; and, together with the Initial Term Loan Facility, the &#8220;Senior Credit Facilities&#8221;), subject to the satisfaction of specified conditions. The Borrower borrowed the loan under the Initial Term Loan Facility on December 30, 2019. In connection with the Credit Agreement, on December 30, 2019, the Company entered into a Security Agreement, by and among the Company, the Borrower, the other guarantors and the collateral agent for the benefit of the secured parties, and a Guarantee Agreement, by the Company and each of the other guarantors in favor of the collateral agent for the benefit of the secured parties. The Senior Credit Facilities were guaranteed by the Company and the Company&#8217;s domestic subsidiaries, subject to certain exceptions. The Senior Credit Facilities were secured by a first priority security interest in all of the capital stock of the borrower and each guarantor (other than the Company) and substantially all of the assets of the borrower and each guarantor, subject to certain exceptions. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The proceeds of the Initial Term Loan were used to finance the transactions contemplated by the Passport APA and pay fees and expenses incurred in connection therewith. The proceeds of the DDTL Facility were permitted to be used, subject to the Company&#8217;s satisfaction of specified conditions, to finance the repayment or repurchase of the Company&#8217;s <ix:nonFraction unitRef="number" contextRef="ife61530204fd4e7bbf85f09284f83168_I20191230" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM183My9mcmFnOjU3M2ZmODBkMmIzNDQ0MTlhMzdlOTRhZjRhNjk0MTBkL3RleHRyZWdpb246NTczZmY4MGQyYjM0NDQxOWEzN2U5NGFmNGE2OTQxMGRfNjkyMg_8f01849b-4a2a-4ac7-8543-a34f47a8a7a8">2.00</ix:nonFraction>% Convertible Senior Notes due December 1, 2021 and to fund permitted acquisitions. &#160;The Initial Term Loan and any loans under the DDTL Facility would have matured on the date that is the earliest of (a) December 30, 2024, (b) the date on which all amounts outstanding under the Credit Agreement would have been declared or have automatically become due and payable under the terms of the Credit Agreement and (c) the date that is ninety-one (<ix:nonNumeric contextRef="i96e7c8227b2041f28199b45cd6df39d8_D20191230-20191230" name="us-gaap:DebtInstrumentTerm" format="ixt-sec:durday" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM183My9mcmFnOjU3M2ZmODBkMmIzNDQ0MTlhMzdlOTRhZjRhNjk0MTBkL3RleHRyZWdpb246NTczZmY4MGQyYjM0NDQxOWEzN2U5NGFmNGE2OTQxMGRfNzM2Ng_bc1b7156-b5e0-4c65-9031-a280e7390b6d">91</ix:nonNumeric>) days prior to the maturity date of the 2021 Convertible Notes unless certain liquidity conditions were satisfied (the foregoing, the &#8220;Maturity Date&#8221;). The interest rate for each loan under the Senior Credit Facilities was calculated, at the option of the Borrower, at either the Eurodollar rate plus <ix:nonFraction unitRef="number" contextRef="ieb668099634e44209035f0f361a970a7_D20191230-20191230" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM183My9mcmFnOjU3M2ZmODBkMmIzNDQ0MTlhMzdlOTRhZjRhNjk0MTBkL3RleHRyZWdpb246NTczZmY4MGQyYjM0NDQxOWEzN2U5NGFmNGE2OTQxMGRfNzY3MA_69ae113d-b741-46a1-a4ab-6ea2d2e14c9e">8.00</ix:nonFraction>%, or the base rate plus <ix:nonFraction unitRef="number" contextRef="icc5f3f563c8f4128a7d55ea114d571c7_D20191230-20191230" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM183My9mcmFnOjU3M2ZmODBkMmIzNDQ0MTlhMzdlOTRhZjRhNjk0MTBkL3RleHRyZWdpb246NTczZmY4MGQyYjM0NDQxOWEzN2U5NGFmNGE2OTQxMGRfNzY5Ng_63c4ee56-f970-4fea-97d8-b2970e27e1cf">7.00</ix:nonFraction>%. A commitment fee of <ix:nonFraction unitRef="number" contextRef="i17e802ca9a354f61a67b176d11db40d2_D20191230-20191230" decimals="INF" name="us-gaap:LineOfCreditFacilityCommitmentFeePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM183My9mcmFnOjU3M2ZmODBkMmIzNDQ0MTlhMzdlOTRhZjRhNjk0MTBkL3RleHRyZWdpb246NTczZmY4MGQyYjM0NDQxOWEzN2U5NGFmNGE2OTQxMGRfNzcyMA_2b82b18c-8e4e-4da8-8dc7-52edc7cb78dd">1.00</ix:nonFraction>% per annum was payable by the Borrower quarterly in arrears on the unused portion of the DDTL Facility. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amounts outstanding under the Senior Credit Facilities could have been prepaid at the option of the Borrower subject to applicable premiums, including a make-whole premium payable on certain prepayments made prior to the second anniversary of the closing of the Senior Credit Facilities, and a call protection premium payable on the amount prepaid in certain instances as follows: (i) <ix:nonFraction unitRef="number" contextRef="ib97b2b6f4e114116bcd48ecd930fff77_D20191230-20191230" decimals="INF" name="evh:DebtInstrumentRedemptionCallProtectionPremiumPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM183My9mcmFnOjU3M2ZmODBkMmIzNDQ0MTlhMzdlOTRhZjRhNjk0MTBkL3RleHRyZWdpb246NTczZmY4MGQyYjM0NDQxOWEzN2U5NGFmNGE2OTQxMGRfODIxMw_0aa4cf6b-f1d9-41b4-b0e6-5012f918a5aa">4.00</ix:nonFraction>% of the principal amount so prepaid after the second anniversary of the closing of the Senior Credit Facilities but prior the third anniversary of the closing of the Senior Credit Facilities; (ii) <ix:nonFraction unitRef="number" contextRef="ida54e6975d324252aa18539914addfb0_D20191230-20191230" decimals="INF" name="evh:DebtInstrumentRedemptionCallProtectionPremiumPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM183My9mcmFnOjU3M2ZmODBkMmIzNDQ0MTlhMzdlOTRhZjRhNjk0MTBkL3RleHRyZWdpb246NTczZmY4MGQyYjM0NDQxOWEzN2U5NGFmNGE2OTQxMGRfODQxMg_28a93fb2-55f9-4ac0-8d21-abb308626628">3.00</ix:nonFraction>% of the principal amount so prepaid after the third anniversary of the closing of the Senior Credit Facilities but prior the fourth anniversary of the closing of the Senior Credit Facilities; and (iii) <ix:nonFraction unitRef="number" contextRef="ibfa29a18103548678c4142edda54a480_D20191230-20191230" decimals="INF" name="evh:DebtInstrumentRedemptionCallProtectionPremiumPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM183My9mcmFnOjU3M2ZmODBkMmIzNDQ0MTlhMzdlOTRhZjRhNjk0MTBkL3RleHRyZWdpb246NTczZmY4MGQyYjM0NDQxOWEzN2U5NGFmNGE2OTQxMGRfODYxNg_3889ae61-be47-4c3c-a09f-f84331f617be">2.00</ix:nonFraction>% of the principal amount so prepaid after the fourth anniversary of the closing of the Senior Credit Facilities but prior the fifth anniversary of the closing of the Senior Credit Facilities. Amounts outstanding under the Senior Credit Facility were subject to mandatory prepayment upon the occurrence of certain events and conditions, including non-ordinary course asset dispositions, receipt of certain casualty proceeds, issuances of certain debt obligations and a change of control transaction.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Senior Credit Facilities contained customary borrowing conditions, affirmative, negative and reporting covenants, representations and warranties, and events of default, including cross-defaults to other material indebtedness. In addition, the Company was required to comply at certain times with certain financial covenants comprised of a minimum net revenue test and a minimum liquidity test commencing upon closing of the Senior Credit Facilities and a total secured leverage ratio commencing on the last day of the fiscal quarter ending March 31, 2021. If an event of default had occurred, the lenders would be entitled to take enforcement action, including foreclosure on collateral and acceleration of amounts owed under the Senior Credit Facilities. We incurred $<ix:nonFraction unitRef="usd" contextRef="i5e8884745c8748e9ac6420974639bd12_I20191230" decimals="-5" name="us-gaap:DeferredFinanceCostsNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM183My9mcmFnOjU3M2ZmODBkMmIzNDQ0MTlhMzdlOTRhZjRhNjk0MTBkL3RleHRyZWdpb246NTczZmY4MGQyYjM0NDQxOWEzN2U5NGFmNGE2OTQxMGRfOTg5MA_9e20bd6f-8077-46ed-bc5a-0df87da75071">4.7</ix:nonFraction> million of debt issuance costs in connection with this Credit Agreement, which was included in long-term debt, net of discount on our consolidated balance sheets and amortized into interest expense over the life of the agreement. The Company recorded $<ix:nonFraction unitRef="usd" contextRef="iab036707b4a24de2813c8c6ec050b319_D20200101-20201231" decimals="-5" name="evh:AmortizationOfDebtDiscountAndDebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM183My9mcmFnOjU3M2ZmODBkMmIzNDQ0MTlhMzdlOTRhZjRhNjk0MTBkL3RleHRyZWdpb246NTczZmY4MGQyYjM0NDQxOWEzN2U5NGFmNGE2OTQxMGRfMTA5OTUxMTY0OTE1OQ_48622004-bf85-4d55-8615-096adb9ab2c7">2.2</ix:nonFraction>&#160;million in interest expense related to the amortization of the debt discount and the issuance costs for the year ended December 31, 2020.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 19, 2020, an amendment to the Company's Credit Agreement became effective. The amendment effected changes to, among other things, permit the Company's use of cash in the exchange transactions in connection with the issuance of the 2024 Notes, permit the issuance of the 2024 Notes and permit certain note repurchases, as well as to implement amendments to certain minimum liquidity thresholds.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 8, 2021, the Company repaid all outstanding amounts owed under and terminated the Credit Agreement with Ares Capital Corporation. The total amount paid to Ares Capital Corporation under the Credit Agreement in connection with the prepayment was </span></div></ix:continuation><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">94</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="ib3793730af1f4504928a5d99fd538797" continuedAt="i6ad96ba7627742d38cbcd0a38a7a1ae2"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usd" contextRef="iadba955835944b7293cfc1935e0382e4_D20210108-20210108" decimals="-5" name="us-gaap:RepaymentsOfLongTermLinesOfCredit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM183My9mcmFnOjU3M2ZmODBkMmIzNDQ0MTlhMzdlOTRhZjRhNjk0MTBkL3RleHRyZWdpb246NTczZmY4MGQyYjM0NDQxOWEzN2U5NGFmNGE2OTQxMGRfMTA5MTg_a5e8c6b4-d59d-4eb8-9ac1-03e0268f9993">98.6</ix:nonFraction>&#160;million, which included $<ix:nonFraction unitRef="usd" contextRef="iadba955835944b7293cfc1935e0382e4_D20210108-20210108" decimals="-5" name="evh:PaymentsOfMakeWholePremium" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM183My9mcmFnOjU3M2ZmODBkMmIzNDQ0MTlhMzdlOTRhZjRhNjk0MTBkL3RleHRyZWdpb246NTczZmY4MGQyYjM0NDQxOWEzN2U5NGFmNGE2OTQxMGRfMTA5Mzc_f573d64f-c230-490e-87c3-333a8ed0b533">9.7</ix:nonFraction>&#160;million for the make-whole premium as well as $<ix:nonFraction unitRef="usd" contextRef="iadba955835944b7293cfc1935e0382e4_D20210108-20210108" decimals="-5" name="us-gaap:InterestPaidNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM183My9mcmFnOjU3M2ZmODBkMmIzNDQ0MTlhMzdlOTRhZjRhNjk0MTBkL3RleHRyZWdpb246NTczZmY4MGQyYjM0NDQxOWEzN2U5NGFmNGE2OTQxMGRfMTA5Nzg_a484879c-ac9a-4db9-bdb5-e638a92a6527">0.2</ix:nonFraction>&#160;million in accrued interest. As a result of this transaction, the Company recorded a loss on the repayment of debt of $<ix:nonFraction unitRef="usd" contextRef="i037876d85b5c4bea9f8460cdbf527197_D20210108-20210108" decimals="-5" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM183My9mcmFnOjU3M2ZmODBkMmIzNDQ0MTlhMzdlOTRhZjRhNjk0MTBkL3RleHRyZWdpb246NTczZmY4MGQyYjM0NDQxOWEzN2U5NGFmNGE2OTQxMGRfMTEwOTE_f4c0bdb7-39c9-4565-bcf1-448e6e86d98e">19.2</ix:nonFraction>&#160;million, representing the remaining unamortized debt issuance costs of $<ix:nonFraction unitRef="usd" contextRef="i037876d85b5c4bea9f8460cdbf527197_D20210108-20210108" decimals="-5" name="us-gaap:WriteOffOfDeferredDebtIssuanceCost" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM183My9mcmFnOjU3M2ZmODBkMmIzNDQ0MTlhMzdlOTRhZjRhNjk0MTBkL3RleHRyZWdpb246NTczZmY4MGQyYjM0NDQxOWEzN2U5NGFmNGE2OTQxMGRfMTExNTc_7620d4dd-3723-443f-8ae4-e6075b1a2b6e">9.5</ix:nonFraction>&#160;million, the make-whole premium and $<ix:nonFraction unitRef="usd" contextRef="i037876d85b5c4bea9f8460cdbf527197_D20210108-20210108" decimals="-3" name="us-gaap:LegalFees" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM183My9mcmFnOjU3M2ZmODBkMmIzNDQ0MTlhMzdlOTRhZjRhNjk0MTBkL3RleHRyZWdpb246NTczZmY4MGQyYjM0NDQxOWEzN2U5NGFmNGE2OTQxMGRfMTExODg_20332177-0523-4350-a315-7fd693b4e53d">35</ix:nonFraction>&#160;thousand of legal expenses.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Warrant Agreement</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In conjunction with the Company&#8217;s entry into the Credit Agreement, the Company entered into warrant agreements whereby it agreed to sell to the holders of the warrants an aggregate of <ix:nonFraction unitRef="shares" contextRef="i88843d45ac464699a3408ba52bbc2f63_I20191230" decimals="INF" name="us-gaap:ClassOfWarrantOrRightUnissued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM183My9mcmFnOjU3M2ZmODBkMmIzNDQ0MTlhMzdlOTRhZjRhNjk0MTBkL3RleHRyZWdpb246NTczZmY4MGQyYjM0NDQxOWEzN2U5NGFmNGE2OTQxMGRfMTE0MTQ_0db005ff-da98-46b4-96b3-9e7701cca383">1,513,786</ix:nonFraction> shares of Class A common stock at a per share purchase price equal to $<ix:nonFraction unitRef="usdPerShare" contextRef="i88843d45ac464699a3408ba52bbc2f63_I20191230" decimals="INF" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM183My9mcmFnOjU3M2ZmODBkMmIzNDQ0MTlhMzdlOTRhZjRhNjk0MTBkL3RleHRyZWdpb246NTczZmY4MGQyYjM0NDQxOWEzN2U5NGFmNGE2OTQxMGRfMTE0ODc_6732cb99-9577-45d5-91de-292d02842f8a">8.05</ix:nonFraction>. The holders could exercise the warrants at any time until <ix:nonNumeric contextRef="id418eef5065f4bf698e75757a9120794_D20191230-20191230" name="evh:ClassOfWarrantOrRightPeriodDuringWhichWarrantsOrRightsExercisableAfterMaturityOfCreditAgreement" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM183My9mcmFnOjU3M2ZmODBkMmIzNDQ0MTlhMzdlOTRhZjRhNjk0MTBkL3RleHRyZWdpb246NTczZmY4MGQyYjM0NDQxOWEzN2U5NGFmNGE2OTQxMGRfMTE1NDk_72379a85-32c5-4ce8-8e6f-17cdd9acbf04">thirty days</ix:nonNumeric> after the maturity of the Credit Agreement.  The Company, at its sole discretion, could elect to pay the holders in cash in an amount determined based on the fair market value of the Class A common stock for the shares of Class A common stock issuable upon exercise of the warrants in lieu of delivering the shares.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 8, 2021, the Company settled the outstanding warrants associated with the Credit Agreement for $<ix:nonFraction unitRef="usd" contextRef="i0b6779acaae746b9a02d20842b794089_D20210108-20210108" decimals="-5" name="us-gaap:PaymentsForRepurchaseOfWarrants" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM183My9mcmFnOjU3M2ZmODBkMmIzNDQ0MTlhMzdlOTRhZjRhNjk0MTBkL3RleHRyZWdpb246NTczZmY4MGQyYjM0NDQxOWEzN2U5NGFmNGE2OTQxMGRfMTE5NzU_f3572197-cbad-4bda-b35a-bcc2ca2987bf">13.7</ix:nonFraction>&#160;million.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2025 Notes</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2018, the Company issued $<ix:nonFraction unitRef="usd" contextRef="i00584134c5844a27a4303a31c0b5f1f3_I20181031" decimals="INF" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM183My9mcmFnOjU3M2ZmODBkMmIzNDQ0MTlhMzdlOTRhZjRhNjk0MTBkL3RleHRyZWdpb246NTczZmY4MGQyYjM0NDQxOWEzN2U5NGFmNGE2OTQxMGRfMTIwMjg_49193742-28e3-4b94-aa3d-bd89f9e3d509">172.5</ix:nonFraction> million aggregate principal amount of its <ix:nonFraction unitRef="number" contextRef="i00584134c5844a27a4303a31c0b5f1f3_I20181031" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM183My9mcmFnOjU3M2ZmODBkMmIzNDQ0MTlhMzdlOTRhZjRhNjk0MTBkL3RleHRyZWdpb246NTczZmY4MGQyYjM0NDQxOWEzN2U5NGFmNGE2OTQxMGRfMTIwNjU_4f35962a-581b-4a99-ae80-da002eda0fea">1.50</ix:nonFraction>% Convertible Senior Notes due 2025 (the &#8220;2025 Notes&#8221;) in a private placement to qualified institutional buyers within the meaning of Rule 144A under the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;). The 2025 Notes were issued at par for net proceeds of $<ix:nonFraction unitRef="usd" contextRef="i339c055665e9485da5895fb20444a7a8_D20181001-20181031" decimals="-5" name="us-gaap:ProceedsFromIssuanceOfDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM183My9mcmFnOjU3M2ZmODBkMmIzNDQ0MTlhMzdlOTRhZjRhNjk0MTBkL3RleHRyZWdpb246NTczZmY4MGQyYjM0NDQxOWEzN2U5NGFmNGE2OTQxMGRfMTIzMzM_f303e7aa-6dab-4a93-ad9e-83ecfabd7d73">166.6</ix:nonFraction> million. We incurred $<ix:nonFraction unitRef="usd" contextRef="i39addcd35f11436480a83296fb4dc83a_I20181031" decimals="-5" name="us-gaap:DeferredFinanceCostsNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM183My9mcmFnOjU3M2ZmODBkMmIzNDQ0MTlhMzdlOTRhZjRhNjk0MTBkL3RleHRyZWdpb246NTczZmY4MGQyYjM0NDQxOWEzN2U5NGFmNGE2OTQxMGRfMTIzNDk_09feb7f9-fc47-4e9d-a2cf-7437e84879a3">5.9</ix:nonFraction> million of debt issuance costs in connection with the 2025 Notes. The closing of the private placement of $<ix:nonFraction unitRef="usd" contextRef="ic55a278f0f0c48b3bdd614bbb0a7eded_I20181022" decimals="INF" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM183My9mcmFnOjU3M2ZmODBkMmIzNDQ0MTlhMzdlOTRhZjRhNjk0MTBkL3RleHRyZWdpb246NTczZmY4MGQyYjM0NDQxOWEzN2U5NGFmNGE2OTQxMGRfMTI0NTA_4223a9de-73e3-4a81-b76b-a19bfc51e2a7">150.0</ix:nonFraction> million aggregate principal amount of the 2025 Notes occurred on October&#160;22, 2018 and the Company completed the offering and sale of an additional $<ix:nonFraction unitRef="usd" contextRef="ic290bfcf094543248295da9fb01e4c88_I20181024" decimals="INF" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM183My9mcmFnOjU3M2ZmODBkMmIzNDQ0MTlhMzdlOTRhZjRhNjk0MTBkL3RleHRyZWdpb246NTczZmY4MGQyYjM0NDQxOWEzN2U5NGFmNGE2OTQxMGRfMTI1Nzg_865f9146-5430-46c8-ba27-4a1ab700ad4d">22.5</ix:nonFraction> million aggregate principal amount of the 2025 Notes on October&#160;24, 2018, pursuant to the initial purchasers&#8217; exercise in full of their option to purchase additional notes.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Holders of the 2025 Notes are entitled to cash interest payments, which are payable semiannually in arrears on&#160;April 15&#160;and&#160;October 15&#160;of each year, beginning on&#160;April&#160;15, 2019, at a rate equal to&#160;<ix:nonFraction unitRef="number" contextRef="i00584134c5844a27a4303a31c0b5f1f3_I20181031" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM183My9mcmFnOjU3M2ZmODBkMmIzNDQ0MTlhMzdlOTRhZjRhNjk0MTBkL3RleHRyZWdpb246NTczZmY4MGQyYjM0NDQxOWEzN2U5NGFmNGE2OTQxMGRfMTI5MTg_4f35962a-581b-4a99-ae80-da002eda0fea">1.50</ix:nonFraction>%&#160;per annum. The Company recorded interest expense of $<ix:nonFraction unitRef="usd" contextRef="i48ca8bc8e051466a9a37e1e1da6febc3_D20210101-20211231" decimals="-5" name="us-gaap:InterestExpenseDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM183My9mcmFnOjU3M2ZmODBkMmIzNDQ0MTlhMzdlOTRhZjRhNjk0MTBkL3RleHRyZWdpb246NTczZmY4MGQyYjM0NDQxOWEzN2U5NGFmNGE2OTQxMGRfMTI5ODA_589b6617-c10a-4ddf-b78a-9c7f1b8c3f3d"><ix:nonFraction unitRef="usd" contextRef="idd22b7a2c5194e22908f4f8bfed93408_D20200101-20201231" decimals="-5" name="us-gaap:InterestExpenseDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM183My9mcmFnOjU3M2ZmODBkMmIzNDQ0MTlhMzdlOTRhZjRhNjk0MTBkL3RleHRyZWdpb246NTczZmY4MGQyYjM0NDQxOWEzN2U5NGFmNGE2OTQxMGRfMTI5ODA_69046aa2-4bfe-4194-9bcd-674b2c25f800"><ix:nonFraction unitRef="usd" contextRef="i36270cc40db54c1cbe5d5fe12dba090b_D20190101-20191231" decimals="-5" name="us-gaap:InterestExpenseDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM183My9mcmFnOjU3M2ZmODBkMmIzNDQ0MTlhMzdlOTRhZjRhNjk0MTBkL3RleHRyZWdpb246NTczZmY4MGQyYjM0NDQxOWEzN2U5NGFmNGE2OTQxMGRfMTI5ODA_d9186e96-6269-48ed-a69f-746893ee375a">2.6</ix:nonFraction></ix:nonFraction></ix:nonFraction> million for the years ended December 31, 2021, 2020 and 2019, respectively. The 2025 Notes will mature on&#160;October&#160;15, 2025, unless earlier repurchased, redeemed or converted in accordance with their terms prior to such date.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prior to the close of business on the business day immediately preceding April&#160;15, 2025, the 2025 Notes will be convertible at the option of the holders only upon the satisfaction of certain conditions, as described in the indenture, dated as of October&#160;22, 2018, between the Company and U.S. Bank National Association, as trustee. At any time on or after April&#160;15, 2025, until the close of business on the business day immediately preceding the maturity date, holders may convert, at their option, all or any portion of their notes at the conversion rate.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2025 Notes will be convertible at an initial conversion rate of 29.9135 shares of Class A common stock per $1,000 principal amount of notes, which is equivalent to an initial conversion price of approximately $<ix:nonFraction unitRef="usdPerShare" contextRef="i00584134c5844a27a4303a31c0b5f1f3_I20181031" decimals="2" name="us-gaap:DebtInstrumentConvertibleConversionPrice1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM183My9mcmFnOjU3M2ZmODBkMmIzNDQ0MTlhMzdlOTRhZjRhNjk0MTBkL3RleHRyZWdpb246NTczZmY4MGQyYjM0NDQxOWEzN2U5NGFmNGE2OTQxMGRfMTM4NzA_21e49450-493d-4bc9-9a0e-25bb5b8fc254">33.43</ix:nonFraction> per share of the Company&#8217;s Class A common stock. In the aggregate, the 2025 Notes are initially convertible into <ix:nonFraction unitRef="shares" contextRef="i339c055665e9485da5895fb20444a7a8_D20181001-20181031" decimals="-5" name="us-gaap:DebtInstrumentConvertibleNumberOfEquityInstruments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM183My9mcmFnOjU3M2ZmODBkMmIzNDQ0MTlhMzdlOTRhZjRhNjk0MTBkL3RleHRyZWdpb246NTczZmY4MGQyYjM0NDQxOWEzN2U5NGFmNGE2OTQxMGRfMTM5ODY_a789527a-e5b2-4540-87c3-50ec8565d5c7">5.2</ix:nonFraction> million shares of the Company&#8217;s Class A common stock (excluding any shares issuable by the Company upon a conversion in connection with a make-whole fundamental change or a notice of redemption as described in the governing indenture). The conversion rate may be adjusted under certain circumstances. Upon conversion, the Company will pay or deliver, as the case may be, cash or shares of the Company&#8217;s Class A common stock, or a combination of cash and shares of the Company&#8217;s Class A common stock, at the Company&#8217;s election.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The option to settle the 2025 Notes in cash or shares of the Company&#8217;s Class A common stock, or a combination of cash and shares of the Company&#8217;s Class A common stock, at the Company&#8217;s election, resulted in a bifurcation of the carrying value of the 2025 Notes into a debt component and an equity component. The debt component was determined to be $<ix:nonFraction unitRef="usd" contextRef="i00584134c5844a27a4303a31c0b5f1f3_I20181031" decimals="-5" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM183My9mcmFnOjU3M2ZmODBkMmIzNDQ0MTlhMzdlOTRhZjRhNjk0MTBkL3RleHRyZWdpb246NTczZmY4MGQyYjM0NDQxOWEzN2U5NGFmNGE2OTQxMGRfMTQ4NTc_f8d51886-7f87-48e3-bda6-dcd18b5922cc">100.7</ix:nonFraction> million, before issuance costs, based on the fair value of a nonconvertible debt instrument with the same term. The equity component was determined to be $<ix:nonFraction unitRef="usd" contextRef="i69e9a51f20134473a4650107c879ce03_D20181001-20181031" decimals="-5" name="us-gaap:ProceedsFromIssuanceOfDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM183My9mcmFnOjU3M2ZmODBkMmIzNDQ0MTlhMzdlOTRhZjRhNjk0MTBkL3RleHRyZWdpb246NTczZmY4MGQyYjM0NDQxOWEzN2U5NGFmNGE2OTQxMGRfMTUwMDY_cba41b6a-1c7b-446f-ba97-832c1479f181">71.8</ix:nonFraction> million, before issuance costs, and was recorded within additional paid-in capital. The equity component is the difference between the aggregate principal amount of the debt and the debt component. Issuance costs of $<ix:nonFraction unitRef="usd" contextRef="i00584134c5844a27a4303a31c0b5f1f3_I20181031" decimals="-5" name="us-gaap:DeferredFinanceCostsNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM183My9mcmFnOjU3M2ZmODBkMmIzNDQ0MTlhMzdlOTRhZjRhNjk0MTBkL3RleHRyZWdpb246NTczZmY4MGQyYjM0NDQxOWEzN2U5NGFmNGE2OTQxMGRfMTUyMTc_a8dcbdde-2a95-4b7f-bfe2-60ac67e73e99">3.4</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ib49940b904c04bd784180584b89ab5bf_I20181031" decimals="-5" name="us-gaap:DeferredFinanceCostsNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM183My9mcmFnOjU3M2ZmODBkMmIzNDQ0MTlhMzdlOTRhZjRhNjk0MTBkL3RleHRyZWdpb246NTczZmY4MGQyYjM0NDQxOWEzN2U5NGFmNGE2OTQxMGRfMTUyMjQ_89844d92-e4bf-4743-b4a0-cb301273535c">2.5</ix:nonFraction> million are allocated to the debt and equity components in proportion to the allocation of proceeds. Along with the equity component of $<ix:nonFraction unitRef="usd" contextRef="i69e9a51f20134473a4650107c879ce03_D20181001-20181031" decimals="-5" name="us-gaap:ProceedsFromIssuanceOfDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM183My9mcmFnOjU3M2ZmODBkMmIzNDQ0MTlhMzdlOTRhZjRhNjk0MTBkL3RleHRyZWdpb246NTczZmY4MGQyYjM0NDQxOWEzN2U5NGFmNGE2OTQxMGRfMTUzNTU_cba41b6a-1c7b-446f-ba97-832c1479f181">71.8</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="i00584134c5844a27a4303a31c0b5f1f3_I20181031" decimals="-5" name="us-gaap:DeferredFinanceCostsNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM183My9mcmFnOjU3M2ZmODBkMmIzNDQ0MTlhMzdlOTRhZjRhNjk0MTBkL3RleHRyZWdpb246NTczZmY4MGQyYjM0NDQxOWEzN2U5NGFmNGE2OTQxMGRfMTUzNTk_a8dcbdde-2a95-4b7f-bfe2-60ac67e73e99">3.4</ix:nonFraction> million of issuance costs will be amortized to interest expense on the consolidated statements of operations and comprehensive income (loss) using the effective interest method over the contractual term of the 2025 Notes. The equity component recorded within additional paid-in capital will not be remeasured as long as it meets the conditions for equity classification. The Company recorded $<ix:nonFraction unitRef="usd" contextRef="i48ca8bc8e051466a9a37e1e1da6febc3_D20210101-20211231" decimals="-5" name="evh:AmortizationOfDebtDiscountAndDebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM183My9mcmFnOjU3M2ZmODBkMmIzNDQ0MTlhMzdlOTRhZjRhNjk0MTBkL3RleHRyZWdpb246NTczZmY4MGQyYjM0NDQxOWEzN2U5NGFmNGE2OTQxMGRfMTU3NTM_4a9ac6e2-313d-4d68-a45d-b7a913c1fc57">10.0</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="idd22b7a2c5194e22908f4f8bfed93408_D20200101-20201231" decimals="-5" name="evh:AmortizationOfDebtDiscountAndDebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM183My9mcmFnOjU3M2ZmODBkMmIzNDQ0MTlhMzdlOTRhZjRhNjk0MTBkL3RleHRyZWdpb246NTczZmY4MGQyYjM0NDQxOWEzN2U5NGFmNGE2OTQxMGRfMTU3ODU_64dafb1f-27e7-4500-ba4e-62ce940550c4">9.2</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i36270cc40db54c1cbe5d5fe12dba090b_D20190101-20191231" decimals="-5" name="evh:AmortizationOfDebtDiscountAndDebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM183My9mcmFnOjU3M2ZmODBkMmIzNDQ0MTlhMzdlOTRhZjRhNjk0MTBkL3RleHRyZWdpb246NTczZmY4MGQyYjM0NDQxOWEzN2U5NGFmNGE2OTQxMGRfMTA5OTUxMTY0OTMyOQ_680509e2-60ba-4347-bfde-41516c5a33ae">8.5</ix:nonFraction> million for the years ended December 31, 2021, 2020 and 2019 respectively, in interest expense related to the amortization of the debt discount and the issuance costs allocated to the debt component.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Holders of the 2025 Notes may require the Company to repurchase all or part of their notes upon the occurrence of a fundamental change at a price equal to <ix:nonFraction unitRef="number" contextRef="i339c055665e9485da5895fb20444a7a8_D20181001-20181031" decimals="INF" name="evh:DebtInstrumentRepurchasePriceDueToFundamentalChangeAsPercentageOfPrincipalAmount" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM183My9mcmFnOjU3M2ZmODBkMmIzNDQ0MTlhMzdlOTRhZjRhNjk0MTBkL3RleHRyZWdpb246NTczZmY4MGQyYjM0NDQxOWEzN2U5NGFmNGE2OTQxMGRfMTYwODc_8d80bb69-e57d-4057-bcad-756ce97fb0a9">100.0</ix:nonFraction>% of the principal amount of the notes being repurchased, plus any accrued and unpaid interest to, but excluding, the fundamental change repurchase date. The Company may not redeem the 2025 Notes prior to October&#160;20, 2022. The Company may redeem for cash all or any portion of the 2025 Notes, at its option, on or after October&#160;20, 2022, if the last reported sale </span></div></ix:continuation><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">95</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i6ad96ba7627742d38cbcd0a38a7a1ae2" continuedAt="i9527dad9e53b44cc83cc31f4e7e0c22c"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">price of the Company&#8217;s Class A common stock has been at least <ix:nonFraction unitRef="number" contextRef="i339c055665e9485da5895fb20444a7a8_D20181001-20181031" decimals="INF" name="evh:DebtInstrumentRepurchaseCovenantSalePriceAsAPercentageOfConversionPrice" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM183My9mcmFnOjU3M2ZmODBkMmIzNDQ0MTlhMzdlOTRhZjRhNjk0MTBkL3RleHRyZWdpb246NTczZmY4MGQyYjM0NDQxOWEzN2U5NGFmNGE2OTQxMGRfMTY0ODY_20dc6d24-de35-4b8b-9267-714be0d61069">130.0</ix:nonFraction>% of the conversion price then in effect for at least <ix:nonNumeric contextRef="i339c055665e9485da5895fb20444a7a8_D20181001-20181031" name="evh:DebtInstrumentRepurchaseCovenantTradingDaysMinimum" format="ixt-sec:durday" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM183My9mcmFnOjU3M2ZmODBkMmIzNDQ0MTlhMzdlOTRhZjRhNjk0MTBkL3RleHRyZWdpb246NTczZmY4MGQyYjM0NDQxOWEzN2U5NGFmNGE2OTQxMGRfMTY1NDE_d716526f-7918-408a-9a6f-9d124469ae17">20</ix:nonNumeric> trading days (whether or not consecutive) during any <ix:nonNumeric contextRef="i339c055665e9485da5895fb20444a7a8_D20181001-20181031" name="evh:DebtInstrumentRepurchaseCovenantConsecutiveTradingDaysMinimum" format="ixt-sec:durday" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM183My9mcmFnOjU3M2ZmODBkMmIzNDQ0MTlhMzdlOTRhZjRhNjk0MTBkL3RleHRyZWdpb246NTczZmY4MGQyYjM0NDQxOWEzN2U5NGFmNGE2OTQxMGRfMTY1OTc_9cf0425e-15ff-4bbf-b168-347e33daf0a3">30</ix:nonNumeric> consecutive trading day period (including the last trading day of such period) ending on, and including, the trading day immediately preceding the date on which the Company provides notice of redemption, at a redemption price equal to <ix:nonFraction unitRef="number" contextRef="i339c055665e9485da5895fb20444a7a8_D20181001-20181031" decimals="INF" name="evh:DebtInstrumentRepurchasePriceDueToChangeInSalePriceAsPercentageOfConversionPrice" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM183My9mcmFnOjU3M2ZmODBkMmIzNDQ0MTlhMzdlOTRhZjRhNjk0MTBkL3RleHRyZWdpb246NTczZmY4MGQyYjM0NDQxOWEzN2U5NGFmNGE2OTQxMGRfMTY4MzU_4ab15acb-024b-4dc0-813e-81ac25de640e">100.0</ix:nonFraction>% of the principal amount of the notes to be redeemed, plus accrued and unpaid interest to, but excluding, the redemption date.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2021 Notes</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2016, the Company issued $<ix:nonFraction unitRef="usd" contextRef="i4f7fefe0fb434989bf906e20f2422c6b_I20161231" decimals="INF" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM183My9mcmFnOjU3M2ZmODBkMmIzNDQ0MTlhMzdlOTRhZjRhNjk0MTBkL3RleHRyZWdpb246NTczZmY4MGQyYjM0NDQxOWEzN2U5NGFmNGE2OTQxMGRfMTcwMDM_ddf7132c-2580-4d0a-be36-7dd8df515070">125.0</ix:nonFraction> million aggregate principal amount of its <ix:nonFraction unitRef="number" contextRef="i4f7fefe0fb434989bf906e20f2422c6b_I20161231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM183My9mcmFnOjU3M2ZmODBkMmIzNDQ0MTlhMzdlOTRhZjRhNjk0MTBkL3RleHRyZWdpb246NTczZmY4MGQyYjM0NDQxOWEzN2U5NGFmNGE2OTQxMGRfMTcwNDA_97417d79-0c17-4578-bfb0-d0339cf10f44">2.00</ix:nonFraction>% Convertible Senior Notes due 2021 (the &#8220;2021 Notes&#8221;) in a private placement to qualified institutional buyers within the meaning of Rule 144A under the Securities Act. The 2021 Notes were issued at par for net proceeds of $<ix:nonFraction unitRef="usd" contextRef="i54bf54f1a88044bab71a8867d4a0c31f_D20161201-20161231" decimals="-5" name="us-gaap:ProceedsFromIssuanceOfDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM183My9mcmFnOjU3M2ZmODBkMmIzNDQ0MTlhMzdlOTRhZjRhNjk0MTBkL3RleHRyZWdpb246NTczZmY4MGQyYjM0NDQxOWEzN2U5NGFmNGE2OTQxMGRfMTcyNjM_0244e816-3359-4461-a521-04e4c89a1628">120.4</ix:nonFraction> million. We incurred $<ix:nonFraction unitRef="usd" contextRef="i4f7fefe0fb434989bf906e20f2422c6b_I20161231" decimals="-5" name="us-gaap:DeferredFinanceCostsNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM183My9mcmFnOjU3M2ZmODBkMmIzNDQ0MTlhMzdlOTRhZjRhNjk0MTBkL3RleHRyZWdpb246NTczZmY4MGQyYjM0NDQxOWEzN2U5NGFmNGE2OTQxMGRfMTcyNzk_630f0084-fc0b-4984-9845-5e36e8cd0dae">4.6</ix:nonFraction> million of debt issuance costs in connection with the 2021 Notes, which we amortized to non-cash interest expense using the straight-line method over the contractual term of the 2021 Notes, since this method was not materially different from the effective interest method. The closing of the private placement of the 2021 Notes occurred on December&#160;5, 2016.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Holders of the 2021 Notes were entitled to cash interest payments, which were paid semiannually in arrears on June 1 and December 1 of each year, beginning on June&#160;1, 2017, at a rate equal to <ix:nonFraction unitRef="number" contextRef="i4f7fefe0fb434989bf906e20f2422c6b_I20161231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM183My9mcmFnOjU3M2ZmODBkMmIzNDQ0MTlhMzdlOTRhZjRhNjk0MTBkL3RleHRyZWdpb246NTczZmY4MGQyYjM0NDQxOWEzN2U5NGFmNGE2OTQxMGRfMTc3OTU_97417d79-0c17-4578-bfb0-d0339cf10f44">2.00</ix:nonFraction>% per annum. The 2021 Notes matured on December&#160;1, 2021. We recorded interest expense of $<ix:nonFraction unitRef="usd" contextRef="i7e9e77d057aa4381855c6fd7a1d6f4ea_D20210101-20211231" decimals="-5" name="us-gaap:InterestExpenseDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM183My9mcmFnOjU3M2ZmODBkMmIzNDQ0MTlhMzdlOTRhZjRhNjk0MTBkL3RleHRyZWdpb246NTczZmY4MGQyYjM0NDQxOWEzN2U5NGFmNGE2OTQxMGRfMTg0MTI_eb81c8f6-4e6c-4d5c-88fb-2063ed3cf9b3">0.5</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="i087fe618f5364968ac66e7869d1caad5_D20200101-20201231" decimals="-5" name="us-gaap:InterestExpenseDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM183My9mcmFnOjU3M2ZmODBkMmIzNDQ0MTlhMzdlOTRhZjRhNjk0MTBkL3RleHRyZWdpb246NTczZmY4MGQyYjM0NDQxOWEzN2U5NGFmNGE2OTQxMGRfMTg0NDQ_012f5b01-bde4-48fb-b04b-2ac42b23fc75">1.7</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i4d8110dbf411438a8a00e05653b625c8_D20190101-20191231" decimals="-5" name="us-gaap:InterestExpenseDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM183My9mcmFnOjU3M2ZmODBkMmIzNDQ0MTlhMzdlOTRhZjRhNjk0MTBkL3RleHRyZWdpb246NTczZmY4MGQyYjM0NDQxOWEzN2U5NGFmNGE2OTQxMGRfMTA5OTUxMTY0OTM3NA_d978deea-1861-455c-9dfc-53cca6523d8a">2.5</ix:nonFraction> million for the years ended December 31, 2021, 2020 and 2019, respectively. We recorded non-cash interest expense related to the amortization of deferred financing costs of $<ix:nonFraction unitRef="usd" contextRef="i7e9e77d057aa4381855c6fd7a1d6f4ea_D20210101-20211231" decimals="-5" name="us-gaap:AmortizationOfFinancingCosts" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM183My9mcmFnOjU3M2ZmODBkMmIzNDQ0MTlhMzdlOTRhZjRhNjk0MTBkL3RleHRyZWdpb246NTczZmY4MGQyYjM0NDQxOWEzN2U5NGFmNGE2OTQxMGRfMTg1Njk_d5635bd8-e757-4c9e-a57d-00ef9ac82305">0.2</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="i087fe618f5364968ac66e7869d1caad5_D20200101-20201231" decimals="-5" name="us-gaap:AmortizationOfFinancingCosts" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM183My9mcmFnOjU3M2ZmODBkMmIzNDQ0MTlhMzdlOTRhZjRhNjk0MTBkL3RleHRyZWdpb246NTczZmY4MGQyYjM0NDQxOWEzN2U5NGFmNGE2OTQxMGRfMTg2MDE_bfd9fdb4-cd17-4029-9cdc-f4a7ff57ca83">0.6</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i4d8110dbf411438a8a00e05653b625c8_D20190101-20191231" decimals="-5" name="us-gaap:AmortizationOfFinancingCosts" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM183My9mcmFnOjU3M2ZmODBkMmIzNDQ0MTlhMzdlOTRhZjRhNjk0MTBkL3RleHRyZWdpb246NTczZmY4MGQyYjM0NDQxOWEzN2U5NGFmNGE2OTQxMGRfMTA5OTUxMTY0OTUyOQ_101166de-bd87-4979-a18e-a8d9d8eb5c42">0.9</ix:nonFraction> million for the years ended December 31, 2021, 2020 and 2019, respectively.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2020, as part of the issuance of the 2024 Notes, the Company issued $<ix:nonFraction unitRef="usd" contextRef="i788309cbaf3c49228dff05dacf3204c0_D20200801-20200831" decimals="-5" name="us-gaap:DebtConversionConvertedInstrumentAmount1" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM183My9mcmFnOjU3M2ZmODBkMmIzNDQ0MTlhMzdlOTRhZjRhNjk0MTBkL3RleHRyZWdpb246NTczZmY4MGQyYjM0NDQxOWEzN2U5NGFmNGE2OTQxMGRfMTk4NzI_88a34ff4-0dd9-4240-b08e-04cd1314cf97">84.2</ix:nonFraction>&#160;million aggregate principal amount of the 2024 Notes in exchange for $<ix:nonFraction unitRef="usd" contextRef="i79f0de790533434b998387bf6c4ab709_D20200801-20200831" decimals="-5" name="us-gaap:DebtConversionOriginalDebtAmount1" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM183My9mcmFnOjU3M2ZmODBkMmIzNDQ0MTlhMzdlOTRhZjRhNjk0MTBkL3RleHRyZWdpb246NTczZmY4MGQyYjM0NDQxOWEzN2U5NGFmNGE2OTQxMGRfMTk5MzY_d1c15fc5-41fe-4c64-b2ba-16e714de0f95">84.2</ix:nonFraction>&#160;million aggregate principal of its 2021 Notes. There was no cash consideration in these exchanges outside of an aggregate cash payment of $<ix:nonFraction unitRef="usd" contextRef="i8584b8487d5e4d7ca2a029dd1993309b_D20200801-20200831" decimals="-5" name="us-gaap:PaymentsOfDebtIssuanceCosts" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM183My9mcmFnOjU3M2ZmODBkMmIzNDQ0MTlhMzdlOTRhZjRhNjk0MTBkL3RleHRyZWdpb246NTczZmY4MGQyYjM0NDQxOWEzN2U5NGFmNGE2OTQxMGRfMjAwNjk_8edabc71-7c86-4b45-a10d-f8c988590b10">2.5</ix:nonFraction>&#160;million paid to exchanging noteholders. These exchanges were accounted for as an extinguishment resulting in a net loss on extinguishment of debt of $<ix:nonFraction unitRef="usd" contextRef="i8584b8487d5e4d7ca2a029dd1993309b_D20200801-20200831" decimals="-5" sign="-" name="us-gaap:GainsLossesOnExtinguishmentOfDebtBeforeWriteOffOfDeferredDebtIssuanceCost" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM183My9mcmFnOjU3M2ZmODBkMmIzNDQ0MTlhMzdlOTRhZjRhNjk0MTBkL3RleHRyZWdpb246NTczZmY4MGQyYjM0NDQxOWEzN2U5NGFmNGE2OTQxMGRfMjAyMTM_a87b2cac-8845-4362-91d5-595b08df44fc">4.8</ix:nonFraction>&#160;million, including an aggregate cash payment of $<ix:nonFraction unitRef="usd" contextRef="i8584b8487d5e4d7ca2a029dd1993309b_D20200801-20200831" decimals="-5" name="us-gaap:PaymentsOfDebtIssuanceCosts" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM183My9mcmFnOjU3M2ZmODBkMmIzNDQ0MTlhMzdlOTRhZjRhNjk0MTBkL3RleHRyZWdpb246NTczZmY4MGQyYjM0NDQxOWEzN2U5NGFmNGE2OTQxMGRfMjAyNTY_a8cf13d9-510a-43c8-8c45-61b06d948e90">2.5</ix:nonFraction>&#160;million paid to exchanging noteholders. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2020, we also repurchased $<ix:nonFraction unitRef="usd" contextRef="i79f0de790533434b998387bf6c4ab709_D20200801-20200831" decimals="-5" name="us-gaap:ExtinguishmentOfDebtAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM183My9mcmFnOjU3M2ZmODBkMmIzNDQ0MTlhMzdlOTRhZjRhNjk0MTBkL3RleHRyZWdpb246NTczZmY4MGQyYjM0NDQxOWEzN2U5NGFmNGE2OTQxMGRfMjAzMjk_30e208e1-df99-4c24-a6d7-12f510664441">14.0</ix:nonFraction>&#160;million of the 2021 Notes with $<ix:nonFraction unitRef="usd" contextRef="i79f0de790533434b998387bf6c4ab709_D20200801-20200831" decimals="-5" name="us-gaap:RepaymentsOfSeniorDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM183My9mcmFnOjU3M2ZmODBkMmIzNDQ0MTlhMzdlOTRhZjRhNjk0MTBkL3RleHRyZWdpb246NTczZmY4MGQyYjM0NDQxOWEzN2U5NGFmNGE2OTQxMGRfMjAzNTU_a475c16d-5809-44ea-b7d5-569fb94736cb">13.9</ix:nonFraction>&#160;million of cash and recorded an immaterial gain on extinguishment of debt.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon maturity of the 2021 Notes on December 1, 2021, outstanding 2021 Notes with a principal amount of $<ix:nonFraction unitRef="usd" contextRef="i9a2926d0e711448fa37fb03edf2470a1_D20211201-20211201" decimals="-5" name="us-gaap:DebtConversionConvertedInstrumentAmount1" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM183My9mcmFnOjU3M2ZmODBkMmIzNDQ0MTlhMzdlOTRhZjRhNjk0MTBkL3RleHRyZWdpb246NTczZmY4MGQyYjM0NDQxOWEzN2U5NGFmNGE2OTQxMGRfMjE5OTAyMzI4MTQ2Ng_757d6b80-5459-410a-b7eb-ef838f2c5c40">26.7</ix:nonFraction>&#160;million were settled, at the option of the holders, by converting $<ix:nonFraction unitRef="usd" contextRef="i9a2926d0e711448fa37fb03edf2470a1_D20211201-20211201" decimals="-5" name="us-gaap:DebtConversionOriginalDebtAmount1" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM183My9mcmFnOjU3M2ZmODBkMmIzNDQ0MTlhMzdlOTRhZjRhNjk0MTBkL3RleHRyZWdpb246NTczZmY4MGQyYjM0NDQxOWEzN2U5NGFmNGE2OTQxMGRfMjE5OTAyMzI4MTQ4MA_9e366f80-3dff-4d29-b518-76d0058360b4">26.3</ix:nonFraction>&#160;million aggregate principal amount of 2021 Notes to common shares and cash repayment of $<ix:nonFraction unitRef="usd" contextRef="i9a2926d0e711448fa37fb03edf2470a1_D20211201-20211201" decimals="-5" name="us-gaap:PaymentsOfDebtIssuanceCosts" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM183My9mcmFnOjU3M2ZmODBkMmIzNDQ0MTlhMzdlOTRhZjRhNjk0MTBkL3RleHRyZWdpb246NTczZmY4MGQyYjM0NDQxOWEzN2U5NGFmNGE2OTQxMGRfMjE5OTAyMzI4MTQ5NA_f147cd65-025f-4f2d-9c11-d97c81d0ee7b">0.4</ix:nonFraction>&#160;million aggregate principal amount of 2021 Notes. Shares issued were valued based on the quoted trading prices on the conversion date for a total fair value of $<ix:nonFraction unitRef="usd" contextRef="ie511597b55e24e0b9a57496e5718443a_I20211201" decimals="-5" name="evh:DebtConversionOriginalDebtFairValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM183My9mcmFnOjU3M2ZmODBkMmIzNDQ0MTlhMzdlOTRhZjRhNjk0MTBkL3RleHRyZWdpb246NTczZmY4MGQyYjM0NDQxOWEzN2U5NGFmNGE2OTQxMGRfMjE5OTAyMzI4MTUwNw_508afcfc-e3cb-43ba-afbb-cbb24f3a45aa">28.5</ix:nonFraction>&#160;million resulting in a loss on debt extinguishment of $<ix:nonFraction unitRef="usd" contextRef="i9a2926d0e711448fa37fb03edf2470a1_D20211201-20211201" decimals="-5" name="us-gaap:GainsLossesOnExtinguishmentOfDebtBeforeWriteOffOfDeferredDebtIssuanceCost" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM183My9mcmFnOjU3M2ZmODBkMmIzNDQ0MTlhMzdlOTRhZjRhNjk0MTBkL3RleHRyZWdpb246NTczZmY4MGQyYjM0NDQxOWEzN2U5NGFmNGE2OTQxMGRfMjE5OTAyMzI4MTUyMQ_7d9b4ba0-9512-4cf2-8e31-afb404320e42">2.2</ix:nonFraction>&#160;million which was recorded in loss on repayment of debt on our consolidated statements of operations and comprehensive income (loss).</span></div></ix:continuation><div><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">96</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i9527dad9e53b44cc83cc31f4e7e0c22c"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Convertible Senior Notes Carrying Value</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2025 Notes and 2024 Notes are recorded on our accompanying consolidated balance sheets at their net carrying values as of December&#160;31, 2021. However, the 2025 Notes and 2024 Notes are privately traded by qualified institutional buyers (within the meaning of Rule 144A under the Securities Act) and their fair values are Level 2 inputs. The 2025 Notes and 2024 Notes also have embedded conversion options and contingent interest provisions, which have not been recorded as separate financial instruments. <ix:nonNumeric contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231" name="us-gaap:ConvertibleDebtTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM183My9mcmFnOjU3M2ZmODBkMmIzNDQ0MTlhMzdlOTRhZjRhNjk0MTBkL3RleHRyZWdpb246NTczZmY4MGQyYjM0NDQxOWEzN2U5NGFmNGE2OTQxMGRfMjExMjA_3b32086d-b221-4545-8187-97fc142a2bf0" continuedAt="id09a097c8db34367844bd11a9dbb9726" escape="true">The following table summarizes the carrying value of the long-term convertible debt as of December&#160;31, 2021 and 2020 (in thousands):</ix:nonNumeric></span></div><ix:continuation id="id09a097c8db34367844bd11a9dbb9726"><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"></td><td style="width:409.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:60.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:60.25pt"></td><td style="width:1.0pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024 Notes</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Carrying value</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id7ce03f7e23c4e8982556c1c3936f37c_I20211231" decimals="-3" name="us-gaap:ConvertibleDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM183My9mcmFnOjU3M2ZmODBkMmIzNDQ0MTlhMzdlOTRhZjRhNjk0MTBkL3RhYmxlOjU4MjJmMjVkMmZjYjQ2MDA4ZTAyNGM5MWI4NjYwY2UyL3RhYmxlcmFuZ2U6NTgyMmYyNWQyZmNiNDYwMDhlMDI0YzkxYjg2NjBjZTJfMi0xLTEtMS0xNzc3NQ_a69c29db-c8ad-4a4e-bef6-0b47e278d299">89,361</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2aac0290566244888dfc87dd98ff26b6_I20201231" decimals="-3" name="us-gaap:ConvertibleDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM183My9mcmFnOjU3M2ZmODBkMmIzNDQ0MTlhMzdlOTRhZjRhNjk0MTBkL3RhYmxlOjU4MjJmMjVkMmZjYjQ2MDA4ZTAyNGM5MWI4NjYwY2UyL3RhYmxlcmFuZ2U6NTgyMmYyNWQyZmNiNDYwMDhlMDI0YzkxYjg2NjBjZTJfMi0zLTEtMS0xNzc3NQ_f0ba85e2-1e23-42ad-8264-4a342d81ca93">81,462</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unamortized debt discount and issuance costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id7ce03f7e23c4e8982556c1c3936f37c_I20211231" decimals="-3" name="us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM183My9mcmFnOjU3M2ZmODBkMmIzNDQ0MTlhMzdlOTRhZjRhNjk0MTBkL3RhYmxlOjU4MjJmMjVkMmZjYjQ2MDA4ZTAyNGM5MWI4NjYwY2UyL3RhYmxlcmFuZ2U6NTgyMmYyNWQyZmNiNDYwMDhlMDI0YzkxYjg2NjBjZTJfMy0xLTEtMS0xNzc3NQ_ec561a01-5b60-4d55-be2e-f1c4894e8a34">27,690</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2aac0290566244888dfc87dd98ff26b6_I20201231" decimals="-3" name="us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM183My9mcmFnOjU3M2ZmODBkMmIzNDQ0MTlhMzdlOTRhZjRhNjk0MTBkL3RhYmxlOjU4MjJmMjVkMmZjYjQ2MDA4ZTAyNGM5MWI4NjYwY2UyL3RhYmxlcmFuZ2U6NTgyMmYyNWQyZmNiNDYwMDhlMDI0YzkxYjg2NjBjZTJfMy0zLTEtMS0xNzc3NQ_d613fba1-f418-45bf-9577-572cb1bcc3f6">35,589</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Principal amount</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id7ce03f7e23c4e8982556c1c3936f37c_I20211231" decimals="-3" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM183My9mcmFnOjU3M2ZmODBkMmIzNDQ0MTlhMzdlOTRhZjRhNjk0MTBkL3RhYmxlOjU4MjJmMjVkMmZjYjQ2MDA4ZTAyNGM5MWI4NjYwY2UyL3RhYmxlcmFuZ2U6NTgyMmYyNWQyZmNiNDYwMDhlMDI0YzkxYjg2NjBjZTJfNC0xLTEtMS0xNzc3NQ_77f8ea8c-8a59-41d7-be1a-2684fbcacbc6">117,051</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2aac0290566244888dfc87dd98ff26b6_I20201231" decimals="-3" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM183My9mcmFnOjU3M2ZmODBkMmIzNDQ0MTlhMzdlOTRhZjRhNjk0MTBkL3RhYmxlOjU4MjJmMjVkMmZjYjQ2MDA4ZTAyNGM5MWI4NjYwY2UyL3RhYmxlcmFuZ2U6NTgyMmYyNWQyZmNiNDYwMDhlMDI0YzkxYjg2NjBjZTJfNC0zLTEtMS0xNzc3NQ_59cc9c66-c453-4289-b6c4-b0ef7f75d551">117,051</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Remaining amortization period (years)</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ifef2fd52529f408dbb3bcb2d3f4ae616_D20210101-20211231" name="us-gaap:DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM183My9mcmFnOjU3M2ZmODBkMmIzNDQ0MTlhMzdlOTRhZjRhNjk0MTBkL3RhYmxlOjU4MjJmMjVkMmZjYjQ2MDA4ZTAyNGM5MWI4NjYwY2UyL3RhYmxlcmFuZ2U6NTgyMmYyNWQyZmNiNDYwMDhlMDI0YzkxYjg2NjBjZTJfNS0xLTEtMS0xNzc3NQ_79272008-528f-494b-ba36-e2b17c1c04d6">2.9</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i2f7a8968a0e74fcfa7af898dd2afb7a6_D20200101-20201231" name="us-gaap:DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM183My9mcmFnOjU3M2ZmODBkMmIzNDQ0MTlhMzdlOTRhZjRhNjk0MTBkL3RhYmxlOjU4MjJmMjVkMmZjYjQ2MDA4ZTAyNGM5MWI4NjYwY2UyL3RhYmxlcmFuZ2U6NTgyMmYyNWQyZmNiNDYwMDhlMDI0YzkxYjg2NjBjZTJfNS0zLTEtMS0xNzc3NQ_640e7230-e487-4e8c-81ef-bbae9e116444">3.9</ix:nonNumeric></span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0f822324d7204951a08832492a541883_I20211231" decimals="-3" name="us-gaap:LongTermDebtFairValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM183My9mcmFnOjU3M2ZmODBkMmIzNDQ0MTlhMzdlOTRhZjRhNjk0MTBkL3RhYmxlOjU4MjJmMjVkMmZjYjQ2MDA4ZTAyNGM5MWI4NjYwY2UyL3RhYmxlcmFuZ2U6NTgyMmYyNWQyZmNiNDYwMDhlMDI0YzkxYjg2NjBjZTJfNi0xLTEtMS0xNzc3NQ_635d20ab-5388-4c9e-a58e-39a0e43c0fcf">195,445</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i40eea1e73a0a4178ad8f4535f4a3950e_I20201231" decimals="-3" name="us-gaap:LongTermDebtFairValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM183My9mcmFnOjU3M2ZmODBkMmIzNDQ0MTlhMzdlOTRhZjRhNjk0MTBkL3RhYmxlOjU4MjJmMjVkMmZjYjQ2MDA4ZTAyNGM5MWI4NjYwY2UyL3RhYmxlcmFuZ2U6NTgyMmYyNWQyZmNiNDYwMDhlMDI0YzkxYjg2NjBjZTJfNi0zLTEtMS0xNzc3NQ_36150e7e-2026-4de6-a739-2f1b54648105">153,220</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2025 Notes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Carrying value</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i974ce0eee5ff4e6280561dba5e0ac368_I20211231" decimals="-3" name="us-gaap:ConvertibleDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM183My9mcmFnOjU3M2ZmODBkMmIzNDQ0MTlhMzdlOTRhZjRhNjk0MTBkL3RhYmxlOjU4MjJmMjVkMmZjYjQ2MDA4ZTAyNGM5MWI4NjYwY2UyL3RhYmxlcmFuZ2U6NTgyMmYyNWQyZmNiNDYwMDhlMDI0YzkxYjg2NjBjZTJfOS0xLTEtMS0xNzc3NQ_5340c550-62de-439d-b9be-28f4cb0f521f">126,315</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i50fb6ca1635f4d128f6a1d489565ad0b_I20201231" decimals="-3" name="us-gaap:ConvertibleDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM183My9mcmFnOjU3M2ZmODBkMmIzNDQ0MTlhMzdlOTRhZjRhNjk0MTBkL3RhYmxlOjU4MjJmMjVkMmZjYjQ2MDA4ZTAyNGM5MWI4NjYwY2UyL3RhYmxlcmFuZ2U6NTgyMmYyNWQyZmNiNDYwMDhlMDI0YzkxYjg2NjBjZTJfOS0zLTEtMS0xNzc3NQ_76650c2b-06ff-4277-8c71-f9ce417d98e2">116,349</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unamortized debt discount and issuance costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i974ce0eee5ff4e6280561dba5e0ac368_I20211231" decimals="-3" name="us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM183My9mcmFnOjU3M2ZmODBkMmIzNDQ0MTlhMzdlOTRhZjRhNjk0MTBkL3RhYmxlOjU4MjJmMjVkMmZjYjQ2MDA4ZTAyNGM5MWI4NjYwY2UyL3RhYmxlcmFuZ2U6NTgyMmYyNWQyZmNiNDYwMDhlMDI0YzkxYjg2NjBjZTJfMTAtMS0xLTEtMTc3NzU_c0ff48c4-c021-445e-bdfb-4200439fd3a4">46,185</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i50fb6ca1635f4d128f6a1d489565ad0b_I20201231" decimals="-3" name="us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM183My9mcmFnOjU3M2ZmODBkMmIzNDQ0MTlhMzdlOTRhZjRhNjk0MTBkL3RhYmxlOjU4MjJmMjVkMmZjYjQ2MDA4ZTAyNGM5MWI4NjYwY2UyL3RhYmxlcmFuZ2U6NTgyMmYyNWQyZmNiNDYwMDhlMDI0YzkxYjg2NjBjZTJfMTAtMy0xLTEtMTc3NzU_d51651ea-3ba5-4c28-b45f-57f824311f0d">56,151</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Principal amount</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i974ce0eee5ff4e6280561dba5e0ac368_I20211231" decimals="-3" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM183My9mcmFnOjU3M2ZmODBkMmIzNDQ0MTlhMzdlOTRhZjRhNjk0MTBkL3RhYmxlOjU4MjJmMjVkMmZjYjQ2MDA4ZTAyNGM5MWI4NjYwY2UyL3RhYmxlcmFuZ2U6NTgyMmYyNWQyZmNiNDYwMDhlMDI0YzkxYjg2NjBjZTJfMTEtMS0xLTEtMTc3NzU_4bfa4a1e-1a82-4fbc-8b68-6449bfc6af4a">172,500</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i50fb6ca1635f4d128f6a1d489565ad0b_I20201231" decimals="-3" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM183My9mcmFnOjU3M2ZmODBkMmIzNDQ0MTlhMzdlOTRhZjRhNjk0MTBkL3RhYmxlOjU4MjJmMjVkMmZjYjQ2MDA4ZTAyNGM5MWI4NjYwY2UyL3RhYmxlcmFuZ2U6NTgyMmYyNWQyZmNiNDYwMDhlMDI0YzkxYjg2NjBjZTJfMTEtMy0xLTEtMTc3NzU_56edd30d-7637-415b-ab2a-ea9eb842d202">172,500</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Remaining amortization period (years)</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i48ca8bc8e051466a9a37e1e1da6febc3_D20210101-20211231" name="us-gaap:DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM183My9mcmFnOjU3M2ZmODBkMmIzNDQ0MTlhMzdlOTRhZjRhNjk0MTBkL3RhYmxlOjU4MjJmMjVkMmZjYjQ2MDA4ZTAyNGM5MWI4NjYwY2UyL3RhYmxlcmFuZ2U6NTgyMmYyNWQyZmNiNDYwMDhlMDI0YzkxYjg2NjBjZTJfMTItMS0xLTEtMTc3NzU_9768c573-4c88-436a-b481-dc005ba5cab9">3.8</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="idd22b7a2c5194e22908f4f8bfed93408_D20200101-20201231" name="us-gaap:DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM183My9mcmFnOjU3M2ZmODBkMmIzNDQ0MTlhMzdlOTRhZjRhNjk0MTBkL3RhYmxlOjU4MjJmMjVkMmZjYjQ2MDA4ZTAyNGM5MWI4NjYwY2UyL3RhYmxlcmFuZ2U6NTgyMmYyNWQyZmNiNDYwMDhlMDI0YzkxYjg2NjBjZTJfMTItMy0xLTEtMTc3NzU_b6a4cea7-1d0b-43b6-9e35-8cb68dc19c02">4.8</ix:nonNumeric></span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7f0d332f713a4f89bb808c44e818aea3_I20211231" decimals="-3" name="us-gaap:LongTermDebtFairValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM183My9mcmFnOjU3M2ZmODBkMmIzNDQ0MTlhMzdlOTRhZjRhNjk0MTBkL3RhYmxlOjU4MjJmMjVkMmZjYjQ2MDA4ZTAyNGM5MWI4NjYwY2UyL3RhYmxlcmFuZ2U6NTgyMmYyNWQyZmNiNDYwMDhlMDI0YzkxYjg2NjBjZTJfMTMtMS0xLTEtMTc3NzU_d59f3705-d018-4262-afd7-9a44bda89357">177,251</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica31b1dea8e04139a2223a01fd1e7439_I20201231" decimals="-3" name="us-gaap:LongTermDebtFairValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM183My9mcmFnOjU3M2ZmODBkMmIzNDQ0MTlhMzdlOTRhZjRhNjk0MTBkL3RhYmxlOjU4MjJmMjVkMmZjYjQ2MDA4ZTAyNGM5MWI4NjYwY2UyL3RhYmxlcmFuZ2U6NTgyMmYyNWQyZmNiNDYwMDhlMDI0YzkxYjg2NjBjZTJfMTMtMy0xLTEtMTc3NzU_f02f0b5b-da58-40bf-a4b3-0f950bc1f063">147,488</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021 Notes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Carrying value</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id04e184022df4434b775ae12babcdd7d_I20211231" decimals="-3" name="us-gaap:ConvertibleDebt" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM183My9mcmFnOjU3M2ZmODBkMmIzNDQ0MTlhMzdlOTRhZjRhNjk0MTBkL3RhYmxlOjU4MjJmMjVkMmZjYjQ2MDA4ZTAyNGM5MWI4NjYwY2UyL3RhYmxlcmFuZ2U6NTgyMmYyNWQyZmNiNDYwMDhlMDI0YzkxYjg2NjBjZTJfMTctMS0xLTEtMzU5NDU_0b9e237c-4781-4fe7-98bc-0f2449b858f2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5f1ed0aa6efc4adda8d9ddf826e7eb41_I20201231" decimals="-3" name="us-gaap:ConvertibleDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM183My9mcmFnOjU3M2ZmODBkMmIzNDQ0MTlhMzdlOTRhZjRhNjk0MTBkL3RhYmxlOjU4MjJmMjVkMmZjYjQ2MDA4ZTAyNGM5MWI4NjYwY2UyL3RhYmxlcmFuZ2U6NTgyMmYyNWQyZmNiNDYwMDhlMDI0YzkxYjg2NjBjZTJfMTctMy0xLTEtMzU5NDU_3646522b-e290-4063-97d3-fdc288b779bd">26,557</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unamortized debt discount and issuance costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id04e184022df4434b775ae12babcdd7d_I20211231" decimals="-3" name="us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM183My9mcmFnOjU3M2ZmODBkMmIzNDQ0MTlhMzdlOTRhZjRhNjk0MTBkL3RhYmxlOjU4MjJmMjVkMmZjYjQ2MDA4ZTAyNGM5MWI4NjYwY2UyL3RhYmxlcmFuZ2U6NTgyMmYyNWQyZmNiNDYwMDhlMDI0YzkxYjg2NjBjZTJfMTgtMS0xLTEtMzU5NDU_cd52499b-bcec-4434-9d85-252c9dd714bf">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5f1ed0aa6efc4adda8d9ddf826e7eb41_I20201231" decimals="-3" name="us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM183My9mcmFnOjU3M2ZmODBkMmIzNDQ0MTlhMzdlOTRhZjRhNjk0MTBkL3RhYmxlOjU4MjJmMjVkMmZjYjQ2MDA4ZTAyNGM5MWI4NjYwY2UyL3RhYmxlcmFuZ2U6NTgyMmYyNWQyZmNiNDYwMDhlMDI0YzkxYjg2NjBjZTJfMTgtMy0xLTEtMzU5NDU_e0ffd5dd-982d-46d5-adb2-dc6d1fc41fb6">180</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Principal amount</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id04e184022df4434b775ae12babcdd7d_I20211231" decimals="-3" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM183My9mcmFnOjU3M2ZmODBkMmIzNDQ0MTlhMzdlOTRhZjRhNjk0MTBkL3RhYmxlOjU4MjJmMjVkMmZjYjQ2MDA4ZTAyNGM5MWI4NjYwY2UyL3RhYmxlcmFuZ2U6NTgyMmYyNWQyZmNiNDYwMDhlMDI0YzkxYjg2NjBjZTJfMTktMS0xLTEtMzU5NDU_217eec06-4489-45a8-9f29-bde1580eb9d8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5f1ed0aa6efc4adda8d9ddf826e7eb41_I20201231" decimals="-3" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM183My9mcmFnOjU3M2ZmODBkMmIzNDQ0MTlhMzdlOTRhZjRhNjk0MTBkL3RhYmxlOjU4MjJmMjVkMmZjYjQ2MDA4ZTAyNGM5MWI4NjYwY2UyL3RhYmxlcmFuZ2U6NTgyMmYyNWQyZmNiNDYwMDhlMDI0YzkxYjg2NjBjZTJfMTktMy0xLTEtMzU5NDU_72124c4c-118f-4ade-9b79-7315bb156dba">26,737</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Remaining amortization period (years)</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i7e9e77d057aa4381855c6fd7a1d6f4ea_D20210101-20211231" name="us-gaap:DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM183My9mcmFnOjU3M2ZmODBkMmIzNDQ0MTlhMzdlOTRhZjRhNjk0MTBkL3RhYmxlOjU4MjJmMjVkMmZjYjQ2MDA4ZTAyNGM5MWI4NjYwY2UyL3RhYmxlcmFuZ2U6NTgyMmYyNWQyZmNiNDYwMDhlMDI0YzkxYjg2NjBjZTJfMjAtMS0xLTEtMzU5NDU_8ecf9174-ab80-4ada-a332-8a5e5036f2f2">0.0</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i087fe618f5364968ac66e7869d1caad5_D20200101-20201231" name="us-gaap:DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM183My9mcmFnOjU3M2ZmODBkMmIzNDQ0MTlhMzdlOTRhZjRhNjk0MTBkL3RhYmxlOjU4MjJmMjVkMmZjYjQ2MDA4ZTAyNGM5MWI4NjYwY2UyL3RhYmxlcmFuZ2U6NTgyMmYyNWQyZmNiNDYwMDhlMDI0YzkxYjg2NjBjZTJfMjAtMy0xLTEtMzU5NDU_1859e54a-14bf-4370-8a9b-56a438373a8f">0.9</ix:nonNumeric></span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id11648efb5084baf81bbd2896c0fcdac_I20211231" decimals="-3" name="us-gaap:LongTermDebtFairValue" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM183My9mcmFnOjU3M2ZmODBkMmIzNDQ0MTlhMzdlOTRhZjRhNjk0MTBkL3RhYmxlOjU4MjJmMjVkMmZjYjQ2MDA4ZTAyNGM5MWI4NjYwY2UyL3RhYmxlcmFuZ2U6NTgyMmYyNWQyZmNiNDYwMDhlMDI0YzkxYjg2NjBjZTJfMjEtMS0xLTEtMzU5NDU_db020b89-ea37-4d74-884c-e02e3019751a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icd0c2590d98d4a87a8626e624f822e5f_I20201231" decimals="-3" name="us-gaap:LongTermDebtFairValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM183My9mcmFnOjU3M2ZmODBkMmIzNDQ0MTlhMzdlOTRhZjRhNjk0MTBkL3RhYmxlOjU4MjJmMjVkMmZjYjQ2MDA4ZTAyNGM5MWI4NjYwY2UyL3RhYmxlcmFuZ2U6NTgyMmYyNWQyZmNiNDYwMDhlMDI0YzkxYjg2NjBjZTJfMjEtMy0xLTEtMzU5NDU_bc7441cf-f5f2-484d-96f2-4c3cdedc90cf">26,470</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:5pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt">Fair values for notes are derived from available trading prices closest to the respective balance sheet date.</span></div></ix:continuation></ix:continuation><div style="margin-top:5pt;text-align:justify"><span><br/></span></div><div id="i9aaa2fddc97e482da5dbe37ac85ae703_79"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 11.  <ix:nonNumeric contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM183OS9mcmFnOmMzNjRjMmIwMjFiMTRiOGFiYzRhOTgzOGJhY2RlZjE5L3RleHRyZWdpb246YzM2NGMyYjAyMWIxNGI4YWJjNGE5ODM4YmFjZGVmMTlfMTIwNjE_2468e8f0-d915-46c5-8973-1ed379e3d503" continuedAt="id17ee7be8b7d48138e233e72c2162751" escape="true">Commitments and Contingencies </ix:nonNumeric></span></div><div><span><br/></span></div><ix:continuation id="id17ee7be8b7d48138e233e72c2162751" continuedAt="i404b0722b4f346068b12b8a2b48a9a36"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Commitments</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Letters of Credit</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2021 and 2020, the Company was party to irrevocable standby letters of credit&#160;with a bank for&#160;$<ix:nonFraction unitRef="usd" contextRef="ia9961196998042f89c9a61f119c53f5e_I20211231" decimals="INF" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM183OS9mcmFnOmMzNjRjMmIwMjFiMTRiOGFiYzRhOTgzOGJhY2RlZjE5L3RleHRyZWdpb246YzM2NGMyYjAyMWIxNGI4YWJjNGE5ODM4YmFjZGVmMTlfMTg5_56003a0b-c4ac-4941-894d-a4e6d669ea11">15.4</ix:nonFraction> million&#160;and $<ix:nonFraction unitRef="usd" contextRef="iede64ab75aa34060b8b77784840d5794_I20201231" decimals="INF" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM183OS9mcmFnOmMzNjRjMmIwMjFiMTRiOGFiYzRhOTgzOGJhY2RlZjE5L3RleHRyZWdpb246YzM2NGMyYjAyMWIxNGI4YWJjNGE5ODM4YmFjZGVmMTlfMTk2_6b9931cd-9f87-4cf5-aaef-d7c9f21d34ba">8.3</ix:nonFraction>&#160;million, respectively, for the benefit of a regulatory authorities, real estate and risk-sharing agreements. As such, we held $<ix:nonFraction unitRef="usd" contextRef="i16c94c74682c4658bb289affc41db310_I20211231" decimals="-5" name="us-gaap:RestrictedCashAndCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM183OS9mcmFnOmMzNjRjMmIwMjFiMTRiOGFiYzRhOTgzOGJhY2RlZjE5L3RleHRyZWdpb246YzM2NGMyYjAyMWIxNGI4YWJjNGE5ODM4YmFjZGVmMTlfMzAy_ab87813f-591b-490c-8a3e-41fa9a485168"><ix:nonFraction unitRef="usd" contextRef="i1ceb37a7eda64dfab33aaf8b47cbcf60_I20211231" decimals="-5" name="us-gaap:RestrictedCashAndCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM183OS9mcmFnOmMzNjRjMmIwMjFiMTRiOGFiYzRhOTgzOGJhY2RlZjE5L3RleHRyZWdpb246YzM2NGMyYjAyMWIxNGI4YWJjNGE5ODM4YmFjZGVmMTlfMzAy_f75d3fb4-bd4a-4ac3-8b24-5b244250c742">15.4</ix:nonFraction></ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i1f3461e188de4f5c80fc4743b6823420_I20201231" decimals="-5" name="us-gaap:RestrictedCashAndCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM183OS9mcmFnOmMzNjRjMmIwMjFiMTRiOGFiYzRhOTgzOGJhY2RlZjE5L3RleHRyZWdpb246YzM2NGMyYjAyMWIxNGI4YWJjNGE5ODM4YmFjZGVmMTlfMzA5_4302a173-c888-49f9-a05b-d582cd8794d0"><ix:nonFraction unitRef="usd" contextRef="iffcd0f576b5c4f27b02cf64ca97d07d5_I20201231" decimals="-5" name="us-gaap:RestrictedCashAndCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM183OS9mcmFnOmMzNjRjMmIwMjFiMTRiOGFiYzRhOTgzOGJhY2RlZjE5L3RleHRyZWdpb246YzM2NGMyYjAyMWIxNGI4YWJjNGE5ODM4YmFjZGVmMTlfMzA5_8db7bd35-524d-4790-b02a-0e39fa8efbb8">8.3</ix:nonFraction></ix:nonFraction>&#160;million in restricted cash and restricted investments as collateral as of December&#160;31, 2021 and December&#160;31, 2020, respectively. The letters of credit have current expiration dates between January 2022 and March 2032 and will automatically extend without amendment for an additional one-year period and will continue to automatically extend after each one-year term from the expiry date unless the bank elects not to extend beyond the initial or any extended expiry date. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Indemnifications</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s customer agreements generally include a provision by which the Company agrees to defend its partners against third-party claims (a) for death, bodily injury, or damage to personal property caused by Company negligence or willful misconduct, (b) by former or current Company employees arising from such managed service agreements, (c) for intellectual property infringement under specified conditions and (d) for Company violation of applicable laws, and to indemnify them against any damages and costs awarded in connection with such claims. To date, the Company has not incurred any material costs as a result of such indemnities and has not accrued any liabilities related to such obligations in the accompanying consolidated financial statements.</span></div></ix:continuation><div style="text-align:justify"><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">97</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i404b0722b4f346068b12b8a2b48a9a36" continuedAt="i09387b23987d448b9f74a75be26186b0"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Pre-IPO Investor Registration Rights Agreement</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We entered into a registration rights agreement with The Advisory Board, UPMC, TPG and another investor to register for sale under the Securities Act shares of our Class A common stock, including those delivered in exchange for Class B common stock and Class B common units. Subject to certain conditions and limitations, this agreement provides these investors with certain demand, piggyback and shelf registration rights. The registration rights granted under the registration rights agreement will terminate upon the date the holders of shares that are a party thereto no longer hold any such shares that are entitled to registration rights. Pursuant to our contractual obligations under this agreement, we filed a registration statement on Form S-3 with the SEC on July 28, 2016, which was declared effective on August 12, 2016.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We will pay all expenses relating to any demand, piggyback or shelf registration, other than underwriting discounts and commissions and any transfer taxes, subject to specified conditions and limitations. The registration rights agreement includes customary indemnification provisions, including indemnification of the participating holders of shares of Class A common stock and their directors, officers and employees by us for any losses, claims, damages or liabilities in respect thereof and expenses to which such holders may become subject under the Securities Act, state law or otherwise. We did not incur any expenses related to secondary offerings or other sales of shares by our investor stockholders during the years ended December 31, 2021, 2020 and 2019, respectively. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Guarantees</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In connection with the Molina Closing, the Company continued to provide administrative support services relating to the Passport Medicaid Contract to Molina through the end of 2020. Following the Molina Closing, EVH Passport began working with regulatory authorities including the Kentucky Department of Insurance (&#8220;KY DOI&#8221;) regarding the wind down of its operations throughout 2021. As part of that wind down process, the Company, as the parent of EVH Passport, entered into a guarantee for the benefit of the KY DOI to satisfy any EVH Passport liability or obligation in the event EVH Passport is not able to meet its wind down liabilities or obligations. As of December&#160;31, 2021, no amounts have been funded under this guarantee.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Reinsurance Agreements</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of the Passport Closing, EVH Passport and UHC entered into an agreement that provided for the administration and assumption of the financial risks by EVH Passport of the D-SNP Business until such time as EVH Passport became certified as a Medicare Advantage Organization and the D-SNP Business could be transferred to EVH Passport.  On October 1, 2020, the D-SNP Business was transferred from UHC to EVH Passport.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the Molina Closing, Molina and EVH Passport entered into an agreement that provided for the assumption of the financial risks by Molina of the D-SNP Business until such time as Molina&#8217;s Kentucky health plan becomes certified as a Medicare Advantage Organization and the D-SNP Business is transferred to Molina. The Company and EVH Passport continued to administer the D-SNP Business until January 1, 2021, at which time Molina became responsible for its administration until the D-SNP Business was officially transferred to Molina effective September 1, 2021.</span></div><div style="text-align:justify"><span><br/></span></div><ix:nonNumeric contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231" name="us-gaap:EffectsOfReinsuranceTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM183OS9mcmFnOmMzNjRjMmIwMjFiMTRiOGFiYzRhOTgzOGJhY2RlZjE5L3RleHRyZWdpb246YzM2NGMyYjAyMWIxNGI4YWJjNGE5ODM4YmFjZGVmMTlfMTIwNjg_5cdc7c38-6b01-4694-a026-f788a67fde0c" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following summarizes premiums and claims assumed under the Reinsurance Agreements for the years ended December 31, 2021, 2020 and 2019 (in thousands):</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"></td><td style="width:387.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:46.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:46.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:46.00pt"></td><td style="width:1.0pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Year Ended December 31,</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reinsurance premiums assumed</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231" decimals="-3" name="us-gaap:AssumedPremiumsWritten" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM183OS9mcmFnOmMzNjRjMmIwMjFiMTRiOGFiYzRhOTgzOGJhY2RlZjE5L3RhYmxlOjFlODc4Y2VjZmM0ZjQ1ZDFhNzYyMzdmNWJjM2ZhMjA1L3RhYmxlcmFuZ2U6MWU4NzhjZWNmYzRmNDVkMWE3NjIzN2Y1YmMzZmEyMDVfMi0xLTEtMS0xNzc3NQ_696509af-1a30-4444-8093-f628aab0859c">23,179</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i12a6d1161de54547bd29f8efccd4c9b0_D20200101-20201231" decimals="-3" name="us-gaap:AssumedPremiumsWritten" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM183OS9mcmFnOmMzNjRjMmIwMjFiMTRiOGFiYzRhOTgzOGJhY2RlZjE5L3RhYmxlOjFlODc4Y2VjZmM0ZjQ1ZDFhNzYyMzdmNWJjM2ZhMjA1L3RhYmxlcmFuZ2U6MWU4NzhjZWNmYzRmNDVkMWE3NjIzN2Y1YmMzZmEyMDVfMi0zLTEtMS0xNzc3NQ_853cbe74-b3cf-421f-a938-165cf0af5b6a">19,130</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e21049ffc224cacb8134d73c9bb5b38_D20190101-20191231" decimals="-3" name="us-gaap:AssumedPremiumsWritten" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM183OS9mcmFnOmMzNjRjMmIwMjFiMTRiOGFiYzRhOTgzOGJhY2RlZjE5L3RhYmxlOjFlODc4Y2VjZmM0ZjQ1ZDFhNzYyMzdmNWJjM2ZhMjA1L3RhYmxlcmFuZ2U6MWU4NzhjZWNmYzRmNDVkMWE3NjIzN2Y1YmMzZmEyMDVfMi01LTEtMS0yNzQ4Ng_682ce907-e17c-42e2-8192-47256a5abeaf">83,325</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reinsurance premiums ceded</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231" decimals="-3" name="us-gaap:CededPremiumsWritten" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM183OS9mcmFnOmMzNjRjMmIwMjFiMTRiOGFiYzRhOTgzOGJhY2RlZjE5L3RhYmxlOjFlODc4Y2VjZmM0ZjQ1ZDFhNzYyMzdmNWJjM2ZhMjA1L3RhYmxlcmFuZ2U6MWU4NzhjZWNmYzRmNDVkMWE3NjIzN2Y1YmMzZmEyMDVfMy0xLTEtMS0xNzc3NQ_11d89676-79dd-4e72-96ee-7147a096fd81">1,614</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i12a6d1161de54547bd29f8efccd4c9b0_D20200101-20201231" decimals="-3" name="us-gaap:CededPremiumsWritten" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM183OS9mcmFnOmMzNjRjMmIwMjFiMTRiOGFiYzRhOTgzOGJhY2RlZjE5L3RhYmxlOjFlODc4Y2VjZmM0ZjQ1ZDFhNzYyMzdmNWJjM2ZhMjA1L3RhYmxlcmFuZ2U6MWU4NzhjZWNmYzRmNDVkMWE3NjIzN2Y1YmMzZmEyMDVfMy0zLTEtMS0xNzc3NQ_e0a68515-38d5-41bb-8873-9bdcb48167b5">3,275</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e21049ffc224cacb8134d73c9bb5b38_D20190101-20191231" decimals="-3" name="us-gaap:CededPremiumsWritten" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM183OS9mcmFnOmMzNjRjMmIwMjFiMTRiOGFiYzRhOTgzOGJhY2RlZjE5L3RhYmxlOjFlODc4Y2VjZmM0ZjQ1ZDFhNzYyMzdmNWJjM2ZhMjA1L3RhYmxlcmFuZ2U6MWU4NzhjZWNmYzRmNDVkMWE3NjIzN2Y1YmMzZmEyMDVfMy01LTEtMS0yNzQ4Ng_5c11fbc5-61ca-47ab-93f7-db0099bb2265">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Claims assumed</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231" decimals="-3" name="us-gaap:ReinsuranceEffectOnClaimsAndBenefitsIncurredAmountAssumed" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM183OS9mcmFnOmMzNjRjMmIwMjFiMTRiOGFiYzRhOTgzOGJhY2RlZjE5L3RhYmxlOjFlODc4Y2VjZmM0ZjQ1ZDFhNzYyMzdmNWJjM2ZhMjA1L3RhYmxlcmFuZ2U6MWU4NzhjZWNmYzRmNDVkMWE3NjIzN2Y1YmMzZmEyMDVfNC0xLTEtMS0xNzc3NQ_0033a2c9-141f-453e-a40b-c577cf14a3eb">20,468</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i12a6d1161de54547bd29f8efccd4c9b0_D20200101-20201231" decimals="-3" name="us-gaap:ReinsuranceEffectOnClaimsAndBenefitsIncurredAmountAssumed" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM183OS9mcmFnOmMzNjRjMmIwMjFiMTRiOGFiYzRhOTgzOGJhY2RlZjE5L3RhYmxlOjFlODc4Y2VjZmM0ZjQ1ZDFhNzYyMzdmNWJjM2ZhMjA1L3RhYmxlcmFuZ2U6MWU4NzhjZWNmYzRmNDVkMWE3NjIzN2Y1YmMzZmEyMDVfNC0zLTEtMS0xNzc3NQ_59329876-dad4-4a07-80f3-11a2725520ac">14,812</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e21049ffc224cacb8134d73c9bb5b38_D20190101-20191231" decimals="-3" name="us-gaap:ReinsuranceEffectOnClaimsAndBenefitsIncurredAmountAssumed" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM183OS9mcmFnOmMzNjRjMmIwMjFiMTRiOGFiYzRhOTgzOGJhY2RlZjE5L3RhYmxlOjFlODc4Y2VjZmM0ZjQ1ZDFhNzYyMzdmNWJjM2ZhMjA1L3RhYmxlcmFuZ2U6MWU4NzhjZWNmYzRmNDVkMWE3NjIzN2Y1YmMzZmEyMDVfNC01LTEtMS0yNzQ4Ng_aa6f4f50-6691-4eb6-8d77-0f7dd95c36bc">72,594</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Claims ceded</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231" decimals="-3" name="us-gaap:ReinsuranceEffectOnClaimsAndBenefitsIncurredAmountCeded" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM183OS9mcmFnOmMzNjRjMmIwMjFiMTRiOGFiYzRhOTgzOGJhY2RlZjE5L3RhYmxlOjFlODc4Y2VjZmM0ZjQ1ZDFhNzYyMzdmNWJjM2ZhMjA1L3RhYmxlcmFuZ2U6MWU4NzhjZWNmYzRmNDVkMWE3NjIzN2Y1YmMzZmEyMDVfNS0xLTEtMS0xNzc3NQ_58e4facc-8748-401f-a8cd-c750e6c748c4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i12a6d1161de54547bd29f8efccd4c9b0_D20200101-20201231" decimals="-3" name="us-gaap:ReinsuranceEffectOnClaimsAndBenefitsIncurredAmountCeded" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM183OS9mcmFnOmMzNjRjMmIwMjFiMTRiOGFiYzRhOTgzOGJhY2RlZjE5L3RhYmxlOjFlODc4Y2VjZmM0ZjQ1ZDFhNzYyMzdmNWJjM2ZhMjA1L3RhYmxlcmFuZ2U6MWU4NzhjZWNmYzRmNDVkMWE3NjIzN2Y1YmMzZmEyMDVfNS0zLTEtMS0xNzc3NQ_4195472a-f8f3-4704-a421-56b8e47a789e">422</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e21049ffc224cacb8134d73c9bb5b38_D20190101-20191231" decimals="-3" name="us-gaap:ReinsuranceEffectOnClaimsAndBenefitsIncurredAmountCeded" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM183OS9mcmFnOmMzNjRjMmIwMjFiMTRiOGFiYzRhOTgzOGJhY2RlZjE5L3RhYmxlOjFlODc4Y2VjZmM0ZjQ1ZDFhNzYyMzdmNWJjM2ZhMjA1L3RhYmxlcmFuZ2U6MWU4NzhjZWNmYzRmNDVkMWE3NjIzN2Y1YmMzZmEyMDVfNS01LTEtMS0yNzQ4Ng_42250b28-9805-48c9-a8e6-4bd350f860fb">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Claims-related administrative expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231" decimals="-3" name="evh:PolicyholderBenefitsAndClaimsIncurredAssumedExpensesRelatedToClaims" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM183OS9mcmFnOmMzNjRjMmIwMjFiMTRiOGFiYzRhOTgzOGJhY2RlZjE5L3RhYmxlOjFlODc4Y2VjZmM0ZjQ1ZDFhNzYyMzdmNWJjM2ZhMjA1L3RhYmxlcmFuZ2U6MWU4NzhjZWNmYzRmNDVkMWE3NjIzN2Y1YmMzZmEyMDVfNi0xLTEtMS0xNzc3NQ_74eacca1-1bbc-4676-94bf-5d840767bbe9">2,159</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i12a6d1161de54547bd29f8efccd4c9b0_D20200101-20201231" decimals="-3" name="evh:PolicyholderBenefitsAndClaimsIncurredAssumedExpensesRelatedToClaims" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM183OS9mcmFnOmMzNjRjMmIwMjFiMTRiOGFiYzRhOTgzOGJhY2RlZjE5L3RhYmxlOjFlODc4Y2VjZmM0ZjQ1ZDFhNzYyMzdmNWJjM2ZhMjA1L3RhYmxlcmFuZ2U6MWU4NzhjZWNmYzRmNDVkMWE3NjIzN2Y1YmMzZmEyMDVfNi0zLTEtMS0xNzc3NQ_461ca761-02fa-40ab-a35e-523d7beeb243">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e21049ffc224cacb8134d73c9bb5b38_D20190101-20191231" decimals="-3" name="evh:PolicyholderBenefitsAndClaimsIncurredAssumedExpensesRelatedToClaims" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM183OS9mcmFnOmMzNjRjMmIwMjFiMTRiOGFiYzRhOTgzOGJhY2RlZjE5L3RhYmxlOjFlODc4Y2VjZmM0ZjQ1ZDFhNzYyMzdmNWJjM2ZhMjA1L3RhYmxlcmFuZ2U6MWU4NzhjZWNmYzRmNDVkMWE3NjIzN2Y1YmMzZmEyMDVfNi01LTEtMS0yNzQ4Ng_8d05da94-8e12-4431-9387-fffd1a9f2f5a">14,024</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:24pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Increase (decrease) in reserves for claims and performance-based arrangements attributable to the Reinsurance Agreement</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231" decimals="-3" name="evh:PremiumsWrittenAndPolicyholderBenefitsAndClaimsIncurredNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM183OS9mcmFnOmMzNjRjMmIwMjFiMTRiOGFiYzRhOTgzOGJhY2RlZjE5L3RhYmxlOjFlODc4Y2VjZmM0ZjQ1ZDFhNzYyMzdmNWJjM2ZhMjA1L3RhYmxlcmFuZ2U6MWU4NzhjZWNmYzRmNDVkMWE3NjIzN2Y1YmMzZmEyMDVfNy0xLTEtMS0xNzc3NQ_ec3432ba-33a0-4301-88e9-c8e11942e677">2,166</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i12a6d1161de54547bd29f8efccd4c9b0_D20200101-20201231" decimals="-3" name="evh:PremiumsWrittenAndPolicyholderBenefitsAndClaimsIncurredNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM183OS9mcmFnOmMzNjRjMmIwMjFiMTRiOGFiYzRhOTgzOGJhY2RlZjE5L3RhYmxlOjFlODc4Y2VjZmM0ZjQ1ZDFhNzYyMzdmNWJjM2ZhMjA1L3RhYmxlcmFuZ2U6MWU4NzhjZWNmYzRmNDVkMWE3NjIzN2Y1YmMzZmEyMDVfNy0zLTEtMS0xNzc3NQ_22c01a7a-3a4d-479e-a07c-aef6baadcc73">1,465</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3e21049ffc224cacb8134d73c9bb5b38_D20190101-20191231" decimals="-3" sign="-" name="evh:PremiumsWrittenAndPolicyholderBenefitsAndClaimsIncurredNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM183OS9mcmFnOmMzNjRjMmIwMjFiMTRiOGFiYzRhOTgzOGJhY2RlZjE5L3RhYmxlOjFlODc4Y2VjZmM0ZjQ1ZDFhNzYyMzdmNWJjM2ZhMjA1L3RhYmxlcmFuZ2U6MWU4NzhjZWNmYzRmNDVkMWE3NjIzN2Y1YmMzZmEyMDVfNy01LTEtMS0yNzQ4Ng_08a70929-7d2e-45da-931b-b259bd9363b8">3,293</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:24pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reserves for claims and performance-based arrangements attributable to the Reinsurance Agreement at the beginning of the period</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc0c0c2b8dc04c5698ca0577a54b2e03_I20201231" decimals="-3" name="us-gaap:AssumedLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM183OS9mcmFnOmMzNjRjMmIwMjFiMTRiOGFiYzRhOTgzOGJhY2RlZjE5L3RhYmxlOjFlODc4Y2VjZmM0ZjQ1ZDFhNzYyMzdmNWJjM2ZhMjA1L3RhYmxlcmFuZ2U6MWU4NzhjZWNmYzRmNDVkMWE3NjIzN2Y1YmMzZmEyMDVfOC0xLTEtMS0xNzc3NQ_67189e3c-4bec-450a-a739-73db4735133a">4,002</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icba6e493923b449aa57c46a563760234_I20191231" decimals="-3" name="us-gaap:AssumedLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM183OS9mcmFnOmMzNjRjMmIwMjFiMTRiOGFiYzRhOTgzOGJhY2RlZjE5L3RhYmxlOjFlODc4Y2VjZmM0ZjQ1ZDFhNzYyMzdmNWJjM2ZhMjA1L3RhYmxlcmFuZ2U6MWU4NzhjZWNmYzRmNDVkMWE3NjIzN2Y1YmMzZmEyMDVfOC0zLTEtMS0xNzc3NQ_de1beb8d-927b-43b7-84d3-2a5395a22a0c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7130cb432c4b4fe7a260e8a3beeb35d8_I20181231" decimals="-3" name="us-gaap:AssumedLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM183OS9mcmFnOmMzNjRjMmIwMjFiMTRiOGFiYzRhOTgzOGJhY2RlZjE5L3RhYmxlOjFlODc4Y2VjZmM0ZjQ1ZDFhNzYyMzdmNWJjM2ZhMjA1L3RhYmxlcmFuZ2U6MWU4NzhjZWNmYzRmNDVkMWE3NjIzN2Y1YmMzZmEyMDVfOC01LTEtMS0yNzQ4Ng_e70ff4d4-9bac-40d1-b29a-5189c000da8f">1,243</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:23pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Impact of consolidation on payable for claims and performance-based arrangements attributable to the Reinsurance Agreement</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231" decimals="-3" name="evh:AssumedLiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseImpactOfConsolidationOnPayables" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM183OS9mcmFnOmMzNjRjMmIwMjFiMTRiOGFiYzRhOTgzOGJhY2RlZjE5L3RhYmxlOjFlODc4Y2VjZmM0ZjQ1ZDFhNzYyMzdmNWJjM2ZhMjA1L3RhYmxlcmFuZ2U6MWU4NzhjZWNmYzRmNDVkMWE3NjIzN2Y1YmMzZmEyMDVfOS0xLTEtMS0xNzc3NQ_376a28b9-f6c8-488c-b7c9-9b42f7f2cea0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i12a6d1161de54547bd29f8efccd4c9b0_D20200101-20201231" decimals="-3" name="evh:AssumedLiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseImpactOfConsolidationOnPayables" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM183OS9mcmFnOmMzNjRjMmIwMjFiMTRiOGFiYzRhOTgzOGJhY2RlZjE5L3RhYmxlOjFlODc4Y2VjZmM0ZjQ1ZDFhNzYyMzdmNWJjM2ZhMjA1L3RhYmxlcmFuZ2U6MWU4NzhjZWNmYzRmNDVkMWE3NjIzN2Y1YmMzZmEyMDVfOS0zLTEtMS0xNzc3NQ_651f7367-4f70-4782-8fcd-4c35d4bfac6d">502</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e21049ffc224cacb8134d73c9bb5b38_D20190101-20191231" decimals="-3" name="evh:AssumedLiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseImpactOfConsolidationOnPayables" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM183OS9mcmFnOmMzNjRjMmIwMjFiMTRiOGFiYzRhOTgzOGJhY2RlZjE5L3RhYmxlOjFlODc4Y2VjZmM0ZjQ1ZDFhNzYyMzdmNWJjM2ZhMjA1L3RhYmxlcmFuZ2U6MWU4NzhjZWNmYzRmNDVkMWE3NjIzN2Y1YmMzZmEyMDVfOS01LTEtMS0yNzQ4Ng_03ab5207-6d00-4e3e-b90d-3d5db0c843ff">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reinsurance payments paid (received)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231" decimals="-3" name="us-gaap:PaymentsForReinsurance" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM183OS9mcmFnOmMzNjRjMmIwMjFiMTRiOGFiYzRhOTgzOGJhY2RlZjE5L3RhYmxlOjFlODc4Y2VjZmM0ZjQ1ZDFhNzYyMzdmNWJjM2ZhMjA1L3RhYmxlcmFuZ2U6MWU4NzhjZWNmYzRmNDVkMWE3NjIzN2Y1YmMzZmEyMDVfMTAtMS0xLTEtMTc3NzU_104bfd1c-dab6-4247-92dd-939435fc7f81">6,078</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i12a6d1161de54547bd29f8efccd4c9b0_D20200101-20201231" decimals="-3" name="evh:ProceedsFromReinsurance" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM183OS9mcmFnOmMzNjRjMmIwMjFiMTRiOGFiYzRhOTgzOGJhY2RlZjE5L3RhYmxlOjFlODc4Y2VjZmM0ZjQ1ZDFhNzYyMzdmNWJjM2ZhMjA1L3RhYmxlcmFuZ2U6MWU4NzhjZWNmYzRmNDVkMWE3NjIzN2Y1YmMzZmEyMDVfMTAtMy0xLTEtMTc3NzU_e705c1f0-8296-4bb3-ab3c-67991c9e9d16">3,039</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e21049ffc224cacb8134d73c9bb5b38_D20190101-20191231" decimals="-3" name="us-gaap:PaymentsForReinsurance" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM183OS9mcmFnOmMzNjRjMmIwMjFiMTRiOGFiYzRhOTgzOGJhY2RlZjE5L3RhYmxlOjFlODc4Y2VjZmM0ZjQ1ZDFhNzYyMzdmNWJjM2ZhMjA1L3RhYmxlcmFuZ2U6MWU4NzhjZWNmYzRmNDVkMWE3NjIzN2Y1YmMzZmEyMDVfMTAtNS0xLTEtMjc0ODY_b2f8ebcc-4586-41e5-9a34-27b568249ba6">4,536</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:24pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payable for claims and performance-based arrangements attributable to the Reinsurance Agreement at the end of the period</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8daff60be410426d8f7bd49343c1ec0c_I20211231" decimals="-3" name="us-gaap:AssumedLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM183OS9mcmFnOmMzNjRjMmIwMjFiMTRiOGFiYzRhOTgzOGJhY2RlZjE5L3RhYmxlOjFlODc4Y2VjZmM0ZjQ1ZDFhNzYyMzdmNWJjM2ZhMjA1L3RhYmxlcmFuZ2U6MWU4NzhjZWNmYzRmNDVkMWE3NjIzN2Y1YmMzZmEyMDVfMTEtMS0xLTEtMTc3NzU_643180ef-46ba-42f1-b215-ee3e4d1d819c">90</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc0c0c2b8dc04c5698ca0577a54b2e03_I20201231" decimals="-3" name="us-gaap:AssumedLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM183OS9mcmFnOmMzNjRjMmIwMjFiMTRiOGFiYzRhOTgzOGJhY2RlZjE5L3RhYmxlOjFlODc4Y2VjZmM0ZjQ1ZDFhNzYyMzdmNWJjM2ZhMjA1L3RhYmxlcmFuZ2U6MWU4NzhjZWNmYzRmNDVkMWE3NjIzN2Y1YmMzZmEyMDVfMTEtMy0xLTEtMTc3NzU_5d9edc6f-f396-4c4e-917f-a70f10bbe98f">4,002</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icba6e493923b449aa57c46a563760234_I20191231" decimals="-3" name="us-gaap:AssumedLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM183OS9mcmFnOmMzNjRjMmIwMjFiMTRiOGFiYzRhOTgzOGJhY2RlZjE5L3RhYmxlOjFlODc4Y2VjZmM0ZjQ1ZDFhNzYyMzdmNWJjM2ZhMjA1L3RhYmxlcmFuZ2U6MWU4NzhjZWNmYzRmNDVkMWE3NjIzN2Y1YmMzZmEyMDVfMTEtNS0xLTEtMjc0ODY_bd73489c-da58-457b-86fa-25cd57840396">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">98</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span><br/></span></div><ix:continuation id="i09387b23987d448b9f74a75be26186b0" continuedAt="i6465ebfcf9a3419b8a24d83a091030c5"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">UPMC Reseller Agreement</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company and UPMC are parties to a reseller, services and non-competition agreement, dated August 31, 2011, which was amended and restated by the parties on June 27, 2013 (as amended through the date hereof, the &#8220;UPMC Reseller Agreement&#8221;). Under the terms of the UPMC Reseller Agreement, UPMC has appointed the Company as a non-exclusive reseller of certain services, subject to certain conditions and limitations specified in the UPMC Reseller Agreement. In consideration for the Company&#8217;s obligations under the UPMC Reseller Agreement and subject to certain conditions described therein, UPMC has agreed not to sell certain products and services directly to a defined list of 20 of the Company&#8217;s customers.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Contingencies</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Tax Receivables Agreement</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Offering Reorganization, the Company entered into the Tax Receivables Agreement (the &#8220;TRA&#8221;) with certain of its investors, which provides for the payment by the Company to these investors of <ix:nonFraction unitRef="number" contextRef="i8daff60be410426d8f7bd49343c1ec0c_I20211231" decimals="INF" name="evh:TaxReceivablesAgreementPercentofTaxSavingstobePaid" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM183OS9mcmFnOmMzNjRjMmIwMjFiMTRiOGFiYzRhOTgzOGJhY2RlZjE5L3RleHRyZWdpb246YzM2NGMyYjAyMWIxNGI4YWJjNGE5ODM4YmFjZGVmMTlfNjA1NA_acab48b8-ee43-4021-991b-a48ad2179509">85</ix:nonFraction>% of the amount of the tax benefits, if any, that the Company is deemed to realize as a result of increases in our tax basis related to exchanges of Class B common units as well as tax benefits attributable to the future utilization of pre-IPO NOLs. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Due to the items noted above, and the fact that Evolent Health, Inc. is in a full valuation allowance position such that the deferred tax assets related to the Company&#8217;s historical pre-IPO losses and tax basis increase benefit from exchanges have not been realized, the Company has not recorded a liability pursuant to the TRA.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Litigation Matters</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are engaged from time to time in certain legal disputes arising in the ordinary course of business, including employment claims. When the likelihood of a loss contingency becomes probable and the amount of the loss can be reasonably estimated, we accrue a liability for the loss contingency. We continue to review accruals and adjust them to reflect ongoing negotiations, settlements, rulings, advice of legal counsel, and other relevant information. To the extent new information is obtained, and our views on the probable outcomes of claims, suits, assessments, investigations or legal proceedings change, changes in our accrued liabilities would be recorded in the period in which such determination is made.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 8, 2019, a shareholder of the Company filed a class action complaint against the Company, asserting claims under Section 10(b) and 20(a) of the Securities Exchange Act of 1934, in the United States District Court, Eastern District of Virginia, Alexandria Division. An amended complaint was filed on January 10, 2020, a second amended complaint was filed on June 8, 2020, and a third amended complaint, now titled </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Plymouth County Retirement System v. Evolent Health, Inc., Frank Williams, Nicholas McGrane, Seth Blackley</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, was filed on December 2, 2021. The case alleges that the Company&#8217;s executives made false or misleading statements regarding its business with Passport. The Company filed a motion to dismiss the second amended complaint, and the Eastern District of Virginia granted in part and denied in part the motion on March 24, 2021. The case entered the discovery phase, but discovery is again stayed pending a decision on the company&#8217;s third motion to dismiss, which was filed December 17, 2021. Briefing on the motion to dismiss was completed on February 10, 2022, and oral argument will be held on March 11, 2022.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Based on the Company&#8217;s investigation, we believe the case has little legal or factual merit. However, the outcome of any litigation is uncertain.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 8, 2021, a shareholder of the Company filed a derivative action in the Delaware Chancery Court against some current and former Board members and against the Company as a nominal defendant, alleging that the Company&#8217;s Board was negligent in its oversight of the Company&#8217;s relationship with Passport Health Plan. The case is Lincolnshire Police Pension Fund, derivatively on behalf of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Evolent Health, Inc., v. Blackley, Williams, Scott, Holder, Farner, D&#8217;Amato, Duffy, Felt, Samet, Hobart, and Payson</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and Evolent Health, Inc. The Company and the Director-Defendants filed a motion to dismiss the complaint on August 27, 2021, and Plaintiffs responded by filing an amended complaint on October 26, 2021. Defendants filed a motion to dismiss the amended complaint on December 17, 2021.  Subsequently, the parties agreed to stay the case pending the decision on the Company&#8217;s motion to dismiss the third amended complaint, currently pending in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Plymouth County Retirement System v. Evolent Health, Frank Williams, Nicky McGrane, and Seth Blackley</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, in federal district court. Based on the Company&#8217;s investigation, we believe the case has little legal or factual merit. However, the outcome of any litigation is uncertain.</span></div></ix:continuation><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">99</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i6465ebfcf9a3419b8a24d83a091030c5" continuedAt="i45b70ea2ec6143c0b8e557d968d557de"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Credit and Concentration Risk</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is subject to significant concentrations of credit risk related to cash and cash equivalents and accounts receivable. As of December&#160;31, 2021, approximately <ix:nonFraction unitRef="number" contextRef="i8daff60be410426d8f7bd49343c1ec0c_I20211231" decimals="3" name="evh:CashFDICInsuredAmountPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM183OS9mcmFnOmMzNjRjMmIwMjFiMTRiOGFiYzRhOTgzOGJhY2RlZjE5L3RleHRyZWdpb246YzM2NGMyYjAyMWIxNGI4YWJjNGE5ODM4YmFjZGVmMTlfMTAzMTE_01d024d7-4f0c-4127-94d6-cea05095bde4">99.4</ix:nonFraction>% of our $<ix:nonFraction unitRef="usd" contextRef="i8daff60be410426d8f7bd49343c1ec0c_I20211231" decimals="-5" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM183OS9mcmFnOmMzNjRjMmIwMjFiMTRiOGFiYzRhOTgzOGJhY2RlZjE5L3RleHRyZWdpb246YzM2NGMyYjAyMWIxNGI4YWJjNGE5ODM4YmFjZGVmMTlfMTAzMjE_32b3b936-4b91-4cd8-9126-709a77f2af18">354.9</ix:nonFraction> million of cash and cash equivalents, restricted cash and restricted investments were held in bank deposits with FDIC participating banks and approximately <ix:nonFraction unitRef="number" contextRef="i8daff60be410426d8f7bd49343c1ec0c_I20211231" decimals="3" name="evh:CashHeldInInternationalBanksPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM183OS9mcmFnOmMzNjRjMmIwMjFiMTRiOGFiYzRhOTgzOGJhY2RlZjE5L3RleHRyZWdpb246YzM2NGMyYjAyMWIxNGI4YWJjNGE5ODM4YmFjZGVmMTlfMTA0NzI_871d261f-6da6-46c6-b5c0-20638639ab2e">0.6</ix:nonFraction>% were held in international banks. While the Company maintains its cash and cash equivalents with financial institutions with high credit ratings, it often maintains these deposits in federally insured financial institutions in excess of federally insured limits. The Company has not experienced any realized losses on cash and cash equivalents to date.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is also subject to significant concentration of accounts receivable risk as a substantial portion of our trade accounts receivable is derived from a small number of our partners. <ix:nonNumeric contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231" name="us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM183OS9mcmFnOmMzNjRjMmIwMjFiMTRiOGFiYzRhOTgzOGJhY2RlZjE5L3RleHRyZWdpb246YzM2NGMyYjAyMWIxNGI4YWJjNGE5ODM4YmFjZGVmMTlfMTIwNTc_b6fed238-72b2-44db-95f2-c5c774283b66" continuedAt="ie0814f3ddc424e90887c28efa489fc8c" escape="true">The following table summarizes the partners who represented at least 10.0% of our consolidated trade accounts receivable as of December&#160;31, 2021 and December&#160;31, 2020:</ix:nonNumeric></span></div><ix:continuation id="ie0814f3ddc424e90887c28efa489fc8c" continuedAt="i23fc8f7ccd31428ba2d76b360794a67e"><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"></td><td style="width:426.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:55.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:48.25pt"></td><td style="width:1.0pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31,</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cook County Health and Hospitals System</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="id08281884be844d0a19d848a335a5a80_D20210101-20210331" decimals="3" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM183OS9mcmFnOmMzNjRjMmIwMjFiMTRiOGFiYzRhOTgzOGJhY2RlZjE5L3RhYmxlOmQ1NjgwNDhhZjc4ODQ2YmJiOTYwZmUxMTM4Zjk4YzBlL3RhYmxlcmFuZ2U6ZDU2ODA0OGFmNzg4NDZiYmI5NjBmZTExMzhmOThjMGVfMS0zLTEtMS0xNzc3NQ_7d867341-d6a8-4592-ad94-ef0314fbfdd4">61.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Florida Blue Medicare, Inc. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ie20505dffcf4431286b007c0fcf4ab14_D20210101-20211231" decimals="3" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM183OS9mcmFnOmMzNjRjMmIwMjFiMTRiOGFiYzRhOTgzOGJhY2RlZjE5L3RhYmxlOmQ1NjgwNDhhZjc4ODQ2YmJiOTYwZmUxMTM4Zjk4YzBlL3RhYmxlcmFuZ2U6ZDU2ODA0OGFmNzg4NDZiYmI5NjBmZTExMzhmOThjMGVfMi0xLTEtMS0xNzc3NQ_9ede5f1a-7305-4202-be73-a14b36109107">46.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">N/A</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Molina Healthcare</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ib97fa9c20ea54ca1841b4c9b1f4ea27c_D20210101-20211231" decimals="3" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM183OS9mcmFnOmMzNjRjMmIwMjFiMTRiOGFiYzRhOTgzOGJhY2RlZjE5L3RhYmxlOmQ1NjgwNDhhZjc4ODQ2YmJiOTYwZmUxMTM4Zjk4YzBlL3RhYmxlcmFuZ2U6ZDU2ODA0OGFmNzg4NDZiYmI5NjBmZTExMzhmOThjMGVfNC0xLTEtMS0yOTk1Ng_866ecd73-955a-4ed4-b284-8b3143ea7ec2">10.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:115%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%;padding-left:11.94pt">Customer added during the year ended December 31, 2021. </span></div></ix:continuation><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the Company is subject to significant concentration of revenue risk as a substantial portion of our revenue is derived from a small number of contractual relationships with our operating partners.</span></div><div style="text-align:justify"><span><br/></span></div><ix:continuation id="i23fc8f7ccd31428ba2d76b360794a67e"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes those partners who represented at least 10.0% of our consolidated revenue for the years ended December 31, 2021, 2020 and 2019:</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"></td><td style="width:380.50pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:48.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:48.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:48.25pt"></td><td style="width:1.0pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Year Ended December 31,</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cook County Health and Hospitals Systems</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i9f2a3a14183a4b9c91ebd0c42eb5510d_D20210101-20211231" decimals="3" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM183OS9mcmFnOmMzNjRjMmIwMjFiMTRiOGFiYzRhOTgzOGJhY2RlZjE5L3RhYmxlOjMzMWFhOTMxYzNjNjQzNzA5Yzg0ODNlNjM5NDVmMDg2L3RhYmxlcmFuZ2U6MzMxYWE5MzFjM2M2NDM3MDljODQ4M2U2Mzk0NWYwODZfMi01LTEtMS0xNzc3NQ_37a37917-fc7e-4194-9ad7-f7186656121b">28.0</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i4c5eb31ee1104de8a5635eca675175eb_D20200101-20201231" decimals="3" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM183OS9mcmFnOmMzNjRjMmIwMjFiMTRiOGFiYzRhOTgzOGJhY2RlZjE5L3RhYmxlOjMzMWFhOTMxYzNjNjQzNzA5Yzg0ODNlNjM5NDVmMDg2L3RhYmxlcmFuZ2U6MzMxYWE5MzFjM2M2NDM3MDljODQ4M2U2Mzk0NWYwODZfMi03LTEtMS0xNzc3NQ_a0e8a927-11e6-4f74-a46c-cdb4c91bcebd">22.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="id0f333276f5e44b698dd6e5f92a87479_D20190101-20191231" decimals="3" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM183OS9mcmFnOmMzNjRjMmIwMjFiMTRiOGFiYzRhOTgzOGJhY2RlZjE5L3RhYmxlOjMzMWFhOTMxYzNjNjQzNzA5Yzg0ODNlNjM5NDVmMDg2L3RhYmxlcmFuZ2U6MzMxYWE5MzFjM2M2NDM3MDljODQ4M2U2Mzk0NWYwODZfMi01LTEtMS0yMDQ5NA_8573402c-b372-41c4-94f3-a25707dc898f">11.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">New Mexico Health Connections</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="iadb6308217bb4ce7bab0e77352bbe86e_D20190101-20191231" decimals="3" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM183OS9mcmFnOmMzNjRjMmIwMjFiMTRiOGFiYzRhOTgzOGJhY2RlZjE5L3RhYmxlOjMzMWFhOTMxYzNjNjQzNzA5Yzg0ODNlNjM5NDVmMDg2L3RhYmxlcmFuZ2U6MzMxYWE5MzFjM2M2NDM3MDljODQ4M2U2Mzk0NWYwODZfMy01LTEtMS0yNTcxOQ_e394e4d9-eef2-4885-ad2c-8b065c0a6153">13.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Florida Blue Medicare, Inc. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="idd6b43aa37f24ee4a2d07a9f35c9f6ce_D20210101-20211231" decimals="3" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM183OS9mcmFnOmMzNjRjMmIwMjFiMTRiOGFiYzRhOTgzOGJhY2RlZjE5L3RhYmxlOjMzMWFhOTMxYzNjNjQzNzA5Yzg0ODNlNjM5NDVmMDg2L3RhYmxlcmFuZ2U6MzMxYWE5MzFjM2M2NDM3MDljODQ4M2U2Mzk0NWYwODZfMy01LTEtMS0xNzc3NQ_79fef8a4-f8ad-40b4-8e75-1535f5c9816e">14.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">N/A</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Passport </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i244051775e1e4019948fa2ba32e4ab27_D20200101-20201231" decimals="3" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM183OS9mcmFnOmMzNjRjMmIwMjFiMTRiOGFiYzRhOTgzOGJhY2RlZjE5L3RhYmxlOjMzMWFhOTMxYzNjNjQzNzA5Yzg0ODNlNjM5NDVmMDg2L3RhYmxlcmFuZ2U6MzMxYWE5MzFjM2M2NDM3MDljODQ4M2U2Mzk0NWYwODZfNC03LTEtMS0xNzc3NQ_96ca31d0-f755-486c-ae9a-bfa441952daf">19.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="id221ab9a660d422d8841139a66fe1f9d_D20190101-20191231" decimals="3" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM183OS9mcmFnOmMzNjRjMmIwMjFiMTRiOGFiYzRhOTgzOGJhY2RlZjE5L3RhYmxlOjMzMWFhOTMxYzNjNjQzNzA5Yzg0ODNlNjM5NDVmMDg2L3RhYmxlcmFuZ2U6MzMxYWE5MzFjM2M2NDM3MDljODQ4M2U2Mzk0NWYwODZfNC01LTEtMS0yMDUwMw_75a28071-d3c7-472f-80e3-67bf6a68fa49">23.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt">The denominator excludes $<ix:nonFraction unitRef="usd" contextRef="i8a931688112a4cc6bf3323cb239d7e4d_D20201001-20201231" decimals="-5" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM183OS9mcmFnOmMzNjRjMmIwMjFiMTRiOGFiYzRhOTgzOGJhY2RlZjE5L3RleHRyZWdpb246YzM2NGMyYjAyMWIxNGI4YWJjNGE5ODM4YmFjZGVmMTlfMTE1ODE_c9ebe0ef-5715-40cc-9417-961f2416184c">44.8</ix:nonFraction>&#160;million, $<ix:nonFraction unitRef="usd" contextRef="i6eca3f13863a45c481c07e49e9f434fe_D20200101-20201231" decimals="-5" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM183OS9mcmFnOmMzNjRjMmIwMjFiMTRiOGFiYzRhOTgzOGJhY2RlZjE5L3RleHRyZWdpb246YzM2NGMyYjAyMWIxNGI4YWJjNGE5ODM4YmFjZGVmMTlfMTE1ODg_dc2e6282-e1b9-4600-b116-a6d30246047b">117.4</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="iae64c322a5eb4929bc01485807d92b3a_D20190101-20191231" decimals="-5" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM183OS9mcmFnOmMzNjRjMmIwMjFiMTRiOGFiYzRhOTgzOGJhY2RlZjE5L3RleHRyZWdpb246YzM2NGMyYjAyMWIxNGI4YWJjNGE5ODM4YmFjZGVmMTlfMjE5OTAyMzI2ODY4Ng_797c55bf-c611-456b-bb17-5b9e16d41414">171.7</ix:nonFraction>&#160;million of True Health premium revenue reclassified to discontinued operations for the years ended December 31, 2021, 2020 and 2019, respectively.</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt">Customer added during the year ended December 31, 2021.</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt">Represents revenues from EVH Passport/UHC through the Molina Closing. Subsequent to the Molina Closing on September 1, 2020, the Company has not received any material revenue from EVH Passport. However, as part of the Molina Closing, we entered into a new contract with Molina on similar terms to our prior services contract with EVH Passport through December 31, 2020 which accounted for approximately <ix:nonFraction unitRef="number" contextRef="i8404c3b22073440a9f092260f57c4d0a_D20200101-20201231" decimals="3" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM183OS9mcmFnOmMzNjRjMmIwMjFiMTRiOGFiYzRhOTgzOGJhY2RlZjE5L3RleHRyZWdpb246YzM2NGMyYjAyMWIxNGI4YWJjNGE5ODM4YmFjZGVmMTlfMzI5ODUzNDkwODEzNw_2a1e4bae-38d7-47e8-a110-9e993f5da392">9.7</ix:nonFraction>% of our consolidated revenues for the year ended December 31, 2020.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">* &#160;&#160;&#160;&#160;Represents less than 10.0% of the respective balance</span></div></ix:continuation></ix:continuation><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i45b70ea2ec6143c0b8e557d968d557de">We derive a significant portion of our revenues from our largest partners. The loss, termination or renegotiation of our relationship or contract with any significant partner or multiple partners in the aggregate could have a material adverse effect on the Company's financial condition and results of operations.</ix:continuation>&#160;</span></div><div style="text-align:justify"><span><br/></span></div><div id="i9aaa2fddc97e482da5dbe37ac85ae703_82"></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 12. <ix:nonNumeric contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231" name="us-gaap:LesseeOperatingLeasesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM184Mi9mcmFnOjBhMDRkZjMzNTJkOTRkOTc5NzU3NGUwYjM5NzQ1MDgyL3RleHRyZWdpb246MGEwNGRmMzM1MmQ5NGQ5Nzk3NTc0ZTBiMzk3NDUwODJfMzI3Mg_a286cfff-544e-4df6-8094-27ffe929f4f2" continuedAt="ia63a2238b4bf4137aad23697e5c028ad" escape="true">Leases</ix:nonNumeric></span></div><div style="text-align:justify"><span><br/></span></div><ix:continuation id="ia63a2238b4bf4137aad23697e5c028ad" continuedAt="i7bedf9a2b7af4d47819c88886e14760a"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company enters into various office space, data center, and equipment lease agreements in conducting its normal business operations. At the inception of any contract, the Company evaluates the agreement to determine whether the contract contains a lease. If the contract contains a lease, the Company then evaluates the term and whether the lease is an operating or finance lease. Most leases include one or more options to renew or may have a termination option. The Company determines whether these options are reasonably certain to be exercised or not at the inception of the lease. In addition, some leases contain escalation clauses.  The rent expense is recognized on a straight-line basis in the consolidated statements of operations and comprehensive income (loss) over the term of the lease. Leases with an initial term of 12 months or less are not recorded on our consolidated balance sheets.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As most of our leases do not provide an implicit rate, we use our incremental borrowing rate based on the information available at commencement date in determining the present value of lease payments. We use the implicit rate when readily determinable. Further, the Company treats all lease and non-lease components as a single combined lease component for all classes of underlying assets. The </span></div></ix:continuation><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">100</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i7bedf9a2b7af4d47819c88886e14760a" continuedAt="i68091016066b498f90489aecba30ea1d"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Company also enters into sublease agreements for some of its leased office space. Immaterial rental income attributable to subleases is offset against rent expense over the terms of the respective leases. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company leases office space and computer and other equipment under operating lease agreements expiring at various dates through 2031. Under the lease agreements, in addition to base rent, the Company is generally responsible for operating and maintenance costs and related fees. Several of these agreements include tenant improvement allowances, rent holidays or rent escalation clauses. When such items are included in a lease agreement, we record a deferred rent asset or liability on our consolidated balance sheets equal to the difference between rent expense and future minimum lease payments due. The rent expense related to these items is recognized on a straight-line basis over the terms of the leases. The Company&#8217;s primary office location is in Arlington, Virginia, which has served as its corporate headquarters since 2013. The Arlington, Virginia office lease expires in January 2032. Certain leases acquired as part of the Valence Health transaction included existing sublease agreements for office locations in Chicago, Illinois. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with various lease agreements, the Company is required to maintain $<ix:nonFraction unitRef="usd" contextRef="i1a21d5a158854825a4cb4f9e1b2d4103_I20211231" decimals="-5" name="us-gaap:LettersOfCreditOutstandingAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM184Mi9mcmFnOjBhMDRkZjMzNTJkOTRkOTc5NzU3NGUwYjM5NzQ1MDgyL3RleHRyZWdpb246MGEwNGRmMzM1MmQ5NGQ5Nzk3NTc0ZTBiMzk3NDUwODJfMjY2Mw_c25b4584-0a70-4818-9539-c1f3db8c8804">3.8</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ic979e1a0ada24d7da7646f2ccae478c7_I20201231" decimals="-5" name="us-gaap:LettersOfCreditOutstandingAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM184Mi9mcmFnOjBhMDRkZjMzNTJkOTRkOTc5NzU3NGUwYjM5NzQ1MDgyL3RleHRyZWdpb246MGEwNGRmMzM1MmQ5NGQ5Nzk3NTc0ZTBiMzk3NDUwODJfMjY3MA_50b9f8df-8c9a-4e14-b768-548ffccb9ef2">3.5</ix:nonFraction>&#160;million in letters of credit as of December&#160;31, 2021 and December&#160;31, 2020. As of December&#160;31, 2021 and 2020, the Company held $<ix:nonFraction unitRef="usd" contextRef="i1a21d5a158854825a4cb4f9e1b2d4103_I20211231" decimals="-5" name="us-gaap:RestrictedCashAndCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM184Mi9mcmFnOjBhMDRkZjMzNTJkOTRkOTc5NzU3NGUwYjM5NzQ1MDgyL3RleHRyZWdpb246MGEwNGRmMzM1MmQ5NGQ5Nzk3NTc0ZTBiMzk3NDUwODJfMjc0NQ_fb44eaa7-d476-4652-a98f-408f03892b1f">3.8</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="ic979e1a0ada24d7da7646f2ccae478c7_I20201231" decimals="-5" name="us-gaap:RestrictedCashAndCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM184Mi9mcmFnOjBhMDRkZjMzNTJkOTRkOTc5NzU3NGUwYjM5NzQ1MDgyL3RleHRyZWdpb246MGEwNGRmMzM1MmQ5NGQ5Nzk3NTc0ZTBiMzk3NDUwODJfMjc1Mg_ad1af4fd-e6a5-4163-be33-2342d6c823d9">3.5</ix:nonFraction> million in restricted cash and restricted investments on the consolidated balance sheet as collateral for the letters of credit, respectively.</span></div><div style="text-align:justify"><span><br/></span></div><ix:nonNumeric contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM184Mi9mcmFnOjBhMDRkZjMzNTJkOTRkOTc5NzU3NGUwYjM5NzQ1MDgyL3RleHRyZWdpb246MGEwNGRmMzM1MmQ5NGQ5Nzk3NTc0ZTBiMzk3NDUwODJfMzI3Mw_ce48048a-0947-4117-97d5-2ce55bbee8c4" continuedAt="iacb30ecb7ed9464187f878945a6741ea" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our primary office leases as of December&#160;31, 2021 (in thousands, other than term):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:539.25pt"><tr><td style="width:1.0pt"></td><td style="width:237.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:94.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:94.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:94.00pt"></td><td style="width:1.0pt"></td></tr><tr style="height:24pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Location</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Lease Termination Term (in years)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Future Minimum Lease Commitments</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Letter of Credit Amount Required</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Arlington, VA</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ie94dd6f6dead455b8b597165bc5ec9ff_I20211231" name="us-gaap:LesseeOperatingLeaseTermOfContract" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM184Mi9mcmFnOjBhMDRkZjMzNTJkOTRkOTc5NzU3NGUwYjM5NzQ1MDgyL3RhYmxlOmQ3MzQyODVlMzRjNTQ2NzVhNDdlMDRiOTJiYzQxZjI2L3RhYmxlcmFuZ2U6ZDczNDI4NWUzNGM1NDY3NWE0N2UwNGI5MmJjNDFmMjZfMS0yLTEtMS0xNzc3NQ_fa8efcfe-e405-44ec-8382-80469e321cbb">10.1</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie94dd6f6dead455b8b597165bc5ec9ff_I20211231" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM184Mi9mcmFnOjBhMDRkZjMzNTJkOTRkOTc5NzU3NGUwYjM5NzQ1MDgyL3RhYmxlOmQ3MzQyODVlMzRjNTQ2NzVhNDdlMDRiOTJiYzQxZjI2L3RhYmxlcmFuZ2U6ZDczNDI4NWUzNGM1NDY3NWE0N2UwNGI5MmJjNDFmMjZfMS00LTEtMS0xNzc3NQ_96823663-239f-48b7-9a10-cebb52f4bb81">35,581</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie94dd6f6dead455b8b597165bc5ec9ff_I20211231" decimals="-3" name="us-gaap:LettersOfCreditOutstandingAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM184Mi9mcmFnOjBhMDRkZjMzNTJkOTRkOTc5NzU3NGUwYjM5NzQ1MDgyL3RhYmxlOmQ3MzQyODVlMzRjNTQ2NzVhNDdlMDRiOTJiYzQxZjI2L3RhYmxlcmFuZ2U6ZDczNDI4NWUzNGM1NDY3NWE0N2UwNGI5MmJjNDFmMjZfMS02LTEtMS0xNzc3NQ_2f62bfb8-e0a8-4308-8e90-9de48a34e1a4">1,579</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Riverside, IL </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i9a6c9ce1bc6a4595b939e65f2d38f28e_I20211231" name="us-gaap:LesseeOperatingLeaseTermOfContract" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM184Mi9mcmFnOjBhMDRkZjMzNTJkOTRkOTc5NzU3NGUwYjM5NzQ1MDgyL3RhYmxlOmQ3MzQyODVlMzRjNTQ2NzVhNDdlMDRiOTJiYzQxZjI2L3RhYmxlcmFuZ2U6ZDczNDI4NWUzNGM1NDY3NWE0N2UwNGI5MmJjNDFmMjZfMi0yLTEtMS0xNzc3NQ_780b03ce-aab2-4372-a60a-1fa1d59d8023">9.3</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9a6c9ce1bc6a4595b939e65f2d38f28e_I20211231" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM184Mi9mcmFnOjBhMDRkZjMzNTJkOTRkOTc5NzU3NGUwYjM5NzQ1MDgyL3RhYmxlOmQ3MzQyODVlMzRjNTQ2NzVhNDdlMDRiOTJiYzQxZjI2L3RhYmxlcmFuZ2U6ZDczNDI4NWUzNGM1NDY3NWE0N2UwNGI5MmJjNDFmMjZfMi00LTEtMS0xNzc3NQ_777423fa-d718-454d-aecf-3569e55582e5">41,408</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9a6c9ce1bc6a4595b939e65f2d38f28e_I20211231" decimals="-3" name="us-gaap:LettersOfCreditOutstandingAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM184Mi9mcmFnOjBhMDRkZjMzNTJkOTRkOTc5NzU3NGUwYjM5NzQ1MDgyL3RhYmxlOmQ3MzQyODVlMzRjNTQ2NzVhNDdlMDRiOTJiYzQxZjI2L3RhYmxlcmFuZ2U6ZDczNDI4NWUzNGM1NDY3NWE0N2UwNGI5MmJjNDFmMjZfMi02LTEtMS0xNzc3NQ_948649c7-4888-4e1d-b330-8b33eafff31d">232</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Edison, NJ</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i16fcb9584de04a43bbe15a5b9cef1417_I20211231" name="us-gaap:LesseeOperatingLeaseTermOfContract" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM184Mi9mcmFnOjBhMDRkZjMzNTJkOTRkOTc5NzU3NGUwYjM5NzQ1MDgyL3RhYmxlOmQ3MzQyODVlMzRjNTQ2NzVhNDdlMDRiOTJiYzQxZjI2L3RhYmxlcmFuZ2U6ZDczNDI4NWUzNGM1NDY3NWE0N2UwNGI5MmJjNDFmMjZfMy0yLTEtMS0yNjI0Mg_9cb0cf31-4fad-4eeb-9d17-0571c0f056d7">4.3</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i16fcb9584de04a43bbe15a5b9cef1417_I20211231" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM184Mi9mcmFnOjBhMDRkZjMzNTJkOTRkOTc5NzU3NGUwYjM5NzQ1MDgyL3RhYmxlOmQ3MzQyODVlMzRjNTQ2NzVhNDdlMDRiOTJiYzQxZjI2L3RhYmxlcmFuZ2U6ZDczNDI4NWUzNGM1NDY3NWE0N2UwNGI5MmJjNDFmMjZfMy00LTEtMS0yNjI1MQ_80f154c7-1b3b-4251-aa93-4d4fffbd97a7">2,180</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i16fcb9584de04a43bbe15a5b9cef1417_I20211231" decimals="-3" name="us-gaap:LettersOfCreditOutstandingAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM184Mi9mcmFnOjBhMDRkZjMzNTJkOTRkOTc5NzU3NGUwYjM5NzQ1MDgyL3RhYmxlOmQ3MzQyODVlMzRjNTQ2NzVhNDdlMDRiOTJiYzQxZjI2L3RhYmxlcmFuZ2U6ZDczNDI4NWUzNGM1NDY3NWE0N2UwNGI5MmJjNDFmMjZfMy02LTEtMS0yNjI1MQ_906c356a-7ed5-4724-939c-756d7ee05ab1">222</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pune, India</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ic6005d9a695a4ec39b064ccaceff712d_I20211231" name="us-gaap:LesseeOperatingLeaseTermOfContract" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM184Mi9mcmFnOjBhMDRkZjMzNTJkOTRkOTc5NzU3NGUwYjM5NzQ1MDgyL3RhYmxlOmQ3MzQyODVlMzRjNTQ2NzVhNDdlMDRiOTJiYzQxZjI2L3RhYmxlcmFuZ2U6ZDczNDI4NWUzNGM1NDY3NWE0N2UwNGI5MmJjNDFmMjZfMy0yLTEtMS0xNzc3NQ_473432f6-4fa0-447c-9d96-3dfac9feea44">1.7</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic6005d9a695a4ec39b064ccaceff712d_I20211231" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM184Mi9mcmFnOjBhMDRkZjMzNTJkOTRkOTc5NzU3NGUwYjM5NzQ1MDgyL3RhYmxlOmQ3MzQyODVlMzRjNTQ2NzVhNDdlMDRiOTJiYzQxZjI2L3RhYmxlcmFuZ2U6ZDczNDI4NWUzNGM1NDY3NWE0N2UwNGI5MmJjNDFmMjZfMy00LTEtMS0xNzc3NQ_bfa6cbcb-efd1-4d0f-89a0-a1dcb55cd4cc">1,382</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic6005d9a695a4ec39b064ccaceff712d_I20211231" decimals="-3" name="us-gaap:LettersOfCreditOutstandingAmount" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM184Mi9mcmFnOjBhMDRkZjMzNTJkOTRkOTc5NzU3NGUwYjM5NzQ1MDgyL3RhYmxlOmQ3MzQyODVlMzRjNTQ2NzVhNDdlMDRiOTJiYzQxZjI2L3RhYmxlcmFuZ2U6ZDczNDI4NWUzNGM1NDY3NWE0N2UwNGI5MmJjNDFmMjZfMy02LTEtMS0xNzc3NQ_61b74cd8-064d-4a16-86e2-f03b1cb15094">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Brea, CA</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ic293662ed0144555ad060c822d4249ce_I20211231" name="us-gaap:LesseeOperatingLeaseTermOfContract" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM184Mi9mcmFnOjBhMDRkZjMzNTJkOTRkOTc5NzU3NGUwYjM5NzQ1MDgyL3RhYmxlOmQ3MzQyODVlMzRjNTQ2NzVhNDdlMDRiOTJiYzQxZjI2L3RhYmxlcmFuZ2U6ZDczNDI4NWUzNGM1NDY3NWE0N2UwNGI5MmJjNDFmMjZfNC0yLTEtMS0xNzc3NQ_96fc9dda-4af0-407d-94bb-94346453cafc">0.4</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic293662ed0144555ad060c822d4249ce_I20211231" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM184Mi9mcmFnOjBhMDRkZjMzNTJkOTRkOTc5NzU3NGUwYjM5NzQ1MDgyL3RhYmxlOmQ3MzQyODVlMzRjNTQ2NzVhNDdlMDRiOTJiYzQxZjI2L3RhYmxlcmFuZ2U6ZDczNDI4NWUzNGM1NDY3NWE0N2UwNGI5MmJjNDFmMjZfNC00LTEtMS0xNzc3NQ_3dbe10da-0777-44ab-b27a-f968f3ad3fcf">462</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic293662ed0144555ad060c822d4249ce_I20211231" decimals="-3" name="us-gaap:LettersOfCreditOutstandingAmount" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM184Mi9mcmFnOjBhMDRkZjMzNTJkOTRkOTc5NzU3NGUwYjM5NzQ1MDgyL3RhYmxlOmQ3MzQyODVlMzRjNTQ2NzVhNDdlMDRiOTJiYzQxZjI2L3RhYmxlcmFuZ2U6ZDczNDI4NWUzNGM1NDY3NWE0N2UwNGI5MmJjNDFmMjZfNC02LTEtMS0xNzc3NQ_1ed15a55-4e73-4e37-b93a-0ed280d3d3d4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="text-align:justify"><span><br/></span></div><ix:nonNumeric contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231" name="us-gaap:LeaseCostTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM184Mi9mcmFnOjBhMDRkZjMzNTJkOTRkOTc5NzU3NGUwYjM5NzQ1MDgyL3RleHRyZWdpb246MGEwNGRmMzM1MmQ5NGQ5Nzk3NTc0ZTBiMzk3NDUwODJfMzI3NA_855c6695-6fe2-40bf-81de-ff86f25636ad" continuedAt="i22ca37aed0ca47d2993f424051076a75" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the components of our lease expense (in thousands): </span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:64.316%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.011%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.011%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.013%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease cost</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231" decimals="-3" name="us-gaap:OperatingLeaseCost" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM184Mi9mcmFnOjBhMDRkZjMzNTJkOTRkOTc5NzU3NGUwYjM5NzQ1MDgyL3RhYmxlOjQ5ZjI5ZGFjNzFmZTQ2ZGE5OWQyNzhlMGFiMjZkYmYxL3RhYmxlcmFuZ2U6NDlmMjlkYWM3MWZlNDZkYTk5ZDI3OGUwYWIyNmRiZjFfMi01LTEtMS0xNzc3NQ_d59388ed-b515-47fa-be6e-74fbee27e213">12,991</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i12a6d1161de54547bd29f8efccd4c9b0_D20200101-20201231" decimals="-3" name="us-gaap:OperatingLeaseCost" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM184Mi9mcmFnOjBhMDRkZjMzNTJkOTRkOTc5NzU3NGUwYjM5NzQ1MDgyL3RhYmxlOjQ5ZjI5ZGFjNzFmZTQ2ZGE5OWQyNzhlMGFiMjZkYmYxL3RhYmxlcmFuZ2U6NDlmMjlkYWM3MWZlNDZkYTk5ZDI3OGUwYWIyNmRiZjFfMi03LTEtMS0xNzc3NQ_640f2bce-9718-4b9a-86e8-59c5d6b4b806">15,848</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e21049ffc224cacb8134d73c9bb5b38_D20190101-20191231" decimals="-3" name="us-gaap:OperatingLeaseCost" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM184Mi9mcmFnOjBhMDRkZjMzNTJkOTRkOTc5NzU3NGUwYjM5NzQ1MDgyL3RhYmxlOjQ5ZjI5ZGFjNzFmZTQ2ZGE5OWQyNzhlMGFiMjZkYmYxL3RhYmxlcmFuZ2U6NDlmMjlkYWM3MWZlNDZkYTk5ZDI3OGUwYWIyNmRiZjFfMi01LTEtMS0yMTc2Ng_d2973d5d-6545-4cf1-a323-7a3f13f59fe9">13,903</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of right-of-use assets</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231" decimals="-3" name="us-gaap:FinanceLeaseRightOfUseAssetAmortization" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM184Mi9mcmFnOjBhMDRkZjMzNTJkOTRkOTc5NzU3NGUwYjM5NzQ1MDgyL3RhYmxlOjQ5ZjI5ZGFjNzFmZTQ2ZGE5OWQyNzhlMGFiMjZkYmYxL3RhYmxlcmFuZ2U6NDlmMjlkYWM3MWZlNDZkYTk5ZDI3OGUwYWIyNmRiZjFfMy01LTEtMS0xNzc3NQ_ce31daee-6187-41f8-bd4c-f0decedb4d27">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i12a6d1161de54547bd29f8efccd4c9b0_D20200101-20201231" decimals="-3" name="us-gaap:FinanceLeaseRightOfUseAssetAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM184Mi9mcmFnOjBhMDRkZjMzNTJkOTRkOTc5NzU3NGUwYjM5NzQ1MDgyL3RhYmxlOjQ5ZjI5ZGFjNzFmZTQ2ZGE5OWQyNzhlMGFiMjZkYmYxL3RhYmxlcmFuZ2U6NDlmMjlkYWM3MWZlNDZkYTk5ZDI3OGUwYWIyNmRiZjFfMy03LTEtMS0xNzc3NQ_1ed533af-99a7-488a-af8d-f56f021365ca">299</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e21049ffc224cacb8134d73c9bb5b38_D20190101-20191231" decimals="-3" name="us-gaap:FinanceLeaseRightOfUseAssetAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM184Mi9mcmFnOjBhMDRkZjMzNTJkOTRkOTc5NzU3NGUwYjM5NzQ1MDgyL3RhYmxlOjQ5ZjI5ZGFjNzFmZTQ2ZGE5OWQyNzhlMGFiMjZkYmYxL3RhYmxlcmFuZ2U6NDlmMjlkYWM3MWZlNDZkYTk5ZDI3OGUwYWIyNmRiZjFfMy01LTEtMS0yMTc2Ng_0cae7fa9-dd0e-4ced-a467-6920dbf408b1">598</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231" decimals="-3" name="us-gaap:FinanceLeaseInterestExpense" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM184Mi9mcmFnOjBhMDRkZjMzNTJkOTRkOTc5NzU3NGUwYjM5NzQ1MDgyL3RhYmxlOjQ5ZjI5ZGFjNzFmZTQ2ZGE5OWQyNzhlMGFiMjZkYmYxL3RhYmxlcmFuZ2U6NDlmMjlkYWM3MWZlNDZkYTk5ZDI3OGUwYWIyNmRiZjFfNC01LTEtMS0xNzc3NQ_45827602-a304-4133-8d5f-33b1d3db0009">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i12a6d1161de54547bd29f8efccd4c9b0_D20200101-20201231" decimals="-3" name="us-gaap:FinanceLeaseInterestExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM184Mi9mcmFnOjBhMDRkZjMzNTJkOTRkOTc5NzU3NGUwYjM5NzQ1MDgyL3RhYmxlOjQ5ZjI5ZGFjNzFmZTQ2ZGE5OWQyNzhlMGFiMjZkYmYxL3RhYmxlcmFuZ2U6NDlmMjlkYWM3MWZlNDZkYTk5ZDI3OGUwYWIyNmRiZjFfNC03LTEtMS0xNzc3NQ_5f8fd9e1-8c1f-4c46-a6bb-19a123236451">3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e21049ffc224cacb8134d73c9bb5b38_D20190101-20191231" decimals="-3" name="us-gaap:FinanceLeaseInterestExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM184Mi9mcmFnOjBhMDRkZjMzNTJkOTRkOTc5NzU3NGUwYjM5NzQ1MDgyL3RhYmxlOjQ5ZjI5ZGFjNzFmZTQ2ZGE5OWQyNzhlMGFiMjZkYmYxL3RhYmxlcmFuZ2U6NDlmMjlkYWM3MWZlNDZkYTk5ZDI3OGUwYWIyNmRiZjFfNC01LTEtMS0yMTc2Ng_70315bba-da95-4d28-80d4-11c018b99645">26</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Variable lease cost</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231" decimals="-3" name="us-gaap:VariableLeaseCost" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM184Mi9mcmFnOjBhMDRkZjMzNTJkOTRkOTc5NzU3NGUwYjM5NzQ1MDgyL3RhYmxlOjQ5ZjI5ZGFjNzFmZTQ2ZGE5OWQyNzhlMGFiMjZkYmYxL3RhYmxlcmFuZ2U6NDlmMjlkYWM3MWZlNDZkYTk5ZDI3OGUwYWIyNmRiZjFfNS01LTEtMS0xNzc3NQ_453acc4e-45e7-4da6-b305-ce0ed4f3bb22">5,036</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i12a6d1161de54547bd29f8efccd4c9b0_D20200101-20201231" decimals="-3" name="us-gaap:VariableLeaseCost" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM184Mi9mcmFnOjBhMDRkZjMzNTJkOTRkOTc5NzU3NGUwYjM5NzQ1MDgyL3RhYmxlOjQ5ZjI5ZGFjNzFmZTQ2ZGE5OWQyNzhlMGFiMjZkYmYxL3RhYmxlcmFuZ2U6NDlmMjlkYWM3MWZlNDZkYTk5ZDI3OGUwYWIyNmRiZjFfNS03LTEtMS0xNzc3NQ_90a2e845-8859-4e27-ae0e-4749d3e4a371">5,097</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e21049ffc224cacb8134d73c9bb5b38_D20190101-20191231" decimals="-3" name="us-gaap:VariableLeaseCost" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM184Mi9mcmFnOjBhMDRkZjMzNTJkOTRkOTc5NzU3NGUwYjM5NzQ1MDgyL3RhYmxlOjQ5ZjI5ZGFjNzFmZTQ2ZGE5OWQyNzhlMGFiMjZkYmYxL3RhYmxlcmFuZ2U6NDlmMjlkYWM3MWZlNDZkYTk5ZDI3OGUwYWIyNmRiZjFfNS01LTEtMS0yMTc2Ng_a222ff80-50bb-478e-9365-2832edcffbbc">4,177</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease cost</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231" decimals="-3" name="us-gaap:LeaseCost" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM184Mi9mcmFnOjBhMDRkZjMzNTJkOTRkOTc5NzU3NGUwYjM5NzQ1MDgyL3RhYmxlOjQ5ZjI5ZGFjNzFmZTQ2ZGE5OWQyNzhlMGFiMjZkYmYxL3RhYmxlcmFuZ2U6NDlmMjlkYWM3MWZlNDZkYTk5ZDI3OGUwYWIyNmRiZjFfNi01LTEtMS0xNzc3NQ_31b654c4-1051-41ec-a828-f29d0b003ac8">18,027</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i12a6d1161de54547bd29f8efccd4c9b0_D20200101-20201231" decimals="-3" name="us-gaap:LeaseCost" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM184Mi9mcmFnOjBhMDRkZjMzNTJkOTRkOTc5NzU3NGUwYjM5NzQ1MDgyL3RhYmxlOjQ5ZjI5ZGFjNzFmZTQ2ZGE5OWQyNzhlMGFiMjZkYmYxL3RhYmxlcmFuZ2U6NDlmMjlkYWM3MWZlNDZkYTk5ZDI3OGUwYWIyNmRiZjFfNi03LTEtMS0xNzc3NQ_b966d66f-6dd3-4ac5-9199-de4f95587249">21,247</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e21049ffc224cacb8134d73c9bb5b38_D20190101-20191231" decimals="-3" name="us-gaap:LeaseCost" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM184Mi9mcmFnOjBhMDRkZjMzNTJkOTRkOTc5NzU3NGUwYjM5NzQ1MDgyL3RhYmxlOjQ5ZjI5ZGFjNzFmZTQ2ZGE5OWQyNzhlMGFiMjZkYmYxL3RhYmxlcmFuZ2U6NDlmMjlkYWM3MWZlNDZkYTk5ZDI3OGUwYWIyNmRiZjFfNi01LTEtMS0yMTc3Mw_3622f232-9a52-4577-874f-411e7b9638bc">18,704</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="text-align:justify"><span><br/></span></div><ix:continuation id="iacb30ecb7ed9464187f878945a6741ea"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Maturity of lease liabilities (in thousands) as of December&#160;31, 2021, is as follows:</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:87.788%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.012%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Operating lease expense</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8daff60be410426d8f7bd49343c1ec0c_I20211231" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM184Mi9mcmFnOjBhMDRkZjMzNTJkOTRkOTc5NzU3NGUwYjM5NzQ1MDgyL3RhYmxlOmY2ZGRmMDhmNjhjNTQyNzU4MTYyMDJjZTllMWUwNThjL3RhYmxlcmFuZ2U6ZjZkZGYwOGY2OGM1NDI3NTgxNjIwMmNlOWUxZTA1OGNfMS0xLTEtMS0xNzc3NQ_f226b232-6d5f-4400-9e4a-b2c92f39958d">10,916</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8daff60be410426d8f7bd49343c1ec0c_I20211231" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM184Mi9mcmFnOjBhMDRkZjMzNTJkOTRkOTc5NzU3NGUwYjM5NzQ1MDgyL3RhYmxlOmY2ZGRmMDhmNjhjNTQyNzU4MTYyMDJjZTllMWUwNThjL3RhYmxlcmFuZ2U6ZjZkZGYwOGY2OGM1NDI3NTgxNjIwMmNlOWUxZTA1OGNfMi0xLTEtMS0xNzc3NQ_6b971748-af42-4cf4-83d4-7232d690f30b">9,258</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8daff60be410426d8f7bd49343c1ec0c_I20211231" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM184Mi9mcmFnOjBhMDRkZjMzNTJkOTRkOTc5NzU3NGUwYjM5NzQ1MDgyL3RhYmxlOmY2ZGRmMDhmNjhjNTQyNzU4MTYyMDJjZTllMWUwNThjL3RhYmxlcmFuZ2U6ZjZkZGYwOGY2OGM1NDI3NTgxNjIwMmNlOWUxZTA1OGNfMy0xLTEtMS0xNzc3NQ_5af12fff-972b-46e0-b309-1b6c169f7968">8,968</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8daff60be410426d8f7bd49343c1ec0c_I20211231" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM184Mi9mcmFnOjBhMDRkZjMzNTJkOTRkOTc5NzU3NGUwYjM5NzQ1MDgyL3RhYmxlOmY2ZGRmMDhmNjhjNTQyNzU4MTYyMDJjZTllMWUwNThjL3RhYmxlcmFuZ2U6ZjZkZGYwOGY2OGM1NDI3NTgxNjIwMmNlOWUxZTA1OGNfNC0xLTEtMS0xNzc3NQ_1abb566e-645d-4de6-b169-4c552f405556">8,653</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8daff60be410426d8f7bd49343c1ec0c_I20211231" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM184Mi9mcmFnOjBhMDRkZjMzNTJkOTRkOTc5NzU3NGUwYjM5NzQ1MDgyL3RhYmxlOmY2ZGRmMDhmNjhjNTQyNzU4MTYyMDJjZTllMWUwNThjL3RhYmxlcmFuZ2U6ZjZkZGYwOGY2OGM1NDI3NTgxNjIwMmNlOWUxZTA1OGNfNS0xLTEtMS0xNzc3NQ_aeb6cffd-c570-4e76-82fa-c85bb6714634">7,988</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8daff60be410426d8f7bd49343c1ec0c_I20211231" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM184Mi9mcmFnOjBhMDRkZjMzNTJkOTRkOTc5NzU3NGUwYjM5NzQ1MDgyL3RhYmxlOmY2ZGRmMDhmNjhjNTQyNzU4MTYyMDJjZTllMWUwNThjL3RhYmxlcmFuZ2U6ZjZkZGYwOGY2OGM1NDI3NTgxNjIwMmNlOWUxZTA1OGNfNi0xLTEtMS0xNzc3NQ_f6355bd7-c2b3-48cd-91d0-bf89bdfb369f">39,972</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease payments</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8daff60be410426d8f7bd49343c1ec0c_I20211231" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM184Mi9mcmFnOjBhMDRkZjMzNTJkOTRkOTc5NzU3NGUwYjM5NzQ1MDgyL3RhYmxlOmY2ZGRmMDhmNjhjNTQyNzU4MTYyMDJjZTllMWUwNThjL3RhYmxlcmFuZ2U6ZjZkZGYwOGY2OGM1NDI3NTgxNjIwMmNlOWUxZTA1OGNfNy0xLTEtMS0xNzc3NQ_0ac4ab61-a2ad-4829-b35b-871498b455bc">85,755</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8daff60be410426d8f7bd49343c1ec0c_I20211231" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM184Mi9mcmFnOjBhMDRkZjMzNTJkOTRkOTc5NzU3NGUwYjM5NzQ1MDgyL3RhYmxlOmY2ZGRmMDhmNjhjNTQyNzU4MTYyMDJjZTllMWUwNThjL3RhYmxlcmFuZ2U6ZjZkZGYwOGY2OGM1NDI3NTgxNjIwMmNlOWUxZTA1OGNfOS0xLTEtMS0xNzc3NQ_48b4b26f-05b3-4bb4-9c9b-1bbeeec33a1f">20,964</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Present value of lease liabilities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8daff60be410426d8f7bd49343c1ec0c_I20211231" decimals="-3" name="us-gaap:OperatingLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM184Mi9mcmFnOjBhMDRkZjMzNTJkOTRkOTc5NzU3NGUwYjM5NzQ1MDgyL3RhYmxlOmY2ZGRmMDhmNjhjNTQyNzU4MTYyMDJjZTllMWUwNThjL3RhYmxlcmFuZ2U6ZjZkZGYwOGY2OGM1NDI3NTgxNjIwMmNlOWUxZTA1OGNfMTAtMS0xLTEtMTc3NzU_e3792fb7-7139-47c2-a42b-831bb9bf3da5">64,791</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:continuation></ix:continuation><div style="text-align:justify"><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">101</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i68091016066b498f90489aecba30ea1d"><ix:continuation id="i22ca37aed0ca47d2993f424051076a75"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our weighted-average discount rate and our weighted remaining lease terms (in years) are as follows:</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:64.455%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.011%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.011%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.013%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average discount rate</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i8daff60be410426d8f7bd49343c1ec0c_I20211231" decimals="4" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM184Mi9mcmFnOjBhMDRkZjMzNTJkOTRkOTc5NzU3NGUwYjM5NzQ1MDgyL3RhYmxlOjI2MjQ0YmM1YTM0ZjQ5MDJiZjQyODdiYTBlYWNlZmFhL3RhYmxlcmFuZ2U6MjYyNDRiYzVhMzRmNDkwMmJmNDI4N2JhMGVhY2VmYWFfMC0xLTEtMS0xNzc3NQ_399b926b-4315-4908-b425-61512dce5f20">6.38</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ibc0c0c2b8dc04c5698ca0577a54b2e03_I20201231" decimals="4" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM184Mi9mcmFnOjBhMDRkZjMzNTJkOTRkOTc5NzU3NGUwYjM5NzQ1MDgyL3RhYmxlOjI2MjQ0YmM1YTM0ZjQ5MDJiZjQyODdiYTBlYWNlZmFhL3RhYmxlcmFuZ2U6MjYyNDRiYzVhMzRmNDkwMmJmNDI4N2JhMGVhY2VmYWFfMi0zLTEtMS0yMTgyOA_0b653ac5-2341-46a5-b1e5-ebb3e0bbfc4e">6.44</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="icba6e493923b449aa57c46a563760234_I20191231" decimals="4" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM184Mi9mcmFnOjBhMDRkZjMzNTJkOTRkOTc5NzU3NGUwYjM5NzQ1MDgyL3RhYmxlOjI2MjQ0YmM1YTM0ZjQ5MDJiZjQyODdiYTBlYWNlZmFhL3RhYmxlcmFuZ2U6MjYyNDRiYzVhMzRmNDkwMmJmNDI4N2JhMGVhY2VmYWFfMi01LTEtMS0yMTgyOA_e4659193-1da1-4cfa-bd79-bea944169a7f">6.25</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average remaining lease term</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i8daff60be410426d8f7bd49343c1ec0c_I20211231" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM184Mi9mcmFnOjBhMDRkZjMzNTJkOTRkOTc5NzU3NGUwYjM5NzQ1MDgyL3RhYmxlOjI2MjQ0YmM1YTM0ZjQ5MDJiZjQyODdiYTBlYWNlZmFhL3RhYmxlcmFuZ2U6MjYyNDRiYzVhMzRmNDkwMmJmNDI4N2JhMGVhY2VmYWFfMS0xLTEtMS0xNzc3NQ_e8d814fa-d223-4dc4-98dd-c6ae8321c492">8.8</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ibc0c0c2b8dc04c5698ca0577a54b2e03_I20201231" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM184Mi9mcmFnOjBhMDRkZjMzNTJkOTRkOTc5NzU3NGUwYjM5NzQ1MDgyL3RhYmxlOjI2MjQ0YmM1YTM0ZjQ5MDJiZjQyODdiYTBlYWNlZmFhL3RhYmxlcmFuZ2U6MjYyNDRiYzVhMzRmNDkwMmJmNDI4N2JhMGVhY2VmYWFfMy0zLTEtMS0yMTgyOA_9fc96102-f6fc-474a-b2ae-4536cf574c08">9.4</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="icba6e493923b449aa57c46a563760234_I20191231" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM184Mi9mcmFnOjBhMDRkZjMzNTJkOTRkOTc5NzU3NGUwYjM5NzQ1MDgyL3RhYmxlOjI2MjQ0YmM1YTM0ZjQ5MDJiZjQyODdiYTBlYWNlZmFhL3RhYmxlcmFuZ2U6MjYyNDRiYzVhMzRmNDkwMmJmNDI4N2JhMGVhY2VmYWFfMy01LTEtMS0yMTgyOA_f70eaa99-4b12-46ef-8af5-8007d65f4974">9.9</ix:nonNumeric></span></td></tr></table></div></ix:continuation></ix:continuation><div><span><br/></span></div><div id="i9aaa2fddc97e482da5dbe37ac85ae703_85"></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 13.  <ix:nonNumeric contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231" name="us-gaap:EarningsPerShareTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM184NS9mcmFnOjdhMDNjNzc3NWZjNDRmMzlhZmY3NjkyYjY5NGQ5YzM3L3RleHRyZWdpb246N2EwM2M3Nzc1ZmM0NGYzOWFmZjc2OTJiNjk0ZDljMzdfMzY0_ec482e50-f474-4b1e-b9bf-d9d780571a9f" continuedAt="i218aec525abb4ba5ac40be9686ff036d" escape="true">Earnings (Loss) Per Common Share</ix:nonNumeric></span></div><div style="text-align:justify"><span><br/></span></div><ix:continuation id="i218aec525abb4ba5ac40be9686ff036d"><ix:nonNumeric contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231" name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM184NS9mcmFnOjdhMDNjNzc3NWZjNDRmMzlhZmY3NjkyYjY5NGQ5YzM3L3RleHRyZWdpb246N2EwM2M3Nzc1ZmM0NGYzOWFmZjc2OTJiNjk0ZDljMzdfMzY2_94b33826-53f3-4da6-a961-03aab9955bbb" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth the computation of basic and diluted earnings per share available for common stockholders (in thousands, except per share data):</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"></td><td style="width:351.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:58.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:58.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:58.00pt"></td><td style="width:1.0pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Year Ended December 31,</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss from continuing operations</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM184NS9mcmFnOjdhMDNjNzc3NWZjNDRmMzlhZmY3NjkyYjY5NGQ5YzM3L3RhYmxlOjhhNDlhNzA4NDcxMDQwZTk4MzBiMDg2ZTIxMzRlYTk1L3RhYmxlcmFuZ2U6OGE0OWE3MDg0NzEwNDBlOTgzMGIwODZlMjEzNGVhOTVfMi01LTEtMS0xNzc3NQ_d76450ef-cfe7-4881-b23e-9a162abc49db">30,284</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i12a6d1161de54547bd29f8efccd4c9b0_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM184NS9mcmFnOjdhMDNjNzc3NWZjNDRmMzlhZmY3NjkyYjY5NGQ5YzM3L3RhYmxlOjhhNDlhNzA4NDcxMDQwZTk4MzBiMDg2ZTIxMzRlYTk1L3RhYmxlcmFuZ2U6OGE0OWE3MDg0NzEwNDBlOTgzMGIwODZlMjEzNGVhOTVfMi03LTEtMS0xNzc3NQ_46bcd607-6919-41ba-bd7e-9e6da2dfd783">328,172</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3e21049ffc224cacb8134d73c9bb5b38_D20190101-20191231" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM184NS9mcmFnOjdhMDNjNzc3NWZjNDRmMzlhZmY3NjkyYjY5NGQ5YzM3L3RhYmxlOjhhNDlhNzA4NDcxMDQwZTk4MzBiMDg2ZTIxMzRlYTk1L3RhYmxlcmFuZ2U6OGE0OWE3MDg0NzEwNDBlOTgzMGIwODZlMjEzNGVhOTVfMi01LTEtMS0yMTkzMQ_7cd677f7-562c-4cff-afb6-94eb73d0af25">307,193</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income (loss) from discontinued operations, net of tax</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM184NS9mcmFnOjdhMDNjNzc3NWZjNDRmMzlhZmY3NjkyYjY5NGQ5YzM3L3RhYmxlOjhhNDlhNzA4NDcxMDQwZTk4MzBiMDg2ZTIxMzRlYTk1L3RhYmxlcmFuZ2U6OGE0OWE3MDg0NzEwNDBlOTgzMGIwODZlMjEzNGVhOTVfMy01LTEtMS0xNzc3NQ_3a7f9340-a2d9-4068-b095-f659267e962c">7,317</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i12a6d1161de54547bd29f8efccd4c9b0_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM184NS9mcmFnOjdhMDNjNzc3NWZjNDRmMzlhZmY3NjkyYjY5NGQ5YzM3L3RhYmxlOjhhNDlhNzA4NDcxMDQwZTk4MzBiMDg2ZTIxMzRlYTk1L3RhYmxlcmFuZ2U6OGE0OWE3MDg0NzEwNDBlOTgzMGIwODZlMjEzNGVhOTVfMy03LTEtMS0xNzc3NQ_6123f20d-b2da-4983-8481-3001d793c73d">6,074</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e21049ffc224cacb8134d73c9bb5b38_D20190101-20191231" decimals="-3" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM184NS9mcmFnOjdhMDNjNzc3NWZjNDRmMzlhZmY3NjkyYjY5NGQ5YzM3L3RhYmxlOjhhNDlhNzA4NDcxMDQwZTk4MzBiMDg2ZTIxMzRlYTk1L3RhYmxlcmFuZ2U6OGE0OWE3MDg0NzEwNDBlOTgzMGIwODZlMjEzNGVhOTVfMy01LTEtMS0yMTkzMQ_cd15aa32-72bb-4df8-a330-8fac8ecbd8bb">1,613</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM184NS9mcmFnOjdhMDNjNzc3NWZjNDRmMzlhZmY3NjkyYjY5NGQ5YzM3L3RhYmxlOjhhNDlhNzA4NDcxMDQwZTk4MzBiMDg2ZTIxMzRlYTk1L3RhYmxlcmFuZ2U6OGE0OWE3MDg0NzEwNDBlOTgzMGIwODZlMjEzNGVhOTVfNC01LTEtMS0xNzc3NQ_c49b99c2-1aef-4003-806b-11d043c6a947">37,601</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i12a6d1161de54547bd29f8efccd4c9b0_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM184NS9mcmFnOjdhMDNjNzc3NWZjNDRmMzlhZmY3NjkyYjY5NGQ5YzM3L3RhYmxlOjhhNDlhNzA4NDcxMDQwZTk4MzBiMDg2ZTIxMzRlYTk1L3RhYmxlcmFuZ2U6OGE0OWE3MDg0NzEwNDBlOTgzMGIwODZlMjEzNGVhOTVfNC03LTEtMS0xNzc3NQ_059445f8-3794-4af1-abe2-9f2515cac297">334,246</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3e21049ffc224cacb8134d73c9bb5b38_D20190101-20191231" decimals="-3" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM184NS9mcmFnOjdhMDNjNzc3NWZjNDRmMzlhZmY3NjkyYjY5NGQ5YzM3L3RhYmxlOjhhNDlhNzA4NDcxMDQwZTk4MzBiMDg2ZTIxMzRlYTk1L3RhYmxlcmFuZ2U6OGE0OWE3MDg0NzEwNDBlOTgzMGIwODZlMjEzNGVhOTVfNC01LTEtMS0yMTkzMQ_29de1fd1-21e6-4603-8e1d-b3241b370b6f">305,580</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss attributable to non-controlling interests</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231" decimals="-3" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM184NS9mcmFnOjdhMDNjNzc3NWZjNDRmMzlhZmY3NjkyYjY5NGQ5YzM3L3RhYmxlOjhhNDlhNzA4NDcxMDQwZTk4MzBiMDg2ZTIxMzRlYTk1L3RhYmxlcmFuZ2U6OGE0OWE3MDg0NzEwNDBlOTgzMGIwODZlMjEzNGVhOTVfNi01LTEtMS0xNzc3NQ_a10ceaab-8664-4942-a66d-497e3968da6b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i12a6d1161de54547bd29f8efccd4c9b0_D20200101-20201231" decimals="-3" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM184NS9mcmFnOjdhMDNjNzc3NWZjNDRmMzlhZmY3NjkyYjY5NGQ5YzM3L3RhYmxlOjhhNDlhNzA4NDcxMDQwZTk4MzBiMDg2ZTIxMzRlYTk1L3RhYmxlcmFuZ2U6OGE0OWE3MDg0NzEwNDBlOTgzMGIwODZlMjEzNGVhOTVfNi03LTEtMS0xNzc3NQ_1026adc1-b9ab-4994-88ed-075d8f12b561">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3e21049ffc224cacb8134d73c9bb5b38_D20190101-20191231" decimals="-3" sign="-" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM184NS9mcmFnOjdhMDNjNzc3NWZjNDRmMzlhZmY3NjkyYjY5NGQ5YzM3L3RhYmxlOjhhNDlhNzA4NDcxMDQwZTk4MzBiMDg2ZTIxMzRlYTk1L3RhYmxlcmFuZ2U6OGE0OWE3MDg0NzEwNDBlOTgzMGIwODZlMjEzNGVhOTVfNi01LTEtMS0yMTkzMQ_c409b687-025d-4187-8d5b-98a09913c94e">3,609</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss available for common shareholders - basic and diluted</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM184NS9mcmFnOjdhMDNjNzc3NWZjNDRmMzlhZmY3NjkyYjY5NGQ5YzM3L3RhYmxlOjhhNDlhNzA4NDcxMDQwZTk4MzBiMDg2ZTIxMzRlYTk1L3RhYmxlcmFuZ2U6OGE0OWE3MDg0NzEwNDBlOTgzMGIwODZlMjEzNGVhOTVfNy01LTEtMS0xNzc3NQ_19b0e485-6260-41f1-b4e9-3c97c234c728"><ix:nonFraction unitRef="usd" contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM184NS9mcmFnOjdhMDNjNzc3NWZjNDRmMzlhZmY3NjkyYjY5NGQ5YzM3L3RhYmxlOjhhNDlhNzA4NDcxMDQwZTk4MzBiMDg2ZTIxMzRlYTk1L3RhYmxlcmFuZ2U6OGE0OWE3MDg0NzEwNDBlOTgzMGIwODZlMjEzNGVhOTVfNy01LTEtMS0xNzc3NQ_34c1e7e0-fc69-4bdc-be43-ddb3ef807107">37,601</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i12a6d1161de54547bd29f8efccd4c9b0_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM184NS9mcmFnOjdhMDNjNzc3NWZjNDRmMzlhZmY3NjkyYjY5NGQ5YzM3L3RhYmxlOjhhNDlhNzA4NDcxMDQwZTk4MzBiMDg2ZTIxMzRlYTk1L3RhYmxlcmFuZ2U6OGE0OWE3MDg0NzEwNDBlOTgzMGIwODZlMjEzNGVhOTVfNy03LTEtMS0xNzc3NQ_47276093-49df-42a8-9bbd-a4f0df34d037"><ix:nonFraction unitRef="usd" contextRef="i12a6d1161de54547bd29f8efccd4c9b0_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM184NS9mcmFnOjdhMDNjNzc3NWZjNDRmMzlhZmY3NjkyYjY5NGQ5YzM3L3RhYmxlOjhhNDlhNzA4NDcxMDQwZTk4MzBiMDg2ZTIxMzRlYTk1L3RhYmxlcmFuZ2U6OGE0OWE3MDg0NzEwNDBlOTgzMGIwODZlMjEzNGVhOTVfNy03LTEtMS0xNzc3NQ_e8f68bad-99dd-4b99-9acb-741a4f5652df">334,246</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3e21049ffc224cacb8134d73c9bb5b38_D20190101-20191231" decimals="-3" sign="-" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM184NS9mcmFnOjdhMDNjNzc3NWZjNDRmMzlhZmY3NjkyYjY5NGQ5YzM3L3RhYmxlOjhhNDlhNzA4NDcxMDQwZTk4MzBiMDg2ZTIxMzRlYTk1L3RhYmxlcmFuZ2U6OGE0OWE3MDg0NzEwNDBlOTgzMGIwODZlMjEzNGVhOTVfNy01LTEtMS0yMTkzMQ_0a6190d1-cda6-4fcd-86a4-1fb62988b96a"><ix:nonFraction unitRef="usd" contextRef="i3e21049ffc224cacb8134d73c9bb5b38_D20190101-20191231" decimals="-3" sign="-" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM184NS9mcmFnOjdhMDNjNzc3NWZjNDRmMzlhZmY3NjkyYjY5NGQ5YzM3L3RhYmxlOjhhNDlhNzA4NDcxMDQwZTk4MzBiMDg2ZTIxMzRlYTk1L3RhYmxlcmFuZ2U6OGE0OWE3MDg0NzEwNDBlOTgzMGIwODZlMjEzNGVhOTVfNy01LTEtMS0yMTkzMQ_77283e80-530b-4696-8342-e4c33faaa8f6">301,971</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average common shares outstanding - basic and diluted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM184NS9mcmFnOjdhMDNjNzc3NWZjNDRmMzlhZmY3NjkyYjY5NGQ5YzM3L3RhYmxlOjhhNDlhNzA4NDcxMDQwZTk4MzBiMDg2ZTIxMzRlYTk1L3RhYmxlcmFuZ2U6OGE0OWE3MDg0NzEwNDBlOTgzMGIwODZlMjEzNGVhOTVfOS01LTEtMS0xNzc3NQ_4d2bf937-f10f-4d10-9f93-6566eaee8855"><ix:nonFraction unitRef="shares" contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM184NS9mcmFnOjdhMDNjNzc3NWZjNDRmMzlhZmY3NjkyYjY5NGQ5YzM3L3RhYmxlOjhhNDlhNzA4NDcxMDQwZTk4MzBiMDg2ZTIxMzRlYTk1L3RhYmxlcmFuZ2U6OGE0OWE3MDg0NzEwNDBlOTgzMGIwODZlMjEzNGVhOTVfOS01LTEtMS0xNzc3NQ_e2c93d99-4d5a-42af-aa15-b4f7a2aa8373">86,067</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i12a6d1161de54547bd29f8efccd4c9b0_D20200101-20201231" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM184NS9mcmFnOjdhMDNjNzc3NWZjNDRmMzlhZmY3NjkyYjY5NGQ5YzM3L3RhYmxlOjhhNDlhNzA4NDcxMDQwZTk4MzBiMDg2ZTIxMzRlYTk1L3RhYmxlcmFuZ2U6OGE0OWE3MDg0NzEwNDBlOTgzMGIwODZlMjEzNGVhOTVfOS03LTEtMS0xNzc3NQ_43f0e345-3af0-4b74-93ae-34e196683016"><ix:nonFraction unitRef="shares" contextRef="i12a6d1161de54547bd29f8efccd4c9b0_D20200101-20201231" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM184NS9mcmFnOjdhMDNjNzc3NWZjNDRmMzlhZmY3NjkyYjY5NGQ5YzM3L3RhYmxlOjhhNDlhNzA4NDcxMDQwZTk4MzBiMDg2ZTIxMzRlYTk1L3RhYmxlcmFuZ2U6OGE0OWE3MDg0NzEwNDBlOTgzMGIwODZlMjEzNGVhOTVfOS03LTEtMS0xNzc3NQ_efcdf457-3aed-4d57-9eff-1d019a73ef97">84,928</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i3e21049ffc224cacb8134d73c9bb5b38_D20190101-20191231" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM184NS9mcmFnOjdhMDNjNzc3NWZjNDRmMzlhZmY3NjkyYjY5NGQ5YzM3L3RhYmxlOjhhNDlhNzA4NDcxMDQwZTk4MzBiMDg2ZTIxMzRlYTk1L3RhYmxlcmFuZ2U6OGE0OWE3MDg0NzEwNDBlOTgzMGIwODZlMjEzNGVhOTVfOS01LTEtMS0yMTk1Mg_25fafb85-ceb4-42c8-926b-7dd11942cafc"><ix:nonFraction unitRef="shares" contextRef="i3e21049ffc224cacb8134d73c9bb5b38_D20190101-20191231" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM184NS9mcmFnOjdhMDNjNzc3NWZjNDRmMzlhZmY3NjkyYjY5NGQ5YzM3L3RhYmxlOjhhNDlhNzA4NDcxMDQwZTk4MzBiMDg2ZTIxMzRlYTk1L3RhYmxlcmFuZ2U6OGE0OWE3MDg0NzEwNDBlOTgzMGIwODZlMjEzNGVhOTVfOS01LTEtMS0yMTk1Mg_2eddbb20-2c74-4c58-a2bc-68f4ca5e9463">82,364</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Income (loss) per common share</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic and diluted</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Continuing operations</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231" decimals="2" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM184NS9mcmFnOjdhMDNjNzc3NWZjNDRmMzlhZmY3NjkyYjY5NGQ5YzM3L3RhYmxlOjhhNDlhNzA4NDcxMDQwZTk4MzBiMDg2ZTIxMzRlYTk1L3RhYmxlcmFuZ2U6OGE0OWE3MDg0NzEwNDBlOTgzMGIwODZlMjEzNGVhOTVfMTMtNS0xLTEtMTc3NzU_1be0d8aa-7784-4a8d-b716-b5e8a6f955e8"><ix:nonFraction unitRef="usdPerShare" contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231" decimals="2" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsPerBasicShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM184NS9mcmFnOjdhMDNjNzc3NWZjNDRmMzlhZmY3NjkyYjY5NGQ5YzM3L3RhYmxlOjhhNDlhNzA4NDcxMDQwZTk4MzBiMDg2ZTIxMzRlYTk1L3RhYmxlcmFuZ2U6OGE0OWE3MDg0NzEwNDBlOTgzMGIwODZlMjEzNGVhOTVfMTMtNS0xLTEtMTc3NzU_e035674e-3c54-4da7-a44d-68e94785e880">0.35</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i12a6d1161de54547bd29f8efccd4c9b0_D20200101-20201231" decimals="2" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsPerBasicShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM184NS9mcmFnOjdhMDNjNzc3NWZjNDRmMzlhZmY3NjkyYjY5NGQ5YzM3L3RhYmxlOjhhNDlhNzA4NDcxMDQwZTk4MzBiMDg2ZTIxMzRlYTk1L3RhYmxlcmFuZ2U6OGE0OWE3MDg0NzEwNDBlOTgzMGIwODZlMjEzNGVhOTVfMTMtNy0xLTEtMTc3NzU_47ab00f1-b3ad-4d5b-8c18-b329fbbc06ba"><ix:nonFraction unitRef="usdPerShare" contextRef="i12a6d1161de54547bd29f8efccd4c9b0_D20200101-20201231" decimals="2" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM184NS9mcmFnOjdhMDNjNzc3NWZjNDRmMzlhZmY3NjkyYjY5NGQ5YzM3L3RhYmxlOjhhNDlhNzA4NDcxMDQwZTk4MzBiMDg2ZTIxMzRlYTk1L3RhYmxlcmFuZ2U6OGE0OWE3MDg0NzEwNDBlOTgzMGIwODZlMjEzNGVhOTVfMTMtNy0xLTEtMTc3NzU_c1dc9607-9bf5-4cf1-a3d2-b0db3afb1c8d">3.86</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i3e21049ffc224cacb8134d73c9bb5b38_D20190101-20191231" decimals="2" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM184NS9mcmFnOjdhMDNjNzc3NWZjNDRmMzlhZmY3NjkyYjY5NGQ5YzM3L3RhYmxlOjhhNDlhNzA4NDcxMDQwZTk4MzBiMDg2ZTIxMzRlYTk1L3RhYmxlcmFuZ2U6OGE0OWE3MDg0NzEwNDBlOTgzMGIwODZlMjEzNGVhOTVfMTMtNS0xLTEtMjE5NTk_297fced9-7321-4394-9d35-8f3d7ae6d0e4"><ix:nonFraction unitRef="usdPerShare" contextRef="i3e21049ffc224cacb8134d73c9bb5b38_D20190101-20191231" decimals="2" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsPerBasicShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM184NS9mcmFnOjdhMDNjNzc3NWZjNDRmMzlhZmY3NjkyYjY5NGQ5YzM3L3RhYmxlOjhhNDlhNzA4NDcxMDQwZTk4MzBiMDg2ZTIxMzRlYTk1L3RhYmxlcmFuZ2U6OGE0OWE3MDg0NzEwNDBlOTgzMGIwODZlMjEzNGVhOTVfMTMtNS0xLTEtMjE5NTk_d87662c3-104c-4c72-8c1f-7e928653cdf7">3.73</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discontinued operations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231" decimals="2" sign="-" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM184NS9mcmFnOjdhMDNjNzc3NWZjNDRmMzlhZmY3NjkyYjY5NGQ5YzM3L3RhYmxlOjhhNDlhNzA4NDcxMDQwZTk4MzBiMDg2ZTIxMzRlYTk1L3RhYmxlcmFuZ2U6OGE0OWE3MDg0NzEwNDBlOTgzMGIwODZlMjEzNGVhOTVfMTQtNS0xLTEtMTc3NzU_3cbafcdb-0f82-465e-b519-e19d64aa375c"><ix:nonFraction unitRef="usdPerShare" contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231" decimals="2" sign="-" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM184NS9mcmFnOjdhMDNjNzc3NWZjNDRmMzlhZmY3NjkyYjY5NGQ5YzM3L3RhYmxlOjhhNDlhNzA4NDcxMDQwZTk4MzBiMDg2ZTIxMzRlYTk1L3RhYmxlcmFuZ2U6OGE0OWE3MDg0NzEwNDBlOTgzMGIwODZlMjEzNGVhOTVfMTQtNS0xLTEtMTc3NzU_697a90c3-40a0-4d50-b5ad-b2ef2b6a2202">0.09</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i12a6d1161de54547bd29f8efccd4c9b0_D20200101-20201231" decimals="2" sign="-" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM184NS9mcmFnOjdhMDNjNzc3NWZjNDRmMzlhZmY3NjkyYjY5NGQ5YzM3L3RhYmxlOjhhNDlhNzA4NDcxMDQwZTk4MzBiMDg2ZTIxMzRlYTk1L3RhYmxlcmFuZ2U6OGE0OWE3MDg0NzEwNDBlOTgzMGIwODZlMjEzNGVhOTVfMTQtNy0xLTEtMTc3NzU_614d8f41-3c14-4669-9dc3-7aef83745f39"><ix:nonFraction unitRef="usdPerShare" contextRef="i12a6d1161de54547bd29f8efccd4c9b0_D20200101-20201231" decimals="2" sign="-" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM184NS9mcmFnOjdhMDNjNzc3NWZjNDRmMzlhZmY3NjkyYjY5NGQ5YzM3L3RhYmxlOjhhNDlhNzA4NDcxMDQwZTk4MzBiMDg2ZTIxMzRlYTk1L3RhYmxlcmFuZ2U6OGE0OWE3MDg0NzEwNDBlOTgzMGIwODZlMjEzNGVhOTVfMTQtNy0xLTEtMTc3NzU_f821a2c7-e60f-4775-af30-3571e62c8d7b">0.08</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i3e21049ffc224cacb8134d73c9bb5b38_D20190101-20191231" decimals="2" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM184NS9mcmFnOjdhMDNjNzc3NWZjNDRmMzlhZmY3NjkyYjY5NGQ5YzM3L3RhYmxlOjhhNDlhNzA4NDcxMDQwZTk4MzBiMDg2ZTIxMzRlYTk1L3RhYmxlcmFuZ2U6OGE0OWE3MDg0NzEwNDBlOTgzMGIwODZlMjEzNGVhOTVfMTQtNS0xLTEtMjE5NTk_65c2769c-8bf5-4a69-9670-8d84e869f596"><ix:nonFraction unitRef="usdPerShare" contextRef="i3e21049ffc224cacb8134d73c9bb5b38_D20190101-20191231" decimals="2" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM184NS9mcmFnOjdhMDNjNzc3NWZjNDRmMzlhZmY3NjkyYjY5NGQ5YzM3L3RhYmxlOjhhNDlhNzA4NDcxMDQwZTk4MzBiMDg2ZTIxMzRlYTk1L3RhYmxlcmFuZ2U6OGE0OWE3MDg0NzEwNDBlOTgzMGIwODZlMjEzNGVhOTVfMTQtNS0xLTEtMjE5NTk_d3da87c4-e160-4bb7-b042-19a87036320a">0.02</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-controlling interests</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231" decimals="2" name="evh:EarningsPerSharePortionAttributableToNoncontrollingInterestDiluted" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM184NS9mcmFnOjdhMDNjNzc3NWZjNDRmMzlhZmY3NjkyYjY5NGQ5YzM3L3RhYmxlOjhhNDlhNzA4NDcxMDQwZTk4MzBiMDg2ZTIxMzRlYTk1L3RhYmxlcmFuZ2U6OGE0OWE3MDg0NzEwNDBlOTgzMGIwODZlMjEzNGVhOTVfMTUtMS0xLTEtMjc1Mjc_b50e84b8-a45a-41d3-9af3-908304b36487"><ix:nonFraction unitRef="usdPerShare" contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231" decimals="2" name="evh:EarningsPerSharePortionAttributableToNoncontrollingInterestBasic" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM184NS9mcmFnOjdhMDNjNzc3NWZjNDRmMzlhZmY3NjkyYjY5NGQ5YzM3L3RhYmxlOjhhNDlhNzA4NDcxMDQwZTk4MzBiMDg2ZTIxMzRlYTk1L3RhYmxlcmFuZ2U6OGE0OWE3MDg0NzEwNDBlOTgzMGIwODZlMjEzNGVhOTVfMTUtMS0xLTEtMjc1Mjc_ee4b7836-0c1c-4e91-a00a-f4f08b39f581">&#8212;</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i12a6d1161de54547bd29f8efccd4c9b0_D20200101-20201231" decimals="2" name="evh:EarningsPerSharePortionAttributableToNoncontrollingInterestBasic" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM184NS9mcmFnOjdhMDNjNzc3NWZjNDRmMzlhZmY3NjkyYjY5NGQ5YzM3L3RhYmxlOjhhNDlhNzA4NDcxMDQwZTk4MzBiMDg2ZTIxMzRlYTk1L3RhYmxlcmFuZ2U6OGE0OWE3MDg0NzEwNDBlOTgzMGIwODZlMjEzNGVhOTVfMTUtMy0xLTEtMjc1Mjc_cebaab0d-cb9a-4d96-96cf-e73e49782c92"><ix:nonFraction unitRef="usdPerShare" contextRef="i12a6d1161de54547bd29f8efccd4c9b0_D20200101-20201231" decimals="2" name="evh:EarningsPerSharePortionAttributableToNoncontrollingInterestDiluted" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM184NS9mcmFnOjdhMDNjNzc3NWZjNDRmMzlhZmY3NjkyYjY5NGQ5YzM3L3RhYmxlOjhhNDlhNzA4NDcxMDQwZTk4MzBiMDg2ZTIxMzRlYTk1L3RhYmxlcmFuZ2U6OGE0OWE3MDg0NzEwNDBlOTgzMGIwODZlMjEzNGVhOTVfMTUtMy0xLTEtMjc1Mjc_f7665397-906b-4348-84a7-07254c898be6">&#8212;</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i3e21049ffc224cacb8134d73c9bb5b38_D20190101-20191231" decimals="2" name="evh:EarningsPerSharePortionAttributableToNoncontrollingInterestBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM184NS9mcmFnOjdhMDNjNzc3NWZjNDRmMzlhZmY3NjkyYjY5NGQ5YzM3L3RhYmxlOjhhNDlhNzA4NDcxMDQwZTk4MzBiMDg2ZTIxMzRlYTk1L3RhYmxlcmFuZ2U6OGE0OWE3MDg0NzEwNDBlOTgzMGIwODZlMjEzNGVhOTVfMTUtNS0xLTEtMjc1Mjc_0d37b9ed-1132-4390-9d72-4c8dc81e16e0"><ix:nonFraction unitRef="usdPerShare" contextRef="i3e21049ffc224cacb8134d73c9bb5b38_D20190101-20191231" decimals="2" name="evh:EarningsPerSharePortionAttributableToNoncontrollingInterestDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM184NS9mcmFnOjdhMDNjNzc3NWZjNDRmMzlhZmY3NjkyYjY5NGQ5YzM3L3RhYmxlOjhhNDlhNzA4NDcxMDQwZTk4MzBiMDg2ZTIxMzRlYTk1L3RhYmxlcmFuZ2U6OGE0OWE3MDg0NzEwNDBlOTgzMGIwODZlMjEzNGVhOTVfMTUtNS0xLTEtMjc1Mjc_38addc30-6b9a-49e7-9ecf-74d51ec59ed6">0.04</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:23pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic and diluted income (loss) per share attributable to common shareholders of Evolent Health, Inc.</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM184NS9mcmFnOjdhMDNjNzc3NWZjNDRmMzlhZmY3NjkyYjY5NGQ5YzM3L3RhYmxlOjhhNDlhNzA4NDcxMDQwZTk4MzBiMDg2ZTIxMzRlYTk1L3RhYmxlcmFuZ2U6OGE0OWE3MDg0NzEwNDBlOTgzMGIwODZlMjEzNGVhOTVfMTUtNS0xLTEtMTc3NzU_1dc36fb6-30b6-45f5-a0d7-06d7a9e9335f"><ix:nonFraction unitRef="usdPerShare" contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM184NS9mcmFnOjdhMDNjNzc3NWZjNDRmMzlhZmY3NjkyYjY5NGQ5YzM3L3RhYmxlOjhhNDlhNzA4NDcxMDQwZTk4MzBiMDg2ZTIxMzRlYTk1L3RhYmxlcmFuZ2U6OGE0OWE3MDg0NzEwNDBlOTgzMGIwODZlMjEzNGVhOTVfMTUtNS0xLTEtMTc3NzU_f8b4468e-36ed-4cf2-b7f3-455155f62856">0.44</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i12a6d1161de54547bd29f8efccd4c9b0_D20200101-20201231" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM184NS9mcmFnOjdhMDNjNzc3NWZjNDRmMzlhZmY3NjkyYjY5NGQ5YzM3L3RhYmxlOjhhNDlhNzA4NDcxMDQwZTk4MzBiMDg2ZTIxMzRlYTk1L3RhYmxlcmFuZ2U6OGE0OWE3MDg0NzEwNDBlOTgzMGIwODZlMjEzNGVhOTVfMTUtNy0xLTEtMTc3NzU_1354653c-22c3-4b3a-bf59-2975c6a7d95b"><ix:nonFraction unitRef="usdPerShare" contextRef="i12a6d1161de54547bd29f8efccd4c9b0_D20200101-20201231" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM184NS9mcmFnOjdhMDNjNzc3NWZjNDRmMzlhZmY3NjkyYjY5NGQ5YzM3L3RhYmxlOjhhNDlhNzA4NDcxMDQwZTk4MzBiMDg2ZTIxMzRlYTk1L3RhYmxlcmFuZ2U6OGE0OWE3MDg0NzEwNDBlOTgzMGIwODZlMjEzNGVhOTVfMTUtNy0xLTEtMTc3NzU_6a13b863-a134-4ff7-b9ae-26c31fbc200f">3.94</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i3e21049ffc224cacb8134d73c9bb5b38_D20190101-20191231" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM184NS9mcmFnOjdhMDNjNzc3NWZjNDRmMzlhZmY3NjkyYjY5NGQ5YzM3L3RhYmxlOjhhNDlhNzA4NDcxMDQwZTk4MzBiMDg2ZTIxMzRlYTk1L3RhYmxlcmFuZ2U6OGE0OWE3MDg0NzEwNDBlOTgzMGIwODZlMjEzNGVhOTVfMTYtNS0xLTEtMjc1MzE_71979723-6e39-4211-8a6d-eaf820918e5d"><ix:nonFraction unitRef="usdPerShare" contextRef="i3e21049ffc224cacb8134d73c9bb5b38_D20190101-20191231" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM184NS9mcmFnOjdhMDNjNzc3NWZjNDRmMzlhZmY3NjkyYjY5NGQ5YzM3L3RhYmxlOjhhNDlhNzA4NDcxMDQwZTk4MzBiMDg2ZTIxMzRlYTk1L3RhYmxlcmFuZ2U6OGE0OWE3MDg0NzEwNDBlOTgzMGIwODZlMjEzNGVhOTVfMTYtNS0xLTEtMjc1MzE_fe462964-8e16-4239-9bc7-5853f6b65425">3.67</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="text-align:justify"><span><br/></span></div><ix:nonNumeric contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM184NS9mcmFnOjdhMDNjNzc3NWZjNDRmMzlhZmY3NjkyYjY5NGQ5YzM3L3RleHRyZWdpb246N2EwM2M3Nzc1ZmM0NGYzOWFmZjc2OTJiNjk0ZDljMzdfMzc2_2c0a4d4d-35d9-4664-ad30-998d7452a132" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Anti-dilutive shares (in thousands) excluded from the calculation of weighted-average common shares presented above are presented below:</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"></td><td style="width:351.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:58.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:58.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:58.00pt"></td><td style="width:1.0pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Year Ended December 31,</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exchangeable Class B common stock</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ifdfd40d05cad486f8f8a1d4f5c27aedc_D20210101-20211231" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM184NS9mcmFnOjdhMDNjNzc3NWZjNDRmMzlhZmY3NjkyYjY5NGQ5YzM3L3RhYmxlOjU1MjNlYmIzYzcwZTQxYTE4MTZlNWIyZmNmZWUzNjkyL3RhYmxlcmFuZ2U6NTUyM2ViYjNjNzBlNDFhMTgxNmU1YjJmY2ZlZTM2OTJfMi0xLTEtMS0yMjAwNg_e28e3107-4088-48db-82e9-dcb9d082d5f7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i52b87d0e43a34ffc9389f5e532dad861_D20200101-20201231" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM184NS9mcmFnOjdhMDNjNzc3NWZjNDRmMzlhZmY3NjkyYjY5NGQ5YzM3L3RhYmxlOjU1MjNlYmIzYzcwZTQxYTE4MTZlNWIyZmNmZWUzNjkyL3RhYmxlcmFuZ2U6NTUyM2ViYjNjNzBlNDFhMTgxNmU1YjJmY2ZlZTM2OTJfMi0zLTEtMS0yMjAwNg_bea7d93b-4625-4db0-891f-7207cb7a8a2a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i7d76227fd72340699f3b20cadd0ca448_D20190101-20191231" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM184NS9mcmFnOjdhMDNjNzc3NWZjNDRmMzlhZmY3NjkyYjY5NGQ5YzM3L3RhYmxlOjU1MjNlYmIzYzcwZTQxYTE4MTZlNWIyZmNmZWUzNjkyL3RhYmxlcmFuZ2U6NTUyM2ViYjNjNzBlNDFhMTgxNmU1YjJmY2ZlZTM2OTJfMi01LTEtMS0yMTk5NQ_e69e92f9-7a20-41d3-be69-bb8b7345b0d9">1,399</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:23pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted stock units ("RSUs"), performance-based RSUs and leveraged stock units ("LSUs")</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i201d78ce09254edeb74a5d8656d986e3_D20210101-20211231" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM184NS9mcmFnOjdhMDNjNzc3NWZjNDRmMzlhZmY3NjkyYjY5NGQ5YzM3L3RhYmxlOjU1MjNlYmIzYzcwZTQxYTE4MTZlNWIyZmNmZWUzNjkyL3RhYmxlcmFuZ2U6NTUyM2ViYjNjNzBlNDFhMTgxNmU1YjJmY2ZlZTM2OTJfMi01LTEtMS0xNzc3NQ_f9c0eea6-4323-4c9e-8efe-bf67a787fbd3">1,807</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ia51882bd916343be8688568234c45e7d_D20200101-20201231" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM184NS9mcmFnOjdhMDNjNzc3NWZjNDRmMzlhZmY3NjkyYjY5NGQ5YzM3L3RhYmxlOjU1MjNlYmIzYzcwZTQxYTE4MTZlNWIyZmNmZWUzNjkyL3RhYmxlcmFuZ2U6NTUyM2ViYjNjNzBlNDFhMTgxNmU1YjJmY2ZlZTM2OTJfMi03LTEtMS0xNzc3NQ_7c4dda4c-6843-4724-8088-60c41808e4e1">797</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ic6ab9363606041b5b1b0664ec16f77e3_D20190101-20191231" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM184NS9mcmFnOjdhMDNjNzc3NWZjNDRmMzlhZmY3NjkyYjY5NGQ5YzM3L3RhYmxlOjU1MjNlYmIzYzcwZTQxYTE4MTZlNWIyZmNmZWUzNjkyL3RhYmxlcmFuZ2U6NTUyM2ViYjNjNzBlNDFhMTgxNmU1YjJmY2ZlZTM2OTJfMy01LTEtMS0yMTk5NQ_1c248206-5c22-49d9-9939-9e89b3ab654c">813</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ia6e4317e0fe84f639d451026ec4811f7_D20210101-20211231" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM184NS9mcmFnOjdhMDNjNzc3NWZjNDRmMzlhZmY3NjkyYjY5NGQ5YzM3L3RhYmxlOjU1MjNlYmIzYzcwZTQxYTE4MTZlNWIyZmNmZWUzNjkyL3RhYmxlcmFuZ2U6NTUyM2ViYjNjNzBlNDFhMTgxNmU1YjJmY2ZlZTM2OTJfMy01LTEtMS0xNzc3NQ_f03c50b6-ac3d-486c-99a8-98db4475b025">2,036</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iebc1de752eaa4389a6a51366f6e15efc_D20200101-20201231" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM184NS9mcmFnOjdhMDNjNzc3NWZjNDRmMzlhZmY3NjkyYjY5NGQ5YzM3L3RhYmxlOjU1MjNlYmIzYzcwZTQxYTE4MTZlNWIyZmNmZWUzNjkyL3RhYmxlcmFuZ2U6NTUyM2ViYjNjNzBlNDFhMTgxNmU1YjJmY2ZlZTM2OTJfMy03LTEtMS0xNzc3NQ_91970b6d-9fca-4ddc-878e-7e05b52f1230">1,141</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i7adc7fd9e069474b9522f7f84242457e_D20190101-20191231" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM184NS9mcmFnOjdhMDNjNzc3NWZjNDRmMzlhZmY3NjkyYjY5NGQ5YzM3L3RhYmxlOjU1MjNlYmIzYzcwZTQxYTE4MTZlNWIyZmNmZWUzNjkyL3RhYmxlcmFuZ2U6NTUyM2ViYjNjNzBlNDFhMTgxNmU1YjJmY2ZlZTM2OTJfNC01LTEtMS0yMTk5NQ_b6b64ab5-5740-49d2-9afb-eb13db227aad">1,324</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Convertible senior notes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="icbc3599f42a84566bfd33e73e504c17e_D20210101-20211231" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM184NS9mcmFnOjdhMDNjNzc3NWZjNDRmMzlhZmY3NjkyYjY5NGQ5YzM3L3RhYmxlOjU1MjNlYmIzYzcwZTQxYTE4MTZlNWIyZmNmZWUzNjkyL3RhYmxlcmFuZ2U6NTUyM2ViYjNjNzBlNDFhMTgxNmU1YjJmY2ZlZTM2OTJfNC01LTEtMS0xNzc3NQ_3e794cb4-f268-4c58-93b9-306b46e507a5">12,602</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="id074b4bed7284281bb2163f48f76bf03_D20200101-20201231" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM184NS9mcmFnOjdhMDNjNzc3NWZjNDRmMzlhZmY3NjkyYjY5NGQ5YzM3L3RhYmxlOjU1MjNlYmIzYzcwZTQxYTE4MTZlNWIyZmNmZWUzNjkyL3RhYmxlcmFuZ2U6NTUyM2ViYjNjNzBlNDFhMTgxNmU1YjJmY2ZlZTM2OTJfNC03LTEtMS0xNzc3NQ_40c20dde-dc6a-43d0-9d59-f5702d484662">11,206</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ib784df78539b41c494661a446433f01c_D20190101-20191231" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM184NS9mcmFnOjdhMDNjNzc3NWZjNDRmMzlhZmY3NjkyYjY5NGQ5YzM3L3RhYmxlOjU1MjNlYmIzYzcwZTQxYTE4MTZlNWIyZmNmZWUzNjkyL3RhYmxlcmFuZ2U6NTUyM2ViYjNjNzBlNDFhMTgxNmU1YjJmY2ZlZTM2OTJfNS01LTEtMS0yMTk5NQ_8adeea3c-d53c-4234-ba22-3cd5f9ef39f3">10,361</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM184NS9mcmFnOjdhMDNjNzc3NWZjNDRmMzlhZmY3NjkyYjY5NGQ5YzM3L3RhYmxlOjU1MjNlYmIzYzcwZTQxYTE4MTZlNWIyZmNmZWUzNjkyL3RhYmxlcmFuZ2U6NTUyM2ViYjNjNzBlNDFhMTgxNmU1YjJmY2ZlZTM2OTJfNS01LTEtMS0xNzc3NQ_677ccf7f-8978-46cf-bea2-ec0552beff35">16,445</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i12a6d1161de54547bd29f8efccd4c9b0_D20200101-20201231" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM184NS9mcmFnOjdhMDNjNzc3NWZjNDRmMzlhZmY3NjkyYjY5NGQ5YzM3L3RhYmxlOjU1MjNlYmIzYzcwZTQxYTE4MTZlNWIyZmNmZWUzNjkyL3RhYmxlcmFuZ2U6NTUyM2ViYjNjNzBlNDFhMTgxNmU1YjJmY2ZlZTM2OTJfNS03LTEtMS0xNzc3NQ_39ce6911-6455-4465-a11b-4590ca369afb">13,144</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i3e21049ffc224cacb8134d73c9bb5b38_D20190101-20191231" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM184NS9mcmFnOjdhMDNjNzc3NWZjNDRmMzlhZmY3NjkyYjY5NGQ5YzM3L3RhYmxlOjU1MjNlYmIzYzcwZTQxYTE4MTZlNWIyZmNmZWUzNjkyL3RhYmxlcmFuZ2U6NTUyM2ViYjNjNzBlNDFhMTgxNmU1YjJmY2ZlZTM2OTJfNi01LTEtMS0yMTk5NQ_ce95fd31-ced7-4585-8129-a7272adea561">13,897</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="text-align:justify"><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">102</span></div></div></div><div id="i9aaa2fddc97e482da5dbe37ac85ae703_91"></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 14.  <ix:nonNumeric contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185MS9mcmFnOjlmMTJhYjBlYWNjMTQ1OTU5ZDhhNjcyY2JmZjdkYjZkL3RleHRyZWdpb246OWYxMmFiMGVhY2MxNDU5NTlkOGE2NzJjYmZmN2RiNmRfMTI2NjA_7435bdb7-f45e-430a-92ff-78701f7de040" continuedAt="i30f31e516d374909b9ae4730c045aa88" escape="true">Stock-based Compensation</ix:nonNumeric></span></div><div style="text-align:justify"><span><br/></span></div><ix:continuation id="i30f31e516d374909b9ae4730c045aa88" continuedAt="i63caf846743541c8af1c657c7de25b58"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2011 and 2015 Equity Incentive Plans</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company issues awards, including stock options, performance-based stock options, restricted stock units, performance-based restricted stock units and leveraged stock units, under the Evolent Health Holdings, Inc. 2011 Equity Incentive Plan (the &#8220;2011 Plan&#8221;) and the 2015 Evolent Health, Inc. Omnibus Incentive Compensation Plan (the &#8220;2015 Plan&#8221;). We assumed the 2011 Plan in connection with the merger of Evolent Health Holdings with and into Evolent Health, Inc. The 2011 Plan allows for the grant of an array of equity-based and cash incentive awards to our directors, employees and other service providers. The 2011 Plan was amended on September 23, 2013, to increase the number of shares authorized to <ix:nonFraction unitRef="shares" contextRef="ie27c749af3f640e6b503c30b7017a0cb_I20130923" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185MS9mcmFnOjlmMTJhYjBlYWNjMTQ1OTU5ZDhhNjcyY2JmZjdkYjZkL3RleHRyZWdpb246OWYxMmFiMGVhY2MxNDU5NTlkOGE2NzJjYmZmN2RiNmRfNzI5_1fb78564-e2b5-40fb-906c-5b2bb34be5ef">9.1</ix:nonFraction>&#160;million of the Company&#8217;s common stock. As of December&#160;31, 2021 and 2020, <ix:nonFraction unitRef="shares" contextRef="i1d4614ce073d4c1dbaf45d31f2350ff7_I20211231" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185MS9mcmFnOjlmMTJhYjBlYWNjMTQ1OTU5ZDhhNjcyY2JmZjdkYjZkL3RleHRyZWdpb246OWYxMmFiMGVhY2MxNDU5NTlkOGE2NzJjYmZmN2RiNmRfNzgw_8cdc7bd1-37c8-4208-88ad-d28d2e425ef1">4.8</ix:nonFraction> million stock options and <ix:nonFraction unitRef="shares" contextRef="i96a77abfddf84842a980b801febda12d_I20201231" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185MS9mcmFnOjlmMTJhYjBlYWNjMTQ1OTU5ZDhhNjcyY2JmZjdkYjZkL3RleHRyZWdpb246OWYxMmFiMGVhY2MxNDU5NTlkOGE2NzJjYmZmN2RiNmRfODAx_0787479b-b24e-459a-8b7b-74ba8767b4d9">3.8</ix:nonFraction> million shares of restricted stock have been issued, net of forfeitures, under the 2011 Plan.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 1, 2015, the Board of Directors approved and authorized the 2015 Plan which provides for the issuance of up to <ix:nonFraction unitRef="shares" contextRef="ie6ac3c72c3d048a79d7e7fab6a952c8d_I20150501" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185MS9mcmFnOjlmMTJhYjBlYWNjMTQ1OTU5ZDhhNjcyY2JmZjdkYjZkL3RleHRyZWdpb246OWYxMmFiMGVhY2MxNDU5NTlkOGE2NzJjYmZmN2RiNmRfMTAxMA_48035389-23ab-45aa-9137-49ccceacc37f">6.0</ix:nonFraction> million shares of the Company&#8217;s Class A common stock to employees and non-employee directors of the Company and its consolidated subsidiaries. The 2015 Plan was amended on June 13, 2018  and April 15, 2021, to increase the number of shares authorized to <ix:nonFraction unitRef="shares" contextRef="i24c60745c92845f2979175286f6cfdb2_I20180613" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185MS9mcmFnOjlmMTJhYjBlYWNjMTQ1OTU5ZDhhNjcyY2JmZjdkYjZkL3RleHRyZWdpb246OWYxMmFiMGVhY2MxNDU5NTlkOGE2NzJjYmZmN2RiNmRfMTIzOQ_77a76488-82d9-40a3-9b5a-f126071b63c9">10.5</ix:nonFraction> million and <ix:nonFraction unitRef="shares" contextRef="ifd8fb1ee9c5446a8804b4991f663185d_I20210415" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185MS9mcmFnOjlmMTJhYjBlYWNjMTQ1OTU5ZDhhNjcyY2JmZjdkYjZkL3RleHRyZWdpb246OWYxMmFiMGVhY2MxNDU5NTlkOGE2NzJjYmZmN2RiNmRfMTA5OTUxMTY1NDM5NQ_8dfb1737-1295-42d4-92db-bce3aa3bb821">15.4</ix:nonFraction> million, respectively. Upon shareholder approval of the amended 2015 Plan in 2018, the 2011 Plan was automatically terminated and no further awards may be granted under the 2011 Plan. The 2011 Plan continues to govern awards previously granted under the 2011 Plan. As of December&#160;31, 2021, <ix:nonFraction unitRef="shares" contextRef="ib2892fd727a044ae9ebfd0032f5bc139_I20211231" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185MS9mcmFnOjlmMTJhYjBlYWNjMTQ1OTU5ZDhhNjcyY2JmZjdkYjZkL3RleHRyZWdpb246OWYxMmFiMGVhY2MxNDU5NTlkOGE2NzJjYmZmN2RiNmRfMTQ5MA_ff783910-2a7a-46c5-b7b1-5b9e967369a1">2.8</ix:nonFraction> million of stock options, <ix:nonFraction unitRef="shares" contextRef="i4266034771344505a1b7761cd97832a1_I20211231" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185MS9mcmFnOjlmMTJhYjBlYWNjMTQ1OTU5ZDhhNjcyY2JmZjdkYjZkL3RleHRyZWdpb246OWYxMmFiMGVhY2MxNDU5NTlkOGE2NzJjYmZmN2RiNmRfMTUxOA_9b6c18e6-0f33-4297-8b80-6dae837efe0d">4.5</ix:nonFraction> million RSUs, <ix:nonFraction unitRef="shares" contextRef="i0017a1e05fa1452c857571fdbc23fd69_I20211231" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185MS9mcmFnOjlmMTJhYjBlYWNjMTQ1OTU5ZDhhNjcyY2JmZjdkYjZkL3RleHRyZWdpb246OWYxMmFiMGVhY2MxNDU5NTlkOGE2NzJjYmZmN2RiNmRfMTA5OTUxMTY1NDkzOA_93896906-7da3-402c-8eac-b9a496b33cb1">1.1</ix:nonFraction> million LSUs and <ix:nonFraction unitRef="shares" contextRef="ic48b20a77e2d4ff0bffc7a7d61a66f9c_I20211231" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185MS9mcmFnOjlmMTJhYjBlYWNjMTQ1OTU5ZDhhNjcyY2JmZjdkYjZkL3RleHRyZWdpb246OWYxMmFiMGVhY2MxNDU5NTlkOGE2NzJjYmZmN2RiNmRfMTA5OTUxMTY1NDk1MQ_402210b9-2b47-4bc9-867a-7476da801be5">0.3</ix:nonFraction> million PSUs, have been issued, net of forfeitures, under the 2015 Plan. As of December 31, 2020, <ix:nonFraction unitRef="shares" contextRef="i0486c1cd30d84075a90f947bf2f00d37_I20201231" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185MS9mcmFnOjlmMTJhYjBlYWNjMTQ1OTU5ZDhhNjcyY2JmZjdkYjZkL3RleHRyZWdpb246OWYxMmFiMGVhY2MxNDU5NTlkOGE2NzJjYmZmN2RiNmRfMTA5OTUxMTY1NDgxOA_36cc4000-0d2f-40fd-88ec-90fc2ff8c135">2.8</ix:nonFraction> million stock options, <ix:nonFraction unitRef="shares" contextRef="i9057bdb4a3f7459a99f31c6dcfaf93e8_I20201231" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185MS9mcmFnOjlmMTJhYjBlYWNjMTQ1OTU5ZDhhNjcyY2JmZjdkYjZkL3RleHRyZWdpb246OWYxMmFiMGVhY2MxNDU5NTlkOGE2NzJjYmZmN2RiNmRfMTA5OTUxMTY1NDg1MQ_7a155796-0771-47bf-8fe5-7be079c2e677">3.5</ix:nonFraction> million RSUs and <ix:nonFraction unitRef="shares" contextRef="i144feb14f3894f2a93baecbdbd67f999_I20201231" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185MS9mcmFnOjlmMTJhYjBlYWNjMTQ1OTU5ZDhhNjcyY2JmZjdkYjZkL3RleHRyZWdpb246OWYxMmFiMGVhY2MxNDU5NTlkOGE2NzJjYmZmN2RiNmRfMTA5OTUxMTY1NDk3OA_259fc1b9-f627-4a92-b305-64ab841d9d0a">1.2</ix:nonFraction> million LSUs, have been issued, net of forfeitures, under the 2015 Plan.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We follow an employee model for our stock-based compensation as awards are granted in the stock of the Company to employees and non-employee directors of the Company or its consolidated subsidiaries. Following the adoption of ASU 2018-07 during 2018, we also follow the employee model for stock-based compensation for awards granted to acquire goods and services from non-employees. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Stock-based Compensation Expense</span></div><div style="text-align:justify"><span><br/></span></div><ix:nonNumeric contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231" name="us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185MS9mcmFnOjlmMTJhYjBlYWNjMTQ1OTU5ZDhhNjcyY2JmZjdkYjZkL3RleHRyZWdpb246OWYxMmFiMGVhY2MxNDU5NTlkOGE2NzJjYmZmN2RiNmRfMTI2NTI_d3f00578-e63d-4919-916b-1c7dd6eb3820" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total compensation expense by award type and line item in our consolidated financial statements was as follows (in thousands):</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"></td><td style="width:379.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:48.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:48.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:48.25pt"></td><td style="width:1.0pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Year Ended December 31,</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Award Type</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i532d2c0bf63243e999d48341920b6775_D20210101-20211231" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185MS9mcmFnOjlmMTJhYjBlYWNjMTQ1OTU5ZDhhNjcyY2JmZjdkYjZkL3RhYmxlOjEyM2UwNzU3YWM2ZTQzNTM4ZWVkNDJjNmViY2YxMmFlL3RhYmxlcmFuZ2U6MTIzZTA3NTdhYzZlNDM1MzhlZWQ0MmM2ZWJjZjEyYWVfMy0xLTEtMS0xNzc3NQ_1204d897-b199-4f2a-9b85-c88fd2222a63">1,337</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3462813a792a43bdb0cd92a0d3fc4085_D20200101-20201231" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185MS9mcmFnOjlmMTJhYjBlYWNjMTQ1OTU5ZDhhNjcyY2JmZjdkYjZkL3RhYmxlOjEyM2UwNzU3YWM2ZTQzNTM4ZWVkNDJjNmViY2YxMmFlL3RhYmxlcmFuZ2U6MTIzZTA3NTdhYzZlNDM1MzhlZWQ0MmM2ZWJjZjEyYWVfMy0zLTEtMS0xNzc3NQ_f4b58520-f30c-4816-8170-f74ed066e975">2,927</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id4cdbac3ed5841318a01e98ea7bb7cb3_D20190101-20191231" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185MS9mcmFnOjlmMTJhYjBlYWNjMTQ1OTU5ZDhhNjcyY2JmZjdkYjZkL3RhYmxlOjEyM2UwNzU3YWM2ZTQzNTM4ZWVkNDJjNmViY2YxMmFlL3RhYmxlcmFuZ2U6MTIzZTA3NTdhYzZlNDM1MzhlZWQ0MmM2ZWJjZjEyYWVfMy01LTEtMS0xNzc3NQ_577ce658-fb98-4b30-83b7-2efd491cb435">4,237</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Performance-based stock options</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i45606ce9dfa74fc7bd724460f67189ab_D20210101-20211231" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185MS9mcmFnOjlmMTJhYjBlYWNjMTQ1OTU5ZDhhNjcyY2JmZjdkYjZkL3RhYmxlOjEyM2UwNzU3YWM2ZTQzNTM4ZWVkNDJjNmViY2YxMmFlL3RhYmxlcmFuZ2U6MTIzZTA3NTdhYzZlNDM1MzhlZWQ0MmM2ZWJjZjEyYWVfNC0xLTEtMS0xNzc3NQ_20144358-15a9-420c-bfb9-c330ffe0e896">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2ef2d194cc634bb5a3f24f06d02c7f5b_D20200101-20201231" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185MS9mcmFnOjlmMTJhYjBlYWNjMTQ1OTU5ZDhhNjcyY2JmZjdkYjZkL3RhYmxlOjEyM2UwNzU3YWM2ZTQzNTM4ZWVkNDJjNmViY2YxMmFlL3RhYmxlcmFuZ2U6MTIzZTA3NTdhYzZlNDM1MzhlZWQ0MmM2ZWJjZjEyYWVfNC0zLTEtMS0xNzc3NQ_437860c4-0125-4293-9c15-30ee95d4824a">75</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i98059f1600aa412c87f3adc6788eb8b5_D20190101-20191231" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185MS9mcmFnOjlmMTJhYjBlYWNjMTQ1OTU5ZDhhNjcyY2JmZjdkYjZkL3RhYmxlOjEyM2UwNzU3YWM2ZTQzNTM4ZWVkNDJjNmViY2YxMmFlL3RhYmxlcmFuZ2U6MTIzZTA3NTdhYzZlNDM1MzhlZWQ0MmM2ZWJjZjEyYWVfNC01LTEtMS0xNzc3NQ_d41fed27-29b1-4515-a7eb-d8ea55d13c43">448</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">RSUs</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i903fc0912d4e492c95e3ce815e897489_D20210101-20211231" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185MS9mcmFnOjlmMTJhYjBlYWNjMTQ1OTU5ZDhhNjcyY2JmZjdkYjZkL3RhYmxlOjEyM2UwNzU3YWM2ZTQzNTM4ZWVkNDJjNmViY2YxMmFlL3RhYmxlcmFuZ2U6MTIzZTA3NTdhYzZlNDM1MzhlZWQ0MmM2ZWJjZjEyYWVfNS0xLTEtMS0xNzc3NQ_dc88c805-09df-460a-bd82-581d1af8874a">9,606</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i117e325270bf4054b07c98692139814a_D20200101-20201231" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185MS9mcmFnOjlmMTJhYjBlYWNjMTQ1OTU5ZDhhNjcyY2JmZjdkYjZkL3RhYmxlOjEyM2UwNzU3YWM2ZTQzNTM4ZWVkNDJjNmViY2YxMmFlL3RhYmxlcmFuZ2U6MTIzZTA3NTdhYzZlNDM1MzhlZWQ0MmM2ZWJjZjEyYWVfNS0zLTEtMS0xNzc3NQ_e3727878-9f80-4cc9-a72e-651ea5793f91">7,763</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4ad066769cd0464cbcbcf7d1ec4ce0ad_D20190101-20191231" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185MS9mcmFnOjlmMTJhYjBlYWNjMTQ1OTU5ZDhhNjcyY2JmZjdkYjZkL3RhYmxlOjEyM2UwNzU3YWM2ZTQzNTM4ZWVkNDJjNmViY2YxMmFlL3RhYmxlcmFuZ2U6MTIzZTA3NTdhYzZlNDM1MzhlZWQ0MmM2ZWJjZjEyYWVfNS01LTEtMS0xNzc3NQ_7ef4dd7f-292e-4257-be41-fe391045e508">8,877</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Performance-based RSUs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i91de07e5bb1e422aa1d46986a0b1006f_D20210101-20211231" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185MS9mcmFnOjlmMTJhYjBlYWNjMTQ1OTU5ZDhhNjcyY2JmZjdkYjZkL3RhYmxlOjEyM2UwNzU3YWM2ZTQzNTM4ZWVkNDJjNmViY2YxMmFlL3RhYmxlcmFuZ2U6MTIzZTA3NTdhYzZlNDM1MzhlZWQ0MmM2ZWJjZjEyYWVfNi0xLTEtMS0xNzc3NQ_b51efb44-a8cc-4cbd-8ed3-eff79e522cea">2,471</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ief3bd4a971ea460990e3d8fb590be11d_D20200101-20201231" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185MS9mcmFnOjlmMTJhYjBlYWNjMTQ1OTU5ZDhhNjcyY2JmZjdkYjZkL3RhYmxlOjEyM2UwNzU3YWM2ZTQzNTM4ZWVkNDJjNmViY2YxMmFlL3RhYmxlcmFuZ2U6MTIzZTA3NTdhYzZlNDM1MzhlZWQ0MmM2ZWJjZjEyYWVfNi0zLTEtMS0xNzc3NQ_3a66062e-1223-494e-aa32-b9e1fad3d31f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i460ef5cbfd2c49989b7ae61f7d7e59b2_D20190101-20191231" decimals="-3" sign="-" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185MS9mcmFnOjlmMTJhYjBlYWNjMTQ1OTU5ZDhhNjcyY2JmZjdkYjZkL3RhYmxlOjEyM2UwNzU3YWM2ZTQzNTM4ZWVkNDJjNmViY2YxMmFlL3RhYmxlcmFuZ2U6MTIzZTA3NTdhYzZlNDM1MzhlZWQ0MmM2ZWJjZjEyYWVfNi01LTEtMS0xNzc3NQ_52898d2e-4bf0-46ac-bf25-fb10e98e19f8">388</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">LSUs</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if0b01289c86a4176ab75517bdfe4ec1f_D20210101-20211231" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185MS9mcmFnOjlmMTJhYjBlYWNjMTQ1OTU5ZDhhNjcyY2JmZjdkYjZkL3RhYmxlOjEyM2UwNzU3YWM2ZTQzNTM4ZWVkNDJjNmViY2YxMmFlL3RhYmxlcmFuZ2U6MTIzZTA3NTdhYzZlNDM1MzhlZWQ0MmM2ZWJjZjEyYWVfNy0xLTEtMS0xNzc3NQ_6c9101ce-9525-4235-ae29-6cb8aa775e46">3,297</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i824c4e26d9414a59ad8f2d73e36714d0_D20200101-20201231" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185MS9mcmFnOjlmMTJhYjBlYWNjMTQ1OTU5ZDhhNjcyY2JmZjdkYjZkL3RhYmxlOjEyM2UwNzU3YWM2ZTQzNTM4ZWVkNDJjNmViY2YxMmFlL3RhYmxlcmFuZ2U6MTIzZTA3NTdhYzZlNDM1MzhlZWQ0MmM2ZWJjZjEyYWVfNy0zLTEtMS0xNzc3NQ_c5d8354b-5961-4daf-987a-7849ed0e7894">3,841</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i89ff4001d069448c9d4b0758b35fcfdb_D20190101-20191231" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185MS9mcmFnOjlmMTJhYjBlYWNjMTQ1OTU5ZDhhNjcyY2JmZjdkYjZkL3RhYmxlOjEyM2UwNzU3YWM2ZTQzNTM4ZWVkNDJjNmViY2YxMmFlL3RhYmxlcmFuZ2U6MTIzZTA3NTdhYzZlNDM1MzhlZWQ0MmM2ZWJjZjEyYWVfNy01LTEtMS0xNzc3NQ_97bcfefd-42e2-4c8e-85c9-aeb43f87ac07">2,444</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total compensation expense by award type</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185MS9mcmFnOjlmMTJhYjBlYWNjMTQ1OTU5ZDhhNjcyY2JmZjdkYjZkL3RhYmxlOjEyM2UwNzU3YWM2ZTQzNTM4ZWVkNDJjNmViY2YxMmFlL3RhYmxlcmFuZ2U6MTIzZTA3NTdhYzZlNDM1MzhlZWQ0MmM2ZWJjZjEyYWVfOC0xLTEtMS0xNzc3NQ_b5b4b55d-7c4e-4bba-9c1f-1886fb15a0f2">16,711</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i12a6d1161de54547bd29f8efccd4c9b0_D20200101-20201231" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185MS9mcmFnOjlmMTJhYjBlYWNjMTQ1OTU5ZDhhNjcyY2JmZjdkYjZkL3RhYmxlOjEyM2UwNzU3YWM2ZTQzNTM4ZWVkNDJjNmViY2YxMmFlL3RhYmxlcmFuZ2U6MTIzZTA3NTdhYzZlNDM1MzhlZWQ0MmM2ZWJjZjEyYWVfOC0zLTEtMS0xNzc3NQ_786be533-7f2d-44a7-a7f5-ae286b3ef8e1">14,606</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e21049ffc224cacb8134d73c9bb5b38_D20190101-20191231" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185MS9mcmFnOjlmMTJhYjBlYWNjMTQ1OTU5ZDhhNjcyY2JmZjdkYjZkL3RhYmxlOjEyM2UwNzU3YWM2ZTQzNTM4ZWVkNDJjNmViY2YxMmFlL3RhYmxlcmFuZ2U6MTIzZTA3NTdhYzZlNDM1MzhlZWQ0MmM2ZWJjZjEyYWVfOC01LTEtMS0xNzc3NQ_150028df-c30e-41ca-a30d-590dff1fefce">15,618</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Line Item</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of revenue</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1d8c81c79de743e8be167a4c88ad5716_D20210101-20211231" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185MS9mcmFnOjlmMTJhYjBlYWNjMTQ1OTU5ZDhhNjcyY2JmZjdkYjZkL3RhYmxlOjEyM2UwNzU3YWM2ZTQzNTM4ZWVkNDJjNmViY2YxMmFlL3RhYmxlcmFuZ2U6MTIzZTA3NTdhYzZlNDM1MzhlZWQ0MmM2ZWJjZjEyYWVfMTEtMS0xLTEtMTc3NzU_f63f25e5-0986-44ee-b9ad-a5e8473739ac">2,263</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3bb865fc0dda42bb8bbc52f03a761729_D20200101-20201231" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185MS9mcmFnOjlmMTJhYjBlYWNjMTQ1OTU5ZDhhNjcyY2JmZjdkYjZkL3RhYmxlOjEyM2UwNzU3YWM2ZTQzNTM4ZWVkNDJjNmViY2YxMmFlL3RhYmxlcmFuZ2U6MTIzZTA3NTdhYzZlNDM1MzhlZWQ0MmM2ZWJjZjEyYWVfMTEtMy0xLTEtMTc3NzU_4f4ef33d-13e2-47f8-9a66-6dcda701c933">1,811</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5542e161a27e454bb0a6172a44d18515_D20190101-20191231" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185MS9mcmFnOjlmMTJhYjBlYWNjMTQ1OTU5ZDhhNjcyY2JmZjdkYjZkL3RhYmxlOjEyM2UwNzU3YWM2ZTQzNTM4ZWVkNDJjNmViY2YxMmFlL3RhYmxlcmFuZ2U6MTIzZTA3NTdhYzZlNDM1MzhlZWQ0MmM2ZWJjZjEyYWVfMTEtNS0xLTEtMTc3NzU_8e9cf725-e191-4eb0-9460-4965fddd2fc3">2,673</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic2fe85c2e61b4a82aefe1b1a25d6bef0_D20210101-20211231" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185MS9mcmFnOjlmMTJhYjBlYWNjMTQ1OTU5ZDhhNjcyY2JmZjdkYjZkL3RhYmxlOjEyM2UwNzU3YWM2ZTQzNTM4ZWVkNDJjNmViY2YxMmFlL3RhYmxlcmFuZ2U6MTIzZTA3NTdhYzZlNDM1MzhlZWQ0MmM2ZWJjZjEyYWVfMTItMS0xLTEtMTc3NzU_3bad0968-0a39-40f9-95c2-32119b34a384">14,448</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i686054032b8e4393aca78c7d43aa5ebd_D20200101-20201231" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185MS9mcmFnOjlmMTJhYjBlYWNjMTQ1OTU5ZDhhNjcyY2JmZjdkYjZkL3RhYmxlOjEyM2UwNzU3YWM2ZTQzNTM4ZWVkNDJjNmViY2YxMmFlL3RhYmxlcmFuZ2U6MTIzZTA3NTdhYzZlNDM1MzhlZWQ0MmM2ZWJjZjEyYWVfMTItMy0xLTEtMTc3NzU_5ddb58fc-9b38-4ce5-a102-433921386744">12,795</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8b9330154a17434f90687e31afeba60a_D20190101-20191231" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185MS9mcmFnOjlmMTJhYjBlYWNjMTQ1OTU5ZDhhNjcyY2JmZjdkYjZkL3RhYmxlOjEyM2UwNzU3YWM2ZTQzNTM4ZWVkNDJjNmViY2YxMmFlL3RhYmxlcmFuZ2U6MTIzZTA3NTdhYzZlNDM1MzhlZWQ0MmM2ZWJjZjEyYWVfMTItNS0xLTEtMTc3NzU_dece53b2-acb3-4bf1-8957-5fe237cdfd4a">12,945</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total compensation expense by financial statement line item</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185MS9mcmFnOjlmMTJhYjBlYWNjMTQ1OTU5ZDhhNjcyY2JmZjdkYjZkL3RhYmxlOjEyM2UwNzU3YWM2ZTQzNTM4ZWVkNDJjNmViY2YxMmFlL3RhYmxlcmFuZ2U6MTIzZTA3NTdhYzZlNDM1MzhlZWQ0MmM2ZWJjZjEyYWVfMTMtMS0xLTEtMTc3NzU_35d76894-ec58-455a-afdd-9c472077f7e0">16,711</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i12a6d1161de54547bd29f8efccd4c9b0_D20200101-20201231" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185MS9mcmFnOjlmMTJhYjBlYWNjMTQ1OTU5ZDhhNjcyY2JmZjdkYjZkL3RhYmxlOjEyM2UwNzU3YWM2ZTQzNTM4ZWVkNDJjNmViY2YxMmFlL3RhYmxlcmFuZ2U6MTIzZTA3NTdhYzZlNDM1MzhlZWQ0MmM2ZWJjZjEyYWVfMTMtMy0xLTEtMTc3NzU_ba4de417-8079-427f-9a86-d92f5e04b161">14,606</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e21049ffc224cacb8134d73c9bb5b38_D20190101-20191231" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185MS9mcmFnOjlmMTJhYjBlYWNjMTQ1OTU5ZDhhNjcyY2JmZjdkYjZkL3RhYmxlOjEyM2UwNzU3YWM2ZTQzNTM4ZWVkNDJjNmViY2YxMmFlL3RhYmxlcmFuZ2U6MTIzZTA3NTdhYzZlNDM1MzhlZWQ0MmM2ZWJjZjEyYWVfMTMtNS0xLTEtMTc3NzU_d906dc99-6a84-4d37-baa6-9d4760151055">15,618</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231" decimals="INF" name="us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185MS9mcmFnOjlmMTJhYjBlYWNjMTQ1OTU5ZDhhNjcyY2JmZjdkYjZkL3RleHRyZWdpb246OWYxMmFiMGVhY2MxNDU5NTlkOGE2NzJjYmZmN2RiNmRfMjE0Mg_5c5c916f-68d1-459b-ba8f-ab4edf706575"><ix:nonFraction unitRef="usd" contextRef="i12a6d1161de54547bd29f8efccd4c9b0_D20200101-20201231" decimals="INF" name="us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185MS9mcmFnOjlmMTJhYjBlYWNjMTQ1OTU5ZDhhNjcyY2JmZjdkYjZkL3RleHRyZWdpb246OWYxMmFiMGVhY2MxNDU5NTlkOGE2NzJjYmZmN2RiNmRfMjE0Mg_7e1ee2ac-28e6-4d54-987c-3023ca9bd385"><ix:nonFraction unitRef="usd" contextRef="i3e21049ffc224cacb8134d73c9bb5b38_D20190101-20191231" decimals="INF" name="us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185MS9mcmFnOjlmMTJhYjBlYWNjMTQ1OTU5ZDhhNjcyY2JmZjdkYjZkL3RleHRyZWdpb246OWYxMmFiMGVhY2MxNDU5NTlkOGE2NzJjYmZmN2RiNmRfMjE0Mg_84a3b053-1522-4988-852d-c5ce72c0ec86">No</ix:nonFraction></ix:nonFraction></ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> stock-based compensation was capitalized as software development costs for the years ended December&#160;31, 2021, 2020 and 2019.</span></div></ix:continuation><div style="text-align:justify"><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">103</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i63caf846743541c8af1c657c7de25b58" continuedAt="ibdce2f92b4b7442f81706798ae04b0fa"><ix:nonNumeric contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231" name="us-gaap:ScheduleOfUnrecognizedCompensationCostNonvestedAwardsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185MS9mcmFnOjlmMTJhYjBlYWNjMTQ1OTU5ZDhhNjcyY2JmZjdkYjZkL3RleHRyZWdpb246OWYxMmFiMGVhY2MxNDU5NTlkOGE2NzJjYmZmN2RiNmRfMTI2Nzc_94ee92b5-d666-4f9e-9670-cd4b971983d0" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total unrecognized compensation expense (in thousands) and expected weighted-average period (in years) by award type for all of our stock-based incentive plans were as follows:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:535.50pt"><tr><td style="width:1.0pt"></td><td style="width:393.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:66.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:66.25pt"></td><td style="width:1.0pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31, 2021</span></td></tr><tr style="height:33pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Unrecognized Compensation Expense</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average Period (years)</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i532ccc69d7f7466ba58c97c04ba645e1_I20211231" decimals="-3" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185MS9mcmFnOjlmMTJhYjBlYWNjMTQ1OTU5ZDhhNjcyY2JmZjdkYjZkL3RhYmxlOjQzMjZlNzkzZTQwYjRlMDViYTI4MTRmZGUxNTgyODI4L3RhYmxlcmFuZ2U6NDMyNmU3OTNlNDBiNGUwNWJhMjgxNGZkZTE1ODI4MjhfMi0xLTEtMS0xNzc3NQ_f6dffdad-e163-41a8-873c-b76d559cf327">512</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i532d2c0bf63243e999d48341920b6775_D20210101-20211231" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185MS9mcmFnOjlmMTJhYjBlYWNjMTQ1OTU5ZDhhNjcyY2JmZjdkYjZkL3RhYmxlOjQzMjZlNzkzZTQwYjRlMDViYTI4MTRmZGUxNTgyODI4L3RhYmxlcmFuZ2U6NDMyNmU3OTNlNDBiNGUwNWJhMjgxNGZkZTE1ODI4MjhfMi0zLTEtMS0xNzc3NQ_7eb91ce6-fc91-4d2c-9dc4-b2b4ffba939c">0.57</ix:nonNumeric></span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">RSUs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0a2bd98f25e64cac9d230b30c39fd652_I20211231" decimals="-3" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185MS9mcmFnOjlmMTJhYjBlYWNjMTQ1OTU5ZDhhNjcyY2JmZjdkYjZkL3RhYmxlOjQzMjZlNzkzZTQwYjRlMDViYTI4MTRmZGUxNTgyODI4L3RhYmxlcmFuZ2U6NDMyNmU3OTNlNDBiNGUwNWJhMjgxNGZkZTE1ODI4MjhfMy0xLTEtMS0xNzc3NQ_acb20ee1-0061-43c3-9c15-f26ac1c64293">26,104</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i903fc0912d4e492c95e3ce815e897489_D20210101-20211231" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185MS9mcmFnOjlmMTJhYjBlYWNjMTQ1OTU5ZDhhNjcyY2JmZjdkYjZkL3RhYmxlOjQzMjZlNzkzZTQwYjRlMDViYTI4MTRmZGUxNTgyODI4L3RhYmxlcmFuZ2U6NDMyNmU3OTNlNDBiNGUwNWJhMjgxNGZkZTE1ODI4MjhfMy0zLTEtMS0xNzc3NQ_a16ef1f1-d8f4-4037-a59e-2bf45b4d7e2d">1.69</ix:nonNumeric></span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">LSUs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i33d73ea883764a2dafec5a1252f33aef_I20211231" decimals="-3" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185MS9mcmFnOjlmMTJhYjBlYWNjMTQ1OTU5ZDhhNjcyY2JmZjdkYjZkL3RhYmxlOjQzMjZlNzkzZTQwYjRlMDViYTI4MTRmZGUxNTgyODI4L3RhYmxlcmFuZ2U6NDMyNmU3OTNlNDBiNGUwNWJhMjgxNGZkZTE1ODI4MjhfNC0xLTEtMS0xNzc3NQ_8a8b7ff5-a185-48c8-84d6-c13ecbe2dee4">2,422</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="if0b01289c86a4176ab75517bdfe4ec1f_D20210101-20211231" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185MS9mcmFnOjlmMTJhYjBlYWNjMTQ1OTU5ZDhhNjcyY2JmZjdkYjZkL3RhYmxlOjQzMjZlNzkzZTQwYjRlMDViYTI4MTRmZGUxNTgyODI4L3RhYmxlcmFuZ2U6NDMyNmU3OTNlNDBiNGUwNWJhMjgxNGZkZTE1ODI4MjhfNC0zLTEtMS0xNzc3NQ_59903601-e04d-44da-bc63-a7a27d532b99">1.19</ix:nonNumeric></span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Performance-based RSUs</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ife9a61a44ecc47e88bb29426256eba9d_I20211231" decimals="-3" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185MS9mcmFnOjlmMTJhYjBlYWNjMTQ1OTU5ZDhhNjcyY2JmZjdkYjZkL3RhYmxlOjQzMjZlNzkzZTQwYjRlMDViYTI4MTRmZGUxNTgyODI4L3RhYmxlcmFuZ2U6NDMyNmU3OTNlNDBiNGUwNWJhMjgxNGZkZTE1ODI4MjhfNS0xLTEtMS0yOTI4Mw_cbe5fd95-831a-4950-9555-79c1350896ee">4,121</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i91de07e5bb1e422aa1d46986a0b1006f_D20210101-20211231" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185MS9mcmFnOjlmMTJhYjBlYWNjMTQ1OTU5ZDhhNjcyY2JmZjdkYjZkL3RhYmxlOjQzMjZlNzkzZTQwYjRlMDViYTI4MTRmZGUxNTgyODI4L3RhYmxlcmFuZ2U6NDMyNmU3OTNlNDBiNGUwNWJhMjgxNGZkZTE1ODI4MjhfNS0zLTEtMS0yOTI5MA_eda99509-6a2e-4650-9946-5c99ea800950">3.17</ix:nonNumeric></span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8daff60be410426d8f7bd49343c1ec0c_I20211231" decimals="-3" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185MS9mcmFnOjlmMTJhYjBlYWNjMTQ1OTU5ZDhhNjcyY2JmZjdkYjZkL3RhYmxlOjQzMjZlNzkzZTQwYjRlMDViYTI4MTRmZGUxNTgyODI4L3RhYmxlcmFuZ2U6NDMyNmU3OTNlNDBiNGUwNWJhMjgxNGZkZTE1ODI4MjhfNS0xLTEtMS0xNzc3NQ_870f1593-71ba-4442-93f8-24de2bd4ff51">33,159</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr></table></div></ix:nonNumeric><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Stock Options</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other than the performance-based stock options described below, options awarded under the incentive compensation plans are generally subject to a <ix:nonNumeric contextRef="i532d2c0bf63243e999d48341920b6775_D20210101-20211231" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185MS9mcmFnOjlmMTJhYjBlYWNjMTQ1OTU5ZDhhNjcyY2JmZjdkYjZkL3RleHRyZWdpb246OWYxMmFiMGVhY2MxNDU5NTlkOGE2NzJjYmZmN2RiNmRfMTI2NzM_81b0d92a-f60e-437f-b392-c67b6fb1fa27">four-year</ix:nonNumeric> graded service vesting period where <ix:nonFraction unitRef="number" contextRef="i532d2c0bf63243e999d48341920b6775_D20210101-20211231" decimals="INF" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185MS9mcmFnOjlmMTJhYjBlYWNjMTQ1OTU5ZDhhNjcyY2JmZjdkYjZkL3RleHRyZWdpb246OWYxMmFiMGVhY2MxNDU5NTlkOGE2NzJjYmZmN2RiNmRfMjYzNw_ed429d8f-60b4-4765-92c4-10be98dfec9f">25</ix:nonFraction>% of the award vests after each year of service and have a maximum term of <ix:nonNumeric contextRef="i532d2c0bf63243e999d48341920b6775_D20210101-20211231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185MS9mcmFnOjlmMTJhYjBlYWNjMTQ1OTU5ZDhhNjcyY2JmZjdkYjZkL3RleHRyZWdpb246OWYxMmFiMGVhY2MxNDU5NTlkOGE2NzJjYmZmN2RiNmRfMjcxMw_5c8ed046-1740-4c3b-b85c-01e8affd3e1f">10</ix:nonNumeric> years. Information with respect to our options is presented in the following disclosures. </span></div><div style="text-align:justify"><span><br/></span></div><ix:nonNumeric contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185MS9mcmFnOjlmMTJhYjBlYWNjMTQ1OTU5ZDhhNjcyY2JmZjdkYjZkL3RleHRyZWdpb246OWYxMmFiMGVhY2MxNDU5NTlkOGE2NzJjYmZmN2RiNmRfMTI2NTg_53cbf333-ffa6-4a8d-9fe9-8d83205e91ce" continuedAt="i6fc7d07593c04b58aad95f175009dfa2" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The option price assumptions used for our stock option awards for the year ended December 31, 2019, were as follows:</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"></td><td style="width:463.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:72.25pt"></td><td style="width:1.0pt"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average fair value per option granted</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i12a6d1161de54547bd29f8efccd4c9b0_D20200101-20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185MS9mcmFnOjlmMTJhYjBlYWNjMTQ1OTU5ZDhhNjcyY2JmZjdkYjZkL3RhYmxlOjQyNmVkZGIyNmYwODQ5MGM5MDRjYTE1ODBmZDZiYzQyL3RhYmxlcmFuZ2U6NDI2ZWRkYjI2ZjA4NDkwYzkwNGNhMTU4MGZkNmJjNDJfMi0xLTEtMS0xNzc3NQ_1c1b91b6-f27f-4be9-923a-164e27e2b0aa">6.52</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assumptions:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected term (in years)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i3462813a792a43bdb0cd92a0d3fc4085_D20200101-20201231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185MS9mcmFnOjlmMTJhYjBlYWNjMTQ1OTU5ZDhhNjcyY2JmZjdkYjZkL3RhYmxlOjQyNmVkZGIyNmYwODQ5MGM5MDRjYTE1ODBmZDZiYzQyL3RhYmxlcmFuZ2U6NDI2ZWRkYjI2ZjA4NDkwYzkwNGNhMTU4MGZkNmJjNDJfNC0xLTEtMS0xNzc3NQ_68b633bb-d68a-475a-9179-d1605d1533f7">6.25</ix:nonNumeric></span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i3462813a792a43bdb0cd92a0d3fc4085_D20200101-20201231" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185MS9mcmFnOjlmMTJhYjBlYWNjMTQ1OTU5ZDhhNjcyY2JmZjdkYjZkL3RhYmxlOjQyNmVkZGIyNmYwODQ5MGM5MDRjYTE1ODBmZDZiYzQyL3RhYmxlcmFuZ2U6NDI2ZWRkYjI2ZjA4NDkwYzkwNGNhMTU4MGZkNmJjNDJfNS0xLTEtMS0xNzc3NQ_1246e083-0e1b-4454-9f05-7ff63862d17e">51.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i3462813a792a43bdb0cd92a0d3fc4085_D20200101-20201231" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185MS9mcmFnOjlmMTJhYjBlYWNjMTQ1OTU5ZDhhNjcyY2JmZjdkYjZkL3RhYmxlOjQyNmVkZGIyNmYwODQ5MGM5MDRjYTE1ODBmZDZiYzQyL3RhYmxlcmFuZ2U6NDI2ZWRkYjI2ZjA4NDkwYzkwNGNhMTU4MGZkNmJjNDJfNi0xLTEtMS0xNzc3NS90ZXh0cmVnaW9uOjFhYWEwOWQ2YjYyYzQ5MGU4MGVlMGE2MGUxM2MwZDIyXzQ_2e9723fe-b514-4350-8a8e-b4b831dea4cf">1.9</ix:nonFraction>% - <ix:nonFraction unitRef="number" contextRef="i3462813a792a43bdb0cd92a0d3fc4085_D20200101-20201231" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185MS9mcmFnOjlmMTJhYjBlYWNjMTQ1OTU5ZDhhNjcyY2JmZjdkYjZkL3RhYmxlOjQyNmVkZGIyNmYwODQ5MGM5MDRjYTE1ODBmZDZiYzQyL3RhYmxlcmFuZ2U6NDI2ZWRkYjI2ZjA4NDkwYzkwNGNhMTU4MGZkNmJjNDJfNi0xLTEtMS0xNzc3NS90ZXh0cmVnaW9uOjFhYWEwOWQ2YjYyYzQ5MGU4MGVlMGE2MGUxM2MwZDIyXzk_2dc4a3bc-4e5e-4a33-b713-444340c8b021">2.7</ix:nonFraction>%</span></div></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividend yield</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i3462813a792a43bdb0cd92a0d3fc4085_D20200101-20201231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185MS9mcmFnOjlmMTJhYjBlYWNjMTQ1OTU5ZDhhNjcyY2JmZjdkYjZkL3RhYmxlOjQyNmVkZGIyNmYwODQ5MGM5MDRjYTE1ODBmZDZiYzQyL3RhYmxlcmFuZ2U6NDI2ZWRkYjI2ZjA4NDkwYzkwNGNhMTU4MGZkNmJjNDJfNy0xLTEtMS0xNzc3NQ_5ce631bc-f2a6-4628-bd73-5d3961ecfb2a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div></ix:nonNumeric><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of options is determined using a Black-Scholes options valuation model with the assumptions disclosed in the table above. The dividend rate is based on the expected dividend rate during the expected life of the option. Expected volatility is based on the historical volatility over the most recent period commensurate with the estimated expected term of the Company&#8217;s awards due to the limited history of our own stock price. The risk-free interest rate is based on the U.S. Treasury yield curve in effect at the time of the grant. The expected life represents the period of time the stock&#160;options&#160;are expected to be outstanding and is based on the&#160;simplified method. Under the&#160;simplified method, the expected life of an option is presumed to be the midpoint between the vesting date and the end of the contractual term. We used the&#160;simplified method&#160;due to the lack of sufficient historical exercise data to provide a reasonable basis upon which to otherwise estimate the expected life of the stock&#160;options.&#160;</span></div><div style="text-align:justify"><span><br/></span></div><ix:nonNumeric contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185MS9mcmFnOjlmMTJhYjBlYWNjMTQ1OTU5ZDhhNjcyY2JmZjdkYjZkL3RleHRyZWdpb246OWYxMmFiMGVhY2MxNDU5NTlkOGE2NzJjYmZmN2RiNmRfMTI2Nzg_b228f1c0-827f-41e3-a8f9-a295dc3fe830" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Information with respect to our stock options (in thousands), including weighted-average remaining contractual term (in years) and aggregate intrinsic value (in thousands) was as follows:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.75pt"><tr><td style="width:1.0pt"></td><td style="width:283.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:58.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:3.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:58.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:3.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:58.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:3.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:58.00pt"></td><td style="width:1.0pt"></td></tr><tr style="height:51pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Options</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average Exercise Price</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average Remaining Contractual Term</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Aggregate Intrinsic Value</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding as of December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ibc0c0c2b8dc04c5698ca0577a54b2e03_I20201231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185MS9mcmFnOjlmMTJhYjBlYWNjMTQ1OTU5ZDhhNjcyY2JmZjdkYjZkL3RhYmxlOjdjOGI2M2JiNDk2ZDQ4MzE4ZmU4ZWIyOWQ3NTc2MzU4L3RhYmxlcmFuZ2U6N2M4YjYzYmI0OTZkNDgzMThmZThlYjI5ZDc1NzYzNThfMS0xLTEtMS0xNzc3NQ_98236723-da60-4b8b-8caa-e06536b4d7d3">4,070</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ibc0c0c2b8dc04c5698ca0577a54b2e03_I20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185MS9mcmFnOjlmMTJhYjBlYWNjMTQ1OTU5ZDhhNjcyY2JmZjdkYjZkL3RhYmxlOjdjOGI2M2JiNDk2ZDQ4MzE4ZmU4ZWIyOWQ3NTc2MzU4L3RhYmxlcmFuZ2U6N2M4YjYzYmI0OTZkNDgzMThmZThlYjI5ZDc1NzYzNThfMS0zLTEtMS0xNzc3NQ_0acd643e-0170-4c0f-bc20-4d9fc097267e">9.32</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i12a6d1161de54547bd29f8efccd4c9b0_D20200101-20201231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185MS9mcmFnOjlmMTJhYjBlYWNjMTQ1OTU5ZDhhNjcyY2JmZjdkYjZkL3RhYmxlOjdjOGI2M2JiNDk2ZDQ4MzE4ZmU4ZWIyOWQ3NTc2MzU4L3RhYmxlcmFuZ2U6N2M4YjYzYmI0OTZkNDgzMThmZThlYjI5ZDc1NzYzNThfMS01LTEtMS0xNzc3NQ_fff7e4e3-e090-4da6-8f02-6afddaaf2797">5.25</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc0c0c2b8dc04c5698ca0577a54b2e03_I20201231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185MS9mcmFnOjlmMTJhYjBlYWNjMTQ1OTU5ZDhhNjcyY2JmZjdkYjZkL3RhYmxlOjdjOGI2M2JiNDk2ZDQ4MzE4ZmU4ZWIyOWQ3NTc2MzU4L3RhYmxlcmFuZ2U6N2M4YjYzYmI0OTZkNDgzMThmZThlYjI5ZDc1NzYzNThfMS03LTEtMS0xNzc3NQ_fc614f5a-8c60-4bf3-9934-3dd166f8bef1">12,578</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185MS9mcmFnOjlmMTJhYjBlYWNjMTQ1OTU5ZDhhNjcyY2JmZjdkYjZkL3RhYmxlOjdjOGI2M2JiNDk2ZDQ4MzE4ZmU4ZWIyOWQ3NTc2MzU4L3RhYmxlcmFuZ2U6N2M4YjYzYmI0OTZkNDgzMThmZThlYjI5ZDc1NzYzNThfMy0xLTEtMS0xNzc3NQ_3df1c705-c678-421a-8bd8-9d51571463c7">1,490</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185MS9mcmFnOjlmMTJhYjBlYWNjMTQ1OTU5ZDhhNjcyY2JmZjdkYjZkL3RhYmxlOjdjOGI2M2JiNDk2ZDQ4MzE4ZmU4ZWIyOWQ3NTc2MzU4L3RhYmxlcmFuZ2U6N2M4YjYzYmI0OTZkNDgzMThmZThlYjI5ZDc1NzYzNThfMy0zLTEtMS0xNzc3NQ_0e2f080e-4f04-42fa-8af3-ba18ff84323b">8.92</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185MS9mcmFnOjlmMTJhYjBlYWNjMTQ1OTU5ZDhhNjcyY2JmZjdkYjZkL3RhYmxlOjdjOGI2M2JiNDk2ZDQ4MzE4ZmU4ZWIyOWQ3NTc2MzU4L3RhYmxlcmFuZ2U6N2M4YjYzYmI0OTZkNDgzMThmZThlYjI5ZDc1NzYzNThfNC0xLTEtMS0xNzc3NQ_f38bd21a-3d2a-4692-830f-754dc542cc11">31</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185MS9mcmFnOjlmMTJhYjBlYWNjMTQ1OTU5ZDhhNjcyY2JmZjdkYjZkL3RhYmxlOjdjOGI2M2JiNDk2ZDQ4MzE4ZmU4ZWIyOWQ3NTc2MzU4L3RhYmxlcmFuZ2U6N2M4YjYzYmI0OTZkNDgzMThmZThlYjI5ZDc1NzYzNThfNC0zLTEtMS0xNzc3NQ_b07bdc97-31d9-4d05-bf63-583d4f67abbd">15.23</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding as of December 31, 2021</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i8daff60be410426d8f7bd49343c1ec0c_I20211231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185MS9mcmFnOjlmMTJhYjBlYWNjMTQ1OTU5ZDhhNjcyY2JmZjdkYjZkL3RhYmxlOjdjOGI2M2JiNDk2ZDQ4MzE4ZmU4ZWIyOWQ3NTc2MzU4L3RhYmxlcmFuZ2U6N2M4YjYzYmI0OTZkNDgzMThmZThlYjI5ZDc1NzYzNThfNS0xLTEtMS0xNzc3NQ_54f0877a-67d6-4065-9efd-753cd26851ee">2,549</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i8daff60be410426d8f7bd49343c1ec0c_I20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185MS9mcmFnOjlmMTJhYjBlYWNjMTQ1OTU5ZDhhNjcyY2JmZjdkYjZkL3RhYmxlOjdjOGI2M2JiNDk2ZDQ4MzE4ZmU4ZWIyOWQ3NTc2MzU4L3RhYmxlcmFuZ2U6N2M4YjYzYmI0OTZkNDgzMThmZThlYjI5ZDc1NzYzNThfNS0zLTEtMS0xNzc3NQ_362bbc4f-91f4-4ac9-9320-55d65ba8f4eb">9.49</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185MS9mcmFnOjlmMTJhYjBlYWNjMTQ1OTU5ZDhhNjcyY2JmZjdkYjZkL3RhYmxlOjdjOGI2M2JiNDk2ZDQ4MzE4ZmU4ZWIyOWQ3NTc2MzU4L3RhYmxlcmFuZ2U6N2M4YjYzYmI0OTZkNDgzMThmZThlYjI5ZDc1NzYzNThfNS01LTEtMS0xNzc3NQ_b5187a1e-09ac-4f04-b1be-7ba544e4378f">3.99</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8daff60be410426d8f7bd49343c1ec0c_I20211231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185MS9mcmFnOjlmMTJhYjBlYWNjMTQ1OTU5ZDhhNjcyY2JmZjdkYjZkL3RhYmxlOjdjOGI2M2JiNDk2ZDQ4MzE4ZmU4ZWIyOWQ3NTc2MzU4L3RhYmxlcmFuZ2U6N2M4YjYzYmI0OTZkNDgzMThmZThlYjI5ZDc1NzYzNThfNS03LTEtMS0xNzc3NQ_3556ad94-ffe4-4434-afd8-9d5dd8f146fe">46,342</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested and expected to vest after December&#160;31, 2021</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i8daff60be410426d8f7bd49343c1ec0c_I20211231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185MS9mcmFnOjlmMTJhYjBlYWNjMTQ1OTU5ZDhhNjcyY2JmZjdkYjZkL3RhYmxlOjdjOGI2M2JiNDk2ZDQ4MzE4ZmU4ZWIyOWQ3NTc2MzU4L3RhYmxlcmFuZ2U6N2M4YjYzYmI0OTZkNDgzMThmZThlYjI5ZDc1NzYzNThfNy0xLTEtMS0xNzc3NQ_37a7437d-df0b-4574-a818-3264be228970">2,549</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i8daff60be410426d8f7bd49343c1ec0c_I20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185MS9mcmFnOjlmMTJhYjBlYWNjMTQ1OTU5ZDhhNjcyY2JmZjdkYjZkL3RhYmxlOjdjOGI2M2JiNDk2ZDQ4MzE4ZmU4ZWIyOWQ3NTc2MzU4L3RhYmxlcmFuZ2U6N2M4YjYzYmI0OTZkNDgzMThmZThlYjI5ZDc1NzYzNThfNy0zLTEtMS0xNzc3NQ_1971456e-faac-49ee-8c32-ccc77d269663">9.49</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185MS9mcmFnOjlmMTJhYjBlYWNjMTQ1OTU5ZDhhNjcyY2JmZjdkYjZkL3RhYmxlOjdjOGI2M2JiNDk2ZDQ4MzE4ZmU4ZWIyOWQ3NTc2MzU4L3RhYmxlcmFuZ2U6N2M4YjYzYmI0OTZkNDgzMThmZThlYjI5ZDc1NzYzNThfNy01LTEtMS0xNzc3NQ_602aa6b1-8e05-4dc4-bfc3-dc401aec2cf2">3.99</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8daff60be410426d8f7bd49343c1ec0c_I20211231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185MS9mcmFnOjlmMTJhYjBlYWNjMTQ1OTU5ZDhhNjcyY2JmZjdkYjZkL3RhYmxlOjdjOGI2M2JiNDk2ZDQ4MzE4ZmU4ZWIyOWQ3NTc2MzU4L3RhYmxlcmFuZ2U6N2M4YjYzYmI0OTZkNDgzMThmZThlYjI5ZDc1NzYzNThfNy03LTEtMS0xNzc3NQ_f2c75035-b5a1-46d9-b104-1c6d1c9b4161">46,342</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable as of December&#160;31, 2021</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i8daff60be410426d8f7bd49343c1ec0c_I20211231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185MS9mcmFnOjlmMTJhYjBlYWNjMTQ1OTU5ZDhhNjcyY2JmZjdkYjZkL3RhYmxlOjdjOGI2M2JiNDk2ZDQ4MzE4ZmU4ZWIyOWQ3NTc2MzU4L3RhYmxlcmFuZ2U6N2M4YjYzYmI0OTZkNDgzMThmZThlYjI5ZDc1NzYzNThfOS0xLTEtMS0xNzc3NQ_ed2e946d-fe36-4779-a58b-b3a189b7a804">2,301</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i8daff60be410426d8f7bd49343c1ec0c_I20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185MS9mcmFnOjlmMTJhYjBlYWNjMTQ1OTU5ZDhhNjcyY2JmZjdkYjZkL3RhYmxlOjdjOGI2M2JiNDk2ZDQ4MzE4ZmU4ZWIyOWQ3NTc2MzU4L3RhYmxlcmFuZ2U6N2M4YjYzYmI0OTZkNDgzMThmZThlYjI5ZDc1NzYzNThfOS0zLTEtMS0xNzc3NQ_505db40b-adc8-468e-9688-7499720bcdbc">9.11</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185MS9mcmFnOjlmMTJhYjBlYWNjMTQ1OTU5ZDhhNjcyY2JmZjdkYjZkL3RhYmxlOjdjOGI2M2JiNDk2ZDQ4MzE4ZmU4ZWIyOWQ3NTc2MzU4L3RhYmxlcmFuZ2U6N2M4YjYzYmI0OTZkNDgzMThmZThlYjI5ZDc1NzYzNThfOS01LTEtMS0xNzc3NQ_8d783cb1-45ac-44b9-af43-9a7d4e7da643">3.71</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8daff60be410426d8f7bd49343c1ec0c_I20211231" decimals="-3" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185MS9mcmFnOjlmMTJhYjBlYWNjMTQ1OTU5ZDhhNjcyY2JmZjdkYjZkL3RhYmxlOjdjOGI2M2JiNDk2ZDQ4MzE4ZmU4ZWIyOWQ3NTc2MzU4L3RhYmxlcmFuZ2U6N2M4YjYzYmI0OTZkNDgzMThmZThlYjI5ZDc1NzYzNThfOS03LTEtMS0xNzc3NQ_60462513-09ee-4498-bec5-fd9c5dca52f6">42,717</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The total fair value of options vested during the years ended December 31, 2021, 2020 and 2019, was $<ix:nonFraction unitRef="usd" contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231" decimals="-5" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185MS9mcmFnOjlmMTJhYjBlYWNjMTQ1OTU5ZDhhNjcyY2JmZjdkYjZkL3RleHRyZWdpb246OWYxMmFiMGVhY2MxNDU5NTlkOGE2NzJjYmZmN2RiNmRfNDIwMQ_de97a17a-3ae6-4650-afde-38b05441339f">4.9</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="i12a6d1161de54547bd29f8efccd4c9b0_D20200101-20201231" decimals="-5" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185MS9mcmFnOjlmMTJhYjBlYWNjMTQ1OTU5ZDhhNjcyY2JmZjdkYjZkL3RleHRyZWdpb246OWYxMmFiMGVhY2MxNDU5NTlkOGE2NzJjYmZmN2RiNmRfNDIwNQ_13a571d8-cc5e-43bb-8c83-8c6934a857e9">3.6</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i3e21049ffc224cacb8134d73c9bb5b38_D20190101-20191231" decimals="-5" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185MS9mcmFnOjlmMTJhYjBlYWNjMTQ1OTU5ZDhhNjcyY2JmZjdkYjZkL3RleHRyZWdpb246OWYxMmFiMGVhY2MxNDU5NTlkOGE2NzJjYmZmN2RiNmRfNDIxMg_66203335-f017-401b-846a-92cd8706708c">5.9</ix:nonFraction> million, respectively. The total intrinsic value of options exercised during 2021, 2020 and 2019 was $<ix:nonFraction unitRef="usd" contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185MS9mcmFnOjlmMTJhYjBlYWNjMTQ1OTU5ZDhhNjcyY2JmZjdkYjZkL3RleHRyZWdpb246OWYxMmFiMGVhY2MxNDU5NTlkOGE2NzJjYmZmN2RiNmRfNDMwMg_7f325296-e522-4646-b1fd-006810eed0c4">20.8</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="i12a6d1161de54547bd29f8efccd4c9b0_D20200101-20201231" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185MS9mcmFnOjlmMTJhYjBlYWNjMTQ1OTU5ZDhhNjcyY2JmZjdkYjZkL3RleHRyZWdpb246OWYxMmFiMGVhY2MxNDU5NTlkOGE2NzJjYmZmN2RiNmRfNDMwNg_e30040d1-a44d-426c-9d18-ba7c2e5cbba1">2.2</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i3e21049ffc224cacb8134d73c9bb5b38_D20190101-20191231" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185MS9mcmFnOjlmMTJhYjBlYWNjMTQ1OTU5ZDhhNjcyY2JmZjdkYjZkL3RleHRyZWdpb246OWYxMmFiMGVhY2MxNDU5NTlkOGE2NzJjYmZmN2RiNmRfNDMxMw_f30e1c7a-f9fc-4d1e-913b-4a2933e59984">0.6</ix:nonFraction> million, respectively. We issue new shares to satisfy option exercises.</span></div></ix:continuation><div style="text-align:justify"><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">104</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="ibdce2f92b4b7442f81706798ae04b0fa" continuedAt="iba845a632d1b402fb80002d6c902942e"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Performance-based stock option awards</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2016, the Company granted approximately <ix:nonFraction unitRef="shares" contextRef="i686710b185af449cbe0de18d10c30d28_D20160301-20160331" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185MS9mcmFnOjlmMTJhYjBlYWNjMTQ1OTU5ZDhhNjcyY2JmZjdkYjZkL3RleHRyZWdpb246OWYxMmFiMGVhY2MxNDU5NTlkOGE2NzJjYmZmN2RiNmRfNDQ2OQ_a4c3ad8f-3e16-46ee-8390-1f4b47f4b25c">0.3</ix:nonFraction>&#160;million performance-based options to certain employees to create incentives for continued long-term success and to more closely align executive pay with our stockholders&#8217; interests. Each of the grants is subject to market-based vesting, as follows:</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:18pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">one-third of the shares subject to the option award will vest in the event that the average closing price of the Company&#8217;s Class A common stock on the NYSE is at least $<ix:nonFraction unitRef="usdPerShare" contextRef="if1cf72bda2494db39c586d33c79355d7_I20160331" decimals="2" name="evh:SharebasedCompensationArrangementbySharebasedPaymentAwardAwardVestingRightsSharePriceThreshold" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185MS9mcmFnOjlmMTJhYjBlYWNjMTQ1OTU5ZDhhNjcyY2JmZjdkYjZkL3RleHRyZWdpb246OWYxMmFiMGVhY2MxNDU5NTlkOGE2NzJjYmZmN2RiNmRfNDg4Mw_44b598f7-f657-4fb1-914f-8ef109ad2b02">13.35</ix:nonFraction> per share for a consecutive <ix:nonNumeric contextRef="i4339469160624451b2787c8a94183aef_D20160301-20160331" name="evh:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsStockPriceTriggerConsecutiveTerm" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185MS9mcmFnOjlmMTJhYjBlYWNjMTQ1OTU5ZDhhNjcyY2JmZjdkYjZkL3RleHRyZWdpb246OWYxMmFiMGVhY2MxNDU5NTlkOGE2NzJjYmZmN2RiNmRfMzI5ODUzNDkxMDU4MQ_f8449e7f-cbb1-43c1-984e-1e998372ec13">ninety day</ix:nonNumeric> period;</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">one-third of the shares subject to the option award will vest in the event that the average closing price of the Company&#8217;s Class A common stock on the NYSE is at least $<ix:nonFraction unitRef="usdPerShare" contextRef="i42f9f4a544794563bbd3b640b97627eb_I20160331" decimals="2" name="evh:SharebasedCompensationArrangementbySharebasedPaymentAwardAwardVestingRightsSharePriceThreshold" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185MS9mcmFnOjlmMTJhYjBlYWNjMTQ1OTU5ZDhhNjcyY2JmZjdkYjZkL3RleHRyZWdpb246OWYxMmFiMGVhY2MxNDU5NTlkOGE2NzJjYmZmN2RiNmRfNTA5Mw_2e7ed541-0edf-45b3-9f15-2c3e399bf694">16.43</ix:nonFraction> per share for a consecutive <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185MS9mcmFnOjlmMTJhYjBlYWNjMTQ1OTU5ZDhhNjcyY2JmZjdkYjZkL3RleHRyZWdpb246OWYxMmFiMGVhY2MxNDU5NTlkOGE2NzJjYmZmN2RiNmRfNTEyNA_e4d931ff-6eba-4d04-bddc-9b3b4429017b">ninety</span> day period; and</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">one-third of the shares subject to the option award will vest in the event that the average closing price of the Company&#8217;s Class A common stock on the NYSE is at least $<ix:nonFraction unitRef="usdPerShare" contextRef="i77ef8b91efad4f9c96efe1dd800f23a2_I20160331" decimals="2" name="evh:SharebasedCompensationArrangementbySharebasedPaymentAwardAwardVestingRightsSharePriceThreshold" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185MS9mcmFnOjlmMTJhYjBlYWNjMTQ1OTU5ZDhhNjcyY2JmZjdkYjZkL3RleHRyZWdpb246OWYxMmFiMGVhY2MxNDU5NTlkOGE2NzJjYmZmN2RiNmRfNTMwNw_73a038c6-680c-41a1-842e-a16926963e27">19.51</ix:nonFraction> per share for a consecutive <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185MS9mcmFnOjlmMTJhYjBlYWNjMTQ1OTU5ZDhhNjcyY2JmZjdkYjZkL3RleHRyZWdpb246OWYxMmFiMGVhY2MxNDU5NTlkOGE2NzJjYmZmN2RiNmRfNTMzOA_19dbae44-014f-4a37-a3b0-0e16f19819c4">ninety</span> day period.</span></div><div style="padding-left:36pt;text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the percentage of options per tranche that has satisfied the market-based performance hurdle is also subject to a service completion schedule. The aggregate percentage of options eligible to vest is based upon each of the service completions dates below:</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:18pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt"><ix:nonFraction unitRef="number" contextRef="i6df38813e0b146839515ddf8e5497101_D20160301-20160331" decimals="INF" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185MS9mcmFnOjlmMTJhYjBlYWNjMTQ1OTU5ZDhhNjcyY2JmZjdkYjZkL3RleHRyZWdpb246OWYxMmFiMGVhY2MxNDU5NTlkOGE2NzJjYmZmN2RiNmRfNTYyMA_70870cab-03b8-4656-864e-d08e9539d445">50</ix:nonFraction>% of the shares subject to the option award vested on March 1, 2019, and</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt"><ix:nonFraction unitRef="number" contextRef="ie92afa03287e4824b694b978705b0da6_D20160301-20160331" decimals="INF" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185MS9mcmFnOjlmMTJhYjBlYWNjMTQ1OTU5ZDhhNjcyY2JmZjdkYjZkL3RleHRyZWdpb246OWYxMmFiMGVhY2MxNDU5NTlkOGE2NzJjYmZmN2RiNmRfNTY5NA_f1d7b848-9df7-4bc1-8c9e-ebd195fbeb5c">50</ix:nonFraction>% of the shares subject to the option award vested on March 1, 2020.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We measured the fair value of the performance-based stock options using a Monte Carlo simulation approach with the following assumptions: risk-free interest rate of <ix:nonFraction unitRef="number" contextRef="i686710b185af449cbe0de18d10c30d28_D20160301-20160331" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185MS9mcmFnOjlmMTJhYjBlYWNjMTQ1OTU5ZDhhNjcyY2JmZjdkYjZkL3RleHRyZWdpb246OWYxMmFiMGVhY2MxNDU5NTlkOGE2NzJjYmZmN2RiNmRfNTkzMA_2a8697d5-1bc4-4139-b80a-c1badcc2cbe7">1.83</ix:nonFraction>%, volatility of <ix:nonFraction unitRef="number" contextRef="i686710b185af449cbe0de18d10c30d28_D20160301-20160331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185MS9mcmFnOjlmMTJhYjBlYWNjMTQ1OTU5ZDhhNjcyY2JmZjdkYjZkL3RleHRyZWdpb246OWYxMmFiMGVhY2MxNDU5NTlkOGE2NzJjYmZmN2RiNmRfNTk0OA_b87618b6-d6ce-4699-9510-ea420bdfe2cf">65</ix:nonFraction>%, expected term of <ix:nonNumeric contextRef="i686710b185af449cbe0de18d10c30d28_D20160301-20160331" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185MS9mcmFnOjlmMTJhYjBlYWNjMTQ1OTU5ZDhhNjcyY2JmZjdkYjZkL3RleHRyZWdpb246OWYxMmFiMGVhY2MxNDU5NTlkOGE2NzJjYmZmN2RiNmRfNTk2OQ_581aabb8-c815-42ee-9f8d-a9b25faa113f">ten years</ix:nonNumeric> and dividend yield of <ix:nonFraction unitRef="number" contextRef="i686710b185af449cbe0de18d10c30d28_D20160301-20160331" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185MS9mcmFnOjlmMTJhYjBlYWNjMTQ1OTU5ZDhhNjcyY2JmZjdkYjZkL3RleHRyZWdpb246OWYxMmFiMGVhY2MxNDU5NTlkOGE2NzJjYmZmN2RiNmRfNTk5NA_6b34526c-81b9-400b-9aee-eb96714feab9">0</ix:nonFraction>% as we do not currently pay dividends nor expect to do so during the expected option term. These inputs resulted in a weighted-average fair value per option granted of $<ix:nonFraction unitRef="usdPerShare" contextRef="i686710b185af449cbe0de18d10c30d28_D20160301-20160331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185MS9mcmFnOjlmMTJhYjBlYWNjMTQ1OTU5ZDhhNjcyY2JmZjdkYjZkL3RleHRyZWdpb246OWYxMmFiMGVhY2MxNDU5NTlkOGE2NzJjYmZmN2RiNmRfNjE2NA_be397dbf-944f-4f31-85c9-acea3488d04e">6.68</ix:nonFraction>. During 2016 all of the average stock price milestones were achieved and therefore the awards are now only subject to the service completion obligations.</span></div><div style="text-align:justify"><span><br/></span></div><ix:nonNumeric contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231" name="us-gaap:ShareBasedCompensationPerformanceSharesAwardOutstandingActivityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185MS9mcmFnOjlmMTJhYjBlYWNjMTQ1OTU5ZDhhNjcyY2JmZjdkYjZkL3RleHRyZWdpb246OWYxMmFiMGVhY2MxNDU5NTlkOGE2NzJjYmZmN2RiNmRfMTI2Njc_88c1a5c0-1502-484d-b664-0bbe99d1be21" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Information with respect to our performance-based stock options (shares and aggregate intrinsic value shown in thousands, weighted-average remaining contractual term shown in years) was as follows:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:539.25pt"><tr><td style="width:1.0pt"></td><td style="width:286.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:58.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:58.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:58.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:58.00pt"></td><td style="width:1.0pt"></td></tr><tr style="height:54pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Options</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average Exercise Price</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average Remaining Contractual Term</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Aggregate Intrinsic Value</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding as of December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i5f4625a059aa4800b22d29c186dc894c_I20201231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185MS9mcmFnOjlmMTJhYjBlYWNjMTQ1OTU5ZDhhNjcyY2JmZjdkYjZkL3RhYmxlOjZjYjk4NzQxYjcwOTQxMzhhMTYzY2RhYTdkN2Y4ZmMyL3RhYmxlcmFuZ2U6NmNiOTg3NDFiNzA5NDEzOGExNjNjZGFhN2Q3ZjhmYzJfMS0xLTEtMS0xNzc3NQ_7b30b51c-7b03-4861-ba7f-65ef358267c2">268</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i5f4625a059aa4800b22d29c186dc894c_I20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185MS9mcmFnOjlmMTJhYjBlYWNjMTQ1OTU5ZDhhNjcyY2JmZjdkYjZkL3RhYmxlOjZjYjk4NzQxYjcwOTQxMzhhMTYzY2RhYTdkN2Y4ZmMyL3RhYmxlcmFuZ2U6NmNiOTg3NDFiNzA5NDEzOGExNjNjZGFhN2Q3ZjhmYzJfMS0zLTEtMS0xNzc3NQ_ee840c1d-8fd9-4efb-ada3-d80fb92e968f">10.27</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i2ef2d194cc634bb5a3f24f06d02c7f5b_D20200101-20201231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185MS9mcmFnOjlmMTJhYjBlYWNjMTQ1OTU5ZDhhNjcyY2JmZjdkYjZkL3RhYmxlOjZjYjk4NzQxYjcwOTQxMzhhMTYzY2RhYTdkN2Y4ZmMyL3RhYmxlcmFuZ2U6NmNiOTg3NDFiNzA5NDEzOGExNjNjZGFhN2Q3ZjhmYzJfMS01LTEtMS0xNzc3NQ_c58f33d3-963b-48a9-919c-d7c0a4631135">6.17</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5f4625a059aa4800b22d29c186dc894c_I20201231" decimals="-3" sign="-" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185MS9mcmFnOjlmMTJhYjBlYWNjMTQ1OTU5ZDhhNjcyY2JmZjdkYjZkL3RhYmxlOjZjYjk4NzQxYjcwOTQxMzhhMTYzY2RhYTdkN2Y4ZmMyL3RhYmxlcmFuZ2U6NmNiOTg3NDFiNzA5NDEzOGExNjNjZGFhN2Q3ZjhmYzJfMS03LTEtMS0xNzc3NQ_0c067165-fc40-44fe-994d-ef14eb74add4">326</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding as of December 31, 2021</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ib4707869ee56405ab1f2a9c58e43b761_I20211231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185MS9mcmFnOjlmMTJhYjBlYWNjMTQ1OTU5ZDhhNjcyY2JmZjdkYjZkL3RhYmxlOjZjYjk4NzQxYjcwOTQxMzhhMTYzY2RhYTdkN2Y4ZmMyL3RhYmxlcmFuZ2U6NmNiOTg3NDFiNzA5NDEzOGExNjNjZGFhN2Q3ZjhmYzJfMi0xLTEtMS0xNzc3NQ_fe1e6225-dcea-4ae5-8417-64836bb5240e">268</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ib4707869ee56405ab1f2a9c58e43b761_I20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185MS9mcmFnOjlmMTJhYjBlYWNjMTQ1OTU5ZDhhNjcyY2JmZjdkYjZkL3RhYmxlOjZjYjk4NzQxYjcwOTQxMzhhMTYzY2RhYTdkN2Y4ZmMyL3RhYmxlcmFuZ2U6NmNiOTg3NDFiNzA5NDEzOGExNjNjZGFhN2Q3ZjhmYzJfMi0zLTEtMS0xNzc3NQ_fc4185ab-5402-44d6-a7b6-d87e491b8ad6">10.27</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i45606ce9dfa74fc7bd724460f67189ab_D20210101-20211231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185MS9mcmFnOjlmMTJhYjBlYWNjMTQ1OTU5ZDhhNjcyY2JmZjdkYjZkL3RhYmxlOjZjYjk4NzQxYjcwOTQxMzhhMTYzY2RhYTdkN2Y4ZmMyL3RhYmxlcmFuZ2U6NmNiOTg3NDFiNzA5NDEzOGExNjNjZGFhN2Q3ZjhmYzJfMi01LTEtMS0xNzc3NQ_c191996d-bc7d-4456-a0af-bb20da0b242c">4.16</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib4707869ee56405ab1f2a9c58e43b761_I20211231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185MS9mcmFnOjlmMTJhYjBlYWNjMTQ1OTU5ZDhhNjcyY2JmZjdkYjZkL3RhYmxlOjZjYjk4NzQxYjcwOTQxMzhhMTYzY2RhYTdkN2Y4ZmMyL3RhYmxlcmFuZ2U6NmNiOTg3NDFiNzA5NDEzOGExNjNjZGFhN2Q3ZjhmYzJfMi03LTEtMS0xNzc3NQ_ec5f05af-4021-4bc5-8c84-7c7f57f56986">5,620</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested and expected to vest after December&#160;31, 2021</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ib4707869ee56405ab1f2a9c58e43b761_I20211231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185MS9mcmFnOjlmMTJhYjBlYWNjMTQ1OTU5ZDhhNjcyY2JmZjdkYjZkL3RhYmxlOjZjYjk4NzQxYjcwOTQxMzhhMTYzY2RhYTdkN2Y4ZmMyL3RhYmxlcmFuZ2U6NmNiOTg3NDFiNzA5NDEzOGExNjNjZGFhN2Q3ZjhmYzJfNC0xLTEtMS0xNzc3NQ_b1c624c2-0e74-4d11-8155-221dc05ed97d">268</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ib4707869ee56405ab1f2a9c58e43b761_I20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185MS9mcmFnOjlmMTJhYjBlYWNjMTQ1OTU5ZDhhNjcyY2JmZjdkYjZkL3RhYmxlOjZjYjk4NzQxYjcwOTQxMzhhMTYzY2RhYTdkN2Y4ZmMyL3RhYmxlcmFuZ2U6NmNiOTg3NDFiNzA5NDEzOGExNjNjZGFhN2Q3ZjhmYzJfNC0zLTEtMS0xNzc3NQ_4e378d50-c598-49dc-8225-088e1f07a113">10.27</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i45606ce9dfa74fc7bd724460f67189ab_D20210101-20211231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185MS9mcmFnOjlmMTJhYjBlYWNjMTQ1OTU5ZDhhNjcyY2JmZjdkYjZkL3RhYmxlOjZjYjk4NzQxYjcwOTQxMzhhMTYzY2RhYTdkN2Y4ZmMyL3RhYmxlcmFuZ2U6NmNiOTg3NDFiNzA5NDEzOGExNjNjZGFhN2Q3ZjhmYzJfNC01LTEtMS0xNzc3NQ_cdc4b397-b783-4ce6-888a-060bf2c278af">4.16</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib4707869ee56405ab1f2a9c58e43b761_I20211231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185MS9mcmFnOjlmMTJhYjBlYWNjMTQ1OTU5ZDhhNjcyY2JmZjdkYjZkL3RhYmxlOjZjYjk4NzQxYjcwOTQxMzhhMTYzY2RhYTdkN2Y4ZmMyL3RhYmxlcmFuZ2U6NmNiOTg3NDFiNzA5NDEzOGExNjNjZGFhN2Q3ZjhmYzJfNC03LTEtMS0xNzc3NQ_725e4f8a-b465-4ea0-b6b6-e42b69c44fd7">5,620</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Restricted Stock Units</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other than the performance-based RSUs described below, and other than RSUs granted to our non-employee directors which have a <ix:nonNumeric contextRef="i643136e202254be08774a096650b7946_D20210101-20211231" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185MS9mcmFnOjlmMTJhYjBlYWNjMTQ1OTU5ZDhhNjcyY2JmZjdkYjZkL3RleHRyZWdpb246OWYxMmFiMGVhY2MxNDU5NTlkOGE2NzJjYmZmN2RiNmRfNjY3Mw_73da71e7-ee88-4fea-bad5-2bcbfab1492b">one year</ix:nonNumeric> vesting period, RSUs awarded under the incentive compensation plans are generally subject to a <ix:nonNumeric contextRef="i903fc0912d4e492c95e3ce815e897489_D20210101-20211231" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185MS9mcmFnOjlmMTJhYjBlYWNjMTQ1OTU5ZDhhNjcyY2JmZjdkYjZkL3RleHRyZWdpb246OWYxMmFiMGVhY2MxNDU5NTlkOGE2NzJjYmZmN2RiNmRfMTI2NTY_0030ede0-3ec8-4a1f-98ea-5a0f4cbfdce3">four-year</ix:nonNumeric> graded service vesting period where <ix:nonFraction unitRef="number" contextRef="i903fc0912d4e492c95e3ce815e897489_D20210101-20211231" decimals="INF" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185MS9mcmFnOjlmMTJhYjBlYWNjMTQ1OTU5ZDhhNjcyY2JmZjdkYjZkL3RleHRyZWdpb246OWYxMmFiMGVhY2MxNDU5NTlkOGE2NzJjYmZmN2RiNmRfNjgxNQ_d0102915-7d69-4e72-ab46-6b7fcb5c8fec">25</ix:nonFraction>% of the award vests after each year of service and are issued to the participants for no consideration. During 2018, we also granted certain RSUs with a <ix:nonNumeric contextRef="i53ca92671b00498d832fcdf0ccb439b2_D20210101-20211231" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185MS9mcmFnOjlmMTJhYjBlYWNjMTQ1OTU5ZDhhNjcyY2JmZjdkYjZkL3RleHRyZWdpb246OWYxMmFiMGVhY2MxNDU5NTlkOGE2NzJjYmZmN2RiNmRfMTI2NzQ_3392a588-0562-476c-99ee-73ffdc6704f3">one-year</ix:nonNumeric> vesting period in conjunction with the New Century Health transaction. <ix:nonNumeric contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231" name="us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185MS9mcmFnOjlmMTJhYjBlYWNjMTQ1OTU5ZDhhNjcyY2JmZjdkYjZkL3RleHRyZWdpb246OWYxMmFiMGVhY2MxNDU5NTlkOGE2NzJjYmZmN2RiNmRfMTI2ODU_30a8bd8d-24d6-4d9a-aaee-f041a9f5f1ec" continuedAt="if0f15b08ff3b4ad3aa3ad6a15e5349c3" escape="true">Information with respect to our RSUs (not including performance-based RSUs) is presented below (in thousands, except for weighted-average grant-date fair value):</ix:nonNumeric></span></div><div style="text-align:justify"><ix:continuation id="if0f15b08ff3b4ad3aa3ad6a15e5349c3"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"></td><td style="width:412.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:58.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:3.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:58.00pt"></td><td style="width:1.0pt"></td></tr><tr style="height:42pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total RSUs</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average Grant Date Fair Value</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding as of December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ia60cbf2c61674250a7870e50684977b4_I20201231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185MS9mcmFnOjlmMTJhYjBlYWNjMTQ1OTU5ZDhhNjcyY2JmZjdkYjZkL3RhYmxlOjg5ODA1ZmFhYmM5MzQ2OTU4NmEzZDE2MmNmNTk0MWM4L3RhYmxlcmFuZ2U6ODk4MDVmYWFiYzkzNDY5NTg2YTNkMTYyY2Y1OTQxYzhfMS0xLTEtMS0xNzc3NQ_4e6b10c5-37eb-48eb-8b89-d01d2142f2b4">1,737</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ia60cbf2c61674250a7870e50684977b4_I20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185MS9mcmFnOjlmMTJhYjBlYWNjMTQ1OTU5ZDhhNjcyY2JmZjdkYjZkL3RhYmxlOjg5ODA1ZmFhYmM5MzQ2OTU4NmEzZDE2MmNmNTk0MWM4L3RhYmxlcmFuZ2U6ODk4MDVmYWFiYzkzNDY5NTg2YTNkMTYyY2Y1OTQxYzhfMS0zLTEtMS0xNzc3NQ_4f552a33-f77c-493b-9a3b-641614afcf71">10.13</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i903fc0912d4e492c95e3ce815e897489_D20210101-20211231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185MS9mcmFnOjlmMTJhYjBlYWNjMTQ1OTU5ZDhhNjcyY2JmZjdkYjZkL3RhYmxlOjg5ODA1ZmFhYmM5MzQ2OTU4NmEzZDE2MmNmNTk0MWM4L3RhYmxlcmFuZ2U6ODk4MDVmYWFiYzkzNDY5NTg2YTNkMTYyY2Y1OTQxYzhfMi0xLTEtMS0xNzc3NQ_10525e2b-43af-4855-b0a8-00ef0a41d1fc">1,276</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i903fc0912d4e492c95e3ce815e897489_D20210101-20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185MS9mcmFnOjlmMTJhYjBlYWNjMTQ1OTU5ZDhhNjcyY2JmZjdkYjZkL3RhYmxlOjg5ODA1ZmFhYmM5MzQ2OTU4NmEzZDE2MmNmNTk0MWM4L3RhYmxlcmFuZ2U6ODk4MDVmYWFiYzkzNDY5NTg2YTNkMTYyY2Y1OTQxYzhfMi0zLTEtMS0xNzc3NQ_5532c66f-c1d2-4036-8d9a-053b2796eab9">21.10</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i903fc0912d4e492c95e3ce815e897489_D20210101-20211231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185MS9mcmFnOjlmMTJhYjBlYWNjMTQ1OTU5ZDhhNjcyY2JmZjdkYjZkL3RhYmxlOjg5ODA1ZmFhYmM5MzQ2OTU4NmEzZDE2MmNmNTk0MWM4L3RhYmxlcmFuZ2U6ODk4MDVmYWFiYzkzNDY5NTg2YTNkMTYyY2Y1OTQxYzhfMy0xLTEtMS0xNzc3NQ_8c4bd326-445b-4d71-ab18-3bbc6f39ed0d">243</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i903fc0912d4e492c95e3ce815e897489_D20210101-20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185MS9mcmFnOjlmMTJhYjBlYWNjMTQ1OTU5ZDhhNjcyY2JmZjdkYjZkL3RhYmxlOjg5ODA1ZmFhYmM5MzQ2OTU4NmEzZDE2MmNmNTk0MWM4L3RhYmxlcmFuZ2U6ODk4MDVmYWFiYzkzNDY5NTg2YTNkMTYyY2Y1OTQxYzhfMy0zLTEtMS0xNzc3NQ_f00ab1de-26df-46a6-a4d0-47e38b17e397">12.74</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i903fc0912d4e492c95e3ce815e897489_D20210101-20211231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185MS9mcmFnOjlmMTJhYjBlYWNjMTQ1OTU5ZDhhNjcyY2JmZjdkYjZkL3RhYmxlOjg5ODA1ZmFhYmM5MzQ2OTU4NmEzZDE2MmNmNTk0MWM4L3RhYmxlcmFuZ2U6ODk4MDVmYWFiYzkzNDY5NTg2YTNkMTYyY2Y1OTQxYzhfNC0xLTEtMS0xNzc3NQ_4e2f4b39-b489-4b8a-9a09-1fc41c0bf13b">683</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i903fc0912d4e492c95e3ce815e897489_D20210101-20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185MS9mcmFnOjlmMTJhYjBlYWNjMTQ1OTU5ZDhhNjcyY2JmZjdkYjZkL3RhYmxlOjg5ODA1ZmFhYmM5MzQ2OTU4NmEzZDE2MmNmNTk0MWM4L3RhYmxlcmFuZ2U6ODk4MDVmYWFiYzkzNDY5NTg2YTNkMTYyY2Y1OTQxYzhfNC0zLTEtMS0xNzc3NQ_7a846a39-ce96-49d0-a910-39f30ed1ffce">10.68</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding as of December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i0a2bd98f25e64cac9d230b30c39fd652_I20211231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185MS9mcmFnOjlmMTJhYjBlYWNjMTQ1OTU5ZDhhNjcyY2JmZjdkYjZkL3RhYmxlOjg5ODA1ZmFhYmM5MzQ2OTU4NmEzZDE2MmNmNTk0MWM4L3RhYmxlcmFuZ2U6ODk4MDVmYWFiYzkzNDY5NTg2YTNkMTYyY2Y1OTQxYzhfNS0xLTEtMS0xNzc3NQ_28be7bf1-b089-4c9b-b2c0-1a92965b2d37">2,087</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i0a2bd98f25e64cac9d230b30c39fd652_I20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185MS9mcmFnOjlmMTJhYjBlYWNjMTQ1OTU5ZDhhNjcyY2JmZjdkYjZkL3RhYmxlOjg5ODA1ZmFhYmM5MzQ2OTU4NmEzZDE2MmNmNTk0MWM4L3RhYmxlcmFuZ2U6ODk4MDVmYWFiYzkzNDY5NTg2YTNkMTYyY2Y1OTQxYzhfNS0zLTEtMS0xNzc3NQ_8dc9fd8a-5163-41bc-86b9-e408e99d61e4">16.35</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the years ended December&#160;31, 2021, 2020 and 2019, we granted RSUs with a weighted-average grant date fair value of $<ix:nonFraction unitRef="usdPerShare" contextRef="i903fc0912d4e492c95e3ce815e897489_D20210101-20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185MS9mcmFnOjlmMTJhYjBlYWNjMTQ1OTU5ZDhhNjcyY2JmZjdkYjZkL3RleHRyZWdpb246OWYxMmFiMGVhY2MxNDU5NTlkOGE2NzJjYmZmN2RiNmRfNzI3OA_5532c66f-c1d2-4036-8d9a-053b2796eab9">21.10</ix:nonFraction>, $<ix:nonFraction unitRef="usdPerShare" contextRef="i117e325270bf4054b07c98692139814a_D20200101-20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185MS9mcmFnOjlmMTJhYjBlYWNjMTQ1OTU5ZDhhNjcyY2JmZjdkYjZkL3RleHRyZWdpb246OWYxMmFiMGVhY2MxNDU5NTlkOGE2NzJjYmZmN2RiNmRfNzI4Mg_a705f5f0-2f61-433e-9052-a77359327ecc">8.88</ix:nonFraction> and $<ix:nonFraction unitRef="usdPerShare" contextRef="i4ad066769cd0464cbcbcf7d1ec4ce0ad_D20190101-20191231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185MS9mcmFnOjlmMTJhYjBlYWNjMTQ1OTU5ZDhhNjcyY2JmZjdkYjZkL3RleHRyZWdpb246OWYxMmFiMGVhY2MxNDU5NTlkOGE2NzJjYmZmN2RiNmRfNzI4OQ_e4ce7afd-ea50-47b0-8578-46019ab1b431">10.66</ix:nonFraction>, respectively, which represents the weighted-average closing price of our common stock on the grant date. </span></div></ix:continuation><div style="text-align:justify"><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">105</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="iba845a632d1b402fb80002d6c902942e" continuedAt="i749db5190b234031bfc5016cd21dee1e"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The total fair value of RSUs vested during the years ended December&#160;31, 2021, 2020 and 2019 was $<ix:nonFraction unitRef="usd" contextRef="i903fc0912d4e492c95e3ce815e897489_D20210101-20211231" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185MS9mcmFnOjlmMTJhYjBlYWNjMTQ1OTU5ZDhhNjcyY2JmZjdkYjZkL3RleHRyZWdpb246OWYxMmFiMGVhY2MxNDU5NTlkOGE2NzJjYmZmN2RiNmRfNzQ3Nw_6e901783-79cd-4a2e-b198-55efd2fc2703">7.3</ix:nonFraction>&#160;million, $<ix:nonFraction unitRef="usd" contextRef="i117e325270bf4054b07c98692139814a_D20200101-20201231" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185MS9mcmFnOjlmMTJhYjBlYWNjMTQ1OTU5ZDhhNjcyY2JmZjdkYjZkL3RleHRyZWdpb246OWYxMmFiMGVhY2MxNDU5NTlkOGE2NzJjYmZmN2RiNmRfNzQ4MQ_ee95a873-24c2-4c45-859e-b100246022ce">6.1</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i4ad066769cd0464cbcbcf7d1ec4ce0ad_D20190101-20191231" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185MS9mcmFnOjlmMTJhYjBlYWNjMTQ1OTU5ZDhhNjcyY2JmZjdkYjZkL3RleHRyZWdpb246OWYxMmFiMGVhY2MxNDU5NTlkOGE2NzJjYmZmN2RiNmRfNzQ4OA_625e3ce3-2726-4485-87fb-e3b2c7ac4f78">7.3</ix:nonFraction>&#160;million, respectively.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Leveraged Stock Unit Awards</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During 2020 and 2019, the Company granted <ix:nonFraction unitRef="shares" contextRef="i824c4e26d9414a59ad8f2d73e36714d0_D20200101-20201231" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185MS9mcmFnOjlmMTJhYjBlYWNjMTQ1OTU5ZDhhNjcyY2JmZjdkYjZkL3RleHRyZWdpb246OWYxMmFiMGVhY2MxNDU5NTlkOGE2NzJjYmZmN2RiNmRfNzU3OA_3f4eb76d-ca82-4be4-88c7-fffcfb697b34">0.5</ix:nonFraction>&#160;million and <ix:nonFraction unitRef="shares" contextRef="i89ff4001d069448c9d4b0758b35fcfdb_D20190101-20191231" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185MS9mcmFnOjlmMTJhYjBlYWNjMTQ1OTU5ZDhhNjcyY2JmZjdkYjZkL3RleHRyZWdpb246OWYxMmFiMGVhY2MxNDU5NTlkOGE2NzJjYmZmN2RiNmRfNzU4NQ_19002fc4-be4d-4ff3-9ad7-33cbdb2a4bf9">0.7</ix:nonFraction>&#160;million leveraged stock units, respectively, to certain employees to create incentives for continued long-term success and to more closely align executive pay with our stockholders&#8217; interests. Each of the grants is subject to share price-based vesting on the business day following the third anniversary of the grant date, as follows:</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:18pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">If the stock price has increased by <ix:nonFraction unitRef="number" contextRef="i74fbd0cbfcb8404bbbc19a496f94e90d_D20210101-20211231" decimals="3" name="evh:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsStockPriceIncreasePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185MS9mcmFnOjlmMTJhYjBlYWNjMTQ1OTU5ZDhhNjcyY2JmZjdkYjZkL3RleHRyZWdpb246OWYxMmFiMGVhY2MxNDU5NTlkOGE2NzJjYmZmN2RiNmRfNzkzOA_8062adc0-e97c-4469-91ce-14efe0c04b91">33.3</ix:nonFraction>%, <ix:nonFraction unitRef="number" contextRef="i74fbd0cbfcb8404bbbc19a496f94e90d_D20210101-20211231" decimals="INF" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185MS9mcmFnOjlmMTJhYjBlYWNjMTQ1OTU5ZDhhNjcyY2JmZjdkYjZkL3RleHRyZWdpb246OWYxMmFiMGVhY2MxNDU5NTlkOGE2NzJjYmZmN2RiNmRfNzk0Mg_8a97dc0c-6bf8-4f7f-81c3-3472560cab9f">75</ix:nonFraction>% of the shares will vest</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">If the stock price has increased by <ix:nonFraction unitRef="number" contextRef="i08583f7a5ec342338d4ec3de61aff226_D20210101-20211231" decimals="3" name="evh:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsStockPriceIncreasePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185MS9mcmFnOjlmMTJhYjBlYWNjMTQ1OTU5ZDhhNjcyY2JmZjdkYjZkL3RleHRyZWdpb246OWYxMmFiMGVhY2MxNDU5NTlkOGE2NzJjYmZmN2RiNmRfODAwNQ_d58c21a5-86fc-4791-80d2-afe83a078511">50</ix:nonFraction>%, <ix:nonFraction unitRef="number" contextRef="i08583f7a5ec342338d4ec3de61aff226_D20210101-20211231" decimals="INF" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185MS9mcmFnOjlmMTJhYjBlYWNjMTQ1OTU5ZDhhNjcyY2JmZjdkYjZkL3RleHRyZWdpb246OWYxMmFiMGVhY2MxNDU5NTlkOGE2NzJjYmZmN2RiNmRfODAwOQ_f7c03cac-3b9a-4a11-afe0-a5e2b22a0e52">100</ix:nonFraction>% of the shares will vest</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">If the stock price has increased by <ix:nonFraction unitRef="number" contextRef="i4b299843c6624a0b86491cf8ede39655_D20210101-20211231" decimals="3" name="evh:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsStockPriceIncreasePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185MS9mcmFnOjlmMTJhYjBlYWNjMTQ1OTU5ZDhhNjcyY2JmZjdkYjZkL3RleHRyZWdpb246OWYxMmFiMGVhY2MxNDU5NTlkOGE2NzJjYmZmN2RiNmRfODA3Mg_4b0d65de-b3f9-4842-8093-8e48dfe5bde7">100</ix:nonFraction>%, <ix:nonFraction unitRef="number" contextRef="i4b299843c6624a0b86491cf8ede39655_D20210101-20211231" decimals="INF" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185MS9mcmFnOjlmMTJhYjBlYWNjMTQ1OTU5ZDhhNjcyY2JmZjdkYjZkL3RleHRyZWdpb246OWYxMmFiMGVhY2MxNDU5NTlkOGE2NzJjYmZmN2RiNmRfODA3Ng_3da13b11-bda8-4b67-9318-f1dd259d7af9">150</ix:nonFraction>% of the shares will vest</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">If the stock price has increased by <ix:nonFraction unitRef="number" contextRef="i04a926a87abf4421b1ca0ae299f722a6_D20210101-20211231" decimals="3" name="evh:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsStockPriceIncreasePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185MS9mcmFnOjlmMTJhYjBlYWNjMTQ1OTU5ZDhhNjcyY2JmZjdkYjZkL3RleHRyZWdpb246OWYxMmFiMGVhY2MxNDU5NTlkOGE2NzJjYmZmN2RiNmRfODEzOQ_81576e15-95bd-47e9-a44e-d878ecec817d">200</ix:nonFraction>%, <ix:nonFraction unitRef="number" contextRef="i04a926a87abf4421b1ca0ae299f722a6_D20210101-20211231" decimals="INF" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185MS9mcmFnOjlmMTJhYjBlYWNjMTQ1OTU5ZDhhNjcyY2JmZjdkYjZkL3RleHRyZWdpb246OWYxMmFiMGVhY2MxNDU5NTlkOGE2NzJjYmZmN2RiNmRfODE0Mw_95d00e46-77a8-428d-ae93-9ffdafe6fc7a">200</ix:nonFraction>% of the shares will vest (this is the maximum possible vest amount)</span></div><div style="text-align:justify"><span><br/></span></div><ix:continuation id="i6fc7d07593c04b58aad95f175009dfa2"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The price assumptions used for our leveraged stock unit awards were as follows:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"></td><td style="width:384.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:73.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:73.00pt"></td><td style="width:1.0pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Year Ended December 31,</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average fair value per leveraged stock unit granted</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="if0b01289c86a4176ab75517bdfe4ec1f_D20210101-20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185MS9mcmFnOjlmMTJhYjBlYWNjMTQ1OTU5ZDhhNjcyY2JmZjdkYjZkL3RhYmxlOmVmMzM5ZmVjNWU3NjRiOWM4ZmI5NDA1M2NmODZkNTUwL3RhYmxlcmFuZ2U6ZWYzMzlmZWM1ZTc2NGI5YzhmYjk0MDUzY2Y4NmQ1NTBfMi0xLTEtMS0xNzc3NQ_ed385c96-359c-4526-8dca-08b9473068b9">8.90</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i824c4e26d9414a59ad8f2d73e36714d0_D20200101-20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185MS9mcmFnOjlmMTJhYjBlYWNjMTQ1OTU5ZDhhNjcyY2JmZjdkYjZkL3RhYmxlOmVmMzM5ZmVjNWU3NjRiOWM4ZmI5NDA1M2NmODZkNTUwL3RhYmxlcmFuZ2U6ZWYzMzlmZWM1ZTc2NGI5YzhmYjk0MDUzY2Y4NmQ1NTBfMi0zLTEtMS0xNzc3NQ_089b087f-fd9b-4ac1-9e3a-9683394e8c65">6.52</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assumptions:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected term</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="if0b01289c86a4176ab75517bdfe4ec1f_D20210101-20211231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185MS9mcmFnOjlmMTJhYjBlYWNjMTQ1OTU5ZDhhNjcyY2JmZjdkYjZkL3RhYmxlOmVmMzM5ZmVjNWU3NjRiOWM4ZmI5NDA1M2NmODZkNTUwL3RhYmxlcmFuZ2U6ZWYzMzlmZWM1ZTc2NGI5YzhmYjk0MDUzY2Y4NmQ1NTBfNC0xLTEtMS0xNzc3NQ_f1709f8a-2c2e-46cf-8231-f56593ba1e40">10</ix:nonNumeric> years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i824c4e26d9414a59ad8f2d73e36714d0_D20200101-20201231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185MS9mcmFnOjlmMTJhYjBlYWNjMTQ1OTU5ZDhhNjcyY2JmZjdkYjZkL3RhYmxlOmVmMzM5ZmVjNWU3NjRiOWM4ZmI5NDA1M2NmODZkNTUwL3RhYmxlcmFuZ2U6ZWYzMzlmZWM1ZTc2NGI5YzhmYjk0MDUzY2Y4NmQ1NTBfNC0zLTEtMS0xNzc3NQ_0d0d23d2-0765-4bc4-a1d3-35dc3030e608">10</ix:nonNumeric> years</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="if0b01289c86a4176ab75517bdfe4ec1f_D20210101-20211231" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185MS9mcmFnOjlmMTJhYjBlYWNjMTQ1OTU5ZDhhNjcyY2JmZjdkYjZkL3RhYmxlOmVmMzM5ZmVjNWU3NjRiOWM4ZmI5NDA1M2NmODZkNTUwL3RhYmxlcmFuZ2U6ZWYzMzlmZWM1ZTc2NGI5YzhmYjk0MDUzY2Y4NmQ1NTBfNS0xLTEtMS0xNzc3NQ_8e7a7ca7-99b0-449e-bc14-f7dfeedaa1c8">62.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i824c4e26d9414a59ad8f2d73e36714d0_D20200101-20201231" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185MS9mcmFnOjlmMTJhYjBlYWNjMTQ1OTU5ZDhhNjcyY2JmZjdkYjZkL3RhYmxlOmVmMzM5ZmVjNWU3NjRiOWM4ZmI5NDA1M2NmODZkNTUwL3RhYmxlcmFuZ2U6ZWYzMzlmZWM1ZTc2NGI5YzhmYjk0MDUzY2Y4NmQ1NTBfNS0zLTEtMS0xNzc3NQ_fdc592e7-cdf2-4ea8-bc55-70b2550ad6ce">51.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="if0b01289c86a4176ab75517bdfe4ec1f_D20210101-20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185MS9mcmFnOjlmMTJhYjBlYWNjMTQ1OTU5ZDhhNjcyY2JmZjdkYjZkL3RhYmxlOmVmMzM5ZmVjNWU3NjRiOWM4ZmI5NDA1M2NmODZkNTUwL3RhYmxlcmFuZ2U6ZWYzMzlmZWM1ZTc2NGI5YzhmYjk0MDUzY2Y4NmQ1NTBfNi0xLTEtMS0xNzc3NQ_6ba6ea22-3f76-4ea4-9f32-74c72a1e9e22">0.85</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i824c4e26d9414a59ad8f2d73e36714d0_D20200101-20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185MS9mcmFnOjlmMTJhYjBlYWNjMTQ1OTU5ZDhhNjcyY2JmZjdkYjZkL3RhYmxlOmVmMzM5ZmVjNWU3NjRiOWM4ZmI5NDA1M2NmODZkNTUwL3RhYmxlcmFuZ2U6ZWYzMzlmZWM1ZTc2NGI5YzhmYjk0MDUzY2Y4NmQ1NTBfNi0zLTEtMS0xNzc3NQ_7cbccf63-bbfd-429a-9b83-7a4eb4015a5c">2.54</ix:nonFraction>%</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividend yield</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="if0b01289c86a4176ab75517bdfe4ec1f_D20210101-20211231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185MS9mcmFnOjlmMTJhYjBlYWNjMTQ1OTU5ZDhhNjcyY2JmZjdkYjZkL3RhYmxlOmVmMzM5ZmVjNWU3NjRiOWM4ZmI5NDA1M2NmODZkNTUwL3RhYmxlcmFuZ2U6ZWYzMzlmZWM1ZTc2NGI5YzhmYjk0MDUzY2Y4NmQ1NTBfNy0xLTEtMS0xNzc3NQ_0f99690d-a45d-461d-972b-e90512bdbe60">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i824c4e26d9414a59ad8f2d73e36714d0_D20200101-20201231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185MS9mcmFnOjlmMTJhYjBlYWNjMTQ1OTU5ZDhhNjcyY2JmZjdkYjZkL3RhYmxlOmVmMzM5ZmVjNWU3NjRiOWM4ZmI5NDA1M2NmODZkNTUwL3RhYmxlcmFuZ2U6ZWYzMzlmZWM1ZTc2NGI5YzhmYjk0MDUzY2Y4NmQ1NTBfNy0zLTEtMS0xNzc3NQ_3e50450e-4831-4d96-aa06-c9c5621e593a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div></ix:continuation><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of leveraged stock units is determined using a Black-Scholes valuation model with the assumptions disclosed in the table above. The dividend rate is based on the expected dividend rate during the expected life of the award. Expected volatility is based on the historical volatility over the most recent period commensurate with the estimated expected term of the Company&#8217;s awards due to the limited history of our own stock price. The risk-free interest rate is based on the U.S. Treasury yield curve in effect at the time of the grant. The expected life represents the period of time the awards&#160;are expected to be outstanding and is based on the&#160;simplified method. Under the&#160;simplified method, the expected life of an award is presumed to be the midpoint between the vesting date and the end of the contractual term. We used the&#160;simplified method&#160;due to the lack of sufficient historical exercise data to provide a reasonable basis upon which to otherwise estimate the expected life of the awards.&#160;</span></div><div style="text-align:justify"><span><br/></span></div><ix:nonNumeric contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231" name="us-gaap:ScheduleOfOtherShareBasedCompensationActivityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185MS9mcmFnOjlmMTJhYjBlYWNjMTQ1OTU5ZDhhNjcyY2JmZjdkYjZkL3RleHRyZWdpb246OWYxMmFiMGVhY2MxNDU5NTlkOGE2NzJjYmZmN2RiNmRfMTI3MDE_39d5ebac-e457-4ffb-a0a0-f77a5fedf8ff" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Information with respect to our leveraged stock unit awards (shares and aggregate intrinsic value shown in thousands, weighted-average remaining contractual term shown in years) was as follows:</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:539.25pt"><tr><td style="width:1.0pt"></td><td style="width:286.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:58.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:58.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:58.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:58.00pt"></td><td style="width:1.0pt"></td></tr><tr style="height:54pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Leveraged Stock Units</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average Grant Date Fair Value</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average Remaining Contractual Term</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Aggregate Intrinsic Value</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding as of December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i33d73ea883764a2dafec5a1252f33aef_I20211231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185MS9mcmFnOjlmMTJhYjBlYWNjMTQ1OTU5ZDhhNjcyY2JmZjdkYjZkL3RhYmxlOmRmYWFmOTk2ZDkzZTQ0NTY5Y2I0MDBmZGI4Y2JlNTAwL3RhYmxlcmFuZ2U6ZGZhYWY5OTZkOTNlNDQ1NjljYjQwMGZkYjhjYmU1MDBfMS0xLTEtMS0xNzc3NQ_1584989d-9855-4a8c-86e4-563252d38435">1,084</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i33d73ea883764a2dafec5a1252f33aef_I20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185MS9mcmFnOjlmMTJhYjBlYWNjMTQ1OTU5ZDhhNjcyY2JmZjdkYjZkL3RhYmxlOmRmYWFmOTk2ZDkzZTQ0NTY5Y2I0MDBmZGI4Y2JlNTAwL3RhYmxlcmFuZ2U6ZGZhYWY5OTZkOTNlNDQ1NjljYjQwMGZkYjhjYmU1MDBfMS0zLTEtMS0xNzc3NQ_fd0f08d3-81fd-4aaa-b93c-9341940e45f1">11.07</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="if0b01289c86a4176ab75517bdfe4ec1f_D20210101-20211231" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185MS9mcmFnOjlmMTJhYjBlYWNjMTQ1OTU5ZDhhNjcyY2JmZjdkYjZkL3RhYmxlOmRmYWFmOTk2ZDkzZTQ0NTY5Y2I0MDBmZGI4Y2JlNTAwL3RhYmxlcmFuZ2U6ZGZhYWY5OTZkOTNlNDQ1NjljYjQwMGZkYjhjYmU1MDBfMS01LTEtMS0xNzc3NQ_d220e54c-93f3-4935-aa6b-e924d328807a">7.68</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i33d73ea883764a2dafec5a1252f33aef_I20211231" decimals="-3" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185MS9mcmFnOjlmMTJhYjBlYWNjMTQ1OTU5ZDhhNjcyY2JmZjdkYjZkL3RhYmxlOmRmYWFmOTk2ZDkzZTQ0NTY5Y2I0MDBmZGI4Y2JlNTAwL3RhYmxlcmFuZ2U6ZGZhYWY5OTZkOTNlNDQ1NjljYjQwMGZkYjhjYmU1MDBfMS03LTEtMS0xNzc3NQ_cd4194d9-f3e0-4ac5-b262-416070fc6506">17,993</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested and expected to vest after December&#160;31, 2021</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i33d73ea883764a2dafec5a1252f33aef_I20211231" decimals="-3" name="evh:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestNumber" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185MS9mcmFnOjlmMTJhYjBlYWNjMTQ1OTU5ZDhhNjcyY2JmZjdkYjZkL3RhYmxlOmRmYWFmOTk2ZDkzZTQ0NTY5Y2I0MDBmZGI4Y2JlNTAwL3RhYmxlcmFuZ2U6ZGZhYWY5OTZkOTNlNDQ1NjljYjQwMGZkYjhjYmU1MDBfMy0xLTEtMS0xNzc3NQ_f4d8dd21-202c-43f1-91ac-150e65a77bff">1,084</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i33d73ea883764a2dafec5a1252f33aef_I20211231" decimals="2" name="evh:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185MS9mcmFnOjlmMTJhYjBlYWNjMTQ1OTU5ZDhhNjcyY2JmZjdkYjZkL3RhYmxlOmRmYWFmOTk2ZDkzZTQ0NTY5Y2I0MDBmZGI4Y2JlNTAwL3RhYmxlcmFuZ2U6ZGZhYWY5OTZkOTNlNDQ1NjljYjQwMGZkYjhjYmU1MDBfMy0zLTEtMS0xNzc3NQ_54c30cb7-60c4-4734-8f43-f32c32b77b70">11.07</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="if0b01289c86a4176ab75517bdfe4ec1f_D20210101-20211231" name="evh:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestWeightedAverageRemainingContractualTerms" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185MS9mcmFnOjlmMTJhYjBlYWNjMTQ1OTU5ZDhhNjcyY2JmZjdkYjZkL3RhYmxlOmRmYWFmOTk2ZDkzZTQ0NTY5Y2I0MDBmZGI4Y2JlNTAwL3RhYmxlcmFuZ2U6ZGZhYWY5OTZkOTNlNDQ1NjljYjQwMGZkYjhjYmU1MDBfMy01LTEtMS0xNzc3NQ_d17fc428-3b43-4ef3-aa1e-070ca90155ef">7.68</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i33d73ea883764a2dafec5a1252f33aef_I20211231" decimals="-3" name="evh:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVestedAndExpectedToVest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185MS9mcmFnOjlmMTJhYjBlYWNjMTQ1OTU5ZDhhNjcyY2JmZjdkYjZkL3RhYmxlOmRmYWFmOTk2ZDkzZTQ0NTY5Y2I0MDBmZGI4Y2JlNTAwL3RhYmxlcmFuZ2U6ZGZhYWY5OTZkOTNlNDQ1NjljYjQwMGZkYjhjYmU1MDBfMy03LTEtMS0xNzc3NQ_953cbeea-a5e8-42d1-af96-14c0b35c633a">17,993</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Performance-based RSUs</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During 2021, the Company granted <ix:nonFraction unitRef="shares" contextRef="i91de07e5bb1e422aa1d46986a0b1006f_D20210101-20211231" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185MS9mcmFnOjlmMTJhYjBlYWNjMTQ1OTU5ZDhhNjcyY2JmZjdkYjZkL3RleHRyZWdpb246OWYxMmFiMGVhY2MxNDU5NTlkOGE2NzJjYmZmN2RiNmRfMTA5OTUxMTY0NjkwNg_756106ef-d0f1-4805-b5d7-64113b31973c">0.3</ix:nonFraction>&#160;million performance-based RSUs to certain employees to create incentives for continued long-term success and to more closely align executive pay with our stockholders&#8217; interests. A <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185MS9mcmFnOjlmMTJhYjBlYWNjMTQ1OTU5ZDhhNjcyY2JmZjdkYjZkL3RleHRyZWdpb246OWYxMmFiMGVhY2MxNDU5NTlkOGE2NzJjYmZmN2RiNmRfMzI5ODUzNDkxMDU4Mg_a8edff10-eb5c-4745-9477-bbe219e0ae2c">two</span> and <ix:nonNumeric contextRef="i3c5f476b4e1249a08e8202ae0113bf9a_D20210101-20211231" name="evh:EarningsBeforeInterestTaxesDepreciationAndAmortizationGoalPeriod" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185MS9mcmFnOjlmMTJhYjBlYWNjMTQ1OTU5ZDhhNjcyY2JmZjdkYjZkL3RleHRyZWdpb246OWYxMmFiMGVhY2MxNDU5NTlkOGE2NzJjYmZmN2RiNmRfMzI5ODUzNDkxMDU5OQ_9fa63a30-6e2c-4bdf-aa68-6da2eb1ed4bf">three-year</ix:nonNumeric> cumulative Adjusted EBITDA goal was approved and began on January 1, 2021. Shares are earned based on a sliding scale of performance above and below the performance goal. The sliding scale is anchored by a minimum performance requirement of cumulative Adjusted EBITDA. If the minimum performance goal is not achieved, then no performance shares are earned. If <ix:nonFraction unitRef="number" contextRef="ife9a61a44ecc47e88bb29426256eba9d_I20211231" decimals="INF" name="evh:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsPerformanceGoalThreshold" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185MS9mcmFnOjlmMTJhYjBlYWNjMTQ1OTU5ZDhhNjcyY2JmZjdkYjZkL3RleHRyZWdpb246OWYxMmFiMGVhY2MxNDU5NTlkOGE2NzJjYmZmN2RiNmRfMzg0ODI5MDcyNDQ1OA_e618c82d-1d54-4a65-9c1d-9f9041369546">100</ix:nonFraction>% of the performance goal is achieved, then award is paid at target and if the maximum performance is achieved, then <ix:nonFraction unitRef="number" contextRef="ife9a61a44ecc47e88bb29426256eba9d_I20211231" decimals="INF" name="evh:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsMaximumPerformanceAchievedPercentageOfTargetedSharesEarned" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185MS9mcmFnOjlmMTJhYjBlYWNjMTQ1OTU5ZDhhNjcyY2JmZjdkYjZkL3RleHRyZWdpb246OWYxMmFiMGVhY2MxNDU5NTlkOGE2NzJjYmZmN2RiNmRfMzg0ODI5MDcyNDQ2NA_f41fd877-5bfa-4732-8740-a1f4ff6a10b3">200</ix:nonFraction>% of the targeted shares are earned. If the cumulative Adjusted EBITDA falls between tiers on the sliding scale, the actual cumulative Adjusted EBITDA payout percentage shall be determined by linear interpolation between the percentages on a straight-line basis. Shares earned by the <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185MS9mcmFnOjlmMTJhYjBlYWNjMTQ1OTU5ZDhhNjcyY2JmZjdkYjZkL3RleHRyZWdpb246OWYxMmFiMGVhY2MxNDU5NTlkOGE2NzJjYmZmN2RiNmRfMzI5ODUzNDkxMDYwMA_5c625e05-1161-4caa-b418-357677b81681">two</span> and <ix:nonNumeric contextRef="i3c5f476b4e1249a08e8202ae0113bf9a_D20210101-20211231" name="evh:EarningsBeforeInterestTaxesDepreciationAndAmortizationGoalPeriod" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185MS9mcmFnOjlmMTJhYjBlYWNjMTQ1OTU5ZDhhNjcyY2JmZjdkYjZkL3RleHRyZWdpb246OWYxMmFiMGVhY2MxNDU5NTlkOGE2NzJjYmZmN2RiNmRfMzI5ODUzNDkxMDYxOA_6902eb41-f4e3-4900-86cf-375482cf5624">three-year</ix:nonNumeric> cumulative Adjusted EBITDA performance will be adjusted based on a respective total shareholder return ("TSR"). Shares earned will be adjusted -<ix:nonFraction unitRef="number" contextRef="ife9a61a44ecc47e88bb29426256eba9d_I20211231" decimals="INF" sign="-" name="evh:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageAdjustmentOfSharesEarnedTotalShareholderReturnInBottomQuartile" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185MS9mcmFnOjlmMTJhYjBlYWNjMTQ1OTU5ZDhhNjcyY2JmZjdkYjZkL3RleHRyZWdpb246OWYxMmFiMGVhY2MxNDU5NTlkOGE2NzJjYmZmN2RiNmRfMzI5ODUzNDkxMDYyMA_89609fd4-2923-44ed-8501-3c3ef1f62105">10</ix:nonFraction>% if TSR performance is in the bottom quartile and will be adjusted +<ix:nonFraction unitRef="number" contextRef="ife9a61a44ecc47e88bb29426256eba9d_I20211231" decimals="INF" name="evh:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageAdjustmentOfSharesEarnedTotalShareholderReturnInTopQuartile" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185MS9mcmFnOjlmMTJhYjBlYWNjMTQ1OTU5ZDhhNjcyY2JmZjdkYjZkL3RleHRyZWdpb246OWYxMmFiMGVhY2MxNDU5NTlkOGE2NzJjYmZmN2RiNmRfMzI5ODUzNDkxMDYyNg_bd195b1b-3a96-4236-9d08-d792ff9312d6">10</ix:nonFraction>% if TSR performance is in the upper quartile. TSR represents stock price appreciation over each of the two performance periods. </span></div></ix:continuation><div style="text-align:justify"><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">106</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i749db5190b234031bfc5016cd21dee1e"><ix:nonNumeric contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231" name="evh:ScheduleOfShareBasedPaymentAwardRestrictedStockUnitValuationAssumptionsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185MS9mcmFnOjlmMTJhYjBlYWNjMTQ1OTU5ZDhhNjcyY2JmZjdkYjZkL3RleHRyZWdpb246OWYxMmFiMGVhY2MxNDU5NTlkOGE2NzJjYmZmN2RiNmRfMTA0NDUzNjA0OTExMTI_3ac2f91c-8017-4cc0-bd1f-0847e56fe95e" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The price assumptions used for our performance based stock unit awards were as follows:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"></td><td style="width:384.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:73.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:73.00pt"></td><td style="width:1.0pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1st Tranche</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2nd Tranche</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average fair value per performance based stock unit granted</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="if24975b6c6fc46f2956741e09150759a_D20210101-20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185MS9mcmFnOjlmMTJhYjBlYWNjMTQ1OTU5ZDhhNjcyY2JmZjdkYjZkL3RhYmxlOjU5MDZhZDBhMjM2NjQ5YzA5NmU5ZWNmNzQ3NDVkNjgxL3RhYmxlcmFuZ2U6NTkwNmFkMGEyMzY2NDljMDk2ZTllY2Y3NDc0NWQ2ODFfMS0xLTEtMS0zNjU5NA_632282f1-a240-498a-8aeb-34de9e274e62">20.64</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i32a9b997fd964b44a992bdf9b2104f0e_D20210101-20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185MS9mcmFnOjlmMTJhYjBlYWNjMTQ1OTU5ZDhhNjcyY2JmZjdkYjZkL3RhYmxlOjU5MDZhZDBhMjM2NjQ5YzA5NmU5ZWNmNzQ3NDVkNjgxL3RhYmxlcmFuZ2U6NTkwNmFkMGEyMzY2NDljMDk2ZTllY2Y3NDc0NWQ2ODFfMS0zLTEtMS0zNjYwMQ_88c9f2bd-3db0-43d1-9f2e-c79c91741a7b">20.69</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assumptions:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected term</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ie5209e47858942b8a833f9d575b7d37c_D20210101-20211231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185MS9mcmFnOjlmMTJhYjBlYWNjMTQ1OTU5ZDhhNjcyY2JmZjdkYjZkL3RhYmxlOjU5MDZhZDBhMjM2NjQ5YzA5NmU5ZWNmNzQ3NDVkNjgxL3RhYmxlcmFuZ2U6NTkwNmFkMGEyMzY2NDljMDk2ZTllY2Y3NDc0NWQ2ODFfMy0xLTEtMS0zNjU5OA_ad1b401b-2929-4381-82c9-e75d79d6a34f">2</ix:nonNumeric> years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i1c1d55717222438abb87e60bcf9b59b9_D20210101-20211231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185MS9mcmFnOjlmMTJhYjBlYWNjMTQ1OTU5ZDhhNjcyY2JmZjdkYjZkL3RhYmxlOjU5MDZhZDBhMjM2NjQ5YzA5NmU5ZWNmNzQ3NDVkNjgxL3RhYmxlcmFuZ2U6NTkwNmFkMGEyMzY2NDljMDk2ZTllY2Y3NDc0NWQ2ODFfMy0zLTEtMS0zNjYwMQ_f165c7f7-8505-4e17-a29d-972e36f49950">3</ix:nonNumeric> years</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ie5209e47858942b8a833f9d575b7d37c_D20210101-20211231" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185MS9mcmFnOjlmMTJhYjBlYWNjMTQ1OTU5ZDhhNjcyY2JmZjdkYjZkL3RhYmxlOjU5MDZhZDBhMjM2NjQ5YzA5NmU5ZWNmNzQ3NDVkNjgxL3RhYmxlcmFuZ2U6NTkwNmFkMGEyMzY2NDljMDk2ZTllY2Y3NDc0NWQ2ODFfNC0xLTEtMS0zNjU5OA_936d344d-4569-46f7-90c9-d3e5c5acb88c">89.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i1c1d55717222438abb87e60bcf9b59b9_D20210101-20211231" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185MS9mcmFnOjlmMTJhYjBlYWNjMTQ1OTU5ZDhhNjcyY2JmZjdkYjZkL3RhYmxlOjU5MDZhZDBhMjM2NjQ5YzA5NmU5ZWNmNzQ3NDVkNjgxL3RhYmxlcmFuZ2U6NTkwNmFkMGEyMzY2NDljMDk2ZTllY2Y3NDc0NWQ2ODFfNC0zLTEtMS0zNjYwMQ_2589ca9e-6ace-4730-94b0-38eb25248d5e">77.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ie5209e47858942b8a833f9d575b7d37c_D20210101-20211231" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185MS9mcmFnOjlmMTJhYjBlYWNjMTQ1OTU5ZDhhNjcyY2JmZjdkYjZkL3RhYmxlOjU5MDZhZDBhMjM2NjQ5YzA5NmU5ZWNmNzQ3NDVkNjgxL3RhYmxlcmFuZ2U6NTkwNmFkMGEyMzY2NDljMDk2ZTllY2Y3NDc0NWQ2ODFfNS0xLTEtMS0zNjU5OA_d7af974e-a6b7-4895-868d-ec25a27d51c2">0.12</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i1c1d55717222438abb87e60bcf9b59b9_D20210101-20211231" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185MS9mcmFnOjlmMTJhYjBlYWNjMTQ1OTU5ZDhhNjcyY2JmZjdkYjZkL3RhYmxlOjU5MDZhZDBhMjM2NjQ5YzA5NmU5ZWNmNzQ3NDVkNjgxL3RhYmxlcmFuZ2U6NTkwNmFkMGEyMzY2NDljMDk2ZTllY2Y3NDc0NWQ2ODFfNS0zLTEtMS0zNjYwMQ_c0e67a56-62d3-4eb1-b3a1-8d4ab22ab0b8">0.25</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividend yield</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ie5209e47858942b8a833f9d575b7d37c_D20210101-20211231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185MS9mcmFnOjlmMTJhYjBlYWNjMTQ1OTU5ZDhhNjcyY2JmZjdkYjZkL3RhYmxlOjU5MDZhZDBhMjM2NjQ5YzA5NmU5ZWNmNzQ3NDVkNjgxL3RhYmxlcmFuZ2U6NTkwNmFkMGEyMzY2NDljMDk2ZTllY2Y3NDc0NWQ2ODFfNi0xLTEtMS0zNjU5OA_691d92d4-6feb-4fbc-a20f-b6f155911a57">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i1c1d55717222438abb87e60bcf9b59b9_D20210101-20211231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185MS9mcmFnOjlmMTJhYjBlYWNjMTQ1OTU5ZDhhNjcyY2JmZjdkYjZkL3RhYmxlOjU5MDZhZDBhMjM2NjQ5YzA5NmU5ZWNmNzQ3NDVkNjgxL3RhYmxlcmFuZ2U6NTkwNmFkMGEyMzY2NDljMDk2ZTllY2Y3NDc0NWQ2ODFfNi0zLTEtMS0zNjYwMQ_f0395fae-f757-4253-84c6-4c86e12ea4fc">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div></ix:nonNumeric><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of performance based stock units is determined using a Black-Scholes valuation model with the assumptions disclosed in the table above. The dividend rate is based on the expected dividend rate during the expected life of the award. Expected volatility is based on the historical volatility over the most recent period commensurate with the estimated expected term of the Company&#8217;s awards due to the limited history of our own stock price. The risk-free interest rate is based on the U.S. Treasury yield curve in effect at the time of the grant. The expected life represents the period of time the awards&#160;are expected to be outstanding and is based on the&#160;simplified method. Under the&#160;simplified method, the expected life of an award is presumed to be the midpoint between the vesting date and the end of the contractual term. We used the&#160;simplified method&#160;due to the lack of sufficient historical exercise data to provide a reasonable basis upon which to otherwise estimate the expected life of the awards.&#160;</span></div><div style="text-align:justify"><span><br/></span></div><ix:nonNumeric contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231" name="us-gaap:ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardRestrictedStockUnitsVestedAndExpectedToVestTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185MS9mcmFnOjlmMTJhYjBlYWNjMTQ1OTU5ZDhhNjcyY2JmZjdkYjZkL3RleHRyZWdpb246OWYxMmFiMGVhY2MxNDU5NTlkOGE2NzJjYmZmN2RiNmRfMTA0NDUzNjA0OTExMTE_507e9d2c-a97c-40cc-a020-531b62fca65d" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Information with respect to our performance based restricted stock unit awards (shares and aggregate intrinsic value shown in thousands, weighted-average remaining contractual term shown in years) was as follows:</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:536.25pt"><tr><td style="width:1.0pt"></td><td style="width:280.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:60.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:58.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:58.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:58.00pt"></td><td style="width:1.0pt"></td></tr><tr style="height:54pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Performance Based  Stock Units</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average Grant Date Fair Value</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average Remaining Contractual Term</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Aggregate Intrinsic Value</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding as of December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ife9a61a44ecc47e88bb29426256eba9d_I20211231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185MS9mcmFnOjlmMTJhYjBlYWNjMTQ1OTU5ZDhhNjcyY2JmZjdkYjZkL3RhYmxlOmM5ZWQyMTI0OTU0NzRlMTJiODBjZDhhOWY3Y2QyZjlhL3RhYmxlcmFuZ2U6YzllZDIxMjQ5NTQ3NGUxMmI4MGNkOGE5ZjdjZDJmOWFfMS0xLTEtMS0yMzU5MQ_7acc1381-d444-49a0-92c0-9c31f82674d4">319</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ife9a61a44ecc47e88bb29426256eba9d_I20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185MS9mcmFnOjlmMTJhYjBlYWNjMTQ1OTU5ZDhhNjcyY2JmZjdkYjZkL3RhYmxlOmM5ZWQyMTI0OTU0NzRlMTJiODBjZDhhOWY3Y2QyZjlhL3RhYmxlcmFuZ2U6YzllZDIxMjQ5NTQ3NGUxMmI4MGNkOGE5ZjdjZDJmOWFfMS0zLTEtMS0yMzU5MQ_8c2600f4-1c17-4632-9085-1b41a30f8cfc">20.67</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i91de07e5bb1e422aa1d46986a0b1006f_D20210101-20211231" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185MS9mcmFnOjlmMTJhYjBlYWNjMTQ1OTU5ZDhhNjcyY2JmZjdkYjZkL3RhYmxlOmM5ZWQyMTI0OTU0NzRlMTJiODBjZDhhOWY3Y2QyZjlhL3RhYmxlcmFuZ2U6YzllZDIxMjQ5NTQ3NGUxMmI4MGNkOGE5ZjdjZDJmOWFfMS01LTEtMS0yMzU5MQ_2327da8f-543a-4de8-ab49-d14a68ede934">9.16</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ife9a61a44ecc47e88bb29426256eba9d_I20211231" decimals="-3" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185MS9mcmFnOjlmMTJhYjBlYWNjMTQ1OTU5ZDhhNjcyY2JmZjdkYjZkL3RhYmxlOmM5ZWQyMTI0OTU0NzRlMTJiODBjZDhhOWY3Y2QyZjlhL3RhYmxlcmFuZ2U6YzllZDIxMjQ5NTQ3NGUxMmI4MGNkOGE5ZjdjZDJmOWFfMS03LTEtMS0yMzU5MQ_c249b57a-4be8-42e1-86fa-18b86aa077ee">2,233</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested and expected to vest after December&#160;31, 2021</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ife9a61a44ecc47e88bb29426256eba9d_I20211231" decimals="-3" name="evh:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestNumber" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185MS9mcmFnOjlmMTJhYjBlYWNjMTQ1OTU5ZDhhNjcyY2JmZjdkYjZkL3RhYmxlOmM5ZWQyMTI0OTU0NzRlMTJiODBjZDhhOWY3Y2QyZjlhL3RhYmxlcmFuZ2U6YzllZDIxMjQ5NTQ3NGUxMmI4MGNkOGE5ZjdjZDJmOWFfMy0xLTEtMS0yMzU5MQ_574fb23d-f560-4aa3-99e8-49cc076949db">319</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ife9a61a44ecc47e88bb29426256eba9d_I20211231" decimals="2" name="evh:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185MS9mcmFnOjlmMTJhYjBlYWNjMTQ1OTU5ZDhhNjcyY2JmZjdkYjZkL3RhYmxlOmM5ZWQyMTI0OTU0NzRlMTJiODBjZDhhOWY3Y2QyZjlhL3RhYmxlcmFuZ2U6YzllZDIxMjQ5NTQ3NGUxMmI4MGNkOGE5ZjdjZDJmOWFfMy0zLTEtMS0yMzU5MQ_f1bdec84-f0c7-4cf3-853f-6d42be2935cc">20.67</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i91de07e5bb1e422aa1d46986a0b1006f_D20210101-20211231" name="evh:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestWeightedAverageRemainingContractualTerms" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185MS9mcmFnOjlmMTJhYjBlYWNjMTQ1OTU5ZDhhNjcyY2JmZjdkYjZkL3RhYmxlOmM5ZWQyMTI0OTU0NzRlMTJiODBjZDhhOWY3Y2QyZjlhL3RhYmxlcmFuZ2U6YzllZDIxMjQ5NTQ3NGUxMmI4MGNkOGE5ZjdjZDJmOWFfMy01LTEtMS0yMzU5MQ_8e1dfc92-7e74-4ec9-8fd5-28f6b85f23af">9.16</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ife9a61a44ecc47e88bb29426256eba9d_I20211231" decimals="-3" name="evh:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVestedAndExpectedToVest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185MS9mcmFnOjlmMTJhYjBlYWNjMTQ1OTU5ZDhhNjcyY2JmZjdkYjZkL3RhYmxlOmM5ZWQyMTI0OTU0NzRlMTJiODBjZDhhOWY3Y2QyZjlhL3RhYmxlcmFuZ2U6YzllZDIxMjQ5NTQ3NGUxMmI4MGNkOGE5ZjdjZDJmOWFfMy03LTEtMS0yMzU5MQ_31a2a57b-28e9-4ff9-961a-fc981af6f827">2,233</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div><span><br/></span></div><div id="i9aaa2fddc97e482da5dbe37ac85ae703_97"></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 15.  </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231" name="us-gaap:IncomeTaxDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185Ny9mcmFnOmJjZWZiM2Q3NjJhNzQ1YWE4MWQ3NzAzMjlmMDdjODMyL3RleHRyZWdpb246YmNlZmIzZDc2MmE3NDVhYTgxZDc3MDMyOWYwN2M4MzJfODQyMA_63453375-5819-4b2f-95b9-ef78a034c398" continuedAt="i45095f5a88f0411cae1300d539a7afd5" escape="true">Income Taxes</ix:nonNumeric></span></div><div style="text-align:justify"><span><br/></span></div><ix:continuation id="i45095f5a88f0411cae1300d539a7afd5" continuedAt="i5d07ae159c6b45e7b17dec99a06c344e"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">An income tax expense (benefit) of $<ix:nonFraction unitRef="usd" contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231" decimals="-5" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185Ny9mcmFnOmJjZWZiM2Q3NjJhNzQ1YWE4MWQ3NzAzMjlmMDdjODMyL3RleHRyZWdpb246YmNlZmIzZDc2MmE3NDVhYTgxZDc3MDMyOWYwN2M4MzJfNjQ_4073ffb7-e4b1-4fe8-921a-55572fa124eb">0.5</ix:nonFraction>&#160;million, $(<ix:nonFraction unitRef="usd" contextRef="i12a6d1161de54547bd29f8efccd4c9b0_D20200101-20201231" decimals="-5" sign="-" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185Ny9mcmFnOmJjZWZiM2Q3NjJhNzQ1YWE4MWQ3NzAzMjlmMDdjODMyL3RleHRyZWdpb246YmNlZmIzZDc2MmE3NDVhYTgxZDc3MDMyOWYwN2M4MzJfNjg_7f3c533b-43b4-4619-9990-218c86c1e046">2.4</ix:nonFraction>)&#160;million, and $(<ix:nonFraction unitRef="usd" contextRef="i3e21049ffc224cacb8134d73c9bb5b38_D20190101-20191231" decimals="-5" sign="-" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185Ny9mcmFnOmJjZWZiM2Q3NjJhNzQ1YWE4MWQ3NzAzMjlmMDdjODMyL3RleHRyZWdpb246YmNlZmIzZDc2MmE3NDVhYTgxZDc3MDMyOWYwN2M4MzJfODU_e19ea87f-3f0d-43eb-bd0c-90554d83c884">22.8</ix:nonFraction>)&#160;million was recognized for the years ended December 31, 2021, 2020 and 2019, respectively.</span></div><div style="text-align:justify"><span><br/></span></div><ix:nonNumeric contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231" name="us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185Ny9mcmFnOmJjZWZiM2Q3NjJhNzQ1YWE4MWQ3NzAzMjlmMDdjODMyL3RleHRyZWdpb246YmNlZmIzZDc2MmE3NDVhYTgxZDc3MDMyOWYwN2M4MzJfODM5Mw_4ae3eb2e-09b5-4892-b204-5f485e27ec23" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our loss from continuing operations before income taxes was as follows (in thousands):</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"></td><td style="width:379.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:48.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:48.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:48.25pt"></td><td style="width:1.0pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Year Ended December 31,</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Domestic</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185Ny9mcmFnOmJjZWZiM2Q3NjJhNzQ1YWE4MWQ3NzAzMjlmMDdjODMyL3RhYmxlOjMwMTM2MmFmZTI2MDQ3NjJhMzVkMmEzOTc2YjY2ZDNmL3RhYmxlcmFuZ2U6MzAxMzYyYWZlMjYwNDc2MmEzNWQyYTM5NzZiNjZkM2ZfMi0xLTEtMS0xNzc3NQ_ee1dce95-a7e3-47dd-a00e-a019221e4f4f">32,719</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i12a6d1161de54547bd29f8efccd4c9b0_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185Ny9mcmFnOmJjZWZiM2Q3NjJhNzQ1YWE4MWQ3NzAzMjlmMDdjODMyL3RhYmxlOjMwMTM2MmFmZTI2MDQ3NjJhMzVkMmEzOTc2YjY2ZDNmL3RhYmxlcmFuZ2U6MzAxMzYyYWZlMjYwNDc2MmEzNWQyYTM5NzZiNjZkM2ZfMi0zLTEtMS0xNzc3NQ_501644f8-7559-4683-a1a6-17088de59d9e">332,373</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3e21049ffc224cacb8134d73c9bb5b38_D20190101-20191231" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185Ny9mcmFnOmJjZWZiM2Q3NjJhNzQ1YWE4MWQ3NzAzMjlmMDdjODMyL3RhYmxlOjMwMTM2MmFmZTI2MDQ3NjJhMzVkMmEzOTc2YjY2ZDNmL3RhYmxlcmFuZ2U6MzAxMzYyYWZlMjYwNDc2MmEzNWQyYTM5NzZiNjZkM2ZfMi01LTEtMS0xNzc3NQ_e6f0630f-7e20-4de7-ab8c-519fcdfa17c5">331,033</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231" decimals="-3" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185Ny9mcmFnOmJjZWZiM2Q3NjJhNzQ1YWE4MWQ3NzAzMjlmMDdjODMyL3RhYmxlOjMwMTM2MmFmZTI2MDQ3NjJhMzVkMmEzOTc2YjY2ZDNmL3RhYmxlcmFuZ2U6MzAxMzYyYWZlMjYwNDc2MmEzNWQyYTM5NzZiNjZkM2ZfMy0xLTEtMS0xNzc3NQ_529173ad-e123-4843-8cc9-93688900544a">2,918</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i12a6d1161de54547bd29f8efccd4c9b0_D20200101-20201231" decimals="-3" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185Ny9mcmFnOmJjZWZiM2Q3NjJhNzQ1YWE4MWQ3NzAzMjlmMDdjODMyL3RhYmxlOjMwMTM2MmFmZTI2MDQ3NjJhMzVkMmEzOTc2YjY2ZDNmL3RhYmxlcmFuZ2U6MzAxMzYyYWZlMjYwNDc2MmEzNWQyYTM5NzZiNjZkM2ZfMy0zLTEtMS0xNzc3NQ_62fbc22b-2eef-4345-a8bb-c0ab051088ae">1,833</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e21049ffc224cacb8134d73c9bb5b38_D20190101-20191231" decimals="-3" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185Ny9mcmFnOmJjZWZiM2Q3NjJhNzQ1YWE4MWQ3NzAzMjlmMDdjODMyL3RhYmxlOjMwMTM2MmFmZTI2MDQ3NjJhMzVkMmEzOTc2YjY2ZDNmL3RhYmxlcmFuZ2U6MzAxMzYyYWZlMjYwNDc2MmEzNWQyYTM5NzZiNjZkM2ZfMy01LTEtMS0xNzc3NQ_384822e2-a939-47c5-9595-9e8503a88189">1,045</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss from continuing operations before income taxes</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185Ny9mcmFnOmJjZWZiM2Q3NjJhNzQ1YWE4MWQ3NzAzMjlmMDdjODMyL3RhYmxlOjMwMTM2MmFmZTI2MDQ3NjJhMzVkMmEzOTc2YjY2ZDNmL3RhYmxlcmFuZ2U6MzAxMzYyYWZlMjYwNDc2MmEzNWQyYTM5NzZiNjZkM2ZfNC0xLTEtMS0xNzc3NQ_f51b3cda-8dc5-47ff-a1e1-ca147fb98040">29,801</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i12a6d1161de54547bd29f8efccd4c9b0_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185Ny9mcmFnOmJjZWZiM2Q3NjJhNzQ1YWE4MWQ3NzAzMjlmMDdjODMyL3RhYmxlOjMwMTM2MmFmZTI2MDQ3NjJhMzVkMmEzOTc2YjY2ZDNmL3RhYmxlcmFuZ2U6MzAxMzYyYWZlMjYwNDc2MmEzNWQyYTM5NzZiNjZkM2ZfNC0zLTEtMS0xNzc3NQ_9b4735a1-013e-4d6c-96fc-ac399319ada6">330,540</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3e21049ffc224cacb8134d73c9bb5b38_D20190101-20191231" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185Ny9mcmFnOmJjZWZiM2Q3NjJhNzQ1YWE4MWQ3NzAzMjlmMDdjODMyL3RhYmxlOjMwMTM2MmFmZTI2MDQ3NjJhMzVkMmEzOTc2YjY2ZDNmL3RhYmxlcmFuZ2U6MzAxMzYyYWZlMjYwNDc2MmEzNWQyYTM5NzZiNjZkM2ZfNC01LTEtMS0xNzc3NQ_ed5e04e2-1d31-46fe-8746-ff8255af990e">329,988</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">107</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span><br/></span></div><ix:continuation id="i5d07ae159c6b45e7b17dec99a06c344e" continuedAt="ia8deb40d96e94f219a281ad14ecb604f"><ix:nonNumeric contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231" name="us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185Ny9mcmFnOmJjZWZiM2Q3NjJhNzQ1YWE4MWQ3NzAzMjlmMDdjODMyL3RleHRyZWdpb246YmNlZmIzZDc2MmE3NDVhYTgxZDc3MDMyOWYwN2M4MzJfODQxNg_3902ee80-9b65-459f-b1db-8ee5e23887ce" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Components of income tax expense (benefit) (in thousands) consist of the following:</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"></td><td style="width:370.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:51.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:51.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:51.25pt"></td><td style="width:1.0pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Year Ended December 31,</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Current</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:CurrentFederalTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185Ny9mcmFnOmJjZWZiM2Q3NjJhNzQ1YWE4MWQ3NzAzMjlmMDdjODMyL3RhYmxlOmFmNmIxZTM1NzRiNzRiZjJhNTJhY2U3ZWRlZmQ1ZTc5L3RhYmxlcmFuZ2U6YWY2YjFlMzU3NGI3NGJmMmE1MmFjZTdlZGVmZDVlNzlfMy0xLTEtMS0xNzc3NQ_4ff6b9d7-d488-4586-b45b-0f84059eb702">1,469</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i12a6d1161de54547bd29f8efccd4c9b0_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:CurrentFederalTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185Ny9mcmFnOmJjZWZiM2Q3NjJhNzQ1YWE4MWQ3NzAzMjlmMDdjODMyL3RhYmxlOmFmNmIxZTM1NzRiNzRiZjJhNTJhY2U3ZWRlZmQ1ZTc5L3RhYmxlcmFuZ2U6YWY2YjFlMzU3NGI3NGJmMmE1MmFjZTdlZGVmZDVlNzlfMy0zLTEtMS0xNzc3NQ_27adb068-96da-4ec3-9541-c3c222942cd1">2,305</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e21049ffc224cacb8134d73c9bb5b38_D20190101-20191231" decimals="-3" name="us-gaap:CurrentFederalTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185Ny9mcmFnOmJjZWZiM2Q3NjJhNzQ1YWE4MWQ3NzAzMjlmMDdjODMyL3RhYmxlOmFmNmIxZTM1NzRiNzRiZjJhNTJhY2U3ZWRlZmQ1ZTc5L3RhYmxlcmFuZ2U6YWY2YjFlMzU3NGI3NGJmMmE1MmFjZTdlZGVmZDVlNzlfMy01LTEtMS0xNzc3NQ_ab85a099-cbfa-40c5-9966-1bf986b6687e">185</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State and local</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231" decimals="-3" name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185Ny9mcmFnOmJjZWZiM2Q3NjJhNzQ1YWE4MWQ3NzAzMjlmMDdjODMyL3RhYmxlOmFmNmIxZTM1NzRiNzRiZjJhNTJhY2U3ZWRlZmQ1ZTc5L3RhYmxlcmFuZ2U6YWY2YjFlMzU3NGI3NGJmMmE1MmFjZTdlZGVmZDVlNzlfNC0xLTEtMS0xNzc3NQ_c283e7b7-e766-462b-a202-b73060acba7b">1,449</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i12a6d1161de54547bd29f8efccd4c9b0_D20200101-20201231" decimals="-3" name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185Ny9mcmFnOmJjZWZiM2Q3NjJhNzQ1YWE4MWQ3NzAzMjlmMDdjODMyL3RhYmxlOmFmNmIxZTM1NzRiNzRiZjJhNTJhY2U3ZWRlZmQ1ZTc5L3RhYmxlcmFuZ2U6YWY2YjFlMzU3NGI3NGJmMmE1MmFjZTdlZGVmZDVlNzlfNC0zLTEtMS0xNzc3NQ_9b85e1f4-126d-43e8-98f2-9c26d7d7d9f2">200</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e21049ffc224cacb8134d73c9bb5b38_D20190101-20191231" decimals="-3" name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185Ny9mcmFnOmJjZWZiM2Q3NjJhNzQ1YWE4MWQ3NzAzMjlmMDdjODMyL3RhYmxlOmFmNmIxZTM1NzRiNzRiZjJhNTJhY2U3ZWRlZmQ1ZTc5L3RhYmxlcmFuZ2U6YWY2YjFlMzU3NGI3NGJmMmE1MmFjZTdlZGVmZDVlNzlfNC01LTEtMS0xNzc3NQ_bd30775d-717b-4f6a-afce-701630023e46">14</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231" decimals="-3" name="us-gaap:CurrentForeignTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185Ny9mcmFnOmJjZWZiM2Q3NjJhNzQ1YWE4MWQ3NzAzMjlmMDdjODMyL3RhYmxlOmFmNmIxZTM1NzRiNzRiZjJhNTJhY2U3ZWRlZmQ1ZTc5L3RhYmxlcmFuZ2U6YWY2YjFlMzU3NGI3NGJmMmE1MmFjZTdlZGVmZDVlNzlfNS0xLTEtMS0xNzc3NQ_ee403e3b-fcb1-4d07-b17b-0e0eada4abbf">1,027</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i12a6d1161de54547bd29f8efccd4c9b0_D20200101-20201231" decimals="-3" name="us-gaap:CurrentForeignTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185Ny9mcmFnOmJjZWZiM2Q3NjJhNzQ1YWE4MWQ3NzAzMjlmMDdjODMyL3RhYmxlOmFmNmIxZTM1NzRiNzRiZjJhNTJhY2U3ZWRlZmQ1ZTc5L3RhYmxlcmFuZ2U6YWY2YjFlMzU3NGI3NGJmMmE1MmFjZTdlZGVmZDVlNzlfNS0zLTEtMS0xNzc3NQ_c2725858-061d-4984-866b-6576f2e46e42">721</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e21049ffc224cacb8134d73c9bb5b38_D20190101-20191231" decimals="-3" name="us-gaap:CurrentForeignTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185Ny9mcmFnOmJjZWZiM2Q3NjJhNzQ1YWE4MWQ3NzAzMjlmMDdjODMyL3RhYmxlOmFmNmIxZTM1NzRiNzRiZjJhNTJhY2U3ZWRlZmQ1ZTc5L3RhYmxlcmFuZ2U6YWY2YjFlMzU3NGI3NGJmMmE1MmFjZTdlZGVmZDVlNzlfNS01LTEtMS0xNzc3NQ_ca627b61-8772-4e76-9201-4ba475c30ead">399</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current tax expense (benefit)</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231" decimals="-3" name="us-gaap:CurrentIncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185Ny9mcmFnOmJjZWZiM2Q3NjJhNzQ1YWE4MWQ3NzAzMjlmMDdjODMyL3RhYmxlOmFmNmIxZTM1NzRiNzRiZjJhNTJhY2U3ZWRlZmQ1ZTc5L3RhYmxlcmFuZ2U6YWY2YjFlMzU3NGI3NGJmMmE1MmFjZTdlZGVmZDVlNzlfNi0xLTEtMS0xNzc3NQ_4b6a7132-928d-4ea8-8379-07c049aed3ac">1,007</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i12a6d1161de54547bd29f8efccd4c9b0_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:CurrentIncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185Ny9mcmFnOmJjZWZiM2Q3NjJhNzQ1YWE4MWQ3NzAzMjlmMDdjODMyL3RhYmxlOmFmNmIxZTM1NzRiNzRiZjJhNTJhY2U3ZWRlZmQ1ZTc5L3RhYmxlcmFuZ2U6YWY2YjFlMzU3NGI3NGJmMmE1MmFjZTdlZGVmZDVlNzlfNi0zLTEtMS0xNzc3NQ_c2a54dbb-0286-4030-8d09-3fe6392cd7e6">1,384</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e21049ffc224cacb8134d73c9bb5b38_D20190101-20191231" decimals="-3" name="us-gaap:CurrentIncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185Ny9mcmFnOmJjZWZiM2Q3NjJhNzQ1YWE4MWQ3NzAzMjlmMDdjODMyL3RhYmxlOmFmNmIxZTM1NzRiNzRiZjJhNTJhY2U3ZWRlZmQ1ZTc5L3RhYmxlcmFuZ2U6YWY2YjFlMzU3NGI3NGJmMmE1MmFjZTdlZGVmZDVlNzlfNi01LTEtMS0xNzc3NQ_171cc2bc-ae1b-451f-ae98-e374b7ca13ea">598</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Deferred</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185Ny9mcmFnOmJjZWZiM2Q3NjJhNzQ1YWE4MWQ3NzAzMjlmMDdjODMyL3RhYmxlOmFmNmIxZTM1NzRiNzRiZjJhNTJhY2U3ZWRlZmQ1ZTc5L3RhYmxlcmFuZ2U6YWY2YjFlMzU3NGI3NGJmMmE1MmFjZTdlZGVmZDVlNzlfOC0xLTEtMS0xNzc3NQ_94548df7-1a65-4eed-913a-b0011a940580">5,866</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i12a6d1161de54547bd29f8efccd4c9b0_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185Ny9mcmFnOmJjZWZiM2Q3NjJhNzQ1YWE4MWQ3NzAzMjlmMDdjODMyL3RhYmxlOmFmNmIxZTM1NzRiNzRiZjJhNTJhY2U3ZWRlZmQ1ZTc5L3RhYmxlcmFuZ2U6YWY2YjFlMzU3NGI3NGJmMmE1MmFjZTdlZGVmZDVlNzlfOC0zLTEtMS0xNzc3NQ_4da7475c-1711-4826-a9be-c12bcd366b15">38,258</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3e21049ffc224cacb8134d73c9bb5b38_D20190101-20191231" decimals="-3" sign="-" name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185Ny9mcmFnOmJjZWZiM2Q3NjJhNzQ1YWE4MWQ3NzAzMjlmMDdjODMyL3RhYmxlOmFmNmIxZTM1NzRiNzRiZjJhNTJhY2U3ZWRlZmQ1ZTc5L3RhYmxlcmFuZ2U6YWY2YjFlMzU3NGI3NGJmMmE1MmFjZTdlZGVmZDVlNzlfOC01LTEtMS0xNzc3NQ_76a321d7-9510-4a2b-9bf3-4775e130009c">27,307</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State and local</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185Ny9mcmFnOmJjZWZiM2Q3NjJhNzQ1YWE4MWQ3NzAzMjlmMDdjODMyL3RhYmxlOmFmNmIxZTM1NzRiNzRiZjJhNTJhY2U3ZWRlZmQ1ZTc5L3RhYmxlcmFuZ2U6YWY2YjFlMzU3NGI3NGJmMmE1MmFjZTdlZGVmZDVlNzlfOS0xLTEtMS0xNzc3NQ_239b1e06-be14-443a-b4de-04272bd3a8d7">4,021</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i12a6d1161de54547bd29f8efccd4c9b0_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185Ny9mcmFnOmJjZWZiM2Q3NjJhNzQ1YWE4MWQ3NzAzMjlmMDdjODMyL3RhYmxlOmFmNmIxZTM1NzRiNzRiZjJhNTJhY2U3ZWRlZmQ1ZTc5L3RhYmxlcmFuZ2U6YWY2YjFlMzU3NGI3NGJmMmE1MmFjZTdlZGVmZDVlNzlfOS0zLTEtMS0xNzc3NQ_1a7a7288-6e16-4dc8-adcf-912bfc25646b">9,565</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3e21049ffc224cacb8134d73c9bb5b38_D20190101-20191231" decimals="-3" sign="-" name="us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185Ny9mcmFnOmJjZWZiM2Q3NjJhNzQ1YWE4MWQ3NzAzMjlmMDdjODMyL3RhYmxlOmFmNmIxZTM1NzRiNzRiZjJhNTJhY2U3ZWRlZmQ1ZTc5L3RhYmxlcmFuZ2U6YWY2YjFlMzU3NGI3NGJmMmE1MmFjZTdlZGVmZDVlNzlfOS01LTEtMS0xNzc3NQ_0b82ffd6-c64f-4b68-a20b-073de9687925">5,046</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:DeferredForeignIncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185Ny9mcmFnOmJjZWZiM2Q3NjJhNzQ1YWE4MWQ3NzAzMjlmMDdjODMyL3RhYmxlOmFmNmIxZTM1NzRiNzRiZjJhNTJhY2U3ZWRlZmQ1ZTc5L3RhYmxlcmFuZ2U6YWY2YjFlMzU3NGI3NGJmMmE1MmFjZTdlZGVmZDVlNzlfMTAtMS0xLTEtMTc3NzU_b3f81ffc-13ca-4ae1-9c55-c73228e3b9bc">493</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i12a6d1161de54547bd29f8efccd4c9b0_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:DeferredForeignIncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185Ny9mcmFnOmJjZWZiM2Q3NjJhNzQ1YWE4MWQ3NzAzMjlmMDdjODMyL3RhYmxlOmFmNmIxZTM1NzRiNzRiZjJhNTJhY2U3ZWRlZmQ1ZTc5L3RhYmxlcmFuZ2U6YWY2YjFlMzU3NGI3NGJmMmE1MmFjZTdlZGVmZDVlNzlfMTAtMy0xLTEtMTc3NzU_74f34817-749a-41b4-9318-ba5353ce4164">303</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e21049ffc224cacb8134d73c9bb5b38_D20190101-20191231" decimals="-3" name="us-gaap:DeferredForeignIncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185Ny9mcmFnOmJjZWZiM2Q3NjJhNzQ1YWE4MWQ3NzAzMjlmMDdjODMyL3RhYmxlOmFmNmIxZTM1NzRiNzRiZjJhNTJhY2U3ZWRlZmQ1ZTc5L3RhYmxlcmFuZ2U6YWY2YjFlMzU3NGI3NGJmMmE1MmFjZTdlZGVmZDVlNzlfMTAtNS0xLTEtMTc3NzU_6bd562ed-aefd-4ccf-80b8-01bd68563fdf">6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred tax expense (benefit)</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:DeferredIncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185Ny9mcmFnOmJjZWZiM2Q3NjJhNzQ1YWE4MWQ3NzAzMjlmMDdjODMyL3RhYmxlOmFmNmIxZTM1NzRiNzRiZjJhNTJhY2U3ZWRlZmQ1ZTc5L3RhYmxlcmFuZ2U6YWY2YjFlMzU3NGI3NGJmMmE1MmFjZTdlZGVmZDVlNzlfMTEtMS0xLTEtMTc3NzU_4061a531-513c-431e-891a-6403cc95c659">10,380</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i12a6d1161de54547bd29f8efccd4c9b0_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:DeferredIncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185Ny9mcmFnOmJjZWZiM2Q3NjJhNzQ1YWE4MWQ3NzAzMjlmMDdjODMyL3RhYmxlOmFmNmIxZTM1NzRiNzRiZjJhNTJhY2U3ZWRlZmQ1ZTc5L3RhYmxlcmFuZ2U6YWY2YjFlMzU3NGI3NGJmMmE1MmFjZTdlZGVmZDVlNzlfMTEtMy0xLTEtMTc3NzU_537b3432-c099-49bd-8e73-a3f07806747e">48,126</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3e21049ffc224cacb8134d73c9bb5b38_D20190101-20191231" decimals="-3" sign="-" name="us-gaap:DeferredIncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185Ny9mcmFnOmJjZWZiM2Q3NjJhNzQ1YWE4MWQ3NzAzMjlmMDdjODMyL3RhYmxlOmFmNmIxZTM1NzRiNzRiZjJhNTJhY2U3ZWRlZmQ1ZTc5L3RhYmxlcmFuZ2U6YWY2YjFlMzU3NGI3NGJmMmE1MmFjZTdlZGVmZDVlNzlfMTEtNS0xLTEtMTc3NzU_3a04a49d-b36a-41a9-9ee0-0a9d9a21198c">32,347</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in valuation allowance</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231" decimals="-3" name="us-gaap:DeferredOtherTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185Ny9mcmFnOmJjZWZiM2Q3NjJhNzQ1YWE4MWQ3NzAzMjlmMDdjODMyL3RhYmxlOmFmNmIxZTM1NzRiNzRiZjJhNTJhY2U3ZWRlZmQ1ZTc5L3RhYmxlcmFuZ2U6YWY2YjFlMzU3NGI3NGJmMmE1MmFjZTdlZGVmZDVlNzlfMTItMS0xLTEtMTc3NzU_116be16f-3da5-4b46-83d8-2287602fd523">9,856</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i12a6d1161de54547bd29f8efccd4c9b0_D20200101-20201231" decimals="-3" name="us-gaap:DeferredOtherTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185Ny9mcmFnOmJjZWZiM2Q3NjJhNzQ1YWE4MWQ3NzAzMjlmMDdjODMyL3RhYmxlOmFmNmIxZTM1NzRiNzRiZjJhNTJhY2U3ZWRlZmQ1ZTc5L3RhYmxlcmFuZ2U6YWY2YjFlMzU3NGI3NGJmMmE1MmFjZTdlZGVmZDVlNzlfMTItMy0xLTEtMTc3NzU_845eb640-5498-4d70-9492-104aaddac834">47,142</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e21049ffc224cacb8134d73c9bb5b38_D20190101-20191231" decimals="-3" name="us-gaap:DeferredOtherTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185Ny9mcmFnOmJjZWZiM2Q3NjJhNzQ1YWE4MWQ3NzAzMjlmMDdjODMyL3RhYmxlOmFmNmIxZTM1NzRiNzRiZjJhNTJhY2U3ZWRlZmQ1ZTc5L3RhYmxlcmFuZ2U6YWY2YjFlMzU3NGI3NGJmMmE1MmFjZTdlZGVmZDVlNzlfMTItNS0xLTEtMTc3NzU_95c6eb65-35a5-4760-870c-e3359db0f0a6">8,954</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total tax expense (benefit)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185Ny9mcmFnOmJjZWZiM2Q3NjJhNzQ1YWE4MWQ3NzAzMjlmMDdjODMyL3RhYmxlOmFmNmIxZTM1NzRiNzRiZjJhNTJhY2U3ZWRlZmQ1ZTc5L3RhYmxlcmFuZ2U6YWY2YjFlMzU3NGI3NGJmMmE1MmFjZTdlZGVmZDVlNzlfMTMtMS0xLTEtMTc3NzU_ea01165c-4b03-4ab0-abac-8b1a64467874">483</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i12a6d1161de54547bd29f8efccd4c9b0_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185Ny9mcmFnOmJjZWZiM2Q3NjJhNzQ1YWE4MWQ3NzAzMjlmMDdjODMyL3RhYmxlOmFmNmIxZTM1NzRiNzRiZjJhNTJhY2U3ZWRlZmQ1ZTc5L3RhYmxlcmFuZ2U6YWY2YjFlMzU3NGI3NGJmMmE1MmFjZTdlZGVmZDVlNzlfMTMtMy0xLTEtMTc3NzU_bde8faf1-daff-42c1-b62b-631722218c31">2,368</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3e21049ffc224cacb8134d73c9bb5b38_D20190101-20191231" decimals="-3" sign="-" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185Ny9mcmFnOmJjZWZiM2Q3NjJhNzQ1YWE4MWQ3NzAzMjlmMDdjODMyL3RhYmxlOmFmNmIxZTM1NzRiNzRiZjJhNTJhY2U3ZWRlZmQ1ZTc5L3RhYmxlcmFuZ2U6YWY2YjFlMzU3NGI3NGJmMmE1MmFjZTdlZGVmZDVlNzlfMTMtNS0xLTEtMTc3NzU_7fec7fd2-fa7e-4d03-8164-8277296044b0">22,795</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="text-align:justify"><span><br/></span></div><ix:nonNumeric contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231" name="us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185Ny9mcmFnOmJjZWZiM2Q3NjJhNzQ1YWE4MWQ3NzAzMjlmMDdjODMyL3RleHRyZWdpb246YmNlZmIzZDc2MmE3NDVhYTgxZDc3MDMyOWYwN2M4MzJfODM5MA_c9e87cf6-fa8f-4f9b-9778-8adb21a689d0" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">A reconciliation of the U.S. statutory tax rate to our effective tax rate is presented below:</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"></td><td style="width:379.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:48.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:48.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:48.25pt"></td><td style="width:1.0pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Year Ended December 31,</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. statutory tax rate</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231" decimals="INF" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185Ny9mcmFnOmJjZWZiM2Q3NjJhNzQ1YWE4MWQ3NzAzMjlmMDdjODMyL3RhYmxlOjFjNjIwNTBlMDM2MjQyZTJhZTQyNmMwYWQ4ZWRiMjYxL3RhYmxlcmFuZ2U6MWM2MjA1MGUwMzYyNDJlMmFlNDI2YzBhZDhlZGIyNjFfMi0xLTEtMS0xNzc3NQ_7e07d0d0-a9ac-4e6d-8243-c9ec7de6abcc">21.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i12a6d1161de54547bd29f8efccd4c9b0_D20200101-20201231" decimals="INF" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185Ny9mcmFnOmJjZWZiM2Q3NjJhNzQ1YWE4MWQ3NzAzMjlmMDdjODMyL3RhYmxlOjFjNjIwNTBlMDM2MjQyZTJhZTQyNmMwYWQ4ZWRiMjYxL3RhYmxlcmFuZ2U6MWM2MjA1MGUwMzYyNDJlMmFlNDI2YzBhZDhlZGIyNjFfMi0zLTEtMS0xNzc3NQ_d268baca-4be7-4d5c-b04b-38a296e9a178">21.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i3e21049ffc224cacb8134d73c9bb5b38_D20190101-20191231" decimals="INF" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185Ny9mcmFnOmJjZWZiM2Q3NjJhNzQ1YWE4MWQ3NzAzMjlmMDdjODMyL3RhYmxlOjFjNjIwNTBlMDM2MjQyZTJhZTQyNmMwYWQ4ZWRiMjYxL3RhYmxlcmFuZ2U6MWM2MjA1MGUwMzYyNDJlMmFlNDI2YzBhZDhlZGIyNjFfMi01LTEtMS0xNzc3NQ_9bc11fa7-29ad-49fb-9416-2387750a824d">21.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. state income taxes, net of U.S. federal tax benefit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185Ny9mcmFnOmJjZWZiM2Q3NjJhNzQ1YWE4MWQ3NzAzMjlmMDdjODMyL3RhYmxlOjFjNjIwNTBlMDM2MjQyZTJhZTQyNmMwYWQ4ZWRiMjYxL3RhYmxlcmFuZ2U6MWM2MjA1MGUwMzYyNDJlMmFlNDI2YzBhZDhlZGIyNjFfMy0xLTEtMS0xNzc3NQ_ad124ab6-b4ac-42c0-9656-a02308155ea8">1.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i12a6d1161de54547bd29f8efccd4c9b0_D20200101-20201231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185Ny9mcmFnOmJjZWZiM2Q3NjJhNzQ1YWE4MWQ3NzAzMjlmMDdjODMyL3RhYmxlOjFjNjIwNTBlMDM2MjQyZTJhZTQyNmMwYWQ4ZWRiMjYxL3RhYmxlcmFuZ2U6MWM2MjA1MGUwMzYyNDJlMmFlNDI2YzBhZDhlZGIyNjFfMy0zLTEtMS0xNzc3NQ_3c3ebcb7-d09f-4856-b28c-704f5630c64c">2.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i3e21049ffc224cacb8134d73c9bb5b38_D20190101-20191231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185Ny9mcmFnOmJjZWZiM2Q3NjJhNzQ1YWE4MWQ3NzAzMjlmMDdjODMyL3RhYmxlOjFjNjIwNTBlMDM2MjQyZTJhZTQyNmMwYWQ4ZWRiMjYxL3RhYmxlcmFuZ2U6MWM2MjA1MGUwMzYyNDJlMmFlNDI2YzBhZDhlZGIyNjFfMy01LTEtMS0xNzc3NQ_1825b587-4d40-47ba-8842-38918e37dbac">5.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign earnings at other than U.S. rates</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185Ny9mcmFnOmJjZWZiM2Q3NjJhNzQ1YWE4MWQ3NzAzMjlmMDdjODMyL3RhYmxlOjFjNjIwNTBlMDM2MjQyZTJhZTQyNmMwYWQ4ZWRiMjYxL3RhYmxlcmFuZ2U6MWM2MjA1MGUwMzYyNDJlMmFlNDI2YzBhZDhlZGIyNjFfNC0xLTEtMS0xNzc3NQ_eb4ce263-1828-4cf5-a56f-2fca4174a8af">0.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i12a6d1161de54547bd29f8efccd4c9b0_D20200101-20201231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185Ny9mcmFnOmJjZWZiM2Q3NjJhNzQ1YWE4MWQ3NzAzMjlmMDdjODMyL3RhYmxlOjFjNjIwNTBlMDM2MjQyZTJhZTQyNmMwYWQ4ZWRiMjYxL3RhYmxlcmFuZ2U6MWM2MjA1MGUwMzYyNDJlMmFlNDI2YzBhZDhlZGIyNjFfNC0zLTEtMS0xNzc3NQ_4ce20ee6-fb2c-4e4a-9ac2-078615280713">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i3e21049ffc224cacb8134d73c9bb5b38_D20190101-20191231" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185Ny9mcmFnOmJjZWZiM2Q3NjJhNzQ1YWE4MWQ3NzAzMjlmMDdjODMyL3RhYmxlOjFjNjIwNTBlMDM2MjQyZTJhZTQyNmMwYWQ4ZWRiMjYxL3RhYmxlcmFuZ2U6MWM2MjA1MGUwMzYyNDJlMmFlNDI2YzBhZDhlZGIyNjFfNC01LTEtMS0xNzc3NQ_b7230dc3-6548-49d5-8d18-70d4ffd2f805">0.1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in valuation allowance</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185Ny9mcmFnOmJjZWZiM2Q3NjJhNzQ1YWE4MWQ3NzAzMjlmMDdjODMyL3RhYmxlOjFjNjIwNTBlMDM2MjQyZTJhZTQyNmMwYWQ4ZWRiMjYxL3RhYmxlcmFuZ2U6MWM2MjA1MGUwMzYyNDJlMmFlNDI2YzBhZDhlZGIyNjFfNS0xLTEtMS0xNzc3NQ_ffc08c4b-5929-45ad-86b4-3e50e96e6258">33.1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i12a6d1161de54547bd29f8efccd4c9b0_D20200101-20201231" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185Ny9mcmFnOmJjZWZiM2Q3NjJhNzQ1YWE4MWQ3NzAzMjlmMDdjODMyL3RhYmxlOjFjNjIwNTBlMDM2MjQyZTJhZTQyNmMwYWQ4ZWRiMjYxL3RhYmxlcmFuZ2U6MWM2MjA1MGUwMzYyNDJlMmFlNDI2YzBhZDhlZGIyNjFfNS0zLTEtMS0xNzc3NQ_d0fa82d8-0897-40bb-ae5f-1ccc20bab5a9">14.3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i3e21049ffc224cacb8134d73c9bb5b38_D20190101-20191231" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185Ny9mcmFnOmJjZWZiM2Q3NjJhNzQ1YWE4MWQ3NzAzMjlmMDdjODMyL3RhYmxlOjFjNjIwNTBlMDM2MjQyZTJhZTQyNmMwYWQ4ZWRiMjYxL3RhYmxlcmFuZ2U6MWM2MjA1MGUwMzYyNDJlMmFlNDI2YzBhZDhlZGIyNjFfNS01LTEtMS0xNzc3NQ_9fa7d237-3f12-49d3-ac3e-3be604d724e3">2.7</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Benefit of net operating loss carryback provision</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231" decimals="3" name="evh:EffectiveIncomeTaxRateReconciliationBenefitOfNetOperatingLossCarrybackProvisionPercent" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185Ny9mcmFnOmJjZWZiM2Q3NjJhNzQ1YWE4MWQ3NzAzMjlmMDdjODMyL3RhYmxlOjFjNjIwNTBlMDM2MjQyZTJhZTQyNmMwYWQ4ZWRiMjYxL3RhYmxlcmFuZ2U6MWM2MjA1MGUwMzYyNDJlMmFlNDI2YzBhZDhlZGIyNjFfNi0xLTEtMS0xNzc3NQ_8722de9a-6b35-40d4-921a-8fe54a54d9b3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i12a6d1161de54547bd29f8efccd4c9b0_D20200101-20201231" decimals="3" name="evh:EffectiveIncomeTaxRateReconciliationBenefitOfNetOperatingLossCarrybackProvisionPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185Ny9mcmFnOmJjZWZiM2Q3NjJhNzQ1YWE4MWQ3NzAzMjlmMDdjODMyL3RhYmxlOjFjNjIwNTBlMDM2MjQyZTJhZTQyNmMwYWQ4ZWRiMjYxL3RhYmxlcmFuZ2U6MWM2MjA1MGUwMzYyNDJlMmFlNDI2YzBhZDhlZGIyNjFfNi0zLTEtMS0xNzc3NQ_e0421eab-683a-4e63-b456-76b5a47a3243">1.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i3e21049ffc224cacb8134d73c9bb5b38_D20190101-20191231" decimals="3" name="evh:EffectiveIncomeTaxRateReconciliationBenefitOfNetOperatingLossCarrybackProvisionPercent" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185Ny9mcmFnOmJjZWZiM2Q3NjJhNzQ1YWE4MWQ3NzAzMjlmMDdjODMyL3RhYmxlOjFjNjIwNTBlMDM2MjQyZTJhZTQyNmMwYWQ4ZWRiMjYxL3RhYmxlcmFuZ2U6MWM2MjA1MGUwMzYyNDJlMmFlNDI2YzBhZDhlZGIyNjFfNi01LTEtMS0xNzc3NQ_869ef70f-2913-4ba1-9e9a-c562c337046e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-deductible goodwill impairment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185Ny9mcmFnOmJjZWZiM2Q3NjJhNzQ1YWE4MWQ3NzAzMjlmMDdjODMyL3RhYmxlOjFjNjIwNTBlMDM2MjQyZTJhZTQyNmMwYWQ4ZWRiMjYxL3RhYmxlcmFuZ2U6MWM2MjA1MGUwMzYyNDJlMmFlNDI2YzBhZDhlZGIyNjFfNy0xLTEtMS0xNzc3NQ_aac890e7-caac-4f2f-bfa1-a39eb9b0e113">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i12a6d1161de54547bd29f8efccd4c9b0_D20200101-20201231" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185Ny9mcmFnOmJjZWZiM2Q3NjJhNzQ1YWE4MWQ3NzAzMjlmMDdjODMyL3RhYmxlOjFjNjIwNTBlMDM2MjQyZTJhZTQyNmMwYWQ4ZWRiMjYxL3RhYmxlcmFuZ2U6MWM2MjA1MGUwMzYyNDJlMmFlNDI2YzBhZDhlZGIyNjFfNy0zLTEtMS0xNzc3NQ_05a1205f-b3fa-47e1-b0cf-bc7c17e9424e">11.5</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i3e21049ffc224cacb8134d73c9bb5b38_D20190101-20191231" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185Ny9mcmFnOmJjZWZiM2Q3NjJhNzQ1YWE4MWQ3NzAzMjlmMDdjODMyL3RhYmxlOjFjNjIwNTBlMDM2MjQyZTJhZTQyNmMwYWQ4ZWRiMjYxL3RhYmxlcmFuZ2U6MWM2MjA1MGUwMzYyNDJlMmFlNDI2YzBhZDhlZGIyNjFfNy01LTEtMS0xNzc3NQ_d09f473b-8fbd-4aa1-9f2c-5fd0e516355a">15.6</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-controlling interest</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationMinorityInterestIncomeExpense" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185Ny9mcmFnOmJjZWZiM2Q3NjJhNzQ1YWE4MWQ3NzAzMjlmMDdjODMyL3RhYmxlOjFjNjIwNTBlMDM2MjQyZTJhZTQyNmMwYWQ4ZWRiMjYxL3RhYmxlcmFuZ2U6MWM2MjA1MGUwMzYyNDJlMmFlNDI2YzBhZDhlZGIyNjFfOC0xLTEtMS0xNzc3NQ_3e034782-8fad-4a7d-a66f-109a40987a1f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i12a6d1161de54547bd29f8efccd4c9b0_D20200101-20201231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationMinorityInterestIncomeExpense" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185Ny9mcmFnOmJjZWZiM2Q3NjJhNzQ1YWE4MWQ3NzAzMjlmMDdjODMyL3RhYmxlOjFjNjIwNTBlMDM2MjQyZTJhZTQyNmMwYWQ4ZWRiMjYxL3RhYmxlcmFuZ2U6MWM2MjA1MGUwMzYyNDJlMmFlNDI2YzBhZDhlZGIyNjFfOC0zLTEtMS0xNzc3NQ_63df89bc-ee39-45f1-960d-34610d8cf575">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i3e21049ffc224cacb8134d73c9bb5b38_D20190101-20191231" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationMinorityInterestIncomeExpense" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185Ny9mcmFnOmJjZWZiM2Q3NjJhNzQ1YWE4MWQ3NzAzMjlmMDdjODMyL3RhYmxlOjFjNjIwNTBlMDM2MjQyZTJhZTQyNmMwYWQ4ZWRiMjYxL3RhYmxlcmFuZ2U6MWM2MjA1MGUwMzYyNDJlMmFlNDI2YzBhZDhlZGIyNjFfOC01LTEtMS0xNzc3NQ_a0cf74e9-d621-45c5-86aa-a86f2e72a924">0.3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nondeductible excess compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231" decimals="3" sign="-" name="evh:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseExcessCompensationPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185Ny9mcmFnOmJjZWZiM2Q3NjJhNzQ1YWE4MWQ3NzAzMjlmMDdjODMyL3RhYmxlOjFjNjIwNTBlMDM2MjQyZTJhZTQyNmMwYWQ4ZWRiMjYxL3RhYmxlcmFuZ2U6MWM2MjA1MGUwMzYyNDJlMmFlNDI2YzBhZDhlZGIyNjFfOS0xLTEtMS0yODkwNw_9351aeaf-11b1-41bf-97da-74aa5d913203">10.1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i12a6d1161de54547bd29f8efccd4c9b0_D20200101-20201231" decimals="3" sign="-" name="evh:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseExcessCompensationPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185Ny9mcmFnOmJjZWZiM2Q3NjJhNzQ1YWE4MWQ3NzAzMjlmMDdjODMyL3RhYmxlOjFjNjIwNTBlMDM2MjQyZTJhZTQyNmMwYWQ4ZWRiMjYxL3RhYmxlcmFuZ2U6MWM2MjA1MGUwMzYyNDJlMmFlNDI2YzBhZDhlZGIyNjFfOS0zLTEtMS0yODkwNw_f0755301-e049-42d0-8b26-b3937494dcb3">0.3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i3e21049ffc224cacb8134d73c9bb5b38_D20190101-20191231" decimals="3" sign="-" name="evh:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseExcessCompensationPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185Ny9mcmFnOmJjZWZiM2Q3NjJhNzQ1YWE4MWQ3NzAzMjlmMDdjODMyL3RhYmxlOjFjNjIwNTBlMDM2MjQyZTJhZTQyNmMwYWQ4ZWRiMjYxL3RhYmxlcmFuZ2U6MWM2MjA1MGUwMzYyNDJlMmFlNDI2YzBhZDhlZGIyNjFfOS01LTEtMS0yODkwNw_4236c03c-a1cb-4e10-90f4-4ac4b853694a">0.5</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Excess tax benefits (shortfalls) on stock-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185Ny9mcmFnOmJjZWZiM2Q3NjJhNzQ1YWE4MWQ3NzAzMjlmMDdjODMyL3RhYmxlOjFjNjIwNTBlMDM2MjQyZTJhZTQyNmMwYWQ4ZWRiMjYxL3RhYmxlcmFuZ2U6MWM2MjA1MGUwMzYyNDJlMmFlNDI2YzBhZDhlZGIyNjFfOS0xLTEtMS0xNzc3NQ_e0056ae3-7b40-4c43-a5c4-c85e335a16d1">8.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i12a6d1161de54547bd29f8efccd4c9b0_D20200101-20201231" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185Ny9mcmFnOmJjZWZiM2Q3NjJhNzQ1YWE4MWQ3NzAzMjlmMDdjODMyL3RhYmxlOjFjNjIwNTBlMDM2MjQyZTJhZTQyNmMwYWQ4ZWRiMjYxL3RhYmxlcmFuZ2U6MWM2MjA1MGUwMzYyNDJlMmFlNDI2YzBhZDhlZGIyNjFfOS0zLTEtMS0xNzc3NQ_54d051d2-5d91-48c4-a12a-df1c60f77a77">0.3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i3e21049ffc224cacb8134d73c9bb5b38_D20190101-20191231" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185Ny9mcmFnOmJjZWZiM2Q3NjJhNzQ1YWE4MWQ3NzAzMjlmMDdjODMyL3RhYmxlOjFjNjIwNTBlMDM2MjQyZTJhZTQyNmMwYWQ4ZWRiMjYxL3RhYmxlcmFuZ2U6MWM2MjA1MGUwMzYyNDJlMmFlNDI2YzBhZDhlZGIyNjFfOS01LTEtMS0xNzc3NQ_f67913d3-cedb-463b-9c82-b794cf0c22ee">0.2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Convertible debt extinguishment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185Ny9mcmFnOmJjZWZiM2Q3NjJhNzQ1YWE4MWQ3NzAzMjlmMDdjODMyL3RhYmxlOjFjNjIwNTBlMDM2MjQyZTJhZTQyNmMwYWQ4ZWRiMjYxL3RhYmxlcmFuZ2U6MWM2MjA1MGUwMzYyNDJlMmFlNDI2YzBhZDhlZGIyNjFfMTAtMS0xLTEtMTc3NzU_2ff66b18-56a1-434e-997e-d51618be3e00">1.5</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i12a6d1161de54547bd29f8efccd4c9b0_D20200101-20201231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185Ny9mcmFnOmJjZWZiM2Q3NjJhNzQ1YWE4MWQ3NzAzMjlmMDdjODMyL3RhYmxlOjFjNjIwNTBlMDM2MjQyZTJhZTQyNmMwYWQ4ZWRiMjYxL3RhYmxlcmFuZ2U6MWM2MjA1MGUwMzYyNDJlMmFlNDI2YzBhZDhlZGIyNjFfMTAtMy0xLTEtMTc3NzU_4d7b261c-4d42-4a9c-9610-5e8e229a5987">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i3e21049ffc224cacb8134d73c9bb5b38_D20190101-20191231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185Ny9mcmFnOmJjZWZiM2Q3NjJhNzQ1YWE4MWQ3NzAzMjlmMDdjODMyL3RhYmxlOjFjNjIwNTBlMDM2MjQyZTJhZTQyNmMwYWQ4ZWRiMjYxL3RhYmxlcmFuZ2U6MWM2MjA1MGUwMzYyNDJlMmFlNDI2YzBhZDhlZGIyNjFfMTAtNS0xLTEtMTc3NzU_e407e726-23af-4c8a-99e2-72c108e8895c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in uncertain tax positions</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231" decimals="3" name="evh:EffectiveIncomeTaxRateReconciliationChangeInUncertainTaxPositions" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185Ny9mcmFnOmJjZWZiM2Q3NjJhNzQ1YWE4MWQ3NzAzMjlmMDdjODMyL3RhYmxlOjFjNjIwNTBlMDM2MjQyZTJhZTQyNmMwYWQ4ZWRiMjYxL3RhYmxlcmFuZ2U6MWM2MjA1MGUwMzYyNDJlMmFlNDI2YzBhZDhlZGIyNjFfMTEtMS0xLTEtMTc3NzU_77a054ac-208b-4e11-97de-ea9da957cb24">0.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i12a6d1161de54547bd29f8efccd4c9b0_D20200101-20201231" decimals="3" name="evh:EffectiveIncomeTaxRateReconciliationChangeInUncertainTaxPositions" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185Ny9mcmFnOmJjZWZiM2Q3NjJhNzQ1YWE4MWQ3NzAzMjlmMDdjODMyL3RhYmxlOjFjNjIwNTBlMDM2MjQyZTJhZTQyNmMwYWQ4ZWRiMjYxL3RhYmxlcmFuZ2U6MWM2MjA1MGUwMzYyNDJlMmFlNDI2YzBhZDhlZGIyNjFfMTEtMy0xLTEtMTc3NzU_29b8a55f-7e1b-4398-8b32-b18e531344c4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i3e21049ffc224cacb8134d73c9bb5b38_D20190101-20191231" decimals="3" name="evh:EffectiveIncomeTaxRateReconciliationChangeInUncertainTaxPositions" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185Ny9mcmFnOmJjZWZiM2Q3NjJhNzQ1YWE4MWQ3NzAzMjlmMDdjODMyL3RhYmxlOjFjNjIwNTBlMDM2MjQyZTJhZTQyNmMwYWQ4ZWRiMjYxL3RhYmxlcmFuZ2U6MWM2MjA1MGUwMzYyNDJlMmFlNDI2YzBhZDhlZGIyNjFfMTEtNS0xLTEtMTc3NzU_33bb9e84-65ed-4740-b3fc-66a3b9713cfc">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nontaxable earnout</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231" decimals="3" name="evh:EffectiveIncomeTaxRateReconciliationEffectOfInvestment" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185Ny9mcmFnOmJjZWZiM2Q3NjJhNzQ1YWE4MWQ3NzAzMjlmMDdjODMyL3RhYmxlOjFjNjIwNTBlMDM2MjQyZTJhZTQyNmMwYWQ4ZWRiMjYxL3RhYmxlcmFuZ2U6MWM2MjA1MGUwMzYyNDJlMmFlNDI2YzBhZDhlZGIyNjFfMTItMS0xLTEtMTc3NzU_30d33f94-b711-476b-95f9-7b27d2d5b88e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i12a6d1161de54547bd29f8efccd4c9b0_D20200101-20201231" decimals="3" name="evh:EffectiveIncomeTaxRateReconciliationEffectOfInvestment" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185Ny9mcmFnOmJjZWZiM2Q3NjJhNzQ1YWE4MWQ3NzAzMjlmMDdjODMyL3RhYmxlOjFjNjIwNTBlMDM2MjQyZTJhZTQyNmMwYWQ4ZWRiMjYxL3RhYmxlcmFuZ2U6MWM2MjA1MGUwMzYyNDJlMmFlNDI2YzBhZDhlZGIyNjFfMTItMy0xLTEtMTc3NzU_f1d68dd5-2e8c-4dc7-9b07-830a4e7f47d5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i3e21049ffc224cacb8134d73c9bb5b38_D20190101-20191231" decimals="3" sign="-" name="evh:EffectiveIncomeTaxRateReconciliationEffectOfInvestment" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185Ny9mcmFnOmJjZWZiM2Q3NjJhNzQ1YWE4MWQ3NzAzMjlmMDdjODMyL3RhYmxlOjFjNjIwNTBlMDM2MjQyZTJhZTQyNmMwYWQ4ZWRiMjYxL3RhYmxlcmFuZ2U6MWM2MjA1MGUwMzYyNDJlMmFlNDI2YzBhZDhlZGIyNjFfMTItNS0xLTEtMTc3NzU_2a04c1fe-a070-42b9-8b53-c1eabc2df770">1.4</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in state rate</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185Ny9mcmFnOmJjZWZiM2Q3NjJhNzQ1YWE4MWQ3NzAzMjlmMDdjODMyL3RhYmxlOjFjNjIwNTBlMDM2MjQyZTJhZTQyNmMwYWQ4ZWRiMjYxL3RhYmxlcmFuZ2U6MWM2MjA1MGUwMzYyNDJlMmFlNDI2YzBhZDhlZGIyNjFfMTMtMS0xLTEtMTc3NzU_e0efa387-f0be-4943-8cab-d16db4effcca">6.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i12a6d1161de54547bd29f8efccd4c9b0_D20200101-20201231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185Ny9mcmFnOmJjZWZiM2Q3NjJhNzQ1YWE4MWQ3NzAzMjlmMDdjODMyL3RhYmxlOjFjNjIwNTBlMDM2MjQyZTJhZTQyNmMwYWQ4ZWRiMjYxL3RhYmxlcmFuZ2U6MWM2MjA1MGUwMzYyNDJlMmFlNDI2YzBhZDhlZGIyNjFfMTMtMy0xLTEtMTc3NzU_36c66402-f213-4afa-94be-c6012a30b679">1.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i3e21049ffc224cacb8134d73c9bb5b38_D20190101-20191231" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185Ny9mcmFnOmJjZWZiM2Q3NjJhNzQ1YWE4MWQ3NzAzMjlmMDdjODMyL3RhYmxlOjFjNjIwNTBlMDM2MjQyZTJhZTQyNmMwYWQ4ZWRiMjYxL3RhYmxlcmFuZ2U6MWM2MjA1MGUwMzYyNDJlMmFlNDI2YzBhZDhlZGIyNjFfMTMtNS0xLTEtMTc3NzU_026b59f5-3cdb-4b1b-80f6-35cc7c2b0249">0.7</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Return to provision</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231" decimals="3" name="evh:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseReturnToProvisionPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185Ny9mcmFnOmJjZWZiM2Q3NjJhNzQ1YWE4MWQ3NzAzMjlmMDdjODMyL3RhYmxlOjFjNjIwNTBlMDM2MjQyZTJhZTQyNmMwYWQ4ZWRiMjYxL3RhYmxlcmFuZ2U6MWM2MjA1MGUwMzYyNDJlMmFlNDI2YzBhZDhlZGIyNjFfMTQtMS0xLTEtMjg4ODE_f182f40a-4a5c-42da-9f0e-f2af441aecc7">6.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i12a6d1161de54547bd29f8efccd4c9b0_D20200101-20201231" decimals="3" sign="-" name="evh:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseReturnToProvisionPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185Ny9mcmFnOmJjZWZiM2Q3NjJhNzQ1YWE4MWQ3NzAzMjlmMDdjODMyL3RhYmxlOjFjNjIwNTBlMDM2MjQyZTJhZTQyNmMwYWQ4ZWRiMjYxL3RhYmxlcmFuZ2U6MWM2MjA1MGUwMzYyNDJlMmFlNDI2YzBhZDhlZGIyNjFfMTQtMy0xLTEtMjg4ODE_1e325454-6708-4e8f-a23f-893f87681c4d">0.8</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i3e21049ffc224cacb8134d73c9bb5b38_D20190101-20191231" decimals="3" name="evh:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseReturnToProvisionPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185Ny9mcmFnOmJjZWZiM2Q3NjJhNzQ1YWE4MWQ3NzAzMjlmMDdjODMyL3RhYmxlOjFjNjIwNTBlMDM2MjQyZTJhZTQyNmMwYWQ4ZWRiMjYxL3RhYmxlcmFuZ2U6MWM2MjA1MGUwMzYyNDJlMmFlNDI2YzBhZDhlZGIyNjFfMTQtNS0xLTEtMjg4ODE_eba1d607-255c-45d4-86dd-e9560c9e18b8">1.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in indefinite reinvestment assertion for domestic subsidiaries </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231" decimals="3" name="evh:EffectiveIncomeTaxRateReconciliationDomesticSubsidiaryException" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185Ny9mcmFnOmJjZWZiM2Q3NjJhNzQ1YWE4MWQ3NzAzMjlmMDdjODMyL3RhYmxlOjFjNjIwNTBlMDM2MjQyZTJhZTQyNmMwYWQ4ZWRiMjYxL3RhYmxlcmFuZ2U6MWM2MjA1MGUwMzYyNDJlMmFlNDI2YzBhZDhlZGIyNjFfMTQtMS0xLTEtMTc3NzU_26378fa5-2f49-40f1-9a14-4567411330dd">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i12a6d1161de54547bd29f8efccd4c9b0_D20200101-20201231" decimals="3" name="evh:EffectiveIncomeTaxRateReconciliationDomesticSubsidiaryException" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185Ny9mcmFnOmJjZWZiM2Q3NjJhNzQ1YWE4MWQ3NzAzMjlmMDdjODMyL3RhYmxlOjFjNjIwNTBlMDM2MjQyZTJhZTQyNmMwYWQ4ZWRiMjYxL3RhYmxlcmFuZ2U6MWM2MjA1MGUwMzYyNDJlMmFlNDI2YzBhZDhlZGIyNjFfMTQtMy0xLTEtMTc3NzU_24d267af-3c59-4cca-82a4-1680f5d325ed">1.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i3e21049ffc224cacb8134d73c9bb5b38_D20190101-20191231" decimals="3" name="evh:EffectiveIncomeTaxRateReconciliationDomesticSubsidiaryException" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185Ny9mcmFnOmJjZWZiM2Q3NjJhNzQ1YWE4MWQ3NzAzMjlmMDdjODMyL3RhYmxlOjFjNjIwNTBlMDM2MjQyZTJhZTQyNmMwYWQ4ZWRiMjYxL3RhYmxlcmFuZ2U6MWM2MjA1MGUwMzYyNDJlMmFlNDI2YzBhZDhlZGIyNjFfMTQtNS0xLTEtMTc3NzU_53fb43d2-e1e5-4b7c-b95e-fe031e9beb07">2.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax sharing settlement</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxSettlements" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185Ny9mcmFnOmJjZWZiM2Q3NjJhNzQ1YWE4MWQ3NzAzMjlmMDdjODMyL3RhYmxlOjFjNjIwNTBlMDM2MjQyZTJhZTQyNmMwYWQ4ZWRiMjYxL3RhYmxlcmFuZ2U6MWM2MjA1MGUwMzYyNDJlMmFlNDI2YzBhZDhlZGIyNjFfMTctMS0xLTEtMzIyNTM_0e471946-4b9e-48c4-82a6-2816321dba8d">1.1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i12a6d1161de54547bd29f8efccd4c9b0_D20200101-20201231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxSettlements" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185Ny9mcmFnOmJjZWZiM2Q3NjJhNzQ1YWE4MWQ3NzAzMjlmMDdjODMyL3RhYmxlOjFjNjIwNTBlMDM2MjQyZTJhZTQyNmMwYWQ4ZWRiMjYxL3RhYmxlcmFuZ2U6MWM2MjA1MGUwMzYyNDJlMmFlNDI2YzBhZDhlZGIyNjFfMTctMy0xLTEtMzIyNTM_67cef7ab-e6f8-48bd-a657-1b5f7b144d78">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i3e21049ffc224cacb8134d73c9bb5b38_D20190101-20191231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxSettlements" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185Ny9mcmFnOmJjZWZiM2Q3NjJhNzQ1YWE4MWQ3NzAzMjlmMDdjODMyL3RhYmxlOjFjNjIwNTBlMDM2MjQyZTJhZTQyNmMwYWQ4ZWRiMjYxL3RhYmxlcmFuZ2U6MWM2MjA1MGUwMzYyNDJlMmFlNDI2YzBhZDhlZGIyNjFfMTctNS0xLTEtMzIyNTM_8de4892f-7c21-41c2-8de7-c2dec7db8590">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185Ny9mcmFnOmJjZWZiM2Q3NjJhNzQ1YWE4MWQ3NzAzMjlmMDdjODMyL3RhYmxlOjFjNjIwNTBlMDM2MjQyZTJhZTQyNmMwYWQ4ZWRiMjYxL3RhYmxlcmFuZ2U6MWM2MjA1MGUwMzYyNDJlMmFlNDI2YzBhZDhlZGIyNjFfMTUtMS0xLTEtMTc3NzU_52f26937-40f4-46be-a6a9-d425366dbe81">0.7</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i12a6d1161de54547bd29f8efccd4c9b0_D20200101-20201231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185Ny9mcmFnOmJjZWZiM2Q3NjJhNzQ1YWE4MWQ3NzAzMjlmMDdjODMyL3RhYmxlOjFjNjIwNTBlMDM2MjQyZTJhZTQyNmMwYWQ4ZWRiMjYxL3RhYmxlcmFuZ2U6MWM2MjA1MGUwMzYyNDJlMmFlNDI2YzBhZDhlZGIyNjFfMTUtMy0xLTEtMTc3NzU_ecda109a-57b2-470d-bc33-5a272c18f348">0.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i3e21049ffc224cacb8134d73c9bb5b38_D20190101-20191231" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185Ny9mcmFnOmJjZWZiM2Q3NjJhNzQ1YWE4MWQ3NzAzMjlmMDdjODMyL3RhYmxlOjFjNjIwNTBlMDM2MjQyZTJhZTQyNmMwYWQ4ZWRiMjYxL3RhYmxlcmFuZ2U6MWM2MjA1MGUwMzYyNDJlMmFlNDI2YzBhZDhlZGIyNjFfMTUtNS0xLTEtMTc3NzU_bae03148-3863-41e4-9472-76a78341791e">1.3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effective tax rate</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185Ny9mcmFnOmJjZWZiM2Q3NjJhNzQ1YWE4MWQ3NzAzMjlmMDdjODMyL3RhYmxlOjFjNjIwNTBlMDM2MjQyZTJhZTQyNmMwYWQ4ZWRiMjYxL3RhYmxlcmFuZ2U6MWM2MjA1MGUwMzYyNDJlMmFlNDI2YzBhZDhlZGIyNjFfMTYtMS0xLTEtMTc3NzU_a7bb9bdc-74e2-4ca8-913b-e488221f75a4">1.6</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i12a6d1161de54547bd29f8efccd4c9b0_D20200101-20201231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185Ny9mcmFnOmJjZWZiM2Q3NjJhNzQ1YWE4MWQ3NzAzMjlmMDdjODMyL3RhYmxlOjFjNjIwNTBlMDM2MjQyZTJhZTQyNmMwYWQ4ZWRiMjYxL3RhYmxlcmFuZ2U6MWM2MjA1MGUwMzYyNDJlMmFlNDI2YzBhZDhlZGIyNjFfMTYtMy0xLTEtMTc3NzU_1ee83c99-41fc-4d96-b5fc-2bcd26bb720c">0.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i3e21049ffc224cacb8134d73c9bb5b38_D20190101-20191231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185Ny9mcmFnOmJjZWZiM2Q3NjJhNzQ1YWE4MWQ3NzAzMjlmMDdjODMyL3RhYmxlOjFjNjIwNTBlMDM2MjQyZTJhZTQyNmMwYWQ4ZWRiMjYxL3RhYmxlcmFuZ2U6MWM2MjA1MGUwMzYyNDJlMmFlNDI2YzBhZDhlZGIyNjFfMTYtNS0xLTEtMTc3NzU_80a617c8-ff5f-44d1-94f1-e1134e1600f4">6.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div></ix:nonNumeric><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred tax balances reflect the impact of temporary differences between the carrying amount of assets and liabilities and their tax basis and are stated at the tax rates expected to be in effect when the temporary differences are expected to be recovered or settled.</span></div></ix:continuation><div style="text-align:justify"><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">108</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="ia8deb40d96e94f219a281ad14ecb604f" continuedAt="i3a6e7f12bea74282a5e98b5e3e913487"><ix:nonNumeric contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231" name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185Ny9mcmFnOmJjZWZiM2Q3NjJhNzQ1YWE4MWQ3NzAzMjlmMDdjODMyL3RleHRyZWdpb246YmNlZmIzZDc2MmE3NDVhYTgxZDc3MDMyOWYwN2M4MzJfODQwNg_dd18ffa0-62cd-4a33-bd00-97ce089af19b" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Significant components of the Company&#8217;s deferred tax assets and liabilities (in thousands) were as follows:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"></td><td style="width:433.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:48.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:48.25pt"></td><td style="width:1.0pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31,</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Deferred Tax Assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Start-up and organizational costs</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8daff60be410426d8f7bd49343c1ec0c_I20211231" decimals="-3" name="evh:DeferredTaxAssetsStartupandOrganizationalCosts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185Ny9mcmFnOmJjZWZiM2Q3NjJhNzQ1YWE4MWQ3NzAzMjlmMDdjODMyL3RhYmxlOjg3Y2UwOTY2YjI2NTQ0ODhiM2M1ZWIyOWFjMGRmNTMzL3RhYmxlcmFuZ2U6ODdjZTA5NjZiMjY1NDQ4OGIzYzVlYjI5YWMwZGY1MzNfMy0xLTEtMS0xNzc3NQ_78307cf2-1faf-4c1a-a8aa-1144ccbc8e8e">103</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc0c0c2b8dc04c5698ca0577a54b2e03_I20201231" decimals="-3" name="evh:DeferredTaxAssetsStartupandOrganizationalCosts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185Ny9mcmFnOmJjZWZiM2Q3NjJhNzQ1YWE4MWQ3NzAzMjlmMDdjODMyL3RhYmxlOjg3Y2UwOTY2YjI2NTQ0ODhiM2M1ZWIyOWFjMGRmNTMzL3RhYmxlcmFuZ2U6ODdjZTA5NjZiMjY1NDQ4OGIzYzVlYjI5YWMwZGY1MzNfMy0zLTEtMS0xNzc3NQ_16bfcd73-b4b3-4d29-bbb6-04e1541931b0">117</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8daff60be410426d8f7bd49343c1ec0c_I20211231" decimals="-3" name="us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185Ny9mcmFnOmJjZWZiM2Q3NjJhNzQ1YWE4MWQ3NzAzMjlmMDdjODMyL3RhYmxlOjg3Y2UwOTY2YjI2NTQ0ODhiM2M1ZWIyOWFjMGRmNTMzL3RhYmxlcmFuZ2U6ODdjZTA5NjZiMjY1NDQ4OGIzYzVlYjI5YWMwZGY1MzNfNC0xLTEtMS0xNzc3NQ_2fcef6dc-4a5a-4e08-a383-23efd766c0ae">18,774</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc0c0c2b8dc04c5698ca0577a54b2e03_I20201231" decimals="-3" name="us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185Ny9mcmFnOmJjZWZiM2Q3NjJhNzQ1YWE4MWQ3NzAzMjlmMDdjODMyL3RhYmxlOjg3Y2UwOTY2YjI2NTQ0ODhiM2M1ZWIyOWFjMGRmNTMzL3RhYmxlcmFuZ2U6ODdjZTA5NjZiMjY1NDQ4OGIzYzVlYjI5YWMwZGY1MzNfNC0zLTEtMS0xNzc3NQ_4e0b6339-e806-4be6-80d1-5c57ba243724">23,778</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8daff60be410426d8f7bd49343c1ec0c_I20211231" decimals="-3" name="evh:DeferredTaxAssetsOperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185Ny9mcmFnOmJjZWZiM2Q3NjJhNzQ1YWE4MWQ3NzAzMjlmMDdjODMyL3RhYmxlOjg3Y2UwOTY2YjI2NTQ0ODhiM2M1ZWIyOWFjMGRmNTMzL3RhYmxlcmFuZ2U6ODdjZTA5NjZiMjY1NDQ4OGIzYzVlYjI5YWMwZGY1MzNfNS0xLTEtMS0xNzc3NQ_d7908ddd-d37c-44cb-9c6a-599c29ff27f7">15,968</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc0c0c2b8dc04c5698ca0577a54b2e03_I20201231" decimals="-3" name="evh:DeferredTaxAssetsOperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185Ny9mcmFnOmJjZWZiM2Q3NjJhNzQ1YWE4MWQ3NzAzMjlmMDdjODMyL3RhYmxlOjg3Y2UwOTY2YjI2NTQ0ODhiM2M1ZWIyOWFjMGRmNTMzL3RhYmxlcmFuZ2U6ODdjZTA5NjZiMjY1NDQ4OGIzYzVlYjI5YWMwZGY1MzNfNS0zLTEtMS0xNzc3NQ_0d46ebc4-3d00-411a-aa51-220b7565a800">15,963</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8daff60be410426d8f7bd49343c1ec0c_I20211231" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185Ny9mcmFnOmJjZWZiM2Q3NjJhNzQ1YWE4MWQ3NzAzMjlmMDdjODMyL3RhYmxlOjg3Y2UwOTY2YjI2NTQ0ODhiM2M1ZWIyOWFjMGRmNTMzL3RhYmxlcmFuZ2U6ODdjZTA5NjZiMjY1NDQ4OGIzYzVlYjI5YWMwZGY1MzNfNi0xLTEtMS0xNzc3NQ_14de74cc-26a8-41b2-bcdd-53a7883f7bc9">10,345</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc0c0c2b8dc04c5698ca0577a54b2e03_I20201231" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185Ny9mcmFnOmJjZWZiM2Q3NjJhNzQ1YWE4MWQ3NzAzMjlmMDdjODMyL3RhYmxlOjg3Y2UwOTY2YjI2NTQ0ODhiM2M1ZWIyOWFjMGRmNTMzL3RhYmxlcmFuZ2U6ODdjZTA5NjZiMjY1NDQ4OGIzYzVlYjI5YWMwZGY1MzNfNi0zLTEtMS0xNzc3NQ_9d3544fa-c21a-4589-b486-a5d89a3684f5">7,434</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8daff60be410426d8f7bd49343c1ec0c_I20211231" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185Ny9mcmFnOmJjZWZiM2Q3NjJhNzQ1YWE4MWQ3NzAzMjlmMDdjODMyL3RhYmxlOjg3Y2UwOTY2YjI2NTQ0ODhiM2M1ZWIyOWFjMGRmNTMzL3RhYmxlcmFuZ2U6ODdjZTA5NjZiMjY1NDQ4OGIzYzVlYjI5YWMwZGY1MzNfNy0xLTEtMS0xNzc3NQ_c998f34a-7c98-4f78-a536-5527e7a44db5">8,714</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc0c0c2b8dc04c5698ca0577a54b2e03_I20201231" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185Ny9mcmFnOmJjZWZiM2Q3NjJhNzQ1YWE4MWQ3NzAzMjlmMDdjODMyL3RhYmxlOjg3Y2UwOTY2YjI2NTQ0ODhiM2M1ZWIyOWFjMGRmNTMzL3RhYmxlcmFuZ2U6ODdjZTA5NjZiMjY1NDQ4OGIzYzVlYjI5YWMwZGY1MzNfNy0zLTEtMS0xNzc3NQ_50e55aba-72f0-4dde-8e92-d9e05184a872">8,530</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net operating loss carryforwards</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8daff60be410426d8f7bd49343c1ec0c_I20211231" decimals="-3" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185Ny9mcmFnOmJjZWZiM2Q3NjJhNzQ1YWE4MWQ3NzAzMjlmMDdjODMyL3RhYmxlOjg3Y2UwOTY2YjI2NTQ0ODhiM2M1ZWIyOWFjMGRmNTMzL3RhYmxlcmFuZ2U6ODdjZTA5NjZiMjY1NDQ4OGIzYzVlYjI5YWMwZGY1MzNfOC0xLTEtMS0xNzc3NQ_bf5745ff-2429-4a61-9d9c-4b1b31dbbb89">130,242</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc0c0c2b8dc04c5698ca0577a54b2e03_I20201231" decimals="-3" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185Ny9mcmFnOmJjZWZiM2Q3NjJhNzQ1YWE4MWQ3NzAzMjlmMDdjODMyL3RhYmxlOjg3Y2UwOTY2YjI2NTQ0ODhiM2M1ZWIyOWFjMGRmNTMzL3RhYmxlcmFuZ2U6ODdjZTA5NjZiMjY1NDQ4OGIzYzVlYjI5YWMwZGY1MzNfOC0zLTEtMS0xNzc3NQ_cf19ac67-9b51-484b-941d-fd35fce1582a">123,604</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal and state research tax credits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8daff60be410426d8f7bd49343c1ec0c_I20211231" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185Ny9mcmFnOmJjZWZiM2Q3NjJhNzQ1YWE4MWQ3NzAzMjlmMDdjODMyL3RhYmxlOjg3Y2UwOTY2YjI2NTQ0ODhiM2M1ZWIyOWFjMGRmNTMzL3RhYmxlcmFuZ2U6ODdjZTA5NjZiMjY1NDQ4OGIzYzVlYjI5YWMwZGY1MzNfOS0xLTEtMS0xNzc3NQ_f4c2fef5-487e-4b5f-a003-c317cd213320">1,828</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc0c0c2b8dc04c5698ca0577a54b2e03_I20201231" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185Ny9mcmFnOmJjZWZiM2Q3NjJhNzQ1YWE4MWQ3NzAzMjlmMDdjODMyL3RhYmxlOjg3Y2UwOTY2YjI2NTQ0ODhiM2M1ZWIyOWFjMGRmNTMzL3RhYmxlcmFuZ2U6ODdjZTA5NjZiMjY1NDQ4OGIzYzVlYjI5YWMwZGY1MzNfOS0zLTEtMS0xNzc3NQ_5a3d9a2f-c317-44f4-b4a9-74d1e85153a6">1,828</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fixed assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8daff60be410426d8f7bd49343c1ec0c_I20211231" decimals="-3" name="us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185Ny9mcmFnOmJjZWZiM2Q3NjJhNzQ1YWE4MWQ3NzAzMjlmMDdjODMyL3RhYmxlOjg3Y2UwOTY2YjI2NTQ0ODhiM2M1ZWIyOWFjMGRmNTMzL3RhYmxlcmFuZ2U6ODdjZTA5NjZiMjY1NDQ4OGIzYzVlYjI5YWMwZGY1MzNfMTAtMS0xLTEtMTc3NzU_aaaea55a-9f90-44c2-9033-25e0c55ce8d5">480</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc0c0c2b8dc04c5698ca0577a54b2e03_I20201231" decimals="-3" name="us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185Ny9mcmFnOmJjZWZiM2Q3NjJhNzQ1YWE4MWQ3NzAzMjlmMDdjODMyL3RhYmxlOjg3Y2UwOTY2YjI2NTQ0ODhiM2M1ZWIyOWFjMGRmNTMzL3RhYmxlcmFuZ2U6ODdjZTA5NjZiMjY1NDQ4OGIzYzVlYjI5YWMwZGY1MzNfMTAtMy0xLTEtMTc3NzU_d2de69b0-4989-4564-8daf-e5045e615b35">131</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest deduction limitation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8daff60be410426d8f7bd49343c1ec0c_I20211231" decimals="-3" name="us-gaap:DeferredTaxAssetInterestCarryforward" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185Ny9mcmFnOmJjZWZiM2Q3NjJhNzQ1YWE4MWQ3NzAzMjlmMDdjODMyL3RhYmxlOjg3Y2UwOTY2YjI2NTQ0ODhiM2M1ZWIyOWFjMGRmNTMzL3RhYmxlcmFuZ2U6ODdjZTA5NjZiMjY1NDQ4OGIzYzVlYjI5YWMwZGY1MzNfMTEtMS0xLTEtMTc3NzU_cd91d03c-9604-4d4d-8ab1-e5f2d76bc7fa">7,795</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc0c0c2b8dc04c5698ca0577a54b2e03_I20201231" decimals="-3" name="us-gaap:DeferredTaxAssetInterestCarryforward" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185Ny9mcmFnOmJjZWZiM2Q3NjJhNzQ1YWE4MWQ3NzAzMjlmMDdjODMyL3RhYmxlOjg3Y2UwOTY2YjI2NTQ0ODhiM2M1ZWIyOWFjMGRmNTMzL3RhYmxlcmFuZ2U6ODdjZTA5NjZiMjY1NDQ4OGIzYzVlYjI5YWMwZGY1MzNfMTEtMy0xLTEtMTc3NzU_177513d9-8806-46f1-8fe7-1c94c35e3543">2,452</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outside basis differences</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8daff60be410426d8f7bd49343c1ec0c_I20211231" decimals="-3" name="evh:DeferredTaxAssetOutsideBasisDifferences" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185Ny9mcmFnOmJjZWZiM2Q3NjJhNzQ1YWE4MWQ3NzAzMjlmMDdjODMyL3RhYmxlOjg3Y2UwOTY2YjI2NTQ0ODhiM2M1ZWIyOWFjMGRmNTMzL3RhYmxlcmFuZ2U6ODdjZTA5NjZiMjY1NDQ4OGIzYzVlYjI5YWMwZGY1MzNfMTItMS0xLTEtMTc3NzU_fb83f43d-3475-4729-a63e-90dd48573fe3">1,972</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc0c0c2b8dc04c5698ca0577a54b2e03_I20201231" decimals="-3" name="evh:DeferredTaxAssetOutsideBasisDifferences" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185Ny9mcmFnOmJjZWZiM2Q3NjJhNzQ1YWE4MWQ3NzAzMjlmMDdjODMyL3RhYmxlOjg3Y2UwOTY2YjI2NTQ0ODhiM2M1ZWIyOWFjMGRmNTMzL3RhYmxlcmFuZ2U6ODdjZTA5NjZiMjY1NDQ4OGIzYzVlYjI5YWMwZGY1MzNfMTItMy0xLTEtMTc3NzU_b757a805-5b50-4f88-8653-d533cf75773d">197</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8daff60be410426d8f7bd49343c1ec0c_I20211231" decimals="-3" name="us-gaap:DeferredTaxAssetsOther" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185Ny9mcmFnOmJjZWZiM2Q3NjJhNzQ1YWE4MWQ3NzAzMjlmMDdjODMyL3RhYmxlOjg3Y2UwOTY2YjI2NTQ0ODhiM2M1ZWIyOWFjMGRmNTMzL3RhYmxlcmFuZ2U6ODdjZTA5NjZiMjY1NDQ4OGIzYzVlYjI5YWMwZGY1MzNfMTMtMS0xLTEtMTc3NzU_665248b2-4c44-4760-9b99-69526f4a5af9">9,236</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc0c0c2b8dc04c5698ca0577a54b2e03_I20201231" decimals="-3" name="us-gaap:DeferredTaxAssetsOther" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185Ny9mcmFnOmJjZWZiM2Q3NjJhNzQ1YWE4MWQ3NzAzMjlmMDdjODMyL3RhYmxlOjg3Y2UwOTY2YjI2NTQ0ODhiM2M1ZWIyOWFjMGRmNTMzL3RhYmxlcmFuZ2U6ODdjZTA5NjZiMjY1NDQ4OGIzYzVlYjI5YWMwZGY1MzNfMTMtMy0xLTEtMTc3NzU_5ed52384-7330-4920-87d4-ab1926a4146a">8,428</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Subtotal</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8daff60be410426d8f7bd49343c1ec0c_I20211231" decimals="-3" name="us-gaap:DeferredTaxAssetsGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185Ny9mcmFnOmJjZWZiM2Q3NjJhNzQ1YWE4MWQ3NzAzMjlmMDdjODMyL3RhYmxlOjg3Y2UwOTY2YjI2NTQ0ODhiM2M1ZWIyOWFjMGRmNTMzL3RhYmxlcmFuZ2U6ODdjZTA5NjZiMjY1NDQ4OGIzYzVlYjI5YWMwZGY1MzNfMTQtMS0xLTEtMTc3NzU_235715a1-0195-4893-99f4-d31ff40cc314">205,457</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc0c0c2b8dc04c5698ca0577a54b2e03_I20201231" decimals="-3" name="us-gaap:DeferredTaxAssetsGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185Ny9mcmFnOmJjZWZiM2Q3NjJhNzQ1YWE4MWQ3NzAzMjlmMDdjODMyL3RhYmxlOjg3Y2UwOTY2YjI2NTQ0ODhiM2M1ZWIyOWFjMGRmNTMzL3RhYmxlcmFuZ2U6ODdjZTA5NjZiMjY1NDQ4OGIzYzVlYjI5YWMwZGY1MzNfMTQtMy0xLTEtMTc3NzU_3af75cb1-6a22-4f9e-9915-b2caeeb3e359">192,462</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Valuation allowance</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8daff60be410426d8f7bd49343c1ec0c_I20211231" decimals="-3" name="us-gaap:DeferredTaxAssetsValuationAllowance" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185Ny9mcmFnOmJjZWZiM2Q3NjJhNzQ1YWE4MWQ3NzAzMjlmMDdjODMyL3RhYmxlOjg3Y2UwOTY2YjI2NTQ0ODhiM2M1ZWIyOWFjMGRmNTMzL3RhYmxlcmFuZ2U6ODdjZTA5NjZiMjY1NDQ4OGIzYzVlYjI5YWMwZGY1MzNfMTUtMS0xLTEtMTc3NzU_4a2ea07f-512d-48f1-9e31-02fc288e0fa0">101,345</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibc0c0c2b8dc04c5698ca0577a54b2e03_I20201231" decimals="-3" name="us-gaap:DeferredTaxAssetsValuationAllowance" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185Ny9mcmFnOmJjZWZiM2Q3NjJhNzQ1YWE4MWQ3NzAzMjlmMDdjODMyL3RhYmxlOjg3Y2UwOTY2YjI2NTQ0ODhiM2M1ZWIyOWFjMGRmNTMzL3RhYmxlcmFuZ2U6ODdjZTA5NjZiMjY1NDQ4OGIzYzVlYjI5YWMwZGY1MzNfMTUtMy0xLTEtMTc3NzU_3b745ee4-95f1-4a24-9e59-cab3429f8397">89,723</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred tax assets</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8daff60be410426d8f7bd49343c1ec0c_I20211231" decimals="-3" name="us-gaap:DeferredTaxAssetsNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185Ny9mcmFnOmJjZWZiM2Q3NjJhNzQ1YWE4MWQ3NzAzMjlmMDdjODMyL3RhYmxlOjg3Y2UwOTY2YjI2NTQ0ODhiM2M1ZWIyOWFjMGRmNTMzL3RhYmxlcmFuZ2U6ODdjZTA5NjZiMjY1NDQ4OGIzYzVlYjI5YWMwZGY1MzNfMTYtMS0xLTEtMTc3NzU_861643c6-453e-4d30-81de-70240142b292">104,112</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc0c0c2b8dc04c5698ca0577a54b2e03_I20201231" decimals="-3" name="us-gaap:DeferredTaxAssetsNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185Ny9mcmFnOmJjZWZiM2Q3NjJhNzQ1YWE4MWQ3NzAzMjlmMDdjODMyL3RhYmxlOjg3Y2UwOTY2YjI2NTQ0ODhiM2M1ZWIyOWFjMGRmNTMzL3RhYmxlcmFuZ2U6ODdjZTA5NjZiMjY1NDQ4OGIzYzVlYjI5YWMwZGY1MzNfMTYtMy0xLTEtMTc3NzU_57827ffb-a94c-468f-a4dd-f9535a528780">102,739</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Deferred Tax Liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Internally developed software costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8daff60be410426d8f7bd49343c1ec0c_I20211231" decimals="-3" name="us-gaap:DeferredTaxLiabilitiesDeferredExpenseCapitalizedSoftware" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185Ny9mcmFnOmJjZWZiM2Q3NjJhNzQ1YWE4MWQ3NzAzMjlmMDdjODMyL3RhYmxlOjg3Y2UwOTY2YjI2NTQ0ODhiM2M1ZWIyOWFjMGRmNTMzL3RhYmxlcmFuZ2U6ODdjZTA5NjZiMjY1NDQ4OGIzYzVlYjI5YWMwZGY1MzNfMTktMS0xLTEtMTc3NzU_74c5eab9-4816-48f3-9829-8c3925c7ef4a">12,501</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc0c0c2b8dc04c5698ca0577a54b2e03_I20201231" decimals="-3" name="us-gaap:DeferredTaxLiabilitiesDeferredExpenseCapitalizedSoftware" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185Ny9mcmFnOmJjZWZiM2Q3NjJhNzQ1YWE4MWQ3NzAzMjlmMDdjODMyL3RhYmxlOjg3Y2UwOTY2YjI2NTQ0ODhiM2M1ZWIyOWFjMGRmNTMzL3RhYmxlcmFuZ2U6ODdjZTA5NjZiMjY1NDQ4OGIzYzVlYjI5YWMwZGY1MzNfMTktMy0xLTEtMTc3NzU_6ef70d61-c8c2-48e0-8429-e7d8df63a232">12,973</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8daff60be410426d8f7bd49343c1ec0c_I20211231" decimals="-3" name="us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185Ny9mcmFnOmJjZWZiM2Q3NjJhNzQ1YWE4MWQ3NzAzMjlmMDdjODMyL3RhYmxlOjg3Y2UwOTY2YjI2NTQ0ODhiM2M1ZWIyOWFjMGRmNTMzL3RhYmxlcmFuZ2U6ODdjZTA5NjZiMjY1NDQ4OGIzYzVlYjI5YWMwZGY1MzNfMjAtMS0xLTEtMTc3NzU_c0458a9c-1996-4e1f-9bf7-b4e288e9b086">48,677</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc0c0c2b8dc04c5698ca0577a54b2e03_I20201231" decimals="-3" name="us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185Ny9mcmFnOmJjZWZiM2Q3NjJhNzQ1YWE4MWQ3NzAzMjlmMDdjODMyL3RhYmxlOjg3Y2UwOTY2YjI2NTQ0ODhiM2M1ZWIyOWFjMGRmNTMzL3RhYmxlcmFuZ2U6ODdjZTA5NjZiMjY1NDQ4OGIzYzVlYjI5YWMwZGY1MzNfMjAtMy0xLTEtMTc3NzU_0cda6a5f-4c58-44fb-9b2a-c33eeabe0f70">49,053</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use assets - Operating</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8daff60be410426d8f7bd49343c1ec0c_I20211231" decimals="-3" name="us-gaap:DeferredTaxLiabilitiesLeasingArrangements" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185Ny9mcmFnOmJjZWZiM2Q3NjJhNzQ1YWE4MWQ3NzAzMjlmMDdjODMyL3RhYmxlOjg3Y2UwOTY2YjI2NTQ0ODhiM2M1ZWIyOWFjMGRmNTMzL3RhYmxlcmFuZ2U6ODdjZTA5NjZiMjY1NDQ4OGIzYzVlYjI5YWMwZGY1MzNfMjItMS0xLTEtMTc3NzU_9cc5d70d-30a6-4ea3-8ef5-26dfea2b0e65">12,284</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc0c0c2b8dc04c5698ca0577a54b2e03_I20201231" decimals="-3" name="us-gaap:DeferredTaxLiabilitiesLeasingArrangements" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185Ny9mcmFnOmJjZWZiM2Q3NjJhNzQ1YWE4MWQ3NzAzMjlmMDdjODMyL3RhYmxlOjg3Y2UwOTY2YjI2NTQ0ODhiM2M1ZWIyOWFjMGRmNTMzL3RhYmxlcmFuZ2U6ODdjZTA5NjZiMjY1NDQ4OGIzYzVlYjI5YWMwZGY1MzNfMjItMy0xLTEtMTc3NzU_a5cb3f2f-c63a-42e9-b6fd-79bcb4b7cdfa">13,122</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contract fulfillment costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8daff60be410426d8f7bd49343c1ec0c_I20211231" decimals="-3" name="us-gaap:DeferredTaxLiabilitiesDeferredExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185Ny9mcmFnOmJjZWZiM2Q3NjJhNzQ1YWE4MWQ3NzAzMjlmMDdjODMyL3RhYmxlOjg3Y2UwOTY2YjI2NTQ0ODhiM2M1ZWIyOWFjMGRmNTMzL3RhYmxlcmFuZ2U6ODdjZTA5NjZiMjY1NDQ4OGIzYzVlYjI5YWMwZGY1MzNfMjMtMS0xLTEtMTc3NzU_a86b6a9e-d68b-4424-bdd0-67c68afb3984">8,317</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc0c0c2b8dc04c5698ca0577a54b2e03_I20201231" decimals="-3" name="us-gaap:DeferredTaxLiabilitiesDeferredExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185Ny9mcmFnOmJjZWZiM2Q3NjJhNzQ1YWE4MWQ3NzAzMjlmMDdjODMyL3RhYmxlOjg3Y2UwOTY2YjI2NTQ0ODhiM2M1ZWIyOWFjMGRmNTMzL3RhYmxlcmFuZ2U6ODdjZTA5NjZiMjY1NDQ4OGIzYzVlYjI5YWMwZGY1MzNfMjMtMy0xLTEtMTc3NzU_89ea72bb-d22b-451f-ac4a-8c2310ba39f5">6,375</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Convertible debt</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8daff60be410426d8f7bd49343c1ec0c_I20211231" decimals="-3" name="us-gaap:DeferredTaxLiabilitiesFinancingArrangements" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185Ny9mcmFnOmJjZWZiM2Q3NjJhNzQ1YWE4MWQ3NzAzMjlmMDdjODMyL3RhYmxlOjg3Y2UwOTY2YjI2NTQ0ODhiM2M1ZWIyOWFjMGRmNTMzL3RhYmxlcmFuZ2U6ODdjZTA5NjZiMjY1NDQ4OGIzYzVlYjI5YWMwZGY1MzNfMjQtMS0xLTEtMTc3NzU_6be58665-0b75-428b-a948-26738e30e2f3">17,604</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc0c0c2b8dc04c5698ca0577a54b2e03_I20201231" decimals="-3" name="us-gaap:DeferredTaxLiabilitiesFinancingArrangements" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185Ny9mcmFnOmJjZWZiM2Q3NjJhNzQ1YWE4MWQ3NzAzMjlmMDdjODMyL3RhYmxlOjg3Y2UwOTY2YjI2NTQ0ODhiM2M1ZWIyOWFjMGRmNTMzL3RhYmxlcmFuZ2U6ODdjZTA5NjZiMjY1NDQ4OGIzYzVlYjI5YWMwZGY1MzNfMjQtMy0xLTEtMTc3NzU_af3172ca-06c0-46be-bb3c-a42489158712">20,411</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8daff60be410426d8f7bd49343c1ec0c_I20211231" decimals="-3" name="us-gaap:DeferredTaxLiabilitiesOther" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185Ny9mcmFnOmJjZWZiM2Q3NjJhNzQ1YWE4MWQ3NzAzMjlmMDdjODMyL3RhYmxlOjg3Y2UwOTY2YjI2NTQ0ODhiM2M1ZWIyOWFjMGRmNTMzL3RhYmxlcmFuZ2U6ODdjZTA5NjZiMjY1NDQ4OGIzYzVlYjI5YWMwZGY1MzNfMjYtMS0xLTEtMTc3NzU_5edfc0b1-0929-4df3-a932-a2e2abbfeffc">5,387</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc0c0c2b8dc04c5698ca0577a54b2e03_I20201231" decimals="-3" name="us-gaap:DeferredTaxLiabilitiesOther" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185Ny9mcmFnOmJjZWZiM2Q3NjJhNzQ1YWE4MWQ3NzAzMjlmMDdjODMyL3RhYmxlOjg3Y2UwOTY2YjI2NTQ0ODhiM2M1ZWIyOWFjMGRmNTMzL3RhYmxlcmFuZ2U6ODdjZTA5NjZiMjY1NDQ4OGIzYzVlYjI5YWMwZGY1MzNfMjYtMy0xLTEtMTc3NzU_88c81d4c-cdc4-49ff-960e-1774becbb101">1,484</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred tax liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8daff60be410426d8f7bd49343c1ec0c_I20211231" decimals="-3" name="us-gaap:DeferredIncomeTaxLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185Ny9mcmFnOmJjZWZiM2Q3NjJhNzQ1YWE4MWQ3NzAzMjlmMDdjODMyL3RhYmxlOjg3Y2UwOTY2YjI2NTQ0ODhiM2M1ZWIyOWFjMGRmNTMzL3RhYmxlcmFuZ2U6ODdjZTA5NjZiMjY1NDQ4OGIzYzVlYjI5YWMwZGY1MzNfMjctMS0xLTEtMTc3NzU_31a72920-a654-49de-b08f-435411cedcd4">104,770</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc0c0c2b8dc04c5698ca0577a54b2e03_I20201231" decimals="-3" name="us-gaap:DeferredIncomeTaxLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185Ny9mcmFnOmJjZWZiM2Q3NjJhNzQ1YWE4MWQ3NzAzMjlmMDdjODMyL3RhYmxlOjg3Y2UwOTY2YjI2NTQ0ODhiM2M1ZWIyOWFjMGRmNTMzL3RhYmxlcmFuZ2U6ODdjZTA5NjZiMjY1NDQ4OGIzYzVlYjI5YWMwZGY1MzNfMjctMy0xLTEtMTc3NzU_438c8abc-550a-40f3-8db7-4423c208ff41">103,418</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net deferred tax assets (liabilities)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8daff60be410426d8f7bd49343c1ec0c_I20211231" decimals="-3" name="us-gaap:DeferredTaxLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185Ny9mcmFnOmJjZWZiM2Q3NjJhNzQ1YWE4MWQ3NzAzMjlmMDdjODMyL3RhYmxlOjg3Y2UwOTY2YjI2NTQ0ODhiM2M1ZWIyOWFjMGRmNTMzL3RhYmxlcmFuZ2U6ODdjZTA5NjZiMjY1NDQ4OGIzYzVlYjI5YWMwZGY1MzNfMjgtMS0xLTEtMTc3NzU_8d832f2d-90d0-47d1-aa9f-35ea949b238d">658</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibc0c0c2b8dc04c5698ca0577a54b2e03_I20201231" decimals="-3" name="us-gaap:DeferredTaxLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185Ny9mcmFnOmJjZWZiM2Q3NjJhNzQ1YWE4MWQ3NzAzMjlmMDdjODMyL3RhYmxlOjg3Y2UwOTY2YjI2NTQ0ODhiM2M1ZWIyOWFjMGRmNTMzL3RhYmxlcmFuZ2U6ODdjZTA5NjZiMjY1NDQ4OGIzYzVlYjI5YWMwZGY1MzNfMjgtMy0xLTEtMTc3NzU_beb3f723-0baa-4afe-a3ef-002d36a821a7">679</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes in our valuation allowance (in thousands) were as follows:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"></td><td style="width:433.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:48.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:48.25pt"></td><td style="width:1.0pt"></td></tr><tr style="height:23pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Year Ended December 31,</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at beginning-of-year</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6126841a44cb4c478fc23b6132251176_I20201231" decimals="-3" name="us-gaap:ValuationAllowancesAndReservesBalance" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185Ny9mcmFnOmJjZWZiM2Q3NjJhNzQ1YWE4MWQ3NzAzMjlmMDdjODMyL3RhYmxlOjBmNjllN2MzZmUyNzQxN2ZiN2MzYjI4ZDRkMmQ0MDQ0L3RhYmxlcmFuZ2U6MGY2OWU3YzNmZTI3NDE3ZmI3YzNiMjhkNGQyZDQwNDRfMi0xLTEtMS0xNzc3NQ_09f87438-a073-4950-8627-c251d118a412">89,723</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4d7d673b0fbf48deaa07f821e1025d2e_I20191231" decimals="-3" name="us-gaap:ValuationAllowancesAndReservesBalance" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185Ny9mcmFnOmJjZWZiM2Q3NjJhNzQ1YWE4MWQ3NzAzMjlmMDdjODMyL3RhYmxlOjBmNjllN2MzZmUyNzQxN2ZiN2MzYjI4ZDRkMmQ0MDQ0L3RhYmxlcmFuZ2U6MGY2OWU3YzNmZTI3NDE3ZmI3YzNiMjhkNGQyZDQwNDRfMi0zLTEtMS0xNzc3NQ_c85e51bf-eced-4f83-93d1-998a22996531">50,519</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Charged to costs and expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6b9dc5b6709f4577a0325ffd62a07675_D20210101-20211231" decimals="-3" name="us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185Ny9mcmFnOmJjZWZiM2Q3NjJhNzQ1YWE4MWQ3NzAzMjlmMDdjODMyL3RhYmxlOjBmNjllN2MzZmUyNzQxN2ZiN2MzYjI4ZDRkMmQ0MDQ0L3RhYmxlcmFuZ2U6MGY2OWU3YzNmZTI3NDE3ZmI3YzNiMjhkNGQyZDQwNDRfMy0xLTEtMS0xNzc3NQ_ea6eeae8-f278-41d5-8f57-d5815daf645f">9,856</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie8b8af0c663c4c6f8a82f961045e3772_D20200101-20201231" decimals="-3" name="us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185Ny9mcmFnOmJjZWZiM2Q3NjJhNzQ1YWE4MWQ3NzAzMjlmMDdjODMyL3RhYmxlOjBmNjllN2MzZmUyNzQxN2ZiN2MzYjI4ZDRkMmQ0MDQ0L3RhYmxlcmFuZ2U6MGY2OWU3YzNmZTI3NDE3ZmI3YzNiMjhkNGQyZDQwNDRfMy0zLTEtMS0xNzc3NQ_a0851cba-9b01-4622-84ef-00e1fce6908c">47,142</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Charged (credited) to other accounts </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6b9dc5b6709f4577a0325ffd62a07675_D20210101-20211231" decimals="-3" name="us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185Ny9mcmFnOmJjZWZiM2Q3NjJhNzQ1YWE4MWQ3NzAzMjlmMDdjODMyL3RhYmxlOjBmNjllN2MzZmUyNzQxN2ZiN2MzYjI4ZDRkMmQ0MDQ0L3RhYmxlcmFuZ2U6MGY2OWU3YzNmZTI3NDE3ZmI3YzNiMjhkNGQyZDQwNDRfNC0xLTEtMS0xNzc3NQ_8445fdeb-678b-4507-b797-88bee9ec8c9e">1,766</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie8b8af0c663c4c6f8a82f961045e3772_D20200101-20201231" decimals="-3" name="us-gaap:ValuationAllowancesAndReservesDeductions" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185Ny9mcmFnOmJjZWZiM2Q3NjJhNzQ1YWE4MWQ3NzAzMjlmMDdjODMyL3RhYmxlOjBmNjllN2MzZmUyNzQxN2ZiN2MzYjI4ZDRkMmQ0MDQ0L3RhYmxlcmFuZ2U6MGY2OWU3YzNmZTI3NDE3ZmI3YzNiMjhkNGQyZDQwNDRfNC0zLTEtMS0xNzc3NQ_4dcecf90-6581-438a-af1f-884d3021a09b">7,938</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at end-of-year</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i39aaea1673c24c3e943c58e39738d3e1_I20211231" decimals="-3" name="us-gaap:ValuationAllowancesAndReservesBalance" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185Ny9mcmFnOmJjZWZiM2Q3NjJhNzQ1YWE4MWQ3NzAzMjlmMDdjODMyL3RhYmxlOjBmNjllN2MzZmUyNzQxN2ZiN2MzYjI4ZDRkMmQ0MDQ0L3RhYmxlcmFuZ2U6MGY2OWU3YzNmZTI3NDE3ZmI3YzNiMjhkNGQyZDQwNDRfNS0xLTEtMS0xNzc3NQ_011a5bf0-8f45-43de-92a0-9c1679dd6e57">101,345</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6126841a44cb4c478fc23b6132251176_I20201231" decimals="-3" name="us-gaap:ValuationAllowancesAndReservesBalance" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185Ny9mcmFnOmJjZWZiM2Q3NjJhNzQ1YWE4MWQ3NzAzMjlmMDdjODMyL3RhYmxlOjBmNjllN2MzZmUyNzQxN2ZiN2MzYjI4ZDRkMmQ0MDQ0L3RhYmxlcmFuZ2U6MGY2OWU3YzNmZTI3NDE3ZmI3YzNiMjhkNGQyZDQwNDRfNS0zLTEtMS0xNzc3NQ_2add819d-fa3c-41c5-a576-ca83e16e6925">89,723</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:3.71pt">Amounts charged (credited) to other accounts includes $<ix:nonFraction unitRef="usd" contextRef="i6b9dc5b6709f4577a0325ffd62a07675_D20210101-20211231" decimals="-5" name="evh:ValuationAllowancesAndReservesChargedCreditedToAdditionalPaidInCapital" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185Ny9mcmFnOmJjZWZiM2Q3NjJhNzQ1YWE4MWQ3NzAzMjlmMDdjODMyL3RleHRyZWdpb246YmNlZmIzZDc2MmE3NDVhYTgxZDc3MDMyOWYwN2M4MzJfMTE0Nw_5c246e85-cf14-4a56-84ab-f510a8a6c73a">1.8</ix:nonFraction>&#160;million charged to discontinued operations for the year ended December&#160;31, 2021 and $<ix:nonFraction unitRef="usd" contextRef="ie8b8af0c663c4c6f8a82f961045e3772_D20200101-20201231" decimals="-5" sign="-" name="evh:ValuationAllowancesAndReservesChargedCreditedToAdditionalPaidInCapital" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185Ny9mcmFnOmJjZWZiM2Q3NjJhNzQ1YWE4MWQ3NzAzMjlmMDdjODMyL3RleHRyZWdpb246YmNlZmIzZDc2MmE3NDVhYTgxZDc3MDMyOWYwN2M4MzJfMTE2Ng_07a863e0-fb50-4280-a17f-fcdaea2310a8">8.6</ix:nonFraction>&#160;million credited to additional paid-in-capital, partially offset by $<ix:nonFraction unitRef="usd" contextRef="ie8b8af0c663c4c6f8a82f961045e3772_D20200101-20201231" decimals="-5" name="evh:ValuationAllowancesAndReservesChargedToRetainedEarnings" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185Ny9mcmFnOmJjZWZiM2Q3NjJhNzQ1YWE4MWQ3NzAzMjlmMDdjODMyL3RleHRyZWdpb246YmNlZmIzZDc2MmE3NDVhYTgxZDc3MDMyOWYwN2M4MzJfMTA5OTUxMTYzOTE5Nw_1b90ba2e-d0a4-4768-a7fc-e267bb2793ee">0.7</ix:nonFraction>&#160;million charged to retained earnings, for the year ended December 31, 2020.</span></div></ix:nonNumeric><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">For the year ended December 31, 2021, the effective tax rate was (<ix:nonFraction unitRef="number" contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185Ny9mcmFnOmJjZWZiM2Q3NjJhNzQ1YWE4MWQ3NzAzMjlmMDdjODMyL3RleHRyZWdpb246YmNlZmIzZDc2MmE3NDVhYTgxZDc3MDMyOWYwN2M4MzJfMTA5OTUxMTYzNzc1OA_458548f1-87fa-47b5-b4bc-59be2750c012">1.6</ix:nonFraction>)% and the corresponding tax expense recorded was $<ix:nonFraction unitRef="usd" contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231" decimals="-5" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185Ny9mcmFnOmJjZWZiM2Q3NjJhNzQ1YWE4MWQ3NzAzMjlmMDdjODMyL3RleHRyZWdpb246YmNlZmIzZDc2MmE3NDVhYTgxZDc3MDMyOWYwN2M4MzJfMTA5OTUxMTYzNzc2Nw_43ad4ada-4437-441f-b33a-cfac701ceee5">0.5</ix:nonFraction>&#160;million. The income tax expense recorded by the Company in 2021 primarily relates to foreign taxes and the impact of the valuation allowance recorded against the Company&#8217;s net deferred tax assets, with the exception of indefinite lived components and those expected to reverse outside of the net operating loss carryover period.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">For the year ended December 31, 2020, the effective tax rate was <ix:nonFraction unitRef="number" contextRef="i12a6d1161de54547bd29f8efccd4c9b0_D20200101-20201231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185Ny9mcmFnOmJjZWZiM2Q3NjJhNzQ1YWE4MWQ3NzAzMjlmMDdjODMyL3RleHRyZWdpb246YmNlZmIzZDc2MmE3NDVhYTgxZDc3MDMyOWYwN2M4MzJfMTM0Mw_b74d0f6a-8b36-4f4a-9d8b-d71b78896fdc">0.7</ix:nonFraction>% and the corresponding tax benefit recorded was $<ix:nonFraction unitRef="usd" contextRef="i12a6d1161de54547bd29f8efccd4c9b0_D20200101-20201231" decimals="-5" sign="-" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185Ny9mcmFnOmJjZWZiM2Q3NjJhNzQ1YWE4MWQ3NzAzMjlmMDdjODMyL3RleHRyZWdpb246YmNlZmIzZDc2MmE3NDVhYTgxZDc3MDMyOWYwN2M4MzJfMTM5NA_4956b151-1f1e-4011-8a7b-e07bc87a6dea">2.4</ix:nonFraction>&#160;million. The income tax benefit recorded by the Company in 2020 primarily relates to the impacts from the Coronavirus Aid, Relief, and Economic Security Act (the &#8220;CARES Act&#8221;). On March 27, 2020, in response to the COVID-19 pandemic, the CARES Act, was signed into law. The CARES Act allowed net operating losses (&#8220;NOLs&#8221;) incurred in 2018, 2019 and 2020 to be carried back to each of the five preceding taxable years for the recovery of previously paid federal income taxes. The Company recorded an income tax benefit related to carrying back New Century Health&#8217;s 2018 NOL as part of a federal income tax refund claim for taxes it paid on income in 2013 and 2014. The remaining income tax provisions included in the CARES Act, apart from the aforementioned NOL carryback, did not have a significant impact on the Company. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the year ended December 31, 2019, the effective tax rate was <ix:nonFraction unitRef="number" contextRef="i3e21049ffc224cacb8134d73c9bb5b38_D20190101-20191231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185Ny9mcmFnOmJjZWZiM2Q3NjJhNzQ1YWE4MWQ3NzAzMjlmMDdjODMyL3RleHRyZWdpb246YmNlZmIzZDc2MmE3NDVhYTgxZDc3MDMyOWYwN2M4MzJfMTA5OTUxMTYzNjY3MA_80a617c8-ff5f-44d1-94f1-e1134e1600f4">6.9</ix:nonFraction>%, and the corresponding tax benefit recorded was $<ix:nonFraction unitRef="usd" contextRef="i3e21049ffc224cacb8134d73c9bb5b38_D20190101-20191231" decimals="-5" sign="-" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185Ny9mcmFnOmJjZWZiM2Q3NjJhNzQ1YWE4MWQ3NzAzMjlmMDdjODMyL3RleHRyZWdpb246YmNlZmIzZDc2MmE3NDVhYTgxZDc3MDMyOWYwN2M4MzJfMjMyNw_bd1494ce-dfdd-4a2b-8270-28d1a1113672">22.8</ix:nonFraction>&#160;million. Our effective tax rate in 2019 was impacted by the tax expense for the impairment of non-deductible goodwill, change in valuation allowance for current year losses, and offset in part by the tax effects resulting from the Company&#8217;s acquisition of all remaining Class </span></div></ix:continuation><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">109</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i3a6e7f12bea74282a5e98b5e3e913487" continuedAt="i9358267f62604bf59d8986a942b902c6"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">B units of Evolent Health LLC, resulting in it becoming a disregarded entity for U.S. federal and state income purposes on December 26, 2019. The change in Evolent Health LLC&#8217;s tax status resulted in a tax benefit from the reversal of the Company&#8217;s deferred tax liability related to its investment in certain U.S. corporate subsidiaries through Evolent Health LLC, offset by an increase in valuation allowance. The Company filed a consolidated tax return beginning January 1, 2020, which resulted in a tax benefit offsetting the change in valuation allowance to the extent the deferred tax liabilities of our U.S. corporate subsidiaries had been used as a source of future taxable income to support the Company&#8217;s deferred tax assets.  Our valuation allowance assessment is made without considering deferred tax liabilities of $<ix:nonFraction unitRef="usd" contextRef="icba6e493923b449aa57c46a563760234_I20191231" decimals="-5" name="evh:DeferredTaxLiabilitiesIndefiniteLivedIntangibleAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185Ny9mcmFnOmJjZWZiM2Q3NjJhNzQ1YWE4MWQ3NzAzMjlmMDdjODMyL3RleHRyZWdpb246YmNlZmIzZDc2MmE3NDVhYTgxZDc3MDMyOWYwN2M4MzJfMzQ0Ng_cb29ee7f-6af6-469b-b94e-69074d0ee348">1.9</ix:nonFraction>&#160;million established with respect to certain indefinite-lived components that cannot be utilized against indefinite-lived deferred tax assets or components that are expected to reverse outside of the net operating loss carryover period, as these are not considered a source of future taxable income for realizing our deferred tax assets. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2021, the Company had $<ix:nonFraction unitRef="usd" contextRef="i8104bf341ae243818cdc049157ebf28d_I20211231" decimals="-5" name="us-gaap:OperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185Ny9mcmFnOmJjZWZiM2Q3NjJhNzQ1YWE4MWQ3NzAzMjlmMDdjODMyL3RleHRyZWdpb246YmNlZmIzZDc2MmE3NDVhYTgxZDc3MDMyOWYwN2M4MzJfNDIwMA_11c3db0d-00c3-45c0-97c7-0038be9265d9">203.7</ix:nonFraction>&#160;million of federal and $<ix:nonFraction unitRef="usd" contextRef="i44a7d440fd3546178704d37b7cd7f209_I20211231" decimals="-5" name="us-gaap:OperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185Ny9mcmFnOmJjZWZiM2Q3NjJhNzQ1YWE4MWQ3NzAzMjlmMDdjODMyL3RleHRyZWdpb246YmNlZmIzZDc2MmE3NDVhYTgxZDc3MDMyOWYwN2M4MzJfNDIxOA_e6df2480-f754-4970-8c46-aa9c782fa7ea">290.8</ix:nonFraction>&#160;million of state NOL carryforwards available to offset future taxable income that begin to expire in 2032 and 2022, respectively, and $<ix:nonFraction unitRef="usd" contextRef="i598bb297864842fe8780e1b67c9dd1d8_I20211231" decimals="-5" name="us-gaap:OperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185Ny9mcmFnOmJjZWZiM2Q3NjJhNzQ1YWE4MWQ3NzAzMjlmMDdjODMyL3RleHRyZWdpb246YmNlZmIzZDc2MmE3NDVhYTgxZDc3MDMyOWYwN2M4MzJfNDM0Mw_2d9d35e0-4b23-4dc2-8403-c33a6371a236">292.9</ix:nonFraction>&#160;million federal and $<ix:nonFraction unitRef="usd" contextRef="ifd7da24ee1294bf3afc9c7ca2280330f_I20211231" decimals="-5" name="us-gaap:OperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185Ny9mcmFnOmJjZWZiM2Q3NjJhNzQ1YWE4MWQ3NzAzMjlmMDdjODMyL3RleHRyZWdpb246YmNlZmIzZDc2MmE3NDVhYTgxZDc3MDMyOWYwN2M4MzJfNDM1OA_ea886504-66d7-429d-b0dd-2b35cd3f740a">196.0</ix:nonFraction>&#160;million of state NOLs with an indefinite carryforward period, subject to a utilization limit of 80% of taxable income in any given year. However, as it is more likely than not that such tax benefit will not be realized based on our evaluation, we have established a valuation allowance against those NOLs. Furthermore, Internal Revenue Code Section 382 imposes limitations on the utilization of NOLs in the event of certain changes in ownership of the Company, which may have occurred or could occur in the future. This could result in an annual limit on the Company&#8217;s ability to utilize NOLs and could cause U.S. federal income taxes to be due sooner than if no such limitations applied.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2021, the Company had $<ix:nonFraction unitRef="usd" contextRef="i898c9db01cf04be08210dc1be3090eca_I20211231" decimals="-5" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185Ny9mcmFnOmJjZWZiM2Q3NjJhNzQ1YWE4MWQ3NzAzMjlmMDdjODMyL3RleHRyZWdpb246YmNlZmIzZDc2MmE3NDVhYTgxZDc3MDMyOWYwN2M4MzJfNTA1OQ_3bb2b74e-7a2a-48d4-8d75-980fe2950676">2.1</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="ibfe040616b3542e3a1e0d4d16022974d_I20211231" decimals="-5" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185Ny9mcmFnOmJjZWZiM2Q3NjJhNzQ1YWE4MWQ3NzAzMjlmMDdjODMyL3RleHRyZWdpb246YmNlZmIzZDc2MmE3NDVhYTgxZDc3MDMyOWYwN2M4MzJfNTA2Ng_d26c2fee-25ef-404b-b5f6-1ee438ece8a3">0.3</ix:nonFraction>&#160;million of research and development credits for federal and state income tax purposes, which could expire unutilized beginning in 2037 and 2028, respectively. The Company has established a valuation allowance against those credits. </span></div><div style="text-align:justify"><span><br/></span></div><ix:nonNumeric contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231" name="us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185Ny9mcmFnOmJjZWZiM2Q3NjJhNzQ1YWE4MWQ3NzAzMjlmMDdjODMyL3RleHRyZWdpb246YmNlZmIzZDc2MmE3NDVhYTgxZDc3MDMyOWYwN2M4MzJfODQxMg_10e1b387-ef66-416a-b36b-f6cd8bbfcde9" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes in our unrecognized tax benefits (in thousands) were as follows:</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"></td><td style="width:402.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:40.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:40.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:40.75pt"></td><td style="width:1.0pt"></td></tr><tr style="height:24pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Year Ended December 31,</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at beginning-of-year</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc0c0c2b8dc04c5698ca0577a54b2e03_I20201231" decimals="-3" name="us-gaap:UnrecognizedTaxBenefits" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185Ny9mcmFnOmJjZWZiM2Q3NjJhNzQ1YWE4MWQ3NzAzMjlmMDdjODMyL3RhYmxlOmVkY2M5NGVkNWI0NTQ0MjNiNGRlY2Y3ZTIzZTEwMDUzL3RhYmxlcmFuZ2U6ZWRjYzk0ZWQ1YjQ1NDQyM2I0ZGVjZjdlMjNlMTAwNTNfMi0xLTEtMS0xNzc3NQ_23953f63-da26-43f1-878d-82660fef4758">678</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icba6e493923b449aa57c46a563760234_I20191231" decimals="-3" name="us-gaap:UnrecognizedTaxBenefits" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185Ny9mcmFnOmJjZWZiM2Q3NjJhNzQ1YWE4MWQ3NzAzMjlmMDdjODMyL3RhYmxlOmVkY2M5NGVkNWI0NTQ0MjNiNGRlY2Y3ZTIzZTEwMDUzL3RhYmxlcmFuZ2U6ZWRjYzk0ZWQ1YjQ1NDQyM2I0ZGVjZjdlMjNlMTAwNTNfMi0zLTEtMS0xNzc3NQ_a67fea3f-afa9-4d57-a71b-c2ff061d565d">753</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7130cb432c4b4fe7a260e8a3beeb35d8_I20181231" decimals="-3" name="us-gaap:UnrecognizedTaxBenefits" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185Ny9mcmFnOmJjZWZiM2Q3NjJhNzQ1YWE4MWQ3NzAzMjlmMDdjODMyL3RhYmxlOmVkY2M5NGVkNWI0NTQ0MjNiNGRlY2Y3ZTIzZTEwMDUzL3RhYmxlcmFuZ2U6ZWRjYzk0ZWQ1YjQ1NDQyM2I0ZGVjZjdlMjNlMTAwNTNfMi01LTEtMS0xNzc3NQ_27953043-f473-479e-92cd-60d457b085ba">934</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lapse of statute of limitations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231" decimals="-3" name="us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185Ny9mcmFnOmJjZWZiM2Q3NjJhNzQ1YWE4MWQ3NzAzMjlmMDdjODMyL3RhYmxlOmVkY2M5NGVkNWI0NTQ0MjNiNGRlY2Y3ZTIzZTEwMDUzL3RhYmxlcmFuZ2U6ZWRjYzk0ZWQ1YjQ1NDQyM2I0ZGVjZjdlMjNlMTAwNTNfNS0xLTEtMS0xNzc3NQ_136e68ad-188e-4368-8fa5-568cefaa1d0b">69</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i12a6d1161de54547bd29f8efccd4c9b0_D20200101-20201231" decimals="-3" name="us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185Ny9mcmFnOmJjZWZiM2Q3NjJhNzQ1YWE4MWQ3NzAzMjlmMDdjODMyL3RhYmxlOmVkY2M5NGVkNWI0NTQ0MjNiNGRlY2Y3ZTIzZTEwMDUzL3RhYmxlcmFuZ2U6ZWRjYzk0ZWQ1YjQ1NDQyM2I0ZGVjZjdlMjNlMTAwNTNfNS0zLTEtMS0xNzc3NQ_e78de632-f929-4e28-8cfb-3a40f1e29203">75</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3e21049ffc224cacb8134d73c9bb5b38_D20190101-20191231" decimals="-3" name="us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185Ny9mcmFnOmJjZWZiM2Q3NjJhNzQ1YWE4MWQ3NzAzMjlmMDdjODMyL3RhYmxlOmVkY2M5NGVkNWI0NTQ0MjNiNGRlY2Y3ZTIzZTEwMDUzL3RhYmxlcmFuZ2U6ZWRjYzk0ZWQ1YjQ1NDQyM2I0ZGVjZjdlMjNlMTAwNTNfNS01LTEtMS0xNzc3NQ_6ab2a026-ca88-4687-85c1-e0e31b305858">181</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at end-of-year</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8daff60be410426d8f7bd49343c1ec0c_I20211231" decimals="-3" name="us-gaap:UnrecognizedTaxBenefits" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185Ny9mcmFnOmJjZWZiM2Q3NjJhNzQ1YWE4MWQ3NzAzMjlmMDdjODMyL3RhYmxlOmVkY2M5NGVkNWI0NTQ0MjNiNGRlY2Y3ZTIzZTEwMDUzL3RhYmxlcmFuZ2U6ZWRjYzk0ZWQ1YjQ1NDQyM2I0ZGVjZjdlMjNlMTAwNTNfNi0xLTEtMS0xNzc3NQ_cc71cb4d-2335-4497-b3e0-92ac6219ca03">609</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc0c0c2b8dc04c5698ca0577a54b2e03_I20201231" decimals="-3" name="us-gaap:UnrecognizedTaxBenefits" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185Ny9mcmFnOmJjZWZiM2Q3NjJhNzQ1YWE4MWQ3NzAzMjlmMDdjODMyL3RhYmxlOmVkY2M5NGVkNWI0NTQ0MjNiNGRlY2Y3ZTIzZTEwMDUzL3RhYmxlcmFuZ2U6ZWRjYzk0ZWQ1YjQ1NDQyM2I0ZGVjZjdlMjNlMTAwNTNfNi0zLTEtMS0xNzc3NQ_ceecb527-e9f7-482c-a4ff-5c08808cbc42">678</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icba6e493923b449aa57c46a563760234_I20191231" decimals="-3" name="us-gaap:UnrecognizedTaxBenefits" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185Ny9mcmFnOmJjZWZiM2Q3NjJhNzQ1YWE4MWQ3NzAzMjlmMDdjODMyL3RhYmxlOmVkY2M5NGVkNWI0NTQ0MjNiNGRlY2Y3ZTIzZTEwMDUzL3RhYmxlcmFuZ2U6ZWRjYzk0ZWQ1YjQ1NDQyM2I0ZGVjZjdlMjNlMTAwNTNfNi01LTEtMS0xNzc3NQ_2f3656ab-2552-43bc-8cb3-4807010970fb">753</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are subject to taxation in various jurisdictions in the U.S. and India. Tax years 2011 and all subsequent periods remain subject to examination by the U.S. federal and state taxing jurisdictions due to the availability of NOL carryforwards. Included in the balance of unrecognized tax benefits as of December&#160;31, 2021, are $<ix:nonFraction unitRef="usd" contextRef="i8daff60be410426d8f7bd49343c1ec0c_I20211231" decimals="-5" name="evh:UnrecognizedTaxBenefitsThatWouldNotImpactEffectiveTaxRate" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185Ny9mcmFnOmJjZWZiM2Q3NjJhNzQ1YWE4MWQ3NzAzMjlmMDdjODMyL3RleHRyZWdpb246YmNlZmIzZDc2MmE3NDVhYTgxZDc3MDMyOWYwN2M4MzJfNTY3OQ_dbf35e08-d0de-49da-8795-ec86ba713812">0.6</ix:nonFraction>&#160;million of tax benefits that, if recognized, would not affect the overall effective tax rate, due to the offsetting impact on the Company&#8217;s valuation allowance. The Company has not recognized interest and penalties related to uncertain tax positions due to the current NOL position. The Company had recognized $<ix:nonFraction unitRef="usd" contextRef="ibc0c0c2b8dc04c5698ca0577a54b2e03_I20201231" decimals="-5" name="us-gaap:UnrecognizedTaxBenefits" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185Ny9mcmFnOmJjZWZiM2Q3NjJhNzQ1YWE4MWQ3NzAzMjlmMDdjODMyL3RleHRyZWdpb246YmNlZmIzZDc2MmE3NDVhYTgxZDc3MDMyOWYwN2M4MzJfNTk4NA_838e571a-8770-49b7-b00f-2e7602ab251d">0.7</ix:nonFraction>&#160;million of uncertain tax positions as of December&#160;31, 2020, and $<ix:nonFraction unitRef="usd" contextRef="icba6e493923b449aa57c46a563760234_I20191231" decimals="-5" name="us-gaap:UnrecognizedTaxBenefits" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185Ny9mcmFnOmJjZWZiM2Q3NjJhNzQ1YWE4MWQ3NzAzMjlmMDdjODMyL3RleHRyZWdpb246YmNlZmIzZDc2MmE3NDVhYTgxZDc3MDMyOWYwN2M4MzJfNjAyOA_3ce06a3d-fc3e-4843-ba87-20352f92ead4">0.8</ix:nonFraction>&#160;million as of December&#160;31, 2019. The Company and its subsidiaries are not currently subject to income tax audits in any U.S. state or local jurisdiction, or any foreign jurisdiction, for any tax year.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Tax Receivables Agreement</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the Offering Reorganization, Class B Exchanges increased our tax basis in our share of Evolent Health LLC&#8217;s tangible and intangible assets. These increases in tax basis increased our depreciation and amortization deductions and create other tax benefits and, therefore, may reduce the amount of tax that we would otherwise be required to pay in the future. In addition, certain NOLs of Evolent Health Holdings (and of an affiliate of TPG) are available to us as a result of the Offering Reorganization.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Offering Reorganization, we entered into the TRA with the holders of Class B common units. The agreement requires us to pay to such holders <ix:nonFraction unitRef="number" contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231" decimals="INF" name="evh:TaxReceivableAgreementPercentofCashSavingsPaidtoShareholders" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185Ny9mcmFnOmJjZWZiM2Q3NjJhNzQ1YWE4MWQ3NzAzMjlmMDdjODMyL3RleHRyZWdpb246YmNlZmIzZDc2MmE3NDVhYTgxZDc3MDMyOWYwN2M4MzJfNjkxNg_48c26b60-cd78-46db-a033-d728ef34af95">85</ix:nonFraction>% of the cash savings, if any, in U.S. federal, state and local, and foreign income tax (as applicable) we realize as a result of any deductions attributable to future increases in tax basis following the Class B Exchanges (calculated assuming that any post-offering transfer of Class B common units had not occurred) or deductions attributable to imputed interest or future increases in tax basis following payments made under the TRA. We are accounting for these payments as contingent liabilities and will recognize them in our Consolidated Statements of Operations and Comprehensive Income (Loss) when their realization becomes probable. Additionally, pursuant to the same agreement we will pay the former stockholders of Evolent Health Holdings <ix:nonFraction unitRef="number" contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231" decimals="INF" name="evh:TaxReceivableAgreementPercentofCashSavingsPaidtoShareholders" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185Ny9mcmFnOmJjZWZiM2Q3NjJhNzQ1YWE4MWQ3NzAzMjlmMDdjODMyL3RleHRyZWdpb246YmNlZmIzZDc2MmE3NDVhYTgxZDc3MDMyOWYwN2M4MzJfNzY2MQ_7e59678c-0a7e-4a43-b670-ed775b34ef67">85</ix:nonFraction>% of the amount of the cash savings, if any, in U.S. federal, state and local, and foreign income tax that we realize as a result of the utilization of the NOLs of Evolent Health Holdings (and the affiliate of TPG) attributable to periods prior to the Offering Reorganization, approximately $<ix:nonFraction unitRef="usd" contextRef="ib0a5f68e764e419481a0d19e2432cafe_I20211231" decimals="-5" name="us-gaap:OperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185Ny9mcmFnOmJjZWZiM2Q3NjJhNzQ1YWE4MWQ3NzAzMjlmMDdjODMyL3RleHRyZWdpb246YmNlZmIzZDc2MmE3NDVhYTgxZDc3MDMyOWYwN2M4MzJfNzk1Mg_ac15a98e-609b-4a2d-b414-3d47d856a396">79.3</ix:nonFraction>&#160;million, as well as deductions attributable to imputed interest on any payments made under the agreement. </span></div></ix:continuation><div style="text-align:justify"><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">110</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i9358267f62604bf59d8986a942b902c6">We will benefit from the remaining <ix:nonFraction unitRef="number" contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231" decimals="INF" name="evh:TaxReceivableAgreementPercentofCashSavingsNotPaidtoShareholders" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185Ny9mcmFnOmJjZWZiM2Q3NjJhNzQ1YWE4MWQ3NzAzMjlmMDdjODMyL3RleHRyZWdpb246YmNlZmIzZDc2MmE3NDVhYTgxZDc3MDMyOWYwN2M4MzJfODA5MA_fe0efa52-da02-4f31-8407-ea3721060a66">15</ix:nonFraction>% of any realized cash savings. The TRA was effective upon the completion of the Offering Reorganization and will remain in effect until all such tax benefits have been used or expired, or until the agreement is terminated.  See Note 11 for additional discussion of the implications of the TRA.</ix:continuation></span></div><div><span><br/></span></div><div id="i9aaa2fddc97e482da5dbe37ac85ae703_103"></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 16.  <ix:nonNumeric contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231" name="us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMDMvZnJhZzpkZWU0NDMzYjE4ODQ0MzMyOTg3NjI5ZTU2Yzg5OWY0Mi90ZXh0cmVnaW9uOmRlZTQ0MzNiMTg4NDQzMzI5ODc2MjllNTZjODk5ZjQyXzQ5MA_1e2f5df7-9000-4bd5-be60-1eeb3ef22570" continuedAt="i0cd55e82b4cd41d483b4bc5d4d6e5c09" escape="true">Employee Benefit Plans</ix:nonNumeric></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><ix:continuation id="i0cd55e82b4cd41d483b4bc5d4d6e5c09"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We sponsor a tax-qualified 401(k) retirement plan that provides eligible U.S. employees with an opportunity to save for retirement on a tax advantaged basis. We make matching contributions to the plan in accordance with the plan documents and various limitations under Section 401(a) of the Internal Revenue Code of 1986, as amended. The Company made $<ix:nonFraction unitRef="usd" contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231" decimals="-5" name="us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMDMvZnJhZzpkZWU0NDMzYjE4ODQ0MzMyOTg3NjI5ZTU2Yzg5OWY0Mi90ZXh0cmVnaW9uOmRlZTQ0MzNiMTg4NDQzMzI5ODc2MjllNTZjODk5ZjQyXzM5MA_e5563ed3-72e4-4d97-bc5f-4a16c31624a8">5.4</ix:nonFraction>&#160;million, $<ix:nonFraction unitRef="usd" contextRef="i12a6d1161de54547bd29f8efccd4c9b0_D20200101-20201231" decimals="-5" name="us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMDMvZnJhZzpkZWU0NDMzYjE4ODQ0MzMyOTg3NjI5ZTU2Yzg5OWY0Mi90ZXh0cmVnaW9uOmRlZTQ0MzNiMTg4NDQzMzI5ODc2MjllNTZjODk5ZjQyXzM5NA_6fb4498c-30d1-43de-90ff-7105bdfaae56">6.2</ix:nonFraction>&#160;million and </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usd" contextRef="i3e21049ffc224cacb8134d73c9bb5b38_D20190101-20191231" decimals="-5" name="us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMDMvZnJhZzpkZWU0NDMzYjE4ODQ0MzMyOTg3NjI5ZTU2Yzg5OWY0Mi90ZXh0cmVnaW9uOmRlZTQ0MzNiMTg4NDQzMzI5ODc2MjllNTZjODk5ZjQyXzQwMQ_3bbe495c-c54b-4b0f-9461-087cc18e77fa">2.6</ix:nonFraction>&#160;million</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in contributions to the 401(k) plan for the years ended December&#160;31, 2021, 2020 and 2019, respectively. Total contributions for the year ended December 31, 2020, are net of $<ix:nonFraction unitRef="usd" contextRef="if7ba948ef00b4ddeabe73338f1155e8b_D20200101-20201231" decimals="-5" name="us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMDMvZnJhZzpkZWU0NDMzYjE4ODQ0MzMyOTg3NjI5ZTU2Yzg5OWY0Mi90ZXh0cmVnaW9uOmRlZTQ0MzNiMTg4NDQzMzI5ODc2MjllNTZjODk5ZjQyXzEwOTk1MTE2Mjg0MzE_04e16e53-615a-44a3-bd75-f466d66e0031">0.2</ix:nonFraction>&#160;million from discontinued operations.</span></ix:continuation></div><div><span><br/></span></div><div id="i9aaa2fddc97e482da5dbe37ac85ae703_106"></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 17.  <ix:nonNumeric contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231" name="us-gaap:EquityMethodInvestmentsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMDYvZnJhZzplOWNhNzhjNDI0NzY0M2NhYmM3OTllZGE4MjA4MDIxYi90ZXh0cmVnaW9uOmU5Y2E3OGM0MjQ3NjQzY2FiYzc5OWVkYTgyMDgwMjFiXzIyMDE_27924f77-5d35-40ec-bfd7-b9aeb8c6e7e6" continuedAt="i6c17292f19634dd4809aed294f18f05c" escape="true">Investments in Equity Method Investees</ix:nonNumeric></span></div><div style="text-align:justify"><span><br/></span></div><ix:continuation id="i6c17292f19634dd4809aed294f18f05c"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company holds ownership interests in joint ventures and other entities which are accounted for under the equity method. The Company evaluates its interests in these entities to determine whether they meet the definition of a VIE and whether the Company is required to consolidate these entities. A VIE is consolidated by its primary beneficiary, which is the party that has both (i) the power to direct the activities that most significantly impact the economic performance of the VIE and (ii) a variable interest that could potentially be significant to the VIE. To determine whether or not a variable interest the Company holds could potentially be significant to the VIE, the Company considers both qualitative and quantitative factors regarding the nature, size and form of the Company's involvement with the VIE. The Company has determined that its interests in these entities meet the definition of a variable interest, however, the Company is not the primary beneficiary since it does not have the power to direct activities, therefore, the Company did not consolidate the VIEs.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of&#160;December&#160;31, 2021 and 2020, the Company&#8217;s economic interests in its equity method investments ranged between <ix:nonFraction unitRef="number" contextRef="i1cb7bef7317f4d90afc92b9268a6542c_I20211231" decimals="2" name="evh:EquityMethodInvestmentEconomicInterestPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMDYvZnJhZzplOWNhNzhjNDI0NzY0M2NhYmM3OTllZGE4MjA4MDIxYi90ZXh0cmVnaW9uOmU5Y2E3OGM0MjQ3NjQzY2FiYzc5OWVkYTgyMDgwMjFiXzEyNjA_65eded90-8a78-4c63-8238-5f022e41e0e7">4</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="i871d99d3c60b41dea330fb287058c6b9_I20211231" decimals="2" name="evh:EquityMethodInvestmentEconomicInterestPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMDYvZnJhZzplOWNhNzhjNDI0NzY0M2NhYmM3OTllZGE4MjA4MDIxYi90ZXh0cmVnaW9uOmU5Y2E3OGM0MjQ3NjQzY2FiYzc5OWVkYTgyMDgwMjFiXzEyNjc_1e2d9420-f7aa-4a5f-8cef-83f090e4df36">39</ix:nonFraction>%, and <ix:nonFraction unitRef="number" contextRef="i7521b01c889643c9931e6cd5cbaf2b96_I20201231" decimals="2" name="evh:EquityMethodInvestmentEconomicInterestPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMDYvZnJhZzplOWNhNzhjNDI0NzY0M2NhYmM3OTllZGE4MjA4MDIxYi90ZXh0cmVnaW9uOmU5Y2E3OGM0MjQ3NjQzY2FiYzc5OWVkYTgyMDgwMjFiXzEyNzU_2019aca8-0719-45b6-ae2f-8dbca31172bc">4</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="i9f8d5e268f3d4eb697463d42a1cc1553_I20201231" decimals="2" name="evh:EquityMethodInvestmentEconomicInterestPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMDYvZnJhZzplOWNhNzhjNDI0NzY0M2NhYmM3OTllZGE4MjA4MDIxYi90ZXh0cmVnaW9uOmU5Y2E3OGM0MjQ3NjQzY2FiYzc5OWVkYTgyMDgwMjFiXzEyODI_210bcddb-78e6-4735-a968-38de423fe9b7">38</ix:nonFraction>%, respectively, and voting interests in its equity method investments ranged between <ix:nonFraction unitRef="number" contextRef="i1cb7bef7317f4d90afc92b9268a6542c_I20211231" decimals="2" name="evh:EquityMethodInvestmentVotingInterestPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMDYvZnJhZzplOWNhNzhjNDI0NzY0M2NhYmM3OTllZGE4MjA4MDIxYi90ZXh0cmVnaW9uOmU5Y2E3OGM0MjQ3NjQzY2FiYzc5OWVkYTgyMDgwMjFiXzEzNjk_4ed8a451-2f7b-4f10-b8b1-4a61e2850e9f"><ix:nonFraction unitRef="number" contextRef="i7521b01c889643c9931e6cd5cbaf2b96_I20201231" decimals="2" name="evh:EquityMethodInvestmentVotingInterestPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMDYvZnJhZzplOWNhNzhjNDI0NzY0M2NhYmM3OTllZGE4MjA4MDIxYi90ZXh0cmVnaW9uOmU5Y2E3OGM0MjQ3NjQzY2FiYzc5OWVkYTgyMDgwMjFiXzEzNjk_f5b953fc-89ec-4244-94bc-19bfb80172bd">25</ix:nonFraction></ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="i871d99d3c60b41dea330fb287058c6b9_I20211231" decimals="2" name="evh:EquityMethodInvestmentVotingInterestPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMDYvZnJhZzplOWNhNzhjNDI0NzY0M2NhYmM3OTllZGE4MjA4MDIxYi90ZXh0cmVnaW9uOmU5Y2E3OGM0MjQ3NjQzY2FiYzc5OWVkYTgyMDgwMjFiXzEzNzY_74500fb3-1def-4b08-b8b1-370f2008bdf2"><ix:nonFraction unitRef="number" contextRef="i9f8d5e268f3d4eb697463d42a1cc1553_I20201231" decimals="2" name="evh:EquityMethodInvestmentVotingInterestPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMDYvZnJhZzplOWNhNzhjNDI0NzY0M2NhYmM3OTllZGE4MjA4MDIxYi90ZXh0cmVnaW9uOmU5Y2E3OGM0MjQ3NjQzY2FiYzc5OWVkYTgyMDgwMjFiXzEzNzY_fe4910ff-c80e-42d1-adcd-00d72f189342">40</ix:nonFraction></ix:nonFraction>%, respectively. The Company determined that it has significant influence over these entities but that it does not have control over any of the entities. Accordingly, the investments are accounted for under the equity method of accounting and the Company is allocated its proportional share of the entities&#8217; earnings and losses for each reporting period. The Company&#8217;s proportional share of the gain (loss) from these investments was approximately $<ix:nonFraction unitRef="usd" contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231" decimals="-5" name="us-gaap:IncomeLossFromEquityMethodInvestments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMDYvZnJhZzplOWNhNzhjNDI0NzY0M2NhYmM3OTllZGE4MjA4MDIxYi90ZXh0cmVnaW9uOmU5Y2E3OGM0MjQ3NjQzY2FiYzc5OWVkYTgyMDgwMjFiXzE4MzQ_b495e1f1-ccd4-44af-b8ee-220a6d4ed35c">13.2</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="i12a6d1161de54547bd29f8efccd4c9b0_D20200101-20201231" decimals="-5" name="us-gaap:IncomeLossFromEquityMethodInvestments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMDYvZnJhZzplOWNhNzhjNDI0NzY0M2NhYmM3OTllZGE4MjA4MDIxYi90ZXh0cmVnaW9uOmU5Y2E3OGM0MjQ3NjQzY2FiYzc5OWVkYTgyMDgwMjFiXzE4NjY_c580dea0-7efb-4173-8c80-fd27b0afe587">10.0</ix:nonFraction> million and $(<ix:nonFraction unitRef="usd" contextRef="i3e21049ffc224cacb8134d73c9bb5b38_D20190101-20191231" decimals="-5" sign="-" name="us-gaap:IncomeLossFromEquityMethodInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMDYvZnJhZzplOWNhNzhjNDI0NzY0M2NhYmM3OTllZGE4MjA4MDIxYi90ZXh0cmVnaW9uOmU5Y2E3OGM0MjQ3NjQzY2FiYzc5OWVkYTgyMDgwMjFiXzIxOTkwMjMyNTc5ODE_889c1815-18f4-4717-b433-0388070488e6">9.5</ix:nonFraction>)&#160;million for the years ended December&#160;31, 2021, 2020 and 2019, respectively.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company signed services agreements with certain of the aforementioned entities to provide certain management, operational and support services to help manage elements of their service offerings. Revenue related to these services agreements were $<ix:nonFraction unitRef="usd" contextRef="id48b2d5a479f4ab58afeb508e8f9bc7c_D20210101-20211231" decimals="-5" name="evh:IncomeLossfromEquityMethodInvestmentsServicesAgreement" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMDYvZnJhZzplOWNhNzhjNDI0NzY0M2NhYmM3OTllZGE4MjA4MDIxYi90ZXh0cmVnaW9uOmU5Y2E3OGM0MjQ3NjQzY2FiYzc5OWVkYTgyMDgwMjFiXzIxNDQ_4f3249a9-c131-4724-ab06-e741ce315876">15.9</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="i441f674d44a64d47a96c0c85ef92310d_D20200101-20201231" decimals="-5" name="evh:IncomeLossfromEquityMethodInvestmentsServicesAgreement" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMDYvZnJhZzplOWNhNzhjNDI0NzY0M2NhYmM3OTllZGE4MjA4MDIxYi90ZXh0cmVnaW9uOmU5Y2E3OGM0MjQ3NjQzY2FiYzc5OWVkYTgyMDgwMjFiXzIxNzY_127f29d9-7fdc-4ed4-a26f-c0436e27fcba">192.8</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i28a8f36df87345df9d28593e38c0563c_D20190101-20191231" decimals="-5" name="evh:IncomeLossfromEquityMethodInvestmentsServicesAgreement" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMDYvZnJhZzplOWNhNzhjNDI0NzY0M2NhYmM3OTllZGE4MjA4MDIxYi90ZXh0cmVnaW9uOmU5Y2E3OGM0MjQ3NjQzY2FiYzc5OWVkYTgyMDgwMjFiXzEwOTk1MTE2MzAxNjk_b9ec0346-798a-4bae-b245-d4d06488e8e9">41.5</ix:nonFraction> million for the years ended December&#160;31, 2021, 2020 and 2019, respectively.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Unconsolidated VIEs</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Global</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March 31, 2020, the Oklahoma Insurance Division (&#8220;OID&#8221;) informed GlobalHealth, Inc. that in response to the COVID-19 pandemic, the OID required GlobalHealth, Inc. to increase its regulatory capital surplus by May 15, 2020. It would otherwise be placed into receivership if additional financing could not be secured. Certain investors agreed to provide liquidity as necessary to increase statutory capital reserves to no lower than <ix:nonFraction unitRef="number" contextRef="ibca1768da73d4a4188df3e08ee08a9ce_I20200331" decimals="INF" name="evh:StatutoryCapitalReservesLiquidityGuaranteedByInvestorsMinimum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMDYvZnJhZzplOWNhNzhjNDI0NzY0M2NhYmM3OTllZGE4MjA4MDIxYi90ZXh0cmVnaW9uOmU5Y2E3OGM0MjQ3NjQzY2FiYzc5OWVkYTgyMDgwMjFiXzM4NDgyOTA3MDI4NjE_9949f896-9170-47fa-8c0c-d41f9b387793">300</ix:nonFraction>%. In connection with the investment, GlobalHealth, Inc. transferred <ix:nonFraction unitRef="number" contextRef="ibca1768da73d4a4188df3e08ee08a9ce_I20200331" decimals="INF" name="evh:EquityInterestToBeTransferred" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMDYvZnJhZzplOWNhNzhjNDI0NzY0M2NhYmM3OTllZGE4MjA4MDIxYi90ZXh0cmVnaW9uOmU5Y2E3OGM0MjQ3NjQzY2FiYzc5OWVkYTgyMDgwMjFiXzM4NDgyOTA3MDI4Njc_cd241798-3c6c-4ad1-be6f-9c6c7f6a2413">100</ix:nonFraction>% of the equity interests in GlobalHealth, Inc. to the new investors for no consideration. Closing of this transaction occurred on May 13, 2020. As a result of this transaction, we recorded a non-cash impairment charge of approximately $<ix:nonFraction unitRef="usd" contextRef="ib755be34efd8414388d2ce5ca242428f_D20200101-20201231" decimals="-5" name="us-gaap:EquityMethodInvestmentOtherThanTemporaryImpairment" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMDYvZnJhZzplOWNhNzhjNDI0NzY0M2NhYmM3OTllZGE4MjA4MDIxYi90ZXh0cmVnaW9uOmU5Y2E3OGM0MjQ3NjQzY2FiYzc5OWVkYTgyMDgwMjFiXzM4NDgyOTA3MDI4NzM_d1684fc0-ed55-4f64-bdb6-d0cd6373d658">47.1</ix:nonFraction>&#160;million, representing the total value of our investment, in impairment of equity method investments on the consolidated statements of operations and comprehensive income (loss) for the year ended December 31, 2020.</span></div></ix:continuation><div style="text-align:justify"><span><br/></span></div><div id="i9aaa2fddc97e482da5dbe37ac85ae703_109"></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 18.  <ix:nonNumeric contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231" name="us-gaap:MinorityInterestDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMDkvZnJhZzo4ZTQzMWU3Y2Y4NmU0MmMxODMzNmZmOGYxMTc0ZjZhYS90ZXh0cmVnaW9uOjhlNDMxZTdjZjg2ZTQyYzE4MzM2ZmY4ZjExNzRmNmFhXzE0NjY_45e09e40-edeb-455e-9058-cf608f5acd61" continuedAt="if043e0d2a8484c2eafade1f1c683f49f" escape="true">Non-controlling Interests</ix:nonNumeric></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="if043e0d2a8484c2eafade1f1c683f49f" continuedAt="i8fc67770629c4f28ababfe794b172422">Immediately following the Offering Reorganization and IPO in May 2015, the Company owned <ix:nonFraction unitRef="number" contextRef="ibde52dbc2c2c4cbda03403d89ddcaca6_I20150531" decimals="3" name="us-gaap:MinorityInterestOwnershipPercentageByParent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMDkvZnJhZzo4ZTQzMWU3Y2Y4NmU0MmMxODMzNmZmOGYxMTc0ZjZhYS90ZXh0cmVnaW9uOjhlNDMxZTdjZjg2ZTQyYzE4MzM2ZmY4ZjExNzRmNmFhXzEzMQ_80141ff7-71b4-449d-95aa-974eea0763aa">70.3</ix:nonFraction>% of Evolent Health LLC. The Company&#8217;s ownership percentage changes with the issuance of Class A or Class B common stock and Class B Exchanges. In order to account for any changes in the Company&#8217;s ownership of Evolent Health LLC, we record a reclassification of equity between non-controlling interests and shareholders&#8217; equity attributable to Evolent Health, Inc.</ix:continuation></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">111</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span><br/></span></div><ix:continuation id="i8fc67770629c4f28ababfe794b172422"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 1, 2020, in connection with the consolidation of EVH Passport, the Company recognized a $<ix:nonFraction unitRef="usd" contextRef="i02e542a70a5046e396e8cd9126fefd99_D20200901-20200901" decimals="-5" name="us-gaap:NoncontrollingInterestIncreaseFromBusinessCombination" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMDkvZnJhZzo4ZTQzMWU3Y2Y4NmU0MmMxODMzNmZmOGYxMTc0ZjZhYS90ZXh0cmVnaW9uOjhlNDMxZTdjZjg2ZTQyYzE4MzM2ZmY4ZjExNzRmNmFhXzYwNQ_36d98815-dbf9-4e42-b878-e596d0bfb850">25.7</ix:nonFraction>&#160;million non-controlling interest for the Sponsors&#8217; <ix:nonFraction unitRef="number" contextRef="i02e542a70a5046e396e8cd9126fefd99_D20200901-20200901" decimals="2" name="us-gaap:VariableInterestEntityOwnershipPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMDkvZnJhZzo4ZTQzMWU3Y2Y4NmU0MmMxODMzNmZmOGYxMTc0ZjZhYS90ZXh0cmVnaW9uOjhlNDMxZTdjZjg2ZTQyYzE4MzM2ZmY4ZjExNzRmNmFhXzY1MQ_dfd5a537-d1fe-464e-a11b-16259d77a0f7">30</ix:nonFraction>% equity interest in EVH Passport which represented the fair value of the non-controlling interest as of the date of consolidation. Pursuant to the shareholders&#8217; agreement with the Sponsors, the Company was required to acquire the Sponsors&#8217; <ix:nonFraction unitRef="number" contextRef="i02e542a70a5046e396e8cd9126fefd99_D20200901-20200901" decimals="2" name="us-gaap:VariableInterestEntityOwnershipPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMDkvZnJhZzo4ZTQzMWU3Y2Y4NmU0MmMxODMzNmZmOGYxMTc0ZjZhYS90ZXh0cmVnaW9uOjhlNDMxZTdjZjg2ZTQyYzE4MzM2ZmY4ZjExNzRmNmFhXzg5Mw_7ab9670c-c379-48ed-ad6c-5804b5b7c6b0">30</ix:nonFraction>% ownership interest for $<ix:nonFraction unitRef="usd" contextRef="ia11440f2d2cf4758bb0c9e18c239042c_I20200901" decimals="-5" name="evh:VariableInterestEntityNewMedicaidContractNotAwardedRequirementToAcquireOwnershipConsiderationAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMDkvZnJhZzo4ZTQzMWU3Y2Y4NmU0MmMxODMzNmZmOGYxMTc0ZjZhYS90ZXh0cmVnaW9uOjhlNDMxZTdjZjg2ZTQyYzE4MzM2ZmY4ZjExNzRmNmFhXzkxOQ_e2ae3e5a-56ef-46fe-8abe-25dc063f5bdf">20.0</ix:nonFraction>&#160;million on or prior to December 31, 2021. On November 16, 2020, the Company acquired the Sponsors&#8217; <ix:nonFraction unitRef="number" contextRef="i553144e874d7414ab395f79f6424736f_D20201116-20201116" decimals="2" name="us-gaap:VariableInterestEntityOwnershipPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMDkvZnJhZzo4ZTQzMWU3Y2Y4NmU0MmMxODMzNmZmOGYxMTc0ZjZhYS90ZXh0cmVnaW9uOjhlNDMxZTdjZjg2ZTQyYzE4MzM2ZmY4ZjExNzRmNmFhXzEwMTM_556c735e-da28-4ef3-a5c0-67be9a0ad4a8">30</ix:nonFraction>% equity interest and reclassified the non-controlling interests into shareholders&#8217; equity attributable to Evolent Health, Inc. As a result of this transaction, the Company recorded a $<ix:nonFraction unitRef="usd" contextRef="i299a8d5a546040409468f7f7fabc44c0_D20200101-20201231" decimals="-5" name="us-gaap:VariableInterestEntityInitialConsolidationGainOrLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMDkvZnJhZzo4ZTQzMWU3Y2Y4NmU0MmMxODMzNmZmOGYxMTc0ZjZhYS90ZXh0cmVnaW9uOjhlNDMxZTdjZjg2ZTQyYzE4MzM2ZmY4ZjExNzRmNmFhXzExOTg_d8b3387c-0edd-4134-8338-739fbdb9e836">5.7</ix:nonFraction>&#160;million gain on consolidation for the year ended December 31, 2020 in gain (loss) on disposal of assets and consolidation on the consolidated statements of operations.</span></div><div style="text-align:justify"><span><br/></span></div><ix:nonNumeric contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231" name="evh:ScheduleofChangesinNoncontrollingInterestTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMDkvZnJhZzo4ZTQzMWU3Y2Y4NmU0MmMxODMzNmZmOGYxMTc0ZjZhYS90ZXh0cmVnaW9uOjhlNDMxZTdjZjg2ZTQyYzE4MzM2ZmY4ZjExNzRmNmFhXzE0NjI_b1fc6d32-a348-4eb6-acef-2bf7f0ea7d1f" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes in non-controlling interests (in thousands) for year ended December 31, 2020, was as follows:</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"></td><td style="width:463.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:72.25pt"></td><td style="width:1.0pt"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-controlling interests balance as of beginning of period</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2d2497909b9e4097b418e747f13bfc16_I20191231" decimals="-3" name="us-gaap:MinorityInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMDkvZnJhZzo4ZTQzMWU3Y2Y4NmU0MmMxODMzNmZmOGYxMTc0ZjZhYS90YWJsZTowZTgzMjRmNTI2OTk0NTgxOWQ1ZjJiMjM0NTU0ZjI4MC90YWJsZXJhbmdlOjBlODMyNGY1MjY5OTQ1ODE5ZDVmMmIyMzQ1NTRmMjgwXzEtMy0xLTEtMTc3NzU_88e1e9a6-5231-4d14-beda-592960da2c54">6,689</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issuance of non-controlling interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic8a05c8bd28c42f4918205dc608cf2de_D20200101-20201231" decimals="-3" name="us-gaap:NoncontrollingInterestIncreaseFromBusinessCombination" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMDkvZnJhZzo4ZTQzMWU3Y2Y4NmU0MmMxODMzNmZmOGYxMTc0ZjZhYS90YWJsZTowZTgzMjRmNTI2OTk0NTgxOWQ1ZjJiMjM0NTU0ZjI4MC90YWJsZXJhbmdlOjBlODMyNGY1MjY5OTQ1ODE5ZDVmMmIyMzQ1NTRmMjgwXzItMy0xLTEtMTc3NzU_adfde652-f377-497d-84d9-7de25972666e">25,749</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Disposal of assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic8a05c8bd28c42f4918205dc608cf2de_D20200101-20201231" decimals="-3" name="evh:NoncontrollingInterestDecreaseFromDisposalOfAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMDkvZnJhZzo4ZTQzMWU3Y2Y4NmU0MmMxODMzNmZmOGYxMTc0ZjZhYS90YWJsZTowZTgzMjRmNTI2OTk0NTgxOWQ1ZjJiMjM0NTU0ZjI4MC90YWJsZXJhbmdlOjBlODMyNGY1MjY5OTQ1ODE5ZDVmMmIyMzQ1NTRmMjgwXzMtMy0xLTEtMTc3NzU_ae3d47e5-b9b2-44ff-97ee-012df157ce9f">6,689</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Redemption of Sponsor&#8217;s equity</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic8a05c8bd28c42f4918205dc608cf2de_D20200101-20201231" decimals="-3" name="us-gaap:MinorityInterestDecreaseFromRedemptions" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMDkvZnJhZzo4ZTQzMWU3Y2Y4NmU0MmMxODMzNmZmOGYxMTc0ZjZhYS90YWJsZTowZTgzMjRmNTI2OTk0NTgxOWQ1ZjJiMjM0NTU0ZjI4MC90YWJsZXJhbmdlOjBlODMyNGY1MjY5OTQ1ODE5ZDVmMmIyMzQ1NTRmMjgwXzQtMy0xLTEtMTc3NzU_2e01520c-c0f2-4300-9f6d-4b448511fe06">25,749</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-controlling interests balance as of end of period</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5724ef529cea411aadb2b6f086af09f1_I20201231" decimals="-3" name="us-gaap:MinorityInterest" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMDkvZnJhZzo4ZTQzMWU3Y2Y4NmU0MmMxODMzNmZmOGYxMTc0ZjZhYS90YWJsZTowZTgzMjRmNTI2OTk0NTgxOWQ1ZjJiMjM0NTU0ZjI4MC90YWJsZXJhbmdlOjBlODMyNGY1MjY5OTQ1ODE5ZDVmMmIyMzQ1NTRmMjgwXzUtMy0xLTEtMTc3NzU_7205c19b-0a81-4d0d-8950-c903170ae90a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="text-align:justify"><span><br/></span></div><div id="i9aaa2fddc97e482da5dbe37ac85ae703_112"></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 19. <ix:continuation id="i7623edd0172b4b279ee25421e8a9a7d1" continuedAt="i29a25a20e80548899c36bdef6d25558d"><ix:nonNumeric contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231" name="us-gaap:FairValueDisclosuresTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMTIvZnJhZzpjMzMwYzUwYWY0YTc0OTlhODRlZTQ3ZWJmNjE2NmE4Yy90ZXh0cmVnaW9uOmMzMzBjNTBhZjRhNzQ5OWE4NGVlNDdlYmY2MTY2YThjXzQ5NzU_cd4bbc82-3f60-46ba-a16a-f052b29146b4" continuedAt="i39bdf0f4dfdf4457b142c425e08e1d6a" escape="true">Fair Value Measurement</ix:nonNumeric></ix:continuation></span></div><div style="text-align:justify"><span><br/></span></div><ix:continuation id="i29a25a20e80548899c36bdef6d25558d" continuedAt="ib17713aa9d984fb480dceb9ddd93f1f2"><ix:continuation id="i39bdf0f4dfdf4457b142c425e08e1d6a" continuedAt="i382161c184c2449c9fb63de9f1a59957"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">GAAP defines fair value as the price that would be received from the sale of an asset or paid to transfer a liability (an exit price) assuming an orderly transaction in the most advantageous market at the measurement date. GAAP also establishes a hierarchical disclosure framework which prioritizes and ranks the level of observability of inputs used in measuring fair value. These tiers include:</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 1 - inputs to the valuation methodology are quoted prices available in active markets for identical instruments as of the reporting date;</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 2 - inputs to the valuation methodology are other than quoted prices in active markets, which are either directly or indirectly observable as of the reporting date and the fair value can be determined through the use of models or other valuation methodologies; and </span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 3 - inputs to the valuation methodology are unobservable inputs in situations where there is little or no market activity for the asset or liability.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In certain cases, the inputs used to measure fair value may fall into different levels of the fair value hierarchy. In such cases, the level within the fair value hierarchy is based on the lowest level of input that is significant to the fair value measurement. Our assessment of the significance of a particular input to the fair value measurement in its entirety requires judgment and considers factors specific to the particular asset or liability being measured. </span></div></ix:continuation></ix:continuation><div style="text-align:justify"><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">112</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i382161c184c2449c9fb63de9f1a59957" continuedAt="i24fbeaa4816e404f8fe0cc2627bdc976"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recurring Fair Value Measurements</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In accordance with GAAP, certain assets and liabilities are required to be recorded at fair value on a recurring basis. <ix:nonNumeric contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231" name="us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMTIvZnJhZzpjMzMwYzUwYWY0YTc0OTlhODRlZTQ3ZWJmNjE2NmE4Yy90ZXh0cmVnaW9uOmMzMzBjNTBhZjRhNzQ5OWE4NGVlNDdlYmY2MTY2YThjXzQ5Njk_11e1fdfa-6119-46a6-b32f-21514c6bfa60" continuedAt="i5fcf1a6bbc5a40999a02847f4e5cf723" escape="true"><ix:nonNumeric contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231" name="us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMTIvZnJhZzpjMzMwYzUwYWY0YTc0OTlhODRlZTQ3ZWJmNjE2NmE4Yy90ZXh0cmVnaW9uOmMzMzBjNTBhZjRhNzQ5OWE4NGVlNDdlYmY2MTY2YThjXzQ5NzQ_6325fb64-a294-467a-99c7-04fa6aed43f1" continuedAt="i6e5286608ddb4daaa39f11ed0e384c75" escape="true">The following table summarizes the Company&#8217;s assets and liabilities measured at fair value on a recurring basis (in thousands):</ix:nonNumeric></ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%"><ix:continuation id="i5fcf1a6bbc5a40999a02847f4e5cf723" continuedAt="i4745277317fa4eea86bff89ad3af6619"><ix:continuation id="i6e5286608ddb4daaa39f11ed0e384c75" continuedAt="i8315e116bb7d4ca3af1598f0b7877bab"> </ix:continuation></ix:continuation></span></div><div style="text-align:justify"><span><br/></span></div><ix:continuation id="i4745277317fa4eea86bff89ad3af6619"><ix:continuation id="i8315e116bb7d4ca3af1598f0b7877bab"><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:59.594%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.205%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.205%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.205%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.209%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0abaa0eac87f4791aa3fc322969844f0_I20211231" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMTIvZnJhZzpjMzMwYzUwYWY0YTc0OTlhODRlZTQ3ZWJmNjE2NmE4Yy90YWJsZTplZjgwNDE2N2YwY2Y0OWQxYTNlZThhMWUxNzkwMTZmNy90YWJsZXJhbmdlOmVmODA0MTY3ZjBjZjQ5ZDFhM2VlOGExZTE3OTAxNmY3XzMtMS0xLTEtMjYxNTE_dcef48f1-b86b-4756-9b1e-91cbc5796f5b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8b0421b968754a01b6e430b519919d13_I20211231" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMTIvZnJhZzpjMzMwYzUwYWY0YTc0OTlhODRlZTQ3ZWJmNjE2NmE4Yy90YWJsZTplZjgwNDE2N2YwY2Y0OWQxYTNlZThhMWUxNzkwMTZmNy90YWJsZXJhbmdlOmVmODA0MTY3ZjBjZjQ5ZDFhM2VlOGExZTE3OTAxNmY3XzMtMy0xLTEtMjYxNTE_0c9938e3-8f38-46cb-93f0-5fdc4b750ee3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2b88f3addfe64f84a6303a37b589e8f5_I20211231" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMTIvZnJhZzpjMzMwYzUwYWY0YTc0OTlhODRlZTQ3ZWJmNjE2NmE4Yy90YWJsZTplZjgwNDE2N2YwY2Y0OWQxYTNlZThhMWUxNzkwMTZmNy90YWJsZXJhbmdlOmVmODA0MTY3ZjBjZjQ5ZDFhM2VlOGExZTE3OTAxNmY3XzMtNS0xLTEtMjYxNTE_975f414e-86f9-4654-8738-c4f77f594627">28,700</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib92fc8f3c5774739b4687eddbea853f3_I20211231" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMTIvZnJhZzpjMzMwYzUwYWY0YTc0OTlhODRlZTQ3ZWJmNjE2NmE4Yy90YWJsZTplZjgwNDE2N2YwY2Y0OWQxYTNlZThhMWUxNzkwMTZmNy90YWJsZXJhbmdlOmVmODA0MTY3ZjBjZjQ5ZDFhM2VlOGExZTE3OTAxNmY3XzMtNy0xLTEtMjYxNTE_b8609198-e48d-4e47-a8b7-69d445bd9285">28,700</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total fair value of liabilities measured on a recurring basis</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0abaa0eac87f4791aa3fc322969844f0_I20211231" decimals="-3" name="us-gaap:LiabilitiesFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMTIvZnJhZzpjMzMwYzUwYWY0YTc0OTlhODRlZTQ3ZWJmNjE2NmE4Yy90YWJsZTplZjgwNDE2N2YwY2Y0OWQxYTNlZThhMWUxNzkwMTZmNy90YWJsZXJhbmdlOmVmODA0MTY3ZjBjZjQ5ZDFhM2VlOGExZTE3OTAxNmY3XzQtMS0xLTEtMjYxNTE_ae07b112-5d5b-4333-b13f-8fa35bdd2217">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8b0421b968754a01b6e430b519919d13_I20211231" decimals="-3" name="us-gaap:LiabilitiesFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMTIvZnJhZzpjMzMwYzUwYWY0YTc0OTlhODRlZTQ3ZWJmNjE2NmE4Yy90YWJsZTplZjgwNDE2N2YwY2Y0OWQxYTNlZThhMWUxNzkwMTZmNy90YWJsZXJhbmdlOmVmODA0MTY3ZjBjZjQ5ZDFhM2VlOGExZTE3OTAxNmY3XzQtMy0xLTEtMjYxNTE_2203fb11-e337-4fe3-8ff6-bd0a01e48347">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2b88f3addfe64f84a6303a37b589e8f5_I20211231" decimals="-3" name="us-gaap:LiabilitiesFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMTIvZnJhZzpjMzMwYzUwYWY0YTc0OTlhODRlZTQ3ZWJmNjE2NmE4Yy90YWJsZTplZjgwNDE2N2YwY2Y0OWQxYTNlZThhMWUxNzkwMTZmNy90YWJsZXJhbmdlOmVmODA0MTY3ZjBjZjQ5ZDFhM2VlOGExZTE3OTAxNmY3XzQtNS0xLTEtMjYxNTE_fa5561be-5392-4e96-80e5-04b2b8414fe6">28,700</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib92fc8f3c5774739b4687eddbea853f3_I20211231" decimals="-3" name="us-gaap:LiabilitiesFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMTIvZnJhZzpjMzMwYzUwYWY0YTc0OTlhODRlZTQ3ZWJmNjE2NmE4Yy90YWJsZTplZjgwNDE2N2YwY2Y0OWQxYTNlZThhMWUxNzkwMTZmNy90YWJsZXJhbmdlOmVmODA0MTY3ZjBjZjQ5ZDFhM2VlOGExZTE3OTAxNmY3XzQtNy0xLTEtMjYxNTE_dbacbda6-9ba0-4100-bbdc-8730bd2802e5">28,700</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"></td><td style="width:325.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:48.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:48.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:48.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:48.25pt"></td><td style="width:1.0pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib80e545347c046f081508ec064bed62f_I20201231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMTIvZnJhZzpjMzMwYzUwYWY0YTc0OTlhODRlZTQ3ZWJmNjE2NmE4Yy90YWJsZTo4NzAzY2Q1YTE1YTE0MWQyODQwMWVhZWE5ODIzNzhhNS90YWJsZXJhbmdlOjg3MDNjZDVhMTVhMTQxZDI4NDAxZWFlYTk4MjM3OGE1XzItMS0xLTEtMTc3NzU_96673849-8429-4c84-b30c-f6f499736b7c">5,877</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i445dcacffbec464ebce55777f4c8895b_I20201231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMTIvZnJhZzpjMzMwYzUwYWY0YTc0OTlhODRlZTQ3ZWJmNjE2NmE4Yy90YWJsZTo4NzAzY2Q1YTE1YTE0MWQyODQwMWVhZWE5ODIzNzhhNS90YWJsZXJhbmdlOjg3MDNjZDVhMTVhMTQxZDI4NDAxZWFlYTk4MjM3OGE1XzItMy0xLTEtMTc3NzU_b9decef5-9c3d-4c0e-b0ae-4e698e51a294">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i44e95c772e54413fb8612a96b7f4dd16_I20201231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMTIvZnJhZzpjMzMwYzUwYWY0YTc0OTlhODRlZTQ3ZWJmNjE2NmE4Yy90YWJsZTo4NzAzY2Q1YTE1YTE0MWQyODQwMWVhZWE5ODIzNzhhNS90YWJsZXJhbmdlOjg3MDNjZDVhMTVhMTQxZDI4NDAxZWFlYTk4MjM3OGE1XzItNS0xLTEtMTc3NzU_4ace7357-4cde-42fc-b9c5-48900953a20e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0c4bfc6064ec4f93a8c1502ece6eaeae_I20201231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMTIvZnJhZzpjMzMwYzUwYWY0YTc0OTlhODRlZTQ3ZWJmNjE2NmE4Yy90YWJsZTo4NzAzY2Q1YTE1YTE0MWQyODQwMWVhZWE5ODIzNzhhNS90YWJsZXJhbmdlOjg3MDNjZDVhMTVhMTQxZDI4NDAxZWFlYTk4MjM3OGE1XzItNy0xLTEtMTc3NzU_8c78a969-9a97-43cb-a2bd-a84015d5c8ca">5,877</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total fair value of assets measured on a recurring basis</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib80e545347c046f081508ec064bed62f_I20201231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMTIvZnJhZzpjMzMwYzUwYWY0YTc0OTlhODRlZTQ3ZWJmNjE2NmE4Yy90YWJsZTo4NzAzY2Q1YTE1YTE0MWQyODQwMWVhZWE5ODIzNzhhNS90YWJsZXJhbmdlOjg3MDNjZDVhMTVhMTQxZDI4NDAxZWFlYTk4MjM3OGE1XzMtMS0xLTEtMTc3NzU_a5f5b9cd-fdb5-4c0d-badc-ad5fb4dd178b">5,877</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i445dcacffbec464ebce55777f4c8895b_I20201231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMTIvZnJhZzpjMzMwYzUwYWY0YTc0OTlhODRlZTQ3ZWJmNjE2NmE4Yy90YWJsZTo4NzAzY2Q1YTE1YTE0MWQyODQwMWVhZWE5ODIzNzhhNS90YWJsZXJhbmdlOjg3MDNjZDVhMTVhMTQxZDI4NDAxZWFlYTk4MjM3OGE1XzMtMy0xLTEtMTc3NzU_28c2a751-85cd-45bf-9ce0-0238170489d1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i44e95c772e54413fb8612a96b7f4dd16_I20201231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMTIvZnJhZzpjMzMwYzUwYWY0YTc0OTlhODRlZTQ3ZWJmNjE2NmE4Yy90YWJsZTo4NzAzY2Q1YTE1YTE0MWQyODQwMWVhZWE5ODIzNzhhNS90YWJsZXJhbmdlOjg3MDNjZDVhMTVhMTQxZDI4NDAxZWFlYTk4MjM3OGE1XzMtNS0xLTEtMTc3NzU_a1edb53b-cf19-4ebc-835a-2f882049f4f0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0c4bfc6064ec4f93a8c1502ece6eaeae_I20201231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMTIvZnJhZzpjMzMwYzUwYWY0YTc0OTlhODRlZTQ3ZWJmNjE2NmE4Yy90YWJsZTo4NzAzY2Q1YTE1YTE0MWQyODQwMWVhZWE5ODIzNzhhNS90YWJsZXJhbmdlOjg3MDNjZDVhMTVhMTQxZDI4NDAxZWFlYTk4MjM3OGE1XzMtNy0xLTEtMTc3NzU_369e4a59-5c6a-4886-8907-ff9d368df906">5,877</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warrants </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib80e545347c046f081508ec064bed62f_I20201231" decimals="-3" name="us-gaap:OtherLiabilitiesFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMTIvZnJhZzpjMzMwYzUwYWY0YTc0OTlhODRlZTQ3ZWJmNjE2NmE4Yy90YWJsZTo4NzAzY2Q1YTE1YTE0MWQyODQwMWVhZWE5ODIzNzhhNS90YWJsZXJhbmdlOjg3MDNjZDVhMTVhMTQxZDI4NDAxZWFlYTk4MjM3OGE1XzYtMS0xLTEtMTc3NzU_ae917525-2bcb-491d-8f45-9ebaf9b2df7a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i445dcacffbec464ebce55777f4c8895b_I20201231" decimals="-3" name="us-gaap:OtherLiabilitiesFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMTIvZnJhZzpjMzMwYzUwYWY0YTc0OTlhODRlZTQ3ZWJmNjE2NmE4Yy90YWJsZTo4NzAzY2Q1YTE1YTE0MWQyODQwMWVhZWE5ODIzNzhhNS90YWJsZXJhbmdlOjg3MDNjZDVhMTVhMTQxZDI4NDAxZWFlYTk4MjM3OGE1XzYtMy0xLTEtMTc3NzU_01ea6d3d-d1a8-41b1-8a3b-8fbcb571c676">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i44e95c772e54413fb8612a96b7f4dd16_I20201231" decimals="-3" name="us-gaap:OtherLiabilitiesFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMTIvZnJhZzpjMzMwYzUwYWY0YTc0OTlhODRlZTQ3ZWJmNjE2NmE4Yy90YWJsZTo4NzAzY2Q1YTE1YTE0MWQyODQwMWVhZWE5ODIzNzhhNS90YWJsZXJhbmdlOjg3MDNjZDVhMTVhMTQxZDI4NDAxZWFlYTk4MjM3OGE1XzYtNS0xLTEtMTc3NzU_e3a21d50-92b3-438c-acea-b603c2b17344">13,730</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0c4bfc6064ec4f93a8c1502ece6eaeae_I20201231" decimals="-3" name="us-gaap:OtherLiabilitiesFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMTIvZnJhZzpjMzMwYzUwYWY0YTc0OTlhODRlZTQ3ZWJmNjE2NmE4Yy90YWJsZTo4NzAzY2Q1YTE1YTE0MWQyODQwMWVhZWE5ODIzNzhhNS90YWJsZXJhbmdlOjg3MDNjZDVhMTVhMTQxZDI4NDAxZWFlYTk4MjM3OGE1XzYtNy0xLTEtMTc3NzU_5e1cf0b3-5b1c-49c9-b65c-80f3f7714af2">13,730</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total fair value of liabilities measured on a recurring basis</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib80e545347c046f081508ec064bed62f_I20201231" decimals="-3" name="us-gaap:LiabilitiesFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMTIvZnJhZzpjMzMwYzUwYWY0YTc0OTlhODRlZTQ3ZWJmNjE2NmE4Yy90YWJsZTo4NzAzY2Q1YTE1YTE0MWQyODQwMWVhZWE5ODIzNzhhNS90YWJsZXJhbmdlOjg3MDNjZDVhMTVhMTQxZDI4NDAxZWFlYTk4MjM3OGE1XzctMS0xLTEtMTc3NzU_0c7e9f52-7aeb-416f-85e3-d001035b03bf">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i445dcacffbec464ebce55777f4c8895b_I20201231" decimals="-3" name="us-gaap:LiabilitiesFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMTIvZnJhZzpjMzMwYzUwYWY0YTc0OTlhODRlZTQ3ZWJmNjE2NmE4Yy90YWJsZTo4NzAzY2Q1YTE1YTE0MWQyODQwMWVhZWE5ODIzNzhhNS90YWJsZXJhbmdlOjg3MDNjZDVhMTVhMTQxZDI4NDAxZWFlYTk4MjM3OGE1XzctMy0xLTEtMTc3NzU_dc5d38db-0e23-4c14-af4a-c665c4a8212d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i44e95c772e54413fb8612a96b7f4dd16_I20201231" decimals="-3" name="us-gaap:LiabilitiesFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMTIvZnJhZzpjMzMwYzUwYWY0YTc0OTlhODRlZTQ3ZWJmNjE2NmE4Yy90YWJsZTo4NzAzY2Q1YTE1YTE0MWQyODQwMWVhZWE5ODIzNzhhNS90YWJsZXJhbmdlOjg3MDNjZDVhMTVhMTQxZDI4NDAxZWFlYTk4MjM3OGE1XzctNS0xLTEtMTc3NzU_fb97c27c-8833-42d1-8099-9e3e932e08ee">13,730</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0c4bfc6064ec4f93a8c1502ece6eaeae_I20201231" decimals="-3" name="us-gaap:LiabilitiesFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMTIvZnJhZzpjMzMwYzUwYWY0YTc0OTlhODRlZTQ3ZWJmNjE2NmE4Yy90YWJsZTo4NzAzY2Q1YTE1YTE0MWQyODQwMWVhZWE5ODIzNzhhNS90YWJsZXJhbmdlOjg3MDNjZDVhMTVhMTQxZDI4NDAxZWFlYTk4MjM3OGE1XzctNy0xLTEtMTc3NzU_e1f867ae-8599-45ae-bd77-d8f1405e825a">13,730</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%"> </span></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Represents the fair value of earn-out consideration related to the Vital Decisions transaction as described in Note 4.</span></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> Represents the cash and cash equivalents and restricted cash and restricted investments that were held in money market funds as of December&#160;31, 2020.</span></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(3)  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Represents the fair value of <ix:nonFraction unitRef="shares" contextRef="ibc0c0c2b8dc04c5698ca0577a54b2e03_I20201231" decimals="INF" name="us-gaap:ClassOfWarrantOrRightOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMTIvZnJhZzpjMzMwYzUwYWY0YTc0OTlhODRlZTQ3ZWJmNjE2NmE4Yy90ZXh0cmVnaW9uOmMzMzBjNTBhZjRhNzQ5OWE4NGVlNDdlYmY2MTY2YThjXzE5NDk_712e3e3b-0247-42f9-8a3e-94de5ed493b5">1,513,786</ix:nonFraction> shares issuable under the warrant agreements discussed in Note 10. The warrants were settled in January 2021.</span></div></ix:continuation></ix:continuation><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes any transfers between levels within the hierarchy as of the beginning of the reporting period. There were no transfers between fair value levels during the years ended December 31, 2021 and 2020, respectively.  </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the absence of observable market prices, the fair value is based on the best information available and involves a significant degree of judgment, taking into consideration a combination of internal and external factors, including the appropriate risk adjustments for non-performance and liquidity risks.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As discussed in Note 4 , the acquisition of Vital Decisions includes a provision for additional equity consideration contingent upon the Company obtaining certain annualized performance metrics during the three months ending December 31, 2022. The fair value of the contingent equity consideration was estimated based on the real options approach, a form of the income approach, which estimated the probability of the Company achieving future revenues under the agreement. The significant unobservable inputs used in the fair value measurement of the Vital Decisions contingent consideration are the risk-neutral (probability weighted) earnout consideration and the applicable discount rate. A significant increase in the risk-neutral (probability weighted) earnout consideration or decrease in discount rate in isolation would result in a significantly higher fair value of the contingent consideration.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In conjunction with the Credit Agreement discussed in Note 10, the Company entered into warrant agreements whereby it agreed to sell to the holders of the warrants an aggregate of <ix:nonFraction unitRef="shares" contextRef="i88843d45ac464699a3408ba52bbc2f63_I20191230" decimals="INF" name="us-gaap:ClassOfWarrantOrRightUnissued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMTIvZnJhZzpjMzMwYzUwYWY0YTc0OTlhODRlZTQ3ZWJmNjE2NmE4Yy90ZXh0cmVnaW9uOmMzMzBjNTBhZjRhNzQ5OWE4NGVlNDdlYmY2MTY2YThjXzI3NDg_0db005ff-da98-46b4-96b3-9e7701cca383">1,513,786</ix:nonFraction> shares of Class A common stock. The fair value of the warrants was estimated based on the Black-Scholes model which incorporates the constant price variation of the stock, the time value of money, the option's strike price, and the time to the option's expiry. The significant unobservable inputs used in the fair value measurement of the warrants are the stock price volatility and annual risk free rate. A significant increase in the stock price or discount rate in isolation would have resulted in a significantly higher fair value of the contingent consideration.</span></div></ix:continuation><div style="text-align:justify"><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">113</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i24fbeaa4816e404f8fe0cc2627bdc976"><ix:nonNumeric contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231" name="us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMTIvZnJhZzpjMzMwYzUwYWY0YTc0OTlhODRlZTQ3ZWJmNjE2NmE4Yy90ZXh0cmVnaW9uOmMzMzBjNTBhZjRhNzQ5OWE4NGVlNDdlYmY2MTY2YThjXzQ5ODI_3066f8b9-4473-48c2-879e-c7ca575db2bf" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The changes in our liabilities measured at fair value for which the Company uses Level 3 inputs to determine fair value for the years ended December 31, 2021 and 2020 are as follows (in thousands): </span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"></td><td style="width:433.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:48.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:48.25pt"></td><td style="width:1.0pt"></td></tr><tr style="height:23pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Year Ended December 31,</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of beginning of period</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc0c0c2b8dc04c5698ca0577a54b2e03_I20201231" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMTIvZnJhZzpjMzMwYzUwYWY0YTc0OTlhODRlZTQ3ZWJmNjE2NmE4Yy90YWJsZTowYjA2OGMwZDkwMDE0YjBmYTRkNzkxZGIzODhmYjZlYi90YWJsZXJhbmdlOjBiMDY4YzBkOTAwMTRiMGZhNGQ3OTFkYjM4OGZiNmViXzItMS0xLTEtMTc3NzU_be0718cc-2b92-473e-a203-48f675e69c10">13,730</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icba6e493923b449aa57c46a563760234_I20191231" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMTIvZnJhZzpjMzMwYzUwYWY0YTc0OTlhODRlZTQ3ZWJmNjE2NmE4Yy90YWJsZTowYjA2OGMwZDkwMDE0YjBmYTRkNzkxZGIzODhmYjZlYi90YWJsZXJhbmdlOjBiMDY4YzBkOTAwMTRiMGZhNGQ3OTFkYjM4OGZiNmViXzItMy0xLTEtMTc3NzU_4ec05091-3024-4f54-9251-7a1e8f356f54">16,975</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMTIvZnJhZzpjMzMwYzUwYWY0YTc0OTlhODRlZTQ3ZWJmNjE2NmE4Yy90YWJsZTowYjA2OGMwZDkwMDE0YjBmYTRkNzkxZGIzODhmYjZlYi90YWJsZXJhbmdlOjBiMDY4YzBkOTAwMTRiMGZhNGQ3OTFkYjM4OGZiNmViXzMtMS0xLTEtMjYxNzg_6f378f54-30af-4a1e-9a28-7f9d878e0245">14,600</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i12a6d1161de54547bd29f8efccd4c9b0_D20200101-20201231" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMTIvZnJhZzpjMzMwYzUwYWY0YTc0OTlhODRlZTQ3ZWJmNjE2NmE4Yy90YWJsZTowYjA2OGMwZDkwMDE0YjBmYTRkNzkxZGIzODhmYjZlYi90YWJsZXJhbmdlOjBiMDY4YzBkOTAwMTRiMGZhNGQ3OTFkYjM4OGZiNmViXzMtMy0xLTEtMjYxNzg_b18a3a31-6116-4653-992b-be720fd1f6d4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Settlements</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMTIvZnJhZzpjMzMwYzUwYWY0YTc0OTlhODRlZTQ3ZWJmNjE2NmE4Yy90YWJsZTowYjA2OGMwZDkwMDE0YjBmYTRkNzkxZGIzODhmYjZlYi90YWJsZXJhbmdlOjBiMDY4YzBkOTAwMTRiMGZhNGQ3OTFkYjM4OGZiNmViXzMtMS0xLTEtMTc3NzU_59ef9db4-e5a4-49a3-aa5c-5e402bb807f8">13,730</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i12a6d1161de54547bd29f8efccd4c9b0_D20200101-20201231" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMTIvZnJhZzpjMzMwYzUwYWY0YTc0OTlhODRlZTQ3ZWJmNjE2NmE4Yy90YWJsZTowYjA2OGMwZDkwMDE0YjBmYTRkNzkxZGIzODhmYjZlYi90YWJsZXJhbmdlOjBiMDY4YzBkOTAwMTRiMGZhNGQ3OTFkYjM4OGZiNmViXzMtMy0xLTEtMTc3NzU_eff675d1-3635-4298-ae9a-67d0b99ffd01">3,500</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Realized and unrealized losses, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMTIvZnJhZzpjMzMwYzUwYWY0YTc0OTlhODRlZTQ3ZWJmNjE2NmE4Yy90YWJsZTowYjA2OGMwZDkwMDE0YjBmYTRkNzkxZGIzODhmYjZlYi90YWJsZXJhbmdlOjBiMDY4YzBkOTAwMTRiMGZhNGQ3OTFkYjM4OGZiNmViXzQtMS0xLTEtMTc3NzU_10a684df-de22-4649-83aa-352d609903b0">14,100</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i12a6d1161de54547bd29f8efccd4c9b0_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMTIvZnJhZzpjMzMwYzUwYWY0YTc0OTlhODRlZTQ3ZWJmNjE2NmE4Yy90YWJsZTowYjA2OGMwZDkwMDE0YjBmYTRkNzkxZGIzODhmYjZlYi90YWJsZXJhbmdlOjBiMDY4YzBkOTAwMTRiMGZhNGQ3OTFkYjM4OGZiNmViXzQtMy0xLTEtMTc3NzU_3f24ac66-cb72-4155-b3f7-d0a6eae62cbc">255</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of end of period</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8daff60be410426d8f7bd49343c1ec0c_I20211231" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMTIvZnJhZzpjMzMwYzUwYWY0YTc0OTlhODRlZTQ3ZWJmNjE2NmE4Yy90YWJsZTowYjA2OGMwZDkwMDE0YjBmYTRkNzkxZGIzODhmYjZlYi90YWJsZXJhbmdlOjBiMDY4YzBkOTAwMTRiMGZhNGQ3OTFkYjM4OGZiNmViXzUtMS0xLTEtMTc3NzU_fb2594cc-3dd4-4537-8435-6881bdad8e47">28,700</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc0c0c2b8dc04c5698ca0577a54b2e03_I20201231" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMTIvZnJhZzpjMzMwYzUwYWY0YTc0OTlhODRlZTQ3ZWJmNjE2NmE4Yy90YWJsZTowYjA2OGMwZDkwMDE0YjBmYTRkNzkxZGIzODhmYjZlYi90YWJsZXJhbmdlOjBiMDY4YzBkOTAwMTRiMGZhNGQ3OTFkYjM4OGZiNmViXzUtMy0xLTEtMTc3NzU_ec83c5cb-6b81-4277-b054-b27b63ddfb86">13,730</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="text-align:justify"><span><br/></span></div><ix:nonNumeric contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231" name="us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMTIvZnJhZzpjMzMwYzUwYWY0YTc0OTlhODRlZTQ3ZWJmNjE2NmE4Yy90ZXh0cmVnaW9uOmMzMzBjNTBhZjRhNzQ5OWE4NGVlNDdlYmY2MTY2YThjXzQ5NjQ_f5a3b80c-cc36-46e8-87f3-37bf3d2ac397" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the fair value (in thousands), valuation techniques and significant unobservable inputs of our Level 3 fair value measurements as of the periods presented:</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:24.177%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.205%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.788%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:30.427%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.821%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair </span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Valuation</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Significant</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assumption or</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Value</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Technique</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Unobservable Inputs</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Input Ranges</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2b88f3addfe64f84a6303a37b589e8f5_I20211231" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMTIvZnJhZzpjMzMwYzUwYWY0YTc0OTlhODRlZTQ3ZWJmNjE2NmE4Yy90YWJsZTpkYzNjNzJlYzQ0OWI0NTAwOGQ3OWM5MTllMzI0NWVhMi90YWJsZXJhbmdlOmRjM2M3MmVjNDQ5YjQ1MDA4ZDc5YzkxOWUzMjQ1ZWEyXzMtMS0xLTEtMzY0NzE_74a20e78-3bcc-4247-b6cc-dbadefc552c3">28,700</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Real options approach</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-neutral expected earnout consideration</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb9299fd51a347b9a7a46a5d71c01525_I20211231" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMTIvZnJhZzpjMzMwYzUwYWY0YTc0OTlhODRlZTQ3ZWJmNjE2NmE4Yy90YWJsZTpkYzNjNzJlYzQ0OWI0NTAwOGQ3OWM5MTllMzI0NWVhMi90YWJsZXJhbmdlOmRjM2M3MmVjNDQ5YjQ1MDA4ZDc5YzkxOWUzMjQ1ZWEyXzMtNy0xLTEtMzY0Nzg_e6d6fce4-83f6-4f5f-a399-7cba72bc43c6">30,935</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discount rate</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i1fec5420a1ee45fd97f27bb260399220_I20211231" decimals="4" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMTIvZnJhZzpjMzMwYzUwYWY0YTc0OTlhODRlZTQ3ZWJmNjE2NmE4Yy90YWJsZTpkYzNjNzJlYzQ0OWI0NTAwOGQ3OWM5MTllMzI0NWVhMi90YWJsZXJhbmdlOmRjM2M3MmVjNDQ5YjQ1MDA4ZDc5YzkxOWUzMjQ1ZWEyXzQtNy0xLTEtMzY0Nzg_4914b5ce-e9b1-4ea6-9ba2-aefd8536ba3e">6.04</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"></td><td style="width:134.50pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:48.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:100.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:168.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:67.75pt"></td><td style="width:1.0pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair </span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Valuation</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Significant</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assumption or</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Value</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Technique</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Unobservable Inputs</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Input Ranges</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warrants</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i44e95c772e54413fb8612a96b7f4dd16_I20201231" decimals="-3" name="us-gaap:OtherLiabilitiesFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMTIvZnJhZzpjMzMwYzUwYWY0YTc0OTlhODRlZTQ3ZWJmNjE2NmE4Yy90YWJsZTo4ZWNmMTA5MDU2NGM0ZDc2ODM4NzVmZDY4MjUxMjQ3Zi90YWJsZXJhbmdlOjhlY2YxMDkwNTY0YzRkNzY4Mzg3NWZkNjgyNTEyNDdmXzItMS0xLTEtMTc3NzU_83ede5c0-e6ff-4624-9913-eaa701c7e508">13,730</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Black-Scholes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock price volatility</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i4e9639a5adcd411a8b02679081819ef5_I20201231" decimals="3" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMTIvZnJhZzpjMzMwYzUwYWY0YTc0OTlhODRlZTQ3ZWJmNjE2NmE4Yy90YWJsZTo4ZWNmMTA5MDU2NGM0ZDc2ODM4NzVmZDY4MjUxMjQ3Zi90YWJsZXJhbmdlOjhlY2YxMDkwNTY0YzRkNzY4Mzg3NWZkNjgyNTEyNDdmXzItNy0xLTEtMTc3NzU_373106d5-2208-4af1-88ab-35b9ffceb902">62.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Annual risk free rate</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i38e7d4598fcf4220b68ea93547e1d444_I20201231" decimals="3" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMTIvZnJhZzpjMzMwYzUwYWY0YTc0OTlhODRlZTQ3ZWJmNjE2NmE4Yy90YWJsZTo4ZWNmMTA5MDU2NGM0ZDc2ODM4NzVmZDY4MjUxMjQ3Zi90YWJsZXJhbmdlOjhlY2YxMDkwNTY0YzRkNzY4Mzg3NWZkNjgyNTEyNDdmXzMtNy0xLTEtMTc3NzU_d82908e9-cf0c-4c9b-99ca-b9aea1bafcf8">0.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div></ix:nonNumeric><div style="text-align:justify"><span><br/></span></div><ix:continuation id="ib17713aa9d984fb480dceb9ddd93f1f2"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Nonrecurring Fair Value Measurements</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the assets and liabilities that are recorded at fair value on a recurring basis, the Company records certain assets and liabilities at fair value on a nonrecurring basis as required by GAAP. Generally, assets are recorded at fair value on a nonrecurring basis as a result of impairment charges. This includes assets and liabilities recorded in business combinations or asset acquisitions, goodwill, intangible assets, property, plant and equipment, held-to-maturity investments and equity method investments. While not carried at fair value on a recurring basis, these items are continually monitored for indicators of impairment that would indicate current carrying value is greater than fair value. In those situations, the assets are considered impaired and written down to current fair value. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Other Fair Value Disclosures</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying amounts of cash and cash equivalents (those not held in a money market fund), restricted cash, receivables, prepaid expenses, accounts payable, accrued liabilities and accrued compensation approximate their fair values because of the relatively short-term maturities of these items and financial instruments.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Note 10 for information regarding the fair value of the 2024 Notes, 2025 Notes and 2021 Notes.</span></div></ix:continuation></ix:continuation><div style="text-align:justify"><span><br/></span></div><div id="i9aaa2fddc97e482da5dbe37ac85ae703_115"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 20. <ix:nonNumeric contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231" name="us-gaap:RelatedPartyTransactionsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMTUvZnJhZzo5ZjFhZjNiMDEwY2U0ODI2OTI2YjA3MGU2ZjBjNTc3NS90ZXh0cmVnaW9uOjlmMWFmM2IwMTBjZTQ4MjY5MjZiMDcwZTZmMGM1Nzc1XzEzMjY_248a69a2-3c3f-4ec7-831a-e210fbb68cf0" continuedAt="i8151f0005748499a88d4f1a473de5979" escape="true">Related Parties </ix:nonNumeric><br/></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i8151f0005748499a88d4f1a473de5979" continuedAt="i97c8b3deb5bc466881b5e6aed846dfd3"> </ix:continuation></span></div><ix:continuation id="i97c8b3deb5bc466881b5e6aed846dfd3" continuedAt="i398cec804b864a18b053d8faf86a722d"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The entities described below are considered related parties and the balances and/or transactions with them are reported in our consolidated financial statements.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">As discussed in Note&#160;17, the Company had economic interests in several entities that are accounted for under the equity method of accounting, including EVH Passport which has been consolidated into the Company&#8217;s financial statements since September 1, 2020. The Company has allocated its proportional share of the investees&#8217; earnings and losses each reporting period. In addition, Evolent has entered into services agreements with certain of the entities to provide certain management, operational and support services to help the entities manage elements of their service offerings. </span></div></ix:continuation><div style="text-align:justify"><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">114</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i398cec804b864a18b053d8faf86a722d"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company also works with UPMC, one of its founding investors. The Company&#8217;s relationship with UPMC is a subcontractor relationship where UPMC has agreed to execute certain tasks (primarily TPA services) relating to certain customer commitments. This relationship is currently in wind-down.</span></div><div style="text-align:justify"><span><br/></span></div><ix:nonNumeric contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231" name="us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMTUvZnJhZzo5ZjFhZjNiMDEwY2U0ODI2OTI2YjA3MGU2ZjBjNTc3NS90ZXh0cmVnaW9uOjlmMWFmM2IwMTBjZTQ4MjY5MjZiMDcwZTZmMGM1Nzc1XzEzMjE_8a929f6a-cc22-4506-b3ab-1547c7f218ef" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents assets and liabilities attributable to our related parties as of December&#160;31, 2021 and 2020 (in thousands):</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:74.594%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.705%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.707%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable, net</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic0d050fa1a3e4a2cb801e14c4a7886a2_I20211231" decimals="-3" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMTUvZnJhZzo5ZjFhZjNiMDEwY2U0ODI2OTI2YjA3MGU2ZjBjNTc3NS90YWJsZTo2NGY0MDlmNTFkMzI0NmUwYmM5NTM0YjdhYWRhMzlmNy90YWJsZXJhbmdlOjY0ZjQwOWY1MWQzMjQ2ZTBiYzk1MzRiN2FhZGEzOWY3XzItMS0xLTEtMTc3NzU_85e2ab46-d6cd-40e7-ba46-686f7c1c7e4d">2,719</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5798a2aee885432aa6df470400a67a94_I20201231" decimals="-3" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMTUvZnJhZzo5ZjFhZjNiMDEwY2U0ODI2OTI2YjA3MGU2ZjBjNTc3NS90YWJsZTo2NGY0MDlmNTFkMzI0NmUwYmM5NTM0YjdhYWRhMzlmNy90YWJsZXJhbmdlOjY0ZjQwOWY1MWQzMjQ2ZTBiYzk1MzRiN2FhZGEzOWY3XzItMy0xLTEtMTc3NzU_3793a6cb-2543-4e40-8240-ba595e535aa1">9,474</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic0d050fa1a3e4a2cb801e14c4a7886a2_I20211231" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMTUvZnJhZzo5ZjFhZjNiMDEwY2U0ODI2OTI2YjA3MGU2ZjBjNTc3NS90YWJsZTo2NGY0MDlmNTFkMzI0NmUwYmM5NTM0YjdhYWRhMzlmNy90YWJsZXJhbmdlOjY0ZjQwOWY1MWQzMjQ2ZTBiYzk1MzRiN2FhZGEzOWY3XzMtMS0xLTEtMTc3NzU_8bae7e94-93a6-4285-9f7f-bccda4820a34">15</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5798a2aee885432aa6df470400a67a94_I20201231" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMTUvZnJhZzo5ZjFhZjNiMDEwY2U0ODI2OTI2YjA3MGU2ZjBjNTc3NS90YWJsZTo2NGY0MDlmNTFkMzI0NmUwYmM5NTM0YjdhYWRhMzlmNy90YWJsZXJhbmdlOjY0ZjQwOWY1MWQzMjQ2ZTBiYzk1MzRiN2FhZGEzOWY3XzMtMy0xLTEtMTc3NzU_016e4e4b-178e-42b6-98c5-9dfba0a19266">51</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other noncurrent assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic0d050fa1a3e4a2cb801e14c4a7886a2_I20211231" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMTUvZnJhZzo5ZjFhZjNiMDEwY2U0ODI2OTI2YjA3MGU2ZjBjNTc3NS90YWJsZTo2NGY0MDlmNTFkMzI0NmUwYmM5NTM0YjdhYWRhMzlmNy90YWJsZXJhbmdlOjY0ZjQwOWY1MWQzMjQ2ZTBiYzk1MzRiN2FhZGEzOWY3XzQtMS0xLTEtMTc3NzU_fb0e66f5-852e-41d7-9fce-38cb4dac64bf">4,877</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5798a2aee885432aa6df470400a67a94_I20201231" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMTUvZnJhZzo5ZjFhZjNiMDEwY2U0ODI2OTI2YjA3MGU2ZjBjNTc3NS90YWJsZTo2NGY0MDlmNTFkMzI0NmUwYmM5NTM0YjdhYWRhMzlmNy90YWJsZXJhbmdlOjY0ZjQwOWY1MWQzMjQ2ZTBiYzk1MzRiN2FhZGEzOWY3XzQtMy0xLTEtMTc3NzU_7cdd5f57-c996-4997-aab0-11d1a47fecbe">4,554</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic0d050fa1a3e4a2cb801e14c4a7886a2_I20211231" decimals="-3" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMTUvZnJhZzo5ZjFhZjNiMDEwY2U0ODI2OTI2YjA3MGU2ZjBjNTc3NS90YWJsZTo2NGY0MDlmNTFkMzI0NmUwYmM5NTM0YjdhYWRhMzlmNy90YWJsZXJhbmdlOjY0ZjQwOWY1MWQzMjQ2ZTBiYzk1MzRiN2FhZGEzOWY3XzctMS0xLTEtMTc3NzU_b377e024-96c5-4202-a857-748fc068e7ec">1,967</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5798a2aee885432aa6df470400a67a94_I20201231" decimals="-3" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMTUvZnJhZzo5ZjFhZjNiMDEwY2U0ODI2OTI2YjA3MGU2ZjBjNTc3NS90YWJsZTo2NGY0MDlmNTFkMzI0NmUwYmM5NTM0YjdhYWRhMzlmNy90YWJsZXJhbmdlOjY0ZjQwOWY1MWQzMjQ2ZTBiYzk1MzRiN2FhZGEzOWY3XzctMy0xLTEtMTc3NzU_ef6e5dce-c791-4d84-8217-7348bcdfde25">2,509</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic0d050fa1a3e4a2cb801e14c4a7886a2_I20211231" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMTUvZnJhZzo5ZjFhZjNiMDEwY2U0ODI2OTI2YjA3MGU2ZjBjNTc3NS90YWJsZTo2NGY0MDlmNTFkMzI0NmUwYmM5NTM0YjdhYWRhMzlmNy90YWJsZXJhbmdlOjY0ZjQwOWY1MWQzMjQ2ZTBiYzk1MzRiN2FhZGEzOWY3XzgtMS0xLTEtMTc3NzU_72fec6b7-dc4a-4cac-b878-9d77c31a207b">1,120</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5798a2aee885432aa6df470400a67a94_I20201231" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMTUvZnJhZzo5ZjFhZjNiMDEwY2U0ODI2OTI2YjA3MGU2ZjBjNTc3NS90YWJsZTo2NGY0MDlmNTFkMzI0NmUwYmM5NTM0YjdhYWRhMzlmNy90YWJsZXJhbmdlOjY0ZjQwOWY1MWQzMjQ2ZTBiYzk1MzRiN2FhZGEzOWY3XzgtMy0xLTEtMTc3NzU_a6573097-2c1b-4aa3-a428-d969ed60d98e">1,520</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reserve for claims and performance-based arrangements</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic0d050fa1a3e4a2cb801e14c4a7886a2_I20211231" decimals="-3" name="us-gaap:LiabilityForFuturePolicyBenefitsAndUnpaidClaimsAndClaimsAdjustmentExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMTUvZnJhZzo5ZjFhZjNiMDEwY2U0ODI2OTI2YjA3MGU2ZjBjNTc3NS90YWJsZTo2NGY0MDlmNTFkMzI0NmUwYmM5NTM0YjdhYWRhMzlmNy90YWJsZXJhbmdlOjY0ZjQwOWY1MWQzMjQ2ZTBiYzk1MzRiN2FhZGEzOWY3XzktMS0xLTEtMTc3NzU_e2ddc112-1659-4dba-86cb-66a2c4d740eb">734</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5798a2aee885432aa6df470400a67a94_I20201231" decimals="-3" name="us-gaap:LiabilityForFuturePolicyBenefitsAndUnpaidClaimsAndClaimsAdjustmentExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMTUvZnJhZzo5ZjFhZjNiMDEwY2U0ODI2OTI2YjA3MGU2ZjBjNTc3NS90YWJsZTo2NGY0MDlmNTFkMzI0NmUwYmM5NTM0YjdhYWRhMzlmNy90YWJsZXJhbmdlOjY0ZjQwOWY1MWQzMjQ2ZTBiYzk1MzRiN2FhZGEzOWY3XzktMy0xLTEtMTc3NzU_52c0967d-384f-425c-98a9-7774ec811ac2">435</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents revenues and expenses attributable to our related parties for the years ended December 31, 2021, 2020 and 2019 (in thousands):</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"></td><td style="width:373.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:49.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:54.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:49.00pt"></td><td style="width:1.0pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Year Ended December 31,</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Revenue</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Transformation services</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7b9f0cfef2b641acb147ef3af438fe7e_D20210101-20211231" decimals="-3" name="us-gaap:Revenues" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMTUvZnJhZzo5ZjFhZjNiMDEwY2U0ODI2OTI2YjA3MGU2ZjBjNTc3NS90YWJsZTpmOWJmNGM2YzU0MTI0ZDRhYmJiYzc4OGUyMjc2NzU1YS90YWJsZXJhbmdlOmY5YmY0YzZjNTQxMjRkNGFiYmJjNzg4ZTIyNzY3NTVhXzMtNS0xLTEtMTc3NzU_44c108ff-8b58-4480-9898-d3921ad7cefa">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib3fa08547d374130bb63c1e8f0b2c225_D20200101-20201231" decimals="-3" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMTUvZnJhZzo5ZjFhZjNiMDEwY2U0ODI2OTI2YjA3MGU2ZjBjNTc3NS90YWJsZTpmOWJmNGM2YzU0MTI0ZDRhYmJiYzc4OGUyMjc2NzU1YS90YWJsZXJhbmdlOmY5YmY0YzZjNTQxMjRkNGFiYmJjNzg4ZTIyNzY3NTVhXzMtNy0xLTEtMTc3NzU_6c64c9d6-9ce9-4cb5-b91f-59c5d6fd14f0">5,416</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6759af249ec643ef9a412f313e3297e3_D20190101-20191231" decimals="-3" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMTUvZnJhZzo5ZjFhZjNiMDEwY2U0ODI2OTI2YjA3MGU2ZjBjNTc3NS90YWJsZTpmOWJmNGM2YzU0MTI0ZDRhYmJiYzc4OGUyMjc2NzU1YS90YWJsZXJhbmdlOmY5YmY0YzZjNTQxMjRkNGFiYmJjNzg4ZTIyNzY3NTVhXzMtNS0xLTEtMjI2NjE_f91f89fb-59ab-4564-9d82-e3f3de6623f5">4,009</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Platform and operations services</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i64859199d5a842baaab416b161ae29c9_D20210101-20211231" decimals="-3" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMTUvZnJhZzo5ZjFhZjNiMDEwY2U0ODI2OTI2YjA3MGU2ZjBjNTc3NS90YWJsZTpmOWJmNGM2YzU0MTI0ZDRhYmJiYzc4OGUyMjc2NzU1YS90YWJsZXJhbmdlOmY5YmY0YzZjNTQxMjRkNGFiYmJjNzg4ZTIyNzY3NTVhXzQtNS0xLTEtMTc3NzU_7123cfa1-6db3-45df-9bdb-e148762ec6cc">45,082</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica89d567d5bb41858b442d7b0d52a944_D20200101-20201231" decimals="-3" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMTUvZnJhZzo5ZjFhZjNiMDEwY2U0ODI2OTI2YjA3MGU2ZjBjNTc3NS90YWJsZTpmOWJmNGM2YzU0MTI0ZDRhYmJiYzc4OGUyMjc2NzU1YS90YWJsZXJhbmdlOmY5YmY0YzZjNTQxMjRkNGFiYmJjNzg4ZTIyNzY3NTVhXzQtNy0xLTEtMTc3NzU_53e8fcbf-f09f-413e-a42f-744e38b32a12">226,339</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibe63fb63b6ff4113a876f8b68f82e70a_D20190101-20191231" decimals="-3" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMTUvZnJhZzo5ZjFhZjNiMDEwY2U0ODI2OTI2YjA3MGU2ZjBjNTc3NS90YWJsZTpmOWJmNGM2YzU0MTI0ZDRhYmJiYzc4OGUyMjc2NzU1YS90YWJsZXJhbmdlOmY5YmY0YzZjNTQxMjRkNGFiYmJjNzg4ZTIyNzY3NTVhXzQtNS0xLTEtMjI2NjE_3c30b3f6-b700-41a2-b8be-89a7d32643fc">60,325</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr style="height:23pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of revenue (exclusive of depreciation and amortization expenses)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2f7f912d67eb4dc4be805fbdba0a463f_D20210101-20211231" decimals="-3" name="evh:CostofGoodsandServicesSoldExcludingDepreciationandAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMTUvZnJhZzo5ZjFhZjNiMDEwY2U0ODI2OTI2YjA3MGU2ZjBjNTc3NS90YWJsZTpmOWJmNGM2YzU0MTI0ZDRhYmJiYzc4OGUyMjc2NzU1YS90YWJsZXJhbmdlOmY5YmY0YzZjNTQxMjRkNGFiYmJjNzg4ZTIyNzY3NTVhXzctNS0xLTEtMTc3NzU_6e936b98-dcd8-4c89-9b5e-c015f0763f37">3,063</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifdb175ec1f9e4b0eb8e3f71649541a13_D20200101-20201231" decimals="-3" name="evh:CostofGoodsandServicesSoldExcludingDepreciationandAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMTUvZnJhZzo5ZjFhZjNiMDEwY2U0ODI2OTI2YjA3MGU2ZjBjNTc3NS90YWJsZTpmOWJmNGM2YzU0MTI0ZDRhYmJiYzc4OGUyMjc2NzU1YS90YWJsZXJhbmdlOmY5YmY0YzZjNTQxMjRkNGFiYmJjNzg4ZTIyNzY3NTVhXzctNy0xLTEtMTc3NzU_90192beb-765f-4dfc-b99e-2f8309c17271">2,863</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie285ae7136404d0386bf1d58aebb605f_D20190101-20191231" decimals="-3" name="evh:CostofGoodsandServicesSoldExcludingDepreciationandAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMTUvZnJhZzo5ZjFhZjNiMDEwY2U0ODI2OTI2YjA3MGU2ZjBjNTc3NS90YWJsZTpmOWJmNGM2YzU0MTI0ZDRhYmJiYzc4OGUyMjc2NzU1YS90YWJsZXJhbmdlOmY5YmY0YzZjNTQxMjRkNGFiYmJjNzg4ZTIyNzY3NTVhXzctNS0xLTEtMjI2NjE_92d80f30-7250-4234-b533-3ecacc4e80c6">28,954</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2f7f912d67eb4dc4be805fbdba0a463f_D20210101-20211231" decimals="-3" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMTUvZnJhZzo5ZjFhZjNiMDEwY2U0ODI2OTI2YjA3MGU2ZjBjNTc3NS90YWJsZTpmOWJmNGM2YzU0MTI0ZDRhYmJiYzc4OGUyMjc2NzU1YS90YWJsZXJhbmdlOmY5YmY0YzZjNTQxMjRkNGFiYmJjNzg4ZTIyNzY3NTVhXzgtNS0xLTEtMTc3NzU_5183b73a-701d-4d16-b386-c321a0fb6cda">285</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifdb175ec1f9e4b0eb8e3f71649541a13_D20200101-20201231" decimals="-3" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMTUvZnJhZzo5ZjFhZjNiMDEwY2U0ODI2OTI2YjA3MGU2ZjBjNTc3NS90YWJsZTpmOWJmNGM2YzU0MTI0ZDRhYmJiYzc4OGUyMjc2NzU1YS90YWJsZXJhbmdlOmY5YmY0YzZjNTQxMjRkNGFiYmJjNzg4ZTIyNzY3NTVhXzgtNy0xLTEtMTc3NzU_0e8a1f2a-1022-4d40-88d1-923f7451b223">113</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie285ae7136404d0386bf1d58aebb605f_D20190101-20191231" decimals="-3" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMTUvZnJhZzo5ZjFhZjNiMDEwY2U0ODI2OTI2YjA3MGU2ZjBjNTc3NS90YWJsZTpmOWJmNGM2YzU0MTI0ZDRhYmJiYzc4OGUyMjc2NzU1YS90YWJsZXJhbmdlOmY5YmY0YzZjNTQxMjRkNGFiYmJjNzg4ZTIyNzY3NTVhXzgtNS0xLTEtMjI2NjE_6d304d6f-7595-4837-947d-48162cb906ce">991</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="text-align:justify"><span><br/></span></div><div id="i9aaa2fddc97e482da5dbe37ac85ae703_118"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 21. <ix:nonNumeric contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231" name="us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMTgvZnJhZzo2Y2ZkN2JlMzYwN2U0NTdjYTk2YzA3YzMwMTIwZWFlZC90ZXh0cmVnaW9uOjZjZmQ3YmUzNjA3ZTQ1N2NhOTZjMDdjMzAxMjBlYWVkXzE0MzQ_0d813cfd-068c-48b2-b2b1-4a736e0ae914" continuedAt="i489d985f17034a1884c33c7431a58073" escape="true">Repositioning and Other Changes</ix:nonNumeric></span></div><div><span><br/></span></div><ix:continuation id="i489d985f17034a1884c33c7431a58073" continuedAt="i014aab4df54a4a3c92252dae39a659c1"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We continually assess opportunities to improve operational effectiveness and efficiency to better align our expenses with revenues, while continuing to make investments in our solutions, systems and people that we believe are important to our long-term goals. Across 2020, we divested or agreed to divest a majority of our health plan assets, including certain assets of EVH Passport, which represented a significant revenue stream for the Company. In parallel with these divestitures, we contracted with a third-party vendor to review our operating model and organizational design in order to improve our profitability, create value through our solutions and invest in strategic opportunities in future periods.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the fourth quarter of 2020, we committed to certain operational efficiency and profitability actions that we are taking in order to accomplish these objectives (&#8220;Repositioning Plan&#8221;). These actions included making organizational changes across our business as well as other profitability initiatives expected to result in reductions in force, re-aligning of resources as well as other potential operational efficiency and cost-reduction initiatives that will provide future benefit to the Company. The Repositioning Plan concluded in the fourth quarter of 2021.</span></div></ix:continuation><div style="text-align:justify"><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">115</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i014aab4df54a4a3c92252dae39a659c1"><ix:nonNumeric contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231" name="us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMTgvZnJhZzo2Y2ZkN2JlMzYwN2U0NTdjYTk2YzA3YzMwMTIwZWFlZC90ZXh0cmVnaW9uOjZjZmQ3YmUzNjA3ZTQ1N2NhOTZjMDdjMzAxMjBlYWVkXzE0MzU_e35335f9-7154-47e8-b0da-7ca8f4dc3b84" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides a summary of our total costs associated with the Repositioning Plan for the years ended December 31, 2021 and 2020, by major type of cost (in thousands):</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:60.011%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.788%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.788%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.903%"></td><td style="width:0.1%"></td></tr><tr style="height:23pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Year Ended December 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cumulative Amount Incurred through December 31, 2021</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Severance and termination benefits</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia2137cc736cb46c28970ad4c0df7a021_D20210101-20211231" decimals="-3" name="us-gaap:RestructuringCharges" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMTgvZnJhZzo2Y2ZkN2JlMzYwN2U0NTdjYTk2YzA3YzMwMTIwZWFlZC90YWJsZTozNjE5NGQ1N2FjZDM0Mjg1OTM4YTBiMWYyNTI3ODQwNi90YWJsZXJhbmdlOjM2MTk0ZDU3YWNkMzQyODU5MzhhMGIxZjI1Mjc4NDA2XzEtMy0xLTEtMTc3NzU_65c3dcb7-d749-483d-9cfb-03923eddac48">185</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic842aeb816144721bb643e4517b1fffb_D20200101-20201231" decimals="-3" name="us-gaap:RestructuringCharges" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMTgvZnJhZzo2Y2ZkN2JlMzYwN2U0NTdjYTk2YzA3YzMwMTIwZWFlZC90YWJsZTozNjE5NGQ1N2FjZDM0Mjg1OTM4YTBiMWYyNTI3ODQwNi90YWJsZXJhbmdlOjM2MTk0ZDU3YWNkMzQyODU5MzhhMGIxZjI1Mjc4NDA2XzItMy0xLTEtMjI3MDc_cbea4e21-83c0-4862-9d23-b5b743fdb959">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id2b0eba26c804a30b8e75757e49f5f5d_I20211231" decimals="-3" name="us-gaap:RestructuringAndRelatedCostCostIncurredToDate1" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMTgvZnJhZzo2Y2ZkN2JlMzYwN2U0NTdjYTk2YzA3YzMwMTIwZWFlZC90YWJsZTozNjE5NGQ1N2FjZDM0Mjg1OTM4YTBiMWYyNTI3ODQwNi90YWJsZXJhbmdlOjM2MTk0ZDU3YWNkMzQyODU5MzhhMGIxZjI1Mjc4NDA2XzEtNy0xLTEtMTc3NzU_846029da-e968-4446-b395-f4c538703ee6">185</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Office space consolidation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i044e3156b9ce469fa3a7efb6527ef6c1_D20210101-20211231" decimals="-3" name="us-gaap:RestructuringCharges" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMTgvZnJhZzo2Y2ZkN2JlMzYwN2U0NTdjYTk2YzA3YzMwMTIwZWFlZC90YWJsZTozNjE5NGQ1N2FjZDM0Mjg1OTM4YTBiMWYyNTI3ODQwNi90YWJsZXJhbmdlOjM2MTk0ZDU3YWNkMzQyODU5MzhhMGIxZjI1Mjc4NDA2XzItMy0xLTEtMTc3NzU_c9b14661-e718-48e9-b8b6-42101d313d8a">2,742</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i40374039e5cf443a857163fd2a9b2b45_D20200101-20201231" decimals="-3" name="us-gaap:RestructuringCharges" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMTgvZnJhZzo2Y2ZkN2JlMzYwN2U0NTdjYTk2YzA3YzMwMTIwZWFlZC90YWJsZTozNjE5NGQ1N2FjZDM0Mjg1OTM4YTBiMWYyNTI3ODQwNi90YWJsZXJhbmdlOjM2MTk0ZDU3YWNkMzQyODU5MzhhMGIxZjI1Mjc4NDA2XzMtMy0xLTEtMjI3MDc_f99cf825-a15b-4f7c-8ac3-03e002c29100">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e648308269a4bea807ba0b660a48b7c_I20211231" decimals="-3" name="us-gaap:RestructuringAndRelatedCostCostIncurredToDate1" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMTgvZnJhZzo2Y2ZkN2JlMzYwN2U0NTdjYTk2YzA3YzMwMTIwZWFlZC90YWJsZTozNjE5NGQ1N2FjZDM0Mjg1OTM4YTBiMWYyNTI3ODQwNi90YWJsZXJhbmdlOjM2MTk0ZDU3YWNkMzQyODU5MzhhMGIxZjI1Mjc4NDA2XzItNy0xLTEtMTc3NzU_c12f47f1-9114-4019-a5fe-668637e12699">2,742</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Professional services</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i27138185aa744ae99ce808c1685e2fee_D20210101-20211231" decimals="-3" name="us-gaap:RestructuringCharges" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMTgvZnJhZzo2Y2ZkN2JlMzYwN2U0NTdjYTk2YzA3YzMwMTIwZWFlZC90YWJsZTozNjE5NGQ1N2FjZDM0Mjg1OTM4YTBiMWYyNTI3ODQwNi90YWJsZXJhbmdlOjM2MTk0ZDU3YWNkMzQyODU5MzhhMGIxZjI1Mjc4NDA2XzMtMy0xLTEtMTc3NzU_dc7f4847-2789-4d5e-979e-5aa0aff8572a">4,391</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if18eac1cd66a4b9b9bcc87d4d6fe437c_D20200101-20201231" decimals="-3" name="us-gaap:RestructuringCharges" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMTgvZnJhZzo2Y2ZkN2JlMzYwN2U0NTdjYTk2YzA3YzMwMTIwZWFlZC90YWJsZTozNjE5NGQ1N2FjZDM0Mjg1OTM4YTBiMWYyNTI3ODQwNi90YWJsZXJhbmdlOjM2MTk0ZDU3YWNkMzQyODU5MzhhMGIxZjI1Mjc4NDA2XzQtMy0xLTEtMjI3MDc_c2ae226e-8dec-40aa-b759-77f5a4b1ba4e">1,275</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i03de94c17d4149bbb0bf7a3e528d5f89_I20211231" decimals="-3" name="us-gaap:RestructuringAndRelatedCostCostIncurredToDate1" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMTgvZnJhZzo2Y2ZkN2JlMzYwN2U0NTdjYTk2YzA3YzMwMTIwZWFlZC90YWJsZTozNjE5NGQ1N2FjZDM0Mjg1OTM4YTBiMWYyNTI3ODQwNi90YWJsZXJhbmdlOjM2MTk0ZDU3YWNkMzQyODU5MzhhMGIxZjI1Mjc4NDA2XzMtNy0xLTEtMTc3NzU_e64dd87e-5fc1-44e2-820d-1e7a3a881da8">5,666</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231" decimals="-3" name="us-gaap:RestructuringCharges" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMTgvZnJhZzo2Y2ZkN2JlMzYwN2U0NTdjYTk2YzA3YzMwMTIwZWFlZC90YWJsZTozNjE5NGQ1N2FjZDM0Mjg1OTM4YTBiMWYyNTI3ODQwNi90YWJsZXJhbmdlOjM2MTk0ZDU3YWNkMzQyODU5MzhhMGIxZjI1Mjc4NDA2XzQtMy0xLTEtMTc3NzU_d6a76e2a-a78c-4ced-8506-28818cfa9079">7,318</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i12a6d1161de54547bd29f8efccd4c9b0_D20200101-20201231" decimals="-3" name="us-gaap:RestructuringCharges" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMTgvZnJhZzo2Y2ZkN2JlMzYwN2U0NTdjYTk2YzA3YzMwMTIwZWFlZC90YWJsZTozNjE5NGQ1N2FjZDM0Mjg1OTM4YTBiMWYyNTI3ODQwNi90YWJsZXJhbmdlOjM2MTk0ZDU3YWNkMzQyODU5MzhhMGIxZjI1Mjc4NDA2XzUtMy0xLTEtMjI3MDc_3e98e4a4-3a20-4c32-9d5f-e38617b25580">1,275</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8daff60be410426d8f7bd49343c1ec0c_I20211231" decimals="-3" name="us-gaap:RestructuringAndRelatedCostCostIncurredToDate1" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMTgvZnJhZzo2Y2ZkN2JlMzYwN2U0NTdjYTk2YzA3YzMwMTIwZWFlZC90YWJsZTozNjE5NGQ1N2FjZDM0Mjg1OTM4YTBiMWYyNTI3ODQwNi90YWJsZXJhbmdlOjM2MTk0ZDU3YWNkMzQyODU5MzhhMGIxZjI1Mjc4NDA2XzQtNy0xLTEtMTc3NzU_e6f22748-ccb7-4e42-a0d4-7a2b49c4f3ad">8,593</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="text-align:justify"><span><br/></span></div><div id="i9aaa2fddc97e482da5dbe37ac85ae703_121"></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 22. <ix:nonNumeric contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231" name="us-gaap:SegmentReportingDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMjEvZnJhZzowZWY2M2NjZTNmMjk0ZGZjOWJlMzhhYWYwZmMyYTQ4Yi90ZXh0cmVnaW9uOjBlZjYzY2NlM2YyOTRkZmM5YmUzOGFhZjBmYzJhNDhiXzM0NjM_6d4b3285-8f5f-48ca-8bf7-a384bf9187b9" continuedAt="i3fb0b79f94774594a155d04caf40d82f" escape="true">Segment Reporting</ix:nonNumeric></span></div><div style="text-align:justify"><span><br/></span></div><ix:continuation id="i3fb0b79f94774594a155d04caf40d82f" continuedAt="i59090495a9a24409b72be9f0a7b69899"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We define our reportable segments based on the way the CODM, the chief executive officer, manages the operations for purposes of allocating resources and assessing performance commencing with the three months ended March 31, 2021. We classify our operations into <ix:nonFraction unitRef="segment" contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231" decimals="INF" name="us-gaap:NumberOfOperatingSegments" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMjEvZnJhZzowZWY2M2NjZTNmMjk0ZGZjOWJlMzhhYWYwZmMyYTQ4Yi90ZXh0cmVnaW9uOjBlZjYzY2NlM2YyOTRkZmM5YmUzOGFhZjBmYzJhNDhiXzI5Nw_f06a53d9-968e-4310-99c8-16fee781d2d3">two</ix:nonFraction> reportable segments as follows:</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">Evolent Health Services, which houses our Administrative Simplification solution and certain supporting population health infrastructure; and</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">Clinical Solutions, which includes our specialty care management and physician-oriented total cost of care solutions, along with the New Century Health and Evolent Care Partners brands. </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the ordinary course of business, our reportable segments enter into transactions with one another. While intersegment transactions are treated like third-party transactions to determine segment performance, the revenues and expenses recognized by the segment that is the counterparty to the transaction are eliminated in consolidation and do not affect consolidated results.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The CODM uses revenue in accordance with U.S. GAAP and Adjusted EBITDA as the relevant segment performance measures to evaluate the performance of the segments and allocate resources. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Adjusted EBITDA is a segment performance financial measure that offers a useful view of the overall operation of our businesses and may be different than similarly-titled segment performance financial measures used by other companies. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Adjusted EBITDA is defined as net loss attributable to common shareholders of Evolent Health, Inc. before interest income, interest expense, (provision) benefit for income taxes, depreciation and amortization expenses, adjusted to exclude equity method investment impairment, gain on transfer of membership, loss on repayment of debt, loss on extinguishment of debt, goodwill impairment, gain (loss) from equity method investees, changes in fair value of contingent consideration and indemnification asset, net loss attributable to non-controlling interests, other income (expense), net, repositioning costs, stock-based compensation expense, severance costs, amortization of contract cost assets, strategy and shareholder advisory services, acquisition-related costs and gain (loss) from discontinued operations. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Management considers revenue and Adjusted EBITDA to be the appropriate metrics to evaluate and compare the ongoing operating performance of our segments on a consistent basis across reporting periods as they eliminate the effect of items which are not indicative of each segment's core operating performance. </span></div><div style="text-align:justify"><span><br/></span></div><ix:nonNumeric contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231" name="us-gaap:ReconciliationOfRevenueFromSegmentsToConsolidatedTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMjEvZnJhZzowZWY2M2NjZTNmMjk0ZGZjOWJlMzhhYWYwZmMyYTQ4Yi90ZXh0cmVnaW9uOjBlZjYzY2NlM2YyOTRkZmM5YmUzOGFhZjBmYzJhNDhiXzM0NjQ_04236a43-c73e-489a-bf2e-85cda8cea6ba" continuedAt="ic2d19979d8e54f4ca5cc522985cfa9ad" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables present our segment information for the years ended December 31, 2021, 2020 and 2019 (in thousands). Segment information for the years ended December 31, 2020 and 2019 (including segments total Adjusted EBITDA) has been restated to conform to the reporting structure change described in Note 2.</span></div><div style="text-align:justify"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"></td><td style="width:145.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:52.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:52.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:67.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:60.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:61.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:67.00pt"></td><td style="width:1.0pt"></td></tr><tr style="height:33pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Evolent Health Services</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Clinical Solutions</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Intersegment<br/>Eliminations</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Subtotal</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Corporate </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Consolidated</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Revenue</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="12" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Year Ended December 31, 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Transformation services</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i41b92360defc47ba8a58871111248034_D20210101-20211231" decimals="-3" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMjEvZnJhZzowZWY2M2NjZTNmMjk0ZGZjOWJlMzhhYWYwZmMyYTQ4Yi90YWJsZTphNDdlYTI3MDk3NTA0ZGU2ODQ1YTc1NWM0ZWQyNzcyNS90YWJsZXJhbmdlOmE0N2VhMjcwOTc1MDRkZTY4NDVhNzU1YzRlZDI3NzI1XzMtMS0xLTEtMTc3NzU_51254808-104b-4e17-bf29-97b6c53d3375">11,204</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic42eb62d04fb4a118704b67ffb9fd515_D20210101-20211231" decimals="-3" name="us-gaap:Revenues" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMjEvZnJhZzowZWY2M2NjZTNmMjk0ZGZjOWJlMzhhYWYwZmMyYTQ4Yi90YWJsZTphNDdlYTI3MDk3NTA0ZGU2ODQ1YTc1NWM0ZWQyNzcyNS90YWJsZXJhbmdlOmE0N2VhMjcwOTc1MDRkZTY4NDVhNzU1YzRlZDI3NzI1XzMtMy0xLTEtMTc3NzU_f2028d7f-1288-4a3e-85eb-151771a1ef22">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaf678763d1004f0e9876b94f94d0a5a6_D20210101-20211231" decimals="-3" name="us-gaap:Revenues" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMjEvZnJhZzowZWY2M2NjZTNmMjk0ZGZjOWJlMzhhYWYwZmMyYTQ4Yi90YWJsZTphNDdlYTI3MDk3NTA0ZGU2ODQ1YTc1NWM0ZWQyNzcyNS90YWJsZXJhbmdlOmE0N2VhMjcwOTc1MDRkZTY4NDVhNzU1YzRlZDI3NzI1XzMtNS0xLTEtMTc3NzU_86db3cbc-c2d7-46c2-affa-954eddc3f46e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i468f13cceecc41368537f1bf4d3bc06e_D20210101-20211231" decimals="-3" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMjEvZnJhZzowZWY2M2NjZTNmMjk0ZGZjOWJlMzhhYWYwZmMyYTQ4Yi90YWJsZTphNDdlYTI3MDk3NTA0ZGU2ODQ1YTc1NWM0ZWQyNzcyNS90YWJsZXJhbmdlOmE0N2VhMjcwOTc1MDRkZTY4NDVhNzU1YzRlZDI3NzI1XzMtNy0xLTEtMTc3NzU_98519aa4-f17e-4499-961c-a889fe0c124d">11,204</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i57ed24791b0544679bd4b966e3ad6122_D20210101-20211231" decimals="-3" name="us-gaap:Revenues" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMjEvZnJhZzowZWY2M2NjZTNmMjk0ZGZjOWJlMzhhYWYwZmMyYTQ4Yi90YWJsZTphNDdlYTI3MDk3NTA0ZGU2ODQ1YTc1NWM0ZWQyNzcyNS90YWJsZXJhbmdlOmE0N2VhMjcwOTc1MDRkZTY4NDVhNzU1YzRlZDI3NzI1XzMtOS0xLTEtMTc3NzU_c6020519-551d-44ef-a0f9-65f904a3f3ac">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iba00e3572dc24848afe0d13147ef9951_D20210101-20211231" decimals="-3" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMjEvZnJhZzowZWY2M2NjZTNmMjk0ZGZjOWJlMzhhYWYwZmMyYTQ4Yi90YWJsZTphNDdlYTI3MDk3NTA0ZGU2ODQ1YTc1NWM0ZWQyNzcyNS90YWJsZXJhbmdlOmE0N2VhMjcwOTc1MDRkZTY4NDVhNzU1YzRlZDI3NzI1XzMtMTEtMS0xLTE3Nzc1_a5b193b9-7505-443d-8b4c-c1dc5965b45c">11,204</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Platform and operations services</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5f219d5f567141958f242abd7cb9efea_D20210101-20211231" decimals="-3" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMjEvZnJhZzowZWY2M2NjZTNmMjk0ZGZjOWJlMzhhYWYwZmMyYTQ4Yi90YWJsZTphNDdlYTI3MDk3NTA0ZGU2ODQ1YTc1NWM0ZWQyNzcyNS90YWJsZXJhbmdlOmE0N2VhMjcwOTc1MDRkZTY4NDVhNzU1YzRlZDI3NzI1XzQtMS0xLTEtMTc3NzU_df8f7bfc-d058-4456-8982-2b2ab31fa4fe">300,423</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia00ff8c8432c4957b4aef14482bbb1ca_D20210101-20211231" decimals="-3" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMjEvZnJhZzowZWY2M2NjZTNmMjk0ZGZjOWJlMzhhYWYwZmMyYTQ4Yi90YWJsZTphNDdlYTI3MDk3NTA0ZGU2ODQ1YTc1NWM0ZWQyNzcyNS90YWJsZXJhbmdlOmE0N2VhMjcwOTc1MDRkZTY4NDVhNzU1YzRlZDI3NzI1XzQtMy0xLTEtMTc3NzU_7d0fa597-daf6-4709-83cb-20df2be1cf20">598,144</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iac839f1f097a424c99205c02214639ed_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMjEvZnJhZzowZWY2M2NjZTNmMjk0ZGZjOWJlMzhhYWYwZmMyYTQ4Yi90YWJsZTphNDdlYTI3MDk3NTA0ZGU2ODQ1YTc1NWM0ZWQyNzcyNS90YWJsZXJhbmdlOmE0N2VhMjcwOTc1MDRkZTY4NDVhNzU1YzRlZDI3NzI1XzQtNS0xLTEtMTc3NzU_7733ae74-dc13-43f2-b770-1f99bf13f9e5">1,814</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id762405c08c64368824019f2ec90b437_D20210101-20211231" decimals="-3" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMjEvZnJhZzowZWY2M2NjZTNmMjk0ZGZjOWJlMzhhYWYwZmMyYTQ4Yi90YWJsZTphNDdlYTI3MDk3NTA0ZGU2ODQ1YTc1NWM0ZWQyNzcyNS90YWJsZXJhbmdlOmE0N2VhMjcwOTc1MDRkZTY4NDVhNzU1YzRlZDI3NzI1XzQtNy0xLTEtMTc3NzU_dc5a0d79-cea0-4f2d-ba4f-c93cb641cfa3">896,753</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie91abff3ebd24744803f889983e86d61_D20210101-20211231" decimals="-3" name="us-gaap:Revenues" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMjEvZnJhZzowZWY2M2NjZTNmMjk0ZGZjOWJlMzhhYWYwZmMyYTQ4Yi90YWJsZTphNDdlYTI3MDk3NTA0ZGU2ODQ1YTc1NWM0ZWQyNzcyNS90YWJsZXJhbmdlOmE0N2VhMjcwOTc1MDRkZTY4NDVhNzU1YzRlZDI3NzI1XzQtOS0xLTEtMTc3NzU_0e273343-6ab3-4fee-af2f-8811033c8845">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic852ce517768443a8289b4dcbd762e47_D20210101-20211231" decimals="-3" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMjEvZnJhZzowZWY2M2NjZTNmMjk0ZGZjOWJlMzhhYWYwZmMyYTQ4Yi90YWJsZTphNDdlYTI3MDk3NTA0ZGU2ODQ1YTc1NWM0ZWQyNzcyNS90YWJsZXJhbmdlOmE0N2VhMjcwOTc1MDRkZTY4NDVhNzU1YzRlZDI3NzI1XzQtMTEtMS0xLTE3Nzc1_bcc3a2f5-f677-4625-8dad-4a1a5640e373">896,753</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenue</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i98988f30813349e1a5594e72b40af5b1_D20210101-20211231" decimals="-3" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMjEvZnJhZzowZWY2M2NjZTNmMjk0ZGZjOWJlMzhhYWYwZmMyYTQ4Yi90YWJsZTphNDdlYTI3MDk3NTA0ZGU2ODQ1YTc1NWM0ZWQyNzcyNS90YWJsZXJhbmdlOmE0N2VhMjcwOTc1MDRkZTY4NDVhNzU1YzRlZDI3NzI1XzUtMS0xLTEtMTc3NzU_c77d140e-2a6a-4441-99d3-3877afe2fd28">311,627</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6d991ef4e2e0416f8c7aaaa6175cf843_D20210101-20211231" decimals="-3" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMjEvZnJhZzowZWY2M2NjZTNmMjk0ZGZjOWJlMzhhYWYwZmMyYTQ4Yi90YWJsZTphNDdlYTI3MDk3NTA0ZGU2ODQ1YTc1NWM0ZWQyNzcyNS90YWJsZXJhbmdlOmE0N2VhMjcwOTc1MDRkZTY4NDVhNzU1YzRlZDI3NzI1XzUtMy0xLTEtMTc3NzU_4b49ffe4-33ba-4c8d-83e3-3f4ec3d083e5">598,144</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i160f9ff72a8f428db94184c59ffafc47_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMjEvZnJhZzowZWY2M2NjZTNmMjk0ZGZjOWJlMzhhYWYwZmMyYTQ4Yi90YWJsZTphNDdlYTI3MDk3NTA0ZGU2ODQ1YTc1NWM0ZWQyNzcyNS90YWJsZXJhbmdlOmE0N2VhMjcwOTc1MDRkZTY4NDVhNzU1YzRlZDI3NzI1XzUtNS0xLTEtMTc3NzU_aa59f336-3357-4dda-90fc-4f1f7e1ca7de">1,814</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6750aca4d3ec49afaa3b71a05c995e4e_D20210101-20211231" decimals="-3" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMjEvZnJhZzowZWY2M2NjZTNmMjk0ZGZjOWJlMzhhYWYwZmMyYTQ4Yi90YWJsZTphNDdlYTI3MDk3NTA0ZGU2ODQ1YTc1NWM0ZWQyNzcyNS90YWJsZXJhbmdlOmE0N2VhMjcwOTc1MDRkZTY4NDVhNzU1YzRlZDI3NzI1XzUtNy0xLTEtMTc3NzU_4371c292-26ce-4ff4-a1ad-bbcd65e7ed29">907,957</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2a43cc2e9054466a9f76a89472b3e611_D20210101-20211231" decimals="-3" name="us-gaap:Revenues" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMjEvZnJhZzowZWY2M2NjZTNmMjk0ZGZjOWJlMzhhYWYwZmMyYTQ4Yi90YWJsZTphNDdlYTI3MDk3NTA0ZGU2ODQ1YTc1NWM0ZWQyNzcyNS90YWJsZXJhbmdlOmE0N2VhMjcwOTc1MDRkZTY4NDVhNzU1YzRlZDI3NzI1XzUtOS0xLTEtMTc3NzU_9f57d58a-ec7d-46bd-8050-2428630b59b5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231" decimals="-3" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMjEvZnJhZzowZWY2M2NjZTNmMjk0ZGZjOWJlMzhhYWYwZmMyYTQ4Yi90YWJsZTphNDdlYTI3MDk3NTA0ZGU2ODQ1YTc1NWM0ZWQyNzcyNS90YWJsZXJhbmdlOmE0N2VhMjcwOTc1MDRkZTY4NDVhNzU1YzRlZDI3NzI1XzUtMTEtMS0xLTE3Nzc1_3959f47a-9979-4a83-9dd3-23b1f26e2957">907,957</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">116</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i59090495a9a24409b72be9f0a7b69899" continuedAt="i7dfafb0674e74eaf9d0e1b161c54bc91"><ix:continuation id="ic2d19979d8e54f4ca5cc522985cfa9ad"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"></td><td style="width:145.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:52.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:52.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:67.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:60.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:61.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:67.00pt"></td><td style="width:1.0pt"></td></tr><tr style="height:12pt"><td colspan="12" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Year Ended December 31, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Transformation services</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e3a96f5efe64f78b6f207c1f9ccaadf_D20200101-20201231" decimals="-3" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMjEvZnJhZzowZWY2M2NjZTNmMjk0ZGZjOWJlMzhhYWYwZmMyYTQ4Yi90YWJsZTphNDdlYTI3MDk3NTA0ZGU2ODQ1YTc1NWM0ZWQyNzcyNS90YWJsZXJhbmdlOmE0N2VhMjcwOTc1MDRkZTY4NDVhNzU1YzRlZDI3NzI1XzgtMS0xLTEtMTc3NzU_2acc1ed1-f903-461b-ae41-7ff3c75c89f3">11,990</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i04129486c45c47ce9cc1fa8184882c54_D20200101-20201231" decimals="-3" name="us-gaap:Revenues" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMjEvZnJhZzowZWY2M2NjZTNmMjk0ZGZjOWJlMzhhYWYwZmMyYTQ4Yi90YWJsZTphNDdlYTI3MDk3NTA0ZGU2ODQ1YTc1NWM0ZWQyNzcyNS90YWJsZXJhbmdlOmE0N2VhMjcwOTc1MDRkZTY4NDVhNzU1YzRlZDI3NzI1XzgtMy0xLTEtMTc3NzU_b83279cb-01c7-4570-8698-d2c69784b90b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i755b7b89c5764b53aede85f57d5ac9de_D20200101-20201231" decimals="-3" name="us-gaap:Revenues" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMjEvZnJhZzowZWY2M2NjZTNmMjk0ZGZjOWJlMzhhYWYwZmMyYTQ4Yi90YWJsZTphNDdlYTI3MDk3NTA0ZGU2ODQ1YTc1NWM0ZWQyNzcyNS90YWJsZXJhbmdlOmE0N2VhMjcwOTc1MDRkZTY4NDVhNzU1YzRlZDI3NzI1XzgtNS0xLTEtMTc3NzU_1fa7710d-c017-4fa7-aa11-fa014d8e9cb7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i51b664fb7925436f8af4dc7608707edc_D20200101-20201231" decimals="-3" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMjEvZnJhZzowZWY2M2NjZTNmMjk0ZGZjOWJlMzhhYWYwZmMyYTQ4Yi90YWJsZTphNDdlYTI3MDk3NTA0ZGU2ODQ1YTc1NWM0ZWQyNzcyNS90YWJsZXJhbmdlOmE0N2VhMjcwOTc1MDRkZTY4NDVhNzU1YzRlZDI3NzI1XzgtNy0xLTEtMTc3NzU_9acf8949-a91f-4967-b8bc-a6a63240735c">11,990</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3c1ca3f52cf44a48a6eb1c640364e98d_D20200101-20201231" decimals="-3" name="us-gaap:Revenues" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMjEvZnJhZzowZWY2M2NjZTNmMjk0ZGZjOWJlMzhhYWYwZmMyYTQ4Yi90YWJsZTphNDdlYTI3MDk3NTA0ZGU2ODQ1YTc1NWM0ZWQyNzcyNS90YWJsZXJhbmdlOmE0N2VhMjcwOTc1MDRkZTY4NDVhNzU1YzRlZDI3NzI1XzgtOS0xLTEtMTc3NzU_2e705fee-2505-41d7-8d5b-5733ccd6481c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib585ca9afa9b4d02874ade8f146f75cd_D20200101-20201231" decimals="-3" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMjEvZnJhZzowZWY2M2NjZTNmMjk0ZGZjOWJlMzhhYWYwZmMyYTQ4Yi90YWJsZTphNDdlYTI3MDk3NTA0ZGU2ODQ1YTc1NWM0ZWQyNzcyNS90YWJsZXJhbmdlOmE0N2VhMjcwOTc1MDRkZTY4NDVhNzU1YzRlZDI3NzI1XzgtMTEtMS0xLTE3Nzc1_8231d282-c0f0-4510-9070-1e77224ae94f">11,990</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Platform and operations services</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ief95fd4bd2a9417aa7c0a210852e8203_D20200101-20201231" decimals="-3" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMjEvZnJhZzowZWY2M2NjZTNmMjk0ZGZjOWJlMzhhYWYwZmMyYTQ4Yi90YWJsZTphNDdlYTI3MDk3NTA0ZGU2ODQ1YTc1NWM0ZWQyNzcyNS90YWJsZXJhbmdlOmE0N2VhMjcwOTc1MDRkZTY4NDVhNzU1YzRlZDI3NzI1XzktMS0xLTEtMTc3NzU_53792f41-4d69-4094-aacb-47ce44def92f">373,144</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i77015663db9441cd9c37ef54417768be_D20200101-20201231" decimals="-3" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMjEvZnJhZzowZWY2M2NjZTNmMjk0ZGZjOWJlMzhhYWYwZmMyYTQ4Yi90YWJsZTphNDdlYTI3MDk3NTA0ZGU2ODQ1YTc1NWM0ZWQyNzcyNS90YWJsZXJhbmdlOmE0N2VhMjcwOTc1MDRkZTY4NDVhNzU1YzRlZDI3NzI1XzktMy0xLTEtMTc3NzU_c25c8ab8-7eb1-4fdb-98d4-be4a531e354d">542,279</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iccbcddcfb8ea4a728d495edce2f63324_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMjEvZnJhZzowZWY2M2NjZTNmMjk0ZGZjOWJlMzhhYWYwZmMyYTQ4Yi90YWJsZTphNDdlYTI3MDk3NTA0ZGU2ODQ1YTc1NWM0ZWQyNzcyNS90YWJsZXJhbmdlOmE0N2VhMjcwOTc1MDRkZTY4NDVhNzU1YzRlZDI3NzI1XzktNS0xLTEtMTc3NzU_727a7b0e-2380-4760-8477-65a36f7b77c0">2,774</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5f1fd6df16314fac900d170f76611052_D20200101-20201231" decimals="-3" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMjEvZnJhZzowZWY2M2NjZTNmMjk0ZGZjOWJlMzhhYWYwZmMyYTQ4Yi90YWJsZTphNDdlYTI3MDk3NTA0ZGU2ODQ1YTc1NWM0ZWQyNzcyNS90YWJsZXJhbmdlOmE0N2VhMjcwOTc1MDRkZTY4NDVhNzU1YzRlZDI3NzI1XzktNy0xLTEtMTc3NzU_e2f9b5c4-1996-4c31-802c-00a883ac5252">912,649</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i05ee1fcfda47445a8c730b607300bcd3_D20200101-20201231" decimals="-3" name="us-gaap:Revenues" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMjEvZnJhZzowZWY2M2NjZTNmMjk0ZGZjOWJlMzhhYWYwZmMyYTQ4Yi90YWJsZTphNDdlYTI3MDk3NTA0ZGU2ODQ1YTc1NWM0ZWQyNzcyNS90YWJsZXJhbmdlOmE0N2VhMjcwOTc1MDRkZTY4NDVhNzU1YzRlZDI3NzI1XzktOS0xLTEtMTc3NzU_0d7cf492-ca79-4af7-8404-59f9ea380f6e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i971b8dd0fb5d4b10b55f27371adadaa7_D20200101-20201231" decimals="-3" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMjEvZnJhZzowZWY2M2NjZTNmMjk0ZGZjOWJlMzhhYWYwZmMyYTQ4Yi90YWJsZTphNDdlYTI3MDk3NTA0ZGU2ODQ1YTc1NWM0ZWQyNzcyNS90YWJsZXJhbmdlOmE0N2VhMjcwOTc1MDRkZTY4NDVhNzU1YzRlZDI3NzI1XzktMTEtMS0xLTE3Nzc1_636e5236-48b2-48c1-a29d-f0482c68866d">912,649</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenue</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i00a9fb2f3f914116b87f14e146d04507_D20200101-20201231" decimals="-3" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMjEvZnJhZzowZWY2M2NjZTNmMjk0ZGZjOWJlMzhhYWYwZmMyYTQ4Yi90YWJsZTphNDdlYTI3MDk3NTA0ZGU2ODQ1YTc1NWM0ZWQyNzcyNS90YWJsZXJhbmdlOmE0N2VhMjcwOTc1MDRkZTY4NDVhNzU1YzRlZDI3NzI1XzEwLTEtMS0xLTE3Nzc1_20fda0de-73d2-4553-9f80-25f2093facf1">385,134</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i73877656554945338d08c1e8006fc13a_D20200101-20201231" decimals="-3" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMjEvZnJhZzowZWY2M2NjZTNmMjk0ZGZjOWJlMzhhYWYwZmMyYTQ4Yi90YWJsZTphNDdlYTI3MDk3NTA0ZGU2ODQ1YTc1NWM0ZWQyNzcyNS90YWJsZXJhbmdlOmE0N2VhMjcwOTc1MDRkZTY4NDVhNzU1YzRlZDI3NzI1XzEwLTMtMS0xLTE3Nzc1_335f2987-456e-4e62-9714-c1564b7f90fb">542,279</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iea90da90740c47ea8a58199dbc28a879_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMjEvZnJhZzowZWY2M2NjZTNmMjk0ZGZjOWJlMzhhYWYwZmMyYTQ4Yi90YWJsZTphNDdlYTI3MDk3NTA0ZGU2ODQ1YTc1NWM0ZWQyNzcyNS90YWJsZXJhbmdlOmE0N2VhMjcwOTc1MDRkZTY4NDVhNzU1YzRlZDI3NzI1XzEwLTUtMS0xLTE3Nzc1_3e4a31e3-3daa-4117-bc51-a74d624ed610">2,774</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if1e0588b36354ec4ad0fe9d8b69a9b09_D20200101-20201231" decimals="-3" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMjEvZnJhZzowZWY2M2NjZTNmMjk0ZGZjOWJlMzhhYWYwZmMyYTQ4Yi90YWJsZTphNDdlYTI3MDk3NTA0ZGU2ODQ1YTc1NWM0ZWQyNzcyNS90YWJsZXJhbmdlOmE0N2VhMjcwOTc1MDRkZTY4NDVhNzU1YzRlZDI3NzI1XzEwLTctMS0xLTE3Nzc1_0178866b-60e4-4ae2-ba8f-6aae96414cb1">924,639</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0de9d5a3b6224de8a58bd015afb42ce0_D20200101-20201231" decimals="-3" name="us-gaap:Revenues" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMjEvZnJhZzowZWY2M2NjZTNmMjk0ZGZjOWJlMzhhYWYwZmMyYTQ4Yi90YWJsZTphNDdlYTI3MDk3NTA0ZGU2ODQ1YTc1NWM0ZWQyNzcyNS90YWJsZXJhbmdlOmE0N2VhMjcwOTc1MDRkZTY4NDVhNzU1YzRlZDI3NzI1XzEwLTktMS0xLTE3Nzc1_97982aad-9a7e-4cbd-82a3-e461099301e7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i12a6d1161de54547bd29f8efccd4c9b0_D20200101-20201231" decimals="-3" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMjEvZnJhZzowZWY2M2NjZTNmMjk0ZGZjOWJlMzhhYWYwZmMyYTQ4Yi90YWJsZTphNDdlYTI3MDk3NTA0ZGU2ODQ1YTc1NWM0ZWQyNzcyNS90YWJsZXJhbmdlOmE0N2VhMjcwOTc1MDRkZTY4NDVhNzU1YzRlZDI3NzI1XzEwLTExLTEtMS0xNzc3NQ_2ab07f55-fd1f-48ea-a10c-771ebcbf2ff3">924,639</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="12" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Year Ended December 31, 2019</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Transformation services</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1b52f1300eeb41f7927ec4e356b5e849_D20190101-20191231" decimals="-3" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMjEvZnJhZzowZWY2M2NjZTNmMjk0ZGZjOWJlMzhhYWYwZmMyYTQ4Yi90YWJsZTphNDdlYTI3MDk3NTA0ZGU2ODQ1YTc1NWM0ZWQyNzcyNS90YWJsZXJhbmdlOmE0N2VhMjcwOTc1MDRkZTY4NDVhNzU1YzRlZDI3NzI1XzEzLTEtMS0xLTM2NDky_20bcbfb7-8a87-4174-b623-e986ca10a4ed">15,203</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a806984574d41c5a8b3b5e54ae8b937_D20190101-20191231" decimals="-3" name="us-gaap:Revenues" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMjEvZnJhZzowZWY2M2NjZTNmMjk0ZGZjOWJlMzhhYWYwZmMyYTQ4Yi90YWJsZTphNDdlYTI3MDk3NTA0ZGU2ODQ1YTc1NWM0ZWQyNzcyNS90YWJsZXJhbmdlOmE0N2VhMjcwOTc1MDRkZTY4NDVhNzU1YzRlZDI3NzI1XzEzLTMtMS0xLTM2NDky_b4d4c855-3d12-4b9d-ba73-4b92db4b3350">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7a1104b23254e04ac79b4e5e6c03ca1_D20190101-20191231" decimals="-3" name="us-gaap:Revenues" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMjEvZnJhZzowZWY2M2NjZTNmMjk0ZGZjOWJlMzhhYWYwZmMyYTQ4Yi90YWJsZTphNDdlYTI3MDk3NTA0ZGU2ODQ1YTc1NWM0ZWQyNzcyNS90YWJsZXJhbmdlOmE0N2VhMjcwOTc1MDRkZTY4NDVhNzU1YzRlZDI3NzI1XzEzLTUtMS0xLTM2NDky_b303b75b-b6d3-444d-8dc6-005bfb6eff69">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8b652a3d61824fc79322c57e9476af89_D20190101-20191231" decimals="-3" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMjEvZnJhZzowZWY2M2NjZTNmMjk0ZGZjOWJlMzhhYWYwZmMyYTQ4Yi90YWJsZTphNDdlYTI3MDk3NTA0ZGU2ODQ1YTc1NWM0ZWQyNzcyNS90YWJsZXJhbmdlOmE0N2VhMjcwOTc1MDRkZTY4NDVhNzU1YzRlZDI3NzI1XzEzLTctMS0xLTM2NDky_46bc0899-9667-4f31-9161-f152ed338e31">15,203</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5276f3d92d824c07b982e9971e0a15e8_D20190101-20191231" decimals="-3" name="us-gaap:Revenues" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMjEvZnJhZzowZWY2M2NjZTNmMjk0ZGZjOWJlMzhhYWYwZmMyYTQ4Yi90YWJsZTphNDdlYTI3MDk3NTA0ZGU2ODQ1YTc1NWM0ZWQyNzcyNS90YWJsZXJhbmdlOmE0N2VhMjcwOTc1MDRkZTY4NDVhNzU1YzRlZDI3NzI1XzEzLTktMS0xLTM2NDky_5302428c-589f-4baa-badf-7f59ed330b70">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia6ba1f43ec4147adbafcb4a00fc450a2_D20190101-20191231" decimals="-3" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMjEvZnJhZzowZWY2M2NjZTNmMjk0ZGZjOWJlMzhhYWYwZmMyYTQ4Yi90YWJsZTphNDdlYTI3MDk3NTA0ZGU2ODQ1YTc1NWM0ZWQyNzcyNS90YWJsZXJhbmdlOmE0N2VhMjcwOTc1MDRkZTY4NDVhNzU1YzRlZDI3NzI1XzEzLTExLTEtMS0zNjQ5Mg_0dbbc8f3-e837-49bc-bf46-5b5f826e44e8">15,203</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Platform and operations services</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0aa78e50814f49e9ad96c352399da780_D20190101-20191231" decimals="-3" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMjEvZnJhZzowZWY2M2NjZTNmMjk0ZGZjOWJlMzhhYWYwZmMyYTQ4Yi90YWJsZTphNDdlYTI3MDk3NTA0ZGU2ODQ1YTc1NWM0ZWQyNzcyNS90YWJsZXJhbmdlOmE0N2VhMjcwOTc1MDRkZTY4NDVhNzU1YzRlZDI3NzI1XzE0LTEtMS0xLTM2NDky_3f5d77d8-a241-44c8-98de-10ff0ec50d33">394,328</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic29edb3405614f9a9149c89d25008350_D20190101-20191231" decimals="-3" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMjEvZnJhZzowZWY2M2NjZTNmMjk0ZGZjOWJlMzhhYWYwZmMyYTQ4Yi90YWJsZTphNDdlYTI3MDk3NTA0ZGU2ODQ1YTc1NWM0ZWQyNzcyNS90YWJsZXJhbmdlOmE0N2VhMjcwOTc1MDRkZTY4NDVhNzU1YzRlZDI3NzI1XzE0LTMtMS0xLTM2NDky_616e73fb-41d6-41bf-a202-d38d2a8aba03">278,217</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i424e54d030c64f9c9b3a971c4a6c858d_D20190101-20191231" decimals="-3" sign="-" name="us-gaap:Revenues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMjEvZnJhZzowZWY2M2NjZTNmMjk0ZGZjOWJlMzhhYWYwZmMyYTQ4Yi90YWJsZTphNDdlYTI3MDk3NTA0ZGU2ODQ1YTc1NWM0ZWQyNzcyNS90YWJsZXJhbmdlOmE0N2VhMjcwOTc1MDRkZTY4NDVhNzU1YzRlZDI3NzI1XzE0LTUtMS0xLTM2NDky_554fd336-8dcc-49c6-b092-c1efb89f10b5">626</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i585a3b5e60524401a57bad2ad2ffe307_D20190101-20191231" decimals="-3" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMjEvZnJhZzowZWY2M2NjZTNmMjk0ZGZjOWJlMzhhYWYwZmMyYTQ4Yi90YWJsZTphNDdlYTI3MDk3NTA0ZGU2ODQ1YTc1NWM0ZWQyNzcyNS90YWJsZXJhbmdlOmE0N2VhMjcwOTc1MDRkZTY4NDVhNzU1YzRlZDI3NzI1XzE0LTctMS0xLTM2NDky_b8c4ae30-3e31-4ce8-ab8b-0e576f5c0a14">671,919</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifb609f7da9704b688626efcd5acd234c_D20190101-20191231" decimals="-3" name="us-gaap:Revenues" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMjEvZnJhZzowZWY2M2NjZTNmMjk0ZGZjOWJlMzhhYWYwZmMyYTQ4Yi90YWJsZTphNDdlYTI3MDk3NTA0ZGU2ODQ1YTc1NWM0ZWQyNzcyNS90YWJsZXJhbmdlOmE0N2VhMjcwOTc1MDRkZTY4NDVhNzU1YzRlZDI3NzI1XzE0LTktMS0xLTM2NDky_067c8144-47b0-4777-8449-9e3e48d6e330">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie0aa3b0e3e5a4d54a32e0a4b60149c35_D20190101-20191231" decimals="-3" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMjEvZnJhZzowZWY2M2NjZTNmMjk0ZGZjOWJlMzhhYWYwZmMyYTQ4Yi90YWJsZTphNDdlYTI3MDk3NTA0ZGU2ODQ1YTc1NWM0ZWQyNzcyNS90YWJsZXJhbmdlOmE0N2VhMjcwOTc1MDRkZTY4NDVhNzU1YzRlZDI3NzI1XzE0LTExLTEtMS0zNjQ5Mg_f00692d9-ed78-4492-bc3b-3447239e45b3">671,919</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenue</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i26a4f846df6445f78bba31f5ba0edcdd_D20190101-20191231" decimals="-3" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMjEvZnJhZzowZWY2M2NjZTNmMjk0ZGZjOWJlMzhhYWYwZmMyYTQ4Yi90YWJsZTphNDdlYTI3MDk3NTA0ZGU2ODQ1YTc1NWM0ZWQyNzcyNS90YWJsZXJhbmdlOmE0N2VhMjcwOTc1MDRkZTY4NDVhNzU1YzRlZDI3NzI1XzE1LTEtMS0xLTM2NDky_e7463c31-8fde-4abf-8605-dcb46f4cdf2e">409,531</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if6faab8365e548b981e0edaddae65523_D20190101-20191231" decimals="-3" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMjEvZnJhZzowZWY2M2NjZTNmMjk0ZGZjOWJlMzhhYWYwZmMyYTQ4Yi90YWJsZTphNDdlYTI3MDk3NTA0ZGU2ODQ1YTc1NWM0ZWQyNzcyNS90YWJsZXJhbmdlOmE0N2VhMjcwOTc1MDRkZTY4NDVhNzU1YzRlZDI3NzI1XzE1LTMtMS0xLTM2NDky_c38e24a1-b736-44c0-ae19-5887cea3cc48">278,217</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icb97bc4a90264c0aa3a7d497791a321c_D20190101-20191231" decimals="-3" sign="-" name="us-gaap:Revenues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMjEvZnJhZzowZWY2M2NjZTNmMjk0ZGZjOWJlMzhhYWYwZmMyYTQ4Yi90YWJsZTphNDdlYTI3MDk3NTA0ZGU2ODQ1YTc1NWM0ZWQyNzcyNS90YWJsZXJhbmdlOmE0N2VhMjcwOTc1MDRkZTY4NDVhNzU1YzRlZDI3NzI1XzE1LTUtMS0xLTM2NDky_a6448a42-0abc-4974-9bb6-15a708d2a8f4">626</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ice1bdb7b2e1c43bbbb3687fa61bb7bfc_D20190101-20191231" decimals="-3" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMjEvZnJhZzowZWY2M2NjZTNmMjk0ZGZjOWJlMzhhYWYwZmMyYTQ4Yi90YWJsZTphNDdlYTI3MDk3NTA0ZGU2ODQ1YTc1NWM0ZWQyNzcyNS90YWJsZXJhbmdlOmE0N2VhMjcwOTc1MDRkZTY4NDVhNzU1YzRlZDI3NzI1XzE1LTctMS0xLTM2NDky_786bdd04-d25b-4db3-918a-545dbef4a530">687,122</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie97138a13af04a0ebbec53523bd2a882_D20190101-20191231" decimals="-3" name="us-gaap:Revenues" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMjEvZnJhZzowZWY2M2NjZTNmMjk0ZGZjOWJlMzhhYWYwZmMyYTQ4Yi90YWJsZTphNDdlYTI3MDk3NTA0ZGU2ODQ1YTc1NWM0ZWQyNzcyNS90YWJsZXJhbmdlOmE0N2VhMjcwOTc1MDRkZTY4NDVhNzU1YzRlZDI3NzI1XzE1LTktMS0xLTM2NDky_a76df027-82e1-40a8-adc4-5f350c39c39a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e21049ffc224cacb8134d73c9bb5b38_D20190101-20191231" decimals="-3" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMjEvZnJhZzowZWY2M2NjZTNmMjk0ZGZjOWJlMzhhYWYwZmMyYTQ4Yi90YWJsZTphNDdlYTI3MDk3NTA0ZGU2ODQ1YTc1NWM0ZWQyNzcyNS90YWJsZXJhbmdlOmE0N2VhMjcwOTc1MDRkZTY4NDVhNzU1YzRlZDI3NzI1XzE1LTExLTEtMS0zNjQ5Mg_b11b1ffe-c662-4a4a-a3c9-d10787fe54ab">687,122</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr style="height:33pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Evolent Health Services</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Clinical Solutions</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Subtotal</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Corporate </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Segments Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="12" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Year Ended December 31, 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjusted EBITDA</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i98988f30813349e1a5594e72b40af5b1_D20210101-20211231" decimals="-3" name="evh:AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMjEvZnJhZzowZWY2M2NjZTNmMjk0ZGZjOWJlMzhhYWYwZmMyYTQ4Yi90YWJsZTphNDdlYTI3MDk3NTA0ZGU2ODQ1YTc1NWM0ZWQyNzcyNS90YWJsZXJhbmdlOmE0N2VhMjcwOTc1MDRkZTY4NDVhNzU1YzRlZDI3NzI1XzE1LTEtMS0xLTE3Nzc1_a39ce908-376a-49a9-bcd5-3bf5d60d7daf">17,063</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6d991ef4e2e0416f8c7aaaa6175cf843_D20210101-20211231" decimals="-3" name="evh:AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMjEvZnJhZzowZWY2M2NjZTNmMjk0ZGZjOWJlMzhhYWYwZmMyYTQ4Yi90YWJsZTphNDdlYTI3MDk3NTA0ZGU2ODQ1YTc1NWM0ZWQyNzcyNS90YWJsZXJhbmdlOmE0N2VhMjcwOTc1MDRkZTY4NDVhNzU1YzRlZDI3NzI1XzE1LTMtMS0xLTE3Nzc1_bd82e9d2-ab3d-4cb5-bc1c-fef8516059c7">82,920</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6750aca4d3ec49afaa3b71a05c995e4e_D20210101-20211231" decimals="-3" name="evh:AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMjEvZnJhZzowZWY2M2NjZTNmMjk0ZGZjOWJlMzhhYWYwZmMyYTQ4Yi90YWJsZTphNDdlYTI3MDk3NTA0ZGU2ODQ1YTc1NWM0ZWQyNzcyNS90YWJsZXJhbmdlOmE0N2VhMjcwOTc1MDRkZTY4NDVhNzU1YzRlZDI3NzI1XzE1LTUtMS0xLTE3Nzc1_d13bfdea-b7e6-4237-a378-19ddf97c773d">99,983</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2a43cc2e9054466a9f76a89472b3e611_D20210101-20211231" decimals="-3" sign="-" name="evh:AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMjEvZnJhZzowZWY2M2NjZTNmMjk0ZGZjOWJlMzhhYWYwZmMyYTQ4Yi90YWJsZTphNDdlYTI3MDk3NTA0ZGU2ODQ1YTc1NWM0ZWQyNzcyNS90YWJsZXJhbmdlOmE0N2VhMjcwOTc1MDRkZTY4NDVhNzU1YzRlZDI3NzI1XzE1LTctMS0xLTE3Nzc1_1f4ef299-89a6-4511-9f94-b7fc2aa48e4b">33,666</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231" decimals="-3" name="evh:AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMjEvZnJhZzowZWY2M2NjZTNmMjk0ZGZjOWJlMzhhYWYwZmMyYTQ4Yi90YWJsZTphNDdlYTI3MDk3NTA0ZGU2ODQ1YTc1NWM0ZWQyNzcyNS90YWJsZXJhbmdlOmE0N2VhMjcwOTc1MDRkZTY4NDVhNzU1YzRlZDI3NzI1XzE1LTktMS0xLTE3Nzc1_5f8b47d5-c666-4f12-b7a4-866b8928daec">66,317</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="12" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Year Ended December 31, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjusted EBITDA</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i00a9fb2f3f914116b87f14e146d04507_D20200101-20201231" decimals="-3" name="evh:AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMjEvZnJhZzowZWY2M2NjZTNmMjk0ZGZjOWJlMzhhYWYwZmMyYTQ4Yi90YWJsZTphNDdlYTI3MDk3NTA0ZGU2ODQ1YTc1NWM0ZWQyNzcyNS90YWJsZXJhbmdlOmE0N2VhMjcwOTc1MDRkZTY4NDVhNzU1YzRlZDI3NzI1XzE4LTEtMS0xLTE3Nzc1_f2a29f57-568d-4187-ad68-9dc315bad7ce">57,731</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i73877656554945338d08c1e8006fc13a_D20200101-20201231" decimals="-3" name="evh:AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMjEvZnJhZzowZWY2M2NjZTNmMjk0ZGZjOWJlMzhhYWYwZmMyYTQ4Yi90YWJsZTphNDdlYTI3MDk3NTA0ZGU2ODQ1YTc1NWM0ZWQyNzcyNS90YWJsZXJhbmdlOmE0N2VhMjcwOTc1MDRkZTY4NDVhNzU1YzRlZDI3NzI1XzE4LTMtMS0xLTE3Nzc1_66ebbc9a-2897-48ad-bdf5-6b57b18f6b9c">26,864</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if1e0588b36354ec4ad0fe9d8b69a9b09_D20200101-20201231" decimals="-3" name="evh:AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMjEvZnJhZzowZWY2M2NjZTNmMjk0ZGZjOWJlMzhhYWYwZmMyYTQ4Yi90YWJsZTphNDdlYTI3MDk3NTA0ZGU2ODQ1YTc1NWM0ZWQyNzcyNS90YWJsZXJhbmdlOmE0N2VhMjcwOTc1MDRkZTY4NDVhNzU1YzRlZDI3NzI1XzE4LTUtMS0xLTE3Nzc1_73c1148e-2fc2-4be8-ba6e-4eb9e43491af">84,595</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0de9d5a3b6224de8a58bd015afb42ce0_D20200101-20201231" decimals="-3" sign="-" name="evh:AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMjEvZnJhZzowZWY2M2NjZTNmMjk0ZGZjOWJlMzhhYWYwZmMyYTQ4Yi90YWJsZTphNDdlYTI3MDk3NTA0ZGU2ODQ1YTc1NWM0ZWQyNzcyNS90YWJsZXJhbmdlOmE0N2VhMjcwOTc1MDRkZTY4NDVhNzU1YzRlZDI3NzI1XzE4LTctMS0xLTE3Nzc1_0d816693-75c3-4b51-84cc-51d11ba2dcaa">36,022</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i12a6d1161de54547bd29f8efccd4c9b0_D20200101-20201231" decimals="-3" name="evh:AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMjEvZnJhZzowZWY2M2NjZTNmMjk0ZGZjOWJlMzhhYWYwZmMyYTQ4Yi90YWJsZTphNDdlYTI3MDk3NTA0ZGU2ODQ1YTc1NWM0ZWQyNzcyNS90YWJsZXJhbmdlOmE0N2VhMjcwOTc1MDRkZTY4NDVhNzU1YzRlZDI3NzI1XzE4LTktMS0xLTE3Nzc1_f942e1c4-b00b-43e5-a7f7-860af0519d16">48,573</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="12" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Year Ended December 31, 2019</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjusted EBITDA</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i26a4f846df6445f78bba31f5ba0edcdd_D20190101-20191231" decimals="-3" sign="-" name="evh:AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMjEvZnJhZzowZWY2M2NjZTNmMjk0ZGZjOWJlMzhhYWYwZmMyYTQ4Yi90YWJsZTphNDdlYTI3MDk3NTA0ZGU2ODQ1YTc1NWM0ZWQyNzcyNS90YWJsZXJhbmdlOmE0N2VhMjcwOTc1MDRkZTY4NDVhNzU1YzRlZDI3NzI1XzI1LTEtMS0xLTM2NDk0_90b176da-7cbb-491f-b731-545185cd3b7c">561</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if6faab8365e548b981e0edaddae65523_D20190101-20191231" decimals="-3" name="evh:AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMjEvZnJhZzowZWY2M2NjZTNmMjk0ZGZjOWJlMzhhYWYwZmMyYTQ4Yi90YWJsZTphNDdlYTI3MDk3NTA0ZGU2ODQ1YTc1NWM0ZWQyNzcyNS90YWJsZXJhbmdlOmE0N2VhMjcwOTc1MDRkZTY4NDVhNzU1YzRlZDI3NzI1XzI1LTMtMS0xLTM2NDk0_d29a9d97-8a9e-4fdc-aa65-7410f709dc92">12,523</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ice1bdb7b2e1c43bbbb3687fa61bb7bfc_D20190101-20191231" decimals="-3" name="evh:AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMjEvZnJhZzowZWY2M2NjZTNmMjk0ZGZjOWJlMzhhYWYwZmMyYTQ4Yi90YWJsZTphNDdlYTI3MDk3NTA0ZGU2ODQ1YTc1NWM0ZWQyNzcyNS90YWJsZXJhbmdlOmE0N2VhMjcwOTc1MDRkZTY4NDVhNzU1YzRlZDI3NzI1XzI1LTUtMS0xLTM2NDk0_8a00d8cb-4f84-4e82-8ed6-bfa52f71cf44">11,962</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie97138a13af04a0ebbec53523bd2a882_D20190101-20191231" decimals="-3" sign="-" name="evh:AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMjEvZnJhZzowZWY2M2NjZTNmMjk0ZGZjOWJlMzhhYWYwZmMyYTQ4Yi90YWJsZTphNDdlYTI3MDk3NTA0ZGU2ODQ1YTc1NWM0ZWQyNzcyNS90YWJsZXJhbmdlOmE0N2VhMjcwOTc1MDRkZTY4NDVhNzU1YzRlZDI3NzI1XzI1LTctMS0xLTM2NDk0_32912dc7-6805-437b-9e77-fb510f6eaf26">25,793</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3e21049ffc224cacb8134d73c9bb5b38_D20190101-20191231" decimals="-3" sign="-" name="evh:AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMjEvZnJhZzowZWY2M2NjZTNmMjk0ZGZjOWJlMzhhYWYwZmMyYTQ4Yi90YWJsZTphNDdlYTI3MDk3NTA0ZGU2ODQ1YTc1NWM0ZWQyNzcyNS90YWJsZXJhbmdlOmE0N2VhMjcwOTc1MDRkZTY4NDVhNzU1YzRlZDI3NzI1XzI1LTktMS0xLTM2NDk0_89b29e6e-43fa-46aa-9683-b5f3499431db">13,831</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr></table></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt">Corporate includes various finance, human resources, legal, executive, and other corporate infrastructure expenses.</span></div></ix:continuation><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span><br/></span></div><ix:nonNumeric contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231" name="us-gaap:ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMjEvZnJhZzowZWY2M2NjZTNmMjk0ZGZjOWJlMzhhYWYwZmMyYTQ4Yi90ZXh0cmVnaW9uOjBlZjYzY2NlM2YyOTRkZmM5YmUzOGFhZjBmYzJhNDhiXzM0NjE_be03bde3-1fac-4797-a4ec-4c270dccb219" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents our reconciliation of consolidated segments total Adjusted EBITDA to net loss attributable to common shareholders of Evolent Health, Inc. for the years ended December 31, 2021, 2020 and 2019 (in thousands): </span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"></td><td style="width:380.50pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:48.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:48.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:48.25pt"></td><td style="width:1.0pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Year Ended December 31,</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net loss attributable to common shareholders of Evolent Health, Inc.</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMjEvZnJhZzowZWY2M2NjZTNmMjk0ZGZjOWJlMzhhYWYwZmMyYTQ4Yi90YWJsZTpiYTNmZWJkNTZkYzc0YTM4OGVhODhlYjg0ZGRkNTBlZS90YWJsZXJhbmdlOmJhM2ZlYmQ1NmRjNzRhMzg4ZWE4OGViODRkZGQ1MGVlXzItNS0xLTEtMTc3NzU_19b0e485-6260-41f1-b4e9-3c97c234c728"><ix:nonFraction unitRef="usd" contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMjEvZnJhZzowZWY2M2NjZTNmMjk0ZGZjOWJlMzhhYWYwZmMyYTQ4Yi90YWJsZTpiYTNmZWJkNTZkYzc0YTM4OGVhODhlYjg0ZGRkNTBlZS90YWJsZXJhbmdlOmJhM2ZlYmQ1NmRjNzRhMzg4ZWE4OGViODRkZGQ1MGVlXzItNS0xLTEtMTc3NzU_34c1e7e0-fc69-4bdc-be43-ddb3ef807107">37,601</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i12a6d1161de54547bd29f8efccd4c9b0_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMjEvZnJhZzowZWY2M2NjZTNmMjk0ZGZjOWJlMzhhYWYwZmMyYTQ4Yi90YWJsZTpiYTNmZWJkNTZkYzc0YTM4OGVhODhlYjg0ZGRkNTBlZS90YWJsZXJhbmdlOmJhM2ZlYmQ1NmRjNzRhMzg4ZWE4OGViODRkZGQ1MGVlXzItNy0xLTEtMTc3NzU_47276093-49df-42a8-9bbd-a4f0df34d037"><ix:nonFraction unitRef="usd" contextRef="i12a6d1161de54547bd29f8efccd4c9b0_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMjEvZnJhZzowZWY2M2NjZTNmMjk0ZGZjOWJlMzhhYWYwZmMyYTQ4Yi90YWJsZTpiYTNmZWJkNTZkYzc0YTM4OGVhODhlYjg0ZGRkNTBlZS90YWJsZXJhbmdlOmJhM2ZlYmQ1NmRjNzRhMzg4ZWE4OGViODRkZGQ1MGVlXzItNy0xLTEtMTc3NzU_e8f68bad-99dd-4b99-9acb-741a4f5652df">334,246</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3e21049ffc224cacb8134d73c9bb5b38_D20190101-20191231" decimals="-3" sign="-" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMjEvZnJhZzowZWY2M2NjZTNmMjk0ZGZjOWJlMzhhYWYwZmMyYTQ4Yi90YWJsZTpiYTNmZWJkNTZkYzc0YTM4OGVhODhlYjg0ZGRkNTBlZS90YWJsZXJhbmdlOmJhM2ZlYmQ1NmRjNzRhMzg4ZWE4OGViODRkZGQ1MGVlXzItNS0xLTEtMjMyMzY_436a8d3c-073f-4296-af03-689f7e52133b"><ix:nonFraction unitRef="usd" contextRef="i3e21049ffc224cacb8134d73c9bb5b38_D20190101-20191231" decimals="-3" sign="-" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMjEvZnJhZzowZWY2M2NjZTNmMjk0ZGZjOWJlMzhhYWYwZmMyYTQ4Yi90YWJsZTpiYTNmZWJkNTZkYzc0YTM4OGVhODhlYjg0ZGRkNTBlZS90YWJsZXJhbmdlOmJhM2ZlYmQ1NmRjNzRhMzg4ZWE4OGViODRkZGQ1MGVlXzItNS0xLTEtMjMyMzY_a8db8b9f-7556-4b88-8d4a-6b128c94ac69">301,971</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231" decimals="-3" name="us-gaap:InvestmentIncomeInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMjEvZnJhZzowZWY2M2NjZTNmMjk0ZGZjOWJlMzhhYWYwZmMyYTQ4Yi90YWJsZTpiYTNmZWJkNTZkYzc0YTM4OGVhODhlYjg0ZGRkNTBlZS90YWJsZXJhbmdlOmJhM2ZlYmQ1NmRjNzRhMzg4ZWE4OGViODRkZGQ1MGVlXzQtNS0xLTEtMTc3NzU_ed8e7c16-ab33-49de-b138-dcd1658371e1">407</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i12a6d1161de54547bd29f8efccd4c9b0_D20200101-20201231" decimals="-3" name="us-gaap:InvestmentIncomeInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMjEvZnJhZzowZWY2M2NjZTNmMjk0ZGZjOWJlMzhhYWYwZmMyYTQ4Yi90YWJsZTpiYTNmZWJkNTZkYzc0YTM4OGVhODhlYjg0ZGRkNTBlZS90YWJsZXJhbmdlOmJhM2ZlYmQ1NmRjNzRhMzg4ZWE4OGViODRkZGQ1MGVlXzQtNy0xLTEtMTc3NzU_2c8a6eb9-f987-4573-a286-c0651b1bac2e">2,633</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e21049ffc224cacb8134d73c9bb5b38_D20190101-20191231" decimals="-3" name="us-gaap:InvestmentIncomeInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMjEvZnJhZzowZWY2M2NjZTNmMjk0ZGZjOWJlMzhhYWYwZmMyYTQ4Yi90YWJsZTpiYTNmZWJkNTZkYzc0YTM4OGVhODhlYjg0ZGRkNTBlZS90YWJsZXJhbmdlOmJhM2ZlYmQ1NmRjNzRhMzg4ZWE4OGViODRkZGQ1MGVlXzQtNS0xLTEtMjMyMzY_02a2ab01-df64-405a-8e99-e04063811304">3,406</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231" decimals="-3" name="us-gaap:InterestExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMjEvZnJhZzowZWY2M2NjZTNmMjk0ZGZjOWJlMzhhYWYwZmMyYTQ4Yi90YWJsZTpiYTNmZWJkNTZkYzc0YTM4OGVhODhlYjg0ZGRkNTBlZS90YWJsZXJhbmdlOmJhM2ZlYmQ1NmRjNzRhMzg4ZWE4OGViODRkZGQ1MGVlXzUtNS0xLTEtMTc3NzU_6a78d6c2-1102-41af-9956-e43dca7ba453">25,425</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i12a6d1161de54547bd29f8efccd4c9b0_D20200101-20201231" decimals="-3" name="us-gaap:InterestExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMjEvZnJhZzowZWY2M2NjZTNmMjk0ZGZjOWJlMzhhYWYwZmMyYTQ4Yi90YWJsZTpiYTNmZWJkNTZkYzc0YTM4OGVhODhlYjg0ZGRkNTBlZS90YWJsZXJhbmdlOmJhM2ZlYmQ1NmRjNzRhMzg4ZWE4OGViODRkZGQ1MGVlXzUtNy0xLTEtMTc3NzU_d9178534-310c-4c1b-a213-f3217edea7a4">28,325</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3e21049ffc224cacb8134d73c9bb5b38_D20190101-20191231" decimals="-3" name="us-gaap:InterestExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMjEvZnJhZzowZWY2M2NjZTNmMjk0ZGZjOWJlMzhhYWYwZmMyYTQ4Yi90YWJsZTpiYTNmZWJkNTZkYzc0YTM4OGVhODhlYjg0ZGRkNTBlZS90YWJsZXJhbmdlOmJhM2ZlYmQ1NmRjNzRhMzg4ZWE4OGViODRkZGQ1MGVlXzUtNS0xLTEtMjMyMzY_7c53cd4e-aeb0-46af-90bb-c9b0f542fead">14,555</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Provision) benefit for income taxes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMjEvZnJhZzowZWY2M2NjZTNmMjk0ZGZjOWJlMzhhYWYwZmMyYTQ4Yi90YWJsZTpiYTNmZWJkNTZkYzc0YTM4OGVhODhlYjg0ZGRkNTBlZS90YWJsZXJhbmdlOmJhM2ZlYmQ1NmRjNzRhMzg4ZWE4OGViODRkZGQ1MGVlXzYtNS0xLTEtMTc3NzU_8763a587-540c-4c14-8863-d8c100f8a012">483</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i12a6d1161de54547bd29f8efccd4c9b0_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMjEvZnJhZzowZWY2M2NjZTNmMjk0ZGZjOWJlMzhhYWYwZmMyYTQ4Yi90YWJsZTpiYTNmZWJkNTZkYzc0YTM4OGVhODhlYjg0ZGRkNTBlZS90YWJsZXJhbmdlOmJhM2ZlYmQ1NmRjNzRhMzg4ZWE4OGViODRkZGQ1MGVlXzYtNy0xLTEtMTc3NzU_3177ea9d-bb7b-46a3-9f76-8e3fef64d535">2,368</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e21049ffc224cacb8134d73c9bb5b38_D20190101-20191231" decimals="-3" sign="-" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMjEvZnJhZzowZWY2M2NjZTNmMjk0ZGZjOWJlMzhhYWYwZmMyYTQ4Yi90YWJsZTpiYTNmZWJkNTZkYzc0YTM4OGVhODhlYjg0ZGRkNTBlZS90YWJsZXJhbmdlOmJhM2ZlYmQ1NmRjNzRhMzg4ZWE4OGViODRkZGQ1MGVlXzYtNS0xLTEtMjMyMzY_5cf3f7eb-def7-4142-a84e-9bd30b336afd">22,795</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231" decimals="-3" name="us-gaap:DepreciationAndAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMjEvZnJhZzowZWY2M2NjZTNmMjk0ZGZjOWJlMzhhYWYwZmMyYTQ4Yi90YWJsZTpiYTNmZWJkNTZkYzc0YTM4OGVhODhlYjg0ZGRkNTBlZS90YWJsZXJhbmdlOmJhM2ZlYmQ1NmRjNzRhMzg4ZWE4OGViODRkZGQ1MGVlXzctNS0xLTEtMTc3NzU_f1afa2f1-e1f9-4119-a437-bbb12c50a407">60,037</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i12a6d1161de54547bd29f8efccd4c9b0_D20200101-20201231" decimals="-3" name="us-gaap:DepreciationAndAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMjEvZnJhZzowZWY2M2NjZTNmMjk0ZGZjOWJlMzhhYWYwZmMyYTQ4Yi90YWJsZTpiYTNmZWJkNTZkYzc0YTM4OGVhODhlYjg0ZGRkNTBlZS90YWJsZXJhbmdlOmJhM2ZlYmQ1NmRjNzRhMzg4ZWE4OGViODRkZGQ1MGVlXzctNy0xLTEtMTc3NzU_c0c6d424-d639-43ff-ae36-e67743473fb8">60,835</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3e21049ffc224cacb8134d73c9bb5b38_D20190101-20191231" decimals="-3" name="us-gaap:DepreciationAndAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMjEvZnJhZzowZWY2M2NjZTNmMjk0ZGZjOWJlMzhhYWYwZmMyYTQ4Yi90YWJsZTpiYTNmZWJkNTZkYzc0YTM4OGVhODhlYjg0ZGRkNTBlZS90YWJsZXJhbmdlOmJhM2ZlYmQ1NmRjNzRhMzg4ZWE4OGViODRkZGQ1MGVlXzctNS0xLTEtMjMyMzY_b5e73f6a-0246-4d47-b7c9-16644fd4a70c">60,323</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity method investment impairment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231" decimals="-3" name="us-gaap:EquityMethodInvestmentOtherThanTemporaryImpairment" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMjEvZnJhZzowZWY2M2NjZTNmMjk0ZGZjOWJlMzhhYWYwZmMyYTQ4Yi90YWJsZTpiYTNmZWJkNTZkYzc0YTM4OGVhODhlYjg0ZGRkNTBlZS90YWJsZXJhbmdlOmJhM2ZlYmQ1NmRjNzRhMzg4ZWE4OGViODRkZGQ1MGVlXzgtNS0xLTEtMTc3NzU_314f9217-cff7-4475-9624-e1acebb48df1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i12a6d1161de54547bd29f8efccd4c9b0_D20200101-20201231" decimals="-3" name="us-gaap:EquityMethodInvestmentOtherThanTemporaryImpairment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMjEvZnJhZzowZWY2M2NjZTNmMjk0ZGZjOWJlMzhhYWYwZmMyYTQ4Yi90YWJsZTpiYTNmZWJkNTZkYzc0YTM4OGVhODhlYjg0ZGRkNTBlZS90YWJsZXJhbmdlOmJhM2ZlYmQ1NmRjNzRhMzg4ZWE4OGViODRkZGQ1MGVlXzgtNy0xLTEtMTc3NzU_912eb6b5-901c-4923-9d50-f2ef2320eaee">47,133</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e21049ffc224cacb8134d73c9bb5b38_D20190101-20191231" decimals="-3" name="us-gaap:EquityMethodInvestmentOtherThanTemporaryImpairment" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMjEvZnJhZzowZWY2M2NjZTNmMjk0ZGZjOWJlMzhhYWYwZmMyYTQ4Yi90YWJsZTpiYTNmZWJkNTZkYzc0YTM4OGVhODhlYjg0ZGRkNTBlZS90YWJsZXJhbmdlOmJhM2ZlYmQ1NmRjNzRhMzg4ZWE4OGViODRkZGQ1MGVlXzgtNS0xLTEtMjMyNDQ_037030bf-fb7c-4f38-88d7-dabe34ff0e65">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain on transfer of membership</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231" decimals="-3" name="evh:GainOnTransferOfMembership" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMjEvZnJhZzowZWY2M2NjZTNmMjk0ZGZjOWJlMzhhYWYwZmMyYTQ4Yi90YWJsZTpiYTNmZWJkNTZkYzc0YTM4OGVhODhlYjg0ZGRkNTBlZS90YWJsZXJhbmdlOmJhM2ZlYmQ1NmRjNzRhMzg4ZWE4OGViODRkZGQ1MGVlXzktNS0xLTEtMTc3NzU_bffb65bb-0bd0-4298-874d-aed5d2b2cef1">45,938</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i12a6d1161de54547bd29f8efccd4c9b0_D20200101-20201231" decimals="-3" name="evh:GainOnTransferOfMembership" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMjEvZnJhZzowZWY2M2NjZTNmMjk0ZGZjOWJlMzhhYWYwZmMyYTQ4Yi90YWJsZTpiYTNmZWJkNTZkYzc0YTM4OGVhODhlYjg0ZGRkNTBlZS90YWJsZXJhbmdlOmJhM2ZlYmQ1NmRjNzRhMzg4ZWE4OGViODRkZGQ1MGVlXzktNy0xLTEtMTc3NzU_6772e0d8-51ed-4616-afa1-8e59535ee9e2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e21049ffc224cacb8134d73c9bb5b38_D20190101-20191231" decimals="-3" name="evh:GainOnTransferOfMembership" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMjEvZnJhZzowZWY2M2NjZTNmMjk0ZGZjOWJlMzhhYWYwZmMyYTQ4Yi90YWJsZTpiYTNmZWJkNTZkYzc0YTM4OGVhODhlYjg0ZGRkNTBlZS90YWJsZXJhbmdlOmJhM2ZlYmQ1NmRjNzRhMzg4ZWE4OGViODRkZGQ1MGVlXzktNS0xLTEtMjMyNjE_81e05d0a-b599-4bfc-91b4-ab67691eb7cb">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss on repayment of debt, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231" decimals="-3" sign="-" name="evh:GainLossOnRepaymentOfDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMjEvZnJhZzowZWY2M2NjZTNmMjk0ZGZjOWJlMzhhYWYwZmMyYTQ4Yi90YWJsZTpiYTNmZWJkNTZkYzc0YTM4OGVhODhlYjg0ZGRkNTBlZS90YWJsZXJhbmdlOmJhM2ZlYmQ1NmRjNzRhMzg4ZWE4OGViODRkZGQ1MGVlXzEwLTUtMS0xLTE3Nzc1_32c2cc83-604a-4434-8547-4d1ae90769e4">21,343</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i12a6d1161de54547bd29f8efccd4c9b0_D20200101-20201231" decimals="-3" name="evh:GainLossOnRepaymentOfDebt" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMjEvZnJhZzowZWY2M2NjZTNmMjk0ZGZjOWJlMzhhYWYwZmMyYTQ4Yi90YWJsZTpiYTNmZWJkNTZkYzc0YTM4OGVhODhlYjg0ZGRkNTBlZS90YWJsZXJhbmdlOmJhM2ZlYmQ1NmRjNzRhMzg4ZWE4OGViODRkZGQ1MGVlXzEwLTctMS0xLTE3Nzc1_90bb2a7d-d061-42be-8575-98c2928c53fb">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e21049ffc224cacb8134d73c9bb5b38_D20190101-20191231" decimals="-3" name="evh:GainLossOnRepaymentOfDebt" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMjEvZnJhZzowZWY2M2NjZTNmMjk0ZGZjOWJlMzhhYWYwZmMyYTQ4Yi90YWJsZTpiYTNmZWJkNTZkYzc0YTM4OGVhODhlYjg0ZGRkNTBlZS90YWJsZXJhbmdlOmJhM2ZlYmQ1NmRjNzRhMzg4ZWE4OGViODRkZGQ1MGVlXzEwLTUtMS0xLTIzMjY4_580d971e-47b9-476b-9317-03d0130cd807">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss on extinguishment of debt</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231" decimals="-3" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMjEvZnJhZzowZWY2M2NjZTNmMjk0ZGZjOWJlMzhhYWYwZmMyYTQ4Yi90YWJsZTpiYTNmZWJkNTZkYzc0YTM4OGVhODhlYjg0ZGRkNTBlZS90YWJsZXJhbmdlOmJhM2ZlYmQ1NmRjNzRhMzg4ZWE4OGViODRkZGQ1MGVlXzExLTUtMS0xLTE3Nzc1_88d34f60-54e6-445d-94a8-a2a1fa0905bc">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i12a6d1161de54547bd29f8efccd4c9b0_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMjEvZnJhZzowZWY2M2NjZTNmMjk0ZGZjOWJlMzhhYWYwZmMyYTQ4Yi90YWJsZTpiYTNmZWJkNTZkYzc0YTM4OGVhODhlYjg0ZGRkNTBlZS90YWJsZXJhbmdlOmJhM2ZlYmQ1NmRjNzRhMzg4ZWE4OGViODRkZGQ1MGVlXzExLTctMS0xLTE3Nzc1_315de6a0-54ab-4d31-a7e8-564a3710365a">4,789</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e21049ffc224cacb8134d73c9bb5b38_D20190101-20191231" decimals="-3" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMjEvZnJhZzowZWY2M2NjZTNmMjk0ZGZjOWJlMzhhYWYwZmMyYTQ4Yi90YWJsZTpiYTNmZWJkNTZkYzc0YTM4OGVhODhlYjg0ZGRkNTBlZS90YWJsZXJhbmdlOmJhM2ZlYmQ1NmRjNzRhMzg4ZWE4OGViODRkZGQ1MGVlXzExLTUtMS0xLTIzMjY4_57f03d61-016b-42db-942d-42cb9d8f1dc0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill impairment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231" decimals="-3" name="us-gaap:GoodwillImpairmentLoss" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMjEvZnJhZzowZWY2M2NjZTNmMjk0ZGZjOWJlMzhhYWYwZmMyYTQ4Yi90YWJsZTpiYTNmZWJkNTZkYzc0YTM4OGVhODhlYjg0ZGRkNTBlZS90YWJsZXJhbmdlOmJhM2ZlYmQ1NmRjNzRhMzg4ZWE4OGViODRkZGQ1MGVlXzEyLTUtMS0xLTE3Nzc1_7ec28ccb-31ef-4083-96d9-d0362787dc96">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i12a6d1161de54547bd29f8efccd4c9b0_D20200101-20201231" decimals="-3" name="us-gaap:GoodwillImpairmentLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMjEvZnJhZzowZWY2M2NjZTNmMjk0ZGZjOWJlMzhhYWYwZmMyYTQ4Yi90YWJsZTpiYTNmZWJkNTZkYzc0YTM4OGVhODhlYjg0ZGRkNTBlZS90YWJsZXJhbmdlOmJhM2ZlYmQ1NmRjNzRhMzg4ZWE4OGViODRkZGQ1MGVlXzEyLTctMS0xLTE3Nzc1_f3903d0a-d181-4884-96b8-217fb1f14fac">215,100</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3e21049ffc224cacb8134d73c9bb5b38_D20190101-20191231" decimals="-3" name="us-gaap:GoodwillImpairmentLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMjEvZnJhZzowZWY2M2NjZTNmMjk0ZGZjOWJlMzhhYWYwZmMyYTQ4Yi90YWJsZTpiYTNmZWJkNTZkYzc0YTM4OGVhODhlYjg0ZGRkNTBlZS90YWJsZXJhbmdlOmJhM2ZlYmQ1NmRjNzRhMzg4ZWE4OGViODRkZGQ1MGVlXzEyLTUtMS0xLTIzMjY4_4c295aac-32ce-4fb7-81cf-7060c596f9a7">199,800</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain (loss) from equity method investees</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231" decimals="-3" name="us-gaap:IncomeLossFromEquityMethodInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMjEvZnJhZzowZWY2M2NjZTNmMjk0ZGZjOWJlMzhhYWYwZmMyYTQ4Yi90YWJsZTpiYTNmZWJkNTZkYzc0YTM4OGVhODhlYjg0ZGRkNTBlZS90YWJsZXJhbmdlOmJhM2ZlYmQ1NmRjNzRhMzg4ZWE4OGViODRkZGQ1MGVlXzEzLTUtMS0xLTE3Nzc1_2f0cbad5-d099-47d2-83ca-4dbf81be40bb">13,179</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i12a6d1161de54547bd29f8efccd4c9b0_D20200101-20201231" decimals="-3" name="us-gaap:IncomeLossFromEquityMethodInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMjEvZnJhZzowZWY2M2NjZTNmMjk0ZGZjOWJlMzhhYWYwZmMyYTQ4Yi90YWJsZTpiYTNmZWJkNTZkYzc0YTM4OGVhODhlYjg0ZGRkNTBlZS90YWJsZXJhbmdlOmJhM2ZlYmQ1NmRjNzRhMzg4ZWE4OGViODRkZGQ1MGVlXzEzLTctMS0xLTE3Nzc1_1f074cc6-4f96-446a-b901-7ff7a087c6a5">10,039</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3e21049ffc224cacb8134d73c9bb5b38_D20190101-20191231" decimals="-3" sign="-" name="us-gaap:IncomeLossFromEquityMethodInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMjEvZnJhZzowZWY2M2NjZTNmMjk0ZGZjOWJlMzhhYWYwZmMyYTQ4Yi90YWJsZTpiYTNmZWJkNTZkYzc0YTM4OGVhODhlYjg0ZGRkNTBlZS90YWJsZXJhbmdlOmJhM2ZlYmQ1NmRjNzRhMzg4ZWE4OGViODRkZGQ1MGVlXzEzLTUtMS0xLTIzMjc1_290de68e-f36e-414b-bd27-42ca3723287b">9,465</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain (loss) on disposal of assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231" decimals="-3" name="us-gaap:GainLossOnDispositionOfAssets1" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMjEvZnJhZzowZWY2M2NjZTNmMjk0ZGZjOWJlMzhhYWYwZmMyYTQ4Yi90YWJsZTpiYTNmZWJkNTZkYzc0YTM4OGVhODhlYjg0ZGRkNTBlZS90YWJsZXJhbmdlOmJhM2ZlYmQ1NmRjNzRhMzg4ZWE4OGViODRkZGQ1MGVlXzE0LTUtMS0xLTE3Nzc1_5362c6cf-ae2c-41ac-a47b-02c1baebd924">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i12a6d1161de54547bd29f8efccd4c9b0_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:GainLossOnDispositionOfAssets1" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMjEvZnJhZzowZWY2M2NjZTNmMjk0ZGZjOWJlMzhhYWYwZmMyYTQ4Yi90YWJsZTpiYTNmZWJkNTZkYzc0YTM4OGVhODhlYjg0ZGRkNTBlZS90YWJsZXJhbmdlOmJhM2ZlYmQ1NmRjNzRhMzg4ZWE4OGViODRkZGQ1MGVlXzE0LTctMS0xLTE3Nzc1_cc529727-46a0-4a88-921b-1d9c5687d220">698</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e21049ffc224cacb8134d73c9bb5b38_D20190101-20191231" decimals="-3" name="us-gaap:GainLossOnDispositionOfAssets1" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMjEvZnJhZzowZWY2M2NjZTNmMjk0ZGZjOWJlMzhhYWYwZmMyYTQ4Yi90YWJsZTpiYTNmZWJkNTZkYzc0YTM4OGVhODhlYjg0ZGRkNTBlZS90YWJsZXJhbmdlOmJhM2ZlYmQ1NmRjNzRhMzg4ZWE4OGViODRkZGQ1MGVlXzE0LTUtMS0xLTIzMjc1_2aa07e04-b162-4e6e-a548-8f79b0f359ce">9,600</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value of contingent consideration and indemnification asset</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMjEvZnJhZzowZWY2M2NjZTNmMjk0ZGZjOWJlMzhhYWYwZmMyYTQ4Yi90YWJsZTpiYTNmZWJkNTZkYzc0YTM4OGVhODhlYjg0ZGRkNTBlZS90YWJsZXJhbmdlOmJhM2ZlYmQ1NmRjNzRhMzg4ZWE4OGViODRkZGQ1MGVlXzE1LTUtMS0xLTE3Nzc1_f5075020-c202-43a7-80e8-ab5df856f8f3">13,281</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i12a6d1161de54547bd29f8efccd4c9b0_D20200101-20201231" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMjEvZnJhZzowZWY2M2NjZTNmMjk0ZGZjOWJlMzhhYWYwZmMyYTQ4Yi90YWJsZTpiYTNmZWJkNTZkYzc0YTM4OGVhODhlYjg0ZGRkNTBlZS90YWJsZXJhbmdlOmJhM2ZlYmQ1NmRjNzRhMzg4ZWE4OGViODRkZGQ1MGVlXzE1LTctMS0xLTE3Nzc1_aeced91b-7536-465a-9a60-30f4047f35e3">3,860</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e21049ffc224cacb8134d73c9bb5b38_D20190101-20191231" decimals="-3" sign="-" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMjEvZnJhZzowZWY2M2NjZTNmMjk0ZGZjOWJlMzhhYWYwZmMyYTQ4Yi90YWJsZTpiYTNmZWJkNTZkYzc0YTM4OGVhODhlYjg0ZGRkNTBlZS90YWJsZXJhbmdlOmJhM2ZlYmQ1NmRjNzRhMzg4ZWE4OGViODRkZGQ1MGVlXzE1LTUtMS0xLTIzMjgy_1042ea0d-d1ac-40df-bcee-cf06f6156393">3,997</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss attributable to non-controlling interests</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231" decimals="-3" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMjEvZnJhZzowZWY2M2NjZTNmMjk0ZGZjOWJlMzhhYWYwZmMyYTQ4Yi90YWJsZTpiYTNmZWJkNTZkYzc0YTM4OGVhODhlYjg0ZGRkNTBlZS90YWJsZXJhbmdlOmJhM2ZlYmQ1NmRjNzRhMzg4ZWE4OGViODRkZGQ1MGVlXzE2LTUtMS0xLTE3Nzc1_51e15338-b561-4630-ba7b-1004644fe8a0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i12a6d1161de54547bd29f8efccd4c9b0_D20200101-20201231" decimals="-3" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMjEvZnJhZzowZWY2M2NjZTNmMjk0ZGZjOWJlMzhhYWYwZmMyYTQ4Yi90YWJsZTpiYTNmZWJkNTZkYzc0YTM4OGVhODhlYjg0ZGRkNTBlZS90YWJsZXJhbmdlOmJhM2ZlYmQ1NmRjNzRhMzg4ZWE4OGViODRkZGQ1MGVlXzE2LTctMS0xLTE3Nzc1_f720fe92-dbd8-4120-8de5-cda5648484c9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e21049ffc224cacb8134d73c9bb5b38_D20190101-20191231" decimals="-3" sign="-" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMjEvZnJhZzowZWY2M2NjZTNmMjk0ZGZjOWJlMzhhYWYwZmMyYTQ4Yi90YWJsZTpiYTNmZWJkNTZkYzc0YTM4OGVhODhlYjg0ZGRkNTBlZS90YWJsZXJhbmdlOmJhM2ZlYmQ1NmRjNzRhMzg4ZWE4OGViODRkZGQ1MGVlXzE2LTUtMS0xLTIzMjg5_1ce9bbe1-da9b-465b-b84a-20e4d750bfff">3,609</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income (expense), net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMjEvZnJhZzowZWY2M2NjZTNmMjk0ZGZjOWJlMzhhYWYwZmMyYTQ4Yi90YWJsZTpiYTNmZWJkNTZkYzc0YTM4OGVhODhlYjg0ZGRkNTBlZS90YWJsZXJhbmdlOmJhM2ZlYmQ1NmRjNzRhMzg4ZWE4OGViODRkZGQ1MGVlXzE3LTUtMS0xLTE3Nzc1_91b26e5a-4311-43ad-9199-79d6719831d4">146</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i12a6d1161de54547bd29f8efccd4c9b0_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMjEvZnJhZzowZWY2M2NjZTNmMjk0ZGZjOWJlMzhhYWYwZmMyYTQ4Yi90YWJsZTpiYTNmZWJkNTZkYzc0YTM4OGVhODhlYjg0ZGRkNTBlZS90YWJsZXJhbmdlOmJhM2ZlYmQ1NmRjNzRhMzg4ZWE4OGViODRkZGQ1MGVlXzE3LTctMS0xLTE3Nzc1_944f36c7-5913-4fa8-9f12-77ab8e2f8862">118</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3e21049ffc224cacb8134d73c9bb5b38_D20190101-20191231" decimals="-3" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMjEvZnJhZzowZWY2M2NjZTNmMjk0ZGZjOWJlMzhhYWYwZmMyYTQ4Yi90YWJsZTpiYTNmZWJkNTZkYzc0YTM4OGVhODhlYjg0ZGRkNTBlZS90YWJsZXJhbmdlOmJhM2ZlYmQ1NmRjNzRhMzg4ZWE4OGViODRkZGQ1MGVlXzE3LTUtMS0xLTIzMjk2_28296252-bcb6-4083-914c-ff96bf48b709">489</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchase accounting adjustments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231" decimals="-3" name="evh:PurchaseAccountingAdjustments" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMjEvZnJhZzowZWY2M2NjZTNmMjk0ZGZjOWJlMzhhYWYwZmMyYTQ4Yi90YWJsZTpiYTNmZWJkNTZkYzc0YTM4OGVhODhlYjg0ZGRkNTBlZS90YWJsZXJhbmdlOmJhM2ZlYmQ1NmRjNzRhMzg4ZWE4OGViODRkZGQ1MGVlXzE4LTEtMS0xLTMzNTc0_cf14d18b-ec0a-4ef9-90a7-d2277cbe7f57">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i12a6d1161de54547bd29f8efccd4c9b0_D20200101-20201231" decimals="-3" name="evh:PurchaseAccountingAdjustments" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMjEvZnJhZzowZWY2M2NjZTNmMjk0ZGZjOWJlMzhhYWYwZmMyYTQ4Yi90YWJsZTpiYTNmZWJkNTZkYzc0YTM4OGVhODhlYjg0ZGRkNTBlZS90YWJsZXJhbmdlOmJhM2ZlYmQ1NmRjNzRhMzg4ZWE4OGViODRkZGQ1MGVlXzE4LTMtMS0xLTMzNTc0_6d4e0543-9fac-4239-b5dc-14173ab78184">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3e21049ffc224cacb8134d73c9bb5b38_D20190101-20191231" decimals="-3" name="evh:PurchaseAccountingAdjustments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMjEvZnJhZzowZWY2M2NjZTNmMjk0ZGZjOWJlMzhhYWYwZmMyYTQ4Yi90YWJsZTpiYTNmZWJkNTZkYzc0YTM4OGVhODhlYjg0ZGRkNTBlZS90YWJsZXJhbmdlOmJhM2ZlYmQ1NmRjNzRhMzg4ZWE4OGViODRkZGQ1MGVlXzE4LTUtMS0xLTMzNTc0_a3daf900-6628-4b37-846e-cd7b93b9643b">1,915</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Repositioning costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231" decimals="-3" name="us-gaap:RestructuringCharges" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMjEvZnJhZzowZWY2M2NjZTNmMjk0ZGZjOWJlMzhhYWYwZmMyYTQ4Yi90YWJsZTpiYTNmZWJkNTZkYzc0YTM4OGVhODhlYjg0ZGRkNTBlZS90YWJsZXJhbmdlOmJhM2ZlYmQ1NmRjNzRhMzg4ZWE4OGViODRkZGQ1MGVlXzE4LTUtMS0xLTE3Nzc1_5910620a-e0b9-42f3-bb48-79d69752f3b1">7,318</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i12a6d1161de54547bd29f8efccd4c9b0_D20200101-20201231" decimals="-3" name="us-gaap:RestructuringCharges" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMjEvZnJhZzowZWY2M2NjZTNmMjk0ZGZjOWJlMzhhYWYwZmMyYTQ4Yi90YWJsZTpiYTNmZWJkNTZkYzc0YTM4OGVhODhlYjg0ZGRkNTBlZS90YWJsZXJhbmdlOmJhM2ZlYmQ1NmRjNzRhMzg4ZWE4OGViODRkZGQ1MGVlXzE4LTctMS0xLTE3Nzc1_d22f66c6-fdc9-4a92-a058-191194888607">1,275</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e21049ffc224cacb8134d73c9bb5b38_D20190101-20191231" decimals="-3" name="us-gaap:RestructuringCharges" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMjEvZnJhZzowZWY2M2NjZTNmMjk0ZGZjOWJlMzhhYWYwZmMyYTQ4Yi90YWJsZTpiYTNmZWJkNTZkYzc0YTM4OGVhODhlYjg0ZGRkNTBlZS90YWJsZXJhbmdlOmJhM2ZlYmQ1NmRjNzRhMzg4ZWE4OGViODRkZGQ1MGVlXzE4LTUtMS0xLTIzMzAz_0493e0d4-f317-46f2-88f1-450c0556cfe9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231" decimals="-3" name="evh:SharebasedCompensationIncludingOnetimeAdjustment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMjEvZnJhZzowZWY2M2NjZTNmMjk0ZGZjOWJlMzhhYWYwZmMyYTQ4Yi90YWJsZTpiYTNmZWJkNTZkYzc0YTM4OGVhODhlYjg0ZGRkNTBlZS90YWJsZXJhbmdlOmJhM2ZlYmQ1NmRjNzRhMzg4ZWE4OGViODRkZGQ1MGVlXzE5LTUtMS0xLTE3Nzc1_6900a919-aedc-4306-8e62-d6cf7a47060c">16,711</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i12a6d1161de54547bd29f8efccd4c9b0_D20200101-20201231" decimals="-3" name="evh:SharebasedCompensationIncludingOnetimeAdjustment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMjEvZnJhZzowZWY2M2NjZTNmMjk0ZGZjOWJlMzhhYWYwZmMyYTQ4Yi90YWJsZTpiYTNmZWJkNTZkYzc0YTM4OGVhODhlYjg0ZGRkNTBlZS90YWJsZXJhbmdlOmJhM2ZlYmQ1NmRjNzRhMzg4ZWE4OGViODRkZGQ1MGVlXzE5LTctMS0xLTE3Nzc1_c9247590-aeea-4eaf-b705-215fbb707484">14,606</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3e21049ffc224cacb8134d73c9bb5b38_D20190101-20191231" decimals="-3" name="evh:SharebasedCompensationIncludingOnetimeAdjustment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMjEvZnJhZzowZWY2M2NjZTNmMjk0ZGZjOWJlMzhhYWYwZmMyYTQ4Yi90YWJsZTpiYTNmZWJkNTZkYzc0YTM4OGVhODhlYjg0ZGRkNTBlZS90YWJsZXJhbmdlOmJhM2ZlYmQ1NmRjNzRhMzg4ZWE4OGViODRkZGQ1MGVlXzE5LTUtMS0xLTIzMzAz_593b31fb-2dca-42b4-9353-1f02ed38e177">15,618</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Severance costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231" decimals="-3" name="us-gaap:SeveranceCosts1" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMjEvZnJhZzowZWY2M2NjZTNmMjk0ZGZjOWJlMzhhYWYwZmMyYTQ4Yi90YWJsZTpiYTNmZWJkNTZkYzc0YTM4OGVhODhlYjg0ZGRkNTBlZS90YWJsZXJhbmdlOmJhM2ZlYmQ1NmRjNzRhMzg4ZWE4OGViODRkZGQ1MGVlXzIwLTUtMS0xLTE3Nzc1_df3dee07-d709-4416-80d0-ce17a94396e7">198</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i12a6d1161de54547bd29f8efccd4c9b0_D20200101-20201231" decimals="-3" name="us-gaap:SeveranceCosts1" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMjEvZnJhZzowZWY2M2NjZTNmMjk0ZGZjOWJlMzhhYWYwZmMyYTQ4Yi90YWJsZTpiYTNmZWJkNTZkYzc0YTM4OGVhODhlYjg0ZGRkNTBlZS90YWJsZXJhbmdlOmJhM2ZlYmQ1NmRjNzRhMzg4ZWE4OGViODRkZGQ1MGVlXzIwLTctMS0xLTE3Nzc1_7e5fa560-0079-47a0-8a0e-9184632ff34f">8,986</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3e21049ffc224cacb8134d73c9bb5b38_D20190101-20191231" decimals="-3" name="us-gaap:SeveranceCosts1" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMjEvZnJhZzowZWY2M2NjZTNmMjk0ZGZjOWJlMzhhYWYwZmMyYTQ4Yi90YWJsZTpiYTNmZWJkNTZkYzc0YTM4OGVhODhlYjg0ZGRkNTBlZS90YWJsZXJhbmdlOmJhM2ZlYmQ1NmRjNzRhMzg4ZWE4OGViODRkZGQ1MGVlXzIwLTUtMS0xLTIzMzAz_50e0b383-7fe3-43bb-a8bc-e225630510e0">17,350</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of contract cost assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231" decimals="-3" name="evh:CapitalizedContractCostAmortizationPurchaseAccountingAdjustments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMjEvZnJhZzowZWY2M2NjZTNmMjk0ZGZjOWJlMzhhYWYwZmMyYTQ4Yi90YWJsZTpiYTNmZWJkNTZkYzc0YTM4OGVhODhlYjg0ZGRkNTBlZS90YWJsZXJhbmdlOmJhM2ZlYmQ1NmRjNzRhMzg4ZWE4OGViODRkZGQ1MGVlXzIxLTUtMS0xLTE3Nzc1_3ee6c607-2133-48ae-8cb6-87855420b6ed">476</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i12a6d1161de54547bd29f8efccd4c9b0_D20200101-20201231" decimals="-3" name="evh:CapitalizedContractCostAmortizationPurchaseAccountingAdjustments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMjEvZnJhZzowZWY2M2NjZTNmMjk0ZGZjOWJlMzhhYWYwZmMyYTQ4Yi90YWJsZTpiYTNmZWJkNTZkYzc0YTM4OGVhODhlYjg0ZGRkNTBlZS90YWJsZXJhbmdlOmJhM2ZlYmQ1NmRjNzRhMzg4ZWE4OGViODRkZGQ1MGVlXzIxLTctMS0xLTE3Nzc1_9b068ce6-82e3-4c20-adb2-14ecf45434d8">3,944</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3e21049ffc224cacb8134d73c9bb5b38_D20190101-20191231" decimals="-3" name="evh:CapitalizedContractCostAmortizationPurchaseAccountingAdjustments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMjEvZnJhZzowZWY2M2NjZTNmMjk0ZGZjOWJlMzhhYWYwZmMyYTQ4Yi90YWJsZTpiYTNmZWJkNTZkYzc0YTM4OGVhODhlYjg0ZGRkNTBlZS90YWJsZXJhbmdlOmJhM2ZlYmQ1NmRjNzRhMzg4ZWE4OGViODRkZGQ1MGVlXzIxLTUtMS0xLTIzMzEy_342aed0e-1888-4673-99c3-7f244269a549">2,876</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Strategy and shareholder advisory expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231" decimals="-3" name="evh:ShareholderAdvisoryServices" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMjEvZnJhZzowZWY2M2NjZTNmMjk0ZGZjOWJlMzhhYWYwZmMyYTQ4Yi90YWJsZTpiYTNmZWJkNTZkYzc0YTM4OGVhODhlYjg0ZGRkNTBlZS90YWJsZXJhbmdlOmJhM2ZlYmQ1NmRjNzRhMzg4ZWE4OGViODRkZGQ1MGVlXzIyLTUtMS0xLTE3Nzc1_21cef35a-545d-4781-80a3-952c24dbf6f0">6,513</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i12a6d1161de54547bd29f8efccd4c9b0_D20200101-20201231" decimals="-3" name="evh:ShareholderAdvisoryServices" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMjEvZnJhZzowZWY2M2NjZTNmMjk0ZGZjOWJlMzhhYWYwZmMyYTQ4Yi90YWJsZTpiYTNmZWJkNTZkYzc0YTM4OGVhODhlYjg0ZGRkNTBlZS90YWJsZXJhbmdlOmJhM2ZlYmQ1NmRjNzRhMzg4ZWE4OGViODRkZGQ1MGVlXzIyLTctMS0xLTE3Nzc1_5482e81f-a076-4189-92ff-57bf50b64171">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e21049ffc224cacb8134d73c9bb5b38_D20190101-20191231" decimals="-3" name="evh:ShareholderAdvisoryServices" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMjEvZnJhZzowZWY2M2NjZTNmMjk0ZGZjOWJlMzhhYWYwZmMyYTQ4Yi90YWJsZTpiYTNmZWJkNTZkYzc0YTM4OGVhODhlYjg0ZGRkNTBlZS90YWJsZXJhbmdlOmJhM2ZlYmQ1NmRjNzRhMzg4ZWE4OGViODRkZGQ1MGVlXzIyLTUtMS0xLTIzMzEy_f71ccdcd-0d74-45ad-b183-4071b0fe36cf">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisition costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231" decimals="-3" name="evh:TransactionCosts" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMjEvZnJhZzowZWY2M2NjZTNmMjk0ZGZjOWJlMzhhYWYwZmMyYTQ4Yi90YWJsZTpiYTNmZWJkNTZkYzc0YTM4OGVhODhlYjg0ZGRkNTBlZS90YWJsZXJhbmdlOmJhM2ZlYmQ1NmRjNzRhMzg4ZWE4OGViODRkZGQ1MGVlXzIzLTUtMS0xLTE3Nzc1_270e52e5-1739-49e4-b2e0-9e4d632891b3">4,194</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i12a6d1161de54547bd29f8efccd4c9b0_D20200101-20201231" decimals="-3" name="evh:TransactionCosts" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMjEvZnJhZzowZWY2M2NjZTNmMjk0ZGZjOWJlMzhhYWYwZmMyYTQ4Yi90YWJsZTpiYTNmZWJkNTZkYzc0YTM4OGVhODhlYjg0ZGRkNTBlZS90YWJsZXJhbmdlOmJhM2ZlYmQ1NmRjNzRhMzg4ZWE4OGViODRkZGQ1MGVlXzIzLTctMS0xLTE3Nzc1_657ca6ab-9c7b-44af-a0e8-4a1ad275ef9e">2,116</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3e21049ffc224cacb8134d73c9bb5b38_D20190101-20191231" decimals="-3" name="evh:TransactionCosts" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMjEvZnJhZzowZWY2M2NjZTNmMjk0ZGZjOWJlMzhhYWYwZmMyYTQ4Yi90YWJsZTpiYTNmZWJkNTZkYzc0YTM4OGVhODhlYjg0ZGRkNTBlZS90YWJsZXJhbmdlOmJhM2ZlYmQ1NmRjNzRhMzg4ZWE4OGViODRkZGQ1MGVlXzIzLTUtMS0xLTIzMzEy_7002bc86-840f-4e36-a16f-6f7a0c33398a">10,769</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain (loss) from discontinued operations </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMjEvZnJhZzowZWY2M2NjZTNmMjk0ZGZjOWJlMzhhYWYwZmMyYTQ4Yi90YWJsZTpiYTNmZWJkNTZkYzc0YTM4OGVhODhlYjg0ZGRkNTBlZS90YWJsZXJhbmdlOmJhM2ZlYmQ1NmRjNzRhMzg4ZWE4OGViODRkZGQ1MGVlXzI0LTUtMS0xLTE3Nzc1_a856c6d6-baae-4acb-be4e-64217d10ef5a">7,317</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i12a6d1161de54547bd29f8efccd4c9b0_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMjEvZnJhZzowZWY2M2NjZTNmMjk0ZGZjOWJlMzhhYWYwZmMyYTQ4Yi90YWJsZTpiYTNmZWJkNTZkYzc0YTM4OGVhODhlYjg0ZGRkNTBlZS90YWJsZXJhbmdlOmJhM2ZlYmQ1NmRjNzRhMzg4ZWE4OGViODRkZGQ1MGVlXzI0LTctMS0xLTE3Nzc1_f300c02c-2d0e-4c59-a835-a3561e122e63">6,074</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e21049ffc224cacb8134d73c9bb5b38_D20190101-20191231" decimals="-3" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMjEvZnJhZzowZWY2M2NjZTNmMjk0ZGZjOWJlMzhhYWYwZmMyYTQ4Yi90YWJsZTpiYTNmZWJkNTZkYzc0YTM4OGVhODhlYjg0ZGRkNTBlZS90YWJsZXJhbmdlOmJhM2ZlYmQ1NmRjNzRhMzg4ZWE4OGViODRkZGQ1MGVlXzI0LTUtMS0xLTIzMzEy_465eefb9-8783-4845-9b2e-d4002de1f108">1,613</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Adjusted EBITDA</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231" decimals="-3" name="evh:AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMjEvZnJhZzowZWY2M2NjZTNmMjk0ZGZjOWJlMzhhYWYwZmMyYTQ4Yi90YWJsZTpiYTNmZWJkNTZkYzc0YTM4OGVhODhlYjg0ZGRkNTBlZS90YWJsZXJhbmdlOmJhM2ZlYmQ1NmRjNzRhMzg4ZWE4OGViODRkZGQ1MGVlXzI1LTUtMS0xLTE3Nzc1_35881580-8928-4553-af01-79c781909b8d">66,317</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i12a6d1161de54547bd29f8efccd4c9b0_D20200101-20201231" decimals="-3" name="evh:AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMjEvZnJhZzowZWY2M2NjZTNmMjk0ZGZjOWJlMzhhYWYwZmMyYTQ4Yi90YWJsZTpiYTNmZWJkNTZkYzc0YTM4OGVhODhlYjg0ZGRkNTBlZS90YWJsZXJhbmdlOmJhM2ZlYmQ1NmRjNzRhMzg4ZWE4OGViODRkZGQ1MGVlXzI1LTctMS0xLTE3Nzc1_cbe2a6e0-b13b-4e63-882f-5ff6a9231942">48,573</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3e21049ffc224cacb8134d73c9bb5b38_D20190101-20191231" decimals="-3" sign="-" name="evh:AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMjEvZnJhZzowZWY2M2NjZTNmMjk0ZGZjOWJlMzhhYWYwZmMyYTQ4Yi90YWJsZTpiYTNmZWJkNTZkYzc0YTM4OGVhODhlYjg0ZGRkNTBlZS90YWJsZXJhbmdlOmJhM2ZlYmQ1NmRjNzRhMzg4ZWE4OGViODRkZGQ1MGVlXzI1LTUtMS0xLTIzMzE5_299b8e27-3fd8-49d7-880d-2e0c2afb10d3">13,831</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt">Includes $<ix:nonFraction unitRef="usd" contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231" decimals="-5" name="us-gaap:DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMjEvZnJhZzowZWY2M2NjZTNmMjk0ZGZjOWJlMzhhYWYwZmMyYTQ4Yi90ZXh0cmVnaW9uOjBlZjYzY2NlM2YyOTRkZmM5YmUzOGFhZjBmYzJhNDhiXzMyMTg_1c53a8ed-a6e9-479b-a61d-3b91b1e95ba4">6.8</ix:nonFraction>&#160;million gain on disposal of discontinued operations for the year ended December 31, 2021.</span></div></ix:nonNumeric></ix:continuation><div style="text-align:justify"><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">117</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i7dfafb0674e74eaf9d0e1b161c54bc91">Asset information by segment is not a key measure of performance used by the CODM. Accordingly, we have not disclosed asset information by segment.</ix:continuation></span></div><div style="text-align:justify"><span><br/></span></div><div id="i9aaa2fddc97e482da5dbe37ac85ae703_124"></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 23. <ix:nonNumeric contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231" name="us-gaap:InsuranceDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMjQvZnJhZzo1NDg0NGVmM2I5YjQ0OTEwOTJiNDFhZjRkM2FjMzVkZi90ZXh0cmVnaW9uOjU0ODQ0ZWYzYjliNDQ5MTA5MmI0MWFmNGQzYWMzNWRmXzQ2MzY_d3ddf522-add5-45d3-a476-e73e4b53d6b7" continuedAt="iee4298b5fbe74c6cbae78e460fab89d0" escape="true">Reserve for Claims and Performance-Based Arrangements</ix:nonNumeric></span></div><div style="text-align:justify"><span><br/></span></div><ix:continuation id="iee4298b5fbe74c6cbae78e460fab89d0" continuedAt="i1c8d5cbf61e9441c98676cf13a6359b3"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company maintains reserves for its liabilities related to payments to providers and pharmacies under performance-based arrangements related to its total cost of care and specialty care management services. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Reserves for claims and performance-based arrangements for our EHS and Clinical Solutions segments reflect actual payments under performance-based arrangements and the ultimate cost of claims that have been incurred but not reported, including expected development on reported claims, those that have been reported but not yet paid (reported claims in process), and other medical care expenses and services payable that are primarily composed of accruals for incentives and other amounts payable to health care professionals and facilities. Reserves for claims and performance-based arrangements also reflect estimated amounts owed under the reinsurance agreements, as discussed further in Note 11.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company uses actuarial principles and assumptions that are consistently applied each reporting period and recognizes the actuarial best estimate of the ultimate liability along with a margin for adverse deviation. This approach is consistent with actuarial standards of practice that the liabilities be adequate under moderately adverse conditions.  </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This liability predominately consists of incurred but not reported amounts and reported claims in process including expected development on reported claims. The liability for reserves related to its total cost of care and specialty care management services is primarily calculated using "completion factors" developed by comparing the claim incurred date to the date claims were paid. Completion factors are impacted by several key items including changes in: 1)&#160;electronic (auto-adjudication) versus manual claim processing, 2)&#160;provider claims submission rates, 3)&#160;membership and 4)&#160;the mix of products.  </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s policy for reserves related to its total cost of care and specialty care management services is to use historical completion factors combined with an analysis of current trends and operational factors to develop current estimates of completion factors. The Company estimates the liability for claims incurred in each month by applying the current estimates of completion factors to the current paid claims data. This approach implicitly assumes that historical completion rates will be a useful indicator for the current period. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For more recent months, and for newer lines of business where there is not sufficient paid claims history to develop completion factors, the Company expects to rely more heavily on medical cost trend and expected loss ratio analysis that reflects expected claim payment patterns and other relevant operational considerations, or authorization analysis. Medical cost trend is primarily impacted by medical service utilization and unit costs that are affected by changes in the level and mix of medical benefits offered, including inpatient, outpatient and pharmacy, the impact of copays and deductibles, changes in provider practices and changes in consumer demographics and consumption behavior. Authorization analysis projects costs on an authorization-level basis and also accounts for the impact of copays and deductibles, unit cost and historic discontinuation rates for treatment. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For each reporting period, the Company compares key assumptions used to establish the reserves for claims and performance-based arrangements to actual experience. When actual experience differs from these assumptions, reserves for claims and performance-based arrangements are adjusted through current period net income. Additionally, the Company evaluates expected future developments and emerging trends that may impact key assumptions. The process used to determine this liability requires the Company to make critical accounting estimates that involve considerable judgment, reflecting the variability inherent in forecasting future claim payments. These estimates are highly sensitive to changes in the Company's key assumptions, specifically completion factors and medical cost trends.</span></div><div style="text-align:justify"><span><br/></span></div><ix:nonNumeric contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231" name="us-gaap:ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMjQvZnJhZzo1NDg0NGVmM2I5YjQ0OTEwOTJiNDFhZjRkM2FjMzVkZi90ZXh0cmVnaW9uOjU0ODQ0ZWYzYjliNDQ5MTA5MmI0MWFmNGQzYWMzNWRmXzQ2MzQ_3d6d15ff-5d13-4538-aa24-149d764eac7d" continuedAt="i68344ad2f4d2431ca9922898471d8e13" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Activity in reserves for claims and performance-based arrangements for the years ended December 31, 2021 and 2020, was as follows (in thousands):</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:539.25pt"><tr><td style="width:1.0pt"></td><td style="width:226.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:37.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:57.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:3.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:40.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:3.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:41.50pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:3.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:57.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:3.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:40.00pt"></td><td style="width:1.0pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="33" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Year Ended December 31,</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr style="height:23pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">EHS </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Clinical Solutions </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">EHS </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Clinical Solutions </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Beginning balance</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if8fd35766cfc4fa8b1cbf4f3cd8a8dfc_I20201231" decimals="-3" name="us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMjQvZnJhZzo1NDg0NGVmM2I5YjQ0OTEwOTJiNDFhZjRkM2FjMzVkZi90YWJsZTo4MzlkNzA4NWM1MWE0YmU4ODQ2OGRlMGU3Yjg5NGE5Yy90YWJsZXJhbmdlOjgzOWQ3MDg1YzUxYTRiZTg4NDY4ZGUwZTdiODk0YTljXzMtMS0xLTEtMTc3NzU_02244d04-10c1-4b9f-ba7e-caaaaa5d4505">56,296</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5f5145421bc94a90bb8982e11bb80abb_I20201231" decimals="-3" name="us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMjQvZnJhZzo1NDg0NGVmM2I5YjQ0OTEwOTJiNDFhZjRkM2FjMzVkZi90YWJsZTo4MzlkNzA4NWM1MWE0YmU4ODQ2OGRlMGU3Yjg5NGE5Yy90YWJsZXJhbmdlOjgzOWQ3MDg1YzUxYTRiZTg4NDY4ZGUwZTdiODk0YTljXzMtMy0xLTEtMTc3NzU_9760a924-ddbb-48aa-b2ed-1417482c28f5">122,531</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc0c0c2b8dc04c5698ca0577a54b2e03_I20201231" decimals="-3" name="us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMjQvZnJhZzo1NDg0NGVmM2I5YjQ0OTEwOTJiNDFhZjRkM2FjMzVkZi90YWJsZTo4MzlkNzA4NWM1MWE0YmU4ODQ2OGRlMGU3Yjg5NGE5Yy90YWJsZXJhbmdlOjgzOWQ3MDg1YzUxYTRiZTg4NDY4ZGUwZTdiODk0YTljXzMtNy0xLTEtMTc3NzU_a42680b7-743f-4f72-9f30-5dd050011917">178,827</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ida02b25c4b5e464a9545df19946134c1_I20191231" decimals="-3" name="us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMjQvZnJhZzo1NDg0NGVmM2I5YjQ0OTEwOTJiNDFhZjRkM2FjMzVkZi90YWJsZTo4MzlkNzA4NWM1MWE0YmU4ODQ2OGRlMGU3Yjg5NGE5Yy90YWJsZXJhbmdlOjgzOWQ3MDg1YzUxYTRiZTg4NDY4ZGUwZTdiODk0YTljXzMtOS0xLTEtMTc3NzU_d56328da-e3e6-4d1f-b857-d5ebb19b613c">4,265</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i14e6a440f7dc431a9e1c85272b43d276_I20191231" decimals="-3" name="us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMjQvZnJhZzo1NDg0NGVmM2I5YjQ0OTEwOTJiNDFhZjRkM2FjMzVkZi90YWJsZTo4MzlkNzA4NWM1MWE0YmU4ODQ2OGRlMGU3Yjg5NGE5Yy90YWJsZXJhbmdlOjgzOWQ3MDg1YzUxYTRiZTg4NDY4ZGUwZTdiODk0YTljXzMtMTEtMS0xLTE3Nzc1_ece0192d-3c9b-4e84-a8bf-bf990af89e6b">50,245</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icba6e493923b449aa57c46a563760234_I20191231" decimals="-3" name="us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMjQvZnJhZzo1NDg0NGVmM2I5YjQ0OTEwOTJiNDFhZjRkM2FjMzVkZi90YWJsZTo4MzlkNzA4NWM1MWE0YmU4ODQ2OGRlMGU3Yjg5NGE5Yy90YWJsZXJhbmdlOjgzOWQ3MDg1YzUxYTRiZTg4NDY4ZGUwZTdiODk0YTljXzMtMTUtMS0xLTE3Nzc1_3274df9b-8411-4d13-9b90-a361e8c7fcb6">54,510</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Incurred costs related to current year</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i98988f30813349e1a5594e72b40af5b1_D20210101-20211231" decimals="-3" name="evh:CurrentYearClaimsAndClaimsAdjustmentExpenseIncludingCostOfGoodsAndServicesSoldExcludingDepreciationAndAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMjQvZnJhZzo1NDg0NGVmM2I5YjQ0OTEwOTJiNDFhZjRkM2FjMzVkZi90YWJsZTo4MzlkNzA4NWM1MWE0YmU4ODQ2OGRlMGU3Yjg5NGE5Yy90YWJsZXJhbmdlOjgzOWQ3MDg1YzUxYTRiZTg4NDY4ZGUwZTdiODk0YTljXzUtMS0xLTEtMTc3NzU_aa461668-8595-479c-8e16-d6dc2cfe6fe8">8,669</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6d991ef4e2e0416f8c7aaaa6175cf843_D20210101-20211231" decimals="-3" name="evh:CurrentYearClaimsAndClaimsAdjustmentExpenseIncludingCostOfGoodsAndServicesSoldExcludingDepreciationAndAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMjQvZnJhZzo1NDg0NGVmM2I5YjQ0OTEwOTJiNDFhZjRkM2FjMzVkZi90YWJsZTo4MzlkNzA4NWM1MWE0YmU4ODQ2OGRlMGU3Yjg5NGE5Yy90YWJsZXJhbmdlOjgzOWQ3MDg1YzUxYTRiZTg4NDY4ZGUwZTdiODk0YTljXzUtMy0xLTEtMTc3NzU_9fff9913-aa78-4f5e-b5b9-31e1d7b0615c">449,172</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231" decimals="-3" name="evh:CurrentYearClaimsAndClaimsAdjustmentExpenseIncludingCostOfGoodsAndServicesSoldExcludingDepreciationAndAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMjQvZnJhZzo1NDg0NGVmM2I5YjQ0OTEwOTJiNDFhZjRkM2FjMzVkZi90YWJsZTo4MzlkNzA4NWM1MWE0YmU4ODQ2OGRlMGU3Yjg5NGE5Yy90YWJsZXJhbmdlOjgzOWQ3MDg1YzUxYTRiZTg4NDY4ZGUwZTdiODk0YTljXzUtNy0xLTEtMTc3NzU_6ac78dcf-0057-4d00-966a-f5e39136843c">457,841</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i00a9fb2f3f914116b87f14e146d04507_D20200101-20201231" decimals="-3" sign="-" name="evh:CurrentYearClaimsAndClaimsAdjustmentExpenseIncludingCostOfGoodsAndServicesSoldExcludingDepreciationAndAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMjQvZnJhZzo1NDg0NGVmM2I5YjQ0OTEwOTJiNDFhZjRkM2FjMzVkZi90YWJsZTo4MzlkNzA4NWM1MWE0YmU4ODQ2OGRlMGU3Yjg5NGE5Yy90YWJsZXJhbmdlOjgzOWQ3MDg1YzUxYTRiZTg4NDY4ZGUwZTdiODk0YTljXzUtOS0xLTEtMTc3NzU_ce89ffa7-4a1f-491a-8840-c1807bc02053">7,542</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i73877656554945338d08c1e8006fc13a_D20200101-20201231" decimals="-3" name="evh:CurrentYearClaimsAndClaimsAdjustmentExpenseIncludingCostOfGoodsAndServicesSoldExcludingDepreciationAndAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMjQvZnJhZzo1NDg0NGVmM2I5YjQ0OTEwOTJiNDFhZjRkM2FjMzVkZi90YWJsZTo4MzlkNzA4NWM1MWE0YmU4ODQ2OGRlMGU3Yjg5NGE5Yy90YWJsZXJhbmdlOjgzOWQ3MDg1YzUxYTRiZTg4NDY4ZGUwZTdiODk0YTljXzUtMTEtMS0xLTE3Nzc1_68486eaf-20a0-4cfa-ae23-1cfff26a33fb">428,139</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i12a6d1161de54547bd29f8efccd4c9b0_D20200101-20201231" decimals="-3" name="evh:CurrentYearClaimsAndClaimsAdjustmentExpenseIncludingCostOfGoodsAndServicesSoldExcludingDepreciationAndAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMjQvZnJhZzo1NDg0NGVmM2I5YjQ0OTEwOTJiNDFhZjRkM2FjMzVkZi90YWJsZTo4MzlkNzA4NWM1MWE0YmU4ODQ2OGRlMGU3Yjg5NGE5Yy90YWJsZXJhbmdlOjgzOWQ3MDg1YzUxYTRiZTg4NDY4ZGUwZTdiODk0YTljXzUtMTUtMS0xLTE3Nzc1_d83f887d-416b-4110-bd89-3855ff44dbc5">420,597</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Incurred costs related to prior year</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i98988f30813349e1a5594e72b40af5b1_D20210101-20211231" decimals="-3" name="us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMjQvZnJhZzo1NDg0NGVmM2I5YjQ0OTEwOTJiNDFhZjRkM2FjMzVkZi90YWJsZTo4MzlkNzA4NWM1MWE0YmU4ODQ2OGRlMGU3Yjg5NGE5Yy90YWJsZXJhbmdlOjgzOWQ3MDg1YzUxYTRiZTg4NDY4ZGUwZTdiODk0YTljXzYtMS0xLTEtMTc3NzU_2ae9a346-4f2f-4362-906f-47f68f041b2b">7,036</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6d991ef4e2e0416f8c7aaaa6175cf843_D20210101-20211231" decimals="-3" name="us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMjQvZnJhZzo1NDg0NGVmM2I5YjQ0OTEwOTJiNDFhZjRkM2FjMzVkZi90YWJsZTo4MzlkNzA4NWM1MWE0YmU4ODQ2OGRlMGU3Yjg5NGE5Yy90YWJsZXJhbmdlOjgzOWQ3MDg1YzUxYTRiZTg4NDY4ZGUwZTdiODk0YTljXzYtMy0xLTEtMTc3NzU_3bae2aa3-d8c0-489d-967f-b61a2370bd97">73</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231" decimals="-3" name="us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMjQvZnJhZzo1NDg0NGVmM2I5YjQ0OTEwOTJiNDFhZjRkM2FjMzVkZi90YWJsZTo4MzlkNzA4NWM1MWE0YmU4ODQ2OGRlMGU3Yjg5NGE5Yy90YWJsZXJhbmdlOjgzOWQ3MDg1YzUxYTRiZTg4NDY4ZGUwZTdiODk0YTljXzYtNy0xLTEtMTc3NzU_cc4d6a76-795f-4ba4-b77a-f2ad26694325">7,109</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i00a9fb2f3f914116b87f14e146d04507_D20200101-20201231" decimals="-3" name="us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMjQvZnJhZzo1NDg0NGVmM2I5YjQ0OTEwOTJiNDFhZjRkM2FjMzVkZi90YWJsZTo4MzlkNzA4NWM1MWE0YmU4ODQ2OGRlMGU3Yjg5NGE5Yy90YWJsZXJhbmdlOjgzOWQ3MDg1YzUxYTRiZTg4NDY4ZGUwZTdiODk0YTljXzYtOS0xLTEtMTc3NzU_fb6e234e-f44a-4f42-bad8-671c57fa6ba8">2,853</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i73877656554945338d08c1e8006fc13a_D20200101-20201231" decimals="-3" name="us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMjQvZnJhZzo1NDg0NGVmM2I5YjQ0OTEwOTJiNDFhZjRkM2FjMzVkZi90YWJsZTo4MzlkNzA4NWM1MWE0YmU4ODQ2OGRlMGU3Yjg5NGE5Yy90YWJsZXJhbmdlOjgzOWQ3MDg1YzUxYTRiZTg4NDY4ZGUwZTdiODk0YTljXzYtMTEtMS0xLTE3Nzc1_30daf74a-5038-4844-a89a-59941485a9dc">25</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i12a6d1161de54547bd29f8efccd4c9b0_D20200101-20201231" decimals="-3" name="us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMjQvZnJhZzo1NDg0NGVmM2I5YjQ0OTEwOTJiNDFhZjRkM2FjMzVkZi90YWJsZTo4MzlkNzA4NWM1MWE0YmU4ODQ2OGRlMGU3Yjg5NGE5Yy90YWJsZXJhbmdlOjgzOWQ3MDg1YzUxYTRiZTg4NDY4ZGUwZTdiODk0YTljXzYtMTUtMS0xLTE3Nzc1_39213925-a920-4153-aee7-605d6d07a229">2,878</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Paid costs related to current year</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i98988f30813349e1a5594e72b40af5b1_D20210101-20211231" decimals="-3" name="us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMjQvZnJhZzo1NDg0NGVmM2I5YjQ0OTEwOTJiNDFhZjRkM2FjMzVkZi90YWJsZTo4MzlkNzA4NWM1MWE0YmU4ODQ2OGRlMGU3Yjg5NGE5Yy90YWJsZXJhbmdlOjgzOWQ3MDg1YzUxYTRiZTg4NDY4ZGUwZTdiODk0YTljXzctMS0xLTEtMTc3NzU_168b9699-9cbb-4d15-b183-323c96789fe8">20,801</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6d991ef4e2e0416f8c7aaaa6175cf843_D20210101-20211231" decimals="-3" name="us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMjQvZnJhZzo1NDg0NGVmM2I5YjQ0OTEwOTJiNDFhZjRkM2FjMzVkZi90YWJsZTo4MzlkNzA4NWM1MWE0YmU4ODQ2OGRlMGU3Yjg5NGE5Yy90YWJsZXJhbmdlOjgzOWQ3MDg1YzUxYTRiZTg4NDY4ZGUwZTdiODk0YTljXzctMy0xLTEtMTc3NzU_1f1a21d0-8e9b-43f8-81e3-6e514518ce60">337,647</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231" decimals="-3" name="us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMjQvZnJhZzo1NDg0NGVmM2I5YjQ0OTEwOTJiNDFhZjRkM2FjMzVkZi90YWJsZTo4MzlkNzA4NWM1MWE0YmU4ODQ2OGRlMGU3Yjg5NGE5Yy90YWJsZXJhbmdlOjgzOWQ3MDg1YzUxYTRiZTg4NDY4ZGUwZTdiODk0YTljXzctNy0xLTEtMTc3NzU_b64a4fad-b24b-45a7-97e5-0def79751953">358,448</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i00a9fb2f3f914116b87f14e146d04507_D20200101-20201231" decimals="-3" name="us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMjQvZnJhZzo1NDg0NGVmM2I5YjQ0OTEwOTJiNDFhZjRkM2FjMzVkZi90YWJsZTo4MzlkNzA4NWM1MWE0YmU4ODQ2OGRlMGU3Yjg5NGE5Yy90YWJsZXJhbmdlOjgzOWQ3MDg1YzUxYTRiZTg4NDY4ZGUwZTdiODk0YTljXzctOS0xLTEtMTc3NzU_d34b187b-c306-45de-8e4a-4d6f66d1fe4d">106,093</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i73877656554945338d08c1e8006fc13a_D20200101-20201231" decimals="-3" name="us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMjQvZnJhZzo1NDg0NGVmM2I5YjQ0OTEwOTJiNDFhZjRkM2FjMzVkZi90YWJsZTo4MzlkNzA4NWM1MWE0YmU4ODQ2OGRlMGU3Yjg5NGE5Yy90YWJsZXJhbmdlOjgzOWQ3MDg1YzUxYTRiZTg4NDY4ZGUwZTdiODk0YTljXzctMTEtMS0xLTE3Nzc1_4ed38248-806d-4fb8-9785-bdf9f44f3d4d">358,478</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i12a6d1161de54547bd29f8efccd4c9b0_D20200101-20201231" decimals="-3" name="us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMjQvZnJhZzo1NDg0NGVmM2I5YjQ0OTEwOTJiNDFhZjRkM2FjMzVkZi90YWJsZTo4MzlkNzA4NWM1MWE0YmU4ODQ2OGRlMGU3Yjg5NGE5Yy90YWJsZXJhbmdlOjgzOWQ3MDg1YzUxYTRiZTg4NDY4ZGUwZTdiODk0YTljXzctMTUtMS0xLTE3Nzc1_7fa1b0ca-a6c4-4149-9942-2ef463eebf48">464,571</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">118</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i1c8d5cbf61e9441c98676cf13a6359b3"><ix:continuation id="i68344ad2f4d2431ca9922898471d8e13"><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:539.25pt"><tr><td style="width:1.0pt"></td><td style="width:226.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:37.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:57.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:3.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:40.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:3.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:41.50pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:3.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:57.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:3.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:40.00pt"></td><td style="width:1.0pt"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Paid costs related to prior year</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i98988f30813349e1a5594e72b40af5b1_D20210101-20211231" decimals="-3" name="us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMjQvZnJhZzo1NDg0NGVmM2I5YjQ0OTEwOTJiNDFhZjRkM2FjMzVkZi90YWJsZTo4MzlkNzA4NWM1MWE0YmU4ODQ2OGRlMGU3Yjg5NGE5Yy90YWJsZXJhbmdlOjgzOWQ3MDg1YzUxYTRiZTg4NDY4ZGUwZTdiODk0YTljXzgtMS0xLTEtMTc3NzU_ccf2f81f-1439-4fd9-b8cb-a66f0bf8aee2">25,544</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6d991ef4e2e0416f8c7aaaa6175cf843_D20210101-20211231" decimals="-3" name="us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMjQvZnJhZzo1NDg0NGVmM2I5YjQ0OTEwOTJiNDFhZjRkM2FjMzVkZi90YWJsZTo4MzlkNzA4NWM1MWE0YmU4ODQ2OGRlMGU3Yjg5NGE5Yy90YWJsZXJhbmdlOjgzOWQ3MDg1YzUxYTRiZTg4NDY4ZGUwZTdiODk0YTljXzgtMy0xLTEtMTc3NzU_5a9a905c-bdc2-4567-8fc7-1f08a72dfd08">100,075</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231" decimals="-3" name="us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMjQvZnJhZzo1NDg0NGVmM2I5YjQ0OTEwOTJiNDFhZjRkM2FjMzVkZi90YWJsZTo4MzlkNzA4NWM1MWE0YmU4ODQ2OGRlMGU3Yjg5NGE5Yy90YWJsZXJhbmdlOjgzOWQ3MDg1YzUxYTRiZTg4NDY4ZGUwZTdiODk0YTljXzgtNy0xLTEtMTc3NzU_34c52f48-c01a-49c2-9c7e-3b0b0980496c">125,619</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i00a9fb2f3f914116b87f14e146d04507_D20200101-20201231" decimals="-3" name="us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMjQvZnJhZzo1NDg0NGVmM2I5YjQ0OTEwOTJiNDFhZjRkM2FjMzVkZi90YWJsZTo4MzlkNzA4NWM1MWE0YmU4ODQ2OGRlMGU3Yjg5NGE5Yy90YWJsZXJhbmdlOjgzOWQ3MDg1YzUxYTRiZTg4NDY4ZGUwZTdiODk0YTljXzgtOS0xLTEtMTc3NzU_41c3f3e9-666b-4bdd-981b-f484fd57d6e7">2,123</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i73877656554945338d08c1e8006fc13a_D20200101-20201231" decimals="-3" name="us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMjQvZnJhZzo1NDg0NGVmM2I5YjQ0OTEwOTJiNDFhZjRkM2FjMzVkZi90YWJsZTo4MzlkNzA4NWM1MWE0YmU4ODQ2OGRlMGU3Yjg5NGE5Yy90YWJsZXJhbmdlOjgzOWQ3MDg1YzUxYTRiZTg4NDY4ZGUwZTdiODk0YTljXzgtMTEtMS0xLTE3Nzc1_34d6ae07-45d9-4198-8424-366de5024499">7,475</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i12a6d1161de54547bd29f8efccd4c9b0_D20200101-20201231" decimals="-3" name="us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMjQvZnJhZzo1NDg0NGVmM2I5YjQ0OTEwOTJiNDFhZjRkM2FjMzVkZi90YWJsZTo4MzlkNzA4NWM1MWE0YmU4ODQ2OGRlMGU3Yjg5NGE5Yy90YWJsZXJhbmdlOjgzOWQ3MDg1YzUxYTRiZTg4NDY4ZGUwZTdiODk0YTljXzgtMTUtMS0xLTE3Nzc1_800e9708-53f2-40a4-84c4-b4214a4ce14c">9,598</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change during the year</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i98988f30813349e1a5594e72b40af5b1_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpensePeriodIncreaseDecrease" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMjQvZnJhZzo1NDg0NGVmM2I5YjQ0OTEwOTJiNDFhZjRkM2FjMzVkZi90YWJsZTo4MzlkNzA4NWM1MWE0YmU4ODQ2OGRlMGU3Yjg5NGE5Yy90YWJsZXJhbmdlOjgzOWQ3MDg1YzUxYTRiZTg4NDY4ZGUwZTdiODk0YTljXzktMS0xLTEtMTc3NzU_8da3b7f1-5655-4709-8968-530513b0ad3c">30,640</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6d991ef4e2e0416f8c7aaaa6175cf843_D20210101-20211231" decimals="-3" name="us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpensePeriodIncreaseDecrease" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMjQvZnJhZzo1NDg0NGVmM2I5YjQ0OTEwOTJiNDFhZjRkM2FjMzVkZi90YWJsZTo4MzlkNzA4NWM1MWE0YmU4ODQ2OGRlMGU3Yjg5NGE5Yy90YWJsZXJhbmdlOjgzOWQ3MDg1YzUxYTRiZTg4NDY4ZGUwZTdiODk0YTljXzktMy0xLTEtMTc3NzU_6b842c48-8afc-4153-b69b-4fded3ced2ae">11,523</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpensePeriodIncreaseDecrease" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMjQvZnJhZzo1NDg0NGVmM2I5YjQ0OTEwOTJiNDFhZjRkM2FjMzVkZi90YWJsZTo4MzlkNzA4NWM1MWE0YmU4ODQ2OGRlMGU3Yjg5NGE5Yy90YWJsZXJhbmdlOjgzOWQ3MDg1YzUxYTRiZTg4NDY4ZGUwZTdiODk0YTljXzktNy0xLTEtMTc3NzU_ff47e257-9b71-4492-8514-53807e2433b5">19,117</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i00a9fb2f3f914116b87f14e146d04507_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpensePeriodIncreaseDecrease" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMjQvZnJhZzo1NDg0NGVmM2I5YjQ0OTEwOTJiNDFhZjRkM2FjMzVkZi90YWJsZTo4MzlkNzA4NWM1MWE0YmU4ODQ2OGRlMGU3Yjg5NGE5Yy90YWJsZXJhbmdlOjgzOWQ3MDg1YzUxYTRiZTg4NDY4ZGUwZTdiODk0YTljXzktOS0xLTEtMTc3NzU_45ede09e-44d1-41e2-833b-d5e481bdad44">112,905</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i73877656554945338d08c1e8006fc13a_D20200101-20201231" decimals="-3" name="us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpensePeriodIncreaseDecrease" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMjQvZnJhZzo1NDg0NGVmM2I5YjQ0OTEwOTJiNDFhZjRkM2FjMzVkZi90YWJsZTo4MzlkNzA4NWM1MWE0YmU4ODQ2OGRlMGU3Yjg5NGE5Yy90YWJsZXJhbmdlOjgzOWQ3MDg1YzUxYTRiZTg4NDY4ZGUwZTdiODk0YTljXzktMTEtMS0xLTE3Nzc1_53b43c23-075c-4ce5-a695-bb144f0b1d7c">62,211</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i12a6d1161de54547bd29f8efccd4c9b0_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpensePeriodIncreaseDecrease" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMjQvZnJhZzo1NDg0NGVmM2I5YjQ0OTEwOTJiNDFhZjRkM2FjMzVkZi90YWJsZTo4MzlkNzA4NWM1MWE0YmU4ODQ2OGRlMGU3Yjg5NGE5Yy90YWJsZXJhbmdlOjgzOWQ3MDg1YzUxYTRiZTg4NDY4ZGUwZTdiODk0YTljXzktMTUtMS0xLTE3Nzc1_6d3fa29d-3d59-4716-8466-f053d4ec8d43">50,694</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr style="height:23pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Impact of consolidation on reserves for claims and performance-based arrangements</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i98988f30813349e1a5594e72b40af5b1_D20210101-20211231" decimals="-3" name="us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseBusinessAcquisitions" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMjQvZnJhZzo1NDg0NGVmM2I5YjQ0OTEwOTJiNDFhZjRkM2FjMzVkZi90YWJsZTo4MzlkNzA4NWM1MWE0YmU4ODQ2OGRlMGU3Yjg5NGE5Yy90YWJsZXJhbmdlOjgzOWQ3MDg1YzUxYTRiZTg4NDY4ZGUwZTdiODk0YTljXzExLTEtMS0xLTE3Nzc1_829378bd-7983-4c16-8cfc-424a1fb0a107">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6d991ef4e2e0416f8c7aaaa6175cf843_D20210101-20211231" decimals="-3" name="us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseBusinessAcquisitions" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMjQvZnJhZzo1NDg0NGVmM2I5YjQ0OTEwOTJiNDFhZjRkM2FjMzVkZi90YWJsZTo4MzlkNzA4NWM1MWE0YmU4ODQ2OGRlMGU3Yjg5NGE5Yy90YWJsZXJhbmdlOjgzOWQ3MDg1YzUxYTRiZTg4NDY4ZGUwZTdiODk0YTljXzExLTMtMS0xLTE3Nzc1_45f6128d-a6d9-4fbe-ad48-9e52526bdf79">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231" decimals="-3" name="us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseBusinessAcquisitions" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMjQvZnJhZzo1NDg0NGVmM2I5YjQ0OTEwOTJiNDFhZjRkM2FjMzVkZi90YWJsZTo4MzlkNzA4NWM1MWE0YmU4ODQ2OGRlMGU3Yjg5NGE5Yy90YWJsZXJhbmdlOjgzOWQ3MDg1YzUxYTRiZTg4NDY4ZGUwZTdiODk0YTljXzExLTctMS0xLTE3Nzc1_c74e7b5e-bdea-4a48-a20a-4886360eab0c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i00a9fb2f3f914116b87f14e146d04507_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseBusinessAcquisitions" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMjQvZnJhZzo1NDg0NGVmM2I5YjQ0OTEwOTJiNDFhZjRkM2FjMzVkZi90YWJsZTo4MzlkNzA4NWM1MWE0YmU4ODQ2OGRlMGU3Yjg5NGE5Yy90YWJsZXJhbmdlOjgzOWQ3MDg1YzUxYTRiZTg4NDY4ZGUwZTdiODk0YTljXzExLTktMS0xLTE3Nzc1_11ab971a-5966-4228-a4f6-af7936a63863">164,297</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i73877656554945338d08c1e8006fc13a_D20200101-20201231" decimals="-3" name="us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseBusinessAcquisitions" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMjQvZnJhZzo1NDg0NGVmM2I5YjQ0OTEwOTJiNDFhZjRkM2FjMzVkZi90YWJsZTo4MzlkNzA4NWM1MWE0YmU4ODQ2OGRlMGU3Yjg5NGE5Yy90YWJsZXJhbmdlOjgzOWQ3MDg1YzUxYTRiZTg4NDY4ZGUwZTdiODk0YTljXzExLTExLTEtMS0xNzc3NQ_79af128a-1ef0-431e-bac1-6a6d0b407853">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i12a6d1161de54547bd29f8efccd4c9b0_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseBusinessAcquisitions" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMjQvZnJhZzo1NDg0NGVmM2I5YjQ0OTEwOTJiNDFhZjRkM2FjMzVkZi90YWJsZTo4MzlkNzA4NWM1MWE0YmU4ODQ2OGRlMGU3Yjg5NGE5Yy90YWJsZXJhbmdlOjgzOWQ3MDg1YzUxYTRiZTg4NDY4ZGUwZTdiODk0YTljXzExLTE1LTEtMS0xNzc3NQ_a3806b1f-6a3d-4602-b87a-773d59fcd01a">164,297</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other adjustments </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icdbca3fab4684e269937d4a61379d67f_I20211231" decimals="-3" name="us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseOpeningBalanceAdjustments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMjQvZnJhZzo1NDg0NGVmM2I5YjQ0OTEwOTJiNDFhZjRkM2FjMzVkZi90YWJsZTo4MzlkNzA4NWM1MWE0YmU4ODQ2OGRlMGU3Yjg5NGE5Yy90YWJsZXJhbmdlOjgzOWQ3MDg1YzUxYTRiZTg4NDY4ZGUwZTdiODk0YTljXzEzLTEtMS0xLTE3Nzc1_826b80ab-ac03-4ef7-b426-57ed5b3d5dbb">38</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie09b385083554dfe92dc601254dfdda8_I20211231" decimals="-3" sign="-" name="us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseOpeningBalanceAdjustments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMjQvZnJhZzo1NDg0NGVmM2I5YjQ0OTEwOTJiNDFhZjRkM2FjMzVkZi90YWJsZTo4MzlkNzA4NWM1MWE0YmU4ODQ2OGRlMGU3Yjg5NGE5Yy90YWJsZXJhbmdlOjgzOWQ3MDg1YzUxYTRiZTg4NDY4ZGUwZTdiODk0YTljXzEzLTMtMS0xLTE3Nzc1_89dea484-af00-4df3-aae1-20e84e998148">11,622</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8daff60be410426d8f7bd49343c1ec0c_I20211231" decimals="-3" sign="-" name="us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseOpeningBalanceAdjustments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMjQvZnJhZzo1NDg0NGVmM2I5YjQ0OTEwOTJiNDFhZjRkM2FjMzVkZi90YWJsZTo4MzlkNzA4NWM1MWE0YmU4ODQ2OGRlMGU3Yjg5NGE5Yy90YWJsZXJhbmdlOjgzOWQ3MDg1YzUxYTRiZTg4NDY4ZGUwZTdiODk0YTljXzEzLTctMS0xLTE3Nzc1_29cdaf18-eefc-4cc2-8a1b-5455021d991d">11,584</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if8fd35766cfc4fa8b1cbf4f3cd8a8dfc_I20201231" decimals="-3" sign="-" name="us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseOpeningBalanceAdjustments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMjQvZnJhZzo1NDg0NGVmM2I5YjQ0OTEwOTJiNDFhZjRkM2FjMzVkZi90YWJsZTo4MzlkNzA4NWM1MWE0YmU4ODQ2OGRlMGU3Yjg5NGE5Yy90YWJsZXJhbmdlOjgzOWQ3MDg1YzUxYTRiZTg4NDY4ZGUwZTdiODk0YTljXzEzLTktMS0xLTE3Nzc1_0672e77f-987d-4980-90b2-c8da8d2f6668">639</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5f5145421bc94a90bb8982e11bb80abb_I20201231" decimals="-3" sign="-" name="us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseOpeningBalanceAdjustments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMjQvZnJhZzo1NDg0NGVmM2I5YjQ0OTEwOTJiNDFhZjRkM2FjMzVkZi90YWJsZTo4MzlkNzA4NWM1MWE0YmU4ODQ2OGRlMGU3Yjg5NGE5Yy90YWJsZXJhbmdlOjgzOWQ3MDg1YzUxYTRiZTg4NDY4ZGUwZTdiODk0YTljXzEzLTExLTEtMS0xNzc3NQ_159738a6-7886-4527-b4ea-149c20254546">10,075</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc0c0c2b8dc04c5698ca0577a54b2e03_I20201231" decimals="-3" sign="-" name="us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseOpeningBalanceAdjustments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMjQvZnJhZzo1NDg0NGVmM2I5YjQ0OTEwOTJiNDFhZjRkM2FjMzVkZi90YWJsZTo4MzlkNzA4NWM1MWE0YmU4ODQ2OGRlMGU3Yjg5NGE5Yy90YWJsZXJhbmdlOjgzOWQ3MDg1YzUxYTRiZTg4NDY4ZGUwZTdiODk0YTljXzEzLTE1LTEtMS0xNzc3NQ_3e00d6bd-8c44-434a-b32f-d1a8076da589">10,714</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ending balance</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icdbca3fab4684e269937d4a61379d67f_I20211231" decimals="-3" name="us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMjQvZnJhZzo1NDg0NGVmM2I5YjQ0OTEwOTJiNDFhZjRkM2FjMzVkZi90YWJsZTo4MzlkNzA4NWM1MWE0YmU4ODQ2OGRlMGU3Yjg5NGE5Yy90YWJsZXJhbmdlOjgzOWQ3MDg1YzUxYTRiZTg4NDY4ZGUwZTdiODk0YTljXzE0LTEtMS0xLTE3Nzc1_91004518-9732-4de7-bec8-90cd98b206db">25,618</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie09b385083554dfe92dc601254dfdda8_I20211231" decimals="-3" name="us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMjQvZnJhZzo1NDg0NGVmM2I5YjQ0OTEwOTJiNDFhZjRkM2FjMzVkZi90YWJsZTo4MzlkNzA4NWM1MWE0YmU4ODQ2OGRlMGU3Yjg5NGE5Yy90YWJsZXJhbmdlOjgzOWQ3MDg1YzUxYTRiZTg4NDY4ZGUwZTdiODk0YTljXzE0LTMtMS0xLTE3Nzc1_3e8f0f1d-5538-454b-ad3c-f8f394e52f27">145,676</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8daff60be410426d8f7bd49343c1ec0c_I20211231" decimals="-3" name="us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMjQvZnJhZzo1NDg0NGVmM2I5YjQ0OTEwOTJiNDFhZjRkM2FjMzVkZi90YWJsZTo4MzlkNzA4NWM1MWE0YmU4ODQ2OGRlMGU3Yjg5NGE5Yy90YWJsZXJhbmdlOjgzOWQ3MDg1YzUxYTRiZTg4NDY4ZGUwZTdiODk0YTljXzE0LTctMS0xLTE3Nzc1_86507022-a436-41b3-8215-7dfae2b6d585">171,294</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if8fd35766cfc4fa8b1cbf4f3cd8a8dfc_I20201231" decimals="-3" name="us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMjQvZnJhZzo1NDg0NGVmM2I5YjQ0OTEwOTJiNDFhZjRkM2FjMzVkZi90YWJsZTo4MzlkNzA4NWM1MWE0YmU4ODQ2OGRlMGU3Yjg5NGE5Yy90YWJsZXJhbmdlOjgzOWQ3MDg1YzUxYTRiZTg4NDY4ZGUwZTdiODk0YTljXzE0LTktMS0xLTE3Nzc1_33f2481e-8bfa-4ed3-a445-11072882c395">56,296</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5f5145421bc94a90bb8982e11bb80abb_I20201231" decimals="-3" name="us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMjQvZnJhZzo1NDg0NGVmM2I5YjQ0OTEwOTJiNDFhZjRkM2FjMzVkZi90YWJsZTo4MzlkNzA4NWM1MWE0YmU4ODQ2OGRlMGU3Yjg5NGE5Yy90YWJsZXJhbmdlOjgzOWQ3MDg1YzUxYTRiZTg4NDY4ZGUwZTdiODk0YTljXzE0LTExLTEtMS0xNzc3NQ_170ee388-a440-42ff-a4dc-10dc780db198">122,531</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc0c0c2b8dc04c5698ca0577a54b2e03_I20201231" decimals="-3" name="us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMjQvZnJhZzo1NDg0NGVmM2I5YjQ0OTEwOTJiNDFhZjRkM2FjMzVkZi90YWJsZTo4MzlkNzA4NWM1MWE0YmU4ODQ2OGRlMGU3Yjg5NGE5Yy90YWJsZXJhbmdlOjgzOWQ3MDg1YzUxYTRiZTg4NDY4ZGUwZTdiODk0YTljXzE0LTE1LTEtMS0xNzc3NQ_3f2ef4ac-2424-4b46-a0df-56fabeb7037a">178,827</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:13.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;</span></div><div style="padding-left:31.5pt;text-align:justify;text-indent:-31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:25.44pt">Costs incurred to provide specialty care management and EVH Passport are recorded within cost of revenue in our statement of operations. </span></div><div style="padding-left:31.5pt;text-align:justify;text-indent:-31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:25.44pt">Amounts exclude $<ix:nonFraction unitRef="usd" contextRef="i98364cf4ba3e41af868d701b4c668283_I20201231" decimals="-5" name="us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMjQvZnJhZzo1NDg0NGVmM2I5YjQ0OTEwOTJiNDFhZjRkM2FjMzVkZi90ZXh0cmVnaW9uOjU0ODQ0ZWYzYjliNDQ5MTA5MmI0MWFmNGQzYWMzNWRmXzEwOTk1MTE2MzI2OTc_7996d21f-9701-4a74-8e7b-93fa5d6e9f35">9.9</ix:nonFraction>&#160;million related to reserves for claims reclassified to discontinued operations as of December&#160;31, 2020.</span></div><div style="padding-left:31.5pt;text-align:justify;text-indent:-31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:25.44pt">Other adjustments to reserves for claims and performance-based arrangements reflect changes in accrual for amounts payable to facilities and amounts owed to our payer partners for claims paid on our behalf.</span></div></ix:continuation></ix:continuation><div style="text-align:justify"><span><br/></span></div><div id="i9aaa2fddc97e482da5dbe37ac85ae703_130"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 24. <ix:nonNumeric contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231" name="us-gaap:QuarterlyFinancialInformationTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMzAvZnJhZzo3NGIwMjA4NWYwNjY0MjYyOGY3OWUzMTNlNjFkZmI3Yy90ZXh0cmVnaW9uOjc0YjAyMDg1ZjA2NjQyNjI4Zjc5ZTMxM2U2MWRmYjdjXzI3Ng_48682086-e682-468e-b97e-5a17728db83a" continuedAt="i99a8acc99e2c46dda0ce2b47dcbcb8b6" escape="true">Quarterly Results of Operations (unaudited)</ix:nonNumeric></span></div><div><span><br/></span></div><ix:continuation id="i99a8acc99e2c46dda0ce2b47dcbcb8b6"><ix:nonNumeric contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231" name="us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMzAvZnJhZzo3NGIwMjA4NWYwNjY0MjYyOGY3OWUzMTNlNjFkZmI3Yy90ZXh0cmVnaW9uOjc0YjAyMDg1ZjA2NjQyNjI4Zjc5ZTMxM2U2MWRmYjdjXzI3Nw_092b2982-a477-44c0-8ec5-3540c0f90376" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The unaudited consolidated quarterly results of operations (in thousands, except per share data) were as follows:</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:53.344%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.094%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.983%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.205%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.209%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="21" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Three Months Ended</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">June 30</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenue</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i546c40c371924532a3d2ed0ace7d354b_D20211001-20211231" decimals="-3" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMzAvZnJhZzo3NGIwMjA4NWYwNjY0MjYyOGY3OWUzMTNlNjFkZmI3Yy90YWJsZTpmYTRmNTRhZWVjNTg0NDBiYmYyYTcwYWUxMDNkNDVlNy90YWJsZXJhbmdlOmZhNGY1NGFlZWM1ODQ0MGJiZjJhNzBhZTEwM2Q0NWU3XzMtMS0xLTEtMTc3NzU_e59df483-a056-4e0f-b2c5-07c3743b7637">248,358</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i973a81e9b0924e4e86048dc6df6379d0_D20210701-20210930" decimals="-3" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMzAvZnJhZzo3NGIwMjA4NWYwNjY0MjYyOGY3OWUzMTNlNjFkZmI3Yy90YWJsZTpmYTRmNTRhZWVjNTg0NDBiYmYyYTcwYWUxMDNkNDVlNy90YWJsZXJhbmdlOmZhNGY1NGFlZWM1ODQ0MGJiZjJhNzBhZTEwM2Q0NWU3XzMtMy0xLTEtMTc3NzU_d4746982-917a-4211-b17c-39a48dcec429">222,471</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8b76d915d864443fbfe177d29bc9e4e4_D20210401-20210630" decimals="-3" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMzAvZnJhZzo3NGIwMjA4NWYwNjY0MjYyOGY3OWUzMTNlNjFkZmI3Yy90YWJsZTpmYTRmNTRhZWVjNTg0NDBiYmYyYTcwYWUxMDNkNDVlNy90YWJsZXJhbmdlOmZhNGY1NGFlZWM1ODQ0MGJiZjJhNzBhZTEwM2Q0NWU3XzMtNS0xLTEtMTc3NzU_6022f7d9-2c00-4043-83de-7d6c68aa5187">222,057</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i035c62f748c14287b929adf98e0b2fbb_D20210101-20210331" decimals="-3" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMzAvZnJhZzo3NGIwMjA4NWYwNjY0MjYyOGY3OWUzMTNlNjFkZmI3Yy90YWJsZTpmYTRmNTRhZWVjNTg0NDBiYmYyYTcwYWUxMDNkNDVlNy90YWJsZXJhbmdlOmZhNGY1NGFlZWM1ODQ0MGJiZjJhNzBhZTEwM2Q0NWU3XzMtNy0xLTEtMTc3NzU_b2a65a5d-6405-409e-9454-47e0d1c72a2b">215,071</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i546c40c371924532a3d2ed0ace7d354b_D20211001-20211231" decimals="-3" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMzAvZnJhZzo3NGIwMjA4NWYwNjY0MjYyOGY3OWUzMTNlNjFkZmI3Yy90YWJsZTpmYTRmNTRhZWVjNTg0NDBiYmYyYTcwYWUxMDNkNDVlNy90YWJsZXJhbmdlOmZhNGY1NGFlZWM1ODQ0MGJiZjJhNzBhZTEwM2Q0NWU3XzQtMS0xLTEtMTc3NzU_d84a2641-b45b-4879-8dcd-74c4a263caf1">260,572</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i973a81e9b0924e4e86048dc6df6379d0_D20210701-20210930" decimals="-3" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMzAvZnJhZzo3NGIwMjA4NWYwNjY0MjYyOGY3OWUzMTNlNjFkZmI3Yy90YWJsZTpmYTRmNTRhZWVjNTg0NDBiYmYyYTcwYWUxMDNkNDVlNy90YWJsZXJhbmdlOmZhNGY1NGFlZWM1ODQ0MGJiZjJhNzBhZTEwM2Q0NWU3XzQtMy0xLTEtMTc3NzU_23cda1f7-8931-4b84-80aa-bdde3c243cb1">229,052</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8b76d915d864443fbfe177d29bc9e4e4_D20210401-20210630" decimals="-3" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMzAvZnJhZzo3NGIwMjA4NWYwNjY0MjYyOGY3OWUzMTNlNjFkZmI3Yy90YWJsZTpmYTRmNTRhZWVjNTg0NDBiYmYyYTcwYWUxMDNkNDVlNy90YWJsZXJhbmdlOmZhNGY1NGFlZWM1ODQ0MGJiZjJhNzBhZTEwM2Q0NWU3XzQtNS0xLTEtMTc3NzU_b32777b7-f56d-46bf-90e4-46fe38bb8876">229,728</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i035c62f748c14287b929adf98e0b2fbb_D20210101-20210331" decimals="-3" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMzAvZnJhZzo3NGIwMjA4NWYwNjY0MjYyOGY3OWUzMTNlNjFkZmI3Yy90YWJsZTpmYTRmNTRhZWVjNTg0NDBiYmYyYTcwYWUxMDNkNDVlNy90YWJsZXJhbmdlOmZhNGY1NGFlZWM1ODQ0MGJiZjJhNzBhZTEwM2Q0NWU3XzQtNy0xLTEtMTc3NzU_c2298f62-f667-4b63-bc96-063e3898e855">231,016</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss from continuing operations</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i546c40c371924532a3d2ed0ace7d354b_D20211001-20211231" decimals="-3" name="us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMzAvZnJhZzo3NGIwMjA4NWYwNjY0MjYyOGY3OWUzMTNlNjFkZmI3Yy90YWJsZTpmYTRmNTRhZWVjNTg0NDBiYmYyYTcwYWUxMDNkNDVlNy90YWJsZXJhbmdlOmZhNGY1NGFlZWM1ODQ0MGJiZjJhNzBhZTEwM2Q0NWU3XzUtMS0xLTEtMTc3NzU_b15e3ca2-6f18-4fc7-a5a9-e7943659f28b">3,053</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i973a81e9b0924e4e86048dc6df6379d0_D20210701-20210930" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMzAvZnJhZzo3NGIwMjA4NWYwNjY0MjYyOGY3OWUzMTNlNjFkZmI3Yy90YWJsZTpmYTRmNTRhZWVjNTg0NDBiYmYyYTcwYWUxMDNkNDVlNy90YWJsZXJhbmdlOmZhNGY1NGFlZWM1ODQ0MGJiZjJhNzBhZTEwM2Q0NWU3XzUtMy0xLTEtMTc3NzU_ab26b235-5211-4610-a807-a74d9ef89cbf">13,040</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8b76d915d864443fbfe177d29bc9e4e4_D20210401-20210630" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMzAvZnJhZzo3NGIwMjA4NWYwNjY0MjYyOGY3OWUzMTNlNjFkZmI3Yy90YWJsZTpmYTRmNTRhZWVjNTg0NDBiYmYyYTcwYWUxMDNkNDVlNy90YWJsZXJhbmdlOmZhNGY1NGFlZWM1ODQ0MGJiZjJhNzBhZTEwM2Q0NWU3XzUtNS0xLTEtMTc3NzU_d4fd8f42-ede1-4a57-9954-377b8f211310">9,107</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i035c62f748c14287b929adf98e0b2fbb_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMzAvZnJhZzo3NGIwMjA4NWYwNjY0MjYyOGY3OWUzMTNlNjFkZmI3Yy90YWJsZTpmYTRmNTRhZWVjNTg0NDBiYmYyYTcwYWUxMDNkNDVlNy90YWJsZXJhbmdlOmZhNGY1NGFlZWM1ODQ0MGJiZjJhNzBhZTEwM2Q0NWU3XzUtNy0xLTEtMTc3NzU_8f405d12-8ea2-42b6-9717-a99a48dc29ed">11,190</ix:nonFraction>)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss) from discontinued operations, net of tax</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i546c40c371924532a3d2ed0ace7d354b_D20211001-20211231" decimals="-3" sign="-" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMzAvZnJhZzo3NGIwMjA4NWYwNjY0MjYyOGY3OWUzMTNlNjFkZmI3Yy90YWJsZTpmYTRmNTRhZWVjNTg0NDBiYmYyYTcwYWUxMDNkNDVlNy90YWJsZXJhbmdlOmZhNGY1NGFlZWM1ODQ0MGJiZjJhNzBhZTEwM2Q0NWU3XzYtMS0xLTEtMzMwOTg_2d028ee7-25e5-43aa-a188-cea5ec2afbd1">8,700</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i973a81e9b0924e4e86048dc6df6379d0_D20210701-20210930" decimals="-3" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMzAvZnJhZzo3NGIwMjA4NWYwNjY0MjYyOGY3OWUzMTNlNjFkZmI3Yy90YWJsZTpmYTRmNTRhZWVjNTg0NDBiYmYyYTcwYWUxMDNkNDVlNy90YWJsZXJhbmdlOmZhNGY1NGFlZWM1ODQ0MGJiZjJhNzBhZTEwM2Q0NWU3XzYtMy0xLTEtMzY1MDY_c686a071-be59-4ba0-86e4-beb26a8b5d91">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8b76d915d864443fbfe177d29bc9e4e4_D20210401-20210630" decimals="-3" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMzAvZnJhZzo3NGIwMjA4NWYwNjY0MjYyOGY3OWUzMTNlNjFkZmI3Yy90YWJsZTpmYTRmNTRhZWVjNTg0NDBiYmYyYTcwYWUxMDNkNDVlNy90YWJsZXJhbmdlOmZhNGY1NGFlZWM1ODQ0MGJiZjJhNzBhZTEwM2Q0NWU3XzYtNS0xLTEtMzY1MDY_9f9e07ab-9e0a-4d3b-b9c2-58e89f6b5fdc">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i035c62f748c14287b929adf98e0b2fbb_D20210101-20210331" decimals="-3" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMzAvZnJhZzo3NGIwMjA4NWYwNjY0MjYyOGY3OWUzMTNlNjFkZmI3Yy90YWJsZTpmYTRmNTRhZWVjNTg0NDBiYmYyYTcwYWUxMDNkNDVlNy90YWJsZXJhbmdlOmZhNGY1NGFlZWM1ODQ0MGJiZjJhNzBhZTEwM2Q0NWU3XzYtNy0xLTEtMzY1MDY_e855419b-4077-4099-9590-8f17b1e35f92">1,383</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss attributable to common shareholders of Evolent Health, Inc.</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i546c40c371924532a3d2ed0ace7d354b_D20211001-20211231" decimals="-3" sign="-" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMzAvZnJhZzo3NGIwMjA4NWYwNjY0MjYyOGY3OWUzMTNlNjFkZmI3Yy90YWJsZTpmYTRmNTRhZWVjNTg0NDBiYmYyYTcwYWUxMDNkNDVlNy90YWJsZXJhbmdlOmZhNGY1NGFlZWM1ODQ0MGJiZjJhNzBhZTEwM2Q0NWU3XzctMS0xLTEtMTc3NzU_970da707-5a06-402a-9bf2-6ae593559fba"><ix:nonFraction unitRef="usd" contextRef="i546c40c371924532a3d2ed0ace7d354b_D20211001-20211231" decimals="-3" sign="-" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMzAvZnJhZzo3NGIwMjA4NWYwNjY0MjYyOGY3OWUzMTNlNjFkZmI3Yy90YWJsZTpmYTRmNTRhZWVjNTg0NDBiYmYyYTcwYWUxMDNkNDVlNy90YWJsZXJhbmdlOmZhNGY1NGFlZWM1ODQ0MGJiZjJhNzBhZTEwM2Q0NWU3XzctMS0xLTEtMTc3NzU_fa1bdb3c-ed90-43d4-8528-fda67caf12cb">5,647</ix:nonFraction></ix:nonFraction>)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i973a81e9b0924e4e86048dc6df6379d0_D20210701-20210930" decimals="-3" sign="-" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMzAvZnJhZzo3NGIwMjA4NWYwNjY0MjYyOGY3OWUzMTNlNjFkZmI3Yy90YWJsZTpmYTRmNTRhZWVjNTg0NDBiYmYyYTcwYWUxMDNkNDVlNy90YWJsZXJhbmdlOmZhNGY1NGFlZWM1ODQ0MGJiZjJhNzBhZTEwM2Q0NWU3XzctMy0xLTEtMTc3NzU_30db6a70-3c51-435d-b9fe-a90a03d918a1"><ix:nonFraction unitRef="usd" contextRef="i973a81e9b0924e4e86048dc6df6379d0_D20210701-20210930" decimals="-3" sign="-" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMzAvZnJhZzo3NGIwMjA4NWYwNjY0MjYyOGY3OWUzMTNlNjFkZmI3Yy90YWJsZTpmYTRmNTRhZWVjNTg0NDBiYmYyYTcwYWUxMDNkNDVlNy90YWJsZXJhbmdlOmZhNGY1NGFlZWM1ODQ0MGJiZjJhNzBhZTEwM2Q0NWU3XzctMy0xLTEtMTc3NzU_e532f44b-4918-467c-bd96-3718b4647f85">13,040</ix:nonFraction></ix:nonFraction>)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8b76d915d864443fbfe177d29bc9e4e4_D20210401-20210630" decimals="-3" sign="-" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMzAvZnJhZzo3NGIwMjA4NWYwNjY0MjYyOGY3OWUzMTNlNjFkZmI3Yy90YWJsZTpmYTRmNTRhZWVjNTg0NDBiYmYyYTcwYWUxMDNkNDVlNy90YWJsZXJhbmdlOmZhNGY1NGFlZWM1ODQ0MGJiZjJhNzBhZTEwM2Q0NWU3XzctNS0xLTEtMTc3NzU_b25539b3-4996-49bc-946d-42d7726b0201"><ix:nonFraction unitRef="usd" contextRef="i8b76d915d864443fbfe177d29bc9e4e4_D20210401-20210630" decimals="-3" sign="-" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMzAvZnJhZzo3NGIwMjA4NWYwNjY0MjYyOGY3OWUzMTNlNjFkZmI3Yy90YWJsZTpmYTRmNTRhZWVjNTg0NDBiYmYyYTcwYWUxMDNkNDVlNy90YWJsZXJhbmdlOmZhNGY1NGFlZWM1ODQ0MGJiZjJhNzBhZTEwM2Q0NWU3XzctNS0xLTEtMTc3NzU_f818ab4a-8027-428a-b0b0-0b77c2cefae5">9,107</ix:nonFraction></ix:nonFraction>)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i035c62f748c14287b929adf98e0b2fbb_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMzAvZnJhZzo3NGIwMjA4NWYwNjY0MjYyOGY3OWUzMTNlNjFkZmI3Yy90YWJsZTpmYTRmNTRhZWVjNTg0NDBiYmYyYTcwYWUxMDNkNDVlNy90YWJsZXJhbmdlOmZhNGY1NGFlZWM1ODQ0MGJiZjJhNzBhZTEwM2Q0NWU3XzctNy0xLTEtMTc3NzU_4fedc226-92af-4e9b-90cc-f65907c1bc59"><ix:nonFraction unitRef="usd" contextRef="i035c62f748c14287b929adf98e0b2fbb_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMzAvZnJhZzo3NGIwMjA4NWYwNjY0MjYyOGY3OWUzMTNlNjFkZmI3Yy90YWJsZTpmYTRmNTRhZWVjNTg0NDBiYmYyYTcwYWUxMDNkNDVlNy90YWJsZXJhbmdlOmZhNGY1NGFlZWM1ODQ0MGJiZjJhNzBhZTEwM2Q0NWU3XzctNy0xLTEtMTc3NzU_5c74a8c5-e697-48b3-898c-fd340a0eea78">9,807</ix:nonFraction></ix:nonFraction>)</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Income (loss) per common share</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic and diluted</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Continuing operations</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i546c40c371924532a3d2ed0ace7d354b_D20211001-20211231" decimals="2" name="us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMzAvZnJhZzo3NGIwMjA4NWYwNjY0MjYyOGY3OWUzMTNlNjFkZmI3Yy90YWJsZTpmYTRmNTRhZWVjNTg0NDBiYmYyYTcwYWUxMDNkNDVlNy90YWJsZXJhbmdlOmZhNGY1NGFlZWM1ODQ0MGJiZjJhNzBhZTEwM2Q0NWU3XzEyLTEtMS0xLTI2OTQ4_2ea9c726-f048-42fe-a835-c99cbe0ee20e"><ix:nonFraction unitRef="usdPerShare" contextRef="i546c40c371924532a3d2ed0ace7d354b_D20211001-20211231" decimals="2" name="us-gaap:IncomeLossFromContinuingOperationsPerBasicShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMzAvZnJhZzo3NGIwMjA4NWYwNjY0MjYyOGY3OWUzMTNlNjFkZmI3Yy90YWJsZTpmYTRmNTRhZWVjNTg0NDBiYmYyYTcwYWUxMDNkNDVlNy90YWJsZXJhbmdlOmZhNGY1NGFlZWM1ODQ0MGJiZjJhNzBhZTEwM2Q0NWU3XzEyLTEtMS0xLTI2OTQ4_de5233e2-a123-422a-b312-ca434ac4f59a">0.03</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i973a81e9b0924e4e86048dc6df6379d0_D20210701-20210930" decimals="2" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMzAvZnJhZzo3NGIwMjA4NWYwNjY0MjYyOGY3OWUzMTNlNjFkZmI3Yy90YWJsZTpmYTRmNTRhZWVjNTg0NDBiYmYyYTcwYWUxMDNkNDVlNy90YWJsZXJhbmdlOmZhNGY1NGFlZWM1ODQ0MGJiZjJhNzBhZTEwM2Q0NWU3XzExLTMtMS0xLTM2NTE0_adac1fbc-2893-48e9-85bb-9359d241a161"><ix:nonFraction unitRef="usdPerShare" contextRef="i973a81e9b0924e4e86048dc6df6379d0_D20210701-20210930" decimals="2" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsPerBasicShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMzAvZnJhZzo3NGIwMjA4NWYwNjY0MjYyOGY3OWUzMTNlNjFkZmI3Yy90YWJsZTpmYTRmNTRhZWVjNTg0NDBiYmYyYTcwYWUxMDNkNDVlNy90YWJsZXJhbmdlOmZhNGY1NGFlZWM1ODQ0MGJiZjJhNzBhZTEwM2Q0NWU3XzExLTMtMS0xLTM2NTE0_f28f1df2-bb0b-4118-bbb1-89566ae61948">0.15</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i8b76d915d864443fbfe177d29bc9e4e4_D20210401-20210630" decimals="2" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMzAvZnJhZzo3NGIwMjA4NWYwNjY0MjYyOGY3OWUzMTNlNjFkZmI3Yy90YWJsZTpmYTRmNTRhZWVjNTg0NDBiYmYyYTcwYWUxMDNkNDVlNy90YWJsZXJhbmdlOmZhNGY1NGFlZWM1ODQ0MGJiZjJhNzBhZTEwM2Q0NWU3XzExLTUtMS0xLTM2NTE2_cc259872-0658-4dd9-a770-26f0c5305cc0"><ix:nonFraction unitRef="usdPerShare" contextRef="i8b76d915d864443fbfe177d29bc9e4e4_D20210401-20210630" decimals="2" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsPerBasicShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMzAvZnJhZzo3NGIwMjA4NWYwNjY0MjYyOGY3OWUzMTNlNjFkZmI3Yy90YWJsZTpmYTRmNTRhZWVjNTg0NDBiYmYyYTcwYWUxMDNkNDVlNy90YWJsZXJhbmdlOmZhNGY1NGFlZWM1ODQ0MGJiZjJhNzBhZTEwM2Q0NWU3XzExLTUtMS0xLTM2NTE2_ff12b3e4-5225-48b6-9ac1-40d8756d3fd1">0.11</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i035c62f748c14287b929adf98e0b2fbb_D20210101-20210331" decimals="2" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMzAvZnJhZzo3NGIwMjA4NWYwNjY0MjYyOGY3OWUzMTNlNjFkZmI3Yy90YWJsZTpmYTRmNTRhZWVjNTg0NDBiYmYyYTcwYWUxMDNkNDVlNy90YWJsZXJhbmdlOmZhNGY1NGFlZWM1ODQ0MGJiZjJhNzBhZTEwM2Q0NWU3XzExLTctMS0xLTM2NTE4_d70a196a-3fa0-47a5-8ed4-9c3a085ad8c2"><ix:nonFraction unitRef="usdPerShare" contextRef="i035c62f748c14287b929adf98e0b2fbb_D20210101-20210331" decimals="2" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsPerBasicShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMzAvZnJhZzo3NGIwMjA4NWYwNjY0MjYyOGY3OWUzMTNlNjFkZmI3Yy90YWJsZTpmYTRmNTRhZWVjNTg0NDBiYmYyYTcwYWUxMDNkNDVlNy90YWJsZXJhbmdlOmZhNGY1NGFlZWM1ODQ0MGJiZjJhNzBhZTEwM2Q0NWU3XzExLTctMS0xLTM2NTE4_ffed93b2-fad8-4c55-92e0-824eeaa0894b">0.13</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discontinued operations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i546c40c371924532a3d2ed0ace7d354b_D20211001-20211231" decimals="2" sign="-" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMzAvZnJhZzo3NGIwMjA4NWYwNjY0MjYyOGY3OWUzMTNlNjFkZmI3Yy90YWJsZTpmYTRmNTRhZWVjNTg0NDBiYmYyYTcwYWUxMDNkNDVlNy90YWJsZXJhbmdlOmZhNGY1NGFlZWM1ODQ0MGJiZjJhNzBhZTEwM2Q0NWU3XzEzLTEtMS0xLTI2OTQ4_71ff7bc5-9d8e-4a6d-9d4e-3bf79b03358f"><ix:nonFraction unitRef="usdPerShare" contextRef="i546c40c371924532a3d2ed0ace7d354b_D20211001-20211231" decimals="2" sign="-" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMzAvZnJhZzo3NGIwMjA4NWYwNjY0MjYyOGY3OWUzMTNlNjFkZmI3Yy90YWJsZTpmYTRmNTRhZWVjNTg0NDBiYmYyYTcwYWUxMDNkNDVlNy90YWJsZXJhbmdlOmZhNGY1NGFlZWM1ODQ0MGJiZjJhNzBhZTEwM2Q0NWU3XzEzLTEtMS0xLTI2OTQ4_d4e997de-823f-434c-81e4-ac6cb667ac0e">0.09</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i973a81e9b0924e4e86048dc6df6379d0_D20210701-20210930" decimals="2" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMzAvZnJhZzo3NGIwMjA4NWYwNjY0MjYyOGY3OWUzMTNlNjFkZmI3Yy90YWJsZTpmYTRmNTRhZWVjNTg0NDBiYmYyYTcwYWUxMDNkNDVlNy90YWJsZXJhbmdlOmZhNGY1NGFlZWM1ODQ0MGJiZjJhNzBhZTEwM2Q0NWU3XzEyLTMtMS0xLTM2NTE0_8108b0e2-93cd-4627-88a1-5a01580763c0"><ix:nonFraction unitRef="usdPerShare" contextRef="i973a81e9b0924e4e86048dc6df6379d0_D20210701-20210930" decimals="2" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMzAvZnJhZzo3NGIwMjA4NWYwNjY0MjYyOGY3OWUzMTNlNjFkZmI3Yy90YWJsZTpmYTRmNTRhZWVjNTg0NDBiYmYyYTcwYWUxMDNkNDVlNy90YWJsZXJhbmdlOmZhNGY1NGFlZWM1ODQ0MGJiZjJhNzBhZTEwM2Q0NWU3XzEyLTMtMS0xLTM2NTE0_aa9ec4cf-2ff6-4e10-a3c0-2021f6c09dc8">&#8212;</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i8b76d915d864443fbfe177d29bc9e4e4_D20210401-20210630" decimals="2" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMzAvZnJhZzo3NGIwMjA4NWYwNjY0MjYyOGY3OWUzMTNlNjFkZmI3Yy90YWJsZTpmYTRmNTRhZWVjNTg0NDBiYmYyYTcwYWUxMDNkNDVlNy90YWJsZXJhbmdlOmZhNGY1NGFlZWM1ODQ0MGJiZjJhNzBhZTEwM2Q0NWU3XzEyLTUtMS0xLTM2NTE2_8bc4704a-735c-43b7-baa7-ae59ae5847ae"><ix:nonFraction unitRef="usdPerShare" contextRef="i8b76d915d864443fbfe177d29bc9e4e4_D20210401-20210630" decimals="2" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMzAvZnJhZzo3NGIwMjA4NWYwNjY0MjYyOGY3OWUzMTNlNjFkZmI3Yy90YWJsZTpmYTRmNTRhZWVjNTg0NDBiYmYyYTcwYWUxMDNkNDVlNy90YWJsZXJhbmdlOmZhNGY1NGFlZWM1ODQ0MGJiZjJhNzBhZTEwM2Q0NWU3XzEyLTUtMS0xLTM2NTE2_f7c87c53-8420-44d0-b53e-cddc38081f96">&#8212;</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i035c62f748c14287b929adf98e0b2fbb_D20210101-20210331" decimals="2" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMzAvZnJhZzo3NGIwMjA4NWYwNjY0MjYyOGY3OWUzMTNlNjFkZmI3Yy90YWJsZTpmYTRmNTRhZWVjNTg0NDBiYmYyYTcwYWUxMDNkNDVlNy90YWJsZXJhbmdlOmZhNGY1NGFlZWM1ODQ0MGJiZjJhNzBhZTEwM2Q0NWU3XzEyLTctMS0xLTM2NTE4_74e34c65-6e81-410b-8670-fc0259fbd9b0"><ix:nonFraction unitRef="usdPerShare" contextRef="i035c62f748c14287b929adf98e0b2fbb_D20210101-20210331" decimals="2" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMzAvZnJhZzo3NGIwMjA4NWYwNjY0MjYyOGY3OWUzMTNlNjFkZmI3Yy90YWJsZTpmYTRmNTRhZWVjNTg0NDBiYmYyYTcwYWUxMDNkNDVlNy90YWJsZXJhbmdlOmZhNGY1NGFlZWM1ODQ0MGJiZjJhNzBhZTEwM2Q0NWU3XzEyLTctMS0xLTM2NTE4_8a38320d-e774-45d7-aeaa-f83be35e5417">0.01</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenue</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6d3bee5994474a229055f5b47133978b_D20201001-20201231" decimals="-3" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMzAvZnJhZzo3NGIwMjA4NWYwNjY0MjYyOGY3OWUzMTNlNjFkZmI3Yy90YWJsZTpmYTRmNTRhZWVjNTg0NDBiYmYyYTcwYWUxMDNkNDVlNy90YWJsZXJhbmdlOmZhNGY1NGFlZWM1ODQ0MGJiZjJhNzBhZTEwM2Q0NWU3XzEzLTEtMS0xLTE3Nzc1_106fbf4c-e28d-4db7-ba72-a014be273555">246,536</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i03844ec391854836b0d4437e624d231c_D20200701-20200930" decimals="-3" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMzAvZnJhZzo3NGIwMjA4NWYwNjY0MjYyOGY3OWUzMTNlNjFkZmI3Yy90YWJsZTpmYTRmNTRhZWVjNTg0NDBiYmYyYTcwYWUxMDNkNDVlNy90YWJsZXJhbmdlOmZhNGY1NGFlZWM1ODQ0MGJiZjJhNzBhZTEwM2Q0NWU3XzEzLTMtMS0xLTE3Nzc1_4ee5a407-8d1e-432d-9e58-fc4cf847bd47">239,572</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i62320e40739f4842b8ffb078d42fa029_D20200401-20200630" decimals="-3" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMzAvZnJhZzo3NGIwMjA4NWYwNjY0MjYyOGY3OWUzMTNlNjFkZmI3Yy90YWJsZTpmYTRmNTRhZWVjNTg0NDBiYmYyYTcwYWUxMDNkNDVlNy90YWJsZXJhbmdlOmZhNGY1NGFlZWM1ODQ0MGJiZjJhNzBhZTEwM2Q0NWU3XzEzLTUtMS0xLTE3Nzc1_1bd9277f-bc22-4062-afdf-42121f6b0984">217,299</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iddbf996a3b1a4aeda47f1e8169c69262_D20200101-20200331" decimals="-3" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMzAvZnJhZzo3NGIwMjA4NWYwNjY0MjYyOGY3OWUzMTNlNjFkZmI3Yy90YWJsZTpmYTRmNTRhZWVjNTg0NDBiYmYyYTcwYWUxMDNkNDVlNy90YWJsZXJhbmdlOmZhNGY1NGFlZWM1ODQ0MGJiZjJhNzBhZTEwM2Q0NWU3XzEzLTctMS0xLTE3Nzc1_7f4d6da2-81c5-4a2f-a664-5b1c318d57e3">221,232</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6d3bee5994474a229055f5b47133978b_D20201001-20201231" decimals="-3" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMzAvZnJhZzo3NGIwMjA4NWYwNjY0MjYyOGY3OWUzMTNlNjFkZmI3Yy90YWJsZTpmYTRmNTRhZWVjNTg0NDBiYmYyYTcwYWUxMDNkNDVlNy90YWJsZXJhbmdlOmZhNGY1NGFlZWM1ODQ0MGJiZjJhNzBhZTEwM2Q0NWU3XzE0LTEtMS0xLTE3Nzc1_8f88a7df-1fff-4855-86fe-9781feddcd7a">246,804</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i03844ec391854836b0d4437e624d231c_D20200701-20200930" decimals="-3" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMzAvZnJhZzo3NGIwMjA4NWYwNjY0MjYyOGY3OWUzMTNlNjFkZmI3Yy90YWJsZTpmYTRmNTRhZWVjNTg0NDBiYmYyYTcwYWUxMDNkNDVlNy90YWJsZXJhbmdlOmZhNGY1NGFlZWM1ODQ0MGJiZjJhNzBhZTEwM2Q0NWU3XzE0LTMtMS0xLTE3Nzc1_9180a47f-5abf-46f0-a62b-c26a2266d945">256,020</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i62320e40739f4842b8ffb078d42fa029_D20200401-20200630" decimals="-3" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMzAvZnJhZzo3NGIwMjA4NWYwNjY0MjYyOGY3OWUzMTNlNjFkZmI3Yy90YWJsZTpmYTRmNTRhZWVjNTg0NDBiYmYyYTcwYWUxMDNkNDVlNy90YWJsZXJhbmdlOmZhNGY1NGFlZWM1ODQ0MGJiZjJhNzBhZTEwM2Q0NWU3XzE0LTUtMS0xLTE3Nzc1_60219787-0541-4333-8ef0-63bf423592cb">443,128</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iddbf996a3b1a4aeda47f1e8169c69262_D20200101-20200331" decimals="-3" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMzAvZnJhZzo3NGIwMjA4NWYwNjY0MjYyOGY3OWUzMTNlNjFkZmI3Yy90YWJsZTpmYTRmNTRhZWVjNTg0NDBiYmYyYTcwYWUxMDNkNDVlNy90YWJsZXJhbmdlOmZhNGY1NGFlZWM1ODQ0MGJiZjJhNzBhZTEwM2Q0NWU3XzE0LTctMS0xLTE3Nzc1_f14df40f-a313-47a4-9359-5250a9c8f7ea">246,323</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss from continuing operations</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6d3bee5994474a229055f5b47133978b_D20201001-20201231" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMzAvZnJhZzo3NGIwMjA4NWYwNjY0MjYyOGY3OWUzMTNlNjFkZmI3Yy90YWJsZTpmYTRmNTRhZWVjNTg0NDBiYmYyYTcwYWUxMDNkNDVlNy90YWJsZXJhbmdlOmZhNGY1NGFlZWM1ODQ0MGJiZjJhNzBhZTEwM2Q0NWU3XzE1LTEtMS0xLTE3Nzc1_d2f1ab6f-9b96-477c-8519-e180fd534ed8">10,637</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i03844ec391854836b0d4437e624d231c_D20200701-20200930" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMzAvZnJhZzo3NGIwMjA4NWYwNjY0MjYyOGY3OWUzMTNlNjFkZmI3Yy90YWJsZTpmYTRmNTRhZWVjNTg0NDBiYmYyYTcwYWUxMDNkNDVlNy90YWJsZXJhbmdlOmZhNGY1NGFlZWM1ODQ0MGJiZjJhNzBhZTEwM2Q0NWU3XzE1LTMtMS0xLTE3Nzc1_20842b0e-edbb-4187-8e6a-66a0bf00a515">37,035</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i62320e40739f4842b8ffb078d42fa029_D20200401-20200630" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMzAvZnJhZzo3NGIwMjA4NWYwNjY0MjYyOGY3OWUzMTNlNjFkZmI3Yy90YWJsZTpmYTRmNTRhZWVjNTg0NDBiYmYyYTcwYWUxMDNkNDVlNy90YWJsZXJhbmdlOmZhNGY1NGFlZWM1ODQ0MGJiZjJhNzBhZTEwM2Q0NWU3XzE1LTUtMS0xLTE3Nzc1_d3ecbc03-39d4-4a58-96f9-ce919098b68f">202,013</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iddbf996a3b1a4aeda47f1e8169c69262_D20200101-20200331" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMzAvZnJhZzo3NGIwMjA4NWYwNjY0MjYyOGY3OWUzMTNlNjFkZmI3Yy90YWJsZTpmYTRmNTRhZWVjNTg0NDBiYmYyYTcwYWUxMDNkNDVlNy90YWJsZXJhbmdlOmZhNGY1NGFlZWM1ODQ0MGJiZjJhNzBhZTEwM2Q0NWU3XzE1LTctMS0xLTE3Nzc1_8a72ee11-ee44-4d2d-8822-55a81845ef01">78,487</ix:nonFraction>)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss from discontinued operations, net of tax</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6d3bee5994474a229055f5b47133978b_D20201001-20201231" decimals="-3" sign="-" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMzAvZnJhZzo3NGIwMjA4NWYwNjY0MjYyOGY3OWUzMTNlNjFkZmI3Yy90YWJsZTpmYTRmNTRhZWVjNTg0NDBiYmYyYTcwYWUxMDNkNDVlNy90YWJsZXJhbmdlOmZhNGY1NGFlZWM1ODQ0MGJiZjJhNzBhZTEwM2Q0NWU3XzE2LTEtMS0xLTE3Nzc1_5445c214-1a15-424a-aee8-876d054144bd">3,166</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i03844ec391854836b0d4437e624d231c_D20200701-20200930" decimals="-3" sign="-" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMzAvZnJhZzo3NGIwMjA4NWYwNjY0MjYyOGY3OWUzMTNlNjFkZmI3Yy90YWJsZTpmYTRmNTRhZWVjNTg0NDBiYmYyYTcwYWUxMDNkNDVlNy90YWJsZXJhbmdlOmZhNGY1NGFlZWM1ODQ0MGJiZjJhNzBhZTEwM2Q0NWU3XzE2LTMtMS0xLTE3Nzc1_99d2cb9e-e1ad-4b66-b12b-4baee565baef">1,135</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i62320e40739f4842b8ffb078d42fa029_D20200401-20200630" decimals="-3" sign="-" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMzAvZnJhZzo3NGIwMjA4NWYwNjY0MjYyOGY3OWUzMTNlNjFkZmI3Yy90YWJsZTpmYTRmNTRhZWVjNTg0NDBiYmYyYTcwYWUxMDNkNDVlNy90YWJsZXJhbmdlOmZhNGY1NGFlZWM1ODQ0MGJiZjJhNzBhZTEwM2Q0NWU3XzE2LTUtMS0xLTE3Nzc1_87a28350-f8f2-48ae-95a3-da1e41f5ba68">1,508</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iddbf996a3b1a4aeda47f1e8169c69262_D20200101-20200331" decimals="-3" sign="-" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMzAvZnJhZzo3NGIwMjA4NWYwNjY0MjYyOGY3OWUzMTNlNjFkZmI3Yy90YWJsZTpmYTRmNTRhZWVjNTg0NDBiYmYyYTcwYWUxMDNkNDVlNy90YWJsZXJhbmdlOmZhNGY1NGFlZWM1ODQ0MGJiZjJhNzBhZTEwM2Q0NWU3XzE2LTctMS0xLTE3Nzc1_0a50e548-9388-459c-a5e5-32f4e0b2d2dd">265</ix:nonFraction>)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss) attributable to non-controlling interests</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6d3bee5994474a229055f5b47133978b_D20201001-20201231" decimals="-3" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMzAvZnJhZzo3NGIwMjA4NWYwNjY0MjYyOGY3OWUzMTNlNjFkZmI3Yy90YWJsZTpmYTRmNTRhZWVjNTg0NDBiYmYyYTcwYWUxMDNkNDVlNy90YWJsZXJhbmdlOmZhNGY1NGFlZWM1ODQ0MGJiZjJhNzBhZTEwM2Q0NWU3XzE3LTEtMS0xLTE3Nzc1_4dcab5c5-b83f-4c5f-bfdf-98be054c69d9">822</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i03844ec391854836b0d4437e624d231c_D20200701-20200930" decimals="-3" sign="-" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMzAvZnJhZzo3NGIwMjA4NWYwNjY0MjYyOGY3OWUzMTNlNjFkZmI3Yy90YWJsZTpmYTRmNTRhZWVjNTg0NDBiYmYyYTcwYWUxMDNkNDVlNy90YWJsZXJhbmdlOmZhNGY1NGFlZWM1ODQ0MGJiZjJhNzBhZTEwM2Q0NWU3XzE3LTMtMS0xLTE3Nzc1_e0be547e-c925-4ec4-8866-1c2b2fe7a29d">822</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i62320e40739f4842b8ffb078d42fa029_D20200401-20200630" decimals="-3" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMzAvZnJhZzo3NGIwMjA4NWYwNjY0MjYyOGY3OWUzMTNlNjFkZmI3Yy90YWJsZTpmYTRmNTRhZWVjNTg0NDBiYmYyYTcwYWUxMDNkNDVlNy90YWJsZXJhbmdlOmZhNGY1NGFlZWM1ODQ0MGJiZjJhNzBhZTEwM2Q0NWU3XzE3LTUtMS0xLTE3Nzc1_afa2c0fe-7711-49a0-b4fe-d67a38e8e3bf">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iddbf996a3b1a4aeda47f1e8169c69262_D20200101-20200331" decimals="-3" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMzAvZnJhZzo3NGIwMjA4NWYwNjY0MjYyOGY3OWUzMTNlNjFkZmI3Yy90YWJsZTpmYTRmNTRhZWVjNTg0NDBiYmYyYTcwYWUxMDNkNDVlNy90YWJsZXJhbmdlOmZhNGY1NGFlZWM1ODQ0MGJiZjJhNzBhZTEwM2Q0NWU3XzE3LTctMS0xLTE3Nzc1_cb0c9cc2-9df4-466d-964a-0d6b2d73758b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss attributable to common shareholders of Evolent Health, Inc.</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6d3bee5994474a229055f5b47133978b_D20201001-20201231" decimals="-3" sign="-" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMzAvZnJhZzo3NGIwMjA4NWYwNjY0MjYyOGY3OWUzMTNlNjFkZmI3Yy90YWJsZTpmYTRmNTRhZWVjNTg0NDBiYmYyYTcwYWUxMDNkNDVlNy90YWJsZXJhbmdlOmZhNGY1NGFlZWM1ODQ0MGJiZjJhNzBhZTEwM2Q0NWU3XzIwLTEtMS0xLTM2NTIw_100a0286-bb27-4c87-bf31-a1400c936877"><ix:nonFraction unitRef="usd" contextRef="i6d3bee5994474a229055f5b47133978b_D20201001-20201231" decimals="-3" sign="-" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMzAvZnJhZzo3NGIwMjA4NWYwNjY0MjYyOGY3OWUzMTNlNjFkZmI3Yy90YWJsZTpmYTRmNTRhZWVjNTg0NDBiYmYyYTcwYWUxMDNkNDVlNy90YWJsZXJhbmdlOmZhNGY1NGFlZWM1ODQ0MGJiZjJhNzBhZTEwM2Q0NWU3XzIwLTEtMS0xLTM2NTIw_9a514bcd-b0ba-4037-abd1-73cd20163929">14,625</ix:nonFraction></ix:nonFraction>)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i03844ec391854836b0d4437e624d231c_D20200701-20200930" decimals="-3" sign="-" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMzAvZnJhZzo3NGIwMjA4NWYwNjY0MjYyOGY3OWUzMTNlNjFkZmI3Yy90YWJsZTpmYTRmNTRhZWVjNTg0NDBiYmYyYTcwYWUxMDNkNDVlNy90YWJsZXJhbmdlOmZhNGY1NGFlZWM1ODQ0MGJiZjJhNzBhZTEwM2Q0NWU3XzIwLTMtMS0xLTM2NTIy_c70744e7-24d4-4b64-8c83-9faf0c54ef7b"><ix:nonFraction unitRef="usd" contextRef="i03844ec391854836b0d4437e624d231c_D20200701-20200930" decimals="-3" sign="-" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMzAvZnJhZzo3NGIwMjA4NWYwNjY0MjYyOGY3OWUzMTNlNjFkZmI3Yy90YWJsZTpmYTRmNTRhZWVjNTg0NDBiYmYyYTcwYWUxMDNkNDVlNy90YWJsZXJhbmdlOmZhNGY1NGFlZWM1ODQ0MGJiZjJhNzBhZTEwM2Q0NWU3XzIwLTMtMS0xLTM2NTIy_ce0890af-def0-4f23-88da-7ef72c95fd71">37,348</ix:nonFraction></ix:nonFraction>)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i62320e40739f4842b8ffb078d42fa029_D20200401-20200630" decimals="-3" sign="-" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMzAvZnJhZzo3NGIwMjA4NWYwNjY0MjYyOGY3OWUzMTNlNjFkZmI3Yy90YWJsZTpmYTRmNTRhZWVjNTg0NDBiYmYyYTcwYWUxMDNkNDVlNy90YWJsZXJhbmdlOmZhNGY1NGFlZWM1ODQ0MGJiZjJhNzBhZTEwM2Q0NWU3XzIwLTUtMS0xLTM2NTI0_6769187a-a0c9-43f7-86cd-97872b0ea43e"><ix:nonFraction unitRef="usd" contextRef="i62320e40739f4842b8ffb078d42fa029_D20200401-20200630" decimals="-3" sign="-" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMzAvZnJhZzo3NGIwMjA4NWYwNjY0MjYyOGY3OWUzMTNlNjFkZmI3Yy90YWJsZTpmYTRmNTRhZWVjNTg0NDBiYmYyYTcwYWUxMDNkNDVlNy90YWJsZXJhbmdlOmZhNGY1NGFlZWM1ODQ0MGJiZjJhNzBhZTEwM2Q0NWU3XzIwLTUtMS0xLTM2NTI0_b71c6d8f-aa0b-4a06-b598-6dd2448f5309">203,521</ix:nonFraction></ix:nonFraction>)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iddbf996a3b1a4aeda47f1e8169c69262_D20200101-20200331" decimals="-3" sign="-" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMzAvZnJhZzo3NGIwMjA4NWYwNjY0MjYyOGY3OWUzMTNlNjFkZmI3Yy90YWJsZTpmYTRmNTRhZWVjNTg0NDBiYmYyYTcwYWUxMDNkNDVlNy90YWJsZXJhbmdlOmZhNGY1NGFlZWM1ODQ0MGJiZjJhNzBhZTEwM2Q0NWU3XzIwLTctMS0xLTM2NTI2_01e700bb-0dba-4928-9c4b-789bda8bd84d"><ix:nonFraction unitRef="usd" contextRef="iddbf996a3b1a4aeda47f1e8169c69262_D20200101-20200331" decimals="-3" sign="-" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMzAvZnJhZzo3NGIwMjA4NWYwNjY0MjYyOGY3OWUzMTNlNjFkZmI3Yy90YWJsZTpmYTRmNTRhZWVjNTg0NDBiYmYyYTcwYWUxMDNkNDVlNy90YWJsZXJhbmdlOmZhNGY1NGFlZWM1ODQ0MGJiZjJhNzBhZTEwM2Q0NWU3XzIwLTctMS0xLTM2NTI2_dd32049a-893f-47b6-aaa5-5296cabc46ad">78,752</ix:nonFraction></ix:nonFraction>)</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Loss per common share</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic and diluted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Continuing operations</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i6d3bee5994474a229055f5b47133978b_D20201001-20201231" decimals="2" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsPerBasicShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMzAvZnJhZzo3NGIwMjA4NWYwNjY0MjYyOGY3OWUzMTNlNjFkZmI3Yy90YWJsZTpmYTRmNTRhZWVjNTg0NDBiYmYyYTcwYWUxMDNkNDVlNy90YWJsZXJhbmdlOmZhNGY1NGFlZWM1ODQ0MGJiZjJhNzBhZTEwM2Q0NWU3XzI0LTEtMS0xLTM1MTAw_7c8ba314-c839-4a84-a475-9abd7a589ce2"><ix:nonFraction unitRef="usdPerShare" contextRef="i6d3bee5994474a229055f5b47133978b_D20201001-20201231" decimals="2" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMzAvZnJhZzo3NGIwMjA4NWYwNjY0MjYyOGY3OWUzMTNlNjFkZmI3Yy90YWJsZTpmYTRmNTRhZWVjNTg0NDBiYmYyYTcwYWUxMDNkNDVlNy90YWJsZXJhbmdlOmZhNGY1NGFlZWM1ODQ0MGJiZjJhNzBhZTEwM2Q0NWU3XzI0LTEtMS0xLTM1MTAw_acee618a-ad17-4389-ba07-298417eb3f4e">0.13</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i03844ec391854836b0d4437e624d231c_D20200701-20200930" decimals="2" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsPerBasicShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMzAvZnJhZzo3NGIwMjA4NWYwNjY0MjYyOGY3OWUzMTNlNjFkZmI3Yy90YWJsZTpmYTRmNTRhZWVjNTg0NDBiYmYyYTcwYWUxMDNkNDVlNy90YWJsZXJhbmdlOmZhNGY1NGFlZWM1ODQ0MGJiZjJhNzBhZTEwM2Q0NWU3XzI0LTMtMS0xLTM2NTI4_a6906016-12c9-4648-b79c-6694337a261d"><ix:nonFraction unitRef="usdPerShare" contextRef="i03844ec391854836b0d4437e624d231c_D20200701-20200930" decimals="2" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMzAvZnJhZzo3NGIwMjA4NWYwNjY0MjYyOGY3OWUzMTNlNjFkZmI3Yy90YWJsZTpmYTRmNTRhZWVjNTg0NDBiYmYyYTcwYWUxMDNkNDVlNy90YWJsZXJhbmdlOmZhNGY1NGFlZWM1ODQ0MGJiZjJhNzBhZTEwM2Q0NWU3XzI0LTMtMS0xLTM2NTI4_c80086aa-209d-430e-aa26-f996d039a2f5">0.43</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i62320e40739f4842b8ffb078d42fa029_D20200401-20200630" decimals="2" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMzAvZnJhZzo3NGIwMjA4NWYwNjY0MjYyOGY3OWUzMTNlNjFkZmI3Yy90YWJsZTpmYTRmNTRhZWVjNTg0NDBiYmYyYTcwYWUxMDNkNDVlNy90YWJsZXJhbmdlOmZhNGY1NGFlZWM1ODQ0MGJiZjJhNzBhZTEwM2Q0NWU3XzI0LTUtMS0xLTM2NTMw_20128d4f-e85e-4af4-9a7a-270e72f663e1"><ix:nonFraction unitRef="usdPerShare" contextRef="i62320e40739f4842b8ffb078d42fa029_D20200401-20200630" decimals="2" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsPerBasicShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMzAvZnJhZzo3NGIwMjA4NWYwNjY0MjYyOGY3OWUzMTNlNjFkZmI3Yy90YWJsZTpmYTRmNTRhZWVjNTg0NDBiYmYyYTcwYWUxMDNkNDVlNy90YWJsZXJhbmdlOmZhNGY1NGFlZWM1ODQ0MGJiZjJhNzBhZTEwM2Q0NWU3XzI0LTUtMS0xLTM2NTMw_8615fb14-33af-4870-8326-cd008f0e9c5f">2.37</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="iddbf996a3b1a4aeda47f1e8169c69262_D20200101-20200331" decimals="2" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsPerBasicShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMzAvZnJhZzo3NGIwMjA4NWYwNjY0MjYyOGY3OWUzMTNlNjFkZmI3Yy90YWJsZTpmYTRmNTRhZWVjNTg0NDBiYmYyYTcwYWUxMDNkNDVlNy90YWJsZXJhbmdlOmZhNGY1NGFlZWM1ODQ0MGJiZjJhNzBhZTEwM2Q0NWU3XzI0LTctMS0xLTM2NTMy_078f12ed-a128-46ca-babc-aa24c441c1a2"><ix:nonFraction unitRef="usdPerShare" contextRef="iddbf996a3b1a4aeda47f1e8169c69262_D20200101-20200331" decimals="2" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMzAvZnJhZzo3NGIwMjA4NWYwNjY0MjYyOGY3OWUzMTNlNjFkZmI3Yy90YWJsZTpmYTRmNTRhZWVjNTg0NDBiYmYyYTcwYWUxMDNkNDVlNy90YWJsZXJhbmdlOmZhNGY1NGFlZWM1ODQ0MGJiZjJhNzBhZTEwM2Q0NWU3XzI0LTctMS0xLTM2NTMy_cb613fa9-8680-49c8-8bd8-88e8190bb840">0.93</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discontinued operations</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i6d3bee5994474a229055f5b47133978b_D20201001-20201231" decimals="2" sign="-" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMzAvZnJhZzo3NGIwMjA4NWYwNjY0MjYyOGY3OWUzMTNlNjFkZmI3Yy90YWJsZTpmYTRmNTRhZWVjNTg0NDBiYmYyYTcwYWUxMDNkNDVlNy90YWJsZXJhbmdlOmZhNGY1NGFlZWM1ODQ0MGJiZjJhNzBhZTEwM2Q0NWU3XzI1LTEtMS0xLTM1MTAw_89f2a51b-0050-4032-904e-8a4ccbe4f405"><ix:nonFraction unitRef="usdPerShare" contextRef="i6d3bee5994474a229055f5b47133978b_D20201001-20201231" decimals="2" sign="-" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMzAvZnJhZzo3NGIwMjA4NWYwNjY0MjYyOGY3OWUzMTNlNjFkZmI3Yy90YWJsZTpmYTRmNTRhZWVjNTg0NDBiYmYyYTcwYWUxMDNkNDVlNy90YWJsZXJhbmdlOmZhNGY1NGFlZWM1ODQ0MGJiZjJhNzBhZTEwM2Q0NWU3XzI1LTEtMS0xLTM1MTAw_a019db42-ac54-4b29-a8cf-c18b87664480">0.04</ix:nonFraction></ix:nonFraction>)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i03844ec391854836b0d4437e624d231c_D20200701-20200930" decimals="2" sign="-" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMzAvZnJhZzo3NGIwMjA4NWYwNjY0MjYyOGY3OWUzMTNlNjFkZmI3Yy90YWJsZTpmYTRmNTRhZWVjNTg0NDBiYmYyYTcwYWUxMDNkNDVlNy90YWJsZXJhbmdlOmZhNGY1NGFlZWM1ODQ0MGJiZjJhNzBhZTEwM2Q0NWU3XzI1LTMtMS0xLTM2NTI4_7daff8f8-49b5-4adf-b772-41909d13bb3c"><ix:nonFraction unitRef="usdPerShare" contextRef="i03844ec391854836b0d4437e624d231c_D20200701-20200930" decimals="2" sign="-" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMzAvZnJhZzo3NGIwMjA4NWYwNjY0MjYyOGY3OWUzMTNlNjFkZmI3Yy90YWJsZTpmYTRmNTRhZWVjNTg0NDBiYmYyYTcwYWUxMDNkNDVlNy90YWJsZXJhbmdlOmZhNGY1NGFlZWM1ODQ0MGJiZjJhNzBhZTEwM2Q0NWU3XzI1LTMtMS0xLTM2NTI4_ad24e020-00de-498f-9211-fcdeaa476259">0.01</ix:nonFraction></ix:nonFraction>)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i62320e40739f4842b8ffb078d42fa029_D20200401-20200630" decimals="2" sign="-" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMzAvZnJhZzo3NGIwMjA4NWYwNjY0MjYyOGY3OWUzMTNlNjFkZmI3Yy90YWJsZTpmYTRmNTRhZWVjNTg0NDBiYmYyYTcwYWUxMDNkNDVlNy90YWJsZXJhbmdlOmZhNGY1NGFlZWM1ODQ0MGJiZjJhNzBhZTEwM2Q0NWU3XzI1LTUtMS0xLTM2NTMw_3e9ac7f1-2b0d-4d1e-b606-1295fed5c86e"><ix:nonFraction unitRef="usdPerShare" contextRef="i62320e40739f4842b8ffb078d42fa029_D20200401-20200630" decimals="2" sign="-" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMzAvZnJhZzo3NGIwMjA4NWYwNjY0MjYyOGY3OWUzMTNlNjFkZmI3Yy90YWJsZTpmYTRmNTRhZWVjNTg0NDBiYmYyYTcwYWUxMDNkNDVlNy90YWJsZXJhbmdlOmZhNGY1NGFlZWM1ODQ0MGJiZjJhNzBhZTEwM2Q0NWU3XzI1LTUtMS0xLTM2NTMw_8406b797-b4f2-4393-afb6-7781b7fc5076">0.01</ix:nonFraction></ix:nonFraction>)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="iddbf996a3b1a4aeda47f1e8169c69262_D20200101-20200331" decimals="2" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMzAvZnJhZzo3NGIwMjA4NWYwNjY0MjYyOGY3OWUzMTNlNjFkZmI3Yy90YWJsZTpmYTRmNTRhZWVjNTg0NDBiYmYyYTcwYWUxMDNkNDVlNy90YWJsZXJhbmdlOmZhNGY1NGFlZWM1ODQ0MGJiZjJhNzBhZTEwM2Q0NWU3XzI1LTctMS0xLTM2NTMy_0a932461-164b-4bf3-9774-79abbfaea65f"><ix:nonFraction unitRef="usdPerShare" contextRef="iddbf996a3b1a4aeda47f1e8169c69262_D20200101-20200331" decimals="2" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMzAvZnJhZzo3NGIwMjA4NWYwNjY0MjYyOGY3OWUzMTNlNjFkZmI3Yy90YWJsZTpmYTRmNTRhZWVjNTg0NDBiYmYyYTcwYWUxMDNkNDVlNy90YWJsZXJhbmdlOmZhNGY1NGFlZWM1ODQ0MGJiZjJhNzBhZTEwM2Q0NWU3XzI1LTctMS0xLTM2NTMy_d3214475-e409-4186-89a3-b67b2118eb6e">&#8212;</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">119</span></div></div></div><div id="i9aaa2fddc97e482da5dbe37ac85ae703_133"></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 25.  <ix:nonNumeric contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231" name="us-gaap:CashFlowSupplementalDisclosuresTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMzMvZnJhZzpmYTExMDg1YWMxYTA0ZTdhYWJlNjA4ZGRmNjhmY2VlZS90ZXh0cmVnaW9uOmZhMTEwODVhYzFhMDRlN2FhYmU2MDhkZGY2OGZjZWVlXzEzNA_3ff9f525-83e8-401e-8997-c5f428edcf71" continuedAt="i9adc84331b6b472a96a312699f67354b" escape="true">Supplemental Cash Flow Information </ix:nonNumeric></span></div><div style="text-align:justify"><span><br/></span></div><ix:continuation id="i9adc84331b6b472a96a312699f67354b"><ix:nonNumeric contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231" name="us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMzMvZnJhZzpmYTExMDg1YWMxYTA0ZTdhYWJlNjA4ZGRmNjhmY2VlZS90ZXh0cmVnaW9uOmZhMTEwODVhYzFhMDRlN2FhYmU2MDhkZGY2OGZjZWVlXzEzOA_7f172474-1532-48f5-a9c1-6119585e87ec" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following represents supplemental cash flow information the years ended December 31, 2021, 2020 and 2019 (in thousands):</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"></td><td style="width:380.50pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:48.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:48.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:48.25pt"></td><td style="width:1.0pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Year Ended December 31,</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Supplemental Disclosure of Non-cash Investing and Financing Activities</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Class A and Class B common stock issued in connection with business combinations</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231" decimals="-3" name="us-gaap:StockIssued1" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMzMvZnJhZzpmYTExMDg1YWMxYTA0ZTdhYWJlNjA4ZGRmNjhmY2VlZS90YWJsZTpiYzAwYmQ2YjAwNzk0MzE1OTE1M2JmYmY5YjAxZTE4MC90YWJsZXJhbmdlOmJjMDBiZDZiMDA3OTQzMTU5MTUzYmZiZjliMDFlMTgwXzMtMS0xLTEtMjMwNDY_9e889208-4f8a-476e-9489-807a3329171c">56,626</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i12a6d1161de54547bd29f8efccd4c9b0_D20200101-20201231" decimals="-3" name="us-gaap:StockIssued1" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMzMvZnJhZzpmYTExMDg1YWMxYTA0ZTdhYWJlNjA4ZGRmNjhmY2VlZS90YWJsZTpiYzAwYmQ2YjAwNzk0MzE1OTE1M2JmYmY5YjAxZTE4MC90YWJsZXJhbmdlOmJjMDBiZDZiMDA3OTQzMTU5MTUzYmZiZjliMDFlMTgwXzMtMy0xLTEtMjMwNDY_509a01e9-77df-4a3d-bd95-4ac822328f72">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e21049ffc224cacb8134d73c9bb5b38_D20190101-20191231" decimals="-3" name="us-gaap:StockIssued1" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMzMvZnJhZzpmYTExMDg1YWMxYTA0ZTdhYWJlNjA4ZGRmNjhmY2VlZS90YWJsZTpiYzAwYmQ2YjAwNzk0MzE1OTE1M2JmYmY5YjAxZTE4MC90YWJsZXJhbmdlOmJjMDBiZDZiMDA3OTQzMTU5MTUzYmZiZjliMDFlMTgwXzMtNS0xLTEtMjMwNDY_ab6f6bb9-27ad-4eb9-b26e-700b3f2876ff">23,556</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;Increase/decrease to goodwill from measurement period adjustments/business combinations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231" decimals="-3" name="evh:NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationMeasurementPeriodAdjustment" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMzMvZnJhZzpmYTExMDg1YWMxYTA0ZTdhYWJlNjA4ZGRmNjhmY2VlZS90YWJsZTpiYzAwYmQ2YjAwNzk0MzE1OTE1M2JmYmY5YjAxZTE4MC90YWJsZXJhbmdlOmJjMDBiZDZiMDA3OTQzMTU5MTUzYmZiZjliMDFlMTgwXzMtMS0xLTEtMTc3NzU_336547e3-5cfc-4010-be5b-9b537f2ca141">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i12a6d1161de54547bd29f8efccd4c9b0_D20200101-20201231" decimals="-3" name="evh:NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationMeasurementPeriodAdjustment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMzMvZnJhZzpmYTExMDg1YWMxYTA0ZTdhYWJlNjA4ZGRmNjhmY2VlZS90YWJsZTpiYzAwYmQ2YjAwNzk0MzE1OTE1M2JmYmY5YjAxZTE4MC90YWJsZXJhbmdlOmJjMDBiZDZiMDA3OTQzMTU5MTUzYmZiZjliMDFlMTgwXzMtMy0xLTEtMTc3NzU_01c310d1-1f91-4a8d-bb2f-081b540a866f">2,200</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3e21049ffc224cacb8134d73c9bb5b38_D20190101-20191231" decimals="-3" sign="-" name="evh:NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationMeasurementPeriodAdjustment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMzMvZnJhZzpmYTExMDg1YWMxYTA0ZTdhYWJlNjA4ZGRmNjhmY2VlZS90YWJsZTpiYzAwYmQ2YjAwNzk0MzE1OTE1M2JmYmY5YjAxZTE4MC90YWJsZXJhbmdlOmJjMDBiZDZiMDA3OTQzMTU5MTUzYmZiZjliMDFlMTgwXzQtNS0xLTEtMjMwNTU_643114ec-e575-435c-a283-579d57f6f024">351</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Class A common stock issued for payment of earn-outs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231" decimals="-3" name="us-gaap:NoncashOrPartNoncashAcquisitionPayablesAssumed1" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMzMvZnJhZzpmYTExMDg1YWMxYTA0ZTdhYWJlNjA4ZGRmNjhmY2VlZS90YWJsZTpiYzAwYmQ2YjAwNzk0MzE1OTE1M2JmYmY5YjAxZTE4MC90YWJsZXJhbmdlOmJjMDBiZDZiMDA3OTQzMTU5MTUzYmZiZjliMDFlMTgwXzQtMS0xLTEtMTc3NzU_c30f4752-c3a5-4c03-ad72-5c7687617d93">450</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i12a6d1161de54547bd29f8efccd4c9b0_D20200101-20201231" decimals="-3" name="us-gaap:NoncashOrPartNoncashAcquisitionPayablesAssumed1" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMzMvZnJhZzpmYTExMDg1YWMxYTA0ZTdhYWJlNjA4ZGRmNjhmY2VlZS90YWJsZTpiYzAwYmQ2YjAwNzk0MzE1OTE1M2JmYmY5YjAxZTE4MC90YWJsZXJhbmdlOmJjMDBiZDZiMDA3OTQzMTU5MTUzYmZiZjliMDFlMTgwXzQtMy0xLTEtMTc3NzU_813fb96b-10b9-44d2-8b66-e34b0dd9f85f">4,185</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e21049ffc224cacb8134d73c9bb5b38_D20190101-20191231" decimals="-3" name="us-gaap:NoncashOrPartNoncashAcquisitionPayablesAssumed1" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMzMvZnJhZzpmYTExMDg1YWMxYTA0ZTdhYWJlNjA4ZGRmNjhmY2VlZS90YWJsZTpiYzAwYmQ2YjAwNzk0MzE1OTE1M2JmYmY5YjAxZTE4MC90YWJsZXJhbmdlOmJjMDBiZDZiMDA3OTQzMTU5MTUzYmZiZjliMDFlMTgwXzUtNS0xLTEtMjMwNTU_619dec06-78b8-49d9-9d97-ad2894de7bbe">800</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;Class A common stock issued in connection with debt repayment </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231" decimals="-3" name="evh:StockIssuedInConnectionWithDebtRepayment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMzMvZnJhZzpmYTExMDg1YWMxYTA0ZTdhYWJlNjA4ZGRmNjhmY2VlZS90YWJsZTpiYzAwYmQ2YjAwNzk0MzE1OTE1M2JmYmY5YjAxZTE4MC90YWJsZXJhbmdlOmJjMDBiZDZiMDA3OTQzMTU5MTUzYmZiZjliMDFlMTgwXzYtMS0xLTEtMzMyMDQ_e5526c16-67ac-44ed-bb5b-c3cc182fbab0">28,492</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i12a6d1161de54547bd29f8efccd4c9b0_D20200101-20201231" decimals="-3" name="evh:StockIssuedInConnectionWithDebtRepayment" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMzMvZnJhZzpmYTExMDg1YWMxYTA0ZTdhYWJlNjA4ZGRmNjhmY2VlZS90YWJsZTpiYzAwYmQ2YjAwNzk0MzE1OTE1M2JmYmY5YjAxZTE4MC90YWJsZXJhbmdlOmJjMDBiZDZiMDA3OTQzMTU5MTUzYmZiZjliMDFlMTgwXzYtMy0xLTEtMzMyMDQ_81199ea5-73ec-450e-967f-4be02fc46935">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e21049ffc224cacb8134d73c9bb5b38_D20190101-20191231" decimals="-3" name="evh:StockIssuedInConnectionWithDebtRepayment" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMzMvZnJhZzpmYTExMDg1YWMxYTA0ZTdhYWJlNjA4ZGRmNjhmY2VlZS90YWJsZTpiYzAwYmQ2YjAwNzk0MzE1OTE1M2JmYmY5YjAxZTE4MC90YWJsZXJhbmdlOmJjMDBiZDZiMDA3OTQzMTU5MTUzYmZiZjliMDFlMTgwXzYtNS0xLTEtMzMyMDQ_2c0c0a64-b4cf-4d8d-9cba-7da8238310ec">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain from transfer of membership</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231" decimals="-3" name="evh:GainLossFromTransferOfMembership" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMzMvZnJhZzpmYTExMDg1YWMxYTA0ZTdhYWJlNjA4ZGRmNjhmY2VlZS90YWJsZTpiYzAwYmQ2YjAwNzk0MzE1OTE1M2JmYmY5YjAxZTE4MC90YWJsZXJhbmdlOmJjMDBiZDZiMDA3OTQzMTU5MTUzYmZiZjliMDFlMTgwXzctMS0xLTEtMzMyMDQ_0b8bb3c7-e82a-418b-ad62-ef758a1af0c1">22,969</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i12a6d1161de54547bd29f8efccd4c9b0_D20200101-20201231" decimals="-3" name="evh:GainLossFromTransferOfMembership" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMzMvZnJhZzpmYTExMDg1YWMxYTA0ZTdhYWJlNjA4ZGRmNjhmY2VlZS90YWJsZTpiYzAwYmQ2YjAwNzk0MzE1OTE1M2JmYmY5YjAxZTE4MC90YWJsZXJhbmdlOmJjMDBiZDZiMDA3OTQzMTU5MTUzYmZiZjliMDFlMTgwXzctMy0xLTEtMzMyMDQ_9b9416bc-dc07-45a5-84c6-632ce1a8271d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e21049ffc224cacb8134d73c9bb5b38_D20190101-20191231" decimals="-3" name="evh:GainLossFromTransferOfMembership" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMzMvZnJhZzpmYTExMDg1YWMxYTA0ZTdhYWJlNjA4ZGRmNjhmY2VlZS90YWJsZTpiYzAwYmQ2YjAwNzk0MzE1OTE1M2JmYmY5YjAxZTE4MC90YWJsZXJhbmdlOmJjMDBiZDZiMDA3OTQzMTU5MTUzYmZiZjliMDFlMTgwXzctNS0xLTEtMzMyMDQ_22002bc5-d9a7-43ef-83cb-0fae8940d042">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued property and equipment purchases</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231" decimals="-3" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMzMvZnJhZzpmYTExMDg1YWMxYTA0ZTdhYWJlNjA4ZGRmNjhmY2VlZS90YWJsZTpiYzAwYmQ2YjAwNzk0MzE1OTE1M2JmYmY5YjAxZTE4MC90YWJsZXJhbmdlOmJjMDBiZDZiMDA3OTQzMTU5MTUzYmZiZjliMDFlMTgwXzUtMS0xLTEtMTc3NzU_e87405ae-4afa-4731-b99c-fda207f8704a">784</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i12a6d1161de54547bd29f8efccd4c9b0_D20200101-20201231" decimals="-3" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMzMvZnJhZzpmYTExMDg1YWMxYTA0ZTdhYWJlNjA4ZGRmNjhmY2VlZS90YWJsZTpiYzAwYmQ2YjAwNzk0MzE1OTE1M2JmYmY5YjAxZTE4MC90YWJsZXJhbmdlOmJjMDBiZDZiMDA3OTQzMTU5MTUzYmZiZjliMDFlMTgwXzUtMy0xLTEtMTc3NzU_7a33b9f8-af5c-4d1b-8418-6fce6797f0e1">11</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3e21049ffc224cacb8134d73c9bb5b38_D20190101-20191231" decimals="-3" name="evh:AccruedPropertyAndEquipmentPurchases" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMzMvZnJhZzpmYTExMDg1YWMxYTA0ZTdhYWJlNjA4ZGRmNjhmY2VlZS90YWJsZTpiYzAwYmQ2YjAwNzk0MzE1OTE1M2JmYmY5YjAxZTE4MC90YWJsZXJhbmdlOmJjMDBiZDZiMDA3OTQzMTU5MTUzYmZiZjliMDFlMTgwXzYtNS0xLTEtMjMxMTc_553436e8-f5d5-400c-9e7c-8939e950da92">527</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Consideration for asset acquisition or business combinations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231" decimals="-3" name="us-gaap:NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMzMvZnJhZzpmYTExMDg1YWMxYTA0ZTdhYWJlNjA4ZGRmNjhmY2VlZS90YWJsZTpiYzAwYmQ2YjAwNzk0MzE1OTE1M2JmYmY5YjAxZTE4MC90YWJsZXJhbmdlOmJjMDBiZDZiMDA3OTQzMTU5MTUzYmZiZjliMDFlMTgwXzgtMS0xLTEtMjMxMjc_19f8997c-ce5e-4adf-9d1f-b3c7392547c2">14,600</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i12a6d1161de54547bd29f8efccd4c9b0_D20200101-20201231" decimals="-3" name="us-gaap:NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMzMvZnJhZzpmYTExMDg1YWMxYTA0ZTdhYWJlNjA4ZGRmNjhmY2VlZS90YWJsZTpiYzAwYmQ2YjAwNzk0MzE1OTE1M2JmYmY5YjAxZTE4MC90YWJsZXJhbmdlOmJjMDBiZDZiMDA3OTQzMTU5MTUzYmZiZjliMDFlMTgwXzgtMy0xLTEtMjMxMjc_e40587de-8756-41b7-9cd5-f9726064f642">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e21049ffc224cacb8134d73c9bb5b38_D20190101-20191231" decimals="-3" name="us-gaap:NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMzMvZnJhZzpmYTExMDg1YWMxYTA0ZTdhYWJlNjA4ZGRmNjhmY2VlZS90YWJsZTpiYzAwYmQ2YjAwNzk0MzE1OTE1M2JmYmY5YjAxZTE4MC90YWJsZXJhbmdlOmJjMDBiZDZiMDA3OTQzMTU5MTUzYmZiZjliMDFlMTgwXzgtNS0xLTEtMjMxMjc_19c4be09-2b1d-44db-95db-1921e932eb9f">16,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Effects of Leases</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;Operating cash flows from operating leases </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231" decimals="-3" name="us-gaap:OperatingLeasePayments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMzMvZnJhZzpmYTExMDg1YWMxYTA0ZTdhYWJlNjA4ZGRmNjhmY2VlZS90YWJsZTpiYzAwYmQ2YjAwNzk0MzE1OTE1M2JmYmY5YjAxZTE4MC90YWJsZXJhbmdlOmJjMDBiZDZiMDA3OTQzMTU5MTUzYmZiZjliMDFlMTgwXzgtMS0xLTEtMTc3NzU_d7ef3dfc-fe1c-4ea9-aedc-0fb10601cc89">13,845</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i12a6d1161de54547bd29f8efccd4c9b0_D20200101-20201231" decimals="-3" name="us-gaap:OperatingLeasePayments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMzMvZnJhZzpmYTExMDg1YWMxYTA0ZTdhYWJlNjA4ZGRmNjhmY2VlZS90YWJsZTpiYzAwYmQ2YjAwNzk0MzE1OTE1M2JmYmY5YjAxZTE4MC90YWJsZXJhbmdlOmJjMDBiZDZiMDA3OTQzMTU5MTUzYmZiZjliMDFlMTgwXzgtMy0xLTEtMTc3NzU_ebf3ce48-e7a7-43d0-89c6-4777d868aca0">13,708</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e21049ffc224cacb8134d73c9bb5b38_D20190101-20191231" decimals="-3" name="us-gaap:OperatingLeasePayments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMzMvZnJhZzpmYTExMDg1YWMxYTA0ZTdhYWJlNjA4ZGRmNjhmY2VlZS90YWJsZTpiYzAwYmQ2YjAwNzk0MzE1OTE1M2JmYmY5YjAxZTE4MC90YWJsZXJhbmdlOmJjMDBiZDZiMDA3OTQzMTU5MTUzYmZiZjliMDFlMTgwXzktNS0xLTEtMjMxMDM_a7fa84e2-4241-473f-b88c-aa41b75fd315">12,330</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;Leased assets obtained in exchange for operating lease liabilities </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231" decimals="-3" name="evh:RightOfUseAssetAcquiredAndDisposedOf" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMzMvZnJhZzpmYTExMDg1YWMxYTA0ZTdhYWJlNjA4ZGRmNjhmY2VlZS90YWJsZTpiYzAwYmQ2YjAwNzk0MzE1OTE1M2JmYmY5YjAxZTE4MC90YWJsZXJhbmdlOmJjMDBiZDZiMDA3OTQzMTU5MTUzYmZiZjliMDFlMTgwXzktMS0xLTEtMTc3NzU_11f88147-b8b9-4468-b991-27be2a876baf">2,583</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i12a6d1161de54547bd29f8efccd4c9b0_D20200101-20201231" decimals="-3" name="evh:RightOfUseAssetAcquiredAndDisposedOf" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMzMvZnJhZzpmYTExMDg1YWMxYTA0ZTdhYWJlNjA4ZGRmNjhmY2VlZS90YWJsZTpiYzAwYmQ2YjAwNzk0MzE1OTE1M2JmYmY5YjAxZTE4MC90YWJsZXJhbmdlOmJjMDBiZDZiMDA3OTQzMTU5MTUzYmZiZjliMDFlMTgwXzktMy0xLTEtMTc3NzU_bfcb7c67-9c54-4116-8f1c-c2aed8db1c22">2,170</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e21049ffc224cacb8134d73c9bb5b38_D20190101-20191231" decimals="-3" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMzMvZnJhZzpmYTExMDg1YWMxYTA0ZTdhYWJlNjA4ZGRmNjhmY2VlZS90YWJsZTpiYzAwYmQ2YjAwNzk0MzE1OTE1M2JmYmY5YjAxZTE4MC90YWJsZXJhbmdlOmJjMDBiZDZiMDA3OTQzMTU5MTUzYmZiZjliMDFlMTgwXzEwLTUtMS0xLTIzMTAz_03a1b0df-ae97-44ea-ad75-3a06a4f4d0b7">30,463</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Effects of Class B Exchanges</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Decrease in non-controlling interests as a result of Class B Exchanges</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231" decimals="-3" name="us-gaap:ConversionOfStockAmountConverted1" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMzMvZnJhZzpmYTExMDg1YWMxYTA0ZTdhYWJlNjA4ZGRmNjhmY2VlZS90YWJsZTpiYzAwYmQ2YjAwNzk0MzE1OTE1M2JmYmY5YjAxZTE4MC90YWJsZXJhbmdlOmJjMDBiZDZiMDA3OTQzMTU5MTUzYmZiZjliMDFlMTgwXzEyLTEtMS0xLTIzMDcy_d776d98b-2326-4b07-aaa1-294d4ba6acd7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i12a6d1161de54547bd29f8efccd4c9b0_D20200101-20201231" decimals="-3" name="us-gaap:ConversionOfStockAmountConverted1" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMzMvZnJhZzpmYTExMDg1YWMxYTA0ZTdhYWJlNjA4ZGRmNjhmY2VlZS90YWJsZTpiYzAwYmQ2YjAwNzk0MzE1OTE1M2JmYmY5YjAxZTE4MC90YWJsZXJhbmdlOmJjMDBiZDZiMDA3OTQzMTU5MTUzYmZiZjliMDFlMTgwXzEyLTMtMS0xLTIzMDcy_3dbd3100-7d57-40e4-ac63-4a67adf41548">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e21049ffc224cacb8134d73c9bb5b38_D20190101-20191231" decimals="-3" name="us-gaap:ConversionOfStockAmountConverted1" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMzMvZnJhZzpmYTExMDg1YWMxYTA0ZTdhYWJlNjA4ZGRmNjhmY2VlZS90YWJsZTpiYzAwYmQ2YjAwNzk0MzE1OTE1M2JmYmY5YjAxZTE4MC90YWJsZXJhbmdlOmJjMDBiZDZiMDA3OTQzMTU5MTUzYmZiZjliMDFlMTgwXzEyLTUtMS0xLTIzMDcy_38f96d7e-5c95-49da-9965-2409f4661f07">42,377</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Decrease in deferred tax liability as a result of securities offerings and exchanges</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231" decimals="-3" name="evh:StockIssuedDecreaseInDeferredTaxLiability" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMzMvZnJhZzpmYTExMDg1YWMxYTA0ZTdhYWJlNjA4ZGRmNjhmY2VlZS90YWJsZTpiYzAwYmQ2YjAwNzk0MzE1OTE1M2JmYmY5YjAxZTE4MC90YWJsZXJhbmdlOmJjMDBiZDZiMDA3OTQzMTU5MTUzYmZiZjliMDFlMTgwXzEzLTEtMS0xLTIzMDcy_157ba297-e029-4933-a7f6-cad61424648f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i12a6d1161de54547bd29f8efccd4c9b0_D20200101-20201231" decimals="-3" name="evh:StockIssuedDecreaseInDeferredTaxLiability" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMzMvZnJhZzpmYTExMDg1YWMxYTA0ZTdhYWJlNjA4ZGRmNjhmY2VlZS90YWJsZTpiYzAwYmQ2YjAwNzk0MzE1OTE1M2JmYmY5YjAxZTE4MC90YWJsZXJhbmdlOmJjMDBiZDZiMDA3OTQzMTU5MTUzYmZiZjliMDFlMTgwXzEzLTMtMS0xLTIzMDcy_92c802f1-645f-415a-8ed4-cbab9399d5b2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3e21049ffc224cacb8134d73c9bb5b38_D20190101-20191231" decimals="-3" sign="-" name="evh:StockIssuedDecreaseInDeferredTaxLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMzMvZnJhZzpmYTExMDg1YWMxYTA0ZTdhYWJlNjA4ZGRmNjhmY2VlZS90YWJsZTpiYzAwYmQ2YjAwNzk0MzE1OTE1M2JmYmY5YjAxZTE4MC90YWJsZXJhbmdlOmJjMDBiZDZiMDA3OTQzMTU5MTUzYmZiZjliMDFlMTgwXzEzLTUtMS0xLTIzMDcy_c6d7f01a-bfe9-4103-92f2-6eab736768a0">22</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Supplemental Disclosures </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid for interest</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231" decimals="-3" name="us-gaap:InterestPaidNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMzMvZnJhZzpmYTExMDg1YWMxYTA0ZTdhYWJlNjA4ZGRmNjhmY2VlZS90YWJsZTpiYzAwYmQ2YjAwNzk0MzE1OTE1M2JmYmY5YjAxZTE4MC90YWJsZXJhbmdlOmJjMDBiZDZiMDA3OTQzMTU5MTUzYmZiZjliMDFlMTgwXzE2LTEtMS0xLTIzMDky_1aff8505-a149-4607-acee-988484d769e0">7,113</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i12a6d1161de54547bd29f8efccd4c9b0_D20200101-20201231" decimals="-3" name="us-gaap:InterestPaidNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMzMvZnJhZzpmYTExMDg1YWMxYTA0ZTdhYWJlNjA4ZGRmNjhmY2VlZS90YWJsZTpiYzAwYmQ2YjAwNzk0MzE1OTE1M2JmYmY5YjAxZTE4MC90YWJsZXJhbmdlOmJjMDBiZDZiMDA3OTQzMTU5MTUzYmZiZjliMDFlMTgwXzE2LTMtMS0xLTIzMDky_fc562177-9f04-4966-b69f-466a60034117">13,352</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e21049ffc224cacb8134d73c9bb5b38_D20190101-20191231" decimals="-3" name="us-gaap:InterestPaidNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMzMvZnJhZzpmYTExMDg1YWMxYTA0ZTdhYWJlNjA4ZGRmNjhmY2VlZS90YWJsZTpiYzAwYmQ2YjAwNzk0MzE1OTE1M2JmYmY5YjAxZTE4MC90YWJsZXJhbmdlOmJjMDBiZDZiMDA3OTQzMTU5MTUzYmZiZjliMDFlMTgwXzE2LTUtMS0xLTIzMDky_89ecf7c2-8920-4f87-8f9a-e20df9e021fd">5,037</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid for taxes, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231" decimals="-3" name="us-gaap:IncomeTaxesPaid" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMzMvZnJhZzpmYTExMDg1YWMxYTA0ZTdhYWJlNjA4ZGRmNjhmY2VlZS90YWJsZTpiYzAwYmQ2YjAwNzk0MzE1OTE1M2JmYmY5YjAxZTE4MC90YWJsZXJhbmdlOmJjMDBiZDZiMDA3OTQzMTU5MTUzYmZiZjliMDFlMTgwXzE3LTEtMS0xLTIzMDky_73b7d954-3ab2-4373-b340-30895233935a">551</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i12a6d1161de54547bd29f8efccd4c9b0_D20200101-20201231" decimals="-3" name="us-gaap:IncomeTaxesPaid" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMzMvZnJhZzpmYTExMDg1YWMxYTA0ZTdhYWJlNjA4ZGRmNjhmY2VlZS90YWJsZTpiYzAwYmQ2YjAwNzk0MzE1OTE1M2JmYmY5YjAxZTE4MC90YWJsZXJhbmdlOmJjMDBiZDZiMDA3OTQzMTU5MTUzYmZiZjliMDFlMTgwXzE3LTMtMS0xLTIzMDky_1eaa4304-42f7-4fee-835d-8b04efd94ece">9,679</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e21049ffc224cacb8134d73c9bb5b38_D20190101-20191231" decimals="-3" name="us-gaap:IncomeTaxesPaid" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMzMvZnJhZzpmYTExMDg1YWMxYTA0ZTdhYWJlNjA4ZGRmNjhmY2VlZS90YWJsZTpiYzAwYmQ2YjAwNzk0MzE1OTE1M2JmYmY5YjAxZTE4MC90YWJsZXJhbmdlOmJjMDBiZDZiMDA3OTQzMTU5MTUzYmZiZjliMDFlMTgwXzE3LTUtMS0xLTIzMDky_ebcd76ed-b5be-41d1-8465-1f9acb9ded05">1,484</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="text-align:justify"><span><br/></span></div><div><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">120</span></div></div></div><div id="i9aaa2fddc97e482da5dbe37ac85ae703_271"></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 9.  Changes in and Disagreements with Accountants on Accounting and Financial Disclosure</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div style="text-align:justify"><span><br/></span></div><div id="i9aaa2fddc97e482da5dbe37ac85ae703_169"></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 9A.  Controls and Procedures</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Evaluation of Disclosure Controls and Procedures </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our management, with the participation of our principal executive officer and principal financial officer, has evaluated the effectiveness of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended, as of the end of the period covered by this Annual Report on Form 10-K. The Chief Executive Officer (CEO) and the Chief Financial Officer (CFO), with assistance from other members of management, have reviewed the effectiveness of our disclosure controls and procedures as of December 31, 2021 and, based on their evaluation, have concluded that the disclosure controls and procedures were effective as of such date.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Management's Annual Report on Internal Control Over Financial Reporting</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our management is responsible for establishing and maintaining adequate internal control over financial reporting as defined in Rule 13a-15(f) under the Exchange Act. Our internal control over financial reporting is designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with U.S. GAAP.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As permitted by the SEC rules, we excluded Vital Decisions from our assessment of internal control over financial reporting as of December 31, 2021. This exclusion considers SEC guidance on newly acquired entities which may allow companies to exclude acquired entities from their assessment of internal control over financial reporting during the first year following the acquisition. Vital Decisions was acquired during the fourth quarter of 2021 through a business combination and is a wholly-owned subsidiary whose total assets excluded from management's assessment represent 8.8% and total revenues excluded from management's assessment represent 0.5% of the related consolidated financial statement amounts as of and for the year ended December 31, 2021.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the supervision of and with the participation of our management, we assessed the effectiveness of our internal control over financial reporting as of December 31, 2021, using the criteria set forth by the Committee of Sponsoring Organizations of the Treadway Commission (COSO) in Internal Control&#8212;Integrated Framework.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Changes in Internal Control over Financial Reporting</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no changes in our internal control over financial reporting during the year ended December 31, 2021 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have not experienced any material impact to our internal controls over financial reporting despite the fact that most of our employees are working remotely due to the COVID-19 pandemic. We are continually monitoring and assessing the COVID-19 situation on our internal controls to minimize the impact on their design and operating effectiveness.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Inherent Limitations of Internal Controls</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our management, including our principal executive officer and principal financial officer, does not expect that our disclosure controls and procedures or our internal control over financial reporting will prevent all errors and all fraud. A control system, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, within the Company have been detected. These inherent limitations include the realities that judgments in decision-making can be faulty, and that breakdowns can occur because of a simple error or mistake. Additionally, controls can be circumvented by the individual acts of some persons, by collusion of two or more people, or by management override of the control. The design of any system of controls also is based in part upon certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions. Over time, controls may become inadequate because of changes in conditions, or the degree of compliance with the policies or procedures may deteriorate. Because of the inherent limitations in a cost-effective control system, misstatements due to error or fraud may occur and not be detected.</span></div><div style="text-align:justify"><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">121</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">To the shareholders and the Board of Directors of Evolent Health, Inc.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Opinion on Internal Control over Financial Reporting</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have audited the internal control over financial reporting of Evolent Health, Inc. and subsidiaries (the &#8220;Company&#8221;) as of December 31, 2021, based on criteria established in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Internal Control &#8212; Integrated Framework (2013)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> issued by the Committee of Sponsoring Organizations of the Treadway Commission (COSO). In our opinion, the Company maintained, in all material respects, effective internal control over financial reporting as of December 31, 2021, based on criteria established in I</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">nternal Control &#8212; Integrated Framework (2013)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> issued by COSO.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have also audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the consolidated financial statements as of and for the year ended December 31, 2021, of the Company and our report dated February 23, 2022, expressed an unqualified opinion on those financial statements.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As described in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Management's Annual Report on Internal Control Over Financial Reporting</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, management excluded from its assessment the internal control over financial reporting at Vital Decisions, which was acquired on October 1, 2021, and whose financial statements constitute 9% of total assets and 1% of revenue of the consolidated financial statement amounts as of and for the year ended December 31, 2021. Accordingly, our audit did not include the internal control over financial reporting at Vital Decisions.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Basis for Opinion </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s management is responsible for maintaining effective internal control over financial reporting and for its assessment of the effectiveness of internal control over financial reporting, included in the accompanying Management&#8217;s Annual Report on Internal Control over Financial Reporting. Our responsibility is to express an opinion on the Company&#8217;s internal control over financial reporting based on our audit. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We conducted our audit in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether effective internal control over financial reporting was maintained in all material respects. Our audit included obtaining an understanding of internal control over financial reporting, assessing the risk that a material weakness exists, testing and evaluating the design and operating effectiveness of internal control based on the assessed risk, and performing such other procedures as we considered necessary in the circumstances. We believe that our audit provides a reasonable basis for our opinion.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Definition and Limitations of Internal Control over Financial Reporting</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A company&#8217;s internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company&#8217;s internal control over financial reporting includes those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company&#8217;s assets that could have a material effect on the financial statements.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Deloitte &amp; Touche LLP</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">McLean, Virginia </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 23, 2022  </span></div><div style="text-align:justify"><span><br/></span></div><div id="i9aaa2fddc97e482da5dbe37ac85ae703_208"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 9B.  Other Information</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div><span><br/></span></div><div><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">122</span></div></div></div><div id="i9aaa2fddc97e482da5dbe37ac85ae703_2529"></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 9C.  Disclosure Regarding Foreign Jurisdictions that Prevent Inspections</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">123</span></div></div></div><div id="i9aaa2fddc97e482da5dbe37ac85ae703_220"></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART III</span></div><div style="text-align:center"><span><br/></span></div><div id="i9aaa2fddc97e482da5dbe37ac85ae703_223"></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 10.  Directors, Executive Officers and Corporate Governance</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"> </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information called for by this Item 10 pertaining to Directors is incorporated herein by reference to Evolent Health, Inc.&#8217;s definitive proxy statement for the Annual Meeting of Shareholders to be held on June 9, 2022, to be filed by Evolent Health, Inc. with the SEC pursuant to Regulation&#160;14A within 120&#160;days after the year ended December&#160;31, 2021&#160;(the &#8220;2022 Proxy Statement&#8221;).</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information called for by this Item 10 pertaining to Executive Officers appears in &#8220;Part I - Item 1.  Business - Information about our Executive Officers&#8221; in this Annual Report on Form 10-K and our&#160;2022&#160;Proxy Statement.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"> </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have adopted a Code of Business Conduct and Ethics that applies to all of our directors, officers and employees, including our principal executive officer and principal financial officer. The Code of Business Conduct and Ethics is posted on our investor relations website (ir.evolenthealth.com) under &#8220;Corporate Governance.&#8221; We intend to satisfy the SEC&#8217;s disclosure requirements regarding amendments to, or waivers of, the code of ethics by posting such information on our website.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span></div><div id="i9aaa2fddc97e482da5dbe37ac85ae703_226"></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 11.  Executive Compensation</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"> </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Information required by this Item&#160;11 is incorporated herein by reference to our 2022 Proxy Statement.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span></div><div id="i9aaa2fddc97e482da5dbe37ac85ae703_229"></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 12.  Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Information required by this Item&#160;12 is incorporated herein by reference to our 2022 Proxy Statement.</span></div><div><span><br/></span></div><div id="i9aaa2fddc97e482da5dbe37ac85ae703_232"></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 13.  Certain Relationships and Related Transactions, and Director Independence</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"> </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Information required by this Item&#160;13 is incorporated herein by reference to our 2022 Proxy Statement.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"> </span></div><div id="i9aaa2fddc97e482da5dbe37ac85ae703_235"></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 14.  Principal Accounting Fees and Services</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"> </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Information required by this Item&#160;14 is incorporated herein by reference to our 2022 Proxy Statement.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"> </span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">124</span></div></div></div><div id="i9aaa2fddc97e482da5dbe37ac85ae703_238"></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART IV</span></div><div id="i9aaa2fddc97e482da5dbe37ac85ae703_211"></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 15.  Exhibits</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a) The following documents are filed as part of this report:</span></div><div style="padding-left:36pt;text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1) The following financial statements of the registrant and report of independent registered public accounting firm are included of Item 8 hereof:</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9aaa2fddc97e482da5dbe37ac85ae703_241">Report of Independent Registered Public Accounting Firm (PCAOB ID No. 34)</a></span></div><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9aaa2fddc97e482da5dbe37ac85ae703_22">Consolidated Balance Sheets</a></span></div><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9aaa2fddc97e482da5dbe37ac85ae703_25">Consolidated Statements of Operations and Comprehensive Income (Loss)</a></span></div><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9aaa2fddc97e482da5dbe37ac85ae703_28">Consolidated Statements of Changes in Shareholders&#8217; Equity (Deficit)</a></span></div><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9aaa2fddc97e482da5dbe37ac85ae703_34">Consolidated Statements of Cash Flows</a></span></div><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9aaa2fddc97e482da5dbe37ac85ae703_37">Notes to Consolidated Financial Statements</a></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2) All financial statement schedules for which provision is made in the applicable accounting regulations of the Securities and Exchange Commission either have been included in the Financial Statements, are not required under the related instructions, or are not applicable and therefore have been omitted.</span></div><div style="padding-left:36pt;text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(3) The Exhibits listed in the Exhibit Index below are filed with or incorporated by reference into this report.</span></div><div style="text-align:justify"><span><br/></span></div><div id="i9aaa2fddc97e482da5dbe37ac85ae703_214"></div><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EVOLENT HEALTH, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit Index</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"></td><td style="width:42.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:490.00pt"></td><td style="width:1.0pt"></td></tr><tr style="height:44pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1628908/000162890816000056/a71216exhibit21.htm">2.1*</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1628908/000162890816000056/a71216exhibit21.htm">Agreement and Plan of Merger, dated July 12, 2016, by and among Evolent Health, Inc., Electra Merger Sub, LLC, Valence Health, Inc. and North Bridge Growth Management Company LLC and Philip Kamp, in their capacity as the Securityholders&#8217; Representative, filed as Exhibit 2.1 to the Company&#8217;s Report on Form 8-K filed with the SEC on July 14, 2016, and incorporated herein by reference</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.</span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:44pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1628908/000162890816000066/a10316exhibit22.htm">2.2*</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1628908/000162890816000066/a10316exhibit22.htm">First Amendment to Agreement and Plan of Merger, dated October 3, 2016, by and among Evolent Health, Inc., Electra Merger Sub, LLC, Valence Health, Inc. and North Bridge Growth Management Company LLC and Philip Kamp, in their capacity as securityholders&#8217; representative, filed as Exhibit 2.2 to the Company&#8217;s Report on Form 8-K filed with the SEC on October 3, 2016, and incorporated herein by reference</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.</span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:44pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1628908/000162890818000069/a912188-kexhibit21.htm">2.3*</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1628908/000162890818000069/a912188-kexhibit21.htm">Agreement and Plan of Merger, dated September 7, 2018, by and among Evolent Health, Inc., Evolent Health LLC, Element Merger Sub, Inc., NCIS Holdings, Inc. and New Century Investment, LLC, in the capacity set forth therein, filed as Exhibit 2.1 to the Company&#8217;s Report on Form 8-K filed with the SEC on September 12, 2018, and incorporated herein by reference</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.</span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:33pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1628908/000162890819000059/a063019exhibit24.htm">2.4*</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1628908/000162890819000059/a063019exhibit24.htm">Asset Purchase Agreement, dated May 28, 2019, by and among University Health Care, Inc., d/b/a Passport Health Plan, Passport Health Solutions, LLC, Evolent Health, Inc. and Justify Holdings, Inc., filed as Exhibit 2.4 to the Company&#8217;s Report on Form 10-Q filed with the SEC on August 9, 2019, and incorporated herein by reference</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.</span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:44pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1628908/000162890819000084/exhibit21passportfirst.htm">2.5*</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1628908/000162890819000084/exhibit21passportfirst.htm">First Amendment to Asset Purchase Agreement, dated as of December 30, 2019, by and among University Health Care, Inc., d/b/a Passport Health Plan, Passport Health Solutions, LLC, Justify Holdings, Inc., and Evolent Health, Inc., filed as Exhibit 2.1 to the Company&#8217;s Report on Form 8-K with the SEC on December 31, 2019, and incorporated herein by reference</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.</span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:45pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1628908/000162890821000109/a202108048-kexhibit21.htm">2.</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1628908/000162890821000109/a202108048-kexhibit21.htm">6</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1628908/000162890821000109/a202108048-kexhibit21.htm">*</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1628908/000162890821000109/a202108048-kexhibit21.htm">Purchase Agreement and Agreement and Plan of Merger, dated August 2, 2021, by and among Evolent Health, Inc., Evolent Health LLC, EV Thunder Merger Sub, LLC, WindRose Health Investors III, L.P., Vital Decisions Acquisition, LLC and WindRose Health Investors, LLC, as the representative,  filed as Exhibit 2.1 to the Company&#8217;s report on Form 8-K filed with the SEC on August 4, 2021 and incorporated herein by reference</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">.</span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:23pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1628908/000162890816000054/exhibit31.htm">3.1</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1628908/000162890816000054/exhibit31.htm">Second Amended and Restated Certificate of Incorporation of Evolent Health, Inc., filed as Exhibit 3.1 to the Company&#8217;s Report on Form 8-K filed with the SEC on June 15, 2016, and incorporated herein by reference</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.</span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:33pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1628908/000162890821000066/a20210610exhibit31.htm">3.2</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1628908/000162890821000066/a20210610exhibit31.htm">Certificate of Amendment of the Second Amended and Restated Certificate of Incorporation of Evolent Health, Inc., dated June 10, 2021, filed as Exhibit 3.1 to the Company&#8217;s report on Form 8-K filed with the SEC on June 10, 2021 and incorporated herein by reference.</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:23pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0001628908/000162890820000143/a20201214form8-kex31.htm">3.3</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0001628908/000162890820000143/a20201214form8-kex31.htm">Third Amended and Restated By-laws of Evolent Health, Inc., filed as Exhibit 3.1 to the Company&#8217;s Report on Form 8-K filed with the SEC on December 14, 2020, and incorporated herein by reference</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.</span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:23pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1628908/000119312515190849/d838828dex41.htm">4.1</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1628908/000119312515190849/d838828dex41.htm">Form of Class A common stock certificate, filed as Exhibit 4.1 to Amendment No. 1 to the Company&#8217;s Registration Statement on Form S-1 filed with the SEC on May 18, 2015, and incorporated herein by reference</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.</span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:33pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1628908/000119312515219372/d939182dex41.htm">4.2</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1628908/000119312515219372/d939182dex41.htm">Registration Rights Agreement, dated as of June 4, 2015, by and among Evolent Health, Inc., TPG Growth II BDH, L.P., TPG Eagle Holdings, L.P., UPMC, The Advisory Board Company and Ptolemy Capital, LLC, filed as Exhibit 4.1 to the Company&#8217;s Current Report on Form 8-K filed with the SEC on June 10, 2015, and incorporated herein by reference</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.</span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">125</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"></td><td style="width:42.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:490.00pt"></td><td style="width:1.0pt"></td></tr><tr style="height:33pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1628908/000095015718001058/ex4-1.htm">4.3</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1628908/000095015718001058/ex4-1.htm">Indenture dated as of October 22, 2018, between Evolent Health, Inc. and U.S. Bank National Association, as trustee, filed as Exhibit 4.1 to the Company&#8217;s Current Report on Form 8-K filed with the SEC on October 23, 2018, and incorporated herein by reference</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.</span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:33pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1628908/000095015718001058/ex4-1.htm">4.4</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1628908/000095015718001058/ex4-1.htm">Form of 1.50% Convertible Senior Notes due 2025, filed as Exhibit A to the Indenture (Item 4.5 above), which was filed as Exhibit 4.1 to the Company&#8217;s Current Report on Form 8-K filed with the SEC on October 23, 2018, and incorporated herein by reference</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.</span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:33pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1628908/000162890819000032/a528198-kexhibit41.htm">4.5</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1628908/000162890819000032/a528198-kexhibit41.htm">Registration Rights Agreement, dated May 24, 2019, by and between Evolent Health, Inc. and Momentum Health Group, LLC, filed as exhibit 4.1 to the Company&#8217;s Report on Form 8-K filed with the SEC on May 28, 2019, and incorporated herein by reference.</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="evh10-kexhibit46.htm">4.6</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="evh10-kexhibit46.htm">Description of Registrant&#8217;s Securities.</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:33pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1628908/000162890820000121/exhibit41-indenture.htm">4.7*</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1628908/000162890820000121/exhibit41-indenture.htm">Indenture, dated as of August 19, 2020, by and between Evolent Health, Inc. and U.S. Bank National Association, as trustee, filed as Exhibit 4.1 to the Company&#8217;s Current Report on Form 8-K with the SEC on August 25, 2020, and incorporated herein by reference</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.</span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:23pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1628908/000162890820000121/exhibit41-indenture.htm">4.8*</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1628908/000162890820000121/exhibit41-indenture.htm">Form of 3.50% Convertible Senior Note due 2024 (included as Exhibit A to Exhibit 4.1), filed as Exhibit 4.2 to the Company&#8217;s Current Report on Form 8-K with the SEC on August 25, 2020, and incorporated herein by reference</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.</span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:33pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1628908/000119312515219372/d939182dex103.htm">10.1</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1628908/000119312515219372/d939182dex103.htm">Third Amended and Restated Operating Agreement of Evolent Health LLC, dated as of June 4, 2015, filed as Exhibit 10.3 to the Company&#8217;s Current Report on Form 8-K filed with the SEC on June 10, 2015, and incorporated herein by reference</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.</span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:33pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1628908/000119312515219372/d939182dex104.htm">10.2</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1628908/000119312515219372/d939182dex104.htm">Income Tax Receivables Agreement, dated as of June 4, 2015, by and among Evolent Health, Inc., Evolent Health LLC and certain stockholders of Evolent Health, Inc., filed as Exhibit 10.4 to the Company&#8217;s Current Report on Form 8-K filed with the SEC on June 10, 2015, and incorporated herein by reference</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.</span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:33pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1628908/000119312515219372/d939182dex101.htm">10.3</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1628908/000119312515219372/d939182dex101.htm">Stockholders Agreement, dated as of June 4, 2015, by and among Evolent Health, Inc., TPG Growth II BDH, L.P., TPG Eagle Holdings, L.P., UPMC and The Advisory Board Company, filed as Exhibit 10.1 to the Company&#8217;s Current Report on Form 8-K filed with the SEC on June 10, 2015, and incorporated herein by reference</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.</span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:23pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1628908/000119312515169530/d838828dex108.htm">10.4</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1628908/000119312515169530/d838828dex108.htm">VPHealth, Inc. 2011 Equity Incentive Plan, filed as Exhibit 10.8 to the Company&#8217;s Registration Statement on Form S-1 filed with the SEC on May 5, 2015, and incorporated herein by reference</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.</span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:23pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1628908/000119312515169530/d838828dex109.htm">10.5+</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1628908/000119312515169530/d838828dex109.htm">Amendment No. 1 to the Evolent Health, Inc. 2011 Equity Incentive Plan, filed as Exhibit 10.9 to the Company&#8217;s Registration Statement on Form S-1 filed with the SEC on May 5, 2015, and incorporated herein by reference</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.</span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:23pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1628908/000119312515190849/d838828dex109.htm">10.6+</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1628908/000119312515190849/d838828dex109.htm">Evolent Health, Inc. 2015 Omnibus Equity Incentive Plan, filed as Exhibit 10.9 to Amendment No. 1 to the Company&#8217;s Registration Statement on Form S-1 filed with the SEC on May 18, 2015, and incorporated herein by reference</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.</span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:23pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1628908/000162890818000021/a2018def14a.htm">10.7+</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1628908/000162890818000021/a2018def14a.htm">Amendment to the Evolent Health, Inc. 2015 Omnibus Equity Incentive Plan, filed as Appendix B to the Company&#8217;s Definitive Proxy Statement on Schedule 14A filed with the SEC on April 27, 2018, and incorporated herein by reference</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.</span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:33pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1628908/000119312515219372/d939182dex105.htm">10.8+</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1628908/000119312515219372/d939182dex105.htm">Form of Executive Officer Option Award Agreement under the Evolent Health, Inc. 2015 Omnibus Incentive Compensation Plan, filed as Exhibit 10.5 to the Company&#8217;s Current Report on Form 8-K filed with the SEC on June 10, 2015, and incorporated herein by reference</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.</span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:33pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1628908/000119312515219372/d939182dex106.htm">10.9+</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1628908/000119312515219372/d939182dex106.htm">Form of Executive Officer Restricted Stock Unit Award Agreement under the Evolent Health, Inc. 2015 Omnibus Incentive Compensation Plan, filed as Exhibit 10.6 to the Company&#8217;s Current Report on Form 8-K filed with the SEC on June 10, 2015, and incorporated herein by reference</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.</span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:33pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1628908/000119312515219372/d939182dex107.htm">10.10+</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1628908/000119312515219372/d939182dex107.htm">Form of Non-Employee Director Restricted Stock Unit Award Agreement under the Evolent Health, Inc., 2015 Omnibus Incentive Compensation Plan, filed as Exhibit 10.7 to the Company&#8217;s Current Report on Form 8-K filed with the SEC on June 10, 2015, and incorporated herein by reference</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.</span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:33pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1628908/000119312515219372/d939182dex108.htm">10.11+</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1628908/000119312515219372/d939182dex108.htm">Form of Non-Qualified Stock Option Agreement under the Evolent Health, Inc. 2011 Equity Incentive Plan, filed as Exhibit 10.8 to the Company&#8217;s Current Report on Form 8-K filed with the SEC on June 10, 2015, and incorporated herein by reference</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.</span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:33pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1628908/000119312515169530/d838828dex1012.htm">10.12&#8224;</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1628908/000119312515169530/d838828dex1012.htm">Amended and Restated HealthPlaNet Technology License Agreement between UPMC and Evolent Health, Inc., dated as of June 27, 2013, filed as Exhibit 10.12 to the Company&#8217;s Registration Statement on Form S-1 filed with the SEC on May 5, 2015, and incorporated herein by reference</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.</span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:33pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1628908/000119312515169530/d838828dex1013.htm">10.13&#8224;</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1628908/000119312515169530/d838828dex1013.htm">Amended and Restated Intellectual Property License and Development Services Agreement between UPMC and Evolent Health, Inc., dated as of June 27, 2013, filed as Exhibit 10.13 to the Company&#8217;s Registration Statement on Form S-1 filed with the SEC on May 5, 2015, and incorporated herein by reference</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.</span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:33pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1628908/000119312515169530/d838828dex1015.htm">10.14</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1628908/000119312515169530/d838828dex1015.htm">Amended and Restated Intellectual Property License and Data Access Agreement by and between The Advisory Board Company and Evolent Health, Inc., dated as of June 27, 2013, filed as Exhibit 10.15 to the Company&#8217;s Registration Statement on Form S-1 filed with the SEC on May 5, 2015, and incorporated herein by reference</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.</span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:33pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1628908/000119312515169530/d838828dex1018.htm">10.15</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1628908/000119312515169530/d838828dex1018.htm">Deed of Lease by and between North Glebe Office, L.L.C. and Evolent Health, Inc., dated as of July 31, 2012, filed as Exhibit 10.18 to the Company&#8217;s Registration Statement on Form S-1 filed with the SEC on May 5, 2015, and incorporated herein by reference</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.</span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">126</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"></td><td style="width:42.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:490.00pt"></td><td style="width:1.0pt"></td></tr><tr style="height:33pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1628908/000119312515169530/d838828dex1019.htm">10.16</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1628908/000119312515169530/d838828dex1019.htm">First Amendment to Deed of Lease by and between North Glebe Office, L.L.C. and Evolent Health, Inc., dated as of March 1, 2013, filed as Exhibit 10.19 to the Company&#8217;s Registration Statement on Form S-1 filed with the SEC on May 5, 2015, and incorporated herein by reference</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.</span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:33pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1628908/000119312515169530/d838828dex1020.htm">10.17</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1628908/000119312515169530/d838828dex1020.htm">Second Amendment to Deed of Lease by and between North Glebe Office, L.L.C. and Evolent Health, Inc., dated as of April 1, 2014, filed as Exhibit 10.20 to the Company&#8217;s Registration Statement on Form S-1 filed with the SEC on May 5, 2015, and incorporated herein by reference</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.</span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:23pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1628908/000119312515199503/d838828dex1020.htm">10.18</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1628908/000119312515199503/d838828dex1020.htm">Form of Director Indemnification Agreement, filed as Exhibit 10.20 to Amendment No. 2 to the Company&#8217;s Registration Statement on Form S-1 filed with the SEC on May 26, 2015, and incorporated herein by reference</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.</span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:33pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1628908/000162890816000051/a033116exhibit101.htm">10.19+</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1628908/000162890816000051/a033116exhibit101.htm">Form of Executive Officer Performance-Based Option Award Agreement Under the Evolent Health, Inc. 2015 Omnibus Incentive Compensation Plan, filed as Exhibit 10.1 to the Company&#8217;s Quarterly Report on Form 10-Q filed with the SEC on May 16, 2016, and incorporated herein by reference</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.</span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:33pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1628908/000162890817000044/a63017exhibit101.htm">10.20+</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1628908/000162890817000044/a63017exhibit101.htm">Form of Non-Employee Director Restricted Stock Unit Agreement under the Evolent Health, Inc. 2015 Omnibus Incentive Compensation Plan, filed as Exhibit 10.1 to the Company&#8217;s Quarterly Report on Form 10-Q filed with the SEC on August 7, 2017, and incorporated herein by reference</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.</span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:33pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1628908/000162890819000006/a123118exhibit1026.htm">10.21+</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1628908/000162890819000006/a123118exhibit1026.htm">Form of Leveraged Stock Unit Award Agreement under the Evolent Health, Inc. 2015 Omnibus Incentive Compensation Plan, filed as Exhibit 10.26 to the Company&#8217;s Annual Report on Form 10-K filed with the SEC on February 28, 2019, and incorporated herein by reference</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.</span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:33pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1628908/000162890820000108/exhibit101evh_molinaapa.htm">10.22*</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1628908/000162890820000108/exhibit101evh_molinaapa.htm">Asset Purchase Agreement, dated July 16, 2020, by and among Passport Health Plan, Inc., Evolent Health LLC, and Molina Healthcare, Inc., filed as Exhibit 10.1 to the Company&#8217;s Quarterly Report on Form 10-Q with the SEC on August 7, 2020, and incorporated herein by reference</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.</span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:53pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1628908/000119312520323903/d12759dex101.htm">10.23</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1628908/000119312520323903/d12759dex101.htm">Cooperation Agreement, dated December 21, 2020, by and among Evolent Health, Inc., Engaged Capital Flagship Master Fund, LP, Engaged Capital Co-Invest XI, LP, Engaged Capital Special Situation Fund, LP, Engaged Capital Flagship Fund, LP, Engaged Capital Flagship Fund, Ltd., Engaged Capital LLC, Engaged Capital Holdings, LLC and Glenn W. Welling, filed as Exhibit 10.1 to the Company&#8217;s Current Report on Form 8-K filed with the SEC on December 22, 2020, and incorporated by reference herein</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.</span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:33pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1628908/000162890821000012/a202101298-kexhibit101.htm">10.24+</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1628908/000162890821000012/a202101298-kexhibit101.htm">Severance and Change-in-Control Agreement, dated as of January 27, 2021, by and between Evolent Health, Inc. and Mr. Frank Williams, filed as Exhibit 10.1 to the Company&#8217;s Current Report on Form 8-K/A filed with the SEC on January 29, 2021, and incorporated by reference herein</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.</span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:33pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1628908/000162890821000012/a202001298-kexhibit102.htm">10.25+</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1628908/000162890821000012/a202001298-kexhibit102.htm">Severance and Change-in-Control Agreement, dated as of January 27, 2021, by and between Evolent Health, Inc. and Mr. Seth Blackley, filed as Exhibit 10.2 to the Company&#8217;s Current Report on Form 8-K/A filed with the SEC on January 29, 2021, and incorporated by reference herein</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.</span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:33pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1628908/000162890821000012/a202001298-kexhibit103.htm">10.26+</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1628908/000162890821000012/a202001298-kexhibit103.htm">Severance and Change-in-Control Agreement, dated as of January 27, 2021, by and between Evolent Health, Inc. and Mr. John Johnson, filed as Exhibit 10.3 to the Company&#8217;s Current Report on Form 8-K/A filed with the SEC on January 29, 2021, and incorporated by reference herein</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.</span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:33pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1628908/000162890821000012/a202001298-kexhibit104.htm">10.27+</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1628908/000162890821000012/a202001298-kexhibit104.htm">Severance and Change-in-Control Agreement, dated as of January 27, 2021, by and between Evolent Health, Inc. and Mr. Jonathan Weinberg, filed as Exhibit 10.4 to the Company&#8217;s Current Report on Form 8-K/A filed with the SEC on January 29, 2021, and incorporated by reference herein</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.</span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:33pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1628908/000162890821000026/a123120exhibit1032.htm">10.28+</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1628908/000162890821000026/a123120exhibit1032.htm">Severance and Change-in-Control Agreement, dated as of January 27, 2021, by and between Evolent Health, Inc. and Mr. Steve Tutewohl, filed  as Exhibit 10.32 to the Company's Annual Report on Form 10-K filed with the SEC on February 26, 2021</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.</span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:23pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1628908/000119312521145029/d159847ddefa14a.htm">10.29+</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1628908/000119312521145029/d159847ddefa14a.htm">Evolent Health, Inc. Amended and Restated 2015 Omnibus Equity Incentive Plan, filed as Appendix D to the Company&#8217;s Definitive Proxy Statement on Schedule 14A filed with the SEC on April 30, 2021, and incorporated herein by reference</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.</span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:33pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1628908/000162890821000054/q12021exhibit102.htm">10.30+</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1628908/000162890821000054/q12021exhibit102.htm">Form of Performance Stock Unit Award Agreement under the Evolent Health, Inc. 2015 Omnibus Incentive Compensation Plan, filed as Exhibit 10.2 to the Company's Quarterly Report on Form 10-Q with the SEC on May 6, 2021.</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:23pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="a123121exhibit1031.htm">10.31+</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="a123121exhibit1031.htm">Form of Executive Officer Restricted Stock Unit Award Agreement under the Evolent Health, Inc. 2015 Omnibus Incentive Compensation Plan.</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:23pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1628908/000162890819000018/a410198-kexhibit161.htm">16.1</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1628908/000162890819000018/a410198-kexhibit161.htm">Letter from PricewaterhouseCoopersLLP, dated April 9, 2019, filed as Exhibit 16.1 to the Company&#8217;s Current Report on Form 8-K filed with the SEC on April 10, 2019, and incorporated herein by reference</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.</span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit211.htm">21.1</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit211.htm">Subsidiaries of Evolent Health, Inc.</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="a123121exhibit231.htm">23.1</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="a123121exhibit231.htm">Consent of Independent Registered Public Accounting Firm.</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="a123121exhibit311.htm">31.1</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="a123121exhibit311.htm">Certification of the Chief Executive Officer pursuant to section 302 of the Sarbanes-Oxley Act of 2002</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.</span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="a123121exhibit312.htm">31.2</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="a123121exhibit312.htm">Certification of the Chief Financial Officer pursuant to section 302 of the Sarbanes-Oxley Act of 2002</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.</span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:24pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="a123121exhibit321.htm">32.1</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="a123121exhibit321.htm">Certification of the Chief Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.</span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">127</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"></td><td style="width:42.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:490.00pt"></td><td style="width:1.0pt"></td></tr><tr style="height:24pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="a123121exhibit322.htm">32.2</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="a123121exhibit322.htm">Certification of the Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.</span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.INS</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Instance Document</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.SCH</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Taxonomy Extension Schema Document</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.CAL</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Taxonomy Extension Calculation Linkbase Document</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.LAB</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Taxonomy Extension Label Linkbase Document</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.PRE</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Taxonomy Extension Presentation Linkbase Document</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.DEF</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Taxonomy Extension Definition Linkbase Document</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The cover page from this Quarterly Report on Form 10-K, formatted as Inline XBRL</span></div></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8224; The Company&#8217;s request for confidential treatment with respect to certain portions of this exhibit has been accepted.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">+ Constitutes a management contract or other compensatory plan or arrangement.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">* The Company agrees to furnish supplementally to the SEC a copy of any omitted schedule or exhibit upon the request of the SEC in accordance with Item 601(b)(2) of Regulation S-K.</span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">128</span></div></div></div><div id="i9aaa2fddc97e482da5dbe37ac85ae703_259"></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 16. Form 10-K Summary</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><br/></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not Applicable.</span></div><div><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">129</span></div></div></div><div id="i9aaa2fddc97e482da5dbe37ac85ae703_253"></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURES</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</span></div><div style="text-align:right"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:46.111%"><tr><td style="width:1.0%"></td><td style="width:16.972%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:39.863%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:39.865%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Evolent Health, Inc.</span></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="6" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ John Johnson</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Name:</span></td><td colspan="6" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">John Johnson</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Title:</span></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Chief Financial Officer</span></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Dated:  February&#160;23, 2022</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:539.25pt"><tr><td style="width:1.0pt"></td><td style="width:163.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:7.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:238.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:7.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:112.75pt"></td><td style="width:1.0pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Signature</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Title</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Date</span></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Seth Blackley</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Executive Officer and Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 23, 2022</span></td></tr><tr style="height:15pt"><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Seth Blackley</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Principal Executive Officer)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ John Johnson</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Financial Officer</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 23, 2022</span></td></tr><tr style="height:15pt"><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">John Johnson</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Principal Financial Officer)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Aammaad Shams</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate Controller</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 23, 2022</span></td></tr><tr style="height:15pt"><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Aammaad Shams</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Principal Accounting Officer)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Craig Barbarosh</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 23, 2022</span></td></tr><tr style="height:15pt"><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Craig Barbarosh</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ M. Bridget Duffy</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 23, 2022</span></td></tr><tr style="height:15pt"><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">M. Bridget Duffy, MD</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ David Farner</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 23, 2022</span></td></tr><tr style="height:15pt"><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">David Farner</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Peter Grua</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 23, 2022</span></td></tr><tr style="height:15pt"><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Peter Grua</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Diane Holder</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 23, 2022</span></td></tr><tr style="height:15pt"><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Diane Holder</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Kim Keck</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 23, 2022</span></td></tr><tr style="height:15pt"><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Kim Keck</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Cheryl Scott</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 23, 2022</span></td></tr><tr style="height:15pt"><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cheryl Scott</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Tunde Sotunde</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 23, 2022</span></td></tr><tr style="height:15pt"><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Tunde Sotunde, MD</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Frank Williams</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 23, 2022</span></td></tr><tr style="height:15pt"><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Frank Williams</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">130</span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.6
<SEQUENCE>2
<FILENAME>evh10-kexhibit46.htm
<DESCRIPTION>EX-4.6
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="i962c741071674a78b7830cb3b37985b3_1"></div><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit 4.6</font></div></div><div style="text-align:right"><font><br></font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:139%">EVOLENT HEALTH, INC.</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:139%">DESCRIPTION OF THE REGISTRANT&#8217;S SECURITIES </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:139%">REGISTERED PURSUANT TO SECTION 12 OF THE </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:139%">SECURITIES EXCHANGE ACT OF 1934</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:139%">DESCRIPTION OF COMMON STOCK</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">As of December 31, 2021, Evolent Health, Inc. (the &#8220;Company,&#8221; &#8220;us,&#8221; &#8220;we,&#8221; or &#8220;our&#8221;) had one class of securities, our Class A common stock, par value $0.01 per share, registered under Section 12 of the Securities Exchange Act of 1934, as amended. Our common stock is listed on New York Stock Exchange under the symbol &#8220;EVH.&#8221;</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">The following summary does not purport to be complete and is subject to and qualified in its entirety by reference to the General Corporation Law of the State of Delaware (the &#8220;DGCL&#8221;) and our second amended and restated certificate of incorporation, as amended (the &#8220;certificate of incorporation&#8221;), and third amended and restated by-laws (the &#8220;by-laws&#8221;), as each may be further amended from time to time.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:139%">General</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">Our certificate of incorporation provides that we may issue up to 750,000,000 shares of Class A common stock, par value $0.01 per share. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:139%">Voting Rights</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">Except as otherwise provided in our certificate of incorporation, or required by law, the holders of Class A common stock are entitled to one vote per share on all matters to be voted upon by the stockholders.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:139%">Dividend and Liquidation Rights</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">Subject to preferences that may be applicable to any outstanding preferred stock, the holders of Class A common stock are entitled to receive ratably such dividends, if any, as may be declared from time to time by the board of directors out of funds legally available therefor. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">We currently anticipate that we will retain all of our future earnings for use in the expansion and operation of our business and do not anticipate paying any cash dividends in the foreseeable future. The declaration and payment of all future dividends to holders of our Class A common stock will be at the discretion of our board of directors and will depend on many factors, including our financial condition, earnings, legal requirements and any debt agreements we are then party to, and other factors our board of directors deems relevant.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">In the event of liquidation, dissolution or winding up of the Company, the holders of Class A common stock are entitled to share ratably in all assets remaining after payment of liabilities, subject to prior distribution rights of preferred stock, if any, then outstanding. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:139%">Other Rights</font></div><div style="text-align:justify"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">The holders of our Class A common stock have no preemptive or conversion rights or other subscription rights. There are no redemption or sinking fund provisions applicable to the Class A common stock. The rights, preferences and privileges of holders of our common stock are subject to those of the holders of any shares of our preferred stock we may issue in the future. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:139%">Election and Removal of Directors&#59; Vacancies </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">Our board of directors consists of up to 10 directors, excluding any directors elected by holders of any preferred stock pursuant to provisions applicable in the case of defaults and subject to applicable laws and stock exchange regulations. The exact number of directors will be fixed from time to time by resolution of the board. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">In accordance with our certificate of incorporation and our by-laws, our board of directors currently consists of 10 members.  Prior to the 2023 annual meeting of stockholders, our board of directors is divided into three classes of directors, as nearly equal in number as possible. Any director elected prior to the date of the 2021 annual meeting of stockholders will serve for a three-year term expiring on the date of the third annual meeting of stockholders following the annual meeting of stockholders at which that Director was elected. Each director elected at the 2021 annual meeting of stockholders was elected for a one-year term expiring at the 2022 annual meeting of stockholders. Each director elected at the 2022 annual meeting of stockholders will be elected for a one-year term expiring at the 2023 annual meeting of stockholders. At the 2023 annual meeting of stockholders and at each annual meeting of stockholders thereafter, all directors will be elected for a one-year term expiring at the next annual meeting of stockholders. There is no limit on the number of terms a director may serve on our board of directors. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">In connection with our IPO, we entered into a stockholders agreement which contains provisions related to the composition of our board of directors, the committees of our board of directors and our corporate governance. Under the stockholders agreement, for so long as University of Pittsburgh Medical Center (&#8220;UPMC&#8221;) owns at least 40% of the shares of common stock held by it following the completion of our IPO, such stockholder will be entitled to nominate two directors to serve on our board of directors. When such stockholder owns less than 40% but at least 5% of the shares of common stock held by it following the completion of our IPO, such stockholder will be entitled to nominate one director. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">Our certificate of incorporation and our by-laws provide that prior to the date of the 2023 annual meeting of stockholders, any director or the entire Board may be removed only for cause and only upon the affirmative vote of holders of at least 75% of the total voting power of all the then outstanding shares of capital stock entitled to vote generally in the election of directors, voting together as a single class. On or after the date of the 2023 annual meeting of stockholders, any director or the entire Board may be removed, at any time, with or without cause, by the affirmative vote of the holders of at least a majority of the voting power of the outstanding shares of Company&#8217;s capital stock entitled to vote generally in the election of directors, voting together as a single class, subject to the terms of the Stockholders Agreement.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">In addition, our certificate of incorporation and our by-laws provide that any newly created directorship on the board of directors that results from an increase in the number of directors and any vacancy occurring on the board of directors shall be filled only by a majority of the directors then in office, although less than a quorum, or by a sole remaining director. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:139%">No Cumulative Voting </font></div><div style="text-align:justify"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">The DGCL provides that stockholders are not entitled to the right to cumulate votes in the election of directors unless our certificate of incorporation provides otherwise. Our certificate of incorporation prohibits cumulative voting. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:139%">Limits on Written Consents </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">The DGCL permits stockholder action by written consent unless otherwise provided by our certificate of incorporation. Our certificate of incorporation precludes stockholder action by written consent. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:139%">Stockholder Meetings </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">Our certificate of incorporation and our by-laws provide that special meetings of stockholders may be called only by or at the direction of the board of directors, the chairman of the board of directors or the chief executive officer.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:139%">Amendment of Certificate of Incorporation </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">The affirmative vote of holders of at least a majority of the voting power of our outstanding shares of stock will generally be required to amend provisions of our certificate of incorporation. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:139%">Amendment of By-laws </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">Our second amended and restated by-laws may generally be altered, amended or repealed, and new by-laws may be adopted, by the affirmative vote of either a majority of directors present at any regular or special meeting of the board of directors called for that purpose or by the affirmative vote of the holders of at least a majority of the voting power of the outstanding shares of stock. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:139%">Other Limitations on Stockholder Actions </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Our by-laws also impose some procedural requirements on stockholders who wish to&#58; </font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:32.5pt">make nominations in the election of directors&#59;</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:32.5pt">propose that a director be removed&#59;</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:32.5pt">propose any repeal or change in our by-laws&#59; or</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:32.5pt">propose any other business to be brought before an annual meeting of stockholders.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Under these procedural requirements, in order to bring a proposal before a meeting of stockholders, a stockholder must deliver timely notice of a proposal pertaining to a proper subject for presentation at the meeting to our corporate secretary along with the following&#58; </font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:32.5pt">a description of the business or nomination to be brought before the meeting and the reasons for conducting such business at the meeting&#59;</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:32.5pt">the stockholder&#8217;s name and address&#59;</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:32.5pt">any material interest of the stockholder in the proposal&#59;</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:32.5pt">the number of shares beneficially owned by the stockholder and evidence of such ownership&#59; and</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:32.5pt">the names and addresses of all persons with whom the stockholder is acting in concert and a description of all arrangements and understandings with those persons, and the number of shares such persons beneficially own.</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">To be timely, a stockholder must generally deliver notice&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:32.5pt">in connection with an annual meeting of stockholders, not less than 120 nor more than 150 days prior to the month and day corresponding to the date on which the annual meeting of stockholders was held in the immediately preceding year, but in the event that the date of the annual meeting is more than 30 days before or more than 30 days after the anniversary date of the preceding annual meeting of stockholders, a stockholder notice will be timely if received by us not later than the close of business on the 10th day following the day on which we first publicly announce the date of the annual meeting&#59; or</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:32.5pt">in connection with the election of a director at a special meeting of stockholders, not less than 40 nor more than 60 days prior to the date of the special meeting, but in the event that less than 50 days&#8217; notice or prior public disclosure of the date of the special meeting of the stockholders is given or made to the stockholders, a stockholder notice will be timely if received by us not later than the close of business on the 10th day following the day on which a notice of the date of the special meeting was mailed to the stockholders or the public disclosure of that date was made.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">In order to submit a nomination for our board of directors, a stockholder must also submit any information with respect to the nominee that we would be required to include in a proxy statement, as well as certain other information. If a stockholder fails to follow the required procedures, the stockholder&#8217;s proposal or nominee will be ineligible and will not be voted on by our stockholders.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:139%">Corporate Opportunity </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">Our certificate of incorporation and the stockholders agreement provide that each of TPG, The Advisory Board and UPMC and their respective affiliates will not have any duty to refrain from (i) engaging, directly or indirectly, in the same or similar business activities or lines of business as us, including those business activities or lines of business deemed to be competing with us, or (ii) doing business with any of our clients, customers or vendors. In the event that TPG, The Advisory Board or UPMC or any of their respective affiliates acquires knowledge of a potential business opportunity which may be a corporate opportunity for us, they will have no duty to communicate or offer such corporate opportunity to us. Our certificate of incorporation and the stockholders agreement also provide that, to the fullest extent permitted by law, none of such stockholders or their respective affiliates will be liable to us, for breach of any fiduciary duty or otherwise, by reason of the fact that any such stockholder or any of its affiliates directs such corporate opportunity to another person, or otherwise does not communicate information regarding such corporate opportunity to us, and we will waive and renounce any claim that such business opportunity constituted a corporate opportunity that should have been presented to us. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:139%">Limitation of Liability of Directors and Officers </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">Our certificate of incorporation provides that no director will be personally liable to us or our stockholders for monetary damages for breach of fiduciary duty as a director, except as required by applicable law, as in effect from time to time. Currently, Delaware law requires that liability be imposed for the following&#58; </font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:32.5pt">any breach of the director&#8217;s duty of loyalty to our company or our stockholders&#59;</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:32.5pt">any act or omission not in good faith or which involved intentional misconduct or a knowing violation of law&#59;</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:32.5pt">unlawful payments of dividends or unlawful stock repurchases or redemptions as provided in Section 174 of the DGCL&#59; and</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:32.5pt">any transaction from which the director derived an improper personal benefit.</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">As a result, neither we nor our stockholders have the right, through stockholders&#8217; derivative suits on our behalf, to recover monetary damages against a director for breach of fiduciary duty as a director, including breaches resulting from grossly negligent behavior, except in the situations described above. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">Our by-laws provide that, to the fullest extent permitted by law, we will indemnify any officer or director of our company against all damages, claims and liabilities arising out of the fact that the person is or was our director or officer, or served any other enterprise at our request as a director, officer, employee, agent or fiduciary. We will reimburse the expenses, including attorneys&#8217; fees, incurred by a person indemnified by this provision when we receive an undertaking to repay such amounts if it is ultimately determined that the person is not entitled to be indemnified by us. Amending these provisions will not reduce our indemnification obligations relating to actions taken before an amendment.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:139%">Forum Selection </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">Our certificate of incorporation requires, to the fullest extent permitted by law, that derivative actions brought on our behalf, any action asserting a claim of breach of a fiduciary duty owed by any of our directors, officers or other employees to us or our stockholders and other similar actions, may be brought only in specified courts in the State of Delaware. Although we believe this provision benefits us by providing increased consistency in the application of Delaware law in the types of lawsuits to which it applies, the provision may have the effect of discouraging lawsuits against our directors and officers. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:139%">Anti-takeover Effects of Some Provisions </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">Some provisions of our certificate of incorporation and by-laws could make the following more difficult&#58; </font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:32.5pt">acquisitions of control of us by means of a proxy contest or otherwise&#59; or</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:32.5pt">removal of our incumbent officers and directors.</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">These provisions, as well as our ability to issue preferred stock, are designed to discourage coercive takeover practices and inadequate takeover bids. These provisions are also designed to encourage persons seeking to acquire control of us to first negotiate with our board of directors. We believe that the benefits of increased protection give us the potential ability to negotiate with the proponent of an unfriendly or unsolicited proposal to acquire or restructure us, and that the benefits of this increased protection outweigh the disadvantages of discouraging those proposals, because negotiation of those proposals could result in an improvement of their terms. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:139%">Delaware Business Combination Statute </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">We have elected in our certificate of incorporation not to be subject to Section 203 of the DGCL, an antitakeover law. In general, Section 203 prohibits a publicly held Delaware corporation from engaging in a business combination, such as a merger, with a person or group owning 15% or more of the corporation&#8217;s voting stock for a period of three years following the date the person became an interested stockholder, unless (with certain exceptions) the business combination or the transaction in which the person became an interested stockholder is approved in a prescribed manner. Accordingly, we will not be subject to any anti-takeover effects of Section 203. Nevertheless, our certificate of incorporation contains provisions that have the same effect as Section 203, except that they provide that each of TPG, UPMC and The Advisory Board and their transferees will not be deemed to be </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8220;interested stockholders,&#8221; regardless of the percentage of our voting stock owned by them, and accordingly will not be subject to such restrictions. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:139%">Transfer Agent and Registrar </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">The transfer agent and registrar for the Class A common stock is American Stock Transfer &#38; Trust Company, LLC. </font></div><div style="text-align:justify"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.31
<SEQUENCE>3
<FILENAME>a123121exhibit1031.htm
<DESCRIPTION>EX-10.31
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="i4bcaefda2dab443994d547a031bb43d0_1"></div><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit 10.31</font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">RESTRICTED STOCK UNIT AWARD AGREEMENT UNDER THE EVOLENT HEALTH, INC. 2015 OMNIBUS INCENTIVE COMPENSATION PLAN, dated as of ________ between EVOLENT HEALTH, INC., a Delaware corporation (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;text-decoration:underline">Company</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8221;), and ___________.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">This Restricted Stock Unit Award Agreement (this &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;text-decoration:underline">Award Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8221;) sets forth the terms and conditions of an award of ___________</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">restricted stock units (this &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;text-decoration:underline">Award</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8221;) that are subject to the terms and conditions specified herein (each such restricted stock unit, an &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;text-decoration:underline">RSU</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8221;) and that are granted to you under the Evolent Health, Inc. 2015 Omnibus Incentive Compensation Plan (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;text-decoration:underline">Plan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8221;).  This Award constitutes an unfunded and unsecured promise of the Company to deliver (or cause to be delivered) to you, subject to the terms of this Award Agreement, shares of the Company&#8217;s Class A Common Stock, $0.01 par value (each, a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;text-decoration:underline">Share</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8221;), as set forth in Section 3 of this Award Agreement.</font></div><div style="text-align:justify;text-indent:72pt"><font><br></font></div><div style="text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">THIS AWARD IS SUBJECT TO ALL TERMS AND CONDITIONS OF THE PLAN AND THIS AWARD AGREEMENT, INCLUDING THE DISPUTE RESOLUTION PROVISIONS SET FORTH IN SECTION 10 OF THIS AWARD AGREEMENT.  BY SIGNING YOUR NAME BELOW, YOU SHALL HAVE CONFIRMED YOUR ACCEPTANCE OF THE TERMS AND CONDITIONS OF THIS AWARD AGREEMENT.</font></div><div style="text-align:justify;text-indent:72pt"><font><br></font></div><div style="text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">SECTION 1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;padding-left:9.36pt;text-decoration:underline">The Plan.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  This Award is made pursuant to the Plan, all the terms of which are hereby incorporated in this Award Agreement.  In the event of any conflict between the terms of the Plan and the terms of this Award Agreement, the terms of the Plan shall govern. </font></div><div style="text-align:justify;text-indent:72pt"><font><br></font></div><div style="text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">SECTION 2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;padding-left:9.36pt;text-decoration:underline">Definitions.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  Capitalized terms used in this Award Agreement that are not defined in this Award Agreement have the meanings as used or defined in the Plan.  As used in this Award Agreement, the following terms have the meanings set forth below&#58;</font></div><div style="text-align:justify;text-indent:72pt"><font><br></font></div><div style="text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;text-decoration:underline">Business Day</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8221; means a day that is not a Saturday, a Sunday or a day on which banking institutions are legally permitted to be closed in the City of New York.</font></div><div style="text-align:justify;text-indent:72pt"><font><br></font></div><div style="text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;text-decoration:underline">Good Reason</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8221; means the occurrence, without your written consent, of any of the events or circumstances set forth in clauses (a) through (d) below&#58;</font></div><div style="text-align:justify;text-indent:72pt"><font><br></font></div><div style="text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">(a) a material reduction in your annual base salary or target bonus opportunity as the same may be increased from time to time&#59; </font></div><div style="text-align:justify;text-indent:72pt"><font><br></font></div><div style="text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">(b) your assignment to duties inconsistent in any material respect with your position, authority or responsibilities with the Company, or any other action or omission by the Company which results in a material diminution of such position, authority or responsibilities&#59;</font></div><div style="text-align:justify;text-indent:72pt"><font><br></font></div><div style="text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">(c) a relocation of your principal work location by more than 50 miles from such location as of immediately prior to the Change of Control&#59; or</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="text-align:justify;text-indent:72pt"><font><br></font></div><div style="text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">(d) any material breach of this Award Agreement by the Company.  </font></div><div style="text-align:justify;text-indent:72pt"><font><br></font></div><div style="text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">Good Reason shall not exist unless you give the Company notice of the event giving rise to Good Reason within 60 days of the date you have knowledge of such event.  Such notice shall specifically delineate such claimed breach and shall inform the Company that it is required to cure such breach (if curable) within 90 days (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;text-decoration:underline">Cure Period</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8221;) after such notice is given in accordance with Section 12 of this Award Agreement.  If such breach is not so cured (or is not curable), you may resign for Good Reason within three months following the end of the Cure Period.  If such breach is cured within the Cure Period or if such breach is not cured but you do not resign for Good Reason within three months following the end of the Cure Period, Good Reason shall not exist hereunder.</font></div><div style="text-align:justify;text-indent:72pt"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;text-decoration:underline">Section 409A</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8221; means Section 409A of the Internal Revenue Code of 1986, as amended, and the regulations and other interpretive guidance promulgated thereunder, as in effect from time to time.</font></div><div style="padding-left:36pt;text-align:justify;text-indent:36pt"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;text-decoration:underline">Settlement Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8221; means each date on which you become entitled to delivery of Shares in settlement of the RSUs subject to this Award Agreement, as provided in Section 3 of this Award Agreement.</font></div><div style="text-align:justify;text-indent:72pt"><font><br></font></div><div style="text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">SECTION 3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;padding-left:9.36pt;text-decoration:underline">Vesting and Settlement.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  (a)  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;text-decoration:underline">Regularly Scheduled Settlement.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  On each Settlement Date set forth below, you shall become vested and entitled to delivery of Shares in settlement of the number of RSUs that corresponds to such Settlement Date, as specified in the chart below, provided that you must be actively employed by the Company or any of its Subsidiaries on the relevant Settlement Date, except (i) as otherwise determined by the Committee in its sole discretion or (ii) as set forth in this Section 3 of this Award Agreement. </font></div><div style="text-align:justify;text-indent:72pt"><font><br></font></div><div style="text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </font><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:40.045%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.288%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.367%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Settlement Date</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Aggregate Percentage Settled</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Number of Restricted Stock Units Vesting on Such Date</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;first anniversary of grant date&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">34 %</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;second anniversary of grant date&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">67 %</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;third anniversary of grant date&#93;</font></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">100 %</font></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">(b) </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;text-decoration:underline">Payment of Shares.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  Payments made pursuant to this Award Agreement shall be payable in Shares.  Subject to Sections 3(a), 3(c) and 7 of this Award Agreement, on each Settlement Date, the Company shall deliver to you or your legal representative one Share for each RSU that is scheduled to vest and be settled. </font></div><div style="text-align:justify;text-indent:72pt"><font><br></font></div><div style="text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">(c) </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;text-decoration:underline">Change of Control.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  Except as explicitly set forth in this Section 3(c), in the event of a Change of Control prior to the final Settlement Date, all outstanding RSUs shall be treated in accordance with Section 8 of the Plan.  Notwithstanding the </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">foregoing or the provisions of Section 8 of the Plan, if, within 12 months following a Change of Control, your employment is terminated by the Company without Cause or by you for Good Reason, all unvested RSUs shall automatically be deemed vested and all restrictions and forfeiture provisions related thereto shall lapse as of the date of such termination and all outstanding RSUs shall be settled not later than the tenth (10th) day following the date of termination of your employment.</font></div><div style="text-align:justify;text-indent:72pt"><font><br></font></div><div style="text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">SECTION 4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;padding-left:9.36pt;text-decoration:underline">Forfeiture of RSUs.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  Notwithstanding the foregoing, unless the Committee determines otherwise, and except as otherwise provided in Section 3 of this Award Agreement, if the Settlement Date with respect to any RSUs awarded to you pursuant to this Award Agreement has not occurred prior to the earlier to occur of (a) the date on which your employment with the Company or any of its Subsidiaries terminates for any reason and (b) the date on which you breach any restrictive covenant contained in any arrangements with the Company (including this Award Agreement) to which you are subject, such RSUs shall be immediately forfeited, and you shall be entitled to no further payments or benefits with respect thereto.  Furthermore, any RSUs awarded pursuant to this Award Agreement and any Shares issued to you upon settlement of such RSUs shall be subject to any recoupment or clawback policy the Company maintains, as in effect from time to time.  </font></div><div style="text-align:justify;text-indent:90pt"><font><br></font></div><div style="text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;text-decoration:underline">SECTION 5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;padding-left:9.36pt;text-decoration:underline">No Rights as a Stockholder.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  You shall not have any rights or privileges of a stockholder with respect to the RSUs subject to this Award Agreement unless and until certificates representing such Shares are actually issued to you or your legal representative or an entry is recorded in the books of the Company (or, as applicable, its transfer agent or stock plan administrator) in settlement of this Award.</font></div><div style="text-align:justify;text-indent:90pt"><font><br></font></div><div style="text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">SECTION 6.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;padding-left:9.36pt;text-decoration:underline">Non-Transferability of RSUs.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  Unless otherwise provided by the Committee in its discretion, RSUs may not be sold, assigned, alienated, transferred, pledged, attached or otherwise encumbered except as provided in Section 9(a) of the Plan.  Any purported sale, assignment, alienation, transfer, pledge, attachment or other encumbrance of RSUs in violation of the provisions of this Section 6 and Section 9(a) of the Plan shall be void. </font></div><div style="text-align:justify;text-indent:90pt"><font><br></font></div><div style="text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">SECTION 7.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;padding-left:9.36pt;text-decoration:underline">Withholding, Consents and Legends.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  (a)  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;text-decoration:underline">Withholding.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  The delivery of Shares pursuant to Section 3(b) or 3(c) of this Award Agreement, is conditioned on satisfaction of any applicable withholding taxes in accordance with this Section 7(a) and Section 9(d) of the Plan.  No later than the date as of which an amount first becomes includible in your gross income for Federal, state, local or foreign income tax purposes with respect to any RSUs you shall pay to the Company, or make arrangements satisfactory to the Company regarding the payment of, any Federal, state, local and foreign taxes that are required by applicable laws and regulations to be withheld with respect to such amount.  In the event that there is withholding tax liability in connection with the settlement of the RSUs you may satisfy, in whole or in part, any withholding tax liability by having the Company withhold from the number of Shares or cash you would be entitled to receive upon settlement of the RSUs an amount in cash or a number of Shares having a Fair Market Value (which shall either have the meaning set forth in the Plan or shall have such other meaning as determined by the Company in </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">3</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">accordance with applicable withholding requirements) equal to such withholding tax liability.</font></div><div style="text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">(b) </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;text-decoration:underline">Consents.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  Your rights in respect of the RSUs are conditioned on the receipt to the full satisfaction of the Committee of any required consents that the Committee may determine to be necessary or advisable (including your consent to the Company&#8217;s supplying to any third-party recordkeeper of the Plan such personal information as the Committee deems advisable to administer the Plan). </font></div><div style="text-align:justify;text-indent:72pt"><font><br></font></div><div style="text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">(c) </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;text-decoration:underline">Legends.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  The Company may affix to certificates for Shares issued pursuant to this Award Agreement any legend that the Committee determines to be necessary or advisable (including to reflect any restrictions to which you may be subject under any applicable securities laws).  The Company may advise the transfer agent to place a stop order against any legended Shares.</font></div><div style="text-align:justify;text-indent:72pt"><font><br></font></div><div style="text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">SECTION 8.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;padding-left:9.36pt;text-decoration:underline">Successors and Assigns of the Company.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  The terms and conditions of this Award Agreement shall be binding upon and shall inure to the benefit of the Company and its successors and assigns.</font></div><div style="text-align:justify;text-indent:72pt"><font><br></font></div><div style="text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">SECTION 9.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;padding-left:9.36pt;text-decoration:underline">Committee Discretion.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  The Committee shall have full and plenary discretion with respect to any actions to be taken or determinations to be made in connection with this Award Agreement, and its determinations shall be final, binding and conclusive.</font></div><div style="text-align:justify;text-indent:72pt"><font><br></font></div><div style="text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">SECTION 10.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;padding-left:3.36pt;text-decoration:underline">Dispute Resolution.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  (a)  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;text-decoration:underline">Jurisdiction and Venue.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  You and the Company irrevocably submit to the exclusive jurisdiction of (i) the United States District Court for the Eastern District of Virginia and (ii) the courts of the State of Virginia for the purposes of any suit, action or other proceeding arising out of this Award Agreement or the Plan.  You and the Company agree to commence any such action, suit or proceeding either in the United States District Court for the Eastern District of Virginia or, if such suit, action or other proceeding may not be brought in such court for jurisdictional reasons, in the courts of the State of Virginia.  You and the Company further agree that service of any process, summons, notice or document by U.S. registered mail to the other party&#8217;s address set forth below shall be effective service of process for any action, suit or proceeding in Virginia with respect to any matters to which you have submitted to jurisdiction in this Section 10(a).  You and the Company irrevocably and unconditionally waive any objection to the laying of venue of any action, suit or proceeding arising out of this Award Agreement or the Plan in (A) the United States District Court for the Eastern District of Virginia or (B) the courts of the State of Virginia, and hereby and thereby further irrevocably and unconditionally waive and agree not to plead or claim in any such court that any such action, suit or proceeding brought in any such court has been brought in an inconvenient forum.</font></div><div style="text-align:justify;text-indent:72pt"><font><br></font></div><div style="text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">(b) </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;text-decoration:underline">Waiver of Jury Trial.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  You and the Company hereby waive, to the fullest extent permitted by applicable law, any right either of you may have to a trial by jury in respect to any litigation directly or indirectly arising out of, under or in connection with this Award Agreement or the Plan. </font></div><div style="text-align:justify;text-indent:72pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">4</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">(c) </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;text-decoration:underline">Confidentiality.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  You hereby agree to keep confidential the existence of, and any information concerning, a dispute described in this Section 10, except that you may disclose information concerning such dispute to the court that is considering such dispute or to your legal counsel (provided that such counsel agrees not to disclose any such information other than as necessary to the prosecution or defense of the dispute).</font></div><div style="text-align:justify;text-indent:72pt"><font><br></font></div><div style="text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">SECTION 11.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;padding-left:3.36pt;text-decoration:underline">Restrictive Covenants.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  In consideration of the grant of RSUs under this Award Agreement and as a condition to the receipt of the RSUs pursuant to this Award Agreement, you agree that&#58;</font></div><div style="text-align:justify;text-indent:72pt"><font><br></font></div><div style="text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">(a) Confidential Information.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">(i)&#160;&#160;&#160;&#160;You acknowledge that the Company and its Affiliates continually develop Confidential Information (as defined below), that you may develop Confidential Information for the Company or its Affiliates and that the you may learn of Confidential Information during the course of your employment.  You will comply with the policies and procedures of the Company and its Affiliates for protecting Confidential Information and shall not disclose to any person or use, other than as required by applicable law or for the proper performance of your duties and responsibilities to the Company and its Affiliates, any Confidential Information obtained by the you incident to your employment or other association with the Company or any of its Affiliates.  You understand that this restriction shall continue to apply after your employment terminates, regardless of the reason for such termination.  The confidentiality obligation under this Section 11 shall not apply to information which is generally known or readily available to the public at the time of disclosure or becomes generally known through no wrongful act on the part of you or any other person having an obligation of confidentiality to the Company or any of its Affiliates or is required to be disclosed in order to enforce this Award Agreement.</font></div><div style="text-align:justify;text-indent:72pt"><font><br></font></div><div style="text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">(ii)&#160;&#160;&#160;&#160;All documents, records, tapes and other media of every kind and description relating to the business, present or otherwise, of the Company or its Affiliates and any copies, in whole or in part, thereof (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;text-decoration:underline">Documents</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8221;), whether or not prepared by the you, shall be the sole and exclusive property of the Company and its Affiliates.  You shall safeguard all Documents and shall surrender to the Company at the time his or her employment terminates, or at such earlier time or times as the Board or its designee may specify, all Documents then in your possession or control.</font></div><div style="text-align:justify;text-indent:72pt"><font><br></font></div><div style="text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">(iii)&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;text-decoration:underline">Confidential Information</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8221; means any and all information of the Company and its Affiliates that is not generally known by those with whom the Company or any of its Affiliates competes or does business, or with whom the Company or any of its Affiliates plans to compete or do business and any and all information, publicly known in whole or in part or not, which, if disclosed by the Company or any of its Affiliates would assist in competition against them.  Confidential Information includes without limitation such information relating to (A) the development, research, testing, manufacturing, marketing and financial activities of the Company and its Affiliates, (B) the products and services of the Company and its Affiliates, (C) the costs, sources of supply, financial performance and strategic plans of the Company and its Affiliates, (D) the identity and special needs of the customers of the Company and its Affiliates and (E) </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">5</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">the people and organizations with whom the Company and its Affiliates have business relationships and the nature and substance of those relationships.  Confidential Information also includes any information that the Company or any of its Affiliates has received, or may receive hereafter, belonging to customers or others with any understanding, express or implied, that the information would not be disclosed.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">(b)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;text-decoration:underline">Non-Competition and Non-Solicitation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">(i)&#160;&#160;&#160;&#160;You agree and acknowledge that the business (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;text-decoration:underline">Business</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8221;) of the Company is any business activity engaged in, or actively contemplated by the Company (or any Subsidiary) to be engaged in, by the Company (or any Subsidiary) and with which you are or were involved on or prior to the your date of termination.</font></div><div style="text-align:justify;text-indent:72pt"><font><br></font></div><div style="text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">(ii)&#160;&#160;&#160;&#160;You agree that, except as the Company expressly agrees in writing, during your employment with the Company and for the 12-month period following termination of your employment for any reason, you shall not within the Territory (defined below), directly or indirectly, as an owner, partner, affiliate, stockholder, joint venturer, director, employee, consultant, contractor, principal, trustee or licensor, or in any other similar capacity whatsoever of or for any person or entity (other than for the Company)&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">(A)&#160;&#160;&#160;&#160;engage in, own, manage, operate, sell, finance, control, advise or participate in the ownership, management, operation, sales, finance or control of, be employed or employed by, or be connected in any manner with, any business that competes with (1) the Business or (2) if you have provided services directly to any health maintenance organization, health insurance company or similar health insurance plan, owned or operated by a customer of the Company, during the twelve-month period preceding the termination of your employment with the Company, such customer (each, a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;text-decoration:underline">Competitor</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8221;).  Notwithstanding this Section 11(b)(ii)(A), you may accept employment with a Competitor whose business is diversified, provided that (I) such employment is with a portion of the Competitor&#8217;s business that does not provide products or services that are the same as, are similar to, or compete with the Company&#8217;s products or services (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;text-decoration:underline">Competing Products or Services</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8221;) and (II) prior to your acceptance of such employment with Competitor, the Company receives separate written assurances satisfactory to the Company from such Competitor and from you that you will not provide any Competing Products or Services&#59;</font></div><div style="padding-left:36pt;text-align:justify;text-indent:36pt"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">(B)&#160;&#160;&#160;&#160;approach, solicit, divert, interfere with, or take away, the business or patronage of any of the actual or prospective members, customers, or clients of the Company, for a purpose that is competitive with the Business&#59; or</font></div><div style="padding-left:36pt;text-align:justify;text-indent:36pt"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">(C)&#160;&#160;&#160;&#160;contact, recruit, solicit, hire, retain, or employ (whether as an employee, consultant, agent, independent contractor, or otherwise) any person who is, or who at any time during the 6-month period prior to your date of termination had been, employed or engaged by the Company, or induce or take any action which is intended to induce any such person to terminate his or her employment or relationship, or otherwise cease his or her relationship, with the </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">6</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">Company, or interfere in any manner with the contractual or employment relationship between the Company and any employee of or any other person engaged by the Company.</font></div><div style="text-align:justify;text-indent:108pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;text-decoration:underline">Territory</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8221; shall mean the United States of America and any other country with respect to which you have been involved on behalf of the Company.   </font></div><div style="text-align:justify;text-indent:31.5pt"><font><br></font></div><div style="text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">(iii)&#160;&#160;&#160;&#160;Notwithstanding anything to the contrary in Section 11(b)(ii) of this Award Agreement, you are permitted to own, individually, as a passive investor (with no director designation rights, voting rights or veto rights or other special governance or voting rights), up to a one percent (1%) interest in any publicly traded entity that is a Competitor.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">(iv)&#160;&#160;&#160;&#160;You shall disclose in writing all of your relationships as a director, employee, consultant, contractor, principal, trustee, licensor, agent, or otherwise, with a Competitor or other business entity, to the Company for the 12-month period after your date of termination.  You shall not disparage the Company or any of its officers, directors, or employees&#59; provided, however, that this Section 11(b)(iv) shall not prohibit or constrain truthful testimony by you compelled by any valid legal process or valid legal dispute resolution process.  Notwithstanding anything herein to the contrary, nothing in this Section 11 shall prevent either party hereto from enforcing such party&#8217;s rights or remedies hereunder or that such party may otherwise be entitled to enforce or assert under any other agreement or applicable law, or shall limit such rights or remedies in any way.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">(v)&#160;&#160;&#160;&#160;During the 12-month period following your date of termination, you shall notify in writing any prospective new employer or entity otherwise seeking to engage you that the provisions of this Section 11 exist prior to accepting employment or such other engagement.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">(c)&#160;&#160;&#160;&#160;The terms of this Section 11 are reasonable and necessary in light of your position with the Company and responsibility and knowledge of the operations of the Company and its Subsidiaries and are not more restrictive than necessary to protect the legitimate interests of the parties hereto.  In addition, any breach of the covenants contained in this Section 11 would cause irreparable harm to the Company, its Subsidiaries and Affiliates and there would be no adequate remedy at law or in damages to compensate the Company, its Subsidiaries and Affiliates for any such breach.  Notwithstanding the foregoing, this Award Agreement is not intended to, and shall be interpreted in a manner that does not, limit or restrict you from exercising any legally protected whistleblower rights (including pursuant to Rule 21F under the Securities Exchange Act of 1934). </font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">SECTION 12.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;padding-left:3.36pt;text-decoration:underline">Notice.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  All notices, requests, demands and other communications required or permitted to be given under the terms of this Award Agreement shall be in writing and shall be deemed to have been duly given when delivered by hand or overnight courier or three Business Days after they have been mailed by U.S. certified or registered mail, return receipt requested, postage prepaid, addressed to the other party as set forth below&#58;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">7</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:83.333%"><tr><td style="width:1.0%"></td><td style="width:47.858%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:49.942%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;text-indent:72pt;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">If to the Company&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">Evolent Health, Inc.<br>800 N. Glebe Road, Suite 500<br>Arlington, VA 22203<br>Attention&#58; General Counsel<br></font></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;text-indent:72pt;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">If to you&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">To your address as most recently supplied to the Company and set forth in the Company&#8217;s records<br></font></td></tr></table></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">The parties may change the address to which notices under this Award Agreement shall be sent by providing written notice to the other in the manner specified above.  </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">SECTION 13.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;padding-left:3.36pt;text-decoration:underline">Governing Law.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  This Award Agreement shall be deemed to be made in the State of Delaware, and the validity, construction and effect of this Award Agreement in all respects shall be determined in accordance with the laws of the State of Delaware, without giving effect to the conflict of law principles thereof.</font></div><div style="text-align:justify;text-indent:72pt"><font><br></font></div><div style="text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">SECTION 14.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;padding-left:3.36pt;text-decoration:underline">Headings and Construction.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  Headings are given to the Sections and subsections of this Award Agreement solely as a convenience to facilitate reference. Such headings shall not be deemed in any way material or relevant to the construction or interpretation of this Award Agreement or any provision thereof.  Whenever the words &#8220;include&#8221;, &#8220;includes&#8221; or &#8220;including&#8221; are used in this Award Agreement, they shall be deemed to be followed by the words &#8220;but not limited to&#8221;.  The term &#8220;or&#8221; is not exclusive.</font></div><div style="text-align:justify;text-indent:72pt"><font><br></font></div><div style="text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">SECTION 15.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;padding-left:3.36pt;text-decoration:underline">Amendment of this Award Agreement.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  The Committee may waive any conditions or rights under, amend any terms of, or alter, suspend, discontinue, cancel or terminate this Award Agreement prospectively or retroactively&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;text-decoration:underline">however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">, that, except as set forth in Section 16(d) of this Award Agreement, any such waiver, amendment, alteration, suspension, discontinuance, cancelation or termination that would impair your rights under this Award Agreement shall not to that extent be effective without your consent (it being understood, notwithstanding the foregoing proviso, that this Award Agreement and the RSUs shall be subject to the provisions of Section 7(c) of the Plan).</font></div><div style="text-align:justify;text-indent:72pt"><font><br></font></div><div style="text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">SECTION 16.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;padding-left:3.36pt;text-decoration:underline">Section 409A.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  (a)  It is intended that the provisions of this Award Agreement be exempt from or comply with Section 409A, and all provisions of this Award Agreement shall be construed and interpreted in a manner consistent with the requirements for avoiding taxes or penalties under Section 409A.</font></div><div style="text-align:justify;text-indent:72pt"><font><br></font></div><div style="text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">(b) Neither you nor any of your creditors or beneficiaries shall have the right to subject any deferred compensation (within the meaning of Section 409A) payable under this Award Agreement to any anticipation, alienation, sale, transfer, assignment, pledge, encumbrance, attachment or garnishment.  Except as permitted under Section 409A, any deferred compensation (within the meaning of Section 409A) payable to you </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">8</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">or for your benefit under this Award Agreement may not be reduced by, or offset against, any amount owing by you to the Company or any of its Affiliates.</font></div><div style="text-align:justify;text-indent:72pt"><font><br></font></div><div style="text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">(c)  If, at the time of your separation from service (within the meaning of Section 409A), (i) you shall be a specified employee (within the meaning of Section 409A and using the identification methodology selected by the Company from time to time) and (ii) the Company shall make a good faith determination that an amount payable hereunder constitutes deferred compensation (within the meaning of Section 409A) the payment of which is required to be delayed pursuant to the six-month delay rule set forth in Section 409A in order to avoid taxes or penalties under Section 409A, then the Company shall not pay such amount on the otherwise scheduled payment date but shall instead pay it, without interest, on the first business day after such six-month period.</font></div><div style="text-align:justify;text-indent:72pt"><font><br></font></div><div style="text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">(d) Notwithstanding any provision of this Award Agreement to the contrary, in light of the uncertainty with respect to the proper application of Section 409A, the Company reserves the right to make amendments to this Award Agreement as the Company deems necessary or desirable to avoid the imposition of taxes or penalties under Section 409A.  In any case, you shall be solely responsible and liable for the satisfaction of all taxes and penalties that may be imposed on you or for your account in connection with this Award Agreement (including any taxes and penalties under Section 409A), and neither the Company nor any of its Affiliates shall have any obligation to indemnify or otherwise hold you harmless from any or all of such taxes or penalties.</font></div><div style="text-align:justify;text-indent:72pt"><font><br></font></div><div style="text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;text-decoration:underline">Counterparts.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  This Award Agreement may be signed in counterparts, each of which shall be an original, with the same effect as if the signatures thereto and hereto were upon the same instrument.  You and the Company hereby acknowledge and agree that signatures delivered by facsimile or electronic means (including by &#8220;pdf&#8221;) shall be deemed effective for all purposes.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">9</font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-21.1
<SEQUENCE>4
<FILENAME>exhibit211.htm
<DESCRIPTION>EX-21.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="icaa2ac738afc4786a67d91a187a08440_33"></div><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 21.1</font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">List of Subsidiaries</font></div><div style="text-align:center"><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:68.291%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:28.868%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Legal Name</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Jurisdiction of Organization</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Evolent Health LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">NCIS Holdings, Inc.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">NCH Management Systems, Inc.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">California</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Evolent Assurance Solutions, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Vermont</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">EH Holding Company, Inc.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Justify Holdings, Inc.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Kentucky</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Evolent Health International Private Ltd.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">India</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Evolent Care Partners Holding Company, Inc.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Evolent Care Partners of Texas, Inc.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Texas</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Accountable Care Organization Ltd.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Michigan</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Evolent Care Partners of North Carolina, Inc. </font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">North Carolina</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">MTS III Vital Decisions Blocker Corp </font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Vital Decisions Acquisition LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Vital Decisions, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">New Jersey</font></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>5
<FILENAME>a123121exhibit231.htm
<DESCRIPTION>EX-23.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="id17b44f580c949578d62759d286784b7_1"></div><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Exhibit 23.1</font></div></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">We consent to the incorporation by reference in Registration Statement No. 333-212709 on Form S-3 and Registration Statement Nos. 333-204785, 333-225714 and 333-257118 on Form S-8 of our reports dated February 23, 2022, relating to the financial statements of Evolent Health, Inc. and subsidiaries (the &#8220;Company&#8221;) and the effectiveness of the Company&#8217;s internal control over financial reporting appearing in this Annual Report on Form 10-K for the year ended December 31, 2021.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#47;s&#47; Deloitte &#38; Touche LLP </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">McLean, Virginia </font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">February 23, 2022</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>6
<FILENAME>a123121exhibit311.htm
<DESCRIPTION>EX-31.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="i4b8b6a0e871b47048bb18b0d860c0247_1"></div><div style="min-height:18pt;width:100%"><div><font><br></font></div></div><div style="padding-left:24.75pt;text-align:right;text-indent:-22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 31.1</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Certification Pursuant to Section 302 of the</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Sarbanes-Oxley Act of 2002</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Seth Blackley, certify that&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">I have reviewed this Annual Report on Form 10-K of Evolent Health, Inc.&#59;</font></div><div style="padding-left:18pt;text-align:justify"><font><br></font></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.07pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.07pt">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The registrant&#8217;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.07pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="padding-left:18pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.944%"><tr><td style="width:1.0%"></td><td style="width:5.999%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.026%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:26.090%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:46.485%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dated&#58; </font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 23, 2022</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47;  Seth Blackley</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Name&#58;  Seth Blackley</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Title&#58;  Chief Executive Officer</font></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><font><br></font></div><div style="height:18pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>7
<FILENAME>a123121exhibit312.htm
<DESCRIPTION>EX-31.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="i71ac9a1d33ef4e8c90f0a082b55538a2_1"></div><div style="min-height:18pt;width:100%"><div><font><br></font></div></div><div style="padding-left:24.75pt;text-align:right;text-indent:-22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 31.2</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Certification Pursuant to Section 302 of the</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Sarbanes-Oxley Act of 2002</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, John Johnson, certify that&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">I have reviewed this Annual Report on Form 10-K of Evolent Health, Inc.&#59;</font></div><div style="padding-left:18pt;text-align:justify"><font><br></font></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.07pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.07pt">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The registrant&#8217;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.07pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="padding-left:18pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.944%"><tr><td style="width:1.0%"></td><td style="width:5.999%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.026%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:26.090%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:46.485%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dated&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 23, 2022</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47;  John Johnson</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Name&#58;  John Johnson</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Title&#58;  Chief Financial Officer</font></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><font><br></font></div><div style="height:18pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>8
<FILENAME>a123121exhibit321.htm
<DESCRIPTION>EX-32.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="i3d87abaa35ef424fad5ceec617a9d450_1"></div><div style="min-height:18pt;width:100%"><div><font><br></font></div></div><div style="padding-left:24.75pt;text-align:right;text-indent:-22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 32.1</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Certification Pursuant to 18 U.S.C. Section 1350,</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">As Adopted Pursuant to Section 906</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Of the Sarbanes-Oxley Act of 2002</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Seth Blackley, Chief Executive Officer of Evolent Health, Inc. (the &#8220;Company&#8221;), certify, pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, 18 U.S.C. Section 1350, that&#58;</font></div><div><font><br></font></div><div style="padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The Annual Report on Form 10-K of the Company for the year ended December&#160;31, 2021 (the &#8220;Report&#8221;), fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934 (15 U.S.C. 78m)&#59; and</font></div><div style="padding-left:18pt"><font><br></font></div><div style="padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div><div><font><br></font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:496.50pt"><tr><td style="width:1.0pt"></td><td style="width:33.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:88.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:133.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:234.25pt"></td><td style="width:1.0pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dated&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 23, 2022</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47;  Seth Blackley</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Name&#58;  Seth Blackley</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Title&#58;  Chief Executive Officer</font></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A signed original of this written statement required by Section 906 has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.</font></div><div><font><br></font></div><div style="height:18pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>9
<FILENAME>a123121exhibit322.htm
<DESCRIPTION>EX-32.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="i8d8794ab9be6491b93e1f15bedc750f4_1"></div><div style="min-height:18pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 32.2</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Certification Pursuant to 18 U.S.C. Section 1350,</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">As Adopted Pursuant to Section 906</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Of the Sarbanes-Oxley Act of 2002</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, John Johnson, Chief Financial Officer of Evolent Health, Inc. (the &#8220;Company&#8221;), certify, pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, 18 U.S.C. Section 1350, that&#58;</font></div><div><font><br></font></div><div style="padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The Annual Report on Form 10-K of the Company for the year ended December&#160;31, 2021 (the &#8220;Report&#8221;), fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934 (15 U.S.C. 78m)&#59; and</font></div><div style="padding-left:18pt"><font><br></font></div><div style="padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:496.50pt"><tr><td style="width:1.0pt"></td><td style="width:33.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:88.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:133.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:234.25pt"></td><td style="width:1.0pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dated&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 23, 2022</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47;  John Johnson</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Name&#58;  John Johnson</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Title&#58;  Chief Financial Officer</font></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A signed original of this written statement required by Section 906 has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.</font></div><div><font><br></font></div><div style="height:18pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>10
<FILENAME>evh-20211231.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:cffd2bd6-4cc3-4881-a14e-c3c94aea5d0e,g:f4f494d2-75b7-48aa-a2de-31bddada82ae-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:evh="http://www.evolenthealth.com/20211231" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.evolenthealth.com/20211231">
  <xs:import namespace="http://fasb.org/srt/2021-01-31" schemaLocation="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd"/>
  <xs:import namespace="http://fasb.org/us-gaap/2021-01-31" schemaLocation="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd"/>
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/country/2021" schemaLocation="https://xbrl.sec.gov/country/2021/country-2021.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2021q4" schemaLocation="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/stpr/2021" schemaLocation="https://xbrl.sec.gov/stpr/2021/stpr-2021.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="evh-20211231_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="evh-20211231_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="evh-20211231_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="evh-20211231_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="CoverPage" roleURI="http://www.evolenthealth.com/role/CoverPage">
        <link:definition>000010001 - Document - Cover Page</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AuditInformation" roleURI="http://www.evolenthealth.com/role/AuditInformation">
        <link:definition>000020002 - Document - Audit Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDBALANCESHEETS" roleURI="http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS">
        <link:definition>100010003 - Statement - CONSOLIDATED BALANCE SHEETS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDBALANCESHEETSParenthetical" roleURI="http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETSParenthetical">
        <link:definition>100020004 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS" roleURI="http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS">
        <link:definition>100030005 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (LOSS)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSSParenthetical" roleURI="http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSSParenthetical">
        <link:definition>100040006 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (LOSS) (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY" roleURI="http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY">
        <link:definition>100050007 - Statement - CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS' EQUITY</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDSTATEMENTSOFCASHFLOWS" roleURI="http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS">
        <link:definition>100060008 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Organization" roleURI="http://www.evolenthealth.com/role/Organization">
        <link:definition>210011001 - Disclosure - Organization</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OrganizationDetails" roleURI="http://www.evolenthealth.com/role/OrganizationDetails">
        <link:definition>240024001 - Disclosure - Organization (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciples" roleURI="http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciples">
        <link:definition>210031002 - Disclosure - Basis of Presentation, Summary of Significant Accounting Policies and Change in Accounting Principles</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesPolicies" roleURI="http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesPolicies">
        <link:definition>220042001 - Disclosure - Basis of Presentation, Summary of Significant Accounting Policies and Change in Accounting Principles (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesTables" roleURI="http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesTables">
        <link:definition>230053001 - Disclosure - Basis of Presentation, Summary of Significant Accounting Policies and Change in Accounting Principles (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesOperatingSegmentsDetails" roleURI="http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesOperatingSegmentsDetails">
        <link:definition>240064002 - Disclosure - Basis of Presentation, Summary of Significant Accounting Policies and Change in Accounting Principles - Operating Segments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesRestrictedCashandRestrictedInvestmentsDetails" roleURI="http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesRestrictedCashandRestrictedInvestmentsDetails">
        <link:definition>240074003 - Disclosure - Basis of Presentation, Summary of Significant Accounting Policies and Change in Accounting Principles - Restricted Cash and Restricted Investments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesEstimatedUsefulLifeofPropertyPlantandEquipmentDetails" roleURI="http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesEstimatedUsefulLifeofPropertyPlantandEquipmentDetails">
        <link:definition>240084004 - Disclosure - Basis of Presentation, Summary of Significant Accounting Policies and Change in Accounting Principles - Estimated Useful Life of Property, Plant and Equipment (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesResearchandDevelopmentCostsDetails" roleURI="http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesResearchandDevelopmentCostsDetails">
        <link:definition>240094005 - Disclosure - Basis of Presentation, Summary of Significant Accounting Policies and Change in Accounting Principles - Research and Development Costs (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesGoodwillDetails" roleURI="http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesGoodwillDetails">
        <link:definition>240104006 - Disclosure - Basis of Presentation, Summary of Significant Accounting Policies and Change in Accounting Principles - Goodwill (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesIntangibleAssetsNetDetails" roleURI="http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesIntangibleAssetsNetDetails">
        <link:definition>240114007 - Disclosure - Basis of Presentation, Summary of Significant Accounting Policies and Change in Accounting Principles - Intangible Assets, Net (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesRightofOffsetDetails" roleURI="http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesRightofOffsetDetails">
        <link:definition>240124008 - Disclosure - Basis of Presentation, Summary of Significant Accounting Policies and Change in Accounting Principles - Right of Offset (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesStockbasedCompensationDetails" roleURI="http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesStockbasedCompensationDetails">
        <link:definition>240134009 - Disclosure - Basis of Presentation, Summary of Significant Accounting Policies and Change in Accounting Principles - Stock-based Compensation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RecentlyIssuedAccountingStandards" roleURI="http://www.evolenthealth.com/role/RecentlyIssuedAccountingStandards">
        <link:definition>210141003 - Disclosure - Recently Issued Accounting Standards</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RecentlyIssuedAccountingStandardsDetails" roleURI="http://www.evolenthealth.com/role/RecentlyIssuedAccountingStandardsDetails">
        <link:definition>240154010 - Disclosure - Recently Issued Accounting Standards (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Transactions" roleURI="http://www.evolenthealth.com/role/Transactions">
        <link:definition>210161004 - Disclosure - Transactions</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="TransactionsTables" roleURI="http://www.evolenthealth.com/role/TransactionsTables">
        <link:definition>230173002 - Disclosure - Transactions (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="TransactionsVitalDecisionsDetails" roleURI="http://www.evolenthealth.com/role/TransactionsVitalDecisionsDetails">
        <link:definition>240184011 - Disclosure - Transactions - Vital Decisions (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="TransactionsEquityInvestmentsDetails" roleURI="http://www.evolenthealth.com/role/TransactionsEquityInvestmentsDetails">
        <link:definition>240194012 - Disclosure - Transactions - Equity Investments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DiscontinuedOperations" roleURI="http://www.evolenthealth.com/role/DiscontinuedOperations">
        <link:definition>210201005 - Disclosure - Discontinued Operations</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DiscontinuedOperationsTables" roleURI="http://www.evolenthealth.com/role/DiscontinuedOperationsTables">
        <link:definition>230213003 - Disclosure - Discontinued Operations (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DiscontinuedOperationsAdditionalInformationDetails" roleURI="http://www.evolenthealth.com/role/DiscontinuedOperationsAdditionalInformationDetails">
        <link:definition>240224013 - Disclosure - Discontinued Operations - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DiscontinuedOperationsSummaryofResultsofOperationsDetails" roleURI="http://www.evolenthealth.com/role/DiscontinuedOperationsSummaryofResultsofOperationsDetails">
        <link:definition>240234014 - Disclosure - Discontinued Operations - Summary of Results of Operations (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DiscontinuedOperationsSummaryofCashFlowsDetails" roleURI="http://www.evolenthealth.com/role/DiscontinuedOperationsSummaryofCashFlowsDetails">
        <link:definition>240244015 - Disclosure - Discontinued Operations - Summary of Cash Flows (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DiscontinuedOperationsSummaryofCurrentandLongtermAssetsandLiabilitiesDetails" roleURI="http://www.evolenthealth.com/role/DiscontinuedOperationsSummaryofCurrentandLongtermAssetsandLiabilitiesDetails">
        <link:definition>240254016 - Disclosure - Discontinued Operations - Summary of Current and Long-term Assets and Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenueRecognition" roleURI="http://www.evolenthealth.com/role/RevenueRecognition">
        <link:definition>210261006 - Disclosure - Revenue Recognition</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenueRecognitionTables" roleURI="http://www.evolenthealth.com/role/RevenueRecognitionTables">
        <link:definition>230273004 - Disclosure - Revenue Recognition (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenueRecognitionDisaggregationofRevenueDetails" roleURI="http://www.evolenthealth.com/role/RevenueRecognitionDisaggregationofRevenueDetails">
        <link:definition>240284017 - Disclosure - Revenue Recognition - Disaggregation of Revenue (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenueRecognitionTransactionPriceAllocatedtotheRemainingPerformanceObligationsDetails" roleURI="http://www.evolenthealth.com/role/RevenueRecognitionTransactionPriceAllocatedtotheRemainingPerformanceObligationsDetails">
        <link:definition>240294018 - Disclosure - Revenue Recognition - Transaction Price Allocated to the Remaining Performance Obligations (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenueRecognitionTransactionPriceAllocatedtotheRemainingPerformanceObligationsDetails_1" roleURI="http://www.evolenthealth.com/role/RevenueRecognitionTransactionPriceAllocatedtotheRemainingPerformanceObligationsDetails_1">
        <link:definition>240294018 - Disclosure - Revenue Recognition - Transaction Price Allocated to the Remaining Performance Obligations (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenueRecognitionContractBalancesDetails" roleURI="http://www.evolenthealth.com/role/RevenueRecognitionContractBalancesDetails">
        <link:definition>240304019 - Disclosure - Revenue Recognition - Contract Balances (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenueRecognitionContractCostsDetails" roleURI="http://www.evolenthealth.com/role/RevenueRecognitionContractCostsDetails">
        <link:definition>240314020 - Disclosure - Revenue Recognition - Contract Costs (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CreditLosses" roleURI="http://www.evolenthealth.com/role/CreditLosses">
        <link:definition>210321007 - Disclosure - Credit Losses</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CreditLossesTables" roleURI="http://www.evolenthealth.com/role/CreditLossesTables">
        <link:definition>230333005 - Disclosure - Credit Losses (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CreditLossesAccountsReceivableNarrativeDetails" roleURI="http://www.evolenthealth.com/role/CreditLossesAccountsReceivableNarrativeDetails">
        <link:definition>240344021 - Disclosure - Credit Losses - Accounts Receivable (Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CreditLossesScheduleofChangesinAllowanceforAccountsReceivableDetails" roleURI="http://www.evolenthealth.com/role/CreditLossesScheduleofChangesinAllowanceforAccountsReceivableDetails">
        <link:definition>240354022 - Disclosure - Credit Losses - Schedule of Changes in Allowance for Accounts Receivable (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyandEquipmentNet" roleURI="http://www.evolenthealth.com/role/PropertyandEquipmentNet">
        <link:definition>210361008 - Disclosure - Property and Equipment, Net</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyandEquipmentNetTables" roleURI="http://www.evolenthealth.com/role/PropertyandEquipmentNetTables">
        <link:definition>230373006 - Disclosure - Property and Equipment, Net (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyandEquipmentNetDetails" roleURI="http://www.evolenthealth.com/role/PropertyandEquipmentNetDetails">
        <link:definition>240384023 - Disclosure - Property and Equipment, Net (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GoodwillandIntangibleAssetsNet" roleURI="http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNet">
        <link:definition>210391009 - Disclosure - Goodwill and Intangible Assets, Net</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GoodwillandIntangibleAssetsNetTables" roleURI="http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNetTables">
        <link:definition>230403007 - Disclosure - Goodwill and Intangible Assets, Net (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GoodwillandIntangibleAssetsNetImpairmentTestingDetails" roleURI="http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNetImpairmentTestingDetails">
        <link:definition>240414024 - Disclosure - Goodwill and Intangible Assets, Net - Impairment Testing (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GoodwillandIntangibleAssetsNetScheduleofGoodwillDetails" roleURI="http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNetScheduleofGoodwillDetails">
        <link:definition>240424025 - Disclosure - Goodwill and Intangible Assets, Net - Schedule of Goodwill (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GoodwillandIntangibleAssetsNetIntangibleAssetsNetDetails" roleURI="http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNetIntangibleAssetsNetDetails">
        <link:definition>240434026 - Disclosure - Goodwill and Intangible Assets, Net - Intangible Assets, Net (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GoodwillandIntangibleAssetsNetAmortizationofIntangibleAssetsDetails" roleURI="http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNetAmortizationofIntangibleAssetsDetails">
        <link:definition>240444027 - Disclosure - Goodwill and Intangible Assets, Net - Amortization of Intangible Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LongtermDebt" roleURI="http://www.evolenthealth.com/role/LongtermDebt">
        <link:definition>210451010 - Disclosure - Long-term Debt</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LongtermDebtTables" roleURI="http://www.evolenthealth.com/role/LongtermDebtTables">
        <link:definition>230463008 - Disclosure - Long-term Debt (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LongtermDebt2024NotesDetails" roleURI="http://www.evolenthealth.com/role/LongtermDebt2024NotesDetails">
        <link:definition>240474028 - Disclosure - Long-term Debt - 2024 Notes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LongtermDebtCreditAgreementDetails" roleURI="http://www.evolenthealth.com/role/LongtermDebtCreditAgreementDetails">
        <link:definition>240484029 - Disclosure - Long-term Debt - Credit Agreement (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LongtermDebtWarrantAgreementDetails" roleURI="http://www.evolenthealth.com/role/LongtermDebtWarrantAgreementDetails">
        <link:definition>240494030 - Disclosure - Long-term Debt - Warrant Agreement (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LongtermDebt2025NotesDetails" roleURI="http://www.evolenthealth.com/role/LongtermDebt2025NotesDetails">
        <link:definition>240504031 - Disclosure - Long-term Debt - 2025 Notes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LongtermDebt2021NotesDetails" roleURI="http://www.evolenthealth.com/role/LongtermDebt2021NotesDetails">
        <link:definition>240514032 - Disclosure - Long-term Debt - 2021 Notes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LongtermDebtConvertibleSeniorNotesCarryingValueDetails" roleURI="http://www.evolenthealth.com/role/LongtermDebtConvertibleSeniorNotesCarryingValueDetails">
        <link:definition>240524033 - Disclosure - Long-term Debt - Convertible Senior Notes Carrying Value (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingencies" roleURI="http://www.evolenthealth.com/role/CommitmentsandContingencies">
        <link:definition>210531011 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingenciesTables" roleURI="http://www.evolenthealth.com/role/CommitmentsandContingenciesTables">
        <link:definition>230543009 - Disclosure - Commitments and Contingencies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingenciesAdditionalInformationDetails" roleURI="http://www.evolenthealth.com/role/CommitmentsandContingenciesAdditionalInformationDetails">
        <link:definition>240554034 - Disclosure - Commitments and Contingencies - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingenciesReinsuranceAgreementsDetails" roleURI="http://www.evolenthealth.com/role/CommitmentsandContingenciesReinsuranceAgreementsDetails">
        <link:definition>240564035 - Disclosure - Commitments and Contingencies - Reinsurance Agreements (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingenciesConcentrationRiskDetails" roleURI="http://www.evolenthealth.com/role/CommitmentsandContingenciesConcentrationRiskDetails">
        <link:definition>240574036 - Disclosure - Commitments and Contingencies - Concentration Risk (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Leases" roleURI="http://www.evolenthealth.com/role/Leases">
        <link:definition>210581012 - Disclosure - Leases</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesTables" roleURI="http://www.evolenthealth.com/role/LeasesTables">
        <link:definition>230593010 - Disclosure - Leases (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesNarrativeDetails" roleURI="http://www.evolenthealth.com/role/LeasesNarrativeDetails">
        <link:definition>240604037 - Disclosure - Leases - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesPrimaryOfficeLeasesDetails" roleURI="http://www.evolenthealth.com/role/LeasesPrimaryOfficeLeasesDetails">
        <link:definition>240614038 - Disclosure - Leases - Primary Office Leases (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesComponentsofLeaseExpenseDetails" roleURI="http://www.evolenthealth.com/role/LeasesComponentsofLeaseExpenseDetails">
        <link:definition>240624039 - Disclosure - Leases - Components of Lease Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesMaturityofLeaseLiabilitiesDetails" roleURI="http://www.evolenthealth.com/role/LeasesMaturityofLeaseLiabilitiesDetails">
        <link:definition>240634040 - Disclosure - Leases - Maturity of Lease Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesMaturityofLeaseLiabilitiesDetails_1" roleURI="http://www.evolenthealth.com/role/LeasesMaturityofLeaseLiabilitiesDetails_1">
        <link:definition>240634040 - Disclosure - Leases - Maturity of Lease Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesWeightedaverageDiscountRateandWeightedremainingLeaseTermsDetails" roleURI="http://www.evolenthealth.com/role/LeasesWeightedaverageDiscountRateandWeightedremainingLeaseTermsDetails">
        <link:definition>240644041 - Disclosure - Leases - Weighted-average Discount Rate and Weighted-remaining Lease Terms (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EarningsLossPerCommonShare" roleURI="http://www.evolenthealth.com/role/EarningsLossPerCommonShare">
        <link:definition>210651013 - Disclosure - Earnings (Loss) Per Common Share</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EarningsLossPerCommonShareTables" roleURI="http://www.evolenthealth.com/role/EarningsLossPerCommonShareTables">
        <link:definition>230663011 - Disclosure - Earnings (Loss) Per Common Share (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EarningsLossPerCommonShareComputationofEarningsperShareDetails" roleURI="http://www.evolenthealth.com/role/EarningsLossPerCommonShareComputationofEarningsperShareDetails">
        <link:definition>240674042 - Disclosure - Earnings (Loss) Per Common Share - Computation of Earnings per Share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EarningsLossPerCommonShareAntidilutiveSecuritiesDetails" roleURI="http://www.evolenthealth.com/role/EarningsLossPerCommonShareAntidilutiveSecuritiesDetails">
        <link:definition>240684043 - Disclosure - Earnings (Loss) Per Common Share - Antidilutive Securities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockbasedCompensation" roleURI="http://www.evolenthealth.com/role/StockbasedCompensation">
        <link:definition>210691014 - Disclosure - Stock-based Compensation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockbasedCompensationTables" roleURI="http://www.evolenthealth.com/role/StockbasedCompensationTables">
        <link:definition>230703012 - Disclosure - Stock-based Compensation (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockbasedCompensation2011and2015EquityIncentivePlansDetails" roleURI="http://www.evolenthealth.com/role/StockbasedCompensation2011and2015EquityIncentivePlansDetails">
        <link:definition>240714044 - Disclosure - Stock-based Compensation - 2011 and 2015 Equity Incentive Plans (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockbasedCompensationStockbasedCompensationExpenseDetails" roleURI="http://www.evolenthealth.com/role/StockbasedCompensationStockbasedCompensationExpenseDetails">
        <link:definition>240724045 - Disclosure - Stock-based Compensation - Stock-based Compensation Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockbasedCompensationAdditionalInformationDetails" roleURI="http://www.evolenthealth.com/role/StockbasedCompensationAdditionalInformationDetails">
        <link:definition>240734046 - Disclosure - Stock-based Compensation - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockbasedCompensationUnrecognizedCompensationExpenseDetails" roleURI="http://www.evolenthealth.com/role/StockbasedCompensationUnrecognizedCompensationExpenseDetails">
        <link:definition>240744047 - Disclosure - Stock-based Compensation - Unrecognized Compensation Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockbasedCompensationStockOptionsDetails" roleURI="http://www.evolenthealth.com/role/StockbasedCompensationStockOptionsDetails">
        <link:definition>240754048 - Disclosure - Stock-based Compensation - Stock Options (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockbasedCompensationStockOptionActivityDetails" roleURI="http://www.evolenthealth.com/role/StockbasedCompensationStockOptionActivityDetails">
        <link:definition>240764049 - Disclosure - Stock-based Compensation - Stock Option Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockbasedCompensationPerformancebasedStockOptionAwardsDetails" roleURI="http://www.evolenthealth.com/role/StockbasedCompensationPerformancebasedStockOptionAwardsDetails">
        <link:definition>240774050 - Disclosure - Stock-based Compensation - Performance-based Stock Option Awards (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockbasedCompensationRestrictedStockUnitsDetails" roleURI="http://www.evolenthealth.com/role/StockbasedCompensationRestrictedStockUnitsDetails">
        <link:definition>240784051 - Disclosure - Stock-based Compensation - Restricted Stock Units (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockbasedCompensationLeveragedStockUnitsDetails" roleURI="http://www.evolenthealth.com/role/StockbasedCompensationLeveragedStockUnitsDetails">
        <link:definition>240794052 - Disclosure - Stock-based Compensation - Leveraged Stock Units (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockbasedCompensationLeveragedStockUnitsActivityDetails" roleURI="http://www.evolenthealth.com/role/StockbasedCompensationLeveragedStockUnitsActivityDetails">
        <link:definition>240804053 - Disclosure - Stock-based Compensation - Leveraged Stock Units Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockbasedCompensationPerformancebasedRSUsDetails" roleURI="http://www.evolenthealth.com/role/StockbasedCompensationPerformancebasedRSUsDetails">
        <link:definition>240814054 - Disclosure - Stock-based Compensation - Performance-based RSUs (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockbasedCompensationPerformancebasedRSUActivityDetails" roleURI="http://www.evolenthealth.com/role/StockbasedCompensationPerformancebasedRSUActivityDetails">
        <link:definition>240824055 - Disclosure - Stock-based Compensation - Performance-based RSU Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxes" roleURI="http://www.evolenthealth.com/role/IncomeTaxes">
        <link:definition>210831015 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesTables" roleURI="http://www.evolenthealth.com/role/IncomeTaxesTables">
        <link:definition>230843013 - Disclosure - Income Taxes (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesNarrativeDetails" roleURI="http://www.evolenthealth.com/role/IncomeTaxesNarrativeDetails">
        <link:definition>240854056 - Disclosure - Income Taxes - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesScheduleofLossBeforeProvisionforIncomeTaxesDetails" roleURI="http://www.evolenthealth.com/role/IncomeTaxesScheduleofLossBeforeProvisionforIncomeTaxesDetails">
        <link:definition>240864057 - Disclosure - Income Taxes - Schedule of Loss Before Provision for Income Taxes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesIncomeTaxExpenseBenefitDetails" roleURI="http://www.evolenthealth.com/role/IncomeTaxesIncomeTaxExpenseBenefitDetails">
        <link:definition>240874058 - Disclosure - Income Taxes - Income Tax Expense (Benefit) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesReconciliationofStatutoryRatetoEffectiveTaxRateDetails" roleURI="http://www.evolenthealth.com/role/IncomeTaxesReconciliationofStatutoryRatetoEffectiveTaxRateDetails">
        <link:definition>240884059 - Disclosure - Income Taxes - Reconciliation of Statutory Rate to Effective Tax Rate (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails" roleURI="http://www.evolenthealth.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails">
        <link:definition>240894060 - Disclosure - Income Taxes - Deferred Tax Assets and Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesChangesinValuationAllowanceDetails" roleURI="http://www.evolenthealth.com/role/IncomeTaxesChangesinValuationAllowanceDetails">
        <link:definition>240904061 - Disclosure - Income Taxes - Changes in Valuation Allowance (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesChangesInUnrecognizedTaxBenefitsDetails" roleURI="http://www.evolenthealth.com/role/IncomeTaxesChangesInUnrecognizedTaxBenefitsDetails">
        <link:definition>240914062 - Disclosure - Income Taxes - Changes In Unrecognized Tax Benefits (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EmployeeBenefitPlans" roleURI="http://www.evolenthealth.com/role/EmployeeBenefitPlans">
        <link:definition>210921016 - Disclosure - Employee Benefit Plans</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EmployeeBenefitPlansDetails" roleURI="http://www.evolenthealth.com/role/EmployeeBenefitPlansDetails">
        <link:definition>240934063 - Disclosure - Employee Benefit Plans (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InvestmentsinEquityMethodInvestees" roleURI="http://www.evolenthealth.com/role/InvestmentsinEquityMethodInvestees">
        <link:definition>210941017 - Disclosure - Investments in Equity Method Investees</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InvestmentsinEquityMethodInvesteesDetails" roleURI="http://www.evolenthealth.com/role/InvestmentsinEquityMethodInvesteesDetails">
        <link:definition>240954064 - Disclosure - Investments in Equity Method Investees (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NoncontrollingInterests" roleURI="http://www.evolenthealth.com/role/NoncontrollingInterests">
        <link:definition>210961018 - Disclosure - Non-controlling Interests</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NoncontrollingInterestsTables" roleURI="http://www.evolenthealth.com/role/NoncontrollingInterestsTables">
        <link:definition>230973014 - Disclosure - Non-controlling Interests (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NoncontrollingInterestsDetails" roleURI="http://www.evolenthealth.com/role/NoncontrollingInterestsDetails">
        <link:definition>240984065 - Disclosure - Non-controlling Interests (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NoncontrollingInterestsScheduleofChangesinNoncontrollingInterestsDetails" roleURI="http://www.evolenthealth.com/role/NoncontrollingInterestsScheduleofChangesinNoncontrollingInterestsDetails">
        <link:definition>240994066 - Disclosure - Non-controlling Interests - Schedule of Changes in Non-controlling Interests (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurement" roleURI="http://www.evolenthealth.com/role/FairValueMeasurement">
        <link:definition>211001019 - Disclosure - Fair Value Measurement</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementTables" roleURI="http://www.evolenthealth.com/role/FairValueMeasurementTables">
        <link:definition>231013015 - Disclosure - Fair Value Measurement (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementAssetsandLiabilitiesonRecurringBasisDetails" roleURI="http://www.evolenthealth.com/role/FairValueMeasurementAssetsandLiabilitiesonRecurringBasisDetails">
        <link:definition>241024067 - Disclosure - Fair Value Measurement - Assets and Liabilities on Recurring Basis (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementAdditionalInformationDetails" roleURI="http://www.evolenthealth.com/role/FairValueMeasurementAdditionalInformationDetails">
        <link:definition>241034068 - Disclosure - Fair Value Measurement - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementChangesinContingentConsiderationandOtherDetails" roleURI="http://www.evolenthealth.com/role/FairValueMeasurementChangesinContingentConsiderationandOtherDetails">
        <link:definition>241044069 - Disclosure - Fair Value Measurement - Changes in Contingent Consideration and Other (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementValuationTechniquesandSignificantUnobservableInputsDetails" roleURI="http://www.evolenthealth.com/role/FairValueMeasurementValuationTechniquesandSignificantUnobservableInputsDetails">
        <link:definition>241054070 - Disclosure - Fair Value Measurement - Valuation Techniques and Significant Unobservable Inputs (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RelatedParties" roleURI="http://www.evolenthealth.com/role/RelatedParties">
        <link:definition>211061020 - Disclosure - Related Parties</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RelatedPartiesTables" roleURI="http://www.evolenthealth.com/role/RelatedPartiesTables">
        <link:definition>231073016 - Disclosure - Related Parties (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RelatedPartiesAssetsandLiabilitiesDetails" roleURI="http://www.evolenthealth.com/role/RelatedPartiesAssetsandLiabilitiesDetails">
        <link:definition>241084071 - Disclosure - Related Parties - Assets and Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RelatedPartiesRevenuesandExpensesDetails" roleURI="http://www.evolenthealth.com/role/RelatedPartiesRevenuesandExpensesDetails">
        <link:definition>241094072 - Disclosure - Related Parties - Revenues and Expenses (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RepositioningandOtherChanges" roleURI="http://www.evolenthealth.com/role/RepositioningandOtherChanges">
        <link:definition>211101021 - Disclosure - Repositioning and Other Changes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RepositioningandOtherChangesTables" roleURI="http://www.evolenthealth.com/role/RepositioningandOtherChangesTables">
        <link:definition>231113017 - Disclosure - Repositioning and Other Changes (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RepositioningandOtherChangesDetails" roleURI="http://www.evolenthealth.com/role/RepositioningandOtherChangesDetails">
        <link:definition>241124073 - Disclosure - Repositioning and Other Changes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentReporting" roleURI="http://www.evolenthealth.com/role/SegmentReporting">
        <link:definition>211131022 - Disclosure - Segment Reporting</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentReportingTables" roleURI="http://www.evolenthealth.com/role/SegmentReportingTables">
        <link:definition>231143018 - Disclosure - Segment Reporting (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentReportingAdditionalInformationDetails" roleURI="http://www.evolenthealth.com/role/SegmentReportingAdditionalInformationDetails">
        <link:definition>241154074 - Disclosure - Segment Reporting - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentReportingRevenuefromSegmentstoConsolidatedDetails" roleURI="http://www.evolenthealth.com/role/SegmentReportingRevenuefromSegmentstoConsolidatedDetails">
        <link:definition>241164075 - Disclosure - Segment Reporting - Revenue from Segments to Consolidated (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentReportingReconciliationofAdjustedEBITDADetails" roleURI="http://www.evolenthealth.com/role/SegmentReportingReconciliationofAdjustedEBITDADetails">
        <link:definition>241174076 - Disclosure - Segment Reporting - Reconciliation of Adjusted EBITDA (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ReservesforClaimsandPerformanceBasedArrangements" roleURI="http://www.evolenthealth.com/role/ReservesforClaimsandPerformanceBasedArrangements">
        <link:definition>211181023 - Disclosure - Reserves for Claims and Performance-Based Arrangements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ReservesforClaimsandPerformanceBasedArrangementsTables" roleURI="http://www.evolenthealth.com/role/ReservesforClaimsandPerformanceBasedArrangementsTables">
        <link:definition>231193019 - Disclosure - Reserves for Claims and Performance-Based Arrangements (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ReservesforClaimsandPerformanceBasedArrangementsDetails" roleURI="http://www.evolenthealth.com/role/ReservesforClaimsandPerformanceBasedArrangementsDetails">
        <link:definition>241204077 - Disclosure - Reserves for Claims and Performance-Based Arrangements (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="QuarterlyResultsofOperationsunaudited" roleURI="http://www.evolenthealth.com/role/QuarterlyResultsofOperationsunaudited">
        <link:definition>211211024 - Disclosure - Quarterly Results of Operations (unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="QuarterlyResultsofOperationsunauditedTables" roleURI="http://www.evolenthealth.com/role/QuarterlyResultsofOperationsunauditedTables">
        <link:definition>231223020 - Disclosure - Quarterly Results of Operations (unaudited) (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="QuarterlyResultsofOperationsunauditedDetails" roleURI="http://www.evolenthealth.com/role/QuarterlyResultsofOperationsunauditedDetails">
        <link:definition>241234078 - Disclosure - Quarterly Results of Operations (unaudited) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="QuarterlyResultsofOperationsunauditedAdditionalInformationDetails" roleURI="http://www.evolenthealth.com/role/QuarterlyResultsofOperationsunauditedAdditionalInformationDetails">
        <link:definition>241244079 - Disclosure - Quarterly Results of Operations (unaudited) - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SupplementalCashFlowInformation" roleURI="http://www.evolenthealth.com/role/SupplementalCashFlowInformation">
        <link:definition>211251025 - Disclosure - Supplemental Cash Flow Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SupplementalCashFlowInformationTables" roleURI="http://www.evolenthealth.com/role/SupplementalCashFlowInformationTables">
        <link:definition>231263021 - Disclosure - Supplemental Cash Flow Information (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SupplementalCashFlowInformationDetails" roleURI="http://www.evolenthealth.com/role/SupplementalCashFlowInformationDetails">
        <link:definition>241274080 - Disclosure - Supplemental Cash Flow Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:element id="evh_PurchaseAccountingAdjustments" abstract="false" name="PurchaseAccountingAdjustments" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="evh_FInancialAssetLessThan120DaysPastDueMember" abstract="true" name="FInancialAssetLessThan120DaysPastDueMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="evh_AssetAcquisitionCashAndEquivalents" abstract="false" name="AssetAcquisitionCashAndEquivalents" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="evh_AccruedPropertyAndEquipmentPurchases" abstract="false" name="AccruedPropertyAndEquipmentPurchases" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="evh_StockIssuedDuringPeriodSharesEquityMethodInvestmentsAndAssetAcquisitions" abstract="false" name="StockIssuedDuringPeriodSharesEquityMethodInvestmentsAndAssetAcquisitions" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="evh_StockIssuedDuringPeriodSharesEarnOuts" abstract="false" name="StockIssuedDuringPeriodSharesEarnOuts" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="evh_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseExcessCompensationPercent" abstract="false" name="EffectiveIncomeTaxRateReconciliationNondeductibleExpenseExcessCompensationPercent" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="evh_SeniorConvertibleNotesDue2024Member" abstract="true" name="SeniorConvertibleNotesDue2024Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="evh_SharebasedCompensationAwardSubTrancheOneMember" abstract="true" name="SharebasedCompensationAwardSubTrancheOneMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="evh_CreditAgreementMember" abstract="true" name="CreditAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="evh_DebtInstrumentRepurchaseCovenantSalePriceAsAPercentageOfConversionPrice" abstract="false" name="DebtInstrumentRepurchaseCovenantSalePriceAsAPercentageOfConversionPrice" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="evh_ShareholderAdvisoryServices" abstract="false" name="ShareholderAdvisoryServices" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="evh_PaymentsOfMakeWholePremium" abstract="false" name="PaymentsOfMakeWholePremium" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="evh_CookCountyHealthAndHospitalsSystemMember" abstract="true" name="CookCountyHealthAndHospitalsSystemMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="evh_GainLossFromTransferOfMembership" abstract="false" name="GainLossFromTransferOfMembership" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="evh_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVestedAndExpectedToVest" abstract="false" name="SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVestedAndExpectedToVest" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="evh_TwoThousandElevenEquityIncentivePlanMember" abstract="true" name="TwoThousandElevenEquityIncentivePlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="evh_CashHeldInInternationalBanksPercentage" abstract="false" name="CashHeldInInternationalBanksPercentage" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="evh_StockIssuedDuringPeriodValueEquityMethodInvestmentsAndAssetAcquisitions" abstract="false" name="StockIssuedDuringPeriodValueEquityMethodInvestmentsAndAssetAcquisitions" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="evh_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsStockPriceIncreasePercentage" abstract="false" name="SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsStockPriceIncreasePercentage" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="evh_CashReleasedFromEscrow" abstract="false" name="CashReleasedFromEscrow" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="evh_DisposalGroupIncludingDiscontinuedOperationInvestmentsNoncurrent" abstract="false" name="DisposalGroupIncludingDiscontinuedOperationInvestmentsNoncurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="evh_TransferOfMembershipPercentageOfPaymentSubjectToSatisfactionOfContingencies" abstract="false" name="TransferOfMembershipPercentageOfPaymentSubjectToSatisfactionOfContingencies" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="evh_StockIssuedDecreaseInDeferredTaxLiability" abstract="false" name="StockIssuedDecreaseInDeferredTaxLiability" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="evh_EarningsLossAvailabletoCommonShareholdersAbstract" abstract="true" name="EarningsLossAvailabletoCommonShareholdersAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="evh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedTangibleAssets" abstract="false" name="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedTangibleAssets" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="evh_EarningsPerSharePortionAttributableToNoncontrollingInterestDiluted" abstract="false" name="EarningsPerSharePortionAttributableToNoncontrollingInterestDiluted" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:perShareItemType"/>
  <xs:element id="evh_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseReturnToProvisionPercent" abstract="false" name="EffectiveIncomeTaxRateReconciliationNondeductibleExpenseReturnToProvisionPercent" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="evh_RightOfOffsetPercentageOfAccountsReceivableNetEligibleForNetBasisSettlement" abstract="false" name="RightOfOffsetPercentageOfAccountsReceivableNetEligibleForNetBasisSettlement" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="evh_AssetAcquisitionAccruedLiabilities" abstract="false" name="AssetAcquisitionAccruedLiabilities" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="evh_PolicyholderBenefitsAndClaimsIncurredAssumedExpensesRelatedToClaims" abstract="false" name="PolicyholderBenefitsAndClaimsIncurredAssumedExpensesRelatedToClaims" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="evh_StockVestedAndRetiredDuringPeriodShares" abstract="false" name="StockVestedAndRetiredDuringPeriodShares" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="evh_AuditInformationAbstract" abstract="true" name="AuditInformationAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="evh_PaymentsToAcquireEquityMethodInvestmentsAmountHeldBack" abstract="false" name="PaymentsToAcquireEquityMethodInvestmentsAmountHeldBack" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="evh_ProceedsFromMaturityOfInvestments" abstract="false" name="ProceedsFromMaturityOfInvestments" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="evh_WeightedAverageRemainingContractualTermAbstract" abstract="true" name="WeightedAverageRemainingContractualTermAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="evh_RestrictedCashForLettersOfCreditForLetterOfCreditFacilityMember" abstract="true" name="RestrictedCashForLettersOfCreditForLetterOfCreditFacilityMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="evh_DisposalGroupIncludingDiscontinuedOperationRestrictedCashCurrent" abstract="false" name="DisposalGroupIncludingDiscontinuedOperationRestrictedCashCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="evh_AssetAcquisitionDebtSecuritiesAvailableForSaleUnsettledSalesReceivables" abstract="false" name="AssetAcquisitionDebtSecuritiesAvailableForSaleUnsettledSalesReceivables" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="evh_AssetAcquisitionOtherAssets" abstract="false" name="AssetAcquisitionOtherAssets" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="evh_StatutoryCapitalReservesLiquidityGuaranteedByInvestorsMinimum" abstract="false" name="StatutoryCapitalReservesLiquidityGuaranteedByInvestorsMinimum" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="evh_ScheduleOfShareBasedPaymentAwardRestrictedStockUnitValuationAssumptionsTableTextBlock" abstract="false" name="ScheduleOfShareBasedPaymentAwardRestrictedStockUnitValuationAssumptionsTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="evh_DebtIssuanceCostsNetDebtComponent" abstract="false" name="DebtIssuanceCostsNetDebtComponent" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="evh_BonusesAndCommissionsMember" abstract="true" name="BonusesAndCommissionsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="evh_PassportNoteMember" abstract="true" name="PassportNoteMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="evh_GlobalHealthMember" abstract="true" name="GlobalHealthMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="evh_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsMaximumPerformanceAchievedPercentageOfTargetedSharesEarned" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsMaximumPerformanceAchievedPercentageOfTargetedSharesEarned" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="evh_RightOfOffsetPercentageOfAccountsReceivableNettedAgainstClaimsPayable" abstract="false" name="RightOfOffsetPercentageOfAccountsReceivableNettedAgainstClaimsPayable" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="evh_PremiumsWrittenAndPolicyholderBenefitsAndClaimsIncurredNet" abstract="false" name="PremiumsWrittenAndPolicyholderBenefitsAndClaimsIncurredNet" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="evh_CollateralwithFinancialInstitutionsMember" abstract="true" name="CollateralwithFinancialInstitutionsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="evh_CapitalizedContractCostAmortizationPurchaseAccountingAdjustments" abstract="false" name="CapitalizedContractCostAmortizationPurchaseAccountingAdjustments" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="evh_DeferredTaxAssetsStartupandOrganizationalCosts" abstract="false" name="DeferredTaxAssetsStartupandOrganizationalCosts" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="evh_MedicareCustomersMember" abstract="true" name="MedicareCustomersMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="evh_IncreaseDecreaseInAccountsReceivableAndContractWithCustomerAsset" abstract="false" name="IncreaseDecreaseInAccountsReceivableAndContractWithCustomerAsset" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="evh_FinancingReceivablePercentNotPastDue" abstract="false" name="FinancingReceivablePercentNotPastDue" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="evh_EarningsBeforeInterestTaxesDepreciationAndAmortizationGoalPeriod" abstract="false" name="EarningsBeforeInterestTaxesDepreciationAndAmortizationGoalPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="evh_GainLossOnRepaymentOfDebt" abstract="false" name="GainLossOnRepaymentOfDebt" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="evh_PaymentsForCustomerAdvanceForRegulatoryCapitalRequirements" abstract="false" name="PaymentsForCustomerAdvanceForRegulatoryCapitalRequirements" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="evh_DisposalGroupIncludingDiscontinuedOperationInvestmentsCurrent" abstract="false" name="DisposalGroupIncludingDiscontinuedOperationInvestmentsCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="evh_EmployeeSeveranceAndTerminationBenefitsMember" abstract="true" name="EmployeeSeveranceAndTerminationBenefitsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="evh_PremiumsRevenueMember" abstract="true" name="PremiumsRevenueMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="evh_ConvertibleSeniorNotesdue2021Member" abstract="true" name="ConvertibleSeniorNotesdue2021Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="evh_ConversionOfStockAbstract" abstract="true" name="ConversionOfStockAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="evh_PaidinKindInterestIncome" abstract="false" name="PaidinKindInterestIncome" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="evh_PeriodsPriortoJune2015Member" abstract="true" name="PeriodsPriortoJune2015Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="evh_EarningsPerSharePortionAttributableToNoncontrollingInterestBasic" abstract="false" name="EarningsPerSharePortionAttributableToNoncontrollingInterestBasic" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:perShareItemType"/>
  <xs:element id="evh_ProceedsFromAssetAcquisitionEscrow" abstract="false" name="ProceedsFromAssetAcquisitionEscrow" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="evh_MeasurementInputRiskNeutralExpectedEarnoutConsiderationMember" abstract="true" name="MeasurementInputRiskNeutralExpectedEarnoutConsiderationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="evh_NewCenturyHealthMember" abstract="true" name="NewCenturyHealthMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="evh_AssetAcquisitionDebtSecuritiesAvailableForSale" abstract="false" name="AssetAcquisitionDebtSecuritiesAvailableForSale" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="evh_CommercialAndOtherCustomersMember" abstract="true" name="CommercialAndOtherCustomersMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="evh_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestAbstract" abstract="true" name="SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="evh_EvolentHealthLLCMember" abstract="true" name="EvolentHealthLLCMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="evh_ContractWithCustomerLiabilityCashReceivedInAdvanceOfSatisfactionOfPerformanceObligations" abstract="false" name="ContractWithCustomerLiabilityCashReceivedInAdvanceOfSatisfactionOfPerformanceObligations" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="evh_ClassOfWarrantOrRightPeriodDuringWhichWarrantsOrRightsExercisableAfterMaturityOfCreditAgreement" abstract="false" name="ClassOfWarrantOrRightPeriodDuringWhichWarrantsOrRightsExercisableAfterMaturityOfCreditAgreement" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="evh_TaxReceivablesAgreementPercentofTaxSavingstobePaid" abstract="false" name="TaxReceivablesAgreementPercentofTaxSavingstobePaid" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="evh_DisposalGroupIncludingDiscontinuedOperationClaimsExpense" abstract="false" name="DisposalGroupIncludingDiscontinuedOperationClaimsExpense" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="evh_PerformanceBasedRestrictedStockUnitsPSUsMember" abstract="true" name="PerformanceBasedRestrictedStockUnitsPSUsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="evh_TaxReceivableAgreementPercentofCashSavingsPaidtoShareholders" abstract="false" name="TaxReceivableAgreementPercentofCashSavingsPaidtoShareholders" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="evh_RestrictedStockUnitsRSUsPerformanceBasedRestrictedStockUnitsPBRSUsAndLeveragedStockUnitsLSUsMember" abstract="true" name="RestrictedStockUnitsRSUsPerformanceBasedRestrictedStockUnitsPBRSUsAndLeveragedStockUnitsLSUsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="evh_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestWeightedAverageGrantDateFairValue" abstract="false" name="SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestWeightedAverageGrantDateFairValue" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:perShareItemType"/>
  <xs:element id="evh_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNetAfterGrossUp" abstract="false" name="DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNetAfterGrossUp" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="evh_DeferredTaxAssetsOperatingLeaseRightOfUseAsset" abstract="false" name="DeferredTaxAssetsOperatingLeaseRightOfUseAsset" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="evh_DebtInstrumentRepurchaseCovenantTradingDaysMinimum" abstract="false" name="DebtInstrumentRepurchaseCovenantTradingDaysMinimum" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="evh_NoncontrollingInterestDecreaseFromDisposalOfAssets" abstract="false" name="NoncontrollingInterestDecreaseFromDisposalOfAssets" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="evh_DebtConversionOriginalDebtFairValue" abstract="false" name="DebtConversionOriginalDebtFairValue" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="evh_ProceedsFromReinsurance" abstract="false" name="ProceedsFromReinsurance" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="evh_FInancialAssetLessThan60DaysMember" abstract="true" name="FInancialAssetLessThan60DaysMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="evh_DebtInstrumentRedemptionCallProtectionPremiumPercentage" abstract="false" name="DebtInstrumentRedemptionCallProtectionPremiumPercentage" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="evh_ContractFulfillmentCostsMember" abstract="true" name="ContractFulfillmentCostsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="evh_SharebasedCompensationAwardSubTrancheTwoMember" abstract="true" name="SharebasedCompensationAwardSubTrancheTwoMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="evh_MolinaHealthcareIncMember" abstract="true" name="MolinaHealthcareIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="evh_MolinaHealthcareMember" abstract="true" name="MolinaHealthcareMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="evh_IncreaseDecreaseInOperatingLeaseRightofUseAsset" abstract="false" name="IncreaseDecreaseInOperatingLeaseRightofUseAsset" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="evh_CurrentYearClaimsAndClaimsAdjustmentExpenseIncludingCostOfGoodsAndServicesSoldExcludingDepreciationAndAmortization" abstract="false" name="CurrentYearClaimsAndClaimsAdjustmentExpenseIncludingCostOfGoodsAndServicesSoldExcludingDepreciationAndAmortization" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="evh_AssetAcquisitionAccruedMedicalExpenses" abstract="false" name="AssetAcquisitionAccruedMedicalExpenses" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="evh_EffectiveIncomeTaxRateReconciliationEffectOfInvestment" abstract="false" name="EffectiveIncomeTaxRateReconciliationEffectOfInvestment" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="evh_UnrecognizedTaxBenefitsThatWouldNotImpactEffectiveTaxRate" abstract="false" name="UnrecognizedTaxBenefitsThatWouldNotImpactEffectiveTaxRate" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="evh_EvolentHealthServicesSegmentMember" abstract="true" name="EvolentHealthServicesSegmentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="evh_DisposalGroupIncludingDiscontinuedOperationRestrictedInvestmentsNoncurrent" abstract="false" name="DisposalGroupIncludingDiscontinuedOperationRestrictedInvestmentsNoncurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="evh_AdjustmentsToAdditionalPaidInCapitalAcquisitions" abstract="false" name="AdjustmentsToAdditionalPaidInCapitalAcquisitions" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="evh_RestrictedCashforOtherContractualCommitmentsMember" abstract="true" name="RestrictedCashforOtherContractualCommitmentsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="evh_EffectiveIncomeTaxRateReconciliationBenefitOfNetOperatingLossCarrybackProvisionPercent" abstract="false" name="EffectiveIncomeTaxRateReconciliationBenefitOfNetOperatingLossCarrybackProvisionPercent" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:pureItemType"/>
  <xs:element id="evh_StockVestedAndRetiredDuringPeriodValue" abstract="false" name="StockVestedAndRetiredDuringPeriodValue" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="evh_IncreaseDecreaseInInsuranceAndPerformanceBasedArrangementsLiabilities" abstract="false" name="IncreaseDecreaseInInsuranceAndPerformanceBasedArrangementsLiabilities" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="evh_FloridaBlueMedicareIncMember" abstract="true" name="FloridaBlueMedicareIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="evh_ClinicalSolutionsSegmentMember" abstract="true" name="ClinicalSolutionsSegmentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="evh_ServicesAgreementsMember" abstract="true" name="ServicesAgreementsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="evh_VivantHealthMSOLLCMember" abstract="true" name="VivantHealthMSOLLCMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="evh_ChangeInContractWithCustomerLiabilityRollForward" abstract="true" name="ChangeInContractWithCustomerLiabilityRollForward" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="evh_DelayedDrawTermLoanFacilityMember" abstract="true" name="DelayedDrawTermLoanFacilityMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="evh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesAccruedCompensationAndEmployeeBenefits" abstract="false" name="BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesAccruedCompensationAndEmployeeBenefits" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="evh_TransferOfMembershipPercentageOfPaymentBasedOnNumberOfEnrollees" abstract="false" name="TransferOfMembershipPercentageOfPaymentBasedOnNumberOfEnrollees" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="evh_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestWeightedAverageRemainingContractualTerms" abstract="false" name="SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestWeightedAverageRemainingContractualTerms" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="evh_SeniorCreditFacilitiesMember" abstract="true" name="SeniorCreditFacilitiesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="evh_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingAbstract" abstract="true" name="SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="evh_NonEmployeeDirectorsMember" abstract="true" name="NonEmployeeDirectorsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="evh_DebtInstrumentRepurchasePriceDueToChangeInSalePriceAsPercentageOfConversionPrice" abstract="false" name="DebtInstrumentRepurchasePriceDueToChangeInSalePriceAsPercentageOfConversionPrice" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="evh_CashFDICInsuredAmountPercentage" abstract="false" name="CashFDICInsuredAmountPercentage" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="evh_SeniorConvertibleNotesDue2025Member" abstract="true" name="SeniorConvertibleNotesDue2025Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="evh_DeferredTaxAssetOutsideBasisDifferences" abstract="false" name="DeferredTaxAssetOutsideBasisDifferences" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="evh_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsNoncurrent" abstract="false" name="DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsNoncurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="evh_StockIssuedDuringPeriodValueEarnOuts" abstract="false" name="StockIssuedDuringPeriodValueEarnOuts" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="evh_IncreaseDecreaseInCapitalizedContractCostNet" abstract="false" name="IncreaseDecreaseInCapitalizedContractCostNet" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="evh_NumberOfReportingUnitsFairValueInExcessOfCarryingAmount" abstract="false" name="NumberOfReportingUnitsFairValueInExcessOfCarryingAmount" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="evh_EquityInterestToBeTransferred" abstract="false" name="EquityInterestToBeTransferred" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="evh_ProfessionalServicesRestructuringMember" abstract="true" name="ProfessionalServicesRestructuringMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="evh_GainOnTransferOfMembership" abstract="false" name="GainOnTransferOfMembership" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="evh_VariableInterestEntityNewMedicaidContractNotAwardedRequirementToAcquireOwnershipConsiderationAmount" abstract="false" name="VariableInterestEntityNewMedicaidContractNotAwardedRequirementToAcquireOwnershipConsiderationAmount" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="evh_DisposalGroupIncludingDiscontinuedOperationRestrictedCashAndRestrictedInvestmentsNoncurrent" abstract="false" name="DisposalGroupIncludingDiscontinuedOperationRestrictedCashAndRestrictedInvestmentsNoncurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="evh_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestNumber" abstract="false" name="SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestNumber" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="evh_TransformationServicesMember" abstract="true" name="TransformationServicesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="evh_RestrictedCashforBenefitManagementServicesMember" abstract="true" name="RestrictedCashforBenefitManagementServicesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="evh_NewMexicoHealthConnectionsMember" abstract="true" name="NewMexicoHealthConnectionsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="evh_StockIssuedInConnectionWithDebtRepayment" abstract="false" name="StockIssuedInConnectionWithDebtRepayment" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="evh_GainLossOnDispositionOfAssetsOperatingActivities" abstract="false" name="GainLossOnDispositionOfAssetsOperatingActivities" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="evh_DisposalGroupIncludingDiscontinuedOperationLiabilityForFuturePolicyBenefitsAndUnpaidClaimsAndClaimsAdjustmentExpenseAndPerformanceBasedArrangementsCurrent" abstract="false" name="DisposalGroupIncludingDiscontinuedOperationLiabilityForFuturePolicyBenefitsAndUnpaidClaimsAndClaimsAdjustmentExpenseAndPerformanceBasedArrangementsCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="evh_BelowMarketLeasesMember" abstract="true" name="BelowMarketLeasesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="evh_AssumedLiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseImpactOfConsolidationOnPayables" abstract="false" name="AssumedLiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseImpactOfConsolidationOnPayables" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="evh_IndefinitelivedTaxCreditCarryforwardMember" abstract="true" name="IndefinitelivedTaxCreditCarryforwardMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="evh_PlatformsAndOperationsServicesMember" abstract="true" name="PlatformsAndOperationsServicesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="evh_AssetPurchaseAgreementEscrowPayments" abstract="false" name="AssetPurchaseAgreementEscrowPayments" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="evh_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsStockPriceTriggerConsecutiveTerm" abstract="false" name="SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsStockPriceTriggerConsecutiveTerm" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="evh_DeferredTaxLiabilitiesIndefiniteLivedIntangibleAssets" abstract="false" name="DeferredTaxLiabilitiesIndefiniteLivedIntangibleAssets" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="evh_IncomeLossfromEquityMethodInvestmentsServicesAgreement" abstract="false" name="IncomeLossfromEquityMethodInvestmentsServicesAgreement" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="evh_EffectiveIncomeTaxRateReconciliationChangeInUncertainTaxPositions" abstract="false" name="EffectiveIncomeTaxRateReconciliationChangeInUncertainTaxPositions" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="evh_RightOfUseAssetAcquiredAndDisposedOf" abstract="false" name="RightOfUseAssetAcquiredAndDisposedOf" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="evh_AccountsReceivableAllowanceForCreditLossAcquiredDuringPeriod" abstract="false" name="AccountsReceivableAllowanceForCreditLossAcquiredDuringPeriod" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="evh_ProceedsFromTransferOfMembership" abstract="false" name="ProceedsFromTransferOfMembership" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="evh_AggregateIntrinsicValueAbstract" abstract="true" name="AggregateIntrinsicValueAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="evh_CostofGoodsandServicesSoldExcludingDepreciationandAmortization" abstract="false" name="CostofGoodsandServicesSoldExcludingDepreciationandAmortization" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="evh_DebtInstrumentRepurchasePriceDueToFundamentalChangeAsPercentageOfPrincipalAmount" abstract="false" name="DebtInstrumentRepurchasePriceDueToFundamentalChangeAsPercentageOfPrincipalAmount" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="evh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesAccruedLiabilities" abstract="false" name="BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesAccruedLiabilities" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="evh_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsPerformanceGoalThreshold" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsPerformanceGoalThreshold" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="evh_ValuationAllowancesAndReservesChargedCreditedToAdditionalPaidInCapital" abstract="false" name="ValuationAllowancesAndReservesChargedCreditedToAdditionalPaidInCapital" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="evh_CashFlowLesseeAbstract" abstract="true" name="CashFlowLesseeAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="evh_NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationMeasurementPeriodAdjustment" abstract="false" name="NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationMeasurementPeriodAdjustment" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="evh_DisposalGroupIncludingDiscontinuedOperationAccruedCompensationAndEmployeeBenefitsCurrent" abstract="false" name="DisposalGroupIncludingDiscontinuedOperationAccruedCompensationAndEmployeeBenefitsCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="evh_AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization" abstract="false" name="AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="evh_EquityMethodInvestmentVotingInterestPercentage" abstract="false" name="EquityMethodInvestmentVotingInterestPercentage" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="evh_SharebasedPaymentArrangementTrancheFourMember" abstract="true" name="SharebasedPaymentArrangementTrancheFourMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="evh_DisposalGroupIncludingDiscontinuedOperationRestrictedCashAndRestrictedInvestmentsCurrent" abstract="false" name="DisposalGroupIncludingDiscontinuedOperationRestrictedCashAndRestrictedInvestmentsCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="evh_SharebasedCompensationIncludingOnetimeAdjustment" abstract="false" name="SharebasedCompensationIncludingOnetimeAdjustment" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="evh_TaxReceivableAgreementPercentofCashSavingsNotPaidtoShareholders" abstract="false" name="TaxReceivableAgreementPercentofCashSavingsNotPaidtoShareholders" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="evh_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageAdjustmentOfSharesEarnedTotalShareholderReturnInTopQuartile" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageAdjustmentOfSharesEarnedTotalShareholderReturnInTopQuartile" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="evh_StockIssuedDuringPeriodSharesConversionofConvertibleSecuritiesTaxImpact" abstract="false" name="StockIssuedDuringPeriodSharesConversionofConvertibleSecuritiesTaxImpact" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="evh_ScheduleofChangesinNoncontrollingInterestTableTextBlock" abstract="false" name="ScheduleofChangesinNoncontrollingInterestTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="evh_ValuationAllowancesAndReservesChargedToRetainedEarnings" abstract="false" name="ValuationAllowancesAndReservesChargedToRetainedEarnings" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="evh_FinitelivedTaxCreditCarryforwardMember" abstract="true" name="FinitelivedTaxCreditCarryforwardMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="evh_CashAndCashEquivalentsAtCarryingValueExcludingDiscontinuedOperations" abstract="false" name="CashAndCashEquivalentsAtCarryingValueExcludingDiscontinuedOperations" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="evh_InitialTermLoanFacilityMember" abstract="true" name="InitialTermLoanFacilityMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="evh_LeveragedStockUnitsLSUsMember" abstract="true" name="LeveragedStockUnitsLSUsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="evh_AmortizationOfDebtDiscountAndDebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction" abstract="false" name="AmortizationOfDebtDiscountAndDebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="evh_RestrictedCashforLettersofCreditforFacilityLeasesMember" abstract="true" name="RestrictedCashforLettersofCreditforFacilityLeasesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="evh_SharebasedCompensationArrangementbySharebasedPaymentAwardAwardVestingRightsSharePriceThreshold" abstract="false" name="SharebasedCompensationArrangementbySharebasedPaymentAwardAwardVestingRightsSharePriceThreshold" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:perShareItemType"/>
  <xs:element id="evh_PaymentsForProceedsFromDisposalOfNonStrategicAssetsAndDivestitureOfDiscontinuedOperationsNet" abstract="false" name="PaymentsForProceedsFromDisposalOfNonStrategicAssetsAndDivestitureOfDiscontinuedOperationsNet" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="evh_PassportAssetAcquisitionMember" abstract="true" name="PassportAssetAcquisitionMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="evh_TwoThousandFifteenEvolentHealthInc.OmnibusIncentiveCompensationPlanMember" abstract="true" name="TwoThousandFifteenEvolentHealthInc.OmnibusIncentiveCompensationPlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="evh_EffectiveIncomeTaxRateReconciliationDomesticSubsidiaryException" abstract="false" name="EffectiveIncomeTaxRateReconciliationDomesticSubsidiaryException" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="evh_NewNotesMember" abstract="true" name="NewNotesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="evh_MedicaidCustomersMember" abstract="true" name="MedicaidCustomersMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="evh_RightOfOffsetPolicyPolicyTextBlock" abstract="false" name="RightOfOffsetPolicyPolicyTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="evh_DebtInstrumentRepurchaseCovenantConsecutiveTradingDaysMinimum" abstract="false" name="DebtInstrumentRepurchaseCovenantConsecutiveTradingDaysMinimum" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="evh_VitalDecisionsMember" abstract="true" name="VitalDecisionsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="evh_UniversityHealthCaredbaPassportHealthPlanMember" abstract="true" name="UniversityHealthCaredbaPassportHealthPlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="evh_PaymentsForProceedsFromClaimsProcessingFinancingActivities" abstract="false" name="PaymentsForProceedsFromClaimsProcessingFinancingActivities" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="evh_TransactionCosts" abstract="false" name="TransactionCosts" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="evh_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageAdjustmentOfSharesEarnedTotalShareholderReturnInBottomQuartile" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageAdjustmentOfSharesEarnedTotalShareholderReturnInBottomQuartile" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="evh_DiscontinuedOperationGainLossOnPurchasePriceAdjustmentsNetOfTax" abstract="false" name="DiscontinuedOperationGainLossOnPurchasePriceAdjustmentsNetOfTax" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="evh_TrueHealthMember" abstract="true" name="TrueHealthMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="evh_EquityMethodInvestmentEconomicInterestPercentage" abstract="false" name="EquityMethodInvestmentEconomicInterestPercentage" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="evh_LiabilityForFuturePolicyBenefitsAndUnpaidClaimsAndClaimsAdjustmentExpenseAndPerformanceBasedArrangements" abstract="false" name="LiabilityForFuturePolicyBenefitsAndUnpaidClaimsAndClaimsAdjustmentExpenseAndPerformanceBasedArrangements" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>11
<FILENAME>evh-20211231_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:cffd2bd6-4cc3-4881-a14e-c3c94aea5d0e,g:f4f494d2-75b7-48aa-a2de-31bddada82ae-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS" xlink:type="simple" xlink:href="evh-20211231.xsd#CONSOLIDATEDBALANCESHEETS"/>
  <link:calculationLink xlink:role="http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_7c91224d-6198-4ebf-beda-d12d3b658b88" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndInvestmentsNoncurrent_004db61e-68e8-4019-8e85-4f9a786376ac" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndInvestmentsNoncurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_7c91224d-6198-4ebf-beda-d12d3b658b88" xlink:to="loc_us-gaap_RestrictedCashAndInvestmentsNoncurrent_004db61e-68e8-4019-8e85-4f9a786376ac" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_caffd467-14bd-43ac-a80d-10bc162794e1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_7c91224d-6198-4ebf-beda-d12d3b658b88" xlink:to="loc_us-gaap_AssetsCurrent_caffd467-14bd-43ac-a80d-10bc162794e1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_123d97f1-01fb-430d-af5a-59b027b67014" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_7c91224d-6198-4ebf-beda-d12d3b658b88" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_123d97f1-01fb-430d-af5a-59b027b67014" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent_044b78aa-8d04-4edf-a3e3-a51c11bd7f9e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_7c91224d-6198-4ebf-beda-d12d3b658b88" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent_044b78aa-8d04-4edf-a3e3-a51c11bd7f9e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_f5176235-e9e2-4221-8833-f986075ae76d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_7c91224d-6198-4ebf-beda-d12d3b658b88" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_f5176235-e9e2-4221-8833-f986075ae76d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedContractCostNetNoncurrent_00c03a9e-b8c3-426a-9ef3-dc20c83fdae5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalizedContractCostNetNoncurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_7c91224d-6198-4ebf-beda-d12d3b658b88" xlink:to="loc_us-gaap_CapitalizedContractCostNetNoncurrent_00c03a9e-b8c3-426a-9ef3-dc20c83fdae5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_74fee7b7-d223-4c3e-8627-604d821e53ae" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_7c91224d-6198-4ebf-beda-d12d3b658b88" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_74fee7b7-d223-4c3e-8627-604d821e53ae" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent_8b353cec-ad5f-40c9-af77-feb36fbad27c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_7c91224d-6198-4ebf-beda-d12d3b658b88" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent_8b353cec-ad5f-40c9-af77-feb36fbad27c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_9de9f4c7-7a75-4f77-9fbd-570f6c1b8e54" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_7c91224d-6198-4ebf-beda-d12d3b658b88" xlink:to="loc_us-gaap_Goodwill_9de9f4c7-7a75-4f77-9fbd-570f6c1b8e54" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures_bac9072f-36e4-4099-b274-a006b5b092ec" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures"/>
    <link:calculationArc order="10" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_7c91224d-6198-4ebf-beda-d12d3b658b88" xlink:to="loc_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures_bac9072f-36e4-4099-b274-a006b5b092ec" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_c3c4f385-dab2-4fac-b91e-f7ade00988c3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_d84c5f45-702a-4752-8094-269f3caa9cc9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_c3c4f385-dab2-4fac-b91e-f7ade00988c3" xlink:to="loc_us-gaap_AccountsPayableCurrent_d84c5f45-702a-4752-8094-269f3caa9cc9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_21ec8d9e-1fde-4f13-953f-c1739d0444be" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_c3c4f385-dab2-4fac-b91e-f7ade00988c3" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_21ec8d9e-1fde-4f13-953f-c1739d0444be" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_LiabilityForFuturePolicyBenefitsAndUnpaidClaimsAndClaimsAdjustmentExpenseAndPerformanceBasedArrangements_b91c693b-fbb0-4c61-915b-f689d86f77a7" xlink:href="evh-20211231.xsd#evh_LiabilityForFuturePolicyBenefitsAndUnpaidClaimsAndClaimsAdjustmentExpenseAndPerformanceBasedArrangements"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_c3c4f385-dab2-4fac-b91e-f7ade00988c3" xlink:to="loc_evh_LiabilityForFuturePolicyBenefitsAndUnpaidClaimsAndClaimsAdjustmentExpenseAndPerformanceBasedArrangements_b91c693b-fbb0-4c61-915b-f689d86f77a7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent_2f586567-cc11-4955-8f63-cf639df6a8b7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_c3c4f385-dab2-4fac-b91e-f7ade00988c3" xlink:to="loc_us-gaap_LongTermDebtCurrent_2f586567-cc11-4955-8f63-cf639df6a8b7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_7831e3e2-8ca8-42cd-b946-2138f5fd6281" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_c3c4f385-dab2-4fac-b91e-f7ade00988c3" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_7831e3e2-8ca8-42cd-b946-2138f5fd6281" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_dc5d1992-2f93-4013-93dd-35b744d3e1aa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_c3c4f385-dab2-4fac-b91e-f7ade00988c3" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_dc5d1992-2f93-4013-93dd-35b744d3e1aa" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_eef825f7-0323-46a5-8f77-ca3711f8dded" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_c3c4f385-dab2-4fac-b91e-f7ade00988c3" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_eef825f7-0323-46a5-8f77-ca3711f8dded" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent_74321c72-9e97-4d02-8183-6f9b9db386c9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_c3c4f385-dab2-4fac-b91e-f7ade00988c3" xlink:to="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent_74321c72-9e97-4d02-8183-6f9b9db386c9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_80ba31e7-6274-4b42-b22d-fdaba713379c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_950bce98-6c5b-401b-bbc9-e028dc6881be" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_80ba31e7-6274-4b42-b22d-fdaba713379c" xlink:to="loc_us-gaap_AdditionalPaidInCapital_950bce98-6c5b-401b-bbc9-e028dc6881be" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_c78b4f38-b612-4f63-8a25-0df747b032fe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_80ba31e7-6274-4b42-b22d-fdaba713379c" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_c78b4f38-b612-4f63-8a25-0df747b032fe" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_c4970380-a71c-41ed-99af-1039260466c5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_80ba31e7-6274-4b42-b22d-fdaba713379c" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_c4970380-a71c-41ed-99af-1039260466c5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_c7483e31-a8c8-45d1-ae2a-b11cd551909c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_80ba31e7-6274-4b42-b22d-fdaba713379c" xlink:to="loc_us-gaap_CommonStockValue_c7483e31-a8c8-45d1-ae2a-b11cd551909c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValue_9468bf6c-f8cb-4665-9b85-5e988832f5b0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockValue"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_80ba31e7-6274-4b42-b22d-fdaba713379c" xlink:to="loc_us-gaap_TreasuryStockValue_9468bf6c-f8cb-4665-9b85-5e988832f5b0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_d802ccf9-41ca-42d6-9118-8ff75243f25e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_482a8397-85c1-4fac-b991-3f083d581fa3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_d802ccf9-41ca-42d6-9118-8ff75243f25e" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_482a8397-85c1-4fac-b991-3f083d581fa3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent_ead3a679-a040-4af1-9af1-95e4d23b074a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_d802ccf9-41ca-42d6-9118-8ff75243f25e" xlink:to="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent_ead3a679-a040-4af1-9af1-95e4d23b074a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndInvestmentsCurrent_9299deb9-0521-47b9-80fc-d9ef51f5013a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndInvestmentsCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_d802ccf9-41ca-42d6-9118-8ff75243f25e" xlink:to="loc_us-gaap_RestrictedCashAndInvestmentsCurrent_9299deb9-0521-47b9-80fc-d9ef51f5013a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_b12b4c82-4d41-41e7-be69-94ed9531e401" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_d802ccf9-41ca-42d6-9118-8ff75243f25e" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_b12b4c82-4d41-41e7-be69-94ed9531e401" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_89064dc5-84b2-427e-ae1d-5c839b6c379a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_d802ccf9-41ca-42d6-9118-8ff75243f25e" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_89064dc5-84b2-427e-ae1d-5c839b6c379a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_4c6631b9-bebe-4383-b7d5-20f960a00d94" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_5f85754c-980e-465d-8363-7b2bd32ddd2a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_4c6631b9-bebe-4383-b7d5-20f960a00d94" xlink:to="loc_us-gaap_Liabilities_5f85754c-980e-465d-8363-7b2bd32ddd2a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_acd951be-376b-465a-85e8-92fbe7394777" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_4c6631b9-bebe-4383-b7d5-20f960a00d94" xlink:to="loc_us-gaap_CommitmentsAndContingencies_acd951be-376b-465a-85e8-92fbe7394777" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_cd632ebf-bfa6-49d4-bbe4-462768a1be37" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_4c6631b9-bebe-4383-b7d5-20f960a00d94" xlink:to="loc_us-gaap_StockholdersEquity_cd632ebf-bfa6-49d4-bbe4-462768a1be37" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_abbd2814-a9b5-4001-aa70-2d0966dd9a4e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_daf2157f-a238-41dd-8b61-08bbba617379" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_abbd2814-a9b5-4001-aa70-2d0966dd9a4e" xlink:to="loc_us-gaap_LiabilitiesCurrent_daf2157f-a238-41dd-8b61-08bbba617379" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_d2c3d7d3-c607-48d3-9c87-771110a1b635" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_abbd2814-a9b5-4001-aa70-2d0966dd9a4e" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_d2c3d7d3-c607-48d3-9c87-771110a1b635" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_31ecbe2e-6062-4f5c-b340-103fe03b4269" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_abbd2814-a9b5-4001-aa70-2d0966dd9a4e" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_31ecbe2e-6062-4f5c-b340-103fe03b4269" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_0e5c5582-d76b-4fb8-a928-8880ce0adb46" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_abbd2814-a9b5-4001-aa70-2d0966dd9a4e" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_0e5c5582-d76b-4fb8-a928-8880ce0adb46" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_004976ae-b098-45e8-a64b-a43caa6ca7a1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_abbd2814-a9b5-4001-aa70-2d0966dd9a4e" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_004976ae-b098-45e8-a64b-a43caa6ca7a1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent_6fca050d-c934-4689-9a9d-b6d5ba824694" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_abbd2814-a9b5-4001-aa70-2d0966dd9a4e" xlink:to="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent_6fca050d-c934-4689-9a9d-b6d5ba824694" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS" xlink:type="simple" xlink:href="evh-20211231.xsd#CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS"/>
  <link:calculationLink xlink:role="http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_616598d8-ff04-4547-ada5-fcd483718dad" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_57ee4187-32df-4a52-ad11-4087f6c567a7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpenses"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_616598d8-ff04-4547-ada5-fcd483718dad" xlink:to="loc_us-gaap_OperatingExpenses_57ee4187-32df-4a52-ad11-4087f6c567a7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_f3a9b40c-14da-49de-9c56-6a9cf30d61b6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Revenues"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_616598d8-ff04-4547-ada5-fcd483718dad" xlink:to="loc_us-gaap_Revenues_f3a9b40c-14da-49de-9c56-6a9cf30d61b6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_b34a2071-89c9-48f1-af00-807080263b50" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_c872ca56-8f82-4be0-93ec-2b945454b433" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ProfitLoss_b34a2071-89c9-48f1-af00-807080263b50" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_c872ca56-8f82-4be0-93ec-2b945454b433" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_a99b51f9-4acd-4d2b-b3c9-0a089436a9eb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ProfitLoss_b34a2071-89c9-48f1-af00-807080263b50" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_a99b51f9-4acd-4d2b-b3c9-0a089436a9eb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_0c88b0c4-9757-4eb9-9a11-fa4415890760" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentOtherThanTemporaryImpairment_84610c61-8303-41f7-8a82-5f9429e9613d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestmentOtherThanTemporaryImpairment"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_0c88b0c4-9757-4eb9-9a11-fa4415890760" xlink:to="loc_us-gaap_EquityMethodInvestmentOtherThanTemporaryImpairment_84610c61-8303-41f7-8a82-5f9429e9613d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest_77b9af4a-52f6-4850-97c7-615dc4894066" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_0c88b0c4-9757-4eb9-9a11-fa4415890760" xlink:to="loc_us-gaap_InvestmentIncomeInterest_77b9af4a-52f6-4850-97c7-615dc4894066" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_22e5ba7a-7b8a-4ce0-9838-7068e5afe111" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_0c88b0c4-9757-4eb9-9a11-fa4415890760" xlink:to="loc_us-gaap_OperatingIncomeLoss_22e5ba7a-7b8a-4ce0-9838-7068e5afe111" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_2da2cba3-f82b-47c5-a1ca-d8929f2f9011" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpense"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_0c88b0c4-9757-4eb9-9a11-fa4415890760" xlink:to="loc_us-gaap_InterestExpense_2da2cba3-f82b-47c5-a1ca-d8929f2f9011" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherOperatingIncomeExpenseNet_116268d4-f48e-471c-9158-28c4a5612160" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherOperatingIncomeExpenseNet"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_0c88b0c4-9757-4eb9-9a11-fa4415890760" xlink:to="loc_us-gaap_OtherOperatingIncomeExpenseNet_116268d4-f48e-471c-9158-28c4a5612160" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_9026a9d8-8710-4526-882e-33a8fba65263" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_0c88b0c4-9757-4eb9-9a11-fa4415890760" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_9026a9d8-8710-4526-882e-33a8fba65263" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_GainOnTransferOfMembership_76fa8fab-64da-449c-9031-838920bf2bcb" xlink:href="evh-20211231.xsd#evh_GainOnTransferOfMembership"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_0c88b0c4-9757-4eb9-9a11-fa4415890760" xlink:to="loc_evh_GainOnTransferOfMembership_76fa8fab-64da-449c-9031-838920bf2bcb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_GainLossOnRepaymentOfDebt_813e2f6b-966a-47b8-bd80-b71bcbf64c31" xlink:href="evh-20211231.xsd#evh_GainLossOnRepaymentOfDebt"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_0c88b0c4-9757-4eb9-9a11-fa4415890760" xlink:to="loc_evh_GainLossOnRepaymentOfDebt_813e2f6b-966a-47b8-bd80-b71bcbf64c31" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_9279e7e2-3d88-4a2c-bf8d-c80b20add327" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_0c5147a8-25ac-44db-a062-0254cf22f7a9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsPerBasicShare"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EarningsPerShareBasic_9279e7e2-3d88-4a2c-bf8d-c80b20add327" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_0c5147a8-25ac-44db-a062-0254cf22f7a9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare_69b0ccf3-6b4c-427b-a71e-9efc7d5764ce" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EarningsPerShareBasic_9279e7e2-3d88-4a2c-bf8d-c80b20add327" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare_69b0ccf3-6b4c-427b-a71e-9efc7d5764ce" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_EarningsPerSharePortionAttributableToNoncontrollingInterestBasic_d65c8b50-9f8e-4e29-aba4-fd3ca3a95ec8" xlink:href="evh-20211231.xsd#evh_EarningsPerSharePortionAttributableToNoncontrollingInterestBasic"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EarningsPerShareBasic_9279e7e2-3d88-4a2c-bf8d-c80b20add327" xlink:to="loc_evh_EarningsPerSharePortionAttributableToNoncontrollingInterestBasic_d65c8b50-9f8e-4e29-aba4-fd3ca3a95ec8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_1fb38fee-7b1c-41e7-9c82-7e7f1665d24a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_27a8eea3-17b0-408a-8a90-3354689a0759" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_1fb38fee-7b1c-41e7-9c82-7e7f1665d24a" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_27a8eea3-17b0-408a-8a90-3354689a0759" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_78862f51-c758-4d53-b254-0791b6639f22" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_1fb38fee-7b1c-41e7-9c82-7e7f1665d24a" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_78862f51-c758-4d53-b254-0791b6639f22" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_9168f67a-b59a-4e46-948b-bfc33bbf26d8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_e014409b-550f-4568-8b7c-7f27e63a2d1c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EarningsPerShareDiluted_9168f67a-b59a-4e46-948b-bfc33bbf26d8" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_e014409b-550f-4568-8b7c-7f27e63a2d1c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare_c4b9caec-bd3d-4dd8-a73f-2cde5c5ba1b3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EarningsPerShareDiluted_9168f67a-b59a-4e46-948b-bfc33bbf26d8" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare_c4b9caec-bd3d-4dd8-a73f-2cde5c5ba1b3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_EarningsPerSharePortionAttributableToNoncontrollingInterestDiluted_c2703a91-828b-4880-bb6a-702810e53942" xlink:href="evh-20211231.xsd#evh_EarningsPerSharePortionAttributableToNoncontrollingInterestDiluted"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EarningsPerShareDiluted_9168f67a-b59a-4e46-948b-bfc33bbf26d8" xlink:to="loc_evh_EarningsPerSharePortionAttributableToNoncontrollingInterestDiluted_c2703a91-828b-4880-bb6a-702810e53942" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_99243bc9-7b0e-4389-977f-d215c3bae8f8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_82de6567-86d3-4dcb-a38c-7d5632957741" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_99243bc9-7b0e-4389-977f-d215c3bae8f8" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_82de6567-86d3-4dcb-a38c-7d5632957741" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_a9f77bc4-5b08-4d9a-a331-db1f46b8c19a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_99243bc9-7b0e-4389-977f-d215c3bae8f8" xlink:to="loc_us-gaap_ProfitLoss_a9f77bc4-5b08-4d9a-a331-db1f46b8c19a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_cd33328a-4858-415e-8355-1dc9bd218ef2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpenses"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_959c3312-74c4-47ea-b03a-c5976e853efc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_cd33328a-4858-415e-8355-1dc9bd218ef2" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_959c3312-74c4-47ea-b03a-c5976e853efc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationAndAmortization_1ae7f5b6-36c0-45e5-83ba-1c4b8a07bcf5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationAndAmortization"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_cd33328a-4858-415e-8355-1dc9bd218ef2" xlink:to="loc_us-gaap_DepreciationAndAmortization_1ae7f5b6-36c0-45e5-83ba-1c4b8a07bcf5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnDispositionOfAssets1_f8e9f3f9-ca33-49ce-97c5-5bea81a302d7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossOnDispositionOfAssets1"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_cd33328a-4858-415e-8355-1dc9bd218ef2" xlink:to="loc_us-gaap_GainLossOnDispositionOfAssets1_f8e9f3f9-ca33-49ce-97c5-5bea81a302d7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_956ca6f1-edd3-43f6-96c9-dbfe0b3a3cd0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_cd33328a-4858-415e-8355-1dc9bd218ef2" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_956ca6f1-edd3-43f6-96c9-dbfe0b3a3cd0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_d78c9122-0193-4d96-82dc-fc75d2f8b686" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_cd33328a-4858-415e-8355-1dc9bd218ef2" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_d78c9122-0193-4d96-82dc-fc75d2f8b686" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairmentLoss_87615dd0-6c40-403a-be9c-d570ce1a9b5f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_cd33328a-4858-415e-8355-1dc9bd218ef2" xlink:to="loc_us-gaap_GoodwillImpairmentLoss_87615dd0-6c40-403a-be9c-d570ce1a9b5f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_CostofGoodsandServicesSoldExcludingDepreciationandAmortization_554f0b7d-0253-4208-891f-9783e6d5d8c5" xlink:href="evh-20211231.xsd#evh_CostofGoodsandServicesSoldExcludingDepreciationandAmortization"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_cd33328a-4858-415e-8355-1dc9bd218ef2" xlink:to="loc_evh_CostofGoodsandServicesSoldExcludingDepreciationandAmortization_554f0b7d-0253-4208-891f-9783e6d5d8c5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_afa4d09e-9774-4166-9145-3ea7a54f9ca8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_d7787198-1393-4f98-a493-257d53688174" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_afa4d09e-9774-4166-9145-3ea7a54f9ca8" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_d7787198-1393-4f98-a493-257d53688174" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_11e69e54-3145-4798-ba8e-103d18f67c14" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_afa4d09e-9774-4166-9145-3ea7a54f9ca8" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_11e69e54-3145-4798-ba8e-103d18f67c14" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_1f914f26-1dc4-40a9-acb0-1b4482365f64" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_0685fbbb-33f8-4834-8134-3141ebad8a2b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_1f914f26-1dc4-40a9-acb0-1b4482365f64" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_0685fbbb-33f8-4834-8134-3141ebad8a2b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_789fb596-e6c7-42a9-9f47-926b79a86404" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_1f914f26-1dc4-40a9-acb0-1b4482365f64" xlink:to="loc_us-gaap_ProfitLoss_789fb596-e6c7-42a9-9f47-926b79a86404" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_1b1dbdc5-3052-4880-b9bf-84143c3324a9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_8774861c-df63-4f9d-82df-e19492a17a79" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_1b1dbdc5-3052-4880-b9bf-84143c3324a9" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_8774861c-df63-4f9d-82df-e19492a17a79" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_bf51933d-d31e-4630-9984-b1abad4ea099" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_1b1dbdc5-3052-4880-b9bf-84143c3324a9" xlink:to="loc_us-gaap_ProfitLoss_bf51933d-d31e-4630-9984-b1abad4ea099" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="simple" xlink:href="evh-20211231.xsd#CONSOLIDATEDSTATEMENTSOFCASHFLOWS"/>
  <link:calculationLink xlink:role="http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_86e12b04-9afd-43a9-9161-7c492429c678" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_45cc95f3-89c4-46ac-b571-2ff9149edc0a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_86e12b04-9afd-43a9-9161-7c492429c678" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_45cc95f3-89c4-46ac-b571-2ff9149edc0a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b62c13f5-1119-4249-8b98-0abc98af913a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_86e12b04-9afd-43a9-9161-7c492429c678" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b62c13f5-1119-4249-8b98-0abc98af913a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_91888f45-a1ef-4663-a6b8-4288dda25390" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_86e12b04-9afd-43a9-9161-7c492429c678" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_91888f45-a1ef-4663-a6b8-4288dda25390" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_26fd80cf-dd83-4d8c-ab1a-b2cf692152b0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_86e12b04-9afd-43a9-9161-7c492429c678" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_26fd80cf-dd83-4d8c-ab1a-b2cf692152b0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_a614bf77-a97b-4b8c-89d3-d2ab9a937f1f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_23632e97-4f18-4a25-be99-9d42cb90427c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_a614bf77-a97b-4b8c-89d3-d2ab9a937f1f" xlink:to="loc_us-gaap_ProfitLoss_23632e97-4f18-4a25-be99-9d42cb90427c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_2ca4bb92-30cf-4670-9b24-f34b24015aba" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_a614bf77-a97b-4b8c-89d3-d2ab9a937f1f" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_2ca4bb92-30cf-4670-9b24-f34b24015aba" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_GainLossOnDispositionOfAssetsOperatingActivities_657c351e-6671-43ae-91a8-0dc46e5a5cc5" xlink:href="evh-20211231.xsd#evh_GainLossOnDispositionOfAssetsOperatingActivities"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_a614bf77-a97b-4b8c-89d3-d2ab9a937f1f" xlink:to="loc_evh_GainLossOnDispositionOfAssetsOperatingActivities_657c351e-6671-43ae-91a8-0dc46e5a5cc5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_bda70da7-e81d-49cc-8504-f1bfac2fc88c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_a614bf77-a97b-4b8c-89d3-d2ab9a937f1f" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_bda70da7-e81d-49cc-8504-f1bfac2fc88c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_66003895-bf0a-4f55-820c-43e47ad0cde7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_a614bf77-a97b-4b8c-89d3-d2ab9a937f1f" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_66003895-bf0a-4f55-820c-43e47ad0cde7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentOtherThanTemporaryImpairment_7e0db1c7-b718-463c-b34d-e9e0ec9cafde" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestmentOtherThanTemporaryImpairment"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_a614bf77-a97b-4b8c-89d3-d2ab9a937f1f" xlink:to="loc_us-gaap_EquityMethodInvestmentOtherThanTemporaryImpairment_7e0db1c7-b718-463c-b34d-e9e0ec9cafde" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_d3d18786-8811-4e72-853a-cbfc47c7df74" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_a614bf77-a97b-4b8c-89d3-d2ab9a937f1f" xlink:to="loc_us-gaap_ShareBasedCompensation_d3d18786-8811-4e72-853a-cbfc47c7df74" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxesAndTaxCredits_28ab1e0c-669d-4854-8796-76b31d1bd382" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxesAndTaxCredits"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_a614bf77-a97b-4b8c-89d3-d2ab9a937f1f" xlink:to="loc_us-gaap_DeferredIncomeTaxesAndTaxCredits_28ab1e0c-669d-4854-8796-76b31d1bd382" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedContractCostAmortization_f1fe6056-ebd5-4589-adb8-301a500c3b60" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalizedContractCostAmortization"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_a614bf77-a97b-4b8c-89d3-d2ab9a937f1f" xlink:to="loc_us-gaap_CapitalizedContractCostAmortization_f1fe6056-ebd5-4589-adb8-301a500c3b60" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCosts_914d39c2-8f64-4a03-8103-045e881e641f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfFinancingCosts"/>
    <link:calculationArc order="10" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_a614bf77-a97b-4b8c-89d3-d2ab9a937f1f" xlink:to="loc_us-gaap_AmortizationOfFinancingCosts_914d39c2-8f64-4a03-8103-045e881e641f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense_ceb963db-3f21-492d-9921-cc392c8522ae" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNoncashIncomeExpense"/>
    <link:calculationArc order="11" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_a614bf77-a97b-4b8c-89d3-d2ab9a937f1f" xlink:to="loc_us-gaap_OtherNoncashIncomeExpense_ceb963db-3f21-492d-9921-cc392c8522ae" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_IncreaseDecreaseInAccountsReceivableAndContractWithCustomerAsset_3dd3160f-8f45-4a68-94cd-b0cd3e3182ab" xlink:href="evh-20211231.xsd#evh_IncreaseDecreaseInAccountsReceivableAndContractWithCustomerAsset"/>
    <link:calculationArc order="12" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_a614bf77-a97b-4b8c-89d3-d2ab9a937f1f" xlink:to="loc_evh_IncreaseDecreaseInAccountsReceivableAndContractWithCustomerAsset_3dd3160f-8f45-4a68-94cd-b0cd3e3182ab" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_4c406d01-4537-4ea9-be29-c8a22b1d3682" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:calculationArc order="13" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_a614bf77-a97b-4b8c-89d3-d2ab9a937f1f" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_4c406d01-4537-4ea9-be29-c8a22b1d3682" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_IncreaseDecreaseInCapitalizedContractCostNet_2f40e74c-e618-4579-9bc8-3e9483f4ce7d" xlink:href="evh-20211231.xsd#evh_IncreaseDecreaseInCapitalizedContractCostNet"/>
    <link:calculationArc order="14" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_a614bf77-a97b-4b8c-89d3-d2ab9a937f1f" xlink:to="loc_evh_IncreaseDecreaseInCapitalizedContractCostNet_2f40e74c-e618-4579-9bc8-3e9483f4ce7d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_07254853-2aba-4806-9453-d2bcdf8bb313" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:calculationArc order="15" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_a614bf77-a97b-4b8c-89d3-d2ab9a937f1f" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_07254853-2aba-4806-9453-d2bcdf8bb313" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_3452c10a-e49f-4b97-9945-719c1b9fc132" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:calculationArc order="16" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_a614bf77-a97b-4b8c-89d3-d2ab9a937f1f" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_3452c10a-e49f-4b97-9945-719c1b9fc132" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_cd7283ad-059e-4ba5-91f6-344829076ef7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities"/>
    <link:calculationArc order="17" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_a614bf77-a97b-4b8c-89d3-d2ab9a937f1f" xlink:to="loc_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_cd7283ad-059e-4ba5-91f6-344829076ef7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_8071c42f-f2e5-4c1c-9770-50d7cc87ff66" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:calculationArc order="18" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_a614bf77-a97b-4b8c-89d3-d2ab9a937f1f" xlink:to="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_8071c42f-f2e5-4c1c-9770-50d7cc87ff66" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_IncreaseDecreaseInInsuranceAndPerformanceBasedArrangementsLiabilities_1382f003-a00d-4a69-a624-156d0c0706de" xlink:href="evh-20211231.xsd#evh_IncreaseDecreaseInInsuranceAndPerformanceBasedArrangementsLiabilities"/>
    <link:calculationArc order="19" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_a614bf77-a97b-4b8c-89d3-d2ab9a937f1f" xlink:to="loc_evh_IncreaseDecreaseInInsuranceAndPerformanceBasedArrangementsLiabilities_1382f003-a00d-4a69-a624-156d0c0706de" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_IncreaseDecreaseInOperatingLeaseRightofUseAsset_ff0124bb-2d8e-4eb0-b403-62453bcc613d" xlink:href="evh-20211231.xsd#evh_IncreaseDecreaseInOperatingLeaseRightofUseAsset"/>
    <link:calculationArc order="20" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_a614bf77-a97b-4b8c-89d3-d2ab9a937f1f" xlink:to="loc_evh_IncreaseDecreaseInOperatingLeaseRightofUseAsset_ff0124bb-2d8e-4eb0-b403-62453bcc613d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_acb327ac-63b0-49e2-b37f-9d7b6f9c0ae6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
    <link:calculationArc order="21" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_a614bf77-a97b-4b8c-89d3-d2ab9a937f1f" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_acb327ac-63b0-49e2-b37f-9d7b6f9c0ae6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_0c0b2d7a-9bc7-43bc-a743-c165a1eb09e9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities"/>
    <link:calculationArc order="22" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_a614bf77-a97b-4b8c-89d3-d2ab9a937f1f" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_0c0b2d7a-9bc7-43bc-a743-c165a1eb09e9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_3fef7234-a89b-483a-84b8-850eef929d9f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:calculationArc order="23" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_a614bf77-a97b-4b8c-89d3-d2ab9a937f1f" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_3fef7234-a89b-483a-84b8-850eef929d9f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_GainOnTransferOfMembership_da128ebb-8faa-4fca-bcce-5f99228fbf6a" xlink:href="evh-20211231.xsd#evh_GainOnTransferOfMembership"/>
    <link:calculationArc order="24" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_a614bf77-a97b-4b8c-89d3-d2ab9a937f1f" xlink:to="loc_evh_GainOnTransferOfMembership_da128ebb-8faa-4fca-bcce-5f99228fbf6a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairmentLoss_758fd5ec-e027-49f2-a21e-7ec9568940d8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <link:calculationArc order="25" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_a614bf77-a97b-4b8c-89d3-d2ab9a937f1f" xlink:to="loc_us-gaap_GoodwillImpairmentLoss_758fd5ec-e027-49f2-a21e-7ec9568940d8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_PaidinKindInterestIncome_0ee0ca46-9c9c-455e-9ab5-94ac12799eac" xlink:href="evh-20211231.xsd#evh_PaidinKindInterestIncome"/>
    <link:calculationArc order="26" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_a614bf77-a97b-4b8c-89d3-d2ab9a937f1f" xlink:to="loc_evh_PaidinKindInterestIncome_0ee0ca46-9c9c-455e-9ab5-94ac12799eac" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_GainLossOnRepaymentOfDebt_60ec93e2-87eb-43f3-8e7d-45b80f32add0" xlink:href="evh-20211231.xsd#evh_GainLossOnRepaymentOfDebt"/>
    <link:calculationArc order="27" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_a614bf77-a97b-4b8c-89d3-d2ab9a937f1f" xlink:to="loc_evh_GainLossOnRepaymentOfDebt_60ec93e2-87eb-43f3-8e7d-45b80f32add0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_5ed3d5f5-739c-4878-84c1-60e00a2fb6c8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromHedgeFinancingActivities_30aff587-2329-4dde-840d-3556e3e46307" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromHedgeFinancingActivities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_5ed3d5f5-739c-4878-84c1-60e00a2fb6c8" xlink:to="loc_us-gaap_ProceedsFromHedgeFinancingActivities_30aff587-2329-4dde-840d-3556e3e46307" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_e162109a-4aed-443a-ab7c-6d9b83ede2fd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_5ed3d5f5-739c-4878-84c1-60e00a2fb6c8" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_e162109a-4aed-443a-ab7c-6d9b83ede2fd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromConvertibleDebt_331a7624-bc0a-42af-a60b-0ada2160cd76" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromConvertibleDebt"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_5ed3d5f5-739c-4878-84c1-60e00a2fb6c8" xlink:to="loc_us-gaap_ProceedsFromConvertibleDebt_331a7624-bc0a-42af-a60b-0ada2160cd76" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_PaymentsForProceedsFromClaimsProcessingFinancingActivities_0ec32dc6-4cc7-4b1b-b8eb-d4ac7010d2a2" xlink:href="evh-20211231.xsd#evh_PaymentsForProceedsFromClaimsProcessingFinancingActivities"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_5ed3d5f5-739c-4878-84c1-60e00a2fb6c8" xlink:to="loc_evh_PaymentsForProceedsFromClaimsProcessingFinancingActivities_0ec32dc6-4cc7-4b1b-b8eb-d4ac7010d2a2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToMinorityShareholders_d212d8e9-5de1-477b-af8c-f60369689789" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToMinorityShareholders"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_5ed3d5f5-739c-4878-84c1-60e00a2fb6c8" xlink:to="loc_us-gaap_PaymentsToMinorityShareholders_d212d8e9-5de1-477b-af8c-f60369689789" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_ProceedsFromAssetAcquisitionEscrow_eabc317d-565b-4f59-9bff-9405b6269587" xlink:href="evh-20211231.xsd#evh_ProceedsFromAssetAcquisitionEscrow"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_5ed3d5f5-739c-4878-84c1-60e00a2fb6c8" xlink:to="loc_evh_ProceedsFromAssetAcquisitionEscrow_eabc317d-565b-4f59-9bff-9405b6269587" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfSeniorDebt_eba8cd64-5923-43c3-b673-7c836c80b48f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfSeniorDebt"/>
    <link:calculationArc order="7" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_5ed3d5f5-739c-4878-84c1-60e00a2fb6c8" xlink:to="loc_us-gaap_RepaymentsOfSeniorDebt_eba8cd64-5923-43c3-b673-7c836c80b48f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_d6389a2d-1da8-40f7-8652-b9b0e3c23e5d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:calculationArc order="8" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_5ed3d5f5-739c-4878-84c1-60e00a2fb6c8" xlink:to="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_d6389a2d-1da8-40f7-8652-b9b0e3c23e5d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDebtExtinguishmentCosts_7bc73933-0c64-4a41-96fe-fbea832f24de" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsOfDebtExtinguishmentCosts"/>
    <link:calculationArc order="9" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_5ed3d5f5-739c-4878-84c1-60e00a2fb6c8" xlink:to="loc_us-gaap_PaymentsOfDebtExtinguishmentCosts_7bc73933-0c64-4a41-96fe-fbea832f24de" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_1971fcba-f4b6-4717-8fac-e75ad23df6ca" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromDivestitureOfInterestInSubsidiariesAndAffiliates_435801c0-9c49-4967-bc71-9e6bd9804a8a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromDivestitureOfInterestInSubsidiariesAndAffiliates"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_1971fcba-f4b6-4717-8fac-e75ad23df6ca" xlink:to="loc_us-gaap_ProceedsFromDivestitureOfInterestInSubsidiariesAndAffiliates_435801c0-9c49-4967-bc71-9e6bd9804a8a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForProceedsFromLoansReceivable_0a36acaa-d990-459a-bc28-f13be7495648" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsForProceedsFromLoansReceivable"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_1971fcba-f4b6-4717-8fac-e75ad23df6ca" xlink:to="loc_us-gaap_PaymentsForProceedsFromLoansReceivable_0a36acaa-d990-459a-bc28-f13be7495648" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_21cad71a-d57c-46ee-8f2d-d4d622ee9d05" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsForProceedsFromOtherInvestingActivities"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_1971fcba-f4b6-4717-8fac-e75ad23df6ca" xlink:to="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_21cad71a-d57c-46ee-8f2d-d4d622ee9d05" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_PaymentsForProceedsFromDisposalOfNonStrategicAssetsAndDivestitureOfDiscontinuedOperationsNet_beaffffd-e81d-4ba8-9494-217eb1ccd479" xlink:href="evh-20211231.xsd#evh_PaymentsForProceedsFromDisposalOfNonStrategicAssetsAndDivestitureOfDiscontinuedOperationsNet"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_1971fcba-f4b6-4717-8fac-e75ad23df6ca" xlink:to="loc_evh_PaymentsForProceedsFromDisposalOfNonStrategicAssetsAndDivestitureOfDiscontinuedOperationsNet_beaffffd-e81d-4ba8-9494-217eb1ccd479" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital_23f6a608-5bb7-4631-bcf1-a571043ca867" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_1971fcba-f4b6-4717-8fac-e75ad23df6ca" xlink:to="loc_us-gaap_ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital_23f6a608-5bb7-4631-bcf1-a571043ca867" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross_3b0ec74a-6aa7-4472-b13a-26bbc764a9eb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesGross"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_1971fcba-f4b6-4717-8fac-e75ad23df6ca" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesGross_3b0ec74a-6aa7-4472-b13a-26bbc764a9eb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireOtherProductiveAssets_8480521c-6770-4d85-87f7-d814ac49eaf2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireOtherProductiveAssets"/>
    <link:calculationArc order="7" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_1971fcba-f4b6-4717-8fac-e75ad23df6ca" xlink:to="loc_us-gaap_PaymentsToAcquireOtherProductiveAssets_8480521c-6770-4d85-87f7-d814ac49eaf2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_ProceedsFromMaturityOfInvestments_f7cb48d6-4342-446a-998d-48309ea96abb" xlink:href="evh-20211231.xsd#evh_ProceedsFromMaturityOfInvestments"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_1971fcba-f4b6-4717-8fac-e75ad23df6ca" xlink:to="loc_evh_ProceedsFromMaturityOfInvestments_f7cb48d6-4342-446a-998d-48309ea96abb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAcquiredFromAcquisition_0bb2f6dd-5771-4f58-8d18-ae0a025b2e81" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAcquiredFromAcquisition"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_1971fcba-f4b6-4717-8fac-e75ad23df6ca" xlink:to="loc_us-gaap_CashAcquiredFromAcquisition_0bb2f6dd-5771-4f58-8d18-ae0a025b2e81" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireInterestInSubsidiariesAndAffiliates_65a16f3d-0bbf-4460-a14d-359f0ee1e01f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireInterestInSubsidiariesAndAffiliates"/>
    <link:calculationArc order="10" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_1971fcba-f4b6-4717-8fac-e75ad23df6ca" xlink:to="loc_us-gaap_PaymentsToAcquireInterestInSubsidiariesAndAffiliates_65a16f3d-0bbf-4460-a14d-359f0ee1e01f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_PaymentsForCustomerAdvanceForRegulatoryCapitalRequirements_5a2ad6c8-3728-4ea6-94bc-a0d68b55b9ec" xlink:href="evh-20211231.xsd#evh_PaymentsForCustomerAdvanceForRegulatoryCapitalRequirements"/>
    <link:calculationArc order="11" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_1971fcba-f4b6-4717-8fac-e75ad23df6ca" xlink:to="loc_evh_PaymentsForCustomerAdvanceForRegulatoryCapitalRequirements_5a2ad6c8-3728-4ea6-94bc-a0d68b55b9ec" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireHeldToMaturitySecurities_4cc83414-b2cb-40b2-92b2-b6e2014ceb8c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireHeldToMaturitySecurities"/>
    <link:calculationArc order="12" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_1971fcba-f4b6-4717-8fac-e75ad23df6ca" xlink:to="loc_us-gaap_PaymentsToAcquireHeldToMaturitySecurities_4cc83414-b2cb-40b2-92b2-b6e2014ceb8c" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesRestrictedCashandRestrictedInvestmentsDetails" xlink:type="simple" xlink:href="evh-20211231.xsd#BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesRestrictedCashandRestrictedInvestmentsDetails"/>
  <link:calculationLink xlink:role="http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesRestrictedCashandRestrictedInvestmentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndInvestmentsCurrent_5ba80fd6-1ef9-4c77-89eb-28f92acc31e9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndInvestmentsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_1cad3fc7-a260-4da3-8ea1-f27a272d06a4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_RestrictedCashAndInvestmentsCurrent_5ba80fd6-1ef9-4c77-89eb-28f92acc31e9" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_1cad3fc7-a260-4da3-8ea1-f27a272d06a4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndInvestmentsNoncurrent_889d0c71-c3fd-408a-bcf1-122f77c89ce0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndInvestmentsNoncurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_75467f50-aab9-408d-b7ad-5fc975c3445d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsNoncurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_RestrictedCashAndInvestmentsNoncurrent_889d0c71-c3fd-408a-bcf1-122f77c89ce0" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_75467f50-aab9-408d-b7ad-5fc975c3445d" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/TransactionsVitalDecisionsDetails" xlink:type="simple" xlink:href="evh-20211231.xsd#TransactionsVitalDecisionsDetails"/>
  <link:calculationLink xlink:role="http://www.evolenthealth.com/role/TransactionsVitalDecisionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_9bdfa869-f839-4a80-8935-6471a11b4bb9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_ca500339-1a5e-4199-ad8e-a87d9db90d42" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_9bdfa869-f839-4a80-8935-6471a11b4bb9" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_ca500339-1a5e-4199-ad8e-a87d9db90d42" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedTangibleAssets_c78453ab-8222-403f-a1ea-cc111e3c18e1" xlink:href="evh-20211231.xsd#evh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedTangibleAssets"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_9bdfa869-f839-4a80-8935-6471a11b4bb9" xlink:to="loc_evh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedTangibleAssets_c78453ab-8222-403f-a1ea-cc111e3c18e1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_71f0d029-e28d-424b-b31a-899688875d2a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_9bdfa869-f839-4a80-8935-6471a11b4bb9" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_71f0d029-e28d-424b-b31a-899688875d2a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_bafbbdd6-8eae-42a8-830c-2a66178f2c56" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_9bdfa869-f839-4a80-8935-6471a11b4bb9" xlink:to="loc_us-gaap_Goodwill_bafbbdd6-8eae-42a8-830c-2a66178f2c56" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedTangibleAssets_34899344-027b-4dec-8306-004bd5c601ec" xlink:href="evh-20211231.xsd#evh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedTangibleAssets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_7cc0c086-152d-4cf4-a38a-8abb81e5c3c7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_evh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedTangibleAssets_34899344-027b-4dec-8306-004bd5c601ec" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_7cc0c086-152d-4cf4-a38a-8abb81e5c3c7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables_9865bc3a-5394-4b43-ac39-ccf062825b34" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_evh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedTangibleAssets_34899344-027b-4dec-8306-004bd5c601ec" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables_9865bc3a-5394-4b43-ac39-ccf062825b34" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets_40df21ca-6dc0-4ec3-867a-a8fa848b28d6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_evh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedTangibleAssets_34899344-027b-4dec-8306-004bd5c601ec" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets_40df21ca-6dc0-4ec3-867a-a8fa848b28d6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_e2c9006f-1760-48d8-aae1-475728d7ea94" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_evh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedTangibleAssets_34899344-027b-4dec-8306-004bd5c601ec" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_e2c9006f-1760-48d8-aae1-475728d7ea94" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_e68a3ed7-9b2e-47a4-8efd-169f48e3286a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesAccruedCompensationAndEmployeeBenefits_3687f947-21ac-4a21-8dad-8222727da009" xlink:href="evh-20211231.xsd#evh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesAccruedCompensationAndEmployeeBenefits"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_e68a3ed7-9b2e-47a4-8efd-169f48e3286a" xlink:to="loc_evh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesAccruedCompensationAndEmployeeBenefits_3687f947-21ac-4a21-8dad-8222727da009" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue_4b1902d6-88d7-43fb-8fe1-b62c0d501847" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_e68a3ed7-9b2e-47a4-8efd-169f48e3286a" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue_4b1902d6-88d7-43fb-8fe1-b62c0d501847" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCapitalLeaseObligation_80d87f83-49e5-411a-90eb-01a36fafd33e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCapitalLeaseObligation"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_e68a3ed7-9b2e-47a4-8efd-169f48e3286a" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCapitalLeaseObligation_80d87f83-49e5-411a-90eb-01a36fafd33e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_2d1e5f3a-8cba-4913-8649-f21e0eeff0d4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_e68a3ed7-9b2e-47a4-8efd-169f48e3286a" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_2d1e5f3a-8cba-4913-8649-f21e0eeff0d4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesAccruedLiabilities_c45e8e4c-dcb6-4be6-97e2-f5320c7f58f3" xlink:href="evh-20211231.xsd#evh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesAccruedLiabilities"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_e68a3ed7-9b2e-47a4-8efd-169f48e3286a" xlink:to="loc_evh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesAccruedLiabilities_c45e8e4c-dcb6-4be6-97e2-f5320c7f58f3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_571af003-7738-4acb-b6d4-d460204a0fc9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_e68a3ed7-9b2e-47a4-8efd-169f48e3286a" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_571af003-7738-4acb-b6d4-d460204a0fc9" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/DiscontinuedOperationsSummaryofResultsofOperationsDetails" xlink:type="simple" xlink:href="evh-20211231.xsd#DiscontinuedOperationsSummaryofResultsofOperationsDetails"/>
  <link:calculationLink xlink:role="http://www.evolenthealth.com/role/DiscontinuedOperationsSummaryofResultsofOperationsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense_a35a1415-fdd0-45dc-bc0a-8f6e3178245c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense_7d61df50-d7a1-4cf5-923b-763bd6a84b49" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense_a35a1415-fdd0-45dc-bc0a-8f6e3178245c" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense_7d61df50-d7a1-4cf5-923b-763bd6a84b49" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationAndAmortizationDiscontinuedOperations_a26755b0-fe45-4819-a9d2-8ac24834135f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationAndAmortizationDiscontinuedOperations"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense_a35a1415-fdd0-45dc-bc0a-8f6e3178245c" xlink:to="loc_us-gaap_DepreciationAndAmortizationDiscontinuedOperations_a26755b0-fe45-4819-a9d2-8ac24834135f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_DisposalGroupIncludingDiscontinuedOperationClaimsExpense_5c4e4daa-606a-4ad1-922a-d80db5a2d01a" xlink:href="evh-20211231.xsd#evh_DisposalGroupIncludingDiscontinuedOperationClaimsExpense"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense_a35a1415-fdd0-45dc-bc0a-8f6e3178245c" xlink:to="loc_evh_DisposalGroupIncludingDiscontinuedOperationClaimsExpense_5c4e4daa-606a-4ad1-922a-d80db5a2d01a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold_8f53c2df-8239-4e70-8f86-72694d2a62d3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense_a35a1415-fdd0-45dc-bc0a-8f6e3178245c" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold_8f53c2df-8239-4e70-8f86-72694d2a62d3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss_20692f2a-f539-49ab-988a-6042c2e7bfe2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense_daa8434b-60bb-4de8-bcb1-fe2ce97d4ee2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss_20692f2a-f539-49ab-988a-6042c2e7bfe2" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense_daa8434b-60bb-4de8-bcb1-fe2ce97d4ee2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue_a166845b-1db6-4f74-95b7-b67f1d62411f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss_20692f2a-f539-49ab-988a-6042c2e7bfe2" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue_a166845b-1db6-4f74-95b7-b67f1d62411f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax_52798956-8d90-486b-b788-ca4042ab10b2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss_5200317d-ecb9-4de4-9e6c-4527ac583fbe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax_52798956-8d90-486b-b788-ca4042ab10b2" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss_5200317d-ecb9-4de4-9e6c-4527ac583fbe" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherExpense_f4ea57fa-ce32-4a05-8cf0-e8789b9da3a5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherExpense"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax_52798956-8d90-486b-b788-ca4042ab10b2" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherExpense_f4ea57fa-ce32-4a05-8cf0-e8789b9da3a5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationInterestExpense_6b8be1b5-c785-41b9-83fa-f5b0328b0486" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationInterestExpense"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax_52798956-8d90-486b-b788-ca4042ab10b2" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationInterestExpense_6b8be1b5-c785-41b9-83fa-f5b0328b0486" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationInterestIncome_e6254f06-f988-48eb-9d5e-a66b89a9ca0a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationInterestIncome"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax_52798956-8d90-486b-b788-ca4042ab10b2" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationInterestIncome_e6254f06-f988-48eb-9d5e-a66b89a9ca0a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_33d12a9f-6b21-48b8-acf7-39e3a26f6e43" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation_ca2188fe-f114-4046-b1ba-40760b52bf1c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_33d12a9f-6b21-48b8-acf7-39e3a26f6e43" xlink:to="loc_us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation_ca2188fe-f114-4046-b1ba-40760b52bf1c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax_42de81aa-5337-4545-8f8b-356458707a9d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_33d12a9f-6b21-48b8-acf7-39e3a26f6e43" xlink:to="loc_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax_42de81aa-5337-4545-8f8b-356458707a9d" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/DiscontinuedOperationsSummaryofCurrentandLongtermAssetsandLiabilitiesDetails" xlink:type="simple" xlink:href="evh-20211231.xsd#DiscontinuedOperationsSummaryofCurrentandLongtermAssetsandLiabilitiesDetails"/>
  <link:calculationLink xlink:role="http://www.evolenthealth.com/role/DiscontinuedOperationsSummaryofCurrentandLongtermAssetsandLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent_2a956c72-2fb1-433f-b34f-4ca3eae09c86" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_DisposalGroupIncludingDiscontinuedOperationLiabilityForFuturePolicyBenefitsAndUnpaidClaimsAndClaimsAdjustmentExpenseAndPerformanceBasedArrangementsCurrent_7131cd46-08f4-4f3c-a83f-a16db3c2d618" xlink:href="evh-20211231.xsd#evh_DisposalGroupIncludingDiscontinuedOperationLiabilityForFuturePolicyBenefitsAndUnpaidClaimsAndClaimsAdjustmentExpenseAndPerformanceBasedArrangementsCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent_2a956c72-2fb1-433f-b34f-4ca3eae09c86" xlink:to="loc_evh_DisposalGroupIncludingDiscontinuedOperationLiabilityForFuturePolicyBenefitsAndUnpaidClaimsAndClaimsAdjustmentExpenseAndPerformanceBasedArrangementsCurrent_7131cd46-08f4-4f3c-a83f-a16db3c2d618" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_DisposalGroupIncludingDiscontinuedOperationAccruedCompensationAndEmployeeBenefitsCurrent_93dcb35c-6452-40ee-a2cb-18fe0a179355" xlink:href="evh-20211231.xsd#evh_DisposalGroupIncludingDiscontinuedOperationAccruedCompensationAndEmployeeBenefitsCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent_2a956c72-2fb1-433f-b34f-4ca3eae09c86" xlink:to="loc_evh_DisposalGroupIncludingDiscontinuedOperationAccruedCompensationAndEmployeeBenefitsCurrent_93dcb35c-6452-40ee-a2cb-18fe0a179355" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilitiesCurrent_3e3fd6f5-cfa3-4955-b1fb-9b5608a267da" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilitiesCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent_2a956c72-2fb1-433f-b34f-4ca3eae09c86" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilitiesCurrent_3e3fd6f5-cfa3-4955-b1fb-9b5608a267da" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredRevenueCurrent_e36d1f43-a386-4e1e-ae2a-2d87de6140bb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredRevenueCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent_2a956c72-2fb1-433f-b34f-4ca3eae09c86" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredRevenueCurrent_e36d1f43-a386-4e1e-ae2a-2d87de6140bb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayableCurrent_fdb6d3e5-810f-407c-a35c-083d422c2e83" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayableCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent_2a956c72-2fb1-433f-b34f-4ca3eae09c86" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayableCurrent_fdb6d3e5-810f-407c-a35c-083d422c2e83" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation_c096a97a-ec2b-4709-a810-aa43838188d2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentLiabilities_197f5314-c43f-47a7-b9b6-888dd9d4d206" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentLiabilities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation_c096a97a-ec2b-4709-a810-aa43838188d2" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentLiabilities_197f5314-c43f-47a7-b9b6-888dd9d4d206" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent_8598e33e-0caf-4701-a3e0-2ef5dae59c36" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation_c096a97a-ec2b-4709-a810-aa43838188d2" xlink:to="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent_8598e33e-0caf-4701-a3e0-2ef5dae59c36" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredTaxLiabilities_0aa37c51-7ae2-460a-a99f-3eb44e981eec" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredTaxLiabilities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation_c096a97a-ec2b-4709-a810-aa43838188d2" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredTaxLiabilities_0aa37c51-7ae2-460a-a99f-3eb44e981eec" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation_ea02cc37-8db0-486b-87f8-f452fa9469bf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_DisposalGroupIncludingDiscontinuedOperationInvestmentsNoncurrent_4a40edbd-b28d-4f59-ad3a-e950b99f701b" xlink:href="evh-20211231.xsd#evh_DisposalGroupIncludingDiscontinuedOperationInvestmentsNoncurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation_ea02cc37-8db0-486b-87f8-f452fa9469bf" xlink:to="loc_evh_DisposalGroupIncludingDiscontinuedOperationInvestmentsNoncurrent_4a40edbd-b28d-4f59-ad3a-e950b99f701b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_DisposalGroupIncludingDiscontinuedOperationRestrictedCashAndRestrictedInvestmentsNoncurrent_ed08a217-e10b-4d85-9ef8-0e7dd3c8aedc" xlink:href="evh-20211231.xsd#evh_DisposalGroupIncludingDiscontinuedOperationRestrictedCashAndRestrictedInvestmentsNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation_ea02cc37-8db0-486b-87f8-f452fa9469bf" xlink:to="loc_evh_DisposalGroupIncludingDiscontinuedOperationRestrictedCashAndRestrictedInvestmentsNoncurrent_ed08a217-e10b-4d85-9ef8-0e7dd3c8aedc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsNoncurrent_8c36e173-2517-47e2-b18e-2a54dfe8030b" xlink:href="evh-20211231.xsd#evh_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsNoncurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation_ea02cc37-8db0-486b-87f8-f452fa9469bf" xlink:to="loc_evh_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsNoncurrent_8c36e173-2517-47e2-b18e-2a54dfe8030b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwillNoncurrent_cec25d7e-1302-4056-8a06-e2c68b4b6150" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwillNoncurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation_ea02cc37-8db0-486b-87f8-f452fa9469bf" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwillNoncurrent_cec25d7e-1302-4056-8a06-e2c68b4b6150" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsNoncurrent_68db65d5-a291-4847-a601-579195b783d7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsNoncurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation_ea02cc37-8db0-486b-87f8-f452fa9469bf" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsNoncurrent_68db65d5-a291-4847-a601-579195b783d7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent_f6cdf75e-4598-482e-a8a2-f55b9ce99264" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation_ea02cc37-8db0-486b-87f8-f452fa9469bf" xlink:to="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent_f6cdf75e-4598-482e-a8a2-f55b9ce99264" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent_4b76bb48-6372-4671-be5f-a948c930b897" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_DisposalGroupIncludingDiscontinuedOperationInvestmentsCurrent_09ed9db5-013f-45da-a9b5-b774d3de5b40" xlink:href="evh-20211231.xsd#evh_DisposalGroupIncludingDiscontinuedOperationInvestmentsCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent_4b76bb48-6372-4671-be5f-a948c930b897" xlink:to="loc_evh_DisposalGroupIncludingDiscontinuedOperationInvestmentsCurrent_09ed9db5-013f-45da-a9b5-b774d3de5b40" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_DisposalGroupIncludingDiscontinuedOperationRestrictedCashAndRestrictedInvestmentsCurrent_c91d5a98-5a81-4aae-a70b-71a3bd9ff67f" xlink:href="evh-20211231.xsd#evh_DisposalGroupIncludingDiscontinuedOperationRestrictedCashAndRestrictedInvestmentsCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent_4b76bb48-6372-4671-be5f-a948c930b897" xlink:to="loc_evh_DisposalGroupIncludingDiscontinuedOperationRestrictedCashAndRestrictedInvestmentsCurrent_c91d5a98-5a81-4aae-a70b-71a3bd9ff67f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet_757b3699-d329-46fb-bd18-d7c54eac5c72" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent_4b76bb48-6372-4671-be5f-a948c930b897" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet_757b3699-d329-46fb-bd18-d7c54eac5c72" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents_73682fdd-787f-49ce-95e9-0cc86e276853" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent_4b76bb48-6372-4671-be5f-a948c930b897" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents_73682fdd-787f-49ce-95e9-0cc86e276853" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent_b0856987-e9c2-488b-a25d-01dc2e0d611f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent_4b76bb48-6372-4671-be5f-a948c930b897" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent_b0856987-e9c2-488b-a25d-01dc2e0d611f" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/PropertyandEquipmentNetDetails" xlink:type="simple" xlink:href="evh-20211231.xsd#PropertyandEquipmentNetDetails"/>
  <link:calculationLink xlink:role="http://www.evolenthealth.com/role/PropertyandEquipmentNetDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_44bce72b-0c6a-436b-8983-9a53781f39af" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_e4e7c2bf-6c50-4190-a0f5-2b81938c6d6e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_44bce72b-0c6a-436b-8983-9a53781f39af" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_e4e7c2bf-6c50-4190-a0f5-2b81938c6d6e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_64bc56ff-2d54-4de4-bbcd-0647507de1fb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_44bce72b-0c6a-436b-8983-9a53781f39af" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_64bc56ff-2d54-4de4-bbcd-0647507de1fb" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNetIntangibleAssetsNetDetails" xlink:type="simple" xlink:href="evh-20211231.xsd#GoodwillandIntangibleAssetsNetIntangibleAssetsNetDetails"/>
  <link:calculationLink xlink:role="http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNetIntangibleAssetsNetDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_0002cd7e-f51c-4c78-831c-f7e9c0287a5b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_a20a79a8-cb19-450f-84b0-5887a2006a1b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_0002cd7e-f51c-4c78-831c-f7e9c0287a5b" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_a20a79a8-cb19-450f-84b0-5887a2006a1b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_23ca75a6-82f2-474e-91e7-f3baadcd746f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_0002cd7e-f51c-4c78-831c-f7e9c0287a5b" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_23ca75a6-82f2-474e-91e7-f3baadcd746f" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNetAmortizationofIntangibleAssetsDetails" xlink:type="simple" xlink:href="evh-20211231.xsd#GoodwillandIntangibleAssetsNetAmortizationofIntangibleAssetsDetails"/>
  <link:calculationLink xlink:role="http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNetAmortizationofIntangibleAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_5e1c0c69-2588-4b23-be05-701bd7cef5ab" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_0b39dad8-9d53-4dd9-836c-c4ab07701a0d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_5e1c0c69-2588-4b23-be05-701bd7cef5ab" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_0b39dad8-9d53-4dd9-836c-c4ab07701a0d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_bfcd7d33-9368-48c3-aada-6505bb605370" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_5e1c0c69-2588-4b23-be05-701bd7cef5ab" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_bfcd7d33-9368-48c3-aada-6505bb605370" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_3fd72694-08d0-4b20-be6d-9f044898fc00" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_5e1c0c69-2588-4b23-be05-701bd7cef5ab" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_3fd72694-08d0-4b20-be6d-9f044898fc00" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_c154afdc-efd4-4e9f-a9d5-dc880612001b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_5e1c0c69-2588-4b23-be05-701bd7cef5ab" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_c154afdc-efd4-4e9f-a9d5-dc880612001b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_14a23d3e-5991-419c-9867-f27362033fc2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_5e1c0c69-2588-4b23-be05-701bd7cef5ab" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_14a23d3e-5991-419c-9867-f27362033fc2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_139aeff1-e0a8-4c42-9cfa-e561ee890423" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_5e1c0c69-2588-4b23-be05-701bd7cef5ab" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_139aeff1-e0a8-4c42-9cfa-e561ee890423" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/LongtermDebtConvertibleSeniorNotesCarryingValueDetails" xlink:type="simple" xlink:href="evh-20211231.xsd#LongtermDebtConvertibleSeniorNotesCarryingValueDetails"/>
  <link:calculationLink xlink:role="http://www.evolenthealth.com/role/LongtermDebtConvertibleSeniorNotesCarryingValueDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebt_2cc1e6af-0469-4a3a-bf62-815760aab4a1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertibleDebt"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_352dbe79-a2a8-4a41-a7c4-3c52723da69f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ConvertibleDebt_2cc1e6af-0469-4a3a-bf62-815760aab4a1" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_352dbe79-a2a8-4a41-a7c4-3c52723da69f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_ba432939-9d54-4f09-ae7d-ab3794e5f1fb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ConvertibleDebt_2cc1e6af-0469-4a3a-bf62-815760aab4a1" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_ba432939-9d54-4f09-ae7d-ab3794e5f1fb" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/LeasesComponentsofLeaseExpenseDetails" xlink:type="simple" xlink:href="evh-20211231.xsd#LeasesComponentsofLeaseExpenseDetails"/>
  <link:calculationLink xlink:role="http://www.evolenthealth.com/role/LeasesComponentsofLeaseExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCost_5db5593f-7248-4dbe-92d4-eecb677662ad" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseCost"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost_fb29b876-1826-4452-a6de-350d719597d0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseCost"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LeaseCost_5db5593f-7248-4dbe-92d4-eecb677662ad" xlink:to="loc_us-gaap_OperatingLeaseCost_fb29b876-1826-4452-a6de-350d719597d0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAssetAmortization_72ddf1c0-a552-44a1-b7e1-feb33e628456" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseRightOfUseAssetAmortization"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LeaseCost_5db5593f-7248-4dbe-92d4-eecb677662ad" xlink:to="loc_us-gaap_FinanceLeaseRightOfUseAssetAmortization_72ddf1c0-a552-44a1-b7e1-feb33e628456" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseInterestExpense_c0b67db0-0638-4a84-8bce-48012fdf736d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseInterestExpense"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LeaseCost_5db5593f-7248-4dbe-92d4-eecb677662ad" xlink:to="loc_us-gaap_FinanceLeaseInterestExpense_c0b67db0-0638-4a84-8bce-48012fdf736d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableLeaseCost_878440d6-84fc-47ea-806a-10fd84c533c1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableLeaseCost"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LeaseCost_5db5593f-7248-4dbe-92d4-eecb677662ad" xlink:to="loc_us-gaap_VariableLeaseCost_878440d6-84fc-47ea-806a-10fd84c533c1" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/LeasesMaturityofLeaseLiabilitiesDetails" xlink:type="simple" xlink:href="evh-20211231.xsd#LeasesMaturityofLeaseLiabilitiesDetails"/>
  <link:calculationLink xlink:role="http://www.evolenthealth.com/role/LeasesMaturityofLeaseLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_f1080ed6-163f-443a-98b6-4ff856ffe422" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_af40113c-6836-46c0-8b34-8015d1107fd9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_f1080ed6-163f-443a-98b6-4ff856ffe422" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_af40113c-6836-46c0-8b34-8015d1107fd9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_d56741b7-f884-43ba-b0f2-2e238f0197c8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_f1080ed6-163f-443a-98b6-4ff856ffe422" xlink:to="loc_us-gaap_OperatingLeaseLiability_d56741b7-f884-43ba-b0f2-2e238f0197c8" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/LeasesMaturityofLeaseLiabilitiesDetails_1" xlink:type="simple" xlink:href="evh-20211231.xsd#LeasesMaturityofLeaseLiabilitiesDetails_1"/>
  <link:calculationLink xlink:role="http://www.evolenthealth.com/role/LeasesMaturityofLeaseLiabilitiesDetails_1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_d0194dda-0118-4813-b666-c12142ca553e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_9d573811-c499-47c7-9a94-47ed9d8e199c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_d0194dda-0118-4813-b666-c12142ca553e" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_9d573811-c499-47c7-9a94-47ed9d8e199c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_0d6cb911-6686-4691-8c66-ec62e2b634e7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_d0194dda-0118-4813-b666-c12142ca553e" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_0d6cb911-6686-4691-8c66-ec62e2b634e7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_c8923b0d-e8f5-41c6-873f-33acb601abcc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_d0194dda-0118-4813-b666-c12142ca553e" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_c8923b0d-e8f5-41c6-873f-33acb601abcc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_9c8ceb62-d18f-40c1-9ec8-3a96ab788894" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_d0194dda-0118-4813-b666-c12142ca553e" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_9c8ceb62-d18f-40c1-9ec8-3a96ab788894" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_959ddf77-4aa9-419c-96ee-17cdcb1dc22f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_d0194dda-0118-4813-b666-c12142ca553e" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_959ddf77-4aa9-419c-96ee-17cdcb1dc22f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_14b3bd13-55fa-4724-889d-cf4eecc8e7f4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_d0194dda-0118-4813-b666-c12142ca553e" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_14b3bd13-55fa-4724-889d-cf4eecc8e7f4" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/StockbasedCompensationUnrecognizedCompensationExpenseDetails" xlink:type="simple" xlink:href="evh-20211231.xsd#StockbasedCompensationUnrecognizedCompensationExpenseDetails"/>
  <link:calculationLink xlink:role="http://www.evolenthealth.com/role/StockbasedCompensationUnrecognizedCompensationExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_cfe40e85-41b6-4a21-b157-7040c57f7f61" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_e96a6555-a8e8-4f0f-8781-30b6b63337b2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_cfe40e85-41b6-4a21-b157-7040c57f7f61" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_e96a6555-a8e8-4f0f-8781-30b6b63337b2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_1caf9630-f067-42c8-8304-b5c57155b25e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_cfe40e85-41b6-4a21-b157-7040c57f7f61" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_1caf9630-f067-42c8-8304-b5c57155b25e" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/IncomeTaxesScheduleofLossBeforeProvisionforIncomeTaxesDetails" xlink:type="simple" xlink:href="evh-20211231.xsd#IncomeTaxesScheduleofLossBeforeProvisionforIncomeTaxesDetails"/>
  <link:calculationLink xlink:role="http://www.evolenthealth.com/role/IncomeTaxesScheduleofLossBeforeProvisionforIncomeTaxesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_7f0f4f09-fb9c-4243-90ea-6364e3c4110b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_a37ef61f-c3f8-4522-b446-6be00d35b6f6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_7f0f4f09-fb9c-4243-90ea-6364e3c4110b" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_a37ef61f-c3f8-4522-b446-6be00d35b6f6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_e897ae5b-a9ef-496e-9897-d4ec60031d39" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_7f0f4f09-fb9c-4243-90ea-6364e3c4110b" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_e897ae5b-a9ef-496e-9897-d4ec60031d39" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/IncomeTaxesIncomeTaxExpenseBenefitDetails" xlink:type="simple" xlink:href="evh-20211231.xsd#IncomeTaxesIncomeTaxExpenseBenefitDetails"/>
  <link:calculationLink xlink:role="http://www.evolenthealth.com/role/IncomeTaxesIncomeTaxExpenseBenefitDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_f7f37c08-1f21-4276-92cc-160ca613a665" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentFederalTaxExpenseBenefit_fee73d8c-e60c-4e90-b2ae-6cc1b2518417" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentFederalTaxExpenseBenefit"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_f7f37c08-1f21-4276-92cc-160ca613a665" xlink:to="loc_us-gaap_CurrentFederalTaxExpenseBenefit_fee73d8c-e60c-4e90-b2ae-6cc1b2518417" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_20bd58a6-75d4-4dad-8261-91ed488b02f7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_f7f37c08-1f21-4276-92cc-160ca613a665" xlink:to="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_20bd58a6-75d4-4dad-8261-91ed488b02f7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentForeignTaxExpenseBenefit_bcf1c3a7-11bc-428c-8e69-1d4a0afe0b9a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentForeignTaxExpenseBenefit"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_f7f37c08-1f21-4276-92cc-160ca613a665" xlink:to="loc_us-gaap_CurrentForeignTaxExpenseBenefit_bcf1c3a7-11bc-428c-8e69-1d4a0afe0b9a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_28846366-6a7c-44e9-905e-84adbf647430" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_5a9dc59c-0ff5-4ab5-b766-05be5b870363" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_28846366-6a7c-44e9-905e-84adbf647430" xlink:to="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_5a9dc59c-0ff5-4ab5-b766-05be5b870363" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_d175337f-5f4c-4642-ba95-a129a05778e4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_28846366-6a7c-44e9-905e-84adbf647430" xlink:to="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_d175337f-5f4c-4642-ba95-a129a05778e4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_d010e2df-f72d-4db6-bc14-e4e7b111e040" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredForeignIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_28846366-6a7c-44e9-905e-84adbf647430" xlink:to="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_d010e2df-f72d-4db6-bc14-e4e7b111e040" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_6791d4f8-38cc-4fdf-a704-0ba6a6bbcd43" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_d38d0076-0761-4ccf-8da7-9bb330a9b572" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_6791d4f8-38cc-4fdf-a704-0ba6a6bbcd43" xlink:to="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_d38d0076-0761-4ccf-8da7-9bb330a9b572" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_6ebe6c35-d379-42a6-a29f-2543e85e01ea" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_6791d4f8-38cc-4fdf-a704-0ba6a6bbcd43" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_6ebe6c35-d379-42a6-a29f-2543e85e01ea" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredOtherTaxExpenseBenefit_b2f4bed2-7fcd-4843-9ea5-8e48949129de" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredOtherTaxExpenseBenefit"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_6791d4f8-38cc-4fdf-a704-0ba6a6bbcd43" xlink:to="loc_us-gaap_DeferredOtherTaxExpenseBenefit_b2f4bed2-7fcd-4843-9ea5-8e48949129de" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/IncomeTaxesReconciliationofStatutoryRatetoEffectiveTaxRateDetails" xlink:type="simple" xlink:href="evh-20211231.xsd#IncomeTaxesReconciliationofStatutoryRatetoEffectiveTaxRateDetails"/>
  <link:calculationLink xlink:role="http://www.evolenthealth.com/role/IncomeTaxesReconciliationofStatutoryRatetoEffectiveTaxRateDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_a817e9aa-8769-45bf-be67-cfadb709703b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_EffectiveIncomeTaxRateReconciliationBenefitOfNetOperatingLossCarrybackProvisionPercent_a472631e-98a8-4793-9158-c3870ce76f38" xlink:href="evh-20211231.xsd#evh_EffectiveIncomeTaxRateReconciliationBenefitOfNetOperatingLossCarrybackProvisionPercent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_a817e9aa-8769-45bf-be67-cfadb709703b" xlink:to="loc_evh_EffectiveIncomeTaxRateReconciliationBenefitOfNetOperatingLossCarrybackProvisionPercent_a472631e-98a8-4793-9158-c3870ce76f38" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseExcessCompensationPercent_1c554967-4afb-47de-a39b-48e73a506647" xlink:href="evh-20211231.xsd#evh_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseExcessCompensationPercent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_a817e9aa-8769-45bf-be67-cfadb709703b" xlink:to="loc_evh_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseExcessCompensationPercent_1c554967-4afb-47de-a39b-48e73a506647" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_EffectiveIncomeTaxRateReconciliationDomesticSubsidiaryException_b13adf6f-a6bf-466e-9910-c09bbac5868c" xlink:href="evh-20211231.xsd#evh_EffectiveIncomeTaxRateReconciliationDomesticSubsidiaryException"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_a817e9aa-8769-45bf-be67-cfadb709703b" xlink:to="loc_evh_EffectiveIncomeTaxRateReconciliationDomesticSubsidiaryException_b13adf6f-a6bf-466e-9910-c09bbac5868c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses_db2068a6-1029-4e2a-b231-cd744023ea49" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_a817e9aa-8769-45bf-be67-cfadb709703b" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses_db2068a6-1029-4e2a-b231-cd744023ea49" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_61eec882-05e4-41d2-8ab3-a1295bd40831" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_a817e9aa-8769-45bf-be67-cfadb709703b" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_61eec882-05e4-41d2-8ab3-a1295bd40831" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlements_faa5bae6-adcb-4050-a6ca-7123946fda3a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlements"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_a817e9aa-8769-45bf-be67-cfadb709703b" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlements_faa5bae6-adcb-4050-a6ca-7123946fda3a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_78842055-93ba-4267-8552-2222da94b08f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_a817e9aa-8769-45bf-be67-cfadb709703b" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_78842055-93ba-4267-8552-2222da94b08f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_0fd7bd1f-dc2a-4ab7-8249-40fe86627438" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_a817e9aa-8769-45bf-be67-cfadb709703b" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_0fd7bd1f-dc2a-4ab7-8249-40fe86627438" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseReturnToProvisionPercent_72c9edbf-0ff5-480b-a145-fcdc33364777" xlink:href="evh-20211231.xsd#evh_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseReturnToProvisionPercent"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_a817e9aa-8769-45bf-be67-cfadb709703b" xlink:to="loc_evh_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseReturnToProvisionPercent_72c9edbf-0ff5-480b-a145-fcdc33364777" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent_22707c46-d49b-4908-b3cb-3479eca8e414" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent"/>
    <link:calculationArc order="10" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_a817e9aa-8769-45bf-be67-cfadb709703b" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent_22707c46-d49b-4908-b3cb-3479eca8e414" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationMinorityInterestIncomeExpense_56223ea3-f122-40e0-87e9-59cc575daf1c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationMinorityInterestIncomeExpense"/>
    <link:calculationArc order="11" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_a817e9aa-8769-45bf-be67-cfadb709703b" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationMinorityInterestIncomeExpense_56223ea3-f122-40e0-87e9-59cc575daf1c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_364cdc32-a943-4dfe-ad7e-8982c01f0fb8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential"/>
    <link:calculationArc order="12" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_a817e9aa-8769-45bf-be67-cfadb709703b" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_364cdc32-a943-4dfe-ad7e-8982c01f0fb8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_EffectiveIncomeTaxRateReconciliationChangeInUncertainTaxPositions_a67011ae-0e2e-439e-acac-c19623460ca6" xlink:href="evh-20211231.xsd#evh_EffectiveIncomeTaxRateReconciliationChangeInUncertainTaxPositions"/>
    <link:calculationArc order="13" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_a817e9aa-8769-45bf-be67-cfadb709703b" xlink:to="loc_evh_EffectiveIncomeTaxRateReconciliationChangeInUncertainTaxPositions_a67011ae-0e2e-439e-acac-c19623460ca6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_EffectiveIncomeTaxRateReconciliationEffectOfInvestment_7e6ed8b3-62d0-40dd-88ae-f14772685ab8" xlink:href="evh-20211231.xsd#evh_EffectiveIncomeTaxRateReconciliationEffectOfInvestment"/>
    <link:calculationArc order="14" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_a817e9aa-8769-45bf-be67-cfadb709703b" xlink:to="loc_evh_EffectiveIncomeTaxRateReconciliationEffectOfInvestment_7e6ed8b3-62d0-40dd-88ae-f14772685ab8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_2f807c8b-c929-42a4-89bf-45546a9dfcf8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
    <link:calculationArc order="15" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_a817e9aa-8769-45bf-be67-cfadb709703b" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_2f807c8b-c929-42a4-89bf-45546a9dfcf8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_9624cb97-5453-4ead-938a-18a24643002b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate"/>
    <link:calculationArc order="16" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_a817e9aa-8769-45bf-be67-cfadb709703b" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_9624cb97-5453-4ead-938a-18a24643002b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_5e55911d-4e24-4362-b007-c82eb786904e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments"/>
    <link:calculationArc order="17" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_a817e9aa-8769-45bf-be67-cfadb709703b" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_5e55911d-4e24-4362-b007-c82eb786904e" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails" xlink:type="simple" xlink:href="evh-20211231.xsd#IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails"/>
  <link:calculationLink xlink:role="http://www.evolenthealth.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_dc61eef8-0e76-40e2-9df7-c702b4414b88" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_bee8c927-74a5-45b4-9cf1-efc3a38f1db3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_dc61eef8-0e76-40e2-9df7-c702b4414b88" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_bee8c927-74a5-45b4-9cf1-efc3a38f1db3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_DeferredTaxAssetsOperatingLeaseRightOfUseAsset_390c6034-ba96-47c0-9fe5-f68ab18d0a7b" xlink:href="evh-20211231.xsd#evh_DeferredTaxAssetsOperatingLeaseRightOfUseAsset"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_dc61eef8-0e76-40e2-9df7-c702b4414b88" xlink:to="loc_evh_DeferredTaxAssetsOperatingLeaseRightOfUseAsset_390c6034-ba96-47c0-9fe5-f68ab18d0a7b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_fa8764a9-c261-4d77-92bb-4af9b21850ff" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_dc61eef8-0e76-40e2-9df7-c702b4414b88" xlink:to="loc_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_fa8764a9-c261-4d77-92bb-4af9b21850ff" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOther_bf01bc7c-9133-4fc2-ac09-5bd36e713213" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsOther"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_dc61eef8-0e76-40e2-9df7-c702b4414b88" xlink:to="loc_us-gaap_DeferredTaxAssetsOther_bf01bc7c-9133-4fc2-ac09-5bd36e713213" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation_d096ac10-df3c-4e42-83cf-9fd293d84352" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_dc61eef8-0e76-40e2-9df7-c702b4414b88" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation_d096ac10-df3c-4e42-83cf-9fd293d84352" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_7025d943-6359-4895-8e26-8a42600cbdbf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_dc61eef8-0e76-40e2-9df7-c702b4414b88" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_7025d943-6359-4895-8e26-8a42600cbdbf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_DeferredTaxAssetsStartupandOrganizationalCosts_1ebc56b7-6119-45a5-a45e-e8110163309a" xlink:href="evh-20211231.xsd#evh_DeferredTaxAssetsStartupandOrganizationalCosts"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_dc61eef8-0e76-40e2-9df7-c702b4414b88" xlink:to="loc_evh_DeferredTaxAssetsStartupandOrganizationalCosts_1ebc56b7-6119-45a5-a45e-e8110163309a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_d4c7e6d4-64be-4d79-b09e-6510fafd8c4f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_dc61eef8-0e76-40e2-9df7-c702b4414b88" xlink:to="loc_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_d4c7e6d4-64be-4d79-b09e-6510fafd8c4f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_8f4296bf-7462-49b3-9ea5-73533e564713" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_dc61eef8-0e76-40e2-9df7-c702b4414b88" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_8f4296bf-7462-49b3-9ea5-73533e564713" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_DeferredTaxAssetOutsideBasisDifferences_ac76354d-0ae0-4791-9aee-ad2db3175867" xlink:href="evh-20211231.xsd#evh_DeferredTaxAssetOutsideBasisDifferences"/>
    <link:calculationArc order="10" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_dc61eef8-0e76-40e2-9df7-c702b4414b88" xlink:to="loc_evh_DeferredTaxAssetOutsideBasisDifferences_ac76354d-0ae0-4791-9aee-ad2db3175867" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetInterestCarryforward_ec79c376-21c7-4aae-b5cc-4191f8b843d9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetInterestCarryforward"/>
    <link:calculationArc order="11" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_dc61eef8-0e76-40e2-9df7-c702b4414b88" xlink:to="loc_us-gaap_DeferredTaxAssetInterestCarryforward_ec79c376-21c7-4aae-b5cc-4191f8b843d9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities_67cf3fff-fbb4-4089-a5b1-f4af74b4b5ed" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedSoftware_420c5b7c-8f16-4ca7-866c-112478c2f285" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedSoftware"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities_67cf3fff-fbb4-4089-a5b1-f4af74b4b5ed" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedSoftware_420c5b7c-8f16-4ca7-866c-112478c2f285" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_4c339a0c-6922-4e39-981c-96e232f59223" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities_67cf3fff-fbb4-4089-a5b1-f4af74b4b5ed" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_4c339a0c-6922-4e39-981c-96e232f59223" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesLeasingArrangements_4fda5e00-2707-474c-9ba3-eb3a55f56370" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilitiesLeasingArrangements"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities_67cf3fff-fbb4-4089-a5b1-f4af74b4b5ed" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesLeasingArrangements_4fda5e00-2707-474c-9ba3-eb3a55f56370" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesDeferredExpense_17e7d30b-5d5e-4f59-a477-b61437ac6046" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilitiesDeferredExpense"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities_67cf3fff-fbb4-4089-a5b1-f4af74b4b5ed" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesDeferredExpense_17e7d30b-5d5e-4f59-a477-b61437ac6046" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesFinancingArrangements_c38a3bb9-26d4-4917-a69d-0bfc8e8ce713" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilitiesFinancingArrangements"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities_67cf3fff-fbb4-4089-a5b1-f4af74b4b5ed" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesFinancingArrangements_c38a3bb9-26d4-4917-a69d-0bfc8e8ce713" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesOther_45a30a9f-ebf9-40aa-83e9-98d125f7d7f1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilitiesOther"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities_67cf3fff-fbb4-4089-a5b1-f4af74b4b5ed" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesOther_45a30a9f-ebf9-40aa-83e9-98d125f7d7f1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilities_92189990-54b8-4198-8798-8b5f7c37f083" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities_bda9936f-fff1-483f-85f2-5fd5a2e0badc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxLiabilities_92189990-54b8-4198-8798-8b5f7c37f083" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilities_bda9936f-fff1-483f-85f2-5fd5a2e0badc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNet_a94d1c4d-4b5a-4cfa-8af8-c560cafec9bd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxLiabilities_92189990-54b8-4198-8798-8b5f7c37f083" xlink:to="loc_us-gaap_DeferredTaxAssetsNet_a94d1c4d-4b5a-4cfa-8af8-c560cafec9bd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNet_0ab2c058-00bd-4222-8f9f-05c80ea79149" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_74e4b8a0-ac52-495d-af46-89f1dd2f032f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsNet_0ab2c058-00bd-4222-8f9f-05c80ea79149" xlink:to="loc_us-gaap_DeferredTaxAssetsGross_74e4b8a0-ac52-495d-af46-89f1dd2f032f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_d6b282c2-f7d9-4481-9fc9-05327c0cc19d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsNet_0ab2c058-00bd-4222-8f9f-05c80ea79149" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_d6b282c2-f7d9-4481-9fc9-05327c0cc19d" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/FairValueMeasurementAssetsandLiabilitiesonRecurringBasisDetails" xlink:type="simple" xlink:href="evh-20211231.xsd#FairValueMeasurementAssetsandLiabilitiesonRecurringBasisDetails"/>
  <link:calculationLink xlink:role="http://www.evolenthealth.com/role/FairValueMeasurementAssetsandLiabilitiesonRecurringBasisDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_79773151-d32d-4d01-990a-66c297ecbcd7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_f0e35dc7-62d8-4ed2-a295-76b3072fca71" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_79773151-d32d-4d01-990a-66c297ecbcd7" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_f0e35dc7-62d8-4ed2-a295-76b3072fca71" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure_a6c971db-22f9-4099-a8fa-96e3acfeaa48" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesFairValueDisclosure_c3068c23-bb6e-4d77-8bdc-c308f44fed4b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesFairValueDisclosure"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosure_a6c971db-22f9-4099-a8fa-96e3acfeaa48" xlink:to="loc_us-gaap_OtherLiabilitiesFairValueDisclosure_c3068c23-bb6e-4d77-8bdc-c308f44fed4b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_7c063cab-e69c-438c-8b45-5d930f6bc69a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosure_a6c971db-22f9-4099-a8fa-96e3acfeaa48" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_7c063cab-e69c-438c-8b45-5d930f6bc69a" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/ReservesforClaimsandPerformanceBasedArrangementsDetails" xlink:type="simple" xlink:href="evh-20211231.xsd#ReservesforClaimsandPerformanceBasedArrangementsDetails"/>
  <link:calculationLink xlink:role="http://www.evolenthealth.com/role/ReservesforClaimsandPerformanceBasedArrangementsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpensePeriodIncreaseDecrease_f725e6be-75cd-41cf-aa38-25d481866f7e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpensePeriodIncreaseDecrease"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense_75ee859d-bf68-4a7c-bd9f-b54b6e79d49b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpensePeriodIncreaseDecrease_f725e6be-75cd-41cf-aa38-25d481866f7e" xlink:to="loc_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense_75ee859d-bf68-4a7c-bd9f-b54b6e79d49b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1_11e4cec5-dd8f-44ad-9f0f-80201ded49f3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpensePeriodIncreaseDecrease_f725e6be-75cd-41cf-aa38-25d481866f7e" xlink:to="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1_11e4cec5-dd8f-44ad-9f0f-80201ded49f3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1_b18a5c6c-af5b-4fbe-a0b2-c248af599255" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpensePeriodIncreaseDecrease_f725e6be-75cd-41cf-aa38-25d481866f7e" xlink:to="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1_b18a5c6c-af5b-4fbe-a0b2-c248af599255" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_CurrentYearClaimsAndClaimsAdjustmentExpenseIncludingCostOfGoodsAndServicesSoldExcludingDepreciationAndAmortization_802faae7-0088-473f-81b4-9f766a705a4f" xlink:href="evh-20211231.xsd#evh_CurrentYearClaimsAndClaimsAdjustmentExpenseIncludingCostOfGoodsAndServicesSoldExcludingDepreciationAndAmortization"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpensePeriodIncreaseDecrease_f725e6be-75cd-41cf-aa38-25d481866f7e" xlink:to="loc_evh_CurrentYearClaimsAndClaimsAdjustmentExpenseIncludingCostOfGoodsAndServicesSoldExcludingDepreciationAndAmortization_802faae7-0088-473f-81b4-9f766a705a4f" xlink:type="arc"/>
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>12
<FILENAME>evh-20211231_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:cffd2bd6-4cc3-4881-a14e-c3c94aea5d0e,g:f4f494d2-75b7-48aa-a2de-31bddada82ae-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS" xlink:type="simple" xlink:href="evh-20211231.xsd#CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS"/>
  <link:definitionLink xlink:role="http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS" xlink:type="extended" id="iea732a0f3b8745bbaa2701f7220090f5_CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_39a33f36-5dbf-4642-860e-c0888373f64b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract_1118e28c-3980-4ed3-a004-9a42623da2a4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenuesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_39a33f36-5dbf-4642-860e-c0888373f64b" xlink:to="loc_us-gaap_RevenuesAbstract_1118e28c-3980-4ed3-a004-9a42623da2a4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_1ec3fa81-edb7-47d0-9a6f-c08dc7ae6bb9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Revenues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenuesAbstract_1118e28c-3980-4ed3-a004-9a42623da2a4" xlink:to="loc_us-gaap_Revenues_1ec3fa81-edb7-47d0-9a6f-c08dc7ae6bb9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract_ac3786fd-8728-4aa8-adaa-16e86d4e9b08" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_39a33f36-5dbf-4642-860e-c0888373f64b" xlink:to="loc_us-gaap_OperatingExpensesAbstract_ac3786fd-8728-4aa8-adaa-16e86d4e9b08" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_CostofGoodsandServicesSoldExcludingDepreciationandAmortization_4f5159f8-6c76-4cd5-8391-f523334ca7ca" xlink:href="evh-20211231.xsd#evh_CostofGoodsandServicesSoldExcludingDepreciationandAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_ac3786fd-8728-4aa8-adaa-16e86d4e9b08" xlink:to="loc_evh_CostofGoodsandServicesSoldExcludingDepreciationandAmortization_4f5159f8-6c76-4cd5-8391-f523334ca7ca" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_8612d2fb-9882-40c3-91df-ac4ac4644de0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_ac3786fd-8728-4aa8-adaa-16e86d4e9b08" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_8612d2fb-9882-40c3-91df-ac4ac4644de0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationAndAmortization_aa80aca2-9582-476d-ae46-36cf0442409a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationAndAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_ac3786fd-8728-4aa8-adaa-16e86d4e9b08" xlink:to="loc_us-gaap_DepreciationAndAmortization_aa80aca2-9582-476d-ae46-36cf0442409a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnDispositionOfAssets1_4b5ff09f-7de7-4320-bcb4-413b7b5444ef" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossOnDispositionOfAssets1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_ac3786fd-8728-4aa8-adaa-16e86d4e9b08" xlink:to="loc_us-gaap_GainLossOnDispositionOfAssets1_4b5ff09f-7de7-4320-bcb4-413b7b5444ef" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_19663706-3fb1-42da-a37e-36969bcc27d3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_ac3786fd-8728-4aa8-adaa-16e86d4e9b08" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_19663706-3fb1-42da-a37e-36969bcc27d3" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairmentLoss_e14def02-181b-47bb-81f6-d7ee4e3b9341" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_ac3786fd-8728-4aa8-adaa-16e86d4e9b08" xlink:to="loc_us-gaap_GoodwillImpairmentLoss_e14def02-181b-47bb-81f6-d7ee4e3b9341" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_8b39195e-4ee2-40c3-b581-9e683933eb2d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_ac3786fd-8728-4aa8-adaa-16e86d4e9b08" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_8b39195e-4ee2-40c3-b581-9e683933eb2d" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_d3e50e0b-0bd5-4b5d-bfd5-46e87cf19586" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpenses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_ac3786fd-8728-4aa8-adaa-16e86d4e9b08" xlink:to="loc_us-gaap_OperatingExpenses_d3e50e0b-0bd5-4b5d-bfd5-46e87cf19586" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_45e255b0-fede-4734-a6b1-a366d01c87e1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_39a33f36-5dbf-4642-860e-c0888373f64b" xlink:to="loc_us-gaap_OperatingIncomeLoss_45e255b0-fede-4734-a6b1-a366d01c87e1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest_b996e1a2-9af6-4941-9c8e-36355e9ecb1f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_39a33f36-5dbf-4642-860e-c0888373f64b" xlink:to="loc_us-gaap_InvestmentIncomeInterest_b996e1a2-9af6-4941-9c8e-36355e9ecb1f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_5aae3e0b-ae5a-49e8-87c4-b98cc17a552a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_39a33f36-5dbf-4642-860e-c0888373f64b" xlink:to="loc_us-gaap_InterestExpense_5aae3e0b-ae5a-49e8-87c4-b98cc17a552a" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentOtherThanTemporaryImpairment_c4ffac51-a0d3-4d2c-b3ee-387f1f2af330" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestmentOtherThanTemporaryImpairment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_39a33f36-5dbf-4642-860e-c0888373f64b" xlink:to="loc_us-gaap_EquityMethodInvestmentOtherThanTemporaryImpairment_c4ffac51-a0d3-4d2c-b3ee-387f1f2af330" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_13d7ec01-5e52-4510-bd3f-0c49a9ce78f1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_39a33f36-5dbf-4642-860e-c0888373f64b" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_13d7ec01-5e52-4510-bd3f-0c49a9ce78f1" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_GainOnTransferOfMembership_7b6095a9-6a48-4652-af29-f4d22a2bb5d6" xlink:href="evh-20211231.xsd#evh_GainOnTransferOfMembership"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_39a33f36-5dbf-4642-860e-c0888373f64b" xlink:to="loc_evh_GainOnTransferOfMembership_7b6095a9-6a48-4652-af29-f4d22a2bb5d6" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_GainLossOnRepaymentOfDebt_f45fe2f2-4cf0-4be4-a062-361e16ebbe58" xlink:href="evh-20211231.xsd#evh_GainLossOnRepaymentOfDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_39a33f36-5dbf-4642-860e-c0888373f64b" xlink:to="loc_evh_GainLossOnRepaymentOfDebt_f45fe2f2-4cf0-4be4-a062-361e16ebbe58" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherOperatingIncomeExpenseNet_32569cb2-9eff-4e90-b4df-7c31ca0b1dc7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherOperatingIncomeExpenseNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_39a33f36-5dbf-4642-860e-c0888373f64b" xlink:to="loc_us-gaap_OtherOperatingIncomeExpenseNet_32569cb2-9eff-4e90-b4df-7c31ca0b1dc7" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_8ea5e8d4-17a0-4813-896a-3e6d62067f3d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_39a33f36-5dbf-4642-860e-c0888373f64b" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_8ea5e8d4-17a0-4813-896a-3e6d62067f3d" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_e18cb947-7b5a-4501-acfd-d45538ae04c8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_39a33f36-5dbf-4642-860e-c0888373f64b" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_e18cb947-7b5a-4501-acfd-d45538ae04c8" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_dbfa4fcf-62ae-4899-8c57-0cf137aaf165" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_39a33f36-5dbf-4642-860e-c0888373f64b" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_dbfa4fcf-62ae-4899-8c57-0cf137aaf165" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_a156f0a1-163b-4243-8de9-319f7ca5beea" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_39a33f36-5dbf-4642-860e-c0888373f64b" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_a156f0a1-163b-4243-8de9-319f7ca5beea" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_2d4be225-eb40-4422-ad71-fe4e51f8cdf6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_39a33f36-5dbf-4642-860e-c0888373f64b" xlink:to="loc_us-gaap_ProfitLoss_2d4be225-eb40-4422-ad71-fe4e51f8cdf6" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_0c2bd874-e320-4d7c-9520-240b3ed15f0d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_39a33f36-5dbf-4642-860e-c0888373f64b" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_0c2bd874-e320-4d7c-9520-240b3ed15f0d" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_3cf8d067-f7be-4a07-808c-f492edae95d4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_39a33f36-5dbf-4642-860e-c0888373f64b" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_3cf8d067-f7be-4a07-808c-f492edae95d4" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_21fbc802-57a4-40f9-85f6-ae3d8a04c99f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_39a33f36-5dbf-4642-860e-c0888373f64b" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_21fbc802-57a4-40f9-85f6-ae3d8a04c99f" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract_fb8a2085-68f6-4f88-871d-5962e354c387" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasicAndDilutedAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_39a33f36-5dbf-4642-860e-c0888373f64b" xlink:to="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract_fb8a2085-68f6-4f88-871d-5962e354c387" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_971de8a2-4b41-4949-8ddc-e2bd942d8610" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsPerBasicShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract_fb8a2085-68f6-4f88-871d-5962e354c387" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_971de8a2-4b41-4949-8ddc-e2bd942d8610" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_0038e51a-f67d-485c-8076-fc72f8eeb05a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract_fb8a2085-68f6-4f88-871d-5962e354c387" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_0038e51a-f67d-485c-8076-fc72f8eeb05a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare_c7404edb-1771-42f4-98b2-f342b131cbbd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract_fb8a2085-68f6-4f88-871d-5962e354c387" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare_c7404edb-1771-42f4-98b2-f342b131cbbd" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare_16d3fe5a-ff91-451a-868f-56e8796cb137" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract_fb8a2085-68f6-4f88-871d-5962e354c387" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare_16d3fe5a-ff91-451a-868f-56e8796cb137" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_EarningsPerSharePortionAttributableToNoncontrollingInterestBasic_c659d2e0-d2bb-406f-b29b-b23e8727a087" xlink:href="evh-20211231.xsd#evh_EarningsPerSharePortionAttributableToNoncontrollingInterestBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract_fb8a2085-68f6-4f88-871d-5962e354c387" xlink:to="loc_evh_EarningsPerSharePortionAttributableToNoncontrollingInterestBasic_c659d2e0-d2bb-406f-b29b-b23e8727a087" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_EarningsPerSharePortionAttributableToNoncontrollingInterestDiluted_35a38303-d7d0-4f88-8356-e6355e442f01" xlink:href="evh-20211231.xsd#evh_EarningsPerSharePortionAttributableToNoncontrollingInterestDiluted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract_fb8a2085-68f6-4f88-871d-5962e354c387" xlink:to="loc_evh_EarningsPerSharePortionAttributableToNoncontrollingInterestDiluted_35a38303-d7d0-4f88-8356-e6355e442f01" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_3d0edb9d-ecfa-4b09-b8e8-0a2945e6d334" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract_fb8a2085-68f6-4f88-871d-5962e354c387" xlink:to="loc_us-gaap_EarningsPerShareBasic_3d0edb9d-ecfa-4b09-b8e8-0a2945e6d334" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_85f692f7-03bf-46e5-9632-2264aab7dca0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract_fb8a2085-68f6-4f88-871d-5962e354c387" xlink:to="loc_us-gaap_EarningsPerShareDiluted_85f692f7-03bf-46e5-9632-2264aab7dca0" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract_1da34deb-9fbb-4279-af00-b59610581040" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_39a33f36-5dbf-4642-860e-c0888373f64b" xlink:to="loc_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract_1da34deb-9fbb-4279-af00-b59610581040" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_19e46e4f-ad05-4aa9-bf7f-bf90c41a5723" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract_1da34deb-9fbb-4279-af00-b59610581040" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_19e46e4f-ad05-4aa9-bf7f-bf90c41a5723" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_7bf02108-b8a6-4262-a96c-2da3fa8070ea" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract_1da34deb-9fbb-4279-af00-b59610581040" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_7bf02108-b8a6-4262-a96c-2da3fa8070ea" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterestAbstract_9e39676b-13af-47d9-82dc-9d97c5817178" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterestAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_39a33f36-5dbf-4642-860e-c0888373f64b" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterestAbstract_9e39676b-13af-47d9-82dc-9d97c5817178" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_12f1dd9d-d335-424a-940a-e9c57ab617bb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_6f2dc2fc-c84c-42a5-93bc-bff1807a79cf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterestAbstract_9e39676b-13af-47d9-82dc-9d97c5817178" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_6f2dc2fc-c84c-42a5-93bc-bff1807a79cf" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_db4c9bbd-ba90-41c6-98bd-119c4c40c8d9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_6f2dc2fc-c84c-42a5-93bc-bff1807a79cf" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_db4c9bbd-ba90-41c6-98bd-119c4c40c8d9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_38ecca8f-063d-4cea-aa06-e93d21ab8089" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterestAbstract_9e39676b-13af-47d9-82dc-9d97c5817178" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_38ecca8f-063d-4cea-aa06-e93d21ab8089" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_65e44782-75e0-4563-9cbd-a728f2bf2250" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterestAbstract_9e39676b-13af-47d9-82dc-9d97c5817178" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_65e44782-75e0-4563-9cbd-a728f2bf2250" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_6b6ebf0b-8bcc-470f-995e-a6cb3c943b31" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterestAbstract_9e39676b-13af-47d9-82dc-9d97c5817178" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_6b6ebf0b-8bcc-470f-995e-a6cb3c943b31" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_06ede67d-c485-4b71-9fb3-fba3e2ad632b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_39a33f36-5dbf-4642-860e-c0888373f64b" xlink:to="loc_us-gaap_StatementTable_06ede67d-c485-4b71-9fb3-fba3e2ad632b" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_97915bca-a61f-41c4-a0e3-52af750edd3a" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_06ede67d-c485-4b71-9fb3-fba3e2ad632b" xlink:to="loc_srt_ProductOrServiceAxis_97915bca-a61f-41c4-a0e3-52af750edd3a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_97915bca-a61f-41c4-a0e3-52af750edd3a_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_97915bca-a61f-41c4-a0e3-52af750edd3a" xlink:to="loc_srt_ProductsAndServicesDomain_97915bca-a61f-41c4-a0e3-52af750edd3a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_85d9c911-b6b5-4c62-aa08-61889f8b3dac" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_97915bca-a61f-41c4-a0e3-52af750edd3a" xlink:to="loc_srt_ProductsAndServicesDomain_85d9c911-b6b5-4c62-aa08-61889f8b3dac" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_TransformationServicesMember_83e463bf-71d3-4bed-b1f5-8f103218373e" xlink:href="evh-20211231.xsd#evh_TransformationServicesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_85d9c911-b6b5-4c62-aa08-61889f8b3dac" xlink:to="loc_evh_TransformationServicesMember_83e463bf-71d3-4bed-b1f5-8f103218373e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_PlatformsAndOperationsServicesMember_8c589b9a-2327-4ee7-bfd4-240b6e1ba1be" xlink:href="evh-20211231.xsd#evh_PlatformsAndOperationsServicesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_85d9c911-b6b5-4c62-aa08-61889f8b3dac" xlink:to="loc_evh_PlatformsAndOperationsServicesMember_8c589b9a-2327-4ee7-bfd4-240b6e1ba1be" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY" xlink:type="simple" xlink:href="evh-20211231.xsd#CONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY"/>
  <link:definitionLink xlink:role="http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY" xlink:type="extended" id="idcc79fff172a47d0980f121953d6252e_CONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_0852afbd-9550-4e03-ae6d-ae087533e466" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_56fc9db8-02fa-41c4-aff8-52fa8f4eccb6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0852afbd-9550-4e03-ae6d-ae087533e466" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_56fc9db8-02fa-41c4-aff8-52fa8f4eccb6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesIssued_6ae67422-798c-4a62-8854-26137ed3bf95" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_56fc9db8-02fa-41c4-aff8-52fa8f4eccb6" xlink:to="loc_us-gaap_SharesIssued_6ae67422-798c-4a62-8854-26137ed3bf95" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_a45e8cdf-1caf-48d4-96a0-d9120916fd07" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_56fc9db8-02fa-41c4-aff8-52fa8f4eccb6" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_a45e8cdf-1caf-48d4-96a0-d9120916fd07" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingStandardsUpdateExtensibleList_1dd0c038-c6b5-41eb-932f-f5267d92755d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingStandardsUpdateExtensibleList"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_56fc9db8-02fa-41c4-aff8-52fa8f4eccb6" xlink:to="loc_us-gaap_AccountingStandardsUpdateExtensibleList_1dd0c038-c6b5-41eb-932f-f5267d92755d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_53b341bb-20ce-4b04-aa05-78a2dd7b4f41" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_56fc9db8-02fa-41c4-aff8-52fa8f4eccb6" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_53b341bb-20ce-4b04-aa05-78a2dd7b4f41" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_056b725e-8bc5-4c18-bfc3-977679e4fead" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_56fc9db8-02fa-41c4-aff8-52fa8f4eccb6" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_056b725e-8bc5-4c18-bfc3-977679e4fead" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_9c778ed3-c440-4486-b262-a41250af0dbc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_56fc9db8-02fa-41c4-aff8-52fa8f4eccb6" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_9c778ed3-c440-4486-b262-a41250af0dbc" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_9e55ce3a-10ef-4a41-a3c4-386e080bc6ce" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_56fc9db8-02fa-41c4-aff8-52fa8f4eccb6" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_9e55ce3a-10ef-4a41-a3c4-386e080bc6ce" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_8454929e-770c-4a39-83fd-847392f3c423" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_56fc9db8-02fa-41c4-aff8-52fa8f4eccb6" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_8454929e-770c-4a39-83fd-847392f3c423" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_95912049-5b9d-4741-b567-52a7feaefc72" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_56fc9db8-02fa-41c4-aff8-52fa8f4eccb6" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_95912049-5b9d-4741-b567-52a7feaefc72" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueAcquisitions_a0290805-4883-457d-b994-c5f6321e6f64" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueAcquisitions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_56fc9db8-02fa-41c4-aff8-52fa8f4eccb6" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueAcquisitions_a0290805-4883-457d-b994-c5f6321e6f64" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockRetiredCostMethodAmount_083424fb-93ab-46fe-b78a-3fded29bc4ce" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockRetiredCostMethodAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_56fc9db8-02fa-41c4-aff8-52fa8f4eccb6" xlink:to="loc_us-gaap_TreasuryStockRetiredCostMethodAmount_083424fb-93ab-46fe-b78a-3fded29bc4ce" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_StockVestedAndRetiredDuringPeriodShares_b187d9fb-871d-4ff6-a6ae-d8286f401819" xlink:href="evh-20211231.xsd#evh_StockVestedAndRetiredDuringPeriodShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_56fc9db8-02fa-41c4-aff8-52fa8f4eccb6" xlink:to="loc_evh_StockVestedAndRetiredDuringPeriodShares_b187d9fb-871d-4ff6-a6ae-d8286f401819" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_StockVestedAndRetiredDuringPeriodValue_62c2c088-9d85-40c2-9d12-b926d1157331" xlink:href="evh-20211231.xsd#evh_StockVestedAndRetiredDuringPeriodValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_56fc9db8-02fa-41c4-aff8-52fa8f4eccb6" xlink:to="loc_evh_StockVestedAndRetiredDuringPeriodValue_62c2c088-9d85-40c2-9d12-b926d1157331" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_StockIssuedDuringPeriodSharesEarnOuts_7e5ee42b-b30c-450b-857b-c21209885137" xlink:href="evh-20211231.xsd#evh_StockIssuedDuringPeriodSharesEarnOuts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_56fc9db8-02fa-41c4-aff8-52fa8f4eccb6" xlink:to="loc_evh_StockIssuedDuringPeriodSharesEarnOuts_7e5ee42b-b30c-450b-857b-c21209885137" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_StockIssuedDuringPeriodValueEarnOuts_57410c8d-27f1-4aaa-8e99-305e1df01690" xlink:href="evh-20211231.xsd#evh_StockIssuedDuringPeriodValueEarnOuts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_56fc9db8-02fa-41c4-aff8-52fa8f4eccb6" xlink:to="loc_evh_StockIssuedDuringPeriodValueEarnOuts_57410c8d-27f1-4aaa-8e99-305e1df01690" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_AdjustmentsToAdditionalPaidInCapitalAcquisitions_657365e4-28a1-49df-89dc-de55448097ce" xlink:href="evh-20211231.xsd#evh_AdjustmentsToAdditionalPaidInCapitalAcquisitions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_56fc9db8-02fa-41c4-aff8-52fa8f4eccb6" xlink:to="loc_evh_AdjustmentsToAdditionalPaidInCapitalAcquisitions_657365e4-28a1-49df-89dc-de55448097ce" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_StockIssuedDuringPeriodSharesEquityMethodInvestmentsAndAssetAcquisitions_6ccdbd73-45fb-4ab8-ab15-f5f852aab61a" xlink:href="evh-20211231.xsd#evh_StockIssuedDuringPeriodSharesEquityMethodInvestmentsAndAssetAcquisitions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_56fc9db8-02fa-41c4-aff8-52fa8f4eccb6" xlink:to="loc_evh_StockIssuedDuringPeriodSharesEquityMethodInvestmentsAndAssetAcquisitions_6ccdbd73-45fb-4ab8-ab15-f5f852aab61a" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_StockIssuedDuringPeriodValueEquityMethodInvestmentsAndAssetAcquisitions_d8a20c6d-9051-4b8a-b17b-0b4b405c208c" xlink:href="evh-20211231.xsd#evh_StockIssuedDuringPeriodValueEquityMethodInvestmentsAndAssetAcquisitions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_56fc9db8-02fa-41c4-aff8-52fa8f4eccb6" xlink:to="loc_evh_StockIssuedDuringPeriodValueEquityMethodInvestmentsAndAssetAcquisitions_d8a20c6d-9051-4b8a-b17b-0b4b405c208c" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_08134d2f-90eb-4a3b-bc60-0d568d6a41de" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_56fc9db8-02fa-41c4-aff8-52fa8f4eccb6" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_08134d2f-90eb-4a3b-bc60-0d568d6a41de" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_dce07df8-d7bf-4cca-a69e-2573dd0a547b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_56fc9db8-02fa-41c4-aff8-52fa8f4eccb6" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_dce07df8-d7bf-4cca-a69e-2573dd0a547b" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_StockIssuedDuringPeriodSharesConversionofConvertibleSecuritiesTaxImpact_9d640dac-7f4a-4116-b96b-c6d6a2f3d764" xlink:href="evh-20211231.xsd#evh_StockIssuedDuringPeriodSharesConversionofConvertibleSecuritiesTaxImpact"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_56fc9db8-02fa-41c4-aff8-52fa8f4eccb6" xlink:to="loc_evh_StockIssuedDuringPeriodSharesConversionofConvertibleSecuritiesTaxImpact_9d640dac-7f4a-4116-b96b-c6d6a2f3d764" xlink:type="arc" order="21"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance_fbf261af-1392-4c24-af11-33b956c620c3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_56fc9db8-02fa-41c4-aff8-52fa8f4eccb6" xlink:to="loc_us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance_fbf261af-1392-4c24-af11-33b956c620c3" xlink:type="arc" order="22"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt_d293ebb1-6004-49c8-b482-e290da4d44f7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_56fc9db8-02fa-41c4-aff8-52fa8f4eccb6" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt_d293ebb1-6004-49c8-b482-e290da4d44f7" xlink:type="arc" order="23"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestDecreaseFromDeconsolidation_0438e7a4-0d39-4a5b-94a5-c4574f571366" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NoncontrollingInterestDecreaseFromDeconsolidation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_56fc9db8-02fa-41c4-aff8-52fa8f4eccb6" xlink:to="loc_us-gaap_NoncontrollingInterestDecreaseFromDeconsolidation_0438e7a4-0d39-4a5b-94a5-c4574f571366" xlink:type="arc" order="24"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_22fd5971-5683-45c6-8e57-36618925c931" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_56fc9db8-02fa-41c4-aff8-52fa8f4eccb6" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_22fd5971-5683-45c6-8e57-36618925c931" xlink:type="arc" order="25"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_1d9f6298-eb93-434a-9134-7a4a6c6f6fe7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_56fc9db8-02fa-41c4-aff8-52fa8f4eccb6" xlink:to="loc_us-gaap_ProfitLoss_1d9f6298-eb93-434a-9134-7a4a6c6f6fe7" xlink:type="arc" order="26"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesIssued_6696ba32-1b03-46d7-a39b-1bf893d444ae" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesIssued"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_519fda6d-5595-452d-a6af-0cf40161bdcd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_a511707b-6988-446e-84c2-eb921ca7596d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_0852afbd-9550-4e03-ae6d-ae087533e466" xlink:to="loc_us-gaap_StatementTable_a511707b-6988-446e-84c2-eb921ca7596d" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_bc54b869-25df-4ea9-abe1-8343e0527115" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_a511707b-6988-446e-84c2-eb921ca7596d" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_bc54b869-25df-4ea9-abe1-8343e0527115" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_bc54b869-25df-4ea9-abe1-8343e0527115_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_bc54b869-25df-4ea9-abe1-8343e0527115" xlink:to="loc_us-gaap_EquityComponentDomain_bc54b869-25df-4ea9-abe1-8343e0527115_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_aca44917-eeb3-4635-8242-bfc2d4756861" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_bc54b869-25df-4ea9-abe1-8343e0527115" xlink:to="loc_us-gaap_EquityComponentDomain_aca44917-eeb3-4635-8242-bfc2d4756861" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ParentMember_14150b1a-bff9-42bc-9887-1f7d871bdec3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ParentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_aca44917-eeb3-4635-8242-bfc2d4756861" xlink:to="loc_us-gaap_ParentMember_14150b1a-bff9-42bc-9887-1f7d871bdec3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_310e6840-3bf7-4826-82cc-99c1390db0c2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ParentMember_14150b1a-bff9-42bc-9887-1f7d871bdec3" xlink:to="loc_us-gaap_CommonStockMember_310e6840-3bf7-4826-82cc-99c1390db0c2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_e8c50949-975d-48e8-a468-f3986260da35" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ParentMember_14150b1a-bff9-42bc-9887-1f7d871bdec3" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_e8c50949-975d-48e8-a468-f3986260da35" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember_c21e15c4-fa0a-4e01-9275-4d203eb7f194" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ParentMember_14150b1a-bff9-42bc-9887-1f7d871bdec3" xlink:to="loc_us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember_c21e15c4-fa0a-4e01-9275-4d203eb7f194" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_66a173ba-20eb-4d35-82c9-dc47fbebb4c2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ParentMember_14150b1a-bff9-42bc-9887-1f7d871bdec3" xlink:to="loc_us-gaap_RetainedEarningsMember_66a173ba-20eb-4d35-82c9-dc47fbebb4c2" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockMember_b9513bfc-948f-41de-a8a9-7acd4ea21867" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ParentMember_14150b1a-bff9-42bc-9887-1f7d871bdec3" xlink:to="loc_us-gaap_TreasuryStockMember_b9513bfc-948f-41de-a8a9-7acd4ea21867" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestMember_34492ce9-78a6-4ba0-8880-bc8d5620eef7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NoncontrollingInterestMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_aca44917-eeb3-4635-8242-bfc2d4756861" xlink:to="loc_us-gaap_NoncontrollingInterestMember_34492ce9-78a6-4ba0-8880-bc8d5620eef7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_6953f4e9-44e3-45ea-9f72-1ef0e35eb568" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_a511707b-6988-446e-84c2-eb921ca7596d" xlink:to="loc_us-gaap_StatementClassOfStockAxis_6953f4e9-44e3-45ea-9f72-1ef0e35eb568" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_6953f4e9-44e3-45ea-9f72-1ef0e35eb568_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_6953f4e9-44e3-45ea-9f72-1ef0e35eb568" xlink:to="loc_us-gaap_ClassOfStockDomain_6953f4e9-44e3-45ea-9f72-1ef0e35eb568_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_e1ecc540-d5a4-4ba5-a8af-b5334d125d55" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_6953f4e9-44e3-45ea-9f72-1ef0e35eb568" xlink:to="loc_us-gaap_ClassOfStockDomain_e1ecc540-d5a4-4ba5-a8af-b5334d125d55" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassAMember_a50579a8-c40a-4752-9f46-b3d857dcab5c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonClassAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_e1ecc540-d5a4-4ba5-a8af-b5334d125d55" xlink:to="loc_us-gaap_CommonClassAMember_a50579a8-c40a-4752-9f46-b3d857dcab5c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassBMember_6a1981b3-0d59-43fb-80fb-42679a0361dc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonClassBMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_e1ecc540-d5a4-4ba5-a8af-b5334d125d55" xlink:to="loc_us-gaap_CommonClassBMember_6a1981b3-0d59-43fb-80fb-42679a0361dc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_7aec5323-5304-4806-bf2e-42a122c9bed6" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_a511707b-6988-446e-84c2-eb921ca7596d" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_7aec5323-5304-4806-bf2e-42a122c9bed6" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_7aec5323-5304-4806-bf2e-42a122c9bed6_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_7aec5323-5304-4806-bf2e-42a122c9bed6" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_7aec5323-5304-4806-bf2e-42a122c9bed6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_c5fa886a-a042-4005-8276-1283c849bc00" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_7aec5323-5304-4806-bf2e-42a122c9bed6" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_c5fa886a-a042-4005-8276-1283c849bc00" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_54c2a728-2c99-43f4-8560-712f2d400416" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_c5fa886a-a042-4005-8276-1283c849bc00" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_54c2a728-2c99-43f4-8560-712f2d400416" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/OrganizationDetails" xlink:type="simple" xlink:href="evh-20211231.xsd#OrganizationDetails"/>
  <link:definitionLink xlink:role="http://www.evolenthealth.com/role/OrganizationDetails" xlink:type="extended" id="ibe9d6c37fdd14bf78173439d55ae3c3a_OrganizationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_9fe19234-187f-42a4-aff4-9947ac6a2e64" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_739e69f2-72d1-4192-86e5-720cf7561d4c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_9fe19234-187f-42a4-aff4-9947ac6a2e64" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_739e69f2-72d1-4192-86e5-720cf7561d4c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_844e2e72-1cfc-4f62-946a-b0a2b08bc516" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfStockLineItems_9fe19234-187f-42a4-aff4-9947ac6a2e64" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_844e2e72-1cfc-4f62-946a-b0a2b08bc516" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_1fffd439-669b-4893-8ff6-8a0f378eda56" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_844e2e72-1cfc-4f62-946a-b0a2b08bc516" xlink:to="loc_us-gaap_StatementClassOfStockAxis_1fffd439-669b-4893-8ff6-8a0f378eda56" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_1fffd439-669b-4893-8ff6-8a0f378eda56_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_1fffd439-669b-4893-8ff6-8a0f378eda56" xlink:to="loc_us-gaap_ClassOfStockDomain_1fffd439-669b-4893-8ff6-8a0f378eda56_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_b2722b5a-9839-4ee7-ac7e-af4dffd2046b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_1fffd439-669b-4893-8ff6-8a0f378eda56" xlink:to="loc_us-gaap_ClassOfStockDomain_b2722b5a-9839-4ee7-ac7e-af4dffd2046b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassBMember_1ccb6e22-b254-4dbb-8476-b87c330ee117" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonClassBMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_b2722b5a-9839-4ee7-ac7e-af4dffd2046b" xlink:to="loc_us-gaap_CommonClassBMember_1ccb6e22-b254-4dbb-8476-b87c330ee117" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesRestrictedCashandRestrictedInvestmentsDetails" xlink:type="simple" xlink:href="evh-20211231.xsd#BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesRestrictedCashandRestrictedInvestmentsDetails"/>
  <link:definitionLink xlink:role="http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesRestrictedCashandRestrictedInvestmentsDetails" xlink:type="extended" id="iff1f8b9fa3184650afbc3f321ee88450_BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesRestrictedCashandRestrictedInvestmentsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems_379067c7-b09d-48e1-89ed-7bb3b2bae73e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalents_6a6ff897-5c0a-4ff5-a26d-72c6e51d1fa2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalents"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems_379067c7-b09d-48e1-89ed-7bb3b2bae73e" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalents_6a6ff897-5c0a-4ff5-a26d-72c6e51d1fa2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_65f88371-4654-4113-9400-2f7c40ab018e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems_379067c7-b09d-48e1-89ed-7bb3b2bae73e" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_65f88371-4654-4113-9400-2f7c40ab018e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndInvestmentsCurrent_b69be51d-42d5-429e-90ad-c3275b1b6e43" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndInvestmentsCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems_379067c7-b09d-48e1-89ed-7bb3b2bae73e" xlink:to="loc_us-gaap_RestrictedCashAndInvestmentsCurrent_b69be51d-42d5-429e-90ad-c3275b1b6e43" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_e0dcc341-9e52-438d-bb02-a30b9eb5b71c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems_379067c7-b09d-48e1-89ed-7bb3b2bae73e" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_e0dcc341-9e52-438d-bb02-a30b9eb5b71c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndInvestmentsNoncurrent_c16b3778-f6ec-438a-b984-a559ba99f45f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndInvestmentsNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems_379067c7-b09d-48e1-89ed-7bb3b2bae73e" xlink:to="loc_us-gaap_RestrictedCashAndInvestmentsNoncurrent_c16b3778-f6ec-438a-b984-a559ba99f45f" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_DisposalGroupIncludingDiscontinuedOperationRestrictedInvestmentsNoncurrent_6ec12f4b-51da-49b4-a253-6a9d080d09e1" xlink:href="evh-20211231.xsd#evh_DisposalGroupIncludingDiscontinuedOperationRestrictedInvestmentsNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems_379067c7-b09d-48e1-89ed-7bb3b2bae73e" xlink:to="loc_evh_DisposalGroupIncludingDiscontinuedOperationRestrictedInvestmentsNoncurrent_6ec12f4b-51da-49b4-a253-6a9d080d09e1" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_DisposalGroupIncludingDiscontinuedOperationRestrictedCashCurrent_fea3b2c9-01eb-4cb0-b353-a9f3e2dc066a" xlink:href="evh-20211231.xsd#evh_DisposalGroupIncludingDiscontinuedOperationRestrictedCashCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems_379067c7-b09d-48e1-89ed-7bb3b2bae73e" xlink:to="loc_evh_DisposalGroupIncludingDiscontinuedOperationRestrictedCashCurrent_fea3b2c9-01eb-4cb0-b353-a9f3e2dc066a" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_CashAndCashEquivalentsAtCarryingValueExcludingDiscontinuedOperations_26da4eb0-2b4a-4722-b8d8-61ebd443c603" xlink:href="evh-20211231.xsd#evh_CashAndCashEquivalentsAtCarryingValueExcludingDiscontinuedOperations"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems_379067c7-b09d-48e1-89ed-7bb3b2bae73e" xlink:to="loc_evh_CashAndCashEquivalentsAtCarryingValueExcludingDiscontinuedOperations_26da4eb0-2b4a-4722-b8d8-61ebd443c603" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndInvestments_077f8753-7989-4af2-8a88-7d4b31a09c41" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems_379067c7-b09d-48e1-89ed-7bb3b2bae73e" xlink:to="loc_us-gaap_RestrictedCashAndInvestments_077f8753-7989-4af2-8a88-7d4b31a09c41" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedInvestments_25801ac1-a5c1-4322-881b-611b825768a5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems_379067c7-b09d-48e1-89ed-7bb3b2bae73e" xlink:to="loc_us-gaap_RestrictedInvestments_25801ac1-a5c1-4322-881b-611b825768a5" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_b04aba55-db28-4adf-bf2d-2421663e432b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems_379067c7-b09d-48e1-89ed-7bb3b2bae73e" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_b04aba55-db28-4adf-bf2d-2421663e432b" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable_67897a2c-65e2-497d-92d1-ff9d44550b31" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems_379067c7-b09d-48e1-89ed-7bb3b2bae73e" xlink:to="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable_67897a2c-65e2-497d-92d1-ff9d44550b31" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_d2563653-61c5-4fcb-92c9-235d3e127dca" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable_67897a2c-65e2-497d-92d1-ff9d44550b31" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_d2563653-61c5-4fcb-92c9-235d3e127dca" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_d2563653-61c5-4fcb-92c9-235d3e127dca_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_d2563653-61c5-4fcb-92c9-235d3e127dca" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_d2563653-61c5-4fcb-92c9-235d3e127dca_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_1a7c7eb0-56d6-40ab-8b7e-1c8a8da2a938" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_d2563653-61c5-4fcb-92c9-235d3e127dca" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_1a7c7eb0-56d6-40ab-8b7e-1c8a8da2a938" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_RestrictedCashforLettersofCreditforFacilityLeasesMember_54191537-7d9b-4f02-ad3c-87e35c212103" xlink:href="evh-20211231.xsd#evh_RestrictedCashforLettersofCreditforFacilityLeasesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_1a7c7eb0-56d6-40ab-8b7e-1c8a8da2a938" xlink:to="loc_evh_RestrictedCashforLettersofCreditforFacilityLeasesMember_54191537-7d9b-4f02-ad3c-87e35c212103" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_CollateralwithFinancialInstitutionsMember_5889c5a9-69ff-46f2-a62d-54d46b4166c8" xlink:href="evh-20211231.xsd#evh_CollateralwithFinancialInstitutionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_1a7c7eb0-56d6-40ab-8b7e-1c8a8da2a938" xlink:to="loc_evh_CollateralwithFinancialInstitutionsMember_5889c5a9-69ff-46f2-a62d-54d46b4166c8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_RestrictedCashforBenefitManagementServicesMember_bb2a47cc-5b45-4697-a43b-abcd68768305" xlink:href="evh-20211231.xsd#evh_RestrictedCashforBenefitManagementServicesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_1a7c7eb0-56d6-40ab-8b7e-1c8a8da2a938" xlink:to="loc_evh_RestrictedCashforBenefitManagementServicesMember_bb2a47cc-5b45-4697-a43b-abcd68768305" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_RestrictedCashforOtherContractualCommitmentsMember_436ebffc-b1cd-4089-a6da-1ac5912d7030" xlink:href="evh-20211231.xsd#evh_RestrictedCashforOtherContractualCommitmentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_1a7c7eb0-56d6-40ab-8b7e-1c8a8da2a938" xlink:to="loc_evh_RestrictedCashforOtherContractualCommitmentsMember_436ebffc-b1cd-4089-a6da-1ac5912d7030" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BankTimeDepositsMember_d69f03ad-d7e3-4144-8334-2914bf8216f7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BankTimeDepositsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_1a7c7eb0-56d6-40ab-8b7e-1c8a8da2a938" xlink:to="loc_us-gaap_BankTimeDepositsMember_d69f03ad-d7e3-4144-8334-2914bf8216f7" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis_da0a950f-397a-4a6f-8b08-14d49524ddc4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupClassificationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable_67897a2c-65e2-497d-92d1-ff9d44550b31" xlink:to="loc_us-gaap_DisposalGroupClassificationAxis_da0a950f-397a-4a6f-8b08-14d49524ddc4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_da0a950f-397a-4a6f-8b08-14d49524ddc4_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_da0a950f-397a-4a6f-8b08-14d49524ddc4" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_da0a950f-397a-4a6f-8b08-14d49524ddc4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_a9fa29c6-7e35-4071-8dce-5a3a4b182d83" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_da0a950f-397a-4a6f-8b08-14d49524ddc4" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_a9fa29c6-7e35-4071-8dce-5a3a4b182d83" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationsDisposedOfBySaleMember_6f71cef6-0bf9-4766-950a-6395c8a44afa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DiscontinuedOperationsDisposedOfBySaleMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain_a9fa29c6-7e35-4071-8dce-5a3a4b182d83" xlink:to="loc_us-gaap_DiscontinuedOperationsDisposedOfBySaleMember_6f71cef6-0bf9-4766-950a-6395c8a44afa" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_c5c03cd2-2e46-41e9-a2a5-535001bff9d5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable_67897a2c-65e2-497d-92d1-ff9d44550b31" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_c5c03cd2-2e46-41e9-a2a5-535001bff9d5" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_c5c03cd2-2e46-41e9-a2a5-535001bff9d5_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_c5c03cd2-2e46-41e9-a2a5-535001bff9d5" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_c5c03cd2-2e46-41e9-a2a5-535001bff9d5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_c258f9ff-dc9b-449e-90e8-82c5d47cdea6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_c5c03cd2-2e46-41e9-a2a5-535001bff9d5" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_c258f9ff-dc9b-449e-90e8-82c5d47cdea6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_TrueHealthMember_7b6ca647-69c3-498e-a25b-30db40adc652" xlink:href="evh-20211231.xsd#evh_TrueHealthMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_c258f9ff-dc9b-449e-90e8-82c5d47cdea6" xlink:to="loc_evh_TrueHealthMember_7b6ca647-69c3-498e-a25b-30db40adc652" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesEstimatedUsefulLifeofPropertyPlantandEquipmentDetails" xlink:type="simple" xlink:href="evh-20211231.xsd#BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesEstimatedUsefulLifeofPropertyPlantandEquipmentDetails"/>
  <link:definitionLink xlink:role="http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesEstimatedUsefulLifeofPropertyPlantandEquipmentDetails" xlink:type="extended" id="i9d47d581f0664c54915462cdf8d43305_BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesEstimatedUsefulLifeofPropertyPlantandEquipmentDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_96afb12f-7a02-4f2a-9cfa-c422b7c7e6e1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_0a8f7e31-81dc-426e-98ea-10054a176120" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_96afb12f-7a02-4f2a-9cfa-c422b7c7e6e1" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_0a8f7e31-81dc-426e-98ea-10054a176120" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_6f53cf6d-3f7b-4ae2-b598-3ec6a1d2c5c1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_96afb12f-7a02-4f2a-9cfa-c422b7c7e6e1" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_6f53cf6d-3f7b-4ae2-b598-3ec6a1d2c5c1" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_d54b54c0-62f4-46f5-bc36-fd1a3f4d64fd" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_6f53cf6d-3f7b-4ae2-b598-3ec6a1d2c5c1" xlink:to="loc_srt_RangeAxis_d54b54c0-62f4-46f5-bc36-fd1a3f4d64fd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_d54b54c0-62f4-46f5-bc36-fd1a3f4d64fd_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_d54b54c0-62f4-46f5-bc36-fd1a3f4d64fd" xlink:to="loc_srt_RangeMember_d54b54c0-62f4-46f5-bc36-fd1a3f4d64fd_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_8ed058b2-7a38-4b7c-a903-9600b68c3ee4" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_d54b54c0-62f4-46f5-bc36-fd1a3f4d64fd" xlink:to="loc_srt_RangeMember_8ed058b2-7a38-4b7c-a903-9600b68c3ee4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_512ed24b-743a-4eab-aef0-e9efecda2ef3" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_8ed058b2-7a38-4b7c-a903-9600b68c3ee4" xlink:to="loc_srt_MinimumMember_512ed24b-743a-4eab-aef0-e9efecda2ef3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_6ffd4338-6110-4e89-b829-6396af848dd0" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_8ed058b2-7a38-4b7c-a903-9600b68c3ee4" xlink:to="loc_srt_MaximumMember_6ffd4338-6110-4e89-b829-6396af848dd0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_4bafe9f2-6152-43ba-8d7b-e25db831243d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_6f53cf6d-3f7b-4ae2-b598-3ec6a1d2c5c1" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_4bafe9f2-6152-43ba-8d7b-e25db831243d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_4bafe9f2-6152-43ba-8d7b-e25db831243d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_4bafe9f2-6152-43ba-8d7b-e25db831243d" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_4bafe9f2-6152-43ba-8d7b-e25db831243d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_b05f45c9-1e33-47ac-af63-0e27db7ee2e9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_4bafe9f2-6152-43ba-8d7b-e25db831243d" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_b05f45c9-1e33-47ac-af63-0e27db7ee2e9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComputerEquipmentMember_ac37778d-658d-4be3-87c1-39871a1f94d5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComputerEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_b05f45c9-1e33-47ac-af63-0e27db7ee2e9" xlink:to="loc_us-gaap_ComputerEquipmentMember_ac37778d-658d-4be3-87c1-39871a1f94d5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_2ea451ec-4601-4772-9dd2-686762f006b6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SoftwareAndSoftwareDevelopmentCostsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_b05f45c9-1e33-47ac-af63-0e27db7ee2e9" xlink:to="loc_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_2ea451ec-4601-4772-9dd2-686762f006b6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_271e9695-9b8c-4037-8a0b-30d9736c1e06" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_b05f45c9-1e33-47ac-af63-0e27db7ee2e9" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_271e9695-9b8c-4037-8a0b-30d9736c1e06" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SoftwareDevelopmentMember_9eb70d84-4d6e-453e-810e-791ed3a6e4af" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SoftwareDevelopmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_b05f45c9-1e33-47ac-af63-0e27db7ee2e9" xlink:to="loc_us-gaap_SoftwareDevelopmentMember_9eb70d84-4d6e-453e-810e-791ed3a6e4af" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesIntangibleAssetsNetDetails" xlink:type="simple" xlink:href="evh-20211231.xsd#BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesIntangibleAssetsNetDetails"/>
  <link:definitionLink xlink:role="http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesIntangibleAssetsNetDetails" xlink:type="extended" id="i60304f607cfa4b4e8b9872e1a9268eef_BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesIntangibleAssetsNetDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_87067f9d-ebfe-43e6-8efc-9a5a10718719" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_6a64226b-34e6-4b19-b886-45ad0d59f8e4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_87067f9d-ebfe-43e6-8efc-9a5a10718719" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_6a64226b-34e6-4b19-b886-45ad0d59f8e4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_c17f95a6-1fe9-4289-bbc7-f1cfdd3041de" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_87067f9d-ebfe-43e6-8efc-9a5a10718719" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_c17f95a6-1fe9-4289-bbc7-f1cfdd3041de" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_f1a40c16-ba11-42e2-8d51-84b89444f157" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_c17f95a6-1fe9-4289-bbc7-f1cfdd3041de" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_f1a40c16-ba11-42e2-8d51-84b89444f157" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_f1a40c16-ba11-42e2-8d51-84b89444f157_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_f1a40c16-ba11-42e2-8d51-84b89444f157" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_f1a40c16-ba11-42e2-8d51-84b89444f157_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_194dd850-54e9-427e-ac11-5aefda288e7c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_f1a40c16-ba11-42e2-8d51-84b89444f157" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_194dd850-54e9-427e-ac11-5aefda288e7c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TradeNamesMember_dd6fbe4b-20e2-4023-932e-f062368c4b14" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TradeNamesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_194dd850-54e9-427e-ac11-5aefda288e7c" xlink:to="loc_us-gaap_TradeNamesMember_dd6fbe4b-20e2-4023-932e-f062368c4b14" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerRelationshipsMember_774fd83b-465b-4095-b4cb-e99492027cd1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CustomerRelationshipsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_194dd850-54e9-427e-ac11-5aefda288e7c" xlink:to="loc_us-gaap_CustomerRelationshipsMember_774fd83b-465b-4095-b4cb-e99492027cd1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DevelopedTechnologyRightsMember_f0fa7e40-d435-470d-930d-e0a2a44ceaac" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DevelopedTechnologyRightsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_194dd850-54e9-427e-ac11-5aefda288e7c" xlink:to="loc_us-gaap_DevelopedTechnologyRightsMember_f0fa7e40-d435-470d-930d-e0a2a44ceaac" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractBasedIntangibleAssetsMember_d92f0150-f520-47cc-987f-c6b91a670752" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractBasedIntangibleAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_194dd850-54e9-427e-ac11-5aefda288e7c" xlink:to="loc_us-gaap_ContractBasedIntangibleAssetsMember_d92f0150-f520-47cc-987f-c6b91a670752" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_e02b2d6a-51d3-4f63-8945-726f8bbcf2f8" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_c17f95a6-1fe9-4289-bbc7-f1cfdd3041de" xlink:to="loc_srt_RangeAxis_e02b2d6a-51d3-4f63-8945-726f8bbcf2f8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_e02b2d6a-51d3-4f63-8945-726f8bbcf2f8_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_e02b2d6a-51d3-4f63-8945-726f8bbcf2f8" xlink:to="loc_srt_RangeMember_e02b2d6a-51d3-4f63-8945-726f8bbcf2f8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_3b70213d-9636-4904-9ed0-5b85b57beaa6" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_e02b2d6a-51d3-4f63-8945-726f8bbcf2f8" xlink:to="loc_srt_RangeMember_3b70213d-9636-4904-9ed0-5b85b57beaa6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_7fdb12a2-03af-439f-b8ee-c7f333cc4d19" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_3b70213d-9636-4904-9ed0-5b85b57beaa6" xlink:to="loc_srt_MinimumMember_7fdb12a2-03af-439f-b8ee-c7f333cc4d19" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_87e3eb59-0f47-4907-8df7-8310cbb3f2eb" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_3b70213d-9636-4904-9ed0-5b85b57beaa6" xlink:to="loc_srt_MaximumMember_87e3eb59-0f47-4907-8df7-8310cbb3f2eb" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesStockbasedCompensationDetails" xlink:type="simple" xlink:href="evh-20211231.xsd#BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesStockbasedCompensationDetails"/>
  <link:definitionLink xlink:role="http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesStockbasedCompensationDetails" xlink:type="extended" id="i81bcac01c0c84ddaa093dea7045f2756_BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesStockbasedCompensationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_16423606-996d-4e33-996c-11dfe538e4e9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_d31073d9-1dee-4267-97aa-58db8c5ed851" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_16423606-996d-4e33-996c-11dfe538e4e9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_d31073d9-1dee-4267-97aa-58db8c5ed851" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_2ff688ab-1c39-4db2-9003-1fb3813a6a69" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_16423606-996d-4e33-996c-11dfe538e4e9" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_2ff688ab-1c39-4db2-9003-1fb3813a6a69" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_86a92490-74df-4e09-92c5-823a960bf6f5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_16423606-996d-4e33-996c-11dfe538e4e9" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_86a92490-74df-4e09-92c5-823a960bf6f5" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_fdeb46cf-02da-465a-89dd-0e10f6df7203" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_86a92490-74df-4e09-92c5-823a960bf6f5" xlink:to="loc_us-gaap_AwardTypeAxis_fdeb46cf-02da-465a-89dd-0e10f6df7203" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_fdeb46cf-02da-465a-89dd-0e10f6df7203_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_fdeb46cf-02da-465a-89dd-0e10f6df7203" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_fdeb46cf-02da-465a-89dd-0e10f6df7203_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3ef73981-bf1c-4adc-925f-9d81ad71fed3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_fdeb46cf-02da-465a-89dd-0e10f6df7203" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3ef73981-bf1c-4adc-925f-9d81ad71fed3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_005b8c52-8521-41a0-9da6-5a2db5784e43" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3ef73981-bf1c-4adc-925f-9d81ad71fed3" xlink:to="loc_us-gaap_EmployeeStockOptionMember_005b8c52-8521-41a0-9da6-5a2db5784e43" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/RecentlyIssuedAccountingStandardsDetails" xlink:type="simple" xlink:href="evh-20211231.xsd#RecentlyIssuedAccountingStandardsDetails"/>
  <link:definitionLink xlink:role="http://www.evolenthealth.com/role/RecentlyIssuedAccountingStandardsDetails" xlink:type="extended" id="ia7f6afdf5e8d40b9ad0f08bc638675cd_RecentlyIssuedAccountingStandardsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_e9301795-e634-4201-9327-d444fb91e033" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_4cdcc774-19f1-482c-836c-44dc760ef3bb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_e9301795-e634-4201-9327-d444fb91e033" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_4cdcc774-19f1-482c-836c-44dc760ef3bb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingStandardsUpdateExtensibleList_d7a02da7-a0b5-4e39-91c2-4dcfe5c8f960" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingStandardsUpdateExtensibleList"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_e9301795-e634-4201-9327-d444fb91e033" xlink:to="loc_us-gaap_AccountingStandardsUpdateExtensibleList_d7a02da7-a0b5-4e39-91c2-4dcfe5c8f960" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_77715a5a-1c1d-4ff1-b914-f859d9bdccad" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_e9301795-e634-4201-9327-d444fb91e033" xlink:to="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_77715a5a-1c1d-4ff1-b914-f859d9bdccad" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_5bbeefda-e674-427c-95bf-c5b68838e07f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_77715a5a-1c1d-4ff1-b914-f859d9bdccad" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_5bbeefda-e674-427c-95bf-c5b68838e07f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_5bbeefda-e674-427c-95bf-c5b68838e07f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_5bbeefda-e674-427c-95bf-c5b68838e07f" xlink:to="loc_us-gaap_EquityComponentDomain_5bbeefda-e674-427c-95bf-c5b68838e07f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_093d6c45-0524-4e05-a065-b5f0cadbda18" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_5bbeefda-e674-427c-95bf-c5b68838e07f" xlink:to="loc_us-gaap_EquityComponentDomain_093d6c45-0524-4e05-a065-b5f0cadbda18" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_6f8fe025-b9bc-4292-aec2-12117568953b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_093d6c45-0524-4e05-a065-b5f0cadbda18" xlink:to="loc_us-gaap_RetainedEarningsMember_6f8fe025-b9bc-4292-aec2-12117568953b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_16936450-f2ec-4553-9257-a7aa5978ecbe" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_77715a5a-1c1d-4ff1-b914-f859d9bdccad" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_16936450-f2ec-4553-9257-a7aa5978ecbe" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_16936450-f2ec-4553-9257-a7aa5978ecbe_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_16936450-f2ec-4553-9257-a7aa5978ecbe" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_16936450-f2ec-4553-9257-a7aa5978ecbe_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_88b7c33a-a77c-4530-93dd-04f835849c08" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_16936450-f2ec-4553-9257-a7aa5978ecbe" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_88b7c33a-a77c-4530-93dd-04f835849c08" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_9f4dade8-0f22-4722-b8e9-32b4a2b712fa" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_88b7c33a-a77c-4530-93dd-04f835849c08" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_9f4dade8-0f22-4722-b8e9-32b4a2b712fa" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/TransactionsVitalDecisionsDetails" xlink:type="simple" xlink:href="evh-20211231.xsd#TransactionsVitalDecisionsDetails"/>
  <link:definitionLink xlink:role="http://www.evolenthealth.com/role/TransactionsVitalDecisionsDetails" xlink:type="extended" id="i010ceaf7453f4fb0941dc9b175d4f2b1_TransactionsVitalDecisionsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_6b109394-4e7d-46d4-adb2-daf3bd67b6c2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_92d90af9-bf1d-491f-95b0-9e8be05caff3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_6b109394-4e7d-46d4-adb2-daf3bd67b6c2" xlink:to="loc_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_92d90af9-bf1d-491f-95b0-9e8be05caff3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_0bebaf2f-4a50-47c2-a7fb-dd3d79270e0f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_6b109394-4e7d-46d4-adb2-daf3bd67b6c2" xlink:to="loc_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_0bebaf2f-4a50-47c2-a7fb-dd3d79270e0f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh_2be1308b-5e52-432c-9096-52663a1e962e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_6b109394-4e7d-46d4-adb2-daf3bd67b6c2" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh_2be1308b-5e52-432c-9096-52663a1e962e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferredAbstract_96e9f00d-08e7-4af2-986d-db3cf6642515" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferredAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_6b109394-4e7d-46d4-adb2-daf3bd67b6c2" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferredAbstract_96e9f00d-08e7-4af2-986d-db3cf6642515" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross_8291fa0d-72c5-4320-bbdc-9e75af50c06b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationConsiderationTransferredAbstract_96e9f00d-08e7-4af2-986d-db3cf6642515" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesGross_8291fa0d-72c5-4320-bbdc-9e75af50c06b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable_94eb35c5-4146-48ad-94f7-66a23bdaa688" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationConsiderationTransferredAbstract_96e9f00d-08e7-4af2-986d-db3cf6642515" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable_94eb35c5-4146-48ad-94f7-66a23bdaa688" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_6d226d8c-7648-4ff5-894d-52d0017456d6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationConsiderationTransferredAbstract_96e9f00d-08e7-4af2-986d-db3cf6642515" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_6d226d8c-7648-4ff5-894d-52d0017456d6" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferred1_7c5d7d10-512f-41af-8139-2ebb188fd088" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferred1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationConsiderationTransferredAbstract_96e9f00d-08e7-4af2-986d-db3cf6642515" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferred1_7c5d7d10-512f-41af-8139-2ebb188fd088" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract_3b3853e5-4439-4470-a61d-aebd9eb13893" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_6b109394-4e7d-46d4-adb2-daf3bd67b6c2" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract_3b3853e5-4439-4470-a61d-aebd9eb13893" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_5192bf51-a18f-4bd0-ac77-be0d60b83bd4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract_3b3853e5-4439-4470-a61d-aebd9eb13893" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_5192bf51-a18f-4bd0-ac77-be0d60b83bd4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables_de4038a9-0341-453c-ad86-9c8cf76840bd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract_3b3853e5-4439-4470-a61d-aebd9eb13893" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables_de4038a9-0341-453c-ad86-9c8cf76840bd" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_8135b2a8-a4f9-467e-8c2f-503b12656d74" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract_3b3853e5-4439-4470-a61d-aebd9eb13893" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_8135b2a8-a4f9-467e-8c2f-503b12656d74" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets_596ad53c-caad-4efc-a6f7-955ed01cd5c2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract_3b3853e5-4439-4470-a61d-aebd9eb13893" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets_596ad53c-caad-4efc-a6f7-955ed01cd5c2" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedTangibleAssets_8599c0f8-736c-467e-b23d-466fd302485d" xlink:href="evh-20211231.xsd#evh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedTangibleAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract_3b3853e5-4439-4470-a61d-aebd9eb13893" xlink:to="loc_evh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedTangibleAssets_8599c0f8-736c-467e-b23d-466fd302485d" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwillAbstract_e64bbf33-7e89-4d17-9530-0a597be9d24f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwillAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_6b109394-4e7d-46d4-adb2-daf3bd67b6c2" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwillAbstract_e64bbf33-7e89-4d17-9530-0a597be9d24f" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_03b8c6a0-5976-40ba-844b-df10e3305d34" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwillAbstract_e64bbf33-7e89-4d17-9530-0a597be9d24f" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_03b8c6a0-5976-40ba-844b-df10e3305d34" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract_ddefb5f6-b060-4e6b-92f3-52f945f2ecc1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_6b109394-4e7d-46d4-adb2-daf3bd67b6c2" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract_ddefb5f6-b060-4e6b-92f3-52f945f2ecc1" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_f4a88da4-0c89-451a-bb37-f2756929ecfc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract_ddefb5f6-b060-4e6b-92f3-52f945f2ecc1" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_f4a88da4-0c89-451a-bb37-f2756929ecfc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesAccruedLiabilities_88832838-ded1-4008-950d-f5c86c6df2f7" xlink:href="evh-20211231.xsd#evh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesAccruedLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract_ddefb5f6-b060-4e6b-92f3-52f945f2ecc1" xlink:to="loc_evh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesAccruedLiabilities_88832838-ded1-4008-950d-f5c86c6df2f7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesAccruedCompensationAndEmployeeBenefits_5c3a63d5-d3cc-4a64-b276-b4b4a8776e5d" xlink:href="evh-20211231.xsd#evh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesAccruedCompensationAndEmployeeBenefits"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract_ddefb5f6-b060-4e6b-92f3-52f945f2ecc1" xlink:to="loc_evh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesAccruedCompensationAndEmployeeBenefits_5c3a63d5-d3cc-4a64-b276-b4b4a8776e5d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_b2020b44-126c-466c-b1a4-bb7fe67dafa5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract_ddefb5f6-b060-4e6b-92f3-52f945f2ecc1" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_b2020b44-126c-466c-b1a4-bb7fe67dafa5" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue_3624a06b-9a98-444a-87ad-24eb655e0a06" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract_ddefb5f6-b060-4e6b-92f3-52f945f2ecc1" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue_3624a06b-9a98-444a-87ad-24eb655e0a06" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCapitalLeaseObligation_446aa1a7-8d2d-4a27-8b08-41c434c349b7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCapitalLeaseObligation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract_ddefb5f6-b060-4e6b-92f3-52f945f2ecc1" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCapitalLeaseObligation_446aa1a7-8d2d-4a27-8b08-41c434c349b7" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_aaac405f-2321-4fc0-8d7d-05ed5d68bb4d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract_ddefb5f6-b060-4e6b-92f3-52f945f2ecc1" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_aaac405f-2321-4fc0-8d7d-05ed5d68bb4d" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_da7f578f-e0c8-4dee-8d59-f99d1c146930" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_6b109394-4e7d-46d4-adb2-daf3bd67b6c2" xlink:to="loc_us-gaap_Goodwill_da7f578f-e0c8-4dee-8d59-f99d1c146930" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_4d83b912-48f7-484c-ba85-6248459b9bea" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_6b109394-4e7d-46d4-adb2-daf3bd67b6c2" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_4d83b912-48f7-484c-ba85-6248459b9bea" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_242fa08d-ca7c-41bf-b768-23933a57ef83" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_6b109394-4e7d-46d4-adb2-daf3bd67b6c2" xlink:to="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_242fa08d-ca7c-41bf-b768-23933a57ef83" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount_9ea55dcc-4069-43d5-a6a1-393ad08200ac" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_6b109394-4e7d-46d4-adb2-daf3bd67b6c2" xlink:to="loc_us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount_9ea55dcc-4069-43d5-a6a1-393ad08200ac" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_894bef58-fe6f-42d5-baf2-7d4479a46f29" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_6b109394-4e7d-46d4-adb2-daf3bd67b6c2" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_894bef58-fe6f-42d5-baf2-7d4479a46f29" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_ee03af95-df0e-4fb1-bfac-a42f313f3413" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_894bef58-fe6f-42d5-baf2-7d4479a46f29" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_ee03af95-df0e-4fb1-bfac-a42f313f3413" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_ee03af95-df0e-4fb1-bfac-a42f313f3413_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_ee03af95-df0e-4fb1-bfac-a42f313f3413" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_ee03af95-df0e-4fb1-bfac-a42f313f3413_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_45848b34-f98c-4679-a8ec-b3ba5e5f18a2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_ee03af95-df0e-4fb1-bfac-a42f313f3413" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_45848b34-f98c-4679-a8ec-b3ba5e5f18a2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_VitalDecisionsMember_df56a59b-47cd-42c4-9557-be4a15196c82" xlink:href="evh-20211231.xsd#evh_VitalDecisionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_45848b34-f98c-4679-a8ec-b3ba5e5f18a2" xlink:to="loc_evh_VitalDecisionsMember_df56a59b-47cd-42c4-9557-be4a15196c82" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_5f6f3594-7e44-4021-83b1-3f82e1f76263" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_894bef58-fe6f-42d5-baf2-7d4479a46f29" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_5f6f3594-7e44-4021-83b1-3f82e1f76263" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_5f6f3594-7e44-4021-83b1-3f82e1f76263_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_5f6f3594-7e44-4021-83b1-3f82e1f76263" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_5f6f3594-7e44-4021-83b1-3f82e1f76263_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_bf391db7-8b0e-4cd9-8ff3-dcbf9c23f899" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_5f6f3594-7e44-4021-83b1-3f82e1f76263" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_bf391db7-8b0e-4cd9-8ff3-dcbf9c23f899" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerRelationshipsMember_3e1a81cb-5775-4586-9e84-16dec3b06b73" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CustomerRelationshipsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_bf391db7-8b0e-4cd9-8ff3-dcbf9c23f899" xlink:to="loc_us-gaap_CustomerRelationshipsMember_3e1a81cb-5775-4586-9e84-16dec3b06b73" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DevelopedTechnologyRightsMember_cc7fdff7-f05b-4009-bb30-e5d829e434d0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DevelopedTechnologyRightsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_bf391db7-8b0e-4cd9-8ff3-dcbf9c23f899" xlink:to="loc_us-gaap_DevelopedTechnologyRightsMember_cc7fdff7-f05b-4009-bb30-e5d829e434d0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TradeNamesMember_bc1ab2fd-3bf3-4f06-a413-e1817ee6f1fc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TradeNamesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_bf391db7-8b0e-4cd9-8ff3-dcbf9c23f899" xlink:to="loc_us-gaap_TradeNamesMember_bc1ab2fd-3bf3-4f06-a413-e1817ee6f1fc" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/TransactionsEquityInvestmentsDetails" xlink:type="simple" xlink:href="evh-20211231.xsd#TransactionsEquityInvestmentsDetails"/>
  <link:definitionLink xlink:role="http://www.evolenthealth.com/role/TransactionsEquityInvestmentsDetails" xlink:type="extended" id="ib8df4757e35d42a2baad512cdd57db0f_TransactionsEquityInvestmentsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_15816d5e-2aff-42d3-b68c-dd248b301c3f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireEquityMethodInvestments_2bf0f5a7-51ea-4660-a16e-65d9503c53fa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireEquityMethodInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_15816d5e-2aff-42d3-b68c-dd248b301c3f" xlink:to="loc_us-gaap_PaymentsToAcquireEquityMethodInvestments_2bf0f5a7-51ea-4660-a16e-65d9503c53fa" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableInterestEntityOwnershipPercentage_7c8ef5c1-106c-46ea-a566-dd5e86ff0576" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableInterestEntityOwnershipPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_15816d5e-2aff-42d3-b68c-dd248b301c3f" xlink:to="loc_us-gaap_VariableInterestEntityOwnershipPercentage_7c8ef5c1-106c-46ea-a566-dd5e86ff0576" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesReceivableNet_66f9bed9-37dd-4385-a795-a299c560ebe4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NotesReceivableNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_15816d5e-2aff-42d3-b68c-dd248b301c3f" xlink:to="loc_us-gaap_NotesReceivableNet_66f9bed9-37dd-4385-a795-a299c560ebe4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_fc3a8d76-6b0e-485b-9177-a7e736edacd0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_15816d5e-2aff-42d3-b68c-dd248b301c3f" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_fc3a8d76-6b0e-485b-9177-a7e736edacd0" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableInterestEntityFinancialOrOtherSupportAmount_3bb94b7e-9487-48ad-8444-8e6b6b80be67" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableInterestEntityFinancialOrOtherSupportAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_15816d5e-2aff-42d3-b68c-dd248b301c3f" xlink:to="loc_us-gaap_VariableInterestEntityFinancialOrOtherSupportAmount_3bb94b7e-9487-48ad-8444-8e6b6b80be67" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_PaymentsToAcquireEquityMethodInvestmentsAmountHeldBack_16ba9ab4-079e-4331-8453-e220c5ccc471" xlink:href="evh-20211231.xsd#evh_PaymentsToAcquireEquityMethodInvestmentsAmountHeldBack"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_15816d5e-2aff-42d3-b68c-dd248b301c3f" xlink:to="loc_evh_PaymentsToAcquireEquityMethodInvestmentsAmountHeldBack_16ba9ab4-079e-4331-8453-e220c5ccc471" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_AssetPurchaseAgreementEscrowPayments_75b02cbd-9128-49a8-b801-350b62b9d9e8" xlink:href="evh-20211231.xsd#evh_AssetPurchaseAgreementEscrowPayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_15816d5e-2aff-42d3-b68c-dd248b301c3f" xlink:to="loc_evh_AssetPurchaseAgreementEscrowPayments_75b02cbd-9128-49a8-b801-350b62b9d9e8" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_CashReleasedFromEscrow_afc54c4e-21e3-4a29-9fe9-14736976f8ef" xlink:href="evh-20211231.xsd#evh_CashReleasedFromEscrow"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_15816d5e-2aff-42d3-b68c-dd248b301c3f" xlink:to="loc_evh_CashReleasedFromEscrow_afc54c4e-21e3-4a29-9fe9-14736976f8ef" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToMinorityShareholders_45666f40-27a1-4979-aca1-56528d08ce3f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToMinorityShareholders"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_15816d5e-2aff-42d3-b68c-dd248b301c3f" xlink:to="loc_us-gaap_PaymentsToMinorityShareholders_45666f40-27a1-4979-aca1-56528d08ce3f" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_AssetAcquisitionCashAndEquivalents_96fb12dc-5711-4a58-83df-78113b958ad7" xlink:href="evh-20211231.xsd#evh_AssetAcquisitionCashAndEquivalents"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_15816d5e-2aff-42d3-b68c-dd248b301c3f" xlink:to="loc_evh_AssetAcquisitionCashAndEquivalents_96fb12dc-5711-4a58-83df-78113b958ad7" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_AssetAcquisitionDebtSecuritiesAvailableForSale_f3569c4b-c5e6-403c-b050-e0e68e404c05" xlink:href="evh-20211231.xsd#evh_AssetAcquisitionDebtSecuritiesAvailableForSale"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_15816d5e-2aff-42d3-b68c-dd248b301c3f" xlink:to="loc_evh_AssetAcquisitionDebtSecuritiesAvailableForSale_f3569c4b-c5e6-403c-b050-e0e68e404c05" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_AssetAcquisitionDebtSecuritiesAvailableForSaleUnsettledSalesReceivables_e3d48ec1-0061-4b9c-b488-e285f74a9d41" xlink:href="evh-20211231.xsd#evh_AssetAcquisitionDebtSecuritiesAvailableForSaleUnsettledSalesReceivables"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_15816d5e-2aff-42d3-b68c-dd248b301c3f" xlink:to="loc_evh_AssetAcquisitionDebtSecuritiesAvailableForSaleUnsettledSalesReceivables_e3d48ec1-0061-4b9c-b488-e285f74a9d41" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_AssetAcquisitionOtherAssets_1f170ba1-f886-4be8-9c5e-9c999cd14e96" xlink:href="evh-20211231.xsd#evh_AssetAcquisitionOtherAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_15816d5e-2aff-42d3-b68c-dd248b301c3f" xlink:to="loc_evh_AssetAcquisitionOtherAssets_1f170ba1-f886-4be8-9c5e-9c999cd14e96" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_AssetAcquisitionAccruedMedicalExpenses_e9af0247-cd93-4995-a1e1-e52c6d3717b9" xlink:href="evh-20211231.xsd#evh_AssetAcquisitionAccruedMedicalExpenses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_15816d5e-2aff-42d3-b68c-dd248b301c3f" xlink:to="loc_evh_AssetAcquisitionAccruedMedicalExpenses_e9af0247-cd93-4995-a1e1-e52c6d3717b9" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_AssetAcquisitionAccruedLiabilities_a5c52945-3e2b-49bc-9aa6-6a19afa22ff3" xlink:href="evh-20211231.xsd#evh_AssetAcquisitionAccruedLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_15816d5e-2aff-42d3-b68c-dd248b301c3f" xlink:to="loc_evh_AssetAcquisitionAccruedLiabilities_a5c52945-3e2b-49bc-9aa6-6a19afa22ff3" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromCollectionOfNotesReceivable_606b53d9-c393-426a-b52c-73b4097c67d2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromCollectionOfNotesReceivable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_15816d5e-2aff-42d3-b68c-dd248b301c3f" xlink:to="loc_us-gaap_ProceedsFromCollectionOfNotesReceivable_606b53d9-c393-426a-b52c-73b4097c67d2" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromInterestReceived_9de0cbdf-1ef9-4529-be29-5b51dd224c22" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromInterestReceived"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_15816d5e-2aff-42d3-b68c-dd248b301c3f" xlink:to="loc_us-gaap_ProceedsFromInterestReceived_9de0cbdf-1ef9-4529-be29-5b51dd224c22" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_ProceedsFromTransferOfMembership_0f15a187-c647-4bc9-aad6-e4fe54e58c23" xlink:href="evh-20211231.xsd#evh_ProceedsFromTransferOfMembership"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_15816d5e-2aff-42d3-b68c-dd248b301c3f" xlink:to="loc_evh_ProceedsFromTransferOfMembership_0f15a187-c647-4bc9-aad6-e4fe54e58c23" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_TransferOfMembershipPercentageOfPaymentBasedOnNumberOfEnrollees_7b85f5a1-e7d9-466f-9095-a8356d0ca93b" xlink:href="evh-20211231.xsd#evh_TransferOfMembershipPercentageOfPaymentBasedOnNumberOfEnrollees"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_15816d5e-2aff-42d3-b68c-dd248b301c3f" xlink:to="loc_evh_TransferOfMembershipPercentageOfPaymentBasedOnNumberOfEnrollees_7b85f5a1-e7d9-466f-9095-a8356d0ca93b" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_TransferOfMembershipPercentageOfPaymentSubjectToSatisfactionOfContingencies_1f317609-729b-475f-ab0f-086118bfc946" xlink:href="evh-20211231.xsd#evh_TransferOfMembershipPercentageOfPaymentSubjectToSatisfactionOfContingencies"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_15816d5e-2aff-42d3-b68c-dd248b301c3f" xlink:to="loc_evh_TransferOfMembershipPercentageOfPaymentSubjectToSatisfactionOfContingencies_1f317609-729b-475f-ab0f-086118bfc946" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnDispositionOfAssets1_ff6982af-fb4d-41f2-9ecb-6634b33e819b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossOnDispositionOfAssets1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_15816d5e-2aff-42d3-b68c-dd248b301c3f" xlink:to="loc_us-gaap_GainLossOnDispositionOfAssets1_ff6982af-fb4d-41f2-9ecb-6634b33e819b" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_4609f7c5-61a0-45f6-8007-0494167784b6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_15816d5e-2aff-42d3-b68c-dd248b301c3f" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_4609f7c5-61a0-45f6-8007-0494167784b6" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_9b3ef79d-d18b-4190-8186-0bd14d3ff16b" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_4609f7c5-61a0-45f6-8007-0494167784b6" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_9b3ef79d-d18b-4190-8186-0bd14d3ff16b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_9b3ef79d-d18b-4190-8186-0bd14d3ff16b_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_9b3ef79d-d18b-4190-8186-0bd14d3ff16b" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_9b3ef79d-d18b-4190-8186-0bd14d3ff16b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_060da934-8f9d-4373-a86e-a187eab32747" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_9b3ef79d-d18b-4190-8186-0bd14d3ff16b" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_060da934-8f9d-4373-a86e-a187eab32747" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_UniversityHealthCaredbaPassportHealthPlanMember_08cadaf9-eab7-4282-806e-a00ed0d0c1b8" xlink:href="evh-20211231.xsd#evh_UniversityHealthCaredbaPassportHealthPlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_060da934-8f9d-4373-a86e-a187eab32747" xlink:to="loc_evh_UniversityHealthCaredbaPassportHealthPlanMember_08cadaf9-eab7-4282-806e-a00ed0d0c1b8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_VivantHealthMSOLLCMember_e60ee32a-d2f2-4962-ac90-3313f14b2332" xlink:href="evh-20211231.xsd#evh_VivantHealthMSOLLCMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_060da934-8f9d-4373-a86e-a187eab32747" xlink:to="loc_evh_VivantHealthMSOLLCMember_e60ee32a-d2f2-4962-ac90-3313f14b2332" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_1a9200be-a88c-40ce-a837-cee3a6b05ee0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_4609f7c5-61a0-45f6-8007-0494167784b6" xlink:to="loc_us-gaap_DebtInstrumentAxis_1a9200be-a88c-40ce-a837-cee3a6b05ee0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_1a9200be-a88c-40ce-a837-cee3a6b05ee0_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_1a9200be-a88c-40ce-a837-cee3a6b05ee0" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_1a9200be-a88c-40ce-a837-cee3a6b05ee0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_1d19770a-ddb2-4425-a37d-76c0c18c7e4e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_1a9200be-a88c-40ce-a837-cee3a6b05ee0" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_1d19770a-ddb2-4425-a37d-76c0c18c7e4e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_PassportNoteMember_eee47c80-d517-415e-b5d5-754f36295c01" xlink:href="evh-20211231.xsd#evh_PassportNoteMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_1d19770a-ddb2-4425-a37d-76c0c18c7e4e" xlink:to="loc_evh_PassportNoteMember_eee47c80-d517-415e-b5d5-754f36295c01" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_14434cbc-a56b-4755-b8ec-fe90ab64b68d" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_4609f7c5-61a0-45f6-8007-0494167784b6" xlink:to="loc_srt_CounterpartyNameAxis_14434cbc-a56b-4755-b8ec-fe90ab64b68d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_14434cbc-a56b-4755-b8ec-fe90ab64b68d_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_14434cbc-a56b-4755-b8ec-fe90ab64b68d" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_14434cbc-a56b-4755-b8ec-fe90ab64b68d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_0fc95a04-3d41-4e22-ae3a-c903785cbb60" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_14434cbc-a56b-4755-b8ec-fe90ab64b68d" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_0fc95a04-3d41-4e22-ae3a-c903785cbb60" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_MolinaHealthcareIncMember_80fefbfe-7960-4fc2-b802-e112b1dca062" xlink:href="evh-20211231.xsd#evh_MolinaHealthcareIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_0fc95a04-3d41-4e22-ae3a-c903785cbb60" xlink:to="loc_evh_MolinaHealthcareIncMember_80fefbfe-7960-4fc2-b802-e112b1dca062" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionAxis_f4c0b8dd-39ad-488e-ad96-b6ab782f65da" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_4609f7c5-61a0-45f6-8007-0494167784b6" xlink:to="loc_us-gaap_AssetAcquisitionAxis_f4c0b8dd-39ad-488e-ad96-b6ab782f65da" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionDomain_f4c0b8dd-39ad-488e-ad96-b6ab782f65da_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetAcquisitionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AssetAcquisitionAxis_f4c0b8dd-39ad-488e-ad96-b6ab782f65da" xlink:to="loc_us-gaap_AssetAcquisitionDomain_f4c0b8dd-39ad-488e-ad96-b6ab782f65da_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionDomain_f7fb1c7f-dc79-4b2f-b8d0-7e4d1b9b5973" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetAcquisitionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AssetAcquisitionAxis_f4c0b8dd-39ad-488e-ad96-b6ab782f65da" xlink:to="loc_us-gaap_AssetAcquisitionDomain_f7fb1c7f-dc79-4b2f-b8d0-7e4d1b9b5973" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_PassportAssetAcquisitionMember_13384df8-d247-4dfb-bc8e-200f46ff6620" xlink:href="evh-20211231.xsd#evh_PassportAssetAcquisitionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetAcquisitionDomain_f7fb1c7f-dc79-4b2f-b8d0-7e4d1b9b5973" xlink:to="loc_evh_PassportAssetAcquisitionMember_13384df8-d247-4dfb-bc8e-200f46ff6620" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesAxis_4c33fc23-1414-4aba-ba63-b58f1f511e49" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ConsolidatedEntitiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_4609f7c5-61a0-45f6-8007-0494167784b6" xlink:to="loc_srt_ConsolidatedEntitiesAxis_4c33fc23-1414-4aba-ba63-b58f1f511e49" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesDomain_4c33fc23-1414-4aba-ba63-b58f1f511e49_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ConsolidatedEntitiesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ConsolidatedEntitiesAxis_4c33fc23-1414-4aba-ba63-b58f1f511e49" xlink:to="loc_srt_ConsolidatedEntitiesDomain_4c33fc23-1414-4aba-ba63-b58f1f511e49_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesDomain_1a1cf93b-ab52-4574-b383-45fc565b0eef" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ConsolidatedEntitiesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ConsolidatedEntitiesAxis_4c33fc23-1414-4aba-ba63-b58f1f511e49" xlink:to="loc_srt_ConsolidatedEntitiesDomain_1a1cf93b-ab52-4574-b383-45fc565b0eef" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableInterestEntityNotPrimaryBeneficiaryMember_4ca910d8-fee6-4318-8879-6b27ea356fef" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableInterestEntityNotPrimaryBeneficiaryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidatedEntitiesDomain_1a1cf93b-ab52-4574-b383-45fc565b0eef" xlink:to="loc_us-gaap_VariableInterestEntityNotPrimaryBeneficiaryMember_4ca910d8-fee6-4318-8879-6b27ea356fef" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_03f7891e-7b22-4b80-b8c2-7ae75a23da6b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_4609f7c5-61a0-45f6-8007-0494167784b6" xlink:to="loc_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_03f7891e-7b22-4b80-b8c2-7ae75a23da6b" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivableTypeDomain_03f7891e-7b22-4b80-b8c2-7ae75a23da6b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReceivableTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_03f7891e-7b22-4b80-b8c2-7ae75a23da6b" xlink:to="loc_us-gaap_ReceivableTypeDomain_03f7891e-7b22-4b80-b8c2-7ae75a23da6b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivableTypeDomain_06354cec-9c39-4dc6-a954-84a8c0a0805d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReceivableTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_03f7891e-7b22-4b80-b8c2-7ae75a23da6b" xlink:to="loc_us-gaap_ReceivableTypeDomain_06354cec-9c39-4dc6-a954-84a8c0a0805d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesReceivableMember_6437f3cb-2b7e-4faf-ba41-e3290eedfaeb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NotesReceivableMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReceivableTypeDomain_06354cec-9c39-4dc6-a954-84a8c0a0805d" xlink:to="loc_us-gaap_NotesReceivableMember_6437f3cb-2b7e-4faf-ba41-e3290eedfaeb" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/DiscontinuedOperationsAdditionalInformationDetails" xlink:type="simple" xlink:href="evh-20211231.xsd#DiscontinuedOperationsAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://www.evolenthealth.com/role/DiscontinuedOperationsAdditionalInformationDetails" xlink:type="extended" id="i1553e8ff13c349a28775c4afe164a156_DiscontinuedOperationsAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_5788119f-ffa1-45d8-9614-fe294cf68a43" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_DiscontinuedOperationGainLossOnPurchasePriceAdjustmentsNetOfTax_b2e8836a-32d9-45a4-9198-5b9d7d350ea5" xlink:href="evh-20211231.xsd#evh_DiscontinuedOperationGainLossOnPurchasePriceAdjustmentsNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_5788119f-ffa1-45d8-9614-fe294cf68a43" xlink:to="loc_evh_DiscontinuedOperationGainLossOnPurchasePriceAdjustmentsNetOfTax_b2e8836a-32d9-45a4-9198-5b9d7d350ea5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_46e66e04-3090-429c-9941-8dbeab27ed07" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_5788119f-ffa1-45d8-9614-fe294cf68a43" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_46e66e04-3090-429c-9941-8dbeab27ed07" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_50fc0bf8-8391-4f8b-a280-a8756df3b2b3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_46e66e04-3090-429c-9941-8dbeab27ed07" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_50fc0bf8-8391-4f8b-a280-a8756df3b2b3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_50fc0bf8-8391-4f8b-a280-a8756df3b2b3_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_50fc0bf8-8391-4f8b-a280-a8756df3b2b3" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_50fc0bf8-8391-4f8b-a280-a8756df3b2b3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_2700f830-f1fd-4091-a898-9e07919d9889" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_50fc0bf8-8391-4f8b-a280-a8756df3b2b3" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_2700f830-f1fd-4091-a898-9e07919d9889" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_TrueHealthMember_f8edbe15-3b75-407e-ba8d-63c2c8829a7b" xlink:href="evh-20211231.xsd#evh_TrueHealthMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_2700f830-f1fd-4091-a898-9e07919d9889" xlink:to="loc_evh_TrueHealthMember_f8edbe15-3b75-407e-ba8d-63c2c8829a7b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis_66340ccd-81ed-49e0-aab2-f03b063b87cf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupClassificationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_46e66e04-3090-429c-9941-8dbeab27ed07" xlink:to="loc_us-gaap_DisposalGroupClassificationAxis_66340ccd-81ed-49e0-aab2-f03b063b87cf" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_66340ccd-81ed-49e0-aab2-f03b063b87cf_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_66340ccd-81ed-49e0-aab2-f03b063b87cf" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_66340ccd-81ed-49e0-aab2-f03b063b87cf_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_3f890bad-8d23-4094-9498-211152290820" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_66340ccd-81ed-49e0-aab2-f03b063b87cf" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_3f890bad-8d23-4094-9498-211152290820" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationsDisposedOfBySaleMember_8f6a741b-17f8-4109-95b5-fbaa1aec7267" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DiscontinuedOperationsDisposedOfBySaleMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain_3f890bad-8d23-4094-9498-211152290820" xlink:to="loc_us-gaap_DiscontinuedOperationsDisposedOfBySaleMember_8f6a741b-17f8-4109-95b5-fbaa1aec7267" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/DiscontinuedOperationsSummaryofResultsofOperationsDetails" xlink:type="simple" xlink:href="evh-20211231.xsd#DiscontinuedOperationsSummaryofResultsofOperationsDetails"/>
  <link:definitionLink xlink:role="http://www.evolenthealth.com/role/DiscontinuedOperationsSummaryofResultsofOperationsDetails" xlink:type="extended" id="i757f4d24d7f34e31923968a5affc2977_DiscontinuedOperationsSummaryofResultsofOperationsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_56712d55-ae35-433a-b5fe-d84d9212d520" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract_ce9bd5d3-cbda-4ee2-a8ac-ca1be757390d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenuesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_56712d55-ae35-433a-b5fe-d84d9212d520" xlink:to="loc_us-gaap_RevenuesAbstract_ce9bd5d3-cbda-4ee2-a8ac-ca1be757390d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue_ae032b2a-0054-4edb-a6cc-5fb5b8c7cf1d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenuesAbstract_ce9bd5d3-cbda-4ee2-a8ac-ca1be757390d" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue_ae032b2a-0054-4edb-a6cc-5fb5b8c7cf1d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract_643b7864-6279-451d-805e-40c25f41f8b0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_56712d55-ae35-433a-b5fe-d84d9212d520" xlink:to="loc_us-gaap_OperatingExpensesAbstract_643b7864-6279-451d-805e-40c25f41f8b0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold_8387402d-7073-430c-81df-4dee0166d8a6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_643b7864-6279-451d-805e-40c25f41f8b0" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold_8387402d-7073-430c-81df-4dee0166d8a6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_DisposalGroupIncludingDiscontinuedOperationClaimsExpense_cf9021d0-ba10-46a0-95b0-063879537628" xlink:href="evh-20211231.xsd#evh_DisposalGroupIncludingDiscontinuedOperationClaimsExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_643b7864-6279-451d-805e-40c25f41f8b0" xlink:to="loc_evh_DisposalGroupIncludingDiscontinuedOperationClaimsExpense_cf9021d0-ba10-46a0-95b0-063879537628" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense_99e1ab62-ef1a-4f5f-b426-5721c79a4120" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_643b7864-6279-451d-805e-40c25f41f8b0" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense_99e1ab62-ef1a-4f5f-b426-5721c79a4120" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationAndAmortizationDiscontinuedOperations_ab0fc99c-2aa7-40dd-b95f-d067f59c2810" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationAndAmortizationDiscontinuedOperations"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_643b7864-6279-451d-805e-40c25f41f8b0" xlink:to="loc_us-gaap_DepreciationAndAmortizationDiscontinuedOperations_ab0fc99c-2aa7-40dd-b95f-d067f59c2810" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense_39db1f93-237a-4b7d-9b09-4add990cfc18" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_643b7864-6279-451d-805e-40c25f41f8b0" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense_39db1f93-237a-4b7d-9b09-4add990cfc18" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss_3badc631-9f98-4910-934a-2c530737d9e2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_56712d55-ae35-433a-b5fe-d84d9212d520" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss_3badc631-9f98-4910-934a-2c530737d9e2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationInterestIncome_282fcaef-263e-4b68-9789-4bf8da1aa868" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationInterestIncome"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_56712d55-ae35-433a-b5fe-d84d9212d520" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationInterestIncome_282fcaef-263e-4b68-9789-4bf8da1aa868" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationInterestExpense_1307a8a0-08b2-4102-aac5-234bd1a6a282" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationInterestExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_56712d55-ae35-433a-b5fe-d84d9212d520" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationInterestExpense_1307a8a0-08b2-4102-aac5-234bd1a6a282" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherExpense_cbf1484d-5bdf-4a48-9416-92606fada8e8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_56712d55-ae35-433a-b5fe-d84d9212d520" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherExpense_cbf1484d-5bdf-4a48-9416-92606fada8e8" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax_7bfd4dff-4966-4cf8-aebe-44976cad7786" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_56712d55-ae35-433a-b5fe-d84d9212d520" xlink:to="loc_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax_7bfd4dff-4966-4cf8-aebe-44976cad7786" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation_fbc58c00-b57d-46c2-8d5b-38c6b6331c61" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_56712d55-ae35-433a-b5fe-d84d9212d520" xlink:to="loc_us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation_fbc58c00-b57d-46c2-8d5b-38c6b6331c61" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_7a798d31-a032-4495-954c-72f96a14313c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_56712d55-ae35-433a-b5fe-d84d9212d520" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_7a798d31-a032-4495-954c-72f96a14313c" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_7bf4ab19-06fb-49e2-90f5-fe73cef4480d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_56712d55-ae35-433a-b5fe-d84d9212d520" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_7bf4ab19-06fb-49e2-90f5-fe73cef4480d" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis_ef7f3cef-f3b4-44f8-9404-e08979c13995" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupClassificationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_7bf4ab19-06fb-49e2-90f5-fe73cef4480d" xlink:to="loc_us-gaap_DisposalGroupClassificationAxis_ef7f3cef-f3b4-44f8-9404-e08979c13995" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_ef7f3cef-f3b4-44f8-9404-e08979c13995_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_ef7f3cef-f3b4-44f8-9404-e08979c13995" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_ef7f3cef-f3b4-44f8-9404-e08979c13995_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_91a6685e-e2d4-4708-8ddb-ab3605ace180" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_ef7f3cef-f3b4-44f8-9404-e08979c13995" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_91a6685e-e2d4-4708-8ddb-ab3605ace180" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationsDisposedOfBySaleMember_c9f5030c-0a2b-477a-9b9e-ef8b0f7298d2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DiscontinuedOperationsDisposedOfBySaleMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain_91a6685e-e2d4-4708-8ddb-ab3605ace180" xlink:to="loc_us-gaap_DiscontinuedOperationsDisposedOfBySaleMember_c9f5030c-0a2b-477a-9b9e-ef8b0f7298d2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_bd7c187b-0cfd-4e5d-83e4-1810870729fe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_7bf4ab19-06fb-49e2-90f5-fe73cef4480d" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_bd7c187b-0cfd-4e5d-83e4-1810870729fe" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_bd7c187b-0cfd-4e5d-83e4-1810870729fe_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_bd7c187b-0cfd-4e5d-83e4-1810870729fe" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_bd7c187b-0cfd-4e5d-83e4-1810870729fe_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_25b780a6-8163-41d3-993d-7fc1f09d97c9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_bd7c187b-0cfd-4e5d-83e4-1810870729fe" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_25b780a6-8163-41d3-993d-7fc1f09d97c9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_TrueHealthMember_3bd5de44-c61b-41f0-9911-68e385524763" xlink:href="evh-20211231.xsd#evh_TrueHealthMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_25b780a6-8163-41d3-993d-7fc1f09d97c9" xlink:to="loc_evh_TrueHealthMember_3bd5de44-c61b-41f0-9911-68e385524763" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_1139854f-9aa6-431d-ac92-661b97c4ad64" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_7bf4ab19-06fb-49e2-90f5-fe73cef4480d" xlink:to="loc_srt_ProductOrServiceAxis_1139854f-9aa6-431d-ac92-661b97c4ad64" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_1139854f-9aa6-431d-ac92-661b97c4ad64_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_1139854f-9aa6-431d-ac92-661b97c4ad64" xlink:to="loc_srt_ProductsAndServicesDomain_1139854f-9aa6-431d-ac92-661b97c4ad64_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_dacaffe9-2bd7-40fa-947e-11d268ab4645" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_1139854f-9aa6-431d-ac92-661b97c4ad64" xlink:to="loc_srt_ProductsAndServicesDomain_dacaffe9-2bd7-40fa-947e-11d268ab4645" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_PlatformsAndOperationsServicesMember_0730d201-52f0-4c39-9991-abf0eccd2a57" xlink:href="evh-20211231.xsd#evh_PlatformsAndOperationsServicesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_dacaffe9-2bd7-40fa-947e-11d268ab4645" xlink:to="loc_evh_PlatformsAndOperationsServicesMember_0730d201-52f0-4c39-9991-abf0eccd2a57" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_PremiumsRevenueMember_f8e4f990-67c4-41c1-86c4-f3e93ae1c30c" xlink:href="evh-20211231.xsd#evh_PremiumsRevenueMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_dacaffe9-2bd7-40fa-947e-11d268ab4645" xlink:to="loc_evh_PremiumsRevenueMember_f8e4f990-67c4-41c1-86c4-f3e93ae1c30c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_ServicesAgreementsMember_e9fb7370-733f-4b68-ac69-b9510c9a2ee6" xlink:href="evh-20211231.xsd#evh_ServicesAgreementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_dacaffe9-2bd7-40fa-947e-11d268ab4645" xlink:to="loc_evh_ServicesAgreementsMember_e9fb7370-733f-4b68-ac69-b9510c9a2ee6" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/DiscontinuedOperationsSummaryofCashFlowsDetails" xlink:type="simple" xlink:href="evh-20211231.xsd#DiscontinuedOperationsSummaryofCashFlowsDetails"/>
  <link:definitionLink xlink:role="http://www.evolenthealth.com/role/DiscontinuedOperationsSummaryofCashFlowsDetails" xlink:type="extended" id="i22dfd6ddd17941bc8c7cf8fa020871f1_DiscontinuedOperationsSummaryofCashFlowsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_8538adfc-11a6-4298-b0f7-16f1fb265df6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations_fdd43acc-1caf-407b-81c9-f022f8a59340" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_8538adfc-11a6-4298-b0f7-16f1fb265df6" xlink:to="loc_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations_fdd43acc-1caf-407b-81c9-f022f8a59340" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations_9bdb6473-df80-413f-b046-4fc206c25996" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_8538adfc-11a6-4298-b0f7-16f1fb265df6" xlink:to="loc_us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations_9bdb6473-df80-413f-b046-4fc206c25996" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations_6e858919-838e-443f-bf66-7f441bf160f2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_8538adfc-11a6-4298-b0f7-16f1fb265df6" xlink:to="loc_us-gaap_CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations_6e858919-838e-443f-bf66-7f441bf160f2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_34082644-cd9c-49e6-a91a-1c4bf5bfe434" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_8538adfc-11a6-4298-b0f7-16f1fb265df6" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_34082644-cd9c-49e6-a91a-1c4bf5bfe434" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_3bdb7b7f-d500-4778-9ea0-2d12db5260c5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_34082644-cd9c-49e6-a91a-1c4bf5bfe434" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_3bdb7b7f-d500-4778-9ea0-2d12db5260c5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_3bdb7b7f-d500-4778-9ea0-2d12db5260c5_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_3bdb7b7f-d500-4778-9ea0-2d12db5260c5" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_3bdb7b7f-d500-4778-9ea0-2d12db5260c5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_41df7aa9-1965-41e3-8e7a-23cc5818bec6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_3bdb7b7f-d500-4778-9ea0-2d12db5260c5" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_41df7aa9-1965-41e3-8e7a-23cc5818bec6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_TrueHealthMember_a5263845-eafb-48d8-bfcf-be4ccf37a769" xlink:href="evh-20211231.xsd#evh_TrueHealthMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_41df7aa9-1965-41e3-8e7a-23cc5818bec6" xlink:to="loc_evh_TrueHealthMember_a5263845-eafb-48d8-bfcf-be4ccf37a769" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis_f4b22bfd-a167-4258-9d68-7ac53420baad" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupClassificationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_34082644-cd9c-49e6-a91a-1c4bf5bfe434" xlink:to="loc_us-gaap_DisposalGroupClassificationAxis_f4b22bfd-a167-4258-9d68-7ac53420baad" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_f4b22bfd-a167-4258-9d68-7ac53420baad_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_f4b22bfd-a167-4258-9d68-7ac53420baad" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_f4b22bfd-a167-4258-9d68-7ac53420baad_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_0740520b-518e-4694-b637-bd1a3f90b585" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_f4b22bfd-a167-4258-9d68-7ac53420baad" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_0740520b-518e-4694-b637-bd1a3f90b585" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationsDisposedOfBySaleMember_97c7b398-6d08-4847-bfc6-527858d51527" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DiscontinuedOperationsDisposedOfBySaleMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain_0740520b-518e-4694-b637-bd1a3f90b585" xlink:to="loc_us-gaap_DiscontinuedOperationsDisposedOfBySaleMember_97c7b398-6d08-4847-bfc6-527858d51527" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/DiscontinuedOperationsSummaryofCurrentandLongtermAssetsandLiabilitiesDetails" xlink:type="simple" xlink:href="evh-20211231.xsd#DiscontinuedOperationsSummaryofCurrentandLongtermAssetsandLiabilitiesDetails"/>
  <link:definitionLink xlink:role="http://www.evolenthealth.com/role/DiscontinuedOperationsSummaryofCurrentandLongtermAssetsandLiabilitiesDetails" xlink:type="extended" id="ib02b3064ec40448cab5da77e8898a35f_DiscontinuedOperationsSummaryofCurrentandLongtermAssetsandLiabilitiesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_5dd6954b-5ad3-4c11-8160-33e91059c057" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationAbstract_41b58b64-fe30-43fb-8b89-1f877e081023" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_5dd6954b-5ad3-4c11-8160-33e91059c057" xlink:to="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationAbstract_41b58b64-fe30-43fb-8b89-1f877e081023" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract_5d77a8e9-811a-426a-8bfd-1ce48f7e94e8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationAbstract_41b58b64-fe30-43fb-8b89-1f877e081023" xlink:to="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract_5d77a8e9-811a-426a-8bfd-1ce48f7e94e8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents_12849716-458a-4d8c-ad20-2646efeb6fd5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract_5d77a8e9-811a-426a-8bfd-1ce48f7e94e8" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents_12849716-458a-4d8c-ad20-2646efeb6fd5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_DisposalGroupIncludingDiscontinuedOperationRestrictedCashAndRestrictedInvestmentsCurrent_59f7d7af-44e3-44db-873b-488c8c31503f" xlink:href="evh-20211231.xsd#evh_DisposalGroupIncludingDiscontinuedOperationRestrictedCashAndRestrictedInvestmentsCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract_5d77a8e9-811a-426a-8bfd-1ce48f7e94e8" xlink:to="loc_evh_DisposalGroupIncludingDiscontinuedOperationRestrictedCashAndRestrictedInvestmentsCurrent_59f7d7af-44e3-44db-873b-488c8c31503f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet_4cf5556e-679e-4ce2-a66a-d44a4356230d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract_5d77a8e9-811a-426a-8bfd-1ce48f7e94e8" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet_4cf5556e-679e-4ce2-a66a-d44a4356230d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent_278cb7e9-e781-42b9-99fc-092aa449c46f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract_5d77a8e9-811a-426a-8bfd-1ce48f7e94e8" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent_278cb7e9-e781-42b9-99fc-092aa449c46f" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_DisposalGroupIncludingDiscontinuedOperationInvestmentsCurrent_39e23660-e26f-4f8c-8082-c92302803b59" xlink:href="evh-20211231.xsd#evh_DisposalGroupIncludingDiscontinuedOperationInvestmentsCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract_5d77a8e9-811a-426a-8bfd-1ce48f7e94e8" xlink:to="loc_evh_DisposalGroupIncludingDiscontinuedOperationInvestmentsCurrent_39e23660-e26f-4f8c-8082-c92302803b59" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent_3a077422-a6ed-41a5-bc03-834c8dfd9086" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract_5d77a8e9-811a-426a-8bfd-1ce48f7e94e8" xlink:to="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent_3a077422-a6ed-41a5-bc03-834c8dfd9086" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_DisposalGroupIncludingDiscontinuedOperationRestrictedCashAndRestrictedInvestmentsNoncurrent_5c475737-d586-44f2-9207-ac9cc6f4f041" xlink:href="evh-20211231.xsd#evh_DisposalGroupIncludingDiscontinuedOperationRestrictedCashAndRestrictedInvestmentsNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationAbstract_41b58b64-fe30-43fb-8b89-1f877e081023" xlink:to="loc_evh_DisposalGroupIncludingDiscontinuedOperationRestrictedCashAndRestrictedInvestmentsNoncurrent_5c475737-d586-44f2-9207-ac9cc6f4f041" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_DisposalGroupIncludingDiscontinuedOperationInvestmentsNoncurrent_6d871824-6677-44e0-8e73-99e8b325e310" xlink:href="evh-20211231.xsd#evh_DisposalGroupIncludingDiscontinuedOperationInvestmentsNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationAbstract_41b58b64-fe30-43fb-8b89-1f877e081023" xlink:to="loc_evh_DisposalGroupIncludingDiscontinuedOperationInvestmentsNoncurrent_6d871824-6677-44e0-8e73-99e8b325e310" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsNoncurrent_3d8e1c30-3576-4f7f-a443-273e1ada75f4" xlink:href="evh-20211231.xsd#evh_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationAbstract_41b58b64-fe30-43fb-8b89-1f877e081023" xlink:to="loc_evh_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsNoncurrent_3d8e1c30-3576-4f7f-a443-273e1ada75f4" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsNoncurrent_293c72b4-02bd-4477-8a39-935c5c7fcc84" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationAbstract_41b58b64-fe30-43fb-8b89-1f877e081023" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsNoncurrent_293c72b4-02bd-4477-8a39-935c5c7fcc84" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwillNoncurrent_4b16478f-975d-4ccb-8422-98701b9c2666" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwillNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationAbstract_41b58b64-fe30-43fb-8b89-1f877e081023" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwillNoncurrent_4b16478f-975d-4ccb-8422-98701b9c2666" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation_b01435a0-7fcc-4262-976a-a96bb4023947" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationAbstract_41b58b64-fe30-43fb-8b89-1f877e081023" xlink:to="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation_b01435a0-7fcc-4262-976a-a96bb4023947" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationAbstract_6b664e64-56d6-4fd7-be8a-a61b068a2073" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_5dd6954b-5ad3-4c11-8160-33e91059c057" xlink:to="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationAbstract_6b664e64-56d6-4fd7-be8a-a61b068a2073" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract_b15c64e6-9098-4c04-aea1-9055495e2f44" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationAbstract_6b664e64-56d6-4fd7-be8a-a61b068a2073" xlink:to="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract_b15c64e6-9098-4c04-aea1-9055495e2f44" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayableCurrent_7c15abec-8bd6-4f7a-a1a0-7506752cd644" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayableCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract_b15c64e6-9098-4c04-aea1-9055495e2f44" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayableCurrent_7c15abec-8bd6-4f7a-a1a0-7506752cd644" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilitiesCurrent_5d7c2b2c-6a84-4af4-a785-12226aa5d6ab" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilitiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract_b15c64e6-9098-4c04-aea1-9055495e2f44" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilitiesCurrent_5d7c2b2c-6a84-4af4-a785-12226aa5d6ab" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_DisposalGroupIncludingDiscontinuedOperationAccruedCompensationAndEmployeeBenefitsCurrent_926f8294-5fd3-483b-993f-ba69327c7189" xlink:href="evh-20211231.xsd#evh_DisposalGroupIncludingDiscontinuedOperationAccruedCompensationAndEmployeeBenefitsCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract_b15c64e6-9098-4c04-aea1-9055495e2f44" xlink:to="loc_evh_DisposalGroupIncludingDiscontinuedOperationAccruedCompensationAndEmployeeBenefitsCurrent_926f8294-5fd3-483b-993f-ba69327c7189" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredRevenueCurrent_527159f7-f7f0-4051-a5c2-85967033ed58" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredRevenueCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract_b15c64e6-9098-4c04-aea1-9055495e2f44" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredRevenueCurrent_527159f7-f7f0-4051-a5c2-85967033ed58" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_DisposalGroupIncludingDiscontinuedOperationLiabilityForFuturePolicyBenefitsAndUnpaidClaimsAndClaimsAdjustmentExpenseAndPerformanceBasedArrangementsCurrent_77bc7b79-0b34-46fc-9cbb-9b95cbb8921e" xlink:href="evh-20211231.xsd#evh_DisposalGroupIncludingDiscontinuedOperationLiabilityForFuturePolicyBenefitsAndUnpaidClaimsAndClaimsAdjustmentExpenseAndPerformanceBasedArrangementsCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract_b15c64e6-9098-4c04-aea1-9055495e2f44" xlink:to="loc_evh_DisposalGroupIncludingDiscontinuedOperationLiabilityForFuturePolicyBenefitsAndUnpaidClaimsAndClaimsAdjustmentExpenseAndPerformanceBasedArrangementsCurrent_77bc7b79-0b34-46fc-9cbb-9b95cbb8921e" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent_1f289b00-f9d7-43aa-93d2-0dddd2ed0d36" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract_b15c64e6-9098-4c04-aea1-9055495e2f44" xlink:to="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent_1f289b00-f9d7-43aa-93d2-0dddd2ed0d36" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentLiabilities_7917d409-c6c9-4ec7-8f74-fec59ef67b13" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationAbstract_6b664e64-56d6-4fd7-be8a-a61b068a2073" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentLiabilities_7917d409-c6c9-4ec7-8f74-fec59ef67b13" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredTaxLiabilities_98e8e8dc-3ba6-47f9-a850-157e070fc0f2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredTaxLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationAbstract_6b664e64-56d6-4fd7-be8a-a61b068a2073" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredTaxLiabilities_98e8e8dc-3ba6-47f9-a850-157e070fc0f2" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation_ecb47b40-3ede-4dd8-bc72-68d85a7ab019" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationAbstract_6b664e64-56d6-4fd7-be8a-a61b068a2073" xlink:to="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation_ecb47b40-3ede-4dd8-bc72-68d85a7ab019" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_6f8783bd-7b86-47b4-b481-30fee5134253" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_5dd6954b-5ad3-4c11-8160-33e91059c057" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_6f8783bd-7b86-47b4-b481-30fee5134253" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_522530ca-fbf8-471d-a239-ef7bc66fb600" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_6f8783bd-7b86-47b4-b481-30fee5134253" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_522530ca-fbf8-471d-a239-ef7bc66fb600" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_522530ca-fbf8-471d-a239-ef7bc66fb600_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_522530ca-fbf8-471d-a239-ef7bc66fb600" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_522530ca-fbf8-471d-a239-ef7bc66fb600_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_08e9a48a-ab7b-428d-9528-f7fe07f86d97" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_522530ca-fbf8-471d-a239-ef7bc66fb600" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_08e9a48a-ab7b-428d-9528-f7fe07f86d97" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_TrueHealthMember_c6268482-19d6-4b16-8f22-3bbcbf4bed73" xlink:href="evh-20211231.xsd#evh_TrueHealthMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_08e9a48a-ab7b-428d-9528-f7fe07f86d97" xlink:to="loc_evh_TrueHealthMember_c6268482-19d6-4b16-8f22-3bbcbf4bed73" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis_9665538d-e280-4274-9b59-788fafc45747" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupClassificationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_6f8783bd-7b86-47b4-b481-30fee5134253" xlink:to="loc_us-gaap_DisposalGroupClassificationAxis_9665538d-e280-4274-9b59-788fafc45747" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_9665538d-e280-4274-9b59-788fafc45747_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_9665538d-e280-4274-9b59-788fafc45747" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_9665538d-e280-4274-9b59-788fafc45747_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_3e937047-868c-47fb-9cc2-e734eaf5d2d8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_9665538d-e280-4274-9b59-788fafc45747" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_3e937047-868c-47fb-9cc2-e734eaf5d2d8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationsDisposedOfBySaleMember_7e63142b-214e-42e1-a4d6-f979e8facf0f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DiscontinuedOperationsDisposedOfBySaleMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain_3e937047-868c-47fb-9cc2-e734eaf5d2d8" xlink:to="loc_us-gaap_DiscontinuedOperationsDisposedOfBySaleMember_7e63142b-214e-42e1-a4d6-f979e8facf0f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_97f1c77a-bcea-4611-82bc-af29f5f5bd6c" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_6f8783bd-7b86-47b4-b481-30fee5134253" xlink:to="loc_srt_ProductOrServiceAxis_97f1c77a-bcea-4611-82bc-af29f5f5bd6c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_97f1c77a-bcea-4611-82bc-af29f5f5bd6c_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_97f1c77a-bcea-4611-82bc-af29f5f5bd6c" xlink:to="loc_srt_ProductsAndServicesDomain_97f1c77a-bcea-4611-82bc-af29f5f5bd6c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_bcb4b3d5-c10f-4677-9668-9d335c7c2281" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_97f1c77a-bcea-4611-82bc-af29f5f5bd6c" xlink:to="loc_srt_ProductsAndServicesDomain_bcb4b3d5-c10f-4677-9668-9d335c7c2281" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_ServicesAgreementsMember_aafeccc8-e402-4a95-be83-47c8ac0901fa" xlink:href="evh-20211231.xsd#evh_ServicesAgreementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_bcb4b3d5-c10f-4677-9668-9d335c7c2281" xlink:to="loc_evh_ServicesAgreementsMember_aafeccc8-e402-4a95-be83-47c8ac0901fa" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/RevenueRecognitionDisaggregationofRevenueDetails" xlink:type="simple" xlink:href="evh-20211231.xsd#RevenueRecognitionDisaggregationofRevenueDetails"/>
  <link:definitionLink xlink:role="http://www.evolenthealth.com/role/RevenueRecognitionDisaggregationofRevenueDetails" xlink:type="extended" id="id1530067dce344dd85d0a324c6009b9b_RevenueRecognitionDisaggregationofRevenueDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_aa323d5d-6266-4b69-8982-84105deef681" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_33967ec8-302b-4626-9533-1c8a2ebd813d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_aa323d5d-6266-4b69-8982-84105deef681" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_33967ec8-302b-4626-9533-1c8a2ebd813d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_f960d9c1-f96e-4c26-b81a-f7001ca68f64" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_aa323d5d-6266-4b69-8982-84105deef681" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_f960d9c1-f96e-4c26-b81a-f7001ca68f64" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_a0a4af27-5ccc-4af5-9f80-bdddb1982d03" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_f960d9c1-f96e-4c26-b81a-f7001ca68f64" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_a0a4af27-5ccc-4af5-9f80-bdddb1982d03" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_a0a4af27-5ccc-4af5-9f80-bdddb1982d03_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_a0a4af27-5ccc-4af5-9f80-bdddb1982d03" xlink:to="loc_us-gaap_SegmentDomain_a0a4af27-5ccc-4af5-9f80-bdddb1982d03_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_361ee94f-2e90-48dd-8e3a-dea052b9fc43" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_a0a4af27-5ccc-4af5-9f80-bdddb1982d03" xlink:to="loc_us-gaap_SegmentDomain_361ee94f-2e90-48dd-8e3a-dea052b9fc43" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_EvolentHealthServicesSegmentMember_6915c65c-1dd2-43b0-a60e-406cfefdc098" xlink:href="evh-20211231.xsd#evh_EvolentHealthServicesSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_361ee94f-2e90-48dd-8e3a-dea052b9fc43" xlink:to="loc_evh_EvolentHealthServicesSegmentMember_6915c65c-1dd2-43b0-a60e-406cfefdc098" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_ClinicalSolutionsSegmentMember_ce22a4cb-1e33-4a3c-b802-69e91a41eb8b" xlink:href="evh-20211231.xsd#evh_ClinicalSolutionsSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_361ee94f-2e90-48dd-8e3a-dea052b9fc43" xlink:to="loc_evh_ClinicalSolutionsSegmentMember_ce22a4cb-1e33-4a3c-b802-69e91a41eb8b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_0cb703eb-6824-40e2-ae94-d82d07526cd2" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MajorCustomersAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_f960d9c1-f96e-4c26-b81a-f7001ca68f64" xlink:to="loc_srt_MajorCustomersAxis_0cb703eb-6824-40e2-ae94-d82d07526cd2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_0cb703eb-6824-40e2-ae94-d82d07526cd2_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_MajorCustomersAxis_0cb703eb-6824-40e2-ae94-d82d07526cd2" xlink:to="loc_srt_NameOfMajorCustomerDomain_0cb703eb-6824-40e2-ae94-d82d07526cd2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_f1c62ed5-6e4d-4668-b36b-42c244fda8a0" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_MajorCustomersAxis_0cb703eb-6824-40e2-ae94-d82d07526cd2" xlink:to="loc_srt_NameOfMajorCustomerDomain_f1c62ed5-6e4d-4668-b36b-42c244fda8a0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_MedicaidCustomersMember_234d8bfe-673a-4f92-b20f-e4023d075a2e" xlink:href="evh-20211231.xsd#evh_MedicaidCustomersMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_f1c62ed5-6e4d-4668-b36b-42c244fda8a0" xlink:to="loc_evh_MedicaidCustomersMember_234d8bfe-673a-4f92-b20f-e4023d075a2e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_MedicareCustomersMember_984a45bf-e8b9-4dd5-a4c1-5dbbc40f1ebc" xlink:href="evh-20211231.xsd#evh_MedicareCustomersMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_f1c62ed5-6e4d-4668-b36b-42c244fda8a0" xlink:to="loc_evh_MedicareCustomersMember_984a45bf-e8b9-4dd5-a4c1-5dbbc40f1ebc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_CommercialAndOtherCustomersMember_50b17bde-0dbb-4420-98a6-2b4e0357fca4" xlink:href="evh-20211231.xsd#evh_CommercialAndOtherCustomersMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_f1c62ed5-6e4d-4668-b36b-42c244fda8a0" xlink:to="loc_evh_CommercialAndOtherCustomersMember_50b17bde-0dbb-4420-98a6-2b4e0357fca4" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/RevenueRecognitionTransactionPriceAllocatedtotheRemainingPerformanceObligationsDetails" xlink:type="simple" xlink:href="evh-20211231.xsd#RevenueRecognitionTransactionPriceAllocatedtotheRemainingPerformanceObligationsDetails"/>
  <link:definitionLink xlink:role="http://www.evolenthealth.com/role/RevenueRecognitionTransactionPriceAllocatedtotheRemainingPerformanceObligationsDetails" xlink:type="extended" id="i85daa102c58e47ca9d1c51d2e0caf47e_RevenueRecognitionTransactionPriceAllocatedtotheRemainingPerformanceObligationsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_3d2a97bb-ea00-4e42-95ea-eac69fa5acb1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationPercentage_72dfc811-2d02-4794-8516-30df269b545a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligationPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_3d2a97bb-ea00-4e42-95ea-eac69fa5acb1" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligationPercentage_72dfc811-2d02-4794-8516-30df269b545a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1_bed390a7-6b25-4c36-a10d-8ae0bc459bdb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_3d2a97bb-ea00-4e42-95ea-eac69fa5acb1" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1_bed390a7-6b25-4c36-a10d-8ae0bc459bdb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable_6ac7de58-f2ce-4be8-a102-9cb8e79eb0f1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_3d2a97bb-ea00-4e42-95ea-eac69fa5acb1" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable_6ac7de58-f2ce-4be8-a102-9cb8e79eb0f1" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_3f7b20f8-691f-4a06-9d7d-0e48e65e4958" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable_6ac7de58-f2ce-4be8-a102-9cb8e79eb0f1" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_3f7b20f8-691f-4a06-9d7d-0e48e65e4958" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/RevenueRecognitionTransactionPriceAllocatedtotheRemainingPerformanceObligationsDetails_1" xlink:type="simple" xlink:href="evh-20211231.xsd#RevenueRecognitionTransactionPriceAllocatedtotheRemainingPerformanceObligationsDetails_1"/>
  <link:definitionLink xlink:role="http://www.evolenthealth.com/role/RevenueRecognitionTransactionPriceAllocatedtotheRemainingPerformanceObligationsDetails_1" xlink:type="extended" id="ic636b8942aaa4235834b1eb06e7a96a1_RevenueRecognitionTransactionPriceAllocatedtotheRemainingPerformanceObligationsDetails_1">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_3d2a97bb-ea00-4e42-95ea-eac69fa5acb1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationPercentage_72dfc811-2d02-4794-8516-30df269b545a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligationPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_3d2a97bb-ea00-4e42-95ea-eac69fa5acb1" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligationPercentage_72dfc811-2d02-4794-8516-30df269b545a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1_bed390a7-6b25-4c36-a10d-8ae0bc459bdb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_3d2a97bb-ea00-4e42-95ea-eac69fa5acb1" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1_bed390a7-6b25-4c36-a10d-8ae0bc459bdb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable_6ac7de58-f2ce-4be8-a102-9cb8e79eb0f1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_3d2a97bb-ea00-4e42-95ea-eac69fa5acb1" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable_6ac7de58-f2ce-4be8-a102-9cb8e79eb0f1" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/RevenueRecognitionContractBalancesDetails" xlink:type="simple" xlink:href="evh-20211231.xsd#RevenueRecognitionContractBalancesDetails"/>
  <link:definitionLink xlink:role="http://www.evolenthealth.com/role/RevenueRecognitionContractBalancesDetails" xlink:type="extended" id="i3b5ba0b27586462d871321cb9aebdc3f_RevenueRecognitionContractBalancesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_f5fca36c-ae96-4b74-bdc0-bc78237f7f98" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNetAfterGrossUp_b641250f-0928-4949-9888-72407c91b398" xlink:href="evh-20211231.xsd#evh_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNetAfterGrossUp"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_f5fca36c-ae96-4b74-bdc0-bc78237f7f98" xlink:to="loc_evh_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNetAfterGrossUp_b641250f-0928-4949-9888-72407c91b398" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredRevenueCurrent_91e8801d-1212-4eb2-ac41-f3794c350533" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredRevenueCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_f5fca36c-ae96-4b74-bdc0-bc78237f7f98" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredRevenueCurrent_91e8801d-1212-4eb2-ac41-f3794c350533" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_d6d86b6a-8832-481f-aaeb-48affe401e58" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_f5fca36c-ae96-4b74-bdc0-bc78237f7f98" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_d6d86b6a-8832-481f-aaeb-48affe401e58" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis_2a665cd1-7c3c-45b8-a382-5a334823f83c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupClassificationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_d6d86b6a-8832-481f-aaeb-48affe401e58" xlink:to="loc_us-gaap_DisposalGroupClassificationAxis_2a665cd1-7c3c-45b8-a382-5a334823f83c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_2a665cd1-7c3c-45b8-a382-5a334823f83c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_2a665cd1-7c3c-45b8-a382-5a334823f83c" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_2a665cd1-7c3c-45b8-a382-5a334823f83c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_9ee080d6-3c13-4db7-98eb-4f75f54c183e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_2a665cd1-7c3c-45b8-a382-5a334823f83c" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_9ee080d6-3c13-4db7-98eb-4f75f54c183e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationsDisposedOfBySaleMember_5eecdedd-b2dc-4d6c-bcc9-60d2ada7b340" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DiscontinuedOperationsDisposedOfBySaleMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain_9ee080d6-3c13-4db7-98eb-4f75f54c183e" xlink:to="loc_us-gaap_DiscontinuedOperationsDisposedOfBySaleMember_5eecdedd-b2dc-4d6c-bcc9-60d2ada7b340" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_4af7e26b-0c78-4ab6-8020-799357d74968" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_d6d86b6a-8832-481f-aaeb-48affe401e58" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_4af7e26b-0c78-4ab6-8020-799357d74968" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_4af7e26b-0c78-4ab6-8020-799357d74968_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_4af7e26b-0c78-4ab6-8020-799357d74968" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_4af7e26b-0c78-4ab6-8020-799357d74968_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_a4af8e5f-9cc7-4a6c-8671-a19c4b9514e0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_4af7e26b-0c78-4ab6-8020-799357d74968" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_a4af8e5f-9cc7-4a6c-8671-a19c4b9514e0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_TrueHealthMember_4a93de11-6c4d-4f64-b5fd-c91343067089" xlink:href="evh-20211231.xsd#evh_TrueHealthMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_a4af8e5f-9cc7-4a6c-8671-a19c4b9514e0" xlink:to="loc_evh_TrueHealthMember_4a93de11-6c4d-4f64-b5fd-c91343067089" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/RevenueRecognitionContractCostsDetails" xlink:type="simple" xlink:href="evh-20211231.xsd#RevenueRecognitionContractCostsDetails"/>
  <link:definitionLink xlink:role="http://www.evolenthealth.com/role/RevenueRecognitionContractCostsDetails" xlink:type="extended" id="i3139416f14af4bf292518b05870ea725_RevenueRecognitionContractCostsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedContractCostLineItems_1650f683-87c8-4652-a914-bf9e9fc27f6d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalizedContractCostLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedContractCostNet_1ef22d58-ea25-4552-8399-5ff66e8c3670" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalizedContractCostNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CapitalizedContractCostLineItems_1650f683-87c8-4652-a914-bf9e9fc27f6d" xlink:to="loc_us-gaap_CapitalizedContractCostNet_1ef22d58-ea25-4552-8399-5ff66e8c3670" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedContractCostAmortization_2ef0d5ac-65f5-4c08-919b-b07cc25e1938" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalizedContractCostAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CapitalizedContractCostLineItems_1650f683-87c8-4652-a914-bf9e9fc27f6d" xlink:to="loc_us-gaap_CapitalizedContractCostAmortization_2ef0d5ac-65f5-4c08-919b-b07cc25e1938" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedContractCostAmortizationPeriod_76715689-4b96-461a-a6c7-507cdd7d3a0b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalizedContractCostAmortizationPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CapitalizedContractCostLineItems_1650f683-87c8-4652-a914-bf9e9fc27f6d" xlink:to="loc_us-gaap_CapitalizedContractCostAmortizationPeriod_76715689-4b96-461a-a6c7-507cdd7d3a0b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedContractCostTable_8c28117f-bf74-4aa4-8d95-da7d8d73869b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalizedContractCostTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CapitalizedContractCostLineItems_1650f683-87c8-4652-a914-bf9e9fc27f6d" xlink:to="loc_us-gaap_CapitalizedContractCostTable_8c28117f-bf74-4aa4-8d95-da7d8d73869b" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedContractCostAxis_43344c3b-148b-47ab-9fed-6dcd780b7378" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalizedContractCostAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_CapitalizedContractCostTable_8c28117f-bf74-4aa4-8d95-da7d8d73869b" xlink:to="loc_us-gaap_CapitalizedContractCostAxis_43344c3b-148b-47ab-9fed-6dcd780b7378" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedContractCostDomain_43344c3b-148b-47ab-9fed-6dcd780b7378_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalizedContractCostDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CapitalizedContractCostAxis_43344c3b-148b-47ab-9fed-6dcd780b7378" xlink:to="loc_us-gaap_CapitalizedContractCostDomain_43344c3b-148b-47ab-9fed-6dcd780b7378_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedContractCostDomain_25907e1b-60c6-4ca7-ae4a-3bb71cde7368" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalizedContractCostDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CapitalizedContractCostAxis_43344c3b-148b-47ab-9fed-6dcd780b7378" xlink:to="loc_us-gaap_CapitalizedContractCostDomain_25907e1b-60c6-4ca7-ae4a-3bb71cde7368" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_BonusesAndCommissionsMember_53677fec-856b-4f87-bbac-8278a50e4c99" xlink:href="evh-20211231.xsd#evh_BonusesAndCommissionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CapitalizedContractCostDomain_25907e1b-60c6-4ca7-ae4a-3bb71cde7368" xlink:to="loc_evh_BonusesAndCommissionsMember_53677fec-856b-4f87-bbac-8278a50e4c99" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_ContractFulfillmentCostsMember_c3cd18df-605f-4efd-897e-a38264931e27" xlink:href="evh-20211231.xsd#evh_ContractFulfillmentCostsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CapitalizedContractCostDomain_25907e1b-60c6-4ca7-ae4a-3bb71cde7368" xlink:to="loc_evh_ContractFulfillmentCostsMember_c3cd18df-605f-4efd-897e-a38264931e27" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/CreditLossesAccountsReceivableNarrativeDetails" xlink:type="simple" xlink:href="evh-20211231.xsd#CreditLossesAccountsReceivableNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.evolenthealth.com/role/CreditLossesAccountsReceivableNarrativeDetails" xlink:type="extended" id="i6353ee40667749b084813d46047d43ba_CreditLossesAccountsReceivableNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNoncurrentPastDueLineItems_5d4ac40f-8cee-4158-a682-f73391480498" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNoncurrentPastDueLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_FinancingReceivablePercentNotPastDue_31e4f473-c65b-4afb-be57-f2e47d42455d" xlink:href="evh-20211231.xsd#evh_FinancingReceivablePercentNotPastDue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccountsReceivableNoncurrentPastDueLineItems_5d4ac40f-8cee-4158-a682-f73391480498" xlink:to="loc_evh_FinancingReceivablePercentNotPastDue_31e4f473-c65b-4afb-be57-f2e47d42455d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancingReceivablePercentPastDue1_6ab64808-b536-4e46-8406-3298fd29b617" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancingReceivablePercentPastDue1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccountsReceivableNoncurrentPastDueLineItems_5d4ac40f-8cee-4158-a682-f73391480498" xlink:to="loc_us-gaap_FinancingReceivablePercentPastDue1_6ab64808-b536-4e46-8406-3298fd29b617" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNet_21a14d3e-5019-4f36-b57b-7ddd10d49e1d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccountsReceivableNoncurrentPastDueLineItems_5d4ac40f-8cee-4158-a682-f73391480498" xlink:to="loc_us-gaap_AccountsReceivableNet_21a14d3e-5019-4f36-b57b-7ddd10d49e1d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_42a7e7f3-4d8f-48e5-a707-356b5f131da5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccountsReceivableNoncurrentPastDueLineItems_5d4ac40f-8cee-4158-a682-f73391480498" xlink:to="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_42a7e7f3-4d8f-48e5-a707-356b5f131da5" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNoncurrentPastDueTable_9be176ed-8777-4804-b4d4-a7d5f4d846db" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNoncurrentPastDueTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AccountsReceivableNoncurrentPastDueLineItems_5d4ac40f-8cee-4158-a682-f73391480498" xlink:to="loc_us-gaap_AccountsReceivableNoncurrentPastDueTable_9be176ed-8777-4804-b4d4-a7d5f4d846db" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancingReceivablesPeriodPastDueAxis_ba60591a-0628-4028-a728-694eba294109" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancingReceivablesPeriodPastDueAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_AccountsReceivableNoncurrentPastDueTable_9be176ed-8777-4804-b4d4-a7d5f4d846db" xlink:to="loc_us-gaap_FinancingReceivablesPeriodPastDueAxis_ba60591a-0628-4028-a728-694eba294109" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancingReceivablesPeriodPastDueDomain_ba60591a-0628-4028-a728-694eba294109_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancingReceivablesPeriodPastDueDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancingReceivablesPeriodPastDueAxis_ba60591a-0628-4028-a728-694eba294109" xlink:to="loc_us-gaap_FinancingReceivablesPeriodPastDueDomain_ba60591a-0628-4028-a728-694eba294109_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancingReceivablesPeriodPastDueDomain_46a6a104-9038-4b6b-9552-bc2d2743e10a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancingReceivablesPeriodPastDueDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancingReceivablesPeriodPastDueAxis_ba60591a-0628-4028-a728-694eba294109" xlink:to="loc_us-gaap_FinancingReceivablesPeriodPastDueDomain_46a6a104-9038-4b6b-9552-bc2d2743e10a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_FInancialAssetLessThan60DaysMember_54f3d06e-7472-4dbc-954e-33045a1b4e8a" xlink:href="evh-20211231.xsd#evh_FInancialAssetLessThan60DaysMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FinancingReceivablesPeriodPastDueDomain_46a6a104-9038-4b6b-9552-bc2d2743e10a" xlink:to="loc_evh_FInancialAssetLessThan60DaysMember_54f3d06e-7472-4dbc-954e-33045a1b4e8a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_FInancialAssetLessThan120DaysPastDueMember_303d5d00-07b8-47ca-9477-3a940eb8b4f3" xlink:href="evh-20211231.xsd#evh_FInancialAssetLessThan120DaysPastDueMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FinancingReceivablesPeriodPastDueDomain_46a6a104-9038-4b6b-9552-bc2d2743e10a" xlink:to="loc_evh_FInancialAssetLessThan120DaysPastDueMember_303d5d00-07b8-47ca-9477-3a940eb8b4f3" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/CreditLossesScheduleofChangesinAllowanceforAccountsReceivableDetails" xlink:type="simple" xlink:href="evh-20211231.xsd#CreditLossesScheduleofChangesinAllowanceforAccountsReceivableDetails"/>
  <link:definitionLink xlink:role="http://www.evolenthealth.com/role/CreditLossesScheduleofChangesinAllowanceforAccountsReceivableDetails" xlink:type="extended" id="i2d57b1b5c8e8447e93a556dc3953ecd5_CreditLossesScheduleofChangesinAllowanceforAccountsReceivableDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_47c2a2ff-bfea-4e01-bb1d-b28e281b97aa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsNotesAndLoansReceivableLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward_a5d4a7ed-6f97-4434-9c4b-ff153a60a7b9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_47c2a2ff-bfea-4e01-bb1d-b28e281b97aa" xlink:to="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward_a5d4a7ed-6f97-4434-9c4b-ff153a60a7b9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_7fcd0e23-8519-4e93-af2b-60890b11a162" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward_a5d4a7ed-6f97-4434-9c4b-ff153a60a7b9" xlink:to="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_7fcd0e23-8519-4e93-af2b-60890b11a162" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_AccountsReceivableAllowanceForCreditLossAcquiredDuringPeriod_bc6e95c5-a29b-4a7d-b607-788f2d755257" xlink:href="evh-20211231.xsd#evh_AccountsReceivableAllowanceForCreditLossAcquiredDuringPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward_a5d4a7ed-6f97-4434-9c4b-ff153a60a7b9" xlink:to="loc_evh_AccountsReceivableAllowanceForCreditLossAcquiredDuringPeriod_bc6e95c5-a29b-4a7d-b607-788f2d755257" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProvisionForDoubtfulAccounts_86485208-1916-400b-8dfb-5262e57205ae" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProvisionForDoubtfulAccounts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward_a5d4a7ed-6f97-4434-9c4b-ff153a60a7b9" xlink:to="loc_us-gaap_ProvisionForDoubtfulAccounts_86485208-1916-400b-8dfb-5262e57205ae" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs_8c395da8-16c8-4412-879d-ef396278f158" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward_a5d4a7ed-6f97-4434-9c4b-ff153a60a7b9" xlink:to="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs_8c395da8-16c8-4412-879d-ef396278f158" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_f6d22b0a-cea0-4adb-986b-e42f6071db53" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_d707873c-6ece-4ad9-8016-ca4b0390bc71" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_47c2a2ff-bfea-4e01-bb1d-b28e281b97aa" xlink:to="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_d707873c-6ece-4ad9-8016-ca4b0390bc71" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_8aa09f74-c382-49dd-854d-0b655ae60f20" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_d707873c-6ece-4ad9-8016-ca4b0390bc71" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_8aa09f74-c382-49dd-854d-0b655ae60f20" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_8aa09f74-c382-49dd-854d-0b655ae60f20_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_8aa09f74-c382-49dd-854d-0b655ae60f20" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_8aa09f74-c382-49dd-854d-0b655ae60f20_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_df615443-fab0-4912-a201-a283229487e2" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_8aa09f74-c382-49dd-854d-0b655ae60f20" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_df615443-fab0-4912-a201-a283229487e2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_6bc9f5f6-b1e4-4626-a176-a52ef125e5f0" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_df615443-fab0-4912-a201-a283229487e2" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_6bc9f5f6-b1e4-4626-a176-a52ef125e5f0" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/PropertyandEquipmentNetDetails" xlink:type="simple" xlink:href="evh-20211231.xsd#PropertyandEquipmentNetDetails"/>
  <link:definitionLink xlink:role="http://www.evolenthealth.com/role/PropertyandEquipmentNetDetails" xlink:type="extended" id="i2773dd265a394f55bc50417da7a70a0f_PropertyandEquipmentNetDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_8580601b-ba4c-496f-81e0-2f35a0ddd371" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_05929645-b7a5-4b21-9709-ae37acf60752" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_8580601b-ba4c-496f-81e0-2f35a0ddd371" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_05929645-b7a5-4b21-9709-ae37acf60752" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_1b9bc7a1-8999-4f97-a860-deeda47ae3ca" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_8580601b-ba4c-496f-81e0-2f35a0ddd371" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_1b9bc7a1-8999-4f97-a860-deeda47ae3ca" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_070ee110-9478-429d-9d0d-1f4a57b61965" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_8580601b-ba4c-496f-81e0-2f35a0ddd371" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_070ee110-9478-429d-9d0d-1f4a57b61965" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedComputerSoftwareAdditions_9eb0b224-5697-4e8b-b4f5-7773a52cf227" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalizedComputerSoftwareAdditions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_8580601b-ba4c-496f-81e0-2f35a0ddd371" xlink:to="loc_us-gaap_CapitalizedComputerSoftwareAdditions_9eb0b224-5697-4e8b-b4f5-7773a52cf227" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation_cff93c83-c3d5-4828-bc7b-b210ddeb4dc7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Depreciation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_8580601b-ba4c-496f-81e0-2f35a0ddd371" xlink:to="loc_us-gaap_Depreciation_cff93c83-c3d5-4828-bc7b-b210ddeb4dc7" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedComputerSoftwareAmortization1_9eb72fd6-c286-48e6-9b9e-e67b0dafdf85" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalizedComputerSoftwareAmortization1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_8580601b-ba4c-496f-81e0-2f35a0ddd371" xlink:to="loc_us-gaap_CapitalizedComputerSoftwareAmortization1_9eb72fd6-c286-48e6-9b9e-e67b0dafdf85" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_f1037d35-4064-479b-9418-26d6dc0f1ad6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_8580601b-ba4c-496f-81e0-2f35a0ddd371" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_f1037d35-4064-479b-9418-26d6dc0f1ad6" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_bde88ecb-b020-4a2a-85e6-4c5bc8cda985" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_f1037d35-4064-479b-9418-26d6dc0f1ad6" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_bde88ecb-b020-4a2a-85e6-4c5bc8cda985" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_bde88ecb-b020-4a2a-85e6-4c5bc8cda985_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_bde88ecb-b020-4a2a-85e6-4c5bc8cda985" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_bde88ecb-b020-4a2a-85e6-4c5bc8cda985_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_a159665a-8452-4f10-809f-c84432e70863" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_bde88ecb-b020-4a2a-85e6-4c5bc8cda985" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_a159665a-8452-4f10-809f-c84432e70863" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComputerEquipmentMember_e2fe26d9-4cbc-4b96-a5d9-465c0e0f02b1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComputerEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_a159665a-8452-4f10-809f-c84432e70863" xlink:to="loc_us-gaap_ComputerEquipmentMember_e2fe26d9-4cbc-4b96-a5d9-465c0e0f02b1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_48da41f4-d4e9-4041-88f0-4e48ea8906ec" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_a159665a-8452-4f10-809f-c84432e70863" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_48da41f4-d4e9-4041-88f0-4e48ea8906ec" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SoftwareDevelopmentMember_a142ff59-2282-4d76-88e3-3751ef1beb0c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SoftwareDevelopmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_a159665a-8452-4f10-809f-c84432e70863" xlink:to="loc_us-gaap_SoftwareDevelopmentMember_a142ff59-2282-4d76-88e3-3751ef1beb0c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_216b365e-ae50-451a-a5e3-5aa282915b21" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_a159665a-8452-4f10-809f-c84432e70863" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_216b365e-ae50-451a-a5e3-5aa282915b21" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNetScheduleofGoodwillDetails" xlink:type="simple" xlink:href="evh-20211231.xsd#GoodwillandIntangibleAssetsNetScheduleofGoodwillDetails"/>
  <link:definitionLink xlink:role="http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNetScheduleofGoodwillDetails" xlink:type="extended" id="i1402b14e72334c9483c0ae286ef8d6de_GoodwillandIntangibleAssetsNetScheduleofGoodwillDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillLineItems_56ebd4a8-4014-4436-acdd-17483f2e9380" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillRollForward_8c869321-f364-462c-82e0-85be3c3b4710" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillLineItems_56ebd4a8-4014-4436-acdd-17483f2e9380" xlink:to="loc_us-gaap_GoodwillRollForward_8c869321-f364-462c-82e0-85be3c3b4710" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_976480fb-41ce-4e19-acd3-18d897dbd7ca" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillRollForward_8c869321-f364-462c-82e0-85be3c3b4710" xlink:to="loc_us-gaap_Goodwill_976480fb-41ce-4e19-acd3-18d897dbd7ca" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit_05fc0e51-19a6-4191-ba63-d0e8a2e47a16" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillRollForward_8c869321-f364-462c-82e0-85be3c3b4710" xlink:to="loc_us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit_05fc0e51-19a6-4191-ba63-d0e8a2e47a16" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairmentLoss_b0c21f27-3648-4afe-9171-8808396ee8e5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillRollForward_8c869321-f364-462c-82e0-85be3c3b4710" xlink:to="loc_us-gaap_GoodwillImpairmentLoss_b0c21f27-3648-4afe-9171-8808396ee8e5" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAcquiredDuringPeriod_349a782a-063c-448f-90d2-8cfa03fc1caf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAcquiredDuringPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillRollForward_8c869321-f364-462c-82e0-85be3c3b4710" xlink:to="loc_us-gaap_GoodwillAcquiredDuringPeriod_349a782a-063c-448f-90d2-8cfa03fc1caf" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillForeignCurrencyTranslationGainLoss_9d3462d6-3801-444e-a6b0-d365609a9d84" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillForeignCurrencyTranslationGainLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillRollForward_8c869321-f364-462c-82e0-85be3c3b4710" xlink:to="loc_us-gaap_GoodwillForeignCurrencyTranslationGainLoss_9d3462d6-3801-444e-a6b0-d365609a9d84" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_231803d8-a06e-4e82-a6bf-cb5dd3237bd4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss_63e42109-92d2-40cb-9719-0934a57f61a0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillImpairedAccumulatedImpairmentLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillLineItems_56ebd4a8-4014-4436-acdd-17483f2e9380" xlink:to="loc_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss_63e42109-92d2-40cb-9719-0934a57f61a0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGoodwillTable_d9cd9198-d963-4e8c-b630-3c825c015cd4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfGoodwillTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_GoodwillLineItems_56ebd4a8-4014-4436-acdd-17483f2e9380" xlink:to="loc_us-gaap_ScheduleOfGoodwillTable_d9cd9198-d963-4e8c-b630-3c825c015cd4" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_a68e275a-42d2-434c-875b-4890c3ba5b4e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_d9cd9198-d963-4e8c-b630-3c825c015cd4" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_a68e275a-42d2-434c-875b-4890c3ba5b4e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_a68e275a-42d2-434c-875b-4890c3ba5b4e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_a68e275a-42d2-434c-875b-4890c3ba5b4e" xlink:to="loc_us-gaap_SegmentDomain_a68e275a-42d2-434c-875b-4890c3ba5b4e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_834a7bac-b969-4a3b-a358-f15acbe38ed6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_a68e275a-42d2-434c-875b-4890c3ba5b4e" xlink:to="loc_us-gaap_SegmentDomain_834a7bac-b969-4a3b-a358-f15acbe38ed6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_EvolentHealthServicesSegmentMember_e1eae180-328d-4b39-be0c-4f2d819d40f8" xlink:href="evh-20211231.xsd#evh_EvolentHealthServicesSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_834a7bac-b969-4a3b-a358-f15acbe38ed6" xlink:to="loc_evh_EvolentHealthServicesSegmentMember_e1eae180-328d-4b39-be0c-4f2d819d40f8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_ClinicalSolutionsSegmentMember_04486897-9052-4b8b-8da5-06369d1c7a72" xlink:href="evh-20211231.xsd#evh_ClinicalSolutionsSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_834a7bac-b969-4a3b-a358-f15acbe38ed6" xlink:to="loc_evh_ClinicalSolutionsSegmentMember_04486897-9052-4b8b-8da5-06369d1c7a72" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNetIntangibleAssetsNetDetails" xlink:type="simple" xlink:href="evh-20211231.xsd#GoodwillandIntangibleAssetsNetIntangibleAssetsNetDetails"/>
  <link:definitionLink xlink:role="http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNetIntangibleAssetsNetDetails" xlink:type="extended" id="i88e412168e4245cc97abb7bfd9e6f7d7_GoodwillandIntangibleAssetsNetIntangibleAssetsNetDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_897841b4-cd06-4f7d-a92c-39b8bde7ebab" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_cd64db2e-d3c6-4d47-89d2-d1caf07db6cc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_897841b4-cd06-4f7d-a92c-39b8bde7ebab" xlink:to="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_cd64db2e-d3c6-4d47-89d2-d1caf07db6cc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_30311c5a-10e5-4852-9f22-c4c93f1df6d8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_897841b4-cd06-4f7d-a92c-39b8bde7ebab" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_30311c5a-10e5-4852-9f22-c4c93f1df6d8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_6b1378e9-5919-4dd5-ae49-32a08bf0ce8e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_897841b4-cd06-4f7d-a92c-39b8bde7ebab" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_6b1378e9-5919-4dd5-ae49-32a08bf0ce8e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_d81233c5-56c5-4ddf-9d31-6257676493df" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_897841b4-cd06-4f7d-a92c-39b8bde7ebab" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_d81233c5-56c5-4ddf-9d31-6257676493df" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsNoncurrent_0b9eaa89-b222-4f17-99da-74b10d95748b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_897841b4-cd06-4f7d-a92c-39b8bde7ebab" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsNoncurrent_0b9eaa89-b222-4f17-99da-74b10d95748b" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_f894408d-5e34-42fc-8716-fa90d0a31273" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_897841b4-cd06-4f7d-a92c-39b8bde7ebab" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_f894408d-5e34-42fc-8716-fa90d0a31273" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_9e47774e-f41f-433f-a05f-38cda204f268" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_897841b4-cd06-4f7d-a92c-39b8bde7ebab" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_9e47774e-f41f-433f-a05f-38cda204f268" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_1d3f0998-74af-43a3-a0eb-304a8560d076" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_9e47774e-f41f-433f-a05f-38cda204f268" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_1d3f0998-74af-43a3-a0eb-304a8560d076" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_1d3f0998-74af-43a3-a0eb-304a8560d076_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_1d3f0998-74af-43a3-a0eb-304a8560d076" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_1d3f0998-74af-43a3-a0eb-304a8560d076_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_f1f2a71d-25e1-4ce8-a12e-ac73c996018c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_1d3f0998-74af-43a3-a0eb-304a8560d076" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_f1f2a71d-25e1-4ce8-a12e-ac73c996018c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TradeNamesMember_a647c6c9-1cf6-48be-8d52-5eb696dac1dc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TradeNamesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_f1f2a71d-25e1-4ce8-a12e-ac73c996018c" xlink:to="loc_us-gaap_TradeNamesMember_a647c6c9-1cf6-48be-8d52-5eb696dac1dc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerRelationshipsMember_78e7b632-e55e-4f6a-92e6-349eb930bc3b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CustomerRelationshipsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_f1f2a71d-25e1-4ce8-a12e-ac73c996018c" xlink:to="loc_us-gaap_CustomerRelationshipsMember_78e7b632-e55e-4f6a-92e6-349eb930bc3b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DevelopedTechnologyRightsMember_cfde05df-78a7-4a2c-b18c-0665cdfd7694" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DevelopedTechnologyRightsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_f1f2a71d-25e1-4ce8-a12e-ac73c996018c" xlink:to="loc_us-gaap_DevelopedTechnologyRightsMember_cfde05df-78a7-4a2c-b18c-0665cdfd7694" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_BelowMarketLeasesMember_71d2fd4b-51d4-4502-a827-40e5f49f2699" xlink:href="evh-20211231.xsd#evh_BelowMarketLeasesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_f1f2a71d-25e1-4ce8-a12e-ac73c996018c" xlink:to="loc_evh_BelowMarketLeasesMember_71d2fd4b-51d4-4502-a827-40e5f49f2699" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractBasedIntangibleAssetsMember_dd1cbc18-13db-434e-bb7c-d2ee05322e5a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractBasedIntangibleAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_f1f2a71d-25e1-4ce8-a12e-ac73c996018c" xlink:to="loc_us-gaap_ContractBasedIntangibleAssetsMember_dd1cbc18-13db-434e-bb7c-d2ee05322e5a" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis_e98e5f97-59c3-4de0-983d-83ff82f51cc3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupClassificationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_9e47774e-f41f-433f-a05f-38cda204f268" xlink:to="loc_us-gaap_DisposalGroupClassificationAxis_e98e5f97-59c3-4de0-983d-83ff82f51cc3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_e98e5f97-59c3-4de0-983d-83ff82f51cc3_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_e98e5f97-59c3-4de0-983d-83ff82f51cc3" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_e98e5f97-59c3-4de0-983d-83ff82f51cc3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_f0ccc473-dd0a-4c30-8edc-5a29505f8e95" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_e98e5f97-59c3-4de0-983d-83ff82f51cc3" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_f0ccc473-dd0a-4c30-8edc-5a29505f8e95" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationsDisposedOfBySaleMember_576875e5-7883-456c-8855-86d79fe48197" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DiscontinuedOperationsDisposedOfBySaleMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain_f0ccc473-dd0a-4c30-8edc-5a29505f8e95" xlink:to="loc_us-gaap_DiscontinuedOperationsDisposedOfBySaleMember_576875e5-7883-456c-8855-86d79fe48197" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_d94c36af-0bb1-43dc-b685-e3cbcf073f33" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_9e47774e-f41f-433f-a05f-38cda204f268" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_d94c36af-0bb1-43dc-b685-e3cbcf073f33" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_d94c36af-0bb1-43dc-b685-e3cbcf073f33_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_d94c36af-0bb1-43dc-b685-e3cbcf073f33" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_d94c36af-0bb1-43dc-b685-e3cbcf073f33_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_a3efb2ff-21f6-44d0-a607-0212eab709d7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_d94c36af-0bb1-43dc-b685-e3cbcf073f33" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_a3efb2ff-21f6-44d0-a607-0212eab709d7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_TrueHealthMember_f07be7f2-eafa-4790-9dba-b9f4cf66b596" xlink:href="evh-20211231.xsd#evh_TrueHealthMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_a3efb2ff-21f6-44d0-a607-0212eab709d7" xlink:to="loc_evh_TrueHealthMember_f07be7f2-eafa-4790-9dba-b9f4cf66b596" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/LongtermDebt2024NotesDetails" xlink:type="simple" xlink:href="evh-20211231.xsd#LongtermDebt2024NotesDetails"/>
  <link:definitionLink xlink:role="http://www.evolenthealth.com/role/LongtermDebt2024NotesDetails" xlink:type="extended" id="i4f50ec73dbd847d18fae781abbf13013_LongtermDebt2024NotesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_0b3194b4-dd74-4ba6-9be3-9095bde29009" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_8ef63b70-ddfc-465d-a272-57b07f6dd763" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0b3194b4-dd74-4ba6-9be3-9095bde29009" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_8ef63b70-ddfc-465d-a272-57b07f6dd763" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_fb8876a4-f09d-4f7e-bb7b-dc754ea13fee" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0b3194b4-dd74-4ba6-9be3-9095bde29009" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_fb8876a4-f09d-4f7e-bb7b-dc754ea13fee" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtConversionConvertedInstrumentAmount1_04209380-cca0-493e-932c-76adee248066" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentAmount1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0b3194b4-dd74-4ba6-9be3-9095bde29009" xlink:to="loc_us-gaap_DebtConversionConvertedInstrumentAmount1_04209380-cca0-493e-932c-76adee248066" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtConversionOriginalDebtAmount1_6df3191f-1d2f-41ab-8a09-44ea9fe218f2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtConversionOriginalDebtAmount1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0b3194b4-dd74-4ba6-9be3-9095bde29009" xlink:to="loc_us-gaap_DebtConversionOriginalDebtAmount1_6df3191f-1d2f-41ab-8a09-44ea9fe218f2" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDebtIssuanceCosts_982b5e7f-7474-4c5e-8730-e87ea8b85a69" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsOfDebtIssuanceCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0b3194b4-dd74-4ba6-9be3-9095bde29009" xlink:to="loc_us-gaap_PaymentsOfDebtIssuanceCosts_982b5e7f-7474-4c5e-8730-e87ea8b85a69" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsNet_221a1bad-1fbb-4353-a45e-ae2c6fe3b0a6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredFinanceCostsNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0b3194b4-dd74-4ba6-9be3-9095bde29009" xlink:to="loc_us-gaap_DeferredFinanceCostsNet_221a1bad-1fbb-4353-a45e-ae2c6fe3b0a6" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseDebt_a2d872d4-06ea-4e35-a22a-9e13db71da43" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpenseDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0b3194b4-dd74-4ba6-9be3-9095bde29009" xlink:to="loc_us-gaap_InterestExpenseDebt_a2d872d4-06ea-4e35-a22a-9e13db71da43" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionRatio1_51e6d02b-8e38-4afb-acce-a86ab21da284" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionRatio1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0b3194b4-dd74-4ba6-9be3-9095bde29009" xlink:to="loc_us-gaap_DebtInstrumentConvertibleConversionRatio1_51e6d02b-8e38-4afb-acce-a86ab21da284" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_8c9526ad-2b88-4f9e-8845-8aacd9097dda" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0b3194b4-dd74-4ba6-9be3-9095bde29009" xlink:to="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_8c9526ad-2b88-4f9e-8845-8aacd9097dda" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleNumberOfEquityInstruments_8d251654-bdc2-4936-b0bf-838ed95cba86" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentConvertibleNumberOfEquityInstruments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0b3194b4-dd74-4ba6-9be3-9095bde29009" xlink:to="loc_us-gaap_DebtInstrumentConvertibleNumberOfEquityInstruments_8d251654-bdc2-4936-b0bf-838ed95cba86" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_64ef08a5-cbee-4cc9-a08e-31bcbfe18ed4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0b3194b4-dd74-4ba6-9be3-9095bde29009" xlink:to="loc_us-gaap_LongTermDebt_64ef08a5-cbee-4cc9-a08e-31bcbfe18ed4" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfDebt_87d0d574-6a1b-4b3e-a296-12afef8e0330" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0b3194b4-dd74-4ba6-9be3-9095bde29009" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfDebt_87d0d574-6a1b-4b3e-a296-12afef8e0330" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_DebtIssuanceCostsNetDebtComponent_63c8c188-8df5-4b22-aecc-c6ebd064b639" xlink:href="evh-20211231.xsd#evh_DebtIssuanceCostsNetDebtComponent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0b3194b4-dd74-4ba6-9be3-9095bde29009" xlink:to="loc_evh_DebtIssuanceCostsNetDebtComponent_63c8c188-8df5-4b22-aecc-c6ebd064b639" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_AmortizationOfDebtDiscountAndDebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction_f8f1f722-c907-4957-b685-b78cdee94da7" xlink:href="evh-20211231.xsd#evh_AmortizationOfDebtDiscountAndDebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0b3194b4-dd74-4ba6-9be3-9095bde29009" xlink:to="loc_evh_AmortizationOfDebtDiscountAndDebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction_f8f1f722-c907-4957-b685-b78cdee94da7" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_DebtInstrumentRepurchasePriceDueToFundamentalChangeAsPercentageOfPrincipalAmount_284e77cd-de85-4c8b-ad51-3a7568b2b05f" xlink:href="evh-20211231.xsd#evh_DebtInstrumentRepurchasePriceDueToFundamentalChangeAsPercentageOfPrincipalAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0b3194b4-dd74-4ba6-9be3-9095bde29009" xlink:to="loc_evh_DebtInstrumentRepurchasePriceDueToFundamentalChangeAsPercentageOfPrincipalAmount_284e77cd-de85-4c8b-ad51-3a7568b2b05f" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_DebtInstrumentRepurchaseCovenantSalePriceAsAPercentageOfConversionPrice_86db0ba3-2cca-48f3-af03-28f684c550bb" xlink:href="evh-20211231.xsd#evh_DebtInstrumentRepurchaseCovenantSalePriceAsAPercentageOfConversionPrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0b3194b4-dd74-4ba6-9be3-9095bde29009" xlink:to="loc_evh_DebtInstrumentRepurchaseCovenantSalePriceAsAPercentageOfConversionPrice_86db0ba3-2cca-48f3-af03-28f684c550bb" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_DebtInstrumentRepurchaseCovenantTradingDaysMinimum_25558af8-4f25-4b76-9022-69e5fd31345c" xlink:href="evh-20211231.xsd#evh_DebtInstrumentRepurchaseCovenantTradingDaysMinimum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0b3194b4-dd74-4ba6-9be3-9095bde29009" xlink:to="loc_evh_DebtInstrumentRepurchaseCovenantTradingDaysMinimum_25558af8-4f25-4b76-9022-69e5fd31345c" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_DebtInstrumentRepurchaseCovenantConsecutiveTradingDaysMinimum_6691de2e-e496-46b8-9937-04ce8eedffd1" xlink:href="evh-20211231.xsd#evh_DebtInstrumentRepurchaseCovenantConsecutiveTradingDaysMinimum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0b3194b4-dd74-4ba6-9be3-9095bde29009" xlink:to="loc_evh_DebtInstrumentRepurchaseCovenantConsecutiveTradingDaysMinimum_6691de2e-e496-46b8-9937-04ce8eedffd1" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_DebtInstrumentRepurchasePriceDueToChangeInSalePriceAsPercentageOfConversionPrice_bcbb7868-c029-48a4-868c-8b5a7bd287d5" xlink:href="evh-20211231.xsd#evh_DebtInstrumentRepurchasePriceDueToChangeInSalePriceAsPercentageOfConversionPrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0b3194b4-dd74-4ba6-9be3-9095bde29009" xlink:to="loc_evh_DebtInstrumentRepurchasePriceDueToChangeInSalePriceAsPercentageOfConversionPrice_bcbb7868-c029-48a4-868c-8b5a7bd287d5" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_045175b8-0c15-4d0d-a83a-ff420c8539eb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0b3194b4-dd74-4ba6-9be3-9095bde29009" xlink:to="loc_us-gaap_DebtInstrumentTable_045175b8-0c15-4d0d-a83a-ff420c8539eb" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_955b2fe7-5fb5-4f25-9f34-014bbeb57fa6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_045175b8-0c15-4d0d-a83a-ff420c8539eb" xlink:to="loc_us-gaap_DebtInstrumentAxis_955b2fe7-5fb5-4f25-9f34-014bbeb57fa6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_955b2fe7-5fb5-4f25-9f34-014bbeb57fa6_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_955b2fe7-5fb5-4f25-9f34-014bbeb57fa6" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_955b2fe7-5fb5-4f25-9f34-014bbeb57fa6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_56560b44-3d64-4952-ae96-60e745909309" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_955b2fe7-5fb5-4f25-9f34-014bbeb57fa6" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_56560b44-3d64-4952-ae96-60e745909309" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_SeniorConvertibleNotesDue2024Member_abe90cb2-ec01-4ab0-9a8b-337def6d0c32" xlink:href="evh-20211231.xsd#evh_SeniorConvertibleNotesDue2024Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_56560b44-3d64-4952-ae96-60e745909309" xlink:to="loc_evh_SeniorConvertibleNotesDue2024Member_abe90cb2-ec01-4ab0-9a8b-337def6d0c32" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_ConvertibleSeniorNotesdue2021Member_61e51f71-d20f-4728-bb67-7c63913ab381" xlink:href="evh-20211231.xsd#evh_ConvertibleSeniorNotesdue2021Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_56560b44-3d64-4952-ae96-60e745909309" xlink:to="loc_evh_ConvertibleSeniorNotesdue2021Member_61e51f71-d20f-4728-bb67-7c63913ab381" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_NewNotesMember_6127f44d-8e9b-4a1c-9c0a-a2ec85a46388" xlink:href="evh-20211231.xsd#evh_NewNotesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_56560b44-3d64-4952-ae96-60e745909309" xlink:to="loc_evh_NewNotesMember_6127f44d-8e9b-4a1c-9c0a-a2ec85a46388" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_a0de710c-3a48-43aa-8b08-3a0150fcb2fc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_045175b8-0c15-4d0d-a83a-ff420c8539eb" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_a0de710c-3a48-43aa-8b08-3a0150fcb2fc" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_a0de710c-3a48-43aa-8b08-3a0150fcb2fc_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_a0de710c-3a48-43aa-8b08-3a0150fcb2fc" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_a0de710c-3a48-43aa-8b08-3a0150fcb2fc_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_ec8e56e3-fd02-47c2-a2ee-90ee1c874055" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_a0de710c-3a48-43aa-8b08-3a0150fcb2fc" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_ec8e56e3-fd02-47c2-a2ee-90ee1c874055" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorNotesMember_5c15672e-6d5e-4261-9ebb-abd4ca87dacc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeniorNotesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_ec8e56e3-fd02-47c2-a2ee-90ee1c874055" xlink:to="loc_us-gaap_SeniorNotesMember_5c15672e-6d5e-4261-9ebb-abd4ca87dacc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_f46e373d-b426-45eb-841a-cb7ad45f32bf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_045175b8-0c15-4d0d-a83a-ff420c8539eb" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_f46e373d-b426-45eb-841a-cb7ad45f32bf" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_f46e373d-b426-45eb-841a-cb7ad45f32bf_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_f46e373d-b426-45eb-841a-cb7ad45f32bf" xlink:to="loc_us-gaap_EquityComponentDomain_f46e373d-b426-45eb-841a-cb7ad45f32bf_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_bddd8e9e-b3cd-489c-9717-297a7d544997" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_f46e373d-b426-45eb-841a-cb7ad45f32bf" xlink:to="loc_us-gaap_EquityComponentDomain_bddd8e9e-b3cd-489c-9717-297a7d544997" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_6a5e65a8-642d-40e8-94ef-e4d518489756" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_bddd8e9e-b3cd-489c-9717-297a7d544997" xlink:to="loc_us-gaap_CommonStockMember_6a5e65a8-642d-40e8-94ef-e4d518489756" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/LongtermDebtCreditAgreementDetails" xlink:type="simple" xlink:href="evh-20211231.xsd#LongtermDebtCreditAgreementDetails"/>
  <link:definitionLink xlink:role="http://www.evolenthealth.com/role/LongtermDebtCreditAgreementDetails" xlink:type="extended" id="i185e7b126bcc4888b9b3b933ebd736f4_LongtermDebtCreditAgreementDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_bb52ef14-b1c8-4e1f-8ff4-f9b2f3e3d9b1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_ea2d81bd-3da1-4f61-a223-adf76c8367fc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_bb52ef14-b1c8-4e1f-8ff4-f9b2f3e3d9b1" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_ea2d81bd-3da1-4f61-a223-adf76c8367fc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_94f7c19c-8b86-45d7-8808-8baf77dbfb13" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_bb52ef14-b1c8-4e1f-8ff4-f9b2f3e3d9b1" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_94f7c19c-8b86-45d7-8808-8baf77dbfb13" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_c73bef9f-488d-4003-aa6b-ed02cf0b7d73" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_bb52ef14-b1c8-4e1f-8ff4-f9b2f3e3d9b1" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_c73bef9f-488d-4003-aa6b-ed02cf0b7d73" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTerm_62c49398-09e3-44d9-9e91-67fc1f95589e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_bb52ef14-b1c8-4e1f-8ff4-f9b2f3e3d9b1" xlink:to="loc_us-gaap_DebtInstrumentTerm_62c49398-09e3-44d9-9e91-67fc1f95589e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_96907b4f-b591-4106-9361-071d1ca2e2d5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_bb52ef14-b1c8-4e1f-8ff4-f9b2f3e3d9b1" xlink:to="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_96907b4f-b591-4106-9361-071d1ca2e2d5" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityCommitmentFeePercentage_56650afc-8522-41bf-b4fe-7e794f4051b9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityCommitmentFeePercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_bb52ef14-b1c8-4e1f-8ff4-f9b2f3e3d9b1" xlink:to="loc_us-gaap_LineOfCreditFacilityCommitmentFeePercentage_56650afc-8522-41bf-b4fe-7e794f4051b9" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_DebtInstrumentRedemptionCallProtectionPremiumPercentage_e20da87e-ac92-4f0f-94b1-42e432ed6927" xlink:href="evh-20211231.xsd#evh_DebtInstrumentRedemptionCallProtectionPremiumPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_bb52ef14-b1c8-4e1f-8ff4-f9b2f3e3d9b1" xlink:to="loc_evh_DebtInstrumentRedemptionCallProtectionPremiumPercentage_e20da87e-ac92-4f0f-94b1-42e432ed6927" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsNet_0040d591-0afb-47d0-a6dc-0457895900a3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredFinanceCostsNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_bb52ef14-b1c8-4e1f-8ff4-f9b2f3e3d9b1" xlink:to="loc_us-gaap_DeferredFinanceCostsNet_0040d591-0afb-47d0-a6dc-0457895900a3" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_AmortizationOfDebtDiscountAndDebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction_bcb8d7cd-3c26-42d3-8a5b-4c3daea1c595" xlink:href="evh-20211231.xsd#evh_AmortizationOfDebtDiscountAndDebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_bb52ef14-b1c8-4e1f-8ff4-f9b2f3e3d9b1" xlink:to="loc_evh_AmortizationOfDebtDiscountAndDebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction_bcb8d7cd-3c26-42d3-8a5b-4c3daea1c595" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermLinesOfCredit_60c3ba99-3e81-435e-adca-fae88ce32ee3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfLongTermLinesOfCredit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_bb52ef14-b1c8-4e1f-8ff4-f9b2f3e3d9b1" xlink:to="loc_us-gaap_RepaymentsOfLongTermLinesOfCredit_60c3ba99-3e81-435e-adca-fae88ce32ee3" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_PaymentsOfMakeWholePremium_3ecbc3cd-e6c5-4b3c-b5b3-8b6eb878ff5f" xlink:href="evh-20211231.xsd#evh_PaymentsOfMakeWholePremium"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_bb52ef14-b1c8-4e1f-8ff4-f9b2f3e3d9b1" xlink:to="loc_evh_PaymentsOfMakeWholePremium_3ecbc3cd-e6c5-4b3c-b5b3-8b6eb878ff5f" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidNet_90c9fc93-ddbd-4b64-a298-5951d4e71ff4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestPaidNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_bb52ef14-b1c8-4e1f-8ff4-f9b2f3e3d9b1" xlink:to="loc_us-gaap_InterestPaidNet_90c9fc93-ddbd-4b64-a298-5951d4e71ff4" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_6fe10b3a-88e3-4672-aa84-a2bc14931767" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_bb52ef14-b1c8-4e1f-8ff4-f9b2f3e3d9b1" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_6fe10b3a-88e3-4672-aa84-a2bc14931767" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WriteOffOfDeferredDebtIssuanceCost_adec09b1-6752-4943-9f40-225d48e519f3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WriteOffOfDeferredDebtIssuanceCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_bb52ef14-b1c8-4e1f-8ff4-f9b2f3e3d9b1" xlink:to="loc_us-gaap_WriteOffOfDeferredDebtIssuanceCost_adec09b1-6752-4943-9f40-225d48e519f3" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LegalFees_f96bb04b-ba47-44a1-aaf3-04ff5629e77a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LegalFees"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_bb52ef14-b1c8-4e1f-8ff4-f9b2f3e3d9b1" xlink:to="loc_us-gaap_LegalFees_f96bb04b-ba47-44a1-aaf3-04ff5629e77a" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_fa880f01-83c1-4b6a-a762-c33d0ee66453" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_bb52ef14-b1c8-4e1f-8ff4-f9b2f3e3d9b1" xlink:to="loc_us-gaap_DebtInstrumentTable_fa880f01-83c1-4b6a-a762-c33d0ee66453" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_f9d0ae49-0531-48e0-926a-e99f35140058" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_fa880f01-83c1-4b6a-a762-c33d0ee66453" xlink:to="loc_us-gaap_DebtInstrumentAxis_f9d0ae49-0531-48e0-926a-e99f35140058" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_f9d0ae49-0531-48e0-926a-e99f35140058_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_f9d0ae49-0531-48e0-926a-e99f35140058" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_f9d0ae49-0531-48e0-926a-e99f35140058_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_e9e0b31d-0b35-4bf8-ba74-ccbd5891e310" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_f9d0ae49-0531-48e0-926a-e99f35140058" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_e9e0b31d-0b35-4bf8-ba74-ccbd5891e310" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_InitialTermLoanFacilityMember_1678617f-8d00-431f-a241-8b4ed0aa5492" xlink:href="evh-20211231.xsd#evh_InitialTermLoanFacilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_e9e0b31d-0b35-4bf8-ba74-ccbd5891e310" xlink:to="loc_evh_InitialTermLoanFacilityMember_1678617f-8d00-431f-a241-8b4ed0aa5492" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_CreditAgreementMember_5860c357-106e-493c-af6c-041c55372ba3" xlink:href="evh-20211231.xsd#evh_CreditAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_e9e0b31d-0b35-4bf8-ba74-ccbd5891e310" xlink:to="loc_evh_CreditAgreementMember_5860c357-106e-493c-af6c-041c55372ba3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_ConvertibleSeniorNotesdue2021Member_559743aa-f5d3-4bd2-a9d5-4032f7139ff3" xlink:href="evh-20211231.xsd#evh_ConvertibleSeniorNotesdue2021Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_e9e0b31d-0b35-4bf8-ba74-ccbd5891e310" xlink:to="loc_evh_ConvertibleSeniorNotesdue2021Member_559743aa-f5d3-4bd2-a9d5-4032f7139ff3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_SeniorCreditFacilitiesMember_14d0a064-c5bb-4f9a-9e9f-df4c93182bbd" xlink:href="evh-20211231.xsd#evh_SeniorCreditFacilitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_e9e0b31d-0b35-4bf8-ba74-ccbd5891e310" xlink:to="loc_evh_SeniorCreditFacilitiesMember_14d0a064-c5bb-4f9a-9e9f-df4c93182bbd" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_ace48b64-49d1-4e98-ae04-22a8fb041c19" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_fa880f01-83c1-4b6a-a762-c33d0ee66453" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_ace48b64-49d1-4e98-ae04-22a8fb041c19" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_ace48b64-49d1-4e98-ae04-22a8fb041c19_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_ace48b64-49d1-4e98-ae04-22a8fb041c19" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_ace48b64-49d1-4e98-ae04-22a8fb041c19_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_df8efab8-a826-492a-8c09-eb91286f49a8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_ace48b64-49d1-4e98-ae04-22a8fb041c19" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_df8efab8-a826-492a-8c09-eb91286f49a8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredDebtMember_598a9b4a-9cc2-414e-bc24-e61c8827ff50" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SecuredDebtMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_df8efab8-a826-492a-8c09-eb91286f49a8" xlink:to="loc_us-gaap_SecuredDebtMember_598a9b4a-9cc2-414e-bc24-e61c8827ff50" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditMember_bcb997a3-f4fc-4a35-99d4-cb0df28d4014" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_df8efab8-a826-492a-8c09-eb91286f49a8" xlink:to="loc_us-gaap_LineOfCreditMember_bcb997a3-f4fc-4a35-99d4-cb0df28d4014" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorNotesMember_a1a698a9-917a-4e46-a15b-35884224077e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeniorNotesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_df8efab8-a826-492a-8c09-eb91286f49a8" xlink:to="loc_us-gaap_SeniorNotesMember_a1a698a9-917a-4e46-a15b-35884224077e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_f598fff0-8e08-44c8-ae4a-82922488ed6b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_fa880f01-83c1-4b6a-a762-c33d0ee66453" xlink:to="loc_us-gaap_CreditFacilityAxis_f598fff0-8e08-44c8-ae4a-82922488ed6b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_f598fff0-8e08-44c8-ae4a-82922488ed6b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CreditFacilityAxis_f598fff0-8e08-44c8-ae4a-82922488ed6b" xlink:to="loc_us-gaap_CreditFacilityDomain_f598fff0-8e08-44c8-ae4a-82922488ed6b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_174951a8-dab5-48bd-a833-8fecbb59df27" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CreditFacilityAxis_f598fff0-8e08-44c8-ae4a-82922488ed6b" xlink:to="loc_us-gaap_CreditFacilityDomain_174951a8-dab5-48bd-a833-8fecbb59df27" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_DelayedDrawTermLoanFacilityMember_41dbc1a0-c9bf-4abd-a062-3d2315338940" xlink:href="evh-20211231.xsd#evh_DelayedDrawTermLoanFacilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_174951a8-dab5-48bd-a833-8fecbb59df27" xlink:to="loc_evh_DelayedDrawTermLoanFacilityMember_41dbc1a0-c9bf-4abd-a062-3d2315338940" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateAxis_f895e6de-7120-4f76-b5f7-675dac516ef2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableRateAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_fa880f01-83c1-4b6a-a762-c33d0ee66453" xlink:to="loc_us-gaap_VariableRateAxis_f895e6de-7120-4f76-b5f7-675dac516ef2" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_f895e6de-7120-4f76-b5f7-675dac516ef2_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableRateDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_VariableRateAxis_f895e6de-7120-4f76-b5f7-675dac516ef2" xlink:to="loc_us-gaap_VariableRateDomain_f895e6de-7120-4f76-b5f7-675dac516ef2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_a408e525-4b34-4b61-9459-fbef3217f9ae" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableRateDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_VariableRateAxis_f895e6de-7120-4f76-b5f7-675dac516ef2" xlink:to="loc_us-gaap_VariableRateDomain_a408e525-4b34-4b61-9459-fbef3217f9ae" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EurodollarMember_022d3a99-a132-42af-88bf-1aef2a25068e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EurodollarMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableRateDomain_a408e525-4b34-4b61-9459-fbef3217f9ae" xlink:to="loc_us-gaap_EurodollarMember_022d3a99-a132-42af-88bf-1aef2a25068e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BaseRateMember_0ed75b8a-2453-480d-a943-c64843b965de" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BaseRateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableRateDomain_a408e525-4b34-4b61-9459-fbef3217f9ae" xlink:to="loc_us-gaap_BaseRateMember_0ed75b8a-2453-480d-a943-c64843b965de" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_14ac3c20-5ca5-480b-bec3-0edd5bfb8462" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_fa880f01-83c1-4b6a-a762-c33d0ee66453" xlink:to="loc_srt_RangeAxis_14ac3c20-5ca5-480b-bec3-0edd5bfb8462" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_14ac3c20-5ca5-480b-bec3-0edd5bfb8462_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_14ac3c20-5ca5-480b-bec3-0edd5bfb8462" xlink:to="loc_srt_RangeMember_14ac3c20-5ca5-480b-bec3-0edd5bfb8462_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_a2861d2d-902e-41d4-ae21-a3e0c7cf78b6" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_14ac3c20-5ca5-480b-bec3-0edd5bfb8462" xlink:to="loc_srt_RangeMember_a2861d2d-902e-41d4-ae21-a3e0c7cf78b6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_61db4b8a-fa0a-4202-816e-995f27329928" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_a2861d2d-902e-41d4-ae21-a3e0c7cf78b6" xlink:to="loc_srt_MaximumMember_61db4b8a-fa0a-4202-816e-995f27329928" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis_e875acf4-f68f-4376-84bb-d8139007bc4c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_fa880f01-83c1-4b6a-a762-c33d0ee66453" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis_e875acf4-f68f-4376-84bb-d8139007bc4c" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_e875acf4-f68f-4376-84bb-d8139007bc4c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis_e875acf4-f68f-4376-84bb-d8139007bc4c" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_e875acf4-f68f-4376-84bb-d8139007bc4c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_d85b74a0-7d02-4b19-a66f-4ea7bd322593" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis_e875acf4-f68f-4376-84bb-d8139007bc4c" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_d85b74a0-7d02-4b19-a66f-4ea7bd322593" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodOneMember_80862fa0-bb1a-46ee-a52f-a62005d865d7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodOneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_d85b74a0-7d02-4b19-a66f-4ea7bd322593" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodOneMember_80862fa0-bb1a-46ee-a52f-a62005d865d7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodTwoMember_a5ff72b1-59d5-444d-a86a-571413998815" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodTwoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_d85b74a0-7d02-4b19-a66f-4ea7bd322593" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodTwoMember_a5ff72b1-59d5-444d-a86a-571413998815" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodThreeMember_7b809d22-f1bf-4fd0-9b27-a560b21ed394" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodThreeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_d85b74a0-7d02-4b19-a66f-4ea7bd322593" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodThreeMember_7b809d22-f1bf-4fd0-9b27-a560b21ed394" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/LongtermDebtWarrantAgreementDetails" xlink:type="simple" xlink:href="evh-20211231.xsd#LongtermDebtWarrantAgreementDetails"/>
  <link:definitionLink xlink:role="http://www.evolenthealth.com/role/LongtermDebtWarrantAgreementDetails" xlink:type="extended" id="ie064d0a9d16844bbb9d89204ec191c9c_LongtermDebtWarrantAgreementDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightLineItems_af0aa18d-34e1-43f0-9cee-3ae86407ffd0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightUnissued_f6484523-1120-4040-859b-91aaa11b6dd1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightUnissued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_af0aa18d-34e1-43f0-9cee-3ae86407ffd0" xlink:to="loc_us-gaap_ClassOfWarrantOrRightUnissued_f6484523-1120-4040-859b-91aaa11b6dd1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_b481273b-a89a-44b2-9308-5cdd40fc065a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_af0aa18d-34e1-43f0-9cee-3ae86407ffd0" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_b481273b-a89a-44b2-9308-5cdd40fc065a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_ClassOfWarrantOrRightPeriodDuringWhichWarrantsOrRightsExercisableAfterMaturityOfCreditAgreement_67aaba20-7864-4777-82c8-e68ad0f673a0" xlink:href="evh-20211231.xsd#evh_ClassOfWarrantOrRightPeriodDuringWhichWarrantsOrRightsExercisableAfterMaturityOfCreditAgreement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_af0aa18d-34e1-43f0-9cee-3ae86407ffd0" xlink:to="loc_evh_ClassOfWarrantOrRightPeriodDuringWhichWarrantsOrRightsExercisableAfterMaturityOfCreditAgreement_67aaba20-7864-4777-82c8-e68ad0f673a0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfWarrants_404696fc-e8f9-4fcd-8710-9d9d7d404380" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsForRepurchaseOfWarrants"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_af0aa18d-34e1-43f0-9cee-3ae86407ffd0" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfWarrants_404696fc-e8f9-4fcd-8710-9d9d7d404380" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightTable_8ed83437-0af0-4413-b4bf-87b56ab1746e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_af0aa18d-34e1-43f0-9cee-3ae86407ffd0" xlink:to="loc_us-gaap_ClassOfWarrantOrRightTable_8ed83437-0af0-4413-b4bf-87b56ab1746e" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_17a868e0-651b-4271-90d7-d13695d1b599" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_8ed83437-0af0-4413-b4bf-87b56ab1746e" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_17a868e0-651b-4271-90d7-d13695d1b599" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_17a868e0-651b-4271-90d7-d13695d1b599_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_17a868e0-651b-4271-90d7-d13695d1b599" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_17a868e0-651b-4271-90d7-d13695d1b599_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_4c35be7e-10e6-46c4-bf95-f4e456960ff9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_17a868e0-651b-4271-90d7-d13695d1b599" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_4c35be7e-10e6-46c4-bf95-f4e456960ff9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassAMember_66bf2d65-43f5-4adf-bb90-22986183a635" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonClassAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_4c35be7e-10e6-46c4-bf95-f4e456960ff9" xlink:to="loc_us-gaap_CommonClassAMember_66bf2d65-43f5-4adf-bb90-22986183a635" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/LongtermDebt2025NotesDetails" xlink:type="simple" xlink:href="evh-20211231.xsd#LongtermDebt2025NotesDetails"/>
  <link:definitionLink xlink:role="http://www.evolenthealth.com/role/LongtermDebt2025NotesDetails" xlink:type="extended" id="i0e414de4442648c288228880e6bc0cfa_LongtermDebt2025NotesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_27a0968f-e229-4a5c-a387-2e367fca02c9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_e69899e1-9bc6-4e5e-a8c4-bcd11e45dfe0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_27a0968f-e229-4a5c-a387-2e367fca02c9" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_e69899e1-9bc6-4e5e-a8c4-bcd11e45dfe0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_38e591cd-4e8f-4273-bbe1-82368eeab16e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_27a0968f-e229-4a5c-a387-2e367fca02c9" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_38e591cd-4e8f-4273-bbe1-82368eeab16e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfDebt_fb4bf5b2-add1-447a-ae8b-72ba69647bee" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_27a0968f-e229-4a5c-a387-2e367fca02c9" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfDebt_fb4bf5b2-add1-447a-ae8b-72ba69647bee" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsNet_ce325219-0553-420b-885b-def914795ebd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredFinanceCostsNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_27a0968f-e229-4a5c-a387-2e367fca02c9" xlink:to="loc_us-gaap_DeferredFinanceCostsNet_ce325219-0553-420b-885b-def914795ebd" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseDebt_842f559f-9a2c-4f2b-95ec-40e3ed003ae8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpenseDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_27a0968f-e229-4a5c-a387-2e367fca02c9" xlink:to="loc_us-gaap_InterestExpenseDebt_842f559f-9a2c-4f2b-95ec-40e3ed003ae8" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionRatio1_af4fd848-6d35-444b-bc98-d572d96bceea" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionRatio1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_27a0968f-e229-4a5c-a387-2e367fca02c9" xlink:to="loc_us-gaap_DebtInstrumentConvertibleConversionRatio1_af4fd848-6d35-444b-bc98-d572d96bceea" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_ba4d0eeb-8edf-4ed0-abdd-9d3c4ad52334" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_27a0968f-e229-4a5c-a387-2e367fca02c9" xlink:to="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_ba4d0eeb-8edf-4ed0-abdd-9d3c4ad52334" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleNumberOfEquityInstruments_2826370f-0814-4670-8f82-eb1ef9e717dd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentConvertibleNumberOfEquityInstruments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_27a0968f-e229-4a5c-a387-2e367fca02c9" xlink:to="loc_us-gaap_DebtInstrumentConvertibleNumberOfEquityInstruments_2826370f-0814-4670-8f82-eb1ef9e717dd" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_1a6ad084-da98-4fae-a251-7d217181f016" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_27a0968f-e229-4a5c-a387-2e367fca02c9" xlink:to="loc_us-gaap_LongTermDebt_1a6ad084-da98-4fae-a251-7d217181f016" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_AmortizationOfDebtDiscountAndDebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction_94b129c3-72a0-4fbd-990c-a7cca7cb35a7" xlink:href="evh-20211231.xsd#evh_AmortizationOfDebtDiscountAndDebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_27a0968f-e229-4a5c-a387-2e367fca02c9" xlink:to="loc_evh_AmortizationOfDebtDiscountAndDebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction_94b129c3-72a0-4fbd-990c-a7cca7cb35a7" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_DebtInstrumentRepurchasePriceDueToFundamentalChangeAsPercentageOfPrincipalAmount_6675c2e7-2ad7-407e-b87b-4ac13f73c083" xlink:href="evh-20211231.xsd#evh_DebtInstrumentRepurchasePriceDueToFundamentalChangeAsPercentageOfPrincipalAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_27a0968f-e229-4a5c-a387-2e367fca02c9" xlink:to="loc_evh_DebtInstrumentRepurchasePriceDueToFundamentalChangeAsPercentageOfPrincipalAmount_6675c2e7-2ad7-407e-b87b-4ac13f73c083" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_DebtInstrumentRepurchaseCovenantSalePriceAsAPercentageOfConversionPrice_a7467031-d8bc-4a7c-8cae-05352deaf852" xlink:href="evh-20211231.xsd#evh_DebtInstrumentRepurchaseCovenantSalePriceAsAPercentageOfConversionPrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_27a0968f-e229-4a5c-a387-2e367fca02c9" xlink:to="loc_evh_DebtInstrumentRepurchaseCovenantSalePriceAsAPercentageOfConversionPrice_a7467031-d8bc-4a7c-8cae-05352deaf852" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_DebtInstrumentRepurchaseCovenantTradingDaysMinimum_517f89ed-1877-4d14-819e-29e89c0755d5" xlink:href="evh-20211231.xsd#evh_DebtInstrumentRepurchaseCovenantTradingDaysMinimum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_27a0968f-e229-4a5c-a387-2e367fca02c9" xlink:to="loc_evh_DebtInstrumentRepurchaseCovenantTradingDaysMinimum_517f89ed-1877-4d14-819e-29e89c0755d5" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_DebtInstrumentRepurchaseCovenantConsecutiveTradingDaysMinimum_4721af3a-3a68-4e67-8f64-3c9902078d2e" xlink:href="evh-20211231.xsd#evh_DebtInstrumentRepurchaseCovenantConsecutiveTradingDaysMinimum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_27a0968f-e229-4a5c-a387-2e367fca02c9" xlink:to="loc_evh_DebtInstrumentRepurchaseCovenantConsecutiveTradingDaysMinimum_4721af3a-3a68-4e67-8f64-3c9902078d2e" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_DebtInstrumentRepurchasePriceDueToChangeInSalePriceAsPercentageOfConversionPrice_b4f402f2-93d3-4360-9b4e-641e57669bfd" xlink:href="evh-20211231.xsd#evh_DebtInstrumentRepurchasePriceDueToChangeInSalePriceAsPercentageOfConversionPrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_27a0968f-e229-4a5c-a387-2e367fca02c9" xlink:to="loc_evh_DebtInstrumentRepurchasePriceDueToChangeInSalePriceAsPercentageOfConversionPrice_b4f402f2-93d3-4360-9b4e-641e57669bfd" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_d9db8322-0f85-46f1-ae67-a71d2bb742a1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_27a0968f-e229-4a5c-a387-2e367fca02c9" xlink:to="loc_us-gaap_DebtInstrumentTable_d9db8322-0f85-46f1-ae67-a71d2bb742a1" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_a1c90c8a-11b4-41aa-9be6-edc3d38ac9bf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_d9db8322-0f85-46f1-ae67-a71d2bb742a1" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_a1c90c8a-11b4-41aa-9be6-edc3d38ac9bf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_a1c90c8a-11b4-41aa-9be6-edc3d38ac9bf_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_a1c90c8a-11b4-41aa-9be6-edc3d38ac9bf" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_a1c90c8a-11b4-41aa-9be6-edc3d38ac9bf_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_bd0de3b4-8fe4-4f20-9af6-af29443c7a29" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_a1c90c8a-11b4-41aa-9be6-edc3d38ac9bf" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_bd0de3b4-8fe4-4f20-9af6-af29443c7a29" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorNotesMember_e7bebffc-66ae-4b6c-b651-f7c40b1bfc6b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeniorNotesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_bd0de3b4-8fe4-4f20-9af6-af29443c7a29" xlink:to="loc_us-gaap_SeniorNotesMember_e7bebffc-66ae-4b6c-b651-f7c40b1bfc6b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_ae17554f-c9a6-40fd-a3e1-504ed76c989e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_d9db8322-0f85-46f1-ae67-a71d2bb742a1" xlink:to="loc_us-gaap_DebtInstrumentAxis_ae17554f-c9a6-40fd-a3e1-504ed76c989e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_ae17554f-c9a6-40fd-a3e1-504ed76c989e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_ae17554f-c9a6-40fd-a3e1-504ed76c989e" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_ae17554f-c9a6-40fd-a3e1-504ed76c989e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_32f07aa8-5817-4695-a5d5-4e3b7b7d8cd2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_ae17554f-c9a6-40fd-a3e1-504ed76c989e" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_32f07aa8-5817-4695-a5d5-4e3b7b7d8cd2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_SeniorConvertibleNotesDue2025Member_4213cb8c-db97-47a1-96cb-83f622f4e5ea" xlink:href="evh-20211231.xsd#evh_SeniorConvertibleNotesDue2025Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_32f07aa8-5817-4695-a5d5-4e3b7b7d8cd2" xlink:to="loc_evh_SeniorConvertibleNotesDue2025Member_4213cb8c-db97-47a1-96cb-83f622f4e5ea" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_cd727220-178c-4ef0-b3be-aa382d87914b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_d9db8322-0f85-46f1-ae67-a71d2bb742a1" xlink:to="loc_us-gaap_StatementClassOfStockAxis_cd727220-178c-4ef0-b3be-aa382d87914b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_cd727220-178c-4ef0-b3be-aa382d87914b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_cd727220-178c-4ef0-b3be-aa382d87914b" xlink:to="loc_us-gaap_ClassOfStockDomain_cd727220-178c-4ef0-b3be-aa382d87914b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_f4054b8b-8de2-43ca-a3e4-d076f44faf8b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_cd727220-178c-4ef0-b3be-aa382d87914b" xlink:to="loc_us-gaap_ClassOfStockDomain_f4054b8b-8de2-43ca-a3e4-d076f44faf8b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassAMember_2490c0bc-42bd-4539-96cd-3659de1cf83d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonClassAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_f4054b8b-8de2-43ca-a3e4-d076f44faf8b" xlink:to="loc_us-gaap_CommonClassAMember_2490c0bc-42bd-4539-96cd-3659de1cf83d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_ed51377a-d784-4769-9b73-b3cdbe2769ba" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_d9db8322-0f85-46f1-ae67-a71d2bb742a1" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_ed51377a-d784-4769-9b73-b3cdbe2769ba" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_ed51377a-d784-4769-9b73-b3cdbe2769ba_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_ed51377a-d784-4769-9b73-b3cdbe2769ba" xlink:to="loc_us-gaap_EquityComponentDomain_ed51377a-d784-4769-9b73-b3cdbe2769ba_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_7e71a7d3-3d5c-4f13-a45f-11e294c8bbe5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_ed51377a-d784-4769-9b73-b3cdbe2769ba" xlink:to="loc_us-gaap_EquityComponentDomain_7e71a7d3-3d5c-4f13-a45f-11e294c8bbe5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_7332738d-acaf-4621-b31b-aff850f699cf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_7e71a7d3-3d5c-4f13-a45f-11e294c8bbe5" xlink:to="loc_us-gaap_CommonStockMember_7332738d-acaf-4621-b31b-aff850f699cf" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/LongtermDebt2021NotesDetails" xlink:type="simple" xlink:href="evh-20211231.xsd#LongtermDebt2021NotesDetails"/>
  <link:definitionLink xlink:role="http://www.evolenthealth.com/role/LongtermDebt2021NotesDetails" xlink:type="extended" id="i2b3c365d338d458fb7fe395afd8d39dd_LongtermDebt2021NotesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_15113ba3-34b9-43ca-a33a-ac92713c4a2c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_38b801af-48a7-4f35-9b8e-3f154e83586f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_15113ba3-34b9-43ca-a33a-ac92713c4a2c" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_38b801af-48a7-4f35-9b8e-3f154e83586f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_212bd3fd-d93d-48fb-b562-2167552a577d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_15113ba3-34b9-43ca-a33a-ac92713c4a2c" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_212bd3fd-d93d-48fb-b562-2167552a577d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfDebt_4fe8afce-2f16-4fcf-8361-508695ee0414" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_15113ba3-34b9-43ca-a33a-ac92713c4a2c" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfDebt_4fe8afce-2f16-4fcf-8361-508695ee0414" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsNet_d73aaeb0-ec5a-467a-b557-ce1fdf5fdc30" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredFinanceCostsNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_15113ba3-34b9-43ca-a33a-ac92713c4a2c" xlink:to="loc_us-gaap_DeferredFinanceCostsNet_d73aaeb0-ec5a-467a-b557-ce1fdf5fdc30" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_DebtInstrumentRepurchasePriceDueToFundamentalChangeAsPercentageOfPrincipalAmount_02eb0aac-3436-4593-9b07-724ce338f7da" xlink:href="evh-20211231.xsd#evh_DebtInstrumentRepurchasePriceDueToFundamentalChangeAsPercentageOfPrincipalAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_15113ba3-34b9-43ca-a33a-ac92713c4a2c" xlink:to="loc_evh_DebtInstrumentRepurchasePriceDueToFundamentalChangeAsPercentageOfPrincipalAmount_02eb0aac-3436-4593-9b07-724ce338f7da" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseDebt_b6b989e6-3a57-4531-9775-1811e4987f6b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpenseDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_15113ba3-34b9-43ca-a33a-ac92713c4a2c" xlink:to="loc_us-gaap_InterestExpenseDebt_b6b989e6-3a57-4531-9775-1811e4987f6b" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCosts_e92d13b9-7fa6-4eb2-a796-dc6b80fe36ca" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfFinancingCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_15113ba3-34b9-43ca-a33a-ac92713c4a2c" xlink:to="loc_us-gaap_AmortizationOfFinancingCosts_e92d13b9-7fa6-4eb2-a796-dc6b80fe36ca" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionRatio1_3d2718a7-5f04-4602-b648-b53db2c0831b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionRatio1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_15113ba3-34b9-43ca-a33a-ac92713c4a2c" xlink:to="loc_us-gaap_DebtInstrumentConvertibleConversionRatio1_3d2718a7-5f04-4602-b648-b53db2c0831b" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_89698d34-da0a-4461-9f0c-1cd8fb0bd95b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_15113ba3-34b9-43ca-a33a-ac92713c4a2c" xlink:to="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_89698d34-da0a-4461-9f0c-1cd8fb0bd95b" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleNumberOfEquityInstruments_e0995269-738e-4495-a0e0-b728cef4a313" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentConvertibleNumberOfEquityInstruments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_15113ba3-34b9-43ca-a33a-ac92713c4a2c" xlink:to="loc_us-gaap_DebtInstrumentConvertibleNumberOfEquityInstruments_e0995269-738e-4495-a0e0-b728cef4a313" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtConversionConvertedInstrumentAmount1_a7e627e5-31cf-480b-9fae-21fa35e88cd4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentAmount1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_15113ba3-34b9-43ca-a33a-ac92713c4a2c" xlink:to="loc_us-gaap_DebtConversionConvertedInstrumentAmount1_a7e627e5-31cf-480b-9fae-21fa35e88cd4" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtConversionOriginalDebtAmount1_85b8ae2b-8f4e-47f2-9677-240452b32c35" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtConversionOriginalDebtAmount1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_15113ba3-34b9-43ca-a33a-ac92713c4a2c" xlink:to="loc_us-gaap_DebtConversionOriginalDebtAmount1_85b8ae2b-8f4e-47f2-9677-240452b32c35" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDebtIssuanceCosts_b829edb1-63d8-4482-abef-2ee2f0414481" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsOfDebtIssuanceCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_15113ba3-34b9-43ca-a33a-ac92713c4a2c" xlink:to="loc_us-gaap_PaymentsOfDebtIssuanceCosts_b829edb1-63d8-4482-abef-2ee2f0414481" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebtBeforeWriteOffOfDeferredDebtIssuanceCost_74306430-e6d5-445a-b249-936923c598cb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebtBeforeWriteOffOfDeferredDebtIssuanceCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_15113ba3-34b9-43ca-a33a-ac92713c4a2c" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebtBeforeWriteOffOfDeferredDebtIssuanceCost_74306430-e6d5-445a-b249-936923c598cb" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ExtinguishmentOfDebtAmount_0500a8f5-191f-4275-a970-4db7a48d5596" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ExtinguishmentOfDebtAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_15113ba3-34b9-43ca-a33a-ac92713c4a2c" xlink:to="loc_us-gaap_ExtinguishmentOfDebtAmount_0500a8f5-191f-4275-a970-4db7a48d5596" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfSeniorDebt_51c5d4bc-9c7d-4644-b9e3-04fe7b03ddfd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfSeniorDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_15113ba3-34b9-43ca-a33a-ac92713c4a2c" xlink:to="loc_us-gaap_RepaymentsOfSeniorDebt_51c5d4bc-9c7d-4644-b9e3-04fe7b03ddfd" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_DebtConversionOriginalDebtFairValue_0bb68ca1-183d-43cc-82a7-c17246b3c494" xlink:href="evh-20211231.xsd#evh_DebtConversionOriginalDebtFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_15113ba3-34b9-43ca-a33a-ac92713c4a2c" xlink:to="loc_evh_DebtConversionOriginalDebtFairValue_0bb68ca1-183d-43cc-82a7-c17246b3c494" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_268474ec-3d62-49e2-99a5-be37a9d20bb4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_15113ba3-34b9-43ca-a33a-ac92713c4a2c" xlink:to="loc_us-gaap_DebtInstrumentTable_268474ec-3d62-49e2-99a5-be37a9d20bb4" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_cced74ec-d88e-477b-9613-bb398e6d3045" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_268474ec-3d62-49e2-99a5-be37a9d20bb4" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_cced74ec-d88e-477b-9613-bb398e6d3045" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_cced74ec-d88e-477b-9613-bb398e6d3045_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_cced74ec-d88e-477b-9613-bb398e6d3045" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_cced74ec-d88e-477b-9613-bb398e6d3045_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_5ee3a14a-3833-47db-8325-f3b7e5e97946" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_cced74ec-d88e-477b-9613-bb398e6d3045" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_5ee3a14a-3833-47db-8325-f3b7e5e97946" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorNotesMember_e52b9e14-c178-4d04-802a-053a9da4a1ee" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeniorNotesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_5ee3a14a-3833-47db-8325-f3b7e5e97946" xlink:to="loc_us-gaap_SeniorNotesMember_e52b9e14-c178-4d04-802a-053a9da4a1ee" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_9d92212b-bb8c-40ef-838b-25db6c6ae0cb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_268474ec-3d62-49e2-99a5-be37a9d20bb4" xlink:to="loc_us-gaap_DebtInstrumentAxis_9d92212b-bb8c-40ef-838b-25db6c6ae0cb" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_9d92212b-bb8c-40ef-838b-25db6c6ae0cb_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_9d92212b-bb8c-40ef-838b-25db6c6ae0cb" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_9d92212b-bb8c-40ef-838b-25db6c6ae0cb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_84b8eab4-2a26-4fb1-89f3-3de05d1cea4e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_9d92212b-bb8c-40ef-838b-25db6c6ae0cb" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_84b8eab4-2a26-4fb1-89f3-3de05d1cea4e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_ConvertibleSeniorNotesdue2021Member_96e505a0-4dc6-46d7-89e2-fb9c3e7456b3" xlink:href="evh-20211231.xsd#evh_ConvertibleSeniorNotesdue2021Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_84b8eab4-2a26-4fb1-89f3-3de05d1cea4e" xlink:to="loc_evh_ConvertibleSeniorNotesdue2021Member_96e505a0-4dc6-46d7-89e2-fb9c3e7456b3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_SeniorConvertibleNotesDue2024Member_15b3ae9d-9c49-44bf-bf5b-70a08144e74c" xlink:href="evh-20211231.xsd#evh_SeniorConvertibleNotesDue2024Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_84b8eab4-2a26-4fb1-89f3-3de05d1cea4e" xlink:to="loc_evh_SeniorConvertibleNotesDue2024Member_15b3ae9d-9c49-44bf-bf5b-70a08144e74c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_58e17506-cd1f-4600-9ce7-590de2707ee6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_268474ec-3d62-49e2-99a5-be37a9d20bb4" xlink:to="loc_us-gaap_StatementClassOfStockAxis_58e17506-cd1f-4600-9ce7-590de2707ee6" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_58e17506-cd1f-4600-9ce7-590de2707ee6_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_58e17506-cd1f-4600-9ce7-590de2707ee6" xlink:to="loc_us-gaap_ClassOfStockDomain_58e17506-cd1f-4600-9ce7-590de2707ee6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_120f60c0-1976-4175-9467-d06787f605e3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_58e17506-cd1f-4600-9ce7-590de2707ee6" xlink:to="loc_us-gaap_ClassOfStockDomain_120f60c0-1976-4175-9467-d06787f605e3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassAMember_6d8c4c4c-f323-4708-ac43-289719a3f325" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonClassAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_120f60c0-1976-4175-9467-d06787f605e3" xlink:to="loc_us-gaap_CommonClassAMember_6d8c4c4c-f323-4708-ac43-289719a3f325" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_084ed833-b872-4ea7-9278-38ed6e6297b4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_268474ec-3d62-49e2-99a5-be37a9d20bb4" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_084ed833-b872-4ea7-9278-38ed6e6297b4" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_084ed833-b872-4ea7-9278-38ed6e6297b4_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_084ed833-b872-4ea7-9278-38ed6e6297b4" xlink:to="loc_us-gaap_EquityComponentDomain_084ed833-b872-4ea7-9278-38ed6e6297b4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_2eaab598-9405-494d-b4c6-18315c7fe313" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_084ed833-b872-4ea7-9278-38ed6e6297b4" xlink:to="loc_us-gaap_EquityComponentDomain_2eaab598-9405-494d-b4c6-18315c7fe313" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_b4dbf4b9-a07e-498b-ad69-a80515fd084f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_2eaab598-9405-494d-b4c6-18315c7fe313" xlink:to="loc_us-gaap_CommonStockMember_b4dbf4b9-a07e-498b-ad69-a80515fd084f" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/LongtermDebtConvertibleSeniorNotesCarryingValueDetails" xlink:type="simple" xlink:href="evh-20211231.xsd#LongtermDebtConvertibleSeniorNotesCarryingValueDetails"/>
  <link:definitionLink xlink:role="http://www.evolenthealth.com/role/LongtermDebtConvertibleSeniorNotesCarryingValueDetails" xlink:type="extended" id="ia425c7c0d6764553b7edcd1e7fa60720_LongtermDebtConvertibleSeniorNotesCarryingValueDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_2e62b8f5-bffd-421b-9495-c92e201d66eb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebt_9341ee13-347b-4db6-a95f-154f4838801a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertibleDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2e62b8f5-bffd-421b-9495-c92e201d66eb" xlink:to="loc_us-gaap_ConvertibleDebt_9341ee13-347b-4db6-a95f-154f4838801a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_a8d6235d-cab9-42c4-b449-0fbe54e1c7c2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2e62b8f5-bffd-421b-9495-c92e201d66eb" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_a8d6235d-cab9-42c4-b449-0fbe54e1c7c2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_60a627cd-846c-437c-8197-19ce30dd6c4a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2e62b8f5-bffd-421b-9495-c92e201d66eb" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_60a627cd-846c-437c-8197-19ce30dd6c4a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1_1336b953-76c5-4506-9beb-21e9b2bfe20a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2e62b8f5-bffd-421b-9495-c92e201d66eb" xlink:to="loc_us-gaap_DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1_1336b953-76c5-4506-9beb-21e9b2bfe20a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtFairValue_c41fec3e-c464-43c4-8644-ede680b13bff" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2e62b8f5-bffd-421b-9495-c92e201d66eb" xlink:to="loc_us-gaap_LongTermDebtFairValue_c41fec3e-c464-43c4-8644-ede680b13bff" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_b831aeba-913b-416b-ad3a-f038589fa7c7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2e62b8f5-bffd-421b-9495-c92e201d66eb" xlink:to="loc_us-gaap_DebtInstrumentTable_b831aeba-913b-416b-ad3a-f038589fa7c7" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_e9ff6f97-f006-4471-a104-630aa3a8a462" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_b831aeba-913b-416b-ad3a-f038589fa7c7" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_e9ff6f97-f006-4471-a104-630aa3a8a462" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_e9ff6f97-f006-4471-a104-630aa3a8a462_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_e9ff6f97-f006-4471-a104-630aa3a8a462" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_e9ff6f97-f006-4471-a104-630aa3a8a462_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_f075eb6c-c92f-454e-946f-d64ccfe3aad3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_e9ff6f97-f006-4471-a104-630aa3a8a462" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_f075eb6c-c92f-454e-946f-d64ccfe3aad3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorNotesMember_409f3650-c062-4df3-8b30-11bd16e02a18" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeniorNotesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_f075eb6c-c92f-454e-946f-d64ccfe3aad3" xlink:to="loc_us-gaap_SeniorNotesMember_409f3650-c062-4df3-8b30-11bd16e02a18" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_cd0726c7-ab83-4917-b393-1b6f7a8f7910" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_b831aeba-913b-416b-ad3a-f038589fa7c7" xlink:to="loc_us-gaap_DebtInstrumentAxis_cd0726c7-ab83-4917-b393-1b6f7a8f7910" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_cd0726c7-ab83-4917-b393-1b6f7a8f7910_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_cd0726c7-ab83-4917-b393-1b6f7a8f7910" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_cd0726c7-ab83-4917-b393-1b6f7a8f7910_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_bd7bc145-601d-4674-ae63-382221c6326d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_cd0726c7-ab83-4917-b393-1b6f7a8f7910" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_bd7bc145-601d-4674-ae63-382221c6326d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_SeniorConvertibleNotesDue2024Member_f5e53bc1-3ce1-443c-a0f3-1cdd88e85de1" xlink:href="evh-20211231.xsd#evh_SeniorConvertibleNotesDue2024Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_bd7bc145-601d-4674-ae63-382221c6326d" xlink:to="loc_evh_SeniorConvertibleNotesDue2024Member_f5e53bc1-3ce1-443c-a0f3-1cdd88e85de1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_SeniorConvertibleNotesDue2025Member_7b01b758-5749-4acd-9c10-afc9abae9c78" xlink:href="evh-20211231.xsd#evh_SeniorConvertibleNotesDue2025Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_bd7bc145-601d-4674-ae63-382221c6326d" xlink:to="loc_evh_SeniorConvertibleNotesDue2025Member_7b01b758-5749-4acd-9c10-afc9abae9c78" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_ConvertibleSeniorNotesdue2021Member_8393c1cf-38b2-47b6-aed1-214a2340dd47" xlink:href="evh-20211231.xsd#evh_ConvertibleSeniorNotesdue2021Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_bd7bc145-601d-4674-ae63-382221c6326d" xlink:to="loc_evh_ConvertibleSeniorNotesdue2021Member_8393c1cf-38b2-47b6-aed1-214a2340dd47" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_5d6dd495-6417-4cdd-a033-2de4cbbf1cb2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_b831aeba-913b-416b-ad3a-f038589fa7c7" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_5d6dd495-6417-4cdd-a033-2de4cbbf1cb2" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_5d6dd495-6417-4cdd-a033-2de4cbbf1cb2_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_5d6dd495-6417-4cdd-a033-2de4cbbf1cb2" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_5d6dd495-6417-4cdd-a033-2de4cbbf1cb2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_4ad3139c-a8d2-47a7-974d-97cf571a0bfe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_5d6dd495-6417-4cdd-a033-2de4cbbf1cb2" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_4ad3139c-a8d2-47a7-974d-97cf571a0bfe" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_4695ee1b-14d2-44f4-b01d-80c26ef1a6ec" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_4ad3139c-a8d2-47a7-974d-97cf571a0bfe" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_4695ee1b-14d2-44f4-b01d-80c26ef1a6ec" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/CommitmentsandContingenciesAdditionalInformationDetails" xlink:type="simple" xlink:href="evh-20211231.xsd#CommitmentsandContingenciesAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://www.evolenthealth.com/role/CommitmentsandContingenciesAdditionalInformationDetails" xlink:type="extended" id="i7e6da90c4fb84c7d8f29d82542904a0a_CommitmentsandContingenciesAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems_fb09cd7d-9338-4f0e-b049-d3a37de0a3d9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_23573c30-3a38-4a2b-acb9-5df6b3f3e7d5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems_fb09cd7d-9338-4f0e-b049-d3a37de0a3d9" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_23573c30-3a38-4a2b-acb9-5df6b3f3e7d5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalents_c52f806c-b689-4d32-954d-e87a46002922" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalents"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems_fb09cd7d-9338-4f0e-b049-d3a37de0a3d9" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalents_c52f806c-b689-4d32-954d-e87a46002922" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_TaxReceivablesAgreementPercentofTaxSavingstobePaid_80f740f7-8ece-44ea-9ab3-55f89b43f9ad" xlink:href="evh-20211231.xsd#evh_TaxReceivablesAgreementPercentofTaxSavingstobePaid"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems_fb09cd7d-9338-4f0e-b049-d3a37de0a3d9" xlink:to="loc_evh_TaxReceivablesAgreementPercentofTaxSavingstobePaid_80f740f7-8ece-44ea-9ab3-55f89b43f9ad" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable_a2e93619-7c1c-4834-9ef2-c0885105611a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems_fb09cd7d-9338-4f0e-b049-d3a37de0a3d9" xlink:to="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable_a2e93619-7c1c-4834-9ef2-c0885105611a" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_b7c5aaa4-5f63-4460-9d0a-d8f4709b8565" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable_a2e93619-7c1c-4834-9ef2-c0885105611a" xlink:to="loc_us-gaap_CreditFacilityAxis_b7c5aaa4-5f63-4460-9d0a-d8f4709b8565" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_b7c5aaa4-5f63-4460-9d0a-d8f4709b8565_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CreditFacilityAxis_b7c5aaa4-5f63-4460-9d0a-d8f4709b8565" xlink:to="loc_us-gaap_CreditFacilityDomain_b7c5aaa4-5f63-4460-9d0a-d8f4709b8565_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_10e2ba5c-8c92-435c-b3aa-42037a11b737" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CreditFacilityAxis_b7c5aaa4-5f63-4460-9d0a-d8f4709b8565" xlink:to="loc_us-gaap_CreditFacilityDomain_10e2ba5c-8c92-435c-b3aa-42037a11b737" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LetterOfCreditMember_45b79623-6cbe-43b6-aafc-55711feca3ce" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LetterOfCreditMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_10e2ba5c-8c92-435c-b3aa-42037a11b737" xlink:to="loc_us-gaap_LetterOfCreditMember_45b79623-6cbe-43b6-aafc-55711feca3ce" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_f97e071d-050d-4c90-b083-bae092c50056" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable_a2e93619-7c1c-4834-9ef2-c0885105611a" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_f97e071d-050d-4c90-b083-bae092c50056" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_f97e071d-050d-4c90-b083-bae092c50056_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_f97e071d-050d-4c90-b083-bae092c50056" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_f97e071d-050d-4c90-b083-bae092c50056_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_423cc032-96b9-4807-8b72-f11c5c7604a9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_f97e071d-050d-4c90-b083-bae092c50056" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_423cc032-96b9-4807-8b72-f11c5c7604a9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditMember_8e57368c-d7a8-47ba-87ce-a67c80d68820" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_423cc032-96b9-4807-8b72-f11c5c7604a9" xlink:to="loc_us-gaap_LineOfCreditMember_8e57368c-d7a8-47ba-87ce-a67c80d68820" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_a542f107-bddd-421a-844e-8b384e5c2162" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable_a2e93619-7c1c-4834-9ef2-c0885105611a" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_a542f107-bddd-421a-844e-8b384e5c2162" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_a542f107-bddd-421a-844e-8b384e5c2162_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_a542f107-bddd-421a-844e-8b384e5c2162" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_a542f107-bddd-421a-844e-8b384e5c2162_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_363a3c30-6d77-43e9-9eba-e8af4627e27a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_a542f107-bddd-421a-844e-8b384e5c2162" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_363a3c30-6d77-43e9-9eba-e8af4627e27a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_RestrictedCashForLettersOfCreditForLetterOfCreditFacilityMember_60d7ceeb-c6b1-4e91-88e1-beae9e7cbe9c" xlink:href="evh-20211231.xsd#evh_RestrictedCashForLettersOfCreditForLetterOfCreditFacilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_363a3c30-6d77-43e9-9eba-e8af4627e27a" xlink:to="loc_evh_RestrictedCashForLettersOfCreditForLetterOfCreditFacilityMember_60d7ceeb-c6b1-4e91-88e1-beae9e7cbe9c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_CollateralwithFinancialInstitutionsMember_27359c1b-f29f-4fd0-8e98-e9783bdc8a48" xlink:href="evh-20211231.xsd#evh_CollateralwithFinancialInstitutionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_363a3c30-6d77-43e9-9eba-e8af4627e27a" xlink:to="loc_evh_CollateralwithFinancialInstitutionsMember_27359c1b-f29f-4fd0-8e98-e9783bdc8a48" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_8fccaaee-69d1-40c0-b5d5-34f8f5e949ac" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable_a2e93619-7c1c-4834-9ef2-c0885105611a" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_8fccaaee-69d1-40c0-b5d5-34f8f5e949ac" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_8fccaaee-69d1-40c0-b5d5-34f8f5e949ac_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_8fccaaee-69d1-40c0-b5d5-34f8f5e949ac" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_8fccaaee-69d1-40c0-b5d5-34f8f5e949ac_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_a6c08f8a-a76c-4dfc-acd6-b4e74b4dc12e" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_8fccaaee-69d1-40c0-b5d5-34f8f5e949ac" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_a6c08f8a-a76c-4dfc-acd6-b4e74b4dc12e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_UniversityHealthCaredbaPassportHealthPlanMember_afcd8f0b-52a4-4f0e-9e3b-fc09922e0e1d" xlink:href="evh-20211231.xsd#evh_UniversityHealthCaredbaPassportHealthPlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_a6c08f8a-a76c-4dfc-acd6-b4e74b4dc12e" xlink:to="loc_evh_UniversityHealthCaredbaPassportHealthPlanMember_afcd8f0b-52a4-4f0e-9e3b-fc09922e0e1d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesAxis_341d9acb-c307-4f72-a467-c260c8094552" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ConsolidatedEntitiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable_a2e93619-7c1c-4834-9ef2-c0885105611a" xlink:to="loc_srt_ConsolidatedEntitiesAxis_341d9acb-c307-4f72-a467-c260c8094552" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesDomain_341d9acb-c307-4f72-a467-c260c8094552_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ConsolidatedEntitiesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ConsolidatedEntitiesAxis_341d9acb-c307-4f72-a467-c260c8094552" xlink:to="loc_srt_ConsolidatedEntitiesDomain_341d9acb-c307-4f72-a467-c260c8094552_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesDomain_919080ed-9cc8-42a1-a505-a8a99ee03a88" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ConsolidatedEntitiesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ConsolidatedEntitiesAxis_341d9acb-c307-4f72-a467-c260c8094552" xlink:to="loc_srt_ConsolidatedEntitiesDomain_919080ed-9cc8-42a1-a505-a8a99ee03a88" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableInterestEntityNotPrimaryBeneficiaryMember_ec3b0e7e-b67f-4447-b5c1-27c73b8678c4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableInterestEntityNotPrimaryBeneficiaryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidatedEntitiesDomain_919080ed-9cc8-42a1-a505-a8a99ee03a88" xlink:to="loc_us-gaap_VariableInterestEntityNotPrimaryBeneficiaryMember_ec3b0e7e-b67f-4447-b5c1-27c73b8678c4" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/CommitmentsandContingenciesConcentrationRiskDetails" xlink:type="simple" xlink:href="evh-20211231.xsd#CommitmentsandContingenciesConcentrationRiskDetails"/>
  <link:definitionLink xlink:role="http://www.evolenthealth.com/role/CommitmentsandContingenciesConcentrationRiskDetails" xlink:type="extended" id="i19b04f2e25894c7081f4fb72646785cb_CommitmentsandContingenciesConcentrationRiskDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskLineItems_b5a19660-a357-4631-bb9e-5497f9f4e384" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_CashFDICInsuredAmountPercentage_1a1a6299-db6b-4b75-b72e-5a58dcea01e3" xlink:href="evh-20211231.xsd#evh_CashFDICInsuredAmountPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_b5a19660-a357-4631-bb9e-5497f9f4e384" xlink:to="loc_evh_CashFDICInsuredAmountPercentage_1a1a6299-db6b-4b75-b72e-5a58dcea01e3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_f4152276-4fa5-458e-a527-cab3da9254da" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_b5a19660-a357-4631-bb9e-5497f9f4e384" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_f4152276-4fa5-458e-a527-cab3da9254da" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_CashHeldInInternationalBanksPercentage_ae811785-dd7d-4632-92ef-031d0030ecb0" xlink:href="evh-20211231.xsd#evh_CashHeldInInternationalBanksPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_b5a19660-a357-4631-bb9e-5497f9f4e384" xlink:to="loc_evh_CashHeldInInternationalBanksPercentage_ae811785-dd7d-4632-92ef-031d0030ecb0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_1f31e41f-1860-47de-ad40-52b67010d809" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_b5a19660-a357-4631-bb9e-5497f9f4e384" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_1f31e41f-1860-47de-ad40-52b67010d809" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue_d75a5a25-2761-4a5c-925f-b817d6d6c205" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_b5a19660-a357-4631-bb9e-5497f9f4e384" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue_d75a5a25-2761-4a5c-925f-b817d6d6c205" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTable_25120b07-eb27-4610-a3d6-8954cbeb2bad" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_b5a19660-a357-4631-bb9e-5497f9f4e384" xlink:to="loc_us-gaap_ConcentrationRiskTable_25120b07-eb27-4610-a3d6-8954cbeb2bad" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_988320e4-7e29-472a-891d-eaad4f1e5801" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MajorCustomersAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ConcentrationRiskTable_25120b07-eb27-4610-a3d6-8954cbeb2bad" xlink:to="loc_srt_MajorCustomersAxis_988320e4-7e29-472a-891d-eaad4f1e5801" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_988320e4-7e29-472a-891d-eaad4f1e5801_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_MajorCustomersAxis_988320e4-7e29-472a-891d-eaad4f1e5801" xlink:to="loc_srt_NameOfMajorCustomerDomain_988320e4-7e29-472a-891d-eaad4f1e5801_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_1be84e0c-15ab-4628-a1f0-e60807b283ac" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_MajorCustomersAxis_988320e4-7e29-472a-891d-eaad4f1e5801" xlink:to="loc_srt_NameOfMajorCustomerDomain_1be84e0c-15ab-4628-a1f0-e60807b283ac" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_CookCountyHealthAndHospitalsSystemMember_1dcaceaa-57b6-42dd-9416-9415d55a3f1e" xlink:href="evh-20211231.xsd#evh_CookCountyHealthAndHospitalsSystemMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_1be84e0c-15ab-4628-a1f0-e60807b283ac" xlink:to="loc_evh_CookCountyHealthAndHospitalsSystemMember_1dcaceaa-57b6-42dd-9416-9415d55a3f1e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_FloridaBlueMedicareIncMember_2ac2f5a6-f264-4a02-a09e-bdf3945cda81" xlink:href="evh-20211231.xsd#evh_FloridaBlueMedicareIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_1be84e0c-15ab-4628-a1f0-e60807b283ac" xlink:to="loc_evh_FloridaBlueMedicareIncMember_2ac2f5a6-f264-4a02-a09e-bdf3945cda81" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_NewMexicoHealthConnectionsMember_4acadcf3-a1b8-4e32-bdc6-c887e34ee6f7" xlink:href="evh-20211231.xsd#evh_NewMexicoHealthConnectionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_1be84e0c-15ab-4628-a1f0-e60807b283ac" xlink:to="loc_evh_NewMexicoHealthConnectionsMember_4acadcf3-a1b8-4e32-bdc6-c887e34ee6f7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_UniversityHealthCaredbaPassportHealthPlanMember_ec922c58-8304-4fa7-8de6-256b1830e021" xlink:href="evh-20211231.xsd#evh_UniversityHealthCaredbaPassportHealthPlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_1be84e0c-15ab-4628-a1f0-e60807b283ac" xlink:to="loc_evh_UniversityHealthCaredbaPassportHealthPlanMember_ec922c58-8304-4fa7-8de6-256b1830e021" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_MolinaHealthcareMember_114f3f23-6b15-4e08-917e-53e0d3b7f75d" xlink:href="evh-20211231.xsd#evh_MolinaHealthcareMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_1be84e0c-15ab-4628-a1f0-e60807b283ac" xlink:to="loc_evh_MolinaHealthcareMember_114f3f23-6b15-4e08-917e-53e0d3b7f75d" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_6f33adc0-d31f-485d-9c15-22fbd3fb6044" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ConcentrationRiskTable_25120b07-eb27-4610-a3d6-8954cbeb2bad" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_6f33adc0-d31f-485d-9c15-22fbd3fb6044" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_6f33adc0-d31f-485d-9c15-22fbd3fb6044_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_6f33adc0-d31f-485d-9c15-22fbd3fb6044" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_6f33adc0-d31f-485d-9c15-22fbd3fb6044_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_69320fa0-7b02-4030-97b6-637be1694756" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_6f33adc0-d31f-485d-9c15-22fbd3fb6044" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_69320fa0-7b02-4030-97b6-637be1694756" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember_c72d75ca-aae2-4b36-aea0-0336d99c31d6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_69320fa0-7b02-4030-97b6-637be1694756" xlink:to="loc_us-gaap_CustomerConcentrationRiskMember_c72d75ca-aae2-4b36-aea0-0336d99c31d6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_06f7ce95-856b-4079-a42f-45b1f80241cd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ConcentrationRiskTable_25120b07-eb27-4610-a3d6-8954cbeb2bad" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_06f7ce95-856b-4079-a42f-45b1f80241cd" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_06f7ce95-856b-4079-a42f-45b1f80241cd_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_06f7ce95-856b-4079-a42f-45b1f80241cd" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_06f7ce95-856b-4079-a42f-45b1f80241cd_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_8ced7610-44ac-4e35-8611-4168fe7660bd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_06f7ce95-856b-4079-a42f-45b1f80241cd" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_8ced7610-44ac-4e35-8611-4168fe7660bd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableMember_9163f0e2-6c79-4027-ac18-0aca0dcef80e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_8ced7610-44ac-4e35-8611-4168fe7660bd" xlink:to="loc_us-gaap_AccountsReceivableMember_9163f0e2-6c79-4027-ac18-0aca0dcef80e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesRevenueNetMember_41c3f528-6c54-42a0-8610-2b8b8c95b4df" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SalesRevenueNetMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_8ced7610-44ac-4e35-8611-4168fe7660bd" xlink:to="loc_us-gaap_SalesRevenueNetMember_41c3f528-6c54-42a0-8610-2b8b8c95b4df" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_1d86ab1f-e4d6-4506-8262-c3637207d85a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ConcentrationRiskTable_25120b07-eb27-4610-a3d6-8954cbeb2bad" xlink:to="loc_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_1d86ab1f-e4d6-4506-8262-c3637207d85a" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivableTypeDomain_1d86ab1f-e4d6-4506-8262-c3637207d85a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReceivableTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_1d86ab1f-e4d6-4506-8262-c3637207d85a" xlink:to="loc_us-gaap_ReceivableTypeDomain_1d86ab1f-e4d6-4506-8262-c3637207d85a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivableTypeDomain_94096a34-1fb0-4f63-bf78-a0d79ef7f973" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReceivableTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_1d86ab1f-e4d6-4506-8262-c3637207d85a" xlink:to="loc_us-gaap_ReceivableTypeDomain_94096a34-1fb0-4f63-bf78-a0d79ef7f973" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceReceivablesMember_c5bea3bb-b83c-4ccb-a64c-04f76d92018e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceReceivablesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReceivableTypeDomain_94096a34-1fb0-4f63-bf78-a0d79ef7f973" xlink:to="loc_us-gaap_FinanceReceivablesMember_c5bea3bb-b83c-4ccb-a64c-04f76d92018e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_eece6f59-bda6-4332-b3e7-4f6ea6ebd008" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ConcentrationRiskTable_25120b07-eb27-4610-a3d6-8954cbeb2bad" xlink:to="loc_srt_ProductOrServiceAxis_eece6f59-bda6-4332-b3e7-4f6ea6ebd008" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_eece6f59-bda6-4332-b3e7-4f6ea6ebd008_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_eece6f59-bda6-4332-b3e7-4f6ea6ebd008" xlink:to="loc_srt_ProductsAndServicesDomain_eece6f59-bda6-4332-b3e7-4f6ea6ebd008_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_b9eb80e7-d187-4730-a89c-39f820001a00" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_eece6f59-bda6-4332-b3e7-4f6ea6ebd008" xlink:to="loc_srt_ProductsAndServicesDomain_b9eb80e7-d187-4730-a89c-39f820001a00" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_PremiumsRevenueMember_5a8ef2f0-1610-4655-9d11-658db0def151" xlink:href="evh-20211231.xsd#evh_PremiumsRevenueMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_b9eb80e7-d187-4730-a89c-39f820001a00" xlink:to="loc_evh_PremiumsRevenueMember_5a8ef2f0-1610-4655-9d11-658db0def151" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis_81b9049b-bfff-4f4c-8844-7c2d6104e177" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupClassificationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ConcentrationRiskTable_25120b07-eb27-4610-a3d6-8954cbeb2bad" xlink:to="loc_us-gaap_DisposalGroupClassificationAxis_81b9049b-bfff-4f4c-8844-7c2d6104e177" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_81b9049b-bfff-4f4c-8844-7c2d6104e177_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_81b9049b-bfff-4f4c-8844-7c2d6104e177" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_81b9049b-bfff-4f4c-8844-7c2d6104e177_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_4ac0547c-d0b9-4a66-bc66-f0a73e1c4a91" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_81b9049b-bfff-4f4c-8844-7c2d6104e177" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_4ac0547c-d0b9-4a66-bc66-f0a73e1c4a91" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationsDisposedOfBySaleMember_b8e8e90c-ca5b-4749-b8e3-0d76fa4954a4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DiscontinuedOperationsDisposedOfBySaleMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain_4ac0547c-d0b9-4a66-bc66-f0a73e1c4a91" xlink:to="loc_us-gaap_DiscontinuedOperationsDisposedOfBySaleMember_b8e8e90c-ca5b-4749-b8e3-0d76fa4954a4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_b4c2d8c4-c0ce-4ffc-b5a6-fc617f0cd80e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ConcentrationRiskTable_25120b07-eb27-4610-a3d6-8954cbeb2bad" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_b4c2d8c4-c0ce-4ffc-b5a6-fc617f0cd80e" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_b4c2d8c4-c0ce-4ffc-b5a6-fc617f0cd80e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_b4c2d8c4-c0ce-4ffc-b5a6-fc617f0cd80e" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_b4c2d8c4-c0ce-4ffc-b5a6-fc617f0cd80e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_5e52167c-0a81-41b5-b2eb-76986b8ac985" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_b4c2d8c4-c0ce-4ffc-b5a6-fc617f0cd80e" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_5e52167c-0a81-41b5-b2eb-76986b8ac985" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_TrueHealthMember_5fe3b31f-f150-4d00-9c76-018cb9910a79" xlink:href="evh-20211231.xsd#evh_TrueHealthMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_5e52167c-0a81-41b5-b2eb-76986b8ac985" xlink:to="loc_evh_TrueHealthMember_5fe3b31f-f150-4d00-9c76-018cb9910a79" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/LeasesNarrativeDetails" xlink:type="simple" xlink:href="evh-20211231.xsd#LeasesNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.evolenthealth.com/role/LeasesNarrativeDetails" xlink:type="extended" id="id9899c7b88c148c89567e943efdfa91f_LeasesNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems_dd28196f-f1f4-45c6-bddf-a4dc2da53d8d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LettersOfCreditOutstandingAmount_b4388a91-d804-4898-b8a9-eac2d903219d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LettersOfCreditOutstandingAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_dd28196f-f1f4-45c6-bddf-a4dc2da53d8d" xlink:to="loc_us-gaap_LettersOfCreditOutstandingAmount_b4388a91-d804-4898-b8a9-eac2d903219d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalents_44b211ae-deca-4b44-8df5-a41dea475304" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalents"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_dd28196f-f1f4-45c6-bddf-a4dc2da53d8d" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalents_44b211ae-deca-4b44-8df5-a41dea475304" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable_42270444-02d6-4e9a-ba20-097ceaed9189" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_dd28196f-f1f4-45c6-bddf-a4dc2da53d8d" xlink:to="loc_us-gaap_LesseeLeaseDescriptionTable_42270444-02d6-4e9a-ba20-097ceaed9189" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsAxis_fb493f62-191a-4d3f-bcb2-106e060b2b38" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherCommitmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_42270444-02d6-4e9a-ba20-097ceaed9189" xlink:to="loc_us-gaap_OtherCommitmentsAxis_fb493f62-191a-4d3f-bcb2-106e060b2b38" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsDomain_fb493f62-191a-4d3f-bcb2-106e060b2b38_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherCommitmentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_OtherCommitmentsAxis_fb493f62-191a-4d3f-bcb2-106e060b2b38" xlink:to="loc_us-gaap_OtherCommitmentsDomain_fb493f62-191a-4d3f-bcb2-106e060b2b38_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsDomain_fe4ab73f-005c-445a-82db-066ac6828cef" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherCommitmentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_OtherCommitmentsAxis_fb493f62-191a-4d3f-bcb2-106e060b2b38" xlink:to="loc_us-gaap_OtherCommitmentsDomain_fe4ab73f-005c-445a-82db-066ac6828cef" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseAgreementsMember_e9a41e3a-27ed-436a-854e-a3d54bba09cd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseAgreementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsDomain_fe4ab73f-005c-445a-82db-066ac6828cef" xlink:to="loc_us-gaap_LeaseAgreementsMember_e9a41e3a-27ed-436a-854e-a3d54bba09cd" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/LeasesPrimaryOfficeLeasesDetails" xlink:type="simple" xlink:href="evh-20211231.xsd#LeasesPrimaryOfficeLeasesDetails"/>
  <link:definitionLink xlink:role="http://www.evolenthealth.com/role/LeasesPrimaryOfficeLeasesDetails" xlink:type="extended" id="i8e2de14006b44b39ac4cee6e86310a39_LeasesPrimaryOfficeLeasesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems_b42c4f17-cac3-4ce8-b24c-99ace281e308" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract_e7b71ca8-bef8-4937-a50a-338c96dcfeb1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_b42c4f17-cac3-4ce8-b24c-99ace281e308" xlink:to="loc_us-gaap_LesseeOperatingLeaseTermOfContract_e7b71ca8-bef8-4937-a50a-338c96dcfeb1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_9fab6498-a397-45be-ad40-e6218227a93a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_b42c4f17-cac3-4ce8-b24c-99ace281e308" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_9fab6498-a397-45be-ad40-e6218227a93a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LettersOfCreditOutstandingAmount_79b99ab1-78e3-43a4-8827-a16c78039f76" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LettersOfCreditOutstandingAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_b42c4f17-cac3-4ce8-b24c-99ace281e308" xlink:to="loc_us-gaap_LettersOfCreditOutstandingAmount_79b99ab1-78e3-43a4-8827-a16c78039f76" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable_e4ef4687-2dfb-4f51-ac3e-d38ae2f66dff" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_b42c4f17-cac3-4ce8-b24c-99ace281e308" xlink:to="loc_us-gaap_LesseeLeaseDescriptionTable_e4ef4687-2dfb-4f51-ac3e-d38ae2f66dff" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_51b76c30-9719-47ec-ae63-0edd174b5971" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_e4ef4687-2dfb-4f51-ac3e-d38ae2f66dff" xlink:to="loc_srt_StatementGeographicalAxis_51b76c30-9719-47ec-ae63-0edd174b5971" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_51b76c30-9719-47ec-ae63-0edd174b5971_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_51b76c30-9719-47ec-ae63-0edd174b5971" xlink:to="loc_srt_SegmentGeographicalDomain_51b76c30-9719-47ec-ae63-0edd174b5971_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_3b4e5c8d-2a30-4961-af81-76afbe07bce7" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_51b76c30-9719-47ec-ae63-0edd174b5971" xlink:to="loc_srt_SegmentGeographicalDomain_3b4e5c8d-2a30-4961-af81-76afbe07bce7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_VA_b07b43b8-88db-44b5-8af0-010af97fc77d" xlink:href="https://xbrl.sec.gov/stpr/2021/stpr-2021.xsd#stpr_VA"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_3b4e5c8d-2a30-4961-af81-76afbe07bce7" xlink:to="loc_stpr_VA_b07b43b8-88db-44b5-8af0-010af97fc77d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_IL_61f4c2b7-5972-4e1b-8322-c1fa8ba51072" xlink:href="https://xbrl.sec.gov/stpr/2021/stpr-2021.xsd#stpr_IL"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_3b4e5c8d-2a30-4961-af81-76afbe07bce7" xlink:to="loc_stpr_IL_61f4c2b7-5972-4e1b-8322-c1fa8ba51072" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_NJ_37019f68-09d4-4100-914c-07557aa1ca00" xlink:href="https://xbrl.sec.gov/stpr/2021/stpr-2021.xsd#stpr_NJ"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_3b4e5c8d-2a30-4961-af81-76afbe07bce7" xlink:to="loc_stpr_NJ_37019f68-09d4-4100-914c-07557aa1ca00" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_IN_71616b39-466d-41e0-9946-2dd5f9aaec3a" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_IN"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_3b4e5c8d-2a30-4961-af81-76afbe07bce7" xlink:to="loc_country_IN_71616b39-466d-41e0-9946-2dd5f9aaec3a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_CA_49789186-ea83-4e18-adb7-55f6122c0ef8" xlink:href="https://xbrl.sec.gov/stpr/2021/stpr-2021.xsd#stpr_CA"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_3b4e5c8d-2a30-4961-af81-76afbe07bce7" xlink:to="loc_stpr_CA_49789186-ea83-4e18-adb7-55f6122c0ef8" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/EarningsLossPerCommonShareAntidilutiveSecuritiesDetails" xlink:type="simple" xlink:href="evh-20211231.xsd#EarningsLossPerCommonShareAntidilutiveSecuritiesDetails"/>
  <link:definitionLink xlink:role="http://www.evolenthealth.com/role/EarningsLossPerCommonShareAntidilutiveSecuritiesDetails" xlink:type="extended" id="i5261d3ce989441ddab361cc780bf095f_EarningsLossPerCommonShareAntidilutiveSecuritiesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_85098122-42d2-45e9-be23-1ea9fe29b2c1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_93cc89fb-e832-4450-b723-6b582df58f73" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_85098122-42d2-45e9-be23-1ea9fe29b2c1" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_93cc89fb-e832-4450-b723-6b582df58f73" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_75c6315f-8878-4d28-b4a4-e561c35b7031" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_85098122-42d2-45e9-be23-1ea9fe29b2c1" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_75c6315f-8878-4d28-b4a4-e561c35b7031" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_d696f5ff-dd6e-4c7a-bc9a-1bd4d89a5847" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_75c6315f-8878-4d28-b4a4-e561c35b7031" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_d696f5ff-dd6e-4c7a-bc9a-1bd4d89a5847" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_d696f5ff-dd6e-4c7a-bc9a-1bd4d89a5847_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_d696f5ff-dd6e-4c7a-bc9a-1bd4d89a5847" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_d696f5ff-dd6e-4c7a-bc9a-1bd4d89a5847_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_a7c843c8-6bd5-4a94-9d64-7aceeaaf2eb3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_d696f5ff-dd6e-4c7a-bc9a-1bd4d89a5847" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_a7c843c8-6bd5-4a94-9d64-7aceeaaf2eb3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassBMember_12336731-5492-45e8-a595-bdebc7b41001" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonClassBMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_a7c843c8-6bd5-4a94-9d64-7aceeaaf2eb3" xlink:to="loc_us-gaap_CommonClassBMember_12336731-5492-45e8-a595-bdebc7b41001" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_RestrictedStockUnitsRSUsPerformanceBasedRestrictedStockUnitsPBRSUsAndLeveragedStockUnitsLSUsMember_1608d29d-0f9b-40b3-a91e-60466e23e45a" xlink:href="evh-20211231.xsd#evh_RestrictedStockUnitsRSUsPerformanceBasedRestrictedStockUnitsPBRSUsAndLeveragedStockUnitsLSUsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_a7c843c8-6bd5-4a94-9d64-7aceeaaf2eb3" xlink:to="loc_evh_RestrictedStockUnitsRSUsPerformanceBasedRestrictedStockUnitsPBRSUsAndLeveragedStockUnitsLSUsMember_1608d29d-0f9b-40b3-a91e-60466e23e45a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_27f5c0ff-8962-4614-82cd-83b958733e2a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_a7c843c8-6bd5-4a94-9d64-7aceeaaf2eb3" xlink:to="loc_us-gaap_EmployeeStockOptionMember_27f5c0ff-8962-4614-82cd-83b958733e2a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtMember_1d5cbb40-0f61-42d5-9313-2df4eb007ec0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertibleDebtMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_a7c843c8-6bd5-4a94-9d64-7aceeaaf2eb3" xlink:to="loc_us-gaap_ConvertibleDebtMember_1d5cbb40-0f61-42d5-9313-2df4eb007ec0" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/StockbasedCompensation2011and2015EquityIncentivePlansDetails" xlink:type="simple" xlink:href="evh-20211231.xsd#StockbasedCompensation2011and2015EquityIncentivePlansDetails"/>
  <link:definitionLink xlink:role="http://www.evolenthealth.com/role/StockbasedCompensation2011and2015EquityIncentivePlansDetails" xlink:type="extended" id="i1d7621eae6c74423905739230e0e1262_StockbasedCompensation2011and2015EquityIncentivePlansDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_343d0734-ea74-4ee9-a2a3-bf128fefb6d0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_41f763df-bd49-4880-9c7c-42585d7ba896" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_343d0734-ea74-4ee9-a2a3-bf128fefb6d0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_41f763df-bd49-4880-9c7c-42585d7ba896" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_839080fc-702b-4a62-bc44-e9939fe07957" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_343d0734-ea74-4ee9-a2a3-bf128fefb6d0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_839080fc-702b-4a62-bc44-e9939fe07957" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_1701c9c9-d23b-4956-8663-f326695c8d62" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_343d0734-ea74-4ee9-a2a3-bf128fefb6d0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_1701c9c9-d23b-4956-8663-f326695c8d62" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_6e8497e2-7a2e-42e9-9e04-99cb100173ab" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_343d0734-ea74-4ee9-a2a3-bf128fefb6d0" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_6e8497e2-7a2e-42e9-9e04-99cb100173ab" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_9f7467be-0a12-4bbd-beba-4e7c2fbf89ef" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_6e8497e2-7a2e-42e9-9e04-99cb100173ab" xlink:to="loc_us-gaap_PlanNameAxis_9f7467be-0a12-4bbd-beba-4e7c2fbf89ef" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_9f7467be-0a12-4bbd-beba-4e7c2fbf89ef_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_9f7467be-0a12-4bbd-beba-4e7c2fbf89ef" xlink:to="loc_us-gaap_PlanNameDomain_9f7467be-0a12-4bbd-beba-4e7c2fbf89ef_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_497d2392-072f-4ae7-b8cc-36819d2ed109" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_9f7467be-0a12-4bbd-beba-4e7c2fbf89ef" xlink:to="loc_us-gaap_PlanNameDomain_497d2392-072f-4ae7-b8cc-36819d2ed109" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_TwoThousandElevenEquityIncentivePlanMember_5f3c5d32-0ab0-44c1-a3e6-4dccc51c75b3" xlink:href="evh-20211231.xsd#evh_TwoThousandElevenEquityIncentivePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_497d2392-072f-4ae7-b8cc-36819d2ed109" xlink:to="loc_evh_TwoThousandElevenEquityIncentivePlanMember_5f3c5d32-0ab0-44c1-a3e6-4dccc51c75b3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_TwoThousandFifteenEvolentHealthInc.OmnibusIncentiveCompensationPlanMember_313bb60d-1848-44a7-9ca8-99a3703ef3b5" xlink:href="evh-20211231.xsd#evh_TwoThousandFifteenEvolentHealthInc.OmnibusIncentiveCompensationPlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_497d2392-072f-4ae7-b8cc-36819d2ed109" xlink:to="loc_evh_TwoThousandFifteenEvolentHealthInc.OmnibusIncentiveCompensationPlanMember_313bb60d-1848-44a7-9ca8-99a3703ef3b5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_698f6f0e-ea44-4e6e-b380-8e7c3332ab33" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_6e8497e2-7a2e-42e9-9e04-99cb100173ab" xlink:to="loc_us-gaap_StatementClassOfStockAxis_698f6f0e-ea44-4e6e-b380-8e7c3332ab33" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_698f6f0e-ea44-4e6e-b380-8e7c3332ab33_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_698f6f0e-ea44-4e6e-b380-8e7c3332ab33" xlink:to="loc_us-gaap_ClassOfStockDomain_698f6f0e-ea44-4e6e-b380-8e7c3332ab33_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_fb47ceb1-3f6d-429a-b6c5-e6da00364cc0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_698f6f0e-ea44-4e6e-b380-8e7c3332ab33" xlink:to="loc_us-gaap_ClassOfStockDomain_fb47ceb1-3f6d-429a-b6c5-e6da00364cc0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassAMember_63c55a85-3fd4-46ea-80cd-04527e4b5fe0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonClassAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_fb47ceb1-3f6d-429a-b6c5-e6da00364cc0" xlink:to="loc_us-gaap_CommonClassAMember_63c55a85-3fd4-46ea-80cd-04527e4b5fe0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_b33c7074-1ddd-49f7-8c7d-aae26873baa2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_6e8497e2-7a2e-42e9-9e04-99cb100173ab" xlink:to="loc_us-gaap_AwardTypeAxis_b33c7074-1ddd-49f7-8c7d-aae26873baa2" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_b33c7074-1ddd-49f7-8c7d-aae26873baa2_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_b33c7074-1ddd-49f7-8c7d-aae26873baa2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_b33c7074-1ddd-49f7-8c7d-aae26873baa2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f097ed58-9192-4447-a06b-cf88b5c652b8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_b33c7074-1ddd-49f7-8c7d-aae26873baa2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f097ed58-9192-4447-a06b-cf88b5c652b8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_30da4f51-34f9-472b-8a08-957779fb416b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f097ed58-9192-4447-a06b-cf88b5c652b8" xlink:to="loc_us-gaap_RestrictedStockMember_30da4f51-34f9-472b-8a08-957779fb416b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_c2eef558-40c7-4087-8035-158a4c892f01" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f097ed58-9192-4447-a06b-cf88b5c652b8" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_c2eef558-40c7-4087-8035-158a4c892f01" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_LeveragedStockUnitsLSUsMember_09fb67fa-5571-46a4-9d00-b3281cb22cfe" xlink:href="evh-20211231.xsd#evh_LeveragedStockUnitsLSUsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f097ed58-9192-4447-a06b-cf88b5c652b8" xlink:to="loc_evh_LeveragedStockUnitsLSUsMember_09fb67fa-5571-46a4-9d00-b3281cb22cfe" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_PerformanceBasedRestrictedStockUnitsPSUsMember_8d8b2ae2-5765-459d-8aa4-6d9d36200e8c" xlink:href="evh-20211231.xsd#evh_PerformanceBasedRestrictedStockUnitsPSUsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f097ed58-9192-4447-a06b-cf88b5c652b8" xlink:to="loc_evh_PerformanceBasedRestrictedStockUnitsPSUsMember_8d8b2ae2-5765-459d-8aa4-6d9d36200e8c" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/StockbasedCompensationStockbasedCompensationExpenseDetails" xlink:type="simple" xlink:href="evh-20211231.xsd#StockbasedCompensationStockbasedCompensationExpenseDetails"/>
  <link:definitionLink xlink:role="http://www.evolenthealth.com/role/StockbasedCompensationStockbasedCompensationExpenseDetails" xlink:type="extended" id="i02c3fa12a528475a97ee871d450d062f_StockbasedCompensationStockbasedCompensationExpenseDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_8e6b0587-f681-433f-b845-6026f3b5bfaf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_96085e21-d5a7-46cb-84ea-702ce6841e69" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_8e6b0587-f681-433f-b845-6026f3b5bfaf" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_96085e21-d5a7-46cb-84ea-702ce6841e69" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_d34c443a-1891-4207-a952-cde93c23db4d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_8e6b0587-f681-433f-b845-6026f3b5bfaf" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_d34c443a-1891-4207-a952-cde93c23db4d" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_f57c9820-1357-47e4-a723-dd75295286d5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_d34c443a-1891-4207-a952-cde93c23db4d" xlink:to="loc_us-gaap_AwardTypeAxis_f57c9820-1357-47e4-a723-dd75295286d5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f57c9820-1357-47e4-a723-dd75295286d5_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_f57c9820-1357-47e4-a723-dd75295286d5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f57c9820-1357-47e4-a723-dd75295286d5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9984a16d-f2ad-4877-b175-54f9fb36660c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_f57c9820-1357-47e4-a723-dd75295286d5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9984a16d-f2ad-4877-b175-54f9fb36660c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_8a96f559-db4d-4cea-b905-5690ba372400" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9984a16d-f2ad-4877-b175-54f9fb36660c" xlink:to="loc_us-gaap_EmployeeStockOptionMember_8a96f559-db4d-4cea-b905-5690ba372400" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember_00406138-0aba-4f13-a090-dde187028a01" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PerformanceSharesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9984a16d-f2ad-4877-b175-54f9fb36660c" xlink:to="loc_us-gaap_PerformanceSharesMember_00406138-0aba-4f13-a090-dde187028a01" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_466f39b5-a972-429b-bfb0-37d0c6bd9cba" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9984a16d-f2ad-4877-b175-54f9fb36660c" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_466f39b5-a972-429b-bfb0-37d0c6bd9cba" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_PerformanceBasedRestrictedStockUnitsPSUsMember_ea8b2281-a64a-486a-8554-c35352f04875" xlink:href="evh-20211231.xsd#evh_PerformanceBasedRestrictedStockUnitsPSUsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9984a16d-f2ad-4877-b175-54f9fb36660c" xlink:to="loc_evh_PerformanceBasedRestrictedStockUnitsPSUsMember_ea8b2281-a64a-486a-8554-c35352f04875" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_LeveragedStockUnitsLSUsMember_b928cd06-4ef9-495a-b01a-782c127be5c8" xlink:href="evh-20211231.xsd#evh_LeveragedStockUnitsLSUsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9984a16d-f2ad-4877-b175-54f9fb36660c" xlink:to="loc_evh_LeveragedStockUnitsLSUsMember_b928cd06-4ef9-495a-b01a-782c127be5c8" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_9ed80f68-cbd0-4bd0-a6cb-334168d9538f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_d34c443a-1891-4207-a952-cde93c23db4d" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_9ed80f68-cbd0-4bd0-a6cb-334168d9538f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_9ed80f68-cbd0-4bd0-a6cb-334168d9538f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_9ed80f68-cbd0-4bd0-a6cb-334168d9538f" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_9ed80f68-cbd0-4bd0-a6cb-334168d9538f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_7531d646-6f49-49f3-bb48-e2c8642e77ce" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_9ed80f68-cbd0-4bd0-a6cb-334168d9538f" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_7531d646-6f49-49f3-bb48-e2c8642e77ce" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfSalesMember_dc4476dd-1059-4e6c-be85-d2ee4136ceaa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfSalesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_7531d646-6f49-49f3-bb48-e2c8642e77ce" xlink:to="loc_us-gaap_CostOfSalesMember_dc4476dd-1059-4e6c-be85-d2ee4136ceaa" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_bb93cd12-d78c-4278-82c1-422feace7dd8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_7531d646-6f49-49f3-bb48-e2c8642e77ce" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_bb93cd12-d78c-4278-82c1-422feace7dd8" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/StockbasedCompensationUnrecognizedCompensationExpenseDetails" xlink:type="simple" xlink:href="evh-20211231.xsd#StockbasedCompensationUnrecognizedCompensationExpenseDetails"/>
  <link:definitionLink xlink:role="http://www.evolenthealth.com/role/StockbasedCompensationUnrecognizedCompensationExpenseDetails" xlink:type="extended" id="i9ca0a36c71d04efb8c9c488efd65f2b3_StockbasedCompensationUnrecognizedCompensationExpenseDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_c6d1432d-53e6-4cbc-92c3-92553ce73de1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_1a004093-4666-4a70-b04b-f31b72a6cfc1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_c6d1432d-53e6-4cbc-92c3-92553ce73de1" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_1a004093-4666-4a70-b04b-f31b72a6cfc1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_0d417cd0-bcee-4913-a3b0-0c1fcc942276" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_c6d1432d-53e6-4cbc-92c3-92553ce73de1" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_0d417cd0-bcee-4913-a3b0-0c1fcc942276" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_00192e33-b1a2-483d-935e-382e9f523e8d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_c6d1432d-53e6-4cbc-92c3-92553ce73de1" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_00192e33-b1a2-483d-935e-382e9f523e8d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_a84369e1-e5d5-46f5-a5f4-e744ddc5af77" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_c6d1432d-53e6-4cbc-92c3-92553ce73de1" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_a84369e1-e5d5-46f5-a5f4-e744ddc5af77" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_d6b44b24-4a2f-428c-8cc4-29b403f21989" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_c6d1432d-53e6-4cbc-92c3-92553ce73de1" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_d6b44b24-4a2f-428c-8cc4-29b403f21989" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_4ea62d3e-b6ee-4369-9598-79772383ca65" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_d6b44b24-4a2f-428c-8cc4-29b403f21989" xlink:to="loc_us-gaap_AwardTypeAxis_4ea62d3e-b6ee-4369-9598-79772383ca65" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_4ea62d3e-b6ee-4369-9598-79772383ca65_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_4ea62d3e-b6ee-4369-9598-79772383ca65" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_4ea62d3e-b6ee-4369-9598-79772383ca65_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f9682953-cc9e-4fba-8c3c-578520995cef" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_4ea62d3e-b6ee-4369-9598-79772383ca65" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f9682953-cc9e-4fba-8c3c-578520995cef" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_813190c7-2c89-4501-a849-7112ab29d65f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f9682953-cc9e-4fba-8c3c-578520995cef" xlink:to="loc_us-gaap_EmployeeStockOptionMember_813190c7-2c89-4501-a849-7112ab29d65f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_e2729ad8-f0dd-4bba-9bc5-74eefddd181c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f9682953-cc9e-4fba-8c3c-578520995cef" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_e2729ad8-f0dd-4bba-9bc5-74eefddd181c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_LeveragedStockUnitsLSUsMember_fc2b01a5-0f47-4aee-9d6a-5257fee5f60e" xlink:href="evh-20211231.xsd#evh_LeveragedStockUnitsLSUsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f9682953-cc9e-4fba-8c3c-578520995cef" xlink:to="loc_evh_LeveragedStockUnitsLSUsMember_fc2b01a5-0f47-4aee-9d6a-5257fee5f60e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_PerformanceBasedRestrictedStockUnitsPSUsMember_d7c6c4bb-7e15-44bc-a50b-95e759d81232" xlink:href="evh-20211231.xsd#evh_PerformanceBasedRestrictedStockUnitsPSUsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f9682953-cc9e-4fba-8c3c-578520995cef" xlink:to="loc_evh_PerformanceBasedRestrictedStockUnitsPSUsMember_d7c6c4bb-7e15-44bc-a50b-95e759d81232" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/StockbasedCompensationStockOptionsDetails" xlink:type="simple" xlink:href="evh-20211231.xsd#StockbasedCompensationStockOptionsDetails"/>
  <link:definitionLink xlink:role="http://www.evolenthealth.com/role/StockbasedCompensationStockOptionsDetails" xlink:type="extended" id="i1eb32b40fc6c4ca98b203637cba6ebef_StockbasedCompensationStockOptionsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c025be87-a827-40d5-8c05-13d769e9903d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_b671e376-fa3c-4898-9d42-4530f8079b83" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c025be87-a827-40d5-8c05-13d769e9903d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_b671e376-fa3c-4898-9d42-4530f8079b83" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_1a26a36c-22b4-4c06-8d5d-1b4f35890903" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c025be87-a827-40d5-8c05-13d769e9903d" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_1a26a36c-22b4-4c06-8d5d-1b4f35890903" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_b8bbe7d8-52e0-41fc-84a1-c3662e782816" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c025be87-a827-40d5-8c05-13d769e9903d" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_b8bbe7d8-52e0-41fc-84a1-c3662e782816" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_d9d931a7-c8ef-43ea-a40a-4d2cf8fc5265" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c025be87-a827-40d5-8c05-13d769e9903d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_d9d931a7-c8ef-43ea-a40a-4d2cf8fc5265" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_a33ad47a-6cbe-4580-b8e1-945c4734b095" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c025be87-a827-40d5-8c05-13d769e9903d" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_a33ad47a-6cbe-4580-b8e1-945c4734b095" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_a38c3436-986e-4d20-a562-71b2336ac63f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c025be87-a827-40d5-8c05-13d769e9903d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_a38c3436-986e-4d20-a562-71b2336ac63f" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_2bfd73aa-347a-49c8-9774-fe80c30f3c1c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c025be87-a827-40d5-8c05-13d769e9903d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_2bfd73aa-347a-49c8-9774-fe80c30f3c1c" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_d4822063-bd3d-4b5c-94d1-376f9b0454e8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c025be87-a827-40d5-8c05-13d769e9903d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_d4822063-bd3d-4b5c-94d1-376f9b0454e8" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_0812d52b-584e-44ac-971d-4fe9ffe714f6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c025be87-a827-40d5-8c05-13d769e9903d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_0812d52b-584e-44ac-971d-4fe9ffe714f6" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_90a3d7c9-5ece-4da9-8409-2ee781b1249e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c025be87-a827-40d5-8c05-13d769e9903d" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_90a3d7c9-5ece-4da9-8409-2ee781b1249e" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_9f4854ef-83eb-47e3-952b-d97a7e90c822" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c025be87-a827-40d5-8c05-13d769e9903d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_9f4854ef-83eb-47e3-952b-d97a7e90c822" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_86f70414-de56-425b-b84d-6ab4d61d9282" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c025be87-a827-40d5-8c05-13d769e9903d" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_86f70414-de56-425b-b84d-6ab4d61d9282" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_555dcffb-1660-46b2-9302-d081cc6bc584" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_86f70414-de56-425b-b84d-6ab4d61d9282" xlink:to="loc_us-gaap_AwardTypeAxis_555dcffb-1660-46b2-9302-d081cc6bc584" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_555dcffb-1660-46b2-9302-d081cc6bc584_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_555dcffb-1660-46b2-9302-d081cc6bc584" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_555dcffb-1660-46b2-9302-d081cc6bc584_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_6cfc3a7a-61a7-45ba-bb66-68ff410696ef" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_555dcffb-1660-46b2-9302-d081cc6bc584" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_6cfc3a7a-61a7-45ba-bb66-68ff410696ef" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_8d482150-8717-4a4a-bff9-01ae729afcc5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_6cfc3a7a-61a7-45ba-bb66-68ff410696ef" xlink:to="loc_us-gaap_EmployeeStockOptionMember_8d482150-8717-4a4a-bff9-01ae729afcc5" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/StockbasedCompensationPerformancebasedStockOptionAwardsDetails" xlink:type="simple" xlink:href="evh-20211231.xsd#StockbasedCompensationPerformancebasedStockOptionAwardsDetails"/>
  <link:definitionLink xlink:role="http://www.evolenthealth.com/role/StockbasedCompensationPerformancebasedStockOptionAwardsDetails" xlink:type="extended" id="ic2937b1355ec47e5abc1fe3cb17639a7_StockbasedCompensationPerformancebasedStockOptionAwardsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_03ee8126-09dd-44d6-b178-5bf168846d18" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_eb10ae10-30a2-4f5d-89fe-484b28016963" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_03ee8126-09dd-44d6-b178-5bf168846d18" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_eb10ae10-30a2-4f5d-89fe-484b28016963" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_b766f0ee-2166-4d1a-980a-d0272c1cee67" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_03ee8126-09dd-44d6-b178-5bf168846d18" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_b766f0ee-2166-4d1a-980a-d0272c1cee67" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_SharebasedCompensationArrangementbySharebasedPaymentAwardAwardVestingRightsSharePriceThreshold_e87e9235-28c0-4c87-a610-0f1a294e5599" xlink:href="evh-20211231.xsd#evh_SharebasedCompensationArrangementbySharebasedPaymentAwardAwardVestingRightsSharePriceThreshold"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_03ee8126-09dd-44d6-b178-5bf168846d18" xlink:to="loc_evh_SharebasedCompensationArrangementbySharebasedPaymentAwardAwardVestingRightsSharePriceThreshold_e87e9235-28c0-4c87-a610-0f1a294e5599" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsStockPriceTriggerConsecutiveTerm_15a510ae-6b19-4b0c-9554-e1df07aad7e0" xlink:href="evh-20211231.xsd#evh_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsStockPriceTriggerConsecutiveTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_03ee8126-09dd-44d6-b178-5bf168846d18" xlink:to="loc_evh_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsStockPriceTriggerConsecutiveTerm_15a510ae-6b19-4b0c-9554-e1df07aad7e0" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_4e19c09a-925e-4a63-8dfc-82a1a8d619a8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_03ee8126-09dd-44d6-b178-5bf168846d18" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_4e19c09a-925e-4a63-8dfc-82a1a8d619a8" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_bdc7bb3a-e474-4d07-bed7-991b71127a0c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_03ee8126-09dd-44d6-b178-5bf168846d18" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_bdc7bb3a-e474-4d07-bed7-991b71127a0c" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_5c056c0f-9ad7-4532-b7e9-b534e8e74890" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_03ee8126-09dd-44d6-b178-5bf168846d18" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_5c056c0f-9ad7-4532-b7e9-b534e8e74890" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_839ef355-ba9d-4ede-82c4-025b1e1dea9f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_03ee8126-09dd-44d6-b178-5bf168846d18" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_839ef355-ba9d-4ede-82c4-025b1e1dea9f" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_1adbb637-9e8c-4176-855b-ad512e55a9ed" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_03ee8126-09dd-44d6-b178-5bf168846d18" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_1adbb637-9e8c-4176-855b-ad512e55a9ed" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_264fd46e-6adc-45e6-9c58-a910258cdfd0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_03ee8126-09dd-44d6-b178-5bf168846d18" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_264fd46e-6adc-45e6-9c58-a910258cdfd0" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_d0c06afd-15ea-4a02-ad04-0a4dccd737da" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_03ee8126-09dd-44d6-b178-5bf168846d18" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_d0c06afd-15ea-4a02-ad04-0a4dccd737da" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_ff494312-665f-4434-ab36-df946caf921c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_03ee8126-09dd-44d6-b178-5bf168846d18" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_ff494312-665f-4434-ab36-df946caf921c" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_02705698-92ec-4239-9f13-0f9c07803969" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_03ee8126-09dd-44d6-b178-5bf168846d18" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_02705698-92ec-4239-9f13-0f9c07803969" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_WeightedAverageRemainingContractualTermAbstract_764960d2-15c5-4c6b-8dd2-34dcd1f7ac25" xlink:href="evh-20211231.xsd#evh_WeightedAverageRemainingContractualTermAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_03ee8126-09dd-44d6-b178-5bf168846d18" xlink:to="loc_evh_WeightedAverageRemainingContractualTermAbstract_764960d2-15c5-4c6b-8dd2-34dcd1f7ac25" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_f00a80dc-36cf-437b-86c1-6c54c1f36db3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_evh_WeightedAverageRemainingContractualTermAbstract_764960d2-15c5-4c6b-8dd2-34dcd1f7ac25" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_f00a80dc-36cf-437b-86c1-6c54c1f36db3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_4d108948-9a50-4f4d-b24b-187001308d7d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_evh_WeightedAverageRemainingContractualTermAbstract_764960d2-15c5-4c6b-8dd2-34dcd1f7ac25" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_4d108948-9a50-4f4d-b24b-187001308d7d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_AggregateIntrinsicValueAbstract_25bcacc2-c310-473d-9347-ba01e5153e39" xlink:href="evh-20211231.xsd#evh_AggregateIntrinsicValueAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_03ee8126-09dd-44d6-b178-5bf168846d18" xlink:to="loc_evh_AggregateIntrinsicValueAbstract_25bcacc2-c310-473d-9347-ba01e5153e39" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_f39531cc-13e0-4123-a23f-3de6da235b41" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_evh_AggregateIntrinsicValueAbstract_25bcacc2-c310-473d-9347-ba01e5153e39" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_f39531cc-13e0-4123-a23f-3de6da235b41" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_537d59eb-78fc-4770-9749-95500585ce33" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_evh_AggregateIntrinsicValueAbstract_25bcacc2-c310-473d-9347-ba01e5153e39" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_537d59eb-78fc-4770-9749-95500585ce33" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_3e22186e-2ebb-4f0c-bb5f-c226cf4fb358" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_03ee8126-09dd-44d6-b178-5bf168846d18" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_3e22186e-2ebb-4f0c-bb5f-c226cf4fb358" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_277f0540-8654-40f2-b1ef-c23c501aea73" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_3e22186e-2ebb-4f0c-bb5f-c226cf4fb358" xlink:to="loc_us-gaap_AwardTypeAxis_277f0540-8654-40f2-b1ef-c23c501aea73" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_277f0540-8654-40f2-b1ef-c23c501aea73_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_277f0540-8654-40f2-b1ef-c23c501aea73" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_277f0540-8654-40f2-b1ef-c23c501aea73_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f44d522b-2b88-4326-85d7-d3d4fb853f86" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_277f0540-8654-40f2-b1ef-c23c501aea73" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f44d522b-2b88-4326-85d7-d3d4fb853f86" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember_a9797d06-3c06-46e0-bc30-153fd7d11be7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PerformanceSharesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f44d522b-2b88-4326-85d7-d3d4fb853f86" xlink:to="loc_us-gaap_PerformanceSharesMember_a9797d06-3c06-46e0-bc30-153fd7d11be7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_6d6f8611-1002-40e0-9d41-45c6651abbbe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_3e22186e-2ebb-4f0c-bb5f-c226cf4fb358" xlink:to="loc_us-gaap_StatementClassOfStockAxis_6d6f8611-1002-40e0-9d41-45c6651abbbe" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_6d6f8611-1002-40e0-9d41-45c6651abbbe_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_6d6f8611-1002-40e0-9d41-45c6651abbbe" xlink:to="loc_us-gaap_ClassOfStockDomain_6d6f8611-1002-40e0-9d41-45c6651abbbe_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_3f367681-a8e1-4b7d-8d61-cd15a0ce2bdc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_6d6f8611-1002-40e0-9d41-45c6651abbbe" xlink:to="loc_us-gaap_ClassOfStockDomain_3f367681-a8e1-4b7d-8d61-cd15a0ce2bdc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassAMember_8b14a6c2-c894-4078-90c9-c66f4d03f69f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonClassAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_3f367681-a8e1-4b7d-8d61-cd15a0ce2bdc" xlink:to="loc_us-gaap_CommonClassAMember_8b14a6c2-c894-4078-90c9-c66f4d03f69f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingAxis_c1335170-4516-4290-94a1-f120bb70e81e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VestingAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_3e22186e-2ebb-4f0c-bb5f-c226cf4fb358" xlink:to="loc_us-gaap_VestingAxis_c1335170-4516-4290-94a1-f120bb70e81e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingDomain_c1335170-4516-4290-94a1-f120bb70e81e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VestingDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_VestingAxis_c1335170-4516-4290-94a1-f120bb70e81e" xlink:to="loc_us-gaap_VestingDomain_c1335170-4516-4290-94a1-f120bb70e81e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingDomain_5611acd8-31b4-4e68-aa2f-79aaea4e6c96" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VestingDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_VestingAxis_c1335170-4516-4290-94a1-f120bb70e81e" xlink:to="loc_us-gaap_VestingDomain_5611acd8-31b4-4e68-aa2f-79aaea4e6c96" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_3462bb6c-96aa-41aa-bcd9-71407d304c11" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VestingDomain_5611acd8-31b4-4e68-aa2f-79aaea4e6c96" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_3462bb6c-96aa-41aa-bcd9-71407d304c11" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_9f55f79a-6272-4920-b89e-ee0461311844" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VestingDomain_5611acd8-31b4-4e68-aa2f-79aaea4e6c96" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_9f55f79a-6272-4920-b89e-ee0461311844" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheThreeMember_959012cf-e09d-4faf-8cda-b4275fd4fe01" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheThreeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VestingDomain_5611acd8-31b4-4e68-aa2f-79aaea4e6c96" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheThreeMember_959012cf-e09d-4faf-8cda-b4275fd4fe01" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_SharebasedCompensationAwardSubTrancheOneMember_e073083b-92ad-4bc6-b6f2-2783548c2d9c" xlink:href="evh-20211231.xsd#evh_SharebasedCompensationAwardSubTrancheOneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VestingDomain_5611acd8-31b4-4e68-aa2f-79aaea4e6c96" xlink:to="loc_evh_SharebasedCompensationAwardSubTrancheOneMember_e073083b-92ad-4bc6-b6f2-2783548c2d9c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_SharebasedCompensationAwardSubTrancheTwoMember_5d054203-9fda-4fd7-bf4b-db16a24b529b" xlink:href="evh-20211231.xsd#evh_SharebasedCompensationAwardSubTrancheTwoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VestingDomain_5611acd8-31b4-4e68-aa2f-79aaea4e6c96" xlink:to="loc_evh_SharebasedCompensationAwardSubTrancheTwoMember_5d054203-9fda-4fd7-bf4b-db16a24b529b" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/StockbasedCompensationRestrictedStockUnitsDetails" xlink:type="simple" xlink:href="evh-20211231.xsd#StockbasedCompensationRestrictedStockUnitsDetails"/>
  <link:definitionLink xlink:role="http://www.evolenthealth.com/role/StockbasedCompensationRestrictedStockUnitsDetails" xlink:type="extended" id="i907020f5b4444f10a82da2f3e3ae00fb_StockbasedCompensationRestrictedStockUnitsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_edcb8ea0-0a75-4008-b1bc-38eba054ef28" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_3cc7f9dd-8d3d-41d0-8379-321ad97b198d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_edcb8ea0-0a75-4008-b1bc-38eba054ef28" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_3cc7f9dd-8d3d-41d0-8379-321ad97b198d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1_f8fdba4c-16d5-4c26-b08e-b76577e007b8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_edcb8ea0-0a75-4008-b1bc-38eba054ef28" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1_f8fdba4c-16d5-4c26-b08e-b76577e007b8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_f350209e-645e-4a9b-a93f-c93db20836b0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_edcb8ea0-0a75-4008-b1bc-38eba054ef28" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_f350209e-645e-4a9b-a93f-c93db20836b0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_45224d3b-5915-498d-a612-cb5d0a9ef76b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_edcb8ea0-0a75-4008-b1bc-38eba054ef28" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_45224d3b-5915-498d-a612-cb5d0a9ef76b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_12a0372a-cb90-469c-a787-f597e571eb34" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_45224d3b-5915-498d-a612-cb5d0a9ef76b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_12a0372a-cb90-469c-a787-f597e571eb34" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_d7a55c74-d6cb-4aef-970e-ea66497bfdd1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_45224d3b-5915-498d-a612-cb5d0a9ef76b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_d7a55c74-d6cb-4aef-970e-ea66497bfdd1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_380620e9-91dd-4155-852f-c8da0bd79e66" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_45224d3b-5915-498d-a612-cb5d0a9ef76b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_380620e9-91dd-4155-852f-c8da0bd79e66" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_4eeed7b5-a945-463b-8ea2-11886cf77257" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_45224d3b-5915-498d-a612-cb5d0a9ef76b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_4eeed7b5-a945-463b-8ea2-11886cf77257" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_85c169d7-cb7e-4c38-9e3c-dd120c7303dc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_e3a58077-2464-4d1f-ac81-b1a15f0793e9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_edcb8ea0-0a75-4008-b1bc-38eba054ef28" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_e3a58077-2464-4d1f-ac81-b1a15f0793e9" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_bbd4d799-8f82-4417-b7ff-0db489523fed" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_e3a58077-2464-4d1f-ac81-b1a15f0793e9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_bbd4d799-8f82-4417-b7ff-0db489523fed" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_09ea6630-30b1-42a3-9e48-bba6083f9c92" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_e3a58077-2464-4d1f-ac81-b1a15f0793e9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_09ea6630-30b1-42a3-9e48-bba6083f9c92" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_193068f4-8ef8-4437-a024-ca05c402d963" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_e3a58077-2464-4d1f-ac81-b1a15f0793e9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_193068f4-8ef8-4437-a024-ca05c402d963" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_ea5be2db-57f7-41d7-aca9-21c391657528" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_e3a58077-2464-4d1f-ac81-b1a15f0793e9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_ea5be2db-57f7-41d7-aca9-21c391657528" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_8b823531-b76f-4d70-91c3-b31d42a293f5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_2ebf3576-f7b5-4be3-a86b-d28ff7d4486e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_edcb8ea0-0a75-4008-b1bc-38eba054ef28" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_2ebf3576-f7b5-4be3-a86b-d28ff7d4486e" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_d685bc1d-7293-4779-9324-bb4d631e61b9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_edcb8ea0-0a75-4008-b1bc-38eba054ef28" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_d685bc1d-7293-4779-9324-bb4d631e61b9" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_9d14fb2b-f9e9-49dc-8b09-78286cf71595" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_d685bc1d-7293-4779-9324-bb4d631e61b9" xlink:to="loc_us-gaap_AwardTypeAxis_9d14fb2b-f9e9-49dc-8b09-78286cf71595" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9d14fb2b-f9e9-49dc-8b09-78286cf71595_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_9d14fb2b-f9e9-49dc-8b09-78286cf71595" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9d14fb2b-f9e9-49dc-8b09-78286cf71595_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_380f1c82-0ec4-4eeb-95c6-5134967ddd86" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_9d14fb2b-f9e9-49dc-8b09-78286cf71595" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_380f1c82-0ec4-4eeb-95c6-5134967ddd86" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_d7a3d34d-b0f6-4ce9-99be-5bd83f73d515" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_380f1c82-0ec4-4eeb-95c6-5134967ddd86" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_d7a3d34d-b0f6-4ce9-99be-5bd83f73d515" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_f50f90dd-6338-4f82-931b-f4d5350f6d41" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_d685bc1d-7293-4779-9324-bb4d631e61b9" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_f50f90dd-6338-4f82-931b-f4d5350f6d41" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_f50f90dd-6338-4f82-931b-f4d5350f6d41_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_f50f90dd-6338-4f82-931b-f4d5350f6d41" xlink:to="loc_us-gaap_RelatedPartyDomain_f50f90dd-6338-4f82-931b-f4d5350f6d41_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_2d22519c-f399-4bc4-9a89-0861b6e72b1b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_f50f90dd-6338-4f82-931b-f4d5350f6d41" xlink:to="loc_us-gaap_RelatedPartyDomain_2d22519c-f399-4bc4-9a89-0861b6e72b1b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_NonEmployeeDirectorsMember_60aa43ee-c644-4d85-b542-d78273615eaf" xlink:href="evh-20211231.xsd#evh_NonEmployeeDirectorsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_2d22519c-f399-4bc4-9a89-0861b6e72b1b" xlink:to="loc_evh_NonEmployeeDirectorsMember_60aa43ee-c644-4d85-b542-d78273615eaf" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_abfb6ddc-d28c-4e0a-a373-49e48cc7ce9f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_d685bc1d-7293-4779-9324-bb4d631e61b9" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_abfb6ddc-d28c-4e0a-a373-49e48cc7ce9f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_abfb6ddc-d28c-4e0a-a373-49e48cc7ce9f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_abfb6ddc-d28c-4e0a-a373-49e48cc7ce9f" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_abfb6ddc-d28c-4e0a-a373-49e48cc7ce9f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_39da7ee3-c47e-4160-931c-c2408e7d1536" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_abfb6ddc-d28c-4e0a-a373-49e48cc7ce9f" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_39da7ee3-c47e-4160-931c-c2408e7d1536" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_NewCenturyHealthMember_284b9e09-e47f-42ec-bd0d-b44ba8938bbf" xlink:href="evh-20211231.xsd#evh_NewCenturyHealthMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_39da7ee3-c47e-4160-931c-c2408e7d1536" xlink:to="loc_evh_NewCenturyHealthMember_284b9e09-e47f-42ec-bd0d-b44ba8938bbf" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/StockbasedCompensationLeveragedStockUnitsDetails" xlink:type="simple" xlink:href="evh-20211231.xsd#StockbasedCompensationLeveragedStockUnitsDetails"/>
  <link:definitionLink xlink:role="http://www.evolenthealth.com/role/StockbasedCompensationLeveragedStockUnitsDetails" xlink:type="extended" id="i52a4dd84045245f4bc9cb599095cd7b5_StockbasedCompensationLeveragedStockUnitsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_bec8b2d2-7d5a-4f58-b8c3-c631a0bad955" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_6db3b868-23ef-4ef8-a9ce-c92055557e1a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_bec8b2d2-7d5a-4f58-b8c3-c631a0bad955" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_6db3b868-23ef-4ef8-a9ce-c92055557e1a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsStockPriceIncreasePercentage_da814a11-e5e0-449d-8ccb-b61e487aba18" xlink:href="evh-20211231.xsd#evh_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsStockPriceIncreasePercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_bec8b2d2-7d5a-4f58-b8c3-c631a0bad955" xlink:to="loc_evh_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsStockPriceIncreasePercentage_da814a11-e5e0-449d-8ccb-b61e487aba18" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_644007b2-54c3-47d3-8a3f-ee00c8b24a48" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_bec8b2d2-7d5a-4f58-b8c3-c631a0bad955" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_644007b2-54c3-47d3-8a3f-ee00c8b24a48" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_9f7b4189-fa03-4786-9ae9-797f9f53dc5e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_bec8b2d2-7d5a-4f58-b8c3-c631a0bad955" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_9f7b4189-fa03-4786-9ae9-797f9f53dc5e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_b1572711-2096-4e36-bbb0-a0be636efc4b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_bec8b2d2-7d5a-4f58-b8c3-c631a0bad955" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_b1572711-2096-4e36-bbb0-a0be636efc4b" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_a7b9d783-f70b-4769-9730-43d22ec61054" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_bec8b2d2-7d5a-4f58-b8c3-c631a0bad955" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_a7b9d783-f70b-4769-9730-43d22ec61054" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_e29509fd-93cc-4eba-abee-b73b068f4034" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_bec8b2d2-7d5a-4f58-b8c3-c631a0bad955" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_e29509fd-93cc-4eba-abee-b73b068f4034" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_1e85bf89-69e2-4f9e-83aa-d2eb06948a72" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_bec8b2d2-7d5a-4f58-b8c3-c631a0bad955" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_1e85bf89-69e2-4f9e-83aa-d2eb06948a72" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_01efb6e3-f369-4a73-a3fd-65c3cc95aee5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_bec8b2d2-7d5a-4f58-b8c3-c631a0bad955" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_01efb6e3-f369-4a73-a3fd-65c3cc95aee5" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_5d2c76eb-f352-4737-89dd-a1e0bd78ac5a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_01efb6e3-f369-4a73-a3fd-65c3cc95aee5" xlink:to="loc_us-gaap_AwardTypeAxis_5d2c76eb-f352-4737-89dd-a1e0bd78ac5a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_5d2c76eb-f352-4737-89dd-a1e0bd78ac5a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_5d2c76eb-f352-4737-89dd-a1e0bd78ac5a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_5d2c76eb-f352-4737-89dd-a1e0bd78ac5a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0f3e9d21-2fcc-4efe-95f6-0bfd4e16ccb0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_5d2c76eb-f352-4737-89dd-a1e0bd78ac5a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0f3e9d21-2fcc-4efe-95f6-0bfd4e16ccb0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_LeveragedStockUnitsLSUsMember_c9274714-459f-4aff-8233-2cb3a40f4ef0" xlink:href="evh-20211231.xsd#evh_LeveragedStockUnitsLSUsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0f3e9d21-2fcc-4efe-95f6-0bfd4e16ccb0" xlink:to="loc_evh_LeveragedStockUnitsLSUsMember_c9274714-459f-4aff-8233-2cb3a40f4ef0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingAxis_94bfcaa4-9c37-48cd-b621-4e697b579ebb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VestingAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_01efb6e3-f369-4a73-a3fd-65c3cc95aee5" xlink:to="loc_us-gaap_VestingAxis_94bfcaa4-9c37-48cd-b621-4e697b579ebb" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingDomain_94bfcaa4-9c37-48cd-b621-4e697b579ebb_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VestingDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_VestingAxis_94bfcaa4-9c37-48cd-b621-4e697b579ebb" xlink:to="loc_us-gaap_VestingDomain_94bfcaa4-9c37-48cd-b621-4e697b579ebb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingDomain_e2f8da15-a136-460c-bcd3-5d74613c19fd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VestingDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_VestingAxis_94bfcaa4-9c37-48cd-b621-4e697b579ebb" xlink:to="loc_us-gaap_VestingDomain_e2f8da15-a136-460c-bcd3-5d74613c19fd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_51c184a1-5e62-4c72-a6e0-33edc1ed8789" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VestingDomain_e2f8da15-a136-460c-bcd3-5d74613c19fd" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_51c184a1-5e62-4c72-a6e0-33edc1ed8789" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_c9e2355e-d58a-4b4f-9976-2bea6deeb3ab" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VestingDomain_e2f8da15-a136-460c-bcd3-5d74613c19fd" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_c9e2355e-d58a-4b4f-9976-2bea6deeb3ab" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheThreeMember_1472e93a-16ae-494c-af63-210390278522" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheThreeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VestingDomain_e2f8da15-a136-460c-bcd3-5d74613c19fd" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheThreeMember_1472e93a-16ae-494c-af63-210390278522" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_SharebasedPaymentArrangementTrancheFourMember_0e97024b-73d7-4637-bfee-9b0b429ada8e" xlink:href="evh-20211231.xsd#evh_SharebasedPaymentArrangementTrancheFourMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VestingDomain_e2f8da15-a136-460c-bcd3-5d74613c19fd" xlink:to="loc_evh_SharebasedPaymentArrangementTrancheFourMember_0e97024b-73d7-4637-bfee-9b0b429ada8e" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/StockbasedCompensationLeveragedStockUnitsActivityDetails" xlink:type="simple" xlink:href="evh-20211231.xsd#StockbasedCompensationLeveragedStockUnitsActivityDetails"/>
  <link:definitionLink xlink:role="http://www.evolenthealth.com/role/StockbasedCompensationLeveragedStockUnitsActivityDetails" xlink:type="extended" id="ib08c0bd45ab14b9e92b47f7402d5c2ec_StockbasedCompensationLeveragedStockUnitsActivityDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9fd091cf-3257-4c5b-acb7-769f189a454b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingAbstract_b458a748-6a4c-496a-8cd5-411717b77b06" xlink:href="evh-20211231.xsd#evh_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9fd091cf-3257-4c5b-acb7-769f189a454b" xlink:to="loc_evh_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingAbstract_b458a748-6a4c-496a-8cd5-411717b77b06" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_5b161b45-813a-4242-a17d-6b724005d2c1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_evh_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingAbstract_b458a748-6a4c-496a-8cd5-411717b77b06" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_5b161b45-813a-4242-a17d-6b724005d2c1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_e147a43c-73c4-40ab-b5fc-a293531b92f3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_evh_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingAbstract_b458a748-6a4c-496a-8cd5-411717b77b06" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_e147a43c-73c4-40ab-b5fc-a293531b92f3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_a1aae7ff-21a5-4446-9b7d-cfdf6f978818" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_evh_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingAbstract_b458a748-6a4c-496a-8cd5-411717b77b06" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_a1aae7ff-21a5-4446-9b7d-cfdf6f978818" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_59e7f10d-1366-4f4f-9b1b-345ad946bd20" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_evh_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingAbstract_b458a748-6a4c-496a-8cd5-411717b77b06" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_59e7f10d-1366-4f4f-9b1b-345ad946bd20" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestAbstract_31095ddf-458e-45ba-9ef5-11cba605567f" xlink:href="evh-20211231.xsd#evh_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9fd091cf-3257-4c5b-acb7-769f189a454b" xlink:to="loc_evh_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestAbstract_31095ddf-458e-45ba-9ef5-11cba605567f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestNumber_9439e6be-17a9-457b-9e89-9dd6e7c47171" xlink:href="evh-20211231.xsd#evh_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_evh_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestAbstract_31095ddf-458e-45ba-9ef5-11cba605567f" xlink:to="loc_evh_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestNumber_9439e6be-17a9-457b-9e89-9dd6e7c47171" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestWeightedAverageGrantDateFairValue_000df0e4-ee29-4f35-9975-ee6d9024832a" xlink:href="evh-20211231.xsd#evh_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_evh_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestAbstract_31095ddf-458e-45ba-9ef5-11cba605567f" xlink:to="loc_evh_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestWeightedAverageGrantDateFairValue_000df0e4-ee29-4f35-9975-ee6d9024832a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestWeightedAverageRemainingContractualTerms_05bbe80b-8434-4c42-8655-6a97c4e299c8" xlink:href="evh-20211231.xsd#evh_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestWeightedAverageRemainingContractualTerms"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_evh_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestAbstract_31095ddf-458e-45ba-9ef5-11cba605567f" xlink:to="loc_evh_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestWeightedAverageRemainingContractualTerms_05bbe80b-8434-4c42-8655-6a97c4e299c8" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVestedAndExpectedToVest_031636a4-10d0-4397-bb40-9956c31bd3e2" xlink:href="evh-20211231.xsd#evh_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVestedAndExpectedToVest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_evh_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestAbstract_31095ddf-458e-45ba-9ef5-11cba605567f" xlink:to="loc_evh_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVestedAndExpectedToVest_031636a4-10d0-4397-bb40-9956c31bd3e2" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_c7cc89f5-39ac-4d56-bd79-9b3e07343176" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9fd091cf-3257-4c5b-acb7-769f189a454b" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_c7cc89f5-39ac-4d56-bd79-9b3e07343176" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_8b57a1b6-56d0-4822-960e-22fb1b8a2b57" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_c7cc89f5-39ac-4d56-bd79-9b3e07343176" xlink:to="loc_us-gaap_AwardTypeAxis_8b57a1b6-56d0-4822-960e-22fb1b8a2b57" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_8b57a1b6-56d0-4822-960e-22fb1b8a2b57_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_8b57a1b6-56d0-4822-960e-22fb1b8a2b57" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_8b57a1b6-56d0-4822-960e-22fb1b8a2b57_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_51d9f1c9-59d8-4f23-8a51-689b89673c6c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_8b57a1b6-56d0-4822-960e-22fb1b8a2b57" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_51d9f1c9-59d8-4f23-8a51-689b89673c6c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_LeveragedStockUnitsLSUsMember_88ca1540-0965-4e3e-bd10-f00cda5a220b" xlink:href="evh-20211231.xsd#evh_LeveragedStockUnitsLSUsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_51d9f1c9-59d8-4f23-8a51-689b89673c6c" xlink:to="loc_evh_LeveragedStockUnitsLSUsMember_88ca1540-0965-4e3e-bd10-f00cda5a220b" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/StockbasedCompensationPerformancebasedRSUsDetails" xlink:type="simple" xlink:href="evh-20211231.xsd#StockbasedCompensationPerformancebasedRSUsDetails"/>
  <link:definitionLink xlink:role="http://www.evolenthealth.com/role/StockbasedCompensationPerformancebasedRSUsDetails" xlink:type="extended" id="i184865d306294f778e95f32c921d3640_StockbasedCompensationPerformancebasedRSUsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2c075704-540e-459d-9a14-470d4e0a75d0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_1863970b-e611-4954-b33d-b13815e86506" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2c075704-540e-459d-9a14-470d4e0a75d0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_1863970b-e611-4954-b33d-b13815e86506" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_EarningsBeforeInterestTaxesDepreciationAndAmortizationGoalPeriod_28769c84-0d0e-43a0-8752-2a880a2844b3" xlink:href="evh-20211231.xsd#evh_EarningsBeforeInterestTaxesDepreciationAndAmortizationGoalPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2c075704-540e-459d-9a14-470d4e0a75d0" xlink:to="loc_evh_EarningsBeforeInterestTaxesDepreciationAndAmortizationGoalPeriod_28769c84-0d0e-43a0-8752-2a880a2844b3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsPerformanceGoalThreshold_1b0236e5-c4f2-4352-ad10-52c109755213" xlink:href="evh-20211231.xsd#evh_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsPerformanceGoalThreshold"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2c075704-540e-459d-9a14-470d4e0a75d0" xlink:to="loc_evh_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsPerformanceGoalThreshold_1b0236e5-c4f2-4352-ad10-52c109755213" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsMaximumPerformanceAchievedPercentageOfTargetedSharesEarned_cd082c4c-1e76-456a-a049-3447624a8e84" xlink:href="evh-20211231.xsd#evh_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsMaximumPerformanceAchievedPercentageOfTargetedSharesEarned"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2c075704-540e-459d-9a14-470d4e0a75d0" xlink:to="loc_evh_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsMaximumPerformanceAchievedPercentageOfTargetedSharesEarned_cd082c4c-1e76-456a-a049-3447624a8e84" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageAdjustmentOfSharesEarnedTotalShareholderReturnInBottomQuartile_fc8b02e8-92bf-4360-9aa5-a0f52c18992c" xlink:href="evh-20211231.xsd#evh_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageAdjustmentOfSharesEarnedTotalShareholderReturnInBottomQuartile"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2c075704-540e-459d-9a14-470d4e0a75d0" xlink:to="loc_evh_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageAdjustmentOfSharesEarnedTotalShareholderReturnInBottomQuartile_fc8b02e8-92bf-4360-9aa5-a0f52c18992c" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageAdjustmentOfSharesEarnedTotalShareholderReturnInTopQuartile_098f31ac-b19a-4d43-a8a4-ca11068fe88a" xlink:href="evh-20211231.xsd#evh_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageAdjustmentOfSharesEarnedTotalShareholderReturnInTopQuartile"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2c075704-540e-459d-9a14-470d4e0a75d0" xlink:to="loc_evh_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageAdjustmentOfSharesEarnedTotalShareholderReturnInTopQuartile_098f31ac-b19a-4d43-a8a4-ca11068fe88a" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_415bab21-81f5-4e86-88f7-d424fb4e3b6e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2c075704-540e-459d-9a14-470d4e0a75d0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_415bab21-81f5-4e86-88f7-d424fb4e3b6e" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_886c6f95-40f3-4535-b7d5-73941c67e456" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2c075704-540e-459d-9a14-470d4e0a75d0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_886c6f95-40f3-4535-b7d5-73941c67e456" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_79d3b7d6-487d-4f9a-a803-730701a35e7f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_886c6f95-40f3-4535-b7d5-73941c67e456" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_79d3b7d6-487d-4f9a-a803-730701a35e7f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_c5b5bcae-dd0b-4435-a8d4-727163f946b6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_886c6f95-40f3-4535-b7d5-73941c67e456" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_c5b5bcae-dd0b-4435-a8d4-727163f946b6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_bbbb7900-d9be-4ecc-83d4-37a87227a06d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_886c6f95-40f3-4535-b7d5-73941c67e456" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_bbbb7900-d9be-4ecc-83d4-37a87227a06d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_31a74dc4-5c93-4d9c-a461-a2d484ceb5af" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_886c6f95-40f3-4535-b7d5-73941c67e456" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_31a74dc4-5c93-4d9c-a461-a2d484ceb5af" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_9d2ac266-4748-4c08-ad8d-f50f885d772f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2c075704-540e-459d-9a14-470d4e0a75d0" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_9d2ac266-4748-4c08-ad8d-f50f885d772f" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_79b90816-f31e-4906-b2e7-35d480335380" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_9d2ac266-4748-4c08-ad8d-f50f885d772f" xlink:to="loc_us-gaap_AwardTypeAxis_79b90816-f31e-4906-b2e7-35d480335380" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_79b90816-f31e-4906-b2e7-35d480335380_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_79b90816-f31e-4906-b2e7-35d480335380" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_79b90816-f31e-4906-b2e7-35d480335380_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_675dbbf1-e7bb-49d6-abab-70972f6df3a0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_79b90816-f31e-4906-b2e7-35d480335380" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_675dbbf1-e7bb-49d6-abab-70972f6df3a0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_PerformanceBasedRestrictedStockUnitsPSUsMember_3933a74f-3d26-4823-ac34-e6acc577f543" xlink:href="evh-20211231.xsd#evh_PerformanceBasedRestrictedStockUnitsPSUsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_675dbbf1-e7bb-49d6-abab-70972f6df3a0" xlink:to="loc_evh_PerformanceBasedRestrictedStockUnitsPSUsMember_3933a74f-3d26-4823-ac34-e6acc577f543" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingAxis_572febce-6302-4741-831a-cd8d3dd546ae" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VestingAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_9d2ac266-4748-4c08-ad8d-f50f885d772f" xlink:to="loc_us-gaap_VestingAxis_572febce-6302-4741-831a-cd8d3dd546ae" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingDomain_572febce-6302-4741-831a-cd8d3dd546ae_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VestingDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_VestingAxis_572febce-6302-4741-831a-cd8d3dd546ae" xlink:to="loc_us-gaap_VestingDomain_572febce-6302-4741-831a-cd8d3dd546ae_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingDomain_3296f7e6-dd5b-476f-896b-f93bba4e64e3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VestingDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_VestingAxis_572febce-6302-4741-831a-cd8d3dd546ae" xlink:to="loc_us-gaap_VestingDomain_3296f7e6-dd5b-476f-896b-f93bba4e64e3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_acabe2cb-ceff-4905-9875-2c8bb3807de4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VestingDomain_3296f7e6-dd5b-476f-896b-f93bba4e64e3" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_acabe2cb-ceff-4905-9875-2c8bb3807de4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_8e643a3a-aad5-4b57-8581-05a0e30ca8b9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VestingDomain_3296f7e6-dd5b-476f-896b-f93bba4e64e3" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_8e643a3a-aad5-4b57-8581-05a0e30ca8b9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_0092b4d7-c089-4440-b7bb-7703e76891bd" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_9d2ac266-4748-4c08-ad8d-f50f885d772f" xlink:to="loc_srt_RangeAxis_0092b4d7-c089-4440-b7bb-7703e76891bd" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_0092b4d7-c089-4440-b7bb-7703e76891bd_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_0092b4d7-c089-4440-b7bb-7703e76891bd" xlink:to="loc_srt_RangeMember_0092b4d7-c089-4440-b7bb-7703e76891bd_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_79ac4f5c-27fb-4d1f-b3db-9bc5d753c5b1" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_0092b4d7-c089-4440-b7bb-7703e76891bd" xlink:to="loc_srt_RangeMember_79ac4f5c-27fb-4d1f-b3db-9bc5d753c5b1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_d9664cd3-77d2-43b8-8b24-1a761d023942" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_79ac4f5c-27fb-4d1f-b3db-9bc5d753c5b1" xlink:to="loc_srt_MinimumMember_d9664cd3-77d2-43b8-8b24-1a761d023942" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_9dac72d7-0f69-43fb-9279-9adfd5ccd4ab" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_79ac4f5c-27fb-4d1f-b3db-9bc5d753c5b1" xlink:to="loc_srt_MaximumMember_9dac72d7-0f69-43fb-9279-9adfd5ccd4ab" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/StockbasedCompensationPerformancebasedRSUActivityDetails" xlink:type="simple" xlink:href="evh-20211231.xsd#StockbasedCompensationPerformancebasedRSUActivityDetails"/>
  <link:definitionLink xlink:role="http://www.evolenthealth.com/role/StockbasedCompensationPerformancebasedRSUActivityDetails" xlink:type="extended" id="ib1d5993907f548cdb0c4877fc78487da_StockbasedCompensationPerformancebasedRSUActivityDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_661128ee-7381-4a03-b7b7-888c7a27f80a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_483d5bc8-5860-4a8a-bc88-707c72ab5b2a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_661128ee-7381-4a03-b7b7-888c7a27f80a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_483d5bc8-5860-4a8a-bc88-707c72ab5b2a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_e2cbb5f4-5896-408c-9ac0-271b5ff65904" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_661128ee-7381-4a03-b7b7-888c7a27f80a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_e2cbb5f4-5896-408c-9ac0-271b5ff65904" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_42657fb9-eb40-4f8c-81c9-70c61dc5f981" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_661128ee-7381-4a03-b7b7-888c7a27f80a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_42657fb9-eb40-4f8c-81c9-70c61dc5f981" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_cd42f51c-ae69-43f2-a2d5-b75ceb425a9a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_661128ee-7381-4a03-b7b7-888c7a27f80a" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_cd42f51c-ae69-43f2-a2d5-b75ceb425a9a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestNumber_d74670b5-073b-4098-b228-20f61ae506fd" xlink:href="evh-20211231.xsd#evh_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_661128ee-7381-4a03-b7b7-888c7a27f80a" xlink:to="loc_evh_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestNumber_d74670b5-073b-4098-b228-20f61ae506fd" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestWeightedAverageGrantDateFairValue_c8428941-24bb-4e82-adb6-fdd2af30bbab" xlink:href="evh-20211231.xsd#evh_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_661128ee-7381-4a03-b7b7-888c7a27f80a" xlink:to="loc_evh_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestWeightedAverageGrantDateFairValue_c8428941-24bb-4e82-adb6-fdd2af30bbab" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestWeightedAverageRemainingContractualTerms_d7b807af-b7ea-4c6d-8950-41c0816d8345" xlink:href="evh-20211231.xsd#evh_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestWeightedAverageRemainingContractualTerms"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_661128ee-7381-4a03-b7b7-888c7a27f80a" xlink:to="loc_evh_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestWeightedAverageRemainingContractualTerms_d7b807af-b7ea-4c6d-8950-41c0816d8345" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVestedAndExpectedToVest_d50b8fd1-5e65-4560-9ce5-8443a2222553" xlink:href="evh-20211231.xsd#evh_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVestedAndExpectedToVest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_661128ee-7381-4a03-b7b7-888c7a27f80a" xlink:to="loc_evh_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVestedAndExpectedToVest_d50b8fd1-5e65-4560-9ce5-8443a2222553" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_3c024efc-e8d3-43bf-a8dd-4f106631e8f0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_661128ee-7381-4a03-b7b7-888c7a27f80a" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_3c024efc-e8d3-43bf-a8dd-4f106631e8f0" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_6badde0e-7cf2-4b3f-a1da-e39fcd2c7b32" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_3c024efc-e8d3-43bf-a8dd-4f106631e8f0" xlink:to="loc_us-gaap_AwardTypeAxis_6badde0e-7cf2-4b3f-a1da-e39fcd2c7b32" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_6badde0e-7cf2-4b3f-a1da-e39fcd2c7b32_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_6badde0e-7cf2-4b3f-a1da-e39fcd2c7b32" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_6badde0e-7cf2-4b3f-a1da-e39fcd2c7b32_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_05fc3727-7b05-47cf-9d2c-095a2a56d612" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_6badde0e-7cf2-4b3f-a1da-e39fcd2c7b32" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_05fc3727-7b05-47cf-9d2c-095a2a56d612" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_LeveragedStockUnitsLSUsMember_91ded9e4-d1d8-4d55-85da-c89e2e0b4891" xlink:href="evh-20211231.xsd#evh_LeveragedStockUnitsLSUsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_05fc3727-7b05-47cf-9d2c-095a2a56d612" xlink:to="loc_evh_LeveragedStockUnitsLSUsMember_91ded9e4-d1d8-4d55-85da-c89e2e0b4891" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_PerformanceBasedRestrictedStockUnitsPSUsMember_bfe5838f-123f-4b4c-85f1-94a75fa142d9" xlink:href="evh-20211231.xsd#evh_PerformanceBasedRestrictedStockUnitsPSUsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_05fc3727-7b05-47cf-9d2c-095a2a56d612" xlink:to="loc_evh_PerformanceBasedRestrictedStockUnitsPSUsMember_bfe5838f-123f-4b4c-85f1-94a75fa142d9" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/IncomeTaxesNarrativeDetails" xlink:type="simple" xlink:href="evh-20211231.xsd#IncomeTaxesNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.evolenthealth.com/role/IncomeTaxesNarrativeDetails" xlink:type="extended" id="i52494077e55147e0aa7b3974ffa4e5c0_IncomeTaxesNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxContingencyLineItems_ef897708-caa8-4acc-a6cb-0b51e7523da7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxContingencyLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_52b1608a-4a5a-4807-b85b-7efbb2a620fc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_ef897708-caa8-4acc-a6cb-0b51e7523da7" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_52b1608a-4a5a-4807-b85b-7efbb2a620fc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_f4363d31-1ba3-4a67-997c-e0ccb275a55b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_ef897708-caa8-4acc-a6cb-0b51e7523da7" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_f4363d31-1ba3-4a67-997c-e0ccb275a55b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_DeferredTaxLiabilitiesIndefiniteLivedIntangibleAssets_63e8636e-502c-4386-90ed-7cf7fdeac782" xlink:href="evh-20211231.xsd#evh_DeferredTaxLiabilitiesIndefiniteLivedIntangibleAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_ef897708-caa8-4acc-a6cb-0b51e7523da7" xlink:to="loc_evh_DeferredTaxLiabilitiesIndefiniteLivedIntangibleAssets_63e8636e-502c-4386-90ed-7cf7fdeac782" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwards_3ee5e02a-29a4-4dca-8eff-6a7d203a8ef8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwards"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_ef897708-caa8-4acc-a6cb-0b51e7523da7" xlink:to="loc_us-gaap_OperatingLossCarryforwards_3ee5e02a-29a4-4dca-8eff-6a7d203a8ef8" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_b6ba0329-4a81-4dc7-822d-a078dbe03898" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_ef897708-caa8-4acc-a6cb-0b51e7523da7" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_b6ba0329-4a81-4dc7-822d-a078dbe03898" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_UnrecognizedTaxBenefitsThatWouldNotImpactEffectiveTaxRate_8204ceb8-e4e3-48a1-8c6c-94c0871555db" xlink:href="evh-20211231.xsd#evh_UnrecognizedTaxBenefitsThatWouldNotImpactEffectiveTaxRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_ef897708-caa8-4acc-a6cb-0b51e7523da7" xlink:to="loc_evh_UnrecognizedTaxBenefitsThatWouldNotImpactEffectiveTaxRate_8204ceb8-e4e3-48a1-8c6c-94c0871555db" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_8c2c3e38-667d-4571-824b-dcc63c22e92d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_ef897708-caa8-4acc-a6cb-0b51e7523da7" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits_8c2c3e38-667d-4571-824b-dcc63c22e92d" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_TaxReceivableAgreementPercentofCashSavingsPaidtoShareholders_b6ae1c30-68b0-4ae5-9e74-b040582d9304" xlink:href="evh-20211231.xsd#evh_TaxReceivableAgreementPercentofCashSavingsPaidtoShareholders"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_ef897708-caa8-4acc-a6cb-0b51e7523da7" xlink:to="loc_evh_TaxReceivableAgreementPercentofCashSavingsPaidtoShareholders_b6ae1c30-68b0-4ae5-9e74-b040582d9304" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_TaxReceivableAgreementPercentofCashSavingsNotPaidtoShareholders_2f73140c-bec2-4011-99a1-34a86b545743" xlink:href="evh-20211231.xsd#evh_TaxReceivableAgreementPercentofCashSavingsNotPaidtoShareholders"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_ef897708-caa8-4acc-a6cb-0b51e7523da7" xlink:to="loc_evh_TaxReceivableAgreementPercentofCashSavingsNotPaidtoShareholders_2f73140c-bec2-4011-99a1-34a86b545743" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxContingencyTable_d63aecd2-cb3e-4053-b296-f5409f0b64f2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxContingencyTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_ef897708-caa8-4acc-a6cb-0b51e7523da7" xlink:to="loc_us-gaap_IncomeTaxContingencyTable_d63aecd2-cb3e-4053-b296-f5409f0b64f2" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAxis_bdf5a98d-74ca-48a3-9826-75158671061e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeTaxContingencyTable_d63aecd2-cb3e-4053-b296-f5409f0b64f2" xlink:to="loc_us-gaap_TaxCreditCarryforwardAxis_bdf5a98d-74ca-48a3-9826-75158671061e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardNameDomain_bdf5a98d-74ca-48a3-9826-75158671061e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TaxCreditCarryforwardAxis_bdf5a98d-74ca-48a3-9826-75158671061e" xlink:to="loc_us-gaap_TaxCreditCarryforwardNameDomain_bdf5a98d-74ca-48a3-9826-75158671061e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardNameDomain_c543e345-5874-4060-b0ce-6c396c3505ed" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TaxCreditCarryforwardAxis_bdf5a98d-74ca-48a3-9826-75158671061e" xlink:to="loc_us-gaap_TaxCreditCarryforwardNameDomain_c543e345-5874-4060-b0ce-6c396c3505ed" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_FinitelivedTaxCreditCarryforwardMember_8f359d55-274f-43bb-9ff8-9fe6224ffe6f" xlink:href="evh-20211231.xsd#evh_FinitelivedTaxCreditCarryforwardMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardNameDomain_c543e345-5874-4060-b0ce-6c396c3505ed" xlink:to="loc_evh_FinitelivedTaxCreditCarryforwardMember_8f359d55-274f-43bb-9ff8-9fe6224ffe6f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_IndefinitelivedTaxCreditCarryforwardMember_c1d524d3-3ad4-4dc5-9e7d-255d584e805a" xlink:href="evh-20211231.xsd#evh_IndefinitelivedTaxCreditCarryforwardMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardNameDomain_c543e345-5874-4060-b0ce-6c396c3505ed" xlink:to="loc_evh_IndefinitelivedTaxCreditCarryforwardMember_c1d524d3-3ad4-4dc5-9e7d-255d584e805a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_7d93adcf-6a10-4e4c-84f6-064d9d8dc22c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeTaxContingencyTable_d63aecd2-cb3e-4053-b296-f5409f0b64f2" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_7d93adcf-6a10-4e4c-84f6-064d9d8dc22c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_7d93adcf-6a10-4e4c-84f6-064d9d8dc22c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_7d93adcf-6a10-4e4c-84f6-064d9d8dc22c" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_7d93adcf-6a10-4e4c-84f6-064d9d8dc22c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_7406481e-ce65-44e4-bd13-871259d41dbf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_7d93adcf-6a10-4e4c-84f6-064d9d8dc22c" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_7406481e-ce65-44e4-bd13-871259d41dbf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticCountryMember_ff4ed577-7d52-462f-aef5-a3eef60c4940" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DomesticCountryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_7406481e-ce65-44e4-bd13-871259d41dbf" xlink:to="loc_us-gaap_DomesticCountryMember_ff4ed577-7d52-462f-aef5-a3eef60c4940" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember_f5c6561c-f8ca-49a2-9b3a-5ca3bab46f96" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_7406481e-ce65-44e4-bd13-871259d41dbf" xlink:to="loc_us-gaap_StateAndLocalJurisdictionMember_f5c6561c-f8ca-49a2-9b3a-5ca3bab46f96" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxPeriodAxis_3956c155-dbb8-4a19-b6dd-184e071dbc2c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxPeriodAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeTaxContingencyTable_d63aecd2-cb3e-4053-b296-f5409f0b64f2" xlink:to="loc_us-gaap_TaxPeriodAxis_3956c155-dbb8-4a19-b6dd-184e071dbc2c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxPeriodDomain_3956c155-dbb8-4a19-b6dd-184e071dbc2c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxPeriodDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TaxPeriodAxis_3956c155-dbb8-4a19-b6dd-184e071dbc2c" xlink:to="loc_us-gaap_TaxPeriodDomain_3956c155-dbb8-4a19-b6dd-184e071dbc2c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxPeriodDomain_f81584e4-04e3-4de8-90fb-b9f86c378243" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxPeriodDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TaxPeriodAxis_3956c155-dbb8-4a19-b6dd-184e071dbc2c" xlink:to="loc_us-gaap_TaxPeriodDomain_f81584e4-04e3-4de8-90fb-b9f86c378243" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_PeriodsPriortoJune2015Member_318b8769-6105-4ecb-a579-98fa9c8ca37e" xlink:href="evh-20211231.xsd#evh_PeriodsPriortoJune2015Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxPeriodDomain_f81584e4-04e3-4de8-90fb-b9f86c378243" xlink:to="loc_evh_PeriodsPriortoJune2015Member_318b8769-6105-4ecb-a579-98fa9c8ca37e" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/IncomeTaxesChangesinValuationAllowanceDetails" xlink:type="simple" xlink:href="evh-20211231.xsd#IncomeTaxesChangesinValuationAllowanceDetails"/>
  <link:definitionLink xlink:role="http://www.evolenthealth.com/role/IncomeTaxesChangesinValuationAllowanceDetails" xlink:type="extended" id="i999bb15cbef14a85b0d0a9c879eb2525_IncomeTaxesChangesinValuationAllowanceDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsLineItems_63605150-4640-45ee-abae-63408d380220" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwardsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_4f58a8a6-df26-4a35-b208-9ff77fca5969" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MovementInValuationAllowancesAndReservesRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_63605150-4640-45ee-abae-63408d380220" xlink:to="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_4f58a8a6-df26-4a35-b208-9ff77fca5969" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance_6f67bffd-8389-48df-9149-2e0b4037433b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowancesAndReservesBalance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_4f58a8a6-df26-4a35-b208-9ff77fca5969" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesBalance_6f67bffd-8389-48df-9149-2e0b4037433b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense_c6e7242a-a2af-4a55-8d0a-35ee51da6f86" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_4f58a8a6-df26-4a35-b208-9ff77fca5969" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense_c6e7242a-a2af-4a55-8d0a-35ee51da6f86" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts_a224daa8-0948-4fa9-bd25-228a13e1af2a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_4f58a8a6-df26-4a35-b208-9ff77fca5969" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts_a224daa8-0948-4fa9-bd25-228a13e1af2a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDeductions_2d8298b5-cbd9-496a-afa8-6dfd9607ed15" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowancesAndReservesDeductions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_4f58a8a6-df26-4a35-b208-9ff77fca5969" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesDeductions_2d8298b5-cbd9-496a-afa8-6dfd9607ed15" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance_42b92b20-050e-4423-b100-72e5b409f878" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowancesAndReservesBalance"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_ValuationAllowancesAndReservesChargedCreditedToAdditionalPaidInCapital_bf99ef9e-2b2e-4193-82e6-46de594e0358" xlink:href="evh-20211231.xsd#evh_ValuationAllowancesAndReservesChargedCreditedToAdditionalPaidInCapital"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_63605150-4640-45ee-abae-63408d380220" xlink:to="loc_evh_ValuationAllowancesAndReservesChargedCreditedToAdditionalPaidInCapital_bf99ef9e-2b2e-4193-82e6-46de594e0358" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_ValuationAllowancesAndReservesChargedToRetainedEarnings_a0e25923-fc02-4aad-991c-04d13a0dae62" xlink:href="evh-20211231.xsd#evh_ValuationAllowancesAndReservesChargedToRetainedEarnings"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_63605150-4640-45ee-abae-63408d380220" xlink:to="loc_evh_ValuationAllowancesAndReservesChargedToRetainedEarnings_a0e25923-fc02-4aad-991c-04d13a0dae62" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsTable_e28867a1-ee96-4745-8b82-153055d061ee" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwardsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_63605150-4640-45ee-abae-63408d380220" xlink:to="loc_us-gaap_OperatingLossCarryforwardsTable_e28867a1-ee96-4745-8b82-153055d061ee" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_5688462d-dff2-4a75-bfc9-4577672eea99" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowancesAndReservesTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_e28867a1-ee96-4745-8b82-153055d061ee" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_5688462d-dff2-4a75-bfc9-4577672eea99" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDomain_5688462d-dff2-4a75-bfc9-4577672eea99_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowancesAndReservesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_5688462d-dff2-4a75-bfc9-4577672eea99" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesDomain_5688462d-dff2-4a75-bfc9-4577672eea99_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDomain_c3648f79-680a-4162-8b1d-4384ebc85253" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowancesAndReservesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_5688462d-dff2-4a75-bfc9-4577672eea99" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesDomain_c3648f79-680a-4162-8b1d-4384ebc85253" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowanceOfDeferredTaxAssetsMember_04d7cde5-8ee1-40f0-95a6-d57d0d74f898" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowanceOfDeferredTaxAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_c3648f79-680a-4162-8b1d-4384ebc85253" xlink:to="loc_us-gaap_ValuationAllowanceOfDeferredTaxAssetsMember_04d7cde5-8ee1-40f0-95a6-d57d0d74f898" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/EmployeeBenefitPlansDetails" xlink:type="simple" xlink:href="evh-20211231.xsd#EmployeeBenefitPlansDetails"/>
  <link:definitionLink xlink:role="http://www.evolenthealth.com/role/EmployeeBenefitPlansDetails" xlink:type="extended" id="i679b8a0ac0e24664a3ab6e0ba6f1e0d0_EmployeeBenefitPlansDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_6bb07c9b-41fe-44f8-984d-b67a6c956496" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_8e20d4a3-be5e-422b-a3f7-20c4121024a3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_6bb07c9b-41fe-44f8-984d-b67a6c956496" xlink:to="loc_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_8e20d4a3-be5e-422b-a3f7-20c4121024a3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_c51cbaf1-f2c4-4d3e-be5a-2139bcc0e7da" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_6bb07c9b-41fe-44f8-984d-b67a6c956496" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_c51cbaf1-f2c4-4d3e-be5a-2139bcc0e7da" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis_679d387e-fea6-4452-8da8-e08a4c027a99" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupClassificationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_c51cbaf1-f2c4-4d3e-be5a-2139bcc0e7da" xlink:to="loc_us-gaap_DisposalGroupClassificationAxis_679d387e-fea6-4452-8da8-e08a4c027a99" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_679d387e-fea6-4452-8da8-e08a4c027a99_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_679d387e-fea6-4452-8da8-e08a4c027a99" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_679d387e-fea6-4452-8da8-e08a4c027a99_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_c5d1b8be-8e1a-441d-856c-42283a7989fe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_679d387e-fea6-4452-8da8-e08a4c027a99" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_c5d1b8be-8e1a-441d-856c-42283a7989fe" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationsDisposedOfBySaleMember_e29a953a-08b4-4bf2-a8bf-4df57c94a6d2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DiscontinuedOperationsDisposedOfBySaleMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain_c5d1b8be-8e1a-441d-856c-42283a7989fe" xlink:to="loc_us-gaap_DiscontinuedOperationsDisposedOfBySaleMember_e29a953a-08b4-4bf2-a8bf-4df57c94a6d2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_04e43643-ceda-4016-b66b-802b3be73731" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_c51cbaf1-f2c4-4d3e-be5a-2139bcc0e7da" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_04e43643-ceda-4016-b66b-802b3be73731" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_04e43643-ceda-4016-b66b-802b3be73731_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_04e43643-ceda-4016-b66b-802b3be73731" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_04e43643-ceda-4016-b66b-802b3be73731_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_950a756b-e709-4683-971e-6863c524901c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_04e43643-ceda-4016-b66b-802b3be73731" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_950a756b-e709-4683-971e-6863c524901c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_TrueHealthMember_b0a8f926-034e-4cf0-b6cd-0fd2871d2194" xlink:href="evh-20211231.xsd#evh_TrueHealthMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_950a756b-e709-4683-971e-6863c524901c" xlink:to="loc_evh_TrueHealthMember_b0a8f926-034e-4cf0-b6cd-0fd2871d2194" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/InvestmentsinEquityMethodInvesteesDetails" xlink:type="simple" xlink:href="evh-20211231.xsd#InvestmentsinEquityMethodInvesteesDetails"/>
  <link:definitionLink xlink:role="http://www.evolenthealth.com/role/InvestmentsinEquityMethodInvesteesDetails" xlink:type="extended" id="iffa79bf9a0b242f6bc5312899933883c_InvestmentsinEquityMethodInvesteesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_aeb1e29a-3c3b-418a-80e3-6caea0abb37b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_EquityMethodInvestmentEconomicInterestPercentage_c8f4a510-5007-4347-a0c6-9ef6f7409fff" xlink:href="evh-20211231.xsd#evh_EquityMethodInvestmentEconomicInterestPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_aeb1e29a-3c3b-418a-80e3-6caea0abb37b" xlink:to="loc_evh_EquityMethodInvestmentEconomicInterestPercentage_c8f4a510-5007-4347-a0c6-9ef6f7409fff" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_EquityMethodInvestmentVotingInterestPercentage_8b05c9bc-6919-4b44-a3db-20dc57c9250a" xlink:href="evh-20211231.xsd#evh_EquityMethodInvestmentVotingInterestPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_aeb1e29a-3c3b-418a-80e3-6caea0abb37b" xlink:to="loc_evh_EquityMethodInvestmentVotingInterestPercentage_8b05c9bc-6919-4b44-a3db-20dc57c9250a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_3a862d39-84d2-4891-898c-5ff51e41ea72" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_aeb1e29a-3c3b-418a-80e3-6caea0abb37b" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_3a862d39-84d2-4891-898c-5ff51e41ea72" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_IncomeLossfromEquityMethodInvestmentsServicesAgreement_0ab424be-9907-4bfd-9772-d290dcc690d4" xlink:href="evh-20211231.xsd#evh_IncomeLossfromEquityMethodInvestmentsServicesAgreement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_aeb1e29a-3c3b-418a-80e3-6caea0abb37b" xlink:to="loc_evh_IncomeLossfromEquityMethodInvestmentsServicesAgreement_0ab424be-9907-4bfd-9772-d290dcc690d4" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_StatutoryCapitalReservesLiquidityGuaranteedByInvestorsMinimum_bf1b7ac3-cc62-437c-92a9-e9ab114a0306" xlink:href="evh-20211231.xsd#evh_StatutoryCapitalReservesLiquidityGuaranteedByInvestorsMinimum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_aeb1e29a-3c3b-418a-80e3-6caea0abb37b" xlink:to="loc_evh_StatutoryCapitalReservesLiquidityGuaranteedByInvestorsMinimum_bf1b7ac3-cc62-437c-92a9-e9ab114a0306" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_EquityInterestToBeTransferred_eaf04d88-9e29-4acf-8308-72e21e656346" xlink:href="evh-20211231.xsd#evh_EquityInterestToBeTransferred"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_aeb1e29a-3c3b-418a-80e3-6caea0abb37b" xlink:to="loc_evh_EquityInterestToBeTransferred_eaf04d88-9e29-4acf-8308-72e21e656346" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentOtherThanTemporaryImpairment_b4b77835-4c0c-40ee-a571-5e2dd36af253" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestmentOtherThanTemporaryImpairment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_aeb1e29a-3c3b-418a-80e3-6caea0abb37b" xlink:to="loc_us-gaap_EquityMethodInvestmentOtherThanTemporaryImpairment_b4b77835-4c0c-40ee-a571-5e2dd36af253" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_c98e9ad8-23d8-489d-bbcb-6f4cf95710ca" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_aeb1e29a-3c3b-418a-80e3-6caea0abb37b" xlink:to="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_c98e9ad8-23d8-489d-bbcb-6f4cf95710ca" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_1c94548f-2ca7-4d72-92ea-5929206a509b" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_c98e9ad8-23d8-489d-bbcb-6f4cf95710ca" xlink:to="loc_srt_RangeAxis_1c94548f-2ca7-4d72-92ea-5929206a509b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_1c94548f-2ca7-4d72-92ea-5929206a509b_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_1c94548f-2ca7-4d72-92ea-5929206a509b" xlink:to="loc_srt_RangeMember_1c94548f-2ca7-4d72-92ea-5929206a509b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_53927c94-6be7-4ec3-917c-829c7121033a" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_1c94548f-2ca7-4d72-92ea-5929206a509b" xlink:to="loc_srt_RangeMember_53927c94-6be7-4ec3-917c-829c7121033a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_8f06a1af-63c6-4857-a343-276ce82bbd2e" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_53927c94-6be7-4ec3-917c-829c7121033a" xlink:to="loc_srt_MinimumMember_8f06a1af-63c6-4857-a343-276ce82bbd2e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_4f65600a-b7ed-474d-9d2b-fffee603600a" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_53927c94-6be7-4ec3-917c-829c7121033a" xlink:to="loc_srt_MaximumMember_4f65600a-b7ed-474d-9d2b-fffee603600a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_8bade582-9063-4a81-aa2a-783c3d28da6d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_c98e9ad8-23d8-489d-bbcb-6f4cf95710ca" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_8bade582-9063-4a81-aa2a-783c3d28da6d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_8bade582-9063-4a81-aa2a-783c3d28da6d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_8bade582-9063-4a81-aa2a-783c3d28da6d" xlink:to="loc_us-gaap_RelatedPartyDomain_8bade582-9063-4a81-aa2a-783c3d28da6d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_d2ff0a70-a9ff-47ac-a7ae-c0a4c8b4d089" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_8bade582-9063-4a81-aa2a-783c3d28da6d" xlink:to="loc_us-gaap_RelatedPartyDomain_d2ff0a70-a9ff-47ac-a7ae-c0a4c8b4d089" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvesteeMember_0b890097-f906-466e-8283-144415278cb0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvesteeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_d2ff0a70-a9ff-47ac-a7ae-c0a4c8b4d089" xlink:to="loc_us-gaap_EquityMethodInvesteeMember_0b890097-f906-466e-8283-144415278cb0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis_1e93bbd6-7a5d-4599-9bde-ddcc1d257d92" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_c98e9ad8-23d8-489d-bbcb-6f4cf95710ca" xlink:to="loc_us-gaap_RelatedPartyTransactionAxis_1e93bbd6-7a5d-4599-9bde-ddcc1d257d92" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_1e93bbd6-7a5d-4599-9bde-ddcc1d257d92_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_1e93bbd6-7a5d-4599-9bde-ddcc1d257d92" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_1e93bbd6-7a5d-4599-9bde-ddcc1d257d92_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_d97bd963-89d9-4d68-8d6d-6424503d867b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_1e93bbd6-7a5d-4599-9bde-ddcc1d257d92" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_d97bd963-89d9-4d68-8d6d-6424503d867b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_ServicesAgreementsMember_5142eda6-88b7-4b21-a9d7-df3278ea75f3" xlink:href="evh-20211231.xsd#evh_ServicesAgreementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_d97bd963-89d9-4d68-8d6d-6424503d867b" xlink:to="loc_evh_ServicesAgreementsMember_5142eda6-88b7-4b21-a9d7-df3278ea75f3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesAxis_9405ef75-c604-4497-88ac-f0e49683c228" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ConsolidatedEntitiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_c98e9ad8-23d8-489d-bbcb-6f4cf95710ca" xlink:to="loc_srt_ConsolidatedEntitiesAxis_9405ef75-c604-4497-88ac-f0e49683c228" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesDomain_9405ef75-c604-4497-88ac-f0e49683c228_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ConsolidatedEntitiesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ConsolidatedEntitiesAxis_9405ef75-c604-4497-88ac-f0e49683c228" xlink:to="loc_srt_ConsolidatedEntitiesDomain_9405ef75-c604-4497-88ac-f0e49683c228_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesDomain_623b07c1-0895-4e92-a1d6-078cb69071fe" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ConsolidatedEntitiesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ConsolidatedEntitiesAxis_9405ef75-c604-4497-88ac-f0e49683c228" xlink:to="loc_srt_ConsolidatedEntitiesDomain_623b07c1-0895-4e92-a1d6-078cb69071fe" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableInterestEntityNotPrimaryBeneficiaryMember_28830f99-5157-48ba-9262-3081cd9d4d5b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableInterestEntityNotPrimaryBeneficiaryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidatedEntitiesDomain_623b07c1-0895-4e92-a1d6-078cb69071fe" xlink:to="loc_us-gaap_VariableInterestEntityNotPrimaryBeneficiaryMember_28830f99-5157-48ba-9262-3081cd9d4d5b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_02069342-cdae-49f7-bec5-c28b50a4682b" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_c98e9ad8-23d8-489d-bbcb-6f4cf95710ca" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_02069342-cdae-49f7-bec5-c28b50a4682b" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_02069342-cdae-49f7-bec5-c28b50a4682b_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_02069342-cdae-49f7-bec5-c28b50a4682b" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_02069342-cdae-49f7-bec5-c28b50a4682b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_48d1266a-58f6-41b9-9ec7-868ead840936" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_02069342-cdae-49f7-bec5-c28b50a4682b" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_48d1266a-58f6-41b9-9ec7-868ead840936" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_GlobalHealthMember_535a7d8c-0911-49c5-8ecb-3096ead2c605" xlink:href="evh-20211231.xsd#evh_GlobalHealthMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_48d1266a-58f6-41b9-9ec7-868ead840936" xlink:to="loc_evh_GlobalHealthMember_535a7d8c-0911-49c5-8ecb-3096ead2c605" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/NoncontrollingInterestsDetails" xlink:type="simple" xlink:href="evh-20211231.xsd#NoncontrollingInterestsDetails"/>
  <link:definitionLink xlink:role="http://www.evolenthealth.com/role/NoncontrollingInterestsDetails" xlink:type="extended" id="i71b6b9a5637a425db720f26add281afd_NoncontrollingInterestsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestLineItems_fe4ef0ac-ccf3-4565-b4fe-7612b1be193d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MinorityInterestLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestOwnershipPercentageByParent_7f6848c3-dd4e-4018-9c14-bee7d0a0e47e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MinorityInterestOwnershipPercentageByParent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MinorityInterestLineItems_fe4ef0ac-ccf3-4565-b4fe-7612b1be193d" xlink:to="loc_us-gaap_MinorityInterestOwnershipPercentageByParent_7f6848c3-dd4e-4018-9c14-bee7d0a0e47e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestIncreaseFromBusinessCombination_59985d87-220a-4cc8-8914-d0491b584022" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NoncontrollingInterestIncreaseFromBusinessCombination"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MinorityInterestLineItems_fe4ef0ac-ccf3-4565-b4fe-7612b1be193d" xlink:to="loc_us-gaap_NoncontrollingInterestIncreaseFromBusinessCombination_59985d87-220a-4cc8-8914-d0491b584022" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableInterestEntityOwnershipPercentage_6f199c8f-d8df-4817-aabc-c9dbc0362341" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableInterestEntityOwnershipPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MinorityInterestLineItems_fe4ef0ac-ccf3-4565-b4fe-7612b1be193d" xlink:to="loc_us-gaap_VariableInterestEntityOwnershipPercentage_6f199c8f-d8df-4817-aabc-c9dbc0362341" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_VariableInterestEntityNewMedicaidContractNotAwardedRequirementToAcquireOwnershipConsiderationAmount_48f67909-59be-4ab3-be3c-4d85022d80aa" xlink:href="evh-20211231.xsd#evh_VariableInterestEntityNewMedicaidContractNotAwardedRequirementToAcquireOwnershipConsiderationAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MinorityInterestLineItems_fe4ef0ac-ccf3-4565-b4fe-7612b1be193d" xlink:to="loc_evh_VariableInterestEntityNewMedicaidContractNotAwardedRequirementToAcquireOwnershipConsiderationAmount_48f67909-59be-4ab3-be3c-4d85022d80aa" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableInterestEntityInitialConsolidationGainOrLoss_c1ecb1d6-f70e-4fd2-9464-4a42555ce988" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableInterestEntityInitialConsolidationGainOrLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MinorityInterestLineItems_fe4ef0ac-ccf3-4565-b4fe-7612b1be193d" xlink:to="loc_us-gaap_VariableInterestEntityInitialConsolidationGainOrLoss_c1ecb1d6-f70e-4fd2-9464-4a42555ce988" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestTable_7e7dad52-e53f-4c1a-8b42-95239a4c37a0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MinorityInterestTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_MinorityInterestLineItems_fe4ef0ac-ccf3-4565-b4fe-7612b1be193d" xlink:to="loc_us-gaap_MinorityInterestTable_7e7dad52-e53f-4c1a-8b42-95239a4c37a0" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipAxis_7ec47f76-7dea-4304-a43e-d11692e4966c" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_OwnershipAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_MinorityInterestTable_7e7dad52-e53f-4c1a-8b42-95239a4c37a0" xlink:to="loc_srt_OwnershipAxis_7ec47f76-7dea-4304-a43e-d11692e4966c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain_7ec47f76-7dea-4304-a43e-d11692e4966c_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_OwnershipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_OwnershipAxis_7ec47f76-7dea-4304-a43e-d11692e4966c" xlink:to="loc_srt_OwnershipDomain_7ec47f76-7dea-4304-a43e-d11692e4966c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain_7073c6c6-8a32-4b30-b897-1afab95af973" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_OwnershipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_OwnershipAxis_7ec47f76-7dea-4304-a43e-d11692e4966c" xlink:to="loc_srt_OwnershipDomain_7073c6c6-8a32-4b30-b897-1afab95af973" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_EvolentHealthLLCMember_85f5c098-11c4-4450-bb6a-56773c69e03a" xlink:href="evh-20211231.xsd#evh_EvolentHealthLLCMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_OwnershipDomain_7073c6c6-8a32-4b30-b897-1afab95af973" xlink:to="loc_evh_EvolentHealthLLCMember_85f5c098-11c4-4450-bb6a-56773c69e03a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_d3f7fd36-3333-485e-a369-7c55eb08b7e9" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_MinorityInterestTable_7e7dad52-e53f-4c1a-8b42-95239a4c37a0" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_d3f7fd36-3333-485e-a369-7c55eb08b7e9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_d3f7fd36-3333-485e-a369-7c55eb08b7e9_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_d3f7fd36-3333-485e-a369-7c55eb08b7e9" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_d3f7fd36-3333-485e-a369-7c55eb08b7e9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_e11de03f-e7af-40e1-bc63-4862655ba641" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_d3f7fd36-3333-485e-a369-7c55eb08b7e9" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_e11de03f-e7af-40e1-bc63-4862655ba641" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_UniversityHealthCaredbaPassportHealthPlanMember_60b4910c-87a4-4ea8-8426-3a5cf42630a8" xlink:href="evh-20211231.xsd#evh_UniversityHealthCaredbaPassportHealthPlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_e11de03f-e7af-40e1-bc63-4862655ba641" xlink:to="loc_evh_UniversityHealthCaredbaPassportHealthPlanMember_60b4910c-87a4-4ea8-8426-3a5cf42630a8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesAxis_d2b39cff-e824-4e99-bab2-8c8ef935a0cc" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ConsolidatedEntitiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_MinorityInterestTable_7e7dad52-e53f-4c1a-8b42-95239a4c37a0" xlink:to="loc_srt_ConsolidatedEntitiesAxis_d2b39cff-e824-4e99-bab2-8c8ef935a0cc" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesDomain_d2b39cff-e824-4e99-bab2-8c8ef935a0cc_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ConsolidatedEntitiesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ConsolidatedEntitiesAxis_d2b39cff-e824-4e99-bab2-8c8ef935a0cc" xlink:to="loc_srt_ConsolidatedEntitiesDomain_d2b39cff-e824-4e99-bab2-8c8ef935a0cc_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesDomain_1f7d4f5f-148e-42f1-8d15-c9282c063cfc" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ConsolidatedEntitiesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ConsolidatedEntitiesAxis_d2b39cff-e824-4e99-bab2-8c8ef935a0cc" xlink:to="loc_srt_ConsolidatedEntitiesDomain_1f7d4f5f-148e-42f1-8d15-c9282c063cfc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableInterestEntityNotPrimaryBeneficiaryMember_536dea1b-dab4-48f3-8b29-617198cf1cfe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableInterestEntityNotPrimaryBeneficiaryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidatedEntitiesDomain_1f7d4f5f-148e-42f1-8d15-c9282c063cfc" xlink:to="loc_us-gaap_VariableInterestEntityNotPrimaryBeneficiaryMember_536dea1b-dab4-48f3-8b29-617198cf1cfe" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/NoncontrollingInterestsScheduleofChangesinNoncontrollingInterestsDetails" xlink:type="simple" xlink:href="evh-20211231.xsd#NoncontrollingInterestsScheduleofChangesinNoncontrollingInterestsDetails"/>
  <link:definitionLink xlink:role="http://www.evolenthealth.com/role/NoncontrollingInterestsScheduleofChangesinNoncontrollingInterestsDetails" xlink:type="extended" id="iac7f9ee41af742ac8c545c4cdddcd692_NoncontrollingInterestsScheduleofChangesinNoncontrollingInterestsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestLineItems_f309b8da-76c8-4978-b381-74a0fa15e607" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MinorityInterestLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MovementInMinorityInterestRollForward_544bfd5c-cbd3-49ea-8542-d2998e3a4d2e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MovementInMinorityInterestRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MinorityInterestLineItems_f309b8da-76c8-4978-b381-74a0fa15e607" xlink:to="loc_us-gaap_MovementInMinorityInterestRollForward_544bfd5c-cbd3-49ea-8542-d2998e3a4d2e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterest_9e5eaccb-7ba9-44af-9f1b-50e4ea1ef81e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MinorityInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MovementInMinorityInterestRollForward_544bfd5c-cbd3-49ea-8542-d2998e3a4d2e" xlink:to="loc_us-gaap_MinorityInterest_9e5eaccb-7ba9-44af-9f1b-50e4ea1ef81e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestIncreaseFromBusinessCombination_90426a62-1e4c-448b-a3f4-05a7e3bf0df5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NoncontrollingInterestIncreaseFromBusinessCombination"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MovementInMinorityInterestRollForward_544bfd5c-cbd3-49ea-8542-d2998e3a4d2e" xlink:to="loc_us-gaap_NoncontrollingInterestIncreaseFromBusinessCombination_90426a62-1e4c-448b-a3f4-05a7e3bf0df5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_b2048cde-76f7-43bd-be07-7459c10a72ac" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MovementInMinorityInterestRollForward_544bfd5c-cbd3-49ea-8542-d2998e3a4d2e" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_b2048cde-76f7-43bd-be07-7459c10a72ac" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_NoncontrollingInterestDecreaseFromDisposalOfAssets_dd7ba5e5-b21d-43d6-ade8-4ed10ab36655" xlink:href="evh-20211231.xsd#evh_NoncontrollingInterestDecreaseFromDisposalOfAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MovementInMinorityInterestRollForward_544bfd5c-cbd3-49ea-8542-d2998e3a4d2e" xlink:to="loc_evh_NoncontrollingInterestDecreaseFromDisposalOfAssets_dd7ba5e5-b21d-43d6-ade8-4ed10ab36655" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestDecreaseFromRedemptions_50af872d-e6e7-4c4e-871b-3b76d2011fd5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MinorityInterestDecreaseFromRedemptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MovementInMinorityInterestRollForward_544bfd5c-cbd3-49ea-8542-d2998e3a4d2e" xlink:to="loc_us-gaap_MinorityInterestDecreaseFromRedemptions_50af872d-e6e7-4c4e-871b-3b76d2011fd5" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterest_e7618fd5-1c4a-4968-8c9e-d3a672179036" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MinorityInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestTable_8050195f-1481-4bda-a1ce-20a3a5de7f3a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MinorityInterestTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_MinorityInterestLineItems_f309b8da-76c8-4978-b381-74a0fa15e607" xlink:to="loc_us-gaap_MinorityInterestTable_8050195f-1481-4bda-a1ce-20a3a5de7f3a" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_58575de5-d555-4bac-8c60-69d7b2c1321d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_MinorityInterestTable_8050195f-1481-4bda-a1ce-20a3a5de7f3a" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_58575de5-d555-4bac-8c60-69d7b2c1321d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_58575de5-d555-4bac-8c60-69d7b2c1321d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_58575de5-d555-4bac-8c60-69d7b2c1321d" xlink:to="loc_us-gaap_EquityComponentDomain_58575de5-d555-4bac-8c60-69d7b2c1321d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_268e5850-10fd-48f5-9256-de50e934d9e3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_58575de5-d555-4bac-8c60-69d7b2c1321d" xlink:to="loc_us-gaap_EquityComponentDomain_268e5850-10fd-48f5-9256-de50e934d9e3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestMember_654c3164-4ae9-428c-b9ea-48642878fc9c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NoncontrollingInterestMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_268e5850-10fd-48f5-9256-de50e934d9e3" xlink:to="loc_us-gaap_NoncontrollingInterestMember_654c3164-4ae9-428c-b9ea-48642878fc9c" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/FairValueMeasurementAssetsandLiabilitiesonRecurringBasisDetails" xlink:type="simple" xlink:href="evh-20211231.xsd#FairValueMeasurementAssetsandLiabilitiesonRecurringBasisDetails"/>
  <link:definitionLink xlink:role="http://www.evolenthealth.com/role/FairValueMeasurementAssetsandLiabilitiesonRecurringBasisDetails" xlink:type="extended" id="i9b562267ab9e4257a7415ed9113939ce_FairValueMeasurementAssetsandLiabilitiesonRecurringBasisDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_db6b12c7-8dbe-449d-bc4f-488eafcde41e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract_6c629a92-6e9c-4c91-811d-77b16fac16fc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsFairValueDisclosureAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_db6b12c7-8dbe-449d-bc4f-488eafcde41e" xlink:to="loc_us-gaap_AssetsFairValueDisclosureAbstract_6c629a92-6e9c-4c91-811d-77b16fac16fc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_2890ccbf-afc9-4866-9a97-06c562423d58" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_6c629a92-6e9c-4c91-811d-77b16fac16fc" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_2890ccbf-afc9-4866-9a97-06c562423d58" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_201a521c-9d10-489f-9a3c-6a6dc320ed57" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_6c629a92-6e9c-4c91-811d-77b16fac16fc" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_201a521c-9d10-489f-9a3c-6a6dc320ed57" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_1a3d266d-e931-4d2e-ad83-0159dd82c1b8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_db6b12c7-8dbe-449d-bc4f-488eafcde41e" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_1a3d266d-e931-4d2e-ad83-0159dd82c1b8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_73332266-75db-4fb2-ad36-f9c5f2a223b3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_1a3d266d-e931-4d2e-ad83-0159dd82c1b8" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_73332266-75db-4fb2-ad36-f9c5f2a223b3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesFairValueDisclosure_ebf99765-c697-40b2-8650-8e6b434b68d6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_1a3d266d-e931-4d2e-ad83-0159dd82c1b8" xlink:to="loc_us-gaap_OtherLiabilitiesFairValueDisclosure_ebf99765-c697-40b2-8650-8e6b434b68d6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure_cf1e787c-7098-4bb8-8f9f-551856d358f3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_1a3d266d-e931-4d2e-ad83-0159dd82c1b8" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosure_cf1e787c-7098-4bb8-8f9f-551856d358f3" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_db93b37e-76b9-465c-9fbf-77f046387633" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_db6b12c7-8dbe-449d-bc4f-488eafcde41e" xlink:to="loc_us-gaap_ClassOfWarrantOrRightOutstanding_db93b37e-76b9-465c-9fbf-77f046387633" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByBalanceSheetGroupingTable_3d759453-69a7-49e3-8f29-c81a2cfb33f8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByBalanceSheetGroupingTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_db6b12c7-8dbe-449d-bc4f-488eafcde41e" xlink:to="loc_us-gaap_FairValueByBalanceSheetGroupingTable_3d759453-69a7-49e3-8f29-c81a2cfb33f8" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_66459e91-dc13-4cad-92df-8ae4a224b55b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_3d759453-69a7-49e3-8f29-c81a2cfb33f8" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_66459e91-dc13-4cad-92df-8ae4a224b55b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_66459e91-dc13-4cad-92df-8ae4a224b55b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_66459e91-dc13-4cad-92df-8ae4a224b55b" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_66459e91-dc13-4cad-92df-8ae4a224b55b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_07dcb40c-94f1-4e16-999a-5753023fd943" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_66459e91-dc13-4cad-92df-8ae4a224b55b" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_07dcb40c-94f1-4e16-999a-5753023fd943" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_4fad7e23-d361-4988-bbcd-9ad5f1a6681c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_07dcb40c-94f1-4e16-999a-5753023fd943" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_4fad7e23-d361-4988-bbcd-9ad5f1a6681c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_64ddb15d-9c84-4969-9133-c4a0657ec4eb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_07dcb40c-94f1-4e16-999a-5753023fd943" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_64ddb15d-9c84-4969-9133-c4a0657ec4eb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_86c0f6eb-b4a8-4b8a-afe2-9abe3a07048b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_07dcb40c-94f1-4e16-999a-5753023fd943" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_86c0f6eb-b4a8-4b8a-afe2-9abe3a07048b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_ca914a01-3d44-4834-b71e-57a63d7847b2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_3d759453-69a7-49e3-8f29-c81a2cfb33f8" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_ca914a01-3d44-4834-b71e-57a63d7847b2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_ca914a01-3d44-4834-b71e-57a63d7847b2_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_ca914a01-3d44-4834-b71e-57a63d7847b2" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_ca914a01-3d44-4834-b71e-57a63d7847b2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_5733c72e-fa13-4951-82c6-10e3c801174e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_ca914a01-3d44-4834-b71e-57a63d7847b2" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_5733c72e-fa13-4951-82c6-10e3c801174e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_3ccf282c-2dea-40c7-aabb-15fb207e29ba" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_5733c72e-fa13-4951-82c6-10e3c801174e" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_3ccf282c-2dea-40c7-aabb-15fb207e29ba" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/FairValueMeasurementAdditionalInformationDetails" xlink:type="simple" xlink:href="evh-20211231.xsd#FairValueMeasurementAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://www.evolenthealth.com/role/FairValueMeasurementAdditionalInformationDetails" xlink:type="extended" id="i2d5dcd64499042ed8594e576e18191cd_FairValueMeasurementAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_91d2faf5-5ca3-4c46-b60e-940120d84dc8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightUnissued_4ba567f0-a7df-45b1-8715-13d0761ff301" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightUnissued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_91d2faf5-5ca3-4c46-b60e-940120d84dc8" xlink:to="loc_us-gaap_ClassOfWarrantOrRightUnissued_4ba567f0-a7df-45b1-8715-13d0761ff301" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_2c36a8b0-7a58-468b-8626-9f46291e81a5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_91d2faf5-5ca3-4c46-b60e-940120d84dc8" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_2c36a8b0-7a58-468b-8626-9f46291e81a5" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_eb4b3820-a783-4ea2-a5a3-f73be839236a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_2c36a8b0-7a58-468b-8626-9f46291e81a5" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_eb4b3820-a783-4ea2-a5a3-f73be839236a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_eb4b3820-a783-4ea2-a5a3-f73be839236a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_eb4b3820-a783-4ea2-a5a3-f73be839236a" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_eb4b3820-a783-4ea2-a5a3-f73be839236a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_cc3b4328-0322-4e0d-bdd2-6b2ed3541398" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_eb4b3820-a783-4ea2-a5a3-f73be839236a" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_cc3b4328-0322-4e0d-bdd2-6b2ed3541398" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassAMember_06c4504f-323a-4bbb-8c5d-bd02ddc1cd43" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonClassAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_cc3b4328-0322-4e0d-bdd2-6b2ed3541398" xlink:to="loc_us-gaap_CommonClassAMember_06c4504f-323a-4bbb-8c5d-bd02ddc1cd43" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/FairValueMeasurementValuationTechniquesandSignificantUnobservableInputsDetails" xlink:type="simple" xlink:href="evh-20211231.xsd#FairValueMeasurementValuationTechniquesandSignificantUnobservableInputsDetails"/>
  <link:definitionLink xlink:role="http://www.evolenthealth.com/role/FairValueMeasurementValuationTechniquesandSignificantUnobservableInputsDetails" xlink:type="extended" id="i0d80e1faa6124aa6a4bf24efb663b37d_FairValueMeasurementValuationTechniquesandSignificantUnobservableInputsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_62975c82-42e8-4e3a-8e44-e85a5d704831" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_9ee80698-ab24-4935-a040-e95a9c2f5129" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_62975c82-42e8-4e3a-8e44-e85a5d704831" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_9ee80698-ab24-4935-a040-e95a9c2f5129" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput_f2327ec0-380a-4500-9a43-de99fb6884eb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_62975c82-42e8-4e3a-8e44-e85a5d704831" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput_f2327ec0-380a-4500-9a43-de99fb6884eb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesFairValueDisclosure_ecb03115-17bd-4ca8-bf19-8bf0df9e3d2f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_62975c82-42e8-4e3a-8e44-e85a5d704831" xlink:to="loc_us-gaap_OtherLiabilitiesFairValueDisclosure_ecb03115-17bd-4ca8-bf19-8bf0df9e3d2f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingMeasurementInput_813f4e78-0461-435a-822d-cdfbd0474e1d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingMeasurementInput"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_62975c82-42e8-4e3a-8e44-e85a5d704831" xlink:to="loc_us-gaap_WarrantsAndRightsOutstandingMeasurementInput_813f4e78-0461-435a-822d-cdfbd0474e1d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_48a75905-9f97-4b92-87b0-57309e5edbe3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_62975c82-42e8-4e3a-8e44-e85a5d704831" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_48a75905-9f97-4b92-87b0-57309e5edbe3" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_f543735e-614e-4813-a75a-697d8666905d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_48a75905-9f97-4b92-87b0-57309e5edbe3" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_f543735e-614e-4813-a75a-697d8666905d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_f543735e-614e-4813-a75a-697d8666905d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_f543735e-614e-4813-a75a-697d8666905d" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_f543735e-614e-4813-a75a-697d8666905d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_f6644e21-d63a-40fa-9078-5d1b8d0ea166" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_f543735e-614e-4813-a75a-697d8666905d" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_f6644e21-d63a-40fa-9078-5d1b8d0ea166" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_87c86253-61da-4372-b73e-0a1116b3fdc3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_f6644e21-d63a-40fa-9078-5d1b8d0ea166" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_87c86253-61da-4372-b73e-0a1116b3fdc3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_907bebb7-ed9f-4ba8-8cf3-4e077bbb1f02" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_48a75905-9f97-4b92-87b0-57309e5edbe3" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_907bebb7-ed9f-4ba8-8cf3-4e077bbb1f02" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_907bebb7-ed9f-4ba8-8cf3-4e077bbb1f02_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_907bebb7-ed9f-4ba8-8cf3-4e077bbb1f02" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_907bebb7-ed9f-4ba8-8cf3-4e077bbb1f02_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_28e13e1f-6e6a-4b07-b058-20485718077b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_907bebb7-ed9f-4ba8-8cf3-4e077bbb1f02" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_28e13e1f-6e6a-4b07-b058-20485718077b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_8b0f797e-238b-4bad-8f81-4624b19a0b5f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_28e13e1f-6e6a-4b07-b058-20485718077b" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_8b0f797e-238b-4bad-8f81-4624b19a0b5f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_36fbf12c-9186-4c53-8dae-43613df77f43" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_48a75905-9f97-4b92-87b0-57309e5edbe3" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_36fbf12c-9186-4c53-8dae-43613df77f43" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_36fbf12c-9186-4c53-8dae-43613df77f43_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_36fbf12c-9186-4c53-8dae-43613df77f43" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_36fbf12c-9186-4c53-8dae-43613df77f43_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_07d60355-6f1b-452c-8cd6-41716f5b1016" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_36fbf12c-9186-4c53-8dae-43613df77f43" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_07d60355-6f1b-452c-8cd6-41716f5b1016" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_MeasurementInputRiskNeutralExpectedEarnoutConsiderationMember_8f495e6e-7059-465d-985d-643dc7f9d199" xlink:href="evh-20211231.xsd#evh_MeasurementInputRiskNeutralExpectedEarnoutConsiderationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_07d60355-6f1b-452c-8cd6-41716f5b1016" xlink:to="loc_evh_MeasurementInputRiskNeutralExpectedEarnoutConsiderationMember_8f495e6e-7059-465d-985d-643dc7f9d199" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputDiscountRateMember_2f1067a8-36c0-4a16-a48b-f998b0547f9f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputDiscountRateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_07d60355-6f1b-452c-8cd6-41716f5b1016" xlink:to="loc_us-gaap_MeasurementInputDiscountRateMember_2f1067a8-36c0-4a16-a48b-f998b0547f9f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputPriceVolatilityMember_4dbc2bca-5eb7-429c-91d0-3384beb8a3ba" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputPriceVolatilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_07d60355-6f1b-452c-8cd6-41716f5b1016" xlink:to="loc_us-gaap_MeasurementInputPriceVolatilityMember_4dbc2bca-5eb7-429c-91d0-3384beb8a3ba" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember_b90039de-7ed6-4054-8032-4a198b33fb79" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_07d60355-6f1b-452c-8cd6-41716f5b1016" xlink:to="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember_b90039de-7ed6-4054-8032-4a198b33fb79" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/RelatedPartiesAssetsandLiabilitiesDetails" xlink:type="simple" xlink:href="evh-20211231.xsd#RelatedPartiesAssetsandLiabilitiesDetails"/>
  <link:definitionLink xlink:role="http://www.evolenthealth.com/role/RelatedPartiesAssetsandLiabilitiesDetails" xlink:type="extended" id="i6869d9ea77c24238af2d5dede8dfbb64_RelatedPartiesAssetsandLiabilitiesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_3083d97b-415e-47f6-8f06-b32f70a9217e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_ef4129fd-6392-4c90-838c-21e40700a80a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_3083d97b-415e-47f6-8f06-b32f70a9217e" xlink:to="loc_us-gaap_AssetsAbstract_ef4129fd-6392-4c90-838c-21e40700a80a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_aa70c1a4-d8e8-41f9-997e-86c953c23d93" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_ef4129fd-6392-4c90-838c-21e40700a80a" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_aa70c1a4-d8e8-41f9-997e-86c953c23d93" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_e2bd6eb9-89b5-4c6f-8ee4-38db283543f5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_ef4129fd-6392-4c90-838c-21e40700a80a" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_e2bd6eb9-89b5-4c6f-8ee4-38db283543f5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent_17ed282e-de90-40ae-90a6-a0e027f12fb1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_ef4129fd-6392-4c90-838c-21e40700a80a" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent_17ed282e-de90-40ae-90a6-a0e027f12fb1" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAbstract_0371de37-d9fd-406a-8d57-d325b8a7ef8e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_3083d97b-415e-47f6-8f06-b32f70a9217e" xlink:to="loc_us-gaap_LiabilitiesAbstract_0371de37-d9fd-406a-8d57-d325b8a7ef8e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_c39e2de8-71ad-425d-859f-29d21803b0b0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAbstract_0371de37-d9fd-406a-8d57-d325b8a7ef8e" xlink:to="loc_us-gaap_AccountsPayableCurrent_c39e2de8-71ad-425d-859f-29d21803b0b0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_dfe42b13-a809-43e9-9056-5d72eaa7054a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAbstract_0371de37-d9fd-406a-8d57-d325b8a7ef8e" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_dfe42b13-a809-43e9-9056-5d72eaa7054a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForFuturePolicyBenefitsAndUnpaidClaimsAndClaimsAdjustmentExpense_7fb0d549-9f82-4c13-a664-f0ff8199e2db" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilityForFuturePolicyBenefitsAndUnpaidClaimsAndClaimsAdjustmentExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAbstract_0371de37-d9fd-406a-8d57-d325b8a7ef8e" xlink:to="loc_us-gaap_LiabilityForFuturePolicyBenefitsAndUnpaidClaimsAndClaimsAdjustmentExpense_7fb0d549-9f82-4c13-a664-f0ff8199e2db" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_8584dc08-3db4-4d3b-9593-75e2c0cdd89c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_3083d97b-415e-47f6-8f06-b32f70a9217e" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_8584dc08-3db4-4d3b-9593-75e2c0cdd89c" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_ae46cfb7-badb-446a-93f1-85b4d0e59614" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_8584dc08-3db4-4d3b-9593-75e2c0cdd89c" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_ae46cfb7-badb-446a-93f1-85b4d0e59614" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_ae46cfb7-badb-446a-93f1-85b4d0e59614_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_ae46cfb7-badb-446a-93f1-85b4d0e59614" xlink:to="loc_us-gaap_RelatedPartyDomain_ae46cfb7-badb-446a-93f1-85b4d0e59614_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_757a201d-aa9c-43dd-92ce-5575327bc7f0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_ae46cfb7-badb-446a-93f1-85b4d0e59614" xlink:to="loc_us-gaap_RelatedPartyDomain_757a201d-aa9c-43dd-92ce-5575327bc7f0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_AffiliatedEntityMember_aa2ddd9b-617c-41ad-9e54-6d775c2627aa" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_AffiliatedEntityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_757a201d-aa9c-43dd-92ce-5575327bc7f0" xlink:to="loc_srt_AffiliatedEntityMember_aa2ddd9b-617c-41ad-9e54-6d775c2627aa" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/RelatedPartiesRevenuesandExpensesDetails" xlink:type="simple" xlink:href="evh-20211231.xsd#RelatedPartiesRevenuesandExpensesDetails"/>
  <link:definitionLink xlink:role="http://www.evolenthealth.com/role/RelatedPartiesRevenuesandExpensesDetails" xlink:type="extended" id="i00489a639c86496e9472eea8b227bf29_RelatedPartiesRevenuesandExpensesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_cc57137f-6e26-423b-a045-828f23c10d40" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract_1afece10-175f-4583-bce7-1b778f6cfff2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenuesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_cc57137f-6e26-423b-a045-828f23c10d40" xlink:to="loc_us-gaap_RevenuesAbstract_1afece10-175f-4583-bce7-1b778f6cfff2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_cc4aa492-8d60-4fb7-bf4d-d59f60256ad1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Revenues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenuesAbstract_1afece10-175f-4583-bce7-1b778f6cfff2" xlink:to="loc_us-gaap_Revenues_cc4aa492-8d60-4fb7-bf4d-d59f60256ad1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract_27fda00f-1efd-471d-a534-4abfa016cbc9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_cc57137f-6e26-423b-a045-828f23c10d40" xlink:to="loc_us-gaap_OperatingExpensesAbstract_27fda00f-1efd-471d-a534-4abfa016cbc9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_CostofGoodsandServicesSoldExcludingDepreciationandAmortization_35f45b08-dbca-4034-ae08-8262558eaedb" xlink:href="evh-20211231.xsd#evh_CostofGoodsandServicesSoldExcludingDepreciationandAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_27fda00f-1efd-471d-a534-4abfa016cbc9" xlink:to="loc_evh_CostofGoodsandServicesSoldExcludingDepreciationandAmortization_35f45b08-dbca-4034-ae08-8262558eaedb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_4dffc484-7987-4b52-8004-16f27d0a8619" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_27fda00f-1efd-471d-a534-4abfa016cbc9" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_4dffc484-7987-4b52-8004-16f27d0a8619" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_eec88460-6b4a-43ba-a77a-0527b3fc41c1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_cc57137f-6e26-423b-a045-828f23c10d40" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_eec88460-6b4a-43ba-a77a-0527b3fc41c1" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_ce58a6d7-309f-4840-81ba-408602e3b8a2" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_eec88460-6b4a-43ba-a77a-0527b3fc41c1" xlink:to="loc_srt_ProductOrServiceAxis_ce58a6d7-309f-4840-81ba-408602e3b8a2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_ce58a6d7-309f-4840-81ba-408602e3b8a2_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_ce58a6d7-309f-4840-81ba-408602e3b8a2" xlink:to="loc_srt_ProductsAndServicesDomain_ce58a6d7-309f-4840-81ba-408602e3b8a2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_bb75db43-5b61-4074-a268-41e4ffe17fa0" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_ce58a6d7-309f-4840-81ba-408602e3b8a2" xlink:to="loc_srt_ProductsAndServicesDomain_bb75db43-5b61-4074-a268-41e4ffe17fa0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_TransformationServicesMember_9f522881-316c-405c-a144-a8ec4ee77b4e" xlink:href="evh-20211231.xsd#evh_TransformationServicesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_bb75db43-5b61-4074-a268-41e4ffe17fa0" xlink:to="loc_evh_TransformationServicesMember_9f522881-316c-405c-a144-a8ec4ee77b4e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_PlatformsAndOperationsServicesMember_751489a6-9a57-4ad0-a5e6-7adcbb3f28d6" xlink:href="evh-20211231.xsd#evh_PlatformsAndOperationsServicesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_bb75db43-5b61-4074-a268-41e4ffe17fa0" xlink:to="loc_evh_PlatformsAndOperationsServicesMember_751489a6-9a57-4ad0-a5e6-7adcbb3f28d6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_d9c3b60c-8359-40d2-bcb8-f0a95bc0b332" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_eec88460-6b4a-43ba-a77a-0527b3fc41c1" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_d9c3b60c-8359-40d2-bcb8-f0a95bc0b332" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_d9c3b60c-8359-40d2-bcb8-f0a95bc0b332_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_d9c3b60c-8359-40d2-bcb8-f0a95bc0b332" xlink:to="loc_us-gaap_RelatedPartyDomain_d9c3b60c-8359-40d2-bcb8-f0a95bc0b332_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_e3213ba0-2896-4ace-8d25-0c6044716954" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_d9c3b60c-8359-40d2-bcb8-f0a95bc0b332" xlink:to="loc_us-gaap_RelatedPartyDomain_e3213ba0-2896-4ace-8d25-0c6044716954" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_AffiliatedEntityMember_df44c8e1-63ac-403e-9a94-1d9e8e752065" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_AffiliatedEntityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_e3213ba0-2896-4ace-8d25-0c6044716954" xlink:to="loc_srt_AffiliatedEntityMember_df44c8e1-63ac-403e-9a94-1d9e8e752065" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/RepositioningandOtherChangesDetails" xlink:type="simple" xlink:href="evh-20211231.xsd#RepositioningandOtherChangesDetails"/>
  <link:definitionLink xlink:role="http://www.evolenthealth.com/role/RepositioningandOtherChangesDetails" xlink:type="extended" id="if78be0e95e7347a4923b868f4c3da949_RepositioningandOtherChangesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems_c566c533-3c29-4683-b77f-7f514d5c669e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringCostAndReserveLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges_dba175d3-514b-4316-bfd7-3cedab224565" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringCharges"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_c566c533-3c29-4683-b77f-7f514d5c669e" xlink:to="loc_us-gaap_RestructuringCharges_dba175d3-514b-4316-bfd7-3cedab224565" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedCostCostIncurredToDate1_70a7031e-10f9-42ec-93b9-dc7e2e596bf1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringAndRelatedCostCostIncurredToDate1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_c566c533-3c29-4683-b77f-7f514d5c669e" xlink:to="loc_us-gaap_RestructuringAndRelatedCostCostIncurredToDate1_70a7031e-10f9-42ec-93b9-dc7e2e596bf1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_82931c4e-fb7b-4ff0-b01f-43843c6386ab" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_c566c533-3c29-4683-b77f-7f514d5c669e" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_82931c4e-fb7b-4ff0-b01f-43843c6386ab" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveAxis_c7ab4f15-252d-4eb8-a20a-71f605d25649" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringCostAndReserveAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_82931c4e-fb7b-4ff0-b01f-43843c6386ab" xlink:to="loc_us-gaap_RestructuringCostAndReserveAxis_c7ab4f15-252d-4eb8-a20a-71f605d25649" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfRestructuringDomain_c7ab4f15-252d-4eb8-a20a-71f605d25649_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfRestructuringDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis_c7ab4f15-252d-4eb8-a20a-71f605d25649" xlink:to="loc_us-gaap_TypeOfRestructuringDomain_c7ab4f15-252d-4eb8-a20a-71f605d25649_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfRestructuringDomain_ab67bf61-dbc7-47f2-a2fe-94fba9e913e7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfRestructuringDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis_c7ab4f15-252d-4eb8-a20a-71f605d25649" xlink:to="loc_us-gaap_TypeOfRestructuringDomain_ab67bf61-dbc7-47f2-a2fe-94fba9e913e7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_EmployeeSeveranceAndTerminationBenefitsMember_9dbe7d52-40cd-46a0-80c3-d49f67fd9e5a" xlink:href="evh-20211231.xsd#evh_EmployeeSeveranceAndTerminationBenefitsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_ab67bf61-dbc7-47f2-a2fe-94fba9e913e7" xlink:to="loc_evh_EmployeeSeveranceAndTerminationBenefitsMember_9dbe7d52-40cd-46a0-80c3-d49f67fd9e5a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FacilityClosingMember_e7dc0ee4-7a3f-457b-b273-4ed3fc796c62" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FacilityClosingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_ab67bf61-dbc7-47f2-a2fe-94fba9e913e7" xlink:to="loc_us-gaap_FacilityClosingMember_e7dc0ee4-7a3f-457b-b273-4ed3fc796c62" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_ProfessionalServicesRestructuringMember_14feae9a-2d0c-4ee7-a33d-1e5a74651a7a" xlink:href="evh-20211231.xsd#evh_ProfessionalServicesRestructuringMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_ab67bf61-dbc7-47f2-a2fe-94fba9e913e7" xlink:to="loc_evh_ProfessionalServicesRestructuringMember_14feae9a-2d0c-4ee7-a33d-1e5a74651a7a" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/SegmentReportingRevenuefromSegmentstoConsolidatedDetails" xlink:type="simple" xlink:href="evh-20211231.xsd#SegmentReportingRevenuefromSegmentstoConsolidatedDetails"/>
  <link:definitionLink xlink:role="http://www.evolenthealth.com/role/SegmentReportingRevenuefromSegmentstoConsolidatedDetails" xlink:type="extended" id="i3a20c462da534d6fab9cd45259463b18_SegmentReportingRevenuefromSegmentstoConsolidatedDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingRevenueReconcilingItemLineItems_6b0c2229-b555-427c-98f0-e20e149d8a0e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingRevenueReconcilingItemLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_e8f872ec-398d-4eac-b099-b08c59c8e2e8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Revenues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingRevenueReconcilingItemLineItems_6b0c2229-b555-427c-98f0-e20e149d8a0e" xlink:to="loc_us-gaap_Revenues_e8f872ec-398d-4eac-b099-b08c59c8e2e8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization_e2a79c46-f7f8-49c4-a428-671e4bf12694" xlink:href="evh-20211231.xsd#evh_AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingRevenueReconcilingItemLineItems_6b0c2229-b555-427c-98f0-e20e149d8a0e" xlink:to="loc_evh_AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization_e2a79c46-f7f8-49c4-a428-671e4bf12694" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable_26342401-5de9-4b25-b267-9f71879af71d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SegmentReportingRevenueReconcilingItemLineItems_6b0c2229-b555-427c-98f0-e20e149d8a0e" xlink:to="loc_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable_26342401-5de9-4b25-b267-9f71879af71d" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_3772cc65-118c-4ee4-ba66-0a1e6ce8753d" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable_26342401-5de9-4b25-b267-9f71879af71d" xlink:to="loc_srt_ProductOrServiceAxis_3772cc65-118c-4ee4-ba66-0a1e6ce8753d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_3772cc65-118c-4ee4-ba66-0a1e6ce8753d_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_3772cc65-118c-4ee4-ba66-0a1e6ce8753d" xlink:to="loc_srt_ProductsAndServicesDomain_3772cc65-118c-4ee4-ba66-0a1e6ce8753d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_31aff86a-9591-4ea5-a931-fc2bad1d8bde" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_3772cc65-118c-4ee4-ba66-0a1e6ce8753d" xlink:to="loc_srt_ProductsAndServicesDomain_31aff86a-9591-4ea5-a931-fc2bad1d8bde" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_TransformationServicesMember_6e196fcf-390d-4d34-9f55-7a91ff4e332a" xlink:href="evh-20211231.xsd#evh_TransformationServicesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_31aff86a-9591-4ea5-a931-fc2bad1d8bde" xlink:to="loc_evh_TransformationServicesMember_6e196fcf-390d-4d34-9f55-7a91ff4e332a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_PlatformsAndOperationsServicesMember_bef01961-5c5c-44a8-a792-afe34d440d5a" xlink:href="evh-20211231.xsd#evh_PlatformsAndOperationsServicesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_31aff86a-9591-4ea5-a931-fc2bad1d8bde" xlink:to="loc_evh_PlatformsAndOperationsServicesMember_bef01961-5c5c-44a8-a792-afe34d440d5a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsAxis_b479509d-f505-4d93-bc3f-2ffb4c60bf2e" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ConsolidationItemsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable_26342401-5de9-4b25-b267-9f71879af71d" xlink:to="loc_srt_ConsolidationItemsAxis_b479509d-f505-4d93-bc3f-2ffb4c60bf2e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_b479509d-f505-4d93-bc3f-2ffb4c60bf2e_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ConsolidationItemsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ConsolidationItemsAxis_b479509d-f505-4d93-bc3f-2ffb4c60bf2e" xlink:to="loc_srt_ConsolidationItemsDomain_b479509d-f505-4d93-bc3f-2ffb4c60bf2e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_94b5e795-cf55-44c9-943f-6bf4b33bbec9" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ConsolidationItemsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ConsolidationItemsAxis_b479509d-f505-4d93-bc3f-2ffb4c60bf2e" xlink:to="loc_srt_ConsolidationItemsDomain_94b5e795-cf55-44c9-943f-6bf4b33bbec9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntersegmentEliminationMember_c2e988c0-2b0d-49e9-b32e-8093e64808c8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntersegmentEliminationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidationItemsDomain_94b5e795-cf55-44c9-943f-6bf4b33bbec9" xlink:to="loc_us-gaap_IntersegmentEliminationMember_c2e988c0-2b0d-49e9-b32e-8093e64808c8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingSegmentsMember_e65ef178-bb68-4249-93d2-527e65024572" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingSegmentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidationItemsDomain_94b5e795-cf55-44c9-943f-6bf4b33bbec9" xlink:to="loc_us-gaap_OperatingSegmentsMember_e65ef178-bb68-4249-93d2-527e65024572" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateNonSegmentMember_a75a877c-06b0-422a-ba53-de848ad1e2a0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CorporateNonSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidationItemsDomain_94b5e795-cf55-44c9-943f-6bf4b33bbec9" xlink:to="loc_us-gaap_CorporateNonSegmentMember_a75a877c-06b0-422a-ba53-de848ad1e2a0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_0972f980-e5aa-41e1-87b6-ce7fe6dad91d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable_26342401-5de9-4b25-b267-9f71879af71d" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_0972f980-e5aa-41e1-87b6-ce7fe6dad91d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_0972f980-e5aa-41e1-87b6-ce7fe6dad91d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_0972f980-e5aa-41e1-87b6-ce7fe6dad91d" xlink:to="loc_us-gaap_SegmentDomain_0972f980-e5aa-41e1-87b6-ce7fe6dad91d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_1a351473-0e98-4994-a4e5-4e486e674758" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_0972f980-e5aa-41e1-87b6-ce7fe6dad91d" xlink:to="loc_us-gaap_SegmentDomain_1a351473-0e98-4994-a4e5-4e486e674758" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_EvolentHealthServicesSegmentMember_c4dd2865-e8b6-4910-8710-de0d8ae0ae1d" xlink:href="evh-20211231.xsd#evh_EvolentHealthServicesSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_1a351473-0e98-4994-a4e5-4e486e674758" xlink:to="loc_evh_EvolentHealthServicesSegmentMember_c4dd2865-e8b6-4910-8710-de0d8ae0ae1d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_ClinicalSolutionsSegmentMember_54fa0184-d6f3-4c1c-aa95-179d0d7036e9" xlink:href="evh-20211231.xsd#evh_ClinicalSolutionsSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_1a351473-0e98-4994-a4e5-4e486e674758" xlink:to="loc_evh_ClinicalSolutionsSegmentMember_54fa0184-d6f3-4c1c-aa95-179d0d7036e9" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/ReservesforClaimsandPerformanceBasedArrangementsDetails" xlink:type="simple" xlink:href="evh-20211231.xsd#ReservesforClaimsandPerformanceBasedArrangementsDetails"/>
  <link:definitionLink xlink:role="http://www.evolenthealth.com/role/ReservesforClaimsandPerformanceBasedArrangementsDetails" xlink:type="extended" id="i45c2119f44b2499c93a032bc36eaa38d_ReservesforClaimsandPerformanceBasedArrangementsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortdurationInsuranceContractsReconciliationOfClaimsDevelopmentToLiabilityLineItems_0d54c84d-c2e8-4cf0-8f80-c5015820f003" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortdurationInsuranceContractsReconciliationOfClaimsDevelopmentToLiabilityLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MovementInLiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetRollForward_8c18c57e-1f70-427f-b875-6f94c53dd7ed" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MovementInLiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShortdurationInsuranceContractsReconciliationOfClaimsDevelopmentToLiabilityLineItems_0d54c84d-c2e8-4cf0-8f80-c5015820f003" xlink:to="loc_us-gaap_MovementInLiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetRollForward_8c18c57e-1f70-427f-b875-6f94c53dd7ed" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense_13c3e4e4-a8ea-4b48-9961-7bbb77e624ac" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MovementInLiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetRollForward_8c18c57e-1f70-427f-b875-6f94c53dd7ed" xlink:to="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense_13c3e4e4-a8ea-4b48-9961-7bbb77e624ac" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_CurrentYearClaimsAndClaimsAdjustmentExpenseIncludingCostOfGoodsAndServicesSoldExcludingDepreciationAndAmortization_fc95e583-7853-436a-82d8-022b7c35ebaa" xlink:href="evh-20211231.xsd#evh_CurrentYearClaimsAndClaimsAdjustmentExpenseIncludingCostOfGoodsAndServicesSoldExcludingDepreciationAndAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MovementInLiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetRollForward_8c18c57e-1f70-427f-b875-6f94c53dd7ed" xlink:to="loc_evh_CurrentYearClaimsAndClaimsAdjustmentExpenseIncludingCostOfGoodsAndServicesSoldExcludingDepreciationAndAmortization_fc95e583-7853-436a-82d8-022b7c35ebaa" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense_d6733832-1777-4c26-94b2-f684daac96f2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MovementInLiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetRollForward_8c18c57e-1f70-427f-b875-6f94c53dd7ed" xlink:to="loc_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense_d6733832-1777-4c26-94b2-f684daac96f2" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1_0bb2436e-3c74-4078-a529-0c98ebdfb0eb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MovementInLiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetRollForward_8c18c57e-1f70-427f-b875-6f94c53dd7ed" xlink:to="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1_0bb2436e-3c74-4078-a529-0c98ebdfb0eb" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1_9ded9c2c-a316-4df2-ae92-36801a30e8de" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MovementInLiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetRollForward_8c18c57e-1f70-427f-b875-6f94c53dd7ed" xlink:to="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1_9ded9c2c-a316-4df2-ae92-36801a30e8de" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpensePeriodIncreaseDecrease_7a37faac-d941-4de5-bb4b-e04ecadb53b2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpensePeriodIncreaseDecrease"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MovementInLiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetRollForward_8c18c57e-1f70-427f-b875-6f94c53dd7ed" xlink:to="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpensePeriodIncreaseDecrease_7a37faac-d941-4de5-bb4b-e04ecadb53b2" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseBusinessAcquisitions_3e297534-0e0e-4d11-bd3b-35dd16d30123" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseBusinessAcquisitions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MovementInLiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetRollForward_8c18c57e-1f70-427f-b875-6f94c53dd7ed" xlink:to="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseBusinessAcquisitions_3e297534-0e0e-4d11-bd3b-35dd16d30123" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseOpeningBalanceAdjustments_338543ca-8924-4073-97c6-9b0de05ad31f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseOpeningBalanceAdjustments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MovementInLiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetRollForward_8c18c57e-1f70-427f-b875-6f94c53dd7ed" xlink:to="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseOpeningBalanceAdjustments_338543ca-8924-4073-97c6-9b0de05ad31f" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense_25c50f16-8f3c-4ec3-925b-1ecf74a7c24a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortdurationInsuranceContractsReconciliationOfClaimsDevelopmentToLiabilityTable_f8f4490e-c938-4acb-bfb0-2e53ace6afe4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortdurationInsuranceContractsReconciliationOfClaimsDevelopmentToLiabilityTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShortdurationInsuranceContractsReconciliationOfClaimsDevelopmentToLiabilityLineItems_0d54c84d-c2e8-4cf0-8f80-c5015820f003" xlink:to="loc_us-gaap_ShortdurationInsuranceContractsReconciliationOfClaimsDevelopmentToLiabilityTable_f8f4490e-c938-4acb-bfb0-2e53ace6afe4" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_14f252c8-2159-4e3d-b0de-9aac334ae158" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ShortdurationInsuranceContractsReconciliationOfClaimsDevelopmentToLiabilityTable_f8f4490e-c938-4acb-bfb0-2e53ace6afe4" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_14f252c8-2159-4e3d-b0de-9aac334ae158" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_14f252c8-2159-4e3d-b0de-9aac334ae158_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_14f252c8-2159-4e3d-b0de-9aac334ae158" xlink:to="loc_us-gaap_SegmentDomain_14f252c8-2159-4e3d-b0de-9aac334ae158_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_5e09c2ca-17b4-4368-b284-55dc5693b37e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_14f252c8-2159-4e3d-b0de-9aac334ae158" xlink:to="loc_us-gaap_SegmentDomain_5e09c2ca-17b4-4368-b284-55dc5693b37e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_EvolentHealthServicesSegmentMember_82f64c42-b07c-41e4-81b9-738a36350389" xlink:href="evh-20211231.xsd#evh_EvolentHealthServicesSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_5e09c2ca-17b4-4368-b284-55dc5693b37e" xlink:to="loc_evh_EvolentHealthServicesSegmentMember_82f64c42-b07c-41e4-81b9-738a36350389" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_ClinicalSolutionsSegmentMember_bb2d7b3c-e736-4233-94f9-7126281b94bd" xlink:href="evh-20211231.xsd#evh_ClinicalSolutionsSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_5e09c2ca-17b4-4368-b284-55dc5693b37e" xlink:to="loc_evh_ClinicalSolutionsSegmentMember_bb2d7b3c-e736-4233-94f9-7126281b94bd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis_7d9e6a79-dfb1-4898-9865-28df27ce39a2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupClassificationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ShortdurationInsuranceContractsReconciliationOfClaimsDevelopmentToLiabilityTable_f8f4490e-c938-4acb-bfb0-2e53ace6afe4" xlink:to="loc_us-gaap_DisposalGroupClassificationAxis_7d9e6a79-dfb1-4898-9865-28df27ce39a2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_7d9e6a79-dfb1-4898-9865-28df27ce39a2_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_7d9e6a79-dfb1-4898-9865-28df27ce39a2" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_7d9e6a79-dfb1-4898-9865-28df27ce39a2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_83b0ff2f-23e1-46ff-9058-f5b091a29706" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_7d9e6a79-dfb1-4898-9865-28df27ce39a2" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_83b0ff2f-23e1-46ff-9058-f5b091a29706" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationsDisposedOfBySaleMember_73c132ea-c165-485f-bc8a-918661692c41" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DiscontinuedOperationsDisposedOfBySaleMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain_83b0ff2f-23e1-46ff-9058-f5b091a29706" xlink:to="loc_us-gaap_DiscontinuedOperationsDisposedOfBySaleMember_73c132ea-c165-485f-bc8a-918661692c41" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_2734ced7-4a60-483a-9b97-501a1cdf1ab4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ShortdurationInsuranceContractsReconciliationOfClaimsDevelopmentToLiabilityTable_f8f4490e-c938-4acb-bfb0-2e53ace6afe4" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_2734ced7-4a60-483a-9b97-501a1cdf1ab4" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_2734ced7-4a60-483a-9b97-501a1cdf1ab4_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_2734ced7-4a60-483a-9b97-501a1cdf1ab4" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_2734ced7-4a60-483a-9b97-501a1cdf1ab4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_78118281-463d-4458-bac9-62de20f31f5e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_2734ced7-4a60-483a-9b97-501a1cdf1ab4" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_78118281-463d-4458-bac9-62de20f31f5e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_TrueHealthMember_022094cf-3faf-4df7-a394-f4f186583699" xlink:href="evh-20211231.xsd#evh_TrueHealthMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_78118281-463d-4458-bac9-62de20f31f5e" xlink:to="loc_evh_TrueHealthMember_022094cf-3faf-4df7-a394-f4f186583699" xlink:type="arc" order="0"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>13
<FILENAME>evh-20211231_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:cffd2bd6-4cc3-4881-a14e-c3c94aea5d0e,g:f4f494d2-75b7-48aa-a2de-31bddada82ae-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_d735a02d-7324-4b59-b732-8e8518c1c99b_terseLabel_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Disclosures</link:label>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_label_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Cash Flow Information [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_NameOfMajorCustomerDomain_15ad0e22-241e-42ad-8124-8a46a3a33525_terseLabel_en-US" xlink:label="lab_srt_NameOfMajorCustomerDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Domain]</link:label>
    <link:label id="lab_srt_NameOfMajorCustomerDomain_label_en-US" xlink:label="lab_srt_NameOfMajorCustomerDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_NameOfMajorCustomerDomain" xlink:to="lab_srt_NameOfMajorCustomerDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LetterOfCreditMember_2c518b98-fca9-4139-99b2-463bf68ce200_terseLabel_en-US" xlink:label="lab_us-gaap_LetterOfCreditMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Letter of Credit</link:label>
    <link:label id="lab_us-gaap_LetterOfCreditMember_label_en-US" xlink:label="lab_us-gaap_LetterOfCreditMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Letter of Credit [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LetterOfCreditMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LetterOfCreditMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LetterOfCreditMember" xlink:to="lab_us-gaap_LetterOfCreditMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_fb2a921a-8de4-4894-938a-1773e249e43c_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash and Cash Equivalents [Axis]</link:label>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_label_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash and Cash Equivalents [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis" xlink:to="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_41802aca-daba-4719-bd67-55829e6e13d0_terseLabel_en-US" xlink:label="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State and local</link:label>
    <link:label id="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current State and Local Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:to="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_108549ac-5f41-493d-a10d-8b987ffcbe26_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseholdImprovementsMember_223ed0ea-eab8-4e94-be97-541bf2038977_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseholdImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leasehold improvements</link:label>
    <link:label id="lab_us-gaap_LeaseholdImprovementsMember_label_en-US" xlink:label="lab_us-gaap_LeaseholdImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leasehold Improvements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseholdImprovementsMember" xlink:to="lab_us-gaap_LeaseholdImprovementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ConsolidatedEntitiesAxis_53fe14b0-6b7f-4f41-8082-f19990ab1330_terseLabel_en-US" xlink:label="lab_srt_ConsolidatedEntitiesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidated Entities [Axis]</link:label>
    <link:label id="lab_srt_ConsolidatedEntitiesAxis_label_en-US" xlink:label="lab_srt_ConsolidatedEntitiesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidated Entities [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ConsolidatedEntitiesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ConsolidatedEntitiesAxis" xlink:to="lab_srt_ConsolidatedEntitiesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock_e9928a15-0d49-4754-b831-5c94006fdd6b_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of allocation of purchase price</link:label>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Business Acquisitions, by Acquisition [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock" xlink:to="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_5ef08928-7f53-44c6-9eaf-d4dd2aced7fb_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Receivable Type [Axis]</link:label>
    <link:label id="lab_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_label_en-US" xlink:label="lab_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Receivable Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" xlink:to="lab_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedSoftware_852c9c55-fdbc-4f0d-a757-cbc67b44d27d_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedSoftware" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Internally developed software costs</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedSoftware_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedSoftware" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Deferred Expense, Capitalized Software</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedSoftware" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedSoftware"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedSoftware" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedSoftware" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_VariableInterestEntityNewMedicaidContractNotAwardedRequirementToAcquireOwnershipConsiderationAmount_ec71c073-bc47-4119-b326-65eff8a31b21_terseLabel_en-US" xlink:label="lab_evh_VariableInterestEntityNewMedicaidContractNotAwardedRequirementToAcquireOwnershipConsiderationAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Requirement to acquire ownership, consideration, amount</link:label>
    <link:label id="lab_evh_VariableInterestEntityNewMedicaidContractNotAwardedRequirementToAcquireOwnershipConsiderationAmount_label_en-US" xlink:label="lab_evh_VariableInterestEntityNewMedicaidContractNotAwardedRequirementToAcquireOwnershipConsiderationAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Interest Entity, New Medicaid Contract Not Awarded, Requirement To Acquire Ownership, Consideration, Amount</link:label>
    <link:label id="lab_evh_VariableInterestEntityNewMedicaidContractNotAwardedRequirementToAcquireOwnershipConsiderationAmount_documentation_en-US" xlink:label="lab_evh_VariableInterestEntityNewMedicaidContractNotAwardedRequirementToAcquireOwnershipConsiderationAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Interest Entity, New Medicaid Contract Not Awarded, Requirement To Acquire Ownership, Consideration, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_VariableInterestEntityNewMedicaidContractNotAwardedRequirementToAcquireOwnershipConsiderationAmount" xlink:href="evh-20211231.xsd#evh_VariableInterestEntityNewMedicaidContractNotAwardedRequirementToAcquireOwnershipConsiderationAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_VariableInterestEntityNewMedicaidContractNotAwardedRequirementToAcquireOwnershipConsiderationAmount" xlink:to="lab_evh_VariableInterestEntityNewMedicaidContractNotAwardedRequirementToAcquireOwnershipConsiderationAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_DisposalGroupIncludingDiscontinuedOperationRestrictedInvestmentsNoncurrent_edac419e-f904-4b67-9e08-95dac8dd0dd5_terseLabel_en-US" xlink:label="lab_evh_DisposalGroupIncludingDiscontinuedOperationRestrictedInvestmentsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-current restricted investments</link:label>
    <link:label id="lab_evh_DisposalGroupIncludingDiscontinuedOperationRestrictedInvestmentsNoncurrent_label_en-US" xlink:label="lab_evh_DisposalGroupIncludingDiscontinuedOperationRestrictedInvestmentsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Restricted Investments, Noncurrent</link:label>
    <link:label id="lab_evh_DisposalGroupIncludingDiscontinuedOperationRestrictedInvestmentsNoncurrent_documentation_en-US" xlink:label="lab_evh_DisposalGroupIncludingDiscontinuedOperationRestrictedInvestmentsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Restricted Investments, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_DisposalGroupIncludingDiscontinuedOperationRestrictedInvestmentsNoncurrent" xlink:href="evh-20211231.xsd#evh_DisposalGroupIncludingDiscontinuedOperationRestrictedInvestmentsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_DisposalGroupIncludingDiscontinuedOperationRestrictedInvestmentsNoncurrent" xlink:to="lab_evh_DisposalGroupIncludingDiscontinuedOperationRestrictedInvestmentsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_b61adc8b-7eb0-4d66-9fb8-cc5af9ffddcc_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_UnrecognizedTaxBenefitsThatWouldNotImpactEffectiveTaxRate_b4533482-91ba-4a5b-938c-d605ead0ce80_terseLabel_en-US" xlink:label="lab_evh_UnrecognizedTaxBenefitsThatWouldNotImpactEffectiveTaxRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized tax benefits that would not impact effective tax rate</link:label>
    <link:label id="lab_evh_UnrecognizedTaxBenefitsThatWouldNotImpactEffectiveTaxRate_label_en-US" xlink:label="lab_evh_UnrecognizedTaxBenefitsThatWouldNotImpactEffectiveTaxRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits That Would Not Impact Effective Tax Rate</link:label>
    <link:label id="lab_evh_UnrecognizedTaxBenefitsThatWouldNotImpactEffectiveTaxRate_documentation_en-US" xlink:label="lab_evh_UnrecognizedTaxBenefitsThatWouldNotImpactEffectiveTaxRate" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits That Would Not Impact Effective Tax Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_UnrecognizedTaxBenefitsThatWouldNotImpactEffectiveTaxRate" xlink:href="evh-20211231.xsd#evh_UnrecognizedTaxBenefitsThatWouldNotImpactEffectiveTaxRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_UnrecognizedTaxBenefitsThatWouldNotImpactEffectiveTaxRate" xlink:to="lab_evh_UnrecognizedTaxBenefitsThatWouldNotImpactEffectiveTaxRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1_3249e190-0697-4369-881b-ca8a0a30e6ad_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Conversion price (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Convertible, Conversion Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:to="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_5fe87670-cbac-4531-a850-a07c62b93de2_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forfeited (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssumedLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense_94ca2096-ff82-45b4-8a09-091188ddae31_periodStartLabel_en-US" xlink:label="lab_us-gaap_AssumedLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reserves for claims and performance-based arrangements attributable to the Reinsurance Agreement at the beginning of the period</link:label>
    <link:label id="lab_us-gaap_AssumedLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense_c39bdcb6-59aa-4908-9160-c84d99ef7aab_periodEndLabel_en-US" xlink:label="lab_us-gaap_AssumedLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payable for claims and performance-based arrangements attributable to the Reinsurance Agreement at the end of the period</link:label>
    <link:label id="lab_us-gaap_AssumedLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense_label_en-US" xlink:label="lab_us-gaap_AssumedLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assumed Liability for Unpaid Claims and Claims Adjustment Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssumedLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssumedLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssumedLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense" xlink:to="lab_us-gaap_AssumedLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_b7c69fc1-0cd3-4d8b-9734-b810b65fe1f4_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with customer, asset and liability</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Contract Asset, Contract Liability, and Receivable [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:to="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_e55208db-00a2-4c50-baa5-78f85edbbbd7_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forfeited (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_464a28a7-49d0-43d1-9768-25f5974454a8_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average remaining lease term</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Weighted Average Remaining Lease Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShortdurationInsuranceContractsReconciliationOfClaimsDevelopmentToLiabilityTable_479eac74-5db2-4d0a-880a-a0bf324ff15c_terseLabel_en-US" xlink:label="lab_us-gaap_ShortdurationInsuranceContractsReconciliationOfClaimsDevelopmentToLiabilityTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-duration Insurance Contracts, Reconciliation of Claims Development to Liability [Table]</link:label>
    <link:label id="lab_us-gaap_ShortdurationInsuranceContractsReconciliationOfClaimsDevelopmentToLiabilityTable_label_en-US" xlink:label="lab_us-gaap_ShortdurationInsuranceContractsReconciliationOfClaimsDevelopmentToLiabilityTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-duration Insurance Contracts, Reconciliation of Claims Development to Liability [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortdurationInsuranceContractsReconciliationOfClaimsDevelopmentToLiabilityTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortdurationInsuranceContractsReconciliationOfClaimsDevelopmentToLiabilityTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortdurationInsuranceContractsReconciliationOfClaimsDevelopmentToLiabilityTable" xlink:to="lab_us-gaap_ShortdurationInsuranceContractsReconciliationOfClaimsDevelopmentToLiabilityTable" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_88bb2693-2e08-486d-90f1-6b16a55588cd_terseLabel_en-US" xlink:label="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment, Name [Axis]</link:label>
    <link:label id="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_label_en-US" xlink:label="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment, Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_276f6bd6-69fa-4f5f-a298-13f915303b47_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_b4f4854f-f58c-46de-b2bd-077326bee0a3_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net increase (decrease) in cash and cash equivalents and restricted cash</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_07aa7ac7-7379-454c-9caf-e9d31742644e_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected volatility</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleNumberOfEquityInstruments_4acc0053-d5d8-4fc1-a499-e2877aac30aa_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleNumberOfEquityInstruments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Initial conversion amount (in shares)</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleNumberOfEquityInstruments_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleNumberOfEquityInstruments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Convertible, Number of Equity Instruments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleNumberOfEquityInstruments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentConvertibleNumberOfEquityInstruments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentConvertibleNumberOfEquityInstruments" xlink:to="lab_us-gaap_DebtInstrumentConvertibleNumberOfEquityInstruments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_7803bc5f-5de5-4885-a0f0-0c3128318859_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_bf8f2af9-b868-4337-9efd-196bd9878b7c_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible assets</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Intangible Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_b637f5f8-30c6-4bb5-8667-c9eeb854dee6_negatedLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Realized and unrealized losses, net</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_80e154fa-1e39-4409-bbe9-4e9938afd8dc_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intrinsic value of options exercised</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainLossOnDispositionOfAssets1_cb6916ca-e5cc-4973-a4cd-8ddb6364f922_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_GainLossOnDispositionOfAssets1" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss (gain) on disposal of assets and consolidation</link:label>
    <link:label id="lab_us-gaap_GainLossOnDispositionOfAssets1_f95b10c6-b59f-4ec5-8274-cf63b3b7eca2_terseLabel_en-US" xlink:label="lab_us-gaap_GainLossOnDispositionOfAssets1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (loss) on disposal of assets</link:label>
    <link:label id="lab_us-gaap_GainLossOnDispositionOfAssets1_label_en-US" xlink:label="lab_us-gaap_GainLossOnDispositionOfAssets1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) on Disposition of Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnDispositionOfAssets1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossOnDispositionOfAssets1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnDispositionOfAssets1" xlink:to="lab_us-gaap_GainLossOnDispositionOfAssets1" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_NewMexicoHealthConnectionsMember_c07ad1c2-2f30-484b-800f-de8d1eee2e32_terseLabel_en-US" xlink:label="lab_evh_NewMexicoHealthConnectionsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Mexico Health Connections</link:label>
    <link:label id="lab_evh_NewMexicoHealthConnectionsMember_label_en-US" xlink:label="lab_evh_NewMexicoHealthConnectionsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Mexico Health Connections [Member]</link:label>
    <link:label id="lab_evh_NewMexicoHealthConnectionsMember_documentation_en-US" xlink:label="lab_evh_NewMexicoHealthConnectionsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Mexico Health Connections [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_NewMexicoHealthConnectionsMember" xlink:href="evh-20211231.xsd#evh_NewMexicoHealthConnectionsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_NewMexicoHealthConnectionsMember" xlink:to="lab_evh_NewMexicoHealthConnectionsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense_96b7269d-68ed-4996-96f2-09e29ff6f9a3_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Charged to costs and expenses</link:label>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense_label_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances and Reserves, Additions, Charge to Cost and Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense" xlink:to="lab_us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionLineItems_d20fdde1-a8af-4f59-8db8-fe851b7ed520_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Line Items]</link:label>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionLineItems_label_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_11692458-488e-4d11-b48c-583c27a68186_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax liabilities, net</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AmortizationOfIntangibleAssets_0d6b27b3-f64a-4f29-b1bb-1b4285af4d01_terseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of intangible assets</link:label>
    <link:label id="lab_us-gaap_AmortizationOfIntangibleAssets_label_en-US" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of Intangible Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfIntangibleAssets" xlink:to="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterestAbstract_223eff96-40df-4dec-876f-d69a7ab97359_terseLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive loss</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterestAbstract_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterestAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_483d9bc3-1e69-4581-8f88-cf2370735c5b_verboseLabel_en-US" xlink:label="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Useful life</link:label>
    <link:label id="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_46a48228-2893-48a3-af9a-c7dc0a6b06af_terseLabel_en-US" xlink:label="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted- Average Remaining Useful Life</link:label>
    <link:label id="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_label_en-US" xlink:label="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquired Finite-lived Intangible Assets, Weighted Average Useful Life</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" xlink:to="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_IncreaseDecreaseInOperatingLeaseRightofUseAsset_d22d3889-62d0-4cdc-8ffd-525aaf6dc258_negatedTerseLabel_en-US" xlink:label="lab_evh_IncreaseDecreaseInOperatingLeaseRightofUseAsset" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-use operating assets</link:label>
    <link:label id="lab_evh_IncreaseDecreaseInOperatingLeaseRightofUseAsset_label_en-US" xlink:label="lab_evh_IncreaseDecreaseInOperatingLeaseRightofUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) In Operating Lease, Right-of-Use Asset</link:label>
    <link:label id="lab_evh_IncreaseDecreaseInOperatingLeaseRightofUseAsset_documentation_en-US" xlink:label="lab_evh_IncreaseDecreaseInOperatingLeaseRightofUseAsset" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) In Operating Lease, Right-of-Use Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_IncreaseDecreaseInOperatingLeaseRightofUseAsset" xlink:href="evh-20211231.xsd#evh_IncreaseDecreaseInOperatingLeaseRightofUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_IncreaseDecreaseInOperatingLeaseRightofUseAsset" xlink:to="lab_evh_IncreaseDecreaseInOperatingLeaseRightofUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_def458d6-20ab-4557-98df-9f90532838a2_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of antidilutive securities excluded from the calculation of earning per share (in shares)</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_ee79c4ec-381d-4768-84ba-47f82c6f1899_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average discount rate</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Weighted Average Discount Rate, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_79c96dc9-2193-4963-b111-17f482ea15f8_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification to revenue, as a result of performance obligations satisfied</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability, Revenue Recognized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsNet_53f452e5-7f48-41c8-a93c-2990441ef498_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total deferred tax assets</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsNet_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Net of Valuation Allowance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsNet" xlink:to="lab_us-gaap_DeferredTaxAssetsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination and Asset Acquisition [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:to="lab_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionAxis_d7540744-81bc-4cd6-91b5-a49b75db3864_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Axis]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionAxis_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAxis" xlink:to="lab_us-gaap_BusinessAcquisitionAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_AuditInformationAbstract_label_en-US" xlink:label="lab_evh_AuditInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Audit Information [Abstract]</link:label>
    <link:label id="lab_evh_AuditInformationAbstract_documentation_en-US" xlink:label="lab_evh_AuditInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Audit Information [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_AuditInformationAbstract" xlink:href="evh-20211231.xsd#evh_AuditInformationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_AuditInformationAbstract" xlink:to="lab_evh_AuditInformationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_CashAndCashEquivalentsAtCarryingValueExcludingDiscontinuedOperations_c4c4ef4c-8934-43a5-85bc-8ef8abc054b8_terseLabel_en-US" xlink:label="lab_evh_CashAndCashEquivalentsAtCarryingValueExcludingDiscontinuedOperations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_evh_CashAndCashEquivalentsAtCarryingValueExcludingDiscontinuedOperations_label_en-US" xlink:label="lab_evh_CashAndCashEquivalentsAtCarryingValueExcludingDiscontinuedOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value, Excluding Discontinued Operations</link:label>
    <link:label id="lab_evh_CashAndCashEquivalentsAtCarryingValueExcludingDiscontinuedOperations_documentation_en-US" xlink:label="lab_evh_CashAndCashEquivalentsAtCarryingValueExcludingDiscontinuedOperations" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value, Excluding Discontinued Operations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_CashAndCashEquivalentsAtCarryingValueExcludingDiscontinuedOperations" xlink:href="evh-20211231.xsd#evh_CashAndCashEquivalentsAtCarryingValueExcludingDiscontinuedOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_CashAndCashEquivalentsAtCarryingValueExcludingDiscontinuedOperations" xlink:to="lab_evh_CashAndCashEquivalentsAtCarryingValueExcludingDiscontinuedOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock_0cc576ec-3498-46ad-8fb0-81d772d1795f_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of liabilities at fair value on recurring basis</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_dadde405-ca85-4028-82eb-9106bbe9d972_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate Intrinsic Value</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_476938a7-e964-4a80-988b-cf42bc4d104e_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_DebtInstrumentRepurchaseCovenantConsecutiveTradingDaysMinimum_2fe19677-a1e2-49a2-b9d7-43aa1827e8d5_terseLabel_en-US" xlink:label="lab_evh_DebtInstrumentRepurchaseCovenantConsecutiveTradingDaysMinimum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repurchase covenant, consecutive trading days, minimum</link:label>
    <link:label id="lab_evh_DebtInstrumentRepurchaseCovenantConsecutiveTradingDaysMinimum_label_en-US" xlink:label="lab_evh_DebtInstrumentRepurchaseCovenantConsecutiveTradingDaysMinimum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Repurchase Covenant, Consecutive Trading Days, Minimum</link:label>
    <link:label id="lab_evh_DebtInstrumentRepurchaseCovenantConsecutiveTradingDaysMinimum_documentation_en-US" xlink:label="lab_evh_DebtInstrumentRepurchaseCovenantConsecutiveTradingDaysMinimum" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Repurchase Covenant, Consecutive Trading Days, Minimum</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_DebtInstrumentRepurchaseCovenantConsecutiveTradingDaysMinimum" xlink:href="evh-20211231.xsd#evh_DebtInstrumentRepurchaseCovenantConsecutiveTradingDaysMinimum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_DebtInstrumentRepurchaseCovenantConsecutiveTradingDaysMinimum" xlink:to="lab_evh_DebtInstrumentRepurchaseCovenantConsecutiveTradingDaysMinimum" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_c051df6a-248e-48f1-a28d-eae7c288b195_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_TaxReceivableAgreementPercentofCashSavingsNotPaidtoShareholders_1d2da206-7313-4310-b6b2-0fc9696046da_terseLabel_en-US" xlink:label="lab_evh_TaxReceivableAgreementPercentofCashSavingsNotPaidtoShareholders" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax receivable agreement, percent of cash savings not paid to shareholders</link:label>
    <link:label id="lab_evh_TaxReceivableAgreementPercentofCashSavingsNotPaidtoShareholders_label_en-US" xlink:label="lab_evh_TaxReceivableAgreementPercentofCashSavingsNotPaidtoShareholders" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Receivable Agreement, Percent of Cash Savings Not Paid to Shareholders</link:label>
    <link:label id="lab_evh_TaxReceivableAgreementPercentofCashSavingsNotPaidtoShareholders_documentation_en-US" xlink:label="lab_evh_TaxReceivableAgreementPercentofCashSavingsNotPaidtoShareholders" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Receivable Agreement, Percent of Cash Savings Not Paid to Shareholders</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_TaxReceivableAgreementPercentofCashSavingsNotPaidtoShareholders" xlink:href="evh-20211231.xsd#evh_TaxReceivableAgreementPercentofCashSavingsNotPaidtoShareholders"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_TaxReceivableAgreementPercentofCashSavingsNotPaidtoShareholders" xlink:to="lab_evh_TaxReceivableAgreementPercentofCashSavingsNotPaidtoShareholders" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLossCarryforwardsLineItems_b11c0693-6b8c-4d3c-bbe6-30334cf0f073_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwardsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Loss Carryforwards [Line Items]</link:label>
    <link:label id="lab_us-gaap_OperatingLossCarryforwardsLineItems_label_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwardsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Loss Carryforwards [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwardsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="lab_us-gaap_OperatingLossCarryforwardsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_bd0e0dd1-bc9f-4e1e-af4b-31ef2a1c99a8_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other long-term liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Other Noncurrent Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_17b445a0-51ce-40ec-a1cc-3db66dfda69b_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements or Change in Accounting Principle [Line Items]</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements or Change in Accounting Principle [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwillNoncurrent_c60ff827-a0c3-4d48-bf5c-cc2cf3b2697f_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwillNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwillNoncurrent_label_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwillNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Goodwill, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwillNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwillNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwillNoncurrent" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwillNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_NumberOfReportingUnitsFairValueInExcessOfCarryingAmount_3e23cce9-f1ca-4657-8101-57fed5deec0b_terseLabel_en-US" xlink:label="lab_evh_NumberOfReportingUnitsFairValueInExcessOfCarryingAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of reporting units, fair value in excess of carrying amount</link:label>
    <link:label id="lab_evh_NumberOfReportingUnitsFairValueInExcessOfCarryingAmount_label_en-US" xlink:label="lab_evh_NumberOfReportingUnitsFairValueInExcessOfCarryingAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Reporting Units, Fair Value In Excess Of Carrying Amount</link:label>
    <link:label id="lab_evh_NumberOfReportingUnitsFairValueInExcessOfCarryingAmount_documentation_en-US" xlink:label="lab_evh_NumberOfReportingUnitsFairValueInExcessOfCarryingAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Reporting Units, Fair Value In Excess Of Carrying Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_NumberOfReportingUnitsFairValueInExcessOfCarryingAmount" xlink:href="evh-20211231.xsd#evh_NumberOfReportingUnitsFairValueInExcessOfCarryingAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_NumberOfReportingUnitsFairValueInExcessOfCarryingAmount" xlink:to="lab_evh_NumberOfReportingUnitsFairValueInExcessOfCarryingAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableNoncurrentPastDueLineItems_d60d360c-15de-48ee-a324-afcff41eceb4_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableNoncurrentPastDueLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, Noncurrent, Past Due [Line Items]</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableNoncurrentPastDueLineItems_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableNoncurrentPastDueLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, Noncurrent, Past Due [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNoncurrentPastDueLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNoncurrentPastDueLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableNoncurrentPastDueLineItems" xlink:to="lab_us-gaap_AccountsReceivableNoncurrentPastDueLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableInterestEntityNotPrimaryBeneficiaryMember_5c47ad0a-ef1c-4291-b90f-7dfa160b800d_terseLabel_en-US" xlink:label="lab_us-gaap_VariableInterestEntityNotPrimaryBeneficiaryMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Interest Entity, Not Primary Beneficiary</link:label>
    <link:label id="lab_us-gaap_VariableInterestEntityNotPrimaryBeneficiaryMember_label_en-US" xlink:label="lab_us-gaap_VariableInterestEntityNotPrimaryBeneficiaryMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Interest Entity, Not Primary Beneficiary [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableInterestEntityNotPrimaryBeneficiaryMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableInterestEntityNotPrimaryBeneficiaryMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableInterestEntityNotPrimaryBeneficiaryMember" xlink:to="lab_us-gaap_VariableInterestEntityNotPrimaryBeneficiaryMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsMember_42f4b66f-d902-423f-9431-adf0059a9341_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_CommercialAndOtherCustomersMember_85d5efe9-bafd-401b-b57d-bc8ee056cf6d_terseLabel_en-US" xlink:label="lab_evh_CommercialAndOtherCustomersMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial and other</link:label>
    <link:label id="lab_evh_CommercialAndOtherCustomersMember_label_en-US" xlink:label="lab_evh_CommercialAndOtherCustomersMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial And Other Customers [Member]</link:label>
    <link:label id="lab_evh_CommercialAndOtherCustomersMember_documentation_en-US" xlink:label="lab_evh_CommercialAndOtherCustomersMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial And Other Customers</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_CommercialAndOtherCustomersMember" xlink:href="evh-20211231.xsd#evh_CommercialAndOtherCustomersMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_CommercialAndOtherCustomersMember" xlink:to="lab_evh_CommercialAndOtherCustomersMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MinorityInterestOwnershipPercentageByParent_065ecda4-f0f3-4616-bc51-be4b6b93ea6b_terseLabel_en-US" xlink:label="lab_us-gaap_MinorityInterestOwnershipPercentageByParent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Parent's ownership percentage</link:label>
    <link:label id="lab_us-gaap_MinorityInterestOwnershipPercentageByParent_label_en-US" xlink:label="lab_us-gaap_MinorityInterestOwnershipPercentageByParent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest, Ownership Percentage by Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestOwnershipPercentageByParent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MinorityInterestOwnershipPercentageByParent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinorityInterestOwnershipPercentageByParent" xlink:to="lab_us-gaap_MinorityInterestOwnershipPercentageByParent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesLeasingArrangements_becc61a4-2af5-4f77-b2a3-48478d6f402a_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesLeasingArrangements" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-use assets - Operating</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesLeasingArrangements_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesLeasingArrangements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Leasing Arrangements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesLeasingArrangements" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilitiesLeasingArrangements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesLeasingArrangements" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesLeasingArrangements" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_dff22fdf-e685-4fde-898e-79c2e8bac3ed_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exchange/conversion</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Conversion of Convertible Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_NewNotesMember_c42036d6-4a83-4a77-91c2-69233c6f9b2c_terseLabel_en-US" xlink:label="lab_evh_NewNotesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Notes</link:label>
    <link:label id="lab_evh_NewNotesMember_label_en-US" xlink:label="lab_evh_NewNotesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Notes [Member]</link:label>
    <link:label id="lab_evh_NewNotesMember_documentation_en-US" xlink:label="lab_evh_NewNotesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Notes</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_NewNotesMember" xlink:href="evh-20211231.xsd#evh_NewNotesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_NewNotesMember" xlink:to="lab_evh_NewNotesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract_4f7b820e-f068-421e-9e85-43004a033bb5_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_0877f907-df7f-44ee-bfc3-6e6d14432b24_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableInterestEntityOwnershipPercentage_09662239-cf3c-420a-9aa8-50933a187412_terseLabel_en-US" xlink:label="lab_us-gaap_VariableInterestEntityOwnershipPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest in investment</link:label>
    <link:label id="lab_us-gaap_VariableInterestEntityOwnershipPercentage_label_en-US" xlink:label="lab_us-gaap_VariableInterestEntityOwnershipPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Interest Entity, Qualitative or Quantitative Information, Ownership Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableInterestEntityOwnershipPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableInterestEntityOwnershipPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableInterestEntityOwnershipPercentage" xlink:to="lab_us-gaap_VariableInterestEntityOwnershipPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_GlobalHealthMember_64909b09-3106-4c38-9168-80f364ef05a8_terseLabel_en-US" xlink:label="lab_evh_GlobalHealthMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Global Health</link:label>
    <link:label id="lab_evh_GlobalHealthMember_label_en-US" xlink:label="lab_evh_GlobalHealthMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Global Health [Member]</link:label>
    <link:label id="lab_evh_GlobalHealthMember_documentation_en-US" xlink:label="lab_evh_GlobalHealthMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Global Health [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_GlobalHealthMember" xlink:href="evh-20211231.xsd#evh_GlobalHealthMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_GlobalHealthMember" xlink:to="lab_evh_GlobalHealthMember" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_ProceedsFromTransferOfMembership_d4daec60-bdbb-4942-a143-e80c3e75b23b_terseLabel_en-US" xlink:label="lab_evh_ProceedsFromTransferOfMembership" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from transfer of membership</link:label>
    <link:label id="lab_evh_ProceedsFromTransferOfMembership_label_en-US" xlink:label="lab_evh_ProceedsFromTransferOfMembership" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds From Transfer Of Membership</link:label>
    <link:label id="lab_evh_ProceedsFromTransferOfMembership_documentation_en-US" xlink:label="lab_evh_ProceedsFromTransferOfMembership" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds From Transfer Of Membership</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_ProceedsFromTransferOfMembership" xlink:href="evh-20211231.xsd#evh_ProceedsFromTransferOfMembership"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_ProceedsFromTransferOfMembership" xlink:to="lab_evh_ProceedsFromTransferOfMembership" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid_bab29550-ae30-45d8-bc8d-1ba6e08c89f9_terseLabel_en-US" xlink:label="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued property and equipment purchases</link:label>
    <link:label id="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid_label_en-US" xlink:label="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capital Expenditures Incurred but Not yet Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:to="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_StatutoryCapitalReservesLiquidityGuaranteedByInvestorsMinimum_751508be-62e9-4765-8c59-442b164d1d20_terseLabel_en-US" xlink:label="lab_evh_StatutoryCapitalReservesLiquidityGuaranteedByInvestorsMinimum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statutory capital reserves, liquidity guaranteed by investors</link:label>
    <link:label id="lab_evh_StatutoryCapitalReservesLiquidityGuaranteedByInvestorsMinimum_label_en-US" xlink:label="lab_evh_StatutoryCapitalReservesLiquidityGuaranteedByInvestorsMinimum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statutory Capital Reserves, Liquidity Guaranteed By Investors, Minimum</link:label>
    <link:label id="lab_evh_StatutoryCapitalReservesLiquidityGuaranteedByInvestorsMinimum_documentation_en-US" xlink:label="lab_evh_StatutoryCapitalReservesLiquidityGuaranteedByInvestorsMinimum" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statutory Capital Reserves, Liquidity Guaranteed By Investors, Minimum</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_StatutoryCapitalReservesLiquidityGuaranteedByInvestorsMinimum" xlink:href="evh-20211231.xsd#evh_StatutoryCapitalReservesLiquidityGuaranteedByInvestorsMinimum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_StatutoryCapitalReservesLiquidityGuaranteedByInvestorsMinimum" xlink:to="lab_evh_StatutoryCapitalReservesLiquidityGuaranteedByInvestorsMinimum" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_FinancingReceivablePercentNotPastDue_3c82e578-35ac-41de-966e-a736a8ee03a4_terseLabel_en-US" xlink:label="lab_evh_FinancingReceivablePercentNotPastDue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of receivables, current</link:label>
    <link:label id="lab_evh_FinancingReceivablePercentNotPastDue_label_en-US" xlink:label="lab_evh_FinancingReceivablePercentNotPastDue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financing Receivable, Percent Not Past Due</link:label>
    <link:label id="lab_evh_FinancingReceivablePercentNotPastDue_documentation_en-US" xlink:label="lab_evh_FinancingReceivablePercentNotPastDue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financing Receivable, Percent Not Past Due</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_FinancingReceivablePercentNotPastDue" xlink:href="evh-20211231.xsd#evh_FinancingReceivablePercentNotPastDue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_FinancingReceivablePercentNotPastDue" xlink:to="lab_evh_FinancingReceivablePercentNotPastDue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_28ea99ab-140d-4ca3-b4c1-c6b80b799098_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and Equipment [Line Items]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityWellKnownSeasonedIssuer_6826d82b-f944-4e2d-8306-42a564ccdb72_terseLabel_en-US" xlink:label="lab_dei_EntityWellKnownSeasonedIssuer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
    <link:label id="lab_dei_EntityWellKnownSeasonedIssuer_label_en-US" xlink:label="lab_dei_EntityWellKnownSeasonedIssuer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityWellKnownSeasonedIssuer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityWellKnownSeasonedIssuer" xlink:to="lab_dei_EntityWellKnownSeasonedIssuer" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_TransferOfMembershipPercentageOfPaymentBasedOnNumberOfEnrollees_784fbbac-5c98-46d0-a668-b8d418d75610_terseLabel_en-US" xlink:label="lab_evh_TransferOfMembershipPercentageOfPaymentBasedOnNumberOfEnrollees" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Transfer of membership, percentage of payment based on number of enrollees</link:label>
    <link:label id="lab_evh_TransferOfMembershipPercentageOfPaymentBasedOnNumberOfEnrollees_label_en-US" xlink:label="lab_evh_TransferOfMembershipPercentageOfPaymentBasedOnNumberOfEnrollees" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Transfer Of Membership, Percentage Of Payment Based on Number Of Enrollees</link:label>
    <link:label id="lab_evh_TransferOfMembershipPercentageOfPaymentBasedOnNumberOfEnrollees_documentation_en-US" xlink:label="lab_evh_TransferOfMembershipPercentageOfPaymentBasedOnNumberOfEnrollees" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Transfer Of Membership, Percentage Of Payment Based on Number Of Enrollees</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_TransferOfMembershipPercentageOfPaymentBasedOnNumberOfEnrollees" xlink:href="evh-20211231.xsd#evh_TransferOfMembershipPercentageOfPaymentBasedOnNumberOfEnrollees"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_TransferOfMembershipPercentageOfPaymentBasedOnNumberOfEnrollees" xlink:to="lab_evh_TransferOfMembershipPercentageOfPaymentBasedOnNumberOfEnrollees" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_9aefce76-e2ee-4ada-9e45-b2caf2241eae_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total comprehensive loss</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TaxPeriodDomain_17ca1853-204d-4dd5-94ba-34a3f372f09a_terseLabel_en-US" xlink:label="lab_us-gaap_TaxPeriodDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Period [Domain]</link:label>
    <link:label id="lab_us-gaap_TaxPeriodDomain_label_en-US" xlink:label="lab_us-gaap_TaxPeriodDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Period [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxPeriodDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxPeriodDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxPeriodDomain" xlink:to="lab_us-gaap_TaxPeriodDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_CashFlowLesseeAbstract_96f03261-58cb-4a97-8465-4447a7f40e61_terseLabel_en-US" xlink:label="lab_evh_CashFlowLesseeAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effects of Leases</link:label>
    <link:label id="lab_evh_CashFlowLesseeAbstract_label_en-US" xlink:label="lab_evh_CashFlowLesseeAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Flow, Lessee [Abstract]</link:label>
    <link:label id="lab_evh_CashFlowLesseeAbstract_documentation_en-US" xlink:label="lab_evh_CashFlowLesseeAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Flow, Lessee [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_CashFlowLesseeAbstract" xlink:href="evh-20211231.xsd#evh_CashFlowLesseeAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_CashFlowLesseeAbstract" xlink:to="lab_evh_CashFlowLesseeAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_RightOfOffsetPolicyPolicyTextBlock_7035061d-e25e-49d2-92bc-4ee4b179021e_terseLabel_en-US" xlink:label="lab_evh_RightOfOffsetPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right of Offset</link:label>
    <link:label id="lab_evh_RightOfOffsetPolicyPolicyTextBlock_label_en-US" xlink:label="lab_evh_RightOfOffsetPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right of Offset, Policy [Policy Text Block]</link:label>
    <link:label id="lab_evh_RightOfOffsetPolicyPolicyTextBlock_documentation_en-US" xlink:label="lab_evh_RightOfOffsetPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right of Offset, Policy</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_RightOfOffsetPolicyPolicyTextBlock" xlink:href="evh-20211231.xsd#evh_RightOfOffsetPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_RightOfOffsetPolicyPolicyTextBlock" xlink:to="lab_evh_RightOfOffsetPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_TwoThousandElevenEquityIncentivePlanMember_4bcdd430-1dac-4a0a-b656-c1608f87d504_terseLabel_en-US" xlink:label="lab_evh_TwoThousandElevenEquityIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2011 Plan</link:label>
    <link:label id="lab_evh_TwoThousandElevenEquityIncentivePlanMember_label_en-US" xlink:label="lab_evh_TwoThousandElevenEquityIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Two Thousand Eleven Equity Incentive Plan [Member]</link:label>
    <link:label id="lab_evh_TwoThousandElevenEquityIncentivePlanMember_documentation_en-US" xlink:label="lab_evh_TwoThousandElevenEquityIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Two Thousand Eleven Equity Incentive Plan [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_TwoThousandElevenEquityIncentivePlanMember" xlink:href="evh-20211231.xsd#evh_TwoThousandElevenEquityIncentivePlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_TwoThousandElevenEquityIncentivePlanMember" xlink:to="lab_evh_TwoThousandElevenEquityIncentivePlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue_7d8e8a89-9de1-496d-92ac-39e9288877c8_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Deferred Revenue</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense_932279e3-8602-4428-89ee-462ab91ec612_terseLabel_en-US" xlink:label="lab_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Incurred costs related to prior year</link:label>
    <link:label id="lab_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense_label_en-US" xlink:label="lab_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prior Year Claims and Claims Adjustment Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense" xlink:to="lab_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_71a3e227-72d4-4c90-b731-0a4e1f7eb8dc_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_2b9d8afb-4e45-47c0-96f6-9e3133675f35_totalLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic loss per share attributable to common shareholders of Evolent Health, Inc. (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic" xlink:to="lab_us-gaap_EarningsPerShareBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_StockVestedAndRetiredDuringPeriodValue_9db01a6c-4453-4fe3-bc99-3d3ebb5f5e83_negatedTerseLabel_en-US" xlink:label="lab_evh_StockVestedAndRetiredDuringPeriodValue" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share retirement</link:label>
    <link:label id="lab_evh_StockVestedAndRetiredDuringPeriodValue_label_en-US" xlink:label="lab_evh_StockVestedAndRetiredDuringPeriodValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Vested And Retired During Period, Value</link:label>
    <link:label id="lab_evh_StockVestedAndRetiredDuringPeriodValue_documentation_en-US" xlink:label="lab_evh_StockVestedAndRetiredDuringPeriodValue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Vested And Retired During Period, Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_StockVestedAndRetiredDuringPeriodValue" xlink:href="evh-20211231.xsd#evh_StockVestedAndRetiredDuringPeriodValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_StockVestedAndRetiredDuringPeriodValue" xlink:to="lab_evh_StockVestedAndRetiredDuringPeriodValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilityForFuturePolicyBenefitsAndUnpaidClaimsAndClaimsAdjustmentExpense_5de12d57-db5e-4470-a641-e71eec1c63d0_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilityForFuturePolicyBenefitsAndUnpaidClaimsAndClaimsAdjustmentExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reserve for claims and performance-based arrangements</link:label>
    <link:label id="lab_us-gaap_LiabilityForFuturePolicyBenefitsAndUnpaidClaimsAndClaimsAdjustmentExpense_label_en-US" xlink:label="lab_us-gaap_LiabilityForFuturePolicyBenefitsAndUnpaidClaimsAndClaimsAdjustmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability for Future Policy Benefits and Unpaid Claims and Claims Adjustment Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForFuturePolicyBenefitsAndUnpaidClaimsAndClaimsAdjustmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilityForFuturePolicyBenefitsAndUnpaidClaimsAndClaimsAdjustmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilityForFuturePolicyBenefitsAndUnpaidClaimsAndClaimsAdjustmentExpense" xlink:to="lab_us-gaap_LiabilityForFuturePolicyBenefitsAndUnpaidClaimsAndClaimsAdjustmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerTextBlock_26fd3edb-9b63-4ba2-8079-5e77def699f9_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Recognition</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerTextBlock_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCashAndInvestmentsCurrent_6ca6c8e2-e8fd-47b3-a017-6fa2d8ef3e27_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashAndInvestmentsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted cash and restricted investments</link:label>
    <link:label id="lab_us-gaap_RestrictedCashAndInvestmentsCurrent_7a60b4a9-67c7-4f75-b103-11a4ca841c22_totalLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashAndInvestmentsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current restricted cash and restricted investments</link:label>
    <link:label id="lab_us-gaap_RestrictedCashAndInvestmentsCurrent_label_en-US" xlink:label="lab_us-gaap_RestrictedCashAndInvestmentsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash and Investments, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndInvestmentsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndInvestmentsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashAndInvestmentsCurrent" xlink:to="lab_us-gaap_RestrictedCashAndInvestmentsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAcquiredFromAcquisition_87a6668c-9abc-4930-b62b-1d5ffc7cb30d_terseLabel_en-US" xlink:label="lab_us-gaap_CashAcquiredFromAcquisition" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impact to cash and cash equivalents and restricted cash from initial consolidation</link:label>
    <link:label id="lab_us-gaap_CashAcquiredFromAcquisition_label_en-US" xlink:label="lab_us-gaap_CashAcquiredFromAcquisition" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Acquired from Acquisition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAcquiredFromAcquisition" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAcquiredFromAcquisition"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAcquiredFromAcquisition" xlink:to="lab_us-gaap_CashAcquiredFromAcquisition" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_d7423354-60ce-47f7-89ce-774e20ec8d24_periodStartLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance as of beginning of period</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_78be80f5-cbd2-4e4c-b878-ed8a2a986cf1_periodEndLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance as of end of period</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_246bc4a2-cfa4-41ed-bf5f-1f86c38ed152_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of awards issued (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_28b26469-b2de-4d9a-9d3d-69a588a27b2c_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding at the beginning of the period (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_0c11873f-f340-4593-932d-87017b98e756_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding at the end of the period (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_d30f0a3d-8c99-42b1-9b0c-6b0c118940cd_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leveraged Stock Units (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_EffectiveIncomeTaxRateReconciliationDomesticSubsidiaryException_97528a24-d24a-4445-8318-04948a80eb37_terseLabel_en-US" xlink:label="lab_evh_EffectiveIncomeTaxRateReconciliationDomesticSubsidiaryException" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in indefinite reinvestment assertion for domestic subsidiaries</link:label>
    <link:label id="lab_evh_EffectiveIncomeTaxRateReconciliationDomesticSubsidiaryException_label_en-US" xlink:label="lab_evh_EffectiveIncomeTaxRateReconciliationDomesticSubsidiaryException" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation Domestic Subsidiary Exception</link:label>
    <link:label id="lab_evh_EffectiveIncomeTaxRateReconciliationDomesticSubsidiaryException_documentation_en-US" xlink:label="lab_evh_EffectiveIncomeTaxRateReconciliationDomesticSubsidiaryException" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation Domestic Subsidiary Exception</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_EffectiveIncomeTaxRateReconciliationDomesticSubsidiaryException" xlink:href="evh-20211231.xsd#evh_EffectiveIncomeTaxRateReconciliationDomesticSubsidiaryException"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_EffectiveIncomeTaxRateReconciliationDomesticSubsidiaryException" xlink:to="lab_evh_EffectiveIncomeTaxRateReconciliationDomesticSubsidiaryException" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_ConversionOfStockAbstract_86b0335a-e50e-4085-a543-764f85ffb725_terseLabel_en-US" xlink:label="lab_evh_ConversionOfStockAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effects of Class B Exchanges</link:label>
    <link:label id="lab_evh_ConversionOfStockAbstract_label_en-US" xlink:label="lab_evh_ConversionOfStockAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Conversion Of Stock [Abstract]</link:label>
    <link:label id="lab_evh_ConversionOfStockAbstract_documentation_en-US" xlink:label="lab_evh_ConversionOfStockAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Conversion Of Stock [Abstract</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_ConversionOfStockAbstract" xlink:href="evh-20211231.xsd#evh_ConversionOfStockAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_ConversionOfStockAbstract" xlink:to="lab_evh_ConversionOfStockAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestExpenseDebt_8a4a6a84-9632-4794-88eb-1c4ec2c69919_terseLabel_en-US" xlink:label="lab_us-gaap_InterestExpenseDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest expense</link:label>
    <link:label id="lab_us-gaap_InterestExpenseDebt_label_en-US" xlink:label="lab_us-gaap_InterestExpenseDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Expense, Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpenseDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpenseDebt" xlink:to="lab_us-gaap_InterestExpenseDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_AccruedPropertyAndEquipmentPurchases_3ff1d570-d053-4605-b1e4-62eb2297dc64_negatedTerseLabel_en-US" xlink:label="lab_evh_AccruedPropertyAndEquipmentPurchases" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued property and equipment purchases</link:label>
    <link:label id="lab_evh_AccruedPropertyAndEquipmentPurchases_label_en-US" xlink:label="lab_evh_AccruedPropertyAndEquipmentPurchases" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Property And Equipment Purchases</link:label>
    <link:label id="lab_evh_AccruedPropertyAndEquipmentPurchases_documentation_en-US" xlink:label="lab_evh_AccruedPropertyAndEquipmentPurchases" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Property And Equipment Purchases</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_AccruedPropertyAndEquipmentPurchases" xlink:href="evh-20211231.xsd#evh_AccruedPropertyAndEquipmentPurchases"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_AccruedPropertyAndEquipmentPurchases" xlink:to="lab_evh_AccruedPropertyAndEquipmentPurchases" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetInterestCarryforward_bca67968-51c7-498f-90a7-4ce7799ecf18_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetInterestCarryforward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest deduction limitation</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetInterestCarryforward_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetInterestCarryforward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Asset, Interest Carryforward</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetInterestCarryforward" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetInterestCarryforward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetInterestCarryforward" xlink:to="lab_us-gaap_DeferredTaxAssetInterestCarryforward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations_d879b9f9-cf96-4a03-b84c-f8c2804d4da7_terseLabel_en-US" xlink:label="lab_us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows (used in) provided by investing activities</link:label>
    <link:label id="lab_us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations_label_en-US" xlink:label="lab_us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Provided by (Used in) Investing Activities, Discontinued Operations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations" xlink:to="lab_us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_DeferredTaxLiabilitiesIndefiniteLivedIntangibleAssets_3e5a424c-bfbe-420f-b74e-fe4bdd6c5240_terseLabel_en-US" xlink:label="lab_evh_DeferredTaxLiabilitiesIndefiniteLivedIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax liabilities, indefinite-lived intangible assets</link:label>
    <link:label id="lab_evh_DeferredTaxLiabilitiesIndefiniteLivedIntangibleAssets_label_en-US" xlink:label="lab_evh_DeferredTaxLiabilitiesIndefiniteLivedIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Indefinite-Lived Intangible Assets</link:label>
    <link:label id="lab_evh_DeferredTaxLiabilitiesIndefiniteLivedIntangibleAssets_documentation_en-US" xlink:label="lab_evh_DeferredTaxLiabilitiesIndefiniteLivedIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Indefinite-Lived Intangible Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_DeferredTaxLiabilitiesIndefiniteLivedIntangibleAssets" xlink:href="evh-20211231.xsd#evh_DeferredTaxLiabilitiesIndefiniteLivedIntangibleAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_DeferredTaxLiabilitiesIndefiniteLivedIntangibleAssets" xlink:to="lab_evh_DeferredTaxLiabilitiesIndefiniteLivedIntangibleAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CapitalizedContractCostNet_d71bc9f4-17a7-4f21-8be6-39af80fb9055_terseLabel_en-US" xlink:label="lab_us-gaap_CapitalizedContractCostNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract cost assets</link:label>
    <link:label id="lab_us-gaap_CapitalizedContractCostNet_label_en-US" xlink:label="lab_us-gaap_CapitalizedContractCostNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capitalized Contract Cost, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedContractCostNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalizedContractCostNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalizedContractCostNet" xlink:to="lab_us-gaap_CapitalizedContractCostNet" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_33e97929-d8da-4230-a1b6-3ae60b234a78_terseLabel_en-US" xlink:label="lab_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative Effect, Period of Adoption, Adjustment</link:label>
    <link:label id="lab_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_label_en-US" xlink:label="lab_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative Effect, Period of Adoption, Adjustment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember" xlink:to="lab_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_ScheduleofChangesinNoncontrollingInterestTableTextBlock_304853b7-64b9-4e58-bfcc-d15004fd9911_terseLabel_en-US" xlink:label="lab_evh_ScheduleofChangesinNoncontrollingInterestTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of changes in non-controlling interests</link:label>
    <link:label id="lab_evh_ScheduleofChangesinNoncontrollingInterestTableTextBlock_label_en-US" xlink:label="lab_evh_ScheduleofChangesinNoncontrollingInterestTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Changes in Noncontrolling Interest [Table Text Block]</link:label>
    <link:label id="lab_evh_ScheduleofChangesinNoncontrollingInterestTableTextBlock_documentation_en-US" xlink:label="lab_evh_ScheduleofChangesinNoncontrollingInterestTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Changes in Noncontrolling Interest [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_ScheduleofChangesinNoncontrollingInterestTableTextBlock" xlink:href="evh-20211231.xsd#evh_ScheduleofChangesinNoncontrollingInterestTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_ScheduleofChangesinNoncontrollingInterestTableTextBlock" xlink:to="lab_evh_ScheduleofChangesinNoncontrollingInterestTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilities_685c4386-3c63-4d48-8f75-061ab759cf91_negatedTotalLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilities" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net deferred tax assets (liabilities)</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilities_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilities" xlink:to="lab_us-gaap_DeferredTaxLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNoncashIncomeExpense_cc44e346-d555-4849-a77f-409f6b09a721_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_OtherNoncashIncomeExpense" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other current operating cash inflows (outflows), net</link:label>
    <link:label id="lab_us-gaap_OtherNoncashIncomeExpense_label_en-US" xlink:label="lab_us-gaap_OtherNoncashIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Noncash Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNoncashIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNoncashIncomeExpense" xlink:to="lab_us-gaap_OtherNoncashIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CapitalizedContractCostNetNoncurrent_11114c56-dbbc-435c-93db-d67bbd900222_terseLabel_en-US" xlink:label="lab_us-gaap_CapitalizedContractCostNetNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract cost assets</link:label>
    <link:label id="lab_us-gaap_CapitalizedContractCostNetNoncurrent_label_en-US" xlink:label="lab_us-gaap_CapitalizedContractCostNetNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capitalized Contract Cost, Net, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedContractCostNetNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalizedContractCostNetNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalizedContractCostNetNoncurrent" xlink:to="lab_us-gaap_CapitalizedContractCostNetNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalents_ee1be4d5-897b-4990-a373-336f66ce3f14_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted funds</link:label>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalents_label_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash and Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalents" xlink:to="lab_us-gaap_RestrictedCashAndCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_6e057569-da5f-4d96-b834-054e8158455d_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]</link:label>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_label_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems" xlink:to="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_NoncontrollingInterestDecreaseFromDisposalOfAssets_3b28c591-fd77-4007-925f-dea1a66c588f_negatedTerseLabel_en-US" xlink:label="lab_evh_NoncontrollingInterestDecreaseFromDisposalOfAssets" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal of assets</link:label>
    <link:label id="lab_evh_NoncontrollingInterestDecreaseFromDisposalOfAssets_label_en-US" xlink:label="lab_evh_NoncontrollingInterestDecreaseFromDisposalOfAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest, Decrease From Disposal Of Assets</link:label>
    <link:label id="lab_evh_NoncontrollingInterestDecreaseFromDisposalOfAssets_documentation_en-US" xlink:label="lab_evh_NoncontrollingInterestDecreaseFromDisposalOfAssets" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest, Decrease From Disposal Of Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_NoncontrollingInterestDecreaseFromDisposalOfAssets" xlink:href="evh-20211231.xsd#evh_NoncontrollingInterestDecreaseFromDisposalOfAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_NoncontrollingInterestDecreaseFromDisposalOfAssets" xlink:to="lab_evh_NoncontrollingInterestDecreaseFromDisposalOfAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_6ff46b57-1a71-4e75-9586-5c80396f542d_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Groups, Including Discontinued Operations [Table]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_label_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Groups, Including Discontinued Operations [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:to="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPeriodTwoMember_8f6411dc-8c66-4871-8626-4c7720f4a6b0_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPeriodTwoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">After the Third Anniversary of the Closing of the Senior Credit Facilities but Prior to the Fourth Anniversary</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPeriodTwoMember_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPeriodTwoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Redemption, Period Two [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodTwoMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodTwoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodTwoMember" xlink:to="lab_us-gaap_DebtInstrumentRedemptionPeriodTwoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityVoluntaryFilers_813250e3-ae4c-4f0b-9b5e-76eab4693b27_terseLabel_en-US" xlink:label="lab_dei_EntityVoluntaryFilers" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Voluntary Filers</link:label>
    <link:label id="lab_dei_EntityVoluntaryFilers_label_en-US" xlink:label="lab_dei_EntityVoluntaryFilers" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Voluntary Filers</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityVoluntaryFilers" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityVoluntaryFilers"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityVoluntaryFilers" xlink:to="lab_dei_EntityVoluntaryFilers" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_84f11d95-27b6-4263-81c5-8e18b7e8f5d8_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of options vested</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosureAbstract_54ee8bb7-fa40-464f-bfae-b5f3bc1c5a01_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Fair Value Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsFairValueDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract" xlink:to="lab_us-gaap_AssetsFairValueDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameAxis_1074ddd4-e782-414d-820c-b9e0db9de828_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:label id="lab_us-gaap_PlanNameAxis_label_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameAxis" xlink:to="lab_us-gaap_PlanNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebt_ffefd1d0-bcff-4441-a966-8c5c29f949eb_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term debt, net of discount</link:label>
    <link:label id="lab_us-gaap_LongTermDebt_f4b8d4c4-4085-4cd7-a685-048063a15881_verboseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebt" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Carrying amount</link:label>
    <link:label id="lab_us-gaap_LongTermDebt_label_en-US" xlink:label="lab_us-gaap_LongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebt" xlink:to="lab_us-gaap_LongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital_c0a10ee6-d850-41f9-9c37-9f3cb0a9b45e_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Return of equity method investments</link:label>
    <link:label id="lab_us-gaap_ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital_label_en-US" xlink:label="lab_us-gaap_ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Equity Method Investment, Distribution, Return of Capital</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital" xlink:to="lab_us-gaap_ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_7f5fa017-55d4-490e-9ed6-b8ddcbfe590d_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 1</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel1Member" xlink:to="lab_us-gaap_FairValueInputsLevel1Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_d325c796-e23e-4511-814f-310045ae8a12_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Flows Provided by (Used In) Investing Activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillImpairmentLoss_db502e63-1428-43a0-ac8a-b1ad8e04017c_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillImpairmentLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill impairment</link:label>
    <link:label id="lab_us-gaap_GoodwillImpairmentLoss_d29e2e6b-7af7-4372-ac89-5289a48125b5_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_GoodwillImpairmentLoss" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment</link:label>
    <link:label id="lab_us-gaap_GoodwillImpairmentLoss_label_en-US" xlink:label="lab_us-gaap_GoodwillImpairmentLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, Impairment Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairmentLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillImpairmentLoss" xlink:to="lab_us-gaap_GoodwillImpairmentLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_StockIssuedDuringPeriodSharesEquityMethodInvestmentsAndAssetAcquisitions_65d5ff7f-87c5-4657-8347-e496fbfe0f1f_terseLabel_en-US" xlink:label="lab_evh_StockIssuedDuringPeriodSharesEquityMethodInvestmentsAndAssetAcquisitions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares issued for equity-method investments and asset acquisitions (in shares)</link:label>
    <link:label id="lab_evh_StockIssuedDuringPeriodSharesEquityMethodInvestmentsAndAssetAcquisitions_label_en-US" xlink:label="lab_evh_StockIssuedDuringPeriodSharesEquityMethodInvestmentsAndAssetAcquisitions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Equity-Method Investments And Asset Acquisitions</link:label>
    <link:label id="lab_evh_StockIssuedDuringPeriodSharesEquityMethodInvestmentsAndAssetAcquisitions_documentation_en-US" xlink:label="lab_evh_StockIssuedDuringPeriodSharesEquityMethodInvestmentsAndAssetAcquisitions" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Equity-Method Investments And Asset Acquisitions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_StockIssuedDuringPeriodSharesEquityMethodInvestmentsAndAssetAcquisitions" xlink:href="evh-20211231.xsd#evh_StockIssuedDuringPeriodSharesEquityMethodInvestmentsAndAssetAcquisitions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_StockIssuedDuringPeriodSharesEquityMethodInvestmentsAndAssetAcquisitions" xlink:to="lab_evh_StockIssuedDuringPeriodSharesEquityMethodInvestmentsAndAssetAcquisitions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_5acf08b1-be9b-473c-93a2-12401c3c69a5_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:to="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitySmallBusiness_9ec90dfd-9aac-46a1-a30f-ebc691d97c78_terseLabel_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:label id="lab_dei_EntitySmallBusiness_label_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntitySmallBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BaseRateMember_31b5a99a-5d97-4c3b-8482-68f5aa3efcb2_terseLabel_en-US" xlink:label="lab_us-gaap_BaseRateMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Base Rate</link:label>
    <link:label id="lab_us-gaap_BaseRateMember_label_en-US" xlink:label="lab_us-gaap_BaseRateMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Base Rate [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BaseRateMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BaseRateMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BaseRateMember" xlink:to="lab_us-gaap_BaseRateMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems_d58a9305-b80e-473b-abaa-0f905794e7e5_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets [Line Items]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation_1443c580-1ced-4132-8803-7cbb58f0445f_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock based compensation</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Employee Compensation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_TransferOfMembershipPercentageOfPaymentSubjectToSatisfactionOfContingencies_d0d81abe-2b86-4a84-8154-2ba14a95626e_terseLabel_en-US" xlink:label="lab_evh_TransferOfMembershipPercentageOfPaymentSubjectToSatisfactionOfContingencies" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Transfer of membership, percentage of payment subject to satisfaction of contingencies</link:label>
    <link:label id="lab_evh_TransferOfMembershipPercentageOfPaymentSubjectToSatisfactionOfContingencies_label_en-US" xlink:label="lab_evh_TransferOfMembershipPercentageOfPaymentSubjectToSatisfactionOfContingencies" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Transfer Of Membership, Percentage Of Payment Subject To Satisfaction Of Contingencies</link:label>
    <link:label id="lab_evh_TransferOfMembershipPercentageOfPaymentSubjectToSatisfactionOfContingencies_documentation_en-US" xlink:label="lab_evh_TransferOfMembershipPercentageOfPaymentSubjectToSatisfactionOfContingencies" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Transfer Of Membership, Percentage Of Payment Subject To Satisfaction Of Contingencies</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_TransferOfMembershipPercentageOfPaymentSubjectToSatisfactionOfContingencies" xlink:href="evh-20211231.xsd#evh_TransferOfMembershipPercentageOfPaymentSubjectToSatisfactionOfContingencies"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_TransferOfMembershipPercentageOfPaymentSubjectToSatisfactionOfContingencies" xlink:to="lab_evh_TransferOfMembershipPercentageOfPaymentSubjectToSatisfactionOfContingencies" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableNet_64432925-a0c7-4e28-89a4-d529ba78c564_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable, net</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableNet_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, after Allowance for Credit Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableNet" xlink:to="lab_us-gaap_AccountsReceivableNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireOtherProductiveAssets_0776a54b-ae02-4553-ad85-d3f183a8e986_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireOtherProductiveAssets" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments in internal-use software and purchases of property and equipment</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireOtherProductiveAssets_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireOtherProductiveAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Other Productive Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireOtherProductiveAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireOtherProductiveAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireOtherProductiveAssets" xlink:to="lab_us-gaap_PaymentsToAcquireOtherProductiveAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceReceivablesMember_41a1d73e-0fa0-421f-9ebd-ca66ec5c8251_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceReceivablesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer Receivable</link:label>
    <link:label id="lab_us-gaap_FinanceReceivablesMember_label_en-US" xlink:label="lab_us-gaap_FinanceReceivablesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financing Receivable [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceReceivablesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceReceivablesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceReceivablesMember" xlink:to="lab_us-gaap_FinanceReceivablesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_fd10f138-e4bc-433d-bef3-2ba4688491da_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional paid-in-capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid in Capital</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapital" xlink:to="lab_us-gaap_AdditionalPaidInCapital" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_603b10c3-e9f4-47bc-93c6-3143a7663e12_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">LIABILITIES AND SHAREHOLDERS&#8217; EQUITY</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_5dc68bab-584c-4160-a648-ac35b86160e7_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_09132735-cfca-4628-9cf5-797d5801f4ca_terseLabel_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_label_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent" xlink:to="lab_dei_EntityInteractiveDataCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_2ec69857-f167-45e3-8718-6976f77104ab_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2025</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CapitalizedContractCostTable_e9374cf4-ab49-40ef-8f9a-cf4cb4b8de21_terseLabel_en-US" xlink:label="lab_us-gaap_CapitalizedContractCostTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capitalized Contract Cost [Table]</link:label>
    <link:label id="lab_us-gaap_CapitalizedContractCostTable_label_en-US" xlink:label="lab_us-gaap_CapitalizedContractCostTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capitalized Contract Cost [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedContractCostTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalizedContractCostTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalizedContractCostTable" xlink:to="lab_us-gaap_CapitalizedContractCostTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_ea742da0-e45d-4a67-b759-edbae293cffa_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible debt extinguishment</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Tax Credit, Research, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_DebtIssuanceCostsNetDebtComponent_69c0f75e-b6e2-42fe-8eb9-752049fe75ed_terseLabel_en-US" xlink:label="lab_evh_DebtIssuanceCostsNetDebtComponent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt issuance costs, net, debt component</link:label>
    <link:label id="lab_evh_DebtIssuanceCostsNetDebtComponent_label_en-US" xlink:label="lab_evh_DebtIssuanceCostsNetDebtComponent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Issuance Costs, Net, Debt Component</link:label>
    <link:label id="lab_evh_DebtIssuanceCostsNetDebtComponent_documentation_en-US" xlink:label="lab_evh_DebtIssuanceCostsNetDebtComponent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Issuance Costs, Net, Debt Component</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_DebtIssuanceCostsNetDebtComponent" xlink:href="evh-20211231.xsd#evh_DebtIssuanceCostsNetDebtComponent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_DebtIssuanceCostsNetDebtComponent" xlink:to="lab_evh_DebtIssuanceCostsNetDebtComponent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_a1f561ea-2cdb-4ccb-8def-0f13bc5153be_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise of stock options</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Stock Options Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_45a31d66-ed2d-4120-b1c7-f50658e13081_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_DisposalGroupIncludingDiscontinuedOperationInvestmentsNoncurrent_5191869e-a88a-4372-b5bf-6698a549f829_terseLabel_en-US" xlink:label="lab_evh_DisposalGroupIncludingDiscontinuedOperationInvestmentsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments, at amortized cost</link:label>
    <link:label id="lab_evh_DisposalGroupIncludingDiscontinuedOperationInvestmentsNoncurrent_label_en-US" xlink:label="lab_evh_DisposalGroupIncludingDiscontinuedOperationInvestmentsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Investments, Noncurrent</link:label>
    <link:label id="lab_evh_DisposalGroupIncludingDiscontinuedOperationInvestmentsNoncurrent_documentation_en-US" xlink:label="lab_evh_DisposalGroupIncludingDiscontinuedOperationInvestmentsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Investments, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_DisposalGroupIncludingDiscontinuedOperationInvestmentsNoncurrent" xlink:href="evh-20211231.xsd#evh_DisposalGroupIncludingDiscontinuedOperationInvestmentsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_DisposalGroupIncludingDiscontinuedOperationInvestmentsNoncurrent" xlink:to="lab_evh_DisposalGroupIncludingDiscontinuedOperationInvestmentsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_ffccf32a-a50f-4345-b15b-ffc0e6ace08e_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in fair value of contingent consideration and indemnification asset</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_4c88ae85-2cab-43a9-abb7-a7562fcf302a_verboseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in fair value of contingent consideration and indemnification asset</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_3234349c-6871-4f4c-8c10-088e27127b8f_negatedLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in fair value of contingent consideration and indemnification asset</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_AffiliatedEntityMember_78606f7d-9c11-42ce-88c7-561b5fe79572_terseLabel_en-US" xlink:label="lab_srt_AffiliatedEntityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Affiliated Entity</link:label>
    <link:label id="lab_srt_AffiliatedEntityMember_label_en-US" xlink:label="lab_srt_AffiliatedEntityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Affiliated Entity [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_AffiliatedEntityMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_AffiliatedEntityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_AffiliatedEntityMember" xlink:to="lab_srt_AffiliatedEntityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NoncontrollingInterestAbstract_fb4f88ae-4db2-4e55-a888-aa8941089623_terseLabel_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest [Abstract]</link:label>
    <link:label id="lab_us-gaap_NoncontrollingInterestAbstract_label_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NoncontrollingInterestAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncontrollingInterestAbstract" xlink:to="lab_us-gaap_NoncontrollingInterestAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseExcessCompensationPercent_f40edc15-7b76-485f-bcd5-3e36a17845c7_terseLabel_en-US" xlink:label="lab_evh_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseExcessCompensationPercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nondeductible excess compensation</link:label>
    <link:label id="lab_evh_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseExcessCompensationPercent_label_en-US" xlink:label="lab_evh_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseExcessCompensationPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Excess Compensation, Percent</link:label>
    <link:label id="lab_evh_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseExcessCompensationPercent_documentation_en-US" xlink:label="lab_evh_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseExcessCompensationPercent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Excess Compensation, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseExcessCompensationPercent" xlink:href="evh-20211231.xsd#evh_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseExcessCompensationPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseExcessCompensationPercent" xlink:to="lab_evh_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseExcessCompensationPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleConversionRatio1_545917aa-51e8-4011-ac1b-f297678dad17_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleConversionRatio1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Initial conversion rate per $ 1000 principal amount</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleConversionRatio1_1ef6fa89-554e-451a-954a-9c93f655bd5f_verboseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleConversionRatio1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Initial conversion rate per $ 1000 principal amount</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleConversionRatio1_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleConversionRatio1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Convertible, Conversion Ratio</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionRatio1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionRatio1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentConvertibleConversionRatio1" xlink:to="lab_us-gaap_DebtInstrumentConvertibleConversionRatio1" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_StockVestedAndRetiredDuringPeriodShares_a5775c58-6b7d-4608-b888-bf060fcd592e_negatedTerseLabel_en-US" xlink:label="lab_evh_StockVestedAndRetiredDuringPeriodShares" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share retirement (in shares)</link:label>
    <link:label id="lab_evh_StockVestedAndRetiredDuringPeriodShares_label_en-US" xlink:label="lab_evh_StockVestedAndRetiredDuringPeriodShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Vested And Retired During Period, Shares</link:label>
    <link:label id="lab_evh_StockVestedAndRetiredDuringPeriodShares_documentation_en-US" xlink:label="lab_evh_StockVestedAndRetiredDuringPeriodShares" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Vested And Retired During Period, Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_StockVestedAndRetiredDuringPeriodShares" xlink:href="evh-20211231.xsd#evh_StockVestedAndRetiredDuringPeriodShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_StockVestedAndRetiredDuringPeriodShares" xlink:to="lab_evh_StockVestedAndRetiredDuringPeriodShares" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_cd96abec-d72b-4574-9e23-9d0b2b70c7d1_terseLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total comprehensive loss attributable to non-controlling interests</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightLineItems_54d1decf-084f-42ab-ace5-7f7bf41320e7_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right [Line Items]</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightLineItems_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="lab_us-gaap_ClassOfWarrantOrRightLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_8951d4be-9b4b-4415-b506-83dc7f87332c_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized tax benefits</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_756ca21c-b96a-42f7-869e-552479fad882_periodStartLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance at beginning-of-year</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_649f540b-964c-4769-ae42-ba22f162c163_periodEndLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance at end-of-year</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefits" xlink:to="lab_us-gaap_UnrecognizedTaxBenefits" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGross_a60ac025-ddbd-46f0-88db-ab11a26cd05c_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGross" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subtotal</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGross_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsGross" xlink:to="lab_us-gaap_DeferredTaxAssetsGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityDomain_dd4bcfb3-ad79-41f6-bc72-d1b2527a42cb_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityDomain_label_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain" xlink:to="lab_us-gaap_IncomeTaxAuthorityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_88c17cba-ef29-4918-93fe-fd15e4c13009_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding (in shares)</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_4e012d78-fe98-41b5-97a0-2a257ff934f1_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss_2b022b06-777c-4ec0-a844-9c429cca19f2_totalLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating income (loss)</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss_label_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Operating Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromInterestReceived_9929aac8-317c-4ce3-a44c-3ebe66dae4d8_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromInterestReceived" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from interest received</link:label>
    <link:label id="lab_us-gaap_ProceedsFromInterestReceived_label_en-US" xlink:label="lab_us-gaap_ProceedsFromInterestReceived" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Interest Received</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromInterestReceived" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromInterestReceived"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromInterestReceived" xlink:to="lab_us-gaap_ProceedsFromInterestReceived" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueAcquisitions_2c1465c1-1dbe-4af9-afb8-6933e9b90030_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares issued for acquisition</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueAcquisitions_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Acquisitions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueAcquisitions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_0bbf26ac-2dda-4aac-8925-9e330f273ca1_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_QuarterlyFinancialDataAbstract_800e61c3-b5ba-4bec-ac37-f7cbd5856d0d_terseLabel_en-US" xlink:label="lab_us-gaap_QuarterlyFinancialDataAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Quarterly Financial Data [Abstract]</link:label>
    <link:label id="lab_us-gaap_QuarterlyFinancialDataAbstract_label_en-US" xlink:label="lab_us-gaap_QuarterlyFinancialDataAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Quarterly Financial Data [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_QuarterlyFinancialDataAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_QuarterlyFinancialDataAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_QuarterlyFinancialDataAbstract" xlink:to="lab_us-gaap_QuarterlyFinancialDataAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReceivableTypeDomain_c6d6d409-532e-48b6-be40-8da4057a0b51_terseLabel_en-US" xlink:label="lab_us-gaap_ReceivableTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Receivable [Domain]</link:label>
    <link:label id="lab_us-gaap_ReceivableTypeDomain_label_en-US" xlink:label="lab_us-gaap_ReceivableTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Receivable [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivableTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReceivableTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReceivableTypeDomain" xlink:to="lab_us-gaap_ReceivableTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations_6f56bfa4-be2f-4272-b167-21a180f40916_terseLabel_en-US" xlink:label="lab_us-gaap_CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows used in financing activities</link:label>
    <link:label id="lab_us-gaap_CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations_label_en-US" xlink:label="lab_us-gaap_CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Provided by (Used in) Financing Activities, Discontinued Operations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations" xlink:to="lab_us-gaap_CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_473b8e2b-5382-449f-983b-814f8732cac1_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Operating Lease Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_df5f779a-49e7-4541-bb05-c74ccf2735cc_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercisable at the end of the period (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestWeightedAverageGrantDateFairValue_6ad5438f-f81c-4dfb-b1b4-165b59883095_terseLabel_en-US" xlink:label="lab_evh_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Grant Date Fair Value (in dollars per share)</link:label>
    <link:label id="lab_evh_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_evh_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement By Share-based Payment Award, Equity Instruments Other Than Options, Vested And Expected To Vest, Weighted Average Grant Date Fair Value</link:label>
    <link:label id="lab_evh_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestWeightedAverageGrantDateFairValue_documentation_en-US" xlink:label="lab_evh_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement By Share-based Payment Award, Equity Instruments Other Than Options, Vested And Expected To Vest, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestWeightedAverageGrantDateFairValue" xlink:href="evh-20211231.xsd#evh_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestWeightedAverageGrantDateFairValue" xlink:to="lab_evh_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CapitalizedContractCostLineItems_6a2ff5bd-6013-483a-8696-59e6835e1ec0_terseLabel_en-US" xlink:label="lab_us-gaap_CapitalizedContractCostLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capitalized Contract Cost [Line Items]</link:label>
    <link:label id="lab_us-gaap_CapitalizedContractCostLineItems_label_en-US" xlink:label="lab_us-gaap_CapitalizedContractCostLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capitalized Contract Cost [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedContractCostLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalizedContractCostLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalizedContractCostLineItems" xlink:to="lab_us-gaap_CapitalizedContractCostLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_c90d3c8b-5703-41a5-a90a-075360215acf_terseLabel_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_label_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract" xlink:to="lab_us-gaap_AccountingPoliciesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MovementInLiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetRollForward_2ada1b57-4de2-47a2-a487-751aa259f6bf_terseLabel_en-US" xlink:label="lab_us-gaap_MovementInLiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability for Unpaid Claims and Claims Adjustment Expense, Period Increase (Decrease) [Abstract]</link:label>
    <link:label id="lab_us-gaap_MovementInLiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetRollForward_label_en-US" xlink:label="lab_us-gaap_MovementInLiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability for Unpaid Claims and Claims Adjustment Expense, Period Increase (Decrease) [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MovementInLiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MovementInLiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MovementInLiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetRollForward" xlink:to="lab_us-gaap_MovementInLiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_afe652d9-d224-4ebe-8770-2e82068accf5_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CapitalizedContractCostAmortizationPeriod_e35ed1ff-543d-49cf-ba24-8b51dfefef8d_terseLabel_en-US" xlink:label="lab_us-gaap_CapitalizedContractCostAmortizationPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capitalized contract cost, amortization period</link:label>
    <link:label id="lab_us-gaap_CapitalizedContractCostAmortizationPeriod_label_en-US" xlink:label="lab_us-gaap_CapitalizedContractCostAmortizationPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capitalized Contract Cost, Amortization Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedContractCostAmortizationPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalizedContractCostAmortizationPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalizedContractCostAmortizationPeriod" xlink:to="lab_us-gaap_CapitalizedContractCostAmortizationPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets_4c2af665-ad9f-44b0-9ada-a2988a0e1411_verboseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other non-current assets</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Other Noncurrent Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentFederalTaxExpenseBenefit_aa65d993-1eb6-4c7e-83d3-db1d33b0aecc_terseLabel_en-US" xlink:label="lab_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Federal</link:label>
    <link:label id="lab_us-gaap_CurrentFederalTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Federal Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentFederalTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:to="lab_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_d1610332-df49-442c-84e0-8cae4b2c50c1_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Present value of lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiability" xlink:to="lab_us-gaap_OperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationPerformanceSharesAwardOutstandingActivityTableTextBlock_2b00592b-a605-4282-af40-e883bda7c858_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationPerformanceSharesAwardOutstandingActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance-based stock option awards activity</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationPerformanceSharesAwardOutstandingActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationPerformanceSharesAwardOutstandingActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Performance Shares, Outstanding Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationPerformanceSharesAwardOutstandingActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationPerformanceSharesAwardOutstandingActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationPerformanceSharesAwardOutstandingActivityTableTextBlock" xlink:to="lab_us-gaap_ShareBasedCompensationPerformanceSharesAwardOutstandingActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentTransitionReport_83393ac0-5a70-4fee-8561-b4f7a5461207_terseLabel_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:label id="lab_dei_DocumentTransitionReport_label_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentTransitionReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport" xlink:to="lab_dei_DocumentTransitionReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockValue_81115d8e-e105-4a7a-b235-68b2f8b8fc5c_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class A common stock - $0.01 par value; 750,000,000 shares authorized; 90,758,318 and 85,894,450 shares issued, respectively</link:label>
    <link:label id="lab_us-gaap_CommonStockValue_label_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue" xlink:to="lab_us-gaap_CommonStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation_e6306d16-ee4f-49f4-bbc9-4ababbb2ce97_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation_label_en-US" xlink:label="lab_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation" xlink:to="lab_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_747130c5-af3b-49e8-bf21-d3761f0b45ef_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Period (years)</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_4a562181-42c2-4ef2-9de8-728fef08cae5_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding at the beginning of the period (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_cf80abd4-f150-454f-b0b2-52b48fca22a1_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding at the end of the period (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_8d903f47-a481-4583-943d-37cb7e0a4470_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Grant Date Fair Value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CustomerConcentrationRiskMember_4b7aa248-c6e1-4983-8f4f-e92a29c8f3a8_terseLabel_en-US" xlink:label="lab_us-gaap_CustomerConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer Concentration Risk</link:label>
    <link:label id="lab_us-gaap_CustomerConcentrationRiskMember_label_en-US" xlink:label="lab_us-gaap_CustomerConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer Concentration Risk [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CustomerConcentrationRiskMember" xlink:to="lab_us-gaap_CustomerConcentrationRiskMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeasesTextBlock_456d1659-fdd5-4634-b2a4-38d479ea753a_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeasesTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Leases [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeasesTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseRightOfUseAssetAmortization_9976b169-6fb8-4f24-a77a-5187cf5fda70_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of right-of-use assets</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseRightOfUseAssetAmortization_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Right-of-Use Asset, Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseRightOfUseAssetAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:to="lab_us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationDisclosureTextBlock_79b77939-bfd7-4137-a6fe-3597bf673223_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Transactions</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:to="lab_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_IcfrAuditorAttestationFlag_234a3be2-2722-49b7-9244-c1b190a60224_terseLabel_en-US" xlink:label="lab_dei_IcfrAuditorAttestationFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ICFR Auditor Attestation Flag</link:label>
    <link:label id="lab_dei_IcfrAuditorAttestationFlag_label_en-US" xlink:label="lab_dei_IcfrAuditorAttestationFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ICFR Auditor Attestation Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_IcfrAuditorAttestationFlag" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_IcfrAuditorAttestationFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_IcfrAuditorAttestationFlag" xlink:to="lab_dei_IcfrAuditorAttestationFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_b01c34c3-4887-4cdc-9da8-ff433027aa99_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Option price assumptions</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance_f4aa11ee-54a9-408a-8719-d3e7290b5f8e_terseLabel_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Redemption of Sponsor&#8217;s equity</link:label>
    <link:label id="lab_us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance_label_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest, Increase from Subsidiary Equity Issuance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance" xlink:to="lab_us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_OwnershipAxis_3e97bcdb-fc98-415d-b716-e068e98230a2_terseLabel_en-US" xlink:label="lab_srt_OwnershipAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ownership [Axis]</link:label>
    <link:label id="lab_srt_OwnershipAxis_label_en-US" xlink:label="lab_srt_OwnershipAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ownership [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_OwnershipAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_OwnershipAxis" xlink:to="lab_srt_OwnershipAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_03cb0f02-2374-42ac-8007-6009feb04bf8_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_dccfaa6c-2bc9-4426-8c7b-5d9e5ccb19c8_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign</link:label>
    <link:label id="lab_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Foreign Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredForeignIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillLineItems_60091000-efa7-45ca-b5cb-241db4588ee7_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill [Line Items]</link:label>
    <link:label id="lab_us-gaap_GoodwillLineItems_label_en-US" xlink:label="lab_us-gaap_GoodwillLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillLineItems" xlink:to="lab_us-gaap_GoodwillLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_e46b1a4a-3045-456d-bbd8-beb3715cfa60_terseLabel_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_label_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementClassOfStockAxis" xlink:to="lab_us-gaap_StatementClassOfStockAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_e8b6d968-079e-47b1-86ed-fde604b7cb9f_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued expenses</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Accrued Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationInterestIncome_5a76a745-4b31-4760-bbe1-1b6f8fee18ad_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationInterestIncome" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest income</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationInterestIncome_label_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationInterestIncome" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Interest Income</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationInterestIncome" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationInterestIncome"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationInterestIncome" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationInterestIncome" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxContingencyLineItems_ba173fca-34b4-4ac2-b642-dbe9a1f9d94d_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxContingencyLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Contingency [Line Items]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxContingencyLineItems_label_en-US" xlink:label="lab_us-gaap_IncomeTaxContingencyLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Contingency [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxContingencyLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxContingencyLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems" xlink:to="lab_us-gaap_IncomeTaxContingencyLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityAxis_58958d3f-3873-436c-912a-46ef280bdc71_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityAxis_label_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis" xlink:to="lab_us-gaap_IncomeTaxAuthorityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_DebtConversionOriginalDebtFairValue_d5d05162-a27c-4ba0-988d-3575b5eb842d_terseLabel_en-US" xlink:label="lab_evh_DebtConversionOriginalDebtFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt conversion, original debt, fair value</link:label>
    <link:label id="lab_evh_DebtConversionOriginalDebtFairValue_label_en-US" xlink:label="lab_evh_DebtConversionOriginalDebtFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Conversion, Original Debt, Fair Value</link:label>
    <link:label id="lab_evh_DebtConversionOriginalDebtFairValue_documentation_en-US" xlink:label="lab_evh_DebtConversionOriginalDebtFairValue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Conversion, Original Debt, Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_DebtConversionOriginalDebtFairValue" xlink:href="evh-20211231.xsd#evh_DebtConversionOriginalDebtFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_DebtConversionOriginalDebtFairValue" xlink:to="lab_evh_DebtConversionOriginalDebtFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MinorityInterestLineItems_6a16a57f-9365-42a0-9b79-19ba2565c971_terseLabel_en-US" xlink:label="lab_us-gaap_MinorityInterestLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest [Line Items]</link:label>
    <link:label id="lab_us-gaap_MinorityInterestLineItems_label_en-US" xlink:label="lab_us-gaap_MinorityInterestLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MinorityInterestLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinorityInterestLineItems" xlink:to="lab_us-gaap_MinorityInterestLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_3473ce8c-ee9d-4a20-8047-76492e9b33d5_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_19f6daa1-31f6-4298-bba0-25366bb0f603_netLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Expense and Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_LiabilityForFuturePolicyBenefitsAndUnpaidClaimsAndClaimsAdjustmentExpenseAndPerformanceBasedArrangements_c6e97d33-63c8-4c04-97a0-248347f67850_terseLabel_en-US" xlink:label="lab_evh_LiabilityForFuturePolicyBenefitsAndUnpaidClaimsAndClaimsAdjustmentExpenseAndPerformanceBasedArrangements" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reserve for claims and performance-based arrangements</link:label>
    <link:label id="lab_evh_LiabilityForFuturePolicyBenefitsAndUnpaidClaimsAndClaimsAdjustmentExpenseAndPerformanceBasedArrangements_label_en-US" xlink:label="lab_evh_LiabilityForFuturePolicyBenefitsAndUnpaidClaimsAndClaimsAdjustmentExpenseAndPerformanceBasedArrangements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability For Future Policy Benefits And Unpaid Claims And Claims Adjustment Expense And Performance-Based Arrangements</link:label>
    <link:label id="lab_evh_LiabilityForFuturePolicyBenefitsAndUnpaidClaimsAndClaimsAdjustmentExpenseAndPerformanceBasedArrangements_documentation_en-US" xlink:label="lab_evh_LiabilityForFuturePolicyBenefitsAndUnpaidClaimsAndClaimsAdjustmentExpenseAndPerformanceBasedArrangements" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability For Future Policy Benefits And Unpaid Claims And Claims Adjustment Expense And Performance-Based Arrangements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_LiabilityForFuturePolicyBenefitsAndUnpaidClaimsAndClaimsAdjustmentExpenseAndPerformanceBasedArrangements" xlink:href="evh-20211231.xsd#evh_LiabilityForFuturePolicyBenefitsAndUnpaidClaimsAndClaimsAdjustmentExpenseAndPerformanceBasedArrangements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_LiabilityForFuturePolicyBenefitsAndUnpaidClaimsAndClaimsAdjustmentExpenseAndPerformanceBasedArrangements" xlink:to="lab_evh_LiabilityForFuturePolicyBenefitsAndUnpaidClaimsAndClaimsAdjustmentExpenseAndPerformanceBasedArrangements" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_EffectiveIncomeTaxRateReconciliationEffectOfInvestment_473a4fc9-18c2-42d8-9f6e-15681dc6a637_terseLabel_en-US" xlink:label="lab_evh_EffectiveIncomeTaxRateReconciliationEffectOfInvestment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nontaxable earnout</link:label>
    <link:label id="lab_evh_EffectiveIncomeTaxRateReconciliationEffectOfInvestment_label_en-US" xlink:label="lab_evh_EffectiveIncomeTaxRateReconciliationEffectOfInvestment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation Effect Of Investment</link:label>
    <link:label id="lab_evh_EffectiveIncomeTaxRateReconciliationEffectOfInvestment_documentation_en-US" xlink:label="lab_evh_EffectiveIncomeTaxRateReconciliationEffectOfInvestment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation Effect Investment Of Investment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_EffectiveIncomeTaxRateReconciliationEffectOfInvestment" xlink:href="evh-20211231.xsd#evh_EffectiveIncomeTaxRateReconciliationEffectOfInvestment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_EffectiveIncomeTaxRateReconciliationEffectOfInvestment" xlink:to="lab_evh_EffectiveIncomeTaxRateReconciliationEffectOfInvestment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember_26ac2c3a-fd00-422f-a334-48018ed527dd_terseLabel_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, general and administrative expenses</link:label>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember_label_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, General and Administrative Expenses [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:to="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_257a06a7-1f1d-40a3-a4d7-ed1185eaecfc_verboseLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued liabilities</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_b13156b2-ea5b-4ae0-a0fc-cc55dad6ff92_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued liabilities</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_e61231e9-575f-485a-b4a6-b86b3cae4308_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total revenue</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer, Excluding Assessed Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract_8d370b18-325a-4830-86fd-fef9cc638005_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tangible assets acquired:</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CapitalizedComputerSoftwareAdditions_a6594fc9-f5d2-4661-8efc-27dc97a4cbe7_terseLabel_en-US" xlink:label="lab_us-gaap_CapitalizedComputerSoftwareAdditions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capitalized computer software additions</link:label>
    <link:label id="lab_us-gaap_CapitalizedComputerSoftwareAdditions_label_en-US" xlink:label="lab_us-gaap_CapitalizedComputerSoftwareAdditions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capitalized Computer Software, Additions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedComputerSoftwareAdditions" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalizedComputerSoftwareAdditions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalizedComputerSoftwareAdditions" xlink:to="lab_us-gaap_CapitalizedComputerSoftwareAdditions" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_FInancialAssetLessThan120DaysPastDueMember_5e474396-b2a6-40f6-96d7-0efd906cdf42_terseLabel_en-US" xlink:label="lab_evh_FInancialAssetLessThan120DaysPastDueMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Past due less than 120 days</link:label>
    <link:label id="lab_evh_FInancialAssetLessThan120DaysPastDueMember_label_en-US" xlink:label="lab_evh_FInancialAssetLessThan120DaysPastDueMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">FInancial Asset, Less Than 120 Days Past Due [Member]</link:label>
    <link:label id="lab_evh_FInancialAssetLessThan120DaysPastDueMember_documentation_en-US" xlink:label="lab_evh_FInancialAssetLessThan120DaysPastDueMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">FInancial Asset, Less Than 120 Days Past Due [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_FInancialAssetLessThan120DaysPastDueMember" xlink:href="evh-20211231.xsd#evh_FInancialAssetLessThan120DaysPastDueMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_FInancialAssetLessThan120DaysPastDueMember" xlink:to="lab_evh_FInancialAssetLessThan120DaysPastDueMember" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_RestrictedCashforOtherContractualCommitmentsMember_52f187f2-ef4a-46cb-9966-9ffcd1418a48_terseLabel_en-US" xlink:label="lab_evh_RestrictedCashforOtherContractualCommitmentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_evh_RestrictedCashforOtherContractualCommitmentsMember_label_en-US" xlink:label="lab_evh_RestrictedCashforOtherContractualCommitmentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash for Other Contractual Commitments [Member]</link:label>
    <link:label id="lab_evh_RestrictedCashforOtherContractualCommitmentsMember_documentation_en-US" xlink:label="lab_evh_RestrictedCashforOtherContractualCommitmentsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash for Other Contractual Commitments [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_RestrictedCashforOtherContractualCommitmentsMember" xlink:href="evh-20211231.xsd#evh_RestrictedCashforOtherContractualCommitmentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_RestrictedCashforOtherContractualCommitmentsMember" xlink:to="lab_evh_RestrictedCashforOtherContractualCommitmentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_2732e2bc-06ed-4450-a951-ccbf38a507fd_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock options</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOptionMember" xlink:to="lab_us-gaap_EmployeeStockOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ConsolidationItemsDomain_39e38670-5a25-4bf0-ac31-603fc44aeaff_terseLabel_en-US" xlink:label="lab_srt_ConsolidationItemsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation Items [Domain]</link:label>
    <link:label id="lab_srt_ConsolidationItemsDomain_label_en-US" xlink:label="lab_srt_ConsolidationItemsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation Items [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ConsolidationItemsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ConsolidationItemsDomain" xlink:to="lab_srt_ConsolidationItemsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_3607b8f5-7810-437b-8f7e-5f4eb36dffe6_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_05457716-240d-4a20-b9b1-64b1855b2b8d_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fixed assets</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Property, Plant and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:to="lab_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_RestrictedCashForLettersOfCreditForLetterOfCreditFacilityMember_7ebf27ce-6951-47ed-83b0-034530108975_terseLabel_en-US" xlink:label="lab_evh_RestrictedCashForLettersOfCreditForLetterOfCreditFacilityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash For Letters Of Credit</link:label>
    <link:label id="lab_evh_RestrictedCashForLettersOfCreditForLetterOfCreditFacilityMember_label_en-US" xlink:label="lab_evh_RestrictedCashForLettersOfCreditForLetterOfCreditFacilityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash For Letters Of Credit For Letter Of Credit Facility [Member]</link:label>
    <link:label id="lab_evh_RestrictedCashForLettersOfCreditForLetterOfCreditFacilityMember_documentation_en-US" xlink:label="lab_evh_RestrictedCashForLettersOfCreditForLetterOfCreditFacilityMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash For Letters Of Credit For Letter Of Credit Facility [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_RestrictedCashForLettersOfCreditForLetterOfCreditFacilityMember" xlink:href="evh-20211231.xsd#evh_RestrictedCashForLettersOfCreditForLetterOfCreditFacilityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_RestrictedCashForLettersOfCreditForLetterOfCreditFacilityMember" xlink:to="lab_evh_RestrictedCashForLettersOfCreditForLetterOfCreditFacilityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_MolinaHealthcareIncMember_e595140d-9521-41ce-ac95-7110e66165be_terseLabel_en-US" xlink:label="lab_evh_MolinaHealthcareIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Molina</link:label>
    <link:label id="lab_evh_MolinaHealthcareIncMember_label_en-US" xlink:label="lab_evh_MolinaHealthcareIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Molina Healthcare, Inc. [Member]</link:label>
    <link:label id="lab_evh_MolinaHealthcareIncMember_documentation_en-US" xlink:label="lab_evh_MolinaHealthcareIncMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Molina Healthcare, Inc.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_MolinaHealthcareIncMember" xlink:href="evh-20211231.xsd#evh_MolinaHealthcareIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_MolinaHealthcareIncMember" xlink:to="lab_evh_MolinaHealthcareIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputTypeDomain_8fa45d9e-5d5c-4b82-9268-76b84682b794_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input Type [Domain]</link:label>
    <link:label id="lab_us-gaap_MeasurementInputTypeDomain_label_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputTypeDomain" xlink:to="lab_us-gaap_MeasurementInputTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_VitalDecisionsMember_9d9ac37b-e9a4-4ba2-9c5d-0e13860dadbe_terseLabel_en-US" xlink:label="lab_evh_VitalDecisionsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vital Decisions</link:label>
    <link:label id="lab_evh_VitalDecisionsMember_label_en-US" xlink:label="lab_evh_VitalDecisionsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vital Decisions [Member]</link:label>
    <link:label id="lab_evh_VitalDecisionsMember_documentation_en-US" xlink:label="lab_evh_VitalDecisionsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vital Decisions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_VitalDecisionsMember" xlink:href="evh-20211231.xsd#evh_VitalDecisionsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_VitalDecisionsMember" xlink:to="lab_evh_VitalDecisionsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLossCarryforwardsTable_c7b27dd6-c5fa-46ff-95c0-d783880a5405_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwardsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Loss Carryforwards [Table]</link:label>
    <link:label id="lab_us-gaap_OperatingLossCarryforwardsTable_label_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwardsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Loss Carryforwards [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwardsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable" xlink:to="lab_us-gaap_OperatingLossCarryforwardsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableRateAxis_68280d31-3b5b-4429-aace-6e10608dc4ed_terseLabel_en-US" xlink:label="lab_us-gaap_VariableRateAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate [Axis]</link:label>
    <link:label id="lab_us-gaap_VariableRateAxis_label_en-US" xlink:label="lab_us-gaap_VariableRateAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableRateAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableRateAxis" xlink:to="lab_us-gaap_VariableRateAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingDisclosureTextBlock_8f23be0b-ee7a-481b-8f68-4058c91bc670_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting</link:label>
    <link:label id="lab_us-gaap_SegmentReportingDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_SegmentReportingDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingDisclosureTextBlock" xlink:to="lab_us-gaap_SegmentReportingDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MinorityInterestDecreaseFromRedemptions_4031c049-15b3-4402-aefe-a00ebc41cfff_negatedLabel_en-US" xlink:label="lab_us-gaap_MinorityInterestDecreaseFromRedemptions" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Redemption of Sponsor&#8217;s equity</link:label>
    <link:label id="lab_us-gaap_MinorityInterestDecreaseFromRedemptions_label_en-US" xlink:label="lab_us-gaap_MinorityInterestDecreaseFromRedemptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest, Decrease from Redemptions or Purchase of Interests</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestDecreaseFromRedemptions" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MinorityInterestDecreaseFromRedemptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinorityInterestDecreaseFromRedemptions" xlink:to="lab_us-gaap_MinorityInterestDecreaseFromRedemptions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_4a4624a8-5833-4ea6-8093-2580933efa21_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageAdjustmentOfSharesEarnedTotalShareholderReturnInBottomQuartile_0b09361c-ae42-4db5-9505-591b50f1e6de_terseLabel_en-US" xlink:label="lab_evh_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageAdjustmentOfSharesEarnedTotalShareholderReturnInBottomQuartile" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage adjustment of shares earned, total shareholder return in bottom quartile</link:label>
    <link:label id="lab_evh_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageAdjustmentOfSharesEarnedTotalShareholderReturnInBottomQuartile_label_en-US" xlink:label="lab_evh_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageAdjustmentOfSharesEarnedTotalShareholderReturnInBottomQuartile" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Percentage Adjustment of Shares Earned, Total Shareholder Return in Bottom Quartile</link:label>
    <link:label id="lab_evh_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageAdjustmentOfSharesEarnedTotalShareholderReturnInBottomQuartile_documentation_en-US" xlink:label="lab_evh_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageAdjustmentOfSharesEarnedTotalShareholderReturnInBottomQuartile" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Percentage Adjustment of Shares Earned, Total Shareholder Return in Bottom Quartile</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageAdjustmentOfSharesEarnedTotalShareholderReturnInBottomQuartile" xlink:href="evh-20211231.xsd#evh_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageAdjustmentOfSharesEarnedTotalShareholderReturnInBottomQuartile"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageAdjustmentOfSharesEarnedTotalShareholderReturnInBottomQuartile" xlink:to="lab_evh_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageAdjustmentOfSharesEarnedTotalShareholderReturnInBottomQuartile" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_EarningsBeforeInterestTaxesDepreciationAndAmortizationGoalPeriod_e5cdff9b-5de4-4d40-b176-5888d618e242_terseLabel_en-US" xlink:label="lab_evh_EarningsBeforeInterestTaxesDepreciationAndAmortizationGoalPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">EBITDA, goal period</link:label>
    <link:label id="lab_evh_EarningsBeforeInterestTaxesDepreciationAndAmortizationGoalPeriod_label_en-US" xlink:label="lab_evh_EarningsBeforeInterestTaxesDepreciationAndAmortizationGoalPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Before Interest, Taxes, Depreciation, and Amortization, Goal Period</link:label>
    <link:label id="lab_evh_EarningsBeforeInterestTaxesDepreciationAndAmortizationGoalPeriod_documentation_en-US" xlink:label="lab_evh_EarningsBeforeInterestTaxesDepreciationAndAmortizationGoalPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Before Interest, Taxes, Depreciation, and Amortization, Goal Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_EarningsBeforeInterestTaxesDepreciationAndAmortizationGoalPeriod" xlink:href="evh-20211231.xsd#evh_EarningsBeforeInterestTaxesDepreciationAndAmortizationGoalPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_EarningsBeforeInterestTaxesDepreciationAndAmortizationGoalPeriod" xlink:to="lab_evh_EarningsBeforeInterestTaxesDepreciationAndAmortizationGoalPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_7a5de29b-598f-4f06-bff0-74d0b65fd6e0_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalYearFocus_81b87ecf-6e60-4abc-b7e0-d4664f624bc3_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalYearFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAbstract_b2d3138d-f8a7-409f-a4b0-6249e9be9e8d_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Abstract]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAbstract_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableRateDomain_7aad074e-c234-462b-84bb-036c52d4599d_terseLabel_en-US" xlink:label="lab_us-gaap_VariableRateDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate [Domain]</link:label>
    <link:label id="lab_us-gaap_VariableRateDomain_label_en-US" xlink:label="lab_us-gaap_VariableRateDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableRateDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableRateDomain" xlink:to="lab_us-gaap_VariableRateDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsMaximumPerformanceAchievedPercentageOfTargetedSharesEarned_2e27d720-9553-407f-9beb-5407f799ed9d_terseLabel_en-US" xlink:label="lab_evh_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsMaximumPerformanceAchievedPercentageOfTargetedSharesEarned" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum performance achieved, percentage of targeted shares earned</link:label>
    <link:label id="lab_evh_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsMaximumPerformanceAchievedPercentageOfTargetedSharesEarned_label_en-US" xlink:label="lab_evh_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsMaximumPerformanceAchievedPercentageOfTargetedSharesEarned" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Maximum Performance Achieved, Percentage of Targeted Shares Earned</link:label>
    <link:label id="lab_evh_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsMaximumPerformanceAchievedPercentageOfTargetedSharesEarned_documentation_en-US" xlink:label="lab_evh_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsMaximumPerformanceAchievedPercentageOfTargetedSharesEarned" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Maximum Performance Achieved, Percentage of Targeted Shares Earned</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsMaximumPerformanceAchievedPercentageOfTargetedSharesEarned" xlink:href="evh-20211231.xsd#evh_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsMaximumPerformanceAchievedPercentageOfTargetedSharesEarned"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsMaximumPerformanceAchievedPercentageOfTargetedSharesEarned" xlink:to="lab_evh_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsMaximumPerformanceAchievedPercentageOfTargetedSharesEarned" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_c8859dcb-e2e3-4c71-9eba-1a6a339ef736_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-In Capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_17c055f6-2d5c-48b9-9b4b-77926867e54a_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeDomain" xlink:to="lab_us-gaap_LongtermDebtTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsForProceedsFromLoansReceivable_933c5911-438f-4bca-969d-904c970e735a_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsForProceedsFromLoansReceivable" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loan for implementation funding</link:label>
    <link:label id="lab_us-gaap_PaymentsForProceedsFromLoansReceivable_label_en-US" xlink:label="lab_us-gaap_PaymentsForProceedsFromLoansReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for (Proceeds from) Loans Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForProceedsFromLoansReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsForProceedsFromLoansReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForProceedsFromLoansReceivable" xlink:to="lab_us-gaap_PaymentsForProceedsFromLoansReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityMethodInvestmentsPolicy_8fbbb4ac-e6a0-4710-acdf-637877d077f5_terseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentsPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investments and Impairment of Equity Method Investments</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestmentsPolicy_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentsPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investments [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentsPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestmentsPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentsPolicy" xlink:to="lab_us-gaap_EquityMethodInvestmentsPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_6064c191-e7fc-40ff-92d7-5af798ac355d_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other income (expense), net</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NotesReceivableNet_d8d90a4b-cf6f-4ac3-aa5f-5c4749a6edf6_terseLabel_en-US" xlink:label="lab_us-gaap_NotesReceivableNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Notes receivable, net</link:label>
    <link:label id="lab_us-gaap_NotesReceivableNet_label_en-US" xlink:label="lab_us-gaap_NotesReceivableNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financing Receivable, after Allowance for Credit Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesReceivableNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NotesReceivableNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NotesReceivableNet" xlink:to="lab_us-gaap_NotesReceivableNet" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_StockIssuedDuringPeriodValueEquityMethodInvestmentsAndAssetAcquisitions_91d8a391-0dd2-4bb8-9bd0-396602b47f98_terseLabel_en-US" xlink:label="lab_evh_StockIssuedDuringPeriodValueEquityMethodInvestmentsAndAssetAcquisitions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares issued for equity-method investments and asset acquisitions</link:label>
    <link:label id="lab_evh_StockIssuedDuringPeriodValueEquityMethodInvestmentsAndAssetAcquisitions_label_en-US" xlink:label="lab_evh_StockIssuedDuringPeriodValueEquityMethodInvestmentsAndAssetAcquisitions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Equity-Method Investments And Asset Acquisitions</link:label>
    <link:label id="lab_evh_StockIssuedDuringPeriodValueEquityMethodInvestmentsAndAssetAcquisitions_documentation_en-US" xlink:label="lab_evh_StockIssuedDuringPeriodValueEquityMethodInvestmentsAndAssetAcquisitions" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Equity-Method Investments And Asset Acquisitions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_StockIssuedDuringPeriodValueEquityMethodInvestmentsAndAssetAcquisitions" xlink:href="evh-20211231.xsd#evh_StockIssuedDuringPeriodValueEquityMethodInvestmentsAndAssetAcquisitions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_StockIssuedDuringPeriodValueEquityMethodInvestmentsAndAssetAcquisitions" xlink:to="lab_evh_StockIssuedDuringPeriodValueEquityMethodInvestmentsAndAssetAcquisitions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtFairValue_a73b3af8-252a-486f-89a9-f428225e93c1_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value</link:label>
    <link:label id="lab_us-gaap_LongTermDebtFairValue_label_en-US" xlink:label="lab_us-gaap_LongTermDebtFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtFairValue" xlink:to="lab_us-gaap_LongTermDebtFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_cfd03273-c85c-4ab1-ab3b-2660a98f0071_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other investing activities</link:label>
    <link:label id="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_label_en-US" xlink:label="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for (Proceeds from) Other Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsForProceedsFromOtherInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:to="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_ContractWithCustomerLiabilityCashReceivedInAdvanceOfSatisfactionOfPerformanceObligations_f884829b-df6b-4320-a8aa-254072872826_terseLabel_en-US" xlink:label="lab_evh_ContractWithCustomerLiabilityCashReceivedInAdvanceOfSatisfactionOfPerformanceObligations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash received in advance of satisfaction of performance obligations</link:label>
    <link:label id="lab_evh_ContractWithCustomerLiabilityCashReceivedInAdvanceOfSatisfactionOfPerformanceObligations_label_en-US" xlink:label="lab_evh_ContractWithCustomerLiabilityCashReceivedInAdvanceOfSatisfactionOfPerformanceObligations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract With Customer, Liability, Cash Received In Advance Of Satisfaction Of Performance Obligations</link:label>
    <link:label id="lab_evh_ContractWithCustomerLiabilityCashReceivedInAdvanceOfSatisfactionOfPerformanceObligations_documentation_en-US" xlink:label="lab_evh_ContractWithCustomerLiabilityCashReceivedInAdvanceOfSatisfactionOfPerformanceObligations" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract With Customer, Liability, Cash Received In Advance Of Satisfaction Of Performance Obligations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_ContractWithCustomerLiabilityCashReceivedInAdvanceOfSatisfactionOfPerformanceObligations" xlink:href="evh-20211231.xsd#evh_ContractWithCustomerLiabilityCashReceivedInAdvanceOfSatisfactionOfPerformanceObligations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_ContractWithCustomerLiabilityCashReceivedInAdvanceOfSatisfactionOfPerformanceObligations" xlink:to="lab_evh_ContractWithCustomerLiabilityCashReceivedInAdvanceOfSatisfactionOfPerformanceObligations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FacilityClosingMember_15d79e9b-454b-4fee-992a-d744d5d687e3_terseLabel_en-US" xlink:label="lab_us-gaap_FacilityClosingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Office space consolidation</link:label>
    <link:label id="lab_us-gaap_FacilityClosingMember_label_en-US" xlink:label="lab_us-gaap_FacilityClosingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Facility Closing [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FacilityClosingMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FacilityClosingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FacilityClosingMember" xlink:to="lab_us-gaap_FacilityClosingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationsAbstract_0df88cf9-80ff-4b94-be13-4972ced3c057_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combinations [Abstract]</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationsAbstract_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combinations [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationsAbstract" xlink:to="lab_us-gaap_BusinessCombinationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_DisposalGroupIncludingDiscontinuedOperationRestrictedCashAndRestrictedInvestmentsNoncurrent_a8f27307-d5d8-4330-8903-95da4320fd5b_terseLabel_en-US" xlink:label="lab_evh_DisposalGroupIncludingDiscontinuedOperationRestrictedCashAndRestrictedInvestmentsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted cash and restricted investments</link:label>
    <link:label id="lab_evh_DisposalGroupIncludingDiscontinuedOperationRestrictedCashAndRestrictedInvestmentsNoncurrent_label_en-US" xlink:label="lab_evh_DisposalGroupIncludingDiscontinuedOperationRestrictedCashAndRestrictedInvestmentsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Restricted Cash And Restricted Investments, Noncurrent</link:label>
    <link:label id="lab_evh_DisposalGroupIncludingDiscontinuedOperationRestrictedCashAndRestrictedInvestmentsNoncurrent_documentation_en-US" xlink:label="lab_evh_DisposalGroupIncludingDiscontinuedOperationRestrictedCashAndRestrictedInvestmentsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Restricted Cash And Restricted Investments, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_DisposalGroupIncludingDiscontinuedOperationRestrictedCashAndRestrictedInvestmentsNoncurrent" xlink:href="evh-20211231.xsd#evh_DisposalGroupIncludingDiscontinuedOperationRestrictedCashAndRestrictedInvestmentsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_DisposalGroupIncludingDiscontinuedOperationRestrictedCashAndRestrictedInvestmentsNoncurrent" xlink:to="lab_evh_DisposalGroupIncludingDiscontinuedOperationRestrictedCashAndRestrictedInvestmentsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MaximumMember_93ec68bd-7e57-44fe-8746-20644d483930_verboseLabel_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_srt_MaximumMember_76adf589-9882-47b0-b34d-1e7559959a6e_terseLabel_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_srt_MaximumMember_label_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember" xlink:to="lab_srt_MaximumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_2bda5e28-3997-4c3b-8b36-0ae0bbcea3b3_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Abstract]</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AwardTypeAxis_e5f396e6-a625-489c-a85c-512e0655b19c_terseLabel_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:label id="lab_us-gaap_AwardTypeAxis_label_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="lab_us-gaap_AwardTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_7729fede-c542-4d8f-a57c-3e6ae9307d82_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Flows Used In Financing Activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_936814df-b0bb-47d6-9a55-8c9ba381bdf7_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of primary office leases and maturity of lease liabilities</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Maturity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquity_6c4eaea8-339e-40fe-943c-2e98f0bfad6f_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total shareholders' equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_RestrictedStockUnitsRSUsPerformanceBasedRestrictedStockUnitsPBRSUsAndLeveragedStockUnitsLSUsMember_f2932505-cbb3-464f-b481-d5e848609a63_terseLabel_en-US" xlink:label="lab_evh_RestrictedStockUnitsRSUsPerformanceBasedRestrictedStockUnitsPBRSUsAndLeveragedStockUnitsLSUsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted stock units ("RSUs"), performance-based RSUs and leveraged stock units ("LSUs")</link:label>
    <link:label id="lab_evh_RestrictedStockUnitsRSUsPerformanceBasedRestrictedStockUnitsPBRSUsAndLeveragedStockUnitsLSUsMember_label_en-US" xlink:label="lab_evh_RestrictedStockUnitsRSUsPerformanceBasedRestrictedStockUnitsPBRSUsAndLeveragedStockUnitsLSUsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock Units (RSUs), Performance-based Restricted Stock Units (PBRSUs), And Leveraged Stock Units (LSUs) [Member]</link:label>
    <link:label id="lab_evh_RestrictedStockUnitsRSUsPerformanceBasedRestrictedStockUnitsPBRSUsAndLeveragedStockUnitsLSUsMember_documentation_en-US" xlink:label="lab_evh_RestrictedStockUnitsRSUsPerformanceBasedRestrictedStockUnitsPBRSUsAndLeveragedStockUnitsLSUsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock and Restricted Stock Units [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_RestrictedStockUnitsRSUsPerformanceBasedRestrictedStockUnitsPBRSUsAndLeveragedStockUnitsLSUsMember" xlink:href="evh-20211231.xsd#evh_RestrictedStockUnitsRSUsPerformanceBasedRestrictedStockUnitsPBRSUsAndLeveragedStockUnitsLSUsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_RestrictedStockUnitsRSUsPerformanceBasedRestrictedStockUnitsPBRSUsAndLeveragedStockUnitsLSUsMember" xlink:to="lab_evh_RestrictedStockUnitsRSUsPerformanceBasedRestrictedStockUnitsPBRSUsAndLeveragedStockUnitsLSUsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_e1b836f7-51ec-4e44-b8ba-81b40f410e18_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_ba1a3ee4-71cd-4d60-bc86-a40dea1d5104_verboseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current restricted cash</link:label>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash and Cash Equivalents, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_ba16f542-b20b-43f4-986c-73556c29eec0_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercisable</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_ClassOfWarrantOrRightPeriodDuringWhichWarrantsOrRightsExercisableAfterMaturityOfCreditAgreement_7e1b9885-eda8-4119-8fa1-dc1073fb6bba_terseLabel_en-US" xlink:label="lab_evh_ClassOfWarrantOrRightPeriodDuringWhichWarrantsOrRightsExercisableAfterMaturityOfCreditAgreement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Period during which warrants or rights exercisable, after maturity of credit agreement</link:label>
    <link:label id="lab_evh_ClassOfWarrantOrRightPeriodDuringWhichWarrantsOrRightsExercisableAfterMaturityOfCreditAgreement_label_en-US" xlink:label="lab_evh_ClassOfWarrantOrRightPeriodDuringWhichWarrantsOrRightsExercisableAfterMaturityOfCreditAgreement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class Of Warrant Or Right, Period During Which Warrants Or Rights Exercisable, After Maturity Of Credit Agreement</link:label>
    <link:label id="lab_evh_ClassOfWarrantOrRightPeriodDuringWhichWarrantsOrRightsExercisableAfterMaturityOfCreditAgreement_documentation_en-US" xlink:label="lab_evh_ClassOfWarrantOrRightPeriodDuringWhichWarrantsOrRightsExercisableAfterMaturityOfCreditAgreement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class Of Warrant Or Right, Period During Which Warrants Or Rights Exercisable, After Maturity Of Credit Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_ClassOfWarrantOrRightPeriodDuringWhichWarrantsOrRightsExercisableAfterMaturityOfCreditAgreement" xlink:href="evh-20211231.xsd#evh_ClassOfWarrantOrRightPeriodDuringWhichWarrantsOrRightsExercisableAfterMaturityOfCreditAgreement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_ClassOfWarrantOrRightPeriodDuringWhichWarrantsOrRightsExercisableAfterMaturityOfCreditAgreement" xlink:to="lab_evh_ClassOfWarrantOrRightPeriodDuringWhichWarrantsOrRightsExercisableAfterMaturityOfCreditAgreement" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_d382f72b-b5f9-4f0d-94ca-add01ba7991e_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Prepaid Expense and Other Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityMethodInvestmentsDisclosureTextBlock_f2a957b7-e515-4f6c-87e1-17458dfc0f36_terseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments in Equity Method Investees</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestmentsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investments and Joint Ventures Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestmentsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentsDisclosureTextBlock" xlink:to="lab_us-gaap_EquityMethodInvestmentsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_EffectiveIncomeTaxRateReconciliationChangeInUncertainTaxPositions_708dfab1-3fe4-4138-b581-151af4a81023_terseLabel_en-US" xlink:label="lab_evh_EffectiveIncomeTaxRateReconciliationChangeInUncertainTaxPositions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in uncertain tax positions</link:label>
    <link:label id="lab_evh_EffectiveIncomeTaxRateReconciliationChangeInUncertainTaxPositions_label_en-US" xlink:label="lab_evh_EffectiveIncomeTaxRateReconciliationChangeInUncertainTaxPositions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Change In Uncertain Tax Positions</link:label>
    <link:label id="lab_evh_EffectiveIncomeTaxRateReconciliationChangeInUncertainTaxPositions_documentation_en-US" xlink:label="lab_evh_EffectiveIncomeTaxRateReconciliationChangeInUncertainTaxPositions" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Change In Uncertain Tax Positions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_EffectiveIncomeTaxRateReconciliationChangeInUncertainTaxPositions" xlink:href="evh-20211231.xsd#evh_EffectiveIncomeTaxRateReconciliationChangeInUncertainTaxPositions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_EffectiveIncomeTaxRateReconciliationChangeInUncertainTaxPositions" xlink:to="lab_evh_EffectiveIncomeTaxRateReconciliationChangeInUncertainTaxPositions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock_7ce84e1f-72f4-49ad-9651-034671f334f9_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of cash flow, supplemental disclosures</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Cash Flow, Supplemental Disclosures [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_ChangeInContractWithCustomerLiabilityRollForward_4960bfa5-f5a7-4d9f-840f-cc96074f46e9_terseLabel_en-US" xlink:label="lab_evh_ChangeInContractWithCustomerLiabilityRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue</link:label>
    <link:label id="lab_evh_ChangeInContractWithCustomerLiabilityRollForward_label_en-US" xlink:label="lab_evh_ChangeInContractWithCustomerLiabilityRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change In Contract With Customer, Liability [Roll Forward]</link:label>
    <link:label id="lab_evh_ChangeInContractWithCustomerLiabilityRollForward_documentation_en-US" xlink:label="lab_evh_ChangeInContractWithCustomerLiabilityRollForward" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change In Contract With Customer, Liability [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_ChangeInContractWithCustomerLiabilityRollForward" xlink:href="evh-20211231.xsd#evh_ChangeInContractWithCustomerLiabilityRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_ChangeInContractWithCustomerLiabilityRollForward" xlink:to="lab_evh_ChangeInContractWithCustomerLiabilityRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_2a745be1-eafd-40d4-bbb4-edbd53b2411e_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtConversionConvertedInstrumentAmount1_ff3ac7d8-7bf4-407c-a5b1-a190595faf98_terseLabel_en-US" xlink:label="lab_us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt conversion, converted instrument, amount</link:label>
    <link:label id="lab_us-gaap_DebtConversionConvertedInstrumentAmount1_label_en-US" xlink:label="lab_us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Conversion, Converted Instrument, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentAmount1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:to="lab_us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RepaymentsOfSeniorDebt_aa859b3e-cdc3-4cbf-9004-e4b89ef04b40_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfSeniorDebt" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayment and repurchase of 2021 Notes and financing fees</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfSeniorDebt_0a053f92-b863-4312-be12-c025f744863a_terseLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfSeniorDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of senior debt</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfSeniorDebt_label_en-US" xlink:label="lab_us-gaap_RepaymentsOfSeniorDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of Senior Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfSeniorDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfSeniorDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfSeniorDebt" xlink:to="lab_us-gaap_RepaymentsOfSeniorDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_0a273b41-1ab8-422a-9766-ec5e4b40bcbb_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Useful life</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Useful Life</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:type="arc" order="1"/>
    <link:label id="lab_country_IN_aa6f6998-346c-4160-83ec-66565963a635_terseLabel_en-US" xlink:label="lab_country_IN" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pune, India</link:label>
    <link:label id="lab_country_IN_label_en-US" xlink:label="lab_country_IN" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">INDIA</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_country_IN" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_IN"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_IN" xlink:to="lab_country_IN" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_FinitelivedTaxCreditCarryforwardMember_12917b78-3639-41d1-a442-de38bdef059f_terseLabel_en-US" xlink:label="lab_evh_FinitelivedTaxCreditCarryforwardMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-lived Tax Credit Carryforward</link:label>
    <link:label id="lab_evh_FinitelivedTaxCreditCarryforwardMember_label_en-US" xlink:label="lab_evh_FinitelivedTaxCreditCarryforwardMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-lived Tax Credit Carryforward [Member]</link:label>
    <link:label id="lab_evh_FinitelivedTaxCreditCarryforwardMember_documentation_en-US" xlink:label="lab_evh_FinitelivedTaxCreditCarryforwardMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-lived Tax Credit Carryforward [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_FinitelivedTaxCreditCarryforwardMember" xlink:href="evh-20211231.xsd#evh_FinitelivedTaxCreditCarryforwardMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_FinitelivedTaxCreditCarryforwardMember" xlink:to="lab_evh_FinitelivedTaxCreditCarryforwardMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod_778d7b59-c796-4b12-9946-f3daff3c6b09_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue recognized from performed obligations</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Performance Obligation Satisfied in Previous Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod" xlink:to="lab_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestWeightedAverageRemainingContractualTerms_fd3e19f9-bfce-4130-b61e-eb00b3d0ec46_terseLabel_en-US" xlink:label="lab_evh_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestWeightedAverageRemainingContractualTerms" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Remaining Contractual Term</link:label>
    <link:label id="lab_evh_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestWeightedAverageRemainingContractualTerms_label_en-US" xlink:label="lab_evh_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestWeightedAverageRemainingContractualTerms" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement By Share-based Payment Award, Equity Instruments Other Than Options, Vested And Expected To Vest, Weighted Average Remaining Contractual Terms</link:label>
    <link:label id="lab_evh_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestWeightedAverageRemainingContractualTerms_documentation_en-US" xlink:label="lab_evh_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestWeightedAverageRemainingContractualTerms" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement By Share-based Payment Award, Equity Instruments Other Than Options, Vested And Expected To Vest, Weighted Average Remaining Contractual Terms</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestWeightedAverageRemainingContractualTerms" xlink:href="evh-20211231.xsd#evh_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestWeightedAverageRemainingContractualTerms"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestWeightedAverageRemainingContractualTerms" xlink:to="lab_evh_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestWeightedAverageRemainingContractualTerms" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_30584277-9f88-4030-a5dc-739a873ad25f_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease liabilities - noncurrent</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentIncomeTaxExpenseBenefit_137b58ea-3c34-4a2c-9f97-73f8194fff1a_totalLabel_en-US" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current tax expense (benefit)</link:label>
    <link:label id="lab_us-gaap_CurrentIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_bef0f8f8-8d5c-4084-b3e3-4ca30d1e3259_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Face amount</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_6ebb6421-2d4e-47c9-80ef-34fb83943c48_verboseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Principal amount</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Face Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentFaceAmount" xlink:to="lab_us-gaap_DebtInstrumentFaceAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_DisposalGroupIncludingDiscontinuedOperationLiabilityForFuturePolicyBenefitsAndUnpaidClaimsAndClaimsAdjustmentExpenseAndPerformanceBasedArrangementsCurrent_f70c8a69-dd47-43ad-9bd4-14531504563c_terseLabel_en-US" xlink:label="lab_evh_DisposalGroupIncludingDiscontinuedOperationLiabilityForFuturePolicyBenefitsAndUnpaidClaimsAndClaimsAdjustmentExpenseAndPerformanceBasedArrangementsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reserve for claims and performance-based arrangements</link:label>
    <link:label id="lab_evh_DisposalGroupIncludingDiscontinuedOperationLiabilityForFuturePolicyBenefitsAndUnpaidClaimsAndClaimsAdjustmentExpenseAndPerformanceBasedArrangementsCurrent_label_en-US" xlink:label="lab_evh_DisposalGroupIncludingDiscontinuedOperationLiabilityForFuturePolicyBenefitsAndUnpaidClaimsAndClaimsAdjustmentExpenseAndPerformanceBasedArrangementsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Liability For Future Policy Benefits And Unpaid Claims And Claims Adjustment Expense And Performance-Based Arrangements, Current</link:label>
    <link:label id="lab_evh_DisposalGroupIncludingDiscontinuedOperationLiabilityForFuturePolicyBenefitsAndUnpaidClaimsAndClaimsAdjustmentExpenseAndPerformanceBasedArrangementsCurrent_documentation_en-US" xlink:label="lab_evh_DisposalGroupIncludingDiscontinuedOperationLiabilityForFuturePolicyBenefitsAndUnpaidClaimsAndClaimsAdjustmentExpenseAndPerformanceBasedArrangementsCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Liability For Future Policy Benefits And Unpaid Claims And Claims Adjustment Expense And Performance-Based Arrangements, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_DisposalGroupIncludingDiscontinuedOperationLiabilityForFuturePolicyBenefitsAndUnpaidClaimsAndClaimsAdjustmentExpenseAndPerformanceBasedArrangementsCurrent" xlink:href="evh-20211231.xsd#evh_DisposalGroupIncludingDiscontinuedOperationLiabilityForFuturePolicyBenefitsAndUnpaidClaimsAndClaimsAdjustmentExpenseAndPerformanceBasedArrangementsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_DisposalGroupIncludingDiscontinuedOperationLiabilityForFuturePolicyBenefitsAndUnpaidClaimsAndClaimsAdjustmentExpenseAndPerformanceBasedArrangementsCurrent" xlink:to="lab_evh_DisposalGroupIncludingDiscontinuedOperationLiabilityForFuturePolicyBenefitsAndUnpaidClaimsAndClaimsAdjustmentExpenseAndPerformanceBasedArrangementsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingSegmentsMember_e9928fac-b080-4431-b41a-6614208ca00d_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingSegmentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Segments</link:label>
    <link:label id="lab_us-gaap_OperatingSegmentsMember_label_en-US" xlink:label="lab_us-gaap_OperatingSegmentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Segments [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingSegmentsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingSegmentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingSegmentsMember" xlink:to="lab_us-gaap_OperatingSegmentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseTermOfContract_d49b88c0-87e8-42a2-9813-44652be1eca0_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease Termination Term (in years)</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseTermOfContract_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Term of Contract</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:to="lab_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_SharebasedPaymentArrangementTrancheFourMember_3360cbb1-24ff-4387-b1cd-e5a8042382b9_terseLabel_en-US" xlink:label="lab_evh_SharebasedPaymentArrangementTrancheFourMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tranche Four</link:label>
    <link:label id="lab_evh_SharebasedPaymentArrangementTrancheFourMember_label_en-US" xlink:label="lab_evh_SharebasedPaymentArrangementTrancheFourMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Tranche Four [Member]</link:label>
    <link:label id="lab_evh_SharebasedPaymentArrangementTrancheFourMember_documentation_en-US" xlink:label="lab_evh_SharebasedPaymentArrangementTrancheFourMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Tranche Four [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_SharebasedPaymentArrangementTrancheFourMember" xlink:href="evh-20211231.xsd#evh_SharebasedPaymentArrangementTrancheFourMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_SharebasedPaymentArrangementTrancheFourMember" xlink:to="lab_evh_SharebasedPaymentArrangementTrancheFourMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConversionOfStockAmountConverted1_fd82dc40-5ed3-4d76-9bb9-eb8c10acfe97_terseLabel_en-US" xlink:label="lab_us-gaap_ConversionOfStockAmountConverted1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Decrease in non-controlling interests as a result of Class B Exchanges</link:label>
    <link:label id="lab_us-gaap_ConversionOfStockAmountConverted1_label_en-US" xlink:label="lab_us-gaap_ConversionOfStockAmountConverted1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Conversion of Stock, Amount Converted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConversionOfStockAmountConverted1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConversionOfStockAmountConverted1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConversionOfStockAmountConverted1" xlink:to="lab_us-gaap_ConversionOfStockAmountConverted1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_dabd2825-93b8-4438-8246-ced8f9a99474_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RSUs</link:label>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_label_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock Units (RSUs) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:to="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_357f5c5b-11e5-49d0-8186-5e7c6086edf1_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of net assets acquired</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts_946211f4-ae1c-42eb-b83c-acc69f3e2a77_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Charged (credited) to other accounts</link:label>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts_label_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances and Reserves, Additions, Charge to Other Account</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts" xlink:to="lab_us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_MolinaHealthcareMember_d2b4074f-b6bd-42e1-bae7-13ee4d7d2784_terseLabel_en-US" xlink:label="lab_evh_MolinaHealthcareMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Molina Healthcare</link:label>
    <link:label id="lab_evh_MolinaHealthcareMember_label_en-US" xlink:label="lab_evh_MolinaHealthcareMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Molina Healthcare [Member]</link:label>
    <link:label id="lab_evh_MolinaHealthcareMember_documentation_en-US" xlink:label="lab_evh_MolinaHealthcareMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Molina Healthcare</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_MolinaHealthcareMember" xlink:href="evh-20211231.xsd#evh_MolinaHealthcareMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_MolinaHealthcareMember" xlink:to="lab_evh_MolinaHealthcareMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilities_0542a338-2e19-4fa3-8f81-c04f5e1e5776_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total deferred tax liabilities</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilities_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities" xlink:to="lab_us-gaap_DeferredIncomeTaxLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionLineItems_ad7f9496-a4ad-455e-96be-8e0a1d81754e_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Line Items]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionLineItems_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems" xlink:to="lab_us-gaap_BusinessAcquisitionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationAbstract_a548cbac-dbec-40f0-92c4-5675fb0cfa6a_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ASSETS</link:label>
    <link:label id="lab_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationAbstract" xlink:to="lab_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_27b39d31-affc-43f4-b239-7c86695a1ebd_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2nd Tranche</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Tranche Two [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:to="lab_us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_SeniorCreditFacilitiesMember_f73dc815-1e27-4fbb-9838-e6d18502a627_terseLabel_en-US" xlink:label="lab_evh_SeniorCreditFacilitiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Credit Facilities</link:label>
    <link:label id="lab_evh_SeniorCreditFacilitiesMember_label_en-US" xlink:label="lab_evh_SeniorCreditFacilitiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Credit Facilities [Member]</link:label>
    <link:label id="lab_evh_SeniorCreditFacilitiesMember_documentation_en-US" xlink:label="lab_evh_SeniorCreditFacilitiesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Credit Facilities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_SeniorCreditFacilitiesMember" xlink:href="evh-20211231.xsd#evh_SeniorCreditFacilitiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_SeniorCreditFacilitiesMember" xlink:to="lab_evh_SeniorCreditFacilitiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock_e48c2ab3-0fe6-4a26-aa3d-75b6f4d9e70e_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of restricted cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restrictions on Cash and Cash Equivalents [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" xlink:to="lab_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_20ea918d-8690-403b-ba38-d91e38c1793e_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="lab_us-gaap_IncomeStatementAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfOtherShareBasedCompensationActivityTableTextBlock_2164d038-fa44-477a-9293-a4618d5614a3_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfOtherShareBasedCompensationActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leveraged stock units activity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfOtherShareBasedCompensationActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfOtherShareBasedCompensationActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Outstanding Award, Activity, Excluding Option [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfOtherShareBasedCompensationActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfOtherShareBasedCompensationActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfOtherShareBasedCompensationActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfOtherShareBasedCompensationActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_c026878a-1147-4002-84b3-88a09d179257_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables_22c17d3c-2926-42bf-acc1-85012ca7d8d9_verboseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Receivables</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesDeductions_fdbbf5e2-7791-4b1d-8530-aaaa470c93c5_negatedLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesDeductions" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Charged (credited) to other accounts</link:label>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesDeductions_label_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesDeductions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances and Reserves, Deduction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDeductions" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowancesAndReservesDeductions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDeductions" xlink:to="lab_us-gaap_ValuationAllowancesAndReservesDeductions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectsOfReinsuranceTableTextBlock_fbb8c3c1-4d1e-4111-920a-2060de4813c1_terseLabel_en-US" xlink:label="lab_us-gaap_EffectsOfReinsuranceTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of premiums and claims assumed</link:label>
    <link:label id="lab_us-gaap_EffectsOfReinsuranceTableTextBlock_label_en-US" xlink:label="lab_us-gaap_EffectsOfReinsuranceTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effects of Reinsurance [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectsOfReinsuranceTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectsOfReinsuranceTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectsOfReinsuranceTableTextBlock" xlink:to="lab_us-gaap_EffectsOfReinsuranceTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConvertibleDebt_38cb4978-b969-48b0-867c-ff8d4403187c_totalLabel_en-US" xlink:label="lab_us-gaap_ConvertibleDebt" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Debt, Total</link:label>
    <link:label id="lab_us-gaap_ConvertibleDebt_label_en-US" xlink:label="lab_us-gaap_ConvertibleDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertibleDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertibleDebt" xlink:to="lab_us-gaap_ConvertibleDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseReturnToProvisionPercent_8db1fdfd-6e61-452f-8020-2c3c2e415131_terseLabel_en-US" xlink:label="lab_evh_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseReturnToProvisionPercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Return to provision</link:label>
    <link:label id="lab_evh_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseReturnToProvisionPercent_label_en-US" xlink:label="lab_evh_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseReturnToProvisionPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Return to Provision, Percent</link:label>
    <link:label id="lab_evh_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseReturnToProvisionPercent_documentation_en-US" xlink:label="lab_evh_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseReturnToProvisionPercent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Return to Provision, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseReturnToProvisionPercent" xlink:href="evh-20211231.xsd#evh_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseReturnToProvisionPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseReturnToProvisionPercent" xlink:to="lab_evh_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseReturnToProvisionPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_79913f3e-bfa0-4cad-b371-eab687e0e9d1_terseLabel_en-US" xlink:label="lab_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Presentation, Summary of Significant Accounting Policies and Change in Accounting Principles</link:label>
    <link:label id="lab_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_label_en-US" xlink:label="lab_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Presentation and Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:to="lab_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionAxis_cb95d4b2-5106-4e7d-91e3-117d12c8d03b_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Axis]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionAxis_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis" xlink:to="lab_us-gaap_RelatedPartyTransactionAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_ab684b80-aebd-4be8-998d-171f2684abd1_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forfeited (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_69a691c0-2a09-45cb-b7a9-3edd6fc612e8_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Provision (benefit) for income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_ea41d5ac-665e-4b14-acde-a62b47d94408_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total tax expense (benefit)</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_0d4a81e8-67dc-4c75-a7cd-f97a9d8e6782_negatedLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">(Provision) benefit for income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherCommitmentsDomain_15918204-f62a-4bc7-8891-0968698ed3aa_terseLabel_en-US" xlink:label="lab_us-gaap_OtherCommitmentsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Commitments [Domain]</link:label>
    <link:label id="lab_us-gaap_OtherCommitmentsDomain_label_en-US" xlink:label="lab_us-gaap_OtherCommitmentsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Commitments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherCommitmentsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherCommitmentsDomain" xlink:to="lab_us-gaap_OtherCommitmentsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_5ceeb24d-0723-4ea4-8fea-c4569f8efe80_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable, net</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_cebb72a1-ba49-45a1-b55a-38057c876259_netLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable, net</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, after Allowance for Credit Loss, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableNetCurrent" xlink:to="lab_us-gaap_AccountsReceivableNetCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InsuranceAbstract_efe7a667-050a-4636-85c7-230c0d83071d_terseLabel_en-US" xlink:label="lab_us-gaap_InsuranceAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Insurance [Abstract]</link:label>
    <link:label id="lab_us-gaap_InsuranceAbstract_label_en-US" xlink:label="lab_us-gaap_InsuranceAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Insurance [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InsuranceAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InsuranceAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InsuranceAbstract" xlink:to="lab_us-gaap_InsuranceAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense_db9a9a9a-75de-444d-8676-3e8eb08fb58f_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, general and administrative expenses</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, General and Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_d417f88f-4cc2-4850-9fd7-aef050e514c1_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_39b7867e-ca97-43d5-9419-e029a86f9d68_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrent_fb34b45e-fcef-4c41-b1ac-dbf34284f76b_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_7d797d30-6fb2-4332-adea-061766ed824a_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Future Minimum Lease Commitments</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_fd4e5597-ef14-48de-9d5d-92cb2b80d8df_totalLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total lease payments</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableMember_d662972c-64c8-4dc2-a7de-2a26b565fb09_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableMember_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableMember" xlink:to="lab_us-gaap_AccountsReceivableMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_ba52b356-1187-42b0-940d-9063b17156b6_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forfeited / Canceled (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_c61e2816-e1b1-4fdd-ac84-6df52de48f02_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock by Class [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock by Class [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable" xlink:to="lab_us-gaap_ScheduleOfStockByClassTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_dbd404d3-94b1-4e96-92d6-f8b70fbba208_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based Compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_bd19dff4-7107-4782-8a72-4176416e74cb_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NoncontrollingInterestIncreaseFromBusinessCombination_f04296c2-354e-4504-b287-b7184e4f5ada_terseLabel_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestIncreaseFromBusinessCombination" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation of equity method investment</link:label>
    <link:label id="lab_us-gaap_NoncontrollingInterestIncreaseFromBusinessCombination_label_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestIncreaseFromBusinessCombination" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest, Increase from Business Combination</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestIncreaseFromBusinessCombination" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NoncontrollingInterestIncreaseFromBusinessCombination"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncontrollingInterestIncreaseFromBusinessCombination" xlink:to="lab_us-gaap_NoncontrollingInterestIncreaseFromBusinessCombination" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_f0b80dd8-7f00-47e3-b9d2-093cdd827f62_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:to="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_7fff7c84-1000-43b0-9569-60be49e60deb_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Compensation Expense</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtCurrent_846a8916-3dca-405b-a871-2470944dde1a_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term debt, net of discount</link:label>
    <link:label id="lab_us-gaap_LongTermDebtCurrent_label_en-US" xlink:label="lab_us-gaap_LongTermDebtCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Current Maturities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtCurrent" xlink:to="lab_us-gaap_LongTermDebtCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_39210248-ae50-4d5b-a0da-7384588f9a0d_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByBalanceSheetGroupingTable_c2a1448d-2070-4321-b0c1-a1c1cc0a9079_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByBalanceSheetGroupingTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, by Balance Sheet Grouping [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueByBalanceSheetGroupingTable_label_en-US" xlink:label="lab_us-gaap_FairValueByBalanceSheetGroupingTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, by Balance Sheet Grouping [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByBalanceSheetGroupingTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByBalanceSheetGroupingTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="lab_us-gaap_FairValueByBalanceSheetGroupingTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_ba9ac7c9-7566-4bd5-9bf8-5ce5fed2e70d_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Compensation Expense</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SalesRevenueNetMember_ebf808e7-43a0-4668-894c-2176d41827c3_terseLabel_en-US" xlink:label="lab_us-gaap_SalesRevenueNetMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues</link:label>
    <link:label id="lab_us-gaap_SalesRevenueNetMember_label_en-US" xlink:label="lab_us-gaap_SalesRevenueNetMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Benchmark [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesRevenueNetMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SalesRevenueNetMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SalesRevenueNetMember" xlink:to="lab_us-gaap_SalesRevenueNetMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_0955e39a-7e2d-4339-91ff-e39f2c2f93b5_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average fair value per option granted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityComponentDomain_fc464777-4606-4359-9a6f-796658b2edcd_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_EarningsPerSharePortionAttributableToNoncontrollingInterestDiluted_caab93a7-c1c4-4230-8245-049164fbce69_terseLabel_en-US" xlink:label="lab_evh_EarningsPerSharePortionAttributableToNoncontrollingInterestDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-controlling interests, diluted (in dollars per share)</link:label>
    <link:label id="lab_evh_EarningsPerSharePortionAttributableToNoncontrollingInterestDiluted_label_en-US" xlink:label="lab_evh_EarningsPerSharePortionAttributableToNoncontrollingInterestDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Portion Attributable to Noncontrolling Interest, Diluted</link:label>
    <link:label id="lab_evh_EarningsPerSharePortionAttributableToNoncontrollingInterestDiluted_documentation_en-US" xlink:label="lab_evh_EarningsPerSharePortionAttributableToNoncontrollingInterestDiluted" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Portion Attributable to Noncontrolling Interest, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_EarningsPerSharePortionAttributableToNoncontrollingInterestDiluted" xlink:href="evh-20211231.xsd#evh_EarningsPerSharePortionAttributableToNoncontrollingInterestDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_EarningsPerSharePortionAttributableToNoncontrollingInterestDiluted" xlink:to="lab_evh_EarningsPerSharePortionAttributableToNoncontrollingInterestDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_62843e05-8951-4024-aa70-b9f977a566a9_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2022</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_4eb3cf33-943f-4e50-81c9-5f3259dbc922_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accounts, Notes, Loans and Financing Receivable [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accounts, Notes, Loans and Financing Receivable [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable" xlink:to="lab_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_a1bb0707-2346-485e-99e6-d9242b88dae3_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group Name [Domain]</link:label>
    <link:label id="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_label_en-US" xlink:label="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:to="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract_8b08b437-4302-4430-8134-fc7234603076_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current assets:</link:label>
    <link:label id="lab_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Assets, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract" xlink:to="lab_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEquityMethodInvestmentsTable_da926ded-d656-4d49-93d9-d33a056c2a3e_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEquityMethodInvestmentsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Equity Method Investments [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEquityMethodInvestmentsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEquityMethodInvestmentsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Equity Method Investments [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable" xlink:to="lab_us-gaap_ScheduleOfEquityMethodInvestmentsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable_2f6368d5-3c30-49fb-bdba-faf3d9be76b5_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of Class A common stock issued</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Consideration Transferred, Equity Interests Issued and Issuable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" xlink:to="lab_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_f6423d10-43e9-4419-8a4f-bc7a74f87cd9_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares issued for acquisition (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Acquisitions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligation_de34af1d-d24d-4359-9123-701804f2efbf_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, remaining performance obligation</link:label>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligation_label_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Remaining Performance Obligation, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligation" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligation" xlink:to="lab_us-gaap_RevenueRemainingPerformanceObligation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues_73d55af3-e5bb-4a31-99b7-eb5589844e78_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additions</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Issuances</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_TrueHealthMember_c2446062-e629-4f88-b975-cab74caea0d3_terseLabel_en-US" xlink:label="lab_evh_TrueHealthMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">True Health</link:label>
    <link:label id="lab_evh_TrueHealthMember_label_en-US" xlink:label="lab_evh_TrueHealthMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">True Health [Member]</link:label>
    <link:label id="lab_evh_TrueHealthMember_documentation_en-US" xlink:label="lab_evh_TrueHealthMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">True Health</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_TrueHealthMember" xlink:href="evh-20211231.xsd#evh_TrueHealthMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_TrueHealthMember" xlink:to="lab_evh_TrueHealthMember" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_DisposalGroupIncludingDiscontinuedOperationRestrictedCashAndRestrictedInvestmentsCurrent_04b24195-2623-4596-ba36-530f5731ec57_terseLabel_en-US" xlink:label="lab_evh_DisposalGroupIncludingDiscontinuedOperationRestrictedCashAndRestrictedInvestmentsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted cash and restricted investments</link:label>
    <link:label id="lab_evh_DisposalGroupIncludingDiscontinuedOperationRestrictedCashAndRestrictedInvestmentsCurrent_label_en-US" xlink:label="lab_evh_DisposalGroupIncludingDiscontinuedOperationRestrictedCashAndRestrictedInvestmentsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Restricted Cash And Restricted Investments, Current</link:label>
    <link:label id="lab_evh_DisposalGroupIncludingDiscontinuedOperationRestrictedCashAndRestrictedInvestmentsCurrent_documentation_en-US" xlink:label="lab_evh_DisposalGroupIncludingDiscontinuedOperationRestrictedCashAndRestrictedInvestmentsCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Restricted Cash And Restricted Investments, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_DisposalGroupIncludingDiscontinuedOperationRestrictedCashAndRestrictedInvestmentsCurrent" xlink:href="evh-20211231.xsd#evh_DisposalGroupIncludingDiscontinuedOperationRestrictedCashAndRestrictedInvestmentsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_DisposalGroupIncludingDiscontinuedOperationRestrictedCashAndRestrictedInvestmentsCurrent" xlink:to="lab_evh_DisposalGroupIncludingDiscontinuedOperationRestrictedCashAndRestrictedInvestmentsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAbstract_f580ed17-cae0-432c-bfd7-0a8ad637341e_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAbstract" xlink:to="lab_us-gaap_LiabilitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_ba8789ca-5649-49a7-ad33-6874dd3eaffe_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted stock units vested, net of shares withheld for taxes</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Restricted Stock Award, Net of Forfeitures</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_1c0079cb-e36d-48ec-9259-53a3bb7dd2df_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation expense</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Cost by Plan [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_be003c9a-9342-48d3-bda1-d0bd3801b86f_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in valuation allowance</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_48632647-2d77-4907-9463-6f30df2a5b1f_terseLabel_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_label_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockRetiredCostMethodAmount_8ae97599-4636-453d-a43e-df35d9aebeaa_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockRetiredCostMethodAmount" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation of equity method investment</link:label>
    <link:label id="lab_us-gaap_TreasuryStockRetiredCostMethodAmount_label_en-US" xlink:label="lab_us-gaap_TreasuryStockRetiredCostMethodAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, Retired, Cost Method, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockRetiredCostMethodAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockRetiredCostMethodAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockRetiredCostMethodAmount" xlink:to="lab_us-gaap_TreasuryStockRetiredCostMethodAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_2c99a6bd-a0eb-4561-a24a-6bb630eaae0c_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2025</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_TransactionCosts_86df6e57-23e3-42df-931b-6bc3d7355145_negatedLabel_en-US" xlink:label="lab_evh_TransactionCosts" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisition costs</link:label>
    <link:label id="lab_evh_TransactionCosts_label_en-US" xlink:label="lab_evh_TransactionCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Transaction Costs</link:label>
    <link:label id="lab_evh_TransactionCosts_documentation_en-US" xlink:label="lab_evh_TransactionCosts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Transaction Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_TransactionCosts" xlink:href="evh-20211231.xsd#evh_TransactionCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_TransactionCosts" xlink:to="lab_evh_TransactionCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_PaymentsForProceedsFromDisposalOfNonStrategicAssetsAndDivestitureOfDiscontinuedOperationsNet_e220c87b-f9ab-49b7-a7d1-a34677b3dc1f_negatedTerseLabel_en-US" xlink:label="lab_evh_PaymentsForProceedsFromDisposalOfNonStrategicAssetsAndDivestitureOfDiscontinuedOperationsNet" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal of non-strategic assets and divestiture of discontinued operations, net</link:label>
    <link:label id="lab_evh_PaymentsForProceedsFromDisposalOfNonStrategicAssetsAndDivestitureOfDiscontinuedOperationsNet_label_en-US" xlink:label="lab_evh_PaymentsForProceedsFromDisposalOfNonStrategicAssetsAndDivestitureOfDiscontinuedOperationsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments For (Proceeds From) Disposal Of Non-Strategic Assets And Divestiture Of Discontinued Operations, Net</link:label>
    <link:label id="lab_evh_PaymentsForProceedsFromDisposalOfNonStrategicAssetsAndDivestitureOfDiscontinuedOperationsNet_documentation_en-US" xlink:label="lab_evh_PaymentsForProceedsFromDisposalOfNonStrategicAssetsAndDivestitureOfDiscontinuedOperationsNet" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments For (Proceeds From) Disposal Of Non-Strategic Assets And Divestiture Of Discontinued Operations, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_PaymentsForProceedsFromDisposalOfNonStrategicAssetsAndDivestitureOfDiscontinuedOperationsNet" xlink:href="evh-20211231.xsd#evh_PaymentsForProceedsFromDisposalOfNonStrategicAssetsAndDivestitureOfDiscontinuedOperationsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_PaymentsForProceedsFromDisposalOfNonStrategicAssetsAndDivestitureOfDiscontinuedOperationsNet" xlink:to="lab_evh_PaymentsForProceedsFromDisposalOfNonStrategicAssetsAndDivestitureOfDiscontinuedOperationsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_2227fe6f-f3c8-4775-89b3-343b823e43e1_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss from continuing operations before income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_1579067d-0556-4403-bc9b-17aecbbfb2c0_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 2</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel2Member" xlink:to="lab_us-gaap_FairValueInputsLevel2Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent_01431de1-c49b-47ce-9ecb-c795d41d3479_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term deferred revenue</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AuditorLocation_9a7c0e50-fcbd-40bc-90b2-7a7ea6cf987e_terseLabel_en-US" xlink:label="lab_dei_AuditorLocation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Location</link:label>
    <link:label id="lab_dei_AuditorLocation_label_en-US" xlink:label="lab_dei_AuditorLocation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Location</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorLocation" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorLocation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AuditorLocation" xlink:to="lab_dei_AuditorLocation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingAbstract_f06ffe1f-ff9a-4725-8e65-3b196334a690_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting [Abstract]</link:label>
    <link:label id="lab_us-gaap_SegmentReportingAbstract_label_en-US" xlink:label="lab_us-gaap_SegmentReportingAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingAbstract" xlink:to="lab_us-gaap_SegmentReportingAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TypeOfRestructuringDomain_3ffdac25-b8da-4dd7-a2f7-bfd7ad58ab99_terseLabel_en-US" xlink:label="lab_us-gaap_TypeOfRestructuringDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Type of Restructuring [Domain]</link:label>
    <link:label id="lab_us-gaap_TypeOfRestructuringDomain_label_en-US" xlink:label="lab_us-gaap_TypeOfRestructuringDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Type of Restructuring [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfRestructuringDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfRestructuringDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfRestructuringDomain" xlink:to="lab_us-gaap_TypeOfRestructuringDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseBusinessAcquisitions_c30703aa-09fd-46f1-940d-d1d8a4948342_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseBusinessAcquisitions" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impact of consolidation on reserves for claims and performance-based arrangements</link:label>
    <link:label id="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseBusinessAcquisitions_label_en-US" xlink:label="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseBusinessAcquisitions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability for Unpaid Claims and Claims Adjustment Expense, Business Acquisitions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseBusinessAcquisitions" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseBusinessAcquisitions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseBusinessAcquisitions" xlink:to="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseBusinessAcquisitions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife_8da42078-e9b1-4cf4-80a3-de3ae47490e1_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Useful life</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Useful Life</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsNotesAndLoansReceivableNetCurrent_da5c9224-d990-497e-8536-657fd8906af6_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsNotesAndLoansReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term receivables</link:label>
    <link:label id="lab_us-gaap_AccountsNotesAndLoansReceivableNetCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsNotesAndLoansReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts and Financing Receivable, after Allowance for Credit Loss, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsNotesAndLoansReceivableNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsNotesAndLoansReceivableNetCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableNetCurrent" xlink:to="lab_us-gaap_AccountsNotesAndLoansReceivableNetCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseInterestExpense_3c241598-bb88-40c4-880e-338b75e78c06_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseInterestExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest expense</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseInterestExpense_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseInterestExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Interest Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseInterestExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseInterestExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseInterestExpense" xlink:to="lab_us-gaap_FinanceLeaseInterestExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UseOfEstimates_4e9ab08f-a328-4858-b187-824deb217abb_terseLabel_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Estimates and Assumptions</link:label>
    <link:label id="lab_us-gaap_UseOfEstimates_label_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UseOfEstimates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UseOfEstimates" xlink:to="lab_us-gaap_UseOfEstimates" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_d8f273b6-3b00-416d-a0a8-fe8e4f4c9cd2_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Computation of basic and diluted earnings per share</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNetAfterGrossUp_3da50818-e757-449f-a2ea-88a39d5c7236_terseLabel_en-US" xlink:label="lab_evh_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNetAfterGrossUp" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable, net, after gross-up</link:label>
    <link:label id="lab_evh_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNetAfterGrossUp_label_en-US" xlink:label="lab_evh_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNetAfterGrossUp" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Accounts, Notes And Loans Receivable, Net, After Gross-Up</link:label>
    <link:label id="lab_evh_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNetAfterGrossUp_documentation_en-US" xlink:label="lab_evh_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNetAfterGrossUp" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Accounts, Notes And Loans Receivable, Net, After Gross-Up</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNetAfterGrossUp" xlink:href="evh-20211231.xsd#evh_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNetAfterGrossUp"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNetAfterGrossUp" xlink:to="lab_evh_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNetAfterGrossUp" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_CreditAgreementMember_5674b033-7142-4cd3-b7cd-5c96fde6131e_terseLabel_en-US" xlink:label="lab_evh_CreditAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Agreement</link:label>
    <link:label id="lab_evh_CreditAgreementMember_label_en-US" xlink:label="lab_evh_CreditAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Agreement [Member]</link:label>
    <link:label id="lab_evh_CreditAgreementMember_documentation_en-US" xlink:label="lab_evh_CreditAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Agreement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_CreditAgreementMember" xlink:href="evh-20211231.xsd#evh_CreditAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_CreditAgreementMember" xlink:to="lab_evh_CreditAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_fffb77fa-6588-407d-9ddd-1d3559e60d9e_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_DebtInstrumentRepurchaseCovenantTradingDaysMinimum_6dea088b-829d-44ca-9528-2997e7d5f88c_terseLabel_en-US" xlink:label="lab_evh_DebtInstrumentRepurchaseCovenantTradingDaysMinimum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repurchase covenant, trading days, minimum</link:label>
    <link:label id="lab_evh_DebtInstrumentRepurchaseCovenantTradingDaysMinimum_label_en-US" xlink:label="lab_evh_DebtInstrumentRepurchaseCovenantTradingDaysMinimum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Repurchase Covenant, Trading Days, Minimum</link:label>
    <link:label id="lab_evh_DebtInstrumentRepurchaseCovenantTradingDaysMinimum_documentation_en-US" xlink:label="lab_evh_DebtInstrumentRepurchaseCovenantTradingDaysMinimum" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Repurchase Covenant, Trading Days, Minimum</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_DebtInstrumentRepurchaseCovenantTradingDaysMinimum" xlink:href="evh-20211231.xsd#evh_DebtInstrumentRepurchaseCovenantTradingDaysMinimum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_DebtInstrumentRepurchaseCovenantTradingDaysMinimum" xlink:to="lab_evh_DebtInstrumentRepurchaseCovenantTradingDaysMinimum" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent_ed0a6aad-ffea-4590-88fb-51f74ddda372_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Prepaid and Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_EquityMethodInvesteeNameDomain_cf59e0c6-453f-4673-aca0-6abeffd3dd15_terseLabel_en-US" xlink:label="lab_srt_EquityMethodInvesteeNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment, Name [Domain]</link:label>
    <link:label id="lab_srt_EquityMethodInvesteeNameDomain_label_en-US" xlink:label="lab_srt_EquityMethodInvesteeNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_EquityMethodInvesteeNameDomain" xlink:to="lab_srt_EquityMethodInvesteeNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxesAndTaxCredits_de415825-5868-4eae-a078-117e3b9a4de2_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxesAndTaxCredits" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax benefit</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxesAndTaxCredits_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxesAndTaxCredits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Taxes and Tax Credits</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxesAndTaxCredits" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxesAndTaxCredits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxesAndTaxCredits" xlink:to="lab_us-gaap_DeferredIncomeTaxesAndTaxCredits" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToMinorityShareholders_e936c64e-b12f-422f-bc63-b58b653c3397_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToMinorityShareholders" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Distributions to Sponsors</link:label>
    <link:label id="lab_us-gaap_PaymentsToMinorityShareholders_2bc4710e-83a8-48f7-8e40-c5da229b21db_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToMinorityShareholders" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to redeem Sponsors' equity</link:label>
    <link:label id="lab_us-gaap_PaymentsToMinorityShareholders_label_en-US" xlink:label="lab_us-gaap_PaymentsToMinorityShareholders" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Noncontrolling Interests</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToMinorityShareholders" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToMinorityShareholders"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToMinorityShareholders" xlink:to="lab_us-gaap_PaymentsToMinorityShareholders" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_9270d4d5-eb90-405a-bf52-e40979ea2a78_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized" xlink:to="lab_us-gaap_CommonStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCashAndInvestmentsNoncurrent_279f4402-39a8-42b0-8958-9eef3c73c0c1_verboseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashAndInvestmentsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted cash and restricted investments</link:label>
    <link:label id="lab_us-gaap_RestrictedCashAndInvestmentsNoncurrent_bd76faf3-ac92-4aa0-a732-2fbd9ee231fe_totalLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashAndInvestmentsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total non-current restricted cash and restricted investments</link:label>
    <link:label id="lab_us-gaap_RestrictedCashAndInvestmentsNoncurrent_label_en-US" xlink:label="lab_us-gaap_RestrictedCashAndInvestmentsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash and Investments, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndInvestmentsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndInvestmentsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashAndInvestmentsNoncurrent" xlink:to="lab_us-gaap_RestrictedCashAndInvestmentsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_67a3e985-8302-4166-8229-2adba5583f82_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss attributable to common shareholders of Evolent Health, Inc. - Diluted</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_374a0f39-e822-4598-98df-51a371b14b96_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss attributable to common shareholders of Evolent Health, Inc.</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_5f2961ba-6cad-4bb7-8a25-4c8bdc5974e9_verboseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss attributable to common shareholders of Evolent Health, Inc. - Diluted</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Available to Common Stockholders, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:to="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlements_1ea23032-6cfc-49da-982b-677aaf8b81a4_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlements" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax sharing settlement</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlements_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Tax Settlement, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlements" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlements" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlements" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_03c9001a-89a0-469e-b698-972146551fc3_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss attributable to common shareholders of Evolent Health, Inc. - Basic</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_5ebdface-da85-434a-8654-0f7ccf11ba45_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss attributable to common shareholders of Evolent Health, Inc.</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_e422879a-ce67-4397-8e42-31dbe038f096_verboseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss attributable to common shareholders of Evolent Health, Inc. - Basic</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Available to Common Stockholders, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_f3dca514-1063-40f9-8612-132132d35e9d_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_ValuationAllowancesAndReservesChargedToRetainedEarnings_8021f995-3c51-4cfa-baaf-437f2e6ff30a_terseLabel_en-US" xlink:label="lab_evh_ValuationAllowancesAndReservesChargedToRetainedEarnings" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation allowance increase (decrease) charged to retained earnings</link:label>
    <link:label id="lab_evh_ValuationAllowancesAndReservesChargedToRetainedEarnings_label_en-US" xlink:label="lab_evh_ValuationAllowancesAndReservesChargedToRetainedEarnings" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation Allowances and Reserves, Charged to Retained Earnings</link:label>
    <link:label id="lab_evh_ValuationAllowancesAndReservesChargedToRetainedEarnings_documentation_en-US" xlink:label="lab_evh_ValuationAllowancesAndReservesChargedToRetainedEarnings" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation Allowances and Reserves, Charged to Retained Earnings</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_ValuationAllowancesAndReservesChargedToRetainedEarnings" xlink:href="evh-20211231.xsd#evh_ValuationAllowancesAndReservesChargedToRetainedEarnings"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_ValuationAllowancesAndReservesChargedToRetainedEarnings" xlink:to="lab_evh_ValuationAllowancesAndReservesChargedToRetainedEarnings" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationConsiderationTransferredAbstract_7f3283f6-9bb5-4ccd-90d7-55370534eeec_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferredAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase consideration:</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationConsiderationTransferredAbstract_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferredAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Consideration Transferred [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferredAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferredAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationConsiderationTransferredAbstract" xlink:to="lab_us-gaap_BusinessCombinationConsiderationTransferredAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductsAndServicesDomain_5191a523-b175-4845-bd2b-3ef050949d7b_terseLabel_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:label id="lab_srt_ProductsAndServicesDomain_label_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductsAndServicesDomain" xlink:to="lab_srt_ProductsAndServicesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense_6d06638d-6a73-428d-a3ab-de27f76c5980_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Activity in claims reserves</link:label>
    <link:label id="lab_us-gaap_ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense_label_en-US" xlink:label="lab_us-gaap_ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Liability for Unpaid Claims and Claims Adjustment Expense [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense" xlink:to="lab_us-gaap_ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_EvolentHealthLLCMember_a99b9020-c513-4727-91dd-8ccc20c3454f_terseLabel_en-US" xlink:label="lab_evh_EvolentHealthLLCMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Evolent Health LLC</link:label>
    <link:label id="lab_evh_EvolentHealthLLCMember_label_en-US" xlink:label="lab_evh_EvolentHealthLLCMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Evolent Health LLC [Member]</link:label>
    <link:label id="lab_evh_EvolentHealthLLCMember_documentation_en-US" xlink:label="lab_evh_EvolentHealthLLCMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Evolent Health LLC [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_EvolentHealthLLCMember" xlink:href="evh-20211231.xsd#evh_EvolentHealthLLCMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_EvolentHealthLLCMember" xlink:to="lab_evh_EvolentHealthLLCMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_b319fbe9-2b04-4443-a561-876fff94c459_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest rate</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Interest Rate, Stated Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:to="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_563d8179-c69b-4400-b79e-8750ac906f0c_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss attributable to non-controlling interests</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_ea7eb221-0f93-4447-84c2-c5171eb1b6d8_negatedLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss attributable to non-controlling interests</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent_0caabd5a-078c-4bb5-8c7f-876787f1aefd_verboseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other noncurrent assets</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Expense and Other Assets, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent" xlink:to="lab_us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MinorityInterestDisclosureTextBlock_e019eba2-50ad-42f7-b695-87d2ad4b0251_terseLabel_en-US" xlink:label="lab_us-gaap_MinorityInterestDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-controlling Interests</link:label>
    <link:label id="lab_us-gaap_MinorityInterestDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_MinorityInterestDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MinorityInterestDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinorityInterestDisclosureTextBlock" xlink:to="lab_us-gaap_MinorityInterestDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinancingReceivablePercentPastDue1_b595c904-a4f0-4bca-84c9-4fdc2211ceef_terseLabel_en-US" xlink:label="lab_us-gaap_FinancingReceivablePercentPastDue1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of receivables, past due</link:label>
    <link:label id="lab_us-gaap_FinancingReceivablePercentPastDue1_label_en-US" xlink:label="lab_us-gaap_FinancingReceivablePercentPastDue1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financing Receivable, Percent Past Due</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancingReceivablePercentPastDue1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancingReceivablePercentPastDue1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancingReceivablePercentPastDue1" xlink:to="lab_us-gaap_FinancingReceivablePercentPastDue1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_c8b9b065-14a5-4a3e-9cd0-a701440037e6_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of contingent consideration</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_111be64d-bbd0-4a2f-b697-61a3054a4474_verboseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_MeasurementInputRiskNeutralExpectedEarnoutConsiderationMember_f4503f6e-fddd-4ac6-87d2-ade4a42ed671_terseLabel_en-US" xlink:label="lab_evh_MeasurementInputRiskNeutralExpectedEarnoutConsiderationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risk-neutral expected earnout consideration</link:label>
    <link:label id="lab_evh_MeasurementInputRiskNeutralExpectedEarnoutConsiderationMember_label_en-US" xlink:label="lab_evh_MeasurementInputRiskNeutralExpectedEarnoutConsiderationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input, Risk-neutral Expected Earnout Consideration [Member]</link:label>
    <link:label id="lab_evh_MeasurementInputRiskNeutralExpectedEarnoutConsiderationMember_documentation_en-US" xlink:label="lab_evh_MeasurementInputRiskNeutralExpectedEarnoutConsiderationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input, Risk-neutral Expected Earnout Consideration</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_MeasurementInputRiskNeutralExpectedEarnoutConsiderationMember" xlink:href="evh-20211231.xsd#evh_MeasurementInputRiskNeutralExpectedEarnoutConsiderationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_MeasurementInputRiskNeutralExpectedEarnoutConsiderationMember" xlink:to="lab_evh_MeasurementInputRiskNeutralExpectedEarnoutConsiderationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3fd67892-5ffc-4277-9ef7-7716ce79a8c5_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_IncomeLossfromEquityMethodInvestmentsServicesAgreement_3789cfd2-fbd6-4d4c-9964-2cba14f58d74_terseLabel_en-US" xlink:label="lab_evh_IncomeLossfromEquityMethodInvestmentsServicesAgreement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income from long-term services agreement</link:label>
    <link:label id="lab_evh_IncomeLossfromEquityMethodInvestmentsServicesAgreement_label_en-US" xlink:label="lab_evh_IncomeLossfromEquityMethodInvestmentsServicesAgreement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Equity Method Investments, Services Agreement</link:label>
    <link:label id="lab_evh_IncomeLossfromEquityMethodInvestmentsServicesAgreement_documentation_en-US" xlink:label="lab_evh_IncomeLossfromEquityMethodInvestmentsServicesAgreement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Equity Method Investments, Services Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_IncomeLossfromEquityMethodInvestmentsServicesAgreement" xlink:href="evh-20211231.xsd#evh_IncomeLossfromEquityMethodInvestmentsServicesAgreement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_IncomeLossfromEquityMethodInvestmentsServicesAgreement" xlink:to="lab_evh_IncomeLossfromEquityMethodInvestmentsServicesAgreement" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_6d683847-6090-4abc-9c67-864138fec271_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationAllowanceOfDeferredTaxAssetsMember_95cf136f-bf20-4a70-a8ba-2a8713842464_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowanceOfDeferredTaxAssetsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation Allowance of Deferred Tax Assets</link:label>
    <link:label id="lab_us-gaap_ValuationAllowanceOfDeferredTaxAssetsMember_label_en-US" xlink:label="lab_us-gaap_ValuationAllowanceOfDeferredTaxAssetsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowance, Deferred Tax Asset [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowanceOfDeferredTaxAssetsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowanceOfDeferredTaxAssetsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowanceOfDeferredTaxAssetsMember" xlink:to="lab_us-gaap_ValuationAllowanceOfDeferredTaxAssetsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesAccruedLiabilities_a98659e3-ec13-4176-ad14-c0eb985d6ec7_terseLabel_en-US" xlink:label="lab_evh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued liabilities</link:label>
    <link:label id="lab_evh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesAccruedLiabilities_label_en-US" xlink:label="lab_evh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Accrued Liabilities</link:label>
    <link:label id="lab_evh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesAccruedLiabilities_documentation_en-US" xlink:label="lab_evh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Accrued Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesAccruedLiabilities" xlink:href="evh-20211231.xsd#evh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesAccruedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesAccruedLiabilities" xlink:to="lab_evh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesAccruedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_GainLossOnDispositionOfAssetsOperatingActivities_5c0688fb-de68-48fe-8da5-27ec4c782f9d_negatedLabel_en-US" xlink:label="lab_evh_GainLossOnDispositionOfAssetsOperatingActivities" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">(Gain) loss on disposal of assets</link:label>
    <link:label id="lab_evh_GainLossOnDispositionOfAssetsOperatingActivities_label_en-US" xlink:label="lab_evh_GainLossOnDispositionOfAssetsOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) On Disposition Of Assets, Operating Activities</link:label>
    <link:label id="lab_evh_GainLossOnDispositionOfAssetsOperatingActivities_documentation_en-US" xlink:label="lab_evh_GainLossOnDispositionOfAssetsOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) On Disposition Of Assets, Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_GainLossOnDispositionOfAssetsOperatingActivities" xlink:href="evh-20211231.xsd#evh_GainLossOnDispositionOfAssetsOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_GainLossOnDispositionOfAssetsOperatingActivities" xlink:to="lab_evh_GainLossOnDispositionOfAssetsOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseCostTableTextBlock_4762c12a-b9cd-469f-aa54-620910893669_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseCostTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of components of lease expense, weighted-average discount rate and weighted-remaining lease terms</link:label>
    <link:label id="lab_us-gaap_LeaseCostTableTextBlock_label_en-US" xlink:label="lab_us-gaap_LeaseCostTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease, Cost [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCostTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseCostTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseCostTableTextBlock" xlink:to="lab_us-gaap_LeaseCostTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_PremiumsWrittenAndPolicyholderBenefitsAndClaimsIncurredNet_36002a8a-9491-4cb9-ad02-fe0214ed5dca_terseLabel_en-US" xlink:label="lab_evh_PremiumsWrittenAndPolicyholderBenefitsAndClaimsIncurredNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (decrease) in reserves for claims and performance-based arrangements attributable to the Reinsurance Agreement</link:label>
    <link:label id="lab_evh_PremiumsWrittenAndPolicyholderBenefitsAndClaimsIncurredNet_label_en-US" xlink:label="lab_evh_PremiumsWrittenAndPolicyholderBenefitsAndClaimsIncurredNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Premiums Written And Policyholder Benefits And Claims Incurred, Net</link:label>
    <link:label id="lab_evh_PremiumsWrittenAndPolicyholderBenefitsAndClaimsIncurredNet_documentation_en-US" xlink:label="lab_evh_PremiumsWrittenAndPolicyholderBenefitsAndClaimsIncurredNet" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Premiums Written And Policyholder Benefits And Claims Incurred, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_PremiumsWrittenAndPolicyholderBenefitsAndClaimsIncurredNet" xlink:href="evh-20211231.xsd#evh_PremiumsWrittenAndPolicyholderBenefitsAndClaimsIncurredNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_PremiumsWrittenAndPolicyholderBenefitsAndClaimsIncurredNet" xlink:to="lab_evh_PremiumsWrittenAndPolicyholderBenefitsAndClaimsIncurredNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReinsuranceEffectOnClaimsAndBenefitsIncurredAmountAssumed_afe6290c-08cd-4ef2-9f49-769a25b4ecb1_terseLabel_en-US" xlink:label="lab_us-gaap_ReinsuranceEffectOnClaimsAndBenefitsIncurredAmountAssumed" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Claims assumed</link:label>
    <link:label id="lab_us-gaap_ReinsuranceEffectOnClaimsAndBenefitsIncurredAmountAssumed_label_en-US" xlink:label="lab_us-gaap_ReinsuranceEffectOnClaimsAndBenefitsIncurredAmountAssumed" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Policyholder Benefits and Claims Incurred, Assumed</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReinsuranceEffectOnClaimsAndBenefitsIncurredAmountAssumed" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReinsuranceEffectOnClaimsAndBenefitsIncurredAmountAssumed"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReinsuranceEffectOnClaimsAndBenefitsIncurredAmountAssumed" xlink:to="lab_us-gaap_ReinsuranceEffectOnClaimsAndBenefitsIncurredAmountAssumed" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationMinorityInterestIncomeExpense_4ba76e5a-6fe5-4506-a6d2-658fb1c8f28d_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationMinorityInterestIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-controlling interest</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationMinorityInterestIncomeExpense_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationMinorityInterestIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Noncontrolling Interest Income (Loss), Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationMinorityInterestIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationMinorityInterestIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationMinorityInterestIncomeExpense" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationMinorityInterestIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_StatementGeographicalAxis_bb4b3284-5bba-41a7-b5b5-157d09913d7d_terseLabel_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:label id="lab_srt_StatementGeographicalAxis_label_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_StatementGeographicalAxis" xlink:to="lab_srt_StatementGeographicalAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_ClinicalSolutionsSegmentMember_41fefdac-5af1-4547-bd66-db73b3494091_terseLabel_en-US" xlink:label="lab_evh_ClinicalSolutionsSegmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Clinical Solutions</link:label>
    <link:label id="lab_evh_ClinicalSolutionsSegmentMember_label_en-US" xlink:label="lab_evh_ClinicalSolutionsSegmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Clinical Solutions Segment [Member]</link:label>
    <link:label id="lab_evh_ClinicalSolutionsSegmentMember_documentation_en-US" xlink:label="lab_evh_ClinicalSolutionsSegmentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Clinical Solutions Segment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_ClinicalSolutionsSegmentMember" xlink:href="evh-20211231.xsd#evh_ClinicalSolutionsSegmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_ClinicalSolutionsSegmentMember" xlink:to="lab_evh_ClinicalSolutionsSegmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StateAndLocalJurisdictionMember_aae9190f-eb40-45cd-ac66-a2a6e58009f9_terseLabel_en-US" xlink:label="lab_us-gaap_StateAndLocalJurisdictionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State and Local Jurisdiction</link:label>
    <link:label id="lab_us-gaap_StateAndLocalJurisdictionMember_label_en-US" xlink:label="lab_us-gaap_StateAndLocalJurisdictionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State and Local Jurisdiction [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StateAndLocalJurisdictionMember" xlink:to="lab_us-gaap_StateAndLocalJurisdictionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VestingDomain_22716ff4-8ad7-40bc-b524-cde822d3ebe4_terseLabel_en-US" xlink:label="lab_us-gaap_VestingDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting [Domain]</link:label>
    <link:label id="lab_us-gaap_VestingDomain_label_en-US" xlink:label="lab_us-gaap_VestingDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VestingDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VestingDomain" xlink:to="lab_us-gaap_VestingDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_SeniorConvertibleNotesDue2024Member_e636b3b9-99ab-4cae-8188-903d716e5f25_terseLabel_en-US" xlink:label="lab_evh_SeniorConvertibleNotesDue2024Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2024 Notes</link:label>
    <link:label id="lab_evh_SeniorConvertibleNotesDue2024Member_label_en-US" xlink:label="lab_evh_SeniorConvertibleNotesDue2024Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Convertible Notes Due 2024 [Member]</link:label>
    <link:label id="lab_evh_SeniorConvertibleNotesDue2024Member_documentation_en-US" xlink:label="lab_evh_SeniorConvertibleNotesDue2024Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Convertible Notes Due 2024</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_SeniorConvertibleNotesDue2024Member" xlink:href="evh-20211231.xsd#evh_SeniorConvertibleNotesDue2024Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_SeniorConvertibleNotesDue2024Member" xlink:to="lab_evh_SeniorConvertibleNotesDue2024Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount_0360643a-eee5-496d-8b80-af0428b2a03f_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, expected tax deductible amount</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Goodwill, Expected Tax Deductible Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount" xlink:to="lab_us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_8521375b-c292-49cd-b1a5-54b2341c44b0_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash and restricted cash used in financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockValue_b885ce54-bcbd-443d-a019-b98ab965c561_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockValue" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury stock, at cost; 1,537,582 shares issued, respectively</link:label>
    <link:label id="lab_us-gaap_TreasuryStockValue_label_en-US" xlink:label="lab_us-gaap_TreasuryStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockValue" xlink:to="lab_us-gaap_TreasuryStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionLineItems_07386a3d-8fcb-47a9-bf36-1309070433c6_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Line Items]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionLineItems_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems" xlink:to="lab_us-gaap_RelatedPartyTransactionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_1b92dfde-62e1-43e5-82b5-f680208e0b83_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Remaining Contractual Term</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Outstanding, Weighted Average Remaining Contractual Terms</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CededPremiumsWritten_c7e5220f-736e-4ec8-9312-038d4308277d_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_CededPremiumsWritten" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reinsurance premiums ceded</link:label>
    <link:label id="lab_us-gaap_CededPremiumsWritten_label_en-US" xlink:label="lab_us-gaap_CededPremiumsWritten" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ceded Premiums Written</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CededPremiumsWritten" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CededPremiumsWritten"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CededPremiumsWritten" xlink:to="lab_us-gaap_CededPremiumsWritten" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_c35adc1d-1151-4c2a-9d7b-e4514988f61b_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting period</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromDivestitureOfInterestInSubsidiariesAndAffiliates_2cd1c24e-029f-463c-8e79-cd79fc8dd67f_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromDivestitureOfInterestInSubsidiariesAndAffiliates" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from transfer of membership and release of Passport escrow</link:label>
    <link:label id="lab_us-gaap_ProceedsFromDivestitureOfInterestInSubsidiariesAndAffiliates_label_en-US" xlink:label="lab_us-gaap_ProceedsFromDivestitureOfInterestInSubsidiariesAndAffiliates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Divestiture of Interest in Subsidiaries and Affiliates</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromDivestitureOfInterestInSubsidiariesAndAffiliates" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromDivestitureOfInterestInSubsidiariesAndAffiliates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromDivestitureOfInterestInSubsidiariesAndAffiliates" xlink:to="lab_us-gaap_ProceedsFromDivestitureOfInterestInSubsidiariesAndAffiliates" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromEquityMethodInvestments_8f1bc27b-ace3-453a-9f58-01513c61b2b2_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (loss) from equity method investees</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromEquityMethodInvestments_3c174e4c-e60a-444a-8fc6-269059d0e301_negatedLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">(Gain) loss from equity method investees</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromEquityMethodInvestments_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Equity Method Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:to="lab_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_f7bb630b-054e-4530-bb91-f84d4260e98b_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted stock units information</link:label>
    <link:label id="lab_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Restricted Stock and Restricted Stock Unit, Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_ProceedsFromMaturityOfInvestments_38f7d613-9575-4b22-b3fc-b5c12a32f12a_terseLabel_en-US" xlink:label="lab_evh_ProceedsFromMaturityOfInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maturities and sales of investments</link:label>
    <link:label id="lab_evh_ProceedsFromMaturityOfInvestments_label_en-US" xlink:label="lab_evh_ProceedsFromMaturityOfInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds From Maturity Of Investments</link:label>
    <link:label id="lab_evh_ProceedsFromMaturityOfInvestments_documentation_en-US" xlink:label="lab_evh_ProceedsFromMaturityOfInvestments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds From Maturity Of Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_ProceedsFromMaturityOfInvestments" xlink:href="evh-20211231.xsd#evh_ProceedsFromMaturityOfInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_ProceedsFromMaturityOfInvestments" xlink:to="lab_evh_ProceedsFromMaturityOfInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_cd4f65e3-86d8-4f32-b669-70932dfee5e8_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:to="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilityReserveEstimatePolicy_bbfa4f02-def7-476a-92e0-4a743785b611_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilityReserveEstimatePolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reserves for Claims and Performance-based Arrangements</link:label>
    <link:label id="lab_us-gaap_LiabilityReserveEstimatePolicy_label_en-US" xlink:label="lab_us-gaap_LiabilityReserveEstimatePolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability Reserve Estimate, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityReserveEstimatePolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilityReserveEstimatePolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilityReserveEstimatePolicy" xlink:to="lab_us-gaap_LiabilityReserveEstimatePolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringCharges_5547429c-6fc7-4eaa-a673-ca373bf68ceb_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringCharges" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repositioning costs incurred</link:label>
    <link:label id="lab_us-gaap_RestructuringCharges_e79fc467-d1cb-4c58-9e12-978c8cba7ebd_negatedLabel_en-US" xlink:label="lab_us-gaap_RestructuringCharges" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repositioning costs</link:label>
    <link:label id="lab_us-gaap_RestructuringCharges_label_en-US" xlink:label="lab_us-gaap_RestructuringCharges" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Charges</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringCharges"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringCharges" xlink:to="lab_us-gaap_RestructuringCharges" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskByTypeAxis_bfcff780-c81a-477d-b663-f8a583943213_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Axis]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskByTypeAxis_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis" xlink:to="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_AssumedLiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseImpactOfConsolidationOnPayables_6bf9337e-de0b-4b1c-a8eb-34b84e168d49_negatedTerseLabel_en-US" xlink:label="lab_evh_AssumedLiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseImpactOfConsolidationOnPayables" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impact of consolidation on payable for claims and performance-based arrangements attributable to the Reinsurance Agreement</link:label>
    <link:label id="lab_evh_AssumedLiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseImpactOfConsolidationOnPayables_label_en-US" xlink:label="lab_evh_AssumedLiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseImpactOfConsolidationOnPayables" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assumed Liability For Unpaid Claims And Claims Adjustment Expense, Impact Of Consolidation On Payables</link:label>
    <link:label id="lab_evh_AssumedLiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseImpactOfConsolidationOnPayables_documentation_en-US" xlink:label="lab_evh_AssumedLiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseImpactOfConsolidationOnPayables" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assumed Liability For Unpaid Claims And Claims Adjustment Expense, Impact Of Consolidation On Payables</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_AssumedLiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseImpactOfConsolidationOnPayables" xlink:href="evh-20211231.xsd#evh_AssumedLiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseImpactOfConsolidationOnPayables"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_AssumedLiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseImpactOfConsolidationOnPayables" xlink:to="lab_evh_AssumedLiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseImpactOfConsolidationOnPayables" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_b8ef5ce0-405f-4122-8b0f-ea43251c9646_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2024</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_SeniorConvertibleNotesDue2025Member_dcfd3808-c70e-4b12-bd83-9b615978382f_terseLabel_en-US" xlink:label="lab_evh_SeniorConvertibleNotesDue2025Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2025 Notes</link:label>
    <link:label id="lab_evh_SeniorConvertibleNotesDue2025Member_label_en-US" xlink:label="lab_evh_SeniorConvertibleNotesDue2025Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Convertible Notes Due 2025 [Member]</link:label>
    <link:label id="lab_evh_SeniorConvertibleNotesDue2025Member_documentation_en-US" xlink:label="lab_evh_SeniorConvertibleNotesDue2025Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Convertible Notes Due 2025 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_SeniorConvertibleNotesDue2025Member" xlink:href="evh-20211231.xsd#evh_SeniorConvertibleNotesDue2025Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_SeniorConvertibleNotesDue2025Member" xlink:to="lab_evh_SeniorConvertibleNotesDue2025Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationsPolicy_98199ea0-01f3-4743-a76b-ef470a2e690c_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationsPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combinations</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationsPolicy_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationsPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combinations Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationsPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationsPolicy" xlink:to="lab_us-gaap_BusinessCombinationsPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromConvertibleDebt_a1cb7441-1fbc-46e9-8c61-6354c9f8800d_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromConvertibleDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from issuance of long term debt, net of offering costs</link:label>
    <link:label id="lab_us-gaap_ProceedsFromConvertibleDebt_label_en-US" xlink:label="lab_us-gaap_ProceedsFromConvertibleDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Convertible Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromConvertibleDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromConvertibleDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromConvertibleDebt" xlink:to="lab_us-gaap_ProceedsFromConvertibleDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_215031bc-7da0-4296-be84-2cbc21c37719_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Accounts Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestAbstract_8da417f1-d27e-44da-9205-f3b92f9ccef9_terseLabel_en-US" xlink:label="lab_evh_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested and expected to vest after December&#160;31, 2021</link:label>
    <link:label id="lab_evh_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestAbstract_label_en-US" xlink:label="lab_evh_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement By Share-based Payment Award, Equity Instruments Other Than Options, Vested And Expected To Vest [Abstract]</link:label>
    <link:label id="lab_evh_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestAbstract_documentation_en-US" xlink:label="lab_evh_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement By Share-based Payment Award, Equity Instruments Other Than Options, Vested And Expected To Vest [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestAbstract" xlink:href="evh-20211231.xsd#evh_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestAbstract" xlink:to="lab_evh_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenuesAbstract_a384a313-e500-4ca3-aac7-46b9ecc031be_terseLabel_en-US" xlink:label="lab_us-gaap_RevenuesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue</link:label>
    <link:label id="lab_us-gaap_RevenuesAbstract_label_en-US" xlink:label="lab_us-gaap_RevenuesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenuesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenuesAbstract" xlink:to="lab_us-gaap_RevenuesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesNetAbstract_12795045-6063-4a9f-a6ef-c470319871b6_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesNetAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesNetAbstract_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesNetAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Net [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesNetAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilitiesNetAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesNetAbstract" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesNetAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestNumber_ce263e45-c1c4-43b0-9880-83af42e95a40_terseLabel_en-US" xlink:label="lab_evh_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leveraged Stock Units (in shares)</link:label>
    <link:label id="lab_evh_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestNumber_61dbdd6b-f8d9-489e-88d9-865940f60cad_verboseLabel_en-US" xlink:label="lab_evh_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestNumber" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance Based Stock Units (in shares)</link:label>
    <link:label id="lab_evh_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestNumber_label_en-US" xlink:label="lab_evh_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement By Share-based Payment Award, Equity Instruments Other Than Options, Vested And Expected To Vest, Number</link:label>
    <link:label id="lab_evh_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestNumber_documentation_en-US" xlink:label="lab_evh_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestNumber" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement By Share-based Payment Award, Equity Instruments Other Than Options, Vested And Expected To Vest, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestNumber" xlink:href="evh-20211231.xsd#evh_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestNumber" xlink:to="lab_evh_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_0aec5dc6-32b5-4e44-8fb7-36b9a36b3b44_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets, Goodwill, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_891dd66a-adae-4386-baba-084fc6f7326f_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NumberOfReportingUnits_3b1da376-7d53-4448-80bf-d5e09051f498_terseLabel_en-US" xlink:label="lab_us-gaap_NumberOfReportingUnits" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of reporting units for goodwill testing</link:label>
    <link:label id="lab_us-gaap_NumberOfReportingUnits_label_en-US" xlink:label="lab_us-gaap_NumberOfReportingUnits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Reporting Units</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfReportingUnits" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NumberOfReportingUnits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfReportingUnits" xlink:to="lab_us-gaap_NumberOfReportingUnits" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_PlatformsAndOperationsServicesMember_8f6e625c-37d5-4b0b-888a-5fa367956c59_verboseLabel_en-US" xlink:label="lab_evh_PlatformsAndOperationsServicesMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Platform and operations services</link:label>
    <link:label id="lab_evh_PlatformsAndOperationsServicesMember_label_en-US" xlink:label="lab_evh_PlatformsAndOperationsServicesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Platforms And Operations Services [Member]</link:label>
    <link:label id="lab_evh_PlatformsAndOperationsServicesMember_documentation_en-US" xlink:label="lab_evh_PlatformsAndOperationsServicesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Platforms And Operations Services [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_PlatformsAndOperationsServicesMember" xlink:href="evh-20211231.xsd#evh_PlatformsAndOperationsServicesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_PlatformsAndOperationsServicesMember" xlink:to="lab_evh_PlatformsAndOperationsServicesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskBenchmarkDomain_b2a668fb-683a-4a7e-a00a-7b19314fe475_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Domain]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskBenchmarkDomain_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock_04a7faa8-6002-4064-91a1-e3a5478fc20f_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unaudited consolidated quarterly results of operations</link:label>
    <link:label id="lab_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Quarterly Financial Information [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_6bac4f91-bc60-4b8f-beba-6d7360f4a5bd_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ConsolidatedEntitiesDomain_b6012066-bd9f-4b7f-8f70-e39594b22731_terseLabel_en-US" xlink:label="lab_srt_ConsolidatedEntitiesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidated Entities [Domain]</link:label>
    <link:label id="lab_srt_ConsolidatedEntitiesDomain_label_en-US" xlink:label="lab_srt_ConsolidatedEntitiesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidated Entities [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ConsolidatedEntitiesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ConsolidatedEntitiesDomain" xlink:to="lab_srt_ConsolidatedEntitiesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_e1f7757d-87b9-4f7a-8d95-4da05a3bd228_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.S. state income taxes, net of U.S. federal tax benefit</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_696afc6b-22d8-4052-a1bf-04a8fd5610c4_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State and local</link:label>
    <link:label id="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred State and Local Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_de4f65c5-4fff-49e3-9e93-a625130ca5a3_verboseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of property and equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_8b6c419b-ee8d-4924-a308-b60eec23a049_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Federal and state research tax credits</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Tax Credit Carryforwards, Research</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_17b3c06b-27c5-40fc-8a5f-adffc83d1434_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationDomain" xlink:to="lab_us-gaap_IncomeStatementLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentTerm_76a9d6bc-8fd6-445c-8ed5-69567fff683d_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentTerm_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTerm" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentTerm" xlink:to="lab_us-gaap_DebtInstrumentTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_3f6bf207-6170-454a-9bee-c7d0a7f202db_terseLabel_en-US" xlink:label="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Disclosure of Non-cash Investing and Financing Activities</link:label>
    <link:label id="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MovementInMinorityInterestRollForward_42dafaef-146f-4f7c-ad3a-ef003bae06e3_terseLabel_en-US" xlink:label="lab_us-gaap_MovementInMinorityInterestRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Noncontrolling Interest [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_MovementInMinorityInterestRollForward_label_en-US" xlink:label="lab_us-gaap_MovementInMinorityInterestRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Noncontrolling Interest [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MovementInMinorityInterestRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MovementInMinorityInterestRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MovementInMinorityInterestRollForward" xlink:to="lab_us-gaap_MovementInMinorityInterestRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_775af2f7-5400-422e-b635-76a4a6db5601_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_ddc630b7-64eb-4607-b486-358a879fe9cb_totalLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total property and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpenses_6466e9b2-3c3c-4b0e-b078-f56e093dfd07_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total operating expenses</link:label>
    <link:label id="lab_us-gaap_OperatingExpenses_d813ac7b-3a96-4dac-8e9c-dccb2edaf3f1_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total operating expenses</link:label>
    <link:label id="lab_us-gaap_OperatingExpenses_label_en-US" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpenses" xlink:to="lab_us-gaap_OperatingExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember_60023ebc-62e5-4538-ab84-eaf3a99d70d9_terseLabel_en-US" xlink:label="lab_us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss)</link:label>
    <link:label id="lab_us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember_label_en-US" xlink:label="lab_us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI Including Portion Attributable to Noncontrolling Interest [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember" xlink:to="lab_us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_IncreaseDecreaseInInsuranceAndPerformanceBasedArrangementsLiabilities_c3a2a418-e45b-424a-b668-1924d16da91c_terseLabel_en-US" xlink:label="lab_evh_IncreaseDecreaseInInsuranceAndPerformanceBasedArrangementsLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reserve for claims and performance-based arrangements</link:label>
    <link:label id="lab_evh_IncreaseDecreaseInInsuranceAndPerformanceBasedArrangementsLiabilities_label_en-US" xlink:label="lab_evh_IncreaseDecreaseInInsuranceAndPerformanceBasedArrangementsLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) In Insurance And Performance-Based Arrangements Liabilities</link:label>
    <link:label id="lab_evh_IncreaseDecreaseInInsuranceAndPerformanceBasedArrangementsLiabilities_documentation_en-US" xlink:label="lab_evh_IncreaseDecreaseInInsuranceAndPerformanceBasedArrangementsLiabilities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) In Insurance And Performance-Based Arrangements Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_IncreaseDecreaseInInsuranceAndPerformanceBasedArrangementsLiabilities" xlink:href="evh-20211231.xsd#evh_IncreaseDecreaseInInsuranceAndPerformanceBasedArrangementsLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_IncreaseDecreaseInInsuranceAndPerformanceBasedArrangementsLiabilities" xlink:to="lab_evh_IncreaseDecreaseInInsuranceAndPerformanceBasedArrangementsLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_PaymentsToAcquireEquityMethodInvestmentsAmountHeldBack_76141b52-fd65-4a5c-94c1-ce348dd37945_terseLabel_en-US" xlink:label="lab_evh_PaymentsToAcquireEquityMethodInvestmentsAmountHeldBack" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to acquire equity method investments, amount held back</link:label>
    <link:label id="lab_evh_PaymentsToAcquireEquityMethodInvestmentsAmountHeldBack_label_en-US" xlink:label="lab_evh_PaymentsToAcquireEquityMethodInvestmentsAmountHeldBack" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments To Acquire Equity Method Investments, Amount Held Back</link:label>
    <link:label id="lab_evh_PaymentsToAcquireEquityMethodInvestmentsAmountHeldBack_documentation_en-US" xlink:label="lab_evh_PaymentsToAcquireEquityMethodInvestmentsAmountHeldBack" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments To Acquire Equity Method Investments, Amount Held Back</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_PaymentsToAcquireEquityMethodInvestmentsAmountHeldBack" xlink:href="evh-20211231.xsd#evh_PaymentsToAcquireEquityMethodInvestmentsAmountHeldBack"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_PaymentsToAcquireEquityMethodInvestmentsAmountHeldBack" xlink:to="lab_evh_PaymentsToAcquireEquityMethodInvestmentsAmountHeldBack" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_12b362b3-b3d2-43cf-ae29-04b5200cec37_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of future estimated amortization of intangible assets</link:label>
    <link:label id="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:to="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_063688b9-4194-4b36-8912-ad9196b7f19e_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareAbstract" xlink:to="lab_us-gaap_EarningsPerShareAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_DisposalGroupIncludingDiscontinuedOperationInvestmentsCurrent_cf000064-5d91-4c67-ae2f-eed2a38d72ab_terseLabel_en-US" xlink:label="lab_evh_DisposalGroupIncludingDiscontinuedOperationInvestmentsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments, at amortized cost</link:label>
    <link:label id="lab_evh_DisposalGroupIncludingDiscontinuedOperationInvestmentsCurrent_label_en-US" xlink:label="lab_evh_DisposalGroupIncludingDiscontinuedOperationInvestmentsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Investments, Current</link:label>
    <link:label id="lab_evh_DisposalGroupIncludingDiscontinuedOperationInvestmentsCurrent_documentation_en-US" xlink:label="lab_evh_DisposalGroupIncludingDiscontinuedOperationInvestmentsCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Investments, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_DisposalGroupIncludingDiscontinuedOperationInvestmentsCurrent" xlink:href="evh-20211231.xsd#evh_DisposalGroupIncludingDiscontinuedOperationInvestmentsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_DisposalGroupIncludingDiscontinuedOperationInvestmentsCurrent" xlink:to="lab_evh_DisposalGroupIncludingDiscontinuedOperationInvestmentsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityMethodInvesteeMember_15d6cf50-ad31-4285-903b-e1a676504df8_terseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvesteeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investee</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvesteeMember_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvesteeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investee [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvesteeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvesteeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvesteeMember" xlink:to="lab_us-gaap_EquityMethodInvesteeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_27aef294-80f2-4f3c-9d1c-9c516c31757b_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total property and equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MinorityInterestTable_7268c325-2206-4ab4-94b8-28ebc455575e_terseLabel_en-US" xlink:label="lab_us-gaap_MinorityInterestTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest [Table]</link:label>
    <link:label id="lab_us-gaap_MinorityInterestTable_label_en-US" xlink:label="lab_us-gaap_MinorityInterestTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MinorityInterestTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinorityInterestTable" xlink:to="lab_us-gaap_MinorityInterestTable" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_DebtInstrumentRedemptionCallProtectionPremiumPercentage_4d62b5b0-22c3-4047-9f5f-1b9e98817da9_terseLabel_en-US" xlink:label="lab_evh_DebtInstrumentRedemptionCallProtectionPremiumPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Redemption, call protection premium, percentage</link:label>
    <link:label id="lab_evh_DebtInstrumentRedemptionCallProtectionPremiumPercentage_label_en-US" xlink:label="lab_evh_DebtInstrumentRedemptionCallProtectionPremiumPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Redemption, Call Protection Premium, Percentage</link:label>
    <link:label id="lab_evh_DebtInstrumentRedemptionCallProtectionPremiumPercentage_documentation_en-US" xlink:label="lab_evh_DebtInstrumentRedemptionCallProtectionPremiumPercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Redemption, Call Protection Premium, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_DebtInstrumentRedemptionCallProtectionPremiumPercentage" xlink:href="evh-20211231.xsd#evh_DebtInstrumentRedemptionCallProtectionPremiumPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_DebtInstrumentRedemptionCallProtectionPremiumPercentage" xlink:to="lab_evh_DebtInstrumentRedemptionCallProtectionPremiumPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Revenues_0b13aaf2-775a-439e-977b-907e58ce5aa6_terseLabel_en-US" xlink:label="lab_us-gaap_Revenues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total revenue</link:label>
    <link:label id="lab_us-gaap_Revenues_6f75b043-1385-4a09-93f2-ae6c1af39f2a_netLabel_en-US" xlink:label="lab_us-gaap_Revenues" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues</link:label>
    <link:label id="lab_us-gaap_Revenues_label_en-US" xlink:label="lab_us-gaap_Revenues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Revenues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Revenues" xlink:to="lab_us-gaap_Revenues" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligationPercentage_9339169d-c137-404a-b464-ebde9913bd2d_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligationPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, remaining performance obligation, percentage</link:label>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligationPercentage_label_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligationPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Remaining Performance Obligation, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligationPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationPercentage" xlink:to="lab_us-gaap_RevenueRemainingPerformanceObligationPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BankTimeDepositsMember_98d7f3c5-b669-463e-82d3-545b07f4654d_terseLabel_en-US" xlink:label="lab_us-gaap_BankTimeDepositsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Bank time deposits</link:label>
    <link:label id="lab_us-gaap_BankTimeDepositsMember_label_en-US" xlink:label="lab_us-gaap_BankTimeDepositsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Bank Time Deposits [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BankTimeDepositsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BankTimeDepositsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BankTimeDepositsMember" xlink:to="lab_us-gaap_BankTimeDepositsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesFairValueDisclosure_86425681-987b-430e-89e9-6ee696b8f421_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesFairValueDisclosure_e4be1965-5050-459b-ae9a-c7cfead33c13_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesFairValueDisclosure" xlink:to="lab_us-gaap_OtherLiabilitiesFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare_ee68afd4-28ad-4dde-af93-c65faf8cb9c2_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discontinued operations, basic (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Discontinued Operations and Disposal of Discontinued Operations, Net of Tax, Per Basic Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" xlink:to="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_092e3ae8-3878-4e24-bf5b-6dd2a49c6171_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding at the beginning of the period (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_e30c9812-37af-484d-8885-4af8a6691228_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding at the end of the period (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_b85dceaf-023d-4d51-b259-9021c1408741_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Exercise Price, outstanding at the end of the period (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_AssetAcquisitionAccruedMedicalExpenses_7ec677c3-8dda-47bc-91ba-d3d1e19a3af0_terseLabel_en-US" xlink:label="lab_evh_AssetAcquisitionAccruedMedicalExpenses" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued medical expenses</link:label>
    <link:label id="lab_evh_AssetAcquisitionAccruedMedicalExpenses_label_en-US" xlink:label="lab_evh_AssetAcquisitionAccruedMedicalExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Acquisition, Accrued Medical Expenses</link:label>
    <link:label id="lab_evh_AssetAcquisitionAccruedMedicalExpenses_documentation_en-US" xlink:label="lab_evh_AssetAcquisitionAccruedMedicalExpenses" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Acquisition, Accrued Medical Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_AssetAcquisitionAccruedMedicalExpenses" xlink:href="evh-20211231.xsd#evh_AssetAcquisitionAccruedMedicalExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_AssetAcquisitionAccruedMedicalExpenses" xlink:to="lab_evh_AssetAcquisitionAccruedMedicalExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetAcquisitionDomain_9479577e-01af-4083-9059-0c829b46c71e_terseLabel_en-US" xlink:label="lab_us-gaap_AssetAcquisitionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Acquisition [Domain]</link:label>
    <link:label id="lab_us-gaap_AssetAcquisitionDomain_label_en-US" xlink:label="lab_us-gaap_AssetAcquisitionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Acquisition [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetAcquisitionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetAcquisitionDomain" xlink:to="lab_us-gaap_AssetAcquisitionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_38ec91ec-96cc-4e5f-ad10-7b72512e3266_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Related Party Transactions, by Related Party [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Related Party Transactions, by Related Party [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_30a5ae34-d2a2-415e-833e-3ac317e0547c_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Equity Method Investments [Line Items]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Equity Method Investments [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:to="lab_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCurrentReportingStatus_db7c3c75-08dd-4289-9972-4f33bb27290f_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCurrentReportingStatus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_f447fec2-7598-46f7-8457-bfb751fdc44a_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-Average Grant-Date Fair Value</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentLiabilities_d34bdc9c-dfa4-47a3-91b3-6f86db6e0e4c_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other long-term liabilities</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentLiabilities_label_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Other Liabilities, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentLiabilities" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_43af46ef-ab35-429d-b25a-b32e7262d4cb_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective rate</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_14046095-92f3-4511-917b-f497cd5b0817_totalLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective tax rate</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableNoncurrentPastDueTable_ce2fd697-50f7-46ab-a992-8983996c890f_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableNoncurrentPastDueTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, Noncurrent, Past Due [Table]</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableNoncurrentPastDueTable_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableNoncurrentPastDueTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, Noncurrent, Past Due [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNoncurrentPastDueTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNoncurrentPastDueTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableNoncurrentPastDueTable" xlink:to="lab_us-gaap_AccountsReceivableNoncurrentPastDueTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AmortizationOfFinancingCosts_05a2bdab-44aa-4fc8-a853-bebac1e672ec_terseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfFinancingCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of deferred financing costs</link:label>
    <link:label id="lab_us-gaap_AmortizationOfFinancingCosts_ec4202b3-621a-4bea-89c1-8868febc5224_verboseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfFinancingCosts" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of deferred financing costs</link:label>
    <link:label id="lab_us-gaap_AmortizationOfFinancingCosts_label_en-US" xlink:label="lab_us-gaap_AmortizationOfFinancingCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of Debt Issuance Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfFinancingCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfFinancingCosts" xlink:to="lab_us-gaap_AmortizationOfFinancingCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CounterpartyNameAxis_9022b984-b476-4646-a043-ecb57b0afa5c_terseLabel_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:label id="lab_srt_CounterpartyNameAxis_label_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CounterpartyNameAxis" xlink:to="lab_srt_CounterpartyNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightAxis_ce39adcc-ee4b-4723-9012-30ecc2852bbc_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right [Axis]</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightAxis_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis" xlink:to="lab_us-gaap_ClassOfWarrantOrRightAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerAssetNetCurrent_92ace67d-d895-4f06-8f18-6ce64afa46c6_verboseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetNetCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term contract assets</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerAssetNetCurrent_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetNetCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Asset, after Allowance for Credit Loss, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerAssetNetCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerAssetNetCurrent" xlink:to="lab_us-gaap_ContractWithCustomerAssetNetCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharesIssued_2acd7b19-d68a-44fa-b69f-dd786d018c15_periodStartLabel_en-US" xlink:label="lab_us-gaap_SharesIssued" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_SharesIssued_8ae27e6e-277f-45d4-aaee-d799ca96e6cf_periodEndLabel_en-US" xlink:label="lab_us-gaap_SharesIssued" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_SharesIssued_label_en-US" xlink:label="lab_us-gaap_SharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesIssued" xlink:to="lab_us-gaap_SharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardNameDomain_94bdcf4e-b6d2-4ea4-b8c0-3aceacecb5c5_terseLabel_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Credit Carryforward, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardNameDomain_label_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Credit Carryforward, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxCreditCarryforwardNameDomain" xlink:to="lab_us-gaap_TaxCreditCarryforwardNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputDiscountRateMember_9e73b723-44ff-4cfc-b260-45e05895b22f_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputDiscountRateMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discount rate</link:label>
    <link:label id="lab_us-gaap_MeasurementInputDiscountRateMember_label_en-US" xlink:label="lab_us-gaap_MeasurementInputDiscountRateMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input, Discount Rate [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputDiscountRateMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputDiscountRateMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputDiscountRateMember" xlink:to="lab_us-gaap_MeasurementInputDiscountRateMember" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_EffectiveIncomeTaxRateReconciliationBenefitOfNetOperatingLossCarrybackProvisionPercent_02c0d500-0f00-4c46-bcea-50ddcd0e1aed_terseLabel_en-US" xlink:label="lab_evh_EffectiveIncomeTaxRateReconciliationBenefitOfNetOperatingLossCarrybackProvisionPercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Benefit of net operating loss carryback provision</link:label>
    <link:label id="lab_evh_EffectiveIncomeTaxRateReconciliationBenefitOfNetOperatingLossCarrybackProvisionPercent_label_en-US" xlink:label="lab_evh_EffectiveIncomeTaxRateReconciliationBenefitOfNetOperatingLossCarrybackProvisionPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Benefit Of Net Operating Loss Carryback Provision, Percent</link:label>
    <link:label id="lab_evh_EffectiveIncomeTaxRateReconciliationBenefitOfNetOperatingLossCarrybackProvisionPercent_documentation_en-US" xlink:label="lab_evh_EffectiveIncomeTaxRateReconciliationBenefitOfNetOperatingLossCarrybackProvisionPercent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Benefit Of Net Operating Loss Carryback Provision, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_EffectiveIncomeTaxRateReconciliationBenefitOfNetOperatingLossCarrybackProvisionPercent" xlink:href="evh-20211231.xsd#evh_EffectiveIncomeTaxRateReconciliationBenefitOfNetOperatingLossCarrybackProvisionPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_EffectiveIncomeTaxRateReconciliationBenefitOfNetOperatingLossCarrybackProvisionPercent" xlink:to="lab_evh_EffectiveIncomeTaxRateReconciliationBenefitOfNetOperatingLossCarrybackProvisionPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsNoncurrent_aa6f450a-fb0a-46b5-9b20-45acf1c14893_terseLabel_en-US" xlink:label="lab_evh_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other noncurrent assets</link:label>
    <link:label id="lab_evh_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsNoncurrent_label_en-US" xlink:label="lab_evh_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Prepaid And Other Assets, Noncurrent</link:label>
    <link:label id="lab_evh_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsNoncurrent_documentation_en-US" xlink:label="lab_evh_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Prepaid And Other Assets, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsNoncurrent" xlink:href="evh-20211231.xsd#evh_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsNoncurrent" xlink:to="lab_evh_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_2727cfbf-09f5-4e28-a2ee-935f79ae0c5d_terseLabel_en-US" xlink:label="lab_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of major customers</link:label>
    <link:label id="lab_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_label_en-US" xlink:label="lab_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedules of Concentration of Risk, by Risk Factor [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:to="lab_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPeriodOneMember_48677834-4ef8-49d9-8267-0409a06d448b_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPeriodOneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">After the Second Anniversary of the Closing of the Senior Credit Facilities but Prior to the Third Anniversary</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPeriodOneMember_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPeriodOneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Redemption, Period One [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodOneMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodOneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodOneMember" xlink:to="lab_us-gaap_DebtInstrumentRedemptionPeriodOneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeasesAbstract_ed706dc0-2f8d-4b45-964d-5e06a99330ee_terseLabel_en-US" xlink:label="lab_us-gaap_LeasesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases [Abstract]</link:label>
    <link:label id="lab_us-gaap_LeasesAbstract_label_en-US" xlink:label="lab_us-gaap_LeasesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeasesAbstract" xlink:to="lab_us-gaap_LeasesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents_9b979c12-ec18-4912-b3b3-b394789d381e_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents_label_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Cash and Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxPolicyTextBlock_2e62b54e-fe6d-4c21-82e8-b58e2301122c_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxPolicyTextBlock" xlink:to="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense_30b4ed99-a416-4dd7-a6ff-199375440a92_periodStartLabel_en-US" xlink:label="lab_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense_82ace647-89c4-42d9-9081-38db34bec60a_periodEndLabel_en-US" xlink:label="lab_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense_label_en-US" xlink:label="lab_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability for Claims and Claims Adjustment Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense" xlink:to="lab_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_SharebasedCompensationArrangementbySharebasedPaymentAwardAwardVestingRightsSharePriceThreshold_24ec0489-de8c-4a6f-8663-68c2d463f38f_terseLabel_en-US" xlink:label="lab_evh_SharebasedCompensationArrangementbySharebasedPaymentAwardAwardVestingRightsSharePriceThreshold" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award vesting rights, share price threshold (in dollars per share)</link:label>
    <link:label id="lab_evh_SharebasedCompensationArrangementbySharebasedPaymentAwardAwardVestingRightsSharePriceThreshold_label_en-US" xlink:label="lab_evh_SharebasedCompensationArrangementbySharebasedPaymentAwardAwardVestingRightsSharePriceThreshold" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Share Price Threshold</link:label>
    <link:label id="lab_evh_SharebasedCompensationArrangementbySharebasedPaymentAwardAwardVestingRightsSharePriceThreshold_documentation_en-US" xlink:label="lab_evh_SharebasedCompensationArrangementbySharebasedPaymentAwardAwardVestingRightsSharePriceThreshold" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Share Price Threshold</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_SharebasedCompensationArrangementbySharebasedPaymentAwardAwardVestingRightsSharePriceThreshold" xlink:href="evh-20211231.xsd#evh_SharebasedCompensationArrangementbySharebasedPaymentAwardAwardVestingRightsSharePriceThreshold"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_SharebasedCompensationArrangementbySharebasedPaymentAwardAwardVestingRightsSharePriceThreshold" xlink:to="lab_evh_SharebasedCompensationArrangementbySharebasedPaymentAwardAwardVestingRightsSharePriceThreshold" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupClassificationDomain_40cb6ecc-f25b-448d-aaa8-099943c58187_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupClassificationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group Classification [Domain]</link:label>
    <link:label id="lab_us-gaap_DisposalGroupClassificationDomain_label_en-US" xlink:label="lab_us-gaap_DisposalGroupClassificationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group Classification [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain" xlink:to="lab_us-gaap_DisposalGroupClassificationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_1a01ca1e-2d19-4c2b-be26-62f7597ab24c_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_daef9513-a115-448e-9969-305609196efe_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Recognition and Cost of Revenue (Exclusive of Depreciation and Amortization)</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_8045b5ea-54e7-426d-80b3-3a4bdcbf2913_verboseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Diluted (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_188c2809-995d-4a75-ab5c-0b2d28c8ecb3_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average common shares outstanding - diluted (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_40f9cab6-108c-4fd1-b0c1-946f2296ac98_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Domestic</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Domestic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtConversionOriginalDebtAmount1_f206808c-e985-4f2a-86ec-264ff5b71ea0_terseLabel_en-US" xlink:label="lab_us-gaap_DebtConversionOriginalDebtAmount1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt conversion, original debt, amount</link:label>
    <link:label id="lab_us-gaap_DebtConversionOriginalDebtAmount1_label_en-US" xlink:label="lab_us-gaap_DebtConversionOriginalDebtAmount1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Conversion, Original Debt, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtConversionOriginalDebtAmount1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtConversionOriginalDebtAmount1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtConversionOriginalDebtAmount1" xlink:to="lab_us-gaap_DebtConversionOriginalDebtAmount1" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_DeferredTaxAssetOutsideBasisDifferences_fce43f38-2a08-4ec7-af2f-c2611f034e73_terseLabel_en-US" xlink:label="lab_evh_DeferredTaxAssetOutsideBasisDifferences" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outside basis differences</link:label>
    <link:label id="lab_evh_DeferredTaxAssetOutsideBasisDifferences_label_en-US" xlink:label="lab_evh_DeferredTaxAssetOutsideBasisDifferences" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Asset, Outside Basis Differences</link:label>
    <link:label id="lab_evh_DeferredTaxAssetOutsideBasisDifferences_documentation_en-US" xlink:label="lab_evh_DeferredTaxAssetOutsideBasisDifferences" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Asset, Outside Basis Differences</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_DeferredTaxAssetOutsideBasisDifferences" xlink:href="evh-20211231.xsd#evh_DeferredTaxAssetOutsideBasisDifferences"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_DeferredTaxAssetOutsideBasisDifferences" xlink:to="lab_evh_DeferredTaxAssetOutsideBasisDifferences" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsNoncurrent_173e0154-8427-44c2-bf5f-07bde63647b0_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible assets, net</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsNoncurrent_label_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Intangible Assets, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsNoncurrent" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_EarningsPerSharePortionAttributableToNoncontrollingInterestBasic_7e1702a7-1f79-4bea-9563-aaed26d4e172_terseLabel_en-US" xlink:label="lab_evh_EarningsPerSharePortionAttributableToNoncontrollingInterestBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-controlling interests, basic (in dollars per share)</link:label>
    <link:label id="lab_evh_EarningsPerSharePortionAttributableToNoncontrollingInterestBasic_label_en-US" xlink:label="lab_evh_EarningsPerSharePortionAttributableToNoncontrollingInterestBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Portion Attributable to Noncontrolling Interest, Basic</link:label>
    <link:label id="lab_evh_EarningsPerSharePortionAttributableToNoncontrollingInterestBasic_documentation_en-US" xlink:label="lab_evh_EarningsPerSharePortionAttributableToNoncontrollingInterestBasic" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Portion Attributable to Noncontrolling Interest, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_EarningsPerSharePortionAttributableToNoncontrollingInterestBasic" xlink:href="evh-20211231.xsd#evh_EarningsPerSharePortionAttributableToNoncontrollingInterestBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_EarningsPerSharePortionAttributableToNoncontrollingInterestBasic" xlink:to="lab_evh_EarningsPerSharePortionAttributableToNoncontrollingInterestBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromCollectionOfNotesReceivable_8b333375-7501-45cf-b59f-33b00ca86918_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromCollectionOfNotesReceivable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from collection of notes receivable</link:label>
    <link:label id="lab_us-gaap_ProceedsFromCollectionOfNotesReceivable_label_en-US" xlink:label="lab_us-gaap_ProceedsFromCollectionOfNotesReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Collection of Notes Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromCollectionOfNotesReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromCollectionOfNotesReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromCollectionOfNotesReceivable" xlink:to="lab_us-gaap_ProceedsFromCollectionOfNotesReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_GainLossFromTransferOfMembership_006c13c5-a53a-4a73-8776-0edfa7997d5e_negatedTerseLabel_en-US" xlink:label="lab_evh_GainLossFromTransferOfMembership" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain from transfer of membership</link:label>
    <link:label id="lab_evh_GainLossFromTransferOfMembership_label_en-US" xlink:label="lab_evh_GainLossFromTransferOfMembership" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) from Transfer of Membership</link:label>
    <link:label id="lab_evh_GainLossFromTransferOfMembership_documentation_en-US" xlink:label="lab_evh_GainLossFromTransferOfMembership" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) from Transfer of Membership</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_GainLossFromTransferOfMembership" xlink:href="evh-20211231.xsd#evh_GainLossFromTransferOfMembership"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_GainLossFromTransferOfMembership" xlink:to="lab_evh_GainLossFromTransferOfMembership" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_da7368cc-5c32-403c-89cd-b600142ae85d_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent_e55327d5-f7ca-4403-90a8-c9a5928ddeed_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-current liabilities from discontinued operations</link:label>
    <link:label id="lab_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Liabilities, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent" xlink:to="lab_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_PurchaseAccountingAdjustments_f4d6969f-6c64-4a0a-bd51-8b814a48510e_negatedTerseLabel_en-US" xlink:label="lab_evh_PurchaseAccountingAdjustments" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase accounting adjustments</link:label>
    <link:label id="lab_evh_PurchaseAccountingAdjustments_label_en-US" xlink:label="lab_evh_PurchaseAccountingAdjustments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase Accounting Adjustments</link:label>
    <link:label id="lab_evh_PurchaseAccountingAdjustments_documentation_en-US" xlink:label="lab_evh_PurchaseAccountingAdjustments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase Accounting Adjustments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_PurchaseAccountingAdjustments" xlink:href="evh-20211231.xsd#evh_PurchaseAccountingAdjustments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_PurchaseAccountingAdjustments" xlink:to="lab_evh_PurchaseAccountingAdjustments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyDomain_146abd45-5315-42c9-bd01-2fb03c44ea22_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party [Domain]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyDomain_label_en-US" xlink:label="lab_us-gaap_RelatedPartyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyDomain" xlink:to="lab_us-gaap_RelatedPartyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_b69cea73-4dae-4fee-b80a-10faf33a1cd3_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeAxis" xlink:to="lab_us-gaap_LongtermDebtTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_a93a53d7-568d-4636-92a6-68804f4e364e_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock option information</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Option, Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_a8650763-f643-475f-b946-a89bc3067cbb_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis spread on variable rate</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Basis Spread on Variable Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:to="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable_3b4aefb2-613f-432d-91f8-fe92acd95d9c_terseLabel_en-US" xlink:label="lab_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of Revenue from Segments to Consolidated [Table]</link:label>
    <link:label id="lab_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable_label_en-US" xlink:label="lab_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of Revenue from Segments to Consolidated [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable" xlink:to="lab_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_RightOfUseAssetAcquiredAndDisposedOf_7801dc13-ac95-423e-b392-f99bc0efb077_negatedTerseLabel_en-US" xlink:label="lab_evh_RightOfUseAssetAcquiredAndDisposedOf" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leased assets obtained in exchange for operating lease liabilities</link:label>
    <link:label id="lab_evh_RightOfUseAssetAcquiredAndDisposedOf_label_en-US" xlink:label="lab_evh_RightOfUseAssetAcquiredAndDisposedOf" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-Of-Use Asset Acquired And Disposed Of</link:label>
    <link:label id="lab_evh_RightOfUseAssetAcquiredAndDisposedOf_documentation_en-US" xlink:label="lab_evh_RightOfUseAssetAcquiredAndDisposedOf" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-Of-Use Asset Acquired And Disposed Of</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_RightOfUseAssetAcquiredAndDisposedOf" xlink:href="evh-20211231.xsd#evh_RightOfUseAssetAcquiredAndDisposedOf"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_RightOfUseAssetAcquiredAndDisposedOf" xlink:to="lab_evh_RightOfUseAssetAcquiredAndDisposedOf" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt_ed6fab22-c114-4a48-a8d0-a99cebae543d_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity component of 2024 notes, net of issuance costs</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Additional Paid in Capital, Equity Component of Convertible Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_3e2795cc-b2b5-491f-81a9-3f8e8a75f208_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCapitalLeaseObligation_118744ad-4158-46bc-979e-c7e42687ae28_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCapitalLeaseObligation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCapitalLeaseObligation_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCapitalLeaseObligation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Asset Acquired and Liability Assumed, Lease Obligation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCapitalLeaseObligation" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCapitalLeaseObligation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCapitalLeaseObligation" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCapitalLeaseObligation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_83d68989-a49e-4162-bdc0-2f9a4037818e_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercisable at the end of the period (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfStockLineItems_60f8fdde-292e-4e9d-9f8e-edfbd657b488_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockLineItems_label_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockLineItems" xlink:to="lab_us-gaap_ClassOfStockLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CreditFacilityAxis_baa3deca-ddf3-467c-a7ae-59ecb1117f4b_terseLabel_en-US" xlink:label="lab_us-gaap_CreditFacilityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Axis]</link:label>
    <link:label id="lab_us-gaap_CreditFacilityAxis_label_en-US" xlink:label="lab_us-gaap_CreditFacilityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CreditFacilityAxis" xlink:to="lab_us-gaap_CreditFacilityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_944e14f0-ee7f-40d3-8a99-9be0ed0457de_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_d7c44a52-cdd3-42d8-a695-e42f496684cf_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine2_74583646-f6f4-45be-8625-6c7e06d30142_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line Two</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine2_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine2" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine2" xlink:to="lab_dei_EntityAddressAddressLine2" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_fce74e18-e0b0-4558-a4a3-d3adb5f8edb4_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated depreciation and amortization expenses</link:label>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_9d25e7b4-19cb-4d1f-a808-a5443f009d4f_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Flows Provided by (Used In) Operating Activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityShellCompany_b12490e0-2b36-4f5d-af58-f9eca4a4669e_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_label_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityShellCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany" xlink:to="lab_dei_EntityShellCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_bb2d4272-0353-4fb5-94be-e98075e005a1_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected term (in years)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_7b82c709-35d7-4c18-8f52-94750b143038_verboseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected term</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_9c1da4b0-f22e-4c84-9acd-a9d5156d6ee0_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_2fe839ea-093a-4e05-bc34-df7f5fdba112_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Taxes withheld and paid for vesting of restricted stock units</link:label>
    <link:label id="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment, Tax Withholding, Share-based Payment Arrangement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:to="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IntersegmentEliminationMember_4a0e3f45-095e-4dfb-982d-209fa1e761eb_terseLabel_en-US" xlink:label="lab_us-gaap_IntersegmentEliminationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intersegment Eliminations</link:label>
    <link:label id="lab_us-gaap_IntersegmentEliminationMember_label_en-US" xlink:label="lab_us-gaap_IntersegmentEliminationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intersegment Eliminations [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntersegmentEliminationMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntersegmentEliminationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntersegmentEliminationMember" xlink:to="lab_us-gaap_IntersegmentEliminationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationInterestExpense_c6693a94-ebb6-431e-9d03-5c9e32b019bf_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationInterestExpense" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest expense</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationInterestExpense_label_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationInterestExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Interest Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationInterestExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationInterestExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationInterestExpense" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationInterestExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableInterestEntityFinancialOrOtherSupportAmount_648f2443-9fef-41ce-ab5c-8f666de9f307_terseLabel_en-US" xlink:label="lab_us-gaap_VariableInterestEntityFinancialOrOtherSupportAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance bond amount</link:label>
    <link:label id="lab_us-gaap_VariableInterestEntityFinancialOrOtherSupportAmount_label_en-US" xlink:label="lab_us-gaap_VariableInterestEntityFinancialOrOtherSupportAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Interest Entity, Financial or Other Support, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableInterestEntityFinancialOrOtherSupportAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableInterestEntityFinancialOrOtherSupportAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableInterestEntityFinancialOrOtherSupportAmount" xlink:to="lab_us-gaap_VariableInterestEntityFinancialOrOtherSupportAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssumedPremiumsWritten_23d0399b-808f-4b6d-ba16-f4443b088fd5_terseLabel_en-US" xlink:label="lab_us-gaap_AssumedPremiumsWritten" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reinsurance premiums assumed</link:label>
    <link:label id="lab_us-gaap_AssumedPremiumsWritten_label_en-US" xlink:label="lab_us-gaap_AssumedPremiumsWritten" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assumed Premiums Written</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssumedPremiumsWritten" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssumedPremiumsWritten"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssumedPremiumsWritten" xlink:to="lab_us-gaap_AssumedPremiumsWritten" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReinsuranceEffectOnClaimsAndBenefitsIncurredAmountCeded_2cf7c2c6-10c7-4e4a-9930-591504f9d41a_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ReinsuranceEffectOnClaimsAndBenefitsIncurredAmountCeded" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Claims ceded</link:label>
    <link:label id="lab_us-gaap_ReinsuranceEffectOnClaimsAndBenefitsIncurredAmountCeded_label_en-US" xlink:label="lab_us-gaap_ReinsuranceEffectOnClaimsAndBenefitsIncurredAmountCeded" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Policyholder Benefits and Claims Incurred, Ceded</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReinsuranceEffectOnClaimsAndBenefitsIncurredAmountCeded" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReinsuranceEffectOnClaimsAndBenefitsIncurredAmountCeded"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReinsuranceEffectOnClaimsAndBenefitsIncurredAmountCeded" xlink:to="lab_us-gaap_ReinsuranceEffectOnClaimsAndBenefitsIncurredAmountCeded" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCashAndInvestments_cf68f02c-a8e5-44f7-a353-4086a382f210_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashAndInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted cash and restricted investments</link:label>
    <link:label id="lab_us-gaap_RestrictedCashAndInvestments_label_en-US" xlink:label="lab_us-gaap_RestrictedCashAndInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash and Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashAndInvestments" xlink:to="lab_us-gaap_RestrictedCashAndInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_5f91966a-8016-4b94-abf4-21e86d58ad6f_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_eb8800eb-97cf-497f-a2a0-a7ecd53b4c4a_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested and expected to vest</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_RestrictedCashforBenefitManagementServicesMember_cfc408a0-3025-47a8-b4c1-4799a5925d18_terseLabel_en-US" xlink:label="lab_evh_RestrictedCashforBenefitManagementServicesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Claims processing services</link:label>
    <link:label id="lab_evh_RestrictedCashforBenefitManagementServicesMember_label_en-US" xlink:label="lab_evh_RestrictedCashforBenefitManagementServicesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash for Benefit Management Services [Member]</link:label>
    <link:label id="lab_evh_RestrictedCashforBenefitManagementServicesMember_documentation_en-US" xlink:label="lab_evh_RestrictedCashforBenefitManagementServicesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash for Benefit Management Services [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_RestrictedCashforBenefitManagementServicesMember" xlink:href="evh-20211231.xsd#evh_RestrictedCashforBenefitManagementServicesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_RestrictedCashforBenefitManagementServicesMember" xlink:to="lab_evh_RestrictedCashforBenefitManagementServicesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_70515097-8835-4322-897f-23e21c8557cb_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_9313e0a0-1d68-4320-8603-b06c04a27855_verboseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unamortized debt discount and issuance costs</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:to="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementTable_c765337a-12cd-48dd-bab9-5972de5e9036_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_label_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_1c25a184-5cae-4598-bdc0-805d3d0ea871_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adoption of New Accounting Standards and Recent Accounting Pronouncements Not Yet Effective</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOther_de59571f-20b7-4fea-9a9e-73a4d5b64373_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOther" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOther_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Other</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOther" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOther" xlink:to="lab_us-gaap_DeferredTaxAssetsOther" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherCommitmentsAxis_028979aa-cf5c-4dfb-a892-e07e6937778d_terseLabel_en-US" xlink:label="lab_us-gaap_OtherCommitmentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Commitments [Axis]</link:label>
    <link:label id="lab_us-gaap_OtherCommitmentsAxis_label_en-US" xlink:label="lab_us-gaap_OtherCommitmentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Commitments [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherCommitmentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherCommitmentsAxis" xlink:to="lab_us-gaap_OtherCommitmentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_ac20e13b-c02f-4fac-aff2-3d936907a3b7_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assumptions:</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions and Methodology [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_45e92c02-68bf-4cc2-9730-3bd3b861b3a9_totalLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Compensation Expense</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPeriodDomain_5d326a32-61a9-4d3b-9c67-05c2bc155db5_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Redemption, Period [Domain]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPeriodDomain_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Redemption, Period [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:to="lab_us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeAxis_52998c2d-d304-4741-8c98-6b42fc7a1934_terseLabel_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:label id="lab_srt_RangeAxis_label_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis" xlink:to="lab_srt_RangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax_aa10d577-bc84-4dd4-b642-1652f5a77f10_totalLabel_en-US" xlink:label="lab_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (loss) before income taxes and non-controlling interests</link:label>
    <link:label id="lab_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax_label_en-US" xlink:label="lab_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discontinued Operation, Income (Loss) from Discontinued Operation, before Income Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax" xlink:to="lab_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_e9b51a22-d228-4f5d-a1a7-55eff747afa8_totalLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total future amortization of intangible assets</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Goodwill_c97438e4-6e86-425a-983c-9fab92ed373a_terseLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:label id="lab_us-gaap_Goodwill_97b31b73-8d68-4ef8-bb6f-0e0a49162bf2_periodStartLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance as of beginning of period</link:label>
    <link:label id="lab_us-gaap_Goodwill_20e66771-1421-4d85-9a3a-ef121d20bf23_periodEndLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance as of end of period</link:label>
    <link:label id="lab_us-gaap_Goodwill_label_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Goodwill" xlink:to="lab_us-gaap_Goodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MinorityInterest_11b73f6a-2fec-4670-80f7-1c1567014187_periodStartLabel_en-US" xlink:label="lab_us-gaap_MinorityInterest" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-controlling interests balance as of beginning of period</link:label>
    <link:label id="lab_us-gaap_MinorityInterest_a4fb4916-e1fb-47ed-beca-411a10cacc47_periodEndLabel_en-US" xlink:label="lab_us-gaap_MinorityInterest" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-controlling interests balance as of end of period</link:label>
    <link:label id="lab_us-gaap_MinorityInterest_label_en-US" xlink:label="lab_us-gaap_MinorityInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MinorityInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinorityInterest" xlink:to="lab_us-gaap_MinorityInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_PaymentsForProceedsFromClaimsProcessingFinancingActivities_ee8ddb99-3723-4ebc-b440-9c2de50fa756_negatedTerseLabel_en-US" xlink:label="lab_evh_PaymentsForProceedsFromClaimsProcessingFinancingActivities" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes in working capital balances related to claims processing on behalf of partners</link:label>
    <link:label id="lab_evh_PaymentsForProceedsFromClaimsProcessingFinancingActivities_label_en-US" xlink:label="lab_evh_PaymentsForProceedsFromClaimsProcessingFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments For (Proceeds From) Claims Processing, Financing Activities</link:label>
    <link:label id="lab_evh_PaymentsForProceedsFromClaimsProcessingFinancingActivities_documentation_en-US" xlink:label="lab_evh_PaymentsForProceedsFromClaimsProcessingFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments For (Proceeds From) Claims Processing, Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_PaymentsForProceedsFromClaimsProcessingFinancingActivities" xlink:href="evh-20211231.xsd#evh_PaymentsForProceedsFromClaimsProcessingFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_PaymentsForProceedsFromClaimsProcessingFinancingActivities" xlink:to="lab_evh_PaymentsForProceedsFromClaimsProcessingFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputPriceVolatilityMember_b814aa2f-88e5-4224-9878-9e414576d757_verboseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputPriceVolatilityMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock price volatility</link:label>
    <link:label id="lab_us-gaap_MeasurementInputPriceVolatilityMember_label_en-US" xlink:label="lab_us-gaap_MeasurementInputPriceVolatilityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input, Price Volatility [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputPriceVolatilityMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputPriceVolatilityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputPriceVolatilityMember" xlink:to="lab_us-gaap_MeasurementInputPriceVolatilityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_68edd03e-5459-42b2-849d-ea7768bfd7fc_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign earnings at other than U.S. rates</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WarrantsAndRightsOutstandingMeasurementInput_1e7b22bd-b489-40e6-9c84-7a4b787105bc_terseLabel_en-US" xlink:label="lab_us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assumption or Input Ranges</link:label>
    <link:label id="lab_us-gaap_WarrantsAndRightsOutstandingMeasurementInput_label_en-US" xlink:label="lab_us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants and Rights Outstanding, Measurement Input</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingMeasurementInput"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:to="lab_us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_PeriodsPriortoJune2015Member_a92db683-2f2c-4da8-95dd-81d08c867b37_terseLabel_en-US" xlink:label="lab_evh_PeriodsPriortoJune2015Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Periods Prior to June 2015</link:label>
    <link:label id="lab_evh_PeriodsPriortoJune2015Member_label_en-US" xlink:label="lab_evh_PeriodsPriortoJune2015Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Periods Prior to June 2015 [Member]</link:label>
    <link:label id="lab_evh_PeriodsPriortoJune2015Member_documentation_en-US" xlink:label="lab_evh_PeriodsPriortoJune2015Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Periods Prior to June 2015 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_PeriodsPriortoJune2015Member" xlink:href="evh-20211231.xsd#evh_PeriodsPriortoJune2015Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_PeriodsPriortoJune2015Member" xlink:to="lab_evh_PeriodsPriortoJune2015Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfGoodwillTextBlock_b2027a81-e399-4499-aed1-02f48c38e727_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfGoodwillTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of goodwill</link:label>
    <link:label id="lab_us-gaap_ScheduleOfGoodwillTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfGoodwillTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Goodwill [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGoodwillTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfGoodwillTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfGoodwillTextBlock" xlink:to="lab_us-gaap_ScheduleOfGoodwillTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_9d0c6d08-6647-4e02-81ab-0cec35539460_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to reconcile net loss to net cash and restricted cash used in operating activities:</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseCost_dd54fe78-0339-4bd6-a029-0ab4f371403f_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease cost</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseCost_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseCost" xlink:to="lab_us-gaap_OperatingLeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComputerEquipmentMember_569e9271-0cc6-4e29-b8b4-e3b18ca55567_terseLabel_en-US" xlink:label="lab_us-gaap_ComputerEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Computer hardware</link:label>
    <link:label id="lab_us-gaap_ComputerEquipmentMember_label_en-US" xlink:label="lab_us-gaap_ComputerEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Computer Equipment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComputerEquipmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComputerEquipmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComputerEquipmentMember" xlink:to="lab_us-gaap_ComputerEquipmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_RightOfOffsetPercentageOfAccountsReceivableNettedAgainstClaimsPayable_f88e7758-a579-4720-8741-4f65a3a36e4c_terseLabel_en-US" xlink:label="lab_evh_RightOfOffsetPercentageOfAccountsReceivableNettedAgainstClaimsPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right of offset, percentage of accounts receivable netted against claims payable</link:label>
    <link:label id="lab_evh_RightOfOffsetPercentageOfAccountsReceivableNettedAgainstClaimsPayable_label_en-US" xlink:label="lab_evh_RightOfOffsetPercentageOfAccountsReceivableNettedAgainstClaimsPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right of Offset, Percentage of Accounts Receivable Netted Against Claims Payable</link:label>
    <link:label id="lab_evh_RightOfOffsetPercentageOfAccountsReceivableNettedAgainstClaimsPayable_documentation_en-US" xlink:label="lab_evh_RightOfOffsetPercentageOfAccountsReceivableNettedAgainstClaimsPayable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right of Offset, Percentage of Accounts Receivable Netted Against Claims Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_RightOfOffsetPercentageOfAccountsReceivableNettedAgainstClaimsPayable" xlink:href="evh-20211231.xsd#evh_RightOfOffsetPercentageOfAccountsReceivableNettedAgainstClaimsPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_RightOfOffsetPercentageOfAccountsReceivableNettedAgainstClaimsPayable" xlink:to="lab_evh_RightOfOffsetPercentageOfAccountsReceivableNettedAgainstClaimsPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_b153b2da-9af6-4354-9d21-a12c7a986ff4_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Parties</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transactions Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPeriodAxis_bb9fc5b0-d194-4d26-b206-f0da44942fdf_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Redemption, Period [Axis]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPeriodAxis_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Redemption, Period [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:to="lab_us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_AmortizationOfDebtDiscountAndDebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction_37ddcc97-b2c1-4489-8b78-f57b6fb36a85_terseLabel_en-US" xlink:label="lab_evh_AmortizationOfDebtDiscountAndDebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-cash amortization of debt discount and debt issuance costs</link:label>
    <link:label id="lab_evh_AmortizationOfDebtDiscountAndDebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction_label_en-US" xlink:label="lab_evh_AmortizationOfDebtDiscountAndDebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization Of Debt Discount And Debt Issuance Costs Incurred During Noncash Or Partial Noncash Transaction</link:label>
    <link:label id="lab_evh_AmortizationOfDebtDiscountAndDebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction_documentation_en-US" xlink:label="lab_evh_AmortizationOfDebtDiscountAndDebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization Of Debt Discount And Debt Issuance Costs Incurred During Noncash Or Partial Noncash Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_AmortizationOfDebtDiscountAndDebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction" xlink:href="evh-20211231.xsd#evh_AmortizationOfDebtDiscountAndDebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_AmortizationOfDebtDiscountAndDebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction" xlink:to="lab_evh_AmortizationOfDebtDiscountAndDebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_StockIssuedInConnectionWithDebtRepayment_595b9d7b-dc36-42cd-92f6-af5a7f0a6206_terseLabel_en-US" xlink:label="lab_evh_StockIssuedInConnectionWithDebtRepayment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class A common stock issued in connection with debt repayment</link:label>
    <link:label id="lab_evh_StockIssuedInConnectionWithDebtRepayment_label_en-US" xlink:label="lab_evh_StockIssuedInConnectionWithDebtRepayment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued in Connection with Debt Repayment</link:label>
    <link:label id="lab_evh_StockIssuedInConnectionWithDebtRepayment_documentation_en-US" xlink:label="lab_evh_StockIssuedInConnectionWithDebtRepayment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued in Connection with Debt Repayment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_StockIssuedInConnectionWithDebtRepayment" xlink:href="evh-20211231.xsd#evh_StockIssuedInConnectionWithDebtRepayment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_StockIssuedInConnectionWithDebtRepayment" xlink:to="lab_evh_StockIssuedInConnectionWithDebtRepayment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_212c04fc-d3d9-4840-972b-66848bc2281c_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total deferred tax expense (benefit)</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_DisposalGroupIncludingDiscontinuedOperationRestrictedCashCurrent_334bd4a1-f91b-45b6-a9c5-8d52a5c554bd_terseLabel_en-US" xlink:label="lab_evh_DisposalGroupIncludingDiscontinuedOperationRestrictedCashCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current restricted cash from claims processing services</link:label>
    <link:label id="lab_evh_DisposalGroupIncludingDiscontinuedOperationRestrictedCashCurrent_label_en-US" xlink:label="lab_evh_DisposalGroupIncludingDiscontinuedOperationRestrictedCashCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Restricted Cash, Current</link:label>
    <link:label id="lab_evh_DisposalGroupIncludingDiscontinuedOperationRestrictedCashCurrent_documentation_en-US" xlink:label="lab_evh_DisposalGroupIncludingDiscontinuedOperationRestrictedCashCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Restricted Cash, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_DisposalGroupIncludingDiscontinuedOperationRestrictedCashCurrent" xlink:href="evh-20211231.xsd#evh_DisposalGroupIncludingDiscontinuedOperationRestrictedCashCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_DisposalGroupIncludingDiscontinuedOperationRestrictedCashCurrent" xlink:to="lab_evh_DisposalGroupIncludingDiscontinuedOperationRestrictedCashCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_RightOfOffsetPercentageOfAccountsReceivableNetEligibleForNetBasisSettlement_05631d2f-f505-45d5-97d8-9cd1360b1724_terseLabel_en-US" xlink:label="lab_evh_RightOfOffsetPercentageOfAccountsReceivableNetEligibleForNetBasisSettlement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right of offset, percentage of accounts receivable, net eligible for net basis settlement</link:label>
    <link:label id="lab_evh_RightOfOffsetPercentageOfAccountsReceivableNetEligibleForNetBasisSettlement_label_en-US" xlink:label="lab_evh_RightOfOffsetPercentageOfAccountsReceivableNetEligibleForNetBasisSettlement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right of Offset, Percentage of Accounts Receivable, Net Eligible for Net Basis Settlement</link:label>
    <link:label id="lab_evh_RightOfOffsetPercentageOfAccountsReceivableNetEligibleForNetBasisSettlement_documentation_en-US" xlink:label="lab_evh_RightOfOffsetPercentageOfAccountsReceivableNetEligibleForNetBasisSettlement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right of Offset, Percentage of Accounts Receivable, Net Eligible for Net Basis Settlement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_RightOfOffsetPercentageOfAccountsReceivableNetEligibleForNetBasisSettlement" xlink:href="evh-20211231.xsd#evh_RightOfOffsetPercentageOfAccountsReceivableNetEligibleForNetBasisSettlement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_RightOfOffsetPercentageOfAccountsReceivableNetEligibleForNetBasisSettlement" xlink:to="lab_evh_RightOfOffsetPercentageOfAccountsReceivableNetEligibleForNetBasisSettlement" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_84c26d4f-6927-4367-b32e-4bad3c4d360b_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested and expected to vest</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy_b764d6d4-8d72-4d71-8659-fcdad55b0bac_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, Unrestricted Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy" xlink:to="lab_us-gaap_CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetAcquisitionAxis_893e78c2-3f17-4df9-8202-23b7f6dfbaad_terseLabel_en-US" xlink:label="lab_us-gaap_AssetAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Acquisition [Axis]</link:label>
    <link:label id="lab_us-gaap_AssetAcquisitionAxis_label_en-US" xlink:label="lab_us-gaap_AssetAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Acquisition [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetAcquisitionAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetAcquisitionAxis" xlink:to="lab_us-gaap_AssetAcquisitionAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_4b1b65a0-3ba9-4618-8a78-fddbf7c19919_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.S. statutory tax rate</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_42fa05ab-7dde-4593-a592-b378102cb295_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings (Loss) Per Share</link:label>
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConvertibleDebtMember_e1aa1c97-8449-4d92-a0e8-f3b22c015375_terseLabel_en-US" xlink:label="lab_us-gaap_ConvertibleDebtMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible senior notes</link:label>
    <link:label id="lab_us-gaap_ConvertibleDebtMember_label_en-US" xlink:label="lab_us-gaap_ConvertibleDebtMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Debt [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertibleDebtMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertibleDebtMember" xlink:to="lab_us-gaap_ConvertibleDebtMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet_dd25370d-6aeb-401e-a151-f2d4451853bd_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable, net</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet_label_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Accounts, Notes and Loans Receivable, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_c861a306-6f83-48c5-867a-3983dedc3b11_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_2f6716a7-6939-47aa-a206-7dd4f2e86161_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-use assets - operating</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Right-of-Use Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_ee76356e-2bff-43ee-a018-40e4dadafe0e_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net operating loss carryforwards</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Operating Loss Carryforwards</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_cac2e396-f3b4-44bd-b639-ebb30b214cdf_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued compensation and employee benefits</link:label>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee-related Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_a603e494-7209-4330-abf5-6c94a961ae72_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis" xlink:to="lab_us-gaap_IncomeStatementLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_5f7a4db6-c1ae-40e2-8582-349ef4388acb_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Amortization</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Accumulated Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeMember_5bf42c6e-6cf0-410d-8ee5-17ede3074e5b_terseLabel_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:label id="lab_srt_RangeMember_label_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember" xlink:to="lab_srt_RangeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock_2d9909d5-1455-4471-b6b6-4a3d56341aba_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Segments</link:label>
    <link:label id="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_5f78bb9d-45f6-43c3-a1b5-68bf98703ac8_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerAbstract_9c31fac4-bebf-4daa-9a54-937d530f5f23_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Abstract]</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerAbstract_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringCostAndReserveAxis_5dec0328-088e-4d79-8119-b0c9195bcadf_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringCostAndReserveAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Type [Axis]</link:label>
    <link:label id="lab_us-gaap_RestructuringCostAndReserveAxis_label_en-US" xlink:label="lab_us-gaap_RestructuringCostAndReserveAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringCostAndReserveAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis" xlink:to="lab_us-gaap_RestructuringCostAndReserveAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementBusinessSegmentsAxis_0943251f-ed6a-4764-9f22-d0818bb1362f_terseLabel_en-US" xlink:label="lab_us-gaap_StatementBusinessSegmentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segments [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementBusinessSegmentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementBusinessSegmentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segments [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis" xlink:to="lab_us-gaap_StatementBusinessSegmentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_ValuationAllowancesAndReservesChargedCreditedToAdditionalPaidInCapital_40e11b19-ce19-4b58-9a27-9d6c277a081d_terseLabel_en-US" xlink:label="lab_evh_ValuationAllowancesAndReservesChargedCreditedToAdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation allowance increase (decrease) charged to additional paid-in capital</link:label>
    <link:label id="lab_evh_ValuationAllowancesAndReservesChargedCreditedToAdditionalPaidInCapital_label_en-US" xlink:label="lab_evh_ValuationAllowancesAndReservesChargedCreditedToAdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation Allowances and Reserves, Charged (Credited) to Additional Paid-in Capital</link:label>
    <link:label id="lab_evh_ValuationAllowancesAndReservesChargedCreditedToAdditionalPaidInCapital_documentation_en-US" xlink:label="lab_evh_ValuationAllowancesAndReservesChargedCreditedToAdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation Allowances and Reserves, Charged (Credited) to Additional Paid-in Capital</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_ValuationAllowancesAndReservesChargedCreditedToAdditionalPaidInCapital" xlink:href="evh-20211231.xsd#evh_ValuationAllowancesAndReservesChargedCreditedToAdditionalPaidInCapital"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_ValuationAllowancesAndReservesChargedCreditedToAdditionalPaidInCapital" xlink:to="lab_evh_ValuationAllowancesAndReservesChargedCreditedToAdditionalPaidInCapital" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_716e3a82-7319-4e68-a62e-17492613a477_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividend yield</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CompensationAndRetirementDisclosureAbstract_25d4087a-8064-4116-b963-97c5463ab907_terseLabel_en-US" xlink:label="lab_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Benefits [Abstract]</link:label>
    <link:label id="lab_us-gaap_CompensationAndRetirementDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Benefits [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="lab_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_a8ea6179-349d-4eab-9967-2f328dd44902_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_6593302e-c861-4549-9727-e1d8c5e757fe_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation expense</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">APIC, Share-based Payment Arrangement, Increase for Cost Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock_a4a02c8e-bdca-4c59-840d-ca6ec4b75f6a_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discontinued Operations</link:label>
    <link:label id="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Groups, Including Discontinued Operations, Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" xlink:to="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_304a5903-b0a1-41e9-9d8d-9b87cadf5d12_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1_bf0f9ca0-6092-4da7-9c52-90a4081d044a_terseLabel_en-US" xlink:label="lab_us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consideration for asset acquisition or business combinations</link:label>
    <link:label id="lab_us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1_label_en-US" xlink:label="lab_us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncash or Part Noncash Acquisition, Net Nonmonetary Assets Acquired (Liabilities Assumed)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1" xlink:to="lab_us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableLeaseCost_e25c8dc3-523d-4007-9db6-9949623afb40_terseLabel_en-US" xlink:label="lab_us-gaap_VariableLeaseCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable lease cost</link:label>
    <link:label id="lab_us-gaap_VariableLeaseCost_label_en-US" xlink:label="lab_us-gaap_VariableLeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableLeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableLeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableLeaseCost" xlink:to="lab_us-gaap_VariableLeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold_4aae4805-295b-4a7d-9cdd-42839738250a_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of revenue (exclusive of depreciation and amortization expenses presented separately below)</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold_label_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Costs of Goods Sold</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableInterestEntityInitialConsolidationGainOrLoss_3f41a9a7-a852-4cb3-b389-97b5224df68d_terseLabel_en-US" xlink:label="lab_us-gaap_VariableInterestEntityInitialConsolidationGainOrLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain on consolidation</link:label>
    <link:label id="lab_us-gaap_VariableInterestEntityInitialConsolidationGainOrLoss_label_en-US" xlink:label="lab_us-gaap_VariableInterestEntityInitialConsolidationGainOrLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Interest Entity, Initial Consolidation, Gain (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableInterestEntityInitialConsolidationGainOrLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableInterestEntityInitialConsolidationGainOrLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableInterestEntityInitialConsolidationGainOrLoss" xlink:to="lab_us-gaap_VariableInterestEntityInitialConsolidationGainOrLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardRestrictedStockUnitsVestedAndExpectedToVestTableTextBlock_70eabc9a-1912-4b4f-930f-cc40e1bedef9_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardRestrictedStockUnitsVestedAndExpectedToVestTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of information of performance based stock units</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardRestrictedStockUnitsVestedAndExpectedToVestTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardRestrictedStockUnitsVestedAndExpectedToVestTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Restricted Stock Units, Vested and Expected to Vest [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardRestrictedStockUnitsVestedAndExpectedToVestTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardRestrictedStockUnitsVestedAndExpectedToVestTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardRestrictedStockUnitsVestedAndExpectedToVestTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardRestrictedStockUnitsVestedAndExpectedToVestTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityMethodInvestmentOtherThanTemporaryImpairment_b48e0d39-975b-4b47-b53d-428d6570a9f7_negatedLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentOtherThanTemporaryImpairment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment of equity method investments</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestmentOtherThanTemporaryImpairment_00459943-77e6-4b1b-9d88-38c668fd5dd8_terseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentOtherThanTemporaryImpairment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment of equity method investments</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestmentOtherThanTemporaryImpairment_e3d125e4-6183-4c5a-bd0a-43cfbeea0c02_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentOtherThanTemporaryImpairment" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity method investment impairment</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestmentOtherThanTemporaryImpairment_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentOtherThanTemporaryImpairment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investment, Other than Temporary Impairment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentOtherThanTemporaryImpairment" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestmentOtherThanTemporaryImpairment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentOtherThanTemporaryImpairment" xlink:to="lab_us-gaap_EquityMethodInvestmentOtherThanTemporaryImpairment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_3c41f995-398f-4d20-b726-04f13e3ff9a7_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate intrinsic value, vested</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_f122b158-2bc4-4ff5-a952-f11f44eab08b_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average fair value per option granted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityCommitmentFeePercentage_ae3ef317-ca5c-414d-be1c-c3acaba76a9a_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityCommitmentFeePercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitment fee percentage</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityCommitmentFeePercentage_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityCommitmentFeePercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Commitment Fee Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityCommitmentFeePercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityCommitmentFeePercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityCommitmentFeePercentage" xlink:to="lab_us-gaap_LineOfCreditFacilityCommitmentFeePercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_TaxReceivablesAgreementPercentofTaxSavingstobePaid_afbb60d3-a0c1-42a4-8fa8-49e7ced213c5_terseLabel_en-US" xlink:label="lab_evh_TaxReceivablesAgreementPercentofTaxSavingstobePaid" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percent of tax savings to be paid</link:label>
    <link:label id="lab_evh_TaxReceivablesAgreementPercentofTaxSavingstobePaid_label_en-US" xlink:label="lab_evh_TaxReceivablesAgreementPercentofTaxSavingstobePaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Receivables Agreement, Percent of Tax Savings to be Paid</link:label>
    <link:label id="lab_evh_TaxReceivablesAgreementPercentofTaxSavingstobePaid_documentation_en-US" xlink:label="lab_evh_TaxReceivablesAgreementPercentofTaxSavingstobePaid" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Receivables Agreement, Percent of Tax Savings to be Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_TaxReceivablesAgreementPercentofTaxSavingstobePaid" xlink:href="evh-20211231.xsd#evh_TaxReceivablesAgreementPercentofTaxSavingstobePaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_TaxReceivablesAgreementPercentofTaxSavingstobePaid" xlink:to="lab_evh_TaxReceivablesAgreementPercentofTaxSavingstobePaid" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_AssetAcquisitionDebtSecuritiesAvailableForSale_db990bca-233a-4954-8c34-422febe45db6_terseLabel_en-US" xlink:label="lab_evh_AssetAcquisitionDebtSecuritiesAvailableForSale" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt securities, available-for-sale</link:label>
    <link:label id="lab_evh_AssetAcquisitionDebtSecuritiesAvailableForSale_label_en-US" xlink:label="lab_evh_AssetAcquisitionDebtSecuritiesAvailableForSale" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Acquisition, Debt Securities, Available-For-Sale</link:label>
    <link:label id="lab_evh_AssetAcquisitionDebtSecuritiesAvailableForSale_documentation_en-US" xlink:label="lab_evh_AssetAcquisitionDebtSecuritiesAvailableForSale" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Acquisition, Debt Securities, Available-For-Sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_AssetAcquisitionDebtSecuritiesAvailableForSale" xlink:href="evh-20211231.xsd#evh_AssetAcquisitionDebtSecuritiesAvailableForSale"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_AssetAcquisitionDebtSecuritiesAvailableForSale" xlink:to="lab_evh_AssetAcquisitionDebtSecuritiesAvailableForSale" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_10041fba-ecca-433e-842d-9f5059c0e5e4_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group Name [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_label_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:to="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems_ce965f45-f996-40e2-ba92-040137e0638d_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash and Cash Equivalents Items [Line Items]</link:label>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems_label_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash and Cash Equivalents Items [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems" xlink:to="lab_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_EquityMethodInvestmentVotingInterestPercentage_c9e418e7-227f-4181-8715-626fe47558ba_terseLabel_en-US" xlink:label="lab_evh_EquityMethodInvestmentVotingInterestPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Voting interest percentage</link:label>
    <link:label id="lab_evh_EquityMethodInvestmentVotingInterestPercentage_label_en-US" xlink:label="lab_evh_EquityMethodInvestmentVotingInterestPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investment, Voting Interest Percentage</link:label>
    <link:label id="lab_evh_EquityMethodInvestmentVotingInterestPercentage_documentation_en-US" xlink:label="lab_evh_EquityMethodInvestmentVotingInterestPercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investment, Voting Interest Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_EquityMethodInvestmentVotingInterestPercentage" xlink:href="evh-20211231.xsd#evh_EquityMethodInvestmentVotingInterestPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_EquityMethodInvestmentVotingInterestPercentage" xlink:to="lab_evh_EquityMethodInvestmentVotingInterestPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_DebtInstrumentRepurchasePriceDueToFundamentalChangeAsPercentageOfPrincipalAmount_4e3b26e4-dde5-47fc-98fd-d536df21aaa6_verboseLabel_en-US" xlink:label="lab_evh_DebtInstrumentRepurchasePriceDueToFundamentalChangeAsPercentageOfPrincipalAmount" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repurchase covenant, repurchase price due to fundamental change as percentage of principal amount</link:label>
    <link:label id="lab_evh_DebtInstrumentRepurchasePriceDueToFundamentalChangeAsPercentageOfPrincipalAmount_label_en-US" xlink:label="lab_evh_DebtInstrumentRepurchasePriceDueToFundamentalChangeAsPercentageOfPrincipalAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Repurchase Price Due To Fundamental Change As Percentage Of Principal Amount</link:label>
    <link:label id="lab_evh_DebtInstrumentRepurchasePriceDueToFundamentalChangeAsPercentageOfPrincipalAmount_documentation_en-US" xlink:label="lab_evh_DebtInstrumentRepurchasePriceDueToFundamentalChangeAsPercentageOfPrincipalAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Repurchase Price Due To Fundamental Change As Percentage Of Principal Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_DebtInstrumentRepurchasePriceDueToFundamentalChangeAsPercentageOfPrincipalAmount" xlink:href="evh-20211231.xsd#evh_DebtInstrumentRepurchasePriceDueToFundamentalChangeAsPercentageOfPrincipalAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_DebtInstrumentRepurchasePriceDueToFundamentalChangeAsPercentageOfPrincipalAmount" xlink:to="lab_evh_DebtInstrumentRepurchasePriceDueToFundamentalChangeAsPercentageOfPrincipalAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConvertibleDebtTableTextBlock_bfe045df-5f25-456d-a60d-63f25ede0bd7_terseLabel_en-US" xlink:label="lab_us-gaap_ConvertibleDebtTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of convertible debt</link:label>
    <link:label id="lab_us-gaap_ConvertibleDebtTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ConvertibleDebtTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Debt [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertibleDebtTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertibleDebtTableTextBlock" xlink:to="lab_us-gaap_ConvertibleDebtTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CreditFacilityDomain_8c02f21d-54f6-4d87-b5a3-8f79fa029ca8_terseLabel_en-US" xlink:label="lab_us-gaap_CreditFacilityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Domain]</link:label>
    <link:label id="lab_us-gaap_CreditFacilityDomain_label_en-US" xlink:label="lab_us-gaap_CreditFacilityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CreditFacilityDomain" xlink:to="lab_us-gaap_CreditFacilityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsAbstract_c849e763-2ee5-4dbe-8811-ac80e121e6f5_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ASSETS</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsAbstract_6b9fe570-d741-4d01-a157-f1f83d620df5_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transactions [Abstract]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsAbstract_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transactions [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract" xlink:to="lab_us-gaap_RelatedPartyTransactionsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss_b41240b4-802c-46a7-b378-90e816a14fa6_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative inception to date impairment</link:label>
    <link:label id="lab_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss_label_en-US" xlink:label="lab_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, Impaired, Accumulated Impairment Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillImpairedAccumulatedImpairmentLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss" xlink:to="lab_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_67e4cf8a-a6b4-43e6-bddb-ae86fa1f5911_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested and expected to vest at the end of the period (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_41a53f09-15ef-45e9-b49a-e552d936c4c9_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Exercise Price, vested and expected to vest at the end of the period (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NoncashOrPartNoncashAcquisitionPayablesAssumed1_0b342fbf-dac8-4ecc-a7f6-b126a88e6e48_terseLabel_en-US" xlink:label="lab_us-gaap_NoncashOrPartNoncashAcquisitionPayablesAssumed1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class A common stock issued for payment of earn-outs</link:label>
    <link:label id="lab_us-gaap_NoncashOrPartNoncashAcquisitionPayablesAssumed1_label_en-US" xlink:label="lab_us-gaap_NoncashOrPartNoncashAcquisitionPayablesAssumed1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncash or Part Noncash Acquisition, Payables Assumed</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncashOrPartNoncashAcquisitionPayablesAssumed1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NoncashOrPartNoncashAcquisitionPayablesAssumed1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncashOrPartNoncashAcquisitionPayablesAssumed1" xlink:to="lab_us-gaap_NoncashOrPartNoncashAcquisitionPayablesAssumed1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_55f5a88a-9d7d-445a-abab-3f5239bddb96_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable_19ad8df6-34bd-4922-bea9-0b16b8179348_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restrictions on Cash and Cash Equivalents [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restrictions on Cash and Cash Equivalents [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable" xlink:to="lab_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskPercentage1_039aaa82-3a5d-4578-b28c-e519ad61e845_verboseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskPercentage1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration risk</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskPercentage1_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskPercentage1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskPercentage1" xlink:to="lab_us-gaap_ConcentrationRiskPercentage1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_909c3a2b-a3b6-4edc-b160-7154eac67661_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets, Net</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_3963e87a-40de-4682-bb57-9aaf1c4fff57_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and Equipment, Net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_2eb545c4-83c1-4866-a7cd-3451fa0406c2_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements or Change in Accounting Principle [Table]</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Standards Update and Change in Accounting Principle [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:to="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_ed5f3186-4777-455c-a792-650a4f88716e_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of options issued (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_38bbbe45-7547-4fed-83fb-885ff7d75566_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding at the beginning of the period (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_748b3c92-83db-4c51-970f-79db9c3d54e4_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding at the end of the period (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_77a9f899-848d-45ad-9103-c2d73333c888_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding at the end of the period (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_AssetPurchaseAgreementEscrowPayments_9c921fdd-5aee-4acc-a032-222c744b5b86_terseLabel_en-US" xlink:label="lab_evh_AssetPurchaseAgreementEscrowPayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Purchase Agreement, escrow payments</link:label>
    <link:label id="lab_evh_AssetPurchaseAgreementEscrowPayments_label_en-US" xlink:label="lab_evh_AssetPurchaseAgreementEscrowPayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Purchase Agreement, Escrow Payments</link:label>
    <link:label id="lab_evh_AssetPurchaseAgreementEscrowPayments_documentation_en-US" xlink:label="lab_evh_AssetPurchaseAgreementEscrowPayments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Purchase Agreement, Escrow Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_AssetPurchaseAgreementEscrowPayments" xlink:href="evh-20211231.xsd#evh_AssetPurchaseAgreementEscrowPayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_AssetPurchaseAgreementEscrowPayments" xlink:to="lab_evh_AssetPurchaseAgreementEscrowPayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TradeNamesMember_e5e8de79-071a-443e-ab9a-54370965ff9e_terseLabel_en-US" xlink:label="lab_us-gaap_TradeNamesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate trade name</link:label>
    <link:label id="lab_us-gaap_TradeNamesMember_label_en-US" xlink:label="lab_us-gaap_TradeNamesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trade Names [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TradeNamesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TradeNamesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TradeNamesMember" xlink:to="lab_us-gaap_TradeNamesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_baf1ec74-1c03-469e-8479-0452d0ce12c3_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentAxis" xlink:to="lab_us-gaap_DebtInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_aeffcefb-58f5-4298-a9c9-ee3255a718b3_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other current and non-current assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_SharebasedCompensationIncludingOnetimeAdjustment_97708347-7619-4064-bb39-fb29565c1108_negatedLabel_en-US" xlink:label="lab_evh_SharebasedCompensationIncludingOnetimeAdjustment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation expense</link:label>
    <link:label id="lab_evh_SharebasedCompensationIncludingOnetimeAdjustment_label_en-US" xlink:label="lab_evh_SharebasedCompensationIncludingOnetimeAdjustment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation, Including One-time Adjustment</link:label>
    <link:label id="lab_evh_SharebasedCompensationIncludingOnetimeAdjustment_documentation_en-US" xlink:label="lab_evh_SharebasedCompensationIncludingOnetimeAdjustment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation, Including One-time Adjustment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_SharebasedCompensationIncludingOnetimeAdjustment" xlink:href="evh-20211231.xsd#evh_SharebasedCompensationIncludingOnetimeAdjustment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_SharebasedCompensationIncludingOnetimeAdjustment" xlink:to="lab_evh_SharebasedCompensationIncludingOnetimeAdjustment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinancingReceivablesPeriodPastDueDomain_344af333-897f-4bc2-91ae-3ff5002a7d05_terseLabel_en-US" xlink:label="lab_us-gaap_FinancingReceivablesPeriodPastDueDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Asset, Period Past Due [Domain]</link:label>
    <link:label id="lab_us-gaap_FinancingReceivablesPeriodPastDueDomain_label_en-US" xlink:label="lab_us-gaap_FinancingReceivablesPeriodPastDueDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Asset, Aging [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancingReceivablesPeriodPastDueDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancingReceivablesPeriodPastDueDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancingReceivablesPeriodPastDueDomain" xlink:to="lab_us-gaap_FinancingReceivablesPeriodPastDueDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_d548b85d-365d-4adf-b8fa-34ccdb3207d5_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_PremiumsRevenueMember_bb53a9c4-de22-43d9-b985-724b6ebaa9ea_terseLabel_en-US" xlink:label="lab_evh_PremiumsRevenueMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Premiums</link:label>
    <link:label id="lab_evh_PremiumsRevenueMember_label_en-US" xlink:label="lab_evh_PremiumsRevenueMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Premiums Revenue [Member]</link:label>
    <link:label id="lab_evh_PremiumsRevenueMember_documentation_en-US" xlink:label="lab_evh_PremiumsRevenueMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Premiums Revenue [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_PremiumsRevenueMember" xlink:href="evh-20211231.xsd#evh_PremiumsRevenueMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_PremiumsRevenueMember" xlink:to="lab_evh_PremiumsRevenueMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_f731bd87-bf8c-4dd8-a856-e90c49c60236_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party [Axis]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_VivantHealthMSOLLCMember_dd625fed-c399-4c47-87af-dacb0a15b445_terseLabel_en-US" xlink:label="lab_evh_VivantHealthMSOLLCMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vivant</link:label>
    <link:label id="lab_evh_VivantHealthMSOLLCMember_label_en-US" xlink:label="lab_evh_VivantHealthMSOLLCMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vivant Health MSO, LLC [Member]</link:label>
    <link:label id="lab_evh_VivantHealthMSOLLCMember_documentation_en-US" xlink:label="lab_evh_VivantHealthMSOLLCMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vivant Health MSO, LLC [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_VivantHealthMSOLLCMember" xlink:href="evh-20211231.xsd#evh_VivantHealthMSOLLCMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_VivantHealthMSOLLCMember" xlink:to="lab_evh_VivantHealthMSOLLCMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput_35b695ee-3518-4a3b-bce8-2f62e63a0e57_verboseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assumption or Input Ranges</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration, Liability, Measurement Input</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingAbstract_3e43822d-e919-4860-be96-acc468abbe5c_terseLabel_en-US" xlink:label="lab_evh_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding as of December 31, 2021</link:label>
    <link:label id="lab_evh_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingAbstract_label_en-US" xlink:label="lab_evh_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement By Share-based Payment Award, Equity Instruments Other Than Options, Outstanding [Abstract]</link:label>
    <link:label id="lab_evh_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingAbstract_documentation_en-US" xlink:label="lab_evh_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement By Share-based Payment Award, Equity Instruments Other Than Options, Outstanding [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingAbstract" xlink:href="evh-20211231.xsd#evh_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingAbstract" xlink:to="lab_evh_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SecuredDebtMember_11760111-caf1-473b-80d6-9dd83eea5cd7_terseLabel_en-US" xlink:label="lab_us-gaap_SecuredDebtMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Secured Debt</link:label>
    <link:label id="lab_us-gaap_SecuredDebtMember_label_en-US" xlink:label="lab_us-gaap_SecuredDebtMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Secured Debt [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredDebtMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SecuredDebtMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SecuredDebtMember" xlink:to="lab_us-gaap_SecuredDebtMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation_e3fc9a0c-2e61-4a86-88d2-ed43ce72ddea_terseLabel_en-US" xlink:label="lab_us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Benefit (provision) for income taxes</link:label>
    <link:label id="lab_us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation_label_en-US" xlink:label="lab_us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discontinued Operation, Tax Effect of Discontinued Operation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation" xlink:to="lab_us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_c2e61bcc-948b-4883-be5f-a87c740a7dc2_terseLabel_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leased assets obtained in exchange for operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-Use Asset Obtained in Exchange for Operating Lease Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:to="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_2d045557-d102-47f0-8aa2-2627f4f78fbe_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of deferred tax assets and liabilities</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Deferred Tax Assets and Liabilities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_6ebdb763-c812-42d7-9650-7f091da78e00_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting percentage</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1_d725c235-45ff-4fac-8c57-81b997e8a0b1_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Paid costs related to prior year</link:label>
    <link:label id="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1_label_en-US" xlink:label="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability for Unpaid Claims and Claims Adjustment Expense, Claims Paid, Prior Years</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1" xlink:to="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_SharebasedCompensationAwardSubTrancheTwoMember_ee460c29-f4da-44b6-9435-724ed18de47b_terseLabel_en-US" xlink:label="lab_evh_SharebasedCompensationAwardSubTrancheTwoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vest on March 1, 2020</link:label>
    <link:label id="lab_evh_SharebasedCompensationAwardSubTrancheTwoMember_label_en-US" xlink:label="lab_evh_SharebasedCompensationAwardSubTrancheTwoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Award, Sub-Tranche Two [Member]</link:label>
    <link:label id="lab_evh_SharebasedCompensationAwardSubTrancheTwoMember_documentation_en-US" xlink:label="lab_evh_SharebasedCompensationAwardSubTrancheTwoMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Award, Sub-Tranche Two [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_SharebasedCompensationAwardSubTrancheTwoMember" xlink:href="evh-20211231.xsd#evh_SharebasedCompensationAwardSubTrancheTwoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_SharebasedCompensationAwardSubTrancheTwoMember" xlink:to="lab_evh_SharebasedCompensationAwardSubTrancheTwoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_8eb6643b-4ce2-4140-8343-ab0bb829243b_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation capitalized as software development costs</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Amount Capitalized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_d71f4335-fdf4-4f68-98c5-4534e5130031_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NoncontrollingInterestDecreaseFromDeconsolidation_923ae377-5944-4c88-a7d9-24424b69572b_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestDecreaseFromDeconsolidation" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal of assets</link:label>
    <link:label id="lab_us-gaap_NoncontrollingInterestDecreaseFromDeconsolidation_label_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestDecreaseFromDeconsolidation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest, Decrease from Deconsolidation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestDecreaseFromDeconsolidation" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NoncontrollingInterestDecreaseFromDeconsolidation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncontrollingInterestDecreaseFromDeconsolidation" xlink:to="lab_us-gaap_NoncontrollingInterestDecreaseFromDeconsolidation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_dd37abe4-8a29-494f-bb84-c385536af6eb_terseLabel_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of operating segments</link:label>
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_label_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Operating Segments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfOperatingSegments" xlink:to="lab_us-gaap_NumberOfOperatingSegments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_451249d6-bf2b-400c-a600-63b22bae28d7_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2024</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredRevenueCurrent_91370f32-556b-48ee-be2a-e501b38a41a9_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredRevenueCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredRevenueCurrent_label_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredRevenueCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Deferred Revenue, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredRevenueCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredRevenueCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredRevenueCurrent" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredRevenueCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseAgreementsMember_fa074555-0392-4d86-9087-bacbf935d720_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease Agreements</link:label>
    <link:label id="lab_us-gaap_LeaseAgreementsMember_label_en-US" xlink:label="lab_us-gaap_LeaseAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease Agreements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseAgreementsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseAgreementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseAgreementsMember" xlink:to="lab_us-gaap_LeaseAgreementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_868b1653-64b6-44b9-9f2b-39996f306cf1_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Thereafter</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, after Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesTypeAxis_71fb81db-9463-4dbc-b9db-7278aeaf18c6_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances and Reserves Type [Axis]</link:label>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesTypeAxis_label_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances and Reserves Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowancesAndReservesTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:to="lab_us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherExpense_4765925f-e5fd-43c6-9666-aa6eadf0f4cf_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherExpense" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other loss</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherExpense_label_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Other Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherExpense" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_ScheduleOfShareBasedPaymentAwardRestrictedStockUnitValuationAssumptionsTableTextBlock_97308aef-b343-4b88-99b4-f44b283ba6f9_terseLabel_en-US" xlink:label="lab_evh_ScheduleOfShareBasedPaymentAwardRestrictedStockUnitValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of price assumptions for performance based stock units</link:label>
    <link:label id="lab_evh_ScheduleOfShareBasedPaymentAwardRestrictedStockUnitValuationAssumptionsTableTextBlock_label_en-US" xlink:label="lab_evh_ScheduleOfShareBasedPaymentAwardRestrictedStockUnitValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Payment Award, Restricted Stock Unit, Valuation Assumptions [Table Text Block]</link:label>
    <link:label id="lab_evh_ScheduleOfShareBasedPaymentAwardRestrictedStockUnitValuationAssumptionsTableTextBlock_documentation_en-US" xlink:label="lab_evh_ScheduleOfShareBasedPaymentAwardRestrictedStockUnitValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Payment Award, Restricted Stock Unit, Valuation Assumptions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_ScheduleOfShareBasedPaymentAwardRestrictedStockUnitValuationAssumptionsTableTextBlock" xlink:href="evh-20211231.xsd#evh_ScheduleOfShareBasedPaymentAwardRestrictedStockUnitValuationAssumptionsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_ScheduleOfShareBasedPaymentAwardRestrictedStockUnitValuationAssumptionsTableTextBlock" xlink:to="lab_evh_ScheduleOfShareBasedPaymentAwardRestrictedStockUnitValuationAssumptionsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTableTextBlock_94c74a14-ddaf-4448-bf5e-d1897cc09f79_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of revenue</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTableTextBlock_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:to="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_IncreaseDecreaseInCapitalizedContractCostNet_26942add-625c-4dbd-b44d-f535dec001f2_negatedTerseLabel_en-US" xlink:label="lab_evh_IncreaseDecreaseInCapitalizedContractCostNet" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract cost assets</link:label>
    <link:label id="lab_evh_IncreaseDecreaseInCapitalizedContractCostNet_label_en-US" xlink:label="lab_evh_IncreaseDecreaseInCapitalizedContractCostNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) In Capitalized Contract Cost, Net</link:label>
    <link:label id="lab_evh_IncreaseDecreaseInCapitalizedContractCostNet_documentation_en-US" xlink:label="lab_evh_IncreaseDecreaseInCapitalizedContractCostNet" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) In Capitalized Contract Cost, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_IncreaseDecreaseInCapitalizedContractCostNet" xlink:href="evh-20211231.xsd#evh_IncreaseDecreaseInCapitalizedContractCostNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_IncreaseDecreaseInCapitalizedContractCostNet" xlink:to="lab_evh_IncreaseDecreaseInCapitalizedContractCostNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_f69de0c2-8032-4782-a1ec-309eaa2818b4_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total RSUs</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_3f886913-07c6-4305-9b3c-41cc29ac9946_verboseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Identifiable intangible assets</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_StockIssuedDecreaseInDeferredTaxLiability_2c2589ea-98fb-4186-b2b9-44af2ad22c44_terseLabel_en-US" xlink:label="lab_evh_StockIssuedDecreaseInDeferredTaxLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Decrease in deferred tax liability as a result of securities offerings and exchanges</link:label>
    <link:label id="lab_evh_StockIssuedDecreaseInDeferredTaxLiability_label_en-US" xlink:label="lab_evh_StockIssuedDecreaseInDeferredTaxLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued, Decrease In Deferred Tax Liability</link:label>
    <link:label id="lab_evh_StockIssuedDecreaseInDeferredTaxLiability_documentation_en-US" xlink:label="lab_evh_StockIssuedDecreaseInDeferredTaxLiability" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued, Decrease In Deferred Tax Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_StockIssuedDecreaseInDeferredTaxLiability" xlink:href="evh-20211231.xsd#evh_StockIssuedDecreaseInDeferredTaxLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_StockIssuedDecreaseInDeferredTaxLiability" xlink:to="lab_evh_StockIssuedDecreaseInDeferredTaxLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_IndefinitelivedTaxCreditCarryforwardMember_416c5b13-93d0-415f-9aba-ac1d5c426b1c_terseLabel_en-US" xlink:label="lab_evh_IndefinitelivedTaxCreditCarryforwardMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-lived Tax Credit Carryforward</link:label>
    <link:label id="lab_evh_IndefinitelivedTaxCreditCarryforwardMember_label_en-US" xlink:label="lab_evh_IndefinitelivedTaxCreditCarryforwardMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-lived Tax Credit Carryforward [Member]</link:label>
    <link:label id="lab_evh_IndefinitelivedTaxCreditCarryforwardMember_documentation_en-US" xlink:label="lab_evh_IndefinitelivedTaxCreditCarryforwardMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-lived Tax Credit Carryforward [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_IndefinitelivedTaxCreditCarryforwardMember" xlink:href="evh-20211231.xsd#evh_IndefinitelivedTaxCreditCarryforwardMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_IndefinitelivedTaxCreditCarryforwardMember" xlink:to="lab_evh_IndefinitelivedTaxCreditCarryforwardMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwillAbstract_b9818ef8-8d93-440b-adf6-ce48b984611a_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwillAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Identifiable intangible assets acquired:</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwillAbstract_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwillAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwillAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwillAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwillAbstract" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwillAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeasePayments_77dd536e-89fb-45a9-bee2-c1efcfeda837_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasePayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating cash flows from operating leases</link:label>
    <link:label id="lab_us-gaap_OperatingLeasePayments_label_en-US" xlink:label="lab_us-gaap_OperatingLeasePayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasePayments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeasePayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasePayments" xlink:to="lab_us-gaap_OperatingLeasePayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_022282ee-3c1f-427b-aea0-65a04d889475_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent_adb1fcbe-e495-4943-8b40-5dd47cf37e40_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Excess tax benefits (shortfalls) on stock-based compensation</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Tax Expense (Benefit), Share-based Payment Arrangement, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_bb645053-9340-46da-941e-4816141d0383_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Costs</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationConsiderationTransferred1_9361e9c4-0c5e-4253-bc0e-0607425bd50a_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total consideration</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationConsiderationTransferred1_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Consideration Transferred</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferred1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:to="lab_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProvisionForDoubtfulAccounts_c36b9fd4-519f-4f48-abe2-378d1a3eab25_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ProvisionForDoubtfulAccounts" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Provision for credit losses</link:label>
    <link:label id="lab_us-gaap_ProvisionForDoubtfulAccounts_label_en-US" xlink:label="lab_us-gaap_ProvisionForDoubtfulAccounts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, Credit Loss Expense (Reversal)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProvisionForDoubtfulAccounts" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProvisionForDoubtfulAccounts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProvisionForDoubtfulAccounts" xlink:to="lab_us-gaap_ProvisionForDoubtfulAccounts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayableCurrent_cbb14c91-a1d2-425e-8495-392f661ec82b_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayableCurrent_label_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Accounts Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayableCurrent" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_WeightedAverageRemainingContractualTermAbstract_447bc072-c01a-4274-9ebb-658ea8e54dab_terseLabel_en-US" xlink:label="lab_evh_WeightedAverageRemainingContractualTermAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Remaining Contractual Term</link:label>
    <link:label id="lab_evh_WeightedAverageRemainingContractualTermAbstract_label_en-US" xlink:label="lab_evh_WeightedAverageRemainingContractualTermAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Remaining Contractual Term [Abstract]</link:label>
    <link:label id="lab_evh_WeightedAverageRemainingContractualTermAbstract_documentation_en-US" xlink:label="lab_evh_WeightedAverageRemainingContractualTermAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Remaining Contractual Term [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_WeightedAverageRemainingContractualTermAbstract" xlink:href="evh-20211231.xsd#evh_WeightedAverageRemainingContractualTermAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_WeightedAverageRemainingContractualTermAbstract" xlink:to="lab_evh_WeightedAverageRemainingContractualTermAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_NonEmployeeDirectorsMember_6c8119e1-5e39-445d-893d-e1acc6c8aa4d_terseLabel_en-US" xlink:label="lab_evh_NonEmployeeDirectorsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-Employee Directors</link:label>
    <link:label id="lab_evh_NonEmployeeDirectorsMember_label_en-US" xlink:label="lab_evh_NonEmployeeDirectorsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-Employee Directors [Member]</link:label>
    <link:label id="lab_evh_NonEmployeeDirectorsMember_documentation_en-US" xlink:label="lab_evh_NonEmployeeDirectorsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-Employee Directors [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_NonEmployeeDirectorsMember" xlink:href="evh-20211231.xsd#evh_NonEmployeeDirectorsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_NonEmployeeDirectorsMember" xlink:to="lab_evh_NonEmployeeDirectorsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillRollForward_f9144395-1bcf-4402-889b-5487f87f30b5_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_GoodwillRollForward_label_en-US" xlink:label="lab_us-gaap_GoodwillRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillRollForward" xlink:to="lab_us-gaap_GoodwillRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationMeasurementPeriodAdjustment_8232b1e4-5316-4793-bb7d-98de1bdb977f_terseLabel_en-US" xlink:label="lab_evh_NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationMeasurementPeriodAdjustment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase/decrease to goodwill from measurement period adjustments/business combinations</link:label>
    <link:label id="lab_evh_NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationMeasurementPeriodAdjustment_label_en-US" xlink:label="lab_evh_NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationMeasurementPeriodAdjustment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncash Or Part Noncash Acquisition, Noncash Financial Or Equity Instrument Consideration, Measurement Period Adjustment</link:label>
    <link:label id="lab_evh_NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationMeasurementPeriodAdjustment_documentation_en-US" xlink:label="lab_evh_NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationMeasurementPeriodAdjustment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncash Or Part Noncash Acquisition, Noncash Financial Or Equity Instrument Consideration, Measurement Period Adjustment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationMeasurementPeriodAdjustment" xlink:href="evh-20211231.xsd#evh_NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationMeasurementPeriodAdjustment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationMeasurementPeriodAdjustment" xlink:to="lab_evh_NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationMeasurementPeriodAdjustment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesFinancingArrangements_557a3550-5720-4819-81b9-4cc422b94ba6_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesFinancingArrangements" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible debt</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesFinancingArrangements_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesFinancingArrangements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Financing Arrangements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesFinancingArrangements" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilitiesFinancingArrangements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesFinancingArrangements" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesFinancingArrangements" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_868fee0e-9aff-4d13-854f-181bc8a0f945_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Continuing operations, diluted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations, Per Diluted Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_67bb63a2-a49c-4eec-8ca7-4de574689a82_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total fair value of assets measured on a recurring basis</link:label>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsFairValueDisclosure" xlink:to="lab_us-gaap_AssetsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_ba4e936b-85c3-43ee-a801-365cca4caa40_terseLabel_en-US" xlink:label="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_label_en-US" xlink:label="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:to="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract_4dc2b6b0-7642-4e59-ac58-0003f4718a77_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average common shares outstanding</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic and Diluted, Other Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract" xlink:to="lab_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SoftwareDevelopmentMember_38511042-643e-47e3-ad6b-701688e05c76_terseLabel_en-US" xlink:label="lab_us-gaap_SoftwareDevelopmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Internal-use software development costs</link:label>
    <link:label id="lab_us-gaap_SoftwareDevelopmentMember_007018dd-707c-420a-8b96-904f353a31b2_verboseLabel_en-US" xlink:label="lab_us-gaap_SoftwareDevelopmentMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Internal-use software development costs</link:label>
    <link:label id="lab_us-gaap_SoftwareDevelopmentMember_label_en-US" xlink:label="lab_us-gaap_SoftwareDevelopmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Software Development [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SoftwareDevelopmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SoftwareDevelopmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SoftwareDevelopmentMember" xlink:to="lab_us-gaap_SoftwareDevelopmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_DebtInstrumentRepurchaseCovenantSalePriceAsAPercentageOfConversionPrice_16079975-9b64-4ff8-9679-af7357f5a093_terseLabel_en-US" xlink:label="lab_evh_DebtInstrumentRepurchaseCovenantSalePriceAsAPercentageOfConversionPrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repurchase covenant, sale price as a percentage of conversion price</link:label>
    <link:label id="lab_evh_DebtInstrumentRepurchaseCovenantSalePriceAsAPercentageOfConversionPrice_1b717ab9-8402-4aa1-9bb6-b182c43c1be9_verboseLabel_en-US" xlink:label="lab_evh_DebtInstrumentRepurchaseCovenantSalePriceAsAPercentageOfConversionPrice" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repurchase covenant, sale price as a percentage of conversion price (at least)</link:label>
    <link:label id="lab_evh_DebtInstrumentRepurchaseCovenantSalePriceAsAPercentageOfConversionPrice_label_en-US" xlink:label="lab_evh_DebtInstrumentRepurchaseCovenantSalePriceAsAPercentageOfConversionPrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Repurchase Covenant, Sale Price As A Percentage Of Conversion Price</link:label>
    <link:label id="lab_evh_DebtInstrumentRepurchaseCovenantSalePriceAsAPercentageOfConversionPrice_documentation_en-US" xlink:label="lab_evh_DebtInstrumentRepurchaseCovenantSalePriceAsAPercentageOfConversionPrice" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Repurchase Covenant, Sale Price As A Percentage Of Conversion Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_DebtInstrumentRepurchaseCovenantSalePriceAsAPercentageOfConversionPrice" xlink:href="evh-20211231.xsd#evh_DebtInstrumentRepurchaseCovenantSalePriceAsAPercentageOfConversionPrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_DebtInstrumentRepurchaseCovenantSalePriceAsAPercentageOfConversionPrice" xlink:to="lab_evh_DebtInstrumentRepurchaseCovenantSalePriceAsAPercentageOfConversionPrice" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_PassportNoteMember_030acac5-2ca7-433e-af5e-aafd8296df05_terseLabel_en-US" xlink:label="lab_evh_PassportNoteMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Passport Note</link:label>
    <link:label id="lab_evh_PassportNoteMember_label_en-US" xlink:label="lab_evh_PassportNoteMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Passport Note [Member]</link:label>
    <link:label id="lab_evh_PassportNoteMember_documentation_en-US" xlink:label="lab_evh_PassportNoteMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Passport Note [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_PassportNoteMember" xlink:href="evh-20211231.xsd#evh_PassportNoteMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_PassportNoteMember" xlink:to="lab_evh_PassportNoteMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_d5063255-b7c9-4030-b3c3-eb2cd2593c9f_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities and shareholders' equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesDeferredExpense_06ae9dd0-83be-466a-9a53-2dda97b4e225_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesDeferredExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract fulfillment costs</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesDeferredExpense_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesDeferredExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Deferred Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesDeferredExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilitiesDeferredExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesDeferredExpense" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesDeferredExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_14f88106-5502-4939-ad52-c7d5d102b150_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other, net</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Other Adjustments, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare_a1af85f2-fc1e-4eea-9dcd-6b582bd2db84_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discontinued operations, diluted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Discontinued Operations and Disposal of Discontinued Operations, Net of Tax, Per Diluted Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" xlink:to="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember_efd5d561-e4f5-463a-b74a-b24db98de797_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1st Tranche</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Tranche One [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:to="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCurrent_e63ed2ca-c1d8-4a6e-947a-3f7c8c0f93e1_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCurrent_00412d54-77ae-4500-88f6-f37155024a9a_verboseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term deferred revenue</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_78a6dd93-0323-40c7-97fd-763381cbc3c6_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2026</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_ea4325e7-583b-485f-9526-84b2669cd5b5_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercised (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsStockPriceTriggerConsecutiveTerm_ba958af5-27fe-42ae-a17e-5d39e65bb616_terseLabel_en-US" xlink:label="lab_evh_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsStockPriceTriggerConsecutiveTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consecutive term</link:label>
    <link:label id="lab_evh_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsStockPriceTriggerConsecutiveTerm_label_en-US" xlink:label="lab_evh_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsStockPriceTriggerConsecutiveTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement By Share-based Payment Award, Award Vesting Rights, Stock Price Trigger, Consecutive Term</link:label>
    <link:label id="lab_evh_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsStockPriceTriggerConsecutiveTerm_documentation_en-US" xlink:label="lab_evh_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsStockPriceTriggerConsecutiveTerm" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement By Share-based Payment Award, Award Vesting Rights, Stock Price Trigger, Consecutive Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsStockPriceTriggerConsecutiveTerm" xlink:href="evh-20211231.xsd#evh_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsStockPriceTriggerConsecutiveTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsStockPriceTriggerConsecutiveTerm" xlink:to="lab_evh_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsStockPriceTriggerConsecutiveTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsStockPriceIncreasePercentage_b85c5132-d3dd-4082-a1b0-f3a6e6eb3a5b_terseLabel_en-US" xlink:label="lab_evh_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsStockPriceIncreasePercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award vesting rights, stock price increase, percentage</link:label>
    <link:label id="lab_evh_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsStockPriceIncreasePercentage_label_en-US" xlink:label="lab_evh_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsStockPriceIncreasePercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement By Share-based Payment Award, Award Vesting Rights, Stock Price Increase, Percentage</link:label>
    <link:label id="lab_evh_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsStockPriceIncreasePercentage_documentation_en-US" xlink:label="lab_evh_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsStockPriceIncreasePercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement By Share-based Payment Award, Award Vesting Rights, Stock Price Increase, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsStockPriceIncreasePercentage" xlink:href="evh-20211231.xsd#evh_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsStockPriceIncreasePercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsStockPriceIncreasePercentage" xlink:to="lab_evh_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsStockPriceIncreasePercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SupplementalCashFlowElementsAbstract_0fef78ea-5f79-490a-a35c-f6a65664b159_terseLabel_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowElementsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Cash Flow Elements [Abstract]</link:label>
    <link:label id="lab_us-gaap_SupplementalCashFlowElementsAbstract_label_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowElementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Cash Flow Elements [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowElementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SupplementalCashFlowElementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalCashFlowElementsAbstract" xlink:to="lab_us-gaap_SupplementalCashFlowElementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionTable_87f6694c-71b0-4f47-9949-1cc7c9dcf0a3_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Table]</link:label>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionTable_label_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable" xlink:to="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskLineItems_8d4ab597-a987-4057-943d-93290da3f8c3_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk [Line Items]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskLineItems_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskLineItems" xlink:to="lab_us-gaap_ConcentrationRiskLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_EarningsLossAvailabletoCommonShareholdersAbstract_a091ba07-a57d-47d0-b90e-2664bb54cceb_verboseLabel_en-US" xlink:label="lab_evh_EarningsLossAvailabletoCommonShareholdersAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less:</link:label>
    <link:label id="lab_evh_EarningsLossAvailabletoCommonShareholdersAbstract_label_en-US" xlink:label="lab_evh_EarningsLossAvailabletoCommonShareholdersAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings (Loss) Available to Common Shareholders [Abstract]</link:label>
    <link:label id="lab_evh_EarningsLossAvailabletoCommonShareholdersAbstract_documentation_en-US" xlink:label="lab_evh_EarningsLossAvailabletoCommonShareholdersAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings (Loss) Available to Common Shareholders [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_EarningsLossAvailabletoCommonShareholdersAbstract" xlink:href="evh-20211231.xsd#evh_EarningsLossAvailabletoCommonShareholdersAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_EarningsLossAvailabletoCommonShareholdersAbstract" xlink:to="lab_evh_EarningsLossAvailabletoCommonShareholdersAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxContingencyTable_c2e1fd56-84e1-4bc0-b7f9-ef6a0eadebb3_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxContingencyTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Contingency [Table]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxContingencyTable_label_en-US" xlink:label="lab_us-gaap_IncomeTaxContingencyTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Contingency [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxContingencyTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxContingencyTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxContingencyTable" xlink:to="lab_us-gaap_IncomeTaxContingencyTable" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_InitialTermLoanFacilityMember_77bd226b-13f7-45ca-88df-c99658e53c91_terseLabel_en-US" xlink:label="lab_evh_InitialTermLoanFacilityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Initial Term Loan Facility</link:label>
    <link:label id="lab_evh_InitialTermLoanFacilityMember_label_en-US" xlink:label="lab_evh_InitialTermLoanFacilityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Initial Term Loan Facility [Member]</link:label>
    <link:label id="lab_evh_InitialTermLoanFacilityMember_documentation_en-US" xlink:label="lab_evh_InitialTermLoanFacilityMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Initial Term Loan Facility [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_InitialTermLoanFacilityMember" xlink:href="evh-20211231.xsd#evh_InitialTermLoanFacilityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_InitialTermLoanFacilityMember" xlink:to="lab_evh_InitialTermLoanFacilityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_3d4c6faa-992a-4863-995e-4aa09e046664_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings (Loss) Per Common Share</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareTextBlock" xlink:to="lab_us-gaap_EarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation_ad416f38-63fa-4060-a9d4-cb3fc96407ab_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation_label_en-US" xlink:label="lab_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation" xlink:to="lab_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_a69e96ef-0b27-458f-828b-fb99c6023771_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expenses</link:label>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_label_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Expenses [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpensesAbstract" xlink:to="lab_us-gaap_OperatingExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_c584c204-7f0b-4e9f-ab3f-cf2b2a53d316_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents [Domain]</link:label>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_label_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MinimumMember_7be42f10-3c6a-484b-89e7-79032bd24458_terseLabel_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum</link:label>
    <link:label id="lab_srt_MinimumMember_label_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember" xlink:to="lab_srt_MinimumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_8d705ce1-5c94-47ee-b207-7f5f0e844cbf_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2023</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_281011e9-73cc-4b14-aa1b-5f08db21d1a4_terseLabel_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect of exchange rate on cash and cash equivalents and restricted cash</link:label>
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosure_e94346a4-6e6a-4682-aa78-009f2a22fd58_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total fair value of liabilities measured on a recurring basis</link:label>
    <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial and Nonfinancial Liabilities, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosure" xlink:to="lab_us-gaap_LiabilitiesFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_3dc4b565-c58e-4f39-91c8-d4f4d3e9bb88_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss from continuing operations before income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpense_be35d717-1726-4458-a02d-65fb82faa198_verboseLabel_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, general and administrative expenses</link:label>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpense_75725b4a-f75e-4701-a4bd-1925162382ff_terseLabel_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, general and administrative expenses</link:label>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, General and Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightUnissued_fed89f2f-b30e-4cd2-969b-14601e293ecb_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightUnissued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants agreed to be sold (in shares)</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightUnissued_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightUnissued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right, Unissued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightUnissued" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightUnissued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightUnissued" xlink:to="lab_us-gaap_ClassOfWarrantOrRightUnissued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredFinanceCostsNet_5a73a1a6-fcc5-4eb3-a81f-e242396e9214_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredFinanceCostsNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt issuance costs</link:label>
    <link:label id="lab_us-gaap_DeferredFinanceCostsNet_label_en-US" xlink:label="lab_us-gaap_DeferredFinanceCostsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Issuance Costs, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredFinanceCostsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredFinanceCostsNet" xlink:to="lab_us-gaap_DeferredFinanceCostsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable_ed845249-a3b9-4134-871c-3ae0d6b02a6d_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Table]</link:label>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable_label_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable" xlink:to="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightDomain_37ec4ceb-248d-4468-90b5-b9f4454ff7e1_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right [Domain]</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightDomain_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain" xlink:to="lab_us-gaap_ClassOfWarrantOrRightDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_ProceedsFromReinsurance_4f79a505-75fb-49c3-9c61-5c2d28e705ec_negatedLabel_en-US" xlink:label="lab_evh_ProceedsFromReinsurance" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reinsurance payments paid (received)</link:label>
    <link:label id="lab_evh_ProceedsFromReinsurance_label_en-US" xlink:label="lab_evh_ProceedsFromReinsurance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds From Reinsurance</link:label>
    <link:label id="lab_evh_ProceedsFromReinsurance_documentation_en-US" xlink:label="lab_evh_ProceedsFromReinsurance" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds From Reinsurance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_ProceedsFromReinsurance" xlink:href="evh-20211231.xsd#evh_ProceedsFromReinsurance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_ProceedsFromReinsurance" xlink:to="lab_evh_ProceedsFromReinsurance" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CumulativeEffectPeriodOfAdoptionAxis_d77a20be-7785-425f-8954-2a31452e9585_terseLabel_en-US" xlink:label="lab_srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative Effect Period Of Adoption [Axis]</link:label>
    <link:label id="lab_srt_CumulativeEffectPeriodOfAdoptionAxis_label_en-US" xlink:label="lab_srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative Effect, Period of Adoption [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:to="lab_srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InsuranceDisclosureTextBlock_bf82f673-329c-45d9-b0f2-0d1070a93147_terseLabel_en-US" xlink:label="lab_us-gaap_InsuranceDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reserves for Claims and Performance-Based Arrangements</link:label>
    <link:label id="lab_us-gaap_InsuranceDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_InsuranceDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Insurance Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InsuranceDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InsuranceDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InsuranceDisclosureTextBlock" xlink:to="lab_us-gaap_InsuranceDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_39adbaa5-5147-4c00-8fe1-0166cdbc9b67_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Voting interests acquired</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Percentage of Voting Interests Acquired</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" xlink:to="lab_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightTable_2823cd2f-f34f-497f-87ca-32f6dc8be094_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right [Table]</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightTable_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable" xlink:to="lab_us-gaap_ClassOfWarrantOrRightTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_25abf1d9-0807-4332-890f-84d2a8cd9344_verboseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-current restricted cash</link:label>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_label_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash and Cash Equivalents, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" xlink:to="lab_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashFlowSupplementalDisclosuresTextBlock_2ce236f6-d856-4770-badc-a3d3c5c9a211_terseLabel_en-US" xlink:label="lab_us-gaap_CashFlowSupplementalDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Cash Flow Information</link:label>
    <link:label id="lab_us-gaap_CashFlowSupplementalDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_CashFlowSupplementalDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Flow, Supplemental Disclosures [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowSupplementalDisclosuresTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashFlowSupplementalDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashFlowSupplementalDisclosuresTextBlock" xlink:to="lab_us-gaap_CashFlowSupplementalDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_4d0619b4-9994-4c69-864b-288ca41bddb5_terseLabel_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt</link:label>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureTextBlock" xlink:to="lab_us-gaap_DebtDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_cbd4c16f-93ea-4bbe-9d3f-f920fe70e99e_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Components of income tax expense (benefit)</link:label>
    <link:label id="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_eb794728-936f-43db-8515-66cd24bc8a3d_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Goodwill and Intangible Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:to="lab_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditMember_9811561e-3f04-41c8-8404-a914ccf703c4_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit</link:label>
    <link:label id="lab_us-gaap_LineOfCreditMember_label_en-US" xlink:label="lab_us-gaap_LineOfCreditMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditMember" xlink:to="lab_us-gaap_LineOfCreditMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_ebd46558-12b9-4e18-872e-a5d2e5a6c64c_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based Compensation</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_ProceedsFromAssetAcquisitionEscrow_8450c36c-d07e-42fa-80e8-7ede9f738256_terseLabel_en-US" xlink:label="lab_evh_ProceedsFromAssetAcquisitionEscrow" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount received from escrow in asset acquisition</link:label>
    <link:label id="lab_evh_ProceedsFromAssetAcquisitionEscrow_label_en-US" xlink:label="lab_evh_ProceedsFromAssetAcquisitionEscrow" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds From Asset Acquisition Escrow</link:label>
    <link:label id="lab_evh_ProceedsFromAssetAcquisitionEscrow_documentation_en-US" xlink:label="lab_evh_ProceedsFromAssetAcquisitionEscrow" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds From Asset Acquisition Escrow</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_ProceedsFromAssetAcquisitionEscrow" xlink:href="evh-20211231.xsd#evh_ProceedsFromAssetAcquisitionEscrow"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_ProceedsFromAssetAcquisitionEscrow" xlink:to="lab_evh_ProceedsFromAssetAcquisitionEscrow" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SeniorNotesMember_b1c495f9-74e7-4595-a756-667153f15000_terseLabel_en-US" xlink:label="lab_us-gaap_SeniorNotesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes</link:label>
    <link:label id="lab_us-gaap_SeniorNotesMember_label_en-US" xlink:label="lab_us-gaap_SeniorNotesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorNotesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeniorNotesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SeniorNotesMember" xlink:to="lab_us-gaap_SeniorNotesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_ab1d25b7-7d78-41a8-a761-60befe72b8c4_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 3</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel3Member" xlink:to="lab_us-gaap_FairValueInputsLevel3Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeasesPolicyTextBlock_94fa0db9-e0b4-4285-889f-a3fab99f50b7_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases</link:label>
    <link:label id="lab_us-gaap_LesseeLeasesPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Leases [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeasesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeasesPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CreditLossFinancialInstrumentTextBlock_88f69b79-0856-4f04-bd8f-b12f611e86d9_terseLabel_en-US" xlink:label="lab_us-gaap_CreditLossFinancialInstrumentTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Losses</link:label>
    <link:label id="lab_us-gaap_CreditLossFinancialInstrumentTextBlock_label_en-US" xlink:label="lab_us-gaap_CreditLossFinancialInstrumentTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Loss, Financial Instrument [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditLossFinancialInstrumentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditLossFinancialInstrumentTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CreditLossFinancialInstrumentTextBlock" xlink:to="lab_us-gaap_CreditLossFinancialInstrumentTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_b4668066-9431-4c92-a942-566a40e39d50_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement Inputs and Valuation Techniques [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement Inputs and Valuation Techniques [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CapitalizedContractCostDomain_ec87deb6-4572-4459-9cf1-76c48f3217ed_terseLabel_en-US" xlink:label="lab_us-gaap_CapitalizedContractCostDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capitalized Contract Cost [Domain]</link:label>
    <link:label id="lab_us-gaap_CapitalizedContractCostDomain_label_en-US" xlink:label="lab_us-gaap_CapitalizedContractCostDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capitalized Contract Cost [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedContractCostDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalizedContractCostDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalizedContractCostDomain" xlink:to="lab_us-gaap_CapitalizedContractCostDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredTaxLiabilities_017b4042-e4c8-4c1c-9227-d3e4b27a2f84_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredTaxLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax liabilities, net</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredTaxLiabilities_label_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredTaxLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Deferred Tax Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredTaxLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredTaxLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredTaxLiabilities" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredTaxLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireInterestInSubsidiariesAndAffiliates_744d116c-41c3-4371-a298-a4eadb3a9cfd_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireInterestInSubsidiariesAndAffiliates" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments in equity method investees</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireInterestInSubsidiariesAndAffiliates_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireInterestInSubsidiariesAndAffiliates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Interest in Subsidiaries and Affiliates</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireInterestInSubsidiariesAndAffiliates" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireInterestInSubsidiariesAndAffiliates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireInterestInSubsidiariesAndAffiliates" xlink:to="lab_us-gaap_PaymentsToAcquireInterestInSubsidiariesAndAffiliates" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesAccruedCompensationAndEmployeeBenefits_ec9f6e28-5ace-45c5-b453-d302aa37a7d0_terseLabel_en-US" xlink:label="lab_evh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesAccruedCompensationAndEmployeeBenefits" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued compensation and employee benefits</link:label>
    <link:label id="lab_evh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesAccruedCompensationAndEmployeeBenefits_label_en-US" xlink:label="lab_evh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesAccruedCompensationAndEmployeeBenefits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Accrued Compensation And Employee Benefits</link:label>
    <link:label id="lab_evh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesAccruedCompensationAndEmployeeBenefits_documentation_en-US" xlink:label="lab_evh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesAccruedCompensationAndEmployeeBenefits" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Accrued Compensation And Employee Benefits</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesAccruedCompensationAndEmployeeBenefits" xlink:href="evh-20211231.xsd#evh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesAccruedCompensationAndEmployeeBenefits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesAccruedCompensationAndEmployeeBenefits" xlink:to="lab_evh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesAccruedCompensationAndEmployeeBenefits" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_MedicareCustomersMember_1a2bc227-b36d-412d-bd4e-9fda0927a690_terseLabel_en-US" xlink:label="lab_evh_MedicareCustomersMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medicare</link:label>
    <link:label id="lab_evh_MedicareCustomersMember_label_en-US" xlink:label="lab_evh_MedicareCustomersMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medicare Customers [Member]</link:label>
    <link:label id="lab_evh_MedicareCustomersMember_documentation_en-US" xlink:label="lab_evh_MedicareCustomersMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medicare Customers</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_MedicareCustomersMember" xlink:href="evh-20211231.xsd#evh_MedicareCustomersMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_MedicareCustomersMember" xlink:to="lab_evh_MedicareCustomersMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LettersOfCreditOutstandingAmount_71d65d24-dfc6-4593-b269-3f37e68c3a8b_verboseLabel_en-US" xlink:label="lab_us-gaap_LettersOfCreditOutstandingAmount" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Letters of credit outstanding, amount</link:label>
    <link:label id="lab_us-gaap_LettersOfCreditOutstandingAmount_ebf38516-b4fd-471f-9e71-d66009fb4234_terseLabel_en-US" xlink:label="lab_us-gaap_LettersOfCreditOutstandingAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Letter of Credit Amount Required</link:label>
    <link:label id="lab_us-gaap_LettersOfCreditOutstandingAmount_label_en-US" xlink:label="lab_us-gaap_LettersOfCreditOutstandingAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Letters of Credit Outstanding, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LettersOfCreditOutstandingAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LettersOfCreditOutstandingAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LettersOfCreditOutstandingAmount" xlink:to="lab_us-gaap_LettersOfCreditOutstandingAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueLineItems_4103dc68-2b2b-459f-96d5-3dc73541881c_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Line Items]</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueLineItems_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems" xlink:to="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAcquiredDuringPeriod_2adebb59-9a69-4bd1-94aa-d549bebd7ec1_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAcquiredDuringPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill acquired</link:label>
    <link:label id="lab_us-gaap_GoodwillAcquiredDuringPeriod_label_en-US" xlink:label="lab_us-gaap_GoodwillAcquiredDuringPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, Acquired During Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAcquiredDuringPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAcquiredDuringPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAcquiredDuringPeriod" xlink:to="lab_us-gaap_GoodwillAcquiredDuringPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_DiscontinuedOperationGainLossOnPurchasePriceAdjustmentsNetOfTax_00210790-2d12-4713-9113-530ba24689b5_negatedLabel_en-US" xlink:label="lab_evh_DiscontinuedOperationGainLossOnPurchasePriceAdjustmentsNetOfTax" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss on purchase price adjustments</link:label>
    <link:label id="lab_evh_DiscontinuedOperationGainLossOnPurchasePriceAdjustmentsNetOfTax_label_en-US" xlink:label="lab_evh_DiscontinuedOperationGainLossOnPurchasePriceAdjustmentsNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discontinued Operation, Gain (Loss) on Purchase Price Adjustments, Net of Tax</link:label>
    <link:label id="lab_evh_DiscontinuedOperationGainLossOnPurchasePriceAdjustmentsNetOfTax_documentation_en-US" xlink:label="lab_evh_DiscontinuedOperationGainLossOnPurchasePriceAdjustmentsNetOfTax" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discontinued Operation, Gain (Loss) on Purchase Price Adjustments, Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_DiscontinuedOperationGainLossOnPurchasePriceAdjustmentsNetOfTax" xlink:href="evh-20211231.xsd#evh_DiscontinuedOperationGainLossOnPurchasePriceAdjustmentsNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_DiscontinuedOperationGainLossOnPurchasePriceAdjustmentsNetOfTax" xlink:to="lab_evh_DiscontinuedOperationGainLossOnPurchasePriceAdjustmentsNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_8300f55c-10ab-40f5-8a0e-300f4cde4d5c_terseLabel_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Presentation</link:label>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Accounting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PerformanceSharesMember_e3f3c295-1e8f-4c56-b966-b63afa259874_terseLabel_en-US" xlink:label="lab_us-gaap_PerformanceSharesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance-based stock options</link:label>
    <link:label id="lab_us-gaap_PerformanceSharesMember_label_en-US" xlink:label="lab_us-gaap_PerformanceSharesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance Shares [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PerformanceSharesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PerformanceSharesMember" xlink:to="lab_us-gaap_PerformanceSharesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_7733b3b0-6583-4266-b5a0-f4ef696ee2fe_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies (See Note 11)</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingencies" xlink:to="lab_us-gaap_CommitmentsAndContingencies" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_StockIssuedDuringPeriodSharesEarnOuts_a197c281-da25-4023-9d21-3c8871ed7cad_terseLabel_en-US" xlink:label="lab_evh_StockIssuedDuringPeriodSharesEarnOuts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class A common stock issued for payment of earn-outs (in shares)</link:label>
    <link:label id="lab_evh_StockIssuedDuringPeriodSharesEarnOuts_label_en-US" xlink:label="lab_evh_StockIssuedDuringPeriodSharesEarnOuts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Earn-outs</link:label>
    <link:label id="lab_evh_StockIssuedDuringPeriodSharesEarnOuts_documentation_en-US" xlink:label="lab_evh_StockIssuedDuringPeriodSharesEarnOuts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Earn-outs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_StockIssuedDuringPeriodSharesEarnOuts" xlink:href="evh-20211231.xsd#evh_StockIssuedDuringPeriodSharesEarnOuts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_StockIssuedDuringPeriodSharesEarnOuts" xlink:to="lab_evh_StockIssuedDuringPeriodSharesEarnOuts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_13439c2d-bff1-4ff3-a070-84f9f24c926f_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated other comprehensive income (loss)</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_67b62838-1165-4826-908f-7c9063fb3e95_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_923c006b-9b20-4660-b663-784796006104_terseLabel_en-US" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Allowance for doubtful accounts, current</link:label>
    <link:label id="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_6c837b81-d06a-42c5-9b87-09b747041a3d_negatedPeriodStartLabel_en-US" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:role="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance as of beginning of period</link:label>
    <link:label id="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_e3e1fcd3-0ed9-4c37-9d47-5db8097a1ade_negatedPeriodEndLabel_en-US" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:role="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance as of end of period</link:label>
    <link:label id="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_label_en-US" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, Allowance for Credit Loss, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:to="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsPerformanceGoalThreshold_6b9b51db-f9f5-4336-b5e5-f5af43b2efe3_terseLabel_en-US" xlink:label="lab_evh_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsPerformanceGoalThreshold" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance goal threshold</link:label>
    <link:label id="lab_evh_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsPerformanceGoalThreshold_label_en-US" xlink:label="lab_evh_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsPerformanceGoalThreshold" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Performance Goal Threshold</link:label>
    <link:label id="lab_evh_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsPerformanceGoalThreshold_documentation_en-US" xlink:label="lab_evh_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsPerformanceGoalThreshold" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Performance Goal Threshold</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsPerformanceGoalThreshold" xlink:href="evh-20211231.xsd#evh_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsPerformanceGoalThreshold"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsPerformanceGoalThreshold" xlink:to="lab_evh_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsPerformanceGoalThreshold" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageAdjustmentOfSharesEarnedTotalShareholderReturnInTopQuartile_27ed9121-a61d-4f8f-aa19-863920ae53fd_terseLabel_en-US" xlink:label="lab_evh_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageAdjustmentOfSharesEarnedTotalShareholderReturnInTopQuartile" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage adjustment of shares earned, total shareholder return in top quartile</link:label>
    <link:label id="lab_evh_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageAdjustmentOfSharesEarnedTotalShareholderReturnInTopQuartile_label_en-US" xlink:label="lab_evh_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageAdjustmentOfSharesEarnedTotalShareholderReturnInTopQuartile" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Percentage Adjustment of Shares Earned, Total Shareholder Return in Top Quartile</link:label>
    <link:label id="lab_evh_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageAdjustmentOfSharesEarnedTotalShareholderReturnInTopQuartile_documentation_en-US" xlink:label="lab_evh_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageAdjustmentOfSharesEarnedTotalShareholderReturnInTopQuartile" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Percentage Adjustment of Shares Earned, Total Shareholder Return in Top Quartile</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageAdjustmentOfSharesEarnedTotalShareholderReturnInTopQuartile" xlink:href="evh-20211231.xsd#evh_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageAdjustmentOfSharesEarnedTotalShareholderReturnInTopQuartile"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageAdjustmentOfSharesEarnedTotalShareholderReturnInTopQuartile" xlink:to="lab_evh_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageAdjustmentOfSharesEarnedTotalShareholderReturnInTopQuartile" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedStockMember_e29a10f5-8777-4b55-805c-454493897c87_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted stock</link:label>
    <link:label id="lab_us-gaap_RestrictedStockMember_label_en-US" xlink:label="lab_us-gaap_RestrictedStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockMember" xlink:to="lab_us-gaap_RestrictedStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsOfDebtIssuanceCosts_e382a5f1-d2b5-4fb8-a14c-60b9d3d88d6e_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsOfDebtIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments of debt issuance costs</link:label>
    <link:label id="lab_us-gaap_PaymentsOfDebtIssuanceCosts_label_en-US" xlink:label="lab_us-gaap_PaymentsOfDebtIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments of Debt Issuance Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDebtIssuanceCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsOfDebtIssuanceCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfDebtIssuanceCosts" xlink:to="lab_us-gaap_PaymentsOfDebtIssuanceCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfDebt_0bb6cffe-e96a-4b96-b83d-1ad21a30678c_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from issuance of debt</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfDebt_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Issuance of Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfDebt" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses_f8df1e4c-bb8f-4604-9aec-0617056e8b56_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-deductible goodwill impairment</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Impairment Losses, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupClassificationAxis_9c0a2ddc-f3f8-4b34-9272-e111e244ea01_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupClassificationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group Classification [Axis]</link:label>
    <link:label id="lab_us-gaap_DisposalGroupClassificationAxis_label_en-US" xlink:label="lab_us-gaap_DisposalGroupClassificationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group Classification [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupClassificationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis" xlink:to="lab_us-gaap_DisposalGroupClassificationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AuditorName_a4d1bf3e-2ae5-4fc6-9d8e-ab25b3df7c01_terseLabel_en-US" xlink:label="lab_dei_AuditorName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Name</link:label>
    <link:label id="lab_dei_AuditorName_label_en-US" xlink:label="lab_dei_AuditorName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorName" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AuditorName" xlink:to="lab_dei_AuditorName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_483efea7-dda4-48c8-bc1a-db41c659bd20_terseLabel_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockShares_8ed71756-2f7e-44c0-b552-a23059f5d2f6_terseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury stock, at cost (in shares)</link:label>
    <link:label id="lab_us-gaap_TreasuryStockShares_label_en-US" xlink:label="lab_us-gaap_TreasuryStockShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockShares" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockShares" xlink:to="lab_us-gaap_TreasuryStockShares" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightOutstanding_f55a3193-f09e-4fb0-8c69-811a22c336c1_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants and rights outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightOutstanding_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:to="lab_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_bf597f1c-520c-4f89-8d31-b094f14af78c_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations_41c3a576-1640-4ae4-a214-1d64541e4c67_terseLabel_en-US" xlink:label="lab_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows provided by (used in) operating activities</link:label>
    <link:label id="lab_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations_label_en-US" xlink:label="lab_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Provided by (Used in) Operating Activities, Discontinued Operations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations" xlink:to="lab_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_stpr_CA_36f6a7ba-bdbe-417b-a415-c77e554cab3c_terseLabel_en-US" xlink:label="lab_stpr_CA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Brea, CA</link:label>
    <link:label id="lab_stpr_CA_label_en-US" xlink:label="lab_stpr_CA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CALIFORNIA</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_CA" xlink:href="https://xbrl.sec.gov/stpr/2021/stpr-2021.xsd#stpr_CA"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_stpr_CA" xlink:to="lab_stpr_CA" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVestedAndExpectedToVest_56644d3a-419d-4bd2-9d19-41641ce2747c_terseLabel_en-US" xlink:label="lab_evh_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVestedAndExpectedToVest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate Intrinsic Value</link:label>
    <link:label id="lab_evh_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVestedAndExpectedToVest_label_en-US" xlink:label="lab_evh_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVestedAndExpectedToVest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement By Share-based Payment Award, Equity Instruments Other Than Options, Aggregate Intrinsic Value, Vested And Expected To Vest</link:label>
    <link:label id="lab_evh_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVestedAndExpectedToVest_documentation_en-US" xlink:label="lab_evh_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVestedAndExpectedToVest" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement By Share-based Payment Award, Equity Instruments Other Than Options, Aggregate Intrinsic Value, Vested And Expected To Vest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVestedAndExpectedToVest" xlink:href="evh-20211231.xsd#evh_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVestedAndExpectedToVest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVestedAndExpectedToVest" xlink:to="lab_evh_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVestedAndExpectedToVest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_6e8f33e4-b85f-4986-8b49-8da9bf76a146_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity interest issued or issuable, number of shares (in shares)</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Equity Interest Issued or Issuable, Number of Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" xlink:to="lab_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_CollateralwithFinancialInstitutionsMember_2141444c-cb43-47bf-be32-6f8c835298e3_terseLabel_en-US" xlink:label="lab_evh_CollateralwithFinancialInstitutionsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collateral with financial institutions</link:label>
    <link:label id="lab_evh_CollateralwithFinancialInstitutionsMember_label_en-US" xlink:label="lab_evh_CollateralwithFinancialInstitutionsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collateral with Financial Institutions [Member]</link:label>
    <link:label id="lab_evh_CollateralwithFinancialInstitutionsMember_documentation_en-US" xlink:label="lab_evh_CollateralwithFinancialInstitutionsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collateral with Financial Institutions [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_CollateralwithFinancialInstitutionsMember" xlink:href="evh-20211231.xsd#evh_CollateralwithFinancialInstitutionsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_CollateralwithFinancialInstitutionsMember" xlink:to="lab_evh_CollateralwithFinancialInstitutionsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense_592dbb92-b1ee-43af-8a30-d4e6da943d9e_totalLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total operating expenses</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense_label_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Operating Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_87a25b46-8dea-4c0e-9046-5cd014bf6530_terseLabel_en-US" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current</link:label>
    <link:label id="lab_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_label_en-US" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Income Tax Expense (Benefit), Continuing Operations [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="lab_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract_0cca827a-a2e0-4ecc-bdca-1c27be325c44_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockMember_aa43c816-764d-4da5-9188-00a3b3219ebf_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_label_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentIncomeInterest_e8ae6729-fa28-4008-ae67-cf643a025875_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentIncomeInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest income</link:label>
    <link:label id="lab_us-gaap_InvestmentIncomeInterest_label_en-US" xlink:label="lab_us-gaap_InvestmentIncomeInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Income, Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentIncomeInterest" xlink:to="lab_us-gaap_InvestmentIncomeInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_2f96386b-8bf7-44e8-b614-3402e066d1ab_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Foreign</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsForReinsurance_f627e88b-7534-4211-9cbe-4cdcceb87c5b_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsForReinsurance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reinsurance payments paid (received)</link:label>
    <link:label id="lab_us-gaap_PaymentsForReinsurance_label_en-US" xlink:label="lab_us-gaap_PaymentsForReinsurance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for Reinsurance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForReinsurance" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsForReinsurance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForReinsurance" xlink:to="lab_us-gaap_PaymentsForReinsurance" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_StockIssuedDuringPeriodSharesConversionofConvertibleSecuritiesTaxImpact_6db31394-4900-48c0-8eb9-90516e708fc0_terseLabel_en-US" xlink:label="lab_evh_StockIssuedDuringPeriodSharesConversionofConvertibleSecuritiesTaxImpact" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax impact of Class B exchange</link:label>
    <link:label id="lab_evh_StockIssuedDuringPeriodSharesConversionofConvertibleSecuritiesTaxImpact_label_en-US" xlink:label="lab_evh_StockIssuedDuringPeriodSharesConversionofConvertibleSecuritiesTaxImpact" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares Conversion of Convertible Securities, Tax Impact</link:label>
    <link:label id="lab_evh_StockIssuedDuringPeriodSharesConversionofConvertibleSecuritiesTaxImpact_documentation_en-US" xlink:label="lab_evh_StockIssuedDuringPeriodSharesConversionofConvertibleSecuritiesTaxImpact" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares Conversion of Convertible Securities, Tax Impact</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_StockIssuedDuringPeriodSharesConversionofConvertibleSecuritiesTaxImpact" xlink:href="evh-20211231.xsd#evh_StockIssuedDuringPeriodSharesConversionofConvertibleSecuritiesTaxImpact"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_StockIssuedDuringPeriodSharesConversionofConvertibleSecuritiesTaxImpact" xlink:to="lab_evh_StockIssuedDuringPeriodSharesConversionofConvertibleSecuritiesTaxImpact" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_8f2ef214-33a7-406f-bac7-3de9e79c197b_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating loss</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="lab_us-gaap_OperatingIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_2748e9a6-d5b1-40a8-9051-ba6cd75a8359_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employer discretionary contribution amount</link:label>
    <link:label id="lab_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_label_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Contribution Plan, Employer Discretionary Contribution Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:to="lab_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinancingReceivablesPeriodPastDueAxis_0e87bc3d-b5e5-455c-b8ee-937eca143aad_terseLabel_en-US" xlink:label="lab_us-gaap_FinancingReceivablesPeriodPastDueAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Asset, Period Past Due [Axis]</link:label>
    <link:label id="lab_us-gaap_FinancingReceivablesPeriodPastDueAxis_label_en-US" xlink:label="lab_us-gaap_FinancingReceivablesPeriodPastDueAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Asset, Aging [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancingReceivablesPeriodPastDueAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancingReceivablesPeriodPastDueAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancingReceivablesPeriodPastDueAxis" xlink:to="lab_us-gaap_FinancingReceivablesPeriodPastDueAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_688198db-1478-49ba-9fda-8accde072128_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease liability - current</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_a4286c24-b99f-4bf9-b822-78d7ce20dc09_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2023</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_GainOnTransferOfMembership_d29aac74-601d-4dc7-a8cd-f3c9a5588bea_terseLabel_en-US" xlink:label="lab_evh_GainOnTransferOfMembership" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain on transfer of membership</link:label>
    <link:label id="lab_evh_GainOnTransferOfMembership_1ebbfaed-36b5-4a46-b7c9-3c3dd6b1e8d2_negatedTerseLabel_en-US" xlink:label="lab_evh_GainOnTransferOfMembership" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain on transfer of membership</link:label>
    <link:label id="lab_evh_GainOnTransferOfMembership_label_en-US" xlink:label="lab_evh_GainOnTransferOfMembership" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain On Transfer Of Membership</link:label>
    <link:label id="lab_evh_GainOnTransferOfMembership_documentation_en-US" xlink:label="lab_evh_GainOnTransferOfMembership" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain On Transfer Of Membership</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_GainOnTransferOfMembership" xlink:href="evh-20211231.xsd#evh_GainOnTransferOfMembership"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_GainOnTransferOfMembership" xlink:to="lab_evh_GainOnTransferOfMembership" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_CurrentYearClaimsAndClaimsAdjustmentExpenseIncludingCostOfGoodsAndServicesSoldExcludingDepreciationAndAmortization_8bd541d7-f2ab-47d7-8204-fa4b01c41fb6_verboseLabel_en-US" xlink:label="lab_evh_CurrentYearClaimsAndClaimsAdjustmentExpenseIncludingCostOfGoodsAndServicesSoldExcludingDepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Incurred costs related to current year</link:label>
    <link:label id="lab_evh_CurrentYearClaimsAndClaimsAdjustmentExpenseIncludingCostOfGoodsAndServicesSoldExcludingDepreciationAndAmortization_label_en-US" xlink:label="lab_evh_CurrentYearClaimsAndClaimsAdjustmentExpenseIncludingCostOfGoodsAndServicesSoldExcludingDepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Year Claims And Claims Adjustment Expense, Including Cost Of Goods And Services Sold, Excluding Depreciation And Amortization</link:label>
    <link:label id="lab_evh_CurrentYearClaimsAndClaimsAdjustmentExpenseIncludingCostOfGoodsAndServicesSoldExcludingDepreciationAndAmortization_documentation_en-US" xlink:label="lab_evh_CurrentYearClaimsAndClaimsAdjustmentExpenseIncludingCostOfGoodsAndServicesSoldExcludingDepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Year Claims And Claims Adjustment Expense, Including Cost Of Goods And Services Sold, Excluding Depreciation And Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_CurrentYearClaimsAndClaimsAdjustmentExpenseIncludingCostOfGoodsAndServicesSoldExcludingDepreciationAndAmortization" xlink:href="evh-20211231.xsd#evh_CurrentYearClaimsAndClaimsAdjustmentExpenseIncludingCostOfGoodsAndServicesSoldExcludingDepreciationAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_CurrentYearClaimsAndClaimsAdjustmentExpenseIncludingCostOfGoodsAndServicesSoldExcludingDepreciationAndAmortization" xlink:to="lab_evh_CurrentYearClaimsAndClaimsAdjustmentExpenseIncludingCostOfGoodsAndServicesSoldExcludingDepreciationAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensation_72dc0760-29f7-4907-b7c1-b2ee9c97b1f7_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation expense</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Noncash Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation" xlink:to="lab_us-gaap_ShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_7625bf80-9780-4b3a-b739-452d0f17b0b2_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repositioning and Other Changes</link:label>
    <link:label id="lab_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring and Related Activities Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:to="lab_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_0cbaa802-4b80-4fc3-b1da-7c3afb376340_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Depreciation_11e69a1b-8f02-4d08-abf2-f5c900207eb3_terseLabel_en-US" xlink:label="lab_us-gaap_Depreciation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation expense</link:label>
    <link:label id="lab_us-gaap_Depreciation_label_en-US" xlink:label="lab_us-gaap_Depreciation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Depreciation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Depreciation" xlink:to="lab_us-gaap_Depreciation" xlink:type="arc" order="1"/>
    <link:label id="lab_stpr_IL_d31868d3-ab3b-47ca-912d-5502204f6939_terseLabel_en-US" xlink:label="lab_stpr_IL" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Riverside, IL</link:label>
    <link:label id="lab_stpr_IL_label_en-US" xlink:label="lab_stpr_IL" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ILLINOIS</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_IL" xlink:href="https://xbrl.sec.gov/stpr/2021/stpr-2021.xsd#stpr_IL"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_stpr_IL" xlink:to="lab_stpr_IL" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_PaymentsOfMakeWholePremium_cd7ba602-eaaa-448b-9e8b-ad654d6f7c47_terseLabel_en-US" xlink:label="lab_evh_PaymentsOfMakeWholePremium" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments of make-whole premium</link:label>
    <link:label id="lab_evh_PaymentsOfMakeWholePremium_label_en-US" xlink:label="lab_evh_PaymentsOfMakeWholePremium" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments Of Make-Whole Premium</link:label>
    <link:label id="lab_evh_PaymentsOfMakeWholePremium_documentation_en-US" xlink:label="lab_evh_PaymentsOfMakeWholePremium" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments Of Make-Whole Premium</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_PaymentsOfMakeWholePremium" xlink:href="evh-20211231.xsd#evh_PaymentsOfMakeWholePremium"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_PaymentsOfMakeWholePremium" xlink:to="lab_evh_PaymentsOfMakeWholePremium" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_ContractFulfillmentCostsMember_7cec8aa5-d2dc-49e1-87cb-7154ffd386e3_terseLabel_en-US" xlink:label="lab_evh_ContractFulfillmentCostsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract Fulfillment Costs</link:label>
    <link:label id="lab_evh_ContractFulfillmentCostsMember_label_en-US" xlink:label="lab_evh_ContractFulfillmentCostsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract Fulfillment Costs [Member]</link:label>
    <link:label id="lab_evh_ContractFulfillmentCostsMember_documentation_en-US" xlink:label="lab_evh_ContractFulfillmentCostsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract Fulfillment Costs [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_ContractFulfillmentCostsMember" xlink:href="evh-20211231.xsd#evh_ContractFulfillmentCostsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_ContractFulfillmentCostsMember" xlink:to="lab_evh_ContractFulfillmentCostsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseOpeningBalanceAdjustments_9fb3d792-26a1-4c45-aea2-81aefc1a54a0_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseOpeningBalanceAdjustments" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other adjustments</link:label>
    <link:label id="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseOpeningBalanceAdjustments_label_en-US" xlink:label="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseOpeningBalanceAdjustments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability for Unpaid Claims and Claims Adjustment Expense, Adjustments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseOpeningBalanceAdjustments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseOpeningBalanceAdjustments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseOpeningBalanceAdjustments" xlink:to="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseOpeningBalanceAdjustments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockMember_24ab4f03-045d-4ca6-9fd6-67b64acc6bfa_terseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock</link:label>
    <link:label id="lab_us-gaap_TreasuryStockMember_label_en-US" xlink:label="lab_us-gaap_TreasuryStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockMember" xlink:to="lab_us-gaap_TreasuryStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_16f1b690-44ee-4271-8a38-0303dd54dc9e_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]</link:label>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_label_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis" xlink:to="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_2d4ba01a-b697-4f7f-9733-7ac45542a769_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accrued Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_SharebasedCompensationAwardSubTrancheOneMember_4ce3d705-56fe-47b1-952f-47a4e6ad01ce_terseLabel_en-US" xlink:label="lab_evh_SharebasedCompensationAwardSubTrancheOneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vest on March 1, 2019</link:label>
    <link:label id="lab_evh_SharebasedCompensationAwardSubTrancheOneMember_label_en-US" xlink:label="lab_evh_SharebasedCompensationAwardSubTrancheOneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Award, Sub-Tranche One [Member]</link:label>
    <link:label id="lab_evh_SharebasedCompensationAwardSubTrancheOneMember_documentation_en-US" xlink:label="lab_evh_SharebasedCompensationAwardSubTrancheOneMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Award, Sub-Tranche One [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_SharebasedCompensationAwardSubTrancheOneMember" xlink:href="evh-20211231.xsd#evh_SharebasedCompensationAwardSubTrancheOneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_SharebasedCompensationAwardSubTrancheOneMember" xlink:to="lab_evh_SharebasedCompensationAwardSubTrancheOneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxesPaid_79ae98b7-892f-4f00-9aed-518ca0141a66_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxesPaid" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash paid for taxes, net</link:label>
    <link:label id="lab_us-gaap_IncomeTaxesPaid_label_en-US" xlink:label="lab_us-gaap_IncomeTaxesPaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesPaid" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxesPaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxesPaid" xlink:to="lab_us-gaap_IncomeTaxesPaid" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_NewCenturyHealthMember_212e486e-b4d0-4193-a1c0-d0424a3d1aaf_terseLabel_en-US" xlink:label="lab_evh_NewCenturyHealthMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Century Health</link:label>
    <link:label id="lab_evh_NewCenturyHealthMember_label_en-US" xlink:label="lab_evh_NewCenturyHealthMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Century Health [Member]</link:label>
    <link:label id="lab_evh_NewCenturyHealthMember_documentation_en-US" xlink:label="lab_evh_NewCenturyHealthMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Century Health [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_NewCenturyHealthMember" xlink:href="evh-20211231.xsd#evh_NewCenturyHealthMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_NewCenturyHealthMember" xlink:to="lab_evh_NewCenturyHealthMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssued1_3776930c-4cf9-49fd-9397-2fb5589bba2d_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssued1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class A and Class B common stock issued in connection with business combinations</link:label>
    <link:label id="lab_us-gaap_StockIssued1_label_en-US" xlink:label="lab_us-gaap_StockIssued1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssued1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssued1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssued1" xlink:to="lab_us-gaap_StockIssued1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LegalFees_3644462f-90cf-4f7e-bdf7-d3bd9ec976e1_terseLabel_en-US" xlink:label="lab_us-gaap_LegalFees" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal expenses</link:label>
    <link:label id="lab_us-gaap_LegalFees_label_en-US" xlink:label="lab_us-gaap_LegalFees" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal Fees</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LegalFees" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LegalFees"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LegalFees" xlink:to="lab_us-gaap_LegalFees" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CreditLossAbstract_4bc455a3-2089-47fe-a6fc-76b721c99e3c_terseLabel_en-US" xlink:label="lab_us-gaap_CreditLossAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Loss [Abstract]</link:label>
    <link:label id="lab_us-gaap_CreditLossAbstract_label_en-US" xlink:label="lab_us-gaap_CreditLossAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Loss [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditLossAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditLossAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CreditLossAbstract" xlink:to="lab_us-gaap_CreditLossAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_UniversityHealthCaredbaPassportHealthPlanMember_3aaff9b4-4700-499d-8de0-69ed3c8b62c8_terseLabel_en-US" xlink:label="lab_evh_UniversityHealthCaredbaPassportHealthPlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Passport</link:label>
    <link:label id="lab_evh_UniversityHealthCaredbaPassportHealthPlanMember_label_en-US" xlink:label="lab_evh_UniversityHealthCaredbaPassportHealthPlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">University Health Care d/b/a Passport Health Plan [Member]</link:label>
    <link:label id="lab_evh_UniversityHealthCaredbaPassportHealthPlanMember_documentation_en-US" xlink:label="lab_evh_UniversityHealthCaredbaPassportHealthPlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">University Health Care d/b/a Passport Health Plan [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_UniversityHealthCaredbaPassportHealthPlanMember" xlink:href="evh-20211231.xsd#evh_UniversityHealthCaredbaPassportHealthPlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_UniversityHealthCaredbaPassportHealthPlanMember" xlink:to="lab_evh_UniversityHealthCaredbaPassportHealthPlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Liabilities_b6b1ce42-c33c-4fda-817f-c9835dadb130_totalLabel_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_Liabilities_label_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities" xlink:to="lab_us-gaap_Liabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermAccountsNotesAndLoansReceivableNetNoncurrent_e2bc2f49-5cb2-46eb-bd05-7ee0cedb1e9a_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermAccountsNotesAndLoansReceivableNetNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term receivables</link:label>
    <link:label id="lab_us-gaap_LongTermAccountsNotesAndLoansReceivableNetNoncurrent_label_en-US" xlink:label="lab_us-gaap_LongTermAccountsNotesAndLoansReceivableNetNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts and Financing Receivable, after Allowance for Credit Loss, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermAccountsNotesAndLoansReceivableNetNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermAccountsNotesAndLoansReceivableNetNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermAccountsNotesAndLoansReceivableNetNoncurrent" xlink:to="lab_us-gaap_LongTermAccountsNotesAndLoansReceivableNetNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingRevenueReconcilingItemLineItems_743108d5-9354-477c-9df0-0400e91acfc4_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingRevenueReconcilingItemLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting, Revenue Reconciling Item [Line Items]</link:label>
    <link:label id="lab_us-gaap_SegmentReportingRevenueReconcilingItemLineItems_label_en-US" xlink:label="lab_us-gaap_SegmentReportingRevenueReconcilingItemLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting, Revenue Reconciling Item [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingRevenueReconcilingItemLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingRevenueReconcilingItemLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingRevenueReconcilingItemLineItems" xlink:to="lab_us-gaap_SegmentReportingRevenueReconcilingItemLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsOfDebtExtinguishmentCosts_b9405e11-f31e-438b-b823-beb422b13606_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsOfDebtExtinguishmentCosts" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayment and termination of Credit Agreement including settlement of warrants</link:label>
    <link:label id="lab_us-gaap_PaymentsOfDebtExtinguishmentCosts_label_en-US" xlink:label="lab_us-gaap_PaymentsOfDebtExtinguishmentCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment for Debt Extinguishment or Debt Prepayment Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDebtExtinguishmentCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsOfDebtExtinguishmentCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfDebtExtinguishmentCosts" xlink:to="lab_us-gaap_PaymentsOfDebtExtinguishmentCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsNetAbstract_870316ad-fab6-45cc-a60f-01f762a81b87_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsNetAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsNetAbstract_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsNetAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Net [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNetAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsNetAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="lab_us-gaap_DeferredTaxAssetsNetAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_6e33de9f-b6d1-41b0-bc68-2e98d99aa8ee_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2022</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_bdb0569e-0f73-4bef-bec3-0abd1b1e8aee_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ConsolidationItemsAxis_946a468e-64c0-40b5-a380-591add65bd52_terseLabel_en-US" xlink:label="lab_srt_ConsolidationItemsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation Items [Axis]</link:label>
    <link:label id="lab_srt_ConsolidationItemsAxis_label_en-US" xlink:label="lab_srt_ConsolidationItemsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation Items [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ConsolidationItemsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ConsolidationItemsAxis" xlink:to="lab_srt_ConsolidationItemsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputTypeAxis_5da6641d-e1b7-47e1-bd66-c31cfe56dde3_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input Type [Axis]</link:label>
    <link:label id="lab_us-gaap_MeasurementInputTypeAxis_label_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputTypeAxis" xlink:to="lab_us-gaap_MeasurementInputTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLossCarryforwards_c4ff6998-67ac-4d9e-8512-3cad434af8bc_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net operating loss carryforwards</link:label>
    <link:label id="lab_us-gaap_OperatingLossCarryforwards_label_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Loss Carryforwards</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwards"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLossCarryforwards" xlink:to="lab_us-gaap_OperatingLossCarryforwards" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_44200ae4-73a3-4774-b6a4-096e94504db8_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued" xlink:to="lab_us-gaap_CommonStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_45f08775-e0c6-48c1-8437-56e7c8aced81_negatedLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Settlements</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedTangibleAssets_40a6db42-19aa-467e-b6cb-6993e711a8f6_totalLabel_en-US" xlink:label="lab_evh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedTangibleAssets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total tangible assets acquired</link:label>
    <link:label id="lab_evh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedTangibleAssets_label_en-US" xlink:label="lab_evh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedTangibleAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Tangible Assets</link:label>
    <link:label id="lab_evh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedTangibleAssets_documentation_en-US" xlink:label="lab_evh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedTangibleAssets" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Tangible Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedTangibleAssets" xlink:href="evh-20211231.xsd#evh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedTangibleAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedTangibleAssets" xlink:to="lab_evh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedTangibleAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_DebtInstrumentRepurchasePriceDueToChangeInSalePriceAsPercentageOfConversionPrice_72b6e606-7b09-4819-9036-f63dcfa4852c_terseLabel_en-US" xlink:label="lab_evh_DebtInstrumentRepurchasePriceDueToChangeInSalePriceAsPercentageOfConversionPrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repurchase covenant, repurchase price due to change in sale price as percentage of conversion price</link:label>
    <link:label id="lab_evh_DebtInstrumentRepurchasePriceDueToChangeInSalePriceAsPercentageOfConversionPrice_label_en-US" xlink:label="lab_evh_DebtInstrumentRepurchasePriceDueToChangeInSalePriceAsPercentageOfConversionPrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Repurchase Price Due To Change In Sale Price As Percentage Of Conversion Price</link:label>
    <link:label id="lab_evh_DebtInstrumentRepurchasePriceDueToChangeInSalePriceAsPercentageOfConversionPrice_documentation_en-US" xlink:label="lab_evh_DebtInstrumentRepurchasePriceDueToChangeInSalePriceAsPercentageOfConversionPrice" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Repurchase Price Due To Change In Sale Price As Percentage Of Conversion Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_DebtInstrumentRepurchasePriceDueToChangeInSalePriceAsPercentageOfConversionPrice" xlink:href="evh-20211231.xsd#evh_DebtInstrumentRepurchasePriceDueToChangeInSalePriceAsPercentageOfConversionPrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_DebtInstrumentRepurchasePriceDueToChangeInSalePriceAsPercentageOfConversionPrice" xlink:to="lab_evh_DebtInstrumentRepurchasePriceDueToChangeInSalePriceAsPercentageOfConversionPrice" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_ProfessionalServicesRestructuringMember_8cb72353-741a-4f32-9de9-693ed890b21b_terseLabel_en-US" xlink:label="lab_evh_ProfessionalServicesRestructuringMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Professional services</link:label>
    <link:label id="lab_evh_ProfessionalServicesRestructuringMember_label_en-US" xlink:label="lab_evh_ProfessionalServicesRestructuringMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Professional Services, Restructuring [Member]</link:label>
    <link:label id="lab_evh_ProfessionalServicesRestructuringMember_documentation_en-US" xlink:label="lab_evh_ProfessionalServicesRestructuringMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Professional Services, Restructuring</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_ProfessionalServicesRestructuringMember" xlink:href="evh-20211231.xsd#evh_ProfessionalServicesRestructuringMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_ProfessionalServicesRestructuringMember" xlink:to="lab_evh_ProfessionalServicesRestructuringMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsForRepurchaseOfWarrants_b12ab3bc-ba9f-4804-aa38-ac4f687d182c_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsForRepurchaseOfWarrants" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to settle outstanding warrants</link:label>
    <link:label id="lab_us-gaap_PaymentsForRepurchaseOfWarrants_label_en-US" xlink:label="lab_us-gaap_PaymentsForRepurchaseOfWarrants" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for Repurchase of Warrants</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfWarrants" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsForRepurchaseOfWarrants"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForRepurchaseOfWarrants" xlink:to="lab_us-gaap_PaymentsForRepurchaseOfWarrants" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_4d2df5ee-82ec-41d2-9073-58ab7f5e3652_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_AccountsReceivableAllowanceForCreditLossAcquiredDuringPeriod_2bf48262-415c-4fc5-b8ff-2cd3d57d0bce_negatedLabel_en-US" xlink:label="lab_evh_AccountsReceivableAllowanceForCreditLossAcquiredDuringPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Passport acquisition</link:label>
    <link:label id="lab_evh_AccountsReceivableAllowanceForCreditLossAcquiredDuringPeriod_label_en-US" xlink:label="lab_evh_AccountsReceivableAllowanceForCreditLossAcquiredDuringPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, Allowance for Credit Loss, Acquired During Period</link:label>
    <link:label id="lab_evh_AccountsReceivableAllowanceForCreditLossAcquiredDuringPeriod_documentation_en-US" xlink:label="lab_evh_AccountsReceivableAllowanceForCreditLossAcquiredDuringPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, Allowance for Credit Loss, Acquired During Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_AccountsReceivableAllowanceForCreditLossAcquiredDuringPeriod" xlink:href="evh-20211231.xsd#evh_AccountsReceivableAllowanceForCreditLossAcquiredDuringPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_AccountsReceivableAllowanceForCreditLossAcquiredDuringPeriod" xlink:to="lab_evh_AccountsReceivableAllowanceForCreditLossAcquiredDuringPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt_a680819a-86df-4ed0-855a-a319e260238b_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss on extinguishment of debt, net</link:label>
    <link:label id="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt_b90ebf89-3fff-4f88-b313-8875d05f65ba_negatedLabel_en-US" xlink:label="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss on repayment of debt</link:label>
    <link:label id="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt_9774273a-94cd-474d-9944-3b7d6fa0f97d_terseLabel_en-US" xlink:label="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss on repayment of debt, net</link:label>
    <link:label id="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt_93c7fc92-b5ed-4270-9d62-66b0c7e1689b_verboseLabel_en-US" xlink:label="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss on extinguishment of debt</link:label>
    <link:label id="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt_label_en-US" xlink:label="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) on Extinguishment of Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:to="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EurodollarMember_36b4cc43-dbd8-412e-b770-d91b87688836_terseLabel_en-US" xlink:label="lab_us-gaap_EurodollarMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Eurodollar</link:label>
    <link:label id="lab_us-gaap_EurodollarMember_label_en-US" xlink:label="lab_us-gaap_EurodollarMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Eurodollar [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EurodollarMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EurodollarMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EurodollarMember" xlink:to="lab_us-gaap_EurodollarMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_e4102dc6-54e7-4560-a510-7be5e0a4c274_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes in unrecognized tax benefits</link:label>
    <link:label id="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Unrecognized Tax Benefits Roll Forward [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_c65aaa30-8dab-4a3f-a7f6-5b4be33de147_verboseLabel_en-US" xlink:label="lab_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Computer software</link:label>
    <link:label id="lab_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_label_en-US" xlink:label="lab_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Software and Software Development Costs [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SoftwareAndSoftwareDevelopmentCostsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xlink:to="lab_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_7d467f48-d0ee-4d27-a46c-757e1c16cf82_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risk-free interest rate, minimum</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_c802c7ff-9ee9-4743-9b1c-78fbefa87567_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestExpense_9458e9e8-f0e2-4f9e-a91a-8d995df87497_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest expense</link:label>
    <link:label id="lab_us-gaap_InterestExpense_label_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpense" xlink:to="lab_us-gaap_InterestExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_d3822c09-b8ed-4e25-9115-daa690dd8721_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued compensation and employee benefits</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Employee Related Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_9f145b98-725a-4a01-bcbf-ae752369c0d2_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Tax Expense (Benefit), Continuing Operations [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_label_en-US" xlink:label="lab_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discontinued Operations and Disposal Groups [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" xlink:to="lab_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NotesReceivableMember_622bd985-65ae-4953-bb93-675eaa753155_terseLabel_en-US" xlink:label="lab_us-gaap_NotesReceivableMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Notes Receivable</link:label>
    <link:label id="lab_us-gaap_NotesReceivableMember_label_en-US" xlink:label="lab_us-gaap_NotesReceivableMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Notes Receivable [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesReceivableMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NotesReceivableMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NotesReceivableMember" xlink:to="lab_us-gaap_NotesReceivableMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_8ca0d6cc-1e4e-4d0d-b8f6-f4ffcf9e510e_totalLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net assets acquired</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CapitalizedContractCostAmortization_69f68aba-14af-49c9-a40f-2dd8b22033dd_terseLabel_en-US" xlink:label="lab_us-gaap_CapitalizedContractCostAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of contract cost assets</link:label>
    <link:label id="lab_us-gaap_CapitalizedContractCostAmortization_b46c9a35-f7ac-45e2-a338-94af7ae8ec63_verboseLabel_en-US" xlink:label="lab_us-gaap_CapitalizedContractCostAmortization" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract cost amortization</link:label>
    <link:label id="lab_us-gaap_CapitalizedContractCostAmortization_label_en-US" xlink:label="lab_us-gaap_CapitalizedContractCostAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capitalized Contract Cost, Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedContractCostAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalizedContractCostAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalizedContractCostAmortization" xlink:to="lab_us-gaap_CapitalizedContractCostAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_71c49878-7113-4da5-82da-400499a75778_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained earnings (accumulated deficit)</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_DisposalGroupIncludingDiscontinuedOperationClaimsExpense_77a08f50-bcd8-4852-ab22-8428fb93478f_terseLabel_en-US" xlink:label="lab_evh_DisposalGroupIncludingDiscontinuedOperationClaimsExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Claims expenses</link:label>
    <link:label id="lab_evh_DisposalGroupIncludingDiscontinuedOperationClaimsExpense_label_en-US" xlink:label="lab_evh_DisposalGroupIncludingDiscontinuedOperationClaimsExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Claims Expense</link:label>
    <link:label id="lab_evh_DisposalGroupIncludingDiscontinuedOperationClaimsExpense_documentation_en-US" xlink:label="lab_evh_DisposalGroupIncludingDiscontinuedOperationClaimsExpense" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Claims Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_DisposalGroupIncludingDiscontinuedOperationClaimsExpense" xlink:href="evh-20211231.xsd#evh_DisposalGroupIncludingDiscontinuedOperationClaimsExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_DisposalGroupIncludingDiscontinuedOperationClaimsExpense" xlink:to="lab_evh_DisposalGroupIncludingDiscontinuedOperationClaimsExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_682daa2b-6dd7-490e-ab43-e14246d3f2d1_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement Inputs and Valuation Techniques [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement Inputs and Valuation Techniques [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_b169feac-9679-49cd-ade0-03efc57b6b17_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expiration period</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_4806960b-3987-4197-be2d-94680f4e272f_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFilerCategory_cd0ef4df-64a5-4fa1-926a-a90945edc7c6_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_label_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFilerCategory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTextBlock_8cc9774d-5065-44ef-aba7-cee183828426_terseLabel_en-US" xlink:label="lab_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of revenue from segments to consolidated</link:label>
    <link:label id="lab_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTextBlock_label_en-US" xlink:label="lab_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of Revenue from Segments to Consolidated [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTextBlock" xlink:to="lab_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_754722cf-3720-475c-a675-3feb34f0bd31_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risk-free interest rate</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskTable_bd12d94c-3a66-4ff6-82d6-db5dd3756923_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk [Table]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskTable_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskTable" xlink:to="lab_us-gaap_ConcentrationRiskTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromHedgeFinancingActivities_96ec9fbe-4e62-49e2-b115-2e7681f933ec_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromHedgeFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of warrant liability</link:label>
    <link:label id="lab_us-gaap_ProceedsFromHedgeFinancingActivities_label_en-US" xlink:label="lab_us-gaap_ProceedsFromHedgeFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Hedge, Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromHedgeFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromHedgeFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromHedgeFinancingActivities" xlink:to="lab_us-gaap_ProceedsFromHedgeFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_BelowMarketLeasesMember_340f1ed3-9e05-41e0-81c8-2676272230b4_terseLabel_en-US" xlink:label="lab_evh_BelowMarketLeasesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Below market lease, net</link:label>
    <link:label id="lab_evh_BelowMarketLeasesMember_label_en-US" xlink:label="lab_evh_BelowMarketLeasesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Below Market Leases [Member]</link:label>
    <link:label id="lab_evh_BelowMarketLeasesMember_documentation_en-US" xlink:label="lab_evh_BelowMarketLeasesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Below Market Leases [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_BelowMarketLeasesMember" xlink:href="evh-20211231.xsd#evh_BelowMarketLeasesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_BelowMarketLeasesMember" xlink:to="lab_evh_BelowMarketLeasesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_a8da66fe-80be-4cb0-8529-09568a4ac7ee_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes in contingent consideration measured at fair value</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationAbstract_d9361de6-c062-48f4-bb90-b8cc5e66b647_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">LIABILITIES</link:label>
    <link:label id="lab_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Liabilities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationAbstract" xlink:to="lab_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock_b3bc6be8-f9db-486e-8600-836d40bf0645_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recently Issued Accounting Standards</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Standards Update and Change in Accounting Principle [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" xlink:to="lab_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1_6a57362a-0fc4-4202-9501-2b2d04e0e665_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Remaining amortization period (years)</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Convertible, Remaining Discount Amortization Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1" xlink:to="lab_us-gaap_DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_faadd7d6-bba5-47b2-834a-d6a972b9b8e7_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from stock option exercises</link:label>
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Stock Options Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromStockOptionsExercised" xlink:to="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_65e85dc6-2391-4568-9408-58e4ffea7643_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_a0ce6077-e702-486c-b061-6310b178dedf_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_2ace7c29-74b7-4d1a-b0d3-ee9abbad9c9b_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_de4ecb32-e6df-4344-8d8a-8ec6422e66a5_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative effect adjustment</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_538fc43e-c110-4b5e-b8b1-073ae09c8f0e_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_17f1ccc2-8349-4e42-9859-71d660f905b9_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MovementInValuationAllowancesAndReservesRollForward_bb58d5ee-699a-434f-9a09-7f62e1c73782_terseLabel_en-US" xlink:label="lab_us-gaap_MovementInValuationAllowancesAndReservesRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_MovementInValuationAllowancesAndReservesRollForward_label_en-US" xlink:label="lab_us-gaap_MovementInValuationAllowancesAndReservesRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MovementInValuationAllowancesAndReservesRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward" xlink:to="lab_us-gaap_MovementInValuationAllowancesAndReservesRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_CashHeldInInternationalBanksPercentage_f728c1cc-5f2d-4078-957c-20775def64ea_terseLabel_en-US" xlink:label="lab_evh_CashHeldInInternationalBanksPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of cash held in international banks (less than)</link:label>
    <link:label id="lab_evh_CashHeldInInternationalBanksPercentage_label_en-US" xlink:label="lab_evh_CashHeldInInternationalBanksPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Held In International Banks, Percentage</link:label>
    <link:label id="lab_evh_CashHeldInInternationalBanksPercentage_documentation_en-US" xlink:label="lab_evh_CashHeldInInternationalBanksPercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Held In International Banks, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_CashHeldInInternationalBanksPercentage" xlink:href="evh-20211231.xsd#evh_CashHeldInInternationalBanksPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_CashHeldInInternationalBanksPercentage" xlink:to="lab_evh_CashHeldInInternationalBanksPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_d3f61e36-9230-4bd6-86cb-05dba329d89b_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract" xlink:to="lab_us-gaap_FairValueDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_88e30221-6636-42fb-bb16-c52e909666e7_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainsLossesOnExtinguishmentOfDebtBeforeWriteOffOfDeferredDebtIssuanceCost_eab4863a-9485-45ba-b09a-5d69a101c547_negatedLabel_en-US" xlink:label="lab_us-gaap_GainsLossesOnExtinguishmentOfDebtBeforeWriteOffOfDeferredDebtIssuanceCost" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss on extinguishment of debt, including fees paid to lenders</link:label>
    <link:label id="lab_us-gaap_GainsLossesOnExtinguishmentOfDebtBeforeWriteOffOfDeferredDebtIssuanceCost_label_en-US" xlink:label="lab_us-gaap_GainsLossesOnExtinguishmentOfDebtBeforeWriteOffOfDeferredDebtIssuanceCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) on Extinguishment of Debt, before Write off of Debt Issuance Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebtBeforeWriteOffOfDeferredDebtIssuanceCost" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebtBeforeWriteOffOfDeferredDebtIssuanceCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainsLossesOnExtinguishmentOfDebtBeforeWriteOffOfDeferredDebtIssuanceCost" xlink:to="lab_us-gaap_GainsLossesOnExtinguishmentOfDebtBeforeWriteOffOfDeferredDebtIssuanceCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskTypeDomain_5a6c88f5-51eb-4fd1-a2e6-6dab7d8d42a0_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskTypeDomain_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain" xlink:to="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTable_305e1110-be7a-4a58-977b-7ec12c23385a_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Table]</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTable_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable" xlink:to="lab_us-gaap_DisaggregationOfRevenueTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract_1d7faa78-2b71-48f8-b219-176556d99f59_terseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investments and Joint Ventures [Abstract]</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investments and Joint Ventures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract" xlink:to="lab_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_40ec32bb-32a2-4609-867b-3ed675662482_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Federal</link:label>
    <link:label id="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Federal Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_PassportAssetAcquisitionMember_4e6104f3-1aa5-4efc-89f3-5fafd1af28c9_terseLabel_en-US" xlink:label="lab_evh_PassportAssetAcquisitionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Passport Asset Acquisition</link:label>
    <link:label id="lab_evh_PassportAssetAcquisitionMember_label_en-US" xlink:label="lab_evh_PassportAssetAcquisitionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Passport Asset Acquisition [Member]</link:label>
    <link:label id="lab_evh_PassportAssetAcquisitionMember_documentation_en-US" xlink:label="lab_evh_PassportAssetAcquisitionMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Passport Asset Acquisition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_PassportAssetAcquisitionMember" xlink:href="evh-20211231.xsd#evh_PassportAssetAcquisitionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_PassportAssetAcquisitionMember" xlink:to="lab_evh_PassportAssetAcquisitionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_cb0c6fa7-ffb3-48f4-bed8-79ad20665c99_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Thereafter</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, after Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock_c5300e73-7b6e-4a43-807f-b7d7cd6d68e9_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of related parties</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Related Party Transactions [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductOrServiceAxis_0a210906-1f5d-4203-b143-560162b76bdf_terseLabel_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:label id="lab_srt_ProductOrServiceAxis_label_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductOrServiceAxis" xlink:to="lab_srt_ProductOrServiceAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward_85a7fbca-3d47-4dd2-ad30-65b50fc79446_terseLabel_en-US" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, Allowance for Credit Loss [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward_label_en-US" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, Allowance for Credit Loss [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward" xlink:to="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilitiesCurrent_2ad8392a-c7ea-4113-a5a5-9f4e8123db6d_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued liabilities</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityPublicFloat_5a629a0e-e85e-4ff7-bdff-1af4b095d45b_terseLabel_en-US" xlink:label="lab_dei_EntityPublicFloat" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Public Float</link:label>
    <link:label id="lab_dei_EntityPublicFloat_label_en-US" xlink:label="lab_dei_EntityPublicFloat" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Public Float</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityPublicFloat" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityPublicFloat"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityPublicFloat" xlink:to="lab_dei_EntityPublicFloat" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentsIncorporatedByReferenceTextBlock_bdab699d-a5db-4eff-a08d-6e3f17071327_terseLabel_en-US" xlink:label="lab_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Documents Incorporated by Reference</link:label>
    <link:label id="lab_dei_DocumentsIncorporatedByReferenceTextBlock_label_en-US" xlink:label="lab_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Documents Incorporated by Reference [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentsIncorporatedByReferenceTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="lab_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_FloridaBlueMedicareIncMember_be4712b3-ef1c-455a-b908-e17e1b882d59_terseLabel_en-US" xlink:label="lab_evh_FloridaBlueMedicareIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Florida Blue Medicare, Inc.</link:label>
    <link:label id="lab_evh_FloridaBlueMedicareIncMember_label_en-US" xlink:label="lab_evh_FloridaBlueMedicareIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Florida Blue Medicare, Inc. [Member]</link:label>
    <link:label id="lab_evh_FloridaBlueMedicareIncMember_documentation_en-US" xlink:label="lab_evh_FloridaBlueMedicareIncMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Florida Blue Medicare, Inc.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_FloridaBlueMedicareIncMember" xlink:href="evh-20211231.xsd#evh_FloridaBlueMedicareIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_FloridaBlueMedicareIncMember" xlink:to="lab_evh_FloridaBlueMedicareIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPeriodThreeMember_c2387153-b16d-4654-aed8-858eaf0cddbc_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPeriodThreeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">After the Fourth Anniversary of the Closing of the Senior Credit Facilities but Prior to the Fifth Anniversary</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPeriodThreeMember_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPeriodThreeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Redemption, Period Three [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodThreeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodThreeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodThreeMember" xlink:to="lab_us-gaap_DebtInstrumentRedemptionPeriodThreeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractBasedIntangibleAssetsMember_9a66318a-3ea7-4b25-bb4a-d298f17fa113_terseLabel_en-US" xlink:label="lab_us-gaap_ContractBasedIntangibleAssetsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Provider network contracts</link:label>
    <link:label id="lab_us-gaap_ContractBasedIntangibleAssetsMember_label_en-US" xlink:label="lab_us-gaap_ContractBasedIntangibleAssetsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract-Based Intangible Assets [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractBasedIntangibleAssetsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractBasedIntangibleAssetsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractBasedIntangibleAssetsMember" xlink:to="lab_us-gaap_ContractBasedIntangibleAssetsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DiscontinuedOperationsDisposedOfBySaleMember_499f760c-6ea2-4859-b962-597c46c6abcf_terseLabel_en-US" xlink:label="lab_us-gaap_DiscontinuedOperationsDisposedOfBySaleMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discontinued Operations, Disposed of by Sale</link:label>
    <link:label id="lab_us-gaap_DiscontinuedOperationsDisposedOfBySaleMember_label_en-US" xlink:label="lab_us-gaap_DiscontinuedOperationsDisposedOfBySaleMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discontinued Operations, Disposed of by Sale [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationsDisposedOfBySaleMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DiscontinuedOperationsDisposedOfBySaleMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DiscontinuedOperationsDisposedOfBySaleMember" xlink:to="lab_us-gaap_DiscontinuedOperationsDisposedOfBySaleMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_0aa1d97a-67c0-4f60-8257-1b23f8bb4a95_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign currency translation adjustment</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_404f418b-d7e7-4669-b28a-363332968202_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign currency translation adjustment</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementLineItems_a76def7c-a67e-4063-ab03-1cc988df6dfc_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_label_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesDomain_f9e482ac-91d4-4a78-bdea-2b437a256b32_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances and Reserves [Domain]</link:label>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesDomain_label_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances and Reserves [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowancesAndReservesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain" xlink:to="lab_us-gaap_ValuationAllowancesAndReservesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_TransformationServicesMember_d7b39c97-0190-48b2-bda6-cc492eef3e3a_verboseLabel_en-US" xlink:label="lab_evh_TransformationServicesMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Transformation services</link:label>
    <link:label id="lab_evh_TransformationServicesMember_label_en-US" xlink:label="lab_evh_TransformationServicesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Transformation Services [Member]</link:label>
    <link:label id="lab_evh_TransformationServicesMember_documentation_en-US" xlink:label="lab_evh_TransformationServicesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Transformation Services [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_TransformationServicesMember" xlink:href="evh-20211231.xsd#evh_TransformationServicesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_TransformationServicesMember" xlink:to="lab_evh_TransformationServicesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_1713a725-ff1e-409b-961b-3ceb8dd2a40a_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="lab_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_88a88e71-21f8-4bcd-9176-1f463c1571f5_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Contract with Customer, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:to="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_fee02d50-41d5-4653-a7f2-08d1dd654b6f_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_ConvertibleSeniorNotesdue2021Member_fb266184-fa8e-4e55-9005-f16ad8c19adc_terseLabel_en-US" xlink:label="lab_evh_ConvertibleSeniorNotesdue2021Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2021 Notes</link:label>
    <link:label id="lab_evh_ConvertibleSeniorNotesdue2021Member_label_en-US" xlink:label="lab_evh_ConvertibleSeniorNotesdue2021Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Senior Notes due 2021 [Member]</link:label>
    <link:label id="lab_evh_ConvertibleSeniorNotesdue2021Member_documentation_en-US" xlink:label="lab_evh_ConvertibleSeniorNotesdue2021Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Senior Notes due 2021 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_ConvertibleSeniorNotesdue2021Member" xlink:href="evh-20211231.xsd#evh_ConvertibleSeniorNotesdue2021Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_ConvertibleSeniorNotesdue2021Member" xlink:to="lab_evh_ConvertibleSeniorNotesdue2021Member" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_CashFDICInsuredAmountPercentage_4d5fb18b-635d-4000-8783-5b18343f663c_terseLabel_en-US" xlink:label="lab_evh_CashFDICInsuredAmountPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of cash and cash equivalents held with FDIC participating bank</link:label>
    <link:label id="lab_evh_CashFDICInsuredAmountPercentage_label_en-US" xlink:label="lab_evh_CashFDICInsuredAmountPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, FDIC Insured Amount, Percentage</link:label>
    <link:label id="lab_evh_CashFDICInsuredAmountPercentage_documentation_en-US" xlink:label="lab_evh_CashFDICInsuredAmountPercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, FDIC Insured Amount, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_CashFDICInsuredAmountPercentage" xlink:href="evh-20211231.xsd#evh_CashFDICInsuredAmountPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_CashFDICInsuredAmountPercentage" xlink:to="lab_evh_CashFDICInsuredAmountPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DomesticCountryMember_325c44e5-0125-4480-a9ad-06c6fefcbd5c_verboseLabel_en-US" xlink:label="lab_us-gaap_DomesticCountryMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Federal</link:label>
    <link:label id="lab_us-gaap_DomesticCountryMember_label_en-US" xlink:label="lab_us-gaap_DomesticCountryMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Domestic Tax Authority [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticCountryMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DomesticCountryMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DomesticCountryMember" xlink:to="lab_us-gaap_DomesticCountryMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InternalUseSoftwarePolicy_3d0bcea9-f9bb-487d-ae4c-f16041e2a2fc_terseLabel_en-US" xlink:label="lab_us-gaap_InternalUseSoftwarePolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Software Development Costs</link:label>
    <link:label id="lab_us-gaap_InternalUseSoftwarePolicy_label_en-US" xlink:label="lab_us-gaap_InternalUseSoftwarePolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Internal Use Software, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InternalUseSoftwarePolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InternalUseSoftwarePolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InternalUseSoftwarePolicy" xlink:to="lab_us-gaap_InternalUseSoftwarePolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_IncreaseDecreaseInAccountsReceivableAndContractWithCustomerAsset_050957f2-088e-4473-a7e6-5200e9484011_negatedTerseLabel_en-US" xlink:label="lab_evh_IncreaseDecreaseInAccountsReceivableAndContractWithCustomerAsset" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable, net and contract assets</link:label>
    <link:label id="lab_evh_IncreaseDecreaseInAccountsReceivableAndContractWithCustomerAsset_label_en-US" xlink:label="lab_evh_IncreaseDecreaseInAccountsReceivableAndContractWithCustomerAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) In Accounts Receivable And Contract With Customer, Asset</link:label>
    <link:label id="lab_evh_IncreaseDecreaseInAccountsReceivableAndContractWithCustomerAsset_documentation_en-US" xlink:label="lab_evh_IncreaseDecreaseInAccountsReceivableAndContractWithCustomerAsset" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) In Accounts Receivable And Contract With Customer, Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_IncreaseDecreaseInAccountsReceivableAndContractWithCustomerAsset" xlink:href="evh-20211231.xsd#evh_IncreaseDecreaseInAccountsReceivableAndContractWithCustomerAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_IncreaseDecreaseInAccountsReceivableAndContractWithCustomerAsset" xlink:to="lab_evh_IncreaseDecreaseInAccountsReceivableAndContractWithCustomerAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh_6760bcec-b14f-402f-b460-2ccd174950b5_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent consideration arrangements (up to)</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_38c3d735-acd5-4cea-9bcc-bee35865350e_terseLabel_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureAbstract" xlink:to="lab_us-gaap_DebtDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_LeveragedStockUnitsLSUsMember_478b1e76-6aa0-483f-bf0e-b99661a94e2c_verboseLabel_en-US" xlink:label="lab_evh_LeveragedStockUnitsLSUsMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">LSUs</link:label>
    <link:label id="lab_evh_LeveragedStockUnitsLSUsMember_2f234823-c6ac-45ee-b8ed-99ca0fea5853_terseLabel_en-US" xlink:label="lab_evh_LeveragedStockUnitsLSUsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leveraged Stock Units (LSUs) [Member]</link:label>
    <link:label id="lab_evh_LeveragedStockUnitsLSUsMember_label_en-US" xlink:label="lab_evh_LeveragedStockUnitsLSUsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leveraged Stock Units (LSUs) [Member]</link:label>
    <link:label id="lab_evh_LeveragedStockUnitsLSUsMember_documentation_en-US" xlink:label="lab_evh_LeveragedStockUnitsLSUsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leveraged Stock Units (LSUs) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_LeveragedStockUnitsLSUsMember" xlink:href="evh-20211231.xsd#evh_LeveragedStockUnitsLSUsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_LeveragedStockUnitsLSUsMember" xlink:to="lab_evh_LeveragedStockUnitsLSUsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TaxPeriodAxis_42b29980-814a-469c-b376-419cb2d9b30a_terseLabel_en-US" xlink:label="lab_us-gaap_TaxPeriodAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Period [Axis]</link:label>
    <link:label id="lab_us-gaap_TaxPeriodAxis_label_en-US" xlink:label="lab_us-gaap_TaxPeriodAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Period [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxPeriodAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxPeriodAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxPeriodAxis" xlink:to="lab_us-gaap_TaxPeriodAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy_1fa673de-a0c6-4793-a5f1-bc424fc0d9f5_terseLabel_en-US" xlink:label="lab_us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable and Allowances</link:label>
    <link:label id="lab_us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy_label_en-US" xlink:label="lab_us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Receivables, Trade and Other Accounts Receivable, Allowance for Doubtful Accounts, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy" xlink:to="lab_us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_66c4131f-d5d3-4d47-afbb-1165b5356345_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsValuationAllowance_c7741b24-64b0-4736-afab-1d70f05232d2_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation allowance</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsValuationAllowance_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Valuation Allowance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent_3f4a01ae-9b6a-497d-8bcd-fc5e66abcb41_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current liabilities of discontinued operations</link:label>
    <link:label id="lab_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent_ccd7cdbe-88e6-4822-8d0a-e6d57787bc4c_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current liabilities of discontinued operations</link:label>
    <link:label id="lab_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent" xlink:to="lab_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CorporateNonSegmentMember_9686817b-a2c9-4802-90e0-03af846af907_terseLabel_en-US" xlink:label="lab_us-gaap_CorporateNonSegmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate</link:label>
    <link:label id="lab_us-gaap_CorporateNonSegmentMember_label_en-US" xlink:label="lab_us-gaap_CorporateNonSegmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate, Non-Segment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateNonSegmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CorporateNonSegmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CorporateNonSegmentMember" xlink:to="lab_us-gaap_CorporateNonSegmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_TwoThousandFifteenEvolentHealthInc.OmnibusIncentiveCompensationPlanMember_36490b41-5d74-4959-b530-d777fc209447_terseLabel_en-US" xlink:label="lab_evh_TwoThousandFifteenEvolentHealthInc.OmnibusIncentiveCompensationPlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2015 Plan</link:label>
    <link:label id="lab_evh_TwoThousandFifteenEvolentHealthInc.OmnibusIncentiveCompensationPlanMember_label_en-US" xlink:label="lab_evh_TwoThousandFifteenEvolentHealthInc.OmnibusIncentiveCompensationPlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Two Thousand Fifteen Evolent Health, Inc. Omnibus Incentive Compensation Plan [Member]</link:label>
    <link:label id="lab_evh_TwoThousandFifteenEvolentHealthInc.OmnibusIncentiveCompensationPlanMember_documentation_en-US" xlink:label="lab_evh_TwoThousandFifteenEvolentHealthInc.OmnibusIncentiveCompensationPlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Two Thousand Fifteen Evolent Health, Inc. Omnibus Incentive Compensation Plan [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_TwoThousandFifteenEvolentHealthInc.OmnibusIncentiveCompensationPlanMember" xlink:href="evh-20211231.xsd#evh_TwoThousandFifteenEvolentHealthInc.OmnibusIncentiveCompensationPlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_TwoThousandFifteenEvolentHealthInc.OmnibusIncentiveCompensationPlanMember" xlink:to="lab_evh_TwoThousandFifteenEvolentHealthInc.OmnibusIncentiveCompensationPlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue_95090324-2ab3-4b96-a0ed-09ca5f92def9_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total revenue</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue_f857d5d8-824f-46c9-98af-d0eb58c0a63f_verboseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue_label_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Revenue</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_EquityInterestToBeTransferred_adcced0c-dd6f-4852-a615-3c07e9e2315b_terseLabel_en-US" xlink:label="lab_evh_EquityInterestToBeTransferred" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity interest to be transferred</link:label>
    <link:label id="lab_evh_EquityInterestToBeTransferred_label_en-US" xlink:label="lab_evh_EquityInterestToBeTransferred" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Interest To Be Transferred</link:label>
    <link:label id="lab_evh_EquityInterestToBeTransferred_documentation_en-US" xlink:label="lab_evh_EquityInterestToBeTransferred" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Interest To Be Transferred</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_EquityInterestToBeTransferred" xlink:href="evh-20211231.xsd#evh_EquityInterestToBeTransferred"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_EquityInterestToBeTransferred" xlink:to="lab_evh_EquityInterestToBeTransferred" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MajorCustomersAxis_04246512-88ea-44c4-8bd7-934ffc82c6c1_terseLabel_en-US" xlink:label="lab_srt_MajorCustomersAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Axis]</link:label>
    <link:label id="lab_srt_MajorCustomersAxis_label_en-US" xlink:label="lab_srt_MajorCustomersAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MajorCustomersAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MajorCustomersAxis" xlink:to="lab_srt_MajorCustomersAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringCostAndReserveLineItems_4486b308-163b-4196-8219-e5e77e367d09_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringCostAndReserveLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Cost and Reserve [Line Items]</link:label>
    <link:label id="lab_us-gaap_RestructuringCostAndReserveLineItems_label_en-US" xlink:label="lab_us-gaap_RestructuringCostAndReserveLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Cost and Reserve [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringCostAndReserveLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems" xlink:to="lab_us-gaap_RestructuringCostAndReserveLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_7a9d5453-7e0b-4f9b-9295-0e158088d15a_terseLabel_en-US" xlink:label="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Benefit Plans</link:label>
    <link:label id="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Benefits [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:to="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_587ba9f1-d87d-4ffa-b770-d2542c60ac93_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_397dc48f-a935-4c0e-b4b9-09f192e772d8_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Business Acquisitions, by Acquisition [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Business Acquisitions, by Acquisition [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentAnnualReport_a32ff0a3-bd78-4b23-a261-4885ab95ed7e_terseLabel_en-US" xlink:label="lab_dei_DocumentAnnualReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Annual Report</link:label>
    <link:label id="lab_dei_DocumentAnnualReport_label_en-US" xlink:label="lab_dei_DocumentAnnualReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Annual Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentAnnualReport" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentAnnualReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentAnnualReport" xlink:to="lab_dei_DocumentAnnualReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VestingAxis_8acbc2f1-288e-495d-925f-93b46fc131c8_terseLabel_en-US" xlink:label="lab_us-gaap_VestingAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting [Axis]</link:label>
    <link:label id="lab_us-gaap_VestingAxis_label_en-US" xlink:label="lab_us-gaap_VestingAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VestingAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VestingAxis" xlink:to="lab_us-gaap_VestingAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit_e9976ce7-669a-416c-b86e-b420e287a114_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill disposal</link:label>
    <link:label id="lab_us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit_label_en-US" xlink:label="lab_us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, Written off Related to Sale of Business Unit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit" xlink:to="lab_us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Assets_5b973db7-c0a2-4aa8-8fae-f6138a17aa24_totalLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_Assets_label_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameDomain_7dd26ac5-85c9-44a3-bf2a-ef8db540d3a0_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:label id="lab_us-gaap_PlanNameDomain_label_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameDomain" xlink:to="lab_us-gaap_PlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestPaidNet_52f31f37-f931-4cb3-90b4-19a007c4f66d_terseLabel_en-US" xlink:label="lab_us-gaap_InterestPaidNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash paid for interest</link:label>
    <link:label id="lab_us-gaap_InterestPaidNet_label_en-US" xlink:label="lab_us-gaap_InterestPaidNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Paid, Excluding Capitalized Interest, Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestPaidNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestPaidNet" xlink:to="lab_us-gaap_InterestPaidNet" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_SegmentGeographicalDomain_1e2fcdb3-cd72-4f00-908c-b6a6b0598498_terseLabel_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:label id="lab_srt_SegmentGeographicalDomain_label_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_SegmentGeographicalDomain" xlink:to="lab_srt_SegmentGeographicalDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_AssetAcquisitionCashAndEquivalents_e0793ffa-47e2-4c52-882c-c0d5751d4121_terseLabel_en-US" xlink:label="lab_evh_AssetAcquisitionCashAndEquivalents" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and equivalents</link:label>
    <link:label id="lab_evh_AssetAcquisitionCashAndEquivalents_label_en-US" xlink:label="lab_evh_AssetAcquisitionCashAndEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Acquisition, Cash And Equivalents</link:label>
    <link:label id="lab_evh_AssetAcquisitionCashAndEquivalents_documentation_en-US" xlink:label="lab_evh_AssetAcquisitionCashAndEquivalents" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Acquisition, Cash And Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_AssetAcquisitionCashAndEquivalents" xlink:href="evh-20211231.xsd#evh_AssetAcquisitionCashAndEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_AssetAcquisitionCashAndEquivalents" xlink:to="lab_evh_AssetAcquisitionCashAndEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_5ae6fee8-2578-4555-ad1d-a3e2d8cbdae7_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development costs</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NoncontrollingInterestMember_c8d1617f-a747-44b6-bcb2-961d5623d778_terseLabel_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-Controlling Interests</link:label>
    <link:label id="lab_us-gaap_NoncontrollingInterestMember_label_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NoncontrollingInterestMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncontrollingInterestMember" xlink:to="lab_us-gaap_NoncontrollingInterestMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DepreciationAndAmortization_6a495191-ae3f-4f13-8818-9d4adca09d82_terseLabel_en-US" xlink:label="lab_us-gaap_DepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation and amortization expenses</link:label>
    <link:label id="lab_us-gaap_DepreciationAndAmortization_309aa307-ec92-4cb9-9eac-c9f93dad6ddf_negatedLabel_en-US" xlink:label="lab_us-gaap_DepreciationAndAmortization" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation and amortization expenses</link:label>
    <link:label id="lab_us-gaap_DepreciationAndAmortization_label_en-US" xlink:label="lab_us-gaap_DepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation, Depletion and Amortization, Nonproduction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationAndAmortization" xlink:to="lab_us-gaap_DepreciationAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax_d0dfa8cd-3ec8-43b4-bf4c-1a66354daf7d_terseLabel_en-US" xlink:label="lab_us-gaap_DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain on disposal of discontinued operations</link:label>
    <link:label id="lab_us-gaap_DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax_label_en-US" xlink:label="lab_us-gaap_DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discontinued Operation, Gain (Loss) on Disposal of Discontinued Operation, Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax" xlink:to="lab_us-gaap_DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_DisposalGroupIncludingDiscontinuedOperationAccruedCompensationAndEmployeeBenefitsCurrent_fa7617b4-f3ee-4971-b0fd-f3f9e5218149_terseLabel_en-US" xlink:label="lab_evh_DisposalGroupIncludingDiscontinuedOperationAccruedCompensationAndEmployeeBenefitsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued compensation and employee benefits</link:label>
    <link:label id="lab_evh_DisposalGroupIncludingDiscontinuedOperationAccruedCompensationAndEmployeeBenefitsCurrent_label_en-US" xlink:label="lab_evh_DisposalGroupIncludingDiscontinuedOperationAccruedCompensationAndEmployeeBenefitsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Accrued Compensation And Employee Benefits, Current</link:label>
    <link:label id="lab_evh_DisposalGroupIncludingDiscontinuedOperationAccruedCompensationAndEmployeeBenefitsCurrent_documentation_en-US" xlink:label="lab_evh_DisposalGroupIncludingDiscontinuedOperationAccruedCompensationAndEmployeeBenefitsCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Accrued Compensation And Employee Benefits, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_DisposalGroupIncludingDiscontinuedOperationAccruedCompensationAndEmployeeBenefitsCurrent" xlink:href="evh-20211231.xsd#evh_DisposalGroupIncludingDiscontinuedOperationAccruedCompensationAndEmployeeBenefitsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_DisposalGroupIncludingDiscontinuedOperationAccruedCompensationAndEmployeeBenefitsCurrent" xlink:to="lab_evh_DisposalGroupIncludingDiscontinuedOperationAccruedCompensationAndEmployeeBenefitsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedInvestments_126a63e2-03ba-489a-ac8c-ae62400abbe8_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_RestrictedInvestments" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted investments included in restricted cash and restricted investments</link:label>
    <link:label id="lab_us-gaap_RestrictedInvestments_label_en-US" xlink:label="lab_us-gaap_RestrictedInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedInvestments" xlink:to="lab_us-gaap_RestrictedInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_BonusesAndCommissionsMember_642cd874-0e6a-4227-b8f2-7612461dd42d_terseLabel_en-US" xlink:label="lab_evh_BonusesAndCommissionsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Bonuses and Commissions</link:label>
    <link:label id="lab_evh_BonusesAndCommissionsMember_label_en-US" xlink:label="lab_evh_BonusesAndCommissionsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Bonuses And Commissions [Member]</link:label>
    <link:label id="lab_evh_BonusesAndCommissionsMember_documentation_en-US" xlink:label="lab_evh_BonusesAndCommissionsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Bonuses And Commissions [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_BonusesAndCommissionsMember" xlink:href="evh-20211231.xsd#evh_BonusesAndCommissionsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_BonusesAndCommissionsMember" xlink:to="lab_evh_BonusesAndCommissionsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_AssetAcquisitionOtherAssets_085c9776-5309-44e5-8104-37803ad738a8_terseLabel_en-US" xlink:label="lab_evh_AssetAcquisitionOtherAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other assets</link:label>
    <link:label id="lab_evh_AssetAcquisitionOtherAssets_label_en-US" xlink:label="lab_evh_AssetAcquisitionOtherAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Acquisition, Other Assets</link:label>
    <link:label id="lab_evh_AssetAcquisitionOtherAssets_documentation_en-US" xlink:label="lab_evh_AssetAcquisitionOtherAssets" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Acquisition, Other Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_AssetAcquisitionOtherAssets" xlink:href="evh-20211231.xsd#evh_AssetAcquisitionOtherAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_AssetAcquisitionOtherAssets" xlink:to="lab_evh_AssetAcquisitionOtherAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfUnrecognizedCompensationCostNonvestedAwardsTableTextBlock_3e4f25c9-5a28-4c2d-ae55-91e16557291b_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfUnrecognizedCompensationCostNonvestedAwardsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of unrecognized compensation expense</link:label>
    <link:label id="lab_us-gaap_ScheduleOfUnrecognizedCompensationCostNonvestedAwardsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfUnrecognizedCompensationCostNonvestedAwardsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Nonvested Award, Cost [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfUnrecognizedCompensationCostNonvestedAwardsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfUnrecognizedCompensationCostNonvestedAwardsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfUnrecognizedCompensationCostNonvestedAwardsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfUnrecognizedCompensationCostNonvestedAwardsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1_79f7f597-67c2-4f26-85de-413c813dbc7b_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, remaining performance obligation, expected timing of satisfaction, period</link:label>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1_label_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" xlink:to="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CumulativeEffectPeriodOfAdoptionDomain_7a760478-f9da-4ad1-9aff-cb89e95965d0_terseLabel_en-US" xlink:label="lab_srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative Effect Period Of Adoption [Domain]</link:label>
    <link:label id="lab_srt_CumulativeEffectPeriodOfAdoptionDomain_label_en-US" xlink:label="lab_srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative Effect, Period of Adoption [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:to="lab_srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_af8d7181-b03a-4cc8-bfc2-be164610c242_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash and restricted cash provided by (used in) operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_StockIssuedDuringPeriodValueEarnOuts_f24e2649-ab02-4bf4-98bf-86760a436048_terseLabel_en-US" xlink:label="lab_evh_StockIssuedDuringPeriodValueEarnOuts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class A common stock issued for payment of earn-outs</link:label>
    <link:label id="lab_evh_StockIssuedDuringPeriodValueEarnOuts_label_en-US" xlink:label="lab_evh_StockIssuedDuringPeriodValueEarnOuts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Earn-outs</link:label>
    <link:label id="lab_evh_StockIssuedDuringPeriodValueEarnOuts_documentation_en-US" xlink:label="lab_evh_StockIssuedDuringPeriodValueEarnOuts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Earn-outs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_StockIssuedDuringPeriodValueEarnOuts" xlink:href="evh-20211231.xsd#evh_StockIssuedDuringPeriodValueEarnOuts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_StockIssuedDuringPeriodValueEarnOuts" xlink:to="lab_evh_StockIssuedDuringPeriodValueEarnOuts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsNotesAndLoansReceivableLineItems_097579f4-021c-4b01-a03d-7f98f7205572_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsNotesAndLoansReceivableLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts, Notes, Loans and Financing Receivable [Line Items]</link:label>
    <link:label id="lab_us-gaap_AccountsNotesAndLoansReceivableLineItems_label_en-US" xlink:label="lab_us-gaap_AccountsNotesAndLoansReceivableLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts, Notes, Loans and Financing Receivable [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsNotesAndLoansReceivableLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems" xlink:to="lab_us-gaap_AccountsNotesAndLoansReceivableLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FurnitureAndFixturesMember_139ffdb0-6496-404b-a113-787d98342aed_terseLabel_en-US" xlink:label="lab_us-gaap_FurnitureAndFixturesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Furniture and equipment</link:label>
    <link:label id="lab_us-gaap_FurnitureAndFixturesMember_label_en-US" xlink:label="lab_us-gaap_FurnitureAndFixturesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Furniture and Fixtures [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FurnitureAndFixturesMember" xlink:to="lab_us-gaap_FurnitureAndFixturesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentTable_a4d2e4b3-e449-4ff4-9a03-56f2b00447af_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentTable_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentTable" xlink:to="lab_us-gaap_DebtInstrumentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CapitalizedContractCostAxis_85d30191-6e9d-4432-acb8-b3bd078f9381_terseLabel_en-US" xlink:label="lab_us-gaap_CapitalizedContractCostAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capitalized Contract Cost [Axis]</link:label>
    <link:label id="lab_us-gaap_CapitalizedContractCostAxis_label_en-US" xlink:label="lab_us-gaap_CapitalizedContractCostAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capitalized Contract Cost [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedContractCostAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalizedContractCostAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalizedContractCostAxis" xlink:to="lab_us-gaap_CapitalizedContractCostAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardAxis_e9572d69-b241-495a-9df1-3a889de0de95_terseLabel_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Credit Carryforward [Axis]</link:label>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardAxis_label_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Credit Carryforward [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxCreditCarryforwardAxis" xlink:to="lab_us-gaap_TaxCreditCarryforwardAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_EvolentHealthServicesSegmentMember_bd2b3291-b1cb-4777-bd16-4dbc29299ebf_terseLabel_en-US" xlink:label="lab_evh_EvolentHealthServicesSegmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Evolent Health Services</link:label>
    <link:label id="lab_evh_EvolentHealthServicesSegmentMember_label_en-US" xlink:label="lab_evh_EvolentHealthServicesSegmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Evolent Health Services Segment [Member]</link:label>
    <link:label id="lab_evh_EvolentHealthServicesSegmentMember_documentation_en-US" xlink:label="lab_evh_EvolentHealthServicesSegmentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Evolent Health Services Segment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_EvolentHealthServicesSegmentMember" xlink:href="evh-20211231.xsd#evh_EvolentHealthServicesSegmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_EvolentHealthServicesSegmentMember" xlink:to="lab_evh_EvolentHealthServicesSegmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_c9af4289-598d-4185-ae19-16a8e7a53529_verboseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_6cdce87a-1766-4020-b56e-cb5787d77ff7_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average common shares outstanding - basic (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_ee1bf28c-ba8f-4640-a47e-3fdbc7c90b49_totalLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Diluted loss per share attributable to common shareholders of Evolent Health, Inc. (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted" xlink:to="lab_us-gaap_EarningsPerShareDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentDomain_80bc148b-c9a5-4b0c-9e2c-e10650700eb2_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segments [Domain]</link:label>
    <link:label id="lab_us-gaap_SegmentDomain_label_en-US" xlink:label="lab_us-gaap_SegmentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentDomain" xlink:to="lab_us-gaap_SegmentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RepaymentsOfLongTermLinesOfCredit_7f4827b9-7e45-494c-8724-d82a4921112a_terseLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfLongTermLinesOfCredit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of long-term lines of credit</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfLongTermLinesOfCredit_label_en-US" xlink:label="lab_us-gaap_RepaymentsOfLongTermLinesOfCredit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of Long-term Lines of Credit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermLinesOfCredit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfLongTermLinesOfCredit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfLongTermLinesOfCredit" xlink:to="lab_us-gaap_RepaymentsOfLongTermLinesOfCredit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures_cba7d5a8-1f39-47d3-a739-9b505789fe58_verboseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments in equity method investees</link:label>
    <link:label id="lab_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures_label_en-US" xlink:label="lab_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments in and Advance to Affiliates, Subsidiaries, Associates, and Joint Ventures</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures" xlink:to="lab_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IntangibleAssetsFiniteLivedPolicy_76d157b7-e836-4c15-9168-5525d54bd25f_terseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets, Net</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsFiniteLivedPolicy_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets, Finite-Lived, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsFiniteLivedPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:to="lab_us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingStandardsUpdateExtensibleList_6d01cc3d-da8a-4c61-9d3c-49586d2a732a_terseLabel_en-US" xlink:label="lab_us-gaap_AccountingStandardsUpdateExtensibleList" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Standards Update [Extensible Enumeration]</link:label>
    <link:label id="lab_us-gaap_AccountingStandardsUpdateExtensibleList_label_en-US" xlink:label="lab_us-gaap_AccountingStandardsUpdateExtensibleList" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Standards Update [Extensible Enumeration]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingStandardsUpdateExtensibleList" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingStandardsUpdateExtensibleList"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingStandardsUpdateExtensibleList" xlink:to="lab_us-gaap_AccountingStandardsUpdateExtensibleList" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_MedicaidCustomersMember_f3d7ebb6-cf92-4333-a893-6e1725c5bd48_terseLabel_en-US" xlink:label="lab_evh_MedicaidCustomersMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medicaid</link:label>
    <link:label id="lab_evh_MedicaidCustomersMember_label_en-US" xlink:label="lab_evh_MedicaidCustomersMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medicaid Customers [Member]</link:label>
    <link:label id="lab_evh_MedicaidCustomersMember_documentation_en-US" xlink:label="lab_evh_MedicaidCustomersMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medicaid Customers</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_MedicaidCustomersMember" xlink:href="evh-20211231.xsd#evh_MedicaidCustomersMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_MedicaidCustomersMember" xlink:to="lab_evh_MedicaidCustomersMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_e42ee6ba-47f6-41f8-b1ac-dec59f5717ec_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Restructuring and Related Costs [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Restructuring and Related Costs [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:to="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_stpr_NJ_68ff7d78-6e39-4723-93ee-26a57eaed568_terseLabel_en-US" xlink:label="lab_stpr_NJ" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Edison, NJ</link:label>
    <link:label id="lab_stpr_NJ_label_en-US" xlink:label="lab_stpr_NJ" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">NEW JERSEY</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_NJ" xlink:href="https://xbrl.sec.gov/stpr/2021/stpr-2021.xsd#stpr_NJ"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_stpr_NJ" xlink:to="lab_stpr_NJ" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_5bef466b-2520-49a8-9f3f-b0c1fd303a1d_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total comprehensive loss attributable to common shareholders of Evolent Health, Inc.</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_7486590e-1acc-4578-9b5d-5f830fd7ad53_terseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible assets, net</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets, Net (Excluding Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:to="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_QuarterlyFinancialInformationTextBlock_749f4e77-f381-4de4-b289-3515cb06ce07_terseLabel_en-US" xlink:label="lab_us-gaap_QuarterlyFinancialInformationTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Quarterly Results of Operations (unaudited)</link:label>
    <link:label id="lab_us-gaap_QuarterlyFinancialInformationTextBlock_label_en-US" xlink:label="lab_us-gaap_QuarterlyFinancialInformationTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Quarterly Financial Information [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_QuarterlyFinancialInformationTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_QuarterlyFinancialInformationTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_QuarterlyFinancialInformationTextBlock" xlink:to="lab_us-gaap_QuarterlyFinancialInformationTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiability_eeb0bf13-fe17-4cb3-a8c2-d676e91bf45c_periodStartLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance as of beginning-of-period</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiability_e5575554-89fb-4a08-ac27-4a2ff67108a1_periodEndLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance as of end of period</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiability_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiability" xlink:to="lab_us-gaap_ContractWithCustomerLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_7e23e382-995a-4fe4-9ca5-f8fe4ba77038_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive loss, net of taxes, related to:</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtPolicyTextBlock_48be901d-e7a6-4c61-8f26-e619a203d171_terseLabel_en-US" xlink:label="lab_us-gaap_DebtPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt</link:label>
    <link:label id="lab_us-gaap_DebtPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_DebtPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtPolicyTextBlock" xlink:to="lab_us-gaap_DebtPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet_e880b323-fb8d-464f-968b-674879d1b90d_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax liabilities, net</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Tax Liabilities, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:to="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_d7898bc7-a350-431b-9058-4837c3b35780_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exchange/conversion (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Conversion of Convertible Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_AssetAcquisitionAccruedLiabilities_00cbcdb4-4d7d-413e-a182-e57c9493cb46_terseLabel_en-US" xlink:label="lab_evh_AssetAcquisitionAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued liabilities</link:label>
    <link:label id="lab_evh_AssetAcquisitionAccruedLiabilities_label_en-US" xlink:label="lab_evh_AssetAcquisitionAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Acquisition, Accrued Liabilities</link:label>
    <link:label id="lab_evh_AssetAcquisitionAccruedLiabilities_documentation_en-US" xlink:label="lab_evh_AssetAcquisitionAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Acquisition, Accrued Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_AssetAcquisitionAccruedLiabilities" xlink:href="evh-20211231.xsd#evh_AssetAcquisitionAccruedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_AssetAcquisitionAccruedLiabilities" xlink:to="lab_evh_AssetAcquisitionAccruedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionAcquireeDomain_6d739b14-29ea-4de3-9502-88be52f9fdce_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Acquiree [Domain]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionAcquireeDomain_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Acquiree [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_bbe8cb1c-eee2-44ab-a79b-46086dda79fd_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Continuing operations, basic (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations, Per Basic Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsPerBasicShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_ca7258ce-2c08-4f94-9e30-3b199f37c605_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (loss) from discontinued operations, net of tax</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_d5dd8ace-4b7e-45e7-b8c7-6218c9c6908a_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (loss) from discontinued operations, net of tax (2)</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_6b4fd2c5-5dbf-4931-8efb-4a368bf2c417_verboseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (loss) from discontinued operations</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Discontinued Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" xlink:to="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_2982eace-a55e-4078-b6b4-c1404207204c_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of reconciliation of the U.S. statutory tax rate to our effective tax rate</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_DeferredTaxAssetsStartupandOrganizationalCosts_3e3960d0-d4ad-4272-b6bb-38a23cac5f18_terseLabel_en-US" xlink:label="lab_evh_DeferredTaxAssetsStartupandOrganizationalCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Start-up and organizational costs</link:label>
    <link:label id="lab_evh_DeferredTaxAssetsStartupandOrganizationalCosts_label_en-US" xlink:label="lab_evh_DeferredTaxAssetsStartupandOrganizationalCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Start-up and Organizational Costs</link:label>
    <link:label id="lab_evh_DeferredTaxAssetsStartupandOrganizationalCosts_documentation_en-US" xlink:label="lab_evh_DeferredTaxAssetsStartupandOrganizationalCosts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Start-up and Organizational Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_DeferredTaxAssetsStartupandOrganizationalCosts" xlink:href="evh-20211231.xsd#evh_DeferredTaxAssetsStartupandOrganizationalCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_DeferredTaxAssetsStartupandOrganizationalCosts" xlink:to="lab_evh_DeferredTaxAssetsStartupandOrganizationalCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_1bc3c384-f99f-408d-ba70-6b24619d0523_verboseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_f6993ac0-b917-4997-b0ed-10cb9f3adeae_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent" xlink:to="lab_us-gaap_AccountsPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_EmployeeSeveranceAndTerminationBenefitsMember_d8f808e5-0c64-4d2e-8cb3-2633724bb142_terseLabel_en-US" xlink:label="lab_evh_EmployeeSeveranceAndTerminationBenefitsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Severance and termination benefits</link:label>
    <link:label id="lab_evh_EmployeeSeveranceAndTerminationBenefitsMember_label_en-US" xlink:label="lab_evh_EmployeeSeveranceAndTerminationBenefitsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Severance And Termination Benefits [Member]</link:label>
    <link:label id="lab_evh_EmployeeSeveranceAndTerminationBenefitsMember_documentation_en-US" xlink:label="lab_evh_EmployeeSeveranceAndTerminationBenefitsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Severance And Termination Benefits</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_EmployeeSeveranceAndTerminationBenefitsMember" xlink:href="evh-20211231.xsd#evh_EmployeeSeveranceAndTerminationBenefitsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_EmployeeSeveranceAndTerminationBenefitsMember" xlink:to="lab_evh_EmployeeSeveranceAndTerminationBenefitsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_DelayedDrawTermLoanFacilityMember_c2d6dee9-6979-4cf2-8a65-ab42a7c23a41_terseLabel_en-US" xlink:label="lab_evh_DelayedDrawTermLoanFacilityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">DDTL Facility</link:label>
    <link:label id="lab_evh_DelayedDrawTermLoanFacilityMember_label_en-US" xlink:label="lab_evh_DelayedDrawTermLoanFacilityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Delayed Draw Term Loan Facility [Member]</link:label>
    <link:label id="lab_evh_DelayedDrawTermLoanFacilityMember_documentation_en-US" xlink:label="lab_evh_DelayedDrawTermLoanFacilityMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Delayed Draw Term Loan Facility [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_DelayedDrawTermLoanFacilityMember" xlink:href="evh-20211231.xsd#evh_DelayedDrawTermLoanFacilityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_DelayedDrawTermLoanFacilityMember" xlink:to="lab_evh_DelayedDrawTermLoanFacilityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_4f37001f-8521-4fae-a3f3-8044614be446_terseLabel_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation and amortization expenses</link:label>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_label_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation, Depletion and Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:to="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ParentMember_d8f926fa-c64b-42c8-99c0-22121a7a1deb_terseLabel_en-US" xlink:label="lab_us-gaap_ParentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Parent</link:label>
    <link:label id="lab_us-gaap_ParentMember_label_en-US" xlink:label="lab_us-gaap_ParentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ParentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ParentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ParentMember" xlink:to="lab_us-gaap_ParentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_ec219b83-96f2-45f6-93b5-bfff783184d0_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in state rate</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Change in Enacted Tax Rate, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_df6b9f2b-2f61-427e-b1e0-27c2de69dc80_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of assets at fair value on recurring basis</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets Measured on Recurring Basis [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:to="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock_f83ccc6b-78a9-429b-8015-06cf6d428f20_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Costs associated with the Repositioning Plan</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring and Related Costs [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock" xlink:to="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_6eff9177-5a8d-4b41-b60c-8967c4459f3c_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding" xlink:to="lab_us-gaap_CommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherOperatingIncomeExpenseNet_8c4bed21-7576-483d-9b5b-5069be9c0e16_terseLabel_en-US" xlink:label="lab_us-gaap_OtherOperatingIncomeExpenseNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other expense, net</link:label>
    <link:label id="lab_us-gaap_OtherOperatingIncomeExpenseNet_label_en-US" xlink:label="lab_us-gaap_OtherOperatingIncomeExpenseNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Operating Income (Expense), Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherOperatingIncomeExpenseNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherOperatingIncomeExpenseNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherOperatingIncomeExpenseNet" xlink:to="lab_us-gaap_OtherOperatingIncomeExpenseNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringAndRelatedActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring and Related Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:to="lab_us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_05e56d0c-4866-4e57-be1d-1f16cfd4bad5_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted stock units vested, net of shares withheld for taxes (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonClassBMember_92c6d57c-7769-4005-9c80-9117f23f2f59_terseLabel_en-US" xlink:label="lab_us-gaap_CommonClassBMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exchangeable Class B common stock</link:label>
    <link:label id="lab_us-gaap_CommonClassBMember_b9e86b33-7b0f-4a82-899e-2fd0f616d986_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonClassBMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class B Common Stock</link:label>
    <link:label id="lab_us-gaap_CommonClassBMember_label_en-US" xlink:label="lab_us-gaap_CommonClassBMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Class B [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassBMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonClassBMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonClassBMember" xlink:to="lab_us-gaap_CommonClassBMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_42ad56b5-d4ff-428b-8a7c-5235482fab16_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_ec12a471-ae3f-4b8a-bc5e-fbcd6d8d2b1c_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_RestrictedCashforLettersofCreditforFacilityLeasesMember_a7fc6a2a-561a-46dc-9c18-0cbd9bd0a34d_verboseLabel_en-US" xlink:label="lab_evh_RestrictedCashforLettersofCreditforFacilityLeasesMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collateral for letters of credit for facility leases</link:label>
    <link:label id="lab_evh_RestrictedCashforLettersofCreditforFacilityLeasesMember_label_en-US" xlink:label="lab_evh_RestrictedCashforLettersofCreditforFacilityLeasesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash for Letters of Credit for Facility Leases [Member]</link:label>
    <link:label id="lab_evh_RestrictedCashforLettersofCreditforFacilityLeasesMember_documentation_en-US" xlink:label="lab_evh_RestrictedCashforLettersofCreditforFacilityLeasesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash for Letters of Credit for Facility Leases [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_RestrictedCashforLettersofCreditforFacilityLeasesMember" xlink:href="evh-20211231.xsd#evh_RestrictedCashforLettersofCreditforFacilityLeasesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_RestrictedCashforLettersofCreditforFacilityLeasesMember" xlink:to="lab_evh_RestrictedCashforLettersofCreditforFacilityLeasesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseCost_073433fe-bbce-4f24-84e9-a1979a38799d_totalLabel_en-US" xlink:label="lab_us-gaap_LeaseCost" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total lease cost</link:label>
    <link:label id="lab_us-gaap_LeaseCost_label_en-US" xlink:label="lab_us-gaap_LeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseCost" xlink:to="lab_us-gaap_LeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_25ffa20b-4b04-4b59-b6f7-e39de47e8e3a_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_label_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:to="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_ShareholderAdvisoryServices_1c62c517-9c31-4866-9635-c01b84332403_negatedLabel_en-US" xlink:label="lab_evh_ShareholderAdvisoryServices" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Strategy and shareholder advisory expenses</link:label>
    <link:label id="lab_evh_ShareholderAdvisoryServices_label_en-US" xlink:label="lab_evh_ShareholderAdvisoryServices" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shareholder Advisory Services</link:label>
    <link:label id="lab_evh_ShareholderAdvisoryServices_documentation_en-US" xlink:label="lab_evh_ShareholderAdvisoryServices" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shareholder Advisory Services</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_ShareholderAdvisoryServices" xlink:href="evh-20211231.xsd#evh_ShareholderAdvisoryServices"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_ShareholderAdvisoryServices" xlink:to="lab_evh_ShareholderAdvisoryServices" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_TaxReceivableAgreementPercentofCashSavingsPaidtoShareholders_bf246a61-a7b7-4749-b031-17d0fcefd54c_terseLabel_en-US" xlink:label="lab_evh_TaxReceivableAgreementPercentofCashSavingsPaidtoShareholders" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax receivable agreement, percent of cash savings paid to shareholders</link:label>
    <link:label id="lab_evh_TaxReceivableAgreementPercentofCashSavingsPaidtoShareholders_label_en-US" xlink:label="lab_evh_TaxReceivableAgreementPercentofCashSavingsPaidtoShareholders" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Receivable Agreement, Percent of Cash Savings Paid to Shareholders</link:label>
    <link:label id="lab_evh_TaxReceivableAgreementPercentofCashSavingsPaidtoShareholders_documentation_en-US" xlink:label="lab_evh_TaxReceivableAgreementPercentofCashSavingsPaidtoShareholders" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Receivable Agreement, Percent of Cash Savings Paid to Shareholders</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_TaxReceivableAgreementPercentofCashSavingsPaidtoShareholders" xlink:href="evh-20211231.xsd#evh_TaxReceivableAgreementPercentofCashSavingsPaidtoShareholders"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_TaxReceivableAgreementPercentofCashSavingsPaidtoShareholders" xlink:to="lab_evh_TaxReceivableAgreementPercentofCashSavingsPaidtoShareholders" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_68cd203e-1b44-4cbe-85b4-edc0def4e513_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shareholders' Equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:to="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CustomerRelationshipsMember_c82c7297-5ec6-4230-81c4-c2f7ea038be5_terseLabel_en-US" xlink:label="lab_us-gaap_CustomerRelationshipsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer relationships</link:label>
    <link:label id="lab_us-gaap_CustomerRelationshipsMember_label_en-US" xlink:label="lab_us-gaap_CustomerRelationshipsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer Relationships [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerRelationshipsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CustomerRelationshipsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CustomerRelationshipsMember" xlink:to="lab_us-gaap_CustomerRelationshipsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_stpr_VA_dac05cb9-1660-4e08-9050-96591359beae_terseLabel_en-US" xlink:label="lab_stpr_VA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Arlington, VA</link:label>
    <link:label id="lab_stpr_VA_label_en-US" xlink:label="lab_stpr_VA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">VIRGINIA</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_VA" xlink:href="https://xbrl.sec.gov/stpr/2021/stpr-2021.xsd#stpr_VA"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_stpr_VA" xlink:to="lab_stpr_VA" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_PolicyholderBenefitsAndClaimsIncurredAssumedExpensesRelatedToClaims_574e8ab6-c438-4d48-a84b-0482426ee4bd_terseLabel_en-US" xlink:label="lab_evh_PolicyholderBenefitsAndClaimsIncurredAssumedExpensesRelatedToClaims" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Claims-related administrative expenses</link:label>
    <link:label id="lab_evh_PolicyholderBenefitsAndClaimsIncurredAssumedExpensesRelatedToClaims_label_en-US" xlink:label="lab_evh_PolicyholderBenefitsAndClaimsIncurredAssumedExpensesRelatedToClaims" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Policyholder Benefits And Claims Incurred, Assumed, Expenses Related To Claims</link:label>
    <link:label id="lab_evh_PolicyholderBenefitsAndClaimsIncurredAssumedExpensesRelatedToClaims_documentation_en-US" xlink:label="lab_evh_PolicyholderBenefitsAndClaimsIncurredAssumedExpensesRelatedToClaims" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Policyholder Benefits And Claims Incurred, Assumed, Expenses Related To Claims</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_PolicyholderBenefitsAndClaimsIncurredAssumedExpensesRelatedToClaims" xlink:href="evh-20211231.xsd#evh_PolicyholderBenefitsAndClaimsIncurredAssumedExpensesRelatedToClaims"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_PolicyholderBenefitsAndClaimsIncurredAssumedExpensesRelatedToClaims" xlink:to="lab_evh_PolicyholderBenefitsAndClaimsIncurredAssumedExpensesRelatedToClaims" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_37a47920-e72e-43a6-b7b9-c014bd6fcc75_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and Equipment, Net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_3e79274c-15b8-4c20-bf07-c2a8ec6e6617_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other long-term liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:to="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_PaidinKindInterestIncome_31a4eabd-d677-4f44-a211-c09c63b460e9_negatedTerseLabel_en-US" xlink:label="lab_evh_PaidinKindInterestIncome" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest from customer advance for regulatory capital requirements</link:label>
    <link:label id="lab_evh_PaidinKindInterestIncome_label_en-US" xlink:label="lab_evh_PaidinKindInterestIncome" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Paid-in-Kind Interest Income</link:label>
    <link:label id="lab_evh_PaidinKindInterestIncome_documentation_en-US" xlink:label="lab_evh_PaidinKindInterestIncome" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Paid-in-Kind Interest Income</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_PaidinKindInterestIncome" xlink:href="evh-20211231.xsd#evh_PaidinKindInterestIncome"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_PaidinKindInterestIncome" xlink:to="lab_evh_PaidinKindInterestIncome" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_08492816-a124-40f1-bfe5-7bd00ee75444_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilitiesGrossDifferenceAmountAbstract_f0d528e5-5a58-478a-9fc9-0deb3b997c67_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilitiesGrossDifferenceAmountAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less:</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilitiesGrossDifferenceAmountAbstract_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilitiesGrossDifferenceAmountAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease Liabilities, Gross Difference, Amount [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilitiesGrossDifferenceAmountAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilitiesGrossDifferenceAmountAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesGrossDifferenceAmountAbstract" xlink:to="lab_us-gaap_OperatingLeaseLiabilitiesGrossDifferenceAmountAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_46c5b6b5-e068-40c7-9510-d49470d0890e_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentLineItems" xlink:to="lab_us-gaap_DebtInstrumentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_64b84480-a024-43a6-9fe9-93dfbf1d256a_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionDomain_63219a66-a3a0-4181-ad35-51cf8eef291e_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Domain]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionDomain_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain" xlink:to="lab_us-gaap_RelatedPartyTransactionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesOther_b633b6be-38de-461d-b1f6-7986d712fd56_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesOther" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesOther_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Other</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesOther" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilitiesOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesOther" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesOther" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_c983e820-9eee-47b3-bdf0-dafa621bb56e_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise price of warrants or rights (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right, Exercise Price of Warrants or Rights</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_32798163-648b-43fd-b5ac-73c23c4742aa_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested and expected to vest at the end of the period (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SeveranceCosts1_f194cf33-a769-4288-a694-a3e5c0a72794_negatedLabel_en-US" xlink:label="lab_us-gaap_SeveranceCosts1" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Severance costs</link:label>
    <link:label id="lab_us-gaap_SeveranceCosts1_label_en-US" xlink:label="lab_us-gaap_SeveranceCosts1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Severance Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeveranceCosts1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeveranceCosts1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SeveranceCosts1" xlink:to="lab_us-gaap_SeveranceCosts1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationAwardTrancheThreeMember_b99ae7ba-9095-42ad-b563-3cc45333988b_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationAwardTrancheThreeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tranche Three</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationAwardTrancheThreeMember_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationAwardTrancheThreeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Tranche Three [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheThreeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheThreeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationAwardTrancheThreeMember" xlink:to="lab_us-gaap_ShareBasedCompensationAwardTrancheThreeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_PaymentsForCustomerAdvanceForRegulatoryCapitalRequirements_25aa5648-c2f0-4b96-a847-cbeb517644dc_negatedTerseLabel_en-US" xlink:label="lab_evh_PaymentsForCustomerAdvanceForRegulatoryCapitalRequirements" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer advance for regulatory capital requirements</link:label>
    <link:label id="lab_evh_PaymentsForCustomerAdvanceForRegulatoryCapitalRequirements_label_en-US" xlink:label="lab_evh_PaymentsForCustomerAdvanceForRegulatoryCapitalRequirements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments For Customer Advance For Regulatory Capital Requirements</link:label>
    <link:label id="lab_evh_PaymentsForCustomerAdvanceForRegulatoryCapitalRequirements_documentation_en-US" xlink:label="lab_evh_PaymentsForCustomerAdvanceForRegulatoryCapitalRequirements" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments For Customer Advance For Regulatory Capital Requirements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_PaymentsForCustomerAdvanceForRegulatoryCapitalRequirements" xlink:href="evh-20211231.xsd#evh_PaymentsForCustomerAdvanceForRegulatoryCapitalRequirements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_PaymentsForCustomerAdvanceForRegulatoryCapitalRequirements" xlink:to="lab_evh_PaymentsForCustomerAdvanceForRegulatoryCapitalRequirements" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_CapitalizedContractCostAmortizationPurchaseAccountingAdjustments_bae6ebc4-3adf-424d-8aa7-560f6c671661_negatedLabel_en-US" xlink:label="lab_evh_CapitalizedContractCostAmortizationPurchaseAccountingAdjustments" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of contract cost assets</link:label>
    <link:label id="lab_evh_CapitalizedContractCostAmortizationPurchaseAccountingAdjustments_label_en-US" xlink:label="lab_evh_CapitalizedContractCostAmortizationPurchaseAccountingAdjustments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capitalized Contract Cost, Amortization, Purchase Accounting Adjustments</link:label>
    <link:label id="lab_evh_CapitalizedContractCostAmortizationPurchaseAccountingAdjustments_documentation_en-US" xlink:label="lab_evh_CapitalizedContractCostAmortizationPurchaseAccountingAdjustments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capitalized Contract Cost, Amortization, Purchase Accounting Adjustments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_CapitalizedContractCostAmortizationPurchaseAccountingAdjustments" xlink:href="evh-20211231.xsd#evh_CapitalizedContractCostAmortizationPurchaseAccountingAdjustments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_CapitalizedContractCostAmortizationPurchaseAccountingAdjustments" xlink:to="lab_evh_CapitalizedContractCostAmortizationPurchaseAccountingAdjustments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtNoncurrent_9c3fdfc9-7f1b-4e3e-b719-0f6a6c55752f_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term debt, net of discount</link:label>
    <link:label id="lab_us-gaap_LongTermDebtNoncurrent_label_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Excluding Current Maturities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtNoncurrent" xlink:to="lab_us-gaap_LongTermDebtNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization_687ce5e5-4d39-4139-a09e-3727004dc0b3_terseLabel_en-US" xlink:label="lab_evh_AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjusted EBITDA</link:label>
    <link:label id="lab_evh_AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization_label_en-US" xlink:label="lab_evh_AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjusted Earnings Before Interest, Taxes, Depreciation And Amortization</link:label>
    <link:label id="lab_evh_AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization_documentation_en-US" xlink:label="lab_evh_AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjusted Earnings Before Interest, Taxes, Depreciation And Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization" xlink:href="evh-20211231.xsd#evh_AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization" xlink:to="lab_evh_AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract_9b86ece9-feaa-4880-bd4f-4bb2a7ed6a8f_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Fair Value Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:to="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfGoodwillTable_40e1346d-3e57-4739-89e2-ff23c93aeb5c_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfGoodwillTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Goodwill [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfGoodwillTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfGoodwillTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Goodwill [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGoodwillTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfGoodwillTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable" xlink:to="lab_us-gaap_ScheduleOfGoodwillTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_17269b2f-557e-49bd-829d-cb1b20f21039_terseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based compensation expense</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_label_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_2f8c46a7-d3cb-40f8-b5ad-7ebbc76e042d_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercisable</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputRiskFreeInterestRateMember_472f8789-077d-4b07-bd37-921409535370_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Annual risk free rate</link:label>
    <link:label id="lab_us-gaap_MeasurementInputRiskFreeInterestRateMember_label_en-US" xlink:label="lab_us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input, Risk Free Interest Rate [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:to="lab_us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasicAndDilutedAbstract_8a46f587-9ab4-4ae4-a18b-ffbddfd13cdc_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss per common share</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasicAndDilutedAbstract_1fd5eb63-d182-4c10-abb6-703c245e847f_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss per common share, Basic and diluted</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasicAndDilutedAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic and Diluted [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasicAndDilutedAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:to="lab_us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_EquityMethodInvestmentEconomicInterestPercentage_7a829052-c286-4878-9a6d-29dce63eb58a_terseLabel_en-US" xlink:label="lab_evh_EquityMethodInvestmentEconomicInterestPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Economic interest percentage</link:label>
    <link:label id="lab_evh_EquityMethodInvestmentEconomicInterestPercentage_label_en-US" xlink:label="lab_evh_EquityMethodInvestmentEconomicInterestPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investment, Economic Interest Percentage</link:label>
    <link:label id="lab_evh_EquityMethodInvestmentEconomicInterestPercentage_documentation_en-US" xlink:label="lab_evh_EquityMethodInvestmentEconomicInterestPercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investment, Economic Interest Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_EquityMethodInvestmentEconomicInterestPercentage" xlink:href="evh-20211231.xsd#evh_EquityMethodInvestmentEconomicInterestPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_EquityMethodInvestmentEconomicInterestPercentage" xlink:to="lab_evh_EquityMethodInvestmentEconomicInterestPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_AssetAcquisitionDebtSecuritiesAvailableForSaleUnsettledSalesReceivables_53f3effe-2450-4212-ae58-d5a89ec2b9f3_terseLabel_en-US" xlink:label="lab_evh_AssetAcquisitionDebtSecuritiesAvailableForSaleUnsettledSalesReceivables" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Receivables related to unsettled sales of securities</link:label>
    <link:label id="lab_evh_AssetAcquisitionDebtSecuritiesAvailableForSaleUnsettledSalesReceivables_label_en-US" xlink:label="lab_evh_AssetAcquisitionDebtSecuritiesAvailableForSaleUnsettledSalesReceivables" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Acquisition, Debt Securities, Available-For-Sale, Unsettled Sales Receivables</link:label>
    <link:label id="lab_evh_AssetAcquisitionDebtSecuritiesAvailableForSaleUnsettledSalesReceivables_documentation_en-US" xlink:label="lab_evh_AssetAcquisitionDebtSecuritiesAvailableForSaleUnsettledSalesReceivables" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Acquisition, Debt Securities, Available-For-Sale, Unsettled Sales Receivables</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_AssetAcquisitionDebtSecuritiesAvailableForSaleUnsettledSalesReceivables" xlink:href="evh-20211231.xsd#evh_AssetAcquisitionDebtSecuritiesAvailableForSaleUnsettledSalesReceivables"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_AssetAcquisitionDebtSecuritiesAvailableForSaleUnsettledSalesReceivables" xlink:to="lab_evh_AssetAcquisitionDebtSecuritiesAvailableForSaleUnsettledSalesReceivables" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProfitLoss_2d862e72-7b95-42dc-8cff-54e069ce884c_totalLabel_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_ProfitLoss_d48f5531-58f8-4dee-8571-6eacdc0a7d22_terseLabel_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_ProfitLoss_2250ab66-f96e-448e-9810-bfed6b25b042_verboseLabel_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income (loss)</link:label>
    <link:label id="lab_us-gaap_ProfitLoss_label_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProfitLoss" xlink:to="lab_us-gaap_ProfitLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_387658ce-2216-40b1-94f5-6e28fca8b9a4_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of loss before provision for income taxes</link:label>
    <link:label id="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_0486a3b8-fd02-4911-b065-59769df0b743_totalLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities assumed</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonClassAMember_9e01a583-c340-41c0-829d-71efa667d5ba_terseLabel_en-US" xlink:label="lab_us-gaap_CommonClassAMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class A Common Stock</link:label>
    <link:label id="lab_us-gaap_CommonClassAMember_010c6db5-f0cf-4311-bebb-0beaf56d9f98_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonClassAMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class A Common Stock</link:label>
    <link:label id="lab_us-gaap_CommonClassAMember_label_en-US" xlink:label="lab_us-gaap_CommonClassAMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Class A [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassAMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonClassAMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonClassAMember" xlink:to="lab_us-gaap_CommonClassAMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_d9d33b46-f659-4b88-9e13-d058526444e6_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents and restricted cash as of beginning-of-period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_82f11656-45eb-483b-9624-93e4ea2d1e1b_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents and restricted cash as of end-of-period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_53397363-08b9-447e-a451-a5471a39039b_terseLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total cash and cash equivalents and restricted cash shown in the consolidated statements of cash flows</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_3e928f44-43f6-40cf-bc51-ac104a74c7cd_verboseLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents (including restricted cash)</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_6a6850cf-ac91-43ff-9f8e-9e695a1a7cac_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_2d05963d-eeef-4feb-9bb0-0edf0698139d_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risk-free interest rate, maximum</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireHeldToMaturitySecurities_c692706c-2eaf-4928-b030-67a7d400b169_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireHeldToMaturitySecurities" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of investments</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireHeldToMaturitySecurities_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireHeldToMaturitySecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Held-to-maturity Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireHeldToMaturitySecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireHeldToMaturitySecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireHeldToMaturitySecurities" xlink:to="lab_us-gaap_PaymentsToAcquireHeldToMaturitySecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_5c0849ed-65a5-4fc6-ad0f-e6dfb69fbd4e_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current assets:</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract" xlink:to="lab_us-gaap_AssetsCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsGross_dec4acb0-2800-4335-aa71-3c1c539b1f2f_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross Carrying Amount</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsGross_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_8123e289-b78b-4440-bf87-c5a52d16e3d3_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of intangible assets</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_29aa217a-7779-4bc2-b1c6-614fe4c268cf_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of intangible assets details</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShortdurationInsuranceContractsReconciliationOfClaimsDevelopmentToLiabilityLineItems_63030e74-3c76-4326-9d05-676f816ac5f9_terseLabel_en-US" xlink:label="lab_us-gaap_ShortdurationInsuranceContractsReconciliationOfClaimsDevelopmentToLiabilityLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-duration Insurance Contracts, Reconciliation of Claims Development to Liability [Line Items]</link:label>
    <link:label id="lab_us-gaap_ShortdurationInsuranceContractsReconciliationOfClaimsDevelopmentToLiabilityLineItems_label_en-US" xlink:label="lab_us-gaap_ShortdurationInsuranceContractsReconciliationOfClaimsDevelopmentToLiabilityLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-duration Insurance Contracts, Reconciliation of Claims Development to Liability [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortdurationInsuranceContractsReconciliationOfClaimsDevelopmentToLiabilityLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortdurationInsuranceContractsReconciliationOfClaimsDevelopmentToLiabilityLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortdurationInsuranceContractsReconciliationOfClaimsDevelopmentToLiabilityLineItems" xlink:to="lab_us-gaap_ShortdurationInsuranceContractsReconciliationOfClaimsDevelopmentToLiabilityLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CapitalizedComputerSoftwareAmortization1_0091956a-abf2-49e9-84ee-9419d6da0de6_terseLabel_en-US" xlink:label="lab_us-gaap_CapitalizedComputerSoftwareAmortization1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capitalized computer software, amortization</link:label>
    <link:label id="lab_us-gaap_CapitalizedComputerSoftwareAmortization1_label_en-US" xlink:label="lab_us-gaap_CapitalizedComputerSoftwareAmortization1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capitalized Computer Software, Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedComputerSoftwareAmortization1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalizedComputerSoftwareAmortization1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalizedComputerSoftwareAmortization1" xlink:to="lab_us-gaap_CapitalizedComputerSoftwareAmortization1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_e5aaaa86-2ad1-4eeb-8971-565e67cf1847_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:to="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_6ff96791-3e0a-4804-8f45-0972ba414402_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise of stock options (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_f158eaf8-8ac3-4471-80a3-605874b1839d_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercised (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_78050ffd-ae7a-4a18-ab44-b3ad89c2e701_verboseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:to="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract_0b816faf-7054-4ff2-b9d5-42c373dc2d8a_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities assumed:</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1_69b6c161-26dd-42eb-9148-de437fecbda4_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Requisite service period for vesting</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Award Requisite Service Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent_2281fc05-799f-4c4e-abb8-ddfb6c8c54f7_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-current assets of discontinued operations</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent_label_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Assets, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs_023ac252-e29e-4487-88c0-24ae7e829165_terseLabel_en-US" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Charge-offs</link:label>
    <link:label id="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs_label_en-US" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, Allowance for Credit Loss, Writeoff</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs" xlink:to="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock_8f4f498f-d0a1-464a-ae84-4830e56dcabd_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of discontinued operations</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Groups, Including Discontinued Operations [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock" xlink:to="lab_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations_0778cc99-9f1c-445d-950f-bbdd8bf53991_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lapse of statute of limitations</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Reduction Resulting from Lapse of Applicable Statute of Limitations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_3dcb4d60-38c1-41d7-8d2b-43ef64d20329_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of antidilutive securities excluded from computation of earnings per share</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_32c4488b-f464-4e4d-bf2e-eb9367ace78c_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2026</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_ServicesAgreementsMember_04c5842b-fdd0-4099-a31b-615a7bca2dce_terseLabel_en-US" xlink:label="lab_evh_ServicesAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Services Agreements</link:label>
    <link:label id="lab_evh_ServicesAgreementsMember_label_en-US" xlink:label="lab_evh_ServicesAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Services Agreements [Member]</link:label>
    <link:label id="lab_evh_ServicesAgreementsMember_documentation_en-US" xlink:label="lab_evh_ServicesAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Services Agreements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_ServicesAgreementsMember" xlink:href="evh-20211231.xsd#evh_ServicesAgreementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_ServicesAgreementsMember" xlink:to="lab_evh_ServicesAgreementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AuditorFirmId_185f7946-c9ba-42d1-8601-a60d3bc0aa57_terseLabel_en-US" xlink:label="lab_dei_AuditorFirmId" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Firm ID</link:label>
    <link:label id="lab_dei_AuditorFirmId_label_en-US" xlink:label="lab_dei_AuditorFirmId" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Firm ID</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorFirmId" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorFirmId"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AuditorFirmId" xlink:to="lab_dei_AuditorFirmId" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireEquityMethodInvestments_456f1f32-6b02-4015-82f8-9083226baafa_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireEquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to acquire interest</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireEquityMethodInvestments_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireEquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Equity Method Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireEquityMethodInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireEquityMethodInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireEquityMethodInvestments" xlink:to="lab_us-gaap_PaymentsToAcquireEquityMethodInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_AdjustmentsToAdditionalPaidInCapitalAcquisitions_116a9b03-65c9-4dae-a404-678a9042a4c4_terseLabel_en-US" xlink:label="lab_evh_AdjustmentsToAdditionalPaidInCapitalAcquisitions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount attributable to NCI from business combination</link:label>
    <link:label id="lab_evh_AdjustmentsToAdditionalPaidInCapitalAcquisitions_label_en-US" xlink:label="lab_evh_AdjustmentsToAdditionalPaidInCapitalAcquisitions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments To Additional Paid In Capital, Acquisitions</link:label>
    <link:label id="lab_evh_AdjustmentsToAdditionalPaidInCapitalAcquisitions_documentation_en-US" xlink:label="lab_evh_AdjustmentsToAdditionalPaidInCapitalAcquisitions" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments To Additional Paid In Capital, Acquisitions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_AdjustmentsToAdditionalPaidInCapitalAcquisitions" xlink:href="evh-20211231.xsd#evh_AdjustmentsToAdditionalPaidInCapitalAcquisitions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_AdjustmentsToAdditionalPaidInCapitalAcquisitions" xlink:to="lab_evh_AdjustmentsToAdditionalPaidInCapitalAcquisitions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_a8504be7-d8e0-408f-9387-0006ebd71efd_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash and restricted cash (used in) provided by investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock_2e3ea967-715c-47fc-ac8a-7a3257e31839_terseLabel_en-US" xlink:label="lab_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of Adjusted EBITDA to net loss</link:label>
    <link:label id="lab_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock_label_en-US" xlink:label="lab_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock" xlink:to="lab_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_9ee28345-a708-4f89-89fc-dd9ca6185c9d_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes in assets and liabilities, net of acquisitions:</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredOtherTaxExpenseBenefit_5c561b2e-0443-4229-aeba-772f167a99aa_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredOtherTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in valuation allowance</link:label>
    <link:label id="lab_us-gaap_DeferredOtherTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_DeferredOtherTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Other Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredOtherTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredOtherTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredOtherTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredOtherTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_302d8828-47ef-41a7-8767-1ca8e49cbe7d_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfStockDomain_1af8ed78-cdc3-4876-bc08-9b2a15ebab39_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockDomain_label_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockDomain" xlink:to="lab_us-gaap_ClassOfStockDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesGross_84e34269-5e2f-4aac-a840-305ac1e1b063_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesGross" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash paid for asset acquisitions and business combinations</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesGross_a4a756f0-3fc8-4ba0-bb7d-adad61fc9608_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesGross_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Businesses, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireBusinessesGross" xlink:to="lab_us-gaap_PaymentsToAcquireBusinessesGross" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_PerformanceBasedRestrictedStockUnitsPSUsMember_bd39c6e2-a4c1-45e0-876e-ffe869691455_terseLabel_en-US" xlink:label="lab_evh_PerformanceBasedRestrictedStockUnitsPSUsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">PSUs</link:label>
    <link:label id="lab_evh_PerformanceBasedRestrictedStockUnitsPSUsMember_label_en-US" xlink:label="lab_evh_PerformanceBasedRestrictedStockUnitsPSUsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance-Based Restricted Stock Units (PSUs) [Member]</link:label>
    <link:label id="lab_evh_PerformanceBasedRestrictedStockUnitsPSUsMember_documentation_en-US" xlink:label="lab_evh_PerformanceBasedRestrictedStockUnitsPSUsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance-Based Restricted Stock Units (PSUs) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_PerformanceBasedRestrictedStockUnitsPSUsMember" xlink:href="evh-20211231.xsd#evh_PerformanceBasedRestrictedStockUnitsPSUsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_PerformanceBasedRestrictedStockUnitsPSUsMember" xlink:to="lab_evh_PerformanceBasedRestrictedStockUnitsPSUsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_b3ba5daa-928d-4922-b9d8-43d8f24bd490_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum borrowing capacity</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Maximum Borrowing Capacity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:to="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillForeignCurrencyTranslationGainLoss_1aa64feb-de1f-4da9-9235-259000d2c915_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillForeignCurrencyTranslationGainLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign currency translation</link:label>
    <link:label id="lab_us-gaap_GoodwillForeignCurrencyTranslationGainLoss_label_en-US" xlink:label="lab_us-gaap_GoodwillForeignCurrencyTranslationGainLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, Foreign Currency Translation Gain (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillForeignCurrencyTranslationGainLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillForeignCurrencyTranslationGainLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillForeignCurrencyTranslationGainLoss" xlink:to="lab_us-gaap_GoodwillForeignCurrencyTranslationGainLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_DeferredTaxAssetsOperatingLeaseRightOfUseAsset_334dff74-d4b7-47f2-a3be-fa57ff32edf1_terseLabel_en-US" xlink:label="lab_evh_DeferredTaxAssetsOperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease liabilities</link:label>
    <link:label id="lab_evh_DeferredTaxAssetsOperatingLeaseRightOfUseAsset_label_en-US" xlink:label="lab_evh_DeferredTaxAssetsOperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Operating Lease, Right-of-Use Asset</link:label>
    <link:label id="lab_evh_DeferredTaxAssetsOperatingLeaseRightOfUseAsset_documentation_en-US" xlink:label="lab_evh_DeferredTaxAssetsOperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Operating Lease, Right-of-Use Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_DeferredTaxAssetsOperatingLeaseRightOfUseAsset" xlink:href="evh-20211231.xsd#evh_DeferredTaxAssetsOperatingLeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_DeferredTaxAssetsOperatingLeaseRightOfUseAsset" xlink:to="lab_evh_DeferredTaxAssetsOperatingLeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_OwnershipDomain_6e498008-1b4e-4d6e-8353-83e2dbc5690c_terseLabel_en-US" xlink:label="lab_srt_OwnershipDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ownership [Domain]</link:label>
    <link:label id="lab_srt_OwnershipDomain_label_en-US" xlink:label="lab_srt_OwnershipDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ownership [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_OwnershipDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_OwnershipDomain" xlink:to="lab_srt_OwnershipDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_CostofGoodsandServicesSoldExcludingDepreciationandAmortization_4f84f0b9-b708-48e4-a850-56a7bc1dd849_terseLabel_en-US" xlink:label="lab_evh_CostofGoodsandServicesSoldExcludingDepreciationandAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of revenue (exclusive of depreciation and amortization expenses presented separately below)</link:label>
    <link:label id="lab_evh_CostofGoodsandServicesSoldExcludingDepreciationandAmortization_dd9cc19e-e8a5-4efd-a55e-42f44895d1ef_verboseLabel_en-US" xlink:label="lab_evh_CostofGoodsandServicesSoldExcludingDepreciationandAmortization" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of revenue (exclusive of depreciation and amortization expenses)</link:label>
    <link:label id="lab_evh_CostofGoodsandServicesSoldExcludingDepreciationandAmortization_label_en-US" xlink:label="lab_evh_CostofGoodsandServicesSoldExcludingDepreciationandAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of Goods and Services Sold, Excluding Depreciation and Amortization</link:label>
    <link:label id="lab_evh_CostofGoodsandServicesSoldExcludingDepreciationandAmortization_documentation_en-US" xlink:label="lab_evh_CostofGoodsandServicesSoldExcludingDepreciationandAmortization" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of Goods and Services Sold, Excluding Depreciation and Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_CostofGoodsandServicesSoldExcludingDepreciationandAmortization" xlink:href="evh-20211231.xsd#evh_CostofGoodsandServicesSoldExcludingDepreciationandAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_CostofGoodsandServicesSoldExcludingDepreciationandAmortization" xlink:to="lab_evh_CostofGoodsandServicesSoldExcludingDepreciationandAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_CookCountyHealthAndHospitalsSystemMember_bca6115b-7979-415b-a5e7-8c1f81df0303_terseLabel_en-US" xlink:label="lab_evh_CookCountyHealthAndHospitalsSystemMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cook County Health and Hospitals System</link:label>
    <link:label id="lab_evh_CookCountyHealthAndHospitalsSystemMember_label_en-US" xlink:label="lab_evh_CookCountyHealthAndHospitalsSystemMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cook County Health And Hospitals System [Member]</link:label>
    <link:label id="lab_evh_CookCountyHealthAndHospitalsSystemMember_documentation_en-US" xlink:label="lab_evh_CookCountyHealthAndHospitalsSystemMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cook County Health And Hospitals System [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_CookCountyHealthAndHospitalsSystemMember" xlink:href="evh-20211231.xsd#evh_CookCountyHealthAndHospitalsSystemMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_CookCountyHealthAndHospitalsSystemMember" xlink:to="lab_evh_CookCountyHealthAndHospitalsSystemMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent_a02e085d-7168-43ad-a37a-5f4796d852ec_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current assets of discontinued operations</link:label>
    <link:label id="lab_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent_d2305890-4fd0-4186-8738-1c89b853a3ca_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent_label_en-US" xlink:label="lab_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent" xlink:to="lab_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_8283824b-da12-4145-a8e0-c06d76020211_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentNameDomain" xlink:to="lab_us-gaap_DebtInstrumentNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_AggregateIntrinsicValueAbstract_161f9a98-10fa-42ce-bbf7-eceb65895ddf_terseLabel_en-US" xlink:label="lab_evh_AggregateIntrinsicValueAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate Intrinsic Value</link:label>
    <link:label id="lab_evh_AggregateIntrinsicValueAbstract_label_en-US" xlink:label="lab_evh_AggregateIntrinsicValueAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate Intrinsic Value [Abstract]</link:label>
    <link:label id="lab_evh_AggregateIntrinsicValueAbstract_documentation_en-US" xlink:label="lab_evh_AggregateIntrinsicValueAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate Intrinsic Value [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_AggregateIntrinsicValueAbstract" xlink:href="evh-20211231.xsd#evh_AggregateIntrinsicValueAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_AggregateIntrinsicValueAbstract" xlink:to="lab_evh_AggregateIntrinsicValueAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringAndRelatedCostCostIncurredToDate1_21bdb44a-70af-4a85-8b45-5696e9233aca_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedCostCostIncurredToDate1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative Amount Incurred through December 31, 2021</link:label>
    <link:label id="lab_us-gaap_RestructuringAndRelatedCostCostIncurredToDate1_label_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedCostCostIncurredToDate1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring and Related Cost, Cost Incurred to Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedCostCostIncurredToDate1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringAndRelatedCostCostIncurredToDate1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringAndRelatedCostCostIncurredToDate1" xlink:to="lab_us-gaap_RestructuringAndRelatedCostCostIncurredToDate1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DepreciationAndAmortizationDiscontinuedOperations_586c542e-fada-417c-84b3-4f0a54e544e6_terseLabel_en-US" xlink:label="lab_us-gaap_DepreciationAndAmortizationDiscontinuedOperations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation and amortization expenses</link:label>
    <link:label id="lab_us-gaap_DepreciationAndAmortizationDiscontinuedOperations_label_en-US" xlink:label="lab_us-gaap_DepreciationAndAmortizationDiscontinuedOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation and Amortization, Discontinued Operations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationAndAmortizationDiscontinuedOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationAndAmortizationDiscontinuedOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationAndAmortizationDiscontinuedOperations" xlink:to="lab_us-gaap_DepreciationAndAmortizationDiscontinuedOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_CashReleasedFromEscrow_5dda0062-f0a1-4cd0-952e-708b56076b70_terseLabel_en-US" xlink:label="lab_evh_CashReleasedFromEscrow" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash released from escrow</link:label>
    <link:label id="lab_evh_CashReleasedFromEscrow_label_en-US" xlink:label="lab_evh_CashReleasedFromEscrow" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Released From Escrow</link:label>
    <link:label id="lab_evh_CashReleasedFromEscrow_documentation_en-US" xlink:label="lab_evh_CashReleasedFromEscrow" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Released From Escrow</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_CashReleasedFromEscrow" xlink:href="evh-20211231.xsd#evh_CashReleasedFromEscrow"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_CashReleasedFromEscrow" xlink:to="lab_evh_CashReleasedFromEscrow" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ExtinguishmentOfDebtAmount_a8d3d1a7-9008-44ed-8132-006a22fe3171_terseLabel_en-US" xlink:label="lab_us-gaap_ExtinguishmentOfDebtAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Face amount of debt repaid</link:label>
    <link:label id="lab_us-gaap_ExtinguishmentOfDebtAmount_label_en-US" xlink:label="lab_us-gaap_ExtinguishmentOfDebtAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Extinguishment of Debt, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ExtinguishmentOfDebtAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ExtinguishmentOfDebtAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ExtinguishmentOfDebtAmount" xlink:to="lab_us-gaap_ExtinguishmentOfDebtAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_83fe6a1f-bd53-47fc-b2e4-e9d69c77ed99_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation techniques and significant unobservable inputs of Level 3 fair value measurements</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesBalance_3f952ac9-03a0-4c59-be87-be75840d8c36_periodStartLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesBalance" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance at beginning-of-year</link:label>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesBalance_6898a338-0260-4a78-b429-d42025919fc3_periodEndLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesBalance" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance at end-of-year</link:label>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesBalance_label_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesBalance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances and Reserves, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowancesAndReservesBalance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesBalance" xlink:to="lab_us-gaap_ValuationAllowancesAndReservesBalance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostOfSalesMember_c428df81-7a82-4f51-bfe0-fbadc572beb9_terseLabel_en-US" xlink:label="lab_us-gaap_CostOfSalesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of revenue</link:label>
    <link:label id="lab_us-gaap_CostOfSalesMember_label_en-US" xlink:label="lab_us-gaap_CostOfSalesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of Sales [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfSalesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfSalesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfSalesMember" xlink:to="lab_us-gaap_CostOfSalesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpensePeriodIncreaseDecrease_af77aeb1-c9b7-4bd9-b4d7-459514b9677c_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpensePeriodIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change during the year</link:label>
    <link:label id="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpensePeriodIncreaseDecrease_label_en-US" xlink:label="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpensePeriodIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability for Unpaid Claims and Claims Adjustment Expense, Period Increase (Decrease)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpensePeriodIncreaseDecrease" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpensePeriodIncreaseDecrease"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpensePeriodIncreaseDecrease" xlink:to="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpensePeriodIncreaseDecrease" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_2bded560-6d57-4a42-bdeb-4fc509fddb0d_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss from continuing operations</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_d420d50d-6db6-4ba3-9309-9a1aec80defb_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss from continuing operations</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WriteOffOfDeferredDebtIssuanceCost_5e6fe63c-0727-4071-a70d-5dbcae0b1906_terseLabel_en-US" xlink:label="lab_us-gaap_WriteOffOfDeferredDebtIssuanceCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unamortized debt issuance cost</link:label>
    <link:label id="lab_us-gaap_WriteOffOfDeferredDebtIssuanceCost_label_en-US" xlink:label="lab_us-gaap_WriteOffOfDeferredDebtIssuanceCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Write off of Deferred Debt Issuance Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WriteOffOfDeferredDebtIssuanceCost" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WriteOffOfDeferredDebtIssuanceCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WriteOffOfDeferredDebtIssuanceCost" xlink:to="lab_us-gaap_WriteOffOfDeferredDebtIssuanceCost" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_FInancialAssetLessThan60DaysMember_ccdad1c4-adc2-4d43-9227-d1448eaa2450_terseLabel_en-US" xlink:label="lab_evh_FInancialAssetLessThan60DaysMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Past due less than 60 days</link:label>
    <link:label id="lab_evh_FInancialAssetLessThan60DaysMember_label_en-US" xlink:label="lab_evh_FInancialAssetLessThan60DaysMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">FInancial Asset, Less Than 60 Days [Member]</link:label>
    <link:label id="lab_evh_FInancialAssetLessThan60DaysMember_documentation_en-US" xlink:label="lab_evh_FInancialAssetLessThan60DaysMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">FInancial Asset, Less Than 60 Days [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_FInancialAssetLessThan60DaysMember" xlink:href="evh-20211231.xsd#evh_FInancialAssetLessThan60DaysMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_FInancialAssetLessThan60DaysMember" xlink:to="lab_evh_FInancialAssetLessThan60DaysMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentForeignTaxExpenseBenefit_81b696ee-cb7d-48e4-8a3d-a84d9598bf1c_terseLabel_en-US" xlink:label="lab_us-gaap_CurrentForeignTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign</link:label>
    <link:label id="lab_us-gaap_CurrentForeignTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_CurrentForeignTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Foreign Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentForeignTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentForeignTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentForeignTaxExpenseBenefit" xlink:to="lab_us-gaap_CurrentForeignTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DevelopedTechnologyRightsMember_be0505e9-4f1e-4e48-a0fd-501d3b65f68a_terseLabel_en-US" xlink:label="lab_us-gaap_DevelopedTechnologyRightsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Technology</link:label>
    <link:label id="lab_us-gaap_DevelopedTechnologyRightsMember_f30c926d-81fa-4b26-be6a-06331f3d48de_verboseLabel_en-US" xlink:label="lab_us-gaap_DevelopedTechnologyRightsMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Technology</link:label>
    <link:label id="lab_us-gaap_DevelopedTechnologyRightsMember_label_en-US" xlink:label="lab_us-gaap_DevelopedTechnologyRightsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Developed Technology Rights [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DevelopedTechnologyRightsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DevelopedTechnologyRightsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DevelopedTechnologyRightsMember" xlink:to="lab_us-gaap_DevelopedTechnologyRightsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_GainLossOnRepaymentOfDebt_e5e3ca3a-022e-4213-a3c2-952c9ed6dc19_terseLabel_en-US" xlink:label="lab_evh_GainLossOnRepaymentOfDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss on repayment of debt</link:label>
    <link:label id="lab_evh_GainLossOnRepaymentOfDebt_9ee5c72d-c458-4ce4-8b29-4586ec383058_negatedTerseLabel_en-US" xlink:label="lab_evh_GainLossOnRepaymentOfDebt" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss on repayment of debt</link:label>
    <link:label id="lab_evh_GainLossOnRepaymentOfDebt_8c495c6d-9bc2-45ca-a474-a6e0d9dbf1c2_verboseLabel_en-US" xlink:label="lab_evh_GainLossOnRepaymentOfDebt" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss on repayment of debt, net</link:label>
    <link:label id="lab_evh_GainLossOnRepaymentOfDebt_label_en-US" xlink:label="lab_evh_GainLossOnRepaymentOfDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) On Repayment Of Debt</link:label>
    <link:label id="lab_evh_GainLossOnRepaymentOfDebt_documentation_en-US" xlink:label="lab_evh_GainLossOnRepaymentOfDebt" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) On Repayment Of Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_GainLossOnRepaymentOfDebt" xlink:href="evh-20211231.xsd#evh_GainLossOnRepaymentOfDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_GainLossOnRepaymentOfDebt" xlink:to="lab_evh_GainLossOnRepaymentOfDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_bdb9662c-20e8-450e-ae80-dfdb2017a703_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Axis]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableAllowanceForCreditLossTableTextBlock_8e26738b-b9ec-42b0-a2b6-c17d7f95c784_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableAllowanceForCreditLossTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable, allowance for credit loss</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableAllowanceForCreditLossTableTextBlock_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableAllowanceForCreditLossTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, Allowance for Credit Loss [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableAllowanceForCreditLossTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableAllowanceForCreditLossTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableAllowanceForCreditLossTableTextBlock" xlink:to="lab_us-gaap_AccountsReceivableAllowanceForCreditLossTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_a929c44a-5fe3-4cba-a7af-254d7ec43526_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1_a8ad22ba-4fe4-4a78-a71a-a119f145f437_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Paid costs related to current year</link:label>
    <link:label id="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1_label_en-US" xlink:label="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability for Unpaid Claims and Claims Adjustment Expense, Claims Paid, Current Year</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1" xlink:to="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingStandardsUpdate201613Member_label_en-US" xlink:label="lab_us-gaap_AccountingStandardsUpdate201613Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Standards Update 2016-13 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingStandardsUpdate201613Member" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingStandardsUpdate201613Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingStandardsUpdate201613Member" xlink:to="lab_us-gaap_AccountingStandardsUpdate201613Member" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>14
<FILENAME>evh-20211231_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:cffd2bd6-4cc3-4881-a14e-c3c94aea5d0e,g:f4f494d2-75b7-48aa-a2de-31bddada82ae-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.evolenthealth.com/role/CoverPage" xlink:type="simple" xlink:href="evh-20211231.xsd#CoverPage"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/CoverPage" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_401e5f51-e13d-46c4-b321-231110c79e33" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_783e9632-5aa4-46b1-b043-501e225c0f2e" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_401e5f51-e13d-46c4-b321-231110c79e33" xlink:to="loc_dei_DocumentType_783e9632-5aa4-46b1-b043-501e225c0f2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentAnnualReport_9345e590-0e5a-44c3-9476-34e46cdb2561" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentAnnualReport"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_401e5f51-e13d-46c4-b321-231110c79e33" xlink:to="loc_dei_DocumentAnnualReport_9345e590-0e5a-44c3-9476-34e46cdb2561" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_089f0399-55a0-4ce4-97fb-b841f76e24d8" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_401e5f51-e13d-46c4-b321-231110c79e33" xlink:to="loc_dei_DocumentPeriodEndDate_089f0399-55a0-4ce4-97fb-b841f76e24d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_f163494f-9971-473b-a0a9-baebcc81fbfa" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_401e5f51-e13d-46c4-b321-231110c79e33" xlink:to="loc_dei_CurrentFiscalYearEndDate_f163494f-9971-473b-a0a9-baebcc81fbfa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_d03a93f1-135b-47d2-b4b1-1161c15c8073" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentTransitionReport"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_401e5f51-e13d-46c4-b321-231110c79e33" xlink:to="loc_dei_DocumentTransitionReport_d03a93f1-135b-47d2-b4b1-1161c15c8073" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_5c7bb7e2-a10b-41e6-883a-4323ef8af6a4" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_401e5f51-e13d-46c4-b321-231110c79e33" xlink:to="loc_dei_EntityFileNumber_5c7bb7e2-a10b-41e6-883a-4323ef8af6a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_17c001b2-2948-44c4-a566-20110c0dfd05" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_401e5f51-e13d-46c4-b321-231110c79e33" xlink:to="loc_dei_EntityRegistrantName_17c001b2-2948-44c4-a566-20110c0dfd05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_5b42a1cd-6b94-485f-9981-d59841c8d92e" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_401e5f51-e13d-46c4-b321-231110c79e33" xlink:to="loc_dei_EntityIncorporationStateCountryCode_5b42a1cd-6b94-485f-9981-d59841c8d92e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_4f4b8872-1da0-4dca-9ce4-e0093c3f915c" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_401e5f51-e13d-46c4-b321-231110c79e33" xlink:to="loc_dei_EntityTaxIdentificationNumber_4f4b8872-1da0-4dca-9ce4-e0093c3f915c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_8178e068-e5f6-43c3-b8f2-9f02296b624d" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_401e5f51-e13d-46c4-b321-231110c79e33" xlink:to="loc_dei_EntityAddressAddressLine1_8178e068-e5f6-43c3-b8f2-9f02296b624d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine2_63cf503e-de2d-4d16-9193-23cf590fafbf" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine2"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_401e5f51-e13d-46c4-b321-231110c79e33" xlink:to="loc_dei_EntityAddressAddressLine2_63cf503e-de2d-4d16-9193-23cf590fafbf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_53adde3d-3c7f-4ba9-9516-634740baf118" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_401e5f51-e13d-46c4-b321-231110c79e33" xlink:to="loc_dei_EntityAddressCityOrTown_53adde3d-3c7f-4ba9-9516-634740baf118" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_52364310-bc01-49ee-860e-65b57bc77280" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_401e5f51-e13d-46c4-b321-231110c79e33" xlink:to="loc_dei_EntityAddressStateOrProvince_52364310-bc01-49ee-860e-65b57bc77280" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_d2f92bad-39d1-4729-a9a0-f8ea8815c16c" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_401e5f51-e13d-46c4-b321-231110c79e33" xlink:to="loc_dei_EntityAddressPostalZipCode_d2f92bad-39d1-4729-a9a0-f8ea8815c16c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_bbb8b263-679c-404e-ad00-76ed18887310" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_401e5f51-e13d-46c4-b321-231110c79e33" xlink:to="loc_dei_CityAreaCode_bbb8b263-679c-404e-ad00-76ed18887310" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_22456698-c648-4661-8637-d0f09f52887f" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_401e5f51-e13d-46c4-b321-231110c79e33" xlink:to="loc_dei_LocalPhoneNumber_22456698-c648-4661-8637-d0f09f52887f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_cea59821-acea-474f-951e-c518874143ae" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_401e5f51-e13d-46c4-b321-231110c79e33" xlink:to="loc_dei_Security12bTitle_cea59821-acea-474f-951e-c518874143ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_945d655e-c971-40a6-83e2-e8bb29d1f69d" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_401e5f51-e13d-46c4-b321-231110c79e33" xlink:to="loc_dei_TradingSymbol_945d655e-c971-40a6-83e2-e8bb29d1f69d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_9f3c9093-4f64-4690-a6ab-c9c37d5fd10a" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_401e5f51-e13d-46c4-b321-231110c79e33" xlink:to="loc_dei_SecurityExchangeName_9f3c9093-4f64-4690-a6ab-c9c37d5fd10a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer_188fdbc3-c24e-4ccc-a983-5072a7b7127d" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityWellKnownSeasonedIssuer"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_401e5f51-e13d-46c4-b321-231110c79e33" xlink:to="loc_dei_EntityWellKnownSeasonedIssuer_188fdbc3-c24e-4ccc-a983-5072a7b7127d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityVoluntaryFilers_9843995e-ffb0-4686-85d2-1253364d1a2b" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityVoluntaryFilers"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_401e5f51-e13d-46c4-b321-231110c79e33" xlink:to="loc_dei_EntityVoluntaryFilers_9843995e-ffb0-4686-85d2-1253364d1a2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_4ee1c11b-050c-400d-af12-412b15d3331a" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCurrentReportingStatus"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_401e5f51-e13d-46c4-b321-231110c79e33" xlink:to="loc_dei_EntityCurrentReportingStatus_4ee1c11b-050c-400d-af12-412b15d3331a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_fcfabe56-fc8a-4389-a1e3-19bfdd9cd9c7" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_401e5f51-e13d-46c4-b321-231110c79e33" xlink:to="loc_dei_EntityInteractiveDataCurrent_fcfabe56-fc8a-4389-a1e3-19bfdd9cd9c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_3100bee4-76e9-402b-a7e9-84380f74eca1" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFilerCategory"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_401e5f51-e13d-46c4-b321-231110c79e33" xlink:to="loc_dei_EntityFilerCategory_3100bee4-76e9-402b-a7e9-84380f74eca1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_3bd16848-bb89-486d-9d10-918810560206" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntitySmallBusiness"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_401e5f51-e13d-46c4-b321-231110c79e33" xlink:to="loc_dei_EntitySmallBusiness_3bd16848-bb89-486d-9d10-918810560206" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_38058e26-6bf5-4e64-a2dc-d3c86ef2de52" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_401e5f51-e13d-46c4-b321-231110c79e33" xlink:to="loc_dei_EntityEmergingGrowthCompany_38058e26-6bf5-4e64-a2dc-d3c86ef2de52" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_IcfrAuditorAttestationFlag_5302b474-45c7-42af-9a89-bb0ff54ea94d" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_IcfrAuditorAttestationFlag"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_401e5f51-e13d-46c4-b321-231110c79e33" xlink:to="loc_dei_IcfrAuditorAttestationFlag_5302b474-45c7-42af-9a89-bb0ff54ea94d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_debe5c4e-11cc-483e-aea3-2763524bf161" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityShellCompany"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_401e5f51-e13d-46c4-b321-231110c79e33" xlink:to="loc_dei_EntityShellCompany_debe5c4e-11cc-483e-aea3-2763524bf161" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityPublicFloat_7e736b0d-1eed-46ac-bfb4-5d655c164f4c" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityPublicFloat"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_401e5f51-e13d-46c4-b321-231110c79e33" xlink:to="loc_dei_EntityPublicFloat_7e736b0d-1eed-46ac-bfb4-5d655c164f4c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_5be74b93-7242-4d07-968f-8735f24c2856" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_401e5f51-e13d-46c4-b321-231110c79e33" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_5be74b93-7242-4d07-968f-8735f24c2856" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentsIncorporatedByReferenceTextBlock_25c4066d-1148-40f9-8ab7-e704c9fde491" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentsIncorporatedByReferenceTextBlock"/>
    <link:presentationArc order="31" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_401e5f51-e13d-46c4-b321-231110c79e33" xlink:to="loc_dei_DocumentsIncorporatedByReferenceTextBlock_25c4066d-1148-40f9-8ab7-e704c9fde491" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_575906e1-76c4-4760-9f50-996eb645b7ad" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="32" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_401e5f51-e13d-46c4-b321-231110c79e33" xlink:to="loc_dei_EntityCentralIndexKey_575906e1-76c4-4760-9f50-996eb645b7ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_88dac937-d6a2-4900-b49e-d63bc55c3726" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="33" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_401e5f51-e13d-46c4-b321-231110c79e33" xlink:to="loc_dei_AmendmentFlag_88dac937-d6a2-4900-b49e-d63bc55c3726" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_30e419f1-2ef8-4c38-b7e2-4abb67df76ae" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalYearFocus"/>
    <link:presentationArc order="34" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_401e5f51-e13d-46c4-b321-231110c79e33" xlink:to="loc_dei_DocumentFiscalYearFocus_30e419f1-2ef8-4c38-b7e2-4abb67df76ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_99cc7894-54b0-4288-8167-1a283691725e" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:presentationArc order="35" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_401e5f51-e13d-46c4-b321-231110c79e33" xlink:to="loc_dei_DocumentFiscalPeriodFocus_99cc7894-54b0-4288-8167-1a283691725e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/AuditInformation" xlink:type="simple" xlink:href="evh-20211231.xsd#AuditInformation"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/AuditInformation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_evh_AuditInformationAbstract_c362c099-1b3e-4650-b39e-5fd309c634a5" xlink:href="evh-20211231.xsd#evh_AuditInformationAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorName_694baf81-f64b-4ff2-bdf8-bd3b0c809a84" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorName"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_evh_AuditInformationAbstract_c362c099-1b3e-4650-b39e-5fd309c634a5" xlink:to="loc_dei_AuditorName_694baf81-f64b-4ff2-bdf8-bd3b0c809a84" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorFirmId_1cfd9f2c-a52b-4517-b255-be91d06ed4b1" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorFirmId"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_evh_AuditInformationAbstract_c362c099-1b3e-4650-b39e-5fd309c634a5" xlink:to="loc_dei_AuditorFirmId_1cfd9f2c-a52b-4517-b255-be91d06ed4b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorLocation_b5358a85-afad-4760-a022-06f17e19b741" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorLocation"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_evh_AuditInformationAbstract_c362c099-1b3e-4650-b39e-5fd309c634a5" xlink:to="loc_dei_AuditorLocation_b5358a85-afad-4760-a022-06f17e19b741" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS" xlink:type="simple" xlink:href="evh-20211231.xsd#CONSOLIDATEDBALANCESHEETS"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_3caa577a-c4cc-4ae8-9acd-b689b589b004" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_b1bc346a-ffb7-4108-8050-71dac102bc5b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_3caa577a-c4cc-4ae8-9acd-b689b589b004" xlink:to="loc_us-gaap_AssetsAbstract_b1bc346a-ffb7-4108-8050-71dac102bc5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_d0952afc-9118-4ee1-be9b-cb6ad454d667" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_b1bc346a-ffb7-4108-8050-71dac102bc5b" xlink:to="loc_us-gaap_AssetsCurrentAbstract_d0952afc-9118-4ee1-be9b-cb6ad454d667" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_b44bfee6-2d7f-4dd0-be99-5157c379a035" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_d0952afc-9118-4ee1-be9b-cb6ad454d667" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_b44bfee6-2d7f-4dd0-be99-5157c379a035" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndInvestmentsCurrent_75d84104-075e-4da0-bbc7-604fef6519d4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndInvestmentsCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_d0952afc-9118-4ee1-be9b-cb6ad454d667" xlink:to="loc_us-gaap_RestrictedCashAndInvestmentsCurrent_75d84104-075e-4da0-bbc7-604fef6519d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_c60183a4-1bd0-46d7-8b62-9a2fd89dbcbd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_d0952afc-9118-4ee1-be9b-cb6ad454d667" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_c60183a4-1bd0-46d7-8b62-9a2fd89dbcbd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_1bf798b2-b56f-4beb-92cd-55cc90af1f62" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_d0952afc-9118-4ee1-be9b-cb6ad454d667" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_1bf798b2-b56f-4beb-92cd-55cc90af1f62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent_7be07dcc-3418-4108-b526-220969152bc1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_d0952afc-9118-4ee1-be9b-cb6ad454d667" xlink:to="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent_7be07dcc-3418-4108-b526-220969152bc1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_73df9b0a-0bcd-4d25-be72-ed4149b33119" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_d0952afc-9118-4ee1-be9b-cb6ad454d667" xlink:to="loc_us-gaap_AssetsCurrent_73df9b0a-0bcd-4d25-be72-ed4149b33119" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndInvestmentsNoncurrent_84db2243-9481-43c1-9ce3-40b4ff37e92f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndInvestmentsNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_b1bc346a-ffb7-4108-8050-71dac102bc5b" xlink:to="loc_us-gaap_RestrictedCashAndInvestmentsNoncurrent_84db2243-9481-43c1-9ce3-40b4ff37e92f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures_27082112-e111-4624-9eac-929a6367a1cd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_b1bc346a-ffb7-4108-8050-71dac102bc5b" xlink:to="loc_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures_27082112-e111-4624-9eac-929a6367a1cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_228fbfa1-688f-4a2f-a673-eda14e36717d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_b1bc346a-ffb7-4108-8050-71dac102bc5b" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_228fbfa1-688f-4a2f-a673-eda14e36717d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_3dce4a82-15ba-4b98-b4d3-3a353b032633" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_b1bc346a-ffb7-4108-8050-71dac102bc5b" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_3dce4a82-15ba-4b98-b4d3-3a353b032633" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent_1e780f11-6bb5-46b8-acc6-3f5fc17747d4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_b1bc346a-ffb7-4108-8050-71dac102bc5b" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent_1e780f11-6bb5-46b8-acc6-3f5fc17747d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedContractCostNetNoncurrent_c913589a-bbce-4c2a-8b69-1913fe55abb7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalizedContractCostNetNoncurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_b1bc346a-ffb7-4108-8050-71dac102bc5b" xlink:to="loc_us-gaap_CapitalizedContractCostNetNoncurrent_c913589a-bbce-4c2a-8b69-1913fe55abb7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_c03e1140-03b3-45df-93f3-e138c43a998f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_b1bc346a-ffb7-4108-8050-71dac102bc5b" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_c03e1140-03b3-45df-93f3-e138c43a998f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_33706ad2-d4af-43f4-a401-9438a25b5bd7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_b1bc346a-ffb7-4108-8050-71dac102bc5b" xlink:to="loc_us-gaap_Goodwill_33706ad2-d4af-43f4-a401-9438a25b5bd7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent_23e59dd9-ec89-4887-a046-4d2dbba94626" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_b1bc346a-ffb7-4108-8050-71dac102bc5b" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent_23e59dd9-ec89-4887-a046-4d2dbba94626" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_65f9d536-2716-436f-ab61-93d553f1d198" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_b1bc346a-ffb7-4108-8050-71dac102bc5b" xlink:to="loc_us-gaap_Assets_65f9d536-2716-436f-ab61-93d553f1d198" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_d2895f3c-7457-437e-b78f-c89b7c4a9275" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_3caa577a-c4cc-4ae8-9acd-b689b589b004" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_d2895f3c-7457-437e-b78f-c89b7c4a9275" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAbstract_d5b103d2-305f-4e72-9ed0-47f66cea37e8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_d2895f3c-7457-437e-b78f-c89b7c4a9275" xlink:to="loc_us-gaap_LiabilitiesAbstract_d5b103d2-305f-4e72-9ed0-47f66cea37e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_9d14c9c0-631e-420f-adb4-3fb53b06dbbb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAbstract_d5b103d2-305f-4e72-9ed0-47f66cea37e8" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_9d14c9c0-631e-420f-adb4-3fb53b06dbbb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_11db1bd4-0d0c-4217-a9ea-a8f26826cb64" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_9d14c9c0-631e-420f-adb4-3fb53b06dbbb" xlink:to="loc_us-gaap_AccountsPayableCurrent_11db1bd4-0d0c-4217-a9ea-a8f26826cb64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_717cb6c8-29fc-4de5-8333-9f0fa20e7c56" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_9d14c9c0-631e-420f-adb4-3fb53b06dbbb" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_717cb6c8-29fc-4de5-8333-9f0fa20e7c56" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent_cb37addd-ba6c-4e46-ad8c-bfd935a415b1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_9d14c9c0-631e-420f-adb4-3fb53b06dbbb" xlink:to="loc_us-gaap_LongTermDebtCurrent_cb37addd-ba6c-4e46-ad8c-bfd935a415b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_e2fe92b1-c1b5-4559-8457-c392ae8a9a1f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_9d14c9c0-631e-420f-adb4-3fb53b06dbbb" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_e2fe92b1-c1b5-4559-8457-c392ae8a9a1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_93db89f7-a11d-4b28-9bfe-d7a1e965191d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_9d14c9c0-631e-420f-adb4-3fb53b06dbbb" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_93db89f7-a11d-4b28-9bfe-d7a1e965191d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_6763195a-ce1c-47ce-95a0-6fda28a42162" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_9d14c9c0-631e-420f-adb4-3fb53b06dbbb" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_6763195a-ce1c-47ce-95a0-6fda28a42162" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_LiabilityForFuturePolicyBenefitsAndUnpaidClaimsAndClaimsAdjustmentExpenseAndPerformanceBasedArrangements_2ceb59ba-4734-4a85-9cfc-c230ec8e22dc" xlink:href="evh-20211231.xsd#evh_LiabilityForFuturePolicyBenefitsAndUnpaidClaimsAndClaimsAdjustmentExpenseAndPerformanceBasedArrangements"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_9d14c9c0-631e-420f-adb4-3fb53b06dbbb" xlink:to="loc_evh_LiabilityForFuturePolicyBenefitsAndUnpaidClaimsAndClaimsAdjustmentExpenseAndPerformanceBasedArrangements_2ceb59ba-4734-4a85-9cfc-c230ec8e22dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent_46b3c11f-d2be-48f0-a092-93250dda785f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_9d14c9c0-631e-420f-adb4-3fb53b06dbbb" xlink:to="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent_46b3c11f-d2be-48f0-a092-93250dda785f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_af63d356-48d6-4f8a-9aec-8a16eab2c370" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_9d14c9c0-631e-420f-adb4-3fb53b06dbbb" xlink:to="loc_us-gaap_LiabilitiesCurrent_af63d356-48d6-4f8a-9aec-8a16eab2c370" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_5dddb1f3-c4e3-411b-9142-849df922f19b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAbstract_d5b103d2-305f-4e72-9ed0-47f66cea37e8" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_5dddb1f3-c4e3-411b-9142-849df922f19b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_39988008-8e25-4523-8154-8706003164e0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAbstract_d5b103d2-305f-4e72-9ed0-47f66cea37e8" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_39988008-8e25-4523-8154-8706003164e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_65e427bb-5505-45a8-a403-d6a31137a68f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAbstract_d5b103d2-305f-4e72-9ed0-47f66cea37e8" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_65e427bb-5505-45a8-a403-d6a31137a68f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_493a7280-0111-4cec-8853-15aa258e54d2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAbstract_d5b103d2-305f-4e72-9ed0-47f66cea37e8" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_493a7280-0111-4cec-8853-15aa258e54d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent_4ccfc783-0225-4ae8-b25f-48780e2bb452" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAbstract_d5b103d2-305f-4e72-9ed0-47f66cea37e8" xlink:to="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent_4ccfc783-0225-4ae8-b25f-48780e2bb452" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_fb0dfbc2-789f-40ec-b424-8718e46ce349" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAbstract_d5b103d2-305f-4e72-9ed0-47f66cea37e8" xlink:to="loc_us-gaap_Liabilities_fb0dfbc2-789f-40ec-b424-8718e46ce349" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_1c9742b8-3caa-4993-938d-abac66acf31a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_d2895f3c-7457-437e-b78f-c89b7c4a9275" xlink:to="loc_us-gaap_CommitmentsAndContingencies_1c9742b8-3caa-4993-938d-abac66acf31a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_bd5a43f7-daa3-4d9c-a3b2-0da54b8fc33a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_d2895f3c-7457-437e-b78f-c89b7c4a9275" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_bd5a43f7-daa3-4d9c-a3b2-0da54b8fc33a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_26e72ed9-7566-4375-97fb-e9ce23446458" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_bd5a43f7-daa3-4d9c-a3b2-0da54b8fc33a" xlink:to="loc_us-gaap_CommonStockValue_26e72ed9-7566-4375-97fb-e9ce23446458" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_df9f376e-14f6-48fd-bf93-405eaae3cfb9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_bd5a43f7-daa3-4d9c-a3b2-0da54b8fc33a" xlink:to="loc_us-gaap_AdditionalPaidInCapital_df9f376e-14f6-48fd-bf93-405eaae3cfb9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_6f87e234-e59a-4bfd-ae85-69aba7e65d52" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_bd5a43f7-daa3-4d9c-a3b2-0da54b8fc33a" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_6f87e234-e59a-4bfd-ae85-69aba7e65d52" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_8fd40162-2ca6-4dec-83df-1c26a32dcdc7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_bd5a43f7-daa3-4d9c-a3b2-0da54b8fc33a" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_8fd40162-2ca6-4dec-83df-1c26a32dcdc7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValue_dde5dbd7-9389-48f4-89ee-2cc77a5e4811" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_bd5a43f7-daa3-4d9c-a3b2-0da54b8fc33a" xlink:to="loc_us-gaap_TreasuryStockValue_dde5dbd7-9389-48f4-89ee-2cc77a5e4811" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_3e922025-9eba-4013-a838-d7ab8d3d7fae" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_bd5a43f7-daa3-4d9c-a3b2-0da54b8fc33a" xlink:to="loc_us-gaap_StockholdersEquity_3e922025-9eba-4013-a838-d7ab8d3d7fae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_b95a8b28-ed07-403f-b14e-fe644711ef8b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_d2895f3c-7457-437e-b78f-c89b7c4a9275" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_b95a8b28-ed07-403f-b14e-fe644711ef8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETSParenthetical" xlink:type="simple" xlink:href="evh-20211231.xsd#CONSOLIDATEDBALANCESHEETSParenthetical"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETSParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_366cb920-314b-4a62-99a2-6b647835b91a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_66cc3078-86d4-495c-ac5a-aaa0a9908983" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_366cb920-314b-4a62-99a2-6b647835b91a" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_66cc3078-86d4-495c-ac5a-aaa0a9908983" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_f8d76b32-4738-46a4-8f26-b17712ee2bfa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_366cb920-314b-4a62-99a2-6b647835b91a" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_f8d76b32-4738-46a4-8f26-b17712ee2bfa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_214ebff0-60bb-4b3e-ad84-b6ab9f060600" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_366cb920-314b-4a62-99a2-6b647835b91a" xlink:to="loc_us-gaap_CommonStockSharesIssued_214ebff0-60bb-4b3e-ad84-b6ab9f060600" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockShares_fec9baf0-2129-4e4f-a2de-b01e264cfe23" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockShares"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_366cb920-314b-4a62-99a2-6b647835b91a" xlink:to="loc_us-gaap_TreasuryStockShares_fec9baf0-2129-4e4f-a2de-b01e264cfe23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS" xlink:type="simple" xlink:href="evh-20211231.xsd#CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract_266c193c-3602-4db7-94a1-4baad6cfe412" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_06ede67d-c485-4b71-9fb3-fba3e2ad632b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_266c193c-3602-4db7-94a1-4baad6cfe412" xlink:to="loc_us-gaap_StatementTable_06ede67d-c485-4b71-9fb3-fba3e2ad632b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_97915bca-a61f-41c4-a0e3-52af750edd3a" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_06ede67d-c485-4b71-9fb3-fba3e2ad632b" xlink:to="loc_srt_ProductOrServiceAxis_97915bca-a61f-41c4-a0e3-52af750edd3a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_85d9c911-b6b5-4c62-aa08-61889f8b3dac" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_97915bca-a61f-41c4-a0e3-52af750edd3a" xlink:to="loc_srt_ProductsAndServicesDomain_85d9c911-b6b5-4c62-aa08-61889f8b3dac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_TransformationServicesMember_83e463bf-71d3-4bed-b1f5-8f103218373e" xlink:href="evh-20211231.xsd#evh_TransformationServicesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_85d9c911-b6b5-4c62-aa08-61889f8b3dac" xlink:to="loc_evh_TransformationServicesMember_83e463bf-71d3-4bed-b1f5-8f103218373e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_PlatformsAndOperationsServicesMember_8c589b9a-2327-4ee7-bfd4-240b6e1ba1be" xlink:href="evh-20211231.xsd#evh_PlatformsAndOperationsServicesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_85d9c911-b6b5-4c62-aa08-61889f8b3dac" xlink:to="loc_evh_PlatformsAndOperationsServicesMember_8c589b9a-2327-4ee7-bfd4-240b6e1ba1be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_39a33f36-5dbf-4642-860e-c0888373f64b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_06ede67d-c485-4b71-9fb3-fba3e2ad632b" xlink:to="loc_us-gaap_StatementLineItems_39a33f36-5dbf-4642-860e-c0888373f64b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract_1118e28c-3980-4ed3-a004-9a42623da2a4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenuesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_39a33f36-5dbf-4642-860e-c0888373f64b" xlink:to="loc_us-gaap_RevenuesAbstract_1118e28c-3980-4ed3-a004-9a42623da2a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_1ec3fa81-edb7-47d0-9a6f-c08dc7ae6bb9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Revenues"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesAbstract_1118e28c-3980-4ed3-a004-9a42623da2a4" xlink:to="loc_us-gaap_Revenues_1ec3fa81-edb7-47d0-9a6f-c08dc7ae6bb9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract_ac3786fd-8728-4aa8-adaa-16e86d4e9b08" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_39a33f36-5dbf-4642-860e-c0888373f64b" xlink:to="loc_us-gaap_OperatingExpensesAbstract_ac3786fd-8728-4aa8-adaa-16e86d4e9b08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_CostofGoodsandServicesSoldExcludingDepreciationandAmortization_4f5159f8-6c76-4cd5-8391-f523334ca7ca" xlink:href="evh-20211231.xsd#evh_CostofGoodsandServicesSoldExcludingDepreciationandAmortization"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_ac3786fd-8728-4aa8-adaa-16e86d4e9b08" xlink:to="loc_evh_CostofGoodsandServicesSoldExcludingDepreciationandAmortization_4f5159f8-6c76-4cd5-8391-f523334ca7ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_8612d2fb-9882-40c3-91df-ac4ac4644de0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_ac3786fd-8728-4aa8-adaa-16e86d4e9b08" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_8612d2fb-9882-40c3-91df-ac4ac4644de0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationAndAmortization_aa80aca2-9582-476d-ae46-36cf0442409a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationAndAmortization"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_ac3786fd-8728-4aa8-adaa-16e86d4e9b08" xlink:to="loc_us-gaap_DepreciationAndAmortization_aa80aca2-9582-476d-ae46-36cf0442409a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnDispositionOfAssets1_4b5ff09f-7de7-4320-bcb4-413b7b5444ef" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossOnDispositionOfAssets1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_ac3786fd-8728-4aa8-adaa-16e86d4e9b08" xlink:to="loc_us-gaap_GainLossOnDispositionOfAssets1_4b5ff09f-7de7-4320-bcb4-413b7b5444ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_19663706-3fb1-42da-a37e-36969bcc27d3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_ac3786fd-8728-4aa8-adaa-16e86d4e9b08" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_19663706-3fb1-42da-a37e-36969bcc27d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairmentLoss_e14def02-181b-47bb-81f6-d7ee4e3b9341" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_ac3786fd-8728-4aa8-adaa-16e86d4e9b08" xlink:to="loc_us-gaap_GoodwillImpairmentLoss_e14def02-181b-47bb-81f6-d7ee4e3b9341" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_8b39195e-4ee2-40c3-b581-9e683933eb2d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_ac3786fd-8728-4aa8-adaa-16e86d4e9b08" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_8b39195e-4ee2-40c3-b581-9e683933eb2d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_d3e50e0b-0bd5-4b5d-bfd5-46e87cf19586" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpenses"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_ac3786fd-8728-4aa8-adaa-16e86d4e9b08" xlink:to="loc_us-gaap_OperatingExpenses_d3e50e0b-0bd5-4b5d-bfd5-46e87cf19586" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_45e255b0-fede-4734-a6b1-a366d01c87e1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_39a33f36-5dbf-4642-860e-c0888373f64b" xlink:to="loc_us-gaap_OperatingIncomeLoss_45e255b0-fede-4734-a6b1-a366d01c87e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest_b996e1a2-9af6-4941-9c8e-36355e9ecb1f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_39a33f36-5dbf-4642-860e-c0888373f64b" xlink:to="loc_us-gaap_InvestmentIncomeInterest_b996e1a2-9af6-4941-9c8e-36355e9ecb1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_5aae3e0b-ae5a-49e8-87c4-b98cc17a552a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpense"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_39a33f36-5dbf-4642-860e-c0888373f64b" xlink:to="loc_us-gaap_InterestExpense_5aae3e0b-ae5a-49e8-87c4-b98cc17a552a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentOtherThanTemporaryImpairment_c4ffac51-a0d3-4d2c-b3ee-387f1f2af330" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestmentOtherThanTemporaryImpairment"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_39a33f36-5dbf-4642-860e-c0888373f64b" xlink:to="loc_us-gaap_EquityMethodInvestmentOtherThanTemporaryImpairment_c4ffac51-a0d3-4d2c-b3ee-387f1f2af330" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_13d7ec01-5e52-4510-bd3f-0c49a9ce78f1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_39a33f36-5dbf-4642-860e-c0888373f64b" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_13d7ec01-5e52-4510-bd3f-0c49a9ce78f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_GainOnTransferOfMembership_7b6095a9-6a48-4652-af29-f4d22a2bb5d6" xlink:href="evh-20211231.xsd#evh_GainOnTransferOfMembership"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_39a33f36-5dbf-4642-860e-c0888373f64b" xlink:to="loc_evh_GainOnTransferOfMembership_7b6095a9-6a48-4652-af29-f4d22a2bb5d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_GainLossOnRepaymentOfDebt_f45fe2f2-4cf0-4be4-a062-361e16ebbe58" xlink:href="evh-20211231.xsd#evh_GainLossOnRepaymentOfDebt"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_39a33f36-5dbf-4642-860e-c0888373f64b" xlink:to="loc_evh_GainLossOnRepaymentOfDebt_f45fe2f2-4cf0-4be4-a062-361e16ebbe58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherOperatingIncomeExpenseNet_32569cb2-9eff-4e90-b4df-7c31ca0b1dc7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherOperatingIncomeExpenseNet"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_39a33f36-5dbf-4642-860e-c0888373f64b" xlink:to="loc_us-gaap_OtherOperatingIncomeExpenseNet_32569cb2-9eff-4e90-b4df-7c31ca0b1dc7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_8ea5e8d4-17a0-4813-896a-3e6d62067f3d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_39a33f36-5dbf-4642-860e-c0888373f64b" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_8ea5e8d4-17a0-4813-896a-3e6d62067f3d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_e18cb947-7b5a-4501-acfd-d45538ae04c8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_39a33f36-5dbf-4642-860e-c0888373f64b" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_e18cb947-7b5a-4501-acfd-d45538ae04c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_dbfa4fcf-62ae-4899-8c57-0cf137aaf165" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_39a33f36-5dbf-4642-860e-c0888373f64b" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_dbfa4fcf-62ae-4899-8c57-0cf137aaf165" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_a156f0a1-163b-4243-8de9-319f7ca5beea" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_39a33f36-5dbf-4642-860e-c0888373f64b" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_a156f0a1-163b-4243-8de9-319f7ca5beea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_2d4be225-eb40-4422-ad71-fe4e51f8cdf6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_39a33f36-5dbf-4642-860e-c0888373f64b" xlink:to="loc_us-gaap_ProfitLoss_2d4be225-eb40-4422-ad71-fe4e51f8cdf6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_0c2bd874-e320-4d7c-9520-240b3ed15f0d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_39a33f36-5dbf-4642-860e-c0888373f64b" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_0c2bd874-e320-4d7c-9520-240b3ed15f0d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_3cf8d067-f7be-4a07-808c-f492edae95d4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_39a33f36-5dbf-4642-860e-c0888373f64b" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_3cf8d067-f7be-4a07-808c-f492edae95d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_21fbc802-57a4-40f9-85f6-ae3d8a04c99f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_39a33f36-5dbf-4642-860e-c0888373f64b" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_21fbc802-57a4-40f9-85f6-ae3d8a04c99f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract_fb8a2085-68f6-4f88-871d-5962e354c387" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasicAndDilutedAbstract"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_39a33f36-5dbf-4642-860e-c0888373f64b" xlink:to="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract_fb8a2085-68f6-4f88-871d-5962e354c387" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_971de8a2-4b41-4949-8ddc-e2bd942d8610" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsPerBasicShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract_fb8a2085-68f6-4f88-871d-5962e354c387" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_971de8a2-4b41-4949-8ddc-e2bd942d8610" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_0038e51a-f67d-485c-8076-fc72f8eeb05a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract_fb8a2085-68f6-4f88-871d-5962e354c387" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_0038e51a-f67d-485c-8076-fc72f8eeb05a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare_c7404edb-1771-42f4-98b2-f342b131cbbd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract_fb8a2085-68f6-4f88-871d-5962e354c387" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare_c7404edb-1771-42f4-98b2-f342b131cbbd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare_16d3fe5a-ff91-451a-868f-56e8796cb137" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract_fb8a2085-68f6-4f88-871d-5962e354c387" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare_16d3fe5a-ff91-451a-868f-56e8796cb137" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_EarningsPerSharePortionAttributableToNoncontrollingInterestBasic_c659d2e0-d2bb-406f-b29b-b23e8727a087" xlink:href="evh-20211231.xsd#evh_EarningsPerSharePortionAttributableToNoncontrollingInterestBasic"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract_fb8a2085-68f6-4f88-871d-5962e354c387" xlink:to="loc_evh_EarningsPerSharePortionAttributableToNoncontrollingInterestBasic_c659d2e0-d2bb-406f-b29b-b23e8727a087" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_EarningsPerSharePortionAttributableToNoncontrollingInterestDiluted_35a38303-d7d0-4f88-8356-e6355e442f01" xlink:href="evh-20211231.xsd#evh_EarningsPerSharePortionAttributableToNoncontrollingInterestDiluted"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract_fb8a2085-68f6-4f88-871d-5962e354c387" xlink:to="loc_evh_EarningsPerSharePortionAttributableToNoncontrollingInterestDiluted_35a38303-d7d0-4f88-8356-e6355e442f01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_3d0edb9d-ecfa-4b09-b8e8-0a2945e6d334" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract_fb8a2085-68f6-4f88-871d-5962e354c387" xlink:to="loc_us-gaap_EarningsPerShareBasic_3d0edb9d-ecfa-4b09-b8e8-0a2945e6d334" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_85f692f7-03bf-46e5-9632-2264aab7dca0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract_fb8a2085-68f6-4f88-871d-5962e354c387" xlink:to="loc_us-gaap_EarningsPerShareDiluted_85f692f7-03bf-46e5-9632-2264aab7dca0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract_1da34deb-9fbb-4279-af00-b59610581040" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_39a33f36-5dbf-4642-860e-c0888373f64b" xlink:to="loc_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract_1da34deb-9fbb-4279-af00-b59610581040" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_19e46e4f-ad05-4aa9-bf7f-bf90c41a5723" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract_1da34deb-9fbb-4279-af00-b59610581040" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_19e46e4f-ad05-4aa9-bf7f-bf90c41a5723" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_7bf02108-b8a6-4262-a96c-2da3fa8070ea" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract_1da34deb-9fbb-4279-af00-b59610581040" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_7bf02108-b8a6-4262-a96c-2da3fa8070ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterestAbstract_9e39676b-13af-47d9-82dc-9d97c5817178" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterestAbstract"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_39a33f36-5dbf-4642-860e-c0888373f64b" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterestAbstract_9e39676b-13af-47d9-82dc-9d97c5817178" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_12f1dd9d-d335-424a-940a-e9c57ab617bb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterestAbstract_9e39676b-13af-47d9-82dc-9d97c5817178" xlink:to="loc_us-gaap_ProfitLoss_12f1dd9d-d335-424a-940a-e9c57ab617bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_6f2dc2fc-c84c-42a5-93bc-bff1807a79cf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterestAbstract_9e39676b-13af-47d9-82dc-9d97c5817178" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_6f2dc2fc-c84c-42a5-93bc-bff1807a79cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_db4c9bbd-ba90-41c6-98bd-119c4c40c8d9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_6f2dc2fc-c84c-42a5-93bc-bff1807a79cf" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_db4c9bbd-ba90-41c6-98bd-119c4c40c8d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_38ecca8f-063d-4cea-aa06-e93d21ab8089" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterestAbstract_9e39676b-13af-47d9-82dc-9d97c5817178" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_38ecca8f-063d-4cea-aa06-e93d21ab8089" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_65e44782-75e0-4563-9cbd-a728f2bf2250" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterestAbstract_9e39676b-13af-47d9-82dc-9d97c5817178" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_65e44782-75e0-4563-9cbd-a728f2bf2250" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_6b6ebf0b-8bcc-470f-995e-a6cb3c943b31" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterestAbstract_9e39676b-13af-47d9-82dc-9d97c5817178" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_6b6ebf0b-8bcc-470f-995e-a6cb3c943b31" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSSParenthetical" xlink:type="simple" xlink:href="evh-20211231.xsd#CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSSParenthetical"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSSParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract_a144c938-9ab8-4c90-940a-ab9a343ef37b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax_7c14b15e-8403-4b75-9bbc-217eb8070db6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_a144c938-9ab8-4c90-940a-ab9a343ef37b" xlink:to="loc_us-gaap_DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax_7c14b15e-8403-4b75-9bbc-217eb8070db6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY" xlink:type="simple" xlink:href="evh-20211231.xsd#CONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_12449e9a-6d12-4919-af84-94d6b090ba22" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_a511707b-6988-446e-84c2-eb921ca7596d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_12449e9a-6d12-4919-af84-94d6b090ba22" xlink:to="loc_us-gaap_StatementTable_a511707b-6988-446e-84c2-eb921ca7596d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_bc54b869-25df-4ea9-abe1-8343e0527115" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_a511707b-6988-446e-84c2-eb921ca7596d" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_bc54b869-25df-4ea9-abe1-8343e0527115" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_aca44917-eeb3-4635-8242-bfc2d4756861" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_bc54b869-25df-4ea9-abe1-8343e0527115" xlink:to="loc_us-gaap_EquityComponentDomain_aca44917-eeb3-4635-8242-bfc2d4756861" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ParentMember_14150b1a-bff9-42bc-9887-1f7d871bdec3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ParentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_aca44917-eeb3-4635-8242-bfc2d4756861" xlink:to="loc_us-gaap_ParentMember_14150b1a-bff9-42bc-9887-1f7d871bdec3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_310e6840-3bf7-4826-82cc-99c1390db0c2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ParentMember_14150b1a-bff9-42bc-9887-1f7d871bdec3" xlink:to="loc_us-gaap_CommonStockMember_310e6840-3bf7-4826-82cc-99c1390db0c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_e8c50949-975d-48e8-a468-f3986260da35" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ParentMember_14150b1a-bff9-42bc-9887-1f7d871bdec3" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_e8c50949-975d-48e8-a468-f3986260da35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember_c21e15c4-fa0a-4e01-9275-4d203eb7f194" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ParentMember_14150b1a-bff9-42bc-9887-1f7d871bdec3" xlink:to="loc_us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember_c21e15c4-fa0a-4e01-9275-4d203eb7f194" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_66a173ba-20eb-4d35-82c9-dc47fbebb4c2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ParentMember_14150b1a-bff9-42bc-9887-1f7d871bdec3" xlink:to="loc_us-gaap_RetainedEarningsMember_66a173ba-20eb-4d35-82c9-dc47fbebb4c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockMember_b9513bfc-948f-41de-a8a9-7acd4ea21867" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ParentMember_14150b1a-bff9-42bc-9887-1f7d871bdec3" xlink:to="loc_us-gaap_TreasuryStockMember_b9513bfc-948f-41de-a8a9-7acd4ea21867" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestMember_34492ce9-78a6-4ba0-8880-bc8d5620eef7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NoncontrollingInterestMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_aca44917-eeb3-4635-8242-bfc2d4756861" xlink:to="loc_us-gaap_NoncontrollingInterestMember_34492ce9-78a6-4ba0-8880-bc8d5620eef7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_6953f4e9-44e3-45ea-9f72-1ef0e35eb568" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_a511707b-6988-446e-84c2-eb921ca7596d" xlink:to="loc_us-gaap_StatementClassOfStockAxis_6953f4e9-44e3-45ea-9f72-1ef0e35eb568" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_e1ecc540-d5a4-4ba5-a8af-b5334d125d55" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_6953f4e9-44e3-45ea-9f72-1ef0e35eb568" xlink:to="loc_us-gaap_ClassOfStockDomain_e1ecc540-d5a4-4ba5-a8af-b5334d125d55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassAMember_a50579a8-c40a-4752-9f46-b3d857dcab5c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonClassAMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_e1ecc540-d5a4-4ba5-a8af-b5334d125d55" xlink:to="loc_us-gaap_CommonClassAMember_a50579a8-c40a-4752-9f46-b3d857dcab5c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassBMember_6a1981b3-0d59-43fb-80fb-42679a0361dc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonClassBMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_e1ecc540-d5a4-4ba5-a8af-b5334d125d55" xlink:to="loc_us-gaap_CommonClassBMember_6a1981b3-0d59-43fb-80fb-42679a0361dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_7aec5323-5304-4806-bf2e-42a122c9bed6" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_a511707b-6988-446e-84c2-eb921ca7596d" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_7aec5323-5304-4806-bf2e-42a122c9bed6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_c5fa886a-a042-4005-8276-1283c849bc00" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_7aec5323-5304-4806-bf2e-42a122c9bed6" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_c5fa886a-a042-4005-8276-1283c849bc00" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_54c2a728-2c99-43f4-8560-712f2d400416" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_c5fa886a-a042-4005-8276-1283c849bc00" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_54c2a728-2c99-43f4-8560-712f2d400416" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_0852afbd-9550-4e03-ae6d-ae087533e466" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_a511707b-6988-446e-84c2-eb921ca7596d" xlink:to="loc_us-gaap_StatementLineItems_0852afbd-9550-4e03-ae6d-ae087533e466" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_56fc9db8-02fa-41c4-aff8-52fa8f4eccb6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_0852afbd-9550-4e03-ae6d-ae087533e466" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_56fc9db8-02fa-41c4-aff8-52fa8f4eccb6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesIssued_6ae67422-798c-4a62-8854-26137ed3bf95" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesIssued"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_56fc9db8-02fa-41c4-aff8-52fa8f4eccb6" xlink:to="loc_us-gaap_SharesIssued_6ae67422-798c-4a62-8854-26137ed3bf95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_a45e8cdf-1caf-48d4-96a0-d9120916fd07" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_56fc9db8-02fa-41c4-aff8-52fa8f4eccb6" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_a45e8cdf-1caf-48d4-96a0-d9120916fd07" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingStandardsUpdateExtensibleList_1dd0c038-c6b5-41eb-932f-f5267d92755d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingStandardsUpdateExtensibleList"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_56fc9db8-02fa-41c4-aff8-52fa8f4eccb6" xlink:to="loc_us-gaap_AccountingStandardsUpdateExtensibleList_1dd0c038-c6b5-41eb-932f-f5267d92755d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_53b341bb-20ce-4b04-aa05-78a2dd7b4f41" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_56fc9db8-02fa-41c4-aff8-52fa8f4eccb6" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_53b341bb-20ce-4b04-aa05-78a2dd7b4f41" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_056b725e-8bc5-4c18-bfc3-977679e4fead" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_56fc9db8-02fa-41c4-aff8-52fa8f4eccb6" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_056b725e-8bc5-4c18-bfc3-977679e4fead" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_9c778ed3-c440-4486-b262-a41250af0dbc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_56fc9db8-02fa-41c4-aff8-52fa8f4eccb6" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_9c778ed3-c440-4486-b262-a41250af0dbc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_9e55ce3a-10ef-4a41-a3c4-386e080bc6ce" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_56fc9db8-02fa-41c4-aff8-52fa8f4eccb6" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_9e55ce3a-10ef-4a41-a3c4-386e080bc6ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_8454929e-770c-4a39-83fd-847392f3c423" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_56fc9db8-02fa-41c4-aff8-52fa8f4eccb6" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_8454929e-770c-4a39-83fd-847392f3c423" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_95912049-5b9d-4741-b567-52a7feaefc72" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_56fc9db8-02fa-41c4-aff8-52fa8f4eccb6" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_95912049-5b9d-4741-b567-52a7feaefc72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueAcquisitions_a0290805-4883-457d-b994-c5f6321e6f64" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueAcquisitions"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_56fc9db8-02fa-41c4-aff8-52fa8f4eccb6" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueAcquisitions_a0290805-4883-457d-b994-c5f6321e6f64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockRetiredCostMethodAmount_083424fb-93ab-46fe-b78a-3fded29bc4ce" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockRetiredCostMethodAmount"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_56fc9db8-02fa-41c4-aff8-52fa8f4eccb6" xlink:to="loc_us-gaap_TreasuryStockRetiredCostMethodAmount_083424fb-93ab-46fe-b78a-3fded29bc4ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_StockVestedAndRetiredDuringPeriodShares_b187d9fb-871d-4ff6-a6ae-d8286f401819" xlink:href="evh-20211231.xsd#evh_StockVestedAndRetiredDuringPeriodShares"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_56fc9db8-02fa-41c4-aff8-52fa8f4eccb6" xlink:to="loc_evh_StockVestedAndRetiredDuringPeriodShares_b187d9fb-871d-4ff6-a6ae-d8286f401819" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_StockVestedAndRetiredDuringPeriodValue_62c2c088-9d85-40c2-9d12-b926d1157331" xlink:href="evh-20211231.xsd#evh_StockVestedAndRetiredDuringPeriodValue"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_56fc9db8-02fa-41c4-aff8-52fa8f4eccb6" xlink:to="loc_evh_StockVestedAndRetiredDuringPeriodValue_62c2c088-9d85-40c2-9d12-b926d1157331" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_StockIssuedDuringPeriodSharesEarnOuts_7e5ee42b-b30c-450b-857b-c21209885137" xlink:href="evh-20211231.xsd#evh_StockIssuedDuringPeriodSharesEarnOuts"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_56fc9db8-02fa-41c4-aff8-52fa8f4eccb6" xlink:to="loc_evh_StockIssuedDuringPeriodSharesEarnOuts_7e5ee42b-b30c-450b-857b-c21209885137" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_StockIssuedDuringPeriodValueEarnOuts_57410c8d-27f1-4aaa-8e99-305e1df01690" xlink:href="evh-20211231.xsd#evh_StockIssuedDuringPeriodValueEarnOuts"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_56fc9db8-02fa-41c4-aff8-52fa8f4eccb6" xlink:to="loc_evh_StockIssuedDuringPeriodValueEarnOuts_57410c8d-27f1-4aaa-8e99-305e1df01690" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_AdjustmentsToAdditionalPaidInCapitalAcquisitions_657365e4-28a1-49df-89dc-de55448097ce" xlink:href="evh-20211231.xsd#evh_AdjustmentsToAdditionalPaidInCapitalAcquisitions"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_56fc9db8-02fa-41c4-aff8-52fa8f4eccb6" xlink:to="loc_evh_AdjustmentsToAdditionalPaidInCapitalAcquisitions_657365e4-28a1-49df-89dc-de55448097ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_StockIssuedDuringPeriodSharesEquityMethodInvestmentsAndAssetAcquisitions_6ccdbd73-45fb-4ab8-ab15-f5f852aab61a" xlink:href="evh-20211231.xsd#evh_StockIssuedDuringPeriodSharesEquityMethodInvestmentsAndAssetAcquisitions"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_56fc9db8-02fa-41c4-aff8-52fa8f4eccb6" xlink:to="loc_evh_StockIssuedDuringPeriodSharesEquityMethodInvestmentsAndAssetAcquisitions_6ccdbd73-45fb-4ab8-ab15-f5f852aab61a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_StockIssuedDuringPeriodValueEquityMethodInvestmentsAndAssetAcquisitions_d8a20c6d-9051-4b8a-b17b-0b4b405c208c" xlink:href="evh-20211231.xsd#evh_StockIssuedDuringPeriodValueEquityMethodInvestmentsAndAssetAcquisitions"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_56fc9db8-02fa-41c4-aff8-52fa8f4eccb6" xlink:to="loc_evh_StockIssuedDuringPeriodValueEquityMethodInvestmentsAndAssetAcquisitions_d8a20c6d-9051-4b8a-b17b-0b4b405c208c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_08134d2f-90eb-4a3b-bc60-0d568d6a41de" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_56fc9db8-02fa-41c4-aff8-52fa8f4eccb6" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_08134d2f-90eb-4a3b-bc60-0d568d6a41de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_dce07df8-d7bf-4cca-a69e-2573dd0a547b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_56fc9db8-02fa-41c4-aff8-52fa8f4eccb6" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_dce07df8-d7bf-4cca-a69e-2573dd0a547b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_StockIssuedDuringPeriodSharesConversionofConvertibleSecuritiesTaxImpact_9d640dac-7f4a-4116-b96b-c6d6a2f3d764" xlink:href="evh-20211231.xsd#evh_StockIssuedDuringPeriodSharesConversionofConvertibleSecuritiesTaxImpact"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_56fc9db8-02fa-41c4-aff8-52fa8f4eccb6" xlink:to="loc_evh_StockIssuedDuringPeriodSharesConversionofConvertibleSecuritiesTaxImpact_9d640dac-7f4a-4116-b96b-c6d6a2f3d764" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance_fbf261af-1392-4c24-af11-33b956c620c3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_56fc9db8-02fa-41c4-aff8-52fa8f4eccb6" xlink:to="loc_us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance_fbf261af-1392-4c24-af11-33b956c620c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt_d293ebb1-6004-49c8-b482-e290da4d44f7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_56fc9db8-02fa-41c4-aff8-52fa8f4eccb6" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt_d293ebb1-6004-49c8-b482-e290da4d44f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestDecreaseFromDeconsolidation_0438e7a4-0d39-4a5b-94a5-c4574f571366" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NoncontrollingInterestDecreaseFromDeconsolidation"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_56fc9db8-02fa-41c4-aff8-52fa8f4eccb6" xlink:to="loc_us-gaap_NoncontrollingInterestDecreaseFromDeconsolidation_0438e7a4-0d39-4a5b-94a5-c4574f571366" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_22fd5971-5683-45c6-8e57-36618925c931" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_56fc9db8-02fa-41c4-aff8-52fa8f4eccb6" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_22fd5971-5683-45c6-8e57-36618925c931" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_1d9f6298-eb93-434a-9134-7a4a6c6f6fe7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_56fc9db8-02fa-41c4-aff8-52fa8f4eccb6" xlink:to="loc_us-gaap_ProfitLoss_1d9f6298-eb93-434a-9134-7a4a6c6f6fe7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesIssued_6696ba32-1b03-46d7-a39b-1bf893d444ae" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesIssued"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_56fc9db8-02fa-41c4-aff8-52fa8f4eccb6" xlink:to="loc_us-gaap_SharesIssued_6696ba32-1b03-46d7-a39b-1bf893d444ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_519fda6d-5595-452d-a6af-0cf40161bdcd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_56fc9db8-02fa-41c4-aff8-52fa8f4eccb6" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_519fda6d-5595-452d-a6af-0cf40161bdcd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="simple" xlink:href="evh-20211231.xsd#CONSOLIDATEDSTATEMENTSOFCASHFLOWS"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_bba8fbcc-5477-4e48-b67b-0eac062610b7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_63af2191-90b7-4c51-8122-f469f49fc40f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_bba8fbcc-5477-4e48-b67b-0eac062610b7" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_63af2191-90b7-4c51-8122-f469f49fc40f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_4471175f-8b06-4703-8fd0-f23a81402fa4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_63af2191-90b7-4c51-8122-f469f49fc40f" xlink:to="loc_us-gaap_ProfitLoss_4471175f-8b06-4703-8fd0-f23a81402fa4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_7f640d7d-2178-4ca6-99b8-5658eda83673" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_63af2191-90b7-4c51-8122-f469f49fc40f" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_7f640d7d-2178-4ca6-99b8-5658eda83673" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_eec1e265-444a-4d24-8f9f-a9b5f512aacd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_7f640d7d-2178-4ca6-99b8-5658eda83673" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_eec1e265-444a-4d24-8f9f-a9b5f512aacd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_GainLossOnDispositionOfAssetsOperatingActivities_bd907db2-d6c4-4df5-9797-534fe3d60ce8" xlink:href="evh-20211231.xsd#evh_GainLossOnDispositionOfAssetsOperatingActivities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_7f640d7d-2178-4ca6-99b8-5658eda83673" xlink:to="loc_evh_GainLossOnDispositionOfAssetsOperatingActivities_bd907db2-d6c4-4df5-9797-534fe3d60ce8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_a59c54a2-6888-44e4-aad1-132c7e6b6963" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_7f640d7d-2178-4ca6-99b8-5658eda83673" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_a59c54a2-6888-44e4-aad1-132c7e6b6963" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_06e05413-25cf-4319-a6bd-95b4945f8b7f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_7f640d7d-2178-4ca6-99b8-5658eda83673" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_06e05413-25cf-4319-a6bd-95b4945f8b7f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentOtherThanTemporaryImpairment_1ff8f528-5772-469f-ba2e-d9fa3030e80d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestmentOtherThanTemporaryImpairment"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_7f640d7d-2178-4ca6-99b8-5658eda83673" xlink:to="loc_us-gaap_EquityMethodInvestmentOtherThanTemporaryImpairment_1ff8f528-5772-469f-ba2e-d9fa3030e80d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_3f8e1383-89e9-46ae-a07d-f528e73b923b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_7f640d7d-2178-4ca6-99b8-5658eda83673" xlink:to="loc_us-gaap_ShareBasedCompensation_3f8e1383-89e9-46ae-a07d-f528e73b923b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxesAndTaxCredits_dddad68a-8cd5-4cdb-902a-00025530c748" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxesAndTaxCredits"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_7f640d7d-2178-4ca6-99b8-5658eda83673" xlink:to="loc_us-gaap_DeferredIncomeTaxesAndTaxCredits_dddad68a-8cd5-4cdb-902a-00025530c748" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedContractCostAmortization_b21a5aa8-70d8-42e2-b961-ae0ae2100d4f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalizedContractCostAmortization"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_7f640d7d-2178-4ca6-99b8-5658eda83673" xlink:to="loc_us-gaap_CapitalizedContractCostAmortization_b21a5aa8-70d8-42e2-b961-ae0ae2100d4f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCosts_b1c9abe8-408d-4f23-926f-c4a632e1f6c8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfFinancingCosts"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_7f640d7d-2178-4ca6-99b8-5658eda83673" xlink:to="loc_us-gaap_AmortizationOfFinancingCosts_b1c9abe8-408d-4f23-926f-c4a632e1f6c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_PaidinKindInterestIncome_b047764a-8288-4020-8f5c-ed20c835397b" xlink:href="evh-20211231.xsd#evh_PaidinKindInterestIncome"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_7f640d7d-2178-4ca6-99b8-5658eda83673" xlink:to="loc_evh_PaidinKindInterestIncome_b047764a-8288-4020-8f5c-ed20c835397b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_GainOnTransferOfMembership_6a42d238-efba-493e-b426-36576dcba439" xlink:href="evh-20211231.xsd#evh_GainOnTransferOfMembership"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_7f640d7d-2178-4ca6-99b8-5658eda83673" xlink:to="loc_evh_GainOnTransferOfMembership_6a42d238-efba-493e-b426-36576dcba439" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairmentLoss_c3d9bae2-122f-4a57-a61d-58e42196cef2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_7f640d7d-2178-4ca6-99b8-5658eda83673" xlink:to="loc_us-gaap_GoodwillImpairmentLoss_c3d9bae2-122f-4a57-a61d-58e42196cef2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_GainLossOnRepaymentOfDebt_d7db78ef-140d-4337-b310-a9460ed8ce76" xlink:href="evh-20211231.xsd#evh_GainLossOnRepaymentOfDebt"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_7f640d7d-2178-4ca6-99b8-5658eda83673" xlink:to="loc_evh_GainLossOnRepaymentOfDebt_d7db78ef-140d-4337-b310-a9460ed8ce76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_9196df58-3734-4e1a-81bd-c8555be45113" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_7f640d7d-2178-4ca6-99b8-5658eda83673" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_9196df58-3734-4e1a-81bd-c8555be45113" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense_fde67f33-f26e-4b64-86ee-29cf21d9348f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNoncashIncomeExpense"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_7f640d7d-2178-4ca6-99b8-5658eda83673" xlink:to="loc_us-gaap_OtherNoncashIncomeExpense_fde67f33-f26e-4b64-86ee-29cf21d9348f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_8957fda5-cf11-444a-b83e-2da50a7a882d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_7f640d7d-2178-4ca6-99b8-5658eda83673" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_8957fda5-cf11-444a-b83e-2da50a7a882d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_IncreaseDecreaseInAccountsReceivableAndContractWithCustomerAsset_fdb195af-4362-4b58-b6d7-18f217c4d573" xlink:href="evh-20211231.xsd#evh_IncreaseDecreaseInAccountsReceivableAndContractWithCustomerAsset"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_8957fda5-cf11-444a-b83e-2da50a7a882d" xlink:to="loc_evh_IncreaseDecreaseInAccountsReceivableAndContractWithCustomerAsset_fdb195af-4362-4b58-b6d7-18f217c4d573" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_52011480-a5bf-4976-acf2-fd94a5d4dcee" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_8957fda5-cf11-444a-b83e-2da50a7a882d" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_52011480-a5bf-4976-acf2-fd94a5d4dcee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_IncreaseDecreaseInCapitalizedContractCostNet_a43e3e98-08fc-4704-8449-5ad87f365e24" xlink:href="evh-20211231.xsd#evh_IncreaseDecreaseInCapitalizedContractCostNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_8957fda5-cf11-444a-b83e-2da50a7a882d" xlink:to="loc_evh_IncreaseDecreaseInCapitalizedContractCostNet_a43e3e98-08fc-4704-8449-5ad87f365e24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_817e219a-6ec0-4061-a8a9-d5fd05559409" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_8957fda5-cf11-444a-b83e-2da50a7a882d" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_817e219a-6ec0-4061-a8a9-d5fd05559409" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_26ab4cfc-b618-4709-adad-2f86cd5c9a21" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_8957fda5-cf11-444a-b83e-2da50a7a882d" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_26ab4cfc-b618-4709-adad-2f86cd5c9a21" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_4f03bd9c-0dff-43fa-8b9e-2d545e532ab8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_8957fda5-cf11-444a-b83e-2da50a7a882d" xlink:to="loc_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_4f03bd9c-0dff-43fa-8b9e-2d545e532ab8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_669ed803-6713-4069-a987-93fc99d3e171" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_8957fda5-cf11-444a-b83e-2da50a7a882d" xlink:to="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_669ed803-6713-4069-a987-93fc99d3e171" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_IncreaseDecreaseInInsuranceAndPerformanceBasedArrangementsLiabilities_d787a1da-3ab2-44ff-855a-3f8492890ce5" xlink:href="evh-20211231.xsd#evh_IncreaseDecreaseInInsuranceAndPerformanceBasedArrangementsLiabilities"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_8957fda5-cf11-444a-b83e-2da50a7a882d" xlink:to="loc_evh_IncreaseDecreaseInInsuranceAndPerformanceBasedArrangementsLiabilities_d787a1da-3ab2-44ff-855a-3f8492890ce5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_IncreaseDecreaseInOperatingLeaseRightofUseAsset_2df9a288-da07-4d5c-a575-bc4b2493b690" xlink:href="evh-20211231.xsd#evh_IncreaseDecreaseInOperatingLeaseRightofUseAsset"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_8957fda5-cf11-444a-b83e-2da50a7a882d" xlink:to="loc_evh_IncreaseDecreaseInOperatingLeaseRightofUseAsset_2df9a288-da07-4d5c-a575-bc4b2493b690" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_e8c036cc-1eea-41a8-90ef-880245c65afc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_8957fda5-cf11-444a-b83e-2da50a7a882d" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_e8c036cc-1eea-41a8-90ef-880245c65afc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_afa2efcd-795e-4ddf-8df8-31cb7ee1c65a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_8957fda5-cf11-444a-b83e-2da50a7a882d" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_afa2efcd-795e-4ddf-8df8-31cb7ee1c65a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_499cf8d0-242b-4687-b4b1-0d05ff5a3b30" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_7f640d7d-2178-4ca6-99b8-5658eda83673" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_499cf8d0-242b-4687-b4b1-0d05ff5a3b30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_0ab66a93-ce97-445c-8dc9-61ba0f0dbae6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_bba8fbcc-5477-4e48-b67b-0eac062610b7" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_0ab66a93-ce97-445c-8dc9-61ba0f0dbae6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross_e5d0700b-bb17-4be1-982b-07c12d45023c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesGross"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_0ab66a93-ce97-445c-8dc9-61ba0f0dbae6" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesGross_e5d0700b-bb17-4be1-982b-07c12d45023c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromDivestitureOfInterestInSubsidiariesAndAffiliates_ef8b70f0-7f5c-4f52-b88e-adf165164274" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromDivestitureOfInterestInSubsidiariesAndAffiliates"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_0ab66a93-ce97-445c-8dc9-61ba0f0dbae6" xlink:to="loc_us-gaap_ProceedsFromDivestitureOfInterestInSubsidiariesAndAffiliates_ef8b70f0-7f5c-4f52-b88e-adf165164274" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForProceedsFromLoansReceivable_b6d1e0d5-9685-4411-b592-77034c709360" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsForProceedsFromLoansReceivable"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_0ab66a93-ce97-445c-8dc9-61ba0f0dbae6" xlink:to="loc_us-gaap_PaymentsForProceedsFromLoansReceivable_b6d1e0d5-9685-4411-b592-77034c709360" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_PaymentsForProceedsFromDisposalOfNonStrategicAssetsAndDivestitureOfDiscontinuedOperationsNet_2efc901f-e591-4fc0-b131-92fc6c546c8f" xlink:href="evh-20211231.xsd#evh_PaymentsForProceedsFromDisposalOfNonStrategicAssetsAndDivestitureOfDiscontinuedOperationsNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_0ab66a93-ce97-445c-8dc9-61ba0f0dbae6" xlink:to="loc_evh_PaymentsForProceedsFromDisposalOfNonStrategicAssetsAndDivestitureOfDiscontinuedOperationsNet_2efc901f-e591-4fc0-b131-92fc6c546c8f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital_b6f27da9-751d-4563-aa65-2ca7d691f852" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_0ab66a93-ce97-445c-8dc9-61ba0f0dbae6" xlink:to="loc_us-gaap_ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital_b6f27da9-751d-4563-aa65-2ca7d691f852" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_PaymentsForCustomerAdvanceForRegulatoryCapitalRequirements_5903da44-3d6f-405f-942a-0e1ca597d997" xlink:href="evh-20211231.xsd#evh_PaymentsForCustomerAdvanceForRegulatoryCapitalRequirements"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_0ab66a93-ce97-445c-8dc9-61ba0f0dbae6" xlink:to="loc_evh_PaymentsForCustomerAdvanceForRegulatoryCapitalRequirements_5903da44-3d6f-405f-942a-0e1ca597d997" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireInterestInSubsidiariesAndAffiliates_11dec3f1-1b5b-4688-8423-00634a3c6e44" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireInterestInSubsidiariesAndAffiliates"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_0ab66a93-ce97-445c-8dc9-61ba0f0dbae6" xlink:to="loc_us-gaap_PaymentsToAcquireInterestInSubsidiariesAndAffiliates_11dec3f1-1b5b-4688-8423-00634a3c6e44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAcquiredFromAcquisition_87f8e3ff-e301-43d2-8993-2e0b91593b47" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAcquiredFromAcquisition"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_0ab66a93-ce97-445c-8dc9-61ba0f0dbae6" xlink:to="loc_us-gaap_CashAcquiredFromAcquisition_87f8e3ff-e301-43d2-8993-2e0b91593b47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireHeldToMaturitySecurities_88e86258-c858-497a-88e9-de89d2d8133b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireHeldToMaturitySecurities"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_0ab66a93-ce97-445c-8dc9-61ba0f0dbae6" xlink:to="loc_us-gaap_PaymentsToAcquireHeldToMaturitySecurities_88e86258-c858-497a-88e9-de89d2d8133b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_ProceedsFromMaturityOfInvestments_10fa16f5-d011-4a6a-81bf-4cde88198425" xlink:href="evh-20211231.xsd#evh_ProceedsFromMaturityOfInvestments"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_0ab66a93-ce97-445c-8dc9-61ba0f0dbae6" xlink:to="loc_evh_ProceedsFromMaturityOfInvestments_10fa16f5-d011-4a6a-81bf-4cde88198425" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireOtherProductiveAssets_7d9d1903-1c78-4b6b-882c-57352bdaf3bf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireOtherProductiveAssets"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_0ab66a93-ce97-445c-8dc9-61ba0f0dbae6" xlink:to="loc_us-gaap_PaymentsToAcquireOtherProductiveAssets_7d9d1903-1c78-4b6b-882c-57352bdaf3bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_3682b552-1086-4d6e-9381-288fbd5b5263" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsForProceedsFromOtherInvestingActivities"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_0ab66a93-ce97-445c-8dc9-61ba0f0dbae6" xlink:to="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_3682b552-1086-4d6e-9381-288fbd5b5263" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_f6d3b4fd-84a5-4039-bb52-84e526b86f11" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_0ab66a93-ce97-445c-8dc9-61ba0f0dbae6" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_f6d3b4fd-84a5-4039-bb52-84e526b86f11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_1216b1bf-efbf-4a4a-8778-37298a2123ca" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_bba8fbcc-5477-4e48-b67b-0eac062610b7" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_1216b1bf-efbf-4a4a-8778-37298a2123ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_PaymentsForProceedsFromClaimsProcessingFinancingActivities_140c5fd7-7019-4a65-afd7-3ebecf05222a" xlink:href="evh-20211231.xsd#evh_PaymentsForProceedsFromClaimsProcessingFinancingActivities"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_1216b1bf-efbf-4a4a-8778-37298a2123ca" xlink:to="loc_evh_PaymentsForProceedsFromClaimsProcessingFinancingActivities_140c5fd7-7019-4a65-afd7-3ebecf05222a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_ProceedsFromAssetAcquisitionEscrow_697e2e54-4b6d-42be-956e-4840c1bdc142" xlink:href="evh-20211231.xsd#evh_ProceedsFromAssetAcquisitionEscrow"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_1216b1bf-efbf-4a4a-8778-37298a2123ca" xlink:to="loc_evh_ProceedsFromAssetAcquisitionEscrow_697e2e54-4b6d-42be-956e-4840c1bdc142" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDebtExtinguishmentCosts_9b4006b3-dea1-4cfb-a3d5-6fdf1f32f13d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsOfDebtExtinguishmentCosts"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_1216b1bf-efbf-4a4a-8778-37298a2123ca" xlink:to="loc_us-gaap_PaymentsOfDebtExtinguishmentCosts_9b4006b3-dea1-4cfb-a3d5-6fdf1f32f13d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromConvertibleDebt_1d1d345e-327f-441b-882b-d89aec8b9fda" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromConvertibleDebt"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_1216b1bf-efbf-4a4a-8778-37298a2123ca" xlink:to="loc_us-gaap_ProceedsFromConvertibleDebt_1d1d345e-327f-441b-882b-d89aec8b9fda" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromHedgeFinancingActivities_960c0fe8-66a5-46a3-a950-c64ec923b155" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromHedgeFinancingActivities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_1216b1bf-efbf-4a4a-8778-37298a2123ca" xlink:to="loc_us-gaap_ProceedsFromHedgeFinancingActivities_960c0fe8-66a5-46a3-a950-c64ec923b155" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfSeniorDebt_e7ede398-6ee9-44ab-9267-2af13a8dd570" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfSeniorDebt"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_1216b1bf-efbf-4a4a-8778-37298a2123ca" xlink:to="loc_us-gaap_RepaymentsOfSeniorDebt_e7ede398-6ee9-44ab-9267-2af13a8dd570" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_87382cf8-71a4-4b2e-9b46-3c6d35f03b28" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_1216b1bf-efbf-4a4a-8778-37298a2123ca" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_87382cf8-71a4-4b2e-9b46-3c6d35f03b28" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToMinorityShareholders_5f1c624d-5c79-459e-99cd-5dc14e4b9e0d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToMinorityShareholders"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_1216b1bf-efbf-4a4a-8778-37298a2123ca" xlink:to="loc_us-gaap_PaymentsToMinorityShareholders_5f1c624d-5c79-459e-99cd-5dc14e4b9e0d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_33d0da39-bee3-4049-960f-f7323b757890" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_1216b1bf-efbf-4a4a-8778-37298a2123ca" xlink:to="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_33d0da39-bee3-4049-960f-f7323b757890" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_38a55ebc-eb4e-45c7-b408-9fef4f0787e6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_1216b1bf-efbf-4a4a-8778-37298a2123ca" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_38a55ebc-eb4e-45c7-b408-9fef4f0787e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_6d5b2439-c115-4c2b-b263-813b5ace9526" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_bba8fbcc-5477-4e48-b67b-0eac062610b7" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_6d5b2439-c115-4c2b-b263-813b5ace9526" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_f7a1ea37-4fae-435d-913f-daaa2521cbdd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_bba8fbcc-5477-4e48-b67b-0eac062610b7" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_f7a1ea37-4fae-435d-913f-daaa2521cbdd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_ce590dab-f9ac-4e90-9ab9-ac199e827d05" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_bba8fbcc-5477-4e48-b67b-0eac062610b7" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_ce590dab-f9ac-4e90-9ab9-ac199e827d05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_bec30b1e-4b3a-406d-85dc-a7505b47c419" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_bba8fbcc-5477-4e48-b67b-0eac062610b7" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_bec30b1e-4b3a-406d-85dc-a7505b47c419" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/Organization" xlink:type="simple" xlink:href="evh-20211231.xsd#Organization"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/Organization" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_7ad5dbe3-3856-4f7d-9b58-969beb802d03" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_deb4101a-d19b-4d23-8f72-f121e5ef961f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_7ad5dbe3-3856-4f7d-9b58-969beb802d03" xlink:to="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_deb4101a-d19b-4d23-8f72-f121e5ef961f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/OrganizationDetails" xlink:type="simple" xlink:href="evh-20211231.xsd#OrganizationDetails"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/OrganizationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_bd270134-1ad4-4afe-b4ed-8c70481d3a30" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_930d9fd2-028d-4a9a-b2f9-2290721d3c40" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_bd270134-1ad4-4afe-b4ed-8c70481d3a30" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_930d9fd2-028d-4a9a-b2f9-2290721d3c40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_844e2e72-1cfc-4f62-946a-b0a2b08bc516" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_bd270134-1ad4-4afe-b4ed-8c70481d3a30" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_844e2e72-1cfc-4f62-946a-b0a2b08bc516" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_1fffd439-669b-4893-8ff6-8a0f378eda56" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_844e2e72-1cfc-4f62-946a-b0a2b08bc516" xlink:to="loc_us-gaap_StatementClassOfStockAxis_1fffd439-669b-4893-8ff6-8a0f378eda56" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_b2722b5a-9839-4ee7-ac7e-af4dffd2046b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_1fffd439-669b-4893-8ff6-8a0f378eda56" xlink:to="loc_us-gaap_ClassOfStockDomain_b2722b5a-9839-4ee7-ac7e-af4dffd2046b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassBMember_1ccb6e22-b254-4dbb-8476-b87c330ee117" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonClassBMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_b2722b5a-9839-4ee7-ac7e-af4dffd2046b" xlink:to="loc_us-gaap_CommonClassBMember_1ccb6e22-b254-4dbb-8476-b87c330ee117" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_9fe19234-187f-42a4-aff4-9947ac6a2e64" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_844e2e72-1cfc-4f62-946a-b0a2b08bc516" xlink:to="loc_us-gaap_ClassOfStockLineItems_9fe19234-187f-42a4-aff4-9947ac6a2e64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_739e69f2-72d1-4192-86e5-720cf7561d4c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_9fe19234-187f-42a4-aff4-9947ac6a2e64" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_739e69f2-72d1-4192-86e5-720cf7561d4c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciples" xlink:type="simple" xlink:href="evh-20211231.xsd#BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciples"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciples" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_0fed10fa-2590-4e73-84ff-0dac37d33ba3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_cda8d1c1-9596-4bdd-9568-200ae489294e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0fed10fa-2590-4e73-84ff-0dac37d33ba3" xlink:to="loc_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_cda8d1c1-9596-4bdd-9568-200ae489294e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesPolicies" xlink:type="simple" xlink:href="evh-20211231.xsd#BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesPolicies"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_78c51740-c8d0-45e7-be82-682c0ddeb632" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_d511f4a0-89a3-48c7-9040-5a5708363d21" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_78c51740-c8d0-45e7-be82-682c0ddeb632" xlink:to="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_d511f4a0-89a3-48c7-9040-5a5708363d21" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates_0eb838a6-9f1d-4f1b-8606-c5b6e5de352e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UseOfEstimates"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_78c51740-c8d0-45e7-be82-682c0ddeb632" xlink:to="loc_us-gaap_UseOfEstimates_0eb838a6-9f1d-4f1b-8606-c5b6e5de352e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock_85982910-f532-4581-b6af-d4349054097b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_78c51740-c8d0-45e7-be82-682c0ddeb632" xlink:to="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock_85982910-f532-4581-b6af-d4349054097b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy_fbd24ade-def3-40dd-8c03-8f08d6332f33" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_78c51740-c8d0-45e7-be82-682c0ddeb632" xlink:to="loc_us-gaap_CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy_fbd24ade-def3-40dd-8c03-8f08d6332f33" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy_4c9d7a0b-cce3-4e37-9da8-9b60598aeca6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_78c51740-c8d0-45e7-be82-682c0ddeb632" xlink:to="loc_us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy_4c9d7a0b-cce3-4e37-9da8-9b60598aeca6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_a18badab-12d1-43d1-9372-d33d52162ef8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_78c51740-c8d0-45e7-be82-682c0ddeb632" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_a18badab-12d1-43d1-9372-d33d52162ef8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InternalUseSoftwarePolicy_84f50ee7-efdd-4d6d-9ba3-451616faeeef" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InternalUseSoftwarePolicy"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_78c51740-c8d0-45e7-be82-682c0ddeb632" xlink:to="loc_us-gaap_InternalUseSoftwarePolicy_84f50ee7-efdd-4d6d-9ba3-451616faeeef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_e308adae-9c27-47a1-9458-ad7b5a6f862f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_78c51740-c8d0-45e7-be82-682c0ddeb632" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_e308adae-9c27-47a1-9458-ad7b5a6f862f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsPolicy_0417b073-ee86-4a85-8a4b-3fcf740ae1f2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationsPolicy"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_78c51740-c8d0-45e7-be82-682c0ddeb632" xlink:to="loc_us-gaap_BusinessCombinationsPolicy_0417b073-ee86-4a85-8a4b-3fcf740ae1f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentsPolicy_35e0c433-7427-463c-a6ef-3b842b60bc69" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestmentsPolicy"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_78c51740-c8d0-45e7-be82-682c0ddeb632" xlink:to="loc_us-gaap_EquityMethodInvestmentsPolicy_35e0c433-7427-463c-a6ef-3b842b60bc69" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_8ca295b7-b341-48f3-8e90-052a167dcf01" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_78c51740-c8d0-45e7-be82-682c0ddeb632" xlink:to="loc_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_8ca295b7-b341-48f3-8e90-052a167dcf01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsFiniteLivedPolicy_8d861669-588c-4342-9e8a-9921cd22e0b3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsFiniteLivedPolicy"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_78c51740-c8d0-45e7-be82-682c0ddeb632" xlink:to="loc_us-gaap_IntangibleAssetsFiniteLivedPolicy_8d861669-588c-4342-9e8a-9921cd22e0b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityReserveEstimatePolicy_95045e63-6ddb-452f-b29f-f6e820463ebf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilityReserveEstimatePolicy"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_78c51740-c8d0-45e7-be82-682c0ddeb632" xlink:to="loc_us-gaap_LiabilityReserveEstimatePolicy_95045e63-6ddb-452f-b29f-f6e820463ebf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_RightOfOffsetPolicyPolicyTextBlock_ed99dead-a752-4038-a72b-18f16dfe9046" xlink:href="evh-20211231.xsd#evh_RightOfOffsetPolicyPolicyTextBlock"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_78c51740-c8d0-45e7-be82-682c0ddeb632" xlink:to="loc_evh_RightOfOffsetPolicyPolicyTextBlock_ed99dead-a752-4038-a72b-18f16dfe9046" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtPolicyTextBlock_11053a26-538a-43e1-9fee-54ff29676425" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtPolicyTextBlock"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_78c51740-c8d0-45e7-be82-682c0ddeb632" xlink:to="loc_us-gaap_DebtPolicyTextBlock_11053a26-538a-43e1-9fee-54ff29676425" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeasesPolicyTextBlock_6b5caefc-75e3-4acd-901b-bd3698e83bbe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeasesPolicyTextBlock"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_78c51740-c8d0-45e7-be82-682c0ddeb632" xlink:to="loc_us-gaap_LesseeLeasesPolicyTextBlock_6b5caefc-75e3-4acd-901b-bd3698e83bbe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_93da58ab-c5f6-4c04-88e7-0c55743a6796" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_78c51740-c8d0-45e7-be82-682c0ddeb632" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_93da58ab-c5f6-4c04-88e7-0c55743a6796" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_451149af-e7a1-46e8-9cb5-186060b44a18" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_78c51740-c8d0-45e7-be82-682c0ddeb632" xlink:to="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_451149af-e7a1-46e8-9cb5-186060b44a18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock_853567ca-8fb1-4a8b-9b9a-b2d27f0c9413" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_78c51740-c8d0-45e7-be82-682c0ddeb632" xlink:to="loc_us-gaap_IncomeTaxPolicyTextBlock_853567ca-8fb1-4a8b-9b9a-b2d27f0c9413" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock_23a7ba6c-53e2-4b2a-8131-b0d66f7705bb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_78c51740-c8d0-45e7-be82-682c0ddeb632" xlink:to="loc_us-gaap_EarningsPerSharePolicyTextBlock_23a7ba6c-53e2-4b2a-8131-b0d66f7705bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_a8d95c70-08b4-486f-9e42-574b743b3668" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_78c51740-c8d0-45e7-be82-682c0ddeb632" xlink:to="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_a8d95c70-08b4-486f-9e42-574b743b3668" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_95b63846-ad3e-4c7c-b54a-73974ee90a46" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_78c51740-c8d0-45e7-be82-682c0ddeb632" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_95b63846-ad3e-4c7c-b54a-73974ee90a46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesTables" xlink:type="simple" xlink:href="evh-20211231.xsd#BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesTables"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_8fa63e6f-332e-4e05-98bf-dac7793ce4cc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock_d24fab85-f829-4837-becd-d6401ae9658a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_8fa63e6f-332e-4e05-98bf-dac7793ce4cc" xlink:to="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock_d24fab85-f829-4837-becd-d6401ae9658a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_e3f0fa4f-5601-4c92-a290-bd236acbd48e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_8fa63e6f-332e-4e05-98bf-dac7793ce4cc" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_e3f0fa4f-5601-4c92-a290-bd236acbd48e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_3823264d-b918-40e0-b77a-3a967b571109" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_8fa63e6f-332e-4e05-98bf-dac7793ce4cc" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_3823264d-b918-40e0-b77a-3a967b571109" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesOperatingSegmentsDetails" xlink:type="simple" xlink:href="evh-20211231.xsd#BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesOperatingSegmentsDetails"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesOperatingSegmentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_d176b7be-c8c4-4b75-8fda-56ee182e1221" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments_f57a1910-8b0e-4bc4-8371-6455054ff1e3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_d176b7be-c8c4-4b75-8fda-56ee182e1221" xlink:to="loc_us-gaap_NumberOfOperatingSegments_f57a1910-8b0e-4bc4-8371-6455054ff1e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesRestrictedCashandRestrictedInvestmentsDetails" xlink:type="simple" xlink:href="evh-20211231.xsd#BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesRestrictedCashandRestrictedInvestmentsDetails"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesRestrictedCashandRestrictedInvestmentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_79d5f0f4-9157-4f36-8b12-0f43cce2a7c8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable_67897a2c-65e2-497d-92d1-ff9d44550b31" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_79d5f0f4-9157-4f36-8b12-0f43cce2a7c8" xlink:to="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable_67897a2c-65e2-497d-92d1-ff9d44550b31" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_d2563653-61c5-4fcb-92c9-235d3e127dca" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable_67897a2c-65e2-497d-92d1-ff9d44550b31" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_d2563653-61c5-4fcb-92c9-235d3e127dca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_1a7c7eb0-56d6-40ab-8b7e-1c8a8da2a938" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_d2563653-61c5-4fcb-92c9-235d3e127dca" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_1a7c7eb0-56d6-40ab-8b7e-1c8a8da2a938" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_RestrictedCashforLettersofCreditforFacilityLeasesMember_54191537-7d9b-4f02-ad3c-87e35c212103" xlink:href="evh-20211231.xsd#evh_RestrictedCashforLettersofCreditforFacilityLeasesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_1a7c7eb0-56d6-40ab-8b7e-1c8a8da2a938" xlink:to="loc_evh_RestrictedCashforLettersofCreditforFacilityLeasesMember_54191537-7d9b-4f02-ad3c-87e35c212103" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_CollateralwithFinancialInstitutionsMember_5889c5a9-69ff-46f2-a62d-54d46b4166c8" xlink:href="evh-20211231.xsd#evh_CollateralwithFinancialInstitutionsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_1a7c7eb0-56d6-40ab-8b7e-1c8a8da2a938" xlink:to="loc_evh_CollateralwithFinancialInstitutionsMember_5889c5a9-69ff-46f2-a62d-54d46b4166c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_RestrictedCashforBenefitManagementServicesMember_bb2a47cc-5b45-4697-a43b-abcd68768305" xlink:href="evh-20211231.xsd#evh_RestrictedCashforBenefitManagementServicesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_1a7c7eb0-56d6-40ab-8b7e-1c8a8da2a938" xlink:to="loc_evh_RestrictedCashforBenefitManagementServicesMember_bb2a47cc-5b45-4697-a43b-abcd68768305" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_RestrictedCashforOtherContractualCommitmentsMember_436ebffc-b1cd-4089-a6da-1ac5912d7030" xlink:href="evh-20211231.xsd#evh_RestrictedCashforOtherContractualCommitmentsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_1a7c7eb0-56d6-40ab-8b7e-1c8a8da2a938" xlink:to="loc_evh_RestrictedCashforOtherContractualCommitmentsMember_436ebffc-b1cd-4089-a6da-1ac5912d7030" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BankTimeDepositsMember_d69f03ad-d7e3-4144-8334-2914bf8216f7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BankTimeDepositsMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_1a7c7eb0-56d6-40ab-8b7e-1c8a8da2a938" xlink:to="loc_us-gaap_BankTimeDepositsMember_d69f03ad-d7e3-4144-8334-2914bf8216f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis_da0a950f-397a-4a6f-8b08-14d49524ddc4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupClassificationAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable_67897a2c-65e2-497d-92d1-ff9d44550b31" xlink:to="loc_us-gaap_DisposalGroupClassificationAxis_da0a950f-397a-4a6f-8b08-14d49524ddc4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_a9fa29c6-7e35-4071-8dce-5a3a4b182d83" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_da0a950f-397a-4a6f-8b08-14d49524ddc4" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_a9fa29c6-7e35-4071-8dce-5a3a4b182d83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationsDisposedOfBySaleMember_6f71cef6-0bf9-4766-950a-6395c8a44afa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DiscontinuedOperationsDisposedOfBySaleMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain_a9fa29c6-7e35-4071-8dce-5a3a4b182d83" xlink:to="loc_us-gaap_DiscontinuedOperationsDisposedOfBySaleMember_6f71cef6-0bf9-4766-950a-6395c8a44afa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_c5c03cd2-2e46-41e9-a2a5-535001bff9d5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable_67897a2c-65e2-497d-92d1-ff9d44550b31" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_c5c03cd2-2e46-41e9-a2a5-535001bff9d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_c258f9ff-dc9b-449e-90e8-82c5d47cdea6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_c5c03cd2-2e46-41e9-a2a5-535001bff9d5" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_c258f9ff-dc9b-449e-90e8-82c5d47cdea6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_TrueHealthMember_7b6ca647-69c3-498e-a25b-30db40adc652" xlink:href="evh-20211231.xsd#evh_TrueHealthMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_c258f9ff-dc9b-449e-90e8-82c5d47cdea6" xlink:to="loc_evh_TrueHealthMember_7b6ca647-69c3-498e-a25b-30db40adc652" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems_379067c7-b09d-48e1-89ed-7bb3b2bae73e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable_67897a2c-65e2-497d-92d1-ff9d44550b31" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems_379067c7-b09d-48e1-89ed-7bb3b2bae73e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalents_6a6ff897-5c0a-4ff5-a26d-72c6e51d1fa2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalents"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems_379067c7-b09d-48e1-89ed-7bb3b2bae73e" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalents_6a6ff897-5c0a-4ff5-a26d-72c6e51d1fa2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_65f88371-4654-4113-9400-2f7c40ab018e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems_379067c7-b09d-48e1-89ed-7bb3b2bae73e" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_65f88371-4654-4113-9400-2f7c40ab018e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndInvestmentsCurrent_b69be51d-42d5-429e-90ad-c3275b1b6e43" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndInvestmentsCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems_379067c7-b09d-48e1-89ed-7bb3b2bae73e" xlink:to="loc_us-gaap_RestrictedCashAndInvestmentsCurrent_b69be51d-42d5-429e-90ad-c3275b1b6e43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_e0dcc341-9e52-438d-bb02-a30b9eb5b71c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems_379067c7-b09d-48e1-89ed-7bb3b2bae73e" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_e0dcc341-9e52-438d-bb02-a30b9eb5b71c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndInvestmentsNoncurrent_c16b3778-f6ec-438a-b984-a559ba99f45f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndInvestmentsNoncurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems_379067c7-b09d-48e1-89ed-7bb3b2bae73e" xlink:to="loc_us-gaap_RestrictedCashAndInvestmentsNoncurrent_c16b3778-f6ec-438a-b984-a559ba99f45f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_DisposalGroupIncludingDiscontinuedOperationRestrictedInvestmentsNoncurrent_6ec12f4b-51da-49b4-a253-6a9d080d09e1" xlink:href="evh-20211231.xsd#evh_DisposalGroupIncludingDiscontinuedOperationRestrictedInvestmentsNoncurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems_379067c7-b09d-48e1-89ed-7bb3b2bae73e" xlink:to="loc_evh_DisposalGroupIncludingDiscontinuedOperationRestrictedInvestmentsNoncurrent_6ec12f4b-51da-49b4-a253-6a9d080d09e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_DisposalGroupIncludingDiscontinuedOperationRestrictedCashCurrent_fea3b2c9-01eb-4cb0-b353-a9f3e2dc066a" xlink:href="evh-20211231.xsd#evh_DisposalGroupIncludingDiscontinuedOperationRestrictedCashCurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems_379067c7-b09d-48e1-89ed-7bb3b2bae73e" xlink:to="loc_evh_DisposalGroupIncludingDiscontinuedOperationRestrictedCashCurrent_fea3b2c9-01eb-4cb0-b353-a9f3e2dc066a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_CashAndCashEquivalentsAtCarryingValueExcludingDiscontinuedOperations_26da4eb0-2b4a-4722-b8d8-61ebd443c603" xlink:href="evh-20211231.xsd#evh_CashAndCashEquivalentsAtCarryingValueExcludingDiscontinuedOperations"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems_379067c7-b09d-48e1-89ed-7bb3b2bae73e" xlink:to="loc_evh_CashAndCashEquivalentsAtCarryingValueExcludingDiscontinuedOperations_26da4eb0-2b4a-4722-b8d8-61ebd443c603" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndInvestments_077f8753-7989-4af2-8a88-7d4b31a09c41" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndInvestments"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems_379067c7-b09d-48e1-89ed-7bb3b2bae73e" xlink:to="loc_us-gaap_RestrictedCashAndInvestments_077f8753-7989-4af2-8a88-7d4b31a09c41" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedInvestments_25801ac1-a5c1-4322-881b-611b825768a5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedInvestments"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems_379067c7-b09d-48e1-89ed-7bb3b2bae73e" xlink:to="loc_us-gaap_RestrictedInvestments_25801ac1-a5c1-4322-881b-611b825768a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_b04aba55-db28-4adf-bf2d-2421663e432b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems_379067c7-b09d-48e1-89ed-7bb3b2bae73e" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_b04aba55-db28-4adf-bf2d-2421663e432b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesEstimatedUsefulLifeofPropertyPlantandEquipmentDetails" xlink:type="simple" xlink:href="evh-20211231.xsd#BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesEstimatedUsefulLifeofPropertyPlantandEquipmentDetails"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesEstimatedUsefulLifeofPropertyPlantandEquipmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_203ab814-a410-4af8-800f-e2910f5ab249" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_6f53cf6d-3f7b-4ae2-b598-3ec6a1d2c5c1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_203ab814-a410-4af8-800f-e2910f5ab249" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_6f53cf6d-3f7b-4ae2-b598-3ec6a1d2c5c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_d54b54c0-62f4-46f5-bc36-fd1a3f4d64fd" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_6f53cf6d-3f7b-4ae2-b598-3ec6a1d2c5c1" xlink:to="loc_srt_RangeAxis_d54b54c0-62f4-46f5-bc36-fd1a3f4d64fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_8ed058b2-7a38-4b7c-a903-9600b68c3ee4" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_d54b54c0-62f4-46f5-bc36-fd1a3f4d64fd" xlink:to="loc_srt_RangeMember_8ed058b2-7a38-4b7c-a903-9600b68c3ee4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_512ed24b-743a-4eab-aef0-e9efecda2ef3" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_8ed058b2-7a38-4b7c-a903-9600b68c3ee4" xlink:to="loc_srt_MinimumMember_512ed24b-743a-4eab-aef0-e9efecda2ef3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_6ffd4338-6110-4e89-b829-6396af848dd0" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_8ed058b2-7a38-4b7c-a903-9600b68c3ee4" xlink:to="loc_srt_MaximumMember_6ffd4338-6110-4e89-b829-6396af848dd0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_4bafe9f2-6152-43ba-8d7b-e25db831243d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_6f53cf6d-3f7b-4ae2-b598-3ec6a1d2c5c1" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_4bafe9f2-6152-43ba-8d7b-e25db831243d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_b05f45c9-1e33-47ac-af63-0e27db7ee2e9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_4bafe9f2-6152-43ba-8d7b-e25db831243d" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_b05f45c9-1e33-47ac-af63-0e27db7ee2e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComputerEquipmentMember_ac37778d-658d-4be3-87c1-39871a1f94d5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComputerEquipmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_b05f45c9-1e33-47ac-af63-0e27db7ee2e9" xlink:to="loc_us-gaap_ComputerEquipmentMember_ac37778d-658d-4be3-87c1-39871a1f94d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_2ea451ec-4601-4772-9dd2-686762f006b6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SoftwareAndSoftwareDevelopmentCostsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_b05f45c9-1e33-47ac-af63-0e27db7ee2e9" xlink:to="loc_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_2ea451ec-4601-4772-9dd2-686762f006b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_271e9695-9b8c-4037-8a0b-30d9736c1e06" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_b05f45c9-1e33-47ac-af63-0e27db7ee2e9" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_271e9695-9b8c-4037-8a0b-30d9736c1e06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SoftwareDevelopmentMember_9eb70d84-4d6e-453e-810e-791ed3a6e4af" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SoftwareDevelopmentMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_b05f45c9-1e33-47ac-af63-0e27db7ee2e9" xlink:to="loc_us-gaap_SoftwareDevelopmentMember_9eb70d84-4d6e-453e-810e-791ed3a6e4af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_96afb12f-7a02-4f2a-9cfa-c422b7c7e6e1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_6f53cf6d-3f7b-4ae2-b598-3ec6a1d2c5c1" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_96afb12f-7a02-4f2a-9cfa-c422b7c7e6e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_0a8f7e31-81dc-426e-98ea-10054a176120" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_96afb12f-7a02-4f2a-9cfa-c422b7c7e6e1" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_0a8f7e31-81dc-426e-98ea-10054a176120" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesResearchandDevelopmentCostsDetails" xlink:type="simple" xlink:href="evh-20211231.xsd#BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesResearchandDevelopmentCostsDetails"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesResearchandDevelopmentCostsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_c94a0fd1-c3b1-4365-9b96-1c06cfee9a2a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_38f0587d-f84a-4ad8-946e-23be153b0921" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_c94a0fd1-c3b1-4365-9b96-1c06cfee9a2a" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_38f0587d-f84a-4ad8-946e-23be153b0921" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesGoodwillDetails" xlink:type="simple" xlink:href="evh-20211231.xsd#BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesGoodwillDetails"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesGoodwillDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_0a93c266-59a7-4da4-9838-32092f725910" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfReportingUnits_57d0ba39-25b4-42e6-9719-7f796c659f36" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NumberOfReportingUnits"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0a93c266-59a7-4da4-9838-32092f725910" xlink:to="loc_us-gaap_NumberOfReportingUnits_57d0ba39-25b4-42e6-9719-7f796c659f36" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesIntangibleAssetsNetDetails" xlink:type="simple" xlink:href="evh-20211231.xsd#BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesIntangibleAssetsNetDetails"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesIntangibleAssetsNetDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_ee16a8c4-6f9f-4cd9-b431-e6a9a3731154" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_c17f95a6-1fe9-4289-bbc7-f1cfdd3041de" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_ee16a8c4-6f9f-4cd9-b431-e6a9a3731154" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_c17f95a6-1fe9-4289-bbc7-f1cfdd3041de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_f1a40c16-ba11-42e2-8d51-84b89444f157" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_c17f95a6-1fe9-4289-bbc7-f1cfdd3041de" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_f1a40c16-ba11-42e2-8d51-84b89444f157" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_194dd850-54e9-427e-ac11-5aefda288e7c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_f1a40c16-ba11-42e2-8d51-84b89444f157" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_194dd850-54e9-427e-ac11-5aefda288e7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TradeNamesMember_dd6fbe4b-20e2-4023-932e-f062368c4b14" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TradeNamesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_194dd850-54e9-427e-ac11-5aefda288e7c" xlink:to="loc_us-gaap_TradeNamesMember_dd6fbe4b-20e2-4023-932e-f062368c4b14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerRelationshipsMember_774fd83b-465b-4095-b4cb-e99492027cd1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CustomerRelationshipsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_194dd850-54e9-427e-ac11-5aefda288e7c" xlink:to="loc_us-gaap_CustomerRelationshipsMember_774fd83b-465b-4095-b4cb-e99492027cd1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DevelopedTechnologyRightsMember_f0fa7e40-d435-470d-930d-e0a2a44ceaac" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DevelopedTechnologyRightsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_194dd850-54e9-427e-ac11-5aefda288e7c" xlink:to="loc_us-gaap_DevelopedTechnologyRightsMember_f0fa7e40-d435-470d-930d-e0a2a44ceaac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractBasedIntangibleAssetsMember_d92f0150-f520-47cc-987f-c6b91a670752" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractBasedIntangibleAssetsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_194dd850-54e9-427e-ac11-5aefda288e7c" xlink:to="loc_us-gaap_ContractBasedIntangibleAssetsMember_d92f0150-f520-47cc-987f-c6b91a670752" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_e02b2d6a-51d3-4f63-8945-726f8bbcf2f8" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_c17f95a6-1fe9-4289-bbc7-f1cfdd3041de" xlink:to="loc_srt_RangeAxis_e02b2d6a-51d3-4f63-8945-726f8bbcf2f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_3b70213d-9636-4904-9ed0-5b85b57beaa6" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_e02b2d6a-51d3-4f63-8945-726f8bbcf2f8" xlink:to="loc_srt_RangeMember_3b70213d-9636-4904-9ed0-5b85b57beaa6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_7fdb12a2-03af-439f-b8ee-c7f333cc4d19" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_3b70213d-9636-4904-9ed0-5b85b57beaa6" xlink:to="loc_srt_MinimumMember_7fdb12a2-03af-439f-b8ee-c7f333cc4d19" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_87e3eb59-0f47-4907-8df7-8310cbb3f2eb" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_3b70213d-9636-4904-9ed0-5b85b57beaa6" xlink:to="loc_srt_MaximumMember_87e3eb59-0f47-4907-8df7-8310cbb3f2eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_87067f9d-ebfe-43e6-8efc-9a5a10718719" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_c17f95a6-1fe9-4289-bbc7-f1cfdd3041de" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_87067f9d-ebfe-43e6-8efc-9a5a10718719" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_6a64226b-34e6-4b19-b886-45ad0d59f8e4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_87067f9d-ebfe-43e6-8efc-9a5a10718719" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_6a64226b-34e6-4b19-b886-45ad0d59f8e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesRightofOffsetDetails" xlink:type="simple" xlink:href="evh-20211231.xsd#BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesRightofOffsetDetails"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesRightofOffsetDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_eaa6547e-eb04-4a14-8386-f7c4e002bca3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_RightOfOffsetPercentageOfAccountsReceivableNettedAgainstClaimsPayable_e5e32954-8b20-416e-bfb3-992df9f0ac7c" xlink:href="evh-20211231.xsd#evh_RightOfOffsetPercentageOfAccountsReceivableNettedAgainstClaimsPayable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_eaa6547e-eb04-4a14-8386-f7c4e002bca3" xlink:to="loc_evh_RightOfOffsetPercentageOfAccountsReceivableNettedAgainstClaimsPayable_e5e32954-8b20-416e-bfb3-992df9f0ac7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_RightOfOffsetPercentageOfAccountsReceivableNetEligibleForNetBasisSettlement_2d89fb0a-ced8-4b70-b454-7ce2410ba691" xlink:href="evh-20211231.xsd#evh_RightOfOffsetPercentageOfAccountsReceivableNetEligibleForNetBasisSettlement"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_eaa6547e-eb04-4a14-8386-f7c4e002bca3" xlink:to="loc_evh_RightOfOffsetPercentageOfAccountsReceivableNetEligibleForNetBasisSettlement_2d89fb0a-ced8-4b70-b454-7ce2410ba691" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesStockbasedCompensationDetails" xlink:type="simple" xlink:href="evh-20211231.xsd#BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesStockbasedCompensationDetails"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesStockbasedCompensationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_455aa8a4-a739-4495-97b9-209a4c80d254" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_86a92490-74df-4e09-92c5-823a960bf6f5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_455aa8a4-a739-4495-97b9-209a4c80d254" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_86a92490-74df-4e09-92c5-823a960bf6f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_fdeb46cf-02da-465a-89dd-0e10f6df7203" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_86a92490-74df-4e09-92c5-823a960bf6f5" xlink:to="loc_us-gaap_AwardTypeAxis_fdeb46cf-02da-465a-89dd-0e10f6df7203" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3ef73981-bf1c-4adc-925f-9d81ad71fed3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_fdeb46cf-02da-465a-89dd-0e10f6df7203" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3ef73981-bf1c-4adc-925f-9d81ad71fed3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_005b8c52-8521-41a0-9da6-5a2db5784e43" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3ef73981-bf1c-4adc-925f-9d81ad71fed3" xlink:to="loc_us-gaap_EmployeeStockOptionMember_005b8c52-8521-41a0-9da6-5a2db5784e43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_16423606-996d-4e33-996c-11dfe538e4e9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_86a92490-74df-4e09-92c5-823a960bf6f5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_16423606-996d-4e33-996c-11dfe538e4e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_d31073d9-1dee-4267-97aa-58db8c5ed851" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_16423606-996d-4e33-996c-11dfe538e4e9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_d31073d9-1dee-4267-97aa-58db8c5ed851" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_2ff688ab-1c39-4db2-9003-1fb3813a6a69" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_16423606-996d-4e33-996c-11dfe538e4e9" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_2ff688ab-1c39-4db2-9003-1fb3813a6a69" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/RecentlyIssuedAccountingStandards" xlink:type="simple" xlink:href="evh-20211231.xsd#RecentlyIssuedAccountingStandards"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/RecentlyIssuedAccountingStandards" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_8cb41513-10e5-43e4-81fe-e7ea241c0697" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock_5cbbd403-0338-407f-a207-50d0e1947e5a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_8cb41513-10e5-43e4-81fe-e7ea241c0697" xlink:to="loc_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock_5cbbd403-0338-407f-a207-50d0e1947e5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/RecentlyIssuedAccountingStandardsDetails" xlink:type="simple" xlink:href="evh-20211231.xsd#RecentlyIssuedAccountingStandardsDetails"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/RecentlyIssuedAccountingStandardsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_b3eb4229-8f75-4434-a66b-6ccff81f42ce" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_77715a5a-1c1d-4ff1-b914-f859d9bdccad" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_b3eb4229-8f75-4434-a66b-6ccff81f42ce" xlink:to="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_77715a5a-1c1d-4ff1-b914-f859d9bdccad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_5bbeefda-e674-427c-95bf-c5b68838e07f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_77715a5a-1c1d-4ff1-b914-f859d9bdccad" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_5bbeefda-e674-427c-95bf-c5b68838e07f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_093d6c45-0524-4e05-a065-b5f0cadbda18" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_5bbeefda-e674-427c-95bf-c5b68838e07f" xlink:to="loc_us-gaap_EquityComponentDomain_093d6c45-0524-4e05-a065-b5f0cadbda18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_6f8fe025-b9bc-4292-aec2-12117568953b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_093d6c45-0524-4e05-a065-b5f0cadbda18" xlink:to="loc_us-gaap_RetainedEarningsMember_6f8fe025-b9bc-4292-aec2-12117568953b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_16936450-f2ec-4553-9257-a7aa5978ecbe" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_77715a5a-1c1d-4ff1-b914-f859d9bdccad" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_16936450-f2ec-4553-9257-a7aa5978ecbe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_88b7c33a-a77c-4530-93dd-04f835849c08" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_16936450-f2ec-4553-9257-a7aa5978ecbe" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_88b7c33a-a77c-4530-93dd-04f835849c08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_9f4dade8-0f22-4722-b8e9-32b4a2b712fa" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_88b7c33a-a77c-4530-93dd-04f835849c08" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_9f4dade8-0f22-4722-b8e9-32b4a2b712fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_e9301795-e634-4201-9327-d444fb91e033" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_77715a5a-1c1d-4ff1-b914-f859d9bdccad" xlink:to="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_e9301795-e634-4201-9327-d444fb91e033" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_4cdcc774-19f1-482c-836c-44dc760ef3bb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_e9301795-e634-4201-9327-d444fb91e033" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_4cdcc774-19f1-482c-836c-44dc760ef3bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingStandardsUpdateExtensibleList_d7a02da7-a0b5-4e39-91c2-4dcfe5c8f960" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingStandardsUpdateExtensibleList"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_e9301795-e634-4201-9327-d444fb91e033" xlink:to="loc_us-gaap_AccountingStandardsUpdateExtensibleList_d7a02da7-a0b5-4e39-91c2-4dcfe5c8f960" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/Transactions" xlink:type="simple" xlink:href="evh-20211231.xsd#Transactions"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/Transactions" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_42e11ab7-2573-4ff2-9042-bfc6cc3e5a1d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationDisclosureTextBlock_bb148848-e72e-4814-bfd4-45826aa9e7f3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_42e11ab7-2573-4ff2-9042-bfc6cc3e5a1d" xlink:to="loc_us-gaap_BusinessCombinationDisclosureTextBlock_bb148848-e72e-4814-bfd4-45826aa9e7f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/TransactionsTables" xlink:type="simple" xlink:href="evh-20211231.xsd#TransactionsTables"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/TransactionsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_bb0d70e1-d9d0-4d79-9074-95acf71b33a3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock_389a881f-4ea5-4948-81e0-8f6e1a428b9f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_bb0d70e1-d9d0-4d79-9074-95acf71b33a3" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock_389a881f-4ea5-4948-81e0-8f6e1a428b9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_679ee5b7-a7ae-4eaa-ab29-2be177581e40" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_bb0d70e1-d9d0-4d79-9074-95acf71b33a3" xlink:to="loc_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_679ee5b7-a7ae-4eaa-ab29-2be177581e40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/TransactionsVitalDecisionsDetails" xlink:type="simple" xlink:href="evh-20211231.xsd#TransactionsVitalDecisionsDetails"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/TransactionsVitalDecisionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsAbstract_edd94299-faa5-4f50-9970-b9d00968bf8d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_894bef58-fe6f-42d5-baf2-7d4479a46f29" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_edd94299-faa5-4f50-9970-b9d00968bf8d" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_894bef58-fe6f-42d5-baf2-7d4479a46f29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_ee03af95-df0e-4fb1-bfac-a42f313f3413" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_894bef58-fe6f-42d5-baf2-7d4479a46f29" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_ee03af95-df0e-4fb1-bfac-a42f313f3413" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_45848b34-f98c-4679-a8ec-b3ba5e5f18a2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_ee03af95-df0e-4fb1-bfac-a42f313f3413" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_45848b34-f98c-4679-a8ec-b3ba5e5f18a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_VitalDecisionsMember_df56a59b-47cd-42c4-9557-be4a15196c82" xlink:href="evh-20211231.xsd#evh_VitalDecisionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_45848b34-f98c-4679-a8ec-b3ba5e5f18a2" xlink:to="loc_evh_VitalDecisionsMember_df56a59b-47cd-42c4-9557-be4a15196c82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_5f6f3594-7e44-4021-83b1-3f82e1f76263" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_894bef58-fe6f-42d5-baf2-7d4479a46f29" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_5f6f3594-7e44-4021-83b1-3f82e1f76263" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_bf391db7-8b0e-4cd9-8ff3-dcbf9c23f899" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_5f6f3594-7e44-4021-83b1-3f82e1f76263" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_bf391db7-8b0e-4cd9-8ff3-dcbf9c23f899" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerRelationshipsMember_3e1a81cb-5775-4586-9e84-16dec3b06b73" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CustomerRelationshipsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_bf391db7-8b0e-4cd9-8ff3-dcbf9c23f899" xlink:to="loc_us-gaap_CustomerRelationshipsMember_3e1a81cb-5775-4586-9e84-16dec3b06b73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DevelopedTechnologyRightsMember_cc7fdff7-f05b-4009-bb30-e5d829e434d0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DevelopedTechnologyRightsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_bf391db7-8b0e-4cd9-8ff3-dcbf9c23f899" xlink:to="loc_us-gaap_DevelopedTechnologyRightsMember_cc7fdff7-f05b-4009-bb30-e5d829e434d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TradeNamesMember_bc1ab2fd-3bf3-4f06-a413-e1817ee6f1fc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TradeNamesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_bf391db7-8b0e-4cd9-8ff3-dcbf9c23f899" xlink:to="loc_us-gaap_TradeNamesMember_bc1ab2fd-3bf3-4f06-a413-e1817ee6f1fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_6b109394-4e7d-46d4-adb2-daf3bd67b6c2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_894bef58-fe6f-42d5-baf2-7d4479a46f29" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_6b109394-4e7d-46d4-adb2-daf3bd67b6c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_92d90af9-bf1d-491f-95b0-9e8be05caff3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_6b109394-4e7d-46d4-adb2-daf3bd67b6c2" xlink:to="loc_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_92d90af9-bf1d-491f-95b0-9e8be05caff3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_0bebaf2f-4a50-47c2-a7fb-dd3d79270e0f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_6b109394-4e7d-46d4-adb2-daf3bd67b6c2" xlink:to="loc_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_0bebaf2f-4a50-47c2-a7fb-dd3d79270e0f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh_2be1308b-5e52-432c-9096-52663a1e962e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_6b109394-4e7d-46d4-adb2-daf3bd67b6c2" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh_2be1308b-5e52-432c-9096-52663a1e962e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferredAbstract_96e9f00d-08e7-4af2-986d-db3cf6642515" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferredAbstract"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_6b109394-4e7d-46d4-adb2-daf3bd67b6c2" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferredAbstract_96e9f00d-08e7-4af2-986d-db3cf6642515" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross_8291fa0d-72c5-4320-bbdc-9e75af50c06b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesGross"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationConsiderationTransferredAbstract_96e9f00d-08e7-4af2-986d-db3cf6642515" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesGross_8291fa0d-72c5-4320-bbdc-9e75af50c06b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable_94eb35c5-4146-48ad-94f7-66a23bdaa688" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationConsiderationTransferredAbstract_96e9f00d-08e7-4af2-986d-db3cf6642515" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable_94eb35c5-4146-48ad-94f7-66a23bdaa688" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_6d226d8c-7648-4ff5-894d-52d0017456d6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationConsiderationTransferredAbstract_96e9f00d-08e7-4af2-986d-db3cf6642515" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_6d226d8c-7648-4ff5-894d-52d0017456d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferred1_7c5d7d10-512f-41af-8139-2ebb188fd088" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferred1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationConsiderationTransferredAbstract_96e9f00d-08e7-4af2-986d-db3cf6642515" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferred1_7c5d7d10-512f-41af-8139-2ebb188fd088" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract_3b3853e5-4439-4470-a61d-aebd9eb13893" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_6b109394-4e7d-46d4-adb2-daf3bd67b6c2" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract_3b3853e5-4439-4470-a61d-aebd9eb13893" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_5192bf51-a18f-4bd0-ac77-be0d60b83bd4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract_3b3853e5-4439-4470-a61d-aebd9eb13893" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_5192bf51-a18f-4bd0-ac77-be0d60b83bd4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables_de4038a9-0341-453c-ad86-9c8cf76840bd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract_3b3853e5-4439-4470-a61d-aebd9eb13893" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables_de4038a9-0341-453c-ad86-9c8cf76840bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_8135b2a8-a4f9-467e-8c2f-503b12656d74" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract_3b3853e5-4439-4470-a61d-aebd9eb13893" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_8135b2a8-a4f9-467e-8c2f-503b12656d74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets_596ad53c-caad-4efc-a6f7-955ed01cd5c2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract_3b3853e5-4439-4470-a61d-aebd9eb13893" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets_596ad53c-caad-4efc-a6f7-955ed01cd5c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedTangibleAssets_8599c0f8-736c-467e-b23d-466fd302485d" xlink:href="evh-20211231.xsd#evh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedTangibleAssets"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract_3b3853e5-4439-4470-a61d-aebd9eb13893" xlink:to="loc_evh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedTangibleAssets_8599c0f8-736c-467e-b23d-466fd302485d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwillAbstract_e64bbf33-7e89-4d17-9530-0a597be9d24f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwillAbstract"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_6b109394-4e7d-46d4-adb2-daf3bd67b6c2" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwillAbstract_e64bbf33-7e89-4d17-9530-0a597be9d24f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_03b8c6a0-5976-40ba-844b-df10e3305d34" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwillAbstract_e64bbf33-7e89-4d17-9530-0a597be9d24f" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_03b8c6a0-5976-40ba-844b-df10e3305d34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract_ddefb5f6-b060-4e6b-92f3-52f945f2ecc1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_6b109394-4e7d-46d4-adb2-daf3bd67b6c2" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract_ddefb5f6-b060-4e6b-92f3-52f945f2ecc1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_f4a88da4-0c89-451a-bb37-f2756929ecfc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract_ddefb5f6-b060-4e6b-92f3-52f945f2ecc1" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_f4a88da4-0c89-451a-bb37-f2756929ecfc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesAccruedLiabilities_88832838-ded1-4008-950d-f5c86c6df2f7" xlink:href="evh-20211231.xsd#evh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesAccruedLiabilities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract_ddefb5f6-b060-4e6b-92f3-52f945f2ecc1" xlink:to="loc_evh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesAccruedLiabilities_88832838-ded1-4008-950d-f5c86c6df2f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesAccruedCompensationAndEmployeeBenefits_5c3a63d5-d3cc-4a64-b276-b4b4a8776e5d" xlink:href="evh-20211231.xsd#evh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesAccruedCompensationAndEmployeeBenefits"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract_ddefb5f6-b060-4e6b-92f3-52f945f2ecc1" xlink:to="loc_evh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesAccruedCompensationAndEmployeeBenefits_5c3a63d5-d3cc-4a64-b276-b4b4a8776e5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_b2020b44-126c-466c-b1a4-bb7fe67dafa5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract_ddefb5f6-b060-4e6b-92f3-52f945f2ecc1" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_b2020b44-126c-466c-b1a4-bb7fe67dafa5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue_3624a06b-9a98-444a-87ad-24eb655e0a06" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract_ddefb5f6-b060-4e6b-92f3-52f945f2ecc1" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue_3624a06b-9a98-444a-87ad-24eb655e0a06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCapitalLeaseObligation_446aa1a7-8d2d-4a27-8b08-41c434c349b7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCapitalLeaseObligation"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract_ddefb5f6-b060-4e6b-92f3-52f945f2ecc1" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCapitalLeaseObligation_446aa1a7-8d2d-4a27-8b08-41c434c349b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_aaac405f-2321-4fc0-8d7d-05ed5d68bb4d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract_ddefb5f6-b060-4e6b-92f3-52f945f2ecc1" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_aaac405f-2321-4fc0-8d7d-05ed5d68bb4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_da7f578f-e0c8-4dee-8d59-f99d1c146930" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_6b109394-4e7d-46d4-adb2-daf3bd67b6c2" xlink:to="loc_us-gaap_Goodwill_da7f578f-e0c8-4dee-8d59-f99d1c146930" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_4d83b912-48f7-484c-ba85-6248459b9bea" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_6b109394-4e7d-46d4-adb2-daf3bd67b6c2" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_4d83b912-48f7-484c-ba85-6248459b9bea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_242fa08d-ca7c-41bf-b768-23933a57ef83" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_6b109394-4e7d-46d4-adb2-daf3bd67b6c2" xlink:to="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_242fa08d-ca7c-41bf-b768-23933a57ef83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount_9ea55dcc-4069-43d5-a6a1-393ad08200ac" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_6b109394-4e7d-46d4-adb2-daf3bd67b6c2" xlink:to="loc_us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount_9ea55dcc-4069-43d5-a6a1-393ad08200ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/TransactionsEquityInvestmentsDetails" xlink:type="simple" xlink:href="evh-20211231.xsd#TransactionsEquityInvestmentsDetails"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/TransactionsEquityInvestmentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_629bed2f-a5c0-4445-ad31-335abcec9b42" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_4609f7c5-61a0-45f6-8007-0494167784b6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_629bed2f-a5c0-4445-ad31-335abcec9b42" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_4609f7c5-61a0-45f6-8007-0494167784b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_9b3ef79d-d18b-4190-8186-0bd14d3ff16b" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_4609f7c5-61a0-45f6-8007-0494167784b6" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_9b3ef79d-d18b-4190-8186-0bd14d3ff16b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_060da934-8f9d-4373-a86e-a187eab32747" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_9b3ef79d-d18b-4190-8186-0bd14d3ff16b" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_060da934-8f9d-4373-a86e-a187eab32747" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_UniversityHealthCaredbaPassportHealthPlanMember_08cadaf9-eab7-4282-806e-a00ed0d0c1b8" xlink:href="evh-20211231.xsd#evh_UniversityHealthCaredbaPassportHealthPlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_060da934-8f9d-4373-a86e-a187eab32747" xlink:to="loc_evh_UniversityHealthCaredbaPassportHealthPlanMember_08cadaf9-eab7-4282-806e-a00ed0d0c1b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_VivantHealthMSOLLCMember_e60ee32a-d2f2-4962-ac90-3313f14b2332" xlink:href="evh-20211231.xsd#evh_VivantHealthMSOLLCMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_060da934-8f9d-4373-a86e-a187eab32747" xlink:to="loc_evh_VivantHealthMSOLLCMember_e60ee32a-d2f2-4962-ac90-3313f14b2332" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_1a9200be-a88c-40ce-a837-cee3a6b05ee0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_4609f7c5-61a0-45f6-8007-0494167784b6" xlink:to="loc_us-gaap_DebtInstrumentAxis_1a9200be-a88c-40ce-a837-cee3a6b05ee0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_1d19770a-ddb2-4425-a37d-76c0c18c7e4e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_1a9200be-a88c-40ce-a837-cee3a6b05ee0" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_1d19770a-ddb2-4425-a37d-76c0c18c7e4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_PassportNoteMember_eee47c80-d517-415e-b5d5-754f36295c01" xlink:href="evh-20211231.xsd#evh_PassportNoteMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_1d19770a-ddb2-4425-a37d-76c0c18c7e4e" xlink:to="loc_evh_PassportNoteMember_eee47c80-d517-415e-b5d5-754f36295c01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_14434cbc-a56b-4755-b8ec-fe90ab64b68d" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_4609f7c5-61a0-45f6-8007-0494167784b6" xlink:to="loc_srt_CounterpartyNameAxis_14434cbc-a56b-4755-b8ec-fe90ab64b68d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_0fc95a04-3d41-4e22-ae3a-c903785cbb60" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_14434cbc-a56b-4755-b8ec-fe90ab64b68d" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_0fc95a04-3d41-4e22-ae3a-c903785cbb60" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_MolinaHealthcareIncMember_80fefbfe-7960-4fc2-b802-e112b1dca062" xlink:href="evh-20211231.xsd#evh_MolinaHealthcareIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_0fc95a04-3d41-4e22-ae3a-c903785cbb60" xlink:to="loc_evh_MolinaHealthcareIncMember_80fefbfe-7960-4fc2-b802-e112b1dca062" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionAxis_f4c0b8dd-39ad-488e-ad96-b6ab782f65da" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetAcquisitionAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_4609f7c5-61a0-45f6-8007-0494167784b6" xlink:to="loc_us-gaap_AssetAcquisitionAxis_f4c0b8dd-39ad-488e-ad96-b6ab782f65da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionDomain_f7fb1c7f-dc79-4b2f-b8d0-7e4d1b9b5973" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetAcquisitionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionAxis_f4c0b8dd-39ad-488e-ad96-b6ab782f65da" xlink:to="loc_us-gaap_AssetAcquisitionDomain_f7fb1c7f-dc79-4b2f-b8d0-7e4d1b9b5973" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_PassportAssetAcquisitionMember_13384df8-d247-4dfb-bc8e-200f46ff6620" xlink:href="evh-20211231.xsd#evh_PassportAssetAcquisitionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionDomain_f7fb1c7f-dc79-4b2f-b8d0-7e4d1b9b5973" xlink:to="loc_evh_PassportAssetAcquisitionMember_13384df8-d247-4dfb-bc8e-200f46ff6620" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesAxis_4c33fc23-1414-4aba-ba63-b58f1f511e49" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ConsolidatedEntitiesAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_4609f7c5-61a0-45f6-8007-0494167784b6" xlink:to="loc_srt_ConsolidatedEntitiesAxis_4c33fc23-1414-4aba-ba63-b58f1f511e49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesDomain_1a1cf93b-ab52-4574-b383-45fc565b0eef" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ConsolidatedEntitiesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidatedEntitiesAxis_4c33fc23-1414-4aba-ba63-b58f1f511e49" xlink:to="loc_srt_ConsolidatedEntitiesDomain_1a1cf93b-ab52-4574-b383-45fc565b0eef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableInterestEntityNotPrimaryBeneficiaryMember_4ca910d8-fee6-4318-8879-6b27ea356fef" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableInterestEntityNotPrimaryBeneficiaryMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidatedEntitiesDomain_1a1cf93b-ab52-4574-b383-45fc565b0eef" xlink:to="loc_us-gaap_VariableInterestEntityNotPrimaryBeneficiaryMember_4ca910d8-fee6-4318-8879-6b27ea356fef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_03f7891e-7b22-4b80-b8c2-7ae75a23da6b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_4609f7c5-61a0-45f6-8007-0494167784b6" xlink:to="loc_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_03f7891e-7b22-4b80-b8c2-7ae75a23da6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivableTypeDomain_06354cec-9c39-4dc6-a954-84a8c0a0805d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReceivableTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_03f7891e-7b22-4b80-b8c2-7ae75a23da6b" xlink:to="loc_us-gaap_ReceivableTypeDomain_06354cec-9c39-4dc6-a954-84a8c0a0805d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesReceivableMember_6437f3cb-2b7e-4faf-ba41-e3290eedfaeb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NotesReceivableMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReceivableTypeDomain_06354cec-9c39-4dc6-a954-84a8c0a0805d" xlink:to="loc_us-gaap_NotesReceivableMember_6437f3cb-2b7e-4faf-ba41-e3290eedfaeb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_15816d5e-2aff-42d3-b68c-dd248b301c3f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_4609f7c5-61a0-45f6-8007-0494167784b6" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_15816d5e-2aff-42d3-b68c-dd248b301c3f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireEquityMethodInvestments_2bf0f5a7-51ea-4660-a16e-65d9503c53fa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireEquityMethodInvestments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_15816d5e-2aff-42d3-b68c-dd248b301c3f" xlink:to="loc_us-gaap_PaymentsToAcquireEquityMethodInvestments_2bf0f5a7-51ea-4660-a16e-65d9503c53fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableInterestEntityOwnershipPercentage_7c8ef5c1-106c-46ea-a566-dd5e86ff0576" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableInterestEntityOwnershipPercentage"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_15816d5e-2aff-42d3-b68c-dd248b301c3f" xlink:to="loc_us-gaap_VariableInterestEntityOwnershipPercentage_7c8ef5c1-106c-46ea-a566-dd5e86ff0576" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesReceivableNet_66f9bed9-37dd-4385-a795-a299c560ebe4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NotesReceivableNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_15816d5e-2aff-42d3-b68c-dd248b301c3f" xlink:to="loc_us-gaap_NotesReceivableNet_66f9bed9-37dd-4385-a795-a299c560ebe4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_fc3a8d76-6b0e-485b-9177-a7e736edacd0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_15816d5e-2aff-42d3-b68c-dd248b301c3f" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_fc3a8d76-6b0e-485b-9177-a7e736edacd0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableInterestEntityFinancialOrOtherSupportAmount_3bb94b7e-9487-48ad-8444-8e6b6b80be67" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableInterestEntityFinancialOrOtherSupportAmount"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_15816d5e-2aff-42d3-b68c-dd248b301c3f" xlink:to="loc_us-gaap_VariableInterestEntityFinancialOrOtherSupportAmount_3bb94b7e-9487-48ad-8444-8e6b6b80be67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_PaymentsToAcquireEquityMethodInvestmentsAmountHeldBack_16ba9ab4-079e-4331-8453-e220c5ccc471" xlink:href="evh-20211231.xsd#evh_PaymentsToAcquireEquityMethodInvestmentsAmountHeldBack"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_15816d5e-2aff-42d3-b68c-dd248b301c3f" xlink:to="loc_evh_PaymentsToAcquireEquityMethodInvestmentsAmountHeldBack_16ba9ab4-079e-4331-8453-e220c5ccc471" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_AssetPurchaseAgreementEscrowPayments_75b02cbd-9128-49a8-b801-350b62b9d9e8" xlink:href="evh-20211231.xsd#evh_AssetPurchaseAgreementEscrowPayments"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_15816d5e-2aff-42d3-b68c-dd248b301c3f" xlink:to="loc_evh_AssetPurchaseAgreementEscrowPayments_75b02cbd-9128-49a8-b801-350b62b9d9e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_CashReleasedFromEscrow_afc54c4e-21e3-4a29-9fe9-14736976f8ef" xlink:href="evh-20211231.xsd#evh_CashReleasedFromEscrow"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_15816d5e-2aff-42d3-b68c-dd248b301c3f" xlink:to="loc_evh_CashReleasedFromEscrow_afc54c4e-21e3-4a29-9fe9-14736976f8ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToMinorityShareholders_45666f40-27a1-4979-aca1-56528d08ce3f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToMinorityShareholders"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_15816d5e-2aff-42d3-b68c-dd248b301c3f" xlink:to="loc_us-gaap_PaymentsToMinorityShareholders_45666f40-27a1-4979-aca1-56528d08ce3f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_AssetAcquisitionCashAndEquivalents_96fb12dc-5711-4a58-83df-78113b958ad7" xlink:href="evh-20211231.xsd#evh_AssetAcquisitionCashAndEquivalents"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_15816d5e-2aff-42d3-b68c-dd248b301c3f" xlink:to="loc_evh_AssetAcquisitionCashAndEquivalents_96fb12dc-5711-4a58-83df-78113b958ad7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_AssetAcquisitionDebtSecuritiesAvailableForSale_f3569c4b-c5e6-403c-b050-e0e68e404c05" xlink:href="evh-20211231.xsd#evh_AssetAcquisitionDebtSecuritiesAvailableForSale"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_15816d5e-2aff-42d3-b68c-dd248b301c3f" xlink:to="loc_evh_AssetAcquisitionDebtSecuritiesAvailableForSale_f3569c4b-c5e6-403c-b050-e0e68e404c05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_AssetAcquisitionDebtSecuritiesAvailableForSaleUnsettledSalesReceivables_e3d48ec1-0061-4b9c-b488-e285f74a9d41" xlink:href="evh-20211231.xsd#evh_AssetAcquisitionDebtSecuritiesAvailableForSaleUnsettledSalesReceivables"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_15816d5e-2aff-42d3-b68c-dd248b301c3f" xlink:to="loc_evh_AssetAcquisitionDebtSecuritiesAvailableForSaleUnsettledSalesReceivables_e3d48ec1-0061-4b9c-b488-e285f74a9d41" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_AssetAcquisitionOtherAssets_1f170ba1-f886-4be8-9c5e-9c999cd14e96" xlink:href="evh-20211231.xsd#evh_AssetAcquisitionOtherAssets"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_15816d5e-2aff-42d3-b68c-dd248b301c3f" xlink:to="loc_evh_AssetAcquisitionOtherAssets_1f170ba1-f886-4be8-9c5e-9c999cd14e96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_AssetAcquisitionAccruedMedicalExpenses_e9af0247-cd93-4995-a1e1-e52c6d3717b9" xlink:href="evh-20211231.xsd#evh_AssetAcquisitionAccruedMedicalExpenses"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_15816d5e-2aff-42d3-b68c-dd248b301c3f" xlink:to="loc_evh_AssetAcquisitionAccruedMedicalExpenses_e9af0247-cd93-4995-a1e1-e52c6d3717b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_AssetAcquisitionAccruedLiabilities_a5c52945-3e2b-49bc-9aa6-6a19afa22ff3" xlink:href="evh-20211231.xsd#evh_AssetAcquisitionAccruedLiabilities"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_15816d5e-2aff-42d3-b68c-dd248b301c3f" xlink:to="loc_evh_AssetAcquisitionAccruedLiabilities_a5c52945-3e2b-49bc-9aa6-6a19afa22ff3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromCollectionOfNotesReceivable_606b53d9-c393-426a-b52c-73b4097c67d2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromCollectionOfNotesReceivable"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_15816d5e-2aff-42d3-b68c-dd248b301c3f" xlink:to="loc_us-gaap_ProceedsFromCollectionOfNotesReceivable_606b53d9-c393-426a-b52c-73b4097c67d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromInterestReceived_9de0cbdf-1ef9-4529-be29-5b51dd224c22" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromInterestReceived"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_15816d5e-2aff-42d3-b68c-dd248b301c3f" xlink:to="loc_us-gaap_ProceedsFromInterestReceived_9de0cbdf-1ef9-4529-be29-5b51dd224c22" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_ProceedsFromTransferOfMembership_0f15a187-c647-4bc9-aad6-e4fe54e58c23" xlink:href="evh-20211231.xsd#evh_ProceedsFromTransferOfMembership"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_15816d5e-2aff-42d3-b68c-dd248b301c3f" xlink:to="loc_evh_ProceedsFromTransferOfMembership_0f15a187-c647-4bc9-aad6-e4fe54e58c23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_TransferOfMembershipPercentageOfPaymentBasedOnNumberOfEnrollees_7b85f5a1-e7d9-466f-9095-a8356d0ca93b" xlink:href="evh-20211231.xsd#evh_TransferOfMembershipPercentageOfPaymentBasedOnNumberOfEnrollees"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_15816d5e-2aff-42d3-b68c-dd248b301c3f" xlink:to="loc_evh_TransferOfMembershipPercentageOfPaymentBasedOnNumberOfEnrollees_7b85f5a1-e7d9-466f-9095-a8356d0ca93b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_TransferOfMembershipPercentageOfPaymentSubjectToSatisfactionOfContingencies_1f317609-729b-475f-ab0f-086118bfc946" xlink:href="evh-20211231.xsd#evh_TransferOfMembershipPercentageOfPaymentSubjectToSatisfactionOfContingencies"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_15816d5e-2aff-42d3-b68c-dd248b301c3f" xlink:to="loc_evh_TransferOfMembershipPercentageOfPaymentSubjectToSatisfactionOfContingencies_1f317609-729b-475f-ab0f-086118bfc946" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnDispositionOfAssets1_ff6982af-fb4d-41f2-9ecb-6634b33e819b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossOnDispositionOfAssets1"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_15816d5e-2aff-42d3-b68c-dd248b301c3f" xlink:to="loc_us-gaap_GainLossOnDispositionOfAssets1_ff6982af-fb4d-41f2-9ecb-6634b33e819b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/DiscontinuedOperations" xlink:type="simple" xlink:href="evh-20211231.xsd#DiscontinuedOperations"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/DiscontinuedOperations" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_a68cc49e-035e-4dc9-9bb8-196d51a70c46" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock_6c141e28-6bbc-4e5f-bdfc-4510ceeb385a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_a68cc49e-035e-4dc9-9bb8-196d51a70c46" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock_6c141e28-6bbc-4e5f-bdfc-4510ceeb385a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/DiscontinuedOperationsTables" xlink:type="simple" xlink:href="evh-20211231.xsd#DiscontinuedOperationsTables"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/DiscontinuedOperationsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_2a705e07-5f86-4888-a1dc-fce54c2854dc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock_6b674a8c-0639-4b3c-9c08-6926ff56ca10" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_2a705e07-5f86-4888-a1dc-fce54c2854dc" xlink:to="loc_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock_6b674a8c-0639-4b3c-9c08-6926ff56ca10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/DiscontinuedOperationsAdditionalInformationDetails" xlink:type="simple" xlink:href="evh-20211231.xsd#DiscontinuedOperationsAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/DiscontinuedOperationsAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_d46dcdff-492a-4471-af19-8cf878a271d4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_46e66e04-3090-429c-9941-8dbeab27ed07" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_d46dcdff-492a-4471-af19-8cf878a271d4" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_46e66e04-3090-429c-9941-8dbeab27ed07" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_50fc0bf8-8391-4f8b-a280-a8756df3b2b3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_46e66e04-3090-429c-9941-8dbeab27ed07" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_50fc0bf8-8391-4f8b-a280-a8756df3b2b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_2700f830-f1fd-4091-a898-9e07919d9889" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_50fc0bf8-8391-4f8b-a280-a8756df3b2b3" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_2700f830-f1fd-4091-a898-9e07919d9889" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_TrueHealthMember_f8edbe15-3b75-407e-ba8d-63c2c8829a7b" xlink:href="evh-20211231.xsd#evh_TrueHealthMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_2700f830-f1fd-4091-a898-9e07919d9889" xlink:to="loc_evh_TrueHealthMember_f8edbe15-3b75-407e-ba8d-63c2c8829a7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis_66340ccd-81ed-49e0-aab2-f03b063b87cf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupClassificationAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_46e66e04-3090-429c-9941-8dbeab27ed07" xlink:to="loc_us-gaap_DisposalGroupClassificationAxis_66340ccd-81ed-49e0-aab2-f03b063b87cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_3f890bad-8d23-4094-9498-211152290820" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_66340ccd-81ed-49e0-aab2-f03b063b87cf" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_3f890bad-8d23-4094-9498-211152290820" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationsDisposedOfBySaleMember_8f6a741b-17f8-4109-95b5-fbaa1aec7267" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DiscontinuedOperationsDisposedOfBySaleMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain_3f890bad-8d23-4094-9498-211152290820" xlink:to="loc_us-gaap_DiscontinuedOperationsDisposedOfBySaleMember_8f6a741b-17f8-4109-95b5-fbaa1aec7267" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_5788119f-ffa1-45d8-9614-fe294cf68a43" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_46e66e04-3090-429c-9941-8dbeab27ed07" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_5788119f-ffa1-45d8-9614-fe294cf68a43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_DiscontinuedOperationGainLossOnPurchasePriceAdjustmentsNetOfTax_b2e8836a-32d9-45a4-9198-5b9d7d350ea5" xlink:href="evh-20211231.xsd#evh_DiscontinuedOperationGainLossOnPurchasePriceAdjustmentsNetOfTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_5788119f-ffa1-45d8-9614-fe294cf68a43" xlink:to="loc_evh_DiscontinuedOperationGainLossOnPurchasePriceAdjustmentsNetOfTax_b2e8836a-32d9-45a4-9198-5b9d7d350ea5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/DiscontinuedOperationsSummaryofResultsofOperationsDetails" xlink:type="simple" xlink:href="evh-20211231.xsd#DiscontinuedOperationsSummaryofResultsofOperationsDetails"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/DiscontinuedOperationsSummaryofResultsofOperationsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_74e0be83-d9e9-4ed7-b65d-24d5da1560b9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_7bf4ab19-06fb-49e2-90f5-fe73cef4480d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_74e0be83-d9e9-4ed7-b65d-24d5da1560b9" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_7bf4ab19-06fb-49e2-90f5-fe73cef4480d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis_ef7f3cef-f3b4-44f8-9404-e08979c13995" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupClassificationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_7bf4ab19-06fb-49e2-90f5-fe73cef4480d" xlink:to="loc_us-gaap_DisposalGroupClassificationAxis_ef7f3cef-f3b4-44f8-9404-e08979c13995" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_91a6685e-e2d4-4708-8ddb-ab3605ace180" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_ef7f3cef-f3b4-44f8-9404-e08979c13995" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_91a6685e-e2d4-4708-8ddb-ab3605ace180" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationsDisposedOfBySaleMember_c9f5030c-0a2b-477a-9b9e-ef8b0f7298d2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DiscontinuedOperationsDisposedOfBySaleMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain_91a6685e-e2d4-4708-8ddb-ab3605ace180" xlink:to="loc_us-gaap_DiscontinuedOperationsDisposedOfBySaleMember_c9f5030c-0a2b-477a-9b9e-ef8b0f7298d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_bd7c187b-0cfd-4e5d-83e4-1810870729fe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_7bf4ab19-06fb-49e2-90f5-fe73cef4480d" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_bd7c187b-0cfd-4e5d-83e4-1810870729fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_25b780a6-8163-41d3-993d-7fc1f09d97c9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_bd7c187b-0cfd-4e5d-83e4-1810870729fe" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_25b780a6-8163-41d3-993d-7fc1f09d97c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_TrueHealthMember_3bd5de44-c61b-41f0-9911-68e385524763" xlink:href="evh-20211231.xsd#evh_TrueHealthMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_25b780a6-8163-41d3-993d-7fc1f09d97c9" xlink:to="loc_evh_TrueHealthMember_3bd5de44-c61b-41f0-9911-68e385524763" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_1139854f-9aa6-431d-ac92-661b97c4ad64" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_7bf4ab19-06fb-49e2-90f5-fe73cef4480d" xlink:to="loc_srt_ProductOrServiceAxis_1139854f-9aa6-431d-ac92-661b97c4ad64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_dacaffe9-2bd7-40fa-947e-11d268ab4645" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_1139854f-9aa6-431d-ac92-661b97c4ad64" xlink:to="loc_srt_ProductsAndServicesDomain_dacaffe9-2bd7-40fa-947e-11d268ab4645" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_PlatformsAndOperationsServicesMember_0730d201-52f0-4c39-9991-abf0eccd2a57" xlink:href="evh-20211231.xsd#evh_PlatformsAndOperationsServicesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_dacaffe9-2bd7-40fa-947e-11d268ab4645" xlink:to="loc_evh_PlatformsAndOperationsServicesMember_0730d201-52f0-4c39-9991-abf0eccd2a57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_PremiumsRevenueMember_f8e4f990-67c4-41c1-86c4-f3e93ae1c30c" xlink:href="evh-20211231.xsd#evh_PremiumsRevenueMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_dacaffe9-2bd7-40fa-947e-11d268ab4645" xlink:to="loc_evh_PremiumsRevenueMember_f8e4f990-67c4-41c1-86c4-f3e93ae1c30c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_ServicesAgreementsMember_e9fb7370-733f-4b68-ac69-b9510c9a2ee6" xlink:href="evh-20211231.xsd#evh_ServicesAgreementsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_dacaffe9-2bd7-40fa-947e-11d268ab4645" xlink:to="loc_evh_ServicesAgreementsMember_e9fb7370-733f-4b68-ac69-b9510c9a2ee6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_56712d55-ae35-433a-b5fe-d84d9212d520" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_7bf4ab19-06fb-49e2-90f5-fe73cef4480d" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_56712d55-ae35-433a-b5fe-d84d9212d520" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract_ce9bd5d3-cbda-4ee2-a8ac-ca1be757390d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenuesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_56712d55-ae35-433a-b5fe-d84d9212d520" xlink:to="loc_us-gaap_RevenuesAbstract_ce9bd5d3-cbda-4ee2-a8ac-ca1be757390d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue_ae032b2a-0054-4edb-a6cc-5fb5b8c7cf1d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesAbstract_ce9bd5d3-cbda-4ee2-a8ac-ca1be757390d" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue_ae032b2a-0054-4edb-a6cc-5fb5b8c7cf1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract_643b7864-6279-451d-805e-40c25f41f8b0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_56712d55-ae35-433a-b5fe-d84d9212d520" xlink:to="loc_us-gaap_OperatingExpensesAbstract_643b7864-6279-451d-805e-40c25f41f8b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold_8387402d-7073-430c-81df-4dee0166d8a6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_643b7864-6279-451d-805e-40c25f41f8b0" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold_8387402d-7073-430c-81df-4dee0166d8a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_DisposalGroupIncludingDiscontinuedOperationClaimsExpense_cf9021d0-ba10-46a0-95b0-063879537628" xlink:href="evh-20211231.xsd#evh_DisposalGroupIncludingDiscontinuedOperationClaimsExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_643b7864-6279-451d-805e-40c25f41f8b0" xlink:to="loc_evh_DisposalGroupIncludingDiscontinuedOperationClaimsExpense_cf9021d0-ba10-46a0-95b0-063879537628" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense_99e1ab62-ef1a-4f5f-b426-5721c79a4120" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_643b7864-6279-451d-805e-40c25f41f8b0" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense_99e1ab62-ef1a-4f5f-b426-5721c79a4120" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationAndAmortizationDiscontinuedOperations_ab0fc99c-2aa7-40dd-b95f-d067f59c2810" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationAndAmortizationDiscontinuedOperations"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_643b7864-6279-451d-805e-40c25f41f8b0" xlink:to="loc_us-gaap_DepreciationAndAmortizationDiscontinuedOperations_ab0fc99c-2aa7-40dd-b95f-d067f59c2810" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense_39db1f93-237a-4b7d-9b09-4add990cfc18" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_643b7864-6279-451d-805e-40c25f41f8b0" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense_39db1f93-237a-4b7d-9b09-4add990cfc18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss_3badc631-9f98-4910-934a-2c530737d9e2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_56712d55-ae35-433a-b5fe-d84d9212d520" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss_3badc631-9f98-4910-934a-2c530737d9e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationInterestIncome_282fcaef-263e-4b68-9789-4bf8da1aa868" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationInterestIncome"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_56712d55-ae35-433a-b5fe-d84d9212d520" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationInterestIncome_282fcaef-263e-4b68-9789-4bf8da1aa868" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationInterestExpense_1307a8a0-08b2-4102-aac5-234bd1a6a282" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationInterestExpense"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_56712d55-ae35-433a-b5fe-d84d9212d520" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationInterestExpense_1307a8a0-08b2-4102-aac5-234bd1a6a282" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherExpense_cbf1484d-5bdf-4a48-9416-92606fada8e8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherExpense"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_56712d55-ae35-433a-b5fe-d84d9212d520" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherExpense_cbf1484d-5bdf-4a48-9416-92606fada8e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax_7bfd4dff-4966-4cf8-aebe-44976cad7786" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_56712d55-ae35-433a-b5fe-d84d9212d520" xlink:to="loc_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax_7bfd4dff-4966-4cf8-aebe-44976cad7786" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation_fbc58c00-b57d-46c2-8d5b-38c6b6331c61" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_56712d55-ae35-433a-b5fe-d84d9212d520" xlink:to="loc_us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation_fbc58c00-b57d-46c2-8d5b-38c6b6331c61" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_7a798d31-a032-4495-954c-72f96a14313c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_56712d55-ae35-433a-b5fe-d84d9212d520" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_7a798d31-a032-4495-954c-72f96a14313c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/DiscontinuedOperationsSummaryofCashFlowsDetails" xlink:type="simple" xlink:href="evh-20211231.xsd#DiscontinuedOperationsSummaryofCashFlowsDetails"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/DiscontinuedOperationsSummaryofCashFlowsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_eb9e9e8c-47fb-4c51-9bfd-dc0a10195945" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_34082644-cd9c-49e6-a91a-1c4bf5bfe434" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_eb9e9e8c-47fb-4c51-9bfd-dc0a10195945" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_34082644-cd9c-49e6-a91a-1c4bf5bfe434" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_3bdb7b7f-d500-4778-9ea0-2d12db5260c5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_34082644-cd9c-49e6-a91a-1c4bf5bfe434" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_3bdb7b7f-d500-4778-9ea0-2d12db5260c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_41df7aa9-1965-41e3-8e7a-23cc5818bec6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_3bdb7b7f-d500-4778-9ea0-2d12db5260c5" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_41df7aa9-1965-41e3-8e7a-23cc5818bec6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_TrueHealthMember_a5263845-eafb-48d8-bfcf-be4ccf37a769" xlink:href="evh-20211231.xsd#evh_TrueHealthMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_41df7aa9-1965-41e3-8e7a-23cc5818bec6" xlink:to="loc_evh_TrueHealthMember_a5263845-eafb-48d8-bfcf-be4ccf37a769" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis_f4b22bfd-a167-4258-9d68-7ac53420baad" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupClassificationAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_34082644-cd9c-49e6-a91a-1c4bf5bfe434" xlink:to="loc_us-gaap_DisposalGroupClassificationAxis_f4b22bfd-a167-4258-9d68-7ac53420baad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_0740520b-518e-4694-b637-bd1a3f90b585" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_f4b22bfd-a167-4258-9d68-7ac53420baad" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_0740520b-518e-4694-b637-bd1a3f90b585" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationsDisposedOfBySaleMember_97c7b398-6d08-4847-bfc6-527858d51527" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DiscontinuedOperationsDisposedOfBySaleMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain_0740520b-518e-4694-b637-bd1a3f90b585" xlink:to="loc_us-gaap_DiscontinuedOperationsDisposedOfBySaleMember_97c7b398-6d08-4847-bfc6-527858d51527" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_8538adfc-11a6-4298-b0f7-16f1fb265df6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_34082644-cd9c-49e6-a91a-1c4bf5bfe434" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_8538adfc-11a6-4298-b0f7-16f1fb265df6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations_fdd43acc-1caf-407b-81c9-f022f8a59340" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_8538adfc-11a6-4298-b0f7-16f1fb265df6" xlink:to="loc_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations_fdd43acc-1caf-407b-81c9-f022f8a59340" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations_9bdb6473-df80-413f-b046-4fc206c25996" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_8538adfc-11a6-4298-b0f7-16f1fb265df6" xlink:to="loc_us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations_9bdb6473-df80-413f-b046-4fc206c25996" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations_6e858919-838e-443f-bf66-7f441bf160f2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_8538adfc-11a6-4298-b0f7-16f1fb265df6" xlink:to="loc_us-gaap_CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations_6e858919-838e-443f-bf66-7f441bf160f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/DiscontinuedOperationsSummaryofCurrentandLongtermAssetsandLiabilitiesDetails" xlink:type="simple" xlink:href="evh-20211231.xsd#DiscontinuedOperationsSummaryofCurrentandLongtermAssetsandLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/DiscontinuedOperationsSummaryofCurrentandLongtermAssetsandLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_6f01b9fe-ff0b-42b5-b3e0-72be724180b3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_6f8783bd-7b86-47b4-b481-30fee5134253" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_6f01b9fe-ff0b-42b5-b3e0-72be724180b3" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_6f8783bd-7b86-47b4-b481-30fee5134253" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_522530ca-fbf8-471d-a239-ef7bc66fb600" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_6f8783bd-7b86-47b4-b481-30fee5134253" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_522530ca-fbf8-471d-a239-ef7bc66fb600" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_08e9a48a-ab7b-428d-9528-f7fe07f86d97" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_522530ca-fbf8-471d-a239-ef7bc66fb600" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_08e9a48a-ab7b-428d-9528-f7fe07f86d97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_TrueHealthMember_c6268482-19d6-4b16-8f22-3bbcbf4bed73" xlink:href="evh-20211231.xsd#evh_TrueHealthMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_08e9a48a-ab7b-428d-9528-f7fe07f86d97" xlink:to="loc_evh_TrueHealthMember_c6268482-19d6-4b16-8f22-3bbcbf4bed73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis_9665538d-e280-4274-9b59-788fafc45747" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupClassificationAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_6f8783bd-7b86-47b4-b481-30fee5134253" xlink:to="loc_us-gaap_DisposalGroupClassificationAxis_9665538d-e280-4274-9b59-788fafc45747" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_3e937047-868c-47fb-9cc2-e734eaf5d2d8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_9665538d-e280-4274-9b59-788fafc45747" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_3e937047-868c-47fb-9cc2-e734eaf5d2d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationsDisposedOfBySaleMember_7e63142b-214e-42e1-a4d6-f979e8facf0f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DiscontinuedOperationsDisposedOfBySaleMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain_3e937047-868c-47fb-9cc2-e734eaf5d2d8" xlink:to="loc_us-gaap_DiscontinuedOperationsDisposedOfBySaleMember_7e63142b-214e-42e1-a4d6-f979e8facf0f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_97f1c77a-bcea-4611-82bc-af29f5f5bd6c" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_6f8783bd-7b86-47b4-b481-30fee5134253" xlink:to="loc_srt_ProductOrServiceAxis_97f1c77a-bcea-4611-82bc-af29f5f5bd6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_bcb4b3d5-c10f-4677-9668-9d335c7c2281" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_97f1c77a-bcea-4611-82bc-af29f5f5bd6c" xlink:to="loc_srt_ProductsAndServicesDomain_bcb4b3d5-c10f-4677-9668-9d335c7c2281" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_ServicesAgreementsMember_aafeccc8-e402-4a95-be83-47c8ac0901fa" xlink:href="evh-20211231.xsd#evh_ServicesAgreementsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_bcb4b3d5-c10f-4677-9668-9d335c7c2281" xlink:to="loc_evh_ServicesAgreementsMember_aafeccc8-e402-4a95-be83-47c8ac0901fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_5dd6954b-5ad3-4c11-8160-33e91059c057" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_6f8783bd-7b86-47b4-b481-30fee5134253" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_5dd6954b-5ad3-4c11-8160-33e91059c057" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationAbstract_41b58b64-fe30-43fb-8b89-1f877e081023" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_5dd6954b-5ad3-4c11-8160-33e91059c057" xlink:to="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationAbstract_41b58b64-fe30-43fb-8b89-1f877e081023" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract_5d77a8e9-811a-426a-8bfd-1ce48f7e94e8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationAbstract_41b58b64-fe30-43fb-8b89-1f877e081023" xlink:to="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract_5d77a8e9-811a-426a-8bfd-1ce48f7e94e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents_12849716-458a-4d8c-ad20-2646efeb6fd5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract_5d77a8e9-811a-426a-8bfd-1ce48f7e94e8" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents_12849716-458a-4d8c-ad20-2646efeb6fd5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_DisposalGroupIncludingDiscontinuedOperationRestrictedCashAndRestrictedInvestmentsCurrent_59f7d7af-44e3-44db-873b-488c8c31503f" xlink:href="evh-20211231.xsd#evh_DisposalGroupIncludingDiscontinuedOperationRestrictedCashAndRestrictedInvestmentsCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract_5d77a8e9-811a-426a-8bfd-1ce48f7e94e8" xlink:to="loc_evh_DisposalGroupIncludingDiscontinuedOperationRestrictedCashAndRestrictedInvestmentsCurrent_59f7d7af-44e3-44db-873b-488c8c31503f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet_4cf5556e-679e-4ce2-a66a-d44a4356230d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract_5d77a8e9-811a-426a-8bfd-1ce48f7e94e8" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet_4cf5556e-679e-4ce2-a66a-d44a4356230d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent_278cb7e9-e781-42b9-99fc-092aa449c46f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract_5d77a8e9-811a-426a-8bfd-1ce48f7e94e8" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent_278cb7e9-e781-42b9-99fc-092aa449c46f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_DisposalGroupIncludingDiscontinuedOperationInvestmentsCurrent_39e23660-e26f-4f8c-8082-c92302803b59" xlink:href="evh-20211231.xsd#evh_DisposalGroupIncludingDiscontinuedOperationInvestmentsCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract_5d77a8e9-811a-426a-8bfd-1ce48f7e94e8" xlink:to="loc_evh_DisposalGroupIncludingDiscontinuedOperationInvestmentsCurrent_39e23660-e26f-4f8c-8082-c92302803b59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent_3a077422-a6ed-41a5-bc03-834c8dfd9086" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract_5d77a8e9-811a-426a-8bfd-1ce48f7e94e8" xlink:to="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent_3a077422-a6ed-41a5-bc03-834c8dfd9086" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_DisposalGroupIncludingDiscontinuedOperationRestrictedCashAndRestrictedInvestmentsNoncurrent_5c475737-d586-44f2-9207-ac9cc6f4f041" xlink:href="evh-20211231.xsd#evh_DisposalGroupIncludingDiscontinuedOperationRestrictedCashAndRestrictedInvestmentsNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationAbstract_41b58b64-fe30-43fb-8b89-1f877e081023" xlink:to="loc_evh_DisposalGroupIncludingDiscontinuedOperationRestrictedCashAndRestrictedInvestmentsNoncurrent_5c475737-d586-44f2-9207-ac9cc6f4f041" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_DisposalGroupIncludingDiscontinuedOperationInvestmentsNoncurrent_6d871824-6677-44e0-8e73-99e8b325e310" xlink:href="evh-20211231.xsd#evh_DisposalGroupIncludingDiscontinuedOperationInvestmentsNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationAbstract_41b58b64-fe30-43fb-8b89-1f877e081023" xlink:to="loc_evh_DisposalGroupIncludingDiscontinuedOperationInvestmentsNoncurrent_6d871824-6677-44e0-8e73-99e8b325e310" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsNoncurrent_3d8e1c30-3576-4f7f-a443-273e1ada75f4" xlink:href="evh-20211231.xsd#evh_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationAbstract_41b58b64-fe30-43fb-8b89-1f877e081023" xlink:to="loc_evh_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsNoncurrent_3d8e1c30-3576-4f7f-a443-273e1ada75f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsNoncurrent_293c72b4-02bd-4477-8a39-935c5c7fcc84" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsNoncurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationAbstract_41b58b64-fe30-43fb-8b89-1f877e081023" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsNoncurrent_293c72b4-02bd-4477-8a39-935c5c7fcc84" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwillNoncurrent_4b16478f-975d-4ccb-8422-98701b9c2666" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwillNoncurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationAbstract_41b58b64-fe30-43fb-8b89-1f877e081023" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwillNoncurrent_4b16478f-975d-4ccb-8422-98701b9c2666" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation_b01435a0-7fcc-4262-976a-a96bb4023947" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationAbstract_41b58b64-fe30-43fb-8b89-1f877e081023" xlink:to="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation_b01435a0-7fcc-4262-976a-a96bb4023947" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationAbstract_6b664e64-56d6-4fd7-be8a-a61b068a2073" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_5dd6954b-5ad3-4c11-8160-33e91059c057" xlink:to="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationAbstract_6b664e64-56d6-4fd7-be8a-a61b068a2073" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract_b15c64e6-9098-4c04-aea1-9055495e2f44" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationAbstract_6b664e64-56d6-4fd7-be8a-a61b068a2073" xlink:to="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract_b15c64e6-9098-4c04-aea1-9055495e2f44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayableCurrent_7c15abec-8bd6-4f7a-a1a0-7506752cd644" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayableCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract_b15c64e6-9098-4c04-aea1-9055495e2f44" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayableCurrent_7c15abec-8bd6-4f7a-a1a0-7506752cd644" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilitiesCurrent_5d7c2b2c-6a84-4af4-a785-12226aa5d6ab" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilitiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract_b15c64e6-9098-4c04-aea1-9055495e2f44" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilitiesCurrent_5d7c2b2c-6a84-4af4-a785-12226aa5d6ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_DisposalGroupIncludingDiscontinuedOperationAccruedCompensationAndEmployeeBenefitsCurrent_926f8294-5fd3-483b-993f-ba69327c7189" xlink:href="evh-20211231.xsd#evh_DisposalGroupIncludingDiscontinuedOperationAccruedCompensationAndEmployeeBenefitsCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract_b15c64e6-9098-4c04-aea1-9055495e2f44" xlink:to="loc_evh_DisposalGroupIncludingDiscontinuedOperationAccruedCompensationAndEmployeeBenefitsCurrent_926f8294-5fd3-483b-993f-ba69327c7189" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredRevenueCurrent_527159f7-f7f0-4051-a5c2-85967033ed58" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredRevenueCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract_b15c64e6-9098-4c04-aea1-9055495e2f44" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredRevenueCurrent_527159f7-f7f0-4051-a5c2-85967033ed58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_DisposalGroupIncludingDiscontinuedOperationLiabilityForFuturePolicyBenefitsAndUnpaidClaimsAndClaimsAdjustmentExpenseAndPerformanceBasedArrangementsCurrent_77bc7b79-0b34-46fc-9cbb-9b95cbb8921e" xlink:href="evh-20211231.xsd#evh_DisposalGroupIncludingDiscontinuedOperationLiabilityForFuturePolicyBenefitsAndUnpaidClaimsAndClaimsAdjustmentExpenseAndPerformanceBasedArrangementsCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract_b15c64e6-9098-4c04-aea1-9055495e2f44" xlink:to="loc_evh_DisposalGroupIncludingDiscontinuedOperationLiabilityForFuturePolicyBenefitsAndUnpaidClaimsAndClaimsAdjustmentExpenseAndPerformanceBasedArrangementsCurrent_77bc7b79-0b34-46fc-9cbb-9b95cbb8921e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent_1f289b00-f9d7-43aa-93d2-0dddd2ed0d36" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract_b15c64e6-9098-4c04-aea1-9055495e2f44" xlink:to="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent_1f289b00-f9d7-43aa-93d2-0dddd2ed0d36" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentLiabilities_7917d409-c6c9-4ec7-8f74-fec59ef67b13" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentLiabilities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationAbstract_6b664e64-56d6-4fd7-be8a-a61b068a2073" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentLiabilities_7917d409-c6c9-4ec7-8f74-fec59ef67b13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredTaxLiabilities_98e8e8dc-3ba6-47f9-a850-157e070fc0f2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredTaxLiabilities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationAbstract_6b664e64-56d6-4fd7-be8a-a61b068a2073" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredTaxLiabilities_98e8e8dc-3ba6-47f9-a850-157e070fc0f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation_ecb47b40-3ede-4dd8-bc72-68d85a7ab019" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationAbstract_6b664e64-56d6-4fd7-be8a-a61b068a2073" xlink:to="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation_ecb47b40-3ede-4dd8-bc72-68d85a7ab019" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/RevenueRecognition" xlink:type="simple" xlink:href="evh-20211231.xsd#RevenueRecognition"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/RevenueRecognition" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_80acd500-f119-411d-a036-c1f0631249ff" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerTextBlock_d882c144-2ee8-47bd-bf05-10910d2b8bc1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_80acd500-f119-411d-a036-c1f0631249ff" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerTextBlock_d882c144-2ee8-47bd-bf05-10910d2b8bc1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/RevenueRecognitionTables" xlink:type="simple" xlink:href="evh-20211231.xsd#RevenueRecognitionTables"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/RevenueRecognitionTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_b3fb20e6-c289-4d97-9c39-b5a02c2d6a99" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTableTextBlock_a085e43c-b277-4685-b40f-1abafcf3373e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_b3fb20e6-c289-4d97-9c39-b5a02c2d6a99" xlink:to="loc_us-gaap_DisaggregationOfRevenueTableTextBlock_a085e43c-b277-4685-b40f-1abafcf3373e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_0eec760e-75ee-4064-8445-90274a843c15" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_b3fb20e6-c289-4d97-9c39-b5a02c2d6a99" xlink:to="loc_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_0eec760e-75ee-4064-8445-90274a843c15" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/RevenueRecognitionDisaggregationofRevenueDetails" xlink:type="simple" xlink:href="evh-20211231.xsd#RevenueRecognitionDisaggregationofRevenueDetails"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/RevenueRecognitionDisaggregationofRevenueDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_a726af92-85f2-48c3-ad19-306eeee69b0c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_f960d9c1-f96e-4c26-b81a-f7001ca68f64" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_a726af92-85f2-48c3-ad19-306eeee69b0c" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_f960d9c1-f96e-4c26-b81a-f7001ca68f64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_a0a4af27-5ccc-4af5-9f80-bdddb1982d03" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_f960d9c1-f96e-4c26-b81a-f7001ca68f64" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_a0a4af27-5ccc-4af5-9f80-bdddb1982d03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_361ee94f-2e90-48dd-8e3a-dea052b9fc43" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_a0a4af27-5ccc-4af5-9f80-bdddb1982d03" xlink:to="loc_us-gaap_SegmentDomain_361ee94f-2e90-48dd-8e3a-dea052b9fc43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_EvolentHealthServicesSegmentMember_6915c65c-1dd2-43b0-a60e-406cfefdc098" xlink:href="evh-20211231.xsd#evh_EvolentHealthServicesSegmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_361ee94f-2e90-48dd-8e3a-dea052b9fc43" xlink:to="loc_evh_EvolentHealthServicesSegmentMember_6915c65c-1dd2-43b0-a60e-406cfefdc098" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_ClinicalSolutionsSegmentMember_ce22a4cb-1e33-4a3c-b802-69e91a41eb8b" xlink:href="evh-20211231.xsd#evh_ClinicalSolutionsSegmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_361ee94f-2e90-48dd-8e3a-dea052b9fc43" xlink:to="loc_evh_ClinicalSolutionsSegmentMember_ce22a4cb-1e33-4a3c-b802-69e91a41eb8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_0cb703eb-6824-40e2-ae94-d82d07526cd2" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MajorCustomersAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_f960d9c1-f96e-4c26-b81a-f7001ca68f64" xlink:to="loc_srt_MajorCustomersAxis_0cb703eb-6824-40e2-ae94-d82d07526cd2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_f1c62ed5-6e4d-4668-b36b-42c244fda8a0" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_MajorCustomersAxis_0cb703eb-6824-40e2-ae94-d82d07526cd2" xlink:to="loc_srt_NameOfMajorCustomerDomain_f1c62ed5-6e4d-4668-b36b-42c244fda8a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_MedicaidCustomersMember_234d8bfe-673a-4f92-b20f-e4023d075a2e" xlink:href="evh-20211231.xsd#evh_MedicaidCustomersMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_f1c62ed5-6e4d-4668-b36b-42c244fda8a0" xlink:to="loc_evh_MedicaidCustomersMember_234d8bfe-673a-4f92-b20f-e4023d075a2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_MedicareCustomersMember_984a45bf-e8b9-4dd5-a4c1-5dbbc40f1ebc" xlink:href="evh-20211231.xsd#evh_MedicareCustomersMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_f1c62ed5-6e4d-4668-b36b-42c244fda8a0" xlink:to="loc_evh_MedicareCustomersMember_984a45bf-e8b9-4dd5-a4c1-5dbbc40f1ebc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_CommercialAndOtherCustomersMember_50b17bde-0dbb-4420-98a6-2b4e0357fca4" xlink:href="evh-20211231.xsd#evh_CommercialAndOtherCustomersMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_f1c62ed5-6e4d-4668-b36b-42c244fda8a0" xlink:to="loc_evh_CommercialAndOtherCustomersMember_50b17bde-0dbb-4420-98a6-2b4e0357fca4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_aa323d5d-6266-4b69-8982-84105deef681" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_f960d9c1-f96e-4c26-b81a-f7001ca68f64" xlink:to="loc_us-gaap_DisaggregationOfRevenueLineItems_aa323d5d-6266-4b69-8982-84105deef681" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_33967ec8-302b-4626-9533-1c8a2ebd813d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_aa323d5d-6266-4b69-8982-84105deef681" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_33967ec8-302b-4626-9533-1c8a2ebd813d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/RevenueRecognitionTransactionPriceAllocatedtotheRemainingPerformanceObligationsDetails" xlink:type="simple" xlink:href="evh-20211231.xsd#RevenueRecognitionTransactionPriceAllocatedtotheRemainingPerformanceObligationsDetails"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/RevenueRecognitionTransactionPriceAllocatedtotheRemainingPerformanceObligationsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_5a75969c-d3c7-43b9-b86b-c2dbd53a1724" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligation_4a053929-c3ba-4d70-827b-d5b1f4583c54" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligation"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_5a75969c-d3c7-43b9-b86b-c2dbd53a1724" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligation_4a053929-c3ba-4d70-827b-d5b1f4583c54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable_6ac7de58-f2ce-4be8-a102-9cb8e79eb0f1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_5a75969c-d3c7-43b9-b86b-c2dbd53a1724" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable_6ac7de58-f2ce-4be8-a102-9cb8e79eb0f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_3f7b20f8-691f-4a06-9d7d-0e48e65e4958" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable_6ac7de58-f2ce-4be8-a102-9cb8e79eb0f1" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_3f7b20f8-691f-4a06-9d7d-0e48e65e4958" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_3d2a97bb-ea00-4e42-95ea-eac69fa5acb1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable_6ac7de58-f2ce-4be8-a102-9cb8e79eb0f1" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_3d2a97bb-ea00-4e42-95ea-eac69fa5acb1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationPercentage_72dfc811-2d02-4794-8516-30df269b545a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligationPercentage"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_3d2a97bb-ea00-4e42-95ea-eac69fa5acb1" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligationPercentage_72dfc811-2d02-4794-8516-30df269b545a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1_bed390a7-6b25-4c36-a10d-8ae0bc459bdb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_3d2a97bb-ea00-4e42-95ea-eac69fa5acb1" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1_bed390a7-6b25-4c36-a10d-8ae0bc459bdb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/RevenueRecognitionTransactionPriceAllocatedtotheRemainingPerformanceObligationsDetails_1" xlink:type="simple" xlink:href="evh-20211231.xsd#RevenueRecognitionTransactionPriceAllocatedtotheRemainingPerformanceObligationsDetails_1"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/RevenueRecognitionTransactionPriceAllocatedtotheRemainingPerformanceObligationsDetails_1" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/RevenueRecognitionContractBalancesDetails" xlink:type="simple" xlink:href="evh-20211231.xsd#RevenueRecognitionContractBalancesDetails"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/RevenueRecognitionContractBalancesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_9b8468d9-9397-43e4-b417-01c080a1defa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsNotesAndLoansReceivableNetCurrent_8f0b22fc-5086-432f-847c-0bdb9fca7866" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsNotesAndLoansReceivableNetCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_9b8468d9-9397-43e4-b417-01c080a1defa" xlink:to="loc_us-gaap_AccountsNotesAndLoansReceivableNetCurrent_8f0b22fc-5086-432f-847c-0bdb9fca7866" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermAccountsNotesAndLoansReceivableNetNoncurrent_2d03d82a-811b-4940-9679-63bd56c6cd5f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermAccountsNotesAndLoansReceivableNetNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_9b8468d9-9397-43e4-b417-01c080a1defa" xlink:to="loc_us-gaap_LongTermAccountsNotesAndLoansReceivableNetNoncurrent_2d03d82a-811b-4940-9679-63bd56c6cd5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetNetCurrent_beec8169-f91a-4056-8213-3ebd3a63bc8b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerAssetNetCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_9b8468d9-9397-43e4-b417-01c080a1defa" xlink:to="loc_us-gaap_ContractWithCustomerAssetNetCurrent_beec8169-f91a-4056-8213-3ebd3a63bc8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_5c75e3f6-5ce0-4095-b769-c91bd286b0ff" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_9b8468d9-9397-43e4-b417-01c080a1defa" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_5c75e3f6-5ce0-4095-b769-c91bd286b0ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_39b36d56-545f-4e1f-931b-1a652c3aae78" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_9b8468d9-9397-43e4-b417-01c080a1defa" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_39b36d56-545f-4e1f-931b-1a652c3aae78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_d6d86b6a-8832-481f-aaeb-48affe401e58" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_9b8468d9-9397-43e4-b417-01c080a1defa" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_d6d86b6a-8832-481f-aaeb-48affe401e58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis_2a665cd1-7c3c-45b8-a382-5a334823f83c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupClassificationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_d6d86b6a-8832-481f-aaeb-48affe401e58" xlink:to="loc_us-gaap_DisposalGroupClassificationAxis_2a665cd1-7c3c-45b8-a382-5a334823f83c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_9ee080d6-3c13-4db7-98eb-4f75f54c183e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_2a665cd1-7c3c-45b8-a382-5a334823f83c" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_9ee080d6-3c13-4db7-98eb-4f75f54c183e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationsDisposedOfBySaleMember_5eecdedd-b2dc-4d6c-bcc9-60d2ada7b340" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DiscontinuedOperationsDisposedOfBySaleMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain_9ee080d6-3c13-4db7-98eb-4f75f54c183e" xlink:to="loc_us-gaap_DiscontinuedOperationsDisposedOfBySaleMember_5eecdedd-b2dc-4d6c-bcc9-60d2ada7b340" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_4af7e26b-0c78-4ab6-8020-799357d74968" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_d6d86b6a-8832-481f-aaeb-48affe401e58" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_4af7e26b-0c78-4ab6-8020-799357d74968" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_a4af8e5f-9cc7-4a6c-8671-a19c4b9514e0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_4af7e26b-0c78-4ab6-8020-799357d74968" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_a4af8e5f-9cc7-4a6c-8671-a19c4b9514e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_TrueHealthMember_4a93de11-6c4d-4f64-b5fd-c91343067089" xlink:href="evh-20211231.xsd#evh_TrueHealthMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_a4af8e5f-9cc7-4a6c-8671-a19c4b9514e0" xlink:to="loc_evh_TrueHealthMember_4a93de11-6c4d-4f64-b5fd-c91343067089" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_f5fca36c-ae96-4b74-bdc0-bc78237f7f98" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_d6d86b6a-8832-481f-aaeb-48affe401e58" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_f5fca36c-ae96-4b74-bdc0-bc78237f7f98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNetAfterGrossUp_b641250f-0928-4949-9888-72407c91b398" xlink:href="evh-20211231.xsd#evh_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNetAfterGrossUp"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_f5fca36c-ae96-4b74-bdc0-bc78237f7f98" xlink:to="loc_evh_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNetAfterGrossUp_b641250f-0928-4949-9888-72407c91b398" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredRevenueCurrent_91e8801d-1212-4eb2-ac41-f3794c350533" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredRevenueCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_f5fca36c-ae96-4b74-bdc0-bc78237f7f98" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredRevenueCurrent_91e8801d-1212-4eb2-ac41-f3794c350533" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_ChangeInContractWithCustomerLiabilityRollForward_84eeffe0-0871-4582-be1e-1d6efd0792ba" xlink:href="evh-20211231.xsd#evh_ChangeInContractWithCustomerLiabilityRollForward"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_9b8468d9-9397-43e4-b417-01c080a1defa" xlink:to="loc_evh_ChangeInContractWithCustomerLiabilityRollForward_84eeffe0-0871-4582-be1e-1d6efd0792ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_ebc3444d-156a-4b06-ade1-62247332eddd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_evh_ChangeInContractWithCustomerLiabilityRollForward_84eeffe0-0871-4582-be1e-1d6efd0792ba" xlink:to="loc_us-gaap_ContractWithCustomerLiability_ebc3444d-156a-4b06-ade1-62247332eddd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_af269436-56d1-4deb-93d3-64c7a85e20c6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_evh_ChangeInContractWithCustomerLiabilityRollForward_84eeffe0-0871-4582-be1e-1d6efd0792ba" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_af269436-56d1-4deb-93d3-64c7a85e20c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_ContractWithCustomerLiabilityCashReceivedInAdvanceOfSatisfactionOfPerformanceObligations_ff16e9fe-0b00-4d67-ab86-e99654568a1f" xlink:href="evh-20211231.xsd#evh_ContractWithCustomerLiabilityCashReceivedInAdvanceOfSatisfactionOfPerformanceObligations"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_evh_ChangeInContractWithCustomerLiabilityRollForward_84eeffe0-0871-4582-be1e-1d6efd0792ba" xlink:to="loc_evh_ContractWithCustomerLiabilityCashReceivedInAdvanceOfSatisfactionOfPerformanceObligations_ff16e9fe-0b00-4d67-ab86-e99654568a1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_32546aa2-de6a-44f5-9105-137aa5a580a2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_evh_ChangeInContractWithCustomerLiabilityRollForward_84eeffe0-0871-4582-be1e-1d6efd0792ba" xlink:to="loc_us-gaap_ContractWithCustomerLiability_32546aa2-de6a-44f5-9105-137aa5a580a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod_833747f8-bd94-4651-85a0-28f5dd1fed87" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_9b8468d9-9397-43e4-b417-01c080a1defa" xlink:to="loc_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod_833747f8-bd94-4651-85a0-28f5dd1fed87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/RevenueRecognitionContractCostsDetails" xlink:type="simple" xlink:href="evh-20211231.xsd#RevenueRecognitionContractCostsDetails"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/RevenueRecognitionContractCostsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_e76485ee-4cd0-4cb0-9cb4-1e98f41e7763" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedContractCostTable_8c28117f-bf74-4aa4-8d95-da7d8d73869b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalizedContractCostTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_e76485ee-4cd0-4cb0-9cb4-1e98f41e7763" xlink:to="loc_us-gaap_CapitalizedContractCostTable_8c28117f-bf74-4aa4-8d95-da7d8d73869b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedContractCostAxis_43344c3b-148b-47ab-9fed-6dcd780b7378" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalizedContractCostAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CapitalizedContractCostTable_8c28117f-bf74-4aa4-8d95-da7d8d73869b" xlink:to="loc_us-gaap_CapitalizedContractCostAxis_43344c3b-148b-47ab-9fed-6dcd780b7378" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedContractCostDomain_25907e1b-60c6-4ca7-ae4a-3bb71cde7368" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalizedContractCostDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CapitalizedContractCostAxis_43344c3b-148b-47ab-9fed-6dcd780b7378" xlink:to="loc_us-gaap_CapitalizedContractCostDomain_25907e1b-60c6-4ca7-ae4a-3bb71cde7368" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_BonusesAndCommissionsMember_53677fec-856b-4f87-bbac-8278a50e4c99" xlink:href="evh-20211231.xsd#evh_BonusesAndCommissionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CapitalizedContractCostDomain_25907e1b-60c6-4ca7-ae4a-3bb71cde7368" xlink:to="loc_evh_BonusesAndCommissionsMember_53677fec-856b-4f87-bbac-8278a50e4c99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_ContractFulfillmentCostsMember_c3cd18df-605f-4efd-897e-a38264931e27" xlink:href="evh-20211231.xsd#evh_ContractFulfillmentCostsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CapitalizedContractCostDomain_25907e1b-60c6-4ca7-ae4a-3bb71cde7368" xlink:to="loc_evh_ContractFulfillmentCostsMember_c3cd18df-605f-4efd-897e-a38264931e27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedContractCostLineItems_1650f683-87c8-4652-a914-bf9e9fc27f6d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalizedContractCostLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CapitalizedContractCostTable_8c28117f-bf74-4aa4-8d95-da7d8d73869b" xlink:to="loc_us-gaap_CapitalizedContractCostLineItems_1650f683-87c8-4652-a914-bf9e9fc27f6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedContractCostNet_1ef22d58-ea25-4552-8399-5ff66e8c3670" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalizedContractCostNet"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CapitalizedContractCostLineItems_1650f683-87c8-4652-a914-bf9e9fc27f6d" xlink:to="loc_us-gaap_CapitalizedContractCostNet_1ef22d58-ea25-4552-8399-5ff66e8c3670" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedContractCostAmortization_2ef0d5ac-65f5-4c08-919b-b07cc25e1938" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalizedContractCostAmortization"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CapitalizedContractCostLineItems_1650f683-87c8-4652-a914-bf9e9fc27f6d" xlink:to="loc_us-gaap_CapitalizedContractCostAmortization_2ef0d5ac-65f5-4c08-919b-b07cc25e1938" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedContractCostAmortizationPeriod_76715689-4b96-461a-a6c7-507cdd7d3a0b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalizedContractCostAmortizationPeriod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CapitalizedContractCostLineItems_1650f683-87c8-4652-a914-bf9e9fc27f6d" xlink:to="loc_us-gaap_CapitalizedContractCostAmortizationPeriod_76715689-4b96-461a-a6c7-507cdd7d3a0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/CreditLosses" xlink:type="simple" xlink:href="evh-20211231.xsd#CreditLosses"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/CreditLosses" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditLossAbstract_d17b9c11-ce82-45de-bb7e-91130106e7d8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditLossAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditLossFinancialInstrumentTextBlock_9f5aa17e-df5c-4219-a798-2b3d0be7b442" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditLossFinancialInstrumentTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditLossAbstract_d17b9c11-ce82-45de-bb7e-91130106e7d8" xlink:to="loc_us-gaap_CreditLossFinancialInstrumentTextBlock_9f5aa17e-df5c-4219-a798-2b3d0be7b442" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/CreditLossesTables" xlink:type="simple" xlink:href="evh-20211231.xsd#CreditLossesTables"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/CreditLossesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditLossAbstract_2bc9c04e-b280-43f3-870a-6058b99fad68" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditLossAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableAllowanceForCreditLossTableTextBlock_86a3c462-4d3b-497c-af77-070fda15edb2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableAllowanceForCreditLossTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditLossAbstract_2bc9c04e-b280-43f3-870a-6058b99fad68" xlink:to="loc_us-gaap_AccountsReceivableAllowanceForCreditLossTableTextBlock_86a3c462-4d3b-497c-af77-070fda15edb2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/CreditLossesAccountsReceivableNarrativeDetails" xlink:type="simple" xlink:href="evh-20211231.xsd#CreditLossesAccountsReceivableNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/CreditLossesAccountsReceivableNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditLossAbstract_658dbafe-1990-4d9e-87a0-fc4231e3e196" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditLossAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNoncurrentPastDueTable_9be176ed-8777-4804-b4d4-a7d5f4d846db" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNoncurrentPastDueTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditLossAbstract_658dbafe-1990-4d9e-87a0-fc4231e3e196" xlink:to="loc_us-gaap_AccountsReceivableNoncurrentPastDueTable_9be176ed-8777-4804-b4d4-a7d5f4d846db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancingReceivablesPeriodPastDueAxis_ba60591a-0628-4028-a728-694eba294109" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancingReceivablesPeriodPastDueAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountsReceivableNoncurrentPastDueTable_9be176ed-8777-4804-b4d4-a7d5f4d846db" xlink:to="loc_us-gaap_FinancingReceivablesPeriodPastDueAxis_ba60591a-0628-4028-a728-694eba294109" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancingReceivablesPeriodPastDueDomain_46a6a104-9038-4b6b-9552-bc2d2743e10a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancingReceivablesPeriodPastDueDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancingReceivablesPeriodPastDueAxis_ba60591a-0628-4028-a728-694eba294109" xlink:to="loc_us-gaap_FinancingReceivablesPeriodPastDueDomain_46a6a104-9038-4b6b-9552-bc2d2743e10a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_FInancialAssetLessThan60DaysMember_54f3d06e-7472-4dbc-954e-33045a1b4e8a" xlink:href="evh-20211231.xsd#evh_FInancialAssetLessThan60DaysMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancingReceivablesPeriodPastDueDomain_46a6a104-9038-4b6b-9552-bc2d2743e10a" xlink:to="loc_evh_FInancialAssetLessThan60DaysMember_54f3d06e-7472-4dbc-954e-33045a1b4e8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_FInancialAssetLessThan120DaysPastDueMember_303d5d00-07b8-47ca-9477-3a940eb8b4f3" xlink:href="evh-20211231.xsd#evh_FInancialAssetLessThan120DaysPastDueMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancingReceivablesPeriodPastDueDomain_46a6a104-9038-4b6b-9552-bc2d2743e10a" xlink:to="loc_evh_FInancialAssetLessThan120DaysPastDueMember_303d5d00-07b8-47ca-9477-3a940eb8b4f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNoncurrentPastDueLineItems_5d4ac40f-8cee-4158-a682-f73391480498" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNoncurrentPastDueLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountsReceivableNoncurrentPastDueTable_9be176ed-8777-4804-b4d4-a7d5f4d846db" xlink:to="loc_us-gaap_AccountsReceivableNoncurrentPastDueLineItems_5d4ac40f-8cee-4158-a682-f73391480498" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_FinancingReceivablePercentNotPastDue_31e4f473-c65b-4afb-be57-f2e47d42455d" xlink:href="evh-20211231.xsd#evh_FinancingReceivablePercentNotPastDue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountsReceivableNoncurrentPastDueLineItems_5d4ac40f-8cee-4158-a682-f73391480498" xlink:to="loc_evh_FinancingReceivablePercentNotPastDue_31e4f473-c65b-4afb-be57-f2e47d42455d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancingReceivablePercentPastDue1_6ab64808-b536-4e46-8406-3298fd29b617" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancingReceivablePercentPastDue1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountsReceivableNoncurrentPastDueLineItems_5d4ac40f-8cee-4158-a682-f73391480498" xlink:to="loc_us-gaap_FinancingReceivablePercentPastDue1_6ab64808-b536-4e46-8406-3298fd29b617" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNet_21a14d3e-5019-4f36-b57b-7ddd10d49e1d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountsReceivableNoncurrentPastDueLineItems_5d4ac40f-8cee-4158-a682-f73391480498" xlink:to="loc_us-gaap_AccountsReceivableNet_21a14d3e-5019-4f36-b57b-7ddd10d49e1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_42a7e7f3-4d8f-48e5-a707-356b5f131da5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountsReceivableNoncurrentPastDueLineItems_5d4ac40f-8cee-4158-a682-f73391480498" xlink:to="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_42a7e7f3-4d8f-48e5-a707-356b5f131da5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/CreditLossesScheduleofChangesinAllowanceforAccountsReceivableDetails" xlink:type="simple" xlink:href="evh-20211231.xsd#CreditLossesScheduleofChangesinAllowanceforAccountsReceivableDetails"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/CreditLossesScheduleofChangesinAllowanceforAccountsReceivableDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditLossAbstract_21e9d772-be24-407e-be54-7c34151cc267" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditLossAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_d707873c-6ece-4ad9-8016-ca4b0390bc71" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditLossAbstract_21e9d772-be24-407e-be54-7c34151cc267" xlink:to="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_d707873c-6ece-4ad9-8016-ca4b0390bc71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_8aa09f74-c382-49dd-854d-0b655ae60f20" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_d707873c-6ece-4ad9-8016-ca4b0390bc71" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_8aa09f74-c382-49dd-854d-0b655ae60f20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_df615443-fab0-4912-a201-a283229487e2" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_8aa09f74-c382-49dd-854d-0b655ae60f20" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_df615443-fab0-4912-a201-a283229487e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_6bc9f5f6-b1e4-4626-a176-a52ef125e5f0" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_df615443-fab0-4912-a201-a283229487e2" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_6bc9f5f6-b1e4-4626-a176-a52ef125e5f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_47c2a2ff-bfea-4e01-bb1d-b28e281b97aa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsNotesAndLoansReceivableLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_d707873c-6ece-4ad9-8016-ca4b0390bc71" xlink:to="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_47c2a2ff-bfea-4e01-bb1d-b28e281b97aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward_a5d4a7ed-6f97-4434-9c4b-ff153a60a7b9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_47c2a2ff-bfea-4e01-bb1d-b28e281b97aa" xlink:to="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward_a5d4a7ed-6f97-4434-9c4b-ff153a60a7b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_7fcd0e23-8519-4e93-af2b-60890b11a162" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward_a5d4a7ed-6f97-4434-9c4b-ff153a60a7b9" xlink:to="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_7fcd0e23-8519-4e93-af2b-60890b11a162" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedPeriodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_AccountsReceivableAllowanceForCreditLossAcquiredDuringPeriod_bc6e95c5-a29b-4a7d-b607-788f2d755257" xlink:href="evh-20211231.xsd#evh_AccountsReceivableAllowanceForCreditLossAcquiredDuringPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward_a5d4a7ed-6f97-4434-9c4b-ff153a60a7b9" xlink:to="loc_evh_AccountsReceivableAllowanceForCreditLossAcquiredDuringPeriod_bc6e95c5-a29b-4a7d-b607-788f2d755257" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProvisionForDoubtfulAccounts_86485208-1916-400b-8dfb-5262e57205ae" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProvisionForDoubtfulAccounts"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward_a5d4a7ed-6f97-4434-9c4b-ff153a60a7b9" xlink:to="loc_us-gaap_ProvisionForDoubtfulAccounts_86485208-1916-400b-8dfb-5262e57205ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs_8c395da8-16c8-4412-879d-ef396278f158" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward_a5d4a7ed-6f97-4434-9c4b-ff153a60a7b9" xlink:to="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs_8c395da8-16c8-4412-879d-ef396278f158" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_f6d22b0a-cea0-4adb-986b-e42f6071db53" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward_a5d4a7ed-6f97-4434-9c4b-ff153a60a7b9" xlink:to="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_f6d22b0a-cea0-4adb-986b-e42f6071db53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedPeriodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/PropertyandEquipmentNet" xlink:type="simple" xlink:href="evh-20211231.xsd#PropertyandEquipmentNet"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/PropertyandEquipmentNet" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_b6547868-a5ef-41d6-86ea-29f62cdf8c4a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_3dd51de4-7a94-44a6-a50f-a74e463a151f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_b6547868-a5ef-41d6-86ea-29f62cdf8c4a" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_3dd51de4-7a94-44a6-a50f-a74e463a151f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/PropertyandEquipmentNetTables" xlink:type="simple" xlink:href="evh-20211231.xsd#PropertyandEquipmentNetTables"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/PropertyandEquipmentNetTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_835d09d0-b70f-4ba3-9c0c-bac35a846dbd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_9d75c40f-d898-4d69-9d66-22f92da51e6a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_835d09d0-b70f-4ba3-9c0c-bac35a846dbd" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_9d75c40f-d898-4d69-9d66-22f92da51e6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/PropertyandEquipmentNetDetails" xlink:type="simple" xlink:href="evh-20211231.xsd#PropertyandEquipmentNetDetails"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/PropertyandEquipmentNetDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_cf0ba7ef-931e-4bbc-ac88-942828d154f0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_f1037d35-4064-479b-9418-26d6dc0f1ad6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_cf0ba7ef-931e-4bbc-ac88-942828d154f0" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_f1037d35-4064-479b-9418-26d6dc0f1ad6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_bde88ecb-b020-4a2a-85e6-4c5bc8cda985" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_f1037d35-4064-479b-9418-26d6dc0f1ad6" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_bde88ecb-b020-4a2a-85e6-4c5bc8cda985" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_a159665a-8452-4f10-809f-c84432e70863" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_bde88ecb-b020-4a2a-85e6-4c5bc8cda985" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_a159665a-8452-4f10-809f-c84432e70863" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComputerEquipmentMember_e2fe26d9-4cbc-4b96-a5d9-465c0e0f02b1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComputerEquipmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_a159665a-8452-4f10-809f-c84432e70863" xlink:to="loc_us-gaap_ComputerEquipmentMember_e2fe26d9-4cbc-4b96-a5d9-465c0e0f02b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_48da41f4-d4e9-4041-88f0-4e48ea8906ec" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_a159665a-8452-4f10-809f-c84432e70863" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_48da41f4-d4e9-4041-88f0-4e48ea8906ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SoftwareDevelopmentMember_a142ff59-2282-4d76-88e3-3751ef1beb0c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SoftwareDevelopmentMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_a159665a-8452-4f10-809f-c84432e70863" xlink:to="loc_us-gaap_SoftwareDevelopmentMember_a142ff59-2282-4d76-88e3-3751ef1beb0c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_216b365e-ae50-451a-a5e3-5aa282915b21" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_a159665a-8452-4f10-809f-c84432e70863" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_216b365e-ae50-451a-a5e3-5aa282915b21" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_8580601b-ba4c-496f-81e0-2f35a0ddd371" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_f1037d35-4064-479b-9418-26d6dc0f1ad6" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_8580601b-ba4c-496f-81e0-2f35a0ddd371" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_05929645-b7a5-4b21-9709-ae37acf60752" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_8580601b-ba4c-496f-81e0-2f35a0ddd371" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_05929645-b7a5-4b21-9709-ae37acf60752" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_1b9bc7a1-8999-4f97-a860-deeda47ae3ca" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_8580601b-ba4c-496f-81e0-2f35a0ddd371" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_1b9bc7a1-8999-4f97-a860-deeda47ae3ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_070ee110-9478-429d-9d0d-1f4a57b61965" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_8580601b-ba4c-496f-81e0-2f35a0ddd371" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_070ee110-9478-429d-9d0d-1f4a57b61965" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedComputerSoftwareAdditions_9eb0b224-5697-4e8b-b4f5-7773a52cf227" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalizedComputerSoftwareAdditions"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_8580601b-ba4c-496f-81e0-2f35a0ddd371" xlink:to="loc_us-gaap_CapitalizedComputerSoftwareAdditions_9eb0b224-5697-4e8b-b4f5-7773a52cf227" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation_cff93c83-c3d5-4828-bc7b-b210ddeb4dc7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Depreciation"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_8580601b-ba4c-496f-81e0-2f35a0ddd371" xlink:to="loc_us-gaap_Depreciation_cff93c83-c3d5-4828-bc7b-b210ddeb4dc7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedComputerSoftwareAmortization1_9eb72fd6-c286-48e6-9b9e-e67b0dafdf85" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalizedComputerSoftwareAmortization1"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_8580601b-ba4c-496f-81e0-2f35a0ddd371" xlink:to="loc_us-gaap_CapitalizedComputerSoftwareAmortization1_9eb72fd6-c286-48e6-9b9e-e67b0dafdf85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNet" xlink:type="simple" xlink:href="evh-20211231.xsd#GoodwillandIntangibleAssetsNet"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNet" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_f3229b58-00a7-4828-b7aa-2adfef4cf3af" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_5cd1647f-7f08-40d3-b7bd-c66a9d4a28d7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_f3229b58-00a7-4828-b7aa-2adfef4cf3af" xlink:to="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_5cd1647f-7f08-40d3-b7bd-c66a9d4a28d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNetTables" xlink:type="simple" xlink:href="evh-20211231.xsd#GoodwillandIntangibleAssetsNetTables"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNetTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_56aee841-4cf8-4ae6-8eb6-ac6b01f79e62" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGoodwillTextBlock_51d8c92c-3c85-4c5b-ac3e-2bc7a63a1149" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfGoodwillTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_56aee841-4cf8-4ae6-8eb6-ac6b01f79e62" xlink:to="loc_us-gaap_ScheduleOfGoodwillTextBlock_51d8c92c-3c85-4c5b-ac3e-2bc7a63a1149" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_22d4e6c0-426d-45fc-839f-d15defd60387" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_56aee841-4cf8-4ae6-8eb6-ac6b01f79e62" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_22d4e6c0-426d-45fc-839f-d15defd60387" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_27e7c1e9-1424-4ef0-94b1-6fe378731d4b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_56aee841-4cf8-4ae6-8eb6-ac6b01f79e62" xlink:to="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_27e7c1e9-1424-4ef0-94b1-6fe378731d4b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNetImpairmentTestingDetails" xlink:type="simple" xlink:href="evh-20211231.xsd#GoodwillandIntangibleAssetsNetImpairmentTestingDetails"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNetImpairmentTestingDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_3c1babbe-1f36-491e-b0ea-ea349b6ac751" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfReportingUnits_aeb44463-ba29-4cfb-8038-f43f309a2711" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NumberOfReportingUnits"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_3c1babbe-1f36-491e-b0ea-ea349b6ac751" xlink:to="loc_us-gaap_NumberOfReportingUnits_aeb44463-ba29-4cfb-8038-f43f309a2711" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairmentLoss_84ff197c-e06d-4703-b580-3460250f080c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_3c1babbe-1f36-491e-b0ea-ea349b6ac751" xlink:to="loc_us-gaap_GoodwillImpairmentLoss_84ff197c-e06d-4703-b580-3460250f080c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_NumberOfReportingUnitsFairValueInExcessOfCarryingAmount_617d35f6-a826-49a2-869f-89ad0346b239" xlink:href="evh-20211231.xsd#evh_NumberOfReportingUnitsFairValueInExcessOfCarryingAmount"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_3c1babbe-1f36-491e-b0ea-ea349b6ac751" xlink:to="loc_evh_NumberOfReportingUnitsFairValueInExcessOfCarryingAmount_617d35f6-a826-49a2-869f-89ad0346b239" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNetScheduleofGoodwillDetails" xlink:type="simple" xlink:href="evh-20211231.xsd#GoodwillandIntangibleAssetsNetScheduleofGoodwillDetails"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNetScheduleofGoodwillDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_52fb8c35-3b04-42c3-a0dd-b558f7dbc664" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGoodwillTable_d9cd9198-d963-4e8c-b630-3c825c015cd4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfGoodwillTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_52fb8c35-3b04-42c3-a0dd-b558f7dbc664" xlink:to="loc_us-gaap_ScheduleOfGoodwillTable_d9cd9198-d963-4e8c-b630-3c825c015cd4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_a68e275a-42d2-434c-875b-4890c3ba5b4e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_d9cd9198-d963-4e8c-b630-3c825c015cd4" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_a68e275a-42d2-434c-875b-4890c3ba5b4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_834a7bac-b969-4a3b-a358-f15acbe38ed6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_a68e275a-42d2-434c-875b-4890c3ba5b4e" xlink:to="loc_us-gaap_SegmentDomain_834a7bac-b969-4a3b-a358-f15acbe38ed6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_EvolentHealthServicesSegmentMember_e1eae180-328d-4b39-be0c-4f2d819d40f8" xlink:href="evh-20211231.xsd#evh_EvolentHealthServicesSegmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_834a7bac-b969-4a3b-a358-f15acbe38ed6" xlink:to="loc_evh_EvolentHealthServicesSegmentMember_e1eae180-328d-4b39-be0c-4f2d819d40f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_ClinicalSolutionsSegmentMember_04486897-9052-4b8b-8da5-06369d1c7a72" xlink:href="evh-20211231.xsd#evh_ClinicalSolutionsSegmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_834a7bac-b969-4a3b-a358-f15acbe38ed6" xlink:to="loc_evh_ClinicalSolutionsSegmentMember_04486897-9052-4b8b-8da5-06369d1c7a72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillLineItems_56ebd4a8-4014-4436-acdd-17483f2e9380" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_d9cd9198-d963-4e8c-b630-3c825c015cd4" xlink:to="loc_us-gaap_GoodwillLineItems_56ebd4a8-4014-4436-acdd-17483f2e9380" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillRollForward_8c869321-f364-462c-82e0-85be3c3b4710" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillLineItems_56ebd4a8-4014-4436-acdd-17483f2e9380" xlink:to="loc_us-gaap_GoodwillRollForward_8c869321-f364-462c-82e0-85be3c3b4710" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_976480fb-41ce-4e19-acd3-18d897dbd7ca" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_8c869321-f364-462c-82e0-85be3c3b4710" xlink:to="loc_us-gaap_Goodwill_976480fb-41ce-4e19-acd3-18d897dbd7ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit_05fc0e51-19a6-4191-ba63-d0e8a2e47a16" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_8c869321-f364-462c-82e0-85be3c3b4710" xlink:to="loc_us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit_05fc0e51-19a6-4191-ba63-d0e8a2e47a16" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairmentLoss_b0c21f27-3648-4afe-9171-8808396ee8e5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_8c869321-f364-462c-82e0-85be3c3b4710" xlink:to="loc_us-gaap_GoodwillImpairmentLoss_b0c21f27-3648-4afe-9171-8808396ee8e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAcquiredDuringPeriod_349a782a-063c-448f-90d2-8cfa03fc1caf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAcquiredDuringPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_8c869321-f364-462c-82e0-85be3c3b4710" xlink:to="loc_us-gaap_GoodwillAcquiredDuringPeriod_349a782a-063c-448f-90d2-8cfa03fc1caf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillForeignCurrencyTranslationGainLoss_9d3462d6-3801-444e-a6b0-d365609a9d84" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillForeignCurrencyTranslationGainLoss"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_8c869321-f364-462c-82e0-85be3c3b4710" xlink:to="loc_us-gaap_GoodwillForeignCurrencyTranslationGainLoss_9d3462d6-3801-444e-a6b0-d365609a9d84" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_231803d8-a06e-4e82-a6bf-cb5dd3237bd4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_8c869321-f364-462c-82e0-85be3c3b4710" xlink:to="loc_us-gaap_Goodwill_231803d8-a06e-4e82-a6bf-cb5dd3237bd4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss_63e42109-92d2-40cb-9719-0934a57f61a0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillImpairedAccumulatedImpairmentLoss"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillLineItems_56ebd4a8-4014-4436-acdd-17483f2e9380" xlink:to="loc_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss_63e42109-92d2-40cb-9719-0934a57f61a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNetIntangibleAssetsNetDetails" xlink:type="simple" xlink:href="evh-20211231.xsd#GoodwillandIntangibleAssetsNetIntangibleAssetsNetDetails"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNetIntangibleAssetsNetDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_8b0d77d8-8df2-4fe4-b75a-bd813c633924" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_9e47774e-f41f-433f-a05f-38cda204f268" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_8b0d77d8-8df2-4fe4-b75a-bd813c633924" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_9e47774e-f41f-433f-a05f-38cda204f268" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_1d3f0998-74af-43a3-a0eb-304a8560d076" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_9e47774e-f41f-433f-a05f-38cda204f268" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_1d3f0998-74af-43a3-a0eb-304a8560d076" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_f1f2a71d-25e1-4ce8-a12e-ac73c996018c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_1d3f0998-74af-43a3-a0eb-304a8560d076" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_f1f2a71d-25e1-4ce8-a12e-ac73c996018c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TradeNamesMember_a647c6c9-1cf6-48be-8d52-5eb696dac1dc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TradeNamesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_f1f2a71d-25e1-4ce8-a12e-ac73c996018c" xlink:to="loc_us-gaap_TradeNamesMember_a647c6c9-1cf6-48be-8d52-5eb696dac1dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerRelationshipsMember_78e7b632-e55e-4f6a-92e6-349eb930bc3b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CustomerRelationshipsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_f1f2a71d-25e1-4ce8-a12e-ac73c996018c" xlink:to="loc_us-gaap_CustomerRelationshipsMember_78e7b632-e55e-4f6a-92e6-349eb930bc3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DevelopedTechnologyRightsMember_cfde05df-78a7-4a2c-b18c-0665cdfd7694" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DevelopedTechnologyRightsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_f1f2a71d-25e1-4ce8-a12e-ac73c996018c" xlink:to="loc_us-gaap_DevelopedTechnologyRightsMember_cfde05df-78a7-4a2c-b18c-0665cdfd7694" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_BelowMarketLeasesMember_71d2fd4b-51d4-4502-a827-40e5f49f2699" xlink:href="evh-20211231.xsd#evh_BelowMarketLeasesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_f1f2a71d-25e1-4ce8-a12e-ac73c996018c" xlink:to="loc_evh_BelowMarketLeasesMember_71d2fd4b-51d4-4502-a827-40e5f49f2699" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractBasedIntangibleAssetsMember_dd1cbc18-13db-434e-bb7c-d2ee05322e5a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractBasedIntangibleAssetsMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_f1f2a71d-25e1-4ce8-a12e-ac73c996018c" xlink:to="loc_us-gaap_ContractBasedIntangibleAssetsMember_dd1cbc18-13db-434e-bb7c-d2ee05322e5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis_e98e5f97-59c3-4de0-983d-83ff82f51cc3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupClassificationAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_9e47774e-f41f-433f-a05f-38cda204f268" xlink:to="loc_us-gaap_DisposalGroupClassificationAxis_e98e5f97-59c3-4de0-983d-83ff82f51cc3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_f0ccc473-dd0a-4c30-8edc-5a29505f8e95" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_e98e5f97-59c3-4de0-983d-83ff82f51cc3" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_f0ccc473-dd0a-4c30-8edc-5a29505f8e95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationsDisposedOfBySaleMember_576875e5-7883-456c-8855-86d79fe48197" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DiscontinuedOperationsDisposedOfBySaleMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain_f0ccc473-dd0a-4c30-8edc-5a29505f8e95" xlink:to="loc_us-gaap_DiscontinuedOperationsDisposedOfBySaleMember_576875e5-7883-456c-8855-86d79fe48197" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_d94c36af-0bb1-43dc-b685-e3cbcf073f33" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_9e47774e-f41f-433f-a05f-38cda204f268" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_d94c36af-0bb1-43dc-b685-e3cbcf073f33" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_a3efb2ff-21f6-44d0-a607-0212eab709d7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_d94c36af-0bb1-43dc-b685-e3cbcf073f33" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_a3efb2ff-21f6-44d0-a607-0212eab709d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_TrueHealthMember_f07be7f2-eafa-4790-9dba-b9f4cf66b596" xlink:href="evh-20211231.xsd#evh_TrueHealthMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_a3efb2ff-21f6-44d0-a607-0212eab709d7" xlink:to="loc_evh_TrueHealthMember_f07be7f2-eafa-4790-9dba-b9f4cf66b596" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_897841b4-cd06-4f7d-a92c-39b8bde7ebab" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_9e47774e-f41f-433f-a05f-38cda204f268" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_897841b4-cd06-4f7d-a92c-39b8bde7ebab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_cd64db2e-d3c6-4d47-89d2-d1caf07db6cc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_897841b4-cd06-4f7d-a92c-39b8bde7ebab" xlink:to="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_cd64db2e-d3c6-4d47-89d2-d1caf07db6cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_30311c5a-10e5-4852-9f22-c4c93f1df6d8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_897841b4-cd06-4f7d-a92c-39b8bde7ebab" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_30311c5a-10e5-4852-9f22-c4c93f1df6d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_6b1378e9-5919-4dd5-ae49-32a08bf0ce8e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_897841b4-cd06-4f7d-a92c-39b8bde7ebab" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_6b1378e9-5919-4dd5-ae49-32a08bf0ce8e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_d81233c5-56c5-4ddf-9d31-6257676493df" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_897841b4-cd06-4f7d-a92c-39b8bde7ebab" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_d81233c5-56c5-4ddf-9d31-6257676493df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsNoncurrent_0b9eaa89-b222-4f17-99da-74b10d95748b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsNoncurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_897841b4-cd06-4f7d-a92c-39b8bde7ebab" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsNoncurrent_0b9eaa89-b222-4f17-99da-74b10d95748b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_f894408d-5e34-42fc-8716-fa90d0a31273" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_897841b4-cd06-4f7d-a92c-39b8bde7ebab" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_f894408d-5e34-42fc-8716-fa90d0a31273" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNetAmortizationofIntangibleAssetsDetails" xlink:type="simple" xlink:href="evh-20211231.xsd#GoodwillandIntangibleAssetsNetAmortizationofIntangibleAssetsDetails"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNetAmortizationofIntangibleAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_660f0e7f-bd53-4bd7-8d41-272b0495faae" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_1b7bf0c1-4991-47d4-9474-692abfccaf08" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_660f0e7f-bd53-4bd7-8d41-272b0495faae" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_1b7bf0c1-4991-47d4-9474-692abfccaf08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_31bdb975-ff35-492e-ac0a-462803bed98d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_660f0e7f-bd53-4bd7-8d41-272b0495faae" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_31bdb975-ff35-492e-ac0a-462803bed98d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_784ae593-2548-45cd-aaaa-c5fb08cee41e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_660f0e7f-bd53-4bd7-8d41-272b0495faae" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_784ae593-2548-45cd-aaaa-c5fb08cee41e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_6122e170-5334-4e1e-99bc-41f3bb5c1f4b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_660f0e7f-bd53-4bd7-8d41-272b0495faae" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_6122e170-5334-4e1e-99bc-41f3bb5c1f4b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_437a0546-3a5e-4bc0-b41f-86b7d14737a3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_660f0e7f-bd53-4bd7-8d41-272b0495faae" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_437a0546-3a5e-4bc0-b41f-86b7d14737a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_ec5bb172-78e7-4df3-aecf-55ebe136cd7a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_660f0e7f-bd53-4bd7-8d41-272b0495faae" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_ec5bb172-78e7-4df3-aecf-55ebe136cd7a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_61c1edf8-122a-47ca-8b39-4ba525a8951f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_660f0e7f-bd53-4bd7-8d41-272b0495faae" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_61c1edf8-122a-47ca-8b39-4ba525a8951f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/LongtermDebt" xlink:type="simple" xlink:href="evh-20211231.xsd#LongtermDebt"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/LongtermDebt" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_c3b62953-8505-42ba-92b7-3512a08dda6b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureTextBlock_5c514b6d-6085-43b2-b382-56b18b89ab38" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_c3b62953-8505-42ba-92b7-3512a08dda6b" xlink:to="loc_us-gaap_DebtDisclosureTextBlock_5c514b6d-6085-43b2-b382-56b18b89ab38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/LongtermDebtTables" xlink:type="simple" xlink:href="evh-20211231.xsd#LongtermDebtTables"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/LongtermDebtTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_e112864a-8949-4ed2-b828-80d6076b09e1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtTableTextBlock_c3916731-8b72-4670-b406-e0554b1d9ca0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertibleDebtTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_e112864a-8949-4ed2-b828-80d6076b09e1" xlink:to="loc_us-gaap_ConvertibleDebtTableTextBlock_c3916731-8b72-4670-b406-e0554b1d9ca0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/LongtermDebt2024NotesDetails" xlink:type="simple" xlink:href="evh-20211231.xsd#LongtermDebt2024NotesDetails"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/LongtermDebt2024NotesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_ee4ab335-2c52-445f-a016-6bda6a040797" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_045175b8-0c15-4d0d-a83a-ff420c8539eb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_ee4ab335-2c52-445f-a016-6bda6a040797" xlink:to="loc_us-gaap_DebtInstrumentTable_045175b8-0c15-4d0d-a83a-ff420c8539eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_955b2fe7-5fb5-4f25-9f34-014bbeb57fa6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_045175b8-0c15-4d0d-a83a-ff420c8539eb" xlink:to="loc_us-gaap_DebtInstrumentAxis_955b2fe7-5fb5-4f25-9f34-014bbeb57fa6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_56560b44-3d64-4952-ae96-60e745909309" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_955b2fe7-5fb5-4f25-9f34-014bbeb57fa6" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_56560b44-3d64-4952-ae96-60e745909309" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_SeniorConvertibleNotesDue2024Member_abe90cb2-ec01-4ab0-9a8b-337def6d0c32" xlink:href="evh-20211231.xsd#evh_SeniorConvertibleNotesDue2024Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_56560b44-3d64-4952-ae96-60e745909309" xlink:to="loc_evh_SeniorConvertibleNotesDue2024Member_abe90cb2-ec01-4ab0-9a8b-337def6d0c32" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_ConvertibleSeniorNotesdue2021Member_61e51f71-d20f-4728-bb67-7c63913ab381" xlink:href="evh-20211231.xsd#evh_ConvertibleSeniorNotesdue2021Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_56560b44-3d64-4952-ae96-60e745909309" xlink:to="loc_evh_ConvertibleSeniorNotesdue2021Member_61e51f71-d20f-4728-bb67-7c63913ab381" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_NewNotesMember_6127f44d-8e9b-4a1c-9c0a-a2ec85a46388" xlink:href="evh-20211231.xsd#evh_NewNotesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_56560b44-3d64-4952-ae96-60e745909309" xlink:to="loc_evh_NewNotesMember_6127f44d-8e9b-4a1c-9c0a-a2ec85a46388" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_a0de710c-3a48-43aa-8b08-3a0150fcb2fc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_045175b8-0c15-4d0d-a83a-ff420c8539eb" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_a0de710c-3a48-43aa-8b08-3a0150fcb2fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_ec8e56e3-fd02-47c2-a2ee-90ee1c874055" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_a0de710c-3a48-43aa-8b08-3a0150fcb2fc" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_ec8e56e3-fd02-47c2-a2ee-90ee1c874055" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorNotesMember_5c15672e-6d5e-4261-9ebb-abd4ca87dacc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeniorNotesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_ec8e56e3-fd02-47c2-a2ee-90ee1c874055" xlink:to="loc_us-gaap_SeniorNotesMember_5c15672e-6d5e-4261-9ebb-abd4ca87dacc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_f46e373d-b426-45eb-841a-cb7ad45f32bf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_045175b8-0c15-4d0d-a83a-ff420c8539eb" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_f46e373d-b426-45eb-841a-cb7ad45f32bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_bddd8e9e-b3cd-489c-9717-297a7d544997" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_f46e373d-b426-45eb-841a-cb7ad45f32bf" xlink:to="loc_us-gaap_EquityComponentDomain_bddd8e9e-b3cd-489c-9717-297a7d544997" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_6a5e65a8-642d-40e8-94ef-e4d518489756" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_bddd8e9e-b3cd-489c-9717-297a7d544997" xlink:to="loc_us-gaap_CommonStockMember_6a5e65a8-642d-40e8-94ef-e4d518489756" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_0b3194b4-dd74-4ba6-9be3-9095bde29009" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_045175b8-0c15-4d0d-a83a-ff420c8539eb" xlink:to="loc_us-gaap_DebtInstrumentLineItems_0b3194b4-dd74-4ba6-9be3-9095bde29009" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_8ef63b70-ddfc-465d-a272-57b07f6dd763" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0b3194b4-dd74-4ba6-9be3-9095bde29009" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_8ef63b70-ddfc-465d-a272-57b07f6dd763" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_fb8876a4-f09d-4f7e-bb7b-dc754ea13fee" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0b3194b4-dd74-4ba6-9be3-9095bde29009" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_fb8876a4-f09d-4f7e-bb7b-dc754ea13fee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtConversionConvertedInstrumentAmount1_04209380-cca0-493e-932c-76adee248066" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentAmount1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0b3194b4-dd74-4ba6-9be3-9095bde29009" xlink:to="loc_us-gaap_DebtConversionConvertedInstrumentAmount1_04209380-cca0-493e-932c-76adee248066" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtConversionOriginalDebtAmount1_6df3191f-1d2f-41ab-8a09-44ea9fe218f2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtConversionOriginalDebtAmount1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0b3194b4-dd74-4ba6-9be3-9095bde29009" xlink:to="loc_us-gaap_DebtConversionOriginalDebtAmount1_6df3191f-1d2f-41ab-8a09-44ea9fe218f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDebtIssuanceCosts_982b5e7f-7474-4c5e-8730-e87ea8b85a69" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsOfDebtIssuanceCosts"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0b3194b4-dd74-4ba6-9be3-9095bde29009" xlink:to="loc_us-gaap_PaymentsOfDebtIssuanceCosts_982b5e7f-7474-4c5e-8730-e87ea8b85a69" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsNet_221a1bad-1fbb-4353-a45e-ae2c6fe3b0a6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredFinanceCostsNet"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0b3194b4-dd74-4ba6-9be3-9095bde29009" xlink:to="loc_us-gaap_DeferredFinanceCostsNet_221a1bad-1fbb-4353-a45e-ae2c6fe3b0a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseDebt_a2d872d4-06ea-4e35-a22a-9e13db71da43" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpenseDebt"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0b3194b4-dd74-4ba6-9be3-9095bde29009" xlink:to="loc_us-gaap_InterestExpenseDebt_a2d872d4-06ea-4e35-a22a-9e13db71da43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionRatio1_51e6d02b-8e38-4afb-acce-a86ab21da284" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionRatio1"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0b3194b4-dd74-4ba6-9be3-9095bde29009" xlink:to="loc_us-gaap_DebtInstrumentConvertibleConversionRatio1_51e6d02b-8e38-4afb-acce-a86ab21da284" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_8c9526ad-2b88-4f9e-8845-8aacd9097dda" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0b3194b4-dd74-4ba6-9be3-9095bde29009" xlink:to="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_8c9526ad-2b88-4f9e-8845-8aacd9097dda" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleNumberOfEquityInstruments_8d251654-bdc2-4936-b0bf-838ed95cba86" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentConvertibleNumberOfEquityInstruments"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0b3194b4-dd74-4ba6-9be3-9095bde29009" xlink:to="loc_us-gaap_DebtInstrumentConvertibleNumberOfEquityInstruments_8d251654-bdc2-4936-b0bf-838ed95cba86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_64ef08a5-cbee-4cc9-a08e-31bcbfe18ed4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebt"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0b3194b4-dd74-4ba6-9be3-9095bde29009" xlink:to="loc_us-gaap_LongTermDebt_64ef08a5-cbee-4cc9-a08e-31bcbfe18ed4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfDebt_87d0d574-6a1b-4b3e-a296-12afef8e0330" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfDebt"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0b3194b4-dd74-4ba6-9be3-9095bde29009" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfDebt_87d0d574-6a1b-4b3e-a296-12afef8e0330" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_DebtIssuanceCostsNetDebtComponent_63c8c188-8df5-4b22-aecc-c6ebd064b639" xlink:href="evh-20211231.xsd#evh_DebtIssuanceCostsNetDebtComponent"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0b3194b4-dd74-4ba6-9be3-9095bde29009" xlink:to="loc_evh_DebtIssuanceCostsNetDebtComponent_63c8c188-8df5-4b22-aecc-c6ebd064b639" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_AmortizationOfDebtDiscountAndDebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction_f8f1f722-c907-4957-b685-b78cdee94da7" xlink:href="evh-20211231.xsd#evh_AmortizationOfDebtDiscountAndDebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0b3194b4-dd74-4ba6-9be3-9095bde29009" xlink:to="loc_evh_AmortizationOfDebtDiscountAndDebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction_f8f1f722-c907-4957-b685-b78cdee94da7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_DebtInstrumentRepurchasePriceDueToFundamentalChangeAsPercentageOfPrincipalAmount_284e77cd-de85-4c8b-ad51-3a7568b2b05f" xlink:href="evh-20211231.xsd#evh_DebtInstrumentRepurchasePriceDueToFundamentalChangeAsPercentageOfPrincipalAmount"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0b3194b4-dd74-4ba6-9be3-9095bde29009" xlink:to="loc_evh_DebtInstrumentRepurchasePriceDueToFundamentalChangeAsPercentageOfPrincipalAmount_284e77cd-de85-4c8b-ad51-3a7568b2b05f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_DebtInstrumentRepurchaseCovenantSalePriceAsAPercentageOfConversionPrice_86db0ba3-2cca-48f3-af03-28f684c550bb" xlink:href="evh-20211231.xsd#evh_DebtInstrumentRepurchaseCovenantSalePriceAsAPercentageOfConversionPrice"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0b3194b4-dd74-4ba6-9be3-9095bde29009" xlink:to="loc_evh_DebtInstrumentRepurchaseCovenantSalePriceAsAPercentageOfConversionPrice_86db0ba3-2cca-48f3-af03-28f684c550bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_DebtInstrumentRepurchaseCovenantTradingDaysMinimum_25558af8-4f25-4b76-9022-69e5fd31345c" xlink:href="evh-20211231.xsd#evh_DebtInstrumentRepurchaseCovenantTradingDaysMinimum"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0b3194b4-dd74-4ba6-9be3-9095bde29009" xlink:to="loc_evh_DebtInstrumentRepurchaseCovenantTradingDaysMinimum_25558af8-4f25-4b76-9022-69e5fd31345c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_DebtInstrumentRepurchaseCovenantConsecutiveTradingDaysMinimum_6691de2e-e496-46b8-9937-04ce8eedffd1" xlink:href="evh-20211231.xsd#evh_DebtInstrumentRepurchaseCovenantConsecutiveTradingDaysMinimum"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0b3194b4-dd74-4ba6-9be3-9095bde29009" xlink:to="loc_evh_DebtInstrumentRepurchaseCovenantConsecutiveTradingDaysMinimum_6691de2e-e496-46b8-9937-04ce8eedffd1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_DebtInstrumentRepurchasePriceDueToChangeInSalePriceAsPercentageOfConversionPrice_bcbb7868-c029-48a4-868c-8b5a7bd287d5" xlink:href="evh-20211231.xsd#evh_DebtInstrumentRepurchasePriceDueToChangeInSalePriceAsPercentageOfConversionPrice"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0b3194b4-dd74-4ba6-9be3-9095bde29009" xlink:to="loc_evh_DebtInstrumentRepurchasePriceDueToChangeInSalePriceAsPercentageOfConversionPrice_bcbb7868-c029-48a4-868c-8b5a7bd287d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/LongtermDebtCreditAgreementDetails" xlink:type="simple" xlink:href="evh-20211231.xsd#LongtermDebtCreditAgreementDetails"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/LongtermDebtCreditAgreementDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_d713e948-1ca0-4bbe-a255-27624e0b4383" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_fa880f01-83c1-4b6a-a762-c33d0ee66453" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_d713e948-1ca0-4bbe-a255-27624e0b4383" xlink:to="loc_us-gaap_DebtInstrumentTable_fa880f01-83c1-4b6a-a762-c33d0ee66453" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_f9d0ae49-0531-48e0-926a-e99f35140058" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_fa880f01-83c1-4b6a-a762-c33d0ee66453" xlink:to="loc_us-gaap_DebtInstrumentAxis_f9d0ae49-0531-48e0-926a-e99f35140058" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_e9e0b31d-0b35-4bf8-ba74-ccbd5891e310" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_f9d0ae49-0531-48e0-926a-e99f35140058" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_e9e0b31d-0b35-4bf8-ba74-ccbd5891e310" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_InitialTermLoanFacilityMember_1678617f-8d00-431f-a241-8b4ed0aa5492" xlink:href="evh-20211231.xsd#evh_InitialTermLoanFacilityMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_e9e0b31d-0b35-4bf8-ba74-ccbd5891e310" xlink:to="loc_evh_InitialTermLoanFacilityMember_1678617f-8d00-431f-a241-8b4ed0aa5492" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_CreditAgreementMember_5860c357-106e-493c-af6c-041c55372ba3" xlink:href="evh-20211231.xsd#evh_CreditAgreementMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_e9e0b31d-0b35-4bf8-ba74-ccbd5891e310" xlink:to="loc_evh_CreditAgreementMember_5860c357-106e-493c-af6c-041c55372ba3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_ConvertibleSeniorNotesdue2021Member_559743aa-f5d3-4bd2-a9d5-4032f7139ff3" xlink:href="evh-20211231.xsd#evh_ConvertibleSeniorNotesdue2021Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_e9e0b31d-0b35-4bf8-ba74-ccbd5891e310" xlink:to="loc_evh_ConvertibleSeniorNotesdue2021Member_559743aa-f5d3-4bd2-a9d5-4032f7139ff3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_SeniorCreditFacilitiesMember_14d0a064-c5bb-4f9a-9e9f-df4c93182bbd" xlink:href="evh-20211231.xsd#evh_SeniorCreditFacilitiesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_e9e0b31d-0b35-4bf8-ba74-ccbd5891e310" xlink:to="loc_evh_SeniorCreditFacilitiesMember_14d0a064-c5bb-4f9a-9e9f-df4c93182bbd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_ace48b64-49d1-4e98-ae04-22a8fb041c19" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_fa880f01-83c1-4b6a-a762-c33d0ee66453" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_ace48b64-49d1-4e98-ae04-22a8fb041c19" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_df8efab8-a826-492a-8c09-eb91286f49a8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_ace48b64-49d1-4e98-ae04-22a8fb041c19" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_df8efab8-a826-492a-8c09-eb91286f49a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredDebtMember_598a9b4a-9cc2-414e-bc24-e61c8827ff50" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SecuredDebtMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_df8efab8-a826-492a-8c09-eb91286f49a8" xlink:to="loc_us-gaap_SecuredDebtMember_598a9b4a-9cc2-414e-bc24-e61c8827ff50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditMember_bcb997a3-f4fc-4a35-99d4-cb0df28d4014" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_df8efab8-a826-492a-8c09-eb91286f49a8" xlink:to="loc_us-gaap_LineOfCreditMember_bcb997a3-f4fc-4a35-99d4-cb0df28d4014" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorNotesMember_a1a698a9-917a-4e46-a15b-35884224077e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeniorNotesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_df8efab8-a826-492a-8c09-eb91286f49a8" xlink:to="loc_us-gaap_SeniorNotesMember_a1a698a9-917a-4e46-a15b-35884224077e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_f598fff0-8e08-44c8-ae4a-82922488ed6b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_fa880f01-83c1-4b6a-a762-c33d0ee66453" xlink:to="loc_us-gaap_CreditFacilityAxis_f598fff0-8e08-44c8-ae4a-82922488ed6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_174951a8-dab5-48bd-a833-8fecbb59df27" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityAxis_f598fff0-8e08-44c8-ae4a-82922488ed6b" xlink:to="loc_us-gaap_CreditFacilityDomain_174951a8-dab5-48bd-a833-8fecbb59df27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_DelayedDrawTermLoanFacilityMember_41dbc1a0-c9bf-4abd-a062-3d2315338940" xlink:href="evh-20211231.xsd#evh_DelayedDrawTermLoanFacilityMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_174951a8-dab5-48bd-a833-8fecbb59df27" xlink:to="loc_evh_DelayedDrawTermLoanFacilityMember_41dbc1a0-c9bf-4abd-a062-3d2315338940" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateAxis_f895e6de-7120-4f76-b5f7-675dac516ef2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableRateAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_fa880f01-83c1-4b6a-a762-c33d0ee66453" xlink:to="loc_us-gaap_VariableRateAxis_f895e6de-7120-4f76-b5f7-675dac516ef2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_a408e525-4b34-4b61-9459-fbef3217f9ae" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableRateDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateAxis_f895e6de-7120-4f76-b5f7-675dac516ef2" xlink:to="loc_us-gaap_VariableRateDomain_a408e525-4b34-4b61-9459-fbef3217f9ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EurodollarMember_022d3a99-a132-42af-88bf-1aef2a25068e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EurodollarMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateDomain_a408e525-4b34-4b61-9459-fbef3217f9ae" xlink:to="loc_us-gaap_EurodollarMember_022d3a99-a132-42af-88bf-1aef2a25068e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BaseRateMember_0ed75b8a-2453-480d-a943-c64843b965de" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BaseRateMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateDomain_a408e525-4b34-4b61-9459-fbef3217f9ae" xlink:to="loc_us-gaap_BaseRateMember_0ed75b8a-2453-480d-a943-c64843b965de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_14ac3c20-5ca5-480b-bec3-0edd5bfb8462" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_fa880f01-83c1-4b6a-a762-c33d0ee66453" xlink:to="loc_srt_RangeAxis_14ac3c20-5ca5-480b-bec3-0edd5bfb8462" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_a2861d2d-902e-41d4-ae21-a3e0c7cf78b6" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_14ac3c20-5ca5-480b-bec3-0edd5bfb8462" xlink:to="loc_srt_RangeMember_a2861d2d-902e-41d4-ae21-a3e0c7cf78b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_61db4b8a-fa0a-4202-816e-995f27329928" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_a2861d2d-902e-41d4-ae21-a3e0c7cf78b6" xlink:to="loc_srt_MaximumMember_61db4b8a-fa0a-4202-816e-995f27329928" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis_e875acf4-f68f-4376-84bb-d8139007bc4c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_fa880f01-83c1-4b6a-a762-c33d0ee66453" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis_e875acf4-f68f-4376-84bb-d8139007bc4c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_d85b74a0-7d02-4b19-a66f-4ea7bd322593" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis_e875acf4-f68f-4376-84bb-d8139007bc4c" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_d85b74a0-7d02-4b19-a66f-4ea7bd322593" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodOneMember_80862fa0-bb1a-46ee-a52f-a62005d865d7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodOneMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_d85b74a0-7d02-4b19-a66f-4ea7bd322593" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodOneMember_80862fa0-bb1a-46ee-a52f-a62005d865d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodTwoMember_a5ff72b1-59d5-444d-a86a-571413998815" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodTwoMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_d85b74a0-7d02-4b19-a66f-4ea7bd322593" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodTwoMember_a5ff72b1-59d5-444d-a86a-571413998815" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodThreeMember_7b809d22-f1bf-4fd0-9b27-a560b21ed394" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodThreeMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_d85b74a0-7d02-4b19-a66f-4ea7bd322593" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodThreeMember_7b809d22-f1bf-4fd0-9b27-a560b21ed394" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_bb52ef14-b1c8-4e1f-8ff4-f9b2f3e3d9b1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_fa880f01-83c1-4b6a-a762-c33d0ee66453" xlink:to="loc_us-gaap_DebtInstrumentLineItems_bb52ef14-b1c8-4e1f-8ff4-f9b2f3e3d9b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_ea2d81bd-3da1-4f61-a223-adf76c8367fc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_bb52ef14-b1c8-4e1f-8ff4-f9b2f3e3d9b1" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_ea2d81bd-3da1-4f61-a223-adf76c8367fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_94f7c19c-8b86-45d7-8808-8baf77dbfb13" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_bb52ef14-b1c8-4e1f-8ff4-f9b2f3e3d9b1" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_94f7c19c-8b86-45d7-8808-8baf77dbfb13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_c73bef9f-488d-4003-aa6b-ed02cf0b7d73" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_bb52ef14-b1c8-4e1f-8ff4-f9b2f3e3d9b1" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_c73bef9f-488d-4003-aa6b-ed02cf0b7d73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTerm_62c49398-09e3-44d9-9e91-67fc1f95589e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTerm"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_bb52ef14-b1c8-4e1f-8ff4-f9b2f3e3d9b1" xlink:to="loc_us-gaap_DebtInstrumentTerm_62c49398-09e3-44d9-9e91-67fc1f95589e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_96907b4f-b591-4106-9361-071d1ca2e2d5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_bb52ef14-b1c8-4e1f-8ff4-f9b2f3e3d9b1" xlink:to="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_96907b4f-b591-4106-9361-071d1ca2e2d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityCommitmentFeePercentage_56650afc-8522-41bf-b4fe-7e794f4051b9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityCommitmentFeePercentage"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_bb52ef14-b1c8-4e1f-8ff4-f9b2f3e3d9b1" xlink:to="loc_us-gaap_LineOfCreditFacilityCommitmentFeePercentage_56650afc-8522-41bf-b4fe-7e794f4051b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_DebtInstrumentRedemptionCallProtectionPremiumPercentage_e20da87e-ac92-4f0f-94b1-42e432ed6927" xlink:href="evh-20211231.xsd#evh_DebtInstrumentRedemptionCallProtectionPremiumPercentage"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_bb52ef14-b1c8-4e1f-8ff4-f9b2f3e3d9b1" xlink:to="loc_evh_DebtInstrumentRedemptionCallProtectionPremiumPercentage_e20da87e-ac92-4f0f-94b1-42e432ed6927" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsNet_0040d591-0afb-47d0-a6dc-0457895900a3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredFinanceCostsNet"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_bb52ef14-b1c8-4e1f-8ff4-f9b2f3e3d9b1" xlink:to="loc_us-gaap_DeferredFinanceCostsNet_0040d591-0afb-47d0-a6dc-0457895900a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_AmortizationOfDebtDiscountAndDebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction_bcb8d7cd-3c26-42d3-8a5b-4c3daea1c595" xlink:href="evh-20211231.xsd#evh_AmortizationOfDebtDiscountAndDebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_bb52ef14-b1c8-4e1f-8ff4-f9b2f3e3d9b1" xlink:to="loc_evh_AmortizationOfDebtDiscountAndDebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction_bcb8d7cd-3c26-42d3-8a5b-4c3daea1c595" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermLinesOfCredit_60c3ba99-3e81-435e-adca-fae88ce32ee3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfLongTermLinesOfCredit"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_bb52ef14-b1c8-4e1f-8ff4-f9b2f3e3d9b1" xlink:to="loc_us-gaap_RepaymentsOfLongTermLinesOfCredit_60c3ba99-3e81-435e-adca-fae88ce32ee3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_PaymentsOfMakeWholePremium_3ecbc3cd-e6c5-4b3c-b5b3-8b6eb878ff5f" xlink:href="evh-20211231.xsd#evh_PaymentsOfMakeWholePremium"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_bb52ef14-b1c8-4e1f-8ff4-f9b2f3e3d9b1" xlink:to="loc_evh_PaymentsOfMakeWholePremium_3ecbc3cd-e6c5-4b3c-b5b3-8b6eb878ff5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidNet_90c9fc93-ddbd-4b64-a298-5951d4e71ff4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestPaidNet"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_bb52ef14-b1c8-4e1f-8ff4-f9b2f3e3d9b1" xlink:to="loc_us-gaap_InterestPaidNet_90c9fc93-ddbd-4b64-a298-5951d4e71ff4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_6fe10b3a-88e3-4672-aa84-a2bc14931767" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_bb52ef14-b1c8-4e1f-8ff4-f9b2f3e3d9b1" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_6fe10b3a-88e3-4672-aa84-a2bc14931767" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WriteOffOfDeferredDebtIssuanceCost_adec09b1-6752-4943-9f40-225d48e519f3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WriteOffOfDeferredDebtIssuanceCost"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_bb52ef14-b1c8-4e1f-8ff4-f9b2f3e3d9b1" xlink:to="loc_us-gaap_WriteOffOfDeferredDebtIssuanceCost_adec09b1-6752-4943-9f40-225d48e519f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LegalFees_f96bb04b-ba47-44a1-aaf3-04ff5629e77a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LegalFees"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_bb52ef14-b1c8-4e1f-8ff4-f9b2f3e3d9b1" xlink:to="loc_us-gaap_LegalFees_f96bb04b-ba47-44a1-aaf3-04ff5629e77a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/LongtermDebtWarrantAgreementDetails" xlink:type="simple" xlink:href="evh-20211231.xsd#LongtermDebtWarrantAgreementDetails"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/LongtermDebtWarrantAgreementDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_89ded901-b24b-4d6c-877e-6147a9f31419" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightTable_8ed83437-0af0-4413-b4bf-87b56ab1746e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_89ded901-b24b-4d6c-877e-6147a9f31419" xlink:to="loc_us-gaap_ClassOfWarrantOrRightTable_8ed83437-0af0-4413-b4bf-87b56ab1746e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_17a868e0-651b-4271-90d7-d13695d1b599" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_8ed83437-0af0-4413-b4bf-87b56ab1746e" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_17a868e0-651b-4271-90d7-d13695d1b599" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_4c35be7e-10e6-46c4-bf95-f4e456960ff9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_17a868e0-651b-4271-90d7-d13695d1b599" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_4c35be7e-10e6-46c4-bf95-f4e456960ff9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassAMember_66bf2d65-43f5-4adf-bb90-22986183a635" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonClassAMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_4c35be7e-10e6-46c4-bf95-f4e456960ff9" xlink:to="loc_us-gaap_CommonClassAMember_66bf2d65-43f5-4adf-bb90-22986183a635" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightLineItems_af0aa18d-34e1-43f0-9cee-3ae86407ffd0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_8ed83437-0af0-4413-b4bf-87b56ab1746e" xlink:to="loc_us-gaap_ClassOfWarrantOrRightLineItems_af0aa18d-34e1-43f0-9cee-3ae86407ffd0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightUnissued_f6484523-1120-4040-859b-91aaa11b6dd1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightUnissued"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_af0aa18d-34e1-43f0-9cee-3ae86407ffd0" xlink:to="loc_us-gaap_ClassOfWarrantOrRightUnissued_f6484523-1120-4040-859b-91aaa11b6dd1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_b481273b-a89a-44b2-9308-5cdd40fc065a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_af0aa18d-34e1-43f0-9cee-3ae86407ffd0" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_b481273b-a89a-44b2-9308-5cdd40fc065a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_ClassOfWarrantOrRightPeriodDuringWhichWarrantsOrRightsExercisableAfterMaturityOfCreditAgreement_67aaba20-7864-4777-82c8-e68ad0f673a0" xlink:href="evh-20211231.xsd#evh_ClassOfWarrantOrRightPeriodDuringWhichWarrantsOrRightsExercisableAfterMaturityOfCreditAgreement"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_af0aa18d-34e1-43f0-9cee-3ae86407ffd0" xlink:to="loc_evh_ClassOfWarrantOrRightPeriodDuringWhichWarrantsOrRightsExercisableAfterMaturityOfCreditAgreement_67aaba20-7864-4777-82c8-e68ad0f673a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfWarrants_404696fc-e8f9-4fcd-8710-9d9d7d404380" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsForRepurchaseOfWarrants"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_af0aa18d-34e1-43f0-9cee-3ae86407ffd0" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfWarrants_404696fc-e8f9-4fcd-8710-9d9d7d404380" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/LongtermDebt2025NotesDetails" xlink:type="simple" xlink:href="evh-20211231.xsd#LongtermDebt2025NotesDetails"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/LongtermDebt2025NotesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_5b470d38-cfa4-4800-aac5-56726a191fb2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_d9db8322-0f85-46f1-ae67-a71d2bb742a1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_5b470d38-cfa4-4800-aac5-56726a191fb2" xlink:to="loc_us-gaap_DebtInstrumentTable_d9db8322-0f85-46f1-ae67-a71d2bb742a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_a1c90c8a-11b4-41aa-9be6-edc3d38ac9bf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_d9db8322-0f85-46f1-ae67-a71d2bb742a1" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_a1c90c8a-11b4-41aa-9be6-edc3d38ac9bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_bd0de3b4-8fe4-4f20-9af6-af29443c7a29" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_a1c90c8a-11b4-41aa-9be6-edc3d38ac9bf" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_bd0de3b4-8fe4-4f20-9af6-af29443c7a29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorNotesMember_e7bebffc-66ae-4b6c-b651-f7c40b1bfc6b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeniorNotesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_bd0de3b4-8fe4-4f20-9af6-af29443c7a29" xlink:to="loc_us-gaap_SeniorNotesMember_e7bebffc-66ae-4b6c-b651-f7c40b1bfc6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_ae17554f-c9a6-40fd-a3e1-504ed76c989e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_d9db8322-0f85-46f1-ae67-a71d2bb742a1" xlink:to="loc_us-gaap_DebtInstrumentAxis_ae17554f-c9a6-40fd-a3e1-504ed76c989e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_32f07aa8-5817-4695-a5d5-4e3b7b7d8cd2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_ae17554f-c9a6-40fd-a3e1-504ed76c989e" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_32f07aa8-5817-4695-a5d5-4e3b7b7d8cd2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_SeniorConvertibleNotesDue2025Member_4213cb8c-db97-47a1-96cb-83f622f4e5ea" xlink:href="evh-20211231.xsd#evh_SeniorConvertibleNotesDue2025Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_32f07aa8-5817-4695-a5d5-4e3b7b7d8cd2" xlink:to="loc_evh_SeniorConvertibleNotesDue2025Member_4213cb8c-db97-47a1-96cb-83f622f4e5ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_cd727220-178c-4ef0-b3be-aa382d87914b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_d9db8322-0f85-46f1-ae67-a71d2bb742a1" xlink:to="loc_us-gaap_StatementClassOfStockAxis_cd727220-178c-4ef0-b3be-aa382d87914b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_f4054b8b-8de2-43ca-a3e4-d076f44faf8b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_cd727220-178c-4ef0-b3be-aa382d87914b" xlink:to="loc_us-gaap_ClassOfStockDomain_f4054b8b-8de2-43ca-a3e4-d076f44faf8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassAMember_2490c0bc-42bd-4539-96cd-3659de1cf83d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonClassAMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_f4054b8b-8de2-43ca-a3e4-d076f44faf8b" xlink:to="loc_us-gaap_CommonClassAMember_2490c0bc-42bd-4539-96cd-3659de1cf83d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_ed51377a-d784-4769-9b73-b3cdbe2769ba" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_d9db8322-0f85-46f1-ae67-a71d2bb742a1" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_ed51377a-d784-4769-9b73-b3cdbe2769ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_7e71a7d3-3d5c-4f13-a45f-11e294c8bbe5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_ed51377a-d784-4769-9b73-b3cdbe2769ba" xlink:to="loc_us-gaap_EquityComponentDomain_7e71a7d3-3d5c-4f13-a45f-11e294c8bbe5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_7332738d-acaf-4621-b31b-aff850f699cf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_7e71a7d3-3d5c-4f13-a45f-11e294c8bbe5" xlink:to="loc_us-gaap_CommonStockMember_7332738d-acaf-4621-b31b-aff850f699cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_27a0968f-e229-4a5c-a387-2e367fca02c9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_d9db8322-0f85-46f1-ae67-a71d2bb742a1" xlink:to="loc_us-gaap_DebtInstrumentLineItems_27a0968f-e229-4a5c-a387-2e367fca02c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_e69899e1-9bc6-4e5e-a8c4-bcd11e45dfe0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_27a0968f-e229-4a5c-a387-2e367fca02c9" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_e69899e1-9bc6-4e5e-a8c4-bcd11e45dfe0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_38e591cd-4e8f-4273-bbe1-82368eeab16e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_27a0968f-e229-4a5c-a387-2e367fca02c9" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_38e591cd-4e8f-4273-bbe1-82368eeab16e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfDebt_fb4bf5b2-add1-447a-ae8b-72ba69647bee" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfDebt"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_27a0968f-e229-4a5c-a387-2e367fca02c9" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfDebt_fb4bf5b2-add1-447a-ae8b-72ba69647bee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsNet_ce325219-0553-420b-885b-def914795ebd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredFinanceCostsNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_27a0968f-e229-4a5c-a387-2e367fca02c9" xlink:to="loc_us-gaap_DeferredFinanceCostsNet_ce325219-0553-420b-885b-def914795ebd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseDebt_842f559f-9a2c-4f2b-95ec-40e3ed003ae8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpenseDebt"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_27a0968f-e229-4a5c-a387-2e367fca02c9" xlink:to="loc_us-gaap_InterestExpenseDebt_842f559f-9a2c-4f2b-95ec-40e3ed003ae8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionRatio1_af4fd848-6d35-444b-bc98-d572d96bceea" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionRatio1"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_27a0968f-e229-4a5c-a387-2e367fca02c9" xlink:to="loc_us-gaap_DebtInstrumentConvertibleConversionRatio1_af4fd848-6d35-444b-bc98-d572d96bceea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_ba4d0eeb-8edf-4ed0-abdd-9d3c4ad52334" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_27a0968f-e229-4a5c-a387-2e367fca02c9" xlink:to="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_ba4d0eeb-8edf-4ed0-abdd-9d3c4ad52334" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleNumberOfEquityInstruments_2826370f-0814-4670-8f82-eb1ef9e717dd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentConvertibleNumberOfEquityInstruments"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_27a0968f-e229-4a5c-a387-2e367fca02c9" xlink:to="loc_us-gaap_DebtInstrumentConvertibleNumberOfEquityInstruments_2826370f-0814-4670-8f82-eb1ef9e717dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_1a6ad084-da98-4fae-a251-7d217181f016" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebt"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_27a0968f-e229-4a5c-a387-2e367fca02c9" xlink:to="loc_us-gaap_LongTermDebt_1a6ad084-da98-4fae-a251-7d217181f016" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_AmortizationOfDebtDiscountAndDebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction_94b129c3-72a0-4fbd-990c-a7cca7cb35a7" xlink:href="evh-20211231.xsd#evh_AmortizationOfDebtDiscountAndDebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_27a0968f-e229-4a5c-a387-2e367fca02c9" xlink:to="loc_evh_AmortizationOfDebtDiscountAndDebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction_94b129c3-72a0-4fbd-990c-a7cca7cb35a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_DebtInstrumentRepurchasePriceDueToFundamentalChangeAsPercentageOfPrincipalAmount_6675c2e7-2ad7-407e-b87b-4ac13f73c083" xlink:href="evh-20211231.xsd#evh_DebtInstrumentRepurchasePriceDueToFundamentalChangeAsPercentageOfPrincipalAmount"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_27a0968f-e229-4a5c-a387-2e367fca02c9" xlink:to="loc_evh_DebtInstrumentRepurchasePriceDueToFundamentalChangeAsPercentageOfPrincipalAmount_6675c2e7-2ad7-407e-b87b-4ac13f73c083" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_DebtInstrumentRepurchaseCovenantSalePriceAsAPercentageOfConversionPrice_a7467031-d8bc-4a7c-8cae-05352deaf852" xlink:href="evh-20211231.xsd#evh_DebtInstrumentRepurchaseCovenantSalePriceAsAPercentageOfConversionPrice"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_27a0968f-e229-4a5c-a387-2e367fca02c9" xlink:to="loc_evh_DebtInstrumentRepurchaseCovenantSalePriceAsAPercentageOfConversionPrice_a7467031-d8bc-4a7c-8cae-05352deaf852" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_DebtInstrumentRepurchaseCovenantTradingDaysMinimum_517f89ed-1877-4d14-819e-29e89c0755d5" xlink:href="evh-20211231.xsd#evh_DebtInstrumentRepurchaseCovenantTradingDaysMinimum"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_27a0968f-e229-4a5c-a387-2e367fca02c9" xlink:to="loc_evh_DebtInstrumentRepurchaseCovenantTradingDaysMinimum_517f89ed-1877-4d14-819e-29e89c0755d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_DebtInstrumentRepurchaseCovenantConsecutiveTradingDaysMinimum_4721af3a-3a68-4e67-8f64-3c9902078d2e" xlink:href="evh-20211231.xsd#evh_DebtInstrumentRepurchaseCovenantConsecutiveTradingDaysMinimum"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_27a0968f-e229-4a5c-a387-2e367fca02c9" xlink:to="loc_evh_DebtInstrumentRepurchaseCovenantConsecutiveTradingDaysMinimum_4721af3a-3a68-4e67-8f64-3c9902078d2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_DebtInstrumentRepurchasePriceDueToChangeInSalePriceAsPercentageOfConversionPrice_b4f402f2-93d3-4360-9b4e-641e57669bfd" xlink:href="evh-20211231.xsd#evh_DebtInstrumentRepurchasePriceDueToChangeInSalePriceAsPercentageOfConversionPrice"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_27a0968f-e229-4a5c-a387-2e367fca02c9" xlink:to="loc_evh_DebtInstrumentRepurchasePriceDueToChangeInSalePriceAsPercentageOfConversionPrice_b4f402f2-93d3-4360-9b4e-641e57669bfd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/LongtermDebt2021NotesDetails" xlink:type="simple" xlink:href="evh-20211231.xsd#LongtermDebt2021NotesDetails"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/LongtermDebt2021NotesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_f13b57fb-3d2b-4003-9454-327b2758d459" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_268474ec-3d62-49e2-99a5-be37a9d20bb4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_f13b57fb-3d2b-4003-9454-327b2758d459" xlink:to="loc_us-gaap_DebtInstrumentTable_268474ec-3d62-49e2-99a5-be37a9d20bb4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_cced74ec-d88e-477b-9613-bb398e6d3045" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_268474ec-3d62-49e2-99a5-be37a9d20bb4" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_cced74ec-d88e-477b-9613-bb398e6d3045" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_5ee3a14a-3833-47db-8325-f3b7e5e97946" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_cced74ec-d88e-477b-9613-bb398e6d3045" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_5ee3a14a-3833-47db-8325-f3b7e5e97946" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorNotesMember_e52b9e14-c178-4d04-802a-053a9da4a1ee" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeniorNotesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_5ee3a14a-3833-47db-8325-f3b7e5e97946" xlink:to="loc_us-gaap_SeniorNotesMember_e52b9e14-c178-4d04-802a-053a9da4a1ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_9d92212b-bb8c-40ef-838b-25db6c6ae0cb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_268474ec-3d62-49e2-99a5-be37a9d20bb4" xlink:to="loc_us-gaap_DebtInstrumentAxis_9d92212b-bb8c-40ef-838b-25db6c6ae0cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_84b8eab4-2a26-4fb1-89f3-3de05d1cea4e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_9d92212b-bb8c-40ef-838b-25db6c6ae0cb" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_84b8eab4-2a26-4fb1-89f3-3de05d1cea4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_ConvertibleSeniorNotesdue2021Member_96e505a0-4dc6-46d7-89e2-fb9c3e7456b3" xlink:href="evh-20211231.xsd#evh_ConvertibleSeniorNotesdue2021Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_84b8eab4-2a26-4fb1-89f3-3de05d1cea4e" xlink:to="loc_evh_ConvertibleSeniorNotesdue2021Member_96e505a0-4dc6-46d7-89e2-fb9c3e7456b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_SeniorConvertibleNotesDue2024Member_15b3ae9d-9c49-44bf-bf5b-70a08144e74c" xlink:href="evh-20211231.xsd#evh_SeniorConvertibleNotesDue2024Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_84b8eab4-2a26-4fb1-89f3-3de05d1cea4e" xlink:to="loc_evh_SeniorConvertibleNotesDue2024Member_15b3ae9d-9c49-44bf-bf5b-70a08144e74c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_58e17506-cd1f-4600-9ce7-590de2707ee6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_268474ec-3d62-49e2-99a5-be37a9d20bb4" xlink:to="loc_us-gaap_StatementClassOfStockAxis_58e17506-cd1f-4600-9ce7-590de2707ee6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_120f60c0-1976-4175-9467-d06787f605e3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_58e17506-cd1f-4600-9ce7-590de2707ee6" xlink:to="loc_us-gaap_ClassOfStockDomain_120f60c0-1976-4175-9467-d06787f605e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassAMember_6d8c4c4c-f323-4708-ac43-289719a3f325" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonClassAMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_120f60c0-1976-4175-9467-d06787f605e3" xlink:to="loc_us-gaap_CommonClassAMember_6d8c4c4c-f323-4708-ac43-289719a3f325" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_084ed833-b872-4ea7-9278-38ed6e6297b4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_268474ec-3d62-49e2-99a5-be37a9d20bb4" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_084ed833-b872-4ea7-9278-38ed6e6297b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_2eaab598-9405-494d-b4c6-18315c7fe313" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_084ed833-b872-4ea7-9278-38ed6e6297b4" xlink:to="loc_us-gaap_EquityComponentDomain_2eaab598-9405-494d-b4c6-18315c7fe313" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_b4dbf4b9-a07e-498b-ad69-a80515fd084f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_2eaab598-9405-494d-b4c6-18315c7fe313" xlink:to="loc_us-gaap_CommonStockMember_b4dbf4b9-a07e-498b-ad69-a80515fd084f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_15113ba3-34b9-43ca-a33a-ac92713c4a2c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_268474ec-3d62-49e2-99a5-be37a9d20bb4" xlink:to="loc_us-gaap_DebtInstrumentLineItems_15113ba3-34b9-43ca-a33a-ac92713c4a2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_38b801af-48a7-4f35-9b8e-3f154e83586f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_15113ba3-34b9-43ca-a33a-ac92713c4a2c" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_38b801af-48a7-4f35-9b8e-3f154e83586f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_212bd3fd-d93d-48fb-b562-2167552a577d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_15113ba3-34b9-43ca-a33a-ac92713c4a2c" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_212bd3fd-d93d-48fb-b562-2167552a577d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfDebt_4fe8afce-2f16-4fcf-8361-508695ee0414" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfDebt"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_15113ba3-34b9-43ca-a33a-ac92713c4a2c" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfDebt_4fe8afce-2f16-4fcf-8361-508695ee0414" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsNet_d73aaeb0-ec5a-467a-b557-ce1fdf5fdc30" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredFinanceCostsNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_15113ba3-34b9-43ca-a33a-ac92713c4a2c" xlink:to="loc_us-gaap_DeferredFinanceCostsNet_d73aaeb0-ec5a-467a-b557-ce1fdf5fdc30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_DebtInstrumentRepurchasePriceDueToFundamentalChangeAsPercentageOfPrincipalAmount_02eb0aac-3436-4593-9b07-724ce338f7da" xlink:href="evh-20211231.xsd#evh_DebtInstrumentRepurchasePriceDueToFundamentalChangeAsPercentageOfPrincipalAmount"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_15113ba3-34b9-43ca-a33a-ac92713c4a2c" xlink:to="loc_evh_DebtInstrumentRepurchasePriceDueToFundamentalChangeAsPercentageOfPrincipalAmount_02eb0aac-3436-4593-9b07-724ce338f7da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseDebt_b6b989e6-3a57-4531-9775-1811e4987f6b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpenseDebt"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_15113ba3-34b9-43ca-a33a-ac92713c4a2c" xlink:to="loc_us-gaap_InterestExpenseDebt_b6b989e6-3a57-4531-9775-1811e4987f6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCosts_e92d13b9-7fa6-4eb2-a796-dc6b80fe36ca" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfFinancingCosts"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_15113ba3-34b9-43ca-a33a-ac92713c4a2c" xlink:to="loc_us-gaap_AmortizationOfFinancingCosts_e92d13b9-7fa6-4eb2-a796-dc6b80fe36ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionRatio1_3d2718a7-5f04-4602-b648-b53db2c0831b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionRatio1"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_15113ba3-34b9-43ca-a33a-ac92713c4a2c" xlink:to="loc_us-gaap_DebtInstrumentConvertibleConversionRatio1_3d2718a7-5f04-4602-b648-b53db2c0831b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_89698d34-da0a-4461-9f0c-1cd8fb0bd95b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_15113ba3-34b9-43ca-a33a-ac92713c4a2c" xlink:to="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_89698d34-da0a-4461-9f0c-1cd8fb0bd95b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleNumberOfEquityInstruments_e0995269-738e-4495-a0e0-b728cef4a313" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentConvertibleNumberOfEquityInstruments"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_15113ba3-34b9-43ca-a33a-ac92713c4a2c" xlink:to="loc_us-gaap_DebtInstrumentConvertibleNumberOfEquityInstruments_e0995269-738e-4495-a0e0-b728cef4a313" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtConversionConvertedInstrumentAmount1_a7e627e5-31cf-480b-9fae-21fa35e88cd4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentAmount1"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_15113ba3-34b9-43ca-a33a-ac92713c4a2c" xlink:to="loc_us-gaap_DebtConversionConvertedInstrumentAmount1_a7e627e5-31cf-480b-9fae-21fa35e88cd4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtConversionOriginalDebtAmount1_85b8ae2b-8f4e-47f2-9677-240452b32c35" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtConversionOriginalDebtAmount1"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_15113ba3-34b9-43ca-a33a-ac92713c4a2c" xlink:to="loc_us-gaap_DebtConversionOriginalDebtAmount1_85b8ae2b-8f4e-47f2-9677-240452b32c35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDebtIssuanceCosts_b829edb1-63d8-4482-abef-2ee2f0414481" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsOfDebtIssuanceCosts"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_15113ba3-34b9-43ca-a33a-ac92713c4a2c" xlink:to="loc_us-gaap_PaymentsOfDebtIssuanceCosts_b829edb1-63d8-4482-abef-2ee2f0414481" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebtBeforeWriteOffOfDeferredDebtIssuanceCost_74306430-e6d5-445a-b249-936923c598cb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebtBeforeWriteOffOfDeferredDebtIssuanceCost"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_15113ba3-34b9-43ca-a33a-ac92713c4a2c" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebtBeforeWriteOffOfDeferredDebtIssuanceCost_74306430-e6d5-445a-b249-936923c598cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ExtinguishmentOfDebtAmount_0500a8f5-191f-4275-a970-4db7a48d5596" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ExtinguishmentOfDebtAmount"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_15113ba3-34b9-43ca-a33a-ac92713c4a2c" xlink:to="loc_us-gaap_ExtinguishmentOfDebtAmount_0500a8f5-191f-4275-a970-4db7a48d5596" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfSeniorDebt_51c5d4bc-9c7d-4644-b9e3-04fe7b03ddfd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfSeniorDebt"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_15113ba3-34b9-43ca-a33a-ac92713c4a2c" xlink:to="loc_us-gaap_RepaymentsOfSeniorDebt_51c5d4bc-9c7d-4644-b9e3-04fe7b03ddfd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_DebtConversionOriginalDebtFairValue_0bb68ca1-183d-43cc-82a7-c17246b3c494" xlink:href="evh-20211231.xsd#evh_DebtConversionOriginalDebtFairValue"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_15113ba3-34b9-43ca-a33a-ac92713c4a2c" xlink:to="loc_evh_DebtConversionOriginalDebtFairValue_0bb68ca1-183d-43cc-82a7-c17246b3c494" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/LongtermDebtConvertibleSeniorNotesCarryingValueDetails" xlink:type="simple" xlink:href="evh-20211231.xsd#LongtermDebtConvertibleSeniorNotesCarryingValueDetails"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/LongtermDebtConvertibleSeniorNotesCarryingValueDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_dfde2bcd-a595-403a-abf7-71c5b98e6e57" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_b831aeba-913b-416b-ad3a-f038589fa7c7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_dfde2bcd-a595-403a-abf7-71c5b98e6e57" xlink:to="loc_us-gaap_DebtInstrumentTable_b831aeba-913b-416b-ad3a-f038589fa7c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_e9ff6f97-f006-4471-a104-630aa3a8a462" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_b831aeba-913b-416b-ad3a-f038589fa7c7" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_e9ff6f97-f006-4471-a104-630aa3a8a462" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_f075eb6c-c92f-454e-946f-d64ccfe3aad3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_e9ff6f97-f006-4471-a104-630aa3a8a462" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_f075eb6c-c92f-454e-946f-d64ccfe3aad3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorNotesMember_409f3650-c062-4df3-8b30-11bd16e02a18" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeniorNotesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_f075eb6c-c92f-454e-946f-d64ccfe3aad3" xlink:to="loc_us-gaap_SeniorNotesMember_409f3650-c062-4df3-8b30-11bd16e02a18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_cd0726c7-ab83-4917-b393-1b6f7a8f7910" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_b831aeba-913b-416b-ad3a-f038589fa7c7" xlink:to="loc_us-gaap_DebtInstrumentAxis_cd0726c7-ab83-4917-b393-1b6f7a8f7910" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_bd7bc145-601d-4674-ae63-382221c6326d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_cd0726c7-ab83-4917-b393-1b6f7a8f7910" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_bd7bc145-601d-4674-ae63-382221c6326d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_SeniorConvertibleNotesDue2024Member_f5e53bc1-3ce1-443c-a0f3-1cdd88e85de1" xlink:href="evh-20211231.xsd#evh_SeniorConvertibleNotesDue2024Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_bd7bc145-601d-4674-ae63-382221c6326d" xlink:to="loc_evh_SeniorConvertibleNotesDue2024Member_f5e53bc1-3ce1-443c-a0f3-1cdd88e85de1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_SeniorConvertibleNotesDue2025Member_7b01b758-5749-4acd-9c10-afc9abae9c78" xlink:href="evh-20211231.xsd#evh_SeniorConvertibleNotesDue2025Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_bd7bc145-601d-4674-ae63-382221c6326d" xlink:to="loc_evh_SeniorConvertibleNotesDue2025Member_7b01b758-5749-4acd-9c10-afc9abae9c78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_ConvertibleSeniorNotesdue2021Member_8393c1cf-38b2-47b6-aed1-214a2340dd47" xlink:href="evh-20211231.xsd#evh_ConvertibleSeniorNotesdue2021Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_bd7bc145-601d-4674-ae63-382221c6326d" xlink:to="loc_evh_ConvertibleSeniorNotesdue2021Member_8393c1cf-38b2-47b6-aed1-214a2340dd47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_5d6dd495-6417-4cdd-a033-2de4cbbf1cb2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_b831aeba-913b-416b-ad3a-f038589fa7c7" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_5d6dd495-6417-4cdd-a033-2de4cbbf1cb2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_4ad3139c-a8d2-47a7-974d-97cf571a0bfe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_5d6dd495-6417-4cdd-a033-2de4cbbf1cb2" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_4ad3139c-a8d2-47a7-974d-97cf571a0bfe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_4695ee1b-14d2-44f4-b01d-80c26ef1a6ec" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_4ad3139c-a8d2-47a7-974d-97cf571a0bfe" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_4695ee1b-14d2-44f4-b01d-80c26ef1a6ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_2e62b8f5-bffd-421b-9495-c92e201d66eb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_b831aeba-913b-416b-ad3a-f038589fa7c7" xlink:to="loc_us-gaap_DebtInstrumentLineItems_2e62b8f5-bffd-421b-9495-c92e201d66eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebt_9341ee13-347b-4db6-a95f-154f4838801a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertibleDebt"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2e62b8f5-bffd-421b-9495-c92e201d66eb" xlink:to="loc_us-gaap_ConvertibleDebt_9341ee13-347b-4db6-a95f-154f4838801a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_a8d6235d-cab9-42c4-b449-0fbe54e1c7c2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2e62b8f5-bffd-421b-9495-c92e201d66eb" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_a8d6235d-cab9-42c4-b449-0fbe54e1c7c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_60a627cd-846c-437c-8197-19ce30dd6c4a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2e62b8f5-bffd-421b-9495-c92e201d66eb" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_60a627cd-846c-437c-8197-19ce30dd6c4a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1_1336b953-76c5-4506-9beb-21e9b2bfe20a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2e62b8f5-bffd-421b-9495-c92e201d66eb" xlink:to="loc_us-gaap_DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1_1336b953-76c5-4506-9beb-21e9b2bfe20a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtFairValue_c41fec3e-c464-43c4-8644-ede680b13bff" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtFairValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2e62b8f5-bffd-421b-9495-c92e201d66eb" xlink:to="loc_us-gaap_LongTermDebtFairValue_c41fec3e-c464-43c4-8644-ede680b13bff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/CommitmentsandContingencies" xlink:type="simple" xlink:href="evh-20211231.xsd#CommitmentsandContingencies"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/CommitmentsandContingencies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_3732354c-5c2a-4247-89ba-d8f18afe0308" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_f0070589-7143-4662-8e01-1a2f08ec86a1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_3732354c-5c2a-4247-89ba-d8f18afe0308" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_f0070589-7143-4662-8e01-1a2f08ec86a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/CommitmentsandContingenciesTables" xlink:type="simple" xlink:href="evh-20211231.xsd#CommitmentsandContingenciesTables"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/CommitmentsandContingenciesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_92745ce0-4956-4fcb-a940-e998d5992e70" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectsOfReinsuranceTableTextBlock_7a5f99b2-80a7-431f-a758-f99624b4616f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectsOfReinsuranceTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_92745ce0-4956-4fcb-a940-e998d5992e70" xlink:to="loc_us-gaap_EffectsOfReinsuranceTableTextBlock_7a5f99b2-80a7-431f-a758-f99624b4616f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_38882783-1027-4fe9-abc8-81b92bb5f26f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_92745ce0-4956-4fcb-a940-e998d5992e70" xlink:to="loc_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_38882783-1027-4fe9-abc8-81b92bb5f26f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/CommitmentsandContingenciesAdditionalInformationDetails" xlink:type="simple" xlink:href="evh-20211231.xsd#CommitmentsandContingenciesAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/CommitmentsandContingenciesAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_ec3d17b6-2e7c-4427-9f05-761326a8cff2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable_a2e93619-7c1c-4834-9ef2-c0885105611a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_ec3d17b6-2e7c-4427-9f05-761326a8cff2" xlink:to="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable_a2e93619-7c1c-4834-9ef2-c0885105611a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_b7c5aaa4-5f63-4460-9d0a-d8f4709b8565" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable_a2e93619-7c1c-4834-9ef2-c0885105611a" xlink:to="loc_us-gaap_CreditFacilityAxis_b7c5aaa4-5f63-4460-9d0a-d8f4709b8565" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_10e2ba5c-8c92-435c-b3aa-42037a11b737" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityAxis_b7c5aaa4-5f63-4460-9d0a-d8f4709b8565" xlink:to="loc_us-gaap_CreditFacilityDomain_10e2ba5c-8c92-435c-b3aa-42037a11b737" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LetterOfCreditMember_45b79623-6cbe-43b6-aafc-55711feca3ce" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LetterOfCreditMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_10e2ba5c-8c92-435c-b3aa-42037a11b737" xlink:to="loc_us-gaap_LetterOfCreditMember_45b79623-6cbe-43b6-aafc-55711feca3ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_f97e071d-050d-4c90-b083-bae092c50056" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable_a2e93619-7c1c-4834-9ef2-c0885105611a" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_f97e071d-050d-4c90-b083-bae092c50056" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_423cc032-96b9-4807-8b72-f11c5c7604a9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_f97e071d-050d-4c90-b083-bae092c50056" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_423cc032-96b9-4807-8b72-f11c5c7604a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditMember_8e57368c-d7a8-47ba-87ce-a67c80d68820" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_423cc032-96b9-4807-8b72-f11c5c7604a9" xlink:to="loc_us-gaap_LineOfCreditMember_8e57368c-d7a8-47ba-87ce-a67c80d68820" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_a542f107-bddd-421a-844e-8b384e5c2162" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable_a2e93619-7c1c-4834-9ef2-c0885105611a" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_a542f107-bddd-421a-844e-8b384e5c2162" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_363a3c30-6d77-43e9-9eba-e8af4627e27a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_a542f107-bddd-421a-844e-8b384e5c2162" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_363a3c30-6d77-43e9-9eba-e8af4627e27a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_RestrictedCashForLettersOfCreditForLetterOfCreditFacilityMember_60d7ceeb-c6b1-4e91-88e1-beae9e7cbe9c" xlink:href="evh-20211231.xsd#evh_RestrictedCashForLettersOfCreditForLetterOfCreditFacilityMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_363a3c30-6d77-43e9-9eba-e8af4627e27a" xlink:to="loc_evh_RestrictedCashForLettersOfCreditForLetterOfCreditFacilityMember_60d7ceeb-c6b1-4e91-88e1-beae9e7cbe9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_CollateralwithFinancialInstitutionsMember_27359c1b-f29f-4fd0-8e98-e9783bdc8a48" xlink:href="evh-20211231.xsd#evh_CollateralwithFinancialInstitutionsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_363a3c30-6d77-43e9-9eba-e8af4627e27a" xlink:to="loc_evh_CollateralwithFinancialInstitutionsMember_27359c1b-f29f-4fd0-8e98-e9783bdc8a48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_8fccaaee-69d1-40c0-b5d5-34f8f5e949ac" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable_a2e93619-7c1c-4834-9ef2-c0885105611a" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_8fccaaee-69d1-40c0-b5d5-34f8f5e949ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_a6c08f8a-a76c-4dfc-acd6-b4e74b4dc12e" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_8fccaaee-69d1-40c0-b5d5-34f8f5e949ac" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_a6c08f8a-a76c-4dfc-acd6-b4e74b4dc12e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_UniversityHealthCaredbaPassportHealthPlanMember_afcd8f0b-52a4-4f0e-9e3b-fc09922e0e1d" xlink:href="evh-20211231.xsd#evh_UniversityHealthCaredbaPassportHealthPlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_a6c08f8a-a76c-4dfc-acd6-b4e74b4dc12e" xlink:to="loc_evh_UniversityHealthCaredbaPassportHealthPlanMember_afcd8f0b-52a4-4f0e-9e3b-fc09922e0e1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesAxis_341d9acb-c307-4f72-a467-c260c8094552" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ConsolidatedEntitiesAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable_a2e93619-7c1c-4834-9ef2-c0885105611a" xlink:to="loc_srt_ConsolidatedEntitiesAxis_341d9acb-c307-4f72-a467-c260c8094552" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesDomain_919080ed-9cc8-42a1-a505-a8a99ee03a88" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ConsolidatedEntitiesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidatedEntitiesAxis_341d9acb-c307-4f72-a467-c260c8094552" xlink:to="loc_srt_ConsolidatedEntitiesDomain_919080ed-9cc8-42a1-a505-a8a99ee03a88" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableInterestEntityNotPrimaryBeneficiaryMember_ec3b0e7e-b67f-4447-b5c1-27c73b8678c4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableInterestEntityNotPrimaryBeneficiaryMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidatedEntitiesDomain_919080ed-9cc8-42a1-a505-a8a99ee03a88" xlink:to="loc_us-gaap_VariableInterestEntityNotPrimaryBeneficiaryMember_ec3b0e7e-b67f-4447-b5c1-27c73b8678c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems_fb09cd7d-9338-4f0e-b049-d3a37de0a3d9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable_a2e93619-7c1c-4834-9ef2-c0885105611a" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems_fb09cd7d-9338-4f0e-b049-d3a37de0a3d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_23573c30-3a38-4a2b-acb9-5df6b3f3e7d5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems_fb09cd7d-9338-4f0e-b049-d3a37de0a3d9" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_23573c30-3a38-4a2b-acb9-5df6b3f3e7d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalents_c52f806c-b689-4d32-954d-e87a46002922" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalents"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems_fb09cd7d-9338-4f0e-b049-d3a37de0a3d9" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalents_c52f806c-b689-4d32-954d-e87a46002922" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_TaxReceivablesAgreementPercentofTaxSavingstobePaid_80f740f7-8ece-44ea-9ab3-55f89b43f9ad" xlink:href="evh-20211231.xsd#evh_TaxReceivablesAgreementPercentofTaxSavingstobePaid"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems_fb09cd7d-9338-4f0e-b049-d3a37de0a3d9" xlink:to="loc_evh_TaxReceivablesAgreementPercentofTaxSavingstobePaid_80f740f7-8ece-44ea-9ab3-55f89b43f9ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/CommitmentsandContingenciesReinsuranceAgreementsDetails" xlink:type="simple" xlink:href="evh-20211231.xsd#CommitmentsandContingenciesReinsuranceAgreementsDetails"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/CommitmentsandContingenciesReinsuranceAgreementsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_58cf5167-0976-4e46-b060-aadd895a0922" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssumedPremiumsWritten_131e2995-c466-4734-ac7a-7c0b0fd64474" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssumedPremiumsWritten"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_58cf5167-0976-4e46-b060-aadd895a0922" xlink:to="loc_us-gaap_AssumedPremiumsWritten_131e2995-c466-4734-ac7a-7c0b0fd64474" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CededPremiumsWritten_b0137f49-feda-44b5-b1cd-89c0d8775b45" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CededPremiumsWritten"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_58cf5167-0976-4e46-b060-aadd895a0922" xlink:to="loc_us-gaap_CededPremiumsWritten_b0137f49-feda-44b5-b1cd-89c0d8775b45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReinsuranceEffectOnClaimsAndBenefitsIncurredAmountAssumed_ea59625c-7357-4429-9248-6187b04739c4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReinsuranceEffectOnClaimsAndBenefitsIncurredAmountAssumed"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_58cf5167-0976-4e46-b060-aadd895a0922" xlink:to="loc_us-gaap_ReinsuranceEffectOnClaimsAndBenefitsIncurredAmountAssumed_ea59625c-7357-4429-9248-6187b04739c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReinsuranceEffectOnClaimsAndBenefitsIncurredAmountCeded_0f341af1-68ed-4ce7-a890-043ae139afe6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReinsuranceEffectOnClaimsAndBenefitsIncurredAmountCeded"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_58cf5167-0976-4e46-b060-aadd895a0922" xlink:to="loc_us-gaap_ReinsuranceEffectOnClaimsAndBenefitsIncurredAmountCeded_0f341af1-68ed-4ce7-a890-043ae139afe6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_PolicyholderBenefitsAndClaimsIncurredAssumedExpensesRelatedToClaims_8a109358-ae12-4ec7-b5a2-2dd75e939a89" xlink:href="evh-20211231.xsd#evh_PolicyholderBenefitsAndClaimsIncurredAssumedExpensesRelatedToClaims"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_58cf5167-0976-4e46-b060-aadd895a0922" xlink:to="loc_evh_PolicyholderBenefitsAndClaimsIncurredAssumedExpensesRelatedToClaims_8a109358-ae12-4ec7-b5a2-2dd75e939a89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_PremiumsWrittenAndPolicyholderBenefitsAndClaimsIncurredNet_f573e9fc-1a24-4cdc-8692-5f5ecc5608d0" xlink:href="evh-20211231.xsd#evh_PremiumsWrittenAndPolicyholderBenefitsAndClaimsIncurredNet"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_58cf5167-0976-4e46-b060-aadd895a0922" xlink:to="loc_evh_PremiumsWrittenAndPolicyholderBenefitsAndClaimsIncurredNet_f573e9fc-1a24-4cdc-8692-5f5ecc5608d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssumedLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense_b988e0c8-7794-4331-8c80-722ecc2f39d5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssumedLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_58cf5167-0976-4e46-b060-aadd895a0922" xlink:to="loc_us-gaap_AssumedLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense_b988e0c8-7794-4331-8c80-722ecc2f39d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_AssumedLiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseImpactOfConsolidationOnPayables_aceade2e-9867-460d-8322-e4f6b4c60f6d" xlink:href="evh-20211231.xsd#evh_AssumedLiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseImpactOfConsolidationOnPayables"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_58cf5167-0976-4e46-b060-aadd895a0922" xlink:to="loc_evh_AssumedLiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseImpactOfConsolidationOnPayables_aceade2e-9867-460d-8322-e4f6b4c60f6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForReinsurance_8564272b-4621-4d78-b1c9-2c72c635e0c0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsForReinsurance"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_58cf5167-0976-4e46-b060-aadd895a0922" xlink:to="loc_us-gaap_PaymentsForReinsurance_8564272b-4621-4d78-b1c9-2c72c635e0c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_ProceedsFromReinsurance_b106dce4-31bc-43f9-879e-b5f810e4ccc9" xlink:href="evh-20211231.xsd#evh_ProceedsFromReinsurance"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_58cf5167-0976-4e46-b060-aadd895a0922" xlink:to="loc_evh_ProceedsFromReinsurance_b106dce4-31bc-43f9-879e-b5f810e4ccc9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssumedLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense_ee2dcbf6-cc51-4a59-8d22-790fa6d27ab0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssumedLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_58cf5167-0976-4e46-b060-aadd895a0922" xlink:to="loc_us-gaap_AssumedLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense_ee2dcbf6-cc51-4a59-8d22-790fa6d27ab0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/CommitmentsandContingenciesConcentrationRiskDetails" xlink:type="simple" xlink:href="evh-20211231.xsd#CommitmentsandContingenciesConcentrationRiskDetails"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/CommitmentsandContingenciesConcentrationRiskDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_1e49e7b0-51af-474a-ad7c-5e624827287e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTable_25120b07-eb27-4610-a3d6-8954cbeb2bad" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_1e49e7b0-51af-474a-ad7c-5e624827287e" xlink:to="loc_us-gaap_ConcentrationRiskTable_25120b07-eb27-4610-a3d6-8954cbeb2bad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_988320e4-7e29-472a-891d-eaad4f1e5801" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MajorCustomersAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_25120b07-eb27-4610-a3d6-8954cbeb2bad" xlink:to="loc_srt_MajorCustomersAxis_988320e4-7e29-472a-891d-eaad4f1e5801" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_1be84e0c-15ab-4628-a1f0-e60807b283ac" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_MajorCustomersAxis_988320e4-7e29-472a-891d-eaad4f1e5801" xlink:to="loc_srt_NameOfMajorCustomerDomain_1be84e0c-15ab-4628-a1f0-e60807b283ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_CookCountyHealthAndHospitalsSystemMember_1dcaceaa-57b6-42dd-9416-9415d55a3f1e" xlink:href="evh-20211231.xsd#evh_CookCountyHealthAndHospitalsSystemMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_1be84e0c-15ab-4628-a1f0-e60807b283ac" xlink:to="loc_evh_CookCountyHealthAndHospitalsSystemMember_1dcaceaa-57b6-42dd-9416-9415d55a3f1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_FloridaBlueMedicareIncMember_2ac2f5a6-f264-4a02-a09e-bdf3945cda81" xlink:href="evh-20211231.xsd#evh_FloridaBlueMedicareIncMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_1be84e0c-15ab-4628-a1f0-e60807b283ac" xlink:to="loc_evh_FloridaBlueMedicareIncMember_2ac2f5a6-f264-4a02-a09e-bdf3945cda81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_NewMexicoHealthConnectionsMember_4acadcf3-a1b8-4e32-bdc6-c887e34ee6f7" xlink:href="evh-20211231.xsd#evh_NewMexicoHealthConnectionsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_1be84e0c-15ab-4628-a1f0-e60807b283ac" xlink:to="loc_evh_NewMexicoHealthConnectionsMember_4acadcf3-a1b8-4e32-bdc6-c887e34ee6f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_UniversityHealthCaredbaPassportHealthPlanMember_ec922c58-8304-4fa7-8de6-256b1830e021" xlink:href="evh-20211231.xsd#evh_UniversityHealthCaredbaPassportHealthPlanMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_1be84e0c-15ab-4628-a1f0-e60807b283ac" xlink:to="loc_evh_UniversityHealthCaredbaPassportHealthPlanMember_ec922c58-8304-4fa7-8de6-256b1830e021" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_MolinaHealthcareMember_114f3f23-6b15-4e08-917e-53e0d3b7f75d" xlink:href="evh-20211231.xsd#evh_MolinaHealthcareMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_1be84e0c-15ab-4628-a1f0-e60807b283ac" xlink:to="loc_evh_MolinaHealthcareMember_114f3f23-6b15-4e08-917e-53e0d3b7f75d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_6f33adc0-d31f-485d-9c15-22fbd3fb6044" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_25120b07-eb27-4610-a3d6-8954cbeb2bad" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_6f33adc0-d31f-485d-9c15-22fbd3fb6044" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_69320fa0-7b02-4030-97b6-637be1694756" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_6f33adc0-d31f-485d-9c15-22fbd3fb6044" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_69320fa0-7b02-4030-97b6-637be1694756" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember_c72d75ca-aae2-4b36-aea0-0336d99c31d6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_69320fa0-7b02-4030-97b6-637be1694756" xlink:to="loc_us-gaap_CustomerConcentrationRiskMember_c72d75ca-aae2-4b36-aea0-0336d99c31d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_06f7ce95-856b-4079-a42f-45b1f80241cd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_25120b07-eb27-4610-a3d6-8954cbeb2bad" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_06f7ce95-856b-4079-a42f-45b1f80241cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_8ced7610-44ac-4e35-8611-4168fe7660bd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_06f7ce95-856b-4079-a42f-45b1f80241cd" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_8ced7610-44ac-4e35-8611-4168fe7660bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableMember_9163f0e2-6c79-4027-ac18-0aca0dcef80e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_8ced7610-44ac-4e35-8611-4168fe7660bd" xlink:to="loc_us-gaap_AccountsReceivableMember_9163f0e2-6c79-4027-ac18-0aca0dcef80e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesRevenueNetMember_41c3f528-6c54-42a0-8610-2b8b8c95b4df" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SalesRevenueNetMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_8ced7610-44ac-4e35-8611-4168fe7660bd" xlink:to="loc_us-gaap_SalesRevenueNetMember_41c3f528-6c54-42a0-8610-2b8b8c95b4df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_1d86ab1f-e4d6-4506-8262-c3637207d85a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_25120b07-eb27-4610-a3d6-8954cbeb2bad" xlink:to="loc_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_1d86ab1f-e4d6-4506-8262-c3637207d85a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivableTypeDomain_94096a34-1fb0-4f63-bf78-a0d79ef7f973" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReceivableTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_1d86ab1f-e4d6-4506-8262-c3637207d85a" xlink:to="loc_us-gaap_ReceivableTypeDomain_94096a34-1fb0-4f63-bf78-a0d79ef7f973" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceReceivablesMember_c5bea3bb-b83c-4ccb-a64c-04f76d92018e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceReceivablesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReceivableTypeDomain_94096a34-1fb0-4f63-bf78-a0d79ef7f973" xlink:to="loc_us-gaap_FinanceReceivablesMember_c5bea3bb-b83c-4ccb-a64c-04f76d92018e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_eece6f59-bda6-4332-b3e7-4f6ea6ebd008" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_25120b07-eb27-4610-a3d6-8954cbeb2bad" xlink:to="loc_srt_ProductOrServiceAxis_eece6f59-bda6-4332-b3e7-4f6ea6ebd008" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_b9eb80e7-d187-4730-a89c-39f820001a00" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_eece6f59-bda6-4332-b3e7-4f6ea6ebd008" xlink:to="loc_srt_ProductsAndServicesDomain_b9eb80e7-d187-4730-a89c-39f820001a00" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_PremiumsRevenueMember_5a8ef2f0-1610-4655-9d11-658db0def151" xlink:href="evh-20211231.xsd#evh_PremiumsRevenueMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_b9eb80e7-d187-4730-a89c-39f820001a00" xlink:to="loc_evh_PremiumsRevenueMember_5a8ef2f0-1610-4655-9d11-658db0def151" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis_81b9049b-bfff-4f4c-8844-7c2d6104e177" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupClassificationAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_25120b07-eb27-4610-a3d6-8954cbeb2bad" xlink:to="loc_us-gaap_DisposalGroupClassificationAxis_81b9049b-bfff-4f4c-8844-7c2d6104e177" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_4ac0547c-d0b9-4a66-bc66-f0a73e1c4a91" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_81b9049b-bfff-4f4c-8844-7c2d6104e177" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_4ac0547c-d0b9-4a66-bc66-f0a73e1c4a91" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationsDisposedOfBySaleMember_b8e8e90c-ca5b-4749-b8e3-0d76fa4954a4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DiscontinuedOperationsDisposedOfBySaleMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain_4ac0547c-d0b9-4a66-bc66-f0a73e1c4a91" xlink:to="loc_us-gaap_DiscontinuedOperationsDisposedOfBySaleMember_b8e8e90c-ca5b-4749-b8e3-0d76fa4954a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_b4c2d8c4-c0ce-4ffc-b5a6-fc617f0cd80e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_25120b07-eb27-4610-a3d6-8954cbeb2bad" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_b4c2d8c4-c0ce-4ffc-b5a6-fc617f0cd80e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_5e52167c-0a81-41b5-b2eb-76986b8ac985" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_b4c2d8c4-c0ce-4ffc-b5a6-fc617f0cd80e" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_5e52167c-0a81-41b5-b2eb-76986b8ac985" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_TrueHealthMember_5fe3b31f-f150-4d00-9c76-018cb9910a79" xlink:href="evh-20211231.xsd#evh_TrueHealthMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_5e52167c-0a81-41b5-b2eb-76986b8ac985" xlink:to="loc_evh_TrueHealthMember_5fe3b31f-f150-4d00-9c76-018cb9910a79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskLineItems_b5a19660-a357-4631-bb9e-5497f9f4e384" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskLineItems"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_25120b07-eb27-4610-a3d6-8954cbeb2bad" xlink:to="loc_us-gaap_ConcentrationRiskLineItems_b5a19660-a357-4631-bb9e-5497f9f4e384" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_CashFDICInsuredAmountPercentage_1a1a6299-db6b-4b75-b72e-5a58dcea01e3" xlink:href="evh-20211231.xsd#evh_CashFDICInsuredAmountPercentage"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_b5a19660-a357-4631-bb9e-5497f9f4e384" xlink:to="loc_evh_CashFDICInsuredAmountPercentage_1a1a6299-db6b-4b75-b72e-5a58dcea01e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_f4152276-4fa5-458e-a527-cab3da9254da" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_b5a19660-a357-4631-bb9e-5497f9f4e384" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_f4152276-4fa5-458e-a527-cab3da9254da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_CashHeldInInternationalBanksPercentage_ae811785-dd7d-4632-92ef-031d0030ecb0" xlink:href="evh-20211231.xsd#evh_CashHeldInInternationalBanksPercentage"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_b5a19660-a357-4631-bb9e-5497f9f4e384" xlink:to="loc_evh_CashHeldInInternationalBanksPercentage_ae811785-dd7d-4632-92ef-031d0030ecb0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_1f31e41f-1860-47de-ad40-52b67010d809" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_b5a19660-a357-4631-bb9e-5497f9f4e384" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_1f31e41f-1860-47de-ad40-52b67010d809" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue_d75a5a25-2761-4a5c-925f-b817d6d6c205" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_b5a19660-a357-4631-bb9e-5497f9f4e384" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue_d75a5a25-2761-4a5c-925f-b817d6d6c205" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/Leases" xlink:type="simple" xlink:href="evh-20211231.xsd#Leases"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/Leases" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_9968ab39-2148-41cd-83e6-e6cba2e5ef2c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock_17457c93-1dba-41f4-a1f9-236ce3f97caa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_9968ab39-2148-41cd-83e6-e6cba2e5ef2c" xlink:to="loc_us-gaap_LesseeOperatingLeasesTextBlock_17457c93-1dba-41f4-a1f9-236ce3f97caa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/LeasesTables" xlink:type="simple" xlink:href="evh-20211231.xsd#LeasesTables"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/LeasesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_36f98312-258a-4f90-82ae-fd24650a3401" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_56579d75-773f-4f40-99e3-63021c84cf25" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_36f98312-258a-4f90-82ae-fd24650a3401" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_56579d75-773f-4f40-99e3-63021c84cf25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCostTableTextBlock_335c74b9-f977-4e0e-a371-c1d8fc4b658b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseCostTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_36f98312-258a-4f90-82ae-fd24650a3401" xlink:to="loc_us-gaap_LeaseCostTableTextBlock_335c74b9-f977-4e0e-a371-c1d8fc4b658b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/LeasesNarrativeDetails" xlink:type="simple" xlink:href="evh-20211231.xsd#LeasesNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/LeasesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_6703f30b-7592-47cd-bf82-1f4947815c98" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable_42270444-02d6-4e9a-ba20-097ceaed9189" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_6703f30b-7592-47cd-bf82-1f4947815c98" xlink:to="loc_us-gaap_LesseeLeaseDescriptionTable_42270444-02d6-4e9a-ba20-097ceaed9189" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsAxis_fb493f62-191a-4d3f-bcb2-106e060b2b38" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherCommitmentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_42270444-02d6-4e9a-ba20-097ceaed9189" xlink:to="loc_us-gaap_OtherCommitmentsAxis_fb493f62-191a-4d3f-bcb2-106e060b2b38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsDomain_fe4ab73f-005c-445a-82db-066ac6828cef" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherCommitmentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsAxis_fb493f62-191a-4d3f-bcb2-106e060b2b38" xlink:to="loc_us-gaap_OtherCommitmentsDomain_fe4ab73f-005c-445a-82db-066ac6828cef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseAgreementsMember_e9a41e3a-27ed-436a-854e-a3d54bba09cd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseAgreementsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsDomain_fe4ab73f-005c-445a-82db-066ac6828cef" xlink:to="loc_us-gaap_LeaseAgreementsMember_e9a41e3a-27ed-436a-854e-a3d54bba09cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems_dd28196f-f1f4-45c6-bddf-a4dc2da53d8d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_42270444-02d6-4e9a-ba20-097ceaed9189" xlink:to="loc_us-gaap_LesseeLeaseDescriptionLineItems_dd28196f-f1f4-45c6-bddf-a4dc2da53d8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LettersOfCreditOutstandingAmount_b4388a91-d804-4898-b8a9-eac2d903219d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LettersOfCreditOutstandingAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_dd28196f-f1f4-45c6-bddf-a4dc2da53d8d" xlink:to="loc_us-gaap_LettersOfCreditOutstandingAmount_b4388a91-d804-4898-b8a9-eac2d903219d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalents_44b211ae-deca-4b44-8df5-a41dea475304" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalents"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_dd28196f-f1f4-45c6-bddf-a4dc2da53d8d" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalents_44b211ae-deca-4b44-8df5-a41dea475304" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/LeasesPrimaryOfficeLeasesDetails" xlink:type="simple" xlink:href="evh-20211231.xsd#LeasesPrimaryOfficeLeasesDetails"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/LeasesPrimaryOfficeLeasesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_d7c481c7-5eb0-4106-b553-224a0ef74998" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable_e4ef4687-2dfb-4f51-ac3e-d38ae2f66dff" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_d7c481c7-5eb0-4106-b553-224a0ef74998" xlink:to="loc_us-gaap_LesseeLeaseDescriptionTable_e4ef4687-2dfb-4f51-ac3e-d38ae2f66dff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_51b76c30-9719-47ec-ae63-0edd174b5971" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_e4ef4687-2dfb-4f51-ac3e-d38ae2f66dff" xlink:to="loc_srt_StatementGeographicalAxis_51b76c30-9719-47ec-ae63-0edd174b5971" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_3b4e5c8d-2a30-4961-af81-76afbe07bce7" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_51b76c30-9719-47ec-ae63-0edd174b5971" xlink:to="loc_srt_SegmentGeographicalDomain_3b4e5c8d-2a30-4961-af81-76afbe07bce7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_VA_b07b43b8-88db-44b5-8af0-010af97fc77d" xlink:href="https://xbrl.sec.gov/stpr/2021/stpr-2021.xsd#stpr_VA"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_3b4e5c8d-2a30-4961-af81-76afbe07bce7" xlink:to="loc_stpr_VA_b07b43b8-88db-44b5-8af0-010af97fc77d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_IL_61f4c2b7-5972-4e1b-8322-c1fa8ba51072" xlink:href="https://xbrl.sec.gov/stpr/2021/stpr-2021.xsd#stpr_IL"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_3b4e5c8d-2a30-4961-af81-76afbe07bce7" xlink:to="loc_stpr_IL_61f4c2b7-5972-4e1b-8322-c1fa8ba51072" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_NJ_37019f68-09d4-4100-914c-07557aa1ca00" xlink:href="https://xbrl.sec.gov/stpr/2021/stpr-2021.xsd#stpr_NJ"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_3b4e5c8d-2a30-4961-af81-76afbe07bce7" xlink:to="loc_stpr_NJ_37019f68-09d4-4100-914c-07557aa1ca00" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_IN_71616b39-466d-41e0-9946-2dd5f9aaec3a" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_IN"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_3b4e5c8d-2a30-4961-af81-76afbe07bce7" xlink:to="loc_country_IN_71616b39-466d-41e0-9946-2dd5f9aaec3a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_CA_49789186-ea83-4e18-adb7-55f6122c0ef8" xlink:href="https://xbrl.sec.gov/stpr/2021/stpr-2021.xsd#stpr_CA"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_3b4e5c8d-2a30-4961-af81-76afbe07bce7" xlink:to="loc_stpr_CA_49789186-ea83-4e18-adb7-55f6122c0ef8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems_b42c4f17-cac3-4ce8-b24c-99ace281e308" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_e4ef4687-2dfb-4f51-ac3e-d38ae2f66dff" xlink:to="loc_us-gaap_LesseeLeaseDescriptionLineItems_b42c4f17-cac3-4ce8-b24c-99ace281e308" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract_e7b71ca8-bef8-4937-a50a-338c96dcfeb1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_b42c4f17-cac3-4ce8-b24c-99ace281e308" xlink:to="loc_us-gaap_LesseeOperatingLeaseTermOfContract_e7b71ca8-bef8-4937-a50a-338c96dcfeb1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_9fab6498-a397-45be-ad40-e6218227a93a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_b42c4f17-cac3-4ce8-b24c-99ace281e308" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_9fab6498-a397-45be-ad40-e6218227a93a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LettersOfCreditOutstandingAmount_79b99ab1-78e3-43a4-8827-a16c78039f76" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LettersOfCreditOutstandingAmount"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_b42c4f17-cac3-4ce8-b24c-99ace281e308" xlink:to="loc_us-gaap_LettersOfCreditOutstandingAmount_79b99ab1-78e3-43a4-8827-a16c78039f76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/LeasesComponentsofLeaseExpenseDetails" xlink:type="simple" xlink:href="evh-20211231.xsd#LeasesComponentsofLeaseExpenseDetails"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/LeasesComponentsofLeaseExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_94b8c9db-9454-4b5b-8918-e8b87d8ab0e6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost_0ed53657-f416-4ee7-94bb-47087f3ad380" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseCost"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_94b8c9db-9454-4b5b-8918-e8b87d8ab0e6" xlink:to="loc_us-gaap_OperatingLeaseCost_0ed53657-f416-4ee7-94bb-47087f3ad380" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAssetAmortization_68aaf57a-e277-4052-8784-213d694b11d1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseRightOfUseAssetAmortization"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_94b8c9db-9454-4b5b-8918-e8b87d8ab0e6" xlink:to="loc_us-gaap_FinanceLeaseRightOfUseAssetAmortization_68aaf57a-e277-4052-8784-213d694b11d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseInterestExpense_ebf80ead-1c67-42ea-a8fc-2660a400a690" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseInterestExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_94b8c9db-9454-4b5b-8918-e8b87d8ab0e6" xlink:to="loc_us-gaap_FinanceLeaseInterestExpense_ebf80ead-1c67-42ea-a8fc-2660a400a690" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableLeaseCost_9ea9c2bf-3332-4ab5-aadf-780c0004abc1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableLeaseCost"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_94b8c9db-9454-4b5b-8918-e8b87d8ab0e6" xlink:to="loc_us-gaap_VariableLeaseCost_9ea9c2bf-3332-4ab5-aadf-780c0004abc1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCost_e4e8f21b-9750-492e-92a4-b3e125692042" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseCost"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_94b8c9db-9454-4b5b-8918-e8b87d8ab0e6" xlink:to="loc_us-gaap_LeaseCost_e4e8f21b-9750-492e-92a4-b3e125692042" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/LeasesMaturityofLeaseLiabilitiesDetails" xlink:type="simple" xlink:href="evh-20211231.xsd#LeasesMaturityofLeaseLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/LeasesMaturityofLeaseLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_912df6c8-d0cd-44d9-881f-187856783ca0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_6656736f-c732-4c3d-bb7d-6bb35735a2ce" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_912df6c8-d0cd-44d9-881f-187856783ca0" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_6656736f-c732-4c3d-bb7d-6bb35735a2ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_a10d995f-ed3c-4a1b-bf8b-295581e702c0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_912df6c8-d0cd-44d9-881f-187856783ca0" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_a10d995f-ed3c-4a1b-bf8b-295581e702c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_eceeb8b8-3b43-4d5d-a31b-020a685032d7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_912df6c8-d0cd-44d9-881f-187856783ca0" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_eceeb8b8-3b43-4d5d-a31b-020a685032d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_05bd5e04-73ba-47d0-a1ff-40b0609c6fb4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_912df6c8-d0cd-44d9-881f-187856783ca0" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_05bd5e04-73ba-47d0-a1ff-40b0609c6fb4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_df84ad60-303b-49d1-8410-351b405080a6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_912df6c8-d0cd-44d9-881f-187856783ca0" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_df84ad60-303b-49d1-8410-351b405080a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_a72c2849-3c8b-4637-8147-e069fbc92d9a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_912df6c8-d0cd-44d9-881f-187856783ca0" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_a72c2849-3c8b-4637-8147-e069fbc92d9a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_82dde371-f291-415b-8620-f5a346b42738" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_912df6c8-d0cd-44d9-881f-187856783ca0" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_82dde371-f291-415b-8620-f5a346b42738" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilitiesGrossDifferenceAmountAbstract_f4c0b9dd-735f-4d05-a9a5-925e69136a86" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilitiesGrossDifferenceAmountAbstract"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_912df6c8-d0cd-44d9-881f-187856783ca0" xlink:to="loc_us-gaap_OperatingLeaseLiabilitiesGrossDifferenceAmountAbstract_f4c0b9dd-735f-4d05-a9a5-925e69136a86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_f0a4af16-01ae-4394-a7a2-65600a0036ce" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesGrossDifferenceAmountAbstract_f4c0b9dd-735f-4d05-a9a5-925e69136a86" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_f0a4af16-01ae-4394-a7a2-65600a0036ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_23e40d2c-c329-491f-abf2-24270d33c6b5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_912df6c8-d0cd-44d9-881f-187856783ca0" xlink:to="loc_us-gaap_OperatingLeaseLiability_23e40d2c-c329-491f-abf2-24270d33c6b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/LeasesMaturityofLeaseLiabilitiesDetails_1" xlink:type="simple" xlink:href="evh-20211231.xsd#LeasesMaturityofLeaseLiabilitiesDetails_1"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/LeasesMaturityofLeaseLiabilitiesDetails_1" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/LeasesWeightedaverageDiscountRateandWeightedremainingLeaseTermsDetails" xlink:type="simple" xlink:href="evh-20211231.xsd#LeasesWeightedaverageDiscountRateandWeightedremainingLeaseTermsDetails"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/LeasesWeightedaverageDiscountRateandWeightedremainingLeaseTermsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_4b32bae5-b840-40bc-988e-604d98ea3a9d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_48afe001-01f5-423a-bb3d-f194e5d91488" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_4b32bae5-b840-40bc-988e-604d98ea3a9d" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_48afe001-01f5-423a-bb3d-f194e5d91488" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_e09f592a-2053-4f9d-9b3b-219735697d25" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_4b32bae5-b840-40bc-988e-604d98ea3a9d" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_e09f592a-2053-4f9d-9b3b-219735697d25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/EarningsLossPerCommonShare" xlink:type="simple" xlink:href="evh-20211231.xsd#EarningsLossPerCommonShare"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/EarningsLossPerCommonShare" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_4b015c3c-5e5e-41d2-9379-adf13d1fee84" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_fe312ac1-c1f6-4b58-90ae-5909108d58ed" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_4b015c3c-5e5e-41d2-9379-adf13d1fee84" xlink:to="loc_us-gaap_EarningsPerShareTextBlock_fe312ac1-c1f6-4b58-90ae-5909108d58ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/EarningsLossPerCommonShareTables" xlink:type="simple" xlink:href="evh-20211231.xsd#EarningsLossPerCommonShareTables"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/EarningsLossPerCommonShareTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_8b981214-5459-4928-a6e2-9aecd9ca466c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_10873284-1ac0-46b7-bfb2-a36e62426ec4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_8b981214-5459-4928-a6e2-9aecd9ca466c" xlink:to="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_10873284-1ac0-46b7-bfb2-a36e62426ec4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_a72a3c67-1e1c-43eb-b031-97764f077041" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_8b981214-5459-4928-a6e2-9aecd9ca466c" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_a72a3c67-1e1c-43eb-b031-97764f077041" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/EarningsLossPerCommonShareComputationofEarningsperShareDetails" xlink:type="simple" xlink:href="evh-20211231.xsd#EarningsLossPerCommonShareComputationofEarningsperShareDetails"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/EarningsLossPerCommonShareComputationofEarningsperShareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_624d2347-74bf-44e2-81e5-8c0d583f35d7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_8f4fdc32-82e7-4fca-907b-691e93a3340e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_624d2347-74bf-44e2-81e5-8c0d583f35d7" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_8f4fdc32-82e7-4fca-907b-691e93a3340e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_28bf2ea2-f618-406d-84b9-624f8a14fd07" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_624d2347-74bf-44e2-81e5-8c0d583f35d7" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_28bf2ea2-f618-406d-84b9-624f8a14fd07" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_bf48a621-da38-4c87-bfcf-0365b4a786a0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_624d2347-74bf-44e2-81e5-8c0d583f35d7" xlink:to="loc_us-gaap_ProfitLoss_bf48a621-da38-4c87-bfcf-0365b4a786a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_EarningsLossAvailabletoCommonShareholdersAbstract_5cfdece5-e36f-4b32-9035-e210f6dbdaf1" xlink:href="evh-20211231.xsd#evh_EarningsLossAvailabletoCommonShareholdersAbstract"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_624d2347-74bf-44e2-81e5-8c0d583f35d7" xlink:to="loc_evh_EarningsLossAvailabletoCommonShareholdersAbstract_5cfdece5-e36f-4b32-9035-e210f6dbdaf1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_c903208b-ef4a-48d4-b2e7-9e951b826c49" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_evh_EarningsLossAvailabletoCommonShareholdersAbstract_5cfdece5-e36f-4b32-9035-e210f6dbdaf1" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_c903208b-ef4a-48d4-b2e7-9e951b826c49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_882e2e82-c8f2-445f-8b52-fa2fcde8addd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_624d2347-74bf-44e2-81e5-8c0d583f35d7" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_882e2e82-c8f2-445f-8b52-fa2fcde8addd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_dfee2c7b-b9dd-48cd-9f85-6023e66f03dc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_624d2347-74bf-44e2-81e5-8c0d583f35d7" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_dfee2c7b-b9dd-48cd-9f85-6023e66f03dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_6872d57a-8b85-4b6c-8825-3d2c82ce711b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_624d2347-74bf-44e2-81e5-8c0d583f35d7" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_6872d57a-8b85-4b6c-8825-3d2c82ce711b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_ab96ac57-90cf-4810-880f-66174ac0f8eb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_624d2347-74bf-44e2-81e5-8c0d583f35d7" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_ab96ac57-90cf-4810-880f-66174ac0f8eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract_5b3565f4-5607-4091-987a-0e78a341c505" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasicAndDilutedAbstract"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_624d2347-74bf-44e2-81e5-8c0d583f35d7" xlink:to="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract_5b3565f4-5607-4091-987a-0e78a341c505" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_5e3f679b-b55b-4cd1-a9bd-226edd194257" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsPerBasicShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract_5b3565f4-5607-4091-987a-0e78a341c505" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_5e3f679b-b55b-4cd1-a9bd-226edd194257" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_61b8da95-5c08-464f-8515-9be3eed383e3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract_5b3565f4-5607-4091-987a-0e78a341c505" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_61b8da95-5c08-464f-8515-9be3eed383e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare_9dffb0d3-e16e-44ac-8ea6-c6ad127093fd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract_5b3565f4-5607-4091-987a-0e78a341c505" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare_9dffb0d3-e16e-44ac-8ea6-c6ad127093fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare_40c24332-afc1-4f1b-9788-10112dfe145e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract_5b3565f4-5607-4091-987a-0e78a341c505" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare_40c24332-afc1-4f1b-9788-10112dfe145e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_EarningsPerSharePortionAttributableToNoncontrollingInterestDiluted_253e1f0a-5c5c-4dba-bbcb-062aea264784" xlink:href="evh-20211231.xsd#evh_EarningsPerSharePortionAttributableToNoncontrollingInterestDiluted"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract_5b3565f4-5607-4091-987a-0e78a341c505" xlink:to="loc_evh_EarningsPerSharePortionAttributableToNoncontrollingInterestDiluted_253e1f0a-5c5c-4dba-bbcb-062aea264784" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_EarningsPerSharePortionAttributableToNoncontrollingInterestBasic_75b4954a-45d3-47bd-8943-ffca3201d0a5" xlink:href="evh-20211231.xsd#evh_EarningsPerSharePortionAttributableToNoncontrollingInterestBasic"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract_5b3565f4-5607-4091-987a-0e78a341c505" xlink:to="loc_evh_EarningsPerSharePortionAttributableToNoncontrollingInterestBasic_75b4954a-45d3-47bd-8943-ffca3201d0a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_f4ab33a3-7682-4c70-8a3d-1da4dc63b3d1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract_5b3565f4-5607-4091-987a-0e78a341c505" xlink:to="loc_us-gaap_EarningsPerShareDiluted_f4ab33a3-7682-4c70-8a3d-1da4dc63b3d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_a9603875-feea-48bb-bbf5-87ec8af3a03b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract_5b3565f4-5607-4091-987a-0e78a341c505" xlink:to="loc_us-gaap_EarningsPerShareBasic_a9603875-feea-48bb-bbf5-87ec8af3a03b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/EarningsLossPerCommonShareAntidilutiveSecuritiesDetails" xlink:type="simple" xlink:href="evh-20211231.xsd#EarningsLossPerCommonShareAntidilutiveSecuritiesDetails"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/EarningsLossPerCommonShareAntidilutiveSecuritiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_3856496c-015d-4873-a233-85e5815756d4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_75c6315f-8878-4d28-b4a4-e561c35b7031" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_3856496c-015d-4873-a233-85e5815756d4" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_75c6315f-8878-4d28-b4a4-e561c35b7031" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_d696f5ff-dd6e-4c7a-bc9a-1bd4d89a5847" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_75c6315f-8878-4d28-b4a4-e561c35b7031" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_d696f5ff-dd6e-4c7a-bc9a-1bd4d89a5847" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_a7c843c8-6bd5-4a94-9d64-7aceeaaf2eb3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_d696f5ff-dd6e-4c7a-bc9a-1bd4d89a5847" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_a7c843c8-6bd5-4a94-9d64-7aceeaaf2eb3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassBMember_12336731-5492-45e8-a595-bdebc7b41001" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonClassBMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_a7c843c8-6bd5-4a94-9d64-7aceeaaf2eb3" xlink:to="loc_us-gaap_CommonClassBMember_12336731-5492-45e8-a595-bdebc7b41001" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_RestrictedStockUnitsRSUsPerformanceBasedRestrictedStockUnitsPBRSUsAndLeveragedStockUnitsLSUsMember_1608d29d-0f9b-40b3-a91e-60466e23e45a" xlink:href="evh-20211231.xsd#evh_RestrictedStockUnitsRSUsPerformanceBasedRestrictedStockUnitsPBRSUsAndLeveragedStockUnitsLSUsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_a7c843c8-6bd5-4a94-9d64-7aceeaaf2eb3" xlink:to="loc_evh_RestrictedStockUnitsRSUsPerformanceBasedRestrictedStockUnitsPBRSUsAndLeveragedStockUnitsLSUsMember_1608d29d-0f9b-40b3-a91e-60466e23e45a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_27f5c0ff-8962-4614-82cd-83b958733e2a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_a7c843c8-6bd5-4a94-9d64-7aceeaaf2eb3" xlink:to="loc_us-gaap_EmployeeStockOptionMember_27f5c0ff-8962-4614-82cd-83b958733e2a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtMember_1d5cbb40-0f61-42d5-9313-2df4eb007ec0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertibleDebtMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_a7c843c8-6bd5-4a94-9d64-7aceeaaf2eb3" xlink:to="loc_us-gaap_ConvertibleDebtMember_1d5cbb40-0f61-42d5-9313-2df4eb007ec0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_85098122-42d2-45e9-be23-1ea9fe29b2c1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_75c6315f-8878-4d28-b4a4-e561c35b7031" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_85098122-42d2-45e9-be23-1ea9fe29b2c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_93cc89fb-e832-4450-b723-6b582df58f73" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_85098122-42d2-45e9-be23-1ea9fe29b2c1" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_93cc89fb-e832-4450-b723-6b582df58f73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/StockbasedCompensation" xlink:type="simple" xlink:href="evh-20211231.xsd#StockbasedCompensation"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/StockbasedCompensation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_4b8dd182-f058-4a7f-9f4e-d4ebc24c6ff5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_92068b01-d7d3-4d82-81a1-3024ba7de962" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_4b8dd182-f058-4a7f-9f4e-d4ebc24c6ff5" xlink:to="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_92068b01-d7d3-4d82-81a1-3024ba7de962" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/StockbasedCompensationTables" xlink:type="simple" xlink:href="evh-20211231.xsd#StockbasedCompensationTables"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/StockbasedCompensationTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_60a40565-afa7-4659-b741-bf40a0f725d4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_8007712e-3770-465b-b10f-b978c120e476" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_60a40565-afa7-4659-b741-bf40a0f725d4" xlink:to="loc_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_8007712e-3770-465b-b10f-b978c120e476" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfUnrecognizedCompensationCostNonvestedAwardsTableTextBlock_7d5d2887-7e00-4696-b371-9a3bcd814280" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfUnrecognizedCompensationCostNonvestedAwardsTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_60a40565-afa7-4659-b741-bf40a0f725d4" xlink:to="loc_us-gaap_ScheduleOfUnrecognizedCompensationCostNonvestedAwardsTableTextBlock_7d5d2887-7e00-4696-b371-9a3bcd814280" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_85546740-5e50-4066-b6b9-9db5c4610b72" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_60a40565-afa7-4659-b741-bf40a0f725d4" xlink:to="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_85546740-5e50-4066-b6b9-9db5c4610b72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_e4e3ada4-9314-49f0-83ea-93904a5a7296" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_60a40565-afa7-4659-b741-bf40a0f725d4" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_e4e3ada4-9314-49f0-83ea-93904a5a7296" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationPerformanceSharesAwardOutstandingActivityTableTextBlock_4a795b57-d7aa-44fd-80cc-4f3d8dfe57ce" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationPerformanceSharesAwardOutstandingActivityTableTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_60a40565-afa7-4659-b741-bf40a0f725d4" xlink:to="loc_us-gaap_ShareBasedCompensationPerformanceSharesAwardOutstandingActivityTableTextBlock_4a795b57-d7aa-44fd-80cc-4f3d8dfe57ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_36ffb55b-783e-4427-89c4-93db787a5585" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_60a40565-afa7-4659-b741-bf40a0f725d4" xlink:to="loc_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_36ffb55b-783e-4427-89c4-93db787a5585" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfOtherShareBasedCompensationActivityTableTextBlock_e42b7d4c-dd0a-42e6-8991-20922d5e0483" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfOtherShareBasedCompensationActivityTableTextBlock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_60a40565-afa7-4659-b741-bf40a0f725d4" xlink:to="loc_us-gaap_ScheduleOfOtherShareBasedCompensationActivityTableTextBlock_e42b7d4c-dd0a-42e6-8991-20922d5e0483" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_ScheduleOfShareBasedPaymentAwardRestrictedStockUnitValuationAssumptionsTableTextBlock_876a2e8a-b577-4da0-8a0f-f16086b89a5c" xlink:href="evh-20211231.xsd#evh_ScheduleOfShareBasedPaymentAwardRestrictedStockUnitValuationAssumptionsTableTextBlock"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_60a40565-afa7-4659-b741-bf40a0f725d4" xlink:to="loc_evh_ScheduleOfShareBasedPaymentAwardRestrictedStockUnitValuationAssumptionsTableTextBlock_876a2e8a-b577-4da0-8a0f-f16086b89a5c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardRestrictedStockUnitsVestedAndExpectedToVestTableTextBlock_e95a8a83-79c0-4483-88f9-5e79dc77907d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardRestrictedStockUnitsVestedAndExpectedToVestTableTextBlock"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_60a40565-afa7-4659-b741-bf40a0f725d4" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardRestrictedStockUnitsVestedAndExpectedToVestTableTextBlock_e95a8a83-79c0-4483-88f9-5e79dc77907d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/StockbasedCompensation2011and2015EquityIncentivePlansDetails" xlink:type="simple" xlink:href="evh-20211231.xsd#StockbasedCompensation2011and2015EquityIncentivePlansDetails"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/StockbasedCompensation2011and2015EquityIncentivePlansDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_a7102cb3-d783-44db-b657-379545b1659f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_6e8497e2-7a2e-42e9-9e04-99cb100173ab" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_a7102cb3-d783-44db-b657-379545b1659f" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_6e8497e2-7a2e-42e9-9e04-99cb100173ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_9f7467be-0a12-4bbd-beba-4e7c2fbf89ef" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_6e8497e2-7a2e-42e9-9e04-99cb100173ab" xlink:to="loc_us-gaap_PlanNameAxis_9f7467be-0a12-4bbd-beba-4e7c2fbf89ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_497d2392-072f-4ae7-b8cc-36819d2ed109" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_9f7467be-0a12-4bbd-beba-4e7c2fbf89ef" xlink:to="loc_us-gaap_PlanNameDomain_497d2392-072f-4ae7-b8cc-36819d2ed109" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_TwoThousandElevenEquityIncentivePlanMember_5f3c5d32-0ab0-44c1-a3e6-4dccc51c75b3" xlink:href="evh-20211231.xsd#evh_TwoThousandElevenEquityIncentivePlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_497d2392-072f-4ae7-b8cc-36819d2ed109" xlink:to="loc_evh_TwoThousandElevenEquityIncentivePlanMember_5f3c5d32-0ab0-44c1-a3e6-4dccc51c75b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_TwoThousandFifteenEvolentHealthInc.OmnibusIncentiveCompensationPlanMember_313bb60d-1848-44a7-9ca8-99a3703ef3b5" xlink:href="evh-20211231.xsd#evh_TwoThousandFifteenEvolentHealthInc.OmnibusIncentiveCompensationPlanMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_497d2392-072f-4ae7-b8cc-36819d2ed109" xlink:to="loc_evh_TwoThousandFifteenEvolentHealthInc.OmnibusIncentiveCompensationPlanMember_313bb60d-1848-44a7-9ca8-99a3703ef3b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_698f6f0e-ea44-4e6e-b380-8e7c3332ab33" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_6e8497e2-7a2e-42e9-9e04-99cb100173ab" xlink:to="loc_us-gaap_StatementClassOfStockAxis_698f6f0e-ea44-4e6e-b380-8e7c3332ab33" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_fb47ceb1-3f6d-429a-b6c5-e6da00364cc0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_698f6f0e-ea44-4e6e-b380-8e7c3332ab33" xlink:to="loc_us-gaap_ClassOfStockDomain_fb47ceb1-3f6d-429a-b6c5-e6da00364cc0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassAMember_63c55a85-3fd4-46ea-80cd-04527e4b5fe0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonClassAMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_fb47ceb1-3f6d-429a-b6c5-e6da00364cc0" xlink:to="loc_us-gaap_CommonClassAMember_63c55a85-3fd4-46ea-80cd-04527e4b5fe0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_b33c7074-1ddd-49f7-8c7d-aae26873baa2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_6e8497e2-7a2e-42e9-9e04-99cb100173ab" xlink:to="loc_us-gaap_AwardTypeAxis_b33c7074-1ddd-49f7-8c7d-aae26873baa2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f097ed58-9192-4447-a06b-cf88b5c652b8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_b33c7074-1ddd-49f7-8c7d-aae26873baa2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f097ed58-9192-4447-a06b-cf88b5c652b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_30da4f51-34f9-472b-8a08-957779fb416b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f097ed58-9192-4447-a06b-cf88b5c652b8" xlink:to="loc_us-gaap_RestrictedStockMember_30da4f51-34f9-472b-8a08-957779fb416b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_c2eef558-40c7-4087-8035-158a4c892f01" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f097ed58-9192-4447-a06b-cf88b5c652b8" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_c2eef558-40c7-4087-8035-158a4c892f01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_LeveragedStockUnitsLSUsMember_09fb67fa-5571-46a4-9d00-b3281cb22cfe" xlink:href="evh-20211231.xsd#evh_LeveragedStockUnitsLSUsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f097ed58-9192-4447-a06b-cf88b5c652b8" xlink:to="loc_evh_LeveragedStockUnitsLSUsMember_09fb67fa-5571-46a4-9d00-b3281cb22cfe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_PerformanceBasedRestrictedStockUnitsPSUsMember_8d8b2ae2-5765-459d-8aa4-6d9d36200e8c" xlink:href="evh-20211231.xsd#evh_PerformanceBasedRestrictedStockUnitsPSUsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f097ed58-9192-4447-a06b-cf88b5c652b8" xlink:to="loc_evh_PerformanceBasedRestrictedStockUnitsPSUsMember_8d8b2ae2-5765-459d-8aa4-6d9d36200e8c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_343d0734-ea74-4ee9-a2a3-bf128fefb6d0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_6e8497e2-7a2e-42e9-9e04-99cb100173ab" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_343d0734-ea74-4ee9-a2a3-bf128fefb6d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_41f763df-bd49-4880-9c7c-42585d7ba896" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_343d0734-ea74-4ee9-a2a3-bf128fefb6d0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_41f763df-bd49-4880-9c7c-42585d7ba896" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_839080fc-702b-4a62-bc44-e9939fe07957" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_343d0734-ea74-4ee9-a2a3-bf128fefb6d0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_839080fc-702b-4a62-bc44-e9939fe07957" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_1701c9c9-d23b-4956-8663-f326695c8d62" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_343d0734-ea74-4ee9-a2a3-bf128fefb6d0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_1701c9c9-d23b-4956-8663-f326695c8d62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/StockbasedCompensationStockbasedCompensationExpenseDetails" xlink:type="simple" xlink:href="evh-20211231.xsd#StockbasedCompensationStockbasedCompensationExpenseDetails"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/StockbasedCompensationStockbasedCompensationExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_ff89cc22-0324-45e8-bafa-6aaf629128f6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_d34c443a-1891-4207-a952-cde93c23db4d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_ff89cc22-0324-45e8-bafa-6aaf629128f6" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_d34c443a-1891-4207-a952-cde93c23db4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_f57c9820-1357-47e4-a723-dd75295286d5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_d34c443a-1891-4207-a952-cde93c23db4d" xlink:to="loc_us-gaap_AwardTypeAxis_f57c9820-1357-47e4-a723-dd75295286d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9984a16d-f2ad-4877-b175-54f9fb36660c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_f57c9820-1357-47e4-a723-dd75295286d5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9984a16d-f2ad-4877-b175-54f9fb36660c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_8a96f559-db4d-4cea-b905-5690ba372400" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9984a16d-f2ad-4877-b175-54f9fb36660c" xlink:to="loc_us-gaap_EmployeeStockOptionMember_8a96f559-db4d-4cea-b905-5690ba372400" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember_00406138-0aba-4f13-a090-dde187028a01" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PerformanceSharesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9984a16d-f2ad-4877-b175-54f9fb36660c" xlink:to="loc_us-gaap_PerformanceSharesMember_00406138-0aba-4f13-a090-dde187028a01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_466f39b5-a972-429b-bfb0-37d0c6bd9cba" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9984a16d-f2ad-4877-b175-54f9fb36660c" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_466f39b5-a972-429b-bfb0-37d0c6bd9cba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_PerformanceBasedRestrictedStockUnitsPSUsMember_ea8b2281-a64a-486a-8554-c35352f04875" xlink:href="evh-20211231.xsd#evh_PerformanceBasedRestrictedStockUnitsPSUsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9984a16d-f2ad-4877-b175-54f9fb36660c" xlink:to="loc_evh_PerformanceBasedRestrictedStockUnitsPSUsMember_ea8b2281-a64a-486a-8554-c35352f04875" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_LeveragedStockUnitsLSUsMember_b928cd06-4ef9-495a-b01a-782c127be5c8" xlink:href="evh-20211231.xsd#evh_LeveragedStockUnitsLSUsMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9984a16d-f2ad-4877-b175-54f9fb36660c" xlink:to="loc_evh_LeveragedStockUnitsLSUsMember_b928cd06-4ef9-495a-b01a-782c127be5c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_9ed80f68-cbd0-4bd0-a6cb-334168d9538f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_d34c443a-1891-4207-a952-cde93c23db4d" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_9ed80f68-cbd0-4bd0-a6cb-334168d9538f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_7531d646-6f49-49f3-bb48-e2c8642e77ce" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_9ed80f68-cbd0-4bd0-a6cb-334168d9538f" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_7531d646-6f49-49f3-bb48-e2c8642e77ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfSalesMember_dc4476dd-1059-4e6c-be85-d2ee4136ceaa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfSalesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_7531d646-6f49-49f3-bb48-e2c8642e77ce" xlink:to="loc_us-gaap_CostOfSalesMember_dc4476dd-1059-4e6c-be85-d2ee4136ceaa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_bb93cd12-d78c-4278-82c1-422feace7dd8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_7531d646-6f49-49f3-bb48-e2c8642e77ce" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_bb93cd12-d78c-4278-82c1-422feace7dd8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_8e6b0587-f681-433f-b845-6026f3b5bfaf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_d34c443a-1891-4207-a952-cde93c23db4d" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_8e6b0587-f681-433f-b845-6026f3b5bfaf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_96085e21-d5a7-46cb-84ea-702ce6841e69" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_8e6b0587-f681-433f-b845-6026f3b5bfaf" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_96085e21-d5a7-46cb-84ea-702ce6841e69" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/StockbasedCompensationAdditionalInformationDetails" xlink:type="simple" xlink:href="evh-20211231.xsd#StockbasedCompensationAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/StockbasedCompensationAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_d6b614dc-9ad3-43a8-b169-e28fe1a447b6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_89661cc6-ee05-4332-b94c-a2e89a970623" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_d6b614dc-9ad3-43a8-b169-e28fe1a447b6" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_89661cc6-ee05-4332-b94c-a2e89a970623" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/StockbasedCompensationUnrecognizedCompensationExpenseDetails" xlink:type="simple" xlink:href="evh-20211231.xsd#StockbasedCompensationUnrecognizedCompensationExpenseDetails"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/StockbasedCompensationUnrecognizedCompensationExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_10676221-caf8-4850-83c2-4c41ff4a5db7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_d6b44b24-4a2f-428c-8cc4-29b403f21989" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_10676221-caf8-4850-83c2-4c41ff4a5db7" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_d6b44b24-4a2f-428c-8cc4-29b403f21989" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_4ea62d3e-b6ee-4369-9598-79772383ca65" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_d6b44b24-4a2f-428c-8cc4-29b403f21989" xlink:to="loc_us-gaap_AwardTypeAxis_4ea62d3e-b6ee-4369-9598-79772383ca65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f9682953-cc9e-4fba-8c3c-578520995cef" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_4ea62d3e-b6ee-4369-9598-79772383ca65" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f9682953-cc9e-4fba-8c3c-578520995cef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_813190c7-2c89-4501-a849-7112ab29d65f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f9682953-cc9e-4fba-8c3c-578520995cef" xlink:to="loc_us-gaap_EmployeeStockOptionMember_813190c7-2c89-4501-a849-7112ab29d65f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_e2729ad8-f0dd-4bba-9bc5-74eefddd181c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f9682953-cc9e-4fba-8c3c-578520995cef" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_e2729ad8-f0dd-4bba-9bc5-74eefddd181c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_LeveragedStockUnitsLSUsMember_fc2b01a5-0f47-4aee-9d6a-5257fee5f60e" xlink:href="evh-20211231.xsd#evh_LeveragedStockUnitsLSUsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f9682953-cc9e-4fba-8c3c-578520995cef" xlink:to="loc_evh_LeveragedStockUnitsLSUsMember_fc2b01a5-0f47-4aee-9d6a-5257fee5f60e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_PerformanceBasedRestrictedStockUnitsPSUsMember_d7c6c4bb-7e15-44bc-a50b-95e759d81232" xlink:href="evh-20211231.xsd#evh_PerformanceBasedRestrictedStockUnitsPSUsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f9682953-cc9e-4fba-8c3c-578520995cef" xlink:to="loc_evh_PerformanceBasedRestrictedStockUnitsPSUsMember_d7c6c4bb-7e15-44bc-a50b-95e759d81232" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_c6d1432d-53e6-4cbc-92c3-92553ce73de1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_d6b44b24-4a2f-428c-8cc4-29b403f21989" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_c6d1432d-53e6-4cbc-92c3-92553ce73de1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_1a004093-4666-4a70-b04b-f31b72a6cfc1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_c6d1432d-53e6-4cbc-92c3-92553ce73de1" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_1a004093-4666-4a70-b04b-f31b72a6cfc1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_0d417cd0-bcee-4913-a3b0-0c1fcc942276" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_c6d1432d-53e6-4cbc-92c3-92553ce73de1" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_0d417cd0-bcee-4913-a3b0-0c1fcc942276" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_00192e33-b1a2-483d-935e-382e9f523e8d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_c6d1432d-53e6-4cbc-92c3-92553ce73de1" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_00192e33-b1a2-483d-935e-382e9f523e8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_a84369e1-e5d5-46f5-a5f4-e744ddc5af77" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_c6d1432d-53e6-4cbc-92c3-92553ce73de1" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_a84369e1-e5d5-46f5-a5f4-e744ddc5af77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/StockbasedCompensationStockOptionsDetails" xlink:type="simple" xlink:href="evh-20211231.xsd#StockbasedCompensationStockOptionsDetails"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/StockbasedCompensationStockOptionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_70c8a523-cb86-4028-bb8a-1ce3d30a7303" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_86f70414-de56-425b-b84d-6ab4d61d9282" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_70c8a523-cb86-4028-bb8a-1ce3d30a7303" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_86f70414-de56-425b-b84d-6ab4d61d9282" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_555dcffb-1660-46b2-9302-d081cc6bc584" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_86f70414-de56-425b-b84d-6ab4d61d9282" xlink:to="loc_us-gaap_AwardTypeAxis_555dcffb-1660-46b2-9302-d081cc6bc584" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_6cfc3a7a-61a7-45ba-bb66-68ff410696ef" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_555dcffb-1660-46b2-9302-d081cc6bc584" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_6cfc3a7a-61a7-45ba-bb66-68ff410696ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_8d482150-8717-4a4a-bff9-01ae729afcc5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_6cfc3a7a-61a7-45ba-bb66-68ff410696ef" xlink:to="loc_us-gaap_EmployeeStockOptionMember_8d482150-8717-4a4a-bff9-01ae729afcc5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c025be87-a827-40d5-8c05-13d769e9903d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_86f70414-de56-425b-b84d-6ab4d61d9282" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c025be87-a827-40d5-8c05-13d769e9903d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_b671e376-fa3c-4898-9d42-4530f8079b83" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c025be87-a827-40d5-8c05-13d769e9903d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_b671e376-fa3c-4898-9d42-4530f8079b83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_1a26a36c-22b4-4c06-8d5d-1b4f35890903" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c025be87-a827-40d5-8c05-13d769e9903d" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_1a26a36c-22b4-4c06-8d5d-1b4f35890903" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_b8bbe7d8-52e0-41fc-84a1-c3662e782816" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c025be87-a827-40d5-8c05-13d769e9903d" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_b8bbe7d8-52e0-41fc-84a1-c3662e782816" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_d9d931a7-c8ef-43ea-a40a-4d2cf8fc5265" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c025be87-a827-40d5-8c05-13d769e9903d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_d9d931a7-c8ef-43ea-a40a-4d2cf8fc5265" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_a33ad47a-6cbe-4580-b8e1-945c4734b095" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c025be87-a827-40d5-8c05-13d769e9903d" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_a33ad47a-6cbe-4580-b8e1-945c4734b095" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_a38c3436-986e-4d20-a562-71b2336ac63f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c025be87-a827-40d5-8c05-13d769e9903d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_a38c3436-986e-4d20-a562-71b2336ac63f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_2bfd73aa-347a-49c8-9774-fe80c30f3c1c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c025be87-a827-40d5-8c05-13d769e9903d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_2bfd73aa-347a-49c8-9774-fe80c30f3c1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_d4822063-bd3d-4b5c-94d1-376f9b0454e8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c025be87-a827-40d5-8c05-13d769e9903d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_d4822063-bd3d-4b5c-94d1-376f9b0454e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_0812d52b-584e-44ac-971d-4fe9ffe714f6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c025be87-a827-40d5-8c05-13d769e9903d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_0812d52b-584e-44ac-971d-4fe9ffe714f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_90a3d7c9-5ece-4da9-8409-2ee781b1249e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c025be87-a827-40d5-8c05-13d769e9903d" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_90a3d7c9-5ece-4da9-8409-2ee781b1249e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_9f4854ef-83eb-47e3-952b-d97a7e90c822" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c025be87-a827-40d5-8c05-13d769e9903d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_9f4854ef-83eb-47e3-952b-d97a7e90c822" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/StockbasedCompensationStockOptionActivityDetails" xlink:type="simple" xlink:href="evh-20211231.xsd#StockbasedCompensationStockOptionActivityDetails"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/StockbasedCompensationStockOptionActivityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_62941a9d-1f35-4ccc-968b-13d5aa0a7287" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_c0bf317e-d620-476c-b442-9df96053c410" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_62941a9d-1f35-4ccc-968b-13d5aa0a7287" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_c0bf317e-d620-476c-b442-9df96053c410" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_fc07ce81-5663-4b01-9302-64eb25c72207" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_c0bf317e-d620-476c-b442-9df96053c410" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_fc07ce81-5663-4b01-9302-64eb25c72207" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_0bdc0e36-fa8f-4117-9fa7-09edfa01dd12" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_c0bf317e-d620-476c-b442-9df96053c410" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_0bdc0e36-fa8f-4117-9fa7-09edfa01dd12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_41b38ee6-592e-485a-88cc-a6c60157789f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_c0bf317e-d620-476c-b442-9df96053c410" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_41b38ee6-592e-485a-88cc-a6c60157789f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_40d10cf4-2a75-4abd-91df-4d209e96d8c3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_c0bf317e-d620-476c-b442-9df96053c410" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_40d10cf4-2a75-4abd-91df-4d209e96d8c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_5fb8c10e-9c3f-46d7-9589-4bacf2c5b8bd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_62941a9d-1f35-4ccc-968b-13d5aa0a7287" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_5fb8c10e-9c3f-46d7-9589-4bacf2c5b8bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_9bcdc415-c4fd-4a1b-b216-1fbbe0ef03fd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_62941a9d-1f35-4ccc-968b-13d5aa0a7287" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_9bcdc415-c4fd-4a1b-b216-1fbbe0ef03fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_c9f0d40c-4ae8-4711-b2b9-15a2a4253259" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_62941a9d-1f35-4ccc-968b-13d5aa0a7287" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_c9f0d40c-4ae8-4711-b2b9-15a2a4253259" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_40ab2ac2-bed7-465e-a4b0-bf91376fd280" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_c9f0d40c-4ae8-4711-b2b9-15a2a4253259" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_40ab2ac2-bed7-465e-a4b0-bf91376fd280" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_ddbb0ed0-a790-4948-9a06-49c28e3a12fe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_c9f0d40c-4ae8-4711-b2b9-15a2a4253259" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_ddbb0ed0-a790-4948-9a06-49c28e3a12fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_915497fc-f0c3-4839-b564-e852f820477a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_c9f0d40c-4ae8-4711-b2b9-15a2a4253259" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_915497fc-f0c3-4839-b564-e852f820477a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_e1c7ca18-570b-4176-aee1-d8f272f1f8bc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_c9f0d40c-4ae8-4711-b2b9-15a2a4253259" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_e1c7ca18-570b-4176-aee1-d8f272f1f8bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_ff3a87bf-a67d-457f-9ff8-2a25085909ab" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_62941a9d-1f35-4ccc-968b-13d5aa0a7287" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_ff3a87bf-a67d-457f-9ff8-2a25085909ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_c35603a5-a6ef-4e0d-a3fb-c5821c6bdaf4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_62941a9d-1f35-4ccc-968b-13d5aa0a7287" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_c35603a5-a6ef-4e0d-a3fb-c5821c6bdaf4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_WeightedAverageRemainingContractualTermAbstract_9f1b0743-f4df-41a5-b6f9-7de43eb45608" xlink:href="evh-20211231.xsd#evh_WeightedAverageRemainingContractualTermAbstract"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_62941a9d-1f35-4ccc-968b-13d5aa0a7287" xlink:to="loc_evh_WeightedAverageRemainingContractualTermAbstract_9f1b0743-f4df-41a5-b6f9-7de43eb45608" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_80f971ad-ce03-434b-affa-732a1e7c77dc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_evh_WeightedAverageRemainingContractualTermAbstract_9f1b0743-f4df-41a5-b6f9-7de43eb45608" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_80f971ad-ce03-434b-affa-732a1e7c77dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_8446f487-7c7e-441b-adde-9f95105779fc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_evh_WeightedAverageRemainingContractualTermAbstract_9f1b0743-f4df-41a5-b6f9-7de43eb45608" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_8446f487-7c7e-441b-adde-9f95105779fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_a33fc14e-7afc-4510-8622-397c0925d5e0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_evh_WeightedAverageRemainingContractualTermAbstract_9f1b0743-f4df-41a5-b6f9-7de43eb45608" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_a33fc14e-7afc-4510-8622-397c0925d5e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_AggregateIntrinsicValueAbstract_5a1d1bcc-28d6-43bc-826f-9b3fbe0ee422" xlink:href="evh-20211231.xsd#evh_AggregateIntrinsicValueAbstract"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_62941a9d-1f35-4ccc-968b-13d5aa0a7287" xlink:to="loc_evh_AggregateIntrinsicValueAbstract_5a1d1bcc-28d6-43bc-826f-9b3fbe0ee422" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_85058390-3701-40c4-b1b8-86821e4a1df9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_evh_AggregateIntrinsicValueAbstract_5a1d1bcc-28d6-43bc-826f-9b3fbe0ee422" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_85058390-3701-40c4-b1b8-86821e4a1df9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_2ccc24dd-30d7-4657-b254-510419bca6bb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_evh_AggregateIntrinsicValueAbstract_5a1d1bcc-28d6-43bc-826f-9b3fbe0ee422" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_2ccc24dd-30d7-4657-b254-510419bca6bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_191ec07d-6589-4ad3-9f59-fec4ee391ee7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_evh_AggregateIntrinsicValueAbstract_5a1d1bcc-28d6-43bc-826f-9b3fbe0ee422" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_191ec07d-6589-4ad3-9f59-fec4ee391ee7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/StockbasedCompensationPerformancebasedStockOptionAwardsDetails" xlink:type="simple" xlink:href="evh-20211231.xsd#StockbasedCompensationPerformancebasedStockOptionAwardsDetails"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/StockbasedCompensationPerformancebasedStockOptionAwardsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_35c7eef6-5ecb-43ee-bb36-298352f8d75c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_3e22186e-2ebb-4f0c-bb5f-c226cf4fb358" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_35c7eef6-5ecb-43ee-bb36-298352f8d75c" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_3e22186e-2ebb-4f0c-bb5f-c226cf4fb358" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_277f0540-8654-40f2-b1ef-c23c501aea73" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_3e22186e-2ebb-4f0c-bb5f-c226cf4fb358" xlink:to="loc_us-gaap_AwardTypeAxis_277f0540-8654-40f2-b1ef-c23c501aea73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f44d522b-2b88-4326-85d7-d3d4fb853f86" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_277f0540-8654-40f2-b1ef-c23c501aea73" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f44d522b-2b88-4326-85d7-d3d4fb853f86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember_a9797d06-3c06-46e0-bc30-153fd7d11be7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PerformanceSharesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f44d522b-2b88-4326-85d7-d3d4fb853f86" xlink:to="loc_us-gaap_PerformanceSharesMember_a9797d06-3c06-46e0-bc30-153fd7d11be7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_6d6f8611-1002-40e0-9d41-45c6651abbbe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_3e22186e-2ebb-4f0c-bb5f-c226cf4fb358" xlink:to="loc_us-gaap_StatementClassOfStockAxis_6d6f8611-1002-40e0-9d41-45c6651abbbe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_3f367681-a8e1-4b7d-8d61-cd15a0ce2bdc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_6d6f8611-1002-40e0-9d41-45c6651abbbe" xlink:to="loc_us-gaap_ClassOfStockDomain_3f367681-a8e1-4b7d-8d61-cd15a0ce2bdc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassAMember_8b14a6c2-c894-4078-90c9-c66f4d03f69f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonClassAMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_3f367681-a8e1-4b7d-8d61-cd15a0ce2bdc" xlink:to="loc_us-gaap_CommonClassAMember_8b14a6c2-c894-4078-90c9-c66f4d03f69f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingAxis_c1335170-4516-4290-94a1-f120bb70e81e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VestingAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_3e22186e-2ebb-4f0c-bb5f-c226cf4fb358" xlink:to="loc_us-gaap_VestingAxis_c1335170-4516-4290-94a1-f120bb70e81e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingDomain_5611acd8-31b4-4e68-aa2f-79aaea4e6c96" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VestingDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingAxis_c1335170-4516-4290-94a1-f120bb70e81e" xlink:to="loc_us-gaap_VestingDomain_5611acd8-31b4-4e68-aa2f-79aaea4e6c96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_3462bb6c-96aa-41aa-bcd9-71407d304c11" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingDomain_5611acd8-31b4-4e68-aa2f-79aaea4e6c96" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_3462bb6c-96aa-41aa-bcd9-71407d304c11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_9f55f79a-6272-4920-b89e-ee0461311844" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingDomain_5611acd8-31b4-4e68-aa2f-79aaea4e6c96" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_9f55f79a-6272-4920-b89e-ee0461311844" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheThreeMember_959012cf-e09d-4faf-8cda-b4275fd4fe01" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheThreeMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingDomain_5611acd8-31b4-4e68-aa2f-79aaea4e6c96" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheThreeMember_959012cf-e09d-4faf-8cda-b4275fd4fe01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_SharebasedCompensationAwardSubTrancheOneMember_e073083b-92ad-4bc6-b6f2-2783548c2d9c" xlink:href="evh-20211231.xsd#evh_SharebasedCompensationAwardSubTrancheOneMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingDomain_5611acd8-31b4-4e68-aa2f-79aaea4e6c96" xlink:to="loc_evh_SharebasedCompensationAwardSubTrancheOneMember_e073083b-92ad-4bc6-b6f2-2783548c2d9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_SharebasedCompensationAwardSubTrancheTwoMember_5d054203-9fda-4fd7-bf4b-db16a24b529b" xlink:href="evh-20211231.xsd#evh_SharebasedCompensationAwardSubTrancheTwoMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingDomain_5611acd8-31b4-4e68-aa2f-79aaea4e6c96" xlink:to="loc_evh_SharebasedCompensationAwardSubTrancheTwoMember_5d054203-9fda-4fd7-bf4b-db16a24b529b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_03ee8126-09dd-44d6-b178-5bf168846d18" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_3e22186e-2ebb-4f0c-bb5f-c226cf4fb358" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_03ee8126-09dd-44d6-b178-5bf168846d18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_eb10ae10-30a2-4f5d-89fe-484b28016963" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_03ee8126-09dd-44d6-b178-5bf168846d18" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_eb10ae10-30a2-4f5d-89fe-484b28016963" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_b766f0ee-2166-4d1a-980a-d0272c1cee67" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_03ee8126-09dd-44d6-b178-5bf168846d18" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_b766f0ee-2166-4d1a-980a-d0272c1cee67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_SharebasedCompensationArrangementbySharebasedPaymentAwardAwardVestingRightsSharePriceThreshold_e87e9235-28c0-4c87-a610-0f1a294e5599" xlink:href="evh-20211231.xsd#evh_SharebasedCompensationArrangementbySharebasedPaymentAwardAwardVestingRightsSharePriceThreshold"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_03ee8126-09dd-44d6-b178-5bf168846d18" xlink:to="loc_evh_SharebasedCompensationArrangementbySharebasedPaymentAwardAwardVestingRightsSharePriceThreshold_e87e9235-28c0-4c87-a610-0f1a294e5599" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsStockPriceTriggerConsecutiveTerm_15a510ae-6b19-4b0c-9554-e1df07aad7e0" xlink:href="evh-20211231.xsd#evh_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsStockPriceTriggerConsecutiveTerm"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_03ee8126-09dd-44d6-b178-5bf168846d18" xlink:to="loc_evh_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsStockPriceTriggerConsecutiveTerm_15a510ae-6b19-4b0c-9554-e1df07aad7e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_4e19c09a-925e-4a63-8dfc-82a1a8d619a8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_03ee8126-09dd-44d6-b178-5bf168846d18" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_4e19c09a-925e-4a63-8dfc-82a1a8d619a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_bdc7bb3a-e474-4d07-bed7-991b71127a0c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_03ee8126-09dd-44d6-b178-5bf168846d18" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_bdc7bb3a-e474-4d07-bed7-991b71127a0c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_5c056c0f-9ad7-4532-b7e9-b534e8e74890" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_03ee8126-09dd-44d6-b178-5bf168846d18" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_5c056c0f-9ad7-4532-b7e9-b534e8e74890" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_839ef355-ba9d-4ede-82c4-025b1e1dea9f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_03ee8126-09dd-44d6-b178-5bf168846d18" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_839ef355-ba9d-4ede-82c4-025b1e1dea9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_1adbb637-9e8c-4176-855b-ad512e55a9ed" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_03ee8126-09dd-44d6-b178-5bf168846d18" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_1adbb637-9e8c-4176-855b-ad512e55a9ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_264fd46e-6adc-45e6-9c58-a910258cdfd0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_03ee8126-09dd-44d6-b178-5bf168846d18" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_264fd46e-6adc-45e6-9c58-a910258cdfd0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_d0c06afd-15ea-4a02-ad04-0a4dccd737da" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_03ee8126-09dd-44d6-b178-5bf168846d18" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_d0c06afd-15ea-4a02-ad04-0a4dccd737da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_ff494312-665f-4434-ab36-df946caf921c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_03ee8126-09dd-44d6-b178-5bf168846d18" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_ff494312-665f-4434-ab36-df946caf921c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_02705698-92ec-4239-9f13-0f9c07803969" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_03ee8126-09dd-44d6-b178-5bf168846d18" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_02705698-92ec-4239-9f13-0f9c07803969" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_WeightedAverageRemainingContractualTermAbstract_764960d2-15c5-4c6b-8dd2-34dcd1f7ac25" xlink:href="evh-20211231.xsd#evh_WeightedAverageRemainingContractualTermAbstract"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_03ee8126-09dd-44d6-b178-5bf168846d18" xlink:to="loc_evh_WeightedAverageRemainingContractualTermAbstract_764960d2-15c5-4c6b-8dd2-34dcd1f7ac25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_f00a80dc-36cf-437b-86c1-6c54c1f36db3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_evh_WeightedAverageRemainingContractualTermAbstract_764960d2-15c5-4c6b-8dd2-34dcd1f7ac25" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_f00a80dc-36cf-437b-86c1-6c54c1f36db3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_4d108948-9a50-4f4d-b24b-187001308d7d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_evh_WeightedAverageRemainingContractualTermAbstract_764960d2-15c5-4c6b-8dd2-34dcd1f7ac25" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_4d108948-9a50-4f4d-b24b-187001308d7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_AggregateIntrinsicValueAbstract_25bcacc2-c310-473d-9347-ba01e5153e39" xlink:href="evh-20211231.xsd#evh_AggregateIntrinsicValueAbstract"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_03ee8126-09dd-44d6-b178-5bf168846d18" xlink:to="loc_evh_AggregateIntrinsicValueAbstract_25bcacc2-c310-473d-9347-ba01e5153e39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_f39531cc-13e0-4123-a23f-3de6da235b41" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_evh_AggregateIntrinsicValueAbstract_25bcacc2-c310-473d-9347-ba01e5153e39" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_f39531cc-13e0-4123-a23f-3de6da235b41" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_537d59eb-78fc-4770-9749-95500585ce33" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_evh_AggregateIntrinsicValueAbstract_25bcacc2-c310-473d-9347-ba01e5153e39" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_537d59eb-78fc-4770-9749-95500585ce33" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/StockbasedCompensationRestrictedStockUnitsDetails" xlink:type="simple" xlink:href="evh-20211231.xsd#StockbasedCompensationRestrictedStockUnitsDetails"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/StockbasedCompensationRestrictedStockUnitsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_ec85188c-fb5d-44d2-8b04-c71b1f880ca6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_d685bc1d-7293-4779-9324-bb4d631e61b9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_ec85188c-fb5d-44d2-8b04-c71b1f880ca6" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_d685bc1d-7293-4779-9324-bb4d631e61b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_9d14fb2b-f9e9-49dc-8b09-78286cf71595" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_d685bc1d-7293-4779-9324-bb4d631e61b9" xlink:to="loc_us-gaap_AwardTypeAxis_9d14fb2b-f9e9-49dc-8b09-78286cf71595" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_380f1c82-0ec4-4eeb-95c6-5134967ddd86" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_9d14fb2b-f9e9-49dc-8b09-78286cf71595" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_380f1c82-0ec4-4eeb-95c6-5134967ddd86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_d7a3d34d-b0f6-4ce9-99be-5bd83f73d515" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_380f1c82-0ec4-4eeb-95c6-5134967ddd86" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_d7a3d34d-b0f6-4ce9-99be-5bd83f73d515" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_f50f90dd-6338-4f82-931b-f4d5350f6d41" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_d685bc1d-7293-4779-9324-bb4d631e61b9" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_f50f90dd-6338-4f82-931b-f4d5350f6d41" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_2d22519c-f399-4bc4-9a89-0861b6e72b1b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_f50f90dd-6338-4f82-931b-f4d5350f6d41" xlink:to="loc_us-gaap_RelatedPartyDomain_2d22519c-f399-4bc4-9a89-0861b6e72b1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_NonEmployeeDirectorsMember_60aa43ee-c644-4d85-b542-d78273615eaf" xlink:href="evh-20211231.xsd#evh_NonEmployeeDirectorsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_2d22519c-f399-4bc4-9a89-0861b6e72b1b" xlink:to="loc_evh_NonEmployeeDirectorsMember_60aa43ee-c644-4d85-b542-d78273615eaf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_abfb6ddc-d28c-4e0a-a373-49e48cc7ce9f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_d685bc1d-7293-4779-9324-bb4d631e61b9" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_abfb6ddc-d28c-4e0a-a373-49e48cc7ce9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_39da7ee3-c47e-4160-931c-c2408e7d1536" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_abfb6ddc-d28c-4e0a-a373-49e48cc7ce9f" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_39da7ee3-c47e-4160-931c-c2408e7d1536" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_NewCenturyHealthMember_284b9e09-e47f-42ec-bd0d-b44ba8938bbf" xlink:href="evh-20211231.xsd#evh_NewCenturyHealthMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_39da7ee3-c47e-4160-931c-c2408e7d1536" xlink:to="loc_evh_NewCenturyHealthMember_284b9e09-e47f-42ec-bd0d-b44ba8938bbf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_edcb8ea0-0a75-4008-b1bc-38eba054ef28" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_d685bc1d-7293-4779-9324-bb4d631e61b9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_edcb8ea0-0a75-4008-b1bc-38eba054ef28" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_3cc7f9dd-8d3d-41d0-8379-321ad97b198d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_edcb8ea0-0a75-4008-b1bc-38eba054ef28" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_3cc7f9dd-8d3d-41d0-8379-321ad97b198d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1_f8fdba4c-16d5-4c26-b08e-b76577e007b8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_edcb8ea0-0a75-4008-b1bc-38eba054ef28" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1_f8fdba4c-16d5-4c26-b08e-b76577e007b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_f350209e-645e-4a9b-a93f-c93db20836b0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_edcb8ea0-0a75-4008-b1bc-38eba054ef28" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_f350209e-645e-4a9b-a93f-c93db20836b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_45224d3b-5915-498d-a612-cb5d0a9ef76b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_edcb8ea0-0a75-4008-b1bc-38eba054ef28" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_45224d3b-5915-498d-a612-cb5d0a9ef76b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_12a0372a-cb90-469c-a787-f597e571eb34" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_45224d3b-5915-498d-a612-cb5d0a9ef76b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_12a0372a-cb90-469c-a787-f597e571eb34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_d7a55c74-d6cb-4aef-970e-ea66497bfdd1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_45224d3b-5915-498d-a612-cb5d0a9ef76b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_d7a55c74-d6cb-4aef-970e-ea66497bfdd1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_380620e9-91dd-4155-852f-c8da0bd79e66" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_45224d3b-5915-498d-a612-cb5d0a9ef76b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_380620e9-91dd-4155-852f-c8da0bd79e66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_4eeed7b5-a945-463b-8ea2-11886cf77257" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_45224d3b-5915-498d-a612-cb5d0a9ef76b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_4eeed7b5-a945-463b-8ea2-11886cf77257" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_85c169d7-cb7e-4c38-9e3c-dd120c7303dc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_45224d3b-5915-498d-a612-cb5d0a9ef76b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_85c169d7-cb7e-4c38-9e3c-dd120c7303dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_e3a58077-2464-4d1f-ac81-b1a15f0793e9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_edcb8ea0-0a75-4008-b1bc-38eba054ef28" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_e3a58077-2464-4d1f-ac81-b1a15f0793e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_bbd4d799-8f82-4417-b7ff-0db489523fed" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_e3a58077-2464-4d1f-ac81-b1a15f0793e9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_bbd4d799-8f82-4417-b7ff-0db489523fed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_09ea6630-30b1-42a3-9e48-bba6083f9c92" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_e3a58077-2464-4d1f-ac81-b1a15f0793e9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_09ea6630-30b1-42a3-9e48-bba6083f9c92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_193068f4-8ef8-4437-a024-ca05c402d963" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_e3a58077-2464-4d1f-ac81-b1a15f0793e9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_193068f4-8ef8-4437-a024-ca05c402d963" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_ea5be2db-57f7-41d7-aca9-21c391657528" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_e3a58077-2464-4d1f-ac81-b1a15f0793e9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_ea5be2db-57f7-41d7-aca9-21c391657528" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_8b823531-b76f-4d70-91c3-b31d42a293f5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_e3a58077-2464-4d1f-ac81-b1a15f0793e9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_8b823531-b76f-4d70-91c3-b31d42a293f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_2ebf3576-f7b5-4be3-a86b-d28ff7d4486e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_edcb8ea0-0a75-4008-b1bc-38eba054ef28" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_2ebf3576-f7b5-4be3-a86b-d28ff7d4486e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/StockbasedCompensationLeveragedStockUnitsDetails" xlink:type="simple" xlink:href="evh-20211231.xsd#StockbasedCompensationLeveragedStockUnitsDetails"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/StockbasedCompensationLeveragedStockUnitsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_37c0a870-f47b-4403-8bd0-ae8336de40a8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_01efb6e3-f369-4a73-a3fd-65c3cc95aee5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_37c0a870-f47b-4403-8bd0-ae8336de40a8" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_01efb6e3-f369-4a73-a3fd-65c3cc95aee5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_5d2c76eb-f352-4737-89dd-a1e0bd78ac5a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_01efb6e3-f369-4a73-a3fd-65c3cc95aee5" xlink:to="loc_us-gaap_AwardTypeAxis_5d2c76eb-f352-4737-89dd-a1e0bd78ac5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0f3e9d21-2fcc-4efe-95f6-0bfd4e16ccb0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_5d2c76eb-f352-4737-89dd-a1e0bd78ac5a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0f3e9d21-2fcc-4efe-95f6-0bfd4e16ccb0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_LeveragedStockUnitsLSUsMember_c9274714-459f-4aff-8233-2cb3a40f4ef0" xlink:href="evh-20211231.xsd#evh_LeveragedStockUnitsLSUsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0f3e9d21-2fcc-4efe-95f6-0bfd4e16ccb0" xlink:to="loc_evh_LeveragedStockUnitsLSUsMember_c9274714-459f-4aff-8233-2cb3a40f4ef0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingAxis_94bfcaa4-9c37-48cd-b621-4e697b579ebb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VestingAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_01efb6e3-f369-4a73-a3fd-65c3cc95aee5" xlink:to="loc_us-gaap_VestingAxis_94bfcaa4-9c37-48cd-b621-4e697b579ebb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingDomain_e2f8da15-a136-460c-bcd3-5d74613c19fd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VestingDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingAxis_94bfcaa4-9c37-48cd-b621-4e697b579ebb" xlink:to="loc_us-gaap_VestingDomain_e2f8da15-a136-460c-bcd3-5d74613c19fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_51c184a1-5e62-4c72-a6e0-33edc1ed8789" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingDomain_e2f8da15-a136-460c-bcd3-5d74613c19fd" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_51c184a1-5e62-4c72-a6e0-33edc1ed8789" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_c9e2355e-d58a-4b4f-9976-2bea6deeb3ab" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingDomain_e2f8da15-a136-460c-bcd3-5d74613c19fd" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_c9e2355e-d58a-4b4f-9976-2bea6deeb3ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheThreeMember_1472e93a-16ae-494c-af63-210390278522" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheThreeMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingDomain_e2f8da15-a136-460c-bcd3-5d74613c19fd" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheThreeMember_1472e93a-16ae-494c-af63-210390278522" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_SharebasedPaymentArrangementTrancheFourMember_0e97024b-73d7-4637-bfee-9b0b429ada8e" xlink:href="evh-20211231.xsd#evh_SharebasedPaymentArrangementTrancheFourMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingDomain_e2f8da15-a136-460c-bcd3-5d74613c19fd" xlink:to="loc_evh_SharebasedPaymentArrangementTrancheFourMember_0e97024b-73d7-4637-bfee-9b0b429ada8e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_bec8b2d2-7d5a-4f58-b8c3-c631a0bad955" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_01efb6e3-f369-4a73-a3fd-65c3cc95aee5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_bec8b2d2-7d5a-4f58-b8c3-c631a0bad955" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_6db3b868-23ef-4ef8-a9ce-c92055557e1a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_bec8b2d2-7d5a-4f58-b8c3-c631a0bad955" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_6db3b868-23ef-4ef8-a9ce-c92055557e1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsStockPriceIncreasePercentage_da814a11-e5e0-449d-8ccb-b61e487aba18" xlink:href="evh-20211231.xsd#evh_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsStockPriceIncreasePercentage"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_bec8b2d2-7d5a-4f58-b8c3-c631a0bad955" xlink:to="loc_evh_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsStockPriceIncreasePercentage_da814a11-e5e0-449d-8ccb-b61e487aba18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_644007b2-54c3-47d3-8a3f-ee00c8b24a48" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_bec8b2d2-7d5a-4f58-b8c3-c631a0bad955" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_644007b2-54c3-47d3-8a3f-ee00c8b24a48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_9f7b4189-fa03-4786-9ae9-797f9f53dc5e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_bec8b2d2-7d5a-4f58-b8c3-c631a0bad955" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_9f7b4189-fa03-4786-9ae9-797f9f53dc5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_b1572711-2096-4e36-bbb0-a0be636efc4b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_bec8b2d2-7d5a-4f58-b8c3-c631a0bad955" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_b1572711-2096-4e36-bbb0-a0be636efc4b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_a7b9d783-f70b-4769-9730-43d22ec61054" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_bec8b2d2-7d5a-4f58-b8c3-c631a0bad955" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_a7b9d783-f70b-4769-9730-43d22ec61054" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_e29509fd-93cc-4eba-abee-b73b068f4034" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_bec8b2d2-7d5a-4f58-b8c3-c631a0bad955" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_e29509fd-93cc-4eba-abee-b73b068f4034" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_1e85bf89-69e2-4f9e-83aa-d2eb06948a72" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_bec8b2d2-7d5a-4f58-b8c3-c631a0bad955" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_1e85bf89-69e2-4f9e-83aa-d2eb06948a72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/StockbasedCompensationLeveragedStockUnitsActivityDetails" xlink:type="simple" xlink:href="evh-20211231.xsd#StockbasedCompensationLeveragedStockUnitsActivityDetails"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/StockbasedCompensationLeveragedStockUnitsActivityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_ed33070f-c28b-4565-af77-2a69f7e3fb1c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_c7cc89f5-39ac-4d56-bd79-9b3e07343176" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_ed33070f-c28b-4565-af77-2a69f7e3fb1c" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_c7cc89f5-39ac-4d56-bd79-9b3e07343176" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_8b57a1b6-56d0-4822-960e-22fb1b8a2b57" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_c7cc89f5-39ac-4d56-bd79-9b3e07343176" xlink:to="loc_us-gaap_AwardTypeAxis_8b57a1b6-56d0-4822-960e-22fb1b8a2b57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_51d9f1c9-59d8-4f23-8a51-689b89673c6c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_8b57a1b6-56d0-4822-960e-22fb1b8a2b57" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_51d9f1c9-59d8-4f23-8a51-689b89673c6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_LeveragedStockUnitsLSUsMember_88ca1540-0965-4e3e-bd10-f00cda5a220b" xlink:href="evh-20211231.xsd#evh_LeveragedStockUnitsLSUsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_51d9f1c9-59d8-4f23-8a51-689b89673c6c" xlink:to="loc_evh_LeveragedStockUnitsLSUsMember_88ca1540-0965-4e3e-bd10-f00cda5a220b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9fd091cf-3257-4c5b-acb7-769f189a454b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_c7cc89f5-39ac-4d56-bd79-9b3e07343176" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9fd091cf-3257-4c5b-acb7-769f189a454b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingAbstract_b458a748-6a4c-496a-8cd5-411717b77b06" xlink:href="evh-20211231.xsd#evh_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9fd091cf-3257-4c5b-acb7-769f189a454b" xlink:to="loc_evh_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingAbstract_b458a748-6a4c-496a-8cd5-411717b77b06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_5b161b45-813a-4242-a17d-6b724005d2c1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_evh_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingAbstract_b458a748-6a4c-496a-8cd5-411717b77b06" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_5b161b45-813a-4242-a17d-6b724005d2c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_e147a43c-73c4-40ab-b5fc-a293531b92f3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_evh_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingAbstract_b458a748-6a4c-496a-8cd5-411717b77b06" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_e147a43c-73c4-40ab-b5fc-a293531b92f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_a1aae7ff-21a5-4446-9b7d-cfdf6f978818" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_evh_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingAbstract_b458a748-6a4c-496a-8cd5-411717b77b06" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_a1aae7ff-21a5-4446-9b7d-cfdf6f978818" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_59e7f10d-1366-4f4f-9b1b-345ad946bd20" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_evh_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingAbstract_b458a748-6a4c-496a-8cd5-411717b77b06" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_59e7f10d-1366-4f4f-9b1b-345ad946bd20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestAbstract_31095ddf-458e-45ba-9ef5-11cba605567f" xlink:href="evh-20211231.xsd#evh_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9fd091cf-3257-4c5b-acb7-769f189a454b" xlink:to="loc_evh_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestAbstract_31095ddf-458e-45ba-9ef5-11cba605567f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestNumber_9439e6be-17a9-457b-9e89-9dd6e7c47171" xlink:href="evh-20211231.xsd#evh_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_evh_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestAbstract_31095ddf-458e-45ba-9ef5-11cba605567f" xlink:to="loc_evh_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestNumber_9439e6be-17a9-457b-9e89-9dd6e7c47171" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestWeightedAverageGrantDateFairValue_000df0e4-ee29-4f35-9975-ee6d9024832a" xlink:href="evh-20211231.xsd#evh_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_evh_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestAbstract_31095ddf-458e-45ba-9ef5-11cba605567f" xlink:to="loc_evh_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestWeightedAverageGrantDateFairValue_000df0e4-ee29-4f35-9975-ee6d9024832a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestWeightedAverageRemainingContractualTerms_05bbe80b-8434-4c42-8655-6a97c4e299c8" xlink:href="evh-20211231.xsd#evh_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestWeightedAverageRemainingContractualTerms"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_evh_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestAbstract_31095ddf-458e-45ba-9ef5-11cba605567f" xlink:to="loc_evh_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestWeightedAverageRemainingContractualTerms_05bbe80b-8434-4c42-8655-6a97c4e299c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVestedAndExpectedToVest_031636a4-10d0-4397-bb40-9956c31bd3e2" xlink:href="evh-20211231.xsd#evh_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVestedAndExpectedToVest"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_evh_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestAbstract_31095ddf-458e-45ba-9ef5-11cba605567f" xlink:to="loc_evh_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVestedAndExpectedToVest_031636a4-10d0-4397-bb40-9956c31bd3e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/StockbasedCompensationPerformancebasedRSUsDetails" xlink:type="simple" xlink:href="evh-20211231.xsd#StockbasedCompensationPerformancebasedRSUsDetails"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/StockbasedCompensationPerformancebasedRSUsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_c65b647c-45a4-4ce9-8753-708e63d98a7c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_9d2ac266-4748-4c08-ad8d-f50f885d772f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_c65b647c-45a4-4ce9-8753-708e63d98a7c" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_9d2ac266-4748-4c08-ad8d-f50f885d772f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_79b90816-f31e-4906-b2e7-35d480335380" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_9d2ac266-4748-4c08-ad8d-f50f885d772f" xlink:to="loc_us-gaap_AwardTypeAxis_79b90816-f31e-4906-b2e7-35d480335380" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_675dbbf1-e7bb-49d6-abab-70972f6df3a0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_79b90816-f31e-4906-b2e7-35d480335380" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_675dbbf1-e7bb-49d6-abab-70972f6df3a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_PerformanceBasedRestrictedStockUnitsPSUsMember_3933a74f-3d26-4823-ac34-e6acc577f543" xlink:href="evh-20211231.xsd#evh_PerformanceBasedRestrictedStockUnitsPSUsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_675dbbf1-e7bb-49d6-abab-70972f6df3a0" xlink:to="loc_evh_PerformanceBasedRestrictedStockUnitsPSUsMember_3933a74f-3d26-4823-ac34-e6acc577f543" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingAxis_572febce-6302-4741-831a-cd8d3dd546ae" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VestingAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_9d2ac266-4748-4c08-ad8d-f50f885d772f" xlink:to="loc_us-gaap_VestingAxis_572febce-6302-4741-831a-cd8d3dd546ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingDomain_3296f7e6-dd5b-476f-896b-f93bba4e64e3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VestingDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingAxis_572febce-6302-4741-831a-cd8d3dd546ae" xlink:to="loc_us-gaap_VestingDomain_3296f7e6-dd5b-476f-896b-f93bba4e64e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_acabe2cb-ceff-4905-9875-2c8bb3807de4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingDomain_3296f7e6-dd5b-476f-896b-f93bba4e64e3" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_acabe2cb-ceff-4905-9875-2c8bb3807de4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_8e643a3a-aad5-4b57-8581-05a0e30ca8b9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingDomain_3296f7e6-dd5b-476f-896b-f93bba4e64e3" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_8e643a3a-aad5-4b57-8581-05a0e30ca8b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_0092b4d7-c089-4440-b7bb-7703e76891bd" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_9d2ac266-4748-4c08-ad8d-f50f885d772f" xlink:to="loc_srt_RangeAxis_0092b4d7-c089-4440-b7bb-7703e76891bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_79ac4f5c-27fb-4d1f-b3db-9bc5d753c5b1" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_0092b4d7-c089-4440-b7bb-7703e76891bd" xlink:to="loc_srt_RangeMember_79ac4f5c-27fb-4d1f-b3db-9bc5d753c5b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_d9664cd3-77d2-43b8-8b24-1a761d023942" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_79ac4f5c-27fb-4d1f-b3db-9bc5d753c5b1" xlink:to="loc_srt_MinimumMember_d9664cd3-77d2-43b8-8b24-1a761d023942" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_9dac72d7-0f69-43fb-9279-9adfd5ccd4ab" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_79ac4f5c-27fb-4d1f-b3db-9bc5d753c5b1" xlink:to="loc_srt_MaximumMember_9dac72d7-0f69-43fb-9279-9adfd5ccd4ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2c075704-540e-459d-9a14-470d4e0a75d0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_9d2ac266-4748-4c08-ad8d-f50f885d772f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2c075704-540e-459d-9a14-470d4e0a75d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_1863970b-e611-4954-b33d-b13815e86506" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2c075704-540e-459d-9a14-470d4e0a75d0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_1863970b-e611-4954-b33d-b13815e86506" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_EarningsBeforeInterestTaxesDepreciationAndAmortizationGoalPeriod_28769c84-0d0e-43a0-8752-2a880a2844b3" xlink:href="evh-20211231.xsd#evh_EarningsBeforeInterestTaxesDepreciationAndAmortizationGoalPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2c075704-540e-459d-9a14-470d4e0a75d0" xlink:to="loc_evh_EarningsBeforeInterestTaxesDepreciationAndAmortizationGoalPeriod_28769c84-0d0e-43a0-8752-2a880a2844b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsPerformanceGoalThreshold_1b0236e5-c4f2-4352-ad10-52c109755213" xlink:href="evh-20211231.xsd#evh_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsPerformanceGoalThreshold"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2c075704-540e-459d-9a14-470d4e0a75d0" xlink:to="loc_evh_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsPerformanceGoalThreshold_1b0236e5-c4f2-4352-ad10-52c109755213" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsMaximumPerformanceAchievedPercentageOfTargetedSharesEarned_cd082c4c-1e76-456a-a049-3447624a8e84" xlink:href="evh-20211231.xsd#evh_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsMaximumPerformanceAchievedPercentageOfTargetedSharesEarned"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2c075704-540e-459d-9a14-470d4e0a75d0" xlink:to="loc_evh_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsMaximumPerformanceAchievedPercentageOfTargetedSharesEarned_cd082c4c-1e76-456a-a049-3447624a8e84" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageAdjustmentOfSharesEarnedTotalShareholderReturnInBottomQuartile_fc8b02e8-92bf-4360-9aa5-a0f52c18992c" xlink:href="evh-20211231.xsd#evh_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageAdjustmentOfSharesEarnedTotalShareholderReturnInBottomQuartile"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2c075704-540e-459d-9a14-470d4e0a75d0" xlink:to="loc_evh_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageAdjustmentOfSharesEarnedTotalShareholderReturnInBottomQuartile_fc8b02e8-92bf-4360-9aa5-a0f52c18992c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageAdjustmentOfSharesEarnedTotalShareholderReturnInTopQuartile_098f31ac-b19a-4d43-a8a4-ca11068fe88a" xlink:href="evh-20211231.xsd#evh_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageAdjustmentOfSharesEarnedTotalShareholderReturnInTopQuartile"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2c075704-540e-459d-9a14-470d4e0a75d0" xlink:to="loc_evh_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageAdjustmentOfSharesEarnedTotalShareholderReturnInTopQuartile_098f31ac-b19a-4d43-a8a4-ca11068fe88a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_415bab21-81f5-4e86-88f7-d424fb4e3b6e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2c075704-540e-459d-9a14-470d4e0a75d0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_415bab21-81f5-4e86-88f7-d424fb4e3b6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_886c6f95-40f3-4535-b7d5-73941c67e456" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2c075704-540e-459d-9a14-470d4e0a75d0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_886c6f95-40f3-4535-b7d5-73941c67e456" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_79d3b7d6-487d-4f9a-a803-730701a35e7f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_886c6f95-40f3-4535-b7d5-73941c67e456" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_79d3b7d6-487d-4f9a-a803-730701a35e7f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_c5b5bcae-dd0b-4435-a8d4-727163f946b6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_886c6f95-40f3-4535-b7d5-73941c67e456" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_c5b5bcae-dd0b-4435-a8d4-727163f946b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_bbbb7900-d9be-4ecc-83d4-37a87227a06d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_886c6f95-40f3-4535-b7d5-73941c67e456" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_bbbb7900-d9be-4ecc-83d4-37a87227a06d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_31a74dc4-5c93-4d9c-a461-a2d484ceb5af" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_886c6f95-40f3-4535-b7d5-73941c67e456" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_31a74dc4-5c93-4d9c-a461-a2d484ceb5af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/StockbasedCompensationPerformancebasedRSUActivityDetails" xlink:type="simple" xlink:href="evh-20211231.xsd#StockbasedCompensationPerformancebasedRSUActivityDetails"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/StockbasedCompensationPerformancebasedRSUActivityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_1008388f-f807-43eb-b598-3085cf32f7cf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_3c024efc-e8d3-43bf-a8dd-4f106631e8f0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_1008388f-f807-43eb-b598-3085cf32f7cf" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_3c024efc-e8d3-43bf-a8dd-4f106631e8f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_6badde0e-7cf2-4b3f-a1da-e39fcd2c7b32" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_3c024efc-e8d3-43bf-a8dd-4f106631e8f0" xlink:to="loc_us-gaap_AwardTypeAxis_6badde0e-7cf2-4b3f-a1da-e39fcd2c7b32" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_05fc3727-7b05-47cf-9d2c-095a2a56d612" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_6badde0e-7cf2-4b3f-a1da-e39fcd2c7b32" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_05fc3727-7b05-47cf-9d2c-095a2a56d612" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_LeveragedStockUnitsLSUsMember_91ded9e4-d1d8-4d55-85da-c89e2e0b4891" xlink:href="evh-20211231.xsd#evh_LeveragedStockUnitsLSUsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_05fc3727-7b05-47cf-9d2c-095a2a56d612" xlink:to="loc_evh_LeveragedStockUnitsLSUsMember_91ded9e4-d1d8-4d55-85da-c89e2e0b4891" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_PerformanceBasedRestrictedStockUnitsPSUsMember_bfe5838f-123f-4b4c-85f1-94a75fa142d9" xlink:href="evh-20211231.xsd#evh_PerformanceBasedRestrictedStockUnitsPSUsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_05fc3727-7b05-47cf-9d2c-095a2a56d612" xlink:to="loc_evh_PerformanceBasedRestrictedStockUnitsPSUsMember_bfe5838f-123f-4b4c-85f1-94a75fa142d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_661128ee-7381-4a03-b7b7-888c7a27f80a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_3c024efc-e8d3-43bf-a8dd-4f106631e8f0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_661128ee-7381-4a03-b7b7-888c7a27f80a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_483d5bc8-5860-4a8a-bc88-707c72ab5b2a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_661128ee-7381-4a03-b7b7-888c7a27f80a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_483d5bc8-5860-4a8a-bc88-707c72ab5b2a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_e2cbb5f4-5896-408c-9ac0-271b5ff65904" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_661128ee-7381-4a03-b7b7-888c7a27f80a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_e2cbb5f4-5896-408c-9ac0-271b5ff65904" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_42657fb9-eb40-4f8c-81c9-70c61dc5f981" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_661128ee-7381-4a03-b7b7-888c7a27f80a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_42657fb9-eb40-4f8c-81c9-70c61dc5f981" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_cd42f51c-ae69-43f2-a2d5-b75ceb425a9a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_661128ee-7381-4a03-b7b7-888c7a27f80a" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_cd42f51c-ae69-43f2-a2d5-b75ceb425a9a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestNumber_d74670b5-073b-4098-b228-20f61ae506fd" xlink:href="evh-20211231.xsd#evh_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_661128ee-7381-4a03-b7b7-888c7a27f80a" xlink:to="loc_evh_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestNumber_d74670b5-073b-4098-b228-20f61ae506fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestWeightedAverageGrantDateFairValue_c8428941-24bb-4e82-adb6-fdd2af30bbab" xlink:href="evh-20211231.xsd#evh_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_661128ee-7381-4a03-b7b7-888c7a27f80a" xlink:to="loc_evh_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestWeightedAverageGrantDateFairValue_c8428941-24bb-4e82-adb6-fdd2af30bbab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestWeightedAverageRemainingContractualTerms_d7b807af-b7ea-4c6d-8950-41c0816d8345" xlink:href="evh-20211231.xsd#evh_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestWeightedAverageRemainingContractualTerms"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_661128ee-7381-4a03-b7b7-888c7a27f80a" xlink:to="loc_evh_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestWeightedAverageRemainingContractualTerms_d7b807af-b7ea-4c6d-8950-41c0816d8345" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVestedAndExpectedToVest_d50b8fd1-5e65-4560-9ce5-8443a2222553" xlink:href="evh-20211231.xsd#evh_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVestedAndExpectedToVest"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_661128ee-7381-4a03-b7b7-888c7a27f80a" xlink:to="loc_evh_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVestedAndExpectedToVest_d50b8fd1-5e65-4560-9ce5-8443a2222553" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/IncomeTaxes" xlink:type="simple" xlink:href="evh-20211231.xsd#IncomeTaxes"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/IncomeTaxes" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_52fe4bad-afff-45bf-a80e-cb3f47f87372" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_f4601bc4-f7a2-4ba8-b5f1-f65e452a6227" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_52fe4bad-afff-45bf-a80e-cb3f47f87372" xlink:to="loc_us-gaap_IncomeTaxDisclosureTextBlock_f4601bc4-f7a2-4ba8-b5f1-f65e452a6227" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/IncomeTaxesTables" xlink:type="simple" xlink:href="evh-20211231.xsd#IncomeTaxesTables"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/IncomeTaxesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_2b919874-46e5-478a-af8d-8730b662be10" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_3cde85ff-e3f5-4e8d-bcb5-480ea12fd3bf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_2b919874-46e5-478a-af8d-8730b662be10" xlink:to="loc_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_3cde85ff-e3f5-4e8d-bcb5-480ea12fd3bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_d5a3673f-90d6-430d-a54e-0d907ef8068a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_2b919874-46e5-478a-af8d-8730b662be10" xlink:to="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_d5a3673f-90d6-430d-a54e-0d907ef8068a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_0d1e930f-0bf1-486c-b84e-7fc1ae205d63" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_2b919874-46e5-478a-af8d-8730b662be10" xlink:to="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_0d1e930f-0bf1-486c-b84e-7fc1ae205d63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_4885f291-c88e-4b4f-803b-d5c80c644d60" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_2b919874-46e5-478a-af8d-8730b662be10" xlink:to="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_4885f291-c88e-4b4f-803b-d5c80c644d60" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_219b046a-d22a-40da-bda2-281567b91eb5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_2b919874-46e5-478a-af8d-8730b662be10" xlink:to="loc_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_219b046a-d22a-40da-bda2-281567b91eb5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/IncomeTaxesNarrativeDetails" xlink:type="simple" xlink:href="evh-20211231.xsd#IncomeTaxesNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/IncomeTaxesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_3bb42497-db7a-42bc-bbfc-0413c0ad6e6c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxContingencyTable_d63aecd2-cb3e-4053-b296-f5409f0b64f2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxContingencyTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_3bb42497-db7a-42bc-bbfc-0413c0ad6e6c" xlink:to="loc_us-gaap_IncomeTaxContingencyTable_d63aecd2-cb3e-4053-b296-f5409f0b64f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAxis_bdf5a98d-74ca-48a3-9826-75158671061e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyTable_d63aecd2-cb3e-4053-b296-f5409f0b64f2" xlink:to="loc_us-gaap_TaxCreditCarryforwardAxis_bdf5a98d-74ca-48a3-9826-75158671061e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardNameDomain_c543e345-5874-4060-b0ce-6c396c3505ed" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardAxis_bdf5a98d-74ca-48a3-9826-75158671061e" xlink:to="loc_us-gaap_TaxCreditCarryforwardNameDomain_c543e345-5874-4060-b0ce-6c396c3505ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_FinitelivedTaxCreditCarryforwardMember_8f359d55-274f-43bb-9ff8-9fe6224ffe6f" xlink:href="evh-20211231.xsd#evh_FinitelivedTaxCreditCarryforwardMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardNameDomain_c543e345-5874-4060-b0ce-6c396c3505ed" xlink:to="loc_evh_FinitelivedTaxCreditCarryforwardMember_8f359d55-274f-43bb-9ff8-9fe6224ffe6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_IndefinitelivedTaxCreditCarryforwardMember_c1d524d3-3ad4-4dc5-9e7d-255d584e805a" xlink:href="evh-20211231.xsd#evh_IndefinitelivedTaxCreditCarryforwardMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardNameDomain_c543e345-5874-4060-b0ce-6c396c3505ed" xlink:to="loc_evh_IndefinitelivedTaxCreditCarryforwardMember_c1d524d3-3ad4-4dc5-9e7d-255d584e805a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_7d93adcf-6a10-4e4c-84f6-064d9d8dc22c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyTable_d63aecd2-cb3e-4053-b296-f5409f0b64f2" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_7d93adcf-6a10-4e4c-84f6-064d9d8dc22c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_7406481e-ce65-44e4-bd13-871259d41dbf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_7d93adcf-6a10-4e4c-84f6-064d9d8dc22c" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_7406481e-ce65-44e4-bd13-871259d41dbf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticCountryMember_ff4ed577-7d52-462f-aef5-a3eef60c4940" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DomesticCountryMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_7406481e-ce65-44e4-bd13-871259d41dbf" xlink:to="loc_us-gaap_DomesticCountryMember_ff4ed577-7d52-462f-aef5-a3eef60c4940" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember_f5c6561c-f8ca-49a2-9b3a-5ca3bab46f96" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_7406481e-ce65-44e4-bd13-871259d41dbf" xlink:to="loc_us-gaap_StateAndLocalJurisdictionMember_f5c6561c-f8ca-49a2-9b3a-5ca3bab46f96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxPeriodAxis_3956c155-dbb8-4a19-b6dd-184e071dbc2c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxPeriodAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyTable_d63aecd2-cb3e-4053-b296-f5409f0b64f2" xlink:to="loc_us-gaap_TaxPeriodAxis_3956c155-dbb8-4a19-b6dd-184e071dbc2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxPeriodDomain_f81584e4-04e3-4de8-90fb-b9f86c378243" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxPeriodDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxPeriodAxis_3956c155-dbb8-4a19-b6dd-184e071dbc2c" xlink:to="loc_us-gaap_TaxPeriodDomain_f81584e4-04e3-4de8-90fb-b9f86c378243" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_PeriodsPriortoJune2015Member_318b8769-6105-4ecb-a579-98fa9c8ca37e" xlink:href="evh-20211231.xsd#evh_PeriodsPriortoJune2015Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxPeriodDomain_f81584e4-04e3-4de8-90fb-b9f86c378243" xlink:to="loc_evh_PeriodsPriortoJune2015Member_318b8769-6105-4ecb-a579-98fa9c8ca37e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxContingencyLineItems_ef897708-caa8-4acc-a6cb-0b51e7523da7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxContingencyLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyTable_d63aecd2-cb3e-4053-b296-f5409f0b64f2" xlink:to="loc_us-gaap_IncomeTaxContingencyLineItems_ef897708-caa8-4acc-a6cb-0b51e7523da7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_52b1608a-4a5a-4807-b85b-7efbb2a620fc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_ef897708-caa8-4acc-a6cb-0b51e7523da7" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_52b1608a-4a5a-4807-b85b-7efbb2a620fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_f4363d31-1ba3-4a67-997c-e0ccb275a55b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_ef897708-caa8-4acc-a6cb-0b51e7523da7" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_f4363d31-1ba3-4a67-997c-e0ccb275a55b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_DeferredTaxLiabilitiesIndefiniteLivedIntangibleAssets_63e8636e-502c-4386-90ed-7cf7fdeac782" xlink:href="evh-20211231.xsd#evh_DeferredTaxLiabilitiesIndefiniteLivedIntangibleAssets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_ef897708-caa8-4acc-a6cb-0b51e7523da7" xlink:to="loc_evh_DeferredTaxLiabilitiesIndefiniteLivedIntangibleAssets_63e8636e-502c-4386-90ed-7cf7fdeac782" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwards_3ee5e02a-29a4-4dca-8eff-6a7d203a8ef8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwards"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_ef897708-caa8-4acc-a6cb-0b51e7523da7" xlink:to="loc_us-gaap_OperatingLossCarryforwards_3ee5e02a-29a4-4dca-8eff-6a7d203a8ef8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_b6ba0329-4a81-4dc7-822d-a078dbe03898" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_ef897708-caa8-4acc-a6cb-0b51e7523da7" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_b6ba0329-4a81-4dc7-822d-a078dbe03898" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_UnrecognizedTaxBenefitsThatWouldNotImpactEffectiveTaxRate_8204ceb8-e4e3-48a1-8c6c-94c0871555db" xlink:href="evh-20211231.xsd#evh_UnrecognizedTaxBenefitsThatWouldNotImpactEffectiveTaxRate"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_ef897708-caa8-4acc-a6cb-0b51e7523da7" xlink:to="loc_evh_UnrecognizedTaxBenefitsThatWouldNotImpactEffectiveTaxRate_8204ceb8-e4e3-48a1-8c6c-94c0871555db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_8c2c3e38-667d-4571-824b-dcc63c22e92d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_ef897708-caa8-4acc-a6cb-0b51e7523da7" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits_8c2c3e38-667d-4571-824b-dcc63c22e92d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_TaxReceivableAgreementPercentofCashSavingsPaidtoShareholders_b6ae1c30-68b0-4ae5-9e74-b040582d9304" xlink:href="evh-20211231.xsd#evh_TaxReceivableAgreementPercentofCashSavingsPaidtoShareholders"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_ef897708-caa8-4acc-a6cb-0b51e7523da7" xlink:to="loc_evh_TaxReceivableAgreementPercentofCashSavingsPaidtoShareholders_b6ae1c30-68b0-4ae5-9e74-b040582d9304" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_TaxReceivableAgreementPercentofCashSavingsNotPaidtoShareholders_2f73140c-bec2-4011-99a1-34a86b545743" xlink:href="evh-20211231.xsd#evh_TaxReceivableAgreementPercentofCashSavingsNotPaidtoShareholders"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_ef897708-caa8-4acc-a6cb-0b51e7523da7" xlink:to="loc_evh_TaxReceivableAgreementPercentofCashSavingsNotPaidtoShareholders_2f73140c-bec2-4011-99a1-34a86b545743" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/IncomeTaxesScheduleofLossBeforeProvisionforIncomeTaxesDetails" xlink:type="simple" xlink:href="evh-20211231.xsd#IncomeTaxesScheduleofLossBeforeProvisionforIncomeTaxesDetails"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/IncomeTaxesScheduleofLossBeforeProvisionforIncomeTaxesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_d0003fcf-bc28-4ff6-8bc6-b1a08b949d98" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract_a24a93f7-df90-477c-920e-603b5accf699" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_d0003fcf-bc28-4ff6-8bc6-b1a08b949d98" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract_a24a93f7-df90-477c-920e-603b5accf699" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_ecde5d75-89cb-46da-8bb9-d4da638b1af9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract_a24a93f7-df90-477c-920e-603b5accf699" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_ecde5d75-89cb-46da-8bb9-d4da638b1af9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_635b6289-2aeb-45c3-a876-bc982aafc0f6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract_a24a93f7-df90-477c-920e-603b5accf699" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_635b6289-2aeb-45c3-a876-bc982aafc0f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_eb01045c-3d16-4e1b-b327-b35720a842e5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract_a24a93f7-df90-477c-920e-603b5accf699" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_eb01045c-3d16-4e1b-b327-b35720a842e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/IncomeTaxesIncomeTaxExpenseBenefitDetails" xlink:type="simple" xlink:href="evh-20211231.xsd#IncomeTaxesIncomeTaxExpenseBenefitDetails"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/IncomeTaxesIncomeTaxExpenseBenefitDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_a09166ec-6b3f-46a9-8ede-8bdc068c4bd7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_5b9abf51-ce31-48ca-84ff-af5244945db9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_a09166ec-6b3f-46a9-8ede-8bdc068c4bd7" xlink:to="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_5b9abf51-ce31-48ca-84ff-af5244945db9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentFederalTaxExpenseBenefit_3c03060a-b117-446c-bb66-52a7c08c64ab" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentFederalTaxExpenseBenefit"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_5b9abf51-ce31-48ca-84ff-af5244945db9" xlink:to="loc_us-gaap_CurrentFederalTaxExpenseBenefit_3c03060a-b117-446c-bb66-52a7c08c64ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_04c1a123-f3d9-4412-a7ea-a3a4a44d6855" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_5b9abf51-ce31-48ca-84ff-af5244945db9" xlink:to="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_04c1a123-f3d9-4412-a7ea-a3a4a44d6855" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentForeignTaxExpenseBenefit_a7fd3968-7510-4951-9943-ee32b991ce1d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentForeignTaxExpenseBenefit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_5b9abf51-ce31-48ca-84ff-af5244945db9" xlink:to="loc_us-gaap_CurrentForeignTaxExpenseBenefit_a7fd3968-7510-4951-9943-ee32b991ce1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_382e9200-596e-49e6-9bb9-f46aeba0f6e2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_5b9abf51-ce31-48ca-84ff-af5244945db9" xlink:to="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_382e9200-596e-49e6-9bb9-f46aeba0f6e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_9f16f277-9ff1-4656-9fb5-1eec15d9e5ba" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_a09166ec-6b3f-46a9-8ede-8bdc068c4bd7" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_9f16f277-9ff1-4656-9fb5-1eec15d9e5ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_6fa68ec7-71fd-41b4-b00e-73338eaf04cf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_9f16f277-9ff1-4656-9fb5-1eec15d9e5ba" xlink:to="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_6fa68ec7-71fd-41b4-b00e-73338eaf04cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_26cb46c1-5700-440e-86c4-027c522271a2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_9f16f277-9ff1-4656-9fb5-1eec15d9e5ba" xlink:to="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_26cb46c1-5700-440e-86c4-027c522271a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_0bf801a5-11d7-464f-b7ab-c90d01870f33" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredForeignIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_9f16f277-9ff1-4656-9fb5-1eec15d9e5ba" xlink:to="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_0bf801a5-11d7-464f-b7ab-c90d01870f33" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_07293139-e813-4bc4-9c0b-551e1ff5159b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_9f16f277-9ff1-4656-9fb5-1eec15d9e5ba" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_07293139-e813-4bc4-9c0b-551e1ff5159b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredOtherTaxExpenseBenefit_80999f86-4f5a-40da-b139-a69d27ddfcc1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredOtherTaxExpenseBenefit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_a09166ec-6b3f-46a9-8ede-8bdc068c4bd7" xlink:to="loc_us-gaap_DeferredOtherTaxExpenseBenefit_80999f86-4f5a-40da-b139-a69d27ddfcc1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_2dff10b8-1828-4178-a552-3c4b161cfe0b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_a09166ec-6b3f-46a9-8ede-8bdc068c4bd7" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_2dff10b8-1828-4178-a552-3c4b161cfe0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/IncomeTaxesReconciliationofStatutoryRatetoEffectiveTaxRateDetails" xlink:type="simple" xlink:href="evh-20211231.xsd#IncomeTaxesReconciliationofStatutoryRatetoEffectiveTaxRateDetails"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/IncomeTaxesReconciliationofStatutoryRatetoEffectiveTaxRateDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_56ee2cdb-a41e-42fb-b22e-f04ca93ca701" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_cbbc8220-7619-4c50-af2e-af4e15094c1b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_56ee2cdb-a41e-42fb-b22e-f04ca93ca701" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_cbbc8220-7619-4c50-af2e-af4e15094c1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_8e913e6a-aece-4501-a560-463ebcd42c31" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_56ee2cdb-a41e-42fb-b22e-f04ca93ca701" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_8e913e6a-aece-4501-a560-463ebcd42c31" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_fd7cf807-cf53-42d7-bb33-1ff3eff24ce4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_56ee2cdb-a41e-42fb-b22e-f04ca93ca701" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_fd7cf807-cf53-42d7-bb33-1ff3eff24ce4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_909ed2c2-e3cf-47b9-be5f-172e961f29b0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_56ee2cdb-a41e-42fb-b22e-f04ca93ca701" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_909ed2c2-e3cf-47b9-be5f-172e961f29b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_EffectiveIncomeTaxRateReconciliationBenefitOfNetOperatingLossCarrybackProvisionPercent_5154c641-1aaa-4eec-ba4f-16d8d7f40252" xlink:href="evh-20211231.xsd#evh_EffectiveIncomeTaxRateReconciliationBenefitOfNetOperatingLossCarrybackProvisionPercent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_56ee2cdb-a41e-42fb-b22e-f04ca93ca701" xlink:to="loc_evh_EffectiveIncomeTaxRateReconciliationBenefitOfNetOperatingLossCarrybackProvisionPercent_5154c641-1aaa-4eec-ba4f-16d8d7f40252" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses_97bb2340-8c06-420d-b237-4c0c5fbdfdfe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_56ee2cdb-a41e-42fb-b22e-f04ca93ca701" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses_97bb2340-8c06-420d-b237-4c0c5fbdfdfe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationMinorityInterestIncomeExpense_28b85801-ba9d-4603-9704-7ebb20313339" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationMinorityInterestIncomeExpense"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_56ee2cdb-a41e-42fb-b22e-f04ca93ca701" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationMinorityInterestIncomeExpense_28b85801-ba9d-4603-9704-7ebb20313339" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseExcessCompensationPercent_22b087fd-b18a-48c0-b411-6b17ef6484b6" xlink:href="evh-20211231.xsd#evh_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseExcessCompensationPercent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_56ee2cdb-a41e-42fb-b22e-f04ca93ca701" xlink:to="loc_evh_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseExcessCompensationPercent_22b087fd-b18a-48c0-b411-6b17ef6484b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent_c9aaca88-55e0-4436-8531-642f71eaf5be" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_56ee2cdb-a41e-42fb-b22e-f04ca93ca701" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent_c9aaca88-55e0-4436-8531-642f71eaf5be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_ddffd3f0-f1cb-4e7e-a3b4-6c3ecc05c712" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_56ee2cdb-a41e-42fb-b22e-f04ca93ca701" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_ddffd3f0-f1cb-4e7e-a3b4-6c3ecc05c712" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_EffectiveIncomeTaxRateReconciliationChangeInUncertainTaxPositions_7a3a62a2-5ed1-4d72-b083-54caba2048cd" xlink:href="evh-20211231.xsd#evh_EffectiveIncomeTaxRateReconciliationChangeInUncertainTaxPositions"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_56ee2cdb-a41e-42fb-b22e-f04ca93ca701" xlink:to="loc_evh_EffectiveIncomeTaxRateReconciliationChangeInUncertainTaxPositions_7a3a62a2-5ed1-4d72-b083-54caba2048cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_EffectiveIncomeTaxRateReconciliationEffectOfInvestment_fb0cc6f5-4e98-428a-b5e6-42a4d0dbfa7e" xlink:href="evh-20211231.xsd#evh_EffectiveIncomeTaxRateReconciliationEffectOfInvestment"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_56ee2cdb-a41e-42fb-b22e-f04ca93ca701" xlink:to="loc_evh_EffectiveIncomeTaxRateReconciliationEffectOfInvestment_fb0cc6f5-4e98-428a-b5e6-42a4d0dbfa7e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_bab65a49-fac9-455f-b2e3-d513e4016ad2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_56ee2cdb-a41e-42fb-b22e-f04ca93ca701" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_bab65a49-fac9-455f-b2e3-d513e4016ad2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseReturnToProvisionPercent_2ed0b58c-9732-4fdd-9319-51ac5d188e9d" xlink:href="evh-20211231.xsd#evh_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseReturnToProvisionPercent"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_56ee2cdb-a41e-42fb-b22e-f04ca93ca701" xlink:to="loc_evh_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseReturnToProvisionPercent_2ed0b58c-9732-4fdd-9319-51ac5d188e9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_EffectiveIncomeTaxRateReconciliationDomesticSubsidiaryException_f425cffc-63bb-49fc-b8a8-0654f03a2f96" xlink:href="evh-20211231.xsd#evh_EffectiveIncomeTaxRateReconciliationDomesticSubsidiaryException"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_56ee2cdb-a41e-42fb-b22e-f04ca93ca701" xlink:to="loc_evh_EffectiveIncomeTaxRateReconciliationDomesticSubsidiaryException_f425cffc-63bb-49fc-b8a8-0654f03a2f96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlements_784d650a-d68f-4452-ab94-c1d90c7d2641" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlements"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_56ee2cdb-a41e-42fb-b22e-f04ca93ca701" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlements_784d650a-d68f-4452-ab94-c1d90c7d2641" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_0700a71a-aa9c-4365-b3ea-d1587e3d55dd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_56ee2cdb-a41e-42fb-b22e-f04ca93ca701" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_0700a71a-aa9c-4365-b3ea-d1587e3d55dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_79d8369c-2ae9-4b80-b603-05fda436ee68" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_56ee2cdb-a41e-42fb-b22e-f04ca93ca701" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_79d8369c-2ae9-4b80-b603-05fda436ee68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails" xlink:type="simple" xlink:href="evh-20211231.xsd#IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_fcb253e5-6d99-42df-b913-da97306abd06" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNetAbstract_672df3de-28ed-46fa-b67f-c6f2200d6405" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsNetAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_fcb253e5-6d99-42df-b913-da97306abd06" xlink:to="loc_us-gaap_DeferredTaxAssetsNetAbstract_672df3de-28ed-46fa-b67f-c6f2200d6405" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_DeferredTaxAssetsStartupandOrganizationalCosts_e99a2ae6-4627-418c-8606-80d412c16744" xlink:href="evh-20211231.xsd#evh_DeferredTaxAssetsStartupandOrganizationalCosts"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_672df3de-28ed-46fa-b67f-c6f2200d6405" xlink:to="loc_evh_DeferredTaxAssetsStartupandOrganizationalCosts_e99a2ae6-4627-418c-8606-80d412c16744" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_8b672946-bbc7-4399-82c7-ee19eb4f07fc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_672df3de-28ed-46fa-b67f-c6f2200d6405" xlink:to="loc_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_8b672946-bbc7-4399-82c7-ee19eb4f07fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_DeferredTaxAssetsOperatingLeaseRightOfUseAsset_b5923527-c33f-43c3-b822-a0f6721cd4ee" xlink:href="evh-20211231.xsd#evh_DeferredTaxAssetsOperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_672df3de-28ed-46fa-b67f-c6f2200d6405" xlink:to="loc_evh_DeferredTaxAssetsOperatingLeaseRightOfUseAsset_b5923527-c33f-43c3-b822-a0f6721cd4ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_97989873-7b91-4ff4-a1ec-362558c0eeec" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_672df3de-28ed-46fa-b67f-c6f2200d6405" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_97989873-7b91-4ff4-a1ec-362558c0eeec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation_7275e177-536a-45ff-961c-f2f0fdb6408b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_672df3de-28ed-46fa-b67f-c6f2200d6405" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation_7275e177-536a-45ff-961c-f2f0fdb6408b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_ad99688e-a8da-4bdf-af25-9de09dbceb27" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_672df3de-28ed-46fa-b67f-c6f2200d6405" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_ad99688e-a8da-4bdf-af25-9de09dbceb27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_7619a9d6-6c20-4d70-add0-d6080c041d74" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_672df3de-28ed-46fa-b67f-c6f2200d6405" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_7619a9d6-6c20-4d70-add0-d6080c041d74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_cf5c7566-5ccb-45be-bb53-3d99e57aee2e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_672df3de-28ed-46fa-b67f-c6f2200d6405" xlink:to="loc_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_cf5c7566-5ccb-45be-bb53-3d99e57aee2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetInterestCarryforward_bb8c9755-2867-4bd7-9231-2a7df175f78e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetInterestCarryforward"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_672df3de-28ed-46fa-b67f-c6f2200d6405" xlink:to="loc_us-gaap_DeferredTaxAssetInterestCarryforward_bb8c9755-2867-4bd7-9231-2a7df175f78e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_DeferredTaxAssetOutsideBasisDifferences_b9f69872-97c6-44fb-9744-c8ac7f3f4240" xlink:href="evh-20211231.xsd#evh_DeferredTaxAssetOutsideBasisDifferences"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_672df3de-28ed-46fa-b67f-c6f2200d6405" xlink:to="loc_evh_DeferredTaxAssetOutsideBasisDifferences_b9f69872-97c6-44fb-9744-c8ac7f3f4240" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOther_18ae2f8a-271c-494c-bd34-d2ea685d7e91" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsOther"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_672df3de-28ed-46fa-b67f-c6f2200d6405" xlink:to="loc_us-gaap_DeferredTaxAssetsOther_18ae2f8a-271c-494c-bd34-d2ea685d7e91" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_8e1794cc-a922-42d3-a5eb-a2eccab4076a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_672df3de-28ed-46fa-b67f-c6f2200d6405" xlink:to="loc_us-gaap_DeferredTaxAssetsGross_8e1794cc-a922-42d3-a5eb-a2eccab4076a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_376cf9ec-56c9-45b3-8ff3-11ea69436059" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_672df3de-28ed-46fa-b67f-c6f2200d6405" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_376cf9ec-56c9-45b3-8ff3-11ea69436059" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNet_7533865c-2ad8-488d-9d3b-c588a2fa8d05" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_672df3de-28ed-46fa-b67f-c6f2200d6405" xlink:to="loc_us-gaap_DeferredTaxAssetsNet_7533865c-2ad8-488d-9d3b-c588a2fa8d05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesNetAbstract_30728462-99f8-4b06-a83f-9e126f40b169" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilitiesNetAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_fcb253e5-6d99-42df-b913-da97306abd06" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesNetAbstract_30728462-99f8-4b06-a83f-9e126f40b169" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedSoftware_4222ce57-66bc-45a9-8d51-ae1ebd4a7558" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedSoftware"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesNetAbstract_30728462-99f8-4b06-a83f-9e126f40b169" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedSoftware_4222ce57-66bc-45a9-8d51-ae1ebd4a7558" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_ad03600b-6cac-42c5-a981-4b56a4bfd4c1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesNetAbstract_30728462-99f8-4b06-a83f-9e126f40b169" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_ad03600b-6cac-42c5-a981-4b56a4bfd4c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesLeasingArrangements_b8cba4ad-31ea-40d5-9ffc-d2daed885c26" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilitiesLeasingArrangements"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesNetAbstract_30728462-99f8-4b06-a83f-9e126f40b169" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesLeasingArrangements_b8cba4ad-31ea-40d5-9ffc-d2daed885c26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesDeferredExpense_866c9b84-55c5-4f8b-a400-4195f9317146" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilitiesDeferredExpense"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesNetAbstract_30728462-99f8-4b06-a83f-9e126f40b169" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesDeferredExpense_866c9b84-55c5-4f8b-a400-4195f9317146" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesFinancingArrangements_d67510d4-5059-4b88-a608-b28d60a17567" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilitiesFinancingArrangements"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesNetAbstract_30728462-99f8-4b06-a83f-9e126f40b169" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesFinancingArrangements_d67510d4-5059-4b88-a608-b28d60a17567" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesOther_54cc6faf-8288-4aca-9c1d-5677c5b4f27f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilitiesOther"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesNetAbstract_30728462-99f8-4b06-a83f-9e126f40b169" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesOther_54cc6faf-8288-4aca-9c1d-5677c5b4f27f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities_935938bc-52f8-4d14-a399-6108358963c8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesNetAbstract_30728462-99f8-4b06-a83f-9e126f40b169" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilities_935938bc-52f8-4d14-a399-6108358963c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilities_5f14a8ad-2dc7-4486-811c-2f011eee44dc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_fcb253e5-6d99-42df-b913-da97306abd06" xlink:to="loc_us-gaap_DeferredTaxLiabilities_5f14a8ad-2dc7-4486-811c-2f011eee44dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/IncomeTaxesChangesinValuationAllowanceDetails" xlink:type="simple" xlink:href="evh-20211231.xsd#IncomeTaxesChangesinValuationAllowanceDetails"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/IncomeTaxesChangesinValuationAllowanceDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_f2679a46-a811-4fab-8f28-95706caae9d6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsTable_e28867a1-ee96-4745-8b82-153055d061ee" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwardsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_f2679a46-a811-4fab-8f28-95706caae9d6" xlink:to="loc_us-gaap_OperatingLossCarryforwardsTable_e28867a1-ee96-4745-8b82-153055d061ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_5688462d-dff2-4a75-bfc9-4577672eea99" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowancesAndReservesTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_e28867a1-ee96-4745-8b82-153055d061ee" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_5688462d-dff2-4a75-bfc9-4577672eea99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDomain_c3648f79-680a-4162-8b1d-4384ebc85253" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowancesAndReservesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_5688462d-dff2-4a75-bfc9-4577672eea99" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesDomain_c3648f79-680a-4162-8b1d-4384ebc85253" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowanceOfDeferredTaxAssetsMember_04d7cde5-8ee1-40f0-95a6-d57d0d74f898" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowanceOfDeferredTaxAssetsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_c3648f79-680a-4162-8b1d-4384ebc85253" xlink:to="loc_us-gaap_ValuationAllowanceOfDeferredTaxAssetsMember_04d7cde5-8ee1-40f0-95a6-d57d0d74f898" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsLineItems_63605150-4640-45ee-abae-63408d380220" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwardsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_e28867a1-ee96-4745-8b82-153055d061ee" xlink:to="loc_us-gaap_OperatingLossCarryforwardsLineItems_63605150-4640-45ee-abae-63408d380220" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_4f58a8a6-df26-4a35-b208-9ff77fca5969" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MovementInValuationAllowancesAndReservesRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_63605150-4640-45ee-abae-63408d380220" xlink:to="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_4f58a8a6-df26-4a35-b208-9ff77fca5969" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance_6f67bffd-8389-48df-9149-2e0b4037433b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowancesAndReservesBalance"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_4f58a8a6-df26-4a35-b208-9ff77fca5969" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesBalance_6f67bffd-8389-48df-9149-2e0b4037433b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense_c6e7242a-a2af-4a55-8d0a-35ee51da6f86" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_4f58a8a6-df26-4a35-b208-9ff77fca5969" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense_c6e7242a-a2af-4a55-8d0a-35ee51da6f86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts_a224daa8-0948-4fa9-bd25-228a13e1af2a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_4f58a8a6-df26-4a35-b208-9ff77fca5969" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts_a224daa8-0948-4fa9-bd25-228a13e1af2a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDeductions_2d8298b5-cbd9-496a-afa8-6dfd9607ed15" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowancesAndReservesDeductions"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_4f58a8a6-df26-4a35-b208-9ff77fca5969" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesDeductions_2d8298b5-cbd9-496a-afa8-6dfd9607ed15" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance_42b92b20-050e-4423-b100-72e5b409f878" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowancesAndReservesBalance"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_4f58a8a6-df26-4a35-b208-9ff77fca5969" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesBalance_42b92b20-050e-4423-b100-72e5b409f878" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_ValuationAllowancesAndReservesChargedCreditedToAdditionalPaidInCapital_bf99ef9e-2b2e-4193-82e6-46de594e0358" xlink:href="evh-20211231.xsd#evh_ValuationAllowancesAndReservesChargedCreditedToAdditionalPaidInCapital"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_63605150-4640-45ee-abae-63408d380220" xlink:to="loc_evh_ValuationAllowancesAndReservesChargedCreditedToAdditionalPaidInCapital_bf99ef9e-2b2e-4193-82e6-46de594e0358" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_ValuationAllowancesAndReservesChargedToRetainedEarnings_a0e25923-fc02-4aad-991c-04d13a0dae62" xlink:href="evh-20211231.xsd#evh_ValuationAllowancesAndReservesChargedToRetainedEarnings"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_63605150-4640-45ee-abae-63408d380220" xlink:to="loc_evh_ValuationAllowancesAndReservesChargedToRetainedEarnings_a0e25923-fc02-4aad-991c-04d13a0dae62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/IncomeTaxesChangesInUnrecognizedTaxBenefitsDetails" xlink:type="simple" xlink:href="evh-20211231.xsd#IncomeTaxesChangesInUnrecognizedTaxBenefitsDetails"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/IncomeTaxesChangesInUnrecognizedTaxBenefitsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_a5f44933-04a6-4ffc-9697-52de7cc48bd8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_a5c69d99-5d9f-4e88-ac69-680c89f9551c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_a5f44933-04a6-4ffc-9697-52de7cc48bd8" xlink:to="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_a5c69d99-5d9f-4e88-ac69-680c89f9551c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_a3fa836d-23f8-4a59-9758-a7fb3b7ae94a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_a5c69d99-5d9f-4e88-ac69-680c89f9551c" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits_a3fa836d-23f8-4a59-9758-a7fb3b7ae94a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations_274e4e81-8b5b-4e21-afc8-50591a69cfe2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_a5c69d99-5d9f-4e88-ac69-680c89f9551c" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations_274e4e81-8b5b-4e21-afc8-50591a69cfe2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_84fd7589-59f6-431a-b6a1-796f7fb4b03c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_a5c69d99-5d9f-4e88-ac69-680c89f9551c" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits_84fd7589-59f6-431a-b6a1-796f7fb4b03c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/EmployeeBenefitPlans" xlink:type="simple" xlink:href="evh-20211231.xsd#EmployeeBenefitPlans"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/EmployeeBenefitPlans" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_60a37894-989e-484b-9aba-0ff06edbd2d9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_930a7c2f-6aa6-416c-8f22-0bd5abdc506f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_60a37894-989e-484b-9aba-0ff06edbd2d9" xlink:to="loc_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_930a7c2f-6aa6-416c-8f22-0bd5abdc506f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/EmployeeBenefitPlansDetails" xlink:type="simple" xlink:href="evh-20211231.xsd#EmployeeBenefitPlansDetails"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/EmployeeBenefitPlansDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_1a574509-0170-4e4d-a1a5-aca641ae9ccc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_c51cbaf1-f2c4-4d3e-be5a-2139bcc0e7da" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_1a574509-0170-4e4d-a1a5-aca641ae9ccc" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_c51cbaf1-f2c4-4d3e-be5a-2139bcc0e7da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis_679d387e-fea6-4452-8da8-e08a4c027a99" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupClassificationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_c51cbaf1-f2c4-4d3e-be5a-2139bcc0e7da" xlink:to="loc_us-gaap_DisposalGroupClassificationAxis_679d387e-fea6-4452-8da8-e08a4c027a99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_c5d1b8be-8e1a-441d-856c-42283a7989fe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_679d387e-fea6-4452-8da8-e08a4c027a99" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_c5d1b8be-8e1a-441d-856c-42283a7989fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationsDisposedOfBySaleMember_e29a953a-08b4-4bf2-a8bf-4df57c94a6d2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DiscontinuedOperationsDisposedOfBySaleMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain_c5d1b8be-8e1a-441d-856c-42283a7989fe" xlink:to="loc_us-gaap_DiscontinuedOperationsDisposedOfBySaleMember_e29a953a-08b4-4bf2-a8bf-4df57c94a6d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_04e43643-ceda-4016-b66b-802b3be73731" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_c51cbaf1-f2c4-4d3e-be5a-2139bcc0e7da" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_04e43643-ceda-4016-b66b-802b3be73731" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_950a756b-e709-4683-971e-6863c524901c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_04e43643-ceda-4016-b66b-802b3be73731" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_950a756b-e709-4683-971e-6863c524901c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_TrueHealthMember_b0a8f926-034e-4cf0-b6cd-0fd2871d2194" xlink:href="evh-20211231.xsd#evh_TrueHealthMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_950a756b-e709-4683-971e-6863c524901c" xlink:to="loc_evh_TrueHealthMember_b0a8f926-034e-4cf0-b6cd-0fd2871d2194" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_6bb07c9b-41fe-44f8-984d-b67a6c956496" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_c51cbaf1-f2c4-4d3e-be5a-2139bcc0e7da" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_6bb07c9b-41fe-44f8-984d-b67a6c956496" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_8e20d4a3-be5e-422b-a3f7-20c4121024a3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_6bb07c9b-41fe-44f8-984d-b67a6c956496" xlink:to="loc_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_8e20d4a3-be5e-422b-a3f7-20c4121024a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/InvestmentsinEquityMethodInvestees" xlink:type="simple" xlink:href="evh-20211231.xsd#InvestmentsinEquityMethodInvestees"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/InvestmentsinEquityMethodInvestees" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract_4f3ff60f-725b-4765-a885-e8bca72ed076" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentsDisclosureTextBlock_8511c14f-d633-4160-8332-a8a9d77a2e64" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestmentsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract_4f3ff60f-725b-4765-a885-e8bca72ed076" xlink:to="loc_us-gaap_EquityMethodInvestmentsDisclosureTextBlock_8511c14f-d633-4160-8332-a8a9d77a2e64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/InvestmentsinEquityMethodInvesteesDetails" xlink:type="simple" xlink:href="evh-20211231.xsd#InvestmentsinEquityMethodInvesteesDetails"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/InvestmentsinEquityMethodInvesteesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract_0c98b182-2539-468e-b904-bcbba2330066" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_c98e9ad8-23d8-489d-bbcb-6f4cf95710ca" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract_0c98b182-2539-468e-b904-bcbba2330066" xlink:to="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_c98e9ad8-23d8-489d-bbcb-6f4cf95710ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_1c94548f-2ca7-4d72-92ea-5929206a509b" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_c98e9ad8-23d8-489d-bbcb-6f4cf95710ca" xlink:to="loc_srt_RangeAxis_1c94548f-2ca7-4d72-92ea-5929206a509b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_53927c94-6be7-4ec3-917c-829c7121033a" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_1c94548f-2ca7-4d72-92ea-5929206a509b" xlink:to="loc_srt_RangeMember_53927c94-6be7-4ec3-917c-829c7121033a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_8f06a1af-63c6-4857-a343-276ce82bbd2e" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_53927c94-6be7-4ec3-917c-829c7121033a" xlink:to="loc_srt_MinimumMember_8f06a1af-63c6-4857-a343-276ce82bbd2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_4f65600a-b7ed-474d-9d2b-fffee603600a" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_53927c94-6be7-4ec3-917c-829c7121033a" xlink:to="loc_srt_MaximumMember_4f65600a-b7ed-474d-9d2b-fffee603600a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_8bade582-9063-4a81-aa2a-783c3d28da6d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_c98e9ad8-23d8-489d-bbcb-6f4cf95710ca" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_8bade582-9063-4a81-aa2a-783c3d28da6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_d2ff0a70-a9ff-47ac-a7ae-c0a4c8b4d089" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_8bade582-9063-4a81-aa2a-783c3d28da6d" xlink:to="loc_us-gaap_RelatedPartyDomain_d2ff0a70-a9ff-47ac-a7ae-c0a4c8b4d089" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvesteeMember_0b890097-f906-466e-8283-144415278cb0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvesteeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_d2ff0a70-a9ff-47ac-a7ae-c0a4c8b4d089" xlink:to="loc_us-gaap_EquityMethodInvesteeMember_0b890097-f906-466e-8283-144415278cb0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis_1e93bbd6-7a5d-4599-9bde-ddcc1d257d92" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_c98e9ad8-23d8-489d-bbcb-6f4cf95710ca" xlink:to="loc_us-gaap_RelatedPartyTransactionAxis_1e93bbd6-7a5d-4599-9bde-ddcc1d257d92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_d97bd963-89d9-4d68-8d6d-6424503d867b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_1e93bbd6-7a5d-4599-9bde-ddcc1d257d92" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_d97bd963-89d9-4d68-8d6d-6424503d867b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_ServicesAgreementsMember_5142eda6-88b7-4b21-a9d7-df3278ea75f3" xlink:href="evh-20211231.xsd#evh_ServicesAgreementsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_d97bd963-89d9-4d68-8d6d-6424503d867b" xlink:to="loc_evh_ServicesAgreementsMember_5142eda6-88b7-4b21-a9d7-df3278ea75f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesAxis_9405ef75-c604-4497-88ac-f0e49683c228" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ConsolidatedEntitiesAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_c98e9ad8-23d8-489d-bbcb-6f4cf95710ca" xlink:to="loc_srt_ConsolidatedEntitiesAxis_9405ef75-c604-4497-88ac-f0e49683c228" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesDomain_623b07c1-0895-4e92-a1d6-078cb69071fe" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ConsolidatedEntitiesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidatedEntitiesAxis_9405ef75-c604-4497-88ac-f0e49683c228" xlink:to="loc_srt_ConsolidatedEntitiesDomain_623b07c1-0895-4e92-a1d6-078cb69071fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableInterestEntityNotPrimaryBeneficiaryMember_28830f99-5157-48ba-9262-3081cd9d4d5b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableInterestEntityNotPrimaryBeneficiaryMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidatedEntitiesDomain_623b07c1-0895-4e92-a1d6-078cb69071fe" xlink:to="loc_us-gaap_VariableInterestEntityNotPrimaryBeneficiaryMember_28830f99-5157-48ba-9262-3081cd9d4d5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_02069342-cdae-49f7-bec5-c28b50a4682b" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_c98e9ad8-23d8-489d-bbcb-6f4cf95710ca" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_02069342-cdae-49f7-bec5-c28b50a4682b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_48d1266a-58f6-41b9-9ec7-868ead840936" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_02069342-cdae-49f7-bec5-c28b50a4682b" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_48d1266a-58f6-41b9-9ec7-868ead840936" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_GlobalHealthMember_535a7d8c-0911-49c5-8ecb-3096ead2c605" xlink:href="evh-20211231.xsd#evh_GlobalHealthMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_48d1266a-58f6-41b9-9ec7-868ead840936" xlink:to="loc_evh_GlobalHealthMember_535a7d8c-0911-49c5-8ecb-3096ead2c605" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_aeb1e29a-3c3b-418a-80e3-6caea0abb37b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsLineItems"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_c98e9ad8-23d8-489d-bbcb-6f4cf95710ca" xlink:to="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_aeb1e29a-3c3b-418a-80e3-6caea0abb37b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_EquityMethodInvestmentEconomicInterestPercentage_c8f4a510-5007-4347-a0c6-9ef6f7409fff" xlink:href="evh-20211231.xsd#evh_EquityMethodInvestmentEconomicInterestPercentage"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_aeb1e29a-3c3b-418a-80e3-6caea0abb37b" xlink:to="loc_evh_EquityMethodInvestmentEconomicInterestPercentage_c8f4a510-5007-4347-a0c6-9ef6f7409fff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_EquityMethodInvestmentVotingInterestPercentage_8b05c9bc-6919-4b44-a3db-20dc57c9250a" xlink:href="evh-20211231.xsd#evh_EquityMethodInvestmentVotingInterestPercentage"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_aeb1e29a-3c3b-418a-80e3-6caea0abb37b" xlink:to="loc_evh_EquityMethodInvestmentVotingInterestPercentage_8b05c9bc-6919-4b44-a3db-20dc57c9250a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_3a862d39-84d2-4891-898c-5ff51e41ea72" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_aeb1e29a-3c3b-418a-80e3-6caea0abb37b" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_3a862d39-84d2-4891-898c-5ff51e41ea72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_IncomeLossfromEquityMethodInvestmentsServicesAgreement_0ab424be-9907-4bfd-9772-d290dcc690d4" xlink:href="evh-20211231.xsd#evh_IncomeLossfromEquityMethodInvestmentsServicesAgreement"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_aeb1e29a-3c3b-418a-80e3-6caea0abb37b" xlink:to="loc_evh_IncomeLossfromEquityMethodInvestmentsServicesAgreement_0ab424be-9907-4bfd-9772-d290dcc690d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_StatutoryCapitalReservesLiquidityGuaranteedByInvestorsMinimum_bf1b7ac3-cc62-437c-92a9-e9ab114a0306" xlink:href="evh-20211231.xsd#evh_StatutoryCapitalReservesLiquidityGuaranteedByInvestorsMinimum"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_aeb1e29a-3c3b-418a-80e3-6caea0abb37b" xlink:to="loc_evh_StatutoryCapitalReservesLiquidityGuaranteedByInvestorsMinimum_bf1b7ac3-cc62-437c-92a9-e9ab114a0306" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_EquityInterestToBeTransferred_eaf04d88-9e29-4acf-8308-72e21e656346" xlink:href="evh-20211231.xsd#evh_EquityInterestToBeTransferred"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_aeb1e29a-3c3b-418a-80e3-6caea0abb37b" xlink:to="loc_evh_EquityInterestToBeTransferred_eaf04d88-9e29-4acf-8308-72e21e656346" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentOtherThanTemporaryImpairment_b4b77835-4c0c-40ee-a571-5e2dd36af253" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestmentOtherThanTemporaryImpairment"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_aeb1e29a-3c3b-418a-80e3-6caea0abb37b" xlink:to="loc_us-gaap_EquityMethodInvestmentOtherThanTemporaryImpairment_b4b77835-4c0c-40ee-a571-5e2dd36af253" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/NoncontrollingInterests" xlink:type="simple" xlink:href="evh-20211231.xsd#NoncontrollingInterests"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/NoncontrollingInterests" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestAbstract_1b028d60-b3c5-483c-b0bb-0d962d8b37e4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NoncontrollingInterestAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestDisclosureTextBlock_ab312108-96e0-4926-a9c3-019c06658dce" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MinorityInterestDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncontrollingInterestAbstract_1b028d60-b3c5-483c-b0bb-0d962d8b37e4" xlink:to="loc_us-gaap_MinorityInterestDisclosureTextBlock_ab312108-96e0-4926-a9c3-019c06658dce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/NoncontrollingInterestsTables" xlink:type="simple" xlink:href="evh-20211231.xsd#NoncontrollingInterestsTables"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/NoncontrollingInterestsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestAbstract_69f6890c-2da5-4350-ae14-304f6d3092ce" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NoncontrollingInterestAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_ScheduleofChangesinNoncontrollingInterestTableTextBlock_cfdbb50e-ad6c-4aed-aeb1-88523427662c" xlink:href="evh-20211231.xsd#evh_ScheduleofChangesinNoncontrollingInterestTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncontrollingInterestAbstract_69f6890c-2da5-4350-ae14-304f6d3092ce" xlink:to="loc_evh_ScheduleofChangesinNoncontrollingInterestTableTextBlock_cfdbb50e-ad6c-4aed-aeb1-88523427662c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/NoncontrollingInterestsDetails" xlink:type="simple" xlink:href="evh-20211231.xsd#NoncontrollingInterestsDetails"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/NoncontrollingInterestsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestAbstract_76d8c04f-d8c2-4f06-88f6-956e2e31eedf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NoncontrollingInterestAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestTable_7e7dad52-e53f-4c1a-8b42-95239a4c37a0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MinorityInterestTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncontrollingInterestAbstract_76d8c04f-d8c2-4f06-88f6-956e2e31eedf" xlink:to="loc_us-gaap_MinorityInterestTable_7e7dad52-e53f-4c1a-8b42-95239a4c37a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipAxis_7ec47f76-7dea-4304-a43e-d11692e4966c" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_OwnershipAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MinorityInterestTable_7e7dad52-e53f-4c1a-8b42-95239a4c37a0" xlink:to="loc_srt_OwnershipAxis_7ec47f76-7dea-4304-a43e-d11692e4966c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain_7073c6c6-8a32-4b30-b897-1afab95af973" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_OwnershipDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_OwnershipAxis_7ec47f76-7dea-4304-a43e-d11692e4966c" xlink:to="loc_srt_OwnershipDomain_7073c6c6-8a32-4b30-b897-1afab95af973" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_EvolentHealthLLCMember_85f5c098-11c4-4450-bb6a-56773c69e03a" xlink:href="evh-20211231.xsd#evh_EvolentHealthLLCMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_OwnershipDomain_7073c6c6-8a32-4b30-b897-1afab95af973" xlink:to="loc_evh_EvolentHealthLLCMember_85f5c098-11c4-4450-bb6a-56773c69e03a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_d3f7fd36-3333-485e-a369-7c55eb08b7e9" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MinorityInterestTable_7e7dad52-e53f-4c1a-8b42-95239a4c37a0" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_d3f7fd36-3333-485e-a369-7c55eb08b7e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_e11de03f-e7af-40e1-bc63-4862655ba641" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_d3f7fd36-3333-485e-a369-7c55eb08b7e9" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_e11de03f-e7af-40e1-bc63-4862655ba641" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_UniversityHealthCaredbaPassportHealthPlanMember_60b4910c-87a4-4ea8-8426-3a5cf42630a8" xlink:href="evh-20211231.xsd#evh_UniversityHealthCaredbaPassportHealthPlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_e11de03f-e7af-40e1-bc63-4862655ba641" xlink:to="loc_evh_UniversityHealthCaredbaPassportHealthPlanMember_60b4910c-87a4-4ea8-8426-3a5cf42630a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesAxis_d2b39cff-e824-4e99-bab2-8c8ef935a0cc" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ConsolidatedEntitiesAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MinorityInterestTable_7e7dad52-e53f-4c1a-8b42-95239a4c37a0" xlink:to="loc_srt_ConsolidatedEntitiesAxis_d2b39cff-e824-4e99-bab2-8c8ef935a0cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesDomain_1f7d4f5f-148e-42f1-8d15-c9282c063cfc" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ConsolidatedEntitiesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidatedEntitiesAxis_d2b39cff-e824-4e99-bab2-8c8ef935a0cc" xlink:to="loc_srt_ConsolidatedEntitiesDomain_1f7d4f5f-148e-42f1-8d15-c9282c063cfc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableInterestEntityNotPrimaryBeneficiaryMember_536dea1b-dab4-48f3-8b29-617198cf1cfe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableInterestEntityNotPrimaryBeneficiaryMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidatedEntitiesDomain_1f7d4f5f-148e-42f1-8d15-c9282c063cfc" xlink:to="loc_us-gaap_VariableInterestEntityNotPrimaryBeneficiaryMember_536dea1b-dab4-48f3-8b29-617198cf1cfe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestLineItems_fe4ef0ac-ccf3-4565-b4fe-7612b1be193d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MinorityInterestLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MinorityInterestTable_7e7dad52-e53f-4c1a-8b42-95239a4c37a0" xlink:to="loc_us-gaap_MinorityInterestLineItems_fe4ef0ac-ccf3-4565-b4fe-7612b1be193d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestOwnershipPercentageByParent_7f6848c3-dd4e-4018-9c14-bee7d0a0e47e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MinorityInterestOwnershipPercentageByParent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MinorityInterestLineItems_fe4ef0ac-ccf3-4565-b4fe-7612b1be193d" xlink:to="loc_us-gaap_MinorityInterestOwnershipPercentageByParent_7f6848c3-dd4e-4018-9c14-bee7d0a0e47e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestIncreaseFromBusinessCombination_59985d87-220a-4cc8-8914-d0491b584022" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NoncontrollingInterestIncreaseFromBusinessCombination"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MinorityInterestLineItems_fe4ef0ac-ccf3-4565-b4fe-7612b1be193d" xlink:to="loc_us-gaap_NoncontrollingInterestIncreaseFromBusinessCombination_59985d87-220a-4cc8-8914-d0491b584022" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableInterestEntityOwnershipPercentage_6f199c8f-d8df-4817-aabc-c9dbc0362341" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableInterestEntityOwnershipPercentage"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MinorityInterestLineItems_fe4ef0ac-ccf3-4565-b4fe-7612b1be193d" xlink:to="loc_us-gaap_VariableInterestEntityOwnershipPercentage_6f199c8f-d8df-4817-aabc-c9dbc0362341" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_VariableInterestEntityNewMedicaidContractNotAwardedRequirementToAcquireOwnershipConsiderationAmount_48f67909-59be-4ab3-be3c-4d85022d80aa" xlink:href="evh-20211231.xsd#evh_VariableInterestEntityNewMedicaidContractNotAwardedRequirementToAcquireOwnershipConsiderationAmount"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MinorityInterestLineItems_fe4ef0ac-ccf3-4565-b4fe-7612b1be193d" xlink:to="loc_evh_VariableInterestEntityNewMedicaidContractNotAwardedRequirementToAcquireOwnershipConsiderationAmount_48f67909-59be-4ab3-be3c-4d85022d80aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableInterestEntityInitialConsolidationGainOrLoss_c1ecb1d6-f70e-4fd2-9464-4a42555ce988" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableInterestEntityInitialConsolidationGainOrLoss"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MinorityInterestLineItems_fe4ef0ac-ccf3-4565-b4fe-7612b1be193d" xlink:to="loc_us-gaap_VariableInterestEntityInitialConsolidationGainOrLoss_c1ecb1d6-f70e-4fd2-9464-4a42555ce988" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/NoncontrollingInterestsScheduleofChangesinNoncontrollingInterestsDetails" xlink:type="simple" xlink:href="evh-20211231.xsd#NoncontrollingInterestsScheduleofChangesinNoncontrollingInterestsDetails"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/NoncontrollingInterestsScheduleofChangesinNoncontrollingInterestsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestAbstract_74e34c1f-e939-4298-add0-a4c00f5bcea9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NoncontrollingInterestAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestTable_8050195f-1481-4bda-a1ce-20a3a5de7f3a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MinorityInterestTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncontrollingInterestAbstract_74e34c1f-e939-4298-add0-a4c00f5bcea9" xlink:to="loc_us-gaap_MinorityInterestTable_8050195f-1481-4bda-a1ce-20a3a5de7f3a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_58575de5-d555-4bac-8c60-69d7b2c1321d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MinorityInterestTable_8050195f-1481-4bda-a1ce-20a3a5de7f3a" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_58575de5-d555-4bac-8c60-69d7b2c1321d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_268e5850-10fd-48f5-9256-de50e934d9e3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_58575de5-d555-4bac-8c60-69d7b2c1321d" xlink:to="loc_us-gaap_EquityComponentDomain_268e5850-10fd-48f5-9256-de50e934d9e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestMember_654c3164-4ae9-428c-b9ea-48642878fc9c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NoncontrollingInterestMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_268e5850-10fd-48f5-9256-de50e934d9e3" xlink:to="loc_us-gaap_NoncontrollingInterestMember_654c3164-4ae9-428c-b9ea-48642878fc9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestLineItems_f309b8da-76c8-4978-b381-74a0fa15e607" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MinorityInterestLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MinorityInterestTable_8050195f-1481-4bda-a1ce-20a3a5de7f3a" xlink:to="loc_us-gaap_MinorityInterestLineItems_f309b8da-76c8-4978-b381-74a0fa15e607" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MovementInMinorityInterestRollForward_544bfd5c-cbd3-49ea-8542-d2998e3a4d2e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MovementInMinorityInterestRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MinorityInterestLineItems_f309b8da-76c8-4978-b381-74a0fa15e607" xlink:to="loc_us-gaap_MovementInMinorityInterestRollForward_544bfd5c-cbd3-49ea-8542-d2998e3a4d2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterest_9e5eaccb-7ba9-44af-9f1b-50e4ea1ef81e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MinorityInterest"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MovementInMinorityInterestRollForward_544bfd5c-cbd3-49ea-8542-d2998e3a4d2e" xlink:to="loc_us-gaap_MinorityInterest_9e5eaccb-7ba9-44af-9f1b-50e4ea1ef81e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestIncreaseFromBusinessCombination_90426a62-1e4c-448b-a3f4-05a7e3bf0df5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NoncontrollingInterestIncreaseFromBusinessCombination"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MovementInMinorityInterestRollForward_544bfd5c-cbd3-49ea-8542-d2998e3a4d2e" xlink:to="loc_us-gaap_NoncontrollingInterestIncreaseFromBusinessCombination_90426a62-1e4c-448b-a3f4-05a7e3bf0df5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_b2048cde-76f7-43bd-be07-7459c10a72ac" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MovementInMinorityInterestRollForward_544bfd5c-cbd3-49ea-8542-d2998e3a4d2e" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_b2048cde-76f7-43bd-be07-7459c10a72ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_NoncontrollingInterestDecreaseFromDisposalOfAssets_dd7ba5e5-b21d-43d6-ade8-4ed10ab36655" xlink:href="evh-20211231.xsd#evh_NoncontrollingInterestDecreaseFromDisposalOfAssets"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MovementInMinorityInterestRollForward_544bfd5c-cbd3-49ea-8542-d2998e3a4d2e" xlink:to="loc_evh_NoncontrollingInterestDecreaseFromDisposalOfAssets_dd7ba5e5-b21d-43d6-ade8-4ed10ab36655" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestDecreaseFromRedemptions_50af872d-e6e7-4c4e-871b-3b76d2011fd5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MinorityInterestDecreaseFromRedemptions"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MovementInMinorityInterestRollForward_544bfd5c-cbd3-49ea-8542-d2998e3a4d2e" xlink:to="loc_us-gaap_MinorityInterestDecreaseFromRedemptions_50af872d-e6e7-4c4e-871b-3b76d2011fd5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterest_e7618fd5-1c4a-4968-8c9e-d3a672179036" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MinorityInterest"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MovementInMinorityInterestRollForward_544bfd5c-cbd3-49ea-8542-d2998e3a4d2e" xlink:to="loc_us-gaap_MinorityInterest_e7618fd5-1c4a-4968-8c9e-d3a672179036" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/FairValueMeasurement" xlink:type="simple" xlink:href="evh-20211231.xsd#FairValueMeasurement"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/FairValueMeasurement" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_9929cc78-bdd8-40f4-9a27-bbdfff76d863" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock_604080f6-2dd5-490c-87c9-1b0c5bb0dd4b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_9929cc78-bdd8-40f4-9a27-bbdfff76d863" xlink:to="loc_us-gaap_FairValueDisclosuresTextBlock_604080f6-2dd5-490c-87c9-1b0c5bb0dd4b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/FairValueMeasurementTables" xlink:type="simple" xlink:href="evh-20211231.xsd#FairValueMeasurementTables"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/FairValueMeasurementTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_3bf8406f-609d-4156-afd0-3679181128a2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_4ed71fa3-7862-460a-bf2c-e32020a34e3e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_3bf8406f-609d-4156-afd0-3679181128a2" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_4ed71fa3-7862-460a-bf2c-e32020a34e3e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock_3d0e245f-843a-4943-bc2a-3637e489f3a7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_3bf8406f-609d-4156-afd0-3679181128a2" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock_3d0e245f-843a-4943-bc2a-3637e489f3a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_01887fb9-09e1-4576-a4c3-1ea2e73819fa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_3bf8406f-609d-4156-afd0-3679181128a2" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_01887fb9-09e1-4576-a4c3-1ea2e73819fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_b51c3a25-6fb6-44ea-9068-aa7268dee808" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_3bf8406f-609d-4156-afd0-3679181128a2" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_b51c3a25-6fb6-44ea-9068-aa7268dee808" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/FairValueMeasurementAssetsandLiabilitiesonRecurringBasisDetails" xlink:type="simple" xlink:href="evh-20211231.xsd#FairValueMeasurementAssetsandLiabilitiesonRecurringBasisDetails"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/FairValueMeasurementAssetsandLiabilitiesonRecurringBasisDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_6b9e0c25-7f74-4c30-bab7-3e7fddf380f5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByBalanceSheetGroupingTable_3d759453-69a7-49e3-8f29-c81a2cfb33f8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByBalanceSheetGroupingTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_6b9e0c25-7f74-4c30-bab7-3e7fddf380f5" xlink:to="loc_us-gaap_FairValueByBalanceSheetGroupingTable_3d759453-69a7-49e3-8f29-c81a2cfb33f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_66459e91-dc13-4cad-92df-8ae4a224b55b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_3d759453-69a7-49e3-8f29-c81a2cfb33f8" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_66459e91-dc13-4cad-92df-8ae4a224b55b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_07dcb40c-94f1-4e16-999a-5753023fd943" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_66459e91-dc13-4cad-92df-8ae4a224b55b" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_07dcb40c-94f1-4e16-999a-5753023fd943" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_4fad7e23-d361-4988-bbcd-9ad5f1a6681c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_07dcb40c-94f1-4e16-999a-5753023fd943" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_4fad7e23-d361-4988-bbcd-9ad5f1a6681c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_64ddb15d-9c84-4969-9133-c4a0657ec4eb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_07dcb40c-94f1-4e16-999a-5753023fd943" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_64ddb15d-9c84-4969-9133-c4a0657ec4eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_86c0f6eb-b4a8-4b8a-afe2-9abe3a07048b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_07dcb40c-94f1-4e16-999a-5753023fd943" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_86c0f6eb-b4a8-4b8a-afe2-9abe3a07048b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_ca914a01-3d44-4834-b71e-57a63d7847b2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_3d759453-69a7-49e3-8f29-c81a2cfb33f8" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_ca914a01-3d44-4834-b71e-57a63d7847b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_5733c72e-fa13-4951-82c6-10e3c801174e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_ca914a01-3d44-4834-b71e-57a63d7847b2" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_5733c72e-fa13-4951-82c6-10e3c801174e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_3ccf282c-2dea-40c7-aabb-15fb207e29ba" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_5733c72e-fa13-4951-82c6-10e3c801174e" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_3ccf282c-2dea-40c7-aabb-15fb207e29ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_db6b12c7-8dbe-449d-bc4f-488eafcde41e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_3d759453-69a7-49e3-8f29-c81a2cfb33f8" xlink:to="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_db6b12c7-8dbe-449d-bc4f-488eafcde41e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract_6c629a92-6e9c-4c91-811d-77b16fac16fc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsFairValueDisclosureAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_db6b12c7-8dbe-449d-bc4f-488eafcde41e" xlink:to="loc_us-gaap_AssetsFairValueDisclosureAbstract_6c629a92-6e9c-4c91-811d-77b16fac16fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_2890ccbf-afc9-4866-9a97-06c562423d58" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_6c629a92-6e9c-4c91-811d-77b16fac16fc" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_2890ccbf-afc9-4866-9a97-06c562423d58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_201a521c-9d10-489f-9a3c-6a6dc320ed57" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_6c629a92-6e9c-4c91-811d-77b16fac16fc" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_201a521c-9d10-489f-9a3c-6a6dc320ed57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_1a3d266d-e931-4d2e-ad83-0159dd82c1b8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_db6b12c7-8dbe-449d-bc4f-488eafcde41e" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_1a3d266d-e931-4d2e-ad83-0159dd82c1b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_73332266-75db-4fb2-ad36-f9c5f2a223b3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_1a3d266d-e931-4d2e-ad83-0159dd82c1b8" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_73332266-75db-4fb2-ad36-f9c5f2a223b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesFairValueDisclosure_ebf99765-c697-40b2-8650-8e6b434b68d6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesFairValueDisclosure"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_1a3d266d-e931-4d2e-ad83-0159dd82c1b8" xlink:to="loc_us-gaap_OtherLiabilitiesFairValueDisclosure_ebf99765-c697-40b2-8650-8e6b434b68d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure_cf1e787c-7098-4bb8-8f9f-551856d358f3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosure"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_1a3d266d-e931-4d2e-ad83-0159dd82c1b8" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosure_cf1e787c-7098-4bb8-8f9f-551856d358f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_db93b37e-76b9-465c-9fbf-77f046387633" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_db6b12c7-8dbe-449d-bc4f-488eafcde41e" xlink:to="loc_us-gaap_ClassOfWarrantOrRightOutstanding_db93b37e-76b9-465c-9fbf-77f046387633" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/FairValueMeasurementAdditionalInformationDetails" xlink:type="simple" xlink:href="evh-20211231.xsd#FairValueMeasurementAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/FairValueMeasurementAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_0a281a32-8295-4586-a972-86ef1828cd80" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_2c36a8b0-7a58-468b-8626-9f46291e81a5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_0a281a32-8295-4586-a972-86ef1828cd80" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_2c36a8b0-7a58-468b-8626-9f46291e81a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_eb4b3820-a783-4ea2-a5a3-f73be839236a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_2c36a8b0-7a58-468b-8626-9f46291e81a5" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_eb4b3820-a783-4ea2-a5a3-f73be839236a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_cc3b4328-0322-4e0d-bdd2-6b2ed3541398" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_eb4b3820-a783-4ea2-a5a3-f73be839236a" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_cc3b4328-0322-4e0d-bdd2-6b2ed3541398" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassAMember_06c4504f-323a-4bbb-8c5d-bd02ddc1cd43" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonClassAMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_cc3b4328-0322-4e0d-bdd2-6b2ed3541398" xlink:to="loc_us-gaap_CommonClassAMember_06c4504f-323a-4bbb-8c5d-bd02ddc1cd43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_91d2faf5-5ca3-4c46-b60e-940120d84dc8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_2c36a8b0-7a58-468b-8626-9f46291e81a5" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_91d2faf5-5ca3-4c46-b60e-940120d84dc8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightUnissued_4ba567f0-a7df-45b1-8715-13d0761ff301" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightUnissued"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_91d2faf5-5ca3-4c46-b60e-940120d84dc8" xlink:to="loc_us-gaap_ClassOfWarrantOrRightUnissued_4ba567f0-a7df-45b1-8715-13d0761ff301" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/FairValueMeasurementChangesinContingentConsiderationandOtherDetails" xlink:type="simple" xlink:href="evh-20211231.xsd#FairValueMeasurementChangesinContingentConsiderationandOtherDetails"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/FairValueMeasurementChangesinContingentConsiderationandOtherDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_c96d9fc1-bba1-44d0-9596-215dfb139efa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_ab04266b-6330-4466-a526-080fcece2920" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_c96d9fc1-bba1-44d0-9596-215dfb139efa" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_ab04266b-6330-4466-a526-080fcece2920" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_95242978-1109-46b9-a7a5-0a398c7e7107" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_ab04266b-6330-4466-a526-080fcece2920" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_95242978-1109-46b9-a7a5-0a398c7e7107" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues_b38b9783-0950-4366-bcd3-97455cd46bd5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_ab04266b-6330-4466-a526-080fcece2920" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues_b38b9783-0950-4366-bcd3-97455cd46bd5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_074f2043-7da8-4946-adf3-4ba4dd7d1d20" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_ab04266b-6330-4466-a526-080fcece2920" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_074f2043-7da8-4946-adf3-4ba4dd7d1d20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_31511f46-2199-43e6-8573-277b60a5cb72" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_ab04266b-6330-4466-a526-080fcece2920" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_31511f46-2199-43e6-8573-277b60a5cb72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_0bec0b01-b77a-42ff-a86b-a6e214c09618" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_ab04266b-6330-4466-a526-080fcece2920" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_0bec0b01-b77a-42ff-a86b-a6e214c09618" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/FairValueMeasurementValuationTechniquesandSignificantUnobservableInputsDetails" xlink:type="simple" xlink:href="evh-20211231.xsd#FairValueMeasurementValuationTechniquesandSignificantUnobservableInputsDetails"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/FairValueMeasurementValuationTechniquesandSignificantUnobservableInputsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_8dfea94a-b89e-4042-a429-11f621eb0d12" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_48a75905-9f97-4b92-87b0-57309e5edbe3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_8dfea94a-b89e-4042-a429-11f621eb0d12" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_48a75905-9f97-4b92-87b0-57309e5edbe3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_f543735e-614e-4813-a75a-697d8666905d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_48a75905-9f97-4b92-87b0-57309e5edbe3" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_f543735e-614e-4813-a75a-697d8666905d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_f6644e21-d63a-40fa-9078-5d1b8d0ea166" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_f543735e-614e-4813-a75a-697d8666905d" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_f6644e21-d63a-40fa-9078-5d1b8d0ea166" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_87c86253-61da-4372-b73e-0a1116b3fdc3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_f6644e21-d63a-40fa-9078-5d1b8d0ea166" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_87c86253-61da-4372-b73e-0a1116b3fdc3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_907bebb7-ed9f-4ba8-8cf3-4e077bbb1f02" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_48a75905-9f97-4b92-87b0-57309e5edbe3" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_907bebb7-ed9f-4ba8-8cf3-4e077bbb1f02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_28e13e1f-6e6a-4b07-b058-20485718077b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_907bebb7-ed9f-4ba8-8cf3-4e077bbb1f02" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_28e13e1f-6e6a-4b07-b058-20485718077b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_8b0f797e-238b-4bad-8f81-4624b19a0b5f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_28e13e1f-6e6a-4b07-b058-20485718077b" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_8b0f797e-238b-4bad-8f81-4624b19a0b5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_36fbf12c-9186-4c53-8dae-43613df77f43" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_48a75905-9f97-4b92-87b0-57309e5edbe3" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_36fbf12c-9186-4c53-8dae-43613df77f43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_07d60355-6f1b-452c-8cd6-41716f5b1016" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_36fbf12c-9186-4c53-8dae-43613df77f43" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_07d60355-6f1b-452c-8cd6-41716f5b1016" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_MeasurementInputRiskNeutralExpectedEarnoutConsiderationMember_8f495e6e-7059-465d-985d-643dc7f9d199" xlink:href="evh-20211231.xsd#evh_MeasurementInputRiskNeutralExpectedEarnoutConsiderationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_07d60355-6f1b-452c-8cd6-41716f5b1016" xlink:to="loc_evh_MeasurementInputRiskNeutralExpectedEarnoutConsiderationMember_8f495e6e-7059-465d-985d-643dc7f9d199" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputDiscountRateMember_2f1067a8-36c0-4a16-a48b-f998b0547f9f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputDiscountRateMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_07d60355-6f1b-452c-8cd6-41716f5b1016" xlink:to="loc_us-gaap_MeasurementInputDiscountRateMember_2f1067a8-36c0-4a16-a48b-f998b0547f9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputPriceVolatilityMember_4dbc2bca-5eb7-429c-91d0-3384beb8a3ba" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputPriceVolatilityMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_07d60355-6f1b-452c-8cd6-41716f5b1016" xlink:to="loc_us-gaap_MeasurementInputPriceVolatilityMember_4dbc2bca-5eb7-429c-91d0-3384beb8a3ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember_b90039de-7ed6-4054-8032-4a198b33fb79" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_07d60355-6f1b-452c-8cd6-41716f5b1016" xlink:to="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember_b90039de-7ed6-4054-8032-4a198b33fb79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_62975c82-42e8-4e3a-8e44-e85a5d704831" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_48a75905-9f97-4b92-87b0-57309e5edbe3" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_62975c82-42e8-4e3a-8e44-e85a5d704831" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_9ee80698-ab24-4935-a040-e95a9c2f5129" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_62975c82-42e8-4e3a-8e44-e85a5d704831" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_9ee80698-ab24-4935-a040-e95a9c2f5129" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput_f2327ec0-380a-4500-9a43-de99fb6884eb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_62975c82-42e8-4e3a-8e44-e85a5d704831" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput_f2327ec0-380a-4500-9a43-de99fb6884eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesFairValueDisclosure_ecb03115-17bd-4ca8-bf19-8bf0df9e3d2f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesFairValueDisclosure"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_62975c82-42e8-4e3a-8e44-e85a5d704831" xlink:to="loc_us-gaap_OtherLiabilitiesFairValueDisclosure_ecb03115-17bd-4ca8-bf19-8bf0df9e3d2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingMeasurementInput_813f4e78-0461-435a-822d-cdfbd0474e1d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingMeasurementInput"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_62975c82-42e8-4e3a-8e44-e85a5d704831" xlink:to="loc_us-gaap_WarrantsAndRightsOutstandingMeasurementInput_813f4e78-0461-435a-822d-cdfbd0474e1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/RelatedParties" xlink:type="simple" xlink:href="evh-20211231.xsd#RelatedParties"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/RelatedParties" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_1b8e83b6-f3be-4c37-893e-e4cc3d76c0f7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_3d9288bd-0972-4844-9199-e43bd1086679" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_1b8e83b6-f3be-4c37-893e-e4cc3d76c0f7" xlink:to="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_3d9288bd-0972-4844-9199-e43bd1086679" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/RelatedPartiesTables" xlink:type="simple" xlink:href="evh-20211231.xsd#RelatedPartiesTables"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/RelatedPartiesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_a1eb41e8-e410-404d-8eb4-6537d983e340" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock_87858588-1bfd-47d3-8ed3-ffb1863c3eaf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_a1eb41e8-e410-404d-8eb4-6537d983e340" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock_87858588-1bfd-47d3-8ed3-ffb1863c3eaf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/RelatedPartiesAssetsandLiabilitiesDetails" xlink:type="simple" xlink:href="evh-20211231.xsd#RelatedPartiesAssetsandLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/RelatedPartiesAssetsandLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_c5151d5e-f0f7-4566-a1ef-c88d677febba" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_8584dc08-3db4-4d3b-9593-75e2c0cdd89c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_c5151d5e-f0f7-4566-a1ef-c88d677febba" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_8584dc08-3db4-4d3b-9593-75e2c0cdd89c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_ae46cfb7-badb-446a-93f1-85b4d0e59614" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_8584dc08-3db4-4d3b-9593-75e2c0cdd89c" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_ae46cfb7-badb-446a-93f1-85b4d0e59614" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_757a201d-aa9c-43dd-92ce-5575327bc7f0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_ae46cfb7-badb-446a-93f1-85b4d0e59614" xlink:to="loc_us-gaap_RelatedPartyDomain_757a201d-aa9c-43dd-92ce-5575327bc7f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_AffiliatedEntityMember_aa2ddd9b-617c-41ad-9e54-6d775c2627aa" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_AffiliatedEntityMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_757a201d-aa9c-43dd-92ce-5575327bc7f0" xlink:to="loc_srt_AffiliatedEntityMember_aa2ddd9b-617c-41ad-9e54-6d775c2627aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_3083d97b-415e-47f6-8f06-b32f70a9217e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_8584dc08-3db4-4d3b-9593-75e2c0cdd89c" xlink:to="loc_us-gaap_RelatedPartyTransactionLineItems_3083d97b-415e-47f6-8f06-b32f70a9217e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_ef4129fd-6392-4c90-838c-21e40700a80a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_3083d97b-415e-47f6-8f06-b32f70a9217e" xlink:to="loc_us-gaap_AssetsAbstract_ef4129fd-6392-4c90-838c-21e40700a80a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_aa70c1a4-d8e8-41f9-997e-86c953c23d93" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_ef4129fd-6392-4c90-838c-21e40700a80a" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_aa70c1a4-d8e8-41f9-997e-86c953c23d93" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_e2bd6eb9-89b5-4c6f-8ee4-38db283543f5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_ef4129fd-6392-4c90-838c-21e40700a80a" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_e2bd6eb9-89b5-4c6f-8ee4-38db283543f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent_17ed282e-de90-40ae-90a6-a0e027f12fb1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_ef4129fd-6392-4c90-838c-21e40700a80a" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent_17ed282e-de90-40ae-90a6-a0e027f12fb1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAbstract_0371de37-d9fd-406a-8d57-d325b8a7ef8e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_3083d97b-415e-47f6-8f06-b32f70a9217e" xlink:to="loc_us-gaap_LiabilitiesAbstract_0371de37-d9fd-406a-8d57-d325b8a7ef8e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_c39e2de8-71ad-425d-859f-29d21803b0b0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAbstract_0371de37-d9fd-406a-8d57-d325b8a7ef8e" xlink:to="loc_us-gaap_AccountsPayableCurrent_c39e2de8-71ad-425d-859f-29d21803b0b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_dfe42b13-a809-43e9-9056-5d72eaa7054a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAbstract_0371de37-d9fd-406a-8d57-d325b8a7ef8e" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_dfe42b13-a809-43e9-9056-5d72eaa7054a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForFuturePolicyBenefitsAndUnpaidClaimsAndClaimsAdjustmentExpense_7fb0d549-9f82-4c13-a664-f0ff8199e2db" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilityForFuturePolicyBenefitsAndUnpaidClaimsAndClaimsAdjustmentExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAbstract_0371de37-d9fd-406a-8d57-d325b8a7ef8e" xlink:to="loc_us-gaap_LiabilityForFuturePolicyBenefitsAndUnpaidClaimsAndClaimsAdjustmentExpense_7fb0d549-9f82-4c13-a664-f0ff8199e2db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/RelatedPartiesRevenuesandExpensesDetails" xlink:type="simple" xlink:href="evh-20211231.xsd#RelatedPartiesRevenuesandExpensesDetails"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/RelatedPartiesRevenuesandExpensesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_a3bae301-bb99-43a6-95ce-2bceba48be20" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_eec88460-6b4a-43ba-a77a-0527b3fc41c1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_a3bae301-bb99-43a6-95ce-2bceba48be20" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_eec88460-6b4a-43ba-a77a-0527b3fc41c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_ce58a6d7-309f-4840-81ba-408602e3b8a2" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_eec88460-6b4a-43ba-a77a-0527b3fc41c1" xlink:to="loc_srt_ProductOrServiceAxis_ce58a6d7-309f-4840-81ba-408602e3b8a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_bb75db43-5b61-4074-a268-41e4ffe17fa0" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_ce58a6d7-309f-4840-81ba-408602e3b8a2" xlink:to="loc_srt_ProductsAndServicesDomain_bb75db43-5b61-4074-a268-41e4ffe17fa0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_TransformationServicesMember_9f522881-316c-405c-a144-a8ec4ee77b4e" xlink:href="evh-20211231.xsd#evh_TransformationServicesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_bb75db43-5b61-4074-a268-41e4ffe17fa0" xlink:to="loc_evh_TransformationServicesMember_9f522881-316c-405c-a144-a8ec4ee77b4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_PlatformsAndOperationsServicesMember_751489a6-9a57-4ad0-a5e6-7adcbb3f28d6" xlink:href="evh-20211231.xsd#evh_PlatformsAndOperationsServicesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_bb75db43-5b61-4074-a268-41e4ffe17fa0" xlink:to="loc_evh_PlatformsAndOperationsServicesMember_751489a6-9a57-4ad0-a5e6-7adcbb3f28d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_d9c3b60c-8359-40d2-bcb8-f0a95bc0b332" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_eec88460-6b4a-43ba-a77a-0527b3fc41c1" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_d9c3b60c-8359-40d2-bcb8-f0a95bc0b332" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_e3213ba0-2896-4ace-8d25-0c6044716954" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_d9c3b60c-8359-40d2-bcb8-f0a95bc0b332" xlink:to="loc_us-gaap_RelatedPartyDomain_e3213ba0-2896-4ace-8d25-0c6044716954" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_AffiliatedEntityMember_df44c8e1-63ac-403e-9a94-1d9e8e752065" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_AffiliatedEntityMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_e3213ba0-2896-4ace-8d25-0c6044716954" xlink:to="loc_srt_AffiliatedEntityMember_df44c8e1-63ac-403e-9a94-1d9e8e752065" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_cc57137f-6e26-423b-a045-828f23c10d40" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_eec88460-6b4a-43ba-a77a-0527b3fc41c1" xlink:to="loc_us-gaap_RelatedPartyTransactionLineItems_cc57137f-6e26-423b-a045-828f23c10d40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract_1afece10-175f-4583-bce7-1b778f6cfff2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenuesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_cc57137f-6e26-423b-a045-828f23c10d40" xlink:to="loc_us-gaap_RevenuesAbstract_1afece10-175f-4583-bce7-1b778f6cfff2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_cc4aa492-8d60-4fb7-bf4d-d59f60256ad1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Revenues"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesAbstract_1afece10-175f-4583-bce7-1b778f6cfff2" xlink:to="loc_us-gaap_Revenues_cc4aa492-8d60-4fb7-bf4d-d59f60256ad1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract_27fda00f-1efd-471d-a534-4abfa016cbc9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_cc57137f-6e26-423b-a045-828f23c10d40" xlink:to="loc_us-gaap_OperatingExpensesAbstract_27fda00f-1efd-471d-a534-4abfa016cbc9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_CostofGoodsandServicesSoldExcludingDepreciationandAmortization_35f45b08-dbca-4034-ae08-8262558eaedb" xlink:href="evh-20211231.xsd#evh_CostofGoodsandServicesSoldExcludingDepreciationandAmortization"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_27fda00f-1efd-471d-a534-4abfa016cbc9" xlink:to="loc_evh_CostofGoodsandServicesSoldExcludingDepreciationandAmortization_35f45b08-dbca-4034-ae08-8262558eaedb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_4dffc484-7987-4b52-8004-16f27d0a8619" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_27fda00f-1efd-471d-a534-4abfa016cbc9" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_4dffc484-7987-4b52-8004-16f27d0a8619" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/RepositioningandOtherChanges" xlink:type="simple" xlink:href="evh-20211231.xsd#RepositioningandOtherChanges"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/RepositioningandOtherChanges" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_8e8ba22e-d0c5-4829-8021-f7a4ca8cf40c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_8fca84c2-22ef-4a3f-a0ed-63abbcc0765a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_8e8ba22e-d0c5-4829-8021-f7a4ca8cf40c" xlink:to="loc_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_8fca84c2-22ef-4a3f-a0ed-63abbcc0765a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/RepositioningandOtherChangesTables" xlink:type="simple" xlink:href="evh-20211231.xsd#RepositioningandOtherChangesTables"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/RepositioningandOtherChangesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_50505369-83b8-4c82-b9d2-a7e0000e45f2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock_93bd567e-2b96-4ce5-8016-d8dcdf72af0d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_50505369-83b8-4c82-b9d2-a7e0000e45f2" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock_93bd567e-2b96-4ce5-8016-d8dcdf72af0d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/RepositioningandOtherChangesDetails" xlink:type="simple" xlink:href="evh-20211231.xsd#RepositioningandOtherChangesDetails"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/RepositioningandOtherChangesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_cb040ac6-b4a6-4b77-bea3-1520b42b62d2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_82931c4e-fb7b-4ff0-b01f-43843c6386ab" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_cb040ac6-b4a6-4b77-bea3-1520b42b62d2" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_82931c4e-fb7b-4ff0-b01f-43843c6386ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveAxis_c7ab4f15-252d-4eb8-a20a-71f605d25649" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringCostAndReserveAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_82931c4e-fb7b-4ff0-b01f-43843c6386ab" xlink:to="loc_us-gaap_RestructuringCostAndReserveAxis_c7ab4f15-252d-4eb8-a20a-71f605d25649" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfRestructuringDomain_ab67bf61-dbc7-47f2-a2fe-94fba9e913e7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfRestructuringDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis_c7ab4f15-252d-4eb8-a20a-71f605d25649" xlink:to="loc_us-gaap_TypeOfRestructuringDomain_ab67bf61-dbc7-47f2-a2fe-94fba9e913e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_EmployeeSeveranceAndTerminationBenefitsMember_9dbe7d52-40cd-46a0-80c3-d49f67fd9e5a" xlink:href="evh-20211231.xsd#evh_EmployeeSeveranceAndTerminationBenefitsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_ab67bf61-dbc7-47f2-a2fe-94fba9e913e7" xlink:to="loc_evh_EmployeeSeveranceAndTerminationBenefitsMember_9dbe7d52-40cd-46a0-80c3-d49f67fd9e5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FacilityClosingMember_e7dc0ee4-7a3f-457b-b273-4ed3fc796c62" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FacilityClosingMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_ab67bf61-dbc7-47f2-a2fe-94fba9e913e7" xlink:to="loc_us-gaap_FacilityClosingMember_e7dc0ee4-7a3f-457b-b273-4ed3fc796c62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_ProfessionalServicesRestructuringMember_14feae9a-2d0c-4ee7-a33d-1e5a74651a7a" xlink:href="evh-20211231.xsd#evh_ProfessionalServicesRestructuringMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_ab67bf61-dbc7-47f2-a2fe-94fba9e913e7" xlink:to="loc_evh_ProfessionalServicesRestructuringMember_14feae9a-2d0c-4ee7-a33d-1e5a74651a7a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems_c566c533-3c29-4683-b77f-7f514d5c669e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringCostAndReserveLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_82931c4e-fb7b-4ff0-b01f-43843c6386ab" xlink:to="loc_us-gaap_RestructuringCostAndReserveLineItems_c566c533-3c29-4683-b77f-7f514d5c669e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges_dba175d3-514b-4316-bfd7-3cedab224565" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringCharges"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_c566c533-3c29-4683-b77f-7f514d5c669e" xlink:to="loc_us-gaap_RestructuringCharges_dba175d3-514b-4316-bfd7-3cedab224565" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedCostCostIncurredToDate1_70a7031e-10f9-42ec-93b9-dc7e2e596bf1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringAndRelatedCostCostIncurredToDate1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_c566c533-3c29-4683-b77f-7f514d5c669e" xlink:to="loc_us-gaap_RestructuringAndRelatedCostCostIncurredToDate1_70a7031e-10f9-42ec-93b9-dc7e2e596bf1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/SegmentReporting" xlink:type="simple" xlink:href="evh-20211231.xsd#SegmentReporting"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/SegmentReporting" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_7fd77c08-f990-4e31-9347-00663a38b63e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingDisclosureTextBlock_860607ec-e421-4d32-b71b-679601b8ca1f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_7fd77c08-f990-4e31-9347-00663a38b63e" xlink:to="loc_us-gaap_SegmentReportingDisclosureTextBlock_860607ec-e421-4d32-b71b-679601b8ca1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/SegmentReportingTables" xlink:type="simple" xlink:href="evh-20211231.xsd#SegmentReportingTables"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/SegmentReportingTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_6cd2d3f8-7de0-4648-a371-9200fddeaaef" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTextBlock_69ffa016-2442-486b-affd-ae7c1994ad3b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_6cd2d3f8-7de0-4648-a371-9200fddeaaef" xlink:to="loc_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTextBlock_69ffa016-2442-486b-affd-ae7c1994ad3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock_fc2cd912-670c-43a2-8baf-016ef507b612" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_6cd2d3f8-7de0-4648-a371-9200fddeaaef" xlink:to="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock_fc2cd912-670c-43a2-8baf-016ef507b612" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/SegmentReportingAdditionalInformationDetails" xlink:type="simple" xlink:href="evh-20211231.xsd#SegmentReportingAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/SegmentReportingAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_bf488c2b-aaef-4a2a-8def-44ef1ac9266b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments_40c0d497-932e-4891-b898-35be8ad2927e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_bf488c2b-aaef-4a2a-8def-44ef1ac9266b" xlink:to="loc_us-gaap_NumberOfOperatingSegments_40c0d497-932e-4891-b898-35be8ad2927e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/SegmentReportingRevenuefromSegmentstoConsolidatedDetails" xlink:type="simple" xlink:href="evh-20211231.xsd#SegmentReportingRevenuefromSegmentstoConsolidatedDetails"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/SegmentReportingRevenuefromSegmentstoConsolidatedDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_75690354-c38e-46fe-aa65-1a0e2c599861" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable_26342401-5de9-4b25-b267-9f71879af71d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_75690354-c38e-46fe-aa65-1a0e2c599861" xlink:to="loc_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable_26342401-5de9-4b25-b267-9f71879af71d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_3772cc65-118c-4ee4-ba66-0a1e6ce8753d" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable_26342401-5de9-4b25-b267-9f71879af71d" xlink:to="loc_srt_ProductOrServiceAxis_3772cc65-118c-4ee4-ba66-0a1e6ce8753d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_31aff86a-9591-4ea5-a931-fc2bad1d8bde" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_3772cc65-118c-4ee4-ba66-0a1e6ce8753d" xlink:to="loc_srt_ProductsAndServicesDomain_31aff86a-9591-4ea5-a931-fc2bad1d8bde" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_TransformationServicesMember_6e196fcf-390d-4d34-9f55-7a91ff4e332a" xlink:href="evh-20211231.xsd#evh_TransformationServicesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_31aff86a-9591-4ea5-a931-fc2bad1d8bde" xlink:to="loc_evh_TransformationServicesMember_6e196fcf-390d-4d34-9f55-7a91ff4e332a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_PlatformsAndOperationsServicesMember_bef01961-5c5c-44a8-a792-afe34d440d5a" xlink:href="evh-20211231.xsd#evh_PlatformsAndOperationsServicesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_31aff86a-9591-4ea5-a931-fc2bad1d8bde" xlink:to="loc_evh_PlatformsAndOperationsServicesMember_bef01961-5c5c-44a8-a792-afe34d440d5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsAxis_b479509d-f505-4d93-bc3f-2ffb4c60bf2e" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ConsolidationItemsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable_26342401-5de9-4b25-b267-9f71879af71d" xlink:to="loc_srt_ConsolidationItemsAxis_b479509d-f505-4d93-bc3f-2ffb4c60bf2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_94b5e795-cf55-44c9-943f-6bf4b33bbec9" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ConsolidationItemsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsAxis_b479509d-f505-4d93-bc3f-2ffb4c60bf2e" xlink:to="loc_srt_ConsolidationItemsDomain_94b5e795-cf55-44c9-943f-6bf4b33bbec9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntersegmentEliminationMember_c2e988c0-2b0d-49e9-b32e-8093e64808c8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntersegmentEliminationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsDomain_94b5e795-cf55-44c9-943f-6bf4b33bbec9" xlink:to="loc_us-gaap_IntersegmentEliminationMember_c2e988c0-2b0d-49e9-b32e-8093e64808c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingSegmentsMember_e65ef178-bb68-4249-93d2-527e65024572" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingSegmentsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsDomain_94b5e795-cf55-44c9-943f-6bf4b33bbec9" xlink:to="loc_us-gaap_OperatingSegmentsMember_e65ef178-bb68-4249-93d2-527e65024572" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateNonSegmentMember_a75a877c-06b0-422a-ba53-de848ad1e2a0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CorporateNonSegmentMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsDomain_94b5e795-cf55-44c9-943f-6bf4b33bbec9" xlink:to="loc_us-gaap_CorporateNonSegmentMember_a75a877c-06b0-422a-ba53-de848ad1e2a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_0972f980-e5aa-41e1-87b6-ce7fe6dad91d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable_26342401-5de9-4b25-b267-9f71879af71d" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_0972f980-e5aa-41e1-87b6-ce7fe6dad91d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_1a351473-0e98-4994-a4e5-4e486e674758" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_0972f980-e5aa-41e1-87b6-ce7fe6dad91d" xlink:to="loc_us-gaap_SegmentDomain_1a351473-0e98-4994-a4e5-4e486e674758" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_EvolentHealthServicesSegmentMember_c4dd2865-e8b6-4910-8710-de0d8ae0ae1d" xlink:href="evh-20211231.xsd#evh_EvolentHealthServicesSegmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_1a351473-0e98-4994-a4e5-4e486e674758" xlink:to="loc_evh_EvolentHealthServicesSegmentMember_c4dd2865-e8b6-4910-8710-de0d8ae0ae1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_ClinicalSolutionsSegmentMember_54fa0184-d6f3-4c1c-aa95-179d0d7036e9" xlink:href="evh-20211231.xsd#evh_ClinicalSolutionsSegmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_1a351473-0e98-4994-a4e5-4e486e674758" xlink:to="loc_evh_ClinicalSolutionsSegmentMember_54fa0184-d6f3-4c1c-aa95-179d0d7036e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingRevenueReconcilingItemLineItems_6b0c2229-b555-427c-98f0-e20e149d8a0e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingRevenueReconcilingItemLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable_26342401-5de9-4b25-b267-9f71879af71d" xlink:to="loc_us-gaap_SegmentReportingRevenueReconcilingItemLineItems_6b0c2229-b555-427c-98f0-e20e149d8a0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_e8f872ec-398d-4eac-b099-b08c59c8e2e8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Revenues"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingRevenueReconcilingItemLineItems_6b0c2229-b555-427c-98f0-e20e149d8a0e" xlink:to="loc_us-gaap_Revenues_e8f872ec-398d-4eac-b099-b08c59c8e2e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization_e2a79c46-f7f8-49c4-a428-671e4bf12694" xlink:href="evh-20211231.xsd#evh_AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingRevenueReconcilingItemLineItems_6b0c2229-b555-427c-98f0-e20e149d8a0e" xlink:to="loc_evh_AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization_e2a79c46-f7f8-49c4-a428-671e4bf12694" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/SegmentReportingReconciliationofAdjustedEBITDADetails" xlink:type="simple" xlink:href="evh-20211231.xsd#SegmentReportingReconciliationofAdjustedEBITDADetails"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/SegmentReportingReconciliationofAdjustedEBITDADetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_cbf8e480-3800-47ed-9676-e3700a6ce6af" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_349715c1-5a8a-4606-b812-7a1d43c97a8b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_cbf8e480-3800-47ed-9676-e3700a6ce6af" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_349715c1-5a8a-4606-b812-7a1d43c97a8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_7a1ed881-5bba-4dff-9ab7-d666737c6f5b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_cbf8e480-3800-47ed-9676-e3700a6ce6af" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_7a1ed881-5bba-4dff-9ab7-d666737c6f5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest_10059d45-ea53-45c3-8799-7852741f65a7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_cbf8e480-3800-47ed-9676-e3700a6ce6af" xlink:to="loc_us-gaap_InvestmentIncomeInterest_10059d45-ea53-45c3-8799-7852741f65a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_89a2de0e-51c1-4096-b6f5-2f5b3783ab58" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpense"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_cbf8e480-3800-47ed-9676-e3700a6ce6af" xlink:to="loc_us-gaap_InterestExpense_89a2de0e-51c1-4096-b6f5-2f5b3783ab58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_ec41803d-2f9d-49f4-b746-f5290e11d45c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_cbf8e480-3800-47ed-9676-e3700a6ce6af" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_ec41803d-2f9d-49f4-b746-f5290e11d45c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationAndAmortization_9b05c8eb-07f7-418a-a43c-870300f6170a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationAndAmortization"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_cbf8e480-3800-47ed-9676-e3700a6ce6af" xlink:to="loc_us-gaap_DepreciationAndAmortization_9b05c8eb-07f7-418a-a43c-870300f6170a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentOtherThanTemporaryImpairment_5309cade-1ef0-45f9-ac0e-88e011e00e2b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestmentOtherThanTemporaryImpairment"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_cbf8e480-3800-47ed-9676-e3700a6ce6af" xlink:to="loc_us-gaap_EquityMethodInvestmentOtherThanTemporaryImpairment_5309cade-1ef0-45f9-ac0e-88e011e00e2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_GainOnTransferOfMembership_cc9eee62-60a6-48f4-8ce2-aba1d8421752" xlink:href="evh-20211231.xsd#evh_GainOnTransferOfMembership"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_cbf8e480-3800-47ed-9676-e3700a6ce6af" xlink:to="loc_evh_GainOnTransferOfMembership_cc9eee62-60a6-48f4-8ce2-aba1d8421752" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_GainLossOnRepaymentOfDebt_fc6f96b9-5ae4-473e-aa03-0cd18cb31f72" xlink:href="evh-20211231.xsd#evh_GainLossOnRepaymentOfDebt"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_cbf8e480-3800-47ed-9676-e3700a6ce6af" xlink:to="loc_evh_GainLossOnRepaymentOfDebt_fc6f96b9-5ae4-473e-aa03-0cd18cb31f72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_4f8904b3-feb2-4225-a345-dc608b36aa17" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_cbf8e480-3800-47ed-9676-e3700a6ce6af" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_4f8904b3-feb2-4225-a345-dc608b36aa17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairmentLoss_3dfd71c1-b2ae-4e71-8666-7c07b1c17a18" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_cbf8e480-3800-47ed-9676-e3700a6ce6af" xlink:to="loc_us-gaap_GoodwillImpairmentLoss_3dfd71c1-b2ae-4e71-8666-7c07b1c17a18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_ba814ed5-4e22-471a-b1a3-5dc8dd8b0713" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_cbf8e480-3800-47ed-9676-e3700a6ce6af" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_ba814ed5-4e22-471a-b1a3-5dc8dd8b0713" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnDispositionOfAssets1_d06d4795-e49a-4b94-b37d-071dbc2c48cf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossOnDispositionOfAssets1"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_cbf8e480-3800-47ed-9676-e3700a6ce6af" xlink:to="loc_us-gaap_GainLossOnDispositionOfAssets1_d06d4795-e49a-4b94-b37d-071dbc2c48cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_4739bc8d-bfd7-4ed3-bbf2-54e6ce65c97b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_cbf8e480-3800-47ed-9676-e3700a6ce6af" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_4739bc8d-bfd7-4ed3-bbf2-54e6ce65c97b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_d2426f3e-b938-4d5f-a2a8-f6530f96346e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_cbf8e480-3800-47ed-9676-e3700a6ce6af" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_d2426f3e-b938-4d5f-a2a8-f6530f96346e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_a8e6705c-c1dc-459b-ae04-43658214d152" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_cbf8e480-3800-47ed-9676-e3700a6ce6af" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_a8e6705c-c1dc-459b-ae04-43658214d152" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_PurchaseAccountingAdjustments_76bfbaa7-38c1-4c8e-8eaa-159f8ff98bf0" xlink:href="evh-20211231.xsd#evh_PurchaseAccountingAdjustments"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_cbf8e480-3800-47ed-9676-e3700a6ce6af" xlink:to="loc_evh_PurchaseAccountingAdjustments_76bfbaa7-38c1-4c8e-8eaa-159f8ff98bf0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges_3db951cb-3c1a-4b4f-bad2-22c9023a5721" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringCharges"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_cbf8e480-3800-47ed-9676-e3700a6ce6af" xlink:to="loc_us-gaap_RestructuringCharges_3db951cb-3c1a-4b4f-bad2-22c9023a5721" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_SharebasedCompensationIncludingOnetimeAdjustment_a4f87622-d99d-4cc6-a6e7-d6c0ad17148b" xlink:href="evh-20211231.xsd#evh_SharebasedCompensationIncludingOnetimeAdjustment"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_cbf8e480-3800-47ed-9676-e3700a6ce6af" xlink:to="loc_evh_SharebasedCompensationIncludingOnetimeAdjustment_a4f87622-d99d-4cc6-a6e7-d6c0ad17148b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeveranceCosts1_32ed3405-2989-442d-a682-03db156c0147" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeveranceCosts1"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_cbf8e480-3800-47ed-9676-e3700a6ce6af" xlink:to="loc_us-gaap_SeveranceCosts1_32ed3405-2989-442d-a682-03db156c0147" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_CapitalizedContractCostAmortizationPurchaseAccountingAdjustments_04786650-c130-42f0-8272-0958de78c80f" xlink:href="evh-20211231.xsd#evh_CapitalizedContractCostAmortizationPurchaseAccountingAdjustments"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_cbf8e480-3800-47ed-9676-e3700a6ce6af" xlink:to="loc_evh_CapitalizedContractCostAmortizationPurchaseAccountingAdjustments_04786650-c130-42f0-8272-0958de78c80f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_ShareholderAdvisoryServices_4ea60619-b7e3-49ba-b2fc-13c2b3ed1999" xlink:href="evh-20211231.xsd#evh_ShareholderAdvisoryServices"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_cbf8e480-3800-47ed-9676-e3700a6ce6af" xlink:to="loc_evh_ShareholderAdvisoryServices_4ea60619-b7e3-49ba-b2fc-13c2b3ed1999" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_TransactionCosts_36d349bb-b208-4093-ac86-4c764b12841c" xlink:href="evh-20211231.xsd#evh_TransactionCosts"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_cbf8e480-3800-47ed-9676-e3700a6ce6af" xlink:to="loc_evh_TransactionCosts_36d349bb-b208-4093-ac86-4c764b12841c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_990369d2-1328-4908-9478-e2b8f2845edd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_cbf8e480-3800-47ed-9676-e3700a6ce6af" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_990369d2-1328-4908-9478-e2b8f2845edd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization_f2386801-8acf-4ffc-8438-caaaf21060b9" xlink:href="evh-20211231.xsd#evh_AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_cbf8e480-3800-47ed-9676-e3700a6ce6af" xlink:to="loc_evh_AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization_f2386801-8acf-4ffc-8438-caaaf21060b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/ReservesforClaimsandPerformanceBasedArrangements" xlink:type="simple" xlink:href="evh-20211231.xsd#ReservesforClaimsandPerformanceBasedArrangements"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/ReservesforClaimsandPerformanceBasedArrangements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InsuranceAbstract_9d5fc95a-00b1-4865-9f64-047a6b8fc966" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InsuranceAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InsuranceDisclosureTextBlock_0a658659-ef00-4e5e-a47e-385199c8c2f0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InsuranceDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InsuranceAbstract_9d5fc95a-00b1-4865-9f64-047a6b8fc966" xlink:to="loc_us-gaap_InsuranceDisclosureTextBlock_0a658659-ef00-4e5e-a47e-385199c8c2f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/ReservesforClaimsandPerformanceBasedArrangementsTables" xlink:type="simple" xlink:href="evh-20211231.xsd#ReservesforClaimsandPerformanceBasedArrangementsTables"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/ReservesforClaimsandPerformanceBasedArrangementsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InsuranceAbstract_edb7e7ea-dcb4-40ef-919b-19ddce38facd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InsuranceAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense_1a2b3ee5-b485-460b-a148-7515dc463d3f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InsuranceAbstract_edb7e7ea-dcb4-40ef-919b-19ddce38facd" xlink:to="loc_us-gaap_ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense_1a2b3ee5-b485-460b-a148-7515dc463d3f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/ReservesforClaimsandPerformanceBasedArrangementsDetails" xlink:type="simple" xlink:href="evh-20211231.xsd#ReservesforClaimsandPerformanceBasedArrangementsDetails"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/ReservesforClaimsandPerformanceBasedArrangementsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InsuranceAbstract_1744f62f-6671-4037-86e6-cce5fc141085" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InsuranceAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortdurationInsuranceContractsReconciliationOfClaimsDevelopmentToLiabilityTable_f8f4490e-c938-4acb-bfb0-2e53ace6afe4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortdurationInsuranceContractsReconciliationOfClaimsDevelopmentToLiabilityTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InsuranceAbstract_1744f62f-6671-4037-86e6-cce5fc141085" xlink:to="loc_us-gaap_ShortdurationInsuranceContractsReconciliationOfClaimsDevelopmentToLiabilityTable_f8f4490e-c938-4acb-bfb0-2e53ace6afe4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_14f252c8-2159-4e3d-b0de-9aac334ae158" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortdurationInsuranceContractsReconciliationOfClaimsDevelopmentToLiabilityTable_f8f4490e-c938-4acb-bfb0-2e53ace6afe4" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_14f252c8-2159-4e3d-b0de-9aac334ae158" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_5e09c2ca-17b4-4368-b284-55dc5693b37e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_14f252c8-2159-4e3d-b0de-9aac334ae158" xlink:to="loc_us-gaap_SegmentDomain_5e09c2ca-17b4-4368-b284-55dc5693b37e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_EvolentHealthServicesSegmentMember_82f64c42-b07c-41e4-81b9-738a36350389" xlink:href="evh-20211231.xsd#evh_EvolentHealthServicesSegmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_5e09c2ca-17b4-4368-b284-55dc5693b37e" xlink:to="loc_evh_EvolentHealthServicesSegmentMember_82f64c42-b07c-41e4-81b9-738a36350389" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_ClinicalSolutionsSegmentMember_bb2d7b3c-e736-4233-94f9-7126281b94bd" xlink:href="evh-20211231.xsd#evh_ClinicalSolutionsSegmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_5e09c2ca-17b4-4368-b284-55dc5693b37e" xlink:to="loc_evh_ClinicalSolutionsSegmentMember_bb2d7b3c-e736-4233-94f9-7126281b94bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis_7d9e6a79-dfb1-4898-9865-28df27ce39a2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupClassificationAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortdurationInsuranceContractsReconciliationOfClaimsDevelopmentToLiabilityTable_f8f4490e-c938-4acb-bfb0-2e53ace6afe4" xlink:to="loc_us-gaap_DisposalGroupClassificationAxis_7d9e6a79-dfb1-4898-9865-28df27ce39a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_83b0ff2f-23e1-46ff-9058-f5b091a29706" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_7d9e6a79-dfb1-4898-9865-28df27ce39a2" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_83b0ff2f-23e1-46ff-9058-f5b091a29706" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationsDisposedOfBySaleMember_73c132ea-c165-485f-bc8a-918661692c41" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DiscontinuedOperationsDisposedOfBySaleMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain_83b0ff2f-23e1-46ff-9058-f5b091a29706" xlink:to="loc_us-gaap_DiscontinuedOperationsDisposedOfBySaleMember_73c132ea-c165-485f-bc8a-918661692c41" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_2734ced7-4a60-483a-9b97-501a1cdf1ab4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortdurationInsuranceContractsReconciliationOfClaimsDevelopmentToLiabilityTable_f8f4490e-c938-4acb-bfb0-2e53ace6afe4" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_2734ced7-4a60-483a-9b97-501a1cdf1ab4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_78118281-463d-4458-bac9-62de20f31f5e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_2734ced7-4a60-483a-9b97-501a1cdf1ab4" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_78118281-463d-4458-bac9-62de20f31f5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_TrueHealthMember_022094cf-3faf-4df7-a394-f4f186583699" xlink:href="evh-20211231.xsd#evh_TrueHealthMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_78118281-463d-4458-bac9-62de20f31f5e" xlink:to="loc_evh_TrueHealthMember_022094cf-3faf-4df7-a394-f4f186583699" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortdurationInsuranceContractsReconciliationOfClaimsDevelopmentToLiabilityLineItems_0d54c84d-c2e8-4cf0-8f80-c5015820f003" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortdurationInsuranceContractsReconciliationOfClaimsDevelopmentToLiabilityLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortdurationInsuranceContractsReconciliationOfClaimsDevelopmentToLiabilityTable_f8f4490e-c938-4acb-bfb0-2e53ace6afe4" xlink:to="loc_us-gaap_ShortdurationInsuranceContractsReconciliationOfClaimsDevelopmentToLiabilityLineItems_0d54c84d-c2e8-4cf0-8f80-c5015820f003" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MovementInLiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetRollForward_8c18c57e-1f70-427f-b875-6f94c53dd7ed" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MovementInLiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortdurationInsuranceContractsReconciliationOfClaimsDevelopmentToLiabilityLineItems_0d54c84d-c2e8-4cf0-8f80-c5015820f003" xlink:to="loc_us-gaap_MovementInLiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetRollForward_8c18c57e-1f70-427f-b875-6f94c53dd7ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense_13c3e4e4-a8ea-4b48-9961-7bbb77e624ac" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MovementInLiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetRollForward_8c18c57e-1f70-427f-b875-6f94c53dd7ed" xlink:to="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense_13c3e4e4-a8ea-4b48-9961-7bbb77e624ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_CurrentYearClaimsAndClaimsAdjustmentExpenseIncludingCostOfGoodsAndServicesSoldExcludingDepreciationAndAmortization_fc95e583-7853-436a-82d8-022b7c35ebaa" xlink:href="evh-20211231.xsd#evh_CurrentYearClaimsAndClaimsAdjustmentExpenseIncludingCostOfGoodsAndServicesSoldExcludingDepreciationAndAmortization"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MovementInLiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetRollForward_8c18c57e-1f70-427f-b875-6f94c53dd7ed" xlink:to="loc_evh_CurrentYearClaimsAndClaimsAdjustmentExpenseIncludingCostOfGoodsAndServicesSoldExcludingDepreciationAndAmortization_fc95e583-7853-436a-82d8-022b7c35ebaa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense_d6733832-1777-4c26-94b2-f684daac96f2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MovementInLiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetRollForward_8c18c57e-1f70-427f-b875-6f94c53dd7ed" xlink:to="loc_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense_d6733832-1777-4c26-94b2-f684daac96f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1_0bb2436e-3c74-4078-a529-0c98ebdfb0eb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MovementInLiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetRollForward_8c18c57e-1f70-427f-b875-6f94c53dd7ed" xlink:to="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1_0bb2436e-3c74-4078-a529-0c98ebdfb0eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1_9ded9c2c-a316-4df2-ae92-36801a30e8de" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MovementInLiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetRollForward_8c18c57e-1f70-427f-b875-6f94c53dd7ed" xlink:to="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1_9ded9c2c-a316-4df2-ae92-36801a30e8de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpensePeriodIncreaseDecrease_7a37faac-d941-4de5-bb4b-e04ecadb53b2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpensePeriodIncreaseDecrease"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MovementInLiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetRollForward_8c18c57e-1f70-427f-b875-6f94c53dd7ed" xlink:to="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpensePeriodIncreaseDecrease_7a37faac-d941-4de5-bb4b-e04ecadb53b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseBusinessAcquisitions_3e297534-0e0e-4d11-bd3b-35dd16d30123" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseBusinessAcquisitions"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MovementInLiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetRollForward_8c18c57e-1f70-427f-b875-6f94c53dd7ed" xlink:to="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseBusinessAcquisitions_3e297534-0e0e-4d11-bd3b-35dd16d30123" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseOpeningBalanceAdjustments_338543ca-8924-4073-97c6-9b0de05ad31f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseOpeningBalanceAdjustments"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MovementInLiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetRollForward_8c18c57e-1f70-427f-b875-6f94c53dd7ed" xlink:to="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseOpeningBalanceAdjustments_338543ca-8924-4073-97c6-9b0de05ad31f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense_25c50f16-8f3c-4ec3-925b-1ecf74a7c24a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MovementInLiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetRollForward_8c18c57e-1f70-427f-b875-6f94c53dd7ed" xlink:to="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense_25c50f16-8f3c-4ec3-925b-1ecf74a7c24a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/QuarterlyResultsofOperationsunaudited" xlink:type="simple" xlink:href="evh-20211231.xsd#QuarterlyResultsofOperationsunaudited"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/QuarterlyResultsofOperationsunaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_QuarterlyFinancialDataAbstract_ed3738b9-6db5-4717-bf78-ece8068387e3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_QuarterlyFinancialDataAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_QuarterlyFinancialInformationTextBlock_17c1d091-89d3-4468-a923-b55d6f7bb3d6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_QuarterlyFinancialInformationTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_QuarterlyFinancialDataAbstract_ed3738b9-6db5-4717-bf78-ece8068387e3" xlink:to="loc_us-gaap_QuarterlyFinancialInformationTextBlock_17c1d091-89d3-4468-a923-b55d6f7bb3d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/QuarterlyResultsofOperationsunauditedTables" xlink:type="simple" xlink:href="evh-20211231.xsd#QuarterlyResultsofOperationsunauditedTables"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/QuarterlyResultsofOperationsunauditedTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_QuarterlyFinancialDataAbstract_0d165be7-d568-49e5-8e16-8351fe5d7067" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_QuarterlyFinancialDataAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock_6ad90684-06cb-4bda-b84b-86170f0aead8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_QuarterlyFinancialDataAbstract_0d165be7-d568-49e5-8e16-8351fe5d7067" xlink:to="loc_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock_6ad90684-06cb-4bda-b84b-86170f0aead8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/QuarterlyResultsofOperationsunauditedDetails" xlink:type="simple" xlink:href="evh-20211231.xsd#QuarterlyResultsofOperationsunauditedDetails"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/QuarterlyResultsofOperationsunauditedDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_QuarterlyFinancialDataAbstract_98b4d491-de5b-4885-a2ea-347f78fec0d9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_QuarterlyFinancialDataAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_adc61bb1-4577-4a68-b24a-207ac9bf5e20" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Revenues"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_QuarterlyFinancialDataAbstract_98b4d491-de5b-4885-a2ea-347f78fec0d9" xlink:to="loc_us-gaap_Revenues_adc61bb1-4577-4a68-b24a-207ac9bf5e20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_5a72ab1f-33ee-4259-9012-bf55abef43f8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpenses"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_QuarterlyFinancialDataAbstract_98b4d491-de5b-4885-a2ea-347f78fec0d9" xlink:to="loc_us-gaap_OperatingExpenses_5a72ab1f-33ee-4259-9012-bf55abef43f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_184c7406-1a66-4810-86f3-c0af04caa7de" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_QuarterlyFinancialDataAbstract_98b4d491-de5b-4885-a2ea-347f78fec0d9" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_184c7406-1a66-4810-86f3-c0af04caa7de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_2a809c34-4e9c-41d7-aa0a-9b061a7ae6c3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_QuarterlyFinancialDataAbstract_98b4d491-de5b-4885-a2ea-347f78fec0d9" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_2a809c34-4e9c-41d7-aa0a-9b061a7ae6c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_7330787e-cb72-48ad-b7f0-f3e50030d820" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_QuarterlyFinancialDataAbstract_98b4d491-de5b-4885-a2ea-347f78fec0d9" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_7330787e-cb72-48ad-b7f0-f3e50030d820" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_23a88850-f217-4abd-8c9d-6eac7c07af71" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_QuarterlyFinancialDataAbstract_98b4d491-de5b-4885-a2ea-347f78fec0d9" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_23a88850-f217-4abd-8c9d-6eac7c07af71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_5ec1317e-97cf-4813-a35e-47f7b197f42c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_QuarterlyFinancialDataAbstract_98b4d491-de5b-4885-a2ea-347f78fec0d9" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_5ec1317e-97cf-4813-a35e-47f7b197f42c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract_53211dfb-0855-4cad-8f70-8024f7317de6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasicAndDilutedAbstract"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_QuarterlyFinancialDataAbstract_98b4d491-de5b-4885-a2ea-347f78fec0d9" xlink:to="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract_53211dfb-0855-4cad-8f70-8024f7317de6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_eb811e7b-b0d9-4d54-8bec-b1aed0a776ed" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsPerBasicShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract_53211dfb-0855-4cad-8f70-8024f7317de6" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_eb811e7b-b0d9-4d54-8bec-b1aed0a776ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_3fa351f4-a51a-4d3d-abe4-4a55f4b8ed31" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract_53211dfb-0855-4cad-8f70-8024f7317de6" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_3fa351f4-a51a-4d3d-abe4-4a55f4b8ed31" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare_f0a4e190-5b13-4e95-af2e-b142e72161e0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract_53211dfb-0855-4cad-8f70-8024f7317de6" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare_f0a4e190-5b13-4e95-af2e-b142e72161e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare_21d4c50b-5312-42d1-b002-8fb21fa75cd1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract_53211dfb-0855-4cad-8f70-8024f7317de6" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare_21d4c50b-5312-42d1-b002-8fb21fa75cd1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/QuarterlyResultsofOperationsunauditedAdditionalInformationDetails" xlink:type="simple" xlink:href="evh-20211231.xsd#QuarterlyResultsofOperationsunauditedAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/QuarterlyResultsofOperationsunauditedAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_QuarterlyFinancialDataAbstract_b1286ac9-3f31-4b2c-96a0-b549f92afd1c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_QuarterlyFinancialDataAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairmentLoss_13166ce1-aca6-4f82-8447-377886c0b806" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_QuarterlyFinancialDataAbstract_b1286ac9-3f31-4b2c-96a0-b549f92afd1c" xlink:to="loc_us-gaap_GoodwillImpairmentLoss_13166ce1-aca6-4f82-8447-377886c0b806" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/SupplementalCashFlowInformation" xlink:type="simple" xlink:href="evh-20211231.xsd#SupplementalCashFlowInformation"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/SupplementalCashFlowInformation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowElementsAbstract_f86c51e3-7d53-471e-bda9-566f9659ac1f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SupplementalCashFlowElementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowSupplementalDisclosuresTextBlock_36464f15-f4e4-4f76-b48f-634a1147e85c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashFlowSupplementalDisclosuresTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowElementsAbstract_f86c51e3-7d53-471e-bda9-566f9659ac1f" xlink:to="loc_us-gaap_CashFlowSupplementalDisclosuresTextBlock_36464f15-f4e4-4f76-b48f-634a1147e85c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/SupplementalCashFlowInformationTables" xlink:type="simple" xlink:href="evh-20211231.xsd#SupplementalCashFlowInformationTables"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/SupplementalCashFlowInformationTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowElementsAbstract_0391112c-03b9-46df-869c-2bdef1855b0f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SupplementalCashFlowElementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock_9ab41662-09fc-444f-8c35-405ab71631c8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowElementsAbstract_0391112c-03b9-46df-869c-2bdef1855b0f" xlink:to="loc_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock_9ab41662-09fc-444f-8c35-405ab71631c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/SupplementalCashFlowInformationDetails" xlink:type="simple" xlink:href="evh-20211231.xsd#SupplementalCashFlowInformationDetails"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/SupplementalCashFlowInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowElementsAbstract_7de21f80-f5e3-4f13-94f0-fef150892c4f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SupplementalCashFlowElementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_dee1434e-c983-4886-b1f9-d8daf7433894" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowElementsAbstract_7de21f80-f5e3-4f13-94f0-fef150892c4f" xlink:to="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_dee1434e-c983-4886-b1f9-d8daf7433894" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssued1_9f2d5f4a-a8cd-45dc-b826-7fb2f6e81c03" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssued1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_dee1434e-c983-4886-b1f9-d8daf7433894" xlink:to="loc_us-gaap_StockIssued1_9f2d5f4a-a8cd-45dc-b826-7fb2f6e81c03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationMeasurementPeriodAdjustment_f06a9d4f-3b42-4017-93d3-a652cf5ce5c7" xlink:href="evh-20211231.xsd#evh_NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationMeasurementPeriodAdjustment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_dee1434e-c983-4886-b1f9-d8daf7433894" xlink:to="loc_evh_NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationMeasurementPeriodAdjustment_f06a9d4f-3b42-4017-93d3-a652cf5ce5c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncashOrPartNoncashAcquisitionPayablesAssumed1_0f26dfd3-03f3-4fd1-bacd-2fb7a924bac8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NoncashOrPartNoncashAcquisitionPayablesAssumed1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_dee1434e-c983-4886-b1f9-d8daf7433894" xlink:to="loc_us-gaap_NoncashOrPartNoncashAcquisitionPayablesAssumed1_0f26dfd3-03f3-4fd1-bacd-2fb7a924bac8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_StockIssuedInConnectionWithDebtRepayment_ad6d60c1-f7bc-4693-812e-d207e899e6f5" xlink:href="evh-20211231.xsd#evh_StockIssuedInConnectionWithDebtRepayment"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_dee1434e-c983-4886-b1f9-d8daf7433894" xlink:to="loc_evh_StockIssuedInConnectionWithDebtRepayment_ad6d60c1-f7bc-4693-812e-d207e899e6f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_GainLossFromTransferOfMembership_f6340c31-6f32-40c8-a05c-96f7ffdb8f6f" xlink:href="evh-20211231.xsd#evh_GainLossFromTransferOfMembership"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_dee1434e-c983-4886-b1f9-d8daf7433894" xlink:to="loc_evh_GainLossFromTransferOfMembership_f6340c31-6f32-40c8-a05c-96f7ffdb8f6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_b25e539f-bd74-4c0b-8642-fc3d7db9df75" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_dee1434e-c983-4886-b1f9-d8daf7433894" xlink:to="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_b25e539f-bd74-4c0b-8642-fc3d7db9df75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_AccruedPropertyAndEquipmentPurchases_cf38ba71-34b6-410d-a971-3025aced5fc8" xlink:href="evh-20211231.xsd#evh_AccruedPropertyAndEquipmentPurchases"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_dee1434e-c983-4886-b1f9-d8daf7433894" xlink:to="loc_evh_AccruedPropertyAndEquipmentPurchases_cf38ba71-34b6-410d-a971-3025aced5fc8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1_d43d5b48-b206-447a-be5c-06e86187c11a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_dee1434e-c983-4886-b1f9-d8daf7433894" xlink:to="loc_us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1_d43d5b48-b206-447a-be5c-06e86187c11a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_CashFlowLesseeAbstract_7e016bd7-c5da-45fc-8343-6471ac5b7292" xlink:href="evh-20211231.xsd#evh_CashFlowLesseeAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowElementsAbstract_7de21f80-f5e3-4f13-94f0-fef150892c4f" xlink:to="loc_evh_CashFlowLesseeAbstract_7e016bd7-c5da-45fc-8343-6471ac5b7292" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasePayments_1878a28a-b5d4-48ac-9964-c20fb4b1d51d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeasePayments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_evh_CashFlowLesseeAbstract_7e016bd7-c5da-45fc-8343-6471ac5b7292" xlink:to="loc_us-gaap_OperatingLeasePayments_1878a28a-b5d4-48ac-9964-c20fb4b1d51d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_RightOfUseAssetAcquiredAndDisposedOf_4523702b-f8f3-4949-8b11-d110c8bd0963" xlink:href="evh-20211231.xsd#evh_RightOfUseAssetAcquiredAndDisposedOf"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_evh_CashFlowLesseeAbstract_7e016bd7-c5da-45fc-8343-6471ac5b7292" xlink:to="loc_evh_RightOfUseAssetAcquiredAndDisposedOf_4523702b-f8f3-4949-8b11-d110c8bd0963" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_88938314-2e08-4cdb-8254-b316fcf8c642" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_evh_CashFlowLesseeAbstract_7e016bd7-c5da-45fc-8343-6471ac5b7292" xlink:to="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_88938314-2e08-4cdb-8254-b316fcf8c642" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_ConversionOfStockAbstract_111711d3-e13d-40f4-87c3-2429e5b94e3a" xlink:href="evh-20211231.xsd#evh_ConversionOfStockAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowElementsAbstract_7de21f80-f5e3-4f13-94f0-fef150892c4f" xlink:to="loc_evh_ConversionOfStockAbstract_111711d3-e13d-40f4-87c3-2429e5b94e3a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConversionOfStockAmountConverted1_7c0cbc81-51bb-446c-a846-e31011a07733" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConversionOfStockAmountConverted1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_evh_ConversionOfStockAbstract_111711d3-e13d-40f4-87c3-2429e5b94e3a" xlink:to="loc_us-gaap_ConversionOfStockAmountConverted1_7c0cbc81-51bb-446c-a846-e31011a07733" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_StockIssuedDecreaseInDeferredTaxLiability_d54abdc7-5b16-4fe4-9bd9-25dfdd926c1d" xlink:href="evh-20211231.xsd#evh_StockIssuedDecreaseInDeferredTaxLiability"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_evh_ConversionOfStockAbstract_111711d3-e13d-40f4-87c3-2429e5b94e3a" xlink:to="loc_evh_StockIssuedDecreaseInDeferredTaxLiability_d54abdc7-5b16-4fe4-9bd9-25dfdd926c1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_5f18c19a-61b9-4ac4-b3e5-5e71842bdae2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowElementsAbstract_7de21f80-f5e3-4f13-94f0-fef150892c4f" xlink:to="loc_us-gaap_SupplementalCashFlowInformationAbstract_5f18c19a-61b9-4ac4-b3e5-5e71842bdae2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidNet_f516087f-7c5d-45d7-bba1-ca46a72a0c1d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestPaidNet"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_5f18c19a-61b9-4ac4-b3e5-5e71842bdae2" xlink:to="loc_us-gaap_InterestPaidNet_f516087f-7c5d-45d7-bba1-ca46a72a0c1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesPaid_5113688a-43e9-40f8-8615-1c3013e78fcb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxesPaid"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_5f18c19a-61b9-4ac4-b3e5-5e71842bdae2" xlink:to="loc_us-gaap_IncomeTaxesPaid_5113688a-43e9-40f8-8615-1c3013e78fcb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>evh-20211231_g1.jpg
<TEXT>
begin 644 evh-20211231_g1.jpg
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M#\ ?^(3;_@J9_P!)=O\ RH:Y_P#'J/\ B$V_X*F?])=O_*AKG_QZOW^HH _
M'_B$V_X*F?\ 27;_ ,J&N?\ QZC_ (A-O^"IG_27;_RH:Y_\>K]_J* /P!_X
MA-O^"IG_ $EV_P#*AKG_ ,>H_P"(3;_@J9_TEV_\J&N?_'J_?ZB@#\ ?^(3;
M_@J9_P!)=O\ RH:Y_P#'J/\ B$V_X*F?])=O_*AKG_QZOW^HH _ '_B$V_X*
MF?\ 27;_ ,J&N?\ QZC_ (A-O^"IG_27;_RH:Y_\>K]_J* /P!_XA-O^"IG_
M $EV_P#*AKG_ ,>H_P"(3;_@J9_TEV_\J&N?_'J_?ZB@#\ ?^(3;_@J9_P!)
M=O\ RH:Y_P#'J/\ B$V_X*F?])=O_*AKG_QZOW^HH _ '_B$V_X*F?\ 27;_
M ,J&N?\ QZC_ (A-O^"IG_27;_RH:Y_\>K]_J* /P!_XA-O^"IG_ $EV_P#*
MAKG_ ,>H_P"(3;_@J9_TEV_\J&N?_'J_?ZB@#\ ?^(3;_@J9_P!)=O\ RH:Y
M_P#'J/\ B$V_X*F?])=O_*AKG_QZOW^HH _ '_B$V_X*F?\ 27;_ ,J&N?\
MQZC_ (A-O^"IG_27;_RH:Y_\>K]_J* /P!_XA-O^"IG_ $EV_P#*AKG_ ,>H
M_P"(3;_@J9_TEV_\J&N?_'J_?ZB@#\ ?^(3;_@J9_P!)=O\ RH:Y_P#'J/\
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M_P!)=O\ RH:Y_P#'J/\ B$V_X*F?])=O_*AKG_QZOW^HH _ '_B$V_X*F?\
M27;_ ,J&N?\ QZC_ (A-O^"IG_27;_RH:Y_\>K]_J* /P!_XA-O^"IG_ $EV
M_P#*AKG_ ,>H_P"(3;_@J9_TEV_\J&N?_'J_?ZB@#\ ?^(3;_@J9_P!)=O\
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M#\ ?^(3;_@J9_P!)=O\ RH:Y_P#'J/\ B$V_X*F?])=O_*AKG_QZOW^HH _
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M_P#'J/\ B$V_X*F?])=O_*AKG_QZOW^HH _ '_B$V_X*F?\ 27;_ ,J&N?\
MQZC_ (A-O^"IG_27;_RH:Y_\>K]_J* /P!_XA-O^"IG_ $EV_P#*AKG_ ,>H
M_P"(3;_@J9_TEV_\J&N?_'J_?ZB@#\ ?^(3;_@J9_P!)=O\ RH:Y_P#'J/\
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M_P!)=O\ RH:Y_P#'J/\ B$V_X*F?])=O_*AKG_QZOW^HH _ '_B$V_X*F?\
M27;_ ,J&N?\ QZC_ (A-O^"IG_27;_RH:Y_\>K]_J* /P!_XA-O^"IG_ $EV
M_P#*AKG_ ,>H_P"(3;_@J9_TEV_\J&N?_'J_?ZB@#\ ?^(3;_@J9_P!)=O\
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MGC4 DO&&4#DG!%?C-_P3-^)*_P#!=W_@XB\<?';]IV-?$/P_^#NB:IJ7PO\
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M+X/:S=_$'18[/2O#UOI.IW;ZG$([2_DTC5(TM9&W824O/"@0X;=*@QDBH/\
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ML\DH*A841X_++R,HWR1("6EC#?N_9V=II]K'8V%K'!!"@2&&% J(H& H X
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH *_A"_:P_Y.F^)?\ V4#6?_2Z:O[O:_A"_:P_Y.F^)?\
MV4#6?_2Z:@#]O_\ @TV_Y2F?M=_]O'_I\GK]_J_ '_@TV_Y2F?M=_P#;Q_Z?
M)Z_?Z@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *_A"_:P_Y.F^)?\ V4#6
M?_2Z:O[O:_A"_:P_Y.F^)?\ V4#6?_2Z:@#]O_\ @TV_Y2F?M=_]O'_I\GK]
M_J_ '_@TV_Y2F?M=_P#;Q_Z?)Z_?Z@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MXQ_Y%B]_ZX&@"YIY+6$!)R3"N2?H*FJ'3O\ D'P?]<5_D*FH **** "BBB@
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MBB@ K(\%R22Z5(TLC,?MDHRQSQNK7K'\#_\ ((E_Z_9O_0J -BBBB@ HHHH
M**** ,[Q<[Q^&KR2-RK"$X93@BK>GDM80$G),*Y)^@JGXQ_Y%B]_ZX&KFG?\
M@^#_ *XK_(4 34444 %%%% !1110 5D>"Y))=*D:61F/VR498YXW5KUC^!_^
M01+_ -?LW_H5 &Q7\(7[6'_)TWQ+_P"R@:S_ .ETU?W>U_"%^UA_R=-\2_\
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M_;L^-?P_NO$GQ3\>:O?>/_'GAOPJK7;B[=%AT_0;9T4M)%:PB"W\X*VYO/F
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ME^&V@WVF?#70_"GAJ;3-+T26^5$O]29;BZN99[N:.-(E.]8X8LJ%=R9:^D*
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M[_UY1?S-;% &/]B\;_\ 0;LO_ 8_XT?8O&__ $&[+_P&/^-;%% &/]B\;_\
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M?^ Q_P :TM._Y!\'_7%?Y"IJ ,?[%XW_ .@W9?\ @,?\:/L7C?\ Z#=E_P"
MQ_QK8HH Q_L7C?\ Z#=E_P" Q_QH^Q>-_P#H-V7_ (#'_&MBB@#'^Q>-_P#H
M-V7_ (#'_&LS7+7Q2NHZ:MUJEL[M<D0,L! 5MO4^M=76/XE_Y"^C_P#7Z?\
MT$T 'V+QO_T&[+_P&/\ C1]B\;_]!NR_\!C_ (UL44 8_P!B\;_]!NR_\!C_
M (T?8O&__0;LO_ 8_P"-;%% &/\ 8O&__0;LO_ 8_P"-'V+QO_T&[+_P&/\
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M_P :/L7C?_H-V7_@,?\ &MBB@#'^Q>-_^@W9?^ Q_P :/L7C?_H-V7_@,?\
M&MBB@#'^Q>-_^@W9?^ Q_P :S/"MKXIDTZ1K#5+:-/M,@*R0$G=NY-=76/X'
M_P"01+_U^S?^A4 'V+QO_P!!NR_\!C_C1]B\;_\ 0;LO_ 8_XUL44 8_V+QO
M_P!!NR_\!C_C1]B\;_\ 0;LO_ 8_XUL44 8_V+QO_P!!NR_\!C_C1]B\;_\
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M_P @B7_K]F_]"K8K'\#_ /((E_Z_9O\ T*@#8HHHH **** "BBB@ K'\#_\
M((E_Z_9O_0JV*Q_ _P#R")?^OV;_ -"H V**** "BBB@ HHHH *Q_ __ "")
M?^OV;_T*MBL?P/\ \@B7_K]F_P#0J -BBBB@ HHHH **** ,WQC_ ,BQ>_\
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M_P @B7_K]F_]"K8H **** "BBB@ HHHH Q_ _P#R")?^OV;_ -"K8K'\#_\
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M-0 4444 %%%% !6/XE_Y"^C_ /7Z?_036Q6/XE_Y"^C_ /7Z?_030!L4444
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M*_A"_:P_Y.F^)?\ V4#6?_2Z:O[O:_A"_:P_Y.F^)?\ V4#6?_2Z:@#]O_\
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M".A?'+X(-H?A73;(S>.9!*;2QCCW@0Y .T#/-?0W]G:?_P ^,/\ WZ% %/\
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M#4'_ 'U5S^SM/_Y\8?\ OT*/[.T__GQA_P"_0H I_P#"8^&/^@U!_P!]4?\
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M<_L[3_\ GQA_[]"C^SM/_P"?&'_OT* *?_"8^&/^@U!_WU1_PF/AC_H-0?\
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M'_OT* *?_"8^&/\ H-0?]]4?\)CX8_Z#4'_?57/[.T__ )\8?^_0H_L[3_\
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M/^$7TL\DY)YM:^>J*_JO_4G@S_H6X?\ \$T__D3^2?\ 7KC;_H:8C_P?4_\
MDC[O_8 _X*+_ +6_QC_:X\)?#CXO_&1=0\.ZC]O_ +1M&T#3X!)Y=A<2Q_/#
M;JZXD1#PPSC!R"17Z5_\)CX8_P"@U!_WU7XW_P#!)^..7]O[P#'+&K*?[5RK
M#(/_ !*KROV<_L[3_P#GQA_[]"OY4\<LKRS*.+:%' T(4H.A%N,(Q@F_:55>
MT4E>R2OO9+L?UMX"YMFF<<(5ZV/KSK35>24IRE-I>SI.R<FW:[;MM=ON4_\
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MQ#XYM;2<V5TND17EO*J75TT101;V38A\MI""Q&2H499@#^HO]G:?_P ^,/\
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M:_A"_:P_Y.F^)?\ V4#6?_2Z:O[O:_A"_:P_Y.F^)?\ V4#6?_2Z:@#]O_\
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M)O?YJ]2HHH **** /!?VN?\ DN'P,_['N7_T17O5>"_M<_\ )</@9_V/<O\
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M383!9?'C8C.7(_X1?2SR3DGFUK]8_P")?.,_^@C#_P#@=3_Y4?D/_$Q?!/\
MT#XC_P  I_\ RX_:>BOQ>_X>R?\ !0'_ *+[_P"6KI7_ ,BU^T-?"\:^'V=<
M">P^OU*<O;<W+[-R=N3EO?FA'^96M?KL??\  _B-DG'_ -8_L^G4A['DYO:*
M*OS\UK<LY_R.][=-^A1117PA]\%%%?.G[?G[?G_##?\ PB?_ !:?_A*/^$H^
MW_\ ,>^Q?9OLWV?_ *82[]WVC_9QL[YX]3)LFS+B#,J> P%/GK3ORQNHWY4Y
M/6325DF]7^)Y6=YWEG#N65,PS"IR486YI6E*W-)16D4V[MI:+\#Z+K'\#_\
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M_&OHNDDCCEC:*5 RL"&5AD$'L:_*/[7X>Q'^\9<H^=&K.'_ISVR_"WD?KO\
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M*1D,K#@@CN*EKZ]24DFG=,]---705C^!_P#D$2_]?LW_ *%6Q6/X'_Y!$O\
MU^S?^A4P-BOX0OVL/^3IOB7_ -E UG_TNFK^[VOX0OVL/^3IOB7_ -E UG_T
MNFH _;__ (--O^4IG[7?_;Q_Z?)Z_?ZOP!_X--O^4IG[7?\ V\?^GR>OW^H
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MHH **** ,?P/_P @B7_K]F_]"K8K'\#_ /((E_Z_9O\ T*MB@ HHHH ****
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M?]M_;5#V6_,ON^U^%S]#J***_P!%S]P"BBB@ K-\8_\ (L7O_7 UI5F^,?\
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M+Z/_ -?I_P#030!L4444 %%%% !1110 5CV7_([WO_7E%_,UL5CV7_([WO\
MUY1?S- &Q1110 4444 %%%% !6/9?\CO>_\ 7E%_,UL5CV7_ ".][_UY1?S-
M &Q1110 4444 %%%% !6/9?\CO>_]>47\S6Q6/9?\CO>_P#7E%_,T ;%%%%
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M<1BZSK5YN<WNY-MOU;U9_6N&PV&P="-'#P4(1VC%))>B6B"BBBL3<*Q_ _\
MR")?^OV;_P!"K8K'\#_\@B7_ *_9O_0J -BBBB@ HHHH RO''C+0?AYX/U+Q
MSXGNQ#8:59R7-U)WVJ,X [L>@'<D#O7X>?ML>(_&WC']ISQ/XQ^(5F;;4]8-
MG?M;$Y\F":R@EMX_^ P-$O//'/-?K'\?7?X]_&K0OV7M.<OHNG>7KOC]T/RF
M!&!M[-O>1\,5Z[=K#H:N?%;_ ()X_L=_&[Q[??$[XG?!X:EKFI"$7MZNO:A
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M2T39C0DJ03M'I7NW[$UM->?L*?".SM[Q[>27X2Z B7$8&Z(G3( &&>,CK^%
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M /$O_(7T?_K]/_H)K8KE-<US49]1TV23PW<QF.Y+(C,N9#MZ"M/_ (275_\
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M7O\ WTM'_"2ZO_T*%[_WTM &Q16/_P )+J__ $*%[_WTM'_"2ZO_ -"A>_\
M?2T ;%%8_P#PDNK_ /0H7O\ WTM'_"2ZO_T*%[_WTM !X'_Y!$O_ %^S?^A5
ML5RGA77-1M=.DCA\-W,X-S(Q=&7 );I^%:?_  DNK_\ 0H7O_?2T ;%%8_\
MPDNK_P#0H7O_ 'TM'_"2ZO\ ]"A>_P#?2T ;%%8__"2ZO_T*%[_WTM'_  DN
MK_\ 0H7O_?2T ;%%8_\ PDNK_P#0H7O_ 'TM'_"2ZO\ ]"A>_P#?2T '@?\
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MO_?2T ;%%8__  DNK_\ 0H7O_?2T?\)+J_\ T*%[_P!]+0!L45C_ /"2ZO\
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M_3_Z":/^$EU?_H4+W_OI:S-<US49]1TV23PW<QF.Y+(C,N9#MZ"@#JZ*Q_\
MA)=7_P"A0O?^^EH_X275_P#H4+W_ +Z6@#8HK'_X275_^A0O?^^EH_X275_^
MA0O?^^EH V**Q_\ A)=7_P"A0O?^^EH_X275_P#H4+W_ +Z6@#8K'LO^1WO?
M^O*+^9H_X275_P#H4+W_ +Z6LRUUS45\4W5TOANY9WMHU: ,NY0">30!U=%8
M_P#PDNK_ /0H7O\ WTM'_"2ZO_T*%[_WTM &Q16/_P )+J__ $*%[_WTM'_"
M2ZO_ -"A>_\ ?2T ;%%8_P#PDNK_ /0H7O\ WTM'_"2ZO_T*%[_WTM &Q6/9
M?\CO>_\ 7E%_,T?\)+J__0H7O_?2UF6NN:BOBFZNE\-W+.]M&K0!EW* 3R:
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MMT_"OM?^)@^,_P#H'P__ (!4_P#EI\-_Q+IP3_T$8C_P.G_\I/R)_P"'3?\
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MX%92+B\()M+5NV!R[*<Y&1P5KP.(\SKY;E]L*D\15:ITD]G.5[-_W8).I/\
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MH]5?3-(TG1;<V>C:7;VD)D9S%:P+&I8G);"@#)/4U8H **** /!?VN?^2X?
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M?^A5L4 %%%% !7@/Q)N[G]K'XNO\"- N7'@;PK=1S>/;^%R%U&Z4[H]-1AU
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M_3_Z": -BBBB@ HHHH **** "L>R_P"1WO?^O*+^9K8K'LO^1WO?^O*+^9H
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M% !1110 4444 %8_@?\ Y!$O_7[-_P"A5L5C^!_^01+_ -?LW_H5 &Q1110
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ML5C^)?\ D+Z/_P!?I_\ 030!L4444 %%%% !1110 5C^)?\ D+Z/_P!?I_\
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M-^*F@>(GNO[6_LFU\/Z&;2.QV_8O-RS$M+OW1XS]WRS_ 'J_5ROSI_X+\?\
M-)_^X]_[CJ_1/"C/I8OC_!T(8:C3B_:?!37-I2F])R<I+;6SU5T]&S\W\7<@
MC@_#S&XB>*K5)+V?QU'RZUJ:UA%1@]]+QT=FM4C\Z:***_LT_B4*_HLK^=.O
MZ+*_F/Z1O_,K_P"X_P#[A/ZF^C3_ ,S7_N!_[F"BBBOYC/ZF"BBB@ K'\#_\
M@B7_ *_9O_0JV*Q_ _\ R")?^OV;_P!"H V**** "BBB@ HHHH *Q_ __((E
M_P"OV;_T*MBL?P/_ ,@B7_K]F_\ 0J -BBBB@ HHHH **** "L?P/_R")?\
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MK^"_%?AWCK-)X# 4JL9Q@YMSC!*RE&-ERSD[WDNEK7U/:****_-C]."BBB@
MK'LO^1WO?^O*+^9K8K'LO^1WO?\ KRB_F: -BBBB@ HHHH *^9O^"LOB31F_
M9!U?X2V]WY_B;QGJ&G67A?0[9#)=:C.FH6TSK'&H).$0Y/3)49RR@^G_ +37
M[37@[]FGP=#JVK64^KZ]J\_V3PKX5TX;KS6+QL!8HU )"@E=SX(4$<%BJMQW
M[,O[,OC&V\8S?M1_M1WL&K_$S5X-EK:QG=9^%K-LXLK09(# $AY!DDE@"<N\
MGV7#="&2U*/$&,TA2FI4H_:K5(--)=J<6E[2?3X8WD]/B^)J\\[IUN'L%K.K
M!QJR^S1IS33;[U))OV<.OQ2M%:_FPO\ P2<_X* .H8? $X(R,^*=*!_]*JB3
M_@E5^WM)?/IJ? ?,T:!W3_A*-+X!Z'/VK%?M/6/9?\CO>_\ 7E%_,U^A_P#$
MP?&?_0/A_P#P"I_\M/S;_B73@G_H(Q'_ ('3_P#E)^.W_#IO_@H#_P!$"_\
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MPNO-6E\*ZMX.\1Z;XE^&WBK1K.-IO"^MZ?('LKN&)L(Z+S&\)P'B=U!0E64
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M_P#1%>]4 8_V+QO_ -!NR_\  8_XT?8O&_\ T&[+_P !C_C6Q10!C_8O&_\
MT&[+_P !C_C1]B\;_P#0;LO_  &/^-;%% 'EO[2_PP\>_%3X$>)_ MKJ%K<3
MWFFE[:WC@(::6)EFC0'L6>-1^-?E=)')#(T4J%64D,K#!!'4$5^T=?#_ .U)
M^ROH/QW_ &F+_P +_L[V<%OK%MI[7WC:YN)BFGP7#X,2#:C%9Y.2P'!SNX(<
MU_./CUP-B<]^JYI@?>KJU'V?VJB;<H\BZN/ON2_EO*ZY=?AN,<HJ8SV>(HZS
M^'EZOJK>FK?EKT/CNECCDFD6*)"S,0%51DDGH *]NNO^"=_[55EJ\.E7'@>S
M5;B7RXKO^VK8QD^N-^\#'/W:^D_V4?\ @G+I'PCUZU^(OQ<U:UUG6[1Q)I^G
MVBL;2SD'20LP!E<=LJ%4\_,<$?@O#WA)QSGN91P\\'.A"_O3J1<%%=6N:SD^
MRC>[[*[7QV"X;S?&5U!TG!=7)-)+Y[_(]0_9H^&'CWX5_ CPQX%NM0M;>>ST
MT/<V\D!+0RRLTTB$]RKR,/PKNOL7C?\ Z#=E_P" Q_QK8HK^^\NP-#*\OHX*
MC\%*$81](I17X(_9:%&&'H1I0VBDEZ)6,?[%XW_Z#=E_X#'_ !H^Q>-_^@W9
M?^ Q_P :V**[34Q_L7C?_H-V7_@,?\:/L7C?_H-V7_@,?\:V** .4M;7Q2?%
M-U''JEL+@6T9DD,!VE<G  K3^Q>-_P#H-V7_ (#'_&BR_P"1WO?^O*+^9K8H
M Q_L7C?_ *#=E_X#'_&N4^,_P6U+XV^ +OP)XFUFT192LME>16Y$MG<IS',A
M!R&4^F,@D=":]#HKFQF#PV882>&Q$5*G-.,D]FGHT9U:5.M3=.:NFK-'C'[.
M'Q3^)?C.VU/X8?$/5;2U\9^$)EM-;MY8.;N/'[J\0\;DD7!R .3T 9:]/^Q>
M-_\ H-V7_@,?\:\T_:<^'?BC2=2T_P#:7^$-D9/%/A2)A?Z?'D?VUI><S6K
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M?6NKK'\2_P#(7T?_ *_3_P"@F@ ^Q>-_^@W9?^ Q_P :/L7C?_H-V7_@,?\
M&MBB@#'^Q>-_^@W9?^ Q_P :/L7C?_H-V7_@,?\ &MBB@#'^Q>-_^@W9?^ Q
M_P :^>O^"JMKXIC_ &"?'CZEJEM)"/[+WI' 5)_XFEICGZXKZ=KYT_X*R?\
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MGZ'\OQ/_ &:?C?X."_ZR;7_A1,(A[AXI'R/?%>9?MC_MN_\ !/\ _;>_9O\
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M<J+W9]DU)>]&+7%C<-.O!3INU2.L7Y]4_*2T?W[I&U17C7[,OQ \3^'=8O\
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MQ_\ VY_8?]D_V7_Q*K2V\CSOMOF_\>\4>[/E1_>SC;QC)S^4=?HM_P $!_\
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MPA?M8?\ )TWQ+_[*!K/_ *735_=[7\(7[6'_ "=-\2_^R@:S_P"ETU '[?\
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M $7W_P M75?_ )%K\7J*^Q_XE\X,_P"@C$?^!T__ )4?%_\ $Q?&W_0/A_\
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M0[1KVZ=%66G_ #\47[TIO^"C7[*.O?%W2+3XM_#G3'N];T:U-OJ&GPKF2\M
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M+;<+V2A*49.ZNX\N5\./),73Q6*:DKVTO:+>B;ONNG2S:?I] 445X_\ '/\
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M2-8^$OQ.^'$FEZ]H-ZUKJ5C+J"L8W !!#(I5E*D,&4D,K @D$&N=_P"%X?\
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M?1A##S<HMSEA7'F<)M:47[635N91C:_+:4HQO)?5HT;]IK]OC][XI75OA/\
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MZBBBO]##_.(*_:'_ ()-_P#*/[P!_P!Q7_TZWE?B]7[0_P#!)O\ Y1_> /\
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M6[U6YLXF6T@12\CA3MWN0NU$W#<[*N1G-?98CQ-X<PE"5:O&<815VVHV2_\
M _\ @]CP,3]$CQ&PN'E6J8S"6BFW^\K=/6@?T)^(;+X/>+E*^*]%T+5 1@C4
M=/CGS_WVIK@_$?[*7[#'BO<=8^ G@7<WWI+308;9S[EH54D_C7K_ /9VG_\
M/C#_ -^A1_9VG_\ /C#_ -^A7\-87-,SP7^[UYP_PRE'\FC^F,5E.5X[_>:$
M)_XHQE^:9\VWW_!./]@"2Y-_H'@J?0KH_P#+UH?BC4(&'T'G%1^50_\ ##?@
M;1OF^'O[:?QE\/[?N6UMX[::W'UCDB.?SKZ8_L[3_P#GQA_[]"H-2?PYHUD^
MHZP]E:6\8S)/<E(T0>I9L 5[$>,^*W:,\94GY3?M/PGS'CO@CA.]Z>"IP?\
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MPCZU(+\.:Y\7_9F*7Q.*]9P7X<USZ?\ ^$Q\,?\ 0:@_[ZH_X3'PQ_T&H/\
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MM\=O%VI?&#QR,,WB;XC7AO4@;.<6]HW[F! >5&UBF/E85]/_ -G:?_SXP_\
M?H4?V=I__/C#_P!^A7SD\SK1BX8=*G%_R[OUD_>?I>WD>#+,*JBX4$J<?[N[
M]9;OTO;R*,7BSPI#&L,.K6Z(BA41> H'0 =J=_PF/AC_ *#4'_?57/[.T_\
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M_OT*/[.T_P#Y\8?^_0H I_\ "8^&/^@U!_WU1_PF/AC_ *#4'_?57/[.T_\
MY\8?^_0H_L[3_P#GQA_[]"@"G_PF/AC_ *#4'_?5'_"8^&/^@U!_WU5S^SM/
M_P"?&'_OT*/[.T__ )\8?^_0H I_\)CX8_Z#4'_?59?A+Q+H-CIDD-WJD4;&
MZE8*Q[%N#70?V=I__/C#_P!^A61X+LK.72I&EM(F/VR49:,'C=0!;_X3'PQ_
MT&H/^^J/^$Q\,?\ 0:@_[ZJY_9VG_P#/C#_WZ%']G:?_ ,^,/_?H4 4_^$Q\
M,?\ 0:@_[ZH_X3'PQ_T&H/\ OJKG]G:?_P ^,/\ WZ%']G:?_P ^,/\ WZ%
M%/\ X3'PQ_T&H/\ OJC_ (3'PQ_T&H/^^JN?V=I__/C#_P!^A1_9VG_\^,/_
M 'Z% &'XH\4>'[SP_=VMKJL3R/$0B*>2:MV/B[PU'90QOK,(98E!!/0XH\76
M-E'X:O'CLXE80G!6, BK>GZ?8-80$V4))A7),8]!0!#_ ,)CX8_Z#4'_ 'U1
M_P )CX8_Z#4'_?57/[.T_P#Y\8?^_0H_L[3_ /GQA_[]"@"G_P )CX8_Z#4'
M_?5'_"8^&/\ H-0?]]5<_L[3_P#GQA_[]"C^SM/_ .?&'_OT* *?_"8^&/\
MH-0?]]4?\)CX8_Z#4'_?57/[.T__ )\8?^_0H_L[3_\ GQA_[]"@"G_PF/AC
M_H-0?]]5!X&8-H\C*<@WDI!_X%6G_9VG_P#/C#_WZ%9G@< :1* /^7R7_P!"
MH V:_A"_:P_Y.F^)?_90-9_]+IJ_N]K^$+]K#_DZ;XE_]E UG_TNFH _;_\
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M_LJ>&[/Q)!X(;0_['CL7\>:Q+>6]CY*P""&_>[-Y JQJ%7RYE*C[I&37H]%
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M8V_!@_%?55%?6_VMB_Y8?^"J?_R!Z7]I8GM#_P %T_\ Y$^5?^&'_P!N&?\
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MX+>&/@YX$M/)TKP[HT%G:Y4!I-J_/*V.KNY9V/=G)[UUU0Z=_P @^#_KBO\
M(5-7#.<ZDW.3NWJ_4XYSE4FY2=V]6%%%%22%%%% !7YH_P#!;C_@G/XI^//Q
MF^'GQA^"NB"36/%.JV_A;Q-LC)5"Q_T:^DQ_ B>8DCGHJ1#M7Z75C^)?^0OH
M_P#U^G_T$UZ&5YEB,IQBQ%'=77DT^_Y_([LOQ];+<4J]+=77K?\ JYF_ [X/
M>#_V?_A!X<^"W@*U\K2?#>E165IE0&DVCYI7QU=W+.Q[LY/>NJHHKAG.=2;G
M)W;U?J<<YRJ3<I.[>K"BBBI)"BBB@ K'\2_\A?1_^OT_^@FMBL?Q+_R%]'_Z
M_3_Z": -BBBB@#YF_:J_8V\=Q?$4?MB_L4ZM:^'?BQ80!=6TR?Y-,\:6BXS9
MWJ @>80,)-P00H+#"21]Q^R%^V3X$_:Q\,WT-OI-UX:\:>')OLGC7P)K/R7^
MBW0X964@%XB0=DH ##@A6!4>PU\\_M>_L5:E\4_$UC^TG^S=XJC\%?&7PW#C
M2/$2)BVUB ==/U% ,30.!M#$%DX(R!MKU:6(I8RFJ&*=FM(S[?W9=X]NL>EU
MH>E2KTL535'$.S6D9=O*7>/XQZ76A]#45X5^QY^VKIO[1,FI_"GXF>%)/!/Q
M8\)@1^,? FH/AXR,#[7:L3^_M7R"KJ3MW*"2&1W]UK@Q&'K86JZ=56:_I-/J
MGT:T9Q5Z%7#U'3J*S7]77=/H^H5CV7_([WO_ %Y1?S-;%8]E_P CO>_]>47\
MS6)D;%%%% !1110 54U[0]'\3Z'>^&O$.G17FGZC:26U]:3INCGAD4HZ,.ZL
MI((]#5NBFFT[H:;3NC^;?]N_]EK6/V.?VHO$_P $+Y)6T^TN_M/AV[EZW6FS
M9>W?/\3!?W;$<;XW':O'Z_6[_@XF\.?L\^*O OASQ=%\3] @^)?AJ\^RCPZE
MZCWU[IDQRRM&F601R8D4OM7:TV"20*_)&OWK(,PGF>54ZU1-2M9WZM=5Y/?\
M#]FR7&SQ^6PJS5I;/S:Z_/<]@_80_9:UC]L;]J+PQ\$+%)5T^[N_M/B*[BZV
MNFPX>X?/\+%?W:D\;Y$'>OZ-K6#PG\/?"MOIUO\ 8M'T;2+..WMT9UA@M8(U
M"(@)("JJ@ >PK\L/^"37_!+?XY:O\%H?VB[?]J/Q!\-(O'-J433O"VD0KJ-Q
MIJR'RY/MLI+0+(P+A$3#*(W)/RA?KO3/^"/W[(=_?QZU\:+KQS\4=1B;<M_\
M1/'-Y>ON]2L;1(WT*D>U? \68[ YAC^2=?W:=U:,6W?K>[BO+1O8^+XEQF#Q
MN-Y)5O=AI:,6W?KNXKRT;V.R^)__  4Q_8+^$+/#XQ_:D\*O/&</::)>G4YE
M;^Z8[-96!]B!7"_\/2O^$]_<_LT?L5?&3Q]O'[C5/^$7_LO2Y/3_ $JY8;?Q
M3I7NGPQ_9B_9R^"PC/PE^!7A+P[)&!BYTCP_;PS'W:54WL?<DFNZKY7VV54O
M@I2F_P"]*R^Z*3_\F/G/:Y;3^&G*7^*5E]T5?_R8^4O^%@?\%@?BMQX7^ /P
MH^%5I+]Y_&/BB?6[R)?5!8@1%O9N*/\ AAO]L_XF?/\ M!?\%,_&26\GW]+^
M&.@VOA\1 ]56Y0/(_P#O,,U]6T4?VI4A_!IPAZ13?WRYG^(?VC4C_"A"'I%-
M_?+F?XGY9_\ !6+_ ()(_#[X=?LP7/Q_^#&I^+-<\2>%KE;CQ1J'BCQ#-J5U
M?Z:WRR.2_"F)BLAVJHV&4G.!CX#_ &$/V6M8_;&_:B\,?!"Q25=/N[O[3XBN
MXNMKIL.'N'S_  L5_=J3QOD0=Z_H]U[0]'\3Z'>^&O$.G17FGZC:26U]:3IN
MCGAD4HZ,.ZLI((]#7R-_P3%_X)Q:7^PK\0/B3J=[=Q7][K6JO!X>N]VZ2#0U
MDWP(Q[2.3F0#@F-/2OJ<KXMK8;)JU.M)NJO@;\]/_)=_P/H\OXFJT,JJTZLK
MU%\#?G_\CO\ @?7.@Z'H_AC0[+PUX>TZ*ST_3K2.VL;2!-L<$,:A$11V55
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M @8V.GQ#=/-SQNQA$SP7D0'K7[A_!'_@E5^Q'\#[F#6[7X21^*=;MXT1=?\
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M]M&K0!EW* 3R:T_^$EU?_H4+W_OI: -BBL?_ (275_\ H4+W_OI:/^$EU?\
MZ%"]_P"^EH V**Q_^$EU?_H4+W_OI:/^$EU?_H4+W_OI: -BBL?_ (275_\
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MZ6@#8HK'_P"$EU?_ *%"]_[Z6C_A)=7_ .A0O?\ OI: #P/_ ,@B7_K]F_\
M0JV*Y3PKKFHVNG21P^&[F<&YD8NC+@$MT_"M/_A)=7_Z%"]_[Z6@#8HK'_X2
M75_^A0O?^^EH_P"$EU?_ *%"]_[Z6@#8HK'_ .$EU?\ Z%"]_P"^EH_X275_
M^A0O?^^EH V**Q_^$EU?_H4+W_OI:/\ A)=7_P"A0O?^^EH / __ "")?^OV
M;_T*MBN4\*ZYJ-KITD</ANYG!N9&+HRX!+=/PK3_ .$EU?\ Z%"]_P"^EH V
M**Q_^$EU?_H4+W_OI:/^$EU?_H4+W_OI: -BBL?_ (275_\ H4+W_OI:/^$E
MU?\ Z%"]_P"^EH V*P_B5H^E^(O &L>']<L(KJROM/DM[RUF7<DT3KM=&'<%
M201[U)_PDNK_ /0H7O\ WTM4?$NO:G<Z#=03>&+J%6B(,KLN%]S33:=T--IW
M1K>$]%TGPUX5TSPYH&GQ6ECI^GPVUE:0+M2&%$"HBCL H  ]!6A6%9>(]52S
MB1?"5XP$2@,&7!XZU+_PDNK_ /0H7O\ WTM#;;NP;;=V;%%8_P#PDNK_ /0H
M7O\ WTM'_"2ZO_T*%[_WTM(1L4C*KJ4=001@@C@BLC_A)=7_ .A0O?\ OI:/
M^$EU?_H4+W_OI: /%M#F7]CGXR#P=?2^3\-/'%^TFB7$C8BT'5&Y:V)/"0R]
M5[ CL ['>^)'[:7[+FB65YX>NOC'ILUTR% MA%-=)NST\R%&3]:^4/\ @H%^
MU?K_ ,5O&MU\(?#\KV?AW0KLQ7D*L";V\C.'9R/X4;*JHXR"W.5V_-M?R1GW
MC36X/S7$Y3P_3A5H4YOE=12:C_/""C*-Z:G?D;>B?*ER*)^;8SBJ>68B>&P4
M5*$7IS7T[I6:T3O;[EI8_7KX6_%_X8?%;1TN?AUXZTW5_(A3[1%:7(,L/&/G
MC.'3\0*ZJOQN\'>,_%7P^\1VOB[P7KMQINI6<F^WN[9]K*?0]B#T*G((X((K
M]-/V7OVF+KX__">T\8CPM(VH6\AM-9CM7&Q+E "2H/(5E97 [;L9.,U^G^%_
MB[A^.ZT\!BZ2I8J*YDDVXSBMW&^J:OK%MZ:IO6WO\/\ $L,XDZ-2/+42OILU
MY>G8]=HK'_X275_^A0O?^^EH_P"$EU?_ *%"]_[Z6OV@^J-BBL?_ (275_\
MH4+W_OI:/^$EU?\ Z%"]_P"^EH V*S?&/_(L7O\ UP-0_P#"2ZO_ -"A>_\
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M7O\ WTM'_"2ZO_T*%[_WTM &Q16/_P )+J__ $*%[_WTM'_"2ZO_ -"A>_\
M?2T ;%8_B7_D+Z/_ -?I_P#031_PDNK_ /0H7O\ WTM9FN:YJ,^HZ;))X;N8
MS'<ED1F7,AV]!0!U=%8__"2ZO_T*%[_WTM'_  DNK_\ 0H7O_?2T ;%%8_\
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M[_WTM9GA77-1M=.DCA\-W,X-S(Q=&7 );I^% '5T5C_\)+J__0H7O_?2T?\
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M0!L45C_\)+J__0H7O_?2T?\ "2ZO_P!"A>_]]+0!L45C_P#"2ZO_ -"A>_\
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M+R"/7?'$$$JS1:39P6\LC6-F\B*T]Q.T<[!!&D(5FD-__@IE^P'X@^.7P_\
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M_([WO_7E%_,UL5CV7_([WO\ UY1?S-;% !1110 4444 %%%% &/9?\CO>_\
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M *%6Q6/X'_Y!$O\ U^S?^A5L4 %%%% !1110 5F^,?\ D6+W_K@:TJS?&/\
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MJV* "BBB@ HHHH *S?&/_(L7O_7 UI5F^,?^18O?^N!H N:=_P @^#_KBO\
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M "=-\2_^R@:S_P"ETU?W>U_"%^UA_P G3?$O_LH&L_\ I=-0!^W_ /P:;?\
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MVH_X0?2/^?F]_P# MJV** ,?_A!](_Y^;W_P+:C_ (0?2/\ GYO?_ MJV**
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M?_ MJ/\ A!](_P"?F]_\"VK8HH Q_P#A!](_Y^;W_P "VH_X0?2/^?F]_P#
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M^;W_ ,"VH_X0?2/^?F]_\"VK8HH Q_\ A!](_P"?F]_\"VH_X0?2/^?F]_\
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M5KF\RT2DXNFQTJ7_ (0?2/\ GYO?_ MJTM._Y!\'_7%?Y"IJ ,?_ (0?2/\
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M^!;5L44 8_\ P@^D?\_-[_X%M1_P@^D?\_-[_P"!;5L44 8__"#Z1_S\WO\
MX%M1_P (/I'_ #\WO_@6U;%% &/_ ,(/I'_/S>_^!;5F>%?"NG:AITDTT]R"
M+F10$N&48#5U=8_@?_D$2_\ 7[-_Z%0 ?\(/I'_/S>_^!;4?\(/I'_/S>_\
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M2_\ 7[-_Z%6Q6/X'_P"01+_U^S?^A5L4 %%%% !1110 4444 8_@?_D$2_\
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M5)?BF?2U:%&LK5(J2\TG^9XO/^P7\ ;29KKP1'XA\+3,<F;PYXEN83GU =G
M_ 4W_AF7XV^'/^2=_MD^+H OW$\2V%OJV?8F0*?QKVJBO ?!'"\7>AA_8_\
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MIUTN);:Z3(SV93U5AV92".Q%>+'2OC=^R ?-\.+J/C_X;Q<OICMYFKZ%$/\
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MD*I^,?\ D6+W_K@:N:=_R#X/^N*_R% $U%%% !1110 4444 %8_@?_D$2_\
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M1110 5F^,?\ D6+W_K@:TJS?&/\ R+%[_P!<#0!<T[_D'P?]<5_D*FJ'3O\
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M_P#((E_Z_9O_ $*@#8HHHH **** "BBB@ K'\#_\@B7_ *_9O_0JV*Q_ _\
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MO&B?]]2?_$5W7_"IOA7_ -$T\/\ _@F@_P#B*/\ A4WPK_Z)IX?_ /!-!_\
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M@#A?^&[OV0_^B\:)_P!]2?\ Q%'_  W=^R'_ -%XT3_OJ3_XBNZ_X5-\*_\
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MU)_\11_PW=^R'_T7C1/^^I/_ (BNZ_X5-\*_^B:>'_\ P30?_$4?\*F^%?\
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M$T'_ ,11_P *F^%?_1-/#_\ X)H/_B* .%_X;N_9#_Z+QHG_ 'U)_P#$4?\
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MNR9&02D*-O4X3@5ZA_PJ;X5_]$T\/_\ @F@_^(KQ/]J3X>> -.^,GP7M=/\
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MJ3_XBC_AN[]D/_HO&B?]]2?_ !%=U_PJ;X5_]$T\/_\ @F@_^(H_X5-\*_\
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M\MT6N-0(.?*Q&#Y:<?,QP<<*.=R_?L/[='['UO"EO;_'/0HXT4*B)Y@"@<
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M\-W?LA_]%XT3_OJ3_P"(H_X;N_9#_P"B\:)_WU)_\17=?\*F^%?_ $33P_\
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M  30?_$4 <+_ ,-W?LA_]%XT3_OJ3_XBC_AN[]D/_HO&B?\ ?4G_ ,17=?\
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M:>'_ /P30?\ Q% '"_\ #=W[(?\ T7C1/^^I/_B*/^&[OV0_^B\:)_WU)_\
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M[(?_ $7C1/\ OJ3_ .(H_P"&[OV0_P#HO&B?]]2?_$5W7_"IOA7_ -$T\/\
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M?##5_@S\:_!%EXC\,:[;"'5-(U!"4E4,'1@5(:.1'5721"KHZ*ZLK*".HHH
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MCE"0>&'0\5I:-I5IH.CVFAZ>K""RMHX( [9(1%"KD]S@"K-% !1110 4444
M%%%% !7-_"WX4^$?@]X=G\+^"X9TM+C4KB^D%Q.9&\Z9][G)[9Z#M7244 %?
MPA?M8?\ )TWQ+_[*!K/_ *735_=[7\(7[6'_ "=-\2_^R@:S_P"ETU '[?\
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M(9M=\:RV8D_M>Q:1BSQV]QIT^H0QVRL1N>,L7D!<^I?\$HOV^_C+KOC?7O\
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MZ%;?"'XK^ ]!3P-\0X/AHFH:3INL64M^EYIEX8+>3[/+.+F.5'90K 8+'^$
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M/6_!'B_P]>FTU/1[G!5I()@"T$R$-'+#(K /&5D0L@Q\]_MN?\$EOA+\#_\
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M^!>B:1XD\<6]Z-/U?Q5IF@"]M85>.SN=0NDM+:2<EALB:XEAB+#.&F3(QD@
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MH!W=?PA?M8?\G3?$O_LH&L_^ETU?W>U_"%^UA_R=-\2_^R@:S_Z734 ?M_\
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M$C!SA60)-+]!O'I^NZ48KJT6>TO+?$D%S!Q)&Z\JZ..A!P58>Q%6* "BBB@
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M>NZUXBU%K#PQX4\,6 NM2UBY6&2=TA1F1%5(8I)'EE>.)%7YG!90?&?VW?\
M@LU_P3>_X)V_$'2OA1^UA^T=:Z!XDU>!+B/1;'2+S4;BVMF)"W%PEI#(8(R0
M=N_#, 2H8 D>(_\ !9SX_>+_ ("^#_V=_P#@K]^SW$?''@3X5^*7O/&EIH4H
MF34O"&O626TM_"P.'V?Z.\;9P&E5F(0.: />OV9O^"K_ .RA^TK\<M2_94DE
M\3?#SXMZ5$9KGX7?%'0&T?6)80"WG6ZEGAO$*@N#;RR?("_W?FK3_8=_XM%X
MF^)/[%E[^[C^'?B3^U?!D1XW>%M9>:[L54=H[>Z74M/0=H]-CYYKQ;_@I+^P
MI\%_^"S?['_A7]IG]DKXC6=C\3-"T^+Q/\ _BWH5R8)H;@8FCM9)EPZ0R.H5
ME;YH)0'V[D=&Y[]AC]J?XK_M0?#3]GW]O[QAX OK+QS::KJ?P?\ VA=!L].;
MS+2Y-U]G%W)"@.SR=5M+1L?=MX=6NB2 K9 (_P#@KU^RK\3?V>/B)9_\%HOV
M"H[>R^+?@"SAL_B)X0W&.V^)WAUI(XVTV9$!,EZO[L6[ -(S+&BAW2!1]N_
M#XB_$+XL_"S3/B'\2_@MJ/P^U#58$N$\*:UJ,-Q?V4;1J=MUY&8HI=Q<>6KR
M84*6*N6C3L+FSM+U42\M8Y1'(LD8E0-M=3E6&>A!Y![5)0 4444 %>:_'[]I
M[PI\!+S2O# \#>*?&7BK7K6[NM#\%>"--CNM2O+:U\K[3<@32Q0Q0Q&>!6DE
MEC7?/$@)>15/C'[57_!</_@E[^Q7\?;7]F7]HO\ :ET[1?&,IA%]IUOI=Y>1
MZ5YH4Q?;)K>%X[4LK*V)&!5&#L%0ACXS_P %=/VC?%7_  3Q_;#_ &??^"HO
MV.XUCX/C3]2^'?Q@GTY#.-+TS59[.ZLM30)NRJW%J&9@/F")$IW3+0!]#_LH
M_P#!3+]C?]O#Q-XH_9_\*ZGJ>C^//#\4EOXR^$GQ'\/R:3KME"0%?S;.<8FB
M*N SQ-(@#KN(W+G4_P"">>J:EX7^$VK_ +*_BF_FGUGX)>(Y?!QFNI"TMUI$
M<4=QHMTS'F1I-+N+(/)SF>.<9)5L?.G_  6%_P""=\W[:/PN\,?\%&?^"?'B
MJWTW]H3X8Z?%XB^%OC;PS,C#Q3IX3SO[,DD3*W,4T3-Y.[<A,AC/[N>3/5_L
M6?M):A^TGK_P(_X*&^#O!5U;:1^T-\-F\,?$;3;"VDDCTG7]+%W>6DKX!*0Q
MO'KUFTKX+-)9*Q!"K0!YE_P4@_9Y^+__  3P_:JT[_@KU_P3Y\(2ZQJ'BC6=
M-\.?'GX*::VT?$&WN;A+>VO;.( _\32*21?F4$LNYSP+@3?H;\-O$/C#Q9X)
ML/$GCOP#)X6U.]B,LWA^XU&*[FLE))2.:2',7G!=N]8VD17W*LDB@.VQ/9V=
MU+#/<VL<CVTADMWDC!,3E60LI/W3M9ER.S$=":DH **** "O+OCC^V=^S9^S
M?\6OAO\ !'XT_%"QT'Q'\6=7N=,\"V5ZQ4:A=01J[IO^ZF3)%&NXC?)-&@RS
M@5XU\2_^"Z'_  2Q^$7[6$7[%7CS]K#2;3Q\VJQZ7=6D>G7<UE8W[L$6UN+V
M.)K>"7>0K!I!Y;<2%",5V/[?G_!,?]E/_@HM\,=;\%?';P) =<O]'CL]!\;V
MT8.J>')89))K>YL93_J'265F8)M$P 23<H4  ]D^+?PO\'_&[X5^)/@U\0M.
M^UZ#XKT*[TC6;8'!DM;F%H95![':YP>QP:\^_82^*'C#XD_LZ:;I7Q4U'[3X
MY\$WUUX1\>S$8:?5]-E-M+=[?X4ND2.]C'_/*[C/>OFS_@E5^W5\;M$^*&L?
M\$G_ /@I!J,<'Q]^'5@)O#GBB0E;;XF>'%R(-7M7;_63A%Q.GW\JSGYEG6+W
M[P_X>U_X.?M_ZV^DZ'>2^%/C+X035KZYMK9W@T_Q)I'D6<DDS*,(UYITUFBE
ML#_B3$9RZ@@'R#^TE\#/C=_P28_;^T7]LG]@3X87_C3X??M!^+XM$^,7P#T"
M6*.>76Y(Y98_$&E+*R11R!8Y7N S)&%#N[*C&2W_ $E\*WWB'4_#EGJ'BS0(
M=*U*:!7O-.@OOM*VSGG9YNQ Y'0D#&<XR,$W'L[22[COY+6-IXD9(IF0%T5B
MI90>H!*KD=]H]!4E !1110 5Y=XY_;._9L^&O[47@[]C7QQ\4+'3OB'X]T.]
MU7PMH-RQ5KV"V95<!ONB1LR%$)RXMYL?ZLUXUX8_X+H?\$L?&?[7L7[#GA?]
MK#2;WX@7&KG2+6V@TZ[-A<:ENV_8H[_ROLSS%OD 60AGPBDN=M7?^"D'_!)S
M]G[_ (*!?#O5+V2Q3PG\6;:>VU+P'\7],1AK'AW5+,9LVBG!\Q;57&6MD94)
MDDD4+,?- ![5^U+\#X/VD/V>_%GP5.KMIEWKFDLNC:PBY?2M2C836-\G^W;W
M4<$Z_P"U$M0?LG_&U_VDOV<?"_Q9UC1$T[5-3TYK?Q1HA.[^S-8MI'M=2L6S
MU,%Y#<0'U,1KYT_X)._\%%?B'^T*WB7]BC]MG0[?PM^TQ\']MIX]T,82'Q#9
MC:L&O6' $EO.K1LVP81I%.%62,5ZU\#/#VO_  5_:^^*'PHCT.\'A+QU';^/
MO#%\ELYM;749-MEK-CO VQDRQ6=\%)W2/J5R0,(: /CJP^#/[0'_  1K_P""
MBNF>%OV)?A#J/Q#^ ?[1^K7MU?\ P?T*\AAG\!>((HU>?5+/SV6*#3)%*"7<
MRI&2B @BWCD_2&7PAI/BBYT#Q3XW\,V3ZSHFZYLD6X:XBT^[DA,4KPLRIN8(
M\D:S%%?9)( %$CJ=?['9_;/[0^RQ_:/+\OS_ "QOV9SMW=<9YQ4E !114=U=
M6MC:R7M[<QPPPQEYII7"JB@9+$G@ #DDT 25\]_M#_\ !1KX;_L_ZAXDM[+X
M&_%3X@V?@B:.'QYJOPU\(#4X/#LCV\=SY<X,T<DKK;RQ3.ELDS11RHT@0,,\
MC^SI_P %QO\ @EW^UA^TW+^R'\!/VI]-U[QN'G33[2/2[R*UU1X%9YEM+N2)
M8+DJJ,PV.=ZJ63>H)KP[]GS]JS4/V#?^"T'Q;_8"_:3N3I_A7]HCQ%%\0?@9
MXKOFVP7FI36=O:W^D-(?E$ADM0(DR.4 ^]<Q @'O/B[XW_!3_@J+^PG?_&K]
M@;XJ:3XRU/0KRV\1> [JTD:*2U\1Z7+'>VME=12!9;4RO&MO*DBJQ@NGX*OS
M[Q\,O'OPV_:E^ 6B?$?2=.@U7PGX_P#"L%ZECJ=JKI<65Y;AC!/$P(.4D*/&
MPX.Y2.HK\U?VW_V>-=_X(V_M_P#AK_@K%^R59-IWPA^)?BNP\-_M0> +!=EC
M"+VY6"#Q!%$/D1DGE!8C!$K8!VW4V/N7]C_P]K_P8^(_Q5_9FN]#O(O#VC>*
M?^$J\!WYMG%L=*UQY[J6S23&S?;ZG%JBB(',=O):#"JRT ?'G[,OPX_:J_X)
M!_MYR_L#_LW_  KU/XK?L]_%2QU#Q1\.](36DBE^%5TDR"[M[NXFW>7I3R3*
MT;$/(S%A%'-,LPE_2:[\&>&-1\5V/CK4=$@FU?3;.:VT^]ERS6L<Q0RK'GA-
M_EH&8 $A "<#%:"6=I'=R:@EK&L\L:1RSA '=%+%5)ZD NY [;CZFI* "BBL
M_P 5^*_#'@3POJ/C?QMXALM)T;1[&6]U75=2N5AM[.VB0O)-+(Y"HBJI9F)
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M.L>)OA/XB71?'.D1,5EL+HQJ_0\O'N\R+>/E\V"5,Y0UYY^PC_P5U_X)^_\
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M"&O[5.D_\$U?VF/%=[JG[.7Q'U61?V:OB?K,Y<^'+R1BQ\+:C,W"C+?Z/(V
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M*S2V$=[,<+]HG6**9X54>6Y<D*SM%']2*JJH55  &  .E+10 445\I_MB?\
M!;3_ ()E?L%_&6Q^ '[3W[3=EH?BV\CBEN-)L](O-0;38I<&.2[:UAD6V#*0
MP$A#%"'V[2&H ]I^/?[27A+X!C2-(N_"?B+Q3XD\1/<+X<\&^#].2ZU+4A;H
M'N)$622.***)63?+-)'&&DB3=OEC5O,?V4?^"IG[(_[8?Q/U[]G#0-1UWPC\
M4/#RO_;_ ,*/B5H#Z1KL$0 )D6"4E+F+:0V^!Y%"LK'"LI/SW_P63_:'\6_L
M6?%S]FW_ (*U>";67Q/\+/!EWJGAGXJ#13]H \.>(5L&BU.$ID,L<]C;N"#B
M1FA3(#Y&Y_P5B_X)[>&O^"F'[/WA7]MW]A7QY::;\<O FGP^)O@C\3?#5TBG
M5H0OGII\DPXEMYP3Y>_*QR/S\CS(X![M_P $_&;X;>%O%O['.J,1=?!CQ(VB
M:%YA^:;PQ.@O-#9<\LD5G,+'=WETV?I7CG_!0[]O[X&_L!?ME>'?B%X_TG5O
M$7BS4_A'?Z-X$^'_ (6LFN=8\5:E>:O9F"SMHE!.-UJY:0C:@/=F1&I_L/\
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M7_V4#6?_ $NFK^[VOX0OVL/^3IOB7_V4#6?_ $NFH _;_P#X--O^4IG[7?\
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MCU>SL=(U/RO&.D>&KW6;N_\ MZV7VIEBAABN"XLS LD<:!9#%M=U^]OV._\
MBS7Q?^*G['%W^ZL] U[_ (3+P)&> = UR:>X>)?:WU2/580@XC@-H. RBL;]
ML#X[?M*>)OB=-^PU^SM^R3XEU.7Q?X2<ZQ\9-?CCM_"7AJUN?-@D8N29+^\C
M4%Q91JI<O$&D1&>1 #T/]I'X,_ W]O/]D#7OACXW\'6GC?P9X]\*>?961N!
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M_ G@>\AM/%=O'!K'@;4)_N6>OZ?/'>Z;,QX.Q;NW@WC(W(74\,: /F[]M?\
M81T7X=?\$N_"W[-G[+/[*^C^+_&OP[OO#4_PKT6PLX[:.#7;&]M9S?R73M&+
M5&$$SSSO(C2J[H6:255:G^PO_P %"/\ @H6?VH+']BW_ (*P_LD>&OAYXL\7
MZ-=ZI\,O&/P]U%[K0?$'V1!)=V!WSSM#=Q1$RX:3YD1SM4!"_P!<?L]?&W0/
MVB/@-X5^/'AFPGM[3Q/H%OJ/]G3C]_92N@,MK*.,312;XG4X(>-@<8KY_P#V
M>?&?QR_;Y^-7A7]HKXJ_LC>)_@YX(^%VIZE=^"--^(OEP^)->U6XLY].-U+9
MQEA86D=I<W:A'=GGDG1@$2$&4 C_ ."@_P#P3('[87[1/P:_:0^$WQ'U+X7?
M$+X<Z_(]_P#%+PN\2ZFV@F*02Z0(Y$>.X\Z21=OGJT42_:"5?S#%)]6>'-"M
M_#&@6?AZUOKVYCLK9(4N=2O9+FXE"C&Z260EY&/4LQ))J[10 4444 %?-?[8
M*>-OBEX\\0_L0^)O$<6F>$?CM\$]=T3PIJ\,)273M>ACF2[B:12&<SV5['-&
MHP572KH@Y850^#O[0'A_XK?ML?M >)OB#XPL].\+_L_OI7AG2SJ-^MO96$UQ
MI<>IZGJ<Q=@BNRW,%L)'_P!7'9RA"HGEWM_:0^,7P:_:V_9FOOCO^Q-\9O"'
MQ-\1?!SQ!:^,= /@+Q/::H9+RP#M<:;OMI'$<E[8-?6(#$?+>$^] ''?\%0O
MV8_%NC? /X46_P#P3]_8[\->)/B=\+_'VE7WPETY[6*PTOP]!;!OM'VBX$D(
MALVMPT;0K(K2N\>U69<KX+_PB_CW_@K\^N?\$P_^"V/[)-K\*OC-X9T?_A-/
MA?X_^&FJ%[6YM4FBMY;_ $JY>28Q2PS2VZS6TDDF]98V94**5_2>'XN^%]8^
M"B?'KP+;7_BC1;KPL-?T:'P[;?:+G5K5K;[1$MK&2OF22H5"+D;F=1D9KP3]
MDO4/CE^U_P#&#2/VW_CS^S+JWP@T_P -^%-4T#X=>"_%MS&^OSQ:E<6,U[J&
MH11Y6QS_ &;:Q0VVYI #.\A&Z-5 .(\&_L-?\%$_&GP1/[%_[:7[4GP^^)OP
MW-Y8I?>./^$5N[7Q5K6F6MS%<"SN8C,UJ)I/)6)KL,S["S;&E(E'VW110 44
M5QG[1WQO\,?LS_L^>.?VC/&UK<3Z/X#\(ZCX@U.WM #+-!9VTEPZ)GC>RQD#
M/<B@#LZ^7/VD_"NJ_M._%?QK_P $^?C7=V9\(>--"\/>*_#"M:E?[3TFPUBT
M7Q#I$N#^\!5+,%O[FLA3Q'SY9^T_XO\ ^"XGP2^&T/[8/P'\7?"/XMZ;:Z:F
MK>)/@59>"[FRG^PE!))'I6JK=R27MPB' :2)!*4+I#EUMZLP_MU_!O\ ;=_8
MF^&G_!7/]G9KF.W^%OB3^U?%^DW.#>:9I3(;+Q'I]R%ZF"TG:^4#B1K"U<85
M@: +7_!5#X)?M':1XX^!'QD_X)I?LA^$/%'QD^'OB#45T?4_$42V&B:/X=FT
M>[L;FVNI8YH&:,RW=H\5K&^XM SJNV.2O$$^$6J_\%MM/UC]FG_@H]\"M1_9
MV_:Q^ ES9:[X2\<^ -2WF"UNG<VNK:7<>8WGVC3VSI+ 97V/$I$L<A_=_I+\
M:_BLWP>^#7B#XP:9\._$GC0Z'I$E_;^&O!.GB]U/5MJY6&TAW*)9&XVC<,UX
M_P#L<:+\:_C1\1=5_;D_:*^!K_#+6/$'A.S\.^$_ %_J,=WJ>EZ1#<3W3SZA
M)$!&ES<2SJ?LR%A EO&"YDDD5 #CO '[(O[?7Q.T#P;\)_V_/CG\,_&WAWP)
MXRTGQ(GB?PKX6NK'6?$UUI=RMU8?:H7D-M9,+F*":5X=XD$9B"1AR]?7U%%
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M7Q=X3UC3)-/ A&O2SZ=]DUN*(Y6%Y=+B6XC'5(]8P,$5K? 7]H_]GO\ 9?\
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M@7LN^!M'N54<N[WLF#AS0!\9>-]6_P""N/[!_P"TK\</''_!.+_@F-X+\2_
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M$^#OAC]GCX%^"_@!X)DF?1O WA/3O#^DO<$&1K:SMH[:(L1U;9&N?>@#QO\
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MGXA\6:WJ=Y_:'B[QQXPU$W>K>(=0,:1M<W,I  Q'''''$@6.*.-(T4*M>F4
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MPCIT*L)-*2_2*XO[=\C:0^IO?W*[> MT%_AY],HHH **** /+/VU/VF--_9
M_9I\1?'[4=-M[QM+DL++3[6]NS;V\E]?WUOI]H)I0K&*'[1=0^8X5BJ;F"DC
M!^5?VQ_VX?\ @IU_P3#$'[07[1WPI\ ?&OX%13(/&FM?"7PW?Z'XA\'Q.P#7
M3V=W?WL5[:ID#>LD1SDN8UP:^G?V_?V2?#W[=O[&?Q%_9)\3:F+&'QOX;ELK
M342A865ZI6:TN2HY817$<,A7C(3&1G-?)/\ P1N_X*,^(?CEH.M_\$K_ /@I
M)I$.C_M&?#&QDT/Q/H/B15>/QSI*1[%U&#S!MN_,@(,P&X2*PF&4D(0 ^4_B
M'\3?V9? G_!6S3_V@/CAXNTWQ3^Q9^VI;:+XCTO6KZW6;PX_B[3+%K*WL]6$
MPVI"'+S203+M$_V=I !9R[/J7XR_\$TOA%^Q!_P4 ^!_[>'_  3Q\-V/@&3Q
MEX]M_!7Q3^'_ (5B6VT;Q+HU_;SN;J.UBQ'%+;&!;@B-51EB,A ,;%\7]@__
M ()Q_#+X$?M)?M,?\$EOBK\.M.\=_L[ZS9:%\2OAQX8\1V_VN'08]4GU"UN;
M(%\M&4N-.8PLK!U6'S-V]W:OL']E?_@FQ^QY^Q?<P7/[/_P[U:Q%C"\&BP:[
MXVU?6H=&A<8>.PCU&ZG2Q5A\K>0$++\K$@   ZK]D[X':W^S?\*YO@U=:U:W
MFBZ3XCU-_!:6RL&L-$GNI+BTL'! '^C)*;9-N1Y4$7.<UZ9110 4444 >0_M
MG?M*7?[-/P[\/W?AZWTR3Q'XY\?:-X,\)?VV[K8Q:EJ5R(8YKCRR'>.-/,E\
MM2K2F-8PZ%]Z_&7[?_[:'[8O[#&A:EX0_P""HOP<\&_%3]F#XC6%QX7\6?%+
MX/Z!?Z3?^%X;^)K9QJ6EW-W>[H7$K(LL,_?O(8XI/IK_ (*S?L3:[^W[^PQX
MN^ ?@+Q*=#\:1M:ZY\/M=6<Q&PUVPF6YLW\Q>8PSIY3.,E%E9@,@5XS_ ,$M
M_P#@H9\/?^"J'[.WBG]BS]N#P!9Z5\;/"6F3^&OCE\)_$MJL+Z@H7R);Z*$X
MWV\V06V?ZF1\9VM#)( >6?L'^#_^"Y?[-'P[TC]F'X(:]\&OC?\ !&XTV/\
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M8G:*-PPD\DN5C<HVX -MYQH_L&?\$]_V>?\ @GC\*9OAU\$M(N[O5-8NC?\
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M]##,C8YC,.%1-D:W_P!@#P?^VS^T9_P1[T'X":O^U!J7PS^*_@[7M6\":O\
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M2X/AJ\N'FO)]&EE&6\@/:&.15!9K?4W8@M,<]S^S+^Q7^S3_ ,%6?V(O@/\
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M$=X)7=I-1O4/VBYM71HT>R^6)Q%ABR22(WT*B)$@CC0*JC"JHP /2@!:***
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MB.'PA^TK\'W:^^&OBD$)'JT(W--H=\3@2VEP&=0'^5&D;.$DE#=)_P $U_\
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MA/\ :I^"NG>)ETBX^T:%JOG2VFI:3-D'S+2]MGCN+<[E4D(X#%%W X%>Q44
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M(RLK,I^JJ* &6UM;V=O':6D"111($BBC4*J*!@  <  =J?110 4444 %%%%
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M_@TA_P#BJ_J3Z_@?^?L?_ E_F?H7MJ/\R^\VJ*Q?^%D?#O\ Z'W1?_!I#_\
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M'J?Q2^+_ (]TCPQX;T:W\_5==U[4([6TM(\@!I)9"%7)(49/)( R2!7YC?\
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MOV57^5_<=57PQ^WW_P %C_%_[!OQZE^#?B/]D?\ MNRGTZ&_T3Q OCDVJZA
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M)-(L,(B@F>1\_*JJSCG?V9_^"CVC?%;]I;QY^Q'\??A;)\-?B]\/](CUR\T
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MTM\+/VQOV=_"'[3WP4U*>Z\+^--&CU'2GNH?+FC5LJ\,J@D++'(KQN 2 Z,
M2.3W] 'X _\ !IM_RE,_:[_[>/\ T^3U^_U?@#_P:;?\I3/VN_\ MX_]/D]?
MO]0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %?P
MA?M8?\G3?$O_ +*!K/\ Z735_=[7\(7[6'_)TWQ+_P"R@:S_ .ETU '[?_\
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M>)H+G6X$;1K5WTU5GNP6_P!&C.<AY-H(#'.%)'ZRQQQPQK%$@55 "JHP !T
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M]H>RN]8\=6%R+G3+.WEM9$29YXMR"/<C@MG V-GH:_36VMK:SMTM+.W2**)
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M$_PJ\3>&M#M?/O=0\/7MM9P[U7S)9('1%RQ &6(&20!W-?C_ /\ #IO_ (*
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M-:2K+(NGZ=#<Q2^6<*^KLCX,94?>[PPR2)-)"K/'G8Q4$KD8.#VIU 'XU_\
M!=WX1?#K_@ESXT^ /_!5;X:?&WQ9J?CCX;?$B"PU'0O'?Q*N]6OM>\-W22)?
M6MH+Z9W^5792(_E"W;NWW17W#\=_^"L?[.WPPT'X'_'GPG\0['Q)\)OB?XFN
M-+U?Q?X>B;4(=*B.F374-S/Y 9H$CECCCFW@&$2DR!=AQ]9TQ[>WDF2XD@1I
M(\^6[*"4SUP>V: /QI_X+=_ S]AO]I?Q?\+?V@_^"8?C_P &:A^USJ/Q+TB;
MP3J?PAURVN[K5[<3!KB^U);)V7[-!&!*][*!M""-I"K[:Z__ (. _P!HWX ^
M!?\ @HC^PC:^,?C1X7TQ_"'QODU7Q:M[KL$?]B60;3S]IO,O_HT9!R'DV@A6
M(.%./U6T/P1X+\,7]UJGAKPCI>GW5\VZ]N;'3XX9+@YSEV107.2>N>M:E 'Q
MQ^UA_P %COV;O!OPGU33/V(/&NF_'_XL:I8O;>!O WP@N4\1O+?R)B&6\EL3
M)%9VR$K))),Z#RU.W)(%>"_L6>#O"7_!MU_P12U;Q-^U3XWT-?B/JLVH^*]5
MT6YU>(?VKXFNH8HK?2[=MV9RJQ6D4KIN5<32Y\L;J_4&B@#XL_9L_P""7'[/
M^H_LLZ3H>I_M1_$KQ;:>)=(N+SQGJ_A3XTZI%HGB+4;]I)M6NXX;6Y%OY5S=
M37,C*HV_O"#GFOEO_@W/_:\^"WP'\??&;_@C%XE^/WAW61\+OB5J)^#.HR:[
M!(GB'0;J=W-K;N&*3312DR21H2V;MP 1$Q'Z[T4 ?E9_P1^\.V7_  1*^*WQ
M9_X)M?M6ZO!X4\#^(_B)<>+?@+\1]>G6WT?Q#97,,4,FF_;)"(HK^!+: FV=
M@[EI&0,FUFZ#_@M3K%E_P5>^'_A[_@E/^Q'XOT_Q?J?BWQIIM]\6/%WAVX2^
MTKP-X?M)/M#RWES$3$EW)(L/DVF[S9 C'"KAC^B/Q9^$GPR^._PXUCX0?&3P
M+IGB7PQX@LFM-9T/6+59K>ZA;JK*W<'!##!5@&!! -?)G[$G_!+WXC_\$K_$
MWB'PG^P_\5+37_@WXHU5M3/PE^(U[/'+X;OG"J\VG:M#',YA954-;3V[D^6C
M>>&+LX!]?^ _!7A_X;>!M%^'7A.U,&E:!I-MINF0%LF.W@B6*-<]\*H%?E+^
MT/\ M.?LYZ=_P=8_!W5+_P".OA&&STO]G34=&U2_E\16RV]GJ3W6JR+9RRE]
MD<Y0J?*8AOG7CYAG];+-[J2TBDOH$BG:-3-%'(75'QR Q W 'O@9]!4E 'Y5
M_P#!WQ\3_AQHO_!)W4_ACJOCO2+?Q)K/C+0YM*T"748Q>W423N[R)"6WL@$;
MY<#:-I&:F_X+A?$3X>P^+OV5O^"I.F_#K1?CE\!/A=XB\06GQ1L-%L[77K1=
M+UJRM8(]2\H[XG%LT!<%L 2-$I9-^:_4ZDDCCFC:*5 RL"&5AD$'J"* /@S]
MD/\ :U_X)@_M!>,9O'/_  2F_9;\&^+K_P +^';[4O$'B[PM\+/["72B;23[
M/IJ7<ME"S7UU(RH($SMA6=I"N(UD_-/]N/\ ;1^%_P#P4!_X("?$GXQ_%3XK
MZ[XN^/\ )J5E+XG\!6%G?Q:;\-DC\3VT8MQI\2_9K&,6R[!>76^XG:5U\XY,
M:?T*Z)H&@^&=/72?#>B6FGVJ,62VL;98HU).20J@ $GFE71-%2*YMUTBU$=Z
M[/>(+=<3L1@EQCYB0 "3F@#\M/\ @M7^UE^SIXUUS]@KX@:5\6=)M]+O?VKO
M"_B*WFU>8V+G1HGGB;4VCN CI9[B"+AE$;*RN&*L"=_]N7XX?"W]GO\ X+[?
MLU_M!_%SQ6FE>"M?^!OB/1=$\1K;RW%M?ZA).LL5K"T*OYLLBO'L1 6<R(%!
M+*#^FU,EM[>=D>>!',3[XRZ@[&P1D>AP2,^] 'YB_!G]H'X(WW_!SQ\4E'Q7
M\/12S?LQ:7I2P7&LP(XU"/5(I9;(@O\ \?$:,&>'[ZC.1P:N?\$5?C+\(_&O
M_!2K]O32O!WQ.T#5+C4OB]IE[ID&GZO#,UY;QV4L4DT(5CYJ+(I1F7(!X)Y%
M?IC10!\3_P#!P%_P3Q\=?\%*/^"<.O\ P;^$*K)XY\,ZS:^*_!-G),L:WM_:
M)+&;;>Q 1Y+>XN$1B0HD9-Q"Y(T/V*/^"TG[&_Q]^#FG'X^_&WPU\)OBGHEA
M%:_$KX;_ !,U:'0-3T75(T N5\B^:)I(2X+)*@*[&4-M;<@^R*R-<\ >!/$V
MJ6VN>)/!6D:A>V>/LEY?:;%++!@Y&QW4E>>>#0!\U?M>?M[_ ! \(_L.?&7]
MJO\ 9.^$Q\967@GP5+>^#M6NH)6M?$5V ?-GMX54/<V%O&1*9U8)<!9!$VU?
M,/YE?M6?M4?LD?$WP?\ L+_M:Z5^T?XB^)FM6G[27@[4OBK\2=6BOI;+197A
MDEN+#RTC%EI;*X8_8+9$?9 '=7.)'_>&JMMH>BV=E%IUII%K%;PR"2&".W54
MC<-NW*H& =W.1WYH _,6?]I?X":G_P '2?AB^7XL:);?VC^QD-!AMM0OTMIX
M]7D\2R7:Z9+%*5>&]\CYS;.%E ZJ#Q7)_P#!2'QU\!?V#O\ @M':_M5?\%$O
MV?-,\6? #XN_"?3_  S;>.-:\$IKEKX1UZPNIY%26-H96B22*1C\B[W\W*AA
M#)C]<*K:OHVD>(--FT;7M*MKZSN%VW%I>0++%*O7#*P(8?44 ?,__!.KXK?L
M3_'BZ\2?$_\ X)_?L_\ AG1OAX+>VLT^(F@> ET&+Q->AY3-!;HUO!+<06P"
M!IRIC,D[(A8Q28^H:CM+2UL+6.QL;:.&&% D4,2!510,!0!P !V%24 %%%%
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MKWQ$\)VT+76HZ=X<NGCB_M.:",$B6&"+?)$NXPM<E2Q6-W&E_P %3=4^$O\
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M:O[O:_A"_:P_Y.F^)?\ V4#6?_2Z:@#]O_\ @TV_Y2F?M=_]O'_I\GK]_J_
M'_@TV_Y2F?M=_P#;Q_Z?)Z_?Z@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH ^0/^"_'_ "AL_:$_[)_-_P"CHJ_$S_@BO_P<R? W
M_@EO^P[8?LG^/?V9/%GBG4+/Q)J.I-JVCZO;0PLERZLJ!9!NR,<FOZ9M?\/:
M!XKT:X\.>*=#L]2T^[C\N[L-0MDFAF3^ZZ."K#V(KC/^&3_V6?\ HVKX?_\
MA&V/_P :H _(#_B-Y_99_P"C'OB!_P"%%8_X4?\ $;S^RS_T8]\0/_"BL?\
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M_A16/^%'_$;S^RS_ -&/?$#_ ,**Q_PK]?\ _AD_]EG_ *-J^'__ (1MC_\
M&J/^&3_V6?\ HVKX?_\ A&V/_P :H _(#_B-Y_99_P"C'OB!_P"%%8_X4?\
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M_HQ[X@?^%%8_X4?\1O/[+/\ T8]\0/\ PHK'_"OU_P#^&3_V6?\ HVKX?_\
MA&V/_P :H_X9/_99_P"C:OA__P"$;8__ !J@#\@/^(WG]EG_ *,>^('_ (45
MC_A1_P 1O/[+/_1CWQ _\**Q_P *_7__ (9/_99_Z-J^'_\ X1MC_P#&J/\
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M &6?^C:OA_\ ^$;8_P#QJ@#\@/\ B-Y_99_Z,>^('_A16/\ A1_Q&\_LL_\
M1CWQ _\ "BL?\*_7_P#X9/\ V6?^C:OA_P#^$;8__&J/^&3_ -EG_HVKX?\
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MBL?\*_7_ /X9/_99_P"C:OA__P"$;8__ !JC_AD_]EG_ *-J^'__ (1MC_\
M&J /R _XC>?V6?\ HQ[X@?\ A16/^%'_ !&\_LL_]&/?$#_PHK'_  K]?_\
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M?$#_ ,**Q_PK]?\ _AD_]EG_ *-J^'__ (1MC_\ &J/^&3_V6?\ HVKX?_\
MA&V/_P :H _(#_B-Y_99_P"C'OB!_P"%%8_X4?\ $;S^RS_T8]\0/_"BL?\
M"OU__P"&3_V6?^C:OA__ .$;8_\ QJC_ (9/_99_Z-J^'_\ X1MC_P#&J /R
M _XC>?V6?^C'OB!_X45C_A1_Q&\_LL_]&/?$#_PHK'_"OU__ .&3_P!EG_HV
MKX?_ /A&V/\ \:H_X9/_ &6?^C:OA_\ ^$;8_P#QJ@#\@/\ B-Y_99_Z,>^(
M'_A16/\ A1_Q&\_LL_\ 1CWQ _\ "BL?\*_7_P#X9/\ V6?^C:OA_P#^$;8_
M_&J/^&3_ -EG_HVKX?\ _A&V/_QJ@#\@/^(WG]EG_HQ[X@?^%%8_X4?\1O/[
M+/\ T8]\0/\ PHK'_"OU_P#^&3_V6?\ HVKX?_\ A&V/_P :H_X9/_99_P"C
M:OA__P"$;8__ !J@#\@/^(WG]EG_ *,>^('_ (45C_A1_P 1O/[+/_1CWQ _
M\**Q_P *_7__ (9/_99_Z-J^'_\ X1MC_P#&J/\ AD_]EG_HVKX?_P#A&V/_
M ,:H _(#_B-Y_99_Z,>^('_A16/^%'_$;S^RS_T8]\0/_"BL?\*_7_\ X9/_
M &6?^C:OA_\ ^$;8_P#QJC_AD_\ 99_Z-J^'_P#X1MC_ /&J /R _P"(WG]E
MG_HQ[X@?^%%8_P"%'_$;S^RS_P!&/?$#_P **Q_PK]?_ /AD_P#99_Z-J^'_
M /X1MC_\:H_X9/\ V6?^C:OA_P#^$;8__&J /R _XC>?V6?^C'OB!_X45C_A
M1_Q&\_LL_P#1CWQ _P#"BL?\*_7_ /X9/_99_P"C:OA__P"$;8__ !JC_AD_
M]EG_ *-J^'__ (1MC_\ &J /R _XC>?V6?\ HQ[X@?\ A16/^%'_ !&\_LL_
M]&/?$#_PHK'_  K]?_\ AD_]EG_HVKX?_P#A&V/_ ,:H_P"&3_V6?^C:OA__
M .$;8_\ QJ@#\@/^(WG]EG_HQ[X@?^%%8_X4?\1O/[+/_1CWQ _\**Q_PK]?
M_P#AD_\ 99_Z-J^'_P#X1MC_ /&J/^&3_P!EG_HVKX?_ /A&V/\ \:H _(#_
M (C>?V6?^C'OB!_X45C_ (4?\1O/[+/_ $8]\0/_  HK'_"OU_\ ^&3_ -EG
M_HVKX?\ _A&V/_QJC_AD_P#99_Z-J^'_ /X1MC_\:H _(#_B-Y_99_Z,>^('
M_A16/^%'_$;S^RS_ -&/?$#_ ,**Q_PK]?\ _AD_]EG_ *-J^'__ (1MC_\
M&J/^&3_V6?\ HVKX?_\ A&V/_P :H _(#_B-Y_99_P"C'OB!_P"%%8_X4?\
M$;S^RS_T8]\0/_"BL?\ "OU__P"&3_V6?^C:OA__ .$;8_\ QJC_ (9/_99_
MZ-J^'_\ X1MC_P#&J /R _XC>?V6?^C'OB!_X45C_A1_Q&\_LL_]&/?$#_PH
MK'_"OU__ .&3_P!EG_HVKX?_ /A&V/\ \:H_X9/_ &6?^C:OA_\ ^$;8_P#Q
MJ@#\@/\ B-Y_99_Z,>^('_A16/\ A1_Q&\_LL_\ 1CWQ _\ "BL?\*_7_P#X
M9/\ V6?^C:OA_P#^$;8__&J/^&3_ -EG_HVKX?\ _A&V/_QJ@#\@/^(WG]EG
M_HQ[X@?^%%8_X4?\1O/[+/\ T8]\0/\ PHK'_"OU_P#^&3_V6?\ HVKX?_\
MA&V/_P :H_X9/_99_P"C:OA__P"$;8__ !J@#\@/^(WG]EG_ *,>^('_ (45
MC_A1_P 1O/[+/_1CWQ _\**Q_P *_7__ (9/_99_Z-J^'_\ X1MC_P#&J/\
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M &6?^C:OA_\ ^$;8_P#QJ@#\@/\ B-Y_99_Z,>^('_A16/\ A1_Q&\_LL_\
M1CWQ _\ "BL?\*_7_P#X9/\ V6?^C:OA_P#^$;8__&J/^&3_ -EG_HVKX?\
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MJX"@#^SW_A_Q_P $;?\ I(3\/_\ P+F_^-T?\/\ C_@C;_TD)^'_ /X%S?\
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M\/\ C_@C;_TD)^'_ /X%S?\ QNOXPJ* /[/?^'_'_!&W_I(3\/\ _P "YO\
MXW1_P_X_X(V_])"?A_\ ^!<W_P ;K^,*B@#^SW_A_P ?\$;?^DA/P_\ _ N;
M_P"-T?\ #_C_ ((V_P#20GX?_P#@7-_\;K^,*B@#^SW_ (?\?\$;?^DA/P__
M / N;_XW1_P_X_X(V_\ 20GX?_\ @7-_\;K^,*B@#^SW_A_Q_P $;?\ I(3\
M/_\ P+F_^-T?\/\ C_@C;_TD)^'_ /X%S?\ QNOXPJ* /[/?^'_'_!&W_I(3
M\/\ _P "YO\ XW1_P_X_X(V_])"?A_\ ^!<W_P ;K^,*B@#^SW_A_P ?\$;?
M^DA/P_\ _ N;_P"-T?\ #_C_ ((V_P#20GX?_P#@7-_\;K^,*B@#^SW_ (?\
M?\$;?^DA/P__ / N;_XW1_P_X_X(V_\ 20GX?_\ @7-_\;K^,*B@#^SW_A_Q
M_P $;?\ I(3\/_\ P+F_^-T?\/\ C_@C;_TD)^'_ /X%S?\ QNOXPJ* /[/?
M^'_'_!&W_I(3\/\ _P "YO\ XW1_P_X_X(V_])"?A_\ ^!<W_P ;K^,*B@#^
MSW_A_P ?\$;?^DA/P_\ _ N;_P"-T?\ #_C_ ((V_P#20GX?_P#@7-_\;K^,
M*B@#^SW_ (?\?\$;?^DA/P__ / N;_XW1_P_X_X(V_\ 20GX?_\ @7-_\;K^
M,*B@#^SW_A_Q_P $;?\ I(3\/_\ P+F_^-T?\/\ C_@C;_TD)^'_ /X%S?\
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M\/\ C_@C;_TD)^'_ /X%S?\ QNOXPJ* /[/?^'_'_!&W_I(3\/\ _P "YO\
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M,*B@#^SW_A_Q_P $;?\ I(3\/_\ P+F_^-T?\/\ C_@C;_TD)^'_ /X%S?\
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M\/\ C_@C;_TD)^'_ /X%S?\ QNOXPJ* /[/?^'_'_!&W_I(3\/\ _P "YO\
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M,*B@#^SW_A_Q_P $;?\ I(3\/_\ P+F_^-T?\/\ C_@C;_TD)^'_ /X%S?\
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M\/\ C_@C;_TD)^'_ /X%S?\ QNOXPJ* /[/?^'_'_!&W_I(3\/\ _P "YO\
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M,*B@#^SW_A_Q_P $;?\ I(3\/_\ P+F_^-T?\/\ C_@C;_TD)^'_ /X%S?\
MQNOXPJ* /[/?^'_'_!&W_I(3\/\ _P "YO\ XW1_P_X_X(V_])"?A_\ ^!<W
M_P ;K^,*B@#^SW_A_P ?\$;?^DA/P_\ _ N;_P"-T?\ #_C_ ((V_P#20GX?
M_P#@7-_\;K^,*B@#^SW_ (?\?\$;?^DA/P__ / N;_XW1_P_X_X(V_\ 20GX
M?_\ @7-_\;K^,*B@#^SW_A_Q_P $;?\ I(3\/_\ P+F_^-T?\/\ C_@C;_TD
M)^'_ /X%S?\ QNOXPJ* /[/?^'_'_!&W_I(3\/\ _P "YO\ XW7\>W[1^OZ-
GXL_:'\>^*?#FHQW>GZGXTU2ZL+N(_)-#)=RNCK[%2"/K7%T4 ?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139858976585528">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover Page - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Feb. 18, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-K<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentAnnualReport', window );">Document Annual Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-37415<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Evolent Health, Inc.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">32-0454912<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">800 N. Glebe Road<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Arlington<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">VA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">22203<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">571<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">389-6000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Class A Common Stock of Evolent Health, Inc., par value $0.01 per share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">EVH<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Large Accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_IcfrAuditorAttestationFlag', window );">ICFR Auditor Attestation Flag</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,600.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">90,827,306<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentsIncorporatedByReferenceTextBlock', window );">Documents Incorporated by Reference</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Selected portions of the Proxy Statement for the Annual Meeting of Shareholders, scheduled for</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> June&#160;9, 2022, hav</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">e been incorporated by reference into Part III of this Form 10-K to the extent stated herein. Such proxy statement will be filed with the Securities and Exchange Commission within 120 days of the registrant&#8217;s fiscal year ended December&#160;31, 2021.</span><span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001628908<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAnnualReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an annual report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAnnualReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentsIncorporatedByReferenceTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Documents incorporated by reference.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-23<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentsIncorporatedByReferenceTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_IcfrAuditorAttestationFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_IcfrAuditorAttestationFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139858984097256">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Audit Information<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_evh_AuditInformationAbstract', window );"><strong>Audit Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AuditorName', window );">Auditor Name</a></td>
<td class="text">Deloitte & Touche LLP<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AuditorFirmId', window );">Auditor Firm ID</a></td>
<td class="text">34<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AuditorLocation', window );">Auditor Location</a></td>
<td class="text">McLean, Virginia<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorFirmId">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>PCAOB issued Audit Firm Identifier</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorFirmId</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:nonemptySequenceNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorLocation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorLocation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_AuditInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Audit Information [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_AuditInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139858976058840">
<tr>
<th class="tl" colspan="2" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED BALANCE SHEETS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 266,280<span></span>
</td>
<td class="nump">$ 319,002<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndInvestmentsCurrent', window );">Restricted cash and restricted investments</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">75,685<span></span>
</td>
<td class="nump">14,374<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">130,604<span></span>
</td>
<td class="nump">124,064<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">51,391<span></span>
</td>
<td class="nump">56,295<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent', window );">Current assets of discontinued operations</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">33,914<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">523,960<span></span>
</td>
<td class="nump">547,649<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndInvestmentsNoncurrent', window );">Restricted cash and restricted investments</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">12,977<span></span>
</td>
<td class="nump">6,654<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures', window );">Investments in equity method investees</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">5,458<span></span>
</td>
<td class="nump">6,498<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">81,365<span></span>
</td>
<td class="nump">86,240<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Right-of-use assets - operating</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">50,203<span></span>
</td>
<td class="nump">57,799<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent', window );">Prepaid expenses and other noncurrent assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">6,790<span></span>
</td>
<td class="nump">5,773<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalizedContractCostNetNoncurrent', window );">Contract cost assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">32,624<span></span>
</td>
<td class="nump">26,687<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Intangible assets, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">279,784<span></span>
</td>
<td class="nump">264,992<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">426,297<span></span>
</td>
<td class="nump">349,029<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent', window );">Non-current assets of discontinued operations</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">20,379<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,419,458<span></span>
</td>
<td class="nump">1,371,700<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">96,084<span></span>
</td>
<td class="nump">31,975<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">107,241<span></span>
</td>
<td class="nump">73,242<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtCurrent', window );">Short-term debt, net of discount</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">26,557<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liability - current</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">7,069<span></span>
</td>
<td class="nump">7,357<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Accrued compensation and employee benefits</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">51,861<span></span>
</td>
<td class="nump">47,163<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Deferred revenue</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">11,944<span></span>
</td>
<td class="nump">10,187<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_evh_LiabilityForFuturePolicyBenefitsAndUnpaidClaimsAndClaimsAdjustmentExpenseAndPerformanceBasedArrangements', window );">Reserve for claims and performance-based arrangements</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">171,294<span></span>
</td>
<td class="nump">178,827<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent', window );">Current liabilities of discontinued operations</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">27,986<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">445,493<span></span>
</td>
<td class="nump">403,294<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Long-term debt, net of discount</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">215,676<span></span>
</td>
<td class="nump">263,343<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other long-term liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">5,531<span></span>
</td>
<td class="nump">22,081<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liabilities - noncurrent</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">57,722<span></span>
</td>
<td class="nump">62,526<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilitiesNet', window );">Deferred tax liabilities, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,403<span></span>
</td>
<td class="nump">679<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent', window );">Non-current liabilities from discontinued operations</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">177<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">725,825<span></span>
</td>
<td class="nump">752,100<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and Contingencies (See Note 11)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract', window );"><strong>Shareholders' Equity</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Class A common stock - $0.01 par value; 750,000,000 shares authorized; 90,758,318 and 85,894,450 shares issued, respectively</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">908<span></span>
</td>
<td class="nump">859<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in-capital</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,340,989<span></span>
</td>
<td class="nump">1,229,320<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive income (loss)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(362)<span></span>
</td>
<td class="num">(278)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Retained earnings (accumulated deficit)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(626,779)<span></span>
</td>
<td class="num">(589,178)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockValue', window );">Treasury stock, at cost; 1,537,582 shares issued, respectively</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(21,123)<span></span>
</td>
<td class="num">(21,123)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total shareholders' equity</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">693,633<span></span>
</td>
<td class="nump">619,600<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and shareholders' equity</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 1,419,458<span></span>
</td>
<td class="nump">$ 1,371,700<span></span>
</td>
</tr>
<tr><td colspan="3"></td></tr>
<tr><td colspan="3"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">See Note 20 for amounts attributable to related parties included in these line items.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_LiabilityForFuturePolicyBenefitsAndUnpaidClaimsAndClaimsAdjustmentExpenseAndPerformanceBasedArrangements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Liability For Future Policy Benefits And Unpaid Claims And Claims Adjustment Expense And Performance-Based Arrangements</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_LiabilityForFuturePolicyBenefitsAndUnpaidClaimsAndClaimsAdjustmentExpenseAndPerformanceBasedArrangements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669686-108580<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e681-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6801-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 15: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount classified as assets attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1107-107759<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721675-107760<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=123351718&amp;loc=d3e2473-110228<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721533-107759<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalizedContractCostNetNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization and accumulated impairment loss, of asset recognized from cost incurred to obtain or fulfill contract with customer; classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 40<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123353750&amp;loc=SL49131252-203054<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalizedContractCostNetNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130532-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e31931-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e31917-109318<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount classified as assets attributable to disposal group held for sale or disposed of, expected to be disposed of after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=123351718&amp;loc=d3e2510-110228<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721533-107759<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721675-107760<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1107-107759<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120320667&amp;loc=SL49117168-202975<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph ((a)(1),(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16212-109274<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in equity method investee and investment in and advance to affiliate.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.12)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 20: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount classified as liabilities attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1107-107759<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721533-107759<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=123351718&amp;loc=d3e2473-110228<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721675-107760<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount classified as liabilities attributable to disposal group held for sale or disposed of, expected to be disposed of beyond one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1107-107759<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721675-107760<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=123351718&amp;loc=d3e2510-110228<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721533-107759<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt, classified as current. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after unamortized (discount) premium and debt issuance costs of long-term debt classified as noncurrent and excluding amounts to be repaid within one year or the normal operating cycle, if longer. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndInvestmentsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The current cash, cash equivalents and investments that are restricted as to withdrawal or usage. Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or entity statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits. Excludes compensating balance arrangements that are not agreements which legally restrict the use of cash amounts shown on the balance sheet. Includes current cash equivalents and investments that are similarly restricted as to withdrawal, usage or disposal.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 210<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=120413173&amp;loc=SL6242262-115580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 210<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120413209&amp;loc=SL6242269-115581<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndInvestmentsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndInvestmentsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The noncurrent cash, cash equivalents and investments that is restricted as to withdrawal or usage. Restrictions may include legally restricted deposits held as compensating balances against borrowing arrangements, contracts entered into with others, or entity statements of intention with regard to particular deposits classified as long-term; that is not expected to be released from such existing restrictions within one year of the balance sheet date or operating cycle, whichever is longer. Excludes compensating balance arrangements that are not agreements which legally restrict the use of cash amounts shown on the balance sheet. Includes noncurrent cash equivalents and investments that are similarly restricted as to withdrawal, usage or disposal.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 210<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=120413173&amp;loc=SL6242262-115580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 210<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120413209&amp;loc=SL6242269-115581<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndInvestmentsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount allocated to treasury stock. Treasury stock is common and preferred shares of an entity that were issued, repurchased by the entity, and are held in its treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=6405834&amp;loc=d3e23315-112656<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29,30)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139858983956456">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares)</a></td>
<td class="nump">750,000,000<span></span>
</td>
<td class="nump">750,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued (in shares)</a></td>
<td class="nump">90,758,318<span></span>
</td>
<td class="nump">85,894,450<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockShares', window );">Treasury stock, at cost (in shares)</a></td>
<td class="nump">1,537,582<span></span>
</td>
<td class="nump">1,537,582<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of common and preferred shares that were previously issued and that were repurchased by the issuing entity and held in treasury on the financial statement date. This stock has no voting rights and receives no dividends.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29,30)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139858979699032">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (LOSS) - USD ($)<br> shares in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenue</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenue</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 907,957,000<span></span>
</td>
<td class="nump">$ 924,639,000<span></span>
</td>
<td class="nump">$ 687,122,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Expenses</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_evh_CostofGoodsandServicesSoldExcludingDepreciationandAmortization', window );">Cost of revenue (exclusive of depreciation and amortization expenses presented separately below)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">657,551,000<span></span>
</td>
<td class="nump">696,581,000<span></span>
</td>
<td class="nump">513,033,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Selling, general and administrative expenses</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">219,499,000<span></span>
</td>
<td class="nump">210,412,000<span></span>
</td>
<td class="nump">236,448,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationAndAmortization', window );">Depreciation and amortization expenses</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">60,037,000<span></span>
</td>
<td class="nump">60,835,000<span></span>
</td>
<td class="nump">60,323,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnDispositionOfAssets1', window );">Loss (gain) on disposal of assets and consolidation</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">698,000<span></span>
</td>
<td class="num">(9,600,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on extinguishment of debt, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">4,789,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillImpairmentLoss', window );">Goodwill impairment</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">215,100,000<span></span>
</td>
<td class="nump">199,800,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1', window );">Change in fair value of contingent consideration and indemnification asset</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">13,281,000<span></span>
</td>
<td class="nump">3,860,000<span></span>
</td>
<td class="num">(3,997,000)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">950,368,000<span></span>
</td>
<td class="nump">1,192,275,000<span></span>
</td>
<td class="nump">996,007,000<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating loss</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(42,411,000)<span></span>
</td>
<td class="num">(267,636,000)<span></span>
</td>
<td class="num">(308,885,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterest', window );">Interest income</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">407,000<span></span>
</td>
<td class="nump">2,633,000<span></span>
</td>
<td class="nump">3,406,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(25,425,000)<span></span>
</td>
<td class="num">(28,325,000)<span></span>
</td>
<td class="num">(14,555,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOtherThanTemporaryImpairment', window );">Impairment of equity method investments</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="num">(47,133,000)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Gain (loss) from equity method investees</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">13,179,000<span></span>
</td>
<td class="nump">10,039,000<span></span>
</td>
<td class="num">(9,465,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_evh_GainOnTransferOfMembership', window );">Gain on transfer of membership</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">45,938,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_evh_GainLossOnRepaymentOfDebt', window );">Loss on repayment of debt</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(21,343,000)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherOperatingIncomeExpenseNet', window );">Other expense, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(146,000)<span></span>
</td>
<td class="num">(118,000)<span></span>
</td>
<td class="num">(489,000)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Loss from continuing operations before income taxes</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(29,801,000)<span></span>
</td>
<td class="num">(330,540,000)<span></span>
</td>
<td class="num">(329,988,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Provision (benefit) for income taxes</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">483,000<span></span>
</td>
<td class="num">(2,368,000)<span></span>
</td>
<td class="num">(22,795,000)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest', window );">Loss from continuing operations</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(30,284,000)<span></span>
</td>
<td class="num">(328,172,000)<span></span>
</td>
<td class="num">(307,193,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax', window );">Income (loss) from discontinued operations, net of tax</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="num">(7,317,000)<span></span>
</td>
<td class="num">(6,074,000)<span></span>
</td>
<td class="nump">1,613,000<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(37,601,000)<span></span>
</td>
<td class="num">(334,246,000)<span></span>
</td>
<td class="num">(305,580,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest', window );">Net loss attributable to non-controlling interests</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(3,609,000)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic', window );">Net loss attributable to common shareholders of Evolent Health, Inc. - Basic</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(37,601,000)<span></span>
</td>
<td class="num">(334,246,000)<span></span>
</td>
<td class="num">(301,971,000)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted', window );">Net loss attributable to common shareholders of Evolent Health, Inc. - Diluted</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">$ (37,601,000)<span></span>
</td>
<td class="num">$ (334,246,000)<span></span>
</td>
<td class="num">$ (301,971,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDilutedAbstract', window );"><strong>Loss per common share</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare', window );">Continuing operations, basic (in dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">$ (0.35)<span></span>
</td>
<td class="num">$ (3.86)<span></span>
</td>
<td class="num">$ (3.73)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare', window );">Continuing operations, diluted (in dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(0.35)<span></span>
</td>
<td class="num">(3.86)<span></span>
</td>
<td class="num">(3.73)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare', window );">Discontinued operations, basic (in dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(0.09)<span></span>
</td>
<td class="num">(0.08)<span></span>
</td>
<td class="nump">0.02<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare', window );">Discontinued operations, diluted (in dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(0.09)<span></span>
</td>
<td class="num">(0.08)<span></span>
</td>
<td class="nump">0.02<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_evh_EarningsPerSharePortionAttributableToNoncontrollingInterestBasic', window );">Non-controlling interests, basic (in dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0.04<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_evh_EarningsPerSharePortionAttributableToNoncontrollingInterestDiluted', window );">Non-controlling interests, diluted (in dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0.04<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic loss per share attributable to common shareholders of Evolent Health, Inc. (in dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(0.44)<span></span>
</td>
<td class="num">(3.94)<span></span>
</td>
<td class="num">(3.67)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted loss per share attributable to common shareholders of Evolent Health, Inc. (in dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">$ (0.44)<span></span>
</td>
<td class="num">$ (3.94)<span></span>
</td>
<td class="num">$ (3.67)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract', window );"><strong>Weighted-average common shares outstanding</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Basic (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">86,067<span></span>
</td>
<td class="nump">84,928<span></span>
</td>
<td class="nump">82,364<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Diluted (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">86,067<span></span>
</td>
<td class="nump">84,928<span></span>
</td>
<td class="nump">82,364<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterestAbstract', window );"><strong>Comprehensive loss</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">$ (37,601,000)<span></span>
</td>
<td class="num">$ (334,246,000)<span></span>
</td>
<td class="num">$ (305,580,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract', window );"><strong>Other comprehensive loss, net of taxes, related to:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Foreign currency translation adjustment</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(84,000)<span></span>
</td>
<td class="num">(44,000)<span></span>
</td>
<td class="num">(52,000)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest', window );">Total comprehensive loss</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(37,685,000)<span></span>
</td>
<td class="num">(334,290,000)<span></span>
</td>
<td class="num">(305,632,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest', window );">Total comprehensive loss attributable to non-controlling interests</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(3,609,000)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Total comprehensive loss attributable to common shareholders of Evolent Health, Inc.</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(37,685,000)<span></span>
</td>
<td class="num">(334,290,000)<span></span>
</td>
<td class="num">(302,023,000)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=evh_TransformationServicesMember', window );">Transformation services</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenue</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenue</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">11,204,000<span></span>
</td>
<td class="nump">11,990,000<span></span>
</td>
<td class="nump">15,203,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=evh_PlatformsAndOperationsServicesMember', window );">Platform and operations services</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenue</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenue</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">$ 896,753,000<span></span>
</td>
<td class="nump">$ 912,649,000<span></span>
</td>
<td class="nump">$ 671,919,000<span></span>
</td>
</tr>
<tr><td colspan="4"></td></tr>
<tr><td colspan="4"><table class="outerFootnotes" width="100%">
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">See Note 20 for amounts attributable to unconsolidated related parties included in these line items.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[2]</td>
<td style="vertical-align: top;" valign="top">Includes $6.8&#160;million loss on disposal of discontinued operations for the year ended December 31, 2021</td>
</tr>
</table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_CostofGoodsandServicesSoldExcludingDepreciationandAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cost of Goods and Services Sold, Excluding Depreciation and Amortization</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_CostofGoodsandServicesSoldExcludingDepreciationandAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_EarningsPerSharePortionAttributableToNoncontrollingInterestBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Earnings Per Share, Portion Attributable to Noncontrolling Interest, Basic</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_EarningsPerSharePortionAttributableToNoncontrollingInterestBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_EarningsPerSharePortionAttributableToNoncontrollingInterestDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Earnings Per Share, Portion Attributable to Noncontrolling Interest, Diluted</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_EarningsPerSharePortionAttributableToNoncontrollingInterestDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_GainLossOnRepaymentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gain (Loss) On Repayment Of Debt</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_GainLossOnRepaymentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_GainOnTransferOfMembership">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gain On Transfer Of Membership</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_GainOnTransferOfMembership</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120321790&amp;loc=d3e7008-128479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e557-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income (loss) and other comprehensive income (loss), attributable to noncontrolling interests. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(21))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4613674-111683<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569643-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569616-111683<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterestAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterestAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDilutedAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDilutedAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentOtherThanTemporaryImpairment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This item represents an other than temporary decline in value that has been recognized against an investment accounted for under the equity method of accounting. The excess of the carrying amount over the fair value of the investment represents the amount of the write down which is or was reflected in earnings. The written down value is a new cost basis with the adjusted value of the investment becoming its new carrying value subject to the equity accounting method. Evidence of a loss in value might include, but would not necessarily be limited to, absence of an ability to recover the carrying amount of the investment or inability of the investee to sustain an earnings capacity which would justify the carrying amount of the investment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 35<br> -Paragraph 32<br> -URI http://asc.fasb.org/extlink&amp;oid=124268079&amp;loc=d3e32787-111569<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentOtherThanTemporaryImpairment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnDispositionOfAssets1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of assets, including but not limited to property plant and equipment, intangible assets and equity in securities of subsidiaries or equity method investee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnDispositionOfAssets1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123467658&amp;loc=d3e12355-112629<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467658&amp;loc=d3e12317-112629<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillImpairmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13854-109267<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13777-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillImpairmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123384075&amp;loc=d3e41242-110953<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of income (loss) from continuing operations including portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569616-111683<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) from continuing operations per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1252-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-03(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868656-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsPerBasicShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) derived from continuing operations during the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-03(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868656-224227<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1252-109256<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of income (loss) from a discontinued operation including the portion attributable to the noncontrolling interest. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3B<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721525-107759<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721675-107760<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e957-107759<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=d3e1361-107760<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3A<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721523-107759<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1012-107759<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109227538&amp;loc=d3e44648-109337<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per basic share amount, after tax, of income (loss) from the day-to-day business activities of the discontinued operation and gain (loss) from the disposal of the discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1278-109256<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per diluted share amount, after tax, of income (loss) from the day-to-day business activities of the discontinued operation and gain (loss) from the disposal of the discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SAB Topic 5.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=120398118&amp;loc=d3e355146-122828<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1278-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) for proportionate share of equity method investee's income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(13)(f))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109237563&amp;loc=d3e33749-111570<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of Net Income (Loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1448-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1377-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities, and addition from assumption of issuance of common shares for dilutive potential common shares; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1930-109256<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1930-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1930-109256<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1505-109256<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1930-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherOperatingIncomeExpenseNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net amount of other operating income and expenses, the components of which are not separately disclosed on the income statement, from items that are associated with the entity's normal revenue producing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherOperatingIncomeExpenseNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3000-108585<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569616-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 29: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9031-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=evh_TransformationServicesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=evh_TransformationServicesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=evh_PlatformsAndOperationsServicesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=evh_PlatformsAndOperationsServicesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139858982745160">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (LOSS) (Parenthetical)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>Income Statement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax', window );">Gain on disposal of discontinued operations</a></td>
<td class="nump">$ 6.8<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of gain (loss) not previously recognized resulting from the disposal of a discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e957-107759<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=d3e1361-107760<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3B<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721525-107759<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721675-107760<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139858971594008">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS' EQUITY - USD ($)<br> shares in Thousands, $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Cumulative Effect, Period of Adoption, Adjustment</div></th>
<th class="th"><div>Parent</div></th>
<th class="th">
<div>Parent </div>
<div>Cumulative Effect, Period of Adoption, Adjustment</div>
</th>
<th class="th">
<div>Common Stock </div>
<div>Class A Common Stock</div>
</th>
<th class="th">
<div>Common Stock </div>
<div>Exchangeable Class B common stock</div>
</th>
<th class="th"><div>Additional Paid-In Capital</div></th>
<th class="th"><div>Accumulated Other Comprehensive Income (Loss)</div></th>
<th class="th"><div>Retained Earnings (Accumulated Deficit)</div></th>
<th class="th">
<div>Retained Earnings (Accumulated Deficit) </div>
<div>Cumulative Effect, Period of Adoption, Adjustment</div>
</th>
<th class="th"><div>Treasury Stock</div></th>
<th class="th"><div>Non-Controlling Interests</div></th>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Beginning balance (in shares) at Dec. 31, 2018</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">79,172<span></span>
</td>
<td class="nump">3,190<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning balance at Dec. 31, 2018</a></td>
<td class="nump">$ 1,189,356<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,143,824<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 792<span></span>
</td>
<td class="nump">$ 31<span></span>
</td>
<td class="nump">$ 1,093,174<span></span>
</td>
<td class="num">$ (182)<span></span>
</td>
<td class="nump">$ 50,009<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 45,532<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingStandardsUpdateExtensibleList', window );">Accounting Standards Update [Extensible Enumeration]</a></td>
<td class="text">Accounting Standards Update 2016-13 [Member]<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="nump">$ 16,006<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,006<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,006<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of stock options (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">138<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of stock options</a></td>
<td class="nump">1,092<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,092<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,091<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures', window );">Restricted stock units vested, net of shares withheld for taxes (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">363<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures', window );">Restricted stock units vested, net of shares withheld for taxes</a></td>
<td class="num">(2,609)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,609)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,613)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_evh_StockVestedAndRetiredDuringPeriodShares', window );">Share retirement (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(5)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_evh_StockVestedAndRetiredDuringPeriodValue', window );">Share retirement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (44)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_evh_StockIssuedDuringPeriodSharesEarnOuts', window );">Class A common stock issued for payment of earn-outs (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">43<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_evh_StockIssuedDuringPeriodValueEarnOuts', window );">Class A common stock issued for payment of earn-outs</a></td>
<td class="nump">800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_evh_AdjustmentsToAdditionalPaidInCapitalAcquisitions', window );">Amount attributable to NCI from business combination</a></td>
<td class="nump">6,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,500<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_evh_StockIssuedDuringPeriodSharesEquityMethodInvestmentsAndAssetAcquisitions', window );">Shares issued for equity-method investments and asset acquisitions (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,732<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_evh_StockIssuedDuringPeriodValueEquityMethodInvestmentsAndAssetAcquisitions', window );">Shares issued for equity-method investments and asset acquisitions</a></td>
<td class="nump">23,556<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23,556<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 18<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23,538<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Exchange/conversion (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,146<span></span>
</td>
<td class="num">(3,146)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities', window );">Exchange/conversion</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">42,377<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 31<span></span>
</td>
<td class="num">$ (31)<span></span>
</td>
<td class="nump">42,377<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(42,377)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_evh_StockIssuedDuringPeriodSharesConversionofConvertibleSecuritiesTaxImpact', window );">Tax impact of Class B exchange</a></td>
<td class="num">(22)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(22)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(22)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance', window );">Redemption of Sponsor&#8217;s equity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(643)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(643)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">643<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Foreign currency translation adjustment</a></td>
<td class="num">(52)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(52)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(52)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">(305,580)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(301,971)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(301,971)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3,609)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Ending balance (in shares) at Dec. 31, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">84,589<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance at Dec. 31, 2019</a></td>
<td class="nump">929,047<span></span>
</td>
<td class="num">$ (2,970)<span></span>
</td>
<td class="nump">922,358<span></span>
</td>
<td class="num">$ (2,970)<span></span>
</td>
<td class="nump">$ 846<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">1,173,708<span></span>
</td>
<td class="num">(234)<span></span>
</td>
<td class="num">(251,962)<span></span>
</td>
<td class="num">$ (2,970)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">6,689<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="nump">14,606<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,606<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,606<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of stock options (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">416<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of stock options</a></td>
<td class="nump">2,577<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,577<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,573<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures', window );">Restricted stock units vested, net of shares withheld for taxes (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">462<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures', window );">Restricted stock units vested, net of shares withheld for taxes</a></td>
<td class="num">(1,851)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,851)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,856)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockRetiredCostMethodAmount', window );">Consolidation of equity method investment</a></td>
<td class="num">(21,123)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(21,123)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(21,123)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_evh_StockVestedAndRetiredDuringPeriodShares', window );">Share retirement (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(188)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_evh_StockVestedAndRetiredDuringPeriodValue', window );">Share retirement</a></td>
<td class="num">(685)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(685)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (2)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(683)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_evh_StockIssuedDuringPeriodSharesEarnOuts', window );">Class A common stock issued for payment of earn-outs (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">616<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_evh_StockIssuedDuringPeriodValueEarnOuts', window );">Class A common stock issued for payment of earn-outs</a></td>
<td class="nump">4,185<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,185<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,179<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt', window );">Equity component of 2024 notes, net of issuance costs</a></td>
<td class="nump">36,793<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">36,793<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">36,793<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncontrollingInterestDecreaseFromDeconsolidation', window );">Disposal of assets</a></td>
<td class="num">(6,689)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(6,689)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Foreign currency translation adjustment</a></td>
<td class="num">(44)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(44)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(44)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">(334,246)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(334,246)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(334,246)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Ending balance (in shares) at Dec. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">85,895<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance at Dec. 31, 2020</a></td>
<td class="nump">619,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">619,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 859<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,229,320<span></span>
</td>
<td class="num">(278)<span></span>
</td>
<td class="num">(589,178)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(21,123)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="nump">$ 16,711<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,711<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,711<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of stock options (in shares)</a></td>
<td class="nump">1,490<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,490<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of stock options</a></td>
<td class="nump">$ 13,289<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,289<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,274<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures', window );">Restricted stock units vested, net of shares withheld for taxes (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">492<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures', window );">Restricted stock units vested, net of shares withheld for taxes</a></td>
<td class="num">(3,850)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3,850)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3,855)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesAcquisitions', window );">Shares issued for acquisition (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,771<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueAcquisitions', window );">Shares issued for acquisition</a></td>
<td class="nump">56,626<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">56,626<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 18<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">56,608<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_evh_StockIssuedDuringPeriodSharesEarnOuts', window );">Class A common stock issued for payment of earn-outs (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_evh_StockIssuedDuringPeriodValueEarnOuts', window );">Class A common stock issued for payment of earn-outs</a></td>
<td class="nump">450<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">450<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">450<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Exchange/conversion (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,095<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities', window );">Exchange/conversion</a></td>
<td class="nump">28,492<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">28,492<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">28,481<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Foreign currency translation adjustment</a></td>
<td class="num">(84)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(84)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(84)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">(37,601)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(37,601)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(37,601)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Ending balance (in shares) at Dec. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">90,759<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance at Dec. 31, 2021</a></td>
<td class="nump">$ 693,633<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 693,633<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 908<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,340,989<span></span>
</td>
<td class="num">$ (362)<span></span>
</td>
<td class="num">$ (626,779)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (21,123)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_AdjustmentsToAdditionalPaidInCapitalAcquisitions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Adjustments To Additional Paid In Capital, Acquisitions</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_AdjustmentsToAdditionalPaidInCapitalAcquisitions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_StockIssuedDuringPeriodSharesConversionofConvertibleSecuritiesTaxImpact">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock Issued During Period, Shares Conversion of Convertible Securities, Tax Impact</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_StockIssuedDuringPeriodSharesConversionofConvertibleSecuritiesTaxImpact</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_StockIssuedDuringPeriodSharesEarnOuts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock Issued During Period, Shares, Earn-outs</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_StockIssuedDuringPeriodSharesEarnOuts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_StockIssuedDuringPeriodSharesEquityMethodInvestmentsAndAssetAcquisitions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock Issued During Period, Shares, Equity-Method Investments And Asset Acquisitions</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_StockIssuedDuringPeriodSharesEquityMethodInvestmentsAndAssetAcquisitions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_StockIssuedDuringPeriodValueEarnOuts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock Issued During Period, Value, Earn-outs</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_StockIssuedDuringPeriodValueEarnOuts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_StockIssuedDuringPeriodValueEquityMethodInvestmentsAndAssetAcquisitions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock Issued During Period, Value, Equity-Method Investments And Asset Acquisitions</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_StockIssuedDuringPeriodValueEquityMethodInvestmentsAndAssetAcquisitions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_StockVestedAndRetiredDuringPeriodShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock Vested And Retired During Period, Shares</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_StockVestedAndRetiredDuringPeriodShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_StockVestedAndRetiredDuringPeriodValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock Vested And Retired During Period, Value</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_StockVestedAndRetiredDuringPeriodValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingStandardsUpdateExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates amendment to accounting standards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123597120&amp;loc=SL121967933-165497<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123597120&amp;loc=SL121967933-165497<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123597120&amp;loc=SL122642865-165497<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123459177&amp;loc=SL121830611-158277<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123597120&amp;loc=SL121967933-165497<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123597120&amp;loc=SL121967933-165497<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123597120&amp;loc=SL120254526-165497<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(iv)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124434974&amp;loc=SL124442142-165695<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=124434974&amp;loc=SL124442142-165695<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 27: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123459177&amp;loc=SL121830611-158277<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124434974&amp;loc=SL124442142-165695<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 848<br> -SubTopic 10<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=122150657&amp;loc=SL122150809-237846<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123597120&amp;loc=SL122642865-165497<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S65<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124359872&amp;loc=SL124427846-239511<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124402435&amp;loc=SL124402458-218513<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124402435&amp;loc=SL124402458-218513<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123597120&amp;loc=SL120254526-165497<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 45: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124434974&amp;loc=SL124442142-165695<br><br>Reference 47: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 49: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=124434974&amp;loc=SL124442142-165695<br><br>Reference 50: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (e)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 51: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 52: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 53: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 54: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 55: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (e)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 56: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 57: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 58: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 59: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 60: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 61: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Publisher FASB<br> -Subparagraph (a)<br><br>Reference 62: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Publisher FASB<br> -Subparagraph (a)(1)<br><br>Reference 63: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Publisher FASB<br> -Subparagraph (a)(2)<br><br>Reference 64: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Publisher FASB<br> -Subparagraph (a)(3)(iii)(01)<br><br>Reference 65: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Publisher FASB<br> -Subparagraph (a)(3)(iii)(03)<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingStandardsUpdateExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Adjustment to additional paid in capital resulting from the recognition of convertible debt instruments as two separate components - a debt component and an equity component. This bifurcation may result in a basis difference associated with the liability component that represents a temporary difference for purposes of applying accounting for income taxes. The initial recognition of deferred taxes for the tax effect of that temporary difference is as an adjustment to additional paid in capital.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 25<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123466103&amp;loc=SL6014347-161799<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=122142933&amp;loc=d3e11149-113907<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=122142933&amp;loc=d3e11178-113907<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123468992&amp;loc=d3e4534-113899<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncontrollingInterestDecreaseFromDeconsolidation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of the reduction or elimination during the period of a noncontrolling interest resulting from the parent's loss of control and deconsolidation of the entity in which one or more outside parties had a noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncontrollingInterestDecreaseFromDeconsolidation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in noncontrolling interest from subsidiary issuance of equity interests to noncontrolling interest holders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569655-111683<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3000-108585<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569616-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 29: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesAcquisitions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued during the period pursuant to acquisitions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesAcquisitions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-30)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21475-112644<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period related to Restricted Stock Awards, net of any shares forfeited.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueAcquisitions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued pursuant to acquisitions during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueAcquisitions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The gross value of stock issued during the period upon the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock related to Restricted Stock Awards issued during the period, net of the stock value of such awards forfeited.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21930-107793<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21914-107793<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442411-227067<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124434974&amp;loc=SL124442142-165695<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=124434974&amp;loc=SL124442142-165695<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4568740-111683<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21711-107793<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123459177&amp;loc=SL121830611-158277<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123459177&amp;loc=SL121830611-158277<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4590271-111686<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 24: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4568447-111683<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Publisher FASB<br> -Subparagraph (a)(3)(iii)(03)<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockRetiredCostMethodAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease of par value, additional paid in capital (APIC) and retained earnings of common and preferred stock retired from treasury when treasury stock is accounted for under the cost method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockRetiredCostMethodAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139858980052648">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash Flows Provided by (Used In) Operating Activities</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">$ (37,601,000)<span></span>
</td>
<td class="num">$ (334,246,000)<span></span>
</td>
<td class="num">$ (305,580,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash and restricted cash used in operating activities:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1', window );">Change in fair value of contingent consideration and indemnification asset</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">13,281,000<span></span>
</td>
<td class="nump">3,860,000<span></span>
</td>
<td class="num">(3,997,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_evh_GainLossOnDispositionOfAssetsOperatingActivities', window );">(Gain) loss on disposal of assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">6,786,000<span></span>
</td>
<td class="nump">698,000<span></span>
</td>
<td class="num">(9,600,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">(Gain) loss from equity method investees</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(13,179,000)<span></span>
</td>
<td class="num">(10,039,000)<span></span>
</td>
<td class="nump">9,465,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization expenses</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">60,037,000<span></span>
</td>
<td class="nump">61,475,000<span></span>
</td>
<td class="nump">60,913,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOtherThanTemporaryImpairment', window );">Impairment of equity method investments</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">47,133,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation expense</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">16,711,000<span></span>
</td>
<td class="nump">14,606,000<span></span>
</td>
<td class="nump">15,618,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxesAndTaxCredits', window );">Deferred tax benefit</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(526,000)<span></span>
</td>
<td class="num">(1,132,000)<span></span>
</td>
<td class="num">(23,124,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalizedContractCostAmortization', window );">Amortization of contract cost assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">13,041,000<span></span>
</td>
<td class="nump">21,195,000<span></span>
</td>
<td class="nump">5,723,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCosts', window );">Amortization of deferred financing costs</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">18,045,000<span></span>
</td>
<td class="nump">14,780,000<span></span>
</td>
<td class="nump">9,370,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_evh_PaidinKindInterestIncome', window );">Interest from customer advance for regulatory capital requirements</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(323,000)<span></span>
</td>
<td class="num">(1,869,000)<span></span>
</td>
<td class="num">(1,300,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_evh_GainOnTransferOfMembership', window );">Gain on transfer of membership</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(45,938,000)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillImpairmentLoss', window );">Goodwill impairment</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">215,100,000<span></span>
</td>
<td class="nump">199,800,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_evh_GainLossOnRepaymentOfDebt', window );">Loss on repayment of debt</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">21,343,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on repayment of debt</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">4,789,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNoncashIncomeExpense', window );">Other current operating cash inflows (outflows), net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">715,000<span></span>
</td>
<td class="nump">2,744,000<span></span>
</td>
<td class="num">(264,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in assets and liabilities, net of acquisitions:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_evh_IncreaseDecreaseInAccountsReceivableAndContractWithCustomerAsset', window );">Accounts receivable, net and contract assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(5,779,000)<span></span>
</td>
<td class="num">(47,017,000)<span></span>
</td>
<td class="nump">6,326,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other current and non-current assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">5,599,000<span></span>
</td>
<td class="nump">7,340,000<span></span>
</td>
<td class="nump">791,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_evh_IncreaseDecreaseInCapitalizedContractCostNet', window );">Contract cost assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(18,979,000)<span></span>
</td>
<td class="num">(11,400,000)<span></span>
</td>
<td class="num">(23,057,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">7,250,000<span></span>
</td>
<td class="nump">3,547,000<span></span>
</td>
<td class="num">(5,480,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilities', window );">Accrued liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(324,000)<span></span>
</td>
<td class="nump">8,801,000<span></span>
</td>
<td class="num">(21,852,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities', window );">Accrued compensation and employee benefits</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">3,538,000<span></span>
</td>
<td class="nump">11,143,000<span></span>
</td>
<td class="nump">9,246,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability', window );">Deferred revenue</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(739,000)<span></span>
</td>
<td class="num">(8,943,000)<span></span>
</td>
<td class="num">(756,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_evh_IncreaseDecreaseInInsuranceAndPerformanceBasedArrangementsLiabilities', window );">Reserve for claims and performance-based arrangements</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(3,799,000)<span></span>
</td>
<td class="num">(36,108,000)<span></span>
</td>
<td class="nump">33,555,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_evh_IncreaseDecreaseInOperatingLeaseRightofUseAsset', window );">Right-of-use operating assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">8,844,000<span></span>
</td>
<td class="nump">11,934,000<span></span>
</td>
<td class="num">(20,811,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability', window );">Operating lease liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(6,522,000)<span></span>
</td>
<td class="num">(2,782,000)<span></span>
</td>
<td class="nump">27,724,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities', window );">Other long-term liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(2,734,000)<span></span>
</td>
<td class="nump">8,166,000<span></span>
</td>
<td class="num">(5,355,000)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash and restricted cash provided by (used in) operating activities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">38,747,000<span></span>
</td>
<td class="num">(16,225,000)<span></span>
</td>
<td class="num">(42,645,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash Flows Provided by (Used In) Investing Activities</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesGross', window );">Cash paid for asset acquisitions and business combinations</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(49,012,000)<span></span>
</td>
<td class="num">(300,000)<span></span>
</td>
<td class="num">(8,575,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromDivestitureOfInterestInSubsidiariesAndAffiliates', window );">Proceeds from transfer of membership and release of Passport escrow</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">42,996,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForProceedsFromLoansReceivable', window );">Loan for implementation funding</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
<td class="nump">5,400,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_evh_PaymentsForProceedsFromDisposalOfNonStrategicAssetsAndDivestitureOfDiscontinuedOperationsNet', window );">Disposal of non-strategic assets and divestiture of discontinued operations, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">3,490,000<span></span>
</td>
<td class="num">(2,287,000)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital', window );">Return of equity method investments</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">14,218,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_evh_PaymentsForCustomerAdvanceForRegulatoryCapitalRequirements', window );">Customer advance for regulatory capital requirements</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(46,400,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireInterestInSubsidiariesAndAffiliates', window );">Investments in equity method investees</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(87,480,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAcquiredFromAcquisition', window );">Impact to cash and cash equivalents and restricted cash from initial consolidation</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">159,755,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireHeldToMaturitySecurities', window );">Purchases of investments</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(2,995,000)<span></span>
</td>
<td class="num">(11,170,000)<span></span>
</td>
<td class="num">(11,125,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_evh_ProceedsFromMaturityOfInvestments', window );">Maturities and sales of investments</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">500,000<span></span>
</td>
<td class="nump">143,441,000<span></span>
</td>
<td class="nump">2,575,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireOtherProductiveAssets', window );">Investments in internal-use software and purchases of property and equipment</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(24,983,000)<span></span>
</td>
<td class="num">(29,473,000)<span></span>
</td>
<td class="num">(35,534,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForProceedsFromOtherInvestingActivities', window );">Other investing activities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">106,000<span></span>
</td>
<td class="num">(495,000)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash and restricted cash (used in) provided by investing activities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(15,786,000)<span></span>
</td>
<td class="nump">261,072,000<span></span>
</td>
<td class="num">(181,634,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash Flows Used In Financing Activities</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_evh_PaymentsForProceedsFromClaimsProcessingFinancingActivities', window );">Changes in working capital balances related to claims processing on behalf of partners</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">61,162,000<span></span>
</td>
<td class="num">(6,044,000)<span></span>
</td>
<td class="num">(104,268,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_evh_ProceedsFromAssetAcquisitionEscrow', window );">Amount received from escrow in asset acquisition</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">500,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfDebtExtinguishmentCosts', window );">Repayment and termination of Credit Agreement including settlement of warrants</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(98,420,000)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromConvertibleDebt', window );">Proceeds from issuance of long term debt, net of offering costs</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">30,062,000<span></span>
</td>
<td class="nump">62,648,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromHedgeFinancingActivities', window );">Issuance of warrant liability</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">7,092,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfSeniorDebt', window );">Repayment and repurchase of 2021 Notes and financing fees</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(429,000)<span></span>
</td>
<td class="num">(16,606,000)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from stock option exercises</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">13,289,000<span></span>
</td>
<td class="nump">2,577,000<span></span>
</td>
<td class="nump">1,092,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToMinorityShareholders', window );">Distributions to Sponsors</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(1,300,000)<span></span>
</td>
<td class="num">(20,000,000)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation', window );">Taxes withheld and paid for vesting of restricted stock units</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(3,850,000)<span></span>
</td>
<td class="num">(1,851,000)<span></span>
</td>
<td class="num">(2,609,000)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash and restricted cash used in financing activities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(29,548,000)<span></span>
</td>
<td class="num">(11,862,000)<span></span>
</td>
<td class="num">(35,545,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Effect of exchange rate on cash and cash equivalents and restricted cash</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(52,000)<span></span>
</td>
<td class="nump">65,000<span></span>
</td>
<td class="nump">30,000<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net increase (decrease) in cash and cash equivalents and restricted cash</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(6,639,000)<span></span>
</td>
<td class="nump">233,050,000<span></span>
</td>
<td class="num">(259,794,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents and restricted cash as of beginning-of-period</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">361,581,000<span></span>
</td>
<td class="nump">128,531,000<span></span>
</td>
<td class="nump">388,325,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents and restricted cash as of end-of-period</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">$ 354,942,000<span></span>
</td>
<td class="nump">$ 361,581,000<span></span>
</td>
<td class="nump">$ 128,531,000<span></span>
</td>
</tr>
<tr><td colspan="4"></td></tr>
<tr><td colspan="4"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">See Note 5.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_GainLossOnDispositionOfAssetsOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gain (Loss) On Disposition Of Assets, Operating Activities</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_GainLossOnDispositionOfAssetsOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_GainLossOnRepaymentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gain (Loss) On Repayment Of Debt</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_GainLossOnRepaymentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_GainOnTransferOfMembership">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gain On Transfer Of Membership</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_GainOnTransferOfMembership</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_IncreaseDecreaseInAccountsReceivableAndContractWithCustomerAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Increase (Decrease) In Accounts Receivable And Contract With Customer, Asset</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_IncreaseDecreaseInAccountsReceivableAndContractWithCustomerAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_IncreaseDecreaseInCapitalizedContractCostNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Increase (Decrease) In Capitalized Contract Cost, Net</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_IncreaseDecreaseInCapitalizedContractCostNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_IncreaseDecreaseInInsuranceAndPerformanceBasedArrangementsLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Increase (Decrease) In Insurance And Performance-Based Arrangements Liabilities</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_IncreaseDecreaseInInsuranceAndPerformanceBasedArrangementsLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_IncreaseDecreaseInOperatingLeaseRightofUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Increase (Decrease) In Operating Lease, Right-of-Use Asset</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_IncreaseDecreaseInOperatingLeaseRightofUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_PaidinKindInterestIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Paid-in-Kind Interest Income</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_PaidinKindInterestIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_PaymentsForCustomerAdvanceForRegulatoryCapitalRequirements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payments For Customer Advance For Regulatory Capital Requirements</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_PaymentsForCustomerAdvanceForRegulatoryCapitalRequirements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_PaymentsForProceedsFromClaimsProcessingFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payments For (Proceeds From) Claims Processing, Financing Activities</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_PaymentsForProceedsFromClaimsProcessingFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_PaymentsForProceedsFromDisposalOfNonStrategicAssetsAndDivestitureOfDiscontinuedOperationsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payments For (Proceeds From) Disposal Of Non-Strategic Assets And Divestiture Of Discontinued Operations, Net</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_PaymentsForProceedsFromDisposalOfNonStrategicAssetsAndDivestitureOfDiscontinuedOperationsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_ProceedsFromAssetAcquisitionEscrow">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Proceeds From Asset Acquisition Escrow</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_ProceedsFromAssetAcquisitionEscrow</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_ProceedsFromMaturityOfInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Proceeds From Maturity Of Investments</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_ProceedsFromMaturityOfInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfFinancingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495355-112611<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfFinancingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120321790&amp;loc=d3e7008-128479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalizedContractCostAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for asset recognized from cost incurred to obtain or fulfill contract with customer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 40<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123353750&amp;loc=SL49131252-203054<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalizedContractCostAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAcquiredFromAcquisition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the acquisition of business during the period (for example, cash that was held by the acquired business).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAcquiredFromAcquisition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxesAndTaxCredits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income tax expense (benefit) and income tax credits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxesAndTaxCredits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentOtherThanTemporaryImpairment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This item represents an other than temporary decline in value that has been recognized against an investment accounted for under the equity method of accounting. The excess of the carrying amount over the fair value of the investment represents the amount of the write down which is or was reflected in earnings. The written down value is a new cost basis with the adjusted value of the investment becoming its new carrying value subject to the equity accounting method. Evidence of a loss in value might include, but would not necessarily be limited to, absence of an ability to recover the carrying amount of the investment or inability of the investee to sustain an earnings capacity which would justify the carrying amount of the investment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 35<br> -Paragraph 32<br> -URI http://asc.fasb.org/extlink&amp;oid=124268079&amp;loc=d3e32787-111569<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentOtherThanTemporaryImpairment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123467658&amp;loc=d3e12355-112629<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467658&amp;loc=d3e12317-112629<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillImpairmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13854-109267<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13777-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillImpairmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) for proportionate share of equity method investee's income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(13)(f))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109237563&amp;loc=d3e33749-111570<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 310<br> -Section 45<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123371682&amp;loc=d3e55415-109406<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in noncurrent operating liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNoncashIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNoncashIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForProceedsFromLoansReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net amount paid or received by the reporting entity associated with purchase (sale or collection) of loans receivable arising from the financing of goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3098-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3095-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForProceedsFromLoansReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForProceedsFromOtherInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash (inflow) outflow from investing activities classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3213-108585<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForProceedsFromOtherInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfDebtExtinguishmentCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for cost from early extinguishment and prepayment of debt. Includes, but is not limited to, third-party cost, premium paid, and other fee paid to lender directly for debt extinguishment or debt prepayment. Excludes accrued interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfDebtExtinguishmentCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireBusinessesGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120321790&amp;loc=d3e6927-128479<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireBusinessesGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireHeldToMaturitySecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow through purchase of long-term held-to-maturity securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3213-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26853-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireHeldToMaturitySecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireInterestInSubsidiariesAndAffiliates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of or advances to an entity that is related to it but not strictly controlled (for example, an unconsolidated subsidiary, affiliate, and joint venture or equity method investment) or the acquisition of an additional interest in a subsidiary (controlled entity).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireInterestInSubsidiariesAndAffiliates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireOtherProductiveAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for the purchase of or improvements to tangible or intangible assets, used to produce goods or deliver services, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireOtherProductiveAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToMinorityShareholders">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to a noncontrolling interest. Includes, but not limited to, reduction of noncontrolling interest ownership. Excludes dividends paid to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToMinorityShareholders</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromConvertibleDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the issuance of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromConvertibleDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromDivestitureOfInterestInSubsidiariesAndAffiliates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the deconsolidation of a previously consolidated subsidiary or sale of an entity that is related to it but not strictly controlled.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromDivestitureOfInterestInSubsidiariesAndAffiliates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of distribution received from equity method investee for return of investment, classified as investing activities. Excludes distribution for return on investment, classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 21D<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=SL94080555-108585<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromHedgeFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a financial contract that meets the hedge criteria as either cash flow hedge, fair value hedge or hedge of net investment in foreign operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 27<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3581-108585<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromHedgeFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=SL79508275-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3000-108585<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569616-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 29: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfSeniorDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for a long-term debt where the holder has highest claim on the entity's asset in case of bankruptcy or liquidation during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfSeniorDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139858976582840">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock', window );">Organization</a></td>
<td class="text">Organization <div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Evolent Health, Inc. was incorporated in December 2014 in the state of Delaware and through its subsidiaries supports leading health systems and physician organizations to move their business models from traditional fee for service reimbursement to value-based care, which we consider to be an integrated clinical and financial responsibility for populations. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since its inception, the Company has incurred losses from operations. As of December&#160;31, 2021, the Company had unrestricted cash and cash equivalents of $266.3 million. The Company believes it has sufficient liquidity for the next twelve months as of the date the financial statements were available to be issued.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s headquarters is located in Arlington, Virginia.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Evolent Health LLC Governance</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our operations are conducted through Evolent Health LLC. Evolent Health, Inc. is a holding company whose only business is to act as the sole managing member of Evolent Health LLC. As such, it controls Evolent Health LLC&#8217;s business and affairs and is responsible for the management of its business. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Issuances of Common Units</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Evolent Health LLC may only issue Class A common units to us, as the sole managing member of Evolent Health LLC. Class B common units may be issued only to persons or entities we permit. Such issuances of Class B common units shall be made in exchange for cash or other consideration. Class B common units may not be transferred as Class B common units except to certain permitted transferees and in accordance with the restrictions on transfer set forth in the third amended and restated operating agreement of Evolent Health LLC. Any such transfer must be accompanied by the transfer of an equal number of shares of our Class B common stock. As of December 31, 2021 and 2020, there are no Class B common units outstanding.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -URI http://asc.fasb.org/topic&amp;trid=2122149<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -URI http://asc.fasb.org/topic&amp;trid=2197479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139858982761480">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation, Summary of Significant Accounting Policies and Change in Accounting Principles<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock', window );">Basis of Presentation, Summary of Significant Accounting Policies and Change in Accounting Principles</a></td>
<td class="text">Basis of Presentation, Summary of Significant Accounting Policies and Change in Accounting Principles<div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Basis of Presentation</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The consolidated financial statements of the Company are prepared in accordance with U.S. GAAP. Our consolidated financial statements include the accounts of all subsidiaries. All intercompany accounts and transactions are eliminated in consolidation. The consolidated balance sheet as of December 31, 2020, has been derived from audited financial statements as of that date and reflects the impact of the sale of True Health. See Note 5 for a complete summary of this transaction. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Summary of Significant Accounting Policies</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain GAAP policies that significantly affect the determination of our financial position, results of operations and cash flows, are summarized below.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Accounting Estimates and Assumptions</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions affecting the reported amounts of assets and liabilities and the disclosures of contingent assets and liabilities as of the date of the financial statements and the reported amounts of revenue and expenses for the reporting period. Those estimates are inherently subject to change and actual results could differ from those estimates. In the accompanying consolidated financial statements, estimates are used for, but not limited to, the valuation of assets (including intangibles assets, goodwill and long-lived assets), liabilities, consideration related to business combinations and asset acquisitions, revenue recognition (including variable consideration), estimated selling prices for performance obligations in contracts with multiple performance obligations, reserves for claims and performance-based arrangements, credit losses, depreciable lives of assets, impairment of long-lived assets, stock-based compensation, deferred income taxes and valuation allowance, contingent liabilities, purchase price allocation in taxable stock transactions and useful lives of intangible assets.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Operating Segments</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating segments are defined as components of a business that may recognize revenue and incur expenses for which discrete financial information is available that is evaluated, on a regular basis, by the chief operating decision maker (&#8220;CODM&#8221;) to decide how </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to allocate resources and assess performance. The Company made organizational changes, including re-evaluating its reportable segments, as a result of the entry into the agreement to sell True Health on January 11, 2021. Effective during the first quarter of 2021, the Company bifurcated its previous Services segment into two segments. The Company&#8217;s Evolent Health Services segment (&#8220;EHS&#8221;) includes our administrative simplification solution and supporting population health infrastructure. Our Clinical Solutions segment includes our specialty care management and physician-oriented total cost of care solutions, along with the New Century Health and Evolent Care Partners brands. Refer to Note 22 for a further discussion of our operating results by segment.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cash and Cash Equivalents</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We consider all highly liquid instruments with original maturities of three months or less to be cash equivalents. The Company holds materially all of our cash in bank deposits with FDIC participating banks, at cost, which approximates fair value. Cash and cash equivalents held in money market funds are carried at fair value, which approximates cost.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Restricted Cash and Restricted Investments</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restricted cash and restricted investments include cash and investments used to collateralize various contractual obligations as of December&#160;31, 2021 and 2020 (in thousands) as follows:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"/><td style="width:421.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:54.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:54.25pt"/><td style="width:1.0pt"/></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Collateral for letters of credit for facility leases </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,769&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,510&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Collateral with financial institutions </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,662&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,743&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Claims processing services </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(4)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73,226&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,064&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">711&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total restricted cash and restricted investments</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88,662&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,028&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current restricted cash</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75,685&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,374&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current restricted cash and restricted investments</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75,685&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,374&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-current restricted cash</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,977&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,654&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total non-current restricted cash and restricted investments</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,977&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,654&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt">Amounts exclude $0.6 million of non-current restricted investments and $0.1&#160;million of current restricted cash from claims processing services reclassified to discontinued operations as of December&#160;31, 2020.</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt">Represents restricted cash related to collateral for letters of credit required in conjunction with lease agreements. See Note 12 for further discussion of our lease commitments. </span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt">Represents collateral held with financial institutions for risk-sharing and other arrangements. As of December&#160;31, 2021 and 2020, approximately $11.7&#160;million and $4.7 million, respectively, of the collateral amounts were held in a FDIC participating bank account. See Note 19 for discussion of fair value measurement and Note 11 for discussion of our risk-sharing arrangements. </span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(4)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt">Represents cash held by the Company related to claims processing services on behalf of partners. These are pass-through amounts and can fluctuate materially from period to period depending on the timing of when the claims are processed.</span></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides a reconciliation of cash and cash equivalents and restricted cash reported within the consolidated balance sheets that sum to the total of the same amounts shown in the consolidated statements of cash flows as of December&#160;31, 2021 and 2020 (in thousands).</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"/><td style="width:433.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:48.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:48.25pt"/><td style="width:1.0pt"/></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">266,280&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">340,490&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash and restricted investments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88,662&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,707&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted investments included in restricted cash and restricted investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(616)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:5.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash and cash equivalents and restricted cash shown in the consolidated statements of cash flows </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">354,942&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">361,581&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt">As a result of the closing of the sale of True Health, the consolidated statements of operations, consolidated balance sheets and related financial information reflect the Company&#8217;s operations and assets and liabilities of True Health as discontinued operations for all periods presented. Cash flows and comprehensive income have not been adjusted and are included in the consolidated statements of cash flows and consolidated statements of comprehensive income (loss) for all periods presented. See Note 5.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Accounts Receivable and Allowances</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounts receivable are recorded and carried at the original invoiced amount less an allowance for any potential uncollectible amounts. We make estimates for the allowance for doubtful accounts and allowance for unbilled receivables based upon our assessment of various factors, including historical experience, the age of the accounts receivable balances, credit quality of our customers, current economic conditions, and other factors that may affect our ability to collect from customers.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Property and Equipment, Net</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment are carried at cost less accumulated depreciation and amortization. Depreciation and amortization of property and equipment are computed using the straight-line method over the shorter of the estimated useful lives of the assets or the lease term. The following summarizes the estimated useful lives by asset classification:</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:63.066%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:34.040%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer hardware</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 years</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer software</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 year</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture and equipment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 - 7 years</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Internal-use software development costs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5 years</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shorter of useful life or remaining lease term</span></td></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">When an item is sold or retired, the cost and related accumulated depreciation or amortization is eliminated and the resulting gain or loss, if any, is recorded in gain (loss) on disposal of assets and consolidation on our consolidated statements of operations and comprehensive income (loss).</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We periodically review the carrying value of our long-lived assets, including property and equipment, for impairment whenever events or circumstances indicate that the carrying amount of such assets may not be fully recoverable. For long-lived assets to be held and used, impairments are recognized when the carrying amount of a long-lived asset group is not recoverable and exceeds fair value. The carrying amount of a long-lived asset group is not recoverable if it exceeds the sum of the undiscounted cash flows expected to result from the use and eventual disposition of the asset group. An impairment loss is measured as the amount by which the carrying amount of a long-lived asset group exceeds its fair value.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Software Development Costs</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company capitalizes the cost of developing internal-use software, consisting primarily of personnel and related expenses (including stock-based compensation and employee taxes and benefits) for employees and third parties who devote time to their respective projects. Internal-use software costs are capitalized during the application development stage &#8211; when the research stage is complete and management has committed to a project to develop software that will be used for its intended purpose. Any costs incurred during subsequent efforts to significantly upgrade and enhance the functionality of the software are also capitalized. Capitalized software costs are included in property and equipment, net on our consolidated balance sheets. Amortization of internal-use software costs are recorded on a straight-line basis over their estimated useful life and begin once the project is substantially complete and the software is ready for its intended purpose.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and Development Costs</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development costs consist primarily of personnel and related expenses (including stock-based compensation and employee taxes and benefits) for employees engaged in research and development activities as well as third-party fees. All such costs are expensed as incurred. We focus our research and development efforts on activities that support our technology infrastructure, clinical program development, data analytics and network development capabilities. Research and development costs are recorded within selling, general and administrative expenses on our consolidated statements of operations and comprehensive income (loss) and were $15.5&#160;million, $15.1&#160;million and $19.8&#160;million for the years ended December 31, 2021, 2020 and 2019, respectively.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Business Combinations</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Companies acquired during each reporting period are reflected in the results of the Company effective from their respective dates of acquisition through the end of the reporting period. The Company allocates the fair value of purchase consideration to the assets acquired and liabilities assumed based on their estimated fair values at the acquisition date. Our estimates of fair value are based upon assumptions believed to be reasonable, but which are inherently uncertain and unpredictable and, as a result, actual results may differ </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">from estimates. Critical estimates used to value certain identifiable assets include, but are not limited to, expected long-term revenues, future expected operating expenses, cost of capital and appropriate discount rates. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The excess of the fair value of purchase consideration over the fair value of the assets acquired and liabilities assumed in the acquired entity is recorded as goodwill. Goodwill is assigned to the reporting unit that benefits from the synergies arising from the business combination. If the Company obtains new information about facts and circumstances that existed as of the acquisition date during the measurement period, which may be up to one year from the acquisition date, the Company may record adjustments to the assets acquired and liabilities assumed, with the corresponding offset to goodwill. Upon the conclusion of the measurement period or final determination of the values of assets acquired or liabilities assumed, whichever comes first, any subsequent adjustments are recorded on the Company's consolidated statements of operations and comprehensive income (loss). </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For contingent consideration recorded as a liability, the Company initially measures the amount at fair value as of the acquisition date and adjusts the liability, if needed, to fair value at each reporting period. Changes in the fair value of contingent consideration, other than measurement period adjustments, are recognized as operating income or expense. Acquisition-related expenses are recognized separately from the business combination and are expensed as incurred.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Equity Method Investments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For entities that are not consolidated, but where the Company has significant influence over the operating or financial decisions of the entity, the Company accounts for the investment under the equity method of accounting. In accordance with the equity method of accounting, the Company will recognize its share of earnings or losses of the investee in the period in which they are reported by the investee. The Company also considers whether there are any indicators of other-than-temporary impairment of its investments accounted for under the equity method. These investments are included in investments in equity method investees on the consolidated balance sheets with income or loss included in gain (loss) from equity method investees on the consolidated statements of operations and comprehensive income (loss).</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Impairment of Equity Method Investments</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company considers certain factors to determine if there is a decrease in its investment fair value for its equity method investments that is other than temporary. The equity method investments will be written down to fair value if there is evidence of a loss in value which is other-than-temporary. The Company may estimate the fair value of its equity method investments by considering recent investee equity transactions, discounted cash flow analysis and recent operating results. If the fair value of the investment is below the carrying amount, management considers several factors when determining whether other-than-temporary impairment has occurred. The estimation of fair value and whether other-than-temporary impairment has occurred requires the application of significant judgment and future results may vary from current assumptions. Refer to Note 17 for additional discussion regarding impairments on equity method investments.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Goodwill</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize the excess of the purchase price, plus the fair value of any non-controlling interests in the acquiree, over the fair value of identifiable net assets acquired as goodwill. Goodwill is not amortized, but is reviewed at least annually for indications of impairment, with consideration given to financial performance and other relevant factors. We perform impairment tests of goodwill at a reporting unit level. Following the sale of True Health, the Company has three reporting units and our annual goodwill impairment review occurs during the fourth quarter of each year. We perform impairment tests between annual tests if an event occurs, or circumstances change, that we believe would more likely than not reduce the fair value of a reporting unit below its carrying amount. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our goodwill impairment analysis first assesses qualitative factors to determine whether events or circumstances existed that would lead the Company to conclude it is more likely than not that the fair value of a reporting unit is below its carrying amount. If the Company determines that it is more likely than not that the fair value of a reporting unit is below the carrying amount, a quantitative goodwill assessment is required. In the quantitative evaluation, the fair value of the relevant reporting unit is determined and compared to the carrying value. If the fair value is greater than the carrying value, then the carrying value is deemed to be recoverable and no further action is required. If the fair value estimate is less than the carrying value, goodwill is considered impaired for the amount by which the carrying amount exceeds the reporting unit&#8217;s fair value and a charge is reported in goodwill impairment on our consolidated statements of operations and comprehensive income (loss). See Note 9 for additional discussion regarding the goodwill impairment tests conducted during 2021 and 2020.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Intangible Assets, Net </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Identified intangible assets are recorded at their estimated fair values at the date of acquisition and are amortized over their respective estimated useful lives using a method of amortization that reflects the pattern in which the economic benefits of the intangible assets are used. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following summarizes the estimated useful lives by asset classification:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"/><td style="width:438.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:97.75pt"/><td style="width:1.0pt"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate trade name</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10 - 20 years</span></div></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer relationships</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10 - 25 years</span></div></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Technology</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5 years</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provider network contracts</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 - 5 years</span></div></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets are reviewed for impairment if circumstances indicate the Company may not be able to recover the asset&#8217;s carrying value. The Company evaluates recoverability by determining whether the undiscounted cash flows expected to result from the use and eventual disposition of that asset or group exceed the carrying value at the evaluation date. If the undiscounted cash flows are not sufficient to cover the carrying value, the Company measures an impairment loss as the excess of the carrying amount of the long-lived asset or group over its fair value. See Note 9 for additional discussion regarding our intangible assets.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Reserves for Claims and Performance-based Arrangements</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Reserves for claims and performance-based arrangements reflect estimates of payments under performance-based arrangements and the ultimate cost of claims that have been incurred but not reported, including expected development on reported claims, those that have been reported but not yet paid (reported claims in process) and other medical care expenses and services payable that are primarily composed of accruals for incentives and other amounts payable to health care professionals and facilities. The Company uses actuarial principles and assumptions that are consistently applied in each reporting period and recognizes the actuarial best estimate of the ultimate liability along with a margin for adverse deviation. This approach is consistent with actuarial standards of practice that the liabilities be adequate under moderately adverse conditions. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The process of estimating reserves involves a considerable degree of judgment by the Company and, as of any given date, is inherently uncertain. The methods for making such estimates and for establishing the resulting liability are continually reviewed and adjustments are reflected in current results of operations in the period in which they are identified as experience develops or new information becomes known. See Note 23 for additional discussion regarding our reserves for claims and performance-based arrangements.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Right of Offset</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain customer arrangements give the Company the legal right to net payment for amounts due from customers and claims payable. As of December 31, 2021 and 2020, approximately 42% and &#8212;% of gross accounts receivable have been netted against claims payable. Furthermore, as of December 31, 2021, approximately 55% of our accounts receivable, net could ultimately be settled on a net basis, once the criteria for netting have been met.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Long-term Debt</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Convertible notes and amounts borrowed under our credit agreement are carried at cost, net of debt discounts and issuance costs, as long-term debt on the consolidated balance sheets. The debt discounts and issuance costs are amortized to interest expense on the consolidated statements of operations and comprehensive income (loss) using the straight-line method over the contractual term of the note if that method is not materially different from the effective interest rate method. Cash interest payments are due either quarterly or semi-annually in arrears and we accrue interest expense monthly based on the annual coupon rate. See Note 10 for further discussion regarding our convertible notes and credit agreement.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Leases</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company enters into various office space, data center and equipment lease agreements in conducting its normal business operations. At the inception of any contract, the Company evaluates the agreement to determine whether the contract contains a lease. If the contract contains a lease, the Company then evaluates the term and whether the lease is an operating or finance lease. Most leases include one or more options to renew or may have a termination option. The Company determines whether these options are reasonably certain to be exercised at the inception of the lease. The rent expense is recognized on a straight-line basis in the consolidated statements of operations and comprehensive income (loss) over the terms of the respective leases. Leases with an initial term of 12 months or less are not recorded on the consolidated balance sheets.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As most of our leases do not provide an implicit rate, we use our incremental borrowing rate based on the information available at commencement date in determining the present value of lease payments. We use the implicit rate when readily determinable. Further, the Company treats all lease and non-lease components as a single combined lease component for all classes of underlying assets.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company also enters into sublease agreements for some of its leased office space. Rental income attributable to subleases is immaterial and is offset against rent expense over the terms of the respective leases.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Refer to Note 12 for additional lease disclosures.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue Recognition</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We derive revenue from two sources: (1) transformation services and (2) platform and operations services. Transformation services consist of implementation services whereby we assist the customer in launching its population health or health plan programs, or implement certain platform and operations services. In certain cases, transformation services can also include revenue associated with our support of certain one-time wind-down activities for clients who are exiting a line of business or population. Platform and operations services generally include multi-year arrangements with customers to provide various population health, health plan operations, specialty care management and claims processing services on an ongoing basis, as well as transition or run-out services to customers receiving primarily TPA services. Revenue is recognized when control of the services is transferred to our customers.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We use the following 5-step model, outlined in Accounting Standards Codification (&#8220;ASC&#8221;) Topic 606, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue from Contracts with Customers</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (&#8220;ASC 606&#8221;), to determine revenue recognition from our contracts with customers:</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"> Identify the contract(s) with a customer</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"> Identify the performance obligations in the contract</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"> Determine the transaction price</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"> Allocate the transaction price to performance obligations</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"> Recognize revenue when (or as) the entity satisfies a performance obligation</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Note 6 for further discussion of our policies related to revenue recognition. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cost of Revenue (Exclusive of Depreciation and Amortization)</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our cost of revenue includes direct expenses and shared resources that perform services in direct support of clients. Costs consist primarily of employee-related expenses (including compensation, benefits and stock-based compensation), expenses for TPA support and other services, as well as other professional fees. In certain cases, our cost of revenue also includes claims and capitation payments to providers and payments for pharmaceutical treatments and other health care expenditures through capitated arrangements.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Stock-based Compensation</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company sponsors a stock-based incentive plan that provides for the issuance of stock-based awards to employees, vendors and non-employee directors of the Company or its consolidated subsidiaries. Our stock-based awards generally vest over a four-year period and stock options expire 10 years from the date of grant.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expense the fair value of stock-based awards granted under our incentive compensation plans. Fair value of stock options is determined using a Black-Scholes options valuation methodology. The fair value of the awards is expensed over the performance or service period, which generally corresponds to the vesting period, on a straight-line basis and is recognized as an increase to additional paid-in capital. Stock-based compensation expense is reflected in cost of revenue and selling, general and administrative expenses in our consolidated statements of operations and comprehensive income (loss). Additionally, and if applicable, we capitalize personnel expenses attributable to the development of internal-use software, which include stock-based compensation costs. We recognize share-based award forfeitures as they occur.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Taxes</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred income taxes are recognized, based on enacted rates, when assets and liabilities have different values for financial statement and tax reporting purposes. A valuation allowance is recorded to the extent required. Considerable judgment and the use of estimates are required in determining whether a valuation allowance is necessary and, if so, the amount of such valuation allowance. In evaluating the need for a valuation allowance, we consider many factors, including: the nature and character of the deferred tax assets and liabilities; taxable income in prior carryback years; future reversals of temporary differences; the length of time carryovers can be utilized; and any tax planning strategies we would employ to avoid a tax benefit from expiring unused.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We use a recognition threshold and a measurement attribute for the financial statement recognition and measurement of uncertain tax positions taken or expected to be taken in a tax return. For those benefits to be recognized, a tax position must be more-likely-than-not to be sustained upon examination by taxing authorities. We recognize interest and penalties accrued on any unrecognized tax exposures as a component of income tax expense, when applicable. As of December 31, 2021 and 2020, our identified balance of uncertain income tax positions would not have a material impact to the consolidated financial statements. We are subject to taxation in various jurisdictions in the U.S. and India and remain subject to examination by taxing jurisdictions for the year 2011 and all subsequent periods due to the availability of NOL carryforwards.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a holding company and our assets consist of our direct ownership in Evolent Health LLC, for which we are the managing member. Prior to the Class B unit exchanges on December 26, 2019, Evolent Health LLC was classified as a partnership for U.S. federal and applicable state and local income tax purposes and, as such, was not subject to U.S. federal, state and local income taxes. Taxable income or loss generated by Evolent Health LLC was allocated to holders of its units, including us, on a pro rata basis. Accordingly, we were subject to U.S. federal, state and local income taxes with respect to our allocable share of any taxable income of Evolent Health LLC. As a result of the 2019 Class B units exchanges, we became the sole owner of Evolent Health LLC and its entity classification changed from a partnership to an entity disregarded as separate from its owner for U.S. federal, state and local income tax purposes. Following the Class B units exchanges, any taxable income or loss generated by Evolent Health LLC is reportable and taxable only on the Company&#8217;s federal, state and local income tax returns. Evolent Health LLC has direct ownership in corporate subsidiaries, which were subject to U.S. and foreign taxes with respect to their own operations during 2019.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Earnings (Loss) per Share</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic earnings (loss) per share is computed by dividing net income (loss) available to Class A common shareholders by the weighted-average number of Class A common shares outstanding.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For periods of net income, and when the effects are not anti-dilutive, we calculate diluted earnings per share by dividing net income available to Class A common shareholders by the weighted average number of Class A common shares plus the weighted average number of Class A common shares assuming the conversion of our convertible notes, as well as the impact of all potential dilutive common shares, consisting primarily of common stock options and unvested restricted stock awards using the treasury stock method and our exchangeable Class B common stock. For periods of net loss, shares used in the diluted earnings (loss) per share calculation represent basic shares as using potentially dilutive shares would be anti-dilutive.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fair Value Measurement</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fair value is the price that would be received from the sale of an asset or paid to transfer a liability assuming an orderly transaction in the most advantageous market at the measurement date. Our consolidated balance sheets include various financial instruments (primarily cash not held in money-market funds, restricted cash, accounts receivable, accounts payable, accrued expenses and other liabilities) that are carried at cost and that approximate fair value.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Note 19 for further discussion regarding fair value measurement.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).  Accounting policies describe all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139858977699768">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Recently Issued Accounting Standards<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock', window );">Recently Issued Accounting Standards</a></td>
<td class="text">Recently Issued Accounting Standards<div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Adoption of New Accounting Standards</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2016, the FASB issued ASU 2016-13, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financial Instruments-Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and subsequently issued additional guidance that modified ASU 2016-13. The standard requires an entity to change its accounting approach for measuring and recognizing credit losses on certain financial assets measured at amortized cost, including trade receivables, certain non-trade receivables, contract assets, held-to-maturity securities, customer advances and certain off-balance sheet credit exposures, by replacing the existing &#8220;incurred loss&#8221; framework with an expected credit loss recognition model.&#160; The new standard results in earlier recognition of credit losses based on past events, current conditions and reasonable and supportable forecasts.&#160;We adopted the requirements of this standard effective January 1, 2020 using the modified retrospective approach and recorded a cumulative effect adjustment of $3.0 million to January 1, 2020 retained earnings (accumulated deficit). Results for reporting periods beginning January 1, 2020 reflect the adoption of <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM180Ni9mcmFnOjhkNTIzNGI1NjdkZjRiMThiNjM1NmFmN2Q4OWQ4MDE3L3RleHRyZWdpb246OGQ1MjM0YjU2N2RmNGIxOGI2MzU2YWY3ZDg5ZDgwMTdfMzI1Ng_c324734f-03c4-4b52-af23-6ac596334a4b">ASU 2016-13</span>, while prior period amounts were not adjusted and continue to be reported in accordance with our historical accounting practices. Refer to Note 7 for additional disclosures related to current expected credit losses.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2019, the FASB issued ASU No. 2019-12,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Simplifying the Accounting for Income Taxes.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The amendments in the ASU remove certain exceptions to the intraperiod tax allocation of losses and gains from different financial statement components and to the method of recognizing income taxes on interim period losses and the recognition of deferred tax liabilities for outside basis differences. In addition, the new guidance simplifies aspects of the accounting for franchise taxes and clarifies the accounting for </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">transactions that result in a step-up in the tax basis of goodwill. The Company adopted this standard starting in the first quarter of 2021, which did not have a material impact on our consolidated financial statements.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2020, the FASB issued ASU 2020-06, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Accounting for Convertible Instruments and Contracts in an Entity&#8217;s Own Equity</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The ASU simplifies the accounting for certain financial instruments with characteristics of liabilities and equity, including convertible instruments and contracts in an entity&#8217;s own equity. Specifically, the ASU removes the separation models for convertible debt with a cash conversion feature or convertible instruments with a beneficial conversion feature and no longer permits the use of the treasury stock method from calculating earnings per share. As a result, after adopting the ASU&#8217;s guidance, we will not separately present in equity an embedded conversion feature of such debt. Instead, we will account for a convertible debt instrument wholly as debt unless (i) a convertible instrument contains features that require bifurcation as a derivative or (ii) a convertible debt instrument was issued at a substantial premium. Additionally, the ASU removes certain conditions for equity classification related to contracts in an entity&#8217;s own equity (e.g., warrants) and amends certain guidance related to the computation of earnings per share for convertible instruments and contracts on an entity&#8217;s own equity. The guidance in this ASU can be adopted using either a full or modified retrospective approach and becomes effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2021. We will adopt the ASU in the first quarter of fiscal 2022, and expect to use modified retrospective approach. The Company is currently assessing the impact, if any, that ASU 2020-06 would have on its financial position, results of operations or cash flows, however, the inability to use the treasury stock method in accounting for the shares issuable upon conversion of the 2024 Notes and the 2025 Notes will adversely affect our diluted earnings per share.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recent Accounting Pronouncements Not Yet Effective</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2021, the FASB issued ASU 2021-08, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Business Combinations (Topic 805): Accounting for Contract Assets and Contract Liabilities from Contracts with Customers</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which requires contract assets and contract liabilities acquired in a business combination to be recognized and measured by the acquirer on the acquisition date in accordance with ASC 606, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue from Contracts with Customers.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> This approach differs from the current requirement to measure contract assets and contract liabilities acquired in a business combination at fair value. This new standard is effective for our interim and annual periods beginning after December 15, 2022, with early adoption permitted. We are currently evaluating the adoption impacts on our consolidated financial statements.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for change in accounting principle. Includes, but is not limited to, nature, reason, and method of adopting amendment to accounting standards or other change in accounting principle.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123338486&amp;loc=SL49131195-203048<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -URI http://asc.fasb.org/topic&amp;trid=2122394<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=124434974&amp;loc=SL124442142-165695<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=123338486&amp;loc=SL49131195-203048<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (e)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123459177&amp;loc=SL121830611-158277<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section S99<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=122038215&amp;loc=SL108384541-122693<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=124402435&amp;loc=SL124402458-218513<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (e)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123597120&amp;loc=SL121967933-165497<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (i)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123338486&amp;loc=SL49131195-203048<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123597120&amp;loc=SL121967933-165497<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123459177&amp;loc=SL121830611-158277<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124402435&amp;loc=SL124402458-218513<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (j)<br> -URI http://asc.fasb.org/extlink&amp;oid=123338486&amp;loc=SL49131195-203048<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(iv)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120154821&amp;loc=SL120154904-197079<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SAB Topic 11.M.Q2)<br> -URI http://asc.fasb.org/extlink&amp;oid=122038215&amp;loc=d3e31137-122693<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120154821&amp;loc=SL120154904-197079<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120154821&amp;loc=SL120154904-197079<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (e)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123597120&amp;loc=SL121967933-165497<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (e)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 848<br> -SubTopic 10<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=122150657&amp;loc=SL122150809-237846<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (e)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123459177&amp;loc=SL121830611-158277<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Publisher FASB<br> -Subparagraph (c)<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139858976989672">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Transactions<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract', window );"><strong>Business Combination and Asset Acquisition [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationDisclosureTextBlock', window );">Transactions</a></td>
<td class="text">Transactions<div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Business Combinations</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Vital Decisions</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> </span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October 1, 2021, the Company completed its acquisition of Vital Decisions, including 100% of the voting equity interests. Vital Decisions is a leading provider of technology-enabled advance care planning services, ensuring that the care of individuals with serious illness aligns with their values and changing preferences throughout their health journey and, in particular, as they approach  end-of-life decisions. The transaction is expected to deepen our capabilities, allowing us to cross-sell across customers and enhance our value proposition to partners. </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total merger consideration, net of cash on hand and certain closing adjustments, was $117.7 million, based on the closing price of the Company&#8217;s Class A common stock on the NYSE on October 1, 2021. The merger consideration consisted of $46.5 million of cash consideration, 1.8&#160;million shares of Class A common stock, fair valued at $56.6 million as of October 1, 2021, and an earn-out of up to $45.0&#160;million, fair valued at $14.6 million as of October 1, 2021. See Note 18 for additional information regarding the fair value determination of the earn-out consideration.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The purchase price was allocated to the assets acquired and liabilities assumed based on their estimated fair values as of October 1, 2021, as follows (in thousands):</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:87.372%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.428%"/><td style="width:0.1%"/></tr><tr><td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Purchase consideration:</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46,500&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of Class A common stock issued</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56,626&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of contingent consideration</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,600&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total consideration</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">117,726&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Tangible assets acquired:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,430&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,301&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:87.372%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.428%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other non-current assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,564&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total tangible assets acquired</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,373&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Identifiable intangible assets acquired:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer relationships</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,500&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Technology</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate trade name</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,500&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total identifiable intangible assets acquired</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,000&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities assumed:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">93&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued liabilities </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">661&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued compensation and employee benefits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">970&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax liabilities, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">499&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,712&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities assumed</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,935&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77,288&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net assets acquired</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">117,726&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The fair value of the receivables acquired, as shown in the table above, approximates the gross contractual amounts and is expected to be collectible in full. Identifiable intangible assets associated with customer relationships, technology and corporate trade names will be amortized on a straight-line basis over their preliminary estimated useful lives of 13 years, 5 years, and 15 years, respectively. The customer relationships are primarily attributable to existing contracts with current customers. The technology consists primarily of a proprietary advance care planning documentation portal where patients can input information, and doctor/patient conversations are populated for later reference. The corporate trade name reflects the value that we believe the Vital Decisions brand name carries in the market. The fair value of the intangible assets was determined using the income approach and the relief from royalty approach. The income approach estimates fair value for an asset based on the present value of cash flows projected to be generated by the asset. Projected cash flows are discounted at a required rate of return that reflects the relative risk of achieving the cash flows and the time value of money. The relief from royalty approach estimates the fair value of an asset by calculating how much an entity would have to spend to lease a similar asset. Goodwill is calculated as the difference between the acquisition date fair value of the total consideration and the fair value of the net assets acquired and represents the future economic benefits that we expect to achieve as a result of the acquisition. The goodwill is attributable primarily to cross-selling opportunities and the acquired assembled workforce and was all allocated to the Clinical Solutions segment. Goodwill is considered to be an indefinite lived asset. $69.6&#160;million of the goodwill recorded on the transaction is deductible for tax purposes.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The amounts above reflect management&#8217;s estimate of the fair value of the tangible and intangible assets acquired and liabilities assumed. Any necessary adjustments will be finalized within one year from the date of acquisition.</span></div><div style="text-align:justify"><span><br/></span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Equity Investments</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Passport</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 28, 2019, UHC, Passport Health Solutions, LLC (&#8220;PHS I&#8221;), the Company and EVH Passport entered into an Asset Purchase Agreement (the &#8220;Passport APA&#8221;), which provided for the sale of substantially all of the assets of UHC and PHS I, including UHC&#8217;s Kentucky Medicaid contract (the &#8220;Passport Medicaid Contract&#8221;), to EVH Passport for a purchase price of $70.0 million in cash and the issuance of a 30% interest in EVH Passport (the &#8220;Passport Purchase Price&#8221;) to The University of Louisville, the University of Louisville Physicians, University Medical Center, the Jewish Heritage Fund for Excellence, Norton Healthcare, Inc. and the Louisville/Jefferson County Primary Care Association (collectively, the &#8220;Sponsors&#8221;). </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 18, 2019, the Company contributed $40.0 million to UHC in the form of an advance for regulatory capital requirements under an agreement with UHC (the &#8220;Passport Note&#8221;). The Passport Note carried a fixed interest rate of 6.5% per annum. Additionally, on </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">June 6, 2019, the Company and UHC entered into an Indemnity Agreement (the &#8220;Indemnity Agreement&#8221;), with an insurance company (the &#8220;Surety&#8221;). The Surety issued a performance bond in the amount of $25.0 million to secure UHC&#8217;s performance under its Medicaid Contract. Pursuant to the Indemnity Agreement, the Company and UHC were jointly and severally liable to the Surety in the maximum amount of the bond, plus certain costs of the Surety, in the event of losses arising under the bond. The bond&#8217;s original expiry date was June 30, 2020 and during the three months ended June 30, 2020, was extended to December 31, 2020. The bond was released in October 2020. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 30, 2019, UHC, PHS I, the Company and EVH Passport consummated the transactions contemplated by the Passport APA (the &#8220;Passport Closing&#8221;).  At the Passport Closing, $16.2 million of the cash Passport Purchase Price was held back until such time as PHS I delivers to EVH Passport certain owned real property and improvements free and clear of all encumbrances. In addition, at the Passport Closing, EVH Passport and UHC entered into an agreement that provided for the administration and assumption of the financial risks by EVH Passport of UHC&#8217;s dual eligible special needs business (the &#8220;DNP Business&#8221;) until such time as EVH Passport became certified as a Medicare Advantage Organization and the D-SNP Business could be transferred to EVH Passport.  On October 1, 2020, the D-SNP Business was transferred from UHC to EVH Passport. At the Passport Closing, EVH Passport assumed UHC&#8217;s obligations under the Passport Note and the Indemnity Agreement. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 16, 2020, EVH Passport, Evolent Health LLC and Molina Healthcare, Inc. (&#8220;Molina&#8221;) entered into an Asset Purchase Agreement (the &#8220;Molina APA&#8221;), which contemplated the sale by EVH Passport to Molina of certain assets, including certain intellectual property rights of EVH Passport and EVH Passport&#8217;s rights under the Passport Medicaid Contract.  On September 1, 2020, EVH Passport and Molina consummated the transactions contemplated by the Molina APA (the &#8220;Molina Closing&#8221;) and the Passport Medicaid Contract was novated to Molina.  As a result, EVH Passport began to wind down its business.  In connection with the Molina Closing, Molina deposited $20.0&#160;million in cash in escrow, which was subsequently released to EVH Passport in January 2021.  In addition, at the Molina Closing, Molina and EVH Passport entered into an agreement that provided for the assumption of the financial risks by Molina of the D-SNP Business until such time as Molina&#8217;s Kentucky health plan becomes certified as a Medicare Advantage Organization and the D-SNP Business is transferred Molina.  The Company and EVH Passport continued to administer the D-SNP Business until January 1, 2021, at which time Molina became responsible for its administration until the D-SNP Business was officially transferred to Molina effective September 1, 2021.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prior to the Molina Closing, the Company accounted for its investment in EVH Passport as an unconsolidated variable interest entity under the equity method of accounting.  As a result of the transaction, the Company concluded that a reconsideration event occurred whereby EVH Passport was determined to be a voting interest entity and that Evolent had a controlling financial interest in EVH Passport; accordingly, the Company consolidated EVH Passport as of September 1, 2020 in its consolidated financial statements. The Company accounted for the transaction as an asset acquisition, as the Company concluded that assets acquired as a result of the consolidation did not meet the criteria to be classified as a business under GAAP.  Following the Molina Closing and consolidation of EVH Passport in the Company&#8217;s consolidated financials, on November 16, 2020, EVH Passport redeemed the Sponsors&#8217; equity interests in EVH Passport for $20.0&#160;million in cash in accordance with the terms of EVH Passport&#8217;s Stockholders&#8217; Agreement, and, as a result, EVH Passport became a wholly owned subsidiary of the Company.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of the consolidation, the Company recorded assets primarily consisting of cash and cash equivalents and restricted cash and cash equivalents of $159.8&#160;million, available for sale securities of $88.6&#160;million, receivables related to unsettled sales of securities of $43.0&#160;million and other assets of $50.2&#160;million and total liabilities primarily comprised of reserve for claims and performance-based arrangements of $164.8&#160;million and accrued liabilities of $50.0&#160;million. Subsequent to winddown activities, any remaining capital will be distributed to the Company subject to regulatory approval from the Kentucky Department of Insurance.  In addition, the Passport Note was eliminated upon consolidation, and as of December 31, 2020, the outstanding principal balance of the $40.0&#160;million Passport Note was repaid in full by EVH Passport including approximately $3.6&#160;million of accrued interest.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the first quarter of 2021, pursuant to the terms of the Molina APA, EVH Passport received a cash payment from Molina in the amount of $23.0&#160;million based on the number of enrollees above a certain threshold in the D-SNP Business and Molina's Medicaid plan following the open enrollment period for plan year 2021. The payment is recorded in gain on transfer of membership on the consolidated statement of operations and comprehensive income (loss). The foregoing amount represents 50% of the payment that EVH Passport is eligible to receive pursuant to the terms of the Molina APA based on the number of such enrollees. The remaining 50% was received in the first quarter of 2022 and was recorded as a receivable on our consolidated balance sheet and a gain on transfer of membership on the consolidated statement of operations and comprehensive income (loss) during the year ended December 31, 2021 as there were no remaining uncertainties related to realization.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Loss on Disposal of Assets</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During 2019, the Company, through a consolidated subsidiary, entered into an agreement with an unrelated party to provide services and support to providers, independent physician associations, and other provider groups. During the first quarter of 2020, the Company sold its interest in the subsidiary and recorded a loss on disposal of assets of $6.4 million in the consolidated statements of operations and comprehensive income (loss). The Company did not have any continuing involvement with the subsidiary after the consummation of this transaction.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationAndAssetAcquisitionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -URI http://asc.fasb.org/topic&amp;trid=2303972<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139858977706808">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Discontinued Operations<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract', window );"><strong>Discontinued Operations and Disposal Groups [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock', window );">Discontinued Operations</a></td>
<td class="text">Discontinued Operations<div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 11, 2021, Evolent Health LLC, EH Holdings and True Health, each wholly owned subsidiaries of the Company, entered into a Stock Purchase Agreement (the &#8220;True Health SPA&#8221;) with Bright Health Management, Inc. (&#8220;Bright HealthCare&#8221;), pursuant to which EH Holdings agreed to sell all of its equity interests in True Health to Bright HealthCare. Closing of the transactions contemplated by the True Health SPA occurred on March 31, 2021 (the &#8220;True Health Closing&#8221;) and the Company has had no continuing involvement with True Health subsequent to the closing except a pre-existing services agreement for claims processing and other health plan administrative functions.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of the first quarter of 2021, the Company determined that True Health met the discontinued operations criteria under ASC 205, and as such, True Health assets and liabilities as of December 31, 2020, and the results of operations for all periods presented are classified as discontinued operations and are not included in continuing operations in the consolidated financial statements.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December 31, 2021, the Company recorded purchase prices adjustments to the True Health Closing of $8.7&#160;million which are included in loss from discontinued operations on the consolidated statements of operations and comprehensive income (loss).</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the results of operations of the Company&#8217;s True Health business, which are included in loss from discontinued operations in the consolidated statements of operations and comprehensive income (loss) for the years ended December 31, 2021, 2020 and 2019:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:69.872%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.205%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.205%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.208%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Revenue</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Platform and operations</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">356&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">145&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Premiums</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,795&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">117,377&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">171,742&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenue</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,833&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">117,733&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">171,887&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Expenses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of revenue (exclusive of depreciation and amortization expenses presented separately below) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,885&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,343&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,633&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Claims expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,954&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87,951&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">135,774&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative expenses </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,764&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,576&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,617&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">160&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">640&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">590&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating expenses</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45,763&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">125,510&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">169,614&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating income (loss)</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(930)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,777)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,273&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">112&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">531&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">581&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(25)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income (loss) before income taxes and non-controlling interests</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(847)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,259)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,872&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:69.872%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.205%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.205%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.208%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Benefit (provision) for income taxes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(326)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,185)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,259&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(521)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,074)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,613&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt">Cost of revenue includes intercompany expenses between the Company and True Health that are recorded in income from continuing operations in the consolidated statements of operations and comprehensive income (loss) related to an existing services agreement for claims processing and other health plan administrative functions of $2.8&#160;million, $13.6&#160;million and $6.6&#160;million for the years ended December 31, 2021, 2020 and 2019, respectively.</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt">Selling, general and administrative expenses includes intercompany expenses between the Company and True Health that are recorded in income from continuing operations on the consolidated statements of operations and comprehensive income (loss) related to an existing services agreement for claims processing and other health plan administrative functions of $1.1 million, $6.4 million and $6.0&#160;million for the years ended December 31, 2021, 2020 and 2019, respectively. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The consolidated statements of cash flows for all periods have not been adjusted to separately disclose cash flows related to discontinued operations. Cash flows related to the True Health business during the year ended December 31, 2021, 2020 and 2019 were as follows:</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:69.872%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.205%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.205%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.208%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash flows provided by (used in) operating activities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,002&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,852&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,642)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash flows (used in) provided by investing activities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,494)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,636&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,172)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash flows used in financing activities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,500)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the current and long-term assets and liabilities of the discontinued True Health business in the consolidated balance sheets as of December&#160;31, 2020:</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:82.927%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.873%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">ASSETS</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,488&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash and restricted investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,437&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,198&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investments, at amortized cost</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,728&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,914&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash and restricted investments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">616&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investments, at amortized cost</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,919&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other noncurrent assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible assets, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,080&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,705&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54,293&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">LIABILITIES</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">93&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,265&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued compensation and employee benefits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,115&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,140&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reserve for claims and performance-based arrangements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,858&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,471&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other long-term liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">128&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:82.927%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.873%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax liabilities, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,648&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt">Accounts payable excludes $1.5&#160;million between the Company and True Health related to an existing services agreement for claims processing and other health plan administrative functions as of December 31, 2020.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -URI http://asc.fasb.org/topic&amp;trid=2155823<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -URI http://asc.fasb.org/subtopic&amp;trid=2122178<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139858977874792">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue Recognition<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue from Contract with Customer [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerTextBlock', window );">Revenue Recognition</a></td>
<td class="text">Revenue Recognition<div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We derive revenue from two sources: (1) transformation services and (2) platform and operations services.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Transformation Services Revenue</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Transformation services consist of implementation services whereby we assist the customer in launching its population health or health plan programs. In certain cases, transformation services can also include revenue associated with our support of certain one-time wind-down activities for clients who are exiting a line of business or population. The transformation services are usually completed within 12 months. We generally receive a fixed fee for transformation services and recognize revenue over time using an input method based on hours incurred compared to the total estimated hours required to satisfy our performance obligation.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Platform and Operations Services Revenue</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Platform and operations services are typically multi-year arrangements with customers to provide various clinical and administrative solutions. In our Clinical Solutions segment, our solutions are designed to lower the medical expenses of our partners and include our total cost of care and specialty care management services.  In our Evolent Health Services segment, our solutions are designed to provide comprehensive health plan operations and claims processing services, and also include transition or run-out services to customers receiving primarily third-party administration (&#8220;TPA&#8221;) services.  </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our performance obligation in these arrangements is to provide an integrated suite of services, including access to our platform that is customized to meet the specialized needs of our customers and members. Generally, we will apply the series guidance to the performance obligation as we have determined that each time increment is distinct. We primarily utilize a variable fee structure for these services that typically includes a monthly payment that is calculated based on a specified per member per month rate, multiplied by the number of members that our partners are managing under a value-based care arrangement or a percentage of plan premiums. Our arrangements may also include other variable fees related to service level agreements, shared medical savings arrangements and other performance measures. Variable consideration is estimated using the most likely amount based on our historical experience and best judgment at the time. Due to the nature of our arrangements, certain estimates may be constrained if it is probable that a significant reversal of revenue will occur when the uncertainty is resolved. We recognize revenue from platform and operations services over time using the time elapsed output method. Fixed consideration is recognized ratably over the contract term. In accordance with the series guidance, we allocate variable consideration to the period to which the fees relate.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In our Clinical Solutions segment, we enter into capitation arrangements that may include performance-based arrangements and/or gainshare features. We recognize capitation revenue on a gross basis when we have established control over the services within our scope and recognize capitation revenue on a net basis when we do not have control over the services within our scope. </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Contracts with Multiple Performance Obligations</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our contracts with customers may contain multiple performance obligations, primarily when the customer has requested both transformation services and platform and operations services as these services are distinct from one another. When a contract has multiple performance obligations, we allocate the transaction price to each performance obligation based on the relative standalone selling price using the expected cost margin approach. This approach requires estimates regarding both the level of effort it will take to satisfy the performance obligation as well as fees that will be received under the variable pricing model. We also take into consideration customer demographics, current market conditions, the scope of services and our overall pricing strategy and objectives when determining the standalone selling price.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Principal vs. Agent</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We occasionally use third parties to assist in satisfying our performance obligations. In order to determine whether we are the principal or agent in the arrangement, we review each third-party relationship on a contract by contract basis. As we integrate goods and services provided by third parties into our overall service, we control the goods and services provided to the customer prior to its delivery. As such, we are the principal and we will recognize revenue on a gross basis. In certain cases, we act as an agent and do not control the services from third parties before it is delivered to the customer thereby recognizing revenue on a net basis.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Disaggregation of Revenue</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table represents Evolent&#8217;s revenue disaggregated by segment and end-market for the years ended December 31, 2021, 2020 and 2019 (in thousands):</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"/><td style="width:220.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:48.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:48.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:48.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:48.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:48.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:48.25pt"/><td style="width:1.0pt"/></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="33" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Year Ended December 31,</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Evolent Health Services</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Clinical Solutions</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicaid</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">215,236&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">236,634&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">267,222&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">205,833&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">274,028&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75,675&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicare</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,358&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68,505&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73,671&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">363,053&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">257,092&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">199,817&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial and other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68,219&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77,221&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68,012&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,258&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,159&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,725&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">309,813&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">382,360&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">408,905&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">598,144&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">542,279&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">278,217&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Transaction Price Allocated to the Remaining Performance Obligations</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For contracts with a term greater than one year, we have allocated approximately $178.8 million of transaction price to performance obligations that are unsatisfied as of December&#160;31, 2021. We do not include variable consideration that is allocated entirely to a wholly unsatisfied performance obligation accounted for under the series guidance in the calculation. As a result, the balance represents the value of the fixed consideration in our long-term contracts that we expect will be recognized as revenue in a future period and excludes the majority of our platform and operations revenue, which is primarily derived based on variable consideration as discussed in Note 2. We expect to recognize revenue on approximately 45%, 70% and 86% of these remaining performance obligations by December 31, 2022, 2023 and 2024, respectively, with the remaining balance to be recognized thereafter. However, because our existing contracts may be canceled or renegotiated including for reasons outside our control, the amount of revenue that we actually receive may be less or greater than this estimate and the timing of recognition may not be as expected.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Contract Balances</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contract balances consist of accounts receivable, contract assets and deferred revenue. Contract assets are recorded when the right to consideration for services is conditional on something other than the passage of time. Contract assets relating to unbilled receivables are transferred to accounts receivable when the right to consideration becomes unconditional. We classify contract assets as current or non-current based on the timing of our rights to the unconditional payments. Our contract assets are generally classified as current and recorded within prepaid expenses and other current assets on our consolidated balance sheets. Our current accounts receivables are classified within accounts receivable, net on our consolidated balance sheets and our non-current accounts receivable are classified within prepaid expenses and other non-current assets on our consolidated balance sheets.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred revenue includes advance customer payments and billings in excess of revenue recognized. We classify deferred revenue as current or non-current based on the timing of when we expect to recognize revenue. Our current deferred revenue is recorded within deferred revenue on our consolidated balance sheets and non-current deferred revenue is recorded within other long-term liabilities on our consolidated balance sheets.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides information about receivables, contract assets and deferred revenue from contracts with customers as of December&#160;31, 2021 and 2020 (in thousands):</span></div><div style="margin-top:5pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"/><td style="width:403.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:58.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:67.75pt"/><td style="width:1.0pt"/></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term receivables </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">129,012&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">118,730&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term receivables </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,877&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,554&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term contract assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">329&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term deferred revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,944&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,187&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term deferred revenue</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,437&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,593&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt">Amounts exclude $3.4&#160;million of short-term receivables and $4.1&#160;million of short-term deferred revenue reclassified to discontinued operations as of December&#160;31, 2020.</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt">Excludes pharmacy claims receivable and premiums receivable.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes in deferred revenue for the year ended December 31, 2021 are as follows (in thousands):</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"/><td style="width:433.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:102.25pt"/><td style="width:1.0pt"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Deferred revenue</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of beginning-of-period</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,780&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reclassification to revenue, as a result of performance obligations satisfied</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10,175)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash received in advance of satisfaction of performance obligations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,776&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of end of period</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,381&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The amount of revenue recognized from performance obligations satisfied (or partially satisfied) in a previous period was $28.3&#160;million and $12.1 million for the years ended December 31, 2021 and 2020, respectively, due primarily to net gain share as well as changes in other estimates.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Contract Cost Assets</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain bonuses and commissions earned by our sales team are considered incremental costs of obtaining a contract with a customer that we expect to be recoverable. The capitalized contract acquisition costs are classified as non-current assets and recorded within contract cost assets on our consolidated balance sheets. Amortization expense is recorded within selling, general and administrative expenses on the accompanying consolidated statements of operations and comprehensive income (loss). As of December&#160;31, 2021 and 2020, the Company had $5.2 million and $3.3 million, respectively, of contract acquisition cost assets, net of accumulated amortization recorded in contract cost assets on the consolidated balance sheets. In addition, the Company recorded </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">amortiza</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">tion expense of  $1.9 million, $1.9 million and $1.0 million for the years ended December 31, 2021, 2020 and 2019, respectively.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In our platforms and operations arrangements, we incur certain costs related to the implementation of our platform before we begin to satisfy our performance obligation to the customer. The costs, which we expect to recover, are considered costs to fulfill a contract. Our contract fulfillment costs primarily include our employee labor costs and third-party vendor costs. The capitalized contract fulfillment costs are classified as non-current and recorded within contract cost assets on our consolidated balance sheets. Amortization expense is recorded within cost of revenue on the accompanying consolidated statements of operations and comprehensive income (loss). As of December&#160;31, 2021 and 2020, the Company had $27.4 million and $23.4 million, respectively, of contract fulfillment cost assets, net of accumulated amortization recorded in contract cost assets on the consolidated balance sheets. In addition, the Company recorded amortization expense of $11.1 million, $13.0 million and $4.7 million, for the years ended December 31, 2021, 2020 and 2019, respectively.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These costs are deferred and then amortized on a straight-line basis over a period of benefit that we have determined to be the shorter of the contract term or five years. The period of benefit was based on our technology, the nature of our customer arrangements and other factors.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -URI http://asc.fasb.org/topic&amp;trid=49130388<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130551-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130556-203045<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130554-203045<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130550-203045<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130554-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130554-203045<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130554-203045<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130558-203045<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130554-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139858977721096">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Credit Losses<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CreditLossAbstract', window );"><strong>Credit Loss [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CreditLossFinancialInstrumentTextBlock', window );">Credit Losses</a></td>
<td class="text">Credit Losses <div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are exposed to credit losses primarily through our accounts receivable from revenue transactions, investments held at amortized cost and customer advances for regulatory capital and other notes receivable. We estimate expected credit losses based on past events, current conditions and reasonable and supportable forecasts. Expected credit losses are measured over the remaining contractual life of these assets. As part of our consideration of current and forward-looking economic conditions, we considered the impact of the COVID-19 pandemic on our customers&#8217; and other third parties&#8217; ability to pay. We did not observe notable increases in delinquencies during the year ended December 31, 2021. Given the nature of our business, our past collection experience during recessionary and pre-recessionary periods and our forecasted impact of the COVID-19 pandemic on our business, we did not record material changes in our allowances due to the COVID-19 pandemic during the year ended December 31, 2021.</span></div><div><span><br/></span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Accounts Receivable from Revenue Transactions</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounts receivable represent the amounts owed to the Company for goods or services provided to customers or third parties. Current accounts receivables are classified within accounts receivable, net on the Company&#8217;s consolidated balance sheets, while non-current accounts receivables are classified within prepaid expenses and other noncurrent assets on the Company&#8217;s consolidated balance sheets. </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We monitor our ongoing credit exposure through active review of counterparty balances against contract terms, due dates and business strategy. Our activities include timely account reconciliation, dispute resolution and payment confirmation. We may employ legal counsel to pursue recovery of defaulted receivables. In addition, the Company will establish a general reserve based on delinquency rates. Historical loss rates are determined for each delinquency bucket in 30-day past-due intervals and then applied to the composition of the reporting date balance based on delinquency. The allowance implied from application of the historical loss rates is then adjusted, as necessary, for current conditions and reasonable and supportable forecasts.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Based on an aging analysis of our trade accounts receivable, non-trade accounts receivable and contract assets as of&#160;December&#160;31, 2021,&#160;90% were current, 2%&#160;were past due less than 60 days, with 3% past due less than 120 days and at December 31, 2020, 59% were current, 24% were past due less than 60 days, with 37% past due less than 120 days. As of&#160;December&#160;31, 2021 and 2020, in total we reported on the consolidated balance sheet&#160;$171.5 million&#160;and $173.7&#160;million of accounts receivable, certain non-trade accounts receivable included in prepaid expenses and other assets, net of allowances of&#160;$3.4 million and $7.1&#160;million, respectively. The following table summarizes the changes in allowance for credit losses on our accounts receivables, certain non-trade accounts receivable and contract assets for the year ended December 31, 2021 and 2020 (in thousands):</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:76.816%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.594%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.596%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of beginning of period</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,056)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(41)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Passport acquisition</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,582)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cumulative transition adjustment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,815)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provision for credit losses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,411)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,283)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Charge-offs</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,093&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,665&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of end of period</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,374)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,056)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt">Charge offs for the year ended December 31, 2021, are primarily due to balances written-off that were previously fully reserved as part of the Passport transaction.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditLossAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditLossAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditLossFinancialInstrumentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for credit loss on financial instrument measured at amortized cost basis, net investment in lease, off-balance sheet credit exposure, and available-for-sale debt security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=124269663&amp;loc=SL82922895-210455<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=124255953&amp;loc=SL82919272-210447<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124255953&amp;loc=SL82919236-210447<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=124255953&amp;loc=SL82919269-210447<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124269663&amp;loc=SL82922888-210455<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124255953&amp;loc=SL82919244-210447<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=124255953&amp;loc=SL82919230-210447<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditLossFinancialInstrumentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139858977649128">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment, Net<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">Property and Equipment, Net</a></td>
<td class="text">Property and Equipment, Net<div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following summarizes our property and equipment (in thousands):</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"/><td style="width:408.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:54.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:67.75pt"/><td style="width:1.0pt"/></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer hardware</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,970&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,866&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture and equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,581&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,559&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Internal-use software development costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">159,587&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">137,085&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,325&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,586&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total property and equipment</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">200,463&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">175,096&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated depreciation and amortization expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(119,098)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(88,856)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total property and equipment, net</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81,365&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">86,240&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company capitalized $22.5 million, $24.6 million and $30.9 million of internal-use software development costs for the years ended December 31, 2021, 2020 and 2019, respectively. The net book value of capitalized internal-use software development costs was $71.2 million and $75.3 million as of December&#160;31, 2021 and 2020, respectively. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation expense related to property and equipment was $30.6 million, $28.3 million and $23.3 million, for the years ended December 31, 2021, 2020 and 2019, respectively, of which amortization expense related to capitalized internal-use software development costs was $26.5 million, $24.3 million and $18.7 million, respectively.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99893-112916<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -URI http://asc.fasb.org/topic&amp;trid=2155823<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=SL120174063-112916<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99779-112916<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139858977649128">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Goodwill and Intangible Assets, Net<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock', window );">Goodwill and Intangible Assets, Net</a></td>
<td class="text">Goodwill and Intangible Assets, Net<div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Goodwill</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Goodwill has an estimated indefinite life and is not amortized; rather, it is reviewed for impairment at least annually or whenever events or changes in circumstances indicate that the carrying amount of the asset may not be recoverable.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Subsequent to the sale of True Health, the Company has three reporting units, each with </span><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">discrete financial information. Our assets and liabilities are employed in and relate to the operations of our reporting units. Therefore, the equity carrying value and future cash flows must be estimated each time a&#160;goodwill impairment&#160;analysis is performed on a reporting unit. As a result, our assets, liabilities and cash flows are assigned to reporting units using reasonable and consistent allocation methodologies. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our annual goodwill impairment review occurs on October 31 of each fiscal </span><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">year. We evaluate qualitative factors that could cause us to believe the estimated fair value of each of our reporting units may be lower than the carrying value and trigger a quantitative assessment, including, but not limited to (i) macroeconomic conditions, (ii) industry and market considerations, (iii) our overall financial performance, including an analysis of our current and projected cash flows, revenues and earnings, (iv) a sustained decrease in share price and (v) other relevant entity-specific events including changes in management, strategy, partners, or litigation.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2021 Goodwill Impairment Test</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October 31, 2021, the Company performed its annual goodwill impairment review for fiscal year 2021. Based on our qualitative assessment, we did not identify sufficient indicators of impairment that would suggest the fair value of any of our three reporting units was below their respective carrying values. As a result, a quantitative goodwill impairment analysis was not required.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2020 Goodwill Impairment Test</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March 31, 2020, the Company assessed whether there were additional events or changes in circumstances since its 2019 annual goodwill impairment test that would indicate that it was more likely than not that the fair values of the reporting units were less than the reporting units&#8217; carrying amounts that would require an additional interim impairment assessment after October 31, 2019. Considering the sharp decrease in the share price of the Company&#8217;s Class A common stock during the three months ended March 31, 2020, the Company determined indicators of an impairment were present and we performed an interim goodwill impairment assessment as of March 31, 2020. As a result of this test, the Company determined that there was no goodwill impairment of the reporting unit which recognized an impairment in the year ended December 31, 2019. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During May 2020, the Kentucky Cabinet for Health and Family Services (&#8220;CHFS&#8221;) announced that EVH Passport was not awarded a Kentucky managed Medicaid contract for the next contract period and the Passport Medicaid Contract would expire on December 31, 2020. As a result of this announcement, the Company determined there were events or changes in circumstances since its 2019 annual goodwill impairment test that indicated it was more likely than not that the fair value of one of its two reporting units in the EHS segment was less than the reporting unit&#8217;s carrying amount triggering an interim quantitative assessment.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In performing this interim quantitative assessment, we estimated the fair value of the reporting unit by considering a discounted cash flow valuation approach (&#8220;income approach&#8221;). In determining the estimated fair value in a quantitative analysis, we projected future cash flows based on management&#8217;s estimates and long-term plans and applied a discount rate based on the Company&#8217;s weighted average cost of capital. This analysis required us to make judgments about revenues, expenses, fixed asset and working capital requirements, capital market assumptions, cash flows and discount rates.  </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of May 31, 2020, we determined that the reporting unit under review had an estimated fair value less than its carrying value.  As a result, we recorded a non-cash goodwill impairment charge of $215.1&#160;million on our consolidated statements of operations and comprehensive income (loss) for the three and six months ended June 30, 2020. In addition, the Company reviewed its interim goodwill impairment analysis as of June 30, 2020 and did not identify any additional information or events that would contradict or change the conclusion reached by the Company as of May 31, 2020. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended September 30, 2020, we evaluated qualitative factors that could indicate the fair value of each of our reporting units may be lower than the carrying value. We did not identify any qualitative factors that would trigger a quantitative goodwill impairment test during the three months ended September 30, 2020. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the Company&#8217;s annual impairment analysis as of October 31, 2020, the Company concluded that previous impairment charges of $199.8&#160;million and $215.1&#160;million recorded during the three months ended December 31, 2019 and June 30, 2020, respectively, in one of our two reporting units in the EHS segment left that specific reporting unit with a limited fair value cushion. Therefore, the Company elected to forego the qualitative assessment and proceed directly to the quantitative assessment of the goodwill impairment test for that specific reporting unit. This election does not preclude management from performing the qualitative assessment in any subsequent period. For the remaining reporting units, after assessing the totality of events and circumstances including the results of our previous valuations, the minimal impacts of the Passport loss and COVID-19, the Company does not believe that an event occurred or circumstances changed during the period under consideration that would, more likely than not, reduce the fair value of any reporting unit below their carrying amount. Therefore, the Company concluded that the quantitative assessment was not required. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In performing our October 31, 2020 impairment test for one of the specific reporting units referenced above, we estimated the fair value of our reporting units by considering a discounted cash flow valuation approach (&#8220;income approach&#8221;). In determining the estimated fair value using the income approach, we projected future cash flows based on management&#8217;s estimates and long-term plans and applied a discount rate based on the Company&#8217;s weighted average cost of capital. This analysis required us to make judgments about revenues, expenses, fixed asset and working capital requirements, capital market assumptions, cash flows and discount rates. As of October 31, 2020, we determined that the specific reporting unit had an estimated fair value greater than its carrying value and as a result, goodwill is not impaired.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2020, the Company assessed whether there were additional events or changes in circumstances since its annual goodwill impairment test that would indicate that it was more likely than not that the fair value of the reporting unit was less than the reporting unit&#8217;s carrying amounts that would require an interim impairment assessment after October 31, 2020. The Company </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">determined there had been no such indicators, therefore, we did not perform an interim goodwill impairment assessment as of December 31, 2020. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Change in Goodwill</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the changes in the carrying amount of goodwill, by reportable segment, for the periods presented (in thousands):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:60.705%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.983%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.772%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.983%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.772%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.985%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">EHS</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Clinical Solutions</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Consolidated</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of December 31, 2019 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">431,684&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">134,675&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">566,359&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill disposal </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,200)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,200)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Impairment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(215,100)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(215,100)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency translation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(30)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(30)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of December 31, 2020</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">214,354&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">134,675&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">349,029&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill acquired</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77,288&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77,288&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency translation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(20)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(20)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of December 31, 2021</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">214,334&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">211,963&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">426,297&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt">Net of cumulative inception to date impairment of $575.5 million and $360.4 million as of December 31, 2020 and 2019, respectively.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt">Goodwill written-off upon disposal of a consolidated subsidiary.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Intangible Assets, Net</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Details of our intangible assets (in thousands, except weighted-average useful lives) as of December&#160;31, 2021 and December&#160;31, 2020  are presented below:</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"/><td style="width:72.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:54.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:48.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:63.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:46.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:54.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:48.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:63.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:45.25pt"/><td style="width:1.0pt"/></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr style="height:44pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted- Average Remaining Useful Life</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross Carrying Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Accumulated Amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net Carrying Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted- Average Remaining Useful Life</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross Carrying Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Accumulated Amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net Carrying Value</span></td></tr><tr style="height:24pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate trade name</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.4</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,800&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,693&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,107&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.2</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,300&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,271&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,029&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:24pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer relationships </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.9</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">311,019&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72,697&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">238,322&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.2</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">278,519&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57,716&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">220,803&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Technology</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.0</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87,922&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73,378&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,544&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.8</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">82,922&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63,507&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,415&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:24pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Below market lease, net</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.3</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,218&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">950&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">268&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.3</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,118&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">648&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">470&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:35pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provider network contracts </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.2</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,417&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,874&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,543&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.9</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,175&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,900&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,275&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:35pt"><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total intangible assets, net</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">442,376&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">162,592&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">279,784&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">398,034&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">133,042&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">264,992&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt">Amounts exclude $2.2&#160;million and $0.9&#160;million of customer relationships and provider network contracts, respectively, net of accumulated amortization, with weighted average remaining useful lives of 15 years and 10 months reclassified to discontinued operations as of December&#160;31, 2020.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amortization expense related to intangible assets for the years ended December 31, 2021, 2020 and 2019, was $29.4 million, $32.3 million and $37.1 million respectively, excluding $0.2&#160;million, $0.6&#160;million and $0.6&#160;million of amortization expense related to discontinued operations for the years ended December 31, 2021, 2020 and 2019, respectively.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Future estimated amortization of intangible assets (in thousands) as of December&#160;31, 2021, is as follows:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"/><td style="width:478.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:58.00pt"/><td style="width:1.0pt"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,102&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,798&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,913&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,403&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,153&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">164,415&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total future amortization of intangible assets</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">279,784&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets are reviewed for impairment if circumstances indicate the Company may not be able to recover the assets&#8217; carrying value. We did not identify any circumstances during&#160;the year ended December 31, 2021, that would require an impairment test for our intangible assets.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -URI http://asc.fasb.org/topic&amp;trid=2144416<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139858983547080">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Long-term Debt<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">Long-term Debt</a></td>
<td class="text">Long-term Debt<div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2024 Notes</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2020, the Company issued $117.1&#160;million aggregate principal amount of its 3.50% Convertible Senior Notes due 2024 (the &#8220;2024 Notes&#8221;) in privately negotiated exchange and/or subscription agreements, with certain holders of its outstanding 2021 Notes and certain new investors. The Company issued $84.2 million aggregate principal amount of 2024 Notes in exchange for $84.2 million aggregate principal amount of the 2021 Notes and an aggregate cash payment of $2.5&#160;million, and issued $32.8 million aggregate principal amount of New Notes for cash at par. We incurred $3.0&#160;million of debt issuance costs in connection with the 2024 Notes, which we are amortizing to non-cash interest expense using the straight-line method over the contractual term of the 2024 Notes. The closing of the private placement of the 2024 Notes occurred on August 19, 2020.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Holders of the 2024 Notes are entitled to cash interest payments, which are payable semiannually in arrears on June 1 and December 1 of each year, beginning on December 1, 2020, at a rate equal to 3.50% per annum. The 2024 Notes will mature on December 1, 2024, unless earlier repurchased, redeemed or converted in accordance with their terms prior to such date. Upon maturity the principal amount of the notes may be settled via shares of the Company&#8217;s Class A common stock. We recorded interest expense of $4.1 million and $1.5 million for the years ended December 31, 2021 and 2020, respectively.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2024 Notes are convertible into cash, shares of the Company's Class A common stock, or a combination of cash and shares of the Company's Class A common stock, at the Company's election, based on an initial conversion rate of 54.8667 shares of Class A common stock per $1,000 principal amount of the 2024 Notes, which is equivalent to an initial conversion price of approximately $18.23 per share of the Company&#8217;s Class A common stock. In the aggregate, the 2024 Notes are initially convertible into 6.4&#160;million shares of the Company&#8217;s Class A common stock (excluding any shares issuable by the Company upon a conversion in connection with a make-whole provision upon a fundamental change or a notice of redemption under the governing indenture). The conversion rate may be adjusted under certain circumstances. Upon conversion, the Company will pay or deliver, as the case may be, cash or shares of the Company&#8217;s Class A common stock, or a combination of cash and shares of the Company&#8217;s Class A common stock, at the Company&#8217;s election.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The option to settle the 2024 Notes in cash or shares of the Company&#8217;s Class A common stock, or a combination of cash and shares of the Company&#8217;s Class A common stock, at the Company&#8217;s election, resulted in a bifurcation of the carrying value of the 2024 Notes into a debt component and an equity component. The debt component was determined to be $78.9&#160;million, before issuance costs, based on the fair value of a nonconvertible debt instrument with the same term. The equity component was determined to be $38.1&#160;million before issuance costs and was recorded within additional paid-in capital. The equity component is the difference between the aggregate principal amount of the debt and the fair value of the debt component. Issuance costs of $1.7&#160;million and $1.3&#160;million are allocated to the debt and equity components in proportion to the allocation of proceeds. Along with the equity component of $38.1&#160;million, $1.7&#160;million of issuance costs will be amortized to interest expense on the consolidated statements of operations and comprehensive income (loss) using the effective interest method over the contractual term of the 2024 Notes. The equity component recorded within additional paid-in capital will not be remeasured as long as it meets the conditions for equity classification. The Company recorded $7.9 million and $2.7 million of interest expense related to the amortization of the debt discount and the issuance costs allocated to the debt component for the years ended December 31, 2021 and 2020, respectively.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Holders of the 2024 Notes may require the Company to repurchase all or part of their notes upon the occurrence of a fundamental change at a price equal to 100.0% of the principal amount of the notes being repurchased, plus any accrued and unpaid interest to, but excluding, the fundamental change repurchase date. The Company may not redeem the 2024 Notes prior to March 1, 2023. The Company may redeem for cash all or any portion of the 2024 Notes, at its option, on or after March 1, 2023, if the last reported sale price of the Company&#8217;s Class A common stock has been at least 130.0% of the conversion price then in effect for at least 20 trading </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">days (whether or not consecutive) during any 30 consecutive trading day period (including the last trading day of such period) ending on, and including, the trading day immediately preceding the date on which the Company provides notice of redemption, at a redemption price equal to 100.0% of the principal amount of the notes to be redeemed, plus accrued and unpaid interest to, but excluding, the redemption date.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Credit Agreement</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 30, 2019, the Company entered into a credit agreement, by and among the Company, Evolent Health LLC, as the borrower (the &#8220;Borrower&#8221;), certain subsidiaries of the Company, as guarantors, the lenders from time to time party thereto, and Ares Capital Corporation, as administrative agent and collateral agent, together with the Company (the &#8220;Credit Agreement&#8221;), pursuant to which the lenders agreed to extend credit to the Borrower in the form of (i) an initial secured term loan in the aggregate principal amount of $75.0 million (the &#8220;Initial Term Loan Facility&#8221;) and (ii) a delayed draw secured term loan facility in the aggregate principal amount of up to $50.0 million (the &#8220;DDTL Facility&#8221; and, together with the Initial Term Loan Facility, the &#8220;Senior Credit Facilities&#8221;), subject to the satisfaction of specified conditions. The Borrower borrowed the loan under the Initial Term Loan Facility on December 30, 2019. In connection with the Credit Agreement, on December 30, 2019, the Company entered into a Security Agreement, by and among the Company, the Borrower, the other guarantors and the collateral agent for the benefit of the secured parties, and a Guarantee Agreement, by the Company and each of the other guarantors in favor of the collateral agent for the benefit of the secured parties. The Senior Credit Facilities were guaranteed by the Company and the Company&#8217;s domestic subsidiaries, subject to certain exceptions. The Senior Credit Facilities were secured by a first priority security interest in all of the capital stock of the borrower and each guarantor (other than the Company) and substantially all of the assets of the borrower and each guarantor, subject to certain exceptions. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The proceeds of the Initial Term Loan were used to finance the transactions contemplated by the Passport APA and pay fees and expenses incurred in connection therewith. The proceeds of the DDTL Facility were permitted to be used, subject to the Company&#8217;s satisfaction of specified conditions, to finance the repayment or repurchase of the Company&#8217;s 2.00% Convertible Senior Notes due December 1, 2021 and to fund permitted acquisitions. &#160;The Initial Term Loan and any loans under the DDTL Facility would have matured on the date that is the earliest of (a) December 30, 2024, (b) the date on which all amounts outstanding under the Credit Agreement would have been declared or have automatically become due and payable under the terms of the Credit Agreement and (c) the date that is ninety-one (91) days prior to the maturity date of the 2021 Convertible Notes unless certain liquidity conditions were satisfied (the foregoing, the &#8220;Maturity Date&#8221;). The interest rate for each loan under the Senior Credit Facilities was calculated, at the option of the Borrower, at either the Eurodollar rate plus 8.00%, or the base rate plus 7.00%. A commitment fee of 1.00% per annum was payable by the Borrower quarterly in arrears on the unused portion of the DDTL Facility. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amounts outstanding under the Senior Credit Facilities could have been prepaid at the option of the Borrower subject to applicable premiums, including a make-whole premium payable on certain prepayments made prior to the second anniversary of the closing of the Senior Credit Facilities, and a call protection premium payable on the amount prepaid in certain instances as follows: (i) 4.00% of the principal amount so prepaid after the second anniversary of the closing of the Senior Credit Facilities but prior the third anniversary of the closing of the Senior Credit Facilities; (ii) 3.00% of the principal amount so prepaid after the third anniversary of the closing of the Senior Credit Facilities but prior the fourth anniversary of the closing of the Senior Credit Facilities; and (iii) 2.00% of the principal amount so prepaid after the fourth anniversary of the closing of the Senior Credit Facilities but prior the fifth anniversary of the closing of the Senior Credit Facilities. Amounts outstanding under the Senior Credit Facility were subject to mandatory prepayment upon the occurrence of certain events and conditions, including non-ordinary course asset dispositions, receipt of certain casualty proceeds, issuances of certain debt obligations and a change of control transaction.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Senior Credit Facilities contained customary borrowing conditions, affirmative, negative and reporting covenants, representations and warranties, and events of default, including cross-defaults to other material indebtedness. In addition, the Company was required to comply at certain times with certain financial covenants comprised of a minimum net revenue test and a minimum liquidity test commencing upon closing of the Senior Credit Facilities and a total secured leverage ratio commencing on the last day of the fiscal quarter ending March 31, 2021. If an event of default had occurred, the lenders would be entitled to take enforcement action, including foreclosure on collateral and acceleration of amounts owed under the Senior Credit Facilities. We incurred $4.7 million of debt issuance costs in connection with this Credit Agreement, which was included in long-term debt, net of discount on our consolidated balance sheets and amortized into interest expense over the life of the agreement. The Company recorded $2.2&#160;million in interest expense related to the amortization of the debt discount and the issuance costs for the year ended December 31, 2020.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 19, 2020, an amendment to the Company's Credit Agreement became effective. The amendment effected changes to, among other things, permit the Company's use of cash in the exchange transactions in connection with the issuance of the 2024 Notes, permit the issuance of the 2024 Notes and permit certain note repurchases, as well as to implement amendments to certain minimum liquidity thresholds.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 8, 2021, the Company repaid all outstanding amounts owed under and terminated the Credit Agreement with Ares Capital Corporation. The total amount paid to Ares Capital Corporation under the Credit Agreement in connection with the prepayment was </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$98.6&#160;million, which included $9.7&#160;million for the make-whole premium as well as $0.2&#160;million in accrued interest. As a result of this transaction, the Company recorded a loss on the repayment of debt of $19.2&#160;million, representing the remaining unamortized debt issuance costs of $9.5&#160;million, the make-whole premium and $35&#160;thousand of legal expenses.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Warrant Agreement</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In conjunction with the Company&#8217;s entry into the Credit Agreement, the Company entered into warrant agreements whereby it agreed to sell to the holders of the warrants an aggregate of 1,513,786 shares of Class A common stock at a per share purchase price equal to $8.05. The holders could exercise the warrants at any time until thirty days after the maturity of the Credit Agreement.  The Company, at its sole discretion, could elect to pay the holders in cash in an amount determined based on the fair market value of the Class A common stock for the shares of Class A common stock issuable upon exercise of the warrants in lieu of delivering the shares.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 8, 2021, the Company settled the outstanding warrants associated with the Credit Agreement for $13.7&#160;million.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2025 Notes</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2018, the Company issued $172.5 million aggregate principal amount of its 1.50% Convertible Senior Notes due 2025 (the &#8220;2025 Notes&#8221;) in a private placement to qualified institutional buyers within the meaning of Rule 144A under the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;). The 2025 Notes were issued at par for net proceeds of $166.6 million. We incurred $5.9 million of debt issuance costs in connection with the 2025 Notes. The closing of the private placement of $150.0 million aggregate principal amount of the 2025 Notes occurred on October&#160;22, 2018 and the Company completed the offering and sale of an additional $22.5 million aggregate principal amount of the 2025 Notes on October&#160;24, 2018, pursuant to the initial purchasers&#8217; exercise in full of their option to purchase additional notes.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Holders of the 2025 Notes are entitled to cash interest payments, which are payable semiannually in arrears on&#160;April 15&#160;and&#160;October 15&#160;of each year, beginning on&#160;April&#160;15, 2019, at a rate equal to&#160;1.50%&#160;per annum. The Company recorded interest expense of $2.6 million for the years ended December 31, 2021, 2020 and 2019, respectively. The 2025 Notes will mature on&#160;October&#160;15, 2025, unless earlier repurchased, redeemed or converted in accordance with their terms prior to such date.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prior to the close of business on the business day immediately preceding April&#160;15, 2025, the 2025 Notes will be convertible at the option of the holders only upon the satisfaction of certain conditions, as described in the indenture, dated as of October&#160;22, 2018, between the Company and U.S. Bank National Association, as trustee. At any time on or after April&#160;15, 2025, until the close of business on the business day immediately preceding the maturity date, holders may convert, at their option, all or any portion of their notes at the conversion rate.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2025 Notes will be convertible at an initial conversion rate of 29.9135 shares of Class A common stock per $1,000 principal amount of notes, which is equivalent to an initial conversion price of approximately $33.43 per share of the Company&#8217;s Class A common stock. In the aggregate, the 2025 Notes are initially convertible into 5.2 million shares of the Company&#8217;s Class A common stock (excluding any shares issuable by the Company upon a conversion in connection with a make-whole fundamental change or a notice of redemption as described in the governing indenture). The conversion rate may be adjusted under certain circumstances. Upon conversion, the Company will pay or deliver, as the case may be, cash or shares of the Company&#8217;s Class A common stock, or a combination of cash and shares of the Company&#8217;s Class A common stock, at the Company&#8217;s election.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The option to settle the 2025 Notes in cash or shares of the Company&#8217;s Class A common stock, or a combination of cash and shares of the Company&#8217;s Class A common stock, at the Company&#8217;s election, resulted in a bifurcation of the carrying value of the 2025 Notes into a debt component and an equity component. The debt component was determined to be $100.7 million, before issuance costs, based on the fair value of a nonconvertible debt instrument with the same term. The equity component was determined to be $71.8 million, before issuance costs, and was recorded within additional paid-in capital. The equity component is the difference between the aggregate principal amount of the debt and the debt component. Issuance costs of $3.4 million and $2.5 million are allocated to the debt and equity components in proportion to the allocation of proceeds. Along with the equity component of $71.8 million, $3.4 million of issuance costs will be amortized to interest expense on the consolidated statements of operations and comprehensive income (loss) using the effective interest method over the contractual term of the 2025 Notes. The equity component recorded within additional paid-in capital will not be remeasured as long as it meets the conditions for equity classification. The Company recorded $10.0 million, $9.2 million and $8.5 million for the years ended December 31, 2021, 2020 and 2019 respectively, in interest expense related to the amortization of the debt discount and the issuance costs allocated to the debt component.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Holders of the 2025 Notes may require the Company to repurchase all or part of their notes upon the occurrence of a fundamental change at a price equal to 100.0% of the principal amount of the notes being repurchased, plus any accrued and unpaid interest to, but excluding, the fundamental change repurchase date. The Company may not redeem the 2025 Notes prior to October&#160;20, 2022. The Company may redeem for cash all or any portion of the 2025 Notes, at its option, on or after October&#160;20, 2022, if the last reported sale </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">price of the Company&#8217;s Class A common stock has been at least 130.0% of the conversion price then in effect for at least 20 trading days (whether or not consecutive) during any 30 consecutive trading day period (including the last trading day of such period) ending on, and including, the trading day immediately preceding the date on which the Company provides notice of redemption, at a redemption price equal to 100.0% of the principal amount of the notes to be redeemed, plus accrued and unpaid interest to, but excluding, the redemption date.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2021 Notes</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2016, the Company issued $125.0 million aggregate principal amount of its 2.00% Convertible Senior Notes due 2021 (the &#8220;2021 Notes&#8221;) in a private placement to qualified institutional buyers within the meaning of Rule 144A under the Securities Act. The 2021 Notes were issued at par for net proceeds of $120.4 million. We incurred $4.6 million of debt issuance costs in connection with the 2021 Notes, which we amortized to non-cash interest expense using the straight-line method over the contractual term of the 2021 Notes, since this method was not materially different from the effective interest method. The closing of the private placement of the 2021 Notes occurred on December&#160;5, 2016.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Holders of the 2021 Notes were entitled to cash interest payments, which were paid semiannually in arrears on June 1 and December 1 of each year, beginning on June&#160;1, 2017, at a rate equal to 2.00% per annum. The 2021 Notes matured on December&#160;1, 2021. We recorded interest expense of $0.5 million, $1.7 million and $2.5 million for the years ended December 31, 2021, 2020 and 2019, respectively. We recorded non-cash interest expense related to the amortization of deferred financing costs of $0.2 million, $0.6 million and $0.9 million for the years ended December 31, 2021, 2020 and 2019, respectively.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2020, as part of the issuance of the 2024 Notes, the Company issued $84.2&#160;million aggregate principal amount of the 2024 Notes in exchange for $84.2&#160;million aggregate principal of its 2021 Notes. There was no cash consideration in these exchanges outside of an aggregate cash payment of $2.5&#160;million paid to exchanging noteholders. These exchanges were accounted for as an extinguishment resulting in a net loss on extinguishment of debt of $4.8&#160;million, including an aggregate cash payment of $2.5&#160;million paid to exchanging noteholders. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2020, we also repurchased $14.0&#160;million of the 2021 Notes with $13.9&#160;million of cash and recorded an immaterial gain on extinguishment of debt.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon maturity of the 2021 Notes on December 1, 2021, outstanding 2021 Notes with a principal amount of $26.7&#160;million were settled, at the option of the holders, by converting $26.3&#160;million aggregate principal amount of 2021 Notes to common shares and cash repayment of $0.4&#160;million aggregate principal amount of 2021 Notes. Shares issued were valued based on the quoted trading prices on the conversion date for a total fair value of $28.5&#160;million resulting in a loss on debt extinguishment of $2.2&#160;million which was recorded in loss on repayment of debt on our consolidated statements of operations and comprehensive income (loss).</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Convertible Senior Notes Carrying Value</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2025 Notes and 2024 Notes are recorded on our accompanying consolidated balance sheets at their net carrying values as of December&#160;31, 2021. However, the 2025 Notes and 2024 Notes are privately traded by qualified institutional buyers (within the meaning of Rule 144A under the Securities Act) and their fair values are Level 2 inputs. The 2025 Notes and 2024 Notes also have embedded conversion options and contingent interest provisions, which have not been recorded as separate financial instruments. The following table summarizes the carrying value of the long-term convertible debt as of December&#160;31, 2021 and 2020 (in thousands):</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"/><td style="width:409.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:60.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:60.25pt"/><td style="width:1.0pt"/></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024 Notes</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Carrying value</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">89,361&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81,462&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unamortized debt discount and issuance costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,690&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,589&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Principal amount</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">117,051&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">117,051&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Remaining amortization period (years)</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.9</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.9</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">195,445&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">153,220&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2025 Notes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Carrying value</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">126,315&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">116,349&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unamortized debt discount and issuance costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46,185&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56,151&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Principal amount</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">172,500&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">172,500&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Remaining amortization period (years)</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.8</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.8</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">177,251&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">147,488&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021 Notes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Carrying value</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,557&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unamortized debt discount and issuance costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">180&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Principal amount</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,737&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Remaining amortization period (years)</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.0</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.9</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,470&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:5pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt">Fair values for notes are derived from available trading prices closest to the respective balance sheet date.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -URI http://asc.fasb.org/topic&amp;trid=2208564<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139858983548472">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text">Commitments and Contingencies <div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Commitments</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Letters of Credit</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2021 and 2020, the Company was party to irrevocable standby letters of credit&#160;with a bank for&#160;$15.4 million&#160;and $8.3&#160;million, respectively, for the benefit of a regulatory authorities, real estate and risk-sharing agreements. As such, we held $15.4 million and $8.3&#160;million in restricted cash and restricted investments as collateral as of December&#160;31, 2021 and December&#160;31, 2020, respectively. The letters of credit have current expiration dates between January 2022 and March 2032 and will automatically extend without amendment for an additional one-year period and will continue to automatically extend after each one-year term from the expiry date unless the bank elects not to extend beyond the initial or any extended expiry date. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Indemnifications</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s customer agreements generally include a provision by which the Company agrees to defend its partners against third-party claims (a) for death, bodily injury, or damage to personal property caused by Company negligence or willful misconduct, (b) by former or current Company employees arising from such managed service agreements, (c) for intellectual property infringement under specified conditions and (d) for Company violation of applicable laws, and to indemnify them against any damages and costs awarded in connection with such claims. To date, the Company has not incurred any material costs as a result of such indemnities and has not accrued any liabilities related to such obligations in the accompanying consolidated financial statements.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Pre-IPO Investor Registration Rights Agreement</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We entered into a registration rights agreement with The Advisory Board, UPMC, TPG and another investor to register for sale under the Securities Act shares of our Class A common stock, including those delivered in exchange for Class B common stock and Class B common units. Subject to certain conditions and limitations, this agreement provides these investors with certain demand, piggyback and shelf registration rights. The registration rights granted under the registration rights agreement will terminate upon the date the holders of shares that are a party thereto no longer hold any such shares that are entitled to registration rights. Pursuant to our contractual obligations under this agreement, we filed a registration statement on Form S-3 with the SEC on July 28, 2016, which was declared effective on August 12, 2016.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We will pay all expenses relating to any demand, piggyback or shelf registration, other than underwriting discounts and commissions and any transfer taxes, subject to specified conditions and limitations. The registration rights agreement includes customary indemnification provisions, including indemnification of the participating holders of shares of Class A common stock and their directors, officers and employees by us for any losses, claims, damages or liabilities in respect thereof and expenses to which such holders may become subject under the Securities Act, state law or otherwise. We did not incur any expenses related to secondary offerings or other sales of shares by our investor stockholders during the years ended December 31, 2021, 2020 and 2019, respectively. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Guarantees</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In connection with the Molina Closing, the Company continued to provide administrative support services relating to the Passport Medicaid Contract to Molina through the end of 2020. Following the Molina Closing, EVH Passport began working with regulatory authorities including the Kentucky Department of Insurance (&#8220;KY DOI&#8221;) regarding the wind down of its operations throughout 2021. As part of that wind down process, the Company, as the parent of EVH Passport, entered into a guarantee for the benefit of the KY DOI to satisfy any EVH Passport liability or obligation in the event EVH Passport is not able to meet its wind down liabilities or obligations. As of December&#160;31, 2021, no amounts have been funded under this guarantee.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Reinsurance Agreements</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of the Passport Closing, EVH Passport and UHC entered into an agreement that provided for the administration and assumption of the financial risks by EVH Passport of the D-SNP Business until such time as EVH Passport became certified as a Medicare Advantage Organization and the D-SNP Business could be transferred to EVH Passport.  On October 1, 2020, the D-SNP Business was transferred from UHC to EVH Passport.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the Molina Closing, Molina and EVH Passport entered into an agreement that provided for the assumption of the financial risks by Molina of the D-SNP Business until such time as Molina&#8217;s Kentucky health plan becomes certified as a Medicare Advantage Organization and the D-SNP Business is transferred to Molina. The Company and EVH Passport continued to administer the D-SNP Business until January 1, 2021, at which time Molina became responsible for its administration until the D-SNP Business was officially transferred to Molina effective September 1, 2021.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following summarizes premiums and claims assumed under the Reinsurance Agreements for the years ended December 31, 2021, 2020 and 2019 (in thousands):</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"/><td style="width:387.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:46.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:46.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:46.00pt"/><td style="width:1.0pt"/></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Year Ended December 31,</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reinsurance premiums assumed</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,179&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,130&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">83,325&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reinsurance premiums ceded</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,614)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,275)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Claims assumed</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,468&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,812&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72,594&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Claims ceded</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(422)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Claims-related administrative expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,159&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,024&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:24pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Increase (decrease) in reserves for claims and performance-based arrangements attributable to the Reinsurance Agreement</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,166&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,465&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,293)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:24pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reserves for claims and performance-based arrangements attributable to the Reinsurance Agreement at the beginning of the period</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,002&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,243&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:23pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Impact of consolidation on payable for claims and performance-based arrangements attributable to the Reinsurance Agreement</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(502)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reinsurance payments paid (received)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,078&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,039)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,536&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:24pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payable for claims and performance-based arrangements attributable to the Reinsurance Agreement at the end of the period</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">90&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,002&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">UPMC Reseller Agreement</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company and UPMC are parties to a reseller, services and non-competition agreement, dated August 31, 2011, which was amended and restated by the parties on June 27, 2013 (as amended through the date hereof, the &#8220;UPMC Reseller Agreement&#8221;). Under the terms of the UPMC Reseller Agreement, UPMC has appointed the Company as a non-exclusive reseller of certain services, subject to certain conditions and limitations specified in the UPMC Reseller Agreement. In consideration for the Company&#8217;s obligations under the UPMC Reseller Agreement and subject to certain conditions described therein, UPMC has agreed not to sell certain products and services directly to a defined list of 20 of the Company&#8217;s customers.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Contingencies</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Tax Receivables Agreement</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Offering Reorganization, the Company entered into the Tax Receivables Agreement (the &#8220;TRA&#8221;) with certain of its investors, which provides for the payment by the Company to these investors of 85% of the amount of the tax benefits, if any, that the Company is deemed to realize as a result of increases in our tax basis related to exchanges of Class B common units as well as tax benefits attributable to the future utilization of pre-IPO NOLs. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Due to the items noted above, and the fact that Evolent Health, Inc. is in a full valuation allowance position such that the deferred tax assets related to the Company&#8217;s historical pre-IPO losses and tax basis increase benefit from exchanges have not been realized, the Company has not recorded a liability pursuant to the TRA.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Litigation Matters</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are engaged from time to time in certain legal disputes arising in the ordinary course of business, including employment claims. When the likelihood of a loss contingency becomes probable and the amount of the loss can be reasonably estimated, we accrue a liability for the loss contingency. We continue to review accruals and adjust them to reflect ongoing negotiations, settlements, rulings, advice of legal counsel, and other relevant information. To the extent new information is obtained, and our views on the probable outcomes of claims, suits, assessments, investigations or legal proceedings change, changes in our accrued liabilities would be recorded in the period in which such determination is made.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 8, 2019, a shareholder of the Company filed a class action complaint against the Company, asserting claims under Section 10(b) and 20(a) of the Securities Exchange Act of 1934, in the United States District Court, Eastern District of Virginia, Alexandria Division. An amended complaint was filed on January 10, 2020, a second amended complaint was filed on June 8, 2020, and a third amended complaint, now titled </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Plymouth County Retirement System v. Evolent Health, Inc., Frank Williams, Nicholas McGrane, Seth Blackley</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, was filed on December 2, 2021. The case alleges that the Company&#8217;s executives made false or misleading statements regarding its business with Passport. The Company filed a motion to dismiss the second amended complaint, and the Eastern District of Virginia granted in part and denied in part the motion on March 24, 2021. The case entered the discovery phase, but discovery is again stayed pending a decision on the company&#8217;s third motion to dismiss, which was filed December 17, 2021. Briefing on the motion to dismiss was completed on February 10, 2022, and oral argument will be held on March 11, 2022.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Based on the Company&#8217;s investigation, we believe the case has little legal or factual merit. However, the outcome of any litigation is uncertain.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 8, 2021, a shareholder of the Company filed a derivative action in the Delaware Chancery Court against some current and former Board members and against the Company as a nominal defendant, alleging that the Company&#8217;s Board was negligent in its oversight of the Company&#8217;s relationship with Passport Health Plan. The case is Lincolnshire Police Pension Fund, derivatively on behalf of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Evolent Health, Inc., v. Blackley, Williams, Scott, Holder, Farner, D&#8217;Amato, Duffy, Felt, Samet, Hobart, and Payson</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and Evolent Health, Inc. The Company and the Director-Defendants filed a motion to dismiss the complaint on August 27, 2021, and Plaintiffs responded by filing an amended complaint on October 26, 2021. Defendants filed a motion to dismiss the amended complaint on December 17, 2021.  Subsequently, the parties agreed to stay the case pending the decision on the Company&#8217;s motion to dismiss the third amended complaint, currently pending in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Plymouth County Retirement System v. Evolent Health, Frank Williams, Nicky McGrane, and Seth Blackley</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, in federal district court. Based on the Company&#8217;s investigation, we believe the case has little legal or factual merit. However, the outcome of any litigation is uncertain.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Credit and Concentration Risk</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is subject to significant concentrations of credit risk related to cash and cash equivalents and accounts receivable. As of December&#160;31, 2021, approximately 99.4% of our $354.9 million of cash and cash equivalents, restricted cash and restricted investments were held in bank deposits with FDIC participating banks and approximately 0.6% were held in international banks. While the Company maintains its cash and cash equivalents with financial institutions with high credit ratings, it often maintains these deposits in federally insured financial institutions in excess of federally insured limits. The Company has not experienced any realized losses on cash and cash equivalents to date.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is also subject to significant concentration of accounts receivable risk as a substantial portion of our trade accounts receivable is derived from a small number of our partners. The following table summarizes the partners who represented at least 10.0% of our consolidated trade accounts receivable as of December&#160;31, 2021 and December&#160;31, 2020:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"/><td style="width:426.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:55.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:48.25pt"/><td style="width:1.0pt"/></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31,</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cook County Health and Hospitals System</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61.5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Florida Blue Medicare, Inc. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">N/A</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Molina Healthcare</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:115%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%;padding-left:11.94pt">Customer added during the year ended December 31, 2021. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the Company is subject to significant concentration of revenue risk as a substantial portion of our revenue is derived from a small number of contractual relationships with our operating partners.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes those partners who represented at least 10.0% of our consolidated revenue for the years ended December 31, 2021, 2020 and 2019:</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"/><td style="width:380.50pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:48.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:48.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:48.25pt"/><td style="width:1.0pt"/></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Year Ended December 31,</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cook County Health and Hospitals Systems</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28.0%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">New Mexico Health Connections</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Florida Blue Medicare, Inc. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">N/A</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Passport </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt">The denominator excludes $44.8&#160;million, $117.4&#160;million and $171.7&#160;million of True Health premium revenue reclassified to discontinued operations for the years ended December 31, 2021, 2020 and 2019, respectively.</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt">Customer added during the year ended December 31, 2021.</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt">Represents revenues from EVH Passport/UHC through the Molina Closing. Subsequent to the Molina Closing on September 1, 2020, the Company has not received any material revenue from EVH Passport. However, as part of the Molina Closing, we entered into a new contract with Molina on similar terms to our prior services contract with EVH Passport through December 31, 2020 which accounted for approximately 9.7% of our consolidated revenues for the year ended December 31, 2020.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">* &#160;&#160;&#160;&#160;Represents less than 10.0% of the respective balance</span></div>We derive a significant portion of our revenues from our largest partners. The loss, termination or renegotiation of our relationship or contract with any significant partner or multiple partners in the aggregate could have a material adverse effect on the Company's financial condition and results of operations.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI http://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI http://asc.fasb.org/topic&amp;trid=2144648<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 440<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6491277&amp;loc=d3e6429-115629<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139859059283544">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeasesTextBlock', window );">Leases</a></td>
<td class="text">Leases<div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company enters into various office space, data center, and equipment lease agreements in conducting its normal business operations. At the inception of any contract, the Company evaluates the agreement to determine whether the contract contains a lease. If the contract contains a lease, the Company then evaluates the term and whether the lease is an operating or finance lease. Most leases include one or more options to renew or may have a termination option. The Company determines whether these options are reasonably certain to be exercised or not at the inception of the lease. In addition, some leases contain escalation clauses.  The rent expense is recognized on a straight-line basis in the consolidated statements of operations and comprehensive income (loss) over the term of the lease. Leases with an initial term of 12 months or less are not recorded on our consolidated balance sheets.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As most of our leases do not provide an implicit rate, we use our incremental borrowing rate based on the information available at commencement date in determining the present value of lease payments. We use the implicit rate when readily determinable. Further, the Company treats all lease and non-lease components as a single combined lease component for all classes of underlying assets. The </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Company also enters into sublease agreements for some of its leased office space. Immaterial rental income attributable to subleases is offset against rent expense over the terms of the respective leases. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company leases office space and computer and other equipment under operating lease agreements expiring at various dates through 2031. Under the lease agreements, in addition to base rent, the Company is generally responsible for operating and maintenance costs and related fees. Several of these agreements include tenant improvement allowances, rent holidays or rent escalation clauses. When such items are included in a lease agreement, we record a deferred rent asset or liability on our consolidated balance sheets equal to the difference between rent expense and future minimum lease payments due. The rent expense related to these items is recognized on a straight-line basis over the terms of the leases. The Company&#8217;s primary office location is in Arlington, Virginia, which has served as its corporate headquarters since 2013. The Arlington, Virginia office lease expires in January 2032. Certain leases acquired as part of the Valence Health transaction included existing sublease agreements for office locations in Chicago, Illinois. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with various lease agreements, the Company is required to maintain $3.8 million and $3.5&#160;million in letters of credit as of December&#160;31, 2021 and December&#160;31, 2020. As of December&#160;31, 2021 and 2020, the Company held $3.8&#160;million and $3.5 million in restricted cash and restricted investments on the consolidated balance sheet as collateral for the letters of credit, respectively.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our primary office leases as of December&#160;31, 2021 (in thousands, other than term):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:539.25pt"><tr><td style="width:1.0pt"/><td style="width:237.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:94.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:94.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:94.00pt"/><td style="width:1.0pt"/></tr><tr style="height:24pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Location</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Lease Termination Term (in years)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Future Minimum Lease Commitments</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Letter of Credit Amount Required</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Arlington, VA</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.1</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,581&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,579&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Riverside, IL </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.3</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41,408&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">232&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Edison, NJ</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.3</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,180&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">222&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pune, India</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.7</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,382&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Brea, CA</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.4</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">462&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the components of our lease expense (in thousands): </span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:64.316%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.011%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.011%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.013%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease cost</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,991&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,848&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,903&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of right-of-use assets</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">299&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">598&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Variable lease cost</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,036&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,097&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,177&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease cost</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,027&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,247&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,704&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Maturity of lease liabilities (in thousands) as of December&#160;31, 2021, is as follows:</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:87.788%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.012%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Operating lease expense</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,916&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,258&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,968&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,653&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,988&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,972&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease payments</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85,755&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,964&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Present value of lease liabilities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64,791&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our weighted-average discount rate and our weighted remaining lease terms (in years) are as follows:</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:64.455%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.011%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.011%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.013%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average discount rate</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.38&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.44&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.25&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average remaining lease term</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.8</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.4</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.9</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -URI http://asc.fasb.org/subtopic&amp;trid=77888251<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139858982759096">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings (Loss) Per Common Share<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Earnings (Loss) Per Common Share</a></td>
<td class="text">Earnings (Loss) Per Common Share<div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth the computation of basic and diluted earnings per share available for common stockholders (in thousands, except per share data):</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"/><td style="width:351.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:58.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:58.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:58.00pt"/><td style="width:1.0pt"/></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Year Ended December 31,</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss from continuing operations</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(30,284)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(328,172)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(307,193)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income (loss) from discontinued operations, net of tax</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,317)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,074)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,613&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(37,601)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(334,246)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(305,580)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss attributable to non-controlling interests</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,609)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss available for common shareholders - basic and diluted</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(37,601)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(334,246)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(301,971)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average common shares outstanding - basic and diluted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">86,067&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84,928&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">82,364&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Income (loss) per common share</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic and diluted</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Continuing operations</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.35)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.86)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.73)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discontinued operations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.09)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.08)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.02&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-controlling interests</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.04&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:23pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic and diluted income (loss) per share attributable to common shareholders of Evolent Health, Inc.</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.44)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.94)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.67)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Anti-dilutive shares (in thousands) excluded from the calculation of weighted-average common shares presented above are presented below:</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"/><td style="width:351.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:58.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:58.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:58.00pt"/><td style="width:1.0pt"/></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Year Ended December 31,</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exchangeable Class B common stock</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,399&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:23pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted stock units ("RSUs"), performance-based RSUs and leveraged stock units ("LSUs")</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,807&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">797&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">813&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,036&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,141&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,324&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Convertible senior notes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,602&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,206&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,361&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,445&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,144&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,897&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109243012&amp;loc=SL65017193-207537<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -URI http://asc.fasb.org/topic&amp;trid=2144383<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139859102577352">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-based Compensation<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Stock-based Compensation</a></td>
<td class="text">Stock-based Compensation<div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2011 and 2015 Equity Incentive Plans</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company issues awards, including stock options, performance-based stock options, restricted stock units, performance-based restricted stock units and leveraged stock units, under the Evolent Health Holdings, Inc. 2011 Equity Incentive Plan (the &#8220;2011 Plan&#8221;) and the 2015 Evolent Health, Inc. Omnibus Incentive Compensation Plan (the &#8220;2015 Plan&#8221;). We assumed the 2011 Plan in connection with the merger of Evolent Health Holdings with and into Evolent Health, Inc. The 2011 Plan allows for the grant of an array of equity-based and cash incentive awards to our directors, employees and other service providers. The 2011 Plan was amended on September 23, 2013, to increase the number of shares authorized to 9.1&#160;million of the Company&#8217;s common stock. As of December&#160;31, 2021 and 2020, 4.8 million stock options and 3.8 million shares of restricted stock have been issued, net of forfeitures, under the 2011 Plan.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 1, 2015, the Board of Directors approved and authorized the 2015 Plan which provides for the issuance of up to 6.0 million shares of the Company&#8217;s Class A common stock to employees and non-employee directors of the Company and its consolidated subsidiaries. The 2015 Plan was amended on June 13, 2018  and April 15, 2021, to increase the number of shares authorized to 10.5 million and 15.4 million, respectively. Upon shareholder approval of the amended 2015 Plan in 2018, the 2011 Plan was automatically terminated and no further awards may be granted under the 2011 Plan. The 2011 Plan continues to govern awards previously granted under the 2011 Plan. As of December&#160;31, 2021, 2.8 million of stock options, 4.5 million RSUs, 1.1 million LSUs and 0.3 million PSUs, have been issued, net of forfeitures, under the 2015 Plan. As of December 31, 2020, 2.8 million stock options, 3.5 million RSUs and 1.2 million LSUs, have been issued, net of forfeitures, under the 2015 Plan.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We follow an employee model for our stock-based compensation as awards are granted in the stock of the Company to employees and non-employee directors of the Company or its consolidated subsidiaries. Following the adoption of ASU 2018-07 during 2018, we also follow the employee model for stock-based compensation for awards granted to acquire goods and services from non-employees. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Stock-based Compensation Expense</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total compensation expense by award type and line item in our consolidated financial statements was as follows (in thousands):</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"/><td style="width:379.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:48.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:48.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:48.25pt"/><td style="width:1.0pt"/></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Year Ended December 31,</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Award Type</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,337&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,927&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,237&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Performance-based stock options</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">448&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">RSUs</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,606&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,763&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,877&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Performance-based RSUs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,471&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(388)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">LSUs</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,297&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,841&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,444&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total compensation expense by award type</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,711&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,606&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,618&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Line Item</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of revenue</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,263&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,811&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,673&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,448&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,795&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,945&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total compensation expense by financial statement line item</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,711&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,606&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,618&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">No</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> stock-based compensation was capitalized as software development costs for the years ended December&#160;31, 2021, 2020 and 2019.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total unrecognized compensation expense (in thousands) and expected weighted-average period (in years) by award type for all of our stock-based incentive plans were as follows:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:535.50pt"><tr><td style="width:1.0pt"/><td style="width:393.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:66.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:66.25pt"/><td style="width:1.0pt"/></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31, 2021</span></td></tr><tr style="height:33pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Unrecognized Compensation Expense</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average Period (years)</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">512&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.57</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">RSUs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,104&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.69</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">LSUs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,422&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.19</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Performance-based RSUs</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,121&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.17</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,159&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Stock Options</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other than the performance-based stock options described below, options awarded under the incentive compensation plans are generally subject to a four-year graded service vesting period where 25% of the award vests after each year of service and have a maximum term of 10 years. Information with respect to our options is presented in the following disclosures. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The option price assumptions used for our stock option awards for the year ended December 31, 2019, were as follows:</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"/><td style="width:463.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:72.25pt"/><td style="width:1.0pt"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average fair value per option granted</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.52&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assumptions:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected term (in years)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.25</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.9% - 2.7%</span></div></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividend yield</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of options is determined using a Black-Scholes options valuation model with the assumptions disclosed in the table above. The dividend rate is based on the expected dividend rate during the expected life of the option. Expected volatility is based on the historical volatility over the most recent period commensurate with the estimated expected term of the Company&#8217;s awards due to the limited history of our own stock price. The risk-free interest rate is based on the U.S. Treasury yield curve in effect at the time of the grant. The expected life represents the period of time the stock&#160;options&#160;are expected to be outstanding and is based on the&#160;simplified method. Under the&#160;simplified method, the expected life of an option is presumed to be the midpoint between the vesting date and the end of the contractual term. We used the&#160;simplified method&#160;due to the lack of sufficient historical exercise data to provide a reasonable basis upon which to otherwise estimate the expected life of the stock&#160;options.&#160;</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Information with respect to our stock options (in thousands), including weighted-average remaining contractual term (in years) and aggregate intrinsic value (in thousands) was as follows:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.75pt"><tr><td style="width:1.0pt"/><td style="width:283.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:58.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:3.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:58.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:3.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:58.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:3.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:58.00pt"/><td style="width:1.0pt"/></tr><tr style="height:51pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Options</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average Exercise Price</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average Remaining Contractual Term</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Aggregate Intrinsic Value</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding as of December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,070&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.32&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.25</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,578&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,490)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.92&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(31)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.23&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding as of December 31, 2021</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,549&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.49&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.99</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46,342&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested and expected to vest after December&#160;31, 2021</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,549&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.49&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.99</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46,342&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable as of December&#160;31, 2021</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,301&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.11&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.71</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42,717&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The total fair value of options vested during the years ended December 31, 2021, 2020 and 2019, was $4.9 million, $3.6 million and $5.9 million, respectively. The total intrinsic value of options exercised during 2021, 2020 and 2019 was $20.8 million, $2.2 million and $0.6 million, respectively. We issue new shares to satisfy option exercises.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Performance-based stock option awards</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2016, the Company granted approximately 0.3&#160;million performance-based options to certain employees to create incentives for continued long-term success and to more closely align executive pay with our stockholders&#8217; interests. Each of the grants is subject to market-based vesting, as follows:</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:18pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">one-third of the shares subject to the option award will vest in the event that the average closing price of the Company&#8217;s Class A common stock on the NYSE is at least $13.35 per share for a consecutive ninety day period;</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">one-third of the shares subject to the option award will vest in the event that the average closing price of the Company&#8217;s Class A common stock on the NYSE is at least $16.43 per share for a consecutive <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185MS9mcmFnOjlmMTJhYjBlYWNjMTQ1OTU5ZDhhNjcyY2JmZjdkYjZkL3RleHRyZWdpb246OWYxMmFiMGVhY2MxNDU5NTlkOGE2NzJjYmZmN2RiNmRfNTEyNA_e4d931ff-6eba-4d04-bddc-9b3b4429017b">ninety</span> day period; and</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">one-third of the shares subject to the option award will vest in the event that the average closing price of the Company&#8217;s Class A common stock on the NYSE is at least $19.51 per share for a consecutive <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185MS9mcmFnOjlmMTJhYjBlYWNjMTQ1OTU5ZDhhNjcyY2JmZjdkYjZkL3RleHRyZWdpb246OWYxMmFiMGVhY2MxNDU5NTlkOGE2NzJjYmZmN2RiNmRfNTMzOA_19dbae44-014f-4a37-a3b0-0e16f19819c4">ninety</span> day period.</span></div><div style="padding-left:36pt;text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the percentage of options per tranche that has satisfied the market-based performance hurdle is also subject to a service completion schedule. The aggregate percentage of options eligible to vest is based upon each of the service completions dates below:</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:18pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">50% of the shares subject to the option award vested on March 1, 2019, and</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">50% of the shares subject to the option award vested on March 1, 2020.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We measured the fair value of the performance-based stock options using a Monte Carlo simulation approach with the following assumptions: risk-free interest rate of 1.83%, volatility of 65%, expected term of ten years and dividend yield of 0% as we do not currently pay dividends nor expect to do so during the expected option term. These inputs resulted in a weighted-average fair value per option granted of $6.68. During 2016 all of the average stock price milestones were achieved and therefore the awards are now only subject to the service completion obligations.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Information with respect to our performance-based stock options (shares and aggregate intrinsic value shown in thousands, weighted-average remaining contractual term shown in years) was as follows:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:539.25pt"><tr><td style="width:1.0pt"/><td style="width:286.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:58.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:58.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:58.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:58.00pt"/><td style="width:1.0pt"/></tr><tr style="height:54pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Options</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average Exercise Price</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average Remaining Contractual Term</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Aggregate Intrinsic Value</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding as of December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">268&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.27&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.17</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(326)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding as of December 31, 2021</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">268&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.27&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.16</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,620&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested and expected to vest after December&#160;31, 2021</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">268&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.27&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.16</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,620&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Restricted Stock Units</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other than the performance-based RSUs described below, and other than RSUs granted to our non-employee directors which have a one year vesting period, RSUs awarded under the incentive compensation plans are generally subject to a four-year graded service vesting period where 25% of the award vests after each year of service and are issued to the participants for no consideration. During 2018, we also granted certain RSUs with a one-year vesting period in conjunction with the New Century Health transaction. Information with respect to our RSUs (not including performance-based RSUs) is presented below (in thousands, except for weighted-average grant-date fair value):</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"/><td style="width:412.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:58.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:3.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:58.00pt"/><td style="width:1.0pt"/></tr><tr style="height:42pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total RSUs</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average Grant Date Fair Value</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding as of December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,737&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.13&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,276&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.10&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(243)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.74&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(683)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.68&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding as of December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,087&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.35&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the years ended December&#160;31, 2021, 2020 and 2019, we granted RSUs with a weighted-average grant date fair value of $21.10, $8.88 and $10.66, respectively, which represents the weighted-average closing price of our common stock on the grant date. </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The total fair value of RSUs vested during the years ended December&#160;31, 2021, 2020 and 2019 was $7.3&#160;million, $6.1&#160;million and $7.3&#160;million, respectively.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Leveraged Stock Unit Awards</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During 2020 and 2019, the Company granted 0.5&#160;million and 0.7&#160;million leveraged stock units, respectively, to certain employees to create incentives for continued long-term success and to more closely align executive pay with our stockholders&#8217; interests. Each of the grants is subject to share price-based vesting on the business day following the third anniversary of the grant date, as follows:</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:18pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">If the stock price has increased by 33.3%, 75% of the shares will vest</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">If the stock price has increased by 50%, 100% of the shares will vest</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">If the stock price has increased by 100%, 150% of the shares will vest</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">If the stock price has increased by 200%, 200% of the shares will vest (this is the maximum possible vest amount)</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The price assumptions used for our leveraged stock unit awards were as follows:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"/><td style="width:384.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:73.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:73.00pt"/><td style="width:1.0pt"/></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Year Ended December 31,</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average fair value per leveraged stock unit granted</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.90&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.52&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assumptions:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected term</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10 years</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.85%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.54%</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividend yield</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of leveraged stock units is determined using a Black-Scholes valuation model with the assumptions disclosed in the table above. The dividend rate is based on the expected dividend rate during the expected life of the award. Expected volatility is based on the historical volatility over the most recent period commensurate with the estimated expected term of the Company&#8217;s awards due to the limited history of our own stock price. The risk-free interest rate is based on the U.S. Treasury yield curve in effect at the time of the grant. The expected life represents the period of time the awards&#160;are expected to be outstanding and is based on the&#160;simplified method. Under the&#160;simplified method, the expected life of an award is presumed to be the midpoint between the vesting date and the end of the contractual term. We used the&#160;simplified method&#160;due to the lack of sufficient historical exercise data to provide a reasonable basis upon which to otherwise estimate the expected life of the awards.&#160;</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Information with respect to our leveraged stock unit awards (shares and aggregate intrinsic value shown in thousands, weighted-average remaining contractual term shown in years) was as follows:</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:539.25pt"><tr><td style="width:1.0pt"/><td style="width:286.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:58.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:58.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:58.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:58.00pt"/><td style="width:1.0pt"/></tr><tr style="height:54pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Leveraged Stock Units</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average Grant Date Fair Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average Remaining Contractual Term</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Aggregate Intrinsic Value</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding as of December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,084&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.07&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.68</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,993&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested and expected to vest after December&#160;31, 2021</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,084&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.07&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.68</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,993&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Performance-based RSUs</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During 2021, the Company granted 0.3&#160;million performance-based RSUs to certain employees to create incentives for continued long-term success and to more closely align executive pay with our stockholders&#8217; interests. A <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185MS9mcmFnOjlmMTJhYjBlYWNjMTQ1OTU5ZDhhNjcyY2JmZjdkYjZkL3RleHRyZWdpb246OWYxMmFiMGVhY2MxNDU5NTlkOGE2NzJjYmZmN2RiNmRfMzI5ODUzNDkxMDU4Mg_a8edff10-eb5c-4745-9477-bbe219e0ae2c">two</span> and three-year cumulative Adjusted EBITDA goal was approved and began on January 1, 2021. Shares are earned based on a sliding scale of performance above and below the performance goal. The sliding scale is anchored by a minimum performance requirement of cumulative Adjusted EBITDA. If the minimum performance goal is not achieved, then no performance shares are earned. If 100% of the performance goal is achieved, then award is paid at target and if the maximum performance is achieved, then 200% of the targeted shares are earned. If the cumulative Adjusted EBITDA falls between tiers on the sliding scale, the actual cumulative Adjusted EBITDA payout percentage shall be determined by linear interpolation between the percentages on a straight-line basis. Shares earned by the <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185MS9mcmFnOjlmMTJhYjBlYWNjMTQ1OTU5ZDhhNjcyY2JmZjdkYjZkL3RleHRyZWdpb246OWYxMmFiMGVhY2MxNDU5NTlkOGE2NzJjYmZmN2RiNmRfMzI5ODUzNDkxMDYwMA_5c625e05-1161-4caa-b418-357677b81681">two</span> and three-year cumulative Adjusted EBITDA performance will be adjusted based on a respective total shareholder return ("TSR"). Shares earned will be adjusted -10% if TSR performance is in the bottom quartile and will be adjusted +10% if TSR performance is in the upper quartile. TSR represents stock price appreciation over each of the two performance periods. </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The price assumptions used for our performance based stock unit awards were as follows:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"/><td style="width:384.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:73.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:73.00pt"/><td style="width:1.0pt"/></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1st Tranche</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2nd Tranche</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average fair value per performance based stock unit granted</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.64&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.69&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assumptions:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected term</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 years</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">89.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.12&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.25&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividend yield</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of performance based stock units is determined using a Black-Scholes valuation model with the assumptions disclosed in the table above. The dividend rate is based on the expected dividend rate during the expected life of the award. Expected volatility is based on the historical volatility over the most recent period commensurate with the estimated expected term of the Company&#8217;s awards due to the limited history of our own stock price. The risk-free interest rate is based on the U.S. Treasury yield curve in effect at the time of the grant. The expected life represents the period of time the awards&#160;are expected to be outstanding and is based on the&#160;simplified method. Under the&#160;simplified method, the expected life of an award is presumed to be the midpoint between the vesting date and the end of the contractual term. We used the&#160;simplified method&#160;due to the lack of sufficient historical exercise data to provide a reasonable basis upon which to otherwise estimate the expected life of the awards.&#160;</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Information with respect to our performance based restricted stock unit awards (shares and aggregate intrinsic value shown in thousands, weighted-average remaining contractual term shown in years) was as follows:</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:536.25pt"><tr><td style="width:1.0pt"/><td style="width:280.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:60.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:58.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:58.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:58.00pt"/><td style="width:1.0pt"/></tr><tr style="height:54pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Performance Based  Stock Units</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average Grant Date Fair Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average Remaining Contractual Term</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Aggregate Intrinsic Value</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding as of December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">319&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.67&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.16</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,233&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested and expected to vest after December&#160;31, 2021</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">319&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.67&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.16</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,233&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI http://asc.fasb.org/topic&amp;trid=2228938<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139858983540120">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text">Income Taxes<div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">An income tax expense (benefit) of $0.5&#160;million, $(2.4)&#160;million, and $(22.8)&#160;million was recognized for the years ended December 31, 2021, 2020 and 2019, respectively.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our loss from continuing operations before income taxes was as follows (in thousands):</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"/><td style="width:379.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:48.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:48.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:48.25pt"/><td style="width:1.0pt"/></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Year Ended December 31,</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Domestic</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(32,719)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(332,373)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(331,033)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,918&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,833&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,045&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss from continuing operations before income taxes</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(29,801)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(330,540)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(329,988)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Components of income tax expense (benefit) (in thousands) consist of the following:</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"/><td style="width:370.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:51.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:51.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:51.25pt"/><td style="width:1.0pt"/></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Year Ended December 31,</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Current</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,469)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,305)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">185&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State and local</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,449&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">200&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,027&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">721&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">399&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current tax expense (benefit)</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,007&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,384)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">598&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Deferred</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,866)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(38,258)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(27,307)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State and local</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,021)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9,565)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,046)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(493)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(303)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred tax expense (benefit)</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10,380)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(48,126)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(32,347)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in valuation allowance</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,856&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47,142&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,954&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total tax expense (benefit)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">483&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,368)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(22,795)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">A reconciliation of the U.S. statutory tax rate to our effective tax rate is presented below:</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"/><td style="width:379.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:48.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:48.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:48.25pt"/><td style="width:1.0pt"/></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Year Ended December 31,</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. statutory tax rate</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. state income taxes, net of U.S. federal tax benefit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign earnings at other than U.S. rates</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in valuation allowance</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(33.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Benefit of net operating loss carryback provision</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-deductible goodwill impairment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-controlling interest</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nondeductible excess compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Excess tax benefits (shortfalls) on stock-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Convertible debt extinguishment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in uncertain tax positions</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nontaxable earnout</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in state rate</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Return to provision</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in indefinite reinvestment assertion for domestic subsidiaries </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax sharing settlement</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effective tax rate</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.6)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.7&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.9&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred tax balances reflect the impact of temporary differences between the carrying amount of assets and liabilities and their tax basis and are stated at the tax rates expected to be in effect when the temporary differences are expected to be recovered or settled.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Significant components of the Company&#8217;s deferred tax assets and liabilities (in thousands) were as follows:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"/><td style="width:433.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:48.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:48.25pt"/><td style="width:1.0pt"/></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31,</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Deferred Tax Assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Start-up and organizational costs</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">103&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">117&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,774&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,778&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,968&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,963&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,345&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,434&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,714&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,530&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net operating loss carryforwards</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">130,242&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">123,604&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal and state research tax credits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,828&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,828&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fixed assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">480&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">131&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest deduction limitation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,795&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,452&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outside basis differences</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,972&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">197&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,236&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,428&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Subtotal</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">205,457&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">192,462&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Valuation allowance</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(101,345)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(89,723)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred tax assets</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104,112&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">102,739&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Deferred Tax Liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Internally developed software costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,501&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,973&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48,677&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49,053&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use assets - Operating</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,284&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,122&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contract fulfillment costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,317&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,375&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Convertible debt</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,604&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,411&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,387&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,484&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred tax liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104,770&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">103,418&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net deferred tax assets (liabilities)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(658)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(679)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes in our valuation allowance (in thousands) were as follows:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"/><td style="width:433.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:48.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:48.25pt"/><td style="width:1.0pt"/></tr><tr style="height:23pt"><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Year Ended December 31,</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at beginning-of-year</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">89,723&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50,519&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Charged to costs and expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,856&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47,142&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Charged (credited) to other accounts </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,766&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,938)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at end-of-year</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101,345&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">89,723&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:3.71pt">Amounts charged (credited) to other accounts includes $1.8&#160;million charged to discontinued operations for the year ended December&#160;31, 2021 and $8.6&#160;million credited to additional paid-in-capital, partially offset by $0.7&#160;million charged to retained earnings, for the year ended December 31, 2020.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">For the year ended December 31, 2021, the effective tax rate was (1.6)% and the corresponding tax expense recorded was $0.5&#160;million. The income tax expense recorded by the Company in 2021 primarily relates to foreign taxes and the impact of the valuation allowance recorded against the Company&#8217;s net deferred tax assets, with the exception of indefinite lived components and those expected to reverse outside of the net operating loss carryover period.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">For the year ended December 31, 2020, the effective tax rate was 0.7% and the corresponding tax benefit recorded was $2.4&#160;million. The income tax benefit recorded by the Company in 2020 primarily relates to the impacts from the Coronavirus Aid, Relief, and Economic Security Act (the &#8220;CARES Act&#8221;). On March 27, 2020, in response to the COVID-19 pandemic, the CARES Act, was signed into law. The CARES Act allowed net operating losses (&#8220;NOLs&#8221;) incurred in 2018, 2019 and 2020 to be carried back to each of the five preceding taxable years for the recovery of previously paid federal income taxes. The Company recorded an income tax benefit related to carrying back New Century Health&#8217;s 2018 NOL as part of a federal income tax refund claim for taxes it paid on income in 2013 and 2014. The remaining income tax provisions included in the CARES Act, apart from the aforementioned NOL carryback, did not have a significant impact on the Company. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the year ended December 31, 2019, the effective tax rate was 6.9%, and the corresponding tax benefit recorded was $22.8&#160;million. Our effective tax rate in 2019 was impacted by the tax expense for the impairment of non-deductible goodwill, change in valuation allowance for current year losses, and offset in part by the tax effects resulting from the Company&#8217;s acquisition of all remaining Class </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">B units of Evolent Health LLC, resulting in it becoming a disregarded entity for U.S. federal and state income purposes on December 26, 2019. The change in Evolent Health LLC&#8217;s tax status resulted in a tax benefit from the reversal of the Company&#8217;s deferred tax liability related to its investment in certain U.S. corporate subsidiaries through Evolent Health LLC, offset by an increase in valuation allowance. The Company filed a consolidated tax return beginning January 1, 2020, which resulted in a tax benefit offsetting the change in valuation allowance to the extent the deferred tax liabilities of our U.S. corporate subsidiaries had been used as a source of future taxable income to support the Company&#8217;s deferred tax assets.  Our valuation allowance assessment is made without considering deferred tax liabilities of $1.9&#160;million established with respect to certain indefinite-lived components that cannot be utilized against indefinite-lived deferred tax assets or components that are expected to reverse outside of the net operating loss carryover period, as these are not considered a source of future taxable income for realizing our deferred tax assets. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2021, the Company had $203.7&#160;million of federal and $290.8&#160;million of state NOL carryforwards available to offset future taxable income that begin to expire in 2032 and 2022, respectively, and $292.9&#160;million federal and $196.0&#160;million of state NOLs with an indefinite carryforward period, subject to a utilization limit of 80% of taxable income in any given year. However, as it is more likely than not that such tax benefit will not be realized based on our evaluation, we have established a valuation allowance against those NOLs. Furthermore, Internal Revenue Code Section 382 imposes limitations on the utilization of NOLs in the event of certain changes in ownership of the Company, which may have occurred or could occur in the future. This could result in an annual limit on the Company&#8217;s ability to utilize NOLs and could cause U.S. federal income taxes to be due sooner than if no such limitations applied.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2021, the Company had $2.1&#160;million and $0.3&#160;million of research and development credits for federal and state income tax purposes, which could expire unutilized beginning in 2037 and 2028, respectively. The Company has established a valuation allowance against those credits. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes in our unrecognized tax benefits (in thousands) were as follows:</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"/><td style="width:402.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:40.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:40.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:40.75pt"/><td style="width:1.0pt"/></tr><tr style="height:24pt"><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Year Ended December 31,</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at beginning-of-year</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">678&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">753&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">934&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lapse of statute of limitations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(69)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(75)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(181)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at end-of-year</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">609&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">678&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">753&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are subject to taxation in various jurisdictions in the U.S. and India. Tax years 2011 and all subsequent periods remain subject to examination by the U.S. federal and state taxing jurisdictions due to the availability of NOL carryforwards. Included in the balance of unrecognized tax benefits as of December&#160;31, 2021, are $0.6&#160;million of tax benefits that, if recognized, would not affect the overall effective tax rate, due to the offsetting impact on the Company&#8217;s valuation allowance. The Company has not recognized interest and penalties related to uncertain tax positions due to the current NOL position. The Company had recognized $0.7&#160;million of uncertain tax positions as of December&#160;31, 2020, and $0.8&#160;million as of December&#160;31, 2019. The Company and its subsidiaries are not currently subject to income tax audits in any U.S. state or local jurisdiction, or any foreign jurisdiction, for any tax year.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Tax Receivables Agreement</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the Offering Reorganization, Class B Exchanges increased our tax basis in our share of Evolent Health LLC&#8217;s tangible and intangible assets. These increases in tax basis increased our depreciation and amortization deductions and create other tax benefits and, therefore, may reduce the amount of tax that we would otherwise be required to pay in the future. In addition, certain NOLs of Evolent Health Holdings (and of an affiliate of TPG) are available to us as a result of the Offering Reorganization.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Offering Reorganization, we entered into the TRA with the holders of Class B common units. The agreement requires us to pay to such holders 85% of the cash savings, if any, in U.S. federal, state and local, and foreign income tax (as applicable) we realize as a result of any deductions attributable to future increases in tax basis following the Class B Exchanges (calculated assuming that any post-offering transfer of Class B common units had not occurred) or deductions attributable to imputed interest or future increases in tax basis following payments made under the TRA. We are accounting for these payments as contingent liabilities and will recognize them in our Consolidated Statements of Operations and Comprehensive Income (Loss) when their realization becomes probable. Additionally, pursuant to the same agreement we will pay the former stockholders of Evolent Health Holdings 85% of the amount of the cash savings, if any, in U.S. federal, state and local, and foreign income tax that we realize as a result of the utilization of the NOLs of Evolent Health Holdings (and the affiliate of TPG) attributable to periods prior to the Offering Reorganization, approximately $79.3&#160;million, as well as deductions attributable to imputed interest on any payments made under the agreement. </span></div>We will benefit from the remaining 15% of any realized cash savings. The TRA was effective upon the completion of the Offering Reorganization and will remain in effect until all such tax benefits have been used or expired, or until the agreement is terminated.  See Note 11 for additional discussion of the implications of the TRA.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32857-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330215-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32705-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6424409&amp;loc=d3e44925-109338<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI http://asc.fasb.org/topic&amp;trid=2144680<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6424122&amp;loc=d3e41874-109331<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139858983537336">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Employee Benefit Plans<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>Retirement Benefits [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock', window );">Employee Benefit Plans</a></td>
<td class="text">Employee Benefit Plans<span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We sponsor a tax-qualified 401(k) retirement plan that provides eligible U.S. employees with an opportunity to save for retirement on a tax advantaged basis. We make matching contributions to the plan in accordance with the plan documents and various limitations under Section 401(a) of the Internal Revenue Code of 1986, as amended. The Company made $5.4&#160;million, $6.2&#160;million and </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$2.6&#160;million</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in contributions to the 401(k) plan for the years ended December&#160;31, 2021, 2020 and 2019, respectively. Total contributions for the year ended December 31, 2020, are net of $0.2&#160;million from discontinued operations.</span><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for retirement benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4179-114921<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section S99<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=21916913&amp;loc=d3e273930-122802<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (o)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (p)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 70<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=49170846&amp;loc=d3e28014-114942<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -URI http://asc.fasb.org/topic&amp;trid=2235017<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 60<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6414203&amp;loc=d3e39689-114964<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iv)(03)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (q)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (r)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (l)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (r)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139858977515944">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Investments in Equity Method Investees<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract', window );"><strong>Equity Method Investments and Joint Ventures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentsDisclosureTextBlock', window );">Investments in Equity Method Investees</a></td>
<td class="text">Investments in Equity Method Investees<div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company holds ownership interests in joint ventures and other entities which are accounted for under the equity method. The Company evaluates its interests in these entities to determine whether they meet the definition of a VIE and whether the Company is required to consolidate these entities. A VIE is consolidated by its primary beneficiary, which is the party that has both (i) the power to direct the activities that most significantly impact the economic performance of the VIE and (ii) a variable interest that could potentially be significant to the VIE. To determine whether or not a variable interest the Company holds could potentially be significant to the VIE, the Company considers both qualitative and quantitative factors regarding the nature, size and form of the Company's involvement with the VIE. The Company has determined that its interests in these entities meet the definition of a variable interest, however, the Company is not the primary beneficiary since it does not have the power to direct activities, therefore, the Company did not consolidate the VIEs.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of&#160;December&#160;31, 2021 and 2020, the Company&#8217;s economic interests in its equity method investments ranged between 4% and 39%, and 4% and 38%, respectively, and voting interests in its equity method investments ranged between 25% and 40%, respectively. The Company determined that it has significant influence over these entities but that it does not have control over any of the entities. Accordingly, the investments are accounted for under the equity method of accounting and the Company is allocated its proportional share of the entities&#8217; earnings and losses for each reporting period. The Company&#8217;s proportional share of the gain (loss) from these investments was approximately $13.2 million, $10.0 million and $(9.5)&#160;million for the years ended December&#160;31, 2021, 2020 and 2019, respectively.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company signed services agreements with certain of the aforementioned entities to provide certain management, operational and support services to help manage elements of their service offerings. Revenue related to these services agreements were $15.9 million, $192.8 million and $41.5 million for the years ended December&#160;31, 2021, 2020 and 2019, respectively.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Unconsolidated VIEs</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Global</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March 31, 2020, the Oklahoma Insurance Division (&#8220;OID&#8221;) informed GlobalHealth, Inc. that in response to the COVID-19 pandemic, the OID required GlobalHealth, Inc. to increase its regulatory capital surplus by May 15, 2020. It would otherwise be placed into receivership if additional financing could not be secured. Certain investors agreed to provide liquidity as necessary to increase statutory capital reserves to no lower than 300%. In connection with the investment, GlobalHealth, Inc. transferred 100% of the equity interests in GlobalHealth, Inc. to the new investors for no consideration. Closing of this transaction occurred on May 13, 2020. As a result of this transaction, we recorded a non-cash impairment charge of approximately $47.1&#160;million, representing the total value of our investment, in impairment of equity method investments on the consolidated statements of operations and comprehensive income (loss) for the year ended December 31, 2020.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for equity method investments and joint ventures. Equity method investments are investments that give the investor the ability to exercise significant influence over the operating and financial policies of an investee. Joint ventures are entities owned and operated by a small group of businesses as a separate and specific business or project for the mutual benefit of the members of the group.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -URI http://asc.fasb.org/topic&amp;trid=2196965<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139858977664104">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Non-controlling Interests<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncontrollingInterestAbstract', window );"><strong>Noncontrolling Interest [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestDisclosureTextBlock', window );">Non-controlling Interests</a></td>
<td class="text">Non-controlling InterestsImmediately following the Offering Reorganization and IPO in May 2015, the Company owned 70.3% of Evolent Health LLC. The Company&#8217;s ownership percentage changes with the issuance of Class A or Class B common stock and Class B Exchanges. In order to account for any changes in the Company&#8217;s ownership of Evolent Health LLC, we record a reclassification of equity between non-controlling interests and shareholders&#8217; equity attributable to Evolent Health, Inc.<div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 1, 2020, in connection with the consolidation of EVH Passport, the Company recognized a $25.7&#160;million non-controlling interest for the Sponsors&#8217; 30% equity interest in EVH Passport which represented the fair value of the non-controlling interest as of the date of consolidation. Pursuant to the shareholders&#8217; agreement with the Sponsors, the Company was required to acquire the Sponsors&#8217; 30% ownership interest for $20.0&#160;million on or prior to December 31, 2021. On November 16, 2020, the Company acquired the Sponsors&#8217; 30% equity interest and reclassified the non-controlling interests into shareholders&#8217; equity attributable to Evolent Health, Inc. As a result of this transaction, the Company recorded a $5.7&#160;million gain on consolidation for the year ended December 31, 2020 in gain (loss) on disposal of assets and consolidation on the consolidated statements of operations.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes in non-controlling interests (in thousands) for year ended December 31, 2020, was as follows:</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"/><td style="width:463.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:72.25pt"/><td style="width:1.0pt"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-controlling interests balance as of beginning of period</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,689&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issuance of non-controlling interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,749&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Disposal of assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,689)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Redemption of Sponsor&#8217;s equity</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(25,749)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-controlling interests balance as of end of period</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterestDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for noncontrolling interest in consolidated subsidiaries, which could include the name of the subsidiary, the ownership percentage held by the parent, the ownership percentage held by the noncontrolling owners, the amount of the noncontrolling interest, the location of this amount on the balance sheet (when not reported separately), an explanation of the increase or decrease in the amount of the noncontrolling interest, the noncontrolling interest share of the net Income or Loss of the subsidiary, the location of this amount on the income statement (when not reported separately), the nature of the noncontrolling interest such as background information and terms, the amount of the noncontrolling interest represented by preferred stock, a description of the preferred stock, and the dividend requirements of the preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -URI http://asc.fasb.org/topic&amp;trid=2197479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterestDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncontrollingInterestAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncontrollingInterestAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139858977574280">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurement<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Fair Value Measurement</a></td>
<td class="text">Fair Value Measurement<div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">GAAP defines fair value as the price that would be received from the sale of an asset or paid to transfer a liability (an exit price) assuming an orderly transaction in the most advantageous market at the measurement date. GAAP also establishes a hierarchical disclosure framework which prioritizes and ranks the level of observability of inputs used in measuring fair value. These tiers include:</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 1 - inputs to the valuation methodology are quoted prices available in active markets for identical instruments as of the reporting date;</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 2 - inputs to the valuation methodology are other than quoted prices in active markets, which are either directly or indirectly observable as of the reporting date and the fair value can be determined through the use of models or other valuation methodologies; and </span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 3 - inputs to the valuation methodology are unobservable inputs in situations where there is little or no market activity for the asset or liability.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In certain cases, the inputs used to measure fair value may fall into different levels of the fair value hierarchy. In such cases, the level within the fair value hierarchy is based on the lowest level of input that is significant to the fair value measurement. Our assessment of the significance of a particular input to the fair value measurement in its entirety requires judgment and considers factors specific to the particular asset or liability being measured. </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recurring Fair Value Measurements</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In accordance with GAAP, certain assets and liabilities are required to be recorded at fair value on a recurring basis. The following table summarizes the Company&#8217;s assets and liabilities measured at fair value on a recurring basis (in thousands):</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:59.594%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.205%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.205%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.205%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.209%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,700&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,700&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total fair value of liabilities measured on a recurring basis</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,700&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,700&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"/><td style="width:325.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:48.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:48.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:48.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:48.25pt"/><td style="width:1.0pt"/></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,877&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,877&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total fair value of assets measured on a recurring basis</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,877&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,877&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warrants </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,730&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,730&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total fair value of liabilities measured on a recurring basis</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,730&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,730&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%"> </span></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Represents the fair value of earn-out consideration related to the Vital Decisions transaction as described in Note 4.</span></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> Represents the cash and cash equivalents and restricted cash and restricted investments that were held in money market funds as of December&#160;31, 2020.</span></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(3)  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Represents the fair value of 1,513,786 shares issuable under the warrant agreements discussed in Note 10. The warrants were settled in January 2021.</span></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes any transfers between levels within the hierarchy as of the beginning of the reporting period. There were no transfers between fair value levels during the years ended December 31, 2021 and 2020, respectively.  </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the absence of observable market prices, the fair value is based on the best information available and involves a significant degree of judgment, taking into consideration a combination of internal and external factors, including the appropriate risk adjustments for non-performance and liquidity risks.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As discussed in Note 4 , the acquisition of Vital Decisions includes a provision for additional equity consideration contingent upon the Company obtaining certain annualized performance metrics during the three months ending December 31, 2022. The fair value of the contingent equity consideration was estimated based on the real options approach, a form of the income approach, which estimated the probability of the Company achieving future revenues under the agreement. The significant unobservable inputs used in the fair value measurement of the Vital Decisions contingent consideration are the risk-neutral (probability weighted) earnout consideration and the applicable discount rate. A significant increase in the risk-neutral (probability weighted) earnout consideration or decrease in discount rate in isolation would result in a significantly higher fair value of the contingent consideration.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In conjunction with the Credit Agreement discussed in Note 10, the Company entered into warrant agreements whereby it agreed to sell to the holders of the warrants an aggregate of 1,513,786 shares of Class A common stock. The fair value of the warrants was estimated based on the Black-Scholes model which incorporates the constant price variation of the stock, the time value of money, the option's strike price, and the time to the option's expiry. The significant unobservable inputs used in the fair value measurement of the warrants are the stock price volatility and annual risk free rate. A significant increase in the stock price or discount rate in isolation would have resulted in a significantly higher fair value of the contingent consideration.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The changes in our liabilities measured at fair value for which the Company uses Level 3 inputs to determine fair value for the years ended December 31, 2021 and 2020 are as follows (in thousands): </span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"/><td style="width:433.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:48.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:48.25pt"/><td style="width:1.0pt"/></tr><tr style="height:23pt"><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Year Ended December 31,</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of beginning of period</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,730&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,975&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,600&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Settlements</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13,730)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,500)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Realized and unrealized losses, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,100&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">255&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of end of period</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,700&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,730&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the fair value (in thousands), valuation techniques and significant unobservable inputs of our Level 3 fair value measurements as of the periods presented:</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:24.177%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.205%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.788%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:30.427%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.821%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair </span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Valuation</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Significant</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assumption or</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Technique</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Unobservable Inputs</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Input Ranges</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,700&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Real options approach</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-neutral expected earnout consideration</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,935&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discount rate</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.04&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"/><td style="width:134.50pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:48.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:100.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:168.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:67.75pt"/><td style="width:1.0pt"/></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair </span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Valuation</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Significant</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assumption or</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Technique</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Unobservable Inputs</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Input Ranges</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warrants</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,730&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Black-Scholes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock price volatility</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Annual risk free rate</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Nonrecurring Fair Value Measurements</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the assets and liabilities that are recorded at fair value on a recurring basis, the Company records certain assets and liabilities at fair value on a nonrecurring basis as required by GAAP. Generally, assets are recorded at fair value on a nonrecurring basis as a result of impairment charges. This includes assets and liabilities recorded in business combinations or asset acquisitions, goodwill, intangible assets, property, plant and equipment, held-to-maturity investments and equity method investments. While not carried at fair value on a recurring basis, these items are continually monitored for indicators of impairment that would indicate current carrying value is greater than fair value. In those situations, the assets are considered impaired and written down to current fair value. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Other Fair Value Disclosures</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying amounts of cash and cash equivalents (those not held in a money market fund), restricted cash, receivables, prepaid expenses, accounts payable, accrued liabilities and accrued compensation approximate their fair values because of the relatively short-term maturities of these items and financial instruments.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Note 10 for information regarding the fair value of the 2024 Notes, 2025 Notes and 2021 Notes.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139858977669192">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Parties<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">Related Parties</a></td>
<td class="text">Related Parties  <div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The entities described below are considered related parties and the balances and/or transactions with them are reported in our consolidated financial statements.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">As discussed in Note&#160;17, the Company had economic interests in several entities that are accounted for under the equity method of accounting, including EVH Passport which has been consolidated into the Company&#8217;s financial statements since September 1, 2020. The Company has allocated its proportional share of the investees&#8217; earnings and losses each reporting period. In addition, Evolent has entered into services agreements with certain of the entities to provide certain management, operational and support services to help the entities manage elements of their service offerings. </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company also works with UPMC, one of its founding investors. The Company&#8217;s relationship with UPMC is a subcontractor relationship where UPMC has agreed to execute certain tasks (primarily TPA services) relating to certain customer commitments. This relationship is currently in wind-down.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents assets and liabilities attributable to our related parties as of December&#160;31, 2021 and 2020 (in thousands):</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:74.594%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.705%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.707%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable, net</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,719&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,474&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other noncurrent assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,877&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,554&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,967&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,509&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,120&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,520&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reserve for claims and performance-based arrangements</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">734&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">435&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents revenues and expenses attributable to our related parties for the years ended December 31, 2021, 2020 and 2019 (in thousands):</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"/><td style="width:373.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:49.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:54.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:49.00pt"/><td style="width:1.0pt"/></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Year Ended December 31,</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Revenue</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Transformation services</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,416&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,009&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Platform and operations services</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45,082&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">226,339&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60,325&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr style="height:23pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of revenue (exclusive of depreciation and amortization expenses)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,063&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,863&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,954&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">285&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">113&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">991&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -URI http://asc.fasb.org/topic&amp;trid=2122745<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39691-107864<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139858977660280">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Repositioning and Other Changes<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedActivitiesAbstract', window );"><strong>Restructuring and Related Activities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock', window );">Repositioning and Other Changes</a></td>
<td class="text">Repositioning and Other Changes<div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We continually assess opportunities to improve operational effectiveness and efficiency to better align our expenses with revenues, while continuing to make investments in our solutions, systems and people that we believe are important to our long-term goals. Across 2020, we divested or agreed to divest a majority of our health plan assets, including certain assets of EVH Passport, which represented a significant revenue stream for the Company. In parallel with these divestitures, we contracted with a third-party vendor to review our operating model and organizational design in order to improve our profitability, create value through our solutions and invest in strategic opportunities in future periods.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the fourth quarter of 2020, we committed to certain operational efficiency and profitability actions that we are taking in order to accomplish these objectives (&#8220;Repositioning Plan&#8221;). These actions included making organizational changes across our business as well as other profitability initiatives expected to result in reductions in force, re-aligning of resources as well as other potential operational efficiency and cost-reduction initiatives that will provide future benefit to the Company. The Repositioning Plan concluded in the fourth quarter of 2021.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides a summary of our total costs associated with the Repositioning Plan for the years ended December 31, 2021 and 2020, by major type of cost (in thousands):</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:60.011%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.788%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.788%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.903%"/><td style="width:0.1%"/></tr><tr style="height:23pt"><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Year Ended December 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cumulative Amount Incurred through December 31, 2021</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Severance and termination benefits</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">185&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">185&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Office space consolidation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,742&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,742&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Professional services</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,391&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,275&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,666&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,318&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,275&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,593&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for restructuring and related activities. Description of restructuring activities such as exit and disposal activities, include facts and circumstances leading to the plan, the expected plan completion date, the major types of costs associated with the plan activities, total expected costs, the accrual balance at the end of the period, and the periods over which the remaining accrual will be settled.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(e))<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -URI http://asc.fasb.org/topic&amp;trid=2175745<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139858976390216">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Reporting<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingDisclosureTextBlock', window );">Segment Reporting</a></td>
<td class="text">Segment Reporting<div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We define our reportable segments based on the way the CODM, the chief executive officer, manages the operations for purposes of allocating resources and assessing performance commencing with the three months ended March 31, 2021. We classify our operations into two reportable segments as follows:</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">Evolent Health Services, which houses our Administrative Simplification solution and certain supporting population health infrastructure; and</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">Clinical Solutions, which includes our specialty care management and physician-oriented total cost of care solutions, along with the New Century Health and Evolent Care Partners brands. </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the ordinary course of business, our reportable segments enter into transactions with one another. While intersegment transactions are treated like third-party transactions to determine segment performance, the revenues and expenses recognized by the segment that is the counterparty to the transaction are eliminated in consolidation and do not affect consolidated results.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The CODM uses revenue in accordance with U.S. GAAP and Adjusted EBITDA as the relevant segment performance measures to evaluate the performance of the segments and allocate resources. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Adjusted EBITDA is a segment performance financial measure that offers a useful view of the overall operation of our businesses and may be different than similarly-titled segment performance financial measures used by other companies. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Adjusted EBITDA is defined as net loss attributable to common shareholders of Evolent Health, Inc. before interest income, interest expense, (provision) benefit for income taxes, depreciation and amortization expenses, adjusted to exclude equity method investment impairment, gain on transfer of membership, loss on repayment of debt, loss on extinguishment of debt, goodwill impairment, gain (loss) from equity method investees, changes in fair value of contingent consideration and indemnification asset, net loss attributable to non-controlling interests, other income (expense), net, repositioning costs, stock-based compensation expense, severance costs, amortization of contract cost assets, strategy and shareholder advisory services, acquisition-related costs and gain (loss) from discontinued operations. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Management considers revenue and Adjusted EBITDA to be the appropriate metrics to evaluate and compare the ongoing operating performance of our segments on a consistent basis across reporting periods as they eliminate the effect of items which are not indicative of each segment's core operating performance. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables present our segment information for the years ended December 31, 2021, 2020 and 2019 (in thousands). Segment information for the years ended December 31, 2020 and 2019 (including segments total Adjusted EBITDA) has been restated to conform to the reporting structure change described in Note 2.</span></div><div style="text-align:justify"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"/><td style="width:145.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:52.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:52.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:67.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:60.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:61.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:67.00pt"/><td style="width:1.0pt"/></tr><tr style="height:33pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Evolent Health Services</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Clinical Solutions</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Intersegment<br/>Eliminations</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Subtotal</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Corporate </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Consolidated</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Revenue</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr style="height:12pt"><td colspan="12" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Year Ended December 31, 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Transformation services</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,204&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,204&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,204&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Platform and operations services</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">300,423&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">598,144&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,814)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">896,753&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">896,753&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenue</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">311,627&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">598,144&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,814)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">907,957&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">907,957&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"/><td style="width:145.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:52.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:52.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:67.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:60.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:61.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:67.00pt"/><td style="width:1.0pt"/></tr><tr style="height:12pt"><td colspan="12" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Year Ended December 31, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Transformation services</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,990&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,990&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,990&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Platform and operations services</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">373,144&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">542,279&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,774)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">912,649&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">912,649&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenue</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">385,134&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">542,279&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,774)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">924,639&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">924,639&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr style="height:12pt"><td colspan="12" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Year Ended December 31, 2019</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Transformation services</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,203&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,203&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,203&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Platform and operations services</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">394,328&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">278,217&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(626)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">671,919&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">671,919&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenue</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">409,531&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">278,217&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(626)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">687,122&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">687,122&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr><tr style="height:33pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Evolent Health Services</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Clinical Solutions</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Subtotal</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Corporate </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Segments Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr style="height:14pt"><td colspan="12" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Year Ended December 31, 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjusted EBITDA</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,063&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">82,920&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99,983&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(33,666)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66,317&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr style="height:14pt"><td colspan="12" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Year Ended December 31, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjusted EBITDA</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57,731&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,864&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84,595&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(36,022)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48,573&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr style="height:12pt"><td colspan="12" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Year Ended December 31, 2019</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjusted EBITDA</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(561)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,523&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,962&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(25,793)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13,831)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr></table></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt">Corporate includes various finance, human resources, legal, executive, and other corporate infrastructure expenses.</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents our reconciliation of consolidated segments total Adjusted EBITDA to net loss attributable to common shareholders of Evolent Health, Inc. for the years ended December 31, 2021, 2020 and 2019 (in thousands): </span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"/><td style="width:380.50pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:48.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:48.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:48.25pt"/><td style="width:1.0pt"/></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Year Ended December 31,</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net loss attributable to common shareholders of Evolent Health, Inc.</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(37,601)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(334,246)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(301,971)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">407&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,633&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,406&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(25,425)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(28,325)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14,555)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Provision) benefit for income taxes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(483)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,368&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,795&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(60,037)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(60,835)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(60,323)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity method investment impairment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(47,133)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain on transfer of membership</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45,938&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss on repayment of debt, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(21,343)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss on extinguishment of debt</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,789)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill impairment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(215,100)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(199,800)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain (loss) from equity method investees</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,179&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,039&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9,465)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain (loss) on disposal of assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(698)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,600&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value of contingent consideration and indemnification asset</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13,281)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,860)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,997&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss attributable to non-controlling interests</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,609&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income (expense), net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(146)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(118)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(489)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchase accounting adjustments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,915)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Repositioning costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,318)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,275)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16,711)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14,606)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15,618)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Severance costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(198)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,986)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(17,350)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of contract cost assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(476)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,944)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,876)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Strategy and shareholder advisory expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,513)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisition costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,194)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,116)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10,769)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain (loss) from discontinued operations </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,317)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,074)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,613&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Adjusted EBITDA</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66,317&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48,573&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13,831)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt">Includes $6.8&#160;million gain on disposal of discontinued operations for the year ended December 31, 2021.</span></div>Asset information by segment is not a key measure of performance used by the CODM. Accordingly, we have not disclosed asset information by segment.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 34<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8981-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8721-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9031-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 26<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8844-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8657-108599<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8721-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -URI http://asc.fasb.org/topic&amp;trid=2134510<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139858977751320">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Reserves for Claims and Performance-Based Arrangements<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InsuranceAbstract', window );"><strong>Insurance [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InsuranceDisclosureTextBlock', window );">Reserves for Claims and Performance-Based Arrangements</a></td>
<td class="text">Reserve for Claims and Performance-Based Arrangements<div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company maintains reserves for its liabilities related to payments to providers and pharmacies under performance-based arrangements related to its total cost of care and specialty care management services. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Reserves for claims and performance-based arrangements for our EHS and Clinical Solutions segments reflect actual payments under performance-based arrangements and the ultimate cost of claims that have been incurred but not reported, including expected development on reported claims, those that have been reported but not yet paid (reported claims in process), and other medical care expenses and services payable that are primarily composed of accruals for incentives and other amounts payable to health care professionals and facilities. Reserves for claims and performance-based arrangements also reflect estimated amounts owed under the reinsurance agreements, as discussed further in Note 11.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company uses actuarial principles and assumptions that are consistently applied each reporting period and recognizes the actuarial best estimate of the ultimate liability along with a margin for adverse deviation. This approach is consistent with actuarial standards of practice that the liabilities be adequate under moderately adverse conditions.  </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This liability predominately consists of incurred but not reported amounts and reported claims in process including expected development on reported claims. The liability for reserves related to its total cost of care and specialty care management services is primarily calculated using "completion factors" developed by comparing the claim incurred date to the date claims were paid. Completion factors are impacted by several key items including changes in: 1)&#160;electronic (auto-adjudication) versus manual claim processing, 2)&#160;provider claims submission rates, 3)&#160;membership and 4)&#160;the mix of products.  </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s policy for reserves related to its total cost of care and specialty care management services is to use historical completion factors combined with an analysis of current trends and operational factors to develop current estimates of completion factors. The Company estimates the liability for claims incurred in each month by applying the current estimates of completion factors to the current paid claims data. This approach implicitly assumes that historical completion rates will be a useful indicator for the current period. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For more recent months, and for newer lines of business where there is not sufficient paid claims history to develop completion factors, the Company expects to rely more heavily on medical cost trend and expected loss ratio analysis that reflects expected claim payment patterns and other relevant operational considerations, or authorization analysis. Medical cost trend is primarily impacted by medical service utilization and unit costs that are affected by changes in the level and mix of medical benefits offered, including inpatient, outpatient and pharmacy, the impact of copays and deductibles, changes in provider practices and changes in consumer demographics and consumption behavior. Authorization analysis projects costs on an authorization-level basis and also accounts for the impact of copays and deductibles, unit cost and historic discontinuation rates for treatment. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For each reporting period, the Company compares key assumptions used to establish the reserves for claims and performance-based arrangements to actual experience. When actual experience differs from these assumptions, reserves for claims and performance-based arrangements are adjusted through current period net income. Additionally, the Company evaluates expected future developments and emerging trends that may impact key assumptions. The process used to determine this liability requires the Company to make critical accounting estimates that involve considerable judgment, reflecting the variability inherent in forecasting future claim payments. These estimates are highly sensitive to changes in the Company's key assumptions, specifically completion factors and medical cost trends.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Activity in reserves for claims and performance-based arrangements for the years ended December 31, 2021 and 2020, was as follows (in thousands):</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:539.25pt"><tr><td style="width:1.0pt"/><td style="width:226.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:37.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:57.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:3.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:40.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:3.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:41.50pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:3.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:57.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:3.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:40.00pt"/><td style="width:1.0pt"/></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="33" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Year Ended December 31,</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr style="height:23pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">EHS </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Clinical Solutions </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">EHS </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Clinical Solutions </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Beginning balance</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56,296&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">122,531&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">178,827&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,265&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50,245&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54,510&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Incurred costs related to current year</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,669&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">449,172&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">457,841&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,542)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">428,139&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">420,597&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Incurred costs related to prior year</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,036&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,109&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,853&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,878&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Paid costs related to current year</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,801&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">337,647&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">358,448&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">106,093&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">358,478&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">464,571&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:539.25pt"><tr><td style="width:1.0pt"/><td style="width:226.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:37.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:57.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:3.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:40.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:3.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:41.50pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:3.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:57.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:3.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:40.00pt"/><td style="width:1.0pt"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Paid costs related to prior year</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,544&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100,075&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">125,619&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,123&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,475&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,598&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change during the year</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(30,640)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,523&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19,117)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(112,905)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62,211&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(50,694)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr style="height:23pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Impact of consolidation on reserves for claims and performance-based arrangements</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">164,297&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">164,297&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other adjustments </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(38)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,622&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,584&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">639&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,075&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,714&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ending balance</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,618&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">145,676&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">171,294&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56,296&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">122,531&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">178,827&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:13.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;</span></div><div style="padding-left:31.5pt;text-align:justify;text-indent:-31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:25.44pt">Costs incurred to provide specialty care management and EVH Passport are recorded within cost of revenue in our statement of operations. </span></div><div style="padding-left:31.5pt;text-align:justify;text-indent:-31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:25.44pt">Amounts exclude $9.9&#160;million related to reserves for claims reclassified to discontinued operations as of December&#160;31, 2020.</span></div><div style="padding-left:31.5pt;text-align:justify;text-indent:-31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:25.44pt">Other adjustments to reserves for claims and performance-based arrangements reflect changes in accrual for amounts payable to facilities and amounts owed to our payer partners for claims paid on our behalf.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InsuranceAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InsuranceAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InsuranceDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the types of coverages and products sold, and the assets, obligations, recorded liabilities, revenues and expenses arising therefrom, and the amounts of and methodologies and assumptions used in determining the amounts of such items.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -URI http://asc.fasb.org/topic&amp;trid=2303980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InsuranceDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139858977592856">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Quarterly Results of Operations (unaudited)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_QuarterlyFinancialDataAbstract', window );"><strong>Quarterly Financial Data [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_QuarterlyFinancialInformationTextBlock', window );">Quarterly Results of Operations (unaudited)</a></td>
<td class="text">Quarterly Results of Operations (unaudited)<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The unaudited consolidated quarterly results of operations (in thousands, except per share data) were as follows:</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:53.344%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.094%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.983%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.205%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.209%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="21" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Three Months Ended</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">June 30</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenue</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">248,358&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">222,471&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">222,057&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">215,071&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">260,572</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">229,052</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">229,728</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">231,016</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss from continuing operations</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,053</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13,040)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9,107)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11,190)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss) from discontinued operations, net of tax</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,700)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,383</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss attributable to common shareholders of Evolent Health, Inc.</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,647)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13,040)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9,107)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9,807)</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Income (loss) per common share</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic and diluted</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Continuing operations</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.03&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.15)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.11)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.13)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discontinued operations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.09)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.01&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenue</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">246,536&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">239,572&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">217,299&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">221,232&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">246,804</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">256,020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">443,128</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">246,323</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss from continuing operations</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10,637)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(37,035)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(202,013)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(78,487)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss from discontinued operations, net of tax</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,166)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,135)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,508)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(265)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss) attributable to non-controlling interests</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">822</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(822)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss attributable to common shareholders of Evolent Health, Inc.</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14,625)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(37,348)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(203,521)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(78,752)</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Loss per common share</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic and diluted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Continuing operations</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.13)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.43)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.37)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.93)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discontinued operations</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.04)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.01)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.01)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_QuarterlyFinancialDataAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_QuarterlyFinancialDataAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_QuarterlyFinancialInformationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for quarterly financial data. Includes, but is not limited to, tabular presentation of financial information for fiscal quarters, effect of year-end adjustments, and an explanation of matters or transactions that affect comparability of the information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 270<br> -URI http://asc.fasb.org/topic&amp;trid=2126967<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 270<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1B<br> -URI http://asc.fasb.org/extlink&amp;oid=124502072&amp;loc=SL124452896-108306<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_QuarterlyFinancialInformationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139858977563704">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Supplemental Cash Flow Information<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowElementsAbstract', window );"><strong>Supplemental Cash Flow Elements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashFlowSupplementalDisclosuresTextBlock', window );">Supplemental Cash Flow Information</a></td>
<td class="text">Supplemental Cash Flow Information <div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following represents supplemental cash flow information the years ended December 31, 2021, 2020 and 2019 (in thousands):</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"/><td style="width:380.50pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:48.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:48.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:48.25pt"/><td style="width:1.0pt"/></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Year Ended December 31,</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Supplemental Disclosure of Non-cash Investing and Financing Activities</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Class A and Class B common stock issued in connection with business combinations</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56,626&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,556&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;Increase/decrease to goodwill from measurement period adjustments/business combinations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,200&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(351)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Class A common stock issued for payment of earn-outs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">450&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,185&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">800&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;Class A common stock issued in connection with debt repayment </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,492&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain from transfer of membership</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(22,969)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued property and equipment purchases</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">784&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(527)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Consideration for asset acquisition or business combinations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,600&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Effects of Leases</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;Operating cash flows from operating leases </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,845&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,708&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,330&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;Leased assets obtained in exchange for operating lease liabilities </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,583)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,170)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,463&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Effects of Class B Exchanges</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Decrease in non-controlling interests as a result of Class B Exchanges</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42,377&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Decrease in deferred tax liability as a result of securities offerings and exchanges</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(22)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Supplemental Disclosures </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid for interest</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,113&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,352&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,037&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid for taxes, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">551&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,679&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,484&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowSupplementalDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for supplemental cash flow activities, including cash, noncash, and part noncash transactions, for the period. Noncash is defined as information about all investing and financing activities of an enterprise during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -URI http://asc.fasb.org/topic&amp;trid=2134446<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFlowSupplementalDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowElementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowElementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139858976472456">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation, Summary of Significant Accounting Policies and Change in Accounting Principles (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation</a></td>
<td class="text">Basis of PresentationThe consolidated financial statements of the Company are prepared in accordance with U.S. GAAP. Our consolidated financial statements include the accounts of all subsidiaries. All intercompany accounts and transactions are eliminated in consolidation. The consolidated balance sheet as of December 31, 2020, has been derived from audited financial statements as of that date and reflects the impact of the sale of True Health. See Note 5 for a complete summary of this transaction.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Accounting Estimates and Assumptions</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Accounting Estimates and Assumptions</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions affecting the reported amounts of assets and liabilities and the disclosures of contingent assets and liabilities as of the date of the financial statements and the reported amounts of revenue and expenses for the reporting period. Those estimates are inherently subject to change and actual results could differ from those estimates. In the accompanying consolidated financial statements, estimates are used for, but not limited to, the valuation of assets (including intangibles assets, goodwill and long-lived assets), liabilities, consideration related to business combinations and asset acquisitions, revenue recognition (including variable consideration), estimated selling prices for performance obligations in contracts with multiple performance obligations, reserves for claims and performance-based arrangements, credit losses, depreciable lives of assets, impairment of long-lived assets, stock-based compensation, deferred income taxes and valuation allowance, contingent liabilities, purchase price allocation in taxable stock transactions and useful lives of intangible assets.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingPolicyPolicyTextBlock', window );">Operating Segments</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Operating Segments</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating segments are defined as components of a business that may recognize revenue and incur expenses for which discrete financial information is available that is evaluated, on a regular basis, by the chief operating decision maker (&#8220;CODM&#8221;) to decide how </span></div>to allocate resources and assess performance. The Company made organizational changes, including re-evaluating its reportable segments, as a result of the entry into the agreement to sell True Health on January 11, 2021. Effective during the first quarter of 2021, the Company bifurcated its previous Services segment into two segments. The Company&#8217;s Evolent Health Services segment (&#8220;EHS&#8221;) includes our administrative simplification solution and supporting population health infrastructure. Our Clinical Solutions segment includes our specialty care management and physician-oriented total cost of care solutions, along with the New Century Health and Evolent Care Partners brands. Refer to Note 22 for a further discussion of our operating results by segment.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy', window );">Cash and Cash Equivalents</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cash and Cash Equivalents</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We consider all highly liquid instruments with original maturities of three months or less to be cash equivalents. The Company holds materially all of our cash in bank deposits with FDIC participating banks, at cost, which approximates fair value. Cash and cash equivalents held in money market funds are carried at fair value, which approximates cost.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy', window );">Accounts Receivable and Allowances</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Accounts Receivable and Allowances</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounts receivable are recorded and carried at the original invoiced amount less an allowance for any potential uncollectible amounts. We make estimates for the allowance for doubtful accounts and allowance for unbilled receivables based upon our assessment of various factors, including historical experience, the age of the accounts receivable balances, credit quality of our customers, current economic conditions, and other factors that may affect our ability to collect from customers.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property and Equipment, Net</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Property and Equipment, Net</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment are carried at cost less accumulated depreciation and amortization. Depreciation and amortization of property and equipment are computed using the straight-line method over the shorter of the estimated useful lives of the assets or the lease term. The following summarizes the estimated useful lives by asset classification:</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:63.066%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:34.040%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer hardware</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 years</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer software</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 year</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture and equipment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 - 7 years</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Internal-use software development costs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5 years</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shorter of useful life or remaining lease term</span></td></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">When an item is sold or retired, the cost and related accumulated depreciation or amortization is eliminated and the resulting gain or loss, if any, is recorded in gain (loss) on disposal of assets and consolidation on our consolidated statements of operations and comprehensive income (loss).</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We periodically review the carrying value of our long-lived assets, including property and equipment, for impairment whenever events or circumstances indicate that the carrying amount of such assets may not be fully recoverable. For long-lived assets to be held and used, impairments are recognized when the carrying amount of a long-lived asset group is not recoverable and exceeds fair value. The carrying amount of a long-lived asset group is not recoverable if it exceeds the sum of the undiscounted cash flows expected to result from the use and eventual disposition of the asset group. An impairment loss is measured as the amount by which the carrying amount of a long-lived asset group exceeds its fair value.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InternalUseSoftwarePolicy', window );">Software Development Costs</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Software Development Costs</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company capitalizes the cost of developing internal-use software, consisting primarily of personnel and related expenses (including stock-based compensation and employee taxes and benefits) for employees and third parties who devote time to their respective projects. Internal-use software costs are capitalized during the application development stage &#8211; when the research stage is complete and management has committed to a project to develop software that will be used for its intended purpose. Any costs incurred during subsequent efforts to significantly upgrade and enhance the functionality of the software are also capitalized. Capitalized software costs are included in property and equipment, net on our consolidated balance sheets. Amortization of internal-use software costs are recorded on a straight-line basis over their estimated useful life and begin once the project is substantially complete and the software is ready for its intended purpose.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development Costs</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and Development Costs</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development costs consist primarily of personnel and related expenses (including stock-based compensation and employee taxes and benefits) for employees engaged in research and development activities as well as third-party fees. All such costs are expensed as incurred. We focus our research and development efforts on activities that support our technology infrastructure, clinical program development, data analytics and network development capabilities. Research and development costs are recorded within selling, general and administrative expenses on our consolidated statements of operations and comprehensive income (loss) and were $15.5&#160;million, $15.1&#160;million and $19.8&#160;million for the years ended December 31, 2021, 2020 and 2019, respectively.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationsPolicy', window );">Business Combinations</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Business Combinations</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Companies acquired during each reporting period are reflected in the results of the Company effective from their respective dates of acquisition through the end of the reporting period. The Company allocates the fair value of purchase consideration to the assets acquired and liabilities assumed based on their estimated fair values at the acquisition date. Our estimates of fair value are based upon assumptions believed to be reasonable, but which are inherently uncertain and unpredictable and, as a result, actual results may differ </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">from estimates. Critical estimates used to value certain identifiable assets include, but are not limited to, expected long-term revenues, future expected operating expenses, cost of capital and appropriate discount rates. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The excess of the fair value of purchase consideration over the fair value of the assets acquired and liabilities assumed in the acquired entity is recorded as goodwill. Goodwill is assigned to the reporting unit that benefits from the synergies arising from the business combination. If the Company obtains new information about facts and circumstances that existed as of the acquisition date during the measurement period, which may be up to one year from the acquisition date, the Company may record adjustments to the assets acquired and liabilities assumed, with the corresponding offset to goodwill. Upon the conclusion of the measurement period or final determination of the values of assets acquired or liabilities assumed, whichever comes first, any subsequent adjustments are recorded on the Company's consolidated statements of operations and comprehensive income (loss). </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For contingent consideration recorded as a liability, the Company initially measures the amount at fair value as of the acquisition date and adjusts the liability, if needed, to fair value at each reporting period. Changes in the fair value of contingent consideration, other than measurement period adjustments, are recognized as operating income or expense. Acquisition-related expenses are recognized separately from the business combination and are expensed as incurred.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentsPolicy', window );">Equity Method Investments and Impairment of Equity Method Investments</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Equity Method Investments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For entities that are not consolidated, but where the Company has significant influence over the operating or financial decisions of the entity, the Company accounts for the investment under the equity method of accounting. In accordance with the equity method of accounting, the Company will recognize its share of earnings or losses of the investee in the period in which they are reported by the investee. The Company also considers whether there are any indicators of other-than-temporary impairment of its investments accounted for under the equity method. These investments are included in investments in equity method investees on the consolidated balance sheets with income or loss included in gain (loss) from equity method investees on the consolidated statements of operations and comprehensive income (loss).</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Impairment of Equity Method Investments</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company considers certain factors to determine if there is a decrease in its investment fair value for its equity method investments that is other than temporary. The equity method investments will be written down to fair value if there is evidence of a loss in value which is other-than-temporary. The Company may estimate the fair value of its equity method investments by considering recent investee equity transactions, discounted cash flow analysis and recent operating results. If the fair value of the investment is below the carrying amount, management considers several factors when determining whether other-than-temporary impairment has occurred. The estimation of fair value and whether other-than-temporary impairment has occurred requires the application of significant judgment and future results may vary from current assumptions. Refer to Note 17 for additional discussion regarding impairments on equity method investments.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy', window );">Goodwill</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Goodwill</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize the excess of the purchase price, plus the fair value of any non-controlling interests in the acquiree, over the fair value of identifiable net assets acquired as goodwill. Goodwill is not amortized, but is reviewed at least annually for indications of impairment, with consideration given to financial performance and other relevant factors. We perform impairment tests of goodwill at a reporting unit level. Following the sale of True Health, the Company has three reporting units and our annual goodwill impairment review occurs during the fourth quarter of each year. We perform impairment tests between annual tests if an event occurs, or circumstances change, that we believe would more likely than not reduce the fair value of a reporting unit below its carrying amount. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our goodwill impairment analysis first assesses qualitative factors to determine whether events or circumstances existed that would lead the Company to conclude it is more likely than not that the fair value of a reporting unit is below its carrying amount. If the Company determines that it is more likely than not that the fair value of a reporting unit is below the carrying amount, a quantitative goodwill assessment is required. In the quantitative evaluation, the fair value of the relevant reporting unit is determined and compared to the carrying value. If the fair value is greater than the carrying value, then the carrying value is deemed to be recoverable and no further action is required. If the fair value estimate is less than the carrying value, goodwill is considered impaired for the amount by which the carrying amount exceeds the reporting unit&#8217;s fair value and a charge is reported in goodwill impairment on our consolidated statements of operations and comprehensive income (loss). See Note 9 for additional discussion regarding the goodwill impairment tests conducted during 2021 and 2020.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsFiniteLivedPolicy', window );">Intangible Assets, Net</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Intangible Assets, Net </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Identified intangible assets are recorded at their estimated fair values at the date of acquisition and are amortized over their respective estimated useful lives using a method of amortization that reflects the pattern in which the economic benefits of the intangible assets are used. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following summarizes the estimated useful lives by asset classification:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"/><td style="width:438.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:97.75pt"/><td style="width:1.0pt"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate trade name</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10 - 20 years</span></div></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer relationships</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10 - 25 years</span></div></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Technology</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5 years</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provider network contracts</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 - 5 years</span></div></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets are reviewed for impairment if circumstances indicate the Company may not be able to recover the asset&#8217;s carrying value. The Company evaluates recoverability by determining whether the undiscounted cash flows expected to result from the use and eventual disposition of that asset or group exceed the carrying value at the evaluation date. If the undiscounted cash flows are not sufficient to cover the carrying value, the Company measures an impairment loss as the excess of the carrying amount of the long-lived asset or group over its fair value. See Note 9 for additional discussion regarding our intangible assets.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilityReserveEstimatePolicy', window );">Reserves for Claims and Performance-based Arrangements</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Reserves for Claims and Performance-based Arrangements</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Reserves for claims and performance-based arrangements reflect estimates of payments under performance-based arrangements and the ultimate cost of claims that have been incurred but not reported, including expected development on reported claims, those that have been reported but not yet paid (reported claims in process) and other medical care expenses and services payable that are primarily composed of accruals for incentives and other amounts payable to health care professionals and facilities. The Company uses actuarial principles and assumptions that are consistently applied in each reporting period and recognizes the actuarial best estimate of the ultimate liability along with a margin for adverse deviation. This approach is consistent with actuarial standards of practice that the liabilities be adequate under moderately adverse conditions. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The process of estimating reserves involves a considerable degree of judgment by the Company and, as of any given date, is inherently uncertain. The methods for making such estimates and for establishing the resulting liability are continually reviewed and adjustments are reflected in current results of operations in the period in which they are identified as experience develops or new information becomes known. See Note 23 for additional discussion regarding our reserves for claims and performance-based arrangements.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_evh_RightOfOffsetPolicyPolicyTextBlock', window );">Right of Offset</a></td>
<td class="text">Right of OffsetCertain customer arrangements give the Company the legal right to net payment for amounts due from customers and claims payable.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtPolicyTextBlock', window );">Long-term Debt</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Long-term Debt</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Convertible notes and amounts borrowed under our credit agreement are carried at cost, net of debt discounts and issuance costs, as long-term debt on the consolidated balance sheets. The debt discounts and issuance costs are amortized to interest expense on the consolidated statements of operations and comprehensive income (loss) using the straight-line method over the contractual term of the note if that method is not materially different from the effective interest rate method. Cash interest payments are due either quarterly or semi-annually in arrears and we accrue interest expense monthly based on the annual coupon rate. See Note 10 for further discussion regarding our convertible notes and credit agreement.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeasesPolicyTextBlock', window );">Leases</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Leases</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company enters into various office space, data center and equipment lease agreements in conducting its normal business operations. At the inception of any contract, the Company evaluates the agreement to determine whether the contract contains a lease. If the contract contains a lease, the Company then evaluates the term and whether the lease is an operating or finance lease. Most leases include one or more options to renew or may have a termination option. The Company determines whether these options are reasonably certain to be exercised at the inception of the lease. The rent expense is recognized on a straight-line basis in the consolidated statements of operations and comprehensive income (loss) over the terms of the respective leases. Leases with an initial term of 12 months or less are not recorded on the consolidated balance sheets.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As most of our leases do not provide an implicit rate, we use our incremental borrowing rate based on the information available at commencement date in determining the present value of lease payments. We use the implicit rate when readily determinable. Further, the Company treats all lease and non-lease components as a single combined lease component for all classes of underlying assets.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company also enters into sublease agreements for some of its leased office space. Rental income attributable to subleases is immaterial and is offset against rent expense over the terms of the respective leases.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Refer to Note 12 for additional lease disclosures.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock', window );">Revenue Recognition and Cost of Revenue (Exclusive of Depreciation and Amortization)</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue Recognition</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We derive revenue from two sources: (1) transformation services and (2) platform and operations services. Transformation services consist of implementation services whereby we assist the customer in launching its population health or health plan programs, or implement certain platform and operations services. In certain cases, transformation services can also include revenue associated with our support of certain one-time wind-down activities for clients who are exiting a line of business or population. Platform and operations services generally include multi-year arrangements with customers to provide various population health, health plan operations, specialty care management and claims processing services on an ongoing basis, as well as transition or run-out services to customers receiving primarily TPA services. Revenue is recognized when control of the services is transferred to our customers.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We use the following 5-step model, outlined in Accounting Standards Codification (&#8220;ASC&#8221;) Topic 606, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue from Contracts with Customers</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (&#8220;ASC 606&#8221;), to determine revenue recognition from our contracts with customers:</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"> Identify the contract(s) with a customer</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"> Identify the performance obligations in the contract</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"> Determine the transaction price</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"> Allocate the transaction price to performance obligations</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"> Recognize revenue when (or as) the entity satisfies a performance obligation</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Note 6 for further discussion of our policies related to revenue recognition. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cost of Revenue (Exclusive of Depreciation and Amortization)</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our cost of revenue includes direct expenses and shared resources that perform services in direct support of clients. Costs consist primarily of employee-related expenses (including compensation, benefits and stock-based compensation), expenses for TPA support and other services, as well as other professional fees. In certain cases, our cost of revenue also includes claims and capitation payments to providers and payments for pharmaceutical treatments and other health care expenditures through capitated arrangements.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Stock-based Compensation</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Stock-based Compensation</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company sponsors a stock-based incentive plan that provides for the issuance of stock-based awards to employees, vendors and non-employee directors of the Company or its consolidated subsidiaries. Our stock-based awards generally vest over a four-year period and stock options expire 10 years from the date of grant.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expense the fair value of stock-based awards granted under our incentive compensation plans. Fair value of stock options is determined using a Black-Scholes options valuation methodology. The fair value of the awards is expensed over the performance or service period, which generally corresponds to the vesting period, on a straight-line basis and is recognized as an increase to additional paid-in capital. Stock-based compensation expense is reflected in cost of revenue and selling, general and administrative expenses in our consolidated statements of operations and comprehensive income (loss). Additionally, and if applicable, we capitalize personnel expenses attributable to the development of internal-use software, which include stock-based compensation costs. We recognize share-based award forfeitures as they occur.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Taxes</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred income taxes are recognized, based on enacted rates, when assets and liabilities have different values for financial statement and tax reporting purposes. A valuation allowance is recorded to the extent required. Considerable judgment and the use of estimates are required in determining whether a valuation allowance is necessary and, if so, the amount of such valuation allowance. In evaluating the need for a valuation allowance, we consider many factors, including: the nature and character of the deferred tax assets and liabilities; taxable income in prior carryback years; future reversals of temporary differences; the length of time carryovers can be utilized; and any tax planning strategies we would employ to avoid a tax benefit from expiring unused.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We use a recognition threshold and a measurement attribute for the financial statement recognition and measurement of uncertain tax positions taken or expected to be taken in a tax return. For those benefits to be recognized, a tax position must be more-likely-than-not to be sustained upon examination by taxing authorities. We recognize interest and penalties accrued on any unrecognized tax exposures as a component of income tax expense, when applicable. As of December 31, 2021 and 2020, our identified balance of uncertain income tax positions would not have a material impact to the consolidated financial statements. We are subject to taxation in various jurisdictions in the U.S. and India and remain subject to examination by taxing jurisdictions for the year 2011 and all subsequent periods due to the availability of NOL carryforwards.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a holding company and our assets consist of our direct ownership in Evolent Health LLC, for which we are the managing member. Prior to the Class B unit exchanges on December 26, 2019, Evolent Health LLC was classified as a partnership for U.S. federal and applicable state and local income tax purposes and, as such, was not subject to U.S. federal, state and local income taxes. Taxable income or loss generated by Evolent Health LLC was allocated to holders of its units, including us, on a pro rata basis. Accordingly, we were subject to U.S. federal, state and local income taxes with respect to our allocable share of any taxable income of Evolent Health LLC. As a result of the 2019 Class B units exchanges, we became the sole owner of Evolent Health LLC and its entity classification changed from a partnership to an entity disregarded as separate from its owner for U.S. federal, state and local income tax purposes. Following the Class B units exchanges, any taxable income or loss generated by Evolent Health LLC is reportable and taxable only on the Company&#8217;s federal, state and local income tax returns. Evolent Health LLC has direct ownership in corporate subsidiaries, which were subject to U.S. and foreign taxes with respect to their own operations during 2019.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Earnings (Loss) Per Share</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Earnings (Loss) per Share</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic earnings (loss) per share is computed by dividing net income (loss) available to Class A common shareholders by the weighted-average number of Class A common shares outstanding.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For periods of net income, and when the effects are not anti-dilutive, we calculate diluted earnings per share by dividing net income available to Class A common shareholders by the weighted average number of Class A common shares plus the weighted average number of Class A common shares assuming the conversion of our convertible notes, as well as the impact of all potential dilutive common shares, consisting primarily of common stock options and unvested restricted stock awards using the treasury stock method and our exchangeable Class B common stock. For periods of net loss, shares used in the diluted earnings (loss) per share calculation represent basic shares as using potentially dilutive shares would be anti-dilutive.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock', window );">Fair Value Measurement</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fair Value Measurement</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fair value is the price that would be received from the sale of an asset or paid to transfer a liability assuming an orderly transaction in the most advantageous market at the measurement date. Our consolidated balance sheets include various financial instruments (primarily cash not held in money-market funds, restricted cash, accounts receivable, accounts payable, accrued expenses and other liabilities) that are carried at cost and that approximate fair value.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Note 19 for further discussion regarding fair value measurement.</span></div>Fair Value Measurement<div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">GAAP defines fair value as the price that would be received from the sale of an asset or paid to transfer a liability (an exit price) assuming an orderly transaction in the most advantageous market at the measurement date. GAAP also establishes a hierarchical disclosure framework which prioritizes and ranks the level of observability of inputs used in measuring fair value. These tiers include:</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 1 - inputs to the valuation methodology are quoted prices available in active markets for identical instruments as of the reporting date;</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 2 - inputs to the valuation methodology are other than quoted prices in active markets, which are either directly or indirectly observable as of the reporting date and the fair value can be determined through the use of models or other valuation methodologies; and </span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 3 - inputs to the valuation methodology are unobservable inputs in situations where there is little or no market activity for the asset or liability.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In certain cases, the inputs used to measure fair value may fall into different levels of the fair value hierarchy. In such cases, the level within the fair value hierarchy is based on the lowest level of input that is significant to the fair value measurement. Our assessment of the significance of a particular input to the fair value measurement in its entirety requires judgment and considers factors specific to the particular asset or liability being measured. </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Nonrecurring Fair Value Measurements</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the assets and liabilities that are recorded at fair value on a recurring basis, the Company records certain assets and liabilities at fair value on a nonrecurring basis as required by GAAP. Generally, assets are recorded at fair value on a nonrecurring basis as a result of impairment charges. This includes assets and liabilities recorded in business combinations or asset acquisitions, goodwill, intangible assets, property, plant and equipment, held-to-maturity investments and equity method investments. While not carried at fair value on a recurring basis, these items are continually monitored for indicators of impairment that would indicate current carrying value is greater than fair value. In those situations, the assets are considered impaired and written down to current fair value. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Other Fair Value Disclosures</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying amounts of cash and cash equivalents (those not held in a money market fund), restricted cash, receivables, prepaid expenses, accounts payable, accrued liabilities and accrued compensation approximate their fair values because of the relatively short-term maturities of these items and financial instruments.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Note 10 for information regarding the fair value of the 2024 Notes, 2025 Notes and 2021 Notes.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Adoption of New Accounting Standards and Recent Accounting Pronouncements Not Yet Effective</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Adoption of New Accounting Standards</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2016, the FASB issued ASU 2016-13, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financial Instruments-Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and subsequently issued additional guidance that modified ASU 2016-13. The standard requires an entity to change its accounting approach for measuring and recognizing credit losses on certain financial assets measured at amortized cost, including trade receivables, certain non-trade receivables, contract assets, held-to-maturity securities, customer advances and certain off-balance sheet credit exposures, by replacing the existing &#8220;incurred loss&#8221; framework with an expected credit loss recognition model.&#160; The new standard results in earlier recognition of credit losses based on past events, current conditions and reasonable and supportable forecasts.&#160;We adopted the requirements of this standard effective January 1, 2020 using the modified retrospective approach and recorded a cumulative effect adjustment of $3.0 million to January 1, 2020 retained earnings (accumulated deficit). Results for reporting periods beginning January 1, 2020 reflect the adoption of <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM180Ni9mcmFnOjhkNTIzNGI1NjdkZjRiMThiNjM1NmFmN2Q4OWQ4MDE3L3RleHRyZWdpb246OGQ1MjM0YjU2N2RmNGIxOGI2MzU2YWY3ZDg5ZDgwMTdfMzI1Ng_c324734f-03c4-4b52-af23-6ac596334a4b">ASU 2016-13</span>, while prior period amounts were not adjusted and continue to be reported in accordance with our historical accounting practices. Refer to Note 7 for additional disclosures related to current expected credit losses.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2019, the FASB issued ASU No. 2019-12,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Simplifying the Accounting for Income Taxes.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The amendments in the ASU remove certain exceptions to the intraperiod tax allocation of losses and gains from different financial statement components and to the method of recognizing income taxes on interim period losses and the recognition of deferred tax liabilities for outside basis differences. In addition, the new guidance simplifies aspects of the accounting for franchise taxes and clarifies the accounting for </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">transactions that result in a step-up in the tax basis of goodwill. The Company adopted this standard starting in the first quarter of 2021, which did not have a material impact on our consolidated financial statements.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2020, the FASB issued ASU 2020-06, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Accounting for Convertible Instruments and Contracts in an Entity&#8217;s Own Equity</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The ASU simplifies the accounting for certain financial instruments with characteristics of liabilities and equity, including convertible instruments and contracts in an entity&#8217;s own equity. Specifically, the ASU removes the separation models for convertible debt with a cash conversion feature or convertible instruments with a beneficial conversion feature and no longer permits the use of the treasury stock method from calculating earnings per share. As a result, after adopting the ASU&#8217;s guidance, we will not separately present in equity an embedded conversion feature of such debt. Instead, we will account for a convertible debt instrument wholly as debt unless (i) a convertible instrument contains features that require bifurcation as a derivative or (ii) a convertible debt instrument was issued at a substantial premium. Additionally, the ASU removes certain conditions for equity classification related to contracts in an entity&#8217;s own equity (e.g., warrants) and amends certain guidance related to the computation of earnings per share for convertible instruments and contracts on an entity&#8217;s own equity. The guidance in this ASU can be adopted using either a full or modified retrospective approach and becomes effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2021. We will adopt the ASU in the first quarter of fiscal 2022, and expect to use modified retrospective approach. The Company is currently assessing the impact, if any, that ASU 2020-06 would have on its financial position, results of operations or cash flows, however, the inability to use the treasury stock method in accounting for the shares issuable upon conversion of the 2024 Notes and the 2025 Notes will adversely affect our diluted earnings per share.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recent Accounting Pronouncements Not Yet Effective</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2021, the FASB issued ASU 2021-08, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Business Combinations (Topic 805): Accounting for Contract Assets and Contract Liabilities from Contracts with Customers</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which requires contract assets and contract liabilities acquired in a business combination to be recognized and measured by the acquirer on the acquisition date in accordance with ASC 606, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue from Contracts with Customers.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> This approach differs from the current requirement to measure contract assets and contract liabilities acquired in a business combination at fair value. This new standard is effective for our interim and annual periods beginning after December 15, 2022, with early adoption permitted. We are currently evaluating the adoption impacts on our consolidated financial statements.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_RightOfOffsetPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Right of Offset, Policy</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_RightOfOffsetPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for completed business combinations (purchase method, acquisition method or combination of entities under common control). This accounting policy may include a general discussion of the purchase method or acquisition method of accounting (including for example, the treatment accorded contingent consideration, the identification of assets and liabilities, the purchase price allocation process, how the fair values of acquired assets and liabilities are determined) and the entity's specific application thereof. An entity that acquires another entity in a leveraged buyout transaction generally discloses the accounting policy followed by the acquiring entity in determining the basis used to value its interest in the acquired entity, and the rationale for that accounting policy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 05<br> -Paragraph 4<br> -Subparagraph (a)-(d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6909625&amp;loc=d3e227-128457<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents with respect to unrestricted balances.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4273-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy related to debt. Includes, but is not limited to, debt issuance costs, the effects of refinancings, method of amortizing debt issuance costs and original issue discount, and classifications of debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123465755&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for equity method of accounting for investments and other interests. Investment includes, but is not limited to, unconsolidated subsidiary, corporate joint venture, noncontrolling interest in real estate venture, limited partnership, and limited liability company. Information includes, but is not limited to, ownership percentage, reason equity method is or is not considered appropriate, and accounting policy election for distribution received.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.12)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 21D<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=SL94080555-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for goodwill. This accounting policy also may address how an entity assesses and measures impairment of goodwill, how reporting units are determined, how goodwill is allocated to such units, and how the fair values of the reporting units are determined.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e32247-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32847-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32840-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL116659661-227067<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e32280-109318<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsFiniteLivedPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for finite-lived intangible assets. This accounting policy also might address: (1) the amortization method used; (2) the useful lives of such assets; and (3) how the entity assesses and measures impairment of such assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120154696&amp;loc=d3e54445-107959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 920<br> -SubTopic 350<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120155617&amp;loc=SL120155638-234783<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123372394&amp;loc=d3e18823-107790<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 920<br> -SubTopic 350<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120155617&amp;loc=SL120155628-234783<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 920<br> -SubTopic 350<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120155617&amp;loc=SL120155628-234783<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsFiniteLivedPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InternalUseSoftwarePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs incurred when both (1) the software is acquired, internally developed, or modified solely to meet the entity's internal needs, and (2) during the software's development or modification, no substantive plan exists or is being developed to market the software externally.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 40<br> -Section 30<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118172244&amp;loc=d3e17916-109280<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 50<br> -Section 25<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=16397303&amp;loc=d3e19379-109286<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InternalUseSoftwarePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for leasing arrangement entered into by lessee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918666-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilityReserveEstimatePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for estimating its liability as of the balance sheet date for the ultimate cost of settling reported and unreported claims incurred and claims adjustment expenses (including effects of inflation and other societal and economic factors).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -URI http://asc.fasb.org/subtopic&amp;trid=2560295<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilityReserveEstimatePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99779-112916<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99893-112916<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for determining the allowance for doubtful accounts for trade and other accounts receivable balances, and when impairments, charge-offs or recoveries are recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=d3e5144-111524<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue from contract with customer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130561-203045<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130566-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130563-203045<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -URI http://asc.fasb.org/topic&amp;trid=49130388<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130566-203045<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130563-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123372394&amp;loc=d3e18823-107790<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130566-203045<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130564-203045<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130566-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8864-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8864-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8864-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8864-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8864-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8864-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b),(f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139858983899416">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation, Summary of Significant Accounting Policies and Change in Accounting Principles (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock', window );">Schedule of restricted cash and cash equivalents</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restricted cash and restricted investments include cash and investments used to collateralize various contractual obligations as of December&#160;31, 2021 and 2020 (in thousands) as follows:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"/><td style="width:421.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:54.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:54.25pt"/><td style="width:1.0pt"/></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Collateral for letters of credit for facility leases </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,769&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,510&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Collateral with financial institutions </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,662&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,743&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Claims processing services </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(4)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73,226&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,064&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">711&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total restricted cash and restricted investments</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88,662&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,028&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current restricted cash</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75,685&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,374&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current restricted cash and restricted investments</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75,685&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,374&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-current restricted cash</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,977&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,654&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total non-current restricted cash and restricted investments</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,977&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,654&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt">Amounts exclude $0.6 million of non-current restricted investments and $0.1&#160;million of current restricted cash from claims processing services reclassified to discontinued operations as of December&#160;31, 2020.</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt">Represents restricted cash related to collateral for letters of credit required in conjunction with lease agreements. See Note 12 for further discussion of our lease commitments. </span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt">Represents collateral held with financial institutions for risk-sharing and other arrangements. As of December&#160;31, 2021 and 2020, approximately $11.7&#160;million and $4.7 million, respectively, of the collateral amounts were held in a FDIC participating bank account. See Note 19 for discussion of fair value measurement and Note 11 for discussion of our risk-sharing arrangements. </span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(4)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt">Represents cash held by the Company related to claims processing services on behalf of partners. These are pass-through amounts and can fluctuate materially from period to period depending on the timing of when the claims are processed.</span></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides a reconciliation of cash and cash equivalents and restricted cash reported within the consolidated balance sheets that sum to the total of the same amounts shown in the consolidated statements of cash flows as of December&#160;31, 2021 and 2020 (in thousands).</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"/><td style="width:433.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:48.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:48.25pt"/><td style="width:1.0pt"/></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">266,280&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">340,490&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash and restricted investments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88,662&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,707&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted investments included in restricted cash and restricted investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(616)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:5.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash and cash equivalents and restricted cash shown in the consolidated statements of cash flows </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">354,942&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">361,581&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt">As a result of the closing of the sale of True Health, the consolidated statements of operations, consolidated balance sheets and related financial information reflect the Company&#8217;s operations and assets and liabilities of True Health as discontinued operations for all periods presented. Cash flows and comprehensive income have not been adjusted and are included in the consolidated statements of cash flows and consolidated statements of comprehensive income (loss) for all periods presented. See Note 5.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Summary of property and equipment</a></td>
<td class="text">The following summarizes the estimated useful lives by asset classification:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:63.066%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:34.040%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer hardware</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 years</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer software</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 year</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture and equipment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 - 7 years</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Internal-use software development costs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5 years</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shorter of useful life or remaining lease term</span></td></tr></table><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following summarizes our property and equipment (in thousands):</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"/><td style="width:408.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:54.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:67.75pt"/><td style="width:1.0pt"/></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer hardware</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,970&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,866&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture and equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,581&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,559&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Internal-use software development costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">159,587&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">137,085&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,325&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,586&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total property and equipment</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">200,463&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">175,096&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated depreciation and amortization expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(119,098)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(88,856)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total property and equipment, net</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81,365&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">86,240&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock', window );">Schedule of intangible assets</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following summarizes the estimated useful lives by asset classification:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"/><td style="width:438.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:97.75pt"/><td style="width:1.0pt"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate trade name</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10 - 20 years</span></div></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer relationships</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10 - 25 years</span></div></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Technology</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5 years</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provider network contracts</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 - 5 years</span></div></td></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Details of our intangible assets (in thousands, except weighted-average useful lives) as of December&#160;31, 2021 and December&#160;31, 2020  are presented below:</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"/><td style="width:72.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:54.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:48.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:63.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:46.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:54.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:48.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:63.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:45.25pt"/><td style="width:1.0pt"/></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr style="height:44pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted- Average Remaining Useful Life</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross Carrying Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Accumulated Amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net Carrying Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted- Average Remaining Useful Life</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross Carrying Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Accumulated Amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net Carrying Value</span></td></tr><tr style="height:24pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate trade name</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.4</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,800&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,693&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,107&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.2</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,300&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,271&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,029&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:24pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer relationships </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.9</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">311,019&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72,697&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">238,322&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.2</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">278,519&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57,716&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">220,803&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Technology</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.0</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87,922&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73,378&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,544&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.8</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">82,922&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63,507&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,415&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:24pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Below market lease, net</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.3</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,218&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">950&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">268&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.3</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,118&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">648&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">470&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:35pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provider network contracts </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.2</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,417&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,874&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,543&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.9</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,175&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,900&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,275&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:35pt"><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total intangible assets, net</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">442,376&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">162,592&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">279,784&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">398,034&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">133,042&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">264,992&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt">Amounts exclude $2.2&#160;million and $0.9&#160;million of customer relationships and provider network contracts, respectively, net of accumulated amortization, with weighted average remaining useful lives of 15 years and 10 months reclassified to discontinued operations as of December&#160;31, 2020.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of cash and cash equivalents restricted as to withdrawal or usage.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=SL98516268-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139858977885544">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Transactions (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract', window );"><strong>Business Combination and Asset Acquisition [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock', window );">Schedule of allocation of purchase price</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The purchase price was allocated to the assets acquired and liabilities assumed based on their estimated fair values as of October 1, 2021, as follows (in thousands):</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:87.372%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.428%"/><td style="width:0.1%"/></tr><tr><td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Purchase consideration:</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46,500&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of Class A common stock issued</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56,626&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of contingent consideration</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,600&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total consideration</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">117,726&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Tangible assets acquired:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,430&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,301&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:87.372%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.428%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other non-current assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,564&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total tangible assets acquired</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,373&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Identifiable intangible assets acquired:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer relationships</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,500&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Technology</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate trade name</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,500&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total identifiable intangible assets acquired</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,000&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities assumed:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">93&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued liabilities </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">661&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued compensation and employee benefits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">970&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax liabilities, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">499&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,712&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities assumed</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,935&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77,288&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net assets acquired</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">117,726&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock', window );">Schedule of net assets acquired</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The purchase price was allocated to the assets acquired and liabilities assumed based on their estimated fair values as of October 1, 2021, as follows (in thousands):</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:87.372%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.428%"/><td style="width:0.1%"/></tr><tr><td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Purchase consideration:</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46,500&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of Class A common stock issued</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56,626&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of contingent consideration</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,600&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total consideration</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">117,726&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Tangible assets acquired:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,430&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,301&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:87.372%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.428%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other non-current assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,564&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total tangible assets acquired</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,373&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Identifiable intangible assets acquired:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer relationships</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,500&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Technology</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate trade name</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,500&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total identifiable intangible assets acquired</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,000&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities assumed:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">93&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued liabilities </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">661&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued compensation and employee benefits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">970&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax liabilities, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">499&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,712&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities assumed</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,935&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77,288&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net assets acquired</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">117,726&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationAndAssetAcquisitionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of a material business combination completed during the period, including background, timing, and recognized assets and liabilities. This table  does not include leveraged buyouts.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1486-128463<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amounts recognized as of the acquisition date for each major class of assets acquired and liabilities assumed. May include but not limited to the following: (a) acquired receivables; (b) contingencies recognized at the acquisition date; and (c) the fair value of noncontrolling interests in the acquiree.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123413009&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139858977515944">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Discontinued Operations (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract', window );"><strong>Discontinued Operations and Disposal Groups [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock', window );">Schedule of discontinued operations</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the results of operations of the Company&#8217;s True Health business, which are included in loss from discontinued operations in the consolidated statements of operations and comprehensive income (loss) for the years ended December 31, 2021, 2020 and 2019:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:69.872%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.205%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.205%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.208%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Revenue</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Platform and operations</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">356&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">145&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Premiums</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,795&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">117,377&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">171,742&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenue</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,833&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">117,733&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">171,887&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Expenses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of revenue (exclusive of depreciation and amortization expenses presented separately below) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,885&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,343&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,633&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Claims expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,954&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87,951&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">135,774&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative expenses </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,764&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,576&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,617&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">160&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">640&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">590&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating expenses</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45,763&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">125,510&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">169,614&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating income (loss)</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(930)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,777)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,273&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">112&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">531&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">581&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(25)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income (loss) before income taxes and non-controlling interests</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(847)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,259)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,872&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:69.872%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.205%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.205%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.208%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Benefit (provision) for income taxes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(326)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,185)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,259&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(521)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,074)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,613&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt">Cost of revenue includes intercompany expenses between the Company and True Health that are recorded in income from continuing operations in the consolidated statements of operations and comprehensive income (loss) related to an existing services agreement for claims processing and other health plan administrative functions of $2.8&#160;million, $13.6&#160;million and $6.6&#160;million for the years ended December 31, 2021, 2020 and 2019, respectively.</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt">Selling, general and administrative expenses includes intercompany expenses between the Company and True Health that are recorded in income from continuing operations on the consolidated statements of operations and comprehensive income (loss) related to an existing services agreement for claims processing and other health plan administrative functions of $1.1 million, $6.4 million and $6.0&#160;million for the years ended December 31, 2021, 2020 and 2019, respectively. </span></div>Cash flows related to the True Health business during the year ended December 31, 2021, 2020 and 2019 were as follows:<div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:69.872%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.205%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.205%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.208%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash flows provided by (used in) operating activities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,002&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,852&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,642)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash flows (used in) provided by investing activities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,494)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,636&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,172)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash flows used in financing activities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,500)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the current and long-term assets and liabilities of the discontinued True Health business in the consolidated balance sheets as of December&#160;31, 2020:</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:82.927%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.873%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">ASSETS</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,488&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash and restricted investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,437&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,198&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investments, at amortized cost</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,728&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,914&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash and restricted investments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">616&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investments, at amortized cost</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,919&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other noncurrent assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible assets, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,080&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,705&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54,293&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">LIABILITIES</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">93&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,265&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued compensation and employee benefits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,115&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,140&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reserve for claims and performance-based arrangements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,858&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,471&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other long-term liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">128&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:82.927%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.873%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax liabilities, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,648&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt">Accounts payable excludes $1.5&#160;million between the Company and True Health related to an existing services agreement for claims processing and other health plan administrative functions as of December 31, 2020.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of information related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3A<br> -URI http://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=SL51724579-110230<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=d3e1474-107760<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5D<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721677-107760<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721533-107759<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3A<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721659-107760<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4B<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721665-107760<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5C<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721675-107760<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=d3e1361-107760<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5A<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721671-107760<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4A<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721663-107760<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139858983842760">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue Recognition (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue from Contract with Customer [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueTableTextBlock', window );">Disaggregation of revenue</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table represents Evolent&#8217;s revenue disaggregated by segment and end-market for the years ended December 31, 2021, 2020 and 2019 (in thousands):</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"/><td style="width:220.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:48.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:48.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:48.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:48.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:48.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:48.25pt"/><td style="width:1.0pt"/></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="33" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Year Ended December 31,</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Evolent Health Services</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Clinical Solutions</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicaid</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">215,236&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">236,634&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">267,222&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">205,833&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">274,028&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75,675&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicare</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,358&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68,505&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73,671&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">363,053&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">257,092&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">199,817&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial and other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68,219&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77,221&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68,012&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,258&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,159&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,725&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">309,813&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">382,360&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">408,905&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">598,144&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">542,279&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">278,217&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock', window );">Contract with customer, asset and liability</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides information about receivables, contract assets and deferred revenue from contracts with customers as of December&#160;31, 2021 and 2020 (in thousands):</span></div><div style="margin-top:5pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"/><td style="width:403.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:58.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:67.75pt"/><td style="width:1.0pt"/></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term receivables </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">129,012&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">118,730&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term receivables </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,877&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,554&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term contract assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">329&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term deferred revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,944&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,187&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term deferred revenue</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,437&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,593&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt">Amounts exclude $3.4&#160;million of short-term receivables and $4.1&#160;million of short-term deferred revenue reclassified to discontinued operations as of December&#160;31, 2020.</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt">Excludes pharmacy claims receivable and premiums receivable.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes in deferred revenue for the year ended December 31, 2021 are as follows (in thousands):</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"/><td style="width:433.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:102.25pt"/><td style="width:1.0pt"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Deferred revenue</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of beginning-of-period</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,780&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reclassification to revenue, as a result of performance obligations satisfied</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10,175)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash received in advance of satisfaction of performance obligations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,776&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of end of period</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,381&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of receivable, contract asset, and contract liability from contract with customer. Includes, but is not limited to, change in contract asset and contract liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130551-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130545-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139858977554840">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Credit Losses (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CreditLossAbstract', window );"><strong>Credit Loss [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableAllowanceForCreditLossTableTextBlock', window );">Accounts receivable, allowance for credit loss</a></td>
<td class="text">The following table summarizes the changes in allowance for credit losses on our accounts receivables, certain non-trade accounts receivable and contract assets for the year ended December 31, 2021 and 2020 (in thousands):<div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:76.816%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.594%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.596%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of beginning of period</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,056)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(41)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Passport acquisition</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,582)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cumulative transition adjustment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,815)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provision for credit losses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,411)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,283)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Charge-offs</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,093&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,665&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of end of period</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,374)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,056)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt">Charge offs for the year ended December 31, 2021, are primarily due to balances written-off that were previously fully reserved as part of the Passport transaction.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableAllowanceForCreditLossTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allowance for credit loss on accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=124255953&amp;loc=SL82919249-210447<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableAllowanceForCreditLossTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditLossAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditLossAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139858977508920">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment, Net (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Summary of property and equipment</a></td>
<td class="text">The following summarizes the estimated useful lives by asset classification:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:63.066%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:34.040%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer hardware</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 years</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer software</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 year</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture and equipment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 - 7 years</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Internal-use software development costs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5 years</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shorter of useful life or remaining lease term</span></td></tr></table><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following summarizes our property and equipment (in thousands):</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"/><td style="width:408.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:54.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:67.75pt"/><td style="width:1.0pt"/></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer hardware</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,970&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,866&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture and equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,581&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,559&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Internal-use software development costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">159,587&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">137,085&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,325&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,586&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total property and equipment</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">200,463&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">175,096&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated depreciation and amortization expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(119,098)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(88,856)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total property and equipment, net</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81,365&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">86,240&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139858977607480">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Goodwill and Intangible Assets, Net (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfGoodwillTextBlock', window );">Schedule of goodwill</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the changes in the carrying amount of goodwill, by reportable segment, for the periods presented (in thousands):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:60.705%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.983%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.772%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.983%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.772%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.985%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">EHS</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Clinical Solutions</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Consolidated</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of December 31, 2019 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">431,684&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">134,675&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">566,359&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill disposal </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,200)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,200)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Impairment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(215,100)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(215,100)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency translation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(30)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(30)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of December 31, 2020</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">214,354&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">134,675&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">349,029&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill acquired</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77,288&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77,288&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency translation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(20)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(20)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of December 31, 2021</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">214,334&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">211,963&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">426,297&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt">Net of cumulative inception to date impairment of $575.5 million and $360.4 million as of December 31, 2020 and 2019, respectively.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt">Goodwill written-off upon disposal of a consolidated subsidiary.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock', window );">Schedule of intangible assets details</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following summarizes the estimated useful lives by asset classification:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"/><td style="width:438.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:97.75pt"/><td style="width:1.0pt"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate trade name</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10 - 20 years</span></div></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer relationships</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10 - 25 years</span></div></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Technology</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5 years</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provider network contracts</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 - 5 years</span></div></td></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Details of our intangible assets (in thousands, except weighted-average useful lives) as of December&#160;31, 2021 and December&#160;31, 2020  are presented below:</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"/><td style="width:72.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:54.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:48.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:63.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:46.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:54.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:48.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:63.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:45.25pt"/><td style="width:1.0pt"/></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr style="height:44pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted- Average Remaining Useful Life</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross Carrying Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Accumulated Amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net Carrying Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted- Average Remaining Useful Life</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross Carrying Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Accumulated Amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net Carrying Value</span></td></tr><tr style="height:24pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate trade name</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.4</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,800&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,693&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,107&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.2</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,300&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,271&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,029&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:24pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer relationships </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.9</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">311,019&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72,697&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">238,322&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.2</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">278,519&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57,716&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">220,803&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Technology</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.0</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87,922&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73,378&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,544&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.8</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">82,922&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63,507&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,415&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:24pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Below market lease, net</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.3</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,218&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">950&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">268&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.3</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,118&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">648&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">470&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:35pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provider network contracts </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.2</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,417&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,874&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,543&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.9</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,175&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,900&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,275&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:35pt"><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total intangible assets, net</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">442,376&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">162,592&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">279,784&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">398,034&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">133,042&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">264,992&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt">Amounts exclude $2.2&#160;million and $0.9&#160;million of customer relationships and provider network contracts, respectively, net of accumulated amortization, with weighted average remaining useful lives of 15 years and 10 months reclassified to discontinued operations as of December&#160;31, 2020.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock', window );">Schedule of future estimated amortization of intangible assets</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Future estimated amortization of intangible assets (in thousands) as of December&#160;31, 2021, is as follows:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"/><td style="width:478.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:58.00pt"/><td style="width:1.0pt"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,102&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,798&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,913&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,403&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,153&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">164,415&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total future amortization of intangible assets</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">279,784&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfGoodwillTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13854-109267<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfGoodwillTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139858977508920">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Long-term Debt (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleDebtTableTextBlock', window );">Schedule of convertible debt</a></td>
<td class="text">The following table summarizes the carrying value of the long-term convertible debt as of December&#160;31, 2021 and 2020 (in thousands):<div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"/><td style="width:409.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:60.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:60.25pt"/><td style="width:1.0pt"/></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024 Notes</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Carrying value</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">89,361&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81,462&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unamortized debt discount and issuance costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,690&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,589&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Principal amount</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">117,051&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">117,051&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Remaining amortization period (years)</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.9</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.9</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">195,445&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">153,220&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2025 Notes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Carrying value</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">126,315&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">116,349&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unamortized debt discount and issuance costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46,185&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56,151&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Principal amount</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">172,500&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">172,500&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Remaining amortization period (years)</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.8</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.8</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">177,251&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">147,488&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021 Notes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Carrying value</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,557&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unamortized debt discount and issuance costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">180&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Principal amount</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,737&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Remaining amortization period (years)</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.0</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.9</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,470&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:5pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt">Fair values for notes are derived from available trading prices closest to the respective balance sheet date.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleDebtTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of convertible debt instrument. Includes, but is not limited to, principal amount and amortized premium or discount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleDebtTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139858982761480">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectsOfReinsuranceTableTextBlock', window );">Summary of premiums and claims assumed</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following summarizes premiums and claims assumed under the Reinsurance Agreements for the years ended December 31, 2021, 2020 and 2019 (in thousands):</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"/><td style="width:387.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:46.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:46.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:46.00pt"/><td style="width:1.0pt"/></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Year Ended December 31,</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reinsurance premiums assumed</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,179&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,130&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">83,325&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reinsurance premiums ceded</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,614)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,275)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Claims assumed</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,468&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,812&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72,594&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Claims ceded</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(422)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Claims-related administrative expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,159&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,024&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:24pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Increase (decrease) in reserves for claims and performance-based arrangements attributable to the Reinsurance Agreement</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,166&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,465&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,293)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:24pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reserves for claims and performance-based arrangements attributable to the Reinsurance Agreement at the beginning of the period</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,002&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,243&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:23pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Impact of consolidation on payable for claims and performance-based arrangements attributable to the Reinsurance Agreement</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(502)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reinsurance payments paid (received)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,078&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,039)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,536&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:24pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payable for claims and performance-based arrangements attributable to the Reinsurance Agreement at the end of the period</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">90&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,002&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock', window );">Summary of major customers</a></td>
<td class="text">The following table summarizes the partners who represented at least 10.0% of our consolidated trade accounts receivable as of December&#160;31, 2021 and December&#160;31, 2020:<div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"/><td style="width:426.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:55.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:48.25pt"/><td style="width:1.0pt"/></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31,</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cook County Health and Hospitals System</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61.5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Florida Blue Medicare, Inc. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">N/A</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Molina Healthcare</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:115%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%;padding-left:11.94pt">Customer added during the year ended December 31, 2021. </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes those partners who represented at least 10.0% of our consolidated revenue for the years ended December 31, 2021, 2020 and 2019:</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"/><td style="width:380.50pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:48.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:48.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:48.25pt"/><td style="width:1.0pt"/></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Year Ended December 31,</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cook County Health and Hospitals Systems</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28.0%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">New Mexico Health Connections</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Florida Blue Medicare, Inc. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">N/A</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Passport </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt">The denominator excludes $44.8&#160;million, $117.4&#160;million and $171.7&#160;million of True Health premium revenue reclassified to discontinued operations for the years ended December 31, 2021, 2020 and 2019, respectively.</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt">Customer added during the year ended December 31, 2021.</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt">Represents revenues from EVH Passport/UHC through the Molina Closing. Subsequent to the Molina Closing on September 1, 2020, the Company has not received any material revenue from EVH Passport. However, as part of the Molina Closing, we entered into a new contract with Molina on similar terms to our prior services contract with EVH Passport through December 31, 2020 which accounted for approximately 9.7% of our consolidated revenues for the year ended December 31, 2020.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">* &#160;&#160;&#160;&#160;Represents less than 10.0% of the respective balance</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectsOfReinsuranceTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the effects of reinsurance, for example, but not limited to, disclosure of direct, assumed, and ceded insurance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 605<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6486672&amp;loc=d3e27261-158547<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectsOfReinsuranceTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13537-108611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13531-108611<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6404-108592<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6327-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6351-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6442-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139858984016120">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Schedule of primary office leases and maturity of lease liabilities</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our primary office leases as of December&#160;31, 2021 (in thousands, other than term):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:539.25pt"><tr><td style="width:1.0pt"/><td style="width:237.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:94.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:94.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:94.00pt"/><td style="width:1.0pt"/></tr><tr style="height:24pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Location</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Lease Termination Term (in years)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Future Minimum Lease Commitments</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Letter of Credit Amount Required</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Arlington, VA</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.1</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,581&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,579&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Riverside, IL </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.3</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41,408&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">232&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Edison, NJ</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.3</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,180&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">222&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pune, India</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.7</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,382&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Brea, CA</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.4</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">462&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Maturity of lease liabilities (in thousands) as of December&#160;31, 2021, is as follows:</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:87.788%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.012%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Operating lease expense</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,916&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,258&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,968&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,653&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,988&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,972&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease payments</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85,755&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,964&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Present value of lease liabilities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64,791&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseCostTableTextBlock', window );">Schedule of components of lease expense, weighted-average discount rate and weighted-remaining lease terms</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the components of our lease expense (in thousands): </span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:64.316%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.011%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.011%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.013%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease cost</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,991&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,848&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,903&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of right-of-use assets</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">299&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">598&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Variable lease cost</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,036&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,097&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,177&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease cost</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,027&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,247&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,704&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our weighted-average discount rate and our weighted remaining lease terms (in years) are as follows:</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:64.455%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.011%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.011%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.013%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average discount rate</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.38&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.44&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.25&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average remaining lease term</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.8</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.4</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.9</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139858983015304">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings (Loss) Per Common Share (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Computation of basic and diluted earnings per share</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth the computation of basic and diluted earnings per share available for common stockholders (in thousands, except per share data):</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"/><td style="width:351.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:58.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:58.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:58.00pt"/><td style="width:1.0pt"/></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Year Ended December 31,</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss from continuing operations</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(30,284)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(328,172)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(307,193)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income (loss) from discontinued operations, net of tax</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,317)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,074)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,613&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(37,601)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(334,246)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(305,580)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss attributable to non-controlling interests</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,609)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss available for common shareholders - basic and diluted</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(37,601)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(334,246)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(301,971)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average common shares outstanding - basic and diluted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">86,067&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84,928&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">82,364&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Income (loss) per common share</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic and diluted</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Continuing operations</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.35)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.86)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.73)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discontinued operations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.09)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.08)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.02&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-controlling interests</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.04&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:23pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic and diluted income (loss) per share attributable to common shareholders of Evolent Health, Inc.</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.44)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.94)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.67)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Schedule of antidilutive securities excluded from computation of earnings per share</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Anti-dilutive shares (in thousands) excluded from the calculation of weighted-average common shares presented above are presented below:</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"/><td style="width:351.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:58.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:58.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:58.00pt"/><td style="width:1.0pt"/></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Year Ended December 31,</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exchangeable Class B common stock</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,399&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:23pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted stock units ("RSUs"), performance-based RSUs and leveraged stock units ("LSUs")</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,807&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">797&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">813&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,036&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,141&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,324&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Convertible senior notes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,602&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,206&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,361&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,445&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,144&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,897&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139858976479976">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-based Compensation (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock', window );">Stock-based compensation expense</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total compensation expense by award type and line item in our consolidated financial statements was as follows (in thousands):</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"/><td style="width:379.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:48.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:48.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:48.25pt"/><td style="width:1.0pt"/></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Year Ended December 31,</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Award Type</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,337&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,927&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,237&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Performance-based stock options</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">448&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">RSUs</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,606&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,763&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,877&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Performance-based RSUs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,471&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(388)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">LSUs</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,297&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,841&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,444&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total compensation expense by award type</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,711&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,606&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,618&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Line Item</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of revenue</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,263&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,811&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,673&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,448&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,795&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,945&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total compensation expense by financial statement line item</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,711&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,606&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,618&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfUnrecognizedCompensationCostNonvestedAwardsTableTextBlock', window );">Schedule of unrecognized compensation expense</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total unrecognized compensation expense (in thousands) and expected weighted-average period (in years) by award type for all of our stock-based incentive plans were as follows:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:535.50pt"><tr><td style="width:1.0pt"/><td style="width:393.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:66.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:66.25pt"/><td style="width:1.0pt"/></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31, 2021</span></td></tr><tr style="height:33pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Unrecognized Compensation Expense</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average Period (years)</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">512&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.57</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">RSUs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,104&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.69</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">LSUs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,422&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.19</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Performance-based RSUs</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,121&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.17</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,159&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Option price assumptions</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The option price assumptions used for our stock option awards for the year ended December 31, 2019, were as follows:</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"/><td style="width:463.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:72.25pt"/><td style="width:1.0pt"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average fair value per option granted</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.52&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assumptions:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected term (in years)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.25</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.9% - 2.7%</span></div></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividend yield</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The price assumptions used for our leveraged stock unit awards were as follows:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"/><td style="width:384.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:73.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:73.00pt"/><td style="width:1.0pt"/></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Year Ended December 31,</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average fair value per leveraged stock unit granted</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.90&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.52&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assumptions:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected term</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10 years</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.85%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.54%</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividend yield</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Stock option information</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Information with respect to our stock options (in thousands), including weighted-average remaining contractual term (in years) and aggregate intrinsic value (in thousands) was as follows:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.75pt"><tr><td style="width:1.0pt"/><td style="width:283.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:58.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:3.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:58.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:3.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:58.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:3.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:58.00pt"/><td style="width:1.0pt"/></tr><tr style="height:51pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Options</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average Exercise Price</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average Remaining Contractual Term</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Aggregate Intrinsic Value</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding as of December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,070&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.32&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.25</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,578&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,490)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.92&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(31)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.23&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding as of December 31, 2021</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,549&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.49&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.99</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46,342&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested and expected to vest after December&#160;31, 2021</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,549&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.49&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.99</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46,342&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable as of December&#160;31, 2021</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,301&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.11&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.71</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42,717&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationPerformanceSharesAwardOutstandingActivityTableTextBlock', window );">Performance-based stock option awards activity</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Information with respect to our performance-based stock options (shares and aggregate intrinsic value shown in thousands, weighted-average remaining contractual term shown in years) was as follows:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:539.25pt"><tr><td style="width:1.0pt"/><td style="width:286.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:58.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:58.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:58.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:58.00pt"/><td style="width:1.0pt"/></tr><tr style="height:54pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Options</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average Exercise Price</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average Remaining Contractual Term</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Aggregate Intrinsic Value</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding as of December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">268&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.27&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.17</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(326)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding as of December 31, 2021</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">268&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.27&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.16</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,620&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested and expected to vest after December&#160;31, 2021</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">268&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.27&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.16</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,620&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock', window );">Restricted stock units information</a></td>
<td class="text">Information with respect to our RSUs (not including performance-based RSUs) is presented below (in thousands, except for weighted-average grant-date fair value):<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"/><td style="width:412.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:58.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:3.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:58.00pt"/><td style="width:1.0pt"/></tr><tr style="height:42pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total RSUs</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average Grant Date Fair Value</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding as of December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,737&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.13&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,276&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.10&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(243)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.74&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(683)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.68&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding as of December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,087&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.35&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfOtherShareBasedCompensationActivityTableTextBlock', window );">Leveraged stock units activity</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Information with respect to our leveraged stock unit awards (shares and aggregate intrinsic value shown in thousands, weighted-average remaining contractual term shown in years) was as follows:</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:539.25pt"><tr><td style="width:1.0pt"/><td style="width:286.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:58.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:58.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:58.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:58.00pt"/><td style="width:1.0pt"/></tr><tr style="height:54pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Leveraged Stock Units</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average Grant Date Fair Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average Remaining Contractual Term</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Aggregate Intrinsic Value</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding as of December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,084&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.07&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.68</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,993&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested and expected to vest after December&#160;31, 2021</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,084&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.07&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.68</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,993&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_evh_ScheduleOfShareBasedPaymentAwardRestrictedStockUnitValuationAssumptionsTableTextBlock', window );">Schedule of price assumptions for performance based stock units</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The price assumptions used for our performance based stock unit awards were as follows:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"/><td style="width:384.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:73.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:73.00pt"/><td style="width:1.0pt"/></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1st Tranche</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2nd Tranche</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average fair value per performance based stock unit granted</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.64&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.69&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assumptions:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected term</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 years</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">89.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.12&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.25&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividend yield</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardRestrictedStockUnitsVestedAndExpectedToVestTableTextBlock', window );">Schedule of information of performance based stock units</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Information with respect to our performance based restricted stock unit awards (shares and aggregate intrinsic value shown in thousands, weighted-average remaining contractual term shown in years) was as follows:</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:536.25pt"><tr><td style="width:1.0pt"/><td style="width:280.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:60.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:58.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:58.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:58.00pt"/><td style="width:1.0pt"/></tr><tr style="height:54pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Performance Based  Stock Units</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average Grant Date Fair Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average Remaining Contractual Term</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Aggregate Intrinsic Value</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding as of December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">319&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.67&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.16</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,233&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested and expected to vest after December&#160;31, 2021</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">319&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.67&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.16</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,233&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_ScheduleOfShareBasedPaymentAwardRestrictedStockUnitValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Schedule of Share-based Payment Award, Restricted Stock Unit, Valuation Assumptions</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_ScheduleOfShareBasedPaymentAwardRestrictedStockUnitValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of cost recognized for award under share-based payment arrangement by plan. Includes, but is not limited to, related tax benefit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfOtherShareBasedCompensationActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of activity for outstanding award under share-based payment arrangement excluding share and unit options and nonvested award.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfOtherShareBasedCompensationActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardRestrictedStockUnitsVestedAndExpectedToVestTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of number, weighted-average exercise price or conversion ratio, aggregate intrinsic value, and weighted-average remaining contractual term for outstanding restricted stock units that are fully vested and expected to vest. Includes, but is not limited to, unvested restricted stock units for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardRestrictedStockUnitsVestedAndExpectedToVestTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of the number and weighted-average grant date fair value for restricted stock and restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock and restricted stock units that were granted, vested, or forfeited during the year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfUnrecognizedCompensationCostNonvestedAwardsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of cost not yet recognized and weighted-average period over which cost is expected to be recognized for nonvested award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfUnrecognizedCompensationCostNonvestedAwardsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationPerformanceSharesAwardOutstandingActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the number and weighted-average grant date fair value for outstanding performance shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationPerformanceSharesAwardOutstandingActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139858982934760">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock', window );">Schedule of loss before provision for income taxes</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our loss from continuing operations before income taxes was as follows (in thousands):</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"/><td style="width:379.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:48.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:48.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:48.25pt"/><td style="width:1.0pt"/></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Year Ended December 31,</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Domestic</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(32,719)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(332,373)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(331,033)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,918&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,833&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,045&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss from continuing operations before income taxes</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(29,801)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(330,540)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(329,988)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock', window );">Components of income tax expense (benefit)</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Components of income tax expense (benefit) (in thousands) consist of the following:</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"/><td style="width:370.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:51.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:51.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:51.25pt"/><td style="width:1.0pt"/></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Year Ended December 31,</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Current</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,469)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,305)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">185&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State and local</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,449&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">200&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,027&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">721&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">399&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current tax expense (benefit)</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,007&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,384)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">598&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Deferred</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,866)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(38,258)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(27,307)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State and local</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,021)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9,565)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,046)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(493)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(303)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred tax expense (benefit)</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10,380)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(48,126)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(32,347)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in valuation allowance</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,856&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47,142&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,954&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total tax expense (benefit)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">483&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,368)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(22,795)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Schedule of reconciliation of the U.S. statutory tax rate to our effective tax rate</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">A reconciliation of the U.S. statutory tax rate to our effective tax rate is presented below:</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"/><td style="width:379.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:48.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:48.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:48.25pt"/><td style="width:1.0pt"/></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Year Ended December 31,</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. statutory tax rate</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. state income taxes, net of U.S. federal tax benefit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign earnings at other than U.S. rates</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in valuation allowance</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(33.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Benefit of net operating loss carryback provision</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-deductible goodwill impairment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-controlling interest</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nondeductible excess compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Excess tax benefits (shortfalls) on stock-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Convertible debt extinguishment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in uncertain tax positions</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nontaxable earnout</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in state rate</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Return to provision</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in indefinite reinvestment assertion for domestic subsidiaries </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax sharing settlement</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effective tax rate</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.6)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.7&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.9&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Schedule of deferred tax assets and liabilities</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Significant components of the Company&#8217;s deferred tax assets and liabilities (in thousands) were as follows:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"/><td style="width:433.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:48.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:48.25pt"/><td style="width:1.0pt"/></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31,</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Deferred Tax Assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Start-up and organizational costs</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">103&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">117&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,774&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,778&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,968&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,963&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,345&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,434&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,714&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,530&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net operating loss carryforwards</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">130,242&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">123,604&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal and state research tax credits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,828&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,828&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fixed assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">480&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">131&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest deduction limitation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,795&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,452&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outside basis differences</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,972&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">197&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,236&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,428&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Subtotal</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">205,457&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">192,462&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Valuation allowance</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(101,345)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(89,723)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred tax assets</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104,112&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">102,739&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Deferred Tax Liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Internally developed software costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,501&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,973&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48,677&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49,053&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use assets - Operating</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,284&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,122&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contract fulfillment costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,317&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,375&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Convertible debt</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,604&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,411&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,387&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,484&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred tax liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104,770&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">103,418&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net deferred tax assets (liabilities)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(658)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(679)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes in our valuation allowance (in thousands) were as follows:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"/><td style="width:433.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:48.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:48.25pt"/><td style="width:1.0pt"/></tr><tr style="height:23pt"><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Year Ended December 31,</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at beginning-of-year</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">89,723&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50,519&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Charged to costs and expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,856&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47,142&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Charged (credited) to other accounts </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,766&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,938)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at end-of-year</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101,345&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">89,723&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:3.71pt">Amounts charged (credited) to other accounts includes $1.8&#160;million charged to discontinued operations for the year ended December&#160;31, 2021 and $8.6&#160;million credited to additional paid-in-capital, partially offset by $0.7&#160;million charged to retained earnings, for the year ended December 31, 2020.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock', window );">Changes in unrecognized tax benefits</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes in our unrecognized tax benefits (in thousands) were as follows:</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"/><td style="width:402.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:40.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:40.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:40.75pt"/><td style="width:1.0pt"/></tr><tr style="height:24pt"><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Year Ended December 31,</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at beginning-of-year</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">678&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">753&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">934&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lapse of statute of limitations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(69)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(75)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(181)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at end-of-year</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">609&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">678&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">753&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of income before income tax between domestic and foreign jurisdictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the change in unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 55<br> -Paragraph 217<br> -URI http://asc.fasb.org/extlink&amp;oid=124434304&amp;loc=d3e36027-109320<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139858977569960">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Non-controlling Interests (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncontrollingInterestAbstract', window );"><strong>Noncontrolling Interest [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_evh_ScheduleofChangesinNoncontrollingInterestTableTextBlock', window );">Schedule of changes in non-controlling interests</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes in non-controlling interests (in thousands) for year ended December 31, 2020, was as follows:</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"/><td style="width:463.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:72.25pt"/><td style="width:1.0pt"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-controlling interests balance as of beginning of period</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,689&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issuance of non-controlling interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,749&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Disposal of assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,689)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Redemption of Sponsor&#8217;s equity</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(25,749)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-controlling interests balance as of end of period</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_ScheduleofChangesinNoncontrollingInterestTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Schedule of Changes in Noncontrolling Interest [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_ScheduleofChangesinNoncontrollingInterestTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncontrollingInterestAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncontrollingInterestAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139858982980792">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurement (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock', window );">Summary of assets at fair value on recurring basis</a></td>
<td class="text">The following table summarizes the Company&#8217;s assets and liabilities measured at fair value on a recurring basis (in thousands): <div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:59.594%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.205%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.205%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.205%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.209%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,700&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,700&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total fair value of liabilities measured on a recurring basis</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,700&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,700&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"/><td style="width:325.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:48.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:48.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:48.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:48.25pt"/><td style="width:1.0pt"/></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,877&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,877&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total fair value of assets measured on a recurring basis</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,877&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,877&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warrants </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,730&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,730&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total fair value of liabilities measured on a recurring basis</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,730&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,730&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%"> </span></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Represents the fair value of earn-out consideration related to the Vital Decisions transaction as described in Note 4.</span></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> Represents the cash and cash equivalents and restricted cash and restricted investments that were held in money market funds as of December&#160;31, 2020.</span></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(3)  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Represents the fair value of 1,513,786 shares issuable under the warrant agreements discussed in Note 10. The warrants were settled in January 2021.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock', window );">Summary of liabilities at fair value on recurring basis</a></td>
<td class="text">The following table summarizes the Company&#8217;s assets and liabilities measured at fair value on a recurring basis (in thousands): <div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:59.594%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.205%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.205%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.205%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.209%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,700&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,700&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total fair value of liabilities measured on a recurring basis</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,700&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,700&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"/><td style="width:325.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:48.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:48.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:48.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:48.25pt"/><td style="width:1.0pt"/></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,877&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,877&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total fair value of assets measured on a recurring basis</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,877&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,877&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warrants </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,730&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,730&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total fair value of liabilities measured on a recurring basis</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,730&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,730&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%"> </span></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Represents the fair value of earn-out consideration related to the Vital Decisions transaction as described in Note 4.</span></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> Represents the cash and cash equivalents and restricted cash and restricted investments that were held in money market funds as of December&#160;31, 2020.</span></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(3)  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Represents the fair value of 1,513,786 shares issuable under the warrant agreements discussed in Note 10. The warrants were settled in January 2021.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock', window );">Changes in contingent consideration measured at fair value</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The changes in our liabilities measured at fair value for which the Company uses Level 3 inputs to determine fair value for the years ended December 31, 2021 and 2020 are as follows (in thousands): </span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"/><td style="width:433.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:48.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:48.25pt"/><td style="width:1.0pt"/></tr><tr style="height:23pt"><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Year Ended December 31,</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of beginning of period</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,730&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,975&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,600&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Settlements</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13,730)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,500)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Realized and unrealized losses, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,100&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">255&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of end of period</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,700&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,730&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock', window );">Valuation techniques and significant unobservable inputs of Level 3 fair value measurements</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the fair value (in thousands), valuation techniques and significant unobservable inputs of our Level 3 fair value measurements as of the periods presented:</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:24.177%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.205%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.788%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:30.427%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.821%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair </span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Valuation</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Significant</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assumption or</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Technique</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Unobservable Inputs</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Input Ranges</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,700&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Real options approach</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-neutral expected earnout consideration</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,935&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discount rate</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.04&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"/><td style="width:134.50pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:48.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:100.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:168.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:67.75pt"/><td style="width:1.0pt"/></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair </span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Valuation</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Significant</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assumption or</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Technique</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Unobservable Inputs</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Input Ranges</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warrants</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,730&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Black-Scholes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock price volatility</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Annual risk free rate</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).  Where the quoted price in an active market for the identical liability is not available, the Level 1 input is the quoted price of an identical liability when traded as an asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19279-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139858977569960">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Parties (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock', window );">Schedule of related parties</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents assets and liabilities attributable to our related parties as of December&#160;31, 2021 and 2020 (in thousands):</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:74.594%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.705%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.707%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable, net</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,719&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,474&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other noncurrent assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,877&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,554&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,967&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,509&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,120&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,520&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reserve for claims and performance-based arrangements</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">734&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">435&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents revenues and expenses attributable to our related parties for the years ended December 31, 2021, 2020 and 2019 (in thousands):</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"/><td style="width:373.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:49.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:54.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:49.00pt"/><td style="width:1.0pt"/></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Year Ended December 31,</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Revenue</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Transformation services</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,416&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,009&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Platform and operations services</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45,082&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">226,339&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60,325&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr style="height:23pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of revenue (exclusive of depreciation and amortization expenses)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,063&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,863&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,954&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">285&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">113&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">991&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of related party transactions. Examples of related party transactions include, but are not limited to, transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139858977654312">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Repositioning and Other Changes (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedActivitiesAbstract', window );"><strong>Restructuring and Related Activities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock', window );">Costs associated with the Repositioning Plan</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides a summary of our total costs associated with the Repositioning Plan for the years ended December 31, 2021 and 2020, by major type of cost (in thousands):</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:60.011%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.788%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.788%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.903%"/><td style="width:0.1%"/></tr><tr style="height:23pt"><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Year Ended December 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cumulative Amount Incurred through December 31, 2021</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Severance and termination benefits</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">185&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">185&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Office space consolidation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,742&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,742&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Professional services</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,391&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,275&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,666&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,318&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,275&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,593&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of costs incurred for restructuring including, but not limited to, exit and disposal activities, remediation, implementation, integration, asset impairment, and charges against earnings from the write-down of assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 5.P.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140864-122747<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB TOPIC 5.P.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139858983820424">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Reporting (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTextBlock', window );">Reconciliation of revenue from segments to consolidated</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables present our segment information for the years ended December 31, 2021, 2020 and 2019 (in thousands). Segment information for the years ended December 31, 2020 and 2019 (including segments total Adjusted EBITDA) has been restated to conform to the reporting structure change described in Note 2.</span></div><div style="text-align:justify"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"/><td style="width:145.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:52.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:52.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:67.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:60.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:61.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:67.00pt"/><td style="width:1.0pt"/></tr><tr style="height:33pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Evolent Health Services</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Clinical Solutions</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Intersegment<br/>Eliminations</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Subtotal</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Corporate </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Consolidated</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Revenue</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr style="height:12pt"><td colspan="12" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Year Ended December 31, 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Transformation services</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,204&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,204&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,204&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Platform and operations services</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">300,423&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">598,144&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,814)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">896,753&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">896,753&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenue</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">311,627&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">598,144&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,814)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">907,957&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">907,957&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"/><td style="width:145.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:52.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:52.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:67.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:60.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:61.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:67.00pt"/><td style="width:1.0pt"/></tr><tr style="height:12pt"><td colspan="12" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Year Ended December 31, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Transformation services</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,990&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,990&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,990&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Platform and operations services</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">373,144&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">542,279&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,774)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">912,649&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">912,649&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenue</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">385,134&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">542,279&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,774)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">924,639&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">924,639&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr style="height:12pt"><td colspan="12" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Year Ended December 31, 2019</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Transformation services</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,203&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,203&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,203&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Platform and operations services</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">394,328&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">278,217&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(626)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">671,919&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">671,919&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenue</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">409,531&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">278,217&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(626)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">687,122&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">687,122&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr><tr style="height:33pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Evolent Health Services</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Clinical Solutions</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Subtotal</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Corporate </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Segments Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr style="height:14pt"><td colspan="12" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Year Ended December 31, 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjusted EBITDA</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,063&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">82,920&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99,983&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(33,666)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66,317&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr style="height:14pt"><td colspan="12" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Year Ended December 31, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjusted EBITDA</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57,731&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,864&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84,595&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(36,022)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48,573&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr style="height:12pt"><td colspan="12" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Year Ended December 31, 2019</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjusted EBITDA</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(561)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,523&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,962&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(25,793)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13,831)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr></table></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt">Corporate includes various finance, human resources, legal, executive, and other corporate infrastructure expenses.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock', window );">Reconciliation of Adjusted EBITDA to net loss</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents our reconciliation of consolidated segments total Adjusted EBITDA to net loss attributable to common shareholders of Evolent Health, Inc. for the years ended December 31, 2021, 2020 and 2019 (in thousands): </span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"/><td style="width:380.50pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:48.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:48.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:48.25pt"/><td style="width:1.0pt"/></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Year Ended December 31,</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net loss attributable to common shareholders of Evolent Health, Inc.</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(37,601)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(334,246)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(301,971)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">407&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,633&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,406&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(25,425)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(28,325)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14,555)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Provision) benefit for income taxes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(483)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,368&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,795&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(60,037)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(60,835)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(60,323)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity method investment impairment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(47,133)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain on transfer of membership</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45,938&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss on repayment of debt, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(21,343)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss on extinguishment of debt</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,789)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill impairment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(215,100)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(199,800)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain (loss) from equity method investees</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,179&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,039&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9,465)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain (loss) on disposal of assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(698)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,600&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value of contingent consideration and indemnification asset</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13,281)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,860)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,997&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss attributable to non-controlling interests</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,609&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income (expense), net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(146)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(118)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(489)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchase accounting adjustments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,915)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Repositioning costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,318)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,275)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16,711)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14,606)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15,618)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Severance costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(198)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,986)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(17,350)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of contract cost assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(476)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,944)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,876)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Strategy and shareholder advisory expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,513)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisition costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,194)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,116)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10,769)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain (loss) from discontinued operations </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,317)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,074)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,613&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Adjusted EBITDA</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66,317&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48,573&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13,831)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt">Includes $6.8&#160;million gain on disposal of discontinued operations for the year ended December 31, 2021.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation of profit (loss) from reportable segments to the consolidated income (loss) before income tax expense (benefit) and discontinued operations. Includes, but is not limited to, reconciliation after income tax if income tax is allocated to the reportable segment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of all significant reconciling items in the reconciliation of total revenues from reportable segments to the entity's consolidated revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139858977669192">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Reserves for Claims and Performance-Based Arrangements (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InsuranceAbstract', window );"><strong>Insurance [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense', window );">Activity in claims reserves</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Activity in reserves for claims and performance-based arrangements for the years ended December 31, 2021 and 2020, was as follows (in thousands):</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:539.25pt"><tr><td style="width:1.0pt"/><td style="width:226.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:37.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:57.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:3.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:40.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:3.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:41.50pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:3.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:57.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:3.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:40.00pt"/><td style="width:1.0pt"/></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="33" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Year Ended December 31,</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr style="height:23pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">EHS </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Clinical Solutions </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">EHS </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Clinical Solutions </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Beginning balance</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56,296&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">122,531&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">178,827&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,265&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50,245&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54,510&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Incurred costs related to current year</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,669&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">449,172&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">457,841&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,542)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">428,139&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">420,597&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Incurred costs related to prior year</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,036&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,109&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,853&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,878&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Paid costs related to current year</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,801&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">337,647&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">358,448&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">106,093&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">358,478&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">464,571&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:539.25pt"><tr><td style="width:1.0pt"/><td style="width:226.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:37.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:57.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:3.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:40.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:3.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:41.50pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:3.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:57.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:3.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:40.00pt"/><td style="width:1.0pt"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Paid costs related to prior year</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,544&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100,075&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">125,619&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,123&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,475&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,598&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change during the year</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(30,640)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,523&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19,117)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(112,905)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62,211&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(50,694)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr style="height:23pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Impact of consolidation on reserves for claims and performance-based arrangements</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">164,297&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">164,297&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other adjustments </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(38)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,622&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,584&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">639&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,075&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,714&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ending balance</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,618&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">145,676&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">171,294&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56,296&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">122,531&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">178,827&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:13.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;</span></div><div style="padding-left:31.5pt;text-align:justify;text-indent:-31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:25.44pt">Costs incurred to provide specialty care management and EVH Passport are recorded within cost of revenue in our statement of operations. </span></div><div style="padding-left:31.5pt;text-align:justify;text-indent:-31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:25.44pt">Amounts exclude $9.9&#160;million related to reserves for claims reclassified to discontinued operations as of December&#160;31, 2020.</span></div><div style="padding-left:31.5pt;text-align:justify;text-indent:-31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:25.44pt">Other adjustments to reserves for claims and performance-based arrangements reflect changes in accrual for amounts payable to facilities and amounts owed to our payer partners for claims paid on our behalf.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InsuranceAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InsuranceAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the activity in the reserve for settling insured claims and expenses incurred in the claims settlement process for the period. The estimated liability includes the amount of money that will be required for future payments of (a) claims that have been reported to the insurer, (b) claims related to insured events that have occurred but that have not been reported to the insurer as of the date the liability is estimated, and (c) claim adjustment expenses. Claim adjustment expenses include costs incurred in the claim settlement process such as legal fees; outside adjuster fees; and costs to record, process, and adjust claims.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=116884095&amp;loc=d3e14764-158437<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139858977679592">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Quarterly Results of Operations (unaudited) (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_QuarterlyFinancialDataAbstract', window );"><strong>Quarterly Financial Data [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock', window );">Unaudited consolidated quarterly results of operations</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The unaudited consolidated quarterly results of operations (in thousands, except per share data) were as follows:</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:53.344%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.094%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.983%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.205%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.209%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="21" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Three Months Ended</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">June 30</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenue</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">248,358&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">222,471&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">222,057&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">215,071&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">260,572</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">229,052</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">229,728</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">231,016</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss from continuing operations</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,053</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13,040)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9,107)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11,190)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss) from discontinued operations, net of tax</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,700)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,383</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss attributable to common shareholders of Evolent Health, Inc.</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,647)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13,040)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9,107)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9,807)</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Income (loss) per common share</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic and diluted</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Continuing operations</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.03&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.15)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.11)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.13)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discontinued operations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.09)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.01&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenue</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">246,536&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">239,572&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">217,299&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">221,232&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">246,804</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">256,020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">443,128</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">246,323</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss from continuing operations</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10,637)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(37,035)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(202,013)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(78,487)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss from discontinued operations, net of tax</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,166)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,135)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,508)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(265)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss) attributable to non-controlling interests</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">822</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(822)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss attributable to common shareholders of Evolent Health, Inc.</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14,625)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(37,348)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(203,521)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(78,752)</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Loss per common share</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic and diluted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Continuing operations</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.13)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.43)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.37)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.93)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discontinued operations</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.04)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.01)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.01)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_QuarterlyFinancialDataAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_QuarterlyFinancialDataAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of quarterly financial data. Includes, but is not limited to, financial information for fiscal quarters, cumulative effect of a change in accounting principle and earnings per share data.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 270<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124502072&amp;loc=d3e1280-108306<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139858977559448">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Supplemental Cash Flow Information (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowElementsAbstract', window );"><strong>Supplemental Cash Flow Elements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock', window );">Schedule of cash flow, supplemental disclosures</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following represents supplemental cash flow information the years ended December 31, 2021, 2020 and 2019 (in thousands):</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"/><td style="width:380.50pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:48.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:48.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:48.25pt"/><td style="width:1.0pt"/></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Year Ended December 31,</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Supplemental Disclosure of Non-cash Investing and Financing Activities</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Class A and Class B common stock issued in connection with business combinations</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56,626&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,556&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;Increase/decrease to goodwill from measurement period adjustments/business combinations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,200&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(351)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Class A common stock issued for payment of earn-outs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">450&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,185&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">800&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;Class A common stock issued in connection with debt repayment </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,492&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain from transfer of membership</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(22,969)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued property and equipment purchases</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">784&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(527)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Consideration for asset acquisition or business combinations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,600&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Effects of Leases</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;Operating cash flows from operating leases </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,845&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,708&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,330&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;Leased assets obtained in exchange for operating lease liabilities </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,583)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,170)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,463&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Effects of Class B Exchanges</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Decrease in non-controlling interests as a result of Class B Exchanges</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42,377&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Decrease in deferred tax liability as a result of securities offerings and exchanges</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(22)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Supplemental Disclosures </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid for interest</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,113&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,352&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,037&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid for taxes, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">551&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,679&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,484&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of supplemental cash flow information for the periods presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowElementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowElementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139858977899640">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Organization (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 266,280<span></span>
</td>
<td class="nump">$ 319,002<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember', window );">Class B Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139858977576440">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation, Summary of Significant Accounting Policies and Change in Accounting Principles - Operating Segments (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2021 </div>
<div>segment</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of operating segments</a></td>
<td class="nump">2<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8672-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139858971170072">
<tr>
<th class="tl" colspan="2" rowspan="1"><div style="width: 200px;"><strong>Basis of Presentation, Summary of Significant Accounting Policies and Change in Accounting Principles - Restricted Cash and Restricted Investments (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems', window );"><strong>Restricted Cash and Cash Equivalents Items [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalents', window );">Restricted funds</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 21,028<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue', window );">Current restricted cash</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 75,685<span></span>
</td>
<td class="nump">14,374<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndInvestmentsCurrent', window );">Total current restricted cash and restricted investments</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">75,685<span></span>
</td>
<td class="nump">14,374<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent', window );">Non-current restricted cash</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">12,977<span></span>
</td>
<td class="nump">6,654<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndInvestmentsNoncurrent', window );">Total non-current restricted cash and restricted investments</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">12,977<span></span>
</td>
<td class="nump">6,654<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_evh_CashAndCashEquivalentsAtCarryingValueExcludingDiscontinuedOperations', window );">Cash and cash equivalents</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">266,280<span></span>
</td>
<td class="nump">340,490<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndInvestments', window );">Restricted cash and restricted investments</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">88,662<span></span>
</td>
<td class="nump">21,707<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedInvestments', window );">Restricted investments included in restricted cash and restricted investments</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="num">(616)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Total cash and cash equivalents and restricted cash shown in the consolidated statements of cash flows</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">354,942<span></span>
</td>
<td class="nump">361,581<span></span>
</td>
<td class="nump">$ 128,531<span></span>
</td>
<td class="nump">$ 388,325<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupClassificationAxis=us-gaap_DiscontinuedOperationsDisposedOfBySaleMember', window );">Discontinued Operations, Disposed of by Sale | True Health</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems', window );"><strong>Restricted Cash and Cash Equivalents Items [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_evh_DisposalGroupIncludingDiscontinuedOperationRestrictedInvestmentsNoncurrent', window );">Non-current restricted investments</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_evh_DisposalGroupIncludingDiscontinuedOperationRestrictedCashCurrent', window );">Current restricted cash from claims processing services</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis=evh_RestrictedCashforLettersofCreditforFacilityLeasesMember', window );">Collateral for letters of credit for facility leases</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems', window );"><strong>Restricted Cash and Cash Equivalents Items [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalents', window );">Restricted funds</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">3,769<span></span>
</td>
<td class="nump">3,510<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis=evh_CollateralwithFinancialInstitutionsMember', window );">Collateral with financial institutions</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems', window );"><strong>Restricted Cash and Cash Equivalents Items [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalents', window );">Restricted funds</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">11,662<span></span>
</td>
<td class="nump">4,743<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis=evh_RestrictedCashforBenefitManagementServicesMember', window );">Claims processing services</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems', window );"><strong>Restricted Cash and Cash Equivalents Items [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalents', window );">Restricted funds</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">73,226<span></span>
</td>
<td class="nump">12,064<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis=evh_RestrictedCashforOtherContractualCommitmentsMember', window );">Other</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems', window );"><strong>Restricted Cash and Cash Equivalents Items [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalents', window );">Restricted funds</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">5<span></span>
</td>
<td class="nump">711<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis=us-gaap_BankTimeDepositsMember', window );">Bank time deposits</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems', window );"><strong>Restricted Cash and Cash Equivalents Items [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalents', window );">Restricted funds</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 11,700<span></span>
</td>
<td class="nump">$ 4,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr><td colspan="5"></td></tr>
<tr><td colspan="5"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">See Note 5.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_CashAndCashEquivalentsAtCarryingValueExcludingDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash and Cash Equivalents, at Carrying Value, Excluding Discontinued Operations</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_CashAndCashEquivalentsAtCarryingValueExcludingDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_DisposalGroupIncludingDiscontinuedOperationRestrictedCashCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disposal Group, Including Discontinued Operation, Restricted Cash, Current</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_DisposalGroupIncludingDiscontinuedOperationRestrictedCashCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_DisposalGroupIncludingDiscontinuedOperationRestrictedInvestmentsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disposal Group, Including Discontinued Operation, Restricted Investments, Noncurrent</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_DisposalGroupIncludingDiscontinuedOperationRestrictedInvestmentsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=SL98516268-108586<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6812-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=SL98516268-108586<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 210<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120413173&amp;loc=SL116631458-115580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalentsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash and investments whose use in whole or in part is restricted for the long-term, generally by contractual agreements or regulatory requirements. For use in an unclassified balance sheet.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 210<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=120413173&amp;loc=SL6242262-115580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 210<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120413209&amp;loc=SL6242269-115581<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndInvestmentsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The current cash, cash equivalents and investments that are restricted as to withdrawal or usage. Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or entity statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits. Excludes compensating balance arrangements that are not agreements which legally restrict the use of cash amounts shown on the balance sheet. Includes current cash equivalents and investments that are similarly restricted as to withdrawal, usage or disposal.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 210<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=120413173&amp;loc=SL6242262-115580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 210<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120413209&amp;loc=SL6242269-115581<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndInvestmentsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndInvestmentsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The noncurrent cash, cash equivalents and investments that is restricted as to withdrawal or usage. Restrictions may include legally restricted deposits held as compensating balances against borrowing arrangements, contracts entered into with others, or entity statements of intention with regard to particular deposits classified as long-term; that is not expected to be released from such existing restrictions within one year of the balance sheet date or operating cycle, whichever is longer. Excludes compensating balance arrangements that are not agreements which legally restrict the use of cash amounts shown on the balance sheet. Includes noncurrent cash equivalents and investments that are similarly restricted as to withdrawal, usage or disposal.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 210<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=120413173&amp;loc=SL6242262-115580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 210<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120413209&amp;loc=SL6242269-115581<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndInvestmentsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Investments which are not defined as or included in marketable (debt, equity, or other) securities whose use is restricted in whole or in part, generally by contractual agreements or regulatory requirements. For use in an unclassified balance sheet.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 210<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=120413173&amp;loc=SL6242262-115580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 210<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120413209&amp;loc=SL6242269-115581<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupClassificationAxis=us-gaap_DiscontinuedOperationsDisposedOfBySaleMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupClassificationAxis=us-gaap_DiscontinuedOperationsDisposedOfBySaleMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=evh_TrueHealthMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=evh_TrueHealthMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis=evh_RestrictedCashforLettersofCreditforFacilityLeasesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis=evh_RestrictedCashforLettersofCreditforFacilityLeasesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis=evh_CollateralwithFinancialInstitutionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis=evh_CollateralwithFinancialInstitutionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis=evh_RestrictedCashforBenefitManagementServicesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis=evh_RestrictedCashforBenefitManagementServicesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis=evh_RestrictedCashforOtherContractualCommitmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis=evh_RestrictedCashforOtherContractualCommitmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis=us-gaap_BankTimeDepositsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis=us-gaap_BankTimeDepositsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139858976346088">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation, Summary of Significant Accounting Policies and Change in Accounting Principles - Estimated Useful Life of Property, Plant and Equipment (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember', window );">Computer hardware</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Useful life</a></td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareAndSoftwareDevelopmentCostsMember', window );">Computer software</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Useful life</a></td>
<td class="text">1 year<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareDevelopmentMember', window );">Internal-use software development costs</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Useful life</a></td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum | Furniture and equipment</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Useful life</a></td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | Furniture and equipment</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Useful life</a></td>
<td class="text">7 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareAndSoftwareDevelopmentCostsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareAndSoftwareDevelopmentCostsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareDevelopmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareDevelopmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139858975963528">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation, Summary of Significant Accounting Policies and Change in Accounting Principles - Research and Development Costs (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development costs</a></td>
<td class="nump">$ 15.5<span></span>
</td>
<td class="nump">$ 15.1<span></span>
</td>
<td class="nump">$ 19.8<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 730<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6472174&amp;loc=d3e58812-109433<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139858983507304">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation, Summary of Significant Accounting Policies and Change in Accounting Principles - Goodwill (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Oct. 31, 2020 </div>
<div>reportingUnit</div>
</th>
<th class="th">
<div>May 31, 2020 </div>
<div>reportingUnit</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>unit</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>reportingUnit</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NumberOfReportingUnits', window );">Number of reporting units for goodwill testing</a></td>
<td class="nump">2<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="nump">3<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfReportingUnits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of reporting units tested for impairment of goodwill. A reporting unit is an operating segment or one level below an operating segment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfReportingUnits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139858979731288">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation, Summary of Significant Accounting Policies and Change in Accounting Principles - Intangible Assets, Net (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TradeNamesMember', window );">Corporate trade name | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Useful life</a></td>
<td class="text">10 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TradeNamesMember', window );">Corporate trade name | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Useful life</a></td>
<td class="text">20 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_CustomerRelationshipsMember', window );">Customer relationships | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Useful life</a></td>
<td class="text">10 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_CustomerRelationshipsMember', window );">Customer relationships | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Useful life</a></td>
<td class="text">25 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember', window );">Technology</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Useful life</a></td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_ContractBasedIntangibleAssetsMember', window );">Provider network contracts | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Useful life</a></td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_ContractBasedIntangibleAssetsMember', window );">Provider network contracts | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Useful life</a></td>
<td class="text">5 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TradeNamesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TradeNamesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_CustomerRelationshipsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_CustomerRelationshipsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_ContractBasedIntangibleAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_ContractBasedIntangibleAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139858977785752">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Basis of Presentation, Summary of Significant Accounting Policies and Change in Accounting Principles - Right of Offset (Details)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_evh_RightOfOffsetPercentageOfAccountsReceivableNettedAgainstClaimsPayable', window );">Right of offset, percentage of accounts receivable netted against claims payable</a></td>
<td class="nump">42.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_evh_RightOfOffsetPercentageOfAccountsReceivableNetEligibleForNetBasisSettlement', window );">Right of offset, percentage of accounts receivable, net eligible for net basis settlement</a></td>
<td class="nump">55.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_RightOfOffsetPercentageOfAccountsReceivableNetEligibleForNetBasisSettlement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Right of Offset, Percentage of Accounts Receivable, Net Eligible for Net Basis Settlement</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_RightOfOffsetPercentageOfAccountsReceivableNetEligibleForNetBasisSettlement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_RightOfOffsetPercentageOfAccountsReceivableNettedAgainstClaimsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Right of Offset, Percentage of Accounts Receivable Netted Against Claims Payable</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_RightOfOffsetPercentageOfAccountsReceivableNettedAgainstClaimsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R64.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139858983770552">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation, Summary of Significant Accounting Policies and Change in Accounting Principles - Stock-based Compensation (Details) - Stock options<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">4 years<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Expiration period</a></td>
<td class="text">10 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R65.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139858979754504">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Recently Issued Accounting Standards (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>New Accounting Pronouncements or Change in Accounting Principle [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Cumulative effect adjustment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (929,047)<span></span>
</td>
<td class="num">$ (693,633)<span></span>
</td>
<td class="num">$ (619,600)<span></span>
</td>
<td class="num">$ (1,189,356)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingStandardsUpdateExtensibleList', window );">Accounting Standards Update [Extensible Enumeration]</a></td>
<td class="text">Accounting Standards Update 2016-13 [Member]<span></span>
</td>
<td class="text">Accounting Standards Update 2016-13 [Member]<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CumulativeEffectPeriodOfAdoptionAxis=srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember', window );">Cumulative Effect, Period of Adoption, Adjustment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>New Accounting Pronouncements or Change in Accounting Principle [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Cumulative effect adjustment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,970<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_RetainedEarningsMember', window );">Retained Earnings (Accumulated Deficit)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>New Accounting Pronouncements or Change in Accounting Principle [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Cumulative effect adjustment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">251,962<span></span>
</td>
<td class="nump">$ 626,779<span></span>
</td>
<td class="nump">$ 589,178<span></span>
</td>
<td class="num">$ (50,009)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_RetainedEarningsMember', window );">Retained Earnings (Accumulated Deficit) | Cumulative Effect, Period of Adoption, Adjustment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>New Accounting Pronouncements or Change in Accounting Principle [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Cumulative effect adjustment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,970<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingStandardsUpdateExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates amendment to accounting standards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123597120&amp;loc=SL121967933-165497<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123597120&amp;loc=SL121967933-165497<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123597120&amp;loc=SL122642865-165497<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123459177&amp;loc=SL121830611-158277<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123597120&amp;loc=SL121967933-165497<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123597120&amp;loc=SL121967933-165497<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123597120&amp;loc=SL120254526-165497<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(iv)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124434974&amp;loc=SL124442142-165695<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=124434974&amp;loc=SL124442142-165695<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 27: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123459177&amp;loc=SL121830611-158277<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124434974&amp;loc=SL124442142-165695<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 848<br> -SubTopic 10<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=122150657&amp;loc=SL122150809-237846<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123597120&amp;loc=SL122642865-165497<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S65<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124359872&amp;loc=SL124427846-239511<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124402435&amp;loc=SL124402458-218513<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124402435&amp;loc=SL124402458-218513<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123597120&amp;loc=SL120254526-165497<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 45: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124434974&amp;loc=SL124442142-165695<br><br>Reference 47: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 49: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=124434974&amp;loc=SL124442142-165695<br><br>Reference 50: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (e)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 51: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 52: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 53: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 54: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 55: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (e)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 56: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 57: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 58: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 59: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 60: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 61: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Publisher FASB<br> -Subparagraph (a)<br><br>Reference 62: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Publisher FASB<br> -Subparagraph (a)(1)<br><br>Reference 63: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Publisher FASB<br> -Subparagraph (a)(2)<br><br>Reference 64: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Publisher FASB<br> -Subparagraph (a)(3)(iii)(01)<br><br>Reference 65: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Publisher FASB<br> -Subparagraph (a)(3)(iii)(03)<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingStandardsUpdateExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21930-107793<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21914-107793<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442411-227067<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124434974&amp;loc=SL124442142-165695<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=124434974&amp;loc=SL124442142-165695<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4568740-111683<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21711-107793<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123459177&amp;loc=SL121830611-158277<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123459177&amp;loc=SL121830611-158277<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4590271-111686<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 24: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4568447-111683<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Publisher FASB<br> -Subparagraph (a)(3)(iii)(03)<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CumulativeEffectPeriodOfAdoptionAxis=srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CumulativeEffectPeriodOfAdoptionAxis=srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_RetainedEarningsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_RetainedEarningsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R66.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139858979403320">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Transactions - Vital Decisions (Details) - USD ($)<br> $ in Thousands, shares in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Oct. 01, 2021</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferredAbstract', window );"><strong>Purchase consideration:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesGross', window );">Cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 49,012<span></span>
</td>
<td class="nump">$ 300<span></span>
</td>
<td class="nump">$ 8,575<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract', window );"><strong>Liabilities assumed:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 426,297<span></span>
</td>
<td class="nump">$ 349,029<span></span>
</td>
<td class="nump">$ 566,359<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_CustomerRelationshipsMember', window );">Customer relationships</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract', window );"><strong>Liabilities assumed:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife', window );">Useful life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">14 years 10 months 24 days<span></span>
</td>
<td class="text">16 years 2 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember', window );">Technology</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract', window );"><strong>Liabilities assumed:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife', window );">Useful life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years<span></span>
</td>
<td class="text">1 year 9 months 18 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TradeNamesMember', window );">Corporate trade name</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract', window );"><strong>Liabilities assumed:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife', window );">Useful life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">12 years 4 months 24 days<span></span>
</td>
<td class="text">13 years 2 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=evh_VitalDecisionsMember', window );">Vital Decisions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired', window );">Voting interests acquired</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued', window );">Equity interest issued or issuable, number of shares (in shares)</a></td>
<td class="nump">1.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh', window );">Contingent consideration arrangements (up to)</a></td>
<td class="nump">$ 45,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferredAbstract', window );"><strong>Purchase consideration:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesGross', window );">Cash</a></td>
<td class="nump">46,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable', window );">Fair value of Class A common stock issued</a></td>
<td class="nump">56,626<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Fair value of contingent consideration</a></td>
<td class="nump">14,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferred1', window );">Total consideration</a></td>
<td class="nump">117,726<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract', window );"><strong>Tangible assets acquired:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents', window );">Cash and cash equivalents</a></td>
<td class="nump">1,430<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables', window );">Accounts receivable</a></td>
<td class="nump">3,301<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">78<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets', window );">Other non-current assets</a></td>
<td class="nump">2,564<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_evh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedTangibleAssets', window );">Total tangible assets acquired</a></td>
<td class="nump">7,373<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwillAbstract', window );"><strong>Identifiable intangible assets acquired:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles', window );">Identifiable intangible assets</a></td>
<td class="nump">40,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract', window );"><strong>Liabilities assumed:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable', window );">Accounts payable</a></td>
<td class="nump">93<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_evh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesAccruedLiabilities', window );">Accrued liabilities</a></td>
<td class="nump">661<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_evh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesAccruedCompensationAndEmployeeBenefits', window );">Accrued compensation and employee benefits</a></td>
<td class="nump">970<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities', window );">Deferred tax liabilities, net</a></td>
<td class="nump">499<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue', window );">Deferred revenue</a></td>
<td class="nump">2,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCapitalLeaseObligation', window );">Operating lease liabilities</a></td>
<td class="nump">2,712<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities', window );">Total liabilities assumed</a></td>
<td class="nump">6,935<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">77,288<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet', window );">Net assets acquired</a></td>
<td class="nump">117,726<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount', window );">Goodwill, expected tax deductible amount</a></td>
<td class="nump">69,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=evh_VitalDecisionsMember', window );">Vital Decisions | Customer relationships</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwillAbstract', window );"><strong>Identifiable intangible assets acquired:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles', window );">Identifiable intangible assets</a></td>
<td class="nump">$ 32,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract', window );"><strong>Liabilities assumed:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife', window );">Useful life</a></td>
<td class="text">13 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=evh_VitalDecisionsMember', window );">Vital Decisions | Technology</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwillAbstract', window );"><strong>Identifiable intangible assets acquired:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles', window );">Identifiable intangible assets</a></td>
<td class="nump">$ 5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract', window );"><strong>Liabilities assumed:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife', window );">Useful life</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=evh_VitalDecisionsMember', window );">Vital Decisions | Corporate trade name</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwillAbstract', window );"><strong>Identifiable intangible assets acquired:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles', window );">Identifiable intangible assets</a></td>
<td class="nump">$ 2,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract', window );"><strong>Liabilities assumed:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife', window );">Useful life</a></td>
<td class="text">15 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedTangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Tangible Assets</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedTangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesAccruedCompensationAndEmployeeBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Accrued Compensation And Employee Benefits</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesAccruedCompensationAndEmployeeBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Accrued Liabilities</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average amortization period of finite-lived intangible assets acquired either individually or as part of a group of assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of equity interests issued or issuable to acquire entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120321790&amp;loc=d3e6927-128479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of voting equity interests acquired at the acquisition date in the business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of goodwill arising from a business combination that is expected to be deductible for tax purposes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120321790&amp;loc=d3e6927-128479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationConsiderationTransferred1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=116859721&amp;loc=d3e6613-128477<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120321790&amp;loc=d3e6927-128479<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=116859721&amp;loc=d3e6578-128477<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationConsiderationTransferred1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationConsiderationTransferredAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationConsiderationTransferredAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of equity interests of the acquirer, including instruments or interests issued or issuable in consideration for the business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=116859721&amp;loc=d3e6613-128477<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=116859721&amp;loc=d3e6578-128477<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For contingent consideration arrangements recognized in connection with a business combination, this element represents an estimate of the high-end of the potential range (undiscounted) of the consideration which may be paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120321790&amp;loc=d3e6927-128479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120321790&amp;loc=d3e6927-128479<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116859824&amp;loc=d3e6819-128478<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCapitalLeaseObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lease obligation assumed in business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123413009&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCapitalLeaseObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions, acquired at the acquisition date. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123413009&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer, acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123413009&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount due from customers or clients for goods or services, including trade receivables, that have been delivered or sold in the normal course of business, and amounts due from others, including related parties expected to be converted to cash, sold or exchanged within one year or the normal operating cycle, if longer, acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123413009&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities incurred for goods and services received that are used in an entity's business and related party payables, assumed at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123413009&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred revenue expected to be recognized as such within one year or the normal operating cycle, if longer, assumed at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123413009&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences assumed at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123413009&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwillAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwillAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of identifiable intangible assets recognized as of the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 55<br> -Paragraph 37<br> -URI http://asc.fasb.org/extlink&amp;oid=123455525&amp;loc=d3e2207-128464<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123413009&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities assumed at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123413009&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of other assets expected to be realized or consumed after one year or the normal operating cycle, if longer, acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123413009&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount recognized for assets, including goodwill, in excess of (less than) the aggregate liabilities assumed.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123413009&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120320667&amp;loc=SL49117168-202975<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireBusinessesGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120321790&amp;loc=d3e6927-128479<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireBusinessesGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_CustomerRelationshipsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_CustomerRelationshipsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TradeNamesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TradeNamesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=evh_VitalDecisionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=evh_VitalDecisionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R67.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139858972107880">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Transactions - Equity Investments (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Nov. 16, 2020</div></th>
<th class="th"><div>Sep. 01, 2020</div></th>
<th class="th"><div>Jun. 06, 2019</div></th>
<th class="th"><div>May 28, 2019</div></th>
<th class="th"><div>Jan. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 30, 2019</div></th>
<th class="th"><div>Jun. 18, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToMinorityShareholders', window );">Payments to redeem Sponsors' equity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,300<span></span>
</td>
<td class="nump">$ 20,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnDispositionOfAssets1', window );">Loss (gain) on disposal of assets and consolidation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 698<span></span>
</td>
<td class="num">$ (9,600)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetAcquisitionAxis=evh_PassportAssetAcquisitionMember', window );">Passport Asset Acquisition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_evh_AssetAcquisitionCashAndEquivalents', window );">Cash and equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 159,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_evh_AssetAcquisitionDebtSecuritiesAvailableForSale', window );">Debt securities, available-for-sale</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">88,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_evh_AssetAcquisitionDebtSecuritiesAvailableForSaleUnsettledSalesReceivables', window );">Receivables related to unsettled sales of securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">43,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_evh_AssetAcquisitionOtherAssets', window );">Other assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_evh_AssetAcquisitionAccruedMedicalExpenses', window );">Accrued medical expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">164,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_evh_AssetAcquisitionAccruedLiabilities', window );">Accrued liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=evh_MolinaHealthcareIncMember', window );">Molina</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_evh_AssetPurchaseAgreementEscrowPayments', window );">Asset Purchase Agreement, escrow payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_evh_CashReleasedFromEscrow', window );">Cash released from escrow</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=evh_PassportNoteMember', window );">Passport Note</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.50%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromCollectionOfNotesReceivable', window );">Proceeds from collection of notes receivable</a></td>
<td class="nump">$ 40,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromInterestReceived', window );">Proceeds from interest received</a></td>
<td class="nump">$ 3,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=evh_PassportNoteMember', window );">Passport Note | Notes Receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesReceivableNet', window );">Notes receivable, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 40,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=evh_UniversityHealthCaredbaPassportHealthPlanMember', window );">Passport | Variable Interest Entity, Not Primary Beneficiary</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireEquityMethodInvestments', window );">Payments to acquire interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 70,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VariableInterestEntityOwnershipPercentage', window );">Interest in investment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30.00%<span></span>
</td>
<td class="nump">30.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VariableInterestEntityFinancialOrOtherSupportAmount', window );">Performance bond amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_evh_PaymentsToAcquireEquityMethodInvestmentsAmountHeldBack', window );">Payments to acquire equity method investments, amount held back</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 16,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToMinorityShareholders', window );">Payments to redeem Sponsors' equity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_evh_ProceedsFromTransferOfMembership', window );">Proceeds from transfer of membership</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 23,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_evh_TransferOfMembershipPercentageOfPaymentBasedOnNumberOfEnrollees', window );">Transfer of membership, percentage of payment based on number of enrollees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_evh_TransferOfMembershipPercentageOfPaymentSubjectToSatisfactionOfContingencies', window );">Transfer of membership, percentage of payment subject to satisfaction of contingencies</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=evh_VivantHealthMSOLLCMember', window );">Vivant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnDispositionOfAssets1', window );">Loss (gain) on disposal of assets and consolidation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_AssetAcquisitionAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Asset Acquisition, Accrued Liabilities</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_AssetAcquisitionAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_AssetAcquisitionAccruedMedicalExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Asset Acquisition, Accrued Medical Expenses</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_AssetAcquisitionAccruedMedicalExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_AssetAcquisitionCashAndEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Asset Acquisition, Cash And Equivalents</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_AssetAcquisitionCashAndEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_AssetAcquisitionDebtSecuritiesAvailableForSale">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Asset Acquisition, Debt Securities, Available-For-Sale</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_AssetAcquisitionDebtSecuritiesAvailableForSale</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_AssetAcquisitionDebtSecuritiesAvailableForSaleUnsettledSalesReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Asset Acquisition, Debt Securities, Available-For-Sale, Unsettled Sales Receivables</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_AssetAcquisitionDebtSecuritiesAvailableForSaleUnsettledSalesReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_AssetAcquisitionOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Asset Acquisition, Other Assets</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_AssetAcquisitionOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_AssetPurchaseAgreementEscrowPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Asset Purchase Agreement, Escrow Payments</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_AssetPurchaseAgreementEscrowPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_CashReleasedFromEscrow">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash Released From Escrow</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_CashReleasedFromEscrow</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_PaymentsToAcquireEquityMethodInvestmentsAmountHeldBack">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payments To Acquire Equity Method Investments, Amount Held Back</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_PaymentsToAcquireEquityMethodInvestmentsAmountHeldBack</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_ProceedsFromTransferOfMembership">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Proceeds From Transfer Of Membership</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_ProceedsFromTransferOfMembership</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_TransferOfMembershipPercentageOfPaymentBasedOnNumberOfEnrollees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Transfer Of Membership, Percentage Of Payment Based on Number Of Enrollees</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_TransferOfMembershipPercentageOfPaymentBasedOnNumberOfEnrollees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_TransferOfMembershipPercentageOfPaymentSubjectToSatisfactionOfContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Transfer Of Membership, Percentage Of Payment Subject To Satisfaction Of Contingencies</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_TransferOfMembershipPercentageOfPaymentSubjectToSatisfactionOfContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnDispositionOfAssets1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of assets, including but not limited to property plant and equipment, intangible assets and equity in securities of subsidiaries or equity method investee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnDispositionOfAssets1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesReceivableNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of financing receivable. Excludes financing receivable covered under loss sharing agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124255953&amp;loc=SL82919230-210447<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4428-111522<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesReceivableNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the purchase of or advances to an equity method investments, which are investments in joint ventures and entities in which the entity has an equity ownership interest normally of 20 to 50 percent and exercises significant influence.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToMinorityShareholders">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to a noncontrolling interest. Includes, but not limited to, reduction of noncontrolling interest ownership. Excludes dividends paid to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToMinorityShareholders</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromCollectionOfNotesReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with principal collections from a borrowing supported by a written promise to pay an obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromCollectionOfNotesReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromInterestReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Interest received on loans and other debt instruments during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3337-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromInterestReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableInterestEntityFinancialOrOtherSupportAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of financial or other support the reporting entity has provided (explicitly or implicitly) to the Variable Interest Entity (VIE) that it was not previously contractually required to provide or that the reporting entity intends to provide, including, for example, situations in which the reporting entity assisted the VIE in obtaining another type of support.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5A<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=SL6759159-111685<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableInterestEntityFinancialOrOtherSupportAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableInterestEntityOwnershipPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the Variable Interest Entity's (VIE) voting interest owned by (or beneficial interest in) the reporting entity (directly or indirectly).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5A<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=SL6759159-111685<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableInterestEntityOwnershipPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionAxis=evh_PassportAssetAcquisitionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionAxis=evh_PassportAssetAcquisitionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=evh_MolinaHealthcareIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=evh_MolinaHealthcareIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=evh_PassportNoteMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=evh_PassportNoteMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis=us-gaap_NotesReceivableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis=us-gaap_NotesReceivableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=evh_UniversityHealthCaredbaPassportHealthPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=evh_UniversityHealthCaredbaPassportHealthPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidatedEntitiesAxis=us-gaap_VariableInterestEntityNotPrimaryBeneficiaryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidatedEntitiesAxis=us-gaap_VariableInterestEntityNotPrimaryBeneficiaryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=evh_VivantHealthMSOLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=evh_VivantHealthMSOLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>R68.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139858983770552">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Discontinued Operations - Additional Information (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th></tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=evh_TrueHealthMember', window );">True Health | Discontinued Operations, Disposed of by Sale</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_evh_DiscontinuedOperationGainLossOnPurchasePriceAdjustmentsNetOfTax', window );">Loss on purchase price adjustments</a></td>
<td class="nump">$ 8.7<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_DiscontinuedOperationGainLossOnPurchasePriceAdjustmentsNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Discontinued Operation, Gain (Loss) on Purchase Price Adjustments, Net of Tax</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_DiscontinuedOperationGainLossOnPurchasePriceAdjustmentsNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=evh_TrueHealthMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=evh_TrueHealthMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupClassificationAxis=us-gaap_DiscontinuedOperationsDisposedOfBySaleMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupClassificationAxis=us-gaap_DiscontinuedOperationsDisposedOfBySaleMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>R69.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139858971013992">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Discontinued Operations - Summary of Results of Operations (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="9">3 Months Ended</th>
<th class="th" colspan="6">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><sup>[1]</sup></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th" colspan="2"><div>Dec. 31, 2021</div></th>
<th class="th" colspan="2"><div>Dec. 31, 2020</div></th>
<th class="th" colspan="2"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Expenses</strong></a></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax', window );">Income (loss) from discontinued operations, net of tax (2)</a></td>
<td colspan="2" class="num">$ (8,700)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 1,383<span></span>
</td>
<td class="num">$ (3,166)<span></span>
</td>
<td class="num">$ (1,135)<span></span>
</td>
<td class="num">$ (1,508)<span></span>
</td>
<td class="num">$ (265)<span></span>
</td>
<td class="num">$ (7,317)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="num">$ (6,074)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">$ 1,613<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupClassificationAxis=us-gaap_DiscontinuedOperationsDisposedOfBySaleMember', window );">Discontinued Operations, Disposed of by Sale | True Health</a></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenue</strong></a></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue', window );">Total revenue</a></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">44,833<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">117,733<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">171,887<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Expenses</strong></a></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold', window );">Cost of revenue (exclusive of depreciation and amortization expenses presented separately below)</a></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,885<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">18,343<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">6,633<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_evh_DisposalGroupIncludingDiscontinuedOperationClaimsExpense', window );">Claims expenses</a></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">33,954<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">87,951<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">135,774<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense', window );">Selling, general and administrative expenses</a></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,764<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">18,576<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">26,617<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationAndAmortizationDiscontinuedOperations', window );">Depreciation and amortization expenses</a></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">160<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">640<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">590<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense', window );">Total operating expenses</a></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">45,763<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">125,510<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">169,614<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss', window );">Operating income (loss)</a></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(930)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(7,777)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">2,273<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationInterestIncome', window );">Interest income</a></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">112<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">531<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">581<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationInterestExpense', window );">Interest expense</a></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(12)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">21<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherExpense', window );">Other loss</a></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(25)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(1)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(3)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax', window );">Income (loss) before income taxes and non-controlling interests</a></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(847)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(7,259)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">2,872<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation', window );">Benefit (provision) for income taxes</a></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(326)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(1,185)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">1,259<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax', window );">Income (loss) from discontinued operations, net of tax (2)</a></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(521)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(6,074)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">1,613<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupClassificationAxis=us-gaap_DiscontinuedOperationsDisposedOfBySaleMember', window );">Discontinued Operations, Disposed of by Sale | True Health | Platform and operations services</a></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenue</strong></a></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue', window );">Total revenue</a></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">38<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">356<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">145<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupClassificationAxis=us-gaap_DiscontinuedOperationsDisposedOfBySaleMember', window );">Discontinued Operations, Disposed of by Sale | True Health | Premiums</a></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenue</strong></a></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue', window );">Total revenue</a></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 44,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">44,795<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">117,377<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">171,742<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupClassificationAxis=us-gaap_DiscontinuedOperationsDisposedOfBySaleMember', window );">Discontinued Operations, Disposed of by Sale | True Health | Services Agreements</a></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Expenses</strong></a></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold', window );">Cost of revenue (exclusive of depreciation and amortization expenses presented separately below)</a></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,800<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">13,600<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">6,600<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense', window );">Selling, general and administrative expenses</a></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,100<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 6,400<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 6,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr><td colspan="16"></td></tr>
<tr><td colspan="16"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">Includes $6.8&#160;million loss on disposal of discontinued operations for the year ended December 31, 2021</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_DisposalGroupIncludingDiscontinuedOperationClaimsExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disposal Group, Including Discontinued Operation, Claims Expense</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_DisposalGroupIncludingDiscontinuedOperationClaimsExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationAndAmortizationDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deprecation and amortization expense attributable to property, plant and equipment and intangible assets of discontinued operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationAndAmortizationDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of income (loss) from a discontinued operation. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=d3e1361-107760<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3A<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721523-107759<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1012-107759<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3B<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721525-107759<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e957-107759<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of tax expense (benefit) related to a discontinued operation. Includes, but is not limited to, tax expense (benefit) related to income (loss) from operations during the phase-out period, tax expense (benefit) related to gain (loss) on disposal, tax expense (benefit) related to gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and tax expense (benefit) related to adjustments of a prior period gain (loss) on disposal.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3B<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721525-107759<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1012-107759<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=d3e1361-107760<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3A<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721523-107759<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721675-107760<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of costs of goods sold attributable to disposal group, including, but not limited to, discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of general and administrative expense attributable to disposal group, including, but not limited to, discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationInterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of interest expense attributable to disposal group, including, but not limited to, discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section S99<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=26872618&amp;loc=d3e7436-122677<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1063-107759<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1060-107759<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationInterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationInterestIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of interest income attributable to disposal group, including, but not limited to, discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationInterestIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of operating expense attributable to disposal group, including, but not limited to, discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of operating income (loss) attributable to disposal group, including, but not limited to, discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of other expense attributable to disposal group, including, but not limited to, discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue attributable to disposal group, including, but not limited to, discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of income (loss) from a discontinued operation including the portion attributable to the noncontrolling interest. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3B<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721525-107759<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721675-107760<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e957-107759<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=d3e1361-107760<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3A<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721523-107759<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1012-107759<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109227538&amp;loc=d3e44648-109337<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupClassificationAxis=us-gaap_DiscontinuedOperationsDisposedOfBySaleMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupClassificationAxis=us-gaap_DiscontinuedOperationsDisposedOfBySaleMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=evh_TrueHealthMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=evh_TrueHealthMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=evh_PlatformsAndOperationsServicesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=evh_PlatformsAndOperationsServicesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=evh_PremiumsRevenueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=evh_PremiumsRevenueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=evh_ServicesAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=evh_ServicesAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>R70.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139858983880504">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Discontinued Operations - Summary of Cash Flows (Details) - True Health - Discontinued Operations, Disposed of by Sale - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations', window );">Cash flows provided by (used in) operating activities</a></td>
<td class="nump">$ 5,002<span></span>
</td>
<td class="nump">$ 6,852<span></span>
</td>
<td class="num">$ (6,642)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations', window );">Cash flows (used in) provided by investing activities</a></td>
<td class="num">(2,494)<span></span>
</td>
<td class="nump">2,636<span></span>
</td>
<td class="num">(7,172)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations', window );">Cash flows used in financing activities</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="num">$ (2,500)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) of financing activities of discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) of investing activities of discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) of operating activities of discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=evh_TrueHealthMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=evh_TrueHealthMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupClassificationAxis=us-gaap_DiscontinuedOperationsDisposedOfBySaleMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupClassificationAxis=us-gaap_DiscontinuedOperationsDisposedOfBySaleMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>R71.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139858971850808">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Discontinued Operations - Summary of Current and Long-term Assets and Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent', window );">Total current assets</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 33,914<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent', window );">Current liabilities of discontinued operations</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">27,986<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=evh_TrueHealthMember', window );">True Health | Discontinued Operations, Disposed of by Sale</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents', window );">Cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21,488<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_evh_DisposalGroupIncludingDiscontinuedOperationRestrictedCashAndRestrictedInvestmentsCurrent', window );">Restricted cash and restricted investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">63<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet', window );">Accounts receivable, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,437<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,198<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_evh_DisposalGroupIncludingDiscontinuedOperationInvestmentsCurrent', window );">Investments, at amortized cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,728<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent', window );">Total current assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">33,914<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_evh_DisposalGroupIncludingDiscontinuedOperationRestrictedCashAndRestrictedInvestmentsNoncurrent', window );">Restricted cash and restricted investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">616<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_evh_DisposalGroupIncludingDiscontinuedOperationInvestmentsNoncurrent', window );">Investments, at amortized cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,919<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_evh_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsNoncurrent', window );">Prepaid expenses and other noncurrent assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">59<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsNoncurrent', window );">Intangible assets, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,080<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwillNoncurrent', window );">Goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,705<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation', window );">Total assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">54,293<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">93<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilitiesCurrent', window );">Accrued liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,265<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_evh_DisposalGroupIncludingDiscontinuedOperationAccruedCompensationAndEmployeeBenefitsCurrent', window );">Accrued compensation and employee benefits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,115<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredRevenueCurrent', window );">Deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,140<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_evh_DisposalGroupIncludingDiscontinuedOperationLiabilityForFuturePolicyBenefitsAndUnpaidClaimsAndClaimsAdjustmentExpenseAndPerformanceBasedArrangementsCurrent', window );">Reserve for claims and performance-based arrangements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,858<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent', window );">Current liabilities of discontinued operations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">26,471<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentLiabilities', window );">Other long-term liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">128<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredTaxLiabilities', window );">Deferred tax liabilities, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">49<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation', window );">Total liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">26,648<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=evh_TrueHealthMember', window );">True Health | Discontinued Operations, Disposed of by Sale | Services Agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet', window );">Accounts receivable, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,500<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,500<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_DisposalGroupIncludingDiscontinuedOperationAccruedCompensationAndEmployeeBenefitsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disposal Group, Including Discontinued Operation, Accrued Compensation And Employee Benefits, Current</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_DisposalGroupIncludingDiscontinuedOperationAccruedCompensationAndEmployeeBenefitsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_DisposalGroupIncludingDiscontinuedOperationInvestmentsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disposal Group, Including Discontinued Operation, Investments, Current</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_DisposalGroupIncludingDiscontinuedOperationInvestmentsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_DisposalGroupIncludingDiscontinuedOperationInvestmentsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disposal Group, Including Discontinued Operation, Investments, Noncurrent</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_DisposalGroupIncludingDiscontinuedOperationInvestmentsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_DisposalGroupIncludingDiscontinuedOperationLiabilityForFuturePolicyBenefitsAndUnpaidClaimsAndClaimsAdjustmentExpenseAndPerformanceBasedArrangementsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disposal Group, Including Discontinued Operation, Liability For Future Policy Benefits And Unpaid Claims And Claims Adjustment Expense And Performance-Based Arrangements, Current</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_DisposalGroupIncludingDiscontinuedOperationLiabilityForFuturePolicyBenefitsAndUnpaidClaimsAndClaimsAdjustmentExpenseAndPerformanceBasedArrangementsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disposal Group, Including Discontinued Operation, Prepaid And Other Assets, Noncurrent</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_DisposalGroupIncludingDiscontinuedOperationRestrictedCashAndRestrictedInvestmentsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disposal Group, Including Discontinued Operation, Restricted Cash And Restricted Investments, Current</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_DisposalGroupIncludingDiscontinuedOperationRestrictedCashAndRestrictedInvestmentsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_DisposalGroupIncludingDiscontinuedOperationRestrictedCashAndRestrictedInvestmentsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disposal Group, Including Discontinued Operation, Restricted Cash And Restricted Investments, Noncurrent</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_DisposalGroupIncludingDiscontinuedOperationRestrictedCashAndRestrictedInvestmentsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount classified as assets attributable to disposal group held for sale or disposed of.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1107-107759<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721533-107759<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721675-107760<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount classified as assets attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1107-107759<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721675-107760<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=123351718&amp;loc=d3e2473-110228<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721533-107759<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount classified as accounts, notes and loans receivable attributable to disposal group held for sale or disposed of.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1107-107759<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721533-107759<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount classified as accounts payable attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=123351718&amp;loc=d3e2473-110228<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721533-107759<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1107-107759<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount classified as accrued liabilities attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1107-107759<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721533-107759<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=123351718&amp;loc=d3e2473-110228<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount classified as cash and cash equivalents attributable to disposal group held for sale or disposed of.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721533-107759<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1107-107759<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredRevenueCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount classified as deferred revenue attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1107-107759<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=123351718&amp;loc=d3e2473-110228<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721533-107759<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredRevenueCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount classified as deferred tax liabilities attributable to disposal group held for sale or disposed of.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1107-107759<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721533-107759<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwillNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount classified as goodwill attributable to disposal group held for sale or disposed of, expected to be disposed of after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1107-107759<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721533-107759<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=123351718&amp;loc=d3e2510-110228<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwillNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount classified as intangible assets, excluding goodwill, attributable to disposal group held for sale or disposed of, expected to be disposed of beyond one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721533-107759<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=123351718&amp;loc=d3e2510-110228<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1107-107759<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount classified as other liabilities attributable to disposal group held for sale or disposed of, expected to be disposed of beyond one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721533-107759<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1107-107759<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=123351718&amp;loc=d3e2510-110228<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount classified as prepaid and other assets attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=123351718&amp;loc=d3e2473-110228<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721533-107759<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1107-107759<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount classified as liabilities attributable to disposal group held for sale or disposed of.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1107-107759<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721675-107760<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721533-107759<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount classified as liabilities attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1107-107759<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721533-107759<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=123351718&amp;loc=d3e2473-110228<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721675-107760<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=evh_TrueHealthMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=evh_TrueHealthMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupClassificationAxis=us-gaap_DiscontinuedOperationsDisposedOfBySaleMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupClassificationAxis=us-gaap_DiscontinuedOperationsDisposedOfBySaleMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=evh_ServicesAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=evh_ServicesAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>87
<FILENAME>R72.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139858971430056">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue Recognition - Disaggregation of Revenue (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=evh_EvolentHealthServicesSegmentMember', window );">Evolent Health Services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">$ 309,813<span></span>
</td>
<td class="nump">$ 382,360<span></span>
</td>
<td class="nump">$ 408,905<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=evh_EvolentHealthServicesSegmentMember', window );">Evolent Health Services | Medicaid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">215,236<span></span>
</td>
<td class="nump">236,634<span></span>
</td>
<td class="nump">267,222<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=evh_EvolentHealthServicesSegmentMember', window );">Evolent Health Services | Medicare</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">26,358<span></span>
</td>
<td class="nump">68,505<span></span>
</td>
<td class="nump">73,671<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=evh_EvolentHealthServicesSegmentMember', window );">Evolent Health Services | Commercial and other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">68,219<span></span>
</td>
<td class="nump">77,221<span></span>
</td>
<td class="nump">68,012<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=evh_ClinicalSolutionsSegmentMember', window );">Clinical Solutions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">598,144<span></span>
</td>
<td class="nump">542,279<span></span>
</td>
<td class="nump">278,217<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=evh_ClinicalSolutionsSegmentMember', window );">Clinical Solutions | Medicaid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">205,833<span></span>
</td>
<td class="nump">274,028<span></span>
</td>
<td class="nump">75,675<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=evh_ClinicalSolutionsSegmentMember', window );">Clinical Solutions | Medicare</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">363,053<span></span>
</td>
<td class="nump">257,092<span></span>
</td>
<td class="nump">199,817<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=evh_ClinicalSolutionsSegmentMember', window );">Clinical Solutions | Commercial and other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">$ 29,258<span></span>
</td>
<td class="nump">$ 11,159<span></span>
</td>
<td class="nump">$ 2,725<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=evh_EvolentHealthServicesSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=evh_EvolentHealthServicesSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=evh_MedicaidCustomersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=evh_MedicaidCustomersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=evh_MedicareCustomersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=evh_MedicareCustomersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=evh_CommercialAndOtherCustomersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=evh_CommercialAndOtherCustomersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=evh_ClinicalSolutionsSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=evh_ClinicalSolutionsSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>88
<FILENAME>R73.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139858980014408">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Revenue Recognition - Transaction Price Allocated to the Remaining Performance Obligations (Details)<br> $ in Millions</strong></div></th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue from Contract with Customer [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligation', window );">Revenue, remaining performance obligation</a></td>
<td class="nump">$ 178.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis=2022-01-01', window );">Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2022-01-01</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems', window );"><strong>Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationPercentage', window );">Revenue, remaining performance obligation, percentage</a></td>
<td class="nump">45.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1', window );">Revenue, remaining performance obligation, expected timing of satisfaction, period</a></td>
<td class="text">12 months<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis=2023-01-01', window );">Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2023-01-01</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems', window );"><strong>Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationPercentage', window );">Revenue, remaining performance obligation, percentage</a></td>
<td class="nump">70.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1', window );">Revenue, remaining performance obligation, expected timing of satisfaction, period</a></td>
<td class="text">12 months<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis=2024-01-01', window );">Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2024-01-01</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems', window );"><strong>Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationPercentage', window );">Revenue, remaining performance obligation, percentage</a></td>
<td class="nump">86.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1', window );">Revenue, remaining performance obligation, expected timing of satisfaction, period</a></td>
<td class="text">12 months<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRemainingPerformanceObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of transaction price allocated to performance obligation that has not been recognized as revenue.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130556-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRemainingPerformanceObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period in which remaining performance obligation is expected to be recognized as revenue, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130556-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRemainingPerformanceObligationPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of remaining performance obligation to total remaining performance obligation not recognized as revenue.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130556-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRemainingPerformanceObligationPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis=2022-01-01">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis=2022-01-01</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis=2023-01-01">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis=2023-01-01</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis=2024-01-01">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis=2024-01-01</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>89
<FILENAME>R74.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139858971466184">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue Recognition - Contract Balances (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue from Contract with Customer [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsNotesAndLoansReceivableNetCurrent', window );">Short-term receivables</a></td>
<td class="nump">$ 129,012<span></span>
</td>
<td class="nump">$ 129,012<span></span>
</td>
<td class="nump">$ 118,730<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermAccountsNotesAndLoansReceivableNetNoncurrent', window );">Long-term receivables</a></td>
<td class="nump">4,877<span></span>
</td>
<td class="nump">4,877<span></span>
</td>
<td class="nump">4,554<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetNetCurrent', window );">Short-term contract assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">329<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Short-term deferred revenue</a></td>
<td class="nump">11,944<span></span>
</td>
<td class="nump">11,944<span></span>
</td>
<td class="nump">10,187<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityNoncurrent', window );">Long-term deferred revenue</a></td>
<td class="nump">4,437<span></span>
</td>
<td class="nump">4,437<span></span>
</td>
<td class="nump">3,593<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_evh_ChangeInContractWithCustomerLiabilityRollForward', window );"><strong>Deferred revenue</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Balance as of beginning-of-period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,780<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized', window );">Reclassification to revenue, as a result of performance obligations satisfied</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(10,175)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_evh_ContractWithCustomerLiabilityCashReceivedInAdvanceOfSatisfactionOfPerformanceObligations', window );">Cash received in advance of satisfaction of performance obligations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,776<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Balance as of end of period</a></td>
<td class="nump">16,381<span></span>
</td>
<td class="nump">$ 16,381<span></span>
</td>
<td class="nump">13,780<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod', window );">Revenue recognized from performed obligations</a></td>
<td class="nump">$ 28,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,100<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupClassificationAxis=us-gaap_DiscontinuedOperationsDisposedOfBySaleMember', window );">Discontinued Operations, Disposed of by Sale | True Health</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_evh_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNetAfterGrossUp', window );">Accounts receivable, net, after gross-up</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,400<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredRevenueCurrent', window );">Deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,140<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_ChangeInContractWithCustomerLiabilityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Change In Contract With Customer, Liability [Roll Forward]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_ChangeInContractWithCustomerLiabilityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_ContractWithCustomerLiabilityCashReceivedInAdvanceOfSatisfactionOfPerformanceObligations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contract With Customer, Liability, Cash Received In Advance Of Satisfaction Of Performance Obligations</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_ContractWithCustomerLiabilityCashReceivedInAdvanceOfSatisfactionOfPerformanceObligations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNetAfterGrossUp">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disposal Group, Including Discontinued Operation, Accounts, Notes And Loans Receivable, Net, After Gross-Up</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNetAfterGrossUp</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsNotesAndLoansReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of accounts and financing receivables, classified as current. Includes, but is not limited to, notes and loan receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.3,4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4428-111522<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsNotesAndLoansReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerAssetNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130533-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerAssetNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130549-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130532-203044<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130532-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130532-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130531-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityRevenueRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from performance obligation satisfied or partially satisfied in previous reporting periods. Includes, but is not limited to, change in transaction price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12A<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL108322424-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredRevenueCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount classified as deferred revenue attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1107-107759<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=123351718&amp;loc=d3e2473-110228<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721533-107759<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredRevenueCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermAccountsNotesAndLoansReceivableNetNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of accounts and financing receivables, classified as noncurrent. Includes, but is not limited to, notes and loan receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermAccountsNotesAndLoansReceivableNetNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupClassificationAxis=us-gaap_DiscontinuedOperationsDisposedOfBySaleMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupClassificationAxis=us-gaap_DiscontinuedOperationsDisposedOfBySaleMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=evh_TrueHealthMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=evh_TrueHealthMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>90
<FILENAME>R75.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139858971366024">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue Recognition - Contract Costs (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalizedContractCostLineItems', window );"><strong>Capitalized Contract Cost [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalizedContractCostAmortization', window );">Contract cost amortization</a></td>
<td class="nump">$ 13,041<span></span>
</td>
<td class="nump">$ 21,195<span></span>
</td>
<td class="nump">$ 5,723<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalizedContractCostAmortizationPeriod', window );">Capitalized contract cost, amortization period</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalizedContractCostAxis=evh_BonusesAndCommissionsMember', window );">Bonuses and Commissions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalizedContractCostLineItems', window );"><strong>Capitalized Contract Cost [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalizedContractCostNet', window );">Contract cost assets</a></td>
<td class="nump">$ 5,200<span></span>
</td>
<td class="nump">3,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalizedContractCostAmortization', window );">Contract cost amortization</a></td>
<td class="nump">1,900<span></span>
</td>
<td class="nump">1,900<span></span>
</td>
<td class="nump">1,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalizedContractCostAxis=evh_ContractFulfillmentCostsMember', window );">Contract Fulfillment Costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalizedContractCostLineItems', window );"><strong>Capitalized Contract Cost [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalizedContractCostNet', window );">Contract cost assets</a></td>
<td class="nump">27,400<span></span>
</td>
<td class="nump">23,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalizedContractCostAmortization', window );">Contract cost amortization</a></td>
<td class="nump">$ 11,100<span></span>
</td>
<td class="nump">$ 13,000<span></span>
</td>
<td class="nump">$ 4,700<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalizedContractCostAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for asset recognized from cost incurred to obtain or fulfill contract with customer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 40<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123353750&amp;loc=SL49131252-203054<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalizedContractCostAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalizedContractCostAmortizationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amortization period of cost capitalized in obtaining or fulfilling contract with customer, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 40<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123353750&amp;loc=SL49131251-203054<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalizedContractCostAmortizationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalizedContractCostLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalizedContractCostLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalizedContractCostNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization and accumulated impairment loss, of asset recognized from cost incurred to obtain or fulfill contract with customer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 40<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123353750&amp;loc=SL49131252-203054<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalizedContractCostNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalizedContractCostAxis=evh_BonusesAndCommissionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalizedContractCostAxis=evh_BonusesAndCommissionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalizedContractCostAxis=evh_ContractFulfillmentCostsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalizedContractCostAxis=evh_ContractFulfillmentCostsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>91
<FILENAME>R76.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139858971540216">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Credit Losses - Accounts Receivable (Narrative) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNoncurrentPastDueLineItems', window );"><strong>Accounts Receivable, Noncurrent, Past Due [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_evh_FinancingReceivablePercentNotPastDue', window );">Percentage of receivables, current</a></td>
<td class="nump">90.00%<span></span>
</td>
<td class="nump">59.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNet', window );">Accounts receivable, net</a></td>
<td class="nump">$ 171,500<span></span>
</td>
<td class="nump">$ 173,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent', window );">Allowance for doubtful accounts, current</a></td>
<td class="nump">$ 3,374<span></span>
</td>
<td class="nump">$ 7,056<span></span>
</td>
<td class="nump">$ 41<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancingReceivablesPeriodPastDueAxis=evh_FInancialAssetLessThan60DaysMember', window );">Past due less than 60 days</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNoncurrentPastDueLineItems', window );"><strong>Accounts Receivable, Noncurrent, Past Due [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancingReceivablePercentPastDue1', window );">Percentage of receivables, past due</a></td>
<td class="nump">2.00%<span></span>
</td>
<td class="nump">24.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancingReceivablesPeriodPastDueAxis=evh_FInancialAssetLessThan120DaysPastDueMember', window );">Past due less than 120 days</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNoncurrentPastDueLineItems', window );"><strong>Accounts Receivable, Noncurrent, Past Due [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancingReceivablePercentPastDue1', window );">Percentage of receivables, past due</a></td>
<td class="nump">3.00%<span></span>
</td>
<td class="nump">37.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_FinancingReceivablePercentNotPastDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Financing Receivable, Percent Not Past Due</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_FinancingReceivablePercentNotPastDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 310<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123366838&amp;loc=d3e3073-115593<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNoncurrentPastDueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNoncurrentPastDueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of allowance for credit loss on accounts receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=d3e5074-111524<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124255206&amp;loc=SL82895884-210446<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancingReceivablePercentPastDue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of financing receivable balance that is past due.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancingReceivablePercentPastDue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancingReceivablesPeriodPastDueAxis=evh_FInancialAssetLessThan60DaysMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancingReceivablesPeriodPastDueAxis=evh_FInancialAssetLessThan60DaysMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancingReceivablesPeriodPastDueAxis=evh_FInancialAssetLessThan120DaysPastDueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancingReceivablesPeriodPastDueAxis=evh_FInancialAssetLessThan120DaysPastDueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>92
<FILENAME>R77.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139858970987848">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Credit Losses - Schedule of Changes in Allowance for Accounts Receivable (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward', window );"><strong>Accounts Receivable, Allowance for Credit Loss [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent', window );">Balance as of beginning of period</a></td>
<td class="num">$ (7,056)<span></span>
</td>
<td class="num">$ (41)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_evh_AccountsReceivableAllowanceForCreditLossAcquiredDuringPeriod', window );">Passport acquisition</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(2,582)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProvisionForDoubtfulAccounts', window );">Provision for credit losses</a></td>
<td class="num">(2,411)<span></span>
</td>
<td class="num">(3,283)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs', window );">Charge-offs</a></td>
<td class="nump">6,093<span></span>
</td>
<td class="nump">1,665<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent', window );">Balance as of end of period</a></td>
<td class="num">(3,374)<span></span>
</td>
<td class="num">(7,056)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CumulativeEffectPeriodOfAdoptionAxis=srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember', window );">Cumulative Effect, Period of Adoption, Adjustment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward', window );"><strong>Accounts Receivable, Allowance for Credit Loss [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent', window );">Balance as of beginning of period</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="num">(2,815)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent', window );">Balance as of end of period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_AccountsReceivableAllowanceForCreditLossAcquiredDuringPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accounts Receivable, Allowance for Credit Loss, Acquired During Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_AccountsReceivableAllowanceForCreditLossAcquiredDuringPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of allowance for credit loss on accounts receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=d3e5074-111524<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124255206&amp;loc=SL82895884-210446<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of direct write-downs of accounts receivable charged against the allowance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=124255953&amp;loc=SL82919249-210447<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProvisionForDoubtfulAccounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (reversal of expense) for expected credit loss on accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124255953&amp;loc=SL82919249-210447<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProvisionForDoubtfulAccounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CumulativeEffectPeriodOfAdoptionAxis=srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CumulativeEffectPeriodOfAdoptionAxis=srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>93
<FILENAME>R78.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139858971463368">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment, Net (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment</a></td>
<td class="nump">$ 200,463<span></span>
</td>
<td class="nump">$ 175,096<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Accumulated depreciation and amortization expenses</a></td>
<td class="num">(119,098)<span></span>
</td>
<td class="num">(88,856)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Total property and equipment, net</a></td>
<td class="nump">81,365<span></span>
</td>
<td class="nump">86,240<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation expense</a></td>
<td class="nump">30,600<span></span>
</td>
<td class="nump">28,300<span></span>
</td>
<td class="nump">$ 23,300<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalizedComputerSoftwareAmortization1', window );">Capitalized computer software, amortization</a></td>
<td class="nump">26,500<span></span>
</td>
<td class="nump">24,300<span></span>
</td>
<td class="nump">18,700<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember', window );">Computer hardware</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment</a></td>
<td class="nump">21,970<span></span>
</td>
<td class="nump">18,866<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment</a></td>
<td class="nump">3,581<span></span>
</td>
<td class="nump">3,559<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareDevelopmentMember', window );">Internal-use software development costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment</a></td>
<td class="nump">159,587<span></span>
</td>
<td class="nump">137,085<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Total property and equipment, net</a></td>
<td class="nump">71,200<span></span>
</td>
<td class="nump">75,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalizedComputerSoftwareAdditions', window );">Capitalized computer software additions</a></td>
<td class="nump">22,500<span></span>
</td>
<td class="nump">24,600<span></span>
</td>
<td class="nump">$ 30,900<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold improvements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment</a></td>
<td class="nump">$ 15,325<span></span>
</td>
<td class="nump">$ 15,586<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.14)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalizedComputerSoftwareAdditions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Additions made to capitalized computer software costs during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalizedComputerSoftwareAdditions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalizedComputerSoftwareAmortization1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for amortization of capitalized computer software costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128487-111756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalizedComputerSoftwareAmortization1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareDevelopmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareDevelopmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>94
<FILENAME>R79.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139858970996568">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Goodwill and Intangible Assets, Net - Impairment Testing (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="3">3 Months Ended</th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="5">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Oct. 31, 2020 </div>
<div>reportingUnit</div>
</th>
<th class="th">
<div>May 31, 2020 </div>
<div>reportingUnit</div>
</th>
<th class="th">
<div>Jun. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>unit</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>reportingUnit</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NumberOfReportingUnits', window );">Number of reporting units for goodwill testing</a></td>
<td class="nump">2<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillImpairmentLoss', window );">Goodwill impairment | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 215,100,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 199,800,000<span></span>
</td>
<td class="nump">$ 215,100,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 215,100,000<span></span>
</td>
<td class="nump">$ 199,800,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_evh_NumberOfReportingUnitsFairValueInExcessOfCarryingAmount', window );">Number of reporting units, fair value in excess of carrying amount | reportingUnit</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_NumberOfReportingUnitsFairValueInExcessOfCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number Of Reporting Units, Fair Value In Excess Of Carrying Amount</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_NumberOfReportingUnitsFairValueInExcessOfCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillImpairmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13854-109267<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13777-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillImpairmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfReportingUnits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of reporting units tested for impairment of goodwill. A reporting unit is an operating segment or one level below an operating segment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfReportingUnits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>95
<FILENAME>R80.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139858971302584">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Goodwill and Intangible Assets, Net - Schedule of Goodwill (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="3">3 Months Ended</th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillRollForward', window );"><strong>Goodwill [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Balance as of beginning of period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 566,359,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 566,359,000<span></span>
</td>
<td class="nump">$ 349,029,000<span></span>
</td>
<td class="nump">$ 566,359,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit', window );">Goodwill disposal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,200,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillImpairmentLoss', window );">Impairment</a></td>
<td class="num">$ (215,100,000)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">$ (199,800,000)<span></span>
</td>
<td class="num">(215,100,000)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(215,100,000)<span></span>
</td>
<td class="num">$ (199,800,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAcquiredDuringPeriod', window );">Goodwill acquired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">77,288,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillForeignCurrencyTranslationGainLoss', window );">Foreign currency translation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(20,000)<span></span>
</td>
<td class="num">(30,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Balance as of end of period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">566,359,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">426,297,000<span></span>
</td>
<td class="nump">349,029,000<span></span>
</td>
<td class="nump">566,359,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss', window );">Cumulative inception to date impairment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">360,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">575,500,000<span></span>
</td>
<td class="nump">360,400,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=evh_EvolentHealthServicesSegmentMember', window );">Evolent Health Services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillRollForward', window );"><strong>Goodwill [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Balance as of beginning of period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">431,684,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">431,684,000<span></span>
</td>
<td class="nump">214,354,000<span></span>
</td>
<td class="nump">431,684,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit', window );">Goodwill disposal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,200,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillImpairmentLoss', window );">Impairment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(215,100,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAcquiredDuringPeriod', window );">Goodwill acquired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillForeignCurrencyTranslationGainLoss', window );">Foreign currency translation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(20,000)<span></span>
</td>
<td class="num">(30,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Balance as of end of period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">431,684,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">214,334,000<span></span>
</td>
<td class="nump">214,354,000<span></span>
</td>
<td class="nump">431,684,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=evh_ClinicalSolutionsSegmentMember', window );">Clinical Solutions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillRollForward', window );"><strong>Goodwill [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Balance as of beginning of period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 134,675,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 134,675,000<span></span>
</td>
<td class="nump">134,675,000<span></span>
</td>
<td class="nump">134,675,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit', window );">Goodwill disposal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillImpairmentLoss', window );">Impairment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAcquiredDuringPeriod', window );">Goodwill acquired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">77,288,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillForeignCurrencyTranslationGainLoss', window );">Foreign currency translation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Balance as of end of period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 134,675,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 211,963,000<span></span>
</td>
<td class="nump">$ 134,675,000<span></span>
</td>
<td class="nump">$ 134,675,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120320667&amp;loc=SL49117168-202975<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAcquiredDuringPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized resulting from a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAcquiredDuringPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillForeignCurrencyTranslationGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of foreign currency translation gain (loss) which increases (decreases) an asset representing future economic benefits from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillForeignCurrencyTranslationGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated impairment loss for an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillImpairedAccumulatedImpairmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillImpairmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13854-109267<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13777-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillImpairmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of divestiture of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=evh_EvolentHealthServicesSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=evh_EvolentHealthServicesSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=evh_ClinicalSolutionsSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=evh_ClinicalSolutionsSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>96
<FILENAME>R81.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139858971917528">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Goodwill and Intangible Assets, Net - Intangible Assets, Net (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross Carrying Amount</a></td>
<td class="nump">$ 442,376<span></span>
</td>
<td class="nump">$ 398,034<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="nump">162,592<span></span>
</td>
<td class="nump">133,042<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Total future amortization of intangible assets</a></td>
<td class="nump">279,784<span></span>
</td>
<td class="nump">264,992<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization of intangible assets</a></td>
<td class="nump">29,400<span></span>
</td>
<td class="nump">32,300<span></span>
</td>
<td class="nump">$ 37,100<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupClassificationAxis=us-gaap_DiscontinuedOperationsDisposedOfBySaleMember', window );">Discontinued Operations, Disposed of by Sale | True Health</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsNoncurrent', window );">Intangible assets, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,080<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization of intangible assets</a></td>
<td class="nump">$ 200<span></span>
</td>
<td class="nump">$ 600<span></span>
</td>
<td class="nump">$ 600<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TradeNamesMember', window );">Corporate trade name</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife', window );">Weighted- Average Remaining Useful Life</a></td>
<td class="text">12 years 4 months 24 days<span></span>
</td>
<td class="text">13 years 2 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross Carrying Amount</a></td>
<td class="nump">$ 25,800<span></span>
</td>
<td class="nump">$ 23,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="nump">7,693<span></span>
</td>
<td class="nump">6,271<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Total future amortization of intangible assets</a></td>
<td class="nump">$ 18,107<span></span>
</td>
<td class="nump">$ 17,029<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_CustomerRelationshipsMember', window );">Customer relationships</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife', window );">Weighted- Average Remaining Useful Life</a></td>
<td class="text">14 years 10 months 24 days<span></span>
</td>
<td class="text">16 years 2 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross Carrying Amount</a></td>
<td class="nump">$ 311,019<span></span>
</td>
<td class="nump">$ 278,519<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="nump">72,697<span></span>
</td>
<td class="nump">57,716<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Total future amortization of intangible assets</a></td>
<td class="nump">$ 238,322<span></span>
</td>
<td class="nump">$ 220,803<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_CustomerRelationshipsMember', window );">Customer relationships | Discontinued Operations, Disposed of by Sale | True Health</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife', window );">Weighted- Average Remaining Useful Life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">15 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsNoncurrent', window );">Intangible assets, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember', window );">Technology</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife', window );">Weighted- Average Remaining Useful Life</a></td>
<td class="text">2 years<span></span>
</td>
<td class="text">1 year 9 months 18 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross Carrying Amount</a></td>
<td class="nump">$ 87,922<span></span>
</td>
<td class="nump">$ 82,922<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="nump">73,378<span></span>
</td>
<td class="nump">63,507<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Total future amortization of intangible assets</a></td>
<td class="nump">$ 14,544<span></span>
</td>
<td class="nump">$ 19,415<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=evh_BelowMarketLeasesMember', window );">Below market lease, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife', window );">Weighted- Average Remaining Useful Life</a></td>
<td class="text">1 year 3 months 18 days<span></span>
</td>
<td class="text">2 years 3 months 18 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross Carrying Amount</a></td>
<td class="nump">$ 1,218<span></span>
</td>
<td class="nump">$ 1,118<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="nump">950<span></span>
</td>
<td class="nump">648<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Total future amortization of intangible assets</a></td>
<td class="nump">$ 268<span></span>
</td>
<td class="nump">$ 470<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_ContractBasedIntangibleAssetsMember', window );">Provider network contracts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife', window );">Weighted- Average Remaining Useful Life</a></td>
<td class="text">2 years 2 months 12 days<span></span>
</td>
<td class="text">2 years 10 months 24 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross Carrying Amount</a></td>
<td class="nump">$ 16,417<span></span>
</td>
<td class="nump">$ 12,175<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="nump">7,874<span></span>
</td>
<td class="nump">4,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Total future amortization of intangible assets</a></td>
<td class="nump">$ 8,543<span></span>
</td>
<td class="nump">$ 7,275<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_ContractBasedIntangibleAssetsMember', window );">Provider network contracts | Discontinued Operations, Disposed of by Sale | True Health</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife', window );">Weighted- Average Remaining Useful Life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsNoncurrent', window );">Intangible assets, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average amortization period of finite-lived intangible assets acquired either individually or as part of a group of assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16225-109274<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount classified as intangible assets, excluding goodwill, attributable to disposal group held for sale or disposed of, expected to be disposed of beyond one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721533-107759<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=123351718&amp;loc=d3e2510-110228<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1107-107759<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 928<br> -SubTopic 340<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6473545&amp;loc=d3e61844-108004<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120154696&amp;loc=d3e54445-107959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupClassificationAxis=us-gaap_DiscontinuedOperationsDisposedOfBySaleMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupClassificationAxis=us-gaap_DiscontinuedOperationsDisposedOfBySaleMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=evh_TrueHealthMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=evh_TrueHealthMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TradeNamesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TradeNamesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_CustomerRelationshipsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_CustomerRelationshipsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=evh_BelowMarketLeasesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=evh_BelowMarketLeasesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_ContractBasedIntangibleAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_ContractBasedIntangibleAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>97
<FILENAME>R82.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139858971504328">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Goodwill and Intangible Assets, Net - Amortization of Intangible Assets (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths', window );">2022</a></td>
<td class="nump">$ 29,102<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo', window );">2023</a></td>
<td class="nump">26,798<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree', window );">2024</a></td>
<td class="nump">20,913<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour', window );">2025</a></td>
<td class="nump">19,403<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive', window );">2026</a></td>
<td class="nump">19,153<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive', window );">Thereafter</a></td>
<td class="nump">164,415<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Total future amortization of intangible assets</a></td>
<td class="nump">$ 279,784<span></span>
</td>
<td class="nump">$ 264,992<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for asset, excluding financial asset and goodwill, lacking physical substance with finite life expected to be recognized after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120154696&amp;loc=d3e54445-107959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>98
<FILENAME>R83.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139858971668504">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Long-term Debt - 2024 Notes (Details) - Senior Notes<br> $ / shares in Units, shares in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Dec. 01, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Aug. 31, 2020 </div>
<div>USD ($) </div>
<div>shares </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2016 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th"><div>Dec. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfDebtIssuanceCosts', window );">Payments of debt issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=evh_SeniorConvertibleNotesDue2024Member', window );">2024 Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Face amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 117,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 117,051,000<span></span>
</td>
<td class="nump">$ 117,051,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentAmount1', window );">Debt conversion, converted instrument, amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 84,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsNet', window );">Debt issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpenseDebt', window );">Interest expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,100,000<span></span>
</td>
<td class="nump">1,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionPrice1', window );">Conversion price (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 18.23<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleNumberOfEquityInstruments', window );">Initial conversion amount (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term debt, net of discount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 78,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_evh_DebtIssuanceCostsNetDebtComponent', window );">Debt issuance costs, net, debt component</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_evh_AmortizationOfDebtDiscountAndDebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction', window );">Non-cash amortization of debt discount and debt issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,900,000<span></span>
</td>
<td class="nump">2,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_evh_DebtInstrumentRepurchasePriceDueToFundamentalChangeAsPercentageOfPrincipalAmount', window );">Repurchase covenant, repurchase price due to fundamental change as percentage of principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_evh_DebtInstrumentRepurchaseCovenantSalePriceAsAPercentageOfConversionPrice', window );">Repurchase covenant, sale price as a percentage of conversion price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">130.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_evh_DebtInstrumentRepurchaseCovenantTradingDaysMinimum', window );">Repurchase covenant, trading days, minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">20 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_evh_DebtInstrumentRepurchaseCovenantConsecutiveTradingDaysMinimum', window );">Repurchase covenant, consecutive trading days, minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">30 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_evh_DebtInstrumentRepurchasePriceDueToChangeInSalePriceAsPercentageOfConversionPrice', window );">Repurchase covenant, repurchase price due to change in sale price as percentage of conversion price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=evh_SeniorConvertibleNotesDue2024Member', window );">2024 Notes | Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsNet', window );">Debt issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfDebt', window );">Proceeds from issuance of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">38,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=evh_ConvertibleSeniorNotesdue2021Member', window );">2021 Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Face amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 125,000,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">26,737,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentAmount1', window );">Debt conversion, converted instrument, amount</a></td>
<td class="nump">$ 26,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionOriginalDebtAmount1', window );">Debt conversion, original debt, amount</a></td>
<td class="nump">26,300,000<span></span>
</td>
<td class="nump">84,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfDebtIssuanceCosts', window );">Payments of debt issuance costs</a></td>
<td class="nump">$ 400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsNet', window );">Debt issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpenseDebt', window );">Interest expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500,000<span></span>
</td>
<td class="nump">$ 1,700,000<span></span>
</td>
<td class="nump">$ 2,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfDebt', window );">Proceeds from issuance of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 120,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=evh_NewNotesMember', window );">New Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentAmount1', window );">Debt conversion, converted instrument, amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 32,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_AmortizationOfDebtDiscountAndDebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amortization Of Debt Discount And Debt Issuance Costs Incurred During Noncash Or Partial Noncash Transaction</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_AmortizationOfDebtDiscountAndDebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_DebtInstrumentRepurchaseCovenantConsecutiveTradingDaysMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Repurchase Covenant, Consecutive Trading Days, Minimum</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_DebtInstrumentRepurchaseCovenantConsecutiveTradingDaysMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_DebtInstrumentRepurchaseCovenantSalePriceAsAPercentageOfConversionPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Repurchase Covenant, Sale Price As A Percentage Of Conversion Price</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_DebtInstrumentRepurchaseCovenantSalePriceAsAPercentageOfConversionPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_DebtInstrumentRepurchaseCovenantTradingDaysMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Repurchase Covenant, Trading Days, Minimum</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_DebtInstrumentRepurchaseCovenantTradingDaysMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_DebtInstrumentRepurchasePriceDueToChangeInSalePriceAsPercentageOfConversionPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Repurchase Price Due To Change In Sale Price As Percentage Of Conversion Price</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_DebtInstrumentRepurchasePriceDueToChangeInSalePriceAsPercentageOfConversionPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_DebtInstrumentRepurchasePriceDueToFundamentalChangeAsPercentageOfPrincipalAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Repurchase Price Due To Fundamental Change As Percentage Of Principal Amount</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_DebtInstrumentRepurchasePriceDueToFundamentalChangeAsPercentageOfPrincipalAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_DebtIssuanceCostsNetDebtComponent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Issuance Costs, Net, Debt Component</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_DebtIssuanceCostsNetDebtComponent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionConvertedInstrumentAmount1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The value of the financial instrument(s) that the original debt is being converted into in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4304-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4332-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionConvertedInstrumentAmount1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionOriginalDebtAmount1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of the original debt being converted in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4304-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4332-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionOriginalDebtAmount1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleConversionPrice1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The price per share of the conversion feature embedded in the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031898-161870<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleConversionPrice1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleNumberOfEquityInstruments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity instruments that the holder of the debt instrument would receive if the debt was converted to equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21475-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21521-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21506-112644<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleNumberOfEquityInstruments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28551-108399<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124429444&amp;loc=SL124452920-239629<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFinanceCostsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFinanceCostsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense for debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6036836-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69F<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495745-112612<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69E<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495743-112612<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495355-112611<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031897-161870<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfDebtIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfDebtIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow during the period from additional borrowings in aggregate debt. Includes proceeds from short-term and long-term debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=evh_SeniorConvertibleNotesDue2024Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=evh_SeniorConvertibleNotesDue2024Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=evh_ConvertibleSeniorNotesdue2021Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=evh_ConvertibleSeniorNotesdue2021Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=evh_NewNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=evh_NewNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>99
<FILENAME>R84.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139858979109160">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Long-term Debt - Credit Agreement (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jan. 08, 2021</div></th>
<th class="th"><div>Dec. 30, 2019</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Cash paid for interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,113,000<span></span>
</td>
<td class="nump">$ 13,352,000<span></span>
</td>
<td class="nump">$ 5,037,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on repayment of debt, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(4,789,000)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=evh_InitialTermLoanFacilityMember', window );">Initial Term Loan Facility | Secured Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Face amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 75,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=evh_CreditAgreementMember', window );">Credit Agreement | Line of Credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on repayment of debt, net</a></td>
<td class="nump">$ 19,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WriteOffOfDeferredDebtIssuanceCost', window );">Unamortized debt issuance cost</a></td>
<td class="nump">9,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LegalFees', window );">Legal expenses</a></td>
<td class="nump">35,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=evh_CreditAgreementMember', window );">Credit Agreement | Line of Credit | DDTL Facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Maximum borrowing capacity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityCommitmentFeePercentage', window );">Commitment fee percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=evh_ConvertibleSeniorNotesdue2021Member', window );">2021 Notes | Senior Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Face amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">26,737,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 125,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsNet', window );">Debt issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,600,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=evh_SeniorCreditFacilitiesMember', window );">Senior Credit Facilities | Secured Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsNet', window );">Debt issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_evh_AmortizationOfDebtDiscountAndDebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction', window );">Non-cash amortization of debt discount and debt issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfLongTermLinesOfCredit', window );">Repayments of long-term lines of credit</a></td>
<td class="nump">98,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_evh_PaymentsOfMakeWholePremium', window );">Payments of make-whole premium</a></td>
<td class="nump">9,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Cash paid for interest</a></td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=evh_SeniorCreditFacilitiesMember', window );">Senior Credit Facilities | Secured Debt | After the Second Anniversary of the Closing of the Senior Credit Facilities but Prior to the Third Anniversary</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_evh_DebtInstrumentRedemptionCallProtectionPremiumPercentage', window );">Redemption, call protection premium, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=evh_SeniorCreditFacilitiesMember', window );">Senior Credit Facilities | Secured Debt | After the Third Anniversary of the Closing of the Senior Credit Facilities but Prior to the Fourth Anniversary</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_evh_DebtInstrumentRedemptionCallProtectionPremiumPercentage', window );">Redemption, call protection premium, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=evh_SeniorCreditFacilitiesMember', window );">Senior Credit Facilities | Secured Debt | After the Fourth Anniversary of the Closing of the Senior Credit Facilities but Prior to the Fifth Anniversary</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_evh_DebtInstrumentRedemptionCallProtectionPremiumPercentage', window );">Redemption, call protection premium, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=evh_SeniorCreditFacilitiesMember', window );">Senior Credit Facilities | Secured Debt | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentTerm', window );">Term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">91 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=evh_SeniorCreditFacilitiesMember', window );">Senior Credit Facilities | Secured Debt | Eurodollar</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Basis spread on variable rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=evh_SeniorCreditFacilitiesMember', window );">Senior Credit Facilities | Secured Debt | Base Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Basis spread on variable rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_AmortizationOfDebtDiscountAndDebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amortization Of Debt Discount And Debt Issuance Costs Incurred During Noncash Or Partial Noncash Transaction</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_AmortizationOfDebtDiscountAndDebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_DebtInstrumentRedemptionCallProtectionPremiumPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Redemption, Call Protection Premium, Percentage</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_DebtInstrumentRedemptionCallProtectionPremiumPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_PaymentsOfMakeWholePremium">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payments Of Make-Whole Premium</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_PaymentsOfMakeWholePremium</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage points added to the reference rate to compute the variable rate on the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentBasisSpreadOnVariableRate1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28551-108399<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124429444&amp;loc=SL124452920-239629<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFinanceCostsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFinanceCostsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123467658&amp;loc=d3e12355-112629<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467658&amp;loc=d3e12317-112629<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4297-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3367-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LegalFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense provided in the period for legal costs incurred on or before the balance sheet date pertaining to resolved, pending or threatened litigation, including arbitration and mediation proceedings.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LegalFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityCommitmentFeePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The fee, expressed as a percentage of the line of credit facility, for the line of credit facility regardless of whether the facility has been used.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityCommitmentFeePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b),22(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfLongTermLinesOfCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for the settlement of obligation drawn from a contractual arrangement with the lender, including letter of credit, standby letter of credit and revolving credit arrangements, under which borrowings can be made up to a specific amount at any point in time with maturities due beyond one year or the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfLongTermLinesOfCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WriteOffOfDeferredDebtIssuanceCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Write-off of amounts previously capitalized as debt issuance cost in an extinguishment of debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WriteOffOfDeferredDebtIssuanceCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=evh_InitialTermLoanFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=evh_InitialTermLoanFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SecuredDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_SecuredDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=evh_CreditAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=evh_CreditAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_LineOfCreditMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_LineOfCreditMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=evh_DelayedDrawTermLoanFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=evh_DelayedDrawTermLoanFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=evh_ConvertibleSeniorNotesdue2021Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=evh_ConvertibleSeniorNotesdue2021Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=evh_SeniorCreditFacilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=evh_SeniorCreditFacilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentRedemptionPeriodAxis=us-gaap_DebtInstrumentRedemptionPeriodOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentRedemptionPeriodAxis=us-gaap_DebtInstrumentRedemptionPeriodOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentRedemptionPeriodAxis=us-gaap_DebtInstrumentRedemptionPeriodTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentRedemptionPeriodAxis=us-gaap_DebtInstrumentRedemptionPeriodTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentRedemptionPeriodAxis=us-gaap_DebtInstrumentRedemptionPeriodThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentRedemptionPeriodAxis=us-gaap_DebtInstrumentRedemptionPeriodThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableRateAxis=us-gaap_EurodollarMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableRateAxis=us-gaap_EurodollarMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableRateAxis=us-gaap_BaseRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableRateAxis=us-gaap_BaseRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>100
<FILENAME>R85.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139858983976856">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Long-term Debt - Warrant Agreement (Details) - Class A Common Stock - USD ($)<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th"><div>Jan. 08, 2021</div></th>
<th class="th"><div>Dec. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightUnissued', window );">Warrants agreed to be sold (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,513,786<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price of warrants or rights (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8.05<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_evh_ClassOfWarrantOrRightPeriodDuringWhichWarrantsOrRightsExercisableAfterMaturityOfCreditAgreement', window );">Period during which warrants or rights exercisable, after maturity of credit agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">30 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForRepurchaseOfWarrants', window );">Payments to settle outstanding warrants</a></td>
<td class="nump">$ 13.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_ClassOfWarrantOrRightPeriodDuringWhichWarrantsOrRightsExercisableAfterMaturityOfCreditAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Class Of Warrant Or Right, Period During Which Warrants Or Rights Exercisable, After Maturity Of Credit Agreement</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_ClassOfWarrantOrRightPeriodDuringWhichWarrantsOrRightsExercisableAfterMaturityOfCreditAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightUnissued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of warrants or rights which entitle the entity to receive future services in exchange for the unvested, forfeitable warrants or rights.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 50<br> -Section S99<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6784392&amp;loc=d3e188667-122775<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightUnissued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRepurchaseOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount paid by the entity to reacquire the right to purchase equity shares at a predetermined price, usually issued together with corporate debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRepurchaseOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=us-gaap_CommonClassAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=us-gaap_CommonClassAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>101
<FILENAME>R86.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139858971388504">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Long-term Debt - 2025 Notes (Details) - 2025 Notes<br> $ / shares in Units, shares in Millions</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Oct. 31, 2018 </div>
<div>USD ($) </div>
<div>shares </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Oct. 24, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Oct. 22, 2018 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsNet', window );">Debt issuance costs</a></td>
<td class="nump">$ 5,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Face amount</a></td>
<td class="nump">$ 172,500,000<span></span>
</td>
<td class="nump">$ 172,500,000<span></span>
</td>
<td class="nump">$ 172,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 22,500,000<span></span>
</td>
<td class="nump">$ 150,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate</a></td>
<td class="nump">1.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfDebt', window );">Proceeds from issuance of debt</a></td>
<td class="nump">$ 166,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsNet', window );">Debt issuance costs</a></td>
<td class="nump">$ 3,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpenseDebt', window );">Interest expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,600,000<span></span>
</td>
<td class="nump">2,600,000<span></span>
</td>
<td class="nump">$ 2,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionPrice1', window );">Conversion price (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 33.43<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleNumberOfEquityInstruments', window );">Initial conversion amount (in shares) | shares</a></td>
<td class="nump">5.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Carrying amount</a></td>
<td class="nump">$ 100,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_evh_AmortizationOfDebtDiscountAndDebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction', window );">Non-cash amortization of debt discount and debt issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000,000<span></span>
</td>
<td class="nump">$ 9,200,000<span></span>
</td>
<td class="nump">$ 8,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_evh_DebtInstrumentRepurchasePriceDueToFundamentalChangeAsPercentageOfPrincipalAmount', window );">Repurchase covenant, repurchase price due to fundamental change as percentage of principal amount</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_evh_DebtInstrumentRepurchaseCovenantSalePriceAsAPercentageOfConversionPrice', window );">Repurchase covenant, sale price as a percentage of conversion price (at least)</a></td>
<td class="nump">130.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_evh_DebtInstrumentRepurchaseCovenantTradingDaysMinimum', window );">Repurchase covenant, trading days, minimum</a></td>
<td class="text">20 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_evh_DebtInstrumentRepurchaseCovenantConsecutiveTradingDaysMinimum', window );">Repurchase covenant, consecutive trading days, minimum</a></td>
<td class="text">30 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_evh_DebtInstrumentRepurchasePriceDueToChangeInSalePriceAsPercentageOfConversionPrice', window );">Repurchase covenant, repurchase price due to change in sale price as percentage of conversion price</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfDebt', window );">Proceeds from issuance of debt</a></td>
<td class="nump">$ 71,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsNet', window );">Debt issuance costs</a></td>
<td class="nump">$ 2,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | Class A Common Stock | Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionRatio1', window );">Initial conversion rate per $ 1000 principal amount</a></td>
<td class="nump">0.0299135<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_AmortizationOfDebtDiscountAndDebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amortization Of Debt Discount And Debt Issuance Costs Incurred During Noncash Or Partial Noncash Transaction</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_AmortizationOfDebtDiscountAndDebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_DebtInstrumentRepurchaseCovenantConsecutiveTradingDaysMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Repurchase Covenant, Consecutive Trading Days, Minimum</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_DebtInstrumentRepurchaseCovenantConsecutiveTradingDaysMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_DebtInstrumentRepurchaseCovenantSalePriceAsAPercentageOfConversionPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Repurchase Covenant, Sale Price As A Percentage Of Conversion Price</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_DebtInstrumentRepurchaseCovenantSalePriceAsAPercentageOfConversionPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_DebtInstrumentRepurchaseCovenantTradingDaysMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Repurchase Covenant, Trading Days, Minimum</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_DebtInstrumentRepurchaseCovenantTradingDaysMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_DebtInstrumentRepurchasePriceDueToChangeInSalePriceAsPercentageOfConversionPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Repurchase Price Due To Change In Sale Price As Percentage Of Conversion Price</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_DebtInstrumentRepurchasePriceDueToChangeInSalePriceAsPercentageOfConversionPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_DebtInstrumentRepurchasePriceDueToFundamentalChangeAsPercentageOfPrincipalAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Repurchase Price Due To Fundamental Change As Percentage Of Principal Amount</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_DebtInstrumentRepurchasePriceDueToFundamentalChangeAsPercentageOfPrincipalAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleConversionPrice1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The price per share of the conversion feature embedded in the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031898-161870<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleConversionPrice1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleConversionRatio1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Ratio applied to the conversion of debt instrument into equity with equity shares divided by debt principal amount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21521-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21506-112644<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleConversionRatio1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleNumberOfEquityInstruments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity instruments that the holder of the debt instrument would receive if the debt was converted to equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21475-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21521-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21506-112644<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleNumberOfEquityInstruments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28551-108399<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124429444&amp;loc=SL124452920-239629<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFinanceCostsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFinanceCostsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense for debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6036836-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69F<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495745-112612<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69E<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495743-112612<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495355-112611<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031897-161870<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow during the period from additional borrowings in aggregate debt. Includes proceeds from short-term and long-term debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=evh_SeniorConvertibleNotesDue2025Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=evh_SeniorConvertibleNotesDue2025Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>102
<FILENAME>R87.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139858979163272">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Long-term Debt - 2021 Notes (Details)<br> $ / shares in Units, shares in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Dec. 01, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Aug. 31, 2020 </div>
<div>USD ($) </div>
<div>shares </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2016 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th"><div>Dec. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCosts', window );">Amortization of deferred financing costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 18,045,000<span></span>
</td>
<td class="nump">$ 14,780,000<span></span>
</td>
<td class="nump">$ 9,370,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfSeniorDebt', window );">Repayments of senior debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">429,000<span></span>
</td>
<td class="nump">16,606,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfDebtIssuanceCosts', window );">Payments of debt issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebtBeforeWriteOffOfDeferredDebtIssuanceCost', window );">Net loss on extinguishment of debt, including fees paid to lenders</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | 2021 Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Face amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 125,000,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">26,737,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfDebt', window );">Proceeds from issuance of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 120,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsNet', window );">Debt issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpenseDebt', window );">Interest expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500,000<span></span>
</td>
<td class="nump">1,700,000<span></span>
</td>
<td class="nump">2,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCosts', window );">Amortization of deferred financing costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200,000<span></span>
</td>
<td class="nump">600,000<span></span>
</td>
<td class="nump">$ 900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentAmount1', window );">Debt conversion, converted instrument, amount</a></td>
<td class="nump">$ 26,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionOriginalDebtAmount1', window );">Debt conversion, original debt, amount</a></td>
<td class="nump">26,300,000<span></span>
</td>
<td class="nump">84,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfDebtIssuanceCosts', window );">Payments of debt issuance costs</a></td>
<td class="nump">400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebtBeforeWriteOffOfDeferredDebtIssuanceCost', window );">Net loss on extinguishment of debt, including fees paid to lenders</a></td>
<td class="num">(2,200,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ExtinguishmentOfDebtAmount', window );">Face amount of debt repaid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfSeniorDebt', window );">Repayments of senior debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_evh_DebtConversionOriginalDebtFairValue', window );">Debt conversion, original debt, fair value</a></td>
<td class="nump">$ 28,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | 2021 Notes | Class A Common Stock | Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionRatio1', window );">Initial conversion rate per $ 1000 principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0416082<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | 2024 Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Face amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 117,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">117,051,000<span></span>
</td>
<td class="nump">117,051,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsNet', window );">Debt issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_evh_DebtInstrumentRepurchasePriceDueToFundamentalChangeAsPercentageOfPrincipalAmount', window );">Repurchase covenant, repurchase price due to fundamental change as percentage of principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpenseDebt', window );">Interest expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,100,000<span></span>
</td>
<td class="nump">$ 1,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionPrice1', window );">Conversion price (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 18.23<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleNumberOfEquityInstruments', window );">Initial conversion amount (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentAmount1', window );">Debt conversion, converted instrument, amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 84,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | 2024 Notes | Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfDebt', window );">Proceeds from issuance of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">38,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsNet', window );">Debt issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | 2024 Notes | Class A Common Stock | Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionRatio1', window );">Initial conversion rate per $ 1000 principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0548667<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_DebtConversionOriginalDebtFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Conversion, Original Debt, Fair Value</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_DebtConversionOriginalDebtFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_DebtInstrumentRepurchasePriceDueToFundamentalChangeAsPercentageOfPrincipalAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Repurchase Price Due To Fundamental Change As Percentage Of Principal Amount</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_DebtInstrumentRepurchasePriceDueToFundamentalChangeAsPercentageOfPrincipalAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfFinancingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495355-112611<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfFinancingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionConvertedInstrumentAmount1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The value of the financial instrument(s) that the original debt is being converted into in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4304-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4332-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionConvertedInstrumentAmount1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionOriginalDebtAmount1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of the original debt being converted in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4304-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4332-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionOriginalDebtAmount1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleConversionPrice1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The price per share of the conversion feature embedded in the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031898-161870<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleConversionPrice1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleConversionRatio1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Ratio applied to the conversion of debt instrument into equity with equity shares divided by debt principal amount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21521-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21506-112644<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleConversionRatio1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleNumberOfEquityInstruments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity instruments that the holder of the debt instrument would receive if the debt was converted to equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21475-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21521-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21506-112644<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleNumberOfEquityInstruments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28551-108399<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124429444&amp;loc=SL124452920-239629<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFinanceCostsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFinanceCostsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ExtinguishmentOfDebtAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross amount of debt extinguished.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ExtinguishmentOfDebtAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebtBeforeWriteOffOfDeferredDebtIssuanceCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Reflects the difference between the fair value of payments made to legally extinguish a debt and its carrying value at that time. This item excludes the write-off of amounts previously capitalized as debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467658&amp;loc=d3e12317-112629<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123467658&amp;loc=d3e12355-112629<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebtBeforeWriteOffOfDeferredDebtIssuanceCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense for debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6036836-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69F<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495745-112612<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69E<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495743-112612<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495355-112611<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfDebtIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfDebtIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow during the period from additional borrowings in aggregate debt. Includes proceeds from short-term and long-term debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfSeniorDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for a long-term debt where the holder has highest claim on the entity's asset in case of bankruptcy or liquidation during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfSeniorDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=evh_ConvertibleSeniorNotesdue2021Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=evh_ConvertibleSeniorNotesdue2021Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=evh_SeniorConvertibleNotesDue2024Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=evh_SeniorConvertibleNotesDue2024Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>103
<FILENAME>R88.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139858971225928">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Long-term Debt - Convertible Senior Notes Carrying Value (Details) - Senior Notes - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Aug. 31, 2020</div></th>
<th class="th"><div>Oct. 31, 2018</div></th>
<th class="th"><div>Oct. 24, 2018</div></th>
<th class="th"><div>Oct. 22, 2018</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">2024 Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleDebt', window );">Convertible Debt, Total</a></td>
<td class="nump">$ 89,361,000<span></span>
</td>
<td class="nump">$ 81,462,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet', window );">Unamortized debt discount and issuance costs</a></td>
<td class="nump">27,690,000<span></span>
</td>
<td class="nump">35,589,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Principal amount</a></td>
<td class="nump">$ 117,051,000<span></span>
</td>
<td class="nump">$ 117,051,000<span></span>
</td>
<td class="nump">$ 117,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1', window );">Remaining amortization period (years)</a></td>
<td class="text">2 years 10 months 24 days<span></span>
</td>
<td class="text">3 years 10 months 24 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">2024 Notes | Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtFairValue', window );">Fair value</a></td>
<td class="nump">$ 195,445,000<span></span>
</td>
<td class="nump">$ 153,220,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">2025 Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleDebt', window );">Convertible Debt, Total</a></td>
<td class="nump">126,315,000<span></span>
</td>
<td class="nump">116,349,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet', window );">Unamortized debt discount and issuance costs</a></td>
<td class="nump">46,185,000<span></span>
</td>
<td class="nump">56,151,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Principal amount</a></td>
<td class="nump">$ 172,500,000<span></span>
</td>
<td class="nump">$ 172,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 172,500,000<span></span>
</td>
<td class="nump">$ 22,500,000<span></span>
</td>
<td class="nump">$ 150,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1', window );">Remaining amortization period (years)</a></td>
<td class="text">3 years 9 months 18 days<span></span>
</td>
<td class="text">4 years 9 months 18 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">2025 Notes | Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtFairValue', window );">Fair value</a></td>
<td class="nump">$ 177,251,000<span></span>
</td>
<td class="nump">$ 147,488,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">2021 Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleDebt', window );">Convertible Debt, Total</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">26,557,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet', window );">Unamortized debt discount and issuance costs</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">180,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Principal amount</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 26,737,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 125,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1', window );">Remaining amortization period (years)</a></td>
<td class="text">0 years<span></span>
</td>
<td class="text">10 months 24 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">2021 Notes | Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtFairValue', window );">Fair value</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 26,470,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Including the current and noncurrent portions, carrying amount of debt identified as being convertible into another form of financial instrument (typically the entity's common stock) as of the balance sheet date, which originally required full repayment more than twelve months after issuance or greater than the normal operating cycle of the company.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Remaining amortization period for discount on the liability component of convertible debt which may be settled in cash upon conversion, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031898-161870<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28551-108399<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124429444&amp;loc=SL124452920-239629<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unamortized debt discount (premium) and debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031897-161870<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The fair value amount of long-term debt whether such amount is presented as a separate caption or as a parenthetical disclosure. Additionally, this element may be used in connection with the fair value disclosures required in the footnote disclosures to the financial statements. The element may be used in both the balance sheet and disclosure in the same submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=evh_SeniorConvertibleNotesDue2024Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=evh_SeniorConvertibleNotesDue2024Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=evh_SeniorConvertibleNotesDue2025Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=evh_SeniorConvertibleNotesDue2025Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=evh_ConvertibleSeniorNotesdue2021Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=evh_ConvertibleSeniorNotesdue2021Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>104
<FILENAME>R89.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139858971490024">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Commitments and Contingencies - Additional Information (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems', window );"><strong>Restricted Cash and Cash Equivalents Items [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalents', window );">Restricted funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 21,028,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_evh_TaxReceivablesAgreementPercentofTaxSavingstobePaid', window );">Percent of tax savings to be paid</a></td>
<td class="nump">85.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis=evh_CollateralwithFinancialInstitutionsMember', window );">Collateral with financial institutions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems', window );"><strong>Restricted Cash and Cash Equivalents Items [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalents', window );">Restricted funds</a></td>
<td class="nump">$ 11,662,000<span></span>
</td>
<td class="nump">4,743,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_LetterOfCreditMember', window );">Letter of Credit | Line of Credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems', window );"><strong>Restricted Cash and Cash Equivalents Items [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Maximum borrowing capacity</a></td>
<td class="nump">15,400,000<span></span>
</td>
<td class="nump">8,300,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_LetterOfCreditMember', window );">Letter of Credit | Line of Credit | Restricted Cash For Letters Of Credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems', window );"><strong>Restricted Cash and Cash Equivalents Items [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalents', window );">Restricted funds</a></td>
<td class="nump">15,400,000<span></span>
</td>
<td class="nump">8,300,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_LetterOfCreditMember', window );">Letter of Credit | Line of Credit | Collateral with financial institutions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems', window );"><strong>Restricted Cash and Cash Equivalents Items [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalents', window );">Restricted funds</a></td>
<td class="nump">$ 15,400,000<span></span>
</td>
<td class="nump">$ 8,300,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_TaxReceivablesAgreementPercentofTaxSavingstobePaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tax Receivables Agreement, Percent of Tax Savings to be Paid</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_TaxReceivablesAgreementPercentofTaxSavingstobePaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b),22(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=SL98516268-108586<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis=evh_CollateralwithFinancialInstitutionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis=evh_CollateralwithFinancialInstitutionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=us-gaap_LetterOfCreditMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=us-gaap_LetterOfCreditMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_LineOfCreditMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_LineOfCreditMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis=evh_RestrictedCashForLettersOfCreditForLetterOfCreditFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis=evh_RestrictedCashForLettersOfCreditForLetterOfCreditFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>105
<FILENAME>R90.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139858971792408">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies - Reinsurance Agreements (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssumedPremiumsWritten', window );">Reinsurance premiums assumed</a></td>
<td class="nump">$ 23,179<span></span>
</td>
<td class="nump">$ 19,130<span></span>
</td>
<td class="nump">$ 83,325<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CededPremiumsWritten', window );">Reinsurance premiums ceded</a></td>
<td class="num">(1,614)<span></span>
</td>
<td class="num">(3,275)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReinsuranceEffectOnClaimsAndBenefitsIncurredAmountAssumed', window );">Claims assumed</a></td>
<td class="nump">20,468<span></span>
</td>
<td class="nump">14,812<span></span>
</td>
<td class="nump">72,594<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReinsuranceEffectOnClaimsAndBenefitsIncurredAmountCeded', window );">Claims ceded</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(422)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_evh_PolicyholderBenefitsAndClaimsIncurredAssumedExpensesRelatedToClaims', window );">Claims-related administrative expenses</a></td>
<td class="nump">2,159<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">14,024<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_evh_PremiumsWrittenAndPolicyholderBenefitsAndClaimsIncurredNet', window );">Increase (decrease) in reserves for claims and performance-based arrangements attributable to the Reinsurance Agreement</a></td>
<td class="nump">2,166<span></span>
</td>
<td class="nump">1,465<span></span>
</td>
<td class="num">(3,293)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssumedLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense', window );">Reserves for claims and performance-based arrangements attributable to the Reinsurance Agreement at the beginning of the period</a></td>
<td class="nump">4,002<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,243<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_evh_AssumedLiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseImpactOfConsolidationOnPayables', window );">Impact of consolidation on payable for claims and performance-based arrangements attributable to the Reinsurance Agreement</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(502)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForReinsurance', window );">Reinsurance payments paid (received)</a></td>
<td class="nump">6,078<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,536<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_evh_ProceedsFromReinsurance', window );">Reinsurance payments paid (received)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3,039)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssumedLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense', window );">Payable for claims and performance-based arrangements attributable to the Reinsurance Agreement at the end of the period</a></td>
<td class="nump">$ 90<span></span>
</td>
<td class="nump">$ 4,002<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_AssumedLiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseImpactOfConsolidationOnPayables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Assumed Liability For Unpaid Claims And Claims Adjustment Expense, Impact Of Consolidation On Payables</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_AssumedLiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseImpactOfConsolidationOnPayables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_PolicyholderBenefitsAndClaimsIncurredAssumedExpensesRelatedToClaims">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Policyholder Benefits And Claims Incurred, Assumed, Expenses Related To Claims</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_PolicyholderBenefitsAndClaimsIncurredAssumedExpensesRelatedToClaims</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_PremiumsWrittenAndPolicyholderBenefitsAndClaimsIncurredNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Premiums Written And Policyholder Benefits And Claims Incurred, Net</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_PremiumsWrittenAndPolicyholderBenefitsAndClaimsIncurredNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_ProceedsFromReinsurance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Proceeds From Reinsurance</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_ProceedsFromReinsurance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssumedLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Liability as of the balance sheet date for the estimated ultimate cost of settling claims and claim adjustment expense relating to insured events that have occurred on or before the balance sheet date for those liabilities owed to another party as a result of assuming another insurer's primary obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (cc)<br> -URI http://asc.fasb.org/extlink&amp;oid=116884095&amp;loc=d3e14764-158437<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116884095&amp;loc=d3e14764-158437<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssumedLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssumedPremiumsWritten">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of written premiums assumed from other entities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 605<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=6486672&amp;loc=d3e27261-158547<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssumedPremiumsWritten</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CededPremiumsWritten">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of written premiums ceded to other entities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 605<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=6486672&amp;loc=d3e27261-158547<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 605<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=6486672&amp;loc=d3e27261-158547<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CededPremiumsWritten</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForReinsurance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash payments made for reinsurance during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForReinsurance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReinsuranceEffectOnClaimsAndBenefitsIncurredAmountAssumed">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of policy benefits and costs incurred for policies assumed.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=99397103&amp;loc=d3e6811-158387<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReinsuranceEffectOnClaimsAndBenefitsIncurredAmountAssumed</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReinsuranceEffectOnClaimsAndBenefitsIncurredAmountCeded">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of reduction of provision for policy benefits and costs incurred for policies ceded.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=99397103&amp;loc=d3e6811-158387<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReinsuranceEffectOnClaimsAndBenefitsIncurredAmountCeded</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>106
<FILENAME>R91.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139858972030936">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies - Concentration Risk (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_evh_CashFDICInsuredAmountPercentage', window );">Percentage of cash and cash equivalents held with FDIC participating bank</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">99.40%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents (including restricted cash)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 361,581<span></span>
</td>
<td class="nump">$ 354,942<span></span>
</td>
<td class="nump">$ 361,581<span></span>
</td>
<td class="nump">$ 128,531<span></span>
</td>
<td class="nump">$ 388,325<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_evh_CashHeldInInternationalBanksPercentage', window );">Percentage of cash held in international banks (less than)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.60%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupClassificationAxis=us-gaap_DiscontinuedOperationsDisposedOfBySaleMember', window );">Discontinued Operations, Disposed of by Sale | True Health</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue', window );">Revenue</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 44,833<span></span>
</td>
<td class="nump">117,733<span></span>
</td>
<td class="nump">171,887<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=evh_PremiumsRevenueMember', window );">Premiums | Discontinued Operations, Disposed of by Sale | True Health</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue', window );">Revenue</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 44,800<span></span>
</td>
<td class="nump">$ 44,795<span></span>
</td>
<td class="nump">$ 117,377<span></span>
</td>
<td class="nump">$ 171,742<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=evh_CookCountyHealthAndHospitalsSystemMember', window );">Cook County Health and Hospitals System | Customer Concentration Risk | Accounts Receivable | Customer Receivable</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">61.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=evh_CookCountyHealthAndHospitalsSystemMember', window );">Cook County Health and Hospitals System | Customer Concentration Risk | Revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">28.00%<span></span>
</td>
<td class="nump">22.30%<span></span>
</td>
<td class="nump">11.60%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=evh_FloridaBlueMedicareIncMember', window );">Florida Blue Medicare, Inc. | Customer Concentration Risk | Accounts Receivable | Customer Receivable</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">46.40%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=evh_FloridaBlueMedicareIncMember', window );">Florida Blue Medicare, Inc. | Customer Concentration Risk | Revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14.10%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=evh_NewMexicoHealthConnectionsMember', window );">New Mexico Health Connections | Customer Concentration Risk | Revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13.40%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=evh_UniversityHealthCaredbaPassportHealthPlanMember', window );">Passport | Customer Concentration Risk | Revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19.00%<span></span>
</td>
<td class="nump">23.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=evh_MolinaHealthcareMember', window );">Molina Healthcare | Customer Concentration Risk | Accounts Receivable | Customer Receivable</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.40%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=evh_MolinaHealthcareMember', window );">Molina Healthcare | Customer Concentration Risk | Revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9.70%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr><td colspan="7"></td></tr>
<tr><td colspan="7"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">See Note 5.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_CashFDICInsuredAmountPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash, FDIC Insured Amount, Percentage</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_CashFDICInsuredAmountPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_CashHeldInInternationalBanksPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash, Held In International Banks, Percentage</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_CashHeldInInternationalBanksPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskPercentage1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6351-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13531-108611<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13537-108611<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6404-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskPercentage1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue attributable to disposal group, including, but not limited to, discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupClassificationAxis=us-gaap_DiscontinuedOperationsDisposedOfBySaleMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupClassificationAxis=us-gaap_DiscontinuedOperationsDisposedOfBySaleMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=evh_TrueHealthMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=evh_TrueHealthMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=evh_PremiumsRevenueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=evh_PremiumsRevenueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=evh_CookCountyHealthAndHospitalsSystemMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=evh_CookCountyHealthAndHospitalsSystemMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis=us-gaap_FinanceReceivablesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis=us-gaap_FinanceReceivablesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=evh_FloridaBlueMedicareIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=evh_FloridaBlueMedicareIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=evh_NewMexicoHealthConnectionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=evh_NewMexicoHealthConnectionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=evh_UniversityHealthCaredbaPassportHealthPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=evh_UniversityHealthCaredbaPassportHealthPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=evh_MolinaHealthcareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=evh_MolinaHealthcareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>107
<FILENAME>R92.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139858983492888">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases - Narrative (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalents', window );">Restricted funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 21,028<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherCommitmentsAxis=us-gaap_LeaseAgreementsMember', window );">Lease Agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LettersOfCreditOutstandingAmount', window );">Letters of credit outstanding, amount</a></td>
<td class="nump">$ 3,800<span></span>
</td>
<td class="nump">3,500<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalents', window );">Restricted funds</a></td>
<td class="nump">$ 3,800<span></span>
</td>
<td class="nump">$ 3,500<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeaseDescriptionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeaseDescriptionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LettersOfCreditOutstandingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total amount of the contingent obligation under letters of credit outstanding as of the reporting date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LettersOfCreditOutstandingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=SL98516268-108586<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCommitmentsAxis=us-gaap_LeaseAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCommitmentsAxis=us-gaap_LeaseAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>108
<FILENAME>R93.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139858979263512">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases - Primary Office Leases (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Future Minimum Lease Commitments</a></td>
<td class="nump">$ 85,755<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=stpr_VA', window );">Arlington, VA</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Lease Termination Term (in years)</a></td>
<td class="text">10 years 1 month 6 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Future Minimum Lease Commitments</a></td>
<td class="nump">$ 35,581<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LettersOfCreditOutstandingAmount', window );">Letter of Credit Amount Required</a></td>
<td class="nump">$ 1,579<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=stpr_IL', window );">Riverside, IL</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Lease Termination Term (in years)</a></td>
<td class="text">9 years 3 months 18 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Future Minimum Lease Commitments</a></td>
<td class="nump">$ 41,408<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LettersOfCreditOutstandingAmount', window );">Letter of Credit Amount Required</a></td>
<td class="nump">$ 232<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=stpr_NJ', window );">Edison, NJ</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Lease Termination Term (in years)</a></td>
<td class="text">4 years 3 months 18 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Future Minimum Lease Commitments</a></td>
<td class="nump">$ 2,180<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LettersOfCreditOutstandingAmount', window );">Letter of Credit Amount Required</a></td>
<td class="nump">$ 222<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_IN', window );">Pune, India</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Lease Termination Term (in years)</a></td>
<td class="text">1 year 8 months 12 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Future Minimum Lease Commitments</a></td>
<td class="nump">$ 1,382<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LettersOfCreditOutstandingAmount', window );">Letter of Credit Amount Required</a></td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=stpr_CA', window );">Brea, CA</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Lease Termination Term (in years)</a></td>
<td class="text">4 months 24 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Future Minimum Lease Commitments</a></td>
<td class="nump">$ 462<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LettersOfCreditOutstandingAmount', window );">Letter of Credit Amount Required</a></td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeaseDescriptionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeaseDescriptionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseTermOfContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseTermOfContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LettersOfCreditOutstandingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total amount of the contingent obligation under letters of credit outstanding as of the reporting date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LettersOfCreditOutstandingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=stpr_VA">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=stpr_VA</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=stpr_IL">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=stpr_IL</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=stpr_NJ">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=stpr_NJ</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_IN">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_IN</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=stpr_CA">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=stpr_CA</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>109
<FILENAME>R94.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139858971347864">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases - Components of Lease Expense (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Operating lease cost</a></td>
<td class="nump">$ 12,991<span></span>
</td>
<td class="nump">$ 15,848<span></span>
</td>
<td class="nump">$ 13,903<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseRightOfUseAssetAmortization', window );">Amortization of right-of-use assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">299<span></span>
</td>
<td class="nump">598<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseInterestExpense', window );">Interest expense</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="nump">26<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VariableLeaseCost', window );">Variable lease cost</a></td>
<td class="nump">5,036<span></span>
</td>
<td class="nump">5,097<span></span>
</td>
<td class="nump">4,177<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseCost', window );">Total lease cost</a></td>
<td class="nump">$ 18,027<span></span>
</td>
<td class="nump">$ 21,247<span></span>
</td>
<td class="nump">$ 18,704<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseInterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of interest expense on finance lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918638-209977<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseInterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseRightOfUseAssetAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to right-of-use asset from finance lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918638-209977<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseRightOfUseAssetAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lease cost recognized by lessee for lease contract.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>110
<FILENAME>R95.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139858979715000">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases - Maturity of Lease Liabilities (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2022</a></td>
<td class="nump">$ 10,916<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2023</a></td>
<td class="nump">9,258<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2024</a></td>
<td class="nump">8,968<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour', window );">2025</a></td>
<td class="nump">8,653<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive', window );">2026</a></td>
<td class="nump">7,988<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive', window );">Thereafter</a></td>
<td class="nump">39,972<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total lease payments</a></td>
<td class="nump">85,755<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilitiesGrossDifferenceAmountAbstract', window );"><strong>Less:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Interest</a></td>
<td class="nump">20,964<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Present value of lease liabilities</a></td>
<td class="nump">$ 64,791<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilitiesGrossDifferenceAmountAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilitiesGrossDifferenceAmountAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>111
<FILENAME>R96.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139858971150472">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases - Weighted-average Discount Rate and Weighted-remaining Lease Terms (Details)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Weighted average discount rate</a></td>
<td class="nump">6.38%<span></span>
</td>
<td class="nump">6.44%<span></span>
</td>
<td class="nump">6.25%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Weighted average remaining lease term</a></td>
<td class="text">8 years 9 months 18 days<span></span>
</td>
<td class="text">9 years 4 months 24 days<span></span>
</td>
<td class="text">9 years 10 months 24 days<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>112
<FILENAME>R97.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139858979005448">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings (Loss) Per Common Share - Computation of Earnings per Share (Details) - USD ($)<br> $ / shares in Units, shares in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="9">3 Months Ended</th>
<th class="th" colspan="6">12 Months Ended</th>
</tr>
<tr>
<th class="th" colspan="2"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th" colspan="2"><div>Dec. 31, 2021</div></th>
<th class="th" colspan="2"><div>Dec. 31, 2020</div></th>
<th class="th" colspan="2"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest', window );">Loss from continuing operations</a></td>
<td class="nump">$ 3,053<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">$ (13,040)<span></span>
</td>
<td class="num">$ (9,107)<span></span>
</td>
<td class="num">$ (11,190)<span></span>
</td>
<td class="num">$ (10,637)<span></span>
</td>
<td class="num">$ (37,035)<span></span>
</td>
<td class="num">$ (202,013)<span></span>
</td>
<td class="num">$ (78,487)<span></span>
</td>
<td class="num">$ (30,284)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">$ (328,172)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">$ (307,193)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax', window );">Income (loss) from discontinued operations, net of tax</a></td>
<td class="num">(8,700)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,383<span></span>
</td>
<td class="num">(3,166)<span></span>
</td>
<td class="num">(1,135)<span></span>
</td>
<td class="num">(1,508)<span></span>
</td>
<td class="num">(265)<span></span>
</td>
<td class="num">(7,317)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="num">(6,074)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">1,613<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income (loss)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(37,601)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(334,246)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(305,580)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_evh_EarningsLossAvailabletoCommonShareholdersAbstract', window );"><strong>Less:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest', window );">Net loss attributable to non-controlling interests</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">822<span></span>
</td>
<td class="num">(822)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(3,609)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic', window );">Net loss attributable to common shareholders of Evolent Health, Inc.</a></td>
<td class="num">(5,647)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(13,040)<span></span>
</td>
<td class="num">(9,107)<span></span>
</td>
<td class="num">(9,807)<span></span>
</td>
<td class="num">(14,625)<span></span>
</td>
<td class="num">(37,348)<span></span>
</td>
<td class="num">(203,521)<span></span>
</td>
<td class="num">(78,752)<span></span>
</td>
<td class="num">(37,601)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(334,246)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(301,971)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted', window );">Net loss attributable to common shareholders of Evolent Health, Inc.</a></td>
<td class="num">$ (5,647)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">$ (13,040)<span></span>
</td>
<td class="num">$ (9,107)<span></span>
</td>
<td class="num">$ (9,807)<span></span>
</td>
<td class="num">$ (14,625)<span></span>
</td>
<td class="num">$ (37,348)<span></span>
</td>
<td class="num">$ (203,521)<span></span>
</td>
<td class="num">$ (78,752)<span></span>
</td>
<td class="num">$ (37,601)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">$ (334,246)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">$ (301,971)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted-average common shares outstanding - basic (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">86,067<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">84,928<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">82,364<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted-average common shares outstanding - diluted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">86,067<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">84,928<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">82,364<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDilutedAbstract', window );"><strong>Loss per common share, Basic and diluted</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare', window );">Continuing operations, basic (in dollars per share)</a></td>
<td class="nump">$ 0.03<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">$ (0.15)<span></span>
</td>
<td class="num">$ (0.11)<span></span>
</td>
<td class="num">$ (0.13)<span></span>
</td>
<td class="num">$ (0.13)<span></span>
</td>
<td class="num">$ (0.43)<span></span>
</td>
<td class="num">$ (2.37)<span></span>
</td>
<td class="num">$ (0.93)<span></span>
</td>
<td class="num">$ (0.35)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">$ (3.86)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">$ (3.73)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare', window );">Continuing operations, diluted (in dollars per share)</a></td>
<td class="nump">0.03<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(0.15)<span></span>
</td>
<td class="num">(0.11)<span></span>
</td>
<td class="num">(0.13)<span></span>
</td>
<td class="num">(0.13)<span></span>
</td>
<td class="num">(0.43)<span></span>
</td>
<td class="num">(2.37)<span></span>
</td>
<td class="num">(0.93)<span></span>
</td>
<td class="num">(0.35)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(3.86)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(3.73)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare', window );">Discontinued operations, diluted (in dollars per share)</a></td>
<td class="num">(0.09)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0.01<span></span>
</td>
<td class="num">(0.04)<span></span>
</td>
<td class="num">(0.01)<span></span>
</td>
<td class="num">(0.01)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(0.09)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(0.08)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">0.02<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare', window );">Discontinued operations, basic (in dollars per share)</a></td>
<td class="num">$ (0.09)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="num">$ (0.04)<span></span>
</td>
<td class="num">$ (0.01)<span></span>
</td>
<td class="num">$ (0.01)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="num">(0.09)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(0.08)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">0.02<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_evh_EarningsPerSharePortionAttributableToNoncontrollingInterestDiluted', window );">Non-controlling interests, diluted (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">0.04<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_evh_EarningsPerSharePortionAttributableToNoncontrollingInterestBasic', window );">Non-controlling interests, basic (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">0.04<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted loss per share attributable to common shareholders of Evolent Health, Inc. (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(0.44)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(3.94)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(3.67)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic loss per share attributable to common shareholders of Evolent Health, Inc. (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (0.44)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">$ (3.94)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">$ (3.67)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr><td colspan="16"></td></tr>
<tr><td colspan="16"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">Includes $6.8&#160;million loss on disposal of discontinued operations for the year ended December 31, 2021</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_EarningsLossAvailabletoCommonShareholdersAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Earnings (Loss) Available to Common Shareholders [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_EarningsLossAvailabletoCommonShareholdersAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_EarningsPerSharePortionAttributableToNoncontrollingInterestBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Earnings Per Share, Portion Attributable to Noncontrolling Interest, Basic</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_EarningsPerSharePortionAttributableToNoncontrollingInterestBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_EarningsPerSharePortionAttributableToNoncontrollingInterestDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Earnings Per Share, Portion Attributable to Noncontrolling Interest, Diluted</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_EarningsPerSharePortionAttributableToNoncontrollingInterestDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDilutedAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDilutedAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of income (loss) from continuing operations including portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569616-111683<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) from continuing operations per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1252-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-03(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868656-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsPerBasicShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) derived from continuing operations during the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-03(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868656-224227<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1252-109256<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of income (loss) from a discontinued operation including the portion attributable to the noncontrolling interest. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3B<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721525-107759<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721675-107760<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e957-107759<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=d3e1361-107760<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3A<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721523-107759<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1012-107759<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109227538&amp;loc=d3e44648-109337<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per basic share amount, after tax, of income (loss) from the day-to-day business activities of the discontinued operation and gain (loss) from the disposal of the discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1278-109256<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per diluted share amount, after tax, of income (loss) from the day-to-day business activities of the discontinued operation and gain (loss) from the disposal of the discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SAB Topic 5.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=120398118&amp;loc=d3e355146-122828<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1278-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of Net Income (Loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1448-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1377-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities, and addition from assumption of issuance of common shares for dilutive potential common shares; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1930-109256<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1930-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1930-109256<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1505-109256<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1930-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3000-108585<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569616-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 29: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>113
<FILENAME>R98.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139858979729704">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings (Loss) Per Common Share - Antidilutive Securities (Details) - shares<br> shares in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Number of antidilutive securities excluded from the calculation of earning per share (in shares)</a></td>
<td class="nump">16,445<span></span>
</td>
<td class="nump">13,144<span></span>
</td>
<td class="nump">13,897<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_CommonClassBMember', window );">Exchangeable Class B common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Number of antidilutive securities excluded from the calculation of earning per share (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,399<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=evh_RestrictedStockUnitsRSUsPerformanceBasedRestrictedStockUnitsPBRSUsAndLeveragedStockUnitsLSUsMember', window );">Restricted stock units ("RSUs"), performance-based RSUs and leveraged stock units ("LSUs")</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Number of antidilutive securities excluded from the calculation of earning per share (in shares)</a></td>
<td class="nump">1,807<span></span>
</td>
<td class="nump">797<span></span>
</td>
<td class="nump">813<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember', window );">Stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Number of antidilutive securities excluded from the calculation of earning per share (in shares)</a></td>
<td class="nump">2,036<span></span>
</td>
<td class="nump">1,141<span></span>
</td>
<td class="nump">1,324<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_ConvertibleDebtMember', window );">Convertible senior notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Number of antidilutive securities excluded from the calculation of earning per share (in shares)</a></td>
<td class="nump">12,602<span></span>
</td>
<td class="nump">11,206<span></span>
</td>
<td class="nump">10,361<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_CommonClassBMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_CommonClassBMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=evh_RestrictedStockUnitsRSUsPerformanceBasedRestrictedStockUnitsPBRSUsAndLeveragedStockUnitsLSUsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=evh_RestrictedStockUnitsRSUsPerformanceBasedRestrictedStockUnitsPBRSUsAndLeveragedStockUnitsLSUsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_ConvertibleDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_ConvertibleDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>114
<FILENAME>R99.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139858971328536">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Stock-based Compensation - 2011 and 2015 Equity Incentive Plans (Details) - shares<br> shares in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Apr. 15, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Jun. 13, 2018</div></th>
<th class="th"><div>May 01, 2015</div></th>
<th class="th"><div>Sep. 23, 2013</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of options issued (in shares)</a></td>
<td class="nump">2,549<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,070<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">RSUs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Number of awards issued (in shares)</a></td>
<td class="nump">2,087<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,737<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=evh_LeveragedStockUnitsLSUsMember', window );">LSUs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Number of awards issued (in shares)</a></td>
<td class="nump">1,084<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=evh_PerformanceBasedRestrictedStockUnitsPSUsMember', window );">PSUs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Number of awards issued (in shares)</a></td>
<td class="nump">319<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=evh_TwoThousandElevenEquityIncentivePlanMember', window );">2011 Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of options issued (in shares)</a></td>
<td class="nump">4,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=evh_TwoThousandElevenEquityIncentivePlanMember', window );">2011 Plan | Restricted stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Number of awards issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=evh_TwoThousandElevenEquityIncentivePlanMember', window );">2011 Plan | Class A Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Number of shares authorized (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,100<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=evh_TwoThousandFifteenEvolentHealthInc.OmnibusIncentiveCompensationPlanMember', window );">2015 Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of options issued (in shares)</a></td>
<td class="nump">2,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=evh_TwoThousandFifteenEvolentHealthInc.OmnibusIncentiveCompensationPlanMember', window );">2015 Plan | RSUs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Number of awards issued (in shares)</a></td>
<td class="nump">4,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=evh_TwoThousandFifteenEvolentHealthInc.OmnibusIncentiveCompensationPlanMember', window );">2015 Plan | LSUs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Number of awards issued (in shares)</a></td>
<td class="nump">1,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=evh_TwoThousandFifteenEvolentHealthInc.OmnibusIncentiveCompensationPlanMember', window );">2015 Plan | PSUs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Number of awards issued (in shares)</a></td>
<td class="nump">300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=evh_TwoThousandFifteenEvolentHealthInc.OmnibusIncentiveCompensationPlanMember', window );">2015 Plan | Class A Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Number of shares authorized (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,500<span></span>
</td>
<td class="nump">6,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=evh_LeveragedStockUnitsLSUsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=evh_LeveragedStockUnitsLSUsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=evh_PerformanceBasedRestrictedStockUnitsPSUsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=evh_PerformanceBasedRestrictedStockUnitsPSUsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=evh_TwoThousandElevenEquityIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=evh_TwoThousandElevenEquityIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=evh_TwoThousandFifteenEvolentHealthInc.OmnibusIncentiveCompensationPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=evh_TwoThousandFifteenEvolentHealthInc.OmnibusIncentiveCompensationPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>115
<FILENAME>R100.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139858979113752">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-based Compensation - Stock-based Compensation Expense (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="nump">$ 16,711<span></span>
</td>
<td class="nump">$ 14,606<span></span>
</td>
<td class="nump">$ 15,618<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember', window );">Cost of revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="nump">2,263<span></span>
</td>
<td class="nump">1,811<span></span>
</td>
<td class="nump">2,673<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember', window );">Selling, general and administrative expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="nump">14,448<span></span>
</td>
<td class="nump">12,795<span></span>
</td>
<td class="nump">12,945<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="nump">1,337<span></span>
</td>
<td class="nump">2,927<span></span>
</td>
<td class="nump">4,237<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember', window );">Performance-based stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">75<span></span>
</td>
<td class="nump">448<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">RSUs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="nump">9,606<span></span>
</td>
<td class="nump">7,763<span></span>
</td>
<td class="nump">8,877<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=evh_PerformanceBasedRestrictedStockUnitsPSUsMember', window );">PSUs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="nump">2,471<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(388)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=evh_LeveragedStockUnitsLSUsMember', window );">LSUs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="nump">$ 3,297<span></span>
</td>
<td class="nump">$ 3,841<span></span>
</td>
<td class="nump">$ 2,444<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=evh_PerformanceBasedRestrictedStockUnitsPSUsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=evh_PerformanceBasedRestrictedStockUnitsPSUsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=evh_LeveragedStockUnitsLSUsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=evh_LeveragedStockUnitsLSUsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>116
<FILENAME>R101.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139858972095288">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-based Compensation - Additional Information (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount', window );">Stock-based compensation capitalized as software development costs</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost capitalized for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>117
<FILENAME>R102.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139858971266024">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-based Compensation - Unrecognized Compensation Expense (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Unrecognized Compensation Expense</a></td>
<td class="nump">$ 33,159<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock options</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Unrecognized Compensation Expense</a></td>
<td class="nump">$ 512<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Weighted Average Period (years)</a></td>
<td class="text">6 months 25 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">RSUs</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions', window );">Unrecognized Compensation Expense</a></td>
<td class="nump">$ 26,104<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Weighted Average Period (years)</a></td>
<td class="text">1 year 8 months 8 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=evh_LeveragedStockUnitsLSUsMember', window );">LSUs</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions', window );">Unrecognized Compensation Expense</a></td>
<td class="nump">$ 2,422<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Weighted Average Period (years)</a></td>
<td class="text">1 year 2 months 8 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=evh_PerformanceBasedRestrictedStockUnitsPSUsMember', window );">PSUs</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions', window );">Unrecognized Compensation Expense</a></td>
<td class="nump">$ 4,121<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Weighted Average Period (years)</a></td>
<td class="text">3 years 2 months 1 day<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost not yet recognized for nonvested award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=evh_LeveragedStockUnitsLSUsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=evh_LeveragedStockUnitsLSUsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=evh_PerformanceBasedRestrictedStockUnitsPSUsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=evh_PerformanceBasedRestrictedStockUnitsPSUsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>118
<FILENAME>R103.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139858971082296">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-based Compensation - Stock Options (Details) - USD ($)<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted-average fair value per option granted (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6.52<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1', window );">Fair value of options vested</a></td>
<td class="nump">$ 4.9<span></span>
</td>
<td class="nump">$ 3.6<span></span>
</td>
<td class="nump">$ 5.9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue', window );">Intrinsic value of options exercised</a></td>
<td class="nump">$ 20.8<span></span>
</td>
<td class="nump">$ 2.2<span></span>
</td>
<td class="nump">$ 0.6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Vesting percentage</a></td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Expiration period</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 years 3 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">51.60%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum', window );">Risk-free interest rate, minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum', window );">Risk-free interest rate, maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.70%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend yield</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The minimum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of vesting of award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of options vested. Excludes equity instruments other than options, for example, but not limited to, share units, stock appreciation rights, restricted stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>119
<FILENAME>R104.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139858979337496">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-based Compensation - Stock Option Activity (Details) - USD ($)<br> $ / shares in Units, shares in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Options</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding at the beginning of the period (in shares)</a></td>
<td class="nump">4,070<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercised (in shares)</a></td>
<td class="num">(1,490)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Forfeited (in shares)</a></td>
<td class="num">(31)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding at the end of the period (in shares)</a></td>
<td class="nump">2,549<span></span>
</td>
<td class="nump">4,070<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Vested and expected to vest at the end of the period (in shares)</a></td>
<td class="nump">2,549<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber', window );">Exercisable at the end of the period (in shares)</a></td>
<td class="nump">2,301<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding at the beginning of the period (in dollars per share)</a></td>
<td class="nump">$ 9.32<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Exercised (in dollars per share)</a></td>
<td class="nump">8.92<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Forfeited (in dollars per share)</a></td>
<td class="nump">15.23<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding at the end of the period (in dollars per share)</a></td>
<td class="nump">9.49<span></span>
</td>
<td class="nump">$ 9.32<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice', window );">Vested and expected to vest at the end of the period (in dollars per share)</a></td>
<td class="nump">9.49<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Exercisable at the end of the period (in dollars per share)</a></td>
<td class="nump">$ 9.11<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_evh_WeightedAverageRemainingContractualTermAbstract', window );"><strong>Weighted Average Remaining Contractual Term</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Outstanding</a></td>
<td class="text">3 years 11 months 26 days<span></span>
</td>
<td class="text">5 years 3 months<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1', window );">Vested and expected to vest</a></td>
<td class="text">3 years 11 months 26 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Exercisable</a></td>
<td class="text">3 years 8 months 15 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_evh_AggregateIntrinsicValueAbstract', window );"><strong>Aggregate Intrinsic Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Outstanding</a></td>
<td class="nump">$ 46,342<span></span>
</td>
<td class="nump">$ 12,578<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue', window );">Vested and expected to vest</a></td>
<td class="nump">46,342<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Exercisable</a></td>
<td class="nump">$ 42,717<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_AggregateIntrinsicValueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate Intrinsic Value [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_AggregateIntrinsicValueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_WeightedAverageRemainingContractualTermAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted Average Remaining Contractual Term [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_WeightedAverageRemainingContractualTermAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest exercisable options that may be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>120
<FILENAME>R105.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139858979277640">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-based Compensation - Performance-based Stock Option Awards (Details) - USD ($)<br> $ / shares in Units, shares in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted-average fair value per option granted (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6.52<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding at the end of the period (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,549<span></span>
</td>
<td class="nump">4,070<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Vested and expected to vest at the end of the period (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,549<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, outstanding at the end of the period (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9.49<span></span>
</td>
<td class="nump">$ 9.32<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, vested and expected to vest at the end of the period (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9.49<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_evh_WeightedAverageRemainingContractualTermAbstract', window );"><strong>Weighted Average Remaining Contractual Term</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years 11 months 26 days<span></span>
</td>
<td class="text">5 years 3 months<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1', window );">Vested and expected to vest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years 11 months 26 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_evh_AggregateIntrinsicValueAbstract', window );"><strong>Aggregate Intrinsic Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 46,342<span></span>
</td>
<td class="nump">$ 12,578<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue', window );">Vested and expected to vest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 46,342<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember', window );">Performance-based stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted (in shares)</a></td>
<td class="nump">300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">1.83%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">65.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (in years)</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted-average fair value per option granted (in dollars per share)</a></td>
<td class="nump">$ 6.68<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding at the end of the period (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">268<span></span>
</td>
<td class="nump">268<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Vested and expected to vest at the end of the period (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">268<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, outstanding at the end of the period (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10.27<span></span>
</td>
<td class="nump">$ 10.27<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, vested and expected to vest at the end of the period (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10.27<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_evh_WeightedAverageRemainingContractualTermAbstract', window );"><strong>Weighted Average Remaining Contractual Term</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years 1 month 28 days<span></span>
</td>
<td class="text">6 years 2 months 1 day<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1', window );">Vested and expected to vest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years 1 month 28 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_evh_AggregateIntrinsicValueAbstract', window );"><strong>Aggregate Intrinsic Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,620<span></span>
</td>
<td class="num">$ (326)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue', window );">Vested and expected to vest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,620<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember', window );">Performance-based stock options | Vest on March 1, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Vesting percentage</a></td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember', window );">Performance-based stock options | Vest on March 1, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Vesting percentage</a></td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember', window );">Performance-based stock options | Class A Common Stock | 1st Tranche</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Vesting percentage</a></td>
<td class="nump">33.33%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_evh_SharebasedCompensationArrangementbySharebasedPaymentAwardAwardVestingRightsSharePriceThreshold', window );">Award vesting rights, share price threshold (in dollars per share)</a></td>
<td class="nump">$ 13.35<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_evh_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsStockPriceTriggerConsecutiveTerm', window );">Consecutive term</a></td>
<td class="text">90 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember', window );">Performance-based stock options | Class A Common Stock | 2nd Tranche</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Vesting percentage</a></td>
<td class="nump">33.33%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_evh_SharebasedCompensationArrangementbySharebasedPaymentAwardAwardVestingRightsSharePriceThreshold', window );">Award vesting rights, share price threshold (in dollars per share)</a></td>
<td class="nump">$ 16.43<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_evh_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsStockPriceTriggerConsecutiveTerm', window );">Consecutive term</a></td>
<td class="text">90 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember', window );">Performance-based stock options | Class A Common Stock | Tranche Three</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Vesting percentage</a></td>
<td class="nump">33.33%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_evh_SharebasedCompensationArrangementbySharebasedPaymentAwardAwardVestingRightsSharePriceThreshold', window );">Award vesting rights, share price threshold (in dollars per share)</a></td>
<td class="nump">$ 19.51<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_evh_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsStockPriceTriggerConsecutiveTerm', window );">Consecutive term</a></td>
<td class="text">90 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_AggregateIntrinsicValueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate Intrinsic Value [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_AggregateIntrinsicValueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsStockPriceTriggerConsecutiveTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement By Share-based Payment Award, Award Vesting Rights, Stock Price Trigger, Consecutive Term</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsStockPriceTriggerConsecutiveTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_SharebasedCompensationArrangementbySharebasedPaymentAwardAwardVestingRightsSharePriceThreshold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Share Price Threshold</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_SharebasedCompensationArrangementbySharebasedPaymentAwardAwardVestingRightsSharePriceThreshold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_WeightedAverageRemainingContractualTermAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted Average Remaining Contractual Term [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_WeightedAverageRemainingContractualTermAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of vesting of award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=evh_SharebasedCompensationAwardSubTrancheOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=evh_SharebasedCompensationAwardSubTrancheOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=evh_SharebasedCompensationAwardSubTrancheTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=evh_SharebasedCompensationAwardSubTrancheTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>121
<FILENAME>R106.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139858978992584">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-based Compensation - Restricted Stock Units (Details) - RSUs - USD ($)<br> $ / shares in Units, shares in Thousands, $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1', window );">Requisite service period for vesting</a></td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Vesting percentage</a></td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>Total RSUs</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Outstanding at the beginning of the period (in shares)</a></td>
<td class="nump">1,737<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted (in shares)</a></td>
<td class="nump">1,276<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Forfeited / Canceled (in shares)</a></td>
<td class="num">(243)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Vested (in shares)</a></td>
<td class="num">(683)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Outstanding at the end of the period (in shares)</a></td>
<td class="nump">2,087<span></span>
</td>
<td class="nump">1,737<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward', window );"><strong>Weighted-Average Grant-Date Fair Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Outstanding at the beginning of the period (in dollars per share)</a></td>
<td class="nump">$ 10.13<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted-average fair value per option granted (in dollars per share)</a></td>
<td class="nump">21.10<span></span>
</td>
<td class="nump">$ 8.88<span></span>
</td>
<td class="nump">$ 10.66<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Forfeited (in dollars per share)</a></td>
<td class="nump">12.74<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Vested (in dollars per share)</a></td>
<td class="nump">10.68<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Outstanding at the end of the period (in dollars per share)</a></td>
<td class="nump">$ 16.35<span></span>
</td>
<td class="nump">$ 10.13<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue', window );">Aggregate intrinsic value, vested</a></td>
<td class="nump">$ 7.3<span></span>
</td>
<td class="nump">$ 6.1<span></span>
</td>
<td class="nump">$ 7.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">New Century Health</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Non-Employee Directors</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Estimated period over which an employee is required to provide service in exchange for the equity-based payment award, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of share-based awards for which the grantee gained the right by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of vesting of award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=evh_NewCenturyHealthMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=evh_NewCenturyHealthMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=evh_NonEmployeeDirectorsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=evh_NonEmployeeDirectorsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>122
<FILENAME>R107.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139858979442216">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-based Compensation - Leveraged Stock Units (Details) - $ / shares<br> shares in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember', window );">1st Tranche</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted-average fair value per option granted (in dollars per share)</a></td>
<td class="nump">$ 20.64<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheTwoMember', window );">2nd Tranche</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted-average fair value per option granted (in dollars per share)</a></td>
<td class="nump">20.69<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=evh_LeveragedStockUnitsLSUsMember', window );">LSUs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.5<span></span>
</td>
<td class="nump">0.7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted-average fair value per option granted (in dollars per share)</a></td>
<td class="nump">$ 8.90<span></span>
</td>
<td class="nump">$ 6.52<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">62.10%<span></span>
</td>
<td class="nump">51.70%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">85.00%<span></span>
</td>
<td class="nump">254.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=evh_LeveragedStockUnitsLSUsMember', window );">LSUs | 1st Tranche</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_evh_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsStockPriceIncreasePercentage', window );">Award vesting rights, stock price increase, percentage</a></td>
<td class="nump">33.30%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Vesting percentage</a></td>
<td class="nump">75.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=evh_LeveragedStockUnitsLSUsMember', window );">LSUs | 2nd Tranche</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_evh_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsStockPriceIncreasePercentage', window );">Award vesting rights, stock price increase, percentage</a></td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Vesting percentage</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=evh_LeveragedStockUnitsLSUsMember', window );">LSUs | Tranche Three</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_evh_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsStockPriceIncreasePercentage', window );">Award vesting rights, stock price increase, percentage</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Vesting percentage</a></td>
<td class="nump">150.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=evh_LeveragedStockUnitsLSUsMember', window );">LSUs | Tranche Four</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_evh_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsStockPriceIncreasePercentage', window );">Award vesting rights, stock price increase, percentage</a></td>
<td class="nump">200.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Vesting percentage</a></td>
<td class="nump">200.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsStockPriceIncreasePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement By Share-based Payment Award, Award Vesting Rights, Stock Price Increase, Percentage</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsStockPriceIncreasePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of vesting of award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=evh_LeveragedStockUnitsLSUsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=evh_LeveragedStockUnitsLSUsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=evh_SharebasedPaymentArrangementTrancheFourMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=evh_SharebasedPaymentArrangementTrancheFourMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>123
<FILENAME>R108.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139859073445800">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-based Compensation - Leveraged Stock Units Activity (Details) - LSUs<br> $ / shares in Units, shares in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_evh_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingAbstract', window );"><strong>Outstanding as of December 31, 2021</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Leveraged Stock Units (in shares) | shares</a></td>
<td class="nump">1,084<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Weighted Average Grant Date Fair Value (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 11.07<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms', window );">Weighted Average Remaining Contractual Term</a></td>
<td class="text">7 years 8 months 4 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding', window );">Aggregate Intrinsic Value | $</a></td>
<td class="nump">$ 17,993<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_evh_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestAbstract', window );"><strong>Vested and expected to vest after December&#160;31, 2021</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_evh_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestNumber', window );">Leveraged Stock Units (in shares) | shares</a></td>
<td class="nump">1,084<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_evh_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestWeightedAverageGrantDateFairValue', window );">Weighted Average Grant Date Fair Value (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 11.07<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_evh_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestWeightedAverageRemainingContractualTerms', window );">Weighted Average Remaining Contractual Term</a></td>
<td class="text">7 years 8 months 4 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_evh_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVestedAndExpectedToVest', window );">Aggregate Intrinsic Value | $</a></td>
<td class="nump">$ 17,993<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVestedAndExpectedToVest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement By Share-based Payment Award, Equity Instruments Other Than Options, Aggregate Intrinsic Value, Vested And Expected To Vest</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVestedAndExpectedToVest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement By Share-based Payment Award, Equity Instruments Other Than Options, Outstanding [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement By Share-based Payment Award, Equity Instruments Other Than Options, Vested And Expected To Vest [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement By Share-based Payment Award, Equity Instruments Other Than Options, Vested And Expected To Vest, Number</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement By Share-based Payment Award, Equity Instruments Other Than Options, Vested And Expected To Vest, Weighted Average Grant Date Fair Value</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestWeightedAverageRemainingContractualTerms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement By Share-based Payment Award, Equity Instruments Other Than Options, Vested And Expected To Vest, Weighted Average Remaining Contractual Terms</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestWeightedAverageRemainingContractualTerms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for equity-based awards excluding options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Intrinsic value of outstanding award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=evh_LeveragedStockUnitsLSUsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=evh_LeveragedStockUnitsLSUsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>124
<FILENAME>R109.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139858971481064">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-based Compensation - Performance-based RSUs (Details)<br> shares in Millions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2021 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember', window );">1st Tranche</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted-average fair value per option granted (in dollars per share)</a></td>
<td class="nump">$ 20.64<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheTwoMember', window );">2nd Tranche</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted-average fair value per option granted (in dollars per share)</a></td>
<td class="nump">$ 20.69<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=evh_PerformanceBasedRestrictedStockUnitsPSUsMember', window );">PSUs</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted (in shares) | shares</a></td>
<td class="nump">0.3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_evh_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsPerformanceGoalThreshold', window );">Performance goal threshold</a></td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_evh_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsMaximumPerformanceAchievedPercentageOfTargetedSharesEarned', window );">Maximum performance achieved, percentage of targeted shares earned</a></td>
<td class="nump">200.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_evh_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageAdjustmentOfSharesEarnedTotalShareholderReturnInBottomQuartile', window );">Percentage adjustment of shares earned, total shareholder return in bottom quartile</a></td>
<td class="num">(10.00%)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_evh_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageAdjustmentOfSharesEarnedTotalShareholderReturnInTopQuartile', window );">Percentage adjustment of shares earned, total shareholder return in top quartile</a></td>
<td class="nump">10.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=evh_PerformanceBasedRestrictedStockUnitsPSUsMember', window );">PSUs | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_evh_EarningsBeforeInterestTaxesDepreciationAndAmortizationGoalPeriod', window );">EBITDA, goal period</a></td>
<td class="text">2 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=evh_PerformanceBasedRestrictedStockUnitsPSUsMember', window );">PSUs | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_evh_EarningsBeforeInterestTaxesDepreciationAndAmortizationGoalPeriod', window );">EBITDA, goal period</a></td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=evh_PerformanceBasedRestrictedStockUnitsPSUsMember', window );">PSUs | 1st Tranche</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract', window );"><strong>Assumptions:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term</a></td>
<td class="text">2 years<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">89.50%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">0.12%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=evh_PerformanceBasedRestrictedStockUnitsPSUsMember', window );">PSUs | 2nd Tranche</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract', window );"><strong>Assumptions:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term</a></td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">77.70%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">0.25%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_EarningsBeforeInterestTaxesDepreciationAndAmortizationGoalPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Earnings Before Interest, Taxes, Depreciation, and Amortization, Goal Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_EarningsBeforeInterestTaxesDepreciationAndAmortizationGoalPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsMaximumPerformanceAchievedPercentageOfTargetedSharesEarned">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Maximum Performance Achieved, Percentage of Targeted Shares Earned</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsMaximumPerformanceAchievedPercentageOfTargetedSharesEarned</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsPerformanceGoalThreshold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Performance Goal Threshold</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsPerformanceGoalThreshold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageAdjustmentOfSharesEarnedTotalShareholderReturnInBottomQuartile">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Percentage Adjustment of Shares Earned, Total Shareholder Return in Bottom Quartile</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageAdjustmentOfSharesEarnedTotalShareholderReturnInBottomQuartile</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageAdjustmentOfSharesEarnedTotalShareholderReturnInTopQuartile">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Percentage Adjustment of Shares Earned, Total Shareholder Return in Top Quartile</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageAdjustmentOfSharesEarnedTotalShareholderReturnInTopQuartile</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=evh_PerformanceBasedRestrictedStockUnitsPSUsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=evh_PerformanceBasedRestrictedStockUnitsPSUsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>125
<FILENAME>R110.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139858979885880">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-based Compensation - Performance-based RSU Activity (Details)<br> $ / shares in Units, shares in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=evh_LeveragedStockUnitsLSUsMember', window );">Leveraged Stock Units (LSUs) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Number of awards issued (in shares) | shares</a></td>
<td class="nump">1,084<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Weighted Average Grant Date Fair Value (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 11.07<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms', window );">Weighted Average Remaining Contractual Term</a></td>
<td class="text">7 years 8 months 4 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding', window );">Aggregate Intrinsic Value | $</a></td>
<td class="nump">$ 17,993<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_evh_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestNumber', window );">Performance Based Stock Units (in shares) | shares</a></td>
<td class="nump">1,084<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_evh_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestWeightedAverageGrantDateFairValue', window );">Weighted Average Grant Date Fair Value (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 11.07<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_evh_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestWeightedAverageRemainingContractualTerms', window );">Weighted Average Remaining Contractual Term</a></td>
<td class="text">7 years 8 months 4 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_evh_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVestedAndExpectedToVest', window );">Aggregate Intrinsic Value | $</a></td>
<td class="nump">$ 17,993<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=evh_PerformanceBasedRestrictedStockUnitsPSUsMember', window );">PSUs</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Number of awards issued (in shares) | shares</a></td>
<td class="nump">319<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Weighted Average Grant Date Fair Value (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 20.67<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms', window );">Weighted Average Remaining Contractual Term</a></td>
<td class="text">9 years 1 month 28 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding', window );">Aggregate Intrinsic Value | $</a></td>
<td class="nump">$ 2,233<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_evh_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestNumber', window );">Performance Based Stock Units (in shares) | shares</a></td>
<td class="nump">319<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_evh_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestWeightedAverageGrantDateFairValue', window );">Weighted Average Grant Date Fair Value (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 20.67<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_evh_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestWeightedAverageRemainingContractualTerms', window );">Weighted Average Remaining Contractual Term</a></td>
<td class="text">9 years 1 month 28 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_evh_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVestedAndExpectedToVest', window );">Aggregate Intrinsic Value | $</a></td>
<td class="nump">$ 2,233<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVestedAndExpectedToVest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement By Share-based Payment Award, Equity Instruments Other Than Options, Aggregate Intrinsic Value, Vested And Expected To Vest</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVestedAndExpectedToVest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement By Share-based Payment Award, Equity Instruments Other Than Options, Vested And Expected To Vest, Number</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement By Share-based Payment Award, Equity Instruments Other Than Options, Vested And Expected To Vest, Weighted Average Grant Date Fair Value</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestWeightedAverageRemainingContractualTerms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement By Share-based Payment Award, Equity Instruments Other Than Options, Vested And Expected To Vest, Weighted Average Remaining Contractual Terms</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestWeightedAverageRemainingContractualTerms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for equity-based awards excluding options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Intrinsic value of outstanding award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=evh_LeveragedStockUnitsLSUsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=evh_LeveragedStockUnitsLSUsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=evh_PerformanceBasedRestrictedStockUnitsPSUsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=evh_PerformanceBasedRestrictedStockUnitsPSUsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>126
<FILENAME>R111.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139858971103560">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Narrative (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxContingencyLineItems', window );"><strong>Income Tax Contingency [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Provision (benefit) for income taxes</a></td>
<td class="nump">$ 483<span></span>
</td>
<td class="num">$ (2,368)<span></span>
</td>
<td class="num">$ (22,795)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Effective rate</a></td>
<td class="num">(1.60%)<span></span>
</td>
<td class="nump">0.70%<span></span>
</td>
<td class="nump">6.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_evh_DeferredTaxLiabilitiesIndefiniteLivedIntangibleAssets', window );">Deferred tax liabilities, indefinite-lived intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch', window );">Federal and state research tax credits</a></td>
<td class="nump">$ 1,828<span></span>
</td>
<td class="nump">$ 1,828<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_evh_UnrecognizedTaxBenefitsThatWouldNotImpactEffectiveTaxRate', window );">Unrecognized tax benefits that would not impact effective tax rate</a></td>
<td class="nump">600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Unrecognized tax benefits</a></td>
<td class="nump">$ 609<span></span>
</td>
<td class="nump">$ 678<span></span>
</td>
<td class="nump">$ 753<span></span>
</td>
<td class="nump">$ 934<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_evh_TaxReceivableAgreementPercentofCashSavingsPaidtoShareholders', window );">Tax receivable agreement, percent of cash savings paid to shareholders</a></td>
<td class="nump">85.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_evh_TaxReceivableAgreementPercentofCashSavingsNotPaidtoShareholders', window );">Tax receivable agreement, percent of cash savings not paid to shareholders</a></td>
<td class="nump">15.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxPeriodAxis=evh_PeriodsPriortoJune2015Member', window );">Periods Prior to June 2015</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxContingencyLineItems', window );"><strong>Income Tax Contingency [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">$ 79,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Federal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxContingencyLineItems', window );"><strong>Income Tax Contingency [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch', window );">Federal and state research tax credits</a></td>
<td class="nump">2,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State and Local Jurisdiction</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxContingencyLineItems', window );"><strong>Income Tax Contingency [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch', window );">Federal and state research tax credits</a></td>
<td class="nump">300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAxis=evh_FinitelivedTaxCreditCarryforwardMember', window );">Finite-lived Tax Credit Carryforward | Federal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxContingencyLineItems', window );"><strong>Income Tax Contingency [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">203,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAxis=evh_FinitelivedTaxCreditCarryforwardMember', window );">Finite-lived Tax Credit Carryforward | State and Local Jurisdiction</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxContingencyLineItems', window );"><strong>Income Tax Contingency [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">290,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAxis=evh_IndefinitelivedTaxCreditCarryforwardMember', window );">Indefinite-lived Tax Credit Carryforward | Federal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxContingencyLineItems', window );"><strong>Income Tax Contingency [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">292,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAxis=evh_IndefinitelivedTaxCreditCarryforwardMember', window );">Indefinite-lived Tax Credit Carryforward | State and Local Jurisdiction</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxContingencyLineItems', window );"><strong>Income Tax Contingency [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">$ 196,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_DeferredTaxLiabilitiesIndefiniteLivedIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Liabilities, Indefinite-Lived Intangible Assets</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_DeferredTaxLiabilitiesIndefiniteLivedIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_TaxReceivableAgreementPercentofCashSavingsNotPaidtoShareholders">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tax Receivable Agreement, Percent of Cash Savings Not Paid to Shareholders</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_TaxReceivableAgreementPercentofCashSavingsNotPaidtoShareholders</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_TaxReceivableAgreementPercentofCashSavingsPaidtoShareholders">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tax Receivable Agreement, Percent of Cash Savings Paid to Shareholders</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_TaxReceivableAgreementPercentofCashSavingsPaidtoShareholders</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_UnrecognizedTaxBenefitsThatWouldNotImpactEffectiveTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Unrecognized Tax Benefits That Would Not Impact Effective Tax Rate</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_UnrecognizedTaxBenefitsThatWouldNotImpactEffectiveTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32559-109319<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxContingencyLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxContingencyLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10B<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=SL37586934-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxPeriodAxis=evh_PeriodsPriortoJune2015Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxPeriodAxis=evh_PeriodsPriortoJune2015Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAxis=evh_FinitelivedTaxCreditCarryforwardMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAxis=evh_FinitelivedTaxCreditCarryforwardMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAxis=evh_IndefinitelivedTaxCreditCarryforwardMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAxis=evh_IndefinitelivedTaxCreditCarryforwardMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>127
<FILENAME>R112.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139858984096216">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Schedule of Loss Before Provision for Income Taxes (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract', window );"><strong>Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic', window );">Domestic</a></td>
<td class="num">$ (32,719)<span></span>
</td>
<td class="num">$ (332,373)<span></span>
</td>
<td class="num">$ (331,033)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign', window );">Foreign</a></td>
<td class="nump">2,918<span></span>
</td>
<td class="nump">1,833<span></span>
</td>
<td class="nump">1,045<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments', window );">Loss from continuing operations before income taxes</a></td>
<td class="num">$ (29,801)<span></span>
</td>
<td class="num">$ (330,540)<span></span>
</td>
<td class="num">$ (329,988)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of earnings or loss from continuing operations before income taxes that is attributable to domestic operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of earnings or loss from continuing operations before income taxes that is attributable to foreign operations, which is defined as Income or Loss generated from operations located outside the entity's country of domicile.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations before deduction of income tax expense (benefit) and income (loss) attributable to noncontrolling interest, and addition of income (loss) from equity method investments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>128
<FILENAME>R113.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139858983005432">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Income Tax Expense (Benefit) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract', window );"><strong>Current</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentFederalTaxExpenseBenefit', window );">Federal</a></td>
<td class="num">$ (1,469)<span></span>
</td>
<td class="num">$ (2,305)<span></span>
</td>
<td class="nump">$ 185<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentStateAndLocalTaxExpenseBenefit', window );">State and local</a></td>
<td class="nump">1,449<span></span>
</td>
<td class="nump">200<span></span>
</td>
<td class="nump">14<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentForeignTaxExpenseBenefit', window );">Foreign</a></td>
<td class="nump">1,027<span></span>
</td>
<td class="nump">721<span></span>
</td>
<td class="nump">399<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentIncomeTaxExpenseBenefit', window );">Total current tax expense (benefit)</a></td>
<td class="nump">1,007<span></span>
</td>
<td class="num">(1,384)<span></span>
</td>
<td class="nump">598<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract', window );"><strong>Deferred</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredFederalIncomeTaxExpenseBenefit', window );">Federal</a></td>
<td class="num">(5,866)<span></span>
</td>
<td class="num">(38,258)<span></span>
</td>
<td class="num">(27,307)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit', window );">State and local</a></td>
<td class="num">(4,021)<span></span>
</td>
<td class="num">(9,565)<span></span>
</td>
<td class="num">(5,046)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredForeignIncomeTaxExpenseBenefit', window );">Foreign</a></td>
<td class="num">(493)<span></span>
</td>
<td class="num">(303)<span></span>
</td>
<td class="nump">6<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefit', window );">Total deferred tax expense (benefit)</a></td>
<td class="num">(10,380)<span></span>
</td>
<td class="num">(48,126)<span></span>
</td>
<td class="num">(32,347)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredOtherTaxExpenseBenefit', window );">Change in valuation allowance</a></td>
<td class="nump">9,856<span></span>
</td>
<td class="nump">47,142<span></span>
</td>
<td class="nump">8,954<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Total tax expense (benefit)</a></td>
<td class="nump">$ 483<span></span>
</td>
<td class="num">$ (2,368)<span></span>
</td>
<td class="num">$ (22,795)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentFederalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current federal tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentFederalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentForeignTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentForeignTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentStateAndLocalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current state and local tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentStateAndLocalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFederalIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred federal income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFederalIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredForeignIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredForeignIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredOtherTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of other deferred income tax expense (benefit) pertaining to income (loss) from continuing operations. For example, but not limited to, acquisition-date income tax benefits or expenses recognized from changes in the acquirer's valuation allowance for its previously existing deferred tax assets resulting from a business combination and adjustments to beginning-of-year balance of a valuation allowance because of a change in circumstance causing a change in judgment about the realizability of the related deferred tax asset in future periods.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredOtherTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred state and local tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>129
<FILENAME>R114.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139858979873656">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Reconciliation of Statutory Rate to Effective Tax Rate (Details)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">U.S. statutory tax rate</a></td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes', window );">U.S. state income taxes, net of U.S. federal tax benefit</a></td>
<td class="nump">1.90%<span></span>
</td>
<td class="nump">2.90%<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential', window );">Foreign earnings at other than U.S. rates</a></td>
<td class="nump">0.30%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="num">(0.10%)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Change in valuation allowance</a></td>
<td class="num">(33.10%)<span></span>
</td>
<td class="num">(14.30%)<span></span>
</td>
<td class="num">(2.70%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_evh_EffectiveIncomeTaxRateReconciliationBenefitOfNetOperatingLossCarrybackProvisionPercent', window );">Benefit of net operating loss carryback provision</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0.011<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses', window );">Non-deductible goodwill impairment</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="num">(11.50%)<span></span>
</td>
<td class="num">(15.60%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationMinorityInterestIncomeExpense', window );">Non-controlling interest</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="num">(0.30%)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_evh_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseExcessCompensationPercent', window );">Nondeductible excess compensation</a></td>
<td class="num">(10.10%)<span></span>
</td>
<td class="num">(0.30%)<span></span>
</td>
<td class="num">(0.50%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent', window );">Excess tax benefits (shortfalls) on stock-based compensation</a></td>
<td class="nump">8.10%<span></span>
</td>
<td class="num">(0.30%)<span></span>
</td>
<td class="num">(0.20%)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch', window );">Convertible debt extinguishment</a></td>
<td class="num">(1.50%)<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_evh_EffectiveIncomeTaxRateReconciliationChangeInUncertainTaxPositions', window );">Change in uncertain tax positions</a></td>
<td class="nump">0.20%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.10%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_evh_EffectiveIncomeTaxRateReconciliationEffectOfInvestment', window );">Nontaxable earnout</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="num">(1.40%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate', window );">Change in state rate</a></td>
<td class="nump">6.80%<span></span>
</td>
<td class="nump">1.30%<span></span>
</td>
<td class="num">(0.70%)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_evh_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseReturnToProvisionPercent', window );">Return to provision</a></td>
<td class="nump">6.60%<span></span>
</td>
<td class="num">(0.80%)<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_evh_EffectiveIncomeTaxRateReconciliationDomesticSubsidiaryException', window );">Change in indefinite reinvestment assertion for domestic subsidiaries</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="nump">2.60%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlements', window );">Tax sharing settlement</a></td>
<td class="num">(1.10%)<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments', window );">Other, net</a></td>
<td class="num">(0.70%)<span></span>
</td>
<td class="nump">0.60%<span></span>
</td>
<td class="num">(1.30%)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Effective tax rate</a></td>
<td class="num">(1.60%)<span></span>
</td>
<td class="nump">0.70%<span></span>
</td>
<td class="nump">6.90%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_EffectiveIncomeTaxRateReconciliationBenefitOfNetOperatingLossCarrybackProvisionPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Effective Income Tax Rate Reconciliation, Benefit Of Net Operating Loss Carryback Provision, Percent</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_EffectiveIncomeTaxRateReconciliationBenefitOfNetOperatingLossCarrybackProvisionPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_EffectiveIncomeTaxRateReconciliationChangeInUncertainTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Effective Income Tax Rate Reconciliation, Change In Uncertain Tax Positions</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_EffectiveIncomeTaxRateReconciliationChangeInUncertainTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_EffectiveIncomeTaxRateReconciliationDomesticSubsidiaryException">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Effective Income Tax Rate Reconciliation Domestic Subsidiary Exception</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_EffectiveIncomeTaxRateReconciliationDomesticSubsidiaryException</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_EffectiveIncomeTaxRateReconciliationEffectOfInvestment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Effective Income Tax Rate Reconciliation Effect Investment Of Investment</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_EffectiveIncomeTaxRateReconciliationEffectOfInvestment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseExcessCompensationPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Effective Income Tax Rate Reconciliation, Nondeductible Expense, Excess Compensation, Percent</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseExcessCompensationPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseReturnToProvisionPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Effective Income Tax Rate Reconciliation, Nondeductible Expense, Return to Provision, Percent</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseReturnToProvisionPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the income tax rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to statutory income tax expense (benefit) outside of the country of domicile.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationMinorityInterestIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to noncontrolling interest income (loss) exempt from income taxes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationMinorityInterestIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to impairment loss.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to expense for award under share-based payment arrangement. Excludes expense determined to be nondeductible upon grant or after for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 740<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120384911&amp;loc=d3e23163-113944<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to income tax settlements. Including, but not limited to, domestic tax settlement, foreign tax settlement, state and local tax settlement, and other tax settlements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>130
<FILENAME>R115.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139858971558616">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Income Taxes - Deferred Tax Assets and Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNetAbstract', window );"><strong>Deferred Tax Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_evh_DeferredTaxAssetsStartupandOrganizationalCosts', window );">Start-up and organizational costs</a></td>
<td class="nump">$ 103<span></span>
</td>
<td class="nump">$ 117<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets', window );">Goodwill</a></td>
<td class="nump">18,774<span></span>
</td>
<td class="nump">23,778<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_evh_DeferredTaxAssetsOperatingLeaseRightOfUseAsset', window );">Operating lease liabilities</a></td>
<td class="nump">15,968<span></span>
</td>
<td class="nump">15,963<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities', window );">Accrued expenses</a></td>
<td class="nump">10,345<span></span>
</td>
<td class="nump">7,434<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation', window );">Stock based compensation</a></td>
<td class="nump">8,714<span></span>
</td>
<td class="nump">8,530<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">130,242<span></span>
</td>
<td class="nump">123,604<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch', window );">Federal and state research tax credits</a></td>
<td class="nump">1,828<span></span>
</td>
<td class="nump">1,828<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment', window );">Fixed assets</a></td>
<td class="nump">480<span></span>
</td>
<td class="nump">131<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetInterestCarryforward', window );">Interest deduction limitation</a></td>
<td class="nump">7,795<span></span>
</td>
<td class="nump">2,452<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_evh_DeferredTaxAssetOutsideBasisDifferences', window );">Outside basis differences</a></td>
<td class="nump">1,972<span></span>
</td>
<td class="nump">197<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOther', window );">Other</a></td>
<td class="nump">9,236<span></span>
</td>
<td class="nump">8,428<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Subtotal</a></td>
<td class="nump">205,457<span></span>
</td>
<td class="nump">192,462<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowance</a></td>
<td class="num">(101,345)<span></span>
</td>
<td class="num">(89,723)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNet', window );">Total deferred tax assets</a></td>
<td class="nump">104,112<span></span>
</td>
<td class="nump">102,739<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesNetAbstract', window );"><strong>Deferred Tax Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedSoftware', window );">Internally developed software costs</a></td>
<td class="nump">12,501<span></span>
</td>
<td class="nump">12,973<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets', window );">Intangible assets</a></td>
<td class="nump">48,677<span></span>
</td>
<td class="nump">49,053<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesLeasingArrangements', window );">Right-of-use assets - Operating</a></td>
<td class="nump">12,284<span></span>
</td>
<td class="nump">13,122<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesDeferredExpense', window );">Contract fulfillment costs</a></td>
<td class="nump">8,317<span></span>
</td>
<td class="nump">6,375<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesFinancingArrangements', window );">Convertible debt</a></td>
<td class="nump">17,604<span></span>
</td>
<td class="nump">20,411<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesOther', window );">Other</a></td>
<td class="nump">5,387<span></span>
</td>
<td class="nump">1,484<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilities', window );">Total deferred tax liabilities</a></td>
<td class="nump">104,770<span></span>
</td>
<td class="nump">103,418<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilities', window );">Net deferred tax assets (liabilities)</a></td>
<td class="num">$ (658)<span></span>
</td>
<td class="num">$ (679)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_DeferredTaxAssetOutsideBasisDifferences">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Asset, Outside Basis Differences</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_DeferredTaxAssetOutsideBasisDifferences</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_DeferredTaxAssetsOperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Assets, Operating Lease, Right-of-Use Asset</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_DeferredTaxAssetsOperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_DeferredTaxAssetsStartupandOrganizationalCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Assets, Start-up and Organizational Costs</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_DeferredTaxAssetsStartupandOrganizationalCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(15)(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetInterestCarryforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible interest carryforward.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetInterestCarryforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from intangible assets including goodwill.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from property, plant, and equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32559-109319<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from employee compensation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences without jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e31931-109318<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesDeferredExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from capitalized costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesDeferredExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedSoftware">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from capitalized software.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedSoftware</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesFinancingArrangements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from financing arrangements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesFinancingArrangements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from intangible assets other than goodwill.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesLeasingArrangements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from leasing arrangements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesLeasingArrangements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>131
<FILENAME>R116.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139858970984936">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Changes in Valuation Allowance (Details) - Valuation Allowance of Deferred Tax Assets - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MovementInValuationAllowancesAndReservesRollForward', window );"><strong>SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Balance at beginning-of-year</a></td>
<td class="nump">$ 89,723<span></span>
</td>
<td class="nump">$ 50,519<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense', window );">Charged to costs and expenses</a></td>
<td class="nump">9,856<span></span>
</td>
<td class="nump">47,142<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts', window );">Charged (credited) to other accounts</a></td>
<td class="nump">1,766<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesDeductions', window );">Charged (credited) to other accounts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(7,938)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Balance at end-of-year</a></td>
<td class="nump">101,345<span></span>
</td>
<td class="nump">89,723<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_evh_ValuationAllowancesAndReservesChargedCreditedToAdditionalPaidInCapital', window );">Valuation allowance increase (decrease) charged to additional paid-in capital</a></td>
<td class="nump">$ 1,800<span></span>
</td>
<td class="num">(8,600)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_evh_ValuationAllowancesAndReservesChargedToRetainedEarnings', window );">Valuation allowance increase (decrease) charged to retained earnings</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 700<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_ValuationAllowancesAndReservesChargedCreditedToAdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Valuation Allowances and Reserves, Charged (Credited) to Additional Paid-in Capital</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_ValuationAllowancesAndReservesChargedCreditedToAdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_ValuationAllowancesAndReservesChargedToRetainedEarnings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Valuation Allowances and Reserves, Charged to Retained Earnings</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_ValuationAllowancesAndReservesChargedToRetainedEarnings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MovementInValuationAllowancesAndReservesRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MovementInValuationAllowancesAndReservesRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesBalance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of valuation and qualifying accounts and reserves.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-09(Column B))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24092-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-09(Column E))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24092-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesBalance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in valuation and qualifying accounts and reserves from charge to cost and expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-09(Column C)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24092-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in valuation and qualifying accounts and reserves from charge to accounts other than cost and expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-09(Column C)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24092-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesDeductions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in valuation and qualifying accounts and reserves.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-09(Column D))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24092-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesDeductions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=us-gaap_ValuationAllowanceOfDeferredTaxAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesTypeAxis=us-gaap_ValuationAllowanceOfDeferredTaxAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>132
<FILENAME>R117.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139858983950728">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Changes In Unrecognized Tax Benefits (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward', window );"><strong>Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Balance at beginning-of-year</a></td>
<td class="nump">$ 678<span></span>
</td>
<td class="nump">$ 753<span></span>
</td>
<td class="nump">$ 934<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations', window );">Lapse of statute of limitations</a></td>
<td class="num">(69)<span></span>
</td>
<td class="num">(75)<span></span>
</td>
<td class="num">(181)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Balance at end-of-year</a></td>
<td class="nump">$ 609<span></span>
</td>
<td class="nump">$ 678<span></span>
</td>
<td class="nump">$ 753<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10B<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=SL37586934-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in unrecognized tax benefits resulting from lapses of applicable statutes of limitations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>133
<FILENAME>R118.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139858976482296">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Employee Benefit Plans (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount', window );">Employer discretionary contribution amount</a></td>
<td class="nump">$ 5.4<span></span>
</td>
<td class="nump">$ 6.2<span></span>
</td>
<td class="nump">$ 2.6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupClassificationAxis=us-gaap_DiscontinuedOperationsDisposedOfBySaleMember', window );">Discontinued Operations, Disposed of by Sale | True Health</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount', window );">Employer discretionary contribution amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of discretionary contributions made by an employer to a defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupClassificationAxis=us-gaap_DiscontinuedOperationsDisposedOfBySaleMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupClassificationAxis=us-gaap_DiscontinuedOperationsDisposedOfBySaleMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=evh_TrueHealthMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=evh_TrueHealthMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>134
<FILENAME>R119.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139858970911496">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Investments in Equity Method Investees (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Gain (loss) from equity method investees</a></td>
<td class="nump">$ 13,179<span></span>
</td>
<td class="nump">$ 10,039<span></span>
</td>
<td class="num">$ (9,465)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOtherThanTemporaryImpairment', window );">Impairment of equity method investments</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">47,133<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ConsolidatedEntitiesAxis=us-gaap_VariableInterestEntityNotPrimaryBeneficiaryMember', window );">Variable Interest Entity, Not Primary Beneficiary | Global Health</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_evh_StatutoryCapitalReservesLiquidityGuaranteedByInvestorsMinimum', window );">Statutory capital reserves, liquidity guaranteed by investors</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">300.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_evh_EquityInterestToBeTransferred', window );">Equity interest to be transferred</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOtherThanTemporaryImpairment', window );">Impairment of equity method investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">47,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_EquityMethodInvesteeMember', window );">Equity Method Investee | Services Agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_evh_IncomeLossfromEquityMethodInvestmentsServicesAgreement', window );">Income from long-term services agreement</a></td>
<td class="nump">$ 15,900<span></span>
</td>
<td class="nump">$ 192,800<span></span>
</td>
<td class="nump">$ 41,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_evh_EquityMethodInvestmentEconomicInterestPercentage', window );">Economic interest percentage</a></td>
<td class="nump">4.00%<span></span>
</td>
<td class="nump">4.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_evh_EquityMethodInvestmentVotingInterestPercentage', window );">Voting interest percentage</a></td>
<td class="nump">25.00%<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_evh_EquityMethodInvestmentEconomicInterestPercentage', window );">Economic interest percentage</a></td>
<td class="nump">39.00%<span></span>
</td>
<td class="nump">38.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_evh_EquityMethodInvestmentVotingInterestPercentage', window );">Voting interest percentage</a></td>
<td class="nump">40.00%<span></span>
</td>
<td class="nump">40.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_EquityInterestToBeTransferred">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity Interest To Be Transferred</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_EquityInterestToBeTransferred</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_EquityMethodInvestmentEconomicInterestPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity Method Investment, Economic Interest Percentage</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_EquityMethodInvestmentEconomicInterestPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_EquityMethodInvestmentVotingInterestPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity Method Investment, Voting Interest Percentage</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_EquityMethodInvestmentVotingInterestPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_IncomeLossfromEquityMethodInvestmentsServicesAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Income (Loss) from Equity Method Investments, Services Agreement</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_IncomeLossfromEquityMethodInvestmentsServicesAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_StatutoryCapitalReservesLiquidityGuaranteedByInvestorsMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Statutory Capital Reserves, Liquidity Guaranteed By Investors, Minimum</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_StatutoryCapitalReservesLiquidityGuaranteedByInvestorsMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentOtherThanTemporaryImpairment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This item represents an other than temporary decline in value that has been recognized against an investment accounted for under the equity method of accounting. The excess of the carrying amount over the fair value of the investment represents the amount of the write down which is or was reflected in earnings. The written down value is a new cost basis with the adjusted value of the investment becoming its new carrying value subject to the equity accounting method. Evidence of a loss in value might include, but would not necessarily be limited to, absence of an ability to recover the carrying amount of the investment or inability of the investee to sustain an earnings capacity which would justify the carrying amount of the investment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 35<br> -Paragraph 32<br> -URI http://asc.fasb.org/extlink&amp;oid=124268079&amp;loc=d3e32787-111569<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentOtherThanTemporaryImpairment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) for proportionate share of equity method investee's income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(13)(f))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109237563&amp;loc=d3e33749-111570<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEquityMethodInvestmentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidatedEntitiesAxis=us-gaap_VariableInterestEntityNotPrimaryBeneficiaryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidatedEntitiesAxis=us-gaap_VariableInterestEntityNotPrimaryBeneficiaryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=evh_GlobalHealthMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=evh_GlobalHealthMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_EquityMethodInvesteeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_EquityMethodInvesteeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=evh_ServicesAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=evh_ServicesAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>135
<FILENAME>R120.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139858979860456">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Non-controlling Interests (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Nov. 16, 2020</div></th>
<th class="th"><div>Sep. 01, 2020</div></th>
<th class="th"><div>May 28, 2019</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>May 31, 2015</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=evh_UniversityHealthCaredbaPassportHealthPlanMember', window );">Passport | Variable Interest Entity, Not Primary Beneficiary</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestLineItems', window );"><strong>Noncontrolling Interest [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncontrollingInterestIncreaseFromBusinessCombination', window );">Consolidation of equity method investment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VariableInterestEntityOwnershipPercentage', window );">Interest in investment</a></td>
<td class="nump">30.00%<span></span>
</td>
<td class="nump">30.00%<span></span>
</td>
<td class="nump">30.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_evh_VariableInterestEntityNewMedicaidContractNotAwardedRequirementToAcquireOwnershipConsiderationAmount', window );">Requirement to acquire ownership, consideration, amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VariableInterestEntityInitialConsolidationGainOrLoss', window );">Gain on consolidation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_OwnershipAxis=evh_EvolentHealthLLCMember', window );">Evolent Health LLC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestLineItems', window );"><strong>Noncontrolling Interest [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestOwnershipPercentageByParent', window );">Parent's ownership percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">70.30%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_VariableInterestEntityNewMedicaidContractNotAwardedRequirementToAcquireOwnershipConsiderationAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Variable Interest Entity, New Medicaid Contract Not Awarded, Requirement To Acquire Ownership, Consideration, Amount</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_VariableInterestEntityNewMedicaidContractNotAwardedRequirementToAcquireOwnershipConsiderationAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterestLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterestLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterestOwnershipPercentageByParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The parent entity's interest in net assets of the subsidiary, expressed as a percentage.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterestOwnershipPercentageByParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncontrollingInterestIncreaseFromBusinessCombination">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in noncontrolling interest from a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123413009&amp;loc=d3e4845-128472<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncontrollingInterestIncreaseFromBusinessCombination</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableInterestEntityInitialConsolidationGainOrLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The gain (loss) recognized on initial consolidation of a variable interest entity (VIE) when the VIE is not a business (as defined).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableInterestEntityInitialConsolidationGainOrLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableInterestEntityOwnershipPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the Variable Interest Entity's (VIE) voting interest owned by (or beneficial interest in) the reporting entity (directly or indirectly).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5A<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=SL6759159-111685<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableInterestEntityOwnershipPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=evh_UniversityHealthCaredbaPassportHealthPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=evh_UniversityHealthCaredbaPassportHealthPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidatedEntitiesAxis=us-gaap_VariableInterestEntityNotPrimaryBeneficiaryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidatedEntitiesAxis=us-gaap_VariableInterestEntityNotPrimaryBeneficiaryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_OwnershipAxis=evh_EvolentHealthLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_OwnershipAxis=evh_EvolentHealthLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>136
<FILENAME>R121.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139858978983960">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Non-controlling Interests - Schedule of Changes in Non-controlling Interests (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="4">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MovementInMinorityInterestRollForward', window );"><strong>Stockholders' Equity Attributable to Noncontrolling Interest [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest', window );">Net loss attributable to non-controlling interests</a></td>
<td class="nump">$ 822<span></span>
</td>
<td class="num">$ (822)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="num">$ (3,609)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_NoncontrollingInterestMember', window );">Non-Controlling Interests</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MovementInMinorityInterestRollForward', window );"><strong>Stockholders' Equity Attributable to Noncontrolling Interest [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterest', window );">Non-controlling interests balance as of beginning of period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,689<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">6,689<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncontrollingInterestIncreaseFromBusinessCombination', window );">Consolidation of equity method investment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,749<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_evh_NoncontrollingInterestDecreaseFromDisposalOfAssets', window );">Disposal of assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(6,689)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestDecreaseFromRedemptions', window );">Redemption of Sponsor&#8217;s equity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(25,749)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterest', window );">Non-controlling interests balance as of end of period</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 6,689<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_NoncontrollingInterestDecreaseFromDisposalOfAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Noncontrolling Interest, Decrease From Disposal Of Assets</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_NoncontrollingInterestDecreaseFromDisposalOfAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which is directly or indirectly attributable to that ownership interest in subsidiary equity which is not attributable to the parent (that is, noncontrolling interest, previously referred to as minority interest).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.31)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterestDecreaseFromRedemptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Decrease in noncontrolling interest (for example, but not limited to, redeeming or purchasing the interests of noncontrolling shareholders, issuance of shares (interests) by the non-wholly owned subsidiary to the parent entity for other than cash, and a buyback of shares (interest) by the non-wholly owned subsidiary from the noncontrolling interests).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569655-111683<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4616395-111683<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterestDecreaseFromRedemptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MovementInMinorityInterestRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MovementInMinorityInterestRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of Net Income (Loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncontrollingInterestIncreaseFromBusinessCombination">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in noncontrolling interest from a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123413009&amp;loc=d3e4845-128472<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncontrollingInterestIncreaseFromBusinessCombination</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_NoncontrollingInterestMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_NoncontrollingInterestMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>137
<FILENAME>R122.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139858971646488">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurement - Assets and Liabilities on Recurring Basis (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants and rights outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,513,786<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,877<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total fair value of assets measured on a recurring basis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,877<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Fair value of contingent consideration</a></td>
<td class="nump">$ 28,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesFairValueDisclosure', window );">Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,730<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total fair value of liabilities measured on a recurring basis</a></td>
<td class="nump">28,700<span></span>
</td>
<td class="nump">13,730<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1 | Fair Value, Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,877<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total fair value of assets measured on a recurring basis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,877<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Fair value of contingent consideration</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesFairValueDisclosure', window );">Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total fair value of liabilities measured on a recurring basis</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 | Fair Value, Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total fair value of assets measured on a recurring basis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Fair value of contingent consideration</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesFairValueDisclosure', window );">Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total fair value of liabilities measured on a recurring basis</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level 3 | Fair Value, Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total fair value of assets measured on a recurring basis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Fair value of contingent consideration</a></td>
<td class="nump">28,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesFairValueDisclosure', window );">Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,730<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total fair value of liabilities measured on a recurring basis</a></td>
<td class="nump">$ 28,700<span></span>
</td>
<td class="nump">$ 13,730<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120321790&amp;loc=d3e6927-128479<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116859824&amp;loc=d3e6819-128478<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial and nonfinancial obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesFairValueDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesFairValueDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of other liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>138
<FILENAME>R123.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139858977746600">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurement - Additional Information (Details)<br></strong></div></th>
<th class="th">
<div>Dec. 30, 2019 </div>
<div>shares</div>
</th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=us-gaap_CommonClassAMember', window );">Class A Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightUnissued', window );">Warrants agreed to be sold (in shares)</a></td>
<td class="nump">1,513,786<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightUnissued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of warrants or rights which entitle the entity to receive future services in exchange for the unvested, forfeitable warrants or rights.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 50<br> -Section S99<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6784392&amp;loc=d3e188667-122775<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightUnissued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=us-gaap_CommonClassAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=us-gaap_CommonClassAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>139
<FILENAME>R124.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139858975055176">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurement - Changes in Contingent Consideration and Other (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward', window );"><strong>Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Balance as of beginning of period</a></td>
<td class="nump">$ 13,730<span></span>
</td>
<td class="nump">$ 16,975<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues', window );">Additions</a></td>
<td class="nump">14,600<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements', window );">Settlements</a></td>
<td class="num">(13,730)<span></span>
</td>
<td class="num">(3,500)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings', window );">Realized and unrealized losses, net</a></td>
<td class="nump">14,100<span></span>
</td>
<td class="nump">255<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Balance as of end of period</a></td>
<td class="nump">$ 28,700<span></span>
</td>
<td class="nump">$ 13,730<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized in income from liability measured at fair value on recurring basis using unobservable input (level 3).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of issuances of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of settlements of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>140
<FILENAME>R125.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139858979899752">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurement - Valuation Techniques and Significant Unobservable Inputs (Details) - Fair Value, Recurring<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Fair Value</a></td>
<td class="nump">$ 28,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesFairValueDisclosure', window );">Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13,730<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Fair Value</a></td>
<td class="nump">$ 28,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesFairValueDisclosure', window );">Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13,730<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 3 | Risk-neutral expected earnout consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput', window );">Assumption or Input Ranges</a></td>
<td class="nump">30,935<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 3 | Discount rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput', window );">Assumption or Input Ranges</a></td>
<td class="nump">0.0604<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 3 | Stock price volatility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Assumption or Input Ranges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.622<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 3 | Annual risk free rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Assumption or Input Ranges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.002<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120321790&amp;loc=d3e6927-128479<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116859824&amp;loc=d3e6819-128478<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of input used to measure contingent consideration liability from business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of other liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of input used to measure outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingMeasurementInput</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=evh_MeasurementInputRiskNeutralExpectedEarnoutConsiderationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=evh_MeasurementInputRiskNeutralExpectedEarnoutConsiderationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDiscountRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDiscountRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>141
<FILENAME>R126.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139858970873016">
<tr>
<th class="tl" colspan="2" rowspan="1"><div style="width: 200px;"><strong>Related Parties - Assets and Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>ASSETS</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">$ 130,604<span></span>
</td>
<td class="nump">$ 124,064<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">51,391<span></span>
</td>
<td class="nump">56,295<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent', window );">Prepaid expenses and other noncurrent assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">6,790<span></span>
</td>
<td class="nump">5,773<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAbstract', window );"><strong>Liabilities</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">96,084<span></span>
</td>
<td class="nump">31,975<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">107,241<span></span>
</td>
<td class="nump">73,242<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_AffiliatedEntityMember', window );">Affiliated Entity</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>ASSETS</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">2,719<span></span>
</td>
<td class="nump">9,474<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">15<span></span>
</td>
<td class="nump">51<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent', window );">Prepaid expenses and other noncurrent assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">4,877<span></span>
</td>
<td class="nump">4,554<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAbstract', window );"><strong>Liabilities</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,967<span></span>
</td>
<td class="nump">2,509<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,120<span></span>
</td>
<td class="nump">1,520<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilityForFuturePolicyBenefitsAndUnpaidClaimsAndClaimsAdjustmentExpense', window );">Reserve for claims and performance-based arrangements</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 734<span></span>
</td>
<td class="nump">$ 435<span></span>
</td>
</tr>
<tr><td colspan="3"></td></tr>
<tr><td colspan="3"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">See Note 20 for amounts attributable to related parties included in these line items.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilityForFuturePolicyBenefitsAndUnpaidClaimsAndClaimsAdjustmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of policy reserves (provided for future obligations including unpaid claims and claims adjustment expenses) and policy benefits (liability for future policy benefits) as of the balance sheet date; grouped amount of all the liabilities associated with the company's insurance policies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(13)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (cc)<br> -URI http://asc.fasb.org/extlink&amp;oid=116884095&amp;loc=d3e14764-158437<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116884095&amp;loc=d3e14764-158437<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilityForFuturePolicyBenefitsAndUnpaidClaimsAndClaimsAdjustmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_AffiliatedEntityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_AffiliatedEntityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>142
<FILENAME>R127.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139858979832600">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Related Parties - Revenues and Expenses (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="8">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenue</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenue</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 248,358<span></span>
</td>
<td class="nump">$ 222,471<span></span>
</td>
<td class="nump">$ 222,057<span></span>
</td>
<td class="nump">$ 215,071<span></span>
</td>
<td class="nump">$ 246,536<span></span>
</td>
<td class="nump">$ 239,572<span></span>
</td>
<td class="nump">$ 217,299<span></span>
</td>
<td class="nump">$ 221,232<span></span>
</td>
<td class="nump">$ 907,957<span></span>
</td>
<td class="nump">$ 924,639<span></span>
</td>
<td class="nump">$ 687,122<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Expenses</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_evh_CostofGoodsandServicesSoldExcludingDepreciationandAmortization', window );">Cost of revenue (exclusive of depreciation and amortization expenses)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">657,551<span></span>
</td>
<td class="nump">696,581<span></span>
</td>
<td class="nump">513,033<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Selling, general and administrative expenses</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">219,499<span></span>
</td>
<td class="nump">210,412<span></span>
</td>
<td class="nump">236,448<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_AffiliatedEntityMember', window );">Affiliated Entity</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Expenses</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_evh_CostofGoodsandServicesSoldExcludingDepreciationandAmortization', window );">Cost of revenue (exclusive of depreciation and amortization expenses)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,063<span></span>
</td>
<td class="nump">2,863<span></span>
</td>
<td class="nump">28,954<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Selling, general and administrative expenses</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">285<span></span>
</td>
<td class="nump">113<span></span>
</td>
<td class="nump">991<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=evh_TransformationServicesMember', window );">Transformation services</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenue</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenue</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,204<span></span>
</td>
<td class="nump">11,990<span></span>
</td>
<td class="nump">15,203<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=evh_TransformationServicesMember', window );">Transformation services | Affiliated Entity</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenue</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenue</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">5,416<span></span>
</td>
<td class="nump">4,009<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=evh_PlatformsAndOperationsServicesMember', window );">Platform and operations services</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenue</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenue</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">896,753<span></span>
</td>
<td class="nump">912,649<span></span>
</td>
<td class="nump">671,919<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=evh_PlatformsAndOperationsServicesMember', window );">Platform and operations services | Affiliated Entity</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenue</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenue</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 45,082<span></span>
</td>
<td class="nump">$ 226,339<span></span>
</td>
<td class="nump">$ 60,325<span></span>
</td>
</tr>
<tr><td colspan="12"></td></tr>
<tr><td colspan="12"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">See Note 20 for amounts attributable to unconsolidated related parties included in these line items.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_CostofGoodsandServicesSoldExcludingDepreciationandAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cost of Goods and Services Sold, Excluding Depreciation and Amortization</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_CostofGoodsandServicesSoldExcludingDepreciationandAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9031-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_AffiliatedEntityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_AffiliatedEntityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=evh_TransformationServicesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=evh_TransformationServicesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=evh_PlatformsAndOperationsServicesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=evh_PlatformsAndOperationsServicesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>143
<FILENAME>R128.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139858982931080">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Repositioning and Other Changes (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Repositioning costs incurred</a></td>
<td class="nump">$ 7,318<span></span>
</td>
<td class="nump">$ 1,275<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostCostIncurredToDate1', window );">Cumulative Amount Incurred through December 31, 2021</a></td>
<td class="nump">8,593<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveAxis=evh_EmployeeSeveranceAndTerminationBenefitsMember', window );">Severance and termination benefits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Repositioning costs incurred</a></td>
<td class="nump">185<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostCostIncurredToDate1', window );">Cumulative Amount Incurred through December 31, 2021</a></td>
<td class="nump">185<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveAxis=us-gaap_FacilityClosingMember', window );">Office space consolidation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Repositioning costs incurred</a></td>
<td class="nump">2,742<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostCostIncurredToDate1', window );">Cumulative Amount Incurred through December 31, 2021</a></td>
<td class="nump">2,742<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveAxis=evh_ProfessionalServicesRestructuringMember', window );">Professional services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Repositioning costs incurred</a></td>
<td class="nump">4,391<span></span>
</td>
<td class="nump">$ 1,275<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostCostIncurredToDate1', window );">Cumulative Amount Incurred through December 31, 2021</a></td>
<td class="nump">$ 5,666<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedCostCostIncurredToDate1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of costs incurred to date for the specified restructuring cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedCostCostIncurredToDate1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109237686&amp;loc=d3e17752-110868<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.P.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140864-122747<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveAxis=evh_EmployeeSeveranceAndTerminationBenefitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveAxis=evh_EmployeeSeveranceAndTerminationBenefitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveAxis=us-gaap_FacilityClosingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveAxis=us-gaap_FacilityClosingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveAxis=evh_ProfessionalServicesRestructuringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveAxis=evh_ProfessionalServicesRestructuringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>144
<FILENAME>R129.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139858983500136">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Reporting - Additional Information (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2021 </div>
<div>segment</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of operating segments</a></td>
<td class="nump">2<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8672-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>145
<FILENAME>R130.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139858968683032">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Segment Reporting - Revenue from Segments to Consolidated (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="8">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingRevenueReconcilingItemLineItems', window );"><strong>Segment Reporting, Revenue Reconciling Item [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 248,358<span></span>
</td>
<td class="nump">$ 222,471<span></span>
</td>
<td class="nump">$ 222,057<span></span>
</td>
<td class="nump">$ 215,071<span></span>
</td>
<td class="nump">$ 246,536<span></span>
</td>
<td class="nump">$ 239,572<span></span>
</td>
<td class="nump">$ 217,299<span></span>
</td>
<td class="nump">$ 221,232<span></span>
</td>
<td class="nump">$ 907,957<span></span>
</td>
<td class="nump">$ 924,639<span></span>
</td>
<td class="nump">$ 687,122<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_evh_AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization', window );">Adjusted EBITDA</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">66,317<span></span>
</td>
<td class="nump">48,573<span></span>
</td>
<td class="num">(13,831)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=evh_EvolentHealthServicesSegmentMember', window );">Evolent Health Services</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingRevenueReconcilingItemLineItems', window );"><strong>Segment Reporting, Revenue Reconciling Item [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">311,627<span></span>
</td>
<td class="nump">385,134<span></span>
</td>
<td class="nump">409,531<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_evh_AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization', window );">Adjusted EBITDA</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,063<span></span>
</td>
<td class="nump">57,731<span></span>
</td>
<td class="num">(561)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=evh_ClinicalSolutionsSegmentMember', window );">Clinical Solutions</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingRevenueReconcilingItemLineItems', window );"><strong>Segment Reporting, Revenue Reconciling Item [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">598,144<span></span>
</td>
<td class="nump">542,279<span></span>
</td>
<td class="nump">278,217<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_evh_AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization', window );">Adjusted EBITDA</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">82,920<span></span>
</td>
<td class="nump">26,864<span></span>
</td>
<td class="nump">12,523<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_IntersegmentEliminationMember', window );">Intersegment Eliminations</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingRevenueReconcilingItemLineItems', window );"><strong>Segment Reporting, Revenue Reconciling Item [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,814)<span></span>
</td>
<td class="num">(2,774)<span></span>
</td>
<td class="num">(626)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingRevenueReconcilingItemLineItems', window );"><strong>Segment Reporting, Revenue Reconciling Item [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">907,957<span></span>
</td>
<td class="nump">924,639<span></span>
</td>
<td class="nump">687,122<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_evh_AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization', window );">Adjusted EBITDA</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">99,983<span></span>
</td>
<td class="nump">84,595<span></span>
</td>
<td class="nump">11,962<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_CorporateNonSegmentMember', window );">Corporate</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingRevenueReconcilingItemLineItems', window );"><strong>Segment Reporting, Revenue Reconciling Item [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_evh_AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization', window );">Adjusted EBITDA</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(33,666)<span></span>
</td>
<td class="num">(36,022)<span></span>
</td>
<td class="num">(25,793)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=evh_TransformationServicesMember', window );">Transformation services</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingRevenueReconcilingItemLineItems', window );"><strong>Segment Reporting, Revenue Reconciling Item [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,204<span></span>
</td>
<td class="nump">11,990<span></span>
</td>
<td class="nump">15,203<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=evh_TransformationServicesMember', window );">Transformation services | Evolent Health Services</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingRevenueReconcilingItemLineItems', window );"><strong>Segment Reporting, Revenue Reconciling Item [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,204<span></span>
</td>
<td class="nump">11,990<span></span>
</td>
<td class="nump">15,203<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=evh_TransformationServicesMember', window );">Transformation services | Clinical Solutions</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingRevenueReconcilingItemLineItems', window );"><strong>Segment Reporting, Revenue Reconciling Item [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=evh_TransformationServicesMember', window );">Transformation services | Intersegment Eliminations</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingRevenueReconcilingItemLineItems', window );"><strong>Segment Reporting, Revenue Reconciling Item [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=evh_TransformationServicesMember', window );">Transformation services | Operating Segments</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingRevenueReconcilingItemLineItems', window );"><strong>Segment Reporting, Revenue Reconciling Item [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,204<span></span>
</td>
<td class="nump">11,990<span></span>
</td>
<td class="nump">15,203<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=evh_TransformationServicesMember', window );">Transformation services | Corporate</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingRevenueReconcilingItemLineItems', window );"><strong>Segment Reporting, Revenue Reconciling Item [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=evh_PlatformsAndOperationsServicesMember', window );">Platform and operations services</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingRevenueReconcilingItemLineItems', window );"><strong>Segment Reporting, Revenue Reconciling Item [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">896,753<span></span>
</td>
<td class="nump">912,649<span></span>
</td>
<td class="nump">671,919<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=evh_PlatformsAndOperationsServicesMember', window );">Platform and operations services | Evolent Health Services</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingRevenueReconcilingItemLineItems', window );"><strong>Segment Reporting, Revenue Reconciling Item [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">300,423<span></span>
</td>
<td class="nump">373,144<span></span>
</td>
<td class="nump">394,328<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=evh_PlatformsAndOperationsServicesMember', window );">Platform and operations services | Clinical Solutions</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingRevenueReconcilingItemLineItems', window );"><strong>Segment Reporting, Revenue Reconciling Item [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">598,144<span></span>
</td>
<td class="nump">542,279<span></span>
</td>
<td class="nump">278,217<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=evh_PlatformsAndOperationsServicesMember', window );">Platform and operations services | Intersegment Eliminations</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingRevenueReconcilingItemLineItems', window );"><strong>Segment Reporting, Revenue Reconciling Item [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,814)<span></span>
</td>
<td class="num">(2,774)<span></span>
</td>
<td class="num">(626)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=evh_PlatformsAndOperationsServicesMember', window );">Platform and operations services | Operating Segments</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingRevenueReconcilingItemLineItems', window );"><strong>Segment Reporting, Revenue Reconciling Item [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">896,753<span></span>
</td>
<td class="nump">912,649<span></span>
</td>
<td class="nump">671,919<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=evh_PlatformsAndOperationsServicesMember', window );">Platform and operations services | Corporate</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingRevenueReconcilingItemLineItems', window );"><strong>Segment Reporting, Revenue Reconciling Item [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr><td colspan="12"></td></tr>
<tr><td colspan="12"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">See Note 20 for amounts attributable to unconsolidated related parties included in these line items.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Adjusted Earnings Before Interest, Taxes, Depreciation And Amortization</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9031-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingRevenueReconcilingItemLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingRevenueReconcilingItemLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=evh_EvolentHealthServicesSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=evh_EvolentHealthServicesSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=evh_ClinicalSolutionsSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=evh_ClinicalSolutionsSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidationItemsAxis=us-gaap_IntersegmentEliminationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidationItemsAxis=us-gaap_IntersegmentEliminationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidationItemsAxis=us-gaap_CorporateNonSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidationItemsAxis=us-gaap_CorporateNonSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=evh_TransformationServicesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=evh_TransformationServicesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=evh_PlatformsAndOperationsServicesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=evh_PlatformsAndOperationsServicesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>146
<FILENAME>R131.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139858978795512">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Reporting - Reconciliation of Adjusted EBITDA (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="10">3 Months Ended</th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="6">12 Months Ended</th>
</tr>
<tr>
<th class="th" colspan="2"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th" colspan="2"><div>Dec. 31, 2021</div></th>
<th class="th" colspan="2"><div>Dec. 31, 2020</div></th>
<th class="th" colspan="2"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic', window );">Net loss attributable to common shareholders of Evolent Health, Inc. - Basic</a></td>
<td class="num">$ (5,647,000)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">$ (13,040,000)<span></span>
</td>
<td class="num">$ (9,107,000)<span></span>
</td>
<td class="num">$ (9,807,000)<span></span>
</td>
<td class="num">$ (14,625,000)<span></span>
</td>
<td class="num">$ (37,348,000)<span></span>
</td>
<td class="num">$ (203,521,000)<span></span>
</td>
<td class="num">$ (78,752,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (37,601,000)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">$ (334,246,000)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">$ (301,971,000)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted', window );">Net loss attributable to common shareholders of Evolent Health, Inc. - Diluted</a></td>
<td class="num">(5,647,000)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(13,040,000)<span></span>
</td>
<td class="num">(9,107,000)<span></span>
</td>
<td class="num">(9,807,000)<span></span>
</td>
<td class="num">(14,625,000)<span></span>
</td>
<td class="num">(37,348,000)<span></span>
</td>
<td class="num">(203,521,000)<span></span>
</td>
<td class="num">(78,752,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(37,601,000)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(334,246,000)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(301,971,000)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterest', window );">Interest income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">407,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">2,633,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">3,406,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(25,425,000)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(28,325,000)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(14,555,000)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">(Provision) benefit for income taxes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(483,000)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">2,368,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">22,795,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationAndAmortization', window );">Depreciation and amortization expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(60,037,000)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(60,835,000)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(60,323,000)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOtherThanTemporaryImpairment', window );">Equity method investment impairment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(47,133,000)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_evh_GainOnTransferOfMembership', window );">Gain on transfer of membership</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">45,938,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_evh_GainLossOnRepaymentOfDebt', window );">Loss on repayment of debt, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(21,343,000)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on extinguishment of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(4,789,000)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillImpairmentLoss', window );">Impairment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(215,100,000)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">$ (199,800,000)<span></span>
</td>
<td class="num">$ (215,100,000)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(215,100,000)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(199,800,000)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Gain (loss) from equity method investees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,179,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">10,039,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(9,465,000)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnDispositionOfAssets1', window );">Gain (loss) on disposal of assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(698,000)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">9,600,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1', window );">Change in fair value of contingent consideration and indemnification asset</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(13,281,000)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(3,860,000)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">3,997,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest', window );">Net loss attributable to non-controlling interests</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(822,000)<span></span>
</td>
<td class="nump">822,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">3,609,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other income (expense), net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(146,000)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(118,000)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(489,000)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_evh_PurchaseAccountingAdjustments', window );">Purchase accounting adjustments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(1,915,000)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Repositioning costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(7,318,000)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(1,275,000)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_evh_SharebasedCompensationIncludingOnetimeAdjustment', window );">Stock-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(16,711,000)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(14,606,000)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(15,618,000)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SeveranceCosts1', window );">Severance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(198,000)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(8,986,000)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(17,350,000)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_evh_CapitalizedContractCostAmortizationPurchaseAccountingAdjustments', window );">Amortization of contract cost assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(476,000)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(3,944,000)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(2,876,000)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_evh_ShareholderAdvisoryServices', window );">Strategy and shareholder advisory expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(6,513,000)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_evh_TransactionCosts', window );">Acquisition costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4,194,000)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(2,116,000)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(10,769,000)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax', window );">Gain (loss) from discontinued operations</a></td>
<td class="num">$ (8,700,000)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 1,383,000<span></span>
</td>
<td class="num">$ (3,166,000)<span></span>
</td>
<td class="num">$ (1,135,000)<span></span>
</td>
<td class="num">$ (1,508,000)<span></span>
</td>
<td class="num">$ (265,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(7,317,000)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="num">(6,074,000)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">1,613,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_evh_AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization', window );">Adjusted EBITDA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 66,317,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 48,573,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">$ (13,831,000)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr><td colspan="18"></td></tr>
<tr><td colspan="18"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">Includes $6.8&#160;million loss on disposal of discontinued operations for the year ended December 31, 2021</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Adjusted Earnings Before Interest, Taxes, Depreciation And Amortization</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_CapitalizedContractCostAmortizationPurchaseAccountingAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Capitalized Contract Cost, Amortization, Purchase Accounting Adjustments</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_CapitalizedContractCostAmortizationPurchaseAccountingAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_GainLossOnRepaymentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gain (Loss) On Repayment Of Debt</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_GainLossOnRepaymentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_GainOnTransferOfMembership">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gain On Transfer Of Membership</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_GainOnTransferOfMembership</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_PurchaseAccountingAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Purchase Accounting Adjustments</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_PurchaseAccountingAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_SharebasedCompensationIncludingOnetimeAdjustment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation, Including One-time Adjustment</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_SharebasedCompensationIncludingOnetimeAdjustment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_ShareholderAdvisoryServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Shareholder Advisory Services</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_ShareholderAdvisoryServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_TransactionCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Transaction Costs</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_TransactionCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120321790&amp;loc=d3e7008-128479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentOtherThanTemporaryImpairment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This item represents an other than temporary decline in value that has been recognized against an investment accounted for under the equity method of accounting. The excess of the carrying amount over the fair value of the investment represents the amount of the write down which is or was reflected in earnings. The written down value is a new cost basis with the adjusted value of the investment becoming its new carrying value subject to the equity accounting method. Evidence of a loss in value might include, but would not necessarily be limited to, absence of an ability to recover the carrying amount of the investment or inability of the investee to sustain an earnings capacity which would justify the carrying amount of the investment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 35<br> -Paragraph 32<br> -URI http://asc.fasb.org/extlink&amp;oid=124268079&amp;loc=d3e32787-111569<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentOtherThanTemporaryImpairment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnDispositionOfAssets1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of assets, including but not limited to property plant and equipment, intangible assets and equity in securities of subsidiaries or equity method investee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnDispositionOfAssets1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123467658&amp;loc=d3e12355-112629<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467658&amp;loc=d3e12317-112629<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillImpairmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13854-109267<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13777-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillImpairmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of income (loss) from a discontinued operation including the portion attributable to the noncontrolling interest. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3B<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721525-107759<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721675-107760<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e957-107759<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=d3e1361-107760<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3A<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721523-107759<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1012-107759<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109227538&amp;loc=d3e44648-109337<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) for proportionate share of equity method investee's income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(13)(f))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109237563&amp;loc=d3e33749-111570<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of Net Income (Loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1448-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1377-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities, and addition from assumption of issuance of common shares for dilutive potential common shares; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1930-109256<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1930-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1930-109256<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1505-109256<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1930-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109237686&amp;loc=d3e17752-110868<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.P.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140864-122747<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SeveranceCosts1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses for special or contractual termination benefits provided to current employees involuntarily terminated under a benefit arrangement associated exit or disposal activities pursuant to an authorized plan. Excludes expenses related to one-time termination benefits, a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SeveranceCosts1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>147
<FILENAME>R132.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139858971820376">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Reserves for Claims and Performance-Based Arrangements (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MovementInLiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetRollForward', window );"><strong>Liability for Unpaid Claims and Claims Adjustment Expense, Period Increase (Decrease) [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense', window );">Beginning balance</a></td>
<td class="nump">$ 178,827<span></span>
</td>
<td class="nump">$ 54,510<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_evh_CurrentYearClaimsAndClaimsAdjustmentExpenseIncludingCostOfGoodsAndServicesSoldExcludingDepreciationAndAmortization', window );">Incurred costs related to current year</a></td>
<td class="nump">457,841<span></span>
</td>
<td class="nump">420,597<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense', window );">Incurred costs related to prior year</a></td>
<td class="nump">7,109<span></span>
</td>
<td class="nump">2,878<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1', window );">Paid costs related to current year</a></td>
<td class="nump">358,448<span></span>
</td>
<td class="nump">464,571<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1', window );">Paid costs related to prior year</a></td>
<td class="nump">125,619<span></span>
</td>
<td class="nump">9,598<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpensePeriodIncreaseDecrease', window );">Change during the year</a></td>
<td class="num">(19,117)<span></span>
</td>
<td class="num">(50,694)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseBusinessAcquisitions', window );">Impact of consolidation on reserves for claims and performance-based arrangements</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">164,297<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseOpeningBalanceAdjustments', window );">Other adjustments</a></td>
<td class="nump">11,584<span></span>
</td>
<td class="nump">10,714<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense', window );">Ending balance</a></td>
<td class="nump">171,294<span></span>
</td>
<td class="nump">178,827<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupClassificationAxis=us-gaap_DiscontinuedOperationsDisposedOfBySaleMember', window );">Discontinued Operations, Disposed of by Sale | True Health</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MovementInLiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetRollForward', window );"><strong>Liability for Unpaid Claims and Claims Adjustment Expense, Period Increase (Decrease) [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense', window );">Beginning balance</a></td>
<td class="nump">9,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense', window );">Ending balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,900<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=evh_EvolentHealthServicesSegmentMember', window );">Evolent Health Services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MovementInLiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetRollForward', window );"><strong>Liability for Unpaid Claims and Claims Adjustment Expense, Period Increase (Decrease) [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense', window );">Beginning balance</a></td>
<td class="nump">56,296<span></span>
</td>
<td class="nump">4,265<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_evh_CurrentYearClaimsAndClaimsAdjustmentExpenseIncludingCostOfGoodsAndServicesSoldExcludingDepreciationAndAmortization', window );">Incurred costs related to current year</a></td>
<td class="nump">8,669<span></span>
</td>
<td class="num">(7,542)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense', window );">Incurred costs related to prior year</a></td>
<td class="nump">7,036<span></span>
</td>
<td class="nump">2,853<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1', window );">Paid costs related to current year</a></td>
<td class="nump">20,801<span></span>
</td>
<td class="nump">106,093<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1', window );">Paid costs related to prior year</a></td>
<td class="nump">25,544<span></span>
</td>
<td class="nump">2,123<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpensePeriodIncreaseDecrease', window );">Change during the year</a></td>
<td class="num">(30,640)<span></span>
</td>
<td class="num">(112,905)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseBusinessAcquisitions', window );">Impact of consolidation on reserves for claims and performance-based arrangements</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">164,297<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseOpeningBalanceAdjustments', window );">Other adjustments</a></td>
<td class="num">(38)<span></span>
</td>
<td class="nump">639<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense', window );">Ending balance</a></td>
<td class="nump">25,618<span></span>
</td>
<td class="nump">56,296<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=evh_ClinicalSolutionsSegmentMember', window );">Clinical Solutions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MovementInLiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetRollForward', window );"><strong>Liability for Unpaid Claims and Claims Adjustment Expense, Period Increase (Decrease) [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense', window );">Beginning balance</a></td>
<td class="nump">122,531<span></span>
</td>
<td class="nump">50,245<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_evh_CurrentYearClaimsAndClaimsAdjustmentExpenseIncludingCostOfGoodsAndServicesSoldExcludingDepreciationAndAmortization', window );">Incurred costs related to current year</a></td>
<td class="nump">449,172<span></span>
</td>
<td class="nump">428,139<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense', window );">Incurred costs related to prior year</a></td>
<td class="nump">73<span></span>
</td>
<td class="nump">25<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1', window );">Paid costs related to current year</a></td>
<td class="nump">337,647<span></span>
</td>
<td class="nump">358,478<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1', window );">Paid costs related to prior year</a></td>
<td class="nump">100,075<span></span>
</td>
<td class="nump">7,475<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpensePeriodIncreaseDecrease', window );">Change during the year</a></td>
<td class="nump">11,523<span></span>
</td>
<td class="nump">62,211<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseBusinessAcquisitions', window );">Impact of consolidation on reserves for claims and performance-based arrangements</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseOpeningBalanceAdjustments', window );">Other adjustments</a></td>
<td class="nump">11,622<span></span>
</td>
<td class="nump">10,075<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense', window );">Ending balance</a></td>
<td class="nump">$ 145,676<span></span>
</td>
<td class="nump">$ 122,531<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_CurrentYearClaimsAndClaimsAdjustmentExpenseIncludingCostOfGoodsAndServicesSoldExcludingDepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Current Year Claims And Claims Adjustment Expense, Including Cost Of Goods And Services Sold, Excluding Depreciation And Amortization</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_CurrentYearClaimsAndClaimsAdjustmentExpenseIncludingCostOfGoodsAndServicesSoldExcludingDepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount needed to reflect the estimated ultimate cost of settling claims relating to insured events that have occurred on or before the balance sheet date, whether or not reported to the insurer at that date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116884095&amp;loc=d3e14764-158437<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (cc)<br> -URI http://asc.fasb.org/extlink&amp;oid=116884095&amp;loc=d3e14764-158437<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseBusinessAcquisitions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the cost of settling unpaid claims after deduction of reinsurance recoveries related to the acquisition of a business. Includes, but is not limited to, claims which have been incurred but not reported.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseBusinessAcquisitions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after effects of reinsurance, of payments to settle claims incurred in the current period and related claims settlement costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=116884095&amp;loc=d3e14764-158437<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after effects of reinsurance, of payments to settle claims incurred in prior periods and related claims settlement costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=116884095&amp;loc=d3e14764-158437<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseOpeningBalanceAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of adjustments to the estimated reserve for unpaid claims and claims adjustment expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=116884095&amp;loc=d3e14764-158437<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseOpeningBalanceAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpensePeriodIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after effects of reinsurance, of increase (decrease) in the liability for unpaid claims and claims adjustment expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=116884095&amp;loc=d3e14764-158437<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpensePeriodIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MovementInLiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MovementInLiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after effects of reinsurance, of expense (reversal of expense) for claims incurred in prior reporting periods and related claims settlement costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116884095&amp;loc=d3e14764-158437<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupClassificationAxis=us-gaap_DiscontinuedOperationsDisposedOfBySaleMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupClassificationAxis=us-gaap_DiscontinuedOperationsDisposedOfBySaleMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=evh_TrueHealthMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=evh_TrueHealthMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=evh_EvolentHealthServicesSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=evh_EvolentHealthServicesSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=evh_ClinicalSolutionsSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=evh_ClinicalSolutionsSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>148
<FILENAME>R133.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139858982853384">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Quarterly Results of Operations (unaudited) (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="9">3 Months Ended</th>
<th class="th" colspan="6">12 Months Ended</th>
</tr>
<tr>
<th class="th" colspan="2"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th" colspan="2"><div>Dec. 31, 2021</div></th>
<th class="th" colspan="2"><div>Dec. 31, 2020</div></th>
<th class="th" colspan="2"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_QuarterlyFinancialDataAbstract', window );"><strong>Quarterly Financial Data [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenue</a></td>
<td class="nump">$ 248,358<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 222,471<span></span>
</td>
<td class="nump">$ 222,057<span></span>
</td>
<td class="nump">$ 215,071<span></span>
</td>
<td class="nump">$ 246,536<span></span>
</td>
<td class="nump">$ 239,572<span></span>
</td>
<td class="nump">$ 217,299<span></span>
</td>
<td class="nump">$ 221,232<span></span>
</td>
<td class="nump">$ 907,957<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 924,639<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 687,122<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">260,572<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">229,052<span></span>
</td>
<td class="nump">229,728<span></span>
</td>
<td class="nump">231,016<span></span>
</td>
<td class="nump">246,804<span></span>
</td>
<td class="nump">256,020<span></span>
</td>
<td class="nump">443,128<span></span>
</td>
<td class="nump">246,323<span></span>
</td>
<td class="nump">950,368<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">1,192,275<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">996,007<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest', window );">Loss from continuing operations</a></td>
<td class="nump">3,053<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(13,040)<span></span>
</td>
<td class="num">(9,107)<span></span>
</td>
<td class="num">(11,190)<span></span>
</td>
<td class="num">(10,637)<span></span>
</td>
<td class="num">(37,035)<span></span>
</td>
<td class="num">(202,013)<span></span>
</td>
<td class="num">(78,487)<span></span>
</td>
<td class="num">(30,284)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(328,172)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(307,193)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax', window );">Income (loss) from discontinued operations, net of tax</a></td>
<td class="num">(8,700)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,383<span></span>
</td>
<td class="num">(3,166)<span></span>
</td>
<td class="num">(1,135)<span></span>
</td>
<td class="num">(1,508)<span></span>
</td>
<td class="num">(265)<span></span>
</td>
<td class="num">(7,317)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="num">(6,074)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">1,613<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest', window );">Net loss attributable to non-controlling interests</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">822<span></span>
</td>
<td class="num">(822)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(3,609)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic', window );">Net loss attributable to common shareholders of Evolent Health, Inc. - Basic</a></td>
<td class="num">(5,647)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(13,040)<span></span>
</td>
<td class="num">(9,107)<span></span>
</td>
<td class="num">(9,807)<span></span>
</td>
<td class="num">(14,625)<span></span>
</td>
<td class="num">(37,348)<span></span>
</td>
<td class="num">(203,521)<span></span>
</td>
<td class="num">(78,752)<span></span>
</td>
<td class="num">(37,601)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(334,246)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(301,971)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted', window );">Net loss attributable to common shareholders of Evolent Health, Inc. - Diluted</a></td>
<td class="num">$ (5,647)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">$ (13,040)<span></span>
</td>
<td class="num">$ (9,107)<span></span>
</td>
<td class="num">$ (9,807)<span></span>
</td>
<td class="num">$ (14,625)<span></span>
</td>
<td class="num">$ (37,348)<span></span>
</td>
<td class="num">$ (203,521)<span></span>
</td>
<td class="num">$ (78,752)<span></span>
</td>
<td class="num">$ (37,601)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">$ (334,246)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">$ (301,971)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDilutedAbstract', window );"><strong>Loss per common share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare', window );">Continuing operations, basic (in dollars per share)</a></td>
<td class="nump">$ 0.03<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">$ (0.15)<span></span>
</td>
<td class="num">$ (0.11)<span></span>
</td>
<td class="num">$ (0.13)<span></span>
</td>
<td class="num">$ (0.13)<span></span>
</td>
<td class="num">$ (0.43)<span></span>
</td>
<td class="num">$ (2.37)<span></span>
</td>
<td class="num">$ (0.93)<span></span>
</td>
<td class="num">$ (0.35)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">$ (3.86)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">$ (3.73)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare', window );">Continuing operations, diluted (in dollars per share)</a></td>
<td class="nump">0.03<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(0.15)<span></span>
</td>
<td class="num">(0.11)<span></span>
</td>
<td class="num">(0.13)<span></span>
</td>
<td class="num">(0.13)<span></span>
</td>
<td class="num">(0.43)<span></span>
</td>
<td class="num">(2.37)<span></span>
</td>
<td class="num">(0.93)<span></span>
</td>
<td class="num">(0.35)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(3.86)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(3.73)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare', window );">Discontinued operations, basic (in dollars per share)</a></td>
<td class="num">(0.09)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0.01<span></span>
</td>
<td class="num">(0.04)<span></span>
</td>
<td class="num">(0.01)<span></span>
</td>
<td class="num">(0.01)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(0.09)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(0.08)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">0.02<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare', window );">Discontinued operations, diluted (in dollars per share)</a></td>
<td class="num">$ (0.09)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="num">$ (0.04)<span></span>
</td>
<td class="num">$ (0.01)<span></span>
</td>
<td class="num">$ (0.01)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="num">$ (0.09)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">$ (0.08)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 0.02<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr><td colspan="16"></td></tr>
<tr><td colspan="16"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">Includes $6.8&#160;million loss on disposal of discontinued operations for the year ended December 31, 2021</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDilutedAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDilutedAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of income (loss) from continuing operations including portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569616-111683<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) from continuing operations per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1252-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-03(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868656-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsPerBasicShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) derived from continuing operations during the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-03(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868656-224227<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1252-109256<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of income (loss) from a discontinued operation including the portion attributable to the noncontrolling interest. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3B<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721525-107759<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721675-107760<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e957-107759<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=d3e1361-107760<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3A<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721523-107759<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1012-107759<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109227538&amp;loc=d3e44648-109337<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per basic share amount, after tax, of income (loss) from the day-to-day business activities of the discontinued operation and gain (loss) from the disposal of the discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1278-109256<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per diluted share amount, after tax, of income (loss) from the day-to-day business activities of the discontinued operation and gain (loss) from the disposal of the discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SAB Topic 5.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=120398118&amp;loc=d3e355146-122828<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1278-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of Net Income (Loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1448-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1377-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities, and addition from assumption of issuance of common shares for dilutive potential common shares; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1930-109256<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1930-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1930-109256<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1505-109256<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1930-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_QuarterlyFinancialDataAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_QuarterlyFinancialDataAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9031-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>149
<FILENAME>R134.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139858979514200">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Quarterly Results of Operations (unaudited) - Additional Information (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="3">3 Months Ended</th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_QuarterlyFinancialDataAbstract', window );"><strong>Quarterly Financial Data [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillImpairmentLoss', window );">Goodwill impairment</a></td>
<td class="nump">$ 215,100,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 199,800,000<span></span>
</td>
<td class="nump">$ 215,100,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 215,100,000<span></span>
</td>
<td class="nump">$ 199,800,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillImpairmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13854-109267<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13777-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillImpairmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_QuarterlyFinancialDataAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_QuarterlyFinancialDataAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>150
<FILENAME>R135.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139858971227576">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Supplemental Cash Flow Information (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract', window );"><strong>Supplemental Disclosure of Non-cash Investing and Financing Activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssued1', window );">Class A and Class B common stock issued in connection with business combinations</a></td>
<td class="nump">$ 56,626<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 23,556<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_evh_NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationMeasurementPeriodAdjustment', window );">Increase/decrease to goodwill from measurement period adjustments/business combinations</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">2,200<span></span>
</td>
<td class="num">(351)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncashOrPartNoncashAcquisitionPayablesAssumed1', window );">Class A common stock issued for payment of earn-outs</a></td>
<td class="nump">450<span></span>
</td>
<td class="nump">4,185<span></span>
</td>
<td class="nump">800<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_evh_StockIssuedInConnectionWithDebtRepayment', window );">Class A common stock issued in connection with debt repayment</a></td>
<td class="nump">28,492<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_evh_GainLossFromTransferOfMembership', window );">Gain from transfer of membership</a></td>
<td class="num">(22,969)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid', window );">Accrued property and equipment purchases</a></td>
<td class="nump">784<span></span>
</td>
<td class="nump">11<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_evh_AccruedPropertyAndEquipmentPurchases', window );">Accrued property and equipment purchases</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(527)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1', window );">Consideration for asset acquisition or business combinations</a></td>
<td class="nump">14,600<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">16,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_evh_CashFlowLesseeAbstract', window );"><strong>Effects of Leases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Operating cash flows from operating leases</a></td>
<td class="nump">13,845<span></span>
</td>
<td class="nump">13,708<span></span>
</td>
<td class="nump">12,330<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_evh_RightOfUseAssetAcquiredAndDisposedOf', window );">Leased assets obtained in exchange for operating lease liabilities</a></td>
<td class="num">(2,583)<span></span>
</td>
<td class="num">(2,170)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">Leased assets obtained in exchange for operating lease liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30,463<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_evh_ConversionOfStockAbstract', window );"><strong>Effects of Class B Exchanges</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockAmountConverted1', window );">Decrease in non-controlling interests as a result of Class B Exchanges</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">42,377<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_evh_StockIssuedDecreaseInDeferredTaxLiability', window );">Decrease in deferred tax liability as a result of securities offerings and exchanges</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(22)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental Disclosures</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Cash paid for interest</a></td>
<td class="nump">7,113<span></span>
</td>
<td class="nump">13,352<span></span>
</td>
<td class="nump">5,037<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxesPaid', window );">Cash paid for taxes, net</a></td>
<td class="nump">$ 551<span></span>
</td>
<td class="nump">$ 9,679<span></span>
</td>
<td class="nump">$ 1,484<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_AccruedPropertyAndEquipmentPurchases">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued Property And Equipment Purchases</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_AccruedPropertyAndEquipmentPurchases</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_CashFlowLesseeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash Flow, Lessee [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_CashFlowLesseeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_ConversionOfStockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Conversion Of Stock [Abstract</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_ConversionOfStockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_GainLossFromTransferOfMembership">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gain (Loss) from Transfer of Membership</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_GainLossFromTransferOfMembership</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationMeasurementPeriodAdjustment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Noncash Or Part Noncash Acquisition, Noncash Financial Or Equity Instrument Consideration, Measurement Period Adjustment</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationMeasurementPeriodAdjustment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_RightOfUseAssetAcquiredAndDisposedOf">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Right-Of-Use Asset Acquired And Disposed Of</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_RightOfUseAssetAcquiredAndDisposedOf</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_StockIssuedDecreaseInDeferredTaxLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock Issued, Decrease In Deferred Tax Liability</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_StockIssuedDecreaseInDeferredTaxLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_StockIssuedInConnectionWithDebtRepayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock Issued in Connection with Debt Repayment</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_StockIssuedInConnectionWithDebtRepayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Future cash outflow to pay for purchases of fixed assets that have occurred.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4332-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4313-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalExpendituresIncurredButNotYetPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockAmountConverted1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The value of the stock converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4313-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4332-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockAmountConverted1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4297-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4297-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3367-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net book value of a nonmonetary asset transferred or exchanged in connection with the acquisition of a business or asset in a noncash transaction. Noncash is defined as transactions during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period. Nonmonetary assets and liabilities are assets and liabilities that will not result in cash receipts or cash payments in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4332-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4304-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4313-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncashOrPartNoncashAcquisitionPayablesAssumed1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of payables that an Entity assumes in acquiring a business or in consideration for an asset received in a noncash (or part noncash) acquisition. Noncash is defined as transactions during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4313-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4332-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncashOrPartNoncashAcquisitionPayablesAssumed1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918643-209977<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The fair value of stock issued in noncash financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4304-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4332-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4313-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>151
<FILENAME>evh-20211231_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:country="http://xbrl.sec.gov/country/2021"
  xmlns:dei="http://xbrl.sec.gov/dei/2021q4"
  xmlns:evh="http://www.evolenthealth.com/20211231"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2021-01-31"
  xmlns:stpr="http://xbrl.sec.gov/stpr/2021"
  xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="evh-20211231.xsd" xlink:type="simple"/>
    <context id="idc0db51272c94df1839131500195947e_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i7db6c6f189754c32a62fbe5b49259ed8_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="ibc44c5b5f9be42eaa992bbd65360561b_I20220218">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
        </entity>
        <period>
            <instant>2022-02-18</instant>
        </period>
    </context>
    <context id="i8daff60be410426d8f7bd49343c1ec0c_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ibc0c0c2b8dc04c5698ca0577a54b2e03_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="iba00e3572dc24848afe0d13147ef9951_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">evh:TransformationServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ib585ca9afa9b4d02874ade8f146f75cd_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">evh:TransformationServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ia6ba1f43ec4147adbafcb4a00fc450a2_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">evh:TransformationServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ic852ce517768443a8289b4dcbd762e47_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">evh:PlatformsAndOperationsServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i971b8dd0fb5d4b10b55f27371adadaa7_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">evh:PlatformsAndOperationsServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ie0aa3b0e3e5a4d54a32e0a4b60149c35_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">evh:PlatformsAndOperationsServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i12a6d1161de54547bd29f8efccd4c9b0_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i3e21049ffc224cacb8134d73c9bb5b38_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i997aac773ca7467b9a246f3420865489_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i5942ca937104445b92561d87e62b671c_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i235a50d4f95f4fe4ad003b456bd4d032_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="ie607b868cccf4190b29e8a645f1622cd_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="ifd10e063c50d49fd882ffd6694d2abea_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="idecb0ab9f980489d88090494dd10781e_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="ia7bd0a6ac576439fb579120cf0ef0c48_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i7130cb432c4b4fe7a260e8a3beeb35d8_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="ib3d180dea9514da28352fbc693ab84a5_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="iff47976e029948eca0df0ec3f59e7929_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="if9d18c41b2a74719afa2195476af7f6b_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i55a4ede774484bd8b99ec882803a31ae_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i07635cd96da44df8aeca179d3ffeeb6d_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="id72c42fac3684e24b4ca0bf829d0e596_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i87534e1639d049319065f8650fc0c762_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i132368a16db343cdb75b4cc5b6d3c936_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i6583965c38874fd5b1853fe21a37624d_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="iea51ead9d5cc49309a974f68850d9313_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i4b90c5fc5160471aba2652f11f6bb706_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ie8e5b6e19bcc4d6aa9434387b2fd038c_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="if4420575740f4afca80c3afb49e6e79e_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="id4af8e59d8e745af8ddd5b829f03f70a_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i2d2497909b9e4097b418e747f13bfc16_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="icba6e493923b449aa57c46a563760234_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i86eec55ebc424a56b5b5394b8b2b2423_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i67b404347634468496e5eb9d721d74b6_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i6464dcea2322451dbc03ac39361c75b9_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ieb0b713eae1b4f908dc2c23586d77948_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i911a108ecf12460193d53b0e6b24331f_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ifead6db34ce543e2beca6b5c57feaf4e_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i843130db221949f4a5068562633a2182_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ic8a05c8bd28c42f4918205dc608cf2de_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ide6ed4433a164b08bcb555a8e1f7a38c_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i88dcc077f08e4577b7b60dca2d354693_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="iaf96f04b17974a2f8e19df7a883c4734_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i1425ebfe96904025b4f40a30737efd06_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i8f416a598c52444597bd56910cd0efbb_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i7de15b24843f43e1bf1e49503dff1359_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="idb7d2cb4638a4234b2407c840694aea3_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i88eadc89dc9a4d4aab536db563f563d5_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i5724ef529cea411aadb2b6f086af09f1_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i8a0a16beae314535bccd01c31668c8fd_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i5f242398851f435581586484404b0dfb_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i8a70782136dc46eb8037c247f5e1694a_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i1bcca85fbf4c425299cf11a4c6626357_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i75b369d853b249f9a6495524752f5913_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i2177056c167d473399f65b5105c9a7f2_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i109ffa352e8c4ce0b59170cf60e46101_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i7fd6de5224704d7187b37d35a519cbfa_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i17d17fcbd53245e7981e707f61c46f1a_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i2c95448403fa4d3b8d864ca25a132fb8_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i8be054225f004416b985533cd8b4d2a6_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i733ca541299f4839bead39679b082534_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i9632fb5d42444a5984c0033bf16be6f0_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i5f1b61732fb142fc9539a36365f230ee_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ibd159a0a266f484882b88b46c1b83d3f_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis">evh:RestrictedCashforLettersofCreditforFacilityLeasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i3a313b63f9a34c26b2a361281eca58df_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis">evh:RestrictedCashforLettersofCreditforFacilityLeasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ia9df011f1efd436cbcdff5e8bfdd9e5a_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis">evh:CollateralwithFinancialInstitutionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ib52a820bc1fa4880b75c578ff17dda8d_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis">evh:CollateralwithFinancialInstitutionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ic5164e2908114e21b24e2e1681c5dcba_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis">evh:RestrictedCashforBenefitManagementServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i83fc6159c69f43e5822b38e95a2a3b46_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis">evh:RestrictedCashforBenefitManagementServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i58c2398f3ddb4809a3cb1af5b5c34db8_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis">evh:RestrictedCashforOtherContractualCommitmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i58e611a688d54093ac555cb27c5810ec_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis">evh:RestrictedCashforOtherContractualCommitmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i98364cf4ba3e41af868d701b4c668283_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DiscontinuedOperationsDisposedOfBySaleMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">evh:TrueHealthMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="id8e4ad0aaaf14d2e8309a07fe17aa411_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis">us-gaap:BankTimeDepositsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i2a39d28f60a44d6bb41fe546afc858b2_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis">us-gaap:BankTimeDepositsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="if8e7fd6ca1724c74bd0f4e3ca2947419_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i703e3ae1f15f4420b40ff930efbc9f87_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareAndSoftwareDevelopmentCostsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ibc96172fcef14618a2c513b85e88be97_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i53d4b22f661d41dbb61ff5dcf8f75f50_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ia186bface90a4c4098c96c8567d34124_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ibff83f3576fa462088fb611595ae2107_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TradeNamesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ie3bf7bed53b145e699f90d4132648c21_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TradeNamesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i3ca5e8fff37648578ddcb5915d42bd23_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i4cff67909d644529824bdb1faef1b019_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i701391050b2e43d082d405d3d16746d2_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i6d3cdc666422461398b727dbf8a5d16e_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:ContractBasedIntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i80595e56a7a74f699957bf0f9a4173ce_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:ContractBasedIntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i532d2c0bf63243e999d48341920b6775_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="iddbf996a3b1a4aeda47f1e8169c69262_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i70301f61588141189fb4444297fae8bd_I20211001">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">evh:VitalDecisionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-10-01</instant>
        </period>
    </context>
    <context id="icc3dde603e5f449c9078821a3218c74e_D20211001-20211001">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">evh:VitalDecisionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2021-10-01</endDate>
        </period>
    </context>
    <context id="i499adfced3fe4274a3f2ca19bf418044_I20211001">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">evh:VitalDecisionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-10-01</instant>
        </period>
    </context>
    <context id="i6f5e720f7a9e4b0d9114b35d5878bf70_I20211001">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">evh:VitalDecisionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-10-01</instant>
        </period>
    </context>
    <context id="i393b8dc21e5b45e585a40c88e5f9cd40_I20211001">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">evh:VitalDecisionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TradeNamesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-10-01</instant>
        </period>
    </context>
    <context id="i93823d3451b643ba8bd3aefc9d052c7c_D20211001-20211001">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">evh:VitalDecisionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2021-10-01</endDate>
        </period>
    </context>
    <context id="i631f51b734d24d66935095cad71b62c0_D20211001-20211001">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">evh:VitalDecisionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2021-10-01</endDate>
        </period>
    </context>
    <context id="i942460901cce441cba62f7e178ca70fd_D20211001-20211001">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">evh:VitalDecisionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TradeNamesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2021-10-01</endDate>
        </period>
    </context>
    <context id="iba85fb86cb9c459986593ba474a68022_D20190528-20190528">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">us-gaap:VariableInterestEntityNotPrimaryBeneficiaryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">evh:UniversityHealthCaredbaPassportHealthPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-05-28</startDate>
            <endDate>2019-05-28</endDate>
        </period>
    </context>
    <context id="i5aae66b17cd7411eb3d40e1f98e41587_I20190618">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">us-gaap:NotesReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:PassportNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-18</instant>
        </period>
    </context>
    <context id="i374acc0d61704b06a1daddce75dda523_I20190618">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:PassportNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-18</instant>
        </period>
    </context>
    <context id="i458a8dd8fe1447e983bf102015ceb976_D20190606-20190606">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">us-gaap:VariableInterestEntityNotPrimaryBeneficiaryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">evh:UniversityHealthCaredbaPassportHealthPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-06-06</startDate>
            <endDate>2019-06-06</endDate>
        </period>
    </context>
    <context id="i50b57c8ae3af4f4d87078314e47600cb_I20191230">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">us-gaap:VariableInterestEntityNotPrimaryBeneficiaryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">evh:UniversityHealthCaredbaPassportHealthPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-30</instant>
        </period>
    </context>
    <context id="i3f3edd8173b642a0af571267b2125442_D20210101-20210131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">evh:MolinaHealthcareIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-01-31</endDate>
        </period>
    </context>
    <context id="i410c11618d854c73bc5727ec26d5ac44_D20200901-20200901">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">evh:MolinaHealthcareIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-09-01</startDate>
            <endDate>2020-09-01</endDate>
        </period>
    </context>
    <context id="i553144e874d7414ab395f79f6424736f_D20201116-20201116">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">us-gaap:VariableInterestEntityNotPrimaryBeneficiaryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">evh:UniversityHealthCaredbaPassportHealthPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-11-16</startDate>
            <endDate>2020-11-16</endDate>
        </period>
    </context>
    <context id="i24eda106b1dc4387aebfe529942c3586_D20200901-20200901">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">evh:PassportAssetAcquisitionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-09-01</startDate>
            <endDate>2020-09-01</endDate>
        </period>
    </context>
    <context id="i8d16ce5f96ed484ea0bd662e9a0da3ec_D20201231-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:PassportNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-12-31</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i660e59a50fb74adf8c9b97dba279e217_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">us-gaap:VariableInterestEntityNotPrimaryBeneficiaryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">evh:UniversityHealthCaredbaPassportHealthPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="ib292e37ea5764045b08aaf86b4bf8282_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">us-gaap:VariableInterestEntityNotPrimaryBeneficiaryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">evh:UniversityHealthCaredbaPassportHealthPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i1857a80445fe4ba78e6b1cd41cf5528f_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">us-gaap:VariableInterestEntityNotPrimaryBeneficiaryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">evh:UniversityHealthCaredbaPassportHealthPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ia321bb1b6e6b403aa6a27cd32dbe25f8_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">evh:VivantHealthMSOLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i1c4a293e5ce54724af5effd8253d4d89_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DiscontinuedOperationsDisposedOfBySaleMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">evh:TrueHealthMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="id9938925ae68403cbd1e3633d8c2af7a_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">evh:PlatformsAndOperationsServicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DiscontinuedOperationsDisposedOfBySaleMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">evh:TrueHealthMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i62b6ff0a18e64449a282407a6971fe18_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">evh:PlatformsAndOperationsServicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DiscontinuedOperationsDisposedOfBySaleMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">evh:TrueHealthMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ic1ed065f23364faeb485521f6be7f439_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">evh:PlatformsAndOperationsServicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DiscontinuedOperationsDisposedOfBySaleMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">evh:TrueHealthMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i15f03ee2332146e4a7e0d5b5717bea28_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">evh:PremiumsRevenueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DiscontinuedOperationsDisposedOfBySaleMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">evh:TrueHealthMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i6eca3f13863a45c481c07e49e9f434fe_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">evh:PremiumsRevenueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DiscontinuedOperationsDisposedOfBySaleMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">evh:TrueHealthMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="iae64c322a5eb4929bc01485807d92b3a_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">evh:PremiumsRevenueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DiscontinuedOperationsDisposedOfBySaleMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">evh:TrueHealthMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="if7ba948ef00b4ddeabe73338f1155e8b_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DiscontinuedOperationsDisposedOfBySaleMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">evh:TrueHealthMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="iae6c9a536db44d69b64c473850d09499_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DiscontinuedOperationsDisposedOfBySaleMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">evh:TrueHealthMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ib1b709ded692440f9e0b6b584a8c0080_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">evh:ServicesAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DiscontinuedOperationsDisposedOfBySaleMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">evh:TrueHealthMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i93a7fe07dcb74ecba6ec18daa2afd21d_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">evh:ServicesAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DiscontinuedOperationsDisposedOfBySaleMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">evh:TrueHealthMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i0725607f45d24e7096771c6e0b9f7133_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">evh:ServicesAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DiscontinuedOperationsDisposedOfBySaleMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">evh:TrueHealthMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i6ea3e63701234a91a969d79c7385efdc_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">evh:ServicesAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DiscontinuedOperationsDisposedOfBySaleMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">evh:TrueHealthMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ic43c6cb369be49d49265e63f4d9abe41_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">evh:MedicaidCustomersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">evh:EvolentHealthServicesSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i535e9398f53d482399e3acaf85d05d83_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">evh:MedicaidCustomersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">evh:EvolentHealthServicesSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="id2bc3ff361f24fefa6cc02e574174d0d_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">evh:MedicaidCustomersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">evh:EvolentHealthServicesSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="id9db9ac43e544bf2a8a53256e34c582f_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">evh:MedicaidCustomersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">evh:ClinicalSolutionsSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i79967d3cee0e4773a3e643d202cac1e7_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">evh:MedicaidCustomersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">evh:ClinicalSolutionsSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="iceaed1bf0ba14aeabbd5e7c285fadb74_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">evh:MedicaidCustomersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">evh:ClinicalSolutionsSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="icb83054796ca43aabbc5e7c5bcd8f242_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">evh:MedicareCustomersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">evh:EvolentHealthServicesSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ide7e8d10e8754aeb98428c460346c2e6_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">evh:MedicareCustomersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">evh:EvolentHealthServicesSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i9dc8f259d0954c4790aef4d1cda35290_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">evh:MedicareCustomersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">evh:EvolentHealthServicesSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="id1eb1d14b8034af8af9fcc8ff413f4a8_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">evh:MedicareCustomersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">evh:ClinicalSolutionsSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i99e6ebd37717409cadbd8a0e52f302d8_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">evh:MedicareCustomersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">evh:ClinicalSolutionsSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ibe57bae9f0e94d19b338958e93a6d9a0_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">evh:MedicareCustomersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">evh:ClinicalSolutionsSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i05cdaab0e8a9475391be6c9bb0290a02_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">evh:CommercialAndOtherCustomersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">evh:EvolentHealthServicesSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i70c4c918cacd44ceb89f531391a51f89_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">evh:CommercialAndOtherCustomersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">evh:EvolentHealthServicesSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i7ae80f06fd7241178ec3bcbf2b433c78_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">evh:CommercialAndOtherCustomersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">evh:EvolentHealthServicesSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i615c66ad61b84863b2bbc22a537fd294_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">evh:CommercialAndOtherCustomersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">evh:ClinicalSolutionsSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i6c3248cb38b348cc83404e78b286c508_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">evh:CommercialAndOtherCustomersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">evh:ClinicalSolutionsSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i62d3399ff7cf4122b4eb5165603a12e2_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">evh:CommercialAndOtherCustomersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">evh:ClinicalSolutionsSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i98988f30813349e1a5594e72b40af5b1_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">evh:EvolentHealthServicesSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i00a9fb2f3f914116b87f14e146d04507_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">evh:EvolentHealthServicesSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i26a4f846df6445f78bba31f5ba0edcdd_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">evh:EvolentHealthServicesSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i6d991ef4e2e0416f8c7aaaa6175cf843_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">evh:ClinicalSolutionsSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i73877656554945338d08c1e8006fc13a_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">evh:ClinicalSolutionsSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="if6faab8365e548b981e0edaddae65523_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">evh:ClinicalSolutionsSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="if14fbffaf3854b8c835ade571c3cc193_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:typedMember dimension="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis">
                    <us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>2022-01-01</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>
                </xbrldi:typedMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i8959430f12264863ae6656497c8cbe17_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:typedMember dimension="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis">
                    <us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>2023-01-01</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>
                </xbrldi:typedMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i25cd20be19e940cf94f2ba0eef170452_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:typedMember dimension="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis">
                    <us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>2024-01-01</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>
                </xbrldi:typedMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i546c40c371924532a3d2ed0ace7d354b_D20211001-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i54aba1ec35ba4673abba7abb46f76ef5_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedContractCostAxis">evh:BonusesAndCommissionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i44f063f12cc04f629ffbb5c7712fd0f2_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedContractCostAxis">evh:BonusesAndCommissionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="icfdf7dc68ad9407fb6453da7eb51ff1e_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedContractCostAxis">evh:BonusesAndCommissionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i32c4356526e94c2a842b0638c13e0da0_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedContractCostAxis">evh:BonusesAndCommissionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i781700715d804fefb7f495ca8b0f9e4a_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedContractCostAxis">evh:BonusesAndCommissionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i1e5e51907f2d489ab6121950881bf006_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedContractCostAxis">evh:ContractFulfillmentCostsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="icf374646ef6b49209d89a39117fda72a_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedContractCostAxis">evh:ContractFulfillmentCostsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i8b41623f6b924d1986071e4349ac5013_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedContractCostAxis">evh:ContractFulfillmentCostsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i764aef4cc3ae4cc1bcebb290a4525192_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedContractCostAxis">evh:ContractFulfillmentCostsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i914217ccb9dc458290c3558593f0487c_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedContractCostAxis">evh:ContractFulfillmentCostsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i409817ab2c13478f8041e2ff229d0614_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancingReceivablesPeriodPastDueAxis">evh:FInancialAssetLessThan60DaysMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="iafc89cf729024311ade0aeb8068cb56d_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancingReceivablesPeriodPastDueAxis">evh:FInancialAssetLessThan120DaysPastDueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="icc5d957904904562b11eb24c12475bd1_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancingReceivablesPeriodPastDueAxis">evh:FInancialAssetLessThan60DaysMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i23f9ca4a3b134c3cb50b438855efd900_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancingReceivablesPeriodPastDueAxis">evh:FInancialAssetLessThan120DaysPastDueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ia1b27c6b1ce44bb4a7d45377795c832d_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i3065c5c08a124284884a61ee233f4e16_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ie08f3e6fd0bf42cf818c1f564fa39108_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ia55f03733cd945fe9d885896e547d383_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ia95d0a4759a840c0a34e767cc306a57e_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i370ec8ac69f6453daffb02508aef709b_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="icd3eb9c2b2874ea99e8f34f94952be94_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i3873f51f572a46ae8f17531700510927_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i0b599414417745fdb6c3cddde5001d4b_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i8c359ea835e64a39b5cab25a3948e3b7_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i3a8f822ce668416caf0bf1e2f7037e11_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i113b515f40aa4b3e9afd7361c65483dc_D20200501-20200531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
        </entity>
        <period>
            <startDate>2020-05-01</startDate>
            <endDate>2020-05-31</endDate>
        </period>
    </context>
    <context id="i62320e40739f4842b8ffb078d42fa029_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="ibd34af6251294e159e55819cc46cbbb6_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="id2d85a5202f44415bdbcb9412ab08509_D20191001-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
        </entity>
        <period>
            <startDate>2019-10-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="id586f68951304ab3ac3fd84a42cb5e48_D20201031-20201031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
        </entity>
        <period>
            <startDate>2020-10-31</startDate>
            <endDate>2020-10-31</endDate>
        </period>
    </context>
    <context id="ida02b25c4b5e464a9545df19946134c1_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">evh:EvolentHealthServicesSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i14e6a440f7dc431a9e1c85272b43d276_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">evh:ClinicalSolutionsSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="if8fd35766cfc4fa8b1cbf4f3cd8a8dfc_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">evh:EvolentHealthServicesSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i5f5145421bc94a90bb8982e11bb80abb_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">evh:ClinicalSolutionsSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="icdbca3fab4684e269937d4a61379d67f_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">evh:EvolentHealthServicesSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ie09b385083554dfe92dc601254dfdda8_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">evh:ClinicalSolutionsSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ie58c5dcefe64400fa99a44a4db35e02d_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TradeNamesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="if54550ac07374463b0640b875a8f1164_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TradeNamesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ie1ed53b5943b4889b309941737607d78_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TradeNamesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="if0eedc514d0a4637960f12892dff3179_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TradeNamesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i202c773f013e42dbaf2ed35f08ba74e4_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i71517c3f53a942378a08da469cfdd069_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i8af88df592574869bf4e7732fd88234d_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i562af9019b024a169c81d1f41361d631_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i9872c8fc2e2849be9d4b8a5ca7abe3dc_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i538bb825405f46a9ad4766eb47fd09f0_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="if49e52c6692f4f418b64ecce40eae504_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="idbec42c300ba44c8b821ff3fa0e1a438_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">evh:BelowMarketLeasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i77a25d5d9d13456bafdeb192f90dc6dd_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">evh:BelowMarketLeasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="id03edbc8f3a0467fb3003d024d0d20bf_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">evh:BelowMarketLeasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i5b2c8aeaa33341d0b0241d264ebd0409_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">evh:BelowMarketLeasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i5bc515c9cd944501946244b550d6dea8_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:ContractBasedIntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i73d07853890d4173bfcafe5a74c9aedf_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:ContractBasedIntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i4865a0a60cf141238d2403348647421d_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:ContractBasedIntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i2916f379be034a929416cb11c770e888_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:ContractBasedIntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ie6213ed773f940469197c948c85ce078_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DiscontinuedOperationsDisposedOfBySaleMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">evh:TrueHealthMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i886c543278f24614931e52b2326361a9_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DiscontinuedOperationsDisposedOfBySaleMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:ContractBasedIntangibleAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">evh:TrueHealthMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i83a4805b397642c7825f71f6f96da143_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DiscontinuedOperationsDisposedOfBySaleMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">evh:TrueHealthMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ib096ee77af354199bc615f81ee527eaa_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DiscontinuedOperationsDisposedOfBySaleMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:ContractBasedIntangibleAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">evh:TrueHealthMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i04c13e91bd034f30a0f4a7c989fc5940_I20200831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:SeniorConvertibleNotesDue2024Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-08-31</instant>
        </period>
    </context>
    <context id="i788309cbaf3c49228dff05dacf3204c0_D20200801-20200831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:SeniorConvertibleNotesDue2024Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-08-01</startDate>
            <endDate>2020-08-31</endDate>
        </period>
    </context>
    <context id="i79f0de790533434b998387bf6c4ab709_D20200801-20200831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:ConvertibleSeniorNotesdue2021Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-08-01</startDate>
            <endDate>2020-08-31</endDate>
        </period>
    </context>
    <context id="i8584b8487d5e4d7ca2a029dd1993309b_D20200801-20200831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-08-01</startDate>
            <endDate>2020-08-31</endDate>
        </period>
    </context>
    <context id="i9b76113417844ee8a46162426a4ed221_D20200801-20200831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:NewNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-08-01</startDate>
            <endDate>2020-08-31</endDate>
        </period>
    </context>
    <context id="ifef2fd52529f408dbb3bcb2d3f4ae616_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:SeniorConvertibleNotesDue2024Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i2f7a8968a0e74fcfa7af898dd2afb7a6_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:SeniorConvertibleNotesDue2024Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i2d6ffa68994846c2afc0f59e2f092900_D20200801-20200831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:SeniorConvertibleNotesDue2024Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-08-01</startDate>
            <endDate>2020-08-31</endDate>
        </period>
    </context>
    <context id="i440e2756c3e94ec7abffeb1fc8c10ab1_I20200831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:SeniorConvertibleNotesDue2024Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-08-31</instant>
        </period>
    </context>
    <context id="ic9f911355bb8445c908c1c5b6b982236_I20191230">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:InitialTermLoanFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-30</instant>
        </period>
    </context>
    <context id="i792aeba7f36b437d85bdf7da6230451c_I20191230">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">evh:DelayedDrawTermLoanFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:CreditAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-30</instant>
        </period>
    </context>
    <context id="ife61530204fd4e7bbf85f09284f83168_I20191230">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:ConvertibleSeniorNotesdue2021Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-30</instant>
        </period>
    </context>
    <context id="i96e7c8227b2041f28199b45cd6df39d8_D20191230-20191230">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:SeniorCreditFacilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2019-12-30</endDate>
        </period>
    </context>
    <context id="ieb668099634e44209035f0f361a970a7_D20191230-20191230">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:SeniorCreditFacilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:EurodollarMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2019-12-30</endDate>
        </period>
    </context>
    <context id="icc5f3f563c8f4128a7d55ea114d571c7_D20191230-20191230">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:SeniorCreditFacilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:BaseRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2019-12-30</endDate>
        </period>
    </context>
    <context id="i17e802ca9a354f61a67b176d11db40d2_D20191230-20191230">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">evh:DelayedDrawTermLoanFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:CreditAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2019-12-30</endDate>
        </period>
    </context>
    <context id="ib97b2b6f4e114116bcd48ecd930fff77_D20191230-20191230">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:SeniorCreditFacilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2019-12-30</endDate>
        </period>
    </context>
    <context id="ida54e6975d324252aa18539914addfb0_D20191230-20191230">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:SeniorCreditFacilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2019-12-30</endDate>
        </period>
    </context>
    <context id="ibfa29a18103548678c4142edda54a480_D20191230-20191230">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:SeniorCreditFacilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodThreeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2019-12-30</endDate>
        </period>
    </context>
    <context id="i5e8884745c8748e9ac6420974639bd12_I20191230">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:SeniorCreditFacilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-30</instant>
        </period>
    </context>
    <context id="iab036707b4a24de2813c8c6ec050b319_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:SeniorCreditFacilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="iadba955835944b7293cfc1935e0382e4_D20210108-20210108">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:SeniorCreditFacilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-08</startDate>
            <endDate>2021-01-08</endDate>
        </period>
    </context>
    <context id="i037876d85b5c4bea9f8460cdbf527197_D20210108-20210108">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:CreditAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-08</startDate>
            <endDate>2021-01-08</endDate>
        </period>
    </context>
    <context id="i88843d45ac464699a3408ba52bbc2f63_I20191230">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-30</instant>
        </period>
    </context>
    <context id="id418eef5065f4bf698e75757a9120794_D20191230-20191230">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2019-12-30</endDate>
        </period>
    </context>
    <context id="i0b6779acaae746b9a02d20842b794089_D20210108-20210108">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-08</startDate>
            <endDate>2021-01-08</endDate>
        </period>
    </context>
    <context id="i00584134c5844a27a4303a31c0b5f1f3_I20181031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:SeniorConvertibleNotesDue2025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-10-31</instant>
        </period>
    </context>
    <context id="i339c055665e9485da5895fb20444a7a8_D20181001-20181031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:SeniorConvertibleNotesDue2025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-10-01</startDate>
            <endDate>2018-10-31</endDate>
        </period>
    </context>
    <context id="i39addcd35f11436480a83296fb4dc83a_I20181031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:SeniorConvertibleNotesDue2025Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-10-31</instant>
        </period>
    </context>
    <context id="ic55a278f0f0c48b3bdd614bbb0a7eded_I20181022">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:SeniorConvertibleNotesDue2025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-10-22</instant>
        </period>
    </context>
    <context id="ic290bfcf094543248295da9fb01e4c88_I20181024">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:SeniorConvertibleNotesDue2025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-10-24</instant>
        </period>
    </context>
    <context id="i48ca8bc8e051466a9a37e1e1da6febc3_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:SeniorConvertibleNotesDue2025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="idd22b7a2c5194e22908f4f8bfed93408_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:SeniorConvertibleNotesDue2025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i36270cc40db54c1cbe5d5fe12dba090b_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:SeniorConvertibleNotesDue2025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i69e9a51f20134473a4650107c879ce03_D20181001-20181031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:SeniorConvertibleNotesDue2025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-10-01</startDate>
            <endDate>2018-10-31</endDate>
        </period>
    </context>
    <context id="ib49940b904c04bd784180584b89ab5bf_I20181031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:SeniorConvertibleNotesDue2025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-10-31</instant>
        </period>
    </context>
    <context id="i4f7fefe0fb434989bf906e20f2422c6b_I20161231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:ConvertibleSeniorNotesdue2021Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2016-12-31</instant>
        </period>
    </context>
    <context id="i54bf54f1a88044bab71a8867d4a0c31f_D20161201-20161231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:ConvertibleSeniorNotesdue2021Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-12-01</startDate>
            <endDate>2016-12-31</endDate>
        </period>
    </context>
    <context id="i7e9e77d057aa4381855c6fd7a1d6f4ea_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:ConvertibleSeniorNotesdue2021Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i087fe618f5364968ac66e7869d1caad5_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:ConvertibleSeniorNotesdue2021Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i4d8110dbf411438a8a00e05653b625c8_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:ConvertibleSeniorNotesdue2021Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i9a2926d0e711448fa37fb03edf2470a1_D20211201-20211201">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:ConvertibleSeniorNotesdue2021Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-12-01</startDate>
            <endDate>2021-12-01</endDate>
        </period>
    </context>
    <context id="ie511597b55e24e0b9a57496e5718443a_I20211201">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:ConvertibleSeniorNotesdue2021Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-01</instant>
        </period>
    </context>
    <context id="id7ce03f7e23c4e8982556c1c3936f37c_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:SeniorConvertibleNotesDue2024Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i2aac0290566244888dfc87dd98ff26b6_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:SeniorConvertibleNotesDue2024Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i0f822324d7204951a08832492a541883_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:SeniorConvertibleNotesDue2024Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i40eea1e73a0a4178ad8f4535f4a3950e_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:SeniorConvertibleNotesDue2024Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i974ce0eee5ff4e6280561dba5e0ac368_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:SeniorConvertibleNotesDue2025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i50fb6ca1635f4d128f6a1d489565ad0b_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:SeniorConvertibleNotesDue2025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i7f0d332f713a4f89bb808c44e818aea3_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:SeniorConvertibleNotesDue2025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ica31b1dea8e04139a2223a01fd1e7439_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:SeniorConvertibleNotesDue2025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="id04e184022df4434b775ae12babcdd7d_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:ConvertibleSeniorNotesdue2021Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i5f1ed0aa6efc4adda8d9ddf826e7eb41_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:ConvertibleSeniorNotesdue2021Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="id11648efb5084baf81bbd2896c0fcdac_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:ConvertibleSeniorNotesdue2021Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="icd0c2590d98d4a87a8626e624f822e5f_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:ConvertibleSeniorNotesdue2021Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i085a0d0eb6ed47f3bad60b4c05e2a3bd_D20200801-20200831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:SeniorConvertibleNotesDue2024Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-08-01</startDate>
            <endDate>2020-08-31</endDate>
        </period>
    </context>
    <context id="i744bd02bcde94561abd08918f859a83e_D20181001-20181031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:SeniorConvertibleNotesDue2025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-10-01</startDate>
            <endDate>2018-10-31</endDate>
        </period>
    </context>
    <context id="i8391049cde8843bea2025728f80db282_D20161201-20161231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:ConvertibleSeniorNotesdue2021Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-12-01</startDate>
            <endDate>2016-12-31</endDate>
        </period>
    </context>
    <context id="ia9961196998042f89c9a61f119c53f5e_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LetterOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="iede64ab75aa34060b8b77784840d5794_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LetterOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i16c94c74682c4658bb289affc41db310_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LetterOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis">evh:RestrictedCashForLettersOfCreditForLetterOfCreditFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i1ceb37a7eda64dfab33aaf8b47cbcf60_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LetterOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis">evh:CollateralwithFinancialInstitutionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i1f3461e188de4f5c80fc4743b6823420_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LetterOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis">evh:CollateralwithFinancialInstitutionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="iffcd0f576b5c4f27b02cf64ca97d07d5_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LetterOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis">evh:RestrictedCashForLettersOfCreditForLetterOfCreditFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="id08281884be844d0a19d848a335a5a80_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">evh:CookCountyHealthAndHospitalsSystemMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">us-gaap:FinanceReceivablesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="ie20505dffcf4431286b007c0fcf4ab14_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">evh:FloridaBlueMedicareIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">us-gaap:FinanceReceivablesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ib97fa9c20ea54ca1841b4c9b1f4ea27c_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">evh:MolinaHealthcareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">us-gaap:FinanceReceivablesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i9f2a3a14183a4b9c91ebd0c42eb5510d_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">evh:CookCountyHealthAndHospitalsSystemMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i4c5eb31ee1104de8a5635eca675175eb_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">evh:CookCountyHealthAndHospitalsSystemMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="id0f333276f5e44b698dd6e5f92a87479_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">evh:CookCountyHealthAndHospitalsSystemMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="iadb6308217bb4ce7bab0e77352bbe86e_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">evh:NewMexicoHealthConnectionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="idd6b43aa37f24ee4a2d07a9f35c9f6ce_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">evh:FloridaBlueMedicareIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i244051775e1e4019948fa2ba32e4ab27_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">evh:UniversityHealthCaredbaPassportHealthPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="id221ab9a660d422d8841139a66fe1f9d_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">evh:UniversityHealthCaredbaPassportHealthPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i8a931688112a4cc6bf3323cb239d7e4d_D20201001-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">evh:PremiumsRevenueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DiscontinuedOperationsDisposedOfBySaleMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">evh:TrueHealthMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i8404c3b22073440a9f092260f57c4d0a_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">evh:MolinaHealthcareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i1a21d5a158854825a4cb4f9e1b2d4103_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">us-gaap:LeaseAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ic979e1a0ada24d7da7646f2ccae478c7_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">us-gaap:LeaseAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ie94dd6f6dead455b8b597165bc5ec9ff_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:VA</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i9a6c9ce1bc6a4595b939e65f2d38f28e_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:IL</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i16fcb9584de04a43bbe15a5b9cef1417_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:NJ</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ic6005d9a695a4ec39b064ccaceff712d_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:IN</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ic293662ed0144555ad060c822d4249ce_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:CA</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ifdfd40d05cad486f8f8a1d4f5c27aedc_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i52b87d0e43a34ffc9389f5e532dad861_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i7d76227fd72340699f3b20cadd0ca448_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i201d78ce09254edeb74a5d8656d986e3_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">evh:RestrictedStockUnitsRSUsPerformanceBasedRestrictedStockUnitsPBRSUsAndLeveragedStockUnitsLSUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ia51882bd916343be8688568234c45e7d_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">evh:RestrictedStockUnitsRSUsPerformanceBasedRestrictedStockUnitsPBRSUsAndLeveragedStockUnitsLSUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ic6ab9363606041b5b1b0664ec16f77e3_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">evh:RestrictedStockUnitsRSUsPerformanceBasedRestrictedStockUnitsPBRSUsAndLeveragedStockUnitsLSUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ia6e4317e0fe84f639d451026ec4811f7_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="iebc1de752eaa4389a6a51366f6e15efc_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i7adc7fd9e069474b9522f7f84242457e_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="icbc3599f42a84566bfd33e73e504c17e_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="id074b4bed7284281bb2163f48f76bf03_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ib784df78539b41c494661a446433f01c_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ie27c749af3f640e6b503c30b7017a0cb_I20130923">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">evh:TwoThousandElevenEquityIncentivePlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2013-09-23</instant>
        </period>
    </context>
    <context id="i1d4614ce073d4c1dbaf45d31f2350ff7_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">evh:TwoThousandElevenEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i96a77abfddf84842a980b801febda12d_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">evh:TwoThousandElevenEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ie6ac3c72c3d048a79d7e7fab6a952c8d_I20150501">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">evh:TwoThousandFifteenEvolentHealthInc.OmnibusIncentiveCompensationPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2015-05-01</instant>
        </period>
    </context>
    <context id="i24c60745c92845f2979175286f6cfdb2_I20180613">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">evh:TwoThousandFifteenEvolentHealthInc.OmnibusIncentiveCompensationPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-06-13</instant>
        </period>
    </context>
    <context id="ifd8fb1ee9c5446a8804b4991f663185d_I20210415">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">evh:TwoThousandFifteenEvolentHealthInc.OmnibusIncentiveCompensationPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-15</instant>
        </period>
    </context>
    <context id="ib2892fd727a044ae9ebfd0032f5bc139_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">evh:TwoThousandFifteenEvolentHealthInc.OmnibusIncentiveCompensationPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i4266034771344505a1b7761cd97832a1_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">evh:TwoThousandFifteenEvolentHealthInc.OmnibusIncentiveCompensationPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i0017a1e05fa1452c857571fdbc23fd69_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">evh:LeveragedStockUnitsLSUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">evh:TwoThousandFifteenEvolentHealthInc.OmnibusIncentiveCompensationPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ic48b20a77e2d4ff0bffc7a7d61a66f9c_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">evh:PerformanceBasedRestrictedStockUnitsPSUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">evh:TwoThousandFifteenEvolentHealthInc.OmnibusIncentiveCompensationPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i0486c1cd30d84075a90f947bf2f00d37_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">evh:TwoThousandFifteenEvolentHealthInc.OmnibusIncentiveCompensationPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i9057bdb4a3f7459a99f31c6dcfaf93e8_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">evh:TwoThousandFifteenEvolentHealthInc.OmnibusIncentiveCompensationPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i144feb14f3894f2a93baecbdbd67f999_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">evh:LeveragedStockUnitsLSUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">evh:TwoThousandFifteenEvolentHealthInc.OmnibusIncentiveCompensationPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i3462813a792a43bdb0cd92a0d3fc4085_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="id4cdbac3ed5841318a01e98ea7bb7cb3_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i45606ce9dfa74fc7bd724460f67189ab_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i2ef2d194cc634bb5a3f24f06d02c7f5b_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i98059f1600aa412c87f3adc6788eb8b5_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i903fc0912d4e492c95e3ce815e897489_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i117e325270bf4054b07c98692139814a_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i4ad066769cd0464cbcbcf7d1ec4ce0ad_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i91de07e5bb1e422aa1d46986a0b1006f_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">evh:PerformanceBasedRestrictedStockUnitsPSUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ief3bd4a971ea460990e3d8fb590be11d_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">evh:PerformanceBasedRestrictedStockUnitsPSUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i460ef5cbfd2c49989b7ae61f7d7e59b2_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">evh:PerformanceBasedRestrictedStockUnitsPSUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="if0b01289c86a4176ab75517bdfe4ec1f_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">evh:LeveragedStockUnitsLSUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i824c4e26d9414a59ad8f2d73e36714d0_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">evh:LeveragedStockUnitsLSUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i89ff4001d069448c9d4b0758b35fcfdb_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">evh:LeveragedStockUnitsLSUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i1d8c81c79de743e8be167a4c88ad5716_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i3bb865fc0dda42bb8bbc52f03a761729_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i5542e161a27e454bb0a6172a44d18515_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ic2fe85c2e61b4a82aefe1b1a25d6bef0_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i686054032b8e4393aca78c7d43aa5ebd_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i8b9330154a17434f90687e31afeba60a_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i532ccc69d7f7466ba58c97c04ba645e1_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i0a2bd98f25e64cac9d230b30c39fd652_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i33d73ea883764a2dafec5a1252f33aef_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">evh:LeveragedStockUnitsLSUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ife9a61a44ecc47e88bb29426256eba9d_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">evh:PerformanceBasedRestrictedStockUnitsPSUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i686710b185af449cbe0de18d10c30d28_D20160301-20160331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-03-01</startDate>
            <endDate>2016-03-31</endDate>
        </period>
    </context>
    <context id="if1cf72bda2494db39c586d33c79355d7_I20160331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2016-03-31</instant>
        </period>
    </context>
    <context id="i4339469160624451b2787c8a94183aef_D20160301-20160331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-03-01</startDate>
            <endDate>2016-03-31</endDate>
        </period>
    </context>
    <context id="i42f9f4a544794563bbd3b640b97627eb_I20160331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2016-03-31</instant>
        </period>
    </context>
    <context id="i0b413462d6244d118fb2d0156e9029e7_D20160301-20160331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-03-01</startDate>
            <endDate>2016-03-31</endDate>
        </period>
    </context>
    <context id="i77ef8b91efad4f9c96efe1dd800f23a2_I20160331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2016-03-31</instant>
        </period>
    </context>
    <context id="ib4a9daf686984e69b26b36bbc92ff33d_D20160301-20160331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-03-01</startDate>
            <endDate>2016-03-31</endDate>
        </period>
    </context>
    <context id="i6df38813e0b146839515ddf8e5497101_D20160301-20160331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">evh:SharebasedCompensationAwardSubTrancheOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-03-01</startDate>
            <endDate>2016-03-31</endDate>
        </period>
    </context>
    <context id="ie92afa03287e4824b694b978705b0da6_D20160301-20160331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">evh:SharebasedCompensationAwardSubTrancheTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-03-01</startDate>
            <endDate>2016-03-31</endDate>
        </period>
    </context>
    <context id="i5f4625a059aa4800b22d29c186dc894c_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ib4707869ee56405ab1f2a9c58e43b761_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i643136e202254be08774a096650b7946_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">evh:NonEmployeeDirectorsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i53ca92671b00498d832fcdf0ccb439b2_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">evh:NewCenturyHealthMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ia60cbf2c61674250a7870e50684977b4_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i74fbd0cbfcb8404bbbc19a496f94e90d_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">evh:LeveragedStockUnitsLSUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i08583f7a5ec342338d4ec3de61aff226_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">evh:LeveragedStockUnitsLSUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i4b299843c6624a0b86491cf8ede39655_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">evh:LeveragedStockUnitsLSUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i04a926a87abf4421b1ca0ae299f722a6_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">evh:LeveragedStockUnitsLSUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">evh:SharebasedPaymentArrangementTrancheFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i4902163dcfd64aac93ef32c5d4cb51e2_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">evh:PerformanceBasedRestrictedStockUnitsPSUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i3c5f476b4e1249a08e8202ae0113bf9a_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">evh:PerformanceBasedRestrictedStockUnitsPSUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="if24975b6c6fc46f2956741e09150759a_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i32a9b997fd964b44a992bdf9b2104f0e_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ie5209e47858942b8a833f9d575b7d37c_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">evh:PerformanceBasedRestrictedStockUnitsPSUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i1c1d55717222438abb87e60bcf9b59b9_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">evh:PerformanceBasedRestrictedStockUnitsPSUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i6126841a44cb4c478fc23b6132251176_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i4d7d673b0fbf48deaa07f821e1025d2e_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i6b9dc5b6709f4577a0325ffd62a07675_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ie8b8af0c663c4c6f8a82f961045e3772_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i39aaea1673c24c3e943c58e39738d3e1_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i8104bf341ae243818cdc049157ebf28d_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">evh:FinitelivedTaxCreditCarryforwardMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i44a7d440fd3546178704d37b7cd7f209_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">evh:FinitelivedTaxCreditCarryforwardMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i598bb297864842fe8780e1b67c9dd1d8_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">evh:IndefinitelivedTaxCreditCarryforwardMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ifd7da24ee1294bf3afc9c7ca2280330f_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">evh:IndefinitelivedTaxCreditCarryforwardMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i898c9db01cf04be08210dc1be3090eca_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ibfe040616b3542e3a1e0d4d16022974d_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ib0a5f68e764e419481a0d19e2432cafe_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">evh:PeriodsPriortoJune2015Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i1cb7bef7317f4d90afc92b9268a6542c_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i871d99d3c60b41dea330fb287058c6b9_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i7521b01c889643c9931e6cd5cbaf2b96_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i9f8d5e268f3d4eb697463d42a1cc1553_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="id48b2d5a479f4ab58afeb508e8f9bc7c_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">evh:ServicesAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:EquityMethodInvesteeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i441f674d44a64d47a96c0c85ef92310d_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">evh:ServicesAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:EquityMethodInvesteeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i28a8f36df87345df9d28593e38c0563c_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">evh:ServicesAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:EquityMethodInvesteeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ibca1768da73d4a4188df3e08ee08a9ce_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">us-gaap:VariableInterestEntityNotPrimaryBeneficiaryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">evh:GlobalHealthMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="ib755be34efd8414388d2ce5ca242428f_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">us-gaap:VariableInterestEntityNotPrimaryBeneficiaryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">evh:GlobalHealthMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ibde52dbc2c2c4cbda03403d89ddcaca6_I20150531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">evh:EvolentHealthLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2015-05-31</instant>
        </period>
    </context>
    <context id="i02e542a70a5046e396e8cd9126fefd99_D20200901-20200901">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">us-gaap:VariableInterestEntityNotPrimaryBeneficiaryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">evh:UniversityHealthCaredbaPassportHealthPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-09-01</startDate>
            <endDate>2020-09-01</endDate>
        </period>
    </context>
    <context id="ia11440f2d2cf4758bb0c9e18c239042c_I20200901">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">us-gaap:VariableInterestEntityNotPrimaryBeneficiaryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">evh:UniversityHealthCaredbaPassportHealthPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-01</instant>
        </period>
    </context>
    <context id="i299a8d5a546040409468f7f7fabc44c0_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">us-gaap:VariableInterestEntityNotPrimaryBeneficiaryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">evh:UniversityHealthCaredbaPassportHealthPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i0abaa0eac87f4791aa3fc322969844f0_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i8b0421b968754a01b6e430b519919d13_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i2b88f3addfe64f84a6303a37b589e8f5_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ib92fc8f3c5774739b4687eddbea853f3_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ib80e545347c046f081508ec064bed62f_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i445dcacffbec464ebce55777f4c8895b_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i44e95c772e54413fb8612a96b7f4dd16_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i0c4bfc6064ec4f93a8c1502ece6eaeae_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="icb9299fd51a347b9a7a46a5d71c01525_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">evh:MeasurementInputRiskNeutralExpectedEarnoutConsiderationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i1fec5420a1ee45fd97f27bb260399220_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i4e9639a5adcd411a8b02679081819ef5_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i38e7d4598fcf4220b68ea93547e1d444_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ic0d050fa1a3e4a2cb801e14c4a7886a2_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i5798a2aee885432aa6df470400a67a94_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i7b9f0cfef2b641acb147ef3af438fe7e_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">evh:TransformationServicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ib3fa08547d374130bb63c1e8f0b2c225_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">evh:TransformationServicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i6759af249ec643ef9a412f313e3297e3_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">evh:TransformationServicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i64859199d5a842baaab416b161ae29c9_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">evh:PlatformsAndOperationsServicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ica89d567d5bb41858b442d7b0d52a944_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">evh:PlatformsAndOperationsServicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ibe63fb63b6ff4113a876f8b68f82e70a_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">evh:PlatformsAndOperationsServicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i2f7f912d67eb4dc4be805fbdba0a463f_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ifdb175ec1f9e4b0eb8e3f71649541a13_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ie285ae7136404d0386bf1d58aebb605f_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ia2137cc736cb46c28970ad4c0df7a021_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">evh:EmployeeSeveranceAndTerminationBenefitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ic842aeb816144721bb643e4517b1fffb_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">evh:EmployeeSeveranceAndTerminationBenefitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="id2b0eba26c804a30b8e75757e49f5f5d_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">evh:EmployeeSeveranceAndTerminationBenefitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i044e3156b9ce469fa3a7efb6527ef6c1_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:FacilityClosingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i40374039e5cf443a857163fd2a9b2b45_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:FacilityClosingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i3e648308269a4bea807ba0b660a48b7c_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:FacilityClosingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i27138185aa744ae99ce808c1685e2fee_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">evh:ProfessionalServicesRestructuringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="if18eac1cd66a4b9b9bcc87d4d6fe437c_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">evh:ProfessionalServicesRestructuringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i03de94c17d4149bbb0bf7a3e528d5f89_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">evh:ProfessionalServicesRestructuringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i41b92360defc47ba8a58871111248034_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">evh:TransformationServicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">evh:EvolentHealthServicesSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ic42eb62d04fb4a118704b67ffb9fd515_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">evh:TransformationServicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">evh:ClinicalSolutionsSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="iaf678763d1004f0e9876b94f94d0a5a6_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:IntersegmentEliminationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">evh:TransformationServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i468f13cceecc41368537f1bf4d3bc06e_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">evh:TransformationServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i57ed24791b0544679bd4b966e3ad6122_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">evh:TransformationServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i5f219d5f567141958f242abd7cb9efea_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">evh:PlatformsAndOperationsServicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">evh:EvolentHealthServicesSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ia00ff8c8432c4957b4aef14482bbb1ca_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">evh:PlatformsAndOperationsServicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">evh:ClinicalSolutionsSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="iac839f1f097a424c99205c02214639ed_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:IntersegmentEliminationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">evh:PlatformsAndOperationsServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="id762405c08c64368824019f2ec90b437_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">evh:PlatformsAndOperationsServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ie91abff3ebd24744803f889983e86d61_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">evh:PlatformsAndOperationsServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i160f9ff72a8f428db94184c59ffafc47_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:IntersegmentEliminationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i6750aca4d3ec49afaa3b71a05c995e4e_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i2a43cc2e9054466a9f76a89472b3e611_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i6e3a96f5efe64f78b6f207c1f9ccaadf_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">evh:TransformationServicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">evh:EvolentHealthServicesSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i04129486c45c47ce9cc1fa8184882c54_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">evh:TransformationServicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">evh:ClinicalSolutionsSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i755b7b89c5764b53aede85f57d5ac9de_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:IntersegmentEliminationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">evh:TransformationServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i51b664fb7925436f8af4dc7608707edc_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">evh:TransformationServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i3c1ca3f52cf44a48a6eb1c640364e98d_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">evh:TransformationServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ief95fd4bd2a9417aa7c0a210852e8203_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">evh:PlatformsAndOperationsServicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">evh:EvolentHealthServicesSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i77015663db9441cd9c37ef54417768be_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">evh:PlatformsAndOperationsServicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">evh:ClinicalSolutionsSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="iccbcddcfb8ea4a728d495edce2f63324_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:IntersegmentEliminationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">evh:PlatformsAndOperationsServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i5f1fd6df16314fac900d170f76611052_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">evh:PlatformsAndOperationsServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i05ee1fcfda47445a8c730b607300bcd3_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">evh:PlatformsAndOperationsServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="iea90da90740c47ea8a58199dbc28a879_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:IntersegmentEliminationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="if1e0588b36354ec4ad0fe9d8b69a9b09_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i0de9d5a3b6224de8a58bd015afb42ce0_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i1b52f1300eeb41f7927ec4e356b5e849_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">evh:TransformationServicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">evh:EvolentHealthServicesSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i5a806984574d41c5a8b3b5e54ae8b937_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">evh:TransformationServicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">evh:ClinicalSolutionsSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ie7a1104b23254e04ac79b4e5e6c03ca1_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:IntersegmentEliminationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">evh:TransformationServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i8b652a3d61824fc79322c57e9476af89_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">evh:TransformationServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i5276f3d92d824c07b982e9971e0a15e8_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">evh:TransformationServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i0aa78e50814f49e9ad96c352399da780_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">evh:PlatformsAndOperationsServicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">evh:EvolentHealthServicesSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ic29edb3405614f9a9149c89d25008350_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">evh:PlatformsAndOperationsServicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">evh:ClinicalSolutionsSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i424e54d030c64f9c9b3a971c4a6c858d_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:IntersegmentEliminationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">evh:PlatformsAndOperationsServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i585a3b5e60524401a57bad2ad2ffe307_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">evh:PlatformsAndOperationsServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ifb609f7da9704b688626efcd5acd234c_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">evh:PlatformsAndOperationsServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="icb97bc4a90264c0aa3a7d497791a321c_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:IntersegmentEliminationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ice1bdb7b2e1c43bbbb3687fa61bb7bfc_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ie97138a13af04a0ebbec53523bd2a882_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i973a81e9b0924e4e86048dc6df6379d0_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i8b76d915d864443fbfe177d29bc9e4e4_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i035c62f748c14287b929adf98e0b2fbb_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i6d3bee5994474a229055f5b47133978b_D20201001-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i03844ec391854836b0d4437e624d231c_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="segment">
        <measure>evh:segment</measure>
    </unit>
    <unit id="unit">
        <measure>evh:unit</measure>
    </unit>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <unit id="reportingunit">
        <measure>evh:reportingUnit</measure>
    </unit>
    <dei:EntityCentralIndexKey
      contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM183L2ZyYWc6MzY5Y2U1M2FlMWViNGI5Yjg2NzUxYjA3NmU0MGNkYzYvdGFibGU6YzJhMDcxY2NhYWI1NDE5ZjhiYTFjZmRhNjMzYTdiYWYvdGFibGVyYW5nZTpjMmEwNzFjY2FhYjU0MTlmOGJhMWNmZGE2MzNhN2JhZl8xLTEtMS0xLTE3Nzc1_c2c90a9b-81c5-41d1-867c-97e2f3a6061b">0001628908</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag
      contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM183L2ZyYWc6MzY5Y2U1M2FlMWViNGI5Yjg2NzUxYjA3NmU0MGNkYzYvdGFibGU6YzJhMDcxY2NhYWI1NDE5ZjhiYTFjZmRhNjMzYTdiYWYvdGFibGVyYW5nZTpjMmEwNzFjY2FhYjU0MTlmOGJhMWNmZGE2MzNhN2JhZl8yLTEtMS0xLTE3Nzc1_0c4d1383-c945-45fd-81ff-d6d41b8b7f5b">false</dei:AmendmentFlag>
    <dei:DocumentFiscalYearFocus
      contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM183L2ZyYWc6MzY5Y2U1M2FlMWViNGI5Yjg2NzUxYjA3NmU0MGNkYzYvdGFibGU6YzJhMDcxY2NhYWI1NDE5ZjhiYTFjZmRhNjMzYTdiYWYvdGFibGVyYW5nZTpjMmEwNzFjY2FhYjU0MTlmOGJhMWNmZGE2MzNhN2JhZl80LTEtMS0xLTE3Nzc1_424c98f8-e3ae-4896-a6f5-fbca9820647b">2021</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus
      contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM183L2ZyYWc6MzY5Y2U1M2FlMWViNGI5Yjg2NzUxYjA3NmU0MGNkYzYvdGFibGU6YzJhMDcxY2NhYWI1NDE5ZjhiYTFjZmRhNjMzYTdiYWYvdGFibGVyYW5nZTpjMmEwNzFjY2FhYjU0MTlmOGJhMWNmZGE2MzNhN2JhZl81LTEtMS0xLTE3Nzc1_2e11bbc1-31bb-4b00-a977-5d7e3618921c">FY</dei:DocumentFiscalPeriodFocus>
    <us-gaap:AccountingStandardsUpdateExtensibleList
      contextRef="i3e21049ffc224cacb8134d73c9bb5b38_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yOC9mcmFnOjVjZWM5NGI5MzY4ODQyMTA5NWE3OThhZmFiNjljNDYwL3RhYmxlOjQzNDA0NmE1MTY4ODQzZDg5M2IxNTEyZjYxODkzYmU4L3RhYmxlcmFuZ2U6NDM0MDQ2YTUxNjg4NDNkODkzYjE1MTJmNjE4OTNiZThfMzMtMC0xLTEtMTc3NzU_a9886287-d75e-4db9-aa6f-bc3365fc9d17">http://fasb.org/us-gaap/2021-01-31#AccountingStandardsUpdate201613Member</us-gaap:AccountingStandardsUpdateExtensibleList>
    <us-gaap:AccountingStandardsUpdateExtensibleList
      contextRef="iddbf996a3b1a4aeda47f1e8169c69262_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM180Ni9mcmFnOjhkNTIzNGI1NjdkZjRiMThiNjM1NmFmN2Q4OWQ4MDE3L3RleHRyZWdpb246OGQ1MjM0YjU2N2RmNGIxOGI2MzU2YWY3ZDg5ZDgwMTdfMzI1Ng_c324734f-03c4-4b52-af23-6ac596334a4b">http://fasb.org/us-gaap/2021-01-31#AccountingStandardsUpdate201613Member</us-gaap:AccountingStandardsUpdateExtensibleList>
    <us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1
      contextRef="if14fbffaf3854b8c835ade571c3cc193_I20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM182MS9mcmFnOjAwMTYzM2MzZWYyYzQ1NWU4NGYzOGRkNTA0MGQ4Nzg4L3RhYmxlOjQzYWMxYWY0YWRhMDQ5YzRhMDQ0ZDJiNjlhZTk5ZWY4L3RhYmxlcmFuZ2U6NDNhYzFhZjRhZGEwNDljNGEwNDRkMmI2OWFlOTllZjhfMi0xLTEtMS0xNzc3NQ_18bc9a30-a2fc-4c2a-8643-5d59b08e0d5b">P12M</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1>
    <us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1
      contextRef="i8959430f12264863ae6656497c8cbe17_I20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM182MS9mcmFnOjAwMTYzM2MzZWYyYzQ1NWU4NGYzOGRkNTA0MGQ4Nzg4L3RhYmxlOjQzYWMxYWY0YWRhMDQ5YzRhMDQ0ZDJiNjlhZTk5ZWY4L3RhYmxlcmFuZ2U6NDNhYzFhZjRhZGEwNDljNGEwNDRkMmI2OWFlOTllZjhfMy0xLTEtMS0xNzc3NQ_a25881b4-0037-445a-a6b8-da595d527c9e">P12M</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1>
    <us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1
      contextRef="i25cd20be19e940cf94f2ba0eef170452_I20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM182MS9mcmFnOjAwMTYzM2MzZWYyYzQ1NWU4NGYzOGRkNTA0MGQ4Nzg4L3RhYmxlOjQzYWMxYWY0YWRhMDQ5YzRhMDQ0ZDJiNjlhZTk5ZWY4L3RhYmxlcmFuZ2U6NDNhYzFhZjRhZGEwNDljNGEwNDRkMmI2OWFlOTllZjhfNC0xLTEtMS0xNzc3NQ_e19f29ab-79b2-43f8-8e63-b93f1cb41c2e">P12M</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1>
    <us-gaap:DebtInstrumentConvertibleConversionRatio1
      contextRef="i085a0d0eb6ed47f3bad60b4c05e2a3bd_D20200801-20200831"
      decimals="7"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM183Ni9mcmFnOjUwOWMxYThiMjdmYzRhNGZhZDEwMmY3MmE1MDQ1Mjc3L3RleHRyZWdpb246NTA5YzFhOGIyN2ZjNGE0ZmFkMTAyZjcyYTUwNDUyNzdfNQ_7bccba39-41a6-4558-a42b-4bc189ef459a"
      unitRef="number">0.0548667</us-gaap:DebtInstrumentConvertibleConversionRatio1>
    <us-gaap:DebtInstrumentConvertibleConversionRatio1
      contextRef="i744bd02bcde94561abd08918f859a83e_D20181001-20181031"
      decimals="7"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM183Ni9mcmFnOjUwOWMxYThiMjdmYzRhNGZhZDEwMmY3MmE1MDQ1Mjc3L3RleHRyZWdpb246NTA5YzFhOGIyN2ZjNGE0ZmFkMTAyZjcyYTUwNDUyNzdfMjE1_1d922635-0798-4711-ad46-33653e9d05d9"
      unitRef="number">0.0299135</us-gaap:DebtInstrumentConvertibleConversionRatio1>
    <us-gaap:DebtInstrumentConvertibleConversionRatio1
      contextRef="i8391049cde8843bea2025728f80db282_D20161201-20161231"
      decimals="7"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM183Ni9mcmFnOjUwOWMxYThiMjdmYzRhNGZhZDEwMmY3MmE1MDQ1Mjc3L3RleHRyZWdpb246NTA5YzFhOGIyN2ZjNGE0ZmFkMTAyZjcyYTUwNDUyNzdfMzkw_9ba0435e-defd-46f5-9c2b-98d60c17b71b"
      unitRef="number">0.0416082</us-gaap:DebtInstrumentConvertibleConversionRatio1>
    <evh:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsStockPriceTriggerConsecutiveTerm
      contextRef="i0b413462d6244d118fb2d0156e9029e7_D20160301-20160331"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185MS9mcmFnOjlmMTJhYjBlYWNjMTQ1OTU5ZDhhNjcyY2JmZjdkYjZkL3RleHRyZWdpb246OWYxMmFiMGVhY2MxNDU5NTlkOGE2NzJjYmZmN2RiNmRfNTEyNA_e4d931ff-6eba-4d04-bddc-9b3b4429017b">P90D</evh:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsStockPriceTriggerConsecutiveTerm>
    <evh:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsStockPriceTriggerConsecutiveTerm
      contextRef="ib4a9daf686984e69b26b36bbc92ff33d_D20160301-20160331"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185MS9mcmFnOjlmMTJhYjBlYWNjMTQ1OTU5ZDhhNjcyY2JmZjdkYjZkL3RleHRyZWdpb246OWYxMmFiMGVhY2MxNDU5NTlkOGE2NzJjYmZmN2RiNmRfNTMzOA_19dbae44-014f-4a37-a3b0-0e16f19819c4">P90D</evh:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsStockPriceTriggerConsecutiveTerm>
    <evh:EarningsBeforeInterestTaxesDepreciationAndAmortizationGoalPeriod
      contextRef="i4902163dcfd64aac93ef32c5d4cb51e2_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185MS9mcmFnOjlmMTJhYjBlYWNjMTQ1OTU5ZDhhNjcyY2JmZjdkYjZkL3RleHRyZWdpb246OWYxMmFiMGVhY2MxNDU5NTlkOGE2NzJjYmZmN2RiNmRfMzI5ODUzNDkxMDU4Mg_a8edff10-eb5c-4745-9477-bbe219e0ae2c">P2Y</evh:EarningsBeforeInterestTaxesDepreciationAndAmortizationGoalPeriod>
    <evh:EarningsBeforeInterestTaxesDepreciationAndAmortizationGoalPeriod
      contextRef="i4902163dcfd64aac93ef32c5d4cb51e2_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185MS9mcmFnOjlmMTJhYjBlYWNjMTQ1OTU5ZDhhNjcyY2JmZjdkYjZkL3RleHRyZWdpb246OWYxMmFiMGVhY2MxNDU5NTlkOGE2NzJjYmZmN2RiNmRfMzI5ODUzNDkxMDYwMA_5c625e05-1161-4caa-b418-357677b81681">P2Y</evh:EarningsBeforeInterestTaxesDepreciationAndAmortizationGoalPeriod>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="i4339469160624451b2787c8a94183aef_D20160301-20160331"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185NC9mcmFnOjQ0NzYzZTZmODRkZjRiOGE5OTNhMjMxZGYyZGE5NzE4L3RhYmxlOmRhYTQ3NzY5NjMyNzQ3M2E4ZWQxYmI0YjU3N2FhY2VlL3RhYmxlcmFuZ2U6ZGFhNDc3Njk2MzI3NDczYThlZDFiYjRiNTc3YWFjZWVfMS0xLTEtMS0xNzc3NQ_5540e65b-e091-4e8f-9fab-5d4432c77071"
      unitRef="number">0.3333</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="i0b413462d6244d118fb2d0156e9029e7_D20160301-20160331"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185NC9mcmFnOjQ0NzYzZTZmODRkZjRiOGE5OTNhMjMxZGYyZGE5NzE4L3RhYmxlOmRhYTQ3NzY5NjMyNzQ3M2E4ZWQxYmI0YjU3N2FhY2VlL3RhYmxlcmFuZ2U6ZGFhNDc3Njk2MzI3NDczYThlZDFiYjRiNTc3YWFjZWVfMi0xLTEtMS0xNzc3NQ_cc65a794-25f3-469b-b497-065b8ba103ae"
      unitRef="number">0.3333</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="ib4a9daf686984e69b26b36bbc92ff33d_D20160301-20160331"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185NC9mcmFnOjQ0NzYzZTZmODRkZjRiOGE5OTNhMjMxZGYyZGE5NzE4L3RhYmxlOmRhYTQ3NzY5NjMyNzQ3M2E4ZWQxYmI0YjU3N2FhY2VlL3RhYmxlcmFuZ2U6ZGFhNDc3Njk2MzI3NDczYThlZDFiYjRiNTc3YWFjZWVfMy0xLTEtMS0xNzc3NQ_d63520d4-a1a0-4ba2-b826-8f2d68dfb036"
      unitRef="number">0.3333</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <dei:DocumentType
      contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM180L2ZyYWc6OTQ1NzYzOGM4N2Q2NGFkYThlMmYzZGZkMmMwNzJiYmUvdGV4dHJlZ2lvbjo5NDU3NjM4Yzg3ZDY0YWRhOGUyZjNkZmQyYzA3MmJiZV8zNzUz_6e89b1d6-7d34-46a6-aadb-178834c248fc">10-K</dei:DocumentType>
    <dei:DocumentAnnualReport
      contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM180L2ZyYWc6OTQ1NzYzOGM4N2Q2NGFkYThlMmYzZGZkMmMwNzJiYmUvdGV4dHJlZ2lvbjo5NDU3NjM4Yzg3ZDY0YWRhOGUyZjNkZmQyYzA3MmJiZV8zNzY5_90b253c0-0e6e-4508-97f0-85417635c227">true</dei:DocumentAnnualReport>
    <dei:DocumentPeriodEndDate
      contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM180L2ZyYWc6OTQ1NzYzOGM4N2Q2NGFkYThlMmYzZGZkMmMwNzJiYmUvdGV4dHJlZ2lvbjo5NDU3NjM4Yzg3ZDY0YWRhOGUyZjNkZmQyYzA3MmJiZV8xOTY_4cfa1ff6-b9d5-422c-a35f-9a16c9aa6cbe">2021-12-31</dei:DocumentPeriodEndDate>
    <dei:CurrentFiscalYearEndDate
      contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM180L2ZyYWc6OTQ1NzYzOGM4N2Q2NGFkYThlMmYzZGZkMmMwNzJiYmUvdGV4dHJlZ2lvbjo5NDU3NjM4Yzg3ZDY0YWRhOGUyZjNkZmQyYzA3MmJiZV8xOTY_ae3577d8-b587-4c78-8d2c-fe86c7d45ed8">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentTransitionReport
      contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM180L2ZyYWc6OTQ1NzYzOGM4N2Q2NGFkYThlMmYzZGZkMmMwNzJiYmUvdGV4dHJlZ2lvbjo5NDU3NjM4Yzg3ZDY0YWRhOGUyZjNkZmQyYzA3MmJiZV8zNzY1_a5a76b5a-d053-4715-b5fa-3713a24bf667">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM180L2ZyYWc6OTQ1NzYzOGM4N2Q2NGFkYThlMmYzZGZkMmMwNzJiYmUvdGV4dHJlZ2lvbjo5NDU3NjM4Yzg3ZDY0YWRhOGUyZjNkZmQyYzA3MmJiZV8zNzYw_06815ecc-200a-42fa-b918-1d22f26ef7d6">001-37415</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM180L2ZyYWc6OTQ1NzYzOGM4N2Q2NGFkYThlMmYzZGZkMmMwNzJiYmUvdGV4dHJlZ2lvbjo5NDU3NjM4Yzg3ZDY0YWRhOGUyZjNkZmQyYzA3MmJiZV8zNzYx_a84c5af3-1ee7-4da4-b967-0790014ffab7">Evolent Health, Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM180L2ZyYWc6OTQ1NzYzOGM4N2Q2NGFkYThlMmYzZGZkMmMwNzJiYmUvdGFibGU6NjcyYTc3Mjc1M2JkNDA5OWI2ZGMyNDk4ZDE2NmRmYjEvdGFibGVyYW5nZTo2NzJhNzcyNzUzYmQ0MDk5YjZkYzI0OThkMTY2ZGZiMV8wLTAtMS0xLTE3Nzc1_1675a454-48fe-4bb8-94a4-7ad9993c19fd">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM180L2ZyYWc6OTQ1NzYzOGM4N2Q2NGFkYThlMmYzZGZkMmMwNzJiYmUvdGFibGU6NjcyYTc3Mjc1M2JkNDA5OWI2ZGMyNDk4ZDE2NmRmYjEvdGFibGVyYW5nZTo2NzJhNzcyNzUzYmQ0MDk5YjZkYzI0OThkMTY2ZGZiMV8wLTgtMS0xLTE3Nzc1_1e877802-bcea-4baf-8eb7-172101c52883">32-0454912</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM180L2ZyYWc6OTQ1NzYzOGM4N2Q2NGFkYThlMmYzZGZkMmMwNzJiYmUvdGFibGU6NjcyYTc3Mjc1M2JkNDA5OWI2ZGMyNDk4ZDE2NmRmYjEvdGFibGVyYW5nZTo2NzJhNzcyNzUzYmQ0MDk5YjZkYzI0OThkMTY2ZGZiMV8zLTAtMS0xLTE3Nzc1_d8a01fcb-ff0d-45da-89a3-55cb04f4bcc9">800 N. Glebe Road</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2
      contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM180L2ZyYWc6OTQ1NzYzOGM4N2Q2NGFkYThlMmYzZGZkMmMwNzJiYmUvdGFibGU6NjcyYTc3Mjc1M2JkNDA5OWI2ZGMyNDk4ZDE2NmRmYjEvdGFibGVyYW5nZTo2NzJhNzcyNzUzYmQ0MDk5YjZkYzI0OThkMTY2ZGZiMV8zLTItMS0xLTE3Nzc1_57ecba0f-9ed1-48f9-867c-e93279162d9f">Suite 500</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown
      contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM180L2ZyYWc6OTQ1NzYzOGM4N2Q2NGFkYThlMmYzZGZkMmMwNzJiYmUvdGFibGU6NjcyYTc3Mjc1M2JkNDA5OWI2ZGMyNDk4ZDE2NmRmYjEvdGFibGVyYW5nZTo2NzJhNzcyNzUzYmQ0MDk5YjZkYzI0OThkMTY2ZGZiMV8zLTQtMS0xLTE3Nzc1_038ae9c0-ac0b-4620-87f7-c92f8619b1e1">Arlington</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM180L2ZyYWc6OTQ1NzYzOGM4N2Q2NGFkYThlMmYzZGZkMmMwNzJiYmUvdGFibGU6NjcyYTc3Mjc1M2JkNDA5OWI2ZGMyNDk4ZDE2NmRmYjEvdGFibGVyYW5nZTo2NzJhNzcyNzUzYmQ0MDk5YjZkYzI0OThkMTY2ZGZiMV8zLTYtMS0xLTE3Nzc1_8fbbe55e-1cbc-4f7e-aef3-861b8ad570bb">VA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM180L2ZyYWc6OTQ1NzYzOGM4N2Q2NGFkYThlMmYzZGZkMmMwNzJiYmUvdGFibGU6NjcyYTc3Mjc1M2JkNDA5OWI2ZGMyNDk4ZDE2NmRmYjEvdGFibGVyYW5nZTo2NzJhNzcyNzUzYmQ0MDk5YjZkYzI0OThkMTY2ZGZiMV8zLTgtMS0xLTE3Nzc1_9ab09a36-9991-4284-8b18-7087cde731c7">22203</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM180L2ZyYWc6OTQ1NzYzOGM4N2Q2NGFkYThlMmYzZGZkMmMwNzJiYmUvdGV4dHJlZ2lvbjo5NDU3NjM4Yzg3ZDY0YWRhOGUyZjNkZmQyYzA3MmJiZV8zNzY2_fa8eedb2-169a-4d20-8893-647a6bee13e8">571</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM180L2ZyYWc6OTQ1NzYzOGM4N2Q2NGFkYThlMmYzZGZkMmMwNzJiYmUvdGV4dHJlZ2lvbjo5NDU3NjM4Yzg3ZDY0YWRhOGUyZjNkZmQyYzA3MmJiZV8zNzU0_b1c1a395-a44d-46cd-93cf-281d5525e51a">389-6000</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM180L2ZyYWc6OTQ1NzYzOGM4N2Q2NGFkYThlMmYzZGZkMmMwNzJiYmUvdGFibGU6ZWRjNTdiNTljNDRiNDQ0ZmE5ZGNhNmE0MmY1OThiNTMvdGFibGVyYW5nZTplZGM1N2I1OWM0NGI0NDRmYTlkY2E2YTQyZjU5OGI1M18xLTAtMS0xLTE3Nzc1_e82c1638-de12-45f9-bb1b-4c0f111f7eeb">Class A Common Stock of Evolent Health, Inc., par value $0.01 per share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM180L2ZyYWc6OTQ1NzYzOGM4N2Q2NGFkYThlMmYzZGZkMmMwNzJiYmUvdGFibGU6ZWRjNTdiNTljNDRiNDQ0ZmE5ZGNhNmE0MmY1OThiNTMvdGFibGVyYW5nZTplZGM1N2I1OWM0NGI0NDRmYTlkY2E2YTQyZjU5OGI1M18xLTEtMS0xLTE3Nzc1_75b8a9a7-9c7f-48ae-8b30-5d484ac70a61">EVH</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM180L2ZyYWc6OTQ1NzYzOGM4N2Q2NGFkYThlMmYzZGZkMmMwNzJiYmUvdGFibGU6ZWRjNTdiNTljNDRiNDQ0ZmE5ZGNhNmE0MmY1OThiNTMvdGFibGVyYW5nZTplZGM1N2I1OWM0NGI0NDRmYTlkY2E2YTQyZjU5OGI1M18xLTItMS0xLTE3Nzc1_46ca054f-b912-4427-ac1b-d5421465f393">NYSE</dei:SecurityExchangeName>
    <dei:EntityWellKnownSeasonedIssuer
      contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM180L2ZyYWc6OTQ1NzYzOGM4N2Q2NGFkYThlMmYzZGZkMmMwNzJiYmUvdGV4dHJlZ2lvbjo5NDU3NjM4Yzg3ZDY0YWRhOGUyZjNkZmQyYzA3MmJiZV8zNzY3_1a596c36-4309-4adb-b5c1-7d981d006d46">Yes</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers
      contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM180L2ZyYWc6OTQ1NzYzOGM4N2Q2NGFkYThlMmYzZGZkMmMwNzJiYmUvdGV4dHJlZ2lvbjo5NDU3NjM4Yzg3ZDY0YWRhOGUyZjNkZmQyYzA3MmJiZV8zNzU1_2528efb1-a19f-4ed6-b163-31c43b8c805c">No</dei:EntityVoluntaryFilers>
    <dei:EntityCurrentReportingStatus
      contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM180L2ZyYWc6OTQ1NzYzOGM4N2Q2NGFkYThlMmYzZGZkMmMwNzJiYmUvdGV4dHJlZ2lvbjo5NDU3NjM4Yzg3ZDY0YWRhOGUyZjNkZmQyYzA3MmJiZV8zNzU2_ebe71ba9-c002-44d8-81ef-4981247c98f6">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM180L2ZyYWc6OTQ1NzYzOGM4N2Q2NGFkYThlMmYzZGZkMmMwNzJiYmUvdGV4dHJlZ2lvbjo5NDU3NjM4Yzg3ZDY0YWRhOGUyZjNkZmQyYzA3MmJiZV8zNzcw_2f47ccfe-893f-47dd-ba1c-57dee85c1998">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM180L2ZyYWc6OTQ1NzYzOGM4N2Q2NGFkYThlMmYzZGZkMmMwNzJiYmUvdGV4dHJlZ2lvbjo5NDU3NjM4Yzg3ZDY0YWRhOGUyZjNkZmQyYzA3MmJiZV8zNzU3_12ee84bf-2cd1-4e18-b9c3-90b4fa776bb2">Large Accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM180L2ZyYWc6OTQ1NzYzOGM4N2Q2NGFkYThlMmYzZGZkMmMwNzJiYmUvdGV4dHJlZ2lvbjo5NDU3NjM4Yzg3ZDY0YWRhOGUyZjNkZmQyYzA3MmJiZV8zNzYy_0c3143bd-5310-49ec-9647-8948fd4f54b9">false</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM180L2ZyYWc6OTQ1NzYzOGM4N2Q2NGFkYThlMmYzZGZkMmMwNzJiYmUvdGV4dHJlZ2lvbjo5NDU3NjM4Yzg3ZDY0YWRhOGUyZjNkZmQyYzA3MmJiZV8zNzU4_f720f2cf-f883-41da-8fc4-1761f7d04e46">false</dei:EntityEmergingGrowthCompany>
    <dei:IcfrAuditorAttestationFlag
      contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM180L2ZyYWc6OTQ1NzYzOGM4N2Q2NGFkYThlMmYzZGZkMmMwNzJiYmUvdGV4dHJlZ2lvbjo5NDU3NjM4Yzg3ZDY0YWRhOGUyZjNkZmQyYzA3MmJiZV8zNzU5_533f6a14-61cd-4c8b-b954-c6be1e097ee1">true</dei:IcfrAuditorAttestationFlag>
    <dei:EntityShellCompany
      contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM180L2ZyYWc6OTQ1NzYzOGM4N2Q2NGFkYThlMmYzZGZkMmMwNzJiYmUvdGV4dHJlZ2lvbjo5NDU3NjM4Yzg3ZDY0YWRhOGUyZjNkZmQyYzA3MmJiZV8zNzY4_3eeb1f50-0436-428a-8394-93fb1ed96184">false</dei:EntityShellCompany>
    <dei:EntityPublicFloat
      contextRef="i7db6c6f189754c32a62fbe5b49259ed8_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM180L2ZyYWc6OTQ1NzYzOGM4N2Q2NGFkYThlMmYzZGZkMmMwNzJiYmUvdGV4dHJlZ2lvbjo5NDU3NjM4Yzg3ZDY0YWRhOGUyZjNkZmQyYzA3MmJiZV8zMjM2_85563606-c8c3-4e73-b86c-c978c57ca85c"
      unitRef="usd">1600000000</dei:EntityPublicFloat>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="ibc44c5b5f9be42eaa992bbd65360561b_I20220218"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM180L2ZyYWc6OTQ1NzYzOGM4N2Q2NGFkYThlMmYzZGZkMmMwNzJiYmUvdGV4dHJlZ2lvbjo5NDU3NjM4Yzg3ZDY0YWRhOGUyZjNkZmQyYzA3MmJiZV8zMjYz_c5e08724-5f7c-471b-83d6-bcb59c719ab0"
      unitRef="shares">90827306</dei:EntityCommonStockSharesOutstanding>
    <dei:DocumentsIncorporatedByReferenceTextBlock
      contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM180L2ZyYWc6OTQ1NzYzOGM4N2Q2NGFkYThlMmYzZGZkMmMwNzJiYmUvdGV4dHJlZ2lvbjo5NDU3NjM4Yzg3ZDY0YWRhOGUyZjNkZmQyYzA3MmJiZV8zNzYz_a24ff7cd-4afc-4dcf-b411-99f076955a76">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;Selected portions of the Proxy Statement for the Annual Meeting of Shareholders, scheduled for&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; June&#160;9, 2022, hav&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;e been incorporated by reference into Part III of this Form 10-K to the extent stated herein. Such proxy statement will be filed with the Securities and Exchange Commission within 120 days of the registrant&#x2019;s fiscal year ended December&#160;31, 2021.&lt;/span&gt;</dei:DocumentsIncorporatedByReferenceTextBlock>
    <dei:AuditorFirmId
      contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xOS9mcmFnOjk5ZDUzNzAxOWNjZTRjMjk4NDQ2M2U4OGI0ZWFlZThkL3RhYmxlOjBjOWI5YTY5OThmYTQ3NWE5MjgwYzUzN2Y1ZGZkYmYzL3RhYmxlcmFuZ2U6MGM5YjlhNjk5OGZhNDc1YTkyODBjNTM3ZjVkZmRiZjNfMS0wLTEtMS0zNTg3OS90ZXh0cmVnaW9uOjc1YmQ4OTk5MDU0OTQ3MTA5NDNiM2ViMGVjOWI0ZTE4XzIxOTkwMjMyNTU4MDU_07bc8f31-6c65-43f4-917d-4687f19c166d">34</dei:AuditorFirmId>
    <dei:AuditorName
      contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yNDEvZnJhZzo1MjI4ODI3YjVkY2Q0Mjg2YjA2YjYxMWNhNjQ4ZTdkYS90ZXh0cmVnaW9uOjUyMjg4MjdiNWRjZDQyODZiMDZiNjExY2E2NDhlN2RhXzMyOTg1MzQ5Mzg3OTg_a33c1eef-a7c3-431b-b840-b324013b0bc7">Deloitte &amp; Touche LLP</dei:AuditorName>
    <dei:AuditorLocation
      contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yNDEvZnJhZzo1MjI4ODI3YjVkY2Q0Mjg2YjA2YjYxMWNhNjQ4ZTdkYS90ZXh0cmVnaW9uOjUyMjg4MjdiNWRjZDQyODZiMDZiNjExY2E2NDhlN2RhXzMyOTg1MzQ5Mzg3OTk_bf12f897-ae6e-4713-b7ec-b573589cc5de">McLean, Virginia</dei:AuditorLocation>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i8daff60be410426d8f7bd49343c1ec0c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yMi9mcmFnOjJiM2Y4ODE3NTVhYTQ5ODk5MzI2NThlODM2YmIyNGI2L3RhYmxlOjQ1MmFlOGFkMjMxZjQ4MWQ4Njg3MGU5MDYxNWI3NTkxL3RhYmxlcmFuZ2U6NDUyYWU4YWQyMzFmNDgxZDg2ODcwZTkwNjE1Yjc1OTFfMy0xLTEtMS0xNzc3NQ_9fd365f1-934d-43ea-b134-3f32d27e9505"
      unitRef="usd">266280000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="ibc0c0c2b8dc04c5698ca0577a54b2e03_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yMi9mcmFnOjJiM2Y4ODE3NTVhYTQ5ODk5MzI2NThlODM2YmIyNGI2L3RhYmxlOjQ1MmFlOGFkMjMxZjQ4MWQ4Njg3MGU5MDYxNWI3NTkxL3RhYmxlcmFuZ2U6NDUyYWU4YWQyMzFmNDgxZDg2ODcwZTkwNjE1Yjc1OTFfMy0zLTEtMS0xNzc3NQ_e64c5520-cb42-49eb-b96e-daf88adbe308"
      unitRef="usd">319002000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCashAndInvestmentsCurrent
      contextRef="i8daff60be410426d8f7bd49343c1ec0c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yMi9mcmFnOjJiM2Y4ODE3NTVhYTQ5ODk5MzI2NThlODM2YmIyNGI2L3RhYmxlOjQ1MmFlOGFkMjMxZjQ4MWQ4Njg3MGU5MDYxNWI3NTkxL3RhYmxlcmFuZ2U6NDUyYWU4YWQyMzFmNDgxZDg2ODcwZTkwNjE1Yjc1OTFfNC0xLTEtMS0xNzc3NQ_b6a4a6c5-78fd-439f-83a3-08492feb5ba8"
      unitRef="usd">75685000</us-gaap:RestrictedCashAndInvestmentsCurrent>
    <us-gaap:RestrictedCashAndInvestmentsCurrent
      contextRef="ibc0c0c2b8dc04c5698ca0577a54b2e03_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yMi9mcmFnOjJiM2Y4ODE3NTVhYTQ5ODk5MzI2NThlODM2YmIyNGI2L3RhYmxlOjQ1MmFlOGFkMjMxZjQ4MWQ4Njg3MGU5MDYxNWI3NTkxL3RhYmxlcmFuZ2U6NDUyYWU4YWQyMzFmNDgxZDg2ODcwZTkwNjE1Yjc1OTFfNC0zLTEtMS0xNzc3NQ_f0652a2c-16e5-46e3-92fa-70da1cdc5238"
      unitRef="usd">14374000</us-gaap:RestrictedCashAndInvestmentsCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="i8daff60be410426d8f7bd49343c1ec0c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yMi9mcmFnOjJiM2Y4ODE3NTVhYTQ5ODk5MzI2NThlODM2YmIyNGI2L3RhYmxlOjQ1MmFlOGFkMjMxZjQ4MWQ4Njg3MGU5MDYxNWI3NTkxL3RhYmxlcmFuZ2U6NDUyYWU4YWQyMzFmNDgxZDg2ODcwZTkwNjE1Yjc1OTFfNS0xLTEtMS0xNzc3NQ_f8d025b8-3255-478d-83d3-8aecd42fa11b"
      unitRef="usd">130604000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="ibc0c0c2b8dc04c5698ca0577a54b2e03_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yMi9mcmFnOjJiM2Y4ODE3NTVhYTQ5ODk5MzI2NThlODM2YmIyNGI2L3RhYmxlOjQ1MmFlOGFkMjMxZjQ4MWQ4Njg3MGU5MDYxNWI3NTkxL3RhYmxlcmFuZ2U6NDUyYWU4YWQyMzFmNDgxZDg2ODcwZTkwNjE1Yjc1OTFfNS0zLTEtMS0xNzc3NQ_1aab1e38-d520-4d8e-a626-6f7e2520afce"
      unitRef="usd">124064000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="i8daff60be410426d8f7bd49343c1ec0c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yMi9mcmFnOjJiM2Y4ODE3NTVhYTQ5ODk5MzI2NThlODM2YmIyNGI2L3RhYmxlOjQ1MmFlOGFkMjMxZjQ4MWQ4Njg3MGU5MDYxNWI3NTkxL3RhYmxlcmFuZ2U6NDUyYWU4YWQyMzFmNDgxZDg2ODcwZTkwNjE1Yjc1OTFfNi0xLTEtMS0xNzc3NQ_469a4400-c2b4-4cf4-8445-c96411a59e90"
      unitRef="usd">51391000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="ibc0c0c2b8dc04c5698ca0577a54b2e03_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yMi9mcmFnOjJiM2Y4ODE3NTVhYTQ5ODk5MzI2NThlODM2YmIyNGI2L3RhYmxlOjQ1MmFlOGFkMjMxZjQ4MWQ4Njg3MGU5MDYxNWI3NTkxL3RhYmxlcmFuZ2U6NDUyYWU4YWQyMzFmNDgxZDg2ODcwZTkwNjE1Yjc1OTFfNi0zLTEtMS0xNzc3NQ_ac001ac4-a8c8-46b0-876f-5bb35a584888"
      unitRef="usd">56295000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent
      contextRef="i8daff60be410426d8f7bd49343c1ec0c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yMi9mcmFnOjJiM2Y4ODE3NTVhYTQ5ODk5MzI2NThlODM2YmIyNGI2L3RhYmxlOjQ1MmFlOGFkMjMxZjQ4MWQ4Njg3MGU5MDYxNWI3NTkxL3RhYmxlcmFuZ2U6NDUyYWU4YWQyMzFmNDgxZDg2ODcwZTkwNjE1Yjc1OTFfNy0xLTEtMS0xNzc3NQ_4fc41f59-a447-4c53-8774-15338c0f0f74"
      unitRef="usd">0</us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent>
    <us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent
      contextRef="ibc0c0c2b8dc04c5698ca0577a54b2e03_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yMi9mcmFnOjJiM2Y4ODE3NTVhYTQ5ODk5MzI2NThlODM2YmIyNGI2L3RhYmxlOjQ1MmFlOGFkMjMxZjQ4MWQ4Njg3MGU5MDYxNWI3NTkxL3RhYmxlcmFuZ2U6NDUyYWU4YWQyMzFmNDgxZDg2ODcwZTkwNjE1Yjc1OTFfNy0zLTEtMS0xNzc3NQ_4b42b99f-52bc-4694-bd5e-33dbc281a7da"
      unitRef="usd">33914000</us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent>
    <us-gaap:AssetsCurrent
      contextRef="i8daff60be410426d8f7bd49343c1ec0c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yMi9mcmFnOjJiM2Y4ODE3NTVhYTQ5ODk5MzI2NThlODM2YmIyNGI2L3RhYmxlOjQ1MmFlOGFkMjMxZjQ4MWQ4Njg3MGU5MDYxNWI3NTkxL3RhYmxlcmFuZ2U6NDUyYWU4YWQyMzFmNDgxZDg2ODcwZTkwNjE1Yjc1OTFfOC0xLTEtMS0xNzc3NQ_d299786d-12af-42b6-bdb2-44f9b5c2cf6a"
      unitRef="usd">523960000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="ibc0c0c2b8dc04c5698ca0577a54b2e03_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yMi9mcmFnOjJiM2Y4ODE3NTVhYTQ5ODk5MzI2NThlODM2YmIyNGI2L3RhYmxlOjQ1MmFlOGFkMjMxZjQ4MWQ4Njg3MGU5MDYxNWI3NTkxL3RhYmxlcmFuZ2U6NDUyYWU4YWQyMzFmNDgxZDg2ODcwZTkwNjE1Yjc1OTFfOC0zLTEtMS0xNzc3NQ_21a9d3d3-e398-4311-9ade-11ce49d81ab0"
      unitRef="usd">547649000</us-gaap:AssetsCurrent>
    <us-gaap:RestrictedCashAndInvestmentsNoncurrent
      contextRef="i8daff60be410426d8f7bd49343c1ec0c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yMi9mcmFnOjJiM2Y4ODE3NTVhYTQ5ODk5MzI2NThlODM2YmIyNGI2L3RhYmxlOjQ1MmFlOGFkMjMxZjQ4MWQ4Njg3MGU5MDYxNWI3NTkxL3RhYmxlcmFuZ2U6NDUyYWU4YWQyMzFmNDgxZDg2ODcwZTkwNjE1Yjc1OTFfOS0xLTEtMS0xNzc3NQ_618c6504-c568-4188-984b-505490148702"
      unitRef="usd">12977000</us-gaap:RestrictedCashAndInvestmentsNoncurrent>
    <us-gaap:RestrictedCashAndInvestmentsNoncurrent
      contextRef="ibc0c0c2b8dc04c5698ca0577a54b2e03_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yMi9mcmFnOjJiM2Y4ODE3NTVhYTQ5ODk5MzI2NThlODM2YmIyNGI2L3RhYmxlOjQ1MmFlOGFkMjMxZjQ4MWQ4Njg3MGU5MDYxNWI3NTkxL3RhYmxlcmFuZ2U6NDUyYWU4YWQyMzFmNDgxZDg2ODcwZTkwNjE1Yjc1OTFfOS0zLTEtMS0xNzc3NQ_b3f97063-3040-4aac-bd50-850696b9dce4"
      unitRef="usd">6654000</us-gaap:RestrictedCashAndInvestmentsNoncurrent>
    <us-gaap:InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures
      contextRef="i8daff60be410426d8f7bd49343c1ec0c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yMi9mcmFnOjJiM2Y4ODE3NTVhYTQ5ODk5MzI2NThlODM2YmIyNGI2L3RhYmxlOjQ1MmFlOGFkMjMxZjQ4MWQ4Njg3MGU5MDYxNWI3NTkxL3RhYmxlcmFuZ2U6NDUyYWU4YWQyMzFmNDgxZDg2ODcwZTkwNjE1Yjc1OTFfMTAtMS0xLTEtMTc3NzU_d29af860-00d5-4a5d-9262-6c381a5f521f"
      unitRef="usd">5458000</us-gaap:InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures>
    <us-gaap:InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures
      contextRef="ibc0c0c2b8dc04c5698ca0577a54b2e03_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yMi9mcmFnOjJiM2Y4ODE3NTVhYTQ5ODk5MzI2NThlODM2YmIyNGI2L3RhYmxlOjQ1MmFlOGFkMjMxZjQ4MWQ4Njg3MGU5MDYxNWI3NTkxL3RhYmxlcmFuZ2U6NDUyYWU4YWQyMzFmNDgxZDg2ODcwZTkwNjE1Yjc1OTFfMTAtMy0xLTEtMTc3NzU_1ea5ab44-5315-446c-9df3-ebd90f777e53"
      unitRef="usd">6498000</us-gaap:InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i8daff60be410426d8f7bd49343c1ec0c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yMi9mcmFnOjJiM2Y4ODE3NTVhYTQ5ODk5MzI2NThlODM2YmIyNGI2L3RhYmxlOjQ1MmFlOGFkMjMxZjQ4MWQ4Njg3MGU5MDYxNWI3NTkxL3RhYmxlcmFuZ2U6NDUyYWU4YWQyMzFmNDgxZDg2ODcwZTkwNjE1Yjc1OTFfMTEtMS0xLTEtMTc3NzU_886389cf-fdc3-401b-b1b0-ef5448561f70"
      unitRef="usd">81365000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="ibc0c0c2b8dc04c5698ca0577a54b2e03_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yMi9mcmFnOjJiM2Y4ODE3NTVhYTQ5ODk5MzI2NThlODM2YmIyNGI2L3RhYmxlOjQ1MmFlOGFkMjMxZjQ4MWQ4Njg3MGU5MDYxNWI3NTkxL3RhYmxlcmFuZ2U6NDUyYWU4YWQyMzFmNDgxZDg2ODcwZTkwNjE1Yjc1OTFfMTEtMy0xLTEtMTc3NzU_8d125e24-2593-4bb6-b42d-825d73239376"
      unitRef="usd">86240000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i8daff60be410426d8f7bd49343c1ec0c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yMi9mcmFnOjJiM2Y4ODE3NTVhYTQ5ODk5MzI2NThlODM2YmIyNGI2L3RhYmxlOjQ1MmFlOGFkMjMxZjQ4MWQ4Njg3MGU5MDYxNWI3NTkxL3RhYmxlcmFuZ2U6NDUyYWU4YWQyMzFmNDgxZDg2ODcwZTkwNjE1Yjc1OTFfMTItMS0xLTEtMTc3NzU_bcb38a9a-b016-4ecf-b0f0-cceffc4cc9e8"
      unitRef="usd">50203000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="ibc0c0c2b8dc04c5698ca0577a54b2e03_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yMi9mcmFnOjJiM2Y4ODE3NTVhYTQ5ODk5MzI2NThlODM2YmIyNGI2L3RhYmxlOjQ1MmFlOGFkMjMxZjQ4MWQ4Njg3MGU5MDYxNWI3NTkxL3RhYmxlcmFuZ2U6NDUyYWU4YWQyMzFmNDgxZDg2ODcwZTkwNjE1Yjc1OTFfMTItMy0xLTEtMTc3NzU_ccf5bef2-7d83-4e03-a304-56cd52a3fec5"
      unitRef="usd">57799000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:PrepaidExpenseAndOtherAssetsNoncurrent
      contextRef="i8daff60be410426d8f7bd49343c1ec0c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yMi9mcmFnOjJiM2Y4ODE3NTVhYTQ5ODk5MzI2NThlODM2YmIyNGI2L3RhYmxlOjQ1MmFlOGFkMjMxZjQ4MWQ4Njg3MGU5MDYxNWI3NTkxL3RhYmxlcmFuZ2U6NDUyYWU4YWQyMzFmNDgxZDg2ODcwZTkwNjE1Yjc1OTFfMTMtMS0xLTEtMTc3NzU_00d8e9df-b51a-4134-ae28-46cb41ed669a"
      unitRef="usd">6790000</us-gaap:PrepaidExpenseAndOtherAssetsNoncurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsNoncurrent
      contextRef="ibc0c0c2b8dc04c5698ca0577a54b2e03_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yMi9mcmFnOjJiM2Y4ODE3NTVhYTQ5ODk5MzI2NThlODM2YmIyNGI2L3RhYmxlOjQ1MmFlOGFkMjMxZjQ4MWQ4Njg3MGU5MDYxNWI3NTkxL3RhYmxlcmFuZ2U6NDUyYWU4YWQyMzFmNDgxZDg2ODcwZTkwNjE1Yjc1OTFfMTMtMy0xLTEtMTc3NzU_46840606-41ef-48ee-84bf-1505ddaef468"
      unitRef="usd">5773000</us-gaap:PrepaidExpenseAndOtherAssetsNoncurrent>
    <us-gaap:CapitalizedContractCostNetNoncurrent
      contextRef="i8daff60be410426d8f7bd49343c1ec0c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yMi9mcmFnOjJiM2Y4ODE3NTVhYTQ5ODk5MzI2NThlODM2YmIyNGI2L3RhYmxlOjQ1MmFlOGFkMjMxZjQ4MWQ4Njg3MGU5MDYxNWI3NTkxL3RhYmxlcmFuZ2U6NDUyYWU4YWQyMzFmNDgxZDg2ODcwZTkwNjE1Yjc1OTFfMTQtMS0xLTEtMTc3NzU_788d837d-0914-4c63-ba66-75f3c0058ab4"
      unitRef="usd">32624000</us-gaap:CapitalizedContractCostNetNoncurrent>
    <us-gaap:CapitalizedContractCostNetNoncurrent
      contextRef="ibc0c0c2b8dc04c5698ca0577a54b2e03_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yMi9mcmFnOjJiM2Y4ODE3NTVhYTQ5ODk5MzI2NThlODM2YmIyNGI2L3RhYmxlOjQ1MmFlOGFkMjMxZjQ4MWQ4Njg3MGU5MDYxNWI3NTkxL3RhYmxlcmFuZ2U6NDUyYWU4YWQyMzFmNDgxZDg2ODcwZTkwNjE1Yjc1OTFfMTQtMy0xLTEtMTc3NzU_ba348ed5-eb6f-45d1-91f4-e6fe1dc68424"
      unitRef="usd">26687000</us-gaap:CapitalizedContractCostNetNoncurrent>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="i8daff60be410426d8f7bd49343c1ec0c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yMi9mcmFnOjJiM2Y4ODE3NTVhYTQ5ODk5MzI2NThlODM2YmIyNGI2L3RhYmxlOjQ1MmFlOGFkMjMxZjQ4MWQ4Njg3MGU5MDYxNWI3NTkxL3RhYmxlcmFuZ2U6NDUyYWU4YWQyMzFmNDgxZDg2ODcwZTkwNjE1Yjc1OTFfMTUtMS0xLTEtMTc3NzU_5d2f7d16-37e3-4d32-add6-eab2555c57ba"
      unitRef="usd">279784000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="ibc0c0c2b8dc04c5698ca0577a54b2e03_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yMi9mcmFnOjJiM2Y4ODE3NTVhYTQ5ODk5MzI2NThlODM2YmIyNGI2L3RhYmxlOjQ1MmFlOGFkMjMxZjQ4MWQ4Njg3MGU5MDYxNWI3NTkxL3RhYmxlcmFuZ2U6NDUyYWU4YWQyMzFmNDgxZDg2ODcwZTkwNjE1Yjc1OTFfMTUtMy0xLTEtMTc3NzU_d464e961-0388-459c-93a7-2eddb6227a7e"
      unitRef="usd">264992000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:Goodwill
      contextRef="i8daff60be410426d8f7bd49343c1ec0c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yMi9mcmFnOjJiM2Y4ODE3NTVhYTQ5ODk5MzI2NThlODM2YmIyNGI2L3RhYmxlOjQ1MmFlOGFkMjMxZjQ4MWQ4Njg3MGU5MDYxNWI3NTkxL3RhYmxlcmFuZ2U6NDUyYWU4YWQyMzFmNDgxZDg2ODcwZTkwNjE1Yjc1OTFfMTYtMS0xLTEtMTc3NzU_7cc889ab-d84b-4e25-a489-d23d04331678"
      unitRef="usd">426297000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="ibc0c0c2b8dc04c5698ca0577a54b2e03_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yMi9mcmFnOjJiM2Y4ODE3NTVhYTQ5ODk5MzI2NThlODM2YmIyNGI2L3RhYmxlOjQ1MmFlOGFkMjMxZjQ4MWQ4Njg3MGU5MDYxNWI3NTkxL3RhYmxlcmFuZ2U6NDUyYWU4YWQyMzFmNDgxZDg2ODcwZTkwNjE1Yjc1OTFfMTYtMy0xLTEtMTc3NzU_79eb79de-1574-40ad-a72c-6affdfb3a25b"
      unitRef="usd">349029000</us-gaap:Goodwill>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent
      contextRef="i8daff60be410426d8f7bd49343c1ec0c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yMi9mcmFnOjJiM2Y4ODE3NTVhYTQ5ODk5MzI2NThlODM2YmIyNGI2L3RhYmxlOjQ1MmFlOGFkMjMxZjQ4MWQ4Njg3MGU5MDYxNWI3NTkxL3RhYmxlcmFuZ2U6NDUyYWU4YWQyMzFmNDgxZDg2ODcwZTkwNjE1Yjc1OTFfMTctMS0xLTEtMTc3NzU_15012c48-18a7-4a99-a2a1-f42320ddbe5a"
      unitRef="usd">0</us-gaap:DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent
      contextRef="ibc0c0c2b8dc04c5698ca0577a54b2e03_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yMi9mcmFnOjJiM2Y4ODE3NTVhYTQ5ODk5MzI2NThlODM2YmIyNGI2L3RhYmxlOjQ1MmFlOGFkMjMxZjQ4MWQ4Njg3MGU5MDYxNWI3NTkxL3RhYmxlcmFuZ2U6NDUyYWU4YWQyMzFmNDgxZDg2ODcwZTkwNjE1Yjc1OTFfMTctMy0xLTEtMTc3NzU_876b3921-4f72-4421-b965-db4fd443d841"
      unitRef="usd">20379000</us-gaap:DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="i8daff60be410426d8f7bd49343c1ec0c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yMi9mcmFnOjJiM2Y4ODE3NTVhYTQ5ODk5MzI2NThlODM2YmIyNGI2L3RhYmxlOjQ1MmFlOGFkMjMxZjQ4MWQ4Njg3MGU5MDYxNWI3NTkxL3RhYmxlcmFuZ2U6NDUyYWU4YWQyMzFmNDgxZDg2ODcwZTkwNjE1Yjc1OTFfMTgtMS0xLTEtMTc3NzU_0004fa08-53d8-4fe1-ab96-52155a6f13b6"
      unitRef="usd">1419458000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="ibc0c0c2b8dc04c5698ca0577a54b2e03_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yMi9mcmFnOjJiM2Y4ODE3NTVhYTQ5ODk5MzI2NThlODM2YmIyNGI2L3RhYmxlOjQ1MmFlOGFkMjMxZjQ4MWQ4Njg3MGU5MDYxNWI3NTkxL3RhYmxlcmFuZ2U6NDUyYWU4YWQyMzFmNDgxZDg2ODcwZTkwNjE1Yjc1OTFfMTgtMy0xLTEtMTc3NzU_9d949807-537b-4ce7-be17-531b01c00033"
      unitRef="usd">1371700000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="i8daff60be410426d8f7bd49343c1ec0c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yMi9mcmFnOjJiM2Y4ODE3NTVhYTQ5ODk5MzI2NThlODM2YmIyNGI2L3RhYmxlOjQ1MmFlOGFkMjMxZjQ4MWQ4Njg3MGU5MDYxNWI3NTkxL3RhYmxlcmFuZ2U6NDUyYWU4YWQyMzFmNDgxZDg2ODcwZTkwNjE1Yjc1OTFfMjItMS0xLTEtMTc3NzU_de2bfa85-6392-4aa3-9252-cf468f01146c"
      unitRef="usd">96084000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="ibc0c0c2b8dc04c5698ca0577a54b2e03_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yMi9mcmFnOjJiM2Y4ODE3NTVhYTQ5ODk5MzI2NThlODM2YmIyNGI2L3RhYmxlOjQ1MmFlOGFkMjMxZjQ4MWQ4Njg3MGU5MDYxNWI3NTkxL3RhYmxlcmFuZ2U6NDUyYWU4YWQyMzFmNDgxZDg2ODcwZTkwNjE1Yjc1OTFfMjItMy0xLTEtMTc3NzU_7665c1f5-8c13-4d79-9699-c169f3c45c6b"
      unitRef="usd">31975000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="i8daff60be410426d8f7bd49343c1ec0c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yMi9mcmFnOjJiM2Y4ODE3NTVhYTQ5ODk5MzI2NThlODM2YmIyNGI2L3RhYmxlOjQ1MmFlOGFkMjMxZjQ4MWQ4Njg3MGU5MDYxNWI3NTkxL3RhYmxlcmFuZ2U6NDUyYWU4YWQyMzFmNDgxZDg2ODcwZTkwNjE1Yjc1OTFfMjMtMS0xLTEtMTc3NzU_0c4a3b28-a401-4580-bd6d-913e346e7efe"
      unitRef="usd">107241000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="ibc0c0c2b8dc04c5698ca0577a54b2e03_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yMi9mcmFnOjJiM2Y4ODE3NTVhYTQ5ODk5MzI2NThlODM2YmIyNGI2L3RhYmxlOjQ1MmFlOGFkMjMxZjQ4MWQ4Njg3MGU5MDYxNWI3NTkxL3RhYmxlcmFuZ2U6NDUyYWU4YWQyMzFmNDgxZDg2ODcwZTkwNjE1Yjc1OTFfMjMtMy0xLTEtMTc3NzU_0c7e2696-05ec-4e48-a7ec-d18b99a2d593"
      unitRef="usd">73242000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:LongTermDebtCurrent
      contextRef="i8daff60be410426d8f7bd49343c1ec0c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yMi9mcmFnOjJiM2Y4ODE3NTVhYTQ5ODk5MzI2NThlODM2YmIyNGI2L3RhYmxlOjQ1MmFlOGFkMjMxZjQ4MWQ4Njg3MGU5MDYxNWI3NTkxL3RhYmxlcmFuZ2U6NDUyYWU4YWQyMzFmNDgxZDg2ODcwZTkwNjE1Yjc1OTFfMjQtMS0xLTEtMTc3NzU_cf7c7622-7169-4db3-accb-aad376f4fc81"
      unitRef="usd">0</us-gaap:LongTermDebtCurrent>
    <us-gaap:LongTermDebtCurrent
      contextRef="ibc0c0c2b8dc04c5698ca0577a54b2e03_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yMi9mcmFnOjJiM2Y4ODE3NTVhYTQ5ODk5MzI2NThlODM2YmIyNGI2L3RhYmxlOjQ1MmFlOGFkMjMxZjQ4MWQ4Njg3MGU5MDYxNWI3NTkxL3RhYmxlcmFuZ2U6NDUyYWU4YWQyMzFmNDgxZDg2ODcwZTkwNjE1Yjc1OTFfMjQtMy0xLTEtMTc3NzU_23dcc40c-aa13-49f4-a200-680f9e477be6"
      unitRef="usd">26557000</us-gaap:LongTermDebtCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="i8daff60be410426d8f7bd49343c1ec0c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yMi9mcmFnOjJiM2Y4ODE3NTVhYTQ5ODk5MzI2NThlODM2YmIyNGI2L3RhYmxlOjQ1MmFlOGFkMjMxZjQ4MWQ4Njg3MGU5MDYxNWI3NTkxL3RhYmxlcmFuZ2U6NDUyYWU4YWQyMzFmNDgxZDg2ODcwZTkwNjE1Yjc1OTFfMjUtMS0xLTEtMTc3NzU_a98a6adb-ca21-42c0-a4d7-25c6c7aba16b"
      unitRef="usd">7069000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="ibc0c0c2b8dc04c5698ca0577a54b2e03_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yMi9mcmFnOjJiM2Y4ODE3NTVhYTQ5ODk5MzI2NThlODM2YmIyNGI2L3RhYmxlOjQ1MmFlOGFkMjMxZjQ4MWQ4Njg3MGU5MDYxNWI3NTkxL3RhYmxlcmFuZ2U6NDUyYWU4YWQyMzFmNDgxZDg2ODcwZTkwNjE1Yjc1OTFfMjUtMy0xLTEtMTc3NzU_8cc1761c-6f36-42e9-99d1-954826577076"
      unitRef="usd">7357000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="i8daff60be410426d8f7bd49343c1ec0c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yMi9mcmFnOjJiM2Y4ODE3NTVhYTQ5ODk5MzI2NThlODM2YmIyNGI2L3RhYmxlOjQ1MmFlOGFkMjMxZjQ4MWQ4Njg3MGU5MDYxNWI3NTkxL3RhYmxlcmFuZ2U6NDUyYWU4YWQyMzFmNDgxZDg2ODcwZTkwNjE1Yjc1OTFfMjYtMS0xLTEtMTc3NzU_4ba8002c-d261-45af-9339-5891b5510b73"
      unitRef="usd">51861000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="ibc0c0c2b8dc04c5698ca0577a54b2e03_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yMi9mcmFnOjJiM2Y4ODE3NTVhYTQ5ODk5MzI2NThlODM2YmIyNGI2L3RhYmxlOjQ1MmFlOGFkMjMxZjQ4MWQ4Njg3MGU5MDYxNWI3NTkxL3RhYmxlcmFuZ2U6NDUyYWU4YWQyMzFmNDgxZDg2ODcwZTkwNjE1Yjc1OTFfMjYtMy0xLTEtMTc3NzU_721d1fab-7a2d-4a0d-aa91-28e0fc200537"
      unitRef="usd">47163000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="i8daff60be410426d8f7bd49343c1ec0c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yMi9mcmFnOjJiM2Y4ODE3NTVhYTQ5ODk5MzI2NThlODM2YmIyNGI2L3RhYmxlOjQ1MmFlOGFkMjMxZjQ4MWQ4Njg3MGU5MDYxNWI3NTkxL3RhYmxlcmFuZ2U6NDUyYWU4YWQyMzFmNDgxZDg2ODcwZTkwNjE1Yjc1OTFfMjctMS0xLTEtMTc3NzU_86546b72-411a-4ec1-95d4-5eaf20208163"
      unitRef="usd">11944000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="ibc0c0c2b8dc04c5698ca0577a54b2e03_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yMi9mcmFnOjJiM2Y4ODE3NTVhYTQ5ODk5MzI2NThlODM2YmIyNGI2L3RhYmxlOjQ1MmFlOGFkMjMxZjQ4MWQ4Njg3MGU5MDYxNWI3NTkxL3RhYmxlcmFuZ2U6NDUyYWU4YWQyMzFmNDgxZDg2ODcwZTkwNjE1Yjc1OTFfMjctMy0xLTEtMTc3NzU_e2188d40-2eb6-40ca-b2bf-4c3c857a7073"
      unitRef="usd">10187000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <evh:LiabilityForFuturePolicyBenefitsAndUnpaidClaimsAndClaimsAdjustmentExpenseAndPerformanceBasedArrangements
      contextRef="i8daff60be410426d8f7bd49343c1ec0c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yMi9mcmFnOjJiM2Y4ODE3NTVhYTQ5ODk5MzI2NThlODM2YmIyNGI2L3RhYmxlOjQ1MmFlOGFkMjMxZjQ4MWQ4Njg3MGU5MDYxNWI3NTkxL3RhYmxlcmFuZ2U6NDUyYWU4YWQyMzFmNDgxZDg2ODcwZTkwNjE1Yjc1OTFfMjgtMS0xLTEtMTc3NzU_03f34cbc-a6ef-428a-8ea2-e2626cbf946a"
      unitRef="usd">171294000</evh:LiabilityForFuturePolicyBenefitsAndUnpaidClaimsAndClaimsAdjustmentExpenseAndPerformanceBasedArrangements>
    <evh:LiabilityForFuturePolicyBenefitsAndUnpaidClaimsAndClaimsAdjustmentExpenseAndPerformanceBasedArrangements
      contextRef="ibc0c0c2b8dc04c5698ca0577a54b2e03_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yMi9mcmFnOjJiM2Y4ODE3NTVhYTQ5ODk5MzI2NThlODM2YmIyNGI2L3RhYmxlOjQ1MmFlOGFkMjMxZjQ4MWQ4Njg3MGU5MDYxNWI3NTkxL3RhYmxlcmFuZ2U6NDUyYWU4YWQyMzFmNDgxZDg2ODcwZTkwNjE1Yjc1OTFfMjgtMy0xLTEtMTc3NzU_4b6e6c26-f2b8-4e61-8c51-c6866fd17f9b"
      unitRef="usd">178827000</evh:LiabilityForFuturePolicyBenefitsAndUnpaidClaimsAndClaimsAdjustmentExpenseAndPerformanceBasedArrangements>
    <us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent
      contextRef="i8daff60be410426d8f7bd49343c1ec0c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yMi9mcmFnOjJiM2Y4ODE3NTVhYTQ5ODk5MzI2NThlODM2YmIyNGI2L3RhYmxlOjQ1MmFlOGFkMjMxZjQ4MWQ4Njg3MGU5MDYxNWI3NTkxL3RhYmxlcmFuZ2U6NDUyYWU4YWQyMzFmNDgxZDg2ODcwZTkwNjE1Yjc1OTFfMjktMS0xLTEtMTc3NzU_c9537b3e-06b0-4877-998a-b363a380fde6"
      unitRef="usd">0</us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent>
    <us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent
      contextRef="ibc0c0c2b8dc04c5698ca0577a54b2e03_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yMi9mcmFnOjJiM2Y4ODE3NTVhYTQ5ODk5MzI2NThlODM2YmIyNGI2L3RhYmxlOjQ1MmFlOGFkMjMxZjQ4MWQ4Njg3MGU5MDYxNWI3NTkxL3RhYmxlcmFuZ2U6NDUyYWU4YWQyMzFmNDgxZDg2ODcwZTkwNjE1Yjc1OTFfMjktMy0xLTEtMTc3NzU_2375d355-de18-4287-a40d-6b23d1e87621"
      unitRef="usd">27986000</us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i8daff60be410426d8f7bd49343c1ec0c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yMi9mcmFnOjJiM2Y4ODE3NTVhYTQ5ODk5MzI2NThlODM2YmIyNGI2L3RhYmxlOjQ1MmFlOGFkMjMxZjQ4MWQ4Njg3MGU5MDYxNWI3NTkxL3RhYmxlcmFuZ2U6NDUyYWU4YWQyMzFmNDgxZDg2ODcwZTkwNjE1Yjc1OTFfMzAtMS0xLTEtMTc3NzU_65fcd4a2-c153-42ff-88a5-fc6824d958d4"
      unitRef="usd">445493000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="ibc0c0c2b8dc04c5698ca0577a54b2e03_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yMi9mcmFnOjJiM2Y4ODE3NTVhYTQ5ODk5MzI2NThlODM2YmIyNGI2L3RhYmxlOjQ1MmFlOGFkMjMxZjQ4MWQ4Njg3MGU5MDYxNWI3NTkxL3RhYmxlcmFuZ2U6NDUyYWU4YWQyMzFmNDgxZDg2ODcwZTkwNjE1Yjc1OTFfMzAtMy0xLTEtMTc3NzU_0b3c4412-f231-43ac-a92b-f65148cdfec9"
      unitRef="usd">403294000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i8daff60be410426d8f7bd49343c1ec0c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yMi9mcmFnOjJiM2Y4ODE3NTVhYTQ5ODk5MzI2NThlODM2YmIyNGI2L3RhYmxlOjQ1MmFlOGFkMjMxZjQ4MWQ4Njg3MGU5MDYxNWI3NTkxL3RhYmxlcmFuZ2U6NDUyYWU4YWQyMzFmNDgxZDg2ODcwZTkwNjE1Yjc1OTFfMzEtMS0xLTEtMTc3NzU_ef15f993-8d97-491b-b049-d15839e35121"
      unitRef="usd">215676000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="ibc0c0c2b8dc04c5698ca0577a54b2e03_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yMi9mcmFnOjJiM2Y4ODE3NTVhYTQ5ODk5MzI2NThlODM2YmIyNGI2L3RhYmxlOjQ1MmFlOGFkMjMxZjQ4MWQ4Njg3MGU5MDYxNWI3NTkxL3RhYmxlcmFuZ2U6NDUyYWU4YWQyMzFmNDgxZDg2ODcwZTkwNjE1Yjc1OTFfMzEtMy0xLTEtMTc3NzU_0f23d363-7ebb-49d8-a628-bfb41fe2415a"
      unitRef="usd">263343000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="i8daff60be410426d8f7bd49343c1ec0c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yMi9mcmFnOjJiM2Y4ODE3NTVhYTQ5ODk5MzI2NThlODM2YmIyNGI2L3RhYmxlOjQ1MmFlOGFkMjMxZjQ4MWQ4Njg3MGU5MDYxNWI3NTkxL3RhYmxlcmFuZ2U6NDUyYWU4YWQyMzFmNDgxZDg2ODcwZTkwNjE1Yjc1OTFfMzItMS0xLTEtMTc3NzU_eda2d901-66bd-43a2-995d-bdac1b81213d"
      unitRef="usd">5531000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="ibc0c0c2b8dc04c5698ca0577a54b2e03_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yMi9mcmFnOjJiM2Y4ODE3NTVhYTQ5ODk5MzI2NThlODM2YmIyNGI2L3RhYmxlOjQ1MmFlOGFkMjMxZjQ4MWQ4Njg3MGU5MDYxNWI3NTkxL3RhYmxlcmFuZ2U6NDUyYWU4YWQyMzFmNDgxZDg2ODcwZTkwNjE1Yjc1OTFfMzItMy0xLTEtMTc3NzU_1fd26956-3a3b-4eda-93fb-98642dc74790"
      unitRef="usd">22081000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="i8daff60be410426d8f7bd49343c1ec0c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yMi9mcmFnOjJiM2Y4ODE3NTVhYTQ5ODk5MzI2NThlODM2YmIyNGI2L3RhYmxlOjQ1MmFlOGFkMjMxZjQ4MWQ4Njg3MGU5MDYxNWI3NTkxL3RhYmxlcmFuZ2U6NDUyYWU4YWQyMzFmNDgxZDg2ODcwZTkwNjE1Yjc1OTFfMzMtMS0xLTEtMTc3NzU_2b5d2c4f-b3ff-4a00-8a44-b6e69ea0f9fa"
      unitRef="usd">57722000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="ibc0c0c2b8dc04c5698ca0577a54b2e03_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yMi9mcmFnOjJiM2Y4ODE3NTVhYTQ5ODk5MzI2NThlODM2YmIyNGI2L3RhYmxlOjQ1MmFlOGFkMjMxZjQ4MWQ4Njg3MGU5MDYxNWI3NTkxL3RhYmxlcmFuZ2U6NDUyYWU4YWQyMzFmNDgxZDg2ODcwZTkwNjE1Yjc1OTFfMzMtMy0xLTEtMTc3NzU_c35da98e-2761-4aec-ae5c-a54a04a0780f"
      unitRef="usd">62526000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:DeferredIncomeTaxLiabilitiesNet
      contextRef="i8daff60be410426d8f7bd49343c1ec0c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yMi9mcmFnOjJiM2Y4ODE3NTVhYTQ5ODk5MzI2NThlODM2YmIyNGI2L3RhYmxlOjQ1MmFlOGFkMjMxZjQ4MWQ4Njg3MGU5MDYxNWI3NTkxL3RhYmxlcmFuZ2U6NDUyYWU4YWQyMzFmNDgxZDg2ODcwZTkwNjE1Yjc1OTFfMzQtMS0xLTEtMTc3NzU_4b390abf-a9da-4951-832a-5b11d40968ea"
      unitRef="usd">1403000</us-gaap:DeferredIncomeTaxLiabilitiesNet>
    <us-gaap:DeferredIncomeTaxLiabilitiesNet
      contextRef="ibc0c0c2b8dc04c5698ca0577a54b2e03_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yMi9mcmFnOjJiM2Y4ODE3NTVhYTQ5ODk5MzI2NThlODM2YmIyNGI2L3RhYmxlOjQ1MmFlOGFkMjMxZjQ4MWQ4Njg3MGU5MDYxNWI3NTkxL3RhYmxlcmFuZ2U6NDUyYWU4YWQyMzFmNDgxZDg2ODcwZTkwNjE1Yjc1OTFfMzQtMy0xLTEtMTc3NzU_56e0b43f-f9ca-4699-a958-007eced58f6b"
      unitRef="usd">679000</us-gaap:DeferredIncomeTaxLiabilitiesNet>
    <us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent
      contextRef="i8daff60be410426d8f7bd49343c1ec0c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yMi9mcmFnOjJiM2Y4ODE3NTVhYTQ5ODk5MzI2NThlODM2YmIyNGI2L3RhYmxlOjQ1MmFlOGFkMjMxZjQ4MWQ4Njg3MGU5MDYxNWI3NTkxL3RhYmxlcmFuZ2U6NDUyYWU4YWQyMzFmNDgxZDg2ODcwZTkwNjE1Yjc1OTFfMzUtMS0xLTEtMTc3NzU_e630f844-bd1f-4f52-b1d7-4a685d97a3d8"
      unitRef="usd">0</us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent>
    <us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent
      contextRef="ibc0c0c2b8dc04c5698ca0577a54b2e03_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yMi9mcmFnOjJiM2Y4ODE3NTVhYTQ5ODk5MzI2NThlODM2YmIyNGI2L3RhYmxlOjQ1MmFlOGFkMjMxZjQ4MWQ4Njg3MGU5MDYxNWI3NTkxL3RhYmxlcmFuZ2U6NDUyYWU4YWQyMzFmNDgxZDg2ODcwZTkwNjE1Yjc1OTFfMzUtMy0xLTEtMTc3NzU_4773c39d-24f3-44f3-b97e-b07ec8e1194a"
      unitRef="usd">177000</us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent>
    <us-gaap:Liabilities
      contextRef="i8daff60be410426d8f7bd49343c1ec0c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yMi9mcmFnOjJiM2Y4ODE3NTVhYTQ5ODk5MzI2NThlODM2YmIyNGI2L3RhYmxlOjQ1MmFlOGFkMjMxZjQ4MWQ4Njg3MGU5MDYxNWI3NTkxL3RhYmxlcmFuZ2U6NDUyYWU4YWQyMzFmNDgxZDg2ODcwZTkwNjE1Yjc1OTFfMzYtMS0xLTEtMTc3NzU_4b1fe76e-0839-409f-91b4-23ad461e6fa5"
      unitRef="usd">725825000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="ibc0c0c2b8dc04c5698ca0577a54b2e03_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yMi9mcmFnOjJiM2Y4ODE3NTVhYTQ5ODk5MzI2NThlODM2YmIyNGI2L3RhYmxlOjQ1MmFlOGFkMjMxZjQ4MWQ4Njg3MGU5MDYxNWI3NTkxL3RhYmxlcmFuZ2U6NDUyYWU4YWQyMzFmNDgxZDg2ODcwZTkwNjE1Yjc1OTFfMzYtMy0xLTEtMTc3NzU_3eac2086-5df3-4156-9d54-a76791b55e5c"
      unitRef="usd">752100000</us-gaap:Liabilities>
    <us-gaap:CommitmentsAndContingencies
      contextRef="i8daff60be410426d8f7bd49343c1ec0c_I20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yMi9mcmFnOjJiM2Y4ODE3NTVhYTQ5ODk5MzI2NThlODM2YmIyNGI2L3RhYmxlOjQ1MmFlOGFkMjMxZjQ4MWQ4Njg3MGU5MDYxNWI3NTkxL3RhYmxlcmFuZ2U6NDUyYWU4YWQyMzFmNDgxZDg2ODcwZTkwNjE1Yjc1OTFfMzctMS0xLTEtMTc3NzU_a6b56c85-7293-4041-ab11-e5cf7dc36d51"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="ibc0c0c2b8dc04c5698ca0577a54b2e03_I20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yMi9mcmFnOjJiM2Y4ODE3NTVhYTQ5ODk5MzI2NThlODM2YmIyNGI2L3RhYmxlOjQ1MmFlOGFkMjMxZjQ4MWQ4Njg3MGU5MDYxNWI3NTkxL3RhYmxlcmFuZ2U6NDUyYWU4YWQyMzFmNDgxZDg2ODcwZTkwNjE1Yjc1OTFfMzctMy0xLTEtMTc3NzU_ffffb78e-b10d-43bc-852b-7cd3b86674a7"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="ibc0c0c2b8dc04c5698ca0577a54b2e03_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yMi9mcmFnOjJiM2Y4ODE3NTVhYTQ5ODk5MzI2NThlODM2YmIyNGI2L3RhYmxlOjQ1MmFlOGFkMjMxZjQ4MWQ4Njg3MGU5MDYxNWI3NTkxL3RhYmxlcmFuZ2U6NDUyYWU4YWQyMzFmNDgxZDg2ODcwZTkwNjE1Yjc1OTFfMzktMC0xLTEtMTc3NzUvdGV4dHJlZ2lvbjpiYWIxOTVjODAyMWM0MmQ0OTM2M2JmMGQwMGRlY2E5OV8yNw_7c48e5e0-e958-4387-aff8-bc1cfcdb96ea"
      unitRef="usdPerShare">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i8daff60be410426d8f7bd49343c1ec0c_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yMi9mcmFnOjJiM2Y4ODE3NTVhYTQ5ODk5MzI2NThlODM2YmIyNGI2L3RhYmxlOjQ1MmFlOGFkMjMxZjQ4MWQ4Njg3MGU5MDYxNWI3NTkxL3RhYmxlcmFuZ2U6NDUyYWU4YWQyMzFmNDgxZDg2ODcwZTkwNjE1Yjc1OTFfMzktMC0xLTEtMTc3NzUvdGV4dHJlZ2lvbjpiYWIxOTVjODAyMWM0MmQ0OTM2M2JmMGQwMGRlY2E5OV8yNw_d79892af-82cd-4a20-ac90-08b9bf6a0440"
      unitRef="usdPerShare">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i8daff60be410426d8f7bd49343c1ec0c_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yMi9mcmFnOjJiM2Y4ODE3NTVhYTQ5ODk5MzI2NThlODM2YmIyNGI2L3RhYmxlOjQ1MmFlOGFkMjMxZjQ4MWQ4Njg3MGU5MDYxNWI3NTkxL3RhYmxlcmFuZ2U6NDUyYWU4YWQyMzFmNDgxZDg2ODcwZTkwNjE1Yjc1OTFfMzktMC0xLTEtMTc3NzUvdGV4dHJlZ2lvbjpiYWIxOTVjODAyMWM0MmQ0OTM2M2JmMGQwMGRlY2E5OV80MQ_0d12a619-7a36-4917-a19f-0461f22a28bb"
      unitRef="shares">750000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="ibc0c0c2b8dc04c5698ca0577a54b2e03_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yMi9mcmFnOjJiM2Y4ODE3NTVhYTQ5ODk5MzI2NThlODM2YmIyNGI2L3RhYmxlOjQ1MmFlOGFkMjMxZjQ4MWQ4Njg3MGU5MDYxNWI3NTkxL3RhYmxlcmFuZ2U6NDUyYWU4YWQyMzFmNDgxZDg2ODcwZTkwNjE1Yjc1OTFfMzktMC0xLTEtMTc3NzUvdGV4dHJlZ2lvbjpiYWIxOTVjODAyMWM0MmQ0OTM2M2JmMGQwMGRlY2E5OV80MQ_aabbf32e-f678-4fa5-834f-809ac75d7311"
      unitRef="shares">750000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="i8daff60be410426d8f7bd49343c1ec0c_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yMi9mcmFnOjJiM2Y4ODE3NTVhYTQ5ODk5MzI2NThlODM2YmIyNGI2L3RhYmxlOjQ1MmFlOGFkMjMxZjQ4MWQ4Njg3MGU5MDYxNWI3NTkxL3RhYmxlcmFuZ2U6NDUyYWU4YWQyMzFmNDgxZDg2ODcwZTkwNjE1Yjc1OTFfMzktMC0xLTEtMTc3NzUvdGV4dHJlZ2lvbjpiYWIxOTVjODAyMWM0MmQ0OTM2M2JmMGQwMGRlY2E5OV82Mw_0e44f980-18d8-41cf-a305-7f2c06217a7c"
      unitRef="shares">90758318</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued
      contextRef="ibc0c0c2b8dc04c5698ca0577a54b2e03_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yMi9mcmFnOjJiM2Y4ODE3NTVhYTQ5ODk5MzI2NThlODM2YmIyNGI2L3RhYmxlOjQ1MmFlOGFkMjMxZjQ4MWQ4Njg3MGU5MDYxNWI3NTkxL3RhYmxlcmFuZ2U6NDUyYWU4YWQyMzFmNDgxZDg2ODcwZTkwNjE1Yjc1OTFfMzktMC0xLTEtMTc3NzUvdGV4dHJlZ2lvbjpiYWIxOTVjODAyMWM0MmQ0OTM2M2JmMGQwMGRlY2E5OV83MA_a4bc4d8a-0a09-441c-a355-6ba22dbb50e4"
      unitRef="shares">85894450</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockValue
      contextRef="i8daff60be410426d8f7bd49343c1ec0c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yMi9mcmFnOjJiM2Y4ODE3NTVhYTQ5ODk5MzI2NThlODM2YmIyNGI2L3RhYmxlOjQ1MmFlOGFkMjMxZjQ4MWQ4Njg3MGU5MDYxNWI3NTkxL3RhYmxlcmFuZ2U6NDUyYWU4YWQyMzFmNDgxZDg2ODcwZTkwNjE1Yjc1OTFfMzktMS0xLTEtMTc3NzU_5c4a1679-a643-4570-bd30-d661e97c1be9"
      unitRef="usd">908000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="ibc0c0c2b8dc04c5698ca0577a54b2e03_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yMi9mcmFnOjJiM2Y4ODE3NTVhYTQ5ODk5MzI2NThlODM2YmIyNGI2L3RhYmxlOjQ1MmFlOGFkMjMxZjQ4MWQ4Njg3MGU5MDYxNWI3NTkxL3RhYmxlcmFuZ2U6NDUyYWU4YWQyMzFmNDgxZDg2ODcwZTkwNjE1Yjc1OTFfMzktMy0xLTEtMTc3NzU_7eb8acc8-6db0-4887-99f3-4bcd89d4884e"
      unitRef="usd">859000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital
      contextRef="i8daff60be410426d8f7bd49343c1ec0c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yMi9mcmFnOjJiM2Y4ODE3NTVhYTQ5ODk5MzI2NThlODM2YmIyNGI2L3RhYmxlOjQ1MmFlOGFkMjMxZjQ4MWQ4Njg3MGU5MDYxNWI3NTkxL3RhYmxlcmFuZ2U6NDUyYWU4YWQyMzFmNDgxZDg2ODcwZTkwNjE1Yjc1OTFfNDAtMS0xLTEtMTc3NzU_c811eb22-d37d-4b7c-ac30-55eef77f97c8"
      unitRef="usd">1340989000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="ibc0c0c2b8dc04c5698ca0577a54b2e03_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yMi9mcmFnOjJiM2Y4ODE3NTVhYTQ5ODk5MzI2NThlODM2YmIyNGI2L3RhYmxlOjQ1MmFlOGFkMjMxZjQ4MWQ4Njg3MGU5MDYxNWI3NTkxL3RhYmxlcmFuZ2U6NDUyYWU4YWQyMzFmNDgxZDg2ODcwZTkwNjE1Yjc1OTFfNDAtMy0xLTEtMTc3NzU_9e2ffa35-9edf-440f-8e7b-ef23e9d47688"
      unitRef="usd">1229320000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i8daff60be410426d8f7bd49343c1ec0c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yMi9mcmFnOjJiM2Y4ODE3NTVhYTQ5ODk5MzI2NThlODM2YmIyNGI2L3RhYmxlOjQ1MmFlOGFkMjMxZjQ4MWQ4Njg3MGU5MDYxNWI3NTkxL3RhYmxlcmFuZ2U6NDUyYWU4YWQyMzFmNDgxZDg2ODcwZTkwNjE1Yjc1OTFfNDEtMS0xLTEtMTc3NzU_6ea35a3d-87d9-4d01-9033-52c5cc04366d"
      unitRef="usd">-362000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="ibc0c0c2b8dc04c5698ca0577a54b2e03_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yMi9mcmFnOjJiM2Y4ODE3NTVhYTQ5ODk5MzI2NThlODM2YmIyNGI2L3RhYmxlOjQ1MmFlOGFkMjMxZjQ4MWQ4Njg3MGU5MDYxNWI3NTkxL3RhYmxlcmFuZ2U6NDUyYWU4YWQyMzFmNDgxZDg2ODcwZTkwNjE1Yjc1OTFfNDEtMy0xLTEtMTc3NzU_c6e4db3f-bea2-41d7-b411-ff3c8bebc7d2"
      unitRef="usd">-278000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i8daff60be410426d8f7bd49343c1ec0c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yMi9mcmFnOjJiM2Y4ODE3NTVhYTQ5ODk5MzI2NThlODM2YmIyNGI2L3RhYmxlOjQ1MmFlOGFkMjMxZjQ4MWQ4Njg3MGU5MDYxNWI3NTkxL3RhYmxlcmFuZ2U6NDUyYWU4YWQyMzFmNDgxZDg2ODcwZTkwNjE1Yjc1OTFfNDItMS0xLTEtMTc3NzU_5435f53f-69e9-4988-9623-02747495a78f"
      unitRef="usd">-626779000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="ibc0c0c2b8dc04c5698ca0577a54b2e03_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yMi9mcmFnOjJiM2Y4ODE3NTVhYTQ5ODk5MzI2NThlODM2YmIyNGI2L3RhYmxlOjQ1MmFlOGFkMjMxZjQ4MWQ4Njg3MGU5MDYxNWI3NTkxL3RhYmxlcmFuZ2U6NDUyYWU4YWQyMzFmNDgxZDg2ODcwZTkwNjE1Yjc1OTFfNDItMy0xLTEtMTc3NzU_2aae0786-0ce1-4421-bd9a-2516e7203a1b"
      unitRef="usd">-589178000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:TreasuryStockShares
      contextRef="ibc0c0c2b8dc04c5698ca0577a54b2e03_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yMi9mcmFnOjJiM2Y4ODE3NTVhYTQ5ODk5MzI2NThlODM2YmIyNGI2L3RhYmxlOjQ1MmFlOGFkMjMxZjQ4MWQ4Njg3MGU5MDYxNWI3NTkxL3RhYmxlcmFuZ2U6NDUyYWU4YWQyMzFmNDgxZDg2ODcwZTkwNjE1Yjc1OTFfNDMtMC0xLTEtMTc3NzUvdGV4dHJlZ2lvbjo4ZTBjYWU0ZDM1MjM0MmY5OGFhZWEyZjU1OWViZmU1NF8yOQ_ce9f4ead-b9b7-4704-9ed3-26192a1f5a0c"
      unitRef="shares">1537582</us-gaap:TreasuryStockShares>
    <us-gaap:TreasuryStockShares
      contextRef="i8daff60be410426d8f7bd49343c1ec0c_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yMi9mcmFnOjJiM2Y4ODE3NTVhYTQ5ODk5MzI2NThlODM2YmIyNGI2L3RhYmxlOjQ1MmFlOGFkMjMxZjQ4MWQ4Njg3MGU5MDYxNWI3NTkxL3RhYmxlcmFuZ2U6NDUyYWU4YWQyMzFmNDgxZDg2ODcwZTkwNjE1Yjc1OTFfNDMtMC0xLTEtMTc3NzUvdGV4dHJlZ2lvbjo4ZTBjYWU0ZDM1MjM0MmY5OGFhZWEyZjU1OWViZmU1NF8yOQ_ceb6030b-adc9-4cc4-873d-667de68ba82e"
      unitRef="shares">1537582</us-gaap:TreasuryStockShares>
    <us-gaap:TreasuryStockValue
      contextRef="i8daff60be410426d8f7bd49343c1ec0c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yMi9mcmFnOjJiM2Y4ODE3NTVhYTQ5ODk5MzI2NThlODM2YmIyNGI2L3RhYmxlOjQ1MmFlOGFkMjMxZjQ4MWQ4Njg3MGU5MDYxNWI3NTkxL3RhYmxlcmFuZ2U6NDUyYWU4YWQyMzFmNDgxZDg2ODcwZTkwNjE1Yjc1OTFfNDMtMS0xLTEtMTc3NzU_70be0207-646e-4132-aa59-bd8d4b63bd10"
      unitRef="usd">21123000</us-gaap:TreasuryStockValue>
    <us-gaap:TreasuryStockValue
      contextRef="ibc0c0c2b8dc04c5698ca0577a54b2e03_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yMi9mcmFnOjJiM2Y4ODE3NTVhYTQ5ODk5MzI2NThlODM2YmIyNGI2L3RhYmxlOjQ1MmFlOGFkMjMxZjQ4MWQ4Njg3MGU5MDYxNWI3NTkxL3RhYmxlcmFuZ2U6NDUyYWU4YWQyMzFmNDgxZDg2ODcwZTkwNjE1Yjc1OTFfNDMtMy0xLTEtMTc3NzU_b123bea9-35ba-4b4f-9d40-400c5ba24410"
      unitRef="usd">21123000</us-gaap:TreasuryStockValue>
    <us-gaap:StockholdersEquity
      contextRef="i8daff60be410426d8f7bd49343c1ec0c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yMi9mcmFnOjJiM2Y4ODE3NTVhYTQ5ODk5MzI2NThlODM2YmIyNGI2L3RhYmxlOjQ1MmFlOGFkMjMxZjQ4MWQ4Njg3MGU5MDYxNWI3NTkxL3RhYmxlcmFuZ2U6NDUyYWU4YWQyMzFmNDgxZDg2ODcwZTkwNjE1Yjc1OTFfNDQtMS0xLTEtMTc3NzU_622f204d-2184-4115-bf69-5466710c54ff"
      unitRef="usd">693633000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ibc0c0c2b8dc04c5698ca0577a54b2e03_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yMi9mcmFnOjJiM2Y4ODE3NTVhYTQ5ODk5MzI2NThlODM2YmIyNGI2L3RhYmxlOjQ1MmFlOGFkMjMxZjQ4MWQ4Njg3MGU5MDYxNWI3NTkxL3RhYmxlcmFuZ2U6NDUyYWU4YWQyMzFmNDgxZDg2ODcwZTkwNjE1Yjc1OTFfNDQtMy0xLTEtMTc3NzU_d633142b-d641-44bf-94a3-205aef009850"
      unitRef="usd">619600000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i8daff60be410426d8f7bd49343c1ec0c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yMi9mcmFnOjJiM2Y4ODE3NTVhYTQ5ODk5MzI2NThlODM2YmIyNGI2L3RhYmxlOjQ1MmFlOGFkMjMxZjQ4MWQ4Njg3MGU5MDYxNWI3NTkxL3RhYmxlcmFuZ2U6NDUyYWU4YWQyMzFmNDgxZDg2ODcwZTkwNjE1Yjc1OTFfNDUtMS0xLTEtMTc3NzU_3aa18918-c15b-42b5-84fb-5fa784804293"
      unitRef="usd">1419458000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="ibc0c0c2b8dc04c5698ca0577a54b2e03_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yMi9mcmFnOjJiM2Y4ODE3NTVhYTQ5ODk5MzI2NThlODM2YmIyNGI2L3RhYmxlOjQ1MmFlOGFkMjMxZjQ4MWQ4Njg3MGU5MDYxNWI3NTkxL3RhYmxlcmFuZ2U6NDUyYWU4YWQyMzFmNDgxZDg2ODcwZTkwNjE1Yjc1OTFfNDUtMy0xLTEtMTc3NzU_9784c573-3207-4375-95b3-4a42be410fec"
      unitRef="usd">1371700000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:Revenues
      contextRef="iba00e3572dc24848afe0d13147ef9951_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yNS9mcmFnOmM5ZGJiZjkwNWNkYjRhM2Y5NGMxZDk0YTNmMjcyZGM2L3RhYmxlOmI3MTFhYTE1OTNiOTQzZWRhOGQ2ZDQyN2QxNTZkOGFjL3RhYmxlcmFuZ2U6YjcxMWFhMTU5M2I5NDNlZGE4ZDZkNDI3ZDE1NmQ4YWNfMy01LTEtMS0xNzc3NQ_46c2cc00-d98a-4db8-8abe-548c1179f2d3"
      unitRef="usd">11204000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ib585ca9afa9b4d02874ade8f146f75cd_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yNS9mcmFnOmM5ZGJiZjkwNWNkYjRhM2Y5NGMxZDk0YTNmMjcyZGM2L3RhYmxlOmI3MTFhYTE1OTNiOTQzZWRhOGQ2ZDQyN2QxNTZkOGFjL3RhYmxlcmFuZ2U6YjcxMWFhMTU5M2I5NDNlZGE4ZDZkNDI3ZDE1NmQ4YWNfMy03LTEtMS0xNzc3NQ_a3433453-2481-4ae7-be53-93f804bda331"
      unitRef="usd">11990000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ia6ba1f43ec4147adbafcb4a00fc450a2_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yNS9mcmFnOmM5ZGJiZjkwNWNkYjRhM2Y5NGMxZDk0YTNmMjcyZGM2L3RhYmxlOmI3MTFhYTE1OTNiOTQzZWRhOGQ2ZDQyN2QxNTZkOGFjL3RhYmxlcmFuZ2U6YjcxMWFhMTU5M2I5NDNlZGE4ZDZkNDI3ZDE1NmQ4YWNfMy01LTEtMS0xOTE3OA_3c9095fd-21fc-41c2-9170-ae15b4f36761"
      unitRef="usd">15203000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ic852ce517768443a8289b4dcbd762e47_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yNS9mcmFnOmM5ZGJiZjkwNWNkYjRhM2Y5NGMxZDk0YTNmMjcyZGM2L3RhYmxlOmI3MTFhYTE1OTNiOTQzZWRhOGQ2ZDQyN2QxNTZkOGFjL3RhYmxlcmFuZ2U6YjcxMWFhMTU5M2I5NDNlZGE4ZDZkNDI3ZDE1NmQ4YWNfNC01LTEtMS0xNzc3NQ_644b3506-ee17-40d9-933c-67a7ebbab750"
      unitRef="usd">896753000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i971b8dd0fb5d4b10b55f27371adadaa7_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yNS9mcmFnOmM5ZGJiZjkwNWNkYjRhM2Y5NGMxZDk0YTNmMjcyZGM2L3RhYmxlOmI3MTFhYTE1OTNiOTQzZWRhOGQ2ZDQyN2QxNTZkOGFjL3RhYmxlcmFuZ2U6YjcxMWFhMTU5M2I5NDNlZGE4ZDZkNDI3ZDE1NmQ4YWNfNC03LTEtMS0xNzc3NQ_acbcefc9-f3d5-494d-a386-35f27c437a74"
      unitRef="usd">912649000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ie0aa3b0e3e5a4d54a32e0a4b60149c35_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yNS9mcmFnOmM5ZGJiZjkwNWNkYjRhM2Y5NGMxZDk0YTNmMjcyZGM2L3RhYmxlOmI3MTFhYTE1OTNiOTQzZWRhOGQ2ZDQyN2QxNTZkOGFjL3RhYmxlcmFuZ2U6YjcxMWFhMTU5M2I5NDNlZGE4ZDZkNDI3ZDE1NmQ4YWNfNC01LTEtMS0xOTE3OA_241368f3-5677-4baa-ba4b-666e2870cf8b"
      unitRef="usd">671919000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yNS9mcmFnOmM5ZGJiZjkwNWNkYjRhM2Y5NGMxZDk0YTNmMjcyZGM2L3RhYmxlOmI3MTFhYTE1OTNiOTQzZWRhOGQ2ZDQyN2QxNTZkOGFjL3RhYmxlcmFuZ2U6YjcxMWFhMTU5M2I5NDNlZGE4ZDZkNDI3ZDE1NmQ4YWNfNS01LTEtMS0xNzc3NQ_92b2259e-d020-49ee-889b-bff94edfa911"
      unitRef="usd">907957000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i12a6d1161de54547bd29f8efccd4c9b0_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yNS9mcmFnOmM5ZGJiZjkwNWNkYjRhM2Y5NGMxZDk0YTNmMjcyZGM2L3RhYmxlOmI3MTFhYTE1OTNiOTQzZWRhOGQ2ZDQyN2QxNTZkOGFjL3RhYmxlcmFuZ2U6YjcxMWFhMTU5M2I5NDNlZGE4ZDZkNDI3ZDE1NmQ4YWNfNS03LTEtMS0xNzc3NQ_0c5c9222-0bd3-4a3c-91e3-abce33ecf611"
      unitRef="usd">924639000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i3e21049ffc224cacb8134d73c9bb5b38_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yNS9mcmFnOmM5ZGJiZjkwNWNkYjRhM2Y5NGMxZDk0YTNmMjcyZGM2L3RhYmxlOmI3MTFhYTE1OTNiOTQzZWRhOGQ2ZDQyN2QxNTZkOGFjL3RhYmxlcmFuZ2U6YjcxMWFhMTU5M2I5NDNlZGE4ZDZkNDI3ZDE1NmQ4YWNfNS01LTEtMS0yMzU3MA_b53eacd3-b461-4ad0-b71e-9be60f83aa6b"
      unitRef="usd">687122000</us-gaap:Revenues>
    <evh:CostofGoodsandServicesSoldExcludingDepreciationandAmortization
      contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yNS9mcmFnOmM5ZGJiZjkwNWNkYjRhM2Y5NGMxZDk0YTNmMjcyZGM2L3RhYmxlOmI3MTFhYTE1OTNiOTQzZWRhOGQ2ZDQyN2QxNTZkOGFjL3RhYmxlcmFuZ2U6YjcxMWFhMTU5M2I5NDNlZGE4ZDZkNDI3ZDE1NmQ4YWNfOC01LTEtMS0xNzc3NQ_1ad8948c-28b0-4494-8a69-63b5046a268c"
      unitRef="usd">657551000</evh:CostofGoodsandServicesSoldExcludingDepreciationandAmortization>
    <evh:CostofGoodsandServicesSoldExcludingDepreciationandAmortization
      contextRef="i12a6d1161de54547bd29f8efccd4c9b0_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yNS9mcmFnOmM5ZGJiZjkwNWNkYjRhM2Y5NGMxZDk0YTNmMjcyZGM2L3RhYmxlOmI3MTFhYTE1OTNiOTQzZWRhOGQ2ZDQyN2QxNTZkOGFjL3RhYmxlcmFuZ2U6YjcxMWFhMTU5M2I5NDNlZGE4ZDZkNDI3ZDE1NmQ4YWNfOC03LTEtMS0xNzc3NQ_943a5b31-2cfc-4168-b222-5a303f55b5aa"
      unitRef="usd">696581000</evh:CostofGoodsandServicesSoldExcludingDepreciationandAmortization>
    <evh:CostofGoodsandServicesSoldExcludingDepreciationandAmortization
      contextRef="i3e21049ffc224cacb8134d73c9bb5b38_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yNS9mcmFnOmM5ZGJiZjkwNWNkYjRhM2Y5NGMxZDk0YTNmMjcyZGM2L3RhYmxlOmI3MTFhYTE1OTNiOTQzZWRhOGQ2ZDQyN2QxNTZkOGFjL3RhYmxlcmFuZ2U6YjcxMWFhMTU5M2I5NDNlZGE4ZDZkNDI3ZDE1NmQ4YWNfOC01LTEtMS0xOTE4Nw_0a57bcb2-3df7-4503-81cc-cba32b4b23a5"
      unitRef="usd">513033000</evh:CostofGoodsandServicesSoldExcludingDepreciationandAmortization>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yNS9mcmFnOmM5ZGJiZjkwNWNkYjRhM2Y5NGMxZDk0YTNmMjcyZGM2L3RhYmxlOmI3MTFhYTE1OTNiOTQzZWRhOGQ2ZDQyN2QxNTZkOGFjL3RhYmxlcmFuZ2U6YjcxMWFhMTU5M2I5NDNlZGE4ZDZkNDI3ZDE1NmQ4YWNfOS01LTEtMS0xNzc3NQ_ffcafb22-b8f3-4ddb-b38a-5a09c149759c"
      unitRef="usd">219499000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="i12a6d1161de54547bd29f8efccd4c9b0_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yNS9mcmFnOmM5ZGJiZjkwNWNkYjRhM2Y5NGMxZDk0YTNmMjcyZGM2L3RhYmxlOmI3MTFhYTE1OTNiOTQzZWRhOGQ2ZDQyN2QxNTZkOGFjL3RhYmxlcmFuZ2U6YjcxMWFhMTU5M2I5NDNlZGE4ZDZkNDI3ZDE1NmQ4YWNfOS03LTEtMS0xNzc3NQ_2a40fbef-ea9c-434a-9dd7-fb55df812da8"
      unitRef="usd">210412000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="i3e21049ffc224cacb8134d73c9bb5b38_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yNS9mcmFnOmM5ZGJiZjkwNWNkYjRhM2Y5NGMxZDk0YTNmMjcyZGM2L3RhYmxlOmI3MTFhYTE1OTNiOTQzZWRhOGQ2ZDQyN2QxNTZkOGFjL3RhYmxlcmFuZ2U6YjcxMWFhMTU5M2I5NDNlZGE4ZDZkNDI3ZDE1NmQ4YWNfOS01LTEtMS0xOTE5NA_260357c9-44f5-47eb-8910-fe9f9be2c529"
      unitRef="usd">236448000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:DepreciationAndAmortization
      contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yNS9mcmFnOmM5ZGJiZjkwNWNkYjRhM2Y5NGMxZDk0YTNmMjcyZGM2L3RhYmxlOmI3MTFhYTE1OTNiOTQzZWRhOGQ2ZDQyN2QxNTZkOGFjL3RhYmxlcmFuZ2U6YjcxMWFhMTU5M2I5NDNlZGE4ZDZkNDI3ZDE1NmQ4YWNfMTAtNS0xLTEtMTc3NzU_0357594c-325b-4aa3-8bd6-3a454899014c"
      unitRef="usd">60037000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="i12a6d1161de54547bd29f8efccd4c9b0_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yNS9mcmFnOmM5ZGJiZjkwNWNkYjRhM2Y5NGMxZDk0YTNmMjcyZGM2L3RhYmxlOmI3MTFhYTE1OTNiOTQzZWRhOGQ2ZDQyN2QxNTZkOGFjL3RhYmxlcmFuZ2U6YjcxMWFhMTU5M2I5NDNlZGE4ZDZkNDI3ZDE1NmQ4YWNfMTAtNy0xLTEtMTc3NzU_3698bf6c-728e-4fb0-9326-3be7d69ce16d"
      unitRef="usd">60835000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="i3e21049ffc224cacb8134d73c9bb5b38_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yNS9mcmFnOmM5ZGJiZjkwNWNkYjRhM2Y5NGMxZDk0YTNmMjcyZGM2L3RhYmxlOmI3MTFhYTE1OTNiOTQzZWRhOGQ2ZDQyN2QxNTZkOGFjL3RhYmxlcmFuZ2U6YjcxMWFhMTU5M2I5NDNlZGE4ZDZkNDI3ZDE1NmQ4YWNfMTAtNS0xLTEtMTkxOTQ_116164ee-d7ed-4efa-a55c-9f885f52e6d3"
      unitRef="usd">60323000</us-gaap:DepreciationAndAmortization>
    <us-gaap:GainLossOnDispositionOfAssets1
      contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yNS9mcmFnOmM5ZGJiZjkwNWNkYjRhM2Y5NGMxZDk0YTNmMjcyZGM2L3RhYmxlOmI3MTFhYTE1OTNiOTQzZWRhOGQ2ZDQyN2QxNTZkOGFjL3RhYmxlcmFuZ2U6YjcxMWFhMTU5M2I5NDNlZGE4ZDZkNDI3ZDE1NmQ4YWNfMTEtNS0xLTEtMTc3NzU_d8f01148-9c70-4aa0-bf27-8476ae51c59d"
      unitRef="usd">0</us-gaap:GainLossOnDispositionOfAssets1>
    <us-gaap:GainLossOnDispositionOfAssets1
      contextRef="i12a6d1161de54547bd29f8efccd4c9b0_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yNS9mcmFnOmM5ZGJiZjkwNWNkYjRhM2Y5NGMxZDk0YTNmMjcyZGM2L3RhYmxlOmI3MTFhYTE1OTNiOTQzZWRhOGQ2ZDQyN2QxNTZkOGFjL3RhYmxlcmFuZ2U6YjcxMWFhMTU5M2I5NDNlZGE4ZDZkNDI3ZDE1NmQ4YWNfMTEtNy0xLTEtMTc3NzU_3c503b77-91c5-4b7d-8c43-768d2c6a0714"
      unitRef="usd">-698000</us-gaap:GainLossOnDispositionOfAssets1>
    <us-gaap:GainLossOnDispositionOfAssets1
      contextRef="i3e21049ffc224cacb8134d73c9bb5b38_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yNS9mcmFnOmM5ZGJiZjkwNWNkYjRhM2Y5NGMxZDk0YTNmMjcyZGM2L3RhYmxlOmI3MTFhYTE1OTNiOTQzZWRhOGQ2ZDQyN2QxNTZkOGFjL3RhYmxlcmFuZ2U6YjcxMWFhMTU5M2I5NDNlZGE4ZDZkNDI3ZDE1NmQ4YWNfMTEtNS0xLTEtMTkxOTQ_027077f6-dbbd-487f-afe6-785813b33185"
      unitRef="usd">9600000</us-gaap:GainLossOnDispositionOfAssets1>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yNS9mcmFnOmM5ZGJiZjkwNWNkYjRhM2Y5NGMxZDk0YTNmMjcyZGM2L3RhYmxlOmI3MTFhYTE1OTNiOTQzZWRhOGQ2ZDQyN2QxNTZkOGFjL3RhYmxlcmFuZ2U6YjcxMWFhMTU5M2I5NDNlZGE4ZDZkNDI3ZDE1NmQ4YWNfMTItNS0xLTEtMTc3NzU_a8c9970a-8e07-49b9-896b-f39467decb53"
      unitRef="usd">0</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="i12a6d1161de54547bd29f8efccd4c9b0_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yNS9mcmFnOmM5ZGJiZjkwNWNkYjRhM2Y5NGMxZDk0YTNmMjcyZGM2L3RhYmxlOmI3MTFhYTE1OTNiOTQzZWRhOGQ2ZDQyN2QxNTZkOGFjL3RhYmxlcmFuZ2U6YjcxMWFhMTU5M2I5NDNlZGE4ZDZkNDI3ZDE1NmQ4YWNfMTItNy0xLTEtMTc3NzU_288fc4b3-6a7c-4898-95e8-38528f8a2227"
      unitRef="usd">-4789000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="i3e21049ffc224cacb8134d73c9bb5b38_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yNS9mcmFnOmM5ZGJiZjkwNWNkYjRhM2Y5NGMxZDk0YTNmMjcyZGM2L3RhYmxlOmI3MTFhYTE1OTNiOTQzZWRhOGQ2ZDQyN2QxNTZkOGFjL3RhYmxlcmFuZ2U6YjcxMWFhMTU5M2I5NDNlZGE4ZDZkNDI3ZDE1NmQ4YWNfMTItNS0xLTEtMTkyMDI_552c3561-6c2b-4ebf-8dc3-afaa7c08f663"
      unitRef="usd">0</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yNS9mcmFnOmM5ZGJiZjkwNWNkYjRhM2Y5NGMxZDk0YTNmMjcyZGM2L3RhYmxlOmI3MTFhYTE1OTNiOTQzZWRhOGQ2ZDQyN2QxNTZkOGFjL3RhYmxlcmFuZ2U6YjcxMWFhMTU5M2I5NDNlZGE4ZDZkNDI3ZDE1NmQ4YWNfMTMtNS0xLTEtMTc3NzU_80c82eff-d414-4c4f-aa27-679d77cbc4a5"
      unitRef="usd">0</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="i12a6d1161de54547bd29f8efccd4c9b0_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yNS9mcmFnOmM5ZGJiZjkwNWNkYjRhM2Y5NGMxZDk0YTNmMjcyZGM2L3RhYmxlOmI3MTFhYTE1OTNiOTQzZWRhOGQ2ZDQyN2QxNTZkOGFjL3RhYmxlcmFuZ2U6YjcxMWFhMTU5M2I5NDNlZGE4ZDZkNDI3ZDE1NmQ4YWNfMTMtNy0xLTEtMTc3NzU_49dc0f5d-bc2d-4491-8ca2-1c167853b9ca"
      unitRef="usd">215100000</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="i3e21049ffc224cacb8134d73c9bb5b38_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yNS9mcmFnOmM5ZGJiZjkwNWNkYjRhM2Y5NGMxZDk0YTNmMjcyZGM2L3RhYmxlOmI3MTFhYTE1OTNiOTQzZWRhOGQ2ZDQyN2QxNTZkOGFjL3RhYmxlcmFuZ2U6YjcxMWFhMTU5M2I5NDNlZGE4ZDZkNDI3ZDE1NmQ4YWNfMTMtNS0xLTEtMTkyMDI_c0975c81-d5ff-4b9c-8c73-e9cba8c13460"
      unitRef="usd">199800000</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
      contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yNS9mcmFnOmM5ZGJiZjkwNWNkYjRhM2Y5NGMxZDk0YTNmMjcyZGM2L3RhYmxlOmI3MTFhYTE1OTNiOTQzZWRhOGQ2ZDQyN2QxNTZkOGFjL3RhYmxlcmFuZ2U6YjcxMWFhMTU5M2I5NDNlZGE4ZDZkNDI3ZDE1NmQ4YWNfMTQtNS0xLTEtMTc3NzU_4e2e85b9-06a6-4b27-9f5d-2a84797355a0"
      unitRef="usd">13281000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
      contextRef="i12a6d1161de54547bd29f8efccd4c9b0_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yNS9mcmFnOmM5ZGJiZjkwNWNkYjRhM2Y5NGMxZDk0YTNmMjcyZGM2L3RhYmxlOmI3MTFhYTE1OTNiOTQzZWRhOGQ2ZDQyN2QxNTZkOGFjL3RhYmxlcmFuZ2U6YjcxMWFhMTU5M2I5NDNlZGE4ZDZkNDI3ZDE1NmQ4YWNfMTQtNy0xLTEtMTc3NzU_c488d7c2-3696-4200-bb0b-a696f7d48699"
      unitRef="usd">3860000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
      contextRef="i3e21049ffc224cacb8134d73c9bb5b38_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yNS9mcmFnOmM5ZGJiZjkwNWNkYjRhM2Y5NGMxZDk0YTNmMjcyZGM2L3RhYmxlOmI3MTFhYTE1OTNiOTQzZWRhOGQ2ZDQyN2QxNTZkOGFjL3RhYmxlcmFuZ2U6YjcxMWFhMTU5M2I5NDNlZGE4ZDZkNDI3ZDE1NmQ4YWNfMTQtNS0xLTEtMTkyMDI_0e2f194b-5e96-485a-ab6b-24e8299a6428"
      unitRef="usd">-3997000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <us-gaap:OperatingExpenses
      contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yNS9mcmFnOmM5ZGJiZjkwNWNkYjRhM2Y5NGMxZDk0YTNmMjcyZGM2L3RhYmxlOmI3MTFhYTE1OTNiOTQzZWRhOGQ2ZDQyN2QxNTZkOGFjL3RhYmxlcmFuZ2U6YjcxMWFhMTU5M2I5NDNlZGE4ZDZkNDI3ZDE1NmQ4YWNfMTUtNS0xLTEtMTc3NzU_a00d0f8e-7cc7-4923-ad6a-6f344ca790ba"
      unitRef="usd">950368000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="i12a6d1161de54547bd29f8efccd4c9b0_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yNS9mcmFnOmM5ZGJiZjkwNWNkYjRhM2Y5NGMxZDk0YTNmMjcyZGM2L3RhYmxlOmI3MTFhYTE1OTNiOTQzZWRhOGQ2ZDQyN2QxNTZkOGFjL3RhYmxlcmFuZ2U6YjcxMWFhMTU5M2I5NDNlZGE4ZDZkNDI3ZDE1NmQ4YWNfMTUtNy0xLTEtMTc3NzU_5bd4d51d-bda6-48d8-ab16-e3d0bffe94f3"
      unitRef="usd">1192275000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="i3e21049ffc224cacb8134d73c9bb5b38_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yNS9mcmFnOmM5ZGJiZjkwNWNkYjRhM2Y5NGMxZDk0YTNmMjcyZGM2L3RhYmxlOmI3MTFhYTE1OTNiOTQzZWRhOGQ2ZDQyN2QxNTZkOGFjL3RhYmxlcmFuZ2U6YjcxMWFhMTU5M2I5NDNlZGE4ZDZkNDI3ZDE1NmQ4YWNfMTUtNS0xLTEtMTkyMDI_92ab6dce-bce4-4135-8b60-f3dd13d49c50"
      unitRef="usd">996007000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yNS9mcmFnOmM5ZGJiZjkwNWNkYjRhM2Y5NGMxZDk0YTNmMjcyZGM2L3RhYmxlOmI3MTFhYTE1OTNiOTQzZWRhOGQ2ZDQyN2QxNTZkOGFjL3RhYmxlcmFuZ2U6YjcxMWFhMTU5M2I5NDNlZGE4ZDZkNDI3ZDE1NmQ4YWNfMTYtNS0xLTEtMTc3NzU_5a9e3c8b-5326-48e4-a504-4963dc49f4ea"
      unitRef="usd">-42411000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i12a6d1161de54547bd29f8efccd4c9b0_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yNS9mcmFnOmM5ZGJiZjkwNWNkYjRhM2Y5NGMxZDk0YTNmMjcyZGM2L3RhYmxlOmI3MTFhYTE1OTNiOTQzZWRhOGQ2ZDQyN2QxNTZkOGFjL3RhYmxlcmFuZ2U6YjcxMWFhMTU5M2I5NDNlZGE4ZDZkNDI3ZDE1NmQ4YWNfMTYtNy0xLTEtMTc3NzU_177902cf-abf1-49d7-8d84-69cac6134564"
      unitRef="usd">-267636000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i3e21049ffc224cacb8134d73c9bb5b38_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yNS9mcmFnOmM5ZGJiZjkwNWNkYjRhM2Y5NGMxZDk0YTNmMjcyZGM2L3RhYmxlOmI3MTFhYTE1OTNiOTQzZWRhOGQ2ZDQyN2QxNTZkOGFjL3RhYmxlcmFuZ2U6YjcxMWFhMTU5M2I5NDNlZGE4ZDZkNDI3ZDE1NmQ4YWNfMTYtNS0xLTEtMTkyMDI_b8dd709a-9991-431b-8085-5676c5ff9c6a"
      unitRef="usd">-308885000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InvestmentIncomeInterest
      contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yNS9mcmFnOmM5ZGJiZjkwNWNkYjRhM2Y5NGMxZDk0YTNmMjcyZGM2L3RhYmxlOmI3MTFhYTE1OTNiOTQzZWRhOGQ2ZDQyN2QxNTZkOGFjL3RhYmxlcmFuZ2U6YjcxMWFhMTU5M2I5NDNlZGE4ZDZkNDI3ZDE1NmQ4YWNfMTctNS0xLTEtMTc3NzU_ed8e7c16-ab33-49de-b138-dcd1658371e1"
      unitRef="usd">407000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="i12a6d1161de54547bd29f8efccd4c9b0_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yNS9mcmFnOmM5ZGJiZjkwNWNkYjRhM2Y5NGMxZDk0YTNmMjcyZGM2L3RhYmxlOmI3MTFhYTE1OTNiOTQzZWRhOGQ2ZDQyN2QxNTZkOGFjL3RhYmxlcmFuZ2U6YjcxMWFhMTU5M2I5NDNlZGE4ZDZkNDI3ZDE1NmQ4YWNfMTctNy0xLTEtMTc3NzU_5fa1f4cc-ec24-4b32-b3bf-a9470d8699ef"
      unitRef="usd">2633000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="i3e21049ffc224cacb8134d73c9bb5b38_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yNS9mcmFnOmM5ZGJiZjkwNWNkYjRhM2Y5NGMxZDk0YTNmMjcyZGM2L3RhYmxlOmI3MTFhYTE1OTNiOTQzZWRhOGQ2ZDQyN2QxNTZkOGFjL3RhYmxlcmFuZ2U6YjcxMWFhMTU5M2I5NDNlZGE4ZDZkNDI3ZDE1NmQ4YWNfMTctNS0xLTEtMTkyMDk_02a2ab01-df64-405a-8e99-e04063811304"
      unitRef="usd">3406000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InterestExpense
      contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yNS9mcmFnOmM5ZGJiZjkwNWNkYjRhM2Y5NGMxZDk0YTNmMjcyZGM2L3RhYmxlOmI3MTFhYTE1OTNiOTQzZWRhOGQ2ZDQyN2QxNTZkOGFjL3RhYmxlcmFuZ2U6YjcxMWFhMTU5M2I5NDNlZGE4ZDZkNDI3ZDE1NmQ4YWNfMTgtNS0xLTEtMTc3NzU_6a78d6c2-1102-41af-9956-e43dca7ba453"
      unitRef="usd">25425000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="i12a6d1161de54547bd29f8efccd4c9b0_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yNS9mcmFnOmM5ZGJiZjkwNWNkYjRhM2Y5NGMxZDk0YTNmMjcyZGM2L3RhYmxlOmI3MTFhYTE1OTNiOTQzZWRhOGQ2ZDQyN2QxNTZkOGFjL3RhYmxlcmFuZ2U6YjcxMWFhMTU5M2I5NDNlZGE4ZDZkNDI3ZDE1NmQ4YWNfMTgtNy0xLTEtMTc3NzU_99ca1463-f660-4524-8ecc-51938d108e3d"
      unitRef="usd">28325000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="i3e21049ffc224cacb8134d73c9bb5b38_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yNS9mcmFnOmM5ZGJiZjkwNWNkYjRhM2Y5NGMxZDk0YTNmMjcyZGM2L3RhYmxlOmI3MTFhYTE1OTNiOTQzZWRhOGQ2ZDQyN2QxNTZkOGFjL3RhYmxlcmFuZ2U6YjcxMWFhMTU5M2I5NDNlZGE4ZDZkNDI3ZDE1NmQ4YWNfMTgtNS0xLTEtMTkyMDk_7c53cd4e-aeb0-46af-90bb-c9b0f542fead"
      unitRef="usd">14555000</us-gaap:InterestExpense>
    <us-gaap:EquityMethodInvestmentOtherThanTemporaryImpairment
      contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yNS9mcmFnOmM5ZGJiZjkwNWNkYjRhM2Y5NGMxZDk0YTNmMjcyZGM2L3RhYmxlOmI3MTFhYTE1OTNiOTQzZWRhOGQ2ZDQyN2QxNTZkOGFjL3RhYmxlcmFuZ2U6YjcxMWFhMTU5M2I5NDNlZGE4ZDZkNDI3ZDE1NmQ4YWNfMTktNS0xLTEtMTc3NzU_f623abc1-715a-4242-bdf3-2cb73a19f981"
      unitRef="usd">0</us-gaap:EquityMethodInvestmentOtherThanTemporaryImpairment>
    <us-gaap:EquityMethodInvestmentOtherThanTemporaryImpairment
      contextRef="i12a6d1161de54547bd29f8efccd4c9b0_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yNS9mcmFnOmM5ZGJiZjkwNWNkYjRhM2Y5NGMxZDk0YTNmMjcyZGM2L3RhYmxlOmI3MTFhYTE1OTNiOTQzZWRhOGQ2ZDQyN2QxNTZkOGFjL3RhYmxlcmFuZ2U6YjcxMWFhMTU5M2I5NDNlZGE4ZDZkNDI3ZDE1NmQ4YWNfMTktNy0xLTEtMTc3NzU_6b50cf8a-2ad6-42c5-a4ec-1c5bbca0c14b"
      unitRef="usd">47133000</us-gaap:EquityMethodInvestmentOtherThanTemporaryImpairment>
    <us-gaap:EquityMethodInvestmentOtherThanTemporaryImpairment
      contextRef="i3e21049ffc224cacb8134d73c9bb5b38_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yNS9mcmFnOmM5ZGJiZjkwNWNkYjRhM2Y5NGMxZDk0YTNmMjcyZGM2L3RhYmxlOmI3MTFhYTE1OTNiOTQzZWRhOGQ2ZDQyN2QxNTZkOGFjL3RhYmxlcmFuZ2U6YjcxMWFhMTU5M2I5NDNlZGE4ZDZkNDI3ZDE1NmQ4YWNfMTktNS0xLTEtMTkyMDk_adf0b0ad-6da5-4047-bd24-49ea7a1947e6"
      unitRef="usd">0</us-gaap:EquityMethodInvestmentOtherThanTemporaryImpairment>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yNS9mcmFnOmM5ZGJiZjkwNWNkYjRhM2Y5NGMxZDk0YTNmMjcyZGM2L3RhYmxlOmI3MTFhYTE1OTNiOTQzZWRhOGQ2ZDQyN2QxNTZkOGFjL3RhYmxlcmFuZ2U6YjcxMWFhMTU5M2I5NDNlZGE4ZDZkNDI3ZDE1NmQ4YWNfMjAtNS0xLTEtMTc3NzU_513dd88f-3329-4fab-bb44-62cfdb086baf"
      unitRef="usd">13179000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="i12a6d1161de54547bd29f8efccd4c9b0_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yNS9mcmFnOmM5ZGJiZjkwNWNkYjRhM2Y5NGMxZDk0YTNmMjcyZGM2L3RhYmxlOmI3MTFhYTE1OTNiOTQzZWRhOGQ2ZDQyN2QxNTZkOGFjL3RhYmxlcmFuZ2U6YjcxMWFhMTU5M2I5NDNlZGE4ZDZkNDI3ZDE1NmQ4YWNfMjAtNy0xLTEtMTc3NzU_3a7067e2-b4dd-4080-acac-eecaaedd5656"
      unitRef="usd">10039000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="i3e21049ffc224cacb8134d73c9bb5b38_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yNS9mcmFnOmM5ZGJiZjkwNWNkYjRhM2Y5NGMxZDk0YTNmMjcyZGM2L3RhYmxlOmI3MTFhYTE1OTNiOTQzZWRhOGQ2ZDQyN2QxNTZkOGFjL3RhYmxlcmFuZ2U6YjcxMWFhMTU5M2I5NDNlZGE4ZDZkNDI3ZDE1NmQ4YWNfMjAtNS0xLTEtMTkyMDk_a4aa33ae-b62f-45ef-841c-965aac144139"
      unitRef="usd">-9465000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <evh:GainOnTransferOfMembership
      contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yNS9mcmFnOmM5ZGJiZjkwNWNkYjRhM2Y5NGMxZDk0YTNmMjcyZGM2L3RhYmxlOmI3MTFhYTE1OTNiOTQzZWRhOGQ2ZDQyN2QxNTZkOGFjL3RhYmxlcmFuZ2U6YjcxMWFhMTU5M2I5NDNlZGE4ZDZkNDI3ZDE1NmQ4YWNfMjEtNS0xLTEtMTc3NzU_2189a2b7-76ab-4792-bdd1-8a29f3c4f5fb"
      unitRef="usd">45938000</evh:GainOnTransferOfMembership>
    <evh:GainOnTransferOfMembership
      contextRef="i12a6d1161de54547bd29f8efccd4c9b0_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yNS9mcmFnOmM5ZGJiZjkwNWNkYjRhM2Y5NGMxZDk0YTNmMjcyZGM2L3RhYmxlOmI3MTFhYTE1OTNiOTQzZWRhOGQ2ZDQyN2QxNTZkOGFjL3RhYmxlcmFuZ2U6YjcxMWFhMTU5M2I5NDNlZGE4ZDZkNDI3ZDE1NmQ4YWNfMjEtNy0xLTEtMTc3NzU_7b9abb88-eef2-4628-a46a-c03d5bbcc3a4"
      unitRef="usd">0</evh:GainOnTransferOfMembership>
    <evh:GainOnTransferOfMembership
      contextRef="i3e21049ffc224cacb8134d73c9bb5b38_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yNS9mcmFnOmM5ZGJiZjkwNWNkYjRhM2Y5NGMxZDk0YTNmMjcyZGM2L3RhYmxlOmI3MTFhYTE1OTNiOTQzZWRhOGQ2ZDQyN2QxNTZkOGFjL3RhYmxlcmFuZ2U6YjcxMWFhMTU5M2I5NDNlZGE4ZDZkNDI3ZDE1NmQ4YWNfMjEtNS0xLTEtMTkyNDU_054e8a73-ab2f-4fc9-8104-50197adfd3ae"
      unitRef="usd">0</evh:GainOnTransferOfMembership>
    <evh:GainLossOnRepaymentOfDebt
      contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yNS9mcmFnOmM5ZGJiZjkwNWNkYjRhM2Y5NGMxZDk0YTNmMjcyZGM2L3RhYmxlOmI3MTFhYTE1OTNiOTQzZWRhOGQ2ZDQyN2QxNTZkOGFjL3RhYmxlcmFuZ2U6YjcxMWFhMTU5M2I5NDNlZGE4ZDZkNDI3ZDE1NmQ4YWNfMjItNS0xLTEtMTc3NzU_84fe278a-0a04-48d8-8928-fdb3b9d5c81e"
      unitRef="usd">-21343000</evh:GainLossOnRepaymentOfDebt>
    <evh:GainLossOnRepaymentOfDebt
      contextRef="i12a6d1161de54547bd29f8efccd4c9b0_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yNS9mcmFnOmM5ZGJiZjkwNWNkYjRhM2Y5NGMxZDk0YTNmMjcyZGM2L3RhYmxlOmI3MTFhYTE1OTNiOTQzZWRhOGQ2ZDQyN2QxNTZkOGFjL3RhYmxlcmFuZ2U6YjcxMWFhMTU5M2I5NDNlZGE4ZDZkNDI3ZDE1NmQ4YWNfMjItNy0xLTEtMTc3NzU_9810b448-5082-441f-a337-1478828e290d"
      unitRef="usd">0</evh:GainLossOnRepaymentOfDebt>
    <evh:GainLossOnRepaymentOfDebt
      contextRef="i3e21049ffc224cacb8134d73c9bb5b38_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yNS9mcmFnOmM5ZGJiZjkwNWNkYjRhM2Y5NGMxZDk0YTNmMjcyZGM2L3RhYmxlOmI3MTFhYTE1OTNiOTQzZWRhOGQ2ZDQyN2QxNTZkOGFjL3RhYmxlcmFuZ2U6YjcxMWFhMTU5M2I5NDNlZGE4ZDZkNDI3ZDE1NmQ4YWNfMjItNS0xLTEtMTkyNTY_42d6422f-f6fc-425a-bd2d-69d7f733c03e"
      unitRef="usd">0</evh:GainLossOnRepaymentOfDebt>
    <us-gaap:OtherOperatingIncomeExpenseNet
      contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yNS9mcmFnOmM5ZGJiZjkwNWNkYjRhM2Y5NGMxZDk0YTNmMjcyZGM2L3RhYmxlOmI3MTFhYTE1OTNiOTQzZWRhOGQ2ZDQyN2QxNTZkOGFjL3RhYmxlcmFuZ2U6YjcxMWFhMTU5M2I5NDNlZGE4ZDZkNDI3ZDE1NmQ4YWNfMjMtNS0xLTEtMTc3NzU_a4c56d1f-7b46-4aa4-bae4-6102339358fc"
      unitRef="usd">-146000</us-gaap:OtherOperatingIncomeExpenseNet>
    <us-gaap:OtherOperatingIncomeExpenseNet
      contextRef="i12a6d1161de54547bd29f8efccd4c9b0_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yNS9mcmFnOmM5ZGJiZjkwNWNkYjRhM2Y5NGMxZDk0YTNmMjcyZGM2L3RhYmxlOmI3MTFhYTE1OTNiOTQzZWRhOGQ2ZDQyN2QxNTZkOGFjL3RhYmxlcmFuZ2U6YjcxMWFhMTU5M2I5NDNlZGE4ZDZkNDI3ZDE1NmQ4YWNfMjMtNy0xLTEtMTc3NzU_83e1e614-ddc5-4c90-87f7-5e94810cc873"
      unitRef="usd">-118000</us-gaap:OtherOperatingIncomeExpenseNet>
    <us-gaap:OtherOperatingIncomeExpenseNet
      contextRef="i3e21049ffc224cacb8134d73c9bb5b38_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yNS9mcmFnOmM5ZGJiZjkwNWNkYjRhM2Y5NGMxZDk0YTNmMjcyZGM2L3RhYmxlOmI3MTFhYTE1OTNiOTQzZWRhOGQ2ZDQyN2QxNTZkOGFjL3RhYmxlcmFuZ2U6YjcxMWFhMTU5M2I5NDNlZGE4ZDZkNDI3ZDE1NmQ4YWNfMjMtNS0xLTEtMTkyNTY_2fce15e8-3942-40d1-ab33-248f86e35123"
      unitRef="usd">-489000</us-gaap:OtherOperatingIncomeExpenseNet>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yNS9mcmFnOmM5ZGJiZjkwNWNkYjRhM2Y5NGMxZDk0YTNmMjcyZGM2L3RhYmxlOmI3MTFhYTE1OTNiOTQzZWRhOGQ2ZDQyN2QxNTZkOGFjL3RhYmxlcmFuZ2U6YjcxMWFhMTU5M2I5NDNlZGE4ZDZkNDI3ZDE1NmQ4YWNfMjQtNS0xLTEtMTc3NzU_5e6b7864-2dc1-4a33-861e-24d2b5b993d1"
      unitRef="usd">-29801000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i12a6d1161de54547bd29f8efccd4c9b0_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yNS9mcmFnOmM5ZGJiZjkwNWNkYjRhM2Y5NGMxZDk0YTNmMjcyZGM2L3RhYmxlOmI3MTFhYTE1OTNiOTQzZWRhOGQ2ZDQyN2QxNTZkOGFjL3RhYmxlcmFuZ2U6YjcxMWFhMTU5M2I5NDNlZGE4ZDZkNDI3ZDE1NmQ4YWNfMjQtNy0xLTEtMTc3NzU_8c28df32-8e64-4612-a55c-a3ec6ac15298"
      unitRef="usd">-330540000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i3e21049ffc224cacb8134d73c9bb5b38_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yNS9mcmFnOmM5ZGJiZjkwNWNkYjRhM2Y5NGMxZDk0YTNmMjcyZGM2L3RhYmxlOmI3MTFhYTE1OTNiOTQzZWRhOGQ2ZDQyN2QxNTZkOGFjL3RhYmxlcmFuZ2U6YjcxMWFhMTU5M2I5NDNlZGE4ZDZkNDI3ZDE1NmQ4YWNfMjQtNS0xLTEtMTkyNTY_32509e42-1c58-47aa-a766-3ae60096c836"
      unitRef="usd">-329988000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yNS9mcmFnOmM5ZGJiZjkwNWNkYjRhM2Y5NGMxZDk0YTNmMjcyZGM2L3RhYmxlOmI3MTFhYTE1OTNiOTQzZWRhOGQ2ZDQyN2QxNTZkOGFjL3RhYmxlcmFuZ2U6YjcxMWFhMTU5M2I5NDNlZGE4ZDZkNDI3ZDE1NmQ4YWNfMjUtNS0xLTEtMTc3NzU_1f00f303-89f9-4899-a27f-5daa78e5cccf"
      unitRef="usd">483000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i12a6d1161de54547bd29f8efccd4c9b0_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yNS9mcmFnOmM5ZGJiZjkwNWNkYjRhM2Y5NGMxZDk0YTNmMjcyZGM2L3RhYmxlOmI3MTFhYTE1OTNiOTQzZWRhOGQ2ZDQyN2QxNTZkOGFjL3RhYmxlcmFuZ2U6YjcxMWFhMTU5M2I5NDNlZGE4ZDZkNDI3ZDE1NmQ4YWNfMjUtNy0xLTEtMTc3NzU_ff1e4f9d-543d-4224-9369-edd44021901f"
      unitRef="usd">-2368000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i3e21049ffc224cacb8134d73c9bb5b38_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yNS9mcmFnOmM5ZGJiZjkwNWNkYjRhM2Y5NGMxZDk0YTNmMjcyZGM2L3RhYmxlOmI3MTFhYTE1OTNiOTQzZWRhOGQ2ZDQyN2QxNTZkOGFjL3RhYmxlcmFuZ2U6YjcxMWFhMTU5M2I5NDNlZGE4ZDZkNDI3ZDE1NmQ4YWNfMjUtNS0xLTEtMTkyNTY_e81e073e-fd96-466f-a7bc-e276283a5f2e"
      unitRef="usd">-22795000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
      contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yNS9mcmFnOmM5ZGJiZjkwNWNkYjRhM2Y5NGMxZDk0YTNmMjcyZGM2L3RhYmxlOmI3MTFhYTE1OTNiOTQzZWRhOGQ2ZDQyN2QxNTZkOGFjL3RhYmxlcmFuZ2U6YjcxMWFhMTU5M2I5NDNlZGE4ZDZkNDI3ZDE1NmQ4YWNfMjYtNS0xLTEtMTc3NzU_d76450ef-cfe7-4881-b23e-9a162abc49db"
      unitRef="usd">-30284000</us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i12a6d1161de54547bd29f8efccd4c9b0_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yNS9mcmFnOmM5ZGJiZjkwNWNkYjRhM2Y5NGMxZDk0YTNmMjcyZGM2L3RhYmxlOmI3MTFhYTE1OTNiOTQzZWRhOGQ2ZDQyN2QxNTZkOGFjL3RhYmxlcmFuZ2U6YjcxMWFhMTU5M2I5NDNlZGE4ZDZkNDI3ZDE1NmQ4YWNfMjYtNy0xLTEtMTc3NzU_46bcd607-6919-41ba-bd7e-9e6da2dfd783"
      unitRef="usd">-328172000</us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i3e21049ffc224cacb8134d73c9bb5b38_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yNS9mcmFnOmM5ZGJiZjkwNWNkYjRhM2Y5NGMxZDk0YTNmMjcyZGM2L3RhYmxlOmI3MTFhYTE1OTNiOTQzZWRhOGQ2ZDQyN2QxNTZkOGFjL3RhYmxlcmFuZ2U6YjcxMWFhMTU5M2I5NDNlZGE4ZDZkNDI3ZDE1NmQ4YWNfMjYtNS0xLTEtMTkyNTY_7cd677f7-562c-4cff-afb6-94eb73d0af25"
      unitRef="usd">-307193000</us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax
      contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yNS9mcmFnOmM5ZGJiZjkwNWNkYjRhM2Y5NGMxZDk0YTNmMjcyZGM2L3RhYmxlOmI3MTFhYTE1OTNiOTQzZWRhOGQ2ZDQyN2QxNTZkOGFjL3RhYmxlcmFuZ2U6YjcxMWFhMTU5M2I5NDNlZGE4ZDZkNDI3ZDE1NmQ4YWNfMjctNS0xLTEtMTc3NzU_3a7f9340-a2d9-4068-b095-f659267e962c"
      unitRef="usd">-7317000</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax
      contextRef="i12a6d1161de54547bd29f8efccd4c9b0_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yNS9mcmFnOmM5ZGJiZjkwNWNkYjRhM2Y5NGMxZDk0YTNmMjcyZGM2L3RhYmxlOmI3MTFhYTE1OTNiOTQzZWRhOGQ2ZDQyN2QxNTZkOGFjL3RhYmxlcmFuZ2U6YjcxMWFhMTU5M2I5NDNlZGE4ZDZkNDI3ZDE1NmQ4YWNfMjctNy0xLTEtMTc3NzU_6123f20d-b2da-4983-8481-3001d793c73d"
      unitRef="usd">-6074000</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax
      contextRef="i3e21049ffc224cacb8134d73c9bb5b38_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yNS9mcmFnOmM5ZGJiZjkwNWNkYjRhM2Y5NGMxZDk0YTNmMjcyZGM2L3RhYmxlOmI3MTFhYTE1OTNiOTQzZWRhOGQ2ZDQyN2QxNTZkOGFjL3RhYmxlcmFuZ2U6YjcxMWFhMTU5M2I5NDNlZGE4ZDZkNDI3ZDE1NmQ4YWNfMjctNS0xLTEtMTkyNTY_cd15aa32-72bb-4df8-a330-8fac8ecbd8bb"
      unitRef="usd">1613000</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax>
    <us-gaap:ProfitLoss
      contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yNS9mcmFnOmM5ZGJiZjkwNWNkYjRhM2Y5NGMxZDk0YTNmMjcyZGM2L3RhYmxlOmI3MTFhYTE1OTNiOTQzZWRhOGQ2ZDQyN2QxNTZkOGFjL3RhYmxlcmFuZ2U6YjcxMWFhMTU5M2I5NDNlZGE4ZDZkNDI3ZDE1NmQ4YWNfMjgtNS0xLTEtMTc3NzU_c49b99c2-1aef-4003-806b-11d043c6a947"
      unitRef="usd">-37601000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i12a6d1161de54547bd29f8efccd4c9b0_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yNS9mcmFnOmM5ZGJiZjkwNWNkYjRhM2Y5NGMxZDk0YTNmMjcyZGM2L3RhYmxlOmI3MTFhYTE1OTNiOTQzZWRhOGQ2ZDQyN2QxNTZkOGFjL3RhYmxlcmFuZ2U6YjcxMWFhMTU5M2I5NDNlZGE4ZDZkNDI3ZDE1NmQ4YWNfMjgtNy0xLTEtMTc3NzU_059445f8-3794-4af1-abe2-9f2515cac297"
      unitRef="usd">-334246000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i3e21049ffc224cacb8134d73c9bb5b38_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yNS9mcmFnOmM5ZGJiZjkwNWNkYjRhM2Y5NGMxZDk0YTNmMjcyZGM2L3RhYmxlOmI3MTFhYTE1OTNiOTQzZWRhOGQ2ZDQyN2QxNTZkOGFjL3RhYmxlcmFuZ2U6YjcxMWFhMTU5M2I5NDNlZGE4ZDZkNDI3ZDE1NmQ4YWNfMjgtNS0xLTEtMTkyNTY_29de1fd1-21e6-4603-8e1d-b3241b370b6f"
      unitRef="usd">-305580000</us-gaap:ProfitLoss>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yNS9mcmFnOmM5ZGJiZjkwNWNkYjRhM2Y5NGMxZDk0YTNmMjcyZGM2L3RhYmxlOmI3MTFhYTE1OTNiOTQzZWRhOGQ2ZDQyN2QxNTZkOGFjL3RhYmxlcmFuZ2U6YjcxMWFhMTU5M2I5NDNlZGE4ZDZkNDI3ZDE1NmQ4YWNfMjktNS0xLTEtMTc3NzU_a10ceaab-8664-4942-a66d-497e3968da6b"
      unitRef="usd">0</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="i12a6d1161de54547bd29f8efccd4c9b0_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yNS9mcmFnOmM5ZGJiZjkwNWNkYjRhM2Y5NGMxZDk0YTNmMjcyZGM2L3RhYmxlOmI3MTFhYTE1OTNiOTQzZWRhOGQ2ZDQyN2QxNTZkOGFjL3RhYmxlcmFuZ2U6YjcxMWFhMTU5M2I5NDNlZGE4ZDZkNDI3ZDE1NmQ4YWNfMjktNy0xLTEtMTc3NzU_1026adc1-b9ab-4994-88ed-075d8f12b561"
      unitRef="usd">0</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="i3e21049ffc224cacb8134d73c9bb5b38_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yNS9mcmFnOmM5ZGJiZjkwNWNkYjRhM2Y5NGMxZDk0YTNmMjcyZGM2L3RhYmxlOmI3MTFhYTE1OTNiOTQzZWRhOGQ2ZDQyN2QxNTZkOGFjL3RhYmxlcmFuZ2U6YjcxMWFhMTU5M2I5NDNlZGE4ZDZkNDI3ZDE1NmQ4YWNfMjktNS0xLTEtMTkyNTY_786f1d03-94cb-48e8-ad31-9c0764623193"
      unitRef="usd">-3609000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yNS9mcmFnOmM5ZGJiZjkwNWNkYjRhM2Y5NGMxZDk0YTNmMjcyZGM2L3RhYmxlOmI3MTFhYTE1OTNiOTQzZWRhOGQ2ZDQyN2QxNTZkOGFjL3RhYmxlcmFuZ2U6YjcxMWFhMTU5M2I5NDNlZGE4ZDZkNDI3ZDE1NmQ4YWNfMzAtNS0xLTEtMTc3NzU_19b0e485-6260-41f1-b4e9-3c97c234c728"
      unitRef="usd">-37601000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted
      contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yNS9mcmFnOmM5ZGJiZjkwNWNkYjRhM2Y5NGMxZDk0YTNmMjcyZGM2L3RhYmxlOmI3MTFhYTE1OTNiOTQzZWRhOGQ2ZDQyN2QxNTZkOGFjL3RhYmxlcmFuZ2U6YjcxMWFhMTU5M2I5NDNlZGE4ZDZkNDI3ZDE1NmQ4YWNfMzAtNS0xLTEtMTc3NzU_34c1e7e0-fc69-4bdc-be43-ddb3ef807107"
      unitRef="usd">-37601000</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="i12a6d1161de54547bd29f8efccd4c9b0_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yNS9mcmFnOmM5ZGJiZjkwNWNkYjRhM2Y5NGMxZDk0YTNmMjcyZGM2L3RhYmxlOmI3MTFhYTE1OTNiOTQzZWRhOGQ2ZDQyN2QxNTZkOGFjL3RhYmxlcmFuZ2U6YjcxMWFhMTU5M2I5NDNlZGE4ZDZkNDI3ZDE1NmQ4YWNfMzAtNy0xLTEtMTc3NzU_47276093-49df-42a8-9bbd-a4f0df34d037"
      unitRef="usd">-334246000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted
      contextRef="i12a6d1161de54547bd29f8efccd4c9b0_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yNS9mcmFnOmM5ZGJiZjkwNWNkYjRhM2Y5NGMxZDk0YTNmMjcyZGM2L3RhYmxlOmI3MTFhYTE1OTNiOTQzZWRhOGQ2ZDQyN2QxNTZkOGFjL3RhYmxlcmFuZ2U6YjcxMWFhMTU5M2I5NDNlZGE4ZDZkNDI3ZDE1NmQ4YWNfMzAtNy0xLTEtMTc3NzU_e8f68bad-99dd-4b99-9acb-741a4f5652df"
      unitRef="usd">-334246000</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="i3e21049ffc224cacb8134d73c9bb5b38_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yNS9mcmFnOmM5ZGJiZjkwNWNkYjRhM2Y5NGMxZDk0YTNmMjcyZGM2L3RhYmxlOmI3MTFhYTE1OTNiOTQzZWRhOGQ2ZDQyN2QxNTZkOGFjL3RhYmxlcmFuZ2U6YjcxMWFhMTU5M2I5NDNlZGE4ZDZkNDI3ZDE1NmQ4YWNfMzAtNS0xLTEtMTkyNTY_436a8d3c-073f-4296-af03-689f7e52133b"
      unitRef="usd">-301971000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted
      contextRef="i3e21049ffc224cacb8134d73c9bb5b38_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yNS9mcmFnOmM5ZGJiZjkwNWNkYjRhM2Y5NGMxZDk0YTNmMjcyZGM2L3RhYmxlOmI3MTFhYTE1OTNiOTQzZWRhOGQ2ZDQyN2QxNTZkOGFjL3RhYmxlcmFuZ2U6YjcxMWFhMTU5M2I5NDNlZGE4ZDZkNDI3ZDE1NmQ4YWNfMzAtNS0xLTEtMTkyNTY_a8db8b9f-7556-4b88-8d4a-6b128c94ac69"
      unitRef="usd">-301971000</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
    <us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare
      contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yNS9mcmFnOmM5ZGJiZjkwNWNkYjRhM2Y5NGMxZDk0YTNmMjcyZGM2L3RhYmxlOmI3MTFhYTE1OTNiOTQzZWRhOGQ2ZDQyN2QxNTZkOGFjL3RhYmxlcmFuZ2U6YjcxMWFhMTU5M2I5NDNlZGE4ZDZkNDI3ZDE1NmQ4YWNfMzQtNS0xLTEtMTc3NzU_1be0d8aa-7784-4a8d-b716-b5e8a6f955e8"
      unitRef="usdPerShare">-0.35</us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerBasicShare
      contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yNS9mcmFnOmM5ZGJiZjkwNWNkYjRhM2Y5NGMxZDk0YTNmMjcyZGM2L3RhYmxlOmI3MTFhYTE1OTNiOTQzZWRhOGQ2ZDQyN2QxNTZkOGFjL3RhYmxlcmFuZ2U6YjcxMWFhMTU5M2I5NDNlZGE4ZDZkNDI3ZDE1NmQ4YWNfMzQtNS0xLTEtMTc3NzU_e035674e-3c54-4da7-a44d-68e94785e880"
      unitRef="usdPerShare">-0.35</us-gaap:IncomeLossFromContinuingOperationsPerBasicShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerBasicShare
      contextRef="i12a6d1161de54547bd29f8efccd4c9b0_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yNS9mcmFnOmM5ZGJiZjkwNWNkYjRhM2Y5NGMxZDk0YTNmMjcyZGM2L3RhYmxlOmI3MTFhYTE1OTNiOTQzZWRhOGQ2ZDQyN2QxNTZkOGFjL3RhYmxlcmFuZ2U6YjcxMWFhMTU5M2I5NDNlZGE4ZDZkNDI3ZDE1NmQ4YWNfMzQtNy0xLTEtMTc3NzU_47ab00f1-b3ad-4d5b-8c18-b329fbbc06ba"
      unitRef="usdPerShare">-3.86</us-gaap:IncomeLossFromContinuingOperationsPerBasicShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare
      contextRef="i12a6d1161de54547bd29f8efccd4c9b0_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yNS9mcmFnOmM5ZGJiZjkwNWNkYjRhM2Y5NGMxZDk0YTNmMjcyZGM2L3RhYmxlOmI3MTFhYTE1OTNiOTQzZWRhOGQ2ZDQyN2QxNTZkOGFjL3RhYmxlcmFuZ2U6YjcxMWFhMTU5M2I5NDNlZGE4ZDZkNDI3ZDE1NmQ4YWNfMzQtNy0xLTEtMTc3NzU_c1dc9607-9bf5-4cf1-a3d2-b0db3afb1c8d"
      unitRef="usdPerShare">-3.86</us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare
      contextRef="i3e21049ffc224cacb8134d73c9bb5b38_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yNS9mcmFnOmM5ZGJiZjkwNWNkYjRhM2Y5NGMxZDk0YTNmMjcyZGM2L3RhYmxlOmI3MTFhYTE1OTNiOTQzZWRhOGQ2ZDQyN2QxNTZkOGFjL3RhYmxlcmFuZ2U6YjcxMWFhMTU5M2I5NDNlZGE4ZDZkNDI3ZDE1NmQ4YWNfMzQtNS0xLTEtMTkyNjg_297fced9-7321-4394-9d35-8f3d7ae6d0e4"
      unitRef="usdPerShare">-3.73</us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerBasicShare
      contextRef="i3e21049ffc224cacb8134d73c9bb5b38_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yNS9mcmFnOmM5ZGJiZjkwNWNkYjRhM2Y5NGMxZDk0YTNmMjcyZGM2L3RhYmxlOmI3MTFhYTE1OTNiOTQzZWRhOGQ2ZDQyN2QxNTZkOGFjL3RhYmxlcmFuZ2U6YjcxMWFhMTU5M2I5NDNlZGE4ZDZkNDI3ZDE1NmQ4YWNfMzQtNS0xLTEtMTkyNjg_d87662c3-104c-4c72-8c1f-7e928653cdf7"
      unitRef="usdPerShare">-3.73</us-gaap:IncomeLossFromContinuingOperationsPerBasicShare>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare
      contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yNS9mcmFnOmM5ZGJiZjkwNWNkYjRhM2Y5NGMxZDk0YTNmMjcyZGM2L3RhYmxlOmI3MTFhYTE1OTNiOTQzZWRhOGQ2ZDQyN2QxNTZkOGFjL3RhYmxlcmFuZ2U6YjcxMWFhMTU5M2I5NDNlZGE4ZDZkNDI3ZDE1NmQ4YWNfMzUtNS0xLTEtMTc3NzU_3cbafcdb-0f82-465e-b519-e19d64aa375c"
      unitRef="usdPerShare">-0.09</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare
      contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yNS9mcmFnOmM5ZGJiZjkwNWNkYjRhM2Y5NGMxZDk0YTNmMjcyZGM2L3RhYmxlOmI3MTFhYTE1OTNiOTQzZWRhOGQ2ZDQyN2QxNTZkOGFjL3RhYmxlcmFuZ2U6YjcxMWFhMTU5M2I5NDNlZGE4ZDZkNDI3ZDE1NmQ4YWNfMzUtNS0xLTEtMTc3NzU_697a90c3-40a0-4d50-b5ad-b2ef2b6a2202"
      unitRef="usdPerShare">-0.09</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare
      contextRef="i12a6d1161de54547bd29f8efccd4c9b0_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yNS9mcmFnOmM5ZGJiZjkwNWNkYjRhM2Y5NGMxZDk0YTNmMjcyZGM2L3RhYmxlOmI3MTFhYTE1OTNiOTQzZWRhOGQ2ZDQyN2QxNTZkOGFjL3RhYmxlcmFuZ2U6YjcxMWFhMTU5M2I5NDNlZGE4ZDZkNDI3ZDE1NmQ4YWNfMzUtNy0xLTEtMTc3NzU_614d8f41-3c14-4669-9dc3-7aef83745f39"
      unitRef="usdPerShare">-0.08</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare
      contextRef="i12a6d1161de54547bd29f8efccd4c9b0_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yNS9mcmFnOmM5ZGJiZjkwNWNkYjRhM2Y5NGMxZDk0YTNmMjcyZGM2L3RhYmxlOmI3MTFhYTE1OTNiOTQzZWRhOGQ2ZDQyN2QxNTZkOGFjL3RhYmxlcmFuZ2U6YjcxMWFhMTU5M2I5NDNlZGE4ZDZkNDI3ZDE1NmQ4YWNfMzUtNy0xLTEtMTc3NzU_f821a2c7-e60f-4775-af30-3571e62c8d7b"
      unitRef="usdPerShare">-0.08</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare
      contextRef="i3e21049ffc224cacb8134d73c9bb5b38_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yNS9mcmFnOmM5ZGJiZjkwNWNkYjRhM2Y5NGMxZDk0YTNmMjcyZGM2L3RhYmxlOmI3MTFhYTE1OTNiOTQzZWRhOGQ2ZDQyN2QxNTZkOGFjL3RhYmxlcmFuZ2U6YjcxMWFhMTU5M2I5NDNlZGE4ZDZkNDI3ZDE1NmQ4YWNfMzUtNS0xLTEtMTkyNjg_65c2769c-8bf5-4a69-9670-8d84e869f596"
      unitRef="usdPerShare">0.02</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare
      contextRef="i3e21049ffc224cacb8134d73c9bb5b38_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yNS9mcmFnOmM5ZGJiZjkwNWNkYjRhM2Y5NGMxZDk0YTNmMjcyZGM2L3RhYmxlOmI3MTFhYTE1OTNiOTQzZWRhOGQ2ZDQyN2QxNTZkOGFjL3RhYmxlcmFuZ2U6YjcxMWFhMTU5M2I5NDNlZGE4ZDZkNDI3ZDE1NmQ4YWNfMzUtNS0xLTEtMTkyNjg_d3da87c4-e160-4bb7-b042-19a87036320a"
      unitRef="usdPerShare">0.02</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare>
    <evh:EarningsPerSharePortionAttributableToNoncontrollingInterestDiluted
      contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yNS9mcmFnOmM5ZGJiZjkwNWNkYjRhM2Y5NGMxZDk0YTNmMjcyZGM2L3RhYmxlOmI3MTFhYTE1OTNiOTQzZWRhOGQ2ZDQyN2QxNTZkOGFjL3RhYmxlcmFuZ2U6YjcxMWFhMTU5M2I5NDNlZGE4ZDZkNDI3ZDE1NmQ4YWNfMzYtMS0xLTEtMjU2MTE_b50e84b8-a45a-41d3-9af3-908304b36487"
      unitRef="usdPerShare">0</evh:EarningsPerSharePortionAttributableToNoncontrollingInterestDiluted>
    <evh:EarningsPerSharePortionAttributableToNoncontrollingInterestBasic
      contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yNS9mcmFnOmM5ZGJiZjkwNWNkYjRhM2Y5NGMxZDk0YTNmMjcyZGM2L3RhYmxlOmI3MTFhYTE1OTNiOTQzZWRhOGQ2ZDQyN2QxNTZkOGFjL3RhYmxlcmFuZ2U6YjcxMWFhMTU5M2I5NDNlZGE4ZDZkNDI3ZDE1NmQ4YWNfMzYtMS0xLTEtMjU2MTE_ee4b7836-0c1c-4e91-a00a-f4f08b39f581"
      unitRef="usdPerShare">0</evh:EarningsPerSharePortionAttributableToNoncontrollingInterestBasic>
    <evh:EarningsPerSharePortionAttributableToNoncontrollingInterestBasic
      contextRef="i12a6d1161de54547bd29f8efccd4c9b0_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yNS9mcmFnOmM5ZGJiZjkwNWNkYjRhM2Y5NGMxZDk0YTNmMjcyZGM2L3RhYmxlOmI3MTFhYTE1OTNiOTQzZWRhOGQ2ZDQyN2QxNTZkOGFjL3RhYmxlcmFuZ2U6YjcxMWFhMTU5M2I5NDNlZGE4ZDZkNDI3ZDE1NmQ4YWNfMzYtMy0xLTEtMjU2MTE_cebaab0d-cb9a-4d96-96cf-e73e49782c92"
      unitRef="usdPerShare">0</evh:EarningsPerSharePortionAttributableToNoncontrollingInterestBasic>
    <evh:EarningsPerSharePortionAttributableToNoncontrollingInterestDiluted
      contextRef="i12a6d1161de54547bd29f8efccd4c9b0_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yNS9mcmFnOmM5ZGJiZjkwNWNkYjRhM2Y5NGMxZDk0YTNmMjcyZGM2L3RhYmxlOmI3MTFhYTE1OTNiOTQzZWRhOGQ2ZDQyN2QxNTZkOGFjL3RhYmxlcmFuZ2U6YjcxMWFhMTU5M2I5NDNlZGE4ZDZkNDI3ZDE1NmQ4YWNfMzYtMy0xLTEtMjU2MTE_f7665397-906b-4348-84a7-07254c898be6"
      unitRef="usdPerShare">0</evh:EarningsPerSharePortionAttributableToNoncontrollingInterestDiluted>
    <evh:EarningsPerSharePortionAttributableToNoncontrollingInterestBasic
      contextRef="i3e21049ffc224cacb8134d73c9bb5b38_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yNS9mcmFnOmM5ZGJiZjkwNWNkYjRhM2Y5NGMxZDk0YTNmMjcyZGM2L3RhYmxlOmI3MTFhYTE1OTNiOTQzZWRhOGQ2ZDQyN2QxNTZkOGFjL3RhYmxlcmFuZ2U6YjcxMWFhMTU5M2I5NDNlZGE4ZDZkNDI3ZDE1NmQ4YWNfMzYtNS0xLTEtMjU2MTE_0d37b9ed-1132-4390-9d72-4c8dc81e16e0"
      unitRef="usdPerShare">0.04</evh:EarningsPerSharePortionAttributableToNoncontrollingInterestBasic>
    <evh:EarningsPerSharePortionAttributableToNoncontrollingInterestDiluted
      contextRef="i3e21049ffc224cacb8134d73c9bb5b38_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yNS9mcmFnOmM5ZGJiZjkwNWNkYjRhM2Y5NGMxZDk0YTNmMjcyZGM2L3RhYmxlOmI3MTFhYTE1OTNiOTQzZWRhOGQ2ZDQyN2QxNTZkOGFjL3RhYmxlcmFuZ2U6YjcxMWFhMTU5M2I5NDNlZGE4ZDZkNDI3ZDE1NmQ4YWNfMzYtNS0xLTEtMjU2MTE_38addc30-6b9a-49e7-9ecf-74d51ec59ed6"
      unitRef="usdPerShare">0.04</evh:EarningsPerSharePortionAttributableToNoncontrollingInterestDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yNS9mcmFnOmM5ZGJiZjkwNWNkYjRhM2Y5NGMxZDk0YTNmMjcyZGM2L3RhYmxlOmI3MTFhYTE1OTNiOTQzZWRhOGQ2ZDQyN2QxNTZkOGFjL3RhYmxlcmFuZ2U6YjcxMWFhMTU5M2I5NDNlZGE4ZDZkNDI3ZDE1NmQ4YWNfMzYtNS0xLTEtMTc3NzU_1dc36fb6-30b6-45f5-a0d7-06d7a9e9335f"
      unitRef="usdPerShare">-0.44</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yNS9mcmFnOmM5ZGJiZjkwNWNkYjRhM2Y5NGMxZDk0YTNmMjcyZGM2L3RhYmxlOmI3MTFhYTE1OTNiOTQzZWRhOGQ2ZDQyN2QxNTZkOGFjL3RhYmxlcmFuZ2U6YjcxMWFhMTU5M2I5NDNlZGE4ZDZkNDI3ZDE1NmQ4YWNfMzYtNS0xLTEtMTc3NzU_f8b4468e-36ed-4cf2-b7f3-455155f62856"
      unitRef="usdPerShare">-0.44</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="i12a6d1161de54547bd29f8efccd4c9b0_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yNS9mcmFnOmM5ZGJiZjkwNWNkYjRhM2Y5NGMxZDk0YTNmMjcyZGM2L3RhYmxlOmI3MTFhYTE1OTNiOTQzZWRhOGQ2ZDQyN2QxNTZkOGFjL3RhYmxlcmFuZ2U6YjcxMWFhMTU5M2I5NDNlZGE4ZDZkNDI3ZDE1NmQ4YWNfMzYtNy0xLTEtMTc3NzU_1354653c-22c3-4b3a-bf59-2975c6a7d95b"
      unitRef="usdPerShare">-3.94</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i12a6d1161de54547bd29f8efccd4c9b0_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yNS9mcmFnOmM5ZGJiZjkwNWNkYjRhM2Y5NGMxZDk0YTNmMjcyZGM2L3RhYmxlOmI3MTFhYTE1OTNiOTQzZWRhOGQ2ZDQyN2QxNTZkOGFjL3RhYmxlcmFuZ2U6YjcxMWFhMTU5M2I5NDNlZGE4ZDZkNDI3ZDE1NmQ4YWNfMzYtNy0xLTEtMTc3NzU_6a13b863-a134-4ff7-b9ae-26c31fbc200f"
      unitRef="usdPerShare">-3.94</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="i3e21049ffc224cacb8134d73c9bb5b38_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yNS9mcmFnOmM5ZGJiZjkwNWNkYjRhM2Y5NGMxZDk0YTNmMjcyZGM2L3RhYmxlOmI3MTFhYTE1OTNiOTQzZWRhOGQ2ZDQyN2QxNTZkOGFjL3RhYmxlcmFuZ2U6YjcxMWFhMTU5M2I5NDNlZGE4ZDZkNDI3ZDE1NmQ4YWNfMzYtNS0xLTEtMTkyNjg_71979723-6e39-4211-8a6d-eaf820918e5d"
      unitRef="usdPerShare">-3.67</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i3e21049ffc224cacb8134d73c9bb5b38_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yNS9mcmFnOmM5ZGJiZjkwNWNkYjRhM2Y5NGMxZDk0YTNmMjcyZGM2L3RhYmxlOmI3MTFhYTE1OTNiOTQzZWRhOGQ2ZDQyN2QxNTZkOGFjL3RhYmxlcmFuZ2U6YjcxMWFhMTU5M2I5NDNlZGE4ZDZkNDI3ZDE1NmQ4YWNfMzYtNS0xLTEtMTkyNjg_fe462964-8e16-4239-9bc7-5853f6b65425"
      unitRef="usdPerShare">-3.67</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yNS9mcmFnOmM5ZGJiZjkwNWNkYjRhM2Y5NGMxZDk0YTNmMjcyZGM2L3RhYmxlOmI3MTFhYTE1OTNiOTQzZWRhOGQ2ZDQyN2QxNTZkOGFjL3RhYmxlcmFuZ2U6YjcxMWFhMTU5M2I5NDNlZGE4ZDZkNDI3ZDE1NmQ4YWNfMzktNS0xLTEtMTc3NzU_4d2bf937-f10f-4d10-9f93-6566eaee8855"
      unitRef="shares">86067000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yNS9mcmFnOmM5ZGJiZjkwNWNkYjRhM2Y5NGMxZDk0YTNmMjcyZGM2L3RhYmxlOmI3MTFhYTE1OTNiOTQzZWRhOGQ2ZDQyN2QxNTZkOGFjL3RhYmxlcmFuZ2U6YjcxMWFhMTU5M2I5NDNlZGE4ZDZkNDI3ZDE1NmQ4YWNfMzktNS0xLTEtMTc3NzU_e2c93d99-4d5a-42af-aa15-b4f7a2aa8373"
      unitRef="shares">86067000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i12a6d1161de54547bd29f8efccd4c9b0_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yNS9mcmFnOmM5ZGJiZjkwNWNkYjRhM2Y5NGMxZDk0YTNmMjcyZGM2L3RhYmxlOmI3MTFhYTE1OTNiOTQzZWRhOGQ2ZDQyN2QxNTZkOGFjL3RhYmxlcmFuZ2U6YjcxMWFhMTU5M2I5NDNlZGE4ZDZkNDI3ZDE1NmQ4YWNfMzktNy0xLTEtMTc3NzU_43f0e345-3af0-4b74-93ae-34e196683016"
      unitRef="shares">84928000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i12a6d1161de54547bd29f8efccd4c9b0_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yNS9mcmFnOmM5ZGJiZjkwNWNkYjRhM2Y5NGMxZDk0YTNmMjcyZGM2L3RhYmxlOmI3MTFhYTE1OTNiOTQzZWRhOGQ2ZDQyN2QxNTZkOGFjL3RhYmxlcmFuZ2U6YjcxMWFhMTU5M2I5NDNlZGE4ZDZkNDI3ZDE1NmQ4YWNfMzktNy0xLTEtMTc3NzU_efcdf457-3aed-4d57-9eff-1d019a73ef97"
      unitRef="shares">84928000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i3e21049ffc224cacb8134d73c9bb5b38_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yNS9mcmFnOmM5ZGJiZjkwNWNkYjRhM2Y5NGMxZDk0YTNmMjcyZGM2L3RhYmxlOmI3MTFhYTE1OTNiOTQzZWRhOGQ2ZDQyN2QxNTZkOGFjL3RhYmxlcmFuZ2U6YjcxMWFhMTU5M2I5NDNlZGE4ZDZkNDI3ZDE1NmQ4YWNfMzktNS0xLTEtMTkyNzU_17b3a8da-cd42-48cf-b771-14854ba34a55"
      unitRef="shares">82364000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i3e21049ffc224cacb8134d73c9bb5b38_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yNS9mcmFnOmM5ZGJiZjkwNWNkYjRhM2Y5NGMxZDk0YTNmMjcyZGM2L3RhYmxlOmI3MTFhYTE1OTNiOTQzZWRhOGQ2ZDQyN2QxNTZkOGFjL3RhYmxlcmFuZ2U6YjcxMWFhMTU5M2I5NDNlZGE4ZDZkNDI3ZDE1NmQ4YWNfMzktNS0xLTEtMTkyNzU_d4138463-e018-4b8c-b6bd-c98de3be60c7"
      unitRef="shares">82364000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:ProfitLoss
      contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yNS9mcmFnOmM5ZGJiZjkwNWNkYjRhM2Y5NGMxZDk0YTNmMjcyZGM2L3RhYmxlOmI3MTFhYTE1OTNiOTQzZWRhOGQ2ZDQyN2QxNTZkOGFjL3RhYmxlcmFuZ2U6YjcxMWFhMTU5M2I5NDNlZGE4ZDZkNDI3ZDE1NmQ4YWNfNDItNS0xLTEtMTc3NzU_d602765a-8408-4f07-91d2-6cc1d0ec20f5"
      unitRef="usd">-37601000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i12a6d1161de54547bd29f8efccd4c9b0_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yNS9mcmFnOmM5ZGJiZjkwNWNkYjRhM2Y5NGMxZDk0YTNmMjcyZGM2L3RhYmxlOmI3MTFhYTE1OTNiOTQzZWRhOGQ2ZDQyN2QxNTZkOGFjL3RhYmxlcmFuZ2U6YjcxMWFhMTU5M2I5NDNlZGE4ZDZkNDI3ZDE1NmQ4YWNfNDItNy0xLTEtMTc3NzU_b3ab09a1-d157-4806-977d-c453a053058a"
      unitRef="usd">-334246000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i3e21049ffc224cacb8134d73c9bb5b38_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yNS9mcmFnOmM5ZGJiZjkwNWNkYjRhM2Y5NGMxZDk0YTNmMjcyZGM2L3RhYmxlOmI3MTFhYTE1OTNiOTQzZWRhOGQ2ZDQyN2QxNTZkOGFjL3RhYmxlcmFuZ2U6YjcxMWFhMTU5M2I5NDNlZGE4ZDZkNDI3ZDE1NmQ4YWNfNDItNS0xLTEtMTkyODI_6d262eba-5c2a-4faa-8da8-8c4c8a3478f8"
      unitRef="usd">-305580000</us-gaap:ProfitLoss>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yNS9mcmFnOmM5ZGJiZjkwNWNkYjRhM2Y5NGMxZDk0YTNmMjcyZGM2L3RhYmxlOmI3MTFhYTE1OTNiOTQzZWRhOGQ2ZDQyN2QxNTZkOGFjL3RhYmxlcmFuZ2U6YjcxMWFhMTU5M2I5NDNlZGE4ZDZkNDI3ZDE1NmQ4YWNfNDQtNS0xLTEtMTc3NzU_ca75e441-0511-4f4b-8784-e16de76c2e93"
      unitRef="usd">-84000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="i12a6d1161de54547bd29f8efccd4c9b0_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yNS9mcmFnOmM5ZGJiZjkwNWNkYjRhM2Y5NGMxZDk0YTNmMjcyZGM2L3RhYmxlOmI3MTFhYTE1OTNiOTQzZWRhOGQ2ZDQyN2QxNTZkOGFjL3RhYmxlcmFuZ2U6YjcxMWFhMTU5M2I5NDNlZGE4ZDZkNDI3ZDE1NmQ4YWNfNDQtNy0xLTEtMTc3NzU_35d2ea27-b7a8-4983-89f1-02aa4c82befd"
      unitRef="usd">-44000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="i3e21049ffc224cacb8134d73c9bb5b38_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yNS9mcmFnOmM5ZGJiZjkwNWNkYjRhM2Y5NGMxZDk0YTNmMjcyZGM2L3RhYmxlOmI3MTFhYTE1OTNiOTQzZWRhOGQ2ZDQyN2QxNTZkOGFjL3RhYmxlcmFuZ2U6YjcxMWFhMTU5M2I5NDNlZGE4ZDZkNDI3ZDE1NmQ4YWNfNDQtNS0xLTEtMTkyODI_f00d44f4-49d9-4c7c-828f-c2680f04f436"
      unitRef="usd">-52000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
      contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yNS9mcmFnOmM5ZGJiZjkwNWNkYjRhM2Y5NGMxZDk0YTNmMjcyZGM2L3RhYmxlOmI3MTFhYTE1OTNiOTQzZWRhOGQ2ZDQyN2QxNTZkOGFjL3RhYmxlcmFuZ2U6YjcxMWFhMTU5M2I5NDNlZGE4ZDZkNDI3ZDE1NmQ4YWNfNDUtNS0xLTEtMTc3NzU_ac920c19-ad66-45fe-921e-ffda5a6b44ba"
      unitRef="usd">-37685000</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i12a6d1161de54547bd29f8efccd4c9b0_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yNS9mcmFnOmM5ZGJiZjkwNWNkYjRhM2Y5NGMxZDk0YTNmMjcyZGM2L3RhYmxlOmI3MTFhYTE1OTNiOTQzZWRhOGQ2ZDQyN2QxNTZkOGFjL3RhYmxlcmFuZ2U6YjcxMWFhMTU5M2I5NDNlZGE4ZDZkNDI3ZDE1NmQ4YWNfNDUtNy0xLTEtMTc3NzU_74fe0cb0-13ed-4246-988e-201aaca5bd16"
      unitRef="usd">-334290000</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i3e21049ffc224cacb8134d73c9bb5b38_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yNS9mcmFnOmM5ZGJiZjkwNWNkYjRhM2Y5NGMxZDk0YTNmMjcyZGM2L3RhYmxlOmI3MTFhYTE1OTNiOTQzZWRhOGQ2ZDQyN2QxNTZkOGFjL3RhYmxlcmFuZ2U6YjcxMWFhMTU5M2I5NDNlZGE4ZDZkNDI3ZDE1NmQ4YWNfNDUtNS0xLTEtMTkyODI_4db18ffb-b824-4b0c-90fe-54f4afa61392"
      unitRef="usd">-305632000</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
      contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yNS9mcmFnOmM5ZGJiZjkwNWNkYjRhM2Y5NGMxZDk0YTNmMjcyZGM2L3RhYmxlOmI3MTFhYTE1OTNiOTQzZWRhOGQ2ZDQyN2QxNTZkOGFjL3RhYmxlcmFuZ2U6YjcxMWFhMTU5M2I5NDNlZGE4ZDZkNDI3ZDE1NmQ4YWNfNDYtNS0xLTEtMTc3NzU_0346c921-27f0-4f47-af85-83bfd26acea1"
      unitRef="usd">0</us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
      contextRef="i12a6d1161de54547bd29f8efccd4c9b0_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yNS9mcmFnOmM5ZGJiZjkwNWNkYjRhM2Y5NGMxZDk0YTNmMjcyZGM2L3RhYmxlOmI3MTFhYTE1OTNiOTQzZWRhOGQ2ZDQyN2QxNTZkOGFjL3RhYmxlcmFuZ2U6YjcxMWFhMTU5M2I5NDNlZGE4ZDZkNDI3ZDE1NmQ4YWNfNDYtNy0xLTEtMTc3NzU_e497689d-657b-4aad-9ce2-a8d0ba646143"
      unitRef="usd">0</us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
      contextRef="i3e21049ffc224cacb8134d73c9bb5b38_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yNS9mcmFnOmM5ZGJiZjkwNWNkYjRhM2Y5NGMxZDk0YTNmMjcyZGM2L3RhYmxlOmI3MTFhYTE1OTNiOTQzZWRhOGQ2ZDQyN2QxNTZkOGFjL3RhYmxlcmFuZ2U6YjcxMWFhMTU5M2I5NDNlZGE4ZDZkNDI3ZDE1NmQ4YWNfNDYtNS0xLTEtMTkyODI_d5b0de02-2d3f-45cf-8c70-28ec4aa6aa76"
      unitRef="usd">-3609000</us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yNS9mcmFnOmM5ZGJiZjkwNWNkYjRhM2Y5NGMxZDk0YTNmMjcyZGM2L3RhYmxlOmI3MTFhYTE1OTNiOTQzZWRhOGQ2ZDQyN2QxNTZkOGFjL3RhYmxlcmFuZ2U6YjcxMWFhMTU5M2I5NDNlZGE4ZDZkNDI3ZDE1NmQ4YWNfNDctNS0xLTEtMTc3NzU_6b3b57be-3454-4345-9f50-dd1c7ebdb83d"
      unitRef="usd">-37685000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i12a6d1161de54547bd29f8efccd4c9b0_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yNS9mcmFnOmM5ZGJiZjkwNWNkYjRhM2Y5NGMxZDk0YTNmMjcyZGM2L3RhYmxlOmI3MTFhYTE1OTNiOTQzZWRhOGQ2ZDQyN2QxNTZkOGFjL3RhYmxlcmFuZ2U6YjcxMWFhMTU5M2I5NDNlZGE4ZDZkNDI3ZDE1NmQ4YWNfNDctNy0xLTEtMTc3NzU_8ba1bc09-a75f-4ba2-9aba-00f801f27ba9"
      unitRef="usd">-334290000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i3e21049ffc224cacb8134d73c9bb5b38_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yNS9mcmFnOmM5ZGJiZjkwNWNkYjRhM2Y5NGMxZDk0YTNmMjcyZGM2L3RhYmxlOmI3MTFhYTE1OTNiOTQzZWRhOGQ2ZDQyN2QxNTZkOGFjL3RhYmxlcmFuZ2U6YjcxMWFhMTU5M2I5NDNlZGE4ZDZkNDI3ZDE1NmQ4YWNfNDctNS0xLTEtMTkyODI_998cfdb4-b259-48be-b5b7-b6903e3a2dc9"
      unitRef="usd">-302023000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax
      contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yNS9mcmFnOmM5ZGJiZjkwNWNkYjRhM2Y5NGMxZDk0YTNmMjcyZGM2L3RleHRyZWdpb246YzlkYmJmOTA1Y2RiNGEzZjk0YzFkOTRhM2YyNzJkYzZfMjY5_1c53a8ed-a6e9-479b-a61d-3b91b1e95ba4"
      unitRef="usd">6800000</us-gaap:DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax>
    <us-gaap:SharesIssued
      contextRef="i997aac773ca7467b9a246f3420865489_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yOC9mcmFnOjVjZWM5NGI5MzY4ODQyMTA5NWE3OThhZmFiNjljNDYwL3RhYmxlOjQzNDA0NmE1MTY4ODQzZDg5M2IxNTEyZjYxODkzYmU4L3RhYmxlcmFuZ2U6NDM0MDQ2YTUxNjg4NDNkODkzYjE1MTJmNjE4OTNiZThfMTktMS0xLTEtMTc3NzU_493e21ae-423f-4406-ae99-5d4959ce3275"
      unitRef="shares">79172000</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i997aac773ca7467b9a246f3420865489_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yOC9mcmFnOjVjZWM5NGI5MzY4ODQyMTA5NWE3OThhZmFiNjljNDYwL3RhYmxlOjQzNDA0NmE1MTY4ODQzZDg5M2IxNTEyZjYxODkzYmU4L3RhYmxlcmFuZ2U6NDM0MDQ2YTUxNjg4NDNkODkzYjE1MTJmNjE4OTNiZThfMTktMy0xLTEtMTc3NzU_118d1a1a-dc50-42f6-b4fc-1ef7ee484080"
      unitRef="usd">792000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesIssued
      contextRef="i5942ca937104445b92561d87e62b671c_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yOC9mcmFnOjVjZWM5NGI5MzY4ODQyMTA5NWE3OThhZmFiNjljNDYwL3RhYmxlOjQzNDA0NmE1MTY4ODQzZDg5M2IxNTEyZjYxODkzYmU4L3RhYmxlcmFuZ2U6NDM0MDQ2YTUxNjg4NDNkODkzYjE1MTJmNjE4OTNiZThfMTktNS0xLTEtMTc3NzU_0161ebda-c3b3-40f7-97ba-599f25475e57"
      unitRef="shares">3190000</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i5942ca937104445b92561d87e62b671c_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yOC9mcmFnOjVjZWM5NGI5MzY4ODQyMTA5NWE3OThhZmFiNjljNDYwL3RhYmxlOjQzNDA0NmE1MTY4ODQzZDg5M2IxNTEyZjYxODkzYmU4L3RhYmxlcmFuZ2U6NDM0MDQ2YTUxNjg4NDNkODkzYjE1MTJmNjE4OTNiZThfMTktNy0xLTEtMTc3NzU_a13ec87d-9490-4300-ab46-55ef88990909"
      unitRef="usd">31000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i235a50d4f95f4fe4ad003b456bd4d032_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yOC9mcmFnOjVjZWM5NGI5MzY4ODQyMTA5NWE3OThhZmFiNjljNDYwL3RhYmxlOjQzNDA0NmE1MTY4ODQzZDg5M2IxNTEyZjYxODkzYmU4L3RhYmxlcmFuZ2U6NDM0MDQ2YTUxNjg4NDNkODkzYjE1MTJmNjE4OTNiZThfMTktOS0xLTEtMTc3NzU_fe5f3080-c5cd-4b3a-a162-1acfd5257083"
      unitRef="usd">1093174000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ie607b868cccf4190b29e8a645f1622cd_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yOC9mcmFnOjVjZWM5NGI5MzY4ODQyMTA5NWE3OThhZmFiNjljNDYwL3RhYmxlOjQzNDA0NmE1MTY4ODQzZDg5M2IxNTEyZjYxODkzYmU4L3RhYmxlcmFuZ2U6NDM0MDQ2YTUxNjg4NDNkODkzYjE1MTJmNjE4OTNiZThfMTktMTEtMS0xLTE3Nzc1_f4644828-25b3-468e-8adc-62f0baa871b2"
      unitRef="usd">-182000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ifd10e063c50d49fd882ffd6694d2abea_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yOC9mcmFnOjVjZWM5NGI5MzY4ODQyMTA5NWE3OThhZmFiNjljNDYwL3RhYmxlOjQzNDA0NmE1MTY4ODQzZDg5M2IxNTEyZjYxODkzYmU4L3RhYmxlcmFuZ2U6NDM0MDQ2YTUxNjg4NDNkODkzYjE1MTJmNjE4OTNiZThfMTktMTMtMS0xLTE3Nzc1_4348e11d-b4ed-45ce-a7ae-93c8903694d1"
      unitRef="usd">50009000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="idecb0ab9f980489d88090494dd10781e_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yOC9mcmFnOjVjZWM5NGI5MzY4ODQyMTA5NWE3OThhZmFiNjljNDYwL3RhYmxlOjQzNDA0NmE1MTY4ODQzZDg5M2IxNTEyZjYxODkzYmU4L3RhYmxlcmFuZ2U6NDM0MDQ2YTUxNjg4NDNkODkzYjE1MTJmNjE4OTNiZThfMTktMTctMS0xLTE3Nzc1_19e5a6e5-bd73-4dcd-a6b8-d222bbd88f1b"
      unitRef="usd">1143824000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ia7bd0a6ac576439fb579120cf0ef0c48_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yOC9mcmFnOjVjZWM5NGI5MzY4ODQyMTA5NWE3OThhZmFiNjljNDYwL3RhYmxlOjQzNDA0NmE1MTY4ODQzZDg5M2IxNTEyZjYxODkzYmU4L3RhYmxlcmFuZ2U6NDM0MDQ2YTUxNjg4NDNkODkzYjE1MTJmNjE4OTNiZThfMTktMTktMS0xLTE3Nzc1_e185a2d7-d365-4589-95a5-e1e9fe0fe6f8"
      unitRef="usd">45532000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i7130cb432c4b4fe7a260e8a3beeb35d8_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yOC9mcmFnOjVjZWM5NGI5MzY4ODQyMTA5NWE3OThhZmFiNjljNDYwL3RhYmxlOjQzNDA0NmE1MTY4ODQzZDg5M2IxNTEyZjYxODkzYmU4L3RhYmxlcmFuZ2U6NDM0MDQ2YTUxNjg4NDNkODkzYjE1MTJmNjE4OTNiZThfMTktMjEtMS0xLTE3Nzc1_a8ec487b-a02f-48b9-8294-a15dc1273e61"
      unitRef="usd">1189356000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="ib3d180dea9514da28352fbc693ab84a5_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yOC9mcmFnOjVjZWM5NGI5MzY4ODQyMTA5NWE3OThhZmFiNjljNDYwL3RhYmxlOjQzNDA0NmE1MTY4ODQzZDg5M2IxNTEyZjYxODkzYmU4L3RhYmxlcmFuZ2U6NDM0MDQ2YTUxNjg4NDNkODkzYjE1MTJmNjE4OTNiZThfMjAtOS0xLTEtMTc3NzU_ac09f50b-c3da-4474-89e2-69e955395137"
      unitRef="usd">16006000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="iff47976e029948eca0df0ec3f59e7929_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yOC9mcmFnOjVjZWM5NGI5MzY4ODQyMTA5NWE3OThhZmFiNjljNDYwL3RhYmxlOjQzNDA0NmE1MTY4ODQzZDg5M2IxNTEyZjYxODkzYmU4L3RhYmxlcmFuZ2U6NDM0MDQ2YTUxNjg4NDNkODkzYjE1MTJmNjE4OTNiZThfMjAtMTctMS0xLTE3Nzc1_9fb5e63d-9993-4c43-aa65-da96cd5ebadc"
      unitRef="usd">16006000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i3e21049ffc224cacb8134d73c9bb5b38_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yOC9mcmFnOjVjZWM5NGI5MzY4ODQyMTA5NWE3OThhZmFiNjljNDYwL3RhYmxlOjQzNDA0NmE1MTY4ODQzZDg5M2IxNTEyZjYxODkzYmU4L3RhYmxlcmFuZ2U6NDM0MDQ2YTUxNjg4NDNkODkzYjE1MTJmNjE4OTNiZThfMjAtMjEtMS0xLTE3Nzc1_87e213e8-02ce-4786-99e9-8371a8568848"
      unitRef="usd">16006000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="if9d18c41b2a74719afa2195476af7f6b_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yOC9mcmFnOjVjZWM5NGI5MzY4ODQyMTA5NWE3OThhZmFiNjljNDYwL3RhYmxlOjQzNDA0NmE1MTY4ODQzZDg5M2IxNTEyZjYxODkzYmU4L3RhYmxlcmFuZ2U6NDM0MDQ2YTUxNjg4NDNkODkzYjE1MTJmNjE4OTNiZThfMjEtMS0xLTEtMTc3NzU_faaf30cd-b01d-46cf-a140-3455b23d9d9f"
      unitRef="shares">138000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="if9d18c41b2a74719afa2195476af7f6b_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yOC9mcmFnOjVjZWM5NGI5MzY4ODQyMTA5NWE3OThhZmFiNjljNDYwL3RhYmxlOjQzNDA0NmE1MTY4ODQzZDg5M2IxNTEyZjYxODkzYmU4L3RhYmxlcmFuZ2U6NDM0MDQ2YTUxNjg4NDNkODkzYjE1MTJmNjE4OTNiZThfMjEtMy0xLTEtMTc3NzU_cae2d2c1-3608-430c-afd5-24595957ceaf"
      unitRef="usd">1000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="ib3d180dea9514da28352fbc693ab84a5_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yOC9mcmFnOjVjZWM5NGI5MzY4ODQyMTA5NWE3OThhZmFiNjljNDYwL3RhYmxlOjQzNDA0NmE1MTY4ODQzZDg5M2IxNTEyZjYxODkzYmU4L3RhYmxlcmFuZ2U6NDM0MDQ2YTUxNjg4NDNkODkzYjE1MTJmNjE4OTNiZThfMjEtOS0xLTEtMTc3NzU_1d47e53f-743b-4bcf-8561-f65cd0695fcc"
      unitRef="usd">1091000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="iff47976e029948eca0df0ec3f59e7929_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yOC9mcmFnOjVjZWM5NGI5MzY4ODQyMTA5NWE3OThhZmFiNjljNDYwL3RhYmxlOjQzNDA0NmE1MTY4ODQzZDg5M2IxNTEyZjYxODkzYmU4L3RhYmxlcmFuZ2U6NDM0MDQ2YTUxNjg4NDNkODkzYjE1MTJmNjE4OTNiZThfMjEtMTctMS0xLTE3Nzc1_1e3c8a31-10b1-411c-9f0f-b9621b376c69"
      unitRef="usd">1092000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i3e21049ffc224cacb8134d73c9bb5b38_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yOC9mcmFnOjVjZWM5NGI5MzY4ODQyMTA5NWE3OThhZmFiNjljNDYwL3RhYmxlOjQzNDA0NmE1MTY4ODQzZDg5M2IxNTEyZjYxODkzYmU4L3RhYmxlcmFuZ2U6NDM0MDQ2YTUxNjg4NDNkODkzYjE1MTJmNjE4OTNiZThfMjEtMjEtMS0xLTE3Nzc1_f4f051f1-a778-4b83-906e-c9ecd785b020"
      unitRef="usd">1092000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures
      contextRef="if9d18c41b2a74719afa2195476af7f6b_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yOC9mcmFnOjVjZWM5NGI5MzY4ODQyMTA5NWE3OThhZmFiNjljNDYwL3RhYmxlOjQzNDA0NmE1MTY4ODQzZDg5M2IxNTEyZjYxODkzYmU4L3RhYmxlcmFuZ2U6NDM0MDQ2YTUxNjg4NDNkODkzYjE1MTJmNjE4OTNiZThfMjItMS0xLTEtMTc3NzU_f4042f8c-d051-4df0-a54c-d793bbeb1785"
      unitRef="shares">363000</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
      contextRef="if9d18c41b2a74719afa2195476af7f6b_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yOC9mcmFnOjVjZWM5NGI5MzY4ODQyMTA5NWE3OThhZmFiNjljNDYwL3RhYmxlOjQzNDA0NmE1MTY4ODQzZDg5M2IxNTEyZjYxODkzYmU4L3RhYmxlcmFuZ2U6NDM0MDQ2YTUxNjg4NDNkODkzYjE1MTJmNjE4OTNiZThfMjItMy0xLTEtMTc3NzU_b07c58ee-990f-41f6-9afa-e986c990615a"
      unitRef="usd">4000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
      contextRef="ib3d180dea9514da28352fbc693ab84a5_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yOC9mcmFnOjVjZWM5NGI5MzY4ODQyMTA5NWE3OThhZmFiNjljNDYwL3RhYmxlOjQzNDA0NmE1MTY4ODQzZDg5M2IxNTEyZjYxODkzYmU4L3RhYmxlcmFuZ2U6NDM0MDQ2YTUxNjg4NDNkODkzYjE1MTJmNjE4OTNiZThfMjItOS0xLTEtMTc3NzU_0b97840c-8bb0-4c36-b5eb-957465b17b6a"
      unitRef="usd">-2613000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
      contextRef="iff47976e029948eca0df0ec3f59e7929_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yOC9mcmFnOjVjZWM5NGI5MzY4ODQyMTA5NWE3OThhZmFiNjljNDYwL3RhYmxlOjQzNDA0NmE1MTY4ODQzZDg5M2IxNTEyZjYxODkzYmU4L3RhYmxlcmFuZ2U6NDM0MDQ2YTUxNjg4NDNkODkzYjE1MTJmNjE4OTNiZThfMjItMTctMS0xLTE3Nzc1_ffcbb0e2-b536-42d9-a662-645c331b02b6"
      unitRef="usd">-2609000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
      contextRef="i3e21049ffc224cacb8134d73c9bb5b38_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yOC9mcmFnOjVjZWM5NGI5MzY4ODQyMTA5NWE3OThhZmFiNjljNDYwL3RhYmxlOjQzNDA0NmE1MTY4ODQzZDg5M2IxNTEyZjYxODkzYmU4L3RhYmxlcmFuZ2U6NDM0MDQ2YTUxNjg4NDNkODkzYjE1MTJmNjE4OTNiZThfMjItMjEtMS0xLTE3Nzc1_0f30651b-c62f-4b43-9610-5415df47ea99"
      unitRef="usd">-2609000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
    <evh:StockVestedAndRetiredDuringPeriodShares
      contextRef="if9d18c41b2a74719afa2195476af7f6b_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yOC9mcmFnOjVjZWM5NGI5MzY4ODQyMTA5NWE3OThhZmFiNjljNDYwL3RhYmxlOjQzNDA0NmE1MTY4ODQzZDg5M2IxNTEyZjYxODkzYmU4L3RhYmxlcmFuZ2U6NDM0MDQ2YTUxNjg4NDNkODkzYjE1MTJmNjE4OTNiZThfMjMtMS0xLTEtMTc3NzU_2aa2d7ae-b353-46f3-b16e-2c3be2ca8654"
      unitRef="shares">5000</evh:StockVestedAndRetiredDuringPeriodShares>
    <evh:StockVestedAndRetiredDuringPeriodValue
      contextRef="i55a4ede774484bd8b99ec882803a31ae_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yOC9mcmFnOjVjZWM5NGI5MzY4ODQyMTA5NWE3OThhZmFiNjljNDYwL3RhYmxlOjQzNDA0NmE1MTY4ODQzZDg5M2IxNTEyZjYxODkzYmU4L3RhYmxlcmFuZ2U6NDM0MDQ2YTUxNjg4NDNkODkzYjE1MTJmNjE4OTNiZThfMjMtNS0xLTEtMTc3NzU_e9a84ff6-c101-4737-b7b3-04338713caf1"
      unitRef="usd">44000</evh:StockVestedAndRetiredDuringPeriodValue>
    <evh:StockIssuedDuringPeriodSharesEarnOuts
      contextRef="if9d18c41b2a74719afa2195476af7f6b_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yOC9mcmFnOjVjZWM5NGI5MzY4ODQyMTA5NWE3OThhZmFiNjljNDYwL3RhYmxlOjQzNDA0NmE1MTY4ODQzZDg5M2IxNTEyZjYxODkzYmU4L3RhYmxlcmFuZ2U6NDM0MDQ2YTUxNjg4NDNkODkzYjE1MTJmNjE4OTNiZThfMjQtMS0xLTEtMTc3NzU_4710e2d9-7ec2-4db2-ab38-5958bc200d1f"
      unitRef="shares">43000</evh:StockIssuedDuringPeriodSharesEarnOuts>
    <evh:StockIssuedDuringPeriodValueEarnOuts
      contextRef="ib3d180dea9514da28352fbc693ab84a5_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yOC9mcmFnOjVjZWM5NGI5MzY4ODQyMTA5NWE3OThhZmFiNjljNDYwL3RhYmxlOjQzNDA0NmE1MTY4ODQzZDg5M2IxNTEyZjYxODkzYmU4L3RhYmxlcmFuZ2U6NDM0MDQ2YTUxNjg4NDNkODkzYjE1MTJmNjE4OTNiZThfMjQtOS0xLTEtMTc3NzU_63ed1033-684e-4a09-8304-3a56a782b220"
      unitRef="usd">800000</evh:StockIssuedDuringPeriodValueEarnOuts>
    <evh:StockIssuedDuringPeriodValueEarnOuts
      contextRef="iff47976e029948eca0df0ec3f59e7929_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yOC9mcmFnOjVjZWM5NGI5MzY4ODQyMTA5NWE3OThhZmFiNjljNDYwL3RhYmxlOjQzNDA0NmE1MTY4ODQzZDg5M2IxNTEyZjYxODkzYmU4L3RhYmxlcmFuZ2U6NDM0MDQ2YTUxNjg4NDNkODkzYjE1MTJmNjE4OTNiZThfMjQtMTctMS0xLTE3Nzc1_02551075-a3eb-4fd7-9745-6fc5b6e5dd17"
      unitRef="usd">800000</evh:StockIssuedDuringPeriodValueEarnOuts>
    <evh:StockIssuedDuringPeriodValueEarnOuts
      contextRef="i3e21049ffc224cacb8134d73c9bb5b38_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yOC9mcmFnOjVjZWM5NGI5MzY4ODQyMTA5NWE3OThhZmFiNjljNDYwL3RhYmxlOjQzNDA0NmE1MTY4ODQzZDg5M2IxNTEyZjYxODkzYmU4L3RhYmxlcmFuZ2U6NDM0MDQ2YTUxNjg4NDNkODkzYjE1MTJmNjE4OTNiZThfMjQtMjEtMS0xLTE3Nzc1_6687c960-b5de-4af1-8f25-4a14380a0466"
      unitRef="usd">800000</evh:StockIssuedDuringPeriodValueEarnOuts>
    <evh:AdjustmentsToAdditionalPaidInCapitalAcquisitions
      contextRef="i07635cd96da44df8aeca179d3ffeeb6d_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yOC9mcmFnOjVjZWM5NGI5MzY4ODQyMTA5NWE3OThhZmFiNjljNDYwL3RhYmxlOjQzNDA0NmE1MTY4ODQzZDg5M2IxNTEyZjYxODkzYmU4L3RhYmxlcmFuZ2U6NDM0MDQ2YTUxNjg4NDNkODkzYjE1MTJmNjE4OTNiZThfMjUtMTktMS0xLTE3Nzc1_1c2d4423-d246-46d0-85f3-6c0bf79d904d"
      unitRef="usd">6500000</evh:AdjustmentsToAdditionalPaidInCapitalAcquisitions>
    <evh:AdjustmentsToAdditionalPaidInCapitalAcquisitions
      contextRef="i3e21049ffc224cacb8134d73c9bb5b38_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yOC9mcmFnOjVjZWM5NGI5MzY4ODQyMTA5NWE3OThhZmFiNjljNDYwL3RhYmxlOjQzNDA0NmE1MTY4ODQzZDg5M2IxNTEyZjYxODkzYmU4L3RhYmxlcmFuZ2U6NDM0MDQ2YTUxNjg4NDNkODkzYjE1MTJmNjE4OTNiZThfMjUtMjEtMS0xLTE3Nzc1_45897c5e-0599-47fb-b3ec-d6eb669a6ca0"
      unitRef="usd">6500000</evh:AdjustmentsToAdditionalPaidInCapitalAcquisitions>
    <evh:StockIssuedDuringPeriodSharesEquityMethodInvestmentsAndAssetAcquisitions
      contextRef="if9d18c41b2a74719afa2195476af7f6b_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yOC9mcmFnOjVjZWM5NGI5MzY4ODQyMTA5NWE3OThhZmFiNjljNDYwL3RhYmxlOjQzNDA0NmE1MTY4ODQzZDg5M2IxNTEyZjYxODkzYmU4L3RhYmxlcmFuZ2U6NDM0MDQ2YTUxNjg4NDNkODkzYjE1MTJmNjE4OTNiZThfMjYtMS0xLTEtMTc3NzU_8537960b-4955-4289-bc12-13b265d69c25"
      unitRef="shares">1732000</evh:StockIssuedDuringPeriodSharesEquityMethodInvestmentsAndAssetAcquisitions>
    <evh:StockIssuedDuringPeriodValueEquityMethodInvestmentsAndAssetAcquisitions
      contextRef="if9d18c41b2a74719afa2195476af7f6b_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yOC9mcmFnOjVjZWM5NGI5MzY4ODQyMTA5NWE3OThhZmFiNjljNDYwL3RhYmxlOjQzNDA0NmE1MTY4ODQzZDg5M2IxNTEyZjYxODkzYmU4L3RhYmxlcmFuZ2U6NDM0MDQ2YTUxNjg4NDNkODkzYjE1MTJmNjE4OTNiZThfMjYtMy0xLTEtMTc3NzU_65f98229-f6a1-4c93-92f1-3d1ee80cd9f2"
      unitRef="usd">18000</evh:StockIssuedDuringPeriodValueEquityMethodInvestmentsAndAssetAcquisitions>
    <evh:StockIssuedDuringPeriodValueEquityMethodInvestmentsAndAssetAcquisitions
      contextRef="ib3d180dea9514da28352fbc693ab84a5_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yOC9mcmFnOjVjZWM5NGI5MzY4ODQyMTA5NWE3OThhZmFiNjljNDYwL3RhYmxlOjQzNDA0NmE1MTY4ODQzZDg5M2IxNTEyZjYxODkzYmU4L3RhYmxlcmFuZ2U6NDM0MDQ2YTUxNjg4NDNkODkzYjE1MTJmNjE4OTNiZThfMjYtOS0xLTEtMTc3NzU_9a7209ba-4ab7-436c-9f51-9ccfb2b4109c"
      unitRef="usd">23538000</evh:StockIssuedDuringPeriodValueEquityMethodInvestmentsAndAssetAcquisitions>
    <evh:StockIssuedDuringPeriodValueEquityMethodInvestmentsAndAssetAcquisitions
      contextRef="iff47976e029948eca0df0ec3f59e7929_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yOC9mcmFnOjVjZWM5NGI5MzY4ODQyMTA5NWE3OThhZmFiNjljNDYwL3RhYmxlOjQzNDA0NmE1MTY4ODQzZDg5M2IxNTEyZjYxODkzYmU4L3RhYmxlcmFuZ2U6NDM0MDQ2YTUxNjg4NDNkODkzYjE1MTJmNjE4OTNiZThfMjYtMTctMS0xLTE3Nzc1_2f77e2aa-d72e-4f54-bf86-89b437d759cc"
      unitRef="usd">23556000</evh:StockIssuedDuringPeriodValueEquityMethodInvestmentsAndAssetAcquisitions>
    <evh:StockIssuedDuringPeriodValueEquityMethodInvestmentsAndAssetAcquisitions
      contextRef="i3e21049ffc224cacb8134d73c9bb5b38_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yOC9mcmFnOjVjZWM5NGI5MzY4ODQyMTA5NWE3OThhZmFiNjljNDYwL3RhYmxlOjQzNDA0NmE1MTY4ODQzZDg5M2IxNTEyZjYxODkzYmU4L3RhYmxlcmFuZ2U6NDM0MDQ2YTUxNjg4NDNkODkzYjE1MTJmNjE4OTNiZThfMjYtMjEtMS0xLTE3Nzc1_d0a4af4a-c652-44ca-a756-47add201c06a"
      unitRef="usd">23556000</evh:StockIssuedDuringPeriodValueEquityMethodInvestmentsAndAssetAcquisitions>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="if9d18c41b2a74719afa2195476af7f6b_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yOC9mcmFnOjVjZWM5NGI5MzY4ODQyMTA5NWE3OThhZmFiNjljNDYwL3RhYmxlOjQzNDA0NmE1MTY4ODQzZDg5M2IxNTEyZjYxODkzYmU4L3RhYmxlcmFuZ2U6NDM0MDQ2YTUxNjg4NDNkODkzYjE1MTJmNjE4OTNiZThfMjctMS0xLTEtMTc3NzU_f45456f6-d3e2-4920-9b44-928420e08a69"
      unitRef="shares">3146000</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="if9d18c41b2a74719afa2195476af7f6b_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yOC9mcmFnOjVjZWM5NGI5MzY4ODQyMTA5NWE3OThhZmFiNjljNDYwL3RhYmxlOjQzNDA0NmE1MTY4ODQzZDg5M2IxNTEyZjYxODkzYmU4L3RhYmxlcmFuZ2U6NDM0MDQ2YTUxNjg4NDNkODkzYjE1MTJmNjE4OTNiZThfMjctMy0xLTEtMTc3NzU_bd73a683-d95a-4553-9950-f755b25c6aee"
      unitRef="usd">31000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="i55a4ede774484bd8b99ec882803a31ae_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yOC9mcmFnOjVjZWM5NGI5MzY4ODQyMTA5NWE3OThhZmFiNjljNDYwL3RhYmxlOjQzNDA0NmE1MTY4ODQzZDg5M2IxNTEyZjYxODkzYmU4L3RhYmxlcmFuZ2U6NDM0MDQ2YTUxNjg4NDNkODkzYjE1MTJmNjE4OTNiZThfMjctNS0xLTEtMTc3NzU_2ca06a4d-e287-496d-b2e1-642c83b68524"
      unitRef="shares">-3146000</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="i55a4ede774484bd8b99ec882803a31ae_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yOC9mcmFnOjVjZWM5NGI5MzY4ODQyMTA5NWE3OThhZmFiNjljNDYwL3RhYmxlOjQzNDA0NmE1MTY4ODQzZDg5M2IxNTEyZjYxODkzYmU4L3RhYmxlcmFuZ2U6NDM0MDQ2YTUxNjg4NDNkODkzYjE1MTJmNjE4OTNiZThfMjctNy0xLTEtMTc3NzU_94a122be-64dc-4b8a-8feb-2f5e74c58b8f"
      unitRef="usd">-31000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="ib3d180dea9514da28352fbc693ab84a5_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yOC9mcmFnOjVjZWM5NGI5MzY4ODQyMTA5NWE3OThhZmFiNjljNDYwL3RhYmxlOjQzNDA0NmE1MTY4ODQzZDg5M2IxNTEyZjYxODkzYmU4L3RhYmxlcmFuZ2U6NDM0MDQ2YTUxNjg4NDNkODkzYjE1MTJmNjE4OTNiZThfMjctOS0xLTEtMTc3NzU_3a846c74-a423-4b50-a905-bf3d8fa337b0"
      unitRef="usd">42377000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="iff47976e029948eca0df0ec3f59e7929_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yOC9mcmFnOjVjZWM5NGI5MzY4ODQyMTA5NWE3OThhZmFiNjljNDYwL3RhYmxlOjQzNDA0NmE1MTY4ODQzZDg5M2IxNTEyZjYxODkzYmU4L3RhYmxlcmFuZ2U6NDM0MDQ2YTUxNjg4NDNkODkzYjE1MTJmNjE4OTNiZThfMjctMTctMS0xLTE3Nzc1_84f1f88e-cfa8-4cfb-9120-3283631b4c92"
      unitRef="usd">42377000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="i07635cd96da44df8aeca179d3ffeeb6d_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yOC9mcmFnOjVjZWM5NGI5MzY4ODQyMTA5NWE3OThhZmFiNjljNDYwL3RhYmxlOjQzNDA0NmE1MTY4ODQzZDg5M2IxNTEyZjYxODkzYmU4L3RhYmxlcmFuZ2U6NDM0MDQ2YTUxNjg4NDNkODkzYjE1MTJmNjE4OTNiZThfMjctMTktMS0xLTE3Nzc1_e44b80a2-3acd-4e3e-8864-51b8f0f204e7"
      unitRef="usd">-42377000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <evh:StockIssuedDuringPeriodSharesConversionofConvertibleSecuritiesTaxImpact
      contextRef="ib3d180dea9514da28352fbc693ab84a5_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yOC9mcmFnOjVjZWM5NGI5MzY4ODQyMTA5NWE3OThhZmFiNjljNDYwL3RhYmxlOjQzNDA0NmE1MTY4ODQzZDg5M2IxNTEyZjYxODkzYmU4L3RhYmxlcmFuZ2U6NDM0MDQ2YTUxNjg4NDNkODkzYjE1MTJmNjE4OTNiZThfMjgtOS0xLTEtMTc3NzU_85d6193a-4ddf-4e8c-86f2-588f2b9233bb"
      unitRef="usd">-22000</evh:StockIssuedDuringPeriodSharesConversionofConvertibleSecuritiesTaxImpact>
    <evh:StockIssuedDuringPeriodSharesConversionofConvertibleSecuritiesTaxImpact
      contextRef="iff47976e029948eca0df0ec3f59e7929_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yOC9mcmFnOjVjZWM5NGI5MzY4ODQyMTA5NWE3OThhZmFiNjljNDYwL3RhYmxlOjQzNDA0NmE1MTY4ODQzZDg5M2IxNTEyZjYxODkzYmU4L3RhYmxlcmFuZ2U6NDM0MDQ2YTUxNjg4NDNkODkzYjE1MTJmNjE4OTNiZThfMjgtMTctMS0xLTE3Nzc1_c5797f71-dcea-4c07-a4a1-6e8bc8ec0cbf"
      unitRef="usd">-22000</evh:StockIssuedDuringPeriodSharesConversionofConvertibleSecuritiesTaxImpact>
    <evh:StockIssuedDuringPeriodSharesConversionofConvertibleSecuritiesTaxImpact
      contextRef="i3e21049ffc224cacb8134d73c9bb5b38_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yOC9mcmFnOjVjZWM5NGI5MzY4ODQyMTA5NWE3OThhZmFiNjljNDYwL3RhYmxlOjQzNDA0NmE1MTY4ODQzZDg5M2IxNTEyZjYxODkzYmU4L3RhYmxlcmFuZ2U6NDM0MDQ2YTUxNjg4NDNkODkzYjE1MTJmNjE4OTNiZThfMjgtMjEtMS0xLTE3Nzc1_b762c9d0-c84c-4f09-95df-e03c40e1fbc4"
      unitRef="usd">-22000</evh:StockIssuedDuringPeriodSharesConversionofConvertibleSecuritiesTaxImpact>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="id72c42fac3684e24b4ca0bf829d0e596_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yOC9mcmFnOjVjZWM5NGI5MzY4ODQyMTA5NWE3OThhZmFiNjljNDYwL3RhYmxlOjQzNDA0NmE1MTY4ODQzZDg5M2IxNTEyZjYxODkzYmU4L3RhYmxlcmFuZ2U6NDM0MDQ2YTUxNjg4NDNkODkzYjE1MTJmNjE4OTNiZThfMjktMTEtMS0xLTE3Nzc1_aa9ac33b-bd0a-4e10-b529-a07156d2ee11"
      unitRef="usd">-52000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="iff47976e029948eca0df0ec3f59e7929_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yOC9mcmFnOjVjZWM5NGI5MzY4ODQyMTA5NWE3OThhZmFiNjljNDYwL3RhYmxlOjQzNDA0NmE1MTY4ODQzZDg5M2IxNTEyZjYxODkzYmU4L3RhYmxlcmFuZ2U6NDM0MDQ2YTUxNjg4NDNkODkzYjE1MTJmNjE4OTNiZThfMjktMTctMS0xLTE3Nzc1_1486874d-80db-416d-973e-3e3db84d4e9e"
      unitRef="usd">-52000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="i3e21049ffc224cacb8134d73c9bb5b38_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yOC9mcmFnOjVjZWM5NGI5MzY4ODQyMTA5NWE3OThhZmFiNjljNDYwL3RhYmxlOjQzNDA0NmE1MTY4ODQzZDg5M2IxNTEyZjYxODkzYmU4L3RhYmxlcmFuZ2U6NDM0MDQ2YTUxNjg4NDNkODkzYjE1MTJmNjE4OTNiZThfMjktMjEtMS0xLTE3Nzc1_2a8b7ec7-d23e-41ed-a95a-6385fb864802"
      unitRef="usd">-52000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:ProfitLoss
      contextRef="i87534e1639d049319065f8650fc0c762_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yOC9mcmFnOjVjZWM5NGI5MzY4ODQyMTA5NWE3OThhZmFiNjljNDYwL3RhYmxlOjQzNDA0NmE1MTY4ODQzZDg5M2IxNTEyZjYxODkzYmU4L3RhYmxlcmFuZ2U6NDM0MDQ2YTUxNjg4NDNkODkzYjE1MTJmNjE4OTNiZThfMzAtMTMtMS0xLTE3Nzc1_2a7c4584-44ba-4ee9-8195-a5431ca397fa"
      unitRef="usd">-301971000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="iff47976e029948eca0df0ec3f59e7929_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yOC9mcmFnOjVjZWM5NGI5MzY4ODQyMTA5NWE3OThhZmFiNjljNDYwL3RhYmxlOjQzNDA0NmE1MTY4ODQzZDg5M2IxNTEyZjYxODkzYmU4L3RhYmxlcmFuZ2U6NDM0MDQ2YTUxNjg4NDNkODkzYjE1MTJmNjE4OTNiZThfMzAtMTctMS0xLTE3Nzc1_ad8cba7d-df93-4c8c-be84-f0e1a9e70657"
      unitRef="usd">-301971000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i07635cd96da44df8aeca179d3ffeeb6d_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yOC9mcmFnOjVjZWM5NGI5MzY4ODQyMTA5NWE3OThhZmFiNjljNDYwL3RhYmxlOjQzNDA0NmE1MTY4ODQzZDg5M2IxNTEyZjYxODkzYmU4L3RhYmxlcmFuZ2U6NDM0MDQ2YTUxNjg4NDNkODkzYjE1MTJmNjE4OTNiZThfMzAtMTktMS0xLTE3Nzc1_1015ac99-e35d-4fa5-a587-8f33833eb183"
      unitRef="usd">-3609000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i3e21049ffc224cacb8134d73c9bb5b38_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yOC9mcmFnOjVjZWM5NGI5MzY4ODQyMTA5NWE3OThhZmFiNjljNDYwL3RhYmxlOjQzNDA0NmE1MTY4ODQzZDg5M2IxNTEyZjYxODkzYmU4L3RhYmxlcmFuZ2U6NDM0MDQ2YTUxNjg4NDNkODkzYjE1MTJmNjE4OTNiZThfMzAtMjEtMS0xLTE3Nzc1_651e1dd2-4023-446b-8f92-3325773b87a7"
      unitRef="usd">-305580000</us-gaap:ProfitLoss>
    <us-gaap:NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance
      contextRef="ib3d180dea9514da28352fbc693ab84a5_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yOC9mcmFnOjVjZWM5NGI5MzY4ODQyMTA5NWE3OThhZmFiNjljNDYwL3RhYmxlOjQzNDA0NmE1MTY4ODQzZDg5M2IxNTEyZjYxODkzYmU4L3RhYmxlcmFuZ2U6NDM0MDQ2YTUxNjg4NDNkODkzYjE1MTJmNjE4OTNiZThfMzEtOS0xLTEtMTc3NzU_77ee7e05-7e2a-4c0e-8464-7ce6c0957a3c"
      unitRef="usd">-643000</us-gaap:NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance>
    <us-gaap:NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance
      contextRef="iff47976e029948eca0df0ec3f59e7929_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yOC9mcmFnOjVjZWM5NGI5MzY4ODQyMTA5NWE3OThhZmFiNjljNDYwL3RhYmxlOjQzNDA0NmE1MTY4ODQzZDg5M2IxNTEyZjYxODkzYmU4L3RhYmxlcmFuZ2U6NDM0MDQ2YTUxNjg4NDNkODkzYjE1MTJmNjE4OTNiZThfMzEtMTctMS0xLTE3Nzc1_80b9be17-3079-41a6-92b4-9c98f2b493cd"
      unitRef="usd">-643000</us-gaap:NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance>
    <us-gaap:NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance
      contextRef="i07635cd96da44df8aeca179d3ffeeb6d_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yOC9mcmFnOjVjZWM5NGI5MzY4ODQyMTA5NWE3OThhZmFiNjljNDYwL3RhYmxlOjQzNDA0NmE1MTY4ODQzZDg5M2IxNTEyZjYxODkzYmU4L3RhYmxlcmFuZ2U6NDM0MDQ2YTUxNjg4NDNkODkzYjE1MTJmNjE4OTNiZThfMzEtMTktMS0xLTE3Nzc1_8d86f9f0-e046-4890-b574-9920391ad9eb"
      unitRef="usd">643000</us-gaap:NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance>
    <us-gaap:SharesIssued
      contextRef="i132368a16db343cdb75b4cc5b6d3c936_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yOC9mcmFnOjVjZWM5NGI5MzY4ODQyMTA5NWE3OThhZmFiNjljNDYwL3RhYmxlOjQzNDA0NmE1MTY4ODQzZDg5M2IxNTEyZjYxODkzYmU4L3RhYmxlcmFuZ2U6NDM0MDQ2YTUxNjg4NDNkODkzYjE1MTJmNjE4OTNiZThfMzItMS0xLTEtMTc3NzU_13dc261d-5631-4289-816c-b4ec7aec587b"
      unitRef="shares">84589000</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i132368a16db343cdb75b4cc5b6d3c936_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yOC9mcmFnOjVjZWM5NGI5MzY4ODQyMTA5NWE3OThhZmFiNjljNDYwL3RhYmxlOjQzNDA0NmE1MTY4ODQzZDg5M2IxNTEyZjYxODkzYmU4L3RhYmxlcmFuZ2U6NDM0MDQ2YTUxNjg4NDNkODkzYjE1MTJmNjE4OTNiZThfMzItMy0xLTEtMTc3NzU_031a8ff4-2ecf-49cd-a11d-6f34e8ae9502"
      unitRef="usd">846000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesIssued
      contextRef="i6583965c38874fd5b1853fe21a37624d_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yOC9mcmFnOjVjZWM5NGI5MzY4ODQyMTA5NWE3OThhZmFiNjljNDYwL3RhYmxlOjQzNDA0NmE1MTY4ODQzZDg5M2IxNTEyZjYxODkzYmU4L3RhYmxlcmFuZ2U6NDM0MDQ2YTUxNjg4NDNkODkzYjE1MTJmNjE4OTNiZThfMzItNS0xLTEtMTc3NzU_779ca2e6-dcba-4a9e-a8cc-356e55713ec7"
      unitRef="shares">0</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i6583965c38874fd5b1853fe21a37624d_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yOC9mcmFnOjVjZWM5NGI5MzY4ODQyMTA5NWE3OThhZmFiNjljNDYwL3RhYmxlOjQzNDA0NmE1MTY4ODQzZDg5M2IxNTEyZjYxODkzYmU4L3RhYmxlcmFuZ2U6NDM0MDQ2YTUxNjg4NDNkODkzYjE1MTJmNjE4OTNiZThfMzItNy0xLTEtMTc3NzU_e2659435-add9-44a3-a49c-3f536a381482"
      unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="iea51ead9d5cc49309a974f68850d9313_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yOC9mcmFnOjVjZWM5NGI5MzY4ODQyMTA5NWE3OThhZmFiNjljNDYwL3RhYmxlOjQzNDA0NmE1MTY4ODQzZDg5M2IxNTEyZjYxODkzYmU4L3RhYmxlcmFuZ2U6NDM0MDQ2YTUxNjg4NDNkODkzYjE1MTJmNjE4OTNiZThfMzItOS0xLTEtMTc3NzU_060321d7-3894-4601-8a67-d12ae2045315"
      unitRef="usd">1173708000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i4b90c5fc5160471aba2652f11f6bb706_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yOC9mcmFnOjVjZWM5NGI5MzY4ODQyMTA5NWE3OThhZmFiNjljNDYwL3RhYmxlOjQzNDA0NmE1MTY4ODQzZDg5M2IxNTEyZjYxODkzYmU4L3RhYmxlcmFuZ2U6NDM0MDQ2YTUxNjg4NDNkODkzYjE1MTJmNjE4OTNiZThfMzItMTEtMS0xLTE3Nzc1_c7eeb083-1aaf-4276-b8f3-050ddd16dc30"
      unitRef="usd">-234000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ie8e5b6e19bcc4d6aa9434387b2fd038c_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yOC9mcmFnOjVjZWM5NGI5MzY4ODQyMTA5NWE3OThhZmFiNjljNDYwL3RhYmxlOjQzNDA0NmE1MTY4ODQzZDg5M2IxNTEyZjYxODkzYmU4L3RhYmxlcmFuZ2U6NDM0MDQ2YTUxNjg4NDNkODkzYjE1MTJmNjE4OTNiZThfMzItMTMtMS0xLTE3Nzc1_c335462a-6fe9-4276-903f-0c5ff2fe35ca"
      unitRef="usd">-251962000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="if4420575740f4afca80c3afb49e6e79e_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yOC9mcmFnOjVjZWM5NGI5MzY4ODQyMTA5NWE3OThhZmFiNjljNDYwL3RhYmxlOjQzNDA0NmE1MTY4ODQzZDg5M2IxNTEyZjYxODkzYmU4L3RhYmxlcmFuZ2U6NDM0MDQ2YTUxNjg4NDNkODkzYjE1MTJmNjE4OTNiZThfMzItMTUtMS0xLTE3Nzc1_15285529-adc8-4388-8f0f-a9453a2a77d4"
      unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="id4af8e59d8e745af8ddd5b829f03f70a_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yOC9mcmFnOjVjZWM5NGI5MzY4ODQyMTA5NWE3OThhZmFiNjljNDYwL3RhYmxlOjQzNDA0NmE1MTY4ODQzZDg5M2IxNTEyZjYxODkzYmU4L3RhYmxlcmFuZ2U6NDM0MDQ2YTUxNjg4NDNkODkzYjE1MTJmNjE4OTNiZThfMzItMTctMS0xLTE3Nzc1_0556e15f-a6cb-41b3-be5e-a35b939850f6"
      unitRef="usd">922358000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i2d2497909b9e4097b418e747f13bfc16_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yOC9mcmFnOjVjZWM5NGI5MzY4ODQyMTA5NWE3OThhZmFiNjljNDYwL3RhYmxlOjQzNDA0NmE1MTY4ODQzZDg5M2IxNTEyZjYxODkzYmU4L3RhYmxlcmFuZ2U6NDM0MDQ2YTUxNjg4NDNkODkzYjE1MTJmNjE4OTNiZThfMzItMTktMS0xLTE3Nzc1_802fa539-54b2-4da0-95fd-ef3d6bcee62e"
      unitRef="usd">6689000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="icba6e493923b449aa57c46a563760234_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yOC9mcmFnOjVjZWM5NGI5MzY4ODQyMTA5NWE3OThhZmFiNjljNDYwL3RhYmxlOjQzNDA0NmE1MTY4ODQzZDg5M2IxNTEyZjYxODkzYmU4L3RhYmxlcmFuZ2U6NDM0MDQ2YTUxNjg4NDNkODkzYjE1MTJmNjE4OTNiZThfMzItMjEtMS0xLTE3Nzc1_3691a4ee-ef7f-4665-b6f9-8d4d080bca5a"
      unitRef="usd">929047000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i86eec55ebc424a56b5b5394b8b2b2423_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yOC9mcmFnOjVjZWM5NGI5MzY4ODQyMTA5NWE3OThhZmFiNjljNDYwL3RhYmxlOjQzNDA0NmE1MTY4ODQzZDg5M2IxNTEyZjYxODkzYmU4L3RhYmxlcmFuZ2U6NDM0MDQ2YTUxNjg4NDNkODkzYjE1MTJmNjE4OTNiZThfMzMtMTMtMS0xLTE3Nzc1_1366957d-c460-4358-8001-987a3dd760e8"
      unitRef="usd">-2970000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i67b404347634468496e5eb9d721d74b6_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yOC9mcmFnOjVjZWM5NGI5MzY4ODQyMTA5NWE3OThhZmFiNjljNDYwL3RhYmxlOjQzNDA0NmE1MTY4ODQzZDg5M2IxNTEyZjYxODkzYmU4L3RhYmxlcmFuZ2U6NDM0MDQ2YTUxNjg4NDNkODkzYjE1MTJmNjE4OTNiZThfMzMtMTctMS0xLTE3Nzc1_5bd08e2f-1931-4272-8426-3aefc2d2724d"
      unitRef="usd">-2970000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i6464dcea2322451dbc03ac39361c75b9_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yOC9mcmFnOjVjZWM5NGI5MzY4ODQyMTA5NWE3OThhZmFiNjljNDYwL3RhYmxlOjQzNDA0NmE1MTY4ODQzZDg5M2IxNTEyZjYxODkzYmU4L3RhYmxlcmFuZ2U6NDM0MDQ2YTUxNjg4NDNkODkzYjE1MTJmNjE4OTNiZThfMzMtMjEtMS0xLTE3Nzc1_9f5eac6d-6640-43d6-8b74-b9ab2d497866"
      unitRef="usd">-2970000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="ieb0b713eae1b4f908dc2c23586d77948_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yOC9mcmFnOjVjZWM5NGI5MzY4ODQyMTA5NWE3OThhZmFiNjljNDYwL3RhYmxlOjQzNDA0NmE1MTY4ODQzZDg5M2IxNTEyZjYxODkzYmU4L3RhYmxlcmFuZ2U6NDM0MDQ2YTUxNjg4NDNkODkzYjE1MTJmNjE4OTNiZThfMzQtOS0xLTEtMTc3NzU_706b32b9-c915-41ca-adc3-579bc03512e4"
      unitRef="usd">14606000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i911a108ecf12460193d53b0e6b24331f_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yOC9mcmFnOjVjZWM5NGI5MzY4ODQyMTA5NWE3OThhZmFiNjljNDYwL3RhYmxlOjQzNDA0NmE1MTY4ODQzZDg5M2IxNTEyZjYxODkzYmU4L3RhYmxlcmFuZ2U6NDM0MDQ2YTUxNjg4NDNkODkzYjE1MTJmNjE4OTNiZThfMzQtMTctMS0xLTE3Nzc1_b729d47c-d68e-439d-8f5f-974ea9688b1a"
      unitRef="usd">14606000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i12a6d1161de54547bd29f8efccd4c9b0_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yOC9mcmFnOjVjZWM5NGI5MzY4ODQyMTA5NWE3OThhZmFiNjljNDYwL3RhYmxlOjQzNDA0NmE1MTY4ODQzZDg5M2IxNTEyZjYxODkzYmU4L3RhYmxlcmFuZ2U6NDM0MDQ2YTUxNjg4NDNkODkzYjE1MTJmNjE4OTNiZThfMzQtMjEtMS0xLTE3Nzc1_2b61eca8-23c3-4b4d-bad8-9750a0e1cdde"
      unitRef="usd">14606000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="ifead6db34ce543e2beca6b5c57feaf4e_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yOC9mcmFnOjVjZWM5NGI5MzY4ODQyMTA5NWE3OThhZmFiNjljNDYwL3RhYmxlOjQzNDA0NmE1MTY4ODQzZDg5M2IxNTEyZjYxODkzYmU4L3RhYmxlcmFuZ2U6NDM0MDQ2YTUxNjg4NDNkODkzYjE1MTJmNjE4OTNiZThfMzUtMS0xLTEtMTc3NzU_dab72ed9-8b06-4d0e-950c-aa625ab02331"
      unitRef="shares">416000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="ifead6db34ce543e2beca6b5c57feaf4e_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yOC9mcmFnOjVjZWM5NGI5MzY4ODQyMTA5NWE3OThhZmFiNjljNDYwL3RhYmxlOjQzNDA0NmE1MTY4ODQzZDg5M2IxNTEyZjYxODkzYmU4L3RhYmxlcmFuZ2U6NDM0MDQ2YTUxNjg4NDNkODkzYjE1MTJmNjE4OTNiZThfMzUtMy0xLTEtMTc3NzU_f9cbdffa-c209-4233-85b2-f85508c2cb6b"
      unitRef="usd">4000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="ieb0b713eae1b4f908dc2c23586d77948_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yOC9mcmFnOjVjZWM5NGI5MzY4ODQyMTA5NWE3OThhZmFiNjljNDYwL3RhYmxlOjQzNDA0NmE1MTY4ODQzZDg5M2IxNTEyZjYxODkzYmU4L3RhYmxlcmFuZ2U6NDM0MDQ2YTUxNjg4NDNkODkzYjE1MTJmNjE4OTNiZThfMzUtOS0xLTEtMTc3NzU_7a361db1-50e9-48b0-a08a-8235113d5a86"
      unitRef="usd">2573000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i911a108ecf12460193d53b0e6b24331f_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yOC9mcmFnOjVjZWM5NGI5MzY4ODQyMTA5NWE3OThhZmFiNjljNDYwL3RhYmxlOjQzNDA0NmE1MTY4ODQzZDg5M2IxNTEyZjYxODkzYmU4L3RhYmxlcmFuZ2U6NDM0MDQ2YTUxNjg4NDNkODkzYjE1MTJmNjE4OTNiZThfMzUtMTctMS0xLTE3Nzc1_4a8768bd-ed90-4091-aec6-facd107db807"
      unitRef="usd">2577000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i12a6d1161de54547bd29f8efccd4c9b0_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yOC9mcmFnOjVjZWM5NGI5MzY4ODQyMTA5NWE3OThhZmFiNjljNDYwL3RhYmxlOjQzNDA0NmE1MTY4ODQzZDg5M2IxNTEyZjYxODkzYmU4L3RhYmxlcmFuZ2U6NDM0MDQ2YTUxNjg4NDNkODkzYjE1MTJmNjE4OTNiZThfMzUtMjEtMS0xLTE3Nzc1_0f32cf30-efb0-4f26-8426-e2e99d4b65c0"
      unitRef="usd">2577000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures
      contextRef="ifead6db34ce543e2beca6b5c57feaf4e_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yOC9mcmFnOjVjZWM5NGI5MzY4ODQyMTA5NWE3OThhZmFiNjljNDYwL3RhYmxlOjQzNDA0NmE1MTY4ODQzZDg5M2IxNTEyZjYxODkzYmU4L3RhYmxlcmFuZ2U6NDM0MDQ2YTUxNjg4NDNkODkzYjE1MTJmNjE4OTNiZThfMzYtMS0xLTEtMTc3NzU_5662fa61-2676-4ea5-8e02-c0f361cd05c0"
      unitRef="shares">462000</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
      contextRef="ifead6db34ce543e2beca6b5c57feaf4e_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yOC9mcmFnOjVjZWM5NGI5MzY4ODQyMTA5NWE3OThhZmFiNjljNDYwL3RhYmxlOjQzNDA0NmE1MTY4ODQzZDg5M2IxNTEyZjYxODkzYmU4L3RhYmxlcmFuZ2U6NDM0MDQ2YTUxNjg4NDNkODkzYjE1MTJmNjE4OTNiZThfMzYtMy0xLTEtMTc3NzU_995c09cd-527e-40ef-888a-a08a55f82bb5"
      unitRef="usd">5000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
      contextRef="ieb0b713eae1b4f908dc2c23586d77948_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yOC9mcmFnOjVjZWM5NGI5MzY4ODQyMTA5NWE3OThhZmFiNjljNDYwL3RhYmxlOjQzNDA0NmE1MTY4ODQzZDg5M2IxNTEyZjYxODkzYmU4L3RhYmxlcmFuZ2U6NDM0MDQ2YTUxNjg4NDNkODkzYjE1MTJmNjE4OTNiZThfMzYtOS0xLTEtMTc3NzU_0bec4a2c-8a6c-4a5d-95b6-7b9bf75e28ce"
      unitRef="usd">-1856000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
      contextRef="i911a108ecf12460193d53b0e6b24331f_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yOC9mcmFnOjVjZWM5NGI5MzY4ODQyMTA5NWE3OThhZmFiNjljNDYwL3RhYmxlOjQzNDA0NmE1MTY4ODQzZDg5M2IxNTEyZjYxODkzYmU4L3RhYmxlcmFuZ2U6NDM0MDQ2YTUxNjg4NDNkODkzYjE1MTJmNjE4OTNiZThfMzYtMTctMS0xLTE3Nzc1_57fea2d4-9ea0-4ad7-982f-28cc07cb77f9"
      unitRef="usd">-1851000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
      contextRef="i12a6d1161de54547bd29f8efccd4c9b0_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yOC9mcmFnOjVjZWM5NGI5MzY4ODQyMTA5NWE3OThhZmFiNjljNDYwL3RhYmxlOjQzNDA0NmE1MTY4ODQzZDg5M2IxNTEyZjYxODkzYmU4L3RhYmxlcmFuZ2U6NDM0MDQ2YTUxNjg4NDNkODkzYjE1MTJmNjE4OTNiZThfMzYtMjEtMS0xLTE3Nzc1_9d2cdc88-98ef-48bc-9228-930db1346b5a"
      unitRef="usd">-1851000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
    <us-gaap:TreasuryStockRetiredCostMethodAmount
      contextRef="i843130db221949f4a5068562633a2182_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yOC9mcmFnOjVjZWM5NGI5MzY4ODQyMTA5NWE3OThhZmFiNjljNDYwL3RhYmxlOjQzNDA0NmE1MTY4ODQzZDg5M2IxNTEyZjYxODkzYmU4L3RhYmxlcmFuZ2U6NDM0MDQ2YTUxNjg4NDNkODkzYjE1MTJmNjE4OTNiZThfMzctMTUtMS0xLTE3Nzc1_cf46b2a8-ec63-474f-a30c-6664379cd322"
      unitRef="usd">21123000</us-gaap:TreasuryStockRetiredCostMethodAmount>
    <us-gaap:TreasuryStockRetiredCostMethodAmount
      contextRef="i911a108ecf12460193d53b0e6b24331f_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yOC9mcmFnOjVjZWM5NGI5MzY4ODQyMTA5NWE3OThhZmFiNjljNDYwL3RhYmxlOjQzNDA0NmE1MTY4ODQzZDg5M2IxNTEyZjYxODkzYmU4L3RhYmxlcmFuZ2U6NDM0MDQ2YTUxNjg4NDNkODkzYjE1MTJmNjE4OTNiZThfMzctMTctMS0xLTE3Nzc1_ffffdac0-9db8-4638-b4a6-f62efe1916af"
      unitRef="usd">21123000</us-gaap:TreasuryStockRetiredCostMethodAmount>
    <us-gaap:TreasuryStockRetiredCostMethodAmount
      contextRef="i12a6d1161de54547bd29f8efccd4c9b0_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yOC9mcmFnOjVjZWM5NGI5MzY4ODQyMTA5NWE3OThhZmFiNjljNDYwL3RhYmxlOjQzNDA0NmE1MTY4ODQzZDg5M2IxNTEyZjYxODkzYmU4L3RhYmxlcmFuZ2U6NDM0MDQ2YTUxNjg4NDNkODkzYjE1MTJmNjE4OTNiZThfMzctMjEtMS0xLTE3Nzc1_3f2a4a57-2370-4f79-a405-61b3ba7bb4f0"
      unitRef="usd">21123000</us-gaap:TreasuryStockRetiredCostMethodAmount>
    <evh:StockVestedAndRetiredDuringPeriodShares
      contextRef="ifead6db34ce543e2beca6b5c57feaf4e_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yOC9mcmFnOjVjZWM5NGI5MzY4ODQyMTA5NWE3OThhZmFiNjljNDYwL3RhYmxlOjQzNDA0NmE1MTY4ODQzZDg5M2IxNTEyZjYxODkzYmU4L3RhYmxlcmFuZ2U6NDM0MDQ2YTUxNjg4NDNkODkzYjE1MTJmNjE4OTNiZThfMzgtMS0xLTEtMTc3NzU_46acda9e-e44a-44cc-ba4c-f54e3ba73457"
      unitRef="shares">188000</evh:StockVestedAndRetiredDuringPeriodShares>
    <evh:StockVestedAndRetiredDuringPeriodValue
      contextRef="ifead6db34ce543e2beca6b5c57feaf4e_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yOC9mcmFnOjVjZWM5NGI5MzY4ODQyMTA5NWE3OThhZmFiNjljNDYwL3RhYmxlOjQzNDA0NmE1MTY4ODQzZDg5M2IxNTEyZjYxODkzYmU4L3RhYmxlcmFuZ2U6NDM0MDQ2YTUxNjg4NDNkODkzYjE1MTJmNjE4OTNiZThfMzgtMy0xLTEtMTc3NzU_dcc8f2e6-cb28-4af5-aa4f-526fd13df037"
      unitRef="usd">2000</evh:StockVestedAndRetiredDuringPeriodValue>
    <evh:StockVestedAndRetiredDuringPeriodValue
      contextRef="ieb0b713eae1b4f908dc2c23586d77948_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yOC9mcmFnOjVjZWM5NGI5MzY4ODQyMTA5NWE3OThhZmFiNjljNDYwL3RhYmxlOjQzNDA0NmE1MTY4ODQzZDg5M2IxNTEyZjYxODkzYmU4L3RhYmxlcmFuZ2U6NDM0MDQ2YTUxNjg4NDNkODkzYjE1MTJmNjE4OTNiZThfMzgtOS0xLTEtMTc3NzU_58ad43ab-56d1-4dc6-84ec-53f76459b10e"
      unitRef="usd">683000</evh:StockVestedAndRetiredDuringPeriodValue>
    <evh:StockVestedAndRetiredDuringPeriodValue
      contextRef="i911a108ecf12460193d53b0e6b24331f_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yOC9mcmFnOjVjZWM5NGI5MzY4ODQyMTA5NWE3OThhZmFiNjljNDYwL3RhYmxlOjQzNDA0NmE1MTY4ODQzZDg5M2IxNTEyZjYxODkzYmU4L3RhYmxlcmFuZ2U6NDM0MDQ2YTUxNjg4NDNkODkzYjE1MTJmNjE4OTNiZThfMzgtMTctMS0xLTE3Nzc1_6e98ec20-e4b0-4b4b-861f-03f49a33e0d6"
      unitRef="usd">685000</evh:StockVestedAndRetiredDuringPeriodValue>
    <evh:StockVestedAndRetiredDuringPeriodValue
      contextRef="i12a6d1161de54547bd29f8efccd4c9b0_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yOC9mcmFnOjVjZWM5NGI5MzY4ODQyMTA5NWE3OThhZmFiNjljNDYwL3RhYmxlOjQzNDA0NmE1MTY4ODQzZDg5M2IxNTEyZjYxODkzYmU4L3RhYmxlcmFuZ2U6NDM0MDQ2YTUxNjg4NDNkODkzYjE1MTJmNjE4OTNiZThfMzgtMjEtMS0xLTE3Nzc1_59d032ec-4c6d-42e0-b01e-b4574d0ac543"
      unitRef="usd">685000</evh:StockVestedAndRetiredDuringPeriodValue>
    <evh:StockIssuedDuringPeriodSharesEarnOuts
      contextRef="ifead6db34ce543e2beca6b5c57feaf4e_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yOC9mcmFnOjVjZWM5NGI5MzY4ODQyMTA5NWE3OThhZmFiNjljNDYwL3RhYmxlOjQzNDA0NmE1MTY4ODQzZDg5M2IxNTEyZjYxODkzYmU4L3RhYmxlcmFuZ2U6NDM0MDQ2YTUxNjg4NDNkODkzYjE1MTJmNjE4OTNiZThfMzktMS0xLTEtMTc3NzU_7fd6a355-9fe2-4a2c-9c9a-5368b69dd5d2"
      unitRef="shares">616000</evh:StockIssuedDuringPeriodSharesEarnOuts>
    <evh:StockIssuedDuringPeriodValueEarnOuts
      contextRef="ifead6db34ce543e2beca6b5c57feaf4e_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yOC9mcmFnOjVjZWM5NGI5MzY4ODQyMTA5NWE3OThhZmFiNjljNDYwL3RhYmxlOjQzNDA0NmE1MTY4ODQzZDg5M2IxNTEyZjYxODkzYmU4L3RhYmxlcmFuZ2U6NDM0MDQ2YTUxNjg4NDNkODkzYjE1MTJmNjE4OTNiZThfMzktMy0xLTEtMTc3NzU_dba75782-45fc-41f1-911d-e2bbfe3ed515"
      unitRef="usd">6000</evh:StockIssuedDuringPeriodValueEarnOuts>
    <evh:StockIssuedDuringPeriodValueEarnOuts
      contextRef="ieb0b713eae1b4f908dc2c23586d77948_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yOC9mcmFnOjVjZWM5NGI5MzY4ODQyMTA5NWE3OThhZmFiNjljNDYwL3RhYmxlOjQzNDA0NmE1MTY4ODQzZDg5M2IxNTEyZjYxODkzYmU4L3RhYmxlcmFuZ2U6NDM0MDQ2YTUxNjg4NDNkODkzYjE1MTJmNjE4OTNiZThfMzktOS0xLTEtMTc3NzU_499c0765-e616-4061-a1ed-bc88b0f03850"
      unitRef="usd">4179000</evh:StockIssuedDuringPeriodValueEarnOuts>
    <evh:StockIssuedDuringPeriodValueEarnOuts
      contextRef="i911a108ecf12460193d53b0e6b24331f_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yOC9mcmFnOjVjZWM5NGI5MzY4ODQyMTA5NWE3OThhZmFiNjljNDYwL3RhYmxlOjQzNDA0NmE1MTY4ODQzZDg5M2IxNTEyZjYxODkzYmU4L3RhYmxlcmFuZ2U6NDM0MDQ2YTUxNjg4NDNkODkzYjE1MTJmNjE4OTNiZThfMzktMTctMS0xLTE3Nzc1_3c3061f2-79bf-40b3-af23-bd491c38428e"
      unitRef="usd">4185000</evh:StockIssuedDuringPeriodValueEarnOuts>
    <evh:StockIssuedDuringPeriodValueEarnOuts
      contextRef="i12a6d1161de54547bd29f8efccd4c9b0_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yOC9mcmFnOjVjZWM5NGI5MzY4ODQyMTA5NWE3OThhZmFiNjljNDYwL3RhYmxlOjQzNDA0NmE1MTY4ODQzZDg5M2IxNTEyZjYxODkzYmU4L3RhYmxlcmFuZ2U6NDM0MDQ2YTUxNjg4NDNkODkzYjE1MTJmNjE4OTNiZThfMzktMjEtMS0xLTE3Nzc1_dc309e90-9735-4822-80a8-6570c05111a4"
      unitRef="usd">4185000</evh:StockIssuedDuringPeriodValueEarnOuts>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt
      contextRef="ieb0b713eae1b4f908dc2c23586d77948_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yOC9mcmFnOjVjZWM5NGI5MzY4ODQyMTA5NWE3OThhZmFiNjljNDYwL3RhYmxlOjQzNDA0NmE1MTY4ODQzZDg5M2IxNTEyZjYxODkzYmU4L3RhYmxlcmFuZ2U6NDM0MDQ2YTUxNjg4NDNkODkzYjE1MTJmNjE4OTNiZThfNDAtOS0xLTEtMTc3NzU_8d714747-1ec8-40b8-b170-948f233f43a0"
      unitRef="usd">36793000</us-gaap:AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt
      contextRef="i911a108ecf12460193d53b0e6b24331f_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yOC9mcmFnOjVjZWM5NGI5MzY4ODQyMTA5NWE3OThhZmFiNjljNDYwL3RhYmxlOjQzNDA0NmE1MTY4ODQzZDg5M2IxNTEyZjYxODkzYmU4L3RhYmxlcmFuZ2U6NDM0MDQ2YTUxNjg4NDNkODkzYjE1MTJmNjE4OTNiZThfNDAtMTctMS0xLTE3Nzc1_8b8a8a73-55fe-4114-b480-daf344f6e581"
      unitRef="usd">36793000</us-gaap:AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt
      contextRef="i12a6d1161de54547bd29f8efccd4c9b0_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yOC9mcmFnOjVjZWM5NGI5MzY4ODQyMTA5NWE3OThhZmFiNjljNDYwL3RhYmxlOjQzNDA0NmE1MTY4ODQzZDg5M2IxNTEyZjYxODkzYmU4L3RhYmxlcmFuZ2U6NDM0MDQ2YTUxNjg4NDNkODkzYjE1MTJmNjE4OTNiZThfNDAtMjEtMS0xLTE3Nzc1_53f3b0aa-917e-4840-a2bd-1b618ceef2d9"
      unitRef="usd">36793000</us-gaap:AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt>
    <us-gaap:NoncontrollingInterestDecreaseFromDeconsolidation
      contextRef="ic8a05c8bd28c42f4918205dc608cf2de_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yOC9mcmFnOjVjZWM5NGI5MzY4ODQyMTA5NWE3OThhZmFiNjljNDYwL3RhYmxlOjQzNDA0NmE1MTY4ODQzZDg5M2IxNTEyZjYxODkzYmU4L3RhYmxlcmFuZ2U6NDM0MDQ2YTUxNjg4NDNkODkzYjE1MTJmNjE4OTNiZThfNDEtMTktMS0xLTE3Nzc1_b9c7b64d-08d8-4e3b-b0a5-916710ba4a59"
      unitRef="usd">6689000</us-gaap:NoncontrollingInterestDecreaseFromDeconsolidation>
    <us-gaap:NoncontrollingInterestDecreaseFromDeconsolidation
      contextRef="i12a6d1161de54547bd29f8efccd4c9b0_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yOC9mcmFnOjVjZWM5NGI5MzY4ODQyMTA5NWE3OThhZmFiNjljNDYwL3RhYmxlOjQzNDA0NmE1MTY4ODQzZDg5M2IxNTEyZjYxODkzYmU4L3RhYmxlcmFuZ2U6NDM0MDQ2YTUxNjg4NDNkODkzYjE1MTJmNjE4OTNiZThfNDEtMjEtMS0xLTE3Nzc1_438cc8d7-7fac-4265-b0d4-73de2722c948"
      unitRef="usd">6689000</us-gaap:NoncontrollingInterestDecreaseFromDeconsolidation>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="ide6ed4433a164b08bcb555a8e1f7a38c_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yOC9mcmFnOjVjZWM5NGI5MzY4ODQyMTA5NWE3OThhZmFiNjljNDYwL3RhYmxlOjQzNDA0NmE1MTY4ODQzZDg5M2IxNTEyZjYxODkzYmU4L3RhYmxlcmFuZ2U6NDM0MDQ2YTUxNjg4NDNkODkzYjE1MTJmNjE4OTNiZThfNDItMTEtMS0xLTE3Nzc1_70553822-bd1e-4b8d-b4bd-3ef2cd689e56"
      unitRef="usd">-44000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="i911a108ecf12460193d53b0e6b24331f_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yOC9mcmFnOjVjZWM5NGI5MzY4ODQyMTA5NWE3OThhZmFiNjljNDYwL3RhYmxlOjQzNDA0NmE1MTY4ODQzZDg5M2IxNTEyZjYxODkzYmU4L3RhYmxlcmFuZ2U6NDM0MDQ2YTUxNjg4NDNkODkzYjE1MTJmNjE4OTNiZThfNDItMTctMS0xLTE3Nzc1_8f0e1b27-5e95-4059-9825-53f6342d9d4f"
      unitRef="usd">-44000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="i12a6d1161de54547bd29f8efccd4c9b0_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yOC9mcmFnOjVjZWM5NGI5MzY4ODQyMTA5NWE3OThhZmFiNjljNDYwL3RhYmxlOjQzNDA0NmE1MTY4ODQzZDg5M2IxNTEyZjYxODkzYmU4L3RhYmxlcmFuZ2U6NDM0MDQ2YTUxNjg4NDNkODkzYjE1MTJmNjE4OTNiZThfNDItMjEtMS0xLTE3Nzc1_17da6005-e318-4a9f-b4f8-677c2b2565ef"
      unitRef="usd">-44000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:ProfitLoss
      contextRef="i88dcc077f08e4577b7b60dca2d354693_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yOC9mcmFnOjVjZWM5NGI5MzY4ODQyMTA5NWE3OThhZmFiNjljNDYwL3RhYmxlOjQzNDA0NmE1MTY4ODQzZDg5M2IxNTEyZjYxODkzYmU4L3RhYmxlcmFuZ2U6NDM0MDQ2YTUxNjg4NDNkODkzYjE1MTJmNjE4OTNiZThfNDMtMTMtMS0xLTE3Nzc1_93e1ac6a-1fd4-4f5c-aae2-4a6771211c60"
      unitRef="usd">-334246000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i911a108ecf12460193d53b0e6b24331f_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yOC9mcmFnOjVjZWM5NGI5MzY4ODQyMTA5NWE3OThhZmFiNjljNDYwL3RhYmxlOjQzNDA0NmE1MTY4ODQzZDg5M2IxNTEyZjYxODkzYmU4L3RhYmxlcmFuZ2U6NDM0MDQ2YTUxNjg4NDNkODkzYjE1MTJmNjE4OTNiZThfNDMtMTctMS0xLTE3Nzc1_ba79e546-8882-4e1c-92e9-471a4bf18320"
      unitRef="usd">-334246000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i12a6d1161de54547bd29f8efccd4c9b0_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yOC9mcmFnOjVjZWM5NGI5MzY4ODQyMTA5NWE3OThhZmFiNjljNDYwL3RhYmxlOjQzNDA0NmE1MTY4ODQzZDg5M2IxNTEyZjYxODkzYmU4L3RhYmxlcmFuZ2U6NDM0MDQ2YTUxNjg4NDNkODkzYjE1MTJmNjE4OTNiZThfNDMtMjEtMS0xLTE3Nzc1_a1eb5d34-d272-40e1-80e6-4d11d1621c89"
      unitRef="usd">-334246000</us-gaap:ProfitLoss>
    <us-gaap:SharesIssued
      contextRef="iaf96f04b17974a2f8e19df7a883c4734_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yOC9mcmFnOjVjZWM5NGI5MzY4ODQyMTA5NWE3OThhZmFiNjljNDYwL3RhYmxlOjQzNDA0NmE1MTY4ODQzZDg5M2IxNTEyZjYxODkzYmU4L3RhYmxlcmFuZ2U6NDM0MDQ2YTUxNjg4NDNkODkzYjE1MTJmNjE4OTNiZThfNDQtMS0xLTEtMTc3NzU_7a868ca8-f47d-4d97-930b-665d404cc448"
      unitRef="shares">85895000</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="iaf96f04b17974a2f8e19df7a883c4734_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yOC9mcmFnOjVjZWM5NGI5MzY4ODQyMTA5NWE3OThhZmFiNjljNDYwL3RhYmxlOjQzNDA0NmE1MTY4ODQzZDg5M2IxNTEyZjYxODkzYmU4L3RhYmxlcmFuZ2U6NDM0MDQ2YTUxNjg4NDNkODkzYjE1MTJmNjE4OTNiZThfNDQtMy0xLTEtMTc3NzU_8f52aae6-c9c9-4c61-9a82-74909959912b"
      unitRef="usd">859000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i1425ebfe96904025b4f40a30737efd06_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yOC9mcmFnOjVjZWM5NGI5MzY4ODQyMTA5NWE3OThhZmFiNjljNDYwL3RhYmxlOjQzNDA0NmE1MTY4ODQzZDg5M2IxNTEyZjYxODkzYmU4L3RhYmxlcmFuZ2U6NDM0MDQ2YTUxNjg4NDNkODkzYjE1MTJmNjE4OTNiZThfNDQtOS0xLTEtMTc3NzU_cf3632e9-c682-4105-a3d7-3a90f0fc0e8b"
      unitRef="usd">1229320000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i8f416a598c52444597bd56910cd0efbb_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yOC9mcmFnOjVjZWM5NGI5MzY4ODQyMTA5NWE3OThhZmFiNjljNDYwL3RhYmxlOjQzNDA0NmE1MTY4ODQzZDg5M2IxNTEyZjYxODkzYmU4L3RhYmxlcmFuZ2U6NDM0MDQ2YTUxNjg4NDNkODkzYjE1MTJmNjE4OTNiZThfNDQtMTEtMS0xLTE3Nzc1_2ac7708e-98d4-426f-b7f9-46768ac24ca2"
      unitRef="usd">-278000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i7de15b24843f43e1bf1e49503dff1359_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yOC9mcmFnOjVjZWM5NGI5MzY4ODQyMTA5NWE3OThhZmFiNjljNDYwL3RhYmxlOjQzNDA0NmE1MTY4ODQzZDg5M2IxNTEyZjYxODkzYmU4L3RhYmxlcmFuZ2U6NDM0MDQ2YTUxNjg4NDNkODkzYjE1MTJmNjE4OTNiZThfNDQtMTMtMS0xLTE3Nzc1_852eb8fc-5b51-4d9c-aece-c1887ca00a51"
      unitRef="usd">-589178000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="idb7d2cb4638a4234b2407c840694aea3_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yOC9mcmFnOjVjZWM5NGI5MzY4ODQyMTA5NWE3OThhZmFiNjljNDYwL3RhYmxlOjQzNDA0NmE1MTY4ODQzZDg5M2IxNTEyZjYxODkzYmU4L3RhYmxlcmFuZ2U6NDM0MDQ2YTUxNjg4NDNkODkzYjE1MTJmNjE4OTNiZThfNDQtMTUtMS0xLTE3Nzc1_25134528-2bc3-4929-98a2-f6f3a59e50d9"
      unitRef="usd">-21123000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i88eadc89dc9a4d4aab536db563f563d5_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yOC9mcmFnOjVjZWM5NGI5MzY4ODQyMTA5NWE3OThhZmFiNjljNDYwL3RhYmxlOjQzNDA0NmE1MTY4ODQzZDg5M2IxNTEyZjYxODkzYmU4L3RhYmxlcmFuZ2U6NDM0MDQ2YTUxNjg4NDNkODkzYjE1MTJmNjE4OTNiZThfNDQtMTctMS0xLTE3Nzc1_f0c4411a-9f50-4f0a-b86c-277432113ea4"
      unitRef="usd">619600000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i5724ef529cea411aadb2b6f086af09f1_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yOC9mcmFnOjVjZWM5NGI5MzY4ODQyMTA5NWE3OThhZmFiNjljNDYwL3RhYmxlOjQzNDA0NmE1MTY4ODQzZDg5M2IxNTEyZjYxODkzYmU4L3RhYmxlcmFuZ2U6NDM0MDQ2YTUxNjg4NDNkODkzYjE1MTJmNjE4OTNiZThfNDQtMTktMS0xLTE3Nzc1_4d978b7f-b0e2-44f9-87b3-f3e867899c99"
      unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ibc0c0c2b8dc04c5698ca0577a54b2e03_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yOC9mcmFnOjVjZWM5NGI5MzY4ODQyMTA5NWE3OThhZmFiNjljNDYwL3RhYmxlOjQzNDA0NmE1MTY4ODQzZDg5M2IxNTEyZjYxODkzYmU4L3RhYmxlcmFuZ2U6NDM0MDQ2YTUxNjg4NDNkODkzYjE1MTJmNjE4OTNiZThfNDQtMjEtMS0xLTE3Nzc1_8c58ed7d-daca-4be3-aabe-17ef1aff0891"
      unitRef="usd">619600000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i8a0a16beae314535bccd01c31668c8fd_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yOC9mcmFnOjVjZWM5NGI5MzY4ODQyMTA5NWE3OThhZmFiNjljNDYwL3RhYmxlOjQzNDA0NmE1MTY4ODQzZDg5M2IxNTEyZjYxODkzYmU4L3RhYmxlcmFuZ2U6NDM0MDQ2YTUxNjg4NDNkODkzYjE1MTJmNjE4OTNiZThfMzItOS0xLTEtMTkzMTk_ce295e66-b901-4729-9ce8-aaef00d991cd"
      unitRef="usd">16711000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i5f242398851f435581586484404b0dfb_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yOC9mcmFnOjVjZWM5NGI5MzY4ODQyMTA5NWE3OThhZmFiNjljNDYwL3RhYmxlOjQzNDA0NmE1MTY4ODQzZDg5M2IxNTEyZjYxODkzYmU4L3RhYmxlcmFuZ2U6NDM0MDQ2YTUxNjg4NDNkODkzYjE1MTJmNjE4OTNiZThfMzItMTctMS0xLTE5MzE5_c1c33bc6-12ef-41f9-9bb9-792b2d5f03ae"
      unitRef="usd">16711000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yOC9mcmFnOjVjZWM5NGI5MzY4ODQyMTA5NWE3OThhZmFiNjljNDYwL3RhYmxlOjQzNDA0NmE1MTY4ODQzZDg5M2IxNTEyZjYxODkzYmU4L3RhYmxlcmFuZ2U6NDM0MDQ2YTUxNjg4NDNkODkzYjE1MTJmNjE4OTNiZThfMzItMjEtMS0xLTE5MzE5_eea8a8ce-24c7-421c-bfd7-1278dc45f045"
      unitRef="usd">16711000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="i8a70782136dc46eb8037c247f5e1694a_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yOC9mcmFnOjVjZWM5NGI5MzY4ODQyMTA5NWE3OThhZmFiNjljNDYwL3RhYmxlOjQzNDA0NmE1MTY4ODQzZDg5M2IxNTEyZjYxODkzYmU4L3RhYmxlcmFuZ2U6NDM0MDQ2YTUxNjg4NDNkODkzYjE1MTJmNjE4OTNiZThfMzMtMS0xLTEtMTkzMTk_f83ec2bc-fc66-49ff-be65-6d0bbaff525c"
      unitRef="shares">1490000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i8a70782136dc46eb8037c247f5e1694a_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yOC9mcmFnOjVjZWM5NGI5MzY4ODQyMTA5NWE3OThhZmFiNjljNDYwL3RhYmxlOjQzNDA0NmE1MTY4ODQzZDg5M2IxNTEyZjYxODkzYmU4L3RhYmxlcmFuZ2U6NDM0MDQ2YTUxNjg4NDNkODkzYjE1MTJmNjE4OTNiZThfMzMtMy0xLTEtMTkzMTk_f2b3a1c6-6476-491c-ae5d-b96bbc72db90"
      unitRef="usd">15000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i8a0a16beae314535bccd01c31668c8fd_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yOC9mcmFnOjVjZWM5NGI5MzY4ODQyMTA5NWE3OThhZmFiNjljNDYwL3RhYmxlOjQzNDA0NmE1MTY4ODQzZDg5M2IxNTEyZjYxODkzYmU4L3RhYmxlcmFuZ2U6NDM0MDQ2YTUxNjg4NDNkODkzYjE1MTJmNjE4OTNiZThfMzMtOS0xLTEtMTkzMTk_390f6ffd-2b8b-480e-983b-b77c0118d7a3"
      unitRef="usd">13274000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i5f242398851f435581586484404b0dfb_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yOC9mcmFnOjVjZWM5NGI5MzY4ODQyMTA5NWE3OThhZmFiNjljNDYwL3RhYmxlOjQzNDA0NmE1MTY4ODQzZDg5M2IxNTEyZjYxODkzYmU4L3RhYmxlcmFuZ2U6NDM0MDQ2YTUxNjg4NDNkODkzYjE1MTJmNjE4OTNiZThfMzMtMTctMS0xLTE5MzE5_9ba403ba-5b29-4ad5-81e0-897aa8ab6d10"
      unitRef="usd">13289000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yOC9mcmFnOjVjZWM5NGI5MzY4ODQyMTA5NWE3OThhZmFiNjljNDYwL3RhYmxlOjQzNDA0NmE1MTY4ODQzZDg5M2IxNTEyZjYxODkzYmU4L3RhYmxlcmFuZ2U6NDM0MDQ2YTUxNjg4NDNkODkzYjE1MTJmNjE4OTNiZThfMzMtMjEtMS0xLTE5MzE5_b937bbd9-3174-4880-be82-bf0b6fcc7711"
      unitRef="usd">13289000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures
      contextRef="i8a70782136dc46eb8037c247f5e1694a_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yOC9mcmFnOjVjZWM5NGI5MzY4ODQyMTA5NWE3OThhZmFiNjljNDYwL3RhYmxlOjQzNDA0NmE1MTY4ODQzZDg5M2IxNTEyZjYxODkzYmU4L3RhYmxlcmFuZ2U6NDM0MDQ2YTUxNjg4NDNkODkzYjE1MTJmNjE4OTNiZThfMzQtMS0xLTEtMTkzMTk_88540ee9-fa4e-4d5a-8bb1-59fe94e85239"
      unitRef="shares">492000</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
      contextRef="i8a70782136dc46eb8037c247f5e1694a_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yOC9mcmFnOjVjZWM5NGI5MzY4ODQyMTA5NWE3OThhZmFiNjljNDYwL3RhYmxlOjQzNDA0NmE1MTY4ODQzZDg5M2IxNTEyZjYxODkzYmU4L3RhYmxlcmFuZ2U6NDM0MDQ2YTUxNjg4NDNkODkzYjE1MTJmNjE4OTNiZThfMzQtMy0xLTEtMTkzMTk_34f94842-38c0-49e7-89fa-de0cd4c52bab"
      unitRef="usd">5000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
      contextRef="i8a0a16beae314535bccd01c31668c8fd_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yOC9mcmFnOjVjZWM5NGI5MzY4ODQyMTA5NWE3OThhZmFiNjljNDYwL3RhYmxlOjQzNDA0NmE1MTY4ODQzZDg5M2IxNTEyZjYxODkzYmU4L3RhYmxlcmFuZ2U6NDM0MDQ2YTUxNjg4NDNkODkzYjE1MTJmNjE4OTNiZThfMzQtOS0xLTEtMTkzMTk_8615ce7e-c8b1-41da-b61a-9eeecf95c199"
      unitRef="usd">-3855000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
      contextRef="i5f242398851f435581586484404b0dfb_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yOC9mcmFnOjVjZWM5NGI5MzY4ODQyMTA5NWE3OThhZmFiNjljNDYwL3RhYmxlOjQzNDA0NmE1MTY4ODQzZDg5M2IxNTEyZjYxODkzYmU4L3RhYmxlcmFuZ2U6NDM0MDQ2YTUxNjg4NDNkODkzYjE1MTJmNjE4OTNiZThfMzQtMTctMS0xLTE5MzE5_1ba22cf7-9b13-48e0-a898-1973665e3454"
      unitRef="usd">-3850000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
      contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yOC9mcmFnOjVjZWM5NGI5MzY4ODQyMTA5NWE3OThhZmFiNjljNDYwL3RhYmxlOjQzNDA0NmE1MTY4ODQzZDg5M2IxNTEyZjYxODkzYmU4L3RhYmxlcmFuZ2U6NDM0MDQ2YTUxNjg4NDNkODkzYjE1MTJmNjE4OTNiZThfMzQtMjEtMS0xLTE5MzE5_5f93955d-da8b-4b86-a234-4d81bd65b0a7"
      unitRef="usd">-3850000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodSharesAcquisitions
      contextRef="i8a70782136dc46eb8037c247f5e1694a_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yOC9mcmFnOjVjZWM5NGI5MzY4ODQyMTA5NWE3OThhZmFiNjljNDYwL3RhYmxlOjQzNDA0NmE1MTY4ODQzZDg5M2IxNTEyZjYxODkzYmU4L3RhYmxlcmFuZ2U6NDM0MDQ2YTUxNjg4NDNkODkzYjE1MTJmNjE4OTNiZThfMzUtMS0xLTEtMTkzMTk_df88fedd-f8a0-40a2-b7ee-abcac4a73d45"
      unitRef="shares">1771000</us-gaap:StockIssuedDuringPeriodSharesAcquisitions>
    <us-gaap:StockIssuedDuringPeriodValueAcquisitions
      contextRef="i8a70782136dc46eb8037c247f5e1694a_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yOC9mcmFnOjVjZWM5NGI5MzY4ODQyMTA5NWE3OThhZmFiNjljNDYwL3RhYmxlOjQzNDA0NmE1MTY4ODQzZDg5M2IxNTEyZjYxODkzYmU4L3RhYmxlcmFuZ2U6NDM0MDQ2YTUxNjg4NDNkODkzYjE1MTJmNjE4OTNiZThfMzUtMy0xLTEtMTkzMTk_15275e53-10b1-4287-bb21-94e7593145f2"
      unitRef="usd">18000</us-gaap:StockIssuedDuringPeriodValueAcquisitions>
    <us-gaap:StockIssuedDuringPeriodValueAcquisitions
      contextRef="i8a0a16beae314535bccd01c31668c8fd_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yOC9mcmFnOjVjZWM5NGI5MzY4ODQyMTA5NWE3OThhZmFiNjljNDYwL3RhYmxlOjQzNDA0NmE1MTY4ODQzZDg5M2IxNTEyZjYxODkzYmU4L3RhYmxlcmFuZ2U6NDM0MDQ2YTUxNjg4NDNkODkzYjE1MTJmNjE4OTNiZThfMzUtOS0xLTEtMTkzMTk_98e2979a-48a7-4cb2-a089-822b84b2608d"
      unitRef="usd">56608000</us-gaap:StockIssuedDuringPeriodValueAcquisitions>
    <us-gaap:StockIssuedDuringPeriodValueAcquisitions
      contextRef="i5f242398851f435581586484404b0dfb_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yOC9mcmFnOjVjZWM5NGI5MzY4ODQyMTA5NWE3OThhZmFiNjljNDYwL3RhYmxlOjQzNDA0NmE1MTY4ODQzZDg5M2IxNTEyZjYxODkzYmU4L3RhYmxlcmFuZ2U6NDM0MDQ2YTUxNjg4NDNkODkzYjE1MTJmNjE4OTNiZThfMzUtMTctMS0xLTE5MzE5_33671f22-f521-4533-9a52-ec2ad415d69d"
      unitRef="usd">56626000</us-gaap:StockIssuedDuringPeriodValueAcquisitions>
    <us-gaap:StockIssuedDuringPeriodValueAcquisitions
      contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yOC9mcmFnOjVjZWM5NGI5MzY4ODQyMTA5NWE3OThhZmFiNjljNDYwL3RhYmxlOjQzNDA0NmE1MTY4ODQzZDg5M2IxNTEyZjYxODkzYmU4L3RhYmxlcmFuZ2U6NDM0MDQ2YTUxNjg4NDNkODkzYjE1MTJmNjE4OTNiZThfMzUtMjEtMS0xLTE5MzE5_3ecf56fe-7b2d-4f64-b915-662e2d07392a"
      unitRef="usd">56626000</us-gaap:StockIssuedDuringPeriodValueAcquisitions>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="i8a70782136dc46eb8037c247f5e1694a_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yOC9mcmFnOjVjZWM5NGI5MzY4ODQyMTA5NWE3OThhZmFiNjljNDYwL3RhYmxlOjQzNDA0NmE1MTY4ODQzZDg5M2IxNTEyZjYxODkzYmU4L3RhYmxlcmFuZ2U6NDM0MDQ2YTUxNjg4NDNkODkzYjE1MTJmNjE4OTNiZThfMzYtMS0xLTEtMjMzNTQ_7f65750b-18ee-473d-b97c-b72f5de8b6bf"
      unitRef="shares">1095000</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="i8a70782136dc46eb8037c247f5e1694a_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yOC9mcmFnOjVjZWM5NGI5MzY4ODQyMTA5NWE3OThhZmFiNjljNDYwL3RhYmxlOjQzNDA0NmE1MTY4ODQzZDg5M2IxNTEyZjYxODkzYmU4L3RhYmxlcmFuZ2U6NDM0MDQ2YTUxNjg4NDNkODkzYjE1MTJmNjE4OTNiZThfMzYtMy0xLTEtMjMzNTQ_9fceaaf7-3fef-4855-8644-c2288c6ed58c"
      unitRef="usd">11000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="i8a0a16beae314535bccd01c31668c8fd_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yOC9mcmFnOjVjZWM5NGI5MzY4ODQyMTA5NWE3OThhZmFiNjljNDYwL3RhYmxlOjQzNDA0NmE1MTY4ODQzZDg5M2IxNTEyZjYxODkzYmU4L3RhYmxlcmFuZ2U6NDM0MDQ2YTUxNjg4NDNkODkzYjE1MTJmNjE4OTNiZThfMzYtOS0xLTEtMjMzNTQ_72eae4a3-98d1-4b58-9346-a59d84a0e72c"
      unitRef="usd">28481000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="i5f242398851f435581586484404b0dfb_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yOC9mcmFnOjVjZWM5NGI5MzY4ODQyMTA5NWE3OThhZmFiNjljNDYwL3RhYmxlOjQzNDA0NmE1MTY4ODQzZDg5M2IxNTEyZjYxODkzYmU4L3RhYmxlcmFuZ2U6NDM0MDQ2YTUxNjg4NDNkODkzYjE1MTJmNjE4OTNiZThfMzYtMTctMS0xLTIzMzU0_022856f5-437a-4cf1-958d-3744ef1ecf60"
      unitRef="usd">28492000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yOC9mcmFnOjVjZWM5NGI5MzY4ODQyMTA5NWE3OThhZmFiNjljNDYwL3RhYmxlOjQzNDA0NmE1MTY4ODQzZDg5M2IxNTEyZjYxODkzYmU4L3RhYmxlcmFuZ2U6NDM0MDQ2YTUxNjg4NDNkODkzYjE1MTJmNjE4OTNiZThfMzYtMjEtMS0xLTIzMzU0_895f72f8-c0a9-4abb-8850-bd28b3d09beb"
      unitRef="usd">28492000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <evh:StockIssuedDuringPeriodSharesEarnOuts
      contextRef="i8a70782136dc46eb8037c247f5e1694a_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yOC9mcmFnOjVjZWM5NGI5MzY4ODQyMTA5NWE3OThhZmFiNjljNDYwL3RhYmxlOjQzNDA0NmE1MTY4ODQzZDg5M2IxNTEyZjYxODkzYmU4L3RhYmxlcmFuZ2U6NDM0MDQ2YTUxNjg4NDNkODkzYjE1MTJmNjE4OTNiZThfMzctMS0xLTEtMjMzNTQ_5ec46929-da5b-4358-8386-5347329ce519"
      unitRef="shares">16000</evh:StockIssuedDuringPeriodSharesEarnOuts>
    <evh:StockIssuedDuringPeriodValueEarnOuts
      contextRef="i8a0a16beae314535bccd01c31668c8fd_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yOC9mcmFnOjVjZWM5NGI5MzY4ODQyMTA5NWE3OThhZmFiNjljNDYwL3RhYmxlOjQzNDA0NmE1MTY4ODQzZDg5M2IxNTEyZjYxODkzYmU4L3RhYmxlcmFuZ2U6NDM0MDQ2YTUxNjg4NDNkODkzYjE1MTJmNjE4OTNiZThfMzctOS0xLTEtMjMzNTQ_2ee1cb17-779e-49d6-ad2e-7acac1a9fe1a"
      unitRef="usd">450000</evh:StockIssuedDuringPeriodValueEarnOuts>
    <evh:StockIssuedDuringPeriodValueEarnOuts
      contextRef="i5f242398851f435581586484404b0dfb_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yOC9mcmFnOjVjZWM5NGI5MzY4ODQyMTA5NWE3OThhZmFiNjljNDYwL3RhYmxlOjQzNDA0NmE1MTY4ODQzZDg5M2IxNTEyZjYxODkzYmU4L3RhYmxlcmFuZ2U6NDM0MDQ2YTUxNjg4NDNkODkzYjE1MTJmNjE4OTNiZThfMzctMTctMS0xLTIzMzU0_b23f9ed9-a11c-4ebe-9e68-904babe69fd2"
      unitRef="usd">450000</evh:StockIssuedDuringPeriodValueEarnOuts>
    <evh:StockIssuedDuringPeriodValueEarnOuts
      contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yOC9mcmFnOjVjZWM5NGI5MzY4ODQyMTA5NWE3OThhZmFiNjljNDYwL3RhYmxlOjQzNDA0NmE1MTY4ODQzZDg5M2IxNTEyZjYxODkzYmU4L3RhYmxlcmFuZ2U6NDM0MDQ2YTUxNjg4NDNkODkzYjE1MTJmNjE4OTNiZThfMzctMjEtMS0xLTIzMzU0_e9d8300a-49bb-42de-88b5-3deb098fee1a"
      unitRef="usd">450000</evh:StockIssuedDuringPeriodValueEarnOuts>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="i1bcca85fbf4c425299cf11a4c6626357_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yOC9mcmFnOjVjZWM5NGI5MzY4ODQyMTA5NWE3OThhZmFiNjljNDYwL3RhYmxlOjQzNDA0NmE1MTY4ODQzZDg5M2IxNTEyZjYxODkzYmU4L3RhYmxlcmFuZ2U6NDM0MDQ2YTUxNjg4NDNkODkzYjE1MTJmNjE4OTNiZThfMzYtMTEtMS0xLTE5MzE5_30e1f232-5857-4ba3-a6ba-ae6a55728993"
      unitRef="usd">-84000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="i5f242398851f435581586484404b0dfb_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yOC9mcmFnOjVjZWM5NGI5MzY4ODQyMTA5NWE3OThhZmFiNjljNDYwL3RhYmxlOjQzNDA0NmE1MTY4ODQzZDg5M2IxNTEyZjYxODkzYmU4L3RhYmxlcmFuZ2U6NDM0MDQ2YTUxNjg4NDNkODkzYjE1MTJmNjE4OTNiZThfMzYtMTctMS0xLTE5MzE5_f0c20374-90b2-4e94-89d8-4f589db4b600"
      unitRef="usd">-84000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yOC9mcmFnOjVjZWM5NGI5MzY4ODQyMTA5NWE3OThhZmFiNjljNDYwL3RhYmxlOjQzNDA0NmE1MTY4ODQzZDg5M2IxNTEyZjYxODkzYmU4L3RhYmxlcmFuZ2U6NDM0MDQ2YTUxNjg4NDNkODkzYjE1MTJmNjE4OTNiZThfMzYtMjEtMS0xLTE5MzE5_6a4138b7-4016-4a72-861e-ede8023d9b2e"
      unitRef="usd">-84000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:ProfitLoss
      contextRef="i75b369d853b249f9a6495524752f5913_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yOC9mcmFnOjVjZWM5NGI5MzY4ODQyMTA5NWE3OThhZmFiNjljNDYwL3RhYmxlOjQzNDA0NmE1MTY4ODQzZDg5M2IxNTEyZjYxODkzYmU4L3RhYmxlcmFuZ2U6NDM0MDQ2YTUxNjg4NDNkODkzYjE1MTJmNjE4OTNiZThfMzctMTMtMS0xLTE5MzE5_d1914d39-5c6f-453b-977d-0b3803568b36"
      unitRef="usd">-37601000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i5f242398851f435581586484404b0dfb_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yOC9mcmFnOjVjZWM5NGI5MzY4ODQyMTA5NWE3OThhZmFiNjljNDYwL3RhYmxlOjQzNDA0NmE1MTY4ODQzZDg5M2IxNTEyZjYxODkzYmU4L3RhYmxlcmFuZ2U6NDM0MDQ2YTUxNjg4NDNkODkzYjE1MTJmNjE4OTNiZThfMzctMTctMS0xLTE5MzE5_2c081a5d-095a-48c1-a8c7-90788af74f34"
      unitRef="usd">-37601000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yOC9mcmFnOjVjZWM5NGI5MzY4ODQyMTA5NWE3OThhZmFiNjljNDYwL3RhYmxlOjQzNDA0NmE1MTY4ODQzZDg5M2IxNTEyZjYxODkzYmU4L3RhYmxlcmFuZ2U6NDM0MDQ2YTUxNjg4NDNkODkzYjE1MTJmNjE4OTNiZThfMzctMjEtMS0xLTE5MzE5_74335710-25b2-4ebf-93b0-0e4945c5ef45"
      unitRef="usd">-37601000</us-gaap:ProfitLoss>
    <us-gaap:SharesIssued
      contextRef="i2177056c167d473399f65b5105c9a7f2_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yOC9mcmFnOjVjZWM5NGI5MzY4ODQyMTA5NWE3OThhZmFiNjljNDYwL3RhYmxlOjQzNDA0NmE1MTY4ODQzZDg5M2IxNTEyZjYxODkzYmU4L3RhYmxlcmFuZ2U6NDM0MDQ2YTUxNjg4NDNkODkzYjE1MTJmNjE4OTNiZThfMzgtMS0xLTEtMTkzMTk_f2060742-74cd-4a88-9cb0-f8a02e84cad4"
      unitRef="shares">90759000</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i2177056c167d473399f65b5105c9a7f2_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yOC9mcmFnOjVjZWM5NGI5MzY4ODQyMTA5NWE3OThhZmFiNjljNDYwL3RhYmxlOjQzNDA0NmE1MTY4ODQzZDg5M2IxNTEyZjYxODkzYmU4L3RhYmxlcmFuZ2U6NDM0MDQ2YTUxNjg4NDNkODkzYjE1MTJmNjE4OTNiZThfMzgtMy0xLTEtMTkzMTk_a96d8026-323e-4fd4-9fc8-0b860fb3cc8f"
      unitRef="usd">908000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i109ffa352e8c4ce0b59170cf60e46101_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yOC9mcmFnOjVjZWM5NGI5MzY4ODQyMTA5NWE3OThhZmFiNjljNDYwL3RhYmxlOjQzNDA0NmE1MTY4ODQzZDg5M2IxNTEyZjYxODkzYmU4L3RhYmxlcmFuZ2U6NDM0MDQ2YTUxNjg4NDNkODkzYjE1MTJmNjE4OTNiZThfMzgtOS0xLTEtMTkzMTk_8a770b7d-5034-473a-98f3-ecd96f41967c"
      unitRef="usd">1340989000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i7fd6de5224704d7187b37d35a519cbfa_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yOC9mcmFnOjVjZWM5NGI5MzY4ODQyMTA5NWE3OThhZmFiNjljNDYwL3RhYmxlOjQzNDA0NmE1MTY4ODQzZDg5M2IxNTEyZjYxODkzYmU4L3RhYmxlcmFuZ2U6NDM0MDQ2YTUxNjg4NDNkODkzYjE1MTJmNjE4OTNiZThfMzgtMTEtMS0xLTE5MzE5_df7ea04d-5e41-4777-b9bc-154977b6050f"
      unitRef="usd">-362000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i17d17fcbd53245e7981e707f61c46f1a_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yOC9mcmFnOjVjZWM5NGI5MzY4ODQyMTA5NWE3OThhZmFiNjljNDYwL3RhYmxlOjQzNDA0NmE1MTY4ODQzZDg5M2IxNTEyZjYxODkzYmU4L3RhYmxlcmFuZ2U6NDM0MDQ2YTUxNjg4NDNkODkzYjE1MTJmNjE4OTNiZThfMzgtMTMtMS0xLTE5MzE5_cff0568c-d39f-4078-8648-04a551ffdf05"
      unitRef="usd">-626779000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i2c95448403fa4d3b8d864ca25a132fb8_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yOC9mcmFnOjVjZWM5NGI5MzY4ODQyMTA5NWE3OThhZmFiNjljNDYwL3RhYmxlOjQzNDA0NmE1MTY4ODQzZDg5M2IxNTEyZjYxODkzYmU4L3RhYmxlcmFuZ2U6NDM0MDQ2YTUxNjg4NDNkODkzYjE1MTJmNjE4OTNiZThfMzgtMTUtMS0xLTE5MzE5_772a06ab-88a7-498b-8b02-94d14c6b233b"
      unitRef="usd">-21123000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i8be054225f004416b985533cd8b4d2a6_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yOC9mcmFnOjVjZWM5NGI5MzY4ODQyMTA5NWE3OThhZmFiNjljNDYwL3RhYmxlOjQzNDA0NmE1MTY4ODQzZDg5M2IxNTEyZjYxODkzYmU4L3RhYmxlcmFuZ2U6NDM0MDQ2YTUxNjg4NDNkODkzYjE1MTJmNjE4OTNiZThfMzgtMTctMS0xLTE5MzE5_61e1a331-3a75-46cc-9d81-031e61f4bc4f"
      unitRef="usd">693633000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i733ca541299f4839bead39679b082534_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yOC9mcmFnOjVjZWM5NGI5MzY4ODQyMTA5NWE3OThhZmFiNjljNDYwL3RhYmxlOjQzNDA0NmE1MTY4ODQzZDg5M2IxNTEyZjYxODkzYmU4L3RhYmxlcmFuZ2U6NDM0MDQ2YTUxNjg4NDNkODkzYjE1MTJmNjE4OTNiZThfMzgtMTktMS0xLTE5MzE5_ba1c1546-e5fa-40a8-a23c-5618b862db36"
      unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i8daff60be410426d8f7bd49343c1ec0c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yOC9mcmFnOjVjZWM5NGI5MzY4ODQyMTA5NWE3OThhZmFiNjljNDYwL3RhYmxlOjQzNDA0NmE1MTY4ODQzZDg5M2IxNTEyZjYxODkzYmU4L3RhYmxlcmFuZ2U6NDM0MDQ2YTUxNjg4NDNkODkzYjE1MTJmNjE4OTNiZThfMzgtMjEtMS0xLTE5MzE5_1066aa92-4101-4539-8063-ddaeb979b4ba"
      unitRef="usd">693633000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ProfitLoss
      contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18zNC9mcmFnOjI3Y2IxNjhkZTFhNTRhNGQ5MGNkYTNlODdlZDg5N2RlL3RhYmxlOmE4OWNjMDNlN2U2MDQyMjY5NTA4MWU1MTFkYTU1MTkwL3RhYmxlcmFuZ2U6YTg5Y2MwM2U3ZTYwNDIyNjk1MDgxZTUxMWRhNTUxOTBfMy0xLTEtMS0xNzc3NQ_c49b99c2-1aef-4003-806b-11d043c6a947"
      unitRef="usd">-37601000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i12a6d1161de54547bd29f8efccd4c9b0_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18zNC9mcmFnOjI3Y2IxNjhkZTFhNTRhNGQ5MGNkYTNlODdlZDg5N2RlL3RhYmxlOmE4OWNjMDNlN2U2MDQyMjY5NTA4MWU1MTFkYTU1MTkwL3RhYmxlcmFuZ2U6YTg5Y2MwM2U3ZTYwNDIyNjk1MDgxZTUxMWRhNTUxOTBfMy0zLTEtMS0xNzc3NQ_059445f8-3794-4af1-abe2-9f2515cac297"
      unitRef="usd">-334246000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i3e21049ffc224cacb8134d73c9bb5b38_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18zNC9mcmFnOjI3Y2IxNjhkZTFhNTRhNGQ5MGNkYTNlODdlZDg5N2RlL3RhYmxlOmE4OWNjMDNlN2U2MDQyMjY5NTA4MWU1MTFkYTU1MTkwL3RhYmxlcmFuZ2U6YTg5Y2MwM2U3ZTYwNDIyNjk1MDgxZTUxMWRhNTUxOTBfMy01LTEtMS0xOTUwNA_c9da1e92-d0a1-4f34-9937-22bf91507069"
      unitRef="usd">-305580000</us-gaap:ProfitLoss>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
      contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18zNC9mcmFnOjI3Y2IxNjhkZTFhNTRhNGQ5MGNkYTNlODdlZDg5N2RlL3RhYmxlOmE4OWNjMDNlN2U2MDQyMjY5NTA4MWU1MTFkYTU1MTkwL3RhYmxlcmFuZ2U6YTg5Y2MwM2U3ZTYwNDIyNjk1MDgxZTUxMWRhNTUxOTBfNS0xLTEtMS0xNzc3NQ_c7998437-f8da-4c5f-aa80-cf3cf5643967"
      unitRef="usd">13281000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
      contextRef="i12a6d1161de54547bd29f8efccd4c9b0_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18zNC9mcmFnOjI3Y2IxNjhkZTFhNTRhNGQ5MGNkYTNlODdlZDg5N2RlL3RhYmxlOmE4OWNjMDNlN2U2MDQyMjY5NTA4MWU1MTFkYTU1MTkwL3RhYmxlcmFuZ2U6YTg5Y2MwM2U3ZTYwNDIyNjk1MDgxZTUxMWRhNTUxOTBfNS0zLTEtMS0xNzc3NQ_33f80b68-1de6-4fcd-b0b0-a8b614075eb1"
      unitRef="usd">3860000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
      contextRef="i3e21049ffc224cacb8134d73c9bb5b38_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18zNC9mcmFnOjI3Y2IxNjhkZTFhNTRhNGQ5MGNkYTNlODdlZDg5N2RlL3RhYmxlOmE4OWNjMDNlN2U2MDQyMjY5NTA4MWU1MTFkYTU1MTkwL3RhYmxlcmFuZ2U6YTg5Y2MwM2U3ZTYwNDIyNjk1MDgxZTUxMWRhNTUxOTBfNS01LTEtMS0xOTUwNA_f932c57c-f9c3-4f92-9b07-2dcf30fafc2b"
      unitRef="usd">-3997000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <evh:GainLossOnDispositionOfAssetsOperatingActivities
      contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18zNC9mcmFnOjI3Y2IxNjhkZTFhNTRhNGQ5MGNkYTNlODdlZDg5N2RlL3RhYmxlOmE4OWNjMDNlN2U2MDQyMjY5NTA4MWU1MTFkYTU1MTkwL3RhYmxlcmFuZ2U6YTg5Y2MwM2U3ZTYwNDIyNjk1MDgxZTUxMWRhNTUxOTBfNi0xLTEtMS0xNzc3NQ_cf075745-e9c5-4cf0-a8c1-49d85f9882f3"
      unitRef="usd">-6786000</evh:GainLossOnDispositionOfAssetsOperatingActivities>
    <evh:GainLossOnDispositionOfAssetsOperatingActivities
      contextRef="i12a6d1161de54547bd29f8efccd4c9b0_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18zNC9mcmFnOjI3Y2IxNjhkZTFhNTRhNGQ5MGNkYTNlODdlZDg5N2RlL3RhYmxlOmE4OWNjMDNlN2U2MDQyMjY5NTA4MWU1MTFkYTU1MTkwL3RhYmxlcmFuZ2U6YTg5Y2MwM2U3ZTYwNDIyNjk1MDgxZTUxMWRhNTUxOTBfNi0zLTEtMS0xNzc3NQ_cf1ce36d-b295-4516-8dc2-fca35d5e3b99"
      unitRef="usd">-698000</evh:GainLossOnDispositionOfAssetsOperatingActivities>
    <evh:GainLossOnDispositionOfAssetsOperatingActivities
      contextRef="i3e21049ffc224cacb8134d73c9bb5b38_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18zNC9mcmFnOjI3Y2IxNjhkZTFhNTRhNGQ5MGNkYTNlODdlZDg5N2RlL3RhYmxlOmE4OWNjMDNlN2U2MDQyMjY5NTA4MWU1MTFkYTU1MTkwL3RhYmxlcmFuZ2U6YTg5Y2MwM2U3ZTYwNDIyNjk1MDgxZTUxMWRhNTUxOTBfNi01LTEtMS0xOTUwNA_400327a2-18d9-4e26-a77f-2808d8896975"
      unitRef="usd">9600000</evh:GainLossOnDispositionOfAssetsOperatingActivities>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18zNC9mcmFnOjI3Y2IxNjhkZTFhNTRhNGQ5MGNkYTNlODdlZDg5N2RlL3RhYmxlOmE4OWNjMDNlN2U2MDQyMjY5NTA4MWU1MTFkYTU1MTkwL3RhYmxlcmFuZ2U6YTg5Y2MwM2U3ZTYwNDIyNjk1MDgxZTUxMWRhNTUxOTBfNy0xLTEtMS0xNzc3NQ_1e765135-12c9-4108-aa47-dd0f3a7c0981"
      unitRef="usd">13179000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="i12a6d1161de54547bd29f8efccd4c9b0_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18zNC9mcmFnOjI3Y2IxNjhkZTFhNTRhNGQ5MGNkYTNlODdlZDg5N2RlL3RhYmxlOmE4OWNjMDNlN2U2MDQyMjY5NTA4MWU1MTFkYTU1MTkwL3RhYmxlcmFuZ2U6YTg5Y2MwM2U3ZTYwNDIyNjk1MDgxZTUxMWRhNTUxOTBfNy0zLTEtMS0xNzc3NQ_612fcbd7-e1f4-42f7-8a20-913f78fa731e"
      unitRef="usd">10039000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="i3e21049ffc224cacb8134d73c9bb5b38_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18zNC9mcmFnOjI3Y2IxNjhkZTFhNTRhNGQ5MGNkYTNlODdlZDg5N2RlL3RhYmxlOmE4OWNjMDNlN2U2MDQyMjY5NTA4MWU1MTFkYTU1MTkwL3RhYmxlcmFuZ2U6YTg5Y2MwM2U3ZTYwNDIyNjk1MDgxZTUxMWRhNTUxOTBfNy01LTEtMS0xOTUwNA_cc8c717d-0758-48ab-8feb-699ef9e8da2c"
      unitRef="usd">-9465000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18zNC9mcmFnOjI3Y2IxNjhkZTFhNTRhNGQ5MGNkYTNlODdlZDg5N2RlL3RhYmxlOmE4OWNjMDNlN2U2MDQyMjY5NTA4MWU1MTFkYTU1MTkwL3RhYmxlcmFuZ2U6YTg5Y2MwM2U3ZTYwNDIyNjk1MDgxZTUxMWRhNTUxOTBfOC0xLTEtMS0xNzc3NQ_1838664f-6107-4739-bd3a-6957978dc208"
      unitRef="usd">60037000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="i12a6d1161de54547bd29f8efccd4c9b0_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18zNC9mcmFnOjI3Y2IxNjhkZTFhNTRhNGQ5MGNkYTNlODdlZDg5N2RlL3RhYmxlOmE4OWNjMDNlN2U2MDQyMjY5NTA4MWU1MTFkYTU1MTkwL3RhYmxlcmFuZ2U6YTg5Y2MwM2U3ZTYwNDIyNjk1MDgxZTUxMWRhNTUxOTBfOC0zLTEtMS0xNzc3NQ_76086d71-1ab2-4754-b7a3-c5075938b0ff"
      unitRef="usd">61475000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="i3e21049ffc224cacb8134d73c9bb5b38_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18zNC9mcmFnOjI3Y2IxNjhkZTFhNTRhNGQ5MGNkYTNlODdlZDg5N2RlL3RhYmxlOmE4OWNjMDNlN2U2MDQyMjY5NTA4MWU1MTFkYTU1MTkwL3RhYmxlcmFuZ2U6YTg5Y2MwM2U3ZTYwNDIyNjk1MDgxZTUxMWRhNTUxOTBfOC01LTEtMS0xOTUxMQ_13ae42d3-4cd6-4264-b5db-54a2590f3bf3"
      unitRef="usd">60913000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:EquityMethodInvestmentOtherThanTemporaryImpairment
      contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18zNC9mcmFnOjI3Y2IxNjhkZTFhNTRhNGQ5MGNkYTNlODdlZDg5N2RlL3RhYmxlOmE4OWNjMDNlN2U2MDQyMjY5NTA4MWU1MTFkYTU1MTkwL3RhYmxlcmFuZ2U6YTg5Y2MwM2U3ZTYwNDIyNjk1MDgxZTUxMWRhNTUxOTBfOS0xLTEtMS0xNzc3NQ_67e64a2a-f40c-409f-8bc8-de9cf08b92df"
      unitRef="usd">0</us-gaap:EquityMethodInvestmentOtherThanTemporaryImpairment>
    <us-gaap:EquityMethodInvestmentOtherThanTemporaryImpairment
      contextRef="i12a6d1161de54547bd29f8efccd4c9b0_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18zNC9mcmFnOjI3Y2IxNjhkZTFhNTRhNGQ5MGNkYTNlODdlZDg5N2RlL3RhYmxlOmE4OWNjMDNlN2U2MDQyMjY5NTA4MWU1MTFkYTU1MTkwL3RhYmxlcmFuZ2U6YTg5Y2MwM2U3ZTYwNDIyNjk1MDgxZTUxMWRhNTUxOTBfOS0zLTEtMS0xNzc3NQ_a1ebe7e4-c0f6-41e5-9a83-36f311feac54"
      unitRef="usd">47133000</us-gaap:EquityMethodInvestmentOtherThanTemporaryImpairment>
    <us-gaap:EquityMethodInvestmentOtherThanTemporaryImpairment
      contextRef="i3e21049ffc224cacb8134d73c9bb5b38_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18zNC9mcmFnOjI3Y2IxNjhkZTFhNTRhNGQ5MGNkYTNlODdlZDg5N2RlL3RhYmxlOmE4OWNjMDNlN2U2MDQyMjY5NTA4MWU1MTFkYTU1MTkwL3RhYmxlcmFuZ2U6YTg5Y2MwM2U3ZTYwNDIyNjk1MDgxZTUxMWRhNTUxOTBfOS01LTEtMS0xOTUxMQ_d8c21d96-8755-48c3-85e1-3a9c57a5de14"
      unitRef="usd">0</us-gaap:EquityMethodInvestmentOtherThanTemporaryImpairment>
    <us-gaap:ShareBasedCompensation
      contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18zNC9mcmFnOjI3Y2IxNjhkZTFhNTRhNGQ5MGNkYTNlODdlZDg5N2RlL3RhYmxlOmE4OWNjMDNlN2U2MDQyMjY5NTA4MWU1MTFkYTU1MTkwL3RhYmxlcmFuZ2U6YTg5Y2MwM2U3ZTYwNDIyNjk1MDgxZTUxMWRhNTUxOTBfMTAtMS0xLTEtMTc3NzU_21fad1be-f4ee-4a44-b7db-7453afb1b067"
      unitRef="usd">16711000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="i12a6d1161de54547bd29f8efccd4c9b0_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18zNC9mcmFnOjI3Y2IxNjhkZTFhNTRhNGQ5MGNkYTNlODdlZDg5N2RlL3RhYmxlOmE4OWNjMDNlN2U2MDQyMjY5NTA4MWU1MTFkYTU1MTkwL3RhYmxlcmFuZ2U6YTg5Y2MwM2U3ZTYwNDIyNjk1MDgxZTUxMWRhNTUxOTBfMTAtMy0xLTEtMTc3NzU_a7be215c-2f15-4733-9b4f-8cd2dbaad197"
      unitRef="usd">14606000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="i3e21049ffc224cacb8134d73c9bb5b38_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18zNC9mcmFnOjI3Y2IxNjhkZTFhNTRhNGQ5MGNkYTNlODdlZDg5N2RlL3RhYmxlOmE4OWNjMDNlN2U2MDQyMjY5NTA4MWU1MTFkYTU1MTkwL3RhYmxlcmFuZ2U6YTg5Y2MwM2U3ZTYwNDIyNjk1MDgxZTUxMWRhNTUxOTBfMTAtNS0xLTEtMTk1MzA_deaf12dc-3b99-468d-b04c-e21155086faa"
      unitRef="usd">15618000</us-gaap:ShareBasedCompensation>
    <us-gaap:DeferredIncomeTaxesAndTaxCredits
      contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18zNC9mcmFnOjI3Y2IxNjhkZTFhNTRhNGQ5MGNkYTNlODdlZDg5N2RlL3RhYmxlOmE4OWNjMDNlN2U2MDQyMjY5NTA4MWU1MTFkYTU1MTkwL3RhYmxlcmFuZ2U6YTg5Y2MwM2U3ZTYwNDIyNjk1MDgxZTUxMWRhNTUxOTBfMTEtMS0xLTEtMTc3NzU_c5210a4d-2ce3-48a8-accf-afd8cfab3498"
      unitRef="usd">-526000</us-gaap:DeferredIncomeTaxesAndTaxCredits>
    <us-gaap:DeferredIncomeTaxesAndTaxCredits
      contextRef="i12a6d1161de54547bd29f8efccd4c9b0_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18zNC9mcmFnOjI3Y2IxNjhkZTFhNTRhNGQ5MGNkYTNlODdlZDg5N2RlL3RhYmxlOmE4OWNjMDNlN2U2MDQyMjY5NTA4MWU1MTFkYTU1MTkwL3RhYmxlcmFuZ2U6YTg5Y2MwM2U3ZTYwNDIyNjk1MDgxZTUxMWRhNTUxOTBfMTEtMy0xLTEtMTc3NzU_ccf6a8cb-157e-49f1-b26b-304b87199e59"
      unitRef="usd">-1132000</us-gaap:DeferredIncomeTaxesAndTaxCredits>
    <us-gaap:DeferredIncomeTaxesAndTaxCredits
      contextRef="i3e21049ffc224cacb8134d73c9bb5b38_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18zNC9mcmFnOjI3Y2IxNjhkZTFhNTRhNGQ5MGNkYTNlODdlZDg5N2RlL3RhYmxlOmE4OWNjMDNlN2U2MDQyMjY5NTA4MWU1MTFkYTU1MTkwL3RhYmxlcmFuZ2U6YTg5Y2MwM2U3ZTYwNDIyNjk1MDgxZTUxMWRhNTUxOTBfMTEtNS0xLTEtMTk1MzA_bf27282e-d186-4792-ba1b-765680c5f7c4"
      unitRef="usd">-23124000</us-gaap:DeferredIncomeTaxesAndTaxCredits>
    <us-gaap:CapitalizedContractCostAmortization
      contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18zNC9mcmFnOjI3Y2IxNjhkZTFhNTRhNGQ5MGNkYTNlODdlZDg5N2RlL3RhYmxlOmE4OWNjMDNlN2U2MDQyMjY5NTA4MWU1MTFkYTU1MTkwL3RhYmxlcmFuZ2U6YTg5Y2MwM2U3ZTYwNDIyNjk1MDgxZTUxMWRhNTUxOTBfMTItMS0xLTEtMTc3NzU_23e7d887-b201-431d-9881-da6b0eec1a84"
      unitRef="usd">13041000</us-gaap:CapitalizedContractCostAmortization>
    <us-gaap:CapitalizedContractCostAmortization
      contextRef="i12a6d1161de54547bd29f8efccd4c9b0_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18zNC9mcmFnOjI3Y2IxNjhkZTFhNTRhNGQ5MGNkYTNlODdlZDg5N2RlL3RhYmxlOmE4OWNjMDNlN2U2MDQyMjY5NTA4MWU1MTFkYTU1MTkwL3RhYmxlcmFuZ2U6YTg5Y2MwM2U3ZTYwNDIyNjk1MDgxZTUxMWRhNTUxOTBfMTItMy0xLTEtMTc3NzU_92068114-9f3d-4829-848d-ebba563336cf"
      unitRef="usd">21195000</us-gaap:CapitalizedContractCostAmortization>
    <us-gaap:CapitalizedContractCostAmortization
      contextRef="i3e21049ffc224cacb8134d73c9bb5b38_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18zNC9mcmFnOjI3Y2IxNjhkZTFhNTRhNGQ5MGNkYTNlODdlZDg5N2RlL3RhYmxlOmE4OWNjMDNlN2U2MDQyMjY5NTA4MWU1MTFkYTU1MTkwL3RhYmxlcmFuZ2U6YTg5Y2MwM2U3ZTYwNDIyNjk1MDgxZTUxMWRhNTUxOTBfMTItNS0xLTEtMTk1MzA_bd212332-47ac-4667-9303-38c08e37a2fb"
      unitRef="usd">5723000</us-gaap:CapitalizedContractCostAmortization>
    <us-gaap:AmortizationOfFinancingCosts
      contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18zNC9mcmFnOjI3Y2IxNjhkZTFhNTRhNGQ5MGNkYTNlODdlZDg5N2RlL3RhYmxlOmE4OWNjMDNlN2U2MDQyMjY5NTA4MWU1MTFkYTU1MTkwL3RhYmxlcmFuZ2U6YTg5Y2MwM2U3ZTYwNDIyNjk1MDgxZTUxMWRhNTUxOTBfMTMtMS0xLTEtMTc3NzU_7c348443-6446-494b-97c3-bfd7de0a37ef"
      unitRef="usd">18045000</us-gaap:AmortizationOfFinancingCosts>
    <us-gaap:AmortizationOfFinancingCosts
      contextRef="i12a6d1161de54547bd29f8efccd4c9b0_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18zNC9mcmFnOjI3Y2IxNjhkZTFhNTRhNGQ5MGNkYTNlODdlZDg5N2RlL3RhYmxlOmE4OWNjMDNlN2U2MDQyMjY5NTA4MWU1MTFkYTU1MTkwL3RhYmxlcmFuZ2U6YTg5Y2MwM2U3ZTYwNDIyNjk1MDgxZTUxMWRhNTUxOTBfMTMtMy0xLTEtMTc3NzU_ba49e390-17fa-4127-9ce7-d76d74bfe9c6"
      unitRef="usd">14780000</us-gaap:AmortizationOfFinancingCosts>
    <us-gaap:AmortizationOfFinancingCosts
      contextRef="i3e21049ffc224cacb8134d73c9bb5b38_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18zNC9mcmFnOjI3Y2IxNjhkZTFhNTRhNGQ5MGNkYTNlODdlZDg5N2RlL3RhYmxlOmE4OWNjMDNlN2U2MDQyMjY5NTA4MWU1MTFkYTU1MTkwL3RhYmxlcmFuZ2U6YTg5Y2MwM2U3ZTYwNDIyNjk1MDgxZTUxMWRhNTUxOTBfMTMtNS0xLTEtMTk1MzA_e26a880e-6481-4579-b231-bc10f1f1f901"
      unitRef="usd">9370000</us-gaap:AmortizationOfFinancingCosts>
    <evh:PaidinKindInterestIncome
      contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18zNC9mcmFnOjI3Y2IxNjhkZTFhNTRhNGQ5MGNkYTNlODdlZDg5N2RlL3RhYmxlOmE4OWNjMDNlN2U2MDQyMjY5NTA4MWU1MTFkYTU1MTkwL3RhYmxlcmFuZ2U6YTg5Y2MwM2U3ZTYwNDIyNjk1MDgxZTUxMWRhNTUxOTBfMTQtMS0xLTEtMTc3NzU_2ca21444-a365-46da-a777-1f0cea566c47"
      unitRef="usd">323000</evh:PaidinKindInterestIncome>
    <evh:PaidinKindInterestIncome
      contextRef="i12a6d1161de54547bd29f8efccd4c9b0_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18zNC9mcmFnOjI3Y2IxNjhkZTFhNTRhNGQ5MGNkYTNlODdlZDg5N2RlL3RhYmxlOmE4OWNjMDNlN2U2MDQyMjY5NTA4MWU1MTFkYTU1MTkwL3RhYmxlcmFuZ2U6YTg5Y2MwM2U3ZTYwNDIyNjk1MDgxZTUxMWRhNTUxOTBfMTQtMy0xLTEtMTc3NzU_2edf0e77-71ff-4c62-855d-c10909cd5a6d"
      unitRef="usd">1869000</evh:PaidinKindInterestIncome>
    <evh:PaidinKindInterestIncome
      contextRef="i3e21049ffc224cacb8134d73c9bb5b38_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18zNC9mcmFnOjI3Y2IxNjhkZTFhNTRhNGQ5MGNkYTNlODdlZDg5N2RlL3RhYmxlOmE4OWNjMDNlN2U2MDQyMjY5NTA4MWU1MTFkYTU1MTkwL3RhYmxlcmFuZ2U6YTg5Y2MwM2U3ZTYwNDIyNjk1MDgxZTUxMWRhNTUxOTBfMTQtNS0xLTEtMTk1Mzk_0a214c28-1e2c-4d51-b7fe-b56521e95683"
      unitRef="usd">1300000</evh:PaidinKindInterestIncome>
    <evh:GainOnTransferOfMembership
      contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18zNC9mcmFnOjI3Y2IxNjhkZTFhNTRhNGQ5MGNkYTNlODdlZDg5N2RlL3RhYmxlOmE4OWNjMDNlN2U2MDQyMjY5NTA4MWU1MTFkYTU1MTkwL3RhYmxlcmFuZ2U6YTg5Y2MwM2U3ZTYwNDIyNjk1MDgxZTUxMWRhNTUxOTBfMTUtMS0xLTEtMTc3NzU_bd5cd449-fe6d-441c-b953-4fc4e48800fd"
      unitRef="usd">45938000</evh:GainOnTransferOfMembership>
    <evh:GainOnTransferOfMembership
      contextRef="i12a6d1161de54547bd29f8efccd4c9b0_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18zNC9mcmFnOjI3Y2IxNjhkZTFhNTRhNGQ5MGNkYTNlODdlZDg5N2RlL3RhYmxlOmE4OWNjMDNlN2U2MDQyMjY5NTA4MWU1MTFkYTU1MTkwL3RhYmxlcmFuZ2U6YTg5Y2MwM2U3ZTYwNDIyNjk1MDgxZTUxMWRhNTUxOTBfMTUtMy0xLTEtMTc3NzU_6a0406af-60ed-4d96-a54d-f687412571d4"
      unitRef="usd">0</evh:GainOnTransferOfMembership>
    <evh:GainOnTransferOfMembership
      contextRef="i3e21049ffc224cacb8134d73c9bb5b38_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18zNC9mcmFnOjI3Y2IxNjhkZTFhNTRhNGQ5MGNkYTNlODdlZDg5N2RlL3RhYmxlOmE4OWNjMDNlN2U2MDQyMjY5NTA4MWU1MTFkYTU1MTkwL3RhYmxlcmFuZ2U6YTg5Y2MwM2U3ZTYwNDIyNjk1MDgxZTUxMWRhNTUxOTBfMTUtNS0xLTEtMTk1NDY_741ee6cd-a268-41f3-94d4-b95a29941e32"
      unitRef="usd">0</evh:GainOnTransferOfMembership>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18zNC9mcmFnOjI3Y2IxNjhkZTFhNTRhNGQ5MGNkYTNlODdlZDg5N2RlL3RhYmxlOmE4OWNjMDNlN2U2MDQyMjY5NTA4MWU1MTFkYTU1MTkwL3RhYmxlcmFuZ2U6YTg5Y2MwM2U3ZTYwNDIyNjk1MDgxZTUxMWRhNTUxOTBfMTYtMS0xLTEtMTc3NzU_e21e10cc-b7e5-4f69-adea-ab6a3dddeec0"
      unitRef="usd">0</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="i12a6d1161de54547bd29f8efccd4c9b0_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18zNC9mcmFnOjI3Y2IxNjhkZTFhNTRhNGQ5MGNkYTNlODdlZDg5N2RlL3RhYmxlOmE4OWNjMDNlN2U2MDQyMjY5NTA4MWU1MTFkYTU1MTkwL3RhYmxlcmFuZ2U6YTg5Y2MwM2U3ZTYwNDIyNjk1MDgxZTUxMWRhNTUxOTBfMTYtMy0xLTEtMTc3NzU_fb8d3561-41d9-4fcf-9f1c-50f257cae9cb"
      unitRef="usd">215100000</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="i3e21049ffc224cacb8134d73c9bb5b38_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18zNC9mcmFnOjI3Y2IxNjhkZTFhNTRhNGQ5MGNkYTNlODdlZDg5N2RlL3RhYmxlOmE4OWNjMDNlN2U2MDQyMjY5NTA4MWU1MTFkYTU1MTkwL3RhYmxlcmFuZ2U6YTg5Y2MwM2U3ZTYwNDIyNjk1MDgxZTUxMWRhNTUxOTBfMTYtNS0xLTEtMTk1NTM_74f1d035-de96-4370-88a3-b039d2cc8a8c"
      unitRef="usd">199800000</us-gaap:GoodwillImpairmentLoss>
    <evh:GainLossOnRepaymentOfDebt
      contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18zNC9mcmFnOjI3Y2IxNjhkZTFhNTRhNGQ5MGNkYTNlODdlZDg5N2RlL3RhYmxlOmE4OWNjMDNlN2U2MDQyMjY5NTA4MWU1MTFkYTU1MTkwL3RhYmxlcmFuZ2U6YTg5Y2MwM2U3ZTYwNDIyNjk1MDgxZTUxMWRhNTUxOTBfMTctMS0xLTEtMTc3NzU_e47c17f3-b24c-4425-b0d9-6f68fbc218d8"
      unitRef="usd">-21343000</evh:GainLossOnRepaymentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="i12a6d1161de54547bd29f8efccd4c9b0_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18zNC9mcmFnOjI3Y2IxNjhkZTFhNTRhNGQ5MGNkYTNlODdlZDg5N2RlL3RhYmxlOmE4OWNjMDNlN2U2MDQyMjY5NTA4MWU1MTFkYTU1MTkwL3RhYmxlcmFuZ2U6YTg5Y2MwM2U3ZTYwNDIyNjk1MDgxZTUxMWRhNTUxOTBfMTctMy0xLTEtMTc3NzU_7e625875-fc60-4f0b-bae1-c38161fa4b1f"
      unitRef="usd">-4789000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="i3e21049ffc224cacb8134d73c9bb5b38_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18zNC9mcmFnOjI3Y2IxNjhkZTFhNTRhNGQ5MGNkYTNlODdlZDg5N2RlL3RhYmxlOmE4OWNjMDNlN2U2MDQyMjY5NTA4MWU1MTFkYTU1MTkwL3RhYmxlcmFuZ2U6YTg5Y2MwM2U3ZTYwNDIyNjk1MDgxZTUxMWRhNTUxOTBfMTctNS0xLTEtMTk1NTg_358996c7-16a3-479f-9de3-fd8450690449"
      unitRef="usd">0</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:OtherNoncashIncomeExpense
      contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18zNC9mcmFnOjI3Y2IxNjhkZTFhNTRhNGQ5MGNkYTNlODdlZDg5N2RlL3RhYmxlOmE4OWNjMDNlN2U2MDQyMjY5NTA4MWU1MTFkYTU1MTkwL3RhYmxlcmFuZ2U6YTg5Y2MwM2U3ZTYwNDIyNjk1MDgxZTUxMWRhNTUxOTBfMTgtMS0xLTEtMTc3NzU_2b1f6b93-5e50-4499-a2c4-1314a3e5f31b"
      unitRef="usd">-715000</us-gaap:OtherNoncashIncomeExpense>
    <us-gaap:OtherNoncashIncomeExpense
      contextRef="i12a6d1161de54547bd29f8efccd4c9b0_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18zNC9mcmFnOjI3Y2IxNjhkZTFhNTRhNGQ5MGNkYTNlODdlZDg5N2RlL3RhYmxlOmE4OWNjMDNlN2U2MDQyMjY5NTA4MWU1MTFkYTU1MTkwL3RhYmxlcmFuZ2U6YTg5Y2MwM2U3ZTYwNDIyNjk1MDgxZTUxMWRhNTUxOTBfMTgtMy0xLTEtMTc3NzU_aaa59f77-dee1-4a91-9182-25a107630b45"
      unitRef="usd">-2744000</us-gaap:OtherNoncashIncomeExpense>
    <us-gaap:OtherNoncashIncomeExpense
      contextRef="i3e21049ffc224cacb8134d73c9bb5b38_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18zNC9mcmFnOjI3Y2IxNjhkZTFhNTRhNGQ5MGNkYTNlODdlZDg5N2RlL3RhYmxlOmE4OWNjMDNlN2U2MDQyMjY5NTA4MWU1MTFkYTU1MTkwL3RhYmxlcmFuZ2U6YTg5Y2MwM2U3ZTYwNDIyNjk1MDgxZTUxMWRhNTUxOTBfMTgtNS0xLTEtMTk1NjU_d61c7c11-fb86-4995-a2a6-ef9d045810a6"
      unitRef="usd">264000</us-gaap:OtherNoncashIncomeExpense>
    <evh:IncreaseDecreaseInAccountsReceivableAndContractWithCustomerAsset
      contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18zNC9mcmFnOjI3Y2IxNjhkZTFhNTRhNGQ5MGNkYTNlODdlZDg5N2RlL3RhYmxlOmE4OWNjMDNlN2U2MDQyMjY5NTA4MWU1MTFkYTU1MTkwL3RhYmxlcmFuZ2U6YTg5Y2MwM2U3ZTYwNDIyNjk1MDgxZTUxMWRhNTUxOTBfMjAtMS0xLTEtMTc3NzU_3f03d1eb-d749-460d-a942-ecb63553ffd4"
      unitRef="usd">5779000</evh:IncreaseDecreaseInAccountsReceivableAndContractWithCustomerAsset>
    <evh:IncreaseDecreaseInAccountsReceivableAndContractWithCustomerAsset
      contextRef="i12a6d1161de54547bd29f8efccd4c9b0_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18zNC9mcmFnOjI3Y2IxNjhkZTFhNTRhNGQ5MGNkYTNlODdlZDg5N2RlL3RhYmxlOmE4OWNjMDNlN2U2MDQyMjY5NTA4MWU1MTFkYTU1MTkwL3RhYmxlcmFuZ2U6YTg5Y2MwM2U3ZTYwNDIyNjk1MDgxZTUxMWRhNTUxOTBfMjAtMy0xLTEtMTc3NzU_0a460cf3-2c31-4a03-8aac-c945728e0942"
      unitRef="usd">47017000</evh:IncreaseDecreaseInAccountsReceivableAndContractWithCustomerAsset>
    <evh:IncreaseDecreaseInAccountsReceivableAndContractWithCustomerAsset
      contextRef="i3e21049ffc224cacb8134d73c9bb5b38_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18zNC9mcmFnOjI3Y2IxNjhkZTFhNTRhNGQ5MGNkYTNlODdlZDg5N2RlL3RhYmxlOmE4OWNjMDNlN2U2MDQyMjY5NTA4MWU1MTFkYTU1MTkwL3RhYmxlcmFuZ2U6YTg5Y2MwM2U3ZTYwNDIyNjk1MDgxZTUxMWRhNTUxOTBfMjAtNS0xLTEtMTk1NzI_0afe8dd3-32c9-4172-b19c-61a83ea98122"
      unitRef="usd">-6326000</evh:IncreaseDecreaseInAccountsReceivableAndContractWithCustomerAsset>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18zNC9mcmFnOjI3Y2IxNjhkZTFhNTRhNGQ5MGNkYTNlODdlZDg5N2RlL3RhYmxlOmE4OWNjMDNlN2U2MDQyMjY5NTA4MWU1MTFkYTU1MTkwL3RhYmxlcmFuZ2U6YTg5Y2MwM2U3ZTYwNDIyNjk1MDgxZTUxMWRhNTUxOTBfMjEtMS0xLTEtMTc3NzU_54c913f3-965c-46e5-a007-4de80972af02"
      unitRef="usd">-5599000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="i12a6d1161de54547bd29f8efccd4c9b0_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18zNC9mcmFnOjI3Y2IxNjhkZTFhNTRhNGQ5MGNkYTNlODdlZDg5N2RlL3RhYmxlOmE4OWNjMDNlN2U2MDQyMjY5NTA4MWU1MTFkYTU1MTkwL3RhYmxlcmFuZ2U6YTg5Y2MwM2U3ZTYwNDIyNjk1MDgxZTUxMWRhNTUxOTBfMjEtMy0xLTEtMTc3NzU_e7ec1856-e0bc-4029-aeb4-4608c2f5d0bb"
      unitRef="usd">-7340000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="i3e21049ffc224cacb8134d73c9bb5b38_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18zNC9mcmFnOjI3Y2IxNjhkZTFhNTRhNGQ5MGNkYTNlODdlZDg5N2RlL3RhYmxlOmE4OWNjMDNlN2U2MDQyMjY5NTA4MWU1MTFkYTU1MTkwL3RhYmxlcmFuZ2U6YTg5Y2MwM2U3ZTYwNDIyNjk1MDgxZTUxMWRhNTUxOTBfMjEtNS0xLTEtMTk1NzI_9b27e22b-2a2e-436f-b45d-dcb9988ae5f4"
      unitRef="usd">-791000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <evh:IncreaseDecreaseInCapitalizedContractCostNet
      contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18zNC9mcmFnOjI3Y2IxNjhkZTFhNTRhNGQ5MGNkYTNlODdlZDg5N2RlL3RhYmxlOmE4OWNjMDNlN2U2MDQyMjY5NTA4MWU1MTFkYTU1MTkwL3RhYmxlcmFuZ2U6YTg5Y2MwM2U3ZTYwNDIyNjk1MDgxZTUxMWRhNTUxOTBfMjItMS0xLTEtMTc3NzU_38d7d599-15f5-4e38-a6cd-6c91ea1a9e2c"
      unitRef="usd">18979000</evh:IncreaseDecreaseInCapitalizedContractCostNet>
    <evh:IncreaseDecreaseInCapitalizedContractCostNet
      contextRef="i12a6d1161de54547bd29f8efccd4c9b0_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18zNC9mcmFnOjI3Y2IxNjhkZTFhNTRhNGQ5MGNkYTNlODdlZDg5N2RlL3RhYmxlOmE4OWNjMDNlN2U2MDQyMjY5NTA4MWU1MTFkYTU1MTkwL3RhYmxlcmFuZ2U6YTg5Y2MwM2U3ZTYwNDIyNjk1MDgxZTUxMWRhNTUxOTBfMjItMy0xLTEtMTc3NzU_5dd74f33-3484-4267-961e-ce05795915ca"
      unitRef="usd">11400000</evh:IncreaseDecreaseInCapitalizedContractCostNet>
    <evh:IncreaseDecreaseInCapitalizedContractCostNet
      contextRef="i3e21049ffc224cacb8134d73c9bb5b38_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18zNC9mcmFnOjI3Y2IxNjhkZTFhNTRhNGQ5MGNkYTNlODdlZDg5N2RlL3RhYmxlOmE4OWNjMDNlN2U2MDQyMjY5NTA4MWU1MTFkYTU1MTkwL3RhYmxlcmFuZ2U6YTg5Y2MwM2U3ZTYwNDIyNjk1MDgxZTUxMWRhNTUxOTBfMjItNS0xLTEtMTk1NzI_a22e0534-0af1-4b78-9cfe-80b0a7ae7291"
      unitRef="usd">23057000</evh:IncreaseDecreaseInCapitalizedContractCostNet>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18zNC9mcmFnOjI3Y2IxNjhkZTFhNTRhNGQ5MGNkYTNlODdlZDg5N2RlL3RhYmxlOmE4OWNjMDNlN2U2MDQyMjY5NTA4MWU1MTFkYTU1MTkwL3RhYmxlcmFuZ2U6YTg5Y2MwM2U3ZTYwNDIyNjk1MDgxZTUxMWRhNTUxOTBfMjMtMS0xLTEtMTc3NzU_2d23c40d-20c4-4396-85b5-5848d1ff55d1"
      unitRef="usd">7250000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="i12a6d1161de54547bd29f8efccd4c9b0_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18zNC9mcmFnOjI3Y2IxNjhkZTFhNTRhNGQ5MGNkYTNlODdlZDg5N2RlL3RhYmxlOmE4OWNjMDNlN2U2MDQyMjY5NTA4MWU1MTFkYTU1MTkwL3RhYmxlcmFuZ2U6YTg5Y2MwM2U3ZTYwNDIyNjk1MDgxZTUxMWRhNTUxOTBfMjMtMy0xLTEtMTc3NzU_46459d7c-3c46-43b5-8262-ef6668e71fd0"
      unitRef="usd">3547000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="i3e21049ffc224cacb8134d73c9bb5b38_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18zNC9mcmFnOjI3Y2IxNjhkZTFhNTRhNGQ5MGNkYTNlODdlZDg5N2RlL3RhYmxlOmE4OWNjMDNlN2U2MDQyMjY5NTA4MWU1MTFkYTU1MTkwL3RhYmxlcmFuZ2U6YTg5Y2MwM2U3ZTYwNDIyNjk1MDgxZTUxMWRhNTUxOTBfMjMtNS0xLTEtMTk1Nzk_b9638903-6fae-4ba4-9fce-1c6c72165b2c"
      unitRef="usd">-5480000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18zNC9mcmFnOjI3Y2IxNjhkZTFhNTRhNGQ5MGNkYTNlODdlZDg5N2RlL3RhYmxlOmE4OWNjMDNlN2U2MDQyMjY5NTA4MWU1MTFkYTU1MTkwL3RhYmxlcmFuZ2U6YTg5Y2MwM2U3ZTYwNDIyNjk1MDgxZTUxMWRhNTUxOTBfMjQtMS0xLTEtMTc3NzU_62cbab05-3415-42fd-bccd-c9ee532fa075"
      unitRef="usd">-324000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="i12a6d1161de54547bd29f8efccd4c9b0_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18zNC9mcmFnOjI3Y2IxNjhkZTFhNTRhNGQ5MGNkYTNlODdlZDg5N2RlL3RhYmxlOmE4OWNjMDNlN2U2MDQyMjY5NTA4MWU1MTFkYTU1MTkwL3RhYmxlcmFuZ2U6YTg5Y2MwM2U3ZTYwNDIyNjk1MDgxZTUxMWRhNTUxOTBfMjQtMy0xLTEtMTc3NzU_8b4d9e0b-2a8e-4d41-bbea-9c29b1ac98db"
      unitRef="usd">8801000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="i3e21049ffc224cacb8134d73c9bb5b38_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18zNC9mcmFnOjI3Y2IxNjhkZTFhNTRhNGQ5MGNkYTNlODdlZDg5N2RlL3RhYmxlOmE4OWNjMDNlN2U2MDQyMjY5NTA4MWU1MTFkYTU1MTkwL3RhYmxlcmFuZ2U6YTg5Y2MwM2U3ZTYwNDIyNjk1MDgxZTUxMWRhNTUxOTBfMjQtNS0xLTEtMTk1Nzk_d6c8b7c3-69c2-41b6-be62-987f5ca5b4aa"
      unitRef="usd">-21852000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities
      contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18zNC9mcmFnOjI3Y2IxNjhkZTFhNTRhNGQ5MGNkYTNlODdlZDg5N2RlL3RhYmxlOmE4OWNjMDNlN2U2MDQyMjY5NTA4MWU1MTFkYTU1MTkwL3RhYmxlcmFuZ2U6YTg5Y2MwM2U3ZTYwNDIyNjk1MDgxZTUxMWRhNTUxOTBfMjUtMS0xLTEtMTc3NzU_47ceb3b0-7c10-4455-aa95-37d6315b032a"
      unitRef="usd">3538000</us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities>
    <us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities
      contextRef="i12a6d1161de54547bd29f8efccd4c9b0_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18zNC9mcmFnOjI3Y2IxNjhkZTFhNTRhNGQ5MGNkYTNlODdlZDg5N2RlL3RhYmxlOmE4OWNjMDNlN2U2MDQyMjY5NTA4MWU1MTFkYTU1MTkwL3RhYmxlcmFuZ2U6YTg5Y2MwM2U3ZTYwNDIyNjk1MDgxZTUxMWRhNTUxOTBfMjUtMy0xLTEtMTc3NzU_12b5d259-432c-48ae-a42f-a47b3a2327c0"
      unitRef="usd">11143000</us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities>
    <us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities
      contextRef="i3e21049ffc224cacb8134d73c9bb5b38_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18zNC9mcmFnOjI3Y2IxNjhkZTFhNTRhNGQ5MGNkYTNlODdlZDg5N2RlL3RhYmxlOmE4OWNjMDNlN2U2MDQyMjY5NTA4MWU1MTFkYTU1MTkwL3RhYmxlcmFuZ2U6YTg5Y2MwM2U3ZTYwNDIyNjk1MDgxZTUxMWRhNTUxOTBfMjUtNS0xLTEtMTk1Nzk_d6206bf9-777c-4ec7-875b-ff2de95decd3"
      unitRef="usd">9246000</us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18zNC9mcmFnOjI3Y2IxNjhkZTFhNTRhNGQ5MGNkYTNlODdlZDg5N2RlL3RhYmxlOmE4OWNjMDNlN2U2MDQyMjY5NTA4MWU1MTFkYTU1MTkwL3RhYmxlcmFuZ2U6YTg5Y2MwM2U3ZTYwNDIyNjk1MDgxZTUxMWRhNTUxOTBfMjYtMS0xLTEtMTc3NzU_ba67d881-c63d-48e6-b8fa-0d41eac8f948"
      unitRef="usd">-739000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="i12a6d1161de54547bd29f8efccd4c9b0_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18zNC9mcmFnOjI3Y2IxNjhkZTFhNTRhNGQ5MGNkYTNlODdlZDg5N2RlL3RhYmxlOmE4OWNjMDNlN2U2MDQyMjY5NTA4MWU1MTFkYTU1MTkwL3RhYmxlcmFuZ2U6YTg5Y2MwM2U3ZTYwNDIyNjk1MDgxZTUxMWRhNTUxOTBfMjYtMy0xLTEtMTc3NzU_07a71f91-f149-45dc-b640-1a6435681d2b"
      unitRef="usd">-8943000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="i3e21049ffc224cacb8134d73c9bb5b38_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18zNC9mcmFnOjI3Y2IxNjhkZTFhNTRhNGQ5MGNkYTNlODdlZDg5N2RlL3RhYmxlOmE4OWNjMDNlN2U2MDQyMjY5NTA4MWU1MTFkYTU1MTkwL3RhYmxlcmFuZ2U6YTg5Y2MwM2U3ZTYwNDIyNjk1MDgxZTUxMWRhNTUxOTBfMjYtNS0xLTEtMTk1ODY_b0f2e60b-806a-4726-a746-3325c424448d"
      unitRef="usd">-756000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <evh:IncreaseDecreaseInInsuranceAndPerformanceBasedArrangementsLiabilities
      contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18zNC9mcmFnOjI3Y2IxNjhkZTFhNTRhNGQ5MGNkYTNlODdlZDg5N2RlL3RhYmxlOmE4OWNjMDNlN2U2MDQyMjY5NTA4MWU1MTFkYTU1MTkwL3RhYmxlcmFuZ2U6YTg5Y2MwM2U3ZTYwNDIyNjk1MDgxZTUxMWRhNTUxOTBfMjctMS0xLTEtMTc3NzU_9b31b02d-4674-4256-9a68-dc5c5c74bf6b"
      unitRef="usd">-3799000</evh:IncreaseDecreaseInInsuranceAndPerformanceBasedArrangementsLiabilities>
    <evh:IncreaseDecreaseInInsuranceAndPerformanceBasedArrangementsLiabilities
      contextRef="i12a6d1161de54547bd29f8efccd4c9b0_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18zNC9mcmFnOjI3Y2IxNjhkZTFhNTRhNGQ5MGNkYTNlODdlZDg5N2RlL3RhYmxlOmE4OWNjMDNlN2U2MDQyMjY5NTA4MWU1MTFkYTU1MTkwL3RhYmxlcmFuZ2U6YTg5Y2MwM2U3ZTYwNDIyNjk1MDgxZTUxMWRhNTUxOTBfMjctMy0xLTEtMTc3NzU_d7ffca92-a61c-48e5-93ed-47325ffc5447"
      unitRef="usd">-36108000</evh:IncreaseDecreaseInInsuranceAndPerformanceBasedArrangementsLiabilities>
    <evh:IncreaseDecreaseInInsuranceAndPerformanceBasedArrangementsLiabilities
      contextRef="i3e21049ffc224cacb8134d73c9bb5b38_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18zNC9mcmFnOjI3Y2IxNjhkZTFhNTRhNGQ5MGNkYTNlODdlZDg5N2RlL3RhYmxlOmE4OWNjMDNlN2U2MDQyMjY5NTA4MWU1MTFkYTU1MTkwL3RhYmxlcmFuZ2U6YTg5Y2MwM2U3ZTYwNDIyNjk1MDgxZTUxMWRhNTUxOTBfMjctNS0xLTEtMTk1ODY_a9260591-b637-41d0-bbee-1f42849ad250"
      unitRef="usd">33555000</evh:IncreaseDecreaseInInsuranceAndPerformanceBasedArrangementsLiabilities>
    <evh:IncreaseDecreaseInOperatingLeaseRightofUseAsset
      contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18zNC9mcmFnOjI3Y2IxNjhkZTFhNTRhNGQ5MGNkYTNlODdlZDg5N2RlL3RhYmxlOmE4OWNjMDNlN2U2MDQyMjY5NTA4MWU1MTFkYTU1MTkwL3RhYmxlcmFuZ2U6YTg5Y2MwM2U3ZTYwNDIyNjk1MDgxZTUxMWRhNTUxOTBfMjgtMS0xLTEtMTc3NzU_ea0c3354-f7ca-4575-b29c-ff18014c6bb8"
      unitRef="usd">-8844000</evh:IncreaseDecreaseInOperatingLeaseRightofUseAsset>
    <evh:IncreaseDecreaseInOperatingLeaseRightofUseAsset
      contextRef="i12a6d1161de54547bd29f8efccd4c9b0_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18zNC9mcmFnOjI3Y2IxNjhkZTFhNTRhNGQ5MGNkYTNlODdlZDg5N2RlL3RhYmxlOmE4OWNjMDNlN2U2MDQyMjY5NTA4MWU1MTFkYTU1MTkwL3RhYmxlcmFuZ2U6YTg5Y2MwM2U3ZTYwNDIyNjk1MDgxZTUxMWRhNTUxOTBfMjgtMy0xLTEtMTc3NzU_3a7559ee-7c21-4472-911b-6a271ee9d640"
      unitRef="usd">-11934000</evh:IncreaseDecreaseInOperatingLeaseRightofUseAsset>
    <evh:IncreaseDecreaseInOperatingLeaseRightofUseAsset
      contextRef="i3e21049ffc224cacb8134d73c9bb5b38_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18zNC9mcmFnOjI3Y2IxNjhkZTFhNTRhNGQ5MGNkYTNlODdlZDg5N2RlL3RhYmxlOmE4OWNjMDNlN2U2MDQyMjY5NTA4MWU1MTFkYTU1MTkwL3RhYmxlcmFuZ2U6YTg5Y2MwM2U3ZTYwNDIyNjk1MDgxZTUxMWRhNTUxOTBfMjgtNS0xLTEtMTk1ODY_b69a0177-7b6a-41cd-9751-36cb5477e915"
      unitRef="usd">20811000</evh:IncreaseDecreaseInOperatingLeaseRightofUseAsset>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability
      contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18zNC9mcmFnOjI3Y2IxNjhkZTFhNTRhNGQ5MGNkYTNlODdlZDg5N2RlL3RhYmxlOmE4OWNjMDNlN2U2MDQyMjY5NTA4MWU1MTFkYTU1MTkwL3RhYmxlcmFuZ2U6YTg5Y2MwM2U3ZTYwNDIyNjk1MDgxZTUxMWRhNTUxOTBfMjktMS0xLTEtMTc3NzU_29906912-17bf-45de-ad62-dc153091d8bf"
      unitRef="usd">-6522000</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability
      contextRef="i12a6d1161de54547bd29f8efccd4c9b0_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18zNC9mcmFnOjI3Y2IxNjhkZTFhNTRhNGQ5MGNkYTNlODdlZDg5N2RlL3RhYmxlOmE4OWNjMDNlN2U2MDQyMjY5NTA4MWU1MTFkYTU1MTkwL3RhYmxlcmFuZ2U6YTg5Y2MwM2U3ZTYwNDIyNjk1MDgxZTUxMWRhNTUxOTBfMjktMy0xLTEtMTc3NzU_870c762a-29d5-4eff-8659-6a43366c72fa"
      unitRef="usd">-2782000</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability
      contextRef="i3e21049ffc224cacb8134d73c9bb5b38_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18zNC9mcmFnOjI3Y2IxNjhkZTFhNTRhNGQ5MGNkYTNlODdlZDg5N2RlL3RhYmxlOmE4OWNjMDNlN2U2MDQyMjY5NTA4MWU1MTFkYTU1MTkwL3RhYmxlcmFuZ2U6YTg5Y2MwM2U3ZTYwNDIyNjk1MDgxZTUxMWRhNTUxOTBfMjktNS0xLTEtMTk1ODY_c1bf7f56-b69c-49c3-bfa5-8fa72db0112a"
      unitRef="usd">27724000</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities
      contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18zNC9mcmFnOjI3Y2IxNjhkZTFhNTRhNGQ5MGNkYTNlODdlZDg5N2RlL3RhYmxlOmE4OWNjMDNlN2U2MDQyMjY5NTA4MWU1MTFkYTU1MTkwL3RhYmxlcmFuZ2U6YTg5Y2MwM2U3ZTYwNDIyNjk1MDgxZTUxMWRhNTUxOTBfMzAtMS0xLTEtMTc3NzU_61ed1312-dea9-441e-8fe3-adfe5551da18"
      unitRef="usd">-2734000</us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities
      contextRef="i12a6d1161de54547bd29f8efccd4c9b0_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18zNC9mcmFnOjI3Y2IxNjhkZTFhNTRhNGQ5MGNkYTNlODdlZDg5N2RlL3RhYmxlOmE4OWNjMDNlN2U2MDQyMjY5NTA4MWU1MTFkYTU1MTkwL3RhYmxlcmFuZ2U6YTg5Y2MwM2U3ZTYwNDIyNjk1MDgxZTUxMWRhNTUxOTBfMzAtMy0xLTEtMTc3NzU_38b4cf34-6148-40d2-bbc7-0890327956e8"
      unitRef="usd">8166000</us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities
      contextRef="i3e21049ffc224cacb8134d73c9bb5b38_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18zNC9mcmFnOjI3Y2IxNjhkZTFhNTRhNGQ5MGNkYTNlODdlZDg5N2RlL3RhYmxlOmE4OWNjMDNlN2U2MDQyMjY5NTA4MWU1MTFkYTU1MTkwL3RhYmxlcmFuZ2U6YTg5Y2MwM2U3ZTYwNDIyNjk1MDgxZTUxMWRhNTUxOTBfMzAtNS0xLTEtMTk1ODY_773b919b-9762-462b-b785-a85992c55558"
      unitRef="usd">-5355000</us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18zNC9mcmFnOjI3Y2IxNjhkZTFhNTRhNGQ5MGNkYTNlODdlZDg5N2RlL3RhYmxlOmE4OWNjMDNlN2U2MDQyMjY5NTA4MWU1MTFkYTU1MTkwL3RhYmxlcmFuZ2U6YTg5Y2MwM2U3ZTYwNDIyNjk1MDgxZTUxMWRhNTUxOTBfMzEtMS0xLTEtMTc3NzU_cc93b6f8-da1d-4ce4-a903-c454433c831b"
      unitRef="usd">38747000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i12a6d1161de54547bd29f8efccd4c9b0_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18zNC9mcmFnOjI3Y2IxNjhkZTFhNTRhNGQ5MGNkYTNlODdlZDg5N2RlL3RhYmxlOmE4OWNjMDNlN2U2MDQyMjY5NTA4MWU1MTFkYTU1MTkwL3RhYmxlcmFuZ2U6YTg5Y2MwM2U3ZTYwNDIyNjk1MDgxZTUxMWRhNTUxOTBfMzEtMy0xLTEtMTc3NzU_62702cbd-3beb-4879-b893-a7468f3f80b7"
      unitRef="usd">-16225000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i3e21049ffc224cacb8134d73c9bb5b38_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18zNC9mcmFnOjI3Y2IxNjhkZTFhNTRhNGQ5MGNkYTNlODdlZDg5N2RlL3RhYmxlOmE4OWNjMDNlN2U2MDQyMjY5NTA4MWU1MTFkYTU1MTkwL3RhYmxlcmFuZ2U6YTg5Y2MwM2U3ZTYwNDIyNjk1MDgxZTUxMWRhNTUxOTBfMzEtNS0xLTEtMTk1ODY_f0798002-74b1-4795-9f3b-988b476791a0"
      unitRef="usd">-42645000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquireBusinessesGross
      contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18zNC9mcmFnOjI3Y2IxNjhkZTFhNTRhNGQ5MGNkYTNlODdlZDg5N2RlL3RhYmxlOmE4OWNjMDNlN2U2MDQyMjY5NTA4MWU1MTFkYTU1MTkwL3RhYmxlcmFuZ2U6YTg5Y2MwM2U3ZTYwNDIyNjk1MDgxZTUxMWRhNTUxOTBfMzMtMS0xLTEtMTc3NzU_bec21ee8-37b2-4cd2-b9b2-a8a32e25a2a0"
      unitRef="usd">49012000</us-gaap:PaymentsToAcquireBusinessesGross>
    <us-gaap:PaymentsToAcquireBusinessesGross
      contextRef="i12a6d1161de54547bd29f8efccd4c9b0_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18zNC9mcmFnOjI3Y2IxNjhkZTFhNTRhNGQ5MGNkYTNlODdlZDg5N2RlL3RhYmxlOmE4OWNjMDNlN2U2MDQyMjY5NTA4MWU1MTFkYTU1MTkwL3RhYmxlcmFuZ2U6YTg5Y2MwM2U3ZTYwNDIyNjk1MDgxZTUxMWRhNTUxOTBfMzMtMy0xLTEtMTc3NzU_77c6e1e3-0eb6-48eb-8381-43982ed8d293"
      unitRef="usd">300000</us-gaap:PaymentsToAcquireBusinessesGross>
    <us-gaap:PaymentsToAcquireBusinessesGross
      contextRef="i3e21049ffc224cacb8134d73c9bb5b38_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18zNC9mcmFnOjI3Y2IxNjhkZTFhNTRhNGQ5MGNkYTNlODdlZDg5N2RlL3RhYmxlOmE4OWNjMDNlN2U2MDQyMjY5NTA4MWU1MTFkYTU1MTkwL3RhYmxlcmFuZ2U6YTg5Y2MwM2U3ZTYwNDIyNjk1MDgxZTUxMWRhNTUxOTBfMzMtNS0xLTEtMTk1OTU_9cf224e6-28e4-4bd2-a780-2c4f338632f7"
      unitRef="usd">8575000</us-gaap:PaymentsToAcquireBusinessesGross>
    <us-gaap:ProceedsFromDivestitureOfInterestInSubsidiariesAndAffiliates
      contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18zNC9mcmFnOjI3Y2IxNjhkZTFhNTRhNGQ5MGNkYTNlODdlZDg5N2RlL3RhYmxlOmE4OWNjMDNlN2U2MDQyMjY5NTA4MWU1MTFkYTU1MTkwL3RhYmxlcmFuZ2U6YTg5Y2MwM2U3ZTYwNDIyNjk1MDgxZTUxMWRhNTUxOTBfMzQtMS0xLTEtMTc3NzU_c0d72b8c-b580-48d6-815b-a06fbbe466c4"
      unitRef="usd">42996000</us-gaap:ProceedsFromDivestitureOfInterestInSubsidiariesAndAffiliates>
    <us-gaap:ProceedsFromDivestitureOfInterestInSubsidiariesAndAffiliates
      contextRef="i12a6d1161de54547bd29f8efccd4c9b0_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18zNC9mcmFnOjI3Y2IxNjhkZTFhNTRhNGQ5MGNkYTNlODdlZDg5N2RlL3RhYmxlOmE4OWNjMDNlN2U2MDQyMjY5NTA4MWU1MTFkYTU1MTkwL3RhYmxlcmFuZ2U6YTg5Y2MwM2U3ZTYwNDIyNjk1MDgxZTUxMWRhNTUxOTBfMzQtMy0xLTEtMTc3NzU_b691db35-3a7e-4237-9d6c-09c22ba97f8b"
      unitRef="usd">0</us-gaap:ProceedsFromDivestitureOfInterestInSubsidiariesAndAffiliates>
    <us-gaap:ProceedsFromDivestitureOfInterestInSubsidiariesAndAffiliates
      contextRef="i3e21049ffc224cacb8134d73c9bb5b38_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18zNC9mcmFnOjI3Y2IxNjhkZTFhNTRhNGQ5MGNkYTNlODdlZDg5N2RlL3RhYmxlOmE4OWNjMDNlN2U2MDQyMjY5NTA4MWU1MTFkYTU1MTkwL3RhYmxlcmFuZ2U6YTg5Y2MwM2U3ZTYwNDIyNjk1MDgxZTUxMWRhNTUxOTBfMzQtNS0xLTEtMTk2MTg_aeeecebc-6855-49af-a128-453f9e01e822"
      unitRef="usd">0</us-gaap:ProceedsFromDivestitureOfInterestInSubsidiariesAndAffiliates>
    <us-gaap:PaymentsForProceedsFromLoansReceivable
      contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18zNC9mcmFnOjI3Y2IxNjhkZTFhNTRhNGQ5MGNkYTNlODdlZDg5N2RlL3RhYmxlOmE4OWNjMDNlN2U2MDQyMjY5NTA4MWU1MTFkYTU1MTkwL3RhYmxlcmFuZ2U6YTg5Y2MwM2U3ZTYwNDIyNjk1MDgxZTUxMWRhNTUxOTBfMzUtMS0xLTEtMTc3NzU_16e08adb-2fc7-401c-a324-207ccb46cfcc"
      unitRef="usd">0</us-gaap:PaymentsForProceedsFromLoansReceivable>
    <us-gaap:PaymentsForProceedsFromLoansReceivable
      contextRef="i12a6d1161de54547bd29f8efccd4c9b0_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18zNC9mcmFnOjI3Y2IxNjhkZTFhNTRhNGQ5MGNkYTNlODdlZDg5N2RlL3RhYmxlOmE4OWNjMDNlN2U2MDQyMjY5NTA4MWU1MTFkYTU1MTkwL3RhYmxlcmFuZ2U6YTg5Y2MwM2U3ZTYwNDIyNjk1MDgxZTUxMWRhNTUxOTBfMzUtMy0xLTEtMTc3NzU_b99c0ff1-b19a-425e-8af5-3cf374708984"
      unitRef="usd">-1000000</us-gaap:PaymentsForProceedsFromLoansReceivable>
    <us-gaap:PaymentsForProceedsFromLoansReceivable
      contextRef="i3e21049ffc224cacb8134d73c9bb5b38_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18zNC9mcmFnOjI3Y2IxNjhkZTFhNTRhNGQ5MGNkYTNlODdlZDg5N2RlL3RhYmxlOmE4OWNjMDNlN2U2MDQyMjY5NTA4MWU1MTFkYTU1MTkwL3RhYmxlcmFuZ2U6YTg5Y2MwM2U3ZTYwNDIyNjk1MDgxZTUxMWRhNTUxOTBfMzUtNS0xLTEtMTk2MjU_2556bc4c-14d5-45fd-9840-80e93b397a84"
      unitRef="usd">-5400000</us-gaap:PaymentsForProceedsFromLoansReceivable>
    <evh:PaymentsForProceedsFromDisposalOfNonStrategicAssetsAndDivestitureOfDiscontinuedOperationsNet
      contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18zNC9mcmFnOjI3Y2IxNjhkZTFhNTRhNGQ5MGNkYTNlODdlZDg5N2RlL3RhYmxlOmE4OWNjMDNlN2U2MDQyMjY5NTA4MWU1MTFkYTU1MTkwL3RhYmxlcmFuZ2U6YTg5Y2MwM2U3ZTYwNDIyNjk1MDgxZTUxMWRhNTUxOTBfMzYtMS0xLTEtMTc3NzU_d98f11a0-f147-47a2-82f9-f6a8ff10d11f"
      unitRef="usd">-3490000</evh:PaymentsForProceedsFromDisposalOfNonStrategicAssetsAndDivestitureOfDiscontinuedOperationsNet>
    <evh:PaymentsForProceedsFromDisposalOfNonStrategicAssetsAndDivestitureOfDiscontinuedOperationsNet
      contextRef="i12a6d1161de54547bd29f8efccd4c9b0_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18zNC9mcmFnOjI3Y2IxNjhkZTFhNTRhNGQ5MGNkYTNlODdlZDg5N2RlL3RhYmxlOmE4OWNjMDNlN2U2MDQyMjY5NTA4MWU1MTFkYTU1MTkwL3RhYmxlcmFuZ2U6YTg5Y2MwM2U3ZTYwNDIyNjk1MDgxZTUxMWRhNTUxOTBfMzYtMy0xLTEtMTc3NzU_4308a274-b602-492b-b580-447d4fe8fcee"
      unitRef="usd">2287000</evh:PaymentsForProceedsFromDisposalOfNonStrategicAssetsAndDivestitureOfDiscontinuedOperationsNet>
    <evh:PaymentsForProceedsFromDisposalOfNonStrategicAssetsAndDivestitureOfDiscontinuedOperationsNet
      contextRef="i3e21049ffc224cacb8134d73c9bb5b38_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18zNC9mcmFnOjI3Y2IxNjhkZTFhNTRhNGQ5MGNkYTNlODdlZDg5N2RlL3RhYmxlOmE4OWNjMDNlN2U2MDQyMjY5NTA4MWU1MTFkYTU1MTkwL3RhYmxlcmFuZ2U6YTg5Y2MwM2U3ZTYwNDIyNjk1MDgxZTUxMWRhNTUxOTBfMzYtNS0xLTEtMTk2MzM_0b4d6453-0828-4c8d-9eb4-caeb54143ef4"
      unitRef="usd">0</evh:PaymentsForProceedsFromDisposalOfNonStrategicAssetsAndDivestitureOfDiscontinuedOperationsNet>
    <us-gaap:ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital
      contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18zNC9mcmFnOjI3Y2IxNjhkZTFhNTRhNGQ5MGNkYTNlODdlZDg5N2RlL3RhYmxlOmE4OWNjMDNlN2U2MDQyMjY5NTA4MWU1MTFkYTU1MTkwL3RhYmxlcmFuZ2U6YTg5Y2MwM2U3ZTYwNDIyNjk1MDgxZTUxMWRhNTUxOTBfMzctMS0xLTEtMTc3NzU_045e0655-3492-407c-9bf2-296604d02c7b"
      unitRef="usd">14218000</us-gaap:ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital>
    <us-gaap:ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital
      contextRef="i12a6d1161de54547bd29f8efccd4c9b0_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18zNC9mcmFnOjI3Y2IxNjhkZTFhNTRhNGQ5MGNkYTNlODdlZDg5N2RlL3RhYmxlOmE4OWNjMDNlN2U2MDQyMjY5NTA4MWU1MTFkYTU1MTkwL3RhYmxlcmFuZ2U6YTg5Y2MwM2U3ZTYwNDIyNjk1MDgxZTUxMWRhNTUxOTBfMzctMy0xLTEtMTc3NzU_41d90fd4-e9f6-4f27-9505-1a5072eba29e"
      unitRef="usd">0</us-gaap:ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital>
    <us-gaap:ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital
      contextRef="i3e21049ffc224cacb8134d73c9bb5b38_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18zNC9mcmFnOjI3Y2IxNjhkZTFhNTRhNGQ5MGNkYTNlODdlZDg5N2RlL3RhYmxlOmE4OWNjMDNlN2U2MDQyMjY5NTA4MWU1MTFkYTU1MTkwL3RhYmxlcmFuZ2U6YTg5Y2MwM2U3ZTYwNDIyNjk1MDgxZTUxMWRhNTUxOTBfMzctNS0xLTEtMTk2NDA_530af99a-40cf-4226-a420-c5ed24138cc4"
      unitRef="usd">0</us-gaap:ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital>
    <evh:PaymentsForCustomerAdvanceForRegulatoryCapitalRequirements
      contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18zNC9mcmFnOjI3Y2IxNjhkZTFhNTRhNGQ5MGNkYTNlODdlZDg5N2RlL3RhYmxlOmE4OWNjMDNlN2U2MDQyMjY5NTA4MWU1MTFkYTU1MTkwL3RhYmxlcmFuZ2U6YTg5Y2MwM2U3ZTYwNDIyNjk1MDgxZTUxMWRhNTUxOTBfMzgtMS0xLTEtMTk3MzM_2bb6edf6-63c5-42f5-aae3-012444441523"
      unitRef="usd">0</evh:PaymentsForCustomerAdvanceForRegulatoryCapitalRequirements>
    <evh:PaymentsForCustomerAdvanceForRegulatoryCapitalRequirements
      contextRef="i12a6d1161de54547bd29f8efccd4c9b0_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18zNC9mcmFnOjI3Y2IxNjhkZTFhNTRhNGQ5MGNkYTNlODdlZDg5N2RlL3RhYmxlOmE4OWNjMDNlN2U2MDQyMjY5NTA4MWU1MTFkYTU1MTkwL3RhYmxlcmFuZ2U6YTg5Y2MwM2U3ZTYwNDIyNjk1MDgxZTUxMWRhNTUxOTBfMzgtMy0xLTEtMTk3MzM_b19f24e1-e830-4fa3-bbf4-ae96ec91279c"
      unitRef="usd">0</evh:PaymentsForCustomerAdvanceForRegulatoryCapitalRequirements>
    <evh:PaymentsForCustomerAdvanceForRegulatoryCapitalRequirements
      contextRef="i3e21049ffc224cacb8134d73c9bb5b38_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18zNC9mcmFnOjI3Y2IxNjhkZTFhNTRhNGQ5MGNkYTNlODdlZDg5N2RlL3RhYmxlOmE4OWNjMDNlN2U2MDQyMjY5NTA4MWU1MTFkYTU1MTkwL3RhYmxlcmFuZ2U6YTg5Y2MwM2U3ZTYwNDIyNjk1MDgxZTUxMWRhNTUxOTBfMzgtNS0xLTEtMTk3MzM_46947d28-6a5d-4359-8397-3b67d2b7e354"
      unitRef="usd">46400000</evh:PaymentsForCustomerAdvanceForRegulatoryCapitalRequirements>
    <us-gaap:PaymentsToAcquireInterestInSubsidiariesAndAffiliates
      contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18zNC9mcmFnOjI3Y2IxNjhkZTFhNTRhNGQ5MGNkYTNlODdlZDg5N2RlL3RhYmxlOmE4OWNjMDNlN2U2MDQyMjY5NTA4MWU1MTFkYTU1MTkwL3RhYmxlcmFuZ2U6YTg5Y2MwM2U3ZTYwNDIyNjk1MDgxZTUxMWRhNTUxOTBfMzktMS0xLTEtMTk3NDI_c121b317-0c36-40d2-bdaf-08d5d56e8872"
      unitRef="usd">0</us-gaap:PaymentsToAcquireInterestInSubsidiariesAndAffiliates>
    <us-gaap:PaymentsToAcquireInterestInSubsidiariesAndAffiliates
      contextRef="i12a6d1161de54547bd29f8efccd4c9b0_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18zNC9mcmFnOjI3Y2IxNjhkZTFhNTRhNGQ5MGNkYTNlODdlZDg5N2RlL3RhYmxlOmE4OWNjMDNlN2U2MDQyMjY5NTA4MWU1MTFkYTU1MTkwL3RhYmxlcmFuZ2U6YTg5Y2MwM2U3ZTYwNDIyNjk1MDgxZTUxMWRhNTUxOTBfMzktMy0xLTEtMTk3NDI_445881b6-a01b-4ffa-af12-ed354d18ff2f"
      unitRef="usd">0</us-gaap:PaymentsToAcquireInterestInSubsidiariesAndAffiliates>
    <us-gaap:PaymentsToAcquireInterestInSubsidiariesAndAffiliates
      contextRef="i3e21049ffc224cacb8134d73c9bb5b38_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18zNC9mcmFnOjI3Y2IxNjhkZTFhNTRhNGQ5MGNkYTNlODdlZDg5N2RlL3RhYmxlOmE4OWNjMDNlN2U2MDQyMjY5NTA4MWU1MTFkYTU1MTkwL3RhYmxlcmFuZ2U6YTg5Y2MwM2U3ZTYwNDIyNjk1MDgxZTUxMWRhNTUxOTBfMzktNS0xLTEtMTk3NDI_ec1c8995-fc70-4874-bbc7-351c073f008a"
      unitRef="usd">87480000</us-gaap:PaymentsToAcquireInterestInSubsidiariesAndAffiliates>
    <us-gaap:CashAcquiredFromAcquisition
      contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18zNC9mcmFnOjI3Y2IxNjhkZTFhNTRhNGQ5MGNkYTNlODdlZDg5N2RlL3RhYmxlOmE4OWNjMDNlN2U2MDQyMjY5NTA4MWU1MTFkYTU1MTkwL3RhYmxlcmFuZ2U6YTg5Y2MwM2U3ZTYwNDIyNjk1MDgxZTUxMWRhNTUxOTBfMzgtMS0xLTEtMTc3NzU_dcbc266e-6ae0-4b86-9241-86ea2b3d336c"
      unitRef="usd">0</us-gaap:CashAcquiredFromAcquisition>
    <us-gaap:CashAcquiredFromAcquisition
      contextRef="i12a6d1161de54547bd29f8efccd4c9b0_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18zNC9mcmFnOjI3Y2IxNjhkZTFhNTRhNGQ5MGNkYTNlODdlZDg5N2RlL3RhYmxlOmE4OWNjMDNlN2U2MDQyMjY5NTA4MWU1MTFkYTU1MTkwL3RhYmxlcmFuZ2U6YTg5Y2MwM2U3ZTYwNDIyNjk1MDgxZTUxMWRhNTUxOTBfMzgtMy0xLTEtMTc3NzU_5cc122a0-56e7-4556-a411-f71feccd3889"
      unitRef="usd">159755000</us-gaap:CashAcquiredFromAcquisition>
    <us-gaap:CashAcquiredFromAcquisition
      contextRef="i3e21049ffc224cacb8134d73c9bb5b38_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18zNC9mcmFnOjI3Y2IxNjhkZTFhNTRhNGQ5MGNkYTNlODdlZDg5N2RlL3RhYmxlOmE4OWNjMDNlN2U2MDQyMjY5NTA4MWU1MTFkYTU1MTkwL3RhYmxlcmFuZ2U6YTg5Y2MwM2U3ZTYwNDIyNjk1MDgxZTUxMWRhNTUxOTBfMzgtNS0xLTEtMTk2NDc_d93b67cd-fb8c-45a2-a85e-9157f34c0d94"
      unitRef="usd">0</us-gaap:CashAcquiredFromAcquisition>
    <us-gaap:PaymentsToAcquireHeldToMaturitySecurities
      contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18zNC9mcmFnOjI3Y2IxNjhkZTFhNTRhNGQ5MGNkYTNlODdlZDg5N2RlL3RhYmxlOmE4OWNjMDNlN2U2MDQyMjY5NTA4MWU1MTFkYTU1MTkwL3RhYmxlcmFuZ2U6YTg5Y2MwM2U3ZTYwNDIyNjk1MDgxZTUxMWRhNTUxOTBfMzktMS0xLTEtMTc3NzU_b1884f30-d681-4e48-9074-9f30d1d48ff6"
      unitRef="usd">2995000</us-gaap:PaymentsToAcquireHeldToMaturitySecurities>
    <us-gaap:PaymentsToAcquireHeldToMaturitySecurities
      contextRef="i12a6d1161de54547bd29f8efccd4c9b0_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18zNC9mcmFnOjI3Y2IxNjhkZTFhNTRhNGQ5MGNkYTNlODdlZDg5N2RlL3RhYmxlOmE4OWNjMDNlN2U2MDQyMjY5NTA4MWU1MTFkYTU1MTkwL3RhYmxlcmFuZ2U6YTg5Y2MwM2U3ZTYwNDIyNjk1MDgxZTUxMWRhNTUxOTBfMzktMy0xLTEtMTc3NzU_7b188519-ea00-4d7d-af29-54831c09cc9d"
      unitRef="usd">11170000</us-gaap:PaymentsToAcquireHeldToMaturitySecurities>
    <us-gaap:PaymentsToAcquireHeldToMaturitySecurities
      contextRef="i3e21049ffc224cacb8134d73c9bb5b38_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18zNC9mcmFnOjI3Y2IxNjhkZTFhNTRhNGQ5MGNkYTNlODdlZDg5N2RlL3RhYmxlOmE4OWNjMDNlN2U2MDQyMjY5NTA4MWU1MTFkYTU1MTkwL3RhYmxlcmFuZ2U6YTg5Y2MwM2U3ZTYwNDIyNjk1MDgxZTUxMWRhNTUxOTBfMzktNS0xLTEtMTk2NTQ_375a6cd8-c7a4-4ab0-94fc-7c4221932a7f"
      unitRef="usd">11125000</us-gaap:PaymentsToAcquireHeldToMaturitySecurities>
    <evh:ProceedsFromMaturityOfInvestments
      contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18zNC9mcmFnOjI3Y2IxNjhkZTFhNTRhNGQ5MGNkYTNlODdlZDg5N2RlL3RhYmxlOmE4OWNjMDNlN2U2MDQyMjY5NTA4MWU1MTFkYTU1MTkwL3RhYmxlcmFuZ2U6YTg5Y2MwM2U3ZTYwNDIyNjk1MDgxZTUxMWRhNTUxOTBfNDAtMS0xLTEtMTc3NzU_59e1b907-efed-41ef-a731-a3c1ca766d70"
      unitRef="usd">500000</evh:ProceedsFromMaturityOfInvestments>
    <evh:ProceedsFromMaturityOfInvestments
      contextRef="i12a6d1161de54547bd29f8efccd4c9b0_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18zNC9mcmFnOjI3Y2IxNjhkZTFhNTRhNGQ5MGNkYTNlODdlZDg5N2RlL3RhYmxlOmE4OWNjMDNlN2U2MDQyMjY5NTA4MWU1MTFkYTU1MTkwL3RhYmxlcmFuZ2U6YTg5Y2MwM2U3ZTYwNDIyNjk1MDgxZTUxMWRhNTUxOTBfNDAtMy0xLTEtMTc3NzU_b3c637c8-409f-4c46-8d35-81aad55c489e"
      unitRef="usd">143441000</evh:ProceedsFromMaturityOfInvestments>
    <evh:ProceedsFromMaturityOfInvestments
      contextRef="i3e21049ffc224cacb8134d73c9bb5b38_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18zNC9mcmFnOjI3Y2IxNjhkZTFhNTRhNGQ5MGNkYTNlODdlZDg5N2RlL3RhYmxlOmE4OWNjMDNlN2U2MDQyMjY5NTA4MWU1MTFkYTU1MTkwL3RhYmxlcmFuZ2U6YTg5Y2MwM2U3ZTYwNDIyNjk1MDgxZTUxMWRhNTUxOTBfNDAtNS0xLTEtMTk2NTQ_6dea82b2-87de-40ed-9240-de4f70cbea16"
      unitRef="usd">2575000</evh:ProceedsFromMaturityOfInvestments>
    <us-gaap:PaymentsToAcquireOtherProductiveAssets
      contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18zNC9mcmFnOjI3Y2IxNjhkZTFhNTRhNGQ5MGNkYTNlODdlZDg5N2RlL3RhYmxlOmE4OWNjMDNlN2U2MDQyMjY5NTA4MWU1MTFkYTU1MTkwL3RhYmxlcmFuZ2U6YTg5Y2MwM2U3ZTYwNDIyNjk1MDgxZTUxMWRhNTUxOTBfNDEtMS0xLTEtMTc3NzU_a5b98bcc-f28d-463d-9d49-ccf97b774d10"
      unitRef="usd">24983000</us-gaap:PaymentsToAcquireOtherProductiveAssets>
    <us-gaap:PaymentsToAcquireOtherProductiveAssets
      contextRef="i12a6d1161de54547bd29f8efccd4c9b0_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18zNC9mcmFnOjI3Y2IxNjhkZTFhNTRhNGQ5MGNkYTNlODdlZDg5N2RlL3RhYmxlOmE4OWNjMDNlN2U2MDQyMjY5NTA4MWU1MTFkYTU1MTkwL3RhYmxlcmFuZ2U6YTg5Y2MwM2U3ZTYwNDIyNjk1MDgxZTUxMWRhNTUxOTBfNDEtMy0xLTEtMTc3NzU_1f51ba99-872b-4a78-8e7a-f9ba2b717de9"
      unitRef="usd">29473000</us-gaap:PaymentsToAcquireOtherProductiveAssets>
    <us-gaap:PaymentsToAcquireOtherProductiveAssets
      contextRef="i3e21049ffc224cacb8134d73c9bb5b38_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18zNC9mcmFnOjI3Y2IxNjhkZTFhNTRhNGQ5MGNkYTNlODdlZDg5N2RlL3RhYmxlOmE4OWNjMDNlN2U2MDQyMjY5NTA4MWU1MTFkYTU1MTkwL3RhYmxlcmFuZ2U6YTg5Y2MwM2U3ZTYwNDIyNjk1MDgxZTUxMWRhNTUxOTBfNDEtNS0xLTEtMTk2MDk_80ce6bc9-1261-4904-a110-e7d14dc424b0"
      unitRef="usd">35534000</us-gaap:PaymentsToAcquireOtherProductiveAssets>
    <us-gaap:PaymentsForProceedsFromOtherInvestingActivities
      contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18zNC9mcmFnOjI3Y2IxNjhkZTFhNTRhNGQ5MGNkYTNlODdlZDg5N2RlL3RhYmxlOmE4OWNjMDNlN2U2MDQyMjY5NTA4MWU1MTFkYTU1MTkwL3RhYmxlcmFuZ2U6YTg5Y2MwM2U3ZTYwNDIyNjk1MDgxZTUxMWRhNTUxOTBfNDItMS0xLTEtMTc3NzU_7bef6996-8ff9-4021-a1fc-c4bdfbb5cabb"
      unitRef="usd">0</us-gaap:PaymentsForProceedsFromOtherInvestingActivities>
    <us-gaap:PaymentsForProceedsFromOtherInvestingActivities
      contextRef="i12a6d1161de54547bd29f8efccd4c9b0_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18zNC9mcmFnOjI3Y2IxNjhkZTFhNTRhNGQ5MGNkYTNlODdlZDg5N2RlL3RhYmxlOmE4OWNjMDNlN2U2MDQyMjY5NTA4MWU1MTFkYTU1MTkwL3RhYmxlcmFuZ2U6YTg5Y2MwM2U3ZTYwNDIyNjk1MDgxZTUxMWRhNTUxOTBfNDItMy0xLTEtMTc3NzU_bea70a93-b391-4b02-9fff-594cb57aeeec"
      unitRef="usd">-106000</us-gaap:PaymentsForProceedsFromOtherInvestingActivities>
    <us-gaap:PaymentsForProceedsFromOtherInvestingActivities
      contextRef="i3e21049ffc224cacb8134d73c9bb5b38_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18zNC9mcmFnOjI3Y2IxNjhkZTFhNTRhNGQ5MGNkYTNlODdlZDg5N2RlL3RhYmxlOmE4OWNjMDNlN2U2MDQyMjY5NTA4MWU1MTFkYTU1MTkwL3RhYmxlcmFuZ2U6YTg5Y2MwM2U3ZTYwNDIyNjk1MDgxZTUxMWRhNTUxOTBfNDItNS0xLTEtMTk2MDk_cab917c4-8936-4df8-aa9f-6f980ab435b9"
      unitRef="usd">495000</us-gaap:PaymentsForProceedsFromOtherInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18zNC9mcmFnOjI3Y2IxNjhkZTFhNTRhNGQ5MGNkYTNlODdlZDg5N2RlL3RhYmxlOmE4OWNjMDNlN2U2MDQyMjY5NTA4MWU1MTFkYTU1MTkwL3RhYmxlcmFuZ2U6YTg5Y2MwM2U3ZTYwNDIyNjk1MDgxZTUxMWRhNTUxOTBfNDMtMS0xLTEtMTc3NzU_10dcb15e-7b1c-49b3-96f5-78c72394e607"
      unitRef="usd">-15786000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="i12a6d1161de54547bd29f8efccd4c9b0_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18zNC9mcmFnOjI3Y2IxNjhkZTFhNTRhNGQ5MGNkYTNlODdlZDg5N2RlL3RhYmxlOmE4OWNjMDNlN2U2MDQyMjY5NTA4MWU1MTFkYTU1MTkwL3RhYmxlcmFuZ2U6YTg5Y2MwM2U3ZTYwNDIyNjk1MDgxZTUxMWRhNTUxOTBfNDMtMy0xLTEtMTc3NzU_9d7b55a4-6a9c-4513-be03-7188d6fa3757"
      unitRef="usd">261072000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="i3e21049ffc224cacb8134d73c9bb5b38_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18zNC9mcmFnOjI3Y2IxNjhkZTFhNTRhNGQ5MGNkYTNlODdlZDg5N2RlL3RhYmxlOmE4OWNjMDNlN2U2MDQyMjY5NTA4MWU1MTFkYTU1MTkwL3RhYmxlcmFuZ2U6YTg5Y2MwM2U3ZTYwNDIyNjk1MDgxZTUxMWRhNTUxOTBfNDMtNS0xLTEtMTk2MDI_9c1a19e9-72d2-4904-b3a0-a29e6954c284"
      unitRef="usd">-181634000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <evh:PaymentsForProceedsFromClaimsProcessingFinancingActivities
      contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18zNC9mcmFnOjI3Y2IxNjhkZTFhNTRhNGQ5MGNkYTNlODdlZDg5N2RlL3RhYmxlOmE4OWNjMDNlN2U2MDQyMjY5NTA4MWU1MTFkYTU1MTkwL3RhYmxlcmFuZ2U6YTg5Y2MwM2U3ZTYwNDIyNjk1MDgxZTUxMWRhNTUxOTBfNDUtMS0xLTEtMTc3NzU_f21672d0-12d2-4348-85ff-60769531ee29"
      unitRef="usd">-61162000</evh:PaymentsForProceedsFromClaimsProcessingFinancingActivities>
    <evh:PaymentsForProceedsFromClaimsProcessingFinancingActivities
      contextRef="i12a6d1161de54547bd29f8efccd4c9b0_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18zNC9mcmFnOjI3Y2IxNjhkZTFhNTRhNGQ5MGNkYTNlODdlZDg5N2RlL3RhYmxlOmE4OWNjMDNlN2U2MDQyMjY5NTA4MWU1MTFkYTU1MTkwL3RhYmxlcmFuZ2U6YTg5Y2MwM2U3ZTYwNDIyNjk1MDgxZTUxMWRhNTUxOTBfNDUtMy0xLTEtMTc3NzU_efce9c15-e85b-4970-b6f2-4fd8b29edae6"
      unitRef="usd">6044000</evh:PaymentsForProceedsFromClaimsProcessingFinancingActivities>
    <evh:PaymentsForProceedsFromClaimsProcessingFinancingActivities
      contextRef="i3e21049ffc224cacb8134d73c9bb5b38_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18zNC9mcmFnOjI3Y2IxNjhkZTFhNTRhNGQ5MGNkYTNlODdlZDg5N2RlL3RhYmxlOmE4OWNjMDNlN2U2MDQyMjY5NTA4MWU1MTFkYTU1MTkwL3RhYmxlcmFuZ2U6YTg5Y2MwM2U3ZTYwNDIyNjk1MDgxZTUxMWRhNTUxOTBfNDUtNS0xLTEtMTk2NjE_22b96416-ee33-4ce6-b881-956c824dd2a9"
      unitRef="usd">104268000</evh:PaymentsForProceedsFromClaimsProcessingFinancingActivities>
    <evh:ProceedsFromAssetAcquisitionEscrow
      contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18zNC9mcmFnOjI3Y2IxNjhkZTFhNTRhNGQ5MGNkYTNlODdlZDg5N2RlL3RhYmxlOmE4OWNjMDNlN2U2MDQyMjY5NTA4MWU1MTFkYTU1MTkwL3RhYmxlcmFuZ2U6YTg5Y2MwM2U3ZTYwNDIyNjk1MDgxZTUxMWRhNTUxOTBfNDgtMS0xLTEtMTk3NjQ_e396c866-a9e9-46a7-977f-abca37418a4e"
      unitRef="usd">0</evh:ProceedsFromAssetAcquisitionEscrow>
    <evh:ProceedsFromAssetAcquisitionEscrow
      contextRef="i12a6d1161de54547bd29f8efccd4c9b0_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18zNC9mcmFnOjI3Y2IxNjhkZTFhNTRhNGQ5MGNkYTNlODdlZDg5N2RlL3RhYmxlOmE4OWNjMDNlN2U2MDQyMjY5NTA4MWU1MTFkYTU1MTkwL3RhYmxlcmFuZ2U6YTg5Y2MwM2U3ZTYwNDIyNjk1MDgxZTUxMWRhNTUxOTBfNDgtMy0xLTEtMTk3NjQ_4693581c-340c-4e12-bb4b-3151fc5c8253"
      unitRef="usd">0</evh:ProceedsFromAssetAcquisitionEscrow>
    <evh:ProceedsFromAssetAcquisitionEscrow
      contextRef="i3e21049ffc224cacb8134d73c9bb5b38_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18zNC9mcmFnOjI3Y2IxNjhkZTFhNTRhNGQ5MGNkYTNlODdlZDg5N2RlL3RhYmxlOmE4OWNjMDNlN2U2MDQyMjY5NTA4MWU1MTFkYTU1MTkwL3RhYmxlcmFuZ2U6YTg5Y2MwM2U3ZTYwNDIyNjk1MDgxZTUxMWRhNTUxOTBfNDgtNS0xLTEtMTk3NjQ_4976dc79-2ec7-4763-9c32-06d1f991e0eb"
      unitRef="usd">500000</evh:ProceedsFromAssetAcquisitionEscrow>
    <us-gaap:PaymentsOfDebtExtinguishmentCosts
      contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18zNC9mcmFnOjI3Y2IxNjhkZTFhNTRhNGQ5MGNkYTNlODdlZDg5N2RlL3RhYmxlOmE4OWNjMDNlN2U2MDQyMjY5NTA4MWU1MTFkYTU1MTkwL3RhYmxlcmFuZ2U6YTg5Y2MwM2U3ZTYwNDIyNjk1MDgxZTUxMWRhNTUxOTBfNDYtMS0xLTEtMTc3NzU_e10a4dea-c689-4d4c-836e-dfec5a79b22d"
      unitRef="usd">98420000</us-gaap:PaymentsOfDebtExtinguishmentCosts>
    <us-gaap:PaymentsOfDebtExtinguishmentCosts
      contextRef="i12a6d1161de54547bd29f8efccd4c9b0_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18zNC9mcmFnOjI3Y2IxNjhkZTFhNTRhNGQ5MGNkYTNlODdlZDg5N2RlL3RhYmxlOmE4OWNjMDNlN2U2MDQyMjY5NTA4MWU1MTFkYTU1MTkwL3RhYmxlcmFuZ2U6YTg5Y2MwM2U3ZTYwNDIyNjk1MDgxZTUxMWRhNTUxOTBfNDYtMy0xLTEtMTc3NzU_9219efdc-5555-4c52-9d27-08d8d2d8034e"
      unitRef="usd">0</us-gaap:PaymentsOfDebtExtinguishmentCosts>
    <us-gaap:PaymentsOfDebtExtinguishmentCosts
      contextRef="i3e21049ffc224cacb8134d73c9bb5b38_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18zNC9mcmFnOjI3Y2IxNjhkZTFhNTRhNGQ5MGNkYTNlODdlZDg5N2RlL3RhYmxlOmE4OWNjMDNlN2U2MDQyMjY5NTA4MWU1MTFkYTU1MTkwL3RhYmxlcmFuZ2U6YTg5Y2MwM2U3ZTYwNDIyNjk1MDgxZTUxMWRhNTUxOTBfNDYtNS0xLTEtMTk2Nzg_d7d9c023-d548-4a13-aea6-94d797d7652b"
      unitRef="usd">0</us-gaap:PaymentsOfDebtExtinguishmentCosts>
    <us-gaap:ProceedsFromConvertibleDebt
      contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18zNC9mcmFnOjI3Y2IxNjhkZTFhNTRhNGQ5MGNkYTNlODdlZDg5N2RlL3RhYmxlOmE4OWNjMDNlN2U2MDQyMjY5NTA4MWU1MTFkYTU1MTkwL3RhYmxlcmFuZ2U6YTg5Y2MwM2U3ZTYwNDIyNjk1MDgxZTUxMWRhNTUxOTBfNDctMS0xLTEtMTc3NzU_d7835603-64d3-44c1-8635-b5709a624dd9"
      unitRef="usd">0</us-gaap:ProceedsFromConvertibleDebt>
    <us-gaap:ProceedsFromConvertibleDebt
      contextRef="i12a6d1161de54547bd29f8efccd4c9b0_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18zNC9mcmFnOjI3Y2IxNjhkZTFhNTRhNGQ5MGNkYTNlODdlZDg5N2RlL3RhYmxlOmE4OWNjMDNlN2U2MDQyMjY5NTA4MWU1MTFkYTU1MTkwL3RhYmxlcmFuZ2U6YTg5Y2MwM2U3ZTYwNDIyNjk1MDgxZTUxMWRhNTUxOTBfNDctMy0xLTEtMTc3NzU_a3599f55-8a1f-4a19-b4ed-c260dc42d73c"
      unitRef="usd">30062000</us-gaap:ProceedsFromConvertibleDebt>
    <us-gaap:ProceedsFromConvertibleDebt
      contextRef="i3e21049ffc224cacb8134d73c9bb5b38_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18zNC9mcmFnOjI3Y2IxNjhkZTFhNTRhNGQ5MGNkYTNlODdlZDg5N2RlL3RhYmxlOmE4OWNjMDNlN2U2MDQyMjY5NTA4MWU1MTFkYTU1MTkwL3RhYmxlcmFuZ2U6YTg5Y2MwM2U3ZTYwNDIyNjk1MDgxZTUxMWRhNTUxOTBfNDctNS0xLTEtMTk2OTU_a5302128-a26f-43ae-bdd8-9a1e0bb595fb"
      unitRef="usd">62648000</us-gaap:ProceedsFromConvertibleDebt>
    <us-gaap:ProceedsFromHedgeFinancingActivities
      contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18zNC9mcmFnOjI3Y2IxNjhkZTFhNTRhNGQ5MGNkYTNlODdlZDg5N2RlL3RhYmxlOmE4OWNjMDNlN2U2MDQyMjY5NTA4MWU1MTFkYTU1MTkwL3RhYmxlcmFuZ2U6YTg5Y2MwM2U3ZTYwNDIyNjk1MDgxZTUxMWRhNTUxOTBfNTAtMS0xLTEtMTk3NTE_db8549ca-e6b8-4c4d-aa24-bae475f8616b"
      unitRef="usd">0</us-gaap:ProceedsFromHedgeFinancingActivities>
    <us-gaap:ProceedsFromHedgeFinancingActivities
      contextRef="i12a6d1161de54547bd29f8efccd4c9b0_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18zNC9mcmFnOjI3Y2IxNjhkZTFhNTRhNGQ5MGNkYTNlODdlZDg5N2RlL3RhYmxlOmE4OWNjMDNlN2U2MDQyMjY5NTA4MWU1MTFkYTU1MTkwL3RhYmxlcmFuZ2U6YTg5Y2MwM2U3ZTYwNDIyNjk1MDgxZTUxMWRhNTUxOTBfNTAtMy0xLTEtMTk3NTE_aa19a600-b9b7-48ee-ae03-2ce676a835a5"
      unitRef="usd">0</us-gaap:ProceedsFromHedgeFinancingActivities>
    <us-gaap:ProceedsFromHedgeFinancingActivities
      contextRef="i3e21049ffc224cacb8134d73c9bb5b38_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18zNC9mcmFnOjI3Y2IxNjhkZTFhNTRhNGQ5MGNkYTNlODdlZDg5N2RlL3RhYmxlOmE4OWNjMDNlN2U2MDQyMjY5NTA4MWU1MTFkYTU1MTkwL3RhYmxlcmFuZ2U6YTg5Y2MwM2U3ZTYwNDIyNjk1MDgxZTUxMWRhNTUxOTBfNTAtNS0xLTEtMTk3NTE_19c9b1af-95b5-4842-9c65-82ec16c88f24"
      unitRef="usd">7092000</us-gaap:ProceedsFromHedgeFinancingActivities>
    <us-gaap:RepaymentsOfSeniorDebt
      contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18zNC9mcmFnOjI3Y2IxNjhkZTFhNTRhNGQ5MGNkYTNlODdlZDg5N2RlL3RhYmxlOmE4OWNjMDNlN2U2MDQyMjY5NTA4MWU1MTFkYTU1MTkwL3RhYmxlcmFuZ2U6YTg5Y2MwM2U3ZTYwNDIyNjk1MDgxZTUxMWRhNTUxOTBfNDgtMS0xLTEtMTc3NzU_b39db2d6-46e7-43ef-b1a9-01057464eebe"
      unitRef="usd">429000</us-gaap:RepaymentsOfSeniorDebt>
    <us-gaap:RepaymentsOfSeniorDebt
      contextRef="i12a6d1161de54547bd29f8efccd4c9b0_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18zNC9mcmFnOjI3Y2IxNjhkZTFhNTRhNGQ5MGNkYTNlODdlZDg5N2RlL3RhYmxlOmE4OWNjMDNlN2U2MDQyMjY5NTA4MWU1MTFkYTU1MTkwL3RhYmxlcmFuZ2U6YTg5Y2MwM2U3ZTYwNDIyNjk1MDgxZTUxMWRhNTUxOTBfNDgtMy0xLTEtMTc3NzU_8966e74c-440f-477c-8349-a44d4fe641b9"
      unitRef="usd">16606000</us-gaap:RepaymentsOfSeniorDebt>
    <us-gaap:RepaymentsOfSeniorDebt
      contextRef="i3e21049ffc224cacb8134d73c9bb5b38_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18zNC9mcmFnOjI3Y2IxNjhkZTFhNTRhNGQ5MGNkYTNlODdlZDg5N2RlL3RhYmxlOmE4OWNjMDNlN2U2MDQyMjY5NTA4MWU1MTFkYTU1MTkwL3RhYmxlcmFuZ2U6YTg5Y2MwM2U3ZTYwNDIyNjk1MDgxZTUxMWRhNTUxOTBfNDgtNS0xLTEtMTk3MDE_72cc4254-0efc-4f4b-9ea9-b7d9795d2f5d"
      unitRef="usd">0</us-gaap:RepaymentsOfSeniorDebt>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18zNC9mcmFnOjI3Y2IxNjhkZTFhNTRhNGQ5MGNkYTNlODdlZDg5N2RlL3RhYmxlOmE4OWNjMDNlN2U2MDQyMjY5NTA4MWU1MTFkYTU1MTkwL3RhYmxlcmFuZ2U6YTg5Y2MwM2U3ZTYwNDIyNjk1MDgxZTUxMWRhNTUxOTBfNDktMS0xLTEtMTc3NzU_0e2d9276-f673-4fdd-b1c5-277cd0b1e2e4"
      unitRef="usd">13289000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="i12a6d1161de54547bd29f8efccd4c9b0_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18zNC9mcmFnOjI3Y2IxNjhkZTFhNTRhNGQ5MGNkYTNlODdlZDg5N2RlL3RhYmxlOmE4OWNjMDNlN2U2MDQyMjY5NTA4MWU1MTFkYTU1MTkwL3RhYmxlcmFuZ2U6YTg5Y2MwM2U3ZTYwNDIyNjk1MDgxZTUxMWRhNTUxOTBfNDktMy0xLTEtMTc3NzU_c92efb4b-5532-4272-a61d-5f4714e42306"
      unitRef="usd">2577000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="i3e21049ffc224cacb8134d73c9bb5b38_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18zNC9mcmFnOjI3Y2IxNjhkZTFhNTRhNGQ5MGNkYTNlODdlZDg5N2RlL3RhYmxlOmE4OWNjMDNlN2U2MDQyMjY5NTA4MWU1MTFkYTU1MTkwL3RhYmxlcmFuZ2U6YTg5Y2MwM2U3ZTYwNDIyNjk1MDgxZTUxMWRhNTUxOTBfNDktNS0xLTEtMTk3MTY_1b67000c-8e9e-4738-83b0-ef05776ad12d"
      unitRef="usd">1092000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:PaymentsToMinorityShareholders
      contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18zNC9mcmFnOjI3Y2IxNjhkZTFhNTRhNGQ5MGNkYTNlODdlZDg5N2RlL3RhYmxlOmE4OWNjMDNlN2U2MDQyMjY5NTA4MWU1MTFkYTU1MTkwL3RhYmxlcmFuZ2U6YTg5Y2MwM2U3ZTYwNDIyNjk1MDgxZTUxMWRhNTUxOTBfNTAtMS0xLTEtMTc3NzU_e7ab7c41-6fc3-4e7d-80ad-c00fb32e9979"
      unitRef="usd">1300000</us-gaap:PaymentsToMinorityShareholders>
    <us-gaap:PaymentsToMinorityShareholders
      contextRef="i12a6d1161de54547bd29f8efccd4c9b0_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18zNC9mcmFnOjI3Y2IxNjhkZTFhNTRhNGQ5MGNkYTNlODdlZDg5N2RlL3RhYmxlOmE4OWNjMDNlN2U2MDQyMjY5NTA4MWU1MTFkYTU1MTkwL3RhYmxlcmFuZ2U6YTg5Y2MwM2U3ZTYwNDIyNjk1MDgxZTUxMWRhNTUxOTBfNTAtMy0xLTEtMTc3NzU_02d4d729-ab5c-4a61-ac9b-d0ca700f48d4"
      unitRef="usd">20000000</us-gaap:PaymentsToMinorityShareholders>
    <us-gaap:PaymentsToMinorityShareholders
      contextRef="i3e21049ffc224cacb8134d73c9bb5b38_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18zNC9mcmFnOjI3Y2IxNjhkZTFhNTRhNGQ5MGNkYTNlODdlZDg5N2RlL3RhYmxlOmE4OWNjMDNlN2U2MDQyMjY5NTA4MWU1MTFkYTU1MTkwL3RhYmxlcmFuZ2U6YTg5Y2MwM2U3ZTYwNDIyNjk1MDgxZTUxMWRhNTUxOTBfNTAtNS0xLTEtMTk3MTY_736a1e87-7e6e-4a11-8583-418f4532111c"
      unitRef="usd">0</us-gaap:PaymentsToMinorityShareholders>
    <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18zNC9mcmFnOjI3Y2IxNjhkZTFhNTRhNGQ5MGNkYTNlODdlZDg5N2RlL3RhYmxlOmE4OWNjMDNlN2U2MDQyMjY5NTA4MWU1MTFkYTU1MTkwL3RhYmxlcmFuZ2U6YTg5Y2MwM2U3ZTYwNDIyNjk1MDgxZTUxMWRhNTUxOTBfNTEtMS0xLTEtMTc3NzU_34f73386-b587-4c3f-8bf1-37cf4e1a98a8"
      unitRef="usd">3850000</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="i12a6d1161de54547bd29f8efccd4c9b0_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18zNC9mcmFnOjI3Y2IxNjhkZTFhNTRhNGQ5MGNkYTNlODdlZDg5N2RlL3RhYmxlOmE4OWNjMDNlN2U2MDQyMjY5NTA4MWU1MTFkYTU1MTkwL3RhYmxlcmFuZ2U6YTg5Y2MwM2U3ZTYwNDIyNjk1MDgxZTUxMWRhNTUxOTBfNTEtMy0xLTEtMTc3NzU_7330dda8-55e2-42d3-ad4f-ad93078d1f05"
      unitRef="usd">1851000</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="i3e21049ffc224cacb8134d73c9bb5b38_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18zNC9mcmFnOjI3Y2IxNjhkZTFhNTRhNGQ5MGNkYTNlODdlZDg5N2RlL3RhYmxlOmE4OWNjMDNlN2U2MDQyMjY5NTA4MWU1MTFkYTU1MTkwL3RhYmxlcmFuZ2U6YTg5Y2MwM2U3ZTYwNDIyNjk1MDgxZTUxMWRhNTUxOTBfNTEtNS0xLTEtMTk3MDg_a95029f1-3d2b-47ad-81d1-ba39fbcbe05f"
      unitRef="usd">2609000</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18zNC9mcmFnOjI3Y2IxNjhkZTFhNTRhNGQ5MGNkYTNlODdlZDg5N2RlL3RhYmxlOmE4OWNjMDNlN2U2MDQyMjY5NTA4MWU1MTFkYTU1MTkwL3RhYmxlcmFuZ2U6YTg5Y2MwM2U3ZTYwNDIyNjk1MDgxZTUxMWRhNTUxOTBfNTItMS0xLTEtMTc3NzU_3c1d4988-14f1-4c04-9b4c-2a385e3d230c"
      unitRef="usd">-29548000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="i12a6d1161de54547bd29f8efccd4c9b0_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18zNC9mcmFnOjI3Y2IxNjhkZTFhNTRhNGQ5MGNkYTNlODdlZDg5N2RlL3RhYmxlOmE4OWNjMDNlN2U2MDQyMjY5NTA4MWU1MTFkYTU1MTkwL3RhYmxlcmFuZ2U6YTg5Y2MwM2U3ZTYwNDIyNjk1MDgxZTUxMWRhNTUxOTBfNTItMy0xLTEtMTc3NzU_553b3c63-2e57-46c9-ac37-ba25bf8726fc"
      unitRef="usd">-11862000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="i3e21049ffc224cacb8134d73c9bb5b38_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18zNC9mcmFnOjI3Y2IxNjhkZTFhNTRhNGQ5MGNkYTNlODdlZDg5N2RlL3RhYmxlOmE4OWNjMDNlN2U2MDQyMjY5NTA4MWU1MTFkYTU1MTkwL3RhYmxlcmFuZ2U6YTg5Y2MwM2U3ZTYwNDIyNjk1MDgxZTUxMWRhNTUxOTBfNTItNS0xLTEtMTk3MDg_b23c69b1-23a9-47cf-a69a-b9f2bb3c5ba4"
      unitRef="usd">-35545000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18zNC9mcmFnOjI3Y2IxNjhkZTFhNTRhNGQ5MGNkYTNlODdlZDg5N2RlL3RhYmxlOmE4OWNjMDNlN2U2MDQyMjY5NTA4MWU1MTFkYTU1MTkwL3RhYmxlcmFuZ2U6YTg5Y2MwM2U3ZTYwNDIyNjk1MDgxZTUxMWRhNTUxOTBfNTMtMS0xLTEtMTc3NzU_439e0807-6662-4266-86a7-17c9edf96341"
      unitRef="usd">-52000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i12a6d1161de54547bd29f8efccd4c9b0_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18zNC9mcmFnOjI3Y2IxNjhkZTFhNTRhNGQ5MGNkYTNlODdlZDg5N2RlL3RhYmxlOmE4OWNjMDNlN2U2MDQyMjY5NTA4MWU1MTFkYTU1MTkwL3RhYmxlcmFuZ2U6YTg5Y2MwM2U3ZTYwNDIyNjk1MDgxZTUxMWRhNTUxOTBfNTMtMy0xLTEtMTc3NzU_60f826f3-d376-4db8-898e-512cbc57392a"
      unitRef="usd">65000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i3e21049ffc224cacb8134d73c9bb5b38_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18zNC9mcmFnOjI3Y2IxNjhkZTFhNTRhNGQ5MGNkYTNlODdlZDg5N2RlL3RhYmxlOmE4OWNjMDNlN2U2MDQyMjY5NTA4MWU1MTFkYTU1MTkwL3RhYmxlcmFuZ2U6YTg5Y2MwM2U3ZTYwNDIyNjk1MDgxZTUxMWRhNTUxOTBfNTMtNS0xLTEtMTk3MDg_11c0acf1-ef7a-4920-bee0-56a3066a0294"
      unitRef="usd">30000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18zNC9mcmFnOjI3Y2IxNjhkZTFhNTRhNGQ5MGNkYTNlODdlZDg5N2RlL3RhYmxlOmE4OWNjMDNlN2U2MDQyMjY5NTA4MWU1MTFkYTU1MTkwL3RhYmxlcmFuZ2U6YTg5Y2MwM2U3ZTYwNDIyNjk1MDgxZTUxMWRhNTUxOTBfNTQtMS0xLTEtMTc3NzU_50417f69-cfa7-413a-941c-1da812d20d57"
      unitRef="usd">-6639000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="i12a6d1161de54547bd29f8efccd4c9b0_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18zNC9mcmFnOjI3Y2IxNjhkZTFhNTRhNGQ5MGNkYTNlODdlZDg5N2RlL3RhYmxlOmE4OWNjMDNlN2U2MDQyMjY5NTA4MWU1MTFkYTU1MTkwL3RhYmxlcmFuZ2U6YTg5Y2MwM2U3ZTYwNDIyNjk1MDgxZTUxMWRhNTUxOTBfNTQtMy0xLTEtMTc3NzU_95ebe89b-a6b1-47e7-91d5-ead0ffba898c"
      unitRef="usd">233050000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="i3e21049ffc224cacb8134d73c9bb5b38_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18zNC9mcmFnOjI3Y2IxNjhkZTFhNTRhNGQ5MGNkYTNlODdlZDg5N2RlL3RhYmxlOmE4OWNjMDNlN2U2MDQyMjY5NTA4MWU1MTFkYTU1MTkwL3RhYmxlcmFuZ2U6YTg5Y2MwM2U3ZTYwNDIyNjk1MDgxZTUxMWRhNTUxOTBfNTQtNS0xLTEtMTk3MDg_e5718c4b-ef9f-4d33-87ad-85fc21d25a3b"
      unitRef="usd">-259794000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="ibc0c0c2b8dc04c5698ca0577a54b2e03_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18zNC9mcmFnOjI3Y2IxNjhkZTFhNTRhNGQ5MGNkYTNlODdlZDg5N2RlL3RhYmxlOmE4OWNjMDNlN2U2MDQyMjY5NTA4MWU1MTFkYTU1MTkwL3RhYmxlcmFuZ2U6YTg5Y2MwM2U3ZTYwNDIyNjk1MDgxZTUxMWRhNTUxOTBfNTUtMS0xLTEtMTc3NzU_dc843966-7f80-4efe-b679-574368ea9780"
      unitRef="usd">361581000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="icba6e493923b449aa57c46a563760234_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18zNC9mcmFnOjI3Y2IxNjhkZTFhNTRhNGQ5MGNkYTNlODdlZDg5N2RlL3RhYmxlOmE4OWNjMDNlN2U2MDQyMjY5NTA4MWU1MTFkYTU1MTkwL3RhYmxlcmFuZ2U6YTg5Y2MwM2U3ZTYwNDIyNjk1MDgxZTUxMWRhNTUxOTBfNTUtMy0xLTEtMTc3NzU_0dbfcc48-1d01-4540-ab2b-aa7e32633e3b"
      unitRef="usd">128531000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i7130cb432c4b4fe7a260e8a3beeb35d8_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18zNC9mcmFnOjI3Y2IxNjhkZTFhNTRhNGQ5MGNkYTNlODdlZDg5N2RlL3RhYmxlOmE4OWNjMDNlN2U2MDQyMjY5NTA4MWU1MTFkYTU1MTkwL3RhYmxlcmFuZ2U6YTg5Y2MwM2U3ZTYwNDIyNjk1MDgxZTUxMWRhNTUxOTBfNTUtNS0xLTEtMTk3MDg_6223642a-5e62-4a5b-967f-f9e515b1dca7"
      unitRef="usd">388325000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i8daff60be410426d8f7bd49343c1ec0c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18zNC9mcmFnOjI3Y2IxNjhkZTFhNTRhNGQ5MGNkYTNlODdlZDg5N2RlL3RhYmxlOmE4OWNjMDNlN2U2MDQyMjY5NTA4MWU1MTFkYTU1MTkwL3RhYmxlcmFuZ2U6YTg5Y2MwM2U3ZTYwNDIyNjk1MDgxZTUxMWRhNTUxOTBfNTYtMS0xLTEtMTc3NzU_ffc6fbc1-32e0-4d84-81d2-24061d12a248"
      unitRef="usd">354942000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="ibc0c0c2b8dc04c5698ca0577a54b2e03_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18zNC9mcmFnOjI3Y2IxNjhkZTFhNTRhNGQ5MGNkYTNlODdlZDg5N2RlL3RhYmxlOmE4OWNjMDNlN2U2MDQyMjY5NTA4MWU1MTFkYTU1MTkwL3RhYmxlcmFuZ2U6YTg5Y2MwM2U3ZTYwNDIyNjk1MDgxZTUxMWRhNTUxOTBfNTYtMy0xLTEtMTc3NzU_4f6ad754-8af7-4679-92ee-c45d9fc9dbf3"
      unitRef="usd">361581000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="icba6e493923b449aa57c46a563760234_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18zNC9mcmFnOjI3Y2IxNjhkZTFhNTRhNGQ5MGNkYTNlODdlZDg5N2RlL3RhYmxlOmE4OWNjMDNlN2U2MDQyMjY5NTA4MWU1MTFkYTU1MTkwL3RhYmxlcmFuZ2U6YTg5Y2MwM2U3ZTYwNDIyNjk1MDgxZTUxMWRhNTUxOTBfNTYtNS0xLTEtMTk3MDg_209232cd-73f4-4e84-8252-0b6a41a6baaa"
      unitRef="usd">128531000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock
      contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM180MC9mcmFnOjhlMmVhMTYxYjgzZTRjMTk5ZjU4ZTNiZTY3Mzg5ODBiL3RleHRyZWdpb246OGUyZWExNjFiODNlNGMxOTlmNThlM2JlNjczODk4MGJfMjA1Nw_e1226a8a-038b-4777-8c8c-114e9901cf3c">Organization &lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Evolent Health, Inc. was incorporated in December 2014 in the state of Delaware and through its subsidiaries supports leading health systems and physician organizations to move their business models from traditional fee for service reimbursement to value-based care, which we consider to be an integrated clinical and financial responsibility for populations. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Since its inception, the Company has incurred losses from operations. As of December&#160;31, 2021, the Company had unrestricted cash and cash equivalents of $266.3 million. The Company believes it has sufficient liquidity for the next twelve months as of the date the financial statements were available to be issued.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s headquarters is located in Arlington, Virginia.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Evolent Health LLC Governance&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our operations are conducted through Evolent Health LLC. Evolent Health, Inc. is a holding company whose only business is to act as the sole managing member of Evolent Health LLC. As such, it controls Evolent Health LLC&#x2019;s business and affairs and is responsible for the management of its business. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Issuances of Common Units&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Evolent Health LLC may only issue Class A common units to us, as the sole managing member of Evolent Health LLC. Class B common units may be issued only to persons or entities we permit. Such issuances of Class B common units shall be made in exchange for cash or other consideration. Class B common units may not be transferred as Class B common units except to certain permitted transferees and in accordance with the restrictions on transfer set forth in the third amended and restated operating agreement of Evolent Health LLC. Any such transfer must be accompanied by the transfer of an equal number of shares of our Class B common stock. As of December 31, 2021 and 2020, there are no Class B common units outstanding.&lt;/span&gt;&lt;/div&gt;</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i8daff60be410426d8f7bd49343c1ec0c_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM180MC9mcmFnOjhlMmVhMTYxYjgzZTRjMTk5ZjU4ZTNiZTY3Mzg5ODBiL3RleHRyZWdpb246OGUyZWExNjFiODNlNGMxOTlmNThlM2JlNjczODk4MGJfMTI3OA_2b7bc196-9fbd-44fd-816e-4d64f8861057"
      unitRef="usd">266300000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i9632fb5d42444a5984c0033bf16be6f0_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM180MC9mcmFnOjhlMmVhMTYxYjgzZTRjMTk5ZjU4ZTNiZTY3Mzg5ODBiL3RleHRyZWdpb246OGUyZWExNjFiODNlNGMxOTlmNThlM2JlNjczODk4MGJfMzI5ODUzNDg4ODYxNw_d7b7e4da-b651-4cc7-a60d-8fbb4b98a704"
      unitRef="shares">0</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i5f1b61732fb142fc9539a36365f230ee_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM180MC9mcmFnOjhlMmVhMTYxYjgzZTRjMTk5ZjU4ZTNiZTY3Mzg5ODBiL3RleHRyZWdpb246OGUyZWExNjFiODNlNGMxOTlmNThlM2JlNjczODk4MGJfMzI5ODUzNDg4ODYxNw_fa7356df-d3f8-4d1e-a83d-8182870de8c6"
      unitRef="shares">0</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock
      contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM180My9mcmFnOjM1ZWJlNTMyYTAzYjQ3MzhiMzdiNGEzNWFjNmNlNzZkL3RleHRyZWdpb246MzVlYmU1MzJhMDNiNDczOGIzN2I0YTM1YWM2Y2U3NmRfMTU3Mjc_422c4c35-dafc-4271-a9f0-772279582c75">Basis of Presentation, Summary of Significant Accounting Policies and Change in Accounting Principles&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Basis of Presentation&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The consolidated financial statements of the Company are prepared in accordance with U.S. GAAP. Our consolidated financial statements include the accounts of all subsidiaries. All intercompany accounts and transactions are eliminated in consolidation. The consolidated balance sheet as of December 31, 2020, has been derived from audited financial statements as of that date and reflects the impact of the sale of True Health. See Note 5 for a complete summary of this transaction. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Summary of Significant Accounting Policies&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Certain GAAP policies that significantly affect the determination of our financial position, results of operations and cash flows, are summarized below.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Accounting Estimates and Assumptions&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions affecting the reported amounts of assets and liabilities and the disclosures of contingent assets and liabilities as of the date of the financial statements and the reported amounts of revenue and expenses for the reporting period. Those estimates are inherently subject to change and actual results could differ from those estimates. In the accompanying consolidated financial statements, estimates are used for, but not limited to, the valuation of assets (including intangibles assets, goodwill and long-lived assets), liabilities, consideration related to business combinations and asset acquisitions, revenue recognition (including variable consideration), estimated selling prices for performance obligations in contracts with multiple performance obligations, reserves for claims and performance-based arrangements, credit losses, depreciable lives of assets, impairment of long-lived assets, stock-based compensation, deferred income taxes and valuation allowance, contingent liabilities, purchase price allocation in taxable stock transactions and useful lives of intangible assets.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Operating Segments&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Operating segments are defined as components of a business that may recognize revenue and incur expenses for which discrete financial information is available that is evaluated, on a regular basis, by the chief operating decision maker (&#x201c;CODM&#x201d;) to decide how &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;to allocate resources and assess performance. The Company made organizational changes, including re-evaluating its reportable segments, as a result of the entry into the agreement to sell True Health on January 11, 2021. Effective during the first quarter of 2021, the Company bifurcated its previous Services segment into two segments. The Company&#x2019;s Evolent Health Services segment (&#x201c;EHS&#x201d;) includes our administrative simplification solution and supporting population health infrastructure. Our Clinical Solutions segment includes our specialty care management and physician-oriented total cost of care solutions, along with the New Century Health and Evolent Care Partners brands. Refer to Note 22 for a further discussion of our operating results by segment.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Cash and Cash Equivalents&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We consider all highly liquid instruments with original maturities of three months or less to be cash equivalents. The Company holds materially all of our cash in bank deposits with FDIC participating banks, at cost, which approximates fair value. Cash and cash equivalents held in money market funds are carried at fair value, which approximates cost.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Restricted Cash and Restricted Investments&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Restricted cash and restricted investments include cash and investments used to collateralize various contractual obligations as of December&#160;31, 2021 and 2020 (in thousands) as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:421.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:54.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:54.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020 &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Collateral for letters of credit for facility leases &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,769&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,510&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Collateral with financial institutions &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,662&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,743&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Claims processing services &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(4)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;73,226&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,064&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;711&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total restricted cash and restricted investments&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;88,662&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,028&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current restricted cash&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;75,685&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,374&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total current restricted cash and restricted investments&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;75,685&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,374&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-current restricted cash&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,977&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,654&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total non-current restricted cash and restricted investments&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,977&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,654&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt"&gt;Amounts exclude $0.6 million of non-current restricted investments and $0.1&#160;million of current restricted cash from claims processing services reclassified to discontinued operations as of December&#160;31, 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt"&gt;Represents restricted cash related to collateral for letters of credit required in conjunction with lease agreements. See Note 12 for further discussion of our lease commitments. &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt"&gt;Represents collateral held with financial institutions for risk-sharing and other arrangements. As of December&#160;31, 2021 and 2020, approximately $11.7&#160;million and $4.7 million, respectively, of the collateral amounts were held in a FDIC participating bank account. See Note 19 for discussion of fair value measurement and Note 11 for discussion of our risk-sharing arrangements. &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(4)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt"&gt;Represents cash held by the Company related to claims processing services on behalf of partners. These are pass-through amounts and can fluctuate materially from period to period depending on the timing of when the claims are processed.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-align:justify;text-indent:-9pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table provides a reconciliation of cash and cash equivalents and restricted cash reported within the consolidated balance sheets that sum to the total of the same amounts shown in the consolidated statements of cash flows as of December&#160;31, 2021 and 2020 (in thousands).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:433.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:48.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:48.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;266,280&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;340,490&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted cash and restricted investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;88,662&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,707&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted investments included in restricted cash and restricted investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(616)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:5.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total cash and cash equivalents and restricted cash shown in the consolidated statements of cash flows &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;354,942&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;361,581&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt"&gt;As a result of the closing of the sale of True Health, the consolidated statements of operations, consolidated balance sheets and related financial information reflect the Company&#x2019;s operations and assets and liabilities of True Health as discontinued operations for all periods presented. Cash flows and comprehensive income have not been adjusted and are included in the consolidated statements of cash flows and consolidated statements of comprehensive income (loss) for all periods presented. See Note 5.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Accounts Receivable and Allowances&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accounts receivable are recorded and carried at the original invoiced amount less an allowance for any potential uncollectible amounts. We make estimates for the allowance for doubtful accounts and allowance for unbilled receivables based upon our assessment of various factors, including historical experience, the age of the accounts receivable balances, credit quality of our customers, current economic conditions, and other factors that may affect our ability to collect from customers.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Property and Equipment, Net&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property and equipment are carried at cost less accumulated depreciation and amortization. Depreciation and amortization of property and equipment are computed using the straight-line method over the shorter of the estimated useful lives of the assets or the lease term. The following summarizes the estimated useful lives by asset classification:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:63.066%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:34.040%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Computer hardware&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Computer software&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1 year&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Furniture and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3 - 7 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Internal-use software development costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Shorter of useful life or remaining lease term&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;When an item is sold or retired, the cost and related accumulated depreciation or amortization is eliminated and the resulting gain or loss, if any, is recorded in gain (loss) on disposal of assets and consolidation on our consolidated statements of operations and comprehensive income (loss).&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We periodically review the carrying value of our long-lived assets, including property and equipment, for impairment whenever events or circumstances indicate that the carrying amount of such assets may not be fully recoverable. For long-lived assets to be held and used, impairments are recognized when the carrying amount of a long-lived asset group is not recoverable and exceeds fair value. The carrying amount of a long-lived asset group is not recoverable if it exceeds the sum of the undiscounted cash flows expected to result from the use and eventual disposition of the asset group. An impairment loss is measured as the amount by which the carrying amount of a long-lived asset group exceeds its fair value.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Software Development Costs&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company capitalizes the cost of developing internal-use software, consisting primarily of personnel and related expenses (including stock-based compensation and employee taxes and benefits) for employees and third parties who devote time to their respective projects. Internal-use software costs are capitalized during the application development stage &#x2013; when the research stage is complete and management has committed to a project to develop software that will be used for its intended purpose. Any costs incurred during subsequent efforts to significantly upgrade and enhance the functionality of the software are also capitalized. Capitalized software costs are included in property and equipment, net on our consolidated balance sheets. Amortization of internal-use software costs are recorded on a straight-line basis over their estimated useful life and begin once the project is substantially complete and the software is ready for its intended purpose.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Research and Development Costs&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Research and development costs consist primarily of personnel and related expenses (including stock-based compensation and employee taxes and benefits) for employees engaged in research and development activities as well as third-party fees. All such costs are expensed as incurred. We focus our research and development efforts on activities that support our technology infrastructure, clinical program development, data analytics and network development capabilities. Research and development costs are recorded within selling, general and administrative expenses on our consolidated statements of operations and comprehensive income (loss) and were $15.5&#160;million, $15.1&#160;million and $19.8&#160;million for the years ended December 31, 2021, 2020 and 2019, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Business Combinations&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Companies acquired during each reporting period are reflected in the results of the Company effective from their respective dates of acquisition through the end of the reporting period. The Company allocates the fair value of purchase consideration to the assets acquired and liabilities assumed based on their estimated fair values at the acquisition date. Our estimates of fair value are based upon assumptions believed to be reasonable, but which are inherently uncertain and unpredictable and, as a result, actual results may differ &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;from estimates. Critical estimates used to value certain identifiable assets include, but are not limited to, expected long-term revenues, future expected operating expenses, cost of capital and appropriate discount rates. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The excess of the fair value of purchase consideration over the fair value of the assets acquired and liabilities assumed in the acquired entity is recorded as goodwill. Goodwill is assigned to the reporting unit that benefits from the synergies arising from the business combination. If the Company obtains new information about facts and circumstances that existed as of the acquisition date during the measurement period, which may be up to one year from the acquisition date, the Company may record adjustments to the assets acquired and liabilities assumed, with the corresponding offset to goodwill. Upon the conclusion of the measurement period or final determination of the values of assets acquired or liabilities assumed, whichever comes first, any subsequent adjustments are recorded on the Company's consolidated statements of operations and comprehensive income (loss). &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For contingent consideration recorded as a liability, the Company initially measures the amount at fair value as of the acquisition date and adjusts the liability, if needed, to fair value at each reporting period. Changes in the fair value of contingent consideration, other than measurement period adjustments, are recognized as operating income or expense. Acquisition-related expenses are recognized separately from the business combination and are expensed as incurred.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Equity Method Investments&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For entities that are not consolidated, but where the Company has significant influence over the operating or financial decisions of the entity, the Company accounts for the investment under the equity method of accounting. In accordance with the equity method of accounting, the Company will recognize its share of earnings or losses of the investee in the period in which they are reported by the investee. The Company also considers whether there are any indicators of other-than-temporary impairment of its investments accounted for under the equity method. These investments are included in investments in equity method investees on the consolidated balance sheets with income or loss included in gain (loss) from equity method investees on the consolidated statements of operations and comprehensive income (loss).&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Impairment of Equity Method Investments&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company considers certain factors to determine if there is a decrease in its investment fair value for its equity method investments that is other than temporary. The equity method investments will be written down to fair value if there is evidence of a loss in value which is other-than-temporary. The Company may estimate the fair value of its equity method investments by considering recent investee equity transactions, discounted cash flow analysis and recent operating results. If the fair value of the investment is below the carrying amount, management considers several factors when determining whether other-than-temporary impairment has occurred. The estimation of fair value and whether other-than-temporary impairment has occurred requires the application of significant judgment and future results may vary from current assumptions. Refer to Note 17 for additional discussion regarding impairments on equity method investments.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Goodwill&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We recognize the excess of the purchase price, plus the fair value of any non-controlling interests in the acquiree, over the fair value of identifiable net assets acquired as goodwill. Goodwill is not amortized, but is reviewed at least annually for indications of impairment, with consideration given to financial performance and other relevant factors. We perform impairment tests of goodwill at a reporting unit level. Following the sale of True Health, the Company has three reporting units and our annual goodwill impairment review occurs during the fourth quarter of each year. We perform impairment tests between annual tests if an event occurs, or circumstances change, that we believe would more likely than not reduce the fair value of a reporting unit below its carrying amount. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our goodwill impairment analysis first assesses qualitative factors to determine whether events or circumstances existed that would lead the Company to conclude it is more likely than not that the fair value of a reporting unit is below its carrying amount. If the Company determines that it is more likely than not that the fair value of a reporting unit is below the carrying amount, a quantitative goodwill assessment is required. In the quantitative evaluation, the fair value of the relevant reporting unit is determined and compared to the carrying value. If the fair value is greater than the carrying value, then the carrying value is deemed to be recoverable and no further action is required. If the fair value estimate is less than the carrying value, goodwill is considered impaired for the amount by which the carrying amount exceeds the reporting unit&#x2019;s fair value and a charge is reported in goodwill impairment on our consolidated statements of operations and comprehensive income (loss). See Note 9 for additional discussion regarding the goodwill impairment tests conducted during 2021 and 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Intangible Assets, Net &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Identified intangible assets are recorded at their estimated fair values at the date of acquisition and are amortized over their respective estimated useful lives using a method of amortization that reflects the pattern in which the economic benefits of the intangible assets are used. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following summarizes the estimated useful lives by asset classification:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:438.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:97.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate trade name&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10 - 20 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Customer relationships&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10 - 25 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Technology&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Provider network contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3 - 5 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Intangible assets are reviewed for impairment if circumstances indicate the Company may not be able to recover the asset&#x2019;s carrying value. The Company evaluates recoverability by determining whether the undiscounted cash flows expected to result from the use and eventual disposition of that asset or group exceed the carrying value at the evaluation date. If the undiscounted cash flows are not sufficient to cover the carrying value, the Company measures an impairment loss as the excess of the carrying amount of the long-lived asset or group over its fair value. See Note 9 for additional discussion regarding our intangible assets.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Reserves for Claims and Performance-based Arrangements&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Reserves for claims and performance-based arrangements reflect estimates of payments under performance-based arrangements and the ultimate cost of claims that have been incurred but not reported, including expected development on reported claims, those that have been reported but not yet paid (reported claims in process) and other medical care expenses and services payable that are primarily composed of accruals for incentives and other amounts payable to health care professionals and facilities. The Company uses actuarial principles and assumptions that are consistently applied in each reporting period and recognizes the actuarial best estimate of the ultimate liability along with a margin for adverse deviation. This approach is consistent with actuarial standards of practice that the liabilities be adequate under moderately adverse conditions. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The process of estimating reserves involves a considerable degree of judgment by the Company and, as of any given date, is inherently uncertain. The methods for making such estimates and for establishing the resulting liability are continually reviewed and adjustments are reflected in current results of operations in the period in which they are identified as experience develops or new information becomes known. See Note 23 for additional discussion regarding our reserves for claims and performance-based arrangements.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Right of Offset&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Certain customer arrangements give the Company the legal right to net payment for amounts due from customers and claims payable. As of December 31, 2021 and 2020, approximately 42% and &#x2014;% of gross accounts receivable have been netted against claims payable. Furthermore, as of December 31, 2021, approximately 55% of our accounts receivable, net could ultimately be settled on a net basis, once the criteria for netting have been met.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Long-term Debt&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Convertible notes and amounts borrowed under our credit agreement are carried at cost, net of debt discounts and issuance costs, as long-term debt on the consolidated balance sheets. The debt discounts and issuance costs are amortized to interest expense on the consolidated statements of operations and comprehensive income (loss) using the straight-line method over the contractual term of the note if that method is not materially different from the effective interest rate method. Cash interest payments are due either quarterly or semi-annually in arrears and we accrue interest expense monthly based on the annual coupon rate. See Note 10 for further discussion regarding our convertible notes and credit agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Leases&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company enters into various office space, data center and equipment lease agreements in conducting its normal business operations. At the inception of any contract, the Company evaluates the agreement to determine whether the contract contains a lease. If the contract contains a lease, the Company then evaluates the term and whether the lease is an operating or finance lease. Most leases include one or more options to renew or may have a termination option. The Company determines whether these options are reasonably certain to be exercised at the inception of the lease. The rent expense is recognized on a straight-line basis in the consolidated statements of operations and comprehensive income (loss) over the terms of the respective leases. Leases with an initial term of 12 months or less are not recorded on the consolidated balance sheets.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As most of our leases do not provide an implicit rate, we use our incremental borrowing rate based on the information available at commencement date in determining the present value of lease payments. We use the implicit rate when readily determinable. Further, the Company treats all lease and non-lease components as a single combined lease component for all classes of underlying assets.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company also enters into sublease agreements for some of its leased office space. Rental income attributable to subleases is immaterial and is offset against rent expense over the terms of the respective leases.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Refer to Note 12 for additional lease disclosures.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Revenue Recognition&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We derive revenue from two sources: (1) transformation services and (2) platform and operations services. Transformation services consist of implementation services whereby we assist the customer in launching its population health or health plan programs, or implement certain platform and operations services. In certain cases, transformation services can also include revenue associated with our support of certain one-time wind-down activities for clients who are exiting a line of business or population. Platform and operations services generally include multi-year arrangements with customers to provide various population health, health plan operations, specialty care management and claims processing services on an ongoing basis, as well as transition or run-out services to customers receiving primarily TPA services. Revenue is recognized when control of the services is transferred to our customers.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We use the following 5-step model, outlined in Accounting Standards Codification (&#x201c;ASC&#x201d;) Topic 606, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Revenue from Contracts with Customers&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (&#x201c;ASC 606&#x201d;), to determine revenue recognition from our contracts with customers:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt; Identify the contract(s) with a customer&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt; Identify the performance obligations in the contract&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt; Determine the transaction price&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt; Allocate the transaction price to performance obligations&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt; Recognize revenue when (or as) the entity satisfies a performance obligation&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;See Note 6 for further discussion of our policies related to revenue recognition. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Cost of Revenue (Exclusive of Depreciation and Amortization)&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our cost of revenue includes direct expenses and shared resources that perform services in direct support of clients. Costs consist primarily of employee-related expenses (including compensation, benefits and stock-based compensation), expenses for TPA support and other services, as well as other professional fees. In certain cases, our cost of revenue also includes claims and capitation payments to providers and payments for pharmaceutical treatments and other health care expenditures through capitated arrangements.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Stock-based Compensation&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company sponsors a stock-based incentive plan that provides for the issuance of stock-based awards to employees, vendors and non-employee directors of the Company or its consolidated subsidiaries. Our stock-based awards generally vest over a four-year period and stock options expire 10 years from the date of grant.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We expense the fair value of stock-based awards granted under our incentive compensation plans. Fair value of stock options is determined using a Black-Scholes options valuation methodology. The fair value of the awards is expensed over the performance or service period, which generally corresponds to the vesting period, on a straight-line basis and is recognized as an increase to additional paid-in capital. Stock-based compensation expense is reflected in cost of revenue and selling, general and administrative expenses in our consolidated statements of operations and comprehensive income (loss). Additionally, and if applicable, we capitalize personnel expenses attributable to the development of internal-use software, which include stock-based compensation costs. We recognize share-based award forfeitures as they occur.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Income Taxes&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Deferred income taxes are recognized, based on enacted rates, when assets and liabilities have different values for financial statement and tax reporting purposes. A valuation allowance is recorded to the extent required. Considerable judgment and the use of estimates are required in determining whether a valuation allowance is necessary and, if so, the amount of such valuation allowance. In evaluating the need for a valuation allowance, we consider many factors, including: the nature and character of the deferred tax assets and liabilities; taxable income in prior carryback years; future reversals of temporary differences; the length of time carryovers can be utilized; and any tax planning strategies we would employ to avoid a tax benefit from expiring unused.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We use a recognition threshold and a measurement attribute for the financial statement recognition and measurement of uncertain tax positions taken or expected to be taken in a tax return. For those benefits to be recognized, a tax position must be more-likely-than-not to be sustained upon examination by taxing authorities. We recognize interest and penalties accrued on any unrecognized tax exposures as a component of income tax expense, when applicable. As of December 31, 2021 and 2020, our identified balance of uncertain income tax positions would not have a material impact to the consolidated financial statements. We are subject to taxation in various jurisdictions in the U.S. and India and remain subject to examination by taxing jurisdictions for the year 2011 and all subsequent periods due to the availability of NOL carryforwards.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We are a holding company and our assets consist of our direct ownership in Evolent Health LLC, for which we are the managing member. Prior to the Class B unit exchanges on December 26, 2019, Evolent Health LLC was classified as a partnership for U.S. federal and applicable state and local income tax purposes and, as such, was not subject to U.S. federal, state and local income taxes. Taxable income or loss generated by Evolent Health LLC was allocated to holders of its units, including us, on a pro rata basis. Accordingly, we were subject to U.S. federal, state and local income taxes with respect to our allocable share of any taxable income of Evolent Health LLC. As a result of the 2019 Class B units exchanges, we became the sole owner of Evolent Health LLC and its entity classification changed from a partnership to an entity disregarded as separate from its owner for U.S. federal, state and local income tax purposes. Following the Class B units exchanges, any taxable income or loss generated by Evolent Health LLC is reportable and taxable only on the Company&#x2019;s federal, state and local income tax returns. Evolent Health LLC has direct ownership in corporate subsidiaries, which were subject to U.S. and foreign taxes with respect to their own operations during 2019.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Earnings (Loss) per Share&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Basic earnings (loss) per share is computed by dividing net income (loss) available to Class A common shareholders by the weighted-average number of Class A common shares outstanding.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For periods of net income, and when the effects are not anti-dilutive, we calculate diluted earnings per share by dividing net income available to Class A common shareholders by the weighted average number of Class A common shares plus the weighted average number of Class A common shares assuming the conversion of our convertible notes, as well as the impact of all potential dilutive common shares, consisting primarily of common stock options and unvested restricted stock awards using the treasury stock method and our exchangeable Class B common stock. For periods of net loss, shares used in the diluted earnings (loss) per share calculation represent basic shares as using potentially dilutive shares would be anti-dilutive.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Fair Value Measurement&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Fair value is the price that would be received from the sale of an asset or paid to transfer a liability assuming an orderly transaction in the most advantageous market at the measurement date. Our consolidated balance sheets include various financial instruments (primarily cash not held in money-market funds, restricted cash, accounts receivable, accounts payable, accrued expenses and other liabilities) that are carried at cost and that approximate fair value.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;See Note 19 for further discussion regarding fair value measurement.&lt;/span&gt;&lt;/div&gt;</us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock
      contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM180My9mcmFnOjM1ZWJlNTMyYTAzYjQ3MzhiMzdiNGEzNWFjNmNlNzZkL3RleHRyZWdpb246MzVlYmU1MzJhMDNiNDczOGIzN2I0YTM1YWM2Y2U3NmRfMTU3NDE_7de823bf-ac93-4557-89ae-d7bb20877132">Basis of PresentationThe consolidated financial statements of the Company are prepared in accordance with U.S. GAAP. Our consolidated financial statements include the accounts of all subsidiaries. All intercompany accounts and transactions are eliminated in consolidation. The consolidated balance sheet as of December 31, 2020, has been derived from audited financial statements as of that date and reflects the impact of the sale of True Health. See Note 5 for a complete summary of this transaction.</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:UseOfEstimates
      contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM180My9mcmFnOjM1ZWJlNTMyYTAzYjQ3MzhiMzdiNGEzNWFjNmNlNzZkL3RleHRyZWdpb246MzVlYmU1MzJhMDNiNDczOGIzN2I0YTM1YWM2Y2U3NmRfMTU3MzU_a12fd2c0-f195-4ae0-81ac-8588863f3e6b">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Accounting Estimates and Assumptions&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions affecting the reported amounts of assets and liabilities and the disclosures of contingent assets and liabilities as of the date of the financial statements and the reported amounts of revenue and expenses for the reporting period. Those estimates are inherently subject to change and actual results could differ from those estimates. In the accompanying consolidated financial statements, estimates are used for, but not limited to, the valuation of assets (including intangibles assets, goodwill and long-lived assets), liabilities, consideration related to business combinations and asset acquisitions, revenue recognition (including variable consideration), estimated selling prices for performance obligations in contracts with multiple performance obligations, reserves for claims and performance-based arrangements, credit losses, depreciable lives of assets, impairment of long-lived assets, stock-based compensation, deferred income taxes and valuation allowance, contingent liabilities, purchase price allocation in taxable stock transactions and useful lives of intangible assets.&lt;/span&gt;&lt;/div&gt;</us-gaap:UseOfEstimates>
    <us-gaap:SegmentReportingPolicyPolicyTextBlock
      contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM180My9mcmFnOjM1ZWJlNTMyYTAzYjQ3MzhiMzdiNGEzNWFjNmNlNzZkL3RleHRyZWdpb246MzVlYmU1MzJhMDNiNDczOGIzN2I0YTM1YWM2Y2U3NmRfMTU3NDM_4cd5d968-a641-4631-a393-ab5b7be26ec2">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Operating Segments&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Operating segments are defined as components of a business that may recognize revenue and incur expenses for which discrete financial information is available that is evaluated, on a regular basis, by the chief operating decision maker (&#x201c;CODM&#x201d;) to decide how &lt;/span&gt;&lt;/div&gt;to allocate resources and assess performance. The Company made organizational changes, including re-evaluating its reportable segments, as a result of the entry into the agreement to sell True Health on January 11, 2021. Effective during the first quarter of 2021, the Company bifurcated its previous Services segment into two segments. The Company&#x2019;s Evolent Health Services segment (&#x201c;EHS&#x201d;) includes our administrative simplification solution and supporting population health infrastructure. Our Clinical Solutions segment includes our specialty care management and physician-oriented total cost of care solutions, along with the New Century Health and Evolent Care Partners brands. Refer to Note 22 for a further discussion of our operating results by segment.</us-gaap:SegmentReportingPolicyPolicyTextBlock>
    <us-gaap:NumberOfOperatingSegments
      contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM180My9mcmFnOjM1ZWJlNTMyYTAzYjQ3MzhiMzdiNGEzNWFjNmNlNzZkL3RleHRyZWdpb246MzVlYmU1MzJhMDNiNDczOGIzN2I0YTM1YWM2Y2U3NmRfMjE5OTAyMzI5NDc2MQ_36996c95-6a0f-49a8-9f69-e7b417168391"
      unitRef="segment">2</us-gaap:NumberOfOperatingSegments>
    <us-gaap:CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy
      contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM180My9mcmFnOjM1ZWJlNTMyYTAzYjQ3MzhiMzdiNGEzNWFjNmNlNzZkL3RleHRyZWdpb246MzVlYmU1MzJhMDNiNDczOGIzN2I0YTM1YWM2Y2U3NmRfMTU3MTE_63b02c16-0ade-4a8e-9f4a-450ddfbec365">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Cash and Cash Equivalents&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We consider all highly liquid instruments with original maturities of three months or less to be cash equivalents. The Company holds materially all of our cash in bank deposits with FDIC participating banks, at cost, which approximates fair value. Cash and cash equivalents held in money market funds are carried at fair value, which approximates cost.&lt;/span&gt;&lt;/div&gt;</us-gaap:CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy>
    <us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock
      contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM180My9mcmFnOjM1ZWJlNTMyYTAzYjQ3MzhiMzdiNGEzNWFjNmNlNzZkL3RleHRyZWdpb246MzVlYmU1MzJhMDNiNDczOGIzN2I0YTM1YWM2Y2U3NmRfMTU3MTY_cebe285d-4d06-4ace-be90-598c28dab2b7">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Restricted cash and restricted investments include cash and investments used to collateralize various contractual obligations as of December&#160;31, 2021 and 2020 (in thousands) as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:421.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:54.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:54.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020 &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Collateral for letters of credit for facility leases &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,769&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,510&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Collateral with financial institutions &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,662&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,743&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Claims processing services &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(4)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;73,226&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,064&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;711&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total restricted cash and restricted investments&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;88,662&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,028&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current restricted cash&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;75,685&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,374&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total current restricted cash and restricted investments&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;75,685&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,374&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-current restricted cash&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,977&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,654&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total non-current restricted cash and restricted investments&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,977&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,654&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt"&gt;Amounts exclude $0.6 million of non-current restricted investments and $0.1&#160;million of current restricted cash from claims processing services reclassified to discontinued operations as of December&#160;31, 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt"&gt;Represents restricted cash related to collateral for letters of credit required in conjunction with lease agreements. See Note 12 for further discussion of our lease commitments. &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt"&gt;Represents collateral held with financial institutions for risk-sharing and other arrangements. As of December&#160;31, 2021 and 2020, approximately $11.7&#160;million and $4.7 million, respectively, of the collateral amounts were held in a FDIC participating bank account. See Note 19 for discussion of fair value measurement and Note 11 for discussion of our risk-sharing arrangements. &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(4)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt"&gt;Represents cash held by the Company related to claims processing services on behalf of partners. These are pass-through amounts and can fluctuate materially from period to period depending on the timing of when the claims are processed.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-align:justify;text-indent:-9pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table provides a reconciliation of cash and cash equivalents and restricted cash reported within the consolidated balance sheets that sum to the total of the same amounts shown in the consolidated statements of cash flows as of December&#160;31, 2021 and 2020 (in thousands).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:433.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:48.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:48.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;266,280&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;340,490&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted cash and restricted investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;88,662&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,707&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted investments included in restricted cash and restricted investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(616)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:5.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total cash and cash equivalents and restricted cash shown in the consolidated statements of cash flows &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;354,942&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;361,581&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt"&gt;As a result of the closing of the sale of True Health, the consolidated statements of operations, consolidated balance sheets and related financial information reflect the Company&#x2019;s operations and assets and liabilities of True Health as discontinued operations for all periods presented. Cash flows and comprehensive income have not been adjusted and are included in the consolidated statements of cash flows and consolidated statements of comprehensive income (loss) for all periods presented. See Note 5.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock>
    <us-gaap:RestrictedCashAndCashEquivalents
      contextRef="ibd159a0a266f484882b88b46c1b83d3f_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM180My9mcmFnOjM1ZWJlNTMyYTAzYjQ3MzhiMzdiNGEzNWFjNmNlNzZkL3RhYmxlOjgzYzE1OWRlMDNkNjRjYzE4NWFmMmUzODVmNTk2MmY1L3RhYmxlcmFuZ2U6ODNjMTU5ZGUwM2Q2NGNjMTg1YWYyZTM4NWY1OTYyZjVfMS0xLTEtMS0xNzc3NQ_6e56af00-f15b-4b02-b9d3-fd356a107df3"
      unitRef="usd">3769000</us-gaap:RestrictedCashAndCashEquivalents>
    <us-gaap:RestrictedCashAndCashEquivalents
      contextRef="i3a313b63f9a34c26b2a361281eca58df_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM180My9mcmFnOjM1ZWJlNTMyYTAzYjQ3MzhiMzdiNGEzNWFjNmNlNzZkL3RhYmxlOjgzYzE1OWRlMDNkNjRjYzE4NWFmMmUzODVmNTk2MmY1L3RhYmxlcmFuZ2U6ODNjMTU5ZGUwM2Q2NGNjMTg1YWYyZTM4NWY1OTYyZjVfMS0zLTEtMS0xNzc3NQ_3e6c5f96-021f-4b71-991f-688075e47b8f"
      unitRef="usd">3510000</us-gaap:RestrictedCashAndCashEquivalents>
    <us-gaap:RestrictedCashAndCashEquivalents
      contextRef="ia9df011f1efd436cbcdff5e8bfdd9e5a_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM180My9mcmFnOjM1ZWJlNTMyYTAzYjQ3MzhiMzdiNGEzNWFjNmNlNzZkL3RhYmxlOjgzYzE1OWRlMDNkNjRjYzE4NWFmMmUzODVmNTk2MmY1L3RhYmxlcmFuZ2U6ODNjMTU5ZGUwM2Q2NGNjMTg1YWYyZTM4NWY1OTYyZjVfMi0xLTEtMS0xNzc3NQ_5b97a3d6-0426-410b-876e-7b4307a8c657"
      unitRef="usd">11662000</us-gaap:RestrictedCashAndCashEquivalents>
    <us-gaap:RestrictedCashAndCashEquivalents
      contextRef="ib52a820bc1fa4880b75c578ff17dda8d_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM180My9mcmFnOjM1ZWJlNTMyYTAzYjQ3MzhiMzdiNGEzNWFjNmNlNzZkL3RhYmxlOjgzYzE1OWRlMDNkNjRjYzE4NWFmMmUzODVmNTk2MmY1L3RhYmxlcmFuZ2U6ODNjMTU5ZGUwM2Q2NGNjMTg1YWYyZTM4NWY1OTYyZjVfMi0zLTEtMS0xNzc3NQ_52e2b1b6-713a-47b0-b710-9698b8cbda5b"
      unitRef="usd">4743000</us-gaap:RestrictedCashAndCashEquivalents>
    <us-gaap:RestrictedCashAndCashEquivalents
      contextRef="ic5164e2908114e21b24e2e1681c5dcba_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM180My9mcmFnOjM1ZWJlNTMyYTAzYjQ3MzhiMzdiNGEzNWFjNmNlNzZkL3RhYmxlOjgzYzE1OWRlMDNkNjRjYzE4NWFmMmUzODVmNTk2MmY1L3RhYmxlcmFuZ2U6ODNjMTU5ZGUwM2Q2NGNjMTg1YWYyZTM4NWY1OTYyZjVfMy0xLTEtMS0xNzc3NQ_8f8f8398-bac5-4882-823c-343938a82bb6"
      unitRef="usd">73226000</us-gaap:RestrictedCashAndCashEquivalents>
    <us-gaap:RestrictedCashAndCashEquivalents
      contextRef="i83fc6159c69f43e5822b38e95a2a3b46_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM180My9mcmFnOjM1ZWJlNTMyYTAzYjQ3MzhiMzdiNGEzNWFjNmNlNzZkL3RhYmxlOjgzYzE1OWRlMDNkNjRjYzE4NWFmMmUzODVmNTk2MmY1L3RhYmxlcmFuZ2U6ODNjMTU5ZGUwM2Q2NGNjMTg1YWYyZTM4NWY1OTYyZjVfMy0zLTEtMS0xNzc3NQ_ee7d3c9d-2e21-4b4c-8b17-f05f2cd03eab"
      unitRef="usd">12064000</us-gaap:RestrictedCashAndCashEquivalents>
    <us-gaap:RestrictedCashAndCashEquivalents
      contextRef="i58c2398f3ddb4809a3cb1af5b5c34db8_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM180My9mcmFnOjM1ZWJlNTMyYTAzYjQ3MzhiMzdiNGEzNWFjNmNlNzZkL3RhYmxlOjgzYzE1OWRlMDNkNjRjYzE4NWFmMmUzODVmNTk2MmY1L3RhYmxlcmFuZ2U6ODNjMTU5ZGUwM2Q2NGNjMTg1YWYyZTM4NWY1OTYyZjVfNC0xLTEtMS0xNzc3NQ_2eb4d5c0-1634-4ece-baa4-e59bd8f147c0"
      unitRef="usd">5000</us-gaap:RestrictedCashAndCashEquivalents>
    <us-gaap:RestrictedCashAndCashEquivalents
      contextRef="i58e611a688d54093ac555cb27c5810ec_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM180My9mcmFnOjM1ZWJlNTMyYTAzYjQ3MzhiMzdiNGEzNWFjNmNlNzZkL3RhYmxlOjgzYzE1OWRlMDNkNjRjYzE4NWFmMmUzODVmNTk2MmY1L3RhYmxlcmFuZ2U6ODNjMTU5ZGUwM2Q2NGNjMTg1YWYyZTM4NWY1OTYyZjVfNC0zLTEtMS0xNzc3NQ_58ee5451-a672-4c79-8a4a-fd87eae02c97"
      unitRef="usd">711000</us-gaap:RestrictedCashAndCashEquivalents>
    <us-gaap:RestrictedCashAndInvestments
      contextRef="i8daff60be410426d8f7bd49343c1ec0c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM180My9mcmFnOjM1ZWJlNTMyYTAzYjQ3MzhiMzdiNGEzNWFjNmNlNzZkL3RhYmxlOjgzYzE1OWRlMDNkNjRjYzE4NWFmMmUzODVmNTk2MmY1L3RhYmxlcmFuZ2U6ODNjMTU5ZGUwM2Q2NGNjMTg1YWYyZTM4NWY1OTYyZjVfNS0xLTEtMS0xNzc3NQ_50e888ff-6074-4576-9815-500ec6808775"
      unitRef="usd">88662000</us-gaap:RestrictedCashAndInvestments>
    <us-gaap:RestrictedCashAndCashEquivalents
      contextRef="ibc0c0c2b8dc04c5698ca0577a54b2e03_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM180My9mcmFnOjM1ZWJlNTMyYTAzYjQ3MzhiMzdiNGEzNWFjNmNlNzZkL3RhYmxlOjgzYzE1OWRlMDNkNjRjYzE4NWFmMmUzODVmNTk2MmY1L3RhYmxlcmFuZ2U6ODNjMTU5ZGUwM2Q2NGNjMTg1YWYyZTM4NWY1OTYyZjVfNS0zLTEtMS0xNzc3NQ_9581c207-ba6c-42d0-a7c6-a1dcf65708c0"
      unitRef="usd">21028000</us-gaap:RestrictedCashAndCashEquivalents>
    <us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue
      contextRef="i8daff60be410426d8f7bd49343c1ec0c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM180My9mcmFnOjM1ZWJlNTMyYTAzYjQ3MzhiMzdiNGEzNWFjNmNlNzZkL3RhYmxlOjgzYzE1OWRlMDNkNjRjYzE4NWFmMmUzODVmNTk2MmY1L3RhYmxlcmFuZ2U6ODNjMTU5ZGUwM2Q2NGNjMTg1YWYyZTM4NWY1OTYyZjVfNy0xLTEtMS0xNzc3NQ_e862900b-883e-4d7e-aa91-68aa85fa46a5"
      unitRef="usd">75685000</us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue
      contextRef="ibc0c0c2b8dc04c5698ca0577a54b2e03_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM180My9mcmFnOjM1ZWJlNTMyYTAzYjQ3MzhiMzdiNGEzNWFjNmNlNzZkL3RhYmxlOjgzYzE1OWRlMDNkNjRjYzE4NWFmMmUzODVmNTk2MmY1L3RhYmxlcmFuZ2U6ODNjMTU5ZGUwM2Q2NGNjMTg1YWYyZTM4NWY1OTYyZjVfNy0zLTEtMS0xNzc3NQ_ce9c8095-1b0c-48a8-b531-74ef1253e0c9"
      unitRef="usd">14374000</us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCashAndInvestmentsCurrent
      contextRef="i8daff60be410426d8f7bd49343c1ec0c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM180My9mcmFnOjM1ZWJlNTMyYTAzYjQ3MzhiMzdiNGEzNWFjNmNlNzZkL3RhYmxlOjgzYzE1OWRlMDNkNjRjYzE4NWFmMmUzODVmNTk2MmY1L3RhYmxlcmFuZ2U6ODNjMTU5ZGUwM2Q2NGNjMTg1YWYyZTM4NWY1OTYyZjVfOC0xLTEtMS0xNzc3NQ_5b7f4023-896e-4357-993e-1df54930a12e"
      unitRef="usd">75685000</us-gaap:RestrictedCashAndInvestmentsCurrent>
    <us-gaap:RestrictedCashAndInvestmentsCurrent
      contextRef="ibc0c0c2b8dc04c5698ca0577a54b2e03_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM180My9mcmFnOjM1ZWJlNTMyYTAzYjQ3MzhiMzdiNGEzNWFjNmNlNzZkL3RhYmxlOjgzYzE1OWRlMDNkNjRjYzE4NWFmMmUzODVmNTk2MmY1L3RhYmxlcmFuZ2U6ODNjMTU5ZGUwM2Q2NGNjMTg1YWYyZTM4NWY1OTYyZjVfOC0zLTEtMS0xNzc3NQ_2a2576c0-859b-41f8-a394-2ce1ef531d12"
      unitRef="usd">14374000</us-gaap:RestrictedCashAndInvestmentsCurrent>
    <us-gaap:RestrictedCashAndCashEquivalentsNoncurrent
      contextRef="i8daff60be410426d8f7bd49343c1ec0c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM180My9mcmFnOjM1ZWJlNTMyYTAzYjQ3MzhiMzdiNGEzNWFjNmNlNzZkL3RhYmxlOjgzYzE1OWRlMDNkNjRjYzE4NWFmMmUzODVmNTk2MmY1L3RhYmxlcmFuZ2U6ODNjMTU5ZGUwM2Q2NGNjMTg1YWYyZTM4NWY1OTYyZjVfMTAtMS0xLTEtMTc3NzU_222be19c-b208-491c-b173-51723b0abc2c"
      unitRef="usd">12977000</us-gaap:RestrictedCashAndCashEquivalentsNoncurrent>
    <us-gaap:RestrictedCashAndCashEquivalentsNoncurrent
      contextRef="ibc0c0c2b8dc04c5698ca0577a54b2e03_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM180My9mcmFnOjM1ZWJlNTMyYTAzYjQ3MzhiMzdiNGEzNWFjNmNlNzZkL3RhYmxlOjgzYzE1OWRlMDNkNjRjYzE4NWFmMmUzODVmNTk2MmY1L3RhYmxlcmFuZ2U6ODNjMTU5ZGUwM2Q2NGNjMTg1YWYyZTM4NWY1OTYyZjVfMTAtMy0xLTEtMTc3NzU_06950652-354c-44bc-89f7-d5b24f095ee9"
      unitRef="usd">6654000</us-gaap:RestrictedCashAndCashEquivalentsNoncurrent>
    <us-gaap:RestrictedCashAndInvestmentsNoncurrent
      contextRef="i8daff60be410426d8f7bd49343c1ec0c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM180My9mcmFnOjM1ZWJlNTMyYTAzYjQ3MzhiMzdiNGEzNWFjNmNlNzZkL3RhYmxlOjgzYzE1OWRlMDNkNjRjYzE4NWFmMmUzODVmNTk2MmY1L3RhYmxlcmFuZ2U6ODNjMTU5ZGUwM2Q2NGNjMTg1YWYyZTM4NWY1OTYyZjVfMTEtMS0xLTEtMTc3NzU_bf8df12c-e4a6-4ec5-89b6-740e4290ec60"
      unitRef="usd">12977000</us-gaap:RestrictedCashAndInvestmentsNoncurrent>
    <us-gaap:RestrictedCashAndInvestmentsNoncurrent
      contextRef="ibc0c0c2b8dc04c5698ca0577a54b2e03_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM180My9mcmFnOjM1ZWJlNTMyYTAzYjQ3MzhiMzdiNGEzNWFjNmNlNzZkL3RhYmxlOjgzYzE1OWRlMDNkNjRjYzE4NWFmMmUzODVmNTk2MmY1L3RhYmxlcmFuZ2U6ODNjMTU5ZGUwM2Q2NGNjMTg1YWYyZTM4NWY1OTYyZjVfMTEtMy0xLTEtMTc3NzU_a3921f95-aab5-4ef7-8eb4-bf54b688882a"
      unitRef="usd">6654000</us-gaap:RestrictedCashAndInvestmentsNoncurrent>
    <evh:DisposalGroupIncludingDiscontinuedOperationRestrictedInvestmentsNoncurrent
      contextRef="i98364cf4ba3e41af868d701b4c668283_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM180My9mcmFnOjM1ZWJlNTMyYTAzYjQ3MzhiMzdiNGEzNWFjNmNlNzZkL3RleHRyZWdpb246MzVlYmU1MzJhMDNiNDczOGIzN2I0YTM1YWM2Y2U3NmRfMzY2OA_63ea49a7-2067-4824-9096-fce9ac7c9f5c"
      unitRef="usd">600000</evh:DisposalGroupIncludingDiscontinuedOperationRestrictedInvestmentsNoncurrent>
    <evh:DisposalGroupIncludingDiscontinuedOperationRestrictedCashCurrent
      contextRef="i98364cf4ba3e41af868d701b4c668283_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM180My9mcmFnOjM1ZWJlNTMyYTAzYjQ3MzhiMzdiNGEzNWFjNmNlNzZkL3RleHRyZWdpb246MzVlYmU1MzJhMDNiNDczOGIzN2I0YTM1YWM2Y2U3NmRfMzcxMw_9dcc1748-6652-4903-8f39-c29ece9cbc15"
      unitRef="usd">100000</evh:DisposalGroupIncludingDiscontinuedOperationRestrictedCashCurrent>
    <us-gaap:RestrictedCashAndCashEquivalents
      contextRef="id8e4ad0aaaf14d2e8309a07fe17aa411_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM180My9mcmFnOjM1ZWJlNTMyYTAzYjQ3MzhiMzdiNGEzNWFjNmNlNzZkL3RleHRyZWdpb246MzVlYmU1MzJhMDNiNDczOGIzN2I0YTM1YWM2Y2U3NmRfNDEzMg_f9c63c32-0905-411e-89f4-537783525aac"
      unitRef="usd">11700000</us-gaap:RestrictedCashAndCashEquivalents>
    <us-gaap:RestrictedCashAndCashEquivalents
      contextRef="i2a39d28f60a44d6bb41fe546afc858b2_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM180My9mcmFnOjM1ZWJlNTMyYTAzYjQ3MzhiMzdiNGEzNWFjNmNlNzZkL3RleHRyZWdpb246MzVlYmU1MzJhMDNiNDczOGIzN2I0YTM1YWM2Y2U3NmRfNDEzOQ_4782f41b-88f4-4af1-b767-48af2fdfe277"
      unitRef="usd">4700000</us-gaap:RestrictedCashAndCashEquivalents>
    <evh:CashAndCashEquivalentsAtCarryingValueExcludingDiscontinuedOperations
      contextRef="i8daff60be410426d8f7bd49343c1ec0c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM180My9mcmFnOjM1ZWJlNTMyYTAzYjQ3MzhiMzdiNGEzNWFjNmNlNzZkL3RhYmxlOjVmZjFiNzM5NjAzNzQ5NmZiYjVmZGU2YWI2ZmY0YTM4L3RhYmxlcmFuZ2U6NWZmMWI3Mzk2MDM3NDk2ZmJiNWZkZTZhYjZmZjRhMzhfMi0xLTEtMS0xNzc3NQ_e543631e-625f-470c-b1d5-0a5c6b9ffd61"
      unitRef="usd">266280000</evh:CashAndCashEquivalentsAtCarryingValueExcludingDiscontinuedOperations>
    <evh:CashAndCashEquivalentsAtCarryingValueExcludingDiscontinuedOperations
      contextRef="ibc0c0c2b8dc04c5698ca0577a54b2e03_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM180My9mcmFnOjM1ZWJlNTMyYTAzYjQ3MzhiMzdiNGEzNWFjNmNlNzZkL3RhYmxlOjVmZjFiNzM5NjAzNzQ5NmZiYjVmZGU2YWI2ZmY0YTM4L3RhYmxlcmFuZ2U6NWZmMWI3Mzk2MDM3NDk2ZmJiNWZkZTZhYjZmZjRhMzhfMi0zLTEtMS0xNzc3NQ_36ebdfef-0850-418c-8f2a-75f62fb682fb"
      unitRef="usd">340490000</evh:CashAndCashEquivalentsAtCarryingValueExcludingDiscontinuedOperations>
    <us-gaap:RestrictedCashAndInvestments
      contextRef="i8daff60be410426d8f7bd49343c1ec0c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM180My9mcmFnOjM1ZWJlNTMyYTAzYjQ3MzhiMzdiNGEzNWFjNmNlNzZkL3RhYmxlOjVmZjFiNzM5NjAzNzQ5NmZiYjVmZGU2YWI2ZmY0YTM4L3RhYmxlcmFuZ2U6NWZmMWI3Mzk2MDM3NDk2ZmJiNWZkZTZhYjZmZjRhMzhfMy0xLTEtMS0xNzc3NQ_457391b8-0225-4315-819d-7cca30db68f9"
      unitRef="usd">88662000</us-gaap:RestrictedCashAndInvestments>
    <us-gaap:RestrictedCashAndInvestments
      contextRef="ibc0c0c2b8dc04c5698ca0577a54b2e03_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM180My9mcmFnOjM1ZWJlNTMyYTAzYjQ3MzhiMzdiNGEzNWFjNmNlNzZkL3RhYmxlOjVmZjFiNzM5NjAzNzQ5NmZiYjVmZGU2YWI2ZmY0YTM4L3RhYmxlcmFuZ2U6NWZmMWI3Mzk2MDM3NDk2ZmJiNWZkZTZhYjZmZjRhMzhfMy0zLTEtMS0xNzc3NQ_fcbe51ce-7276-428d-9e0b-2dafb1c72b22"
      unitRef="usd">21707000</us-gaap:RestrictedCashAndInvestments>
    <us-gaap:RestrictedInvestments
      contextRef="i8daff60be410426d8f7bd49343c1ec0c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM180My9mcmFnOjM1ZWJlNTMyYTAzYjQ3MzhiMzdiNGEzNWFjNmNlNzZkL3RhYmxlOjVmZjFiNzM5NjAzNzQ5NmZiYjVmZGU2YWI2ZmY0YTM4L3RhYmxlcmFuZ2U6NWZmMWI3Mzk2MDM3NDk2ZmJiNWZkZTZhYjZmZjRhMzhfNC0xLTEtMS0xNzc3NQ_98d77601-4ad0-4c46-b3ef-0938bcf0cc7b"
      unitRef="usd">0</us-gaap:RestrictedInvestments>
    <us-gaap:RestrictedInvestments
      contextRef="ibc0c0c2b8dc04c5698ca0577a54b2e03_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM180My9mcmFnOjM1ZWJlNTMyYTAzYjQ3MzhiMzdiNGEzNWFjNmNlNzZkL3RhYmxlOjVmZjFiNzM5NjAzNzQ5NmZiYjVmZGU2YWI2ZmY0YTM4L3RhYmxlcmFuZ2U6NWZmMWI3Mzk2MDM3NDk2ZmJiNWZkZTZhYjZmZjRhMzhfNC0zLTEtMS0xNzc3NQ_caa0d8d9-5677-4cab-b95e-862fcda05712"
      unitRef="usd">616000</us-gaap:RestrictedInvestments>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i8daff60be410426d8f7bd49343c1ec0c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM180My9mcmFnOjM1ZWJlNTMyYTAzYjQ3MzhiMzdiNGEzNWFjNmNlNzZkL3RhYmxlOjVmZjFiNzM5NjAzNzQ5NmZiYjVmZGU2YWI2ZmY0YTM4L3RhYmxlcmFuZ2U6NWZmMWI3Mzk2MDM3NDk2ZmJiNWZkZTZhYjZmZjRhMzhfNS0xLTEtMS0xNzc3NQ_c3287692-dacc-4544-b15c-bc9b9a0803e3"
      unitRef="usd">354942000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="ibc0c0c2b8dc04c5698ca0577a54b2e03_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM180My9mcmFnOjM1ZWJlNTMyYTAzYjQ3MzhiMzdiNGEzNWFjNmNlNzZkL3RhYmxlOjVmZjFiNzM5NjAzNzQ5NmZiYjVmZGU2YWI2ZmY0YTM4L3RhYmxlcmFuZ2U6NWZmMWI3Mzk2MDM3NDk2ZmJiNWZkZTZhYjZmZjRhMzhfNS0zLTEtMS0xNzc3NQ_d826fd2d-b0b8-48cc-a16f-35f524ae3b3a"
      unitRef="usd">361581000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy
      contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM180My9mcmFnOjM1ZWJlNTMyYTAzYjQ3MzhiMzdiNGEzNWFjNmNlNzZkL3RleHRyZWdpb246MzVlYmU1MzJhMDNiNDczOGIzN2I0YTM1YWM2Y2U3NmRfMzI5ODUzNDkyNzIyNA_d0245fa4-b636-442b-afd5-d6c20a5bcc6d">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Accounts Receivable and Allowances&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accounts receivable are recorded and carried at the original invoiced amount less an allowance for any potential uncollectible amounts. We make estimates for the allowance for doubtful accounts and allowance for unbilled receivables based upon our assessment of various factors, including historical experience, the age of the accounts receivable balances, credit quality of our customers, current economic conditions, and other factors that may affect our ability to collect from customers.&lt;/span&gt;&lt;/div&gt;</us-gaap:ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock
      contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM180My9mcmFnOjM1ZWJlNTMyYTAzYjQ3MzhiMzdiNGEzNWFjNmNlNzZkL3RleHRyZWdpb246MzVlYmU1MzJhMDNiNDczOGIzN2I0YTM1YWM2Y2U3NmRfMzI5ODUzNDkyNzIyNQ_2eff441d-02fd-451e-88c8-eaf14667b9ee">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Property and Equipment, Net&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property and equipment are carried at cost less accumulated depreciation and amortization. Depreciation and amortization of property and equipment are computed using the straight-line method over the shorter of the estimated useful lives of the assets or the lease term. The following summarizes the estimated useful lives by asset classification:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:63.066%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:34.040%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Computer hardware&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Computer software&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1 year&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Furniture and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3 - 7 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Internal-use software development costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Shorter of useful life or remaining lease term&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;When an item is sold or retired, the cost and related accumulated depreciation or amortization is eliminated and the resulting gain or loss, if any, is recorded in gain (loss) on disposal of assets and consolidation on our consolidated statements of operations and comprehensive income (loss).&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We periodically review the carrying value of our long-lived assets, including property and equipment, for impairment whenever events or circumstances indicate that the carrying amount of such assets may not be fully recoverable. For long-lived assets to be held and used, impairments are recognized when the carrying amount of a long-lived asset group is not recoverable and exceeds fair value. The carrying amount of a long-lived asset group is not recoverable if it exceeds the sum of the undiscounted cash flows expected to result from the use and eventual disposition of the asset group. An impairment loss is measured as the amount by which the carrying amount of a long-lived asset group exceeds its fair value.&lt;/span&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock
      contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM180My9mcmFnOjM1ZWJlNTMyYTAzYjQ3MzhiMzdiNGEzNWFjNmNlNzZkL3RleHRyZWdpb246MzVlYmU1MzJhMDNiNDczOGIzN2I0YTM1YWM2Y2U3NmRfMzI5ODUzNDkyNzIyNg_09c7d2f1-b2d5-4467-96bc-103e7017b4d1">The following summarizes the estimated useful lives by asset classification:&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:63.066%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:34.040%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Computer hardware&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Computer software&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1 year&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Furniture and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3 - 7 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Internal-use software development costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Shorter of useful life or remaining lease term&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following summarizes our property and equipment (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:408.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:54.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:67.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Computer hardware&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,970&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,866&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Furniture and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,581&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,559&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Internal-use software development costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;159,587&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;137,085&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,325&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,586&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total property and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;200,463&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;175,096&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accumulated depreciation and amortization expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(119,098)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(88,856)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total property and equipment, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;81,365&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;86,240&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="if8e7fd6ca1724c74bd0f4e3ca2947419_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM180My9mcmFnOjM1ZWJlNTMyYTAzYjQ3MzhiMzdiNGEzNWFjNmNlNzZkL3RhYmxlOmRiYTVlMDFlNzIxNDRkNWU4ZGVkMTk5ODhiYjU2OWMyL3RhYmxlcmFuZ2U6ZGJhNWUwMWU3MjE0NGQ1ZThkZWQxOTk4OGJiNTY5YzJfMC0yLTEtMS0xOTkxNQ_6d3b409c-6055-40d2-a72a-0c2a5175925f">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="i703e3ae1f15f4420b40ff930efbc9f87_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM180My9mcmFnOjM1ZWJlNTMyYTAzYjQ3MzhiMzdiNGEzNWFjNmNlNzZkL3RhYmxlOmRiYTVlMDFlNzIxNDRkNWU4ZGVkMTk5ODhiYjU2OWMyL3RhYmxlcmFuZ2U6ZGJhNWUwMWU3MjE0NGQ1ZThkZWQxOTk4OGJiNTY5YzJfMS0yLTEtMS0xOTkxNQ_9a5879bd-bb18-4bbc-97e8-bf95ef090cba">P1Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="ibc96172fcef14618a2c513b85e88be97_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM180My9mcmFnOjM1ZWJlNTMyYTAzYjQ3MzhiMzdiNGEzNWFjNmNlNzZkL3RhYmxlOmRiYTVlMDFlNzIxNDRkNWU4ZGVkMTk5ODhiYjU2OWMyL3RhYmxlcmFuZ2U6ZGJhNWUwMWU3MjE0NGQ1ZThkZWQxOTk4OGJiNTY5YzJfMi0yLTEtMS0xOTkxNS90ZXh0cmVnaW9uOjBkMDQwM2ZlZjQ2YTQ2MzZiYjhlNDVkYTljMjZiY2YzXzIxOTkwMjMyNTU1Njg_28bbe26f-e125-4ad4-a2eb-e5ae50634313">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="i53d4b22f661d41dbb61ff5dcf8f75f50_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM180My9mcmFnOjM1ZWJlNTMyYTAzYjQ3MzhiMzdiNGEzNWFjNmNlNzZkL3RhYmxlOmRiYTVlMDFlNzIxNDRkNWU4ZGVkMTk5ODhiYjU2OWMyL3RhYmxlcmFuZ2U6ZGJhNWUwMWU3MjE0NGQ1ZThkZWQxOTk4OGJiNTY5YzJfMi0yLTEtMS0xOTkxNS90ZXh0cmVnaW9uOjBkMDQwM2ZlZjQ2YTQ2MzZiYjhlNDVkYTljMjZiY2YzXzIxOTkwMjMyNTU1NzI_125668fa-060d-4dc9-9987-546e3f202010">P7Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="ia186bface90a4c4098c96c8567d34124_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM180My9mcmFnOjM1ZWJlNTMyYTAzYjQ3MzhiMzdiNGEzNWFjNmNlNzZkL3RhYmxlOmRiYTVlMDFlNzIxNDRkNWU4ZGVkMTk5ODhiYjU2OWMyL3RhYmxlcmFuZ2U6ZGJhNWUwMWU3MjE0NGQ1ZThkZWQxOTk4OGJiNTY5YzJfMy0yLTEtMS0xOTkxNQ_5b4bfbb4-d4ec-4f13-a2b3-6c8befb9f330">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:InternalUseSoftwarePolicy
      contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM180My9mcmFnOjM1ZWJlNTMyYTAzYjQ3MzhiMzdiNGEzNWFjNmNlNzZkL3RleHRyZWdpb246MzVlYmU1MzJhMDNiNDczOGIzN2I0YTM1YWM2Y2U3NmRfMzI5ODUzNDkyNzIyNw_64b720ae-b587-4045-8809-ef3c8614f21b">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Software Development Costs&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company capitalizes the cost of developing internal-use software, consisting primarily of personnel and related expenses (including stock-based compensation and employee taxes and benefits) for employees and third parties who devote time to their respective projects. Internal-use software costs are capitalized during the application development stage &#x2013; when the research stage is complete and management has committed to a project to develop software that will be used for its intended purpose. Any costs incurred during subsequent efforts to significantly upgrade and enhance the functionality of the software are also capitalized. Capitalized software costs are included in property and equipment, net on our consolidated balance sheets. Amortization of internal-use software costs are recorded on a straight-line basis over their estimated useful life and begin once the project is substantially complete and the software is ready for its intended purpose.&lt;/span&gt;&lt;/div&gt;</us-gaap:InternalUseSoftwarePolicy>
    <us-gaap:ResearchAndDevelopmentExpensePolicy
      contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM180My9mcmFnOjM1ZWJlNTMyYTAzYjQ3MzhiMzdiNGEzNWFjNmNlNzZkL3RleHRyZWdpb246MzVlYmU1MzJhMDNiNDczOGIzN2I0YTM1YWM2Y2U3NmRfMzI5ODUzNDkyNzIyOA_5104750a-44f9-4dfc-a87f-42a0341ce72d">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Research and Development Costs&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Research and development costs consist primarily of personnel and related expenses (including stock-based compensation and employee taxes and benefits) for employees engaged in research and development activities as well as third-party fees. All such costs are expensed as incurred. We focus our research and development efforts on activities that support our technology infrastructure, clinical program development, data analytics and network development capabilities. Research and development costs are recorded within selling, general and administrative expenses on our consolidated statements of operations and comprehensive income (loss) and were $15.5&#160;million, $15.1&#160;million and $19.8&#160;million for the years ended December 31, 2021, 2020 and 2019, respectively.&lt;/span&gt;&lt;/div&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM180My9mcmFnOjM1ZWJlNTMyYTAzYjQ3MzhiMzdiNGEzNWFjNmNlNzZkL3RleHRyZWdpb246MzVlYmU1MzJhMDNiNDczOGIzN2I0YTM1YWM2Y2U3NmRfMTA5OTUxMTY1NzU1Nw_1c01de54-e546-42c2-8a09-eef9a6486985"
      unitRef="usd">15500000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i12a6d1161de54547bd29f8efccd4c9b0_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM180My9mcmFnOjM1ZWJlNTMyYTAzYjQ3MzhiMzdiNGEzNWFjNmNlNzZkL3RleHRyZWdpb246MzVlYmU1MzJhMDNiNDczOGIzN2I0YTM1YWM2Y2U3NmRfMTA5OTUxMTY1NzUyNw_753d9ca8-60cf-4c45-baab-28b5afb34634"
      unitRef="usd">15100000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i3e21049ffc224cacb8134d73c9bb5b38_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM180My9mcmFnOjM1ZWJlNTMyYTAzYjQ3MzhiMzdiNGEzNWFjNmNlNzZkL3RleHRyZWdpb246MzVlYmU1MzJhMDNiNDczOGIzN2I0YTM1YWM2Y2U3NmRfMTA5OTUxMTY1NzU0Mg_964905bf-d0d8-4329-82b5-63f3f974ff22"
      unitRef="usd">19800000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:BusinessCombinationsPolicy
      contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM180My9mcmFnOjM1ZWJlNTMyYTAzYjQ3MzhiMzdiNGEzNWFjNmNlNzZkL3RleHRyZWdpb246MzVlYmU1MzJhMDNiNDczOGIzN2I0YTM1YWM2Y2U3NmRfMTU3MTI_2678520d-5511-4c93-ba73-e11e12a4388a">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Business Combinations&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Companies acquired during each reporting period are reflected in the results of the Company effective from their respective dates of acquisition through the end of the reporting period. The Company allocates the fair value of purchase consideration to the assets acquired and liabilities assumed based on their estimated fair values at the acquisition date. Our estimates of fair value are based upon assumptions believed to be reasonable, but which are inherently uncertain and unpredictable and, as a result, actual results may differ &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;from estimates. Critical estimates used to value certain identifiable assets include, but are not limited to, expected long-term revenues, future expected operating expenses, cost of capital and appropriate discount rates. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The excess of the fair value of purchase consideration over the fair value of the assets acquired and liabilities assumed in the acquired entity is recorded as goodwill. Goodwill is assigned to the reporting unit that benefits from the synergies arising from the business combination. If the Company obtains new information about facts and circumstances that existed as of the acquisition date during the measurement period, which may be up to one year from the acquisition date, the Company may record adjustments to the assets acquired and liabilities assumed, with the corresponding offset to goodwill. Upon the conclusion of the measurement period or final determination of the values of assets acquired or liabilities assumed, whichever comes first, any subsequent adjustments are recorded on the Company's consolidated statements of operations and comprehensive income (loss). &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For contingent consideration recorded as a liability, the Company initially measures the amount at fair value as of the acquisition date and adjusts the liability, if needed, to fair value at each reporting period. Changes in the fair value of contingent consideration, other than measurement period adjustments, are recognized as operating income or expense. Acquisition-related expenses are recognized separately from the business combination and are expensed as incurred.&lt;/span&gt;&lt;/div&gt;</us-gaap:BusinessCombinationsPolicy>
    <us-gaap:EquityMethodInvestmentsPolicy
      contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM180My9mcmFnOjM1ZWJlNTMyYTAzYjQ3MzhiMzdiNGEzNWFjNmNlNzZkL3RleHRyZWdpb246MzVlYmU1MzJhMDNiNDczOGIzN2I0YTM1YWM2Y2U3NmRfMzI5ODUzNDkyNzIyOQ_25b4dfe5-e591-47d4-8d13-94fedf64c564">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Equity Method Investments&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For entities that are not consolidated, but where the Company has significant influence over the operating or financial decisions of the entity, the Company accounts for the investment under the equity method of accounting. In accordance with the equity method of accounting, the Company will recognize its share of earnings or losses of the investee in the period in which they are reported by the investee. The Company also considers whether there are any indicators of other-than-temporary impairment of its investments accounted for under the equity method. These investments are included in investments in equity method investees on the consolidated balance sheets with income or loss included in gain (loss) from equity method investees on the consolidated statements of operations and comprehensive income (loss).&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Impairment of Equity Method Investments&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company considers certain factors to determine if there is a decrease in its investment fair value for its equity method investments that is other than temporary. The equity method investments will be written down to fair value if there is evidence of a loss in value which is other-than-temporary. The Company may estimate the fair value of its equity method investments by considering recent investee equity transactions, discounted cash flow analysis and recent operating results. If the fair value of the investment is below the carrying amount, management considers several factors when determining whether other-than-temporary impairment has occurred. The estimation of fair value and whether other-than-temporary impairment has occurred requires the application of significant judgment and future results may vary from current assumptions. Refer to Note 17 for additional discussion regarding impairments on equity method investments.&lt;/span&gt;&lt;/div&gt;</us-gaap:EquityMethodInvestmentsPolicy>
    <us-gaap:GoodwillAndIntangibleAssetsGoodwillPolicy
      contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM180My9mcmFnOjM1ZWJlNTMyYTAzYjQ3MzhiMzdiNGEzNWFjNmNlNzZkL3RleHRyZWdpb246MzVlYmU1MzJhMDNiNDczOGIzN2I0YTM1YWM2Y2U3NmRfMTU3MjI_aef6fdfe-96b4-4d8b-bd92-8fcfc41a42f2">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Goodwill&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We recognize the excess of the purchase price, plus the fair value of any non-controlling interests in the acquiree, over the fair value of identifiable net assets acquired as goodwill. Goodwill is not amortized, but is reviewed at least annually for indications of impairment, with consideration given to financial performance and other relevant factors. We perform impairment tests of goodwill at a reporting unit level. Following the sale of True Health, the Company has three reporting units and our annual goodwill impairment review occurs during the fourth quarter of each year. We perform impairment tests between annual tests if an event occurs, or circumstances change, that we believe would more likely than not reduce the fair value of a reporting unit below its carrying amount. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our goodwill impairment analysis first assesses qualitative factors to determine whether events or circumstances existed that would lead the Company to conclude it is more likely than not that the fair value of a reporting unit is below its carrying amount. If the Company determines that it is more likely than not that the fair value of a reporting unit is below the carrying amount, a quantitative goodwill assessment is required. In the quantitative evaluation, the fair value of the relevant reporting unit is determined and compared to the carrying value. If the fair value is greater than the carrying value, then the carrying value is deemed to be recoverable and no further action is required. If the fair value estimate is less than the carrying value, goodwill is considered impaired for the amount by which the carrying amount exceeds the reporting unit&#x2019;s fair value and a charge is reported in goodwill impairment on our consolidated statements of operations and comprehensive income (loss). See Note 9 for additional discussion regarding the goodwill impairment tests conducted during 2021 and 2020.&lt;/span&gt;&lt;/div&gt;</us-gaap:GoodwillAndIntangibleAssetsGoodwillPolicy>
    <us-gaap:NumberOfReportingUnits
      contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM180My9mcmFnOjM1ZWJlNTMyYTAzYjQ3MzhiMzdiNGEzNWFjNmNlNzZkL3RleHRyZWdpb246MzVlYmU1MzJhMDNiNDczOGIzN2I0YTM1YWM2Y2U3NmRfODA0OQ_369d52b2-e96e-40fb-b338-7a284aa52c23"
      unitRef="unit">3</us-gaap:NumberOfReportingUnits>
    <us-gaap:IntangibleAssetsFiniteLivedPolicy
      contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM180My9mcmFnOjM1ZWJlNTMyYTAzYjQ3MzhiMzdiNGEzNWFjNmNlNzZkL3RleHRyZWdpb246MzVlYmU1MzJhMDNiNDczOGIzN2I0YTM1YWM2Y2U3NmRfMTU3NjE_f429d292-7193-4d9e-8668-9537eaef5469">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Intangible Assets, Net &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Identified intangible assets are recorded at their estimated fair values at the date of acquisition and are amortized over their respective estimated useful lives using a method of amortization that reflects the pattern in which the economic benefits of the intangible assets are used. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following summarizes the estimated useful lives by asset classification:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:438.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:97.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate trade name&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10 - 20 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Customer relationships&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10 - 25 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Technology&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Provider network contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3 - 5 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Intangible assets are reviewed for impairment if circumstances indicate the Company may not be able to recover the asset&#x2019;s carrying value. The Company evaluates recoverability by determining whether the undiscounted cash flows expected to result from the use and eventual disposition of that asset or group exceed the carrying value at the evaluation date. If the undiscounted cash flows are not sufficient to cover the carrying value, the Company measures an impairment loss as the excess of the carrying amount of the long-lived asset or group over its fair value. See Note 9 for additional discussion regarding our intangible assets.&lt;/span&gt;&lt;/div&gt;</us-gaap:IntangibleAssetsFiniteLivedPolicy>
    <us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock
      contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM180My9mcmFnOjM1ZWJlNTMyYTAzYjQ3MzhiMzdiNGEzNWFjNmNlNzZkL3RleHRyZWdpb246MzVlYmU1MzJhMDNiNDczOGIzN2I0YTM1YWM2Y2U3NmRfMTU3Mjg_9ee25e6e-93c9-4f2d-bf08-a149ddda1f92">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following summarizes the estimated useful lives by asset classification:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:438.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:97.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate trade name&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10 - 20 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Customer relationships&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10 - 25 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Technology&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Provider network contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3 - 5 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Details of our intangible assets (in thousands, except weighted-average useful lives) as of December&#160;31, 2021 and December&#160;31, 2020  are presented below:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:72.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:54.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:48.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:63.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:46.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:54.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:48.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:63.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:45.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:44pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted- Average Remaining Useful Life&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Gross Carrying Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Accumulated Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Net Carrying Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted- Average Remaining Useful Life&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Gross Carrying Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Accumulated Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Net Carrying Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:24pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate trade name&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12.4&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,800&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,693&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,107&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13.2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,300&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,271&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,029&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:24pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Customer relationships &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14.9&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;311,019&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;72,697&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;238,322&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16.2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;278,519&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;57,716&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;220,803&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Technology&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.0&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;87,922&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;73,378&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,544&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.8&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;82,922&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;63,507&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,415&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:24pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Below market lease, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,218&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;950&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;268&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,118&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;648&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;470&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:35pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Provider network contracts &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,417&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,874&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,543&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.9&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,175&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,900&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,275&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:35pt"&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total intangible assets, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;442,376&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;162,592&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;279,784&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;398,034&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;133,042&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;264,992&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt"&gt;Amounts exclude $2.2&#160;million and $0.9&#160;million of customer relationships and provider network contracts, respectively, net of accumulated amortization, with weighted average remaining useful lives of 15 years and 10 months reclassified to discontinued operations as of December&#160;31, 2020.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="ibff83f3576fa462088fb611595ae2107_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM180My9mcmFnOjM1ZWJlNTMyYTAzYjQ3MzhiMzdiNGEzNWFjNmNlNzZkL3RhYmxlOmNiNDQzOTY5NjgzYzQ4NThhNDJmYjg0MTI4ZTViMTE2L3RhYmxlcmFuZ2U6Y2I0NDM5Njk2ODNjNDg1OGE0MmZiODQxMjhlNWIxMTZfMC0xLTEtMS0xNzc3NS90ZXh0cmVnaW9uOjMwMWQwMGQxYTQzMDQwMDQ4ZjM0MmNkZWZjYWE3Yjc3XzQ_ffb16074-a85f-4f3f-93a1-de9e296bdf07">P10Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="ie3bf7bed53b145e699f90d4132648c21_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM180My9mcmFnOjM1ZWJlNTMyYTAzYjQ3MzhiMzdiNGEzNWFjNmNlNzZkL3RhYmxlOmNiNDQzOTY5NjgzYzQ4NThhNDJmYjg0MTI4ZTViMTE2L3RhYmxlcmFuZ2U6Y2I0NDM5Njk2ODNjNDg1OGE0MmZiODQxMjhlNWIxMTZfMC0xLTEtMS0xNzc3NS90ZXh0cmVnaW9uOjMwMWQwMGQxYTQzMDQwMDQ4ZjM0MmNkZWZjYWE3Yjc3Xzk_ffc6009b-8a5b-4d6d-a494-9f7eaa84de9d">P20Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="i3ca5e8fff37648578ddcb5915d42bd23_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM180My9mcmFnOjM1ZWJlNTMyYTAzYjQ3MzhiMzdiNGEzNWFjNmNlNzZkL3RhYmxlOmNiNDQzOTY5NjgzYzQ4NThhNDJmYjg0MTI4ZTViMTE2L3RhYmxlcmFuZ2U6Y2I0NDM5Njk2ODNjNDg1OGE0MmZiODQxMjhlNWIxMTZfMS0xLTEtMS0xNzc3NS90ZXh0cmVnaW9uOjk1YzJlMzVlNmFiYzRhN2I4OWE5OTZiMTJmZjEzZGEyXzQ_23e9e49e-5186-467d-b55e-a311b9a92e35">P10Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="i4cff67909d644529824bdb1faef1b019_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM180My9mcmFnOjM1ZWJlNTMyYTAzYjQ3MzhiMzdiNGEzNWFjNmNlNzZkL3RhYmxlOmNiNDQzOTY5NjgzYzQ4NThhNDJmYjg0MTI4ZTViMTE2L3RhYmxlcmFuZ2U6Y2I0NDM5Njk2ODNjNDg1OGE0MmZiODQxMjhlNWIxMTZfMS0xLTEtMS0xNzc3NS90ZXh0cmVnaW9uOjk1YzJlMzVlNmFiYzRhN2I4OWE5OTZiMTJmZjEzZGEyXzk_7a6d5078-ec48-4803-a08a-43e5d7caff77">P25Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="i701391050b2e43d082d405d3d16746d2_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM180My9mcmFnOjM1ZWJlNTMyYTAzYjQ3MzhiMzdiNGEzNWFjNmNlNzZkL3RhYmxlOmNiNDQzOTY5NjgzYzQ4NThhNDJmYjg0MTI4ZTViMTE2L3RhYmxlcmFuZ2U6Y2I0NDM5Njk2ODNjNDg1OGE0MmZiODQxMjhlNWIxMTZfMi0xLTEtMS0xNzc3NQ_2f86b2be-0027-4fb4-ba98-bb258fd6f0da">P5Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="i6d3cdc666422461398b727dbf8a5d16e_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM180My9mcmFnOjM1ZWJlNTMyYTAzYjQ3MzhiMzdiNGEzNWFjNmNlNzZkL3RhYmxlOmNiNDQzOTY5NjgzYzQ4NThhNDJmYjg0MTI4ZTViMTE2L3RhYmxlcmFuZ2U6Y2I0NDM5Njk2ODNjNDg1OGE0MmZiODQxMjhlNWIxMTZfMy0xLTEtMS0xNzc3NS90ZXh0cmVnaW9uOjNiMjEzMTYwNWQyNjQ0NTNiM2ZkZWMzY2Q4NGE0NGJmXzQ_1834ad11-72b1-4a35-8632-97b5b45a3951">P3Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="i80595e56a7a74f699957bf0f9a4173ce_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM180My9mcmFnOjM1ZWJlNTMyYTAzYjQ3MzhiMzdiNGEzNWFjNmNlNzZkL3RhYmxlOmNiNDQzOTY5NjgzYzQ4NThhNDJmYjg0MTI4ZTViMTE2L3RhYmxlcmFuZ2U6Y2I0NDM5Njk2ODNjNDg1OGE0MmZiODQxMjhlNWIxMTZfMy0xLTEtMS0xNzc3NS90ZXh0cmVnaW9uOjNiMjEzMTYwNWQyNjQ0NTNiM2ZkZWMzY2Q4NGE0NGJmXzk_87d2a928-cf0e-4531-87d3-4e2baf17f7a7">P5Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:LiabilityReserveEstimatePolicy
      contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM180My9mcmFnOjM1ZWJlNTMyYTAzYjQ3MzhiMzdiNGEzNWFjNmNlNzZkL3RleHRyZWdpb246MzVlYmU1MzJhMDNiNDczOGIzN2I0YTM1YWM2Y2U3NmRfMTU3NzI_3199dda7-a656-4043-9fd2-388d217d151d">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Reserves for Claims and Performance-based Arrangements&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Reserves for claims and performance-based arrangements reflect estimates of payments under performance-based arrangements and the ultimate cost of claims that have been incurred but not reported, including expected development on reported claims, those that have been reported but not yet paid (reported claims in process) and other medical care expenses and services payable that are primarily composed of accruals for incentives and other amounts payable to health care professionals and facilities. The Company uses actuarial principles and assumptions that are consistently applied in each reporting period and recognizes the actuarial best estimate of the ultimate liability along with a margin for adverse deviation. This approach is consistent with actuarial standards of practice that the liabilities be adequate under moderately adverse conditions. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The process of estimating reserves involves a considerable degree of judgment by the Company and, as of any given date, is inherently uncertain. The methods for making such estimates and for establishing the resulting liability are continually reviewed and adjustments are reflected in current results of operations in the period in which they are identified as experience develops or new information becomes known. See Note 23 for additional discussion regarding our reserves for claims and performance-based arrangements.&lt;/span&gt;&lt;/div&gt;</us-gaap:LiabilityReserveEstimatePolicy>
    <evh:RightOfOffsetPolicyPolicyTextBlock
      contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM180My9mcmFnOjM1ZWJlNTMyYTAzYjQ3MzhiMzdiNGEzNWFjNmNlNzZkL3RleHRyZWdpb246MzVlYmU1MzJhMDNiNDczOGIzN2I0YTM1YWM2Y2U3NmRfMzg0ODI5MDc0MzYxOA_4c35f945-774d-4b38-b2a2-be1ff089ec6b">Right of OffsetCertain customer arrangements give the Company the legal right to net payment for amounts due from customers and claims payable.</evh:RightOfOffsetPolicyPolicyTextBlock>
    <evh:RightOfOffsetPercentageOfAccountsReceivableNettedAgainstClaimsPayable
      contextRef="i8daff60be410426d8f7bd49343c1ec0c_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM180My9mcmFnOjM1ZWJlNTMyYTAzYjQ3MzhiMzdiNGEzNWFjNmNlNzZkL3RleHRyZWdpb246MzVlYmU1MzJhMDNiNDczOGIzN2I0YTM1YWM2Y2U3NmRfMjc0ODc3OTExNjAyMg_9a3ab4fb-cbe2-4a22-8f0c-c70e665c54af"
      unitRef="number">0.42</evh:RightOfOffsetPercentageOfAccountsReceivableNettedAgainstClaimsPayable>
    <evh:RightOfOffsetPercentageOfAccountsReceivableNettedAgainstClaimsPayable
      contextRef="ibc0c0c2b8dc04c5698ca0577a54b2e03_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM180My9mcmFnOjM1ZWJlNTMyYTAzYjQ3MzhiMzdiNGEzNWFjNmNlNzZkL3RleHRyZWdpb246MzVlYmU1MzJhMDNiNDczOGIzN2I0YTM1YWM2Y2U3NmRfMjc0ODc3OTExNjAyNw_0f5f2fa4-0af4-4568-a856-01d55b4d2feb"
      unitRef="number">0</evh:RightOfOffsetPercentageOfAccountsReceivableNettedAgainstClaimsPayable>
    <evh:RightOfOffsetPercentageOfAccountsReceivableNetEligibleForNetBasisSettlement
      contextRef="i8daff60be410426d8f7bd49343c1ec0c_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM180My9mcmFnOjM1ZWJlNTMyYTAzYjQ3MzhiMzdiNGEzNWFjNmNlNzZkL3RleHRyZWdpb246MzVlYmU1MzJhMDNiNDczOGIzN2I0YTM1YWM2Y2U3NmRfMzg0ODI5MDc0MzYxNA_d0667495-3a79-4e7c-8490-5648a87418ee"
      unitRef="number">0.55</evh:RightOfOffsetPercentageOfAccountsReceivableNetEligibleForNetBasisSettlement>
    <us-gaap:DebtPolicyTextBlock
      contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM180My9mcmFnOjM1ZWJlNTMyYTAzYjQ3MzhiMzdiNGEzNWFjNmNlNzZkL3RleHRyZWdpb246MzVlYmU1MzJhMDNiNDczOGIzN2I0YTM1YWM2Y2U3NmRfMzI5ODUzNDkyNzIzMA_05421567-51fc-413f-9891-d847c5a069f3">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Long-term Debt&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Convertible notes and amounts borrowed under our credit agreement are carried at cost, net of debt discounts and issuance costs, as long-term debt on the consolidated balance sheets. The debt discounts and issuance costs are amortized to interest expense on the consolidated statements of operations and comprehensive income (loss) using the straight-line method over the contractual term of the note if that method is not materially different from the effective interest rate method. Cash interest payments are due either quarterly or semi-annually in arrears and we accrue interest expense monthly based on the annual coupon rate. See Note 10 for further discussion regarding our convertible notes and credit agreement.&lt;/span&gt;&lt;/div&gt;</us-gaap:DebtPolicyTextBlock>
    <us-gaap:LesseeLeasesPolicyTextBlock
      contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM180My9mcmFnOjM1ZWJlNTMyYTAzYjQ3MzhiMzdiNGEzNWFjNmNlNzZkL3RleHRyZWdpb246MzVlYmU1MzJhMDNiNDczOGIzN2I0YTM1YWM2Y2U3NmRfMTU3NDk_579805a1-24fa-4be6-a5c4-a877829d26c6">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Leases&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company enters into various office space, data center and equipment lease agreements in conducting its normal business operations. At the inception of any contract, the Company evaluates the agreement to determine whether the contract contains a lease. If the contract contains a lease, the Company then evaluates the term and whether the lease is an operating or finance lease. Most leases include one or more options to renew or may have a termination option. The Company determines whether these options are reasonably certain to be exercised at the inception of the lease. The rent expense is recognized on a straight-line basis in the consolidated statements of operations and comprehensive income (loss) over the terms of the respective leases. Leases with an initial term of 12 months or less are not recorded on the consolidated balance sheets.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As most of our leases do not provide an implicit rate, we use our incremental borrowing rate based on the information available at commencement date in determining the present value of lease payments. We use the implicit rate when readily determinable. Further, the Company treats all lease and non-lease components as a single combined lease component for all classes of underlying assets.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company also enters into sublease agreements for some of its leased office space. Rental income attributable to subleases is immaterial and is offset against rent expense over the terms of the respective leases.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Refer to Note 12 for additional lease disclosures.&lt;/span&gt;&lt;/div&gt;</us-gaap:LesseeLeasesPolicyTextBlock>
    <us-gaap:RevenueFromContractWithCustomerPolicyTextBlock
      contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM180My9mcmFnOjM1ZWJlNTMyYTAzYjQ3MzhiMzdiNGEzNWFjNmNlNzZkL3RleHRyZWdpb246MzVlYmU1MzJhMDNiNDczOGIzN2I0YTM1YWM2Y2U3NmRfMTU3ODM_64f13be4-2989-4748-af49-5666bfb45f3e">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Revenue Recognition&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We derive revenue from two sources: (1) transformation services and (2) platform and operations services. Transformation services consist of implementation services whereby we assist the customer in launching its population health or health plan programs, or implement certain platform and operations services. In certain cases, transformation services can also include revenue associated with our support of certain one-time wind-down activities for clients who are exiting a line of business or population. Platform and operations services generally include multi-year arrangements with customers to provide various population health, health plan operations, specialty care management and claims processing services on an ongoing basis, as well as transition or run-out services to customers receiving primarily TPA services. Revenue is recognized when control of the services is transferred to our customers.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We use the following 5-step model, outlined in Accounting Standards Codification (&#x201c;ASC&#x201d;) Topic 606, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Revenue from Contracts with Customers&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (&#x201c;ASC 606&#x201d;), to determine revenue recognition from our contracts with customers:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt; Identify the contract(s) with a customer&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt; Identify the performance obligations in the contract&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt; Determine the transaction price&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt; Allocate the transaction price to performance obligations&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt; Recognize revenue when (or as) the entity satisfies a performance obligation&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;See Note 6 for further discussion of our policies related to revenue recognition. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Cost of Revenue (Exclusive of Depreciation and Amortization)&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our cost of revenue includes direct expenses and shared resources that perform services in direct support of clients. Costs consist primarily of employee-related expenses (including compensation, benefits and stock-based compensation), expenses for TPA support and other services, as well as other professional fees. In certain cases, our cost of revenue also includes claims and capitation payments to providers and payments for pharmaceutical treatments and other health care expenditures through capitated arrangements.&lt;/span&gt;&lt;/div&gt;</us-gaap:RevenueFromContractWithCustomerPolicyTextBlock>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy
      contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM180My9mcmFnOjM1ZWJlNTMyYTAzYjQ3MzhiMzdiNGEzNWFjNmNlNzZkL3RleHRyZWdpb246MzVlYmU1MzJhMDNiNDczOGIzN2I0YTM1YWM2Y2U3NmRfMzI5ODUzNDkyNzIzMg_e85c8950-7fab-47ce-b91a-fa497083973a">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Stock-based Compensation&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company sponsors a stock-based incentive plan that provides for the issuance of stock-based awards to employees, vendors and non-employee directors of the Company or its consolidated subsidiaries. Our stock-based awards generally vest over a four-year period and stock options expire 10 years from the date of grant.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We expense the fair value of stock-based awards granted under our incentive compensation plans. Fair value of stock options is determined using a Black-Scholes options valuation methodology. The fair value of the awards is expensed over the performance or service period, which generally corresponds to the vesting period, on a straight-line basis and is recognized as an increase to additional paid-in capital. Stock-based compensation expense is reflected in cost of revenue and selling, general and administrative expenses in our consolidated statements of operations and comprehensive income (loss). Additionally, and if applicable, we capitalize personnel expenses attributable to the development of internal-use software, which include stock-based compensation costs. We recognize share-based award forfeitures as they occur.&lt;/span&gt;&lt;/div&gt;</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="i532d2c0bf63243e999d48341920b6775_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM180My9mcmFnOjM1ZWJlNTMyYTAzYjQ3MzhiMzdiNGEzNWFjNmNlNzZkL3RleHRyZWdpb246MzVlYmU1MzJhMDNiNDczOGIzN2I0YTM1YWM2Y2U3NmRfMzg0ODI5MDc0MTEzNA_d4494652-32d7-49d7-8853-12a923bc9643">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
      contextRef="i532d2c0bf63243e999d48341920b6775_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM180My9mcmFnOjM1ZWJlNTMyYTAzYjQ3MzhiMzdiNGEzNWFjNmNlNzZkL3RleHRyZWdpb246MzVlYmU1MzJhMDNiNDczOGIzN2I0YTM1YWM2Y2U3NmRfMzg0ODI5MDc0MTEzNg_5fd38458-7d35-4a5a-94f2-c0d7e5204f18">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:IncomeTaxPolicyTextBlock
      contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM180My9mcmFnOjM1ZWJlNTMyYTAzYjQ3MzhiMzdiNGEzNWFjNmNlNzZkL3RleHRyZWdpb246MzVlYmU1MzJhMDNiNDczOGIzN2I0YTM1YWM2Y2U3NmRfMzI5ODUzNDkyNzIzMw_3d57bda3-3d01-4962-98ad-036fb128a5c7">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Income Taxes&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Deferred income taxes are recognized, based on enacted rates, when assets and liabilities have different values for financial statement and tax reporting purposes. A valuation allowance is recorded to the extent required. Considerable judgment and the use of estimates are required in determining whether a valuation allowance is necessary and, if so, the amount of such valuation allowance. In evaluating the need for a valuation allowance, we consider many factors, including: the nature and character of the deferred tax assets and liabilities; taxable income in prior carryback years; future reversals of temporary differences; the length of time carryovers can be utilized; and any tax planning strategies we would employ to avoid a tax benefit from expiring unused.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We use a recognition threshold and a measurement attribute for the financial statement recognition and measurement of uncertain tax positions taken or expected to be taken in a tax return. For those benefits to be recognized, a tax position must be more-likely-than-not to be sustained upon examination by taxing authorities. We recognize interest and penalties accrued on any unrecognized tax exposures as a component of income tax expense, when applicable. As of December 31, 2021 and 2020, our identified balance of uncertain income tax positions would not have a material impact to the consolidated financial statements. We are subject to taxation in various jurisdictions in the U.S. and India and remain subject to examination by taxing jurisdictions for the year 2011 and all subsequent periods due to the availability of NOL carryforwards.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We are a holding company and our assets consist of our direct ownership in Evolent Health LLC, for which we are the managing member. Prior to the Class B unit exchanges on December 26, 2019, Evolent Health LLC was classified as a partnership for U.S. federal and applicable state and local income tax purposes and, as such, was not subject to U.S. federal, state and local income taxes. Taxable income or loss generated by Evolent Health LLC was allocated to holders of its units, including us, on a pro rata basis. Accordingly, we were subject to U.S. federal, state and local income taxes with respect to our allocable share of any taxable income of Evolent Health LLC. As a result of the 2019 Class B units exchanges, we became the sole owner of Evolent Health LLC and its entity classification changed from a partnership to an entity disregarded as separate from its owner for U.S. federal, state and local income tax purposes. Following the Class B units exchanges, any taxable income or loss generated by Evolent Health LLC is reportable and taxable only on the Company&#x2019;s federal, state and local income tax returns. Evolent Health LLC has direct ownership in corporate subsidiaries, which were subject to U.S. and foreign taxes with respect to their own operations during 2019.&lt;/span&gt;&lt;/div&gt;</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:EarningsPerSharePolicyTextBlock
      contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM180My9mcmFnOjM1ZWJlNTMyYTAzYjQ3MzhiMzdiNGEzNWFjNmNlNzZkL3RleHRyZWdpb246MzVlYmU1MzJhMDNiNDczOGIzN2I0YTM1YWM2Y2U3NmRfMzI5ODUzNDkyNzIzNA_fa83dabe-1371-4bee-8b53-be3658e204ea">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Earnings (Loss) per Share&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Basic earnings (loss) per share is computed by dividing net income (loss) available to Class A common shareholders by the weighted-average number of Class A common shares outstanding.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For periods of net income, and when the effects are not anti-dilutive, we calculate diluted earnings per share by dividing net income available to Class A common shareholders by the weighted average number of Class A common shares plus the weighted average number of Class A common shares assuming the conversion of our convertible notes, as well as the impact of all potential dilutive common shares, consisting primarily of common stock options and unvested restricted stock awards using the treasury stock method and our exchangeable Class B common stock. For periods of net loss, shares used in the diluted earnings (loss) per share calculation represent basic shares as using potentially dilutive shares would be anti-dilutive.&lt;/span&gt;&lt;/div&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:FairValueMeasurementPolicyPolicyTextBlock
      contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM180My9mcmFnOjM1ZWJlNTMyYTAzYjQ3MzhiMzdiNGEzNWFjNmNlNzZkL3RleHRyZWdpb246MzVlYmU1MzJhMDNiNDczOGIzN2I0YTM1YWM2Y2U3NmRfMzI5ODUzNDkyNzIzNQ_4d429f21-2f85-483e-be24-d34e1d2a4a83">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Fair Value Measurement&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Fair value is the price that would be received from the sale of an asset or paid to transfer a liability assuming an orderly transaction in the most advantageous market at the measurement date. Our consolidated balance sheets include various financial instruments (primarily cash not held in money-market funds, restricted cash, accounts receivable, accounts payable, accrued expenses and other liabilities) that are carried at cost and that approximate fair value.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;See Note 19 for further discussion regarding fair value measurement.&lt;/span&gt;&lt;/div&gt;Fair Value Measurement&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;GAAP defines fair value as the price that would be received from the sale of an asset or paid to transfer a liability (an exit price) assuming an orderly transaction in the most advantageous market at the measurement date. GAAP also establishes a hierarchical disclosure framework which prioritizes and ranks the level of observability of inputs used in measuring fair value. These tiers include:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:54pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Level 1 - inputs to the valuation methodology are quoted prices available in active markets for identical instruments as of the reporting date;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:54pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Level 2 - inputs to the valuation methodology are other than quoted prices in active markets, which are either directly or indirectly observable as of the reporting date and the fair value can be determined through the use of models or other valuation methodologies; and &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:54pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Level 3 - inputs to the valuation methodology are unobservable inputs in situations where there is little or no market activity for the asset or liability.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In certain cases, the inputs used to measure fair value may fall into different levels of the fair value hierarchy. In such cases, the level within the fair value hierarchy is based on the lowest level of input that is significant to the fair value measurement. Our assessment of the significance of a particular input to the fair value measurement in its entirety requires judgment and considers factors specific to the particular asset or liability being measured. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Nonrecurring Fair Value Measurements&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In addition to the assets and liabilities that are recorded at fair value on a recurring basis, the Company records certain assets and liabilities at fair value on a nonrecurring basis as required by GAAP. Generally, assets are recorded at fair value on a nonrecurring basis as a result of impairment charges. This includes assets and liabilities recorded in business combinations or asset acquisitions, goodwill, intangible assets, property, plant and equipment, held-to-maturity investments and equity method investments. While not carried at fair value on a recurring basis, these items are continually monitored for indicators of impairment that would indicate current carrying value is greater than fair value. In those situations, the assets are considered impaired and written down to current fair value. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Other Fair Value Disclosures&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The carrying amounts of cash and cash equivalents (those not held in a money market fund), restricted cash, receivables, prepaid expenses, accounts payable, accrued liabilities and accrued compensation approximate their fair values because of the relatively short-term maturities of these items and financial instruments.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;See Note 10 for information regarding the fair value of the 2024 Notes, 2025 Notes and 2021 Notes.&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueMeasurementPolicyPolicyTextBlock>
    <us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock
      contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM180Ni9mcmFnOjhkNTIzNGI1NjdkZjRiMThiNjM1NmFmN2Q4OWQ4MDE3L3RleHRyZWdpb246OGQ1MjM0YjU2N2RmNGIxOGI2MzU2YWY3ZDg5ZDgwMTdfMzI1MQ_8eac6c15-ccb7-4661-b943-77271c40d263">Recently Issued Accounting Standards&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Adoption of New Accounting Standards&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In June 2016, the FASB issued ASU 2016-13, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Financial Instruments-Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;and subsequently issued additional guidance that modified ASU 2016-13. The standard requires an entity to change its accounting approach for measuring and recognizing credit losses on certain financial assets measured at amortized cost, including trade receivables, certain non-trade receivables, contract assets, held-to-maturity securities, customer advances and certain off-balance sheet credit exposures, by replacing the existing &#x201c;incurred loss&#x201d; framework with an expected credit loss recognition model.&#160; The new standard results in earlier recognition of credit losses based on past events, current conditions and reasonable and supportable forecasts.&#160;We adopted the requirements of this standard effective January 1, 2020 using the modified retrospective approach and recorded a cumulative effect adjustment of $3.0 million to January 1, 2020 retained earnings (accumulated deficit). Results for reporting periods beginning January 1, 2020 reflect the adoption of &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM180Ni9mcmFnOjhkNTIzNGI1NjdkZjRiMThiNjM1NmFmN2Q4OWQ4MDE3L3RleHRyZWdpb246OGQ1MjM0YjU2N2RmNGIxOGI2MzU2YWY3ZDg5ZDgwMTdfMzI1Ng_c324734f-03c4-4b52-af23-6ac596334a4b"&gt;ASU 2016-13&lt;/span&gt;, while prior period amounts were not adjusted and continue to be reported in accordance with our historical accounting practices. Refer to Note 7 for additional disclosures related to current expected credit losses.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2019, the FASB issued ASU No. 2019-12,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; Simplifying the Accounting for Income Taxes.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; The amendments in the ASU remove certain exceptions to the intraperiod tax allocation of losses and gains from different financial statement components and to the method of recognizing income taxes on interim period losses and the recognition of deferred tax liabilities for outside basis differences. In addition, the new guidance simplifies aspects of the accounting for franchise taxes and clarifies the accounting for &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;transactions that result in a step-up in the tax basis of goodwill. The Company adopted this standard starting in the first quarter of 2021, which did not have a material impact on our consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In August 2020, the FASB issued ASU 2020-06, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Accounting for Convertible Instruments and Contracts in an Entity&#x2019;s Own Equity&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. The ASU simplifies the accounting for certain financial instruments with characteristics of liabilities and equity, including convertible instruments and contracts in an entity&#x2019;s own equity. Specifically, the ASU removes the separation models for convertible debt with a cash conversion feature or convertible instruments with a beneficial conversion feature and no longer permits the use of the treasury stock method from calculating earnings per share. As a result, after adopting the ASU&#x2019;s guidance, we will not separately present in equity an embedded conversion feature of such debt. Instead, we will account for a convertible debt instrument wholly as debt unless (i) a convertible instrument contains features that require bifurcation as a derivative or (ii) a convertible debt instrument was issued at a substantial premium. Additionally, the ASU removes certain conditions for equity classification related to contracts in an entity&#x2019;s own equity (e.g., warrants) and amends certain guidance related to the computation of earnings per share for convertible instruments and contracts on an entity&#x2019;s own equity. The guidance in this ASU can be adopted using either a full or modified retrospective approach and becomes effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2021. We will adopt the ASU in the first quarter of fiscal 2022, and expect to use modified retrospective approach. The Company is currently assessing the impact, if any, that ASU 2020-06 would have on its financial position, results of operations or cash flows, however, the inability to use the treasury stock method in accounting for the shares issuable upon conversion of the 2024 Notes and the 2025 Notes will adversely affect our diluted earnings per share.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Recent Accounting Pronouncements Not Yet Effective&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In October 2021, the FASB issued ASU 2021-08, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Business Combinations (Topic 805): Accounting for Contract Assets and Contract Liabilities from Contracts with Customers&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, which requires contract assets and contract liabilities acquired in a business combination to be recognized and measured by the acquirer on the acquisition date in accordance with ASC 606, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Revenue from Contracts with Customers.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; This approach differs from the current requirement to measure contract assets and contract liabilities acquired in a business combination at fair value. This new standard is effective for our interim and annual periods beginning after December 15, 2022, with early adoption permitted. We are currently evaluating the adoption impacts on our consolidated financial statements.&lt;/span&gt;&lt;/div&gt;</us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM180Ni9mcmFnOjhkNTIzNGI1NjdkZjRiMThiNjM1NmFmN2Q4OWQ4MDE3L3RleHRyZWdpb246OGQ1MjM0YjU2N2RmNGIxOGI2MzU2YWY3ZDg5ZDgwMTdfMzI1OA_37d6f2b0-c14d-4240-b146-49442d63621f">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Adoption of New Accounting Standards&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In June 2016, the FASB issued ASU 2016-13, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Financial Instruments-Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;and subsequently issued additional guidance that modified ASU 2016-13. The standard requires an entity to change its accounting approach for measuring and recognizing credit losses on certain financial assets measured at amortized cost, including trade receivables, certain non-trade receivables, contract assets, held-to-maturity securities, customer advances and certain off-balance sheet credit exposures, by replacing the existing &#x201c;incurred loss&#x201d; framework with an expected credit loss recognition model.&#160; The new standard results in earlier recognition of credit losses based on past events, current conditions and reasonable and supportable forecasts.&#160;We adopted the requirements of this standard effective January 1, 2020 using the modified retrospective approach and recorded a cumulative effect adjustment of $3.0 million to January 1, 2020 retained earnings (accumulated deficit). Results for reporting periods beginning January 1, 2020 reflect the adoption of &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM180Ni9mcmFnOjhkNTIzNGI1NjdkZjRiMThiNjM1NmFmN2Q4OWQ4MDE3L3RleHRyZWdpb246OGQ1MjM0YjU2N2RmNGIxOGI2MzU2YWY3ZDg5ZDgwMTdfMzI1Ng_c324734f-03c4-4b52-af23-6ac596334a4b"&gt;ASU 2016-13&lt;/span&gt;, while prior period amounts were not adjusted and continue to be reported in accordance with our historical accounting practices. Refer to Note 7 for additional disclosures related to current expected credit losses.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2019, the FASB issued ASU No. 2019-12,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; Simplifying the Accounting for Income Taxes.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; The amendments in the ASU remove certain exceptions to the intraperiod tax allocation of losses and gains from different financial statement components and to the method of recognizing income taxes on interim period losses and the recognition of deferred tax liabilities for outside basis differences. In addition, the new guidance simplifies aspects of the accounting for franchise taxes and clarifies the accounting for &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;transactions that result in a step-up in the tax basis of goodwill. The Company adopted this standard starting in the first quarter of 2021, which did not have a material impact on our consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In August 2020, the FASB issued ASU 2020-06, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Accounting for Convertible Instruments and Contracts in an Entity&#x2019;s Own Equity&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. The ASU simplifies the accounting for certain financial instruments with characteristics of liabilities and equity, including convertible instruments and contracts in an entity&#x2019;s own equity. Specifically, the ASU removes the separation models for convertible debt with a cash conversion feature or convertible instruments with a beneficial conversion feature and no longer permits the use of the treasury stock method from calculating earnings per share. As a result, after adopting the ASU&#x2019;s guidance, we will not separately present in equity an embedded conversion feature of such debt. Instead, we will account for a convertible debt instrument wholly as debt unless (i) a convertible instrument contains features that require bifurcation as a derivative or (ii) a convertible debt instrument was issued at a substantial premium. Additionally, the ASU removes certain conditions for equity classification related to contracts in an entity&#x2019;s own equity (e.g., warrants) and amends certain guidance related to the computation of earnings per share for convertible instruments and contracts on an entity&#x2019;s own equity. The guidance in this ASU can be adopted using either a full or modified retrospective approach and becomes effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2021. We will adopt the ASU in the first quarter of fiscal 2022, and expect to use modified retrospective approach. The Company is currently assessing the impact, if any, that ASU 2020-06 would have on its financial position, results of operations or cash flows, however, the inability to use the treasury stock method in accounting for the shares issuable upon conversion of the 2024 Notes and the 2025 Notes will adversely affect our diluted earnings per share.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Recent Accounting Pronouncements Not Yet Effective&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In October 2021, the FASB issued ASU 2021-08, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Business Combinations (Topic 805): Accounting for Contract Assets and Contract Liabilities from Contracts with Customers&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, which requires contract assets and contract liabilities acquired in a business combination to be recognized and measured by the acquirer on the acquisition date in accordance with ASC 606, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Revenue from Contracts with Customers.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; This approach differs from the current requirement to measure contract assets and contract liabilities acquired in a business combination at fair value. This new standard is effective for our interim and annual periods beginning after December 15, 2022, with early adoption permitted. We are currently evaluating the adoption impacts on our consolidated financial statements.&lt;/span&gt;&lt;/div&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i86eec55ebc424a56b5b5394b8b2b2423_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM180Ni9mcmFnOjhkNTIzNGI1NjdkZjRiMThiNjM1NmFmN2Q4OWQ4MDE3L3RleHRyZWdpb246OGQ1MjM0YjU2N2RmNGIxOGI2MzU2YWY3ZDg5ZDgwMTdfMTIwMA_61779148-74c7-47d4-add9-d77a7dad7e40"
      unitRef="usd">-3000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:BusinessCombinationDisclosureTextBlock
      contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM181Mi9mcmFnOmJiYjIzMTBlOTRkMjQ4NzFhNjRjNTllMTk2ZDJiZDBmL3RleHRyZWdpb246YmJiMjMxMGU5NGQyNDg3MWE2NGM1OWUxOTZkMmJkMGZfNjU2NQ_6edfe19f-8b57-4708-9f6a-84526c99cf9a">Transactions&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Business Combinations&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Vital Decisions&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On October 1, 2021, the Company completed its acquisition of Vital Decisions, including 100% of the voting equity interests. Vital Decisions is a leading provider of technology-enabled advance care planning services, ensuring that the care of individuals with serious illness aligns with their values and changing preferences throughout their health journey and, in particular, as they approach  end-of-life decisions. The transaction is expected to deepen our capabilities, allowing us to cross-sell across customers and enhance our value proposition to partners. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total merger consideration, net of cash on hand and certain closing adjustments, was $117.7 million, based on the closing price of the Company&#x2019;s Class A common stock on the NYSE on October 1, 2021. The merger consideration consisted of $46.5 million of cash consideration, 1.8&#160;million shares of Class A common stock, fair valued at $56.6 million as of October 1, 2021, and an earn-out of up to $45.0&#160;million, fair valued at $14.6 million as of October 1, 2021. See Note 18 for additional information regarding the fair value determination of the earn-out consideration.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The purchase price was allocated to the assets acquired and liabilities assumed based on their estimated fair values as of October 1, 2021, as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:87.372%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.428%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Purchase consideration:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value of Class A common stock issued&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;56,626&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value of contingent consideration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total consideration&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;117,726&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Tangible assets acquired:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,430&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accounts receivable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,301&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:87.372%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.428%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prepaid expenses and other current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;78&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other non-current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,564&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total tangible assets acquired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,373&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Identifiable intangible assets acquired:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Customer relationships&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Technology&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate trade name&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total identifiable intangible assets acquired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Liabilities assumed:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accounts payable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;93&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued liabilities &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;661&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued compensation and employee benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;970&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred tax liabilities, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;499&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,712&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total liabilities assumed&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,935&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goodwill&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;77,288&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net assets acquired&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;117,726&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;The fair value of the receivables acquired, as shown in the table above, approximates the gross contractual amounts and is expected to be collectible in full. Identifiable intangible assets associated with customer relationships, technology and corporate trade names will be amortized on a straight-line basis over their preliminary estimated useful lives of 13 years, 5 years, and 15 years, respectively. The customer relationships are primarily attributable to existing contracts with current customers. The technology consists primarily of a proprietary advance care planning documentation portal where patients can input information, and doctor/patient conversations are populated for later reference. The corporate trade name reflects the value that we believe the Vital Decisions brand name carries in the market. The fair value of the intangible assets was determined using the income approach and the relief from royalty approach. The income approach estimates fair value for an asset based on the present value of cash flows projected to be generated by the asset. Projected cash flows are discounted at a required rate of return that reflects the relative risk of achieving the cash flows and the time value of money. The relief from royalty approach estimates the fair value of an asset by calculating how much an entity would have to spend to lease a similar asset. Goodwill is calculated as the difference between the acquisition date fair value of the total consideration and the fair value of the net assets acquired and represents the future economic benefits that we expect to achieve as a result of the acquisition. The goodwill is attributable primarily to cross-selling opportunities and the acquired assembled workforce and was all allocated to the Clinical Solutions segment. Goodwill is considered to be an indefinite lived asset. $69.6&#160;million of the goodwill recorded on the transaction is deductible for tax purposes.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The amounts above reflect management&#x2019;s estimate of the fair value of the tangible and intangible assets acquired and liabilities assumed. Any necessary adjustments will be finalized within one year from the date of acquisition.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Equity Investments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Passport&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On May 28, 2019, UHC, Passport Health Solutions, LLC (&#x201c;PHS I&#x201d;), the Company and EVH Passport entered into an Asset Purchase Agreement (the &#x201c;Passport APA&#x201d;), which provided for the sale of substantially all of the assets of UHC and PHS I, including UHC&#x2019;s Kentucky Medicaid contract (the &#x201c;Passport Medicaid Contract&#x201d;), to EVH Passport for a purchase price of $70.0 million in cash and the issuance of a 30% interest in EVH Passport (the &#x201c;Passport Purchase Price&#x201d;) to The University of Louisville, the University of Louisville Physicians, University Medical Center, the Jewish Heritage Fund for Excellence, Norton Healthcare, Inc. and the Louisville/Jefferson County Primary Care Association (collectively, the &#x201c;Sponsors&#x201d;). &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On June 18, 2019, the Company contributed $40.0 million to UHC in the form of an advance for regulatory capital requirements under an agreement with UHC (the &#x201c;Passport Note&#x201d;). The Passport Note carried a fixed interest rate of 6.5% per annum. Additionally, on &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;June 6, 2019, the Company and UHC entered into an Indemnity Agreement (the &#x201c;Indemnity Agreement&#x201d;), with an insurance company (the &#x201c;Surety&#x201d;). The Surety issued a performance bond in the amount of $25.0 million to secure UHC&#x2019;s performance under its Medicaid Contract. Pursuant to the Indemnity Agreement, the Company and UHC were jointly and severally liable to the Surety in the maximum amount of the bond, plus certain costs of the Surety, in the event of losses arising under the bond. The bond&#x2019;s original expiry date was June 30, 2020 and during the three months ended June 30, 2020, was extended to December 31, 2020. The bond was released in October 2020. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On December 30, 2019, UHC, PHS I, the Company and EVH Passport consummated the transactions contemplated by the Passport APA (the &#x201c;Passport Closing&#x201d;).  At the Passport Closing, $16.2 million of the cash Passport Purchase Price was held back until such time as PHS I delivers to EVH Passport certain owned real property and improvements free and clear of all encumbrances. In addition, at the Passport Closing, EVH Passport and UHC entered into an agreement that provided for the administration and assumption of the financial risks by EVH Passport of UHC&#x2019;s dual eligible special needs business (the &#x201c;DNP Business&#x201d;) until such time as EVH Passport became certified as a Medicare Advantage Organization and the D-SNP Business could be transferred to EVH Passport.  On October 1, 2020, the D-SNP Business was transferred from UHC to EVH Passport. At the Passport Closing, EVH Passport assumed UHC&#x2019;s obligations under the Passport Note and the Indemnity Agreement. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On July 16, 2020, EVH Passport, Evolent Health LLC and Molina Healthcare, Inc. (&#x201c;Molina&#x201d;) entered into an Asset Purchase Agreement (the &#x201c;Molina APA&#x201d;), which contemplated the sale by EVH Passport to Molina of certain assets, including certain intellectual property rights of EVH Passport and EVH Passport&#x2019;s rights under the Passport Medicaid Contract.  On September 1, 2020, EVH Passport and Molina consummated the transactions contemplated by the Molina APA (the &#x201c;Molina Closing&#x201d;) and the Passport Medicaid Contract was novated to Molina.  As a result, EVH Passport began to wind down its business.  In connection with the Molina Closing, Molina deposited $20.0&#160;million in cash in escrow, which was subsequently released to EVH Passport in January 2021.  In addition, at the Molina Closing, Molina and EVH Passport entered into an agreement that provided for the assumption of the financial risks by Molina of the D-SNP Business until such time as Molina&#x2019;s Kentucky health plan becomes certified as a Medicare Advantage Organization and the D-SNP Business is transferred Molina.  The Company and EVH Passport continued to administer the D-SNP Business until January 1, 2021, at which time Molina became responsible for its administration until the D-SNP Business was officially transferred to Molina effective September 1, 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Prior to the Molina Closing, the Company accounted for its investment in EVH Passport as an unconsolidated variable interest entity under the equity method of accounting.  As a result of the transaction, the Company concluded that a reconsideration event occurred whereby EVH Passport was determined to be a voting interest entity and that Evolent had a controlling financial interest in EVH Passport; accordingly, the Company consolidated EVH Passport as of September 1, 2020 in its consolidated financial statements. The Company accounted for the transaction as an asset acquisition, as the Company concluded that assets acquired as a result of the consolidation did not meet the criteria to be classified as a business under GAAP.  Following the Molina Closing and consolidation of EVH Passport in the Company&#x2019;s consolidated financials, on November 16, 2020, EVH Passport redeemed the Sponsors&#x2019; equity interests in EVH Passport for $20.0&#160;million in cash in accordance with the terms of EVH Passport&#x2019;s Stockholders&#x2019; Agreement, and, as a result, EVH Passport became a wholly owned subsidiary of the Company.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As part of the consolidation, the Company recorded assets primarily consisting of cash and cash equivalents and restricted cash and cash equivalents of $159.8&#160;million, available for sale securities of $88.6&#160;million, receivables related to unsettled sales of securities of $43.0&#160;million and other assets of $50.2&#160;million and total liabilities primarily comprised of reserve for claims and performance-based arrangements of $164.8&#160;million and accrued liabilities of $50.0&#160;million. Subsequent to winddown activities, any remaining capital will be distributed to the Company subject to regulatory approval from the Kentucky Department of Insurance.  In addition, the Passport Note was eliminated upon consolidation, and as of December 31, 2020, the outstanding principal balance of the $40.0&#160;million Passport Note was repaid in full by EVH Passport including approximately $3.6&#160;million of accrued interest.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the first quarter of 2021, pursuant to the terms of the Molina APA, EVH Passport received a cash payment from Molina in the amount of $23.0&#160;million based on the number of enrollees above a certain threshold in the D-SNP Business and Molina's Medicaid plan following the open enrollment period for plan year 2021. The payment is recorded in gain on transfer of membership on the consolidated statement of operations and comprehensive income (loss). The foregoing amount represents 50% of the payment that EVH Passport is eligible to receive pursuant to the terms of the Molina APA based on the number of such enrollees. The remaining 50% was received in the first quarter of 2022 and was recorded as a receivable on our consolidated balance sheet and a gain on transfer of membership on the consolidated statement of operations and comprehensive income (loss) during the year ended December 31, 2021 as there were no remaining uncertainties related to realization.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Loss on Disposal of Assets&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During 2019, the Company, through a consolidated subsidiary, entered into an agreement with an unrelated party to provide services and support to providers, independent physician associations, and other provider groups. During the first quarter of 2020, the Company sold its interest in the subsidiary and recorded a loss on disposal of assets of $6.4 million in the consolidated statements of operations and comprehensive income (loss). The Company did not have any continuing involvement with the subsidiary after the consummation of this transaction.&lt;/span&gt;&lt;/div&gt;</us-gaap:BusinessCombinationDisclosureTextBlock>
    <us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired
      contextRef="i70301f61588141189fb4444297fae8bd_I20211001"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM181Mi9mcmFnOmJiYjIzMTBlOTRkMjQ4NzFhNjRjNTllMTk2ZDJiZDBmL3RleHRyZWdpb246YmJiMjMxMGU5NGQyNDg3MWE2NGM1OWUxOTZkMmJkMGZfMTA0NDUzNjA1MTc3NTg_dbd20f6a-b410-4e25-b1f8-c01c2034c6f1"
      unitRef="number">1</us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired>
    <us-gaap:BusinessCombinationConsiderationTransferred1
      contextRef="icc3dde603e5f449c9078821a3218c74e_D20211001-20211001"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM181Mi9mcmFnOmJiYjIzMTBlOTRkMjQ4NzFhNjRjNTllMTk2ZDJiZDBmL3RleHRyZWdpb246YmJiMjMxMGU5NGQyNDg3MWE2NGM1OWUxOTZkMmJkMGZfMjE5OTAyMzMwOTY1Mw_0781d6e4-6a44-4edb-afef-40dec9031e30"
      unitRef="usd">117700000</us-gaap:BusinessCombinationConsiderationTransferred1>
    <us-gaap:PaymentsToAcquireBusinessesGross
      contextRef="icc3dde603e5f449c9078821a3218c74e_D20211001-20211001"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM181Mi9mcmFnOmJiYjIzMTBlOTRkMjQ4NzFhNjRjNTllMTk2ZDJiZDBmL3RleHRyZWdpb246YmJiMjMxMGU5NGQyNDg3MWE2NGM1OWUxOTZkMmJkMGZfMjE5OTAyMzMwOTU0MQ_5dd3d400-5f6b-4015-8fc9-a08c2d00ffff"
      unitRef="usd">46500000</us-gaap:PaymentsToAcquireBusinessesGross>
    <us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued
      contextRef="icc3dde603e5f449c9078821a3218c74e_D20211001-20211001"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM181Mi9mcmFnOmJiYjIzMTBlOTRkMjQ4NzFhNjRjNTllMTk2ZDJiZDBmL3RleHRyZWdpb246YmJiMjMxMGU5NGQyNDg3MWE2NGM1OWUxOTZkMmJkMGZfMzg0ODI5MDc1MTEyNA_e6947cd3-790a-44b5-9e69-de7d4b7f52b8"
      unitRef="shares">1800000</us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued>
    <us-gaap:BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable
      contextRef="icc3dde603e5f449c9078821a3218c74e_D20211001-20211001"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM181Mi9mcmFnOmJiYjIzMTBlOTRkMjQ4NzFhNjRjNTllMTk2ZDJiZDBmL3RleHRyZWdpb246YmJiMjMxMGU5NGQyNDg3MWE2NGM1OWUxOTZkMmJkMGZfMjE5OTAyMzMwOTU4NA_f4020e29-197c-423e-8cdf-dda02974bb2b"
      unitRef="usd">56600000</us-gaap:BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh
      contextRef="i70301f61588141189fb4444297fae8bd_I20211001"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM181Mi9mcmFnOmJiYjIzMTBlOTRkMjQ4NzFhNjRjNTllMTk2ZDJiZDBmL3RleHRyZWdpb246YmJiMjMxMGU5NGQyNDg3MWE2NGM1OWUxOTZkMmJkMGZfMzg0ODI5MDc1MTEwOQ_75859655-4725-49fd-98e6-b578f13347fd"
      unitRef="usd">45000000</us-gaap:BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i70301f61588141189fb4444297fae8bd_I20211001"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM181Mi9mcmFnOmJiYjIzMTBlOTRkMjQ4NzFhNjRjNTllMTk2ZDJiZDBmL3RleHRyZWdpb246YmJiMjMxMGU5NGQyNDg3MWE2NGM1OWUxOTZkMmJkMGZfMjE5OTAyMzMwOTYxOA_12729a9a-ab6f-4252-9a36-164ef6765061"
      unitRef="usd">14600000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock
      contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM181Mi9mcmFnOmJiYjIzMTBlOTRkMjQ4NzFhNjRjNTllMTk2ZDJiZDBmL3RleHRyZWdpb246YmJiMjMxMGU5NGQyNDg3MWE2NGM1OWUxOTZkMmJkMGZfMzI5ODUzNDkzNjI0Mw_d097634a-3f79-4fe5-8b11-eeeb7f316adf">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The purchase price was allocated to the assets acquired and liabilities assumed based on their estimated fair values as of October 1, 2021, as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:87.372%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.428%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Purchase consideration:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value of Class A common stock issued&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;56,626&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value of contingent consideration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total consideration&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;117,726&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Tangible assets acquired:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,430&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accounts receivable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,301&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:87.372%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.428%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prepaid expenses and other current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;78&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other non-current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,564&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total tangible assets acquired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,373&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Identifiable intangible assets acquired:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Customer relationships&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Technology&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate trade name&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total identifiable intangible assets acquired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Liabilities assumed:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accounts payable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;93&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued liabilities &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;661&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued compensation and employee benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;970&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred tax liabilities, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;499&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,712&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total liabilities assumed&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,935&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goodwill&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;77,288&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net assets acquired&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;117,726&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock>
    <us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock
      contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM181Mi9mcmFnOmJiYjIzMTBlOTRkMjQ4NzFhNjRjNTllMTk2ZDJiZDBmL3RleHRyZWdpb246YmJiMjMxMGU5NGQyNDg3MWE2NGM1OWUxOTZkMmJkMGZfMzI5ODUzNDkzNjI0Mg_4dbbee18-b16a-42eb-a11e-b30dd4cc68cb">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The purchase price was allocated to the assets acquired and liabilities assumed based on their estimated fair values as of October 1, 2021, as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:87.372%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.428%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Purchase consideration:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value of Class A common stock issued&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;56,626&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value of contingent consideration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total consideration&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;117,726&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Tangible assets acquired:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,430&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accounts receivable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,301&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:87.372%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.428%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prepaid expenses and other current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;78&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other non-current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,564&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total tangible assets acquired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,373&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Identifiable intangible assets acquired:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Customer relationships&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Technology&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate trade name&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total identifiable intangible assets acquired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Liabilities assumed:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accounts payable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;93&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued liabilities &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;661&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued compensation and employee benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;970&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred tax liabilities, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;499&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,712&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total liabilities assumed&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,935&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goodwill&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;77,288&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net assets acquired&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;117,726&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock>
    <us-gaap:PaymentsToAcquireBusinessesGross
      contextRef="icc3dde603e5f449c9078821a3218c74e_D20211001-20211001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM181Mi9mcmFnOmJiYjIzMTBlOTRkMjQ4NzFhNjRjNTllMTk2ZDJiZDBmL3RhYmxlOjRhYzE5YzhjN2Q1MTRhZTViZjMwYTBmMmI5MWVkMjQxL3RhYmxlcmFuZ2U6NGFjMTljOGM3ZDUxNGFlNWJmMzBhMGYyYjkxZWQyNDFfMS0xLTEtMS0yOTE3OQ_0fe3a0cb-e9b7-4d10-99f5-230dde376804"
      unitRef="usd">46500000</us-gaap:PaymentsToAcquireBusinessesGross>
    <us-gaap:BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable
      contextRef="icc3dde603e5f449c9078821a3218c74e_D20211001-20211001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM181Mi9mcmFnOmJiYjIzMTBlOTRkMjQ4NzFhNjRjNTllMTk2ZDJiZDBmL3RhYmxlOjRhYzE5YzhjN2Q1MTRhZTViZjMwYTBmMmI5MWVkMjQxL3RhYmxlcmFuZ2U6NGFjMTljOGM3ZDUxNGFlNWJmMzBhMGYyYjkxZWQyNDFfMi0xLTEtMS0yOTgxMA_0430d8a2-81ec-4c5a-a11a-1f8bd1107a16"
      unitRef="usd">56626000</us-gaap:BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i70301f61588141189fb4444297fae8bd_I20211001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM181Mi9mcmFnOmJiYjIzMTBlOTRkMjQ4NzFhNjRjNTllMTk2ZDJiZDBmL3RhYmxlOjRhYzE5YzhjN2Q1MTRhZTViZjMwYTBmMmI5MWVkMjQxL3RhYmxlcmFuZ2U6NGFjMTljOGM3ZDUxNGFlNWJmMzBhMGYyYjkxZWQyNDFfMy0xLTEtMS0yODcwMQ_868e5de0-b29a-4c5f-8d4b-8df671ce1821"
      unitRef="usd">14600000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationConsiderationTransferred1
      contextRef="icc3dde603e5f449c9078821a3218c74e_D20211001-20211001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM181Mi9mcmFnOmJiYjIzMTBlOTRkMjQ4NzFhNjRjNTllMTk2ZDJiZDBmL3RhYmxlOjRhYzE5YzhjN2Q1MTRhZTViZjMwYTBmMmI5MWVkMjQxL3RhYmxlcmFuZ2U6NGFjMTljOGM3ZDUxNGFlNWJmMzBhMGYyYjkxZWQyNDFfNC0xLTEtMS0yOTE2OQ_ce01334c-b8c0-4883-9b93-90c91630fa1c"
      unitRef="usd">117726000</us-gaap:BusinessCombinationConsiderationTransferred1>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents
      contextRef="i70301f61588141189fb4444297fae8bd_I20211001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM181Mi9mcmFnOmJiYjIzMTBlOTRkMjQ4NzFhNjRjNTllMTk2ZDJiZDBmL3RhYmxlOjRhYzE5YzhjN2Q1MTRhZTViZjMwYTBmMmI5MWVkMjQxL3RhYmxlcmFuZ2U6NGFjMTljOGM3ZDUxNGFlNWJmMzBhMGYyYjkxZWQyNDFfNy0xLTEtMS0zNjYzNg_66914969-7977-4c9c-a3ac-5bf2b2cf21ef"
      unitRef="usd">1430000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables
      contextRef="i70301f61588141189fb4444297fae8bd_I20211001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM181Mi9mcmFnOmJiYjIzMTBlOTRkMjQ4NzFhNjRjNTllMTk2ZDJiZDBmL3RhYmxlOjRhYzE5YzhjN2Q1MTRhZTViZjMwYTBmMmI5MWVkMjQxL3RhYmxlcmFuZ2U6NGFjMTljOGM3ZDUxNGFlNWJmMzBhMGYyYjkxZWQyNDFfOC0xLTEtMS0zNjYzOA_05314b17-3e78-4dbd-b938-6a9d677f8f99"
      unitRef="usd">3301000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets
      contextRef="i70301f61588141189fb4444297fae8bd_I20211001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM181Mi9mcmFnOmJiYjIzMTBlOTRkMjQ4NzFhNjRjNTllMTk2ZDJiZDBmL3RhYmxlOjRhYzE5YzhjN2Q1MTRhZTViZjMwYTBmMmI5MWVkMjQxL3RhYmxlcmFuZ2U6NGFjMTljOGM3ZDUxNGFlNWJmMzBhMGYyYjkxZWQyNDFfOS0xLTEtMS0zNjYzOA_922529b9-0346-4f6a-a967-bbe4dc4919eb"
      unitRef="usd">78000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets
      contextRef="i70301f61588141189fb4444297fae8bd_I20211001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM181Mi9mcmFnOmJiYjIzMTBlOTRkMjQ4NzFhNjRjNTllMTk2ZDJiZDBmL3RhYmxlOjRhYzE5YzhjN2Q1MTRhZTViZjMwYTBmMmI5MWVkMjQxL3RhYmxlcmFuZ2U6NGFjMTljOGM3ZDUxNGFlNWJmMzBhMGYyYjkxZWQyNDFfMTAtMS0xLTEtMzY2Mzg_b7da90e7-aff2-42a7-8e81-74f5a5d48737"
      unitRef="usd">2564000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets>
    <evh:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedTangibleAssets
      contextRef="i70301f61588141189fb4444297fae8bd_I20211001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM181Mi9mcmFnOmJiYjIzMTBlOTRkMjQ4NzFhNjRjNTllMTk2ZDJiZDBmL3RhYmxlOjRhYzE5YzhjN2Q1MTRhZTViZjMwYTBmMmI5MWVkMjQxL3RhYmxlcmFuZ2U6NGFjMTljOGM3ZDUxNGFlNWJmMzBhMGYyYjkxZWQyNDFfMTEtMS0xLTEtMzY2Mzg_929ac431-3019-4054-b857-7c0f7c6ceccc"
      unitRef="usd">7373000</evh:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedTangibleAssets>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles
      contextRef="i499adfced3fe4274a3f2ca19bf418044_I20211001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM181Mi9mcmFnOmJiYjIzMTBlOTRkMjQ4NzFhNjRjNTllMTk2ZDJiZDBmL3RhYmxlOjRhYzE5YzhjN2Q1MTRhZTViZjMwYTBmMmI5MWVkMjQxL3RhYmxlcmFuZ2U6NGFjMTljOGM3ZDUxNGFlNWJmMzBhMGYyYjkxZWQyNDFfMTQtMS0xLTEtMzY2NTI_053b8b64-7ce1-4af9-852c-c6a82044cc44"
      unitRef="usd">32500000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles
      contextRef="i6f5e720f7a9e4b0d9114b35d5878bf70_I20211001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM181Mi9mcmFnOmJiYjIzMTBlOTRkMjQ4NzFhNjRjNTllMTk2ZDJiZDBmL3RhYmxlOjRhYzE5YzhjN2Q1MTRhZTViZjMwYTBmMmI5MWVkMjQxL3RhYmxlcmFuZ2U6NGFjMTljOGM3ZDUxNGFlNWJmMzBhMGYyYjkxZWQyNDFfMTUtMS0xLTEtMzY2NTI_6e2c0fa8-d52c-4703-8418-cb4587f2366a"
      unitRef="usd">5000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles
      contextRef="i393b8dc21e5b45e585a40c88e5f9cd40_I20211001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM181Mi9mcmFnOmJiYjIzMTBlOTRkMjQ4NzFhNjRjNTllMTk2ZDJiZDBmL3RhYmxlOjRhYzE5YzhjN2Q1MTRhZTViZjMwYTBmMmI5MWVkMjQxL3RhYmxlcmFuZ2U6NGFjMTljOGM3ZDUxNGFlNWJmMzBhMGYyYjkxZWQyNDFfMTYtMS0xLTEtMzY2NTI_3fa892a9-af2b-4858-863c-55d193c243ed"
      unitRef="usd">2500000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles
      contextRef="i70301f61588141189fb4444297fae8bd_I20211001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM181Mi9mcmFnOmJiYjIzMTBlOTRkMjQ4NzFhNjRjNTllMTk2ZDJiZDBmL3RhYmxlOjRhYzE5YzhjN2Q1MTRhZTViZjMwYTBmMmI5MWVkMjQxL3RhYmxlcmFuZ2U6NGFjMTljOGM3ZDUxNGFlNWJmMzBhMGYyYjkxZWQyNDFfMTctMS0xLTEtMzY2NTI_b261ae49-8b9c-48b0-bd49-894db6cc02a3"
      unitRef="usd">40000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable
      contextRef="i70301f61588141189fb4444297fae8bd_I20211001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM181Mi9mcmFnOmJiYjIzMTBlOTRkMjQ4NzFhNjRjNTllMTk2ZDJiZDBmL3RhYmxlOjRhYzE5YzhjN2Q1MTRhZTViZjMwYTBmMmI5MWVkMjQxL3RhYmxlcmFuZ2U6NGFjMTljOGM3ZDUxNGFlNWJmMzBhMGYyYjkxZWQyNDFfMjAtMS0xLTEtMzY2NTY_eb1587f3-2941-4d15-8dd4-92b0e02e6806"
      unitRef="usd">93000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable>
    <evh:BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesAccruedLiabilities
      contextRef="i70301f61588141189fb4444297fae8bd_I20211001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM181Mi9mcmFnOmJiYjIzMTBlOTRkMjQ4NzFhNjRjNTllMTk2ZDJiZDBmL3RhYmxlOjRhYzE5YzhjN2Q1MTRhZTViZjMwYTBmMmI5MWVkMjQxL3RhYmxlcmFuZ2U6NGFjMTljOGM3ZDUxNGFlNWJmMzBhMGYyYjkxZWQyNDFfMjEtMS0xLTEtMzY2NTY_4b828a83-1517-47f1-a469-ee67a39ee69e"
      unitRef="usd">661000</evh:BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesAccruedLiabilities>
    <evh:BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesAccruedCompensationAndEmployeeBenefits
      contextRef="i70301f61588141189fb4444297fae8bd_I20211001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM181Mi9mcmFnOmJiYjIzMTBlOTRkMjQ4NzFhNjRjNTllMTk2ZDJiZDBmL3RhYmxlOjRhYzE5YzhjN2Q1MTRhZTViZjMwYTBmMmI5MWVkMjQxL3RhYmxlcmFuZ2U6NGFjMTljOGM3ZDUxNGFlNWJmMzBhMGYyYjkxZWQyNDFfMjItMS0xLTEtMzY2NTY_54785064-4233-459b-afd3-0351fce1f701"
      unitRef="usd">970000</evh:BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesAccruedCompensationAndEmployeeBenefits>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities
      contextRef="i70301f61588141189fb4444297fae8bd_I20211001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM181Mi9mcmFnOmJiYjIzMTBlOTRkMjQ4NzFhNjRjNTllMTk2ZDJiZDBmL3RhYmxlOjRhYzE5YzhjN2Q1MTRhZTViZjMwYTBmMmI5MWVkMjQxL3RhYmxlcmFuZ2U6NGFjMTljOGM3ZDUxNGFlNWJmMzBhMGYyYjkxZWQyNDFfMjMtMS0xLTEtMzY2NTY_3bb09c74-55fe-448b-923a-11e580f6a546"
      unitRef="usd">499000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue
      contextRef="i70301f61588141189fb4444297fae8bd_I20211001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM181Mi9mcmFnOmJiYjIzMTBlOTRkMjQ4NzFhNjRjNTllMTk2ZDJiZDBmL3RhYmxlOjRhYzE5YzhjN2Q1MTRhZTViZjMwYTBmMmI5MWVkMjQxL3RhYmxlcmFuZ2U6NGFjMTljOGM3ZDUxNGFlNWJmMzBhMGYyYjkxZWQyNDFfMjQtMS0xLTEtMzY2NTY_8b0005da-660f-4e8b-be0d-caad7216a62d"
      unitRef="usd">2000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCapitalLeaseObligation
      contextRef="i70301f61588141189fb4444297fae8bd_I20211001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM181Mi9mcmFnOmJiYjIzMTBlOTRkMjQ4NzFhNjRjNTllMTk2ZDJiZDBmL3RhYmxlOjRhYzE5YzhjN2Q1MTRhZTViZjMwYTBmMmI5MWVkMjQxL3RhYmxlcmFuZ2U6NGFjMTljOGM3ZDUxNGFlNWJmMzBhMGYyYjkxZWQyNDFfMjUtMS0xLTEtMzY2NTY_34be5355-049c-47b5-8b00-bf757da58db6"
      unitRef="usd">2712000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCapitalLeaseObligation>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities
      contextRef="i70301f61588141189fb4444297fae8bd_I20211001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM181Mi9mcmFnOmJiYjIzMTBlOTRkMjQ4NzFhNjRjNTllMTk2ZDJiZDBmL3RhYmxlOjRhYzE5YzhjN2Q1MTRhZTViZjMwYTBmMmI5MWVkMjQxL3RhYmxlcmFuZ2U6NGFjMTljOGM3ZDUxNGFlNWJmMzBhMGYyYjkxZWQyNDFfMjYtMS0xLTEtMzY2NTY_64dbb1d9-fc2d-4ee4-9511-5d97ddd31432"
      unitRef="usd">6935000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities>
    <us-gaap:Goodwill
      contextRef="i70301f61588141189fb4444297fae8bd_I20211001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM181Mi9mcmFnOmJiYjIzMTBlOTRkMjQ4NzFhNjRjNTllMTk2ZDJiZDBmL3RhYmxlOjRhYzE5YzhjN2Q1MTRhZTViZjMwYTBmMmI5MWVkMjQxL3RhYmxlcmFuZ2U6NGFjMTljOGM3ZDUxNGFlNWJmMzBhMGYyYjkxZWQyNDFfMjgtMS0xLTEtMzY2NzQ_dc534251-11f8-44ab-ab20-ee3d07cb6964"
      unitRef="usd">77288000</us-gaap:Goodwill>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet
      contextRef="i70301f61588141189fb4444297fae8bd_I20211001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM181Mi9mcmFnOmJiYjIzMTBlOTRkMjQ4NzFhNjRjNTllMTk2ZDJiZDBmL3RhYmxlOjRhYzE5YzhjN2Q1MTRhZTViZjMwYTBmMmI5MWVkMjQxL3RhYmxlcmFuZ2U6NGFjMTljOGM3ZDUxNGFlNWJmMzBhMGYyYjkxZWQyNDFfMjktMS0xLTEtMzY2NzQ_8540945c-8872-4b83-8e8d-67425c7fc7ca"
      unitRef="usd">117726000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet>
    <us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife
      contextRef="i93823d3451b643ba8bd3aefc9d052c7c_D20211001-20211001"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM181Mi9mcmFnOmJiYjIzMTBlOTRkMjQ4NzFhNjRjNTllMTk2ZDJiZDBmL3RleHRyZWdpb246YmJiMjMxMGU5NGQyNDg3MWE2NGM1OWUxOTZkMmJkMGZfMzg0ODI5MDc1MTEzNg_f8394840-05a5-4221-8fbd-7fba26eaa442">P13Y</us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife>
    <us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife
      contextRef="i631f51b734d24d66935095cad71b62c0_D20211001-20211001"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM181Mi9mcmFnOmJiYjIzMTBlOTRkMjQ4NzFhNjRjNTllMTk2ZDJiZDBmL3RleHRyZWdpb246YmJiMjMxMGU5NGQyNDg3MWE2NGM1OWUxOTZkMmJkMGZfMzg0ODI5MDc1MTE0OQ_a24aac1c-cf5e-4990-982f-43073226619b">P5Y</us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife>
    <us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife
      contextRef="i942460901cce441cba62f7e178ca70fd_D20211001-20211001"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM181Mi9mcmFnOmJiYjIzMTBlOTRkMjQ4NzFhNjRjNTllMTk2ZDJiZDBmL3RleHRyZWdpb246YmJiMjMxMGU5NGQyNDg3MWE2NGM1OWUxOTZkMmJkMGZfMzg0ODI5MDc1MTE2MQ_b75e1e22-9dd5-402c-99f7-c58582d1a8b4">P15Y</us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife>
    <us-gaap:BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount
      contextRef="i70301f61588141189fb4444297fae8bd_I20211001"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM181Mi9mcmFnOmJiYjIzMTBlOTRkMjQ4NzFhNjRjNTllMTk2ZDJiZDBmL3RleHRyZWdpb246YmJiMjMxMGU5NGQyNDg3MWE2NGM1OWUxOTZkMmJkMGZfMzg0ODI5MDc1MTE3Ng_d0906338-15e5-4d69-af77-49f3a9341004"
      unitRef="usd">69600000</us-gaap:BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount>
    <us-gaap:PaymentsToAcquireEquityMethodInvestments
      contextRef="iba85fb86cb9c459986593ba474a68022_D20190528-20190528"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM181Mi9mcmFnOmJiYjIzMTBlOTRkMjQ4NzFhNjRjNTllMTk2ZDJiZDBmL3RleHRyZWdpb246YmJiMjMxMGU5NGQyNDg3MWE2NGM1OWUxOTZkMmJkMGZfMzk0_526475b8-a550-4d0f-84e3-74a3c86c9251"
      unitRef="usd">70000000</us-gaap:PaymentsToAcquireEquityMethodInvestments>
    <us-gaap:VariableInterestEntityOwnershipPercentage
      contextRef="iba85fb86cb9c459986593ba474a68022_D20190528-20190528"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM181Mi9mcmFnOmJiYjIzMTBlOTRkMjQ4NzFhNjRjNTllMTk2ZDJiZDBmL3RleHRyZWdpb246YmJiMjMxMGU5NGQyNDg3MWE2NGM1OWUxOTZkMmJkMGZfNDI3_a7351fbc-3dbf-4109-9f45-e274509e451a"
      unitRef="number">0.30</us-gaap:VariableInterestEntityOwnershipPercentage>
    <us-gaap:NotesReceivableNet
      contextRef="i5aae66b17cd7411eb3d40e1f98e41587_I20190618"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM181Mi9mcmFnOmJiYjIzMTBlOTRkMjQ4NzFhNjRjNTllMTk2ZDJiZDBmL3RleHRyZWdpb246YmJiMjMxMGU5NGQyNDg3MWE2NGM1OWUxOTZkMmJkMGZfNzkw_4716399f-b538-49c9-b2fd-b94f7ca49951"
      unitRef="usd">40000000</us-gaap:NotesReceivableNet>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i374acc0d61704b06a1daddce75dda523_I20190618"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM181Mi9mcmFnOmJiYjIzMTBlOTRkMjQ4NzFhNjRjNTllMTk2ZDJiZDBmL3RleHRyZWdpb246YmJiMjMxMGU5NGQyNDg3MWE2NGM1OWUxOTZkMmJkMGZfOTY0_c8f34cfc-751c-4f98-b6b9-6d143dc761ed"
      unitRef="number">0.065</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:VariableInterestEntityFinancialOrOtherSupportAmount
      contextRef="i458a8dd8fe1447e983bf102015ceb976_D20190606-20190606"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM181Mi9mcmFnOmJiYjIzMTBlOTRkMjQ4NzFhNjRjNTllMTk2ZDJiZDBmL3RleHRyZWdpb246YmJiMjMxMGU5NGQyNDg3MWE2NGM1OWUxOTZkMmJkMGZfMTE5MQ_fceb1ef1-47a2-413d-b0c6-3047deb2fcb0"
      unitRef="usd">25000000</us-gaap:VariableInterestEntityFinancialOrOtherSupportAmount>
    <evh:PaymentsToAcquireEquityMethodInvestmentsAmountHeldBack
      contextRef="i50b57c8ae3af4f4d87078314e47600cb_I20191230"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM181Mi9mcmFnOmJiYjIzMTBlOTRkMjQ4NzFhNjRjNTllMTk2ZDJiZDBmL3RleHRyZWdpb246YmJiMjMxMGU5NGQyNDg3MWE2NGM1OWUxOTZkMmJkMGZfMTgyNA_4582d01d-2190-450b-931e-b65bbd34ed15"
      unitRef="usd">16200000</evh:PaymentsToAcquireEquityMethodInvestmentsAmountHeldBack>
    <evh:CashReleasedFromEscrow
      contextRef="i3f3edd8173b642a0af571267b2125442_D20210101-20210131"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM181Mi9mcmFnOmJiYjIzMTBlOTRkMjQ4NzFhNjRjNTllMTk2ZDJiZDBmL3RleHRyZWdpb246YmJiMjMxMGU5NGQyNDg3MWE2NGM1OWUxOTZkMmJkMGZfMzI1Ng_296ed786-8e93-4144-a110-44548996b7fb"
      unitRef="usd">20000000</evh:CashReleasedFromEscrow>
    <evh:AssetPurchaseAgreementEscrowPayments
      contextRef="i410c11618d854c73bc5727ec26d5ac44_D20200901-20200901"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM181Mi9mcmFnOmJiYjIzMTBlOTRkMjQ4NzFhNjRjNTllMTk2ZDJiZDBmL3RleHRyZWdpb246YmJiMjMxMGU5NGQyNDg3MWE2NGM1OWUxOTZkMmJkMGZfMzI1Ng_96c71c80-edb0-4c5a-a12f-845c52411a51"
      unitRef="usd">20000000</evh:AssetPurchaseAgreementEscrowPayments>
    <us-gaap:PaymentsToMinorityShareholders
      contextRef="i553144e874d7414ab395f79f6424736f_D20201116-20201116"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM181Mi9mcmFnOmJiYjIzMTBlOTRkMjQ4NzFhNjRjNTllMTk2ZDJiZDBmL3RleHRyZWdpb246YmJiMjMxMGU5NGQyNDg3MWE2NGM1OWUxOTZkMmJkMGZfNDg1Mw_914e9020-eff1-4695-a589-f3e6728da0be"
      unitRef="usd">20000000</us-gaap:PaymentsToMinorityShareholders>
    <evh:AssetAcquisitionCashAndEquivalents
      contextRef="i24eda106b1dc4387aebfe529942c3586_D20200901-20200901"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM181Mi9mcmFnOmJiYjIzMTBlOTRkMjQ4NzFhNjRjNTllMTk2ZDJiZDBmL3RleHRyZWdpb246YmJiMjMxMGU5NGQyNDg3MWE2NGM1OWUxOTZkMmJkMGZfNTE2OQ_eadc1049-72c9-498a-95c0-cec01eb4a089"
      unitRef="usd">159800000</evh:AssetAcquisitionCashAndEquivalents>
    <evh:AssetAcquisitionDebtSecuritiesAvailableForSale
      contextRef="i24eda106b1dc4387aebfe529942c3586_D20200901-20200901"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM181Mi9mcmFnOmJiYjIzMTBlOTRkMjQ4NzFhNjRjNTllMTk2ZDJiZDBmL3RleHRyZWdpb246YmJiMjMxMGU5NGQyNDg3MWE2NGM1OWUxOTZkMmJkMGZfNTIwNg_2ffa8448-a3e6-494a-b6d0-8d4b869aca76"
      unitRef="usd">88600000</evh:AssetAcquisitionDebtSecuritiesAvailableForSale>
    <evh:AssetAcquisitionDebtSecuritiesAvailableForSaleUnsettledSalesReceivables
      contextRef="i24eda106b1dc4387aebfe529942c3586_D20200901-20200901"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM181Mi9mcmFnOmJiYjIzMTBlOTRkMjQ4NzFhNjRjNTllMTk2ZDJiZDBmL3RleHRyZWdpb246YmJiMjMxMGU5NGQyNDg3MWE2NGM1OWUxOTZkMmJkMGZfNTI2Ng_231a5b8e-c071-4449-8338-5cc61d6011ae"
      unitRef="usd">43000000</evh:AssetAcquisitionDebtSecuritiesAvailableForSaleUnsettledSalesReceivables>
    <evh:AssetAcquisitionOtherAssets
      contextRef="i24eda106b1dc4387aebfe529942c3586_D20200901-20200901"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM181Mi9mcmFnOmJiYjIzMTBlOTRkMjQ4NzFhNjRjNTllMTk2ZDJiZDBmL3RleHRyZWdpb246YmJiMjMxMGU5NGQyNDg3MWE2NGM1OWUxOTZkMmJkMGZfNTI4OQ_0f0baf49-9e45-4188-89f5-5ccb7317febf"
      unitRef="usd">50200000</evh:AssetAcquisitionOtherAssets>
    <evh:AssetAcquisitionAccruedMedicalExpenses
      contextRef="i24eda106b1dc4387aebfe529942c3586_D20200901-20200901"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM181Mi9mcmFnOmJiYjIzMTBlOTRkMjQ4NzFhNjRjNTllMTk2ZDJiZDBmL3RleHRyZWdpb246YmJiMjMxMGU5NGQyNDg3MWE2NGM1OWUxOTZkMmJkMGZfNTM5NA_4a5d76dd-24be-463a-901d-61ce63c3591e"
      unitRef="usd">164800000</evh:AssetAcquisitionAccruedMedicalExpenses>
    <evh:AssetAcquisitionAccruedLiabilities
      contextRef="i24eda106b1dc4387aebfe529942c3586_D20200901-20200901"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM181Mi9mcmFnOmJiYjIzMTBlOTRkMjQ4NzFhNjRjNTllMTk2ZDJiZDBmL3RleHRyZWdpb246YmJiMjMxMGU5NGQyNDg3MWE2NGM1OWUxOTZkMmJkMGZfNTQyNA_5592f0b1-efdb-4054-8e62-8a97d29775af"
      unitRef="usd">50000000</evh:AssetAcquisitionAccruedLiabilities>
    <us-gaap:ProceedsFromCollectionOfNotesReceivable
      contextRef="i8d16ce5f96ed484ea0bd662e9a0da3ec_D20201231-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM181Mi9mcmFnOmJiYjIzMTBlOTRkMjQ4NzFhNjRjNTllMTk2ZDJiZDBmL3RleHRyZWdpb246YmJiMjMxMGU5NGQyNDg3MWE2NGM1OWUxOTZkMmJkMGZfNTczMQ_ee169de5-f1b0-4710-93af-fe7eecd8009d"
      unitRef="usd">40000000</us-gaap:ProceedsFromCollectionOfNotesReceivable>
    <us-gaap:ProceedsFromInterestReceived
      contextRef="i8d16ce5f96ed484ea0bd662e9a0da3ec_D20201231-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM181Mi9mcmFnOmJiYjIzMTBlOTRkMjQ4NzFhNjRjNTllMTk2ZDJiZDBmL3RleHRyZWdpb246YmJiMjMxMGU5NGQyNDg3MWE2NGM1OWUxOTZkMmJkMGZfNTgwNw_7bfa2bf6-3172-4218-afd2-c45a7ad656f5"
      unitRef="usd">3600000</us-gaap:ProceedsFromInterestReceived>
    <evh:ProceedsFromTransferOfMembership
      contextRef="i660e59a50fb74adf8c9b97dba279e217_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM181Mi9mcmFnOmJiYjIzMTBlOTRkMjQ4NzFhNjRjNTllMTk2ZDJiZDBmL3RleHRyZWdpb246YmJiMjMxMGU5NGQyNDg3MWE2NGM1OWUxOTZkMmJkMGZfNTk3Mw_d7d3a9be-a3d2-4cb5-b59e-9677b7ab7310"
      unitRef="usd">23000000</evh:ProceedsFromTransferOfMembership>
    <evh:TransferOfMembershipPercentageOfPaymentBasedOnNumberOfEnrollees
      contextRef="ib292e37ea5764045b08aaf86b4bf8282_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM181Mi9mcmFnOmJiYjIzMTBlOTRkMjQ4NzFhNjRjNTllMTk2ZDJiZDBmL3RleHRyZWdpb246YmJiMjMxMGU5NGQyNDg3MWE2NGM1OWUxOTZkMmJkMGZfNjMwOA_72e003f6-0741-4226-8a0f-42d0409a34b7"
      unitRef="number">0.50</evh:TransferOfMembershipPercentageOfPaymentBasedOnNumberOfEnrollees>
    <evh:TransferOfMembershipPercentageOfPaymentSubjectToSatisfactionOfContingencies
      contextRef="i1857a80445fe4ba78e6b1cd41cf5528f_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM181Mi9mcmFnOmJiYjIzMTBlOTRkMjQ4NzFhNjRjNTllMTk2ZDJiZDBmL3RleHRyZWdpb246YmJiMjMxMGU5NGQyNDg3MWE2NGM1OWUxOTZkMmJkMGZfNjQ2MA_b386d4c4-9e83-4ce4-8dd4-1497077d0923"
      unitRef="number">0.50</evh:TransferOfMembershipPercentageOfPaymentSubjectToSatisfactionOfContingencies>
    <us-gaap:GainLossOnDispositionOfAssets1
      contextRef="ia321bb1b6e6b403aa6a27cd32dbe25f8_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM181Mi9mcmFnOmJiYjIzMTBlOTRkMjQ4NzFhNjRjNTllMTk2ZDJiZDBmL3RleHRyZWdpb246YmJiMjMxMGU5NGQyNDg3MWE2NGM1OWUxOTZkMmJkMGZfMTA5OTUxMTYzNDc0OQ_22670ac8-6fb0-46b3-8784-98117c18e4e4"
      unitRef="usd">-6400000</us-gaap:GainLossOnDispositionOfAssets1>
    <us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock
      contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM181NS9mcmFnOmNmZTY4OTBkMjFiYTQxZjE5OTA1MWYzYTFkMzI4MjZiL3RleHRyZWdpb246Y2ZlNjg5MGQyMWJhNDFmMTk5MDUxZjNhMWQzMjgyNmJfMjcyMQ_3c2cd643-68d6-491b-a602-5cbeeb31c11a">Discontinued Operations&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On January 11, 2021, Evolent Health LLC, EH Holdings and True Health, each wholly owned subsidiaries of the Company, entered into a Stock Purchase Agreement (the &#x201c;True Health SPA&#x201d;) with Bright Health Management, Inc. (&#x201c;Bright HealthCare&#x201d;), pursuant to which EH Holdings agreed to sell all of its equity interests in True Health to Bright HealthCare. Closing of the transactions contemplated by the True Health SPA occurred on March 31, 2021 (the &#x201c;True Health Closing&#x201d;) and the Company has had no continuing involvement with True Health subsequent to the closing except a pre-existing services agreement for claims processing and other health plan administrative functions.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of the first quarter of 2021, the Company determined that True Health met the discontinued operations criteria under ASC 205, and as such, True Health assets and liabilities as of December 31, 2020, and the results of operations for all periods presented are classified as discontinued operations and are not included in continuing operations in the consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the year ended December 31, 2021, the Company recorded purchase prices adjustments to the True Health Closing of $8.7&#160;million which are included in loss from discontinued operations on the consolidated statements of operations and comprehensive income (loss).&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the results of operations of the Company&#x2019;s True Health business, which are included in loss from discontinued operations in the consolidated statements of operations and comprehensive income (loss) for the years ended December 31, 2021, 2020 and 2019:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:69.872%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.205%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.355%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.205%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.355%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.208%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;For the Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Platform and operations&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;356&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;145&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Premiums&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44,795&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;117,377&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;171,742&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44,833&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;117,733&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;171,887&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cost of revenue (exclusive of depreciation and amortization expenses presented separately below) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,885&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,343&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,633&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Claims expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,954&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;87,951&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;135,774&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Selling, general and administrative expenses &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,764&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,576&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26,617&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Depreciation and amortization expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;160&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;640&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;590&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total operating expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45,763&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;125,510&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;169,614&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating income (loss)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(930)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7,777)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,273&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;112&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;531&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;581&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(12)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(25)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income (loss) before income taxes and non-controlling interests&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(847)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7,259)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,872&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:69.872%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.205%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.355%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.205%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.355%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.208%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Benefit (provision) for income taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(326)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,185)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,259&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income (loss)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(521)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6,074)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,613&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt"&gt;Cost of revenue includes intercompany expenses between the Company and True Health that are recorded in income from continuing operations in the consolidated statements of operations and comprehensive income (loss) related to an existing services agreement for claims processing and other health plan administrative functions of $2.8&#160;million, $13.6&#160;million and $6.6&#160;million for the years ended December 31, 2021, 2020 and 2019, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt"&gt;Selling, general and administrative expenses includes intercompany expenses between the Company and True Health that are recorded in income from continuing operations on the consolidated statements of operations and comprehensive income (loss) related to an existing services agreement for claims processing and other health plan administrative functions of $1.1 million, $6.4 million and $6.0&#160;million for the years ended December 31, 2021, 2020 and 2019, respectively. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The consolidated statements of cash flows for all periods have not been adjusted to separately disclose cash flows related to discontinued operations. Cash flows related to the True Health business during the year ended December 31, 2021, 2020 and 2019 were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:69.872%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.205%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.355%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.205%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.355%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.208%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;For the Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash flows provided by (used in) operating activities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,002&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,852&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6,642)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash flows (used in) provided by investing activities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,494)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,636&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7,172)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash flows used in financing activities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,500)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the current and long-term assets and liabilities of the discontinued True Health business in the consolidated balance sheets as of December&#160;31, 2020:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:82.927%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.873%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;ASSETS&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,488&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted cash and restricted investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;63&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accounts receivable, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,437&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prepaid expenses and other current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,198&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Investments, at amortized cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,728&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,914&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted cash and restricted investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;616&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Investments, at amortized cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,919&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prepaid expenses and other noncurrent assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;59&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Intangible assets, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,080&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goodwill&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,705&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;54,293&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;LIABILITIES&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accounts payable &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;93&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,265&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued compensation and employee benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,115&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,140&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reserve for claims and performance-based arrangements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,858&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26,471&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other long-term liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;128&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:82.927%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.873%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred tax liabilities, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;49&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26,648&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt"&gt;Accounts payable excludes $1.5&#160;million between the Company and True Health related to an existing services agreement for claims processing and other health plan administrative functions as of December 31, 2020.&lt;/span&gt;&lt;/div&gt;</us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock>
    <evh:DiscontinuedOperationGainLossOnPurchasePriceAdjustmentsNetOfTax
      contextRef="i1c4a293e5ce54724af5effd8253d4d89_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM181NS9mcmFnOmNmZTY4OTBkMjFiYTQxZjE5OTA1MWYzYTFkMzI4MjZiL3RleHRyZWdpb246Y2ZlNjg5MGQyMWJhNDFmMTk5MDUxZjNhMWQzMjgyNmJfMjE5OTAyMzI1ODg4NA_37906391-e19a-4062-b493-e2fc5d54d217"
      unitRef="usd">-8700000</evh:DiscontinuedOperationGainLossOnPurchasePriceAdjustmentsNetOfTax>
    <us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock
      contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM181NS9mcmFnOmNmZTY4OTBkMjFiYTQxZjE5OTA1MWYzYTFkMzI4MjZiL3RleHRyZWdpb246Y2ZlNjg5MGQyMWJhNDFmMTk5MDUxZjNhMWQzMjgyNmJfMjcyMg_7e1c4ddc-a82a-42cc-8295-c655c3b84c53">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the results of operations of the Company&#x2019;s True Health business, which are included in loss from discontinued operations in the consolidated statements of operations and comprehensive income (loss) for the years ended December 31, 2021, 2020 and 2019:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:69.872%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.205%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.355%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.205%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.355%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.208%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;For the Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Platform and operations&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;356&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;145&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Premiums&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44,795&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;117,377&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;171,742&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44,833&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;117,733&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;171,887&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cost of revenue (exclusive of depreciation and amortization expenses presented separately below) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,885&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,343&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,633&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Claims expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,954&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;87,951&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;135,774&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Selling, general and administrative expenses &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,764&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,576&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26,617&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Depreciation and amortization expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;160&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;640&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;590&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total operating expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45,763&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;125,510&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;169,614&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating income (loss)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(930)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7,777)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,273&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;112&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;531&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;581&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(12)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(25)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income (loss) before income taxes and non-controlling interests&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(847)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7,259)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,872&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:69.872%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.205%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.355%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.205%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.355%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.208%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Benefit (provision) for income taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(326)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,185)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,259&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income (loss)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(521)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6,074)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,613&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt"&gt;Cost of revenue includes intercompany expenses between the Company and True Health that are recorded in income from continuing operations in the consolidated statements of operations and comprehensive income (loss) related to an existing services agreement for claims processing and other health plan administrative functions of $2.8&#160;million, $13.6&#160;million and $6.6&#160;million for the years ended December 31, 2021, 2020 and 2019, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt"&gt;Selling, general and administrative expenses includes intercompany expenses between the Company and True Health that are recorded in income from continuing operations on the consolidated statements of operations and comprehensive income (loss) related to an existing services agreement for claims processing and other health plan administrative functions of $1.1 million, $6.4 million and $6.0&#160;million for the years ended December 31, 2021, 2020 and 2019, respectively. &lt;/span&gt;&lt;/div&gt;Cash flows related to the True Health business during the year ended December 31, 2021, 2020 and 2019 were as follows:&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:69.872%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.205%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.355%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.205%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.355%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.208%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;For the Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash flows provided by (used in) operating activities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,002&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,852&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6,642)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash flows (used in) provided by investing activities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,494)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,636&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7,172)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash flows used in financing activities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,500)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the current and long-term assets and liabilities of the discontinued True Health business in the consolidated balance sheets as of December&#160;31, 2020:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:82.927%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.873%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;ASSETS&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,488&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted cash and restricted investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;63&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accounts receivable, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,437&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prepaid expenses and other current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,198&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Investments, at amortized cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,728&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,914&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted cash and restricted investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;616&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Investments, at amortized cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,919&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prepaid expenses and other noncurrent assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;59&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Intangible assets, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,080&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goodwill&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,705&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;54,293&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;LIABILITIES&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accounts payable &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;93&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,265&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued compensation and employee benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,115&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,140&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reserve for claims and performance-based arrangements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,858&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26,471&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other long-term liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;128&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:82.927%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.873%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred tax liabilities, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;49&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26,648&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt"&gt;Accounts payable excludes $1.5&#160;million between the Company and True Health related to an existing services agreement for claims processing and other health plan administrative functions as of December 31, 2020.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue
      contextRef="id9938925ae68403cbd1e3633d8c2af7a_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM181NS9mcmFnOmNmZTY4OTBkMjFiYTQxZjE5OTA1MWYzYTFkMzI4MjZiL3RhYmxlOmIwOTBmOWQ1ZjljZDQxMDI5Y2ZhZGU2ZTMyOTIyMTE0L3RhYmxlcmFuZ2U6YjA5MGY5ZDVmOWNkNDEwMjljZmFkZTZlMzI5MjIxMTRfMy01LTEtMS0xNzc3NQ_0869a7cf-9ebc-4ad2-88d1-d6ed083dafa9"
      unitRef="usd">38000</us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue
      contextRef="i62b6ff0a18e64449a282407a6971fe18_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM181NS9mcmFnOmNmZTY4OTBkMjFiYTQxZjE5OTA1MWYzYTFkMzI4MjZiL3RhYmxlOmIwOTBmOWQ1ZjljZDQxMDI5Y2ZhZGU2ZTMyOTIyMTE0L3RhYmxlcmFuZ2U6YjA5MGY5ZDVmOWNkNDEwMjljZmFkZTZlMzI5MjIxMTRfMy03LTEtMS0xNzc3NQ_e6f92011-a02c-45ce-98cd-8248666b4c20"
      unitRef="usd">356000</us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue
      contextRef="ic1ed065f23364faeb485521f6be7f439_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM181NS9mcmFnOmNmZTY4OTBkMjFiYTQxZjE5OTA1MWYzYTFkMzI4MjZiL3RhYmxlOmIwOTBmOWQ1ZjljZDQxMDI5Y2ZhZGU2ZTMyOTIyMTE0L3RhYmxlcmFuZ2U6YjA5MGY5ZDVmOWNkNDEwMjljZmFkZTZlMzI5MjIxMTRfMy01LTEtMS0xOTk2OA_b9d90580-6d5b-41dd-afed-79bbd6df44a4"
      unitRef="usd">145000</us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue
      contextRef="i15f03ee2332146e4a7e0d5b5717bea28_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM181NS9mcmFnOmNmZTY4OTBkMjFiYTQxZjE5OTA1MWYzYTFkMzI4MjZiL3RhYmxlOmIwOTBmOWQ1ZjljZDQxMDI5Y2ZhZGU2ZTMyOTIyMTE0L3RhYmxlcmFuZ2U6YjA5MGY5ZDVmOWNkNDEwMjljZmFkZTZlMzI5MjIxMTRfNC01LTEtMS0xNzc3NQ_122c5c50-a033-43eb-bfe7-8c5aad88d1e5"
      unitRef="usd">44795000</us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue
      contextRef="i6eca3f13863a45c481c07e49e9f434fe_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM181NS9mcmFnOmNmZTY4OTBkMjFiYTQxZjE5OTA1MWYzYTFkMzI4MjZiL3RhYmxlOmIwOTBmOWQ1ZjljZDQxMDI5Y2ZhZGU2ZTMyOTIyMTE0L3RhYmxlcmFuZ2U6YjA5MGY5ZDVmOWNkNDEwMjljZmFkZTZlMzI5MjIxMTRfNC03LTEtMS0xNzc3NQ_0fb0b667-2b01-46b8-ab54-5d88059b56b1"
      unitRef="usd">117377000</us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue
      contextRef="iae64c322a5eb4929bc01485807d92b3a_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM181NS9mcmFnOmNmZTY4OTBkMjFiYTQxZjE5OTA1MWYzYTFkMzI4MjZiL3RhYmxlOmIwOTBmOWQ1ZjljZDQxMDI5Y2ZhZGU2ZTMyOTIyMTE0L3RhYmxlcmFuZ2U6YjA5MGY5ZDVmOWNkNDEwMjljZmFkZTZlMzI5MjIxMTRfNC01LTEtMS0xOTk2OA_5ddf2948-9982-4f8d-bcce-2b996430ff71"
      unitRef="usd">171742000</us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue
      contextRef="i1c4a293e5ce54724af5effd8253d4d89_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM181NS9mcmFnOmNmZTY4OTBkMjFiYTQxZjE5OTA1MWYzYTFkMzI4MjZiL3RhYmxlOmIwOTBmOWQ1ZjljZDQxMDI5Y2ZhZGU2ZTMyOTIyMTE0L3RhYmxlcmFuZ2U6YjA5MGY5ZDVmOWNkNDEwMjljZmFkZTZlMzI5MjIxMTRfNS01LTEtMS0xNzc3NQ_19a45f0e-9a28-4435-8dea-a917177f49aa"
      unitRef="usd">44833000</us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue
      contextRef="if7ba948ef00b4ddeabe73338f1155e8b_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM181NS9mcmFnOmNmZTY4OTBkMjFiYTQxZjE5OTA1MWYzYTFkMzI4MjZiL3RhYmxlOmIwOTBmOWQ1ZjljZDQxMDI5Y2ZhZGU2ZTMyOTIyMTE0L3RhYmxlcmFuZ2U6YjA5MGY5ZDVmOWNkNDEwMjljZmFkZTZlMzI5MjIxMTRfNS03LTEtMS0xNzc3NQ_2632799e-76ac-4963-bfb2-7f86f67a12a3"
      unitRef="usd">117733000</us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue
      contextRef="iae6c9a536db44d69b64c473850d09499_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM181NS9mcmFnOmNmZTY4OTBkMjFiYTQxZjE5OTA1MWYzYTFkMzI4MjZiL3RhYmxlOmIwOTBmOWQ1ZjljZDQxMDI5Y2ZhZGU2ZTMyOTIyMTE0L3RhYmxlcmFuZ2U6YjA5MGY5ZDVmOWNkNDEwMjljZmFkZTZlMzI5MjIxMTRfNS01LTEtMS0xOTk2OA_1335472f-8c2b-4211-a572-e08e96400074"
      unitRef="usd">171887000</us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold
      contextRef="i1c4a293e5ce54724af5effd8253d4d89_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM181NS9mcmFnOmNmZTY4OTBkMjFiYTQxZjE5OTA1MWYzYTFkMzI4MjZiL3RhYmxlOmIwOTBmOWQ1ZjljZDQxMDI5Y2ZhZGU2ZTMyOTIyMTE0L3RhYmxlcmFuZ2U6YjA5MGY5ZDVmOWNkNDEwMjljZmFkZTZlMzI5MjIxMTRfOC01LTEtMS0xNzc3NQ_728c7882-60f2-4755-8765-f83c000d4c83"
      unitRef="usd">5885000</us-gaap:DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold
      contextRef="if7ba948ef00b4ddeabe73338f1155e8b_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM181NS9mcmFnOmNmZTY4OTBkMjFiYTQxZjE5OTA1MWYzYTFkMzI4MjZiL3RhYmxlOmIwOTBmOWQ1ZjljZDQxMDI5Y2ZhZGU2ZTMyOTIyMTE0L3RhYmxlcmFuZ2U6YjA5MGY5ZDVmOWNkNDEwMjljZmFkZTZlMzI5MjIxMTRfOC03LTEtMS0xNzc3NQ_a1e19b8e-95dc-4085-a076-e8f8bdad4c8a"
      unitRef="usd">18343000</us-gaap:DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold
      contextRef="iae6c9a536db44d69b64c473850d09499_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM181NS9mcmFnOmNmZTY4OTBkMjFiYTQxZjE5OTA1MWYzYTFkMzI4MjZiL3RhYmxlOmIwOTBmOWQ1ZjljZDQxMDI5Y2ZhZGU2ZTMyOTIyMTE0L3RhYmxlcmFuZ2U6YjA5MGY5ZDVmOWNkNDEwMjljZmFkZTZlMzI5MjIxMTRfOC01LTEtMS0xOTk3NQ_a3de4705-6c7a-4506-9bfe-467136a573e5"
      unitRef="usd">6633000</us-gaap:DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold>
    <evh:DisposalGroupIncludingDiscontinuedOperationClaimsExpense
      contextRef="i1c4a293e5ce54724af5effd8253d4d89_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM181NS9mcmFnOmNmZTY4OTBkMjFiYTQxZjE5OTA1MWYzYTFkMzI4MjZiL3RhYmxlOmIwOTBmOWQ1ZjljZDQxMDI5Y2ZhZGU2ZTMyOTIyMTE0L3RhYmxlcmFuZ2U6YjA5MGY5ZDVmOWNkNDEwMjljZmFkZTZlMzI5MjIxMTRfOS01LTEtMS0xNzc3NQ_67cf4722-de0b-44c3-b3d3-4f13120d4ed3"
      unitRef="usd">33954000</evh:DisposalGroupIncludingDiscontinuedOperationClaimsExpense>
    <evh:DisposalGroupIncludingDiscontinuedOperationClaimsExpense
      contextRef="if7ba948ef00b4ddeabe73338f1155e8b_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM181NS9mcmFnOmNmZTY4OTBkMjFiYTQxZjE5OTA1MWYzYTFkMzI4MjZiL3RhYmxlOmIwOTBmOWQ1ZjljZDQxMDI5Y2ZhZGU2ZTMyOTIyMTE0L3RhYmxlcmFuZ2U6YjA5MGY5ZDVmOWNkNDEwMjljZmFkZTZlMzI5MjIxMTRfOS03LTEtMS0xNzc3NQ_a5689e8d-5a1b-4ee5-9964-4a23459fc9a0"
      unitRef="usd">87951000</evh:DisposalGroupIncludingDiscontinuedOperationClaimsExpense>
    <evh:DisposalGroupIncludingDiscontinuedOperationClaimsExpense
      contextRef="iae6c9a536db44d69b64c473850d09499_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM181NS9mcmFnOmNmZTY4OTBkMjFiYTQxZjE5OTA1MWYzYTFkMzI4MjZiL3RhYmxlOmIwOTBmOWQ1ZjljZDQxMDI5Y2ZhZGU2ZTMyOTIyMTE0L3RhYmxlcmFuZ2U6YjA5MGY5ZDVmOWNkNDEwMjljZmFkZTZlMzI5MjIxMTRfOS01LTEtMS0xOTk3NQ_915f8fb2-5df5-44ee-be63-c48292fe0103"
      unitRef="usd">135774000</evh:DisposalGroupIncludingDiscontinuedOperationClaimsExpense>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense
      contextRef="i1c4a293e5ce54724af5effd8253d4d89_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM181NS9mcmFnOmNmZTY4OTBkMjFiYTQxZjE5OTA1MWYzYTFkMzI4MjZiL3RhYmxlOmIwOTBmOWQ1ZjljZDQxMDI5Y2ZhZGU2ZTMyOTIyMTE0L3RhYmxlcmFuZ2U6YjA5MGY5ZDVmOWNkNDEwMjljZmFkZTZlMzI5MjIxMTRfMTAtNS0xLTEtMTc3NzU_e8f7a524-6d7b-4a4d-ab77-10dc03016b7c"
      unitRef="usd">5764000</us-gaap:DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense
      contextRef="if7ba948ef00b4ddeabe73338f1155e8b_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM181NS9mcmFnOmNmZTY4OTBkMjFiYTQxZjE5OTA1MWYzYTFkMzI4MjZiL3RhYmxlOmIwOTBmOWQ1ZjljZDQxMDI5Y2ZhZGU2ZTMyOTIyMTE0L3RhYmxlcmFuZ2U6YjA5MGY5ZDVmOWNkNDEwMjljZmFkZTZlMzI5MjIxMTRfMTAtNy0xLTEtMTc3NzU_0cc8c709-bd86-4e45-b501-3fc1290140f6"
      unitRef="usd">18576000</us-gaap:DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense
      contextRef="iae6c9a536db44d69b64c473850d09499_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM181NS9mcmFnOmNmZTY4OTBkMjFiYTQxZjE5OTA1MWYzYTFkMzI4MjZiL3RhYmxlOmIwOTBmOWQ1ZjljZDQxMDI5Y2ZhZGU2ZTMyOTIyMTE0L3RhYmxlcmFuZ2U6YjA5MGY5ZDVmOWNkNDEwMjljZmFkZTZlMzI5MjIxMTRfMTAtNS0xLTEtMTk5NzU_7f5b6b68-0de8-4330-ba9b-cdf45bcbcd3a"
      unitRef="usd">26617000</us-gaap:DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense>
    <us-gaap:DepreciationAndAmortizationDiscontinuedOperations
      contextRef="i1c4a293e5ce54724af5effd8253d4d89_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM181NS9mcmFnOmNmZTY4OTBkMjFiYTQxZjE5OTA1MWYzYTFkMzI4MjZiL3RhYmxlOmIwOTBmOWQ1ZjljZDQxMDI5Y2ZhZGU2ZTMyOTIyMTE0L3RhYmxlcmFuZ2U6YjA5MGY5ZDVmOWNkNDEwMjljZmFkZTZlMzI5MjIxMTRfMTEtNS0xLTEtMTc3NzU_fc7502a5-14e6-4c9f-a577-06e7c8e2c087"
      unitRef="usd">160000</us-gaap:DepreciationAndAmortizationDiscontinuedOperations>
    <us-gaap:DepreciationAndAmortizationDiscontinuedOperations
      contextRef="if7ba948ef00b4ddeabe73338f1155e8b_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM181NS9mcmFnOmNmZTY4OTBkMjFiYTQxZjE5OTA1MWYzYTFkMzI4MjZiL3RhYmxlOmIwOTBmOWQ1ZjljZDQxMDI5Y2ZhZGU2ZTMyOTIyMTE0L3RhYmxlcmFuZ2U6YjA5MGY5ZDVmOWNkNDEwMjljZmFkZTZlMzI5MjIxMTRfMTEtNy0xLTEtMTc3NzU_e150b216-d697-4dbd-9716-a10d5b78e82a"
      unitRef="usd">640000</us-gaap:DepreciationAndAmortizationDiscontinuedOperations>
    <us-gaap:DepreciationAndAmortizationDiscontinuedOperations
      contextRef="iae6c9a536db44d69b64c473850d09499_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM181NS9mcmFnOmNmZTY4OTBkMjFiYTQxZjE5OTA1MWYzYTFkMzI4MjZiL3RhYmxlOmIwOTBmOWQ1ZjljZDQxMDI5Y2ZhZGU2ZTMyOTIyMTE0L3RhYmxlcmFuZ2U6YjA5MGY5ZDVmOWNkNDEwMjljZmFkZTZlMzI5MjIxMTRfMTEtNS0xLTEtMTk5NzU_6e816e99-9bbc-4084-bad6-97d62b8379d7"
      unitRef="usd">590000</us-gaap:DepreciationAndAmortizationDiscontinuedOperations>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingExpense
      contextRef="i1c4a293e5ce54724af5effd8253d4d89_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM181NS9mcmFnOmNmZTY4OTBkMjFiYTQxZjE5OTA1MWYzYTFkMzI4MjZiL3RhYmxlOmIwOTBmOWQ1ZjljZDQxMDI5Y2ZhZGU2ZTMyOTIyMTE0L3RhYmxlcmFuZ2U6YjA5MGY5ZDVmOWNkNDEwMjljZmFkZTZlMzI5MjIxMTRfMTItNS0xLTEtMTc3NzU_7c56ed0c-4f99-4d47-94b9-f6e3af61da89"
      unitRef="usd">45763000</us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingExpense>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingExpense
      contextRef="if7ba948ef00b4ddeabe73338f1155e8b_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM181NS9mcmFnOmNmZTY4OTBkMjFiYTQxZjE5OTA1MWYzYTFkMzI4MjZiL3RhYmxlOmIwOTBmOWQ1ZjljZDQxMDI5Y2ZhZGU2ZTMyOTIyMTE0L3RhYmxlcmFuZ2U6YjA5MGY5ZDVmOWNkNDEwMjljZmFkZTZlMzI5MjIxMTRfMTItNy0xLTEtMTc3NzU_90ef6432-64b7-4d6b-83ca-f92e6a996d05"
      unitRef="usd">125510000</us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingExpense>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingExpense
      contextRef="iae6c9a536db44d69b64c473850d09499_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM181NS9mcmFnOmNmZTY4OTBkMjFiYTQxZjE5OTA1MWYzYTFkMzI4MjZiL3RhYmxlOmIwOTBmOWQ1ZjljZDQxMDI5Y2ZhZGU2ZTMyOTIyMTE0L3RhYmxlcmFuZ2U6YjA5MGY5ZDVmOWNkNDEwMjljZmFkZTZlMzI5MjIxMTRfMTItNS0xLTEtMTk5NzU_7e30c4e6-2a59-4f99-9987-fde335d1e298"
      unitRef="usd">169614000</us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingExpense>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss
      contextRef="i1c4a293e5ce54724af5effd8253d4d89_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM181NS9mcmFnOmNmZTY4OTBkMjFiYTQxZjE5OTA1MWYzYTFkMzI4MjZiL3RhYmxlOmIwOTBmOWQ1ZjljZDQxMDI5Y2ZhZGU2ZTMyOTIyMTE0L3RhYmxlcmFuZ2U6YjA5MGY5ZDVmOWNkNDEwMjljZmFkZTZlMzI5MjIxMTRfMTMtNS0xLTEtMTc3NzU_77bf358e-f420-4451-8a80-7df5d156e27b"
      unitRef="usd">-930000</us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss
      contextRef="if7ba948ef00b4ddeabe73338f1155e8b_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM181NS9mcmFnOmNmZTY4OTBkMjFiYTQxZjE5OTA1MWYzYTFkMzI4MjZiL3RhYmxlOmIwOTBmOWQ1ZjljZDQxMDI5Y2ZhZGU2ZTMyOTIyMTE0L3RhYmxlcmFuZ2U6YjA5MGY5ZDVmOWNkNDEwMjljZmFkZTZlMzI5MjIxMTRfMTMtNy0xLTEtMTc3NzU_300cc81d-2c8f-4f5b-9f4b-3241c92d58da"
      unitRef="usd">-7777000</us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss
      contextRef="iae6c9a536db44d69b64c473850d09499_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM181NS9mcmFnOmNmZTY4OTBkMjFiYTQxZjE5OTA1MWYzYTFkMzI4MjZiL3RhYmxlOmIwOTBmOWQ1ZjljZDQxMDI5Y2ZhZGU2ZTMyOTIyMTE0L3RhYmxlcmFuZ2U6YjA5MGY5ZDVmOWNkNDEwMjljZmFkZTZlMzI5MjIxMTRfMTMtNS0xLTEtMTk5NzU_f82dba4a-fa4e-4d43-bd0a-2b9dbf92a7bb"
      unitRef="usd">2273000</us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationInterestIncome
      contextRef="i1c4a293e5ce54724af5effd8253d4d89_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM181NS9mcmFnOmNmZTY4OTBkMjFiYTQxZjE5OTA1MWYzYTFkMzI4MjZiL3RhYmxlOmIwOTBmOWQ1ZjljZDQxMDI5Y2ZhZGU2ZTMyOTIyMTE0L3RhYmxlcmFuZ2U6YjA5MGY5ZDVmOWNkNDEwMjljZmFkZTZlMzI5MjIxMTRfMTQtNS0xLTEtMTc3NzU_fa86cc48-66b3-45e2-a16b-ee6a0aeee684"
      unitRef="usd">112000</us-gaap:DisposalGroupIncludingDiscontinuedOperationInterestIncome>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationInterestIncome
      contextRef="if7ba948ef00b4ddeabe73338f1155e8b_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM181NS9mcmFnOmNmZTY4OTBkMjFiYTQxZjE5OTA1MWYzYTFkMzI4MjZiL3RhYmxlOmIwOTBmOWQ1ZjljZDQxMDI5Y2ZhZGU2ZTMyOTIyMTE0L3RhYmxlcmFuZ2U6YjA5MGY5ZDVmOWNkNDEwMjljZmFkZTZlMzI5MjIxMTRfMTQtNy0xLTEtMTc3NzU_3385302c-d4c2-4408-baf8-da64df6ff9a6"
      unitRef="usd">531000</us-gaap:DisposalGroupIncludingDiscontinuedOperationInterestIncome>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationInterestIncome
      contextRef="iae6c9a536db44d69b64c473850d09499_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM181NS9mcmFnOmNmZTY4OTBkMjFiYTQxZjE5OTA1MWYzYTFkMzI4MjZiL3RhYmxlOmIwOTBmOWQ1ZjljZDQxMDI5Y2ZhZGU2ZTMyOTIyMTE0L3RhYmxlcmFuZ2U6YjA5MGY5ZDVmOWNkNDEwMjljZmFkZTZlMzI5MjIxMTRfMTQtNS0xLTEtMTk5NzU_3d1129d2-aca1-4b8d-aa60-3d8db973323c"
      unitRef="usd">581000</us-gaap:DisposalGroupIncludingDiscontinuedOperationInterestIncome>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationInterestExpense
      contextRef="i1c4a293e5ce54724af5effd8253d4d89_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM181NS9mcmFnOmNmZTY4OTBkMjFiYTQxZjE5OTA1MWYzYTFkMzI4MjZiL3RhYmxlOmIwOTBmOWQ1ZjljZDQxMDI5Y2ZhZGU2ZTMyOTIyMTE0L3RhYmxlcmFuZ2U6YjA5MGY5ZDVmOWNkNDEwMjljZmFkZTZlMzI5MjIxMTRfMTUtNS0xLTEtMTc3NzU_ddbb686d-21f9-4db6-8907-6d729580f2a7"
      unitRef="usd">4000</us-gaap:DisposalGroupIncludingDiscontinuedOperationInterestExpense>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationInterestExpense
      contextRef="if7ba948ef00b4ddeabe73338f1155e8b_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM181NS9mcmFnOmNmZTY4OTBkMjFiYTQxZjE5OTA1MWYzYTFkMzI4MjZiL3RhYmxlOmIwOTBmOWQ1ZjljZDQxMDI5Y2ZhZGU2ZTMyOTIyMTE0L3RhYmxlcmFuZ2U6YjA5MGY5ZDVmOWNkNDEwMjljZmFkZTZlMzI5MjIxMTRfMTUtNy0xLTEtMTc3NzU_37da96e5-3ffd-4eaf-b509-26302b763417"
      unitRef="usd">12000</us-gaap:DisposalGroupIncludingDiscontinuedOperationInterestExpense>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationInterestExpense
      contextRef="iae6c9a536db44d69b64c473850d09499_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM181NS9mcmFnOmNmZTY4OTBkMjFiYTQxZjE5OTA1MWYzYTFkMzI4MjZiL3RhYmxlOmIwOTBmOWQ1ZjljZDQxMDI5Y2ZhZGU2ZTMyOTIyMTE0L3RhYmxlcmFuZ2U6YjA5MGY5ZDVmOWNkNDEwMjljZmFkZTZlMzI5MjIxMTRfMTUtNS0xLTEtMTk5NzU_db9549b2-eb3e-43ce-8232-30344c3540b1"
      unitRef="usd">-21000</us-gaap:DisposalGroupIncludingDiscontinuedOperationInterestExpense>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationOtherExpense
      contextRef="i1c4a293e5ce54724af5effd8253d4d89_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM181NS9mcmFnOmNmZTY4OTBkMjFiYTQxZjE5OTA1MWYzYTFkMzI4MjZiL3RhYmxlOmIwOTBmOWQ1ZjljZDQxMDI5Y2ZhZGU2ZTMyOTIyMTE0L3RhYmxlcmFuZ2U6YjA5MGY5ZDVmOWNkNDEwMjljZmFkZTZlMzI5MjIxMTRfMTYtNS0xLTEtMTc3NzU_12dd6c5c-5a26-4368-bafa-0ba88167337b"
      unitRef="usd">25000</us-gaap:DisposalGroupIncludingDiscontinuedOperationOtherExpense>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationOtherExpense
      contextRef="if7ba948ef00b4ddeabe73338f1155e8b_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM181NS9mcmFnOmNmZTY4OTBkMjFiYTQxZjE5OTA1MWYzYTFkMzI4MjZiL3RhYmxlOmIwOTBmOWQ1ZjljZDQxMDI5Y2ZhZGU2ZTMyOTIyMTE0L3RhYmxlcmFuZ2U6YjA5MGY5ZDVmOWNkNDEwMjljZmFkZTZlMzI5MjIxMTRfMTYtNy0xLTEtMTc3NzU_0bc545cb-4d5c-4931-85e9-dc5ea65e56d5"
      unitRef="usd">1000</us-gaap:DisposalGroupIncludingDiscontinuedOperationOtherExpense>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationOtherExpense
      contextRef="iae6c9a536db44d69b64c473850d09499_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM181NS9mcmFnOmNmZTY4OTBkMjFiYTQxZjE5OTA1MWYzYTFkMzI4MjZiL3RhYmxlOmIwOTBmOWQ1ZjljZDQxMDI5Y2ZhZGU2ZTMyOTIyMTE0L3RhYmxlcmFuZ2U6YjA5MGY5ZDVmOWNkNDEwMjljZmFkZTZlMzI5MjIxMTRfMTYtNS0xLTEtMTk5NzU_2df149dc-3ac2-4585-b776-199cd9c0e188"
      unitRef="usd">3000</us-gaap:DisposalGroupIncludingDiscontinuedOperationOtherExpense>
    <us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax
      contextRef="i1c4a293e5ce54724af5effd8253d4d89_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM181NS9mcmFnOmNmZTY4OTBkMjFiYTQxZjE5OTA1MWYzYTFkMzI4MjZiL3RhYmxlOmIwOTBmOWQ1ZjljZDQxMDI5Y2ZhZGU2ZTMyOTIyMTE0L3RhYmxlcmFuZ2U6YjA5MGY5ZDVmOWNkNDEwMjljZmFkZTZlMzI5MjIxMTRfMTctNS0xLTEtMTc3NzU_1316f185-a286-4eb7-95a0-171bc64706d1"
      unitRef="usd">-847000</us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax>
    <us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax
      contextRef="if7ba948ef00b4ddeabe73338f1155e8b_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM181NS9mcmFnOmNmZTY4OTBkMjFiYTQxZjE5OTA1MWYzYTFkMzI4MjZiL3RhYmxlOmIwOTBmOWQ1ZjljZDQxMDI5Y2ZhZGU2ZTMyOTIyMTE0L3RhYmxlcmFuZ2U6YjA5MGY5ZDVmOWNkNDEwMjljZmFkZTZlMzI5MjIxMTRfMTctNy0xLTEtMTc3NzU_7a8d8716-5756-4564-801b-ab868cb6cfee"
      unitRef="usd">-7259000</us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax>
    <us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax
      contextRef="iae6c9a536db44d69b64c473850d09499_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM181NS9mcmFnOmNmZTY4OTBkMjFiYTQxZjE5OTA1MWYzYTFkMzI4MjZiL3RhYmxlOmIwOTBmOWQ1ZjljZDQxMDI5Y2ZhZGU2ZTMyOTIyMTE0L3RhYmxlcmFuZ2U6YjA5MGY5ZDVmOWNkNDEwMjljZmFkZTZlMzI5MjIxMTRfMTctNS0xLTEtMTk5NzU_c2d0f499-ecb1-4641-b1e3-e34ed36576ce"
      unitRef="usd">2872000</us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax>
    <us-gaap:DiscontinuedOperationTaxEffectOfDiscontinuedOperation
      contextRef="i1c4a293e5ce54724af5effd8253d4d89_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM181NS9mcmFnOmNmZTY4OTBkMjFiYTQxZjE5OTA1MWYzYTFkMzI4MjZiL3RhYmxlOmIwOTBmOWQ1ZjljZDQxMDI5Y2ZhZGU2ZTMyOTIyMTE0L3RhYmxlcmFuZ2U6YjA5MGY5ZDVmOWNkNDEwMjljZmFkZTZlMzI5MjIxMTRfMTgtNS0xLTEtMTc3NzU_7c143a07-316c-466f-956c-17506c1537b5"
      unitRef="usd">-326000</us-gaap:DiscontinuedOperationTaxEffectOfDiscontinuedOperation>
    <us-gaap:DiscontinuedOperationTaxEffectOfDiscontinuedOperation
      contextRef="if7ba948ef00b4ddeabe73338f1155e8b_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM181NS9mcmFnOmNmZTY4OTBkMjFiYTQxZjE5OTA1MWYzYTFkMzI4MjZiL3RhYmxlOmIwOTBmOWQ1ZjljZDQxMDI5Y2ZhZGU2ZTMyOTIyMTE0L3RhYmxlcmFuZ2U6YjA5MGY5ZDVmOWNkNDEwMjljZmFkZTZlMzI5MjIxMTRfMTgtNy0xLTEtMTc3NzU_106c3902-c690-4b4b-a258-2efff2f8547c"
      unitRef="usd">-1185000</us-gaap:DiscontinuedOperationTaxEffectOfDiscontinuedOperation>
    <us-gaap:DiscontinuedOperationTaxEffectOfDiscontinuedOperation
      contextRef="iae6c9a536db44d69b64c473850d09499_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM181NS9mcmFnOmNmZTY4OTBkMjFiYTQxZjE5OTA1MWYzYTFkMzI4MjZiL3RhYmxlOmIwOTBmOWQ1ZjljZDQxMDI5Y2ZhZGU2ZTMyOTIyMTE0L3RhYmxlcmFuZ2U6YjA5MGY5ZDVmOWNkNDEwMjljZmFkZTZlMzI5MjIxMTRfMTgtNS0xLTEtMTk5NzU_de379250-e2a8-442b-804e-9bd3294a1a8c"
      unitRef="usd">1259000</us-gaap:DiscontinuedOperationTaxEffectOfDiscontinuedOperation>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax
      contextRef="i1c4a293e5ce54724af5effd8253d4d89_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM181NS9mcmFnOmNmZTY4OTBkMjFiYTQxZjE5OTA1MWYzYTFkMzI4MjZiL3RhYmxlOmIwOTBmOWQ1ZjljZDQxMDI5Y2ZhZGU2ZTMyOTIyMTE0L3RhYmxlcmFuZ2U6YjA5MGY5ZDVmOWNkNDEwMjljZmFkZTZlMzI5MjIxMTRfMTktNS0xLTEtMTc3NzU_ffe52d6e-5582-488c-8ca2-74fa0de34439"
      unitRef="usd">-521000</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax
      contextRef="if7ba948ef00b4ddeabe73338f1155e8b_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM181NS9mcmFnOmNmZTY4OTBkMjFiYTQxZjE5OTA1MWYzYTFkMzI4MjZiL3RhYmxlOmIwOTBmOWQ1ZjljZDQxMDI5Y2ZhZGU2ZTMyOTIyMTE0L3RhYmxlcmFuZ2U6YjA5MGY5ZDVmOWNkNDEwMjljZmFkZTZlMzI5MjIxMTRfMTktNy0xLTEtMTc3NzU_b2b99bf1-5b4a-4963-bf0c-45941b96654b"
      unitRef="usd">-6074000</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax
      contextRef="iae6c9a536db44d69b64c473850d09499_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM181NS9mcmFnOmNmZTY4OTBkMjFiYTQxZjE5OTA1MWYzYTFkMzI4MjZiL3RhYmxlOmIwOTBmOWQ1ZjljZDQxMDI5Y2ZhZGU2ZTMyOTIyMTE0L3RhYmxlcmFuZ2U6YjA5MGY5ZDVmOWNkNDEwMjljZmFkZTZlMzI5MjIxMTRfMTktNS0xLTEtMTk5NzU_afc0fa76-6f38-4640-9a01-437f756ff6dd"
      unitRef="usd">1613000</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold
      contextRef="ib1b709ded692440f9e0b6b584a8c0080_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM181NS9mcmFnOmNmZTY4OTBkMjFiYTQxZjE5OTA1MWYzYTFkMzI4MjZiL3RleHRyZWdpb246Y2ZlNjg5MGQyMWJhNDFmMTk5MDUxZjNhMWQzMjgyNmJfMTY1OA_6c5b4578-fdba-463b-85ac-45bb101c65ab"
      unitRef="usd">2800000</us-gaap:DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold
      contextRef="i93a7fe07dcb74ecba6ec18daa2afd21d_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM181NS9mcmFnOmNmZTY4OTBkMjFiYTQxZjE5OTA1MWYzYTFkMzI4MjZiL3RleHRyZWdpb246Y2ZlNjg5MGQyMWJhNDFmMTk5MDUxZjNhMWQzMjgyNmJfMTY2NQ_375b88e2-9c7b-47f6-96a8-b6ce0b859bfa"
      unitRef="usd">13600000</us-gaap:DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold
      contextRef="i0725607f45d24e7096771c6e0b9f7133_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM181NS9mcmFnOmNmZTY4OTBkMjFiYTQxZjE5OTA1MWYzYTFkMzI4MjZiL3RleHRyZWdpb246Y2ZlNjg5MGQyMWJhNDFmMTk5MDUxZjNhMWQzMjgyNmJfMTA5OTUxMTYzMDY5OA_2a2b60c5-60cf-438b-8459-0329367a2ec1"
      unitRef="usd">6600000</us-gaap:DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense
      contextRef="ib1b709ded692440f9e0b6b584a8c0080_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM181NS9mcmFnOmNmZTY4OTBkMjFiYTQxZjE5OTA1MWYzYTFkMzI4MjZiL3RleHRyZWdpb246Y2ZlNjg5MGQyMWJhNDFmMTk5MDUxZjNhMWQzMjgyNmJfMjA2OQ_50ab129b-0bf1-400c-ab51-676f20d7265e"
      unitRef="usd">1100000</us-gaap:DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense
      contextRef="i93a7fe07dcb74ecba6ec18daa2afd21d_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM181NS9mcmFnOmNmZTY4OTBkMjFiYTQxZjE5OTA1MWYzYTFkMzI4MjZiL3RleHRyZWdpb246Y2ZlNjg5MGQyMWJhNDFmMTk5MDUxZjNhMWQzMjgyNmJfMjA3Ng_f904a473-edb4-42a2-bba2-5a3245bb5d41"
      unitRef="usd">6400000</us-gaap:DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense
      contextRef="i0725607f45d24e7096771c6e0b9f7133_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM181NS9mcmFnOmNmZTY4OTBkMjFiYTQxZjE5OTA1MWYzYTFkMzI4MjZiL3RleHRyZWdpb246Y2ZlNjg5MGQyMWJhNDFmMTk5MDUxZjNhMWQzMjgyNmJfMTA5OTUxMTYzMDc4OA_c73509cb-ecdc-454d-b9d7-579ba4814115"
      unitRef="usd">6000000</us-gaap:DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense>
    <us-gaap:CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations
      contextRef="i1c4a293e5ce54724af5effd8253d4d89_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM181NS9mcmFnOmNmZTY4OTBkMjFiYTQxZjE5OTA1MWYzYTFkMzI4MjZiL3RhYmxlOjQyNjgyYTc0MDg3NTQ5M2M5MjNhZWE3ZWI5YmIzMGRhL3RhYmxlcmFuZ2U6NDI2ODJhNzQwODc1NDkzYzkyM2FlYTdlYjliYjMwZGFfMi0xLTEtMS0xNzc3NQ_5e249f92-6cb9-4d0b-9388-7d26475844ac"
      unitRef="usd">5002000</us-gaap:CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations>
    <us-gaap:CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations
      contextRef="if7ba948ef00b4ddeabe73338f1155e8b_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM181NS9mcmFnOmNmZTY4OTBkMjFiYTQxZjE5OTA1MWYzYTFkMzI4MjZiL3RhYmxlOjQyNjgyYTc0MDg3NTQ5M2M5MjNhZWE3ZWI5YmIzMGRhL3RhYmxlcmFuZ2U6NDI2ODJhNzQwODc1NDkzYzkyM2FlYTdlYjliYjMwZGFfMi0zLTEtMS0xNzc3NQ_cbc4096e-9fdb-4e9d-ad44-7d048937f593"
      unitRef="usd">6852000</us-gaap:CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations>
    <us-gaap:CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations
      contextRef="iae6c9a536db44d69b64c473850d09499_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM181NS9mcmFnOmNmZTY4OTBkMjFiYTQxZjE5OTA1MWYzYTFkMzI4MjZiL3RhYmxlOjQyNjgyYTc0MDg3NTQ5M2M5MjNhZWE3ZWI5YmIzMGRhL3RhYmxlcmFuZ2U6NDI2ODJhNzQwODc1NDkzYzkyM2FlYTdlYjliYjMwZGFfMi01LTEtMS0yNzA0OQ_7815f47c-2799-4a3b-825f-fdcee94bfe71"
      unitRef="usd">-6642000</us-gaap:CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations>
    <us-gaap:CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations
      contextRef="i1c4a293e5ce54724af5effd8253d4d89_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM181NS9mcmFnOmNmZTY4OTBkMjFiYTQxZjE5OTA1MWYzYTFkMzI4MjZiL3RhYmxlOjQyNjgyYTc0MDg3NTQ5M2M5MjNhZWE3ZWI5YmIzMGRhL3RhYmxlcmFuZ2U6NDI2ODJhNzQwODc1NDkzYzkyM2FlYTdlYjliYjMwZGFfMy0xLTEtMS0xNzc3NQ_f596583e-17af-4794-b817-90a88cc117a4"
      unitRef="usd">-2494000</us-gaap:CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations>
    <us-gaap:CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations
      contextRef="if7ba948ef00b4ddeabe73338f1155e8b_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM181NS9mcmFnOmNmZTY4OTBkMjFiYTQxZjE5OTA1MWYzYTFkMzI4MjZiL3RhYmxlOjQyNjgyYTc0MDg3NTQ5M2M5MjNhZWE3ZWI5YmIzMGRhL3RhYmxlcmFuZ2U6NDI2ODJhNzQwODc1NDkzYzkyM2FlYTdlYjliYjMwZGFfMy0zLTEtMS0xNzc3NQ_77e1747c-92c8-4eb5-8a46-fcaea34b73ff"
      unitRef="usd">2636000</us-gaap:CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations>
    <us-gaap:CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations
      contextRef="iae6c9a536db44d69b64c473850d09499_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM181NS9mcmFnOmNmZTY4OTBkMjFiYTQxZjE5OTA1MWYzYTFkMzI4MjZiL3RhYmxlOjQyNjgyYTc0MDg3NTQ5M2M5MjNhZWE3ZWI5YmIzMGRhL3RhYmxlcmFuZ2U6NDI2ODJhNzQwODc1NDkzYzkyM2FlYTdlYjliYjMwZGFfMy01LTEtMS0yNzA0OQ_bce50828-92e5-4cac-8509-4715d13840a0"
      unitRef="usd">-7172000</us-gaap:CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations>
    <us-gaap:CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations
      contextRef="i1c4a293e5ce54724af5effd8253d4d89_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM181NS9mcmFnOmNmZTY4OTBkMjFiYTQxZjE5OTA1MWYzYTFkMzI4MjZiL3RhYmxlOjQyNjgyYTc0MDg3NTQ5M2M5MjNhZWE3ZWI5YmIzMGRhL3RhYmxlcmFuZ2U6NDI2ODJhNzQwODc1NDkzYzkyM2FlYTdlYjliYjMwZGFfNC0xLTEtMS0yNzA2NA_c6096468-ec6a-4bcf-b98b-4f1def1f1eb0"
      unitRef="usd">0</us-gaap:CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations>
    <us-gaap:CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations
      contextRef="if7ba948ef00b4ddeabe73338f1155e8b_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM181NS9mcmFnOmNmZTY4OTBkMjFiYTQxZjE5OTA1MWYzYTFkMzI4MjZiL3RhYmxlOjQyNjgyYTc0MDg3NTQ5M2M5MjNhZWE3ZWI5YmIzMGRhL3RhYmxlcmFuZ2U6NDI2ODJhNzQwODc1NDkzYzkyM2FlYTdlYjliYjMwZGFfNC0zLTEtMS0yNzA2NA_b471dfc3-b326-4a9d-ab7f-22312a2c16ca"
      unitRef="usd">0</us-gaap:CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations>
    <us-gaap:CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations
      contextRef="iae6c9a536db44d69b64c473850d09499_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM181NS9mcmFnOmNmZTY4OTBkMjFiYTQxZjE5OTA1MWYzYTFkMzI4MjZiL3RhYmxlOjQyNjgyYTc0MDg3NTQ5M2M5MjNhZWE3ZWI5YmIzMGRhL3RhYmxlcmFuZ2U6NDI2ODJhNzQwODc1NDkzYzkyM2FlYTdlYjliYjMwZGFfNC01LTEtMS0yNzA2NA_3e2a8096-bbef-4041-b661-e577d9ab5501"
      unitRef="usd">-2500000</us-gaap:CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents
      contextRef="i98364cf4ba3e41af868d701b4c668283_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM181NS9mcmFnOmNmZTY4OTBkMjFiYTQxZjE5OTA1MWYzYTFkMzI4MjZiL3RhYmxlOmRmNTY5NGIzNmMxYjQwY2U5NzlkOTAzYjI0YWM0NGY4L3RhYmxlcmFuZ2U6ZGY1Njk0YjM2YzFiNDBjZTk3OWQ5MDNiMjRhYzQ0ZjhfMy0xLTEtMS0xNzc3NQ_7cc467bd-27a8-4ac0-b420-f8a5b10f3d68"
      unitRef="usd">21488000</us-gaap:DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents>
    <evh:DisposalGroupIncludingDiscontinuedOperationRestrictedCashAndRestrictedInvestmentsCurrent
      contextRef="i98364cf4ba3e41af868d701b4c668283_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM181NS9mcmFnOmNmZTY4OTBkMjFiYTQxZjE5OTA1MWYzYTFkMzI4MjZiL3RhYmxlOmRmNTY5NGIzNmMxYjQwY2U5NzlkOTAzYjI0YWM0NGY4L3RhYmxlcmFuZ2U6ZGY1Njk0YjM2YzFiNDBjZTk3OWQ5MDNiMjRhYzQ0ZjhfNC0xLTEtMS0xNzc3NQ_e44e8a62-6a48-4e4d-8727-663018619f7f"
      unitRef="usd">63000</evh:DisposalGroupIncludingDiscontinuedOperationRestrictedCashAndRestrictedInvestmentsCurrent>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet
      contextRef="i98364cf4ba3e41af868d701b4c668283_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM181NS9mcmFnOmNmZTY4OTBkMjFiYTQxZjE5OTA1MWYzYTFkMzI4MjZiL3RhYmxlOmRmNTY5NGIzNmMxYjQwY2U5NzlkOTAzYjI0YWM0NGY4L3RhYmxlcmFuZ2U6ZGY1Njk0YjM2YzFiNDBjZTk3OWQ5MDNiMjRhYzQ0ZjhfNS0xLTEtMS0xNzc3NQ_b6751419-5506-49c0-9e68-8831d01fa211"
      unitRef="usd">3437000</us-gaap:DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent
      contextRef="i98364cf4ba3e41af868d701b4c668283_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM181NS9mcmFnOmNmZTY4OTBkMjFiYTQxZjE5OTA1MWYzYTFkMzI4MjZiL3RhYmxlOmRmNTY5NGIzNmMxYjQwY2U5NzlkOTAzYjI0YWM0NGY4L3RhYmxlcmFuZ2U6ZGY1Njk0YjM2YzFiNDBjZTk3OWQ5MDNiMjRhYzQ0ZjhfNi0xLTEtMS0xNzc3NQ_486e3e34-bc19-460d-90f3-549c733d77fb"
      unitRef="usd">5198000</us-gaap:DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent>
    <evh:DisposalGroupIncludingDiscontinuedOperationInvestmentsCurrent
      contextRef="i98364cf4ba3e41af868d701b4c668283_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM181NS9mcmFnOmNmZTY4OTBkMjFiYTQxZjE5OTA1MWYzYTFkMzI4MjZiL3RhYmxlOmRmNTY5NGIzNmMxYjQwY2U5NzlkOTAzYjI0YWM0NGY4L3RhYmxlcmFuZ2U6ZGY1Njk0YjM2YzFiNDBjZTk3OWQ5MDNiMjRhYzQ0ZjhfNy0xLTEtMS0xNzc3NQ_aac02375-a946-41ea-b0ef-a9f93e2004db"
      unitRef="usd">3728000</evh:DisposalGroupIncludingDiscontinuedOperationInvestmentsCurrent>
    <us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent
      contextRef="i98364cf4ba3e41af868d701b4c668283_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM181NS9mcmFnOmNmZTY4OTBkMjFiYTQxZjE5OTA1MWYzYTFkMzI4MjZiL3RhYmxlOmRmNTY5NGIzNmMxYjQwY2U5NzlkOTAzYjI0YWM0NGY4L3RhYmxlcmFuZ2U6ZGY1Njk0YjM2YzFiNDBjZTk3OWQ5MDNiMjRhYzQ0ZjhfOC0xLTEtMS0xNzc3NQ_7361fea5-01bf-461b-bf09-0ed38d8e33e9"
      unitRef="usd">33914000</us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent>
    <evh:DisposalGroupIncludingDiscontinuedOperationRestrictedCashAndRestrictedInvestmentsNoncurrent
      contextRef="i98364cf4ba3e41af868d701b4c668283_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM181NS9mcmFnOmNmZTY4OTBkMjFiYTQxZjE5OTA1MWYzYTFkMzI4MjZiL3RhYmxlOmRmNTY5NGIzNmMxYjQwY2U5NzlkOTAzYjI0YWM0NGY4L3RhYmxlcmFuZ2U6ZGY1Njk0YjM2YzFiNDBjZTk3OWQ5MDNiMjRhYzQ0ZjhfOS0xLTEtMS0xNzc3NQ_ee999fe7-272e-489e-9e97-b52253720d4c"
      unitRef="usd">616000</evh:DisposalGroupIncludingDiscontinuedOperationRestrictedCashAndRestrictedInvestmentsNoncurrent>
    <evh:DisposalGroupIncludingDiscontinuedOperationInvestmentsNoncurrent
      contextRef="i98364cf4ba3e41af868d701b4c668283_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM181NS9mcmFnOmNmZTY4OTBkMjFiYTQxZjE5OTA1MWYzYTFkMzI4MjZiL3RhYmxlOmRmNTY5NGIzNmMxYjQwY2U5NzlkOTAzYjI0YWM0NGY4L3RhYmxlcmFuZ2U6ZGY1Njk0YjM2YzFiNDBjZTk3OWQ5MDNiMjRhYzQ0ZjhfMTAtMS0xLTEtMTc3NzU_8af7b227-c8b4-4b23-8dc6-e7229fd9c413"
      unitRef="usd">10919000</evh:DisposalGroupIncludingDiscontinuedOperationInvestmentsNoncurrent>
    <evh:DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsNoncurrent
      contextRef="i98364cf4ba3e41af868d701b4c668283_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM181NS9mcmFnOmNmZTY4OTBkMjFiYTQxZjE5OTA1MWYzYTFkMzI4MjZiL3RhYmxlOmRmNTY5NGIzNmMxYjQwY2U5NzlkOTAzYjI0YWM0NGY4L3RhYmxlcmFuZ2U6ZGY1Njk0YjM2YzFiNDBjZTk3OWQ5MDNiMjRhYzQ0ZjhfMTEtMS0xLTEtMTc3NzU_f2636dbb-df86-4db8-806f-d8d31daff131"
      unitRef="usd">59000</evh:DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsNoncurrent>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsNoncurrent
      contextRef="i98364cf4ba3e41af868d701b4c668283_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM181NS9mcmFnOmNmZTY4OTBkMjFiYTQxZjE5OTA1MWYzYTFkMzI4MjZiL3RhYmxlOmRmNTY5NGIzNmMxYjQwY2U5NzlkOTAzYjI0YWM0NGY4L3RhYmxlcmFuZ2U6ZGY1Njk0YjM2YzFiNDBjZTk3OWQ5MDNiMjRhYzQ0ZjhfMTItMS0xLTEtMTc3NzU_44ae2047-63f2-4113-9b41-afea98f233ed"
      unitRef="usd">3080000</us-gaap:DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsNoncurrent>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationGoodwillNoncurrent
      contextRef="i98364cf4ba3e41af868d701b4c668283_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM181NS9mcmFnOmNmZTY4OTBkMjFiYTQxZjE5OTA1MWYzYTFkMzI4MjZiL3RhYmxlOmRmNTY5NGIzNmMxYjQwY2U5NzlkOTAzYjI0YWM0NGY4L3RhYmxlcmFuZ2U6ZGY1Njk0YjM2YzFiNDBjZTk3OWQ5MDNiMjRhYzQ0ZjhfMTMtMS0xLTEtMTc3NzU_23406174-29a0-4731-a0cf-fc486f305972"
      unitRef="usd">5705000</us-gaap:DisposalGroupIncludingDiscontinuedOperationGoodwillNoncurrent>
    <us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperation
      contextRef="i98364cf4ba3e41af868d701b4c668283_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM181NS9mcmFnOmNmZTY4OTBkMjFiYTQxZjE5OTA1MWYzYTFkMzI4MjZiL3RhYmxlOmRmNTY5NGIzNmMxYjQwY2U5NzlkOTAzYjI0YWM0NGY4L3RhYmxlcmFuZ2U6ZGY1Njk0YjM2YzFiNDBjZTk3OWQ5MDNiMjRhYzQ0ZjhfMTQtMS0xLTEtMTc3NzU_43bb81f7-0462-4aba-a8c1-98862ecfc10e"
      unitRef="usd">54293000</us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperation>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationAccountsPayableCurrent
      contextRef="i98364cf4ba3e41af868d701b4c668283_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM181NS9mcmFnOmNmZTY4OTBkMjFiYTQxZjE5OTA1MWYzYTFkMzI4MjZiL3RhYmxlOmRmNTY5NGIzNmMxYjQwY2U5NzlkOTAzYjI0YWM0NGY4L3RhYmxlcmFuZ2U6ZGY1Njk0YjM2YzFiNDBjZTk3OWQ5MDNiMjRhYzQ0ZjhfMTgtMS0xLTEtMTc3NzU_c53c9254-a2f9-4d67-8241-2b0f869d2384"
      unitRef="usd">93000</us-gaap:DisposalGroupIncludingDiscontinuedOperationAccountsPayableCurrent>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationAccruedLiabilitiesCurrent
      contextRef="i98364cf4ba3e41af868d701b4c668283_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM181NS9mcmFnOmNmZTY4OTBkMjFiYTQxZjE5OTA1MWYzYTFkMzI4MjZiL3RhYmxlOmRmNTY5NGIzNmMxYjQwY2U5NzlkOTAzYjI0YWM0NGY4L3RhYmxlcmFuZ2U6ZGY1Njk0YjM2YzFiNDBjZTk3OWQ5MDNiMjRhYzQ0ZjhfMTktMS0xLTEtMTc3NzU_339e114c-9201-434e-a3f5-04a79735b5c7"
      unitRef="usd">11265000</us-gaap:DisposalGroupIncludingDiscontinuedOperationAccruedLiabilitiesCurrent>
    <evh:DisposalGroupIncludingDiscontinuedOperationAccruedCompensationAndEmployeeBenefitsCurrent
      contextRef="i98364cf4ba3e41af868d701b4c668283_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM181NS9mcmFnOmNmZTY4OTBkMjFiYTQxZjE5OTA1MWYzYTFkMzI4MjZiL3RhYmxlOmRmNTY5NGIzNmMxYjQwY2U5NzlkOTAzYjI0YWM0NGY4L3RhYmxlcmFuZ2U6ZGY1Njk0YjM2YzFiNDBjZTk3OWQ5MDNiMjRhYzQ0ZjhfMjAtMS0xLTEtMTc3NzU_9d2f5763-08fe-4013-b863-bb7a8d2cf72f"
      unitRef="usd">1115000</evh:DisposalGroupIncludingDiscontinuedOperationAccruedCompensationAndEmployeeBenefitsCurrent>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationDeferredRevenueCurrent
      contextRef="i98364cf4ba3e41af868d701b4c668283_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM181NS9mcmFnOmNmZTY4OTBkMjFiYTQxZjE5OTA1MWYzYTFkMzI4MjZiL3RhYmxlOmRmNTY5NGIzNmMxYjQwY2U5NzlkOTAzYjI0YWM0NGY4L3RhYmxlcmFuZ2U6ZGY1Njk0YjM2YzFiNDBjZTk3OWQ5MDNiMjRhYzQ0ZjhfMjEtMS0xLTEtMTc3NzU_7d697d4e-4866-41d0-8fb6-bb8129bd8786"
      unitRef="usd">4140000</us-gaap:DisposalGroupIncludingDiscontinuedOperationDeferredRevenueCurrent>
    <evh:DisposalGroupIncludingDiscontinuedOperationLiabilityForFuturePolicyBenefitsAndUnpaidClaimsAndClaimsAdjustmentExpenseAndPerformanceBasedArrangementsCurrent
      contextRef="i98364cf4ba3e41af868d701b4c668283_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM181NS9mcmFnOmNmZTY4OTBkMjFiYTQxZjE5OTA1MWYzYTFkMzI4MjZiL3RhYmxlOmRmNTY5NGIzNmMxYjQwY2U5NzlkOTAzYjI0YWM0NGY4L3RhYmxlcmFuZ2U6ZGY1Njk0YjM2YzFiNDBjZTk3OWQ5MDNiMjRhYzQ0ZjhfMjItMS0xLTEtMTc3NzU_366a4d58-0b2b-482d-8c0e-46a72b238186"
      unitRef="usd">9858000</evh:DisposalGroupIncludingDiscontinuedOperationLiabilityForFuturePolicyBenefitsAndUnpaidClaimsAndClaimsAdjustmentExpenseAndPerformanceBasedArrangementsCurrent>
    <us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent
      contextRef="i98364cf4ba3e41af868d701b4c668283_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM181NS9mcmFnOmNmZTY4OTBkMjFiYTQxZjE5OTA1MWYzYTFkMzI4MjZiL3RhYmxlOmRmNTY5NGIzNmMxYjQwY2U5NzlkOTAzYjI0YWM0NGY4L3RhYmxlcmFuZ2U6ZGY1Njk0YjM2YzFiNDBjZTk3OWQ5MDNiMjRhYzQ0ZjhfMjMtMS0xLTEtMTc3NzU_148e40ec-7977-4937-8d77-97eed0ccf2ce"
      unitRef="usd">26471000</us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentLiabilities
      contextRef="i98364cf4ba3e41af868d701b4c668283_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM181NS9mcmFnOmNmZTY4OTBkMjFiYTQxZjE5OTA1MWYzYTFkMzI4MjZiL3RhYmxlOmRmNTY5NGIzNmMxYjQwY2U5NzlkOTAzYjI0YWM0NGY4L3RhYmxlcmFuZ2U6ZGY1Njk0YjM2YzFiNDBjZTk3OWQ5MDNiMjRhYzQ0ZjhfMjQtMS0xLTEtMTc3NzU_89cbe27b-c63b-4d13-bc21-ef03eb4284a8"
      unitRef="usd">128000</us-gaap:DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentLiabilities>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationDeferredTaxLiabilities
      contextRef="i98364cf4ba3e41af868d701b4c668283_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM181NS9mcmFnOmNmZTY4OTBkMjFiYTQxZjE5OTA1MWYzYTFkMzI4MjZiL3RhYmxlOmRmNTY5NGIzNmMxYjQwY2U5NzlkOTAzYjI0YWM0NGY4L3RhYmxlcmFuZ2U6ZGY1Njk0YjM2YzFiNDBjZTk3OWQ5MDNiMjRhYzQ0ZjhfMjUtMS0xLTEtMTc3NzU_758dfbcc-7076-4a9f-88e2-2070a87f3b1e"
      unitRef="usd">49000</us-gaap:DisposalGroupIncludingDiscontinuedOperationDeferredTaxLiabilities>
    <us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation
      contextRef="i98364cf4ba3e41af868d701b4c668283_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM181NS9mcmFnOmNmZTY4OTBkMjFiYTQxZjE5OTA1MWYzYTFkMzI4MjZiL3RhYmxlOmRmNTY5NGIzNmMxYjQwY2U5NzlkOTAzYjI0YWM0NGY4L3RhYmxlcmFuZ2U6ZGY1Njk0YjM2YzFiNDBjZTk3OWQ5MDNiMjRhYzQ0ZjhfMjYtMS0xLTEtMTc3NzU_2ddddd50-0a46-47c8-924f-c6a897f7d66c"
      unitRef="usd">26648000</us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationAccountsPayableCurrent
      contextRef="i6ea3e63701234a91a969d79c7385efdc_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM181NS9mcmFnOmNmZTY4OTBkMjFiYTQxZjE5OTA1MWYzYTFkMzI4MjZiL3RleHRyZWdpb246Y2ZlNjg5MGQyMWJhNDFmMTk5MDUxZjNhMWQzMjgyNmJfMjU0NQ_462ed816-eda3-4efc-ba58-f4f70bf326a9"
      unitRef="usd">1500000</us-gaap:DisposalGroupIncludingDiscontinuedOperationAccountsPayableCurrent>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet
      contextRef="i6ea3e63701234a91a969d79c7385efdc_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM181NS9mcmFnOmNmZTY4OTBkMjFiYTQxZjE5OTA1MWYzYTFkMzI4MjZiL3RleHRyZWdpb246Y2ZlNjg5MGQyMWJhNDFmMTk5MDUxZjNhMWQzMjgyNmJfMjU0NQ_e61df0f7-7174-46f1-a2d0-578fb44b4b77"
      unitRef="usd">1500000</us-gaap:DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet>
    <us-gaap:RevenueFromContractWithCustomerTextBlock
      contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM181OC9mcmFnOjdkZGUxNTIxODMxMzQ3YThhZTFjZmNjNDcyNGZlNmFlL3RleHRyZWdpb246N2RkZTE1MjE4MzEzNDdhOGFlMWNmY2M0NzI0ZmU2YWVfMTAyMTQ_d4b14138-16b1-426e-a0a5-1212a2187358">Revenue Recognition&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We derive revenue from two sources: (1) transformation services and (2) platform and operations services.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Transformation Services Revenue&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Transformation services consist of implementation services whereby we assist the customer in launching its population health or health plan programs. In certain cases, transformation services can also include revenue associated with our support of certain one-time wind-down activities for clients who are exiting a line of business or population. The transformation services are usually completed within 12 months. We generally receive a fixed fee for transformation services and recognize revenue over time using an input method based on hours incurred compared to the total estimated hours required to satisfy our performance obligation.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Platform and Operations Services Revenue&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Platform and operations services are typically multi-year arrangements with customers to provide various clinical and administrative solutions. In our Clinical Solutions segment, our solutions are designed to lower the medical expenses of our partners and include our total cost of care and specialty care management services.  In our Evolent Health Services segment, our solutions are designed to provide comprehensive health plan operations and claims processing services, and also include transition or run-out services to customers receiving primarily third-party administration (&#x201c;TPA&#x201d;) services.  &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our performance obligation in these arrangements is to provide an integrated suite of services, including access to our platform that is customized to meet the specialized needs of our customers and members. Generally, we will apply the series guidance to the performance obligation as we have determined that each time increment is distinct. We primarily utilize a variable fee structure for these services that typically includes a monthly payment that is calculated based on a specified per member per month rate, multiplied by the number of members that our partners are managing under a value-based care arrangement or a percentage of plan premiums. Our arrangements may also include other variable fees related to service level agreements, shared medical savings arrangements and other performance measures. Variable consideration is estimated using the most likely amount based on our historical experience and best judgment at the time. Due to the nature of our arrangements, certain estimates may be constrained if it is probable that a significant reversal of revenue will occur when the uncertainty is resolved. We recognize revenue from platform and operations services over time using the time elapsed output method. Fixed consideration is recognized ratably over the contract term. In accordance with the series guidance, we allocate variable consideration to the period to which the fees relate.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In our Clinical Solutions segment, we enter into capitation arrangements that may include performance-based arrangements and/or gainshare features. We recognize capitation revenue on a gross basis when we have established control over the services within our scope and recognize capitation revenue on a net basis when we do not have control over the services within our scope. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Contracts with Multiple Performance Obligations&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our contracts with customers may contain multiple performance obligations, primarily when the customer has requested both transformation services and platform and operations services as these services are distinct from one another. When a contract has multiple performance obligations, we allocate the transaction price to each performance obligation based on the relative standalone selling price using the expected cost margin approach. This approach requires estimates regarding both the level of effort it will take to satisfy the performance obligation as well as fees that will be received under the variable pricing model. We also take into consideration customer demographics, current market conditions, the scope of services and our overall pricing strategy and objectives when determining the standalone selling price.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Principal vs. Agent&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We occasionally use third parties to assist in satisfying our performance obligations. In order to determine whether we are the principal or agent in the arrangement, we review each third-party relationship on a contract by contract basis. As we integrate goods and services provided by third parties into our overall service, we control the goods and services provided to the customer prior to its delivery. As such, we are the principal and we will recognize revenue on a gross basis. In certain cases, we act as an agent and do not control the services from third parties before it is delivered to the customer thereby recognizing revenue on a net basis.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Disaggregation of Revenue&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table represents Evolent&#x2019;s revenue disaggregated by segment and end-market for the years ended December 31, 2021, 2020 and 2019 (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:220.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:48.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:48.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:48.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:48.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:48.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:48.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="33" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;For the Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Evolent Health Services&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Clinical Solutions&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Medicaid&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;215,236&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;236,634&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;267,222&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;205,833&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;274,028&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;75,675&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Medicare&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26,358&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;68,505&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;73,671&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;363,053&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;257,092&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;199,817&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;68,219&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;77,221&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;68,012&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29,258&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,159&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,725&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;309,813&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;382,360&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;408,905&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;598,144&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;542,279&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;278,217&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Transaction Price Allocated to the Remaining Performance Obligations&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For contracts with a term greater than one year, we have allocated approximately $178.8 million of transaction price to performance obligations that are unsatisfied as of December&#160;31, 2021. We do not include variable consideration that is allocated entirely to a wholly unsatisfied performance obligation accounted for under the series guidance in the calculation. As a result, the balance represents the value of the fixed consideration in our long-term contracts that we expect will be recognized as revenue in a future period and excludes the majority of our platform and operations revenue, which is primarily derived based on variable consideration as discussed in Note 2. We expect to recognize revenue on approximately 45%, 70% and 86% of these remaining performance obligations by December 31, 2022, 2023 and 2024, respectively, with the remaining balance to be recognized thereafter. However, because our existing contracts may be canceled or renegotiated including for reasons outside our control, the amount of revenue that we actually receive may be less or greater than this estimate and the timing of recognition may not be as expected.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Contract Balances&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Contract balances consist of accounts receivable, contract assets and deferred revenue. Contract assets are recorded when the right to consideration for services is conditional on something other than the passage of time. Contract assets relating to unbilled receivables are transferred to accounts receivable when the right to consideration becomes unconditional. We classify contract assets as current or non-current based on the timing of our rights to the unconditional payments. Our contract assets are generally classified as current and recorded within prepaid expenses and other current assets on our consolidated balance sheets. Our current accounts receivables are classified within accounts receivable, net on our consolidated balance sheets and our non-current accounts receivable are classified within prepaid expenses and other non-current assets on our consolidated balance sheets.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Deferred revenue includes advance customer payments and billings in excess of revenue recognized. We classify deferred revenue as current or non-current based on the timing of when we expect to recognize revenue. Our current deferred revenue is recorded within deferred revenue on our consolidated balance sheets and non-current deferred revenue is recorded within other long-term liabilities on our consolidated balance sheets.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table provides information about receivables, contract assets and deferred revenue from contracts with customers as of December&#160;31, 2021 and 2020 (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;padding-left:9pt;text-align:justify;text-indent:-9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:403.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:58.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:67.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020 &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Short-term receivables &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;129,012&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;118,730&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Long-term receivables &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,877&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,554&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Short-term contract assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;329&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Short-term deferred revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,944&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,187&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Long-term deferred revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,437&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,593&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-align:justify;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt"&gt;Amounts exclude $3.4&#160;million of short-term receivables and $4.1&#160;million of short-term deferred revenue reclassified to discontinued operations as of December&#160;31, 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt"&gt;Excludes pharmacy claims receivable and premiums receivable.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Changes in deferred revenue for the year ended December 31, 2021 are as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:433.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:102.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Deferred revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance as of beginning-of-period&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,780&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reclassification to revenue, as a result of performance obligations satisfied&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(10,175)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash received in advance of satisfaction of performance obligations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,776&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance as of end of period&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,381&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The amount of revenue recognized from performance obligations satisfied (or partially satisfied) in a previous period was $28.3&#160;million and $12.1 million for the years ended December 31, 2021 and 2020, respectively, due primarily to net gain share as well as changes in other estimates.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Contract Cost Assets&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Certain bonuses and commissions earned by our sales team are considered incremental costs of obtaining a contract with a customer that we expect to be recoverable. The capitalized contract acquisition costs are classified as non-current assets and recorded within contract cost assets on our consolidated balance sheets. Amortization expense is recorded within selling, general and administrative expenses on the accompanying consolidated statements of operations and comprehensive income (loss). As of December&#160;31, 2021 and 2020, the Company had $5.2 million and $3.3 million, respectively, of contract acquisition cost assets, net of accumulated amortization recorded in contract cost assets on the consolidated balance sheets. In addition, the Company recorded &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;amortiza&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;tion expense of  $1.9 million, $1.9 million and $1.0 million for the years ended December 31, 2021, 2020 and 2019, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In our platforms and operations arrangements, we incur certain costs related to the implementation of our platform before we begin to satisfy our performance obligation to the customer. The costs, which we expect to recover, are considered costs to fulfill a contract. Our contract fulfillment costs primarily include our employee labor costs and third-party vendor costs. The capitalized contract fulfillment costs are classified as non-current and recorded within contract cost assets on our consolidated balance sheets. Amortization expense is recorded within cost of revenue on the accompanying consolidated statements of operations and comprehensive income (loss). As of December&#160;31, 2021 and 2020, the Company had $27.4 million and $23.4 million, respectively, of contract fulfillment cost assets, net of accumulated amortization recorded in contract cost assets on the consolidated balance sheets. In addition, the Company recorded amortization expense of $11.1 million, $13.0 million and $4.7 million, for the years ended December 31, 2021, 2020 and 2019, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;These costs are deferred and then amortized on a straight-line basis over a period of benefit that we have determined to be the shorter of the contract term or five years. The period of benefit was based on our technology, the nature of our customer arrangements and other factors.&lt;/span&gt;&lt;/div&gt;</us-gaap:RevenueFromContractWithCustomerTextBlock>
    <us-gaap:DisaggregationOfRevenueTableTextBlock
      contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM181OC9mcmFnOjdkZGUxNTIxODMxMzQ3YThhZTFjZmNjNDcyNGZlNmFlL3RleHRyZWdpb246N2RkZTE1MjE4MzEzNDdhOGFlMWNmY2M0NzI0ZmU2YWVfMTAyMTU_b83b9a25-c0bb-456c-bc5b-c2ae84adda36">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table represents Evolent&#x2019;s revenue disaggregated by segment and end-market for the years ended December 31, 2021, 2020 and 2019 (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:220.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:48.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:48.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:48.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:48.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:48.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:48.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="33" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;For the Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Evolent Health Services&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Clinical Solutions&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Medicaid&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;215,236&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;236,634&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;267,222&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;205,833&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;274,028&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;75,675&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Medicare&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26,358&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;68,505&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;73,671&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;363,053&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;257,092&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;199,817&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;68,219&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;77,221&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;68,012&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29,258&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,159&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,725&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;309,813&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;382,360&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;408,905&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;598,144&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;542,279&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;278,217&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DisaggregationOfRevenueTableTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic43c6cb369be49d49265e63f4d9abe41_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM181OC9mcmFnOjdkZGUxNTIxODMxMzQ3YThhZTFjZmNjNDcyNGZlNmFlL3RhYmxlOjFhM2IwOTk4MjA3ZDQzYTZhNzdhOGViZmM4OWMxMWEzL3RhYmxlcmFuZ2U6MWEzYjA5OTgyMDdkNDNhNmE3N2E4ZWJmYzg5YzExYTNfMy05LTEtMS0xNzc3NQ_69001b6a-af70-4404-b19d-e55f392cfee2"
      unitRef="usd">215236000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i535e9398f53d482399e3acaf85d05d83_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM181OC9mcmFnOjdkZGUxNTIxODMxMzQ3YThhZTFjZmNjNDcyNGZlNmFlL3RhYmxlOjFhM2IwOTk4MjA3ZDQzYTZhNzdhOGViZmM4OWMxMWEzL3RhYmxlcmFuZ2U6MWEzYjA5OTgyMDdkNDNhNmE3N2E4ZWJmYzg5YzExYTNfMy0xMS0xLTEtMTc3NzU_4cf4fd4d-0b20-4c73-ba1e-1437f2f516cd"
      unitRef="usd">236634000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id2bc3ff361f24fefa6cc02e574174d0d_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM181OC9mcmFnOjdkZGUxNTIxODMxMzQ3YThhZTFjZmNjNDcyNGZlNmFlL3RhYmxlOjFhM2IwOTk4MjA3ZDQzYTZhNzdhOGViZmM4OWMxMWEzL3RhYmxlcmFuZ2U6MWEzYjA5OTgyMDdkNDNhNmE3N2E4ZWJmYzg5YzExYTNfMy01LTEtMS0yNzkzNw_7be15cdf-22dc-4990-bb20-51deb55c7434"
      unitRef="usd">267222000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id9db9ac43e544bf2a8a53256e34c582f_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM181OC9mcmFnOjdkZGUxNTIxODMxMzQ3YThhZTFjZmNjNDcyNGZlNmFlL3RhYmxlOjFhM2IwOTk4MjA3ZDQzYTZhNzdhOGViZmM4OWMxMWEzL3RhYmxlcmFuZ2U6MWEzYjA5OTgyMDdkNDNhNmE3N2E4ZWJmYzg5YzExYTNfMy0xMy0xLTEtMTc3NzU_70ee04d2-a19e-4c17-bb2f-0f9c25d62b49"
      unitRef="usd">205833000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i79967d3cee0e4773a3e643d202cac1e7_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM181OC9mcmFnOjdkZGUxNTIxODMxMzQ3YThhZTFjZmNjNDcyNGZlNmFlL3RhYmxlOjFhM2IwOTk4MjA3ZDQzYTZhNzdhOGViZmM4OWMxMWEzL3RhYmxlcmFuZ2U6MWEzYjA5OTgyMDdkNDNhNmE3N2E4ZWJmYzg5YzExYTNfMy0xNS0xLTEtMTc3NzU_e4705806-9d23-4448-8051-f4ff8de6858d"
      unitRef="usd">274028000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iceaed1bf0ba14aeabbd5e7c285fadb74_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM181OC9mcmFnOjdkZGUxNTIxODMxMzQ3YThhZTFjZmNjNDcyNGZlNmFlL3RhYmxlOjFhM2IwOTk4MjA3ZDQzYTZhNzdhOGViZmM4OWMxMWEzL3RhYmxlcmFuZ2U6MWEzYjA5OTgyMDdkNDNhNmE3N2E4ZWJmYzg5YzExYTNfMy0xMS0xLTEtMjc5NDk_7ef439bd-b212-4a5b-a77b-0e0c5f75a7bd"
      unitRef="usd">75675000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="icb83054796ca43aabbc5e7c5bcd8f242_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM181OC9mcmFnOjdkZGUxNTIxODMxMzQ3YThhZTFjZmNjNDcyNGZlNmFlL3RhYmxlOjFhM2IwOTk4MjA3ZDQzYTZhNzdhOGViZmM4OWMxMWEzL3RhYmxlcmFuZ2U6MWEzYjA5OTgyMDdkNDNhNmE3N2E4ZWJmYzg5YzExYTNfNC05LTEtMS0xNzc3NQ_a79d0139-1d1c-4202-a24e-bfdc9fd51a6a"
      unitRef="usd">26358000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ide7e8d10e8754aeb98428c460346c2e6_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM181OC9mcmFnOjdkZGUxNTIxODMxMzQ3YThhZTFjZmNjNDcyNGZlNmFlL3RhYmxlOjFhM2IwOTk4MjA3ZDQzYTZhNzdhOGViZmM4OWMxMWEzL3RhYmxlcmFuZ2U6MWEzYjA5OTgyMDdkNDNhNmE3N2E4ZWJmYzg5YzExYTNfNC0xMS0xLTEtMTc3NzU_07c63450-21b9-42e7-a3f3-42f13d0e118d"
      unitRef="usd">68505000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i9dc8f259d0954c4790aef4d1cda35290_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM181OC9mcmFnOjdkZGUxNTIxODMxMzQ3YThhZTFjZmNjNDcyNGZlNmFlL3RhYmxlOjFhM2IwOTk4MjA3ZDQzYTZhNzdhOGViZmM4OWMxMWEzL3RhYmxlcmFuZ2U6MWEzYjA5OTgyMDdkNDNhNmE3N2E4ZWJmYzg5YzExYTNfNC01LTEtMS0yNzkzNw_fac91037-3af4-46ac-82db-aa3e6b5f4b5a"
      unitRef="usd">73671000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id1eb1d14b8034af8af9fcc8ff413f4a8_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM181OC9mcmFnOjdkZGUxNTIxODMxMzQ3YThhZTFjZmNjNDcyNGZlNmFlL3RhYmxlOjFhM2IwOTk4MjA3ZDQzYTZhNzdhOGViZmM4OWMxMWEzL3RhYmxlcmFuZ2U6MWEzYjA5OTgyMDdkNDNhNmE3N2E4ZWJmYzg5YzExYTNfNC0xMy0xLTEtMTc3NzU_0b99259d-bade-477a-9936-518817e365f0"
      unitRef="usd">363053000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i99e6ebd37717409cadbd8a0e52f302d8_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM181OC9mcmFnOjdkZGUxNTIxODMxMzQ3YThhZTFjZmNjNDcyNGZlNmFlL3RhYmxlOjFhM2IwOTk4MjA3ZDQzYTZhNzdhOGViZmM4OWMxMWEzL3RhYmxlcmFuZ2U6MWEzYjA5OTgyMDdkNDNhNmE3N2E4ZWJmYzg5YzExYTNfNC0xNS0xLTEtMTc3NzU_bd5d5f9e-2871-402b-8adb-519e5f1766e1"
      unitRef="usd">257092000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ibe57bae9f0e94d19b338958e93a6d9a0_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM181OC9mcmFnOjdkZGUxNTIxODMxMzQ3YThhZTFjZmNjNDcyNGZlNmFlL3RhYmxlOjFhM2IwOTk4MjA3ZDQzYTZhNzdhOGViZmM4OWMxMWEzL3RhYmxlcmFuZ2U6MWEzYjA5OTgyMDdkNDNhNmE3N2E4ZWJmYzg5YzExYTNfNC0xMS0xLTEtMjc5NDk_ca2fb73f-e7ee-41c2-a163-1a9939b66fc3"
      unitRef="usd">199817000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i05cdaab0e8a9475391be6c9bb0290a02_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM181OC9mcmFnOjdkZGUxNTIxODMxMzQ3YThhZTFjZmNjNDcyNGZlNmFlL3RhYmxlOjFhM2IwOTk4MjA3ZDQzYTZhNzdhOGViZmM4OWMxMWEzL3RhYmxlcmFuZ2U6MWEzYjA5OTgyMDdkNDNhNmE3N2E4ZWJmYzg5YzExYTNfNS05LTEtMS0xNzc3NQ_69f819c9-3bc0-49c2-9945-ade65fa594f8"
      unitRef="usd">68219000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i70c4c918cacd44ceb89f531391a51f89_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM181OC9mcmFnOjdkZGUxNTIxODMxMzQ3YThhZTFjZmNjNDcyNGZlNmFlL3RhYmxlOjFhM2IwOTk4MjA3ZDQzYTZhNzdhOGViZmM4OWMxMWEzL3RhYmxlcmFuZ2U6MWEzYjA5OTgyMDdkNDNhNmE3N2E4ZWJmYzg5YzExYTNfNS0xMS0xLTEtMTc3NzU_ba5bfc25-6bb0-4a64-aebb-451a67ee1ea3"
      unitRef="usd">77221000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i7ae80f06fd7241178ec3bcbf2b433c78_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM181OC9mcmFnOjdkZGUxNTIxODMxMzQ3YThhZTFjZmNjNDcyNGZlNmFlL3RhYmxlOjFhM2IwOTk4MjA3ZDQzYTZhNzdhOGViZmM4OWMxMWEzL3RhYmxlcmFuZ2U6MWEzYjA5OTgyMDdkNDNhNmE3N2E4ZWJmYzg5YzExYTNfNS01LTEtMS0yNzkzNw_47796c13-8ea8-4b1e-93c4-2a954b355507"
      unitRef="usd">68012000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i615c66ad61b84863b2bbc22a537fd294_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM181OC9mcmFnOjdkZGUxNTIxODMxMzQ3YThhZTFjZmNjNDcyNGZlNmFlL3RhYmxlOjFhM2IwOTk4MjA3ZDQzYTZhNzdhOGViZmM4OWMxMWEzL3RhYmxlcmFuZ2U6MWEzYjA5OTgyMDdkNDNhNmE3N2E4ZWJmYzg5YzExYTNfNS0xMy0xLTEtMTc3NzU_825ab137-14ce-4d3b-8152-7218c6129bfb"
      unitRef="usd">29258000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i6c3248cb38b348cc83404e78b286c508_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM181OC9mcmFnOjdkZGUxNTIxODMxMzQ3YThhZTFjZmNjNDcyNGZlNmFlL3RhYmxlOjFhM2IwOTk4MjA3ZDQzYTZhNzdhOGViZmM4OWMxMWEzL3RhYmxlcmFuZ2U6MWEzYjA5OTgyMDdkNDNhNmE3N2E4ZWJmYzg5YzExYTNfNS0xNS0xLTEtMTc3NzU_ec425148-a045-4a7f-84f5-f0e4f729b78d"
      unitRef="usd">11159000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i62d3399ff7cf4122b4eb5165603a12e2_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM181OC9mcmFnOjdkZGUxNTIxODMxMzQ3YThhZTFjZmNjNDcyNGZlNmFlL3RhYmxlOjFhM2IwOTk4MjA3ZDQzYTZhNzdhOGViZmM4OWMxMWEzL3RhYmxlcmFuZ2U6MWEzYjA5OTgyMDdkNDNhNmE3N2E4ZWJmYzg5YzExYTNfNS0xMS0xLTEtMjc5NDk_753836f3-c39e-4ca1-957f-2761ed4e61cd"
      unitRef="usd">2725000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i98988f30813349e1a5594e72b40af5b1_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM181OC9mcmFnOjdkZGUxNTIxODMxMzQ3YThhZTFjZmNjNDcyNGZlNmFlL3RhYmxlOjFhM2IwOTk4MjA3ZDQzYTZhNzdhOGViZmM4OWMxMWEzL3RhYmxlcmFuZ2U6MWEzYjA5OTgyMDdkNDNhNmE3N2E4ZWJmYzg5YzExYTNfNi05LTEtMS0xNzc3NQ_1fa1e5b6-1a4d-4267-8d4e-ccf9b9c6a78e"
      unitRef="usd">309813000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i00a9fb2f3f914116b87f14e146d04507_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM181OC9mcmFnOjdkZGUxNTIxODMxMzQ3YThhZTFjZmNjNDcyNGZlNmFlL3RhYmxlOjFhM2IwOTk4MjA3ZDQzYTZhNzdhOGViZmM4OWMxMWEzL3RhYmxlcmFuZ2U6MWEzYjA5OTgyMDdkNDNhNmE3N2E4ZWJmYzg5YzExYTNfNi0xMS0xLTEtMTc3NzU_90f9a9c5-db84-47e4-9acc-6a9fd87ae52e"
      unitRef="usd">382360000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i26a4f846df6445f78bba31f5ba0edcdd_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM181OC9mcmFnOjdkZGUxNTIxODMxMzQ3YThhZTFjZmNjNDcyNGZlNmFlL3RhYmxlOjFhM2IwOTk4MjA3ZDQzYTZhNzdhOGViZmM4OWMxMWEzL3RhYmxlcmFuZ2U6MWEzYjA5OTgyMDdkNDNhNmE3N2E4ZWJmYzg5YzExYTNfNi01LTEtMS0yNzkzNw_76c00934-f5c0-4166-92e6-4dedb4747d92"
      unitRef="usd">408905000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i6d991ef4e2e0416f8c7aaaa6175cf843_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM181OC9mcmFnOjdkZGUxNTIxODMxMzQ3YThhZTFjZmNjNDcyNGZlNmFlL3RhYmxlOjFhM2IwOTk4MjA3ZDQzYTZhNzdhOGViZmM4OWMxMWEzL3RhYmxlcmFuZ2U6MWEzYjA5OTgyMDdkNDNhNmE3N2E4ZWJmYzg5YzExYTNfNi0xMy0xLTEtMTc3NzU_2d88272c-67c6-4f8d-bb54-8ce9ed31637b"
      unitRef="usd">598144000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i73877656554945338d08c1e8006fc13a_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM181OC9mcmFnOjdkZGUxNTIxODMxMzQ3YThhZTFjZmNjNDcyNGZlNmFlL3RhYmxlOjFhM2IwOTk4MjA3ZDQzYTZhNzdhOGViZmM4OWMxMWEzL3RhYmxlcmFuZ2U6MWEzYjA5OTgyMDdkNDNhNmE3N2E4ZWJmYzg5YzExYTNfNi0xNS0xLTEtMTc3NzU_752706fd-3843-4a5a-a30f-ef7e6b782c35"
      unitRef="usd">542279000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if6faab8365e548b981e0edaddae65523_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM181OC9mcmFnOjdkZGUxNTIxODMxMzQ3YThhZTFjZmNjNDcyNGZlNmFlL3RhYmxlOjFhM2IwOTk4MjA3ZDQzYTZhNzdhOGViZmM4OWMxMWEzL3RhYmxlcmFuZ2U6MWEzYjA5OTgyMDdkNDNhNmE3N2E4ZWJmYzg5YzExYTNfNi0xMS0xLTEtMjc5NDk_eba868c8-563c-4b70-ac7f-6be4f8eaee1c"
      unitRef="usd">278217000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueRemainingPerformanceObligation
      contextRef="i8daff60be410426d8f7bd49343c1ec0c_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM181OC9mcmFnOjdkZGUxNTIxODMxMzQ3YThhZTFjZmNjNDcyNGZlNmFlL3RleHRyZWdpb246N2RkZTE1MjE4MzEzNDdhOGFlMWNmY2M0NzI0ZmU2YWVfNTA5OA_34e97489-3ff7-4378-a40d-26accb3bef2d"
      unitRef="usd">178800000</us-gaap:RevenueRemainingPerformanceObligation>
    <us-gaap:RevenueRemainingPerformanceObligationPercentage
      contextRef="if14fbffaf3854b8c835ade571c3cc193_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM181OC9mcmFnOjdkZGUxNTIxODMxMzQ3YThhZTFjZmNjNDcyNGZlNmFlL3RleHRyZWdpb246N2RkZTE1MjE4MzEzNDdhOGFlMWNmY2M0NzI0ZmU2YWVfNTcxNw_a1d99de6-2165-4119-aaaa-88b7fc644797"
      unitRef="number">0.45</us-gaap:RevenueRemainingPerformanceObligationPercentage>
    <us-gaap:RevenueRemainingPerformanceObligationPercentage
      contextRef="i8959430f12264863ae6656497c8cbe17_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM181OC9mcmFnOjdkZGUxNTIxODMxMzQ3YThhZTFjZmNjNDcyNGZlNmFlL3RleHRyZWdpb246N2RkZTE1MjE4MzEzNDdhOGFlMWNmY2M0NzI0ZmU2YWVfNTcyMQ_8732b237-f7aa-4e10-b82f-a4b67eec151d"
      unitRef="number">0.70</us-gaap:RevenueRemainingPerformanceObligationPercentage>
    <us-gaap:RevenueRemainingPerformanceObligationPercentage
      contextRef="i25cd20be19e940cf94f2ba0eef170452_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM181OC9mcmFnOjdkZGUxNTIxODMxMzQ3YThhZTFjZmNjNDcyNGZlNmFlL3RleHRyZWdpb246N2RkZTE1MjE4MzEzNDdhOGFlMWNmY2M0NzI0ZmU2YWVfNTcyOA_925caa09-4802-4b61-8b54-76aad6a46165"
      unitRef="number">0.86</us-gaap:RevenueRemainingPerformanceObligationPercentage>
    <us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock
      contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM181OC9mcmFnOjdkZGUxNTIxODMxMzQ3YThhZTFjZmNjNDcyNGZlNmFlL3RleHRyZWdpb246N2RkZTE1MjE4MzEzNDdhOGFlMWNmY2M0NzI0ZmU2YWVfMTAyMTg_01db16d2-409e-431e-9360-27d31dd3343a">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table provides information about receivables, contract assets and deferred revenue from contracts with customers as of December&#160;31, 2021 and 2020 (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;padding-left:9pt;text-align:justify;text-indent:-9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:403.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:58.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:67.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020 &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Short-term receivables &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;129,012&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;118,730&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Long-term receivables &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,877&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,554&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Short-term contract assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;329&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Short-term deferred revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,944&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,187&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Long-term deferred revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,437&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,593&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-align:justify;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt"&gt;Amounts exclude $3.4&#160;million of short-term receivables and $4.1&#160;million of short-term deferred revenue reclassified to discontinued operations as of December&#160;31, 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt"&gt;Excludes pharmacy claims receivable and premiums receivable.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Changes in deferred revenue for the year ended December 31, 2021 are as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:433.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:102.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Deferred revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance as of beginning-of-period&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,780&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reclassification to revenue, as a result of performance obligations satisfied&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(10,175)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash received in advance of satisfaction of performance obligations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,776&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance as of end of period&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,381&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock>
    <us-gaap:AccountsNotesAndLoansReceivableNetCurrent
      contextRef="i8daff60be410426d8f7bd49343c1ec0c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM181OC9mcmFnOjdkZGUxNTIxODMxMzQ3YThhZTFjZmNjNDcyNGZlNmFlL3RhYmxlOmFkMmJhNWVlN2E5ODRhNzM5ZTEzNzAxZjA4Y2IyMzE4L3RhYmxlcmFuZ2U6YWQyYmE1ZWU3YTk4NGE3MzllMTM3MDFmMDhjYjIzMThfMS0xLTEtMS0xNzc3NQ_04d3789c-3d5d-4ffa-b9d5-5245ea64589c"
      unitRef="usd">129012000</us-gaap:AccountsNotesAndLoansReceivableNetCurrent>
    <us-gaap:AccountsNotesAndLoansReceivableNetCurrent
      contextRef="ibc0c0c2b8dc04c5698ca0577a54b2e03_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM181OC9mcmFnOjdkZGUxNTIxODMxMzQ3YThhZTFjZmNjNDcyNGZlNmFlL3RhYmxlOmFkMmJhNWVlN2E5ODRhNzM5ZTEzNzAxZjA4Y2IyMzE4L3RhYmxlcmFuZ2U6YWQyYmE1ZWU3YTk4NGE3MzllMTM3MDFmMDhjYjIzMThfMS0zLTEtMS0xNzc3NQ_8ce8808f-600c-458c-82e0-fabccce1c1eb"
      unitRef="usd">118730000</us-gaap:AccountsNotesAndLoansReceivableNetCurrent>
    <us-gaap:LongTermAccountsNotesAndLoansReceivableNetNoncurrent
      contextRef="i8daff60be410426d8f7bd49343c1ec0c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM181OC9mcmFnOjdkZGUxNTIxODMxMzQ3YThhZTFjZmNjNDcyNGZlNmFlL3RhYmxlOmFkMmJhNWVlN2E5ODRhNzM5ZTEzNzAxZjA4Y2IyMzE4L3RhYmxlcmFuZ2U6YWQyYmE1ZWU3YTk4NGE3MzllMTM3MDFmMDhjYjIzMThfMi0xLTEtMS0xNzc3NQ_767ab6fe-dc65-4552-ab7d-b2ab84137f8d"
      unitRef="usd">4877000</us-gaap:LongTermAccountsNotesAndLoansReceivableNetNoncurrent>
    <us-gaap:LongTermAccountsNotesAndLoansReceivableNetNoncurrent
      contextRef="ibc0c0c2b8dc04c5698ca0577a54b2e03_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM181OC9mcmFnOjdkZGUxNTIxODMxMzQ3YThhZTFjZmNjNDcyNGZlNmFlL3RhYmxlOmFkMmJhNWVlN2E5ODRhNzM5ZTEzNzAxZjA4Y2IyMzE4L3RhYmxlcmFuZ2U6YWQyYmE1ZWU3YTk4NGE3MzllMTM3MDFmMDhjYjIzMThfMi0zLTEtMS0xNzc3NQ_408c7757-8bc5-436b-9c0d-d51c3b7c4f39"
      unitRef="usd">4554000</us-gaap:LongTermAccountsNotesAndLoansReceivableNetNoncurrent>
    <us-gaap:ContractWithCustomerAssetNetCurrent
      contextRef="i8daff60be410426d8f7bd49343c1ec0c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM181OC9mcmFnOjdkZGUxNTIxODMxMzQ3YThhZTFjZmNjNDcyNGZlNmFlL3RhYmxlOmFkMmJhNWVlN2E5ODRhNzM5ZTEzNzAxZjA4Y2IyMzE4L3RhYmxlcmFuZ2U6YWQyYmE1ZWU3YTk4NGE3MzllMTM3MDFmMDhjYjIzMThfMy0xLTEtMS0xNzc3NQ_4f1d190a-5b81-40bb-86bd-da0cc9ca0406"
      unitRef="usd">0</us-gaap:ContractWithCustomerAssetNetCurrent>
    <us-gaap:ContractWithCustomerAssetNetCurrent
      contextRef="ibc0c0c2b8dc04c5698ca0577a54b2e03_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM181OC9mcmFnOjdkZGUxNTIxODMxMzQ3YThhZTFjZmNjNDcyNGZlNmFlL3RhYmxlOmFkMmJhNWVlN2E5ODRhNzM5ZTEzNzAxZjA4Y2IyMzE4L3RhYmxlcmFuZ2U6YWQyYmE1ZWU3YTk4NGE3MzllMTM3MDFmMDhjYjIzMThfMy0zLTEtMS0xNzc3NQ_4407aa62-ffee-46d4-b5f4-075f713420d9"
      unitRef="usd">329000</us-gaap:ContractWithCustomerAssetNetCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="i8daff60be410426d8f7bd49343c1ec0c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM181OC9mcmFnOjdkZGUxNTIxODMxMzQ3YThhZTFjZmNjNDcyNGZlNmFlL3RhYmxlOmFkMmJhNWVlN2E5ODRhNzM5ZTEzNzAxZjA4Y2IyMzE4L3RhYmxlcmFuZ2U6YWQyYmE1ZWU3YTk4NGE3MzllMTM3MDFmMDhjYjIzMThfNC0xLTEtMS0xNzc3NQ_23dbb1c2-9608-4772-b14d-146215857653"
      unitRef="usd">11944000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="ibc0c0c2b8dc04c5698ca0577a54b2e03_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM181OC9mcmFnOjdkZGUxNTIxODMxMzQ3YThhZTFjZmNjNDcyNGZlNmFlL3RhYmxlOmFkMmJhNWVlN2E5ODRhNzM5ZTEzNzAxZjA4Y2IyMzE4L3RhYmxlcmFuZ2U6YWQyYmE1ZWU3YTk4NGE3MzllMTM3MDFmMDhjYjIzMThfNC0zLTEtMS0xNzc3NQ_58672868-e761-441f-b226-b4d217556462"
      unitRef="usd">10187000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="i8daff60be410426d8f7bd49343c1ec0c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM181OC9mcmFnOjdkZGUxNTIxODMxMzQ3YThhZTFjZmNjNDcyNGZlNmFlL3RhYmxlOmFkMmJhNWVlN2E5ODRhNzM5ZTEzNzAxZjA4Y2IyMzE4L3RhYmxlcmFuZ2U6YWQyYmE1ZWU3YTk4NGE3MzllMTM3MDFmMDhjYjIzMThfNS0xLTEtMS0xNzc3NQ_9ca78e6c-00e8-4643-866f-7acb76ed7a61"
      unitRef="usd">4437000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="ibc0c0c2b8dc04c5698ca0577a54b2e03_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM181OC9mcmFnOjdkZGUxNTIxODMxMzQ3YThhZTFjZmNjNDcyNGZlNmFlL3RhYmxlOmFkMmJhNWVlN2E5ODRhNzM5ZTEzNzAxZjA4Y2IyMzE4L3RhYmxlcmFuZ2U6YWQyYmE1ZWU3YTk4NGE3MzllMTM3MDFmMDhjYjIzMThfNS0zLTEtMS0xNzc3NQ_391cee09-d295-48f6-948f-fc847210e0f0"
      unitRef="usd">3593000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <evh:DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNetAfterGrossUp
      contextRef="i98364cf4ba3e41af868d701b4c668283_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM181OC9mcmFnOjdkZGUxNTIxODMxMzQ3YThhZTFjZmNjNDcyNGZlNmFlL3RleHRyZWdpb246N2RkZTE1MjE4MzEzNDdhOGFlMWNmY2M0NzI0ZmU2YWVfNzY3NA_b5e621bd-0acd-4853-b186-0498553542bc"
      unitRef="usd">3400000</evh:DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNetAfterGrossUp>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationDeferredRevenueCurrent
      contextRef="i98364cf4ba3e41af868d701b4c668283_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM181OC9mcmFnOjdkZGUxNTIxODMxMzQ3YThhZTFjZmNjNDcyNGZlNmFlL3RleHRyZWdpb246N2RkZTE1MjE4MzEzNDdhOGFlMWNmY2M0NzI0ZmU2YWVfNzcwNw_c00a39c9-b104-40b0-bce9-5e0e18b77d94"
      unitRef="usd">4100000</us-gaap:DisposalGroupIncludingDiscontinuedOperationDeferredRevenueCurrent>
    <us-gaap:ContractWithCustomerLiability
      contextRef="ibc0c0c2b8dc04c5698ca0577a54b2e03_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM181OC9mcmFnOjdkZGUxNTIxODMxMzQ3YThhZTFjZmNjNDcyNGZlNmFlL3RhYmxlOmZkMmFmYWZkNmRjYzQyMmRhODU1NGNlNzYzOTIxYjQxL3RhYmxlcmFuZ2U6ZmQyYWZhZmQ2ZGNjNDIyZGE4NTU0Y2U3NjM5MjFiNDFfMS0xLTEtMS0xNzc3NQ_300d74d4-7bff-4dfd-aa9c-e40e66afeb4a"
      unitRef="usd">13780000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiabilityRevenueRecognized
      contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM181OC9mcmFnOjdkZGUxNTIxODMxMzQ3YThhZTFjZmNjNDcyNGZlNmFlL3RhYmxlOmZkMmFmYWZkNmRjYzQyMmRhODU1NGNlNzYzOTIxYjQxL3RhYmxlcmFuZ2U6ZmQyYWZhZmQ2ZGNjNDIyZGE4NTU0Y2U3NjM5MjFiNDFfMi0xLTEtMS0xNzc3NQ_a0313c38-4f7c-4fe4-b6de-b5b43fd0697f"
      unitRef="usd">10175000</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
    <evh:ContractWithCustomerLiabilityCashReceivedInAdvanceOfSatisfactionOfPerformanceObligations
      contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM181OC9mcmFnOjdkZGUxNTIxODMxMzQ3YThhZTFjZmNjNDcyNGZlNmFlL3RhYmxlOmZkMmFmYWZkNmRjYzQyMmRhODU1NGNlNzYzOTIxYjQxL3RhYmxlcmFuZ2U6ZmQyYWZhZmQ2ZGNjNDIyZGE4NTU0Y2U3NjM5MjFiNDFfMy0xLTEtMS0xNzc3NQ_82171695-50bc-48cd-af8e-02e281f4dbc2"
      unitRef="usd">12776000</evh:ContractWithCustomerLiabilityCashReceivedInAdvanceOfSatisfactionOfPerformanceObligations>
    <us-gaap:ContractWithCustomerLiability
      contextRef="i8daff60be410426d8f7bd49343c1ec0c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM181OC9mcmFnOjdkZGUxNTIxODMxMzQ3YThhZTFjZmNjNDcyNGZlNmFlL3RhYmxlOmZkMmFmYWZkNmRjYzQyMmRhODU1NGNlNzYzOTIxYjQxL3RhYmxlcmFuZ2U6ZmQyYWZhZmQ2ZGNjNDIyZGE4NTU0Y2U3NjM5MjFiNDFfNC0xLTEtMS0xNzc3NQ_b5ce2a20-e98f-4ac3-95a4-eb506ed4f895"
      unitRef="usd">16381000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod
      contextRef="i546c40c371924532a3d2ed0ace7d354b_D20211001-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM181OC9mcmFnOjdkZGUxNTIxODMxMzQ3YThhZTFjZmNjNDcyNGZlNmFlL3RleHRyZWdpb246N2RkZTE1MjE4MzEzNDdhOGFlMWNmY2M0NzI0ZmU2YWVfODA0MQ_81716abb-8956-4292-8547-8c65f02d1965"
      unitRef="usd">28300000</us-gaap:ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod>
    <us-gaap:ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod
      contextRef="i12a6d1161de54547bd29f8efccd4c9b0_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM181OC9mcmFnOjdkZGUxNTIxODMxMzQ3YThhZTFjZmNjNDcyNGZlNmFlL3RleHRyZWdpb246N2RkZTE1MjE4MzEzNDdhOGFlMWNmY2M0NzI0ZmU2YWVfODA0OA_d3f8c792-bb35-4578-8066-b621bf606c6b"
      unitRef="usd">12100000</us-gaap:ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod>
    <us-gaap:CapitalizedContractCostNet
      contextRef="i54aba1ec35ba4673abba7abb46f76ef5_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM181OC9mcmFnOjdkZGUxNTIxODMxMzQ3YThhZTFjZmNjNDcyNGZlNmFlL3RleHRyZWdpb246N2RkZTE1MjE4MzEzNDdhOGFlMWNmY2M0NzI0ZmU2YWVfMTA5OTUxMTYzODI5Mw_d55c2735-07e1-4f2d-8e34-cbf30537a595"
      unitRef="usd">5200000</us-gaap:CapitalizedContractCostNet>
    <us-gaap:CapitalizedContractCostNet
      contextRef="i44f063f12cc04f629ffbb5c7712fd0f2_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM181OC9mcmFnOjdkZGUxNTIxODMxMzQ3YThhZTFjZmNjNDcyNGZlNmFlL3RleHRyZWdpb246N2RkZTE1MjE4MzEzNDdhOGFlMWNmY2M0NzI0ZmU2YWVfODY5OA_30bf530d-13d4-4dd5-a628-2f8f81b5a01e"
      unitRef="usd">3300000</us-gaap:CapitalizedContractCostNet>
    <us-gaap:CapitalizedContractCostAmortization
      contextRef="icfdf7dc68ad9407fb6453da7eb51ff1e_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM181OC9mcmFnOjdkZGUxNTIxODMxMzQ3YThhZTFjZmNjNDcyNGZlNmFlL3RleHRyZWdpb246N2RkZTE1MjE4MzEzNDdhOGFlMWNmY2M0NzI0ZmU2YWVfODkwNg_483e5190-9336-4903-99b6-9bf3b181a9f3"
      unitRef="usd">1900000</us-gaap:CapitalizedContractCostAmortization>
    <us-gaap:CapitalizedContractCostAmortization
      contextRef="i32c4356526e94c2a842b0638c13e0da0_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM181OC9mcmFnOjdkZGUxNTIxODMxMzQ3YThhZTFjZmNjNDcyNGZlNmFlL3RleHRyZWdpb246N2RkZTE1MjE4MzEzNDdhOGFlMWNmY2M0NzI0ZmU2YWVfODkzNw_1415429b-43f8-4d2c-803c-04574544b0ea"
      unitRef="usd">1900000</us-gaap:CapitalizedContractCostAmortization>
    <us-gaap:CapitalizedContractCostAmortization
      contextRef="i781700715d804fefb7f495ca8b0f9e4a_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM181OC9mcmFnOjdkZGUxNTIxODMxMzQ3YThhZTFjZmNjNDcyNGZlNmFlL3RleHRyZWdpb246N2RkZTE1MjE4MzEzNDdhOGFlMWNmY2M0NzI0ZmU2YWVfMTA5OTUxMTYzODA5Ng_33f6d24c-9891-4aeb-9be8-9c598a8c204e"
      unitRef="usd">1000000</us-gaap:CapitalizedContractCostAmortization>
    <us-gaap:CapitalizedContractCostNet
      contextRef="i1e5e51907f2d489ab6121950881bf006_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM181OC9mcmFnOjdkZGUxNTIxODMxMzQ3YThhZTFjZmNjNDcyNGZlNmFlL3RleHRyZWdpb246N2RkZTE1MjE4MzEzNDdhOGFlMWNmY2M0NzI0ZmU2YWVfOTY2Mg_d2069cac-782b-4b05-a4b2-353aadbe6037"
      unitRef="usd">27400000</us-gaap:CapitalizedContractCostNet>
    <us-gaap:CapitalizedContractCostNet
      contextRef="icf374646ef6b49209d89a39117fda72a_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM181OC9mcmFnOjdkZGUxNTIxODMxMzQ3YThhZTFjZmNjNDcyNGZlNmFlL3RleHRyZWdpb246N2RkZTE1MjE4MzEzNDdhOGFlMWNmY2M0NzI0ZmU2YWVfOTY2OQ_37c3b32f-8d61-41f6-9941-98e6e5ef9e03"
      unitRef="usd">23400000</us-gaap:CapitalizedContractCostNet>
    <us-gaap:CapitalizedContractCostAmortization
      contextRef="i8b41623f6b924d1986071e4349ac5013_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM181OC9mcmFnOjdkZGUxNTIxODMxMzQ3YThhZTFjZmNjNDcyNGZlNmFlL3RleHRyZWdpb246N2RkZTE1MjE4MzEzNDdhOGFlMWNmY2M0NzI0ZmU2YWVfOTg5MA_f8ac4179-f495-4bd7-ae5b-6cccc99093eb"
      unitRef="usd">11100000</us-gaap:CapitalizedContractCostAmortization>
    <us-gaap:CapitalizedContractCostAmortization
      contextRef="i764aef4cc3ae4cc1bcebb290a4525192_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM181OC9mcmFnOjdkZGUxNTIxODMxMzQ3YThhZTFjZmNjNDcyNGZlNmFlL3RleHRyZWdpb246N2RkZTE1MjE4MzEzNDdhOGFlMWNmY2M0NzI0ZmU2YWVfOTkxOA_86636262-085c-4fe4-a064-ae260f508e18"
      unitRef="usd">13000000</us-gaap:CapitalizedContractCostAmortization>
    <us-gaap:CapitalizedContractCostAmortization
      contextRef="i914217ccb9dc458290c3558593f0487c_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM181OC9mcmFnOjdkZGUxNTIxODMxMzQ3YThhZTFjZmNjNDcyNGZlNmFlL3RleHRyZWdpb246N2RkZTE1MjE4MzEzNDdhOGFlMWNmY2M0NzI0ZmU2YWVfMTA5OTUxMTYzODI3OQ_11ef14dd-1afd-44f5-a3c3-98db61b542b7"
      unitRef="usd">4700000</us-gaap:CapitalizedContractCostAmortization>
    <us-gaap:CapitalizedContractCostAmortizationPeriod
      contextRef="i8daff60be410426d8f7bd49343c1ec0c_I20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM181OC9mcmFnOjdkZGUxNTIxODMxMzQ3YThhZTFjZmNjNDcyNGZlNmFlL3RleHRyZWdpb246N2RkZTE1MjE4MzEzNDdhOGFlMWNmY2M0NzI0ZmU2YWVfMTAxMDA_1c5aa8fa-76e8-48fa-bc03-f50a0a8425c3">P5Y</us-gaap:CapitalizedContractCostAmortizationPeriod>
    <us-gaap:CreditLossFinancialInstrumentTextBlock
      contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM182NC9mcmFnOjVmZDYzMzVhZDUyYjRiMGM5MjRmODY5Mzg3MzViZTdhL3RleHRyZWdpb246NWZkNjMzNWFkNTJiNGIwYzkyNGY4NjkzODczNWJlN2FfMzAwNQ_7ff2d314-9337-4c28-8e26-ed3af5f6b17c">Credit Losses &lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We are exposed to credit losses primarily through our accounts receivable from revenue transactions, investments held at amortized cost and customer advances for regulatory capital and other notes receivable. We estimate expected credit losses based on past events, current conditions and reasonable and supportable forecasts. Expected credit losses are measured over the remaining contractual life of these assets. As part of our consideration of current and forward-looking economic conditions, we considered the impact of the COVID-19 pandemic on our customers&#x2019; and other third parties&#x2019; ability to pay. We did not observe notable increases in delinquencies during the year ended December 31, 2021. Given the nature of our business, our past collection experience during recessionary and pre-recessionary periods and our forecasted impact of the COVID-19 pandemic on our business, we did not record material changes in our allowances due to the COVID-19 pandemic during the year ended December 31, 2021.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Accounts Receivable from Revenue Transactions&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accounts receivable represent the amounts owed to the Company for goods or services provided to customers or third parties. Current accounts receivables are classified within accounts receivable, net on the Company&#x2019;s consolidated balance sheets, while non-current accounts receivables are classified within prepaid expenses and other noncurrent assets on the Company&#x2019;s consolidated balance sheets. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We monitor our ongoing credit exposure through active review of counterparty balances against contract terms, due dates and business strategy. Our activities include timely account reconciliation, dispute resolution and payment confirmation. We may employ legal counsel to pursue recovery of defaulted receivables. In addition, the Company will establish a general reserve based on delinquency rates. Historical loss rates are determined for each delinquency bucket in 30-day past-due intervals and then applied to the composition of the reporting date balance based on delinquency. The allowance implied from application of the historical loss rates is then adjusted, as necessary, for current conditions and reasonable and supportable forecasts.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Based on an aging analysis of our trade accounts receivable, non-trade accounts receivable and contract assets as of&#160;December&#160;31, 2021,&#160;90% were current, 2%&#160;were past due less than 60 days, with 3% past due less than 120 days and at December 31, 2020, 59% were current, 24% were past due less than 60 days, with 37% past due less than 120 days. As of&#160;December&#160;31, 2021 and 2020, in total we reported on the consolidated balance sheet&#160;$171.5 million&#160;and $173.7&#160;million of accounts receivable, certain non-trade accounts receivable included in prepaid expenses and other assets, net of allowances of&#160;$3.4 million and $7.1&#160;million, respectively. The following table summarizes the changes in allowance for credit losses on our accounts receivables, certain non-trade accounts receivable and contract assets for the year ended December 31, 2021 and 2020 (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:76.816%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.594%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.596%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;For the Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance as of beginning of period&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7,056)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(41)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Passport acquisition&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,582)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cumulative transition adjustment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,815)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Provision for credit losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,411)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,283)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Charge-offs&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,093&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,665&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance as of end of period&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,374)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7,056)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt"&gt;Charge offs for the year ended December 31, 2021, are primarily due to balances written-off that were previously fully reserved as part of the Passport transaction.&lt;/span&gt;&lt;/div&gt;</us-gaap:CreditLossFinancialInstrumentTextBlock>
    <evh:FinancingReceivablePercentNotPastDue
      contextRef="i8daff60be410426d8f7bd49343c1ec0c_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM182NC9mcmFnOjVmZDYzMzVhZDUyYjRiMGM5MjRmODY5Mzg3MzViZTdhL3RleHRyZWdpb246NWZkNjMzNWFkNTJiNGIwYzkyNGY4NjkzODczNWJlN2FfMjM4NQ_51822d52-d22c-4fce-8503-1df7a04f93f2"
      unitRef="number">0.90</evh:FinancingReceivablePercentNotPastDue>
    <us-gaap:FinancingReceivablePercentPastDue1
      contextRef="i409817ab2c13478f8041e2ff229d0614_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM182NC9mcmFnOjVmZDYzMzVhZDUyYjRiMGM5MjRmODY5Mzg3MzViZTdhL3RleHRyZWdpb246NWZkNjMzNWFkNTJiNGIwYzkyNGY4NjkzODczNWJlN2FfMjQwMg_dd8eed4e-bff3-48e2-a459-d052a40a0111"
      unitRef="number">0.02</us-gaap:FinancingReceivablePercentPastDue1>
    <us-gaap:FinancingReceivablePercentPastDue1
      contextRef="iafc89cf729024311ade0aeb8068cb56d_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM182NC9mcmFnOjVmZDYzMzVhZDUyYjRiMGM5MjRmODY5Mzg3MzViZTdhL3RleHRyZWdpb246NWZkNjMzNWFkNTJiNGIwYzkyNGY4NjkzODczNWJlN2FfMjQ0Mw_996f9edf-703a-41db-9f9e-5713978de60b"
      unitRef="number">0.03</us-gaap:FinancingReceivablePercentPastDue1>
    <evh:FinancingReceivablePercentNotPastDue
      contextRef="ibc0c0c2b8dc04c5698ca0577a54b2e03_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM182NC9mcmFnOjVmZDYzMzVhZDUyYjRiMGM5MjRmODY5Mzg3MzViZTdhL3RleHRyZWdpb246NWZkNjMzNWFkNTJiNGIwYzkyNGY4NjkzODczNWJlN2FfMzI5ODUzNDg4NjcxNw_7dd9b4f2-684d-44c7-9ef2-21f7ce138007"
      unitRef="number">0.59</evh:FinancingReceivablePercentNotPastDue>
    <us-gaap:FinancingReceivablePercentPastDue1
      contextRef="icc5d957904904562b11eb24c12475bd1_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM182NC9mcmFnOjVmZDYzMzVhZDUyYjRiMGM5MjRmODY5Mzg3MzViZTdhL3RleHRyZWdpb246NWZkNjMzNWFkNTJiNGIwYzkyNGY4NjkzODczNWJlN2FfMzI5ODUzNDg4NjcyMg_12e37e76-53dc-4182-a49d-9eae0998010f"
      unitRef="number">0.24</us-gaap:FinancingReceivablePercentPastDue1>
    <us-gaap:FinancingReceivablePercentPastDue1
      contextRef="i23f9ca4a3b134c3cb50b438855efd900_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM182NC9mcmFnOjVmZDYzMzVhZDUyYjRiMGM5MjRmODY5Mzg3MzViZTdhL3RleHRyZWdpb246NWZkNjMzNWFkNTJiNGIwYzkyNGY4NjkzODczNWJlN2FfMzI5ODUzNDg4NjcyNw_c5b5d5a2-80ce-4364-8c32-9ea6dd4d936c"
      unitRef="number">0.37</us-gaap:FinancingReceivablePercentPastDue1>
    <us-gaap:AccountsReceivableNet
      contextRef="i8daff60be410426d8f7bd49343c1ec0c_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM182NC9mcmFnOjVmZDYzMzVhZDUyYjRiMGM5MjRmODY5Mzg3MzViZTdhL3RleHRyZWdpb246NWZkNjMzNWFkNTJiNGIwYzkyNGY4NjkzODczNWJlN2FfMjQ5NA_2f96a278-8841-449b-b7fe-6ca2dfe2ad9a"
      unitRef="usd">171500000</us-gaap:AccountsReceivableNet>
    <us-gaap:AccountsReceivableNet
      contextRef="ibc0c0c2b8dc04c5698ca0577a54b2e03_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM182NC9mcmFnOjVmZDYzMzVhZDUyYjRiMGM5MjRmODY5Mzg3MzViZTdhL3RleHRyZWdpb246NWZkNjMzNWFkNTJiNGIwYzkyNGY4NjkzODczNWJlN2FfMzI5ODUzNDg4NjczMg_7f382ce6-5ca6-4add-a48e-b6716173e312"
      unitRef="usd">173700000</us-gaap:AccountsReceivableNet>
    <us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent
      contextRef="i8daff60be410426d8f7bd49343c1ec0c_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM182NC9mcmFnOjVmZDYzMzVhZDUyYjRiMGM5MjRmODY5Mzg3MzViZTdhL3RleHRyZWdpb246NWZkNjMzNWFkNTJiNGIwYzkyNGY4NjkzODczNWJlN2FfMjY4MQ_ec84ddad-86c6-4557-9879-0c1563bc6888"
      unitRef="usd">3400000</us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent>
    <us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent
      contextRef="ibc0c0c2b8dc04c5698ca0577a54b2e03_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM182NC9mcmFnOjVmZDYzMzVhZDUyYjRiMGM5MjRmODY5Mzg3MzViZTdhL3RleHRyZWdpb246NWZkNjMzNWFkNTJiNGIwYzkyNGY4NjkzODczNWJlN2FfMzI5ODUzNDg4Njc0OA_0f1682e4-c0a9-4364-9fdd-1f95f04e5d18"
      unitRef="usd">7100000</us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent>
    <us-gaap:AccountsReceivableAllowanceForCreditLossTableTextBlock
      contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM182NC9mcmFnOjVmZDYzMzVhZDUyYjRiMGM5MjRmODY5Mzg3MzViZTdhL3RleHRyZWdpb246NWZkNjMzNWFkNTJiNGIwYzkyNGY4NjkzODczNWJlN2FfMzAwNg_0ba67b3d-0fa7-4665-b0fe-66d91709e716">The following table summarizes the changes in allowance for credit losses on our accounts receivables, certain non-trade accounts receivable and contract assets for the year ended December 31, 2021 and 2020 (in thousands):&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:76.816%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.594%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.596%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;For the Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance as of beginning of period&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7,056)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(41)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Passport acquisition&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,582)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cumulative transition adjustment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,815)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Provision for credit losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,411)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,283)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Charge-offs&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,093&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,665&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance as of end of period&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,374)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7,056)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt"&gt;Charge offs for the year ended December 31, 2021, are primarily due to balances written-off that were previously fully reserved as part of the Passport transaction.&lt;/span&gt;&lt;/div&gt;</us-gaap:AccountsReceivableAllowanceForCreditLossTableTextBlock>
    <us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent
      contextRef="ibc0c0c2b8dc04c5698ca0577a54b2e03_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM182NC9mcmFnOjVmZDYzMzVhZDUyYjRiMGM5MjRmODY5Mzg3MzViZTdhL3RhYmxlOjZiOGIxZmE4ZDk0NTRhMWQ4OTdmYjYxNzU2ZmUzYjQ3L3RhYmxlcmFuZ2U6NmI4YjFmYThkOTQ1NGExZDg5N2ZiNjE3NTZmZTNiNDdfMi0xLTEtMS0xNzc3NQ_feb05c87-a09b-48ee-a7e8-29f3d84b2e05"
      unitRef="usd">7056000</us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent>
    <us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent
      contextRef="icba6e493923b449aa57c46a563760234_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM182NC9mcmFnOjVmZDYzMzVhZDUyYjRiMGM5MjRmODY5Mzg3MzViZTdhL3RhYmxlOjZiOGIxZmE4ZDk0NTRhMWQ4OTdmYjYxNzU2ZmUzYjQ3L3RhYmxlcmFuZ2U6NmI4YjFmYThkOTQ1NGExZDg5N2ZiNjE3NTZmZTNiNDdfMi0zLTEtMS0xNzc3NQ_7c11150c-bf6f-4b26-99a4-ac8fb029d4b7"
      unitRef="usd">41000</us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent>
    <evh:AccountsReceivableAllowanceForCreditLossAcquiredDuringPeriod
      contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM182NC9mcmFnOjVmZDYzMzVhZDUyYjRiMGM5MjRmODY5Mzg3MzViZTdhL3RhYmxlOjZiOGIxZmE4ZDk0NTRhMWQ4OTdmYjYxNzU2ZmUzYjQ3L3RhYmxlcmFuZ2U6NmI4YjFmYThkOTQ1NGExZDg5N2ZiNjE3NTZmZTNiNDdfMy0xLTEtMS0xNzc3NQ_c0103e75-99be-4bcf-bc54-d69b487a04e9"
      unitRef="usd">0</evh:AccountsReceivableAllowanceForCreditLossAcquiredDuringPeriod>
    <evh:AccountsReceivableAllowanceForCreditLossAcquiredDuringPeriod
      contextRef="i12a6d1161de54547bd29f8efccd4c9b0_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM182NC9mcmFnOjVmZDYzMzVhZDUyYjRiMGM5MjRmODY5Mzg3MzViZTdhL3RhYmxlOjZiOGIxZmE4ZDk0NTRhMWQ4OTdmYjYxNzU2ZmUzYjQ3L3RhYmxlcmFuZ2U6NmI4YjFmYThkOTQ1NGExZDg5N2ZiNjE3NTZmZTNiNDdfMy0zLTEtMS0xNzc3NQ_68c1acfe-7933-4c49-8352-5e2cfea66520"
      unitRef="usd">2582000</evh:AccountsReceivableAllowanceForCreditLossAcquiredDuringPeriod>
    <us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent
      contextRef="ia1b27c6b1ce44bb4a7d45377795c832d_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM182NC9mcmFnOjVmZDYzMzVhZDUyYjRiMGM5MjRmODY5Mzg3MzViZTdhL3RhYmxlOjZiOGIxZmE4ZDk0NTRhMWQ4OTdmYjYxNzU2ZmUzYjQ3L3RhYmxlcmFuZ2U6NmI4YjFmYThkOTQ1NGExZDg5N2ZiNjE3NTZmZTNiNDdfNC0xLTEtMS0xNzc3NQ_d8abb709-ec26-4d6b-99dc-0196a61c5bdb"
      unitRef="usd">0</us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent>
    <us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent
      contextRef="i6464dcea2322451dbc03ac39361c75b9_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM182NC9mcmFnOjVmZDYzMzVhZDUyYjRiMGM5MjRmODY5Mzg3MzViZTdhL3RhYmxlOjZiOGIxZmE4ZDk0NTRhMWQ4OTdmYjYxNzU2ZmUzYjQ3L3RhYmxlcmFuZ2U6NmI4YjFmYThkOTQ1NGExZDg5N2ZiNjE3NTZmZTNiNDdfNC0zLTEtMS0xNzc3NQ_c3462162-c76e-4f82-9d06-cce6f148c253"
      unitRef="usd">2815000</us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent>
    <us-gaap:ProvisionForDoubtfulAccounts
      contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM182NC9mcmFnOjVmZDYzMzVhZDUyYjRiMGM5MjRmODY5Mzg3MzViZTdhL3RhYmxlOjZiOGIxZmE4ZDk0NTRhMWQ4OTdmYjYxNzU2ZmUzYjQ3L3RhYmxlcmFuZ2U6NmI4YjFmYThkOTQ1NGExZDg5N2ZiNjE3NTZmZTNiNDdfNS0xLTEtMS0xNzc3NQ_816ee80b-08b0-4f9d-b328-2e6d0bd5fc01"
      unitRef="usd">2411000</us-gaap:ProvisionForDoubtfulAccounts>
    <us-gaap:ProvisionForDoubtfulAccounts
      contextRef="i12a6d1161de54547bd29f8efccd4c9b0_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM182NC9mcmFnOjVmZDYzMzVhZDUyYjRiMGM5MjRmODY5Mzg3MzViZTdhL3RhYmxlOjZiOGIxZmE4ZDk0NTRhMWQ4OTdmYjYxNzU2ZmUzYjQ3L3RhYmxlcmFuZ2U6NmI4YjFmYThkOTQ1NGExZDg5N2ZiNjE3NTZmZTNiNDdfNS0zLTEtMS0xNzc3NQ_74b4252d-81af-494d-86a5-8bd909eb0277"
      unitRef="usd">3283000</us-gaap:ProvisionForDoubtfulAccounts>
    <us-gaap:AllowanceForDoubtfulAccountsReceivableWriteOffs
      contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM182NC9mcmFnOjVmZDYzMzVhZDUyYjRiMGM5MjRmODY5Mzg3MzViZTdhL3RhYmxlOjZiOGIxZmE4ZDk0NTRhMWQ4OTdmYjYxNzU2ZmUzYjQ3L3RhYmxlcmFuZ2U6NmI4YjFmYThkOTQ1NGExZDg5N2ZiNjE3NTZmZTNiNDdfNi0xLTEtMS0xNzc3NQ_b67be07b-9fba-45e6-bf88-0da6c3fdb1a4"
      unitRef="usd">6093000</us-gaap:AllowanceForDoubtfulAccountsReceivableWriteOffs>
    <us-gaap:AllowanceForDoubtfulAccountsReceivableWriteOffs
      contextRef="i12a6d1161de54547bd29f8efccd4c9b0_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM182NC9mcmFnOjVmZDYzMzVhZDUyYjRiMGM5MjRmODY5Mzg3MzViZTdhL3RhYmxlOjZiOGIxZmE4ZDk0NTRhMWQ4OTdmYjYxNzU2ZmUzYjQ3L3RhYmxlcmFuZ2U6NmI4YjFmYThkOTQ1NGExZDg5N2ZiNjE3NTZmZTNiNDdfNi0zLTEtMS0xNzc3NQ_e456afa9-cea5-430f-a4f4-eda6d0aa7349"
      unitRef="usd">1665000</us-gaap:AllowanceForDoubtfulAccountsReceivableWriteOffs>
    <us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent
      contextRef="i8daff60be410426d8f7bd49343c1ec0c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM182NC9mcmFnOjVmZDYzMzVhZDUyYjRiMGM5MjRmODY5Mzg3MzViZTdhL3RhYmxlOjZiOGIxZmE4ZDk0NTRhMWQ4OTdmYjYxNzU2ZmUzYjQ3L3RhYmxlcmFuZ2U6NmI4YjFmYThkOTQ1NGExZDg5N2ZiNjE3NTZmZTNiNDdfNy0xLTEtMS0xNzc3NQ_40e9b127-7a9c-42fb-ab3f-9585f4f34292"
      unitRef="usd">3374000</us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent>
    <us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent
      contextRef="ibc0c0c2b8dc04c5698ca0577a54b2e03_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM182NC9mcmFnOjVmZDYzMzVhZDUyYjRiMGM5MjRmODY5Mzg3MzViZTdhL3RhYmxlOjZiOGIxZmE4ZDk0NTRhMWQ4OTdmYjYxNzU2ZmUzYjQ3L3RhYmxlcmFuZ2U6NmI4YjFmYThkOTQ1NGExZDg5N2ZiNjE3NTZmZTNiNDdfNy0zLTEtMS0xNzc3NQ_373439e8-1931-420b-a0de-2c40f7ba7c7e"
      unitRef="usd">7056000</us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent>
    <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock
      contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM182Ny9mcmFnOjk0OWExZWFiYjQwNTQ1MmZhNDdhZTI4NjMyNDliOTZiL3RleHRyZWdpb246OTQ5YTFlYWJiNDA1NDUyZmE0N2FlMjg2MzI0OWI5NmJfNjYy_28bffe8d-e7bd-4e46-98a8-18283077e5db">Property and Equipment, Net&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following summarizes our property and equipment (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:408.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:54.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:67.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Computer hardware&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,970&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,866&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Furniture and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,581&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,559&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Internal-use software development costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;159,587&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;137,085&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,325&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,586&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total property and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;200,463&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;175,096&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accumulated depreciation and amortization expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(119,098)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(88,856)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total property and equipment, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;81,365&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;86,240&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company capitalized $22.5 million, $24.6 million and $30.9 million of internal-use software development costs for the years ended December 31, 2021, 2020 and 2019, respectively. The net book value of capitalized internal-use software development costs was $71.2 million and $75.3 million as of December&#160;31, 2021 and 2020, respectively. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Depreciation expense related to property and equipment was $30.6 million, $28.3 million and $23.3 million, for the years ended December 31, 2021, 2020 and 2019, respectively, of which amortization expense related to capitalized internal-use software development costs was $26.5 million, $24.3 million and $18.7 million, respectively.&lt;/span&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i3065c5c08a124284884a61ee233f4e16_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM182Ny9mcmFnOjk0OWExZWFiYjQwNTQ1MmZhNDdhZTI4NjMyNDliOTZiL3RhYmxlOjE3OTQwMmM0YjIzNjQxMGJiZDk1NjFkZDc5YzM2MzUwL3RhYmxlcmFuZ2U6MTc5NDAyYzRiMjM2NDEwYmJkOTU2MWRkNzljMzYzNTBfMS0xLTEtMS0xNzc3NQ_ecaf647d-3273-4867-b2a2-599878304387"
      unitRef="usd">21970000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="ie08f3e6fd0bf42cf818c1f564fa39108_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM182Ny9mcmFnOjk0OWExZWFiYjQwNTQ1MmZhNDdhZTI4NjMyNDliOTZiL3RhYmxlOjE3OTQwMmM0YjIzNjQxMGJiZDk1NjFkZDc5YzM2MzUwL3RhYmxlcmFuZ2U6MTc5NDAyYzRiMjM2NDEwYmJkOTU2MWRkNzljMzYzNTBfMS0zLTEtMS0xNzc3NQ_490164d0-c71d-4e59-ac42-8139ee786a5c"
      unitRef="usd">18866000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="ia55f03733cd945fe9d885896e547d383_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM182Ny9mcmFnOjk0OWExZWFiYjQwNTQ1MmZhNDdhZTI4NjMyNDliOTZiL3RhYmxlOjE3OTQwMmM0YjIzNjQxMGJiZDk1NjFkZDc5YzM2MzUwL3RhYmxlcmFuZ2U6MTc5NDAyYzRiMjM2NDEwYmJkOTU2MWRkNzljMzYzNTBfMi0xLTEtMS0xNzc3NQ_90891177-ead0-420e-8c70-bf12f147b32e"
      unitRef="usd">3581000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="ia95d0a4759a840c0a34e767cc306a57e_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM182Ny9mcmFnOjk0OWExZWFiYjQwNTQ1MmZhNDdhZTI4NjMyNDliOTZiL3RhYmxlOjE3OTQwMmM0YjIzNjQxMGJiZDk1NjFkZDc5YzM2MzUwL3RhYmxlcmFuZ2U6MTc5NDAyYzRiMjM2NDEwYmJkOTU2MWRkNzljMzYzNTBfMi0zLTEtMS0xNzc3NQ_6e8858f6-0a1f-4c75-8ede-c1eb1520092a"
      unitRef="usd">3559000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i370ec8ac69f6453daffb02508aef709b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM182Ny9mcmFnOjk0OWExZWFiYjQwNTQ1MmZhNDdhZTI4NjMyNDliOTZiL3RhYmxlOjE3OTQwMmM0YjIzNjQxMGJiZDk1NjFkZDc5YzM2MzUwL3RhYmxlcmFuZ2U6MTc5NDAyYzRiMjM2NDEwYmJkOTU2MWRkNzljMzYzNTBfMy0xLTEtMS0xNzc3NQ_ad41c4b0-d01e-48f7-9d21-99ba6e90ce2c"
      unitRef="usd">159587000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="icd3eb9c2b2874ea99e8f34f94952be94_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM182Ny9mcmFnOjk0OWExZWFiYjQwNTQ1MmZhNDdhZTI4NjMyNDliOTZiL3RhYmxlOjE3OTQwMmM0YjIzNjQxMGJiZDk1NjFkZDc5YzM2MzUwL3RhYmxlcmFuZ2U6MTc5NDAyYzRiMjM2NDEwYmJkOTU2MWRkNzljMzYzNTBfMy0zLTEtMS0xNzc3NQ_8591bc18-be11-4d50-8908-237f60844c65"
      unitRef="usd">137085000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i3873f51f572a46ae8f17531700510927_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM182Ny9mcmFnOjk0OWExZWFiYjQwNTQ1MmZhNDdhZTI4NjMyNDliOTZiL3RhYmxlOjE3OTQwMmM0YjIzNjQxMGJiZDk1NjFkZDc5YzM2MzUwL3RhYmxlcmFuZ2U6MTc5NDAyYzRiMjM2NDEwYmJkOTU2MWRkNzljMzYzNTBfNC0xLTEtMS0xNzc3NQ_e6953dbd-f5b9-4cba-886e-613622fd0f60"
      unitRef="usd">15325000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i0b599414417745fdb6c3cddde5001d4b_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM182Ny9mcmFnOjk0OWExZWFiYjQwNTQ1MmZhNDdhZTI4NjMyNDliOTZiL3RhYmxlOjE3OTQwMmM0YjIzNjQxMGJiZDk1NjFkZDc5YzM2MzUwL3RhYmxlcmFuZ2U6MTc5NDAyYzRiMjM2NDEwYmJkOTU2MWRkNzljMzYzNTBfNC0zLTEtMS0xNzc3NQ_394d3d17-211f-4a01-a7e0-bef36f771342"
      unitRef="usd">15586000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i8daff60be410426d8f7bd49343c1ec0c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM182Ny9mcmFnOjk0OWExZWFiYjQwNTQ1MmZhNDdhZTI4NjMyNDliOTZiL3RhYmxlOjE3OTQwMmM0YjIzNjQxMGJiZDk1NjFkZDc5YzM2MzUwL3RhYmxlcmFuZ2U6MTc5NDAyYzRiMjM2NDEwYmJkOTU2MWRkNzljMzYzNTBfNS0xLTEtMS0xNzc3NQ_6bb41cc0-613c-4ec3-b434-bc9d244b41bb"
      unitRef="usd">200463000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="ibc0c0c2b8dc04c5698ca0577a54b2e03_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM182Ny9mcmFnOjk0OWExZWFiYjQwNTQ1MmZhNDdhZTI4NjMyNDliOTZiL3RhYmxlOjE3OTQwMmM0YjIzNjQxMGJiZDk1NjFkZDc5YzM2MzUwL3RhYmxlcmFuZ2U6MTc5NDAyYzRiMjM2NDEwYmJkOTU2MWRkNzljMzYzNTBfNS0zLTEtMS0xNzc3NQ_11eb0ad5-6d58-42fa-bf32-6843e68facd6"
      unitRef="usd">175096000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="i8daff60be410426d8f7bd49343c1ec0c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM182Ny9mcmFnOjk0OWExZWFiYjQwNTQ1MmZhNDdhZTI4NjMyNDliOTZiL3RhYmxlOjE3OTQwMmM0YjIzNjQxMGJiZDk1NjFkZDc5YzM2MzUwL3RhYmxlcmFuZ2U6MTc5NDAyYzRiMjM2NDEwYmJkOTU2MWRkNzljMzYzNTBfNi0xLTEtMS0xNzc3NQ_f52e0746-7282-4955-8a27-beffbc206dc2"
      unitRef="usd">119098000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="ibc0c0c2b8dc04c5698ca0577a54b2e03_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM182Ny9mcmFnOjk0OWExZWFiYjQwNTQ1MmZhNDdhZTI4NjMyNDliOTZiL3RhYmxlOjE3OTQwMmM0YjIzNjQxMGJiZDk1NjFkZDc5YzM2MzUwL3RhYmxlcmFuZ2U6MTc5NDAyYzRiMjM2NDEwYmJkOTU2MWRkNzljMzYzNTBfNi0zLTEtMS0xNzc3NQ_c559e04b-4b1f-4ef6-a01b-0335b8f39b40"
      unitRef="usd">88856000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i8daff60be410426d8f7bd49343c1ec0c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM182Ny9mcmFnOjk0OWExZWFiYjQwNTQ1MmZhNDdhZTI4NjMyNDliOTZiL3RhYmxlOjE3OTQwMmM0YjIzNjQxMGJiZDk1NjFkZDc5YzM2MzUwL3RhYmxlcmFuZ2U6MTc5NDAyYzRiMjM2NDEwYmJkOTU2MWRkNzljMzYzNTBfNy0xLTEtMS0xNzc3NQ_c2f10906-3c57-4f81-8135-445aeec89128"
      unitRef="usd">81365000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="ibc0c0c2b8dc04c5698ca0577a54b2e03_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM182Ny9mcmFnOjk0OWExZWFiYjQwNTQ1MmZhNDdhZTI4NjMyNDliOTZiL3RhYmxlOjE3OTQwMmM0YjIzNjQxMGJiZDk1NjFkZDc5YzM2MzUwL3RhYmxlcmFuZ2U6MTc5NDAyYzRiMjM2NDEwYmJkOTU2MWRkNzljMzYzNTBfNy0zLTEtMS0xNzc3NQ_b4698117-19d3-4fc9-9968-7c2de2c33d85"
      unitRef="usd">86240000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:CapitalizedComputerSoftwareAdditions
      contextRef="ia186bface90a4c4098c96c8567d34124_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM182Ny9mcmFnOjk0OWExZWFiYjQwNTQ1MmZhNDdhZTI4NjMyNDliOTZiL3RleHRyZWdpb246OTQ5YTFlYWJiNDA1NDUyZmE0N2FlMjg2MzI0OWI5NmJfMTYy_d6955ec8-f453-4a71-baa3-5d636c1a1023"
      unitRef="usd">22500000</us-gaap:CapitalizedComputerSoftwareAdditions>
    <us-gaap:CapitalizedComputerSoftwareAdditions
      contextRef="i8c359ea835e64a39b5cab25a3948e3b7_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM182Ny9mcmFnOjk0OWExZWFiYjQwNTQ1MmZhNDdhZTI4NjMyNDliOTZiL3RleHRyZWdpb246OTQ5YTFlYWJiNDA1NDUyZmE0N2FlMjg2MzI0OWI5NmJfMjM4_2df21e0f-7a5b-46e1-ba50-3133a4bfa6f9"
      unitRef="usd">24600000</us-gaap:CapitalizedComputerSoftwareAdditions>
    <us-gaap:CapitalizedComputerSoftwareAdditions
      contextRef="i3a8f822ce668416caf0bf1e2f7037e11_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM182Ny9mcmFnOjk0OWExZWFiYjQwNTQ1MmZhNDdhZTI4NjMyNDliOTZiL3RleHRyZWdpb246OTQ5YTFlYWJiNDA1NDUyZmE0N2FlMjg2MzI0OWI5NmJfMTA5OTUxMTYyODU4Mw_b313d975-d7d5-437f-8891-7994ee742adf"
      unitRef="usd">30900000</us-gaap:CapitalizedComputerSoftwareAdditions>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i370ec8ac69f6453daffb02508aef709b_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM182Ny9mcmFnOjk0OWExZWFiYjQwNTQ1MmZhNDdhZTI4NjMyNDliOTZiL3RleHRyZWdpb246OTQ5YTFlYWJiNDA1NDUyZmE0N2FlMjg2MzI0OWI5NmJfMzM3_b42b6e46-d8e2-4a40-a1a7-5c26932f4117"
      unitRef="usd">71200000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="icd3eb9c2b2874ea99e8f34f94952be94_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM182Ny9mcmFnOjk0OWExZWFiYjQwNTQ1MmZhNDdhZTI4NjMyNDliOTZiL3RleHRyZWdpb246OTQ5YTFlYWJiNDA1NDUyZmE0N2FlMjg2MzI0OWI5NmJfMzQ0_93925f9d-2d74-4f37-9890-80886b0b8640"
      unitRef="usd">75300000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:Depreciation
      contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM182Ny9mcmFnOjk0OWExZWFiYjQwNTQ1MmZhNDdhZTI4NjMyNDliOTZiL3RleHRyZWdpb246OTQ5YTFlYWJiNDA1NDUyZmE0N2FlMjg2MzI0OWI5NmJfNDQ2_787a09fb-b541-4334-9f9e-8b7abc6769b2"
      unitRef="usd">30600000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="i12a6d1161de54547bd29f8efccd4c9b0_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM182Ny9mcmFnOjk0OWExZWFiYjQwNTQ1MmZhNDdhZTI4NjMyNDliOTZiL3RleHRyZWdpb246OTQ5YTFlYWJiNDA1NDUyZmE0N2FlMjg2MzI0OWI5NmJfNDc4_3ba29408-9860-4b08-b24f-08fb4b76a172"
      unitRef="usd">28300000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="i3e21049ffc224cacb8134d73c9bb5b38_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM182Ny9mcmFnOjk0OWExZWFiYjQwNTQ1MmZhNDdhZTI4NjMyNDliOTZiL3RleHRyZWdpb246OTQ5YTFlYWJiNDA1NDUyZmE0N2FlMjg2MzI0OWI5NmJfMTA5OTUxMTYyODc3MQ_b8b47505-eea3-4903-ad3a-90e55b6a49ae"
      unitRef="usd">23300000</us-gaap:Depreciation>
    <us-gaap:CapitalizedComputerSoftwareAmortization1
      contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM182Ny9mcmFnOjk0OWExZWFiYjQwNTQ1MmZhNDdhZTI4NjMyNDliOTZiL3RleHRyZWdpb246OTQ5YTFlYWJiNDA1NDUyZmE0N2FlMjg2MzI0OWI5NmJfNjAz_c28efbd5-65b9-40b7-83e0-a8b77aba9b11"
      unitRef="usd">26500000</us-gaap:CapitalizedComputerSoftwareAmortization1>
    <us-gaap:CapitalizedComputerSoftwareAmortization1
      contextRef="i12a6d1161de54547bd29f8efccd4c9b0_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM182Ny9mcmFnOjk0OWExZWFiYjQwNTQ1MmZhNDdhZTI4NjMyNDliOTZiL3RleHRyZWdpb246OTQ5YTFlYWJiNDA1NDUyZmE0N2FlMjg2MzI0OWI5NmJfNjM1_f1738cf3-8317-4f2c-8f4f-0b0bf2f80b96"
      unitRef="usd">24300000</us-gaap:CapitalizedComputerSoftwareAmortization1>
    <us-gaap:CapitalizedComputerSoftwareAmortization1
      contextRef="i3e21049ffc224cacb8134d73c9bb5b38_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM182Ny9mcmFnOjk0OWExZWFiYjQwNTQ1MmZhNDdhZTI4NjMyNDliOTZiL3RleHRyZWdpb246OTQ5YTFlYWJiNDA1NDUyZmE0N2FlMjg2MzI0OWI5NmJfMTA5OTUxMTYyODg4Mg_d9037ad2-e0a1-4ec5-bfc4-eb101df7331d"
      unitRef="usd">18700000</us-gaap:CapitalizedComputerSoftwareAmortization1>
    <us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock
      contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM183MC9mcmFnOmIxYjdhNmFmNjEzYzQ3NWM5ZGI4Y2JlNmQzNTE1NDk3L3RleHRyZWdpb246YjFiN2E2YWY2MTNjNDc1YzlkYjhjYmU2ZDM1MTU0OTdfODYwMg_1a0abe50-36b7-4bf6-90d8-5ceb9bebf69a">Goodwill and Intangible Assets, Net&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Goodwill&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Goodwill has an estimated indefinite life and is not amortized; rather, it is reviewed for impairment at least annually or whenever events or changes in circumstances indicate that the carrying amount of the asset may not be recoverable.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Subsequent to the sale of True Health, the Company has three reporting units, each with &lt;/span&gt;&lt;span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;discrete financial information. Our assets and liabilities are employed in and relate to the operations of our reporting units. Therefore, the equity carrying value and future cash flows must be estimated each time a&#160;goodwill impairment&#160;analysis is performed on a reporting unit. As a result, our assets, liabilities and cash flows are assigned to reporting units using reasonable and consistent allocation methodologies. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our annual goodwill impairment review occurs on October 31 of each fiscal &lt;/span&gt;&lt;span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;year. We evaluate qualitative factors that could cause us to believe the estimated fair value of each of our reporting units may be lower than the carrying value and trigger a quantitative assessment, including, but not limited to (i) macroeconomic conditions, (ii) industry and market considerations, (iii) our overall financial performance, including an analysis of our current and projected cash flows, revenues and earnings, (iv) a sustained decrease in share price and (v) other relevant entity-specific events including changes in management, strategy, partners, or litigation.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;2021 Goodwill Impairment Test&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On October 31, 2021, the Company performed its annual goodwill impairment review for fiscal year 2021. Based on our qualitative assessment, we did not identify sufficient indicators of impairment that would suggest the fair value of any of our three reporting units was below their respective carrying values. As a result, a quantitative goodwill impairment analysis was not required.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;2020 Goodwill Impairment Test&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of March 31, 2020, the Company assessed whether there were additional events or changes in circumstances since its 2019 annual goodwill impairment test that would indicate that it was more likely than not that the fair values of the reporting units were less than the reporting units&#x2019; carrying amounts that would require an additional interim impairment assessment after October 31, 2019. Considering the sharp decrease in the share price of the Company&#x2019;s Class A common stock during the three months ended March 31, 2020, the Company determined indicators of an impairment were present and we performed an interim goodwill impairment assessment as of March 31, 2020. As a result of this test, the Company determined that there was no goodwill impairment of the reporting unit which recognized an impairment in the year ended December 31, 2019. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During May 2020, the Kentucky Cabinet for Health and Family Services (&#x201c;CHFS&#x201d;) announced that EVH Passport was not awarded a Kentucky managed Medicaid contract for the next contract period and the Passport Medicaid Contract would expire on December 31, 2020. As a result of this announcement, the Company determined there were events or changes in circumstances since its 2019 annual goodwill impairment test that indicated it was more likely than not that the fair value of one of its two reporting units in the EHS segment was less than the reporting unit&#x2019;s carrying amount triggering an interim quantitative assessment.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In performing this interim quantitative assessment, we estimated the fair value of the reporting unit by considering a discounted cash flow valuation approach (&#x201c;income approach&#x201d;). In determining the estimated fair value in a quantitative analysis, we projected future cash flows based on management&#x2019;s estimates and long-term plans and applied a discount rate based on the Company&#x2019;s weighted average cost of capital. This analysis required us to make judgments about revenues, expenses, fixed asset and working capital requirements, capital market assumptions, cash flows and discount rates.  &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of May 31, 2020, we determined that the reporting unit under review had an estimated fair value less than its carrying value.  As a result, we recorded a non-cash goodwill impairment charge of $215.1&#160;million on our consolidated statements of operations and comprehensive income (loss) for the three and six months ended June 30, 2020. In addition, the Company reviewed its interim goodwill impairment analysis as of June 30, 2020 and did not identify any additional information or events that would contradict or change the conclusion reached by the Company as of May 31, 2020. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the three months ended September 30, 2020, we evaluated qualitative factors that could indicate the fair value of each of our reporting units may be lower than the carrying value. We did not identify any qualitative factors that would trigger a quantitative goodwill impairment test during the three months ended September 30, 2020. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the Company&#x2019;s annual impairment analysis as of October 31, 2020, the Company concluded that previous impairment charges of $199.8&#160;million and $215.1&#160;million recorded during the three months ended December 31, 2019 and June 30, 2020, respectively, in one of our two reporting units in the EHS segment left that specific reporting unit with a limited fair value cushion. Therefore, the Company elected to forego the qualitative assessment and proceed directly to the quantitative assessment of the goodwill impairment test for that specific reporting unit. This election does not preclude management from performing the qualitative assessment in any subsequent period. For the remaining reporting units, after assessing the totality of events and circumstances including the results of our previous valuations, the minimal impacts of the Passport loss and COVID-19, the Company does not believe that an event occurred or circumstances changed during the period under consideration that would, more likely than not, reduce the fair value of any reporting unit below their carrying amount. Therefore, the Company concluded that the quantitative assessment was not required. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In performing our October 31, 2020 impairment test for one of the specific reporting units referenced above, we estimated the fair value of our reporting units by considering a discounted cash flow valuation approach (&#x201c;income approach&#x201d;). In determining the estimated fair value using the income approach, we projected future cash flows based on management&#x2019;s estimates and long-term plans and applied a discount rate based on the Company&#x2019;s weighted average cost of capital. This analysis required us to make judgments about revenues, expenses, fixed asset and working capital requirements, capital market assumptions, cash flows and discount rates. As of October 31, 2020, we determined that the specific reporting unit had an estimated fair value greater than its carrying value and as a result, goodwill is not impaired.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December 31, 2020, the Company assessed whether there were additional events or changes in circumstances since its annual goodwill impairment test that would indicate that it was more likely than not that the fair value of the reporting unit was less than the reporting unit&#x2019;s carrying amounts that would require an interim impairment assessment after October 31, 2020. The Company &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;determined there had been no such indicators, therefore, we did not perform an interim goodwill impairment assessment as of December 31, 2020. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Change in Goodwill&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the changes in the carrying amount of goodwill, by reportable segment, for the periods presented (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:60.705%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.983%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.772%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.983%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.772%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.985%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;EHS&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Clinical Solutions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Consolidated&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance as of December 31, 2019 &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;431,684&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;134,675&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;566,359&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goodwill disposal &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,200)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,200)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Impairment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(215,100)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(215,100)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign currency translation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(30)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(30)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance as of December 31, 2020&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;214,354&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;134,675&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;349,029&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goodwill acquired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;77,288&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;77,288&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign currency translation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(20)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(20)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance as of December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;214,334&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;211,963&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;426,297&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-align:justify;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt"&gt;Net of cumulative inception to date impairment of $575.5 million and $360.4 million as of December 31, 2020 and 2019, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt"&gt;Goodwill written-off upon disposal of a consolidated subsidiary.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Intangible Assets, Net&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Details of our intangible assets (in thousands, except weighted-average useful lives) as of December&#160;31, 2021 and December&#160;31, 2020  are presented below:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:72.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:54.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:48.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:63.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:46.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:54.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:48.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:63.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:45.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:44pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted- Average Remaining Useful Life&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Gross Carrying Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Accumulated Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Net Carrying Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted- Average Remaining Useful Life&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Gross Carrying Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Accumulated Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Net Carrying Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:24pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate trade name&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12.4&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,800&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,693&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,107&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13.2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,300&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,271&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,029&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:24pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Customer relationships &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14.9&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;311,019&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;72,697&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;238,322&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16.2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;278,519&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;57,716&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;220,803&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Technology&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.0&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;87,922&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;73,378&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,544&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.8&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;82,922&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;63,507&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,415&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:24pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Below market lease, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,218&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;950&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;268&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,118&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;648&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;470&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:35pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Provider network contracts &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,417&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,874&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,543&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.9&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,175&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,900&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,275&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:35pt"&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total intangible assets, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;442,376&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;162,592&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;279,784&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;398,034&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;133,042&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;264,992&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt"&gt;Amounts exclude $2.2&#160;million and $0.9&#160;million of customer relationships and provider network contracts, respectively, net of accumulated amortization, with weighted average remaining useful lives of 15 years and 10 months reclassified to discontinued operations as of December&#160;31, 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Amortization expense related to intangible assets for the years ended December 31, 2021, 2020 and 2019, was $29.4 million, $32.3 million and $37.1 million respectively, excluding $0.2&#160;million, $0.6&#160;million and $0.6&#160;million of amortization expense related to discontinued operations for the years ended December 31, 2021, 2020 and 2019, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Future estimated amortization of intangible assets (in thousands) as of December&#160;31, 2021, is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:478.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:58.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29,102&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26,798&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,913&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,403&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,153&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;164,415&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total future amortization of intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;279,784&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Intangible assets are reviewed for impairment if circumstances indicate the Company may not be able to recover the assets&#x2019; carrying value. We did not identify any circumstances during&#160;the year ended December 31, 2021, that would require an impairment test for our intangible assets.&lt;/span&gt;&lt;/div&gt;</us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock>
    <us-gaap:NumberOfReportingUnits
      contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM183MC9mcmFnOmIxYjdhNmFmNjEzYzQ3NWM5ZGI4Y2JlNmQzNTE1NDk3L3RleHRyZWdpb246YjFiN2E2YWY2MTNjNDc1YzlkYjhjYmU2ZDM1MTU0OTdfMzU2_c8cafdff-4a85-4bce-a4fd-4fd28f16f87f"
      unitRef="reportingunit">3</us-gaap:NumberOfReportingUnits>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="iddbf996a3b1a4aeda47f1e8169c69262_D20200101-20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM183MC9mcmFnOmIxYjdhNmFmNjEzYzQ3NWM5ZGI4Y2JlNmQzNTE1NDk3L3RleHRyZWdpb246YjFiN2E2YWY2MTNjNDc1YzlkYjhjYmU2ZDM1MTU0OTdfMjUwOA_d8ae2c21-cb0d-4657-924a-15e980c0fc9d"
      unitRef="usd">0</us-gaap:GoodwillImpairmentLoss>
    <evh:NumberOfReportingUnitsFairValueInExcessOfCarryingAmount
      contextRef="i113b515f40aa4b3e9afd7361c65483dc_D20200501-20200531"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM183MC9mcmFnOmIxYjdhNmFmNjEzYzQ3NWM5ZGI4Y2JlNmQzNTE1NDk3L3RleHRyZWdpb246YjFiN2E2YWY2MTNjNDc1YzlkYjhjYmU2ZDM1MTU0OTdfMzA5Nw_d9f61b8a-15f8-411d-903d-7837e874889f"
      unitRef="reportingunit">1</evh:NumberOfReportingUnitsFairValueInExcessOfCarryingAmount>
    <us-gaap:NumberOfReportingUnits
      contextRef="i113b515f40aa4b3e9afd7361c65483dc_D20200501-20200531"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM183MC9mcmFnOmIxYjdhNmFmNjEzYzQ3NWM5ZGI4Y2JlNmQzNTE1NDk3L3RleHRyZWdpb246YjFiN2E2YWY2MTNjNDc1YzlkYjhjYmU2ZDM1MTU0OTdfMzEwNw_0f6f319a-4d15-4ba1-a647-7f737906b142"
      unitRef="reportingunit">2</us-gaap:NumberOfReportingUnits>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="i62320e40739f4842b8ffb078d42fa029_D20200401-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM183MC9mcmFnOmIxYjdhNmFmNjEzYzQ3NWM5ZGI4Y2JlNmQzNTE1NDk3L3RleHRyZWdpb246YjFiN2E2YWY2MTNjNDc1YzlkYjhjYmU2ZDM1MTU0OTdfNDAzNA_2ce57fc7-de9d-4a63-a2c6-d7c202b860d9"
      unitRef="usd">215100000</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="ibd34af6251294e159e55819cc46cbbb6_D20200101-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM183MC9mcmFnOmIxYjdhNmFmNjEzYzQ3NWM5ZGI4Y2JlNmQzNTE1NDk3L3RleHRyZWdpb246YjFiN2E2YWY2MTNjNDc1YzlkYjhjYmU2ZDM1MTU0OTdfNDAzNA_a5cac6a5-ef5f-4be2-987d-01d10e187357"
      unitRef="usd">215100000</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="id2d85a5202f44415bdbcb9412ab08509_D20191001-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM183MC9mcmFnOmIxYjdhNmFmNjEzYzQ3NWM5ZGI4Y2JlNmQzNTE1NDk3L3RleHRyZWdpb246YjFiN2E2YWY2MTNjNDc1YzlkYjhjYmU2ZDM1MTU0OTdfNDg4MQ_34006fbc-07a3-4662-a1df-e350fe012bc3"
      unitRef="usd">199800000</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="i62320e40739f4842b8ffb078d42fa029_D20200401-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM183MC9mcmFnOmIxYjdhNmFmNjEzYzQ3NWM5ZGI4Y2JlNmQzNTE1NDk3L3RleHRyZWdpb246YjFiN2E2YWY2MTNjNDc1YzlkYjhjYmU2ZDM1MTU0OTdfNDg4OA_32d62e43-8aff-49b9-89f7-ac2d6b86ff33"
      unitRef="usd">215100000</us-gaap:GoodwillImpairmentLoss>
    <evh:NumberOfReportingUnitsFairValueInExcessOfCarryingAmount
      contextRef="id586f68951304ab3ac3fd84a42cb5e48_D20201031-20201031"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM183MC9mcmFnOmIxYjdhNmFmNjEzYzQ3NWM5ZGI4Y2JlNmQzNTE1NDk3L3RleHRyZWdpb246YjFiN2E2YWY2MTNjNDc1YzlkYjhjYmU2ZDM1MTU0OTdfNDk4NA_2533f69b-16ce-41cd-bd9a-581a81d3b8db"
      unitRef="reportingunit">1</evh:NumberOfReportingUnitsFairValueInExcessOfCarryingAmount>
    <us-gaap:NumberOfReportingUnits
      contextRef="id586f68951304ab3ac3fd84a42cb5e48_D20201031-20201031"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM183MC9mcmFnOmIxYjdhNmFmNjEzYzQ3NWM5ZGI4Y2JlNmQzNTE1NDk3L3RleHRyZWdpb246YjFiN2E2YWY2MTNjNDc1YzlkYjhjYmU2ZDM1MTU0OTdfNDk5NA_0b209d7a-c8d2-49b5-903d-c7ac6766c703"
      unitRef="reportingunit">2</us-gaap:NumberOfReportingUnits>
    <evh:NumberOfReportingUnitsFairValueInExcessOfCarryingAmount
      contextRef="id586f68951304ab3ac3fd84a42cb5e48_D20201031-20201031"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM183MC9mcmFnOmIxYjdhNmFmNjEzYzQ3NWM5ZGI4Y2JlNmQzNTE1NDk3L3RleHRyZWdpb246YjFiN2E2YWY2MTNjNDc1YzlkYjhjYmU2ZDM1MTU0OTdfNTk1OQ_5015ca66-91d2-4ed9-aa2d-a2c4c4c29b81"
      unitRef="reportingunit">1</evh:NumberOfReportingUnitsFairValueInExcessOfCarryingAmount>
    <us-gaap:ScheduleOfGoodwillTextBlock
      contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM183MC9mcmFnOmIxYjdhNmFmNjEzYzQ3NWM5ZGI4Y2JlNmQzNTE1NDk3L3RleHRyZWdpb246YjFiN2E2YWY2MTNjNDc1YzlkYjhjYmU2ZDM1MTU0OTdfODYxMQ_fce16faa-7fae-4173-96fb-73dc4d19971d">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the changes in the carrying amount of goodwill, by reportable segment, for the periods presented (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:60.705%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.983%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.772%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.983%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.772%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.985%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;EHS&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Clinical Solutions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Consolidated&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance as of December 31, 2019 &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;431,684&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;134,675&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;566,359&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goodwill disposal &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,200)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,200)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Impairment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(215,100)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(215,100)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign currency translation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(30)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(30)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance as of December 31, 2020&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;214,354&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;134,675&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;349,029&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goodwill acquired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;77,288&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;77,288&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign currency translation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(20)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(20)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance as of December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;214,334&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;211,963&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;426,297&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-align:justify;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt"&gt;Net of cumulative inception to date impairment of $575.5 million and $360.4 million as of December 31, 2020 and 2019, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt"&gt;Goodwill written-off upon disposal of a consolidated subsidiary.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfGoodwillTextBlock>
    <us-gaap:Goodwill
      contextRef="ida02b25c4b5e464a9545df19946134c1_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM183MC9mcmFnOmIxYjdhNmFmNjEzYzQ3NWM5ZGI4Y2JlNmQzNTE1NDk3L3RhYmxlOjU0MjkzMDQ2ZWJiMjRjNjdhZWI0NmZhZmM1ZjNjNTdhL3RhYmxlcmFuZ2U6NTQyOTMwNDZlYmIyNGM2N2FlYjQ2ZmFmYzVmM2M1N2FfMS0xLTEtMS0xNzc3NQ_07ac5111-4bfa-4f4b-b8ab-7ea55ed767a3"
      unitRef="usd">431684000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="i14e6a440f7dc431a9e1c85272b43d276_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM183MC9mcmFnOmIxYjdhNmFmNjEzYzQ3NWM5ZGI4Y2JlNmQzNTE1NDk3L3RhYmxlOjU0MjkzMDQ2ZWJiMjRjNjdhZWI0NmZhZmM1ZjNjNTdhL3RhYmxlcmFuZ2U6NTQyOTMwNDZlYmIyNGM2N2FlYjQ2ZmFmYzVmM2M1N2FfMS0zLTEtMS0xNzc3NQ_cf640a78-0ac5-4114-a47d-b03173de4cf5"
      unitRef="usd">134675000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="icba6e493923b449aa57c46a563760234_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM183MC9mcmFnOmIxYjdhNmFmNjEzYzQ3NWM5ZGI4Y2JlNmQzNTE1NDk3L3RhYmxlOjU0MjkzMDQ2ZWJiMjRjNjdhZWI0NmZhZmM1ZjNjNTdhL3RhYmxlcmFuZ2U6NTQyOTMwNDZlYmIyNGM2N2FlYjQ2ZmFmYzVmM2M1N2FfMS01LTEtMS0xNzc3NQ_de7f0beb-c6e0-43c6-84c6-95c0f1efe680"
      unitRef="usd">566359000</us-gaap:Goodwill>
    <us-gaap:GoodwillWrittenOffRelatedToSaleOfBusinessUnit
      contextRef="i00a9fb2f3f914116b87f14e146d04507_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM183MC9mcmFnOmIxYjdhNmFmNjEzYzQ3NWM5ZGI4Y2JlNmQzNTE1NDk3L3RhYmxlOjU0MjkzMDQ2ZWJiMjRjNjdhZWI0NmZhZmM1ZjNjNTdhL3RhYmxlcmFuZ2U6NTQyOTMwNDZlYmIyNGM2N2FlYjQ2ZmFmYzVmM2M1N2FfMi0xLTEtMS0xNzc3NQ_456d1861-a3b5-418b-b9d3-62639e9949de"
      unitRef="usd">2200000</us-gaap:GoodwillWrittenOffRelatedToSaleOfBusinessUnit>
    <us-gaap:GoodwillWrittenOffRelatedToSaleOfBusinessUnit
      contextRef="i73877656554945338d08c1e8006fc13a_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM183MC9mcmFnOmIxYjdhNmFmNjEzYzQ3NWM5ZGI4Y2JlNmQzNTE1NDk3L3RhYmxlOjU0MjkzMDQ2ZWJiMjRjNjdhZWI0NmZhZmM1ZjNjNTdhL3RhYmxlcmFuZ2U6NTQyOTMwNDZlYmIyNGM2N2FlYjQ2ZmFmYzVmM2M1N2FfMi0zLTEtMS0xNzc3NQ_ec861440-832d-4dce-bad9-0d4a8a0d6274"
      unitRef="usd">0</us-gaap:GoodwillWrittenOffRelatedToSaleOfBusinessUnit>
    <us-gaap:GoodwillWrittenOffRelatedToSaleOfBusinessUnit
      contextRef="i12a6d1161de54547bd29f8efccd4c9b0_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM183MC9mcmFnOmIxYjdhNmFmNjEzYzQ3NWM5ZGI4Y2JlNmQzNTE1NDk3L3RhYmxlOjU0MjkzMDQ2ZWJiMjRjNjdhZWI0NmZhZmM1ZjNjNTdhL3RhYmxlcmFuZ2U6NTQyOTMwNDZlYmIyNGM2N2FlYjQ2ZmFmYzVmM2M1N2FfMi01LTEtMS0xNzc3NQ_8b524ecc-9b7a-4dad-8e7c-4cf0a45e7d99"
      unitRef="usd">2200000</us-gaap:GoodwillWrittenOffRelatedToSaleOfBusinessUnit>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="i00a9fb2f3f914116b87f14e146d04507_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM183MC9mcmFnOmIxYjdhNmFmNjEzYzQ3NWM5ZGI4Y2JlNmQzNTE1NDk3L3RhYmxlOjU0MjkzMDQ2ZWJiMjRjNjdhZWI0NmZhZmM1ZjNjNTdhL3RhYmxlcmFuZ2U6NTQyOTMwNDZlYmIyNGM2N2FlYjQ2ZmFmYzVmM2M1N2FfMy0xLTEtMS0xNzc3NQ_99234612-db50-402c-92c3-095db58d8143"
      unitRef="usd">215100000</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="i73877656554945338d08c1e8006fc13a_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM183MC9mcmFnOmIxYjdhNmFmNjEzYzQ3NWM5ZGI4Y2JlNmQzNTE1NDk3L3RhYmxlOjU0MjkzMDQ2ZWJiMjRjNjdhZWI0NmZhZmM1ZjNjNTdhL3RhYmxlcmFuZ2U6NTQyOTMwNDZlYmIyNGM2N2FlYjQ2ZmFmYzVmM2M1N2FfMy0zLTEtMS0xNzc3NQ_7ac790ab-5cb6-4565-83d6-bdc0c0870487"
      unitRef="usd">0</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="i12a6d1161de54547bd29f8efccd4c9b0_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM183MC9mcmFnOmIxYjdhNmFmNjEzYzQ3NWM5ZGI4Y2JlNmQzNTE1NDk3L3RhYmxlOjU0MjkzMDQ2ZWJiMjRjNjdhZWI0NmZhZmM1ZjNjNTdhL3RhYmxlcmFuZ2U6NTQyOTMwNDZlYmIyNGM2N2FlYjQ2ZmFmYzVmM2M1N2FfMy01LTEtMS0xNzc3NQ_49e92921-1b25-4a23-a354-86b06907ab25"
      unitRef="usd">215100000</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:GoodwillForeignCurrencyTranslationGainLoss
      contextRef="i00a9fb2f3f914116b87f14e146d04507_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM183MC9mcmFnOmIxYjdhNmFmNjEzYzQ3NWM5ZGI4Y2JlNmQzNTE1NDk3L3RhYmxlOjU0MjkzMDQ2ZWJiMjRjNjdhZWI0NmZhZmM1ZjNjNTdhL3RhYmxlcmFuZ2U6NTQyOTMwNDZlYmIyNGM2N2FlYjQ2ZmFmYzVmM2M1N2FfNC0xLTEtMS0xNzc3NQ_56161dc0-d27e-4b57-816c-f0fc0aeb794b"
      unitRef="usd">-30000</us-gaap:GoodwillForeignCurrencyTranslationGainLoss>
    <us-gaap:GoodwillForeignCurrencyTranslationGainLoss
      contextRef="i73877656554945338d08c1e8006fc13a_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM183MC9mcmFnOmIxYjdhNmFmNjEzYzQ3NWM5ZGI4Y2JlNmQzNTE1NDk3L3RhYmxlOjU0MjkzMDQ2ZWJiMjRjNjdhZWI0NmZhZmM1ZjNjNTdhL3RhYmxlcmFuZ2U6NTQyOTMwNDZlYmIyNGM2N2FlYjQ2ZmFmYzVmM2M1N2FfNC0zLTEtMS0xNzc3NQ_123439d1-27b4-4379-b488-96e80975db29"
      unitRef="usd">0</us-gaap:GoodwillForeignCurrencyTranslationGainLoss>
    <us-gaap:GoodwillForeignCurrencyTranslationGainLoss
      contextRef="i12a6d1161de54547bd29f8efccd4c9b0_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM183MC9mcmFnOmIxYjdhNmFmNjEzYzQ3NWM5ZGI4Y2JlNmQzNTE1NDk3L3RhYmxlOjU0MjkzMDQ2ZWJiMjRjNjdhZWI0NmZhZmM1ZjNjNTdhL3RhYmxlcmFuZ2U6NTQyOTMwNDZlYmIyNGM2N2FlYjQ2ZmFmYzVmM2M1N2FfNC01LTEtMS0xNzc3NQ_3753f51d-32ef-4a88-a49f-585a4d7046f5"
      unitRef="usd">-30000</us-gaap:GoodwillForeignCurrencyTranslationGainLoss>
    <us-gaap:Goodwill
      contextRef="if8fd35766cfc4fa8b1cbf4f3cd8a8dfc_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM183MC9mcmFnOmIxYjdhNmFmNjEzYzQ3NWM5ZGI4Y2JlNmQzNTE1NDk3L3RhYmxlOjU0MjkzMDQ2ZWJiMjRjNjdhZWI0NmZhZmM1ZjNjNTdhL3RhYmxlcmFuZ2U6NTQyOTMwNDZlYmIyNGM2N2FlYjQ2ZmFmYzVmM2M1N2FfNS0xLTEtMS0xNzc3NQ_5d158e10-52fa-4a08-a9d0-ba2e01ca899d"
      unitRef="usd">214354000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="i5f5145421bc94a90bb8982e11bb80abb_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM183MC9mcmFnOmIxYjdhNmFmNjEzYzQ3NWM5ZGI4Y2JlNmQzNTE1NDk3L3RhYmxlOjU0MjkzMDQ2ZWJiMjRjNjdhZWI0NmZhZmM1ZjNjNTdhL3RhYmxlcmFuZ2U6NTQyOTMwNDZlYmIyNGM2N2FlYjQ2ZmFmYzVmM2M1N2FfNS0zLTEtMS0xNzc3NQ_65c3c627-30ae-48fa-8880-dc2a804712bc"
      unitRef="usd">134675000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="ibc0c0c2b8dc04c5698ca0577a54b2e03_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM183MC9mcmFnOmIxYjdhNmFmNjEzYzQ3NWM5ZGI4Y2JlNmQzNTE1NDk3L3RhYmxlOjU0MjkzMDQ2ZWJiMjRjNjdhZWI0NmZhZmM1ZjNjNTdhL3RhYmxlcmFuZ2U6NTQyOTMwNDZlYmIyNGM2N2FlYjQ2ZmFmYzVmM2M1N2FfNS01LTEtMS0xNzc3NQ_e43cc33e-39a2-4309-93f4-3e431362c727"
      unitRef="usd">349029000</us-gaap:Goodwill>
    <us-gaap:GoodwillAcquiredDuringPeriod
      contextRef="i98988f30813349e1a5594e72b40af5b1_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM183MC9mcmFnOmIxYjdhNmFmNjEzYzQ3NWM5ZGI4Y2JlNmQzNTE1NDk3L3RhYmxlOjU0MjkzMDQ2ZWJiMjRjNjdhZWI0NmZhZmM1ZjNjNTdhL3RhYmxlcmFuZ2U6NTQyOTMwNDZlYmIyNGM2N2FlYjQ2ZmFmYzVmM2M1N2FfNi0xLTEtMS0yMTE4NA_87b8353a-d6d7-4f20-b863-3e6a73b644ce"
      unitRef="usd">0</us-gaap:GoodwillAcquiredDuringPeriod>
    <us-gaap:GoodwillAcquiredDuringPeriod
      contextRef="i6d991ef4e2e0416f8c7aaaa6175cf843_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM183MC9mcmFnOmIxYjdhNmFmNjEzYzQ3NWM5ZGI4Y2JlNmQzNTE1NDk3L3RhYmxlOjU0MjkzMDQ2ZWJiMjRjNjdhZWI0NmZhZmM1ZjNjNTdhL3RhYmxlcmFuZ2U6NTQyOTMwNDZlYmIyNGM2N2FlYjQ2ZmFmYzVmM2M1N2FfNi0zLTEtMS0yMTE5MQ_f3527def-6ae5-47d6-86dd-5d026cc04ac7"
      unitRef="usd">77288000</us-gaap:GoodwillAcquiredDuringPeriod>
    <us-gaap:GoodwillAcquiredDuringPeriod
      contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM183MC9mcmFnOmIxYjdhNmFmNjEzYzQ3NWM5ZGI4Y2JlNmQzNTE1NDk3L3RhYmxlOjU0MjkzMDQ2ZWJiMjRjNjdhZWI0NmZhZmM1ZjNjNTdhL3RhYmxlcmFuZ2U6NTQyOTMwNDZlYmIyNGM2N2FlYjQ2ZmFmYzVmM2M1N2FfNi01LTEtMS0yMTE5OQ_907d03a3-cce2-4dec-9e6d-581662916ec3"
      unitRef="usd">77288000</us-gaap:GoodwillAcquiredDuringPeriod>
    <us-gaap:GoodwillForeignCurrencyTranslationGainLoss
      contextRef="i98988f30813349e1a5594e72b40af5b1_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM183MC9mcmFnOmIxYjdhNmFmNjEzYzQ3NWM5ZGI4Y2JlNmQzNTE1NDk3L3RhYmxlOjU0MjkzMDQ2ZWJiMjRjNjdhZWI0NmZhZmM1ZjNjNTdhL3RhYmxlcmFuZ2U6NTQyOTMwNDZlYmIyNGM2N2FlYjQ2ZmFmYzVmM2M1N2FfNy0xLTEtMS0yMTIwOQ_75b9c87b-df99-405c-a74e-90dd6ad5e146"
      unitRef="usd">-20000</us-gaap:GoodwillForeignCurrencyTranslationGainLoss>
    <us-gaap:GoodwillForeignCurrencyTranslationGainLoss
      contextRef="i6d991ef4e2e0416f8c7aaaa6175cf843_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM183MC9mcmFnOmIxYjdhNmFmNjEzYzQ3NWM5ZGI4Y2JlNmQzNTE1NDk3L3RhYmxlOjU0MjkzMDQ2ZWJiMjRjNjdhZWI0NmZhZmM1ZjNjNTdhL3RhYmxlcmFuZ2U6NTQyOTMwNDZlYmIyNGM2N2FlYjQ2ZmFmYzVmM2M1N2FfNy0zLTEtMS0yMTIxNA_41ab3ca8-90a2-4caf-ba2d-01105f3da480"
      unitRef="usd">0</us-gaap:GoodwillForeignCurrencyTranslationGainLoss>
    <us-gaap:GoodwillForeignCurrencyTranslationGainLoss
      contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM183MC9mcmFnOmIxYjdhNmFmNjEzYzQ3NWM5ZGI4Y2JlNmQzNTE1NDk3L3RhYmxlOjU0MjkzMDQ2ZWJiMjRjNjdhZWI0NmZhZmM1ZjNjNTdhL3RhYmxlcmFuZ2U6NTQyOTMwNDZlYmIyNGM2N2FlYjQ2ZmFmYzVmM2M1N2FfNy01LTEtMS0yMTIyMg_cf56fd3f-1448-49d2-82fa-1d4a5f775de6"
      unitRef="usd">-20000</us-gaap:GoodwillForeignCurrencyTranslationGainLoss>
    <us-gaap:Goodwill
      contextRef="icdbca3fab4684e269937d4a61379d67f_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM183MC9mcmFnOmIxYjdhNmFmNjEzYzQ3NWM5ZGI4Y2JlNmQzNTE1NDk3L3RhYmxlOjU0MjkzMDQ2ZWJiMjRjNjdhZWI0NmZhZmM1ZjNjNTdhL3RhYmxlcmFuZ2U6NTQyOTMwNDZlYmIyNGM2N2FlYjQ2ZmFmYzVmM2M1N2FfOC0xLTEtMS0yMTIyNw_4c644c9c-861a-40cf-9d43-88a5b25d7996"
      unitRef="usd">214334000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="ie09b385083554dfe92dc601254dfdda8_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM183MC9mcmFnOmIxYjdhNmFmNjEzYzQ3NWM5ZGI4Y2JlNmQzNTE1NDk3L3RhYmxlOjU0MjkzMDQ2ZWJiMjRjNjdhZWI0NmZhZmM1ZjNjNTdhL3RhYmxlcmFuZ2U6NTQyOTMwNDZlYmIyNGM2N2FlYjQ2ZmFmYzVmM2M1N2FfOC0zLTEtMS0yMTIzMg_1976e705-df90-4e8a-b9c0-d27ec32c3670"
      unitRef="usd">211963000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="i8daff60be410426d8f7bd49343c1ec0c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM183MC9mcmFnOmIxYjdhNmFmNjEzYzQ3NWM5ZGI4Y2JlNmQzNTE1NDk3L3RhYmxlOjU0MjkzMDQ2ZWJiMjRjNjdhZWI0NmZhZmM1ZjNjNTdhL3RhYmxlcmFuZ2U6NTQyOTMwNDZlYmIyNGM2N2FlYjQ2ZmFmYzVmM2M1N2FfOC01LTEtMS0yMTI0MA_d8560f96-329b-472d-ad51-6fc4c5d38bb3"
      unitRef="usd">426297000</us-gaap:Goodwill>
    <us-gaap:GoodwillImpairedAccumulatedImpairmentLoss
      contextRef="ibc0c0c2b8dc04c5698ca0577a54b2e03_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM183MC9mcmFnOmIxYjdhNmFmNjEzYzQ3NWM5ZGI4Y2JlNmQzNTE1NDk3L3RleHRyZWdpb246YjFiN2E2YWY2MTNjNDc1YzlkYjhjYmU2ZDM1MTU0OTdfNzQ1MA_01412ce1-c4a1-47d6-bf76-e901dff2b712"
      unitRef="usd">575500000</us-gaap:GoodwillImpairedAccumulatedImpairmentLoss>
    <us-gaap:GoodwillImpairedAccumulatedImpairmentLoss
      contextRef="icba6e493923b449aa57c46a563760234_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM183MC9mcmFnOmIxYjdhNmFmNjEzYzQ3NWM5ZGI4Y2JlNmQzNTE1NDk3L3RleHRyZWdpb246YjFiN2E2YWY2MTNjNDc1YzlkYjhjYmU2ZDM1MTU0OTdfNzQ1Nw_8247f5c6-6406-47b5-b300-496348082a89"
      unitRef="usd">360400000</us-gaap:GoodwillImpairedAccumulatedImpairmentLoss>
    <us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife
      contextRef="ie58c5dcefe64400fa99a44a4db35e02d_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM183MC9mcmFnOmIxYjdhNmFmNjEzYzQ3NWM5ZGI4Y2JlNmQzNTE1NDk3L3RhYmxlOmM0ZGIzYWY3Y2RlYTQ3MTQ5Y2ZhYzhiZmJmNmQ1NDViL3RhYmxlcmFuZ2U6YzRkYjNhZjdjZGVhNDcxNDljZmFjOGJmYmY2ZDU0NWJfMi0xLTEtMS0xNzc3NQ_73a528b9-8b0e-4207-ad6d-a9f9e7b17955">P12Y4M24D</us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="if54550ac07374463b0640b875a8f1164_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM183MC9mcmFnOmIxYjdhNmFmNjEzYzQ3NWM5ZGI4Y2JlNmQzNTE1NDk3L3RhYmxlOmM0ZGIzYWY3Y2RlYTQ3MTQ5Y2ZhYzhiZmJmNmQ1NDViL3RhYmxlcmFuZ2U6YzRkYjNhZjdjZGVhNDcxNDljZmFjOGJmYmY2ZDU0NWJfMi0zLTEtMS0xNzc3NQ_426546ce-30cd-4423-85c5-802f099397de"
      unitRef="usd">25800000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="if54550ac07374463b0640b875a8f1164_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM183MC9mcmFnOmIxYjdhNmFmNjEzYzQ3NWM5ZGI4Y2JlNmQzNTE1NDk3L3RhYmxlOmM0ZGIzYWY3Y2RlYTQ3MTQ5Y2ZhYzhiZmJmNmQ1NDViL3RhYmxlcmFuZ2U6YzRkYjNhZjdjZGVhNDcxNDljZmFjOGJmYmY2ZDU0NWJfMi01LTEtMS0xNzc3NQ_5ec0de42-7697-468f-a613-f15eca6580f5"
      unitRef="usd">7693000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="if54550ac07374463b0640b875a8f1164_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM183MC9mcmFnOmIxYjdhNmFmNjEzYzQ3NWM5ZGI4Y2JlNmQzNTE1NDk3L3RhYmxlOmM0ZGIzYWY3Y2RlYTQ3MTQ5Y2ZhYzhiZmJmNmQ1NDViL3RhYmxlcmFuZ2U6YzRkYjNhZjdjZGVhNDcxNDljZmFjOGJmYmY2ZDU0NWJfMi03LTEtMS0xNzc3NQ_11c468e8-1c06-4762-90c0-8d52d183ecab"
      unitRef="usd">18107000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife
      contextRef="ie1ed53b5943b4889b309941737607d78_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM183MC9mcmFnOmIxYjdhNmFmNjEzYzQ3NWM5ZGI4Y2JlNmQzNTE1NDk3L3RhYmxlOmM0ZGIzYWY3Y2RlYTQ3MTQ5Y2ZhYzhiZmJmNmQ1NDViL3RhYmxlcmFuZ2U6YzRkYjNhZjdjZGVhNDcxNDljZmFjOGJmYmY2ZDU0NWJfMi05LTEtMS0xNzc3NQ_f76130c4-d061-4f52-8aa6-9e261933b426">P13Y2M12D</us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="if0eedc514d0a4637960f12892dff3179_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM183MC9mcmFnOmIxYjdhNmFmNjEzYzQ3NWM5ZGI4Y2JlNmQzNTE1NDk3L3RhYmxlOmM0ZGIzYWY3Y2RlYTQ3MTQ5Y2ZhYzhiZmJmNmQ1NDViL3RhYmxlcmFuZ2U6YzRkYjNhZjdjZGVhNDcxNDljZmFjOGJmYmY2ZDU0NWJfMi0xMS0xLTEtMTc3NzU_9b8eb0cd-3f6b-420e-be9a-349b1b09d770"
      unitRef="usd">23300000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="if0eedc514d0a4637960f12892dff3179_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM183MC9mcmFnOmIxYjdhNmFmNjEzYzQ3NWM5ZGI4Y2JlNmQzNTE1NDk3L3RhYmxlOmM0ZGIzYWY3Y2RlYTQ3MTQ5Y2ZhYzhiZmJmNmQ1NDViL3RhYmxlcmFuZ2U6YzRkYjNhZjdjZGVhNDcxNDljZmFjOGJmYmY2ZDU0NWJfMi0xMy0xLTEtMTc3NzU_47899088-cb1a-4f60-b0e6-577163db53e4"
      unitRef="usd">6271000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="if0eedc514d0a4637960f12892dff3179_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM183MC9mcmFnOmIxYjdhNmFmNjEzYzQ3NWM5ZGI4Y2JlNmQzNTE1NDk3L3RhYmxlOmM0ZGIzYWY3Y2RlYTQ3MTQ5Y2ZhYzhiZmJmNmQ1NDViL3RhYmxlcmFuZ2U6YzRkYjNhZjdjZGVhNDcxNDljZmFjOGJmYmY2ZDU0NWJfMi0xNS0xLTEtMTc3NzU_cfa97264-d497-4422-a9f5-529096de20f7"
      unitRef="usd">17029000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife
      contextRef="i202c773f013e42dbaf2ed35f08ba74e4_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM183MC9mcmFnOmIxYjdhNmFmNjEzYzQ3NWM5ZGI4Y2JlNmQzNTE1NDk3L3RhYmxlOmM0ZGIzYWY3Y2RlYTQ3MTQ5Y2ZhYzhiZmJmNmQ1NDViL3RhYmxlcmFuZ2U6YzRkYjNhZjdjZGVhNDcxNDljZmFjOGJmYmY2ZDU0NWJfMy0xLTEtMS0xNzc3NQ_2636f3af-635e-4dd9-a8d8-b4fc11d470ee">P14Y10M24D</us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i71517c3f53a942378a08da469cfdd069_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM183MC9mcmFnOmIxYjdhNmFmNjEzYzQ3NWM5ZGI4Y2JlNmQzNTE1NDk3L3RhYmxlOmM0ZGIzYWY3Y2RlYTQ3MTQ5Y2ZhYzhiZmJmNmQ1NDViL3RhYmxlcmFuZ2U6YzRkYjNhZjdjZGVhNDcxNDljZmFjOGJmYmY2ZDU0NWJfMy0zLTEtMS0xNzc3NQ_9462cc40-c872-4243-8e9a-8dea1ac6d3bd"
      unitRef="usd">311019000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i71517c3f53a942378a08da469cfdd069_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM183MC9mcmFnOmIxYjdhNmFmNjEzYzQ3NWM5ZGI4Y2JlNmQzNTE1NDk3L3RhYmxlOmM0ZGIzYWY3Y2RlYTQ3MTQ5Y2ZhYzhiZmJmNmQ1NDViL3RhYmxlcmFuZ2U6YzRkYjNhZjdjZGVhNDcxNDljZmFjOGJmYmY2ZDU0NWJfMy01LTEtMS0xNzc3NQ_0382f102-a2fa-4b9b-a50b-52c911b2f335"
      unitRef="usd">72697000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i71517c3f53a942378a08da469cfdd069_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM183MC9mcmFnOmIxYjdhNmFmNjEzYzQ3NWM5ZGI4Y2JlNmQzNTE1NDk3L3RhYmxlOmM0ZGIzYWY3Y2RlYTQ3MTQ5Y2ZhYzhiZmJmNmQ1NDViL3RhYmxlcmFuZ2U6YzRkYjNhZjdjZGVhNDcxNDljZmFjOGJmYmY2ZDU0NWJfMy03LTEtMS0xNzc3NQ_33bb2216-34d9-48df-aab9-73ab8011aa2c"
      unitRef="usd">238322000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife
      contextRef="i8af88df592574869bf4e7732fd88234d_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM183MC9mcmFnOmIxYjdhNmFmNjEzYzQ3NWM5ZGI4Y2JlNmQzNTE1NDk3L3RhYmxlOmM0ZGIzYWY3Y2RlYTQ3MTQ5Y2ZhYzhiZmJmNmQ1NDViL3RhYmxlcmFuZ2U6YzRkYjNhZjdjZGVhNDcxNDljZmFjOGJmYmY2ZDU0NWJfMy05LTEtMS0xNzc3NQ_2dbda7e4-ef6b-405a-9986-eab7dea4973b">P16Y2M12D</us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i562af9019b024a169c81d1f41361d631_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM183MC9mcmFnOmIxYjdhNmFmNjEzYzQ3NWM5ZGI4Y2JlNmQzNTE1NDk3L3RhYmxlOmM0ZGIzYWY3Y2RlYTQ3MTQ5Y2ZhYzhiZmJmNmQ1NDViL3RhYmxlcmFuZ2U6YzRkYjNhZjdjZGVhNDcxNDljZmFjOGJmYmY2ZDU0NWJfMy0xMS0xLTEtMTc3NzU_bf048af1-86bf-473b-a99a-87b6249a2b85"
      unitRef="usd">278519000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i562af9019b024a169c81d1f41361d631_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM183MC9mcmFnOmIxYjdhNmFmNjEzYzQ3NWM5ZGI4Y2JlNmQzNTE1NDk3L3RhYmxlOmM0ZGIzYWY3Y2RlYTQ3MTQ5Y2ZhYzhiZmJmNmQ1NDViL3RhYmxlcmFuZ2U6YzRkYjNhZjdjZGVhNDcxNDljZmFjOGJmYmY2ZDU0NWJfMy0xMy0xLTEtMTc3NzU_dde09662-a87e-4f85-b07e-61fd713019b4"
      unitRef="usd">57716000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i562af9019b024a169c81d1f41361d631_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM183MC9mcmFnOmIxYjdhNmFmNjEzYzQ3NWM5ZGI4Y2JlNmQzNTE1NDk3L3RhYmxlOmM0ZGIzYWY3Y2RlYTQ3MTQ5Y2ZhYzhiZmJmNmQ1NDViL3RhYmxlcmFuZ2U6YzRkYjNhZjdjZGVhNDcxNDljZmFjOGJmYmY2ZDU0NWJfMy0xNS0xLTEtMTc3NzU_8dd8beb6-d364-4275-8045-33be27011e35"
      unitRef="usd">220803000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife
      contextRef="i701391050b2e43d082d405d3d16746d2_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM183MC9mcmFnOmIxYjdhNmFmNjEzYzQ3NWM5ZGI4Y2JlNmQzNTE1NDk3L3RhYmxlOmM0ZGIzYWY3Y2RlYTQ3MTQ5Y2ZhYzhiZmJmNmQ1NDViL3RhYmxlcmFuZ2U6YzRkYjNhZjdjZGVhNDcxNDljZmFjOGJmYmY2ZDU0NWJfNC0xLTEtMS0xNzc3NQ_00f7bcbf-845e-40dd-bc92-360e40eb1773">P2Y</us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i9872c8fc2e2849be9d4b8a5ca7abe3dc_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM183MC9mcmFnOmIxYjdhNmFmNjEzYzQ3NWM5ZGI4Y2JlNmQzNTE1NDk3L3RhYmxlOmM0ZGIzYWY3Y2RlYTQ3MTQ5Y2ZhYzhiZmJmNmQ1NDViL3RhYmxlcmFuZ2U6YzRkYjNhZjdjZGVhNDcxNDljZmFjOGJmYmY2ZDU0NWJfNC0zLTEtMS0xNzc3NQ_d70aad25-d4ec-4959-a25c-69a8e0a3c01e"
      unitRef="usd">87922000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i9872c8fc2e2849be9d4b8a5ca7abe3dc_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM183MC9mcmFnOmIxYjdhNmFmNjEzYzQ3NWM5ZGI4Y2JlNmQzNTE1NDk3L3RhYmxlOmM0ZGIzYWY3Y2RlYTQ3MTQ5Y2ZhYzhiZmJmNmQ1NDViL3RhYmxlcmFuZ2U6YzRkYjNhZjdjZGVhNDcxNDljZmFjOGJmYmY2ZDU0NWJfNC01LTEtMS0xNzc3NQ_cceb6844-dd61-4b46-a5e3-d2000a3bbc5b"
      unitRef="usd">73378000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i9872c8fc2e2849be9d4b8a5ca7abe3dc_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM183MC9mcmFnOmIxYjdhNmFmNjEzYzQ3NWM5ZGI4Y2JlNmQzNTE1NDk3L3RhYmxlOmM0ZGIzYWY3Y2RlYTQ3MTQ5Y2ZhYzhiZmJmNmQ1NDViL3RhYmxlcmFuZ2U6YzRkYjNhZjdjZGVhNDcxNDljZmFjOGJmYmY2ZDU0NWJfNC03LTEtMS0xNzc3NQ_3299c27f-cca3-48a0-9e68-959f95c3ea87"
      unitRef="usd">14544000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife
      contextRef="i538bb825405f46a9ad4766eb47fd09f0_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM183MC9mcmFnOmIxYjdhNmFmNjEzYzQ3NWM5ZGI4Y2JlNmQzNTE1NDk3L3RhYmxlOmM0ZGIzYWY3Y2RlYTQ3MTQ5Y2ZhYzhiZmJmNmQ1NDViL3RhYmxlcmFuZ2U6YzRkYjNhZjdjZGVhNDcxNDljZmFjOGJmYmY2ZDU0NWJfNC05LTEtMS0xNzc3NQ_9194bbb7-22ff-4160-9ac7-5e3b5c488be0">P1Y9M18D</us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="if49e52c6692f4f418b64ecce40eae504_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM183MC9mcmFnOmIxYjdhNmFmNjEzYzQ3NWM5ZGI4Y2JlNmQzNTE1NDk3L3RhYmxlOmM0ZGIzYWY3Y2RlYTQ3MTQ5Y2ZhYzhiZmJmNmQ1NDViL3RhYmxlcmFuZ2U6YzRkYjNhZjdjZGVhNDcxNDljZmFjOGJmYmY2ZDU0NWJfNC0xMS0xLTEtMTc3NzU_c519bbfb-c23f-4c1d-9f7b-9e1a6ec34b17"
      unitRef="usd">82922000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="if49e52c6692f4f418b64ecce40eae504_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM183MC9mcmFnOmIxYjdhNmFmNjEzYzQ3NWM5ZGI4Y2JlNmQzNTE1NDk3L3RhYmxlOmM0ZGIzYWY3Y2RlYTQ3MTQ5Y2ZhYzhiZmJmNmQ1NDViL3RhYmxlcmFuZ2U6YzRkYjNhZjdjZGVhNDcxNDljZmFjOGJmYmY2ZDU0NWJfNC0xMy0xLTEtMTc3NzU_881d2173-4b13-4d40-afd1-2cd222ea410a"
      unitRef="usd">63507000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="if49e52c6692f4f418b64ecce40eae504_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM183MC9mcmFnOmIxYjdhNmFmNjEzYzQ3NWM5ZGI4Y2JlNmQzNTE1NDk3L3RhYmxlOmM0ZGIzYWY3Y2RlYTQ3MTQ5Y2ZhYzhiZmJmNmQ1NDViL3RhYmxlcmFuZ2U6YzRkYjNhZjdjZGVhNDcxNDljZmFjOGJmYmY2ZDU0NWJfNC0xNS0xLTEtMTc3NzU_765096f2-6593-41c0-aaf9-70778e16465d"
      unitRef="usd">19415000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife
      contextRef="idbec42c300ba44c8b821ff3fa0e1a438_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM183MC9mcmFnOmIxYjdhNmFmNjEzYzQ3NWM5ZGI4Y2JlNmQzNTE1NDk3L3RhYmxlOmM0ZGIzYWY3Y2RlYTQ3MTQ5Y2ZhYzhiZmJmNmQ1NDViL3RhYmxlcmFuZ2U6YzRkYjNhZjdjZGVhNDcxNDljZmFjOGJmYmY2ZDU0NWJfNS0xLTEtMS0xNzc3NQ_80a46397-e879-4d39-9348-669601b224d5">P1Y3M18D</us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i77a25d5d9d13456bafdeb192f90dc6dd_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM183MC9mcmFnOmIxYjdhNmFmNjEzYzQ3NWM5ZGI4Y2JlNmQzNTE1NDk3L3RhYmxlOmM0ZGIzYWY3Y2RlYTQ3MTQ5Y2ZhYzhiZmJmNmQ1NDViL3RhYmxlcmFuZ2U6YzRkYjNhZjdjZGVhNDcxNDljZmFjOGJmYmY2ZDU0NWJfNS0zLTEtMS0xNzc3NQ_c0d7b370-f296-48f7-a55d-7aa3d5f1aef0"
      unitRef="usd">1218000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i77a25d5d9d13456bafdeb192f90dc6dd_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM183MC9mcmFnOmIxYjdhNmFmNjEzYzQ3NWM5ZGI4Y2JlNmQzNTE1NDk3L3RhYmxlOmM0ZGIzYWY3Y2RlYTQ3MTQ5Y2ZhYzhiZmJmNmQ1NDViL3RhYmxlcmFuZ2U6YzRkYjNhZjdjZGVhNDcxNDljZmFjOGJmYmY2ZDU0NWJfNS01LTEtMS0xNzc3NQ_2c651885-94d1-4e79-8bed-1cf74e340d04"
      unitRef="usd">950000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i77a25d5d9d13456bafdeb192f90dc6dd_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM183MC9mcmFnOmIxYjdhNmFmNjEzYzQ3NWM5ZGI4Y2JlNmQzNTE1NDk3L3RhYmxlOmM0ZGIzYWY3Y2RlYTQ3MTQ5Y2ZhYzhiZmJmNmQ1NDViL3RhYmxlcmFuZ2U6YzRkYjNhZjdjZGVhNDcxNDljZmFjOGJmYmY2ZDU0NWJfNS03LTEtMS0xNzc3NQ_12a21485-9f96-4c49-b37b-f6adfc182d6c"
      unitRef="usd">268000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife
      contextRef="id03edbc8f3a0467fb3003d024d0d20bf_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM183MC9mcmFnOmIxYjdhNmFmNjEzYzQ3NWM5ZGI4Y2JlNmQzNTE1NDk3L3RhYmxlOmM0ZGIzYWY3Y2RlYTQ3MTQ5Y2ZhYzhiZmJmNmQ1NDViL3RhYmxlcmFuZ2U6YzRkYjNhZjdjZGVhNDcxNDljZmFjOGJmYmY2ZDU0NWJfNS05LTEtMS0xNzc3NQ_a804101a-b221-4a47-84f2-837721367f8f">P2Y3M18D</us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i5b2c8aeaa33341d0b0241d264ebd0409_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM183MC9mcmFnOmIxYjdhNmFmNjEzYzQ3NWM5ZGI4Y2JlNmQzNTE1NDk3L3RhYmxlOmM0ZGIzYWY3Y2RlYTQ3MTQ5Y2ZhYzhiZmJmNmQ1NDViL3RhYmxlcmFuZ2U6YzRkYjNhZjdjZGVhNDcxNDljZmFjOGJmYmY2ZDU0NWJfNS0xMS0xLTEtMTc3NzU_3a803c6d-fc9a-48d9-83af-36e6f83c139f"
      unitRef="usd">1118000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i5b2c8aeaa33341d0b0241d264ebd0409_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM183MC9mcmFnOmIxYjdhNmFmNjEzYzQ3NWM5ZGI4Y2JlNmQzNTE1NDk3L3RhYmxlOmM0ZGIzYWY3Y2RlYTQ3MTQ5Y2ZhYzhiZmJmNmQ1NDViL3RhYmxlcmFuZ2U6YzRkYjNhZjdjZGVhNDcxNDljZmFjOGJmYmY2ZDU0NWJfNS0xMy0xLTEtMTc3NzU_cf114ad2-a172-4947-b1bd-abc365e34043"
      unitRef="usd">648000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i5b2c8aeaa33341d0b0241d264ebd0409_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM183MC9mcmFnOmIxYjdhNmFmNjEzYzQ3NWM5ZGI4Y2JlNmQzNTE1NDk3L3RhYmxlOmM0ZGIzYWY3Y2RlYTQ3MTQ5Y2ZhYzhiZmJmNmQ1NDViL3RhYmxlcmFuZ2U6YzRkYjNhZjdjZGVhNDcxNDljZmFjOGJmYmY2ZDU0NWJfNS0xNS0xLTEtMTc3NzU_31f09b62-676c-47f1-9bec-751c11867f82"
      unitRef="usd">470000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife
      contextRef="i5bc515c9cd944501946244b550d6dea8_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM183MC9mcmFnOmIxYjdhNmFmNjEzYzQ3NWM5ZGI4Y2JlNmQzNTE1NDk3L3RhYmxlOmM0ZGIzYWY3Y2RlYTQ3MTQ5Y2ZhYzhiZmJmNmQ1NDViL3RhYmxlcmFuZ2U6YzRkYjNhZjdjZGVhNDcxNDljZmFjOGJmYmY2ZDU0NWJfNi0xLTEtMS0xNzc3NQ_7cbacfa8-b523-4b80-bbcc-ec8afc0cddff">P2Y2M12D</us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i73d07853890d4173bfcafe5a74c9aedf_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM183MC9mcmFnOmIxYjdhNmFmNjEzYzQ3NWM5ZGI4Y2JlNmQzNTE1NDk3L3RhYmxlOmM0ZGIzYWY3Y2RlYTQ3MTQ5Y2ZhYzhiZmJmNmQ1NDViL3RhYmxlcmFuZ2U6YzRkYjNhZjdjZGVhNDcxNDljZmFjOGJmYmY2ZDU0NWJfNi0zLTEtMS0xNzc3NQ_521ab21e-1656-4a7c-bd21-466a847010bd"
      unitRef="usd">16417000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i73d07853890d4173bfcafe5a74c9aedf_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM183MC9mcmFnOmIxYjdhNmFmNjEzYzQ3NWM5ZGI4Y2JlNmQzNTE1NDk3L3RhYmxlOmM0ZGIzYWY3Y2RlYTQ3MTQ5Y2ZhYzhiZmJmNmQ1NDViL3RhYmxlcmFuZ2U6YzRkYjNhZjdjZGVhNDcxNDljZmFjOGJmYmY2ZDU0NWJfNi01LTEtMS0xNzc3NQ_0135a807-9c4a-4aa3-beca-656aa905f404"
      unitRef="usd">7874000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i73d07853890d4173bfcafe5a74c9aedf_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM183MC9mcmFnOmIxYjdhNmFmNjEzYzQ3NWM5ZGI4Y2JlNmQzNTE1NDk3L3RhYmxlOmM0ZGIzYWY3Y2RlYTQ3MTQ5Y2ZhYzhiZmJmNmQ1NDViL3RhYmxlcmFuZ2U6YzRkYjNhZjdjZGVhNDcxNDljZmFjOGJmYmY2ZDU0NWJfNi03LTEtMS0xNzc3NQ_f342b040-31a6-470f-91ef-f6ce519ffc04"
      unitRef="usd">8543000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife
      contextRef="i4865a0a60cf141238d2403348647421d_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM183MC9mcmFnOmIxYjdhNmFmNjEzYzQ3NWM5ZGI4Y2JlNmQzNTE1NDk3L3RhYmxlOmM0ZGIzYWY3Y2RlYTQ3MTQ5Y2ZhYzhiZmJmNmQ1NDViL3RhYmxlcmFuZ2U6YzRkYjNhZjdjZGVhNDcxNDljZmFjOGJmYmY2ZDU0NWJfNi05LTEtMS0xNzc3NQ_53a0927c-6eef-482b-91ab-df0758b04c43">P2Y10M24D</us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i2916f379be034a929416cb11c770e888_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM183MC9mcmFnOmIxYjdhNmFmNjEzYzQ3NWM5ZGI4Y2JlNmQzNTE1NDk3L3RhYmxlOmM0ZGIzYWY3Y2RlYTQ3MTQ5Y2ZhYzhiZmJmNmQ1NDViL3RhYmxlcmFuZ2U6YzRkYjNhZjdjZGVhNDcxNDljZmFjOGJmYmY2ZDU0NWJfNi0xMS0xLTEtMTc3NzU_e3bbf0d0-3f11-478b-985c-e9622546815b"
      unitRef="usd">12175000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i2916f379be034a929416cb11c770e888_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM183MC9mcmFnOmIxYjdhNmFmNjEzYzQ3NWM5ZGI4Y2JlNmQzNTE1NDk3L3RhYmxlOmM0ZGIzYWY3Y2RlYTQ3MTQ5Y2ZhYzhiZmJmNmQ1NDViL3RhYmxlcmFuZ2U6YzRkYjNhZjdjZGVhNDcxNDljZmFjOGJmYmY2ZDU0NWJfNi0xMy0xLTEtMTc3NzU_0da4681d-9570-48cf-b335-d938319eaaad"
      unitRef="usd">4900000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i2916f379be034a929416cb11c770e888_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM183MC9mcmFnOmIxYjdhNmFmNjEzYzQ3NWM5ZGI4Y2JlNmQzNTE1NDk3L3RhYmxlOmM0ZGIzYWY3Y2RlYTQ3MTQ5Y2ZhYzhiZmJmNmQ1NDViL3RhYmxlcmFuZ2U6YzRkYjNhZjdjZGVhNDcxNDljZmFjOGJmYmY2ZDU0NWJfNi0xNS0xLTEtMTc3NzU_495c92d4-230a-4ffc-aeac-4ad52553f945"
      unitRef="usd">7275000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i8daff60be410426d8f7bd49343c1ec0c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM183MC9mcmFnOmIxYjdhNmFmNjEzYzQ3NWM5ZGI4Y2JlNmQzNTE1NDk3L3RhYmxlOmM0ZGIzYWY3Y2RlYTQ3MTQ5Y2ZhYzhiZmJmNmQ1NDViL3RhYmxlcmFuZ2U6YzRkYjNhZjdjZGVhNDcxNDljZmFjOGJmYmY2ZDU0NWJfNy0zLTEtMS0xNzc3NQ_8c97145a-2f6c-48a1-92f1-4639efd8c5ed"
      unitRef="usd">442376000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i8daff60be410426d8f7bd49343c1ec0c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM183MC9mcmFnOmIxYjdhNmFmNjEzYzQ3NWM5ZGI4Y2JlNmQzNTE1NDk3L3RhYmxlOmM0ZGIzYWY3Y2RlYTQ3MTQ5Y2ZhYzhiZmJmNmQ1NDViL3RhYmxlcmFuZ2U6YzRkYjNhZjdjZGVhNDcxNDljZmFjOGJmYmY2ZDU0NWJfNy01LTEtMS0xNzc3NQ_105abf74-b3bb-480a-9e19-db5f1646868c"
      unitRef="usd">162592000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i8daff60be410426d8f7bd49343c1ec0c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM183MC9mcmFnOmIxYjdhNmFmNjEzYzQ3NWM5ZGI4Y2JlNmQzNTE1NDk3L3RhYmxlOmM0ZGIzYWY3Y2RlYTQ3MTQ5Y2ZhYzhiZmJmNmQ1NDViL3RhYmxlcmFuZ2U6YzRkYjNhZjdjZGVhNDcxNDljZmFjOGJmYmY2ZDU0NWJfNy03LTEtMS0xNzc3NQ_23b890fc-9d77-41b9-8586-dc1d876eac8b"
      unitRef="usd">279784000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="ibc0c0c2b8dc04c5698ca0577a54b2e03_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM183MC9mcmFnOmIxYjdhNmFmNjEzYzQ3NWM5ZGI4Y2JlNmQzNTE1NDk3L3RhYmxlOmM0ZGIzYWY3Y2RlYTQ3MTQ5Y2ZhYzhiZmJmNmQ1NDViL3RhYmxlcmFuZ2U6YzRkYjNhZjdjZGVhNDcxNDljZmFjOGJmYmY2ZDU0NWJfNy0xMS0xLTEtMTc3NzU_f2d8f16b-6365-42b3-aa89-642fd8e2f7e6"
      unitRef="usd">398034000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="ibc0c0c2b8dc04c5698ca0577a54b2e03_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM183MC9mcmFnOmIxYjdhNmFmNjEzYzQ3NWM5ZGI4Y2JlNmQzNTE1NDk3L3RhYmxlOmM0ZGIzYWY3Y2RlYTQ3MTQ5Y2ZhYzhiZmJmNmQ1NDViL3RhYmxlcmFuZ2U6YzRkYjNhZjdjZGVhNDcxNDljZmFjOGJmYmY2ZDU0NWJfNy0xMy0xLTEtMTc3NzU_e24c16ab-42f8-4494-bdb0-c215aa0bb0ff"
      unitRef="usd">133042000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="ibc0c0c2b8dc04c5698ca0577a54b2e03_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM183MC9mcmFnOmIxYjdhNmFmNjEzYzQ3NWM5ZGI4Y2JlNmQzNTE1NDk3L3RhYmxlOmM0ZGIzYWY3Y2RlYTQ3MTQ5Y2ZhYzhiZmJmNmQ1NDViL3RhYmxlcmFuZ2U6YzRkYjNhZjdjZGVhNDcxNDljZmFjOGJmYmY2ZDU0NWJfNy0xNS0xLTEtMTc3NzU_b82032d1-1541-41e8-b086-4ef6dab04f97"
      unitRef="usd">264992000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsNoncurrent
      contextRef="ie6213ed773f940469197c948c85ce078_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM183MC9mcmFnOmIxYjdhNmFmNjEzYzQ3NWM5ZGI4Y2JlNmQzNTE1NDk3L3RleHRyZWdpb246YjFiN2E2YWY2MTNjNDc1YzlkYjhjYmU2ZDM1MTU0OTdfNzc1MQ_f2c31656-8f0b-44ed-95b9-dddc85d472aa"
      unitRef="usd">2200000</us-gaap:DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsNoncurrent>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsNoncurrent
      contextRef="i886c543278f24614931e52b2326361a9_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM183MC9mcmFnOmIxYjdhNmFmNjEzYzQ3NWM5ZGI4Y2JlNmQzNTE1NDk3L3RleHRyZWdpb246YjFiN2E2YWY2MTNjNDc1YzlkYjhjYmU2ZDM1MTU0OTdfNzc1OA_4a4f88cd-a300-4d38-bb2e-15742f1b9172"
      unitRef="usd">900000</us-gaap:DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsNoncurrent>
    <us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife
      contextRef="i83a4805b397642c7825f71f6f96da143_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM183MC9mcmFnOmIxYjdhNmFmNjEzYzQ3NWM5ZGI4Y2JlNmQzNTE1NDk3L3RleHRyZWdpb246YjFiN2E2YWY2MTNjNDc1YzlkYjhjYmU2ZDM1MTU0OTdfNzkxNA_3070ca93-72f2-4d62-80f0-fbb9b1ec8dbe">P15Y</us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife>
    <us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife
      contextRef="ib096ee77af354199bc615f81ee527eaa_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM183MC9mcmFnOmIxYjdhNmFmNjEzYzQ3NWM5ZGI4Y2JlNmQzNTE1NDk3L3RleHRyZWdpb246YjFiN2E2YWY2MTNjNDc1YzlkYjhjYmU2ZDM1MTU0OTdfNzkyMQ_eb6d0ce2-3123-4369-95f4-591fbd4e93b1">P10M</us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM183MC9mcmFnOmIxYjdhNmFmNjEzYzQ3NWM5ZGI4Y2JlNmQzNTE1NDk3L3RleHRyZWdpb246YjFiN2E2YWY2MTNjNDc1YzlkYjhjYmU2ZDM1MTU0OTdfODA0MA_4f627e2e-339a-4685-9e79-cd4c5983e125"
      unitRef="usd">29400000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="i12a6d1161de54547bd29f8efccd4c9b0_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM183MC9mcmFnOmIxYjdhNmFmNjEzYzQ3NWM5ZGI4Y2JlNmQzNTE1NDk3L3RleHRyZWdpb246YjFiN2E2YWY2MTNjNDc1YzlkYjhjYmU2ZDM1MTU0OTdfODEyMg_73e3a2ad-94b9-4ad0-ae6f-176770b62d55"
      unitRef="usd">32300000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="i3e21049ffc224cacb8134d73c9bb5b38_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM183MC9mcmFnOmIxYjdhNmFmNjEzYzQ3NWM5ZGI4Y2JlNmQzNTE1NDk3L3RleHRyZWdpb246YjFiN2E2YWY2MTNjNDc1YzlkYjhjYmU2ZDM1MTU0OTdfMTA5OTUxMTYzNzE2OQ_3b3bbb50-d88b-473d-99aa-6d0b114448ae"
      unitRef="usd">37100000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="i1c4a293e5ce54724af5effd8253d4d89_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM183MC9mcmFnOmIxYjdhNmFmNjEzYzQ3NWM5ZGI4Y2JlNmQzNTE1NDk3L3RleHRyZWdpb246YjFiN2E2YWY2MTNjNDc1YzlkYjhjYmU2ZDM1MTU0OTdfMjE5OTAyMzI2ODEyNA_28f8b05a-268d-4fc6-b8dc-015b4dfd891a"
      unitRef="usd">200000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="if7ba948ef00b4ddeabe73338f1155e8b_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM183MC9mcmFnOmIxYjdhNmFmNjEzYzQ3NWM5ZGI4Y2JlNmQzNTE1NDk3L3RleHRyZWdpb246YjFiN2E2YWY2MTNjNDc1YzlkYjhjYmU2ZDM1MTU0OTdfODE1Nw_cdd78c6c-b488-4351-adc5-5bf73d469b9e"
      unitRef="usd">600000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="iae6c9a536db44d69b64c473850d09499_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM183MC9mcmFnOmIxYjdhNmFmNjEzYzQ3NWM5ZGI4Y2JlNmQzNTE1NDk3L3RleHRyZWdpb246YjFiN2E2YWY2MTNjNDc1YzlkYjhjYmU2ZDM1MTU0OTdfMTA5OTUxMTYzNzAwOA_a75a2702-2419-4431-8f45-70b6c4a1ba1b"
      unitRef="usd">600000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock
      contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM183MC9mcmFnOmIxYjdhNmFmNjEzYzQ3NWM5ZGI4Y2JlNmQzNTE1NDk3L3RleHRyZWdpb246YjFiN2E2YWY2MTNjNDc1YzlkYjhjYmU2ZDM1MTU0OTdfODYyMw_8b53952d-abb5-45fa-a816-9ae6b01745f4">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Future estimated amortization of intangible assets (in thousands) as of December&#160;31, 2021, is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:478.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:58.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29,102&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26,798&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,913&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,403&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,153&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;164,415&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total future amortization of intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;279,784&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths
      contextRef="i8daff60be410426d8f7bd49343c1ec0c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM183MC9mcmFnOmIxYjdhNmFmNjEzYzQ3NWM5ZGI4Y2JlNmQzNTE1NDk3L3RhYmxlOjVhZGViNTY2ZGFlNzQ0MjA4NTM2Njc3NWU5ZDE1MzMzL3RhYmxlcmFuZ2U6NWFkZWI1NjZkYWU3NDQyMDg1MzY2Nzc1ZTlkMTUzMzNfMC0xLTEtMS0xNzc3NQ_181bf812-2381-4fe8-b98e-66ce43e597a5"
      unitRef="usd">29102000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
      contextRef="i8daff60be410426d8f7bd49343c1ec0c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM183MC9mcmFnOmIxYjdhNmFmNjEzYzQ3NWM5ZGI4Y2JlNmQzNTE1NDk3L3RhYmxlOjVhZGViNTY2ZGFlNzQ0MjA4NTM2Njc3NWU5ZDE1MzMzL3RhYmxlcmFuZ2U6NWFkZWI1NjZkYWU3NDQyMDg1MzY2Nzc1ZTlkMTUzMzNfMS0xLTEtMS0xNzc3NQ_f00e23bf-4218-4d98-859c-3fe89ad78c2c"
      unitRef="usd">26798000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
      contextRef="i8daff60be410426d8f7bd49343c1ec0c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM183MC9mcmFnOmIxYjdhNmFmNjEzYzQ3NWM5ZGI4Y2JlNmQzNTE1NDk3L3RhYmxlOjVhZGViNTY2ZGFlNzQ0MjA4NTM2Njc3NWU5ZDE1MzMzL3RhYmxlcmFuZ2U6NWFkZWI1NjZkYWU3NDQyMDg1MzY2Nzc1ZTlkMTUzMzNfMi0xLTEtMS0xNzc3NQ_9653138d-56d7-4cb7-97fc-fb530852ae32"
      unitRef="usd">20913000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour
      contextRef="i8daff60be410426d8f7bd49343c1ec0c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM183MC9mcmFnOmIxYjdhNmFmNjEzYzQ3NWM5ZGI4Y2JlNmQzNTE1NDk3L3RhYmxlOjVhZGViNTY2ZGFlNzQ0MjA4NTM2Njc3NWU5ZDE1MzMzL3RhYmxlcmFuZ2U6NWFkZWI1NjZkYWU3NDQyMDg1MzY2Nzc1ZTlkMTUzMzNfMy0xLTEtMS0xNzc3NQ_39fdfa66-b09a-4dc5-922b-0ffae57b58a1"
      unitRef="usd">19403000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive
      contextRef="i8daff60be410426d8f7bd49343c1ec0c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM183MC9mcmFnOmIxYjdhNmFmNjEzYzQ3NWM5ZGI4Y2JlNmQzNTE1NDk3L3RhYmxlOjVhZGViNTY2ZGFlNzQ0MjA4NTM2Njc3NWU5ZDE1MzMzL3RhYmxlcmFuZ2U6NWFkZWI1NjZkYWU3NDQyMDg1MzY2Nzc1ZTlkMTUzMzNfNC0xLTEtMS0xNzc3NQ_cf9193a3-891c-43a7-8efb-485030a4ba83"
      unitRef="usd">19153000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive
      contextRef="i8daff60be410426d8f7bd49343c1ec0c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM183MC9mcmFnOmIxYjdhNmFmNjEzYzQ3NWM5ZGI4Y2JlNmQzNTE1NDk3L3RhYmxlOjVhZGViNTY2ZGFlNzQ0MjA4NTM2Njc3NWU5ZDE1MzMzL3RhYmxlcmFuZ2U6NWFkZWI1NjZkYWU3NDQyMDg1MzY2Nzc1ZTlkMTUzMzNfNS0xLTEtMS0xNzc3NQ_e3395371-2799-48a3-b732-23ba24a8e524"
      unitRef="usd">164415000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i8daff60be410426d8f7bd49343c1ec0c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM183MC9mcmFnOmIxYjdhNmFmNjEzYzQ3NWM5ZGI4Y2JlNmQzNTE1NDk3L3RhYmxlOjVhZGViNTY2ZGFlNzQ0MjA4NTM2Njc3NWU5ZDE1MzMzL3RhYmxlcmFuZ2U6NWFkZWI1NjZkYWU3NDQyMDg1MzY2Nzc1ZTlkMTUzMzNfNi0xLTEtMS0xNzc3NQ_6f04266a-f2e8-4f1e-8e38-10502a130397"
      unitRef="usd">279784000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:DebtDisclosureTextBlock
      contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM183My9mcmFnOjU3M2ZmODBkMmIzNDQ0MTlhMzdlOTRhZjRhNjk0MTBkL3RleHRyZWdpb246NTczZmY4MGQyYjM0NDQxOWEzN2U5NGFmNGE2OTQxMGRfMjExMjM_5613be9e-9566-4711-b469-db5ea6bf73e2">Long-term Debt&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;2024 Notes&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In August 2020, the Company issued $117.1&#160;million aggregate principal amount of its 3.50% Convertible Senior Notes due 2024 (the &#x201c;2024 Notes&#x201d;) in privately negotiated exchange and/or subscription agreements, with certain holders of its outstanding 2021 Notes and certain new investors. The Company issued $84.2 million aggregate principal amount of 2024 Notes in exchange for $84.2 million aggregate principal amount of the 2021 Notes and an aggregate cash payment of $2.5&#160;million, and issued $32.8 million aggregate principal amount of New Notes for cash at par. We incurred $3.0&#160;million of debt issuance costs in connection with the 2024 Notes, which we are amortizing to non-cash interest expense using the straight-line method over the contractual term of the 2024 Notes. The closing of the private placement of the 2024 Notes occurred on August 19, 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Holders of the 2024 Notes are entitled to cash interest payments, which are payable semiannually in arrears on June 1 and December 1 of each year, beginning on December 1, 2020, at a rate equal to 3.50% per annum. The 2024 Notes will mature on December 1, 2024, unless earlier repurchased, redeemed or converted in accordance with their terms prior to such date. Upon maturity the principal amount of the notes may be settled via shares of the Company&#x2019;s Class A common stock. We recorded interest expense of $4.1 million and $1.5 million for the years ended December 31, 2021 and 2020, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The 2024 Notes are convertible into cash, shares of the Company's Class A common stock, or a combination of cash and shares of the Company's Class A common stock, at the Company's election, based on an initial conversion rate of 54.8667 shares of Class A common stock per $1,000 principal amount of the 2024 Notes, which is equivalent to an initial conversion price of approximately $18.23 per share of the Company&#x2019;s Class A common stock. In the aggregate, the 2024 Notes are initially convertible into 6.4&#160;million shares of the Company&#x2019;s Class A common stock (excluding any shares issuable by the Company upon a conversion in connection with a make-whole provision upon a fundamental change or a notice of redemption under the governing indenture). The conversion rate may be adjusted under certain circumstances. Upon conversion, the Company will pay or deliver, as the case may be, cash or shares of the Company&#x2019;s Class A common stock, or a combination of cash and shares of the Company&#x2019;s Class A common stock, at the Company&#x2019;s election.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The option to settle the 2024 Notes in cash or shares of the Company&#x2019;s Class A common stock, or a combination of cash and shares of the Company&#x2019;s Class A common stock, at the Company&#x2019;s election, resulted in a bifurcation of the carrying value of the 2024 Notes into a debt component and an equity component. The debt component was determined to be $78.9&#160;million, before issuance costs, based on the fair value of a nonconvertible debt instrument with the same term. The equity component was determined to be $38.1&#160;million before issuance costs and was recorded within additional paid-in capital. The equity component is the difference between the aggregate principal amount of the debt and the fair value of the debt component. Issuance costs of $1.7&#160;million and $1.3&#160;million are allocated to the debt and equity components in proportion to the allocation of proceeds. Along with the equity component of $38.1&#160;million, $1.7&#160;million of issuance costs will be amortized to interest expense on the consolidated statements of operations and comprehensive income (loss) using the effective interest method over the contractual term of the 2024 Notes. The equity component recorded within additional paid-in capital will not be remeasured as long as it meets the conditions for equity classification. The Company recorded $7.9 million and $2.7 million of interest expense related to the amortization of the debt discount and the issuance costs allocated to the debt component for the years ended December 31, 2021 and 2020, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Holders of the 2024 Notes may require the Company to repurchase all or part of their notes upon the occurrence of a fundamental change at a price equal to 100.0% of the principal amount of the notes being repurchased, plus any accrued and unpaid interest to, but excluding, the fundamental change repurchase date. The Company may not redeem the 2024 Notes prior to March 1, 2023. The Company may redeem for cash all or any portion of the 2024 Notes, at its option, on or after March 1, 2023, if the last reported sale price of the Company&#x2019;s Class A common stock has been at least 130.0% of the conversion price then in effect for at least 20 trading &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;days (whether or not consecutive) during any 30 consecutive trading day period (including the last trading day of such period) ending on, and including, the trading day immediately preceding the date on which the Company provides notice of redemption, at a redemption price equal to 100.0% of the principal amount of the notes to be redeemed, plus accrued and unpaid interest to, but excluding, the redemption date.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Credit Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On December 30, 2019, the Company entered into a credit agreement, by and among the Company, Evolent Health LLC, as the borrower (the &#x201c;Borrower&#x201d;), certain subsidiaries of the Company, as guarantors, the lenders from time to time party thereto, and Ares Capital Corporation, as administrative agent and collateral agent, together with the Company (the &#x201c;Credit Agreement&#x201d;), pursuant to which the lenders agreed to extend credit to the Borrower in the form of (i) an initial secured term loan in the aggregate principal amount of $75.0 million (the &#x201c;Initial Term Loan Facility&#x201d;) and (ii) a delayed draw secured term loan facility in the aggregate principal amount of up to $50.0 million (the &#x201c;DDTL Facility&#x201d; and, together with the Initial Term Loan Facility, the &#x201c;Senior Credit Facilities&#x201d;), subject to the satisfaction of specified conditions. The Borrower borrowed the loan under the Initial Term Loan Facility on December 30, 2019. In connection with the Credit Agreement, on December 30, 2019, the Company entered into a Security Agreement, by and among the Company, the Borrower, the other guarantors and the collateral agent for the benefit of the secured parties, and a Guarantee Agreement, by the Company and each of the other guarantors in favor of the collateral agent for the benefit of the secured parties. The Senior Credit Facilities were guaranteed by the Company and the Company&#x2019;s domestic subsidiaries, subject to certain exceptions. The Senior Credit Facilities were secured by a first priority security interest in all of the capital stock of the borrower and each guarantor (other than the Company) and substantially all of the assets of the borrower and each guarantor, subject to certain exceptions. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The proceeds of the Initial Term Loan were used to finance the transactions contemplated by the Passport APA and pay fees and expenses incurred in connection therewith. The proceeds of the DDTL Facility were permitted to be used, subject to the Company&#x2019;s satisfaction of specified conditions, to finance the repayment or repurchase of the Company&#x2019;s 2.00% Convertible Senior Notes due December 1, 2021 and to fund permitted acquisitions. &#160;The Initial Term Loan and any loans under the DDTL Facility would have matured on the date that is the earliest of (a) December 30, 2024, (b) the date on which all amounts outstanding under the Credit Agreement would have been declared or have automatically become due and payable under the terms of the Credit Agreement and (c) the date that is ninety-one (91) days prior to the maturity date of the 2021 Convertible Notes unless certain liquidity conditions were satisfied (the foregoing, the &#x201c;Maturity Date&#x201d;). The interest rate for each loan under the Senior Credit Facilities was calculated, at the option of the Borrower, at either the Eurodollar rate plus 8.00%, or the base rate plus 7.00%. A commitment fee of 1.00% per annum was payable by the Borrower quarterly in arrears on the unused portion of the DDTL Facility. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Amounts outstanding under the Senior Credit Facilities could have been prepaid at the option of the Borrower subject to applicable premiums, including a make-whole premium payable on certain prepayments made prior to the second anniversary of the closing of the Senior Credit Facilities, and a call protection premium payable on the amount prepaid in certain instances as follows: (i) 4.00% of the principal amount so prepaid after the second anniversary of the closing of the Senior Credit Facilities but prior the third anniversary of the closing of the Senior Credit Facilities; (ii) 3.00% of the principal amount so prepaid after the third anniversary of the closing of the Senior Credit Facilities but prior the fourth anniversary of the closing of the Senior Credit Facilities; and (iii) 2.00% of the principal amount so prepaid after the fourth anniversary of the closing of the Senior Credit Facilities but prior the fifth anniversary of the closing of the Senior Credit Facilities. Amounts outstanding under the Senior Credit Facility were subject to mandatory prepayment upon the occurrence of certain events and conditions, including non-ordinary course asset dispositions, receipt of certain casualty proceeds, issuances of certain debt obligations and a change of control transaction.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Senior Credit Facilities contained customary borrowing conditions, affirmative, negative and reporting covenants, representations and warranties, and events of default, including cross-defaults to other material indebtedness. In addition, the Company was required to comply at certain times with certain financial covenants comprised of a minimum net revenue test and a minimum liquidity test commencing upon closing of the Senior Credit Facilities and a total secured leverage ratio commencing on the last day of the fiscal quarter ending March 31, 2021. If an event of default had occurred, the lenders would be entitled to take enforcement action, including foreclosure on collateral and acceleration of amounts owed under the Senior Credit Facilities. We incurred $4.7 million of debt issuance costs in connection with this Credit Agreement, which was included in long-term debt, net of discount on our consolidated balance sheets and amortized into interest expense over the life of the agreement. The Company recorded $2.2&#160;million in interest expense related to the amortization of the debt discount and the issuance costs for the year ended December 31, 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On August 19, 2020, an amendment to the Company's Credit Agreement became effective. The amendment effected changes to, among other things, permit the Company's use of cash in the exchange transactions in connection with the issuance of the 2024 Notes, permit the issuance of the 2024 Notes and permit certain note repurchases, as well as to implement amendments to certain minimum liquidity thresholds.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On January 8, 2021, the Company repaid all outstanding amounts owed under and terminated the Credit Agreement with Ares Capital Corporation. The total amount paid to Ares Capital Corporation under the Credit Agreement in connection with the prepayment was &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$98.6&#160;million, which included $9.7&#160;million for the make-whole premium as well as $0.2&#160;million in accrued interest. As a result of this transaction, the Company recorded a loss on the repayment of debt of $19.2&#160;million, representing the remaining unamortized debt issuance costs of $9.5&#160;million, the make-whole premium and $35&#160;thousand of legal expenses.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Warrant Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In conjunction with the Company&#x2019;s entry into the Credit Agreement, the Company entered into warrant agreements whereby it agreed to sell to the holders of the warrants an aggregate of 1,513,786 shares of Class A common stock at a per share purchase price equal to $8.05. The holders could exercise the warrants at any time until thirty days after the maturity of the Credit Agreement.  The Company, at its sole discretion, could elect to pay the holders in cash in an amount determined based on the fair market value of the Class A common stock for the shares of Class A common stock issuable upon exercise of the warrants in lieu of delivering the shares.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On January 8, 2021, the Company settled the outstanding warrants associated with the Credit Agreement for $13.7&#160;million.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;2025 Notes&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In October 2018, the Company issued $172.5 million aggregate principal amount of its 1.50% Convertible Senior Notes due 2025 (the &#x201c;2025 Notes&#x201d;) in a private placement to qualified institutional buyers within the meaning of Rule 144A under the Securities Act of 1933, as amended (the &#x201c;Securities Act&#x201d;). The 2025 Notes were issued at par for net proceeds of $166.6 million. We incurred $5.9 million of debt issuance costs in connection with the 2025 Notes. The closing of the private placement of $150.0 million aggregate principal amount of the 2025 Notes occurred on October&#160;22, 2018 and the Company completed the offering and sale of an additional $22.5 million aggregate principal amount of the 2025 Notes on October&#160;24, 2018, pursuant to the initial purchasers&#x2019; exercise in full of their option to purchase additional notes.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Holders of the 2025 Notes are entitled to cash interest payments, which are payable semiannually in arrears on&#160;April 15&#160;and&#160;October 15&#160;of each year, beginning on&#160;April&#160;15, 2019, at a rate equal to&#160;1.50%&#160;per annum. The Company recorded interest expense of $2.6 million for the years ended December 31, 2021, 2020 and 2019, respectively. The 2025 Notes will mature on&#160;October&#160;15, 2025, unless earlier repurchased, redeemed or converted in accordance with their terms prior to such date.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Prior to the close of business on the business day immediately preceding April&#160;15, 2025, the 2025 Notes will be convertible at the option of the holders only upon the satisfaction of certain conditions, as described in the indenture, dated as of October&#160;22, 2018, between the Company and U.S. Bank National Association, as trustee. At any time on or after April&#160;15, 2025, until the close of business on the business day immediately preceding the maturity date, holders may convert, at their option, all or any portion of their notes at the conversion rate.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The 2025 Notes will be convertible at an initial conversion rate of 29.9135 shares of Class A common stock per $1,000 principal amount of notes, which is equivalent to an initial conversion price of approximately $33.43 per share of the Company&#x2019;s Class A common stock. In the aggregate, the 2025 Notes are initially convertible into 5.2 million shares of the Company&#x2019;s Class A common stock (excluding any shares issuable by the Company upon a conversion in connection with a make-whole fundamental change or a notice of redemption as described in the governing indenture). The conversion rate may be adjusted under certain circumstances. Upon conversion, the Company will pay or deliver, as the case may be, cash or shares of the Company&#x2019;s Class A common stock, or a combination of cash and shares of the Company&#x2019;s Class A common stock, at the Company&#x2019;s election.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The option to settle the 2025 Notes in cash or shares of the Company&#x2019;s Class A common stock, or a combination of cash and shares of the Company&#x2019;s Class A common stock, at the Company&#x2019;s election, resulted in a bifurcation of the carrying value of the 2025 Notes into a debt component and an equity component. The debt component was determined to be $100.7 million, before issuance costs, based on the fair value of a nonconvertible debt instrument with the same term. The equity component was determined to be $71.8 million, before issuance costs, and was recorded within additional paid-in capital. The equity component is the difference between the aggregate principal amount of the debt and the debt component. Issuance costs of $3.4 million and $2.5 million are allocated to the debt and equity components in proportion to the allocation of proceeds. Along with the equity component of $71.8 million, $3.4 million of issuance costs will be amortized to interest expense on the consolidated statements of operations and comprehensive income (loss) using the effective interest method over the contractual term of the 2025 Notes. The equity component recorded within additional paid-in capital will not be remeasured as long as it meets the conditions for equity classification. The Company recorded $10.0 million, $9.2 million and $8.5 million for the years ended December 31, 2021, 2020 and 2019 respectively, in interest expense related to the amortization of the debt discount and the issuance costs allocated to the debt component.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Holders of the 2025 Notes may require the Company to repurchase all or part of their notes upon the occurrence of a fundamental change at a price equal to 100.0% of the principal amount of the notes being repurchased, plus any accrued and unpaid interest to, but excluding, the fundamental change repurchase date. The Company may not redeem the 2025 Notes prior to October&#160;20, 2022. The Company may redeem for cash all or any portion of the 2025 Notes, at its option, on or after October&#160;20, 2022, if the last reported sale &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;price of the Company&#x2019;s Class A common stock has been at least 130.0% of the conversion price then in effect for at least 20 trading days (whether or not consecutive) during any 30 consecutive trading day period (including the last trading day of such period) ending on, and including, the trading day immediately preceding the date on which the Company provides notice of redemption, at a redemption price equal to 100.0% of the principal amount of the notes to be redeemed, plus accrued and unpaid interest to, but excluding, the redemption date.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;2021 Notes&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2016, the Company issued $125.0 million aggregate principal amount of its 2.00% Convertible Senior Notes due 2021 (the &#x201c;2021 Notes&#x201d;) in a private placement to qualified institutional buyers within the meaning of Rule 144A under the Securities Act. The 2021 Notes were issued at par for net proceeds of $120.4 million. We incurred $4.6 million of debt issuance costs in connection with the 2021 Notes, which we amortized to non-cash interest expense using the straight-line method over the contractual term of the 2021 Notes, since this method was not materially different from the effective interest method. The closing of the private placement of the 2021 Notes occurred on December&#160;5, 2016.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Holders of the 2021 Notes were entitled to cash interest payments, which were paid semiannually in arrears on June 1 and December 1 of each year, beginning on June&#160;1, 2017, at a rate equal to 2.00% per annum. The 2021 Notes matured on December&#160;1, 2021. We recorded interest expense of $0.5 million, $1.7 million and $2.5 million for the years ended December 31, 2021, 2020 and 2019, respectively. We recorded non-cash interest expense related to the amortization of deferred financing costs of $0.2 million, $0.6 million and $0.9 million for the years ended December 31, 2021, 2020 and 2019, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In August 2020, as part of the issuance of the 2024 Notes, the Company issued $84.2&#160;million aggregate principal amount of the 2024 Notes in exchange for $84.2&#160;million aggregate principal of its 2021 Notes. There was no cash consideration in these exchanges outside of an aggregate cash payment of $2.5&#160;million paid to exchanging noteholders. These exchanges were accounted for as an extinguishment resulting in a net loss on extinguishment of debt of $4.8&#160;million, including an aggregate cash payment of $2.5&#160;million paid to exchanging noteholders. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In August 2020, we also repurchased $14.0&#160;million of the 2021 Notes with $13.9&#160;million of cash and recorded an immaterial gain on extinguishment of debt.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Upon maturity of the 2021 Notes on December 1, 2021, outstanding 2021 Notes with a principal amount of $26.7&#160;million were settled, at the option of the holders, by converting $26.3&#160;million aggregate principal amount of 2021 Notes to common shares and cash repayment of $0.4&#160;million aggregate principal amount of 2021 Notes. Shares issued were valued based on the quoted trading prices on the conversion date for a total fair value of $28.5&#160;million resulting in a loss on debt extinguishment of $2.2&#160;million which was recorded in loss on repayment of debt on our consolidated statements of operations and comprehensive income (loss).&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%"&gt;Convertible Senior Notes Carrying Value&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The 2025 Notes and 2024 Notes are recorded on our accompanying consolidated balance sheets at their net carrying values as of December&#160;31, 2021. However, the 2025 Notes and 2024 Notes are privately traded by qualified institutional buyers (within the meaning of Rule 144A under the Securities Act) and their fair values are Level 2 inputs. The 2025 Notes and 2024 Notes also have embedded conversion options and contingent interest provisions, which have not been recorded as separate financial instruments. The following table summarizes the carrying value of the long-term convertible debt as of December&#160;31, 2021 and 2020 (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:409.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:60.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:60.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#160;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2024 Notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Carrying value&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;89,361&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;81,462&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unamortized debt discount and issuance costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,690&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35,589&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Principal amount&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;117,051&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;117,051&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Remaining amortization period (years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.9&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.9&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;195,445&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;153,220&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2025 Notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Carrying value&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;126,315&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;116,349&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unamortized debt discount and issuance costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46,185&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;56,151&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Principal amount&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;172,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;172,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Remaining amortization period (years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.8&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.8&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;177,251&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;147,488&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021 Notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Carrying value&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26,557&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unamortized debt discount and issuance costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;180&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Principal amount&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26,737&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Remaining amortization period (years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.0&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.9&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26,470&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;padding-left:9pt;text-align:justify;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt"&gt;Fair values for notes are derived from available trading prices closest to the respective balance sheet date.&lt;/span&gt;&lt;/div&gt;</us-gaap:DebtDisclosureTextBlock>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i04c13e91bd034f30a0f4a7c989fc5940_I20200831"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM183My9mcmFnOjU3M2ZmODBkMmIzNDQ0MTlhMzdlOTRhZjRhNjk0MTBkL3RleHRyZWdpb246NTczZmY4MGQyYjM0NDQxOWEzN2U5NGFmNGE2OTQxMGRfNzg_574bcff7-500c-4499-9d34-8c27e733a868"
      unitRef="usd">117100000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i04c13e91bd034f30a0f4a7c989fc5940_I20200831"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM183My9mcmFnOjU3M2ZmODBkMmIzNDQ0MTlhMzdlOTRhZjRhNjk0MTBkL3RleHRyZWdpb246NTczZmY4MGQyYjM0NDQxOWEzN2U5NGFmNGE2OTQxMGRfMTE1_ea74df94-0dfd-4346-bbd3-e26875bd87db"
      unitRef="number">0.0350</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtConversionConvertedInstrumentAmount1
      contextRef="i788309cbaf3c49228dff05dacf3204c0_D20200801-20200831"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM183My9mcmFnOjU3M2ZmODBkMmIzNDQ0MTlhMzdlOTRhZjRhNjk0MTBkL3RleHRyZWdpb246NTczZmY4MGQyYjM0NDQxOWEzN2U5NGFmNGE2OTQxMGRfMzMz_4a58f4eb-8046-49a6-850b-9b240847a1ea"
      unitRef="usd">84200000</us-gaap:DebtConversionConvertedInstrumentAmount1>
    <us-gaap:DebtConversionOriginalDebtAmount1
      contextRef="i79f0de790533434b998387bf6c4ab709_D20200801-20200831"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM183My9mcmFnOjU3M2ZmODBkMmIzNDQ0MTlhMzdlOTRhZjRhNjk0MTBkL3RleHRyZWdpb246NTczZmY4MGQyYjM0NDQxOWEzN2U5NGFmNGE2OTQxMGRfNDAx_c364fe2d-7281-41db-b945-3adb48b8ed9d"
      unitRef="usd">84200000</us-gaap:DebtConversionOriginalDebtAmount1>
    <us-gaap:PaymentsOfDebtIssuanceCosts
      contextRef="i8584b8487d5e4d7ca2a029dd1993309b_D20200801-20200831"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM183My9mcmFnOjU3M2ZmODBkMmIzNDQ0MTlhMzdlOTRhZjRhNjk0MTBkL3RleHRyZWdpb246NTczZmY4MGQyYjM0NDQxOWEzN2U5NGFmNGE2OTQxMGRfNDkw_8384681f-e453-4c80-9523-8d742f175c06"
      unitRef="usd">2500000</us-gaap:PaymentsOfDebtIssuanceCosts>
    <us-gaap:DebtConversionConvertedInstrumentAmount1
      contextRef="i9b76113417844ee8a46162426a4ed221_D20200801-20200831"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM183My9mcmFnOjU3M2ZmODBkMmIzNDQ0MTlhMzdlOTRhZjRhNjk0MTBkL3RleHRyZWdpb246NTczZmY4MGQyYjM0NDQxOWEzN2U5NGFmNGE2OTQxMGRfNTA1_be91ef5c-1807-488d-b099-5c6dcd0c0cba"
      unitRef="usd">32800000</us-gaap:DebtConversionConvertedInstrumentAmount1>
    <us-gaap:DeferredFinanceCostsNet
      contextRef="i04c13e91bd034f30a0f4a7c989fc5940_I20200831"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM183My9mcmFnOjU3M2ZmODBkMmIzNDQ0MTlhMzdlOTRhZjRhNjk0MTBkL3RleHRyZWdpb246NTczZmY4MGQyYjM0NDQxOWEzN2U5NGFmNGE2OTQxMGRfNTg1_46775315-edfb-4dc4-a155-a22e886c78e7"
      unitRef="usd">3000000</us-gaap:DeferredFinanceCostsNet>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i04c13e91bd034f30a0f4a7c989fc5940_I20200831"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM183My9mcmFnOjU3M2ZmODBkMmIzNDQ0MTlhMzdlOTRhZjRhNjk0MTBkL3RleHRyZWdpb246NTczZmY4MGQyYjM0NDQxOWEzN2U5NGFmNGE2OTQxMGRfMTA1Nw_141f9ca7-b3c8-4255-99e4-55cbf0abf8a6"
      unitRef="number">0.0350</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:InterestExpenseDebt
      contextRef="ifef2fd52529f408dbb3bcb2d3f4ae616_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM183My9mcmFnOjU3M2ZmODBkMmIzNDQ0MTlhMzdlOTRhZjRhNjk0MTBkL3RleHRyZWdpb246NTczZmY4MGQyYjM0NDQxOWEzN2U5NGFmNGE2OTQxMGRfMTM3Mg_543bbfd6-c76e-48d5-974e-ed1787a36922"
      unitRef="usd">4100000</us-gaap:InterestExpenseDebt>
    <us-gaap:InterestExpenseDebt
      contextRef="i2f7a8968a0e74fcfa7af898dd2afb7a6_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM183My9mcmFnOjU3M2ZmODBkMmIzNDQ0MTlhMzdlOTRhZjRhNjk0MTBkL3RleHRyZWdpb246NTczZmY4MGQyYjM0NDQxOWEzN2U5NGFmNGE2OTQxMGRfMTA5OTUxMTY0OTAwMQ_e3744a74-8f99-49dd-80fa-621092978621"
      unitRef="usd">1500000</us-gaap:InterestExpenseDebt>
    <us-gaap:DebtInstrumentConvertibleConversionPrice1
      contextRef="i04c13e91bd034f30a0f4a7c989fc5940_I20200831"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM183My9mcmFnOjU3M2ZmODBkMmIzNDQ0MTlhMzdlOTRhZjRhNjk0MTBkL3RleHRyZWdpb246NTczZmY4MGQyYjM0NDQxOWEzN2U5NGFmNGE2OTQxMGRfMTc2Mw_7e0c908c-5913-41e3-bb21-3f0418bbc1fa"
      unitRef="usdPerShare">18.23</us-gaap:DebtInstrumentConvertibleConversionPrice1>
    <us-gaap:DebtInstrumentConvertibleNumberOfEquityInstruments
      contextRef="i788309cbaf3c49228dff05dacf3204c0_D20200801-20200831"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM183My9mcmFnOjU3M2ZmODBkMmIzNDQ0MTlhMzdlOTRhZjRhNjk0MTBkL3RleHRyZWdpb246NTczZmY4MGQyYjM0NDQxOWEzN2U5NGFmNGE2OTQxMGRfMTg3OQ_06ab1b0d-5746-4296-bc42-6bcdccda02ff"
      unitRef="shares">6400000</us-gaap:DebtInstrumentConvertibleNumberOfEquityInstruments>
    <us-gaap:LongTermDebt
      contextRef="i04c13e91bd034f30a0f4a7c989fc5940_I20200831"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM183My9mcmFnOjU3M2ZmODBkMmIzNDQ0MTlhMzdlOTRhZjRhNjk0MTBkL3RleHRyZWdpb246NTczZmY4MGQyYjM0NDQxOWEzN2U5NGFmNGE2OTQxMGRfMjc1Nw_47429047-fe29-4c8e-a8ee-e49e11af9658"
      unitRef="usd">78900000</us-gaap:LongTermDebt>
    <us-gaap:ProceedsFromIssuanceOfDebt
      contextRef="i2d6ffa68994846c2afc0f59e2f092900_D20200801-20200831"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM183My9mcmFnOjU3M2ZmODBkMmIzNDQ0MTlhMzdlOTRhZjRhNjk0MTBkL3RleHRyZWdpb246NTczZmY4MGQyYjM0NDQxOWEzN2U5NGFmNGE2OTQxMGRfMjkwNg_0987102c-c5b2-47f0-ad17-64ef397edef1"
      unitRef="usd">38100000</us-gaap:ProceedsFromIssuanceOfDebt>
    <evh:DebtIssuanceCostsNetDebtComponent
      contextRef="i04c13e91bd034f30a0f4a7c989fc5940_I20200831"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM183My9mcmFnOjU3M2ZmODBkMmIzNDQ0MTlhMzdlOTRhZjRhNjk0MTBkL3RleHRyZWdpb246NTczZmY4MGQyYjM0NDQxOWEzN2U5NGFmNGE2OTQxMGRfMzEzMw_d633f0b4-100d-4a24-8448-e3be0e8b3661"
      unitRef="usd">1700000</evh:DebtIssuanceCostsNetDebtComponent>
    <us-gaap:DeferredFinanceCostsNet
      contextRef="i440e2756c3e94ec7abffeb1fc8c10ab1_I20200831"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM183My9mcmFnOjU3M2ZmODBkMmIzNDQ0MTlhMzdlOTRhZjRhNjk0MTBkL3RleHRyZWdpb246NTczZmY4MGQyYjM0NDQxOWEzN2U5NGFmNGE2OTQxMGRfMzE0MA_539bc1c6-1bb9-46c6-a809-aebadf54830d"
      unitRef="usd">1300000</us-gaap:DeferredFinanceCostsNet>
    <us-gaap:ProceedsFromIssuanceOfDebt
      contextRef="i2d6ffa68994846c2afc0f59e2f092900_D20200801-20200831"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM183My9mcmFnOjU3M2ZmODBkMmIzNDQ0MTlhMzdlOTRhZjRhNjk0MTBkL3RleHRyZWdpb246NTczZmY4MGQyYjM0NDQxOWEzN2U5NGFmNGE2OTQxMGRfMzI3MQ_7d892bad-7156-4226-bdb2-5e5772771f60"
      unitRef="usd">38100000</us-gaap:ProceedsFromIssuanceOfDebt>
    <evh:DebtIssuanceCostsNetDebtComponent
      contextRef="i04c13e91bd034f30a0f4a7c989fc5940_I20200831"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM183My9mcmFnOjU3M2ZmODBkMmIzNDQ0MTlhMzdlOTRhZjRhNjk0MTBkL3RleHRyZWdpb246NTczZmY4MGQyYjM0NDQxOWEzN2U5NGFmNGE2OTQxMGRfMzI3NQ_f823aa0f-d7c9-4bd6-aef1-64c21a65a779"
      unitRef="usd">1700000</evh:DebtIssuanceCostsNetDebtComponent>
    <evh:AmortizationOfDebtDiscountAndDebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction
      contextRef="ifef2fd52529f408dbb3bcb2d3f4ae616_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM183My9mcmFnOjU3M2ZmODBkMmIzNDQ0MTlhMzdlOTRhZjRhNjk0MTBkL3RleHRyZWdpb246NTczZmY4MGQyYjM0NDQxOWEzN2U5NGFmNGE2OTQxMGRfMzY2OQ_c9ab91b6-8fb3-4e8c-8cc1-8102429a869e"
      unitRef="usd">7900000</evh:AmortizationOfDebtDiscountAndDebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction>
    <evh:AmortizationOfDebtDiscountAndDebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction
      contextRef="i2f7a8968a0e74fcfa7af898dd2afb7a6_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM183My9mcmFnOjU3M2ZmODBkMmIzNDQ0MTlhMzdlOTRhZjRhNjk0MTBkL3RleHRyZWdpb246NTczZmY4MGQyYjM0NDQxOWEzN2U5NGFmNGE2OTQxMGRfMTA5OTUxMTY0OTAxOQ_adc8ee10-108d-4643-97c8-cc13db6596ed"
      unitRef="usd">2700000</evh:AmortizationOfDebtDiscountAndDebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction>
    <evh:DebtInstrumentRepurchasePriceDueToFundamentalChangeAsPercentageOfPrincipalAmount
      contextRef="i788309cbaf3c49228dff05dacf3204c0_D20200801-20200831"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM183My9mcmFnOjU3M2ZmODBkMmIzNDQ0MTlhMzdlOTRhZjRhNjk0MTBkL3RleHRyZWdpb246NTczZmY4MGQyYjM0NDQxOWEzN2U5NGFmNGE2OTQxMGRfMzk1Ng_b67246ee-c079-481a-9b53-3f1020376d40"
      unitRef="number">1.000</evh:DebtInstrumentRepurchasePriceDueToFundamentalChangeAsPercentageOfPrincipalAmount>
    <evh:DebtInstrumentRepurchaseCovenantSalePriceAsAPercentageOfConversionPrice
      contextRef="i788309cbaf3c49228dff05dacf3204c0_D20200801-20200831"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM183My9mcmFnOjU3M2ZmODBkMmIzNDQ0MTlhMzdlOTRhZjRhNjk0MTBkL3RleHRyZWdpb246NTczZmY4MGQyYjM0NDQxOWEzN2U5NGFmNGE2OTQxMGRfNDM3Nw_9ddc6c48-14af-48ae-86b8-8d0f11a3a047"
      unitRef="number">1.300</evh:DebtInstrumentRepurchaseCovenantSalePriceAsAPercentageOfConversionPrice>
    <evh:DebtInstrumentRepurchaseCovenantTradingDaysMinimum
      contextRef="i788309cbaf3c49228dff05dacf3204c0_D20200801-20200831"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM183My9mcmFnOjU3M2ZmODBkMmIzNDQ0MTlhMzdlOTRhZjRhNjk0MTBkL3RleHRyZWdpb246NTczZmY4MGQyYjM0NDQxOWEzN2U5NGFmNGE2OTQxMGRfNDQzMg_73f5af25-2787-43bb-8a93-eb065a6f46b3">P20D</evh:DebtInstrumentRepurchaseCovenantTradingDaysMinimum>
    <evh:DebtInstrumentRepurchaseCovenantConsecutiveTradingDaysMinimum
      contextRef="i788309cbaf3c49228dff05dacf3204c0_D20200801-20200831"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM183My9mcmFnOjU3M2ZmODBkMmIzNDQ0MTlhMzdlOTRhZjRhNjk0MTBkL3RleHRyZWdpb246NTczZmY4MGQyYjM0NDQxOWEzN2U5NGFmNGE2OTQxMGRfNDQ4OA_9a6edacf-c498-4a92-adb4-75b3571253a0">P30D</evh:DebtInstrumentRepurchaseCovenantConsecutiveTradingDaysMinimum>
    <evh:DebtInstrumentRepurchasePriceDueToChangeInSalePriceAsPercentageOfConversionPrice
      contextRef="i788309cbaf3c49228dff05dacf3204c0_D20200801-20200831"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM183My9mcmFnOjU3M2ZmODBkMmIzNDQ0MTlhMzdlOTRhZjRhNjk0MTBkL3RleHRyZWdpb246NTczZmY4MGQyYjM0NDQxOWEzN2U5NGFmNGE2OTQxMGRfNDcyNg_bf569a9c-4465-4821-accd-ecb5cfa5340a"
      unitRef="number">1.000</evh:DebtInstrumentRepurchasePriceDueToChangeInSalePriceAsPercentageOfConversionPrice>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="ic9f911355bb8445c908c1c5b6b982236_I20191230"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM183My9mcmFnOjU3M2ZmODBkMmIzNDQ0MTlhMzdlOTRhZjRhNjk0MTBkL3RleHRyZWdpb246NTczZmY4MGQyYjM0NDQxOWEzN2U5NGFmNGE2OTQxMGRfNTQwMQ_f9cae012-89bf-4612-b6b9-bc539ae18ad2"
      unitRef="usd">75000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="i792aeba7f36b437d85bdf7da6230451c_I20191230"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM183My9mcmFnOjU3M2ZmODBkMmIzNDQ0MTlhMzdlOTRhZjRhNjk0MTBkL3RleHRyZWdpb246NTczZmY4MGQyYjM0NDQxOWEzN2U5NGFmNGE2OTQxMGRfNTUzMw_341b191c-90c7-4c37-bd94-5006989ec3ad"
      unitRef="usd">50000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="ife61530204fd4e7bbf85f09284f83168_I20191230"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM183My9mcmFnOjU3M2ZmODBkMmIzNDQ0MTlhMzdlOTRhZjRhNjk0MTBkL3RleHRyZWdpb246NTczZmY4MGQyYjM0NDQxOWEzN2U5NGFmNGE2OTQxMGRfNjkyMg_8f01849b-4a2a-4ac7-8543-a34f47a8a7a8"
      unitRef="number">0.0200</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentTerm
      contextRef="i96e7c8227b2041f28199b45cd6df39d8_D20191230-20191230"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM183My9mcmFnOjU3M2ZmODBkMmIzNDQ0MTlhMzdlOTRhZjRhNjk0MTBkL3RleHRyZWdpb246NTczZmY4MGQyYjM0NDQxOWEzN2U5NGFmNGE2OTQxMGRfNzM2Ng_bc1b7156-b5e0-4c65-9031-a280e7390b6d">P91D</us-gaap:DebtInstrumentTerm>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="ieb668099634e44209035f0f361a970a7_D20191230-20191230"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM183My9mcmFnOjU3M2ZmODBkMmIzNDQ0MTlhMzdlOTRhZjRhNjk0MTBkL3RleHRyZWdpb246NTczZmY4MGQyYjM0NDQxOWEzN2U5NGFmNGE2OTQxMGRfNzY3MA_69ae113d-b741-46a1-a4ab-6ea2d2e14c9e"
      unitRef="number">0.0800</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="icc5f3f563c8f4128a7d55ea114d571c7_D20191230-20191230"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM183My9mcmFnOjU3M2ZmODBkMmIzNDQ0MTlhMzdlOTRhZjRhNjk0MTBkL3RleHRyZWdpb246NTczZmY4MGQyYjM0NDQxOWEzN2U5NGFmNGE2OTQxMGRfNzY5Ng_63c4ee56-f970-4fea-97d8-b2970e27e1cf"
      unitRef="number">0.0700</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:LineOfCreditFacilityCommitmentFeePercentage
      contextRef="i17e802ca9a354f61a67b176d11db40d2_D20191230-20191230"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM183My9mcmFnOjU3M2ZmODBkMmIzNDQ0MTlhMzdlOTRhZjRhNjk0MTBkL3RleHRyZWdpb246NTczZmY4MGQyYjM0NDQxOWEzN2U5NGFmNGE2OTQxMGRfNzcyMA_2b82b18c-8e4e-4da8-8dc7-52edc7cb78dd"
      unitRef="number">0.0100</us-gaap:LineOfCreditFacilityCommitmentFeePercentage>
    <evh:DebtInstrumentRedemptionCallProtectionPremiumPercentage
      contextRef="ib97b2b6f4e114116bcd48ecd930fff77_D20191230-20191230"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM183My9mcmFnOjU3M2ZmODBkMmIzNDQ0MTlhMzdlOTRhZjRhNjk0MTBkL3RleHRyZWdpb246NTczZmY4MGQyYjM0NDQxOWEzN2U5NGFmNGE2OTQxMGRfODIxMw_0aa4cf6b-f1d9-41b4-b0e6-5012f918a5aa"
      unitRef="number">0.0400</evh:DebtInstrumentRedemptionCallProtectionPremiumPercentage>
    <evh:DebtInstrumentRedemptionCallProtectionPremiumPercentage
      contextRef="ida54e6975d324252aa18539914addfb0_D20191230-20191230"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM183My9mcmFnOjU3M2ZmODBkMmIzNDQ0MTlhMzdlOTRhZjRhNjk0MTBkL3RleHRyZWdpb246NTczZmY4MGQyYjM0NDQxOWEzN2U5NGFmNGE2OTQxMGRfODQxMg_28a93fb2-55f9-4ac0-8d21-abb308626628"
      unitRef="number">0.0300</evh:DebtInstrumentRedemptionCallProtectionPremiumPercentage>
    <evh:DebtInstrumentRedemptionCallProtectionPremiumPercentage
      contextRef="ibfa29a18103548678c4142edda54a480_D20191230-20191230"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM183My9mcmFnOjU3M2ZmODBkMmIzNDQ0MTlhMzdlOTRhZjRhNjk0MTBkL3RleHRyZWdpb246NTczZmY4MGQyYjM0NDQxOWEzN2U5NGFmNGE2OTQxMGRfODYxNg_3889ae61-be47-4c3c-a09f-f84331f617be"
      unitRef="number">0.0200</evh:DebtInstrumentRedemptionCallProtectionPremiumPercentage>
    <us-gaap:DeferredFinanceCostsNet
      contextRef="i5e8884745c8748e9ac6420974639bd12_I20191230"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM183My9mcmFnOjU3M2ZmODBkMmIzNDQ0MTlhMzdlOTRhZjRhNjk0MTBkL3RleHRyZWdpb246NTczZmY4MGQyYjM0NDQxOWEzN2U5NGFmNGE2OTQxMGRfOTg5MA_9e20bd6f-8077-46ed-bc5a-0df87da75071"
      unitRef="usd">4700000</us-gaap:DeferredFinanceCostsNet>
    <evh:AmortizationOfDebtDiscountAndDebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction
      contextRef="iab036707b4a24de2813c8c6ec050b319_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM183My9mcmFnOjU3M2ZmODBkMmIzNDQ0MTlhMzdlOTRhZjRhNjk0MTBkL3RleHRyZWdpb246NTczZmY4MGQyYjM0NDQxOWEzN2U5NGFmNGE2OTQxMGRfMTA5OTUxMTY0OTE1OQ_48622004-bf85-4d55-8615-096adb9ab2c7"
      unitRef="usd">2200000</evh:AmortizationOfDebtDiscountAndDebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction>
    <us-gaap:RepaymentsOfLongTermLinesOfCredit
      contextRef="iadba955835944b7293cfc1935e0382e4_D20210108-20210108"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM183My9mcmFnOjU3M2ZmODBkMmIzNDQ0MTlhMzdlOTRhZjRhNjk0MTBkL3RleHRyZWdpb246NTczZmY4MGQyYjM0NDQxOWEzN2U5NGFmNGE2OTQxMGRfMTA5MTg_a5e8c6b4-d59d-4eb8-9ac1-03e0268f9993"
      unitRef="usd">98600000</us-gaap:RepaymentsOfLongTermLinesOfCredit>
    <evh:PaymentsOfMakeWholePremium
      contextRef="iadba955835944b7293cfc1935e0382e4_D20210108-20210108"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM183My9mcmFnOjU3M2ZmODBkMmIzNDQ0MTlhMzdlOTRhZjRhNjk0MTBkL3RleHRyZWdpb246NTczZmY4MGQyYjM0NDQxOWEzN2U5NGFmNGE2OTQxMGRfMTA5Mzc_f573d64f-c230-490e-87c3-333a8ed0b533"
      unitRef="usd">9700000</evh:PaymentsOfMakeWholePremium>
    <us-gaap:InterestPaidNet
      contextRef="iadba955835944b7293cfc1935e0382e4_D20210108-20210108"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM183My9mcmFnOjU3M2ZmODBkMmIzNDQ0MTlhMzdlOTRhZjRhNjk0MTBkL3RleHRyZWdpb246NTczZmY4MGQyYjM0NDQxOWEzN2U5NGFmNGE2OTQxMGRfMTA5Nzg_a484879c-ac9a-4db9-bdb5-e638a92a6527"
      unitRef="usd">200000</us-gaap:InterestPaidNet>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="i037876d85b5c4bea9f8460cdbf527197_D20210108-20210108"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM183My9mcmFnOjU3M2ZmODBkMmIzNDQ0MTlhMzdlOTRhZjRhNjk0MTBkL3RleHRyZWdpb246NTczZmY4MGQyYjM0NDQxOWEzN2U5NGFmNGE2OTQxMGRfMTEwOTE_f4c0bdb7-39c9-4565-bcf1-448e6e86d98e"
      unitRef="usd">19200000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:WriteOffOfDeferredDebtIssuanceCost
      contextRef="i037876d85b5c4bea9f8460cdbf527197_D20210108-20210108"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM183My9mcmFnOjU3M2ZmODBkMmIzNDQ0MTlhMzdlOTRhZjRhNjk0MTBkL3RleHRyZWdpb246NTczZmY4MGQyYjM0NDQxOWEzN2U5NGFmNGE2OTQxMGRfMTExNTc_7620d4dd-3723-443f-8ae4-e6075b1a2b6e"
      unitRef="usd">9500000</us-gaap:WriteOffOfDeferredDebtIssuanceCost>
    <us-gaap:LegalFees
      contextRef="i037876d85b5c4bea9f8460cdbf527197_D20210108-20210108"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM183My9mcmFnOjU3M2ZmODBkMmIzNDQ0MTlhMzdlOTRhZjRhNjk0MTBkL3RleHRyZWdpb246NTczZmY4MGQyYjM0NDQxOWEzN2U5NGFmNGE2OTQxMGRfMTExODg_20332177-0523-4350-a315-7fd693b4e53d"
      unitRef="usd">35000</us-gaap:LegalFees>
    <us-gaap:ClassOfWarrantOrRightUnissued
      contextRef="i88843d45ac464699a3408ba52bbc2f63_I20191230"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM183My9mcmFnOjU3M2ZmODBkMmIzNDQ0MTlhMzdlOTRhZjRhNjk0MTBkL3RleHRyZWdpb246NTczZmY4MGQyYjM0NDQxOWEzN2U5NGFmNGE2OTQxMGRfMTE0MTQ_0db005ff-da98-46b4-96b3-9e7701cca383"
      unitRef="shares">1513786</us-gaap:ClassOfWarrantOrRightUnissued>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="i88843d45ac464699a3408ba52bbc2f63_I20191230"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM183My9mcmFnOjU3M2ZmODBkMmIzNDQ0MTlhMzdlOTRhZjRhNjk0MTBkL3RleHRyZWdpb246NTczZmY4MGQyYjM0NDQxOWEzN2U5NGFmNGE2OTQxMGRfMTE0ODc_6732cb99-9577-45d5-91de-292d02842f8a"
      unitRef="usdPerShare">8.05</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <evh:ClassOfWarrantOrRightPeriodDuringWhichWarrantsOrRightsExercisableAfterMaturityOfCreditAgreement
      contextRef="id418eef5065f4bf698e75757a9120794_D20191230-20191230"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM183My9mcmFnOjU3M2ZmODBkMmIzNDQ0MTlhMzdlOTRhZjRhNjk0MTBkL3RleHRyZWdpb246NTczZmY4MGQyYjM0NDQxOWEzN2U5NGFmNGE2OTQxMGRfMTE1NDk_72379a85-32c5-4ce8-8e6f-17cdd9acbf04">P30D</evh:ClassOfWarrantOrRightPeriodDuringWhichWarrantsOrRightsExercisableAfterMaturityOfCreditAgreement>
    <us-gaap:PaymentsForRepurchaseOfWarrants
      contextRef="i0b6779acaae746b9a02d20842b794089_D20210108-20210108"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM183My9mcmFnOjU3M2ZmODBkMmIzNDQ0MTlhMzdlOTRhZjRhNjk0MTBkL3RleHRyZWdpb246NTczZmY4MGQyYjM0NDQxOWEzN2U5NGFmNGE2OTQxMGRfMTE5NzU_f3572197-cbad-4bda-b35a-bcc2ca2987bf"
      unitRef="usd">13700000</us-gaap:PaymentsForRepurchaseOfWarrants>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i00584134c5844a27a4303a31c0b5f1f3_I20181031"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM183My9mcmFnOjU3M2ZmODBkMmIzNDQ0MTlhMzdlOTRhZjRhNjk0MTBkL3RleHRyZWdpb246NTczZmY4MGQyYjM0NDQxOWEzN2U5NGFmNGE2OTQxMGRfMTIwMjg_49193742-28e3-4b94-aa3d-bd89f9e3d509"
      unitRef="usd">172500000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i00584134c5844a27a4303a31c0b5f1f3_I20181031"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM183My9mcmFnOjU3M2ZmODBkMmIzNDQ0MTlhMzdlOTRhZjRhNjk0MTBkL3RleHRyZWdpb246NTczZmY4MGQyYjM0NDQxOWEzN2U5NGFmNGE2OTQxMGRfMTIwNjU_4f35962a-581b-4a99-ae80-da002eda0fea"
      unitRef="number">0.0150</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:ProceedsFromIssuanceOfDebt
      contextRef="i339c055665e9485da5895fb20444a7a8_D20181001-20181031"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM183My9mcmFnOjU3M2ZmODBkMmIzNDQ0MTlhMzdlOTRhZjRhNjk0MTBkL3RleHRyZWdpb246NTczZmY4MGQyYjM0NDQxOWEzN2U5NGFmNGE2OTQxMGRfMTIzMzM_f303e7aa-6dab-4a93-ad9e-83ecfabd7d73"
      unitRef="usd">166600000</us-gaap:ProceedsFromIssuanceOfDebt>
    <us-gaap:DeferredFinanceCostsNet
      contextRef="i39addcd35f11436480a83296fb4dc83a_I20181031"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM183My9mcmFnOjU3M2ZmODBkMmIzNDQ0MTlhMzdlOTRhZjRhNjk0MTBkL3RleHRyZWdpb246NTczZmY4MGQyYjM0NDQxOWEzN2U5NGFmNGE2OTQxMGRfMTIzNDk_09feb7f9-fc47-4e9d-a2cf-7437e84879a3"
      unitRef="usd">5900000</us-gaap:DeferredFinanceCostsNet>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="ic55a278f0f0c48b3bdd614bbb0a7eded_I20181022"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM183My9mcmFnOjU3M2ZmODBkMmIzNDQ0MTlhMzdlOTRhZjRhNjk0MTBkL3RleHRyZWdpb246NTczZmY4MGQyYjM0NDQxOWEzN2U5NGFmNGE2OTQxMGRfMTI0NTA_4223a9de-73e3-4a81-b76b-a19bfc51e2a7"
      unitRef="usd">150000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="ic290bfcf094543248295da9fb01e4c88_I20181024"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM183My9mcmFnOjU3M2ZmODBkMmIzNDQ0MTlhMzdlOTRhZjRhNjk0MTBkL3RleHRyZWdpb246NTczZmY4MGQyYjM0NDQxOWEzN2U5NGFmNGE2OTQxMGRfMTI1Nzg_865f9146-5430-46c8-ba27-4a1ab700ad4d"
      unitRef="usd">22500000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i00584134c5844a27a4303a31c0b5f1f3_I20181031"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM183My9mcmFnOjU3M2ZmODBkMmIzNDQ0MTlhMzdlOTRhZjRhNjk0MTBkL3RleHRyZWdpb246NTczZmY4MGQyYjM0NDQxOWEzN2U5NGFmNGE2OTQxMGRfMTI5MTg_4f35962a-581b-4a99-ae80-da002eda0fea"
      unitRef="number">0.0150</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:InterestExpenseDebt
      contextRef="i48ca8bc8e051466a9a37e1e1da6febc3_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM183My9mcmFnOjU3M2ZmODBkMmIzNDQ0MTlhMzdlOTRhZjRhNjk0MTBkL3RleHRyZWdpb246NTczZmY4MGQyYjM0NDQxOWEzN2U5NGFmNGE2OTQxMGRfMTI5ODA_589b6617-c10a-4ddf-b78a-9c7f1b8c3f3d"
      unitRef="usd">2600000</us-gaap:InterestExpenseDebt>
    <us-gaap:InterestExpenseDebt
      contextRef="idd22b7a2c5194e22908f4f8bfed93408_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM183My9mcmFnOjU3M2ZmODBkMmIzNDQ0MTlhMzdlOTRhZjRhNjk0MTBkL3RleHRyZWdpb246NTczZmY4MGQyYjM0NDQxOWEzN2U5NGFmNGE2OTQxMGRfMTI5ODA_69046aa2-4bfe-4194-9bcd-674b2c25f800"
      unitRef="usd">2600000</us-gaap:InterestExpenseDebt>
    <us-gaap:InterestExpenseDebt
      contextRef="i36270cc40db54c1cbe5d5fe12dba090b_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM183My9mcmFnOjU3M2ZmODBkMmIzNDQ0MTlhMzdlOTRhZjRhNjk0MTBkL3RleHRyZWdpb246NTczZmY4MGQyYjM0NDQxOWEzN2U5NGFmNGE2OTQxMGRfMTI5ODA_d9186e96-6269-48ed-a69f-746893ee375a"
      unitRef="usd">2600000</us-gaap:InterestExpenseDebt>
    <us-gaap:DebtInstrumentConvertibleConversionPrice1
      contextRef="i00584134c5844a27a4303a31c0b5f1f3_I20181031"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM183My9mcmFnOjU3M2ZmODBkMmIzNDQ0MTlhMzdlOTRhZjRhNjk0MTBkL3RleHRyZWdpb246NTczZmY4MGQyYjM0NDQxOWEzN2U5NGFmNGE2OTQxMGRfMTM4NzA_21e49450-493d-4bc9-9a0e-25bb5b8fc254"
      unitRef="usdPerShare">33.43</us-gaap:DebtInstrumentConvertibleConversionPrice1>
    <us-gaap:DebtInstrumentConvertibleNumberOfEquityInstruments
      contextRef="i339c055665e9485da5895fb20444a7a8_D20181001-20181031"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM183My9mcmFnOjU3M2ZmODBkMmIzNDQ0MTlhMzdlOTRhZjRhNjk0MTBkL3RleHRyZWdpb246NTczZmY4MGQyYjM0NDQxOWEzN2U5NGFmNGE2OTQxMGRfMTM5ODY_a789527a-e5b2-4540-87c3-50ec8565d5c7"
      unitRef="shares">5200000</us-gaap:DebtInstrumentConvertibleNumberOfEquityInstruments>
    <us-gaap:LongTermDebt
      contextRef="i00584134c5844a27a4303a31c0b5f1f3_I20181031"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM183My9mcmFnOjU3M2ZmODBkMmIzNDQ0MTlhMzdlOTRhZjRhNjk0MTBkL3RleHRyZWdpb246NTczZmY4MGQyYjM0NDQxOWEzN2U5NGFmNGE2OTQxMGRfMTQ4NTc_f8d51886-7f87-48e3-bda6-dcd18b5922cc"
      unitRef="usd">100700000</us-gaap:LongTermDebt>
    <us-gaap:ProceedsFromIssuanceOfDebt
      contextRef="i69e9a51f20134473a4650107c879ce03_D20181001-20181031"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM183My9mcmFnOjU3M2ZmODBkMmIzNDQ0MTlhMzdlOTRhZjRhNjk0MTBkL3RleHRyZWdpb246NTczZmY4MGQyYjM0NDQxOWEzN2U5NGFmNGE2OTQxMGRfMTUwMDY_cba41b6a-1c7b-446f-ba97-832c1479f181"
      unitRef="usd">71800000</us-gaap:ProceedsFromIssuanceOfDebt>
    <us-gaap:DeferredFinanceCostsNet
      contextRef="i00584134c5844a27a4303a31c0b5f1f3_I20181031"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM183My9mcmFnOjU3M2ZmODBkMmIzNDQ0MTlhMzdlOTRhZjRhNjk0MTBkL3RleHRyZWdpb246NTczZmY4MGQyYjM0NDQxOWEzN2U5NGFmNGE2OTQxMGRfMTUyMTc_a8dcbdde-2a95-4b7f-bfe2-60ac67e73e99"
      unitRef="usd">3400000</us-gaap:DeferredFinanceCostsNet>
    <us-gaap:DeferredFinanceCostsNet
      contextRef="ib49940b904c04bd784180584b89ab5bf_I20181031"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM183My9mcmFnOjU3M2ZmODBkMmIzNDQ0MTlhMzdlOTRhZjRhNjk0MTBkL3RleHRyZWdpb246NTczZmY4MGQyYjM0NDQxOWEzN2U5NGFmNGE2OTQxMGRfMTUyMjQ_89844d92-e4bf-4743-b4a0-cb301273535c"
      unitRef="usd">2500000</us-gaap:DeferredFinanceCostsNet>
    <us-gaap:ProceedsFromIssuanceOfDebt
      contextRef="i69e9a51f20134473a4650107c879ce03_D20181001-20181031"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM183My9mcmFnOjU3M2ZmODBkMmIzNDQ0MTlhMzdlOTRhZjRhNjk0MTBkL3RleHRyZWdpb246NTczZmY4MGQyYjM0NDQxOWEzN2U5NGFmNGE2OTQxMGRfMTUzNTU_cba41b6a-1c7b-446f-ba97-832c1479f181"
      unitRef="usd">71800000</us-gaap:ProceedsFromIssuanceOfDebt>
    <us-gaap:DeferredFinanceCostsNet
      contextRef="i00584134c5844a27a4303a31c0b5f1f3_I20181031"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM183My9mcmFnOjU3M2ZmODBkMmIzNDQ0MTlhMzdlOTRhZjRhNjk0MTBkL3RleHRyZWdpb246NTczZmY4MGQyYjM0NDQxOWEzN2U5NGFmNGE2OTQxMGRfMTUzNTk_a8dcbdde-2a95-4b7f-bfe2-60ac67e73e99"
      unitRef="usd">3400000</us-gaap:DeferredFinanceCostsNet>
    <evh:AmortizationOfDebtDiscountAndDebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction
      contextRef="i48ca8bc8e051466a9a37e1e1da6febc3_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM183My9mcmFnOjU3M2ZmODBkMmIzNDQ0MTlhMzdlOTRhZjRhNjk0MTBkL3RleHRyZWdpb246NTczZmY4MGQyYjM0NDQxOWEzN2U5NGFmNGE2OTQxMGRfMTU3NTM_4a9ac6e2-313d-4d68-a45d-b7a913c1fc57"
      unitRef="usd">10000000</evh:AmortizationOfDebtDiscountAndDebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction>
    <evh:AmortizationOfDebtDiscountAndDebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction
      contextRef="idd22b7a2c5194e22908f4f8bfed93408_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM183My9mcmFnOjU3M2ZmODBkMmIzNDQ0MTlhMzdlOTRhZjRhNjk0MTBkL3RleHRyZWdpb246NTczZmY4MGQyYjM0NDQxOWEzN2U5NGFmNGE2OTQxMGRfMTU3ODU_64dafb1f-27e7-4500-ba4e-62ce940550c4"
      unitRef="usd">9200000</evh:AmortizationOfDebtDiscountAndDebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction>
    <evh:AmortizationOfDebtDiscountAndDebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction
      contextRef="i36270cc40db54c1cbe5d5fe12dba090b_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM183My9mcmFnOjU3M2ZmODBkMmIzNDQ0MTlhMzdlOTRhZjRhNjk0MTBkL3RleHRyZWdpb246NTczZmY4MGQyYjM0NDQxOWEzN2U5NGFmNGE2OTQxMGRfMTA5OTUxMTY0OTMyOQ_680509e2-60ba-4347-bfde-41516c5a33ae"
      unitRef="usd">8500000</evh:AmortizationOfDebtDiscountAndDebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction>
    <evh:DebtInstrumentRepurchasePriceDueToFundamentalChangeAsPercentageOfPrincipalAmount
      contextRef="i339c055665e9485da5895fb20444a7a8_D20181001-20181031"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM183My9mcmFnOjU3M2ZmODBkMmIzNDQ0MTlhMzdlOTRhZjRhNjk0MTBkL3RleHRyZWdpb246NTczZmY4MGQyYjM0NDQxOWEzN2U5NGFmNGE2OTQxMGRfMTYwODc_8d80bb69-e57d-4057-bcad-756ce97fb0a9"
      unitRef="number">1.000</evh:DebtInstrumentRepurchasePriceDueToFundamentalChangeAsPercentageOfPrincipalAmount>
    <evh:DebtInstrumentRepurchaseCovenantSalePriceAsAPercentageOfConversionPrice
      contextRef="i339c055665e9485da5895fb20444a7a8_D20181001-20181031"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM183My9mcmFnOjU3M2ZmODBkMmIzNDQ0MTlhMzdlOTRhZjRhNjk0MTBkL3RleHRyZWdpb246NTczZmY4MGQyYjM0NDQxOWEzN2U5NGFmNGE2OTQxMGRfMTY0ODY_20dc6d24-de35-4b8b-9267-714be0d61069"
      unitRef="number">1.300</evh:DebtInstrumentRepurchaseCovenantSalePriceAsAPercentageOfConversionPrice>
    <evh:DebtInstrumentRepurchaseCovenantTradingDaysMinimum
      contextRef="i339c055665e9485da5895fb20444a7a8_D20181001-20181031"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM183My9mcmFnOjU3M2ZmODBkMmIzNDQ0MTlhMzdlOTRhZjRhNjk0MTBkL3RleHRyZWdpb246NTczZmY4MGQyYjM0NDQxOWEzN2U5NGFmNGE2OTQxMGRfMTY1NDE_d716526f-7918-408a-9a6f-9d124469ae17">P20D</evh:DebtInstrumentRepurchaseCovenantTradingDaysMinimum>
    <evh:DebtInstrumentRepurchaseCovenantConsecutiveTradingDaysMinimum
      contextRef="i339c055665e9485da5895fb20444a7a8_D20181001-20181031"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM183My9mcmFnOjU3M2ZmODBkMmIzNDQ0MTlhMzdlOTRhZjRhNjk0MTBkL3RleHRyZWdpb246NTczZmY4MGQyYjM0NDQxOWEzN2U5NGFmNGE2OTQxMGRfMTY1OTc_9cf0425e-15ff-4bbf-b168-347e33daf0a3">P30D</evh:DebtInstrumentRepurchaseCovenantConsecutiveTradingDaysMinimum>
    <evh:DebtInstrumentRepurchasePriceDueToChangeInSalePriceAsPercentageOfConversionPrice
      contextRef="i339c055665e9485da5895fb20444a7a8_D20181001-20181031"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM183My9mcmFnOjU3M2ZmODBkMmIzNDQ0MTlhMzdlOTRhZjRhNjk0MTBkL3RleHRyZWdpb246NTczZmY4MGQyYjM0NDQxOWEzN2U5NGFmNGE2OTQxMGRfMTY4MzU_4ab15acb-024b-4dc0-813e-81ac25de640e"
      unitRef="number">1.000</evh:DebtInstrumentRepurchasePriceDueToChangeInSalePriceAsPercentageOfConversionPrice>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i4f7fefe0fb434989bf906e20f2422c6b_I20161231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM183My9mcmFnOjU3M2ZmODBkMmIzNDQ0MTlhMzdlOTRhZjRhNjk0MTBkL3RleHRyZWdpb246NTczZmY4MGQyYjM0NDQxOWEzN2U5NGFmNGE2OTQxMGRfMTcwMDM_ddf7132c-2580-4d0a-be36-7dd8df515070"
      unitRef="usd">125000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i4f7fefe0fb434989bf906e20f2422c6b_I20161231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM183My9mcmFnOjU3M2ZmODBkMmIzNDQ0MTlhMzdlOTRhZjRhNjk0MTBkL3RleHRyZWdpb246NTczZmY4MGQyYjM0NDQxOWEzN2U5NGFmNGE2OTQxMGRfMTcwNDA_97417d79-0c17-4578-bfb0-d0339cf10f44"
      unitRef="number">0.0200</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:ProceedsFromIssuanceOfDebt
      contextRef="i54bf54f1a88044bab71a8867d4a0c31f_D20161201-20161231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM183My9mcmFnOjU3M2ZmODBkMmIzNDQ0MTlhMzdlOTRhZjRhNjk0MTBkL3RleHRyZWdpb246NTczZmY4MGQyYjM0NDQxOWEzN2U5NGFmNGE2OTQxMGRfMTcyNjM_0244e816-3359-4461-a521-04e4c89a1628"
      unitRef="usd">120400000</us-gaap:ProceedsFromIssuanceOfDebt>
    <us-gaap:DeferredFinanceCostsNet
      contextRef="i4f7fefe0fb434989bf906e20f2422c6b_I20161231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM183My9mcmFnOjU3M2ZmODBkMmIzNDQ0MTlhMzdlOTRhZjRhNjk0MTBkL3RleHRyZWdpb246NTczZmY4MGQyYjM0NDQxOWEzN2U5NGFmNGE2OTQxMGRfMTcyNzk_630f0084-fc0b-4984-9845-5e36e8cd0dae"
      unitRef="usd">4600000</us-gaap:DeferredFinanceCostsNet>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i4f7fefe0fb434989bf906e20f2422c6b_I20161231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM183My9mcmFnOjU3M2ZmODBkMmIzNDQ0MTlhMzdlOTRhZjRhNjk0MTBkL3RleHRyZWdpb246NTczZmY4MGQyYjM0NDQxOWEzN2U5NGFmNGE2OTQxMGRfMTc3OTU_97417d79-0c17-4578-bfb0-d0339cf10f44"
      unitRef="number">0.0200</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:InterestExpenseDebt
      contextRef="i7e9e77d057aa4381855c6fd7a1d6f4ea_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM183My9mcmFnOjU3M2ZmODBkMmIzNDQ0MTlhMzdlOTRhZjRhNjk0MTBkL3RleHRyZWdpb246NTczZmY4MGQyYjM0NDQxOWEzN2U5NGFmNGE2OTQxMGRfMTg0MTI_eb81c8f6-4e6c-4d5c-88fb-2063ed3cf9b3"
      unitRef="usd">500000</us-gaap:InterestExpenseDebt>
    <us-gaap:InterestExpenseDebt
      contextRef="i087fe618f5364968ac66e7869d1caad5_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM183My9mcmFnOjU3M2ZmODBkMmIzNDQ0MTlhMzdlOTRhZjRhNjk0MTBkL3RleHRyZWdpb246NTczZmY4MGQyYjM0NDQxOWEzN2U5NGFmNGE2OTQxMGRfMTg0NDQ_012f5b01-bde4-48fb-b04b-2ac42b23fc75"
      unitRef="usd">1700000</us-gaap:InterestExpenseDebt>
    <us-gaap:InterestExpenseDebt
      contextRef="i4d8110dbf411438a8a00e05653b625c8_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM183My9mcmFnOjU3M2ZmODBkMmIzNDQ0MTlhMzdlOTRhZjRhNjk0MTBkL3RleHRyZWdpb246NTczZmY4MGQyYjM0NDQxOWEzN2U5NGFmNGE2OTQxMGRfMTA5OTUxMTY0OTM3NA_d978deea-1861-455c-9dfc-53cca6523d8a"
      unitRef="usd">2500000</us-gaap:InterestExpenseDebt>
    <us-gaap:AmortizationOfFinancingCosts
      contextRef="i7e9e77d057aa4381855c6fd7a1d6f4ea_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM183My9mcmFnOjU3M2ZmODBkMmIzNDQ0MTlhMzdlOTRhZjRhNjk0MTBkL3RleHRyZWdpb246NTczZmY4MGQyYjM0NDQxOWEzN2U5NGFmNGE2OTQxMGRfMTg1Njk_d5635bd8-e757-4c9e-a57d-00ef9ac82305"
      unitRef="usd">200000</us-gaap:AmortizationOfFinancingCosts>
    <us-gaap:AmortizationOfFinancingCosts
      contextRef="i087fe618f5364968ac66e7869d1caad5_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM183My9mcmFnOjU3M2ZmODBkMmIzNDQ0MTlhMzdlOTRhZjRhNjk0MTBkL3RleHRyZWdpb246NTczZmY4MGQyYjM0NDQxOWEzN2U5NGFmNGE2OTQxMGRfMTg2MDE_bfd9fdb4-cd17-4029-9cdc-f4a7ff57ca83"
      unitRef="usd">600000</us-gaap:AmortizationOfFinancingCosts>
    <us-gaap:AmortizationOfFinancingCosts
      contextRef="i4d8110dbf411438a8a00e05653b625c8_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM183My9mcmFnOjU3M2ZmODBkMmIzNDQ0MTlhMzdlOTRhZjRhNjk0MTBkL3RleHRyZWdpb246NTczZmY4MGQyYjM0NDQxOWEzN2U5NGFmNGE2OTQxMGRfMTA5OTUxMTY0OTUyOQ_101166de-bd87-4979-a18e-a8d9d8eb5c42"
      unitRef="usd">900000</us-gaap:AmortizationOfFinancingCosts>
    <us-gaap:DebtConversionConvertedInstrumentAmount1
      contextRef="i788309cbaf3c49228dff05dacf3204c0_D20200801-20200831"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM183My9mcmFnOjU3M2ZmODBkMmIzNDQ0MTlhMzdlOTRhZjRhNjk0MTBkL3RleHRyZWdpb246NTczZmY4MGQyYjM0NDQxOWEzN2U5NGFmNGE2OTQxMGRfMTk4NzI_88a34ff4-0dd9-4240-b08e-04cd1314cf97"
      unitRef="usd">84200000</us-gaap:DebtConversionConvertedInstrumentAmount1>
    <us-gaap:DebtConversionOriginalDebtAmount1
      contextRef="i79f0de790533434b998387bf6c4ab709_D20200801-20200831"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM183My9mcmFnOjU3M2ZmODBkMmIzNDQ0MTlhMzdlOTRhZjRhNjk0MTBkL3RleHRyZWdpb246NTczZmY4MGQyYjM0NDQxOWEzN2U5NGFmNGE2OTQxMGRfMTk5MzY_d1c15fc5-41fe-4c64-b2ba-16e714de0f95"
      unitRef="usd">84200000</us-gaap:DebtConversionOriginalDebtAmount1>
    <us-gaap:PaymentsOfDebtIssuanceCosts
      contextRef="i8584b8487d5e4d7ca2a029dd1993309b_D20200801-20200831"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM183My9mcmFnOjU3M2ZmODBkMmIzNDQ0MTlhMzdlOTRhZjRhNjk0MTBkL3RleHRyZWdpb246NTczZmY4MGQyYjM0NDQxOWEzN2U5NGFmNGE2OTQxMGRfMjAwNjk_8edabc71-7c86-4b45-a10d-f8c988590b10"
      unitRef="usd">2500000</us-gaap:PaymentsOfDebtIssuanceCosts>
    <us-gaap:GainsLossesOnExtinguishmentOfDebtBeforeWriteOffOfDeferredDebtIssuanceCost
      contextRef="i8584b8487d5e4d7ca2a029dd1993309b_D20200801-20200831"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM183My9mcmFnOjU3M2ZmODBkMmIzNDQ0MTlhMzdlOTRhZjRhNjk0MTBkL3RleHRyZWdpb246NTczZmY4MGQyYjM0NDQxOWEzN2U5NGFmNGE2OTQxMGRfMjAyMTM_a87b2cac-8845-4362-91d5-595b08df44fc"
      unitRef="usd">-4800000</us-gaap:GainsLossesOnExtinguishmentOfDebtBeforeWriteOffOfDeferredDebtIssuanceCost>
    <us-gaap:PaymentsOfDebtIssuanceCosts
      contextRef="i8584b8487d5e4d7ca2a029dd1993309b_D20200801-20200831"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM183My9mcmFnOjU3M2ZmODBkMmIzNDQ0MTlhMzdlOTRhZjRhNjk0MTBkL3RleHRyZWdpb246NTczZmY4MGQyYjM0NDQxOWEzN2U5NGFmNGE2OTQxMGRfMjAyNTY_a8cf13d9-510a-43c8-8c45-61b06d948e90"
      unitRef="usd">2500000</us-gaap:PaymentsOfDebtIssuanceCosts>
    <us-gaap:ExtinguishmentOfDebtAmount
      contextRef="i79f0de790533434b998387bf6c4ab709_D20200801-20200831"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM183My9mcmFnOjU3M2ZmODBkMmIzNDQ0MTlhMzdlOTRhZjRhNjk0MTBkL3RleHRyZWdpb246NTczZmY4MGQyYjM0NDQxOWEzN2U5NGFmNGE2OTQxMGRfMjAzMjk_30e208e1-df99-4c24-a6d7-12f510664441"
      unitRef="usd">14000000</us-gaap:ExtinguishmentOfDebtAmount>
    <us-gaap:RepaymentsOfSeniorDebt
      contextRef="i79f0de790533434b998387bf6c4ab709_D20200801-20200831"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM183My9mcmFnOjU3M2ZmODBkMmIzNDQ0MTlhMzdlOTRhZjRhNjk0MTBkL3RleHRyZWdpb246NTczZmY4MGQyYjM0NDQxOWEzN2U5NGFmNGE2OTQxMGRfMjAzNTU_a475c16d-5809-44ea-b7d5-569fb94736cb"
      unitRef="usd">13900000</us-gaap:RepaymentsOfSeniorDebt>
    <us-gaap:DebtConversionConvertedInstrumentAmount1
      contextRef="i9a2926d0e711448fa37fb03edf2470a1_D20211201-20211201"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM183My9mcmFnOjU3M2ZmODBkMmIzNDQ0MTlhMzdlOTRhZjRhNjk0MTBkL3RleHRyZWdpb246NTczZmY4MGQyYjM0NDQxOWEzN2U5NGFmNGE2OTQxMGRfMjE5OTAyMzI4MTQ2Ng_757d6b80-5459-410a-b7eb-ef838f2c5c40"
      unitRef="usd">26700000</us-gaap:DebtConversionConvertedInstrumentAmount1>
    <us-gaap:DebtConversionOriginalDebtAmount1
      contextRef="i9a2926d0e711448fa37fb03edf2470a1_D20211201-20211201"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM183My9mcmFnOjU3M2ZmODBkMmIzNDQ0MTlhMzdlOTRhZjRhNjk0MTBkL3RleHRyZWdpb246NTczZmY4MGQyYjM0NDQxOWEzN2U5NGFmNGE2OTQxMGRfMjE5OTAyMzI4MTQ4MA_9e366f80-3dff-4d29-b518-76d0058360b4"
      unitRef="usd">26300000</us-gaap:DebtConversionOriginalDebtAmount1>
    <us-gaap:PaymentsOfDebtIssuanceCosts
      contextRef="i9a2926d0e711448fa37fb03edf2470a1_D20211201-20211201"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM183My9mcmFnOjU3M2ZmODBkMmIzNDQ0MTlhMzdlOTRhZjRhNjk0MTBkL3RleHRyZWdpb246NTczZmY4MGQyYjM0NDQxOWEzN2U5NGFmNGE2OTQxMGRfMjE5OTAyMzI4MTQ5NA_f147cd65-025f-4f2d-9c11-d97c81d0ee7b"
      unitRef="usd">400000</us-gaap:PaymentsOfDebtIssuanceCosts>
    <evh:DebtConversionOriginalDebtFairValue
      contextRef="ie511597b55e24e0b9a57496e5718443a_I20211201"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM183My9mcmFnOjU3M2ZmODBkMmIzNDQ0MTlhMzdlOTRhZjRhNjk0MTBkL3RleHRyZWdpb246NTczZmY4MGQyYjM0NDQxOWEzN2U5NGFmNGE2OTQxMGRfMjE5OTAyMzI4MTUwNw_508afcfc-e3cb-43ba-afbb-cbb24f3a45aa"
      unitRef="usd">28500000</evh:DebtConversionOriginalDebtFairValue>
    <us-gaap:GainsLossesOnExtinguishmentOfDebtBeforeWriteOffOfDeferredDebtIssuanceCost
      contextRef="i9a2926d0e711448fa37fb03edf2470a1_D20211201-20211201"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM183My9mcmFnOjU3M2ZmODBkMmIzNDQ0MTlhMzdlOTRhZjRhNjk0MTBkL3RleHRyZWdpb246NTczZmY4MGQyYjM0NDQxOWEzN2U5NGFmNGE2OTQxMGRfMjE5OTAyMzI4MTUyMQ_7d9b4ba0-9512-4cf2-8e31-afb404320e42"
      unitRef="usd">2200000</us-gaap:GainsLossesOnExtinguishmentOfDebtBeforeWriteOffOfDeferredDebtIssuanceCost>
    <us-gaap:ConvertibleDebtTableTextBlock
      contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM183My9mcmFnOjU3M2ZmODBkMmIzNDQ0MTlhMzdlOTRhZjRhNjk0MTBkL3RleHRyZWdpb246NTczZmY4MGQyYjM0NDQxOWEzN2U5NGFmNGE2OTQxMGRfMjExMjA_3b32086d-b221-4545-8187-97fc142a2bf0">The following table summarizes the carrying value of the long-term convertible debt as of December&#160;31, 2021 and 2020 (in thousands):&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:409.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:60.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:60.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#160;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2024 Notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Carrying value&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;89,361&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;81,462&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unamortized debt discount and issuance costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,690&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35,589&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Principal amount&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;117,051&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;117,051&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Remaining amortization period (years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.9&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.9&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;195,445&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;153,220&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2025 Notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Carrying value&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;126,315&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;116,349&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unamortized debt discount and issuance costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46,185&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;56,151&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Principal amount&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;172,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;172,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Remaining amortization period (years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.8&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.8&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;177,251&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;147,488&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021 Notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Carrying value&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26,557&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unamortized debt discount and issuance costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;180&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Principal amount&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26,737&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Remaining amortization period (years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.0&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.9&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26,470&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;padding-left:9pt;text-align:justify;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt"&gt;Fair values for notes are derived from available trading prices closest to the respective balance sheet date.&lt;/span&gt;&lt;/div&gt;</us-gaap:ConvertibleDebtTableTextBlock>
    <us-gaap:ConvertibleDebt
      contextRef="id7ce03f7e23c4e8982556c1c3936f37c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM183My9mcmFnOjU3M2ZmODBkMmIzNDQ0MTlhMzdlOTRhZjRhNjk0MTBkL3RhYmxlOjU4MjJmMjVkMmZjYjQ2MDA4ZTAyNGM5MWI4NjYwY2UyL3RhYmxlcmFuZ2U6NTgyMmYyNWQyZmNiNDYwMDhlMDI0YzkxYjg2NjBjZTJfMi0xLTEtMS0xNzc3NQ_a69c29db-c8ad-4a4e-bef6-0b47e278d299"
      unitRef="usd">89361000</us-gaap:ConvertibleDebt>
    <us-gaap:ConvertibleDebt
      contextRef="i2aac0290566244888dfc87dd98ff26b6_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM183My9mcmFnOjU3M2ZmODBkMmIzNDQ0MTlhMzdlOTRhZjRhNjk0MTBkL3RhYmxlOjU4MjJmMjVkMmZjYjQ2MDA4ZTAyNGM5MWI4NjYwY2UyL3RhYmxlcmFuZ2U6NTgyMmYyNWQyZmNiNDYwMDhlMDI0YzkxYjg2NjBjZTJfMi0zLTEtMS0xNzc3NQ_f0ba85e2-1e23-42ad-8264-4a342d81ca93"
      unitRef="usd">81462000</us-gaap:ConvertibleDebt>
    <us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet
      contextRef="id7ce03f7e23c4e8982556c1c3936f37c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM183My9mcmFnOjU3M2ZmODBkMmIzNDQ0MTlhMzdlOTRhZjRhNjk0MTBkL3RhYmxlOjU4MjJmMjVkMmZjYjQ2MDA4ZTAyNGM5MWI4NjYwY2UyL3RhYmxlcmFuZ2U6NTgyMmYyNWQyZmNiNDYwMDhlMDI0YzkxYjg2NjBjZTJfMy0xLTEtMS0xNzc3NQ_ec561a01-5b60-4d55-be2e-f1c4894e8a34"
      unitRef="usd">27690000</us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet>
    <us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet
      contextRef="i2aac0290566244888dfc87dd98ff26b6_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM183My9mcmFnOjU3M2ZmODBkMmIzNDQ0MTlhMzdlOTRhZjRhNjk0MTBkL3RhYmxlOjU4MjJmMjVkMmZjYjQ2MDA4ZTAyNGM5MWI4NjYwY2UyL3RhYmxlcmFuZ2U6NTgyMmYyNWQyZmNiNDYwMDhlMDI0YzkxYjg2NjBjZTJfMy0zLTEtMS0xNzc3NQ_d613fba1-f418-45bf-9577-572cb1bcc3f6"
      unitRef="usd">35589000</us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="id7ce03f7e23c4e8982556c1c3936f37c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM183My9mcmFnOjU3M2ZmODBkMmIzNDQ0MTlhMzdlOTRhZjRhNjk0MTBkL3RhYmxlOjU4MjJmMjVkMmZjYjQ2MDA4ZTAyNGM5MWI4NjYwY2UyL3RhYmxlcmFuZ2U6NTgyMmYyNWQyZmNiNDYwMDhlMDI0YzkxYjg2NjBjZTJfNC0xLTEtMS0xNzc3NQ_77f8ea8c-8a59-41d7-be1a-2684fbcacbc6"
      unitRef="usd">117051000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i2aac0290566244888dfc87dd98ff26b6_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM183My9mcmFnOjU3M2ZmODBkMmIzNDQ0MTlhMzdlOTRhZjRhNjk0MTBkL3RhYmxlOjU4MjJmMjVkMmZjYjQ2MDA4ZTAyNGM5MWI4NjYwY2UyL3RhYmxlcmFuZ2U6NTgyMmYyNWQyZmNiNDYwMDhlMDI0YzkxYjg2NjBjZTJfNC0zLTEtMS0xNzc3NQ_59cc9c66-c453-4289-b6c4-b0ef7f75d551"
      unitRef="usd">117051000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1
      contextRef="ifef2fd52529f408dbb3bcb2d3f4ae616_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM183My9mcmFnOjU3M2ZmODBkMmIzNDQ0MTlhMzdlOTRhZjRhNjk0MTBkL3RhYmxlOjU4MjJmMjVkMmZjYjQ2MDA4ZTAyNGM5MWI4NjYwY2UyL3RhYmxlcmFuZ2U6NTgyMmYyNWQyZmNiNDYwMDhlMDI0YzkxYjg2NjBjZTJfNS0xLTEtMS0xNzc3NQ_79272008-528f-494b-ba36-e2b17c1c04d6">P2Y10M24D</us-gaap:DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1>
    <us-gaap:DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1
      contextRef="i2f7a8968a0e74fcfa7af898dd2afb7a6_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM183My9mcmFnOjU3M2ZmODBkMmIzNDQ0MTlhMzdlOTRhZjRhNjk0MTBkL3RhYmxlOjU4MjJmMjVkMmZjYjQ2MDA4ZTAyNGM5MWI4NjYwY2UyL3RhYmxlcmFuZ2U6NTgyMmYyNWQyZmNiNDYwMDhlMDI0YzkxYjg2NjBjZTJfNS0zLTEtMS0xNzc3NQ_640e7230-e487-4e8c-81ef-bbae9e116444">P3Y10M24D</us-gaap:DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1>
    <us-gaap:LongTermDebtFairValue
      contextRef="i0f822324d7204951a08832492a541883_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM183My9mcmFnOjU3M2ZmODBkMmIzNDQ0MTlhMzdlOTRhZjRhNjk0MTBkL3RhYmxlOjU4MjJmMjVkMmZjYjQ2MDA4ZTAyNGM5MWI4NjYwY2UyL3RhYmxlcmFuZ2U6NTgyMmYyNWQyZmNiNDYwMDhlMDI0YzkxYjg2NjBjZTJfNi0xLTEtMS0xNzc3NQ_635d20ab-5388-4c9e-a58e-39a0e43c0fcf"
      unitRef="usd">195445000</us-gaap:LongTermDebtFairValue>
    <us-gaap:LongTermDebtFairValue
      contextRef="i40eea1e73a0a4178ad8f4535f4a3950e_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM183My9mcmFnOjU3M2ZmODBkMmIzNDQ0MTlhMzdlOTRhZjRhNjk0MTBkL3RhYmxlOjU4MjJmMjVkMmZjYjQ2MDA4ZTAyNGM5MWI4NjYwY2UyL3RhYmxlcmFuZ2U6NTgyMmYyNWQyZmNiNDYwMDhlMDI0YzkxYjg2NjBjZTJfNi0zLTEtMS0xNzc3NQ_36150e7e-2026-4de6-a739-2f1b54648105"
      unitRef="usd">153220000</us-gaap:LongTermDebtFairValue>
    <us-gaap:ConvertibleDebt
      contextRef="i974ce0eee5ff4e6280561dba5e0ac368_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM183My9mcmFnOjU3M2ZmODBkMmIzNDQ0MTlhMzdlOTRhZjRhNjk0MTBkL3RhYmxlOjU4MjJmMjVkMmZjYjQ2MDA4ZTAyNGM5MWI4NjYwY2UyL3RhYmxlcmFuZ2U6NTgyMmYyNWQyZmNiNDYwMDhlMDI0YzkxYjg2NjBjZTJfOS0xLTEtMS0xNzc3NQ_5340c550-62de-439d-b9be-28f4cb0f521f"
      unitRef="usd">126315000</us-gaap:ConvertibleDebt>
    <us-gaap:ConvertibleDebt
      contextRef="i50fb6ca1635f4d128f6a1d489565ad0b_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM183My9mcmFnOjU3M2ZmODBkMmIzNDQ0MTlhMzdlOTRhZjRhNjk0MTBkL3RhYmxlOjU4MjJmMjVkMmZjYjQ2MDA4ZTAyNGM5MWI4NjYwY2UyL3RhYmxlcmFuZ2U6NTgyMmYyNWQyZmNiNDYwMDhlMDI0YzkxYjg2NjBjZTJfOS0zLTEtMS0xNzc3NQ_76650c2b-06ff-4277-8c71-f9ce417d98e2"
      unitRef="usd">116349000</us-gaap:ConvertibleDebt>
    <us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet
      contextRef="i974ce0eee5ff4e6280561dba5e0ac368_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM183My9mcmFnOjU3M2ZmODBkMmIzNDQ0MTlhMzdlOTRhZjRhNjk0MTBkL3RhYmxlOjU4MjJmMjVkMmZjYjQ2MDA4ZTAyNGM5MWI4NjYwY2UyL3RhYmxlcmFuZ2U6NTgyMmYyNWQyZmNiNDYwMDhlMDI0YzkxYjg2NjBjZTJfMTAtMS0xLTEtMTc3NzU_c0ff48c4-c021-445e-bdfb-4200439fd3a4"
      unitRef="usd">46185000</us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet>
    <us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet
      contextRef="i50fb6ca1635f4d128f6a1d489565ad0b_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM183My9mcmFnOjU3M2ZmODBkMmIzNDQ0MTlhMzdlOTRhZjRhNjk0MTBkL3RhYmxlOjU4MjJmMjVkMmZjYjQ2MDA4ZTAyNGM5MWI4NjYwY2UyL3RhYmxlcmFuZ2U6NTgyMmYyNWQyZmNiNDYwMDhlMDI0YzkxYjg2NjBjZTJfMTAtMy0xLTEtMTc3NzU_d51651ea-3ba5-4c28-b45f-57f824311f0d"
      unitRef="usd">56151000</us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i974ce0eee5ff4e6280561dba5e0ac368_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM183My9mcmFnOjU3M2ZmODBkMmIzNDQ0MTlhMzdlOTRhZjRhNjk0MTBkL3RhYmxlOjU4MjJmMjVkMmZjYjQ2MDA4ZTAyNGM5MWI4NjYwY2UyL3RhYmxlcmFuZ2U6NTgyMmYyNWQyZmNiNDYwMDhlMDI0YzkxYjg2NjBjZTJfMTEtMS0xLTEtMTc3NzU_4bfa4a1e-1a82-4fbc-8b68-6449bfc6af4a"
      unitRef="usd">172500000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i50fb6ca1635f4d128f6a1d489565ad0b_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM183My9mcmFnOjU3M2ZmODBkMmIzNDQ0MTlhMzdlOTRhZjRhNjk0MTBkL3RhYmxlOjU4MjJmMjVkMmZjYjQ2MDA4ZTAyNGM5MWI4NjYwY2UyL3RhYmxlcmFuZ2U6NTgyMmYyNWQyZmNiNDYwMDhlMDI0YzkxYjg2NjBjZTJfMTEtMy0xLTEtMTc3NzU_56edd30d-7637-415b-ab2a-ea9eb842d202"
      unitRef="usd">172500000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1
      contextRef="i48ca8bc8e051466a9a37e1e1da6febc3_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM183My9mcmFnOjU3M2ZmODBkMmIzNDQ0MTlhMzdlOTRhZjRhNjk0MTBkL3RhYmxlOjU4MjJmMjVkMmZjYjQ2MDA4ZTAyNGM5MWI4NjYwY2UyL3RhYmxlcmFuZ2U6NTgyMmYyNWQyZmNiNDYwMDhlMDI0YzkxYjg2NjBjZTJfMTItMS0xLTEtMTc3NzU_9768c573-4c88-436a-b481-dc005ba5cab9">P3Y9M18D</us-gaap:DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1>
    <us-gaap:DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1
      contextRef="idd22b7a2c5194e22908f4f8bfed93408_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM183My9mcmFnOjU3M2ZmODBkMmIzNDQ0MTlhMzdlOTRhZjRhNjk0MTBkL3RhYmxlOjU4MjJmMjVkMmZjYjQ2MDA4ZTAyNGM5MWI4NjYwY2UyL3RhYmxlcmFuZ2U6NTgyMmYyNWQyZmNiNDYwMDhlMDI0YzkxYjg2NjBjZTJfMTItMy0xLTEtMTc3NzU_b6a4cea7-1d0b-43b6-9e35-8cb68dc19c02">P4Y9M18D</us-gaap:DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1>
    <us-gaap:LongTermDebtFairValue
      contextRef="i7f0d332f713a4f89bb808c44e818aea3_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM183My9mcmFnOjU3M2ZmODBkMmIzNDQ0MTlhMzdlOTRhZjRhNjk0MTBkL3RhYmxlOjU4MjJmMjVkMmZjYjQ2MDA4ZTAyNGM5MWI4NjYwY2UyL3RhYmxlcmFuZ2U6NTgyMmYyNWQyZmNiNDYwMDhlMDI0YzkxYjg2NjBjZTJfMTMtMS0xLTEtMTc3NzU_d59f3705-d018-4262-afd7-9a44bda89357"
      unitRef="usd">177251000</us-gaap:LongTermDebtFairValue>
    <us-gaap:LongTermDebtFairValue
      contextRef="ica31b1dea8e04139a2223a01fd1e7439_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM183My9mcmFnOjU3M2ZmODBkMmIzNDQ0MTlhMzdlOTRhZjRhNjk0MTBkL3RhYmxlOjU4MjJmMjVkMmZjYjQ2MDA4ZTAyNGM5MWI4NjYwY2UyL3RhYmxlcmFuZ2U6NTgyMmYyNWQyZmNiNDYwMDhlMDI0YzkxYjg2NjBjZTJfMTMtMy0xLTEtMTc3NzU_f02f0b5b-da58-40bf-a4b3-0f950bc1f063"
      unitRef="usd">147488000</us-gaap:LongTermDebtFairValue>
    <us-gaap:ConvertibleDebt
      contextRef="id04e184022df4434b775ae12babcdd7d_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM183My9mcmFnOjU3M2ZmODBkMmIzNDQ0MTlhMzdlOTRhZjRhNjk0MTBkL3RhYmxlOjU4MjJmMjVkMmZjYjQ2MDA4ZTAyNGM5MWI4NjYwY2UyL3RhYmxlcmFuZ2U6NTgyMmYyNWQyZmNiNDYwMDhlMDI0YzkxYjg2NjBjZTJfMTctMS0xLTEtMzU5NDU_0b9e237c-4781-4fe7-98bc-0f2449b858f2"
      unitRef="usd">0</us-gaap:ConvertibleDebt>
    <us-gaap:ConvertibleDebt
      contextRef="i5f1ed0aa6efc4adda8d9ddf826e7eb41_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM183My9mcmFnOjU3M2ZmODBkMmIzNDQ0MTlhMzdlOTRhZjRhNjk0MTBkL3RhYmxlOjU4MjJmMjVkMmZjYjQ2MDA4ZTAyNGM5MWI4NjYwY2UyL3RhYmxlcmFuZ2U6NTgyMmYyNWQyZmNiNDYwMDhlMDI0YzkxYjg2NjBjZTJfMTctMy0xLTEtMzU5NDU_3646522b-e290-4063-97d3-fdc288b779bd"
      unitRef="usd">26557000</us-gaap:ConvertibleDebt>
    <us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet
      contextRef="id04e184022df4434b775ae12babcdd7d_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM183My9mcmFnOjU3M2ZmODBkMmIzNDQ0MTlhMzdlOTRhZjRhNjk0MTBkL3RhYmxlOjU4MjJmMjVkMmZjYjQ2MDA4ZTAyNGM5MWI4NjYwY2UyL3RhYmxlcmFuZ2U6NTgyMmYyNWQyZmNiNDYwMDhlMDI0YzkxYjg2NjBjZTJfMTgtMS0xLTEtMzU5NDU_cd52499b-bcec-4434-9d85-252c9dd714bf"
      unitRef="usd">0</us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet>
    <us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet
      contextRef="i5f1ed0aa6efc4adda8d9ddf826e7eb41_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM183My9mcmFnOjU3M2ZmODBkMmIzNDQ0MTlhMzdlOTRhZjRhNjk0MTBkL3RhYmxlOjU4MjJmMjVkMmZjYjQ2MDA4ZTAyNGM5MWI4NjYwY2UyL3RhYmxlcmFuZ2U6NTgyMmYyNWQyZmNiNDYwMDhlMDI0YzkxYjg2NjBjZTJfMTgtMy0xLTEtMzU5NDU_e0ffd5dd-982d-46d5-adb2-dc6d1fc41fb6"
      unitRef="usd">180000</us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="id04e184022df4434b775ae12babcdd7d_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM183My9mcmFnOjU3M2ZmODBkMmIzNDQ0MTlhMzdlOTRhZjRhNjk0MTBkL3RhYmxlOjU4MjJmMjVkMmZjYjQ2MDA4ZTAyNGM5MWI4NjYwY2UyL3RhYmxlcmFuZ2U6NTgyMmYyNWQyZmNiNDYwMDhlMDI0YzkxYjg2NjBjZTJfMTktMS0xLTEtMzU5NDU_217eec06-4489-45a8-9f29-bde1580eb9d8"
      unitRef="usd">0</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i5f1ed0aa6efc4adda8d9ddf826e7eb41_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM183My9mcmFnOjU3M2ZmODBkMmIzNDQ0MTlhMzdlOTRhZjRhNjk0MTBkL3RhYmxlOjU4MjJmMjVkMmZjYjQ2MDA4ZTAyNGM5MWI4NjYwY2UyL3RhYmxlcmFuZ2U6NTgyMmYyNWQyZmNiNDYwMDhlMDI0YzkxYjg2NjBjZTJfMTktMy0xLTEtMzU5NDU_72124c4c-118f-4ade-9b79-7315bb156dba"
      unitRef="usd">26737000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1
      contextRef="i7e9e77d057aa4381855c6fd7a1d6f4ea_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM183My9mcmFnOjU3M2ZmODBkMmIzNDQ0MTlhMzdlOTRhZjRhNjk0MTBkL3RhYmxlOjU4MjJmMjVkMmZjYjQ2MDA4ZTAyNGM5MWI4NjYwY2UyL3RhYmxlcmFuZ2U6NTgyMmYyNWQyZmNiNDYwMDhlMDI0YzkxYjg2NjBjZTJfMjAtMS0xLTEtMzU5NDU_8ecf9174-ab80-4ada-a332-8a5e5036f2f2">P0Y</us-gaap:DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1>
    <us-gaap:DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1
      contextRef="i087fe618f5364968ac66e7869d1caad5_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM183My9mcmFnOjU3M2ZmODBkMmIzNDQ0MTlhMzdlOTRhZjRhNjk0MTBkL3RhYmxlOjU4MjJmMjVkMmZjYjQ2MDA4ZTAyNGM5MWI4NjYwY2UyL3RhYmxlcmFuZ2U6NTgyMmYyNWQyZmNiNDYwMDhlMDI0YzkxYjg2NjBjZTJfMjAtMy0xLTEtMzU5NDU_1859e54a-14bf-4370-8a9b-56a438373a8f">P0Y10M24D</us-gaap:DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1>
    <us-gaap:LongTermDebtFairValue
      contextRef="id11648efb5084baf81bbd2896c0fcdac_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM183My9mcmFnOjU3M2ZmODBkMmIzNDQ0MTlhMzdlOTRhZjRhNjk0MTBkL3RhYmxlOjU4MjJmMjVkMmZjYjQ2MDA4ZTAyNGM5MWI4NjYwY2UyL3RhYmxlcmFuZ2U6NTgyMmYyNWQyZmNiNDYwMDhlMDI0YzkxYjg2NjBjZTJfMjEtMS0xLTEtMzU5NDU_db020b89-ea37-4d74-884c-e02e3019751a"
      unitRef="usd">0</us-gaap:LongTermDebtFairValue>
    <us-gaap:LongTermDebtFairValue
      contextRef="icd0c2590d98d4a87a8626e624f822e5f_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM183My9mcmFnOjU3M2ZmODBkMmIzNDQ0MTlhMzdlOTRhZjRhNjk0MTBkL3RhYmxlOjU4MjJmMjVkMmZjYjQ2MDA4ZTAyNGM5MWI4NjYwY2UyL3RhYmxlcmFuZ2U6NTgyMmYyNWQyZmNiNDYwMDhlMDI0YzkxYjg2NjBjZTJfMjEtMy0xLTEtMzU5NDU_bc7441cf-f5f2-484d-96f2-4c3cdedc90cf"
      unitRef="usd">26470000</us-gaap:LongTermDebtFairValue>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock
      contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM183OS9mcmFnOmMzNjRjMmIwMjFiMTRiOGFiYzRhOTgzOGJhY2RlZjE5L3RleHRyZWdpb246YzM2NGMyYjAyMWIxNGI4YWJjNGE5ODM4YmFjZGVmMTlfMTIwNjE_2468e8f0-d915-46c5-8973-1ed379e3d503">Commitments and Contingencies &lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Commitments&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Letters of Credit&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2021 and 2020, the Company was party to irrevocable standby letters of credit&#160;with a bank for&#160;$15.4 million&#160;and $8.3&#160;million, respectively, for the benefit of a regulatory authorities, real estate and risk-sharing agreements. As such, we held $15.4 million and $8.3&#160;million in restricted cash and restricted investments as collateral as of December&#160;31, 2021 and December&#160;31, 2020, respectively. The letters of credit have current expiration dates between January 2022 and March 2032 and will automatically extend without amendment for an additional one-year period and will continue to automatically extend after each one-year term from the expiry date unless the bank elects not to extend beyond the initial or any extended expiry date. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Indemnifications&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s customer agreements generally include a provision by which the Company agrees to defend its partners against third-party claims (a) for death, bodily injury, or damage to personal property caused by Company negligence or willful misconduct, (b) by former or current Company employees arising from such managed service agreements, (c) for intellectual property infringement under specified conditions and (d) for Company violation of applicable laws, and to indemnify them against any damages and costs awarded in connection with such claims. To date, the Company has not incurred any material costs as a result of such indemnities and has not accrued any liabilities related to such obligations in the accompanying consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Pre-IPO Investor Registration Rights Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We entered into a registration rights agreement with The Advisory Board, UPMC, TPG and another investor to register for sale under the Securities Act shares of our Class A common stock, including those delivered in exchange for Class B common stock and Class B common units. Subject to certain conditions and limitations, this agreement provides these investors with certain demand, piggyback and shelf registration rights. The registration rights granted under the registration rights agreement will terminate upon the date the holders of shares that are a party thereto no longer hold any such shares that are entitled to registration rights. Pursuant to our contractual obligations under this agreement, we filed a registration statement on Form S-3 with the SEC on July 28, 2016, which was declared effective on August 12, 2016.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We will pay all expenses relating to any demand, piggyback or shelf registration, other than underwriting discounts and commissions and any transfer taxes, subject to specified conditions and limitations. The registration rights agreement includes customary indemnification provisions, including indemnification of the participating holders of shares of Class A common stock and their directors, officers and employees by us for any losses, claims, damages or liabilities in respect thereof and expenses to which such holders may become subject under the Securities Act, state law or otherwise. We did not incur any expenses related to secondary offerings or other sales of shares by our investor stockholders during the years ended December 31, 2021, 2020 and 2019, respectively. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Guarantees&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;In connection with the Molina Closing, the Company continued to provide administrative support services relating to the Passport Medicaid Contract to Molina through the end of 2020. Following the Molina Closing, EVH Passport began working with regulatory authorities including the Kentucky Department of Insurance (&#x201c;KY DOI&#x201d;) regarding the wind down of its operations throughout 2021. As part of that wind down process, the Company, as the parent of EVH Passport, entered into a guarantee for the benefit of the KY DOI to satisfy any EVH Passport liability or obligation in the event EVH Passport is not able to meet its wind down liabilities or obligations. As of December&#160;31, 2021, no amounts have been funded under this guarantee.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Reinsurance Agreements&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As part of the Passport Closing, EVH Passport and UHC entered into an agreement that provided for the administration and assumption of the financial risks by EVH Passport of the D-SNP Business until such time as EVH Passport became certified as a Medicare Advantage Organization and the D-SNP Business could be transferred to EVH Passport.  On October 1, 2020, the D-SNP Business was transferred from UHC to EVH Passport.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At the Molina Closing, Molina and EVH Passport entered into an agreement that provided for the assumption of the financial risks by Molina of the D-SNP Business until such time as Molina&#x2019;s Kentucky health plan becomes certified as a Medicare Advantage Organization and the D-SNP Business is transferred to Molina. The Company and EVH Passport continued to administer the D-SNP Business until January 1, 2021, at which time Molina became responsible for its administration until the D-SNP Business was officially transferred to Molina effective September 1, 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following summarizes premiums and claims assumed under the Reinsurance Agreements for the years ended December 31, 2021, 2020 and 2019 (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:387.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:46.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:46.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:46.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;For the Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reinsurance premiums assumed&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,179&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,130&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;83,325&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reinsurance premiums ceded&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,614)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,275)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Claims assumed&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,468&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,812&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;72,594&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Claims ceded&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(422)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Claims-related administrative expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,159&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,024&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:24pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Increase (decrease) in reserves for claims and performance-based arrangements attributable to the Reinsurance Agreement&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,166&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,465&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,293)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:24pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reserves for claims and performance-based arrangements attributable to the Reinsurance Agreement at the beginning of the period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,002&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,243&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:23pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Impact of consolidation on payable for claims and performance-based arrangements attributable to the Reinsurance Agreement&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(502)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reinsurance payments paid (received)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,078&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,039)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,536&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:24pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Payable for claims and performance-based arrangements attributable to the Reinsurance Agreement at the end of the period&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;90&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,002&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;UPMC Reseller Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company and UPMC are parties to a reseller, services and non-competition agreement, dated August 31, 2011, which was amended and restated by the parties on June 27, 2013 (as amended through the date hereof, the &#x201c;UPMC Reseller Agreement&#x201d;). Under the terms of the UPMC Reseller Agreement, UPMC has appointed the Company as a non-exclusive reseller of certain services, subject to certain conditions and limitations specified in the UPMC Reseller Agreement. In consideration for the Company&#x2019;s obligations under the UPMC Reseller Agreement and subject to certain conditions described therein, UPMC has agreed not to sell certain products and services directly to a defined list of 20 of the Company&#x2019;s customers.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Contingencies&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Tax Receivables Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with the Offering Reorganization, the Company entered into the Tax Receivables Agreement (the &#x201c;TRA&#x201d;) with certain of its investors, which provides for the payment by the Company to these investors of 85% of the amount of the tax benefits, if any, that the Company is deemed to realize as a result of increases in our tax basis related to exchanges of Class B common units as well as tax benefits attributable to the future utilization of pre-IPO NOLs. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Due to the items noted above, and the fact that Evolent Health, Inc. is in a full valuation allowance position such that the deferred tax assets related to the Company&#x2019;s historical pre-IPO losses and tax basis increase benefit from exchanges have not been realized, the Company has not recorded a liability pursuant to the TRA.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Litigation Matters&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We are engaged from time to time in certain legal disputes arising in the ordinary course of business, including employment claims. When the likelihood of a loss contingency becomes probable and the amount of the loss can be reasonably estimated, we accrue a liability for the loss contingency. We continue to review accruals and adjust them to reflect ongoing negotiations, settlements, rulings, advice of legal counsel, and other relevant information. To the extent new information is obtained, and our views on the probable outcomes of claims, suits, assessments, investigations or legal proceedings change, changes in our accrued liabilities would be recorded in the period in which such determination is made.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On August 8, 2019, a shareholder of the Company filed a class action complaint against the Company, asserting claims under Section 10(b) and 20(a) of the Securities Exchange Act of 1934, in the United States District Court, Eastern District of Virginia, Alexandria Division. An amended complaint was filed on January 10, 2020, a second amended complaint was filed on June 8, 2020, and a third amended complaint, now titled &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Plymouth County Retirement System v. Evolent Health, Inc., Frank Williams, Nicholas McGrane, Seth Blackley&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, was filed on December 2, 2021. The case alleges that the Company&#x2019;s executives made false or misleading statements regarding its business with Passport. The Company filed a motion to dismiss the second amended complaint, and the Eastern District of Virginia granted in part and denied in part the motion on March 24, 2021. The case entered the discovery phase, but discovery is again stayed pending a decision on the company&#x2019;s third motion to dismiss, which was filed December 17, 2021. Briefing on the motion to dismiss was completed on February 10, 2022, and oral argument will be held on March 11, 2022.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Based on the Company&#x2019;s investigation, we believe the case has little legal or factual merit. However, the outcome of any litigation is uncertain.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On June 8, 2021, a shareholder of the Company filed a derivative action in the Delaware Chancery Court against some current and former Board members and against the Company as a nominal defendant, alleging that the Company&#x2019;s Board was negligent in its oversight of the Company&#x2019;s relationship with Passport Health Plan. The case is Lincolnshire Police Pension Fund, derivatively on behalf of &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Evolent Health, Inc., v. Blackley, Williams, Scott, Holder, Farner, D&#x2019;Amato, Duffy, Felt, Samet, Hobart, and Payson&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, and Evolent Health, Inc. The Company and the Director-Defendants filed a motion to dismiss the complaint on August 27, 2021, and Plaintiffs responded by filing an amended complaint on October 26, 2021. Defendants filed a motion to dismiss the amended complaint on December 17, 2021.  Subsequently, the parties agreed to stay the case pending the decision on the Company&#x2019;s motion to dismiss the third amended complaint, currently pending in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Plymouth County Retirement System v. Evolent Health, Frank Williams, Nicky McGrane, and Seth Blackley&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, in federal district court. Based on the Company&#x2019;s investigation, we believe the case has little legal or factual merit. However, the outcome of any litigation is uncertain.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Credit and Concentration Risk&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is subject to significant concentrations of credit risk related to cash and cash equivalents and accounts receivable. As of December&#160;31, 2021, approximately 99.4% of our $354.9 million of cash and cash equivalents, restricted cash and restricted investments were held in bank deposits with FDIC participating banks and approximately 0.6% were held in international banks. While the Company maintains its cash and cash equivalents with financial institutions with high credit ratings, it often maintains these deposits in federally insured financial institutions in excess of federally insured limits. The Company has not experienced any realized losses on cash and cash equivalents to date.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is also subject to significant concentration of accounts receivable risk as a substantial portion of our trade accounts receivable is derived from a small number of our partners. The following table summarizes the partners who represented at least 10.0% of our consolidated trade accounts receivable as of December&#160;31, 2021 and December&#160;31, 2020:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:426.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:55.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:48.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;As of December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cook County Health and Hospitals System&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;61.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Florida Blue Medicare, Inc. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;N/A&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Molina Healthcare&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:115%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%;padding-left:11.94pt"&gt;Customer added during the year ended December 31, 2021. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In addition, the Company is subject to significant concentration of revenue risk as a substantial portion of our revenue is derived from a small number of contractual relationships with our operating partners.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes those partners who represented at least 10.0% of our consolidated revenue for the years ended December 31, 2021, 2020 and 2019:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:380.50pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:48.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:48.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:48.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;For the Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021 &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020 &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019 &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cook County Health and Hospitals Systems&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28.0%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;New Mexico Health Connections&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Florida Blue Medicare, Inc. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;N/A&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;N/A&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Passport &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt"&gt;The denominator excludes $44.8&#160;million, $117.4&#160;million and $171.7&#160;million of True Health premium revenue reclassified to discontinued operations for the years ended December 31, 2021, 2020 and 2019, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt"&gt;Customer added during the year ended December 31, 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt"&gt;Represents revenues from EVH Passport/UHC through the Molina Closing. Subsequent to the Molina Closing on September 1, 2020, the Company has not received any material revenue from EVH Passport. However, as part of the Molina Closing, we entered into a new contract with Molina on similar terms to our prior services contract with EVH Passport through December 31, 2020 which accounted for approximately 9.7% of our consolidated revenues for the year ended December 31, 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;* &#160;&#160;&#160;&#160;Represents less than 10.0% of the respective balance&lt;/span&gt;&lt;/div&gt;We derive a significant portion of our revenues from our largest partners. The loss, termination or renegotiation of our relationship or contract with any significant partner or multiple partners in the aggregate could have a material adverse effect on the Company's financial condition and results of operations.</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="ia9961196998042f89c9a61f119c53f5e_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM183OS9mcmFnOmMzNjRjMmIwMjFiMTRiOGFiYzRhOTgzOGJhY2RlZjE5L3RleHRyZWdpb246YzM2NGMyYjAyMWIxNGI4YWJjNGE5ODM4YmFjZGVmMTlfMTg5_56003a0b-c4ac-4941-894d-a4e6d669ea11"
      unitRef="usd">15400000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="iede64ab75aa34060b8b77784840d5794_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM183OS9mcmFnOmMzNjRjMmIwMjFiMTRiOGFiYzRhOTgzOGJhY2RlZjE5L3RleHRyZWdpb246YzM2NGMyYjAyMWIxNGI4YWJjNGE5ODM4YmFjZGVmMTlfMTk2_6b9931cd-9f87-4cf5-aaef-d7c9f21d34ba"
      unitRef="usd">8300000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:RestrictedCashAndCashEquivalents
      contextRef="i16c94c74682c4658bb289affc41db310_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM183OS9mcmFnOmMzNjRjMmIwMjFiMTRiOGFiYzRhOTgzOGJhY2RlZjE5L3RleHRyZWdpb246YzM2NGMyYjAyMWIxNGI4YWJjNGE5ODM4YmFjZGVmMTlfMzAy_ab87813f-591b-490c-8a3e-41fa9a485168"
      unitRef="usd">15400000</us-gaap:RestrictedCashAndCashEquivalents>
    <us-gaap:RestrictedCashAndCashEquivalents
      contextRef="i1ceb37a7eda64dfab33aaf8b47cbcf60_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM183OS9mcmFnOmMzNjRjMmIwMjFiMTRiOGFiYzRhOTgzOGJhY2RlZjE5L3RleHRyZWdpb246YzM2NGMyYjAyMWIxNGI4YWJjNGE5ODM4YmFjZGVmMTlfMzAy_f75d3fb4-bd4a-4ac3-8b24-5b244250c742"
      unitRef="usd">15400000</us-gaap:RestrictedCashAndCashEquivalents>
    <us-gaap:RestrictedCashAndCashEquivalents
      contextRef="i1f3461e188de4f5c80fc4743b6823420_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM183OS9mcmFnOmMzNjRjMmIwMjFiMTRiOGFiYzRhOTgzOGJhY2RlZjE5L3RleHRyZWdpb246YzM2NGMyYjAyMWIxNGI4YWJjNGE5ODM4YmFjZGVmMTlfMzA5_4302a173-c888-49f9-a05b-d582cd8794d0"
      unitRef="usd">8300000</us-gaap:RestrictedCashAndCashEquivalents>
    <us-gaap:RestrictedCashAndCashEquivalents
      contextRef="iffcd0f576b5c4f27b02cf64ca97d07d5_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM183OS9mcmFnOmMzNjRjMmIwMjFiMTRiOGFiYzRhOTgzOGJhY2RlZjE5L3RleHRyZWdpb246YzM2NGMyYjAyMWIxNGI4YWJjNGE5ODM4YmFjZGVmMTlfMzA5_8db7bd35-524d-4790-b02a-0e39fa8efbb8"
      unitRef="usd">8300000</us-gaap:RestrictedCashAndCashEquivalents>
    <us-gaap:EffectsOfReinsuranceTableTextBlock
      contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM183OS9mcmFnOmMzNjRjMmIwMjFiMTRiOGFiYzRhOTgzOGJhY2RlZjE5L3RleHRyZWdpb246YzM2NGMyYjAyMWIxNGI4YWJjNGE5ODM4YmFjZGVmMTlfMTIwNjg_5cdc7c38-6b01-4694-a026-f788a67fde0c">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following summarizes premiums and claims assumed under the Reinsurance Agreements for the years ended December 31, 2021, 2020 and 2019 (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:387.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:46.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:46.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:46.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;For the Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reinsurance premiums assumed&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,179&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,130&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;83,325&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reinsurance premiums ceded&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,614)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,275)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Claims assumed&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,468&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,812&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;72,594&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Claims ceded&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(422)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Claims-related administrative expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,159&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,024&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:24pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Increase (decrease) in reserves for claims and performance-based arrangements attributable to the Reinsurance Agreement&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,166&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,465&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,293)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:24pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reserves for claims and performance-based arrangements attributable to the Reinsurance Agreement at the beginning of the period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,002&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,243&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:23pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Impact of consolidation on payable for claims and performance-based arrangements attributable to the Reinsurance Agreement&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(502)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reinsurance payments paid (received)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,078&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,039)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,536&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:24pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Payable for claims and performance-based arrangements attributable to the Reinsurance Agreement at the end of the period&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;90&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,002&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:EffectsOfReinsuranceTableTextBlock>
    <us-gaap:AssumedPremiumsWritten
      contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM183OS9mcmFnOmMzNjRjMmIwMjFiMTRiOGFiYzRhOTgzOGJhY2RlZjE5L3RhYmxlOjFlODc4Y2VjZmM0ZjQ1ZDFhNzYyMzdmNWJjM2ZhMjA1L3RhYmxlcmFuZ2U6MWU4NzhjZWNmYzRmNDVkMWE3NjIzN2Y1YmMzZmEyMDVfMi0xLTEtMS0xNzc3NQ_696509af-1a30-4444-8093-f628aab0859c"
      unitRef="usd">23179000</us-gaap:AssumedPremiumsWritten>
    <us-gaap:AssumedPremiumsWritten
      contextRef="i12a6d1161de54547bd29f8efccd4c9b0_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM183OS9mcmFnOmMzNjRjMmIwMjFiMTRiOGFiYzRhOTgzOGJhY2RlZjE5L3RhYmxlOjFlODc4Y2VjZmM0ZjQ1ZDFhNzYyMzdmNWJjM2ZhMjA1L3RhYmxlcmFuZ2U6MWU4NzhjZWNmYzRmNDVkMWE3NjIzN2Y1YmMzZmEyMDVfMi0zLTEtMS0xNzc3NQ_853cbe74-b3cf-421f-a938-165cf0af5b6a"
      unitRef="usd">19130000</us-gaap:AssumedPremiumsWritten>
    <us-gaap:AssumedPremiumsWritten
      contextRef="i3e21049ffc224cacb8134d73c9bb5b38_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM183OS9mcmFnOmMzNjRjMmIwMjFiMTRiOGFiYzRhOTgzOGJhY2RlZjE5L3RhYmxlOjFlODc4Y2VjZmM0ZjQ1ZDFhNzYyMzdmNWJjM2ZhMjA1L3RhYmxlcmFuZ2U6MWU4NzhjZWNmYzRmNDVkMWE3NjIzN2Y1YmMzZmEyMDVfMi01LTEtMS0yNzQ4Ng_682ce907-e17c-42e2-8192-47256a5abeaf"
      unitRef="usd">83325000</us-gaap:AssumedPremiumsWritten>
    <us-gaap:CededPremiumsWritten
      contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM183OS9mcmFnOmMzNjRjMmIwMjFiMTRiOGFiYzRhOTgzOGJhY2RlZjE5L3RhYmxlOjFlODc4Y2VjZmM0ZjQ1ZDFhNzYyMzdmNWJjM2ZhMjA1L3RhYmxlcmFuZ2U6MWU4NzhjZWNmYzRmNDVkMWE3NjIzN2Y1YmMzZmEyMDVfMy0xLTEtMS0xNzc3NQ_11d89676-79dd-4e72-96ee-7147a096fd81"
      unitRef="usd">1614000</us-gaap:CededPremiumsWritten>
    <us-gaap:CededPremiumsWritten
      contextRef="i12a6d1161de54547bd29f8efccd4c9b0_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM183OS9mcmFnOmMzNjRjMmIwMjFiMTRiOGFiYzRhOTgzOGJhY2RlZjE5L3RhYmxlOjFlODc4Y2VjZmM0ZjQ1ZDFhNzYyMzdmNWJjM2ZhMjA1L3RhYmxlcmFuZ2U6MWU4NzhjZWNmYzRmNDVkMWE3NjIzN2Y1YmMzZmEyMDVfMy0zLTEtMS0xNzc3NQ_e0a68515-38d5-41bb-8873-9bdcb48167b5"
      unitRef="usd">3275000</us-gaap:CededPremiumsWritten>
    <us-gaap:CededPremiumsWritten
      contextRef="i3e21049ffc224cacb8134d73c9bb5b38_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM183OS9mcmFnOmMzNjRjMmIwMjFiMTRiOGFiYzRhOTgzOGJhY2RlZjE5L3RhYmxlOjFlODc4Y2VjZmM0ZjQ1ZDFhNzYyMzdmNWJjM2ZhMjA1L3RhYmxlcmFuZ2U6MWU4NzhjZWNmYzRmNDVkMWE3NjIzN2Y1YmMzZmEyMDVfMy01LTEtMS0yNzQ4Ng_5c11fbc5-61ca-47ab-93f7-db0099bb2265"
      unitRef="usd">0</us-gaap:CededPremiumsWritten>
    <us-gaap:ReinsuranceEffectOnClaimsAndBenefitsIncurredAmountAssumed
      contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM183OS9mcmFnOmMzNjRjMmIwMjFiMTRiOGFiYzRhOTgzOGJhY2RlZjE5L3RhYmxlOjFlODc4Y2VjZmM0ZjQ1ZDFhNzYyMzdmNWJjM2ZhMjA1L3RhYmxlcmFuZ2U6MWU4NzhjZWNmYzRmNDVkMWE3NjIzN2Y1YmMzZmEyMDVfNC0xLTEtMS0xNzc3NQ_0033a2c9-141f-453e-a40b-c577cf14a3eb"
      unitRef="usd">20468000</us-gaap:ReinsuranceEffectOnClaimsAndBenefitsIncurredAmountAssumed>
    <us-gaap:ReinsuranceEffectOnClaimsAndBenefitsIncurredAmountAssumed
      contextRef="i12a6d1161de54547bd29f8efccd4c9b0_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM183OS9mcmFnOmMzNjRjMmIwMjFiMTRiOGFiYzRhOTgzOGJhY2RlZjE5L3RhYmxlOjFlODc4Y2VjZmM0ZjQ1ZDFhNzYyMzdmNWJjM2ZhMjA1L3RhYmxlcmFuZ2U6MWU4NzhjZWNmYzRmNDVkMWE3NjIzN2Y1YmMzZmEyMDVfNC0zLTEtMS0xNzc3NQ_59329876-dad4-4a07-80f3-11a2725520ac"
      unitRef="usd">14812000</us-gaap:ReinsuranceEffectOnClaimsAndBenefitsIncurredAmountAssumed>
    <us-gaap:ReinsuranceEffectOnClaimsAndBenefitsIncurredAmountAssumed
      contextRef="i3e21049ffc224cacb8134d73c9bb5b38_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM183OS9mcmFnOmMzNjRjMmIwMjFiMTRiOGFiYzRhOTgzOGJhY2RlZjE5L3RhYmxlOjFlODc4Y2VjZmM0ZjQ1ZDFhNzYyMzdmNWJjM2ZhMjA1L3RhYmxlcmFuZ2U6MWU4NzhjZWNmYzRmNDVkMWE3NjIzN2Y1YmMzZmEyMDVfNC01LTEtMS0yNzQ4Ng_aa6f4f50-6691-4eb6-8d77-0f7dd95c36bc"
      unitRef="usd">72594000</us-gaap:ReinsuranceEffectOnClaimsAndBenefitsIncurredAmountAssumed>
    <us-gaap:ReinsuranceEffectOnClaimsAndBenefitsIncurredAmountCeded
      contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM183OS9mcmFnOmMzNjRjMmIwMjFiMTRiOGFiYzRhOTgzOGJhY2RlZjE5L3RhYmxlOjFlODc4Y2VjZmM0ZjQ1ZDFhNzYyMzdmNWJjM2ZhMjA1L3RhYmxlcmFuZ2U6MWU4NzhjZWNmYzRmNDVkMWE3NjIzN2Y1YmMzZmEyMDVfNS0xLTEtMS0xNzc3NQ_58e4facc-8748-401f-a8cd-c750e6c748c4"
      unitRef="usd">0</us-gaap:ReinsuranceEffectOnClaimsAndBenefitsIncurredAmountCeded>
    <us-gaap:ReinsuranceEffectOnClaimsAndBenefitsIncurredAmountCeded
      contextRef="i12a6d1161de54547bd29f8efccd4c9b0_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM183OS9mcmFnOmMzNjRjMmIwMjFiMTRiOGFiYzRhOTgzOGJhY2RlZjE5L3RhYmxlOjFlODc4Y2VjZmM0ZjQ1ZDFhNzYyMzdmNWJjM2ZhMjA1L3RhYmxlcmFuZ2U6MWU4NzhjZWNmYzRmNDVkMWE3NjIzN2Y1YmMzZmEyMDVfNS0zLTEtMS0xNzc3NQ_4195472a-f8f3-4704-a421-56b8e47a789e"
      unitRef="usd">422000</us-gaap:ReinsuranceEffectOnClaimsAndBenefitsIncurredAmountCeded>
    <us-gaap:ReinsuranceEffectOnClaimsAndBenefitsIncurredAmountCeded
      contextRef="i3e21049ffc224cacb8134d73c9bb5b38_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM183OS9mcmFnOmMzNjRjMmIwMjFiMTRiOGFiYzRhOTgzOGJhY2RlZjE5L3RhYmxlOjFlODc4Y2VjZmM0ZjQ1ZDFhNzYyMzdmNWJjM2ZhMjA1L3RhYmxlcmFuZ2U6MWU4NzhjZWNmYzRmNDVkMWE3NjIzN2Y1YmMzZmEyMDVfNS01LTEtMS0yNzQ4Ng_42250b28-9805-48c9-a8e6-4bd350f860fb"
      unitRef="usd">0</us-gaap:ReinsuranceEffectOnClaimsAndBenefitsIncurredAmountCeded>
    <evh:PolicyholderBenefitsAndClaimsIncurredAssumedExpensesRelatedToClaims
      contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM183OS9mcmFnOmMzNjRjMmIwMjFiMTRiOGFiYzRhOTgzOGJhY2RlZjE5L3RhYmxlOjFlODc4Y2VjZmM0ZjQ1ZDFhNzYyMzdmNWJjM2ZhMjA1L3RhYmxlcmFuZ2U6MWU4NzhjZWNmYzRmNDVkMWE3NjIzN2Y1YmMzZmEyMDVfNi0xLTEtMS0xNzc3NQ_74eacca1-1bbc-4676-94bf-5d840767bbe9"
      unitRef="usd">2159000</evh:PolicyholderBenefitsAndClaimsIncurredAssumedExpensesRelatedToClaims>
    <evh:PolicyholderBenefitsAndClaimsIncurredAssumedExpensesRelatedToClaims
      contextRef="i12a6d1161de54547bd29f8efccd4c9b0_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM183OS9mcmFnOmMzNjRjMmIwMjFiMTRiOGFiYzRhOTgzOGJhY2RlZjE5L3RhYmxlOjFlODc4Y2VjZmM0ZjQ1ZDFhNzYyMzdmNWJjM2ZhMjA1L3RhYmxlcmFuZ2U6MWU4NzhjZWNmYzRmNDVkMWE3NjIzN2Y1YmMzZmEyMDVfNi0zLTEtMS0xNzc3NQ_461ca761-02fa-40ab-a35e-523d7beeb243"
      unitRef="usd">0</evh:PolicyholderBenefitsAndClaimsIncurredAssumedExpensesRelatedToClaims>
    <evh:PolicyholderBenefitsAndClaimsIncurredAssumedExpensesRelatedToClaims
      contextRef="i3e21049ffc224cacb8134d73c9bb5b38_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM183OS9mcmFnOmMzNjRjMmIwMjFiMTRiOGFiYzRhOTgzOGJhY2RlZjE5L3RhYmxlOjFlODc4Y2VjZmM0ZjQ1ZDFhNzYyMzdmNWJjM2ZhMjA1L3RhYmxlcmFuZ2U6MWU4NzhjZWNmYzRmNDVkMWE3NjIzN2Y1YmMzZmEyMDVfNi01LTEtMS0yNzQ4Ng_8d05da94-8e12-4431-9387-fffd1a9f2f5a"
      unitRef="usd">14024000</evh:PolicyholderBenefitsAndClaimsIncurredAssumedExpensesRelatedToClaims>
    <evh:PremiumsWrittenAndPolicyholderBenefitsAndClaimsIncurredNet
      contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM183OS9mcmFnOmMzNjRjMmIwMjFiMTRiOGFiYzRhOTgzOGJhY2RlZjE5L3RhYmxlOjFlODc4Y2VjZmM0ZjQ1ZDFhNzYyMzdmNWJjM2ZhMjA1L3RhYmxlcmFuZ2U6MWU4NzhjZWNmYzRmNDVkMWE3NjIzN2Y1YmMzZmEyMDVfNy0xLTEtMS0xNzc3NQ_ec3432ba-33a0-4301-88e9-c8e11942e677"
      unitRef="usd">2166000</evh:PremiumsWrittenAndPolicyholderBenefitsAndClaimsIncurredNet>
    <evh:PremiumsWrittenAndPolicyholderBenefitsAndClaimsIncurredNet
      contextRef="i12a6d1161de54547bd29f8efccd4c9b0_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM183OS9mcmFnOmMzNjRjMmIwMjFiMTRiOGFiYzRhOTgzOGJhY2RlZjE5L3RhYmxlOjFlODc4Y2VjZmM0ZjQ1ZDFhNzYyMzdmNWJjM2ZhMjA1L3RhYmxlcmFuZ2U6MWU4NzhjZWNmYzRmNDVkMWE3NjIzN2Y1YmMzZmEyMDVfNy0zLTEtMS0xNzc3NQ_22c01a7a-3a4d-479e-a07c-aef6baadcc73"
      unitRef="usd">1465000</evh:PremiumsWrittenAndPolicyholderBenefitsAndClaimsIncurredNet>
    <evh:PremiumsWrittenAndPolicyholderBenefitsAndClaimsIncurredNet
      contextRef="i3e21049ffc224cacb8134d73c9bb5b38_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM183OS9mcmFnOmMzNjRjMmIwMjFiMTRiOGFiYzRhOTgzOGJhY2RlZjE5L3RhYmxlOjFlODc4Y2VjZmM0ZjQ1ZDFhNzYyMzdmNWJjM2ZhMjA1L3RhYmxlcmFuZ2U6MWU4NzhjZWNmYzRmNDVkMWE3NjIzN2Y1YmMzZmEyMDVfNy01LTEtMS0yNzQ4Ng_08a70929-7d2e-45da-931b-b259bd9363b8"
      unitRef="usd">-3293000</evh:PremiumsWrittenAndPolicyholderBenefitsAndClaimsIncurredNet>
    <us-gaap:AssumedLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense
      contextRef="ibc0c0c2b8dc04c5698ca0577a54b2e03_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM183OS9mcmFnOmMzNjRjMmIwMjFiMTRiOGFiYzRhOTgzOGJhY2RlZjE5L3RhYmxlOjFlODc4Y2VjZmM0ZjQ1ZDFhNzYyMzdmNWJjM2ZhMjA1L3RhYmxlcmFuZ2U6MWU4NzhjZWNmYzRmNDVkMWE3NjIzN2Y1YmMzZmEyMDVfOC0xLTEtMS0xNzc3NQ_67189e3c-4bec-450a-a739-73db4735133a"
      unitRef="usd">4002000</us-gaap:AssumedLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense>
    <us-gaap:AssumedLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense
      contextRef="icba6e493923b449aa57c46a563760234_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM183OS9mcmFnOmMzNjRjMmIwMjFiMTRiOGFiYzRhOTgzOGJhY2RlZjE5L3RhYmxlOjFlODc4Y2VjZmM0ZjQ1ZDFhNzYyMzdmNWJjM2ZhMjA1L3RhYmxlcmFuZ2U6MWU4NzhjZWNmYzRmNDVkMWE3NjIzN2Y1YmMzZmEyMDVfOC0zLTEtMS0xNzc3NQ_de1beb8d-927b-43b7-84d3-2a5395a22a0c"
      unitRef="usd">0</us-gaap:AssumedLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense>
    <us-gaap:AssumedLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense
      contextRef="i7130cb432c4b4fe7a260e8a3beeb35d8_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM183OS9mcmFnOmMzNjRjMmIwMjFiMTRiOGFiYzRhOTgzOGJhY2RlZjE5L3RhYmxlOjFlODc4Y2VjZmM0ZjQ1ZDFhNzYyMzdmNWJjM2ZhMjA1L3RhYmxlcmFuZ2U6MWU4NzhjZWNmYzRmNDVkMWE3NjIzN2Y1YmMzZmEyMDVfOC01LTEtMS0yNzQ4Ng_e70ff4d4-9bac-40d1-b29a-5189c000da8f"
      unitRef="usd">1243000</us-gaap:AssumedLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense>
    <evh:AssumedLiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseImpactOfConsolidationOnPayables
      contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM183OS9mcmFnOmMzNjRjMmIwMjFiMTRiOGFiYzRhOTgzOGJhY2RlZjE5L3RhYmxlOjFlODc4Y2VjZmM0ZjQ1ZDFhNzYyMzdmNWJjM2ZhMjA1L3RhYmxlcmFuZ2U6MWU4NzhjZWNmYzRmNDVkMWE3NjIzN2Y1YmMzZmEyMDVfOS0xLTEtMS0xNzc3NQ_376a28b9-f6c8-488c-b7c9-9b42f7f2cea0"
      unitRef="usd">0</evh:AssumedLiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseImpactOfConsolidationOnPayables>
    <evh:AssumedLiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseImpactOfConsolidationOnPayables
      contextRef="i12a6d1161de54547bd29f8efccd4c9b0_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM183OS9mcmFnOmMzNjRjMmIwMjFiMTRiOGFiYzRhOTgzOGJhY2RlZjE5L3RhYmxlOjFlODc4Y2VjZmM0ZjQ1ZDFhNzYyMzdmNWJjM2ZhMjA1L3RhYmxlcmFuZ2U6MWU4NzhjZWNmYzRmNDVkMWE3NjIzN2Y1YmMzZmEyMDVfOS0zLTEtMS0xNzc3NQ_651f7367-4f70-4782-8fcd-4c35d4bfac6d"
      unitRef="usd">502000</evh:AssumedLiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseImpactOfConsolidationOnPayables>
    <evh:AssumedLiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseImpactOfConsolidationOnPayables
      contextRef="i3e21049ffc224cacb8134d73c9bb5b38_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM183OS9mcmFnOmMzNjRjMmIwMjFiMTRiOGFiYzRhOTgzOGJhY2RlZjE5L3RhYmxlOjFlODc4Y2VjZmM0ZjQ1ZDFhNzYyMzdmNWJjM2ZhMjA1L3RhYmxlcmFuZ2U6MWU4NzhjZWNmYzRmNDVkMWE3NjIzN2Y1YmMzZmEyMDVfOS01LTEtMS0yNzQ4Ng_03ab5207-6d00-4e3e-b90d-3d5db0c843ff"
      unitRef="usd">0</evh:AssumedLiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseImpactOfConsolidationOnPayables>
    <us-gaap:PaymentsForReinsurance
      contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM183OS9mcmFnOmMzNjRjMmIwMjFiMTRiOGFiYzRhOTgzOGJhY2RlZjE5L3RhYmxlOjFlODc4Y2VjZmM0ZjQ1ZDFhNzYyMzdmNWJjM2ZhMjA1L3RhYmxlcmFuZ2U6MWU4NzhjZWNmYzRmNDVkMWE3NjIzN2Y1YmMzZmEyMDVfMTAtMS0xLTEtMTc3NzU_104bfd1c-dab6-4247-92dd-939435fc7f81"
      unitRef="usd">6078000</us-gaap:PaymentsForReinsurance>
    <evh:ProceedsFromReinsurance
      contextRef="i12a6d1161de54547bd29f8efccd4c9b0_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM183OS9mcmFnOmMzNjRjMmIwMjFiMTRiOGFiYzRhOTgzOGJhY2RlZjE5L3RhYmxlOjFlODc4Y2VjZmM0ZjQ1ZDFhNzYyMzdmNWJjM2ZhMjA1L3RhYmxlcmFuZ2U6MWU4NzhjZWNmYzRmNDVkMWE3NjIzN2Y1YmMzZmEyMDVfMTAtMy0xLTEtMTc3NzU_e705c1f0-8296-4bb3-ab3c-67991c9e9d16"
      unitRef="usd">3039000</evh:ProceedsFromReinsurance>
    <us-gaap:PaymentsForReinsurance
      contextRef="i3e21049ffc224cacb8134d73c9bb5b38_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM183OS9mcmFnOmMzNjRjMmIwMjFiMTRiOGFiYzRhOTgzOGJhY2RlZjE5L3RhYmxlOjFlODc4Y2VjZmM0ZjQ1ZDFhNzYyMzdmNWJjM2ZhMjA1L3RhYmxlcmFuZ2U6MWU4NzhjZWNmYzRmNDVkMWE3NjIzN2Y1YmMzZmEyMDVfMTAtNS0xLTEtMjc0ODY_b2f8ebcc-4586-41e5-9a34-27b568249ba6"
      unitRef="usd">4536000</us-gaap:PaymentsForReinsurance>
    <us-gaap:AssumedLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense
      contextRef="i8daff60be410426d8f7bd49343c1ec0c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM183OS9mcmFnOmMzNjRjMmIwMjFiMTRiOGFiYzRhOTgzOGJhY2RlZjE5L3RhYmxlOjFlODc4Y2VjZmM0ZjQ1ZDFhNzYyMzdmNWJjM2ZhMjA1L3RhYmxlcmFuZ2U6MWU4NzhjZWNmYzRmNDVkMWE3NjIzN2Y1YmMzZmEyMDVfMTEtMS0xLTEtMTc3NzU_643180ef-46ba-42f1-b215-ee3e4d1d819c"
      unitRef="usd">90000</us-gaap:AssumedLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense>
    <us-gaap:AssumedLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense
      contextRef="ibc0c0c2b8dc04c5698ca0577a54b2e03_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM183OS9mcmFnOmMzNjRjMmIwMjFiMTRiOGFiYzRhOTgzOGJhY2RlZjE5L3RhYmxlOjFlODc4Y2VjZmM0ZjQ1ZDFhNzYyMzdmNWJjM2ZhMjA1L3RhYmxlcmFuZ2U6MWU4NzhjZWNmYzRmNDVkMWE3NjIzN2Y1YmMzZmEyMDVfMTEtMy0xLTEtMTc3NzU_5d9edc6f-f396-4c4e-917f-a70f10bbe98f"
      unitRef="usd">4002000</us-gaap:AssumedLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense>
    <us-gaap:AssumedLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense
      contextRef="icba6e493923b449aa57c46a563760234_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM183OS9mcmFnOmMzNjRjMmIwMjFiMTRiOGFiYzRhOTgzOGJhY2RlZjE5L3RhYmxlOjFlODc4Y2VjZmM0ZjQ1ZDFhNzYyMzdmNWJjM2ZhMjA1L3RhYmxlcmFuZ2U6MWU4NzhjZWNmYzRmNDVkMWE3NjIzN2Y1YmMzZmEyMDVfMTEtNS0xLTEtMjc0ODY_bd73489c-da58-457b-86fa-25cd57840396"
      unitRef="usd">0</us-gaap:AssumedLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense>
    <evh:TaxReceivablesAgreementPercentofTaxSavingstobePaid
      contextRef="i8daff60be410426d8f7bd49343c1ec0c_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM183OS9mcmFnOmMzNjRjMmIwMjFiMTRiOGFiYzRhOTgzOGJhY2RlZjE5L3RleHRyZWdpb246YzM2NGMyYjAyMWIxNGI4YWJjNGE5ODM4YmFjZGVmMTlfNjA1NA_acab48b8-ee43-4021-991b-a48ad2179509"
      unitRef="number">0.85</evh:TaxReceivablesAgreementPercentofTaxSavingstobePaid>
    <evh:CashFDICInsuredAmountPercentage
      contextRef="i8daff60be410426d8f7bd49343c1ec0c_I20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM183OS9mcmFnOmMzNjRjMmIwMjFiMTRiOGFiYzRhOTgzOGJhY2RlZjE5L3RleHRyZWdpb246YzM2NGMyYjAyMWIxNGI4YWJjNGE5ODM4YmFjZGVmMTlfMTAzMTE_01d024d7-4f0c-4127-94d6-cea05095bde4"
      unitRef="number">0.994</evh:CashFDICInsuredAmountPercentage>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i8daff60be410426d8f7bd49343c1ec0c_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM183OS9mcmFnOmMzNjRjMmIwMjFiMTRiOGFiYzRhOTgzOGJhY2RlZjE5L3RleHRyZWdpb246YzM2NGMyYjAyMWIxNGI4YWJjNGE5ODM4YmFjZGVmMTlfMTAzMjE_32b3b936-4b91-4cd8-9126-709a77f2af18"
      unitRef="usd">354900000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <evh:CashHeldInInternationalBanksPercentage
      contextRef="i8daff60be410426d8f7bd49343c1ec0c_I20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM183OS9mcmFnOmMzNjRjMmIwMjFiMTRiOGFiYzRhOTgzOGJhY2RlZjE5L3RleHRyZWdpb246YzM2NGMyYjAyMWIxNGI4YWJjNGE5ODM4YmFjZGVmMTlfMTA0NzI_871d261f-6da6-46c6-b5c0-20638639ab2e"
      unitRef="number">0.006</evh:CashHeldInInternationalBanksPercentage>
    <us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock
      contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM183OS9mcmFnOmMzNjRjMmIwMjFiMTRiOGFiYzRhOTgzOGJhY2RlZjE5L3RleHRyZWdpb246YzM2NGMyYjAyMWIxNGI4YWJjNGE5ODM4YmFjZGVmMTlfMTIwNTc_b6fed238-72b2-44db-95f2-c5c774283b66">The following table summarizes the partners who represented at least 10.0% of our consolidated trade accounts receivable as of December&#160;31, 2021 and December&#160;31, 2020:&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:426.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:55.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:48.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;As of December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cook County Health and Hospitals System&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;61.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Florida Blue Medicare, Inc. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;N/A&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Molina Healthcare&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:115%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%;padding-left:11.94pt"&gt;Customer added during the year ended December 31, 2021. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes those partners who represented at least 10.0% of our consolidated revenue for the years ended December 31, 2021, 2020 and 2019:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:380.50pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:48.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:48.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:48.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;For the Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021 &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020 &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019 &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cook County Health and Hospitals Systems&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28.0%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;New Mexico Health Connections&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Florida Blue Medicare, Inc. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;N/A&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;N/A&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Passport &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt"&gt;The denominator excludes $44.8&#160;million, $117.4&#160;million and $171.7&#160;million of True Health premium revenue reclassified to discontinued operations for the years ended December 31, 2021, 2020 and 2019, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt"&gt;Customer added during the year ended December 31, 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt"&gt;Represents revenues from EVH Passport/UHC through the Molina Closing. Subsequent to the Molina Closing on September 1, 2020, the Company has not received any material revenue from EVH Passport. However, as part of the Molina Closing, we entered into a new contract with Molina on similar terms to our prior services contract with EVH Passport through December 31, 2020 which accounted for approximately 9.7% of our consolidated revenues for the year ended December 31, 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;* &#160;&#160;&#160;&#160;Represents less than 10.0% of the respective balance&lt;/span&gt;&lt;/div&gt;</us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="id08281884be844d0a19d848a335a5a80_D20210101-20210331"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM183OS9mcmFnOmMzNjRjMmIwMjFiMTRiOGFiYzRhOTgzOGJhY2RlZjE5L3RhYmxlOmQ1NjgwNDhhZjc4ODQ2YmJiOTYwZmUxMTM4Zjk4YzBlL3RhYmxlcmFuZ2U6ZDU2ODA0OGFmNzg4NDZiYmI5NjBmZTExMzhmOThjMGVfMS0zLTEtMS0xNzc3NQ_7d867341-d6a8-4592-ad94-ef0314fbfdd4"
      unitRef="number">0.615</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="ie20505dffcf4431286b007c0fcf4ab14_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM183OS9mcmFnOmMzNjRjMmIwMjFiMTRiOGFiYzRhOTgzOGJhY2RlZjE5L3RhYmxlOmQ1NjgwNDhhZjc4ODQ2YmJiOTYwZmUxMTM4Zjk4YzBlL3RhYmxlcmFuZ2U6ZDU2ODA0OGFmNzg4NDZiYmI5NjBmZTExMzhmOThjMGVfMi0xLTEtMS0xNzc3NQ_9ede5f1a-7305-4202-be73-a14b36109107"
      unitRef="number">0.464</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="ib97fa9c20ea54ca1841b4c9b1f4ea27c_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM183OS9mcmFnOmMzNjRjMmIwMjFiMTRiOGFiYzRhOTgzOGJhY2RlZjE5L3RhYmxlOmQ1NjgwNDhhZjc4ODQ2YmJiOTYwZmUxMTM4Zjk4YzBlL3RhYmxlcmFuZ2U6ZDU2ODA0OGFmNzg4NDZiYmI5NjBmZTExMzhmOThjMGVfNC0xLTEtMS0yOTk1Ng_866ecd73-955a-4ed4-b284-8b3143ea7ec2"
      unitRef="number">0.104</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i9f2a3a14183a4b9c91ebd0c42eb5510d_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM183OS9mcmFnOmMzNjRjMmIwMjFiMTRiOGFiYzRhOTgzOGJhY2RlZjE5L3RhYmxlOjMzMWFhOTMxYzNjNjQzNzA5Yzg0ODNlNjM5NDVmMDg2L3RhYmxlcmFuZ2U6MzMxYWE5MzFjM2M2NDM3MDljODQ4M2U2Mzk0NWYwODZfMi01LTEtMS0xNzc3NQ_37a37917-fc7e-4194-9ad7-f7186656121b"
      unitRef="number">0.280</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i4c5eb31ee1104de8a5635eca675175eb_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM183OS9mcmFnOmMzNjRjMmIwMjFiMTRiOGFiYzRhOTgzOGJhY2RlZjE5L3RhYmxlOjMzMWFhOTMxYzNjNjQzNzA5Yzg0ODNlNjM5NDVmMDg2L3RhYmxlcmFuZ2U6MzMxYWE5MzFjM2M2NDM3MDljODQ4M2U2Mzk0NWYwODZfMi03LTEtMS0xNzc3NQ_a0e8a927-11e6-4f74-a46c-cdb4c91bcebd"
      unitRef="number">0.223</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="id0f333276f5e44b698dd6e5f92a87479_D20190101-20191231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM183OS9mcmFnOmMzNjRjMmIwMjFiMTRiOGFiYzRhOTgzOGJhY2RlZjE5L3RhYmxlOjMzMWFhOTMxYzNjNjQzNzA5Yzg0ODNlNjM5NDVmMDg2L3RhYmxlcmFuZ2U6MzMxYWE5MzFjM2M2NDM3MDljODQ4M2U2Mzk0NWYwODZfMi01LTEtMS0yMDQ5NA_8573402c-b372-41c4-94f3-a25707dc898f"
      unitRef="number">0.116</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="iadb6308217bb4ce7bab0e77352bbe86e_D20190101-20191231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM183OS9mcmFnOmMzNjRjMmIwMjFiMTRiOGFiYzRhOTgzOGJhY2RlZjE5L3RhYmxlOjMzMWFhOTMxYzNjNjQzNzA5Yzg0ODNlNjM5NDVmMDg2L3RhYmxlcmFuZ2U6MzMxYWE5MzFjM2M2NDM3MDljODQ4M2U2Mzk0NWYwODZfMy01LTEtMS0yNTcxOQ_e394e4d9-eef2-4885-ad2c-8b065c0a6153"
      unitRef="number">0.134</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="idd6b43aa37f24ee4a2d07a9f35c9f6ce_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM183OS9mcmFnOmMzNjRjMmIwMjFiMTRiOGFiYzRhOTgzOGJhY2RlZjE5L3RhYmxlOjMzMWFhOTMxYzNjNjQzNzA5Yzg0ODNlNjM5NDVmMDg2L3RhYmxlcmFuZ2U6MzMxYWE5MzFjM2M2NDM3MDljODQ4M2U2Mzk0NWYwODZfMy01LTEtMS0xNzc3NQ_79fef8a4-f8ad-40b4-8e75-1535f5c9816e"
      unitRef="number">0.141</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i244051775e1e4019948fa2ba32e4ab27_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM183OS9mcmFnOmMzNjRjMmIwMjFiMTRiOGFiYzRhOTgzOGJhY2RlZjE5L3RhYmxlOjMzMWFhOTMxYzNjNjQzNzA5Yzg0ODNlNjM5NDVmMDg2L3RhYmxlcmFuZ2U6MzMxYWE5MzFjM2M2NDM3MDljODQ4M2U2Mzk0NWYwODZfNC03LTEtMS0xNzc3NQ_96ca31d0-f755-486c-ae9a-bfa441952daf"
      unitRef="number">0.190</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="id221ab9a660d422d8841139a66fe1f9d_D20190101-20191231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM183OS9mcmFnOmMzNjRjMmIwMjFiMTRiOGFiYzRhOTgzOGJhY2RlZjE5L3RhYmxlOjMzMWFhOTMxYzNjNjQzNzA5Yzg0ODNlNjM5NDVmMDg2L3RhYmxlcmFuZ2U6MzMxYWE5MzFjM2M2NDM3MDljODQ4M2U2Mzk0NWYwODZfNC01LTEtMS0yMDUwMw_75a28071-d3c7-472f-80e3-67bf6a68fa49"
      unitRef="number">0.230</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue
      contextRef="i8a931688112a4cc6bf3323cb239d7e4d_D20201001-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM183OS9mcmFnOmMzNjRjMmIwMjFiMTRiOGFiYzRhOTgzOGJhY2RlZjE5L3RleHRyZWdpb246YzM2NGMyYjAyMWIxNGI4YWJjNGE5ODM4YmFjZGVmMTlfMTE1ODE_c9ebe0ef-5715-40cc-9417-961f2416184c"
      unitRef="usd">44800000</us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue
      contextRef="i6eca3f13863a45c481c07e49e9f434fe_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM183OS9mcmFnOmMzNjRjMmIwMjFiMTRiOGFiYzRhOTgzOGJhY2RlZjE5L3RleHRyZWdpb246YzM2NGMyYjAyMWIxNGI4YWJjNGE5ODM4YmFjZGVmMTlfMTE1ODg_dc2e6282-e1b9-4600-b116-a6d30246047b"
      unitRef="usd">117400000</us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue
      contextRef="iae64c322a5eb4929bc01485807d92b3a_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM183OS9mcmFnOmMzNjRjMmIwMjFiMTRiOGFiYzRhOTgzOGJhY2RlZjE5L3RleHRyZWdpb246YzM2NGMyYjAyMWIxNGI4YWJjNGE5ODM4YmFjZGVmMTlfMjE5OTAyMzI2ODY4Ng_797c55bf-c611-456b-bb17-5b9e16d41414"
      unitRef="usd">171700000</us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i8404c3b22073440a9f092260f57c4d0a_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM183OS9mcmFnOmMzNjRjMmIwMjFiMTRiOGFiYzRhOTgzOGJhY2RlZjE5L3RleHRyZWdpb246YzM2NGMyYjAyMWIxNGI4YWJjNGE5ODM4YmFjZGVmMTlfMzI5ODUzNDkwODEzNw_2a1e4bae-38d7-47e8-a110-9e993f5da392"
      unitRef="number">0.097</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:LesseeOperatingLeasesTextBlock
      contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM184Mi9mcmFnOjBhMDRkZjMzNTJkOTRkOTc5NzU3NGUwYjM5NzQ1MDgyL3RleHRyZWdpb246MGEwNGRmMzM1MmQ5NGQ5Nzk3NTc0ZTBiMzk3NDUwODJfMzI3Mg_a286cfff-544e-4df6-8094-27ffe929f4f2">Leases&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company enters into various office space, data center, and equipment lease agreements in conducting its normal business operations. At the inception of any contract, the Company evaluates the agreement to determine whether the contract contains a lease. If the contract contains a lease, the Company then evaluates the term and whether the lease is an operating or finance lease. Most leases include one or more options to renew or may have a termination option. The Company determines whether these options are reasonably certain to be exercised or not at the inception of the lease. In addition, some leases contain escalation clauses.  The rent expense is recognized on a straight-line basis in the consolidated statements of operations and comprehensive income (loss) over the term of the lease. Leases with an initial term of 12 months or less are not recorded on our consolidated balance sheets.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As most of our leases do not provide an implicit rate, we use our incremental borrowing rate based on the information available at commencement date in determining the present value of lease payments. We use the implicit rate when readily determinable. Further, the Company treats all lease and non-lease components as a single combined lease component for all classes of underlying assets. The &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Company also enters into sublease agreements for some of its leased office space. Immaterial rental income attributable to subleases is offset against rent expense over the terms of the respective leases. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company leases office space and computer and other equipment under operating lease agreements expiring at various dates through 2031. Under the lease agreements, in addition to base rent, the Company is generally responsible for operating and maintenance costs and related fees. Several of these agreements include tenant improvement allowances, rent holidays or rent escalation clauses. When such items are included in a lease agreement, we record a deferred rent asset or liability on our consolidated balance sheets equal to the difference between rent expense and future minimum lease payments due. The rent expense related to these items is recognized on a straight-line basis over the terms of the leases. The Company&#x2019;s primary office location is in Arlington, Virginia, which has served as its corporate headquarters since 2013. The Arlington, Virginia office lease expires in January 2032. Certain leases acquired as part of the Valence Health transaction included existing sublease agreements for office locations in Chicago, Illinois. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with various lease agreements, the Company is required to maintain $3.8 million and $3.5&#160;million in letters of credit as of December&#160;31, 2021 and December&#160;31, 2020. As of December&#160;31, 2021 and 2020, the Company held $3.8&#160;million and $3.5 million in restricted cash and restricted investments on the consolidated balance sheet as collateral for the letters of credit, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes our primary office leases as of December&#160;31, 2021 (in thousands, other than term):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:539.25pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:237.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:94.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:94.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:94.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr style="height:24pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Location&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Lease Termination Term (in years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Future Minimum Lease Commitments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Letter of Credit Amount Required&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Arlington, VA&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35,581&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,579&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Riverside, IL &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41,408&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;232&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Edison, NJ&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,180&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;222&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Pune, India&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.7&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,382&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Brea, CA&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.4&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;462&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the components of our lease expense (in thousands): &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:64.316%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.011%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.011%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.355%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.013%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;For the Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease cost&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,991&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,848&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,903&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amortization of right-of-use assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;299&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;598&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Variable lease cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,036&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,097&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,177&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total lease cost&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,027&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,247&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,704&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Maturity of lease liabilities (in thousands) as of December&#160;31, 2021, is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:87.788%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.012%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Operating lease expense&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,916&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,258&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,968&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,653&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,988&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39,972&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;85,755&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,964&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Present value of lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;64,791&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our weighted-average discount rate and our weighted remaining lease terms (in years) are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:64.455%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.011%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.355%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.011%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.355%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.013%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average discount rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.38&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.44&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average remaining lease term&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.8&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.4&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.9&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LesseeOperatingLeasesTextBlock>
    <us-gaap:LettersOfCreditOutstandingAmount
      contextRef="i1a21d5a158854825a4cb4f9e1b2d4103_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM184Mi9mcmFnOjBhMDRkZjMzNTJkOTRkOTc5NzU3NGUwYjM5NzQ1MDgyL3RleHRyZWdpb246MGEwNGRmMzM1MmQ5NGQ5Nzk3NTc0ZTBiMzk3NDUwODJfMjY2Mw_c25b4584-0a70-4818-9539-c1f3db8c8804"
      unitRef="usd">3800000</us-gaap:LettersOfCreditOutstandingAmount>
    <us-gaap:LettersOfCreditOutstandingAmount
      contextRef="ic979e1a0ada24d7da7646f2ccae478c7_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM184Mi9mcmFnOjBhMDRkZjMzNTJkOTRkOTc5NzU3NGUwYjM5NzQ1MDgyL3RleHRyZWdpb246MGEwNGRmMzM1MmQ5NGQ5Nzk3NTc0ZTBiMzk3NDUwODJfMjY3MA_50b9f8df-8c9a-4e14-b768-548ffccb9ef2"
      unitRef="usd">3500000</us-gaap:LettersOfCreditOutstandingAmount>
    <us-gaap:RestrictedCashAndCashEquivalents
      contextRef="i1a21d5a158854825a4cb4f9e1b2d4103_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM184Mi9mcmFnOjBhMDRkZjMzNTJkOTRkOTc5NzU3NGUwYjM5NzQ1MDgyL3RleHRyZWdpb246MGEwNGRmMzM1MmQ5NGQ5Nzk3NTc0ZTBiMzk3NDUwODJfMjc0NQ_fb44eaa7-d476-4652-a98f-408f03892b1f"
      unitRef="usd">3800000</us-gaap:RestrictedCashAndCashEquivalents>
    <us-gaap:RestrictedCashAndCashEquivalents
      contextRef="ic979e1a0ada24d7da7646f2ccae478c7_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM184Mi9mcmFnOjBhMDRkZjMzNTJkOTRkOTc5NzU3NGUwYjM5NzQ1MDgyL3RleHRyZWdpb246MGEwNGRmMzM1MmQ5NGQ5Nzk3NTc0ZTBiMzk3NDUwODJfMjc1Mg_ad1af4fd-e6a5-4163-be33-2342d6c823d9"
      unitRef="usd">3500000</us-gaap:RestrictedCashAndCashEquivalents>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock
      contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM184Mi9mcmFnOjBhMDRkZjMzNTJkOTRkOTc5NzU3NGUwYjM5NzQ1MDgyL3RleHRyZWdpb246MGEwNGRmMzM1MmQ5NGQ5Nzk3NTc0ZTBiMzk3NDUwODJfMzI3Mw_ce48048a-0947-4117-97d5-2ce55bbee8c4">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes our primary office leases as of December&#160;31, 2021 (in thousands, other than term):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:539.25pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:237.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:94.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:94.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:94.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr style="height:24pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Location&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Lease Termination Term (in years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Future Minimum Lease Commitments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Letter of Credit Amount Required&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Arlington, VA&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35,581&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,579&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Riverside, IL &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41,408&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;232&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Edison, NJ&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,180&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;222&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Pune, India&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.7&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,382&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Brea, CA&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.4&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;462&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Maturity of lease liabilities (in thousands) as of December&#160;31, 2021, is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:87.788%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.012%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Operating lease expense&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,916&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,258&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,968&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,653&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,988&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39,972&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;85,755&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,964&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Present value of lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;64,791&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseTermOfContract
      contextRef="ie94dd6f6dead455b8b597165bc5ec9ff_I20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM184Mi9mcmFnOjBhMDRkZjMzNTJkOTRkOTc5NzU3NGUwYjM5NzQ1MDgyL3RhYmxlOmQ3MzQyODVlMzRjNTQ2NzVhNDdlMDRiOTJiYzQxZjI2L3RhYmxlcmFuZ2U6ZDczNDI4NWUzNGM1NDY3NWE0N2UwNGI5MmJjNDFmMjZfMS0yLTEtMS0xNzc3NQ_fa8efcfe-e405-44ec-8382-80469e321cbb">P10Y1M6D</us-gaap:LesseeOperatingLeaseTermOfContract>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="ie94dd6f6dead455b8b597165bc5ec9ff_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM184Mi9mcmFnOjBhMDRkZjMzNTJkOTRkOTc5NzU3NGUwYjM5NzQ1MDgyL3RhYmxlOmQ3MzQyODVlMzRjNTQ2NzVhNDdlMDRiOTJiYzQxZjI2L3RhYmxlcmFuZ2U6ZDczNDI4NWUzNGM1NDY3NWE0N2UwNGI5MmJjNDFmMjZfMS00LTEtMS0xNzc3NQ_96823663-239f-48b7-9a10-cebb52f4bb81"
      unitRef="usd">35581000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LettersOfCreditOutstandingAmount
      contextRef="ie94dd6f6dead455b8b597165bc5ec9ff_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM184Mi9mcmFnOjBhMDRkZjMzNTJkOTRkOTc5NzU3NGUwYjM5NzQ1MDgyL3RhYmxlOmQ3MzQyODVlMzRjNTQ2NzVhNDdlMDRiOTJiYzQxZjI2L3RhYmxlcmFuZ2U6ZDczNDI4NWUzNGM1NDY3NWE0N2UwNGI5MmJjNDFmMjZfMS02LTEtMS0xNzc3NQ_2f62bfb8-e0a8-4308-8e90-9de48a34e1a4"
      unitRef="usd">1579000</us-gaap:LettersOfCreditOutstandingAmount>
    <us-gaap:LesseeOperatingLeaseTermOfContract
      contextRef="i9a6c9ce1bc6a4595b939e65f2d38f28e_I20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM184Mi9mcmFnOjBhMDRkZjMzNTJkOTRkOTc5NzU3NGUwYjM5NzQ1MDgyL3RhYmxlOmQ3MzQyODVlMzRjNTQ2NzVhNDdlMDRiOTJiYzQxZjI2L3RhYmxlcmFuZ2U6ZDczNDI4NWUzNGM1NDY3NWE0N2UwNGI5MmJjNDFmMjZfMi0yLTEtMS0xNzc3NQ_780b03ce-aab2-4372-a60a-1fa1d59d8023">P9Y3M18D</us-gaap:LesseeOperatingLeaseTermOfContract>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="i9a6c9ce1bc6a4595b939e65f2d38f28e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM184Mi9mcmFnOjBhMDRkZjMzNTJkOTRkOTc5NzU3NGUwYjM5NzQ1MDgyL3RhYmxlOmQ3MzQyODVlMzRjNTQ2NzVhNDdlMDRiOTJiYzQxZjI2L3RhYmxlcmFuZ2U6ZDczNDI4NWUzNGM1NDY3NWE0N2UwNGI5MmJjNDFmMjZfMi00LTEtMS0xNzc3NQ_777423fa-d718-454d-aecf-3569e55582e5"
      unitRef="usd">41408000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LettersOfCreditOutstandingAmount
      contextRef="i9a6c9ce1bc6a4595b939e65f2d38f28e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM184Mi9mcmFnOjBhMDRkZjMzNTJkOTRkOTc5NzU3NGUwYjM5NzQ1MDgyL3RhYmxlOmQ3MzQyODVlMzRjNTQ2NzVhNDdlMDRiOTJiYzQxZjI2L3RhYmxlcmFuZ2U6ZDczNDI4NWUzNGM1NDY3NWE0N2UwNGI5MmJjNDFmMjZfMi02LTEtMS0xNzc3NQ_948649c7-4888-4e1d-b330-8b33eafff31d"
      unitRef="usd">232000</us-gaap:LettersOfCreditOutstandingAmount>
    <us-gaap:LesseeOperatingLeaseTermOfContract
      contextRef="i16fcb9584de04a43bbe15a5b9cef1417_I20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM184Mi9mcmFnOjBhMDRkZjMzNTJkOTRkOTc5NzU3NGUwYjM5NzQ1MDgyL3RhYmxlOmQ3MzQyODVlMzRjNTQ2NzVhNDdlMDRiOTJiYzQxZjI2L3RhYmxlcmFuZ2U6ZDczNDI4NWUzNGM1NDY3NWE0N2UwNGI5MmJjNDFmMjZfMy0yLTEtMS0yNjI0Mg_9cb0cf31-4fad-4eeb-9d17-0571c0f056d7">P4Y3M18D</us-gaap:LesseeOperatingLeaseTermOfContract>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="i16fcb9584de04a43bbe15a5b9cef1417_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM184Mi9mcmFnOjBhMDRkZjMzNTJkOTRkOTc5NzU3NGUwYjM5NzQ1MDgyL3RhYmxlOmQ3MzQyODVlMzRjNTQ2NzVhNDdlMDRiOTJiYzQxZjI2L3RhYmxlcmFuZ2U6ZDczNDI4NWUzNGM1NDY3NWE0N2UwNGI5MmJjNDFmMjZfMy00LTEtMS0yNjI1MQ_80f154c7-1b3b-4251-aa93-4d4fffbd97a7"
      unitRef="usd">2180000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LettersOfCreditOutstandingAmount
      contextRef="i16fcb9584de04a43bbe15a5b9cef1417_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM184Mi9mcmFnOjBhMDRkZjMzNTJkOTRkOTc5NzU3NGUwYjM5NzQ1MDgyL3RhYmxlOmQ3MzQyODVlMzRjNTQ2NzVhNDdlMDRiOTJiYzQxZjI2L3RhYmxlcmFuZ2U6ZDczNDI4NWUzNGM1NDY3NWE0N2UwNGI5MmJjNDFmMjZfMy02LTEtMS0yNjI1MQ_906c356a-7ed5-4724-939c-756d7ee05ab1"
      unitRef="usd">222000</us-gaap:LettersOfCreditOutstandingAmount>
    <us-gaap:LesseeOperatingLeaseTermOfContract
      contextRef="ic6005d9a695a4ec39b064ccaceff712d_I20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM184Mi9mcmFnOjBhMDRkZjMzNTJkOTRkOTc5NzU3NGUwYjM5NzQ1MDgyL3RhYmxlOmQ3MzQyODVlMzRjNTQ2NzVhNDdlMDRiOTJiYzQxZjI2L3RhYmxlcmFuZ2U6ZDczNDI4NWUzNGM1NDY3NWE0N2UwNGI5MmJjNDFmMjZfMy0yLTEtMS0xNzc3NQ_473432f6-4fa0-447c-9d96-3dfac9feea44">P1Y8M12D</us-gaap:LesseeOperatingLeaseTermOfContract>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="ic6005d9a695a4ec39b064ccaceff712d_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM184Mi9mcmFnOjBhMDRkZjMzNTJkOTRkOTc5NzU3NGUwYjM5NzQ1MDgyL3RhYmxlOmQ3MzQyODVlMzRjNTQ2NzVhNDdlMDRiOTJiYzQxZjI2L3RhYmxlcmFuZ2U6ZDczNDI4NWUzNGM1NDY3NWE0N2UwNGI5MmJjNDFmMjZfMy00LTEtMS0xNzc3NQ_bfa6cbcb-efd1-4d0f-89a0-a1dcb55cd4cc"
      unitRef="usd">1382000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LettersOfCreditOutstandingAmount
      contextRef="ic6005d9a695a4ec39b064ccaceff712d_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM184Mi9mcmFnOjBhMDRkZjMzNTJkOTRkOTc5NzU3NGUwYjM5NzQ1MDgyL3RhYmxlOmQ3MzQyODVlMzRjNTQ2NzVhNDdlMDRiOTJiYzQxZjI2L3RhYmxlcmFuZ2U6ZDczNDI4NWUzNGM1NDY3NWE0N2UwNGI5MmJjNDFmMjZfMy02LTEtMS0xNzc3NQ_61b74cd8-064d-4a16-86e2-f03b1cb15094"
      unitRef="usd">0</us-gaap:LettersOfCreditOutstandingAmount>
    <us-gaap:LesseeOperatingLeaseTermOfContract
      contextRef="ic293662ed0144555ad060c822d4249ce_I20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM184Mi9mcmFnOjBhMDRkZjMzNTJkOTRkOTc5NzU3NGUwYjM5NzQ1MDgyL3RhYmxlOmQ3MzQyODVlMzRjNTQ2NzVhNDdlMDRiOTJiYzQxZjI2L3RhYmxlcmFuZ2U6ZDczNDI4NWUzNGM1NDY3NWE0N2UwNGI5MmJjNDFmMjZfNC0yLTEtMS0xNzc3NQ_96fc9dda-4af0-407d-94bb-94346453cafc">P0Y4M24D</us-gaap:LesseeOperatingLeaseTermOfContract>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="ic293662ed0144555ad060c822d4249ce_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM184Mi9mcmFnOjBhMDRkZjMzNTJkOTRkOTc5NzU3NGUwYjM5NzQ1MDgyL3RhYmxlOmQ3MzQyODVlMzRjNTQ2NzVhNDdlMDRiOTJiYzQxZjI2L3RhYmxlcmFuZ2U6ZDczNDI4NWUzNGM1NDY3NWE0N2UwNGI5MmJjNDFmMjZfNC00LTEtMS0xNzc3NQ_3dbe10da-0777-44ab-b27a-f968f3ad3fcf"
      unitRef="usd">462000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LettersOfCreditOutstandingAmount
      contextRef="ic293662ed0144555ad060c822d4249ce_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM184Mi9mcmFnOjBhMDRkZjMzNTJkOTRkOTc5NzU3NGUwYjM5NzQ1MDgyL3RhYmxlOmQ3MzQyODVlMzRjNTQ2NzVhNDdlMDRiOTJiYzQxZjI2L3RhYmxlcmFuZ2U6ZDczNDI4NWUzNGM1NDY3NWE0N2UwNGI5MmJjNDFmMjZfNC02LTEtMS0xNzc3NQ_1ed15a55-4e73-4e37-b93a-0ed280d3d3d4"
      unitRef="usd">0</us-gaap:LettersOfCreditOutstandingAmount>
    <us-gaap:LeaseCostTableTextBlock
      contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM184Mi9mcmFnOjBhMDRkZjMzNTJkOTRkOTc5NzU3NGUwYjM5NzQ1MDgyL3RleHRyZWdpb246MGEwNGRmMzM1MmQ5NGQ5Nzk3NTc0ZTBiMzk3NDUwODJfMzI3NA_855c6695-6fe2-40bf-81de-ff86f25636ad">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the components of our lease expense (in thousands): &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:64.316%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.011%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.011%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.355%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.013%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;For the Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease cost&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,991&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,848&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,903&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amortization of right-of-use assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;299&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;598&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Variable lease cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,036&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,097&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,177&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total lease cost&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,027&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,247&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,704&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our weighted-average discount rate and our weighted remaining lease terms (in years) are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:64.455%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.011%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.355%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.011%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.355%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.013%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average discount rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.38&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.44&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average remaining lease term&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.8&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.4&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.9&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LeaseCostTableTextBlock>
    <us-gaap:OperatingLeaseCost
      contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM184Mi9mcmFnOjBhMDRkZjMzNTJkOTRkOTc5NzU3NGUwYjM5NzQ1MDgyL3RhYmxlOjQ5ZjI5ZGFjNzFmZTQ2ZGE5OWQyNzhlMGFiMjZkYmYxL3RhYmxlcmFuZ2U6NDlmMjlkYWM3MWZlNDZkYTk5ZDI3OGUwYWIyNmRiZjFfMi01LTEtMS0xNzc3NQ_d59388ed-b515-47fa-be6e-74fbee27e213"
      unitRef="usd">12991000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="i12a6d1161de54547bd29f8efccd4c9b0_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM184Mi9mcmFnOjBhMDRkZjMzNTJkOTRkOTc5NzU3NGUwYjM5NzQ1MDgyL3RhYmxlOjQ5ZjI5ZGFjNzFmZTQ2ZGE5OWQyNzhlMGFiMjZkYmYxL3RhYmxlcmFuZ2U6NDlmMjlkYWM3MWZlNDZkYTk5ZDI3OGUwYWIyNmRiZjFfMi03LTEtMS0xNzc3NQ_640f2bce-9718-4b9a-86e8-59c5d6b4b806"
      unitRef="usd">15848000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="i3e21049ffc224cacb8134d73c9bb5b38_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM184Mi9mcmFnOjBhMDRkZjMzNTJkOTRkOTc5NzU3NGUwYjM5NzQ1MDgyL3RhYmxlOjQ5ZjI5ZGFjNzFmZTQ2ZGE5OWQyNzhlMGFiMjZkYmYxL3RhYmxlcmFuZ2U6NDlmMjlkYWM3MWZlNDZkYTk5ZDI3OGUwYWIyNmRiZjFfMi01LTEtMS0yMTc2Ng_d2973d5d-6545-4cf1-a323-7a3f13f59fe9"
      unitRef="usd">13903000</us-gaap:OperatingLeaseCost>
    <us-gaap:FinanceLeaseRightOfUseAssetAmortization
      contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM184Mi9mcmFnOjBhMDRkZjMzNTJkOTRkOTc5NzU3NGUwYjM5NzQ1MDgyL3RhYmxlOjQ5ZjI5ZGFjNzFmZTQ2ZGE5OWQyNzhlMGFiMjZkYmYxL3RhYmxlcmFuZ2U6NDlmMjlkYWM3MWZlNDZkYTk5ZDI3OGUwYWIyNmRiZjFfMy01LTEtMS0xNzc3NQ_ce31daee-6187-41f8-bd4c-f0decedb4d27"
      unitRef="usd">0</us-gaap:FinanceLeaseRightOfUseAssetAmortization>
    <us-gaap:FinanceLeaseRightOfUseAssetAmortization
      contextRef="i12a6d1161de54547bd29f8efccd4c9b0_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM184Mi9mcmFnOjBhMDRkZjMzNTJkOTRkOTc5NzU3NGUwYjM5NzQ1MDgyL3RhYmxlOjQ5ZjI5ZGFjNzFmZTQ2ZGE5OWQyNzhlMGFiMjZkYmYxL3RhYmxlcmFuZ2U6NDlmMjlkYWM3MWZlNDZkYTk5ZDI3OGUwYWIyNmRiZjFfMy03LTEtMS0xNzc3NQ_1ed533af-99a7-488a-af8d-f56f021365ca"
      unitRef="usd">299000</us-gaap:FinanceLeaseRightOfUseAssetAmortization>
    <us-gaap:FinanceLeaseRightOfUseAssetAmortization
      contextRef="i3e21049ffc224cacb8134d73c9bb5b38_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM184Mi9mcmFnOjBhMDRkZjMzNTJkOTRkOTc5NzU3NGUwYjM5NzQ1MDgyL3RhYmxlOjQ5ZjI5ZGFjNzFmZTQ2ZGE5OWQyNzhlMGFiMjZkYmYxL3RhYmxlcmFuZ2U6NDlmMjlkYWM3MWZlNDZkYTk5ZDI3OGUwYWIyNmRiZjFfMy01LTEtMS0yMTc2Ng_0cae7fa9-dd0e-4ced-a467-6920dbf408b1"
      unitRef="usd">598000</us-gaap:FinanceLeaseRightOfUseAssetAmortization>
    <us-gaap:FinanceLeaseInterestExpense
      contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM184Mi9mcmFnOjBhMDRkZjMzNTJkOTRkOTc5NzU3NGUwYjM5NzQ1MDgyL3RhYmxlOjQ5ZjI5ZGFjNzFmZTQ2ZGE5OWQyNzhlMGFiMjZkYmYxL3RhYmxlcmFuZ2U6NDlmMjlkYWM3MWZlNDZkYTk5ZDI3OGUwYWIyNmRiZjFfNC01LTEtMS0xNzc3NQ_45827602-a304-4133-8d5f-33b1d3db0009"
      unitRef="usd">0</us-gaap:FinanceLeaseInterestExpense>
    <us-gaap:FinanceLeaseInterestExpense
      contextRef="i12a6d1161de54547bd29f8efccd4c9b0_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM184Mi9mcmFnOjBhMDRkZjMzNTJkOTRkOTc5NzU3NGUwYjM5NzQ1MDgyL3RhYmxlOjQ5ZjI5ZGFjNzFmZTQ2ZGE5OWQyNzhlMGFiMjZkYmYxL3RhYmxlcmFuZ2U6NDlmMjlkYWM3MWZlNDZkYTk5ZDI3OGUwYWIyNmRiZjFfNC03LTEtMS0xNzc3NQ_5f8fd9e1-8c1f-4c46-a6bb-19a123236451"
      unitRef="usd">3000</us-gaap:FinanceLeaseInterestExpense>
    <us-gaap:FinanceLeaseInterestExpense
      contextRef="i3e21049ffc224cacb8134d73c9bb5b38_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM184Mi9mcmFnOjBhMDRkZjMzNTJkOTRkOTc5NzU3NGUwYjM5NzQ1MDgyL3RhYmxlOjQ5ZjI5ZGFjNzFmZTQ2ZGE5OWQyNzhlMGFiMjZkYmYxL3RhYmxlcmFuZ2U6NDlmMjlkYWM3MWZlNDZkYTk5ZDI3OGUwYWIyNmRiZjFfNC01LTEtMS0yMTc2Ng_70315bba-da95-4d28-80d4-11c018b99645"
      unitRef="usd">26000</us-gaap:FinanceLeaseInterestExpense>
    <us-gaap:VariableLeaseCost
      contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM184Mi9mcmFnOjBhMDRkZjMzNTJkOTRkOTc5NzU3NGUwYjM5NzQ1MDgyL3RhYmxlOjQ5ZjI5ZGFjNzFmZTQ2ZGE5OWQyNzhlMGFiMjZkYmYxL3RhYmxlcmFuZ2U6NDlmMjlkYWM3MWZlNDZkYTk5ZDI3OGUwYWIyNmRiZjFfNS01LTEtMS0xNzc3NQ_453acc4e-45e7-4da6-b305-ce0ed4f3bb22"
      unitRef="usd">5036000</us-gaap:VariableLeaseCost>
    <us-gaap:VariableLeaseCost
      contextRef="i12a6d1161de54547bd29f8efccd4c9b0_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM184Mi9mcmFnOjBhMDRkZjMzNTJkOTRkOTc5NzU3NGUwYjM5NzQ1MDgyL3RhYmxlOjQ5ZjI5ZGFjNzFmZTQ2ZGE5OWQyNzhlMGFiMjZkYmYxL3RhYmxlcmFuZ2U6NDlmMjlkYWM3MWZlNDZkYTk5ZDI3OGUwYWIyNmRiZjFfNS03LTEtMS0xNzc3NQ_90a2e845-8859-4e27-ae0e-4749d3e4a371"
      unitRef="usd">5097000</us-gaap:VariableLeaseCost>
    <us-gaap:VariableLeaseCost
      contextRef="i3e21049ffc224cacb8134d73c9bb5b38_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM184Mi9mcmFnOjBhMDRkZjMzNTJkOTRkOTc5NzU3NGUwYjM5NzQ1MDgyL3RhYmxlOjQ5ZjI5ZGFjNzFmZTQ2ZGE5OWQyNzhlMGFiMjZkYmYxL3RhYmxlcmFuZ2U6NDlmMjlkYWM3MWZlNDZkYTk5ZDI3OGUwYWIyNmRiZjFfNS01LTEtMS0yMTc2Ng_a222ff80-50bb-478e-9365-2832edcffbbc"
      unitRef="usd">4177000</us-gaap:VariableLeaseCost>
    <us-gaap:LeaseCost
      contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM184Mi9mcmFnOjBhMDRkZjMzNTJkOTRkOTc5NzU3NGUwYjM5NzQ1MDgyL3RhYmxlOjQ5ZjI5ZGFjNzFmZTQ2ZGE5OWQyNzhlMGFiMjZkYmYxL3RhYmxlcmFuZ2U6NDlmMjlkYWM3MWZlNDZkYTk5ZDI3OGUwYWIyNmRiZjFfNi01LTEtMS0xNzc3NQ_31b654c4-1051-41ec-a828-f29d0b003ac8"
      unitRef="usd">18027000</us-gaap:LeaseCost>
    <us-gaap:LeaseCost
      contextRef="i12a6d1161de54547bd29f8efccd4c9b0_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM184Mi9mcmFnOjBhMDRkZjMzNTJkOTRkOTc5NzU3NGUwYjM5NzQ1MDgyL3RhYmxlOjQ5ZjI5ZGFjNzFmZTQ2ZGE5OWQyNzhlMGFiMjZkYmYxL3RhYmxlcmFuZ2U6NDlmMjlkYWM3MWZlNDZkYTk5ZDI3OGUwYWIyNmRiZjFfNi03LTEtMS0xNzc3NQ_b966d66f-6dd3-4ac5-9199-de4f95587249"
      unitRef="usd">21247000</us-gaap:LeaseCost>
    <us-gaap:LeaseCost
      contextRef="i3e21049ffc224cacb8134d73c9bb5b38_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM184Mi9mcmFnOjBhMDRkZjMzNTJkOTRkOTc5NzU3NGUwYjM5NzQ1MDgyL3RhYmxlOjQ5ZjI5ZGFjNzFmZTQ2ZGE5OWQyNzhlMGFiMjZkYmYxL3RhYmxlcmFuZ2U6NDlmMjlkYWM3MWZlNDZkYTk5ZDI3OGUwYWIyNmRiZjFfNi01LTEtMS0yMTc3Mw_3622f232-9a52-4577-874f-411e7b9638bc"
      unitRef="usd">18704000</us-gaap:LeaseCost>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="i8daff60be410426d8f7bd49343c1ec0c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM184Mi9mcmFnOjBhMDRkZjMzNTJkOTRkOTc5NzU3NGUwYjM5NzQ1MDgyL3RhYmxlOmY2ZGRmMDhmNjhjNTQyNzU4MTYyMDJjZTllMWUwNThjL3RhYmxlcmFuZ2U6ZjZkZGYwOGY2OGM1NDI3NTgxNjIwMmNlOWUxZTA1OGNfMS0xLTEtMS0xNzc3NQ_f226b232-6d5f-4400-9e4a-b2c92f39958d"
      unitRef="usd">10916000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
      contextRef="i8daff60be410426d8f7bd49343c1ec0c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM184Mi9mcmFnOjBhMDRkZjMzNTJkOTRkOTc5NzU3NGUwYjM5NzQ1MDgyL3RhYmxlOmY2ZGRmMDhmNjhjNTQyNzU4MTYyMDJjZTllMWUwNThjL3RhYmxlcmFuZ2U6ZjZkZGYwOGY2OGM1NDI3NTgxNjIwMmNlOWUxZTA1OGNfMi0xLTEtMS0xNzc3NQ_6b971748-af42-4cf4-83d4-7232d690f30b"
      unitRef="usd">9258000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree
      contextRef="i8daff60be410426d8f7bd49343c1ec0c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM184Mi9mcmFnOjBhMDRkZjMzNTJkOTRkOTc5NzU3NGUwYjM5NzQ1MDgyL3RhYmxlOmY2ZGRmMDhmNjhjNTQyNzU4MTYyMDJjZTllMWUwNThjL3RhYmxlcmFuZ2U6ZjZkZGYwOGY2OGM1NDI3NTgxNjIwMmNlOWUxZTA1OGNfMy0xLTEtMS0xNzc3NQ_5af12fff-972b-46e0-b309-1b6c169f7968"
      unitRef="usd">8968000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour
      contextRef="i8daff60be410426d8f7bd49343c1ec0c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM184Mi9mcmFnOjBhMDRkZjMzNTJkOTRkOTc5NzU3NGUwYjM5NzQ1MDgyL3RhYmxlOmY2ZGRmMDhmNjhjNTQyNzU4MTYyMDJjZTllMWUwNThjL3RhYmxlcmFuZ2U6ZjZkZGYwOGY2OGM1NDI3NTgxNjIwMmNlOWUxZTA1OGNfNC0xLTEtMS0xNzc3NQ_1abb566e-645d-4de6-b169-4c552f405556"
      unitRef="usd">8653000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive
      contextRef="i8daff60be410426d8f7bd49343c1ec0c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM184Mi9mcmFnOjBhMDRkZjMzNTJkOTRkOTc5NzU3NGUwYjM5NzQ1MDgyL3RhYmxlOmY2ZGRmMDhmNjhjNTQyNzU4MTYyMDJjZTllMWUwNThjL3RhYmxlcmFuZ2U6ZjZkZGYwOGY2OGM1NDI3NTgxNjIwMmNlOWUxZTA1OGNfNS0xLTEtMS0xNzc3NQ_aeb6cffd-c570-4e76-82fa-c85bb6714634"
      unitRef="usd">7988000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive
      contextRef="i8daff60be410426d8f7bd49343c1ec0c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM184Mi9mcmFnOjBhMDRkZjMzNTJkOTRkOTc5NzU3NGUwYjM5NzQ1MDgyL3RhYmxlOmY2ZGRmMDhmNjhjNTQyNzU4MTYyMDJjZTllMWUwNThjL3RhYmxlcmFuZ2U6ZjZkZGYwOGY2OGM1NDI3NTgxNjIwMmNlOWUxZTA1OGNfNi0xLTEtMS0xNzc3NQ_f6355bd7-c2b3-48cd-91d0-bf89bdfb369f"
      unitRef="usd">39972000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="i8daff60be410426d8f7bd49343c1ec0c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM184Mi9mcmFnOjBhMDRkZjMzNTJkOTRkOTc5NzU3NGUwYjM5NzQ1MDgyL3RhYmxlOmY2ZGRmMDhmNjhjNTQyNzU4MTYyMDJjZTllMWUwNThjL3RhYmxlcmFuZ2U6ZjZkZGYwOGY2OGM1NDI3NTgxNjIwMmNlOWUxZTA1OGNfNy0xLTEtMS0xNzc3NQ_0ac4ab61-a2ad-4829-b35b-871498b455bc"
      unitRef="usd">85755000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
      contextRef="i8daff60be410426d8f7bd49343c1ec0c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM184Mi9mcmFnOjBhMDRkZjMzNTJkOTRkOTc5NzU3NGUwYjM5NzQ1MDgyL3RhYmxlOmY2ZGRmMDhmNjhjNTQyNzU4MTYyMDJjZTllMWUwNThjL3RhYmxlcmFuZ2U6ZjZkZGYwOGY2OGM1NDI3NTgxNjIwMmNlOWUxZTA1OGNfOS0xLTEtMS0xNzc3NQ_48b4b26f-05b3-4bb4-9c9b-1bbeeec33a1f"
      unitRef="usd">20964000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability
      contextRef="i8daff60be410426d8f7bd49343c1ec0c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM184Mi9mcmFnOjBhMDRkZjMzNTJkOTRkOTc5NzU3NGUwYjM5NzQ1MDgyL3RhYmxlOmY2ZGRmMDhmNjhjNTQyNzU4MTYyMDJjZTllMWUwNThjL3RhYmxlcmFuZ2U6ZjZkZGYwOGY2OGM1NDI3NTgxNjIwMmNlOWUxZTA1OGNfMTAtMS0xLTEtMTc3NzU_e3792fb7-7139-47c2-a42b-831bb9bf3da5"
      unitRef="usd">64791000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="i8daff60be410426d8f7bd49343c1ec0c_I20211231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM184Mi9mcmFnOjBhMDRkZjMzNTJkOTRkOTc5NzU3NGUwYjM5NzQ1MDgyL3RhYmxlOjI2MjQ0YmM1YTM0ZjQ5MDJiZjQyODdiYTBlYWNlZmFhL3RhYmxlcmFuZ2U6MjYyNDRiYzVhMzRmNDkwMmJmNDI4N2JhMGVhY2VmYWFfMC0xLTEtMS0xNzc3NQ_399b926b-4315-4908-b425-61512dce5f20"
      unitRef="number">0.0638</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="ibc0c0c2b8dc04c5698ca0577a54b2e03_I20201231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM184Mi9mcmFnOjBhMDRkZjMzNTJkOTRkOTc5NzU3NGUwYjM5NzQ1MDgyL3RhYmxlOjI2MjQ0YmM1YTM0ZjQ5MDJiZjQyODdiYTBlYWNlZmFhL3RhYmxlcmFuZ2U6MjYyNDRiYzVhMzRmNDkwMmJmNDI4N2JhMGVhY2VmYWFfMi0zLTEtMS0yMTgyOA_0b653ac5-2341-46a5-b1e5-ebb3e0bbfc4e"
      unitRef="number">0.0644</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="icba6e493923b449aa57c46a563760234_I20191231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM184Mi9mcmFnOjBhMDRkZjMzNTJkOTRkOTc5NzU3NGUwYjM5NzQ1MDgyL3RhYmxlOjI2MjQ0YmM1YTM0ZjQ5MDJiZjQyODdiYTBlYWNlZmFhL3RhYmxlcmFuZ2U6MjYyNDRiYzVhMzRmNDkwMmJmNDI4N2JhMGVhY2VmYWFfMi01LTEtMS0yMTgyOA_e4659193-1da1-4cfa-bd79-bea944169a7f"
      unitRef="number">0.0625</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="i8daff60be410426d8f7bd49343c1ec0c_I20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM184Mi9mcmFnOjBhMDRkZjMzNTJkOTRkOTc5NzU3NGUwYjM5NzQ1MDgyL3RhYmxlOjI2MjQ0YmM1YTM0ZjQ5MDJiZjQyODdiYTBlYWNlZmFhL3RhYmxlcmFuZ2U6MjYyNDRiYzVhMzRmNDkwMmJmNDI4N2JhMGVhY2VmYWFfMS0xLTEtMS0xNzc3NQ_e8d814fa-d223-4dc4-98dd-c6ae8321c492">P8Y9M18D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="ibc0c0c2b8dc04c5698ca0577a54b2e03_I20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM184Mi9mcmFnOjBhMDRkZjMzNTJkOTRkOTc5NzU3NGUwYjM5NzQ1MDgyL3RhYmxlOjI2MjQ0YmM1YTM0ZjQ5MDJiZjQyODdiYTBlYWNlZmFhL3RhYmxlcmFuZ2U6MjYyNDRiYzVhMzRmNDkwMmJmNDI4N2JhMGVhY2VmYWFfMy0zLTEtMS0yMTgyOA_9fc96102-f6fc-474a-b2ae-4536cf574c08">P9Y4M24D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="icba6e493923b449aa57c46a563760234_I20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM184Mi9mcmFnOjBhMDRkZjMzNTJkOTRkOTc5NzU3NGUwYjM5NzQ1MDgyL3RhYmxlOjI2MjQ0YmM1YTM0ZjQ5MDJiZjQyODdiYTBlYWNlZmFhL3RhYmxlcmFuZ2U6MjYyNDRiYzVhMzRmNDkwMmJmNDI4N2JhMGVhY2VmYWFfMy01LTEtMS0yMTgyOA_f70eaa99-4b12-46ef-8af5-8007d65f4974">P9Y10M24D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:EarningsPerShareTextBlock
      contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM184NS9mcmFnOjdhMDNjNzc3NWZjNDRmMzlhZmY3NjkyYjY5NGQ5YzM3L3RleHRyZWdpb246N2EwM2M3Nzc1ZmM0NGYzOWFmZjc2OTJiNjk0ZDljMzdfMzY0_ec482e50-f474-4b1e-b9bf-d9d780571a9f">Earnings (Loss) Per Common Share&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table sets forth the computation of basic and diluted earnings per share available for common stockholders (in thousands, except per share data):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:351.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:58.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:58.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:58.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;For the Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Loss from continuing operations&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(30,284)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(328,172)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(307,193)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income (loss) from discontinued operations, net of tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7,317)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6,074)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,613&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(37,601)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(334,246)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(305,580)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net loss attributable to non-controlling interests&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,609)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net loss available for common shareholders - basic and diluted&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(37,601)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(334,246)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(301,971)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average common shares outstanding - basic and diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;86,067&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;84,928&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;82,364&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Income (loss) per common share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Basic and diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Continuing operations&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.35)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3.86)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3.73)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Discontinued operations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.09)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.08)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.02&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-controlling interests&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.04&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:23pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Basic and diluted income (loss) per share attributable to common shareholders of Evolent Health, Inc.&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.44)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3.94)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3.67)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Anti-dilutive shares (in thousands) excluded from the calculation of weighted-average common shares presented above are presented below:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:351.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:58.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:58.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:58.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;For the Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exchangeable Class B common stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,399&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:23pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted stock units ("RSUs"), performance-based RSUs and leveraged stock units ("LSUs")&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,807&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;797&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;813&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,036&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,141&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,324&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Convertible senior notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,602&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,206&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,361&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,445&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,144&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,897&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock
      contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM184NS9mcmFnOjdhMDNjNzc3NWZjNDRmMzlhZmY3NjkyYjY5NGQ5YzM3L3RleHRyZWdpb246N2EwM2M3Nzc1ZmM0NGYzOWFmZjc2OTJiNjk0ZDljMzdfMzY2_94b33826-53f3-4da6-a961-03aab9955bbb">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table sets forth the computation of basic and diluted earnings per share available for common stockholders (in thousands, except per share data):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:351.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:58.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:58.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:58.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;For the Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Loss from continuing operations&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(30,284)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(328,172)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(307,193)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income (loss) from discontinued operations, net of tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7,317)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6,074)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,613&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(37,601)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(334,246)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(305,580)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net loss attributable to non-controlling interests&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,609)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net loss available for common shareholders - basic and diluted&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(37,601)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(334,246)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(301,971)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average common shares outstanding - basic and diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;86,067&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;84,928&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;82,364&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Income (loss) per common share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Basic and diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Continuing operations&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.35)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3.86)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3.73)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Discontinued operations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.09)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.08)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.02&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-controlling interests&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.04&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:23pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Basic and diluted income (loss) per share attributable to common shareholders of Evolent Health, Inc.&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.44)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3.94)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3.67)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
      contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM184NS9mcmFnOjdhMDNjNzc3NWZjNDRmMzlhZmY3NjkyYjY5NGQ5YzM3L3RhYmxlOjhhNDlhNzA4NDcxMDQwZTk4MzBiMDg2ZTIxMzRlYTk1L3RhYmxlcmFuZ2U6OGE0OWE3MDg0NzEwNDBlOTgzMGIwODZlMjEzNGVhOTVfMi01LTEtMS0xNzc3NQ_d76450ef-cfe7-4881-b23e-9a162abc49db"
      unitRef="usd">-30284000</us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i12a6d1161de54547bd29f8efccd4c9b0_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM184NS9mcmFnOjdhMDNjNzc3NWZjNDRmMzlhZmY3NjkyYjY5NGQ5YzM3L3RhYmxlOjhhNDlhNzA4NDcxMDQwZTk4MzBiMDg2ZTIxMzRlYTk1L3RhYmxlcmFuZ2U6OGE0OWE3MDg0NzEwNDBlOTgzMGIwODZlMjEzNGVhOTVfMi03LTEtMS0xNzc3NQ_46bcd607-6919-41ba-bd7e-9e6da2dfd783"
      unitRef="usd">-328172000</us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i3e21049ffc224cacb8134d73c9bb5b38_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM184NS9mcmFnOjdhMDNjNzc3NWZjNDRmMzlhZmY3NjkyYjY5NGQ5YzM3L3RhYmxlOjhhNDlhNzA4NDcxMDQwZTk4MzBiMDg2ZTIxMzRlYTk1L3RhYmxlcmFuZ2U6OGE0OWE3MDg0NzEwNDBlOTgzMGIwODZlMjEzNGVhOTVfMi01LTEtMS0yMTkzMQ_7cd677f7-562c-4cff-afb6-94eb73d0af25"
      unitRef="usd">-307193000</us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax
      contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM184NS9mcmFnOjdhMDNjNzc3NWZjNDRmMzlhZmY3NjkyYjY5NGQ5YzM3L3RhYmxlOjhhNDlhNzA4NDcxMDQwZTk4MzBiMDg2ZTIxMzRlYTk1L3RhYmxlcmFuZ2U6OGE0OWE3MDg0NzEwNDBlOTgzMGIwODZlMjEzNGVhOTVfMy01LTEtMS0xNzc3NQ_3a7f9340-a2d9-4068-b095-f659267e962c"
      unitRef="usd">-7317000</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax
      contextRef="i12a6d1161de54547bd29f8efccd4c9b0_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM184NS9mcmFnOjdhMDNjNzc3NWZjNDRmMzlhZmY3NjkyYjY5NGQ5YzM3L3RhYmxlOjhhNDlhNzA4NDcxMDQwZTk4MzBiMDg2ZTIxMzRlYTk1L3RhYmxlcmFuZ2U6OGE0OWE3MDg0NzEwNDBlOTgzMGIwODZlMjEzNGVhOTVfMy03LTEtMS0xNzc3NQ_6123f20d-b2da-4983-8481-3001d793c73d"
      unitRef="usd">-6074000</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax
      contextRef="i3e21049ffc224cacb8134d73c9bb5b38_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM184NS9mcmFnOjdhMDNjNzc3NWZjNDRmMzlhZmY3NjkyYjY5NGQ5YzM3L3RhYmxlOjhhNDlhNzA4NDcxMDQwZTk4MzBiMDg2ZTIxMzRlYTk1L3RhYmxlcmFuZ2U6OGE0OWE3MDg0NzEwNDBlOTgzMGIwODZlMjEzNGVhOTVfMy01LTEtMS0yMTkzMQ_cd15aa32-72bb-4df8-a330-8fac8ecbd8bb"
      unitRef="usd">1613000</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax>
    <us-gaap:ProfitLoss
      contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM184NS9mcmFnOjdhMDNjNzc3NWZjNDRmMzlhZmY3NjkyYjY5NGQ5YzM3L3RhYmxlOjhhNDlhNzA4NDcxMDQwZTk4MzBiMDg2ZTIxMzRlYTk1L3RhYmxlcmFuZ2U6OGE0OWE3MDg0NzEwNDBlOTgzMGIwODZlMjEzNGVhOTVfNC01LTEtMS0xNzc3NQ_c49b99c2-1aef-4003-806b-11d043c6a947"
      unitRef="usd">-37601000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i12a6d1161de54547bd29f8efccd4c9b0_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM184NS9mcmFnOjdhMDNjNzc3NWZjNDRmMzlhZmY3NjkyYjY5NGQ5YzM3L3RhYmxlOjhhNDlhNzA4NDcxMDQwZTk4MzBiMDg2ZTIxMzRlYTk1L3RhYmxlcmFuZ2U6OGE0OWE3MDg0NzEwNDBlOTgzMGIwODZlMjEzNGVhOTVfNC03LTEtMS0xNzc3NQ_059445f8-3794-4af1-abe2-9f2515cac297"
      unitRef="usd">-334246000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i3e21049ffc224cacb8134d73c9bb5b38_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM184NS9mcmFnOjdhMDNjNzc3NWZjNDRmMzlhZmY3NjkyYjY5NGQ5YzM3L3RhYmxlOjhhNDlhNzA4NDcxMDQwZTk4MzBiMDg2ZTIxMzRlYTk1L3RhYmxlcmFuZ2U6OGE0OWE3MDg0NzEwNDBlOTgzMGIwODZlMjEzNGVhOTVfNC01LTEtMS0yMTkzMQ_29de1fd1-21e6-4603-8e1d-b3241b370b6f"
      unitRef="usd">-305580000</us-gaap:ProfitLoss>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM184NS9mcmFnOjdhMDNjNzc3NWZjNDRmMzlhZmY3NjkyYjY5NGQ5YzM3L3RhYmxlOjhhNDlhNzA4NDcxMDQwZTk4MzBiMDg2ZTIxMzRlYTk1L3RhYmxlcmFuZ2U6OGE0OWE3MDg0NzEwNDBlOTgzMGIwODZlMjEzNGVhOTVfNi01LTEtMS0xNzc3NQ_a10ceaab-8664-4942-a66d-497e3968da6b"
      unitRef="usd">0</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="i12a6d1161de54547bd29f8efccd4c9b0_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM184NS9mcmFnOjdhMDNjNzc3NWZjNDRmMzlhZmY3NjkyYjY5NGQ5YzM3L3RhYmxlOjhhNDlhNzA4NDcxMDQwZTk4MzBiMDg2ZTIxMzRlYTk1L3RhYmxlcmFuZ2U6OGE0OWE3MDg0NzEwNDBlOTgzMGIwODZlMjEzNGVhOTVfNi03LTEtMS0xNzc3NQ_1026adc1-b9ab-4994-88ed-075d8f12b561"
      unitRef="usd">0</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="i3e21049ffc224cacb8134d73c9bb5b38_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM184NS9mcmFnOjdhMDNjNzc3NWZjNDRmMzlhZmY3NjkyYjY5NGQ5YzM3L3RhYmxlOjhhNDlhNzA4NDcxMDQwZTk4MzBiMDg2ZTIxMzRlYTk1L3RhYmxlcmFuZ2U6OGE0OWE3MDg0NzEwNDBlOTgzMGIwODZlMjEzNGVhOTVfNi01LTEtMS0yMTkzMQ_c409b687-025d-4187-8d5b-98a09913c94e"
      unitRef="usd">-3609000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM184NS9mcmFnOjdhMDNjNzc3NWZjNDRmMzlhZmY3NjkyYjY5NGQ5YzM3L3RhYmxlOjhhNDlhNzA4NDcxMDQwZTk4MzBiMDg2ZTIxMzRlYTk1L3RhYmxlcmFuZ2U6OGE0OWE3MDg0NzEwNDBlOTgzMGIwODZlMjEzNGVhOTVfNy01LTEtMS0xNzc3NQ_19b0e485-6260-41f1-b4e9-3c97c234c728"
      unitRef="usd">-37601000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted
      contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM184NS9mcmFnOjdhMDNjNzc3NWZjNDRmMzlhZmY3NjkyYjY5NGQ5YzM3L3RhYmxlOjhhNDlhNzA4NDcxMDQwZTk4MzBiMDg2ZTIxMzRlYTk1L3RhYmxlcmFuZ2U6OGE0OWE3MDg0NzEwNDBlOTgzMGIwODZlMjEzNGVhOTVfNy01LTEtMS0xNzc3NQ_34c1e7e0-fc69-4bdc-be43-ddb3ef807107"
      unitRef="usd">-37601000</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="i12a6d1161de54547bd29f8efccd4c9b0_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM184NS9mcmFnOjdhMDNjNzc3NWZjNDRmMzlhZmY3NjkyYjY5NGQ5YzM3L3RhYmxlOjhhNDlhNzA4NDcxMDQwZTk4MzBiMDg2ZTIxMzRlYTk1L3RhYmxlcmFuZ2U6OGE0OWE3MDg0NzEwNDBlOTgzMGIwODZlMjEzNGVhOTVfNy03LTEtMS0xNzc3NQ_47276093-49df-42a8-9bbd-a4f0df34d037"
      unitRef="usd">-334246000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted
      contextRef="i12a6d1161de54547bd29f8efccd4c9b0_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM184NS9mcmFnOjdhMDNjNzc3NWZjNDRmMzlhZmY3NjkyYjY5NGQ5YzM3L3RhYmxlOjhhNDlhNzA4NDcxMDQwZTk4MzBiMDg2ZTIxMzRlYTk1L3RhYmxlcmFuZ2U6OGE0OWE3MDg0NzEwNDBlOTgzMGIwODZlMjEzNGVhOTVfNy03LTEtMS0xNzc3NQ_e8f68bad-99dd-4b99-9acb-741a4f5652df"
      unitRef="usd">-334246000</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="i3e21049ffc224cacb8134d73c9bb5b38_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM184NS9mcmFnOjdhMDNjNzc3NWZjNDRmMzlhZmY3NjkyYjY5NGQ5YzM3L3RhYmxlOjhhNDlhNzA4NDcxMDQwZTk4MzBiMDg2ZTIxMzRlYTk1L3RhYmxlcmFuZ2U6OGE0OWE3MDg0NzEwNDBlOTgzMGIwODZlMjEzNGVhOTVfNy01LTEtMS0yMTkzMQ_0a6190d1-cda6-4fcd-86a4-1fb62988b96a"
      unitRef="usd">-301971000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted
      contextRef="i3e21049ffc224cacb8134d73c9bb5b38_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM184NS9mcmFnOjdhMDNjNzc3NWZjNDRmMzlhZmY3NjkyYjY5NGQ5YzM3L3RhYmxlOjhhNDlhNzA4NDcxMDQwZTk4MzBiMDg2ZTIxMzRlYTk1L3RhYmxlcmFuZ2U6OGE0OWE3MDg0NzEwNDBlOTgzMGIwODZlMjEzNGVhOTVfNy01LTEtMS0yMTkzMQ_77283e80-530b-4696-8342-e4c33faaa8f6"
      unitRef="usd">-301971000</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM184NS9mcmFnOjdhMDNjNzc3NWZjNDRmMzlhZmY3NjkyYjY5NGQ5YzM3L3RhYmxlOjhhNDlhNzA4NDcxMDQwZTk4MzBiMDg2ZTIxMzRlYTk1L3RhYmxlcmFuZ2U6OGE0OWE3MDg0NzEwNDBlOTgzMGIwODZlMjEzNGVhOTVfOS01LTEtMS0xNzc3NQ_4d2bf937-f10f-4d10-9f93-6566eaee8855"
      unitRef="shares">86067000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM184NS9mcmFnOjdhMDNjNzc3NWZjNDRmMzlhZmY3NjkyYjY5NGQ5YzM3L3RhYmxlOjhhNDlhNzA4NDcxMDQwZTk4MzBiMDg2ZTIxMzRlYTk1L3RhYmxlcmFuZ2U6OGE0OWE3MDg0NzEwNDBlOTgzMGIwODZlMjEzNGVhOTVfOS01LTEtMS0xNzc3NQ_e2c93d99-4d5a-42af-aa15-b4f7a2aa8373"
      unitRef="shares">86067000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i12a6d1161de54547bd29f8efccd4c9b0_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM184NS9mcmFnOjdhMDNjNzc3NWZjNDRmMzlhZmY3NjkyYjY5NGQ5YzM3L3RhYmxlOjhhNDlhNzA4NDcxMDQwZTk4MzBiMDg2ZTIxMzRlYTk1L3RhYmxlcmFuZ2U6OGE0OWE3MDg0NzEwNDBlOTgzMGIwODZlMjEzNGVhOTVfOS03LTEtMS0xNzc3NQ_43f0e345-3af0-4b74-93ae-34e196683016"
      unitRef="shares">84928000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i12a6d1161de54547bd29f8efccd4c9b0_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM184NS9mcmFnOjdhMDNjNzc3NWZjNDRmMzlhZmY3NjkyYjY5NGQ5YzM3L3RhYmxlOjhhNDlhNzA4NDcxMDQwZTk4MzBiMDg2ZTIxMzRlYTk1L3RhYmxlcmFuZ2U6OGE0OWE3MDg0NzEwNDBlOTgzMGIwODZlMjEzNGVhOTVfOS03LTEtMS0xNzc3NQ_efcdf457-3aed-4d57-9eff-1d019a73ef97"
      unitRef="shares">84928000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i3e21049ffc224cacb8134d73c9bb5b38_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM184NS9mcmFnOjdhMDNjNzc3NWZjNDRmMzlhZmY3NjkyYjY5NGQ5YzM3L3RhYmxlOjhhNDlhNzA4NDcxMDQwZTk4MzBiMDg2ZTIxMzRlYTk1L3RhYmxlcmFuZ2U6OGE0OWE3MDg0NzEwNDBlOTgzMGIwODZlMjEzNGVhOTVfOS01LTEtMS0yMTk1Mg_25fafb85-ceb4-42c8-926b-7dd11942cafc"
      unitRef="shares">82364000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i3e21049ffc224cacb8134d73c9bb5b38_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM184NS9mcmFnOjdhMDNjNzc3NWZjNDRmMzlhZmY3NjkyYjY5NGQ5YzM3L3RhYmxlOjhhNDlhNzA4NDcxMDQwZTk4MzBiMDg2ZTIxMzRlYTk1L3RhYmxlcmFuZ2U6OGE0OWE3MDg0NzEwNDBlOTgzMGIwODZlMjEzNGVhOTVfOS01LTEtMS0yMTk1Mg_2eddbb20-2c74-4c58-a2bc-68f4ca5e9463"
      unitRef="shares">82364000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare
      contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM184NS9mcmFnOjdhMDNjNzc3NWZjNDRmMzlhZmY3NjkyYjY5NGQ5YzM3L3RhYmxlOjhhNDlhNzA4NDcxMDQwZTk4MzBiMDg2ZTIxMzRlYTk1L3RhYmxlcmFuZ2U6OGE0OWE3MDg0NzEwNDBlOTgzMGIwODZlMjEzNGVhOTVfMTMtNS0xLTEtMTc3NzU_1be0d8aa-7784-4a8d-b716-b5e8a6f955e8"
      unitRef="usdPerShare">-0.35</us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerBasicShare
      contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM184NS9mcmFnOjdhMDNjNzc3NWZjNDRmMzlhZmY3NjkyYjY5NGQ5YzM3L3RhYmxlOjhhNDlhNzA4NDcxMDQwZTk4MzBiMDg2ZTIxMzRlYTk1L3RhYmxlcmFuZ2U6OGE0OWE3MDg0NzEwNDBlOTgzMGIwODZlMjEzNGVhOTVfMTMtNS0xLTEtMTc3NzU_e035674e-3c54-4da7-a44d-68e94785e880"
      unitRef="usdPerShare">-0.35</us-gaap:IncomeLossFromContinuingOperationsPerBasicShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerBasicShare
      contextRef="i12a6d1161de54547bd29f8efccd4c9b0_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM184NS9mcmFnOjdhMDNjNzc3NWZjNDRmMzlhZmY3NjkyYjY5NGQ5YzM3L3RhYmxlOjhhNDlhNzA4NDcxMDQwZTk4MzBiMDg2ZTIxMzRlYTk1L3RhYmxlcmFuZ2U6OGE0OWE3MDg0NzEwNDBlOTgzMGIwODZlMjEzNGVhOTVfMTMtNy0xLTEtMTc3NzU_47ab00f1-b3ad-4d5b-8c18-b329fbbc06ba"
      unitRef="usdPerShare">-3.86</us-gaap:IncomeLossFromContinuingOperationsPerBasicShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare
      contextRef="i12a6d1161de54547bd29f8efccd4c9b0_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM184NS9mcmFnOjdhMDNjNzc3NWZjNDRmMzlhZmY3NjkyYjY5NGQ5YzM3L3RhYmxlOjhhNDlhNzA4NDcxMDQwZTk4MzBiMDg2ZTIxMzRlYTk1L3RhYmxlcmFuZ2U6OGE0OWE3MDg0NzEwNDBlOTgzMGIwODZlMjEzNGVhOTVfMTMtNy0xLTEtMTc3NzU_c1dc9607-9bf5-4cf1-a3d2-b0db3afb1c8d"
      unitRef="usdPerShare">-3.86</us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare
      contextRef="i3e21049ffc224cacb8134d73c9bb5b38_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM184NS9mcmFnOjdhMDNjNzc3NWZjNDRmMzlhZmY3NjkyYjY5NGQ5YzM3L3RhYmxlOjhhNDlhNzA4NDcxMDQwZTk4MzBiMDg2ZTIxMzRlYTk1L3RhYmxlcmFuZ2U6OGE0OWE3MDg0NzEwNDBlOTgzMGIwODZlMjEzNGVhOTVfMTMtNS0xLTEtMjE5NTk_297fced9-7321-4394-9d35-8f3d7ae6d0e4"
      unitRef="usdPerShare">-3.73</us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerBasicShare
      contextRef="i3e21049ffc224cacb8134d73c9bb5b38_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM184NS9mcmFnOjdhMDNjNzc3NWZjNDRmMzlhZmY3NjkyYjY5NGQ5YzM3L3RhYmxlOjhhNDlhNzA4NDcxMDQwZTk4MzBiMDg2ZTIxMzRlYTk1L3RhYmxlcmFuZ2U6OGE0OWE3MDg0NzEwNDBlOTgzMGIwODZlMjEzNGVhOTVfMTMtNS0xLTEtMjE5NTk_d87662c3-104c-4c72-8c1f-7e928653cdf7"
      unitRef="usdPerShare">-3.73</us-gaap:IncomeLossFromContinuingOperationsPerBasicShare>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare
      contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM184NS9mcmFnOjdhMDNjNzc3NWZjNDRmMzlhZmY3NjkyYjY5NGQ5YzM3L3RhYmxlOjhhNDlhNzA4NDcxMDQwZTk4MzBiMDg2ZTIxMzRlYTk1L3RhYmxlcmFuZ2U6OGE0OWE3MDg0NzEwNDBlOTgzMGIwODZlMjEzNGVhOTVfMTQtNS0xLTEtMTc3NzU_3cbafcdb-0f82-465e-b519-e19d64aa375c"
      unitRef="usdPerShare">-0.09</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare
      contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM184NS9mcmFnOjdhMDNjNzc3NWZjNDRmMzlhZmY3NjkyYjY5NGQ5YzM3L3RhYmxlOjhhNDlhNzA4NDcxMDQwZTk4MzBiMDg2ZTIxMzRlYTk1L3RhYmxlcmFuZ2U6OGE0OWE3MDg0NzEwNDBlOTgzMGIwODZlMjEzNGVhOTVfMTQtNS0xLTEtMTc3NzU_697a90c3-40a0-4d50-b5ad-b2ef2b6a2202"
      unitRef="usdPerShare">-0.09</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare
      contextRef="i12a6d1161de54547bd29f8efccd4c9b0_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM184NS9mcmFnOjdhMDNjNzc3NWZjNDRmMzlhZmY3NjkyYjY5NGQ5YzM3L3RhYmxlOjhhNDlhNzA4NDcxMDQwZTk4MzBiMDg2ZTIxMzRlYTk1L3RhYmxlcmFuZ2U6OGE0OWE3MDg0NzEwNDBlOTgzMGIwODZlMjEzNGVhOTVfMTQtNy0xLTEtMTc3NzU_614d8f41-3c14-4669-9dc3-7aef83745f39"
      unitRef="usdPerShare">-0.08</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare
      contextRef="i12a6d1161de54547bd29f8efccd4c9b0_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM184NS9mcmFnOjdhMDNjNzc3NWZjNDRmMzlhZmY3NjkyYjY5NGQ5YzM3L3RhYmxlOjhhNDlhNzA4NDcxMDQwZTk4MzBiMDg2ZTIxMzRlYTk1L3RhYmxlcmFuZ2U6OGE0OWE3MDg0NzEwNDBlOTgzMGIwODZlMjEzNGVhOTVfMTQtNy0xLTEtMTc3NzU_f821a2c7-e60f-4775-af30-3571e62c8d7b"
      unitRef="usdPerShare">-0.08</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare
      contextRef="i3e21049ffc224cacb8134d73c9bb5b38_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM184NS9mcmFnOjdhMDNjNzc3NWZjNDRmMzlhZmY3NjkyYjY5NGQ5YzM3L3RhYmxlOjhhNDlhNzA4NDcxMDQwZTk4MzBiMDg2ZTIxMzRlYTk1L3RhYmxlcmFuZ2U6OGE0OWE3MDg0NzEwNDBlOTgzMGIwODZlMjEzNGVhOTVfMTQtNS0xLTEtMjE5NTk_65c2769c-8bf5-4a69-9670-8d84e869f596"
      unitRef="usdPerShare">0.02</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare
      contextRef="i3e21049ffc224cacb8134d73c9bb5b38_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM184NS9mcmFnOjdhMDNjNzc3NWZjNDRmMzlhZmY3NjkyYjY5NGQ5YzM3L3RhYmxlOjhhNDlhNzA4NDcxMDQwZTk4MzBiMDg2ZTIxMzRlYTk1L3RhYmxlcmFuZ2U6OGE0OWE3MDg0NzEwNDBlOTgzMGIwODZlMjEzNGVhOTVfMTQtNS0xLTEtMjE5NTk_d3da87c4-e160-4bb7-b042-19a87036320a"
      unitRef="usdPerShare">0.02</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare>
    <evh:EarningsPerSharePortionAttributableToNoncontrollingInterestDiluted
      contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM184NS9mcmFnOjdhMDNjNzc3NWZjNDRmMzlhZmY3NjkyYjY5NGQ5YzM3L3RhYmxlOjhhNDlhNzA4NDcxMDQwZTk4MzBiMDg2ZTIxMzRlYTk1L3RhYmxlcmFuZ2U6OGE0OWE3MDg0NzEwNDBlOTgzMGIwODZlMjEzNGVhOTVfMTUtMS0xLTEtMjc1Mjc_b50e84b8-a45a-41d3-9af3-908304b36487"
      unitRef="usdPerShare">0</evh:EarningsPerSharePortionAttributableToNoncontrollingInterestDiluted>
    <evh:EarningsPerSharePortionAttributableToNoncontrollingInterestBasic
      contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM184NS9mcmFnOjdhMDNjNzc3NWZjNDRmMzlhZmY3NjkyYjY5NGQ5YzM3L3RhYmxlOjhhNDlhNzA4NDcxMDQwZTk4MzBiMDg2ZTIxMzRlYTk1L3RhYmxlcmFuZ2U6OGE0OWE3MDg0NzEwNDBlOTgzMGIwODZlMjEzNGVhOTVfMTUtMS0xLTEtMjc1Mjc_ee4b7836-0c1c-4e91-a00a-f4f08b39f581"
      unitRef="usdPerShare">0</evh:EarningsPerSharePortionAttributableToNoncontrollingInterestBasic>
    <evh:EarningsPerSharePortionAttributableToNoncontrollingInterestBasic
      contextRef="i12a6d1161de54547bd29f8efccd4c9b0_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM184NS9mcmFnOjdhMDNjNzc3NWZjNDRmMzlhZmY3NjkyYjY5NGQ5YzM3L3RhYmxlOjhhNDlhNzA4NDcxMDQwZTk4MzBiMDg2ZTIxMzRlYTk1L3RhYmxlcmFuZ2U6OGE0OWE3MDg0NzEwNDBlOTgzMGIwODZlMjEzNGVhOTVfMTUtMy0xLTEtMjc1Mjc_cebaab0d-cb9a-4d96-96cf-e73e49782c92"
      unitRef="usdPerShare">0</evh:EarningsPerSharePortionAttributableToNoncontrollingInterestBasic>
    <evh:EarningsPerSharePortionAttributableToNoncontrollingInterestDiluted
      contextRef="i12a6d1161de54547bd29f8efccd4c9b0_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM184NS9mcmFnOjdhMDNjNzc3NWZjNDRmMzlhZmY3NjkyYjY5NGQ5YzM3L3RhYmxlOjhhNDlhNzA4NDcxMDQwZTk4MzBiMDg2ZTIxMzRlYTk1L3RhYmxlcmFuZ2U6OGE0OWE3MDg0NzEwNDBlOTgzMGIwODZlMjEzNGVhOTVfMTUtMy0xLTEtMjc1Mjc_f7665397-906b-4348-84a7-07254c898be6"
      unitRef="usdPerShare">0</evh:EarningsPerSharePortionAttributableToNoncontrollingInterestDiluted>
    <evh:EarningsPerSharePortionAttributableToNoncontrollingInterestBasic
      contextRef="i3e21049ffc224cacb8134d73c9bb5b38_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM184NS9mcmFnOjdhMDNjNzc3NWZjNDRmMzlhZmY3NjkyYjY5NGQ5YzM3L3RhYmxlOjhhNDlhNzA4NDcxMDQwZTk4MzBiMDg2ZTIxMzRlYTk1L3RhYmxlcmFuZ2U6OGE0OWE3MDg0NzEwNDBlOTgzMGIwODZlMjEzNGVhOTVfMTUtNS0xLTEtMjc1Mjc_0d37b9ed-1132-4390-9d72-4c8dc81e16e0"
      unitRef="usdPerShare">0.04</evh:EarningsPerSharePortionAttributableToNoncontrollingInterestBasic>
    <evh:EarningsPerSharePortionAttributableToNoncontrollingInterestDiluted
      contextRef="i3e21049ffc224cacb8134d73c9bb5b38_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM184NS9mcmFnOjdhMDNjNzc3NWZjNDRmMzlhZmY3NjkyYjY5NGQ5YzM3L3RhYmxlOjhhNDlhNzA4NDcxMDQwZTk4MzBiMDg2ZTIxMzRlYTk1L3RhYmxlcmFuZ2U6OGE0OWE3MDg0NzEwNDBlOTgzMGIwODZlMjEzNGVhOTVfMTUtNS0xLTEtMjc1Mjc_38addc30-6b9a-49e7-9ecf-74d51ec59ed6"
      unitRef="usdPerShare">0.04</evh:EarningsPerSharePortionAttributableToNoncontrollingInterestDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM184NS9mcmFnOjdhMDNjNzc3NWZjNDRmMzlhZmY3NjkyYjY5NGQ5YzM3L3RhYmxlOjhhNDlhNzA4NDcxMDQwZTk4MzBiMDg2ZTIxMzRlYTk1L3RhYmxlcmFuZ2U6OGE0OWE3MDg0NzEwNDBlOTgzMGIwODZlMjEzNGVhOTVfMTUtNS0xLTEtMTc3NzU_1dc36fb6-30b6-45f5-a0d7-06d7a9e9335f"
      unitRef="usdPerShare">-0.44</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM184NS9mcmFnOjdhMDNjNzc3NWZjNDRmMzlhZmY3NjkyYjY5NGQ5YzM3L3RhYmxlOjhhNDlhNzA4NDcxMDQwZTk4MzBiMDg2ZTIxMzRlYTk1L3RhYmxlcmFuZ2U6OGE0OWE3MDg0NzEwNDBlOTgzMGIwODZlMjEzNGVhOTVfMTUtNS0xLTEtMTc3NzU_f8b4468e-36ed-4cf2-b7f3-455155f62856"
      unitRef="usdPerShare">-0.44</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="i12a6d1161de54547bd29f8efccd4c9b0_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM184NS9mcmFnOjdhMDNjNzc3NWZjNDRmMzlhZmY3NjkyYjY5NGQ5YzM3L3RhYmxlOjhhNDlhNzA4NDcxMDQwZTk4MzBiMDg2ZTIxMzRlYTk1L3RhYmxlcmFuZ2U6OGE0OWE3MDg0NzEwNDBlOTgzMGIwODZlMjEzNGVhOTVfMTUtNy0xLTEtMTc3NzU_1354653c-22c3-4b3a-bf59-2975c6a7d95b"
      unitRef="usdPerShare">-3.94</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i12a6d1161de54547bd29f8efccd4c9b0_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM184NS9mcmFnOjdhMDNjNzc3NWZjNDRmMzlhZmY3NjkyYjY5NGQ5YzM3L3RhYmxlOjhhNDlhNzA4NDcxMDQwZTk4MzBiMDg2ZTIxMzRlYTk1L3RhYmxlcmFuZ2U6OGE0OWE3MDg0NzEwNDBlOTgzMGIwODZlMjEzNGVhOTVfMTUtNy0xLTEtMTc3NzU_6a13b863-a134-4ff7-b9ae-26c31fbc200f"
      unitRef="usdPerShare">-3.94</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="i3e21049ffc224cacb8134d73c9bb5b38_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM184NS9mcmFnOjdhMDNjNzc3NWZjNDRmMzlhZmY3NjkyYjY5NGQ5YzM3L3RhYmxlOjhhNDlhNzA4NDcxMDQwZTk4MzBiMDg2ZTIxMzRlYTk1L3RhYmxlcmFuZ2U6OGE0OWE3MDg0NzEwNDBlOTgzMGIwODZlMjEzNGVhOTVfMTYtNS0xLTEtMjc1MzE_71979723-6e39-4211-8a6d-eaf820918e5d"
      unitRef="usdPerShare">-3.67</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i3e21049ffc224cacb8134d73c9bb5b38_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM184NS9mcmFnOjdhMDNjNzc3NWZjNDRmMzlhZmY3NjkyYjY5NGQ5YzM3L3RhYmxlOjhhNDlhNzA4NDcxMDQwZTk4MzBiMDg2ZTIxMzRlYTk1L3RhYmxlcmFuZ2U6OGE0OWE3MDg0NzEwNDBlOTgzMGIwODZlMjEzNGVhOTVfMTYtNS0xLTEtMjc1MzE_fe462964-8e16-4239-9bc7-5853f6b65425"
      unitRef="usdPerShare">-3.67</us-gaap:EarningsPerShareDiluted>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock
      contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM184NS9mcmFnOjdhMDNjNzc3NWZjNDRmMzlhZmY3NjkyYjY5NGQ5YzM3L3RleHRyZWdpb246N2EwM2M3Nzc1ZmM0NGYzOWFmZjc2OTJiNjk0ZDljMzdfMzc2_2c0a4d4d-35d9-4664-ad30-998d7452a132">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Anti-dilutive shares (in thousands) excluded from the calculation of weighted-average common shares presented above are presented below:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:351.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:58.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:58.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:58.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;For the Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exchangeable Class B common stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,399&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:23pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted stock units ("RSUs"), performance-based RSUs and leveraged stock units ("LSUs")&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,807&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;797&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;813&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,036&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,141&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,324&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Convertible senior notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,602&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,206&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,361&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,445&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,144&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,897&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="ifdfd40d05cad486f8f8a1d4f5c27aedc_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM184NS9mcmFnOjdhMDNjNzc3NWZjNDRmMzlhZmY3NjkyYjY5NGQ5YzM3L3RhYmxlOjU1MjNlYmIzYzcwZTQxYTE4MTZlNWIyZmNmZWUzNjkyL3RhYmxlcmFuZ2U6NTUyM2ViYjNjNzBlNDFhMTgxNmU1YjJmY2ZlZTM2OTJfMi0xLTEtMS0yMjAwNg_e28e3107-4088-48db-82e9-dcb9d082d5f7"
      unitRef="shares">0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i52b87d0e43a34ffc9389f5e532dad861_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM184NS9mcmFnOjdhMDNjNzc3NWZjNDRmMzlhZmY3NjkyYjY5NGQ5YzM3L3RhYmxlOjU1MjNlYmIzYzcwZTQxYTE4MTZlNWIyZmNmZWUzNjkyL3RhYmxlcmFuZ2U6NTUyM2ViYjNjNzBlNDFhMTgxNmU1YjJmY2ZlZTM2OTJfMi0zLTEtMS0yMjAwNg_bea7d93b-4625-4db0-891f-7207cb7a8a2a"
      unitRef="shares">0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i7d76227fd72340699f3b20cadd0ca448_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM184NS9mcmFnOjdhMDNjNzc3NWZjNDRmMzlhZmY3NjkyYjY5NGQ5YzM3L3RhYmxlOjU1MjNlYmIzYzcwZTQxYTE4MTZlNWIyZmNmZWUzNjkyL3RhYmxlcmFuZ2U6NTUyM2ViYjNjNzBlNDFhMTgxNmU1YjJmY2ZlZTM2OTJfMi01LTEtMS0yMTk5NQ_e69e92f9-7a20-41d3-be69-bb8b7345b0d9"
      unitRef="shares">1399000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i201d78ce09254edeb74a5d8656d986e3_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM184NS9mcmFnOjdhMDNjNzc3NWZjNDRmMzlhZmY3NjkyYjY5NGQ5YzM3L3RhYmxlOjU1MjNlYmIzYzcwZTQxYTE4MTZlNWIyZmNmZWUzNjkyL3RhYmxlcmFuZ2U6NTUyM2ViYjNjNzBlNDFhMTgxNmU1YjJmY2ZlZTM2OTJfMi01LTEtMS0xNzc3NQ_f9c0eea6-4323-4c9e-8efe-bf67a787fbd3"
      unitRef="shares">1807000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="ia51882bd916343be8688568234c45e7d_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM184NS9mcmFnOjdhMDNjNzc3NWZjNDRmMzlhZmY3NjkyYjY5NGQ5YzM3L3RhYmxlOjU1MjNlYmIzYzcwZTQxYTE4MTZlNWIyZmNmZWUzNjkyL3RhYmxlcmFuZ2U6NTUyM2ViYjNjNzBlNDFhMTgxNmU1YjJmY2ZlZTM2OTJfMi03LTEtMS0xNzc3NQ_7c4dda4c-6843-4724-8088-60c41808e4e1"
      unitRef="shares">797000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="ic6ab9363606041b5b1b0664ec16f77e3_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM184NS9mcmFnOjdhMDNjNzc3NWZjNDRmMzlhZmY3NjkyYjY5NGQ5YzM3L3RhYmxlOjU1MjNlYmIzYzcwZTQxYTE4MTZlNWIyZmNmZWUzNjkyL3RhYmxlcmFuZ2U6NTUyM2ViYjNjNzBlNDFhMTgxNmU1YjJmY2ZlZTM2OTJfMy01LTEtMS0yMTk5NQ_1c248206-5c22-49d9-9939-9e89b3ab654c"
      unitRef="shares">813000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="ia6e4317e0fe84f639d451026ec4811f7_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM184NS9mcmFnOjdhMDNjNzc3NWZjNDRmMzlhZmY3NjkyYjY5NGQ5YzM3L3RhYmxlOjU1MjNlYmIzYzcwZTQxYTE4MTZlNWIyZmNmZWUzNjkyL3RhYmxlcmFuZ2U6NTUyM2ViYjNjNzBlNDFhMTgxNmU1YjJmY2ZlZTM2OTJfMy01LTEtMS0xNzc3NQ_f03c50b6-ac3d-486c-99a8-98db4475b025"
      unitRef="shares">2036000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="iebc1de752eaa4389a6a51366f6e15efc_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM184NS9mcmFnOjdhMDNjNzc3NWZjNDRmMzlhZmY3NjkyYjY5NGQ5YzM3L3RhYmxlOjU1MjNlYmIzYzcwZTQxYTE4MTZlNWIyZmNmZWUzNjkyL3RhYmxlcmFuZ2U6NTUyM2ViYjNjNzBlNDFhMTgxNmU1YjJmY2ZlZTM2OTJfMy03LTEtMS0xNzc3NQ_91970b6d-9fca-4ddc-878e-7e05b52f1230"
      unitRef="shares">1141000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i7adc7fd9e069474b9522f7f84242457e_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM184NS9mcmFnOjdhMDNjNzc3NWZjNDRmMzlhZmY3NjkyYjY5NGQ5YzM3L3RhYmxlOjU1MjNlYmIzYzcwZTQxYTE4MTZlNWIyZmNmZWUzNjkyL3RhYmxlcmFuZ2U6NTUyM2ViYjNjNzBlNDFhMTgxNmU1YjJmY2ZlZTM2OTJfNC01LTEtMS0yMTk5NQ_b6b64ab5-5740-49d2-9afb-eb13db227aad"
      unitRef="shares">1324000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="icbc3599f42a84566bfd33e73e504c17e_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM184NS9mcmFnOjdhMDNjNzc3NWZjNDRmMzlhZmY3NjkyYjY5NGQ5YzM3L3RhYmxlOjU1MjNlYmIzYzcwZTQxYTE4MTZlNWIyZmNmZWUzNjkyL3RhYmxlcmFuZ2U6NTUyM2ViYjNjNzBlNDFhMTgxNmU1YjJmY2ZlZTM2OTJfNC01LTEtMS0xNzc3NQ_3e794cb4-f268-4c58-93b9-306b46e507a5"
      unitRef="shares">12602000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="id074b4bed7284281bb2163f48f76bf03_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM184NS9mcmFnOjdhMDNjNzc3NWZjNDRmMzlhZmY3NjkyYjY5NGQ5YzM3L3RhYmxlOjU1MjNlYmIzYzcwZTQxYTE4MTZlNWIyZmNmZWUzNjkyL3RhYmxlcmFuZ2U6NTUyM2ViYjNjNzBlNDFhMTgxNmU1YjJmY2ZlZTM2OTJfNC03LTEtMS0xNzc3NQ_40c20dde-dc6a-43d0-9d59-f5702d484662"
      unitRef="shares">11206000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="ib784df78539b41c494661a446433f01c_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM184NS9mcmFnOjdhMDNjNzc3NWZjNDRmMzlhZmY3NjkyYjY5NGQ5YzM3L3RhYmxlOjU1MjNlYmIzYzcwZTQxYTE4MTZlNWIyZmNmZWUzNjkyL3RhYmxlcmFuZ2U6NTUyM2ViYjNjNzBlNDFhMTgxNmU1YjJmY2ZlZTM2OTJfNS01LTEtMS0yMTk5NQ_8adeea3c-d53c-4234-ba22-3cd5f9ef39f3"
      unitRef="shares">10361000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM184NS9mcmFnOjdhMDNjNzc3NWZjNDRmMzlhZmY3NjkyYjY5NGQ5YzM3L3RhYmxlOjU1MjNlYmIzYzcwZTQxYTE4MTZlNWIyZmNmZWUzNjkyL3RhYmxlcmFuZ2U6NTUyM2ViYjNjNzBlNDFhMTgxNmU1YjJmY2ZlZTM2OTJfNS01LTEtMS0xNzc3NQ_677ccf7f-8978-46cf-bea2-ec0552beff35"
      unitRef="shares">16445000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i12a6d1161de54547bd29f8efccd4c9b0_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM184NS9mcmFnOjdhMDNjNzc3NWZjNDRmMzlhZmY3NjkyYjY5NGQ5YzM3L3RhYmxlOjU1MjNlYmIzYzcwZTQxYTE4MTZlNWIyZmNmZWUzNjkyL3RhYmxlcmFuZ2U6NTUyM2ViYjNjNzBlNDFhMTgxNmU1YjJmY2ZlZTM2OTJfNS03LTEtMS0xNzc3NQ_39ce6911-6455-4465-a11b-4590ca369afb"
      unitRef="shares">13144000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i3e21049ffc224cacb8134d73c9bb5b38_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM184NS9mcmFnOjdhMDNjNzc3NWZjNDRmMzlhZmY3NjkyYjY5NGQ5YzM3L3RhYmxlOjU1MjNlYmIzYzcwZTQxYTE4MTZlNWIyZmNmZWUzNjkyL3RhYmxlcmFuZ2U6NTUyM2ViYjNjNzBlNDFhMTgxNmU1YjJmY2ZlZTM2OTJfNi01LTEtMS0yMTk5NQ_ce95fd31-ced7-4585-8129-a7272adea561"
      unitRef="shares">13897000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
      contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185MS9mcmFnOjlmMTJhYjBlYWNjMTQ1OTU5ZDhhNjcyY2JmZjdkYjZkL3RleHRyZWdpb246OWYxMmFiMGVhY2MxNDU5NTlkOGE2NzJjYmZmN2RiNmRfMTI2NjA_7435bdb7-f45e-430a-92ff-78701f7de040">Stock-based Compensation&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;2011 and 2015 Equity Incentive Plans&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company issues awards, including stock options, performance-based stock options, restricted stock units, performance-based restricted stock units and leveraged stock units, under the Evolent Health Holdings, Inc. 2011 Equity Incentive Plan (the &#x201c;2011 Plan&#x201d;) and the 2015 Evolent Health, Inc. Omnibus Incentive Compensation Plan (the &#x201c;2015 Plan&#x201d;). We assumed the 2011 Plan in connection with the merger of Evolent Health Holdings with and into Evolent Health, Inc. The 2011 Plan allows for the grant of an array of equity-based and cash incentive awards to our directors, employees and other service providers. The 2011 Plan was amended on September 23, 2013, to increase the number of shares authorized to 9.1&#160;million of the Company&#x2019;s common stock. As of December&#160;31, 2021 and 2020, 4.8 million stock options and 3.8 million shares of restricted stock have been issued, net of forfeitures, under the 2011 Plan.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On May 1, 2015, the Board of Directors approved and authorized the 2015 Plan which provides for the issuance of up to 6.0 million shares of the Company&#x2019;s Class A common stock to employees and non-employee directors of the Company and its consolidated subsidiaries. The 2015 Plan was amended on June 13, 2018  and April 15, 2021, to increase the number of shares authorized to 10.5 million and 15.4 million, respectively. Upon shareholder approval of the amended 2015 Plan in 2018, the 2011 Plan was automatically terminated and no further awards may be granted under the 2011 Plan. The 2011 Plan continues to govern awards previously granted under the 2011 Plan. As of December&#160;31, 2021, 2.8 million of stock options, 4.5 million RSUs, 1.1 million LSUs and 0.3 million PSUs, have been issued, net of forfeitures, under the 2015 Plan. As of December 31, 2020, 2.8 million stock options, 3.5 million RSUs and 1.2 million LSUs, have been issued, net of forfeitures, under the 2015 Plan.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We follow an employee model for our stock-based compensation as awards are granted in the stock of the Company to employees and non-employee directors of the Company or its consolidated subsidiaries. Following the adoption of ASU 2018-07 during 2018, we also follow the employee model for stock-based compensation for awards granted to acquire goods and services from non-employees. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Stock-based Compensation Expense&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total compensation expense by award type and line item in our consolidated financial statements was as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:379.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:48.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:48.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:48.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;For the Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Award Type&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock options&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,337&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,927&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,237&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Performance-based stock options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;75&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;448&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;RSUs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,606&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,763&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,877&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Performance-based RSUs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,471&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(388)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;LSUs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,297&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,841&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,444&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total compensation expense by award type&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,711&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,606&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,618&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Line Item&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cost of revenue&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,263&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,811&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,673&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Selling, general and administrative expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,448&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,795&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,945&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total compensation expense by financial statement line item&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,711&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,606&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,618&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;No&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; stock-based compensation was capitalized as software development costs for the years ended December&#160;31, 2021, 2020 and 2019.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total unrecognized compensation expense (in thousands) and expected weighted-average period (in years) by award type for all of our stock-based incentive plans were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:535.50pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:393.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:66.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:66.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;As of December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:33pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Unrecognized Compensation Expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted Average Period (years)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock options&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;512&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.57&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;RSUs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26,104&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.69&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;LSUs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,422&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.19&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Performance-based RSUs&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,121&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.17&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,159&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Stock Options&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other than the performance-based stock options described below, options awarded under the incentive compensation plans are generally subject to a four-year graded service vesting period where 25% of the award vests after each year of service and have a maximum term of 10 years. Information with respect to our options is presented in the following disclosures. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The option price assumptions used for our stock option awards for the year ended December 31, 2019, were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:463.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:72.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average fair value per option granted&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.52&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Assumptions:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected term (in years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.25&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;51.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.9% - 2.7%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of options is determined using a Black-Scholes options valuation model with the assumptions disclosed in the table above. The dividend rate is based on the expected dividend rate during the expected life of the option. Expected volatility is based on the historical volatility over the most recent period commensurate with the estimated expected term of the Company&#x2019;s awards due to the limited history of our own stock price. The risk-free interest rate is based on the U.S. Treasury yield curve in effect at the time of the grant. The expected life represents the period of time the stock&#160;options&#160;are expected to be outstanding and is based on the&#160;simplified method. Under the&#160;simplified method, the expected life of an option is presumed to be the midpoint between the vesting date and the end of the contractual term. We used the&#160;simplified method&#160;due to the lack of sufficient historical exercise data to provide a reasonable basis upon which to otherwise estimate the expected life of the stock&#160;options.&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Information with respect to our stock options (in thousands), including weighted-average remaining contractual term (in years) and aggregate intrinsic value (in thousands) was as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.75pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:283.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:58.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:3.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:58.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:3.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:58.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:3.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:58.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr style="height:51pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted Average Exercise Price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted Average Remaining Contractual Term&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Aggregate Intrinsic Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding as of December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,070&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.32&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.25&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,578&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,490)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.92&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(31)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15.23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding as of December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,549&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.49&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.99&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46,342&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested and expected to vest after December&#160;31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,549&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.49&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.99&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46,342&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercisable as of December&#160;31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,301&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.71&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42,717&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The total fair value of options vested during the years ended December 31, 2021, 2020 and 2019, was $4.9 million, $3.6 million and $5.9 million, respectively. The total intrinsic value of options exercised during 2021, 2020 and 2019 was $20.8 million, $2.2 million and $0.6 million, respectively. We issue new shares to satisfy option exercises.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Performance-based stock option awards&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In March 2016, the Company granted approximately 0.3&#160;million performance-based options to certain employees to create incentives for continued long-term success and to more closely align executive pay with our stockholders&#x2019; interests. Each of the grants is subject to market-based vesting, as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt"&gt;one-third of the shares subject to the option award will vest in the event that the average closing price of the Company&#x2019;s Class A common stock on the NYSE is at least $13.35 per share for a consecutive ninety day period;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt"&gt;one-third of the shares subject to the option award will vest in the event that the average closing price of the Company&#x2019;s Class A common stock on the NYSE is at least $16.43 per share for a consecutive &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185MS9mcmFnOjlmMTJhYjBlYWNjMTQ1OTU5ZDhhNjcyY2JmZjdkYjZkL3RleHRyZWdpb246OWYxMmFiMGVhY2MxNDU5NTlkOGE2NzJjYmZmN2RiNmRfNTEyNA_e4d931ff-6eba-4d04-bddc-9b3b4429017b"&gt;ninety&lt;/span&gt; day period; and&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt"&gt;one-third of the shares subject to the option award will vest in the event that the average closing price of the Company&#x2019;s Class A common stock on the NYSE is at least $19.51 per share for a consecutive &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185MS9mcmFnOjlmMTJhYjBlYWNjMTQ1OTU5ZDhhNjcyY2JmZjdkYjZkL3RleHRyZWdpb246OWYxMmFiMGVhY2MxNDU5NTlkOGE2NzJjYmZmN2RiNmRfNTMzOA_19dbae44-014f-4a37-a3b0-0e16f19819c4"&gt;ninety&lt;/span&gt; day period.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In addition, the percentage of options per tranche that has satisfied the market-based performance hurdle is also subject to a service completion schedule. The aggregate percentage of options eligible to vest is based upon each of the service completions dates below:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt"&gt;50% of the shares subject to the option award vested on March 1, 2019, and&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt"&gt;50% of the shares subject to the option award vested on March 1, 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We measured the fair value of the performance-based stock options using a Monte Carlo simulation approach with the following assumptions: risk-free interest rate of 1.83%, volatility of 65%, expected term of ten years and dividend yield of 0% as we do not currently pay dividends nor expect to do so during the expected option term. These inputs resulted in a weighted-average fair value per option granted of $6.68. During 2016 all of the average stock price milestones were achieved and therefore the awards are now only subject to the service completion obligations.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Information with respect to our performance-based stock options (shares and aggregate intrinsic value shown in thousands, weighted-average remaining contractual term shown in years) was as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:539.25pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:286.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:58.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:58.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:58.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:58.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr style="height:54pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted Average Exercise Price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted Average Remaining Contractual Term&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Aggregate Intrinsic Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding as of December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;268&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.27&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.17&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(326)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding as of December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;268&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.27&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.16&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,620&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested and expected to vest after December&#160;31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;268&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.27&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.16&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,620&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Restricted Stock Units&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other than the performance-based RSUs described below, and other than RSUs granted to our non-employee directors which have a one year vesting period, RSUs awarded under the incentive compensation plans are generally subject to a four-year graded service vesting period where 25% of the award vests after each year of service and are issued to the participants for no consideration. During 2018, we also granted certain RSUs with a one-year vesting period in conjunction with the New Century Health transaction. Information with respect to our RSUs (not including performance-based RSUs) is presented below (in thousands, except for weighted-average grant-date fair value):&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:412.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:58.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:3.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:58.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr style="height:42pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total RSUs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted Average Grant Date Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding as of December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,737&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,276&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(243)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12.74&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(683)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.68&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding as of December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,087&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16.35&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the years ended December&#160;31, 2021, 2020 and 2019, we granted RSUs with a weighted-average grant date fair value of $21.10, $8.88 and $10.66, respectively, which represents the weighted-average closing price of our common stock on the grant date. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The total fair value of RSUs vested during the years ended December&#160;31, 2021, 2020 and 2019 was $7.3&#160;million, $6.1&#160;million and $7.3&#160;million, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Leveraged Stock Unit Awards&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During 2020 and 2019, the Company granted 0.5&#160;million and 0.7&#160;million leveraged stock units, respectively, to certain employees to create incentives for continued long-term success and to more closely align executive pay with our stockholders&#x2019; interests. Each of the grants is subject to share price-based vesting on the business day following the third anniversary of the grant date, as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt"&gt;If the stock price has increased by 33.3%, 75% of the shares will vest&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt"&gt;If the stock price has increased by 50%, 100% of the shares will vest&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt"&gt;If the stock price has increased by 100%, 150% of the shares will vest&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt"&gt;If the stock price has increased by 200%, 200% of the shares will vest (this is the maximum possible vest amount)&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The price assumptions used for our leveraged stock unit awards were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:384.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:73.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:73.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;For the Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average fair value per leveraged stock unit granted&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.90&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.52&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Assumptions:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected term&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;62.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;51.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.85%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.54%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of leveraged stock units is determined using a Black-Scholes valuation model with the assumptions disclosed in the table above. The dividend rate is based on the expected dividend rate during the expected life of the award. Expected volatility is based on the historical volatility over the most recent period commensurate with the estimated expected term of the Company&#x2019;s awards due to the limited history of our own stock price. The risk-free interest rate is based on the U.S. Treasury yield curve in effect at the time of the grant. The expected life represents the period of time the awards&#160;are expected to be outstanding and is based on the&#160;simplified method. Under the&#160;simplified method, the expected life of an award is presumed to be the midpoint between the vesting date and the end of the contractual term. We used the&#160;simplified method&#160;due to the lack of sufficient historical exercise data to provide a reasonable basis upon which to otherwise estimate the expected life of the awards.&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Information with respect to our leveraged stock unit awards (shares and aggregate intrinsic value shown in thousands, weighted-average remaining contractual term shown in years) was as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:539.25pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:286.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:58.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:58.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:58.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:58.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr style="height:54pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Leveraged Stock Units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted Average Grant Date Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted Average Remaining Contractual Term&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Aggregate Intrinsic Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding as of December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,084&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.07&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.68&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,993&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested and expected to vest after December&#160;31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,084&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.07&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.68&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,993&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Performance-based RSUs&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During 2021, the Company granted 0.3&#160;million performance-based RSUs to certain employees to create incentives for continued long-term success and to more closely align executive pay with our stockholders&#x2019; interests. A &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185MS9mcmFnOjlmMTJhYjBlYWNjMTQ1OTU5ZDhhNjcyY2JmZjdkYjZkL3RleHRyZWdpb246OWYxMmFiMGVhY2MxNDU5NTlkOGE2NzJjYmZmN2RiNmRfMzI5ODUzNDkxMDU4Mg_a8edff10-eb5c-4745-9477-bbe219e0ae2c"&gt;two&lt;/span&gt; and three-year cumulative Adjusted EBITDA goal was approved and began on January 1, 2021. Shares are earned based on a sliding scale of performance above and below the performance goal. The sliding scale is anchored by a minimum performance requirement of cumulative Adjusted EBITDA. If the minimum performance goal is not achieved, then no performance shares are earned. If 100% of the performance goal is achieved, then award is paid at target and if the maximum performance is achieved, then 200% of the targeted shares are earned. If the cumulative Adjusted EBITDA falls between tiers on the sliding scale, the actual cumulative Adjusted EBITDA payout percentage shall be determined by linear interpolation between the percentages on a straight-line basis. Shares earned by the &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185MS9mcmFnOjlmMTJhYjBlYWNjMTQ1OTU5ZDhhNjcyY2JmZjdkYjZkL3RleHRyZWdpb246OWYxMmFiMGVhY2MxNDU5NTlkOGE2NzJjYmZmN2RiNmRfMzI5ODUzNDkxMDYwMA_5c625e05-1161-4caa-b418-357677b81681"&gt;two&lt;/span&gt; and three-year cumulative Adjusted EBITDA performance will be adjusted based on a respective total shareholder return ("TSR"). Shares earned will be adjusted -10% if TSR performance is in the bottom quartile and will be adjusted +10% if TSR performance is in the upper quartile. TSR represents stock price appreciation over each of the two performance periods. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The price assumptions used for our performance based stock unit awards were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:384.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:73.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:73.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1st Tranche&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2nd Tranche&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average fair value per performance based stock unit granted&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20.64&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20.69&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Assumptions:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected term&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;89.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;77.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of performance based stock units is determined using a Black-Scholes valuation model with the assumptions disclosed in the table above. The dividend rate is based on the expected dividend rate during the expected life of the award. Expected volatility is based on the historical volatility over the most recent period commensurate with the estimated expected term of the Company&#x2019;s awards due to the limited history of our own stock price. The risk-free interest rate is based on the U.S. Treasury yield curve in effect at the time of the grant. The expected life represents the period of time the awards&#160;are expected to be outstanding and is based on the&#160;simplified method. Under the&#160;simplified method, the expected life of an award is presumed to be the midpoint between the vesting date and the end of the contractual term. We used the&#160;simplified method&#160;due to the lack of sufficient historical exercise data to provide a reasonable basis upon which to otherwise estimate the expected life of the awards.&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Information with respect to our performance based restricted stock unit awards (shares and aggregate intrinsic value shown in thousands, weighted-average remaining contractual term shown in years) was as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:536.25pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:280.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:60.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:58.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:58.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:58.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr style="height:54pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Performance Based  Stock Units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted Average Grant Date Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted Average Remaining Contractual Term&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Aggregate Intrinsic Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding as of December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;319&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20.67&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.16&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,233&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested and expected to vest after December&#160;31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;319&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20.67&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.16&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,233&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="ie27c749af3f640e6b503c30b7017a0cb_I20130923"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185MS9mcmFnOjlmMTJhYjBlYWNjMTQ1OTU5ZDhhNjcyY2JmZjdkYjZkL3RleHRyZWdpb246OWYxMmFiMGVhY2MxNDU5NTlkOGE2NzJjYmZmN2RiNmRfNzI5_1fb78564-e2b5-40fb-906c-5b2bb34be5ef"
      unitRef="shares">9100000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i1d4614ce073d4c1dbaf45d31f2350ff7_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185MS9mcmFnOjlmMTJhYjBlYWNjMTQ1OTU5ZDhhNjcyY2JmZjdkYjZkL3RleHRyZWdpb246OWYxMmFiMGVhY2MxNDU5NTlkOGE2NzJjYmZmN2RiNmRfNzgw_8cdc7bd1-37c8-4208-88ad-d28d2e425ef1"
      unitRef="shares">4800000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="i96a77abfddf84842a980b801febda12d_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185MS9mcmFnOjlmMTJhYjBlYWNjMTQ1OTU5ZDhhNjcyY2JmZjdkYjZkL3RleHRyZWdpb246OWYxMmFiMGVhY2MxNDU5NTlkOGE2NzJjYmZmN2RiNmRfODAx_0787479b-b24e-459a-8b7b-74ba8767b4d9"
      unitRef="shares">3800000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="ie6ac3c72c3d048a79d7e7fab6a952c8d_I20150501"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185MS9mcmFnOjlmMTJhYjBlYWNjMTQ1OTU5ZDhhNjcyY2JmZjdkYjZkL3RleHRyZWdpb246OWYxMmFiMGVhY2MxNDU5NTlkOGE2NzJjYmZmN2RiNmRfMTAxMA_48035389-23ab-45aa-9137-49ccceacc37f"
      unitRef="shares">6000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="i24c60745c92845f2979175286f6cfdb2_I20180613"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185MS9mcmFnOjlmMTJhYjBlYWNjMTQ1OTU5ZDhhNjcyY2JmZjdkYjZkL3RleHRyZWdpb246OWYxMmFiMGVhY2MxNDU5NTlkOGE2NzJjYmZmN2RiNmRfMTIzOQ_77a76488-82d9-40a3-9b5a-f126071b63c9"
      unitRef="shares">10500000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="ifd8fb1ee9c5446a8804b4991f663185d_I20210415"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185MS9mcmFnOjlmMTJhYjBlYWNjMTQ1OTU5ZDhhNjcyY2JmZjdkYjZkL3RleHRyZWdpb246OWYxMmFiMGVhY2MxNDU5NTlkOGE2NzJjYmZmN2RiNmRfMTA5OTUxMTY1NDM5NQ_8dfb1737-1295-42d4-92db-bce3aa3bb821"
      unitRef="shares">15400000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="ib2892fd727a044ae9ebfd0032f5bc139_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185MS9mcmFnOjlmMTJhYjBlYWNjMTQ1OTU5ZDhhNjcyY2JmZjdkYjZkL3RleHRyZWdpb246OWYxMmFiMGVhY2MxNDU5NTlkOGE2NzJjYmZmN2RiNmRfMTQ5MA_ff783910-2a7a-46c5-b7b1-5b9e967369a1"
      unitRef="shares">2800000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="i4266034771344505a1b7761cd97832a1_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185MS9mcmFnOjlmMTJhYjBlYWNjMTQ1OTU5ZDhhNjcyY2JmZjdkYjZkL3RleHRyZWdpb246OWYxMmFiMGVhY2MxNDU5NTlkOGE2NzJjYmZmN2RiNmRfMTUxOA_9b6c18e6-0f33-4297-8b80-6dae837efe0d"
      unitRef="shares">4500000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="i0017a1e05fa1452c857571fdbc23fd69_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185MS9mcmFnOjlmMTJhYjBlYWNjMTQ1OTU5ZDhhNjcyY2JmZjdkYjZkL3RleHRyZWdpb246OWYxMmFiMGVhY2MxNDU5NTlkOGE2NzJjYmZmN2RiNmRfMTA5OTUxMTY1NDkzOA_93896906-7da3-402c-8eac-b9a496b33cb1"
      unitRef="shares">1100000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="ic48b20a77e2d4ff0bffc7a7d61a66f9c_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185MS9mcmFnOjlmMTJhYjBlYWNjMTQ1OTU5ZDhhNjcyY2JmZjdkYjZkL3RleHRyZWdpb246OWYxMmFiMGVhY2MxNDU5NTlkOGE2NzJjYmZmN2RiNmRfMTA5OTUxMTY1NDk1MQ_402210b9-2b47-4bc9-867a-7476da801be5"
      unitRef="shares">300000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i0486c1cd30d84075a90f947bf2f00d37_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185MS9mcmFnOjlmMTJhYjBlYWNjMTQ1OTU5ZDhhNjcyY2JmZjdkYjZkL3RleHRyZWdpb246OWYxMmFiMGVhY2MxNDU5NTlkOGE2NzJjYmZmN2RiNmRfMTA5OTUxMTY1NDgxOA_36cc4000-0d2f-40fd-88ec-90fc2ff8c135"
      unitRef="shares">2800000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="i9057bdb4a3f7459a99f31c6dcfaf93e8_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185MS9mcmFnOjlmMTJhYjBlYWNjMTQ1OTU5ZDhhNjcyY2JmZjdkYjZkL3RleHRyZWdpb246OWYxMmFiMGVhY2MxNDU5NTlkOGE2NzJjYmZmN2RiNmRfMTA5OTUxMTY1NDg1MQ_7a155796-0771-47bf-8fe5-7be079c2e677"
      unitRef="shares">3500000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="i144feb14f3894f2a93baecbdbd67f999_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185MS9mcmFnOjlmMTJhYjBlYWNjMTQ1OTU5ZDhhNjcyY2JmZjdkYjZkL3RleHRyZWdpb246OWYxMmFiMGVhY2MxNDU5NTlkOGE2NzJjYmZmN2RiNmRfMTA5OTUxMTY1NDk3OA_259fc1b9-f627-4a92-b305-64ab841d9d0a"
      unitRef="shares">1200000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock
      contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185MS9mcmFnOjlmMTJhYjBlYWNjMTQ1OTU5ZDhhNjcyY2JmZjdkYjZkL3RleHRyZWdpb246OWYxMmFiMGVhY2MxNDU5NTlkOGE2NzJjYmZmN2RiNmRfMTI2NTI_d3f00578-e63d-4919-916b-1c7dd6eb3820">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total compensation expense by award type and line item in our consolidated financial statements was as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:379.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:48.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:48.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:48.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;For the Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Award Type&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock options&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,337&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,927&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,237&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Performance-based stock options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;75&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;448&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;RSUs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,606&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,763&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,877&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Performance-based RSUs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,471&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(388)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;LSUs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,297&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,841&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,444&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total compensation expense by award type&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,711&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,606&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,618&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Line Item&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cost of revenue&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,263&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,811&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,673&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Selling, general and administrative expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,448&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,795&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,945&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total compensation expense by financial statement line item&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,711&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,606&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,618&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i532d2c0bf63243e999d48341920b6775_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185MS9mcmFnOjlmMTJhYjBlYWNjMTQ1OTU5ZDhhNjcyY2JmZjdkYjZkL3RhYmxlOjEyM2UwNzU3YWM2ZTQzNTM4ZWVkNDJjNmViY2YxMmFlL3RhYmxlcmFuZ2U6MTIzZTA3NTdhYzZlNDM1MzhlZWQ0MmM2ZWJjZjEyYWVfMy0xLTEtMS0xNzc3NQ_1204d897-b199-4f2a-9b85-c88fd2222a63"
      unitRef="usd">1337000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i3462813a792a43bdb0cd92a0d3fc4085_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185MS9mcmFnOjlmMTJhYjBlYWNjMTQ1OTU5ZDhhNjcyY2JmZjdkYjZkL3RhYmxlOjEyM2UwNzU3YWM2ZTQzNTM4ZWVkNDJjNmViY2YxMmFlL3RhYmxlcmFuZ2U6MTIzZTA3NTdhYzZlNDM1MzhlZWQ0MmM2ZWJjZjEyYWVfMy0zLTEtMS0xNzc3NQ_f4b58520-f30c-4816-8170-f74ed066e975"
      unitRef="usd">2927000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="id4cdbac3ed5841318a01e98ea7bb7cb3_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185MS9mcmFnOjlmMTJhYjBlYWNjMTQ1OTU5ZDhhNjcyY2JmZjdkYjZkL3RhYmxlOjEyM2UwNzU3YWM2ZTQzNTM4ZWVkNDJjNmViY2YxMmFlL3RhYmxlcmFuZ2U6MTIzZTA3NTdhYzZlNDM1MzhlZWQ0MmM2ZWJjZjEyYWVfMy01LTEtMS0xNzc3NQ_577ce658-fb98-4b30-83b7-2efd491cb435"
      unitRef="usd">4237000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i45606ce9dfa74fc7bd724460f67189ab_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185MS9mcmFnOjlmMTJhYjBlYWNjMTQ1OTU5ZDhhNjcyY2JmZjdkYjZkL3RhYmxlOjEyM2UwNzU3YWM2ZTQzNTM4ZWVkNDJjNmViY2YxMmFlL3RhYmxlcmFuZ2U6MTIzZTA3NTdhYzZlNDM1MzhlZWQ0MmM2ZWJjZjEyYWVfNC0xLTEtMS0xNzc3NQ_20144358-15a9-420c-bfb9-c330ffe0e896"
      unitRef="usd">0</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i2ef2d194cc634bb5a3f24f06d02c7f5b_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185MS9mcmFnOjlmMTJhYjBlYWNjMTQ1OTU5ZDhhNjcyY2JmZjdkYjZkL3RhYmxlOjEyM2UwNzU3YWM2ZTQzNTM4ZWVkNDJjNmViY2YxMmFlL3RhYmxlcmFuZ2U6MTIzZTA3NTdhYzZlNDM1MzhlZWQ0MmM2ZWJjZjEyYWVfNC0zLTEtMS0xNzc3NQ_437860c4-0125-4293-9c15-30ee95d4824a"
      unitRef="usd">75000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i98059f1600aa412c87f3adc6788eb8b5_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185MS9mcmFnOjlmMTJhYjBlYWNjMTQ1OTU5ZDhhNjcyY2JmZjdkYjZkL3RhYmxlOjEyM2UwNzU3YWM2ZTQzNTM4ZWVkNDJjNmViY2YxMmFlL3RhYmxlcmFuZ2U6MTIzZTA3NTdhYzZlNDM1MzhlZWQ0MmM2ZWJjZjEyYWVfNC01LTEtMS0xNzc3NQ_d41fed27-29b1-4515-a7eb-d8ea55d13c43"
      unitRef="usd">448000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i903fc0912d4e492c95e3ce815e897489_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185MS9mcmFnOjlmMTJhYjBlYWNjMTQ1OTU5ZDhhNjcyY2JmZjdkYjZkL3RhYmxlOjEyM2UwNzU3YWM2ZTQzNTM4ZWVkNDJjNmViY2YxMmFlL3RhYmxlcmFuZ2U6MTIzZTA3NTdhYzZlNDM1MzhlZWQ0MmM2ZWJjZjEyYWVfNS0xLTEtMS0xNzc3NQ_dc88c805-09df-460a-bd82-581d1af8874a"
      unitRef="usd">9606000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i117e325270bf4054b07c98692139814a_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185MS9mcmFnOjlmMTJhYjBlYWNjMTQ1OTU5ZDhhNjcyY2JmZjdkYjZkL3RhYmxlOjEyM2UwNzU3YWM2ZTQzNTM4ZWVkNDJjNmViY2YxMmFlL3RhYmxlcmFuZ2U6MTIzZTA3NTdhYzZlNDM1MzhlZWQ0MmM2ZWJjZjEyYWVfNS0zLTEtMS0xNzc3NQ_e3727878-9f80-4cc9-a72e-651ea5793f91"
      unitRef="usd">7763000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i4ad066769cd0464cbcbcf7d1ec4ce0ad_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185MS9mcmFnOjlmMTJhYjBlYWNjMTQ1OTU5ZDhhNjcyY2JmZjdkYjZkL3RhYmxlOjEyM2UwNzU3YWM2ZTQzNTM4ZWVkNDJjNmViY2YxMmFlL3RhYmxlcmFuZ2U6MTIzZTA3NTdhYzZlNDM1MzhlZWQ0MmM2ZWJjZjEyYWVfNS01LTEtMS0xNzc3NQ_7ef4dd7f-292e-4257-be41-fe391045e508"
      unitRef="usd">8877000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i91de07e5bb1e422aa1d46986a0b1006f_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185MS9mcmFnOjlmMTJhYjBlYWNjMTQ1OTU5ZDhhNjcyY2JmZjdkYjZkL3RhYmxlOjEyM2UwNzU3YWM2ZTQzNTM4ZWVkNDJjNmViY2YxMmFlL3RhYmxlcmFuZ2U6MTIzZTA3NTdhYzZlNDM1MzhlZWQ0MmM2ZWJjZjEyYWVfNi0xLTEtMS0xNzc3NQ_b51efb44-a8cc-4cbd-8ed3-eff79e522cea"
      unitRef="usd">2471000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ief3bd4a971ea460990e3d8fb590be11d_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185MS9mcmFnOjlmMTJhYjBlYWNjMTQ1OTU5ZDhhNjcyY2JmZjdkYjZkL3RhYmxlOjEyM2UwNzU3YWM2ZTQzNTM4ZWVkNDJjNmViY2YxMmFlL3RhYmxlcmFuZ2U6MTIzZTA3NTdhYzZlNDM1MzhlZWQ0MmM2ZWJjZjEyYWVfNi0zLTEtMS0xNzc3NQ_3a66062e-1223-494e-aa32-b9e1fad3d31f"
      unitRef="usd">0</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i460ef5cbfd2c49989b7ae61f7d7e59b2_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185MS9mcmFnOjlmMTJhYjBlYWNjMTQ1OTU5ZDhhNjcyY2JmZjdkYjZkL3RhYmxlOjEyM2UwNzU3YWM2ZTQzNTM4ZWVkNDJjNmViY2YxMmFlL3RhYmxlcmFuZ2U6MTIzZTA3NTdhYzZlNDM1MzhlZWQ0MmM2ZWJjZjEyYWVfNi01LTEtMS0xNzc3NQ_52898d2e-4bf0-46ac-bf25-fb10e98e19f8"
      unitRef="usd">-388000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="if0b01289c86a4176ab75517bdfe4ec1f_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185MS9mcmFnOjlmMTJhYjBlYWNjMTQ1OTU5ZDhhNjcyY2JmZjdkYjZkL3RhYmxlOjEyM2UwNzU3YWM2ZTQzNTM4ZWVkNDJjNmViY2YxMmFlL3RhYmxlcmFuZ2U6MTIzZTA3NTdhYzZlNDM1MzhlZWQ0MmM2ZWJjZjEyYWVfNy0xLTEtMS0xNzc3NQ_6c9101ce-9525-4235-ae29-6cb8aa775e46"
      unitRef="usd">3297000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i824c4e26d9414a59ad8f2d73e36714d0_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185MS9mcmFnOjlmMTJhYjBlYWNjMTQ1OTU5ZDhhNjcyY2JmZjdkYjZkL3RhYmxlOjEyM2UwNzU3YWM2ZTQzNTM4ZWVkNDJjNmViY2YxMmFlL3RhYmxlcmFuZ2U6MTIzZTA3NTdhYzZlNDM1MzhlZWQ0MmM2ZWJjZjEyYWVfNy0zLTEtMS0xNzc3NQ_c5d8354b-5961-4daf-987a-7849ed0e7894"
      unitRef="usd">3841000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i89ff4001d069448c9d4b0758b35fcfdb_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185MS9mcmFnOjlmMTJhYjBlYWNjMTQ1OTU5ZDhhNjcyY2JmZjdkYjZkL3RhYmxlOjEyM2UwNzU3YWM2ZTQzNTM4ZWVkNDJjNmViY2YxMmFlL3RhYmxlcmFuZ2U6MTIzZTA3NTdhYzZlNDM1MzhlZWQ0MmM2ZWJjZjEyYWVfNy01LTEtMS0xNzc3NQ_97bcfefd-42e2-4c8e-85c9-aeb43f87ac07"
      unitRef="usd">2444000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185MS9mcmFnOjlmMTJhYjBlYWNjMTQ1OTU5ZDhhNjcyY2JmZjdkYjZkL3RhYmxlOjEyM2UwNzU3YWM2ZTQzNTM4ZWVkNDJjNmViY2YxMmFlL3RhYmxlcmFuZ2U6MTIzZTA3NTdhYzZlNDM1MzhlZWQ0MmM2ZWJjZjEyYWVfOC0xLTEtMS0xNzc3NQ_b5b4b55d-7c4e-4bba-9c1f-1886fb15a0f2"
      unitRef="usd">16711000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i12a6d1161de54547bd29f8efccd4c9b0_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185MS9mcmFnOjlmMTJhYjBlYWNjMTQ1OTU5ZDhhNjcyY2JmZjdkYjZkL3RhYmxlOjEyM2UwNzU3YWM2ZTQzNTM4ZWVkNDJjNmViY2YxMmFlL3RhYmxlcmFuZ2U6MTIzZTA3NTdhYzZlNDM1MzhlZWQ0MmM2ZWJjZjEyYWVfOC0zLTEtMS0xNzc3NQ_786be533-7f2d-44a7-a7f5-ae286b3ef8e1"
      unitRef="usd">14606000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i3e21049ffc224cacb8134d73c9bb5b38_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185MS9mcmFnOjlmMTJhYjBlYWNjMTQ1OTU5ZDhhNjcyY2JmZjdkYjZkL3RhYmxlOjEyM2UwNzU3YWM2ZTQzNTM4ZWVkNDJjNmViY2YxMmFlL3RhYmxlcmFuZ2U6MTIzZTA3NTdhYzZlNDM1MzhlZWQ0MmM2ZWJjZjEyYWVfOC01LTEtMS0xNzc3NQ_150028df-c30e-41ca-a30d-590dff1fefce"
      unitRef="usd">15618000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i1d8c81c79de743e8be167a4c88ad5716_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185MS9mcmFnOjlmMTJhYjBlYWNjMTQ1OTU5ZDhhNjcyY2JmZjdkYjZkL3RhYmxlOjEyM2UwNzU3YWM2ZTQzNTM4ZWVkNDJjNmViY2YxMmFlL3RhYmxlcmFuZ2U6MTIzZTA3NTdhYzZlNDM1MzhlZWQ0MmM2ZWJjZjEyYWVfMTEtMS0xLTEtMTc3NzU_f63f25e5-0986-44ee-b9ad-a5e8473739ac"
      unitRef="usd">2263000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i3bb865fc0dda42bb8bbc52f03a761729_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185MS9mcmFnOjlmMTJhYjBlYWNjMTQ1OTU5ZDhhNjcyY2JmZjdkYjZkL3RhYmxlOjEyM2UwNzU3YWM2ZTQzNTM4ZWVkNDJjNmViY2YxMmFlL3RhYmxlcmFuZ2U6MTIzZTA3NTdhYzZlNDM1MzhlZWQ0MmM2ZWJjZjEyYWVfMTEtMy0xLTEtMTc3NzU_4f4ef33d-13e2-47f8-9a66-6dcda701c933"
      unitRef="usd">1811000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i5542e161a27e454bb0a6172a44d18515_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185MS9mcmFnOjlmMTJhYjBlYWNjMTQ1OTU5ZDhhNjcyY2JmZjdkYjZkL3RhYmxlOjEyM2UwNzU3YWM2ZTQzNTM4ZWVkNDJjNmViY2YxMmFlL3RhYmxlcmFuZ2U6MTIzZTA3NTdhYzZlNDM1MzhlZWQ0MmM2ZWJjZjEyYWVfMTEtNS0xLTEtMTc3NzU_8e9cf725-e191-4eb0-9460-4965fddd2fc3"
      unitRef="usd">2673000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ic2fe85c2e61b4a82aefe1b1a25d6bef0_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185MS9mcmFnOjlmMTJhYjBlYWNjMTQ1OTU5ZDhhNjcyY2JmZjdkYjZkL3RhYmxlOjEyM2UwNzU3YWM2ZTQzNTM4ZWVkNDJjNmViY2YxMmFlL3RhYmxlcmFuZ2U6MTIzZTA3NTdhYzZlNDM1MzhlZWQ0MmM2ZWJjZjEyYWVfMTItMS0xLTEtMTc3NzU_3bad0968-0a39-40f9-95c2-32119b34a384"
      unitRef="usd">14448000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i686054032b8e4393aca78c7d43aa5ebd_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185MS9mcmFnOjlmMTJhYjBlYWNjMTQ1OTU5ZDhhNjcyY2JmZjdkYjZkL3RhYmxlOjEyM2UwNzU3YWM2ZTQzNTM4ZWVkNDJjNmViY2YxMmFlL3RhYmxlcmFuZ2U6MTIzZTA3NTdhYzZlNDM1MzhlZWQ0MmM2ZWJjZjEyYWVfMTItMy0xLTEtMTc3NzU_5ddb58fc-9b38-4ce5-a102-433921386744"
      unitRef="usd">12795000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i8b9330154a17434f90687e31afeba60a_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185MS9mcmFnOjlmMTJhYjBlYWNjMTQ1OTU5ZDhhNjcyY2JmZjdkYjZkL3RhYmxlOjEyM2UwNzU3YWM2ZTQzNTM4ZWVkNDJjNmViY2YxMmFlL3RhYmxlcmFuZ2U6MTIzZTA3NTdhYzZlNDM1MzhlZWQ0MmM2ZWJjZjEyYWVfMTItNS0xLTEtMTc3NzU_dece53b2-acb3-4bf1-8957-5fe237cdfd4a"
      unitRef="usd">12945000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185MS9mcmFnOjlmMTJhYjBlYWNjMTQ1OTU5ZDhhNjcyY2JmZjdkYjZkL3RhYmxlOjEyM2UwNzU3YWM2ZTQzNTM4ZWVkNDJjNmViY2YxMmFlL3RhYmxlcmFuZ2U6MTIzZTA3NTdhYzZlNDM1MzhlZWQ0MmM2ZWJjZjEyYWVfMTMtMS0xLTEtMTc3NzU_35d76894-ec58-455a-afdd-9c472077f7e0"
      unitRef="usd">16711000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i12a6d1161de54547bd29f8efccd4c9b0_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185MS9mcmFnOjlmMTJhYjBlYWNjMTQ1OTU5ZDhhNjcyY2JmZjdkYjZkL3RhYmxlOjEyM2UwNzU3YWM2ZTQzNTM4ZWVkNDJjNmViY2YxMmFlL3RhYmxlcmFuZ2U6MTIzZTA3NTdhYzZlNDM1MzhlZWQ0MmM2ZWJjZjEyYWVfMTMtMy0xLTEtMTc3NzU_ba4de417-8079-427f-9a86-d92f5e04b161"
      unitRef="usd">14606000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i3e21049ffc224cacb8134d73c9bb5b38_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185MS9mcmFnOjlmMTJhYjBlYWNjMTQ1OTU5ZDhhNjcyY2JmZjdkYjZkL3RhYmxlOjEyM2UwNzU3YWM2ZTQzNTM4ZWVkNDJjNmViY2YxMmFlL3RhYmxlcmFuZ2U6MTIzZTA3NTdhYzZlNDM1MzhlZWQ0MmM2ZWJjZjEyYWVfMTMtNS0xLTEtMTc3NzU_d906dc99-6a84-4d37-baa6-9d4760151055"
      unitRef="usd">15618000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount
      contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185MS9mcmFnOjlmMTJhYjBlYWNjMTQ1OTU5ZDhhNjcyY2JmZjdkYjZkL3RleHRyZWdpb246OWYxMmFiMGVhY2MxNDU5NTlkOGE2NzJjYmZmN2RiNmRfMjE0Mg_5c5c916f-68d1-459b-ba8f-ab4edf706575"
      unitRef="usd">0</us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount>
    <us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount
      contextRef="i12a6d1161de54547bd29f8efccd4c9b0_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185MS9mcmFnOjlmMTJhYjBlYWNjMTQ1OTU5ZDhhNjcyY2JmZjdkYjZkL3RleHRyZWdpb246OWYxMmFiMGVhY2MxNDU5NTlkOGE2NzJjYmZmN2RiNmRfMjE0Mg_7e1ee2ac-28e6-4d54-987c-3023ca9bd385"
      unitRef="usd">0</us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount>
    <us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount
      contextRef="i3e21049ffc224cacb8134d73c9bb5b38_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185MS9mcmFnOjlmMTJhYjBlYWNjMTQ1OTU5ZDhhNjcyY2JmZjdkYjZkL3RleHRyZWdpb246OWYxMmFiMGVhY2MxNDU5NTlkOGE2NzJjYmZmN2RiNmRfMjE0Mg_84a3b053-1522-4988-852d-c5ce72c0ec86"
      unitRef="usd">0</us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount>
    <us-gaap:ScheduleOfUnrecognizedCompensationCostNonvestedAwardsTableTextBlock
      contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185MS9mcmFnOjlmMTJhYjBlYWNjMTQ1OTU5ZDhhNjcyY2JmZjdkYjZkL3RleHRyZWdpb246OWYxMmFiMGVhY2MxNDU5NTlkOGE2NzJjYmZmN2RiNmRfMTI2Nzc_94ee92b5-d666-4f9e-9670-cd4b971983d0">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total unrecognized compensation expense (in thousands) and expected weighted-average period (in years) by award type for all of our stock-based incentive plans were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:535.50pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:393.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:66.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:66.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;As of December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:33pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Unrecognized Compensation Expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted Average Period (years)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock options&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;512&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.57&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;RSUs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26,104&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.69&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;LSUs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,422&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.19&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Performance-based RSUs&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,121&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.17&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,159&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfUnrecognizedCompensationCostNonvestedAwardsTableTextBlock>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
      contextRef="i532ccc69d7f7466ba58c97c04ba645e1_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185MS9mcmFnOjlmMTJhYjBlYWNjMTQ1OTU5ZDhhNjcyY2JmZjdkYjZkL3RhYmxlOjQzMjZlNzkzZTQwYjRlMDViYTI4MTRmZGUxNTgyODI4L3RhYmxlcmFuZ2U6NDMyNmU3OTNlNDBiNGUwNWJhMjgxNGZkZTE1ODI4MjhfMi0xLTEtMS0xNzc3NQ_f6dffdad-e163-41a8-873c-b76d559cf327"
      unitRef="usd">512000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="i532d2c0bf63243e999d48341920b6775_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185MS9mcmFnOjlmMTJhYjBlYWNjMTQ1OTU5ZDhhNjcyY2JmZjdkYjZkL3RhYmxlOjQzMjZlNzkzZTQwYjRlMDViYTI4MTRmZGUxNTgyODI4L3RhYmxlcmFuZ2U6NDMyNmU3OTNlNDBiNGUwNWJhMjgxNGZkZTE1ODI4MjhfMi0zLTEtMS0xNzc3NQ_7eb91ce6-fc91-4d2c-9dc4-b2b4ffba939c">P0Y6M25D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions
      contextRef="i0a2bd98f25e64cac9d230b30c39fd652_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185MS9mcmFnOjlmMTJhYjBlYWNjMTQ1OTU5ZDhhNjcyY2JmZjdkYjZkL3RhYmxlOjQzMjZlNzkzZTQwYjRlMDViYTI4MTRmZGUxNTgyODI4L3RhYmxlcmFuZ2U6NDMyNmU3OTNlNDBiNGUwNWJhMjgxNGZkZTE1ODI4MjhfMy0xLTEtMS0xNzc3NQ_acb20ee1-0061-43c3-9c15-f26ac1c64293"
      unitRef="usd">26104000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="i903fc0912d4e492c95e3ce815e897489_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185MS9mcmFnOjlmMTJhYjBlYWNjMTQ1OTU5ZDhhNjcyY2JmZjdkYjZkL3RhYmxlOjQzMjZlNzkzZTQwYjRlMDViYTI4MTRmZGUxNTgyODI4L3RhYmxlcmFuZ2U6NDMyNmU3OTNlNDBiNGUwNWJhMjgxNGZkZTE1ODI4MjhfMy0zLTEtMS0xNzc3NQ_a16ef1f1-d8f4-4037-a59e-2bf45b4d7e2d">P1Y8M8D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions
      contextRef="i33d73ea883764a2dafec5a1252f33aef_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185MS9mcmFnOjlmMTJhYjBlYWNjMTQ1OTU5ZDhhNjcyY2JmZjdkYjZkL3RhYmxlOjQzMjZlNzkzZTQwYjRlMDViYTI4MTRmZGUxNTgyODI4L3RhYmxlcmFuZ2U6NDMyNmU3OTNlNDBiNGUwNWJhMjgxNGZkZTE1ODI4MjhfNC0xLTEtMS0xNzc3NQ_8a8b7ff5-a185-48c8-84d6-c13ecbe2dee4"
      unitRef="usd">2422000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="if0b01289c86a4176ab75517bdfe4ec1f_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185MS9mcmFnOjlmMTJhYjBlYWNjMTQ1OTU5ZDhhNjcyY2JmZjdkYjZkL3RhYmxlOjQzMjZlNzkzZTQwYjRlMDViYTI4MTRmZGUxNTgyODI4L3RhYmxlcmFuZ2U6NDMyNmU3OTNlNDBiNGUwNWJhMjgxNGZkZTE1ODI4MjhfNC0zLTEtMS0xNzc3NQ_59903601-e04d-44da-bc63-a7a27d532b99">P1Y2M8D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions
      contextRef="ife9a61a44ecc47e88bb29426256eba9d_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185MS9mcmFnOjlmMTJhYjBlYWNjMTQ1OTU5ZDhhNjcyY2JmZjdkYjZkL3RhYmxlOjQzMjZlNzkzZTQwYjRlMDViYTI4MTRmZGUxNTgyODI4L3RhYmxlcmFuZ2U6NDMyNmU3OTNlNDBiNGUwNWJhMjgxNGZkZTE1ODI4MjhfNS0xLTEtMS0yOTI4Mw_cbe5fd95-831a-4950-9555-79c1350896ee"
      unitRef="usd">4121000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="i91de07e5bb1e422aa1d46986a0b1006f_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185MS9mcmFnOjlmMTJhYjBlYWNjMTQ1OTU5ZDhhNjcyY2JmZjdkYjZkL3RhYmxlOjQzMjZlNzkzZTQwYjRlMDViYTI4MTRmZGUxNTgyODI4L3RhYmxlcmFuZ2U6NDMyNmU3OTNlNDBiNGUwNWJhMjgxNGZkZTE1ODI4MjhfNS0zLTEtMS0yOTI5MA_eda99509-6a2e-4650-9946-5c99ea800950">P3Y2M1D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="i8daff60be410426d8f7bd49343c1ec0c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185MS9mcmFnOjlmMTJhYjBlYWNjMTQ1OTU5ZDhhNjcyY2JmZjdkYjZkL3RhYmxlOjQzMjZlNzkzZTQwYjRlMDViYTI4MTRmZGUxNTgyODI4L3RhYmxlcmFuZ2U6NDMyNmU3OTNlNDBiNGUwNWJhMjgxNGZkZTE1ODI4MjhfNS0xLTEtMS0xNzc3NQ_870f1593-71ba-4442-93f8-24de2bd4ff51"
      unitRef="usd">33159000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="i532d2c0bf63243e999d48341920b6775_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185MS9mcmFnOjlmMTJhYjBlYWNjMTQ1OTU5ZDhhNjcyY2JmZjdkYjZkL3RleHRyZWdpb246OWYxMmFiMGVhY2MxNDU5NTlkOGE2NzJjYmZmN2RiNmRfMTI2NzM_81b0d92a-f60e-437f-b392-c67b6fb1fa27">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="i532d2c0bf63243e999d48341920b6775_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185MS9mcmFnOjlmMTJhYjBlYWNjMTQ1OTU5ZDhhNjcyY2JmZjdkYjZkL3RleHRyZWdpb246OWYxMmFiMGVhY2MxNDU5NTlkOGE2NzJjYmZmN2RiNmRfMjYzNw_ed429d8f-60b4-4765-92c4-10be98dfec9f"
      unitRef="number">0.25</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
      contextRef="i532d2c0bf63243e999d48341920b6775_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185MS9mcmFnOjlmMTJhYjBlYWNjMTQ1OTU5ZDhhNjcyY2JmZjdkYjZkL3RleHRyZWdpb246OWYxMmFiMGVhY2MxNDU5NTlkOGE2NzJjYmZmN2RiNmRfMjcxMw_5c8ed046-1740-4c3b-b85c-01e8affd3e1f">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock
      contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185MS9mcmFnOjlmMTJhYjBlYWNjMTQ1OTU5ZDhhNjcyY2JmZjdkYjZkL3RleHRyZWdpb246OWYxMmFiMGVhY2MxNDU5NTlkOGE2NzJjYmZmN2RiNmRfMTI2NTg_53cbf333-ffa6-4a8d-9fe9-8d83205e91ce">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The option price assumptions used for our stock option awards for the year ended December 31, 2019, were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:463.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:72.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average fair value per option granted&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.52&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Assumptions:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected term (in years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.25&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;51.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.9% - 2.7%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The price assumptions used for our leveraged stock unit awards were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:384.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:73.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:73.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;For the Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average fair value per leveraged stock unit granted&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.90&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.52&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Assumptions:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected term&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;62.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;51.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.85%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.54%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i12a6d1161de54547bd29f8efccd4c9b0_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185MS9mcmFnOjlmMTJhYjBlYWNjMTQ1OTU5ZDhhNjcyY2JmZjdkYjZkL3RhYmxlOjQyNmVkZGIyNmYwODQ5MGM5MDRjYTE1ODBmZDZiYzQyL3RhYmxlcmFuZ2U6NDI2ZWRkYjI2ZjA4NDkwYzkwNGNhMTU4MGZkNmJjNDJfMi0xLTEtMS0xNzc3NQ_1c1b91b6-f27f-4be9-923a-164e27e2b0aa"
      unitRef="usdPerShare">6.52</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="i3462813a792a43bdb0cd92a0d3fc4085_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185MS9mcmFnOjlmMTJhYjBlYWNjMTQ1OTU5ZDhhNjcyY2JmZjdkYjZkL3RhYmxlOjQyNmVkZGIyNmYwODQ5MGM5MDRjYTE1ODBmZDZiYzQyL3RhYmxlcmFuZ2U6NDI2ZWRkYjI2ZjA4NDkwYzkwNGNhMTU4MGZkNmJjNDJfNC0xLTEtMS0xNzc3NQ_68b633bb-d68a-475a-9179-d1605d1533f7">P6Y3M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="i3462813a792a43bdb0cd92a0d3fc4085_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185MS9mcmFnOjlmMTJhYjBlYWNjMTQ1OTU5ZDhhNjcyY2JmZjdkYjZkL3RhYmxlOjQyNmVkZGIyNmYwODQ5MGM5MDRjYTE1ODBmZDZiYzQyL3RhYmxlcmFuZ2U6NDI2ZWRkYjI2ZjA4NDkwYzkwNGNhMTU4MGZkNmJjNDJfNS0xLTEtMS0xNzc3NQ_1246e083-0e1b-4454-9f05-7ff63862d17e"
      unitRef="number">0.516</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
      contextRef="i3462813a792a43bdb0cd92a0d3fc4085_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185MS9mcmFnOjlmMTJhYjBlYWNjMTQ1OTU5ZDhhNjcyY2JmZjdkYjZkL3RhYmxlOjQyNmVkZGIyNmYwODQ5MGM5MDRjYTE1ODBmZDZiYzQyL3RhYmxlcmFuZ2U6NDI2ZWRkYjI2ZjA4NDkwYzkwNGNhMTU4MGZkNmJjNDJfNi0xLTEtMS0xNzc3NS90ZXh0cmVnaW9uOjFhYWEwOWQ2YjYyYzQ5MGU4MGVlMGE2MGUxM2MwZDIyXzQ_2e9723fe-b514-4350-8a8e-b4b831dea4cf"
      unitRef="number">0.019</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
      contextRef="i3462813a792a43bdb0cd92a0d3fc4085_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185MS9mcmFnOjlmMTJhYjBlYWNjMTQ1OTU5ZDhhNjcyY2JmZjdkYjZkL3RhYmxlOjQyNmVkZGIyNmYwODQ5MGM5MDRjYTE1ODBmZDZiYzQyL3RhYmxlcmFuZ2U6NDI2ZWRkYjI2ZjA4NDkwYzkwNGNhMTU4MGZkNmJjNDJfNi0xLTEtMS0xNzc3NS90ZXh0cmVnaW9uOjFhYWEwOWQ2YjYyYzQ5MGU4MGVlMGE2MGUxM2MwZDIyXzk_2dc4a3bc-4e5e-4a33-b713-444340c8b021"
      unitRef="number">0.027</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="i3462813a792a43bdb0cd92a0d3fc4085_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185MS9mcmFnOjlmMTJhYjBlYWNjMTQ1OTU5ZDhhNjcyY2JmZjdkYjZkL3RhYmxlOjQyNmVkZGIyNmYwODQ5MGM5MDRjYTE1ODBmZDZiYzQyL3RhYmxlcmFuZ2U6NDI2ZWRkYjI2ZjA4NDkwYzkwNGNhMTU4MGZkNmJjNDJfNy0xLTEtMS0xNzc3NQ_5ce631bc-f2a6-4628-bd73-5d3961ecfb2a"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock
      contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185MS9mcmFnOjlmMTJhYjBlYWNjMTQ1OTU5ZDhhNjcyY2JmZjdkYjZkL3RleHRyZWdpb246OWYxMmFiMGVhY2MxNDU5NTlkOGE2NzJjYmZmN2RiNmRfMTI2Nzg_b228f1c0-827f-41e3-a8f9-a295dc3fe830">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Information with respect to our stock options (in thousands), including weighted-average remaining contractual term (in years) and aggregate intrinsic value (in thousands) was as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.75pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:283.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:58.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:3.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:58.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:3.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:58.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:3.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:58.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr style="height:51pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted Average Exercise Price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted Average Remaining Contractual Term&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Aggregate Intrinsic Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding as of December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,070&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.32&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.25&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,578&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,490)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.92&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(31)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15.23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding as of December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,549&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.49&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.99&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46,342&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested and expected to vest after December&#160;31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,549&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.49&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.99&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46,342&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercisable as of December&#160;31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,301&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.71&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42,717&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="ibc0c0c2b8dc04c5698ca0577a54b2e03_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185MS9mcmFnOjlmMTJhYjBlYWNjMTQ1OTU5ZDhhNjcyY2JmZjdkYjZkL3RhYmxlOjdjOGI2M2JiNDk2ZDQ4MzE4ZmU4ZWIyOWQ3NTc2MzU4L3RhYmxlcmFuZ2U6N2M4YjYzYmI0OTZkNDgzMThmZThlYjI5ZDc1NzYzNThfMS0xLTEtMS0xNzc3NQ_98236723-da60-4b8b-8caa-e06536b4d7d3"
      unitRef="shares">4070000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="ibc0c0c2b8dc04c5698ca0577a54b2e03_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185MS9mcmFnOjlmMTJhYjBlYWNjMTQ1OTU5ZDhhNjcyY2JmZjdkYjZkL3RhYmxlOjdjOGI2M2JiNDk2ZDQ4MzE4ZmU4ZWIyOWQ3NTc2MzU4L3RhYmxlcmFuZ2U6N2M4YjYzYmI0OTZkNDgzMThmZThlYjI5ZDc1NzYzNThfMS0zLTEtMS0xNzc3NQ_0acd643e-0170-4c0f-bc20-4d9fc097267e"
      unitRef="usdPerShare">9.32</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="i12a6d1161de54547bd29f8efccd4c9b0_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185MS9mcmFnOjlmMTJhYjBlYWNjMTQ1OTU5ZDhhNjcyY2JmZjdkYjZkL3RhYmxlOjdjOGI2M2JiNDk2ZDQ4MzE4ZmU4ZWIyOWQ3NTc2MzU4L3RhYmxlcmFuZ2U6N2M4YjYzYmI0OTZkNDgzMThmZThlYjI5ZDc1NzYzNThfMS01LTEtMS0xNzc3NQ_fff7e4e3-e090-4da6-8f02-6afddaaf2797">P5Y3M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="ibc0c0c2b8dc04c5698ca0577a54b2e03_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185MS9mcmFnOjlmMTJhYjBlYWNjMTQ1OTU5ZDhhNjcyY2JmZjdkYjZkL3RhYmxlOjdjOGI2M2JiNDk2ZDQ4MzE4ZmU4ZWIyOWQ3NTc2MzU4L3RhYmxlcmFuZ2U6N2M4YjYzYmI0OTZkNDgzMThmZThlYjI5ZDc1NzYzNThfMS03LTEtMS0xNzc3NQ_fc614f5a-8c60-4bf3-9934-3dd166f8bef1"
      unitRef="usd">12578000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185MS9mcmFnOjlmMTJhYjBlYWNjMTQ1OTU5ZDhhNjcyY2JmZjdkYjZkL3RhYmxlOjdjOGI2M2JiNDk2ZDQ4MzE4ZmU4ZWIyOWQ3NTc2MzU4L3RhYmxlcmFuZ2U6N2M4YjYzYmI0OTZkNDgzMThmZThlYjI5ZDc1NzYzNThfMy0xLTEtMS0xNzc3NQ_3df1c705-c678-421a-8bd8-9d51571463c7"
      unitRef="shares">1490000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185MS9mcmFnOjlmMTJhYjBlYWNjMTQ1OTU5ZDhhNjcyY2JmZjdkYjZkL3RhYmxlOjdjOGI2M2JiNDk2ZDQ4MzE4ZmU4ZWIyOWQ3NTc2MzU4L3RhYmxlcmFuZ2U6N2M4YjYzYmI0OTZkNDgzMThmZThlYjI5ZDc1NzYzNThfMy0zLTEtMS0xNzc3NQ_0e2f080e-4f04-42fa-8af3-ba18ff84323b"
      unitRef="usdPerShare">8.92</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185MS9mcmFnOjlmMTJhYjBlYWNjMTQ1OTU5ZDhhNjcyY2JmZjdkYjZkL3RhYmxlOjdjOGI2M2JiNDk2ZDQ4MzE4ZmU4ZWIyOWQ3NTc2MzU4L3RhYmxlcmFuZ2U6N2M4YjYzYmI0OTZkNDgzMThmZThlYjI5ZDc1NzYzNThfNC0xLTEtMS0xNzc3NQ_f38bd21a-3d2a-4692-830f-754dc542cc11"
      unitRef="shares">31000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185MS9mcmFnOjlmMTJhYjBlYWNjMTQ1OTU5ZDhhNjcyY2JmZjdkYjZkL3RhYmxlOjdjOGI2M2JiNDk2ZDQ4MzE4ZmU4ZWIyOWQ3NTc2MzU4L3RhYmxlcmFuZ2U6N2M4YjYzYmI0OTZkNDgzMThmZThlYjI5ZDc1NzYzNThfNC0zLTEtMS0xNzc3NQ_b07bdc97-31d9-4d05-bf63-583d4f67abbd"
      unitRef="usdPerShare">15.23</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i8daff60be410426d8f7bd49343c1ec0c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185MS9mcmFnOjlmMTJhYjBlYWNjMTQ1OTU5ZDhhNjcyY2JmZjdkYjZkL3RhYmxlOjdjOGI2M2JiNDk2ZDQ4MzE4ZmU4ZWIyOWQ3NTc2MzU4L3RhYmxlcmFuZ2U6N2M4YjYzYmI0OTZkNDgzMThmZThlYjI5ZDc1NzYzNThfNS0xLTEtMS0xNzc3NQ_54f0877a-67d6-4065-9efd-753cd26851ee"
      unitRef="shares">2549000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="i8daff60be410426d8f7bd49343c1ec0c_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185MS9mcmFnOjlmMTJhYjBlYWNjMTQ1OTU5ZDhhNjcyY2JmZjdkYjZkL3RhYmxlOjdjOGI2M2JiNDk2ZDQ4MzE4ZmU4ZWIyOWQ3NTc2MzU4L3RhYmxlcmFuZ2U6N2M4YjYzYmI0OTZkNDgzMThmZThlYjI5ZDc1NzYzNThfNS0zLTEtMS0xNzc3NQ_362bbc4f-91f4-4ac9-9320-55d65ba8f4eb"
      unitRef="usdPerShare">9.49</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185MS9mcmFnOjlmMTJhYjBlYWNjMTQ1OTU5ZDhhNjcyY2JmZjdkYjZkL3RhYmxlOjdjOGI2M2JiNDk2ZDQ4MzE4ZmU4ZWIyOWQ3NTc2MzU4L3RhYmxlcmFuZ2U6N2M4YjYzYmI0OTZkNDgzMThmZThlYjI5ZDc1NzYzNThfNS01LTEtMS0xNzc3NQ_b5187a1e-09ac-4f04-b1be-7ba544e4378f">P3Y11M26D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="i8daff60be410426d8f7bd49343c1ec0c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185MS9mcmFnOjlmMTJhYjBlYWNjMTQ1OTU5ZDhhNjcyY2JmZjdkYjZkL3RhYmxlOjdjOGI2M2JiNDk2ZDQ4MzE4ZmU4ZWIyOWQ3NTc2MzU4L3RhYmxlcmFuZ2U6N2M4YjYzYmI0OTZkNDgzMThmZThlYjI5ZDc1NzYzNThfNS03LTEtMS0xNzc3NQ_3556ad94-ffe4-4434-afd8-9d5dd8f146fe"
      unitRef="usd">46342000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
      contextRef="i8daff60be410426d8f7bd49343c1ec0c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185MS9mcmFnOjlmMTJhYjBlYWNjMTQ1OTU5ZDhhNjcyY2JmZjdkYjZkL3RhYmxlOjdjOGI2M2JiNDk2ZDQ4MzE4ZmU4ZWIyOWQ3NTc2MzU4L3RhYmxlcmFuZ2U6N2M4YjYzYmI0OTZkNDgzMThmZThlYjI5ZDc1NzYzNThfNy0xLTEtMS0xNzc3NQ_37a7437d-df0b-4574-a818-3264be228970"
      unitRef="shares">2549000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
      contextRef="i8daff60be410426d8f7bd49343c1ec0c_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185MS9mcmFnOjlmMTJhYjBlYWNjMTQ1OTU5ZDhhNjcyY2JmZjdkYjZkL3RhYmxlOjdjOGI2M2JiNDk2ZDQ4MzE4ZmU4ZWIyOWQ3NTc2MzU4L3RhYmxlcmFuZ2U6N2M4YjYzYmI0OTZkNDgzMThmZThlYjI5ZDc1NzYzNThfNy0zLTEtMS0xNzc3NQ_1971456e-faac-49ee-8c32-ccc77d269663"
      unitRef="usdPerShare">9.49</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
      contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185MS9mcmFnOjlmMTJhYjBlYWNjMTQ1OTU5ZDhhNjcyY2JmZjdkYjZkL3RhYmxlOjdjOGI2M2JiNDk2ZDQ4MzE4ZmU4ZWIyOWQ3NTc2MzU4L3RhYmxlcmFuZ2U6N2M4YjYzYmI0OTZkNDgzMThmZThlYjI5ZDc1NzYzNThfNy01LTEtMS0xNzc3NQ_602aa6b1-8e05-4dc4-bfc3-dc401aec2cf2">P3Y11M26D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
      contextRef="i8daff60be410426d8f7bd49343c1ec0c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185MS9mcmFnOjlmMTJhYjBlYWNjMTQ1OTU5ZDhhNjcyY2JmZjdkYjZkL3RhYmxlOjdjOGI2M2JiNDk2ZDQ4MzE4ZmU4ZWIyOWQ3NTc2MzU4L3RhYmxlcmFuZ2U6N2M4YjYzYmI0OTZkNDgzMThmZThlYjI5ZDc1NzYzNThfNy03LTEtMS0xNzc3NQ_f2c75035-b5a1-46d9-b104-1c6d1c9b4161"
      unitRef="usd">46342000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber
      contextRef="i8daff60be410426d8f7bd49343c1ec0c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185MS9mcmFnOjlmMTJhYjBlYWNjMTQ1OTU5ZDhhNjcyY2JmZjdkYjZkL3RhYmxlOjdjOGI2M2JiNDk2ZDQ4MzE4ZmU4ZWIyOWQ3NTc2MzU4L3RhYmxlcmFuZ2U6N2M4YjYzYmI0OTZkNDgzMThmZThlYjI5ZDc1NzYzNThfOS0xLTEtMS0xNzc3NQ_ed2e946d-fe36-4779-a58b-b3a189b7a804"
      unitRef="shares">2301000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="i8daff60be410426d8f7bd49343c1ec0c_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185MS9mcmFnOjlmMTJhYjBlYWNjMTQ1OTU5ZDhhNjcyY2JmZjdkYjZkL3RhYmxlOjdjOGI2M2JiNDk2ZDQ4MzE4ZmU4ZWIyOWQ3NTc2MzU4L3RhYmxlcmFuZ2U6N2M4YjYzYmI0OTZkNDgzMThmZThlYjI5ZDc1NzYzNThfOS0zLTEtMS0xNzc3NQ_505db40b-adc8-468e-9688-7499720bcdbc"
      unitRef="usdPerShare">9.11</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
      contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185MS9mcmFnOjlmMTJhYjBlYWNjMTQ1OTU5ZDhhNjcyY2JmZjdkYjZkL3RhYmxlOjdjOGI2M2JiNDk2ZDQ4MzE4ZmU4ZWIyOWQ3NTc2MzU4L3RhYmxlcmFuZ2U6N2M4YjYzYmI0OTZkNDgzMThmZThlYjI5ZDc1NzYzNThfOS01LTEtMS0xNzc3NQ_8d783cb1-45ac-44b9-af43-9a7d4e7da643">P3Y8M15D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="i8daff60be410426d8f7bd49343c1ec0c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185MS9mcmFnOjlmMTJhYjBlYWNjMTQ1OTU5ZDhhNjcyY2JmZjdkYjZkL3RhYmxlOjdjOGI2M2JiNDk2ZDQ4MzE4ZmU4ZWIyOWQ3NTc2MzU4L3RhYmxlcmFuZ2U6N2M4YjYzYmI0OTZkNDgzMThmZThlYjI5ZDc1NzYzNThfOS03LTEtMS0xNzc3NQ_60462513-09ee-4498-bec5-fd9c5dca52f6"
      unitRef="usd">42717000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
      contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185MS9mcmFnOjlmMTJhYjBlYWNjMTQ1OTU5ZDhhNjcyY2JmZjdkYjZkL3RleHRyZWdpb246OWYxMmFiMGVhY2MxNDU5NTlkOGE2NzJjYmZmN2RiNmRfNDIwMQ_de97a17a-3ae6-4650-afde-38b05441339f"
      unitRef="usd">4900000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
      contextRef="i12a6d1161de54547bd29f8efccd4c9b0_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185MS9mcmFnOjlmMTJhYjBlYWNjMTQ1OTU5ZDhhNjcyY2JmZjdkYjZkL3RleHRyZWdpb246OWYxMmFiMGVhY2MxNDU5NTlkOGE2NzJjYmZmN2RiNmRfNDIwNQ_13a571d8-cc5e-43bb-8c83-8c6934a857e9"
      unitRef="usd">3600000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
      contextRef="i3e21049ffc224cacb8134d73c9bb5b38_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185MS9mcmFnOjlmMTJhYjBlYWNjMTQ1OTU5ZDhhNjcyY2JmZjdkYjZkL3RleHRyZWdpb246OWYxMmFiMGVhY2MxNDU5NTlkOGE2NzJjYmZmN2RiNmRfNDIxMg_66203335-f017-401b-846a-92cd8706708c"
      unitRef="usd">5900000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185MS9mcmFnOjlmMTJhYjBlYWNjMTQ1OTU5ZDhhNjcyY2JmZjdkYjZkL3RleHRyZWdpb246OWYxMmFiMGVhY2MxNDU5NTlkOGE2NzJjYmZmN2RiNmRfNDMwMg_7f325296-e522-4646-b1fd-006810eed0c4"
      unitRef="usd">20800000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="i12a6d1161de54547bd29f8efccd4c9b0_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185MS9mcmFnOjlmMTJhYjBlYWNjMTQ1OTU5ZDhhNjcyY2JmZjdkYjZkL3RleHRyZWdpb246OWYxMmFiMGVhY2MxNDU5NTlkOGE2NzJjYmZmN2RiNmRfNDMwNg_e30040d1-a44d-426c-9d18-ba7c2e5cbba1"
      unitRef="usd">2200000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="i3e21049ffc224cacb8134d73c9bb5b38_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185MS9mcmFnOjlmMTJhYjBlYWNjMTQ1OTU5ZDhhNjcyY2JmZjdkYjZkL3RleHRyZWdpb246OWYxMmFiMGVhY2MxNDU5NTlkOGE2NzJjYmZmN2RiNmRfNDMxMw_f30e1c7a-f9fc-4d1e-913b-4a2933e59984"
      unitRef="usd">600000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="i686710b185af449cbe0de18d10c30d28_D20160301-20160331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185MS9mcmFnOjlmMTJhYjBlYWNjMTQ1OTU5ZDhhNjcyY2JmZjdkYjZkL3RleHRyZWdpb246OWYxMmFiMGVhY2MxNDU5NTlkOGE2NzJjYmZmN2RiNmRfNDQ2OQ_a4c3ad8f-3e16-46ee-8390-1f4b47f4b25c"
      unitRef="shares">300000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <evh:SharebasedCompensationArrangementbySharebasedPaymentAwardAwardVestingRightsSharePriceThreshold
      contextRef="if1cf72bda2494db39c586d33c79355d7_I20160331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185MS9mcmFnOjlmMTJhYjBlYWNjMTQ1OTU5ZDhhNjcyY2JmZjdkYjZkL3RleHRyZWdpb246OWYxMmFiMGVhY2MxNDU5NTlkOGE2NzJjYmZmN2RiNmRfNDg4Mw_44b598f7-f657-4fb1-914f-8ef109ad2b02"
      unitRef="usdPerShare">13.35</evh:SharebasedCompensationArrangementbySharebasedPaymentAwardAwardVestingRightsSharePriceThreshold>
    <evh:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsStockPriceTriggerConsecutiveTerm
      contextRef="i4339469160624451b2787c8a94183aef_D20160301-20160331"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185MS9mcmFnOjlmMTJhYjBlYWNjMTQ1OTU5ZDhhNjcyY2JmZjdkYjZkL3RleHRyZWdpb246OWYxMmFiMGVhY2MxNDU5NTlkOGE2NzJjYmZmN2RiNmRfMzI5ODUzNDkxMDU4MQ_f8449e7f-cbb1-43c1-984e-1e998372ec13">P90D</evh:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsStockPriceTriggerConsecutiveTerm>
    <evh:SharebasedCompensationArrangementbySharebasedPaymentAwardAwardVestingRightsSharePriceThreshold
      contextRef="i42f9f4a544794563bbd3b640b97627eb_I20160331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185MS9mcmFnOjlmMTJhYjBlYWNjMTQ1OTU5ZDhhNjcyY2JmZjdkYjZkL3RleHRyZWdpb246OWYxMmFiMGVhY2MxNDU5NTlkOGE2NzJjYmZmN2RiNmRfNTA5Mw_2e7ed541-0edf-45b3-9f15-2c3e399bf694"
      unitRef="usdPerShare">16.43</evh:SharebasedCompensationArrangementbySharebasedPaymentAwardAwardVestingRightsSharePriceThreshold>
    <evh:SharebasedCompensationArrangementbySharebasedPaymentAwardAwardVestingRightsSharePriceThreshold
      contextRef="i77ef8b91efad4f9c96efe1dd800f23a2_I20160331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185MS9mcmFnOjlmMTJhYjBlYWNjMTQ1OTU5ZDhhNjcyY2JmZjdkYjZkL3RleHRyZWdpb246OWYxMmFiMGVhY2MxNDU5NTlkOGE2NzJjYmZmN2RiNmRfNTMwNw_73a038c6-680c-41a1-842e-a16926963e27"
      unitRef="usdPerShare">19.51</evh:SharebasedCompensationArrangementbySharebasedPaymentAwardAwardVestingRightsSharePriceThreshold>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="i6df38813e0b146839515ddf8e5497101_D20160301-20160331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185MS9mcmFnOjlmMTJhYjBlYWNjMTQ1OTU5ZDhhNjcyY2JmZjdkYjZkL3RleHRyZWdpb246OWYxMmFiMGVhY2MxNDU5NTlkOGE2NzJjYmZmN2RiNmRfNTYyMA_70870cab-03b8-4656-864e-d08e9539d445"
      unitRef="number">0.50</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="ie92afa03287e4824b694b978705b0da6_D20160301-20160331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185MS9mcmFnOjlmMTJhYjBlYWNjMTQ1OTU5ZDhhNjcyY2JmZjdkYjZkL3RleHRyZWdpb246OWYxMmFiMGVhY2MxNDU5NTlkOGE2NzJjYmZmN2RiNmRfNTY5NA_f1d7b848-9df7-4bc1-8c9e-ebd195fbeb5c"
      unitRef="number">0.50</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="i686710b185af449cbe0de18d10c30d28_D20160301-20160331"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185MS9mcmFnOjlmMTJhYjBlYWNjMTQ1OTU5ZDhhNjcyY2JmZjdkYjZkL3RleHRyZWdpb246OWYxMmFiMGVhY2MxNDU5NTlkOGE2NzJjYmZmN2RiNmRfNTkzMA_2a8697d5-1bc4-4139-b80a-c1badcc2cbe7"
      unitRef="number">0.0183</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="i686710b185af449cbe0de18d10c30d28_D20160301-20160331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185MS9mcmFnOjlmMTJhYjBlYWNjMTQ1OTU5ZDhhNjcyY2JmZjdkYjZkL3RleHRyZWdpb246OWYxMmFiMGVhY2MxNDU5NTlkOGE2NzJjYmZmN2RiNmRfNTk0OA_b87618b6-d6ce-4699-9510-ea420bdfe2cf"
      unitRef="number">0.65</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="i686710b185af449cbe0de18d10c30d28_D20160301-20160331"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185MS9mcmFnOjlmMTJhYjBlYWNjMTQ1OTU5ZDhhNjcyY2JmZjdkYjZkL3RleHRyZWdpb246OWYxMmFiMGVhY2MxNDU5NTlkOGE2NzJjYmZmN2RiNmRfNTk2OQ_581aabb8-c815-42ee-9f8d-a9b25faa113f">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="i686710b185af449cbe0de18d10c30d28_D20160301-20160331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185MS9mcmFnOjlmMTJhYjBlYWNjMTQ1OTU5ZDhhNjcyY2JmZjdkYjZkL3RleHRyZWdpb246OWYxMmFiMGVhY2MxNDU5NTlkOGE2NzJjYmZmN2RiNmRfNTk5NA_6b34526c-81b9-400b-9aee-eb96714feab9"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i686710b185af449cbe0de18d10c30d28_D20160301-20160331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185MS9mcmFnOjlmMTJhYjBlYWNjMTQ1OTU5ZDhhNjcyY2JmZjdkYjZkL3RleHRyZWdpb246OWYxMmFiMGVhY2MxNDU5NTlkOGE2NzJjYmZmN2RiNmRfNjE2NA_be397dbf-944f-4f31-85c9-acea3488d04e"
      unitRef="usdPerShare">6.68</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationPerformanceSharesAwardOutstandingActivityTableTextBlock
      contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185MS9mcmFnOjlmMTJhYjBlYWNjMTQ1OTU5ZDhhNjcyY2JmZjdkYjZkL3RleHRyZWdpb246OWYxMmFiMGVhY2MxNDU5NTlkOGE2NzJjYmZmN2RiNmRfMTI2Njc_88c1a5c0-1502-484d-b664-0bbe99d1be21">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Information with respect to our performance-based stock options (shares and aggregate intrinsic value shown in thousands, weighted-average remaining contractual term shown in years) was as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:539.25pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:286.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:58.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:58.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:58.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:58.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr style="height:54pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted Average Exercise Price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted Average Remaining Contractual Term&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Aggregate Intrinsic Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding as of December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;268&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.27&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.17&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(326)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding as of December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;268&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.27&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.16&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,620&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested and expected to vest after December&#160;31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;268&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.27&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.16&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,620&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ShareBasedCompensationPerformanceSharesAwardOutstandingActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i5f4625a059aa4800b22d29c186dc894c_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185MS9mcmFnOjlmMTJhYjBlYWNjMTQ1OTU5ZDhhNjcyY2JmZjdkYjZkL3RhYmxlOjZjYjk4NzQxYjcwOTQxMzhhMTYzY2RhYTdkN2Y4ZmMyL3RhYmxlcmFuZ2U6NmNiOTg3NDFiNzA5NDEzOGExNjNjZGFhN2Q3ZjhmYzJfMS0xLTEtMS0xNzc3NQ_7b30b51c-7b03-4861-ba7f-65ef358267c2"
      unitRef="shares">268000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="i5f4625a059aa4800b22d29c186dc894c_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185MS9mcmFnOjlmMTJhYjBlYWNjMTQ1OTU5ZDhhNjcyY2JmZjdkYjZkL3RhYmxlOjZjYjk4NzQxYjcwOTQxMzhhMTYzY2RhYTdkN2Y4ZmMyL3RhYmxlcmFuZ2U6NmNiOTg3NDFiNzA5NDEzOGExNjNjZGFhN2Q3ZjhmYzJfMS0zLTEtMS0xNzc3NQ_ee840c1d-8fd9-4efb-ada3-d80fb92e968f"
      unitRef="usdPerShare">10.27</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="i2ef2d194cc634bb5a3f24f06d02c7f5b_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185MS9mcmFnOjlmMTJhYjBlYWNjMTQ1OTU5ZDhhNjcyY2JmZjdkYjZkL3RhYmxlOjZjYjk4NzQxYjcwOTQxMzhhMTYzY2RhYTdkN2Y4ZmMyL3RhYmxlcmFuZ2U6NmNiOTg3NDFiNzA5NDEzOGExNjNjZGFhN2Q3ZjhmYzJfMS01LTEtMS0xNzc3NQ_c58f33d3-963b-48a9-919c-d7c0a4631135">P6Y2M1D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="i5f4625a059aa4800b22d29c186dc894c_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185MS9mcmFnOjlmMTJhYjBlYWNjMTQ1OTU5ZDhhNjcyY2JmZjdkYjZkL3RhYmxlOjZjYjk4NzQxYjcwOTQxMzhhMTYzY2RhYTdkN2Y4ZmMyL3RhYmxlcmFuZ2U6NmNiOTg3NDFiNzA5NDEzOGExNjNjZGFhN2Q3ZjhmYzJfMS03LTEtMS0xNzc3NQ_0c067165-fc40-44fe-994d-ef14eb74add4"
      unitRef="usd">-326000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="ib4707869ee56405ab1f2a9c58e43b761_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185MS9mcmFnOjlmMTJhYjBlYWNjMTQ1OTU5ZDhhNjcyY2JmZjdkYjZkL3RhYmxlOjZjYjk4NzQxYjcwOTQxMzhhMTYzY2RhYTdkN2Y4ZmMyL3RhYmxlcmFuZ2U6NmNiOTg3NDFiNzA5NDEzOGExNjNjZGFhN2Q3ZjhmYzJfMi0xLTEtMS0xNzc3NQ_fe1e6225-dcea-4ae5-8417-64836bb5240e"
      unitRef="shares">268000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="ib4707869ee56405ab1f2a9c58e43b761_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185MS9mcmFnOjlmMTJhYjBlYWNjMTQ1OTU5ZDhhNjcyY2JmZjdkYjZkL3RhYmxlOjZjYjk4NzQxYjcwOTQxMzhhMTYzY2RhYTdkN2Y4ZmMyL3RhYmxlcmFuZ2U6NmNiOTg3NDFiNzA5NDEzOGExNjNjZGFhN2Q3ZjhmYzJfMi0zLTEtMS0xNzc3NQ_fc4185ab-5402-44d6-a7b6-d87e491b8ad6"
      unitRef="usdPerShare">10.27</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="i45606ce9dfa74fc7bd724460f67189ab_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185MS9mcmFnOjlmMTJhYjBlYWNjMTQ1OTU5ZDhhNjcyY2JmZjdkYjZkL3RhYmxlOjZjYjk4NzQxYjcwOTQxMzhhMTYzY2RhYTdkN2Y4ZmMyL3RhYmxlcmFuZ2U6NmNiOTg3NDFiNzA5NDEzOGExNjNjZGFhN2Q3ZjhmYzJfMi01LTEtMS0xNzc3NQ_c191996d-bc7d-4456-a0af-bb20da0b242c">P4Y1M28D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="ib4707869ee56405ab1f2a9c58e43b761_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185MS9mcmFnOjlmMTJhYjBlYWNjMTQ1OTU5ZDhhNjcyY2JmZjdkYjZkL3RhYmxlOjZjYjk4NzQxYjcwOTQxMzhhMTYzY2RhYTdkN2Y4ZmMyL3RhYmxlcmFuZ2U6NmNiOTg3NDFiNzA5NDEzOGExNjNjZGFhN2Q3ZjhmYzJfMi03LTEtMS0xNzc3NQ_ec5f05af-4021-4bc5-8c84-7c7f57f56986"
      unitRef="usd">5620000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
      contextRef="ib4707869ee56405ab1f2a9c58e43b761_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185MS9mcmFnOjlmMTJhYjBlYWNjMTQ1OTU5ZDhhNjcyY2JmZjdkYjZkL3RhYmxlOjZjYjk4NzQxYjcwOTQxMzhhMTYzY2RhYTdkN2Y4ZmMyL3RhYmxlcmFuZ2U6NmNiOTg3NDFiNzA5NDEzOGExNjNjZGFhN2Q3ZjhmYzJfNC0xLTEtMS0xNzc3NQ_b1c624c2-0e74-4d11-8155-221dc05ed97d"
      unitRef="shares">268000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
      contextRef="ib4707869ee56405ab1f2a9c58e43b761_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185MS9mcmFnOjlmMTJhYjBlYWNjMTQ1OTU5ZDhhNjcyY2JmZjdkYjZkL3RhYmxlOjZjYjk4NzQxYjcwOTQxMzhhMTYzY2RhYTdkN2Y4ZmMyL3RhYmxlcmFuZ2U6NmNiOTg3NDFiNzA5NDEzOGExNjNjZGFhN2Q3ZjhmYzJfNC0zLTEtMS0xNzc3NQ_4e378d50-c598-49dc-8225-088e1f07a113"
      unitRef="usdPerShare">10.27</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
      contextRef="i45606ce9dfa74fc7bd724460f67189ab_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185MS9mcmFnOjlmMTJhYjBlYWNjMTQ1OTU5ZDhhNjcyY2JmZjdkYjZkL3RhYmxlOjZjYjk4NzQxYjcwOTQxMzhhMTYzY2RhYTdkN2Y4ZmMyL3RhYmxlcmFuZ2U6NmNiOTg3NDFiNzA5NDEzOGExNjNjZGFhN2Q3ZjhmYzJfNC01LTEtMS0xNzc3NQ_cdc4b397-b783-4ce6-888a-060bf2c278af">P4Y1M28D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
      contextRef="ib4707869ee56405ab1f2a9c58e43b761_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185MS9mcmFnOjlmMTJhYjBlYWNjMTQ1OTU5ZDhhNjcyY2JmZjdkYjZkL3RhYmxlOjZjYjk4NzQxYjcwOTQxMzhhMTYzY2RhYTdkN2Y4ZmMyL3RhYmxlcmFuZ2U6NmNiOTg3NDFiNzA5NDEzOGExNjNjZGFhN2Q3ZjhmYzJfNC03LTEtMS0xNzc3NQ_725e4f8a-b465-4ea0-b6b6-e42b69c44fd7"
      unitRef="usd">5620000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="i643136e202254be08774a096650b7946_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185MS9mcmFnOjlmMTJhYjBlYWNjMTQ1OTU5ZDhhNjcyY2JmZjdkYjZkL3RleHRyZWdpb246OWYxMmFiMGVhY2MxNDU5NTlkOGE2NzJjYmZmN2RiNmRfNjY3Mw_73da71e7-ee88-4fea-bad5-2bcbfab1492b">P1Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1
      contextRef="i903fc0912d4e492c95e3ce815e897489_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185MS9mcmFnOjlmMTJhYjBlYWNjMTQ1OTU5ZDhhNjcyY2JmZjdkYjZkL3RleHRyZWdpb246OWYxMmFiMGVhY2MxNDU5NTlkOGE2NzJjYmZmN2RiNmRfMTI2NTY_0030ede0-3ec8-4a1f-98ea-5a0f4cbfdce3">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="i903fc0912d4e492c95e3ce815e897489_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185MS9mcmFnOjlmMTJhYjBlYWNjMTQ1OTU5ZDhhNjcyY2JmZjdkYjZkL3RleHRyZWdpb246OWYxMmFiMGVhY2MxNDU5NTlkOGE2NzJjYmZmN2RiNmRfNjgxNQ_d0102915-7d69-4e72-ab46-6b7fcb5c8fec"
      unitRef="number">0.25</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="i53ca92671b00498d832fcdf0ccb439b2_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185MS9mcmFnOjlmMTJhYjBlYWNjMTQ1OTU5ZDhhNjcyY2JmZjdkYjZkL3RleHRyZWdpb246OWYxMmFiMGVhY2MxNDU5NTlkOGE2NzJjYmZmN2RiNmRfMTI2NzQ_3392a588-0562-476c-99ee-73ffdc6704f3">P1Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock
      contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185MS9mcmFnOjlmMTJhYjBlYWNjMTQ1OTU5ZDhhNjcyY2JmZjdkYjZkL3RleHRyZWdpb246OWYxMmFiMGVhY2MxNDU5NTlkOGE2NzJjYmZmN2RiNmRfMTI2ODU_30a8bd8d-24d6-4d9a-aaee-f041a9f5f1ec">Information with respect to our RSUs (not including performance-based RSUs) is presented below (in thousands, except for weighted-average grant-date fair value):&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:412.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:58.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:3.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:58.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr style="height:42pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total RSUs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted Average Grant Date Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding as of December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,737&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,276&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(243)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12.74&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(683)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.68&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding as of December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,087&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16.35&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="ia60cbf2c61674250a7870e50684977b4_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185MS9mcmFnOjlmMTJhYjBlYWNjMTQ1OTU5ZDhhNjcyY2JmZjdkYjZkL3RhYmxlOjg5ODA1ZmFhYmM5MzQ2OTU4NmEzZDE2MmNmNTk0MWM4L3RhYmxlcmFuZ2U6ODk4MDVmYWFiYzkzNDY5NTg2YTNkMTYyY2Y1OTQxYzhfMS0xLTEtMS0xNzc3NQ_4e6b10c5-37eb-48eb-8b89-d01d2142f2b4"
      unitRef="shares">1737000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="ia60cbf2c61674250a7870e50684977b4_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185MS9mcmFnOjlmMTJhYjBlYWNjMTQ1OTU5ZDhhNjcyY2JmZjdkYjZkL3RhYmxlOjg5ODA1ZmFhYmM5MzQ2OTU4NmEzZDE2MmNmNTk0MWM4L3RhYmxlcmFuZ2U6ODk4MDVmYWFiYzkzNDY5NTg2YTNkMTYyY2Y1OTQxYzhfMS0zLTEtMS0xNzc3NQ_4f552a33-f77c-493b-9a3b-641614afcf71"
      unitRef="usdPerShare">10.13</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="i903fc0912d4e492c95e3ce815e897489_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185MS9mcmFnOjlmMTJhYjBlYWNjMTQ1OTU5ZDhhNjcyY2JmZjdkYjZkL3RhYmxlOjg5ODA1ZmFhYmM5MzQ2OTU4NmEzZDE2MmNmNTk0MWM4L3RhYmxlcmFuZ2U6ODk4MDVmYWFiYzkzNDY5NTg2YTNkMTYyY2Y1OTQxYzhfMi0xLTEtMS0xNzc3NQ_10525e2b-43af-4855-b0a8-00ef0a41d1fc"
      unitRef="shares">1276000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i903fc0912d4e492c95e3ce815e897489_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185MS9mcmFnOjlmMTJhYjBlYWNjMTQ1OTU5ZDhhNjcyY2JmZjdkYjZkL3RhYmxlOjg5ODA1ZmFhYmM5MzQ2OTU4NmEzZDE2MmNmNTk0MWM4L3RhYmxlcmFuZ2U6ODk4MDVmYWFiYzkzNDY5NTg2YTNkMTYyY2Y1OTQxYzhfMi0zLTEtMS0xNzc3NQ_5532c66f-c1d2-4036-8d9a-053b2796eab9"
      unitRef="usdPerShare">21.10</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="i903fc0912d4e492c95e3ce815e897489_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185MS9mcmFnOjlmMTJhYjBlYWNjMTQ1OTU5ZDhhNjcyY2JmZjdkYjZkL3RhYmxlOjg5ODA1ZmFhYmM5MzQ2OTU4NmEzZDE2MmNmNTk0MWM4L3RhYmxlcmFuZ2U6ODk4MDVmYWFiYzkzNDY5NTg2YTNkMTYyY2Y1OTQxYzhfMy0xLTEtMS0xNzc3NQ_8c4bd326-445b-4d71-ab18-3bbc6f39ed0d"
      unitRef="shares">243000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="i903fc0912d4e492c95e3ce815e897489_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185MS9mcmFnOjlmMTJhYjBlYWNjMTQ1OTU5ZDhhNjcyY2JmZjdkYjZkL3RhYmxlOjg5ODA1ZmFhYmM5MzQ2OTU4NmEzZDE2MmNmNTk0MWM4L3RhYmxlcmFuZ2U6ODk4MDVmYWFiYzkzNDY5NTg2YTNkMTYyY2Y1OTQxYzhfMy0zLTEtMS0xNzc3NQ_f00ab1de-26df-46a6-a4d0-47e38b17e397"
      unitRef="usdPerShare">12.74</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="i903fc0912d4e492c95e3ce815e897489_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185MS9mcmFnOjlmMTJhYjBlYWNjMTQ1OTU5ZDhhNjcyY2JmZjdkYjZkL3RhYmxlOjg5ODA1ZmFhYmM5MzQ2OTU4NmEzZDE2MmNmNTk0MWM4L3RhYmxlcmFuZ2U6ODk4MDVmYWFiYzkzNDY5NTg2YTNkMTYyY2Y1OTQxYzhfNC0xLTEtMS0xNzc3NQ_4e2f4b39-b489-4b8a-9a09-1fc41c0bf13b"
      unitRef="shares">683000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="i903fc0912d4e492c95e3ce815e897489_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185MS9mcmFnOjlmMTJhYjBlYWNjMTQ1OTU5ZDhhNjcyY2JmZjdkYjZkL3RhYmxlOjg5ODA1ZmFhYmM5MzQ2OTU4NmEzZDE2MmNmNTk0MWM4L3RhYmxlcmFuZ2U6ODk4MDVmYWFiYzkzNDY5NTg2YTNkMTYyY2Y1OTQxYzhfNC0zLTEtMS0xNzc3NQ_7a846a39-ce96-49d0-a910-39f30ed1ffce"
      unitRef="usdPerShare">10.68</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="i0a2bd98f25e64cac9d230b30c39fd652_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185MS9mcmFnOjlmMTJhYjBlYWNjMTQ1OTU5ZDhhNjcyY2JmZjdkYjZkL3RhYmxlOjg5ODA1ZmFhYmM5MzQ2OTU4NmEzZDE2MmNmNTk0MWM4L3RhYmxlcmFuZ2U6ODk4MDVmYWFiYzkzNDY5NTg2YTNkMTYyY2Y1OTQxYzhfNS0xLTEtMS0xNzc3NQ_28be7bf1-b089-4c9b-b2c0-1a92965b2d37"
      unitRef="shares">2087000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="i0a2bd98f25e64cac9d230b30c39fd652_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185MS9mcmFnOjlmMTJhYjBlYWNjMTQ1OTU5ZDhhNjcyY2JmZjdkYjZkL3RhYmxlOjg5ODA1ZmFhYmM5MzQ2OTU4NmEzZDE2MmNmNTk0MWM4L3RhYmxlcmFuZ2U6ODk4MDVmYWFiYzkzNDY5NTg2YTNkMTYyY2Y1OTQxYzhfNS0zLTEtMS0xNzc3NQ_8dc9fd8a-5163-41bc-86b9-e408e99d61e4"
      unitRef="usdPerShare">16.35</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i903fc0912d4e492c95e3ce815e897489_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185MS9mcmFnOjlmMTJhYjBlYWNjMTQ1OTU5ZDhhNjcyY2JmZjdkYjZkL3RleHRyZWdpb246OWYxMmFiMGVhY2MxNDU5NTlkOGE2NzJjYmZmN2RiNmRfNzI3OA_5532c66f-c1d2-4036-8d9a-053b2796eab9"
      unitRef="usdPerShare">21.10</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i117e325270bf4054b07c98692139814a_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185MS9mcmFnOjlmMTJhYjBlYWNjMTQ1OTU5ZDhhNjcyY2JmZjdkYjZkL3RleHRyZWdpb246OWYxMmFiMGVhY2MxNDU5NTlkOGE2NzJjYmZmN2RiNmRfNzI4Mg_a705f5f0-2f61-433e-9052-a77359327ecc"
      unitRef="usdPerShare">8.88</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i4ad066769cd0464cbcbcf7d1ec4ce0ad_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185MS9mcmFnOjlmMTJhYjBlYWNjMTQ1OTU5ZDhhNjcyY2JmZjdkYjZkL3RleHRyZWdpb246OWYxMmFiMGVhY2MxNDU5NTlkOGE2NzJjYmZmN2RiNmRfNzI4OQ_e4ce7afd-ea50-47b0-8578-46019ab1b431"
      unitRef="usdPerShare">10.66</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue
      contextRef="i903fc0912d4e492c95e3ce815e897489_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185MS9mcmFnOjlmMTJhYjBlYWNjMTQ1OTU5ZDhhNjcyY2JmZjdkYjZkL3RleHRyZWdpb246OWYxMmFiMGVhY2MxNDU5NTlkOGE2NzJjYmZmN2RiNmRfNzQ3Nw_6e901783-79cd-4a2e-b198-55efd2fc2703"
      unitRef="usd">7300000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue
      contextRef="i117e325270bf4054b07c98692139814a_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185MS9mcmFnOjlmMTJhYjBlYWNjMTQ1OTU5ZDhhNjcyY2JmZjdkYjZkL3RleHRyZWdpb246OWYxMmFiMGVhY2MxNDU5NTlkOGE2NzJjYmZmN2RiNmRfNzQ4MQ_ee95a873-24c2-4c45-859e-b100246022ce"
      unitRef="usd">6100000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue
      contextRef="i4ad066769cd0464cbcbcf7d1ec4ce0ad_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185MS9mcmFnOjlmMTJhYjBlYWNjMTQ1OTU5ZDhhNjcyY2JmZjdkYjZkL3RleHRyZWdpb246OWYxMmFiMGVhY2MxNDU5NTlkOGE2NzJjYmZmN2RiNmRfNzQ4OA_625e3ce3-2726-4485-87fb-e3b2c7ac4f78"
      unitRef="usd">7300000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="i824c4e26d9414a59ad8f2d73e36714d0_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185MS9mcmFnOjlmMTJhYjBlYWNjMTQ1OTU5ZDhhNjcyY2JmZjdkYjZkL3RleHRyZWdpb246OWYxMmFiMGVhY2MxNDU5NTlkOGE2NzJjYmZmN2RiNmRfNzU3OA_3f4eb76d-ca82-4be4-88c7-fffcfb697b34"
      unitRef="shares">500000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="i89ff4001d069448c9d4b0758b35fcfdb_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185MS9mcmFnOjlmMTJhYjBlYWNjMTQ1OTU5ZDhhNjcyY2JmZjdkYjZkL3RleHRyZWdpb246OWYxMmFiMGVhY2MxNDU5NTlkOGE2NzJjYmZmN2RiNmRfNzU4NQ_19002fc4-be4d-4ff3-9ad7-33cbdb2a4bf9"
      unitRef="shares">700000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <evh:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsStockPriceIncreasePercentage
      contextRef="i74fbd0cbfcb8404bbbc19a496f94e90d_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185MS9mcmFnOjlmMTJhYjBlYWNjMTQ1OTU5ZDhhNjcyY2JmZjdkYjZkL3RleHRyZWdpb246OWYxMmFiMGVhY2MxNDU5NTlkOGE2NzJjYmZmN2RiNmRfNzkzOA_8062adc0-e97c-4469-91ce-14efe0c04b91"
      unitRef="number">0.333</evh:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsStockPriceIncreasePercentage>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="i74fbd0cbfcb8404bbbc19a496f94e90d_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185MS9mcmFnOjlmMTJhYjBlYWNjMTQ1OTU5ZDhhNjcyY2JmZjdkYjZkL3RleHRyZWdpb246OWYxMmFiMGVhY2MxNDU5NTlkOGE2NzJjYmZmN2RiNmRfNzk0Mg_8a97dc0c-6bf8-4f7f-81c3-3472560cab9f"
      unitRef="number">0.75</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <evh:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsStockPriceIncreasePercentage
      contextRef="i08583f7a5ec342338d4ec3de61aff226_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185MS9mcmFnOjlmMTJhYjBlYWNjMTQ1OTU5ZDhhNjcyY2JmZjdkYjZkL3RleHRyZWdpb246OWYxMmFiMGVhY2MxNDU5NTlkOGE2NzJjYmZmN2RiNmRfODAwNQ_d58c21a5-86fc-4791-80d2-afe83a078511"
      unitRef="number">0.50</evh:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsStockPriceIncreasePercentage>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="i08583f7a5ec342338d4ec3de61aff226_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185MS9mcmFnOjlmMTJhYjBlYWNjMTQ1OTU5ZDhhNjcyY2JmZjdkYjZkL3RleHRyZWdpb246OWYxMmFiMGVhY2MxNDU5NTlkOGE2NzJjYmZmN2RiNmRfODAwOQ_f7c03cac-3b9a-4a11-afe0-a5e2b22a0e52"
      unitRef="number">1</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <evh:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsStockPriceIncreasePercentage
      contextRef="i4b299843c6624a0b86491cf8ede39655_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185MS9mcmFnOjlmMTJhYjBlYWNjMTQ1OTU5ZDhhNjcyY2JmZjdkYjZkL3RleHRyZWdpb246OWYxMmFiMGVhY2MxNDU5NTlkOGE2NzJjYmZmN2RiNmRfODA3Mg_4b0d65de-b3f9-4842-8093-8e48dfe5bde7"
      unitRef="number">1</evh:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsStockPriceIncreasePercentage>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="i4b299843c6624a0b86491cf8ede39655_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185MS9mcmFnOjlmMTJhYjBlYWNjMTQ1OTU5ZDhhNjcyY2JmZjdkYjZkL3RleHRyZWdpb246OWYxMmFiMGVhY2MxNDU5NTlkOGE2NzJjYmZmN2RiNmRfODA3Ng_3da13b11-bda8-4b67-9318-f1dd259d7af9"
      unitRef="number">1.50</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <evh:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsStockPriceIncreasePercentage
      contextRef="i04a926a87abf4421b1ca0ae299f722a6_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185MS9mcmFnOjlmMTJhYjBlYWNjMTQ1OTU5ZDhhNjcyY2JmZjdkYjZkL3RleHRyZWdpb246OWYxMmFiMGVhY2MxNDU5NTlkOGE2NzJjYmZmN2RiNmRfODEzOQ_81576e15-95bd-47e9-a44e-d878ecec817d"
      unitRef="number">2</evh:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsStockPriceIncreasePercentage>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="i04a926a87abf4421b1ca0ae299f722a6_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185MS9mcmFnOjlmMTJhYjBlYWNjMTQ1OTU5ZDhhNjcyY2JmZjdkYjZkL3RleHRyZWdpb246OWYxMmFiMGVhY2MxNDU5NTlkOGE2NzJjYmZmN2RiNmRfODE0Mw_95d00e46-77a8-428d-ae93-9ffdafe6fc7a"
      unitRef="number">2</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="if0b01289c86a4176ab75517bdfe4ec1f_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185MS9mcmFnOjlmMTJhYjBlYWNjMTQ1OTU5ZDhhNjcyY2JmZjdkYjZkL3RhYmxlOmVmMzM5ZmVjNWU3NjRiOWM4ZmI5NDA1M2NmODZkNTUwL3RhYmxlcmFuZ2U6ZWYzMzlmZWM1ZTc2NGI5YzhmYjk0MDUzY2Y4NmQ1NTBfMi0xLTEtMS0xNzc3NQ_ed385c96-359c-4526-8dca-08b9473068b9"
      unitRef="usdPerShare">8.90</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i824c4e26d9414a59ad8f2d73e36714d0_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185MS9mcmFnOjlmMTJhYjBlYWNjMTQ1OTU5ZDhhNjcyY2JmZjdkYjZkL3RhYmxlOmVmMzM5ZmVjNWU3NjRiOWM4ZmI5NDA1M2NmODZkNTUwL3RhYmxlcmFuZ2U6ZWYzMzlmZWM1ZTc2NGI5YzhmYjk0MDUzY2Y4NmQ1NTBfMi0zLTEtMS0xNzc3NQ_089b087f-fd9b-4ac1-9e3a-9683394e8c65"
      unitRef="usdPerShare">6.52</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="if0b01289c86a4176ab75517bdfe4ec1f_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185MS9mcmFnOjlmMTJhYjBlYWNjMTQ1OTU5ZDhhNjcyY2JmZjdkYjZkL3RhYmxlOmVmMzM5ZmVjNWU3NjRiOWM4ZmI5NDA1M2NmODZkNTUwL3RhYmxlcmFuZ2U6ZWYzMzlmZWM1ZTc2NGI5YzhmYjk0MDUzY2Y4NmQ1NTBfNC0xLTEtMS0xNzc3NQ_f1709f8a-2c2e-46cf-8231-f56593ba1e40">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="i824c4e26d9414a59ad8f2d73e36714d0_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185MS9mcmFnOjlmMTJhYjBlYWNjMTQ1OTU5ZDhhNjcyY2JmZjdkYjZkL3RhYmxlOmVmMzM5ZmVjNWU3NjRiOWM4ZmI5NDA1M2NmODZkNTUwL3RhYmxlcmFuZ2U6ZWYzMzlmZWM1ZTc2NGI5YzhmYjk0MDUzY2Y4NmQ1NTBfNC0zLTEtMS0xNzc3NQ_0d0d23d2-0765-4bc4-a1d3-35dc3030e608">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="if0b01289c86a4176ab75517bdfe4ec1f_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185MS9mcmFnOjlmMTJhYjBlYWNjMTQ1OTU5ZDhhNjcyY2JmZjdkYjZkL3RhYmxlOmVmMzM5ZmVjNWU3NjRiOWM4ZmI5NDA1M2NmODZkNTUwL3RhYmxlcmFuZ2U6ZWYzMzlmZWM1ZTc2NGI5YzhmYjk0MDUzY2Y4NmQ1NTBfNS0xLTEtMS0xNzc3NQ_8e7a7ca7-99b0-449e-bc14-f7dfeedaa1c8"
      unitRef="number">0.621</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="i824c4e26d9414a59ad8f2d73e36714d0_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185MS9mcmFnOjlmMTJhYjBlYWNjMTQ1OTU5ZDhhNjcyY2JmZjdkYjZkL3RhYmxlOmVmMzM5ZmVjNWU3NjRiOWM4ZmI5NDA1M2NmODZkNTUwL3RhYmxlcmFuZ2U6ZWYzMzlmZWM1ZTc2NGI5YzhmYjk0MDUzY2Y4NmQ1NTBfNS0zLTEtMS0xNzc3NQ_fdc592e7-cdf2-4ea8-bc55-70b2550ad6ce"
      unitRef="number">0.517</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="if0b01289c86a4176ab75517bdfe4ec1f_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185MS9mcmFnOjlmMTJhYjBlYWNjMTQ1OTU5ZDhhNjcyY2JmZjdkYjZkL3RhYmxlOmVmMzM5ZmVjNWU3NjRiOWM4ZmI5NDA1M2NmODZkNTUwL3RhYmxlcmFuZ2U6ZWYzMzlmZWM1ZTc2NGI5YzhmYjk0MDUzY2Y4NmQ1NTBfNi0xLTEtMS0xNzc3NQ_6ba6ea22-3f76-4ea4-9f32-74c72a1e9e22"
      unitRef="number">0.85</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="i824c4e26d9414a59ad8f2d73e36714d0_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185MS9mcmFnOjlmMTJhYjBlYWNjMTQ1OTU5ZDhhNjcyY2JmZjdkYjZkL3RhYmxlOmVmMzM5ZmVjNWU3NjRiOWM4ZmI5NDA1M2NmODZkNTUwL3RhYmxlcmFuZ2U6ZWYzMzlmZWM1ZTc2NGI5YzhmYjk0MDUzY2Y4NmQ1NTBfNi0zLTEtMS0xNzc3NQ_7cbccf63-bbfd-429a-9b83-7a4eb4015a5c"
      unitRef="number">2.54</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="if0b01289c86a4176ab75517bdfe4ec1f_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185MS9mcmFnOjlmMTJhYjBlYWNjMTQ1OTU5ZDhhNjcyY2JmZjdkYjZkL3RhYmxlOmVmMzM5ZmVjNWU3NjRiOWM4ZmI5NDA1M2NmODZkNTUwL3RhYmxlcmFuZ2U6ZWYzMzlmZWM1ZTc2NGI5YzhmYjk0MDUzY2Y4NmQ1NTBfNy0xLTEtMS0xNzc3NQ_0f99690d-a45d-461d-972b-e90512bdbe60"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="i824c4e26d9414a59ad8f2d73e36714d0_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185MS9mcmFnOjlmMTJhYjBlYWNjMTQ1OTU5ZDhhNjcyY2JmZjdkYjZkL3RhYmxlOmVmMzM5ZmVjNWU3NjRiOWM4ZmI5NDA1M2NmODZkNTUwL3RhYmxlcmFuZ2U6ZWYzMzlmZWM1ZTc2NGI5YzhmYjk0MDUzY2Y4NmQ1NTBfNy0zLTEtMS0xNzc3NQ_3e50450e-4831-4d96-aa06-c9c5621e593a"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ScheduleOfOtherShareBasedCompensationActivityTableTextBlock
      contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185MS9mcmFnOjlmMTJhYjBlYWNjMTQ1OTU5ZDhhNjcyY2JmZjdkYjZkL3RleHRyZWdpb246OWYxMmFiMGVhY2MxNDU5NTlkOGE2NzJjYmZmN2RiNmRfMTI3MDE_39d5ebac-e457-4ffb-a0a0-f77a5fedf8ff">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Information with respect to our leveraged stock unit awards (shares and aggregate intrinsic value shown in thousands, weighted-average remaining contractual term shown in years) was as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:539.25pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:286.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:58.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:58.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:58.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:58.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr style="height:54pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Leveraged Stock Units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted Average Grant Date Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted Average Remaining Contractual Term&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Aggregate Intrinsic Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding as of December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,084&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.07&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.68&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,993&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested and expected to vest after December&#160;31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,084&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.07&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.68&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,993&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfOtherShareBasedCompensationActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="i33d73ea883764a2dafec5a1252f33aef_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185MS9mcmFnOjlmMTJhYjBlYWNjMTQ1OTU5ZDhhNjcyY2JmZjdkYjZkL3RhYmxlOmRmYWFmOTk2ZDkzZTQ0NTY5Y2I0MDBmZGI4Y2JlNTAwL3RhYmxlcmFuZ2U6ZGZhYWY5OTZkOTNlNDQ1NjljYjQwMGZkYjhjYmU1MDBfMS0xLTEtMS0xNzc3NQ_1584989d-9855-4a8c-86e4-563252d38435"
      unitRef="shares">1084000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="i33d73ea883764a2dafec5a1252f33aef_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185MS9mcmFnOjlmMTJhYjBlYWNjMTQ1OTU5ZDhhNjcyY2JmZjdkYjZkL3RhYmxlOmRmYWFmOTk2ZDkzZTQ0NTY5Y2I0MDBmZGI4Y2JlNTAwL3RhYmxlcmFuZ2U6ZGZhYWY5OTZkOTNlNDQ1NjljYjQwMGZkYjhjYmU1MDBfMS0zLTEtMS0xNzc3NQ_fd0f08d3-81fd-4aaa-b93c-9341940e45f1"
      unitRef="usdPerShare">11.07</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms
      contextRef="if0b01289c86a4176ab75517bdfe4ec1f_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185MS9mcmFnOjlmMTJhYjBlYWNjMTQ1OTU5ZDhhNjcyY2JmZjdkYjZkL3RhYmxlOmRmYWFmOTk2ZDkzZTQ0NTY5Y2I0MDBmZGI4Y2JlNTAwL3RhYmxlcmFuZ2U6ZGZhYWY5OTZkOTNlNDQ1NjljYjQwMGZkYjhjYmU1MDBfMS01LTEtMS0xNzc3NQ_d220e54c-93f3-4935-aa6b-e924d328807a">P7Y8M4D</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding
      contextRef="i33d73ea883764a2dafec5a1252f33aef_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185MS9mcmFnOjlmMTJhYjBlYWNjMTQ1OTU5ZDhhNjcyY2JmZjdkYjZkL3RhYmxlOmRmYWFmOTk2ZDkzZTQ0NTY5Y2I0MDBmZGI4Y2JlNTAwL3RhYmxlcmFuZ2U6ZGZhYWY5OTZkOTNlNDQ1NjljYjQwMGZkYjhjYmU1MDBfMS03LTEtMS0xNzc3NQ_cd4194d9-f3e0-4ac5-b262-416070fc6506"
      unitRef="usd">17993000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding>
    <evh:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestNumber
      contextRef="i33d73ea883764a2dafec5a1252f33aef_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185MS9mcmFnOjlmMTJhYjBlYWNjMTQ1OTU5ZDhhNjcyY2JmZjdkYjZkL3RhYmxlOmRmYWFmOTk2ZDkzZTQ0NTY5Y2I0MDBmZGI4Y2JlNTAwL3RhYmxlcmFuZ2U6ZGZhYWY5OTZkOTNlNDQ1NjljYjQwMGZkYjhjYmU1MDBfMy0xLTEtMS0xNzc3NQ_f4d8dd21-202c-43f1-91ac-150e65a77bff"
      unitRef="shares">1084000</evh:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestNumber>
    <evh:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestWeightedAverageGrantDateFairValue
      contextRef="i33d73ea883764a2dafec5a1252f33aef_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185MS9mcmFnOjlmMTJhYjBlYWNjMTQ1OTU5ZDhhNjcyY2JmZjdkYjZkL3RhYmxlOmRmYWFmOTk2ZDkzZTQ0NTY5Y2I0MDBmZGI4Y2JlNTAwL3RhYmxlcmFuZ2U6ZGZhYWY5OTZkOTNlNDQ1NjljYjQwMGZkYjhjYmU1MDBfMy0zLTEtMS0xNzc3NQ_54c30cb7-60c4-4734-8f43-f32c32b77b70"
      unitRef="usdPerShare">11.07</evh:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestWeightedAverageGrantDateFairValue>
    <evh:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestWeightedAverageRemainingContractualTerms
      contextRef="if0b01289c86a4176ab75517bdfe4ec1f_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185MS9mcmFnOjlmMTJhYjBlYWNjMTQ1OTU5ZDhhNjcyY2JmZjdkYjZkL3RhYmxlOmRmYWFmOTk2ZDkzZTQ0NTY5Y2I0MDBmZGI4Y2JlNTAwL3RhYmxlcmFuZ2U6ZGZhYWY5OTZkOTNlNDQ1NjljYjQwMGZkYjhjYmU1MDBfMy01LTEtMS0xNzc3NQ_d17fc428-3b43-4ef3-aa1e-070ca90155ef">P7Y8M4D</evh:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestWeightedAverageRemainingContractualTerms>
    <evh:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVestedAndExpectedToVest
      contextRef="i33d73ea883764a2dafec5a1252f33aef_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185MS9mcmFnOjlmMTJhYjBlYWNjMTQ1OTU5ZDhhNjcyY2JmZjdkYjZkL3RhYmxlOmRmYWFmOTk2ZDkzZTQ0NTY5Y2I0MDBmZGI4Y2JlNTAwL3RhYmxlcmFuZ2U6ZGZhYWY5OTZkOTNlNDQ1NjljYjQwMGZkYjhjYmU1MDBfMy03LTEtMS0xNzc3NQ_953cbeea-a5e8-42d1-af96-14c0b35c633a"
      unitRef="usd">17993000</evh:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVestedAndExpectedToVest>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="i91de07e5bb1e422aa1d46986a0b1006f_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185MS9mcmFnOjlmMTJhYjBlYWNjMTQ1OTU5ZDhhNjcyY2JmZjdkYjZkL3RleHRyZWdpb246OWYxMmFiMGVhY2MxNDU5NTlkOGE2NzJjYmZmN2RiNmRfMTA5OTUxMTY0NjkwNg_756106ef-d0f1-4805-b5d7-64113b31973c"
      unitRef="shares">300000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <evh:EarningsBeforeInterestTaxesDepreciationAndAmortizationGoalPeriod
      contextRef="i3c5f476b4e1249a08e8202ae0113bf9a_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185MS9mcmFnOjlmMTJhYjBlYWNjMTQ1OTU5ZDhhNjcyY2JmZjdkYjZkL3RleHRyZWdpb246OWYxMmFiMGVhY2MxNDU5NTlkOGE2NzJjYmZmN2RiNmRfMzI5ODUzNDkxMDU5OQ_9fa63a30-6e2c-4bdf-aa68-6da2eb1ed4bf">P3Y</evh:EarningsBeforeInterestTaxesDepreciationAndAmortizationGoalPeriod>
    <evh:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsPerformanceGoalThreshold
      contextRef="ife9a61a44ecc47e88bb29426256eba9d_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185MS9mcmFnOjlmMTJhYjBlYWNjMTQ1OTU5ZDhhNjcyY2JmZjdkYjZkL3RleHRyZWdpb246OWYxMmFiMGVhY2MxNDU5NTlkOGE2NzJjYmZmN2RiNmRfMzg0ODI5MDcyNDQ1OA_e618c82d-1d54-4a65-9c1d-9f9041369546"
      unitRef="number">1</evh:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsPerformanceGoalThreshold>
    <evh:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsMaximumPerformanceAchievedPercentageOfTargetedSharesEarned
      contextRef="ife9a61a44ecc47e88bb29426256eba9d_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185MS9mcmFnOjlmMTJhYjBlYWNjMTQ1OTU5ZDhhNjcyY2JmZjdkYjZkL3RleHRyZWdpb246OWYxMmFiMGVhY2MxNDU5NTlkOGE2NzJjYmZmN2RiNmRfMzg0ODI5MDcyNDQ2NA_f41fd877-5bfa-4732-8740-a1f4ff6a10b3"
      unitRef="number">2</evh:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsMaximumPerformanceAchievedPercentageOfTargetedSharesEarned>
    <evh:EarningsBeforeInterestTaxesDepreciationAndAmortizationGoalPeriod
      contextRef="i3c5f476b4e1249a08e8202ae0113bf9a_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185MS9mcmFnOjlmMTJhYjBlYWNjMTQ1OTU5ZDhhNjcyY2JmZjdkYjZkL3RleHRyZWdpb246OWYxMmFiMGVhY2MxNDU5NTlkOGE2NzJjYmZmN2RiNmRfMzI5ODUzNDkxMDYxOA_6902eb41-f4e3-4900-86cf-375482cf5624">P3Y</evh:EarningsBeforeInterestTaxesDepreciationAndAmortizationGoalPeriod>
    <evh:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageAdjustmentOfSharesEarnedTotalShareholderReturnInBottomQuartile
      contextRef="ife9a61a44ecc47e88bb29426256eba9d_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185MS9mcmFnOjlmMTJhYjBlYWNjMTQ1OTU5ZDhhNjcyY2JmZjdkYjZkL3RleHRyZWdpb246OWYxMmFiMGVhY2MxNDU5NTlkOGE2NzJjYmZmN2RiNmRfMzI5ODUzNDkxMDYyMA_89609fd4-2923-44ed-8501-3c3ef1f62105"
      unitRef="number">-0.10</evh:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageAdjustmentOfSharesEarnedTotalShareholderReturnInBottomQuartile>
    <evh:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageAdjustmentOfSharesEarnedTotalShareholderReturnInTopQuartile
      contextRef="ife9a61a44ecc47e88bb29426256eba9d_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185MS9mcmFnOjlmMTJhYjBlYWNjMTQ1OTU5ZDhhNjcyY2JmZjdkYjZkL3RleHRyZWdpb246OWYxMmFiMGVhY2MxNDU5NTlkOGE2NzJjYmZmN2RiNmRfMzI5ODUzNDkxMDYyNg_bd195b1b-3a96-4236-9d08-d792ff9312d6"
      unitRef="number">0.10</evh:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageAdjustmentOfSharesEarnedTotalShareholderReturnInTopQuartile>
    <evh:ScheduleOfShareBasedPaymentAwardRestrictedStockUnitValuationAssumptionsTableTextBlock
      contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185MS9mcmFnOjlmMTJhYjBlYWNjMTQ1OTU5ZDhhNjcyY2JmZjdkYjZkL3RleHRyZWdpb246OWYxMmFiMGVhY2MxNDU5NTlkOGE2NzJjYmZmN2RiNmRfMTA0NDUzNjA0OTExMTI_3ac2f91c-8017-4cc0-bd1f-0847e56fe95e">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The price assumptions used for our performance based stock unit awards were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:384.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:73.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:73.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1st Tranche&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2nd Tranche&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average fair value per performance based stock unit granted&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20.64&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20.69&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Assumptions:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected term&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;89.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;77.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</evh:ScheduleOfShareBasedPaymentAwardRestrictedStockUnitValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="if24975b6c6fc46f2956741e09150759a_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185MS9mcmFnOjlmMTJhYjBlYWNjMTQ1OTU5ZDhhNjcyY2JmZjdkYjZkL3RhYmxlOjU5MDZhZDBhMjM2NjQ5YzA5NmU5ZWNmNzQ3NDVkNjgxL3RhYmxlcmFuZ2U6NTkwNmFkMGEyMzY2NDljMDk2ZTllY2Y3NDc0NWQ2ODFfMS0xLTEtMS0zNjU5NA_632282f1-a240-498a-8aeb-34de9e274e62"
      unitRef="usdPerShare">20.64</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i32a9b997fd964b44a992bdf9b2104f0e_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185MS9mcmFnOjlmMTJhYjBlYWNjMTQ1OTU5ZDhhNjcyY2JmZjdkYjZkL3RhYmxlOjU5MDZhZDBhMjM2NjQ5YzA5NmU5ZWNmNzQ3NDVkNjgxL3RhYmxlcmFuZ2U6NTkwNmFkMGEyMzY2NDljMDk2ZTllY2Y3NDc0NWQ2ODFfMS0zLTEtMS0zNjYwMQ_88c9f2bd-3db0-43d1-9f2e-c79c91741a7b"
      unitRef="usdPerShare">20.69</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="ie5209e47858942b8a833f9d575b7d37c_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185MS9mcmFnOjlmMTJhYjBlYWNjMTQ1OTU5ZDhhNjcyY2JmZjdkYjZkL3RhYmxlOjU5MDZhZDBhMjM2NjQ5YzA5NmU5ZWNmNzQ3NDVkNjgxL3RhYmxlcmFuZ2U6NTkwNmFkMGEyMzY2NDljMDk2ZTllY2Y3NDc0NWQ2ODFfMy0xLTEtMS0zNjU5OA_ad1b401b-2929-4381-82c9-e75d79d6a34f">P2Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="i1c1d55717222438abb87e60bcf9b59b9_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185MS9mcmFnOjlmMTJhYjBlYWNjMTQ1OTU5ZDhhNjcyY2JmZjdkYjZkL3RhYmxlOjU5MDZhZDBhMjM2NjQ5YzA5NmU5ZWNmNzQ3NDVkNjgxL3RhYmxlcmFuZ2U6NTkwNmFkMGEyMzY2NDljMDk2ZTllY2Y3NDc0NWQ2ODFfMy0zLTEtMS0zNjYwMQ_f165c7f7-8505-4e17-a29d-972e36f49950">P3Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="ie5209e47858942b8a833f9d575b7d37c_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185MS9mcmFnOjlmMTJhYjBlYWNjMTQ1OTU5ZDhhNjcyY2JmZjdkYjZkL3RhYmxlOjU5MDZhZDBhMjM2NjQ5YzA5NmU5ZWNmNzQ3NDVkNjgxL3RhYmxlcmFuZ2U6NTkwNmFkMGEyMzY2NDljMDk2ZTllY2Y3NDc0NWQ2ODFfNC0xLTEtMS0zNjU5OA_936d344d-4569-46f7-90c9-d3e5c5acb88c"
      unitRef="number">0.895</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="i1c1d55717222438abb87e60bcf9b59b9_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185MS9mcmFnOjlmMTJhYjBlYWNjMTQ1OTU5ZDhhNjcyY2JmZjdkYjZkL3RhYmxlOjU5MDZhZDBhMjM2NjQ5YzA5NmU5ZWNmNzQ3NDVkNjgxL3RhYmxlcmFuZ2U6NTkwNmFkMGEyMzY2NDljMDk2ZTllY2Y3NDc0NWQ2ODFfNC0zLTEtMS0zNjYwMQ_2589ca9e-6ace-4730-94b0-38eb25248d5e"
      unitRef="number">0.777</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="ie5209e47858942b8a833f9d575b7d37c_D20210101-20211231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185MS9mcmFnOjlmMTJhYjBlYWNjMTQ1OTU5ZDhhNjcyY2JmZjdkYjZkL3RhYmxlOjU5MDZhZDBhMjM2NjQ5YzA5NmU5ZWNmNzQ3NDVkNjgxL3RhYmxlcmFuZ2U6NTkwNmFkMGEyMzY2NDljMDk2ZTllY2Y3NDc0NWQ2ODFfNS0xLTEtMS0zNjU5OA_d7af974e-a6b7-4895-868d-ec25a27d51c2"
      unitRef="number">0.0012</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="i1c1d55717222438abb87e60bcf9b59b9_D20210101-20211231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185MS9mcmFnOjlmMTJhYjBlYWNjMTQ1OTU5ZDhhNjcyY2JmZjdkYjZkL3RhYmxlOjU5MDZhZDBhMjM2NjQ5YzA5NmU5ZWNmNzQ3NDVkNjgxL3RhYmxlcmFuZ2U6NTkwNmFkMGEyMzY2NDljMDk2ZTllY2Y3NDc0NWQ2ODFfNS0zLTEtMS0zNjYwMQ_c0e67a56-62d3-4eb1-b3a1-8d4ab22ab0b8"
      unitRef="number">0.0025</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="ie5209e47858942b8a833f9d575b7d37c_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185MS9mcmFnOjlmMTJhYjBlYWNjMTQ1OTU5ZDhhNjcyY2JmZjdkYjZkL3RhYmxlOjU5MDZhZDBhMjM2NjQ5YzA5NmU5ZWNmNzQ3NDVkNjgxL3RhYmxlcmFuZ2U6NTkwNmFkMGEyMzY2NDljMDk2ZTllY2Y3NDc0NWQ2ODFfNi0xLTEtMS0zNjU5OA_691d92d4-6feb-4fbc-a20f-b6f155911a57"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="i1c1d55717222438abb87e60bcf9b59b9_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185MS9mcmFnOjlmMTJhYjBlYWNjMTQ1OTU5ZDhhNjcyY2JmZjdkYjZkL3RhYmxlOjU5MDZhZDBhMjM2NjQ5YzA5NmU5ZWNmNzQ3NDVkNjgxL3RhYmxlcmFuZ2U6NTkwNmFkMGEyMzY2NDljMDk2ZTllY2Y3NDc0NWQ2ODFfNi0zLTEtMS0zNjYwMQ_f0395fae-f757-4253-84c6-4c86e12ea4fc"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardRestrictedStockUnitsVestedAndExpectedToVestTableTextBlock
      contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185MS9mcmFnOjlmMTJhYjBlYWNjMTQ1OTU5ZDhhNjcyY2JmZjdkYjZkL3RleHRyZWdpb246OWYxMmFiMGVhY2MxNDU5NTlkOGE2NzJjYmZmN2RiNmRfMTA0NDUzNjA0OTExMTE_507e9d2c-a97c-40cc-a020-531b62fca65d">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Information with respect to our performance based restricted stock unit awards (shares and aggregate intrinsic value shown in thousands, weighted-average remaining contractual term shown in years) was as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:536.25pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:280.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:60.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:58.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:58.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:58.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr style="height:54pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Performance Based  Stock Units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted Average Grant Date Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted Average Remaining Contractual Term&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Aggregate Intrinsic Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding as of December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;319&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20.67&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.16&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,233&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested and expected to vest after December&#160;31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;319&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20.67&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.16&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,233&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardRestrictedStockUnitsVestedAndExpectedToVestTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="ife9a61a44ecc47e88bb29426256eba9d_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185MS9mcmFnOjlmMTJhYjBlYWNjMTQ1OTU5ZDhhNjcyY2JmZjdkYjZkL3RhYmxlOmM5ZWQyMTI0OTU0NzRlMTJiODBjZDhhOWY3Y2QyZjlhL3RhYmxlcmFuZ2U6YzllZDIxMjQ5NTQ3NGUxMmI4MGNkOGE5ZjdjZDJmOWFfMS0xLTEtMS0yMzU5MQ_7acc1381-d444-49a0-92c0-9c31f82674d4"
      unitRef="shares">319000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="ife9a61a44ecc47e88bb29426256eba9d_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185MS9mcmFnOjlmMTJhYjBlYWNjMTQ1OTU5ZDhhNjcyY2JmZjdkYjZkL3RhYmxlOmM5ZWQyMTI0OTU0NzRlMTJiODBjZDhhOWY3Y2QyZjlhL3RhYmxlcmFuZ2U6YzllZDIxMjQ5NTQ3NGUxMmI4MGNkOGE5ZjdjZDJmOWFfMS0zLTEtMS0yMzU5MQ_8c2600f4-1c17-4632-9085-1b41a30f8cfc"
      unitRef="usdPerShare">20.67</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms
      contextRef="i91de07e5bb1e422aa1d46986a0b1006f_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185MS9mcmFnOjlmMTJhYjBlYWNjMTQ1OTU5ZDhhNjcyY2JmZjdkYjZkL3RhYmxlOmM5ZWQyMTI0OTU0NzRlMTJiODBjZDhhOWY3Y2QyZjlhL3RhYmxlcmFuZ2U6YzllZDIxMjQ5NTQ3NGUxMmI4MGNkOGE5ZjdjZDJmOWFfMS01LTEtMS0yMzU5MQ_2327da8f-543a-4de8-ab49-d14a68ede934">P9Y1M28D</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding
      contextRef="ife9a61a44ecc47e88bb29426256eba9d_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185MS9mcmFnOjlmMTJhYjBlYWNjMTQ1OTU5ZDhhNjcyY2JmZjdkYjZkL3RhYmxlOmM5ZWQyMTI0OTU0NzRlMTJiODBjZDhhOWY3Y2QyZjlhL3RhYmxlcmFuZ2U6YzllZDIxMjQ5NTQ3NGUxMmI4MGNkOGE5ZjdjZDJmOWFfMS03LTEtMS0yMzU5MQ_c249b57a-4be8-42e1-86fa-18b86aa077ee"
      unitRef="usd">2233000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding>
    <evh:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestNumber
      contextRef="ife9a61a44ecc47e88bb29426256eba9d_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185MS9mcmFnOjlmMTJhYjBlYWNjMTQ1OTU5ZDhhNjcyY2JmZjdkYjZkL3RhYmxlOmM5ZWQyMTI0OTU0NzRlMTJiODBjZDhhOWY3Y2QyZjlhL3RhYmxlcmFuZ2U6YzllZDIxMjQ5NTQ3NGUxMmI4MGNkOGE5ZjdjZDJmOWFfMy0xLTEtMS0yMzU5MQ_574fb23d-f560-4aa3-99e8-49cc076949db"
      unitRef="shares">319000</evh:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestNumber>
    <evh:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestWeightedAverageGrantDateFairValue
      contextRef="ife9a61a44ecc47e88bb29426256eba9d_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185MS9mcmFnOjlmMTJhYjBlYWNjMTQ1OTU5ZDhhNjcyY2JmZjdkYjZkL3RhYmxlOmM5ZWQyMTI0OTU0NzRlMTJiODBjZDhhOWY3Y2QyZjlhL3RhYmxlcmFuZ2U6YzllZDIxMjQ5NTQ3NGUxMmI4MGNkOGE5ZjdjZDJmOWFfMy0zLTEtMS0yMzU5MQ_f1bdec84-f0c7-4cf3-853f-6d42be2935cc"
      unitRef="usdPerShare">20.67</evh:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestWeightedAverageGrantDateFairValue>
    <evh:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestWeightedAverageRemainingContractualTerms
      contextRef="i91de07e5bb1e422aa1d46986a0b1006f_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185MS9mcmFnOjlmMTJhYjBlYWNjMTQ1OTU5ZDhhNjcyY2JmZjdkYjZkL3RhYmxlOmM5ZWQyMTI0OTU0NzRlMTJiODBjZDhhOWY3Y2QyZjlhL3RhYmxlcmFuZ2U6YzllZDIxMjQ5NTQ3NGUxMmI4MGNkOGE5ZjdjZDJmOWFfMy01LTEtMS0yMzU5MQ_8e1dfc92-7e74-4ec9-8fd5-28f6b85f23af">P9Y1M28D</evh:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestWeightedAverageRemainingContractualTerms>
    <evh:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVestedAndExpectedToVest
      contextRef="ife9a61a44ecc47e88bb29426256eba9d_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185MS9mcmFnOjlmMTJhYjBlYWNjMTQ1OTU5ZDhhNjcyY2JmZjdkYjZkL3RhYmxlOmM5ZWQyMTI0OTU0NzRlMTJiODBjZDhhOWY3Y2QyZjlhL3RhYmxlcmFuZ2U6YzllZDIxMjQ5NTQ3NGUxMmI4MGNkOGE5ZjdjZDJmOWFfMy03LTEtMS0yMzU5MQ_31a2a57b-28e9-4ff9-961a-fc981af6f827"
      unitRef="usd">2233000</evh:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVestedAndExpectedToVest>
    <us-gaap:IncomeTaxDisclosureTextBlock
      contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185Ny9mcmFnOmJjZWZiM2Q3NjJhNzQ1YWE4MWQ3NzAzMjlmMDdjODMyL3RleHRyZWdpb246YmNlZmIzZDc2MmE3NDVhYTgxZDc3MDMyOWYwN2M4MzJfODQyMA_63453375-5819-4b2f-95b9-ef78a034c398">Income Taxes&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;An income tax expense (benefit) of $0.5&#160;million, $(2.4)&#160;million, and $(22.8)&#160;million was recognized for the years ended December 31, 2021, 2020 and 2019, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our loss from continuing operations before income taxes was as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:379.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:48.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:48.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:48.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;For the Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Domestic&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(32,719)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(332,373)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(331,033)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,918&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,833&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,045&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Loss from continuing operations before income taxes&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(29,801)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(330,540)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(329,988)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Components of income tax expense (benefit) (in thousands) consist of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:370.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:51.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:51.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:51.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;For the Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Federal&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,469)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,305)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;185&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;State and local&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,449&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;200&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,027&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;721&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;399&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total current tax expense (benefit)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,007&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,384)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;598&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Deferred&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Federal&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5,866)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(38,258)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(27,307)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;State and local&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,021)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9,565)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5,046)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(493)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(303)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total deferred tax expense (benefit)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(10,380)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(48,126)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(32,347)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change in valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,856&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47,142&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,954&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total tax expense (benefit)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;483&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,368)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(22,795)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;A reconciliation of the U.S. statutory tax rate to our effective tax rate is presented below:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:379.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:48.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:48.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:48.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;For the Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. statutory tax rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. state income taxes, net of U.S. federal tax benefit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign earnings at other than U.S. rates&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change in valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(33.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(14.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Benefit of net operating loss carryback provision&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-deductible goodwill impairment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(11.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(15.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-controlling interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Nondeductible excess compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(10.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Excess tax benefits (shortfalls) on stock-based compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Convertible debt extinguishment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change in uncertain tax positions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Nontaxable earnout&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change in state rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Return to provision&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change in indefinite reinvestment assertion for domestic subsidiaries &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Tax sharing settlement&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Effective tax rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Deferred tax balances reflect the impact of temporary differences between the carrying amount of assets and liabilities and their tax basis and are stated at the tax rates expected to be in effect when the temporary differences are expected to be recovered or settled.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Significant components of the Company&#x2019;s deferred tax assets and liabilities (in thousands) were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:433.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:48.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:48.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;As of December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Deferred Tax Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Start-up and organizational costs&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;103&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;117&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goodwill&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,774&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,778&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,968&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,963&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,345&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,434&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock based compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,714&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,530&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net operating loss carryforwards&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;130,242&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;123,604&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Federal and state research tax credits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,828&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,828&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fixed assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;480&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;131&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest deduction limitation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,795&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,452&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outside basis differences&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,972&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;197&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,236&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,428&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Subtotal&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;205,457&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;192,462&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(101,345)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(89,723)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total deferred tax assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;104,112&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;102,739&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Deferred Tax Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Internally developed software costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,501&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,973&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;48,677&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;49,053&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Right-of-use assets - Operating&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,284&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,122&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contract fulfillment costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,317&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,375&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Convertible debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,604&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,411&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,387&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,484&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total deferred tax liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;104,770&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;103,418&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net deferred tax assets (liabilities)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(658)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(679)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Changes in our valuation allowance (in thousands) were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:433.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:48.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:48.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr style="height:23pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;For the Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at beginning-of-year&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;89,723&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50,519&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Charged to costs and expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,856&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47,142&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Charged (credited) to other accounts &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,766&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7,938)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at end-of-year&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;101,345&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;89,723&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-align:justify;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:3.71pt"&gt;Amounts charged (credited) to other accounts includes $1.8&#160;million charged to discontinued operations for the year ended December&#160;31, 2021 and $8.6&#160;million credited to additional paid-in-capital, partially offset by $0.7&#160;million charged to retained earnings, for the year ended December 31, 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;For the year ended December 31, 2021, the effective tax rate was (1.6)% and the corresponding tax expense recorded was $0.5&#160;million. The income tax expense recorded by the Company in 2021 primarily relates to foreign taxes and the impact of the valuation allowance recorded against the Company&#x2019;s net deferred tax assets, with the exception of indefinite lived components and those expected to reverse outside of the net operating loss carryover period.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;For the year ended December 31, 2020, the effective tax rate was 0.7% and the corresponding tax benefit recorded was $2.4&#160;million. The income tax benefit recorded by the Company in 2020 primarily relates to the impacts from the Coronavirus Aid, Relief, and Economic Security Act (the &#x201c;CARES Act&#x201d;). On March 27, 2020, in response to the COVID-19 pandemic, the CARES Act, was signed into law. The CARES Act allowed net operating losses (&#x201c;NOLs&#x201d;) incurred in 2018, 2019 and 2020 to be carried back to each of the five preceding taxable years for the recovery of previously paid federal income taxes. The Company recorded an income tax benefit related to carrying back New Century Health&#x2019;s 2018 NOL as part of a federal income tax refund claim for taxes it paid on income in 2013 and 2014. The remaining income tax provisions included in the CARES Act, apart from the aforementioned NOL carryback, did not have a significant impact on the Company. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For the year ended December 31, 2019, the effective tax rate was 6.9%, and the corresponding tax benefit recorded was $22.8&#160;million. Our effective tax rate in 2019 was impacted by the tax expense for the impairment of non-deductible goodwill, change in valuation allowance for current year losses, and offset in part by the tax effects resulting from the Company&#x2019;s acquisition of all remaining Class &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;B units of Evolent Health LLC, resulting in it becoming a disregarded entity for U.S. federal and state income purposes on December 26, 2019. The change in Evolent Health LLC&#x2019;s tax status resulted in a tax benefit from the reversal of the Company&#x2019;s deferred tax liability related to its investment in certain U.S. corporate subsidiaries through Evolent Health LLC, offset by an increase in valuation allowance. The Company filed a consolidated tax return beginning January 1, 2020, which resulted in a tax benefit offsetting the change in valuation allowance to the extent the deferred tax liabilities of our U.S. corporate subsidiaries had been used as a source of future taxable income to support the Company&#x2019;s deferred tax assets.  Our valuation allowance assessment is made without considering deferred tax liabilities of $1.9&#160;million established with respect to certain indefinite-lived components that cannot be utilized against indefinite-lived deferred tax assets or components that are expected to reverse outside of the net operating loss carryover period, as these are not considered a source of future taxable income for realizing our deferred tax assets. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2021, the Company had $203.7&#160;million of federal and $290.8&#160;million of state NOL carryforwards available to offset future taxable income that begin to expire in 2032 and 2022, respectively, and $292.9&#160;million federal and $196.0&#160;million of state NOLs with an indefinite carryforward period, subject to a utilization limit of 80% of taxable income in any given year. However, as it is more likely than not that such tax benefit will not be realized based on our evaluation, we have established a valuation allowance against those NOLs. Furthermore, Internal Revenue Code Section 382 imposes limitations on the utilization of NOLs in the event of certain changes in ownership of the Company, which may have occurred or could occur in the future. This could result in an annual limit on the Company&#x2019;s ability to utilize NOLs and could cause U.S. federal income taxes to be due sooner than if no such limitations applied.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2021, the Company had $2.1&#160;million and $0.3&#160;million of research and development credits for federal and state income tax purposes, which could expire unutilized beginning in 2037 and 2028, respectively. The Company has established a valuation allowance against those credits. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Changes in our unrecognized tax benefits (in thousands) were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:402.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:40.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:40.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:40.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr style="height:24pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;For the Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at beginning-of-year&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;678&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;753&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;934&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Lapse of statute of limitations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(69)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(75)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(181)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at end-of-year&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;609&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;678&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;753&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We are subject to taxation in various jurisdictions in the U.S. and India. Tax years 2011 and all subsequent periods remain subject to examination by the U.S. federal and state taxing jurisdictions due to the availability of NOL carryforwards. Included in the balance of unrecognized tax benefits as of December&#160;31, 2021, are $0.6&#160;million of tax benefits that, if recognized, would not affect the overall effective tax rate, due to the offsetting impact on the Company&#x2019;s valuation allowance. The Company has not recognized interest and penalties related to uncertain tax positions due to the current NOL position. The Company had recognized $0.7&#160;million of uncertain tax positions as of December&#160;31, 2020, and $0.8&#160;million as of December&#160;31, 2019. The Company and its subsidiaries are not currently subject to income tax audits in any U.S. state or local jurisdiction, or any foreign jurisdiction, for any tax year.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Tax Receivables Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Pursuant to the Offering Reorganization, Class B Exchanges increased our tax basis in our share of Evolent Health LLC&#x2019;s tangible and intangible assets. These increases in tax basis increased our depreciation and amortization deductions and create other tax benefits and, therefore, may reduce the amount of tax that we would otherwise be required to pay in the future. In addition, certain NOLs of Evolent Health Holdings (and of an affiliate of TPG) are available to us as a result of the Offering Reorganization.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with the Offering Reorganization, we entered into the TRA with the holders of Class B common units. The agreement requires us to pay to such holders 85% of the cash savings, if any, in U.S. federal, state and local, and foreign income tax (as applicable) we realize as a result of any deductions attributable to future increases in tax basis following the Class B Exchanges (calculated assuming that any post-offering transfer of Class B common units had not occurred) or deductions attributable to imputed interest or future increases in tax basis following payments made under the TRA. We are accounting for these payments as contingent liabilities and will recognize them in our Consolidated Statements of Operations and Comprehensive Income (Loss) when their realization becomes probable. Additionally, pursuant to the same agreement we will pay the former stockholders of Evolent Health Holdings 85% of the amount of the cash savings, if any, in U.S. federal, state and local, and foreign income tax that we realize as a result of the utilization of the NOLs of Evolent Health Holdings (and the affiliate of TPG) attributable to periods prior to the Offering Reorganization, approximately $79.3&#160;million, as well as deductions attributable to imputed interest on any payments made under the agreement. &lt;/span&gt;&lt;/div&gt;We will benefit from the remaining 15% of any realized cash savings. The TRA was effective upon the completion of the Offering Reorganization and will remain in effect until all such tax benefits have been used or expired, or until the agreement is terminated.  See Note 11 for additional discussion of the implications of the TRA.</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185Ny9mcmFnOmJjZWZiM2Q3NjJhNzQ1YWE4MWQ3NzAzMjlmMDdjODMyL3RleHRyZWdpb246YmNlZmIzZDc2MmE3NDVhYTgxZDc3MDMyOWYwN2M4MzJfNjQ_4073ffb7-e4b1-4fe8-921a-55572fa124eb"
      unitRef="usd">500000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i12a6d1161de54547bd29f8efccd4c9b0_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185Ny9mcmFnOmJjZWZiM2Q3NjJhNzQ1YWE4MWQ3NzAzMjlmMDdjODMyL3RleHRyZWdpb246YmNlZmIzZDc2MmE3NDVhYTgxZDc3MDMyOWYwN2M4MzJfNjg_7f3c533b-43b4-4619-9990-218c86c1e046"
      unitRef="usd">-2400000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i3e21049ffc224cacb8134d73c9bb5b38_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185Ny9mcmFnOmJjZWZiM2Q3NjJhNzQ1YWE4MWQ3NzAzMjlmMDdjODMyL3RleHRyZWdpb246YmNlZmIzZDc2MmE3NDVhYTgxZDc3MDMyOWYwN2M4MzJfODU_e19ea87f-3f0d-43eb-bd0c-90554d83c884"
      unitRef="usd">-22800000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock
      contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185Ny9mcmFnOmJjZWZiM2Q3NjJhNzQ1YWE4MWQ3NzAzMjlmMDdjODMyL3RleHRyZWdpb246YmNlZmIzZDc2MmE3NDVhYTgxZDc3MDMyOWYwN2M4MzJfODM5Mw_4ae3eb2e-09b5-4892-b204-5f485e27ec23">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our loss from continuing operations before income taxes was as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:379.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:48.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:48.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:48.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;For the Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Domestic&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(32,719)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(332,373)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(331,033)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,918&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,833&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,045&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Loss from continuing operations before income taxes&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(29,801)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(330,540)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(329,988)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
      contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185Ny9mcmFnOmJjZWZiM2Q3NjJhNzQ1YWE4MWQ3NzAzMjlmMDdjODMyL3RhYmxlOjMwMTM2MmFmZTI2MDQ3NjJhMzVkMmEzOTc2YjY2ZDNmL3RhYmxlcmFuZ2U6MzAxMzYyYWZlMjYwNDc2MmEzNWQyYTM5NzZiNjZkM2ZfMi0xLTEtMS0xNzc3NQ_ee1dce95-a7e3-47dd-a00e-a019221e4f4f"
      unitRef="usd">-32719000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
      contextRef="i12a6d1161de54547bd29f8efccd4c9b0_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185Ny9mcmFnOmJjZWZiM2Q3NjJhNzQ1YWE4MWQ3NzAzMjlmMDdjODMyL3RhYmxlOjMwMTM2MmFmZTI2MDQ3NjJhMzVkMmEzOTc2YjY2ZDNmL3RhYmxlcmFuZ2U6MzAxMzYyYWZlMjYwNDc2MmEzNWQyYTM5NzZiNjZkM2ZfMi0zLTEtMS0xNzc3NQ_501644f8-7559-4683-a1a6-17088de59d9e"
      unitRef="usd">-332373000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
      contextRef="i3e21049ffc224cacb8134d73c9bb5b38_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185Ny9mcmFnOmJjZWZiM2Q3NjJhNzQ1YWE4MWQ3NzAzMjlmMDdjODMyL3RhYmxlOjMwMTM2MmFmZTI2MDQ3NjJhMzVkMmEzOTc2YjY2ZDNmL3RhYmxlcmFuZ2U6MzAxMzYyYWZlMjYwNDc2MmEzNWQyYTM5NzZiNjZkM2ZfMi01LTEtMS0xNzc3NQ_e6f0630f-7e20-4de7-ab8c-519fcdfa17c5"
      unitRef="usd">-331033000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
      contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185Ny9mcmFnOmJjZWZiM2Q3NjJhNzQ1YWE4MWQ3NzAzMjlmMDdjODMyL3RhYmxlOjMwMTM2MmFmZTI2MDQ3NjJhMzVkMmEzOTc2YjY2ZDNmL3RhYmxlcmFuZ2U6MzAxMzYyYWZlMjYwNDc2MmEzNWQyYTM5NzZiNjZkM2ZfMy0xLTEtMS0xNzc3NQ_529173ad-e123-4843-8cc9-93688900544a"
      unitRef="usd">2918000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
      contextRef="i12a6d1161de54547bd29f8efccd4c9b0_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185Ny9mcmFnOmJjZWZiM2Q3NjJhNzQ1YWE4MWQ3NzAzMjlmMDdjODMyL3RhYmxlOjMwMTM2MmFmZTI2MDQ3NjJhMzVkMmEzOTc2YjY2ZDNmL3RhYmxlcmFuZ2U6MzAxMzYyYWZlMjYwNDc2MmEzNWQyYTM5NzZiNjZkM2ZfMy0zLTEtMS0xNzc3NQ_62fbc22b-2eef-4345-a8bb-c0ab051088ae"
      unitRef="usd">1833000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
      contextRef="i3e21049ffc224cacb8134d73c9bb5b38_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185Ny9mcmFnOmJjZWZiM2Q3NjJhNzQ1YWE4MWQ3NzAzMjlmMDdjODMyL3RhYmxlOjMwMTM2MmFmZTI2MDQ3NjJhMzVkMmEzOTc2YjY2ZDNmL3RhYmxlcmFuZ2U6MzAxMzYyYWZlMjYwNDc2MmEzNWQyYTM5NzZiNjZkM2ZfMy01LTEtMS0xNzc3NQ_384822e2-a939-47c5-9595-9e8503a88189"
      unitRef="usd">1045000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
      contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185Ny9mcmFnOmJjZWZiM2Q3NjJhNzQ1YWE4MWQ3NzAzMjlmMDdjODMyL3RhYmxlOjMwMTM2MmFmZTI2MDQ3NjJhMzVkMmEzOTc2YjY2ZDNmL3RhYmxlcmFuZ2U6MzAxMzYyYWZlMjYwNDc2MmEzNWQyYTM5NzZiNjZkM2ZfNC0xLTEtMS0xNzc3NQ_f51b3cda-8dc5-47ff-a1e1-ca147fb98040"
      unitRef="usd">-29801000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
      contextRef="i12a6d1161de54547bd29f8efccd4c9b0_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185Ny9mcmFnOmJjZWZiM2Q3NjJhNzQ1YWE4MWQ3NzAzMjlmMDdjODMyL3RhYmxlOjMwMTM2MmFmZTI2MDQ3NjJhMzVkMmEzOTc2YjY2ZDNmL3RhYmxlcmFuZ2U6MzAxMzYyYWZlMjYwNDc2MmEzNWQyYTM5NzZiNjZkM2ZfNC0zLTEtMS0xNzc3NQ_9b4735a1-013e-4d6c-96fc-ac399319ada6"
      unitRef="usd">-330540000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
      contextRef="i3e21049ffc224cacb8134d73c9bb5b38_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185Ny9mcmFnOmJjZWZiM2Q3NjJhNzQ1YWE4MWQ3NzAzMjlmMDdjODMyL3RhYmxlOjMwMTM2MmFmZTI2MDQ3NjJhMzVkMmEzOTc2YjY2ZDNmL3RhYmxlcmFuZ2U6MzAxMzYyYWZlMjYwNDc2MmEzNWQyYTM5NzZiNjZkM2ZfNC01LTEtMS0xNzc3NQ_ed5e04e2-1d31-46fe-8746-ff8255af990e"
      unitRef="usd">-329988000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
    <us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock
      contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185Ny9mcmFnOmJjZWZiM2Q3NjJhNzQ1YWE4MWQ3NzAzMjlmMDdjODMyL3RleHRyZWdpb246YmNlZmIzZDc2MmE3NDVhYTgxZDc3MDMyOWYwN2M4MzJfODQxNg_3902ee80-9b65-459f-b1db-8ee5e23887ce">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Components of income tax expense (benefit) (in thousands) consist of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:370.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:51.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:51.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:51.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;For the Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Federal&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,469)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,305)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;185&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;State and local&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,449&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;200&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,027&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;721&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;399&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total current tax expense (benefit)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,007&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,384)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;598&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Deferred&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Federal&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5,866)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(38,258)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(27,307)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;State and local&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,021)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9,565)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5,046)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(493)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(303)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total deferred tax expense (benefit)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(10,380)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(48,126)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(32,347)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change in valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,856&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47,142&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,954&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total tax expense (benefit)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;483&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,368)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(22,795)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock>
    <us-gaap:CurrentFederalTaxExpenseBenefit
      contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185Ny9mcmFnOmJjZWZiM2Q3NjJhNzQ1YWE4MWQ3NzAzMjlmMDdjODMyL3RhYmxlOmFmNmIxZTM1NzRiNzRiZjJhNTJhY2U3ZWRlZmQ1ZTc5L3RhYmxlcmFuZ2U6YWY2YjFlMzU3NGI3NGJmMmE1MmFjZTdlZGVmZDVlNzlfMy0xLTEtMS0xNzc3NQ_4ff6b9d7-d488-4586-b45b-0f84059eb702"
      unitRef="usd">-1469000</us-gaap:CurrentFederalTaxExpenseBenefit>
    <us-gaap:CurrentFederalTaxExpenseBenefit
      contextRef="i12a6d1161de54547bd29f8efccd4c9b0_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185Ny9mcmFnOmJjZWZiM2Q3NjJhNzQ1YWE4MWQ3NzAzMjlmMDdjODMyL3RhYmxlOmFmNmIxZTM1NzRiNzRiZjJhNTJhY2U3ZWRlZmQ1ZTc5L3RhYmxlcmFuZ2U6YWY2YjFlMzU3NGI3NGJmMmE1MmFjZTdlZGVmZDVlNzlfMy0zLTEtMS0xNzc3NQ_27adb068-96da-4ec3-9541-c3c222942cd1"
      unitRef="usd">-2305000</us-gaap:CurrentFederalTaxExpenseBenefit>
    <us-gaap:CurrentFederalTaxExpenseBenefit
      contextRef="i3e21049ffc224cacb8134d73c9bb5b38_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185Ny9mcmFnOmJjZWZiM2Q3NjJhNzQ1YWE4MWQ3NzAzMjlmMDdjODMyL3RhYmxlOmFmNmIxZTM1NzRiNzRiZjJhNTJhY2U3ZWRlZmQ1ZTc5L3RhYmxlcmFuZ2U6YWY2YjFlMzU3NGI3NGJmMmE1MmFjZTdlZGVmZDVlNzlfMy01LTEtMS0xNzc3NQ_ab85a099-cbfa-40c5-9966-1bf986b6687e"
      unitRef="usd">185000</us-gaap:CurrentFederalTaxExpenseBenefit>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit
      contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185Ny9mcmFnOmJjZWZiM2Q3NjJhNzQ1YWE4MWQ3NzAzMjlmMDdjODMyL3RhYmxlOmFmNmIxZTM1NzRiNzRiZjJhNTJhY2U3ZWRlZmQ1ZTc5L3RhYmxlcmFuZ2U6YWY2YjFlMzU3NGI3NGJmMmE1MmFjZTdlZGVmZDVlNzlfNC0xLTEtMS0xNzc3NQ_c283e7b7-e766-462b-a202-b73060acba7b"
      unitRef="usd">1449000</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit
      contextRef="i12a6d1161de54547bd29f8efccd4c9b0_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185Ny9mcmFnOmJjZWZiM2Q3NjJhNzQ1YWE4MWQ3NzAzMjlmMDdjODMyL3RhYmxlOmFmNmIxZTM1NzRiNzRiZjJhNTJhY2U3ZWRlZmQ1ZTc5L3RhYmxlcmFuZ2U6YWY2YjFlMzU3NGI3NGJmMmE1MmFjZTdlZGVmZDVlNzlfNC0zLTEtMS0xNzc3NQ_9b85e1f4-126d-43e8-98f2-9c26d7d7d9f2"
      unitRef="usd">200000</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit
      contextRef="i3e21049ffc224cacb8134d73c9bb5b38_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185Ny9mcmFnOmJjZWZiM2Q3NjJhNzQ1YWE4MWQ3NzAzMjlmMDdjODMyL3RhYmxlOmFmNmIxZTM1NzRiNzRiZjJhNTJhY2U3ZWRlZmQ1ZTc5L3RhYmxlcmFuZ2U6YWY2YjFlMzU3NGI3NGJmMmE1MmFjZTdlZGVmZDVlNzlfNC01LTEtMS0xNzc3NQ_bd30775d-717b-4f6a-afce-701630023e46"
      unitRef="usd">14000</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:CurrentForeignTaxExpenseBenefit
      contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185Ny9mcmFnOmJjZWZiM2Q3NjJhNzQ1YWE4MWQ3NzAzMjlmMDdjODMyL3RhYmxlOmFmNmIxZTM1NzRiNzRiZjJhNTJhY2U3ZWRlZmQ1ZTc5L3RhYmxlcmFuZ2U6YWY2YjFlMzU3NGI3NGJmMmE1MmFjZTdlZGVmZDVlNzlfNS0xLTEtMS0xNzc3NQ_ee403e3b-fcb1-4d07-b17b-0e0eada4abbf"
      unitRef="usd">1027000</us-gaap:CurrentForeignTaxExpenseBenefit>
    <us-gaap:CurrentForeignTaxExpenseBenefit
      contextRef="i12a6d1161de54547bd29f8efccd4c9b0_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185Ny9mcmFnOmJjZWZiM2Q3NjJhNzQ1YWE4MWQ3NzAzMjlmMDdjODMyL3RhYmxlOmFmNmIxZTM1NzRiNzRiZjJhNTJhY2U3ZWRlZmQ1ZTc5L3RhYmxlcmFuZ2U6YWY2YjFlMzU3NGI3NGJmMmE1MmFjZTdlZGVmZDVlNzlfNS0zLTEtMS0xNzc3NQ_c2725858-061d-4984-866b-6576f2e46e42"
      unitRef="usd">721000</us-gaap:CurrentForeignTaxExpenseBenefit>
    <us-gaap:CurrentForeignTaxExpenseBenefit
      contextRef="i3e21049ffc224cacb8134d73c9bb5b38_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185Ny9mcmFnOmJjZWZiM2Q3NjJhNzQ1YWE4MWQ3NzAzMjlmMDdjODMyL3RhYmxlOmFmNmIxZTM1NzRiNzRiZjJhNTJhY2U3ZWRlZmQ1ZTc5L3RhYmxlcmFuZ2U6YWY2YjFlMzU3NGI3NGJmMmE1MmFjZTdlZGVmZDVlNzlfNS01LTEtMS0xNzc3NQ_ca627b61-8772-4e76-9201-4ba475c30ead"
      unitRef="usd">399000</us-gaap:CurrentForeignTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185Ny9mcmFnOmJjZWZiM2Q3NjJhNzQ1YWE4MWQ3NzAzMjlmMDdjODMyL3RhYmxlOmFmNmIxZTM1NzRiNzRiZjJhNTJhY2U3ZWRlZmQ1ZTc5L3RhYmxlcmFuZ2U6YWY2YjFlMzU3NGI3NGJmMmE1MmFjZTdlZGVmZDVlNzlfNi0xLTEtMS0xNzc3NQ_4b6a7132-928d-4ea8-8379-07c049aed3ac"
      unitRef="usd">1007000</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="i12a6d1161de54547bd29f8efccd4c9b0_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185Ny9mcmFnOmJjZWZiM2Q3NjJhNzQ1YWE4MWQ3NzAzMjlmMDdjODMyL3RhYmxlOmFmNmIxZTM1NzRiNzRiZjJhNTJhY2U3ZWRlZmQ1ZTc5L3RhYmxlcmFuZ2U6YWY2YjFlMzU3NGI3NGJmMmE1MmFjZTdlZGVmZDVlNzlfNi0zLTEtMS0xNzc3NQ_c2a54dbb-0286-4030-8d09-3fe6392cd7e6"
      unitRef="usd">-1384000</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="i3e21049ffc224cacb8134d73c9bb5b38_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185Ny9mcmFnOmJjZWZiM2Q3NjJhNzQ1YWE4MWQ3NzAzMjlmMDdjODMyL3RhYmxlOmFmNmIxZTM1NzRiNzRiZjJhNTJhY2U3ZWRlZmQ1ZTc5L3RhYmxlcmFuZ2U6YWY2YjFlMzU3NGI3NGJmMmE1MmFjZTdlZGVmZDVlNzlfNi01LTEtMS0xNzc3NQ_171cc2bc-ae1b-451f-ae98-e374b7ca13ea"
      unitRef="usd">598000</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit
      contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185Ny9mcmFnOmJjZWZiM2Q3NjJhNzQ1YWE4MWQ3NzAzMjlmMDdjODMyL3RhYmxlOmFmNmIxZTM1NzRiNzRiZjJhNTJhY2U3ZWRlZmQ1ZTc5L3RhYmxlcmFuZ2U6YWY2YjFlMzU3NGI3NGJmMmE1MmFjZTdlZGVmZDVlNzlfOC0xLTEtMS0xNzc3NQ_94548df7-1a65-4eed-913a-b0011a940580"
      unitRef="usd">-5866000</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit
      contextRef="i12a6d1161de54547bd29f8efccd4c9b0_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185Ny9mcmFnOmJjZWZiM2Q3NjJhNzQ1YWE4MWQ3NzAzMjlmMDdjODMyL3RhYmxlOmFmNmIxZTM1NzRiNzRiZjJhNTJhY2U3ZWRlZmQ1ZTc5L3RhYmxlcmFuZ2U6YWY2YjFlMzU3NGI3NGJmMmE1MmFjZTdlZGVmZDVlNzlfOC0zLTEtMS0xNzc3NQ_4da7475c-1711-4826-a9be-c12bcd366b15"
      unitRef="usd">-38258000</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit
      contextRef="i3e21049ffc224cacb8134d73c9bb5b38_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185Ny9mcmFnOmJjZWZiM2Q3NjJhNzQ1YWE4MWQ3NzAzMjlmMDdjODMyL3RhYmxlOmFmNmIxZTM1NzRiNzRiZjJhNTJhY2U3ZWRlZmQ1ZTc5L3RhYmxlcmFuZ2U6YWY2YjFlMzU3NGI3NGJmMmE1MmFjZTdlZGVmZDVlNzlfOC01LTEtMS0xNzc3NQ_76a321d7-9510-4a2b-9bf3-4775e130009c"
      unitRef="usd">-27307000</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit
      contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185Ny9mcmFnOmJjZWZiM2Q3NjJhNzQ1YWE4MWQ3NzAzMjlmMDdjODMyL3RhYmxlOmFmNmIxZTM1NzRiNzRiZjJhNTJhY2U3ZWRlZmQ1ZTc5L3RhYmxlcmFuZ2U6YWY2YjFlMzU3NGI3NGJmMmE1MmFjZTdlZGVmZDVlNzlfOS0xLTEtMS0xNzc3NQ_239b1e06-be14-443a-b4de-04272bd3a8d7"
      unitRef="usd">-4021000</us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit
      contextRef="i12a6d1161de54547bd29f8efccd4c9b0_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185Ny9mcmFnOmJjZWZiM2Q3NjJhNzQ1YWE4MWQ3NzAzMjlmMDdjODMyL3RhYmxlOmFmNmIxZTM1NzRiNzRiZjJhNTJhY2U3ZWRlZmQ1ZTc5L3RhYmxlcmFuZ2U6YWY2YjFlMzU3NGI3NGJmMmE1MmFjZTdlZGVmZDVlNzlfOS0zLTEtMS0xNzc3NQ_1a7a7288-6e16-4dc8-adcf-912bfc25646b"
      unitRef="usd">-9565000</us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit
      contextRef="i3e21049ffc224cacb8134d73c9bb5b38_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185Ny9mcmFnOmJjZWZiM2Q3NjJhNzQ1YWE4MWQ3NzAzMjlmMDdjODMyL3RhYmxlOmFmNmIxZTM1NzRiNzRiZjJhNTJhY2U3ZWRlZmQ1ZTc5L3RhYmxlcmFuZ2U6YWY2YjFlMzU3NGI3NGJmMmE1MmFjZTdlZGVmZDVlNzlfOS01LTEtMS0xNzc3NQ_0b82ffd6-c64f-4b68-a20b-073de9687925"
      unitRef="usd">-5046000</us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredForeignIncomeTaxExpenseBenefit
      contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185Ny9mcmFnOmJjZWZiM2Q3NjJhNzQ1YWE4MWQ3NzAzMjlmMDdjODMyL3RhYmxlOmFmNmIxZTM1NzRiNzRiZjJhNTJhY2U3ZWRlZmQ1ZTc5L3RhYmxlcmFuZ2U6YWY2YjFlMzU3NGI3NGJmMmE1MmFjZTdlZGVmZDVlNzlfMTAtMS0xLTEtMTc3NzU_b3f81ffc-13ca-4ae1-9c55-c73228e3b9bc"
      unitRef="usd">-493000</us-gaap:DeferredForeignIncomeTaxExpenseBenefit>
    <us-gaap:DeferredForeignIncomeTaxExpenseBenefit
      contextRef="i12a6d1161de54547bd29f8efccd4c9b0_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185Ny9mcmFnOmJjZWZiM2Q3NjJhNzQ1YWE4MWQ3NzAzMjlmMDdjODMyL3RhYmxlOmFmNmIxZTM1NzRiNzRiZjJhNTJhY2U3ZWRlZmQ1ZTc5L3RhYmxlcmFuZ2U6YWY2YjFlMzU3NGI3NGJmMmE1MmFjZTdlZGVmZDVlNzlfMTAtMy0xLTEtMTc3NzU_74f34817-749a-41b4-9318-ba5353ce4164"
      unitRef="usd">-303000</us-gaap:DeferredForeignIncomeTaxExpenseBenefit>
    <us-gaap:DeferredForeignIncomeTaxExpenseBenefit
      contextRef="i3e21049ffc224cacb8134d73c9bb5b38_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185Ny9mcmFnOmJjZWZiM2Q3NjJhNzQ1YWE4MWQ3NzAzMjlmMDdjODMyL3RhYmxlOmFmNmIxZTM1NzRiNzRiZjJhNTJhY2U3ZWRlZmQ1ZTc5L3RhYmxlcmFuZ2U6YWY2YjFlMzU3NGI3NGJmMmE1MmFjZTdlZGVmZDVlNzlfMTAtNS0xLTEtMTc3NzU_6bd562ed-aefd-4ccf-80b8-01bd68563fdf"
      unitRef="usd">6000</us-gaap:DeferredForeignIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185Ny9mcmFnOmJjZWZiM2Q3NjJhNzQ1YWE4MWQ3NzAzMjlmMDdjODMyL3RhYmxlOmFmNmIxZTM1NzRiNzRiZjJhNTJhY2U3ZWRlZmQ1ZTc5L3RhYmxlcmFuZ2U6YWY2YjFlMzU3NGI3NGJmMmE1MmFjZTdlZGVmZDVlNzlfMTEtMS0xLTEtMTc3NzU_4061a531-513c-431e-891a-6403cc95c659"
      unitRef="usd">-10380000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="i12a6d1161de54547bd29f8efccd4c9b0_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185Ny9mcmFnOmJjZWZiM2Q3NjJhNzQ1YWE4MWQ3NzAzMjlmMDdjODMyL3RhYmxlOmFmNmIxZTM1NzRiNzRiZjJhNTJhY2U3ZWRlZmQ1ZTc5L3RhYmxlcmFuZ2U6YWY2YjFlMzU3NGI3NGJmMmE1MmFjZTdlZGVmZDVlNzlfMTEtMy0xLTEtMTc3NzU_537b3432-c099-49bd-8e73-a3f07806747e"
      unitRef="usd">-48126000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="i3e21049ffc224cacb8134d73c9bb5b38_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185Ny9mcmFnOmJjZWZiM2Q3NjJhNzQ1YWE4MWQ3NzAzMjlmMDdjODMyL3RhYmxlOmFmNmIxZTM1NzRiNzRiZjJhNTJhY2U3ZWRlZmQ1ZTc5L3RhYmxlcmFuZ2U6YWY2YjFlMzU3NGI3NGJmMmE1MmFjZTdlZGVmZDVlNzlfMTEtNS0xLTEtMTc3NzU_3a04a49d-b36a-41a9-9ee0-0a9d9a21198c"
      unitRef="usd">-32347000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredOtherTaxExpenseBenefit
      contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185Ny9mcmFnOmJjZWZiM2Q3NjJhNzQ1YWE4MWQ3NzAzMjlmMDdjODMyL3RhYmxlOmFmNmIxZTM1NzRiNzRiZjJhNTJhY2U3ZWRlZmQ1ZTc5L3RhYmxlcmFuZ2U6YWY2YjFlMzU3NGI3NGJmMmE1MmFjZTdlZGVmZDVlNzlfMTItMS0xLTEtMTc3NzU_116be16f-3da5-4b46-83d8-2287602fd523"
      unitRef="usd">9856000</us-gaap:DeferredOtherTaxExpenseBenefit>
    <us-gaap:DeferredOtherTaxExpenseBenefit
      contextRef="i12a6d1161de54547bd29f8efccd4c9b0_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185Ny9mcmFnOmJjZWZiM2Q3NjJhNzQ1YWE4MWQ3NzAzMjlmMDdjODMyL3RhYmxlOmFmNmIxZTM1NzRiNzRiZjJhNTJhY2U3ZWRlZmQ1ZTc5L3RhYmxlcmFuZ2U6YWY2YjFlMzU3NGI3NGJmMmE1MmFjZTdlZGVmZDVlNzlfMTItMy0xLTEtMTc3NzU_845eb640-5498-4d70-9492-104aaddac834"
      unitRef="usd">47142000</us-gaap:DeferredOtherTaxExpenseBenefit>
    <us-gaap:DeferredOtherTaxExpenseBenefit
      contextRef="i3e21049ffc224cacb8134d73c9bb5b38_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185Ny9mcmFnOmJjZWZiM2Q3NjJhNzQ1YWE4MWQ3NzAzMjlmMDdjODMyL3RhYmxlOmFmNmIxZTM1NzRiNzRiZjJhNTJhY2U3ZWRlZmQ1ZTc5L3RhYmxlcmFuZ2U6YWY2YjFlMzU3NGI3NGJmMmE1MmFjZTdlZGVmZDVlNzlfMTItNS0xLTEtMTc3NzU_95c6eb65-35a5-4760-870c-e3359db0f0a6"
      unitRef="usd">8954000</us-gaap:DeferredOtherTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185Ny9mcmFnOmJjZWZiM2Q3NjJhNzQ1YWE4MWQ3NzAzMjlmMDdjODMyL3RhYmxlOmFmNmIxZTM1NzRiNzRiZjJhNTJhY2U3ZWRlZmQ1ZTc5L3RhYmxlcmFuZ2U6YWY2YjFlMzU3NGI3NGJmMmE1MmFjZTdlZGVmZDVlNzlfMTMtMS0xLTEtMTc3NzU_ea01165c-4b03-4ab0-abac-8b1a64467874"
      unitRef="usd">483000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i12a6d1161de54547bd29f8efccd4c9b0_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185Ny9mcmFnOmJjZWZiM2Q3NjJhNzQ1YWE4MWQ3NzAzMjlmMDdjODMyL3RhYmxlOmFmNmIxZTM1NzRiNzRiZjJhNTJhY2U3ZWRlZmQ1ZTc5L3RhYmxlcmFuZ2U6YWY2YjFlMzU3NGI3NGJmMmE1MmFjZTdlZGVmZDVlNzlfMTMtMy0xLTEtMTc3NzU_bde8faf1-daff-42c1-b62b-631722218c31"
      unitRef="usd">-2368000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i3e21049ffc224cacb8134d73c9bb5b38_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185Ny9mcmFnOmJjZWZiM2Q3NjJhNzQ1YWE4MWQ3NzAzMjlmMDdjODMyL3RhYmxlOmFmNmIxZTM1NzRiNzRiZjJhNTJhY2U3ZWRlZmQ1ZTc5L3RhYmxlcmFuZ2U6YWY2YjFlMzU3NGI3NGJmMmE1MmFjZTdlZGVmZDVlNzlfMTMtNS0xLTEtMTc3NzU_7fec7fd2-fa7e-4d03-8164-8277296044b0"
      unitRef="usd">-22795000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock
      contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185Ny9mcmFnOmJjZWZiM2Q3NjJhNzQ1YWE4MWQ3NzAzMjlmMDdjODMyL3RleHRyZWdpb246YmNlZmIzZDc2MmE3NDVhYTgxZDc3MDMyOWYwN2M4MzJfODM5MA_c9e87cf6-fa8f-4f9b-9778-8adb21a689d0">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;A reconciliation of the U.S. statutory tax rate to our effective tax rate is presented below:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:379.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:48.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:48.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:48.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;For the Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. statutory tax rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. state income taxes, net of U.S. federal tax benefit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign earnings at other than U.S. rates&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change in valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(33.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(14.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Benefit of net operating loss carryback provision&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-deductible goodwill impairment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(11.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(15.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-controlling interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Nondeductible excess compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(10.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Excess tax benefits (shortfalls) on stock-based compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Convertible debt extinguishment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change in uncertain tax positions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Nontaxable earnout&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change in state rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Return to provision&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change in indefinite reinvestment assertion for domestic subsidiaries &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Tax sharing settlement&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Effective tax rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185Ny9mcmFnOmJjZWZiM2Q3NjJhNzQ1YWE4MWQ3NzAzMjlmMDdjODMyL3RhYmxlOjFjNjIwNTBlMDM2MjQyZTJhZTQyNmMwYWQ4ZWRiMjYxL3RhYmxlcmFuZ2U6MWM2MjA1MGUwMzYyNDJlMmFlNDI2YzBhZDhlZGIyNjFfMi0xLTEtMS0xNzc3NQ_7e07d0d0-a9ac-4e6d-8243-c9ec7de6abcc"
      unitRef="number">0.210</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="i12a6d1161de54547bd29f8efccd4c9b0_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185Ny9mcmFnOmJjZWZiM2Q3NjJhNzQ1YWE4MWQ3NzAzMjlmMDdjODMyL3RhYmxlOjFjNjIwNTBlMDM2MjQyZTJhZTQyNmMwYWQ4ZWRiMjYxL3RhYmxlcmFuZ2U6MWM2MjA1MGUwMzYyNDJlMmFlNDI2YzBhZDhlZGIyNjFfMi0zLTEtMS0xNzc3NQ_d268baca-4be7-4d5c-b04b-38a296e9a178"
      unitRef="number">0.210</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="i3e21049ffc224cacb8134d73c9bb5b38_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185Ny9mcmFnOmJjZWZiM2Q3NjJhNzQ1YWE4MWQ3NzAzMjlmMDdjODMyL3RhYmxlOjFjNjIwNTBlMDM2MjQyZTJhZTQyNmMwYWQ4ZWRiMjYxL3RhYmxlcmFuZ2U6MWM2MjA1MGUwMzYyNDJlMmFlNDI2YzBhZDhlZGIyNjFfMi01LTEtMS0xNzc3NQ_9bc11fa7-29ad-49fb-9416-2387750a824d"
      unitRef="number">0.210</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185Ny9mcmFnOmJjZWZiM2Q3NjJhNzQ1YWE4MWQ3NzAzMjlmMDdjODMyL3RhYmxlOjFjNjIwNTBlMDM2MjQyZTJhZTQyNmMwYWQ4ZWRiMjYxL3RhYmxlcmFuZ2U6MWM2MjA1MGUwMzYyNDJlMmFlNDI2YzBhZDhlZGIyNjFfMy0xLTEtMS0xNzc3NQ_ad124ab6-b4ac-42c0-9656-a02308155ea8"
      unitRef="number">0.019</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="i12a6d1161de54547bd29f8efccd4c9b0_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185Ny9mcmFnOmJjZWZiM2Q3NjJhNzQ1YWE4MWQ3NzAzMjlmMDdjODMyL3RhYmxlOjFjNjIwNTBlMDM2MjQyZTJhZTQyNmMwYWQ4ZWRiMjYxL3RhYmxlcmFuZ2U6MWM2MjA1MGUwMzYyNDJlMmFlNDI2YzBhZDhlZGIyNjFfMy0zLTEtMS0xNzc3NQ_3c3ebcb7-d09f-4856-b28c-704f5630c64c"
      unitRef="number">0.029</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="i3e21049ffc224cacb8134d73c9bb5b38_D20190101-20191231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185Ny9mcmFnOmJjZWZiM2Q3NjJhNzQ1YWE4MWQ3NzAzMjlmMDdjODMyL3RhYmxlOjFjNjIwNTBlMDM2MjQyZTJhZTQyNmMwYWQ4ZWRiMjYxL3RhYmxlcmFuZ2U6MWM2MjA1MGUwMzYyNDJlMmFlNDI2YzBhZDhlZGIyNjFfMy01LTEtMS0xNzc3NQ_1825b587-4d40-47ba-8842-38918e37dbac"
      unitRef="number">0.050</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential
      contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185Ny9mcmFnOmJjZWZiM2Q3NjJhNzQ1YWE4MWQ3NzAzMjlmMDdjODMyL3RhYmxlOjFjNjIwNTBlMDM2MjQyZTJhZTQyNmMwYWQ4ZWRiMjYxL3RhYmxlcmFuZ2U6MWM2MjA1MGUwMzYyNDJlMmFlNDI2YzBhZDhlZGIyNjFfNC0xLTEtMS0xNzc3NQ_eb4ce263-1828-4cf5-a56f-2fca4174a8af"
      unitRef="number">0.003</us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential
      contextRef="i12a6d1161de54547bd29f8efccd4c9b0_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185Ny9mcmFnOmJjZWZiM2Q3NjJhNzQ1YWE4MWQ3NzAzMjlmMDdjODMyL3RhYmxlOjFjNjIwNTBlMDM2MjQyZTJhZTQyNmMwYWQ4ZWRiMjYxL3RhYmxlcmFuZ2U6MWM2MjA1MGUwMzYyNDJlMmFlNDI2YzBhZDhlZGIyNjFfNC0zLTEtMS0xNzc3NQ_4ce20ee6-fb2c-4e4a-9ac2-078615280713"
      unitRef="number">0</us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential
      contextRef="i3e21049ffc224cacb8134d73c9bb5b38_D20190101-20191231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185Ny9mcmFnOmJjZWZiM2Q3NjJhNzQ1YWE4MWQ3NzAzMjlmMDdjODMyL3RhYmxlOjFjNjIwNTBlMDM2MjQyZTJhZTQyNmMwYWQ4ZWRiMjYxL3RhYmxlcmFuZ2U6MWM2MjA1MGUwMzYyNDJlMmFlNDI2YzBhZDhlZGIyNjFfNC01LTEtMS0xNzc3NQ_b7230dc3-6548-49d5-8d18-70d4ffd2f805"
      unitRef="number">-0.001</us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185Ny9mcmFnOmJjZWZiM2Q3NjJhNzQ1YWE4MWQ3NzAzMjlmMDdjODMyL3RhYmxlOjFjNjIwNTBlMDM2MjQyZTJhZTQyNmMwYWQ4ZWRiMjYxL3RhYmxlcmFuZ2U6MWM2MjA1MGUwMzYyNDJlMmFlNDI2YzBhZDhlZGIyNjFfNS0xLTEtMS0xNzc3NQ_ffc08c4b-5929-45ad-86b4-3e50e96e6258"
      unitRef="number">-0.331</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="i12a6d1161de54547bd29f8efccd4c9b0_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185Ny9mcmFnOmJjZWZiM2Q3NjJhNzQ1YWE4MWQ3NzAzMjlmMDdjODMyL3RhYmxlOjFjNjIwNTBlMDM2MjQyZTJhZTQyNmMwYWQ4ZWRiMjYxL3RhYmxlcmFuZ2U6MWM2MjA1MGUwMzYyNDJlMmFlNDI2YzBhZDhlZGIyNjFfNS0zLTEtMS0xNzc3NQ_d0fa82d8-0897-40bb-ae5f-1ccc20bab5a9"
      unitRef="number">-0.143</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="i3e21049ffc224cacb8134d73c9bb5b38_D20190101-20191231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185Ny9mcmFnOmJjZWZiM2Q3NjJhNzQ1YWE4MWQ3NzAzMjlmMDdjODMyL3RhYmxlOjFjNjIwNTBlMDM2MjQyZTJhZTQyNmMwYWQ4ZWRiMjYxL3RhYmxlcmFuZ2U6MWM2MjA1MGUwMzYyNDJlMmFlNDI2YzBhZDhlZGIyNjFfNS01LTEtMS0xNzc3NQ_9fa7d237-3f12-49d3-ac3e-3be604d724e3"
      unitRef="number">-0.027</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <evh:EffectiveIncomeTaxRateReconciliationBenefitOfNetOperatingLossCarrybackProvisionPercent
      contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185Ny9mcmFnOmJjZWZiM2Q3NjJhNzQ1YWE4MWQ3NzAzMjlmMDdjODMyL3RhYmxlOjFjNjIwNTBlMDM2MjQyZTJhZTQyNmMwYWQ4ZWRiMjYxL3RhYmxlcmFuZ2U6MWM2MjA1MGUwMzYyNDJlMmFlNDI2YzBhZDhlZGIyNjFfNi0xLTEtMS0xNzc3NQ_8722de9a-6b35-40d4-921a-8fe54a54d9b3"
      unitRef="number">0</evh:EffectiveIncomeTaxRateReconciliationBenefitOfNetOperatingLossCarrybackProvisionPercent>
    <evh:EffectiveIncomeTaxRateReconciliationBenefitOfNetOperatingLossCarrybackProvisionPercent
      contextRef="i12a6d1161de54547bd29f8efccd4c9b0_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185Ny9mcmFnOmJjZWZiM2Q3NjJhNzQ1YWE4MWQ3NzAzMjlmMDdjODMyL3RhYmxlOjFjNjIwNTBlMDM2MjQyZTJhZTQyNmMwYWQ4ZWRiMjYxL3RhYmxlcmFuZ2U6MWM2MjA1MGUwMzYyNDJlMmFlNDI2YzBhZDhlZGIyNjFfNi0zLTEtMS0xNzc3NQ_e0421eab-683a-4e63-b456-76b5a47a3243"
      unitRef="number">0.011</evh:EffectiveIncomeTaxRateReconciliationBenefitOfNetOperatingLossCarrybackProvisionPercent>
    <evh:EffectiveIncomeTaxRateReconciliationBenefitOfNetOperatingLossCarrybackProvisionPercent
      contextRef="i3e21049ffc224cacb8134d73c9bb5b38_D20190101-20191231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185Ny9mcmFnOmJjZWZiM2Q3NjJhNzQ1YWE4MWQ3NzAzMjlmMDdjODMyL3RhYmxlOjFjNjIwNTBlMDM2MjQyZTJhZTQyNmMwYWQ4ZWRiMjYxL3RhYmxlcmFuZ2U6MWM2MjA1MGUwMzYyNDJlMmFlNDI2YzBhZDhlZGIyNjFfNi01LTEtMS0xNzc3NQ_869ef70f-2913-4ba1-9e9a-c562c337046e"
      unitRef="number">0</evh:EffectiveIncomeTaxRateReconciliationBenefitOfNetOperatingLossCarrybackProvisionPercent>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses
      contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185Ny9mcmFnOmJjZWZiM2Q3NjJhNzQ1YWE4MWQ3NzAzMjlmMDdjODMyL3RhYmxlOjFjNjIwNTBlMDM2MjQyZTJhZTQyNmMwYWQ4ZWRiMjYxL3RhYmxlcmFuZ2U6MWM2MjA1MGUwMzYyNDJlMmFlNDI2YzBhZDhlZGIyNjFfNy0xLTEtMS0xNzc3NQ_aac890e7-caac-4f2f-bfa1-a39eb9b0e113"
      unitRef="number">0</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses
      contextRef="i12a6d1161de54547bd29f8efccd4c9b0_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185Ny9mcmFnOmJjZWZiM2Q3NjJhNzQ1YWE4MWQ3NzAzMjlmMDdjODMyL3RhYmxlOjFjNjIwNTBlMDM2MjQyZTJhZTQyNmMwYWQ4ZWRiMjYxL3RhYmxlcmFuZ2U6MWM2MjA1MGUwMzYyNDJlMmFlNDI2YzBhZDhlZGIyNjFfNy0zLTEtMS0xNzc3NQ_05a1205f-b3fa-47e1-b0cf-bc7c17e9424e"
      unitRef="number">-0.115</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses
      contextRef="i3e21049ffc224cacb8134d73c9bb5b38_D20190101-20191231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185Ny9mcmFnOmJjZWZiM2Q3NjJhNzQ1YWE4MWQ3NzAzMjlmMDdjODMyL3RhYmxlOjFjNjIwNTBlMDM2MjQyZTJhZTQyNmMwYWQ4ZWRiMjYxL3RhYmxlcmFuZ2U6MWM2MjA1MGUwMzYyNDJlMmFlNDI2YzBhZDhlZGIyNjFfNy01LTEtMS0xNzc3NQ_d09f473b-8fbd-4aa1-9f2c-5fd0e516355a"
      unitRef="number">-0.156</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses>
    <us-gaap:EffectiveIncomeTaxRateReconciliationMinorityInterestIncomeExpense
      contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185Ny9mcmFnOmJjZWZiM2Q3NjJhNzQ1YWE4MWQ3NzAzMjlmMDdjODMyL3RhYmxlOjFjNjIwNTBlMDM2MjQyZTJhZTQyNmMwYWQ4ZWRiMjYxL3RhYmxlcmFuZ2U6MWM2MjA1MGUwMzYyNDJlMmFlNDI2YzBhZDhlZGIyNjFfOC0xLTEtMS0xNzc3NQ_3e034782-8fad-4a7d-a66f-109a40987a1f"
      unitRef="number">0</us-gaap:EffectiveIncomeTaxRateReconciliationMinorityInterestIncomeExpense>
    <us-gaap:EffectiveIncomeTaxRateReconciliationMinorityInterestIncomeExpense
      contextRef="i12a6d1161de54547bd29f8efccd4c9b0_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185Ny9mcmFnOmJjZWZiM2Q3NjJhNzQ1YWE4MWQ3NzAzMjlmMDdjODMyL3RhYmxlOjFjNjIwNTBlMDM2MjQyZTJhZTQyNmMwYWQ4ZWRiMjYxL3RhYmxlcmFuZ2U6MWM2MjA1MGUwMzYyNDJlMmFlNDI2YzBhZDhlZGIyNjFfOC0zLTEtMS0xNzc3NQ_63df89bc-ee39-45f1-960d-34610d8cf575"
      unitRef="number">0</us-gaap:EffectiveIncomeTaxRateReconciliationMinorityInterestIncomeExpense>
    <us-gaap:EffectiveIncomeTaxRateReconciliationMinorityInterestIncomeExpense
      contextRef="i3e21049ffc224cacb8134d73c9bb5b38_D20190101-20191231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185Ny9mcmFnOmJjZWZiM2Q3NjJhNzQ1YWE4MWQ3NzAzMjlmMDdjODMyL3RhYmxlOjFjNjIwNTBlMDM2MjQyZTJhZTQyNmMwYWQ4ZWRiMjYxL3RhYmxlcmFuZ2U6MWM2MjA1MGUwMzYyNDJlMmFlNDI2YzBhZDhlZGIyNjFfOC01LTEtMS0xNzc3NQ_a0cf74e9-d621-45c5-86aa-a86f2e72a924"
      unitRef="number">-0.003</us-gaap:EffectiveIncomeTaxRateReconciliationMinorityInterestIncomeExpense>
    <evh:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseExcessCompensationPercent
      contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185Ny9mcmFnOmJjZWZiM2Q3NjJhNzQ1YWE4MWQ3NzAzMjlmMDdjODMyL3RhYmxlOjFjNjIwNTBlMDM2MjQyZTJhZTQyNmMwYWQ4ZWRiMjYxL3RhYmxlcmFuZ2U6MWM2MjA1MGUwMzYyNDJlMmFlNDI2YzBhZDhlZGIyNjFfOS0xLTEtMS0yODkwNw_9351aeaf-11b1-41bf-97da-74aa5d913203"
      unitRef="number">-0.101</evh:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseExcessCompensationPercent>
    <evh:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseExcessCompensationPercent
      contextRef="i12a6d1161de54547bd29f8efccd4c9b0_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185Ny9mcmFnOmJjZWZiM2Q3NjJhNzQ1YWE4MWQ3NzAzMjlmMDdjODMyL3RhYmxlOjFjNjIwNTBlMDM2MjQyZTJhZTQyNmMwYWQ4ZWRiMjYxL3RhYmxlcmFuZ2U6MWM2MjA1MGUwMzYyNDJlMmFlNDI2YzBhZDhlZGIyNjFfOS0zLTEtMS0yODkwNw_f0755301-e049-42d0-8b26-b3937494dcb3"
      unitRef="number">-0.003</evh:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseExcessCompensationPercent>
    <evh:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseExcessCompensationPercent
      contextRef="i3e21049ffc224cacb8134d73c9bb5b38_D20190101-20191231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185Ny9mcmFnOmJjZWZiM2Q3NjJhNzQ1YWE4MWQ3NzAzMjlmMDdjODMyL3RhYmxlOjFjNjIwNTBlMDM2MjQyZTJhZTQyNmMwYWQ4ZWRiMjYxL3RhYmxlcmFuZ2U6MWM2MjA1MGUwMzYyNDJlMmFlNDI2YzBhZDhlZGIyNjFfOS01LTEtMS0yODkwNw_4236c03c-a1cb-4e10-90f4-4ac4b853694a"
      unitRef="number">-0.005</evh:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseExcessCompensationPercent>
    <us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent
      contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185Ny9mcmFnOmJjZWZiM2Q3NjJhNzQ1YWE4MWQ3NzAzMjlmMDdjODMyL3RhYmxlOjFjNjIwNTBlMDM2MjQyZTJhZTQyNmMwYWQ4ZWRiMjYxL3RhYmxlcmFuZ2U6MWM2MjA1MGUwMzYyNDJlMmFlNDI2YzBhZDhlZGIyNjFfOS0xLTEtMS0xNzc3NQ_e0056ae3-7b40-4c43-a5c4-c85e335a16d1"
      unitRef="number">0.081</us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent>
    <us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent
      contextRef="i12a6d1161de54547bd29f8efccd4c9b0_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185Ny9mcmFnOmJjZWZiM2Q3NjJhNzQ1YWE4MWQ3NzAzMjlmMDdjODMyL3RhYmxlOjFjNjIwNTBlMDM2MjQyZTJhZTQyNmMwYWQ4ZWRiMjYxL3RhYmxlcmFuZ2U6MWM2MjA1MGUwMzYyNDJlMmFlNDI2YzBhZDhlZGIyNjFfOS0zLTEtMS0xNzc3NQ_54d051d2-5d91-48c4-a12a-df1c60f77a77"
      unitRef="number">-0.003</us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent>
    <us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent
      contextRef="i3e21049ffc224cacb8134d73c9bb5b38_D20190101-20191231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185Ny9mcmFnOmJjZWZiM2Q3NjJhNzQ1YWE4MWQ3NzAzMjlmMDdjODMyL3RhYmxlOjFjNjIwNTBlMDM2MjQyZTJhZTQyNmMwYWQ4ZWRiMjYxL3RhYmxlcmFuZ2U6MWM2MjA1MGUwMzYyNDJlMmFlNDI2YzBhZDhlZGIyNjFfOS01LTEtMS0xNzc3NQ_f67913d3-cedb-463b-9c82-b794cf0c22ee"
      unitRef="number">-0.002</us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
      contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185Ny9mcmFnOmJjZWZiM2Q3NjJhNzQ1YWE4MWQ3NzAzMjlmMDdjODMyL3RhYmxlOjFjNjIwNTBlMDM2MjQyZTJhZTQyNmMwYWQ4ZWRiMjYxL3RhYmxlcmFuZ2U6MWM2MjA1MGUwMzYyNDJlMmFlNDI2YzBhZDhlZGIyNjFfMTAtMS0xLTEtMTc3NzU_2ff66b18-56a1-434e-997e-d51618be3e00"
      unitRef="number">0.015</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
      contextRef="i12a6d1161de54547bd29f8efccd4c9b0_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185Ny9mcmFnOmJjZWZiM2Q3NjJhNzQ1YWE4MWQ3NzAzMjlmMDdjODMyL3RhYmxlOjFjNjIwNTBlMDM2MjQyZTJhZTQyNmMwYWQ4ZWRiMjYxL3RhYmxlcmFuZ2U6MWM2MjA1MGUwMzYyNDJlMmFlNDI2YzBhZDhlZGIyNjFfMTAtMy0xLTEtMTc3NzU_4d7b261c-4d42-4a9c-9610-5e8e229a5987"
      unitRef="number">0</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
      contextRef="i3e21049ffc224cacb8134d73c9bb5b38_D20190101-20191231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185Ny9mcmFnOmJjZWZiM2Q3NjJhNzQ1YWE4MWQ3NzAzMjlmMDdjODMyL3RhYmxlOjFjNjIwNTBlMDM2MjQyZTJhZTQyNmMwYWQ4ZWRiMjYxL3RhYmxlcmFuZ2U6MWM2MjA1MGUwMzYyNDJlMmFlNDI2YzBhZDhlZGIyNjFfMTAtNS0xLTEtMTc3NzU_e407e726-23af-4c8a-99e2-72c108e8895c"
      unitRef="number">0</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch>
    <evh:EffectiveIncomeTaxRateReconciliationChangeInUncertainTaxPositions
      contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185Ny9mcmFnOmJjZWZiM2Q3NjJhNzQ1YWE4MWQ3NzAzMjlmMDdjODMyL3RhYmxlOjFjNjIwNTBlMDM2MjQyZTJhZTQyNmMwYWQ4ZWRiMjYxL3RhYmxlcmFuZ2U6MWM2MjA1MGUwMzYyNDJlMmFlNDI2YzBhZDhlZGIyNjFfMTEtMS0xLTEtMTc3NzU_77a054ac-208b-4e11-97de-ea9da957cb24"
      unitRef="number">0.002</evh:EffectiveIncomeTaxRateReconciliationChangeInUncertainTaxPositions>
    <evh:EffectiveIncomeTaxRateReconciliationChangeInUncertainTaxPositions
      contextRef="i12a6d1161de54547bd29f8efccd4c9b0_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185Ny9mcmFnOmJjZWZiM2Q3NjJhNzQ1YWE4MWQ3NzAzMjlmMDdjODMyL3RhYmxlOjFjNjIwNTBlMDM2MjQyZTJhZTQyNmMwYWQ4ZWRiMjYxL3RhYmxlcmFuZ2U6MWM2MjA1MGUwMzYyNDJlMmFlNDI2YzBhZDhlZGIyNjFfMTEtMy0xLTEtMTc3NzU_29b8a55f-7e1b-4398-8b32-b18e531344c4"
      unitRef="number">0</evh:EffectiveIncomeTaxRateReconciliationChangeInUncertainTaxPositions>
    <evh:EffectiveIncomeTaxRateReconciliationChangeInUncertainTaxPositions
      contextRef="i3e21049ffc224cacb8134d73c9bb5b38_D20190101-20191231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185Ny9mcmFnOmJjZWZiM2Q3NjJhNzQ1YWE4MWQ3NzAzMjlmMDdjODMyL3RhYmxlOjFjNjIwNTBlMDM2MjQyZTJhZTQyNmMwYWQ4ZWRiMjYxL3RhYmxlcmFuZ2U6MWM2MjA1MGUwMzYyNDJlMmFlNDI2YzBhZDhlZGIyNjFfMTEtNS0xLTEtMTc3NzU_33bb9e84-65ed-4740-b3fc-66a3b9713cfc"
      unitRef="number">0.001</evh:EffectiveIncomeTaxRateReconciliationChangeInUncertainTaxPositions>
    <evh:EffectiveIncomeTaxRateReconciliationEffectOfInvestment
      contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185Ny9mcmFnOmJjZWZiM2Q3NjJhNzQ1YWE4MWQ3NzAzMjlmMDdjODMyL3RhYmxlOjFjNjIwNTBlMDM2MjQyZTJhZTQyNmMwYWQ4ZWRiMjYxL3RhYmxlcmFuZ2U6MWM2MjA1MGUwMzYyNDJlMmFlNDI2YzBhZDhlZGIyNjFfMTItMS0xLTEtMTc3NzU_30d33f94-b711-476b-95f9-7b27d2d5b88e"
      unitRef="number">0</evh:EffectiveIncomeTaxRateReconciliationEffectOfInvestment>
    <evh:EffectiveIncomeTaxRateReconciliationEffectOfInvestment
      contextRef="i12a6d1161de54547bd29f8efccd4c9b0_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185Ny9mcmFnOmJjZWZiM2Q3NjJhNzQ1YWE4MWQ3NzAzMjlmMDdjODMyL3RhYmxlOjFjNjIwNTBlMDM2MjQyZTJhZTQyNmMwYWQ4ZWRiMjYxL3RhYmxlcmFuZ2U6MWM2MjA1MGUwMzYyNDJlMmFlNDI2YzBhZDhlZGIyNjFfMTItMy0xLTEtMTc3NzU_f1d68dd5-2e8c-4dc7-9b07-830a4e7f47d5"
      unitRef="number">0</evh:EffectiveIncomeTaxRateReconciliationEffectOfInvestment>
    <evh:EffectiveIncomeTaxRateReconciliationEffectOfInvestment
      contextRef="i3e21049ffc224cacb8134d73c9bb5b38_D20190101-20191231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185Ny9mcmFnOmJjZWZiM2Q3NjJhNzQ1YWE4MWQ3NzAzMjlmMDdjODMyL3RhYmxlOjFjNjIwNTBlMDM2MjQyZTJhZTQyNmMwYWQ4ZWRiMjYxL3RhYmxlcmFuZ2U6MWM2MjA1MGUwMzYyNDJlMmFlNDI2YzBhZDhlZGIyNjFfMTItNS0xLTEtMTc3NzU_2a04c1fe-a070-42b9-8b53-c1eabc2df770"
      unitRef="number">-0.014</evh:EffectiveIncomeTaxRateReconciliationEffectOfInvestment>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate
      contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185Ny9mcmFnOmJjZWZiM2Q3NjJhNzQ1YWE4MWQ3NzAzMjlmMDdjODMyL3RhYmxlOjFjNjIwNTBlMDM2MjQyZTJhZTQyNmMwYWQ4ZWRiMjYxL3RhYmxlcmFuZ2U6MWM2MjA1MGUwMzYyNDJlMmFlNDI2YzBhZDhlZGIyNjFfMTMtMS0xLTEtMTc3NzU_e0efa387-f0be-4943-8cab-d16db4effcca"
      unitRef="number">0.068</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate
      contextRef="i12a6d1161de54547bd29f8efccd4c9b0_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185Ny9mcmFnOmJjZWZiM2Q3NjJhNzQ1YWE4MWQ3NzAzMjlmMDdjODMyL3RhYmxlOjFjNjIwNTBlMDM2MjQyZTJhZTQyNmMwYWQ4ZWRiMjYxL3RhYmxlcmFuZ2U6MWM2MjA1MGUwMzYyNDJlMmFlNDI2YzBhZDhlZGIyNjFfMTMtMy0xLTEtMTc3NzU_36c66402-f213-4afa-94be-c6012a30b679"
      unitRef="number">0.013</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate
      contextRef="i3e21049ffc224cacb8134d73c9bb5b38_D20190101-20191231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185Ny9mcmFnOmJjZWZiM2Q3NjJhNzQ1YWE4MWQ3NzAzMjlmMDdjODMyL3RhYmxlOjFjNjIwNTBlMDM2MjQyZTJhZTQyNmMwYWQ4ZWRiMjYxL3RhYmxlcmFuZ2U6MWM2MjA1MGUwMzYyNDJlMmFlNDI2YzBhZDhlZGIyNjFfMTMtNS0xLTEtMTc3NzU_026b59f5-3cdb-4b1b-80f6-35cc7c2b0249"
      unitRef="number">-0.007</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate>
    <evh:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseReturnToProvisionPercent
      contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185Ny9mcmFnOmJjZWZiM2Q3NjJhNzQ1YWE4MWQ3NzAzMjlmMDdjODMyL3RhYmxlOjFjNjIwNTBlMDM2MjQyZTJhZTQyNmMwYWQ4ZWRiMjYxL3RhYmxlcmFuZ2U6MWM2MjA1MGUwMzYyNDJlMmFlNDI2YzBhZDhlZGIyNjFfMTQtMS0xLTEtMjg4ODE_f182f40a-4a5c-42da-9f0e-f2af441aecc7"
      unitRef="number">0.066</evh:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseReturnToProvisionPercent>
    <evh:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseReturnToProvisionPercent
      contextRef="i12a6d1161de54547bd29f8efccd4c9b0_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185Ny9mcmFnOmJjZWZiM2Q3NjJhNzQ1YWE4MWQ3NzAzMjlmMDdjODMyL3RhYmxlOjFjNjIwNTBlMDM2MjQyZTJhZTQyNmMwYWQ4ZWRiMjYxL3RhYmxlcmFuZ2U6MWM2MjA1MGUwMzYyNDJlMmFlNDI2YzBhZDhlZGIyNjFfMTQtMy0xLTEtMjg4ODE_1e325454-6708-4e8f-a23f-893f87681c4d"
      unitRef="number">-0.008</evh:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseReturnToProvisionPercent>
    <evh:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseReturnToProvisionPercent
      contextRef="i3e21049ffc224cacb8134d73c9bb5b38_D20190101-20191231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185Ny9mcmFnOmJjZWZiM2Q3NjJhNzQ1YWE4MWQ3NzAzMjlmMDdjODMyL3RhYmxlOjFjNjIwNTBlMDM2MjQyZTJhZTQyNmMwYWQ4ZWRiMjYxL3RhYmxlcmFuZ2U6MWM2MjA1MGUwMzYyNDJlMmFlNDI2YzBhZDhlZGIyNjFfMTQtNS0xLTEtMjg4ODE_eba1d607-255c-45d4-86dd-e9560c9e18b8"
      unitRef="number">0.010</evh:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseReturnToProvisionPercent>
    <evh:EffectiveIncomeTaxRateReconciliationDomesticSubsidiaryException
      contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185Ny9mcmFnOmJjZWZiM2Q3NjJhNzQ1YWE4MWQ3NzAzMjlmMDdjODMyL3RhYmxlOjFjNjIwNTBlMDM2MjQyZTJhZTQyNmMwYWQ4ZWRiMjYxL3RhYmxlcmFuZ2U6MWM2MjA1MGUwMzYyNDJlMmFlNDI2YzBhZDhlZGIyNjFfMTQtMS0xLTEtMTc3NzU_26378fa5-2f49-40f1-9a14-4567411330dd"
      unitRef="number">0</evh:EffectiveIncomeTaxRateReconciliationDomesticSubsidiaryException>
    <evh:EffectiveIncomeTaxRateReconciliationDomesticSubsidiaryException
      contextRef="i12a6d1161de54547bd29f8efccd4c9b0_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185Ny9mcmFnOmJjZWZiM2Q3NjJhNzQ1YWE4MWQ3NzAzMjlmMDdjODMyL3RhYmxlOjFjNjIwNTBlMDM2MjQyZTJhZTQyNmMwYWQ4ZWRiMjYxL3RhYmxlcmFuZ2U6MWM2MjA1MGUwMzYyNDJlMmFlNDI2YzBhZDhlZGIyNjFfMTQtMy0xLTEtMTc3NzU_24d267af-3c59-4cca-82a4-1680f5d325ed"
      unitRef="number">0.010</evh:EffectiveIncomeTaxRateReconciliationDomesticSubsidiaryException>
    <evh:EffectiveIncomeTaxRateReconciliationDomesticSubsidiaryException
      contextRef="i3e21049ffc224cacb8134d73c9bb5b38_D20190101-20191231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185Ny9mcmFnOmJjZWZiM2Q3NjJhNzQ1YWE4MWQ3NzAzMjlmMDdjODMyL3RhYmxlOjFjNjIwNTBlMDM2MjQyZTJhZTQyNmMwYWQ4ZWRiMjYxL3RhYmxlcmFuZ2U6MWM2MjA1MGUwMzYyNDJlMmFlNDI2YzBhZDhlZGIyNjFfMTQtNS0xLTEtMTc3NzU_53fb43d2-e1e5-4b7c-b95e-fe031e9beb07"
      unitRef="number">0.026</evh:EffectiveIncomeTaxRateReconciliationDomesticSubsidiaryException>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxSettlements
      contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185Ny9mcmFnOmJjZWZiM2Q3NjJhNzQ1YWE4MWQ3NzAzMjlmMDdjODMyL3RhYmxlOjFjNjIwNTBlMDM2MjQyZTJhZTQyNmMwYWQ4ZWRiMjYxL3RhYmxlcmFuZ2U6MWM2MjA1MGUwMzYyNDJlMmFlNDI2YzBhZDhlZGIyNjFfMTctMS0xLTEtMzIyNTM_0e471946-4b9e-48c4-82a6-2816321dba8d"
      unitRef="number">-0.011</us-gaap:EffectiveIncomeTaxRateReconciliationTaxSettlements>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxSettlements
      contextRef="i12a6d1161de54547bd29f8efccd4c9b0_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185Ny9mcmFnOmJjZWZiM2Q3NjJhNzQ1YWE4MWQ3NzAzMjlmMDdjODMyL3RhYmxlOjFjNjIwNTBlMDM2MjQyZTJhZTQyNmMwYWQ4ZWRiMjYxL3RhYmxlcmFuZ2U6MWM2MjA1MGUwMzYyNDJlMmFlNDI2YzBhZDhlZGIyNjFfMTctMy0xLTEtMzIyNTM_67cef7ab-e6f8-48bd-a657-1b5f7b144d78"
      unitRef="number">0</us-gaap:EffectiveIncomeTaxRateReconciliationTaxSettlements>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxSettlements
      contextRef="i3e21049ffc224cacb8134d73c9bb5b38_D20190101-20191231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185Ny9mcmFnOmJjZWZiM2Q3NjJhNzQ1YWE4MWQ3NzAzMjlmMDdjODMyL3RhYmxlOjFjNjIwNTBlMDM2MjQyZTJhZTQyNmMwYWQ4ZWRiMjYxL3RhYmxlcmFuZ2U6MWM2MjA1MGUwMzYyNDJlMmFlNDI2YzBhZDhlZGIyNjFfMTctNS0xLTEtMzIyNTM_8de4892f-7c21-41c2-8de7-c2dec7db8590"
      unitRef="number">0</us-gaap:EffectiveIncomeTaxRateReconciliationTaxSettlements>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments
      contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185Ny9mcmFnOmJjZWZiM2Q3NjJhNzQ1YWE4MWQ3NzAzMjlmMDdjODMyL3RhYmxlOjFjNjIwNTBlMDM2MjQyZTJhZTQyNmMwYWQ4ZWRiMjYxL3RhYmxlcmFuZ2U6MWM2MjA1MGUwMzYyNDJlMmFlNDI2YzBhZDhlZGIyNjFfMTUtMS0xLTEtMTc3NzU_52f26937-40f4-46be-a6a9-d425366dbe81"
      unitRef="number">-0.007</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments
      contextRef="i12a6d1161de54547bd29f8efccd4c9b0_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185Ny9mcmFnOmJjZWZiM2Q3NjJhNzQ1YWE4MWQ3NzAzMjlmMDdjODMyL3RhYmxlOjFjNjIwNTBlMDM2MjQyZTJhZTQyNmMwYWQ4ZWRiMjYxL3RhYmxlcmFuZ2U6MWM2MjA1MGUwMzYyNDJlMmFlNDI2YzBhZDhlZGIyNjFfMTUtMy0xLTEtMTc3NzU_ecda109a-57b2-470d-bc33-5a272c18f348"
      unitRef="number">0.006</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments
      contextRef="i3e21049ffc224cacb8134d73c9bb5b38_D20190101-20191231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185Ny9mcmFnOmJjZWZiM2Q3NjJhNzQ1YWE4MWQ3NzAzMjlmMDdjODMyL3RhYmxlOjFjNjIwNTBlMDM2MjQyZTJhZTQyNmMwYWQ4ZWRiMjYxL3RhYmxlcmFuZ2U6MWM2MjA1MGUwMzYyNDJlMmFlNDI2YzBhZDhlZGIyNjFfMTUtNS0xLTEtMTc3NzU_bae03148-3863-41e4-9472-76a78341791e"
      unitRef="number">-0.013</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185Ny9mcmFnOmJjZWZiM2Q3NjJhNzQ1YWE4MWQ3NzAzMjlmMDdjODMyL3RhYmxlOjFjNjIwNTBlMDM2MjQyZTJhZTQyNmMwYWQ4ZWRiMjYxL3RhYmxlcmFuZ2U6MWM2MjA1MGUwMzYyNDJlMmFlNDI2YzBhZDhlZGIyNjFfMTYtMS0xLTEtMTc3NzU_a7bb9bdc-74e2-4ca8-913b-e488221f75a4"
      unitRef="number">-0.016</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="i12a6d1161de54547bd29f8efccd4c9b0_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185Ny9mcmFnOmJjZWZiM2Q3NjJhNzQ1YWE4MWQ3NzAzMjlmMDdjODMyL3RhYmxlOjFjNjIwNTBlMDM2MjQyZTJhZTQyNmMwYWQ4ZWRiMjYxL3RhYmxlcmFuZ2U6MWM2MjA1MGUwMzYyNDJlMmFlNDI2YzBhZDhlZGIyNjFfMTYtMy0xLTEtMTc3NzU_1ee83c99-41fc-4d96-b5fc-2bcd26bb720c"
      unitRef="number">0.007</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="i3e21049ffc224cacb8134d73c9bb5b38_D20190101-20191231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185Ny9mcmFnOmJjZWZiM2Q3NjJhNzQ1YWE4MWQ3NzAzMjlmMDdjODMyL3RhYmxlOjFjNjIwNTBlMDM2MjQyZTJhZTQyNmMwYWQ4ZWRiMjYxL3RhYmxlcmFuZ2U6MWM2MjA1MGUwMzYyNDJlMmFlNDI2YzBhZDhlZGIyNjFfMTYtNS0xLTEtMTc3NzU_80a617c8-ff5f-44d1-94f1-e1134e1600f4"
      unitRef="number">0.069</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock
      contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185Ny9mcmFnOmJjZWZiM2Q3NjJhNzQ1YWE4MWQ3NzAzMjlmMDdjODMyL3RleHRyZWdpb246YmNlZmIzZDc2MmE3NDVhYTgxZDc3MDMyOWYwN2M4MzJfODQwNg_dd18ffa0-62cd-4a33-bd00-97ce089af19b">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Significant components of the Company&#x2019;s deferred tax assets and liabilities (in thousands) were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:433.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:48.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:48.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;As of December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Deferred Tax Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Start-up and organizational costs&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;103&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;117&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goodwill&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,774&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,778&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,968&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,963&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,345&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,434&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock based compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,714&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,530&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net operating loss carryforwards&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;130,242&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;123,604&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Federal and state research tax credits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,828&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,828&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fixed assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;480&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;131&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest deduction limitation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,795&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,452&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outside basis differences&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,972&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;197&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,236&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,428&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Subtotal&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;205,457&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;192,462&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(101,345)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(89,723)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total deferred tax assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;104,112&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;102,739&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Deferred Tax Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Internally developed software costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,501&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,973&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;48,677&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;49,053&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Right-of-use assets - Operating&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,284&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,122&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contract fulfillment costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,317&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,375&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Convertible debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,604&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,411&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,387&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,484&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total deferred tax liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;104,770&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;103,418&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net deferred tax assets (liabilities)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(658)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(679)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Changes in our valuation allowance (in thousands) were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:433.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:48.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:48.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr style="height:23pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;For the Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at beginning-of-year&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;89,723&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50,519&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Charged to costs and expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,856&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47,142&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Charged (credited) to other accounts &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,766&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7,938)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at end-of-year&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;101,345&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;89,723&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-align:justify;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:3.71pt"&gt;Amounts charged (credited) to other accounts includes $1.8&#160;million charged to discontinued operations for the year ended December&#160;31, 2021 and $8.6&#160;million credited to additional paid-in-capital, partially offset by $0.7&#160;million charged to retained earnings, for the year ended December 31, 2020.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <evh:DeferredTaxAssetsStartupandOrganizationalCosts
      contextRef="i8daff60be410426d8f7bd49343c1ec0c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185Ny9mcmFnOmJjZWZiM2Q3NjJhNzQ1YWE4MWQ3NzAzMjlmMDdjODMyL3RhYmxlOjg3Y2UwOTY2YjI2NTQ0ODhiM2M1ZWIyOWFjMGRmNTMzL3RhYmxlcmFuZ2U6ODdjZTA5NjZiMjY1NDQ4OGIzYzVlYjI5YWMwZGY1MzNfMy0xLTEtMS0xNzc3NQ_78307cf2-1faf-4c1a-a8aa-1144ccbc8e8e"
      unitRef="usd">103000</evh:DeferredTaxAssetsStartupandOrganizationalCosts>
    <evh:DeferredTaxAssetsStartupandOrganizationalCosts
      contextRef="ibc0c0c2b8dc04c5698ca0577a54b2e03_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185Ny9mcmFnOmJjZWZiM2Q3NjJhNzQ1YWE4MWQ3NzAzMjlmMDdjODMyL3RhYmxlOjg3Y2UwOTY2YjI2NTQ0ODhiM2M1ZWIyOWFjMGRmNTMzL3RhYmxlcmFuZ2U6ODdjZTA5NjZiMjY1NDQ4OGIzYzVlYjI5YWMwZGY1MzNfMy0zLTEtMS0xNzc3NQ_16bfcd73-b4b3-4d29-bbb6-04e1541931b0"
      unitRef="usd">117000</evh:DeferredTaxAssetsStartupandOrganizationalCosts>
    <us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets
      contextRef="i8daff60be410426d8f7bd49343c1ec0c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185Ny9mcmFnOmJjZWZiM2Q3NjJhNzQ1YWE4MWQ3NzAzMjlmMDdjODMyL3RhYmxlOjg3Y2UwOTY2YjI2NTQ0ODhiM2M1ZWIyOWFjMGRmNTMzL3RhYmxlcmFuZ2U6ODdjZTA5NjZiMjY1NDQ4OGIzYzVlYjI5YWMwZGY1MzNfNC0xLTEtMS0xNzc3NQ_2fcef6dc-4a5a-4e08-a383-23efd766c0ae"
      unitRef="usd">18774000</us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets>
    <us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets
      contextRef="ibc0c0c2b8dc04c5698ca0577a54b2e03_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185Ny9mcmFnOmJjZWZiM2Q3NjJhNzQ1YWE4MWQ3NzAzMjlmMDdjODMyL3RhYmxlOjg3Y2UwOTY2YjI2NTQ0ODhiM2M1ZWIyOWFjMGRmNTMzL3RhYmxlcmFuZ2U6ODdjZTA5NjZiMjY1NDQ4OGIzYzVlYjI5YWMwZGY1MzNfNC0zLTEtMS0xNzc3NQ_4e0b6339-e806-4be6-80d1-5c57ba243724"
      unitRef="usd">23778000</us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets>
    <evh:DeferredTaxAssetsOperatingLeaseRightOfUseAsset
      contextRef="i8daff60be410426d8f7bd49343c1ec0c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185Ny9mcmFnOmJjZWZiM2Q3NjJhNzQ1YWE4MWQ3NzAzMjlmMDdjODMyL3RhYmxlOjg3Y2UwOTY2YjI2NTQ0ODhiM2M1ZWIyOWFjMGRmNTMzL3RhYmxlcmFuZ2U6ODdjZTA5NjZiMjY1NDQ4OGIzYzVlYjI5YWMwZGY1MzNfNS0xLTEtMS0xNzc3NQ_d7908ddd-d37c-44cb-9c6a-599c29ff27f7"
      unitRef="usd">15968000</evh:DeferredTaxAssetsOperatingLeaseRightOfUseAsset>
    <evh:DeferredTaxAssetsOperatingLeaseRightOfUseAsset
      contextRef="ibc0c0c2b8dc04c5698ca0577a54b2e03_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185Ny9mcmFnOmJjZWZiM2Q3NjJhNzQ1YWE4MWQ3NzAzMjlmMDdjODMyL3RhYmxlOjg3Y2UwOTY2YjI2NTQ0ODhiM2M1ZWIyOWFjMGRmNTMzL3RhYmxlcmFuZ2U6ODdjZTA5NjZiMjY1NDQ4OGIzYzVlYjI5YWMwZGY1MzNfNS0zLTEtMS0xNzc3NQ_0d46ebc4-3d00-411a-aa51-220b7565a800"
      unitRef="usd">15963000</evh:DeferredTaxAssetsOperatingLeaseRightOfUseAsset>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities
      contextRef="i8daff60be410426d8f7bd49343c1ec0c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185Ny9mcmFnOmJjZWZiM2Q3NjJhNzQ1YWE4MWQ3NzAzMjlmMDdjODMyL3RhYmxlOjg3Y2UwOTY2YjI2NTQ0ODhiM2M1ZWIyOWFjMGRmNTMzL3RhYmxlcmFuZ2U6ODdjZTA5NjZiMjY1NDQ4OGIzYzVlYjI5YWMwZGY1MzNfNi0xLTEtMS0xNzc3NQ_14de74cc-26a8-41b2-bcdd-53a7883f7bc9"
      unitRef="usd">10345000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities
      contextRef="ibc0c0c2b8dc04c5698ca0577a54b2e03_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185Ny9mcmFnOmJjZWZiM2Q3NjJhNzQ1YWE4MWQ3NzAzMjlmMDdjODMyL3RhYmxlOjg3Y2UwOTY2YjI2NTQ0ODhiM2M1ZWIyOWFjMGRmNTMzL3RhYmxlcmFuZ2U6ODdjZTA5NjZiMjY1NDQ4OGIzYzVlYjI5YWMwZGY1MzNfNi0zLTEtMS0xNzc3NQ_9d3544fa-c21a-4589-b486-a5d89a3684f5"
      unitRef="usd">7434000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation
      contextRef="i8daff60be410426d8f7bd49343c1ec0c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185Ny9mcmFnOmJjZWZiM2Q3NjJhNzQ1YWE4MWQ3NzAzMjlmMDdjODMyL3RhYmxlOjg3Y2UwOTY2YjI2NTQ0ODhiM2M1ZWIyOWFjMGRmNTMzL3RhYmxlcmFuZ2U6ODdjZTA5NjZiMjY1NDQ4OGIzYzVlYjI5YWMwZGY1MzNfNy0xLTEtMS0xNzc3NQ_c998f34a-7c98-4f78-a536-5527e7a44db5"
      unitRef="usd">8714000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation
      contextRef="ibc0c0c2b8dc04c5698ca0577a54b2e03_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185Ny9mcmFnOmJjZWZiM2Q3NjJhNzQ1YWE4MWQ3NzAzMjlmMDdjODMyL3RhYmxlOjg3Y2UwOTY2YjI2NTQ0ODhiM2M1ZWIyOWFjMGRmNTMzL3RhYmxlcmFuZ2U6ODdjZTA5NjZiMjY1NDQ4OGIzYzVlYjI5YWMwZGY1MzNfNy0zLTEtMS0xNzc3NQ_50e55aba-72f0-4dde-8e92-d9e05184a872"
      unitRef="usd">8530000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="i8daff60be410426d8f7bd49343c1ec0c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185Ny9mcmFnOmJjZWZiM2Q3NjJhNzQ1YWE4MWQ3NzAzMjlmMDdjODMyL3RhYmxlOjg3Y2UwOTY2YjI2NTQ0ODhiM2M1ZWIyOWFjMGRmNTMzL3RhYmxlcmFuZ2U6ODdjZTA5NjZiMjY1NDQ4OGIzYzVlYjI5YWMwZGY1MzNfOC0xLTEtMS0xNzc3NQ_bf5745ff-2429-4a61-9d9c-4b1b31dbbb89"
      unitRef="usd">130242000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="ibc0c0c2b8dc04c5698ca0577a54b2e03_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185Ny9mcmFnOmJjZWZiM2Q3NjJhNzQ1YWE4MWQ3NzAzMjlmMDdjODMyL3RhYmxlOjg3Y2UwOTY2YjI2NTQ0ODhiM2M1ZWIyOWFjMGRmNTMzL3RhYmxlcmFuZ2U6ODdjZTA5NjZiMjY1NDQ4OGIzYzVlYjI5YWMwZGY1MzNfOC0zLTEtMS0xNzc3NQ_cf19ac67-9b51-484b-941d-fd35fce1582a"
      unitRef="usd">123604000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch
      contextRef="i8daff60be410426d8f7bd49343c1ec0c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185Ny9mcmFnOmJjZWZiM2Q3NjJhNzQ1YWE4MWQ3NzAzMjlmMDdjODMyL3RhYmxlOjg3Y2UwOTY2YjI2NTQ0ODhiM2M1ZWIyOWFjMGRmNTMzL3RhYmxlcmFuZ2U6ODdjZTA5NjZiMjY1NDQ4OGIzYzVlYjI5YWMwZGY1MzNfOS0xLTEtMS0xNzc3NQ_f4c2fef5-487e-4b5f-a003-c317cd213320"
      unitRef="usd">1828000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch
      contextRef="ibc0c0c2b8dc04c5698ca0577a54b2e03_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185Ny9mcmFnOmJjZWZiM2Q3NjJhNzQ1YWE4MWQ3NzAzMjlmMDdjODMyL3RhYmxlOjg3Y2UwOTY2YjI2NTQ0ODhiM2M1ZWIyOWFjMGRmNTMzL3RhYmxlcmFuZ2U6ODdjZTA5NjZiMjY1NDQ4OGIzYzVlYjI5YWMwZGY1MzNfOS0zLTEtMS0xNzc3NQ_5a3d9a2f-c317-44f4-b4a9-74d1e85153a6"
      unitRef="usd">1828000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment
      contextRef="i8daff60be410426d8f7bd49343c1ec0c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185Ny9mcmFnOmJjZWZiM2Q3NjJhNzQ1YWE4MWQ3NzAzMjlmMDdjODMyL3RhYmxlOjg3Y2UwOTY2YjI2NTQ0ODhiM2M1ZWIyOWFjMGRmNTMzL3RhYmxlcmFuZ2U6ODdjZTA5NjZiMjY1NDQ4OGIzYzVlYjI5YWMwZGY1MzNfMTAtMS0xLTEtMTc3NzU_aaaea55a-9f90-44c2-9033-25e0c55ce8d5"
      unitRef="usd">480000</us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment>
    <us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment
      contextRef="ibc0c0c2b8dc04c5698ca0577a54b2e03_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185Ny9mcmFnOmJjZWZiM2Q3NjJhNzQ1YWE4MWQ3NzAzMjlmMDdjODMyL3RhYmxlOjg3Y2UwOTY2YjI2NTQ0ODhiM2M1ZWIyOWFjMGRmNTMzL3RhYmxlcmFuZ2U6ODdjZTA5NjZiMjY1NDQ4OGIzYzVlYjI5YWMwZGY1MzNfMTAtMy0xLTEtMTc3NzU_d2de69b0-4989-4564-8daf-e5045e615b35"
      unitRef="usd">131000</us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment>
    <us-gaap:DeferredTaxAssetInterestCarryforward
      contextRef="i8daff60be410426d8f7bd49343c1ec0c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185Ny9mcmFnOmJjZWZiM2Q3NjJhNzQ1YWE4MWQ3NzAzMjlmMDdjODMyL3RhYmxlOjg3Y2UwOTY2YjI2NTQ0ODhiM2M1ZWIyOWFjMGRmNTMzL3RhYmxlcmFuZ2U6ODdjZTA5NjZiMjY1NDQ4OGIzYzVlYjI5YWMwZGY1MzNfMTEtMS0xLTEtMTc3NzU_cd91d03c-9604-4d4d-8ab1-e5f2d76bc7fa"
      unitRef="usd">7795000</us-gaap:DeferredTaxAssetInterestCarryforward>
    <us-gaap:DeferredTaxAssetInterestCarryforward
      contextRef="ibc0c0c2b8dc04c5698ca0577a54b2e03_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185Ny9mcmFnOmJjZWZiM2Q3NjJhNzQ1YWE4MWQ3NzAzMjlmMDdjODMyL3RhYmxlOjg3Y2UwOTY2YjI2NTQ0ODhiM2M1ZWIyOWFjMGRmNTMzL3RhYmxlcmFuZ2U6ODdjZTA5NjZiMjY1NDQ4OGIzYzVlYjI5YWMwZGY1MzNfMTEtMy0xLTEtMTc3NzU_177513d9-8806-46f1-8fe7-1c94c35e3543"
      unitRef="usd">2452000</us-gaap:DeferredTaxAssetInterestCarryforward>
    <evh:DeferredTaxAssetOutsideBasisDifferences
      contextRef="i8daff60be410426d8f7bd49343c1ec0c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185Ny9mcmFnOmJjZWZiM2Q3NjJhNzQ1YWE4MWQ3NzAzMjlmMDdjODMyL3RhYmxlOjg3Y2UwOTY2YjI2NTQ0ODhiM2M1ZWIyOWFjMGRmNTMzL3RhYmxlcmFuZ2U6ODdjZTA5NjZiMjY1NDQ4OGIzYzVlYjI5YWMwZGY1MzNfMTItMS0xLTEtMTc3NzU_fb83f43d-3475-4729-a63e-90dd48573fe3"
      unitRef="usd">1972000</evh:DeferredTaxAssetOutsideBasisDifferences>
    <evh:DeferredTaxAssetOutsideBasisDifferences
      contextRef="ibc0c0c2b8dc04c5698ca0577a54b2e03_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185Ny9mcmFnOmJjZWZiM2Q3NjJhNzQ1YWE4MWQ3NzAzMjlmMDdjODMyL3RhYmxlOjg3Y2UwOTY2YjI2NTQ0ODhiM2M1ZWIyOWFjMGRmNTMzL3RhYmxlcmFuZ2U6ODdjZTA5NjZiMjY1NDQ4OGIzYzVlYjI5YWMwZGY1MzNfMTItMy0xLTEtMTc3NzU_b757a805-5b50-4f88-8653-d533cf75773d"
      unitRef="usd">197000</evh:DeferredTaxAssetOutsideBasisDifferences>
    <us-gaap:DeferredTaxAssetsOther
      contextRef="i8daff60be410426d8f7bd49343c1ec0c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185Ny9mcmFnOmJjZWZiM2Q3NjJhNzQ1YWE4MWQ3NzAzMjlmMDdjODMyL3RhYmxlOjg3Y2UwOTY2YjI2NTQ0ODhiM2M1ZWIyOWFjMGRmNTMzL3RhYmxlcmFuZ2U6ODdjZTA5NjZiMjY1NDQ4OGIzYzVlYjI5YWMwZGY1MzNfMTMtMS0xLTEtMTc3NzU_665248b2-4c44-4760-9b99-69526f4a5af9"
      unitRef="usd">9236000</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsOther
      contextRef="ibc0c0c2b8dc04c5698ca0577a54b2e03_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185Ny9mcmFnOmJjZWZiM2Q3NjJhNzQ1YWE4MWQ3NzAzMjlmMDdjODMyL3RhYmxlOjg3Y2UwOTY2YjI2NTQ0ODhiM2M1ZWIyOWFjMGRmNTMzL3RhYmxlcmFuZ2U6ODdjZTA5NjZiMjY1NDQ4OGIzYzVlYjI5YWMwZGY1MzNfMTMtMy0xLTEtMTc3NzU_5ed52384-7330-4920-87d4-ab1926a4146a"
      unitRef="usd">8428000</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="i8daff60be410426d8f7bd49343c1ec0c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185Ny9mcmFnOmJjZWZiM2Q3NjJhNzQ1YWE4MWQ3NzAzMjlmMDdjODMyL3RhYmxlOjg3Y2UwOTY2YjI2NTQ0ODhiM2M1ZWIyOWFjMGRmNTMzL3RhYmxlcmFuZ2U6ODdjZTA5NjZiMjY1NDQ4OGIzYzVlYjI5YWMwZGY1MzNfMTQtMS0xLTEtMTc3NzU_235715a1-0195-4893-99f4-d31ff40cc314"
      unitRef="usd">205457000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="ibc0c0c2b8dc04c5698ca0577a54b2e03_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185Ny9mcmFnOmJjZWZiM2Q3NjJhNzQ1YWE4MWQ3NzAzMjlmMDdjODMyL3RhYmxlOjg3Y2UwOTY2YjI2NTQ0ODhiM2M1ZWIyOWFjMGRmNTMzL3RhYmxlcmFuZ2U6ODdjZTA5NjZiMjY1NDQ4OGIzYzVlYjI5YWMwZGY1MzNfMTQtMy0xLTEtMTc3NzU_3af75cb1-6a22-4f9e-9915-b2caeeb3e359"
      unitRef="usd">192462000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="i8daff60be410426d8f7bd49343c1ec0c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185Ny9mcmFnOmJjZWZiM2Q3NjJhNzQ1YWE4MWQ3NzAzMjlmMDdjODMyL3RhYmxlOjg3Y2UwOTY2YjI2NTQ0ODhiM2M1ZWIyOWFjMGRmNTMzL3RhYmxlcmFuZ2U6ODdjZTA5NjZiMjY1NDQ4OGIzYzVlYjI5YWMwZGY1MzNfMTUtMS0xLTEtMTc3NzU_4a2ea07f-512d-48f1-9e31-02fc288e0fa0"
      unitRef="usd">101345000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="ibc0c0c2b8dc04c5698ca0577a54b2e03_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185Ny9mcmFnOmJjZWZiM2Q3NjJhNzQ1YWE4MWQ3NzAzMjlmMDdjODMyL3RhYmxlOjg3Y2UwOTY2YjI2NTQ0ODhiM2M1ZWIyOWFjMGRmNTMzL3RhYmxlcmFuZ2U6ODdjZTA5NjZiMjY1NDQ4OGIzYzVlYjI5YWMwZGY1MzNfMTUtMy0xLTEtMTc3NzU_3b745ee4-95f1-4a24-9e59-cab3429f8397"
      unitRef="usd">89723000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="i8daff60be410426d8f7bd49343c1ec0c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185Ny9mcmFnOmJjZWZiM2Q3NjJhNzQ1YWE4MWQ3NzAzMjlmMDdjODMyL3RhYmxlOjg3Y2UwOTY2YjI2NTQ0ODhiM2M1ZWIyOWFjMGRmNTMzL3RhYmxlcmFuZ2U6ODdjZTA5NjZiMjY1NDQ4OGIzYzVlYjI5YWMwZGY1MzNfMTYtMS0xLTEtMTc3NzU_861643c6-453e-4d30-81de-70240142b292"
      unitRef="usd">104112000</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="ibc0c0c2b8dc04c5698ca0577a54b2e03_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185Ny9mcmFnOmJjZWZiM2Q3NjJhNzQ1YWE4MWQ3NzAzMjlmMDdjODMyL3RhYmxlOjg3Y2UwOTY2YjI2NTQ0ODhiM2M1ZWIyOWFjMGRmNTMzL3RhYmxlcmFuZ2U6ODdjZTA5NjZiMjY1NDQ4OGIzYzVlYjI5YWMwZGY1MzNfMTYtMy0xLTEtMTc3NzU_57827ffb-a94c-468f-a4dd-f9535a528780"
      unitRef="usd">102739000</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:DeferredTaxLiabilitiesDeferredExpenseCapitalizedSoftware
      contextRef="i8daff60be410426d8f7bd49343c1ec0c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185Ny9mcmFnOmJjZWZiM2Q3NjJhNzQ1YWE4MWQ3NzAzMjlmMDdjODMyL3RhYmxlOjg3Y2UwOTY2YjI2NTQ0ODhiM2M1ZWIyOWFjMGRmNTMzL3RhYmxlcmFuZ2U6ODdjZTA5NjZiMjY1NDQ4OGIzYzVlYjI5YWMwZGY1MzNfMTktMS0xLTEtMTc3NzU_74c5eab9-4816-48f3-9829-8c3925c7ef4a"
      unitRef="usd">12501000</us-gaap:DeferredTaxLiabilitiesDeferredExpenseCapitalizedSoftware>
    <us-gaap:DeferredTaxLiabilitiesDeferredExpenseCapitalizedSoftware
      contextRef="ibc0c0c2b8dc04c5698ca0577a54b2e03_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185Ny9mcmFnOmJjZWZiM2Q3NjJhNzQ1YWE4MWQ3NzAzMjlmMDdjODMyL3RhYmxlOjg3Y2UwOTY2YjI2NTQ0ODhiM2M1ZWIyOWFjMGRmNTMzL3RhYmxlcmFuZ2U6ODdjZTA5NjZiMjY1NDQ4OGIzYzVlYjI5YWMwZGY1MzNfMTktMy0xLTEtMTc3NzU_6ef70d61-c8c2-48e0-8429-e7d8df63a232"
      unitRef="usd">12973000</us-gaap:DeferredTaxLiabilitiesDeferredExpenseCapitalizedSoftware>
    <us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets
      contextRef="i8daff60be410426d8f7bd49343c1ec0c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185Ny9mcmFnOmJjZWZiM2Q3NjJhNzQ1YWE4MWQ3NzAzMjlmMDdjODMyL3RhYmxlOjg3Y2UwOTY2YjI2NTQ0ODhiM2M1ZWIyOWFjMGRmNTMzL3RhYmxlcmFuZ2U6ODdjZTA5NjZiMjY1NDQ4OGIzYzVlYjI5YWMwZGY1MzNfMjAtMS0xLTEtMTc3NzU_c0458a9c-1996-4e1f-9bf7-b4e288e9b086"
      unitRef="usd">48677000</us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets>
    <us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets
      contextRef="ibc0c0c2b8dc04c5698ca0577a54b2e03_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185Ny9mcmFnOmJjZWZiM2Q3NjJhNzQ1YWE4MWQ3NzAzMjlmMDdjODMyL3RhYmxlOjg3Y2UwOTY2YjI2NTQ0ODhiM2M1ZWIyOWFjMGRmNTMzL3RhYmxlcmFuZ2U6ODdjZTA5NjZiMjY1NDQ4OGIzYzVlYjI5YWMwZGY1MzNfMjAtMy0xLTEtMTc3NzU_0cda6a5f-4c58-44fb-9b2a-c33eeabe0f70"
      unitRef="usd">49053000</us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets>
    <us-gaap:DeferredTaxLiabilitiesLeasingArrangements
      contextRef="i8daff60be410426d8f7bd49343c1ec0c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185Ny9mcmFnOmJjZWZiM2Q3NjJhNzQ1YWE4MWQ3NzAzMjlmMDdjODMyL3RhYmxlOjg3Y2UwOTY2YjI2NTQ0ODhiM2M1ZWIyOWFjMGRmNTMzL3RhYmxlcmFuZ2U6ODdjZTA5NjZiMjY1NDQ4OGIzYzVlYjI5YWMwZGY1MzNfMjItMS0xLTEtMTc3NzU_9cc5d70d-30a6-4ea3-8ef5-26dfea2b0e65"
      unitRef="usd">12284000</us-gaap:DeferredTaxLiabilitiesLeasingArrangements>
    <us-gaap:DeferredTaxLiabilitiesLeasingArrangements
      contextRef="ibc0c0c2b8dc04c5698ca0577a54b2e03_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185Ny9mcmFnOmJjZWZiM2Q3NjJhNzQ1YWE4MWQ3NzAzMjlmMDdjODMyL3RhYmxlOjg3Y2UwOTY2YjI2NTQ0ODhiM2M1ZWIyOWFjMGRmNTMzL3RhYmxlcmFuZ2U6ODdjZTA5NjZiMjY1NDQ4OGIzYzVlYjI5YWMwZGY1MzNfMjItMy0xLTEtMTc3NzU_a5cb3f2f-c63a-42e9-b6fd-79bcb4b7cdfa"
      unitRef="usd">13122000</us-gaap:DeferredTaxLiabilitiesLeasingArrangements>
    <us-gaap:DeferredTaxLiabilitiesDeferredExpense
      contextRef="i8daff60be410426d8f7bd49343c1ec0c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185Ny9mcmFnOmJjZWZiM2Q3NjJhNzQ1YWE4MWQ3NzAzMjlmMDdjODMyL3RhYmxlOjg3Y2UwOTY2YjI2NTQ0ODhiM2M1ZWIyOWFjMGRmNTMzL3RhYmxlcmFuZ2U6ODdjZTA5NjZiMjY1NDQ4OGIzYzVlYjI5YWMwZGY1MzNfMjMtMS0xLTEtMTc3NzU_a86b6a9e-d68b-4424-bdd0-67c68afb3984"
      unitRef="usd">8317000</us-gaap:DeferredTaxLiabilitiesDeferredExpense>
    <us-gaap:DeferredTaxLiabilitiesDeferredExpense
      contextRef="ibc0c0c2b8dc04c5698ca0577a54b2e03_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185Ny9mcmFnOmJjZWZiM2Q3NjJhNzQ1YWE4MWQ3NzAzMjlmMDdjODMyL3RhYmxlOjg3Y2UwOTY2YjI2NTQ0ODhiM2M1ZWIyOWFjMGRmNTMzL3RhYmxlcmFuZ2U6ODdjZTA5NjZiMjY1NDQ4OGIzYzVlYjI5YWMwZGY1MzNfMjMtMy0xLTEtMTc3NzU_89ea72bb-d22b-451f-ac4a-8c2310ba39f5"
      unitRef="usd">6375000</us-gaap:DeferredTaxLiabilitiesDeferredExpense>
    <us-gaap:DeferredTaxLiabilitiesFinancingArrangements
      contextRef="i8daff60be410426d8f7bd49343c1ec0c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185Ny9mcmFnOmJjZWZiM2Q3NjJhNzQ1YWE4MWQ3NzAzMjlmMDdjODMyL3RhYmxlOjg3Y2UwOTY2YjI2NTQ0ODhiM2M1ZWIyOWFjMGRmNTMzL3RhYmxlcmFuZ2U6ODdjZTA5NjZiMjY1NDQ4OGIzYzVlYjI5YWMwZGY1MzNfMjQtMS0xLTEtMTc3NzU_6be58665-0b75-428b-a948-26738e30e2f3"
      unitRef="usd">17604000</us-gaap:DeferredTaxLiabilitiesFinancingArrangements>
    <us-gaap:DeferredTaxLiabilitiesFinancingArrangements
      contextRef="ibc0c0c2b8dc04c5698ca0577a54b2e03_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185Ny9mcmFnOmJjZWZiM2Q3NjJhNzQ1YWE4MWQ3NzAzMjlmMDdjODMyL3RhYmxlOjg3Y2UwOTY2YjI2NTQ0ODhiM2M1ZWIyOWFjMGRmNTMzL3RhYmxlcmFuZ2U6ODdjZTA5NjZiMjY1NDQ4OGIzYzVlYjI5YWMwZGY1MzNfMjQtMy0xLTEtMTc3NzU_af3172ca-06c0-46be-bb3c-a42489158712"
      unitRef="usd">20411000</us-gaap:DeferredTaxLiabilitiesFinancingArrangements>
    <us-gaap:DeferredTaxLiabilitiesOther
      contextRef="i8daff60be410426d8f7bd49343c1ec0c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185Ny9mcmFnOmJjZWZiM2Q3NjJhNzQ1YWE4MWQ3NzAzMjlmMDdjODMyL3RhYmxlOjg3Y2UwOTY2YjI2NTQ0ODhiM2M1ZWIyOWFjMGRmNTMzL3RhYmxlcmFuZ2U6ODdjZTA5NjZiMjY1NDQ4OGIzYzVlYjI5YWMwZGY1MzNfMjYtMS0xLTEtMTc3NzU_5edfc0b1-0929-4df3-a932-a2e2abbfeffc"
      unitRef="usd">5387000</us-gaap:DeferredTaxLiabilitiesOther>
    <us-gaap:DeferredTaxLiabilitiesOther
      contextRef="ibc0c0c2b8dc04c5698ca0577a54b2e03_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185Ny9mcmFnOmJjZWZiM2Q3NjJhNzQ1YWE4MWQ3NzAzMjlmMDdjODMyL3RhYmxlOjg3Y2UwOTY2YjI2NTQ0ODhiM2M1ZWIyOWFjMGRmNTMzL3RhYmxlcmFuZ2U6ODdjZTA5NjZiMjY1NDQ4OGIzYzVlYjI5YWMwZGY1MzNfMjYtMy0xLTEtMTc3NzU_88c81d4c-cdc4-49ff-960e-1774becbb101"
      unitRef="usd">1484000</us-gaap:DeferredTaxLiabilitiesOther>
    <us-gaap:DeferredIncomeTaxLiabilities
      contextRef="i8daff60be410426d8f7bd49343c1ec0c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185Ny9mcmFnOmJjZWZiM2Q3NjJhNzQ1YWE4MWQ3NzAzMjlmMDdjODMyL3RhYmxlOjg3Y2UwOTY2YjI2NTQ0ODhiM2M1ZWIyOWFjMGRmNTMzL3RhYmxlcmFuZ2U6ODdjZTA5NjZiMjY1NDQ4OGIzYzVlYjI5YWMwZGY1MzNfMjctMS0xLTEtMTc3NzU_31a72920-a654-49de-b08f-435411cedcd4"
      unitRef="usd">104770000</us-gaap:DeferredIncomeTaxLiabilities>
    <us-gaap:DeferredIncomeTaxLiabilities
      contextRef="ibc0c0c2b8dc04c5698ca0577a54b2e03_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185Ny9mcmFnOmJjZWZiM2Q3NjJhNzQ1YWE4MWQ3NzAzMjlmMDdjODMyL3RhYmxlOjg3Y2UwOTY2YjI2NTQ0ODhiM2M1ZWIyOWFjMGRmNTMzL3RhYmxlcmFuZ2U6ODdjZTA5NjZiMjY1NDQ4OGIzYzVlYjI5YWMwZGY1MzNfMjctMy0xLTEtMTc3NzU_438c8abc-550a-40f3-8db7-4423c208ff41"
      unitRef="usd">103418000</us-gaap:DeferredIncomeTaxLiabilities>
    <us-gaap:DeferredTaxLiabilities
      contextRef="i8daff60be410426d8f7bd49343c1ec0c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185Ny9mcmFnOmJjZWZiM2Q3NjJhNzQ1YWE4MWQ3NzAzMjlmMDdjODMyL3RhYmxlOjg3Y2UwOTY2YjI2NTQ0ODhiM2M1ZWIyOWFjMGRmNTMzL3RhYmxlcmFuZ2U6ODdjZTA5NjZiMjY1NDQ4OGIzYzVlYjI5YWMwZGY1MzNfMjgtMS0xLTEtMTc3NzU_8d832f2d-90d0-47d1-aa9f-35ea949b238d"
      unitRef="usd">658000</us-gaap:DeferredTaxLiabilities>
    <us-gaap:DeferredTaxLiabilities
      contextRef="ibc0c0c2b8dc04c5698ca0577a54b2e03_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185Ny9mcmFnOmJjZWZiM2Q3NjJhNzQ1YWE4MWQ3NzAzMjlmMDdjODMyL3RhYmxlOjg3Y2UwOTY2YjI2NTQ0ODhiM2M1ZWIyOWFjMGRmNTMzL3RhYmxlcmFuZ2U6ODdjZTA5NjZiMjY1NDQ4OGIzYzVlYjI5YWMwZGY1MzNfMjgtMy0xLTEtMTc3NzU_beb3f723-0baa-4afe-a3ef-002d36a821a7"
      unitRef="usd">679000</us-gaap:DeferredTaxLiabilities>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="i6126841a44cb4c478fc23b6132251176_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185Ny9mcmFnOmJjZWZiM2Q3NjJhNzQ1YWE4MWQ3NzAzMjlmMDdjODMyL3RhYmxlOjBmNjllN2MzZmUyNzQxN2ZiN2MzYjI4ZDRkMmQ0MDQ0L3RhYmxlcmFuZ2U6MGY2OWU3YzNmZTI3NDE3ZmI3YzNiMjhkNGQyZDQwNDRfMi0xLTEtMS0xNzc3NQ_09f87438-a073-4950-8627-c251d118a412"
      unitRef="usd">89723000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="i4d7d673b0fbf48deaa07f821e1025d2e_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185Ny9mcmFnOmJjZWZiM2Q3NjJhNzQ1YWE4MWQ3NzAzMjlmMDdjODMyL3RhYmxlOjBmNjllN2MzZmUyNzQxN2ZiN2MzYjI4ZDRkMmQ0MDQ0L3RhYmxlcmFuZ2U6MGY2OWU3YzNmZTI3NDE3ZmI3YzNiMjhkNGQyZDQwNDRfMi0zLTEtMS0xNzc3NQ_c85e51bf-eced-4f83-93d1-998a22996531"
      unitRef="usd">50519000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense
      contextRef="i6b9dc5b6709f4577a0325ffd62a07675_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185Ny9mcmFnOmJjZWZiM2Q3NjJhNzQ1YWE4MWQ3NzAzMjlmMDdjODMyL3RhYmxlOjBmNjllN2MzZmUyNzQxN2ZiN2MzYjI4ZDRkMmQ0MDQ0L3RhYmxlcmFuZ2U6MGY2OWU3YzNmZTI3NDE3ZmI3YzNiMjhkNGQyZDQwNDRfMy0xLTEtMS0xNzc3NQ_ea6eeae8-f278-41d5-8f57-d5815daf645f"
      unitRef="usd">9856000</us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense>
    <us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense
      contextRef="ie8b8af0c663c4c6f8a82f961045e3772_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185Ny9mcmFnOmJjZWZiM2Q3NjJhNzQ1YWE4MWQ3NzAzMjlmMDdjODMyL3RhYmxlOjBmNjllN2MzZmUyNzQxN2ZiN2MzYjI4ZDRkMmQ0MDQ0L3RhYmxlcmFuZ2U6MGY2OWU3YzNmZTI3NDE3ZmI3YzNiMjhkNGQyZDQwNDRfMy0zLTEtMS0xNzc3NQ_a0851cba-9b01-4622-84ef-00e1fce6908c"
      unitRef="usd">47142000</us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense>
    <us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts
      contextRef="i6b9dc5b6709f4577a0325ffd62a07675_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185Ny9mcmFnOmJjZWZiM2Q3NjJhNzQ1YWE4MWQ3NzAzMjlmMDdjODMyL3RhYmxlOjBmNjllN2MzZmUyNzQxN2ZiN2MzYjI4ZDRkMmQ0MDQ0L3RhYmxlcmFuZ2U6MGY2OWU3YzNmZTI3NDE3ZmI3YzNiMjhkNGQyZDQwNDRfNC0xLTEtMS0xNzc3NQ_8445fdeb-678b-4507-b797-88bee9ec8c9e"
      unitRef="usd">1766000</us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts>
    <us-gaap:ValuationAllowancesAndReservesDeductions
      contextRef="ie8b8af0c663c4c6f8a82f961045e3772_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185Ny9mcmFnOmJjZWZiM2Q3NjJhNzQ1YWE4MWQ3NzAzMjlmMDdjODMyL3RhYmxlOjBmNjllN2MzZmUyNzQxN2ZiN2MzYjI4ZDRkMmQ0MDQ0L3RhYmxlcmFuZ2U6MGY2OWU3YzNmZTI3NDE3ZmI3YzNiMjhkNGQyZDQwNDRfNC0zLTEtMS0xNzc3NQ_4dcecf90-6581-438a-af1f-884d3021a09b"
      unitRef="usd">7938000</us-gaap:ValuationAllowancesAndReservesDeductions>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="i39aaea1673c24c3e943c58e39738d3e1_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185Ny9mcmFnOmJjZWZiM2Q3NjJhNzQ1YWE4MWQ3NzAzMjlmMDdjODMyL3RhYmxlOjBmNjllN2MzZmUyNzQxN2ZiN2MzYjI4ZDRkMmQ0MDQ0L3RhYmxlcmFuZ2U6MGY2OWU3YzNmZTI3NDE3ZmI3YzNiMjhkNGQyZDQwNDRfNS0xLTEtMS0xNzc3NQ_011a5bf0-8f45-43de-92a0-9c1679dd6e57"
      unitRef="usd">101345000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="i6126841a44cb4c478fc23b6132251176_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185Ny9mcmFnOmJjZWZiM2Q3NjJhNzQ1YWE4MWQ3NzAzMjlmMDdjODMyL3RhYmxlOjBmNjllN2MzZmUyNzQxN2ZiN2MzYjI4ZDRkMmQ0MDQ0L3RhYmxlcmFuZ2U6MGY2OWU3YzNmZTI3NDE3ZmI3YzNiMjhkNGQyZDQwNDRfNS0zLTEtMS0xNzc3NQ_2add819d-fa3c-41c5-a576-ca83e16e6925"
      unitRef="usd">89723000</us-gaap:ValuationAllowancesAndReservesBalance>
    <evh:ValuationAllowancesAndReservesChargedCreditedToAdditionalPaidInCapital
      contextRef="i6b9dc5b6709f4577a0325ffd62a07675_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185Ny9mcmFnOmJjZWZiM2Q3NjJhNzQ1YWE4MWQ3NzAzMjlmMDdjODMyL3RleHRyZWdpb246YmNlZmIzZDc2MmE3NDVhYTgxZDc3MDMyOWYwN2M4MzJfMTE0Nw_5c246e85-cf14-4a56-84ab-f510a8a6c73a"
      unitRef="usd">1800000</evh:ValuationAllowancesAndReservesChargedCreditedToAdditionalPaidInCapital>
    <evh:ValuationAllowancesAndReservesChargedCreditedToAdditionalPaidInCapital
      contextRef="ie8b8af0c663c4c6f8a82f961045e3772_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185Ny9mcmFnOmJjZWZiM2Q3NjJhNzQ1YWE4MWQ3NzAzMjlmMDdjODMyL3RleHRyZWdpb246YmNlZmIzZDc2MmE3NDVhYTgxZDc3MDMyOWYwN2M4MzJfMTE2Ng_07a863e0-fb50-4280-a17f-fcdaea2310a8"
      unitRef="usd">-8600000</evh:ValuationAllowancesAndReservesChargedCreditedToAdditionalPaidInCapital>
    <evh:ValuationAllowancesAndReservesChargedToRetainedEarnings
      contextRef="ie8b8af0c663c4c6f8a82f961045e3772_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185Ny9mcmFnOmJjZWZiM2Q3NjJhNzQ1YWE4MWQ3NzAzMjlmMDdjODMyL3RleHRyZWdpb246YmNlZmIzZDc2MmE3NDVhYTgxZDc3MDMyOWYwN2M4MzJfMTA5OTUxMTYzOTE5Nw_1b90ba2e-d0a4-4768-a7fc-e267bb2793ee"
      unitRef="usd">700000</evh:ValuationAllowancesAndReservesChargedToRetainedEarnings>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185Ny9mcmFnOmJjZWZiM2Q3NjJhNzQ1YWE4MWQ3NzAzMjlmMDdjODMyL3RleHRyZWdpb246YmNlZmIzZDc2MmE3NDVhYTgxZDc3MDMyOWYwN2M4MzJfMTA5OTUxMTYzNzc1OA_458548f1-87fa-47b5-b4bc-59be2750c012"
      unitRef="number">-0.016</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185Ny9mcmFnOmJjZWZiM2Q3NjJhNzQ1YWE4MWQ3NzAzMjlmMDdjODMyL3RleHRyZWdpb246YmNlZmIzZDc2MmE3NDVhYTgxZDc3MDMyOWYwN2M4MzJfMTA5OTUxMTYzNzc2Nw_43ad4ada-4437-441f-b33a-cfac701ceee5"
      unitRef="usd">500000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="i12a6d1161de54547bd29f8efccd4c9b0_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185Ny9mcmFnOmJjZWZiM2Q3NjJhNzQ1YWE4MWQ3NzAzMjlmMDdjODMyL3RleHRyZWdpb246YmNlZmIzZDc2MmE3NDVhYTgxZDc3MDMyOWYwN2M4MzJfMTM0Mw_b74d0f6a-8b36-4f4a-9d8b-d71b78896fdc"
      unitRef="number">0.007</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i12a6d1161de54547bd29f8efccd4c9b0_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185Ny9mcmFnOmJjZWZiM2Q3NjJhNzQ1YWE4MWQ3NzAzMjlmMDdjODMyL3RleHRyZWdpb246YmNlZmIzZDc2MmE3NDVhYTgxZDc3MDMyOWYwN2M4MzJfMTM5NA_4956b151-1f1e-4011-8a7b-e07bc87a6dea"
      unitRef="usd">-2400000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="i3e21049ffc224cacb8134d73c9bb5b38_D20190101-20191231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185Ny9mcmFnOmJjZWZiM2Q3NjJhNzQ1YWE4MWQ3NzAzMjlmMDdjODMyL3RleHRyZWdpb246YmNlZmIzZDc2MmE3NDVhYTgxZDc3MDMyOWYwN2M4MzJfMTA5OTUxMTYzNjY3MA_80a617c8-ff5f-44d1-94f1-e1134e1600f4"
      unitRef="number">0.069</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i3e21049ffc224cacb8134d73c9bb5b38_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185Ny9mcmFnOmJjZWZiM2Q3NjJhNzQ1YWE4MWQ3NzAzMjlmMDdjODMyL3RleHRyZWdpb246YmNlZmIzZDc2MmE3NDVhYTgxZDc3MDMyOWYwN2M4MzJfMjMyNw_bd1494ce-dfdd-4a2b-8270-28d1a1113672"
      unitRef="usd">-22800000</us-gaap:IncomeTaxExpenseBenefit>
    <evh:DeferredTaxLiabilitiesIndefiniteLivedIntangibleAssets
      contextRef="icba6e493923b449aa57c46a563760234_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185Ny9mcmFnOmJjZWZiM2Q3NjJhNzQ1YWE4MWQ3NzAzMjlmMDdjODMyL3RleHRyZWdpb246YmNlZmIzZDc2MmE3NDVhYTgxZDc3MDMyOWYwN2M4MzJfMzQ0Ng_cb29ee7f-6af6-469b-b94e-69074d0ee348"
      unitRef="usd">1900000</evh:DeferredTaxLiabilitiesIndefiniteLivedIntangibleAssets>
    <us-gaap:OperatingLossCarryforwards
      contextRef="i8104bf341ae243818cdc049157ebf28d_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185Ny9mcmFnOmJjZWZiM2Q3NjJhNzQ1YWE4MWQ3NzAzMjlmMDdjODMyL3RleHRyZWdpb246YmNlZmIzZDc2MmE3NDVhYTgxZDc3MDMyOWYwN2M4MzJfNDIwMA_11c3db0d-00c3-45c0-97c7-0038be9265d9"
      unitRef="usd">203700000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="i44a7d440fd3546178704d37b7cd7f209_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185Ny9mcmFnOmJjZWZiM2Q3NjJhNzQ1YWE4MWQ3NzAzMjlmMDdjODMyL3RleHRyZWdpb246YmNlZmIzZDc2MmE3NDVhYTgxZDc3MDMyOWYwN2M4MzJfNDIxOA_e6df2480-f754-4970-8c46-aa9c782fa7ea"
      unitRef="usd">290800000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="i598bb297864842fe8780e1b67c9dd1d8_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185Ny9mcmFnOmJjZWZiM2Q3NjJhNzQ1YWE4MWQ3NzAzMjlmMDdjODMyL3RleHRyZWdpb246YmNlZmIzZDc2MmE3NDVhYTgxZDc3MDMyOWYwN2M4MzJfNDM0Mw_2d9d35e0-4b23-4dc2-8403-c33a6371a236"
      unitRef="usd">292900000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="ifd7da24ee1294bf3afc9c7ca2280330f_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185Ny9mcmFnOmJjZWZiM2Q3NjJhNzQ1YWE4MWQ3NzAzMjlmMDdjODMyL3RleHRyZWdpb246YmNlZmIzZDc2MmE3NDVhYTgxZDc3MDMyOWYwN2M4MzJfNDM1OA_ea886504-66d7-429d-b0dd-2b35cd3f740a"
      unitRef="usd">196000000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch
      contextRef="i898c9db01cf04be08210dc1be3090eca_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185Ny9mcmFnOmJjZWZiM2Q3NjJhNzQ1YWE4MWQ3NzAzMjlmMDdjODMyL3RleHRyZWdpb246YmNlZmIzZDc2MmE3NDVhYTgxZDc3MDMyOWYwN2M4MzJfNTA1OQ_3bb2b74e-7a2a-48d4-8d75-980fe2950676"
      unitRef="usd">2100000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch
      contextRef="ibfe040616b3542e3a1e0d4d16022974d_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185Ny9mcmFnOmJjZWZiM2Q3NjJhNzQ1YWE4MWQ3NzAzMjlmMDdjODMyL3RleHRyZWdpb246YmNlZmIzZDc2MmE3NDVhYTgxZDc3MDMyOWYwN2M4MzJfNTA2Ng_d26c2fee-25ef-404b-b5f6-1ee438ece8a3"
      unitRef="usd">300000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock
      contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185Ny9mcmFnOmJjZWZiM2Q3NjJhNzQ1YWE4MWQ3NzAzMjlmMDdjODMyL3RleHRyZWdpb246YmNlZmIzZDc2MmE3NDVhYTgxZDc3MDMyOWYwN2M4MzJfODQxMg_10e1b387-ef66-416a-b36b-f6cd8bbfcde9">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Changes in our unrecognized tax benefits (in thousands) were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:402.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:40.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:40.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:40.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr style="height:24pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;For the Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at beginning-of-year&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;678&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;753&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;934&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Lapse of statute of limitations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(69)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(75)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(181)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at end-of-year&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;609&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;678&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;753&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="ibc0c0c2b8dc04c5698ca0577a54b2e03_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185Ny9mcmFnOmJjZWZiM2Q3NjJhNzQ1YWE4MWQ3NzAzMjlmMDdjODMyL3RhYmxlOmVkY2M5NGVkNWI0NTQ0MjNiNGRlY2Y3ZTIzZTEwMDUzL3RhYmxlcmFuZ2U6ZWRjYzk0ZWQ1YjQ1NDQyM2I0ZGVjZjdlMjNlMTAwNTNfMi0xLTEtMS0xNzc3NQ_23953f63-da26-43f1-878d-82660fef4758"
      unitRef="usd">678000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="icba6e493923b449aa57c46a563760234_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185Ny9mcmFnOmJjZWZiM2Q3NjJhNzQ1YWE4MWQ3NzAzMjlmMDdjODMyL3RhYmxlOmVkY2M5NGVkNWI0NTQ0MjNiNGRlY2Y3ZTIzZTEwMDUzL3RhYmxlcmFuZ2U6ZWRjYzk0ZWQ1YjQ1NDQyM2I0ZGVjZjdlMjNlMTAwNTNfMi0zLTEtMS0xNzc3NQ_a67fea3f-afa9-4d57-a71b-c2ff061d565d"
      unitRef="usd">753000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="i7130cb432c4b4fe7a260e8a3beeb35d8_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185Ny9mcmFnOmJjZWZiM2Q3NjJhNzQ1YWE4MWQ3NzAzMjlmMDdjODMyL3RhYmxlOmVkY2M5NGVkNWI0NTQ0MjNiNGRlY2Y3ZTIzZTEwMDUzL3RhYmxlcmFuZ2U6ZWRjYzk0ZWQ1YjQ1NDQyM2I0ZGVjZjdlMjNlMTAwNTNfMi01LTEtMS0xNzc3NQ_27953043-f473-479e-92cd-60d457b085ba"
      unitRef="usd">934000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations
      contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185Ny9mcmFnOmJjZWZiM2Q3NjJhNzQ1YWE4MWQ3NzAzMjlmMDdjODMyL3RhYmxlOmVkY2M5NGVkNWI0NTQ0MjNiNGRlY2Y3ZTIzZTEwMDUzL3RhYmxlcmFuZ2U6ZWRjYzk0ZWQ1YjQ1NDQyM2I0ZGVjZjdlMjNlMTAwNTNfNS0xLTEtMS0xNzc3NQ_136e68ad-188e-4368-8fa5-568cefaa1d0b"
      unitRef="usd">69000</us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations>
    <us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations
      contextRef="i12a6d1161de54547bd29f8efccd4c9b0_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185Ny9mcmFnOmJjZWZiM2Q3NjJhNzQ1YWE4MWQ3NzAzMjlmMDdjODMyL3RhYmxlOmVkY2M5NGVkNWI0NTQ0MjNiNGRlY2Y3ZTIzZTEwMDUzL3RhYmxlcmFuZ2U6ZWRjYzk0ZWQ1YjQ1NDQyM2I0ZGVjZjdlMjNlMTAwNTNfNS0zLTEtMS0xNzc3NQ_e78de632-f929-4e28-8cfb-3a40f1e29203"
      unitRef="usd">75000</us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations>
    <us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations
      contextRef="i3e21049ffc224cacb8134d73c9bb5b38_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185Ny9mcmFnOmJjZWZiM2Q3NjJhNzQ1YWE4MWQ3NzAzMjlmMDdjODMyL3RhYmxlOmVkY2M5NGVkNWI0NTQ0MjNiNGRlY2Y3ZTIzZTEwMDUzL3RhYmxlcmFuZ2U6ZWRjYzk0ZWQ1YjQ1NDQyM2I0ZGVjZjdlMjNlMTAwNTNfNS01LTEtMS0xNzc3NQ_6ab2a026-ca88-4687-85c1-e0e31b305858"
      unitRef="usd">181000</us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="i8daff60be410426d8f7bd49343c1ec0c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185Ny9mcmFnOmJjZWZiM2Q3NjJhNzQ1YWE4MWQ3NzAzMjlmMDdjODMyL3RhYmxlOmVkY2M5NGVkNWI0NTQ0MjNiNGRlY2Y3ZTIzZTEwMDUzL3RhYmxlcmFuZ2U6ZWRjYzk0ZWQ1YjQ1NDQyM2I0ZGVjZjdlMjNlMTAwNTNfNi0xLTEtMS0xNzc3NQ_cc71cb4d-2335-4497-b3e0-92ac6219ca03"
      unitRef="usd">609000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="ibc0c0c2b8dc04c5698ca0577a54b2e03_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185Ny9mcmFnOmJjZWZiM2Q3NjJhNzQ1YWE4MWQ3NzAzMjlmMDdjODMyL3RhYmxlOmVkY2M5NGVkNWI0NTQ0MjNiNGRlY2Y3ZTIzZTEwMDUzL3RhYmxlcmFuZ2U6ZWRjYzk0ZWQ1YjQ1NDQyM2I0ZGVjZjdlMjNlMTAwNTNfNi0zLTEtMS0xNzc3NQ_ceecb527-e9f7-482c-a4ff-5c08808cbc42"
      unitRef="usd">678000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="icba6e493923b449aa57c46a563760234_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185Ny9mcmFnOmJjZWZiM2Q3NjJhNzQ1YWE4MWQ3NzAzMjlmMDdjODMyL3RhYmxlOmVkY2M5NGVkNWI0NTQ0MjNiNGRlY2Y3ZTIzZTEwMDUzL3RhYmxlcmFuZ2U6ZWRjYzk0ZWQ1YjQ1NDQyM2I0ZGVjZjdlMjNlMTAwNTNfNi01LTEtMS0xNzc3NQ_2f3656ab-2552-43bc-8cb3-4807010970fb"
      unitRef="usd">753000</us-gaap:UnrecognizedTaxBenefits>
    <evh:UnrecognizedTaxBenefitsThatWouldNotImpactEffectiveTaxRate
      contextRef="i8daff60be410426d8f7bd49343c1ec0c_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185Ny9mcmFnOmJjZWZiM2Q3NjJhNzQ1YWE4MWQ3NzAzMjlmMDdjODMyL3RleHRyZWdpb246YmNlZmIzZDc2MmE3NDVhYTgxZDc3MDMyOWYwN2M4MzJfNTY3OQ_dbf35e08-d0de-49da-8795-ec86ba713812"
      unitRef="usd">600000</evh:UnrecognizedTaxBenefitsThatWouldNotImpactEffectiveTaxRate>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="ibc0c0c2b8dc04c5698ca0577a54b2e03_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185Ny9mcmFnOmJjZWZiM2Q3NjJhNzQ1YWE4MWQ3NzAzMjlmMDdjODMyL3RleHRyZWdpb246YmNlZmIzZDc2MmE3NDVhYTgxZDc3MDMyOWYwN2M4MzJfNTk4NA_838e571a-8770-49b7-b00f-2e7602ab251d"
      unitRef="usd">700000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="icba6e493923b449aa57c46a563760234_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185Ny9mcmFnOmJjZWZiM2Q3NjJhNzQ1YWE4MWQ3NzAzMjlmMDdjODMyL3RleHRyZWdpb246YmNlZmIzZDc2MmE3NDVhYTgxZDc3MDMyOWYwN2M4MzJfNjAyOA_3ce06a3d-fc3e-4843-ba87-20352f92ead4"
      unitRef="usd">800000</us-gaap:UnrecognizedTaxBenefits>
    <evh:TaxReceivableAgreementPercentofCashSavingsPaidtoShareholders
      contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185Ny9mcmFnOmJjZWZiM2Q3NjJhNzQ1YWE4MWQ3NzAzMjlmMDdjODMyL3RleHRyZWdpb246YmNlZmIzZDc2MmE3NDVhYTgxZDc3MDMyOWYwN2M4MzJfNjkxNg_48c26b60-cd78-46db-a033-d728ef34af95"
      unitRef="number">0.85</evh:TaxReceivableAgreementPercentofCashSavingsPaidtoShareholders>
    <evh:TaxReceivableAgreementPercentofCashSavingsPaidtoShareholders
      contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185Ny9mcmFnOmJjZWZiM2Q3NjJhNzQ1YWE4MWQ3NzAzMjlmMDdjODMyL3RleHRyZWdpb246YmNlZmIzZDc2MmE3NDVhYTgxZDc3MDMyOWYwN2M4MzJfNzY2MQ_7e59678c-0a7e-4a43-b670-ed775b34ef67"
      unitRef="number">0.85</evh:TaxReceivableAgreementPercentofCashSavingsPaidtoShareholders>
    <us-gaap:OperatingLossCarryforwards
      contextRef="ib0a5f68e764e419481a0d19e2432cafe_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185Ny9mcmFnOmJjZWZiM2Q3NjJhNzQ1YWE4MWQ3NzAzMjlmMDdjODMyL3RleHRyZWdpb246YmNlZmIzZDc2MmE3NDVhYTgxZDc3MDMyOWYwN2M4MzJfNzk1Mg_ac15a98e-609b-4a2d-b414-3d47d856a396"
      unitRef="usd">79300000</us-gaap:OperatingLossCarryforwards>
    <evh:TaxReceivableAgreementPercentofCashSavingsNotPaidtoShareholders
      contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM185Ny9mcmFnOmJjZWZiM2Q3NjJhNzQ1YWE4MWQ3NzAzMjlmMDdjODMyL3RleHRyZWdpb246YmNlZmIzZDc2MmE3NDVhYTgxZDc3MDMyOWYwN2M4MzJfODA5MA_fe0efa52-da02-4f31-8407-ea3721060a66"
      unitRef="number">0.15</evh:TaxReceivableAgreementPercentofCashSavingsNotPaidtoShareholders>
    <us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock
      contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMDMvZnJhZzpkZWU0NDMzYjE4ODQ0MzMyOTg3NjI5ZTU2Yzg5OWY0Mi90ZXh0cmVnaW9uOmRlZTQ0MzNiMTg4NDQzMzI5ODc2MjllNTZjODk5ZjQyXzQ5MA_1e2f5df7-9000-4bd5-be60-1eeb3ef22570">Employee Benefit Plans&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We sponsor a tax-qualified 401(k) retirement plan that provides eligible U.S. employees with an opportunity to save for retirement on a tax advantaged basis. We make matching contributions to the plan in accordance with the plan documents and various limitations under Section 401(a) of the Internal Revenue Code of 1986, as amended. The Company made $5.4&#160;million, $6.2&#160;million and &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$2.6&#160;million&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; in contributions to the 401(k) plan for the years ended December&#160;31, 2021, 2020 and 2019, respectively. Total contributions for the year ended December 31, 2020, are net of $0.2&#160;million from discontinued operations.&lt;/span&gt;</us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock>
    <us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount
      contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMDMvZnJhZzpkZWU0NDMzYjE4ODQ0MzMyOTg3NjI5ZTU2Yzg5OWY0Mi90ZXh0cmVnaW9uOmRlZTQ0MzNiMTg4NDQzMzI5ODc2MjllNTZjODk5ZjQyXzM5MA_e5563ed3-72e4-4d97-bc5f-4a16c31624a8"
      unitRef="usd">5400000</us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount>
    <us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount
      contextRef="i12a6d1161de54547bd29f8efccd4c9b0_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMDMvZnJhZzpkZWU0NDMzYjE4ODQ0MzMyOTg3NjI5ZTU2Yzg5OWY0Mi90ZXh0cmVnaW9uOmRlZTQ0MzNiMTg4NDQzMzI5ODc2MjllNTZjODk5ZjQyXzM5NA_6fb4498c-30d1-43de-90ff-7105bdfaae56"
      unitRef="usd">6200000</us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount>
    <us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount
      contextRef="i3e21049ffc224cacb8134d73c9bb5b38_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMDMvZnJhZzpkZWU0NDMzYjE4ODQ0MzMyOTg3NjI5ZTU2Yzg5OWY0Mi90ZXh0cmVnaW9uOmRlZTQ0MzNiMTg4NDQzMzI5ODc2MjllNTZjODk5ZjQyXzQwMQ_3bbe495c-c54b-4b0f-9461-087cc18e77fa"
      unitRef="usd">2600000</us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount>
    <us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount
      contextRef="if7ba948ef00b4ddeabe73338f1155e8b_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMDMvZnJhZzpkZWU0NDMzYjE4ODQ0MzMyOTg3NjI5ZTU2Yzg5OWY0Mi90ZXh0cmVnaW9uOmRlZTQ0MzNiMTg4NDQzMzI5ODc2MjllNTZjODk5ZjQyXzEwOTk1MTE2Mjg0MzE_04e16e53-615a-44a3-bd75-f466d66e0031"
      unitRef="usd">200000</us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount>
    <us-gaap:EquityMethodInvestmentsDisclosureTextBlock
      contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMDYvZnJhZzplOWNhNzhjNDI0NzY0M2NhYmM3OTllZGE4MjA4MDIxYi90ZXh0cmVnaW9uOmU5Y2E3OGM0MjQ3NjQzY2FiYzc5OWVkYTgyMDgwMjFiXzIyMDE_27924f77-5d35-40ec-bfd7-b9aeb8c6e7e6">Investments in Equity Method Investees&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company holds ownership interests in joint ventures and other entities which are accounted for under the equity method. The Company evaluates its interests in these entities to determine whether they meet the definition of a VIE and whether the Company is required to consolidate these entities. A VIE is consolidated by its primary beneficiary, which is the party that has both (i) the power to direct the activities that most significantly impact the economic performance of the VIE and (ii) a variable interest that could potentially be significant to the VIE. To determine whether or not a variable interest the Company holds could potentially be significant to the VIE, the Company considers both qualitative and quantitative factors regarding the nature, size and form of the Company's involvement with the VIE. The Company has determined that its interests in these entities meet the definition of a variable interest, however, the Company is not the primary beneficiary since it does not have the power to direct activities, therefore, the Company did not consolidate the VIEs.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of&#160;December&#160;31, 2021 and 2020, the Company&#x2019;s economic interests in its equity method investments ranged between 4% and 39%, and 4% and 38%, respectively, and voting interests in its equity method investments ranged between 25% and 40%, respectively. The Company determined that it has significant influence over these entities but that it does not have control over any of the entities. Accordingly, the investments are accounted for under the equity method of accounting and the Company is allocated its proportional share of the entities&#x2019; earnings and losses for each reporting period. The Company&#x2019;s proportional share of the gain (loss) from these investments was approximately $13.2 million, $10.0 million and $(9.5)&#160;million for the years ended December&#160;31, 2021, 2020 and 2019, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company signed services agreements with certain of the aforementioned entities to provide certain management, operational and support services to help manage elements of their service offerings. Revenue related to these services agreements were $15.9 million, $192.8 million and $41.5 million for the years ended December&#160;31, 2021, 2020 and 2019, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Unconsolidated VIEs&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Global&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of March 31, 2020, the Oklahoma Insurance Division (&#x201c;OID&#x201d;) informed GlobalHealth, Inc. that in response to the COVID-19 pandemic, the OID required GlobalHealth, Inc. to increase its regulatory capital surplus by May 15, 2020. It would otherwise be placed into receivership if additional financing could not be secured. Certain investors agreed to provide liquidity as necessary to increase statutory capital reserves to no lower than 300%. In connection with the investment, GlobalHealth, Inc. transferred 100% of the equity interests in GlobalHealth, Inc. to the new investors for no consideration. Closing of this transaction occurred on May 13, 2020. As a result of this transaction, we recorded a non-cash impairment charge of approximately $47.1&#160;million, representing the total value of our investment, in impairment of equity method investments on the consolidated statements of operations and comprehensive income (loss) for the year ended December 31, 2020.&lt;/span&gt;&lt;/div&gt;</us-gaap:EquityMethodInvestmentsDisclosureTextBlock>
    <evh:EquityMethodInvestmentEconomicInterestPercentage
      contextRef="i1cb7bef7317f4d90afc92b9268a6542c_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMDYvZnJhZzplOWNhNzhjNDI0NzY0M2NhYmM3OTllZGE4MjA4MDIxYi90ZXh0cmVnaW9uOmU5Y2E3OGM0MjQ3NjQzY2FiYzc5OWVkYTgyMDgwMjFiXzEyNjA_65eded90-8a78-4c63-8238-5f022e41e0e7"
      unitRef="number">0.04</evh:EquityMethodInvestmentEconomicInterestPercentage>
    <evh:EquityMethodInvestmentEconomicInterestPercentage
      contextRef="i871d99d3c60b41dea330fb287058c6b9_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMDYvZnJhZzplOWNhNzhjNDI0NzY0M2NhYmM3OTllZGE4MjA4MDIxYi90ZXh0cmVnaW9uOmU5Y2E3OGM0MjQ3NjQzY2FiYzc5OWVkYTgyMDgwMjFiXzEyNjc_1e2d9420-f7aa-4a5f-8cef-83f090e4df36"
      unitRef="number">0.39</evh:EquityMethodInvestmentEconomicInterestPercentage>
    <evh:EquityMethodInvestmentEconomicInterestPercentage
      contextRef="i7521b01c889643c9931e6cd5cbaf2b96_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMDYvZnJhZzplOWNhNzhjNDI0NzY0M2NhYmM3OTllZGE4MjA4MDIxYi90ZXh0cmVnaW9uOmU5Y2E3OGM0MjQ3NjQzY2FiYzc5OWVkYTgyMDgwMjFiXzEyNzU_2019aca8-0719-45b6-ae2f-8dbca31172bc"
      unitRef="number">0.04</evh:EquityMethodInvestmentEconomicInterestPercentage>
    <evh:EquityMethodInvestmentEconomicInterestPercentage
      contextRef="i9f8d5e268f3d4eb697463d42a1cc1553_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMDYvZnJhZzplOWNhNzhjNDI0NzY0M2NhYmM3OTllZGE4MjA4MDIxYi90ZXh0cmVnaW9uOmU5Y2E3OGM0MjQ3NjQzY2FiYzc5OWVkYTgyMDgwMjFiXzEyODI_210bcddb-78e6-4735-a968-38de423fe9b7"
      unitRef="number">0.38</evh:EquityMethodInvestmentEconomicInterestPercentage>
    <evh:EquityMethodInvestmentVotingInterestPercentage
      contextRef="i1cb7bef7317f4d90afc92b9268a6542c_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMDYvZnJhZzplOWNhNzhjNDI0NzY0M2NhYmM3OTllZGE4MjA4MDIxYi90ZXh0cmVnaW9uOmU5Y2E3OGM0MjQ3NjQzY2FiYzc5OWVkYTgyMDgwMjFiXzEzNjk_4ed8a451-2f7b-4f10-b8b1-4a61e2850e9f"
      unitRef="number">0.25</evh:EquityMethodInvestmentVotingInterestPercentage>
    <evh:EquityMethodInvestmentVotingInterestPercentage
      contextRef="i7521b01c889643c9931e6cd5cbaf2b96_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMDYvZnJhZzplOWNhNzhjNDI0NzY0M2NhYmM3OTllZGE4MjA4MDIxYi90ZXh0cmVnaW9uOmU5Y2E3OGM0MjQ3NjQzY2FiYzc5OWVkYTgyMDgwMjFiXzEzNjk_f5b953fc-89ec-4244-94bc-19bfb80172bd"
      unitRef="number">0.25</evh:EquityMethodInvestmentVotingInterestPercentage>
    <evh:EquityMethodInvestmentVotingInterestPercentage
      contextRef="i871d99d3c60b41dea330fb287058c6b9_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMDYvZnJhZzplOWNhNzhjNDI0NzY0M2NhYmM3OTllZGE4MjA4MDIxYi90ZXh0cmVnaW9uOmU5Y2E3OGM0MjQ3NjQzY2FiYzc5OWVkYTgyMDgwMjFiXzEzNzY_74500fb3-1def-4b08-b8b1-370f2008bdf2"
      unitRef="number">0.40</evh:EquityMethodInvestmentVotingInterestPercentage>
    <evh:EquityMethodInvestmentVotingInterestPercentage
      contextRef="i9f8d5e268f3d4eb697463d42a1cc1553_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMDYvZnJhZzplOWNhNzhjNDI0NzY0M2NhYmM3OTllZGE4MjA4MDIxYi90ZXh0cmVnaW9uOmU5Y2E3OGM0MjQ3NjQzY2FiYzc5OWVkYTgyMDgwMjFiXzEzNzY_fe4910ff-c80e-42d1-adcd-00d72f189342"
      unitRef="number">0.40</evh:EquityMethodInvestmentVotingInterestPercentage>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMDYvZnJhZzplOWNhNzhjNDI0NzY0M2NhYmM3OTllZGE4MjA4MDIxYi90ZXh0cmVnaW9uOmU5Y2E3OGM0MjQ3NjQzY2FiYzc5OWVkYTgyMDgwMjFiXzE4MzQ_b495e1f1-ccd4-44af-b8ee-220a6d4ed35c"
      unitRef="usd">13200000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="i12a6d1161de54547bd29f8efccd4c9b0_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMDYvZnJhZzplOWNhNzhjNDI0NzY0M2NhYmM3OTllZGE4MjA4MDIxYi90ZXh0cmVnaW9uOmU5Y2E3OGM0MjQ3NjQzY2FiYzc5OWVkYTgyMDgwMjFiXzE4NjY_c580dea0-7efb-4173-8c80-fd27b0afe587"
      unitRef="usd">10000000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="i3e21049ffc224cacb8134d73c9bb5b38_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMDYvZnJhZzplOWNhNzhjNDI0NzY0M2NhYmM3OTllZGE4MjA4MDIxYi90ZXh0cmVnaW9uOmU5Y2E3OGM0MjQ3NjQzY2FiYzc5OWVkYTgyMDgwMjFiXzIxOTkwMjMyNTc5ODE_889c1815-18f4-4717-b433-0388070488e6"
      unitRef="usd">-9500000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <evh:IncomeLossfromEquityMethodInvestmentsServicesAgreement
      contextRef="id48b2d5a479f4ab58afeb508e8f9bc7c_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMDYvZnJhZzplOWNhNzhjNDI0NzY0M2NhYmM3OTllZGE4MjA4MDIxYi90ZXh0cmVnaW9uOmU5Y2E3OGM0MjQ3NjQzY2FiYzc5OWVkYTgyMDgwMjFiXzIxNDQ_4f3249a9-c131-4724-ab06-e741ce315876"
      unitRef="usd">15900000</evh:IncomeLossfromEquityMethodInvestmentsServicesAgreement>
    <evh:IncomeLossfromEquityMethodInvestmentsServicesAgreement
      contextRef="i441f674d44a64d47a96c0c85ef92310d_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMDYvZnJhZzplOWNhNzhjNDI0NzY0M2NhYmM3OTllZGE4MjA4MDIxYi90ZXh0cmVnaW9uOmU5Y2E3OGM0MjQ3NjQzY2FiYzc5OWVkYTgyMDgwMjFiXzIxNzY_127f29d9-7fdc-4ed4-a26f-c0436e27fcba"
      unitRef="usd">192800000</evh:IncomeLossfromEquityMethodInvestmentsServicesAgreement>
    <evh:IncomeLossfromEquityMethodInvestmentsServicesAgreement
      contextRef="i28a8f36df87345df9d28593e38c0563c_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMDYvZnJhZzplOWNhNzhjNDI0NzY0M2NhYmM3OTllZGE4MjA4MDIxYi90ZXh0cmVnaW9uOmU5Y2E3OGM0MjQ3NjQzY2FiYzc5OWVkYTgyMDgwMjFiXzEwOTk1MTE2MzAxNjk_b9ec0346-798a-4bae-b245-d4d06488e8e9"
      unitRef="usd">41500000</evh:IncomeLossfromEquityMethodInvestmentsServicesAgreement>
    <evh:StatutoryCapitalReservesLiquidityGuaranteedByInvestorsMinimum
      contextRef="ibca1768da73d4a4188df3e08ee08a9ce_I20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMDYvZnJhZzplOWNhNzhjNDI0NzY0M2NhYmM3OTllZGE4MjA4MDIxYi90ZXh0cmVnaW9uOmU5Y2E3OGM0MjQ3NjQzY2FiYzc5OWVkYTgyMDgwMjFiXzM4NDgyOTA3MDI4NjE_9949f896-9170-47fa-8c0c-d41f9b387793"
      unitRef="number">3</evh:StatutoryCapitalReservesLiquidityGuaranteedByInvestorsMinimum>
    <evh:EquityInterestToBeTransferred
      contextRef="ibca1768da73d4a4188df3e08ee08a9ce_I20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMDYvZnJhZzplOWNhNzhjNDI0NzY0M2NhYmM3OTllZGE4MjA4MDIxYi90ZXh0cmVnaW9uOmU5Y2E3OGM0MjQ3NjQzY2FiYzc5OWVkYTgyMDgwMjFiXzM4NDgyOTA3MDI4Njc_cd241798-3c6c-4ad1-be6f-9c6c7f6a2413"
      unitRef="number">1</evh:EquityInterestToBeTransferred>
    <us-gaap:EquityMethodInvestmentOtherThanTemporaryImpairment
      contextRef="ib755be34efd8414388d2ce5ca242428f_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMDYvZnJhZzplOWNhNzhjNDI0NzY0M2NhYmM3OTllZGE4MjA4MDIxYi90ZXh0cmVnaW9uOmU5Y2E3OGM0MjQ3NjQzY2FiYzc5OWVkYTgyMDgwMjFiXzM4NDgyOTA3MDI4NzM_d1684fc0-ed55-4f64-bdb6-d0cd6373d658"
      unitRef="usd">47100000</us-gaap:EquityMethodInvestmentOtherThanTemporaryImpairment>
    <us-gaap:MinorityInterestDisclosureTextBlock
      contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMDkvZnJhZzo4ZTQzMWU3Y2Y4NmU0MmMxODMzNmZmOGYxMTc0ZjZhYS90ZXh0cmVnaW9uOjhlNDMxZTdjZjg2ZTQyYzE4MzM2ZmY4ZjExNzRmNmFhXzE0NjY_45e09e40-edeb-455e-9058-cf608f5acd61">Non-controlling InterestsImmediately following the Offering Reorganization and IPO in May 2015, the Company owned 70.3% of Evolent Health LLC. The Company&#x2019;s ownership percentage changes with the issuance of Class A or Class B common stock and Class B Exchanges. In order to account for any changes in the Company&#x2019;s ownership of Evolent Health LLC, we record a reclassification of equity between non-controlling interests and shareholders&#x2019; equity attributable to Evolent Health, Inc.&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On September 1, 2020, in connection with the consolidation of EVH Passport, the Company recognized a $25.7&#160;million non-controlling interest for the Sponsors&#x2019; 30% equity interest in EVH Passport which represented the fair value of the non-controlling interest as of the date of consolidation. Pursuant to the shareholders&#x2019; agreement with the Sponsors, the Company was required to acquire the Sponsors&#x2019; 30% ownership interest for $20.0&#160;million on or prior to December 31, 2021. On November 16, 2020, the Company acquired the Sponsors&#x2019; 30% equity interest and reclassified the non-controlling interests into shareholders&#x2019; equity attributable to Evolent Health, Inc. As a result of this transaction, the Company recorded a $5.7&#160;million gain on consolidation for the year ended December 31, 2020 in gain (loss) on disposal of assets and consolidation on the consolidated statements of operations.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Changes in non-controlling interests (in thousands) for year ended December 31, 2020, was as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:463.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:72.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-controlling interests balance as of beginning of period&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,689&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Issuance of non-controlling interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,749&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Disposal of assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6,689)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Redemption of Sponsor&#x2019;s equity&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(25,749)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-controlling interests balance as of end of period&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:MinorityInterestDisclosureTextBlock>
    <us-gaap:MinorityInterestOwnershipPercentageByParent
      contextRef="ibde52dbc2c2c4cbda03403d89ddcaca6_I20150531"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMDkvZnJhZzo4ZTQzMWU3Y2Y4NmU0MmMxODMzNmZmOGYxMTc0ZjZhYS90ZXh0cmVnaW9uOjhlNDMxZTdjZjg2ZTQyYzE4MzM2ZmY4ZjExNzRmNmFhXzEzMQ_80141ff7-71b4-449d-95aa-974eea0763aa"
      unitRef="number">0.703</us-gaap:MinorityInterestOwnershipPercentageByParent>
    <us-gaap:NoncontrollingInterestIncreaseFromBusinessCombination
      contextRef="i02e542a70a5046e396e8cd9126fefd99_D20200901-20200901"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMDkvZnJhZzo4ZTQzMWU3Y2Y4NmU0MmMxODMzNmZmOGYxMTc0ZjZhYS90ZXh0cmVnaW9uOjhlNDMxZTdjZjg2ZTQyYzE4MzM2ZmY4ZjExNzRmNmFhXzYwNQ_36d98815-dbf9-4e42-b878-e596d0bfb850"
      unitRef="usd">25700000</us-gaap:NoncontrollingInterestIncreaseFromBusinessCombination>
    <us-gaap:VariableInterestEntityOwnershipPercentage
      contextRef="i02e542a70a5046e396e8cd9126fefd99_D20200901-20200901"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMDkvZnJhZzo4ZTQzMWU3Y2Y4NmU0MmMxODMzNmZmOGYxMTc0ZjZhYS90ZXh0cmVnaW9uOjhlNDMxZTdjZjg2ZTQyYzE4MzM2ZmY4ZjExNzRmNmFhXzY1MQ_dfd5a537-d1fe-464e-a11b-16259d77a0f7"
      unitRef="number">0.30</us-gaap:VariableInterestEntityOwnershipPercentage>
    <us-gaap:VariableInterestEntityOwnershipPercentage
      contextRef="i02e542a70a5046e396e8cd9126fefd99_D20200901-20200901"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMDkvZnJhZzo4ZTQzMWU3Y2Y4NmU0MmMxODMzNmZmOGYxMTc0ZjZhYS90ZXh0cmVnaW9uOjhlNDMxZTdjZjg2ZTQyYzE4MzM2ZmY4ZjExNzRmNmFhXzg5Mw_7ab9670c-c379-48ed-ad6c-5804b5b7c6b0"
      unitRef="number">0.30</us-gaap:VariableInterestEntityOwnershipPercentage>
    <evh:VariableInterestEntityNewMedicaidContractNotAwardedRequirementToAcquireOwnershipConsiderationAmount
      contextRef="ia11440f2d2cf4758bb0c9e18c239042c_I20200901"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMDkvZnJhZzo4ZTQzMWU3Y2Y4NmU0MmMxODMzNmZmOGYxMTc0ZjZhYS90ZXh0cmVnaW9uOjhlNDMxZTdjZjg2ZTQyYzE4MzM2ZmY4ZjExNzRmNmFhXzkxOQ_e2ae3e5a-56ef-46fe-8abe-25dc063f5bdf"
      unitRef="usd">20000000</evh:VariableInterestEntityNewMedicaidContractNotAwardedRequirementToAcquireOwnershipConsiderationAmount>
    <us-gaap:VariableInterestEntityOwnershipPercentage
      contextRef="i553144e874d7414ab395f79f6424736f_D20201116-20201116"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMDkvZnJhZzo4ZTQzMWU3Y2Y4NmU0MmMxODMzNmZmOGYxMTc0ZjZhYS90ZXh0cmVnaW9uOjhlNDMxZTdjZjg2ZTQyYzE4MzM2ZmY4ZjExNzRmNmFhXzEwMTM_556c735e-da28-4ef3-a5c0-67be9a0ad4a8"
      unitRef="number">0.30</us-gaap:VariableInterestEntityOwnershipPercentage>
    <us-gaap:VariableInterestEntityInitialConsolidationGainOrLoss
      contextRef="i299a8d5a546040409468f7f7fabc44c0_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMDkvZnJhZzo4ZTQzMWU3Y2Y4NmU0MmMxODMzNmZmOGYxMTc0ZjZhYS90ZXh0cmVnaW9uOjhlNDMxZTdjZjg2ZTQyYzE4MzM2ZmY4ZjExNzRmNmFhXzExOTg_d8b3387c-0edd-4134-8338-739fbdb9e836"
      unitRef="usd">5700000</us-gaap:VariableInterestEntityInitialConsolidationGainOrLoss>
    <evh:ScheduleofChangesinNoncontrollingInterestTableTextBlock
      contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMDkvZnJhZzo4ZTQzMWU3Y2Y4NmU0MmMxODMzNmZmOGYxMTc0ZjZhYS90ZXh0cmVnaW9uOjhlNDMxZTdjZjg2ZTQyYzE4MzM2ZmY4ZjExNzRmNmFhXzE0NjI_b1fc6d32-a348-4eb6-acef-2bf7f0ea7d1f">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Changes in non-controlling interests (in thousands) for year ended December 31, 2020, was as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:463.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:72.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-controlling interests balance as of beginning of period&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,689&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Issuance of non-controlling interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,749&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Disposal of assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6,689)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Redemption of Sponsor&#x2019;s equity&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(25,749)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-controlling interests balance as of end of period&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</evh:ScheduleofChangesinNoncontrollingInterestTableTextBlock>
    <us-gaap:MinorityInterest
      contextRef="i2d2497909b9e4097b418e747f13bfc16_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMDkvZnJhZzo4ZTQzMWU3Y2Y4NmU0MmMxODMzNmZmOGYxMTc0ZjZhYS90YWJsZTowZTgzMjRmNTI2OTk0NTgxOWQ1ZjJiMjM0NTU0ZjI4MC90YWJsZXJhbmdlOjBlODMyNGY1MjY5OTQ1ODE5ZDVmMmIyMzQ1NTRmMjgwXzEtMy0xLTEtMTc3NzU_88e1e9a6-5231-4d14-beda-592960da2c54"
      unitRef="usd">6689000</us-gaap:MinorityInterest>
    <us-gaap:NoncontrollingInterestIncreaseFromBusinessCombination
      contextRef="ic8a05c8bd28c42f4918205dc608cf2de_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMDkvZnJhZzo4ZTQzMWU3Y2Y4NmU0MmMxODMzNmZmOGYxMTc0ZjZhYS90YWJsZTowZTgzMjRmNTI2OTk0NTgxOWQ1ZjJiMjM0NTU0ZjI4MC90YWJsZXJhbmdlOjBlODMyNGY1MjY5OTQ1ODE5ZDVmMmIyMzQ1NTRmMjgwXzItMy0xLTEtMTc3NzU_adfde652-f377-497d-84d9-7de25972666e"
      unitRef="usd">25749000</us-gaap:NoncontrollingInterestIncreaseFromBusinessCombination>
    <evh:NoncontrollingInterestDecreaseFromDisposalOfAssets
      contextRef="ic8a05c8bd28c42f4918205dc608cf2de_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMDkvZnJhZzo4ZTQzMWU3Y2Y4NmU0MmMxODMzNmZmOGYxMTc0ZjZhYS90YWJsZTowZTgzMjRmNTI2OTk0NTgxOWQ1ZjJiMjM0NTU0ZjI4MC90YWJsZXJhbmdlOjBlODMyNGY1MjY5OTQ1ODE5ZDVmMmIyMzQ1NTRmMjgwXzMtMy0xLTEtMTc3NzU_ae3d47e5-b9b2-44ff-97ee-012df157ce9f"
      unitRef="usd">6689000</evh:NoncontrollingInterestDecreaseFromDisposalOfAssets>
    <us-gaap:MinorityInterestDecreaseFromRedemptions
      contextRef="ic8a05c8bd28c42f4918205dc608cf2de_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMDkvZnJhZzo4ZTQzMWU3Y2Y4NmU0MmMxODMzNmZmOGYxMTc0ZjZhYS90YWJsZTowZTgzMjRmNTI2OTk0NTgxOWQ1ZjJiMjM0NTU0ZjI4MC90YWJsZXJhbmdlOjBlODMyNGY1MjY5OTQ1ODE5ZDVmMmIyMzQ1NTRmMjgwXzQtMy0xLTEtMTc3NzU_2e01520c-c0f2-4300-9f6d-4b448511fe06"
      unitRef="usd">25749000</us-gaap:MinorityInterestDecreaseFromRedemptions>
    <us-gaap:MinorityInterest
      contextRef="i5724ef529cea411aadb2b6f086af09f1_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMDkvZnJhZzo4ZTQzMWU3Y2Y4NmU0MmMxODMzNmZmOGYxMTc0ZjZhYS90YWJsZTowZTgzMjRmNTI2OTk0NTgxOWQ1ZjJiMjM0NTU0ZjI4MC90YWJsZXJhbmdlOjBlODMyNGY1MjY5OTQ1ODE5ZDVmMmIyMzQ1NTRmMjgwXzUtMy0xLTEtMTc3NzU_7205c19b-0a81-4d0d-8950-c903170ae90a"
      unitRef="usd">0</us-gaap:MinorityInterest>
    <us-gaap:FairValueDisclosuresTextBlock
      contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMTIvZnJhZzpjMzMwYzUwYWY0YTc0OTlhODRlZTQ3ZWJmNjE2NmE4Yy90ZXh0cmVnaW9uOmMzMzBjNTBhZjRhNzQ5OWE4NGVlNDdlYmY2MTY2YThjXzQ5NzU_cd4bbc82-3f60-46ba-a16a-f052b29146b4">Fair Value Measurement&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;GAAP defines fair value as the price that would be received from the sale of an asset or paid to transfer a liability (an exit price) assuming an orderly transaction in the most advantageous market at the measurement date. GAAP also establishes a hierarchical disclosure framework which prioritizes and ranks the level of observability of inputs used in measuring fair value. These tiers include:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:54pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Level 1 - inputs to the valuation methodology are quoted prices available in active markets for identical instruments as of the reporting date;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:54pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Level 2 - inputs to the valuation methodology are other than quoted prices in active markets, which are either directly or indirectly observable as of the reporting date and the fair value can be determined through the use of models or other valuation methodologies; and &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:54pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Level 3 - inputs to the valuation methodology are unobservable inputs in situations where there is little or no market activity for the asset or liability.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In certain cases, the inputs used to measure fair value may fall into different levels of the fair value hierarchy. In such cases, the level within the fair value hierarchy is based on the lowest level of input that is significant to the fair value measurement. Our assessment of the significance of a particular input to the fair value measurement in its entirety requires judgment and considers factors specific to the particular asset or liability being measured. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Recurring Fair Value Measurements&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In accordance with GAAP, certain assets and liabilities are required to be recorded at fair value on a recurring basis. The following table summarizes the Company&#x2019;s assets and liabilities measured at fair value on a recurring basis (in thousands):&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:59.594%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.205%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.205%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.205%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.209%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contingent consideration&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28,700&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28,700&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total fair value of liabilities measured on a recurring basis&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28,700&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28,700&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:325.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:48.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:48.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:48.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:48.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,877&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,877&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total fair value of assets measured on a recurring basis&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,877&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,877&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Warrants &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,730&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,730&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total fair value of liabilities measured on a recurring basis&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,730&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,730&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-align:justify;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Represents the fair value of earn-out consideration related to the Vital Decisions transaction as described in Note 4.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-align:justify;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; Represents the cash and cash equivalents and restricted cash and restricted investments that were held in money market funds as of December&#160;31, 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-align:justify;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(3)  &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Represents the fair value of 1,513,786 shares issuable under the warrant agreements discussed in Note 10. The warrants were settled in January 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-align:justify;text-indent:-9pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recognizes any transfers between levels within the hierarchy as of the beginning of the reporting period. There were no transfers between fair value levels during the years ended December 31, 2021 and 2020, respectively.  &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In the absence of observable market prices, the fair value is based on the best information available and involves a significant degree of judgment, taking into consideration a combination of internal and external factors, including the appropriate risk adjustments for non-performance and liquidity risks.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As discussed in Note 4 , the acquisition of Vital Decisions includes a provision for additional equity consideration contingent upon the Company obtaining certain annualized performance metrics during the three months ending December 31, 2022. The fair value of the contingent equity consideration was estimated based on the real options approach, a form of the income approach, which estimated the probability of the Company achieving future revenues under the agreement. The significant unobservable inputs used in the fair value measurement of the Vital Decisions contingent consideration are the risk-neutral (probability weighted) earnout consideration and the applicable discount rate. A significant increase in the risk-neutral (probability weighted) earnout consideration or decrease in discount rate in isolation would result in a significantly higher fair value of the contingent consideration.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In conjunction with the Credit Agreement discussed in Note 10, the Company entered into warrant agreements whereby it agreed to sell to the holders of the warrants an aggregate of 1,513,786 shares of Class A common stock. The fair value of the warrants was estimated based on the Black-Scholes model which incorporates the constant price variation of the stock, the time value of money, the option's strike price, and the time to the option's expiry. The significant unobservable inputs used in the fair value measurement of the warrants are the stock price volatility and annual risk free rate. A significant increase in the stock price or discount rate in isolation would have resulted in a significantly higher fair value of the contingent consideration.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The changes in our liabilities measured at fair value for which the Company uses Level 3 inputs to determine fair value for the years ended December 31, 2021 and 2020 are as follows (in thousands): &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:433.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:48.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:48.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr style="height:23pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;For the Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance as of beginning of period&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,730&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,975&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Additions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Settlements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(13,730)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,500)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Realized and unrealized losses, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;255&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance as of end of period&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28,700&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,730&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the fair value (in thousands), valuation techniques and significant unobservable inputs of our Level 3 fair value measurements as of the periods presented:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:24.177%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.205%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.788%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:30.427%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.821%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Fair &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Valuation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Significant&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Assumption or&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Technique&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Unobservable Inputs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Input Ranges&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contingent consideration&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28,700&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Real options approach&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-neutral expected earnout consideration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30,935&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Discount rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.04&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:134.50pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:48.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:100.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:168.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:67.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Fair &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Valuation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Significant&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Assumption or&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Technique&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Unobservable Inputs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Input Ranges&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Warrants&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,730&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Black-Scholes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock price volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;62.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Annual risk free rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Nonrecurring Fair Value Measurements&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In addition to the assets and liabilities that are recorded at fair value on a recurring basis, the Company records certain assets and liabilities at fair value on a nonrecurring basis as required by GAAP. Generally, assets are recorded at fair value on a nonrecurring basis as a result of impairment charges. This includes assets and liabilities recorded in business combinations or asset acquisitions, goodwill, intangible assets, property, plant and equipment, held-to-maturity investments and equity method investments. While not carried at fair value on a recurring basis, these items are continually monitored for indicators of impairment that would indicate current carrying value is greater than fair value. In those situations, the assets are considered impaired and written down to current fair value. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Other Fair Value Disclosures&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The carrying amounts of cash and cash equivalents (those not held in a money market fund), restricted cash, receivables, prepaid expenses, accounts payable, accrued liabilities and accrued compensation approximate their fair values because of the relatively short-term maturities of these items and financial instruments.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;See Note 10 for information regarding the fair value of the 2024 Notes, 2025 Notes and 2021 Notes.&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock
      contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMTIvZnJhZzpjMzMwYzUwYWY0YTc0OTlhODRlZTQ3ZWJmNjE2NmE4Yy90ZXh0cmVnaW9uOmMzMzBjNTBhZjRhNzQ5OWE4NGVlNDdlYmY2MTY2YThjXzQ5Njk_11e1fdfa-6119-46a6-b32f-21514c6bfa60">The following table summarizes the Company&#x2019;s assets and liabilities measured at fair value on a recurring basis (in thousands): &lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:59.594%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.205%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.205%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.205%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.209%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contingent consideration&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28,700&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28,700&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total fair value of liabilities measured on a recurring basis&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28,700&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28,700&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:325.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:48.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:48.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:48.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:48.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,877&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,877&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total fair value of assets measured on a recurring basis&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,877&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,877&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Warrants &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,730&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,730&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total fair value of liabilities measured on a recurring basis&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,730&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,730&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-align:justify;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Represents the fair value of earn-out consideration related to the Vital Decisions transaction as described in Note 4.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-align:justify;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; Represents the cash and cash equivalents and restricted cash and restricted investments that were held in money market funds as of December&#160;31, 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-align:justify;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(3)  &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Represents the fair value of 1,513,786 shares issuable under the warrant agreements discussed in Note 10. The warrants were settled in January 2021.&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock>
    <us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock
      contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMTIvZnJhZzpjMzMwYzUwYWY0YTc0OTlhODRlZTQ3ZWJmNjE2NmE4Yy90ZXh0cmVnaW9uOmMzMzBjNTBhZjRhNzQ5OWE4NGVlNDdlYmY2MTY2YThjXzQ5NzQ_6325fb64-a294-467a-99c7-04fa6aed43f1">The following table summarizes the Company&#x2019;s assets and liabilities measured at fair value on a recurring basis (in thousands): &lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:59.594%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.205%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.205%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.205%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.209%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contingent consideration&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28,700&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28,700&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total fair value of liabilities measured on a recurring basis&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28,700&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28,700&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:325.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:48.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:48.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:48.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:48.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,877&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,877&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total fair value of assets measured on a recurring basis&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,877&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,877&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Warrants &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,730&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,730&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total fair value of liabilities measured on a recurring basis&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,730&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,730&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-align:justify;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Represents the fair value of earn-out consideration related to the Vital Decisions transaction as described in Note 4.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-align:justify;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; Represents the cash and cash equivalents and restricted cash and restricted investments that were held in money market funds as of December&#160;31, 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-align:justify;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(3)  &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Represents the fair value of 1,513,786 shares issuable under the warrant agreements discussed in Note 10. The warrants were settled in January 2021.&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i0abaa0eac87f4791aa3fc322969844f0_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMTIvZnJhZzpjMzMwYzUwYWY0YTc0OTlhODRlZTQ3ZWJmNjE2NmE4Yy90YWJsZTplZjgwNDE2N2YwY2Y0OWQxYTNlZThhMWUxNzkwMTZmNy90YWJsZXJhbmdlOmVmODA0MTY3ZjBjZjQ5ZDFhM2VlOGExZTE3OTAxNmY3XzMtMS0xLTEtMjYxNTE_dcef48f1-b86b-4756-9b1e-91cbc5796f5b"
      unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i8b0421b968754a01b6e430b519919d13_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMTIvZnJhZzpjMzMwYzUwYWY0YTc0OTlhODRlZTQ3ZWJmNjE2NmE4Yy90YWJsZTplZjgwNDE2N2YwY2Y0OWQxYTNlZThhMWUxNzkwMTZmNy90YWJsZXJhbmdlOmVmODA0MTY3ZjBjZjQ5ZDFhM2VlOGExZTE3OTAxNmY3XzMtMy0xLTEtMjYxNTE_0c9938e3-8f38-46cb-93f0-5fdc4b750ee3"
      unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i2b88f3addfe64f84a6303a37b589e8f5_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMTIvZnJhZzpjMzMwYzUwYWY0YTc0OTlhODRlZTQ3ZWJmNjE2NmE4Yy90YWJsZTplZjgwNDE2N2YwY2Y0OWQxYTNlZThhMWUxNzkwMTZmNy90YWJsZXJhbmdlOmVmODA0MTY3ZjBjZjQ5ZDFhM2VlOGExZTE3OTAxNmY3XzMtNS0xLTEtMjYxNTE_975f414e-86f9-4654-8738-c4f77f594627"
      unitRef="usd">28700000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="ib92fc8f3c5774739b4687eddbea853f3_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMTIvZnJhZzpjMzMwYzUwYWY0YTc0OTlhODRlZTQ3ZWJmNjE2NmE4Yy90YWJsZTplZjgwNDE2N2YwY2Y0OWQxYTNlZThhMWUxNzkwMTZmNy90YWJsZXJhbmdlOmVmODA0MTY3ZjBjZjQ5ZDFhM2VlOGExZTE3OTAxNmY3XzMtNy0xLTEtMjYxNTE_b8609198-e48d-4e47-a8b7-69d445bd9285"
      unitRef="usd">28700000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i0abaa0eac87f4791aa3fc322969844f0_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMTIvZnJhZzpjMzMwYzUwYWY0YTc0OTlhODRlZTQ3ZWJmNjE2NmE4Yy90YWJsZTplZjgwNDE2N2YwY2Y0OWQxYTNlZThhMWUxNzkwMTZmNy90YWJsZXJhbmdlOmVmODA0MTY3ZjBjZjQ5ZDFhM2VlOGExZTE3OTAxNmY3XzQtMS0xLTEtMjYxNTE_ae07b112-5d5b-4333-b13f-8fa35bdd2217"
      unitRef="usd">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i8b0421b968754a01b6e430b519919d13_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMTIvZnJhZzpjMzMwYzUwYWY0YTc0OTlhODRlZTQ3ZWJmNjE2NmE4Yy90YWJsZTplZjgwNDE2N2YwY2Y0OWQxYTNlZThhMWUxNzkwMTZmNy90YWJsZXJhbmdlOmVmODA0MTY3ZjBjZjQ5ZDFhM2VlOGExZTE3OTAxNmY3XzQtMy0xLTEtMjYxNTE_2203fb11-e337-4fe3-8ff6-bd0a01e48347"
      unitRef="usd">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i2b88f3addfe64f84a6303a37b589e8f5_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMTIvZnJhZzpjMzMwYzUwYWY0YTc0OTlhODRlZTQ3ZWJmNjE2NmE4Yy90YWJsZTplZjgwNDE2N2YwY2Y0OWQxYTNlZThhMWUxNzkwMTZmNy90YWJsZXJhbmdlOmVmODA0MTY3ZjBjZjQ5ZDFhM2VlOGExZTE3OTAxNmY3XzQtNS0xLTEtMjYxNTE_fa5561be-5392-4e96-80e5-04b2b8414fe6"
      unitRef="usd">28700000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="ib92fc8f3c5774739b4687eddbea853f3_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMTIvZnJhZzpjMzMwYzUwYWY0YTc0OTlhODRlZTQ3ZWJmNjE2NmE4Yy90YWJsZTplZjgwNDE2N2YwY2Y0OWQxYTNlZThhMWUxNzkwMTZmNy90YWJsZXJhbmdlOmVmODA0MTY3ZjBjZjQ5ZDFhM2VlOGExZTE3OTAxNmY3XzQtNy0xLTEtMjYxNTE_dbacbda6-9ba0-4100-bbdc-8730bd2802e5"
      unitRef="usd">28700000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="ib80e545347c046f081508ec064bed62f_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMTIvZnJhZzpjMzMwYzUwYWY0YTc0OTlhODRlZTQ3ZWJmNjE2NmE4Yy90YWJsZTo4NzAzY2Q1YTE1YTE0MWQyODQwMWVhZWE5ODIzNzhhNS90YWJsZXJhbmdlOjg3MDNjZDVhMTVhMTQxZDI4NDAxZWFlYTk4MjM3OGE1XzItMS0xLTEtMTc3NzU_96673849-8429-4c84-b30c-f6f499736b7c"
      unitRef="usd">5877000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i445dcacffbec464ebce55777f4c8895b_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMTIvZnJhZzpjMzMwYzUwYWY0YTc0OTlhODRlZTQ3ZWJmNjE2NmE4Yy90YWJsZTo4NzAzY2Q1YTE1YTE0MWQyODQwMWVhZWE5ODIzNzhhNS90YWJsZXJhbmdlOjg3MDNjZDVhMTVhMTQxZDI4NDAxZWFlYTk4MjM3OGE1XzItMy0xLTEtMTc3NzU_b9decef5-9c3d-4c0e-b0ae-4e698e51a294"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i44e95c772e54413fb8612a96b7f4dd16_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMTIvZnJhZzpjMzMwYzUwYWY0YTc0OTlhODRlZTQ3ZWJmNjE2NmE4Yy90YWJsZTo4NzAzY2Q1YTE1YTE0MWQyODQwMWVhZWE5ODIzNzhhNS90YWJsZXJhbmdlOjg3MDNjZDVhMTVhMTQxZDI4NDAxZWFlYTk4MjM3OGE1XzItNS0xLTEtMTc3NzU_4ace7357-4cde-42fc-b9c5-48900953a20e"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i0c4bfc6064ec4f93a8c1502ece6eaeae_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMTIvZnJhZzpjMzMwYzUwYWY0YTc0OTlhODRlZTQ3ZWJmNjE2NmE4Yy90YWJsZTo4NzAzY2Q1YTE1YTE0MWQyODQwMWVhZWE5ODIzNzhhNS90YWJsZXJhbmdlOjg3MDNjZDVhMTVhMTQxZDI4NDAxZWFlYTk4MjM3OGE1XzItNy0xLTEtMTc3NzU_8c78a969-9a97-43cb-a2bd-a84015d5c8ca"
      unitRef="usd">5877000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ib80e545347c046f081508ec064bed62f_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMTIvZnJhZzpjMzMwYzUwYWY0YTc0OTlhODRlZTQ3ZWJmNjE2NmE4Yy90YWJsZTo4NzAzY2Q1YTE1YTE0MWQyODQwMWVhZWE5ODIzNzhhNS90YWJsZXJhbmdlOjg3MDNjZDVhMTVhMTQxZDI4NDAxZWFlYTk4MjM3OGE1XzMtMS0xLTEtMTc3NzU_a5f5b9cd-fdb5-4c0d-badc-ad5fb4dd178b"
      unitRef="usd">5877000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i445dcacffbec464ebce55777f4c8895b_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMTIvZnJhZzpjMzMwYzUwYWY0YTc0OTlhODRlZTQ3ZWJmNjE2NmE4Yy90YWJsZTo4NzAzY2Q1YTE1YTE0MWQyODQwMWVhZWE5ODIzNzhhNS90YWJsZXJhbmdlOjg3MDNjZDVhMTVhMTQxZDI4NDAxZWFlYTk4MjM3OGE1XzMtMy0xLTEtMTc3NzU_28c2a751-85cd-45bf-9ce0-0238170489d1"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i44e95c772e54413fb8612a96b7f4dd16_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMTIvZnJhZzpjMzMwYzUwYWY0YTc0OTlhODRlZTQ3ZWJmNjE2NmE4Yy90YWJsZTo4NzAzY2Q1YTE1YTE0MWQyODQwMWVhZWE5ODIzNzhhNS90YWJsZXJhbmdlOjg3MDNjZDVhMTVhMTQxZDI4NDAxZWFlYTk4MjM3OGE1XzMtNS0xLTEtMTc3NzU_a1edb53b-cf19-4ebc-835a-2f882049f4f0"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i0c4bfc6064ec4f93a8c1502ece6eaeae_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMTIvZnJhZzpjMzMwYzUwYWY0YTc0OTlhODRlZTQ3ZWJmNjE2NmE4Yy90YWJsZTo4NzAzY2Q1YTE1YTE0MWQyODQwMWVhZWE5ODIzNzhhNS90YWJsZXJhbmdlOjg3MDNjZDVhMTVhMTQxZDI4NDAxZWFlYTk4MjM3OGE1XzMtNy0xLTEtMTc3NzU_369e4a59-5c6a-4886-8907-ff9d368df906"
      unitRef="usd">5877000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:OtherLiabilitiesFairValueDisclosure
      contextRef="ib80e545347c046f081508ec064bed62f_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMTIvZnJhZzpjMzMwYzUwYWY0YTc0OTlhODRlZTQ3ZWJmNjE2NmE4Yy90YWJsZTo4NzAzY2Q1YTE1YTE0MWQyODQwMWVhZWE5ODIzNzhhNS90YWJsZXJhbmdlOjg3MDNjZDVhMTVhMTQxZDI4NDAxZWFlYTk4MjM3OGE1XzYtMS0xLTEtMTc3NzU_ae917525-2bcb-491d-8f45-9ebaf9b2df7a"
      unitRef="usd">0</us-gaap:OtherLiabilitiesFairValueDisclosure>
    <us-gaap:OtherLiabilitiesFairValueDisclosure
      contextRef="i445dcacffbec464ebce55777f4c8895b_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMTIvZnJhZzpjMzMwYzUwYWY0YTc0OTlhODRlZTQ3ZWJmNjE2NmE4Yy90YWJsZTo4NzAzY2Q1YTE1YTE0MWQyODQwMWVhZWE5ODIzNzhhNS90YWJsZXJhbmdlOjg3MDNjZDVhMTVhMTQxZDI4NDAxZWFlYTk4MjM3OGE1XzYtMy0xLTEtMTc3NzU_01ea6d3d-d1a8-41b1-8a3b-8fbcb571c676"
      unitRef="usd">0</us-gaap:OtherLiabilitiesFairValueDisclosure>
    <us-gaap:OtherLiabilitiesFairValueDisclosure
      contextRef="i44e95c772e54413fb8612a96b7f4dd16_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMTIvZnJhZzpjMzMwYzUwYWY0YTc0OTlhODRlZTQ3ZWJmNjE2NmE4Yy90YWJsZTo4NzAzY2Q1YTE1YTE0MWQyODQwMWVhZWE5ODIzNzhhNS90YWJsZXJhbmdlOjg3MDNjZDVhMTVhMTQxZDI4NDAxZWFlYTk4MjM3OGE1XzYtNS0xLTEtMTc3NzU_e3a21d50-92b3-438c-acea-b603c2b17344"
      unitRef="usd">13730000</us-gaap:OtherLiabilitiesFairValueDisclosure>
    <us-gaap:OtherLiabilitiesFairValueDisclosure
      contextRef="i0c4bfc6064ec4f93a8c1502ece6eaeae_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMTIvZnJhZzpjMzMwYzUwYWY0YTc0OTlhODRlZTQ3ZWJmNjE2NmE4Yy90YWJsZTo4NzAzY2Q1YTE1YTE0MWQyODQwMWVhZWE5ODIzNzhhNS90YWJsZXJhbmdlOjg3MDNjZDVhMTVhMTQxZDI4NDAxZWFlYTk4MjM3OGE1XzYtNy0xLTEtMTc3NzU_5e1cf0b3-5b1c-49c9-b65c-80f3f7714af2"
      unitRef="usd">13730000</us-gaap:OtherLiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="ib80e545347c046f081508ec064bed62f_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMTIvZnJhZzpjMzMwYzUwYWY0YTc0OTlhODRlZTQ3ZWJmNjE2NmE4Yy90YWJsZTo4NzAzY2Q1YTE1YTE0MWQyODQwMWVhZWE5ODIzNzhhNS90YWJsZXJhbmdlOjg3MDNjZDVhMTVhMTQxZDI4NDAxZWFlYTk4MjM3OGE1XzctMS0xLTEtMTc3NzU_0c7e9f52-7aeb-416f-85e3-d001035b03bf"
      unitRef="usd">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i445dcacffbec464ebce55777f4c8895b_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMTIvZnJhZzpjMzMwYzUwYWY0YTc0OTlhODRlZTQ3ZWJmNjE2NmE4Yy90YWJsZTo4NzAzY2Q1YTE1YTE0MWQyODQwMWVhZWE5ODIzNzhhNS90YWJsZXJhbmdlOjg3MDNjZDVhMTVhMTQxZDI4NDAxZWFlYTk4MjM3OGE1XzctMy0xLTEtMTc3NzU_dc5d38db-0e23-4c14-af4a-c665c4a8212d"
      unitRef="usd">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i44e95c772e54413fb8612a96b7f4dd16_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMTIvZnJhZzpjMzMwYzUwYWY0YTc0OTlhODRlZTQ3ZWJmNjE2NmE4Yy90YWJsZTo4NzAzY2Q1YTE1YTE0MWQyODQwMWVhZWE5ODIzNzhhNS90YWJsZXJhbmdlOjg3MDNjZDVhMTVhMTQxZDI4NDAxZWFlYTk4MjM3OGE1XzctNS0xLTEtMTc3NzU_fb97c27c-8833-42d1-8099-9e3e932e08ee"
      unitRef="usd">13730000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i0c4bfc6064ec4f93a8c1502ece6eaeae_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMTIvZnJhZzpjMzMwYzUwYWY0YTc0OTlhODRlZTQ3ZWJmNjE2NmE4Yy90YWJsZTo4NzAzY2Q1YTE1YTE0MWQyODQwMWVhZWE5ODIzNzhhNS90YWJsZXJhbmdlOjg3MDNjZDVhMTVhMTQxZDI4NDAxZWFlYTk4MjM3OGE1XzctNy0xLTEtMTc3NzU_e1f867ae-8599-45ae-bd77-d8f1405e825a"
      unitRef="usd">13730000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="ibc0c0c2b8dc04c5698ca0577a54b2e03_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMTIvZnJhZzpjMzMwYzUwYWY0YTc0OTlhODRlZTQ3ZWJmNjE2NmE4Yy90ZXh0cmVnaW9uOmMzMzBjNTBhZjRhNzQ5OWE4NGVlNDdlYmY2MTY2YThjXzE5NDk_712e3e3b-0247-42f9-8a3e-94de5ed493b5"
      unitRef="shares">1513786</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightUnissued
      contextRef="i88843d45ac464699a3408ba52bbc2f63_I20191230"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMTIvZnJhZzpjMzMwYzUwYWY0YTc0OTlhODRlZTQ3ZWJmNjE2NmE4Yy90ZXh0cmVnaW9uOmMzMzBjNTBhZjRhNzQ5OWE4NGVlNDdlYmY2MTY2YThjXzI3NDg_0db005ff-da98-46b4-96b3-9e7701cca383"
      unitRef="shares">1513786</us-gaap:ClassOfWarrantOrRightUnissued>
    <us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock
      contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMTIvZnJhZzpjMzMwYzUwYWY0YTc0OTlhODRlZTQ3ZWJmNjE2NmE4Yy90ZXh0cmVnaW9uOmMzMzBjNTBhZjRhNzQ5OWE4NGVlNDdlYmY2MTY2YThjXzQ5ODI_3066f8b9-4473-48c2-879e-c7ca575db2bf">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The changes in our liabilities measured at fair value for which the Company uses Level 3 inputs to determine fair value for the years ended December 31, 2021 and 2020 are as follows (in thousands): &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:433.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:48.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:48.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr style="height:23pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;For the Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance as of beginning of period&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,730&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,975&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Additions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Settlements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(13,730)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,500)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Realized and unrealized losses, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;255&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance as of end of period&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28,700&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,730&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="ibc0c0c2b8dc04c5698ca0577a54b2e03_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMTIvZnJhZzpjMzMwYzUwYWY0YTc0OTlhODRlZTQ3ZWJmNjE2NmE4Yy90YWJsZTowYjA2OGMwZDkwMDE0YjBmYTRkNzkxZGIzODhmYjZlYi90YWJsZXJhbmdlOjBiMDY4YzBkOTAwMTRiMGZhNGQ3OTFkYjM4OGZiNmViXzItMS0xLTEtMTc3NzU_be0718cc-2b92-473e-a203-48f675e69c10"
      unitRef="usd">13730000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="icba6e493923b449aa57c46a563760234_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMTIvZnJhZzpjMzMwYzUwYWY0YTc0OTlhODRlZTQ3ZWJmNjE2NmE4Yy90YWJsZTowYjA2OGMwZDkwMDE0YjBmYTRkNzkxZGIzODhmYjZlYi90YWJsZXJhbmdlOjBiMDY4YzBkOTAwMTRiMGZhNGQ3OTFkYjM4OGZiNmViXzItMy0xLTEtMTc3NzU_4ec05091-3024-4f54-9251-7a1e8f356f54"
      unitRef="usd">16975000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues
      contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMTIvZnJhZzpjMzMwYzUwYWY0YTc0OTlhODRlZTQ3ZWJmNjE2NmE4Yy90YWJsZTowYjA2OGMwZDkwMDE0YjBmYTRkNzkxZGIzODhmYjZlYi90YWJsZXJhbmdlOjBiMDY4YzBkOTAwMTRiMGZhNGQ3OTFkYjM4OGZiNmViXzMtMS0xLTEtMjYxNzg_6f378f54-30af-4a1e-9a28-7f9d878e0245"
      unitRef="usd">14600000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues
      contextRef="i12a6d1161de54547bd29f8efccd4c9b0_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMTIvZnJhZzpjMzMwYzUwYWY0YTc0OTlhODRlZTQ3ZWJmNjE2NmE4Yy90YWJsZTowYjA2OGMwZDkwMDE0YjBmYTRkNzkxZGIzODhmYjZlYi90YWJsZXJhbmdlOjBiMDY4YzBkOTAwMTRiMGZhNGQ3OTFkYjM4OGZiNmViXzMtMy0xLTEtMjYxNzg_b18a3a31-6116-4653-992b-be720fd1f6d4"
      unitRef="usd">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements
      contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMTIvZnJhZzpjMzMwYzUwYWY0YTc0OTlhODRlZTQ3ZWJmNjE2NmE4Yy90YWJsZTowYjA2OGMwZDkwMDE0YjBmYTRkNzkxZGIzODhmYjZlYi90YWJsZXJhbmdlOjBiMDY4YzBkOTAwMTRiMGZhNGQ3OTFkYjM4OGZiNmViXzMtMS0xLTEtMTc3NzU_59ef9db4-e5a4-49a3-aa5c-5e402bb807f8"
      unitRef="usd">13730000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements
      contextRef="i12a6d1161de54547bd29f8efccd4c9b0_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMTIvZnJhZzpjMzMwYzUwYWY0YTc0OTlhODRlZTQ3ZWJmNjE2NmE4Yy90YWJsZTowYjA2OGMwZDkwMDE0YjBmYTRkNzkxZGIzODhmYjZlYi90YWJsZXJhbmdlOjBiMDY4YzBkOTAwMTRiMGZhNGQ3OTFkYjM4OGZiNmViXzMtMy0xLTEtMTc3NzU_eff675d1-3635-4298-ae9a-67d0b99ffd01"
      unitRef="usd">3500000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
      contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMTIvZnJhZzpjMzMwYzUwYWY0YTc0OTlhODRlZTQ3ZWJmNjE2NmE4Yy90YWJsZTowYjA2OGMwZDkwMDE0YjBmYTRkNzkxZGIzODhmYjZlYi90YWJsZXJhbmdlOjBiMDY4YzBkOTAwMTRiMGZhNGQ3OTFkYjM4OGZiNmViXzQtMS0xLTEtMTc3NzU_10a684df-de22-4649-83aa-352d609903b0"
      unitRef="usd">-14100000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
      contextRef="i12a6d1161de54547bd29f8efccd4c9b0_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMTIvZnJhZzpjMzMwYzUwYWY0YTc0OTlhODRlZTQ3ZWJmNjE2NmE4Yy90YWJsZTowYjA2OGMwZDkwMDE0YjBmYTRkNzkxZGIzODhmYjZlYi90YWJsZXJhbmdlOjBiMDY4YzBkOTAwMTRiMGZhNGQ3OTFkYjM4OGZiNmViXzQtMy0xLTEtMTc3NzU_3f24ac66-cb72-4155-b3f7-d0a6eae62cbc"
      unitRef="usd">-255000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="i8daff60be410426d8f7bd49343c1ec0c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMTIvZnJhZzpjMzMwYzUwYWY0YTc0OTlhODRlZTQ3ZWJmNjE2NmE4Yy90YWJsZTowYjA2OGMwZDkwMDE0YjBmYTRkNzkxZGIzODhmYjZlYi90YWJsZXJhbmdlOjBiMDY4YzBkOTAwMTRiMGZhNGQ3OTFkYjM4OGZiNmViXzUtMS0xLTEtMTc3NzU_fb2594cc-3dd4-4537-8435-6881bdad8e47"
      unitRef="usd">28700000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="ibc0c0c2b8dc04c5698ca0577a54b2e03_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMTIvZnJhZzpjMzMwYzUwYWY0YTc0OTlhODRlZTQ3ZWJmNjE2NmE4Yy90YWJsZTowYjA2OGMwZDkwMDE0YjBmYTRkNzkxZGIzODhmYjZlYi90YWJsZXJhbmdlOjBiMDY4YzBkOTAwMTRiMGZhNGQ3OTFkYjM4OGZiNmViXzUtMy0xLTEtMTc3NzU_ec83c5cb-6b81-4277-b054-b27b63ddfb86"
      unitRef="usd">13730000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock
      contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMTIvZnJhZzpjMzMwYzUwYWY0YTc0OTlhODRlZTQ3ZWJmNjE2NmE4Yy90ZXh0cmVnaW9uOmMzMzBjNTBhZjRhNzQ5OWE4NGVlNDdlYmY2MTY2YThjXzQ5NjQ_f5a3b80c-cc36-46e8-87f3-37bf3d2ac397">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the fair value (in thousands), valuation techniques and significant unobservable inputs of our Level 3 fair value measurements as of the periods presented:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:24.177%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.205%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.788%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:30.427%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.821%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Fair &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Valuation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Significant&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Assumption or&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Technique&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Unobservable Inputs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Input Ranges&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contingent consideration&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28,700&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Real options approach&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-neutral expected earnout consideration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30,935&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Discount rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.04&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:134.50pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:48.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:100.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:168.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:67.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Fair &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Valuation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Significant&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Assumption or&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Technique&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Unobservable Inputs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Input Ranges&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Warrants&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,730&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Black-Scholes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock price volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;62.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Annual risk free rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i2b88f3addfe64f84a6303a37b589e8f5_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMTIvZnJhZzpjMzMwYzUwYWY0YTc0OTlhODRlZTQ3ZWJmNjE2NmE4Yy90YWJsZTpkYzNjNzJlYzQ0OWI0NTAwOGQ3OWM5MTllMzI0NWVhMi90YWJsZXJhbmdlOmRjM2M3MmVjNDQ5YjQ1MDA4ZDc5YzkxOWUzMjQ1ZWEyXzMtMS0xLTEtMzY0NzE_74a20e78-3bcc-4247-b6cc-dbadefc552c3"
      unitRef="usd">28700000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput
      contextRef="icb9299fd51a347b9a7a46a5d71c01525_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMTIvZnJhZzpjMzMwYzUwYWY0YTc0OTlhODRlZTQ3ZWJmNjE2NmE4Yy90YWJsZTpkYzNjNzJlYzQ0OWI0NTAwOGQ3OWM5MTllMzI0NWVhMi90YWJsZXJhbmdlOmRjM2M3MmVjNDQ5YjQ1MDA4ZDc5YzkxOWUzMjQ1ZWEyXzMtNy0xLTEtMzY0Nzg_e6d6fce4-83f6-4f5f-a399-7cba72bc43c6"
      unitRef="usd">30935000</us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput
      contextRef="i1fec5420a1ee45fd97f27bb260399220_I20211231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMTIvZnJhZzpjMzMwYzUwYWY0YTc0OTlhODRlZTQ3ZWJmNjE2NmE4Yy90YWJsZTpkYzNjNzJlYzQ0OWI0NTAwOGQ3OWM5MTllMzI0NWVhMi90YWJsZXJhbmdlOmRjM2M3MmVjNDQ5YjQ1MDA4ZDc5YzkxOWUzMjQ1ZWEyXzQtNy0xLTEtMzY0Nzg_4914b5ce-e9b1-4ea6-9ba2-aefd8536ba3e"
      unitRef="number">0.0604</us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput>
    <us-gaap:OtherLiabilitiesFairValueDisclosure
      contextRef="i44e95c772e54413fb8612a96b7f4dd16_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMTIvZnJhZzpjMzMwYzUwYWY0YTc0OTlhODRlZTQ3ZWJmNjE2NmE4Yy90YWJsZTo4ZWNmMTA5MDU2NGM0ZDc2ODM4NzVmZDY4MjUxMjQ3Zi90YWJsZXJhbmdlOjhlY2YxMDkwNTY0YzRkNzY4Mzg3NWZkNjgyNTEyNDdmXzItMS0xLTEtMTc3NzU_83ede5c0-e6ff-4624-9913-eaa701c7e508"
      unitRef="usd">13730000</us-gaap:OtherLiabilitiesFairValueDisclosure>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="i4e9639a5adcd411a8b02679081819ef5_I20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMTIvZnJhZzpjMzMwYzUwYWY0YTc0OTlhODRlZTQ3ZWJmNjE2NmE4Yy90YWJsZTo4ZWNmMTA5MDU2NGM0ZDc2ODM4NzVmZDY4MjUxMjQ3Zi90YWJsZXJhbmdlOjhlY2YxMDkwNTY0YzRkNzY4Mzg3NWZkNjgyNTEyNDdmXzItNy0xLTEtMTc3NzU_373106d5-2208-4af1-88ab-35b9ffceb902"
      unitRef="number">0.622</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="i38e7d4598fcf4220b68ea93547e1d444_I20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMTIvZnJhZzpjMzMwYzUwYWY0YTc0OTlhODRlZTQ3ZWJmNjE2NmE4Yy90YWJsZTo4ZWNmMTA5MDU2NGM0ZDc2ODM4NzVmZDY4MjUxMjQ3Zi90YWJsZXJhbmdlOjhlY2YxMDkwNTY0YzRkNzY4Mzg3NWZkNjgyNTEyNDdmXzMtNy0xLTEtMTc3NzU_d82908e9-cf0c-4c9b-99ca-b9aea1bafcf8"
      unitRef="number">0.002</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:RelatedPartyTransactionsDisclosureTextBlock
      contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMTUvZnJhZzo5ZjFhZjNiMDEwY2U0ODI2OTI2YjA3MGU2ZjBjNTc3NS90ZXh0cmVnaW9uOjlmMWFmM2IwMTBjZTQ4MjY5MjZiMDcwZTZmMGM1Nzc1XzEzMjY_248a69a2-3c3f-4ec7-831a-e210fbb68cf0">Related Parties  &lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The entities described below are considered related parties and the balances and/or transactions with them are reported in our consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;As discussed in Note&#160;17, the Company had economic interests in several entities that are accounted for under the equity method of accounting, including EVH Passport which has been consolidated into the Company&#x2019;s financial statements since September 1, 2020. The Company has allocated its proportional share of the investees&#x2019; earnings and losses each reporting period. In addition, Evolent has entered into services agreements with certain of the entities to provide certain management, operational and support services to help the entities manage elements of their service offerings. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company also works with UPMC, one of its founding investors. The Company&#x2019;s relationship with UPMC is a subcontractor relationship where UPMC has agreed to execute certain tasks (primarily TPA services) relating to certain customer commitments. This relationship is currently in wind-down.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents assets and liabilities attributable to our related parties as of December&#160;31, 2021 and 2020 (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:74.594%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.705%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.707%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accounts receivable, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,719&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,474&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prepaid expenses and other current assets &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;51&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prepaid expenses and other noncurrent assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,877&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,554&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accounts payable&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,967&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,509&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,120&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,520&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reserve for claims and performance-based arrangements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;734&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;435&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents revenues and expenses attributable to our related parties for the years ended December 31, 2021, 2020 and 2019 (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:373.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:49.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:54.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:49.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;For the Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Transformation services&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,416&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,009&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Platform and operations services&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45,082&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;226,339&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;60,325&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:23pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cost of revenue (exclusive of depreciation and amortization expenses)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,063&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,863&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28,954&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Selling, general and administrative expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;285&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;113&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;991&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
    <us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock
      contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMTUvZnJhZzo5ZjFhZjNiMDEwY2U0ODI2OTI2YjA3MGU2ZjBjNTc3NS90ZXh0cmVnaW9uOjlmMWFmM2IwMTBjZTQ4MjY5MjZiMDcwZTZmMGM1Nzc1XzEzMjE_8a929f6a-cc22-4506-b3ab-1547c7f218ef">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents assets and liabilities attributable to our related parties as of December&#160;31, 2021 and 2020 (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:74.594%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.705%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.707%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accounts receivable, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,719&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,474&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prepaid expenses and other current assets &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;51&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prepaid expenses and other noncurrent assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,877&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,554&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accounts payable&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,967&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,509&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,120&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,520&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reserve for claims and performance-based arrangements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;734&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;435&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents revenues and expenses attributable to our related parties for the years ended December 31, 2021, 2020 and 2019 (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:373.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:49.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:54.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:49.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;For the Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Transformation services&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,416&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,009&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Platform and operations services&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45,082&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;226,339&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;60,325&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:23pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cost of revenue (exclusive of depreciation and amortization expenses)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,063&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,863&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28,954&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Selling, general and administrative expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;285&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;113&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;991&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="ic0d050fa1a3e4a2cb801e14c4a7886a2_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMTUvZnJhZzo5ZjFhZjNiMDEwY2U0ODI2OTI2YjA3MGU2ZjBjNTc3NS90YWJsZTo2NGY0MDlmNTFkMzI0NmUwYmM5NTM0YjdhYWRhMzlmNy90YWJsZXJhbmdlOjY0ZjQwOWY1MWQzMjQ2ZTBiYzk1MzRiN2FhZGEzOWY3XzItMS0xLTEtMTc3NzU_85e2ab46-d6cd-40e7-ba46-686f7c1c7e4d"
      unitRef="usd">2719000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="i5798a2aee885432aa6df470400a67a94_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMTUvZnJhZzo5ZjFhZjNiMDEwY2U0ODI2OTI2YjA3MGU2ZjBjNTc3NS90YWJsZTo2NGY0MDlmNTFkMzI0NmUwYmM5NTM0YjdhYWRhMzlmNy90YWJsZXJhbmdlOjY0ZjQwOWY1MWQzMjQ2ZTBiYzk1MzRiN2FhZGEzOWY3XzItMy0xLTEtMTc3NzU_3793a6cb-2543-4e40-8240-ba595e535aa1"
      unitRef="usd">9474000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="ic0d050fa1a3e4a2cb801e14c4a7886a2_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMTUvZnJhZzo5ZjFhZjNiMDEwY2U0ODI2OTI2YjA3MGU2ZjBjNTc3NS90YWJsZTo2NGY0MDlmNTFkMzI0NmUwYmM5NTM0YjdhYWRhMzlmNy90YWJsZXJhbmdlOjY0ZjQwOWY1MWQzMjQ2ZTBiYzk1MzRiN2FhZGEzOWY3XzMtMS0xLTEtMTc3NzU_8bae7e94-93a6-4285-9f7f-bccda4820a34"
      unitRef="usd">15000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="i5798a2aee885432aa6df470400a67a94_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMTUvZnJhZzo5ZjFhZjNiMDEwY2U0ODI2OTI2YjA3MGU2ZjBjNTc3NS90YWJsZTo2NGY0MDlmNTFkMzI0NmUwYmM5NTM0YjdhYWRhMzlmNy90YWJsZXJhbmdlOjY0ZjQwOWY1MWQzMjQ2ZTBiYzk1MzRiN2FhZGEzOWY3XzMtMy0xLTEtMTc3NzU_016e4e4b-178e-42b6-98c5-9dfba0a19266"
      unitRef="usd">51000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsNoncurrent
      contextRef="ic0d050fa1a3e4a2cb801e14c4a7886a2_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMTUvZnJhZzo5ZjFhZjNiMDEwY2U0ODI2OTI2YjA3MGU2ZjBjNTc3NS90YWJsZTo2NGY0MDlmNTFkMzI0NmUwYmM5NTM0YjdhYWRhMzlmNy90YWJsZXJhbmdlOjY0ZjQwOWY1MWQzMjQ2ZTBiYzk1MzRiN2FhZGEzOWY3XzQtMS0xLTEtMTc3NzU_fb0e66f5-852e-41d7-9fce-38cb4dac64bf"
      unitRef="usd">4877000</us-gaap:PrepaidExpenseAndOtherAssetsNoncurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsNoncurrent
      contextRef="i5798a2aee885432aa6df470400a67a94_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMTUvZnJhZzo5ZjFhZjNiMDEwY2U0ODI2OTI2YjA3MGU2ZjBjNTc3NS90YWJsZTo2NGY0MDlmNTFkMzI0NmUwYmM5NTM0YjdhYWRhMzlmNy90YWJsZXJhbmdlOjY0ZjQwOWY1MWQzMjQ2ZTBiYzk1MzRiN2FhZGEzOWY3XzQtMy0xLTEtMTc3NzU_7cdd5f57-c996-4997-aab0-11d1a47fecbe"
      unitRef="usd">4554000</us-gaap:PrepaidExpenseAndOtherAssetsNoncurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="ic0d050fa1a3e4a2cb801e14c4a7886a2_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMTUvZnJhZzo5ZjFhZjNiMDEwY2U0ODI2OTI2YjA3MGU2ZjBjNTc3NS90YWJsZTo2NGY0MDlmNTFkMzI0NmUwYmM5NTM0YjdhYWRhMzlmNy90YWJsZXJhbmdlOjY0ZjQwOWY1MWQzMjQ2ZTBiYzk1MzRiN2FhZGEzOWY3XzctMS0xLTEtMTc3NzU_b377e024-96c5-4202-a857-748fc068e7ec"
      unitRef="usd">1967000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="i5798a2aee885432aa6df470400a67a94_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMTUvZnJhZzo5ZjFhZjNiMDEwY2U0ODI2OTI2YjA3MGU2ZjBjNTc3NS90YWJsZTo2NGY0MDlmNTFkMzI0NmUwYmM5NTM0YjdhYWRhMzlmNy90YWJsZXJhbmdlOjY0ZjQwOWY1MWQzMjQ2ZTBiYzk1MzRiN2FhZGEzOWY3XzctMy0xLTEtMTc3NzU_ef6e5dce-c791-4d84-8217-7348bcdfde25"
      unitRef="usd">2509000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="ic0d050fa1a3e4a2cb801e14c4a7886a2_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMTUvZnJhZzo5ZjFhZjNiMDEwY2U0ODI2OTI2YjA3MGU2ZjBjNTc3NS90YWJsZTo2NGY0MDlmNTFkMzI0NmUwYmM5NTM0YjdhYWRhMzlmNy90YWJsZXJhbmdlOjY0ZjQwOWY1MWQzMjQ2ZTBiYzk1MzRiN2FhZGEzOWY3XzgtMS0xLTEtMTc3NzU_72fec6b7-dc4a-4cac-b878-9d77c31a207b"
      unitRef="usd">1120000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="i5798a2aee885432aa6df470400a67a94_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMTUvZnJhZzo5ZjFhZjNiMDEwY2U0ODI2OTI2YjA3MGU2ZjBjNTc3NS90YWJsZTo2NGY0MDlmNTFkMzI0NmUwYmM5NTM0YjdhYWRhMzlmNy90YWJsZXJhbmdlOjY0ZjQwOWY1MWQzMjQ2ZTBiYzk1MzRiN2FhZGEzOWY3XzgtMy0xLTEtMTc3NzU_a6573097-2c1b-4aa3-a428-d969ed60d98e"
      unitRef="usd">1520000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:LiabilityForFuturePolicyBenefitsAndUnpaidClaimsAndClaimsAdjustmentExpense
      contextRef="ic0d050fa1a3e4a2cb801e14c4a7886a2_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMTUvZnJhZzo5ZjFhZjNiMDEwY2U0ODI2OTI2YjA3MGU2ZjBjNTc3NS90YWJsZTo2NGY0MDlmNTFkMzI0NmUwYmM5NTM0YjdhYWRhMzlmNy90YWJsZXJhbmdlOjY0ZjQwOWY1MWQzMjQ2ZTBiYzk1MzRiN2FhZGEzOWY3XzktMS0xLTEtMTc3NzU_e2ddc112-1659-4dba-86cb-66a2c4d740eb"
      unitRef="usd">734000</us-gaap:LiabilityForFuturePolicyBenefitsAndUnpaidClaimsAndClaimsAdjustmentExpense>
    <us-gaap:LiabilityForFuturePolicyBenefitsAndUnpaidClaimsAndClaimsAdjustmentExpense
      contextRef="i5798a2aee885432aa6df470400a67a94_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMTUvZnJhZzo5ZjFhZjNiMDEwY2U0ODI2OTI2YjA3MGU2ZjBjNTc3NS90YWJsZTo2NGY0MDlmNTFkMzI0NmUwYmM5NTM0YjdhYWRhMzlmNy90YWJsZXJhbmdlOjY0ZjQwOWY1MWQzMjQ2ZTBiYzk1MzRiN2FhZGEzOWY3XzktMy0xLTEtMTc3NzU_52c0967d-384f-425c-98a9-7774ec811ac2"
      unitRef="usd">435000</us-gaap:LiabilityForFuturePolicyBenefitsAndUnpaidClaimsAndClaimsAdjustmentExpense>
    <us-gaap:Revenues
      contextRef="i7b9f0cfef2b641acb147ef3af438fe7e_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMTUvZnJhZzo5ZjFhZjNiMDEwY2U0ODI2OTI2YjA3MGU2ZjBjNTc3NS90YWJsZTpmOWJmNGM2YzU0MTI0ZDRhYmJiYzc4OGUyMjc2NzU1YS90YWJsZXJhbmdlOmY5YmY0YzZjNTQxMjRkNGFiYmJjNzg4ZTIyNzY3NTVhXzMtNS0xLTEtMTc3NzU_44c108ff-8b58-4480-9898-d3921ad7cefa"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ib3fa08547d374130bb63c1e8f0b2c225_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMTUvZnJhZzo5ZjFhZjNiMDEwY2U0ODI2OTI2YjA3MGU2ZjBjNTc3NS90YWJsZTpmOWJmNGM2YzU0MTI0ZDRhYmJiYzc4OGUyMjc2NzU1YS90YWJsZXJhbmdlOmY5YmY0YzZjNTQxMjRkNGFiYmJjNzg4ZTIyNzY3NTVhXzMtNy0xLTEtMTc3NzU_6c64c9d6-9ce9-4cb5-b91f-59c5d6fd14f0"
      unitRef="usd">5416000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i6759af249ec643ef9a412f313e3297e3_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMTUvZnJhZzo5ZjFhZjNiMDEwY2U0ODI2OTI2YjA3MGU2ZjBjNTc3NS90YWJsZTpmOWJmNGM2YzU0MTI0ZDRhYmJiYzc4OGUyMjc2NzU1YS90YWJsZXJhbmdlOmY5YmY0YzZjNTQxMjRkNGFiYmJjNzg4ZTIyNzY3NTVhXzMtNS0xLTEtMjI2NjE_f91f89fb-59ab-4564-9d82-e3f3de6623f5"
      unitRef="usd">4009000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i64859199d5a842baaab416b161ae29c9_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMTUvZnJhZzo5ZjFhZjNiMDEwY2U0ODI2OTI2YjA3MGU2ZjBjNTc3NS90YWJsZTpmOWJmNGM2YzU0MTI0ZDRhYmJiYzc4OGUyMjc2NzU1YS90YWJsZXJhbmdlOmY5YmY0YzZjNTQxMjRkNGFiYmJjNzg4ZTIyNzY3NTVhXzQtNS0xLTEtMTc3NzU_7123cfa1-6db3-45df-9bdb-e148762ec6cc"
      unitRef="usd">45082000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ica89d567d5bb41858b442d7b0d52a944_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMTUvZnJhZzo5ZjFhZjNiMDEwY2U0ODI2OTI2YjA3MGU2ZjBjNTc3NS90YWJsZTpmOWJmNGM2YzU0MTI0ZDRhYmJiYzc4OGUyMjc2NzU1YS90YWJsZXJhbmdlOmY5YmY0YzZjNTQxMjRkNGFiYmJjNzg4ZTIyNzY3NTVhXzQtNy0xLTEtMTc3NzU_53e8fcbf-f09f-413e-a42f-744e38b32a12"
      unitRef="usd">226339000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ibe63fb63b6ff4113a876f8b68f82e70a_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMTUvZnJhZzo5ZjFhZjNiMDEwY2U0ODI2OTI2YjA3MGU2ZjBjNTc3NS90YWJsZTpmOWJmNGM2YzU0MTI0ZDRhYmJiYzc4OGUyMjc2NzU1YS90YWJsZXJhbmdlOmY5YmY0YzZjNTQxMjRkNGFiYmJjNzg4ZTIyNzY3NTVhXzQtNS0xLTEtMjI2NjE_3c30b3f6-b700-41a2-b8be-89a7d32643fc"
      unitRef="usd">60325000</us-gaap:Revenues>
    <evh:CostofGoodsandServicesSoldExcludingDepreciationandAmortization
      contextRef="i2f7f912d67eb4dc4be805fbdba0a463f_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMTUvZnJhZzo5ZjFhZjNiMDEwY2U0ODI2OTI2YjA3MGU2ZjBjNTc3NS90YWJsZTpmOWJmNGM2YzU0MTI0ZDRhYmJiYzc4OGUyMjc2NzU1YS90YWJsZXJhbmdlOmY5YmY0YzZjNTQxMjRkNGFiYmJjNzg4ZTIyNzY3NTVhXzctNS0xLTEtMTc3NzU_6e936b98-dcd8-4c89-9b5e-c015f0763f37"
      unitRef="usd">3063000</evh:CostofGoodsandServicesSoldExcludingDepreciationandAmortization>
    <evh:CostofGoodsandServicesSoldExcludingDepreciationandAmortization
      contextRef="ifdb175ec1f9e4b0eb8e3f71649541a13_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMTUvZnJhZzo5ZjFhZjNiMDEwY2U0ODI2OTI2YjA3MGU2ZjBjNTc3NS90YWJsZTpmOWJmNGM2YzU0MTI0ZDRhYmJiYzc4OGUyMjc2NzU1YS90YWJsZXJhbmdlOmY5YmY0YzZjNTQxMjRkNGFiYmJjNzg4ZTIyNzY3NTVhXzctNy0xLTEtMTc3NzU_90192beb-765f-4dfc-b99e-2f8309c17271"
      unitRef="usd">2863000</evh:CostofGoodsandServicesSoldExcludingDepreciationandAmortization>
    <evh:CostofGoodsandServicesSoldExcludingDepreciationandAmortization
      contextRef="ie285ae7136404d0386bf1d58aebb605f_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMTUvZnJhZzo5ZjFhZjNiMDEwY2U0ODI2OTI2YjA3MGU2ZjBjNTc3NS90YWJsZTpmOWJmNGM2YzU0MTI0ZDRhYmJiYzc4OGUyMjc2NzU1YS90YWJsZXJhbmdlOmY5YmY0YzZjNTQxMjRkNGFiYmJjNzg4ZTIyNzY3NTVhXzctNS0xLTEtMjI2NjE_92d80f30-7250-4234-b533-3ecacc4e80c6"
      unitRef="usd">28954000</evh:CostofGoodsandServicesSoldExcludingDepreciationandAmortization>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="i2f7f912d67eb4dc4be805fbdba0a463f_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMTUvZnJhZzo5ZjFhZjNiMDEwY2U0ODI2OTI2YjA3MGU2ZjBjNTc3NS90YWJsZTpmOWJmNGM2YzU0MTI0ZDRhYmJiYzc4OGUyMjc2NzU1YS90YWJsZXJhbmdlOmY5YmY0YzZjNTQxMjRkNGFiYmJjNzg4ZTIyNzY3NTVhXzgtNS0xLTEtMTc3NzU_5183b73a-701d-4d16-b386-c321a0fb6cda"
      unitRef="usd">285000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="ifdb175ec1f9e4b0eb8e3f71649541a13_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMTUvZnJhZzo5ZjFhZjNiMDEwY2U0ODI2OTI2YjA3MGU2ZjBjNTc3NS90YWJsZTpmOWJmNGM2YzU0MTI0ZDRhYmJiYzc4OGUyMjc2NzU1YS90YWJsZXJhbmdlOmY5YmY0YzZjNTQxMjRkNGFiYmJjNzg4ZTIyNzY3NTVhXzgtNy0xLTEtMTc3NzU_0e8a1f2a-1022-4d40-88d1-923f7451b223"
      unitRef="usd">113000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="ie285ae7136404d0386bf1d58aebb605f_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMTUvZnJhZzo5ZjFhZjNiMDEwY2U0ODI2OTI2YjA3MGU2ZjBjNTc3NS90YWJsZTpmOWJmNGM2YzU0MTI0ZDRhYmJiYzc4OGUyMjc2NzU1YS90YWJsZXJhbmdlOmY5YmY0YzZjNTQxMjRkNGFiYmJjNzg4ZTIyNzY3NTVhXzgtNS0xLTEtMjI2NjE_6d304d6f-7595-4837-947d-48162cb906ce"
      unitRef="usd">991000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock
      contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMTgvZnJhZzo2Y2ZkN2JlMzYwN2U0NTdjYTk2YzA3YzMwMTIwZWFlZC90ZXh0cmVnaW9uOjZjZmQ3YmUzNjA3ZTQ1N2NhOTZjMDdjMzAxMjBlYWVkXzE0MzQ_0d813cfd-068c-48b2-b2b1-4a736e0ae914">Repositioning and Other Changes&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We continually assess opportunities to improve operational effectiveness and efficiency to better align our expenses with revenues, while continuing to make investments in our solutions, systems and people that we believe are important to our long-term goals. Across 2020, we divested or agreed to divest a majority of our health plan assets, including certain assets of EVH Passport, which represented a significant revenue stream for the Company. In parallel with these divestitures, we contracted with a third-party vendor to review our operating model and organizational design in order to improve our profitability, create value through our solutions and invest in strategic opportunities in future periods.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In the fourth quarter of 2020, we committed to certain operational efficiency and profitability actions that we are taking in order to accomplish these objectives (&#x201c;Repositioning Plan&#x201d;). These actions included making organizational changes across our business as well as other profitability initiatives expected to result in reductions in force, re-aligning of resources as well as other potential operational efficiency and cost-reduction initiatives that will provide future benefit to the Company. The Repositioning Plan concluded in the fourth quarter of 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table provides a summary of our total costs associated with the Repositioning Plan for the years ended December 31, 2021 and 2020, by major type of cost (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:60.011%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.788%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.355%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.788%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.355%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.903%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:23pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;For the Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Cumulative Amount Incurred through December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Severance and termination benefits&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;185&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;185&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Office space consolidation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,742&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,742&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Professional services&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,391&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,275&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,666&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,318&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,275&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,593&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock>
    <us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock
      contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMTgvZnJhZzo2Y2ZkN2JlMzYwN2U0NTdjYTk2YzA3YzMwMTIwZWFlZC90ZXh0cmVnaW9uOjZjZmQ3YmUzNjA3ZTQ1N2NhOTZjMDdjMzAxMjBlYWVkXzE0MzU_e35335f9-7154-47e8-b0da-7ca8f4dc3b84">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table provides a summary of our total costs associated with the Repositioning Plan for the years ended December 31, 2021 and 2020, by major type of cost (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:60.011%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.788%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.355%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.788%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.355%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.903%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:23pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;For the Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Cumulative Amount Incurred through December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Severance and termination benefits&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;185&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;185&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Office space consolidation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,742&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,742&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Professional services&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,391&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,275&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,666&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,318&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,275&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,593&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock>
    <us-gaap:RestructuringCharges
      contextRef="ia2137cc736cb46c28970ad4c0df7a021_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMTgvZnJhZzo2Y2ZkN2JlMzYwN2U0NTdjYTk2YzA3YzMwMTIwZWFlZC90YWJsZTozNjE5NGQ1N2FjZDM0Mjg1OTM4YTBiMWYyNTI3ODQwNi90YWJsZXJhbmdlOjM2MTk0ZDU3YWNkMzQyODU5MzhhMGIxZjI1Mjc4NDA2XzEtMy0xLTEtMTc3NzU_65c3dcb7-d749-483d-9cfb-03923eddac48"
      unitRef="usd">185000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges
      contextRef="ic842aeb816144721bb643e4517b1fffb_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMTgvZnJhZzo2Y2ZkN2JlMzYwN2U0NTdjYTk2YzA3YzMwMTIwZWFlZC90YWJsZTozNjE5NGQ1N2FjZDM0Mjg1OTM4YTBiMWYyNTI3ODQwNi90YWJsZXJhbmdlOjM2MTk0ZDU3YWNkMzQyODU5MzhhMGIxZjI1Mjc4NDA2XzItMy0xLTEtMjI3MDc_cbea4e21-83c0-4862-9d23-b5b743fdb959"
      unitRef="usd">0</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringAndRelatedCostCostIncurredToDate1
      contextRef="id2b0eba26c804a30b8e75757e49f5f5d_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMTgvZnJhZzo2Y2ZkN2JlMzYwN2U0NTdjYTk2YzA3YzMwMTIwZWFlZC90YWJsZTozNjE5NGQ1N2FjZDM0Mjg1OTM4YTBiMWYyNTI3ODQwNi90YWJsZXJhbmdlOjM2MTk0ZDU3YWNkMzQyODU5MzhhMGIxZjI1Mjc4NDA2XzEtNy0xLTEtMTc3NzU_846029da-e968-4446-b395-f4c538703ee6"
      unitRef="usd">185000</us-gaap:RestructuringAndRelatedCostCostIncurredToDate1>
    <us-gaap:RestructuringCharges
      contextRef="i044e3156b9ce469fa3a7efb6527ef6c1_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMTgvZnJhZzo2Y2ZkN2JlMzYwN2U0NTdjYTk2YzA3YzMwMTIwZWFlZC90YWJsZTozNjE5NGQ1N2FjZDM0Mjg1OTM4YTBiMWYyNTI3ODQwNi90YWJsZXJhbmdlOjM2MTk0ZDU3YWNkMzQyODU5MzhhMGIxZjI1Mjc4NDA2XzItMy0xLTEtMTc3NzU_c9b14661-e718-48e9-b8b6-42101d313d8a"
      unitRef="usd">2742000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges
      contextRef="i40374039e5cf443a857163fd2a9b2b45_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMTgvZnJhZzo2Y2ZkN2JlMzYwN2U0NTdjYTk2YzA3YzMwMTIwZWFlZC90YWJsZTozNjE5NGQ1N2FjZDM0Mjg1OTM4YTBiMWYyNTI3ODQwNi90YWJsZXJhbmdlOjM2MTk0ZDU3YWNkMzQyODU5MzhhMGIxZjI1Mjc4NDA2XzMtMy0xLTEtMjI3MDc_f99cf825-a15b-4f7c-8ac3-03e002c29100"
      unitRef="usd">0</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringAndRelatedCostCostIncurredToDate1
      contextRef="i3e648308269a4bea807ba0b660a48b7c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMTgvZnJhZzo2Y2ZkN2JlMzYwN2U0NTdjYTk2YzA3YzMwMTIwZWFlZC90YWJsZTozNjE5NGQ1N2FjZDM0Mjg1OTM4YTBiMWYyNTI3ODQwNi90YWJsZXJhbmdlOjM2MTk0ZDU3YWNkMzQyODU5MzhhMGIxZjI1Mjc4NDA2XzItNy0xLTEtMTc3NzU_c12f47f1-9114-4019-a5fe-668637e12699"
      unitRef="usd">2742000</us-gaap:RestructuringAndRelatedCostCostIncurredToDate1>
    <us-gaap:RestructuringCharges
      contextRef="i27138185aa744ae99ce808c1685e2fee_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMTgvZnJhZzo2Y2ZkN2JlMzYwN2U0NTdjYTk2YzA3YzMwMTIwZWFlZC90YWJsZTozNjE5NGQ1N2FjZDM0Mjg1OTM4YTBiMWYyNTI3ODQwNi90YWJsZXJhbmdlOjM2MTk0ZDU3YWNkMzQyODU5MzhhMGIxZjI1Mjc4NDA2XzMtMy0xLTEtMTc3NzU_dc7f4847-2789-4d5e-979e-5aa0aff8572a"
      unitRef="usd">4391000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges
      contextRef="if18eac1cd66a4b9b9bcc87d4d6fe437c_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMTgvZnJhZzo2Y2ZkN2JlMzYwN2U0NTdjYTk2YzA3YzMwMTIwZWFlZC90YWJsZTozNjE5NGQ1N2FjZDM0Mjg1OTM4YTBiMWYyNTI3ODQwNi90YWJsZXJhbmdlOjM2MTk0ZDU3YWNkMzQyODU5MzhhMGIxZjI1Mjc4NDA2XzQtMy0xLTEtMjI3MDc_c2ae226e-8dec-40aa-b759-77f5a4b1ba4e"
      unitRef="usd">1275000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringAndRelatedCostCostIncurredToDate1
      contextRef="i03de94c17d4149bbb0bf7a3e528d5f89_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMTgvZnJhZzo2Y2ZkN2JlMzYwN2U0NTdjYTk2YzA3YzMwMTIwZWFlZC90YWJsZTozNjE5NGQ1N2FjZDM0Mjg1OTM4YTBiMWYyNTI3ODQwNi90YWJsZXJhbmdlOjM2MTk0ZDU3YWNkMzQyODU5MzhhMGIxZjI1Mjc4NDA2XzMtNy0xLTEtMTc3NzU_e64dd87e-5fc1-44e2-820d-1e7a3a881da8"
      unitRef="usd">5666000</us-gaap:RestructuringAndRelatedCostCostIncurredToDate1>
    <us-gaap:RestructuringCharges
      contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMTgvZnJhZzo2Y2ZkN2JlMzYwN2U0NTdjYTk2YzA3YzMwMTIwZWFlZC90YWJsZTozNjE5NGQ1N2FjZDM0Mjg1OTM4YTBiMWYyNTI3ODQwNi90YWJsZXJhbmdlOjM2MTk0ZDU3YWNkMzQyODU5MzhhMGIxZjI1Mjc4NDA2XzQtMy0xLTEtMTc3NzU_d6a76e2a-a78c-4ced-8506-28818cfa9079"
      unitRef="usd">7318000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges
      contextRef="i12a6d1161de54547bd29f8efccd4c9b0_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMTgvZnJhZzo2Y2ZkN2JlMzYwN2U0NTdjYTk2YzA3YzMwMTIwZWFlZC90YWJsZTozNjE5NGQ1N2FjZDM0Mjg1OTM4YTBiMWYyNTI3ODQwNi90YWJsZXJhbmdlOjM2MTk0ZDU3YWNkMzQyODU5MzhhMGIxZjI1Mjc4NDA2XzUtMy0xLTEtMjI3MDc_3e98e4a4-3a20-4c32-9d5f-e38617b25580"
      unitRef="usd">1275000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringAndRelatedCostCostIncurredToDate1
      contextRef="i8daff60be410426d8f7bd49343c1ec0c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMTgvZnJhZzo2Y2ZkN2JlMzYwN2U0NTdjYTk2YzA3YzMwMTIwZWFlZC90YWJsZTozNjE5NGQ1N2FjZDM0Mjg1OTM4YTBiMWYyNTI3ODQwNi90YWJsZXJhbmdlOjM2MTk0ZDU3YWNkMzQyODU5MzhhMGIxZjI1Mjc4NDA2XzQtNy0xLTEtMTc3NzU_e6f22748-ccb7-4e42-a0d4-7a2b49c4f3ad"
      unitRef="usd">8593000</us-gaap:RestructuringAndRelatedCostCostIncurredToDate1>
    <us-gaap:SegmentReportingDisclosureTextBlock
      contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMjEvZnJhZzowZWY2M2NjZTNmMjk0ZGZjOWJlMzhhYWYwZmMyYTQ4Yi90ZXh0cmVnaW9uOjBlZjYzY2NlM2YyOTRkZmM5YmUzOGFhZjBmYzJhNDhiXzM0NjM_6d4b3285-8f5f-48ca-8bf7-a384bf9187b9">Segment Reporting&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We define our reportable segments based on the way the CODM, the chief executive officer, manages the operations for purposes of allocating resources and assessing performance commencing with the three months ended March 31, 2021. We classify our operations into two reportable segments as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt"&gt;Evolent Health Services, which houses our Administrative Simplification solution and certain supporting population health infrastructure; and&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt"&gt;Clinical Solutions, which includes our specialty care management and physician-oriented total cost of care solutions, along with the New Century Health and Evolent Care Partners brands. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In the ordinary course of business, our reportable segments enter into transactions with one another. While intersegment transactions are treated like third-party transactions to determine segment performance, the revenues and expenses recognized by the segment that is the counterparty to the transaction are eliminated in consolidation and do not affect consolidated results.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The CODM uses revenue in accordance with U.S. GAAP and Adjusted EBITDA as the relevant segment performance measures to evaluate the performance of the segments and allocate resources. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Adjusted EBITDA is a segment performance financial measure that offers a useful view of the overall operation of our businesses and may be different than similarly-titled segment performance financial measures used by other companies. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Adjusted EBITDA is defined as net loss attributable to common shareholders of Evolent Health, Inc. before interest income, interest expense, (provision) benefit for income taxes, depreciation and amortization expenses, adjusted to exclude equity method investment impairment, gain on transfer of membership, loss on repayment of debt, loss on extinguishment of debt, goodwill impairment, gain (loss) from equity method investees, changes in fair value of contingent consideration and indemnification asset, net loss attributable to non-controlling interests, other income (expense), net, repositioning costs, stock-based compensation expense, severance costs, amortization of contract cost assets, strategy and shareholder advisory services, acquisition-related costs and gain (loss) from discontinued operations. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Management considers revenue and Adjusted EBITDA to be the appropriate metrics to evaluate and compare the ongoing operating performance of our segments on a consistent basis across reporting periods as they eliminate the effect of items which are not indicative of each segment's core operating performance. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following tables present our segment information for the years ended December 31, 2021, 2020 and 2019 (in thousands). Segment information for the years ended December 31, 2020 and 2019 (including segments total Adjusted EBITDA) has been restated to conform to the reporting structure change described in Note 2.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:145.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:52.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:52.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:67.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:60.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:61.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:67.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr style="height:33pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Evolent Health Services&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Clinical Solutions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Intersegment&lt;br/&gt;Eliminations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Subtotal&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Corporate &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Consolidated&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="12" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;For the Year Ended December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Transformation services&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,204&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,204&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,204&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Platform and operations services&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;300,423&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;598,144&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,814)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;896,753&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;896,753&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total revenue&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;311,627&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;598,144&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,814)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;907,957&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;907,957&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:145.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:52.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:52.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:67.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:60.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:61.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:67.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="12" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;For the Year Ended December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Transformation services&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,990&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,990&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,990&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Platform and operations services&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;373,144&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;542,279&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,774)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;912,649&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;912,649&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total revenue&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;385,134&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;542,279&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,774)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;924,639&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;924,639&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="12" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;For the Year Ended December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Transformation services&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,203&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,203&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,203&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Platform and operations services&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;394,328&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;278,217&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(626)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;671,919&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;671,919&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total revenue&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;409,531&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;278,217&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(626)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;687,122&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;687,122&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:33pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Evolent Health Services&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Clinical Solutions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Subtotal&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Corporate &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Segments Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="12" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;For the Year Ended December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Adjusted EBITDA&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,063&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;82,920&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;99,983&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(33,666)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;66,317&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="12" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;For the Year Ended December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Adjusted EBITDA&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;57,731&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26,864&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;84,595&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(36,022)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;48,573&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="12" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;For the Year Ended December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Adjusted EBITDA&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(561)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,523&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,962&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(25,793)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(13,831)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt"&gt;Corporate includes various finance, human resources, legal, executive, and other corporate infrastructure expenses.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents our reconciliation of consolidated segments total Adjusted EBITDA to net loss attributable to common shareholders of Evolent Health, Inc. for the years ended December 31, 2021, 2020 and 2019 (in thousands): &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:380.50pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:48.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:48.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:48.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;For the Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Net loss attributable to common shareholders of Evolent Health, Inc.&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(37,601)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(334,246)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(301,971)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;407&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,633&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,406&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(25,425)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(28,325)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(14,555)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(Provision) benefit for income taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(483)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,368&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,795&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Depreciation and amortization expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(60,037)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(60,835)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(60,323)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Equity method investment impairment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(47,133)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gain on transfer of membership&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45,938&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Loss on repayment of debt, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(21,343)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Loss on extinguishment of debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,789)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goodwill impairment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(215,100)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(199,800)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gain (loss) from equity method investees&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,179&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,039&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9,465)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gain (loss) on disposal of assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(698)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change in fair value of contingent consideration and indemnification asset&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(13,281)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,860)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,997&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net loss attributable to non-controlling interests&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,609&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other income (expense), net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(146)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(118)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(489)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Purchase accounting adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,915)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Repositioning costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7,318)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,275)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock-based compensation expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(16,711)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(14,606)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(15,618)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Severance costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(198)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8,986)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(17,350)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amortization of contract cost assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(476)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,944)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,876)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Strategy and shareholder advisory expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6,513)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Acquisition costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,194)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,116)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(10,769)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gain (loss) from discontinued operations &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7,317)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6,074)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,613&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Adjusted EBITDA&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;66,317&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;48,573&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(13,831)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt"&gt;Includes $6.8&#160;million gain on disposal of discontinued operations for the year ended December 31, 2021.&lt;/span&gt;&lt;/div&gt;Asset information by segment is not a key measure of performance used by the CODM. Accordingly, we have not disclosed asset information by segment.</us-gaap:SegmentReportingDisclosureTextBlock>
    <us-gaap:NumberOfOperatingSegments
      contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMjEvZnJhZzowZWY2M2NjZTNmMjk0ZGZjOWJlMzhhYWYwZmMyYTQ4Yi90ZXh0cmVnaW9uOjBlZjYzY2NlM2YyOTRkZmM5YmUzOGFhZjBmYzJhNDhiXzI5Nw_f06a53d9-968e-4310-99c8-16fee781d2d3"
      unitRef="segment">2</us-gaap:NumberOfOperatingSegments>
    <us-gaap:ReconciliationOfRevenueFromSegmentsToConsolidatedTextBlock
      contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMjEvZnJhZzowZWY2M2NjZTNmMjk0ZGZjOWJlMzhhYWYwZmMyYTQ4Yi90ZXh0cmVnaW9uOjBlZjYzY2NlM2YyOTRkZmM5YmUzOGFhZjBmYzJhNDhiXzM0NjQ_04236a43-c73e-489a-bf2e-85cda8cea6ba">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following tables present our segment information for the years ended December 31, 2021, 2020 and 2019 (in thousands). Segment information for the years ended December 31, 2020 and 2019 (including segments total Adjusted EBITDA) has been restated to conform to the reporting structure change described in Note 2.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:145.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:52.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:52.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:67.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:60.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:61.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:67.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr style="height:33pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Evolent Health Services&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Clinical Solutions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Intersegment&lt;br/&gt;Eliminations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Subtotal&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Corporate &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Consolidated&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="12" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;For the Year Ended December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Transformation services&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,204&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,204&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,204&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Platform and operations services&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;300,423&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;598,144&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,814)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;896,753&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;896,753&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total revenue&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;311,627&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;598,144&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,814)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;907,957&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;907,957&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:145.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:52.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:52.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:67.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:60.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:61.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:67.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="12" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;For the Year Ended December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Transformation services&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,990&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,990&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,990&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Platform and operations services&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;373,144&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;542,279&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,774)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;912,649&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;912,649&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total revenue&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;385,134&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;542,279&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,774)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;924,639&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;924,639&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="12" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;For the Year Ended December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Transformation services&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,203&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,203&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,203&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Platform and operations services&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;394,328&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;278,217&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(626)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;671,919&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;671,919&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total revenue&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;409,531&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;278,217&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(626)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;687,122&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;687,122&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:33pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Evolent Health Services&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Clinical Solutions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Subtotal&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Corporate &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Segments Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="12" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;For the Year Ended December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Adjusted EBITDA&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,063&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;82,920&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;99,983&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(33,666)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;66,317&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="12" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;For the Year Ended December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Adjusted EBITDA&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;57,731&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26,864&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;84,595&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(36,022)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;48,573&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="12" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;For the Year Ended December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Adjusted EBITDA&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(561)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,523&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,962&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(25,793)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(13,831)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt"&gt;Corporate includes various finance, human resources, legal, executive, and other corporate infrastructure expenses.&lt;/span&gt;&lt;/div&gt;</us-gaap:ReconciliationOfRevenueFromSegmentsToConsolidatedTextBlock>
    <us-gaap:Revenues
      contextRef="i41b92360defc47ba8a58871111248034_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMjEvZnJhZzowZWY2M2NjZTNmMjk0ZGZjOWJlMzhhYWYwZmMyYTQ4Yi90YWJsZTphNDdlYTI3MDk3NTA0ZGU2ODQ1YTc1NWM0ZWQyNzcyNS90YWJsZXJhbmdlOmE0N2VhMjcwOTc1MDRkZTY4NDVhNzU1YzRlZDI3NzI1XzMtMS0xLTEtMTc3NzU_51254808-104b-4e17-bf29-97b6c53d3375"
      unitRef="usd">11204000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ic42eb62d04fb4a118704b67ffb9fd515_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMjEvZnJhZzowZWY2M2NjZTNmMjk0ZGZjOWJlMzhhYWYwZmMyYTQ4Yi90YWJsZTphNDdlYTI3MDk3NTA0ZGU2ODQ1YTc1NWM0ZWQyNzcyNS90YWJsZXJhbmdlOmE0N2VhMjcwOTc1MDRkZTY4NDVhNzU1YzRlZDI3NzI1XzMtMy0xLTEtMTc3NzU_f2028d7f-1288-4a3e-85eb-151771a1ef22"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="iaf678763d1004f0e9876b94f94d0a5a6_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMjEvZnJhZzowZWY2M2NjZTNmMjk0ZGZjOWJlMzhhYWYwZmMyYTQ4Yi90YWJsZTphNDdlYTI3MDk3NTA0ZGU2ODQ1YTc1NWM0ZWQyNzcyNS90YWJsZXJhbmdlOmE0N2VhMjcwOTc1MDRkZTY4NDVhNzU1YzRlZDI3NzI1XzMtNS0xLTEtMTc3NzU_86db3cbc-c2d7-46c2-affa-954eddc3f46e"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i468f13cceecc41368537f1bf4d3bc06e_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMjEvZnJhZzowZWY2M2NjZTNmMjk0ZGZjOWJlMzhhYWYwZmMyYTQ4Yi90YWJsZTphNDdlYTI3MDk3NTA0ZGU2ODQ1YTc1NWM0ZWQyNzcyNS90YWJsZXJhbmdlOmE0N2VhMjcwOTc1MDRkZTY4NDVhNzU1YzRlZDI3NzI1XzMtNy0xLTEtMTc3NzU_98519aa4-f17e-4499-961c-a889fe0c124d"
      unitRef="usd">11204000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i57ed24791b0544679bd4b966e3ad6122_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMjEvZnJhZzowZWY2M2NjZTNmMjk0ZGZjOWJlMzhhYWYwZmMyYTQ4Yi90YWJsZTphNDdlYTI3MDk3NTA0ZGU2ODQ1YTc1NWM0ZWQyNzcyNS90YWJsZXJhbmdlOmE0N2VhMjcwOTc1MDRkZTY4NDVhNzU1YzRlZDI3NzI1XzMtOS0xLTEtMTc3NzU_c6020519-551d-44ef-a0f9-65f904a3f3ac"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="iba00e3572dc24848afe0d13147ef9951_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMjEvZnJhZzowZWY2M2NjZTNmMjk0ZGZjOWJlMzhhYWYwZmMyYTQ4Yi90YWJsZTphNDdlYTI3MDk3NTA0ZGU2ODQ1YTc1NWM0ZWQyNzcyNS90YWJsZXJhbmdlOmE0N2VhMjcwOTc1MDRkZTY4NDVhNzU1YzRlZDI3NzI1XzMtMTEtMS0xLTE3Nzc1_a5b193b9-7505-443d-8b4c-c1dc5965b45c"
      unitRef="usd">11204000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i5f219d5f567141958f242abd7cb9efea_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMjEvZnJhZzowZWY2M2NjZTNmMjk0ZGZjOWJlMzhhYWYwZmMyYTQ4Yi90YWJsZTphNDdlYTI3MDk3NTA0ZGU2ODQ1YTc1NWM0ZWQyNzcyNS90YWJsZXJhbmdlOmE0N2VhMjcwOTc1MDRkZTY4NDVhNzU1YzRlZDI3NzI1XzQtMS0xLTEtMTc3NzU_df8f7bfc-d058-4456-8982-2b2ab31fa4fe"
      unitRef="usd">300423000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ia00ff8c8432c4957b4aef14482bbb1ca_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMjEvZnJhZzowZWY2M2NjZTNmMjk0ZGZjOWJlMzhhYWYwZmMyYTQ4Yi90YWJsZTphNDdlYTI3MDk3NTA0ZGU2ODQ1YTc1NWM0ZWQyNzcyNS90YWJsZXJhbmdlOmE0N2VhMjcwOTc1MDRkZTY4NDVhNzU1YzRlZDI3NzI1XzQtMy0xLTEtMTc3NzU_7d0fa597-daf6-4709-83cb-20df2be1cf20"
      unitRef="usd">598144000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="iac839f1f097a424c99205c02214639ed_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMjEvZnJhZzowZWY2M2NjZTNmMjk0ZGZjOWJlMzhhYWYwZmMyYTQ4Yi90YWJsZTphNDdlYTI3MDk3NTA0ZGU2ODQ1YTc1NWM0ZWQyNzcyNS90YWJsZXJhbmdlOmE0N2VhMjcwOTc1MDRkZTY4NDVhNzU1YzRlZDI3NzI1XzQtNS0xLTEtMTc3NzU_7733ae74-dc13-43f2-b770-1f99bf13f9e5"
      unitRef="usd">-1814000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="id762405c08c64368824019f2ec90b437_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMjEvZnJhZzowZWY2M2NjZTNmMjk0ZGZjOWJlMzhhYWYwZmMyYTQ4Yi90YWJsZTphNDdlYTI3MDk3NTA0ZGU2ODQ1YTc1NWM0ZWQyNzcyNS90YWJsZXJhbmdlOmE0N2VhMjcwOTc1MDRkZTY4NDVhNzU1YzRlZDI3NzI1XzQtNy0xLTEtMTc3NzU_dc5a0d79-cea0-4f2d-ba4f-c93cb641cfa3"
      unitRef="usd">896753000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ie91abff3ebd24744803f889983e86d61_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMjEvZnJhZzowZWY2M2NjZTNmMjk0ZGZjOWJlMzhhYWYwZmMyYTQ4Yi90YWJsZTphNDdlYTI3MDk3NTA0ZGU2ODQ1YTc1NWM0ZWQyNzcyNS90YWJsZXJhbmdlOmE0N2VhMjcwOTc1MDRkZTY4NDVhNzU1YzRlZDI3NzI1XzQtOS0xLTEtMTc3NzU_0e273343-6ab3-4fee-af2f-8811033c8845"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ic852ce517768443a8289b4dcbd762e47_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMjEvZnJhZzowZWY2M2NjZTNmMjk0ZGZjOWJlMzhhYWYwZmMyYTQ4Yi90YWJsZTphNDdlYTI3MDk3NTA0ZGU2ODQ1YTc1NWM0ZWQyNzcyNS90YWJsZXJhbmdlOmE0N2VhMjcwOTc1MDRkZTY4NDVhNzU1YzRlZDI3NzI1XzQtMTEtMS0xLTE3Nzc1_bcc3a2f5-f677-4625-8dad-4a1a5640e373"
      unitRef="usd">896753000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i98988f30813349e1a5594e72b40af5b1_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMjEvZnJhZzowZWY2M2NjZTNmMjk0ZGZjOWJlMzhhYWYwZmMyYTQ4Yi90YWJsZTphNDdlYTI3MDk3NTA0ZGU2ODQ1YTc1NWM0ZWQyNzcyNS90YWJsZXJhbmdlOmE0N2VhMjcwOTc1MDRkZTY4NDVhNzU1YzRlZDI3NzI1XzUtMS0xLTEtMTc3NzU_c77d140e-2a6a-4441-99d3-3877afe2fd28"
      unitRef="usd">311627000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i6d991ef4e2e0416f8c7aaaa6175cf843_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMjEvZnJhZzowZWY2M2NjZTNmMjk0ZGZjOWJlMzhhYWYwZmMyYTQ4Yi90YWJsZTphNDdlYTI3MDk3NTA0ZGU2ODQ1YTc1NWM0ZWQyNzcyNS90YWJsZXJhbmdlOmE0N2VhMjcwOTc1MDRkZTY4NDVhNzU1YzRlZDI3NzI1XzUtMy0xLTEtMTc3NzU_4b49ffe4-33ba-4c8d-83e3-3f4ec3d083e5"
      unitRef="usd">598144000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i160f9ff72a8f428db94184c59ffafc47_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMjEvZnJhZzowZWY2M2NjZTNmMjk0ZGZjOWJlMzhhYWYwZmMyYTQ4Yi90YWJsZTphNDdlYTI3MDk3NTA0ZGU2ODQ1YTc1NWM0ZWQyNzcyNS90YWJsZXJhbmdlOmE0N2VhMjcwOTc1MDRkZTY4NDVhNzU1YzRlZDI3NzI1XzUtNS0xLTEtMTc3NzU_aa59f336-3357-4dda-90fc-4f1f7e1ca7de"
      unitRef="usd">-1814000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i6750aca4d3ec49afaa3b71a05c995e4e_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMjEvZnJhZzowZWY2M2NjZTNmMjk0ZGZjOWJlMzhhYWYwZmMyYTQ4Yi90YWJsZTphNDdlYTI3MDk3NTA0ZGU2ODQ1YTc1NWM0ZWQyNzcyNS90YWJsZXJhbmdlOmE0N2VhMjcwOTc1MDRkZTY4NDVhNzU1YzRlZDI3NzI1XzUtNy0xLTEtMTc3NzU_4371c292-26ce-4ff4-a1ad-bbcd65e7ed29"
      unitRef="usd">907957000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i2a43cc2e9054466a9f76a89472b3e611_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMjEvZnJhZzowZWY2M2NjZTNmMjk0ZGZjOWJlMzhhYWYwZmMyYTQ4Yi90YWJsZTphNDdlYTI3MDk3NTA0ZGU2ODQ1YTc1NWM0ZWQyNzcyNS90YWJsZXJhbmdlOmE0N2VhMjcwOTc1MDRkZTY4NDVhNzU1YzRlZDI3NzI1XzUtOS0xLTEtMTc3NzU_9f57d58a-ec7d-46bd-8050-2428630b59b5"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMjEvZnJhZzowZWY2M2NjZTNmMjk0ZGZjOWJlMzhhYWYwZmMyYTQ4Yi90YWJsZTphNDdlYTI3MDk3NTA0ZGU2ODQ1YTc1NWM0ZWQyNzcyNS90YWJsZXJhbmdlOmE0N2VhMjcwOTc1MDRkZTY4NDVhNzU1YzRlZDI3NzI1XzUtMTEtMS0xLTE3Nzc1_3959f47a-9979-4a83-9dd3-23b1f26e2957"
      unitRef="usd">907957000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i6e3a96f5efe64f78b6f207c1f9ccaadf_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMjEvZnJhZzowZWY2M2NjZTNmMjk0ZGZjOWJlMzhhYWYwZmMyYTQ4Yi90YWJsZTphNDdlYTI3MDk3NTA0ZGU2ODQ1YTc1NWM0ZWQyNzcyNS90YWJsZXJhbmdlOmE0N2VhMjcwOTc1MDRkZTY4NDVhNzU1YzRlZDI3NzI1XzgtMS0xLTEtMTc3NzU_2acc1ed1-f903-461b-ae41-7ff3c75c89f3"
      unitRef="usd">11990000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i04129486c45c47ce9cc1fa8184882c54_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMjEvZnJhZzowZWY2M2NjZTNmMjk0ZGZjOWJlMzhhYWYwZmMyYTQ4Yi90YWJsZTphNDdlYTI3MDk3NTA0ZGU2ODQ1YTc1NWM0ZWQyNzcyNS90YWJsZXJhbmdlOmE0N2VhMjcwOTc1MDRkZTY4NDVhNzU1YzRlZDI3NzI1XzgtMy0xLTEtMTc3NzU_b83279cb-01c7-4570-8698-d2c69784b90b"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i755b7b89c5764b53aede85f57d5ac9de_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMjEvZnJhZzowZWY2M2NjZTNmMjk0ZGZjOWJlMzhhYWYwZmMyYTQ4Yi90YWJsZTphNDdlYTI3MDk3NTA0ZGU2ODQ1YTc1NWM0ZWQyNzcyNS90YWJsZXJhbmdlOmE0N2VhMjcwOTc1MDRkZTY4NDVhNzU1YzRlZDI3NzI1XzgtNS0xLTEtMTc3NzU_1fa7710d-c017-4fa7-aa11-fa014d8e9cb7"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i51b664fb7925436f8af4dc7608707edc_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMjEvZnJhZzowZWY2M2NjZTNmMjk0ZGZjOWJlMzhhYWYwZmMyYTQ4Yi90YWJsZTphNDdlYTI3MDk3NTA0ZGU2ODQ1YTc1NWM0ZWQyNzcyNS90YWJsZXJhbmdlOmE0N2VhMjcwOTc1MDRkZTY4NDVhNzU1YzRlZDI3NzI1XzgtNy0xLTEtMTc3NzU_9acf8949-a91f-4967-b8bc-a6a63240735c"
      unitRef="usd">11990000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i3c1ca3f52cf44a48a6eb1c640364e98d_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMjEvZnJhZzowZWY2M2NjZTNmMjk0ZGZjOWJlMzhhYWYwZmMyYTQ4Yi90YWJsZTphNDdlYTI3MDk3NTA0ZGU2ODQ1YTc1NWM0ZWQyNzcyNS90YWJsZXJhbmdlOmE0N2VhMjcwOTc1MDRkZTY4NDVhNzU1YzRlZDI3NzI1XzgtOS0xLTEtMTc3NzU_2e705fee-2505-41d7-8d5b-5733ccd6481c"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ib585ca9afa9b4d02874ade8f146f75cd_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMjEvZnJhZzowZWY2M2NjZTNmMjk0ZGZjOWJlMzhhYWYwZmMyYTQ4Yi90YWJsZTphNDdlYTI3MDk3NTA0ZGU2ODQ1YTc1NWM0ZWQyNzcyNS90YWJsZXJhbmdlOmE0N2VhMjcwOTc1MDRkZTY4NDVhNzU1YzRlZDI3NzI1XzgtMTEtMS0xLTE3Nzc1_8231d282-c0f0-4510-9070-1e77224ae94f"
      unitRef="usd">11990000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ief95fd4bd2a9417aa7c0a210852e8203_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMjEvZnJhZzowZWY2M2NjZTNmMjk0ZGZjOWJlMzhhYWYwZmMyYTQ4Yi90YWJsZTphNDdlYTI3MDk3NTA0ZGU2ODQ1YTc1NWM0ZWQyNzcyNS90YWJsZXJhbmdlOmE0N2VhMjcwOTc1MDRkZTY4NDVhNzU1YzRlZDI3NzI1XzktMS0xLTEtMTc3NzU_53792f41-4d69-4094-aacb-47ce44def92f"
      unitRef="usd">373144000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i77015663db9441cd9c37ef54417768be_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMjEvZnJhZzowZWY2M2NjZTNmMjk0ZGZjOWJlMzhhYWYwZmMyYTQ4Yi90YWJsZTphNDdlYTI3MDk3NTA0ZGU2ODQ1YTc1NWM0ZWQyNzcyNS90YWJsZXJhbmdlOmE0N2VhMjcwOTc1MDRkZTY4NDVhNzU1YzRlZDI3NzI1XzktMy0xLTEtMTc3NzU_c25c8ab8-7eb1-4fdb-98d4-be4a531e354d"
      unitRef="usd">542279000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="iccbcddcfb8ea4a728d495edce2f63324_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMjEvZnJhZzowZWY2M2NjZTNmMjk0ZGZjOWJlMzhhYWYwZmMyYTQ4Yi90YWJsZTphNDdlYTI3MDk3NTA0ZGU2ODQ1YTc1NWM0ZWQyNzcyNS90YWJsZXJhbmdlOmE0N2VhMjcwOTc1MDRkZTY4NDVhNzU1YzRlZDI3NzI1XzktNS0xLTEtMTc3NzU_727a7b0e-2380-4760-8477-65a36f7b77c0"
      unitRef="usd">-2774000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i5f1fd6df16314fac900d170f76611052_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMjEvZnJhZzowZWY2M2NjZTNmMjk0ZGZjOWJlMzhhYWYwZmMyYTQ4Yi90YWJsZTphNDdlYTI3MDk3NTA0ZGU2ODQ1YTc1NWM0ZWQyNzcyNS90YWJsZXJhbmdlOmE0N2VhMjcwOTc1MDRkZTY4NDVhNzU1YzRlZDI3NzI1XzktNy0xLTEtMTc3NzU_e2f9b5c4-1996-4c31-802c-00a883ac5252"
      unitRef="usd">912649000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i05ee1fcfda47445a8c730b607300bcd3_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMjEvZnJhZzowZWY2M2NjZTNmMjk0ZGZjOWJlMzhhYWYwZmMyYTQ4Yi90YWJsZTphNDdlYTI3MDk3NTA0ZGU2ODQ1YTc1NWM0ZWQyNzcyNS90YWJsZXJhbmdlOmE0N2VhMjcwOTc1MDRkZTY4NDVhNzU1YzRlZDI3NzI1XzktOS0xLTEtMTc3NzU_0d7cf492-ca79-4af7-8404-59f9ea380f6e"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i971b8dd0fb5d4b10b55f27371adadaa7_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMjEvZnJhZzowZWY2M2NjZTNmMjk0ZGZjOWJlMzhhYWYwZmMyYTQ4Yi90YWJsZTphNDdlYTI3MDk3NTA0ZGU2ODQ1YTc1NWM0ZWQyNzcyNS90YWJsZXJhbmdlOmE0N2VhMjcwOTc1MDRkZTY4NDVhNzU1YzRlZDI3NzI1XzktMTEtMS0xLTE3Nzc1_636e5236-48b2-48c1-a29d-f0482c68866d"
      unitRef="usd">912649000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i00a9fb2f3f914116b87f14e146d04507_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMjEvZnJhZzowZWY2M2NjZTNmMjk0ZGZjOWJlMzhhYWYwZmMyYTQ4Yi90YWJsZTphNDdlYTI3MDk3NTA0ZGU2ODQ1YTc1NWM0ZWQyNzcyNS90YWJsZXJhbmdlOmE0N2VhMjcwOTc1MDRkZTY4NDVhNzU1YzRlZDI3NzI1XzEwLTEtMS0xLTE3Nzc1_20fda0de-73d2-4553-9f80-25f2093facf1"
      unitRef="usd">385134000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i73877656554945338d08c1e8006fc13a_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMjEvZnJhZzowZWY2M2NjZTNmMjk0ZGZjOWJlMzhhYWYwZmMyYTQ4Yi90YWJsZTphNDdlYTI3MDk3NTA0ZGU2ODQ1YTc1NWM0ZWQyNzcyNS90YWJsZXJhbmdlOmE0N2VhMjcwOTc1MDRkZTY4NDVhNzU1YzRlZDI3NzI1XzEwLTMtMS0xLTE3Nzc1_335f2987-456e-4e62-9714-c1564b7f90fb"
      unitRef="usd">542279000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="iea90da90740c47ea8a58199dbc28a879_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMjEvZnJhZzowZWY2M2NjZTNmMjk0ZGZjOWJlMzhhYWYwZmMyYTQ4Yi90YWJsZTphNDdlYTI3MDk3NTA0ZGU2ODQ1YTc1NWM0ZWQyNzcyNS90YWJsZXJhbmdlOmE0N2VhMjcwOTc1MDRkZTY4NDVhNzU1YzRlZDI3NzI1XzEwLTUtMS0xLTE3Nzc1_3e4a31e3-3daa-4117-bc51-a74d624ed610"
      unitRef="usd">-2774000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="if1e0588b36354ec4ad0fe9d8b69a9b09_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMjEvZnJhZzowZWY2M2NjZTNmMjk0ZGZjOWJlMzhhYWYwZmMyYTQ4Yi90YWJsZTphNDdlYTI3MDk3NTA0ZGU2ODQ1YTc1NWM0ZWQyNzcyNS90YWJsZXJhbmdlOmE0N2VhMjcwOTc1MDRkZTY4NDVhNzU1YzRlZDI3NzI1XzEwLTctMS0xLTE3Nzc1_0178866b-60e4-4ae2-ba8f-6aae96414cb1"
      unitRef="usd">924639000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i0de9d5a3b6224de8a58bd015afb42ce0_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMjEvZnJhZzowZWY2M2NjZTNmMjk0ZGZjOWJlMzhhYWYwZmMyYTQ4Yi90YWJsZTphNDdlYTI3MDk3NTA0ZGU2ODQ1YTc1NWM0ZWQyNzcyNS90YWJsZXJhbmdlOmE0N2VhMjcwOTc1MDRkZTY4NDVhNzU1YzRlZDI3NzI1XzEwLTktMS0xLTE3Nzc1_97982aad-9a7e-4cbd-82a3-e461099301e7"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i12a6d1161de54547bd29f8efccd4c9b0_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMjEvZnJhZzowZWY2M2NjZTNmMjk0ZGZjOWJlMzhhYWYwZmMyYTQ4Yi90YWJsZTphNDdlYTI3MDk3NTA0ZGU2ODQ1YTc1NWM0ZWQyNzcyNS90YWJsZXJhbmdlOmE0N2VhMjcwOTc1MDRkZTY4NDVhNzU1YzRlZDI3NzI1XzEwLTExLTEtMS0xNzc3NQ_2ab07f55-fd1f-48ea-a10c-771ebcbf2ff3"
      unitRef="usd">924639000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i1b52f1300eeb41f7927ec4e356b5e849_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMjEvZnJhZzowZWY2M2NjZTNmMjk0ZGZjOWJlMzhhYWYwZmMyYTQ4Yi90YWJsZTphNDdlYTI3MDk3NTA0ZGU2ODQ1YTc1NWM0ZWQyNzcyNS90YWJsZXJhbmdlOmE0N2VhMjcwOTc1MDRkZTY4NDVhNzU1YzRlZDI3NzI1XzEzLTEtMS0xLTM2NDky_20bcbfb7-8a87-4174-b623-e986ca10a4ed"
      unitRef="usd">15203000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i5a806984574d41c5a8b3b5e54ae8b937_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMjEvZnJhZzowZWY2M2NjZTNmMjk0ZGZjOWJlMzhhYWYwZmMyYTQ4Yi90YWJsZTphNDdlYTI3MDk3NTA0ZGU2ODQ1YTc1NWM0ZWQyNzcyNS90YWJsZXJhbmdlOmE0N2VhMjcwOTc1MDRkZTY4NDVhNzU1YzRlZDI3NzI1XzEzLTMtMS0xLTM2NDky_b4d4c855-3d12-4b9d-ba73-4b92db4b3350"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ie7a1104b23254e04ac79b4e5e6c03ca1_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMjEvZnJhZzowZWY2M2NjZTNmMjk0ZGZjOWJlMzhhYWYwZmMyYTQ4Yi90YWJsZTphNDdlYTI3MDk3NTA0ZGU2ODQ1YTc1NWM0ZWQyNzcyNS90YWJsZXJhbmdlOmE0N2VhMjcwOTc1MDRkZTY4NDVhNzU1YzRlZDI3NzI1XzEzLTUtMS0xLTM2NDky_b303b75b-b6d3-444d-8dc6-005bfb6eff69"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i8b652a3d61824fc79322c57e9476af89_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMjEvZnJhZzowZWY2M2NjZTNmMjk0ZGZjOWJlMzhhYWYwZmMyYTQ4Yi90YWJsZTphNDdlYTI3MDk3NTA0ZGU2ODQ1YTc1NWM0ZWQyNzcyNS90YWJsZXJhbmdlOmE0N2VhMjcwOTc1MDRkZTY4NDVhNzU1YzRlZDI3NzI1XzEzLTctMS0xLTM2NDky_46bc0899-9667-4f31-9161-f152ed338e31"
      unitRef="usd">15203000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i5276f3d92d824c07b982e9971e0a15e8_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMjEvZnJhZzowZWY2M2NjZTNmMjk0ZGZjOWJlMzhhYWYwZmMyYTQ4Yi90YWJsZTphNDdlYTI3MDk3NTA0ZGU2ODQ1YTc1NWM0ZWQyNzcyNS90YWJsZXJhbmdlOmE0N2VhMjcwOTc1MDRkZTY4NDVhNzU1YzRlZDI3NzI1XzEzLTktMS0xLTM2NDky_5302428c-589f-4baa-badf-7f59ed330b70"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ia6ba1f43ec4147adbafcb4a00fc450a2_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMjEvZnJhZzowZWY2M2NjZTNmMjk0ZGZjOWJlMzhhYWYwZmMyYTQ4Yi90YWJsZTphNDdlYTI3MDk3NTA0ZGU2ODQ1YTc1NWM0ZWQyNzcyNS90YWJsZXJhbmdlOmE0N2VhMjcwOTc1MDRkZTY4NDVhNzU1YzRlZDI3NzI1XzEzLTExLTEtMS0zNjQ5Mg_0dbbc8f3-e837-49bc-bf46-5b5f826e44e8"
      unitRef="usd">15203000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i0aa78e50814f49e9ad96c352399da780_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMjEvZnJhZzowZWY2M2NjZTNmMjk0ZGZjOWJlMzhhYWYwZmMyYTQ4Yi90YWJsZTphNDdlYTI3MDk3NTA0ZGU2ODQ1YTc1NWM0ZWQyNzcyNS90YWJsZXJhbmdlOmE0N2VhMjcwOTc1MDRkZTY4NDVhNzU1YzRlZDI3NzI1XzE0LTEtMS0xLTM2NDky_3f5d77d8-a241-44c8-98de-10ff0ec50d33"
      unitRef="usd">394328000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ic29edb3405614f9a9149c89d25008350_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMjEvZnJhZzowZWY2M2NjZTNmMjk0ZGZjOWJlMzhhYWYwZmMyYTQ4Yi90YWJsZTphNDdlYTI3MDk3NTA0ZGU2ODQ1YTc1NWM0ZWQyNzcyNS90YWJsZXJhbmdlOmE0N2VhMjcwOTc1MDRkZTY4NDVhNzU1YzRlZDI3NzI1XzE0LTMtMS0xLTM2NDky_616e73fb-41d6-41bf-a202-d38d2a8aba03"
      unitRef="usd">278217000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i424e54d030c64f9c9b3a971c4a6c858d_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMjEvZnJhZzowZWY2M2NjZTNmMjk0ZGZjOWJlMzhhYWYwZmMyYTQ4Yi90YWJsZTphNDdlYTI3MDk3NTA0ZGU2ODQ1YTc1NWM0ZWQyNzcyNS90YWJsZXJhbmdlOmE0N2VhMjcwOTc1MDRkZTY4NDVhNzU1YzRlZDI3NzI1XzE0LTUtMS0xLTM2NDky_554fd336-8dcc-49c6-b092-c1efb89f10b5"
      unitRef="usd">-626000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i585a3b5e60524401a57bad2ad2ffe307_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMjEvZnJhZzowZWY2M2NjZTNmMjk0ZGZjOWJlMzhhYWYwZmMyYTQ4Yi90YWJsZTphNDdlYTI3MDk3NTA0ZGU2ODQ1YTc1NWM0ZWQyNzcyNS90YWJsZXJhbmdlOmE0N2VhMjcwOTc1MDRkZTY4NDVhNzU1YzRlZDI3NzI1XzE0LTctMS0xLTM2NDky_b8c4ae30-3e31-4ce8-ab8b-0e576f5c0a14"
      unitRef="usd">671919000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ifb609f7da9704b688626efcd5acd234c_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMjEvZnJhZzowZWY2M2NjZTNmMjk0ZGZjOWJlMzhhYWYwZmMyYTQ4Yi90YWJsZTphNDdlYTI3MDk3NTA0ZGU2ODQ1YTc1NWM0ZWQyNzcyNS90YWJsZXJhbmdlOmE0N2VhMjcwOTc1MDRkZTY4NDVhNzU1YzRlZDI3NzI1XzE0LTktMS0xLTM2NDky_067c8144-47b0-4777-8449-9e3e48d6e330"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ie0aa3b0e3e5a4d54a32e0a4b60149c35_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMjEvZnJhZzowZWY2M2NjZTNmMjk0ZGZjOWJlMzhhYWYwZmMyYTQ4Yi90YWJsZTphNDdlYTI3MDk3NTA0ZGU2ODQ1YTc1NWM0ZWQyNzcyNS90YWJsZXJhbmdlOmE0N2VhMjcwOTc1MDRkZTY4NDVhNzU1YzRlZDI3NzI1XzE0LTExLTEtMS0zNjQ5Mg_f00692d9-ed78-4492-bc3b-3447239e45b3"
      unitRef="usd">671919000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i26a4f846df6445f78bba31f5ba0edcdd_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMjEvZnJhZzowZWY2M2NjZTNmMjk0ZGZjOWJlMzhhYWYwZmMyYTQ4Yi90YWJsZTphNDdlYTI3MDk3NTA0ZGU2ODQ1YTc1NWM0ZWQyNzcyNS90YWJsZXJhbmdlOmE0N2VhMjcwOTc1MDRkZTY4NDVhNzU1YzRlZDI3NzI1XzE1LTEtMS0xLTM2NDky_e7463c31-8fde-4abf-8605-dcb46f4cdf2e"
      unitRef="usd">409531000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="if6faab8365e548b981e0edaddae65523_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMjEvZnJhZzowZWY2M2NjZTNmMjk0ZGZjOWJlMzhhYWYwZmMyYTQ4Yi90YWJsZTphNDdlYTI3MDk3NTA0ZGU2ODQ1YTc1NWM0ZWQyNzcyNS90YWJsZXJhbmdlOmE0N2VhMjcwOTc1MDRkZTY4NDVhNzU1YzRlZDI3NzI1XzE1LTMtMS0xLTM2NDky_c38e24a1-b736-44c0-ae19-5887cea3cc48"
      unitRef="usd">278217000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="icb97bc4a90264c0aa3a7d497791a321c_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMjEvZnJhZzowZWY2M2NjZTNmMjk0ZGZjOWJlMzhhYWYwZmMyYTQ4Yi90YWJsZTphNDdlYTI3MDk3NTA0ZGU2ODQ1YTc1NWM0ZWQyNzcyNS90YWJsZXJhbmdlOmE0N2VhMjcwOTc1MDRkZTY4NDVhNzU1YzRlZDI3NzI1XzE1LTUtMS0xLTM2NDky_a6448a42-0abc-4974-9bb6-15a708d2a8f4"
      unitRef="usd">-626000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ice1bdb7b2e1c43bbbb3687fa61bb7bfc_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMjEvZnJhZzowZWY2M2NjZTNmMjk0ZGZjOWJlMzhhYWYwZmMyYTQ4Yi90YWJsZTphNDdlYTI3MDk3NTA0ZGU2ODQ1YTc1NWM0ZWQyNzcyNS90YWJsZXJhbmdlOmE0N2VhMjcwOTc1MDRkZTY4NDVhNzU1YzRlZDI3NzI1XzE1LTctMS0xLTM2NDky_786bdd04-d25b-4db3-918a-545dbef4a530"
      unitRef="usd">687122000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ie97138a13af04a0ebbec53523bd2a882_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMjEvZnJhZzowZWY2M2NjZTNmMjk0ZGZjOWJlMzhhYWYwZmMyYTQ4Yi90YWJsZTphNDdlYTI3MDk3NTA0ZGU2ODQ1YTc1NWM0ZWQyNzcyNS90YWJsZXJhbmdlOmE0N2VhMjcwOTc1MDRkZTY4NDVhNzU1YzRlZDI3NzI1XzE1LTktMS0xLTM2NDky_a76df027-82e1-40a8-adc4-5f350c39c39a"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i3e21049ffc224cacb8134d73c9bb5b38_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMjEvZnJhZzowZWY2M2NjZTNmMjk0ZGZjOWJlMzhhYWYwZmMyYTQ4Yi90YWJsZTphNDdlYTI3MDk3NTA0ZGU2ODQ1YTc1NWM0ZWQyNzcyNS90YWJsZXJhbmdlOmE0N2VhMjcwOTc1MDRkZTY4NDVhNzU1YzRlZDI3NzI1XzE1LTExLTEtMS0zNjQ5Mg_b11b1ffe-c662-4a4a-a3c9-d10787fe54ab"
      unitRef="usd">687122000</us-gaap:Revenues>
    <evh:AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization
      contextRef="i98988f30813349e1a5594e72b40af5b1_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMjEvZnJhZzowZWY2M2NjZTNmMjk0ZGZjOWJlMzhhYWYwZmMyYTQ4Yi90YWJsZTphNDdlYTI3MDk3NTA0ZGU2ODQ1YTc1NWM0ZWQyNzcyNS90YWJsZXJhbmdlOmE0N2VhMjcwOTc1MDRkZTY4NDVhNzU1YzRlZDI3NzI1XzE1LTEtMS0xLTE3Nzc1_a39ce908-376a-49a9-bcd5-3bf5d60d7daf"
      unitRef="usd">17063000</evh:AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization>
    <evh:AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization
      contextRef="i6d991ef4e2e0416f8c7aaaa6175cf843_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMjEvZnJhZzowZWY2M2NjZTNmMjk0ZGZjOWJlMzhhYWYwZmMyYTQ4Yi90YWJsZTphNDdlYTI3MDk3NTA0ZGU2ODQ1YTc1NWM0ZWQyNzcyNS90YWJsZXJhbmdlOmE0N2VhMjcwOTc1MDRkZTY4NDVhNzU1YzRlZDI3NzI1XzE1LTMtMS0xLTE3Nzc1_bd82e9d2-ab3d-4cb5-bc1c-fef8516059c7"
      unitRef="usd">82920000</evh:AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization>
    <evh:AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization
      contextRef="i6750aca4d3ec49afaa3b71a05c995e4e_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMjEvZnJhZzowZWY2M2NjZTNmMjk0ZGZjOWJlMzhhYWYwZmMyYTQ4Yi90YWJsZTphNDdlYTI3MDk3NTA0ZGU2ODQ1YTc1NWM0ZWQyNzcyNS90YWJsZXJhbmdlOmE0N2VhMjcwOTc1MDRkZTY4NDVhNzU1YzRlZDI3NzI1XzE1LTUtMS0xLTE3Nzc1_d13bfdea-b7e6-4237-a378-19ddf97c773d"
      unitRef="usd">99983000</evh:AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization>
    <evh:AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization
      contextRef="i2a43cc2e9054466a9f76a89472b3e611_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMjEvZnJhZzowZWY2M2NjZTNmMjk0ZGZjOWJlMzhhYWYwZmMyYTQ4Yi90YWJsZTphNDdlYTI3MDk3NTA0ZGU2ODQ1YTc1NWM0ZWQyNzcyNS90YWJsZXJhbmdlOmE0N2VhMjcwOTc1MDRkZTY4NDVhNzU1YzRlZDI3NzI1XzE1LTctMS0xLTE3Nzc1_1f4ef299-89a6-4511-9f94-b7fc2aa48e4b"
      unitRef="usd">-33666000</evh:AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization>
    <evh:AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization
      contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMjEvZnJhZzowZWY2M2NjZTNmMjk0ZGZjOWJlMzhhYWYwZmMyYTQ4Yi90YWJsZTphNDdlYTI3MDk3NTA0ZGU2ODQ1YTc1NWM0ZWQyNzcyNS90YWJsZXJhbmdlOmE0N2VhMjcwOTc1MDRkZTY4NDVhNzU1YzRlZDI3NzI1XzE1LTktMS0xLTE3Nzc1_5f8b47d5-c666-4f12-b7a4-866b8928daec"
      unitRef="usd">66317000</evh:AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization>
    <evh:AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization
      contextRef="i00a9fb2f3f914116b87f14e146d04507_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMjEvZnJhZzowZWY2M2NjZTNmMjk0ZGZjOWJlMzhhYWYwZmMyYTQ4Yi90YWJsZTphNDdlYTI3MDk3NTA0ZGU2ODQ1YTc1NWM0ZWQyNzcyNS90YWJsZXJhbmdlOmE0N2VhMjcwOTc1MDRkZTY4NDVhNzU1YzRlZDI3NzI1XzE4LTEtMS0xLTE3Nzc1_f2a29f57-568d-4187-ad68-9dc315bad7ce"
      unitRef="usd">57731000</evh:AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization>
    <evh:AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization
      contextRef="i73877656554945338d08c1e8006fc13a_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMjEvZnJhZzowZWY2M2NjZTNmMjk0ZGZjOWJlMzhhYWYwZmMyYTQ4Yi90YWJsZTphNDdlYTI3MDk3NTA0ZGU2ODQ1YTc1NWM0ZWQyNzcyNS90YWJsZXJhbmdlOmE0N2VhMjcwOTc1MDRkZTY4NDVhNzU1YzRlZDI3NzI1XzE4LTMtMS0xLTE3Nzc1_66ebbc9a-2897-48ad-bdf5-6b57b18f6b9c"
      unitRef="usd">26864000</evh:AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization>
    <evh:AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization
      contextRef="if1e0588b36354ec4ad0fe9d8b69a9b09_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMjEvZnJhZzowZWY2M2NjZTNmMjk0ZGZjOWJlMzhhYWYwZmMyYTQ4Yi90YWJsZTphNDdlYTI3MDk3NTA0ZGU2ODQ1YTc1NWM0ZWQyNzcyNS90YWJsZXJhbmdlOmE0N2VhMjcwOTc1MDRkZTY4NDVhNzU1YzRlZDI3NzI1XzE4LTUtMS0xLTE3Nzc1_73c1148e-2fc2-4be8-ba6e-4eb9e43491af"
      unitRef="usd">84595000</evh:AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization>
    <evh:AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization
      contextRef="i0de9d5a3b6224de8a58bd015afb42ce0_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMjEvZnJhZzowZWY2M2NjZTNmMjk0ZGZjOWJlMzhhYWYwZmMyYTQ4Yi90YWJsZTphNDdlYTI3MDk3NTA0ZGU2ODQ1YTc1NWM0ZWQyNzcyNS90YWJsZXJhbmdlOmE0N2VhMjcwOTc1MDRkZTY4NDVhNzU1YzRlZDI3NzI1XzE4LTctMS0xLTE3Nzc1_0d816693-75c3-4b51-84cc-51d11ba2dcaa"
      unitRef="usd">-36022000</evh:AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization>
    <evh:AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization
      contextRef="i12a6d1161de54547bd29f8efccd4c9b0_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMjEvZnJhZzowZWY2M2NjZTNmMjk0ZGZjOWJlMzhhYWYwZmMyYTQ4Yi90YWJsZTphNDdlYTI3MDk3NTA0ZGU2ODQ1YTc1NWM0ZWQyNzcyNS90YWJsZXJhbmdlOmE0N2VhMjcwOTc1MDRkZTY4NDVhNzU1YzRlZDI3NzI1XzE4LTktMS0xLTE3Nzc1_f942e1c4-b00b-43e5-a7f7-860af0519d16"
      unitRef="usd">48573000</evh:AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization>
    <evh:AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization
      contextRef="i26a4f846df6445f78bba31f5ba0edcdd_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMjEvZnJhZzowZWY2M2NjZTNmMjk0ZGZjOWJlMzhhYWYwZmMyYTQ4Yi90YWJsZTphNDdlYTI3MDk3NTA0ZGU2ODQ1YTc1NWM0ZWQyNzcyNS90YWJsZXJhbmdlOmE0N2VhMjcwOTc1MDRkZTY4NDVhNzU1YzRlZDI3NzI1XzI1LTEtMS0xLTM2NDk0_90b176da-7cbb-491f-b731-545185cd3b7c"
      unitRef="usd">-561000</evh:AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization>
    <evh:AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization
      contextRef="if6faab8365e548b981e0edaddae65523_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMjEvZnJhZzowZWY2M2NjZTNmMjk0ZGZjOWJlMzhhYWYwZmMyYTQ4Yi90YWJsZTphNDdlYTI3MDk3NTA0ZGU2ODQ1YTc1NWM0ZWQyNzcyNS90YWJsZXJhbmdlOmE0N2VhMjcwOTc1MDRkZTY4NDVhNzU1YzRlZDI3NzI1XzI1LTMtMS0xLTM2NDk0_d29a9d97-8a9e-4fdc-aa65-7410f709dc92"
      unitRef="usd">12523000</evh:AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization>
    <evh:AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization
      contextRef="ice1bdb7b2e1c43bbbb3687fa61bb7bfc_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMjEvZnJhZzowZWY2M2NjZTNmMjk0ZGZjOWJlMzhhYWYwZmMyYTQ4Yi90YWJsZTphNDdlYTI3MDk3NTA0ZGU2ODQ1YTc1NWM0ZWQyNzcyNS90YWJsZXJhbmdlOmE0N2VhMjcwOTc1MDRkZTY4NDVhNzU1YzRlZDI3NzI1XzI1LTUtMS0xLTM2NDk0_8a00d8cb-4f84-4e82-8ed6-bfa52f71cf44"
      unitRef="usd">11962000</evh:AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization>
    <evh:AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization
      contextRef="ie97138a13af04a0ebbec53523bd2a882_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMjEvZnJhZzowZWY2M2NjZTNmMjk0ZGZjOWJlMzhhYWYwZmMyYTQ4Yi90YWJsZTphNDdlYTI3MDk3NTA0ZGU2ODQ1YTc1NWM0ZWQyNzcyNS90YWJsZXJhbmdlOmE0N2VhMjcwOTc1MDRkZTY4NDVhNzU1YzRlZDI3NzI1XzI1LTctMS0xLTM2NDk0_32912dc7-6805-437b-9e77-fb510f6eaf26"
      unitRef="usd">-25793000</evh:AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization>
    <evh:AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization
      contextRef="i3e21049ffc224cacb8134d73c9bb5b38_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMjEvZnJhZzowZWY2M2NjZTNmMjk0ZGZjOWJlMzhhYWYwZmMyYTQ4Yi90YWJsZTphNDdlYTI3MDk3NTA0ZGU2ODQ1YTc1NWM0ZWQyNzcyNS90YWJsZXJhbmdlOmE0N2VhMjcwOTc1MDRkZTY4NDVhNzU1YzRlZDI3NzI1XzI1LTktMS0xLTM2NDk0_89b29e6e-43fa-46aa-9683-b5f3499431db"
      unitRef="usd">-13831000</evh:AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization>
    <us-gaap:ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock
      contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMjEvZnJhZzowZWY2M2NjZTNmMjk0ZGZjOWJlMzhhYWYwZmMyYTQ4Yi90ZXh0cmVnaW9uOjBlZjYzY2NlM2YyOTRkZmM5YmUzOGFhZjBmYzJhNDhiXzM0NjE_be03bde3-1fac-4797-a4ec-4c270dccb219">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents our reconciliation of consolidated segments total Adjusted EBITDA to net loss attributable to common shareholders of Evolent Health, Inc. for the years ended December 31, 2021, 2020 and 2019 (in thousands): &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:380.50pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:48.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:48.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:48.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;For the Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Net loss attributable to common shareholders of Evolent Health, Inc.&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(37,601)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(334,246)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(301,971)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;407&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,633&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,406&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(25,425)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(28,325)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(14,555)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(Provision) benefit for income taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(483)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,368&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,795&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Depreciation and amortization expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(60,037)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(60,835)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(60,323)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Equity method investment impairment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(47,133)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gain on transfer of membership&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45,938&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Loss on repayment of debt, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(21,343)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Loss on extinguishment of debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,789)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goodwill impairment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(215,100)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(199,800)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gain (loss) from equity method investees&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,179&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,039&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9,465)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gain (loss) on disposal of assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(698)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change in fair value of contingent consideration and indemnification asset&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(13,281)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,860)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,997&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net loss attributable to non-controlling interests&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,609&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other income (expense), net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(146)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(118)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(489)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Purchase accounting adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,915)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Repositioning costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7,318)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,275)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock-based compensation expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(16,711)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(14,606)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(15,618)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Severance costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(198)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8,986)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(17,350)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amortization of contract cost assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(476)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,944)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,876)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Strategy and shareholder advisory expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6,513)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Acquisition costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,194)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,116)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(10,769)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gain (loss) from discontinued operations &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7,317)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6,074)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,613&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Adjusted EBITDA&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;66,317&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;48,573&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(13,831)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt"&gt;Includes $6.8&#160;million gain on disposal of discontinued operations for the year ended December 31, 2021.&lt;/span&gt;&lt;/div&gt;</us-gaap:ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMjEvZnJhZzowZWY2M2NjZTNmMjk0ZGZjOWJlMzhhYWYwZmMyYTQ4Yi90YWJsZTpiYTNmZWJkNTZkYzc0YTM4OGVhODhlYjg0ZGRkNTBlZS90YWJsZXJhbmdlOmJhM2ZlYmQ1NmRjNzRhMzg4ZWE4OGViODRkZGQ1MGVlXzItNS0xLTEtMTc3NzU_19b0e485-6260-41f1-b4e9-3c97c234c728"
      unitRef="usd">-37601000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted
      contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMjEvZnJhZzowZWY2M2NjZTNmMjk0ZGZjOWJlMzhhYWYwZmMyYTQ4Yi90YWJsZTpiYTNmZWJkNTZkYzc0YTM4OGVhODhlYjg0ZGRkNTBlZS90YWJsZXJhbmdlOmJhM2ZlYmQ1NmRjNzRhMzg4ZWE4OGViODRkZGQ1MGVlXzItNS0xLTEtMTc3NzU_34c1e7e0-fc69-4bdc-be43-ddb3ef807107"
      unitRef="usd">-37601000</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="i12a6d1161de54547bd29f8efccd4c9b0_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMjEvZnJhZzowZWY2M2NjZTNmMjk0ZGZjOWJlMzhhYWYwZmMyYTQ4Yi90YWJsZTpiYTNmZWJkNTZkYzc0YTM4OGVhODhlYjg0ZGRkNTBlZS90YWJsZXJhbmdlOmJhM2ZlYmQ1NmRjNzRhMzg4ZWE4OGViODRkZGQ1MGVlXzItNy0xLTEtMTc3NzU_47276093-49df-42a8-9bbd-a4f0df34d037"
      unitRef="usd">-334246000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted
      contextRef="i12a6d1161de54547bd29f8efccd4c9b0_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMjEvZnJhZzowZWY2M2NjZTNmMjk0ZGZjOWJlMzhhYWYwZmMyYTQ4Yi90YWJsZTpiYTNmZWJkNTZkYzc0YTM4OGVhODhlYjg0ZGRkNTBlZS90YWJsZXJhbmdlOmJhM2ZlYmQ1NmRjNzRhMzg4ZWE4OGViODRkZGQ1MGVlXzItNy0xLTEtMTc3NzU_e8f68bad-99dd-4b99-9acb-741a4f5652df"
      unitRef="usd">-334246000</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="i3e21049ffc224cacb8134d73c9bb5b38_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMjEvZnJhZzowZWY2M2NjZTNmMjk0ZGZjOWJlMzhhYWYwZmMyYTQ4Yi90YWJsZTpiYTNmZWJkNTZkYzc0YTM4OGVhODhlYjg0ZGRkNTBlZS90YWJsZXJhbmdlOmJhM2ZlYmQ1NmRjNzRhMzg4ZWE4OGViODRkZGQ1MGVlXzItNS0xLTEtMjMyMzY_436a8d3c-073f-4296-af03-689f7e52133b"
      unitRef="usd">-301971000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted
      contextRef="i3e21049ffc224cacb8134d73c9bb5b38_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMjEvZnJhZzowZWY2M2NjZTNmMjk0ZGZjOWJlMzhhYWYwZmMyYTQ4Yi90YWJsZTpiYTNmZWJkNTZkYzc0YTM4OGVhODhlYjg0ZGRkNTBlZS90YWJsZXJhbmdlOmJhM2ZlYmQ1NmRjNzRhMzg4ZWE4OGViODRkZGQ1MGVlXzItNS0xLTEtMjMyMzY_a8db8b9f-7556-4b88-8d4a-6b128c94ac69"
      unitRef="usd">-301971000</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
    <us-gaap:InvestmentIncomeInterest
      contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMjEvZnJhZzowZWY2M2NjZTNmMjk0ZGZjOWJlMzhhYWYwZmMyYTQ4Yi90YWJsZTpiYTNmZWJkNTZkYzc0YTM4OGVhODhlYjg0ZGRkNTBlZS90YWJsZXJhbmdlOmJhM2ZlYmQ1NmRjNzRhMzg4ZWE4OGViODRkZGQ1MGVlXzQtNS0xLTEtMTc3NzU_ed8e7c16-ab33-49de-b138-dcd1658371e1"
      unitRef="usd">407000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="i12a6d1161de54547bd29f8efccd4c9b0_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMjEvZnJhZzowZWY2M2NjZTNmMjk0ZGZjOWJlMzhhYWYwZmMyYTQ4Yi90YWJsZTpiYTNmZWJkNTZkYzc0YTM4OGVhODhlYjg0ZGRkNTBlZS90YWJsZXJhbmdlOmJhM2ZlYmQ1NmRjNzRhMzg4ZWE4OGViODRkZGQ1MGVlXzQtNy0xLTEtMTc3NzU_2c8a6eb9-f987-4573-a286-c0651b1bac2e"
      unitRef="usd">2633000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="i3e21049ffc224cacb8134d73c9bb5b38_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMjEvZnJhZzowZWY2M2NjZTNmMjk0ZGZjOWJlMzhhYWYwZmMyYTQ4Yi90YWJsZTpiYTNmZWJkNTZkYzc0YTM4OGVhODhlYjg0ZGRkNTBlZS90YWJsZXJhbmdlOmJhM2ZlYmQ1NmRjNzRhMzg4ZWE4OGViODRkZGQ1MGVlXzQtNS0xLTEtMjMyMzY_02a2ab01-df64-405a-8e99-e04063811304"
      unitRef="usd">3406000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InterestExpense
      contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMjEvZnJhZzowZWY2M2NjZTNmMjk0ZGZjOWJlMzhhYWYwZmMyYTQ4Yi90YWJsZTpiYTNmZWJkNTZkYzc0YTM4OGVhODhlYjg0ZGRkNTBlZS90YWJsZXJhbmdlOmJhM2ZlYmQ1NmRjNzRhMzg4ZWE4OGViODRkZGQ1MGVlXzUtNS0xLTEtMTc3NzU_6a78d6c2-1102-41af-9956-e43dca7ba453"
      unitRef="usd">25425000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="i12a6d1161de54547bd29f8efccd4c9b0_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMjEvZnJhZzowZWY2M2NjZTNmMjk0ZGZjOWJlMzhhYWYwZmMyYTQ4Yi90YWJsZTpiYTNmZWJkNTZkYzc0YTM4OGVhODhlYjg0ZGRkNTBlZS90YWJsZXJhbmdlOmJhM2ZlYmQ1NmRjNzRhMzg4ZWE4OGViODRkZGQ1MGVlXzUtNy0xLTEtMTc3NzU_d9178534-310c-4c1b-a213-f3217edea7a4"
      unitRef="usd">28325000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="i3e21049ffc224cacb8134d73c9bb5b38_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMjEvZnJhZzowZWY2M2NjZTNmMjk0ZGZjOWJlMzhhYWYwZmMyYTQ4Yi90YWJsZTpiYTNmZWJkNTZkYzc0YTM4OGVhODhlYjg0ZGRkNTBlZS90YWJsZXJhbmdlOmJhM2ZlYmQ1NmRjNzRhMzg4ZWE4OGViODRkZGQ1MGVlXzUtNS0xLTEtMjMyMzY_7c53cd4e-aeb0-46af-90bb-c9b0f542fead"
      unitRef="usd">14555000</us-gaap:InterestExpense>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMjEvZnJhZzowZWY2M2NjZTNmMjk0ZGZjOWJlMzhhYWYwZmMyYTQ4Yi90YWJsZTpiYTNmZWJkNTZkYzc0YTM4OGVhODhlYjg0ZGRkNTBlZS90YWJsZXJhbmdlOmJhM2ZlYmQ1NmRjNzRhMzg4ZWE4OGViODRkZGQ1MGVlXzYtNS0xLTEtMTc3NzU_8763a587-540c-4c14-8863-d8c100f8a012"
      unitRef="usd">483000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i12a6d1161de54547bd29f8efccd4c9b0_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMjEvZnJhZzowZWY2M2NjZTNmMjk0ZGZjOWJlMzhhYWYwZmMyYTQ4Yi90YWJsZTpiYTNmZWJkNTZkYzc0YTM4OGVhODhlYjg0ZGRkNTBlZS90YWJsZXJhbmdlOmJhM2ZlYmQ1NmRjNzRhMzg4ZWE4OGViODRkZGQ1MGVlXzYtNy0xLTEtMTc3NzU_3177ea9d-bb7b-46a3-9f76-8e3fef64d535"
      unitRef="usd">-2368000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i3e21049ffc224cacb8134d73c9bb5b38_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMjEvZnJhZzowZWY2M2NjZTNmMjk0ZGZjOWJlMzhhYWYwZmMyYTQ4Yi90YWJsZTpiYTNmZWJkNTZkYzc0YTM4OGVhODhlYjg0ZGRkNTBlZS90YWJsZXJhbmdlOmJhM2ZlYmQ1NmRjNzRhMzg4ZWE4OGViODRkZGQ1MGVlXzYtNS0xLTEtMjMyMzY_5cf3f7eb-def7-4142-a84e-9bd30b336afd"
      unitRef="usd">-22795000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:DepreciationAndAmortization
      contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMjEvZnJhZzowZWY2M2NjZTNmMjk0ZGZjOWJlMzhhYWYwZmMyYTQ4Yi90YWJsZTpiYTNmZWJkNTZkYzc0YTM4OGVhODhlYjg0ZGRkNTBlZS90YWJsZXJhbmdlOmJhM2ZlYmQ1NmRjNzRhMzg4ZWE4OGViODRkZGQ1MGVlXzctNS0xLTEtMTc3NzU_f1afa2f1-e1f9-4119-a437-bbb12c50a407"
      unitRef="usd">60037000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="i12a6d1161de54547bd29f8efccd4c9b0_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMjEvZnJhZzowZWY2M2NjZTNmMjk0ZGZjOWJlMzhhYWYwZmMyYTQ4Yi90YWJsZTpiYTNmZWJkNTZkYzc0YTM4OGVhODhlYjg0ZGRkNTBlZS90YWJsZXJhbmdlOmJhM2ZlYmQ1NmRjNzRhMzg4ZWE4OGViODRkZGQ1MGVlXzctNy0xLTEtMTc3NzU_c0c6d424-d639-43ff-ae36-e67743473fb8"
      unitRef="usd">60835000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="i3e21049ffc224cacb8134d73c9bb5b38_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMjEvZnJhZzowZWY2M2NjZTNmMjk0ZGZjOWJlMzhhYWYwZmMyYTQ4Yi90YWJsZTpiYTNmZWJkNTZkYzc0YTM4OGVhODhlYjg0ZGRkNTBlZS90YWJsZXJhbmdlOmJhM2ZlYmQ1NmRjNzRhMzg4ZWE4OGViODRkZGQ1MGVlXzctNS0xLTEtMjMyMzY_b5e73f6a-0246-4d47-b7c9-16644fd4a70c"
      unitRef="usd">60323000</us-gaap:DepreciationAndAmortization>
    <us-gaap:EquityMethodInvestmentOtherThanTemporaryImpairment
      contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMjEvZnJhZzowZWY2M2NjZTNmMjk0ZGZjOWJlMzhhYWYwZmMyYTQ4Yi90YWJsZTpiYTNmZWJkNTZkYzc0YTM4OGVhODhlYjg0ZGRkNTBlZS90YWJsZXJhbmdlOmJhM2ZlYmQ1NmRjNzRhMzg4ZWE4OGViODRkZGQ1MGVlXzgtNS0xLTEtMTc3NzU_314f9217-cff7-4475-9624-e1acebb48df1"
      unitRef="usd">0</us-gaap:EquityMethodInvestmentOtherThanTemporaryImpairment>
    <us-gaap:EquityMethodInvestmentOtherThanTemporaryImpairment
      contextRef="i12a6d1161de54547bd29f8efccd4c9b0_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMjEvZnJhZzowZWY2M2NjZTNmMjk0ZGZjOWJlMzhhYWYwZmMyYTQ4Yi90YWJsZTpiYTNmZWJkNTZkYzc0YTM4OGVhODhlYjg0ZGRkNTBlZS90YWJsZXJhbmdlOmJhM2ZlYmQ1NmRjNzRhMzg4ZWE4OGViODRkZGQ1MGVlXzgtNy0xLTEtMTc3NzU_912eb6b5-901c-4923-9d50-f2ef2320eaee"
      unitRef="usd">47133000</us-gaap:EquityMethodInvestmentOtherThanTemporaryImpairment>
    <us-gaap:EquityMethodInvestmentOtherThanTemporaryImpairment
      contextRef="i3e21049ffc224cacb8134d73c9bb5b38_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMjEvZnJhZzowZWY2M2NjZTNmMjk0ZGZjOWJlMzhhYWYwZmMyYTQ4Yi90YWJsZTpiYTNmZWJkNTZkYzc0YTM4OGVhODhlYjg0ZGRkNTBlZS90YWJsZXJhbmdlOmJhM2ZlYmQ1NmRjNzRhMzg4ZWE4OGViODRkZGQ1MGVlXzgtNS0xLTEtMjMyNDQ_037030bf-fb7c-4f38-88d7-dabe34ff0e65"
      unitRef="usd">0</us-gaap:EquityMethodInvestmentOtherThanTemporaryImpairment>
    <evh:GainOnTransferOfMembership
      contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMjEvZnJhZzowZWY2M2NjZTNmMjk0ZGZjOWJlMzhhYWYwZmMyYTQ4Yi90YWJsZTpiYTNmZWJkNTZkYzc0YTM4OGVhODhlYjg0ZGRkNTBlZS90YWJsZXJhbmdlOmJhM2ZlYmQ1NmRjNzRhMzg4ZWE4OGViODRkZGQ1MGVlXzktNS0xLTEtMTc3NzU_bffb65bb-0bd0-4298-874d-aed5d2b2cef1"
      unitRef="usd">45938000</evh:GainOnTransferOfMembership>
    <evh:GainOnTransferOfMembership
      contextRef="i12a6d1161de54547bd29f8efccd4c9b0_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMjEvZnJhZzowZWY2M2NjZTNmMjk0ZGZjOWJlMzhhYWYwZmMyYTQ4Yi90YWJsZTpiYTNmZWJkNTZkYzc0YTM4OGVhODhlYjg0ZGRkNTBlZS90YWJsZXJhbmdlOmJhM2ZlYmQ1NmRjNzRhMzg4ZWE4OGViODRkZGQ1MGVlXzktNy0xLTEtMTc3NzU_6772e0d8-51ed-4616-afa1-8e59535ee9e2"
      unitRef="usd">0</evh:GainOnTransferOfMembership>
    <evh:GainOnTransferOfMembership
      contextRef="i3e21049ffc224cacb8134d73c9bb5b38_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMjEvZnJhZzowZWY2M2NjZTNmMjk0ZGZjOWJlMzhhYWYwZmMyYTQ4Yi90YWJsZTpiYTNmZWJkNTZkYzc0YTM4OGVhODhlYjg0ZGRkNTBlZS90YWJsZXJhbmdlOmJhM2ZlYmQ1NmRjNzRhMzg4ZWE4OGViODRkZGQ1MGVlXzktNS0xLTEtMjMyNjE_81e05d0a-b599-4bfc-91b4-ab67691eb7cb"
      unitRef="usd">0</evh:GainOnTransferOfMembership>
    <evh:GainLossOnRepaymentOfDebt
      contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMjEvZnJhZzowZWY2M2NjZTNmMjk0ZGZjOWJlMzhhYWYwZmMyYTQ4Yi90YWJsZTpiYTNmZWJkNTZkYzc0YTM4OGVhODhlYjg0ZGRkNTBlZS90YWJsZXJhbmdlOmJhM2ZlYmQ1NmRjNzRhMzg4ZWE4OGViODRkZGQ1MGVlXzEwLTUtMS0xLTE3Nzc1_32c2cc83-604a-4434-8547-4d1ae90769e4"
      unitRef="usd">-21343000</evh:GainLossOnRepaymentOfDebt>
    <evh:GainLossOnRepaymentOfDebt
      contextRef="i12a6d1161de54547bd29f8efccd4c9b0_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMjEvZnJhZzowZWY2M2NjZTNmMjk0ZGZjOWJlMzhhYWYwZmMyYTQ4Yi90YWJsZTpiYTNmZWJkNTZkYzc0YTM4OGVhODhlYjg0ZGRkNTBlZS90YWJsZXJhbmdlOmJhM2ZlYmQ1NmRjNzRhMzg4ZWE4OGViODRkZGQ1MGVlXzEwLTctMS0xLTE3Nzc1_90bb2a7d-d061-42be-8575-98c2928c53fb"
      unitRef="usd">0</evh:GainLossOnRepaymentOfDebt>
    <evh:GainLossOnRepaymentOfDebt
      contextRef="i3e21049ffc224cacb8134d73c9bb5b38_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMjEvZnJhZzowZWY2M2NjZTNmMjk0ZGZjOWJlMzhhYWYwZmMyYTQ4Yi90YWJsZTpiYTNmZWJkNTZkYzc0YTM4OGVhODhlYjg0ZGRkNTBlZS90YWJsZXJhbmdlOmJhM2ZlYmQ1NmRjNzRhMzg4ZWE4OGViODRkZGQ1MGVlXzEwLTUtMS0xLTIzMjY4_580d971e-47b9-476b-9317-03d0130cd807"
      unitRef="usd">0</evh:GainLossOnRepaymentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMjEvZnJhZzowZWY2M2NjZTNmMjk0ZGZjOWJlMzhhYWYwZmMyYTQ4Yi90YWJsZTpiYTNmZWJkNTZkYzc0YTM4OGVhODhlYjg0ZGRkNTBlZS90YWJsZXJhbmdlOmJhM2ZlYmQ1NmRjNzRhMzg4ZWE4OGViODRkZGQ1MGVlXzExLTUtMS0xLTE3Nzc1_88d34f60-54e6-445d-94a8-a2a1fa0905bc"
      unitRef="usd">0</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="i12a6d1161de54547bd29f8efccd4c9b0_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMjEvZnJhZzowZWY2M2NjZTNmMjk0ZGZjOWJlMzhhYWYwZmMyYTQ4Yi90YWJsZTpiYTNmZWJkNTZkYzc0YTM4OGVhODhlYjg0ZGRkNTBlZS90YWJsZXJhbmdlOmJhM2ZlYmQ1NmRjNzRhMzg4ZWE4OGViODRkZGQ1MGVlXzExLTctMS0xLTE3Nzc1_315de6a0-54ab-4d31-a7e8-564a3710365a"
      unitRef="usd">-4789000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="i3e21049ffc224cacb8134d73c9bb5b38_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMjEvZnJhZzowZWY2M2NjZTNmMjk0ZGZjOWJlMzhhYWYwZmMyYTQ4Yi90YWJsZTpiYTNmZWJkNTZkYzc0YTM4OGVhODhlYjg0ZGRkNTBlZS90YWJsZXJhbmdlOmJhM2ZlYmQ1NmRjNzRhMzg4ZWE4OGViODRkZGQ1MGVlXzExLTUtMS0xLTIzMjY4_57f03d61-016b-42db-942d-42cb9d8f1dc0"
      unitRef="usd">0</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMjEvZnJhZzowZWY2M2NjZTNmMjk0ZGZjOWJlMzhhYWYwZmMyYTQ4Yi90YWJsZTpiYTNmZWJkNTZkYzc0YTM4OGVhODhlYjg0ZGRkNTBlZS90YWJsZXJhbmdlOmJhM2ZlYmQ1NmRjNzRhMzg4ZWE4OGViODRkZGQ1MGVlXzEyLTUtMS0xLTE3Nzc1_7ec28ccb-31ef-4083-96d9-d0362787dc96"
      unitRef="usd">0</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="i12a6d1161de54547bd29f8efccd4c9b0_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMjEvZnJhZzowZWY2M2NjZTNmMjk0ZGZjOWJlMzhhYWYwZmMyYTQ4Yi90YWJsZTpiYTNmZWJkNTZkYzc0YTM4OGVhODhlYjg0ZGRkNTBlZS90YWJsZXJhbmdlOmJhM2ZlYmQ1NmRjNzRhMzg4ZWE4OGViODRkZGQ1MGVlXzEyLTctMS0xLTE3Nzc1_f3903d0a-d181-4884-96b8-217fb1f14fac"
      unitRef="usd">215100000</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="i3e21049ffc224cacb8134d73c9bb5b38_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMjEvZnJhZzowZWY2M2NjZTNmMjk0ZGZjOWJlMzhhYWYwZmMyYTQ4Yi90YWJsZTpiYTNmZWJkNTZkYzc0YTM4OGVhODhlYjg0ZGRkNTBlZS90YWJsZXJhbmdlOmJhM2ZlYmQ1NmRjNzRhMzg4ZWE4OGViODRkZGQ1MGVlXzEyLTUtMS0xLTIzMjY4_4c295aac-32ce-4fb7-81cf-7060c596f9a7"
      unitRef="usd">199800000</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMjEvZnJhZzowZWY2M2NjZTNmMjk0ZGZjOWJlMzhhYWYwZmMyYTQ4Yi90YWJsZTpiYTNmZWJkNTZkYzc0YTM4OGVhODhlYjg0ZGRkNTBlZS90YWJsZXJhbmdlOmJhM2ZlYmQ1NmRjNzRhMzg4ZWE4OGViODRkZGQ1MGVlXzEzLTUtMS0xLTE3Nzc1_2f0cbad5-d099-47d2-83ca-4dbf81be40bb"
      unitRef="usd">13179000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="i12a6d1161de54547bd29f8efccd4c9b0_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMjEvZnJhZzowZWY2M2NjZTNmMjk0ZGZjOWJlMzhhYWYwZmMyYTQ4Yi90YWJsZTpiYTNmZWJkNTZkYzc0YTM4OGVhODhlYjg0ZGRkNTBlZS90YWJsZXJhbmdlOmJhM2ZlYmQ1NmRjNzRhMzg4ZWE4OGViODRkZGQ1MGVlXzEzLTctMS0xLTE3Nzc1_1f074cc6-4f96-446a-b901-7ff7a087c6a5"
      unitRef="usd">10039000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="i3e21049ffc224cacb8134d73c9bb5b38_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMjEvZnJhZzowZWY2M2NjZTNmMjk0ZGZjOWJlMzhhYWYwZmMyYTQ4Yi90YWJsZTpiYTNmZWJkNTZkYzc0YTM4OGVhODhlYjg0ZGRkNTBlZS90YWJsZXJhbmdlOmJhM2ZlYmQ1NmRjNzRhMzg4ZWE4OGViODRkZGQ1MGVlXzEzLTUtMS0xLTIzMjc1_290de68e-f36e-414b-bd27-42ca3723287b"
      unitRef="usd">-9465000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:GainLossOnDispositionOfAssets1
      contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMjEvZnJhZzowZWY2M2NjZTNmMjk0ZGZjOWJlMzhhYWYwZmMyYTQ4Yi90YWJsZTpiYTNmZWJkNTZkYzc0YTM4OGVhODhlYjg0ZGRkNTBlZS90YWJsZXJhbmdlOmJhM2ZlYmQ1NmRjNzRhMzg4ZWE4OGViODRkZGQ1MGVlXzE0LTUtMS0xLTE3Nzc1_5362c6cf-ae2c-41ac-a47b-02c1baebd924"
      unitRef="usd">0</us-gaap:GainLossOnDispositionOfAssets1>
    <us-gaap:GainLossOnDispositionOfAssets1
      contextRef="i12a6d1161de54547bd29f8efccd4c9b0_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMjEvZnJhZzowZWY2M2NjZTNmMjk0ZGZjOWJlMzhhYWYwZmMyYTQ4Yi90YWJsZTpiYTNmZWJkNTZkYzc0YTM4OGVhODhlYjg0ZGRkNTBlZS90YWJsZXJhbmdlOmJhM2ZlYmQ1NmRjNzRhMzg4ZWE4OGViODRkZGQ1MGVlXzE0LTctMS0xLTE3Nzc1_cc529727-46a0-4a88-921b-1d9c5687d220"
      unitRef="usd">-698000</us-gaap:GainLossOnDispositionOfAssets1>
    <us-gaap:GainLossOnDispositionOfAssets1
      contextRef="i3e21049ffc224cacb8134d73c9bb5b38_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMjEvZnJhZzowZWY2M2NjZTNmMjk0ZGZjOWJlMzhhYWYwZmMyYTQ4Yi90YWJsZTpiYTNmZWJkNTZkYzc0YTM4OGVhODhlYjg0ZGRkNTBlZS90YWJsZXJhbmdlOmJhM2ZlYmQ1NmRjNzRhMzg4ZWE4OGViODRkZGQ1MGVlXzE0LTUtMS0xLTIzMjc1_2aa07e04-b162-4e6e-a548-8f79b0f359ce"
      unitRef="usd">9600000</us-gaap:GainLossOnDispositionOfAssets1>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
      contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMjEvZnJhZzowZWY2M2NjZTNmMjk0ZGZjOWJlMzhhYWYwZmMyYTQ4Yi90YWJsZTpiYTNmZWJkNTZkYzc0YTM4OGVhODhlYjg0ZGRkNTBlZS90YWJsZXJhbmdlOmJhM2ZlYmQ1NmRjNzRhMzg4ZWE4OGViODRkZGQ1MGVlXzE1LTUtMS0xLTE3Nzc1_f5075020-c202-43a7-80e8-ab5df856f8f3"
      unitRef="usd">13281000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
      contextRef="i12a6d1161de54547bd29f8efccd4c9b0_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMjEvZnJhZzowZWY2M2NjZTNmMjk0ZGZjOWJlMzhhYWYwZmMyYTQ4Yi90YWJsZTpiYTNmZWJkNTZkYzc0YTM4OGVhODhlYjg0ZGRkNTBlZS90YWJsZXJhbmdlOmJhM2ZlYmQ1NmRjNzRhMzg4ZWE4OGViODRkZGQ1MGVlXzE1LTctMS0xLTE3Nzc1_aeced91b-7536-465a-9a60-30f4047f35e3"
      unitRef="usd">3860000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
      contextRef="i3e21049ffc224cacb8134d73c9bb5b38_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMjEvZnJhZzowZWY2M2NjZTNmMjk0ZGZjOWJlMzhhYWYwZmMyYTQ4Yi90YWJsZTpiYTNmZWJkNTZkYzc0YTM4OGVhODhlYjg0ZGRkNTBlZS90YWJsZXJhbmdlOmJhM2ZlYmQ1NmRjNzRhMzg4ZWE4OGViODRkZGQ1MGVlXzE1LTUtMS0xLTIzMjgy_1042ea0d-d1ac-40df-bcee-cf06f6156393"
      unitRef="usd">-3997000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMjEvZnJhZzowZWY2M2NjZTNmMjk0ZGZjOWJlMzhhYWYwZmMyYTQ4Yi90YWJsZTpiYTNmZWJkNTZkYzc0YTM4OGVhODhlYjg0ZGRkNTBlZS90YWJsZXJhbmdlOmJhM2ZlYmQ1NmRjNzRhMzg4ZWE4OGViODRkZGQ1MGVlXzE2LTUtMS0xLTE3Nzc1_51e15338-b561-4630-ba7b-1004644fe8a0"
      unitRef="usd">0</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="i12a6d1161de54547bd29f8efccd4c9b0_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMjEvZnJhZzowZWY2M2NjZTNmMjk0ZGZjOWJlMzhhYWYwZmMyYTQ4Yi90YWJsZTpiYTNmZWJkNTZkYzc0YTM4OGVhODhlYjg0ZGRkNTBlZS90YWJsZXJhbmdlOmJhM2ZlYmQ1NmRjNzRhMzg4ZWE4OGViODRkZGQ1MGVlXzE2LTctMS0xLTE3Nzc1_f720fe92-dbd8-4120-8de5-cda5648484c9"
      unitRef="usd">0</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="i3e21049ffc224cacb8134d73c9bb5b38_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMjEvZnJhZzowZWY2M2NjZTNmMjk0ZGZjOWJlMzhhYWYwZmMyYTQ4Yi90YWJsZTpiYTNmZWJkNTZkYzc0YTM4OGVhODhlYjg0ZGRkNTBlZS90YWJsZXJhbmdlOmJhM2ZlYmQ1NmRjNzRhMzg4ZWE4OGViODRkZGQ1MGVlXzE2LTUtMS0xLTIzMjg5_1ce9bbe1-da9b-465b-b84a-20e4d750bfff"
      unitRef="usd">-3609000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMjEvZnJhZzowZWY2M2NjZTNmMjk0ZGZjOWJlMzhhYWYwZmMyYTQ4Yi90YWJsZTpiYTNmZWJkNTZkYzc0YTM4OGVhODhlYjg0ZGRkNTBlZS90YWJsZXJhbmdlOmJhM2ZlYmQ1NmRjNzRhMzg4ZWE4OGViODRkZGQ1MGVlXzE3LTUtMS0xLTE3Nzc1_91b26e5a-4311-43ad-9199-79d6719831d4"
      unitRef="usd">-146000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i12a6d1161de54547bd29f8efccd4c9b0_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMjEvZnJhZzowZWY2M2NjZTNmMjk0ZGZjOWJlMzhhYWYwZmMyYTQ4Yi90YWJsZTpiYTNmZWJkNTZkYzc0YTM4OGVhODhlYjg0ZGRkNTBlZS90YWJsZXJhbmdlOmJhM2ZlYmQ1NmRjNzRhMzg4ZWE4OGViODRkZGQ1MGVlXzE3LTctMS0xLTE3Nzc1_944f36c7-5913-4fa8-9f12-77ab8e2f8862"
      unitRef="usd">-118000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i3e21049ffc224cacb8134d73c9bb5b38_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMjEvZnJhZzowZWY2M2NjZTNmMjk0ZGZjOWJlMzhhYWYwZmMyYTQ4Yi90YWJsZTpiYTNmZWJkNTZkYzc0YTM4OGVhODhlYjg0ZGRkNTBlZS90YWJsZXJhbmdlOmJhM2ZlYmQ1NmRjNzRhMzg4ZWE4OGViODRkZGQ1MGVlXzE3LTUtMS0xLTIzMjk2_28296252-bcb6-4083-914c-ff96bf48b709"
      unitRef="usd">-489000</us-gaap:OtherNonoperatingIncomeExpense>
    <evh:PurchaseAccountingAdjustments
      contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMjEvZnJhZzowZWY2M2NjZTNmMjk0ZGZjOWJlMzhhYWYwZmMyYTQ4Yi90YWJsZTpiYTNmZWJkNTZkYzc0YTM4OGVhODhlYjg0ZGRkNTBlZS90YWJsZXJhbmdlOmJhM2ZlYmQ1NmRjNzRhMzg4ZWE4OGViODRkZGQ1MGVlXzE4LTEtMS0xLTMzNTc0_cf14d18b-ec0a-4ef9-90a7-d2277cbe7f57"
      unitRef="usd">0</evh:PurchaseAccountingAdjustments>
    <evh:PurchaseAccountingAdjustments
      contextRef="i12a6d1161de54547bd29f8efccd4c9b0_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMjEvZnJhZzowZWY2M2NjZTNmMjk0ZGZjOWJlMzhhYWYwZmMyYTQ4Yi90YWJsZTpiYTNmZWJkNTZkYzc0YTM4OGVhODhlYjg0ZGRkNTBlZS90YWJsZXJhbmdlOmJhM2ZlYmQ1NmRjNzRhMzg4ZWE4OGViODRkZGQ1MGVlXzE4LTMtMS0xLTMzNTc0_6d4e0543-9fac-4239-b5dc-14173ab78184"
      unitRef="usd">0</evh:PurchaseAccountingAdjustments>
    <evh:PurchaseAccountingAdjustments
      contextRef="i3e21049ffc224cacb8134d73c9bb5b38_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMjEvZnJhZzowZWY2M2NjZTNmMjk0ZGZjOWJlMzhhYWYwZmMyYTQ4Yi90YWJsZTpiYTNmZWJkNTZkYzc0YTM4OGVhODhlYjg0ZGRkNTBlZS90YWJsZXJhbmdlOmJhM2ZlYmQ1NmRjNzRhMzg4ZWE4OGViODRkZGQ1MGVlXzE4LTUtMS0xLTMzNTc0_a3daf900-6628-4b37-846e-cd7b93b9643b"
      unitRef="usd">1915000</evh:PurchaseAccountingAdjustments>
    <us-gaap:RestructuringCharges
      contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMjEvZnJhZzowZWY2M2NjZTNmMjk0ZGZjOWJlMzhhYWYwZmMyYTQ4Yi90YWJsZTpiYTNmZWJkNTZkYzc0YTM4OGVhODhlYjg0ZGRkNTBlZS90YWJsZXJhbmdlOmJhM2ZlYmQ1NmRjNzRhMzg4ZWE4OGViODRkZGQ1MGVlXzE4LTUtMS0xLTE3Nzc1_5910620a-e0b9-42f3-bb48-79d69752f3b1"
      unitRef="usd">7318000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges
      contextRef="i12a6d1161de54547bd29f8efccd4c9b0_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMjEvZnJhZzowZWY2M2NjZTNmMjk0ZGZjOWJlMzhhYWYwZmMyYTQ4Yi90YWJsZTpiYTNmZWJkNTZkYzc0YTM4OGVhODhlYjg0ZGRkNTBlZS90YWJsZXJhbmdlOmJhM2ZlYmQ1NmRjNzRhMzg4ZWE4OGViODRkZGQ1MGVlXzE4LTctMS0xLTE3Nzc1_d22f66c6-fdc9-4a92-a058-191194888607"
      unitRef="usd">1275000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges
      contextRef="i3e21049ffc224cacb8134d73c9bb5b38_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMjEvZnJhZzowZWY2M2NjZTNmMjk0ZGZjOWJlMzhhYWYwZmMyYTQ4Yi90YWJsZTpiYTNmZWJkNTZkYzc0YTM4OGVhODhlYjg0ZGRkNTBlZS90YWJsZXJhbmdlOmJhM2ZlYmQ1NmRjNzRhMzg4ZWE4OGViODRkZGQ1MGVlXzE4LTUtMS0xLTIzMzAz_0493e0d4-f317-46f2-88f1-450c0556cfe9"
      unitRef="usd">0</us-gaap:RestructuringCharges>
    <evh:SharebasedCompensationIncludingOnetimeAdjustment
      contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMjEvZnJhZzowZWY2M2NjZTNmMjk0ZGZjOWJlMzhhYWYwZmMyYTQ4Yi90YWJsZTpiYTNmZWJkNTZkYzc0YTM4OGVhODhlYjg0ZGRkNTBlZS90YWJsZXJhbmdlOmJhM2ZlYmQ1NmRjNzRhMzg4ZWE4OGViODRkZGQ1MGVlXzE5LTUtMS0xLTE3Nzc1_6900a919-aedc-4306-8e62-d6cf7a47060c"
      unitRef="usd">16711000</evh:SharebasedCompensationIncludingOnetimeAdjustment>
    <evh:SharebasedCompensationIncludingOnetimeAdjustment
      contextRef="i12a6d1161de54547bd29f8efccd4c9b0_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMjEvZnJhZzowZWY2M2NjZTNmMjk0ZGZjOWJlMzhhYWYwZmMyYTQ4Yi90YWJsZTpiYTNmZWJkNTZkYzc0YTM4OGVhODhlYjg0ZGRkNTBlZS90YWJsZXJhbmdlOmJhM2ZlYmQ1NmRjNzRhMzg4ZWE4OGViODRkZGQ1MGVlXzE5LTctMS0xLTE3Nzc1_c9247590-aeea-4eaf-b705-215fbb707484"
      unitRef="usd">14606000</evh:SharebasedCompensationIncludingOnetimeAdjustment>
    <evh:SharebasedCompensationIncludingOnetimeAdjustment
      contextRef="i3e21049ffc224cacb8134d73c9bb5b38_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMjEvZnJhZzowZWY2M2NjZTNmMjk0ZGZjOWJlMzhhYWYwZmMyYTQ4Yi90YWJsZTpiYTNmZWJkNTZkYzc0YTM4OGVhODhlYjg0ZGRkNTBlZS90YWJsZXJhbmdlOmJhM2ZlYmQ1NmRjNzRhMzg4ZWE4OGViODRkZGQ1MGVlXzE5LTUtMS0xLTIzMzAz_593b31fb-2dca-42b4-9353-1f02ed38e177"
      unitRef="usd">15618000</evh:SharebasedCompensationIncludingOnetimeAdjustment>
    <us-gaap:SeveranceCosts1
      contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMjEvZnJhZzowZWY2M2NjZTNmMjk0ZGZjOWJlMzhhYWYwZmMyYTQ4Yi90YWJsZTpiYTNmZWJkNTZkYzc0YTM4OGVhODhlYjg0ZGRkNTBlZS90YWJsZXJhbmdlOmJhM2ZlYmQ1NmRjNzRhMzg4ZWE4OGViODRkZGQ1MGVlXzIwLTUtMS0xLTE3Nzc1_df3dee07-d709-4416-80d0-ce17a94396e7"
      unitRef="usd">198000</us-gaap:SeveranceCosts1>
    <us-gaap:SeveranceCosts1
      contextRef="i12a6d1161de54547bd29f8efccd4c9b0_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMjEvZnJhZzowZWY2M2NjZTNmMjk0ZGZjOWJlMzhhYWYwZmMyYTQ4Yi90YWJsZTpiYTNmZWJkNTZkYzc0YTM4OGVhODhlYjg0ZGRkNTBlZS90YWJsZXJhbmdlOmJhM2ZlYmQ1NmRjNzRhMzg4ZWE4OGViODRkZGQ1MGVlXzIwLTctMS0xLTE3Nzc1_7e5fa560-0079-47a0-8a0e-9184632ff34f"
      unitRef="usd">8986000</us-gaap:SeveranceCosts1>
    <us-gaap:SeveranceCosts1
      contextRef="i3e21049ffc224cacb8134d73c9bb5b38_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMjEvZnJhZzowZWY2M2NjZTNmMjk0ZGZjOWJlMzhhYWYwZmMyYTQ4Yi90YWJsZTpiYTNmZWJkNTZkYzc0YTM4OGVhODhlYjg0ZGRkNTBlZS90YWJsZXJhbmdlOmJhM2ZlYmQ1NmRjNzRhMzg4ZWE4OGViODRkZGQ1MGVlXzIwLTUtMS0xLTIzMzAz_50e0b383-7fe3-43bb-a8bc-e225630510e0"
      unitRef="usd">17350000</us-gaap:SeveranceCosts1>
    <evh:CapitalizedContractCostAmortizationPurchaseAccountingAdjustments
      contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMjEvZnJhZzowZWY2M2NjZTNmMjk0ZGZjOWJlMzhhYWYwZmMyYTQ4Yi90YWJsZTpiYTNmZWJkNTZkYzc0YTM4OGVhODhlYjg0ZGRkNTBlZS90YWJsZXJhbmdlOmJhM2ZlYmQ1NmRjNzRhMzg4ZWE4OGViODRkZGQ1MGVlXzIxLTUtMS0xLTE3Nzc1_3ee6c607-2133-48ae-8cb6-87855420b6ed"
      unitRef="usd">476000</evh:CapitalizedContractCostAmortizationPurchaseAccountingAdjustments>
    <evh:CapitalizedContractCostAmortizationPurchaseAccountingAdjustments
      contextRef="i12a6d1161de54547bd29f8efccd4c9b0_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMjEvZnJhZzowZWY2M2NjZTNmMjk0ZGZjOWJlMzhhYWYwZmMyYTQ4Yi90YWJsZTpiYTNmZWJkNTZkYzc0YTM4OGVhODhlYjg0ZGRkNTBlZS90YWJsZXJhbmdlOmJhM2ZlYmQ1NmRjNzRhMzg4ZWE4OGViODRkZGQ1MGVlXzIxLTctMS0xLTE3Nzc1_9b068ce6-82e3-4c20-adb2-14ecf45434d8"
      unitRef="usd">3944000</evh:CapitalizedContractCostAmortizationPurchaseAccountingAdjustments>
    <evh:CapitalizedContractCostAmortizationPurchaseAccountingAdjustments
      contextRef="i3e21049ffc224cacb8134d73c9bb5b38_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMjEvZnJhZzowZWY2M2NjZTNmMjk0ZGZjOWJlMzhhYWYwZmMyYTQ4Yi90YWJsZTpiYTNmZWJkNTZkYzc0YTM4OGVhODhlYjg0ZGRkNTBlZS90YWJsZXJhbmdlOmJhM2ZlYmQ1NmRjNzRhMzg4ZWE4OGViODRkZGQ1MGVlXzIxLTUtMS0xLTIzMzEy_342aed0e-1888-4673-99c3-7f244269a549"
      unitRef="usd">2876000</evh:CapitalizedContractCostAmortizationPurchaseAccountingAdjustments>
    <evh:ShareholderAdvisoryServices
      contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMjEvZnJhZzowZWY2M2NjZTNmMjk0ZGZjOWJlMzhhYWYwZmMyYTQ4Yi90YWJsZTpiYTNmZWJkNTZkYzc0YTM4OGVhODhlYjg0ZGRkNTBlZS90YWJsZXJhbmdlOmJhM2ZlYmQ1NmRjNzRhMzg4ZWE4OGViODRkZGQ1MGVlXzIyLTUtMS0xLTE3Nzc1_21cef35a-545d-4781-80a3-952c24dbf6f0"
      unitRef="usd">6513000</evh:ShareholderAdvisoryServices>
    <evh:ShareholderAdvisoryServices
      contextRef="i12a6d1161de54547bd29f8efccd4c9b0_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMjEvZnJhZzowZWY2M2NjZTNmMjk0ZGZjOWJlMzhhYWYwZmMyYTQ4Yi90YWJsZTpiYTNmZWJkNTZkYzc0YTM4OGVhODhlYjg0ZGRkNTBlZS90YWJsZXJhbmdlOmJhM2ZlYmQ1NmRjNzRhMzg4ZWE4OGViODRkZGQ1MGVlXzIyLTctMS0xLTE3Nzc1_5482e81f-a076-4189-92ff-57bf50b64171"
      unitRef="usd">0</evh:ShareholderAdvisoryServices>
    <evh:ShareholderAdvisoryServices
      contextRef="i3e21049ffc224cacb8134d73c9bb5b38_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMjEvZnJhZzowZWY2M2NjZTNmMjk0ZGZjOWJlMzhhYWYwZmMyYTQ4Yi90YWJsZTpiYTNmZWJkNTZkYzc0YTM4OGVhODhlYjg0ZGRkNTBlZS90YWJsZXJhbmdlOmJhM2ZlYmQ1NmRjNzRhMzg4ZWE4OGViODRkZGQ1MGVlXzIyLTUtMS0xLTIzMzEy_f71ccdcd-0d74-45ad-b183-4071b0fe36cf"
      unitRef="usd">0</evh:ShareholderAdvisoryServices>
    <evh:TransactionCosts
      contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMjEvZnJhZzowZWY2M2NjZTNmMjk0ZGZjOWJlMzhhYWYwZmMyYTQ4Yi90YWJsZTpiYTNmZWJkNTZkYzc0YTM4OGVhODhlYjg0ZGRkNTBlZS90YWJsZXJhbmdlOmJhM2ZlYmQ1NmRjNzRhMzg4ZWE4OGViODRkZGQ1MGVlXzIzLTUtMS0xLTE3Nzc1_270e52e5-1739-49e4-b2e0-9e4d632891b3"
      unitRef="usd">4194000</evh:TransactionCosts>
    <evh:TransactionCosts
      contextRef="i12a6d1161de54547bd29f8efccd4c9b0_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMjEvZnJhZzowZWY2M2NjZTNmMjk0ZGZjOWJlMzhhYWYwZmMyYTQ4Yi90YWJsZTpiYTNmZWJkNTZkYzc0YTM4OGVhODhlYjg0ZGRkNTBlZS90YWJsZXJhbmdlOmJhM2ZlYmQ1NmRjNzRhMzg4ZWE4OGViODRkZGQ1MGVlXzIzLTctMS0xLTE3Nzc1_657ca6ab-9c7b-44af-a0e8-4a1ad275ef9e"
      unitRef="usd">2116000</evh:TransactionCosts>
    <evh:TransactionCosts
      contextRef="i3e21049ffc224cacb8134d73c9bb5b38_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMjEvZnJhZzowZWY2M2NjZTNmMjk0ZGZjOWJlMzhhYWYwZmMyYTQ4Yi90YWJsZTpiYTNmZWJkNTZkYzc0YTM4OGVhODhlYjg0ZGRkNTBlZS90YWJsZXJhbmdlOmJhM2ZlYmQ1NmRjNzRhMzg4ZWE4OGViODRkZGQ1MGVlXzIzLTUtMS0xLTIzMzEy_7002bc86-840f-4e36-a16f-6f7a0c33398a"
      unitRef="usd">10769000</evh:TransactionCosts>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax
      contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMjEvZnJhZzowZWY2M2NjZTNmMjk0ZGZjOWJlMzhhYWYwZmMyYTQ4Yi90YWJsZTpiYTNmZWJkNTZkYzc0YTM4OGVhODhlYjg0ZGRkNTBlZS90YWJsZXJhbmdlOmJhM2ZlYmQ1NmRjNzRhMzg4ZWE4OGViODRkZGQ1MGVlXzI0LTUtMS0xLTE3Nzc1_a856c6d6-baae-4acb-be4e-64217d10ef5a"
      unitRef="usd">-7317000</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax
      contextRef="i12a6d1161de54547bd29f8efccd4c9b0_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMjEvZnJhZzowZWY2M2NjZTNmMjk0ZGZjOWJlMzhhYWYwZmMyYTQ4Yi90YWJsZTpiYTNmZWJkNTZkYzc0YTM4OGVhODhlYjg0ZGRkNTBlZS90YWJsZXJhbmdlOmJhM2ZlYmQ1NmRjNzRhMzg4ZWE4OGViODRkZGQ1MGVlXzI0LTctMS0xLTE3Nzc1_f300c02c-2d0e-4c59-a835-a3561e122e63"
      unitRef="usd">-6074000</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax
      contextRef="i3e21049ffc224cacb8134d73c9bb5b38_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMjEvZnJhZzowZWY2M2NjZTNmMjk0ZGZjOWJlMzhhYWYwZmMyYTQ4Yi90YWJsZTpiYTNmZWJkNTZkYzc0YTM4OGVhODhlYjg0ZGRkNTBlZS90YWJsZXJhbmdlOmJhM2ZlYmQ1NmRjNzRhMzg4ZWE4OGViODRkZGQ1MGVlXzI0LTUtMS0xLTIzMzEy_465eefb9-8783-4845-9b2e-d4002de1f108"
      unitRef="usd">1613000</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax>
    <evh:AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization
      contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMjEvZnJhZzowZWY2M2NjZTNmMjk0ZGZjOWJlMzhhYWYwZmMyYTQ4Yi90YWJsZTpiYTNmZWJkNTZkYzc0YTM4OGVhODhlYjg0ZGRkNTBlZS90YWJsZXJhbmdlOmJhM2ZlYmQ1NmRjNzRhMzg4ZWE4OGViODRkZGQ1MGVlXzI1LTUtMS0xLTE3Nzc1_35881580-8928-4553-af01-79c781909b8d"
      unitRef="usd">66317000</evh:AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization>
    <evh:AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization
      contextRef="i12a6d1161de54547bd29f8efccd4c9b0_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMjEvZnJhZzowZWY2M2NjZTNmMjk0ZGZjOWJlMzhhYWYwZmMyYTQ4Yi90YWJsZTpiYTNmZWJkNTZkYzc0YTM4OGVhODhlYjg0ZGRkNTBlZS90YWJsZXJhbmdlOmJhM2ZlYmQ1NmRjNzRhMzg4ZWE4OGViODRkZGQ1MGVlXzI1LTctMS0xLTE3Nzc1_cbe2a6e0-b13b-4e63-882f-5ff6a9231942"
      unitRef="usd">48573000</evh:AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization>
    <evh:AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization
      contextRef="i3e21049ffc224cacb8134d73c9bb5b38_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMjEvZnJhZzowZWY2M2NjZTNmMjk0ZGZjOWJlMzhhYWYwZmMyYTQ4Yi90YWJsZTpiYTNmZWJkNTZkYzc0YTM4OGVhODhlYjg0ZGRkNTBlZS90YWJsZXJhbmdlOmJhM2ZlYmQ1NmRjNzRhMzg4ZWE4OGViODRkZGQ1MGVlXzI1LTUtMS0xLTIzMzE5_299b8e27-3fd8-49d7-880d-2e0c2afb10d3"
      unitRef="usd">-13831000</evh:AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization>
    <us-gaap:DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax
      contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMjEvZnJhZzowZWY2M2NjZTNmMjk0ZGZjOWJlMzhhYWYwZmMyYTQ4Yi90ZXh0cmVnaW9uOjBlZjYzY2NlM2YyOTRkZmM5YmUzOGFhZjBmYzJhNDhiXzMyMTg_1c53a8ed-a6e9-479b-a61d-3b91b1e95ba4"
      unitRef="usd">6800000</us-gaap:DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax>
    <us-gaap:InsuranceDisclosureTextBlock
      contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMjQvZnJhZzo1NDg0NGVmM2I5YjQ0OTEwOTJiNDFhZjRkM2FjMzVkZi90ZXh0cmVnaW9uOjU0ODQ0ZWYzYjliNDQ5MTA5MmI0MWFmNGQzYWMzNWRmXzQ2MzY_d3ddf522-add5-45d3-a476-e73e4b53d6b7">Reserve for Claims and Performance-Based Arrangements&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company maintains reserves for its liabilities related to payments to providers and pharmacies under performance-based arrangements related to its total cost of care and specialty care management services. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Reserves for claims and performance-based arrangements for our EHS and Clinical Solutions segments reflect actual payments under performance-based arrangements and the ultimate cost of claims that have been incurred but not reported, including expected development on reported claims, those that have been reported but not yet paid (reported claims in process), and other medical care expenses and services payable that are primarily composed of accruals for incentives and other amounts payable to health care professionals and facilities. Reserves for claims and performance-based arrangements also reflect estimated amounts owed under the reinsurance agreements, as discussed further in Note 11.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company uses actuarial principles and assumptions that are consistently applied each reporting period and recognizes the actuarial best estimate of the ultimate liability along with a margin for adverse deviation. This approach is consistent with actuarial standards of practice that the liabilities be adequate under moderately adverse conditions.  &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;This liability predominately consists of incurred but not reported amounts and reported claims in process including expected development on reported claims. The liability for reserves related to its total cost of care and specialty care management services is primarily calculated using "completion factors" developed by comparing the claim incurred date to the date claims were paid. Completion factors are impacted by several key items including changes in: 1)&#160;electronic (auto-adjudication) versus manual claim processing, 2)&#160;provider claims submission rates, 3)&#160;membership and 4)&#160;the mix of products.  &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s policy for reserves related to its total cost of care and specialty care management services is to use historical completion factors combined with an analysis of current trends and operational factors to develop current estimates of completion factors. The Company estimates the liability for claims incurred in each month by applying the current estimates of completion factors to the current paid claims data. This approach implicitly assumes that historical completion rates will be a useful indicator for the current period. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For more recent months, and for newer lines of business where there is not sufficient paid claims history to develop completion factors, the Company expects to rely more heavily on medical cost trend and expected loss ratio analysis that reflects expected claim payment patterns and other relevant operational considerations, or authorization analysis. Medical cost trend is primarily impacted by medical service utilization and unit costs that are affected by changes in the level and mix of medical benefits offered, including inpatient, outpatient and pharmacy, the impact of copays and deductibles, changes in provider practices and changes in consumer demographics and consumption behavior. Authorization analysis projects costs on an authorization-level basis and also accounts for the impact of copays and deductibles, unit cost and historic discontinuation rates for treatment. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For each reporting period, the Company compares key assumptions used to establish the reserves for claims and performance-based arrangements to actual experience. When actual experience differs from these assumptions, reserves for claims and performance-based arrangements are adjusted through current period net income. Additionally, the Company evaluates expected future developments and emerging trends that may impact key assumptions. The process used to determine this liability requires the Company to make critical accounting estimates that involve considerable judgment, reflecting the variability inherent in forecasting future claim payments. These estimates are highly sensitive to changes in the Company's key assumptions, specifically completion factors and medical cost trends.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Activity in reserves for claims and performance-based arrangements for the years ended December 31, 2021 and 2020, was as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:539.25pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:226.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:37.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:57.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:3.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:40.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:3.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:41.50pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:3.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:57.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:3.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:40.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="33" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;For the Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:23pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;EHS &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Clinical Solutions &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;EHS &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Clinical Solutions &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Beginning balance&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;56,296&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;122,531&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;178,827&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,265&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50,245&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;54,510&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Incurred costs related to current year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,669&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;449,172&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;457,841&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7,542)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;428,139&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;420,597&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Incurred costs related to prior year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,036&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;73&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,109&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,853&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,878&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Paid costs related to current year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,801&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;337,647&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;358,448&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;106,093&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;358,478&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;464,571&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:539.25pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:226.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:37.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:57.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:3.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:40.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:3.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:41.50pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:3.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:57.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:3.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:40.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Paid costs related to prior year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,544&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100,075&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;125,619&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,123&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,475&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,598&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change during the year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(30,640)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,523&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(19,117)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(112,905)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;62,211&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(50,694)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:23pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Impact of consolidation on reserves for claims and performance-based arrangements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;164,297&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;164,297&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other adjustments &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(38)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,622&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,584&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;639&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,075&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,714&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Ending balance&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,618&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;145,676&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;171,294&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;56,296&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;122,531&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;178,827&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:13.5pt;text-align:justify;text-indent:-13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:31.5pt;text-align:justify;text-indent:-31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:25.44pt"&gt;Costs incurred to provide specialty care management and EVH Passport are recorded within cost of revenue in our statement of operations. &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:31.5pt;text-align:justify;text-indent:-31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:25.44pt"&gt;Amounts exclude $9.9&#160;million related to reserves for claims reclassified to discontinued operations as of December&#160;31, 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:31.5pt;text-align:justify;text-indent:-31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:25.44pt"&gt;Other adjustments to reserves for claims and performance-based arrangements reflect changes in accrual for amounts payable to facilities and amounts owed to our payer partners for claims paid on our behalf.&lt;/span&gt;&lt;/div&gt;</us-gaap:InsuranceDisclosureTextBlock>
    <us-gaap:ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense
      contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMjQvZnJhZzo1NDg0NGVmM2I5YjQ0OTEwOTJiNDFhZjRkM2FjMzVkZi90ZXh0cmVnaW9uOjU0ODQ0ZWYzYjliNDQ5MTA5MmI0MWFmNGQzYWMzNWRmXzQ2MzQ_3d6d15ff-5d13-4538-aa24-149d764eac7d">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Activity in reserves for claims and performance-based arrangements for the years ended December 31, 2021 and 2020, was as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:539.25pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:226.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:37.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:57.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:3.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:40.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:3.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:41.50pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:3.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:57.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:3.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:40.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="33" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;For the Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:23pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;EHS &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Clinical Solutions &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;EHS &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Clinical Solutions &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Beginning balance&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;56,296&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;122,531&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;178,827&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,265&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50,245&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;54,510&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Incurred costs related to current year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,669&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;449,172&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;457,841&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7,542)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;428,139&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;420,597&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Incurred costs related to prior year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,036&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;73&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,109&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,853&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,878&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Paid costs related to current year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,801&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;337,647&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;358,448&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;106,093&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;358,478&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;464,571&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:539.25pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:226.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:37.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:57.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:3.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:40.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:3.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:41.50pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:3.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:57.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:3.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:40.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Paid costs related to prior year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,544&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100,075&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;125,619&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,123&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,475&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,598&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change during the year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(30,640)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,523&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(19,117)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(112,905)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;62,211&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(50,694)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:23pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Impact of consolidation on reserves for claims and performance-based arrangements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;164,297&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;164,297&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other adjustments &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(38)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,622&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,584&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;639&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,075&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,714&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Ending balance&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,618&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;145,676&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;171,294&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;56,296&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;122,531&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;178,827&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:13.5pt;text-align:justify;text-indent:-13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:31.5pt;text-align:justify;text-indent:-31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:25.44pt"&gt;Costs incurred to provide specialty care management and EVH Passport are recorded within cost of revenue in our statement of operations. &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:31.5pt;text-align:justify;text-indent:-31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:25.44pt"&gt;Amounts exclude $9.9&#160;million related to reserves for claims reclassified to discontinued operations as of December&#160;31, 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:31.5pt;text-align:justify;text-indent:-31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:25.44pt"&gt;Other adjustments to reserves for claims and performance-based arrangements reflect changes in accrual for amounts payable to facilities and amounts owed to our payer partners for claims paid on our behalf.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense>
    <us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense
      contextRef="if8fd35766cfc4fa8b1cbf4f3cd8a8dfc_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMjQvZnJhZzo1NDg0NGVmM2I5YjQ0OTEwOTJiNDFhZjRkM2FjMzVkZi90YWJsZTo4MzlkNzA4NWM1MWE0YmU4ODQ2OGRlMGU3Yjg5NGE5Yy90YWJsZXJhbmdlOjgzOWQ3MDg1YzUxYTRiZTg4NDY4ZGUwZTdiODk0YTljXzMtMS0xLTEtMTc3NzU_02244d04-10c1-4b9f-ba7e-caaaaa5d4505"
      unitRef="usd">56296000</us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense>
    <us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense
      contextRef="i5f5145421bc94a90bb8982e11bb80abb_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMjQvZnJhZzo1NDg0NGVmM2I5YjQ0OTEwOTJiNDFhZjRkM2FjMzVkZi90YWJsZTo4MzlkNzA4NWM1MWE0YmU4ODQ2OGRlMGU3Yjg5NGE5Yy90YWJsZXJhbmdlOjgzOWQ3MDg1YzUxYTRiZTg4NDY4ZGUwZTdiODk0YTljXzMtMy0xLTEtMTc3NzU_9760a924-ddbb-48aa-b2ed-1417482c28f5"
      unitRef="usd">122531000</us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense>
    <us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense
      contextRef="ibc0c0c2b8dc04c5698ca0577a54b2e03_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMjQvZnJhZzo1NDg0NGVmM2I5YjQ0OTEwOTJiNDFhZjRkM2FjMzVkZi90YWJsZTo4MzlkNzA4NWM1MWE0YmU4ODQ2OGRlMGU3Yjg5NGE5Yy90YWJsZXJhbmdlOjgzOWQ3MDg1YzUxYTRiZTg4NDY4ZGUwZTdiODk0YTljXzMtNy0xLTEtMTc3NzU_a42680b7-743f-4f72-9f30-5dd050011917"
      unitRef="usd">178827000</us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense>
    <us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense
      contextRef="ida02b25c4b5e464a9545df19946134c1_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMjQvZnJhZzo1NDg0NGVmM2I5YjQ0OTEwOTJiNDFhZjRkM2FjMzVkZi90YWJsZTo4MzlkNzA4NWM1MWE0YmU4ODQ2OGRlMGU3Yjg5NGE5Yy90YWJsZXJhbmdlOjgzOWQ3MDg1YzUxYTRiZTg4NDY4ZGUwZTdiODk0YTljXzMtOS0xLTEtMTc3NzU_d56328da-e3e6-4d1f-b857-d5ebb19b613c"
      unitRef="usd">4265000</us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense>
    <us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense
      contextRef="i14e6a440f7dc431a9e1c85272b43d276_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMjQvZnJhZzo1NDg0NGVmM2I5YjQ0OTEwOTJiNDFhZjRkM2FjMzVkZi90YWJsZTo4MzlkNzA4NWM1MWE0YmU4ODQ2OGRlMGU3Yjg5NGE5Yy90YWJsZXJhbmdlOjgzOWQ3MDg1YzUxYTRiZTg4NDY4ZGUwZTdiODk0YTljXzMtMTEtMS0xLTE3Nzc1_ece0192d-3c9b-4e84-a8bf-bf990af89e6b"
      unitRef="usd">50245000</us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense>
    <us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense
      contextRef="icba6e493923b449aa57c46a563760234_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMjQvZnJhZzo1NDg0NGVmM2I5YjQ0OTEwOTJiNDFhZjRkM2FjMzVkZi90YWJsZTo4MzlkNzA4NWM1MWE0YmU4ODQ2OGRlMGU3Yjg5NGE5Yy90YWJsZXJhbmdlOjgzOWQ3MDg1YzUxYTRiZTg4NDY4ZGUwZTdiODk0YTljXzMtMTUtMS0xLTE3Nzc1_3274df9b-8411-4d13-9b90-a361e8c7fcb6"
      unitRef="usd">54510000</us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense>
    <evh:CurrentYearClaimsAndClaimsAdjustmentExpenseIncludingCostOfGoodsAndServicesSoldExcludingDepreciationAndAmortization
      contextRef="i98988f30813349e1a5594e72b40af5b1_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMjQvZnJhZzo1NDg0NGVmM2I5YjQ0OTEwOTJiNDFhZjRkM2FjMzVkZi90YWJsZTo4MzlkNzA4NWM1MWE0YmU4ODQ2OGRlMGU3Yjg5NGE5Yy90YWJsZXJhbmdlOjgzOWQ3MDg1YzUxYTRiZTg4NDY4ZGUwZTdiODk0YTljXzUtMS0xLTEtMTc3NzU_aa461668-8595-479c-8e16-d6dc2cfe6fe8"
      unitRef="usd">8669000</evh:CurrentYearClaimsAndClaimsAdjustmentExpenseIncludingCostOfGoodsAndServicesSoldExcludingDepreciationAndAmortization>
    <evh:CurrentYearClaimsAndClaimsAdjustmentExpenseIncludingCostOfGoodsAndServicesSoldExcludingDepreciationAndAmortization
      contextRef="i6d991ef4e2e0416f8c7aaaa6175cf843_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMjQvZnJhZzo1NDg0NGVmM2I5YjQ0OTEwOTJiNDFhZjRkM2FjMzVkZi90YWJsZTo4MzlkNzA4NWM1MWE0YmU4ODQ2OGRlMGU3Yjg5NGE5Yy90YWJsZXJhbmdlOjgzOWQ3MDg1YzUxYTRiZTg4NDY4ZGUwZTdiODk0YTljXzUtMy0xLTEtMTc3NzU_9fff9913-aa78-4f5e-b5b9-31e1d7b0615c"
      unitRef="usd">449172000</evh:CurrentYearClaimsAndClaimsAdjustmentExpenseIncludingCostOfGoodsAndServicesSoldExcludingDepreciationAndAmortization>
    <evh:CurrentYearClaimsAndClaimsAdjustmentExpenseIncludingCostOfGoodsAndServicesSoldExcludingDepreciationAndAmortization
      contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMjQvZnJhZzo1NDg0NGVmM2I5YjQ0OTEwOTJiNDFhZjRkM2FjMzVkZi90YWJsZTo4MzlkNzA4NWM1MWE0YmU4ODQ2OGRlMGU3Yjg5NGE5Yy90YWJsZXJhbmdlOjgzOWQ3MDg1YzUxYTRiZTg4NDY4ZGUwZTdiODk0YTljXzUtNy0xLTEtMTc3NzU_6ac78dcf-0057-4d00-966a-f5e39136843c"
      unitRef="usd">457841000</evh:CurrentYearClaimsAndClaimsAdjustmentExpenseIncludingCostOfGoodsAndServicesSoldExcludingDepreciationAndAmortization>
    <evh:CurrentYearClaimsAndClaimsAdjustmentExpenseIncludingCostOfGoodsAndServicesSoldExcludingDepreciationAndAmortization
      contextRef="i00a9fb2f3f914116b87f14e146d04507_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMjQvZnJhZzo1NDg0NGVmM2I5YjQ0OTEwOTJiNDFhZjRkM2FjMzVkZi90YWJsZTo4MzlkNzA4NWM1MWE0YmU4ODQ2OGRlMGU3Yjg5NGE5Yy90YWJsZXJhbmdlOjgzOWQ3MDg1YzUxYTRiZTg4NDY4ZGUwZTdiODk0YTljXzUtOS0xLTEtMTc3NzU_ce89ffa7-4a1f-491a-8840-c1807bc02053"
      unitRef="usd">-7542000</evh:CurrentYearClaimsAndClaimsAdjustmentExpenseIncludingCostOfGoodsAndServicesSoldExcludingDepreciationAndAmortization>
    <evh:CurrentYearClaimsAndClaimsAdjustmentExpenseIncludingCostOfGoodsAndServicesSoldExcludingDepreciationAndAmortization
      contextRef="i73877656554945338d08c1e8006fc13a_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMjQvZnJhZzo1NDg0NGVmM2I5YjQ0OTEwOTJiNDFhZjRkM2FjMzVkZi90YWJsZTo4MzlkNzA4NWM1MWE0YmU4ODQ2OGRlMGU3Yjg5NGE5Yy90YWJsZXJhbmdlOjgzOWQ3MDg1YzUxYTRiZTg4NDY4ZGUwZTdiODk0YTljXzUtMTEtMS0xLTE3Nzc1_68486eaf-20a0-4cfa-ae23-1cfff26a33fb"
      unitRef="usd">428139000</evh:CurrentYearClaimsAndClaimsAdjustmentExpenseIncludingCostOfGoodsAndServicesSoldExcludingDepreciationAndAmortization>
    <evh:CurrentYearClaimsAndClaimsAdjustmentExpenseIncludingCostOfGoodsAndServicesSoldExcludingDepreciationAndAmortization
      contextRef="i12a6d1161de54547bd29f8efccd4c9b0_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMjQvZnJhZzo1NDg0NGVmM2I5YjQ0OTEwOTJiNDFhZjRkM2FjMzVkZi90YWJsZTo4MzlkNzA4NWM1MWE0YmU4ODQ2OGRlMGU3Yjg5NGE5Yy90YWJsZXJhbmdlOjgzOWQ3MDg1YzUxYTRiZTg4NDY4ZGUwZTdiODk0YTljXzUtMTUtMS0xLTE3Nzc1_d83f887d-416b-4110-bd89-3855ff44dbc5"
      unitRef="usd">420597000</evh:CurrentYearClaimsAndClaimsAdjustmentExpenseIncludingCostOfGoodsAndServicesSoldExcludingDepreciationAndAmortization>
    <us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense
      contextRef="i98988f30813349e1a5594e72b40af5b1_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMjQvZnJhZzo1NDg0NGVmM2I5YjQ0OTEwOTJiNDFhZjRkM2FjMzVkZi90YWJsZTo4MzlkNzA4NWM1MWE0YmU4ODQ2OGRlMGU3Yjg5NGE5Yy90YWJsZXJhbmdlOjgzOWQ3MDg1YzUxYTRiZTg4NDY4ZGUwZTdiODk0YTljXzYtMS0xLTEtMTc3NzU_2ae9a346-4f2f-4362-906f-47f68f041b2b"
      unitRef="usd">7036000</us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense>
    <us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense
      contextRef="i6d991ef4e2e0416f8c7aaaa6175cf843_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMjQvZnJhZzo1NDg0NGVmM2I5YjQ0OTEwOTJiNDFhZjRkM2FjMzVkZi90YWJsZTo4MzlkNzA4NWM1MWE0YmU4ODQ2OGRlMGU3Yjg5NGE5Yy90YWJsZXJhbmdlOjgzOWQ3MDg1YzUxYTRiZTg4NDY4ZGUwZTdiODk0YTljXzYtMy0xLTEtMTc3NzU_3bae2aa3-d8c0-489d-967f-b61a2370bd97"
      unitRef="usd">73000</us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense>
    <us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense
      contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMjQvZnJhZzo1NDg0NGVmM2I5YjQ0OTEwOTJiNDFhZjRkM2FjMzVkZi90YWJsZTo4MzlkNzA4NWM1MWE0YmU4ODQ2OGRlMGU3Yjg5NGE5Yy90YWJsZXJhbmdlOjgzOWQ3MDg1YzUxYTRiZTg4NDY4ZGUwZTdiODk0YTljXzYtNy0xLTEtMTc3NzU_cc4d6a76-795f-4ba4-b77a-f2ad26694325"
      unitRef="usd">7109000</us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense>
    <us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense
      contextRef="i00a9fb2f3f914116b87f14e146d04507_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMjQvZnJhZzo1NDg0NGVmM2I5YjQ0OTEwOTJiNDFhZjRkM2FjMzVkZi90YWJsZTo4MzlkNzA4NWM1MWE0YmU4ODQ2OGRlMGU3Yjg5NGE5Yy90YWJsZXJhbmdlOjgzOWQ3MDg1YzUxYTRiZTg4NDY4ZGUwZTdiODk0YTljXzYtOS0xLTEtMTc3NzU_fb6e234e-f44a-4f42-bad8-671c57fa6ba8"
      unitRef="usd">2853000</us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense>
    <us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense
      contextRef="i73877656554945338d08c1e8006fc13a_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMjQvZnJhZzo1NDg0NGVmM2I5YjQ0OTEwOTJiNDFhZjRkM2FjMzVkZi90YWJsZTo4MzlkNzA4NWM1MWE0YmU4ODQ2OGRlMGU3Yjg5NGE5Yy90YWJsZXJhbmdlOjgzOWQ3MDg1YzUxYTRiZTg4NDY4ZGUwZTdiODk0YTljXzYtMTEtMS0xLTE3Nzc1_30daf74a-5038-4844-a89a-59941485a9dc"
      unitRef="usd">25000</us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense>
    <us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense
      contextRef="i12a6d1161de54547bd29f8efccd4c9b0_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMjQvZnJhZzo1NDg0NGVmM2I5YjQ0OTEwOTJiNDFhZjRkM2FjMzVkZi90YWJsZTo4MzlkNzA4NWM1MWE0YmU4ODQ2OGRlMGU3Yjg5NGE5Yy90YWJsZXJhbmdlOjgzOWQ3MDg1YzUxYTRiZTg4NDY4ZGUwZTdiODk0YTljXzYtMTUtMS0xLTE3Nzc1_39213925-a920-4153-aee7-605d6d07a229"
      unitRef="usd">2878000</us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense>
    <us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1
      contextRef="i98988f30813349e1a5594e72b40af5b1_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMjQvZnJhZzo1NDg0NGVmM2I5YjQ0OTEwOTJiNDFhZjRkM2FjMzVkZi90YWJsZTo4MzlkNzA4NWM1MWE0YmU4ODQ2OGRlMGU3Yjg5NGE5Yy90YWJsZXJhbmdlOjgzOWQ3MDg1YzUxYTRiZTg4NDY4ZGUwZTdiODk0YTljXzctMS0xLTEtMTc3NzU_168b9699-9cbb-4d15-b183-323c96789fe8"
      unitRef="usd">20801000</us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1>
    <us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1
      contextRef="i6d991ef4e2e0416f8c7aaaa6175cf843_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMjQvZnJhZzo1NDg0NGVmM2I5YjQ0OTEwOTJiNDFhZjRkM2FjMzVkZi90YWJsZTo4MzlkNzA4NWM1MWE0YmU4ODQ2OGRlMGU3Yjg5NGE5Yy90YWJsZXJhbmdlOjgzOWQ3MDg1YzUxYTRiZTg4NDY4ZGUwZTdiODk0YTljXzctMy0xLTEtMTc3NzU_1f1a21d0-8e9b-43f8-81e3-6e514518ce60"
      unitRef="usd">337647000</us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1>
    <us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1
      contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMjQvZnJhZzo1NDg0NGVmM2I5YjQ0OTEwOTJiNDFhZjRkM2FjMzVkZi90YWJsZTo4MzlkNzA4NWM1MWE0YmU4ODQ2OGRlMGU3Yjg5NGE5Yy90YWJsZXJhbmdlOjgzOWQ3MDg1YzUxYTRiZTg4NDY4ZGUwZTdiODk0YTljXzctNy0xLTEtMTc3NzU_b64a4fad-b24b-45a7-97e5-0def79751953"
      unitRef="usd">358448000</us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1>
    <us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1
      contextRef="i00a9fb2f3f914116b87f14e146d04507_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMjQvZnJhZzo1NDg0NGVmM2I5YjQ0OTEwOTJiNDFhZjRkM2FjMzVkZi90YWJsZTo4MzlkNzA4NWM1MWE0YmU4ODQ2OGRlMGU3Yjg5NGE5Yy90YWJsZXJhbmdlOjgzOWQ3MDg1YzUxYTRiZTg4NDY4ZGUwZTdiODk0YTljXzctOS0xLTEtMTc3NzU_d34b187b-c306-45de-8e4a-4d6f66d1fe4d"
      unitRef="usd">106093000</us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1>
    <us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1
      contextRef="i73877656554945338d08c1e8006fc13a_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMjQvZnJhZzo1NDg0NGVmM2I5YjQ0OTEwOTJiNDFhZjRkM2FjMzVkZi90YWJsZTo4MzlkNzA4NWM1MWE0YmU4ODQ2OGRlMGU3Yjg5NGE5Yy90YWJsZXJhbmdlOjgzOWQ3MDg1YzUxYTRiZTg4NDY4ZGUwZTdiODk0YTljXzctMTEtMS0xLTE3Nzc1_4ed38248-806d-4fb8-9785-bdf9f44f3d4d"
      unitRef="usd">358478000</us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1>
    <us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1
      contextRef="i12a6d1161de54547bd29f8efccd4c9b0_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMjQvZnJhZzo1NDg0NGVmM2I5YjQ0OTEwOTJiNDFhZjRkM2FjMzVkZi90YWJsZTo4MzlkNzA4NWM1MWE0YmU4ODQ2OGRlMGU3Yjg5NGE5Yy90YWJsZXJhbmdlOjgzOWQ3MDg1YzUxYTRiZTg4NDY4ZGUwZTdiODk0YTljXzctMTUtMS0xLTE3Nzc1_7fa1b0ca-a6c4-4149-9942-2ef463eebf48"
      unitRef="usd">464571000</us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1>
    <us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1
      contextRef="i98988f30813349e1a5594e72b40af5b1_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMjQvZnJhZzo1NDg0NGVmM2I5YjQ0OTEwOTJiNDFhZjRkM2FjMzVkZi90YWJsZTo4MzlkNzA4NWM1MWE0YmU4ODQ2OGRlMGU3Yjg5NGE5Yy90YWJsZXJhbmdlOjgzOWQ3MDg1YzUxYTRiZTg4NDY4ZGUwZTdiODk0YTljXzgtMS0xLTEtMTc3NzU_ccf2f81f-1439-4fd9-b8cb-a66f0bf8aee2"
      unitRef="usd">25544000</us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1>
    <us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1
      contextRef="i6d991ef4e2e0416f8c7aaaa6175cf843_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMjQvZnJhZzo1NDg0NGVmM2I5YjQ0OTEwOTJiNDFhZjRkM2FjMzVkZi90YWJsZTo4MzlkNzA4NWM1MWE0YmU4ODQ2OGRlMGU3Yjg5NGE5Yy90YWJsZXJhbmdlOjgzOWQ3MDg1YzUxYTRiZTg4NDY4ZGUwZTdiODk0YTljXzgtMy0xLTEtMTc3NzU_5a9a905c-bdc2-4567-8fc7-1f08a72dfd08"
      unitRef="usd">100075000</us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1>
    <us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1
      contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMjQvZnJhZzo1NDg0NGVmM2I5YjQ0OTEwOTJiNDFhZjRkM2FjMzVkZi90YWJsZTo4MzlkNzA4NWM1MWE0YmU4ODQ2OGRlMGU3Yjg5NGE5Yy90YWJsZXJhbmdlOjgzOWQ3MDg1YzUxYTRiZTg4NDY4ZGUwZTdiODk0YTljXzgtNy0xLTEtMTc3NzU_34c52f48-c01a-49c2-9c7e-3b0b0980496c"
      unitRef="usd">125619000</us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1>
    <us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1
      contextRef="i00a9fb2f3f914116b87f14e146d04507_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMjQvZnJhZzo1NDg0NGVmM2I5YjQ0OTEwOTJiNDFhZjRkM2FjMzVkZi90YWJsZTo4MzlkNzA4NWM1MWE0YmU4ODQ2OGRlMGU3Yjg5NGE5Yy90YWJsZXJhbmdlOjgzOWQ3MDg1YzUxYTRiZTg4NDY4ZGUwZTdiODk0YTljXzgtOS0xLTEtMTc3NzU_41c3f3e9-666b-4bdd-981b-f484fd57d6e7"
      unitRef="usd">2123000</us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1>
    <us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1
      contextRef="i73877656554945338d08c1e8006fc13a_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMjQvZnJhZzo1NDg0NGVmM2I5YjQ0OTEwOTJiNDFhZjRkM2FjMzVkZi90YWJsZTo4MzlkNzA4NWM1MWE0YmU4ODQ2OGRlMGU3Yjg5NGE5Yy90YWJsZXJhbmdlOjgzOWQ3MDg1YzUxYTRiZTg4NDY4ZGUwZTdiODk0YTljXzgtMTEtMS0xLTE3Nzc1_34d6ae07-45d9-4198-8424-366de5024499"
      unitRef="usd">7475000</us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1>
    <us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1
      contextRef="i12a6d1161de54547bd29f8efccd4c9b0_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMjQvZnJhZzo1NDg0NGVmM2I5YjQ0OTEwOTJiNDFhZjRkM2FjMzVkZi90YWJsZTo4MzlkNzA4NWM1MWE0YmU4ODQ2OGRlMGU3Yjg5NGE5Yy90YWJsZXJhbmdlOjgzOWQ3MDg1YzUxYTRiZTg4NDY4ZGUwZTdiODk0YTljXzgtMTUtMS0xLTE3Nzc1_800e9708-53f2-40a4-84c4-b4214a4ce14c"
      unitRef="usd">9598000</us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1>
    <us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpensePeriodIncreaseDecrease
      contextRef="i98988f30813349e1a5594e72b40af5b1_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMjQvZnJhZzo1NDg0NGVmM2I5YjQ0OTEwOTJiNDFhZjRkM2FjMzVkZi90YWJsZTo4MzlkNzA4NWM1MWE0YmU4ODQ2OGRlMGU3Yjg5NGE5Yy90YWJsZXJhbmdlOjgzOWQ3MDg1YzUxYTRiZTg4NDY4ZGUwZTdiODk0YTljXzktMS0xLTEtMTc3NzU_8da3b7f1-5655-4709-8968-530513b0ad3c"
      unitRef="usd">-30640000</us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpensePeriodIncreaseDecrease>
    <us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpensePeriodIncreaseDecrease
      contextRef="i6d991ef4e2e0416f8c7aaaa6175cf843_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMjQvZnJhZzo1NDg0NGVmM2I5YjQ0OTEwOTJiNDFhZjRkM2FjMzVkZi90YWJsZTo4MzlkNzA4NWM1MWE0YmU4ODQ2OGRlMGU3Yjg5NGE5Yy90YWJsZXJhbmdlOjgzOWQ3MDg1YzUxYTRiZTg4NDY4ZGUwZTdiODk0YTljXzktMy0xLTEtMTc3NzU_6b842c48-8afc-4153-b69b-4fded3ced2ae"
      unitRef="usd">11523000</us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpensePeriodIncreaseDecrease>
    <us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpensePeriodIncreaseDecrease
      contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMjQvZnJhZzo1NDg0NGVmM2I5YjQ0OTEwOTJiNDFhZjRkM2FjMzVkZi90YWJsZTo4MzlkNzA4NWM1MWE0YmU4ODQ2OGRlMGU3Yjg5NGE5Yy90YWJsZXJhbmdlOjgzOWQ3MDg1YzUxYTRiZTg4NDY4ZGUwZTdiODk0YTljXzktNy0xLTEtMTc3NzU_ff47e257-9b71-4492-8514-53807e2433b5"
      unitRef="usd">-19117000</us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpensePeriodIncreaseDecrease>
    <us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpensePeriodIncreaseDecrease
      contextRef="i00a9fb2f3f914116b87f14e146d04507_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMjQvZnJhZzo1NDg0NGVmM2I5YjQ0OTEwOTJiNDFhZjRkM2FjMzVkZi90YWJsZTo4MzlkNzA4NWM1MWE0YmU4ODQ2OGRlMGU3Yjg5NGE5Yy90YWJsZXJhbmdlOjgzOWQ3MDg1YzUxYTRiZTg4NDY4ZGUwZTdiODk0YTljXzktOS0xLTEtMTc3NzU_45ede09e-44d1-41e2-833b-d5e481bdad44"
      unitRef="usd">-112905000</us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpensePeriodIncreaseDecrease>
    <us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpensePeriodIncreaseDecrease
      contextRef="i73877656554945338d08c1e8006fc13a_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMjQvZnJhZzo1NDg0NGVmM2I5YjQ0OTEwOTJiNDFhZjRkM2FjMzVkZi90YWJsZTo4MzlkNzA4NWM1MWE0YmU4ODQ2OGRlMGU3Yjg5NGE5Yy90YWJsZXJhbmdlOjgzOWQ3MDg1YzUxYTRiZTg4NDY4ZGUwZTdiODk0YTljXzktMTEtMS0xLTE3Nzc1_53b43c23-075c-4ce5-a695-bb144f0b1d7c"
      unitRef="usd">62211000</us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpensePeriodIncreaseDecrease>
    <us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpensePeriodIncreaseDecrease
      contextRef="i12a6d1161de54547bd29f8efccd4c9b0_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMjQvZnJhZzo1NDg0NGVmM2I5YjQ0OTEwOTJiNDFhZjRkM2FjMzVkZi90YWJsZTo4MzlkNzA4NWM1MWE0YmU4ODQ2OGRlMGU3Yjg5NGE5Yy90YWJsZXJhbmdlOjgzOWQ3MDg1YzUxYTRiZTg4NDY4ZGUwZTdiODk0YTljXzktMTUtMS0xLTE3Nzc1_6d3fa29d-3d59-4716-8466-f053d4ec8d43"
      unitRef="usd">-50694000</us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpensePeriodIncreaseDecrease>
    <us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseBusinessAcquisitions
      contextRef="i98988f30813349e1a5594e72b40af5b1_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMjQvZnJhZzo1NDg0NGVmM2I5YjQ0OTEwOTJiNDFhZjRkM2FjMzVkZi90YWJsZTo4MzlkNzA4NWM1MWE0YmU4ODQ2OGRlMGU3Yjg5NGE5Yy90YWJsZXJhbmdlOjgzOWQ3MDg1YzUxYTRiZTg4NDY4ZGUwZTdiODk0YTljXzExLTEtMS0xLTE3Nzc1_829378bd-7983-4c16-8cfc-424a1fb0a107"
      unitRef="usd">0</us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseBusinessAcquisitions>
    <us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseBusinessAcquisitions
      contextRef="i6d991ef4e2e0416f8c7aaaa6175cf843_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMjQvZnJhZzo1NDg0NGVmM2I5YjQ0OTEwOTJiNDFhZjRkM2FjMzVkZi90YWJsZTo4MzlkNzA4NWM1MWE0YmU4ODQ2OGRlMGU3Yjg5NGE5Yy90YWJsZXJhbmdlOjgzOWQ3MDg1YzUxYTRiZTg4NDY4ZGUwZTdiODk0YTljXzExLTMtMS0xLTE3Nzc1_45f6128d-a6d9-4fbe-ad48-9e52526bdf79"
      unitRef="usd">0</us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseBusinessAcquisitions>
    <us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseBusinessAcquisitions
      contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMjQvZnJhZzo1NDg0NGVmM2I5YjQ0OTEwOTJiNDFhZjRkM2FjMzVkZi90YWJsZTo4MzlkNzA4NWM1MWE0YmU4ODQ2OGRlMGU3Yjg5NGE5Yy90YWJsZXJhbmdlOjgzOWQ3MDg1YzUxYTRiZTg4NDY4ZGUwZTdiODk0YTljXzExLTctMS0xLTE3Nzc1_c74e7b5e-bdea-4a48-a20a-4886360eab0c"
      unitRef="usd">0</us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseBusinessAcquisitions>
    <us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseBusinessAcquisitions
      contextRef="i00a9fb2f3f914116b87f14e146d04507_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMjQvZnJhZzo1NDg0NGVmM2I5YjQ0OTEwOTJiNDFhZjRkM2FjMzVkZi90YWJsZTo4MzlkNzA4NWM1MWE0YmU4ODQ2OGRlMGU3Yjg5NGE5Yy90YWJsZXJhbmdlOjgzOWQ3MDg1YzUxYTRiZTg4NDY4ZGUwZTdiODk0YTljXzExLTktMS0xLTE3Nzc1_11ab971a-5966-4228-a4f6-af7936a63863"
      unitRef="usd">-164297000</us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseBusinessAcquisitions>
    <us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseBusinessAcquisitions
      contextRef="i73877656554945338d08c1e8006fc13a_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMjQvZnJhZzo1NDg0NGVmM2I5YjQ0OTEwOTJiNDFhZjRkM2FjMzVkZi90YWJsZTo4MzlkNzA4NWM1MWE0YmU4ODQ2OGRlMGU3Yjg5NGE5Yy90YWJsZXJhbmdlOjgzOWQ3MDg1YzUxYTRiZTg4NDY4ZGUwZTdiODk0YTljXzExLTExLTEtMS0xNzc3NQ_79af128a-1ef0-431e-bac1-6a6d0b407853"
      unitRef="usd">0</us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseBusinessAcquisitions>
    <us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseBusinessAcquisitions
      contextRef="i12a6d1161de54547bd29f8efccd4c9b0_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMjQvZnJhZzo1NDg0NGVmM2I5YjQ0OTEwOTJiNDFhZjRkM2FjMzVkZi90YWJsZTo4MzlkNzA4NWM1MWE0YmU4ODQ2OGRlMGU3Yjg5NGE5Yy90YWJsZXJhbmdlOjgzOWQ3MDg1YzUxYTRiZTg4NDY4ZGUwZTdiODk0YTljXzExLTE1LTEtMS0xNzc3NQ_a3806b1f-6a3d-4602-b87a-773d59fcd01a"
      unitRef="usd">-164297000</us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseBusinessAcquisitions>
    <us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseOpeningBalanceAdjustments
      contextRef="icdbca3fab4684e269937d4a61379d67f_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMjQvZnJhZzo1NDg0NGVmM2I5YjQ0OTEwOTJiNDFhZjRkM2FjMzVkZi90YWJsZTo4MzlkNzA4NWM1MWE0YmU4ODQ2OGRlMGU3Yjg5NGE5Yy90YWJsZXJhbmdlOjgzOWQ3MDg1YzUxYTRiZTg4NDY4ZGUwZTdiODk0YTljXzEzLTEtMS0xLTE3Nzc1_826b80ab-ac03-4ef7-b426-57ed5b3d5dbb"
      unitRef="usd">38000</us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseOpeningBalanceAdjustments>
    <us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseOpeningBalanceAdjustments
      contextRef="ie09b385083554dfe92dc601254dfdda8_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMjQvZnJhZzo1NDg0NGVmM2I5YjQ0OTEwOTJiNDFhZjRkM2FjMzVkZi90YWJsZTo4MzlkNzA4NWM1MWE0YmU4ODQ2OGRlMGU3Yjg5NGE5Yy90YWJsZXJhbmdlOjgzOWQ3MDg1YzUxYTRiZTg4NDY4ZGUwZTdiODk0YTljXzEzLTMtMS0xLTE3Nzc1_89dea484-af00-4df3-aae1-20e84e998148"
      unitRef="usd">-11622000</us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseOpeningBalanceAdjustments>
    <us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseOpeningBalanceAdjustments
      contextRef="i8daff60be410426d8f7bd49343c1ec0c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMjQvZnJhZzo1NDg0NGVmM2I5YjQ0OTEwOTJiNDFhZjRkM2FjMzVkZi90YWJsZTo4MzlkNzA4NWM1MWE0YmU4ODQ2OGRlMGU3Yjg5NGE5Yy90YWJsZXJhbmdlOjgzOWQ3MDg1YzUxYTRiZTg4NDY4ZGUwZTdiODk0YTljXzEzLTctMS0xLTE3Nzc1_29cdaf18-eefc-4cc2-8a1b-5455021d991d"
      unitRef="usd">-11584000</us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseOpeningBalanceAdjustments>
    <us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseOpeningBalanceAdjustments
      contextRef="if8fd35766cfc4fa8b1cbf4f3cd8a8dfc_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMjQvZnJhZzo1NDg0NGVmM2I5YjQ0OTEwOTJiNDFhZjRkM2FjMzVkZi90YWJsZTo4MzlkNzA4NWM1MWE0YmU4ODQ2OGRlMGU3Yjg5NGE5Yy90YWJsZXJhbmdlOjgzOWQ3MDg1YzUxYTRiZTg4NDY4ZGUwZTdiODk0YTljXzEzLTktMS0xLTE3Nzc1_0672e77f-987d-4980-90b2-c8da8d2f6668"
      unitRef="usd">-639000</us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseOpeningBalanceAdjustments>
    <us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseOpeningBalanceAdjustments
      contextRef="i5f5145421bc94a90bb8982e11bb80abb_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMjQvZnJhZzo1NDg0NGVmM2I5YjQ0OTEwOTJiNDFhZjRkM2FjMzVkZi90YWJsZTo4MzlkNzA4NWM1MWE0YmU4ODQ2OGRlMGU3Yjg5NGE5Yy90YWJsZXJhbmdlOjgzOWQ3MDg1YzUxYTRiZTg4NDY4ZGUwZTdiODk0YTljXzEzLTExLTEtMS0xNzc3NQ_159738a6-7886-4527-b4ea-149c20254546"
      unitRef="usd">-10075000</us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseOpeningBalanceAdjustments>
    <us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseOpeningBalanceAdjustments
      contextRef="ibc0c0c2b8dc04c5698ca0577a54b2e03_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMjQvZnJhZzo1NDg0NGVmM2I5YjQ0OTEwOTJiNDFhZjRkM2FjMzVkZi90YWJsZTo4MzlkNzA4NWM1MWE0YmU4ODQ2OGRlMGU3Yjg5NGE5Yy90YWJsZXJhbmdlOjgzOWQ3MDg1YzUxYTRiZTg4NDY4ZGUwZTdiODk0YTljXzEzLTE1LTEtMS0xNzc3NQ_3e00d6bd-8c44-434a-b32f-d1a8076da589"
      unitRef="usd">-10714000</us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseOpeningBalanceAdjustments>
    <us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense
      contextRef="icdbca3fab4684e269937d4a61379d67f_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMjQvZnJhZzo1NDg0NGVmM2I5YjQ0OTEwOTJiNDFhZjRkM2FjMzVkZi90YWJsZTo4MzlkNzA4NWM1MWE0YmU4ODQ2OGRlMGU3Yjg5NGE5Yy90YWJsZXJhbmdlOjgzOWQ3MDg1YzUxYTRiZTg4NDY4ZGUwZTdiODk0YTljXzE0LTEtMS0xLTE3Nzc1_91004518-9732-4de7-bec8-90cd98b206db"
      unitRef="usd">25618000</us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense>
    <us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense
      contextRef="ie09b385083554dfe92dc601254dfdda8_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMjQvZnJhZzo1NDg0NGVmM2I5YjQ0OTEwOTJiNDFhZjRkM2FjMzVkZi90YWJsZTo4MzlkNzA4NWM1MWE0YmU4ODQ2OGRlMGU3Yjg5NGE5Yy90YWJsZXJhbmdlOjgzOWQ3MDg1YzUxYTRiZTg4NDY4ZGUwZTdiODk0YTljXzE0LTMtMS0xLTE3Nzc1_3e8f0f1d-5538-454b-ad3c-f8f394e52f27"
      unitRef="usd">145676000</us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense>
    <us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense
      contextRef="i8daff60be410426d8f7bd49343c1ec0c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMjQvZnJhZzo1NDg0NGVmM2I5YjQ0OTEwOTJiNDFhZjRkM2FjMzVkZi90YWJsZTo4MzlkNzA4NWM1MWE0YmU4ODQ2OGRlMGU3Yjg5NGE5Yy90YWJsZXJhbmdlOjgzOWQ3MDg1YzUxYTRiZTg4NDY4ZGUwZTdiODk0YTljXzE0LTctMS0xLTE3Nzc1_86507022-a436-41b3-8215-7dfae2b6d585"
      unitRef="usd">171294000</us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense>
    <us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense
      contextRef="if8fd35766cfc4fa8b1cbf4f3cd8a8dfc_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMjQvZnJhZzo1NDg0NGVmM2I5YjQ0OTEwOTJiNDFhZjRkM2FjMzVkZi90YWJsZTo4MzlkNzA4NWM1MWE0YmU4ODQ2OGRlMGU3Yjg5NGE5Yy90YWJsZXJhbmdlOjgzOWQ3MDg1YzUxYTRiZTg4NDY4ZGUwZTdiODk0YTljXzE0LTktMS0xLTE3Nzc1_33f2481e-8bfa-4ed3-a445-11072882c395"
      unitRef="usd">56296000</us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense>
    <us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense
      contextRef="i5f5145421bc94a90bb8982e11bb80abb_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMjQvZnJhZzo1NDg0NGVmM2I5YjQ0OTEwOTJiNDFhZjRkM2FjMzVkZi90YWJsZTo4MzlkNzA4NWM1MWE0YmU4ODQ2OGRlMGU3Yjg5NGE5Yy90YWJsZXJhbmdlOjgzOWQ3MDg1YzUxYTRiZTg4NDY4ZGUwZTdiODk0YTljXzE0LTExLTEtMS0xNzc3NQ_170ee388-a440-42ff-a4dc-10dc780db198"
      unitRef="usd">122531000</us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense>
    <us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense
      contextRef="ibc0c0c2b8dc04c5698ca0577a54b2e03_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMjQvZnJhZzo1NDg0NGVmM2I5YjQ0OTEwOTJiNDFhZjRkM2FjMzVkZi90YWJsZTo4MzlkNzA4NWM1MWE0YmU4ODQ2OGRlMGU3Yjg5NGE5Yy90YWJsZXJhbmdlOjgzOWQ3MDg1YzUxYTRiZTg4NDY4ZGUwZTdiODk0YTljXzE0LTE1LTEtMS0xNzc3NQ_3f2ef4ac-2424-4b46-a0df-56fabeb7037a"
      unitRef="usd">178827000</us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense>
    <us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense
      contextRef="i98364cf4ba3e41af868d701b4c668283_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMjQvZnJhZzo1NDg0NGVmM2I5YjQ0OTEwOTJiNDFhZjRkM2FjMzVkZi90ZXh0cmVnaW9uOjU0ODQ0ZWYzYjliNDQ5MTA5MmI0MWFmNGQzYWMzNWRmXzEwOTk1MTE2MzI2OTc_7996d21f-9701-4a74-8e7b-93fa5d6e9f35"
      unitRef="usd">9900000</us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense>
    <us-gaap:QuarterlyFinancialInformationTextBlock
      contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMzAvZnJhZzo3NGIwMjA4NWYwNjY0MjYyOGY3OWUzMTNlNjFkZmI3Yy90ZXh0cmVnaW9uOjc0YjAyMDg1ZjA2NjQyNjI4Zjc5ZTMxM2U2MWRmYjdjXzI3Ng_48682086-e682-468e-b97e-5a17728db83a">Quarterly Results of Operations (unaudited)&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The unaudited consolidated quarterly results of operations (in thousands, except per share data) were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:53.344%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.094%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.355%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.983%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.355%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.205%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.355%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.209%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="21" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;September 30&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;June 30&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;March 31&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total revenue&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;248,358&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;222,471&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;222,057&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;215,071&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total operating expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;260,572&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;229,052&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;229,728&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;231,016&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net loss from continuing operations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,053&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(13,040)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9,107)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(11,190)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income (loss) from discontinued operations, net of tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8,700)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,383&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net loss attributable to common shareholders of Evolent Health, Inc.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5,647)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(13,040)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9,107)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9,807)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Income (loss) per common share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Basic and diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Continuing operations&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.03&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.15)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.11)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.13)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Discontinued operations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.09)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.01&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total revenue&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;246,536&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;239,572&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;217,299&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;221,232&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total operating expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;246,804&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;256,020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;443,128&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;246,323&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net loss from continuing operations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(10,637)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(37,035)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(202,013)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(78,487)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net loss from discontinued operations, net of tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,166)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,135)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,508)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(265)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income (loss) attributable to non-controlling interests&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;822&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(822)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net loss attributable to common shareholders of Evolent Health, Inc.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(14,625)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(37,348)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(203,521)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(78,752)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Loss per common share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Basic and diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Continuing operations&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.13)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.43)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2.37)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.93)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Discontinued operations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.04)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.01)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.01)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:QuarterlyFinancialInformationTextBlock>
    <us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock
      contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMzAvZnJhZzo3NGIwMjA4NWYwNjY0MjYyOGY3OWUzMTNlNjFkZmI3Yy90ZXh0cmVnaW9uOjc0YjAyMDg1ZjA2NjQyNjI4Zjc5ZTMxM2U2MWRmYjdjXzI3Nw_092b2982-a477-44c0-8ec5-3540c0f90376">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The unaudited consolidated quarterly results of operations (in thousands, except per share data) were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:53.344%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.094%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.355%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.983%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.355%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.205%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.355%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.209%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="21" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;September 30&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;June 30&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;March 31&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total revenue&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;248,358&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;222,471&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;222,057&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;215,071&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total operating expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;260,572&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;229,052&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;229,728&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;231,016&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net loss from continuing operations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,053&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(13,040)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9,107)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(11,190)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income (loss) from discontinued operations, net of tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8,700)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,383&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net loss attributable to common shareholders of Evolent Health, Inc.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5,647)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(13,040)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9,107)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9,807)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Income (loss) per common share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Basic and diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Continuing operations&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.03&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.15)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.11)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.13)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Discontinued operations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.09)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.01&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total revenue&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;246,536&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;239,572&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;217,299&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;221,232&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total operating expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;246,804&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;256,020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;443,128&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;246,323&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net loss from continuing operations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(10,637)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(37,035)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(202,013)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(78,487)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net loss from discontinued operations, net of tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,166)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,135)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,508)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(265)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income (loss) attributable to non-controlling interests&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;822&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(822)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net loss attributable to common shareholders of Evolent Health, Inc.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(14,625)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(37,348)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(203,521)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(78,752)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Loss per common share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Basic and diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Continuing operations&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.13)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.43)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2.37)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.93)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Discontinued operations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.04)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.01)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.01)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock>
    <us-gaap:Revenues
      contextRef="i546c40c371924532a3d2ed0ace7d354b_D20211001-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMzAvZnJhZzo3NGIwMjA4NWYwNjY0MjYyOGY3OWUzMTNlNjFkZmI3Yy90YWJsZTpmYTRmNTRhZWVjNTg0NDBiYmYyYTcwYWUxMDNkNDVlNy90YWJsZXJhbmdlOmZhNGY1NGFlZWM1ODQ0MGJiZjJhNzBhZTEwM2Q0NWU3XzMtMS0xLTEtMTc3NzU_e59df483-a056-4e0f-b2c5-07c3743b7637"
      unitRef="usd">248358000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i973a81e9b0924e4e86048dc6df6379d0_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMzAvZnJhZzo3NGIwMjA4NWYwNjY0MjYyOGY3OWUzMTNlNjFkZmI3Yy90YWJsZTpmYTRmNTRhZWVjNTg0NDBiYmYyYTcwYWUxMDNkNDVlNy90YWJsZXJhbmdlOmZhNGY1NGFlZWM1ODQ0MGJiZjJhNzBhZTEwM2Q0NWU3XzMtMy0xLTEtMTc3NzU_d4746982-917a-4211-b17c-39a48dcec429"
      unitRef="usd">222471000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i8b76d915d864443fbfe177d29bc9e4e4_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMzAvZnJhZzo3NGIwMjA4NWYwNjY0MjYyOGY3OWUzMTNlNjFkZmI3Yy90YWJsZTpmYTRmNTRhZWVjNTg0NDBiYmYyYTcwYWUxMDNkNDVlNy90YWJsZXJhbmdlOmZhNGY1NGFlZWM1ODQ0MGJiZjJhNzBhZTEwM2Q0NWU3XzMtNS0xLTEtMTc3NzU_6022f7d9-2c00-4043-83de-7d6c68aa5187"
      unitRef="usd">222057000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i035c62f748c14287b929adf98e0b2fbb_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMzAvZnJhZzo3NGIwMjA4NWYwNjY0MjYyOGY3OWUzMTNlNjFkZmI3Yy90YWJsZTpmYTRmNTRhZWVjNTg0NDBiYmYyYTcwYWUxMDNkNDVlNy90YWJsZXJhbmdlOmZhNGY1NGFlZWM1ODQ0MGJiZjJhNzBhZTEwM2Q0NWU3XzMtNy0xLTEtMTc3NzU_b2a65a5d-6405-409e-9454-47e0d1c72a2b"
      unitRef="usd">215071000</us-gaap:Revenues>
    <us-gaap:OperatingExpenses
      contextRef="i546c40c371924532a3d2ed0ace7d354b_D20211001-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMzAvZnJhZzo3NGIwMjA4NWYwNjY0MjYyOGY3OWUzMTNlNjFkZmI3Yy90YWJsZTpmYTRmNTRhZWVjNTg0NDBiYmYyYTcwYWUxMDNkNDVlNy90YWJsZXJhbmdlOmZhNGY1NGFlZWM1ODQ0MGJiZjJhNzBhZTEwM2Q0NWU3XzQtMS0xLTEtMTc3NzU_d84a2641-b45b-4879-8dcd-74c4a263caf1"
      unitRef="usd">260572000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="i973a81e9b0924e4e86048dc6df6379d0_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMzAvZnJhZzo3NGIwMjA4NWYwNjY0MjYyOGY3OWUzMTNlNjFkZmI3Yy90YWJsZTpmYTRmNTRhZWVjNTg0NDBiYmYyYTcwYWUxMDNkNDVlNy90YWJsZXJhbmdlOmZhNGY1NGFlZWM1ODQ0MGJiZjJhNzBhZTEwM2Q0NWU3XzQtMy0xLTEtMTc3NzU_23cda1f7-8931-4b84-80aa-bdde3c243cb1"
      unitRef="usd">229052000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="i8b76d915d864443fbfe177d29bc9e4e4_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMzAvZnJhZzo3NGIwMjA4NWYwNjY0MjYyOGY3OWUzMTNlNjFkZmI3Yy90YWJsZTpmYTRmNTRhZWVjNTg0NDBiYmYyYTcwYWUxMDNkNDVlNy90YWJsZXJhbmdlOmZhNGY1NGFlZWM1ODQ0MGJiZjJhNzBhZTEwM2Q0NWU3XzQtNS0xLTEtMTc3NzU_b32777b7-f56d-46bf-90e4-46fe38bb8876"
      unitRef="usd">229728000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="i035c62f748c14287b929adf98e0b2fbb_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMzAvZnJhZzo3NGIwMjA4NWYwNjY0MjYyOGY3OWUzMTNlNjFkZmI3Yy90YWJsZTpmYTRmNTRhZWVjNTg0NDBiYmYyYTcwYWUxMDNkNDVlNy90YWJsZXJhbmdlOmZhNGY1NGFlZWM1ODQ0MGJiZjJhNzBhZTEwM2Q0NWU3XzQtNy0xLTEtMTc3NzU_c2298f62-f667-4b63-bc96-063e3898e855"
      unitRef="usd">231016000</us-gaap:OperatingExpenses>
    <us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i546c40c371924532a3d2ed0ace7d354b_D20211001-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMzAvZnJhZzo3NGIwMjA4NWYwNjY0MjYyOGY3OWUzMTNlNjFkZmI3Yy90YWJsZTpmYTRmNTRhZWVjNTg0NDBiYmYyYTcwYWUxMDNkNDVlNy90YWJsZXJhbmdlOmZhNGY1NGFlZWM1ODQ0MGJiZjJhNzBhZTEwM2Q0NWU3XzUtMS0xLTEtMTc3NzU_b15e3ca2-6f18-4fc7-a5a9-e7943659f28b"
      unitRef="usd">3053000</us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i973a81e9b0924e4e86048dc6df6379d0_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMzAvZnJhZzo3NGIwMjA4NWYwNjY0MjYyOGY3OWUzMTNlNjFkZmI3Yy90YWJsZTpmYTRmNTRhZWVjNTg0NDBiYmYyYTcwYWUxMDNkNDVlNy90YWJsZXJhbmdlOmZhNGY1NGFlZWM1ODQ0MGJiZjJhNzBhZTEwM2Q0NWU3XzUtMy0xLTEtMTc3NzU_ab26b235-5211-4610-a807-a74d9ef89cbf"
      unitRef="usd">-13040000</us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i8b76d915d864443fbfe177d29bc9e4e4_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMzAvZnJhZzo3NGIwMjA4NWYwNjY0MjYyOGY3OWUzMTNlNjFkZmI3Yy90YWJsZTpmYTRmNTRhZWVjNTg0NDBiYmYyYTcwYWUxMDNkNDVlNy90YWJsZXJhbmdlOmZhNGY1NGFlZWM1ODQ0MGJiZjJhNzBhZTEwM2Q0NWU3XzUtNS0xLTEtMTc3NzU_d4fd8f42-ede1-4a57-9954-377b8f211310"
      unitRef="usd">-9107000</us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i035c62f748c14287b929adf98e0b2fbb_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMzAvZnJhZzo3NGIwMjA4NWYwNjY0MjYyOGY3OWUzMTNlNjFkZmI3Yy90YWJsZTpmYTRmNTRhZWVjNTg0NDBiYmYyYTcwYWUxMDNkNDVlNy90YWJsZXJhbmdlOmZhNGY1NGFlZWM1ODQ0MGJiZjJhNzBhZTEwM2Q0NWU3XzUtNy0xLTEtMTc3NzU_8f405d12-8ea2-42b6-9717-a99a48dc29ed"
      unitRef="usd">-11190000</us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax
      contextRef="i546c40c371924532a3d2ed0ace7d354b_D20211001-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMzAvZnJhZzo3NGIwMjA4NWYwNjY0MjYyOGY3OWUzMTNlNjFkZmI3Yy90YWJsZTpmYTRmNTRhZWVjNTg0NDBiYmYyYTcwYWUxMDNkNDVlNy90YWJsZXJhbmdlOmZhNGY1NGFlZWM1ODQ0MGJiZjJhNzBhZTEwM2Q0NWU3XzYtMS0xLTEtMzMwOTg_2d028ee7-25e5-43aa-a188-cea5ec2afbd1"
      unitRef="usd">-8700000</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax
      contextRef="i973a81e9b0924e4e86048dc6df6379d0_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMzAvZnJhZzo3NGIwMjA4NWYwNjY0MjYyOGY3OWUzMTNlNjFkZmI3Yy90YWJsZTpmYTRmNTRhZWVjNTg0NDBiYmYyYTcwYWUxMDNkNDVlNy90YWJsZXJhbmdlOmZhNGY1NGFlZWM1ODQ0MGJiZjJhNzBhZTEwM2Q0NWU3XzYtMy0xLTEtMzY1MDY_c686a071-be59-4ba0-86e4-beb26a8b5d91"
      unitRef="usd">0</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax
      contextRef="i8b76d915d864443fbfe177d29bc9e4e4_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMzAvZnJhZzo3NGIwMjA4NWYwNjY0MjYyOGY3OWUzMTNlNjFkZmI3Yy90YWJsZTpmYTRmNTRhZWVjNTg0NDBiYmYyYTcwYWUxMDNkNDVlNy90YWJsZXJhbmdlOmZhNGY1NGFlZWM1ODQ0MGJiZjJhNzBhZTEwM2Q0NWU3XzYtNS0xLTEtMzY1MDY_9f9e07ab-9e0a-4d3b-b9c2-58e89f6b5fdc"
      unitRef="usd">0</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax
      contextRef="i035c62f748c14287b929adf98e0b2fbb_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMzAvZnJhZzo3NGIwMjA4NWYwNjY0MjYyOGY3OWUzMTNlNjFkZmI3Yy90YWJsZTpmYTRmNTRhZWVjNTg0NDBiYmYyYTcwYWUxMDNkNDVlNy90YWJsZXJhbmdlOmZhNGY1NGFlZWM1ODQ0MGJiZjJhNzBhZTEwM2Q0NWU3XzYtNy0xLTEtMzY1MDY_e855419b-4077-4099-9590-8f17b1e35f92"
      unitRef="usd">1383000</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="i546c40c371924532a3d2ed0ace7d354b_D20211001-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMzAvZnJhZzo3NGIwMjA4NWYwNjY0MjYyOGY3OWUzMTNlNjFkZmI3Yy90YWJsZTpmYTRmNTRhZWVjNTg0NDBiYmYyYTcwYWUxMDNkNDVlNy90YWJsZXJhbmdlOmZhNGY1NGFlZWM1ODQ0MGJiZjJhNzBhZTEwM2Q0NWU3XzctMS0xLTEtMTc3NzU_970da707-5a06-402a-9bf2-6ae593559fba"
      unitRef="usd">-5647000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted
      contextRef="i546c40c371924532a3d2ed0ace7d354b_D20211001-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMzAvZnJhZzo3NGIwMjA4NWYwNjY0MjYyOGY3OWUzMTNlNjFkZmI3Yy90YWJsZTpmYTRmNTRhZWVjNTg0NDBiYmYyYTcwYWUxMDNkNDVlNy90YWJsZXJhbmdlOmZhNGY1NGFlZWM1ODQ0MGJiZjJhNzBhZTEwM2Q0NWU3XzctMS0xLTEtMTc3NzU_fa1bdb3c-ed90-43d4-8528-fda67caf12cb"
      unitRef="usd">-5647000</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted
      contextRef="i973a81e9b0924e4e86048dc6df6379d0_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMzAvZnJhZzo3NGIwMjA4NWYwNjY0MjYyOGY3OWUzMTNlNjFkZmI3Yy90YWJsZTpmYTRmNTRhZWVjNTg0NDBiYmYyYTcwYWUxMDNkNDVlNy90YWJsZXJhbmdlOmZhNGY1NGFlZWM1ODQ0MGJiZjJhNzBhZTEwM2Q0NWU3XzctMy0xLTEtMTc3NzU_30db6a70-3c51-435d-b9fe-a90a03d918a1"
      unitRef="usd">-13040000</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="i973a81e9b0924e4e86048dc6df6379d0_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMzAvZnJhZzo3NGIwMjA4NWYwNjY0MjYyOGY3OWUzMTNlNjFkZmI3Yy90YWJsZTpmYTRmNTRhZWVjNTg0NDBiYmYyYTcwYWUxMDNkNDVlNy90YWJsZXJhbmdlOmZhNGY1NGFlZWM1ODQ0MGJiZjJhNzBhZTEwM2Q0NWU3XzctMy0xLTEtMTc3NzU_e532f44b-4918-467c-bd96-3718b4647f85"
      unitRef="usd">-13040000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="i8b76d915d864443fbfe177d29bc9e4e4_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMzAvZnJhZzo3NGIwMjA4NWYwNjY0MjYyOGY3OWUzMTNlNjFkZmI3Yy90YWJsZTpmYTRmNTRhZWVjNTg0NDBiYmYyYTcwYWUxMDNkNDVlNy90YWJsZXJhbmdlOmZhNGY1NGFlZWM1ODQ0MGJiZjJhNzBhZTEwM2Q0NWU3XzctNS0xLTEtMTc3NzU_b25539b3-4996-49bc-946d-42d7726b0201"
      unitRef="usd">-9107000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted
      contextRef="i8b76d915d864443fbfe177d29bc9e4e4_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMzAvZnJhZzo3NGIwMjA4NWYwNjY0MjYyOGY3OWUzMTNlNjFkZmI3Yy90YWJsZTpmYTRmNTRhZWVjNTg0NDBiYmYyYTcwYWUxMDNkNDVlNy90YWJsZXJhbmdlOmZhNGY1NGFlZWM1ODQ0MGJiZjJhNzBhZTEwM2Q0NWU3XzctNS0xLTEtMTc3NzU_f818ab4a-8027-428a-b0b0-0b77c2cefae5"
      unitRef="usd">-9107000</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted
      contextRef="i035c62f748c14287b929adf98e0b2fbb_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMzAvZnJhZzo3NGIwMjA4NWYwNjY0MjYyOGY3OWUzMTNlNjFkZmI3Yy90YWJsZTpmYTRmNTRhZWVjNTg0NDBiYmYyYTcwYWUxMDNkNDVlNy90YWJsZXJhbmdlOmZhNGY1NGFlZWM1ODQ0MGJiZjJhNzBhZTEwM2Q0NWU3XzctNy0xLTEtMTc3NzU_4fedc226-92af-4e9b-90cc-f65907c1bc59"
      unitRef="usd">-9807000</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="i035c62f748c14287b929adf98e0b2fbb_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMzAvZnJhZzo3NGIwMjA4NWYwNjY0MjYyOGY3OWUzMTNlNjFkZmI3Yy90YWJsZTpmYTRmNTRhZWVjNTg0NDBiYmYyYTcwYWUxMDNkNDVlNy90YWJsZXJhbmdlOmZhNGY1NGFlZWM1ODQ0MGJiZjJhNzBhZTEwM2Q0NWU3XzctNy0xLTEtMTc3NzU_5c74a8c5-e697-48b3-898c-fd340a0eea78"
      unitRef="usd">-9807000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare
      contextRef="i546c40c371924532a3d2ed0ace7d354b_D20211001-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMzAvZnJhZzo3NGIwMjA4NWYwNjY0MjYyOGY3OWUzMTNlNjFkZmI3Yy90YWJsZTpmYTRmNTRhZWVjNTg0NDBiYmYyYTcwYWUxMDNkNDVlNy90YWJsZXJhbmdlOmZhNGY1NGFlZWM1ODQ0MGJiZjJhNzBhZTEwM2Q0NWU3XzEyLTEtMS0xLTI2OTQ4_2ea9c726-f048-42fe-a835-c99cbe0ee20e"
      unitRef="usdPerShare">0.03</us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerBasicShare
      contextRef="i546c40c371924532a3d2ed0ace7d354b_D20211001-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMzAvZnJhZzo3NGIwMjA4NWYwNjY0MjYyOGY3OWUzMTNlNjFkZmI3Yy90YWJsZTpmYTRmNTRhZWVjNTg0NDBiYmYyYTcwYWUxMDNkNDVlNy90YWJsZXJhbmdlOmZhNGY1NGFlZWM1ODQ0MGJiZjJhNzBhZTEwM2Q0NWU3XzEyLTEtMS0xLTI2OTQ4_de5233e2-a123-422a-b312-ca434ac4f59a"
      unitRef="usdPerShare">0.03</us-gaap:IncomeLossFromContinuingOperationsPerBasicShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare
      contextRef="i973a81e9b0924e4e86048dc6df6379d0_D20210701-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMzAvZnJhZzo3NGIwMjA4NWYwNjY0MjYyOGY3OWUzMTNlNjFkZmI3Yy90YWJsZTpmYTRmNTRhZWVjNTg0NDBiYmYyYTcwYWUxMDNkNDVlNy90YWJsZXJhbmdlOmZhNGY1NGFlZWM1ODQ0MGJiZjJhNzBhZTEwM2Q0NWU3XzExLTMtMS0xLTM2NTE0_adac1fbc-2893-48e9-85bb-9359d241a161"
      unitRef="usdPerShare">-0.15</us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerBasicShare
      contextRef="i973a81e9b0924e4e86048dc6df6379d0_D20210701-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMzAvZnJhZzo3NGIwMjA4NWYwNjY0MjYyOGY3OWUzMTNlNjFkZmI3Yy90YWJsZTpmYTRmNTRhZWVjNTg0NDBiYmYyYTcwYWUxMDNkNDVlNy90YWJsZXJhbmdlOmZhNGY1NGFlZWM1ODQ0MGJiZjJhNzBhZTEwM2Q0NWU3XzExLTMtMS0xLTM2NTE0_f28f1df2-bb0b-4118-bbb1-89566ae61948"
      unitRef="usdPerShare">-0.15</us-gaap:IncomeLossFromContinuingOperationsPerBasicShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare
      contextRef="i8b76d915d864443fbfe177d29bc9e4e4_D20210401-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMzAvZnJhZzo3NGIwMjA4NWYwNjY0MjYyOGY3OWUzMTNlNjFkZmI3Yy90YWJsZTpmYTRmNTRhZWVjNTg0NDBiYmYyYTcwYWUxMDNkNDVlNy90YWJsZXJhbmdlOmZhNGY1NGFlZWM1ODQ0MGJiZjJhNzBhZTEwM2Q0NWU3XzExLTUtMS0xLTM2NTE2_cc259872-0658-4dd9-a770-26f0c5305cc0"
      unitRef="usdPerShare">-0.11</us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerBasicShare
      contextRef="i8b76d915d864443fbfe177d29bc9e4e4_D20210401-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMzAvZnJhZzo3NGIwMjA4NWYwNjY0MjYyOGY3OWUzMTNlNjFkZmI3Yy90YWJsZTpmYTRmNTRhZWVjNTg0NDBiYmYyYTcwYWUxMDNkNDVlNy90YWJsZXJhbmdlOmZhNGY1NGFlZWM1ODQ0MGJiZjJhNzBhZTEwM2Q0NWU3XzExLTUtMS0xLTM2NTE2_ff12b3e4-5225-48b6-9ac1-40d8756d3fd1"
      unitRef="usdPerShare">-0.11</us-gaap:IncomeLossFromContinuingOperationsPerBasicShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare
      contextRef="i035c62f748c14287b929adf98e0b2fbb_D20210101-20210331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMzAvZnJhZzo3NGIwMjA4NWYwNjY0MjYyOGY3OWUzMTNlNjFkZmI3Yy90YWJsZTpmYTRmNTRhZWVjNTg0NDBiYmYyYTcwYWUxMDNkNDVlNy90YWJsZXJhbmdlOmZhNGY1NGFlZWM1ODQ0MGJiZjJhNzBhZTEwM2Q0NWU3XzExLTctMS0xLTM2NTE4_d70a196a-3fa0-47a5-8ed4-9c3a085ad8c2"
      unitRef="usdPerShare">-0.13</us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerBasicShare
      contextRef="i035c62f748c14287b929adf98e0b2fbb_D20210101-20210331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMzAvZnJhZzo3NGIwMjA4NWYwNjY0MjYyOGY3OWUzMTNlNjFkZmI3Yy90YWJsZTpmYTRmNTRhZWVjNTg0NDBiYmYyYTcwYWUxMDNkNDVlNy90YWJsZXJhbmdlOmZhNGY1NGFlZWM1ODQ0MGJiZjJhNzBhZTEwM2Q0NWU3XzExLTctMS0xLTM2NTE4_ffed93b2-fad8-4c55-92e0-824eeaa0894b"
      unitRef="usdPerShare">-0.13</us-gaap:IncomeLossFromContinuingOperationsPerBasicShare>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare
      contextRef="i546c40c371924532a3d2ed0ace7d354b_D20211001-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMzAvZnJhZzo3NGIwMjA4NWYwNjY0MjYyOGY3OWUzMTNlNjFkZmI3Yy90YWJsZTpmYTRmNTRhZWVjNTg0NDBiYmYyYTcwYWUxMDNkNDVlNy90YWJsZXJhbmdlOmZhNGY1NGFlZWM1ODQ0MGJiZjJhNzBhZTEwM2Q0NWU3XzEzLTEtMS0xLTI2OTQ4_71ff7bc5-9d8e-4a6d-9d4e-3bf79b03358f"
      unitRef="usdPerShare">-0.09</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare
      contextRef="i546c40c371924532a3d2ed0ace7d354b_D20211001-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMzAvZnJhZzo3NGIwMjA4NWYwNjY0MjYyOGY3OWUzMTNlNjFkZmI3Yy90YWJsZTpmYTRmNTRhZWVjNTg0NDBiYmYyYTcwYWUxMDNkNDVlNy90YWJsZXJhbmdlOmZhNGY1NGFlZWM1ODQ0MGJiZjJhNzBhZTEwM2Q0NWU3XzEzLTEtMS0xLTI2OTQ4_d4e997de-823f-434c-81e4-ac6cb667ac0e"
      unitRef="usdPerShare">-0.09</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare
      contextRef="i973a81e9b0924e4e86048dc6df6379d0_D20210701-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMzAvZnJhZzo3NGIwMjA4NWYwNjY0MjYyOGY3OWUzMTNlNjFkZmI3Yy90YWJsZTpmYTRmNTRhZWVjNTg0NDBiYmYyYTcwYWUxMDNkNDVlNy90YWJsZXJhbmdlOmZhNGY1NGFlZWM1ODQ0MGJiZjJhNzBhZTEwM2Q0NWU3XzEyLTMtMS0xLTM2NTE0_8108b0e2-93cd-4627-88a1-5a01580763c0"
      unitRef="usdPerShare">0</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare
      contextRef="i973a81e9b0924e4e86048dc6df6379d0_D20210701-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMzAvZnJhZzo3NGIwMjA4NWYwNjY0MjYyOGY3OWUzMTNlNjFkZmI3Yy90YWJsZTpmYTRmNTRhZWVjNTg0NDBiYmYyYTcwYWUxMDNkNDVlNy90YWJsZXJhbmdlOmZhNGY1NGFlZWM1ODQ0MGJiZjJhNzBhZTEwM2Q0NWU3XzEyLTMtMS0xLTM2NTE0_aa9ec4cf-2ff6-4e10-a3c0-2021f6c09dc8"
      unitRef="usdPerShare">0</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare
      contextRef="i8b76d915d864443fbfe177d29bc9e4e4_D20210401-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMzAvZnJhZzo3NGIwMjA4NWYwNjY0MjYyOGY3OWUzMTNlNjFkZmI3Yy90YWJsZTpmYTRmNTRhZWVjNTg0NDBiYmYyYTcwYWUxMDNkNDVlNy90YWJsZXJhbmdlOmZhNGY1NGFlZWM1ODQ0MGJiZjJhNzBhZTEwM2Q0NWU3XzEyLTUtMS0xLTM2NTE2_8bc4704a-735c-43b7-baa7-ae59ae5847ae"
      unitRef="usdPerShare">0</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare
      contextRef="i8b76d915d864443fbfe177d29bc9e4e4_D20210401-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMzAvZnJhZzo3NGIwMjA4NWYwNjY0MjYyOGY3OWUzMTNlNjFkZmI3Yy90YWJsZTpmYTRmNTRhZWVjNTg0NDBiYmYyYTcwYWUxMDNkNDVlNy90YWJsZXJhbmdlOmZhNGY1NGFlZWM1ODQ0MGJiZjJhNzBhZTEwM2Q0NWU3XzEyLTUtMS0xLTM2NTE2_f7c87c53-8420-44d0-b53e-cddc38081f96"
      unitRef="usdPerShare">0</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare
      contextRef="i035c62f748c14287b929adf98e0b2fbb_D20210101-20210331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMzAvZnJhZzo3NGIwMjA4NWYwNjY0MjYyOGY3OWUzMTNlNjFkZmI3Yy90YWJsZTpmYTRmNTRhZWVjNTg0NDBiYmYyYTcwYWUxMDNkNDVlNy90YWJsZXJhbmdlOmZhNGY1NGFlZWM1ODQ0MGJiZjJhNzBhZTEwM2Q0NWU3XzEyLTctMS0xLTM2NTE4_74e34c65-6e81-410b-8670-fc0259fbd9b0"
      unitRef="usdPerShare">0.01</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare
      contextRef="i035c62f748c14287b929adf98e0b2fbb_D20210101-20210331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMzAvZnJhZzo3NGIwMjA4NWYwNjY0MjYyOGY3OWUzMTNlNjFkZmI3Yy90YWJsZTpmYTRmNTRhZWVjNTg0NDBiYmYyYTcwYWUxMDNkNDVlNy90YWJsZXJhbmdlOmZhNGY1NGFlZWM1ODQ0MGJiZjJhNzBhZTEwM2Q0NWU3XzEyLTctMS0xLTM2NTE4_8a38320d-e774-45d7-aeaa-f83be35e5417"
      unitRef="usdPerShare">0.01</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare>
    <us-gaap:Revenues
      contextRef="i6d3bee5994474a229055f5b47133978b_D20201001-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMzAvZnJhZzo3NGIwMjA4NWYwNjY0MjYyOGY3OWUzMTNlNjFkZmI3Yy90YWJsZTpmYTRmNTRhZWVjNTg0NDBiYmYyYTcwYWUxMDNkNDVlNy90YWJsZXJhbmdlOmZhNGY1NGFlZWM1ODQ0MGJiZjJhNzBhZTEwM2Q0NWU3XzEzLTEtMS0xLTE3Nzc1_106fbf4c-e28d-4db7-ba72-a014be273555"
      unitRef="usd">246536000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i03844ec391854836b0d4437e624d231c_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMzAvZnJhZzo3NGIwMjA4NWYwNjY0MjYyOGY3OWUzMTNlNjFkZmI3Yy90YWJsZTpmYTRmNTRhZWVjNTg0NDBiYmYyYTcwYWUxMDNkNDVlNy90YWJsZXJhbmdlOmZhNGY1NGFlZWM1ODQ0MGJiZjJhNzBhZTEwM2Q0NWU3XzEzLTMtMS0xLTE3Nzc1_4ee5a407-8d1e-432d-9e58-fc4cf847bd47"
      unitRef="usd">239572000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i62320e40739f4842b8ffb078d42fa029_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMzAvZnJhZzo3NGIwMjA4NWYwNjY0MjYyOGY3OWUzMTNlNjFkZmI3Yy90YWJsZTpmYTRmNTRhZWVjNTg0NDBiYmYyYTcwYWUxMDNkNDVlNy90YWJsZXJhbmdlOmZhNGY1NGFlZWM1ODQ0MGJiZjJhNzBhZTEwM2Q0NWU3XzEzLTUtMS0xLTE3Nzc1_1bd9277f-bc22-4062-afdf-42121f6b0984"
      unitRef="usd">217299000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="iddbf996a3b1a4aeda47f1e8169c69262_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMzAvZnJhZzo3NGIwMjA4NWYwNjY0MjYyOGY3OWUzMTNlNjFkZmI3Yy90YWJsZTpmYTRmNTRhZWVjNTg0NDBiYmYyYTcwYWUxMDNkNDVlNy90YWJsZXJhbmdlOmZhNGY1NGFlZWM1ODQ0MGJiZjJhNzBhZTEwM2Q0NWU3XzEzLTctMS0xLTE3Nzc1_7f4d6da2-81c5-4a2f-a664-5b1c318d57e3"
      unitRef="usd">221232000</us-gaap:Revenues>
    <us-gaap:OperatingExpenses
      contextRef="i6d3bee5994474a229055f5b47133978b_D20201001-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMzAvZnJhZzo3NGIwMjA4NWYwNjY0MjYyOGY3OWUzMTNlNjFkZmI3Yy90YWJsZTpmYTRmNTRhZWVjNTg0NDBiYmYyYTcwYWUxMDNkNDVlNy90YWJsZXJhbmdlOmZhNGY1NGFlZWM1ODQ0MGJiZjJhNzBhZTEwM2Q0NWU3XzE0LTEtMS0xLTE3Nzc1_8f88a7df-1fff-4855-86fe-9781feddcd7a"
      unitRef="usd">246804000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="i03844ec391854836b0d4437e624d231c_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMzAvZnJhZzo3NGIwMjA4NWYwNjY0MjYyOGY3OWUzMTNlNjFkZmI3Yy90YWJsZTpmYTRmNTRhZWVjNTg0NDBiYmYyYTcwYWUxMDNkNDVlNy90YWJsZXJhbmdlOmZhNGY1NGFlZWM1ODQ0MGJiZjJhNzBhZTEwM2Q0NWU3XzE0LTMtMS0xLTE3Nzc1_9180a47f-5abf-46f0-a62b-c26a2266d945"
      unitRef="usd">256020000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="i62320e40739f4842b8ffb078d42fa029_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMzAvZnJhZzo3NGIwMjA4NWYwNjY0MjYyOGY3OWUzMTNlNjFkZmI3Yy90YWJsZTpmYTRmNTRhZWVjNTg0NDBiYmYyYTcwYWUxMDNkNDVlNy90YWJsZXJhbmdlOmZhNGY1NGFlZWM1ODQ0MGJiZjJhNzBhZTEwM2Q0NWU3XzE0LTUtMS0xLTE3Nzc1_60219787-0541-4333-8ef0-63bf423592cb"
      unitRef="usd">443128000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="iddbf996a3b1a4aeda47f1e8169c69262_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMzAvZnJhZzo3NGIwMjA4NWYwNjY0MjYyOGY3OWUzMTNlNjFkZmI3Yy90YWJsZTpmYTRmNTRhZWVjNTg0NDBiYmYyYTcwYWUxMDNkNDVlNy90YWJsZXJhbmdlOmZhNGY1NGFlZWM1ODQ0MGJiZjJhNzBhZTEwM2Q0NWU3XzE0LTctMS0xLTE3Nzc1_f14df40f-a313-47a4-9359-5250a9c8f7ea"
      unitRef="usd">246323000</us-gaap:OperatingExpenses>
    <us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i6d3bee5994474a229055f5b47133978b_D20201001-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMzAvZnJhZzo3NGIwMjA4NWYwNjY0MjYyOGY3OWUzMTNlNjFkZmI3Yy90YWJsZTpmYTRmNTRhZWVjNTg0NDBiYmYyYTcwYWUxMDNkNDVlNy90YWJsZXJhbmdlOmZhNGY1NGFlZWM1ODQ0MGJiZjJhNzBhZTEwM2Q0NWU3XzE1LTEtMS0xLTE3Nzc1_d2f1ab6f-9b96-477c-8519-e180fd534ed8"
      unitRef="usd">-10637000</us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i03844ec391854836b0d4437e624d231c_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMzAvZnJhZzo3NGIwMjA4NWYwNjY0MjYyOGY3OWUzMTNlNjFkZmI3Yy90YWJsZTpmYTRmNTRhZWVjNTg0NDBiYmYyYTcwYWUxMDNkNDVlNy90YWJsZXJhbmdlOmZhNGY1NGFlZWM1ODQ0MGJiZjJhNzBhZTEwM2Q0NWU3XzE1LTMtMS0xLTE3Nzc1_20842b0e-edbb-4187-8e6a-66a0bf00a515"
      unitRef="usd">-37035000</us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i62320e40739f4842b8ffb078d42fa029_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMzAvZnJhZzo3NGIwMjA4NWYwNjY0MjYyOGY3OWUzMTNlNjFkZmI3Yy90YWJsZTpmYTRmNTRhZWVjNTg0NDBiYmYyYTcwYWUxMDNkNDVlNy90YWJsZXJhbmdlOmZhNGY1NGFlZWM1ODQ0MGJiZjJhNzBhZTEwM2Q0NWU3XzE1LTUtMS0xLTE3Nzc1_d3ecbc03-39d4-4a58-96f9-ce919098b68f"
      unitRef="usd">-202013000</us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
      contextRef="iddbf996a3b1a4aeda47f1e8169c69262_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMzAvZnJhZzo3NGIwMjA4NWYwNjY0MjYyOGY3OWUzMTNlNjFkZmI3Yy90YWJsZTpmYTRmNTRhZWVjNTg0NDBiYmYyYTcwYWUxMDNkNDVlNy90YWJsZXJhbmdlOmZhNGY1NGFlZWM1ODQ0MGJiZjJhNzBhZTEwM2Q0NWU3XzE1LTctMS0xLTE3Nzc1_8a72ee11-ee44-4d2d-8822-55a81845ef01"
      unitRef="usd">-78487000</us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax
      contextRef="i6d3bee5994474a229055f5b47133978b_D20201001-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMzAvZnJhZzo3NGIwMjA4NWYwNjY0MjYyOGY3OWUzMTNlNjFkZmI3Yy90YWJsZTpmYTRmNTRhZWVjNTg0NDBiYmYyYTcwYWUxMDNkNDVlNy90YWJsZXJhbmdlOmZhNGY1NGFlZWM1ODQ0MGJiZjJhNzBhZTEwM2Q0NWU3XzE2LTEtMS0xLTE3Nzc1_5445c214-1a15-424a-aee8-876d054144bd"
      unitRef="usd">-3166000</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax
      contextRef="i03844ec391854836b0d4437e624d231c_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMzAvZnJhZzo3NGIwMjA4NWYwNjY0MjYyOGY3OWUzMTNlNjFkZmI3Yy90YWJsZTpmYTRmNTRhZWVjNTg0NDBiYmYyYTcwYWUxMDNkNDVlNy90YWJsZXJhbmdlOmZhNGY1NGFlZWM1ODQ0MGJiZjJhNzBhZTEwM2Q0NWU3XzE2LTMtMS0xLTE3Nzc1_99d2cb9e-e1ad-4b66-b12b-4baee565baef"
      unitRef="usd">-1135000</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax
      contextRef="i62320e40739f4842b8ffb078d42fa029_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMzAvZnJhZzo3NGIwMjA4NWYwNjY0MjYyOGY3OWUzMTNlNjFkZmI3Yy90YWJsZTpmYTRmNTRhZWVjNTg0NDBiYmYyYTcwYWUxMDNkNDVlNy90YWJsZXJhbmdlOmZhNGY1NGFlZWM1ODQ0MGJiZjJhNzBhZTEwM2Q0NWU3XzE2LTUtMS0xLTE3Nzc1_87a28350-f8f2-48ae-95a3-da1e41f5ba68"
      unitRef="usd">-1508000</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax
      contextRef="iddbf996a3b1a4aeda47f1e8169c69262_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMzAvZnJhZzo3NGIwMjA4NWYwNjY0MjYyOGY3OWUzMTNlNjFkZmI3Yy90YWJsZTpmYTRmNTRhZWVjNTg0NDBiYmYyYTcwYWUxMDNkNDVlNy90YWJsZXJhbmdlOmZhNGY1NGFlZWM1ODQ0MGJiZjJhNzBhZTEwM2Q0NWU3XzE2LTctMS0xLTE3Nzc1_0a50e548-9388-459c-a5e5-32f4e0b2d2dd"
      unitRef="usd">-265000</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="i6d3bee5994474a229055f5b47133978b_D20201001-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMzAvZnJhZzo3NGIwMjA4NWYwNjY0MjYyOGY3OWUzMTNlNjFkZmI3Yy90YWJsZTpmYTRmNTRhZWVjNTg0NDBiYmYyYTcwYWUxMDNkNDVlNy90YWJsZXJhbmdlOmZhNGY1NGFlZWM1ODQ0MGJiZjJhNzBhZTEwM2Q0NWU3XzE3LTEtMS0xLTE3Nzc1_4dcab5c5-b83f-4c5f-bfdf-98be054c69d9"
      unitRef="usd">822000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="i03844ec391854836b0d4437e624d231c_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMzAvZnJhZzo3NGIwMjA4NWYwNjY0MjYyOGY3OWUzMTNlNjFkZmI3Yy90YWJsZTpmYTRmNTRhZWVjNTg0NDBiYmYyYTcwYWUxMDNkNDVlNy90YWJsZXJhbmdlOmZhNGY1NGFlZWM1ODQ0MGJiZjJhNzBhZTEwM2Q0NWU3XzE3LTMtMS0xLTE3Nzc1_e0be547e-c925-4ec4-8866-1c2b2fe7a29d"
      unitRef="usd">-822000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="i62320e40739f4842b8ffb078d42fa029_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMzAvZnJhZzo3NGIwMjA4NWYwNjY0MjYyOGY3OWUzMTNlNjFkZmI3Yy90YWJsZTpmYTRmNTRhZWVjNTg0NDBiYmYyYTcwYWUxMDNkNDVlNy90YWJsZXJhbmdlOmZhNGY1NGFlZWM1ODQ0MGJiZjJhNzBhZTEwM2Q0NWU3XzE3LTUtMS0xLTE3Nzc1_afa2c0fe-7711-49a0-b4fe-d67a38e8e3bf"
      unitRef="usd">0</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="iddbf996a3b1a4aeda47f1e8169c69262_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMzAvZnJhZzo3NGIwMjA4NWYwNjY0MjYyOGY3OWUzMTNlNjFkZmI3Yy90YWJsZTpmYTRmNTRhZWVjNTg0NDBiYmYyYTcwYWUxMDNkNDVlNy90YWJsZXJhbmdlOmZhNGY1NGFlZWM1ODQ0MGJiZjJhNzBhZTEwM2Q0NWU3XzE3LTctMS0xLTE3Nzc1_cb0c9cc2-9df4-466d-964a-0d6b2d73758b"
      unitRef="usd">0</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted
      contextRef="i6d3bee5994474a229055f5b47133978b_D20201001-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMzAvZnJhZzo3NGIwMjA4NWYwNjY0MjYyOGY3OWUzMTNlNjFkZmI3Yy90YWJsZTpmYTRmNTRhZWVjNTg0NDBiYmYyYTcwYWUxMDNkNDVlNy90YWJsZXJhbmdlOmZhNGY1NGFlZWM1ODQ0MGJiZjJhNzBhZTEwM2Q0NWU3XzIwLTEtMS0xLTM2NTIw_100a0286-bb27-4c87-bf31-a1400c936877"
      unitRef="usd">-14625000</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="i6d3bee5994474a229055f5b47133978b_D20201001-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMzAvZnJhZzo3NGIwMjA4NWYwNjY0MjYyOGY3OWUzMTNlNjFkZmI3Yy90YWJsZTpmYTRmNTRhZWVjNTg0NDBiYmYyYTcwYWUxMDNkNDVlNy90YWJsZXJhbmdlOmZhNGY1NGFlZWM1ODQ0MGJiZjJhNzBhZTEwM2Q0NWU3XzIwLTEtMS0xLTM2NTIw_9a514bcd-b0ba-4037-abd1-73cd20163929"
      unitRef="usd">-14625000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="i03844ec391854836b0d4437e624d231c_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMzAvZnJhZzo3NGIwMjA4NWYwNjY0MjYyOGY3OWUzMTNlNjFkZmI3Yy90YWJsZTpmYTRmNTRhZWVjNTg0NDBiYmYyYTcwYWUxMDNkNDVlNy90YWJsZXJhbmdlOmZhNGY1NGFlZWM1ODQ0MGJiZjJhNzBhZTEwM2Q0NWU3XzIwLTMtMS0xLTM2NTIy_c70744e7-24d4-4b64-8c83-9faf0c54ef7b"
      unitRef="usd">-37348000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted
      contextRef="i03844ec391854836b0d4437e624d231c_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMzAvZnJhZzo3NGIwMjA4NWYwNjY0MjYyOGY3OWUzMTNlNjFkZmI3Yy90YWJsZTpmYTRmNTRhZWVjNTg0NDBiYmYyYTcwYWUxMDNkNDVlNy90YWJsZXJhbmdlOmZhNGY1NGFlZWM1ODQ0MGJiZjJhNzBhZTEwM2Q0NWU3XzIwLTMtMS0xLTM2NTIy_ce0890af-def0-4f23-88da-7ef72c95fd71"
      unitRef="usd">-37348000</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="i62320e40739f4842b8ffb078d42fa029_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMzAvZnJhZzo3NGIwMjA4NWYwNjY0MjYyOGY3OWUzMTNlNjFkZmI3Yy90YWJsZTpmYTRmNTRhZWVjNTg0NDBiYmYyYTcwYWUxMDNkNDVlNy90YWJsZXJhbmdlOmZhNGY1NGFlZWM1ODQ0MGJiZjJhNzBhZTEwM2Q0NWU3XzIwLTUtMS0xLTM2NTI0_6769187a-a0c9-43f7-86cd-97872b0ea43e"
      unitRef="usd">-203521000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted
      contextRef="i62320e40739f4842b8ffb078d42fa029_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMzAvZnJhZzo3NGIwMjA4NWYwNjY0MjYyOGY3OWUzMTNlNjFkZmI3Yy90YWJsZTpmYTRmNTRhZWVjNTg0NDBiYmYyYTcwYWUxMDNkNDVlNy90YWJsZXJhbmdlOmZhNGY1NGFlZWM1ODQ0MGJiZjJhNzBhZTEwM2Q0NWU3XzIwLTUtMS0xLTM2NTI0_b71c6d8f-aa0b-4a06-b598-6dd2448f5309"
      unitRef="usd">-203521000</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted
      contextRef="iddbf996a3b1a4aeda47f1e8169c69262_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMzAvZnJhZzo3NGIwMjA4NWYwNjY0MjYyOGY3OWUzMTNlNjFkZmI3Yy90YWJsZTpmYTRmNTRhZWVjNTg0NDBiYmYyYTcwYWUxMDNkNDVlNy90YWJsZXJhbmdlOmZhNGY1NGFlZWM1ODQ0MGJiZjJhNzBhZTEwM2Q0NWU3XzIwLTctMS0xLTM2NTI2_01e700bb-0dba-4928-9c4b-789bda8bd84d"
      unitRef="usd">-78752000</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="iddbf996a3b1a4aeda47f1e8169c69262_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMzAvZnJhZzo3NGIwMjA4NWYwNjY0MjYyOGY3OWUzMTNlNjFkZmI3Yy90YWJsZTpmYTRmNTRhZWVjNTg0NDBiYmYyYTcwYWUxMDNkNDVlNy90YWJsZXJhbmdlOmZhNGY1NGFlZWM1ODQ0MGJiZjJhNzBhZTEwM2Q0NWU3XzIwLTctMS0xLTM2NTI2_dd32049a-893f-47b6-aaa5-5296cabc46ad"
      unitRef="usd">-78752000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:IncomeLossFromContinuingOperationsPerBasicShare
      contextRef="i6d3bee5994474a229055f5b47133978b_D20201001-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMzAvZnJhZzo3NGIwMjA4NWYwNjY0MjYyOGY3OWUzMTNlNjFkZmI3Yy90YWJsZTpmYTRmNTRhZWVjNTg0NDBiYmYyYTcwYWUxMDNkNDVlNy90YWJsZXJhbmdlOmZhNGY1NGFlZWM1ODQ0MGJiZjJhNzBhZTEwM2Q0NWU3XzI0LTEtMS0xLTM1MTAw_7c8ba314-c839-4a84-a475-9abd7a589ce2"
      unitRef="usdPerShare">-0.13</us-gaap:IncomeLossFromContinuingOperationsPerBasicShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare
      contextRef="i6d3bee5994474a229055f5b47133978b_D20201001-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMzAvZnJhZzo3NGIwMjA4NWYwNjY0MjYyOGY3OWUzMTNlNjFkZmI3Yy90YWJsZTpmYTRmNTRhZWVjNTg0NDBiYmYyYTcwYWUxMDNkNDVlNy90YWJsZXJhbmdlOmZhNGY1NGFlZWM1ODQ0MGJiZjJhNzBhZTEwM2Q0NWU3XzI0LTEtMS0xLTM1MTAw_acee618a-ad17-4389-ba07-298417eb3f4e"
      unitRef="usdPerShare">-0.13</us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerBasicShare
      contextRef="i03844ec391854836b0d4437e624d231c_D20200701-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMzAvZnJhZzo3NGIwMjA4NWYwNjY0MjYyOGY3OWUzMTNlNjFkZmI3Yy90YWJsZTpmYTRmNTRhZWVjNTg0NDBiYmYyYTcwYWUxMDNkNDVlNy90YWJsZXJhbmdlOmZhNGY1NGFlZWM1ODQ0MGJiZjJhNzBhZTEwM2Q0NWU3XzI0LTMtMS0xLTM2NTI4_a6906016-12c9-4648-b79c-6694337a261d"
      unitRef="usdPerShare">-0.43</us-gaap:IncomeLossFromContinuingOperationsPerBasicShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare
      contextRef="i03844ec391854836b0d4437e624d231c_D20200701-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMzAvZnJhZzo3NGIwMjA4NWYwNjY0MjYyOGY3OWUzMTNlNjFkZmI3Yy90YWJsZTpmYTRmNTRhZWVjNTg0NDBiYmYyYTcwYWUxMDNkNDVlNy90YWJsZXJhbmdlOmZhNGY1NGFlZWM1ODQ0MGJiZjJhNzBhZTEwM2Q0NWU3XzI0LTMtMS0xLTM2NTI4_c80086aa-209d-430e-aa26-f996d039a2f5"
      unitRef="usdPerShare">-0.43</us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare
      contextRef="i62320e40739f4842b8ffb078d42fa029_D20200401-20200630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMzAvZnJhZzo3NGIwMjA4NWYwNjY0MjYyOGY3OWUzMTNlNjFkZmI3Yy90YWJsZTpmYTRmNTRhZWVjNTg0NDBiYmYyYTcwYWUxMDNkNDVlNy90YWJsZXJhbmdlOmZhNGY1NGFlZWM1ODQ0MGJiZjJhNzBhZTEwM2Q0NWU3XzI0LTUtMS0xLTM2NTMw_20128d4f-e85e-4af4-9a7a-270e72f663e1"
      unitRef="usdPerShare">-2.37</us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerBasicShare
      contextRef="i62320e40739f4842b8ffb078d42fa029_D20200401-20200630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMzAvZnJhZzo3NGIwMjA4NWYwNjY0MjYyOGY3OWUzMTNlNjFkZmI3Yy90YWJsZTpmYTRmNTRhZWVjNTg0NDBiYmYyYTcwYWUxMDNkNDVlNy90YWJsZXJhbmdlOmZhNGY1NGFlZWM1ODQ0MGJiZjJhNzBhZTEwM2Q0NWU3XzI0LTUtMS0xLTM2NTMw_8615fb14-33af-4870-8326-cd008f0e9c5f"
      unitRef="usdPerShare">-2.37</us-gaap:IncomeLossFromContinuingOperationsPerBasicShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerBasicShare
      contextRef="iddbf996a3b1a4aeda47f1e8169c69262_D20200101-20200331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMzAvZnJhZzo3NGIwMjA4NWYwNjY0MjYyOGY3OWUzMTNlNjFkZmI3Yy90YWJsZTpmYTRmNTRhZWVjNTg0NDBiYmYyYTcwYWUxMDNkNDVlNy90YWJsZXJhbmdlOmZhNGY1NGFlZWM1ODQ0MGJiZjJhNzBhZTEwM2Q0NWU3XzI0LTctMS0xLTM2NTMy_078f12ed-a128-46ca-babc-aa24c441c1a2"
      unitRef="usdPerShare">-0.93</us-gaap:IncomeLossFromContinuingOperationsPerBasicShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare
      contextRef="iddbf996a3b1a4aeda47f1e8169c69262_D20200101-20200331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMzAvZnJhZzo3NGIwMjA4NWYwNjY0MjYyOGY3OWUzMTNlNjFkZmI3Yy90YWJsZTpmYTRmNTRhZWVjNTg0NDBiYmYyYTcwYWUxMDNkNDVlNy90YWJsZXJhbmdlOmZhNGY1NGFlZWM1ODQ0MGJiZjJhNzBhZTEwM2Q0NWU3XzI0LTctMS0xLTM2NTMy_cb613fa9-8680-49c8-8bd8-88e8190bb840"
      unitRef="usdPerShare">-0.93</us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare
      contextRef="i6d3bee5994474a229055f5b47133978b_D20201001-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMzAvZnJhZzo3NGIwMjA4NWYwNjY0MjYyOGY3OWUzMTNlNjFkZmI3Yy90YWJsZTpmYTRmNTRhZWVjNTg0NDBiYmYyYTcwYWUxMDNkNDVlNy90YWJsZXJhbmdlOmZhNGY1NGFlZWM1ODQ0MGJiZjJhNzBhZTEwM2Q0NWU3XzI1LTEtMS0xLTM1MTAw_89f2a51b-0050-4032-904e-8a4ccbe4f405"
      unitRef="usdPerShare">-0.04</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare
      contextRef="i6d3bee5994474a229055f5b47133978b_D20201001-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMzAvZnJhZzo3NGIwMjA4NWYwNjY0MjYyOGY3OWUzMTNlNjFkZmI3Yy90YWJsZTpmYTRmNTRhZWVjNTg0NDBiYmYyYTcwYWUxMDNkNDVlNy90YWJsZXJhbmdlOmZhNGY1NGFlZWM1ODQ0MGJiZjJhNzBhZTEwM2Q0NWU3XzI1LTEtMS0xLTM1MTAw_a019db42-ac54-4b29-a8cf-c18b87664480"
      unitRef="usdPerShare">-0.04</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare
      contextRef="i03844ec391854836b0d4437e624d231c_D20200701-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMzAvZnJhZzo3NGIwMjA4NWYwNjY0MjYyOGY3OWUzMTNlNjFkZmI3Yy90YWJsZTpmYTRmNTRhZWVjNTg0NDBiYmYyYTcwYWUxMDNkNDVlNy90YWJsZXJhbmdlOmZhNGY1NGFlZWM1ODQ0MGJiZjJhNzBhZTEwM2Q0NWU3XzI1LTMtMS0xLTM2NTI4_7daff8f8-49b5-4adf-b772-41909d13bb3c"
      unitRef="usdPerShare">-0.01</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare
      contextRef="i03844ec391854836b0d4437e624d231c_D20200701-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMzAvZnJhZzo3NGIwMjA4NWYwNjY0MjYyOGY3OWUzMTNlNjFkZmI3Yy90YWJsZTpmYTRmNTRhZWVjNTg0NDBiYmYyYTcwYWUxMDNkNDVlNy90YWJsZXJhbmdlOmZhNGY1NGFlZWM1ODQ0MGJiZjJhNzBhZTEwM2Q0NWU3XzI1LTMtMS0xLTM2NTI4_ad24e020-00de-498f-9211-fcdeaa476259"
      unitRef="usdPerShare">-0.01</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare
      contextRef="i62320e40739f4842b8ffb078d42fa029_D20200401-20200630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMzAvZnJhZzo3NGIwMjA4NWYwNjY0MjYyOGY3OWUzMTNlNjFkZmI3Yy90YWJsZTpmYTRmNTRhZWVjNTg0NDBiYmYyYTcwYWUxMDNkNDVlNy90YWJsZXJhbmdlOmZhNGY1NGFlZWM1ODQ0MGJiZjJhNzBhZTEwM2Q0NWU3XzI1LTUtMS0xLTM2NTMw_3e9ac7f1-2b0d-4d1e-b606-1295fed5c86e"
      unitRef="usdPerShare">-0.01</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare
      contextRef="i62320e40739f4842b8ffb078d42fa029_D20200401-20200630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMzAvZnJhZzo3NGIwMjA4NWYwNjY0MjYyOGY3OWUzMTNlNjFkZmI3Yy90YWJsZTpmYTRmNTRhZWVjNTg0NDBiYmYyYTcwYWUxMDNkNDVlNy90YWJsZXJhbmdlOmZhNGY1NGFlZWM1ODQ0MGJiZjJhNzBhZTEwM2Q0NWU3XzI1LTUtMS0xLTM2NTMw_8406b797-b4f2-4393-afb6-7781b7fc5076"
      unitRef="usdPerShare">-0.01</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare
      contextRef="iddbf996a3b1a4aeda47f1e8169c69262_D20200101-20200331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMzAvZnJhZzo3NGIwMjA4NWYwNjY0MjYyOGY3OWUzMTNlNjFkZmI3Yy90YWJsZTpmYTRmNTRhZWVjNTg0NDBiYmYyYTcwYWUxMDNkNDVlNy90YWJsZXJhbmdlOmZhNGY1NGFlZWM1ODQ0MGJiZjJhNzBhZTEwM2Q0NWU3XzI1LTctMS0xLTM2NTMy_0a932461-164b-4bf3-9774-79abbfaea65f"
      unitRef="usdPerShare">0</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare
      contextRef="iddbf996a3b1a4aeda47f1e8169c69262_D20200101-20200331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMzAvZnJhZzo3NGIwMjA4NWYwNjY0MjYyOGY3OWUzMTNlNjFkZmI3Yy90YWJsZTpmYTRmNTRhZWVjNTg0NDBiYmYyYTcwYWUxMDNkNDVlNy90YWJsZXJhbmdlOmZhNGY1NGFlZWM1ODQ0MGJiZjJhNzBhZTEwM2Q0NWU3XzI1LTctMS0xLTM2NTMy_d3214475-e409-4186-89a3-b67b2118eb6e"
      unitRef="usdPerShare">0</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare>
    <us-gaap:CashFlowSupplementalDisclosuresTextBlock
      contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMzMvZnJhZzpmYTExMDg1YWMxYTA0ZTdhYWJlNjA4ZGRmNjhmY2VlZS90ZXh0cmVnaW9uOmZhMTEwODVhYzFhMDRlN2FhYmU2MDhkZGY2OGZjZWVlXzEzNA_3ff9f525-83e8-401e-8997-c5f428edcf71">Supplemental Cash Flow Information &lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following represents supplemental cash flow information the years ended December 31, 2021, 2020 and 2019 (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:380.50pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:48.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:48.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:48.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;For the Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Supplemental Disclosure of Non-cash Investing and Financing Activities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Class A and Class B common stock issued in connection with business combinations&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;56,626&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,556&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;Increase/decrease to goodwill from measurement period adjustments/business combinations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,200&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(351)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Class A common stock issued for payment of earn-outs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;450&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,185&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;800&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;Class A common stock issued in connection with debt repayment &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28,492&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gain from transfer of membership&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(22,969)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued property and equipment purchases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;784&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(527)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Consideration for asset acquisition or business combinations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Effects of Leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;Operating cash flows from operating leases &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,845&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,708&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,330&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;Leased assets obtained in exchange for operating lease liabilities &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,583)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,170)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30,463&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Effects of Class B Exchanges&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Decrease in non-controlling interests as a result of Class B Exchanges&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42,377&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Decrease in deferred tax liability as a result of securities offerings and exchanges&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(22)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Supplemental Disclosures &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash paid for interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,113&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,352&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,037&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash paid for taxes, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;551&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,679&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,484&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:CashFlowSupplementalDisclosuresTextBlock>
    <us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock
      contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMzMvZnJhZzpmYTExMDg1YWMxYTA0ZTdhYWJlNjA4ZGRmNjhmY2VlZS90ZXh0cmVnaW9uOmZhMTEwODVhYzFhMDRlN2FhYmU2MDhkZGY2OGZjZWVlXzEzOA_7f172474-1532-48f5-a9c1-6119585e87ec">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following represents supplemental cash flow information the years ended December 31, 2021, 2020 and 2019 (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:380.50pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:48.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:48.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:48.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;For the Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Supplemental Disclosure of Non-cash Investing and Financing Activities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Class A and Class B common stock issued in connection with business combinations&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;56,626&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,556&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;Increase/decrease to goodwill from measurement period adjustments/business combinations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,200&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(351)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Class A common stock issued for payment of earn-outs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;450&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,185&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;800&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;Class A common stock issued in connection with debt repayment &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28,492&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gain from transfer of membership&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(22,969)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued property and equipment purchases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;784&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(527)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Consideration for asset acquisition or business combinations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Effects of Leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;Operating cash flows from operating leases &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,845&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,708&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,330&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;Leased assets obtained in exchange for operating lease liabilities &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,583)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,170)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30,463&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Effects of Class B Exchanges&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Decrease in non-controlling interests as a result of Class B Exchanges&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42,377&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Decrease in deferred tax liability as a result of securities offerings and exchanges&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(22)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Supplemental Disclosures &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash paid for interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,113&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,352&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,037&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash paid for taxes, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;551&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,679&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,484&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock>
    <us-gaap:StockIssued1
      contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMzMvZnJhZzpmYTExMDg1YWMxYTA0ZTdhYWJlNjA4ZGRmNjhmY2VlZS90YWJsZTpiYzAwYmQ2YjAwNzk0MzE1OTE1M2JmYmY5YjAxZTE4MC90YWJsZXJhbmdlOmJjMDBiZDZiMDA3OTQzMTU5MTUzYmZiZjliMDFlMTgwXzMtMS0xLTEtMjMwNDY_9e889208-4f8a-476e-9489-807a3329171c"
      unitRef="usd">56626000</us-gaap:StockIssued1>
    <us-gaap:StockIssued1
      contextRef="i12a6d1161de54547bd29f8efccd4c9b0_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMzMvZnJhZzpmYTExMDg1YWMxYTA0ZTdhYWJlNjA4ZGRmNjhmY2VlZS90YWJsZTpiYzAwYmQ2YjAwNzk0MzE1OTE1M2JmYmY5YjAxZTE4MC90YWJsZXJhbmdlOmJjMDBiZDZiMDA3OTQzMTU5MTUzYmZiZjliMDFlMTgwXzMtMy0xLTEtMjMwNDY_509a01e9-77df-4a3d-bd95-4ac822328f72"
      unitRef="usd">0</us-gaap:StockIssued1>
    <us-gaap:StockIssued1
      contextRef="i3e21049ffc224cacb8134d73c9bb5b38_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMzMvZnJhZzpmYTExMDg1YWMxYTA0ZTdhYWJlNjA4ZGRmNjhmY2VlZS90YWJsZTpiYzAwYmQ2YjAwNzk0MzE1OTE1M2JmYmY5YjAxZTE4MC90YWJsZXJhbmdlOmJjMDBiZDZiMDA3OTQzMTU5MTUzYmZiZjliMDFlMTgwXzMtNS0xLTEtMjMwNDY_ab6f6bb9-27ad-4eb9-b26e-700b3f2876ff"
      unitRef="usd">23556000</us-gaap:StockIssued1>
    <evh:NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationMeasurementPeriodAdjustment
      contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMzMvZnJhZzpmYTExMDg1YWMxYTA0ZTdhYWJlNjA4ZGRmNjhmY2VlZS90YWJsZTpiYzAwYmQ2YjAwNzk0MzE1OTE1M2JmYmY5YjAxZTE4MC90YWJsZXJhbmdlOmJjMDBiZDZiMDA3OTQzMTU5MTUzYmZiZjliMDFlMTgwXzMtMS0xLTEtMTc3NzU_336547e3-5cfc-4010-be5b-9b537f2ca141"
      unitRef="usd">0</evh:NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationMeasurementPeriodAdjustment>
    <evh:NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationMeasurementPeriodAdjustment
      contextRef="i12a6d1161de54547bd29f8efccd4c9b0_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMzMvZnJhZzpmYTExMDg1YWMxYTA0ZTdhYWJlNjA4ZGRmNjhmY2VlZS90YWJsZTpiYzAwYmQ2YjAwNzk0MzE1OTE1M2JmYmY5YjAxZTE4MC90YWJsZXJhbmdlOmJjMDBiZDZiMDA3OTQzMTU5MTUzYmZiZjliMDFlMTgwXzMtMy0xLTEtMTc3NzU_01c310d1-1f91-4a8d-bb2f-081b540a866f"
      unitRef="usd">2200000</evh:NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationMeasurementPeriodAdjustment>
    <evh:NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationMeasurementPeriodAdjustment
      contextRef="i3e21049ffc224cacb8134d73c9bb5b38_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMzMvZnJhZzpmYTExMDg1YWMxYTA0ZTdhYWJlNjA4ZGRmNjhmY2VlZS90YWJsZTpiYzAwYmQ2YjAwNzk0MzE1OTE1M2JmYmY5YjAxZTE4MC90YWJsZXJhbmdlOmJjMDBiZDZiMDA3OTQzMTU5MTUzYmZiZjliMDFlMTgwXzQtNS0xLTEtMjMwNTU_643114ec-e575-435c-a283-579d57f6f024"
      unitRef="usd">-351000</evh:NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationMeasurementPeriodAdjustment>
    <us-gaap:NoncashOrPartNoncashAcquisitionPayablesAssumed1
      contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMzMvZnJhZzpmYTExMDg1YWMxYTA0ZTdhYWJlNjA4ZGRmNjhmY2VlZS90YWJsZTpiYzAwYmQ2YjAwNzk0MzE1OTE1M2JmYmY5YjAxZTE4MC90YWJsZXJhbmdlOmJjMDBiZDZiMDA3OTQzMTU5MTUzYmZiZjliMDFlMTgwXzQtMS0xLTEtMTc3NzU_c30f4752-c3a5-4c03-ad72-5c7687617d93"
      unitRef="usd">450000</us-gaap:NoncashOrPartNoncashAcquisitionPayablesAssumed1>
    <us-gaap:NoncashOrPartNoncashAcquisitionPayablesAssumed1
      contextRef="i12a6d1161de54547bd29f8efccd4c9b0_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMzMvZnJhZzpmYTExMDg1YWMxYTA0ZTdhYWJlNjA4ZGRmNjhmY2VlZS90YWJsZTpiYzAwYmQ2YjAwNzk0MzE1OTE1M2JmYmY5YjAxZTE4MC90YWJsZXJhbmdlOmJjMDBiZDZiMDA3OTQzMTU5MTUzYmZiZjliMDFlMTgwXzQtMy0xLTEtMTc3NzU_813fb96b-10b9-44d2-8b66-e34b0dd9f85f"
      unitRef="usd">4185000</us-gaap:NoncashOrPartNoncashAcquisitionPayablesAssumed1>
    <us-gaap:NoncashOrPartNoncashAcquisitionPayablesAssumed1
      contextRef="i3e21049ffc224cacb8134d73c9bb5b38_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMzMvZnJhZzpmYTExMDg1YWMxYTA0ZTdhYWJlNjA4ZGRmNjhmY2VlZS90YWJsZTpiYzAwYmQ2YjAwNzk0MzE1OTE1M2JmYmY5YjAxZTE4MC90YWJsZXJhbmdlOmJjMDBiZDZiMDA3OTQzMTU5MTUzYmZiZjliMDFlMTgwXzUtNS0xLTEtMjMwNTU_619dec06-78b8-49d9-9d97-ad2894de7bbe"
      unitRef="usd">800000</us-gaap:NoncashOrPartNoncashAcquisitionPayablesAssumed1>
    <evh:StockIssuedInConnectionWithDebtRepayment
      contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMzMvZnJhZzpmYTExMDg1YWMxYTA0ZTdhYWJlNjA4ZGRmNjhmY2VlZS90YWJsZTpiYzAwYmQ2YjAwNzk0MzE1OTE1M2JmYmY5YjAxZTE4MC90YWJsZXJhbmdlOmJjMDBiZDZiMDA3OTQzMTU5MTUzYmZiZjliMDFlMTgwXzYtMS0xLTEtMzMyMDQ_e5526c16-67ac-44ed-bb5b-c3cc182fbab0"
      unitRef="usd">28492000</evh:StockIssuedInConnectionWithDebtRepayment>
    <evh:StockIssuedInConnectionWithDebtRepayment
      contextRef="i12a6d1161de54547bd29f8efccd4c9b0_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMzMvZnJhZzpmYTExMDg1YWMxYTA0ZTdhYWJlNjA4ZGRmNjhmY2VlZS90YWJsZTpiYzAwYmQ2YjAwNzk0MzE1OTE1M2JmYmY5YjAxZTE4MC90YWJsZXJhbmdlOmJjMDBiZDZiMDA3OTQzMTU5MTUzYmZiZjliMDFlMTgwXzYtMy0xLTEtMzMyMDQ_81199ea5-73ec-450e-967f-4be02fc46935"
      unitRef="usd">0</evh:StockIssuedInConnectionWithDebtRepayment>
    <evh:StockIssuedInConnectionWithDebtRepayment
      contextRef="i3e21049ffc224cacb8134d73c9bb5b38_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMzMvZnJhZzpmYTExMDg1YWMxYTA0ZTdhYWJlNjA4ZGRmNjhmY2VlZS90YWJsZTpiYzAwYmQ2YjAwNzk0MzE1OTE1M2JmYmY5YjAxZTE4MC90YWJsZXJhbmdlOmJjMDBiZDZiMDA3OTQzMTU5MTUzYmZiZjliMDFlMTgwXzYtNS0xLTEtMzMyMDQ_2c0c0a64-b4cf-4d8d-9cba-7da8238310ec"
      unitRef="usd">0</evh:StockIssuedInConnectionWithDebtRepayment>
    <evh:GainLossFromTransferOfMembership
      contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMzMvZnJhZzpmYTExMDg1YWMxYTA0ZTdhYWJlNjA4ZGRmNjhmY2VlZS90YWJsZTpiYzAwYmQ2YjAwNzk0MzE1OTE1M2JmYmY5YjAxZTE4MC90YWJsZXJhbmdlOmJjMDBiZDZiMDA3OTQzMTU5MTUzYmZiZjliMDFlMTgwXzctMS0xLTEtMzMyMDQ_0b8bb3c7-e82a-418b-ad62-ef758a1af0c1"
      unitRef="usd">22969000</evh:GainLossFromTransferOfMembership>
    <evh:GainLossFromTransferOfMembership
      contextRef="i12a6d1161de54547bd29f8efccd4c9b0_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMzMvZnJhZzpmYTExMDg1YWMxYTA0ZTdhYWJlNjA4ZGRmNjhmY2VlZS90YWJsZTpiYzAwYmQ2YjAwNzk0MzE1OTE1M2JmYmY5YjAxZTE4MC90YWJsZXJhbmdlOmJjMDBiZDZiMDA3OTQzMTU5MTUzYmZiZjliMDFlMTgwXzctMy0xLTEtMzMyMDQ_9b9416bc-dc07-45a5-84c6-632ce1a8271d"
      unitRef="usd">0</evh:GainLossFromTransferOfMembership>
    <evh:GainLossFromTransferOfMembership
      contextRef="i3e21049ffc224cacb8134d73c9bb5b38_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMzMvZnJhZzpmYTExMDg1YWMxYTA0ZTdhYWJlNjA4ZGRmNjhmY2VlZS90YWJsZTpiYzAwYmQ2YjAwNzk0MzE1OTE1M2JmYmY5YjAxZTE4MC90YWJsZXJhbmdlOmJjMDBiZDZiMDA3OTQzMTU5MTUzYmZiZjliMDFlMTgwXzctNS0xLTEtMzMyMDQ_22002bc5-d9a7-43ef-83cb-0fae8940d042"
      unitRef="usd">0</evh:GainLossFromTransferOfMembership>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMzMvZnJhZzpmYTExMDg1YWMxYTA0ZTdhYWJlNjA4ZGRmNjhmY2VlZS90YWJsZTpiYzAwYmQ2YjAwNzk0MzE1OTE1M2JmYmY5YjAxZTE4MC90YWJsZXJhbmdlOmJjMDBiZDZiMDA3OTQzMTU5MTUzYmZiZjliMDFlMTgwXzUtMS0xLTEtMTc3NzU_e87405ae-4afa-4731-b99c-fda207f8704a"
      unitRef="usd">784000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="i12a6d1161de54547bd29f8efccd4c9b0_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMzMvZnJhZzpmYTExMDg1YWMxYTA0ZTdhYWJlNjA4ZGRmNjhmY2VlZS90YWJsZTpiYzAwYmQ2YjAwNzk0MzE1OTE1M2JmYmY5YjAxZTE4MC90YWJsZXJhbmdlOmJjMDBiZDZiMDA3OTQzMTU5MTUzYmZiZjliMDFlMTgwXzUtMy0xLTEtMTc3NzU_7a33b9f8-af5c-4d1b-8418-6fce6797f0e1"
      unitRef="usd">11000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <evh:AccruedPropertyAndEquipmentPurchases
      contextRef="i3e21049ffc224cacb8134d73c9bb5b38_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMzMvZnJhZzpmYTExMDg1YWMxYTA0ZTdhYWJlNjA4ZGRmNjhmY2VlZS90YWJsZTpiYzAwYmQ2YjAwNzk0MzE1OTE1M2JmYmY5YjAxZTE4MC90YWJsZXJhbmdlOmJjMDBiZDZiMDA3OTQzMTU5MTUzYmZiZjliMDFlMTgwXzYtNS0xLTEtMjMxMTc_553436e8-f5d5-400c-9e7c-8939e950da92"
      unitRef="usd">527000</evh:AccruedPropertyAndEquipmentPurchases>
    <us-gaap:NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1
      contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMzMvZnJhZzpmYTExMDg1YWMxYTA0ZTdhYWJlNjA4ZGRmNjhmY2VlZS90YWJsZTpiYzAwYmQ2YjAwNzk0MzE1OTE1M2JmYmY5YjAxZTE4MC90YWJsZXJhbmdlOmJjMDBiZDZiMDA3OTQzMTU5MTUzYmZiZjliMDFlMTgwXzgtMS0xLTEtMjMxMjc_19f8997c-ce5e-4adf-9d1f-b3c7392547c2"
      unitRef="usd">14600000</us-gaap:NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1>
    <us-gaap:NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1
      contextRef="i12a6d1161de54547bd29f8efccd4c9b0_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMzMvZnJhZzpmYTExMDg1YWMxYTA0ZTdhYWJlNjA4ZGRmNjhmY2VlZS90YWJsZTpiYzAwYmQ2YjAwNzk0MzE1OTE1M2JmYmY5YjAxZTE4MC90YWJsZXJhbmdlOmJjMDBiZDZiMDA3OTQzMTU5MTUzYmZiZjliMDFlMTgwXzgtMy0xLTEtMjMxMjc_e40587de-8756-41b7-9cd5-f9726064f642"
      unitRef="usd">0</us-gaap:NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1>
    <us-gaap:NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1
      contextRef="i3e21049ffc224cacb8134d73c9bb5b38_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMzMvZnJhZzpmYTExMDg1YWMxYTA0ZTdhYWJlNjA4ZGRmNjhmY2VlZS90YWJsZTpiYzAwYmQ2YjAwNzk0MzE1OTE1M2JmYmY5YjAxZTE4MC90YWJsZXJhbmdlOmJjMDBiZDZiMDA3OTQzMTU5MTUzYmZiZjliMDFlMTgwXzgtNS0xLTEtMjMxMjc_19c4be09-2b1d-44db-95db-1921e932eb9f"
      unitRef="usd">16000000</us-gaap:NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1>
    <us-gaap:OperatingLeasePayments
      contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMzMvZnJhZzpmYTExMDg1YWMxYTA0ZTdhYWJlNjA4ZGRmNjhmY2VlZS90YWJsZTpiYzAwYmQ2YjAwNzk0MzE1OTE1M2JmYmY5YjAxZTE4MC90YWJsZXJhbmdlOmJjMDBiZDZiMDA3OTQzMTU5MTUzYmZiZjliMDFlMTgwXzgtMS0xLTEtMTc3NzU_d7ef3dfc-fe1c-4ea9-aedc-0fb10601cc89"
      unitRef="usd">13845000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments
      contextRef="i12a6d1161de54547bd29f8efccd4c9b0_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMzMvZnJhZzpmYTExMDg1YWMxYTA0ZTdhYWJlNjA4ZGRmNjhmY2VlZS90YWJsZTpiYzAwYmQ2YjAwNzk0MzE1OTE1M2JmYmY5YjAxZTE4MC90YWJsZXJhbmdlOmJjMDBiZDZiMDA3OTQzMTU5MTUzYmZiZjliMDFlMTgwXzgtMy0xLTEtMTc3NzU_ebf3ce48-e7a7-43d0-89c6-4777d868aca0"
      unitRef="usd">13708000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments
      contextRef="i3e21049ffc224cacb8134d73c9bb5b38_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMzMvZnJhZzpmYTExMDg1YWMxYTA0ZTdhYWJlNjA4ZGRmNjhmY2VlZS90YWJsZTpiYzAwYmQ2YjAwNzk0MzE1OTE1M2JmYmY5YjAxZTE4MC90YWJsZXJhbmdlOmJjMDBiZDZiMDA3OTQzMTU5MTUzYmZiZjliMDFlMTgwXzktNS0xLTEtMjMxMDM_a7fa84e2-4241-473f-b88c-aa41b75fd315"
      unitRef="usd">12330000</us-gaap:OperatingLeasePayments>
    <evh:RightOfUseAssetAcquiredAndDisposedOf
      contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMzMvZnJhZzpmYTExMDg1YWMxYTA0ZTdhYWJlNjA4ZGRmNjhmY2VlZS90YWJsZTpiYzAwYmQ2YjAwNzk0MzE1OTE1M2JmYmY5YjAxZTE4MC90YWJsZXJhbmdlOmJjMDBiZDZiMDA3OTQzMTU5MTUzYmZiZjliMDFlMTgwXzktMS0xLTEtMTc3NzU_11f88147-b8b9-4468-b991-27be2a876baf"
      unitRef="usd">2583000</evh:RightOfUseAssetAcquiredAndDisposedOf>
    <evh:RightOfUseAssetAcquiredAndDisposedOf
      contextRef="i12a6d1161de54547bd29f8efccd4c9b0_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMzMvZnJhZzpmYTExMDg1YWMxYTA0ZTdhYWJlNjA4ZGRmNjhmY2VlZS90YWJsZTpiYzAwYmQ2YjAwNzk0MzE1OTE1M2JmYmY5YjAxZTE4MC90YWJsZXJhbmdlOmJjMDBiZDZiMDA3OTQzMTU5MTUzYmZiZjliMDFlMTgwXzktMy0xLTEtMTc3NzU_bfcb7c67-9c54-4116-8f1c-c2aed8db1c22"
      unitRef="usd">2170000</evh:RightOfUseAssetAcquiredAndDisposedOf>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="i3e21049ffc224cacb8134d73c9bb5b38_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMzMvZnJhZzpmYTExMDg1YWMxYTA0ZTdhYWJlNjA4ZGRmNjhmY2VlZS90YWJsZTpiYzAwYmQ2YjAwNzk0MzE1OTE1M2JmYmY5YjAxZTE4MC90YWJsZXJhbmdlOmJjMDBiZDZiMDA3OTQzMTU5MTUzYmZiZjliMDFlMTgwXzEwLTUtMS0xLTIzMTAz_03a1b0df-ae97-44ea-ad75-3a06a4f4d0b7"
      unitRef="usd">30463000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:ConversionOfStockAmountConverted1
      contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMzMvZnJhZzpmYTExMDg1YWMxYTA0ZTdhYWJlNjA4ZGRmNjhmY2VlZS90YWJsZTpiYzAwYmQ2YjAwNzk0MzE1OTE1M2JmYmY5YjAxZTE4MC90YWJsZXJhbmdlOmJjMDBiZDZiMDA3OTQzMTU5MTUzYmZiZjliMDFlMTgwXzEyLTEtMS0xLTIzMDcy_d776d98b-2326-4b07-aaa1-294d4ba6acd7"
      unitRef="usd">0</us-gaap:ConversionOfStockAmountConverted1>
    <us-gaap:ConversionOfStockAmountConverted1
      contextRef="i12a6d1161de54547bd29f8efccd4c9b0_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMzMvZnJhZzpmYTExMDg1YWMxYTA0ZTdhYWJlNjA4ZGRmNjhmY2VlZS90YWJsZTpiYzAwYmQ2YjAwNzk0MzE1OTE1M2JmYmY5YjAxZTE4MC90YWJsZXJhbmdlOmJjMDBiZDZiMDA3OTQzMTU5MTUzYmZiZjliMDFlMTgwXzEyLTMtMS0xLTIzMDcy_3dbd3100-7d57-40e4-ac63-4a67adf41548"
      unitRef="usd">0</us-gaap:ConversionOfStockAmountConverted1>
    <us-gaap:ConversionOfStockAmountConverted1
      contextRef="i3e21049ffc224cacb8134d73c9bb5b38_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMzMvZnJhZzpmYTExMDg1YWMxYTA0ZTdhYWJlNjA4ZGRmNjhmY2VlZS90YWJsZTpiYzAwYmQ2YjAwNzk0MzE1OTE1M2JmYmY5YjAxZTE4MC90YWJsZXJhbmdlOmJjMDBiZDZiMDA3OTQzMTU5MTUzYmZiZjliMDFlMTgwXzEyLTUtMS0xLTIzMDcy_38f96d7e-5c95-49da-9965-2409f4661f07"
      unitRef="usd">42377000</us-gaap:ConversionOfStockAmountConverted1>
    <evh:StockIssuedDecreaseInDeferredTaxLiability
      contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMzMvZnJhZzpmYTExMDg1YWMxYTA0ZTdhYWJlNjA4ZGRmNjhmY2VlZS90YWJsZTpiYzAwYmQ2YjAwNzk0MzE1OTE1M2JmYmY5YjAxZTE4MC90YWJsZXJhbmdlOmJjMDBiZDZiMDA3OTQzMTU5MTUzYmZiZjliMDFlMTgwXzEzLTEtMS0xLTIzMDcy_157ba297-e029-4933-a7f6-cad61424648f"
      unitRef="usd">0</evh:StockIssuedDecreaseInDeferredTaxLiability>
    <evh:StockIssuedDecreaseInDeferredTaxLiability
      contextRef="i12a6d1161de54547bd29f8efccd4c9b0_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMzMvZnJhZzpmYTExMDg1YWMxYTA0ZTdhYWJlNjA4ZGRmNjhmY2VlZS90YWJsZTpiYzAwYmQ2YjAwNzk0MzE1OTE1M2JmYmY5YjAxZTE4MC90YWJsZXJhbmdlOmJjMDBiZDZiMDA3OTQzMTU5MTUzYmZiZjliMDFlMTgwXzEzLTMtMS0xLTIzMDcy_92c802f1-645f-415a-8ed4-cbab9399d5b2"
      unitRef="usd">0</evh:StockIssuedDecreaseInDeferredTaxLiability>
    <evh:StockIssuedDecreaseInDeferredTaxLiability
      contextRef="i3e21049ffc224cacb8134d73c9bb5b38_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMzMvZnJhZzpmYTExMDg1YWMxYTA0ZTdhYWJlNjA4ZGRmNjhmY2VlZS90YWJsZTpiYzAwYmQ2YjAwNzk0MzE1OTE1M2JmYmY5YjAxZTE4MC90YWJsZXJhbmdlOmJjMDBiZDZiMDA3OTQzMTU5MTUzYmZiZjliMDFlMTgwXzEzLTUtMS0xLTIzMDcy_c6d7f01a-bfe9-4103-92f2-6eab736768a0"
      unitRef="usd">-22000</evh:StockIssuedDecreaseInDeferredTaxLiability>
    <us-gaap:InterestPaidNet
      contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMzMvZnJhZzpmYTExMDg1YWMxYTA0ZTdhYWJlNjA4ZGRmNjhmY2VlZS90YWJsZTpiYzAwYmQ2YjAwNzk0MzE1OTE1M2JmYmY5YjAxZTE4MC90YWJsZXJhbmdlOmJjMDBiZDZiMDA3OTQzMTU5MTUzYmZiZjliMDFlMTgwXzE2LTEtMS0xLTIzMDky_1aff8505-a149-4607-acee-988484d769e0"
      unitRef="usd">7113000</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet
      contextRef="i12a6d1161de54547bd29f8efccd4c9b0_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMzMvZnJhZzpmYTExMDg1YWMxYTA0ZTdhYWJlNjA4ZGRmNjhmY2VlZS90YWJsZTpiYzAwYmQ2YjAwNzk0MzE1OTE1M2JmYmY5YjAxZTE4MC90YWJsZXJhbmdlOmJjMDBiZDZiMDA3OTQzMTU5MTUzYmZiZjliMDFlMTgwXzE2LTMtMS0xLTIzMDky_fc562177-9f04-4966-b69f-466a60034117"
      unitRef="usd">13352000</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet
      contextRef="i3e21049ffc224cacb8134d73c9bb5b38_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMzMvZnJhZzpmYTExMDg1YWMxYTA0ZTdhYWJlNjA4ZGRmNjhmY2VlZS90YWJsZTpiYzAwYmQ2YjAwNzk0MzE1OTE1M2JmYmY5YjAxZTE4MC90YWJsZXJhbmdlOmJjMDBiZDZiMDA3OTQzMTU5MTUzYmZiZjliMDFlMTgwXzE2LTUtMS0xLTIzMDky_89ecf7c2-8920-4f87-8f9a-e20df9e021fd"
      unitRef="usd">5037000</us-gaap:InterestPaidNet>
    <us-gaap:IncomeTaxesPaid
      contextRef="idc0db51272c94df1839131500195947e_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMzMvZnJhZzpmYTExMDg1YWMxYTA0ZTdhYWJlNjA4ZGRmNjhmY2VlZS90YWJsZTpiYzAwYmQ2YjAwNzk0MzE1OTE1M2JmYmY5YjAxZTE4MC90YWJsZXJhbmdlOmJjMDBiZDZiMDA3OTQzMTU5MTUzYmZiZjliMDFlMTgwXzE3LTEtMS0xLTIzMDky_73b7d954-3ab2-4373-b340-30895233935a"
      unitRef="usd">551000</us-gaap:IncomeTaxesPaid>
    <us-gaap:IncomeTaxesPaid
      contextRef="i12a6d1161de54547bd29f8efccd4c9b0_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMzMvZnJhZzpmYTExMDg1YWMxYTA0ZTdhYWJlNjA4ZGRmNjhmY2VlZS90YWJsZTpiYzAwYmQ2YjAwNzk0MzE1OTE1M2JmYmY5YjAxZTE4MC90YWJsZXJhbmdlOmJjMDBiZDZiMDA3OTQzMTU5MTUzYmZiZjliMDFlMTgwXzE3LTMtMS0xLTIzMDky_1eaa4304-42f7-4fee-835d-8b04efd94ece"
      unitRef="usd">9679000</us-gaap:IncomeTaxesPaid>
    <us-gaap:IncomeTaxesPaid
      contextRef="i3e21049ffc224cacb8134d73c9bb5b38_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMzMvZnJhZzpmYTExMDg1YWMxYTA0ZTdhYWJlNjA4ZGRmNjhmY2VlZS90YWJsZTpiYzAwYmQ2YjAwNzk0MzE1OTE1M2JmYmY5YjAxZTE4MC90YWJsZXJhbmdlOmJjMDBiZDZiMDA3OTQzMTU5MTUzYmZiZjliMDFlMTgwXzE3LTUtMS0xLTIzMDky_ebcd76ed-b5be-41d1-8465-1f9acb9ded05"
      unitRef="usd">1484000</us-gaap:IncomeTaxesPaid>
    <link:footnoteLink
      xlink:role="http://www.xbrl.org/2003/role/link"
      xlink:type="extended">
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18zNC9mcmFnOjI3Y2IxNjhkZTFhNTRhNGQ5MGNkYTNlODdlZDg5N2RlL3RhYmxlOmE4OWNjMDNlN2U2MDQyMjY5NTA4MWU1MTFkYTU1MTkwL3RhYmxlcmFuZ2U6YTg5Y2MwM2U3ZTYwNDIyNjk1MDgxZTUxMWRhNTUxOTBfNTUtNS0xLTEtMTk3MDg_6223642a-5e62-4a5b-967f-f9e515b1dca7"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18zNC9mcmFnOjI3Y2IxNjhkZTFhNTRhNGQ5MGNkYTNlODdlZDg5N2RlL3RhYmxlOmE4OWNjMDNlN2U2MDQyMjY5NTA4MWU1MTFkYTU1MTkwL3RhYmxlcmFuZ2U6YTg5Y2MwM2U3ZTYwNDIyNjk1MDgxZTUxMWRhNTUxOTBfNTUtNS0xLTEtMTk3MDg_6223642a-5e62-4a5b-967f-f9e515b1dca7"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18zNC9mcmFnOjI3Y2IxNjhkZTFhNTRhNGQ5MGNkYTNlODdlZDg5N2RlL3RhYmxlOmE4OWNjMDNlN2U2MDQyMjY5NTA4MWU1MTFkYTU1MTkwL3RhYmxlcmFuZ2U6YTg5Y2MwM2U3ZTYwNDIyNjk1MDgxZTUxMWRhNTUxOTBfNTYtMy0xLTEtMTc3NzU_4f6ad754-8af7-4679-92ee-c45d9fc9dbf3"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18zNC9mcmFnOjI3Y2IxNjhkZTFhNTRhNGQ5MGNkYTNlODdlZDg5N2RlL3RhYmxlOmE4OWNjMDNlN2U2MDQyMjY5NTA4MWU1MTFkYTU1MTkwL3RhYmxlcmFuZ2U6YTg5Y2MwM2U3ZTYwNDIyNjk1MDgxZTUxMWRhNTUxOTBfNTYtMy0xLTEtMTc3NzU_4f6ad754-8af7-4679-92ee-c45d9fc9dbf3"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18zNC9mcmFnOjI3Y2IxNjhkZTFhNTRhNGQ5MGNkYTNlODdlZDg5N2RlL3RhYmxlOmE4OWNjMDNlN2U2MDQyMjY5NTA4MWU1MTFkYTU1MTkwL3RhYmxlcmFuZ2U6YTg5Y2MwM2U3ZTYwNDIyNjk1MDgxZTUxMWRhNTUxOTBfNTYtMS0xLTEtMTc3NzU_ffc6fbc1-32e0-4d84-81d2-24061d12a248"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18zNC9mcmFnOjI3Y2IxNjhkZTFhNTRhNGQ5MGNkYTNlODdlZDg5N2RlL3RhYmxlOmE4OWNjMDNlN2U2MDQyMjY5NTA4MWU1MTFkYTU1MTkwL3RhYmxlcmFuZ2U6YTg5Y2MwM2U3ZTYwNDIyNjk1MDgxZTUxMWRhNTUxOTBfNTYtMS0xLTEtMTc3NzU_ffc6fbc1-32e0-4d84-81d2-24061d12a248"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18zNC9mcmFnOjI3Y2IxNjhkZTFhNTRhNGQ5MGNkYTNlODdlZDg5N2RlL3RhYmxlOmE4OWNjMDNlN2U2MDQyMjY5NTA4MWU1MTFkYTU1MTkwL3RhYmxlcmFuZ2U6YTg5Y2MwM2U3ZTYwNDIyNjk1MDgxZTUxMWRhNTUxOTBfNTUtMy0xLTEtMTc3NzU_0dbfcc48-1d01-4540-ab2b-aa7e32633e3b"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18zNC9mcmFnOjI3Y2IxNjhkZTFhNTRhNGQ5MGNkYTNlODdlZDg5N2RlL3RhYmxlOmE4OWNjMDNlN2U2MDQyMjY5NTA4MWU1MTFkYTU1MTkwL3RhYmxlcmFuZ2U6YTg5Y2MwM2U3ZTYwNDIyNjk1MDgxZTUxMWRhNTUxOTBfNTUtMy0xLTEtMTc3NzU_0dbfcc48-1d01-4540-ab2b-aa7e32633e3b"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18zNC9mcmFnOjI3Y2IxNjhkZTFhNTRhNGQ5MGNkYTNlODdlZDg5N2RlL3RhYmxlOmE4OWNjMDNlN2U2MDQyMjY5NTA4MWU1MTFkYTU1MTkwL3RhYmxlcmFuZ2U6YTg5Y2MwM2U3ZTYwNDIyNjk1MDgxZTUxMWRhNTUxOTBfNTUtMS0xLTEtMTc3NzU_dc843966-7f80-4efe-b679-574368ea9780"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18zNC9mcmFnOjI3Y2IxNjhkZTFhNTRhNGQ5MGNkYTNlODdlZDg5N2RlL3RhYmxlOmE4OWNjMDNlN2U2MDQyMjY5NTA4MWU1MTFkYTU1MTkwL3RhYmxlcmFuZ2U6YTg5Y2MwM2U3ZTYwNDIyNjk1MDgxZTUxMWRhNTUxOTBfNTUtMS0xLTEtMTc3NzU_dc843966-7f80-4efe-b679-574368ea9780"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18zNC9mcmFnOjI3Y2IxNjhkZTFhNTRhNGQ5MGNkYTNlODdlZDg5N2RlL3RhYmxlOmE4OWNjMDNlN2U2MDQyMjY5NTA4MWU1MTFkYTU1MTkwL3RhYmxlcmFuZ2U6YTg5Y2MwM2U3ZTYwNDIyNjk1MDgxZTUxMWRhNTUxOTBfNTYtNS0xLTEtMTk3MDg_209232cd-73f4-4e84-8252-0b6a41a6baaa"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18zNC9mcmFnOjI3Y2IxNjhkZTFhNTRhNGQ5MGNkYTNlODdlZDg5N2RlL3RhYmxlOmE4OWNjMDNlN2U2MDQyMjY5NTA4MWU1MTFkYTU1MTkwL3RhYmxlcmFuZ2U6YTg5Y2MwM2U3ZTYwNDIyNjk1MDgxZTUxMWRhNTUxOTBfNTYtNS0xLTEtMTk3MDg_209232cd-73f4-4e84-8252-0b6a41a6baaa"
          xlink:type="locator"/>
        <link:footnote id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18zNC9mcmFnOjI3Y2IxNjhkZTFhNTRhNGQ5MGNkYTNlODdlZDg5N2RlL3RleHRyZWdpb246MjdjYjE2OGRlMWE1NGE0ZDkwY2RhM2U4N2VkODk3ZGVfNjE0_407cd0f7-2686-4510-bcd4-91690222a249" xlink:label="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18zNC9mcmFnOjI3Y2IxNjhkZTFhNTRhNGQ5MGNkYTNlODdlZDg5N2RlL3RleHRyZWdpb246MjdjYjE2OGRlMWE1NGE0ZDkwY2RhM2U4N2VkODk3ZGVfNjE0_407cd0f7-2686-4510-bcd4-91690222a249" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">See Note 5.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18zNC9mcmFnOjI3Y2IxNjhkZTFhNTRhNGQ5MGNkYTNlODdlZDg5N2RlL3RhYmxlOmE4OWNjMDNlN2U2MDQyMjY5NTA4MWU1MTFkYTU1MTkwL3RhYmxlcmFuZ2U6YTg5Y2MwM2U3ZTYwNDIyNjk1MDgxZTUxMWRhNTUxOTBfNTUtNS0xLTEtMTk3MDg_6223642a-5e62-4a5b-967f-f9e515b1dca7"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18zNC9mcmFnOjI3Y2IxNjhkZTFhNTRhNGQ5MGNkYTNlODdlZDg5N2RlL3RleHRyZWdpb246MjdjYjE2OGRlMWE1NGE0ZDkwY2RhM2U4N2VkODk3ZGVfNjE0_407cd0f7-2686-4510-bcd4-91690222a249"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18zNC9mcmFnOjI3Y2IxNjhkZTFhNTRhNGQ5MGNkYTNlODdlZDg5N2RlL3RhYmxlOmE4OWNjMDNlN2U2MDQyMjY5NTA4MWU1MTFkYTU1MTkwL3RhYmxlcmFuZ2U6YTg5Y2MwM2U3ZTYwNDIyNjk1MDgxZTUxMWRhNTUxOTBfNTYtMy0xLTEtMTc3NzU_4f6ad754-8af7-4679-92ee-c45d9fc9dbf3"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18zNC9mcmFnOjI3Y2IxNjhkZTFhNTRhNGQ5MGNkYTNlODdlZDg5N2RlL3RleHRyZWdpb246MjdjYjE2OGRlMWE1NGE0ZDkwY2RhM2U4N2VkODk3ZGVfNjE0_407cd0f7-2686-4510-bcd4-91690222a249"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18zNC9mcmFnOjI3Y2IxNjhkZTFhNTRhNGQ5MGNkYTNlODdlZDg5N2RlL3RhYmxlOmE4OWNjMDNlN2U2MDQyMjY5NTA4MWU1MTFkYTU1MTkwL3RhYmxlcmFuZ2U6YTg5Y2MwM2U3ZTYwNDIyNjk1MDgxZTUxMWRhNTUxOTBfNTYtMS0xLTEtMTc3NzU_ffc6fbc1-32e0-4d84-81d2-24061d12a248"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18zNC9mcmFnOjI3Y2IxNjhkZTFhNTRhNGQ5MGNkYTNlODdlZDg5N2RlL3RleHRyZWdpb246MjdjYjE2OGRlMWE1NGE0ZDkwY2RhM2U4N2VkODk3ZGVfNjE0_407cd0f7-2686-4510-bcd4-91690222a249"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18zNC9mcmFnOjI3Y2IxNjhkZTFhNTRhNGQ5MGNkYTNlODdlZDg5N2RlL3RhYmxlOmE4OWNjMDNlN2U2MDQyMjY5NTA4MWU1MTFkYTU1MTkwL3RhYmxlcmFuZ2U6YTg5Y2MwM2U3ZTYwNDIyNjk1MDgxZTUxMWRhNTUxOTBfNTUtMy0xLTEtMTc3NzU_0dbfcc48-1d01-4540-ab2b-aa7e32633e3b"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18zNC9mcmFnOjI3Y2IxNjhkZTFhNTRhNGQ5MGNkYTNlODdlZDg5N2RlL3RleHRyZWdpb246MjdjYjE2OGRlMWE1NGE0ZDkwY2RhM2U4N2VkODk3ZGVfNjE0_407cd0f7-2686-4510-bcd4-91690222a249"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18zNC9mcmFnOjI3Y2IxNjhkZTFhNTRhNGQ5MGNkYTNlODdlZDg5N2RlL3RhYmxlOmE4OWNjMDNlN2U2MDQyMjY5NTA4MWU1MTFkYTU1MTkwL3RhYmxlcmFuZ2U6YTg5Y2MwM2U3ZTYwNDIyNjk1MDgxZTUxMWRhNTUxOTBfNTUtMS0xLTEtMTc3NzU_dc843966-7f80-4efe-b679-574368ea9780"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18zNC9mcmFnOjI3Y2IxNjhkZTFhNTRhNGQ5MGNkYTNlODdlZDg5N2RlL3RleHRyZWdpb246MjdjYjE2OGRlMWE1NGE0ZDkwY2RhM2U4N2VkODk3ZGVfNjE0_407cd0f7-2686-4510-bcd4-91690222a249"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18zNC9mcmFnOjI3Y2IxNjhkZTFhNTRhNGQ5MGNkYTNlODdlZDg5N2RlL3RhYmxlOmE4OWNjMDNlN2U2MDQyMjY5NTA4MWU1MTFkYTU1MTkwL3RhYmxlcmFuZ2U6YTg5Y2MwM2U3ZTYwNDIyNjk1MDgxZTUxMWRhNTUxOTBfNTYtNS0xLTEtMTk3MDg_209232cd-73f4-4e84-8252-0b6a41a6baaa"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18zNC9mcmFnOjI3Y2IxNjhkZTFhNTRhNGQ5MGNkYTNlODdlZDg5N2RlL3RleHRyZWdpb246MjdjYjE2OGRlMWE1NGE0ZDkwY2RhM2U4N2VkODk3ZGVfNjE0_407cd0f7-2686-4510-bcd4-91690222a249"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yNS9mcmFnOmM5ZGJiZjkwNWNkYjRhM2Y5NGMxZDk0YTNmMjcyZGM2L3RhYmxlOmI3MTFhYTE1OTNiOTQzZWRhOGQ2ZDQyN2QxNTZkOGFjL3RhYmxlcmFuZ2U6YjcxMWFhMTU5M2I5NDNlZGE4ZDZkNDI3ZDE1NmQ4YWNfOC03LTEtMS0xNzc3NQ_943a5b31-2cfc-4168-b222-5a303f55b5aa"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yNS9mcmFnOmM5ZGJiZjkwNWNkYjRhM2Y5NGMxZDk0YTNmMjcyZGM2L3RhYmxlOmI3MTFhYTE1OTNiOTQzZWRhOGQ2ZDQyN2QxNTZkOGFjL3RhYmxlcmFuZ2U6YjcxMWFhMTU5M2I5NDNlZGE4ZDZkNDI3ZDE1NmQ4YWNfOC03LTEtMS0xNzc3NQ_943a5b31-2cfc-4168-b222-5a303f55b5aa"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yNS9mcmFnOmM5ZGJiZjkwNWNkYjRhM2Y5NGMxZDk0YTNmMjcyZGM2L3RhYmxlOmI3MTFhYTE1OTNiOTQzZWRhOGQ2ZDQyN2QxNTZkOGFjL3RhYmxlcmFuZ2U6YjcxMWFhMTU5M2I5NDNlZGE4ZDZkNDI3ZDE1NmQ4YWNfMy03LTEtMS0xNzc3NQ_a3433453-2481-4ae7-be53-93f804bda331"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yNS9mcmFnOmM5ZGJiZjkwNWNkYjRhM2Y5NGMxZDk0YTNmMjcyZGM2L3RhYmxlOmI3MTFhYTE1OTNiOTQzZWRhOGQ2ZDQyN2QxNTZkOGFjL3RhYmxlcmFuZ2U6YjcxMWFhMTU5M2I5NDNlZGE4ZDZkNDI3ZDE1NmQ4YWNfMy03LTEtMS0xNzc3NQ_a3433453-2481-4ae7-be53-93f804bda331"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yNS9mcmFnOmM5ZGJiZjkwNWNkYjRhM2Y5NGMxZDk0YTNmMjcyZGM2L3RhYmxlOmI3MTFhYTE1OTNiOTQzZWRhOGQ2ZDQyN2QxNTZkOGFjL3RhYmxlcmFuZ2U6YjcxMWFhMTU5M2I5NDNlZGE4ZDZkNDI3ZDE1NmQ4YWNfOC01LTEtMS0xOTE4Nw_0a57bcb2-3df7-4503-81cc-cba32b4b23a5"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yNS9mcmFnOmM5ZGJiZjkwNWNkYjRhM2Y5NGMxZDk0YTNmMjcyZGM2L3RhYmxlOmI3MTFhYTE1OTNiOTQzZWRhOGQ2ZDQyN2QxNTZkOGFjL3RhYmxlcmFuZ2U6YjcxMWFhMTU5M2I5NDNlZGE4ZDZkNDI3ZDE1NmQ4YWNfOC01LTEtMS0xOTE4Nw_0a57bcb2-3df7-4503-81cc-cba32b4b23a5"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yNS9mcmFnOmM5ZGJiZjkwNWNkYjRhM2Y5NGMxZDk0YTNmMjcyZGM2L3RhYmxlOmI3MTFhYTE1OTNiOTQzZWRhOGQ2ZDQyN2QxNTZkOGFjL3RhYmxlcmFuZ2U6YjcxMWFhMTU5M2I5NDNlZGE4ZDZkNDI3ZDE1NmQ4YWNfOC01LTEtMS0xNzc3NQ_1ad8948c-28b0-4494-8a69-63b5046a268c"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yNS9mcmFnOmM5ZGJiZjkwNWNkYjRhM2Y5NGMxZDk0YTNmMjcyZGM2L3RhYmxlOmI3MTFhYTE1OTNiOTQzZWRhOGQ2ZDQyN2QxNTZkOGFjL3RhYmxlcmFuZ2U6YjcxMWFhMTU5M2I5NDNlZGE4ZDZkNDI3ZDE1NmQ4YWNfOC01LTEtMS0xNzc3NQ_1ad8948c-28b0-4494-8a69-63b5046a268c"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yNS9mcmFnOmM5ZGJiZjkwNWNkYjRhM2Y5NGMxZDk0YTNmMjcyZGM2L3RhYmxlOmI3MTFhYTE1OTNiOTQzZWRhOGQ2ZDQyN2QxNTZkOGFjL3RhYmxlcmFuZ2U6YjcxMWFhMTU5M2I5NDNlZGE4ZDZkNDI3ZDE1NmQ4YWNfNC01LTEtMS0xNzc3NQ_644b3506-ee17-40d9-933c-67a7ebbab750"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yNS9mcmFnOmM5ZGJiZjkwNWNkYjRhM2Y5NGMxZDk0YTNmMjcyZGM2L3RhYmxlOmI3MTFhYTE1OTNiOTQzZWRhOGQ2ZDQyN2QxNTZkOGFjL3RhYmxlcmFuZ2U6YjcxMWFhMTU5M2I5NDNlZGE4ZDZkNDI3ZDE1NmQ4YWNfNC01LTEtMS0xNzc3NQ_644b3506-ee17-40d9-933c-67a7ebbab750"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yNS9mcmFnOmM5ZGJiZjkwNWNkYjRhM2Y5NGMxZDk0YTNmMjcyZGM2L3RhYmxlOmI3MTFhYTE1OTNiOTQzZWRhOGQ2ZDQyN2QxNTZkOGFjL3RhYmxlcmFuZ2U6YjcxMWFhMTU5M2I5NDNlZGE4ZDZkNDI3ZDE1NmQ4YWNfNC01LTEtMS0xOTE3OA_241368f3-5677-4baa-ba4b-666e2870cf8b"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yNS9mcmFnOmM5ZGJiZjkwNWNkYjRhM2Y5NGMxZDk0YTNmMjcyZGM2L3RhYmxlOmI3MTFhYTE1OTNiOTQzZWRhOGQ2ZDQyN2QxNTZkOGFjL3RhYmxlcmFuZ2U6YjcxMWFhMTU5M2I5NDNlZGE4ZDZkNDI3ZDE1NmQ4YWNfNC01LTEtMS0xOTE3OA_241368f3-5677-4baa-ba4b-666e2870cf8b"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yNS9mcmFnOmM5ZGJiZjkwNWNkYjRhM2Y5NGMxZDk0YTNmMjcyZGM2L3RhYmxlOmI3MTFhYTE1OTNiOTQzZWRhOGQ2ZDQyN2QxNTZkOGFjL3RhYmxlcmFuZ2U6YjcxMWFhMTU5M2I5NDNlZGE4ZDZkNDI3ZDE1NmQ4YWNfOS03LTEtMS0xNzc3NQ_2a40fbef-ea9c-434a-9dd7-fb55df812da8"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yNS9mcmFnOmM5ZGJiZjkwNWNkYjRhM2Y5NGMxZDk0YTNmMjcyZGM2L3RhYmxlOmI3MTFhYTE1OTNiOTQzZWRhOGQ2ZDQyN2QxNTZkOGFjL3RhYmxlcmFuZ2U6YjcxMWFhMTU5M2I5NDNlZGE4ZDZkNDI3ZDE1NmQ4YWNfOS03LTEtMS0xNzc3NQ_2a40fbef-ea9c-434a-9dd7-fb55df812da8"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yNS9mcmFnOmM5ZGJiZjkwNWNkYjRhM2Y5NGMxZDk0YTNmMjcyZGM2L3RhYmxlOmI3MTFhYTE1OTNiOTQzZWRhOGQ2ZDQyN2QxNTZkOGFjL3RhYmxlcmFuZ2U6YjcxMWFhMTU5M2I5NDNlZGE4ZDZkNDI3ZDE1NmQ4YWNfOS01LTEtMS0xNzc3NQ_ffcafb22-b8f3-4ddb-b38a-5a09c149759c"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yNS9mcmFnOmM5ZGJiZjkwNWNkYjRhM2Y5NGMxZDk0YTNmMjcyZGM2L3RhYmxlOmI3MTFhYTE1OTNiOTQzZWRhOGQ2ZDQyN2QxNTZkOGFjL3RhYmxlcmFuZ2U6YjcxMWFhMTU5M2I5NDNlZGE4ZDZkNDI3ZDE1NmQ4YWNfOS01LTEtMS0xNzc3NQ_ffcafb22-b8f3-4ddb-b38a-5a09c149759c"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yNS9mcmFnOmM5ZGJiZjkwNWNkYjRhM2Y5NGMxZDk0YTNmMjcyZGM2L3RhYmxlOmI3MTFhYTE1OTNiOTQzZWRhOGQ2ZDQyN2QxNTZkOGFjL3RhYmxlcmFuZ2U6YjcxMWFhMTU5M2I5NDNlZGE4ZDZkNDI3ZDE1NmQ4YWNfMy01LTEtMS0xNzc3NQ_46c2cc00-d98a-4db8-8abe-548c1179f2d3"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yNS9mcmFnOmM5ZGJiZjkwNWNkYjRhM2Y5NGMxZDk0YTNmMjcyZGM2L3RhYmxlOmI3MTFhYTE1OTNiOTQzZWRhOGQ2ZDQyN2QxNTZkOGFjL3RhYmxlcmFuZ2U6YjcxMWFhMTU5M2I5NDNlZGE4ZDZkNDI3ZDE1NmQ4YWNfMy01LTEtMS0xNzc3NQ_46c2cc00-d98a-4db8-8abe-548c1179f2d3"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yNS9mcmFnOmM5ZGJiZjkwNWNkYjRhM2Y5NGMxZDk0YTNmMjcyZGM2L3RhYmxlOmI3MTFhYTE1OTNiOTQzZWRhOGQ2ZDQyN2QxNTZkOGFjL3RhYmxlcmFuZ2U6YjcxMWFhMTU5M2I5NDNlZGE4ZDZkNDI3ZDE1NmQ4YWNfOS01LTEtMS0xOTE5NA_260357c9-44f5-47eb-8910-fe9f9be2c529"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yNS9mcmFnOmM5ZGJiZjkwNWNkYjRhM2Y5NGMxZDk0YTNmMjcyZGM2L3RhYmxlOmI3MTFhYTE1OTNiOTQzZWRhOGQ2ZDQyN2QxNTZkOGFjL3RhYmxlcmFuZ2U6YjcxMWFhMTU5M2I5NDNlZGE4ZDZkNDI3ZDE1NmQ4YWNfOS01LTEtMS0xOTE5NA_260357c9-44f5-47eb-8910-fe9f9be2c529"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yNS9mcmFnOmM5ZGJiZjkwNWNkYjRhM2Y5NGMxZDk0YTNmMjcyZGM2L3RhYmxlOmI3MTFhYTE1OTNiOTQzZWRhOGQ2ZDQyN2QxNTZkOGFjL3RhYmxlcmFuZ2U6YjcxMWFhMTU5M2I5NDNlZGE4ZDZkNDI3ZDE1NmQ4YWNfNC03LTEtMS0xNzc3NQ_acbcefc9-f3d5-494d-a386-35f27c437a74"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yNS9mcmFnOmM5ZGJiZjkwNWNkYjRhM2Y5NGMxZDk0YTNmMjcyZGM2L3RhYmxlOmI3MTFhYTE1OTNiOTQzZWRhOGQ2ZDQyN2QxNTZkOGFjL3RhYmxlcmFuZ2U6YjcxMWFhMTU5M2I5NDNlZGE4ZDZkNDI3ZDE1NmQ4YWNfNC03LTEtMS0xNzc3NQ_acbcefc9-f3d5-494d-a386-35f27c437a74"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yNS9mcmFnOmM5ZGJiZjkwNWNkYjRhM2Y5NGMxZDk0YTNmMjcyZGM2L3RhYmxlOmI3MTFhYTE1OTNiOTQzZWRhOGQ2ZDQyN2QxNTZkOGFjL3RhYmxlcmFuZ2U6YjcxMWFhMTU5M2I5NDNlZGE4ZDZkNDI3ZDE1NmQ4YWNfMy01LTEtMS0xOTE3OA_3c9095fd-21fc-41c2-9170-ae15b4f36761"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yNS9mcmFnOmM5ZGJiZjkwNWNkYjRhM2Y5NGMxZDk0YTNmMjcyZGM2L3RhYmxlOmI3MTFhYTE1OTNiOTQzZWRhOGQ2ZDQyN2QxNTZkOGFjL3RhYmxlcmFuZ2U6YjcxMWFhMTU5M2I5NDNlZGE4ZDZkNDI3ZDE1NmQ4YWNfMy01LTEtMS0xOTE3OA_3c9095fd-21fc-41c2-9170-ae15b4f36761"
          xlink:type="locator"/>
        <link:footnote id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yNS9mcmFnOmM5ZGJiZjkwNWNkYjRhM2Y5NGMxZDk0YTNmMjcyZGM2L3RleHRyZWdpb246YzlkYmJmOTA1Y2RiNGEzZjk0YzFkOTRhM2YyNzJkYzZfMzI2_1383af2f-4f0a-411f-acf7-955e4538706b" xlink:label="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yNS9mcmFnOmM5ZGJiZjkwNWNkYjRhM2Y5NGMxZDk0YTNmMjcyZGM2L3RleHRyZWdpb246YzlkYmJmOTA1Y2RiNGEzZjk0YzFkOTRhM2YyNzJkYzZfMzI2_1383af2f-4f0a-411f-acf7-955e4538706b" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">See Note 20 for amounts attributable to unconsolidated related parties included in these line items.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yNS9mcmFnOmM5ZGJiZjkwNWNkYjRhM2Y5NGMxZDk0YTNmMjcyZGM2L3RhYmxlOmI3MTFhYTE1OTNiOTQzZWRhOGQ2ZDQyN2QxNTZkOGFjL3RhYmxlcmFuZ2U6YjcxMWFhMTU5M2I5NDNlZGE4ZDZkNDI3ZDE1NmQ4YWNfOC03LTEtMS0xNzc3NQ_943a5b31-2cfc-4168-b222-5a303f55b5aa"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yNS9mcmFnOmM5ZGJiZjkwNWNkYjRhM2Y5NGMxZDk0YTNmMjcyZGM2L3RleHRyZWdpb246YzlkYmJmOTA1Y2RiNGEzZjk0YzFkOTRhM2YyNzJkYzZfMzI2_1383af2f-4f0a-411f-acf7-955e4538706b"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yNS9mcmFnOmM5ZGJiZjkwNWNkYjRhM2Y5NGMxZDk0YTNmMjcyZGM2L3RhYmxlOmI3MTFhYTE1OTNiOTQzZWRhOGQ2ZDQyN2QxNTZkOGFjL3RhYmxlcmFuZ2U6YjcxMWFhMTU5M2I5NDNlZGE4ZDZkNDI3ZDE1NmQ4YWNfMy03LTEtMS0xNzc3NQ_a3433453-2481-4ae7-be53-93f804bda331"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yNS9mcmFnOmM5ZGJiZjkwNWNkYjRhM2Y5NGMxZDk0YTNmMjcyZGM2L3RleHRyZWdpb246YzlkYmJmOTA1Y2RiNGEzZjk0YzFkOTRhM2YyNzJkYzZfMzI2_1383af2f-4f0a-411f-acf7-955e4538706b"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yNS9mcmFnOmM5ZGJiZjkwNWNkYjRhM2Y5NGMxZDk0YTNmMjcyZGM2L3RhYmxlOmI3MTFhYTE1OTNiOTQzZWRhOGQ2ZDQyN2QxNTZkOGFjL3RhYmxlcmFuZ2U6YjcxMWFhMTU5M2I5NDNlZGE4ZDZkNDI3ZDE1NmQ4YWNfOC01LTEtMS0xOTE4Nw_0a57bcb2-3df7-4503-81cc-cba32b4b23a5"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yNS9mcmFnOmM5ZGJiZjkwNWNkYjRhM2Y5NGMxZDk0YTNmMjcyZGM2L3RleHRyZWdpb246YzlkYmJmOTA1Y2RiNGEzZjk0YzFkOTRhM2YyNzJkYzZfMzI2_1383af2f-4f0a-411f-acf7-955e4538706b"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yNS9mcmFnOmM5ZGJiZjkwNWNkYjRhM2Y5NGMxZDk0YTNmMjcyZGM2L3RhYmxlOmI3MTFhYTE1OTNiOTQzZWRhOGQ2ZDQyN2QxNTZkOGFjL3RhYmxlcmFuZ2U6YjcxMWFhMTU5M2I5NDNlZGE4ZDZkNDI3ZDE1NmQ4YWNfOC01LTEtMS0xNzc3NQ_1ad8948c-28b0-4494-8a69-63b5046a268c"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yNS9mcmFnOmM5ZGJiZjkwNWNkYjRhM2Y5NGMxZDk0YTNmMjcyZGM2L3RleHRyZWdpb246YzlkYmJmOTA1Y2RiNGEzZjk0YzFkOTRhM2YyNzJkYzZfMzI2_1383af2f-4f0a-411f-acf7-955e4538706b"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yNS9mcmFnOmM5ZGJiZjkwNWNkYjRhM2Y5NGMxZDk0YTNmMjcyZGM2L3RhYmxlOmI3MTFhYTE1OTNiOTQzZWRhOGQ2ZDQyN2QxNTZkOGFjL3RhYmxlcmFuZ2U6YjcxMWFhMTU5M2I5NDNlZGE4ZDZkNDI3ZDE1NmQ4YWNfNC01LTEtMS0xNzc3NQ_644b3506-ee17-40d9-933c-67a7ebbab750"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yNS9mcmFnOmM5ZGJiZjkwNWNkYjRhM2Y5NGMxZDk0YTNmMjcyZGM2L3RleHRyZWdpb246YzlkYmJmOTA1Y2RiNGEzZjk0YzFkOTRhM2YyNzJkYzZfMzI2_1383af2f-4f0a-411f-acf7-955e4538706b"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yNS9mcmFnOmM5ZGJiZjkwNWNkYjRhM2Y5NGMxZDk0YTNmMjcyZGM2L3RhYmxlOmI3MTFhYTE1OTNiOTQzZWRhOGQ2ZDQyN2QxNTZkOGFjL3RhYmxlcmFuZ2U6YjcxMWFhMTU5M2I5NDNlZGE4ZDZkNDI3ZDE1NmQ4YWNfNC01LTEtMS0xOTE3OA_241368f3-5677-4baa-ba4b-666e2870cf8b"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yNS9mcmFnOmM5ZGJiZjkwNWNkYjRhM2Y5NGMxZDk0YTNmMjcyZGM2L3RleHRyZWdpb246YzlkYmJmOTA1Y2RiNGEzZjk0YzFkOTRhM2YyNzJkYzZfMzI2_1383af2f-4f0a-411f-acf7-955e4538706b"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yNS9mcmFnOmM5ZGJiZjkwNWNkYjRhM2Y5NGMxZDk0YTNmMjcyZGM2L3RhYmxlOmI3MTFhYTE1OTNiOTQzZWRhOGQ2ZDQyN2QxNTZkOGFjL3RhYmxlcmFuZ2U6YjcxMWFhMTU5M2I5NDNlZGE4ZDZkNDI3ZDE1NmQ4YWNfOS03LTEtMS0xNzc3NQ_2a40fbef-ea9c-434a-9dd7-fb55df812da8"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yNS9mcmFnOmM5ZGJiZjkwNWNkYjRhM2Y5NGMxZDk0YTNmMjcyZGM2L3RleHRyZWdpb246YzlkYmJmOTA1Y2RiNGEzZjk0YzFkOTRhM2YyNzJkYzZfMzI2_1383af2f-4f0a-411f-acf7-955e4538706b"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yNS9mcmFnOmM5ZGJiZjkwNWNkYjRhM2Y5NGMxZDk0YTNmMjcyZGM2L3RhYmxlOmI3MTFhYTE1OTNiOTQzZWRhOGQ2ZDQyN2QxNTZkOGFjL3RhYmxlcmFuZ2U6YjcxMWFhMTU5M2I5NDNlZGE4ZDZkNDI3ZDE1NmQ4YWNfOS01LTEtMS0xNzc3NQ_ffcafb22-b8f3-4ddb-b38a-5a09c149759c"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yNS9mcmFnOmM5ZGJiZjkwNWNkYjRhM2Y5NGMxZDk0YTNmMjcyZGM2L3RleHRyZWdpb246YzlkYmJmOTA1Y2RiNGEzZjk0YzFkOTRhM2YyNzJkYzZfMzI2_1383af2f-4f0a-411f-acf7-955e4538706b"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yNS9mcmFnOmM5ZGJiZjkwNWNkYjRhM2Y5NGMxZDk0YTNmMjcyZGM2L3RhYmxlOmI3MTFhYTE1OTNiOTQzZWRhOGQ2ZDQyN2QxNTZkOGFjL3RhYmxlcmFuZ2U6YjcxMWFhMTU5M2I5NDNlZGE4ZDZkNDI3ZDE1NmQ4YWNfMy01LTEtMS0xNzc3NQ_46c2cc00-d98a-4db8-8abe-548c1179f2d3"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yNS9mcmFnOmM5ZGJiZjkwNWNkYjRhM2Y5NGMxZDk0YTNmMjcyZGM2L3RleHRyZWdpb246YzlkYmJmOTA1Y2RiNGEzZjk0YzFkOTRhM2YyNzJkYzZfMzI2_1383af2f-4f0a-411f-acf7-955e4538706b"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yNS9mcmFnOmM5ZGJiZjkwNWNkYjRhM2Y5NGMxZDk0YTNmMjcyZGM2L3RhYmxlOmI3MTFhYTE1OTNiOTQzZWRhOGQ2ZDQyN2QxNTZkOGFjL3RhYmxlcmFuZ2U6YjcxMWFhMTU5M2I5NDNlZGE4ZDZkNDI3ZDE1NmQ4YWNfOS01LTEtMS0xOTE5NA_260357c9-44f5-47eb-8910-fe9f9be2c529"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yNS9mcmFnOmM5ZGJiZjkwNWNkYjRhM2Y5NGMxZDk0YTNmMjcyZGM2L3RleHRyZWdpb246YzlkYmJmOTA1Y2RiNGEzZjk0YzFkOTRhM2YyNzJkYzZfMzI2_1383af2f-4f0a-411f-acf7-955e4538706b"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yNS9mcmFnOmM5ZGJiZjkwNWNkYjRhM2Y5NGMxZDk0YTNmMjcyZGM2L3RhYmxlOmI3MTFhYTE1OTNiOTQzZWRhOGQ2ZDQyN2QxNTZkOGFjL3RhYmxlcmFuZ2U6YjcxMWFhMTU5M2I5NDNlZGE4ZDZkNDI3ZDE1NmQ4YWNfNC03LTEtMS0xNzc3NQ_acbcefc9-f3d5-494d-a386-35f27c437a74"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yNS9mcmFnOmM5ZGJiZjkwNWNkYjRhM2Y5NGMxZDk0YTNmMjcyZGM2L3RleHRyZWdpb246YzlkYmJmOTA1Y2RiNGEzZjk0YzFkOTRhM2YyNzJkYzZfMzI2_1383af2f-4f0a-411f-acf7-955e4538706b"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yNS9mcmFnOmM5ZGJiZjkwNWNkYjRhM2Y5NGMxZDk0YTNmMjcyZGM2L3RhYmxlOmI3MTFhYTE1OTNiOTQzZWRhOGQ2ZDQyN2QxNTZkOGFjL3RhYmxlcmFuZ2U6YjcxMWFhMTU5M2I5NDNlZGE4ZDZkNDI3ZDE1NmQ4YWNfMy01LTEtMS0xOTE3OA_3c9095fd-21fc-41c2-9170-ae15b4f36761"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yNS9mcmFnOmM5ZGJiZjkwNWNkYjRhM2Y5NGMxZDk0YTNmMjcyZGM2L3RleHRyZWdpb246YzlkYmJmOTA1Y2RiNGEzZjk0YzFkOTRhM2YyNzJkYzZfMzI2_1383af2f-4f0a-411f-acf7-955e4538706b"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yMi9mcmFnOjJiM2Y4ODE3NTVhYTQ5ODk5MzI2NThlODM2YmIyNGI2L3RhYmxlOjQ1MmFlOGFkMjMxZjQ4MWQ4Njg3MGU5MDYxNWI3NTkxL3RhYmxlcmFuZ2U6NDUyYWU4YWQyMzFmNDgxZDg2ODcwZTkwNjE1Yjc1OTFfNS0zLTEtMS0xNzc3NQ_1aab1e38-d520-4d8e-a626-6f7e2520afce"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yMi9mcmFnOjJiM2Y4ODE3NTVhYTQ5ODk5MzI2NThlODM2YmIyNGI2L3RhYmxlOjQ1MmFlOGFkMjMxZjQ4MWQ4Njg3MGU5MDYxNWI3NTkxL3RhYmxlcmFuZ2U6NDUyYWU4YWQyMzFmNDgxZDg2ODcwZTkwNjE1Yjc1OTFfNS0zLTEtMS0xNzc3NQ_1aab1e38-d520-4d8e-a626-6f7e2520afce"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yMi9mcmFnOjJiM2Y4ODE3NTVhYTQ5ODk5MzI2NThlODM2YmIyNGI2L3RhYmxlOjQ1MmFlOGFkMjMxZjQ4MWQ4Njg3MGU5MDYxNWI3NTkxL3RhYmxlcmFuZ2U6NDUyYWU4YWQyMzFmNDgxZDg2ODcwZTkwNjE1Yjc1OTFfMjMtMS0xLTEtMTc3NzU_0c4a3b28-a401-4580-bd6d-913e346e7efe"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yMi9mcmFnOjJiM2Y4ODE3NTVhYTQ5ODk5MzI2NThlODM2YmIyNGI2L3RhYmxlOjQ1MmFlOGFkMjMxZjQ4MWQ4Njg3MGU5MDYxNWI3NTkxL3RhYmxlcmFuZ2U6NDUyYWU4YWQyMzFmNDgxZDg2ODcwZTkwNjE1Yjc1OTFfMjMtMS0xLTEtMTc3NzU_0c4a3b28-a401-4580-bd6d-913e346e7efe"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yMi9mcmFnOjJiM2Y4ODE3NTVhYTQ5ODk5MzI2NThlODM2YmIyNGI2L3RhYmxlOjQ1MmFlOGFkMjMxZjQ4MWQ4Njg3MGU5MDYxNWI3NTkxL3RhYmxlcmFuZ2U6NDUyYWU4YWQyMzFmNDgxZDg2ODcwZTkwNjE1Yjc1OTFfMjItMy0xLTEtMTc3NzU_7665c1f5-8c13-4d79-9699-c169f3c45c6b"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yMi9mcmFnOjJiM2Y4ODE3NTVhYTQ5ODk5MzI2NThlODM2YmIyNGI2L3RhYmxlOjQ1MmFlOGFkMjMxZjQ4MWQ4Njg3MGU5MDYxNWI3NTkxL3RhYmxlcmFuZ2U6NDUyYWU4YWQyMzFmNDgxZDg2ODcwZTkwNjE1Yjc1OTFfMjItMy0xLTEtMTc3NzU_7665c1f5-8c13-4d79-9699-c169f3c45c6b"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yMi9mcmFnOjJiM2Y4ODE3NTVhYTQ5ODk5MzI2NThlODM2YmIyNGI2L3RhYmxlOjQ1MmFlOGFkMjMxZjQ4MWQ4Njg3MGU5MDYxNWI3NTkxL3RhYmxlcmFuZ2U6NDUyYWU4YWQyMzFmNDgxZDg2ODcwZTkwNjE1Yjc1OTFfMTMtMy0xLTEtMTc3NzU_46840606-41ef-48ee-84bf-1505ddaef468"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yMi9mcmFnOjJiM2Y4ODE3NTVhYTQ5ODk5MzI2NThlODM2YmIyNGI2L3RhYmxlOjQ1MmFlOGFkMjMxZjQ4MWQ4Njg3MGU5MDYxNWI3NTkxL3RhYmxlcmFuZ2U6NDUyYWU4YWQyMzFmNDgxZDg2ODcwZTkwNjE1Yjc1OTFfMTMtMy0xLTEtMTc3NzU_46840606-41ef-48ee-84bf-1505ddaef468"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yMi9mcmFnOjJiM2Y4ODE3NTVhYTQ5ODk5MzI2NThlODM2YmIyNGI2L3RhYmxlOjQ1MmFlOGFkMjMxZjQ4MWQ4Njg3MGU5MDYxNWI3NTkxL3RhYmxlcmFuZ2U6NDUyYWU4YWQyMzFmNDgxZDg2ODcwZTkwNjE1Yjc1OTFfMjMtMy0xLTEtMTc3NzU_0c7e2696-05ec-4e48-a7ec-d18b99a2d593"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yMi9mcmFnOjJiM2Y4ODE3NTVhYTQ5ODk5MzI2NThlODM2YmIyNGI2L3RhYmxlOjQ1MmFlOGFkMjMxZjQ4MWQ4Njg3MGU5MDYxNWI3NTkxL3RhYmxlcmFuZ2U6NDUyYWU4YWQyMzFmNDgxZDg2ODcwZTkwNjE1Yjc1OTFfMjMtMy0xLTEtMTc3NzU_0c7e2696-05ec-4e48-a7ec-d18b99a2d593"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yMi9mcmFnOjJiM2Y4ODE3NTVhYTQ5ODk5MzI2NThlODM2YmIyNGI2L3RhYmxlOjQ1MmFlOGFkMjMxZjQ4MWQ4Njg3MGU5MDYxNWI3NTkxL3RhYmxlcmFuZ2U6NDUyYWU4YWQyMzFmNDgxZDg2ODcwZTkwNjE1Yjc1OTFfNi0zLTEtMS0xNzc3NQ_ac001ac4-a8c8-46b0-876f-5bb35a584888"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yMi9mcmFnOjJiM2Y4ODE3NTVhYTQ5ODk5MzI2NThlODM2YmIyNGI2L3RhYmxlOjQ1MmFlOGFkMjMxZjQ4MWQ4Njg3MGU5MDYxNWI3NTkxL3RhYmxlcmFuZ2U6NDUyYWU4YWQyMzFmNDgxZDg2ODcwZTkwNjE1Yjc1OTFfNi0zLTEtMS0xNzc3NQ_ac001ac4-a8c8-46b0-876f-5bb35a584888"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yMi9mcmFnOjJiM2Y4ODE3NTVhYTQ5ODk5MzI2NThlODM2YmIyNGI2L3RhYmxlOjQ1MmFlOGFkMjMxZjQ4MWQ4Njg3MGU5MDYxNWI3NTkxL3RhYmxlcmFuZ2U6NDUyYWU4YWQyMzFmNDgxZDg2ODcwZTkwNjE1Yjc1OTFfMjItMS0xLTEtMTc3NzU_de2bfa85-6392-4aa3-9252-cf468f01146c"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yMi9mcmFnOjJiM2Y4ODE3NTVhYTQ5ODk5MzI2NThlODM2YmIyNGI2L3RhYmxlOjQ1MmFlOGFkMjMxZjQ4MWQ4Njg3MGU5MDYxNWI3NTkxL3RhYmxlcmFuZ2U6NDUyYWU4YWQyMzFmNDgxZDg2ODcwZTkwNjE1Yjc1OTFfMjItMS0xLTEtMTc3NzU_de2bfa85-6392-4aa3-9252-cf468f01146c"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yMi9mcmFnOjJiM2Y4ODE3NTVhYTQ5ODk5MzI2NThlODM2YmIyNGI2L3RhYmxlOjQ1MmFlOGFkMjMxZjQ4MWQ4Njg3MGU5MDYxNWI3NTkxL3RhYmxlcmFuZ2U6NDUyYWU4YWQyMzFmNDgxZDg2ODcwZTkwNjE1Yjc1OTFfMjgtMy0xLTEtMTc3NzU_4b6e6c26-f2b8-4e61-8c51-c6866fd17f9b"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yMi9mcmFnOjJiM2Y4ODE3NTVhYTQ5ODk5MzI2NThlODM2YmIyNGI2L3RhYmxlOjQ1MmFlOGFkMjMxZjQ4MWQ4Njg3MGU5MDYxNWI3NTkxL3RhYmxlcmFuZ2U6NDUyYWU4YWQyMzFmNDgxZDg2ODcwZTkwNjE1Yjc1OTFfMjgtMy0xLTEtMTc3NzU_4b6e6c26-f2b8-4e61-8c51-c6866fd17f9b"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yMi9mcmFnOjJiM2Y4ODE3NTVhYTQ5ODk5MzI2NThlODM2YmIyNGI2L3RhYmxlOjQ1MmFlOGFkMjMxZjQ4MWQ4Njg3MGU5MDYxNWI3NTkxL3RhYmxlcmFuZ2U6NDUyYWU4YWQyMzFmNDgxZDg2ODcwZTkwNjE1Yjc1OTFfNS0xLTEtMS0xNzc3NQ_f8d025b8-3255-478d-83d3-8aecd42fa11b"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yMi9mcmFnOjJiM2Y4ODE3NTVhYTQ5ODk5MzI2NThlODM2YmIyNGI2L3RhYmxlOjQ1MmFlOGFkMjMxZjQ4MWQ4Njg3MGU5MDYxNWI3NTkxL3RhYmxlcmFuZ2U6NDUyYWU4YWQyMzFmNDgxZDg2ODcwZTkwNjE1Yjc1OTFfNS0xLTEtMS0xNzc3NQ_f8d025b8-3255-478d-83d3-8aecd42fa11b"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yMi9mcmFnOjJiM2Y4ODE3NTVhYTQ5ODk5MzI2NThlODM2YmIyNGI2L3RhYmxlOjQ1MmFlOGFkMjMxZjQ4MWQ4Njg3MGU5MDYxNWI3NTkxL3RhYmxlcmFuZ2U6NDUyYWU4YWQyMzFmNDgxZDg2ODcwZTkwNjE1Yjc1OTFfMjgtMS0xLTEtMTc3NzU_03f34cbc-a6ef-428a-8ea2-e2626cbf946a"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yMi9mcmFnOjJiM2Y4ODE3NTVhYTQ5ODk5MzI2NThlODM2YmIyNGI2L3RhYmxlOjQ1MmFlOGFkMjMxZjQ4MWQ4Njg3MGU5MDYxNWI3NTkxL3RhYmxlcmFuZ2U6NDUyYWU4YWQyMzFmNDgxZDg2ODcwZTkwNjE1Yjc1OTFfMjgtMS0xLTEtMTc3NzU_03f34cbc-a6ef-428a-8ea2-e2626cbf946a"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yMi9mcmFnOjJiM2Y4ODE3NTVhYTQ5ODk5MzI2NThlODM2YmIyNGI2L3RhYmxlOjQ1MmFlOGFkMjMxZjQ4MWQ4Njg3MGU5MDYxNWI3NTkxL3RhYmxlcmFuZ2U6NDUyYWU4YWQyMzFmNDgxZDg2ODcwZTkwNjE1Yjc1OTFfNi0xLTEtMS0xNzc3NQ_469a4400-c2b4-4cf4-8445-c96411a59e90"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yMi9mcmFnOjJiM2Y4ODE3NTVhYTQ5ODk5MzI2NThlODM2YmIyNGI2L3RhYmxlOjQ1MmFlOGFkMjMxZjQ4MWQ4Njg3MGU5MDYxNWI3NTkxL3RhYmxlcmFuZ2U6NDUyYWU4YWQyMzFmNDgxZDg2ODcwZTkwNjE1Yjc1OTFfNi0xLTEtMS0xNzc3NQ_469a4400-c2b4-4cf4-8445-c96411a59e90"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yMi9mcmFnOjJiM2Y4ODE3NTVhYTQ5ODk5MzI2NThlODM2YmIyNGI2L3RhYmxlOjQ1MmFlOGFkMjMxZjQ4MWQ4Njg3MGU5MDYxNWI3NTkxL3RhYmxlcmFuZ2U6NDUyYWU4YWQyMzFmNDgxZDg2ODcwZTkwNjE1Yjc1OTFfMTMtMS0xLTEtMTc3NzU_00d8e9df-b51a-4134-ae28-46cb41ed669a"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yMi9mcmFnOjJiM2Y4ODE3NTVhYTQ5ODk5MzI2NThlODM2YmIyNGI2L3RhYmxlOjQ1MmFlOGFkMjMxZjQ4MWQ4Njg3MGU5MDYxNWI3NTkxL3RhYmxlcmFuZ2U6NDUyYWU4YWQyMzFmNDgxZDg2ODcwZTkwNjE1Yjc1OTFfMTMtMS0xLTEtMTc3NzU_00d8e9df-b51a-4134-ae28-46cb41ed669a"
          xlink:type="locator"/>
        <link:footnote id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yMi9mcmFnOjJiM2Y4ODE3NTVhYTQ5ODk5MzI2NThlODM2YmIyNGI2L3RleHRyZWdpb246MmIzZjg4MTc1NWFhNDk4OTkzMjY1OGU4MzZiYjI0YjZfMjA1_0cf9d253-8d73-4596-9d10-31e28ee4f8d6" xlink:label="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yMi9mcmFnOjJiM2Y4ODE3NTVhYTQ5ODk5MzI2NThlODM2YmIyNGI2L3RleHRyZWdpb246MmIzZjg4MTc1NWFhNDk4OTkzMjY1OGU4MzZiYjI0YjZfMjA1_0cf9d253-8d73-4596-9d10-31e28ee4f8d6" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">See Note 20 for amounts attributable to related parties included in these line items.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yMi9mcmFnOjJiM2Y4ODE3NTVhYTQ5ODk5MzI2NThlODM2YmIyNGI2L3RhYmxlOjQ1MmFlOGFkMjMxZjQ4MWQ4Njg3MGU5MDYxNWI3NTkxL3RhYmxlcmFuZ2U6NDUyYWU4YWQyMzFmNDgxZDg2ODcwZTkwNjE1Yjc1OTFfNS0zLTEtMS0xNzc3NQ_1aab1e38-d520-4d8e-a626-6f7e2520afce"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yMi9mcmFnOjJiM2Y4ODE3NTVhYTQ5ODk5MzI2NThlODM2YmIyNGI2L3RleHRyZWdpb246MmIzZjg4MTc1NWFhNDk4OTkzMjY1OGU4MzZiYjI0YjZfMjA1_0cf9d253-8d73-4596-9d10-31e28ee4f8d6"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yMi9mcmFnOjJiM2Y4ODE3NTVhYTQ5ODk5MzI2NThlODM2YmIyNGI2L3RhYmxlOjQ1MmFlOGFkMjMxZjQ4MWQ4Njg3MGU5MDYxNWI3NTkxL3RhYmxlcmFuZ2U6NDUyYWU4YWQyMzFmNDgxZDg2ODcwZTkwNjE1Yjc1OTFfMjMtMS0xLTEtMTc3NzU_0c4a3b28-a401-4580-bd6d-913e346e7efe"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yMi9mcmFnOjJiM2Y4ODE3NTVhYTQ5ODk5MzI2NThlODM2YmIyNGI2L3RleHRyZWdpb246MmIzZjg4MTc1NWFhNDk4OTkzMjY1OGU4MzZiYjI0YjZfMjA1_0cf9d253-8d73-4596-9d10-31e28ee4f8d6"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yMi9mcmFnOjJiM2Y4ODE3NTVhYTQ5ODk5MzI2NThlODM2YmIyNGI2L3RhYmxlOjQ1MmFlOGFkMjMxZjQ4MWQ4Njg3MGU5MDYxNWI3NTkxL3RhYmxlcmFuZ2U6NDUyYWU4YWQyMzFmNDgxZDg2ODcwZTkwNjE1Yjc1OTFfMjItMy0xLTEtMTc3NzU_7665c1f5-8c13-4d79-9699-c169f3c45c6b"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yMi9mcmFnOjJiM2Y4ODE3NTVhYTQ5ODk5MzI2NThlODM2YmIyNGI2L3RleHRyZWdpb246MmIzZjg4MTc1NWFhNDk4OTkzMjY1OGU4MzZiYjI0YjZfMjA1_0cf9d253-8d73-4596-9d10-31e28ee4f8d6"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yMi9mcmFnOjJiM2Y4ODE3NTVhYTQ5ODk5MzI2NThlODM2YmIyNGI2L3RhYmxlOjQ1MmFlOGFkMjMxZjQ4MWQ4Njg3MGU5MDYxNWI3NTkxL3RhYmxlcmFuZ2U6NDUyYWU4YWQyMzFmNDgxZDg2ODcwZTkwNjE1Yjc1OTFfMTMtMy0xLTEtMTc3NzU_46840606-41ef-48ee-84bf-1505ddaef468"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yMi9mcmFnOjJiM2Y4ODE3NTVhYTQ5ODk5MzI2NThlODM2YmIyNGI2L3RleHRyZWdpb246MmIzZjg4MTc1NWFhNDk4OTkzMjY1OGU4MzZiYjI0YjZfMjA1_0cf9d253-8d73-4596-9d10-31e28ee4f8d6"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yMi9mcmFnOjJiM2Y4ODE3NTVhYTQ5ODk5MzI2NThlODM2YmIyNGI2L3RhYmxlOjQ1MmFlOGFkMjMxZjQ4MWQ4Njg3MGU5MDYxNWI3NTkxL3RhYmxlcmFuZ2U6NDUyYWU4YWQyMzFmNDgxZDg2ODcwZTkwNjE1Yjc1OTFfMjMtMy0xLTEtMTc3NzU_0c7e2696-05ec-4e48-a7ec-d18b99a2d593"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yMi9mcmFnOjJiM2Y4ODE3NTVhYTQ5ODk5MzI2NThlODM2YmIyNGI2L3RleHRyZWdpb246MmIzZjg4MTc1NWFhNDk4OTkzMjY1OGU4MzZiYjI0YjZfMjA1_0cf9d253-8d73-4596-9d10-31e28ee4f8d6"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yMi9mcmFnOjJiM2Y4ODE3NTVhYTQ5ODk5MzI2NThlODM2YmIyNGI2L3RhYmxlOjQ1MmFlOGFkMjMxZjQ4MWQ4Njg3MGU5MDYxNWI3NTkxL3RhYmxlcmFuZ2U6NDUyYWU4YWQyMzFmNDgxZDg2ODcwZTkwNjE1Yjc1OTFfNi0zLTEtMS0xNzc3NQ_ac001ac4-a8c8-46b0-876f-5bb35a584888"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yMi9mcmFnOjJiM2Y4ODE3NTVhYTQ5ODk5MzI2NThlODM2YmIyNGI2L3RleHRyZWdpb246MmIzZjg4MTc1NWFhNDk4OTkzMjY1OGU4MzZiYjI0YjZfMjA1_0cf9d253-8d73-4596-9d10-31e28ee4f8d6"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yMi9mcmFnOjJiM2Y4ODE3NTVhYTQ5ODk5MzI2NThlODM2YmIyNGI2L3RhYmxlOjQ1MmFlOGFkMjMxZjQ4MWQ4Njg3MGU5MDYxNWI3NTkxL3RhYmxlcmFuZ2U6NDUyYWU4YWQyMzFmNDgxZDg2ODcwZTkwNjE1Yjc1OTFfMjItMS0xLTEtMTc3NzU_de2bfa85-6392-4aa3-9252-cf468f01146c"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yMi9mcmFnOjJiM2Y4ODE3NTVhYTQ5ODk5MzI2NThlODM2YmIyNGI2L3RleHRyZWdpb246MmIzZjg4MTc1NWFhNDk4OTkzMjY1OGU4MzZiYjI0YjZfMjA1_0cf9d253-8d73-4596-9d10-31e28ee4f8d6"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yMi9mcmFnOjJiM2Y4ODE3NTVhYTQ5ODk5MzI2NThlODM2YmIyNGI2L3RhYmxlOjQ1MmFlOGFkMjMxZjQ4MWQ4Njg3MGU5MDYxNWI3NTkxL3RhYmxlcmFuZ2U6NDUyYWU4YWQyMzFmNDgxZDg2ODcwZTkwNjE1Yjc1OTFfMjgtMy0xLTEtMTc3NzU_4b6e6c26-f2b8-4e61-8c51-c6866fd17f9b"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yMi9mcmFnOjJiM2Y4ODE3NTVhYTQ5ODk5MzI2NThlODM2YmIyNGI2L3RleHRyZWdpb246MmIzZjg4MTc1NWFhNDk4OTkzMjY1OGU4MzZiYjI0YjZfMjA1_0cf9d253-8d73-4596-9d10-31e28ee4f8d6"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yMi9mcmFnOjJiM2Y4ODE3NTVhYTQ5ODk5MzI2NThlODM2YmIyNGI2L3RhYmxlOjQ1MmFlOGFkMjMxZjQ4MWQ4Njg3MGU5MDYxNWI3NTkxL3RhYmxlcmFuZ2U6NDUyYWU4YWQyMzFmNDgxZDg2ODcwZTkwNjE1Yjc1OTFfNS0xLTEtMS0xNzc3NQ_f8d025b8-3255-478d-83d3-8aecd42fa11b"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yMi9mcmFnOjJiM2Y4ODE3NTVhYTQ5ODk5MzI2NThlODM2YmIyNGI2L3RleHRyZWdpb246MmIzZjg4MTc1NWFhNDk4OTkzMjY1OGU4MzZiYjI0YjZfMjA1_0cf9d253-8d73-4596-9d10-31e28ee4f8d6"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yMi9mcmFnOjJiM2Y4ODE3NTVhYTQ5ODk5MzI2NThlODM2YmIyNGI2L3RhYmxlOjQ1MmFlOGFkMjMxZjQ4MWQ4Njg3MGU5MDYxNWI3NTkxL3RhYmxlcmFuZ2U6NDUyYWU4YWQyMzFmNDgxZDg2ODcwZTkwNjE1Yjc1OTFfMjgtMS0xLTEtMTc3NzU_03f34cbc-a6ef-428a-8ea2-e2626cbf946a"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yMi9mcmFnOjJiM2Y4ODE3NTVhYTQ5ODk5MzI2NThlODM2YmIyNGI2L3RleHRyZWdpb246MmIzZjg4MTc1NWFhNDk4OTkzMjY1OGU4MzZiYjI0YjZfMjA1_0cf9d253-8d73-4596-9d10-31e28ee4f8d6"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yMi9mcmFnOjJiM2Y4ODE3NTVhYTQ5ODk5MzI2NThlODM2YmIyNGI2L3RhYmxlOjQ1MmFlOGFkMjMxZjQ4MWQ4Njg3MGU5MDYxNWI3NTkxL3RhYmxlcmFuZ2U6NDUyYWU4YWQyMzFmNDgxZDg2ODcwZTkwNjE1Yjc1OTFfNi0xLTEtMS0xNzc3NQ_469a4400-c2b4-4cf4-8445-c96411a59e90"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yMi9mcmFnOjJiM2Y4ODE3NTVhYTQ5ODk5MzI2NThlODM2YmIyNGI2L3RleHRyZWdpb246MmIzZjg4MTc1NWFhNDk4OTkzMjY1OGU4MzZiYjI0YjZfMjA1_0cf9d253-8d73-4596-9d10-31e28ee4f8d6"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yMi9mcmFnOjJiM2Y4ODE3NTVhYTQ5ODk5MzI2NThlODM2YmIyNGI2L3RhYmxlOjQ1MmFlOGFkMjMxZjQ4MWQ4Njg3MGU5MDYxNWI3NTkxL3RhYmxlcmFuZ2U6NDUyYWU4YWQyMzFmNDgxZDg2ODcwZTkwNjE1Yjc1OTFfMTMtMS0xLTEtMTc3NzU_00d8e9df-b51a-4134-ae28-46cb41ed669a"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yMi9mcmFnOjJiM2Y4ODE3NTVhYTQ5ODk5MzI2NThlODM2YmIyNGI2L3RleHRyZWdpb246MmIzZjg4MTc1NWFhNDk4OTkzMjY1OGU4MzZiYjI0YjZfMjA1_0cf9d253-8d73-4596-9d10-31e28ee4f8d6"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM184NS9mcmFnOjdhMDNjNzc3NWZjNDRmMzlhZmY3NjkyYjY5NGQ5YzM3L3RhYmxlOjhhNDlhNzA4NDcxMDQwZTk4MzBiMDg2ZTIxMzRlYTk1L3RhYmxlcmFuZ2U6OGE0OWE3MDg0NzEwNDBlOTgzMGIwODZlMjEzNGVhOTVfMy01LTEtMS0xNzc3NQ_3a7f9340-a2d9-4068-b095-f659267e962c"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM184NS9mcmFnOjdhMDNjNzc3NWZjNDRmMzlhZmY3NjkyYjY5NGQ5YzM3L3RhYmxlOjhhNDlhNzA4NDcxMDQwZTk4MzBiMDg2ZTIxMzRlYTk1L3RhYmxlcmFuZ2U6OGE0OWE3MDg0NzEwNDBlOTgzMGIwODZlMjEzNGVhOTVfMy01LTEtMS0xNzc3NQ_3a7f9340-a2d9-4068-b095-f659267e962c"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yNS9mcmFnOmM5ZGJiZjkwNWNkYjRhM2Y5NGMxZDk0YTNmMjcyZGM2L3RhYmxlOmI3MTFhYTE1OTNiOTQzZWRhOGQ2ZDQyN2QxNTZkOGFjL3RhYmxlcmFuZ2U6YjcxMWFhMTU5M2I5NDNlZGE4ZDZkNDI3ZDE1NmQ4YWNfMjctNS0xLTEtMTc3NzU_3a7f9340-a2d9-4068-b095-f659267e962c"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yNS9mcmFnOmM5ZGJiZjkwNWNkYjRhM2Y5NGMxZDk0YTNmMjcyZGM2L3RhYmxlOmI3MTFhYTE1OTNiOTQzZWRhOGQ2ZDQyN2QxNTZkOGFjL3RhYmxlcmFuZ2U6YjcxMWFhMTU5M2I5NDNlZGE4ZDZkNDI3ZDE1NmQ4YWNfMjctNS0xLTEtMTc3NzU_3a7f9340-a2d9-4068-b095-f659267e962c"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM184NS9mcmFnOjdhMDNjNzc3NWZjNDRmMzlhZmY3NjkyYjY5NGQ5YzM3L3RhYmxlOjhhNDlhNzA4NDcxMDQwZTk4MzBiMDg2ZTIxMzRlYTk1L3RhYmxlcmFuZ2U6OGE0OWE3MDg0NzEwNDBlOTgzMGIwODZlMjEzNGVhOTVfMy01LTEtMS0yMTkzMQ_cd15aa32-72bb-4df8-a330-8fac8ecbd8bb"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM184NS9mcmFnOjdhMDNjNzc3NWZjNDRmMzlhZmY3NjkyYjY5NGQ5YzM3L3RhYmxlOjhhNDlhNzA4NDcxMDQwZTk4MzBiMDg2ZTIxMzRlYTk1L3RhYmxlcmFuZ2U6OGE0OWE3MDg0NzEwNDBlOTgzMGIwODZlMjEzNGVhOTVfMy01LTEtMS0yMTkzMQ_cd15aa32-72bb-4df8-a330-8fac8ecbd8bb"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMzAvZnJhZzo3NGIwMjA4NWYwNjY0MjYyOGY3OWUzMTNlNjFkZmI3Yy90YWJsZTpmYTRmNTRhZWVjNTg0NDBiYmYyYTcwYWUxMDNkNDVlNy90YWJsZXJhbmdlOmZhNGY1NGFlZWM1ODQ0MGJiZjJhNzBhZTEwM2Q0NWU3XzYtMS0xLTEtMzMwOTg_2d028ee7-25e5-43aa-a188-cea5ec2afbd1"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMzAvZnJhZzo3NGIwMjA4NWYwNjY0MjYyOGY3OWUzMTNlNjFkZmI3Yy90YWJsZTpmYTRmNTRhZWVjNTg0NDBiYmYyYTcwYWUxMDNkNDVlNy90YWJsZXJhbmdlOmZhNGY1NGFlZWM1ODQ0MGJiZjJhNzBhZTEwM2Q0NWU3XzYtMS0xLTEtMzMwOTg_2d028ee7-25e5-43aa-a188-cea5ec2afbd1"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM184NS9mcmFnOjdhMDNjNzc3NWZjNDRmMzlhZmY3NjkyYjY5NGQ5YzM3L3RhYmxlOjhhNDlhNzA4NDcxMDQwZTk4MzBiMDg2ZTIxMzRlYTk1L3RhYmxlcmFuZ2U6OGE0OWE3MDg0NzEwNDBlOTgzMGIwODZlMjEzNGVhOTVfMy03LTEtMS0xNzc3NQ_6123f20d-b2da-4983-8481-3001d793c73d"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM184NS9mcmFnOjdhMDNjNzc3NWZjNDRmMzlhZmY3NjkyYjY5NGQ5YzM3L3RhYmxlOjhhNDlhNzA4NDcxMDQwZTk4MzBiMDg2ZTIxMzRlYTk1L3RhYmxlcmFuZ2U6OGE0OWE3MDg0NzEwNDBlOTgzMGIwODZlMjEzNGVhOTVfMy03LTEtMS0xNzc3NQ_6123f20d-b2da-4983-8481-3001d793c73d"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yNS9mcmFnOmM5ZGJiZjkwNWNkYjRhM2Y5NGMxZDk0YTNmMjcyZGM2L3RhYmxlOmI3MTFhYTE1OTNiOTQzZWRhOGQ2ZDQyN2QxNTZkOGFjL3RhYmxlcmFuZ2U6YjcxMWFhMTU5M2I5NDNlZGE4ZDZkNDI3ZDE1NmQ4YWNfMjctNy0xLTEtMTc3NzU_6123f20d-b2da-4983-8481-3001d793c73d"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yNS9mcmFnOmM5ZGJiZjkwNWNkYjRhM2Y5NGMxZDk0YTNmMjcyZGM2L3RhYmxlOmI3MTFhYTE1OTNiOTQzZWRhOGQ2ZDQyN2QxNTZkOGFjL3RhYmxlcmFuZ2U6YjcxMWFhMTU5M2I5NDNlZGE4ZDZkNDI3ZDE1NmQ4YWNfMjctNy0xLTEtMTc3NzU_6123f20d-b2da-4983-8481-3001d793c73d"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yNS9mcmFnOmM5ZGJiZjkwNWNkYjRhM2Y5NGMxZDk0YTNmMjcyZGM2L3RhYmxlOmI3MTFhYTE1OTNiOTQzZWRhOGQ2ZDQyN2QxNTZkOGFjL3RhYmxlcmFuZ2U6YjcxMWFhMTU5M2I5NDNlZGE4ZDZkNDI3ZDE1NmQ4YWNfMjctNS0xLTEtMTkyNTY_cd15aa32-72bb-4df8-a330-8fac8ecbd8bb"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yNS9mcmFnOmM5ZGJiZjkwNWNkYjRhM2Y5NGMxZDk0YTNmMjcyZGM2L3RhYmxlOmI3MTFhYTE1OTNiOTQzZWRhOGQ2ZDQyN2QxNTZkOGFjL3RhYmxlcmFuZ2U6YjcxMWFhMTU5M2I5NDNlZGE4ZDZkNDI3ZDE1NmQ4YWNfMjctNS0xLTEtMTkyNTY_cd15aa32-72bb-4df8-a330-8fac8ecbd8bb"
          xlink:type="locator"/>
        <link:footnote id="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yNS9mcmFnOmM5ZGJiZjkwNWNkYjRhM2Y5NGMxZDk0YTNmMjcyZGM2L3RleHRyZWdpb246YzlkYmJmOTA1Y2RiNGEzZjk0YzFkOTRhM2YyNzJkYzZfMzIy_8cef74d3-e3cd-4cfd-a2b6-5f17f7e0cd7f" xlink:label="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yNS9mcmFnOmM5ZGJiZjkwNWNkYjRhM2Y5NGMxZDk0YTNmMjcyZGM2L3RleHRyZWdpb246YzlkYmJmOTA1Y2RiNGEzZjk0YzFkOTRhM2YyNzJkYzZfMzIy_8cef74d3-e3cd-4cfd-a2b6-5f17f7e0cd7f" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Includes $6.8&#160;million loss on disposal of discontinued operations for the year ended December 31, 2021</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM184NS9mcmFnOjdhMDNjNzc3NWZjNDRmMzlhZmY3NjkyYjY5NGQ5YzM3L3RhYmxlOjhhNDlhNzA4NDcxMDQwZTk4MzBiMDg2ZTIxMzRlYTk1L3RhYmxlcmFuZ2U6OGE0OWE3MDg0NzEwNDBlOTgzMGIwODZlMjEzNGVhOTVfMy01LTEtMS0xNzc3NQ_3a7f9340-a2d9-4068-b095-f659267e962c"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yNS9mcmFnOmM5ZGJiZjkwNWNkYjRhM2Y5NGMxZDk0YTNmMjcyZGM2L3RleHRyZWdpb246YzlkYmJmOTA1Y2RiNGEzZjk0YzFkOTRhM2YyNzJkYzZfMzIy_8cef74d3-e3cd-4cfd-a2b6-5f17f7e0cd7f"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yNS9mcmFnOmM5ZGJiZjkwNWNkYjRhM2Y5NGMxZDk0YTNmMjcyZGM2L3RhYmxlOmI3MTFhYTE1OTNiOTQzZWRhOGQ2ZDQyN2QxNTZkOGFjL3RhYmxlcmFuZ2U6YjcxMWFhMTU5M2I5NDNlZGE4ZDZkNDI3ZDE1NmQ4YWNfMjctNS0xLTEtMTc3NzU_3a7f9340-a2d9-4068-b095-f659267e962c"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yNS9mcmFnOmM5ZGJiZjkwNWNkYjRhM2Y5NGMxZDk0YTNmMjcyZGM2L3RleHRyZWdpb246YzlkYmJmOTA1Y2RiNGEzZjk0YzFkOTRhM2YyNzJkYzZfMzIy_8cef74d3-e3cd-4cfd-a2b6-5f17f7e0cd7f"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM184NS9mcmFnOjdhMDNjNzc3NWZjNDRmMzlhZmY3NjkyYjY5NGQ5YzM3L3RhYmxlOjhhNDlhNzA4NDcxMDQwZTk4MzBiMDg2ZTIxMzRlYTk1L3RhYmxlcmFuZ2U6OGE0OWE3MDg0NzEwNDBlOTgzMGIwODZlMjEzNGVhOTVfMy01LTEtMS0yMTkzMQ_cd15aa32-72bb-4df8-a330-8fac8ecbd8bb"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yNS9mcmFnOmM5ZGJiZjkwNWNkYjRhM2Y5NGMxZDk0YTNmMjcyZGM2L3RleHRyZWdpb246YzlkYmJmOTA1Y2RiNGEzZjk0YzFkOTRhM2YyNzJkYzZfMzIy_8cef74d3-e3cd-4cfd-a2b6-5f17f7e0cd7f"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18xMzAvZnJhZzo3NGIwMjA4NWYwNjY0MjYyOGY3OWUzMTNlNjFkZmI3Yy90YWJsZTpmYTRmNTRhZWVjNTg0NDBiYmYyYTcwYWUxMDNkNDVlNy90YWJsZXJhbmdlOmZhNGY1NGFlZWM1ODQ0MGJiZjJhNzBhZTEwM2Q0NWU3XzYtMS0xLTEtMzMwOTg_2d028ee7-25e5-43aa-a188-cea5ec2afbd1"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yNS9mcmFnOmM5ZGJiZjkwNWNkYjRhM2Y5NGMxZDk0YTNmMjcyZGM2L3RleHRyZWdpb246YzlkYmJmOTA1Y2RiNGEzZjk0YzFkOTRhM2YyNzJkYzZfMzIy_8cef74d3-e3cd-4cfd-a2b6-5f17f7e0cd7f"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM184NS9mcmFnOjdhMDNjNzc3NWZjNDRmMzlhZmY3NjkyYjY5NGQ5YzM3L3RhYmxlOjhhNDlhNzA4NDcxMDQwZTk4MzBiMDg2ZTIxMzRlYTk1L3RhYmxlcmFuZ2U6OGE0OWE3MDg0NzEwNDBlOTgzMGIwODZlMjEzNGVhOTVfMy03LTEtMS0xNzc3NQ_6123f20d-b2da-4983-8481-3001d793c73d"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yNS9mcmFnOmM5ZGJiZjkwNWNkYjRhM2Y5NGMxZDk0YTNmMjcyZGM2L3RleHRyZWdpb246YzlkYmJmOTA1Y2RiNGEzZjk0YzFkOTRhM2YyNzJkYzZfMzIy_8cef74d3-e3cd-4cfd-a2b6-5f17f7e0cd7f"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yNS9mcmFnOmM5ZGJiZjkwNWNkYjRhM2Y5NGMxZDk0YTNmMjcyZGM2L3RhYmxlOmI3MTFhYTE1OTNiOTQzZWRhOGQ2ZDQyN2QxNTZkOGFjL3RhYmxlcmFuZ2U6YjcxMWFhMTU5M2I5NDNlZGE4ZDZkNDI3ZDE1NmQ4YWNfMjctNy0xLTEtMTc3NzU_6123f20d-b2da-4983-8481-3001d793c73d"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yNS9mcmFnOmM5ZGJiZjkwNWNkYjRhM2Y5NGMxZDk0YTNmMjcyZGM2L3RleHRyZWdpb246YzlkYmJmOTA1Y2RiNGEzZjk0YzFkOTRhM2YyNzJkYzZfMzIy_8cef74d3-e3cd-4cfd-a2b6-5f17f7e0cd7f"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yNS9mcmFnOmM5ZGJiZjkwNWNkYjRhM2Y5NGMxZDk0YTNmMjcyZGM2L3RhYmxlOmI3MTFhYTE1OTNiOTQzZWRhOGQ2ZDQyN2QxNTZkOGFjL3RhYmxlcmFuZ2U6YjcxMWFhMTU5M2I5NDNlZGE4ZDZkNDI3ZDE1NmQ4YWNfMjctNS0xLTEtMTkyNTY_cd15aa32-72bb-4df8-a330-8fac8ecbd8bb"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjlhYWEyZmRkYzk3ZTQ4MmRhNWRiZTM3YWM4NWFlNzAzL3NlYzo5YWFhMmZkZGM5N2U0ODJkYTVkYmUzN2FjODVhZTcwM18yNS9mcmFnOmM5ZGJiZjkwNWNkYjRhM2Y5NGMxZDk0YTNmMjcyZGM2L3RleHRyZWdpb246YzlkYmJmOTA1Y2RiNGEzZjk0YzFkOTRhM2YyNzJkYzZfMzIy_8cef74d3-e3cd-4cfd-a2b6-5f17f7e0cd7f"
          xlink:type="arc"/>
    </link:footnoteLink>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>152
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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MC$S=8<P9Y '[ -Q?2FEV)_8%Q8>N\_\ 4$L#!!0    ( "&/5U0%D: B'P(
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M"U/,%*<^ *A>#58WN,K6V)RN 8/!!HN>=QFACJ-.O==:B'P ,#VM6NDVWAR
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M#",/]DD\[NSL['"/)YUUM[XB"N*^UL:?3JH0FK>SF<\JJJ6?VH8,OBFLJV7
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M9 GD8QONO9O( $;4N3 NFVN!AMWZ\A\GL.Q7VQ65"\UOR?;X9?*4W,,EXBV
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M89YZ&R^RZ0DO1DVZ[]O.FX5V&9&3:]&WB< %H5B(+0V'984_-7&M<51=T#6
M&7V,R2GE1F##GJ7_T35G#UVS;Q)[])L$'-2#Q>B#.!&Y@T=(,_+K^,?1Z%I7
M?UNJ,B^=;_^%:?I8DL#@BTRHN3*YK9B?DBQ$0*1@3LSASW_P]X(N43NNBH(V
M0G5(/.VDN/!UC<*MP85K/';$8.=0J,@PS$-+M0LZ2I[]0KYG'(%?A'7R$/MR
MB&R,I5)2/_^@O,Q/D;?^/FF(X2JQQTOZL;A"HIJ=+(7TN)DFX*$)5HNZ0^H>
M\0T-07:P;--1\39)L@NCJ)!N2FSZ 8E$7U%^ZT-P"7&D$2[-N:MY6[,._O+;
MY+9\_1V59Q%F%[%!Y S'OSER&/_F2![+%SZ?3^/6_(>"CLM]F)"DRCD?&P6F
M!Q$N=W0M+4?X^&5 T$U#S^66_#MA1-.7YL^F?J+S>?1#JAO;K>CG8NFGX)J>
M?U/5?YKI+])>\ ^QAL?YYVQ_(JPO%MR7\.K1[/ST":,@]1]]NZ6?95VT?=]N
MZ,^U-2 T^ !\OVQA@?(/G,#_3N]W_PM02P,$%     @ (8]75-5->=+H"
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MZ!*6P"9290!=RWIZS*B.% !6_)+BDHI1"B\?A2Q+D\DVB,0KSLD*ZX&.-95
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MB5S_APM,4A!$)*3_E# ;12R0#HY+'[, )C)-\;,\1/&KM@H,0$L[ETNFE^*
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MNBGPTVS52 (:J,(9BIBDW*)JS)9UV2 V8>=]B"VEK@S[@GB&/VBQ">BAH9G
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M2AOY:[,@.B;;5*W$FD-S@5:YH,'VF(V]8Q9!)A1-G" ,V,R909'+IB[V+(+
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M6$D,);"E0BZH]\B/%$?7R(*F6U0KP/P-CP?8T%0\@K9I"IC'@0I#I$T<-SL
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M;"]W;W)K<VAE971S+W-H965T,38N>&ULK5;;CMLX#/T5(LC##."-;['C#)(
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M*$M3KUV6])N!VBG0]ZU2]K1Q#OH?E]7_4$L#!!0    ( "&/5U1'!3/R4@X
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M]/ 4CY&8"*!\SPNBC-]+ZYP15T'++^)-4H4S$59OTJ0,(,KREC2$1'68E6:
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MN_"C6F]JO'#UXODN7<MWLOYY][:"7U=^E%QM96F4+D4E5U^=W<9?O)SB\_3
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MY@?$2;#FVD2@XO5&9$ #. VQT44N*^-H!,=A:AA E6O2 $L;7/%OE&#K"G@
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MV"%Q@J6L[Z7L^<"CKIM81VH.Q50?K ?XUBX;N W'HWE_&YZT%Q!R%H7.*-(
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M)K;IDK*C%N&;:@OAJN(0 !QF)OTD.84LI0TN0M,A-)R#1@RA71=TM_#W"?;
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MV;C5]EL.0GM$."Y 9_?)\,)>]$[>R]N+6%RPS&N 9R&3["V0L1J>XZQ9, U
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MT;-9404PJ=53F_IG"D/O(L3)^7P*T095!N)$"4<]4A03*'%Y:A,Y-+>91F0
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M^8MWADWB<F$M>\DL9LDSPJ\F;]X6!LS$9!_P%^D'SQ[X)>G)@(G3&U;OG<3
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MTF2Q$% FR7P\Y\$H60Q&#*D+YB_5'KV=R*==O>0#5SS!=-&EBP5-%G/ @K2
MO)W/[00@.(74X%#"@1\X,$D&HRG_+F8T3H:S&7VV?&0Y]G&>#-(9!NDP2<>S
M>&<V&--[!:)(0VJ/AFV/,@#U&+"GF)O(BY-OLN-?/0*JC0634U I60RG/![1
M(DDG<QZ.:9XLIC*<8#B=C'@XI5FRF,\Y]6#%B@D[6B2+67H48M?AYI-D-IF
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M1M:$;CPL>V!<>##"<0C.(A5J>5\K4:$FA[@D=-4:0C(AX&.):WN 4%&E]L^
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ME25<$^PDUJATG'=>$S!%59AEX"K7H>E9=ZVGO[I^T^Y(&ENDHJ1ZL2>FD\4
M)2UPYV2TC;Z;TNQ+R '%.W#_'2S_,&I$".1V2X.'D?.9G'^(NT=0-N^=J=?,
MX=I::<T5E$$8*U5FQ2G[ZQW'8'U674'5G8.N>[S$8-]?N.M(K'?9YH!LZLX&
M]S@GJXX2FXN^<YZQCSAR0@=FDP,'9@-W"@/SW='PP('9H:.SWOAPKX.TK_D
MC4WAV_G9GW!^UJH7_Z2#,X.@OYV;=7SA'F7XH9CZ=93@?6CIWAC]?U67>\#T
M@^F0H+?G#B9BXIH">>+,9L&#*NQ#]/:\Y/.J?=C3#QD/'94PC:\7%%Z(8J/X
MWSV@0KL=W.XN'80,'K;CO>TY^^"^NKX+(!Q<K $*/BJ@H?T[.P05? L0@@-
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M&)D//:A,$L!Q,C-99"9!DIW%Q6(_M,B6U1N*U+!)R]Y??T]5-ZFF33G)8(%
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MT#>=*%@M0=EJ:1T.@"!.%F!LADT_M^N&P4 <SK',$L.PW"(6?XREIBB,2'*
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MMPK4UC0 [S=5U70_:(/^ORR\^G]02P,$%     @ (8]75*/UD[<; P  Q08
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M'QWXO'&.3D9,,/VYUM\!4$L#!!0    ( "&/5U3FC\;*UP8  'P1   9
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MJH'P2RVU"I+Y/ :)-9]8>C$#/-;Q$<^ERY691TU&<A+W8>VO),. K<!JS/S
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M#/886LD U<1&6I05U0W,O\D>7=9(2O:AN:_7;F>S!WJ[+,2NZXM##8).[;K
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M96F@\4MP-6B#G-*<E%MO\55!SY_?4"4]%6(IK5?D3H<>H/QIF'< EQ$@^P%
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M.SK2=>/=/6.!O1(T98B72T[M8\5$H#&C2\VVW(K-@F.$)V7TRI)K/?%7G!K
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M3&1#/9(T4(X3E@D^U"//*/)//LJ_$-A61\%(!T-,_":$D?E7)):.0\/WS:X
M3_T/I@<_X [-37AF6"+>*S?\B_>C^Y?,Z? #OU\^/(/H?KMIB$.+*W*-)WD6
M@1F>%D/'Z77XG2^UH\=!,&MZC:'Q"VA^I;7;=7R _?ONY&]02P,$%     @
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MIL\M5'8#O5]+:?83ZV#X@%O\#5!+ P04    "  ACU=4X'SCZZ4I  "ICP
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M@+=MB030N@0.'3+QC>U@HGJ/E/<[P $!5C"')T 5_0 K@JV!Y'.PMZ$N8<,
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MTY,,\LV.SA[.^=JN"<133/;D&*C4/W,@6>SW#W9RK \F!L["3TY_0J(#4,.
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M8-YP9&0_ E8"36_CX7/TXQN8U-3[OBH82D!K&*-.C\OLO$]R=M>I)H2%KA2
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M@WR\"L+MC;FQ7.;JTYRT\DZ%<9P\ZFDI3EN@HQ;!S6,CCF)YX&B*X)*4*?:
M:("S978V&D"2F1!Q'T:6UM92#BPB<93O@,\1R%0F!S *Q41<PJS),53<1'%H
M<LIV0.].[$)TOQ###G-IP:4?L,TV9'CQ[+"ZE24\QU'(XV *G^(1\[*!UHB1
MXHYLR% Q/ZY(]6N6Q!X.29/'@W6B(TD%[$%BDUZ\)'ZZ)6!0T 4US511PL=N
M,H,<@,U@@Q4UF)'%I WT[R@5O/(5U>BVPNBP89];6*X,X&=':5$"$V#T12%4
M%5'&<!Q_0YE1@CZ+RV+\WK9DBZ.IH:L(E14SJ1INE;FIWXF]9TQS6.)2T[$&
MVQ[/LK1K-)7A*^\S$B^Y]XM+K%]<'>P+X-AHY283!GA!K)<P6FW-!]84 $II
M&3+E3SG,*JA J/L*9,U+CTZ%D0%^':+4;S%0#D.046*)NKBBY))(-[XK>% %
M3="XJ'1&Z9[LV7% >VDY8/JA:6^;2$8L'M];2'Q>4>I)21)*^>:G"_"H60G"
MZ0V%I"=%Q">-<"7>>"WB2=DSHE1J["-! #3JK*-Q@.$TQ!_W[)5O T\J!SNJ
M#V)KAP$F'.LD5$)AV_QT%=IKGU'RPBZG@?(I \!N&R!EKA\#$:!<4#:V;#M8
M(6K1Q '(V./R*X,4>ZR,2#)<,1D;IE MBX>N@,&2PXZRZXBH0Y8,O7]WM(AI
M^\[!1X8-'*"Z1%58?=%HT;WKF-0 8%=<YZL-$/X<8<&*-/%9LV\U*O?DC"9"
M056;0VJ:WR#9,AK(N^*R4'GDU18J*4+71$425MR*F+;:@0#?5N?>6XOY5\"_
MC"#VK66!;0\!2@6M\$6<8:9N1S@HS"3I2 GW[ @,**0E]:8<Y47%)*:.T?$D
ME87*O/GI:CHJIYK62N_S86H[(8@H [KUI9$M6A: )E@D+EFK!;TW*@GCVBR_
M.>TL@)X-\O#WB!W A^N0YA#P=99=]F)%%W;G>S1PA)(0,+5=@I%'9^8)?-*-
M&N,Q_8-RJ@ROV)M81]_(QZRV&4U/=!&'J)@=4X24K*N); .KL__,I8QT%-KE
M!M.L4 E AVFK"AY:H"@V23O8LVILLB1M:1?:UDRX8J/5N3 N2W]);]S[,#![
M$NU'VQ65"Q7 R?'X;?*47,@JM"5)=9+L<C3'O_J2/,TS+=RR"UY;[QAB,,\R
MP7Q6.!M-;O+\;;X8U[JKF3W.U#I=$8$N;S:;J+*.)RU;&FG'GA:QO;$I%//!
M'!D6NA;8[BTX.0F)AL0;J:C(+A.>E:0&^IX()."V6]2]B#;(I5:EL5K2Y+C;
M4_!U,^HJZZ5HS>!8X4C6RJ%?+)Y $\FGT'%-'K/($>V@A]M1$P#A%N2=;L[Y
MKZB#!.6BH8BB-B>8#&7+;/06JS4P%CG(V,PEV5^SDX(]!8<I*S&3<\/R@&_A
ML(YR.SBB3R^4"1_$B"^=BB"@Z?NN LM4K3T=EJKCJJU*1)'[FKAH,%$$Y5],
M./=&XE',>3%6E'E?4:.A4^)F$>KG%J=+WMY)ZXYW47,::CTAJ*[/SW[Z2/F7
M-Y:;9(UJK^-RH<FF;Y^QC-^L--SR_458Z[B% P%R FOO678V?\@I%H%BO/V/
MZSI;/,QVM>DI-DD6?> _^B+@U)$1M*J&(\0UTV[Z"J6K81R$?%GX,C$2U?.!
M/FL#AN%&9>:NW0WLPU4? ARS_ L6VFAQ"0=$_:R>D=^]F5>-?[DPE-)]#$ %
MM7APK1=4OH^+<RV>KE2=$//R13(K/SR0[3F5"@(?*\\I92<JK6&[K>+TGDTK
M28]5SUY[$AHP5E >N@@VL^SM'?O4\A?2$'GUU.CHG/*9$_.* _K>/ (24VZM
M.M'!H>3)D83I\PSI%DB_W[/O)TJIB<TN]D5P>QU9+Q$*_/^ZY?XGU, F+H#"
M0ZJT>+T;FG/,"?>?HQO8;X&;4Z15I._?7D9(H/24RFUB\)*GX4L.=0;M(R?-
MEC ]/&YND<B-$/QX<NYZNR,'30THRWU RU%KR&OO^[EJ2Q_Z\(UY+J^O?%^>
M]^VN*K*G%T]SOP>B^JNTJ=65AT4T"'ZF ^6I[CC5@XO&%?4^'MMO^1D5I"Z>
M/M=PV#[1+,] 1Q$OF:?WR0].].I*-%7]^(5?-@F.D$$FK:OTO4LIUCGR&B+Z
MD9EUA'<'+9P(1<Y0],#N>I\RFV$]H%M1=OR148-9]?28526JTTZ[9D8MU28.
M:/:GA)!THN0!='1A%:"V51WYU!/'\<9PCIE(%S:&-;$ET$FC7\<LD1G=3*HU
M)\LQM4SR,)<\JL1,6Y_YH"2M[TB1YL,\;;=%G$"6%IS8NOZ$Z?"CV($MQ9>'
M0J2= &<L/%SLI./B(<9%-?D#WQ53WC^A?G8 _"VH8@/71I%J&8(7O,[8Z4X[
M+JF7":4[4:F;3/L)/L%%*/A=G*[/O8Z@?Q5!?U+9^;RA$MT6RV(<IA*9Y.!]
M@()%$Z,H@S7*8%=?%*9%1A^;6V+"<!*^9#?/X"C+5HX$E7=?[LM8+JG>L=XO
MF<"IE9=T;47:FY@XR&S,AF3=V%!J&8OM*(K!C?C4JH73KCKRUW#$VKN?-*\
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M(79L>7:Y>/ (O@RO__#=SJSMS]0<#5L*K.#3B]G73QYPQR;]HV]W.&2V;'O
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M'+3I2X O:9RS& AZ(JQ)GW!.<H-+!AOE6<P@?1SA\X(N*X!G#+T@;)3!0LF
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MN)*@L5@$J\'L:N3\O<-?'/?FZ!E<)ENE[MWB<[X(8B<(!6;6(3#Z>\ U"N&
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M='1[BVX75M7^YKI5EOK#/Y;TX8':.=!^H90]+!Q!_RFS_ ]02P,$%     @
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M))!&]#6$:!RQ((F )RD+)AS"R81E84HR:D@VN20J+@6*0M7.E1/YU.T9NEE
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MV@70?JF4O9VX!,,G</434$L#!!0    ( "&/5U2M.%I81P,  $4'   9
M>&PO=V]R:W-H965T<R]S:&5E=#0P+GAM;(U576_;.@S]*X2QAQ;PZH_$CA,D
M =INPP9L0[#VWOLP[$&QZ5B8+'F2W+3[]:-LQTV!)G<OUA?/(7E,4<N]TC]-
MA6CAL1;2K+S*VF81!":OL&;F2C4HZ:14NF:6EGH7F$8C*SI0+8(X#-.@9EQZ
MZV6WM]'KI6JMX!(W&DQ;UTP_W:!0^Y47>8>-;WQ76;<1K)<-V^$=VG^:C:95
M,+(4O$9IN)*@L5QYU]'B9NKL.X-_.>[-T1Q<)ENE?KK%IV+EA2X@%)A;Q\!H
M>,!;%,(141B_!DYO=.F Q_,#^X<N=\IERPS>*O$?+VRU\C(/"BQ9*^PWM?^(
M0SZ)X\N5,-T7]KWME#SFK;&J'L"TKKGL1_8XZ' $R,(3@'@ Q%W<O:,NRG?,
MLO52JSUH9TUL;M*EVJ$I."[=3[FSFDXYX>QZH^G_:OL$3!;P_E?+&U+<^O"5
MZN'BGFT%FLME8,F3LP_R@?6F9XU/L$8Q?%'25@;>RP*+EP0!A3C&&1_BO(G/
M,K[#_ HFD0]Q&$=G^"9CWI..;_(_>?NP$4S:E^G#]^NML9HJYL<95]/1U;1S
M-3WAZJZO=U E-,=JX\'=:_J>I70W=6$:EN/*HZMH4#^@M[ZO$$HEZ)IQN1MN
M&?^-!BP=H+&<:A@+: V6K0!!E\' ED(QAOYU+FCD)<^9NRP+N%5UTUK44#%=
M[)E&F, 3,FV>3XPJ;7<2=2?PH=62VY8V7F1'P+<P&\"?)"$E$V\IBF>" A^H
M._36N3+60#+8?T:Z<942!?":Q'M 9V/@KE+:A4"2CNF4"$I3GW"=R D@'!3(
MJH:3RJA6G_@G<,$E":=:0]OF<@%4@%AOR>>A"-TG?$6G-Q!'_GP6TB3*_"Q-
M3POC)UGDOLG\KX6)DCFA9A!-9GZ8):<$BA)_$B=N2+(4[I5EXE2BU+[]:3J!
M:);XX3R%ZSQOZU9TM5(@E5?.6=] "<9J$I[_[C?PD9X&0S)>1-&<L-DE7&24
M<I)>GG7I@Z2*>P-9Y$_2Q$U2/YZ&\-I="XY:6XUZUS5P0V*TTO9=;MP=WXCK
MOC4^F_</S!>F=UP:*HR2H.'5+/% ]TV[7UC5=(URJRRUW6Y:T3N'VAG0>:F4
M/2R<@_'E7/\!4$L#!!0    ( "&/5U1.'9/[&P8  )P/   9    >&PO=V]R
M:W-H965T<R]S:&5E=#0Q+GAM;+U76V_;-AC]*X17# G VA)USY( 2;I>@'4H
MFK1]&/9 2[1-5!)=DHJ;_OH=4K9BM[;;;L >;/'V7?F=0_)\I?1'LQ#"DL]-
MW9J+T<+:Y=ED8LJ%:+@9JZ5H,3-3NN$673V?F*46O/)"33UA09!.&B[;T>6Y
M'WNC+\]59VO9BC>:F*YIN'ZX%K5:78S"T6;@K9POK!N87)XO^5S<"OMN^4:C
M-QFT5+(1K9&J)5K,+D97X=EUZM;[!>^E6)FM-G&13)7ZZ#JOJHM1X!P2M2BM
MT\#QN1<WHJZ=(KCQ::US-)AT@MOMC?;G/G;$,N5&W*CZ@ZSLXF*4CT@E9KRK
M[5NU>BG6\21.7ZEJX__)JE^;1B-2=L:J9BT,#QK9]E_^>9V'+8$\."# U@+,
M^]T;\EX^XY9?GFNU(MJMAC;7\*%Z:3@G6[<IMU9C5D+.7KY0JEK)NB:\K<BK
MUO)V+J>U(%?&"&LH^1-U<7+',61.SR<6%IW<I%QKO^ZULP/:0T9>J]8N#/F]
MK42UJV "5P=_V<;?:W94XS-1CDD44L("%A[1%PWQ1UY?]*_B)\^D*6ME.BW(
M7U=38S6JZ.\C9N/!;.S-Q@?,W@)<50<[:D;F:Q?VI?>XEKN%(#-5 UBRG1/K
M=FF-+OE%&&(Q72X0$=JR[;M<ZP>WF#>J:^VV>4JF#X#94NFU(C$'^"R%!>UE
MET)+51D"\!M,B(J<>*VJ,TB>.3TCO[^\)3=P4I:\)K>J[ASP#+G!GZIEQ9W,
M-:]Y6PK"C3..[13-5.CUEH8%.0E/R1,2HY_F,5IA%-,T2]!*TI1&24&&+:ND
M62H#4R?L%#\*(CHEO_Z2LY#]-O1?-4LNM8L$0V%"P]U%FQ% ' !N 3FM15L^
M$&QU:VKNJ>,DVI9QG:-1L,!'P<(8_L9#!%%<T(!M^<_+3YW4R,E&=991EN>;
MSW&7V$X8WW4I1 *]0U'L6R$MTL@EFJ64%=E&U4]_?*2.)&"S[)K.N7<O4&ZE
M6'I'K2)NXXE\W <L?9)DR3@!H=6UYV: [TF4!N/X<>A 9MU25R@4M6J6PI-Z
M_3#V-3!D=J6EM:)]JF8STBVA;2@5Z.2DW"Y(TTV-K"1.I/$18"<#L),?!K9\
MI!/>TTDE+)>UV8?TXVIWD?X5QH6QLO&Q=$;,NIK4R(EQ</9F25GC*V= I=N1
M,^!1 ^5N4U!1E2 M;P0) _(4B24/@FM UI\\R+L6?<&9A5R:]:)DO>A.E(M6
MU6K^0#9#;[2ZEQ7D6F'=<>Q2[4G3D BBFV7/^CRX)*E.[TG4#K-0(CZ[<B(K
M?\:*ZBF_%QI7AIUX3P]6OBN9/84$3G^DLJF[GISM$?Y6\,/&"W*U=N.M<-<?
MMS/O>H?^D#-!7FAED,D-XU[UC'M5KF$"HQC25G[I$>U -"Q^S^M._(^6]I<$
M&WNR2&@>!&AD-"T<9X0Y.#,#KXV9FXYHY*=!))FCF3#S-'>@A!Q?A/&X0#Y#
MZ@@_8U";04U.(\9(F$(KRW*:8"[):!:FA+$ +D3;!<?& <DS6D B@P-9#J4T
MB<&VXYSDS$^D$4V<GP6-PX3X"RBN3OHCPJ\%;G+452D$(A)2%N:D2 +"TARZ
MW4B(D33.29P%Q\K:,_W8^0TK&7*49S&!]W&$X0(YI"&X/Z8%<@1>1_M.61#1
M-S7?>P-&CAGB25TB4T:3PN<X*VCFC\.HR&D0]0=C1(/8SZ90CW7_B</[HC$.
M:G6'"GCB@MKAYP#A; 8\V^_=7[=T>3!=NZS=A^PH>:M4^5:I4MR&[6+ /=G@
M7@\PV&$\: HW%./\ %TU_?53BPT)0HL[DG"OPXQL._3QPM%]!(=.G6,G0SJ<
M#.D/GPRSSKHKY2-Q;P>]]^C8=V0<M>=><V=FR4MQ,?(TI^_%Z/+Y3QO^ZI)W
MB&0ID3Y[_2%ESMR@K\T"7,%<#WA(:5;DKAWCCQ9AY-J)!VC@VZEKAPF0OA!X
M8LXL+(2H;H??'C;KS'W?[4?0[-N[R=:+"34\]^]"@SH%!OK'TS Z/#VO^A?7
MX_+^W?J:Z[E$Z=1B!M%@G.$DU_U;L.]8M?3OKZFR (QO+O!\%MHMP/Q,*;OI
M. /#@_SR'U!+ P04    "  ACU=4CL7"CF@#   K"   &0   'AL+W=O<FMS
M:&5E=',O<VAE970T,BYX;6R55FUOVS80_BL'K1@20+/>+3ES#.1E10>L19"T
MVX=A'VCI;!.E2(^DXJ:_OD=*5IW-#IH/LH[DW</G.>IXGN^4_FPVB!:^M$*:
MRV!C[?8BBDR]P9:9B=JBI)65TBVS--3KR&PULL8'M2)*XW@:M8S+8#'W<W=Z
M,5>=%5SBG0;3M2W33]<HU.XR2(+]Q#U?;ZR;B!;S+5OC ]I/VSM-HVA$:7B+
MTG E0>/J,KA*+JYSY^\=_N2X,P<V."5+I3Z[P>_-91 [0BBPM@Z!T>L1;U (
M!T0T_ATP@W%+%WAH[]'?>NVD9<D,WBCQ%V_LYC*H FAPQ3IA[]7N'0YZ"H=7
M*V'\+^QZWW060-T9J]HAF!BT7/9O]F7(PT% %9\(2(> U//N-_(L;YEEB[E6
M.]#.F]"<X:7Z:"+'I3N4!ZMIE5.<7?RAY/H7B[J%6UQ:./O(E@+-^3RR!.Y<
MHGH NNZ!TA- 20KOE;0; [_)!IOG !&Q&JFE>VK7Z8N(MUA/($M"2.,T>0$O
M&Z5F'B\[B4<";[FIA3*=1OC[:FFLIL_BGQ? \Q$\]^#Y"? 'JI:F$PAJ!;62
MCZ@MITS2![*TQY+Y,MK'#<)*":H8+M=@W9D,9<._H@%+RS73^LFM/C+1^6W=
MK!B/\[\D@!GG1$G%=HEZ3"PPV3@CAC,N"4-UAF;,^<415^]&/SE\4)9XW#SG
M\ :J69A-$V<D83Y-X9-DK2(27['I2324?M5)ZW?EQG1,UJ1%&6L@+</I+(:L
M"(MJ!G>:RYIOF0""<!%O($G*,"Z2 ^L>W;WC& S[,%_J6]1<-7#VA$R;<T@G
M,\CH><NX'JB>)><.9E:$>5XXJ\C"M!=7G!*7I-,P2[QW0E8^>YV\?!HF50$%
MO8CY,7EE&A9Q?&#]F+QL4D%.S__EE668]OG*RS"OJOX43\C[^:<J3=)?R2*=
M15&^3MT^.JGB8]J>@9=9^8/2XDE,SY&3>X:7E_%^XM4OC_<=WE#9:9 ^0TR[
MRM'4-!I8:=4">V1<^%JD:Z-QW+>:U^3I;A0T%JSR1:C1;-%W&VH8PB>I;[ -
MLS@Y=ME$!Q=XBWKMVQ3ANNSU=_DX.W;"J[X!?'?OV^A[IM=<&A"XHM!X4A8!
MZ+XU]0.KMKX=+)6EYN+-#75SU,Z!UE>*U \#M\'X_V#Q#5!+ P04    "  A
MCU=4+B:@9/(%  #W#P  &0   'AL+W=O<FMS:&5E=',O<VAE970T,RYX;6RU
M5VMOVS84_2L77CK$A2I+\CM+ B1NB_1#AJ!I.PS#/M 28W.31)6DZGB_?N=2
MLF.GC=>U*)!8%,7[//<>DJ<K;?ZV2RD=W1=Y:<\Z2^>JDU[/IDM9"!OJ2I;X
M<J=-(1Q>S:)G*R-%YH6*O)=$T:A7"%5VSD_]W(TY/]6URU4I;PS9NBB$65_*
M7*_..G%G,_%6+9:.)WKGIY58R%OIWE<W!F^]K99,%;*T2I=DY-U9YR(^N1SR
M>K_@@Y(KNS,FCF2N]=_\\B8[ZT3LD,QEZEB#P..3G,D\9T5PXV.KL[,UR8*[
MXXWVUSYVQ#(75LYT_IO*W/*L,^E0)N]$G;NW>G4EVWB\@ZG.K?^E5;-VF'0H
MK:W312L,#PI5-D]QW^9A1V 2/2&0M *)][LQY+U\*9PX/S5Z18970QL/?*A>
M&LZIDD&Y=09?%>3<^4P7A7+(LK,DRHQFNG2J7,@R5=+2\3LQSZ7MGO8<;+%$
M+VWU7C9ZDR?TQ@E=0]72TJLRD]F^@AZ<W'J:;#R]3 YJ?"G3D/IQ0$F4Q ?T
M];>1][V^_C=%_E+9-->V-I+^N)A;9U ^?QZP.MA:'7BK@R>LWC;%3_J.T$2%
MJHO&>IH+Q4.+[GB<KB8[!_5R[Y[82J3RK .]5II/LG/^;BGI3N=H/ 36]IWZ
M!]$=,$TU\#+D(/I6JA(9$&4JZ6)AI&R2!2;PG]=2&$N2X26 (XLYY#8 ^=_(
MZT^B>$K'JH20KBUF;/>$7K=*?H>2ID0^U]&H\.*[KCPXWWI\1$D_B,=3#.)I
M$/<C#";]H)\,ORR72C9W' >C>-"EXWZ0C(==^OFG21(GO]!L/QU)% Q&$XH'
MP00U/4Z"X72P6=,HV@@>#Y+DL9H71N;"89'(T+R*ZXA9B.0]6-4"B22(A].M
M$*Q$R8#>E"D(UDHZSF0SZI)B#O2X-@AL4$."*VD\.R/(%\Q0L&80\J+%2SAG
MU+QVW,KD]-/0LC.C$<4(>.C3,NUWL?('&Q7.?YS+A2I+KE.T!D_ @-(9(2-1
M\I"@(!GTZ4V!2G>\,-6EU;G*A*=X_%5B[4W^*&^W8 ^C';#WRDRL&Z654*@R
M@ZH&XEF71D$TGG!>H_ZTB[B&_1'=_&!WV^2B21^E]8BFW"9-=H^V@1Q@N.&6
MX89?RW"%^(OC\KN8-/9+K'98USZ!-?'NT)B/1QA70CFMEAH=XLFO]!WG*$?K
M.(JC,'K&[NC:[!0,EJ ;,XF#0:IK3FL#E3<B+ M\SD@,SN/9Z(0NGECN"6R&
M(PE^8&)-5U+D;NG57&E;*2=R2[=KZV1!SVD4AT-Z1J]S;> A7>:UI&N9J508
M&3 KA& ME,XH'&#9K[T+[+%(F6C5\C*.EC\^WT#ZOQ_>Q*S%#+S%%)?5Q@/0
MLOY3I!_2?P*F[?=!9N0G6=;RFS:AK]QU.'XOUPQX\^*,?!V*8/0)^YXD81\P
MQ'$X8JAP.KV6]RK5&UF<-LKF8&J!U7.*^QZV@]"#<.)!&+?0\_\-=JE*&P=6
MZ;*2:1CA:]+WC^\J  8RDZ7&KB4<LB;OT[S. .'18!!.<!+-<_@>T%$<C^%Y
M^^Y3<A2/XW"\G0**[PRB:0-O=^$MD&BZ'%&H.\4-J2G#P<N?Q&J\X^YA1).D
M;P$\X"VSDO[@GZ^;#'YK91_[O;"M5;MQ'WX97="K#U=;+'KOKV;09W2]6'J]
M;8_.<)R$J9!NZ[F5'VNFYY:[]U?P-G8K*]=XT,84^(4XLU:B7-,2_%1J1YO-
MA7@25Q1PN\@?>N2Q:R'*=86/)F""XS;<[ K['@2TXCT#ZJ!:E?!24(D29F#X
M((P["I!L9>"M50 ;R8, &@#+N6TK[#.X_>'PH%+D:5]VUZMMLCXC5A"$2I<;
M@H8O7 2BJHR^5QQMOJ9I.#Y(%/N%\P2\48CFV0$75Q[F*E$^$!%K>"@F7 1S
MWFF_M%WV=BYCJ+.%OW)R_ BAN9=M9[>WVHOF,O>PO+D27PN#0Q'[<P?1*!QC
MMS3--;-Y<;KR5[NY=BAJ/USB9BX-+\#W.ZW=YH4-;._ZY_\"4$L#!!0    (
M "&/5U2>LC685P0  !H*   9    >&PO=V]R:W-H965T<R]S:&5E=#0T+GAM
M;(U6;6_;-A#^*P>M'1I L25*LB3/,>"D+9HA68,D2S$,^T!;9YNH)+HD%2?]
M]3M2MF*OCM</MDXD[^%S+X_(T5JJKWJ):."I*FM]YBV-60W[?3U;8L5U3ZZP
MIIFY5!4W]*H6?;U2R OG5)5]%@2#?L5%[8U';NQ&C4>R,:6H\4:!;JJ*J^=S
M+.7ZS N][<"M6"R-'>B/1RN^P#LT?ZYN%+WU.Y1"5%AK(6M0.#_S)N'P/+'K
MW8('@6N]8X.-9"KE5_MR69QY@26$)<Z,1>#T>,0++$L+1#2^;3"];DOKN&MO
MT3^ZV"F6*==X(<LOHC#+,R_SH, Y;TIS*]>?<!./(SB3I7;_L-ZL#3R8-=K(
M:N-,#"I1MT_^M,G#SSBPC0-SO-N-',OWW/#Q2,DU*+N:T*SA0G7>1$[4MBAW
M1M&L(#\SOD(*2<.[>SXM49^,^H9 [51_M@$X;P'8*P A@VM9FZ6&#W6!Q3Y
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M\J(PFF.57@M[=Z"@Q'U ,OA>@%=HVDN>;B5O6#]JO^T/_2E;E^@*.X"-.M&
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M>S9/Y._/ U]IB_NZ,>D<.MRND^&;8]-0J=A(HS:Z7J)_$?O##./H;!BLOL-
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MX*;[8--MG-[ZCR0+[9QN_'*C)$* +N#Y2N/UL=^0@/&KV=G_ %!+ P04
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MEAV /0_U)_T32 WUD&B[2?Y+67P[F-VGL/Y*8;='X3Q2R/<I#-I^)>!)<.M
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M)\W"L%.R*VN'Y0B&UW+9H!W-QHX\>_MQL?5RVGL1SWCA CYHY2H+;U2)Y6.
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M28;5!2TJ+BM@U3_4W*[(HM,^#X[2D Y8&&1%,NR%G1)#68.6/3LG%"\*N/A
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M&K4KH/N54O9YXZ9 -_2+OU!+ P04    "  ACU=418*8S#0"  "W!   &0
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M<'=S^M[,:^\$FUR _0B?REU7<O[)T8U\MR5W8Y%SH\@E?H\#FI2,R:">2Z[
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M;EB9[HW2 LQ^(83>3VR _O\@^0=02P,$%     @ (8]75.7XFC!: @  "P8
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M9$[F%9,E$"Y?>&@N,]X(Z_.!?%(J[[@0Y-T"D'%AWB<4K7ZG@F:#UIM>:W1
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M+W-H965T-C(N>&ULO5?!;MLX$/V5@4XMD$8BG3A)81N(DRT:H%D82=L]+/;
M2".)*$5J2;I.@'[\DI0CN>B&"FK %TLDY[T9/A'/P]E&Z6^F1K3PV AIYDEM
M;?L^34U>8\/,L6I1NI52Z899-]15:EJ-K B@1J0TRZ9IP[A,%K,PM]*+F5I;
MP26N-)AUTS#]M$2A-O.$),\3=[RJK9](%[.657B/]DN[TFZ4]BP%;U :KB1H
M+.?))7F_I!,/"!%?.6[,SCOXK3PH]<T/;HIYDOF*4&!N/05SC^]XA4)X)E?'
MOUO2I,_I@;OOS^P?PN;=9AZ8P2LE_N*%K>?)>0(%EFPM[)W:?,3MADX]7ZZ$
M";^PV<9F">1K8U6S!;L*&BZ[)WO<"K$#(-,7 '0+H*'N+E&H\II9MIAIM0'M
MHQV;?PE;#6A7')?^J]Q;[5:YP]G%DAEN0)6PTFA06N:U.H+[[B/YA7M>25[R
MG$D+EWFNUM)R6<%*"9YS-,!D 5<UDQ4"ES]%:"YSW@H7\PYN'+6L^(- N#0&
MK3F"/]V9>W.-EG%AWLY2ZW;C:TKS;>7+KG+Z0N6$PJV2MC;PARRP^)D@=3+T
M6M!G+98TRGB-^3%,R!'0C)((WZ37=A+X3E[@NU*Z59I9!*M9@2!9@_ #;KGD
MS;J))#CI$YR$!),7$GQP3!;??7+GNOA58?C[DXN'&XN-^2>2[;3/=AK=SA>#
MY5J X"7^W]>*@TD&3\BTB=0Q[>N8_I:L['%$UK,^P=D!9#WOLYWO(VL<3,=E
MO>CKN(C+&LP&M?-:$5S U+PUKSJO)!O<)CN M&3'W<@^XHZ@7W%H"1U*H;^I
M[^C!)8/CD,DA]!T,B)SLI6\<34_']1W<B<0=YC/FM51"54\QNL%DR/002@Z>
M0\[V4C*.?H60@Q^1N*>LM/K."W=0)5K?4D'N_F:U:Y]>:0:#X9"+ TA,!_.A
MV3X2CZ GHQ+3P99HW%CB$H_Z 1U,A])#2#SX#XVW/&,2Q]&14YSNM+C.1*O0
MR!L(S6;7[?:S_67ALFN1A_#NIG'+=,6E 8&E@V;'9\Y7=->\=P.KVM P/RCK
M'#N\UN["@]H'N/52*?L\\ GZ*]3B/U!+ P04    "  ACU=4^O:]1F "  #E
M!0  &0   'AL+W=O<FMS:&5E=',O<VAE970V,RYX;6RM5%%OTS 0_BNG2$@@
ME29-6T!36VGKA. !4:T"'A /KG-)K#EVL*_K^/><G2SJ1%OM@9?$9]_WW=UG
MWRT.UMW[&I'@L='&+Y.:J+U*4R]K;(0?VQ8-GY36-8+8=%7J6X>BB*!&IWF6
MO4L;H4RR6L2]C5LM[)ZT,KAQX/=-(]R?&]3VL$PFR=/&G:IJ"AOI:M&*"K=(
MW]J-8RL=6 K5H/'*&G!8+I/KR=5Z%ORCPW>%!W^TAE#)SMK[8'PNEDD6$D*-
MD@*#X-\#KE'K0,1I_.XYDR%D !ZOG]@_QMJYEIWPN+;ZARJH7B8?$BBP%'M-
M=_;P"?MZYH%/6NWC%PZ];Y: W'NR30_F#!IENK]X['4X DQF9P!Y#\A?"ICV
M@&DLM,LLEG4K2*P6SA[ !6]F"XNH341S-<J$6]R2XU/%.%K="*\\V!(V#CT:
M$D'<$6R[2PT'6U4952HI#,&UE'9O2)D*-E8KJ="#, 6L:V$J!&6>>3AEI&HU
M^[R%^#P"W=>R]/PX7]\B":7]FT5*7$9()I5]RC==ROF9E&]1CF$Z&4&>Y9,3
M\/7+X=ES>,KB#0KF@X)YY)N>X3NER<_KG2?'3_37A0#3(< T!IB="3!(9Z-T
M(VC1R7!5K#COBBZ^YYZ2J![$3B,8),("1,5M[ FD%JKQT(H_X?24XI<SF.7C
M+'MU2NK+N.Q?V#,%9H,"L_^LP"A( *A5I8(>/.WBQBZ^=J8@C3R*Z)04EU.9
MS\_5E!XU81B 7X2K6'W06#)3-GX_3\!U0Z4SR+:Q+W>6N,OCLN8YC"XX\'EI
M+3T9H=6'R;[Z"U!+ P04    "  ACU=4*GYMT5\"  "-!0  &0   'AL+W=O
M<FMS:&5E=',O<VAE970V-"YX;6Q]5,MNVS 0_)6%3BV01 \[:1'8!NPD10,T
M@!&CZ:'H@996$F$^5')=Q7\?DI)5!XAUD?B8'<X.N3MKM=G9&I'@50IEYU%-
MU-S&L<UKE,Q>Z0:5VRFUD8S<U%2Q;0RR(@1)$6=)<A-+QE6TF(6UM5G,])X$
M5[@V8/=2,G-8H=#M/$JCX\(SKVKR"_%BUK *-T@_F[5QLWA@*;A$9;E68+"<
M1\OT=G7M\0'PPK&U)V/PF6RUWOG)8S&/$B\(!>;D&9C[_<,[%,(3.1E_>\YH
M.-('GHZ/[-]"[BZ7+;-XI\4O7E ]C[Y&4&#)]H*>=?L=^WR"P%P+&[[0]M@D
M@GQO2<L^V"F07'5_]MK[<!*0WIP)R/J +.CN#@HJ[QFQQ<SH%HQ'.S8_"*F&
M:">.*W\I&S)NE[LX6JR8Y19T"6N#%A4Q[]4%;+H[\AL;7BE>\IPI@F6>Z[TB
MKBI8:\%SCA:8*N"N9JI"X.H=PG"5\T8XS"5L2.>[2^^?0VOIWI0-1\&G>R3&
MA?U\!(%N_(:=Q>3R\RKCO,]EU>62G<DES>!)*ZHM/*@"B_<$L3-F<"<[NK/*
M1AGO,;^"27H!69*E(WR3P>U)X)N<X=O4S.!'+BR-\0ZZUTZP/< I;LT.87G9
M,E/ [Q^.$AX)I?TS(F@Z")H&0=,S@E[0AKMJT'!=?&3Y>/P4#LB,'5%R/2BY
M'F5Z>&VXZ<PX+V:<(DW.JXE/2D2BJ4(CL! >:U<MP^K0:Y9=B?V'=XWJB9F*
M*PL"2Q>:7'UQJDQ7_-V$=!,*;JO)E6\8UJY?HO$ MU]J3<>)/V#HP(LW4$L#
M!!0    ( "&/5U0R[3<'F@,  (\-   9    >&PO=V]R:W-H965T<R]S:&5E
M=#8U+GAM;,U7WV_B.!#^5ZQH'[92V\0)"60%2"U07:7K";77NX?5/IAD -\F
M-F<[I2O='W_C$ )T781.G-07L)WYOOGA\8S=7TOU72\!#'DM"Z$'WM*8U1??
MU]D22J:OY0H$?IE+53*#4[7P]4H!RVM06?AA$"1^R;CPAOUZ;:J&?5F9@@N8
M*J*KLF3JQRT4<CWPJ+==>.2+I;$+_K"_8@MX O.\FBJ<^2U+SDL0FDM!%,P'
MW@W]<D<[%E!+_,%AK??&Q+HRD_*[G=SG R^P%D$!F;$4#/]>8 1%89G0CK\;
M4J_5:8'[XRW[7>T\.C-C&D:R^)/G9CGP>A[)8<ZJPCS*]2_0.!1;ODP6NOXE
MZT8V\$A6:2/+!HP6E%QL_MEK$X@]0"=^!Q V@/!40-0 HC< #*4;T&D G5,!
M<0.(3P4D#2"I8[\)5AWI,3-LV%=R39251C8[J+>K1F. N;"9]604?N6(,\-'
MR$"8X@>YU[J"G-QDF:R$X6)!G@P3.5.Y)I_'8!@O] 6Y(L]/8_+YTP7Y1+@@
MOR]EI5%*]WV#QEA*/VL4WVX4A^\HCLB#%&:IR43DD#OPH^-X&AXA\#$*;2C"
M;2ANPZ.,#TQ=DXA>DC ( Y=!Q^%CR+9PFCK@XY/A(77 )Z?#7<;?G6Y\[T@L
MHS:MHIHO>H?O-RPI>ZDT55+@. .L2483J<AHR<0"; X=B'&1\54!Y.NO2$CN
M#93ZVQ%S.JTYG=J<SCOFC*JR*IBM803F<RQJA.5_X>&RYKAV>L,6UVRV-K\,
MK](P#3K=OO^ROZ4.N22-DB@ZE)NXY&B:!,&AW)U#CM)>&L5)*WC@?]SZ'Q_U
MWWFJGU<Y,QCJR:NQG6*&89^(J@3%;,W_YCK2_UT+YE5R12/R]0'*&2@7^^C_
M8C\(6=*&+#DU929URER2*2@N<R+GY":7*QND2QRY\^A 9[?5V?T(IZ;7FM,[
MZZGI_92]8=H-W)F;MC:D1VUXM)U'8&.:,"706VQ&Z/K&,%P=PYQGW%P<\98&
MNU88?(3PT[W>3,^Z 0U=LK\#,=:9\$W9:N3V=RH)DVXW?5.V'')Q+Z7=WINR
MY9"[BH,@2-U[3\-= ,)S[#[YAYSSN-)=EZ,?HLW179^CYVUT].>.XSBS_M[]
M$OO#HGX):%([M+EJMJOM:^.FOF/[._'-4P4O60LN-"E@CM#@NHNJU>;VOYD8
MN:IOJS-I\.Y;#Y?X8@)E!?#[7$JSG5@%[1ML^"]02P,$%     @ (8]75'3$
M8.._!@  ;R   !D   !X;"]W;W)K<VAE971S+W-H965T-C8N>&ULM9I;;]LV
M%,>_"F%L0 JTL7B3[2()T%RZ%6C7H$V[AV$/C$3'0B71I>A<@'WX'<JR:$<B
M;2_>2R/)/(=_'A[^>$3UY$'I']5,2H,>B[RL3@<S8^9OA\,JF<E"5,=J+DOX
M9:IT(0S<ZKMA-==2I+51D0])%,7#0F3EX.RD?G:MST[4PN19*:\UJA9%(?33
MN<S5P^D #U8/OF1W,V,?#,].YN).?I7FV_Q:P]VP]9)FA2RK3)5(R^GIX!U^
M>\7'UJ!N\3V3#]7:-;)#N57JA[WYD)X.(JM(YC(QUH6 /_?R0N:Y]00Z?C9.
M!VV?UG#]>N7]?3UX&,RMJ.2%RO_,4C,['8P'*)53L<C-%_7PNVP&Q*V_1.55
M_2]Z:-I& Y0L*J.*QA@4%%FY_"L>FT"L&6#F,2"- 7EF0$8> ]H8T.<&L<>
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MY?KGG?6#%LOL\GLJM!9Q]G$!/ !I%N#[F<!Q(G\P]^G%CVQG_P)02P,$%
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MR"6$ G/K&!@]5GB)0C@B2N-/QQGT(1UP\_V)_<IK)RUWS."E$C]Y8<M)\#:
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MBK)<?M ^OJ_NT/MW'] [Q$KT;<</4K>6\['2RDW_X[11^;%625PJ(;U"(;Y
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M410 ]7S#N3PUB@&:#R?+_P!02P,$%     @ (8]75'A:>(<$ P  G P  !D
M  !X;"]W;W)K<VAE971S+W-H965T-S,N>&ULS5=M;]HP$/XK5K1)K41)'%Y;
M 5)+-ZW2JB%HMP]5/YAP(5:=F-GF9?]^9P.!2C1!6K4B(>*WNWON[G'NTEE*
M]:(3 $-6J<ATUTN,F5WYOHX22)FNRAEDN!-+E3*#4S7U]4P!FSBA5/AA$#3]
ME/',ZW7<VD#U.G)N!,]@H(B>IRE3?VY R&77H]YV8<BGB;$+?J\S8U,8@7F<
M#13._%S+A*>0:2XSHB#N>M?TZH8VK( [\9/#4N^-B75E+.6+G=Q-NEY@$8&
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M>,W$@PQ>F,3NL2RY@P%J"@^<5"0RM*8;QCF#F(GL=DLE$]WEPKW,E1]&/?<
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MH!@6)$O4G&^^02&H8_@BGDC[%VURVY[OH"B3BJ<%6$>04I;_DI<B$14 [AX
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MTM.*7:[T! K"&.CO"\[5=F,<E#/M^!]02P,$%     @ (8]75"9OUV[K @
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M;:#^SQF3VXD^[^L+X?@74$L#!!0    ( "&/5U2#%?/^2 ,  " *   9
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MCVP[Y'M&<%R"LG2('"<89CC)!]-).?;(IA-Z$&F2DT<&^"'+,/MY2U)ZNA[
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M3%:,/>C)53ES/!T04"BD]H#5YQ$60*EVI,+X.?AT1J06[HZ?O7\PN:M<5EC
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M(FV+1. N$O\GTO6XO#[49-D]TK:J!$<Y/0AL@0C<!>(M(MW2W+=%VA:0P%U
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MBJ?V<4EP3(01T-_G7">Z>#$3E/>JD_\!4$L#!!0    ( "&/5U1 1[E-3 8
M  T>   9    >&PO=V]R:W-H965T<R]S:&5E=#@W+GAM;+U946_;-A#^*X31
M 2V0VB(I2TKA!&CDI G0%D&#;@_#'AB9MH5*HD=223KLQX^46%&.)%I9Y[TD
MDGQW_(X\?M]16CPR_DUL*97@*<\*<3;92KE[-YN)9$MS(J9L1POURYKQG$AU
MRS<SL>.4K"JG/)LASPMF.4F+R?FB>G;+SQ>LE%E:T%L.1)GGA'^_H!E[/)O
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MNN3+H5AS2L(<E,1#L"QOF) H'4S'^;U[/AVSC8RCE-YS)#9)0OCK)8W9;C+
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MS74T;VZ112CM!/-\+81^[=@[:?67PNPG4$L#!!0    ( "&/5U13, A,ZP(
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M< U0[]>,R7U'3U#_79G\ U!+ P04    "  ACU=4.PD_6*0"  "Q!P  &0
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M)2AK@/?7$@77+.P![9@Z^P]02P,$%     @ (H]75*/3KUU7!   @!<  !D
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MC^!CK5JQ&DB&WM7TEX,9VH,YX#DJ>([:E!>=Q_!E7J-C7I[;L/G8+?NM:WW
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MA:8[@/W,Z-:%T@R@_U,A]+)A")I[W.@O4$L#!!0    ( "*/5U0L?D"6B00
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MR;[^'ZU)6LD_?4_YI_ORWU"3M))_^J;R_P3ZRVN25O)/7UG^Z;[\'ZA)MS:
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M3.G(V10TX[DZQ[=?[Z?D[,4Y>4%X2;YD8JE8F:JQIS$ 8\9+*F=7:V>TPUE
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MI3)0L_V05 D!3@GAM4L(-DN)Q9)G6AJ"'OP@#0U30U24I793:6\JG3Q-:]B
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MB1[@)J?:EG%[8^3.-5'7TAC9N,LML!*4_0#?5U*:IQL[0-^X7_T/4$L#!!0
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M0LD]4M8:HMF+*C>5-[P-+^PT/AH%OW+P,\O[(I4Y0T_TP#2:HCNV9DJQS#Y
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MS8=;\L$J?RWE3E-1Z(EO, 0+XN<-[KS&C2[@AA'Y(H4I-?DD"BA.!7R,O4U
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MQ$L2*&N []=2FM>)_4![[9K]!E!+ P04    "  BCU=4)NY"@]\"  "J!P
M&@   'AL+W=O<FMS:&5E=',O<VAE970Q,3<N>&ULC55=;]HP%/TK5K2'5BK-
M%X2V J1".JW2*B':;@_3'DQRDUAU;&8[A>[7SW9"1B$@7A)_W'-\CJ_M.UIS
M\28+ (4V)65R[!1*K>Y<5R8%E%A>\Q4P/9-Q46*ENR)WY4H 3BVHI&[@>9%;
M8L*<R<B.S<5DQ"M%"8.Y0+(J2RP^ID#Y>NSXSG9@0?)"F0%W,EKA')Y!O:[F
M0O?<EB4E)3!).$,"LK%S[]_%D8FW 3\(K.5.&QDG2\[?3.<Q'3N>$004$F48
ML/Z]PPPH-41:QI^&TVF7-,#=]I;]J_6NO2RQA!FG/TFJBK%SXZ 4,EQ1M>#K
M;]#X&1B^A%-IOVC=Q'H.2BJI>-F M8*2L/J/-\T^[ #\Z @@: #!/J!_!! V
M@/!<0+\!].W.U%;L/L18X<E(\#42)EJSF8;=3(O6]@DS:7]60L\2C5.31Y;P
M$M +WH!$/30K,,MUZY&A5R8@X3DC?R$U\V@*##*B)+J(06%"Y:4&O#['Z.++
M)?J""$,O!:\D9JD<N4IK,RNX2:-C6NL(CNCP _3$F2HD>F II)\)7&VJ=19L
MG4V#DXPQ)-<H]*]0X 5^AZ#9^7"O QZ?#?=O3[@)VSR%EB\\PK?0N6 )H03;
MZ\*SX_FY0@^;A%8I83FZ+WG%=,KF('3*F!E27,]C?90:V )4)9A$OQ:<4J0O
MTQJ+]/<)R?U6<M]*[A^1/,44LP005F@).6%F]1[/>A^ 1=<!J=D&ELV\5N^3
M:'@S<M]W<W88,QR$GV/BPYC;L-_&?+(R:*T,3EKYCE<2S*9+A56E;).2DBB;
MC<[C7A-&.RIZT>V>FXZ8X6#/34>,?^-WVXE:.]&YF0&6GLI)=)@3;]]%1\Q^
MWN+#F-V\U2;<G5>L!)';:B!18DYP?>W;T;;@W-MW=F]\J@M173?^T]15[ D+
M?1 EHI!I2N]ZJ!6)NC+4'<57]JU<<J5?7MLL=#$%80+T?,:YVG;, FUYGOP#
M4$L#!!0    ( "*/5U1YV./"T@(  .$'   :    >&PO=V]R:W-H965T<R]S
M:&5E=#$Q."YX;6S554UO&C$0_2NC50Z)1-EE^6HB0 J0MI$:%86F/50]F-T!
MK'CMK>T-0>J/[]B[;,D'*)<>>@%[=MZ;-S.V9[!1^MZL$2T\9D*:8;"V-K\(
M0Y.L,6.FJ7*4]&6I=,8L;?4J-+E&EGI0)L(XBGIAQK@,1@-OF^G10!56<(DS
M#:;(,J:W8Q1J,PQ:P<YPRU=KZPSA:)"S%<[1WN4S3;NP9DEYAM)P)4'C<AA<
MMBZF?>?O';YQW)B]-;A,%DK=N\UU.@PB)P@%)M8Q,/I[P D*X8A(QJ^*,ZA#
M.N#^>L?^P>=.N2R8P8D2WWEJU\/@?0 I+EDA[*W:?,(JGZ[C2Y0P_A<VE6\4
M0%(8J[(*3 HR+LM_]EC580_0ZAT Q!4@?@[H' "T*T#[K8!.!>CXRI2I^#I,
MF66C@58;T,Z;V-S"%].C*7TN7=OG5M-73C@[NLIRH;:(,$:)2VYA)I@T<#I%
MR[@P9_ .[N93.#TY@Q/@$FZX$-0O,P@M17<<85)%&I>1X@.16C'<*&G7!JYD
MBNE3@I!DU]KCG?9Q?)1QBDD3VJT&Q%'<>D70Y.WPZ!7X],WPUOF1;-IU)]J>
MKWV [UHF*D.86V:1[I5MP)A1+Q(R^?O/9 J7:<K==6$"IMPD0IE"HX'%UFUS
M9<C^4:LB-PT@.E&D7*Z\)Q6>RP)3^)*C9H["P(_/I "N*9KY>41_I];?\?H[
MQT^2AI3B:?0R]19<:,T717G+,U5(^]K9*;G//;=[JAY&W69G$#[LM_.E3Z\9
M/_69OO2)F[W:YTEBW3JQ[M'$#M2O4=6<C&KI6C!G N$W?-4%PB=DPJZ/5+57
M!^_]EZ>B7^OO_[M3,>F_Z&:TU_%24+CW^&6H5WZ(&(I G.5;4EOK.77IG^=G
M]C'-KW+<_*4IA]\-TRM.M1&X),JHV:<#H\N!4FZLROT3NU"6'FR_7-,,1NT<
MZ/M2*;O;N #U5!_] 5!+ P04    "  BCU=4X\N463($  ";$   &@   'AL
M+W=O<FMS:&5E=',O<VAE970Q,3DN>&ULO5C?;^(X$/Y7++0G=:5M$R<!2D61
MVL+M5MJ>JN5V[^%T#R89P-K$9FVGM-+]\3=.0@(T&/IP?6GS8[YOYIN9S-0=
MKJ7ZJ9< ACQGJ=#7G:4QJRO/T_$2,J8OY H$OIE+E3&#MVKAZ94"EA2@+/4"
MW^]Y&>.B,QH6SQ[5:"ASDW(!CXKH/,N8>KF%5*ZO.[2S>?"-+Y;&/O!&PQ5;
MP!3,]]6CPCNO9DEX!D)S*8B"^77GAEY-@@)06/S@L-9;U\1*F4GYT][<)]<=
MWT8$*<3&4C#\]01WD*:6">/X59%V:I\6N'V]8?^]$(]B9DS#G4S_XHE97G<N
M.R2!.<M3\TVNOT EJ&OY8IGJXB=9E[;]J$/B7!N956",(..B_,V>JT1L 6CO
M ""H ,$^X)"'L *$IP*B"A"="NA6@$*Z5VHO$C=FAHV&2JZ)LM;(9B^*[!=H
MS!<7ME&F1N%;CC@SNA=/H U6WFC"!9G\RKEY(0]@EC(AY4L 3<[&8!A/]4=R
M3KY/Q^3LPT?RP0+^7,I<,Y'HH6<P'$OJQ97KV])U<, U#<B#%&:IR40DD.P2
M>*BC%A-LQ-P&3L8QQ!<DI)](X >T):"[T^%^"WQ\,IP.6N 3-_R!J4/>=Y(1
MUI4-"[[P -\49TJ2IT#DO+6L9<W__HHP<F\@T_\XG$:UTZAP&AUP^AE'$SE+
MI<9.F2N9$2@]9Z5GOFFHMFXIF;L%LYUO3R,:TCYF\FF[A"U6OA_N68U?6YT/
MHEZWMMH1UZW%=9WB[K,5X\KFS>:T35F1TS9M)7%O*QY_3]=KBZA/PW!/EXMG
M1U.OUM1S:OK!%&<S[))[84"A!/P8#>KZ1/Z0ACPJ;M<'N04!<QYS>_TO^9S*
M&4O)%V"I63J:IE_'T'^_3KVLG5XZA4\-,[F1*"AF*VY0#ZH'A?X^D91C%(F-
M8Y$SQ3 SD)#92U5DJ=I*/'&["WW_PO=_<P0^J ,?.)FJ#/%-O8PD,R &P]1S
M4&I_D);!N2GIT>"HW^P3_W_Z2.XJYKUOP#_0X71KQ=%3,K:WU+"1IUAO'N-Z
MNUDH@):X=AT&C</@_1J:-@.?AN[4BUAF4,[=5(K%.79(1O1&)-N(;%W5X>NY
MVAWX^U.JS6P07.[;C5OL(MH]6,IFO5#W?GG@@F=YYDI7,\UI]QVKU Q<ZIZX
MDU@*F?&X^8)7H&+TA7^7MU;&31>]_G*K4KT9MRNHF=ZT[UXATG"Q.%F.FRSH
M'M3S=N"NH&8S4/>L?F#/QYJL&=9T\'Y-%C13.'!/X;<VV1&Z<'"H*L> ET>J
M$C13/'!/\;>UV1&RJ&7A58+>#BP%>5N'L S4HCC]:A++7)CR"%,_K4_8-\6Y
M<N_Y+;T:E^?DAJ8\MN,18<&%)BG,D=*_Z.. 4^5)N+PQ<E4<]6;2X,&QN%P"
M2T!9 WP_E])L;JR#^O\1H_\ 4$L#!!0    ( "*/5U35[NE:& ,  )\)   :
M    >&PO=V]R:W-H965T<R]S:&5E=#$R,"YX;6RU5EMOTS 4_BM'$0B01G/K
M94-M)=9N;-*&JDW  ^+!2T\;"\<.MMLRB1_/L9.% FD82+RT/K:_[SNWV![O
ME/YL<D0+7PLAS23(K2U?A:')<BR8Z:D2):VLE"Z8)5.O0U-J9$L/*D281-$P
M+!B7P73LYQ9Z.E8;*[C$A0:S*0JF[T]1J-TDB(.'B1N^SJV;"*?CDJWQ%NV[
M<J')"AN6)2]0&JXD:%Q-@M?QJ_,X<@"_XSW'G=D;@POE3JG/SKA<3H+(>80"
M,^LH&/UM<89".";RXTM-&C2:#K@_?F _]\%3,'?,X$R)#WQI\TEP', 25VPC
M[(W:76 =T,#Q94H8_PN[:N^0%+.-L:JHP6077%;_[&N=B#U W#\ 2&I \EA
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M "NZ)D6JGOCA [4)E003GLKR%QSLW"@ 22$5SVRP9I"QO/HGOVPA&@%PT!.
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M54 2&BTK"VU-F67CH58[I/UNI^8O IL0[;KATH]Q;K5[REV<'7]@7*//3!2
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M'DIKZ108)[VSSPOL.:'CS^US.WT#9J[OA(W9%3N_9N=/QK3F<"0T1?"DQ$=
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M!FI^QU26JA>]0-W_+OX%4$L#!!0    ( "*/5U1TZTGH4 4  'P7   :
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M ?1Y(1C0YX5@G7U>OO$;J%W[>X3O5<4F-ZK-!V^K<*/9?.>VRA5OMS3 ?0_
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M Z.C<;8Y0T@<!<.MM,M.[_7&/JH00R3B)](Y#"4V<Q"$, Z'HFV[.(C'(FW
M1/Q@.AVBQ($.%&(K'VRS"&,T\O6'&,"0(]_8?@9!B<V>(4&])OV^&3@1/YQ.
M@B>QP8.0#NU0G\.LETY]C89/Q,^GXP#=.^A].0["*!XNNUUV_4+>2IP>G'N4
M3*R;XR"IAW]7J?:4H'O:'3E=-0<M@^?7Z.VB/3@R;MISK$]4:/)(4+![[1*^
MB;4HT1X-M3>*;YO3E257BI?-Y8;1C(G:0/]^S[EZOJE?T!W0S?\#4$L#!!0
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M#0",V%CW=@/EYMC,V<6& ,9\VZ6[V"T4U*6^OXN-H"H0RC1O8Q/SL>OK-9T
MF*H#TX+>F9CCN82^!=WI?'O3^7:+SA?5 I(^(?ZJ]KXY!Q>!RI.S76T'&XW8
M!S#J8UO#KD',I9JJ!@#&""9:!]\ F.5XV-)T &"V4X[U'1V8F&4QHN<V H,R
MRC0=F)AO8^9HWB8F1HA/J6MK0@#<^0[&+BP$9R,$IU$('T6>HUDF$C152W&4
M+@LUB,W& M*#8R3"L*U5OF]"QX1A2VOQ:P#S"=8G!<B9:B3-V0V$88=IWH8
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MQ9)K]T\VI6W@D3C71J8EC!&D3!1/^E*NPPZ .O5 5 +1/M ^ +1*H-44:)=
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MA*$;+IWGT_AU4=-S1-1%N%X0-'K.'!#4#@A&'?# 8SA/%7426CX@+=!.B.3
MTA1MI<A0!M,0'!,ME%/)1()(\A_L73.CG(O]4!H2#C-<=Q$N'/ M-W1!5UZ
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M]^>!FO)SXAA6%?.&[6 <25,,@5KTUVB2(+.3P,>_/M@NB>,T]2. ^1W$,8;
M;L01S %XP) XMN_!O?=1M'Y/19O_5@Y_ U!+ P04    "  BCU=4EXJ[',
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MT]LM9<%&V?[#YET'*P)8$2U6?SJ93\>C0>]N.& ?>^/>I#]D\R_#X=W< 6P
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MPOV@P>7,9$"]6H_S"% G$O#6;+Z,/CQ0G$F V$PGH.Y M^U*>:#03-3Y!4Y
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M5;TK0.^J>E> WDWU;@"]F^K= 'HWU;L!]&ZJ=P/HW53O!M"[J=X-H'=3O1M
M[^9N%@3HW53O!M"[J=X-H'=7O3M [ZYZ=X#>7?7N +V[ZMT!>G?5NP/T[JIW
M!^C=5>\.T+NKWAV@=W<W>P/T[JIW!^@]5.\!T'NHW@.@]U"]!T#OH7H/@-Y#
M]1X O8?J/0!Z#]5[ /0>JO< Z#U4[P'0>[A8!Z"W!9_K /RVX(*= !#<@DMV
M L!P"R[:"0#%+;AL)P <M^#"G0"0W()+=P+ <@LNW@D S2VX?"< /+?@ IY
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M2P$"% ,4    "  ACU=4!T%-8H$   "Q    $               @ $
M9&]C4')O<',O87!P+GAM;%!+ 0(4 Q0    ( "&/5U3F[9/J[@   "L"   1
M              "  :\   !D;V-0<F]P<R]C;W)E+GAM;%!+ 0(4 Q0    (
M "&/5U297)PC$ 8  )PG   3              "  <P!  !X;"]T:&5M92]T
M:&5M93$N>&UL4$L! A0#%     @ (8]75 +&7[K&!@  ]!H  !@
M     ("!#0@  'AL+W=O<FMS:&5E=',O<VAE970Q+GAM;%!+ 0(4 Q0    (
M "&/5U0%D: B'P(  &\%   8              " @0D/  !X;"]W;W)K<VAE
M971S+W-H965T,BYX;6Q02P$"% ,4    "  ACU=4>7H;:DX(   0(P  &
M            @(%>$0  >&PO=V]R:W-H965T<R]S:&5E=#,N>&UL4$L! A0#
M%     @ (8]75%1$S\B2 @  P08  !@              ("!XAD  'AL+W=O
M<FMS:&5E=',O<VAE970T+GAM;%!+ 0(4 Q0    ( "&/5U1G>F%-6PH  -(Q
M   8              " @:H<  !X;"]W;W)K<VAE971S+W-H965T-2YX;6Q0
M2P$"% ,4    "  ACU=41LPX25("  "D!   &               @($[)P
M>&PO=V]R:W-H965T<R]S:&5E=#8N>&UL4$L! A0#%     @ (8]75(> A^/(
M"@  D3D  !@              ("!PRD  'AL+W=O<FMS:&5E=',O<VAE970W
M+GAM;%!+ 0(4 Q0    ( "&/5U0(I]'XN0P   4[   8              "
M@<$T  !X;"]W;W)K<VAE971S+W-H965T."YX;6Q02P$"% ,4    "  ACU=4
M$@8IK?\$  "8"P  &               @(&P00  >&PO=V]R:W-H965T<R]S
M:&5E=#DN>&UL4$L! A0#%     @ (8]75(MUGNV/)   LW<  !D
M     ("!Y48  'AL+W=O<FMS:&5E=',O<VAE970Q,"YX;6Q02P$"% ,4
M"  ACU=4U4UYTN@(  #<%@  &0              @(&K:P  >&PO=V]R:W-H
M965T<R]S:&5E=#$Q+GAM;%!+ 0(4 Q0    ( "&/5U1^%CVW\1$  '\S   9
M              " @<IT  !X;"]W;W)K<VAE971S+W-H965T,3(N>&UL4$L!
M A0#%     @ (8]75%L49_NA"   WQ@  !D              ("!\H8  'AL
M+W=O<FMS:&5E=',O<VAE970Q,RYX;6Q02P$"% ,4    "  ACU=485$S]%D0
M  !7,0  &0              @('*CP  >&PO=V]R:W-H965T<R]S:&5E=#$T
M+GAM;%!+ 0(4 Q0    ( "&/5U3)@5S5+P<  ",2   9              "
M@5J@  !X;"]W;W)K<VAE971S+W-H965T,34N>&UL4$L! A0#%     @ (8]7
M5.C 2H.$ P  Q @  !D              ("!P*<  'AL+W=O<FMS:&5E=',O
M<VAE970Q-BYX;6Q02P$"% ,4    "  ACU=41P4S\E(.  !D+0  &0
M        @(%[JP  >&PO=V]R:W-H965T<R]S:&5E=#$W+GAM;%!+ 0(4 Q0
M   ( "&/5U1_9U(:Q18   !;   9              " @02Z  !X;"]W;W)K
M<VAE971S+W-H965T,3@N>&UL4$L! A0#%     @ (8]75,/DK--2%   @#H
M !D              ("! -$  'AL+W=O<FMS:&5E=',O<VAE970Q.2YX;6Q0
M2P$"% ,4    "  ACU=4:+V*:&L(  !R%   &0              @(&)Y0
M>&PO=V]R:W-H965T<R]S:&5E=#(P+GAM;%!+ 0(4 Q0    ( "&/5U0Q$J,<
M8@0  " *   9              " @2ON  !X;"]W;W)K<VAE971S+W-H965T
M,C$N>&UL4$L! A0#%     @ (8]75&.QRV':#P  13X  !D
M ("!Q/(  'AL+W=O<FMS:&5E=',O<VAE970R,BYX;6Q02P$"% ,4    "  A
MCU=4,^ODL5P1  "^,   &0              @('5 @$ >&PO=V]R:W-H965T
M<R]S:&5E=#(S+GAM;%!+ 0(4 Q0    ( "&/5U2C]9.W&P,  ,4&   9
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M970R."YX;6Q02P$"% ,4    "  ACU=4QVXX>R8%  !R"P  &0
M    @(&N- $ >&PO=V]R:W-H965T<R]S:&5E=#(Y+GAM;%!+ 0(4 Q0    (
M "&/5U3(X,[[3@H  (8<   9              " @0LZ 0!X;"]W;W)K<VAE
M971S+W-H965T,S N>&UL4$L! A0#%     @ (8]75 9%;[/S"0  IAH  !D
M             ("!D$0! 'AL+W=O<FMS:&5E=',O<VAE970S,2YX;6Q02P$"
M% ,4    "  ACU=4X9]X 1H$  #K"0  &0              @(&Z3@$ >&PO
M=V]R:W-H965T<R]S:&5E=#,R+GAM;%!+ 0(4 Q0    ( "&/5U0,E0L 2P0
M ,P)   9              " @0M3 0!X;"]W;W)K<VAE971S+W-H965T,S,N
M>&UL4$L! A0#%     @ (8]75.!\X^NE*0  J8\  !D              ("!
MC5<! 'AL+W=O<FMS:&5E=',O<VAE970S-"YX;6Q02P$"% ,4    "  ACU=4
MCT7UOC0)  #=&0  &0              @(%I@0$ >&PO=V]R:W-H965T<R]S
M:&5E=#,U+GAM;%!+ 0(4 Q0    ( "&/5U1I0&GL\0,  -8,   9
M      " @=2* 0!X;"]W;W)K<VAE971S+W-H965T,S8N>&UL4$L! A0#%
M  @ (8]75([K-7:X!@  >A(  !D              ("!_(X! 'AL+W=O<FMS
M:&5E=',O<VAE970S-RYX;6Q02P$"% ,4    "  ACU=4:.1M5,\$  !/"P
M&0              @('KE0$ >&PO=V]R:W-H965T<R]S:&5E=#,X+GAM;%!+
M 0(4 Q0    ( "&/5U05;*WK. ,   X'   9              " @?&: 0!X
M;"]W;W)K<VAE971S+W-H965T,SDN>&UL4$L! A0#%     @ (8]75*TX6EA'
M P  10<  !D              ("!8)X! 'AL+W=O<FMS:&5E=',O<VAE970T
M,"YX;6Q02P$"% ,4    "  ACU=43AV3^QL&  "<#P  &0
M@('>H0$ >&PO=V]R:W-H965T<R]S:&5E=#0Q+GAM;%!+ 0(4 Q0    ( "&/
M5U2.Q<*.: ,  "L(   9              " @3"H 0!X;"]W;W)K<VAE971S
M+W-H965T-#(N>&UL4$L! A0#%     @ (8]75"XFH&3R!0  ]P\  !D
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M=#0W+GAM;%!+ 0(4 Q0    ( "&/5U1D- A=H0(  .H%   9
M  " @:;+ 0!X;"]W;W)K<VAE971S+W-H965T-#@N>&UL4$L! A0#%     @
M(8]75*>/K?YI!0  ]Q,  !D              ("!?LX! 'AL+W=O<FMS:&5E
M=',O<VAE970T.2YX;6Q02P$"% ,4    "  ACU=4:NB.RJ #   *"   &0
M            @($>U $ >&PO=V]R:W-H965T<R]S:&5E=#4P+GAM;%!+ 0(4
M Q0    ( "&/5U19]4T_! ,  %X&   9              " @?77 0!X;"]W
M;W)K<VAE971S+W-H965T-3$N>&UL4$L! A0#%     @ (8]75&,B'A9#!P
M01,  !D              ("!,-L! 'AL+W=O<FMS:&5E=',O<VAE970U,BYX
M;6Q02P$"% ,4    "  ACU=4BE'I_I8$  !@"@  &0              @(&J
MX@$ >&PO=V]R:W-H965T<R]S:&5E=#4S+GAM;%!+ 0(4 Q0    ( "&/5U02
MJ)?N* 0  -,)   9              " @7?G 0!X;"]W;W)K<VAE971S+W-H
M965T-30N>&UL4$L! A0#%     @ (8]75)GQF>-B!   OPD  !D
M     ("!UNL! 'AL+W=O<FMS:&5E=',O<VAE970U-2YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( "&/5U1G)Y1S@ (  !L&   9              "
M@4O^ 0!X;"]W;W)K<VAE971S+W-H965T-C N>&UL4$L! A0#%     @ (8]7
M5.7XFC!: @  "P8  !D              ("! @$" 'AL+W=O<FMS:&5E=',O
M<VAE970V,2YX;6Q02P$"% ,4    "  ACU=4],HO[S0#  !.#0  &0
M        @(&3 P( >&PO=V]R:W-H965T<R]S:&5E=#8R+GAM;%!+ 0(4 Q0
M   ( "&/5U3Z]KU&8 (  .4%   9              " @?X& @!X;"]W;W)K
M<VAE971S+W-H965T-C,N>&UL4$L! A0#%     @ (8]75"I^;=%? @  C04
M !D              ("!E0D" 'AL+W=O<FMS:&5E=',O<VAE970V-"YX;6Q0
M2P$"% ,4    "  ACU=4,NTW!YH#  "/#0  &0              @($K# (
M>&PO=V]R:W-H965T<R]S:&5E=#8U+GAM;%!+ 0(4 Q0    ( "&/5U1TQ&#C
MOP8  &\@   9              " @?P/ @!X;"]W;W)K<VAE971S+W-H965T
M-C8N>&UL4$L! A0#%     @ (8]75,FX 0DX!@  <!L  !D
M ("!\A8" 'AL+W=O<FMS:&5E=',O<VAE970V-RYX;6Q02P$"% ,4    "  A
MCU=41+$2'GP"  !M!0  &0              @(%A'0( >&PO=V]R:W-H965T
M<R]S:&5E=#8X+GAM;%!+ 0(4 Q0    ( "&/5U0D(1GCE0<  "@C   9
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M970W,RYX;6Q02P$"% ,4    "  ACU=4B7%8NGP$  !A#P  &0
M    @(&.-P( >&PO=V]R:W-H965T<R]S:&5E=#<T+GAM;%!+ 0(4 Q0    (
M "&/5U3Q+,-8(0,  -\*   9              " @4$\ @!X;"]W;W)K<VAE
M971S+W-H965T-S4N>&UL4$L! A0#%     @ (8]75"9OUV[K @  ' H  !D
M             ("!F3\" 'AL+W=O<FMS:&5E=',O<VAE970W-BYX;6Q02P$"
M% ,4    "  ACU=4@Q7S_D@#   @"@  &0              @(&[0@( >&PO
M=V]R:W-H965T<R]S:&5E=#<W+GAM;%!+ 0(4 Q0    ( "&/5U3>I@.C%00
M !D0   9              " @3I& @!X;"]W;W)K<VAE971S+W-H965T-S@N
M>&UL4$L! A0#%     @ (8]75!+:3S,> P  >0L  !D              ("!
MADH" 'AL+W=O<FMS:&5E=',O<VAE970W.2YX;6Q02P$"% ,4    "  ACU=4
M26NR/=L$   O%P  &0              @(';30( >&PO=V]R:W-H965T<R]S
M:&5E=#@P+GAM;%!+ 0(4 Q0    ( "&/5U2!,:V\5@8  -PA   9
M      " @>U2 @!X;"]W;W)K<VAE971S+W-H965T.#$N>&UL4$L! A0#%
M  @ (8]75(KR+?V5 @  8@<  !D              ("!>ED" 'AL+W=O<FMS
M:&5E=',O<VAE970X,BYX;6Q02P$"% ,4    "  ACU=4+GW0=L %  #%&@
M&0              @(%&7 ( >&PO=V]R:W-H965T<R]S:&5E=#@S+GAM;%!+
M 0(4 Q0    ( "&/5U1YY[C'VP4  !@=   9              " @3UB @!X
M;"]W;W)K<VAE971S+W-H965T.#0N>&UL4$L! A0#%     @ (8]75$5'<'C/
M @  J 8  !D              ("!3V@" 'AL+W=O<FMS:&5E=',O<VAE970X
M-2YX;6Q02P$"% ,4    "  ACU=4LHG P1D%  !C%0  &0
M@(%5:P( >&PO=V]R:W-H965T<R]S:&5E=#@V+GAM;%!+ 0(4 Q0    ( "&/
M5U1 1[E-3 8   T>   9              " @:5P @!X;"]W;W)K<VAE971S
M+W-H965T.#<N>&UL4$L! A0#%     @ (8]75(\8=;O)!   =!8  !D
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M 'AL+W=O<FMS:&5E=',O<VAE970Y,2YX;6Q02P$"% ,4    "  ACU=43-"
M*%X"  !1!@  &0              @(&,B0( >&PO=V]R:W-H965T<R]S:&5E
M=#DR+GAM;%!+ 0(4 Q0    ( "&/5U1^T:OVEP,  %X0   9
M  " @2&, @!X;"]W;W)K<VAE971S+W-H965T.3,N>&UL4$L! A0#%     @
M(8]75%,P"$SK @  N@@  !D              ("![X\" 'AL+W=O<FMS:&5E
M=',O<VAE970Y-"YX;6Q02P$"% ,4    "  ACU=4.PD_6*0"  "Q!P  &0
M            @($1DP( >&PO=V]R:W-H965T<R]S:&5E=#DU+GAM;%!+ 0(4
M Q0    ( "&/5U3>8U6]3@(  )(&   9              " @>R5 @!X;"]W
M;W)K<VAE971S+W-H965T.38N>&UL4$L! A0#%     @ (H]75%)Q1&QH!P
M1"8  !D              ("!<9@" 'AL+W=O<FMS:&5E=',O<VAE970Y-RYX
M;6Q02P$"% ,4    "  BCU=42(>4!ZL#  "R#@  &0              @($0
MH ( >&PO=V]R:W-H965T<R]S:&5E=#DX+GAM;%!+ 0(4 Q0    ( "*/5U2C
MTZ]=5P0  ( 7   9              " @?*C @!X;"]W;W)K<VAE971S+W-H
M965T.3DN>&UL4$L! A0#%     @ (H]75-71L$3P P  ,!(  !H
M     ("!@*@" 'AL+W=O<FMS:&5E=',O<VAE970Q,# N>&UL4$L! A0#%
M  @ (H]75"/NWV9@ @  WP4  !H              ("!J*P" 'AL+W=O<FMS
M:&5E=',O<VAE970Q,#$N>&UL4$L! A0#%     @ (H]75+PK'!HU P  #0T
M !H              ("!0*\" 'AL+W=O<FMS:&5E=',O<VAE970Q,#(N>&UL
M4$L! A0#%     @ (H]75,IPXXG- P   0T  !H              ("!K;("
M 'AL+W=O<FMS:&5E=',O<VAE970Q,#,N>&UL4$L! A0#%     @ (H]75/JD
M6@1E!   ?Q$  !H              ("!LK8" 'AL+W=O<FMS:&5E=',O<VAE
M970Q,#0N>&UL4$L! A0#%     @ (H]75.8A>725!@   "0  !H
M     ("!3[L" 'AL+W=O<FMS:&5E=',O<VAE970Q,#4N>&UL4$L! A0#%
M  @ (H]75%:\@(Z6!   >Q$  !H              ("!',(" 'AL+W=O<FMS
M:&5E=',O<VAE970Q,#8N>&UL4$L! A0#%     @ (H]75(5A$8""!   [A4
M !H              ("!ZL8" 'AL+W=O<FMS:&5E=',O<VAE970Q,#<N>&UL
M4$L! A0#%     @ (H]75#8$9Q8N P  TPD  !H              ("!I,L"
M 'AL+W=O<FMS:&5E=',O<VAE970Q,#@N>&UL4$L! A0#%     @ (H]75"Q^
M0):)!   UQ,  !H              ("!"L\" 'AL+W=O<FMS:&5E=',O<VAE
M970Q,#DN>&UL4$L! A0#%     @ (H]75%] >ZW4 P  [ \  !H
M     ("!R]," 'AL+W=O<FMS:&5E=',O<VAE970Q,3 N>&UL4$L! A0#%
M  @ (H]75+VYD+SE!   7Q4  !H              ("!U]<" 'AL+W=O<FMS
M:&5E=',O<VAE970Q,3$N>&UL4$L! A0#%     @ (H]75'760A?P @  S <
M !H              ("!]-P" 'AL+W=O<FMS:&5E=',O<VAE970Q,3(N>&UL
M4$L! A0#%     @ (H]75((D+&F; P  ]@P  !H              ("!'. "
M 'AL+W=O<FMS:&5E=',O<VAE970Q,3,N>&UL4$L! A0#%     @ (H]75%L
MI<50!0  Q!<  !H              ("![^," 'AL+W=O<FMS:&5E=',O<VAE
M970Q,30N>&UL4$L! A0#%     @ (H]75)+R22GJ!   GQ(  !H
M     ("!=^D" 'AL+W=O<FMS:&5E=',O<VAE970Q,34N>&UL4$L! A0#%
M  @ (H]75!5-KOE< P  @@D  !H              ("!F>X" 'AL+W=O<FMS
M:&5E=',O<VAE970Q,38N>&UL4$L! A0#%     @ (H]75";N0H/? @  J@<
M !H              ("!+?(" 'AL+W=O<FMS:&5E=',O<VAE970Q,3<N>&UL
M4$L! A0#%     @ (H]75'G8X\+2 @  X0<  !H              ("!1/4"
M 'AL+W=O<FMS:&5E=',O<VAE970Q,3@N>&UL4$L! A0#%     @ (H]75./+
ME%DR!   FQ   !H              ("!3O@" 'AL+W=O<FMS:&5E=',O<VAE
M970Q,3DN>&UL4$L! A0#%     @ (H]75-7NZ5H8 P  GPD  !H
M     ("!N/P" 'AL+W=O<FMS:&5E=',O<VAE970Q,C N>&UL4$L! A0#%
M  @ (H]75)I*IFRI P  ' T  !H              ("!"  # 'AL+W=O<FMS
M:&5E=',O<VAE970Q,C$N>&UL4$L! A0#%     @ (H]75%S%AT,(!   (A0
M !H              ("!Z0,# 'AL+W=O<FMS:&5E=',O<VAE970Q,C(N>&UL
M4$L! A0#%     @ (H]75-#1/^85 @  2 0  !H              ("!*0@#
M 'AL+W=O<FMS:&5E=',O<VAE970Q,C,N>&UL4$L! A0#%     @ (H]75+\$
M4A,/ P  *0@  !H              ("!=@H# 'AL+W=O<FMS:&5E=',O<VAE
M970Q,C0N>&UL4$L! A0#%     @ (H]75$%NCL!& P  N0P  !H
M     ("!O0T# 'AL+W=O<FMS:&5E=',O<VAE970Q,C4N>&UL4$L! A0#%
M  @ (H]75%7AO3T+!   "P\  !H              ("!.Q$# 'AL+W=O<FMS
M:&5E=',O<VAE970Q,C8N>&UL4$L! A0#%     @ (H]75'3K2>A0!0  ?!<
M !H              ("!?A4# 'AL+W=O<FMS:&5E=',O<VAE970Q,C<N>&UL
M4$L! A0#%     @ (H]75$?5^G9A P  FPP  !H              ("!!AL#
M 'AL+W=O<FMS:&5E=',O<VAE970Q,C@N>&UL4$L! A0#%     @ (H]75"3)
M'XT* @  900  !H              ("!GQX# 'AL+W=O<FMS:&5E=',O<VAE
M970Q,CDN>&UL4$L! A0#%     @ (H]75+G1&XE@!P  JRP  !H
M     ("!X2 # 'AL+W=O<FMS:&5E=',O<VAE970Q,S N>&UL4$L! A0#%
M  @ (H]75-W/!!1A"   &R@  !H              ("!>2@# 'AL+W=O<FMS
M:&5E=',O<VAE970Q,S$N>&UL4$L! A0#%     @ (H]75.X/@B;?!0  K!L
M !H              ("!$C$# 'AL+W=O<FMS:&5E=',O<VAE970Q,S(N>&UL
M4$L! A0#%     @ (H]75+2SSN$Y!P  !B,  !H              ("!*3<#
M 'AL+W=O<FMS:&5E=',O<VAE970Q,S,N>&UL4$L! A0#%     @ (H]75"6N
MYZ;# @  Q @  !H              ("!FCX# 'AL+W=O<FMS:&5E=',O<VAE
M970Q,S0N>&UL4$L! A0#%     @ (H]75%U*1;\U!0  _A(  !H
M     ("!E4$# 'AL+W=O<FMS:&5E=',O<VAE970Q,S4N>&UL4$L! A0#%
M  @ (H]75/;/;_]$ P  NA0   T              ( ! D<# 'AL+W-T>6QE
M<RYX;6Q02P$"% ,4    "  BCU=4EXJ[',     3 @  "P
M@ %Q2@, 7W)E;',O+G)E;'-02P$"% ,4    "  BCU=4:%)RES$)  ";6
M#P              @ %:2P, >&PO=V]R:V)O;VLN>&UL4$L! A0#%     @
M(H]75+Q1.:6H P  )D\  !H              ( !N%0# 'AL+U]R96QS+W=O
M<FMB;V]K+GAM;"YR96QS4$L! A0#%     @ (H]75'$>%:G( @  H4L  !,
M             ( !F%@# %M#;VYT96YT7U1Y<&5S72YX;6Q02P4&     (\
,CP"$)P  D5L#

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>153
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>154
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>155
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.22.0.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>472</ContextCount>
  <ElementCount>753</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>true</FootnotesReported>
  <SegmentCount>132</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>7</UnitCount>
  <MyReports>
    <Report instance="evh-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>000010001 - Document - Cover Page</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/CoverPage</Role>
      <ShortName>Cover Page</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="evh-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>000020002 - Document - Audit Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/AuditInformation</Role>
      <ShortName>Audit Information</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="evh-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>100010003 - Statement - CONSOLIDATED BALANCE SHEETS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS</Role>
      <ShortName>CONSOLIDATED BALANCE SHEETS</ShortName>
      <MenuCategory>Uncategorized</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="evh-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>100020004 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETSParenthetical</Role>
      <ShortName>CONSOLIDATED BALANCE SHEETS (Parenthetical)</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="evh-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>100030005 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (LOSS)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (LOSS)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="evh-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>100040006 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (LOSS) (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSSParenthetical</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (LOSS) (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="evh-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>100050007 - Statement - CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS' EQUITY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS' EQUITY</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="evh-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>100060008 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF CASH FLOWS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="evh-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>210011001 - Disclosure - Organization</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/Organization</Role>
      <ShortName>Organization</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="evh-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>210031002 - Disclosure - Basis of Presentation, Summary of Significant Accounting Policies and Change in Accounting Principles</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciples</Role>
      <ShortName>Basis of Presentation, Summary of Significant Accounting Policies and Change in Accounting Principles</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="evh-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>210141003 - Disclosure - Recently Issued Accounting Standards</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/RecentlyIssuedAccountingStandards</Role>
      <ShortName>Recently Issued Accounting Standards</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="evh-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>210161004 - Disclosure - Transactions</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/Transactions</Role>
      <ShortName>Transactions</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="evh-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>210201005 - Disclosure - Discontinued Operations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/DiscontinuedOperations</Role>
      <ShortName>Discontinued Operations</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="evh-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>210261006 - Disclosure - Revenue Recognition</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/RevenueRecognition</Role>
      <ShortName>Revenue Recognition</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="evh-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>210321007 - Disclosure - Credit Losses</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/CreditLosses</Role>
      <ShortName>Credit Losses</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="evh-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>210361008 - Disclosure - Property and Equipment, Net</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/PropertyandEquipmentNet</Role>
      <ShortName>Property and Equipment, Net</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="evh-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>210391009 - Disclosure - Goodwill and Intangible Assets, Net</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNet</Role>
      <ShortName>Goodwill and Intangible Assets, Net</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="evh-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>210451010 - Disclosure - Long-term Debt</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/LongtermDebt</Role>
      <ShortName>Long-term Debt</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="evh-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>210531011 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/CommitmentsandContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="evh-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>210581012 - Disclosure - Leases</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/Leases</Role>
      <ShortName>Leases</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="evh-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>210651013 - Disclosure - Earnings (Loss) Per Common Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/EarningsLossPerCommonShare</Role>
      <ShortName>Earnings (Loss) Per Common Share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="evh-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>210691014 - Disclosure - Stock-based Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/StockbasedCompensation</Role>
      <ShortName>Stock-based Compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="evh-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>210831015 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/IncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="evh-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>210921016 - Disclosure - Employee Benefit Plans</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/EmployeeBenefitPlans</Role>
      <ShortName>Employee Benefit Plans</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="evh-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>210941017 - Disclosure - Investments in Equity Method Investees</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/InvestmentsinEquityMethodInvestees</Role>
      <ShortName>Investments in Equity Method Investees</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>25</Position>
    </Report>
    <Report instance="evh-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>210961018 - Disclosure - Non-controlling Interests</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/NoncontrollingInterests</Role>
      <ShortName>Non-controlling Interests</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>26</Position>
    </Report>
    <Report instance="evh-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>211001019 - Disclosure - Fair Value Measurement</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/FairValueMeasurement</Role>
      <ShortName>Fair Value Measurement</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>27</Position>
    </Report>
    <Report instance="evh-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>211061020 - Disclosure - Related Parties</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/RelatedParties</Role>
      <ShortName>Related Parties</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>28</Position>
    </Report>
    <Report instance="evh-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>211101021 - Disclosure - Repositioning and Other Changes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/RepositioningandOtherChanges</Role>
      <ShortName>Repositioning and Other Changes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>29</Position>
    </Report>
    <Report instance="evh-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>211131022 - Disclosure - Segment Reporting</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/SegmentReporting</Role>
      <ShortName>Segment Reporting</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>30</Position>
    </Report>
    <Report instance="evh-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>211181023 - Disclosure - Reserves for Claims and Performance-Based Arrangements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/ReservesforClaimsandPerformanceBasedArrangements</Role>
      <ShortName>Reserves for Claims and Performance-Based Arrangements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>31</Position>
    </Report>
    <Report instance="evh-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>211211024 - Disclosure - Quarterly Results of Operations (unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/QuarterlyResultsofOperationsunaudited</Role>
      <ShortName>Quarterly Results of Operations (unaudited)</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>32</Position>
    </Report>
    <Report instance="evh-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>211251025 - Disclosure - Supplemental Cash Flow Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/SupplementalCashFlowInformation</Role>
      <ShortName>Supplemental Cash Flow Information</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>33</Position>
    </Report>
    <Report instance="evh-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>220042001 - Disclosure - Basis of Presentation, Summary of Significant Accounting Policies and Change in Accounting Principles (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesPolicies</Role>
      <ShortName>Basis of Presentation, Summary of Significant Accounting Policies and Change in Accounting Principles (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciples</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="evh-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>230053001 - Disclosure - Basis of Presentation, Summary of Significant Accounting Policies and Change in Accounting Principles (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesTables</Role>
      <ShortName>Basis of Presentation, Summary of Significant Accounting Policies and Change in Accounting Principles (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciples</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="evh-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>230173002 - Disclosure - Transactions (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/TransactionsTables</Role>
      <ShortName>Transactions (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.evolenthealth.com/role/Transactions</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="evh-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>230213003 - Disclosure - Discontinued Operations (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/DiscontinuedOperationsTables</Role>
      <ShortName>Discontinued Operations (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.evolenthealth.com/role/DiscontinuedOperations</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="evh-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>230273004 - Disclosure - Revenue Recognition (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/RevenueRecognitionTables</Role>
      <ShortName>Revenue Recognition (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.evolenthealth.com/role/RevenueRecognition</ParentRole>
      <Position>38</Position>
    </Report>
    <Report instance="evh-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>230333005 - Disclosure - Credit Losses (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/CreditLossesTables</Role>
      <ShortName>Credit Losses (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.evolenthealth.com/role/CreditLosses</ParentRole>
      <Position>39</Position>
    </Report>
    <Report instance="evh-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>230373006 - Disclosure - Property and Equipment, Net (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/PropertyandEquipmentNetTables</Role>
      <ShortName>Property and Equipment, Net (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.evolenthealth.com/role/PropertyandEquipmentNet</ParentRole>
      <Position>40</Position>
    </Report>
    <Report instance="evh-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>230403007 - Disclosure - Goodwill and Intangible Assets, Net (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNetTables</Role>
      <ShortName>Goodwill and Intangible Assets, Net (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNet</ParentRole>
      <Position>41</Position>
    </Report>
    <Report instance="evh-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>230463008 - Disclosure - Long-term Debt (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/LongtermDebtTables</Role>
      <ShortName>Long-term Debt (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.evolenthealth.com/role/LongtermDebt</ParentRole>
      <Position>42</Position>
    </Report>
    <Report instance="evh-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>230543009 - Disclosure - Commitments and Contingencies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/CommitmentsandContingenciesTables</Role>
      <ShortName>Commitments and Contingencies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.evolenthealth.com/role/CommitmentsandContingencies</ParentRole>
      <Position>43</Position>
    </Report>
    <Report instance="evh-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>230593010 - Disclosure - Leases (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/LeasesTables</Role>
      <ShortName>Leases (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.evolenthealth.com/role/Leases</ParentRole>
      <Position>44</Position>
    </Report>
    <Report instance="evh-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>230663011 - Disclosure - Earnings (Loss) Per Common Share (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/EarningsLossPerCommonShareTables</Role>
      <ShortName>Earnings (Loss) Per Common Share (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.evolenthealth.com/role/EarningsLossPerCommonShare</ParentRole>
      <Position>45</Position>
    </Report>
    <Report instance="evh-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>230703012 - Disclosure - Stock-based Compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/StockbasedCompensationTables</Role>
      <ShortName>Stock-based Compensation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.evolenthealth.com/role/StockbasedCompensation</ParentRole>
      <Position>46</Position>
    </Report>
    <Report instance="evh-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>230843013 - Disclosure - Income Taxes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/IncomeTaxesTables</Role>
      <ShortName>Income Taxes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.evolenthealth.com/role/IncomeTaxes</ParentRole>
      <Position>47</Position>
    </Report>
    <Report instance="evh-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>230973014 - Disclosure - Non-controlling Interests (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/NoncontrollingInterestsTables</Role>
      <ShortName>Non-controlling Interests (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.evolenthealth.com/role/NoncontrollingInterests</ParentRole>
      <Position>48</Position>
    </Report>
    <Report instance="evh-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>231013015 - Disclosure - Fair Value Measurement (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/FairValueMeasurementTables</Role>
      <ShortName>Fair Value Measurement (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.evolenthealth.com/role/FairValueMeasurement</ParentRole>
      <Position>49</Position>
    </Report>
    <Report instance="evh-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>231073016 - Disclosure - Related Parties (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/RelatedPartiesTables</Role>
      <ShortName>Related Parties (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.evolenthealth.com/role/RelatedParties</ParentRole>
      <Position>50</Position>
    </Report>
    <Report instance="evh-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>231113017 - Disclosure - Repositioning and Other Changes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/RepositioningandOtherChangesTables</Role>
      <ShortName>Repositioning and Other Changes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.evolenthealth.com/role/RepositioningandOtherChanges</ParentRole>
      <Position>51</Position>
    </Report>
    <Report instance="evh-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>231143018 - Disclosure - Segment Reporting (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/SegmentReportingTables</Role>
      <ShortName>Segment Reporting (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.evolenthealth.com/role/SegmentReporting</ParentRole>
      <Position>52</Position>
    </Report>
    <Report instance="evh-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>231193019 - Disclosure - Reserves for Claims and Performance-Based Arrangements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/ReservesforClaimsandPerformanceBasedArrangementsTables</Role>
      <ShortName>Reserves for Claims and Performance-Based Arrangements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.evolenthealth.com/role/ReservesforClaimsandPerformanceBasedArrangements</ParentRole>
      <Position>53</Position>
    </Report>
    <Report instance="evh-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>231223020 - Disclosure - Quarterly Results of Operations (unaudited) (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/QuarterlyResultsofOperationsunauditedTables</Role>
      <ShortName>Quarterly Results of Operations (unaudited) (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.evolenthealth.com/role/QuarterlyResultsofOperationsunaudited</ParentRole>
      <Position>54</Position>
    </Report>
    <Report instance="evh-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>231263021 - Disclosure - Supplemental Cash Flow Information (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/SupplementalCashFlowInformationTables</Role>
      <ShortName>Supplemental Cash Flow Information (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.evolenthealth.com/role/SupplementalCashFlowInformation</ParentRole>
      <Position>55</Position>
    </Report>
    <Report instance="evh-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>240024001 - Disclosure - Organization (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/OrganizationDetails</Role>
      <ShortName>Organization (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.evolenthealth.com/role/Organization</ParentRole>
      <Position>56</Position>
    </Report>
    <Report instance="evh-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>240064002 - Disclosure - Basis of Presentation, Summary of Significant Accounting Policies and Change in Accounting Principles - Operating Segments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesOperatingSegmentsDetails</Role>
      <ShortName>Basis of Presentation, Summary of Significant Accounting Policies and Change in Accounting Principles - Operating Segments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesTables</ParentRole>
      <Position>57</Position>
    </Report>
    <Report instance="evh-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>240074003 - Disclosure - Basis of Presentation, Summary of Significant Accounting Policies and Change in Accounting Principles - Restricted Cash and Restricted Investments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesRestrictedCashandRestrictedInvestmentsDetails</Role>
      <ShortName>Basis of Presentation, Summary of Significant Accounting Policies and Change in Accounting Principles - Restricted Cash and Restricted Investments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>58</Position>
    </Report>
    <Report instance="evh-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>240084004 - Disclosure - Basis of Presentation, Summary of Significant Accounting Policies and Change in Accounting Principles - Estimated Useful Life of Property, Plant and Equipment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesEstimatedUsefulLifeofPropertyPlantandEquipmentDetails</Role>
      <ShortName>Basis of Presentation, Summary of Significant Accounting Policies and Change in Accounting Principles - Estimated Useful Life of Property, Plant and Equipment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>59</Position>
    </Report>
    <Report instance="evh-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>240094005 - Disclosure - Basis of Presentation, Summary of Significant Accounting Policies and Change in Accounting Principles - Research and Development Costs (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesResearchandDevelopmentCostsDetails</Role>
      <ShortName>Basis of Presentation, Summary of Significant Accounting Policies and Change in Accounting Principles - Research and Development Costs (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>60</Position>
    </Report>
    <Report instance="evh-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>240104006 - Disclosure - Basis of Presentation, Summary of Significant Accounting Policies and Change in Accounting Principles - Goodwill (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesGoodwillDetails</Role>
      <ShortName>Basis of Presentation, Summary of Significant Accounting Policies and Change in Accounting Principles - Goodwill (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesTables</ParentRole>
      <Position>61</Position>
    </Report>
    <Report instance="evh-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>240114007 - Disclosure - Basis of Presentation, Summary of Significant Accounting Policies and Change in Accounting Principles - Intangible Assets, Net (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesIntangibleAssetsNetDetails</Role>
      <ShortName>Basis of Presentation, Summary of Significant Accounting Policies and Change in Accounting Principles - Intangible Assets, Net (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesTables</ParentRole>
      <Position>62</Position>
    </Report>
    <Report instance="evh-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>240124008 - Disclosure - Basis of Presentation, Summary of Significant Accounting Policies and Change in Accounting Principles - Right of Offset (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesRightofOffsetDetails</Role>
      <ShortName>Basis of Presentation, Summary of Significant Accounting Policies and Change in Accounting Principles - Right of Offset (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesTables</ParentRole>
      <Position>63</Position>
    </Report>
    <Report instance="evh-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R64.htm</HtmlFileName>
      <LongName>240134009 - Disclosure - Basis of Presentation, Summary of Significant Accounting Policies and Change in Accounting Principles - Stock-based Compensation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesStockbasedCompensationDetails</Role>
      <ShortName>Basis of Presentation, Summary of Significant Accounting Policies and Change in Accounting Principles - Stock-based Compensation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>64</Position>
    </Report>
    <Report instance="evh-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R65.htm</HtmlFileName>
      <LongName>240154010 - Disclosure - Recently Issued Accounting Standards (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/RecentlyIssuedAccountingStandardsDetails</Role>
      <ShortName>Recently Issued Accounting Standards (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.evolenthealth.com/role/RecentlyIssuedAccountingStandards</ParentRole>
      <Position>65</Position>
    </Report>
    <Report instance="evh-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R66.htm</HtmlFileName>
      <LongName>240184011 - Disclosure - Transactions - Vital Decisions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/TransactionsVitalDecisionsDetails</Role>
      <ShortName>Transactions - Vital Decisions (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>66</Position>
    </Report>
    <Report instance="evh-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R67.htm</HtmlFileName>
      <LongName>240194012 - Disclosure - Transactions - Equity Investments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/TransactionsEquityInvestmentsDetails</Role>
      <ShortName>Transactions - Equity Investments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>67</Position>
    </Report>
    <Report instance="evh-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R68.htm</HtmlFileName>
      <LongName>240224013 - Disclosure - Discontinued Operations - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/DiscontinuedOperationsAdditionalInformationDetails</Role>
      <ShortName>Discontinued Operations - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>68</Position>
    </Report>
    <Report instance="evh-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R69.htm</HtmlFileName>
      <LongName>240234014 - Disclosure - Discontinued Operations - Summary of Results of Operations (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/DiscontinuedOperationsSummaryofResultsofOperationsDetails</Role>
      <ShortName>Discontinued Operations - Summary of Results of Operations (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>69</Position>
    </Report>
    <Report instance="evh-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R70.htm</HtmlFileName>
      <LongName>240244015 - Disclosure - Discontinued Operations - Summary of Cash Flows (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/DiscontinuedOperationsSummaryofCashFlowsDetails</Role>
      <ShortName>Discontinued Operations - Summary of Cash Flows (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>70</Position>
    </Report>
    <Report instance="evh-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R71.htm</HtmlFileName>
      <LongName>240254016 - Disclosure - Discontinued Operations - Summary of Current and Long-term Assets and Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/DiscontinuedOperationsSummaryofCurrentandLongtermAssetsandLiabilitiesDetails</Role>
      <ShortName>Discontinued Operations - Summary of Current and Long-term Assets and Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>71</Position>
    </Report>
    <Report instance="evh-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R72.htm</HtmlFileName>
      <LongName>240284017 - Disclosure - Revenue Recognition - Disaggregation of Revenue (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/RevenueRecognitionDisaggregationofRevenueDetails</Role>
      <ShortName>Revenue Recognition - Disaggregation of Revenue (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>72</Position>
    </Report>
    <Report instance="evh-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R73.htm</HtmlFileName>
      <LongName>240294018 - Disclosure - Revenue Recognition - Transaction Price Allocated to the Remaining Performance Obligations (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/RevenueRecognitionTransactionPriceAllocatedtotheRemainingPerformanceObligationsDetails</Role>
      <ShortName>Revenue Recognition - Transaction Price Allocated to the Remaining Performance Obligations (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>73</Position>
    </Report>
    <Report instance="evh-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R74.htm</HtmlFileName>
      <LongName>240304019 - Disclosure - Revenue Recognition - Contract Balances (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/RevenueRecognitionContractBalancesDetails</Role>
      <ShortName>Revenue Recognition - Contract Balances (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>74</Position>
    </Report>
    <Report instance="evh-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R75.htm</HtmlFileName>
      <LongName>240314020 - Disclosure - Revenue Recognition - Contract Costs (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/RevenueRecognitionContractCostsDetails</Role>
      <ShortName>Revenue Recognition - Contract Costs (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>75</Position>
    </Report>
    <Report instance="evh-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R76.htm</HtmlFileName>
      <LongName>240344021 - Disclosure - Credit Losses - Accounts Receivable (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/CreditLossesAccountsReceivableNarrativeDetails</Role>
      <ShortName>Credit Losses - Accounts Receivable (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>76</Position>
    </Report>
    <Report instance="evh-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R77.htm</HtmlFileName>
      <LongName>240354022 - Disclosure - Credit Losses - Schedule of Changes in Allowance for Accounts Receivable (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/CreditLossesScheduleofChangesinAllowanceforAccountsReceivableDetails</Role>
      <ShortName>Credit Losses - Schedule of Changes in Allowance for Accounts Receivable (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>77</Position>
    </Report>
    <Report instance="evh-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R78.htm</HtmlFileName>
      <LongName>240384023 - Disclosure - Property and Equipment, Net (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/PropertyandEquipmentNetDetails</Role>
      <ShortName>Property and Equipment, Net (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.evolenthealth.com/role/PropertyandEquipmentNetTables</ParentRole>
      <Position>78</Position>
    </Report>
    <Report instance="evh-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R79.htm</HtmlFileName>
      <LongName>240414024 - Disclosure - Goodwill and Intangible Assets, Net - Impairment Testing (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNetImpairmentTestingDetails</Role>
      <ShortName>Goodwill and Intangible Assets, Net - Impairment Testing (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>79</Position>
    </Report>
    <Report instance="evh-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R80.htm</HtmlFileName>
      <LongName>240424025 - Disclosure - Goodwill and Intangible Assets, Net - Schedule of Goodwill (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNetScheduleofGoodwillDetails</Role>
      <ShortName>Goodwill and Intangible Assets, Net - Schedule of Goodwill (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>80</Position>
    </Report>
    <Report instance="evh-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R81.htm</HtmlFileName>
      <LongName>240434026 - Disclosure - Goodwill and Intangible Assets, Net - Intangible Assets, Net (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNetIntangibleAssetsNetDetails</Role>
      <ShortName>Goodwill and Intangible Assets, Net - Intangible Assets, Net (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>81</Position>
    </Report>
    <Report instance="evh-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R82.htm</HtmlFileName>
      <LongName>240444027 - Disclosure - Goodwill and Intangible Assets, Net - Amortization of Intangible Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNetAmortizationofIntangibleAssetsDetails</Role>
      <ShortName>Goodwill and Intangible Assets, Net - Amortization of Intangible Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>82</Position>
    </Report>
    <Report instance="evh-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R83.htm</HtmlFileName>
      <LongName>240474028 - Disclosure - Long-term Debt - 2024 Notes (Details)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.evolenthealth.com/role/LongtermDebt2024NotesDetails</Role>
      <ShortName>Long-term Debt - 2024 Notes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>83</Position>
    </Report>
    <Report instance="evh-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R84.htm</HtmlFileName>
      <LongName>240484029 - Disclosure - Long-term Debt - Credit Agreement (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/LongtermDebtCreditAgreementDetails</Role>
      <ShortName>Long-term Debt - Credit Agreement (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>84</Position>
    </Report>
    <Report instance="evh-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R85.htm</HtmlFileName>
      <LongName>240494030 - Disclosure - Long-term Debt - Warrant Agreement (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/LongtermDebtWarrantAgreementDetails</Role>
      <ShortName>Long-term Debt - Warrant Agreement (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>85</Position>
    </Report>
    <Report instance="evh-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R86.htm</HtmlFileName>
      <LongName>240504031 - Disclosure - Long-term Debt - 2025 Notes (Details)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.evolenthealth.com/role/LongtermDebt2025NotesDetails</Role>
      <ShortName>Long-term Debt - 2025 Notes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>86</Position>
    </Report>
    <Report instance="evh-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R87.htm</HtmlFileName>
      <LongName>240514032 - Disclosure - Long-term Debt - 2021 Notes (Details)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.evolenthealth.com/role/LongtermDebt2021NotesDetails</Role>
      <ShortName>Long-term Debt - 2021 Notes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>87</Position>
    </Report>
    <Report instance="evh-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R88.htm</HtmlFileName>
      <LongName>240524033 - Disclosure - Long-term Debt - Convertible Senior Notes Carrying Value (Details)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.evolenthealth.com/role/LongtermDebtConvertibleSeniorNotesCarryingValueDetails</Role>
      <ShortName>Long-term Debt - Convertible Senior Notes Carrying Value (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>88</Position>
    </Report>
    <Report instance="evh-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R89.htm</HtmlFileName>
      <LongName>240554034 - Disclosure - Commitments and Contingencies - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/CommitmentsandContingenciesAdditionalInformationDetails</Role>
      <ShortName>Commitments and Contingencies - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>89</Position>
    </Report>
    <Report instance="evh-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R90.htm</HtmlFileName>
      <LongName>240564035 - Disclosure - Commitments and Contingencies - Reinsurance Agreements (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/CommitmentsandContingenciesReinsuranceAgreementsDetails</Role>
      <ShortName>Commitments and Contingencies - Reinsurance Agreements (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>90</Position>
    </Report>
    <Report instance="evh-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R91.htm</HtmlFileName>
      <LongName>240574036 - Disclosure - Commitments and Contingencies - Concentration Risk (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/CommitmentsandContingenciesConcentrationRiskDetails</Role>
      <ShortName>Commitments and Contingencies - Concentration Risk (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>91</Position>
    </Report>
    <Report instance="evh-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R92.htm</HtmlFileName>
      <LongName>240604037 - Disclosure - Leases - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/LeasesNarrativeDetails</Role>
      <ShortName>Leases - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>92</Position>
    </Report>
    <Report instance="evh-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R93.htm</HtmlFileName>
      <LongName>240614038 - Disclosure - Leases - Primary Office Leases (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/LeasesPrimaryOfficeLeasesDetails</Role>
      <ShortName>Leases - Primary Office Leases (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>93</Position>
    </Report>
    <Report instance="evh-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R94.htm</HtmlFileName>
      <LongName>240624039 - Disclosure - Leases - Components of Lease Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/LeasesComponentsofLeaseExpenseDetails</Role>
      <ShortName>Leases - Components of Lease Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>94</Position>
    </Report>
    <Report instance="evh-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R95.htm</HtmlFileName>
      <LongName>240634040 - Disclosure - Leases - Maturity of Lease Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/LeasesMaturityofLeaseLiabilitiesDetails</Role>
      <ShortName>Leases - Maturity of Lease Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>95</Position>
    </Report>
    <Report instance="evh-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R96.htm</HtmlFileName>
      <LongName>240644041 - Disclosure - Leases - Weighted-average Discount Rate and Weighted-remaining Lease Terms (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/LeasesWeightedaverageDiscountRateandWeightedremainingLeaseTermsDetails</Role>
      <ShortName>Leases - Weighted-average Discount Rate and Weighted-remaining Lease Terms (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>96</Position>
    </Report>
    <Report instance="evh-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R97.htm</HtmlFileName>
      <LongName>240674042 - Disclosure - Earnings (Loss) Per Common Share - Computation of Earnings per Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/EarningsLossPerCommonShareComputationofEarningsperShareDetails</Role>
      <ShortName>Earnings (Loss) Per Common Share - Computation of Earnings per Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.evolenthealth.com/role/EarningsLossPerCommonShareTables</ParentRole>
      <Position>97</Position>
    </Report>
    <Report instance="evh-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R98.htm</HtmlFileName>
      <LongName>240684043 - Disclosure - Earnings (Loss) Per Common Share - Antidilutive Securities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/EarningsLossPerCommonShareAntidilutiveSecuritiesDetails</Role>
      <ShortName>Earnings (Loss) Per Common Share - Antidilutive Securities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.evolenthealth.com/role/EarningsLossPerCommonShareTables</ParentRole>
      <Position>98</Position>
    </Report>
    <Report instance="evh-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R99.htm</HtmlFileName>
      <LongName>240714044 - Disclosure - Stock-based Compensation - 2011 and 2015 Equity Incentive Plans (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/StockbasedCompensation2011and2015EquityIncentivePlansDetails</Role>
      <ShortName>Stock-based Compensation - 2011 and 2015 Equity Incentive Plans (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>99</Position>
    </Report>
    <Report instance="evh-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R100.htm</HtmlFileName>
      <LongName>240724045 - Disclosure - Stock-based Compensation - Stock-based Compensation Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/StockbasedCompensationStockbasedCompensationExpenseDetails</Role>
      <ShortName>Stock-based Compensation - Stock-based Compensation Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>100</Position>
    </Report>
    <Report instance="evh-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R101.htm</HtmlFileName>
      <LongName>240734046 - Disclosure - Stock-based Compensation - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/StockbasedCompensationAdditionalInformationDetails</Role>
      <ShortName>Stock-based Compensation - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>101</Position>
    </Report>
    <Report instance="evh-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R102.htm</HtmlFileName>
      <LongName>240744047 - Disclosure - Stock-based Compensation - Unrecognized Compensation Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/StockbasedCompensationUnrecognizedCompensationExpenseDetails</Role>
      <ShortName>Stock-based Compensation - Unrecognized Compensation Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>102</Position>
    </Report>
    <Report instance="evh-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R103.htm</HtmlFileName>
      <LongName>240754048 - Disclosure - Stock-based Compensation - Stock Options (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/StockbasedCompensationStockOptionsDetails</Role>
      <ShortName>Stock-based Compensation - Stock Options (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>103</Position>
    </Report>
    <Report instance="evh-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R104.htm</HtmlFileName>
      <LongName>240764049 - Disclosure - Stock-based Compensation - Stock Option Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/StockbasedCompensationStockOptionActivityDetails</Role>
      <ShortName>Stock-based Compensation - Stock Option Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>104</Position>
    </Report>
    <Report instance="evh-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R105.htm</HtmlFileName>
      <LongName>240774050 - Disclosure - Stock-based Compensation - Performance-based Stock Option Awards (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/StockbasedCompensationPerformancebasedStockOptionAwardsDetails</Role>
      <ShortName>Stock-based Compensation - Performance-based Stock Option Awards (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>105</Position>
    </Report>
    <Report instance="evh-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R106.htm</HtmlFileName>
      <LongName>240784051 - Disclosure - Stock-based Compensation - Restricted Stock Units (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/StockbasedCompensationRestrictedStockUnitsDetails</Role>
      <ShortName>Stock-based Compensation - Restricted Stock Units (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>106</Position>
    </Report>
    <Report instance="evh-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R107.htm</HtmlFileName>
      <LongName>240794052 - Disclosure - Stock-based Compensation - Leveraged Stock Units (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/StockbasedCompensationLeveragedStockUnitsDetails</Role>
      <ShortName>Stock-based Compensation - Leveraged Stock Units (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>107</Position>
    </Report>
    <Report instance="evh-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R108.htm</HtmlFileName>
      <LongName>240804053 - Disclosure - Stock-based Compensation - Leveraged Stock Units Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/StockbasedCompensationLeveragedStockUnitsActivityDetails</Role>
      <ShortName>Stock-based Compensation - Leveraged Stock Units Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>108</Position>
    </Report>
    <Report instance="evh-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R109.htm</HtmlFileName>
      <LongName>240814054 - Disclosure - Stock-based Compensation - Performance-based RSUs (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/StockbasedCompensationPerformancebasedRSUsDetails</Role>
      <ShortName>Stock-based Compensation - Performance-based RSUs (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>109</Position>
    </Report>
    <Report instance="evh-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R110.htm</HtmlFileName>
      <LongName>240824055 - Disclosure - Stock-based Compensation - Performance-based RSU Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/StockbasedCompensationPerformancebasedRSUActivityDetails</Role>
      <ShortName>Stock-based Compensation - Performance-based RSU Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>110</Position>
    </Report>
    <Report instance="evh-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R111.htm</HtmlFileName>
      <LongName>240854056 - Disclosure - Income Taxes - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/IncomeTaxesNarrativeDetails</Role>
      <ShortName>Income Taxes - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>111</Position>
    </Report>
    <Report instance="evh-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R112.htm</HtmlFileName>
      <LongName>240864057 - Disclosure - Income Taxes - Schedule of Loss Before Provision for Income Taxes (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/IncomeTaxesScheduleofLossBeforeProvisionforIncomeTaxesDetails</Role>
      <ShortName>Income Taxes - Schedule of Loss Before Provision for Income Taxes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>112</Position>
    </Report>
    <Report instance="evh-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R113.htm</HtmlFileName>
      <LongName>240874058 - Disclosure - Income Taxes - Income Tax Expense (Benefit) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/IncomeTaxesIncomeTaxExpenseBenefitDetails</Role>
      <ShortName>Income Taxes - Income Tax Expense (Benefit) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>113</Position>
    </Report>
    <Report instance="evh-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R114.htm</HtmlFileName>
      <LongName>240884059 - Disclosure - Income Taxes - Reconciliation of Statutory Rate to Effective Tax Rate (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/IncomeTaxesReconciliationofStatutoryRatetoEffectiveTaxRateDetails</Role>
      <ShortName>Income Taxes - Reconciliation of Statutory Rate to Effective Tax Rate (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>114</Position>
    </Report>
    <Report instance="evh-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R115.htm</HtmlFileName>
      <LongName>240894060 - Disclosure - Income Taxes - Deferred Tax Assets and Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails</Role>
      <ShortName>Income Taxes - Deferred Tax Assets and Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>115</Position>
    </Report>
    <Report instance="evh-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R116.htm</HtmlFileName>
      <LongName>240904061 - Disclosure - Income Taxes - Changes in Valuation Allowance (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/IncomeTaxesChangesinValuationAllowanceDetails</Role>
      <ShortName>Income Taxes - Changes in Valuation Allowance (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>116</Position>
    </Report>
    <Report instance="evh-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R117.htm</HtmlFileName>
      <LongName>240914062 - Disclosure - Income Taxes - Changes In Unrecognized Tax Benefits (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/IncomeTaxesChangesInUnrecognizedTaxBenefitsDetails</Role>
      <ShortName>Income Taxes - Changes In Unrecognized Tax Benefits (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>117</Position>
    </Report>
    <Report instance="evh-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R118.htm</HtmlFileName>
      <LongName>240934063 - Disclosure - Employee Benefit Plans (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/EmployeeBenefitPlansDetails</Role>
      <ShortName>Employee Benefit Plans (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.evolenthealth.com/role/EmployeeBenefitPlans</ParentRole>
      <Position>118</Position>
    </Report>
    <Report instance="evh-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R119.htm</HtmlFileName>
      <LongName>240954064 - Disclosure - Investments in Equity Method Investees (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/InvestmentsinEquityMethodInvesteesDetails</Role>
      <ShortName>Investments in Equity Method Investees (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.evolenthealth.com/role/InvestmentsinEquityMethodInvestees</ParentRole>
      <Position>119</Position>
    </Report>
    <Report instance="evh-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R120.htm</HtmlFileName>
      <LongName>240984065 - Disclosure - Non-controlling Interests (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/NoncontrollingInterestsDetails</Role>
      <ShortName>Non-controlling Interests (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.evolenthealth.com/role/NoncontrollingInterestsTables</ParentRole>
      <Position>120</Position>
    </Report>
    <Report instance="evh-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R121.htm</HtmlFileName>
      <LongName>240994066 - Disclosure - Non-controlling Interests - Schedule of Changes in Non-controlling Interests (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/NoncontrollingInterestsScheduleofChangesinNoncontrollingInterestsDetails</Role>
      <ShortName>Non-controlling Interests - Schedule of Changes in Non-controlling Interests (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>121</Position>
    </Report>
    <Report instance="evh-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R122.htm</HtmlFileName>
      <LongName>241024067 - Disclosure - Fair Value Measurement - Assets and Liabilities on Recurring Basis (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/FairValueMeasurementAssetsandLiabilitiesonRecurringBasisDetails</Role>
      <ShortName>Fair Value Measurement - Assets and Liabilities on Recurring Basis (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>122</Position>
    </Report>
    <Report instance="evh-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R123.htm</HtmlFileName>
      <LongName>241034068 - Disclosure - Fair Value Measurement - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/FairValueMeasurementAdditionalInformationDetails</Role>
      <ShortName>Fair Value Measurement - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>123</Position>
    </Report>
    <Report instance="evh-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R124.htm</HtmlFileName>
      <LongName>241044069 - Disclosure - Fair Value Measurement - Changes in Contingent Consideration and Other (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/FairValueMeasurementChangesinContingentConsiderationandOtherDetails</Role>
      <ShortName>Fair Value Measurement - Changes in Contingent Consideration and Other (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>124</Position>
    </Report>
    <Report instance="evh-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R125.htm</HtmlFileName>
      <LongName>241054070 - Disclosure - Fair Value Measurement - Valuation Techniques and Significant Unobservable Inputs (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/FairValueMeasurementValuationTechniquesandSignificantUnobservableInputsDetails</Role>
      <ShortName>Fair Value Measurement - Valuation Techniques and Significant Unobservable Inputs (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>125</Position>
    </Report>
    <Report instance="evh-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R126.htm</HtmlFileName>
      <LongName>241084071 - Disclosure - Related Parties - Assets and Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/RelatedPartiesAssetsandLiabilitiesDetails</Role>
      <ShortName>Related Parties - Assets and Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>126</Position>
    </Report>
    <Report instance="evh-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R127.htm</HtmlFileName>
      <LongName>241094072 - Disclosure - Related Parties - Revenues and Expenses (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/RelatedPartiesRevenuesandExpensesDetails</Role>
      <ShortName>Related Parties - Revenues and Expenses (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>127</Position>
    </Report>
    <Report instance="evh-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R128.htm</HtmlFileName>
      <LongName>241124073 - Disclosure - Repositioning and Other Changes (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/RepositioningandOtherChangesDetails</Role>
      <ShortName>Repositioning and Other Changes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.evolenthealth.com/role/RepositioningandOtherChangesTables</ParentRole>
      <Position>128</Position>
    </Report>
    <Report instance="evh-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R129.htm</HtmlFileName>
      <LongName>241154074 - Disclosure - Segment Reporting - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/SegmentReportingAdditionalInformationDetails</Role>
      <ShortName>Segment Reporting - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>129</Position>
    </Report>
    <Report instance="evh-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R130.htm</HtmlFileName>
      <LongName>241164075 - Disclosure - Segment Reporting - Revenue from Segments to Consolidated (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/SegmentReportingRevenuefromSegmentstoConsolidatedDetails</Role>
      <ShortName>Segment Reporting - Revenue from Segments to Consolidated (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>130</Position>
    </Report>
    <Report instance="evh-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R131.htm</HtmlFileName>
      <LongName>241174076 - Disclosure - Segment Reporting - Reconciliation of Adjusted EBITDA (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/SegmentReportingReconciliationofAdjustedEBITDADetails</Role>
      <ShortName>Segment Reporting - Reconciliation of Adjusted EBITDA (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>131</Position>
    </Report>
    <Report instance="evh-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R132.htm</HtmlFileName>
      <LongName>241204077 - Disclosure - Reserves for Claims and Performance-Based Arrangements (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/ReservesforClaimsandPerformanceBasedArrangementsDetails</Role>
      <ShortName>Reserves for Claims and Performance-Based Arrangements (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.evolenthealth.com/role/ReservesforClaimsandPerformanceBasedArrangementsTables</ParentRole>
      <Position>132</Position>
    </Report>
    <Report instance="evh-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R133.htm</HtmlFileName>
      <LongName>241234078 - Disclosure - Quarterly Results of Operations (unaudited) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/QuarterlyResultsofOperationsunauditedDetails</Role>
      <ShortName>Quarterly Results of Operations (unaudited) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.evolenthealth.com/role/QuarterlyResultsofOperationsunauditedTables</ParentRole>
      <Position>133</Position>
    </Report>
    <Report instance="evh-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R134.htm</HtmlFileName>
      <LongName>241244079 - Disclosure - Quarterly Results of Operations (unaudited) - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/QuarterlyResultsofOperationsunauditedAdditionalInformationDetails</Role>
      <ShortName>Quarterly Results of Operations (unaudited) - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.evolenthealth.com/role/QuarterlyResultsofOperationsunauditedTables</ParentRole>
      <Position>134</Position>
    </Report>
    <Report instance="evh-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R135.htm</HtmlFileName>
      <LongName>241274080 - Disclosure - Supplemental Cash Flow Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/SupplementalCashFlowInformationDetails</Role>
      <ShortName>Supplemental Cash Flow Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.evolenthealth.com/role/SupplementalCashFlowInformationTables</ParentRole>
      <Position>135</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-K" original="evh-20211231.htm">evh-20211231.htm</File>
    <File>a123121exhibit1031.htm</File>
    <File>a123121exhibit231.htm</File>
    <File>a123121exhibit311.htm</File>
    <File>a123121exhibit312.htm</File>
    <File>a123121exhibit321.htm</File>
    <File>a123121exhibit322.htm</File>
    <File>evh-20211231.xsd</File>
    <File>evh-20211231_cal.xml</File>
    <File>evh-20211231_def.xml</File>
    <File>evh-20211231_lab.xml</File>
    <File>evh-20211231_pre.xml</File>
    <File>evh10-kexhibit46.htm</File>
    <File>exhibit211.htm</File>
  </InputFiles>
  <SupplementalFiles>
    <File>evh-20211231_g1.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="1820">http://fasb.org/us-gaap/2021-01-31</BaseTaxonomy>
    <BaseTaxonomy items="38">http://xbrl.sec.gov/dei/2021q4</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>158
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "evh-20211231.htm": {
   "axisCustom": 0,
   "axisStandard": 48,
   "contextCount": 472,
   "dts": {
    "calculationLink": {
     "local": [
      "evh-20211231_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "evh-20211231_def.xml"
     ]
    },
    "inline": {
     "local": [
      "evh-20211231.htm"
     ]
    },
    "labelLink": {
     "local": [
      "evh-20211231_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "evh-20211231_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "evh-20211231.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd",
      "https://xbrl.sec.gov/country/2021/country-2021.xsd",
      "https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd",
      "https://xbrl.sec.gov/stpr/2021/stpr-2021.xsd"
     ]
    }
   },
   "elementCount": 1039,
   "entityCount": 1,
   "hidden": {
    "http://fasb.org/us-gaap/2021-01-31": 11,
    "http://www.evolenthealth.com/20211231": 4,
    "http://xbrl.sec.gov/dei/2021q4": 4,
    "total": 19
   },
   "keyCustom": 127,
   "keyStandard": 626,
   "memberCustom": 56,
   "memberStandard": 71,
   "nsprefix": "evh",
   "nsuri": "http://www.evolenthealth.com/20211231",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "evh-20211231.htm",
      "contextRef": "idc0db51272c94df1839131500195947e_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "000010001 - Document - Cover Page",
     "role": "http://www.evolenthealth.com/role/CoverPage",
     "shortName": "Cover Page",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "evh-20211231.htm",
      "contextRef": "idc0db51272c94df1839131500195947e_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "evh-20211231.htm",
      "contextRef": "idc0db51272c94df1839131500195947e_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "210031002 - Disclosure - Basis of Presentation, Summary of Significant Accounting Policies and Change in Accounting Principles",
     "role": "http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciples",
     "shortName": "Basis of Presentation, Summary of Significant Accounting Policies and Change in Accounting Principles",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "evh-20211231.htm",
      "contextRef": "idc0db51272c94df1839131500195947e_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R100": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20211231.htm",
      "contextRef": "idc0db51272c94df1839131500195947e_D20210101-20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240724045 - Disclosure - Stock-based Compensation - Stock-based Compensation Expense (Details)",
     "role": "http://www.evolenthealth.com/role/StockbasedCompensationStockbasedCompensationExpenseDetails",
     "shortName": "Stock-based Compensation - Stock-based Compensation Expense (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20211231.htm",
      "contextRef": "idc0db51272c94df1839131500195947e_D20210101-20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R101": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20211231.htm",
      "contextRef": "idc0db51272c94df1839131500195947e_D20210101-20211231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240734046 - Disclosure - Stock-based Compensation - Additional Information (Details)",
     "role": "http://www.evolenthealth.com/role/StockbasedCompensationAdditionalInformationDetails",
     "shortName": "Stock-based Compensation - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20211231.htm",
      "contextRef": "idc0db51272c94df1839131500195947e_D20210101-20211231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R102": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfUnrecognizedCompensationCostNonvestedAwardsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20211231.htm",
      "contextRef": "i8daff60be410426d8f7bd49343c1ec0c_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240744047 - Disclosure - Stock-based Compensation - Unrecognized Compensation Expense (Details)",
     "role": "http://www.evolenthealth.com/role/StockbasedCompensationUnrecognizedCompensationExpenseDetails",
     "shortName": "Stock-based Compensation - Unrecognized Compensation Expense (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfUnrecognizedCompensationCostNonvestedAwardsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20211231.htm",
      "contextRef": "i8daff60be410426d8f7bd49343c1ec0c_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R103": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20211231.htm",
      "contextRef": "i12a6d1161de54547bd29f8efccd4c9b0_D20200101-20201231",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
      "reportCount": 1,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240754048 - Disclosure - Stock-based Compensation - Stock Options (Details)",
     "role": "http://www.evolenthealth.com/role/StockbasedCompensationStockOptionsDetails",
     "shortName": "Stock-based Compensation - Stock Options (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20211231.htm",
      "contextRef": "idc0db51272c94df1839131500195947e_D20210101-20211231",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R104": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20211231.htm",
      "contextRef": "ibc0c0c2b8dc04c5698ca0577a54b2e03_I20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240764049 - Disclosure - Stock-based Compensation - Stock Option Activity (Details)",
     "role": "http://www.evolenthealth.com/role/StockbasedCompensationStockOptionActivityDetails",
     "shortName": "Stock-based Compensation - Stock Option Activity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20211231.htm",
      "contextRef": "idc0db51272c94df1839131500195947e_D20210101-20211231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R105": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20211231.htm",
      "contextRef": "i12a6d1161de54547bd29f8efccd4c9b0_D20200101-20201231",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
      "reportCount": 1,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240774050 - Disclosure - Stock-based Compensation - Performance-based Stock Option Awards (Details)",
     "role": "http://www.evolenthealth.com/role/StockbasedCompensationPerformancebasedStockOptionAwardsDetails",
     "shortName": "Stock-based Compensation - Performance-based Stock Option Awards (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20211231.htm",
      "contextRef": "i686710b185af449cbe0de18d10c30d28_D20160301-20160331",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R106": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20211231.htm",
      "contextRef": "i903fc0912d4e492c95e3ce815e897489_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240784051 - Disclosure - Stock-based Compensation - Restricted Stock Units (Details)",
     "role": "http://www.evolenthealth.com/role/StockbasedCompensationRestrictedStockUnitsDetails",
     "shortName": "Stock-based Compensation - Restricted Stock Units (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20211231.htm",
      "contextRef": "i903fc0912d4e492c95e3ce815e897489_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R107": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "evh:ScheduleOfShareBasedPaymentAwardRestrictedStockUnitValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20211231.htm",
      "contextRef": "if24975b6c6fc46f2956741e09150759a_D20210101-20211231",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
      "reportCount": 1,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240794052 - Disclosure - Stock-based Compensation - Leveraged Stock Units (Details)",
     "role": "http://www.evolenthealth.com/role/StockbasedCompensationLeveragedStockUnitsDetails",
     "shortName": "Stock-based Compensation - Leveraged Stock Units (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20211231.htm",
      "contextRef": "i824c4e26d9414a59ad8f2d73e36714d0_D20200101-20201231",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R108": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfOtherShareBasedCompensationActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20211231.htm",
      "contextRef": "i33d73ea883764a2dafec5a1252f33aef_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240804053 - Disclosure - Stock-based Compensation - Leveraged Stock Units Activity (Details)",
     "role": "http://www.evolenthealth.com/role/StockbasedCompensationLeveragedStockUnitsActivityDetails",
     "shortName": "Stock-based Compensation - Leveraged Stock Units Activity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R109": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "evh:ScheduleOfShareBasedPaymentAwardRestrictedStockUnitValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20211231.htm",
      "contextRef": "if24975b6c6fc46f2956741e09150759a_D20210101-20211231",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
      "reportCount": 1,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240814054 - Disclosure - Stock-based Compensation - Performance-based RSUs (Details)",
     "role": "http://www.evolenthealth.com/role/StockbasedCompensationPerformancebasedRSUsDetails",
     "shortName": "Stock-based Compensation - Performance-based RSUs (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20211231.htm",
      "contextRef": "i91de07e5bb1e422aa1d46986a0b1006f_D20210101-20211231",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "evh-20211231.htm",
      "contextRef": "idc0db51272c94df1839131500195947e_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "210141003 - Disclosure - Recently Issued Accounting Standards",
     "role": "http://www.evolenthealth.com/role/RecentlyIssuedAccountingStandards",
     "shortName": "Recently Issued Accounting Standards",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "evh-20211231.htm",
      "contextRef": "idc0db51272c94df1839131500195947e_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R110": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfOtherShareBasedCompensationActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20211231.htm",
      "contextRef": "i33d73ea883764a2dafec5a1252f33aef_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240824055 - Disclosure - Stock-based Compensation - Performance-based RSU Activity (Details)",
     "role": "http://www.evolenthealth.com/role/StockbasedCompensationPerformancebasedRSUActivityDetails",
     "shortName": "Stock-based Compensation - Performance-based RSU Activity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardRestrictedStockUnitsVestedAndExpectedToVestTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20211231.htm",
      "contextRef": "ife9a61a44ecc47e88bb29426256eba9d_I20211231",
      "decimals": "2",
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     }
    },
    "R111": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20211231.htm",
      "contextRef": "idc0db51272c94df1839131500195947e_D20210101-20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxExpenseBenefit",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240854056 - Disclosure - Income Taxes - Narrative (Details)",
     "role": "http://www.evolenthealth.com/role/IncomeTaxesNarrativeDetails",
     "shortName": "Income Taxes - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20211231.htm",
      "contextRef": "icba6e493923b449aa57c46a563760234_I20191231",
      "decimals": "-5",
      "lang": "en-US",
      "name": "evh:DeferredTaxLiabilitiesIndefiniteLivedIntangibleAssets",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R112": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20211231.htm",
      "contextRef": "idc0db51272c94df1839131500195947e_D20210101-20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240864057 - Disclosure - Income Taxes - Schedule of Loss Before Provision for Income Taxes (Details)",
     "role": "http://www.evolenthealth.com/role/IncomeTaxesScheduleofLossBeforeProvisionforIncomeTaxesDetails",
     "shortName": "Income Taxes - Schedule of Loss Before Provision for Income Taxes (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20211231.htm",
      "contextRef": "idc0db51272c94df1839131500195947e_D20210101-20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R113": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20211231.htm",
      "contextRef": "idc0db51272c94df1839131500195947e_D20210101-20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CurrentFederalTaxExpenseBenefit",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240874058 - Disclosure - Income Taxes - Income Tax Expense (Benefit) (Details)",
     "role": "http://www.evolenthealth.com/role/IncomeTaxesIncomeTaxExpenseBenefitDetails",
     "shortName": "Income Taxes - Income Tax Expense (Benefit) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20211231.htm",
      "contextRef": "idc0db51272c94df1839131500195947e_D20210101-20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CurrentFederalTaxExpenseBenefit",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R114": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20211231.htm",
      "contextRef": "idc0db51272c94df1839131500195947e_D20210101-20211231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240884059 - Disclosure - Income Taxes - Reconciliation of Statutory Rate to Effective Tax Rate (Details)",
     "role": "http://www.evolenthealth.com/role/IncomeTaxesReconciliationofStatutoryRatetoEffectiveTaxRateDetails",
     "shortName": "Income Taxes - Reconciliation of Statutory Rate to Effective Tax Rate (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20211231.htm",
      "contextRef": "idc0db51272c94df1839131500195947e_D20210101-20211231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R115": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20211231.htm",
      "contextRef": "i8daff60be410426d8f7bd49343c1ec0c_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "evh:DeferredTaxAssetsStartupandOrganizationalCosts",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240894060 - Disclosure - Income Taxes - Deferred Tax Assets and Liabilities (Details)",
     "role": "http://www.evolenthealth.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails",
     "shortName": "Income Taxes - Deferred Tax Assets and Liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20211231.htm",
      "contextRef": "i8daff60be410426d8f7bd49343c1ec0c_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "evh:DeferredTaxAssetsStartupandOrganizationalCosts",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R116": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20211231.htm",
      "contextRef": "i6126841a44cb4c478fc23b6132251176_I20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ValuationAllowancesAndReservesBalance",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240904061 - Disclosure - Income Taxes - Changes in Valuation Allowance (Details)",
     "role": "http://www.evolenthealth.com/role/IncomeTaxesChangesinValuationAllowanceDetails",
     "shortName": "Income Taxes - Changes in Valuation Allowance (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20211231.htm",
      "contextRef": "i4d7d673b0fbf48deaa07f821e1025d2e_I20191231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:ValuationAllowancesAndReservesBalance",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R117": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20211231.htm",
      "contextRef": "ibc0c0c2b8dc04c5698ca0577a54b2e03_I20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:UnrecognizedTaxBenefits",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240914062 - Disclosure - Income Taxes - Changes In Unrecognized Tax Benefits (Details)",
     "role": "http://www.evolenthealth.com/role/IncomeTaxesChangesInUnrecognizedTaxBenefitsDetails",
     "shortName": "Income Taxes - Changes In Unrecognized Tax Benefits (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20211231.htm",
      "contextRef": "idc0db51272c94df1839131500195947e_D20210101-20211231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R118": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "evh-20211231.htm",
      "contextRef": "idc0db51272c94df1839131500195947e_D20210101-20211231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240934063 - Disclosure - Employee Benefit Plans (Details)",
     "role": "http://www.evolenthealth.com/role/EmployeeBenefitPlansDetails",
     "shortName": "Employee Benefit Plans (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "evh-20211231.htm",
      "contextRef": "idc0db51272c94df1839131500195947e_D20210101-20211231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R119": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "evh-20211231.htm",
      "contextRef": "idc0db51272c94df1839131500195947e_D20210101-20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeLossFromEquityMethodInvestments",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240954064 - Disclosure - Investments in Equity Method Investees (Details)",
     "role": "http://www.evolenthealth.com/role/InvestmentsinEquityMethodInvesteesDetails",
     "shortName": "Investments in Equity Method Investees (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20211231.htm",
      "contextRef": "ibca1768da73d4a4188df3e08ee08a9ce_I20200331",
      "decimals": "INF",
      "lang": "en-US",
      "name": "evh:StatutoryCapitalReservesLiquidityGuaranteedByInvestorsMinimum",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "evh-20211231.htm",
      "contextRef": "idc0db51272c94df1839131500195947e_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "210161004 - Disclosure - Transactions",
     "role": "http://www.evolenthealth.com/role/Transactions",
     "shortName": "Transactions",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "evh-20211231.htm",
      "contextRef": "idc0db51272c94df1839131500195947e_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R120": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20211231.htm",
      "contextRef": "i02e542a70a5046e396e8cd9126fefd99_D20200901-20200901",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NoncontrollingInterestIncreaseFromBusinessCombination",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240984065 - Disclosure - Non-controlling Interests (Details)",
     "role": "http://www.evolenthealth.com/role/NoncontrollingInterestsDetails",
     "shortName": "Non-controlling Interests (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20211231.htm",
      "contextRef": "i02e542a70a5046e396e8cd9126fefd99_D20200901-20200901",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NoncontrollingInterestIncreaseFromBusinessCombination",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R121": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20211231.htm",
      "contextRef": "i6d3bee5994474a229055f5b47133978b_D20201001-20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLossAttributableToNoncontrollingInterest",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240994066 - Disclosure - Non-controlling Interests - Schedule of Changes in Non-controlling Interests (Details)",
     "role": "http://www.evolenthealth.com/role/NoncontrollingInterestsScheduleofChangesinNoncontrollingInterestsDetails",
     "shortName": "Non-controlling Interests - Schedule of Changes in Non-controlling Interests (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "evh:ScheduleofChangesinNoncontrollingInterestTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20211231.htm",
      "contextRef": "ic8a05c8bd28c42f4918205dc608cf2de_D20200101-20201231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:NoncontrollingInterestIncreaseFromBusinessCombination",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R122": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20211231.htm",
      "contextRef": "ibc0c0c2b8dc04c5698ca0577a54b2e03_I20201231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ClassOfWarrantOrRightOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "241024067 - Disclosure - Fair Value Measurement - Assets and Liabilities on Recurring Basis (Details)",
     "role": "http://www.evolenthealth.com/role/FairValueMeasurementAssetsandLiabilitiesonRecurringBasisDetails",
     "shortName": "Fair Value Measurement - Assets and Liabilities on Recurring Basis (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20211231.htm",
      "contextRef": "ibc0c0c2b8dc04c5698ca0577a54b2e03_I20201231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ClassOfWarrantOrRightOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R123": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20211231.htm",
      "contextRef": "i88843d45ac464699a3408ba52bbc2f63_I20191230",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ClassOfWarrantOrRightUnissued",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "241034068 - Disclosure - Fair Value Measurement - Additional Information (Details)",
     "role": "http://www.evolenthealth.com/role/FairValueMeasurementAdditionalInformationDetails",
     "shortName": "Fair Value Measurement - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R124": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20211231.htm",
      "contextRef": "ibc0c0c2b8dc04c5698ca0577a54b2e03_I20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "241044069 - Disclosure - Fair Value Measurement - Changes in Contingent Consideration and Other (Details)",
     "role": "http://www.evolenthealth.com/role/FairValueMeasurementChangesinContingentConsiderationandOtherDetails",
     "shortName": "Fair Value Measurement - Changes in Contingent Consideration and Other (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20211231.htm",
      "contextRef": "icba6e493923b449aa57c46a563760234_I20191231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R125": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20211231.htm",
      "contextRef": "ib92fc8f3c5774739b4687eddbea853f3_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationContingentConsiderationLiability",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "241054070 - Disclosure - Fair Value Measurement - Valuation Techniques and Significant Unobservable Inputs (Details)",
     "role": "http://www.evolenthealth.com/role/FairValueMeasurementValuationTechniquesandSignificantUnobservableInputsDetails",
     "shortName": "Fair Value Measurement - Valuation Techniques and Significant Unobservable Inputs (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20211231.htm",
      "contextRef": "icb9299fd51a347b9a7a46a5d71c01525_I20211231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R126": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "evh-20211231.htm",
      "contextRef": "i8daff60be410426d8f7bd49343c1ec0c_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsReceivableNetCurrent",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "241084071 - Disclosure - Related Parties - Assets and Liabilities (Details)",
     "role": "http://www.evolenthealth.com/role/RelatedPartiesAssetsandLiabilitiesDetails",
     "shortName": "Related Parties - Assets and Liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20211231.htm",
      "contextRef": "ic0d050fa1a3e4a2cb801e14c4a7886a2_I20211231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:AccountsReceivableNetCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R127": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20211231.htm",
      "contextRef": "i546c40c371924532a3d2ed0ace7d354b_D20211001-20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "241094072 - Disclosure - Related Parties - Revenues and Expenses (Details)",
     "role": "http://www.evolenthealth.com/role/RelatedPartiesRevenuesandExpensesDetails",
     "shortName": "Related Parties - Revenues and Expenses (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20211231.htm",
      "contextRef": "i2f7f912d67eb4dc4be805fbdba0a463f_D20210101-20211231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "evh:CostofGoodsandServicesSoldExcludingDepreciationandAmortization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R128": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20211231.htm",
      "contextRef": "idc0db51272c94df1839131500195947e_D20210101-20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RestructuringCharges",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "241124073 - Disclosure - Repositioning and Other Changes (Details)",
     "role": "http://www.evolenthealth.com/role/RepositioningandOtherChangesDetails",
     "shortName": "Repositioning and Other Changes (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20211231.htm",
      "contextRef": "i8daff60be410426d8f7bd49343c1ec0c_I20211231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:RestructuringAndRelatedCostCostIncurredToDate1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R129": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20211231.htm",
      "contextRef": "idc0db51272c94df1839131500195947e_D20210101-20211231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NumberOfOperatingSegments",
      "reportCount": 1,
      "unitRef": "segment",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "241154074 - Disclosure - Segment Reporting - Additional Information (Details)",
     "role": "http://www.evolenthealth.com/role/SegmentReportingAdditionalInformationDetails",
     "shortName": "Segment Reporting - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "evh-20211231.htm",
      "contextRef": "idc0db51272c94df1839131500195947e_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "210201005 - Disclosure - Discontinued Operations",
     "role": "http://www.evolenthealth.com/role/DiscontinuedOperations",
     "shortName": "Discontinued Operations",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "evh-20211231.htm",
      "contextRef": "idc0db51272c94df1839131500195947e_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R130": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20211231.htm",
      "contextRef": "i546c40c371924532a3d2ed0ace7d354b_D20211001-20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "241164075 - Disclosure - Segment Reporting - Revenue from Segments to Consolidated (Details)",
     "role": "http://www.evolenthealth.com/role/SegmentReportingRevenuefromSegmentstoConsolidatedDetails",
     "shortName": "Segment Reporting - Revenue from Segments to Consolidated (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ReconciliationOfRevenueFromSegmentsToConsolidatedTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20211231.htm",
      "contextRef": "i98988f30813349e1a5594e72b40af5b1_D20210101-20211231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R131": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20211231.htm",
      "contextRef": "i546c40c371924532a3d2ed0ace7d354b_D20211001-20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "241174076 - Disclosure - Segment Reporting - Reconciliation of Adjusted EBITDA (Details)",
     "role": "http://www.evolenthealth.com/role/SegmentReportingReconciliationofAdjustedEBITDADetails",
     "shortName": "Segment Reporting - Reconciliation of Adjusted EBITDA (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20211231.htm",
      "contextRef": "idc0db51272c94df1839131500195947e_D20210101-20211231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:OtherNonoperatingIncomeExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R132": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20211231.htm",
      "contextRef": "ibc0c0c2b8dc04c5698ca0577a54b2e03_I20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "241204077 - Disclosure - Reserves for Claims and Performance-Based Arrangements (Details)",
     "role": "http://www.evolenthealth.com/role/ReservesforClaimsandPerformanceBasedArrangementsDetails",
     "shortName": "Reserves for Claims and Performance-Based Arrangements (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20211231.htm",
      "contextRef": "icba6e493923b449aa57c46a563760234_I20191231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R133": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20211231.htm",
      "contextRef": "i546c40c371924532a3d2ed0ace7d354b_D20211001-20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "241234078 - Disclosure - Quarterly Results of Operations (unaudited) (Details)",
     "role": "http://www.evolenthealth.com/role/QuarterlyResultsofOperationsunauditedDetails",
     "shortName": "Quarterly Results of Operations (unaudited) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20211231.htm",
      "contextRef": "i546c40c371924532a3d2ed0ace7d354b_D20211001-20211231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:OperatingExpenses",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R134": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20211231.htm",
      "contextRef": "i62320e40739f4842b8ffb078d42fa029_D20200401-20200630",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:GoodwillImpairmentLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "241244079 - Disclosure - Quarterly Results of Operations (unaudited) - Additional Information (Details)",
     "role": "http://www.evolenthealth.com/role/QuarterlyResultsofOperationsunauditedAdditionalInformationDetails",
     "shortName": "Quarterly Results of Operations (unaudited) - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R135": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20211231.htm",
      "contextRef": "idc0db51272c94df1839131500195947e_D20210101-20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockIssued1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "241274080 - Disclosure - Supplemental Cash Flow Information (Details)",
     "role": "http://www.evolenthealth.com/role/SupplementalCashFlowInformationDetails",
     "shortName": "Supplemental Cash Flow Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20211231.htm",
      "contextRef": "idc0db51272c94df1839131500195947e_D20210101-20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockIssued1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "evh-20211231.htm",
      "contextRef": "idc0db51272c94df1839131500195947e_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "210261006 - Disclosure - Revenue Recognition",
     "role": "http://www.evolenthealth.com/role/RevenueRecognition",
     "shortName": "Revenue Recognition",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "evh-20211231.htm",
      "contextRef": "idc0db51272c94df1839131500195947e_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "evh-20211231.htm",
      "contextRef": "idc0db51272c94df1839131500195947e_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CreditLossFinancialInstrumentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "210321007 - Disclosure - Credit Losses",
     "role": "http://www.evolenthealth.com/role/CreditLosses",
     "shortName": "Credit Losses",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "evh-20211231.htm",
      "contextRef": "idc0db51272c94df1839131500195947e_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CreditLossFinancialInstrumentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "evh-20211231.htm",
      "contextRef": "idc0db51272c94df1839131500195947e_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "210361008 - Disclosure - Property and Equipment, Net",
     "role": "http://www.evolenthealth.com/role/PropertyandEquipmentNet",
     "shortName": "Property and Equipment, Net",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "evh-20211231.htm",
      "contextRef": "idc0db51272c94df1839131500195947e_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "evh-20211231.htm",
      "contextRef": "idc0db51272c94df1839131500195947e_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "210391009 - Disclosure - Goodwill and Intangible Assets, Net",
     "role": "http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNet",
     "shortName": "Goodwill and Intangible Assets, Net",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "evh-20211231.htm",
      "contextRef": "idc0db51272c94df1839131500195947e_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "evh-20211231.htm",
      "contextRef": "idc0db51272c94df1839131500195947e_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "210451010 - Disclosure - Long-term Debt",
     "role": "http://www.evolenthealth.com/role/LongtermDebt",
     "shortName": "Long-term Debt",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "evh-20211231.htm",
      "contextRef": "idc0db51272c94df1839131500195947e_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "evh-20211231.htm",
      "contextRef": "idc0db51272c94df1839131500195947e_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "210531011 - Disclosure - Commitments and Contingencies",
     "role": "http://www.evolenthealth.com/role/CommitmentsandContingencies",
     "shortName": "Commitments and Contingencies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "evh-20211231.htm",
      "contextRef": "idc0db51272c94df1839131500195947e_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "evh-20211231.htm",
      "contextRef": "idc0db51272c94df1839131500195947e_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:AuditorName",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "false",
     "longName": "000020002 - Document - Audit Information",
     "role": "http://www.evolenthealth.com/role/AuditInformation",
     "shortName": "Audit Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "evh-20211231.htm",
      "contextRef": "idc0db51272c94df1839131500195947e_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:AuditorName",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "evh-20211231.htm",
      "contextRef": "idc0db51272c94df1839131500195947e_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "210581012 - Disclosure - Leases",
     "role": "http://www.evolenthealth.com/role/Leases",
     "shortName": "Leases",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "evh-20211231.htm",
      "contextRef": "idc0db51272c94df1839131500195947e_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "evh-20211231.htm",
      "contextRef": "idc0db51272c94df1839131500195947e_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "210651013 - Disclosure - Earnings (Loss) Per Common Share",
     "role": "http://www.evolenthealth.com/role/EarningsLossPerCommonShare",
     "shortName": "Earnings (Loss) Per Common Share",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "evh-20211231.htm",
      "contextRef": "idc0db51272c94df1839131500195947e_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "evh-20211231.htm",
      "contextRef": "idc0db51272c94df1839131500195947e_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "210691014 - Disclosure - Stock-based Compensation",
     "role": "http://www.evolenthealth.com/role/StockbasedCompensation",
     "shortName": "Stock-based Compensation",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "evh-20211231.htm",
      "contextRef": "idc0db51272c94df1839131500195947e_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "evh-20211231.htm",
      "contextRef": "idc0db51272c94df1839131500195947e_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "210831015 - Disclosure - Income Taxes",
     "role": "http://www.evolenthealth.com/role/IncomeTaxes",
     "shortName": "Income Taxes",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "evh-20211231.htm",
      "contextRef": "idc0db51272c94df1839131500195947e_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "evh-20211231.htm",
      "contextRef": "idc0db51272c94df1839131500195947e_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "210921016 - Disclosure - Employee Benefit Plans",
     "role": "http://www.evolenthealth.com/role/EmployeeBenefitPlans",
     "shortName": "Employee Benefit Plans",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "evh-20211231.htm",
      "contextRef": "idc0db51272c94df1839131500195947e_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "evh-20211231.htm",
      "contextRef": "idc0db51272c94df1839131500195947e_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EquityMethodInvestmentsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "210941017 - Disclosure - Investments in Equity Method Investees",
     "role": "http://www.evolenthealth.com/role/InvestmentsinEquityMethodInvestees",
     "shortName": "Investments in Equity Method Investees",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "evh-20211231.htm",
      "contextRef": "idc0db51272c94df1839131500195947e_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EquityMethodInvestmentsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "evh-20211231.htm",
      "contextRef": "idc0db51272c94df1839131500195947e_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:MinorityInterestDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "210961018 - Disclosure - Non-controlling Interests",
     "role": "http://www.evolenthealth.com/role/NoncontrollingInterests",
     "shortName": "Non-controlling Interests",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "evh-20211231.htm",
      "contextRef": "idc0db51272c94df1839131500195947e_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:MinorityInterestDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "evh-20211231.htm",
      "contextRef": "idc0db51272c94df1839131500195947e_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "211001019 - Disclosure - Fair Value Measurement",
     "role": "http://www.evolenthealth.com/role/FairValueMeasurement",
     "shortName": "Fair Value Measurement",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "evh-20211231.htm",
      "contextRef": "idc0db51272c94df1839131500195947e_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "evh-20211231.htm",
      "contextRef": "idc0db51272c94df1839131500195947e_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "211061020 - Disclosure - Related Parties",
     "role": "http://www.evolenthealth.com/role/RelatedParties",
     "shortName": "Related Parties",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "evh-20211231.htm",
      "contextRef": "idc0db51272c94df1839131500195947e_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "evh-20211231.htm",
      "contextRef": "idc0db51272c94df1839131500195947e_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "211101021 - Disclosure - Repositioning and Other Changes",
     "role": "http://www.evolenthealth.com/role/RepositioningandOtherChanges",
     "shortName": "Repositioning and Other Changes",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "evh-20211231.htm",
      "contextRef": "idc0db51272c94df1839131500195947e_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "evh-20211231.htm",
      "contextRef": "i8daff60be410426d8f7bd49343c1ec0c_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "100010003 - Statement - CONSOLIDATED BALANCE SHEETS",
     "role": "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS",
     "shortName": "CONSOLIDATED BALANCE SHEETS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "evh-20211231.htm",
      "contextRef": "i8daff60be410426d8f7bd49343c1ec0c_I20211231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:AssetsCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "evh-20211231.htm",
      "contextRef": "idc0db51272c94df1839131500195947e_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "211131022 - Disclosure - Segment Reporting",
     "role": "http://www.evolenthealth.com/role/SegmentReporting",
     "shortName": "Segment Reporting",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "evh-20211231.htm",
      "contextRef": "idc0db51272c94df1839131500195947e_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "evh-20211231.htm",
      "contextRef": "idc0db51272c94df1839131500195947e_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InsuranceDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "211181023 - Disclosure - Reserves for Claims and Performance-Based Arrangements",
     "role": "http://www.evolenthealth.com/role/ReservesforClaimsandPerformanceBasedArrangements",
     "shortName": "Reserves for Claims and Performance-Based Arrangements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "evh-20211231.htm",
      "contextRef": "idc0db51272c94df1839131500195947e_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InsuranceDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "evh-20211231.htm",
      "contextRef": "idc0db51272c94df1839131500195947e_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:QuarterlyFinancialInformationTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "211211024 - Disclosure - Quarterly Results of Operations (unaudited)",
     "role": "http://www.evolenthealth.com/role/QuarterlyResultsofOperationsunaudited",
     "shortName": "Quarterly Results of Operations (unaudited)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "evh-20211231.htm",
      "contextRef": "idc0db51272c94df1839131500195947e_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:QuarterlyFinancialInformationTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "evh-20211231.htm",
      "contextRef": "idc0db51272c94df1839131500195947e_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashFlowSupplementalDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "211251025 - Disclosure - Supplemental Cash Flow Information",
     "role": "http://www.evolenthealth.com/role/SupplementalCashFlowInformation",
     "shortName": "Supplemental Cash Flow Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "evh-20211231.htm",
      "contextRef": "idc0db51272c94df1839131500195947e_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashFlowSupplementalDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20211231.htm",
      "contextRef": "idc0db51272c94df1839131500195947e_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "220042001 - Disclosure - Basis of Presentation, Summary of Significant Accounting Policies and Change in Accounting Principles (Policies)",
     "role": "http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesPolicies",
     "shortName": "Basis of Presentation, Summary of Significant Accounting Policies and Change in Accounting Principles (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20211231.htm",
      "contextRef": "idc0db51272c94df1839131500195947e_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20211231.htm",
      "contextRef": "idc0db51272c94df1839131500195947e_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "230053001 - Disclosure - Basis of Presentation, Summary of Significant Accounting Policies and Change in Accounting Principles (Tables)",
     "role": "http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesTables",
     "shortName": "Basis of Presentation, Summary of Significant Accounting Policies and Change in Accounting Principles (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20211231.htm",
      "contextRef": "idc0db51272c94df1839131500195947e_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20211231.htm",
      "contextRef": "idc0db51272c94df1839131500195947e_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "230173002 - Disclosure - Transactions (Tables)",
     "role": "http://www.evolenthealth.com/role/TransactionsTables",
     "shortName": "Transactions (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20211231.htm",
      "contextRef": "idc0db51272c94df1839131500195947e_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20211231.htm",
      "contextRef": "idc0db51272c94df1839131500195947e_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "230213003 - Disclosure - Discontinued Operations (Tables)",
     "role": "http://www.evolenthealth.com/role/DiscontinuedOperationsTables",
     "shortName": "Discontinued Operations (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20211231.htm",
      "contextRef": "idc0db51272c94df1839131500195947e_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20211231.htm",
      "contextRef": "idc0db51272c94df1839131500195947e_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisaggregationOfRevenueTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "230273004 - Disclosure - Revenue Recognition (Tables)",
     "role": "http://www.evolenthealth.com/role/RevenueRecognitionTables",
     "shortName": "Revenue Recognition (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20211231.htm",
      "contextRef": "idc0db51272c94df1839131500195947e_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisaggregationOfRevenueTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20211231.htm",
      "contextRef": "idc0db51272c94df1839131500195947e_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsReceivableAllowanceForCreditLossTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "230333005 - Disclosure - Credit Losses (Tables)",
     "role": "http://www.evolenthealth.com/role/CreditLossesTables",
     "shortName": "Credit Losses (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20211231.htm",
      "contextRef": "idc0db51272c94df1839131500195947e_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsReceivableAllowanceForCreditLossTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:CommonStockParOrStatedValuePerShare",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "evh-20211231.htm",
      "contextRef": "i8daff60be410426d8f7bd49343c1ec0c_I20211231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "100020004 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)",
     "role": "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETSParenthetical",
     "shortName": "CONSOLIDATED BALANCE SHEETS (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:CommonStockParOrStatedValuePerShare",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "evh-20211231.htm",
      "contextRef": "i8daff60be410426d8f7bd49343c1ec0c_I20211231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20211231.htm",
      "contextRef": "idc0db51272c94df1839131500195947e_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "230373006 - Disclosure - Property and Equipment, Net (Tables)",
     "role": "http://www.evolenthealth.com/role/PropertyandEquipmentNetTables",
     "shortName": "Property and Equipment, Net (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": null
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20211231.htm",
      "contextRef": "idc0db51272c94df1839131500195947e_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfGoodwillTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "230403007 - Disclosure - Goodwill and Intangible Assets, Net (Tables)",
     "role": "http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNetTables",
     "shortName": "Goodwill and Intangible Assets, Net (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20211231.htm",
      "contextRef": "idc0db51272c94df1839131500195947e_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfGoodwillTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20211231.htm",
      "contextRef": "idc0db51272c94df1839131500195947e_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ConvertibleDebtTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "230463008 - Disclosure - Long-term Debt (Tables)",
     "role": "http://www.evolenthealth.com/role/LongtermDebtTables",
     "shortName": "Long-term Debt (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20211231.htm",
      "contextRef": "idc0db51272c94df1839131500195947e_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ConvertibleDebtTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20211231.htm",
      "contextRef": "idc0db51272c94df1839131500195947e_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EffectsOfReinsuranceTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "230543009 - Disclosure - Commitments and Contingencies (Tables)",
     "role": "http://www.evolenthealth.com/role/CommitmentsandContingenciesTables",
     "shortName": "Commitments and Contingencies (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20211231.htm",
      "contextRef": "idc0db51272c94df1839131500195947e_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EffectsOfReinsuranceTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R44": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20211231.htm",
      "contextRef": "idc0db51272c94df1839131500195947e_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "230593010 - Disclosure - Leases (Tables)",
     "role": "http://www.evolenthealth.com/role/LeasesTables",
     "shortName": "Leases (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20211231.htm",
      "contextRef": "idc0db51272c94df1839131500195947e_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R45": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20211231.htm",
      "contextRef": "idc0db51272c94df1839131500195947e_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "230663011 - Disclosure - Earnings (Loss) Per Common Share (Tables)",
     "role": "http://www.evolenthealth.com/role/EarningsLossPerCommonShareTables",
     "shortName": "Earnings (Loss) Per Common Share (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20211231.htm",
      "contextRef": "idc0db51272c94df1839131500195947e_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R46": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20211231.htm",
      "contextRef": "idc0db51272c94df1839131500195947e_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "230703012 - Disclosure - Stock-based Compensation (Tables)",
     "role": "http://www.evolenthealth.com/role/StockbasedCompensationTables",
     "shortName": "Stock-based Compensation (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20211231.htm",
      "contextRef": "idc0db51272c94df1839131500195947e_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R47": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20211231.htm",
      "contextRef": "idc0db51272c94df1839131500195947e_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "230843013 - Disclosure - Income Taxes (Tables)",
     "role": "http://www.evolenthealth.com/role/IncomeTaxesTables",
     "shortName": "Income Taxes (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20211231.htm",
      "contextRef": "idc0db51272c94df1839131500195947e_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R48": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20211231.htm",
      "contextRef": "idc0db51272c94df1839131500195947e_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "evh:ScheduleofChangesinNoncontrollingInterestTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "230973014 - Disclosure - Non-controlling Interests (Tables)",
     "role": "http://www.evolenthealth.com/role/NoncontrollingInterestsTables",
     "shortName": "Non-controlling Interests (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20211231.htm",
      "contextRef": "idc0db51272c94df1839131500195947e_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "evh:ScheduleofChangesinNoncontrollingInterestTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R49": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20211231.htm",
      "contextRef": "idc0db51272c94df1839131500195947e_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "231013015 - Disclosure - Fair Value Measurement (Tables)",
     "role": "http://www.evolenthealth.com/role/FairValueMeasurementTables",
     "shortName": "Fair Value Measurement (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20211231.htm",
      "contextRef": "idc0db51272c94df1839131500195947e_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "evh-20211231.htm",
      "contextRef": "idc0db51272c94df1839131500195947e_D20210101-20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "100030005 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (LOSS)",
     "role": "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS",
     "shortName": "CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (LOSS)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "evh-20211231.htm",
      "contextRef": "idc0db51272c94df1839131500195947e_D20210101-20211231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:OperatingIncomeLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R50": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20211231.htm",
      "contextRef": "idc0db51272c94df1839131500195947e_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "231073016 - Disclosure - Related Parties (Tables)",
     "role": "http://www.evolenthealth.com/role/RelatedPartiesTables",
     "shortName": "Related Parties (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20211231.htm",
      "contextRef": "idc0db51272c94df1839131500195947e_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R51": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20211231.htm",
      "contextRef": "idc0db51272c94df1839131500195947e_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "231113017 - Disclosure - Repositioning and Other Changes (Tables)",
     "role": "http://www.evolenthealth.com/role/RepositioningandOtherChangesTables",
     "shortName": "Repositioning and Other Changes (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20211231.htm",
      "contextRef": "idc0db51272c94df1839131500195947e_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R52": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20211231.htm",
      "contextRef": "idc0db51272c94df1839131500195947e_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ReconciliationOfRevenueFromSegmentsToConsolidatedTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "231143018 - Disclosure - Segment Reporting (Tables)",
     "role": "http://www.evolenthealth.com/role/SegmentReportingTables",
     "shortName": "Segment Reporting (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20211231.htm",
      "contextRef": "idc0db51272c94df1839131500195947e_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ReconciliationOfRevenueFromSegmentsToConsolidatedTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R53": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20211231.htm",
      "contextRef": "idc0db51272c94df1839131500195947e_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "231193019 - Disclosure - Reserves for Claims and Performance-Based Arrangements (Tables)",
     "role": "http://www.evolenthealth.com/role/ReservesforClaimsandPerformanceBasedArrangementsTables",
     "shortName": "Reserves for Claims and Performance-Based Arrangements (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20211231.htm",
      "contextRef": "idc0db51272c94df1839131500195947e_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R54": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20211231.htm",
      "contextRef": "idc0db51272c94df1839131500195947e_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "231223020 - Disclosure - Quarterly Results of Operations (unaudited) (Tables)",
     "role": "http://www.evolenthealth.com/role/QuarterlyResultsofOperationsunauditedTables",
     "shortName": "Quarterly Results of Operations (unaudited) (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20211231.htm",
      "contextRef": "idc0db51272c94df1839131500195947e_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R55": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20211231.htm",
      "contextRef": "idc0db51272c94df1839131500195947e_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "231263021 - Disclosure - Supplemental Cash Flow Information (Tables)",
     "role": "http://www.evolenthealth.com/role/SupplementalCashFlowInformationTables",
     "shortName": "Supplemental Cash Flow Information (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20211231.htm",
      "contextRef": "idc0db51272c94df1839131500195947e_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R56": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "evh-20211231.htm",
      "contextRef": "i8daff60be410426d8f7bd49343c1ec0c_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240024001 - Disclosure - Organization (Details)",
     "role": "http://www.evolenthealth.com/role/OrganizationDetails",
     "shortName": "Organization (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:CommonStockSharesOutstanding",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20211231.htm",
      "contextRef": "i5f1b61732fb142fc9539a36365f230ee_I20211231",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:CommonStockSharesOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R57": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20211231.htm",
      "contextRef": "idc0db51272c94df1839131500195947e_D20210101-20211231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NumberOfOperatingSegments",
      "reportCount": 1,
      "unitRef": "segment",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240064002 - Disclosure - Basis of Presentation, Summary of Significant Accounting Policies and Change in Accounting Principles - Operating Segments (Details)",
     "role": "http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesOperatingSegmentsDetails",
     "shortName": "Basis of Presentation, Summary of Significant Accounting Policies and Change in Accounting Principles - Operating Segments (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R58": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20211231.htm",
      "contextRef": "ibc0c0c2b8dc04c5698ca0577a54b2e03_I20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RestrictedCashAndCashEquivalents",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240074003 - Disclosure - Basis of Presentation, Summary of Significant Accounting Policies and Change in Accounting Principles - Restricted Cash and Restricted Investments (Details)",
     "role": "http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesRestrictedCashandRestrictedInvestmentsDetails",
     "shortName": "Basis of Presentation, Summary of Significant Accounting Policies and Change in Accounting Principles - Restricted Cash and Restricted Investments (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20211231.htm",
      "contextRef": "i8daff60be410426d8f7bd49343c1ec0c_I20211231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R59": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20211231.htm",
      "contextRef": "if8e7fd6ca1724c74bd0f4e3ca2947419_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240084004 - Disclosure - Basis of Presentation, Summary of Significant Accounting Policies and Change in Accounting Principles - Estimated Useful Life of Property, Plant and Equipment (Details)",
     "role": "http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesEstimatedUsefulLifeofPropertyPlantandEquipmentDetails",
     "shortName": "Basis of Presentation, Summary of Significant Accounting Policies and Change in Accounting Principles - Estimated Useful Life of Property, Plant and Equipment (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20211231.htm",
      "contextRef": "if8e7fd6ca1724c74bd0f4e3ca2947419_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20211231.htm",
      "contextRef": "idc0db51272c94df1839131500195947e_D20210101-20211231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "100040006 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (LOSS) (Parenthetical)",
     "role": "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSSParenthetical",
     "shortName": "CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (LOSS) (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20211231.htm",
      "contextRef": "idc0db51272c94df1839131500195947e_D20210101-20211231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R60": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:ResearchAndDevelopmentExpensePolicy",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20211231.htm",
      "contextRef": "idc0db51272c94df1839131500195947e_D20210101-20211231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240094005 - Disclosure - Basis of Presentation, Summary of Significant Accounting Policies and Change in Accounting Principles - Research and Development Costs (Details)",
     "role": "http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesResearchandDevelopmentCostsDetails",
     "shortName": "Basis of Presentation, Summary of Significant Accounting Policies and Change in Accounting Principles - Research and Development Costs (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:ResearchAndDevelopmentExpensePolicy",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20211231.htm",
      "contextRef": "idc0db51272c94df1839131500195947e_D20210101-20211231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R61": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20211231.htm",
      "contextRef": "id586f68951304ab3ac3fd84a42cb5e48_D20201031-20201031",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NumberOfReportingUnits",
      "reportCount": 1,
      "unitRef": "reportingunit",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240104006 - Disclosure - Basis of Presentation, Summary of Significant Accounting Policies and Change in Accounting Principles - Goodwill (Details)",
     "role": "http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesGoodwillDetails",
     "shortName": "Basis of Presentation, Summary of Significant Accounting Policies and Change in Accounting Principles - Goodwill (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R62": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
       "us-gaap:IntangibleAssetsFiniteLivedPolicy",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20211231.htm",
      "contextRef": "ibff83f3576fa462088fb611595ae2107_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FiniteLivedIntangibleAssetUsefulLife",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240114007 - Disclosure - Basis of Presentation, Summary of Significant Accounting Policies and Change in Accounting Principles - Intangible Assets, Net (Details)",
     "role": "http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesIntangibleAssetsNetDetails",
     "shortName": "Basis of Presentation, Summary of Significant Accounting Policies and Change in Accounting Principles - Intangible Assets, Net (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
       "us-gaap:IntangibleAssetsFiniteLivedPolicy",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20211231.htm",
      "contextRef": "ibff83f3576fa462088fb611595ae2107_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FiniteLivedIntangibleAssetUsefulLife",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R63": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20211231.htm",
      "contextRef": "i8daff60be410426d8f7bd49343c1ec0c_I20211231",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "evh:RightOfOffsetPercentageOfAccountsReceivableNettedAgainstClaimsPayable",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240124008 - Disclosure - Basis of Presentation, Summary of Significant Accounting Policies and Change in Accounting Principles - Right of Offset (Details)",
     "role": "http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesRightofOffsetDetails",
     "shortName": "Basis of Presentation, Summary of Significant Accounting Policies and Change in Accounting Principles - Right of Offset (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20211231.htm",
      "contextRef": "i8daff60be410426d8f7bd49343c1ec0c_I20211231",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "evh:RightOfOffsetPercentageOfAccountsReceivableNettedAgainstClaimsPayable",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R64": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20211231.htm",
      "contextRef": "i532d2c0bf63243e999d48341920b6775_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
      "reportCount": 1,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240134009 - Disclosure - Basis of Presentation, Summary of Significant Accounting Policies and Change in Accounting Principles - Stock-based Compensation (Details)",
     "role": "http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesStockbasedCompensationDetails",
     "shortName": "Basis of Presentation, Summary of Significant Accounting Policies and Change in Accounting Principles - Stock-based Compensation (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R65": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "evh-20211231.htm",
      "contextRef": "icba6e493923b449aa57c46a563760234_I20191231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240154010 - Disclosure - Recently Issued Accounting Standards (Details)",
     "role": "http://www.evolenthealth.com/role/RecentlyIssuedAccountingStandardsDetails",
     "shortName": "Recently Issued Accounting Standards (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R66": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "evh-20211231.htm",
      "contextRef": "idc0db51272c94df1839131500195947e_D20210101-20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PaymentsToAcquireBusinessesGross",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240184011 - Disclosure - Transactions - Vital Decisions (Details)",
     "role": "http://www.evolenthealth.com/role/TransactionsVitalDecisionsDetails",
     "shortName": "Transactions - Vital Decisions (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20211231.htm",
      "contextRef": "i70301f61588141189fb4444297fae8bd_I20211001",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R67": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "evh-20211231.htm",
      "contextRef": "idc0db51272c94df1839131500195947e_D20210101-20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PaymentsToMinorityShareholders",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240194012 - Disclosure - Transactions - Equity Investments (Details)",
     "role": "http://www.evolenthealth.com/role/TransactionsEquityInvestmentsDetails",
     "shortName": "Transactions - Equity Investments (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20211231.htm",
      "contextRef": "i24eda106b1dc4387aebfe529942c3586_D20200901-20200901",
      "decimals": "-5",
      "lang": "en-US",
      "name": "evh:AssetAcquisitionCashAndEquivalents",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R68": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20211231.htm",
      "contextRef": "i1c4a293e5ce54724af5effd8253d4d89_D20210101-20211231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "evh:DiscontinuedOperationGainLossOnPurchasePriceAdjustmentsNetOfTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240224013 - Disclosure - Discontinued Operations - Additional Information (Details)",
     "role": "http://www.evolenthealth.com/role/DiscontinuedOperationsAdditionalInformationDetails",
     "shortName": "Discontinued Operations - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20211231.htm",
      "contextRef": "i1c4a293e5ce54724af5effd8253d4d89_D20210101-20211231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "evh:DiscontinuedOperationGainLossOnPurchasePriceAdjustmentsNetOfTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R69": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20211231.htm",
      "contextRef": "i546c40c371924532a3d2ed0ace7d354b_D20211001-20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240234014 - Disclosure - Discontinued Operations - Summary of Results of Operations (Details)",
     "role": "http://www.evolenthealth.com/role/DiscontinuedOperationsSummaryofResultsofOperationsDetails",
     "shortName": "Discontinued Operations - Summary of Results of Operations (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20211231.htm",
      "contextRef": "i1c4a293e5ce54724af5effd8253d4d89_D20210101-20211231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "evh-20211231.htm",
      "contextRef": "i997aac773ca7467b9a246f3420865489_I20181231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SharesIssued",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "100050007 - Statement - CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS' EQUITY",
     "role": "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY",
     "shortName": "CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS' EQUITY",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "evh-20211231.htm",
      "contextRef": "i997aac773ca7467b9a246f3420865489_I20181231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SharesIssued",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R70": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20211231.htm",
      "contextRef": "i1c4a293e5ce54724af5effd8253d4d89_D20210101-20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240244015 - Disclosure - Discontinued Operations - Summary of Cash Flows (Details)",
     "role": "http://www.evolenthealth.com/role/DiscontinuedOperationsSummaryofCashFlowsDetails",
     "shortName": "Discontinued Operations - Summary of Cash Flows (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20211231.htm",
      "contextRef": "i1c4a293e5ce54724af5effd8253d4d89_D20210101-20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R71": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "evh-20211231.htm",
      "contextRef": "i8daff60be410426d8f7bd49343c1ec0c_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240254016 - Disclosure - Discontinued Operations - Summary of Current and Long-term Assets and Liabilities (Details)",
     "role": "http://www.evolenthealth.com/role/DiscontinuedOperationsSummaryofCurrentandLongtermAssetsandLiabilitiesDetails",
     "shortName": "Discontinued Operations - Summary of Current and Long-term Assets and Liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20211231.htm",
      "contextRef": "i98364cf4ba3e41af868d701b4c668283_I20201231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R72": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DisaggregationOfRevenueTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20211231.htm",
      "contextRef": "i98988f30813349e1a5594e72b40af5b1_D20210101-20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240284017 - Disclosure - Revenue Recognition - Disaggregation of Revenue (Details)",
     "role": "http://www.evolenthealth.com/role/RevenueRecognitionDisaggregationofRevenueDetails",
     "shortName": "Revenue Recognition - Disaggregation of Revenue (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DisaggregationOfRevenueTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20211231.htm",
      "contextRef": "i98988f30813349e1a5594e72b40af5b1_D20210101-20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R73": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20211231.htm",
      "contextRef": "i8daff60be410426d8f7bd49343c1ec0c_I20211231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueRemainingPerformanceObligation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240294018 - Disclosure - Revenue Recognition - Transaction Price Allocated to the Remaining Performance Obligations (Details)",
     "role": "http://www.evolenthealth.com/role/RevenueRecognitionTransactionPriceAllocatedtotheRemainingPerformanceObligationsDetails",
     "shortName": "Revenue Recognition - Transaction Price Allocated to the Remaining Performance Obligations (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20211231.htm",
      "contextRef": "i8daff60be410426d8f7bd49343c1ec0c_I20211231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueRemainingPerformanceObligation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R74": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20211231.htm",
      "contextRef": "i8daff60be410426d8f7bd49343c1ec0c_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsNotesAndLoansReceivableNetCurrent",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240304019 - Disclosure - Revenue Recognition - Contract Balances (Details)",
     "role": "http://www.evolenthealth.com/role/RevenueRecognitionContractBalancesDetails",
     "shortName": "Revenue Recognition - Contract Balances (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20211231.htm",
      "contextRef": "ibc0c0c2b8dc04c5698ca0577a54b2e03_I20201231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:AccountsNotesAndLoansReceivableNetCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R75": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "evh-20211231.htm",
      "contextRef": "idc0db51272c94df1839131500195947e_D20210101-20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CapitalizedContractCostAmortization",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240314020 - Disclosure - Revenue Recognition - Contract Costs (Details)",
     "role": "http://www.evolenthealth.com/role/RevenueRecognitionContractCostsDetails",
     "shortName": "Revenue Recognition - Contract Costs (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20211231.htm",
      "contextRef": "i8daff60be410426d8f7bd49343c1ec0c_I20211231",
      "decimals": null,
      "lang": "en-US",
      "name": "us-gaap:CapitalizedContractCostAmortizationPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R76": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20211231.htm",
      "contextRef": "i8daff60be410426d8f7bd49343c1ec0c_I20211231",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "evh:FinancingReceivablePercentNotPastDue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240344021 - Disclosure - Credit Losses - Accounts Receivable (Narrative) (Details)",
     "role": "http://www.evolenthealth.com/role/CreditLossesAccountsReceivableNarrativeDetails",
     "shortName": "Credit Losses - Accounts Receivable (Narrative) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20211231.htm",
      "contextRef": "i8daff60be410426d8f7bd49343c1ec0c_I20211231",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "evh:FinancingReceivablePercentNotPastDue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R77": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20211231.htm",
      "contextRef": "ibc0c0c2b8dc04c5698ca0577a54b2e03_I20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240354022 - Disclosure - Credit Losses - Schedule of Changes in Allowance for Accounts Receivable (Details)",
     "role": "http://www.evolenthealth.com/role/CreditLossesScheduleofChangesinAllowanceforAccountsReceivableDetails",
     "shortName": "Credit Losses - Schedule of Changes in Allowance for Accounts Receivable (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20211231.htm",
      "contextRef": "idc0db51272c94df1839131500195947e_D20210101-20211231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "evh:AccountsReceivableAllowanceForCreditLossAcquiredDuringPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R78": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20211231.htm",
      "contextRef": "i8daff60be410426d8f7bd49343c1ec0c_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240384023 - Disclosure - Property and Equipment, Net (Details)",
     "role": "http://www.evolenthealth.com/role/PropertyandEquipmentNetDetails",
     "shortName": "Property and Equipment, Net (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20211231.htm",
      "contextRef": "i8daff60be410426d8f7bd49343c1ec0c_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R79": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20211231.htm",
      "contextRef": "id586f68951304ab3ac3fd84a42cb5e48_D20201031-20201031",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NumberOfReportingUnits",
      "reportCount": 1,
      "unitRef": "reportingunit",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240414024 - Disclosure - Goodwill and Intangible Assets, Net - Impairment Testing (Details)",
     "role": "http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNetImpairmentTestingDetails",
     "shortName": "Goodwill and Intangible Assets, Net - Impairment Testing (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20211231.htm",
      "contextRef": "id586f68951304ab3ac3fd84a42cb5e48_D20201031-20201031",
      "decimals": "INF",
      "lang": "en-US",
      "name": "evh:NumberOfReportingUnitsFairValueInExcessOfCarryingAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "reportingunit",
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "evh-20211231.htm",
      "contextRef": "idc0db51272c94df1839131500195947e_D20210101-20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "100060008 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS",
     "role": "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
     "shortName": "CONSOLIDATED STATEMENTS OF CASH FLOWS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "evh-20211231.htm",
      "contextRef": "idc0db51272c94df1839131500195947e_D20210101-20211231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "evh:GainLossOnDispositionOfAssetsOperatingActivities",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R80": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfGoodwillTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20211231.htm",
      "contextRef": "icba6e493923b449aa57c46a563760234_I20191231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Goodwill",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240424025 - Disclosure - Goodwill and Intangible Assets, Net - Schedule of Goodwill (Details)",
     "role": "http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNetScheduleofGoodwillDetails",
     "shortName": "Goodwill and Intangible Assets, Net - Schedule of Goodwill (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfGoodwillTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20211231.htm",
      "contextRef": "i12a6d1161de54547bd29f8efccd4c9b0_D20200101-20201231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:GoodwillWrittenOffRelatedToSaleOfBusinessUnit",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R81": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20211231.htm",
      "contextRef": "i8daff60be410426d8f7bd49343c1ec0c_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FiniteLivedIntangibleAssetsGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240434026 - Disclosure - Goodwill and Intangible Assets, Net - Intangible Assets, Net (Details)",
     "role": "http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNetIntangibleAssetsNetDetails",
     "shortName": "Goodwill and Intangible Assets, Net - Intangible Assets, Net (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20211231.htm",
      "contextRef": "i8daff60be410426d8f7bd49343c1ec0c_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FiniteLivedIntangibleAssetsGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R82": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20211231.htm",
      "contextRef": "i8daff60be410426d8f7bd49343c1ec0c_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240444027 - Disclosure - Goodwill and Intangible Assets, Net - Amortization of Intangible Assets (Details)",
     "role": "http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNetAmortizationofIntangibleAssetsDetails",
     "shortName": "Goodwill and Intangible Assets, Net - Amortization of Intangible Assets (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20211231.htm",
      "contextRef": "i8daff60be410426d8f7bd49343c1ec0c_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R83": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20211231.htm",
      "contextRef": "i8584b8487d5e4d7ca2a029dd1993309b_D20200801-20200831",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PaymentsOfDebtIssuanceCosts",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240474028 - Disclosure - Long-term Debt - 2024 Notes (Details)",
     "role": "http://www.evolenthealth.com/role/LongtermDebt2024NotesDetails",
     "shortName": "Long-term Debt - 2024 Notes (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20211231.htm",
      "contextRef": "i04c13e91bd034f30a0f4a7c989fc5940_I20200831",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:LongTermDebt",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R84": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20211231.htm",
      "contextRef": "idc0db51272c94df1839131500195947e_D20210101-20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InterestPaidNet",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240484029 - Disclosure - Long-term Debt - Credit Agreement (Details)",
     "role": "http://www.evolenthealth.com/role/LongtermDebtCreditAgreementDetails",
     "shortName": "Long-term Debt - Credit Agreement (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20211231.htm",
      "contextRef": "ic9f911355bb8445c908c1c5b6b982236_I20191230",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:DebtInstrumentFaceAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R85": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20211231.htm",
      "contextRef": "i88843d45ac464699a3408ba52bbc2f63_I20191230",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ClassOfWarrantOrRightUnissued",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240494030 - Disclosure - Long-term Debt - Warrant Agreement (Details)",
     "role": "http://www.evolenthealth.com/role/LongtermDebtWarrantAgreementDetails",
     "shortName": "Long-term Debt - Warrant Agreement (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20211231.htm",
      "contextRef": "i88843d45ac464699a3408ba52bbc2f63_I20191230",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     }
    },
    "R86": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20211231.htm",
      "contextRef": "i39addcd35f11436480a83296fb4dc83a_I20181031",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DeferredFinanceCostsNet",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240504031 - Disclosure - Long-term Debt - 2025 Notes (Details)",
     "role": "http://www.evolenthealth.com/role/LongtermDebt2025NotesDetails",
     "shortName": "Long-term Debt - 2025 Notes (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20211231.htm",
      "contextRef": "i39addcd35f11436480a83296fb4dc83a_I20181031",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DeferredFinanceCostsNet",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R87": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "evh-20211231.htm",
      "contextRef": "idc0db51272c94df1839131500195947e_D20210101-20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AmortizationOfFinancingCosts",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240514032 - Disclosure - Long-term Debt - 2021 Notes (Details)",
     "role": "http://www.evolenthealth.com/role/LongtermDebt2021NotesDetails",
     "shortName": "Long-term Debt - 2021 Notes (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20211231.htm",
      "contextRef": "i8584b8487d5e4d7ca2a029dd1993309b_D20200801-20200831",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:GainsLossesOnExtinguishmentOfDebtBeforeWriteOffOfDeferredDebtIssuanceCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R88": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20211231.htm",
      "contextRef": "id7ce03f7e23c4e8982556c1c3936f37c_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ConvertibleDebt",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240524033 - Disclosure - Long-term Debt - Convertible Senior Notes Carrying Value (Details)",
     "role": "http://www.evolenthealth.com/role/LongtermDebtConvertibleSeniorNotesCarryingValueDetails",
     "shortName": "Long-term Debt - Convertible Senior Notes Carrying Value (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20211231.htm",
      "contextRef": "id7ce03f7e23c4e8982556c1c3936f37c_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ConvertibleDebt",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R89": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20211231.htm",
      "contextRef": "ibc0c0c2b8dc04c5698ca0577a54b2e03_I20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RestrictedCashAndCashEquivalents",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240554034 - Disclosure - Commitments and Contingencies - Additional Information (Details)",
     "role": "http://www.evolenthealth.com/role/CommitmentsandContingenciesAdditionalInformationDetails",
     "shortName": "Commitments and Contingencies - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20211231.htm",
      "contextRef": "i8daff60be410426d8f7bd49343c1ec0c_I20211231",
      "decimals": "INF",
      "lang": "en-US",
      "name": "evh:TaxReceivablesAgreementPercentofTaxSavingstobePaid",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "evh-20211231.htm",
      "contextRef": "idc0db51272c94df1839131500195947e_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "210011001 - Disclosure - Organization",
     "role": "http://www.evolenthealth.com/role/Organization",
     "shortName": "Organization",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "evh-20211231.htm",
      "contextRef": "idc0db51272c94df1839131500195947e_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R90": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:EffectsOfReinsuranceTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20211231.htm",
      "contextRef": "idc0db51272c94df1839131500195947e_D20210101-20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AssumedPremiumsWritten",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240564035 - Disclosure - Commitments and Contingencies - Reinsurance Agreements (Details)",
     "role": "http://www.evolenthealth.com/role/CommitmentsandContingenciesReinsuranceAgreementsDetails",
     "shortName": "Commitments and Contingencies - Reinsurance Agreements (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:EffectsOfReinsuranceTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20211231.htm",
      "contextRef": "idc0db51272c94df1839131500195947e_D20210101-20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AssumedPremiumsWritten",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R91": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20211231.htm",
      "contextRef": "i8daff60be410426d8f7bd49343c1ec0c_I20211231",
      "decimals": "3",
      "first": true,
      "lang": "en-US",
      "name": "evh:CashFDICInsuredAmountPercentage",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240574036 - Disclosure - Commitments and Contingencies - Concentration Risk (Details)",
     "role": "http://www.evolenthealth.com/role/CommitmentsandContingenciesConcentrationRiskDetails",
     "shortName": "Commitments and Contingencies - Concentration Risk (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20211231.htm",
      "contextRef": "i8daff60be410426d8f7bd49343c1ec0c_I20211231",
      "decimals": "3",
      "first": true,
      "lang": "en-US",
      "name": "evh:CashFDICInsuredAmountPercentage",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R92": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20211231.htm",
      "contextRef": "ibc0c0c2b8dc04c5698ca0577a54b2e03_I20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RestrictedCashAndCashEquivalents",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240604037 - Disclosure - Leases - Narrative (Details)",
     "role": "http://www.evolenthealth.com/role/LeasesNarrativeDetails",
     "shortName": "Leases - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20211231.htm",
      "contextRef": "i1a21d5a158854825a4cb4f9e1b2d4103_I20211231",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:LettersOfCreditOutstandingAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R93": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20211231.htm",
      "contextRef": "i8daff60be410426d8f7bd49343c1ec0c_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240614038 - Disclosure - Leases - Primary Office Leases (Details)",
     "role": "http://www.evolenthealth.com/role/LeasesPrimaryOfficeLeasesDetails",
     "shortName": "Leases - Primary Office Leases (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20211231.htm",
      "contextRef": "ie94dd6f6dead455b8b597165bc5ec9ff_I20211231",
      "decimals": null,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseTermOfContract",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R94": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LeaseCostTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20211231.htm",
      "contextRef": "idc0db51272c94df1839131500195947e_D20210101-20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240624039 - Disclosure - Leases - Components of Lease Expense (Details)",
     "role": "http://www.evolenthealth.com/role/LeasesComponentsofLeaseExpenseDetails",
     "shortName": "Leases - Components of Lease Expense (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LeaseCostTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20211231.htm",
      "contextRef": "idc0db51272c94df1839131500195947e_D20210101-20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R95": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20211231.htm",
      "contextRef": "i8daff60be410426d8f7bd49343c1ec0c_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240634040 - Disclosure - Leases - Maturity of Lease Liabilities (Details)",
     "role": "http://www.evolenthealth.com/role/LeasesMaturityofLeaseLiabilitiesDetails",
     "shortName": "Leases - Maturity of Lease Liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20211231.htm",
      "contextRef": "i8daff60be410426d8f7bd49343c1ec0c_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R96": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20211231.htm",
      "contextRef": "i8daff60be410426d8f7bd49343c1ec0c_I20211231",
      "decimals": "4",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240644041 - Disclosure - Leases - Weighted-average Discount Rate and Weighted-remaining Lease Terms (Details)",
     "role": "http://www.evolenthealth.com/role/LeasesWeightedaverageDiscountRateandWeightedremainingLeaseTermsDetails",
     "shortName": "Leases - Weighted-average Discount Rate and Weighted-remaining Lease Terms (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20211231.htm",
      "contextRef": "i8daff60be410426d8f7bd49343c1ec0c_I20211231",
      "decimals": "4",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R97": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20211231.htm",
      "contextRef": "i546c40c371924532a3d2ed0ace7d354b_D20211001-20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240674042 - Disclosure - Earnings (Loss) Per Common Share - Computation of Earnings per Share (Details)",
     "role": "http://www.evolenthealth.com/role/EarningsLossPerCommonShareComputationofEarningsperShareDetails",
     "shortName": "Earnings (Loss) Per Common Share - Computation of Earnings per Share (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R98": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20211231.htm",
      "contextRef": "idc0db51272c94df1839131500195947e_D20210101-20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240684043 - Disclosure - Earnings (Loss) Per Common Share - Antidilutive Securities (Details)",
     "role": "http://www.evolenthealth.com/role/EarningsLossPerCommonShareAntidilutiveSecuritiesDetails",
     "shortName": "Earnings (Loss) Per Common Share - Antidilutive Securities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20211231.htm",
      "contextRef": "idc0db51272c94df1839131500195947e_D20210101-20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R99": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20211231.htm",
      "contextRef": "i8daff60be410426d8f7bd49343c1ec0c_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240714044 - Disclosure - Stock-based Compensation - 2011 and 2015 Equity Incentive Plans (Details)",
     "role": "http://www.evolenthealth.com/role/StockbasedCompensation2011and2015EquityIncentivePlansDetails",
     "shortName": "Stock-based Compensation - 2011 and 2015 Equity Incentive Plans (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20211231.htm",
      "contextRef": "i1d4614ce073d4c1dbaf45d31f2350ff7_I20211231",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 132,
   "tag": {
    "country_IN": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "INDIA",
        "terseLabel": "Pune, India"
       }
      }
     },
     "localname": "IN",
     "nsuri": "http://xbrl.sec.gov/country/2021",
     "presentation": [
      "http://www.evolenthealth.com/role/LeasesPrimaryOfficeLeasesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.evolenthealth.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AuditorFirmId": {
     "auth_ref": [
      "r925",
      "r926",
      "r927"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "PCAOB issued Audit Firm Identifier",
        "label": "Auditor Firm ID",
        "terseLabel": "Auditor Firm ID"
       }
      }
     },
     "localname": "AuditorFirmId",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.evolenthealth.com/role/AuditInformation"
     ],
     "xbrltype": "nonemptySequenceNumberItemType"
    },
    "dei_AuditorLocation": {
     "auth_ref": [
      "r925",
      "r926",
      "r927"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Location",
        "terseLabel": "Auditor Location"
       }
      }
     },
     "localname": "AuditorLocation",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.evolenthealth.com/role/AuditInformation"
     ],
     "xbrltype": "internationalNameItemType"
    },
    "dei_AuditorName": {
     "auth_ref": [
      "r925",
      "r926",
      "r927"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Name",
        "terseLabel": "Auditor Name"
       }
      }
     },
     "localname": "AuditorName",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.evolenthealth.com/role/AuditInformation"
     ],
     "xbrltype": "internationalNameItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.evolenthealth.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]",
        "terseLabel": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.evolenthealth.com/role/CoverPage"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentAnnualReport": {
     "auth_ref": [
      "r925",
      "r926",
      "r927"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an annual report.",
        "label": "Document Annual Report",
        "terseLabel": "Document Annual Report"
       }
      }
     },
     "localname": "DocumentAnnualReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.evolenthealth.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.evolenthealth.com/role/CoverPage"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.evolenthealth.com/role/CoverPage"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.evolenthealth.com/role/CoverPage"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r928"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report",
        "terseLabel": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.evolenthealth.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.evolenthealth.com/role/CoverPage"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "auth_ref": [
      "r923"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Documents incorporated by reference.",
        "label": "Documents Incorporated by Reference [Text Block]",
        "terseLabel": "Documents Incorporated by Reference"
       }
      }
     },
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.evolenthealth.com/role/CoverPage"
     ],
     "xbrltype": "textBlockItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.evolenthealth.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address, Address Line Two",
        "terseLabel": "Entity Address, Address Line Two"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.evolenthealth.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.evolenthealth.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.evolenthealth.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.evolenthealth.com/role/CoverPage"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r922"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.evolenthealth.com/role/CoverPage"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding",
        "terseLabel": "Entity Common Stock, Shares Outstanding (in shares)"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.evolenthealth.com/role/CoverPage"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.evolenthealth.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r922"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.evolenthealth.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.evolenthealth.com/role/CoverPage"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r922"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.evolenthealth.com/role/CoverPage"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.evolenthealth.com/role/CoverPage"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r930"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current",
        "terseLabel": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.evolenthealth.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityPublicFloat": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.",
        "label": "Entity Public Float",
        "terseLabel": "Entity Public Float"
       }
      }
     },
     "localname": "EntityPublicFloat",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.evolenthealth.com/role/CoverPage"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r922"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.evolenthealth.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r922"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.evolenthealth.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r922"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business",
        "terseLabel": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.evolenthealth.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r922"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.evolenthealth.com/role/CoverPage"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_EntityVoluntaryFilers": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.",
        "label": "Entity Voluntary Filers",
        "terseLabel": "Entity Voluntary Filers"
       }
      }
     },
     "localname": "EntityVoluntaryFilers",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.evolenthealth.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "auth_ref": [
      "r931"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.",
        "label": "Entity Well-known Seasoned Issuer",
        "terseLabel": "Entity Well-known Seasoned Issuer"
       }
      }
     },
     "localname": "EntityWellKnownSeasonedIssuer",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.evolenthealth.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_IcfrAuditorAttestationFlag": {
     "auth_ref": [
      "r925",
      "r926",
      "r927"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ICFR Auditor Attestation Flag",
        "terseLabel": "ICFR Auditor Attestation Flag"
       }
      }
     },
     "localname": "IcfrAuditorAttestationFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.evolenthealth.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.evolenthealth.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r921"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.evolenthealth.com/role/CoverPage"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r924"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.evolenthealth.com/role/CoverPage"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.evolenthealth.com/role/CoverPage"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "evh_AccountsReceivableAllowanceForCreditLossAcquiredDuringPeriod": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accounts Receivable, Allowance for Credit Loss, Acquired During Period",
        "label": "Accounts Receivable, Allowance for Credit Loss, Acquired During Period",
        "negatedLabel": "Passport acquisition"
       }
      }
     },
     "localname": "AccountsReceivableAllowanceForCreditLossAcquiredDuringPeriod",
     "nsuri": "http://www.evolenthealth.com/20211231",
     "presentation": [
      "http://www.evolenthealth.com/role/CreditLossesScheduleofChangesinAllowanceforAccountsReceivableDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "evh_AccruedPropertyAndEquipmentPurchases": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued Property And Equipment Purchases",
        "label": "Accrued Property And Equipment Purchases",
        "negatedTerseLabel": "Accrued property and equipment purchases"
       }
      }
     },
     "localname": "AccruedPropertyAndEquipmentPurchases",
     "nsuri": "http://www.evolenthealth.com/20211231",
     "presentation": [
      "http://www.evolenthealth.com/role/SupplementalCashFlowInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "evh_AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Adjusted Earnings Before Interest, Taxes, Depreciation And Amortization",
        "label": "Adjusted Earnings Before Interest, Taxes, Depreciation And Amortization",
        "terseLabel": "Adjusted EBITDA"
       }
      }
     },
     "localname": "AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization",
     "nsuri": "http://www.evolenthealth.com/20211231",
     "presentation": [
      "http://www.evolenthealth.com/role/SegmentReportingReconciliationofAdjustedEBITDADetails",
      "http://www.evolenthealth.com/role/SegmentReportingRevenuefromSegmentstoConsolidatedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "evh_AdjustmentsToAdditionalPaidInCapitalAcquisitions": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Adjustments To Additional Paid In Capital, Acquisitions",
        "label": "Adjustments To Additional Paid In Capital, Acquisitions",
        "terseLabel": "Amount attributable to NCI from business combination"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalAcquisitions",
     "nsuri": "http://www.evolenthealth.com/20211231",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "evh_AggregateIntrinsicValueAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate Intrinsic Value [Abstract]",
        "label": "Aggregate Intrinsic Value [Abstract]",
        "terseLabel": "Aggregate Intrinsic Value"
       }
      }
     },
     "localname": "AggregateIntrinsicValueAbstract",
     "nsuri": "http://www.evolenthealth.com/20211231",
     "presentation": [
      "http://www.evolenthealth.com/role/StockbasedCompensationPerformancebasedStockOptionAwardsDetails",
      "http://www.evolenthealth.com/role/StockbasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "evh_AmortizationOfDebtDiscountAndDebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortization Of Debt Discount And Debt Issuance Costs Incurred During Noncash Or Partial Noncash Transaction",
        "label": "Amortization Of Debt Discount And Debt Issuance Costs Incurred During Noncash Or Partial Noncash Transaction",
        "terseLabel": "Non-cash amortization of debt discount and debt issuance costs"
       }
      }
     },
     "localname": "AmortizationOfDebtDiscountAndDebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction",
     "nsuri": "http://www.evolenthealth.com/20211231",
     "presentation": [
      "http://www.evolenthealth.com/role/LongtermDebt2024NotesDetails",
      "http://www.evolenthealth.com/role/LongtermDebt2025NotesDetails",
      "http://www.evolenthealth.com/role/LongtermDebtCreditAgreementDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "evh_AssetAcquisitionAccruedLiabilities": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Asset Acquisition, Accrued Liabilities",
        "label": "Asset Acquisition, Accrued Liabilities",
        "terseLabel": "Accrued liabilities"
       }
      }
     },
     "localname": "AssetAcquisitionAccruedLiabilities",
     "nsuri": "http://www.evolenthealth.com/20211231",
     "presentation": [
      "http://www.evolenthealth.com/role/TransactionsEquityInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "evh_AssetAcquisitionAccruedMedicalExpenses": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Asset Acquisition, Accrued Medical Expenses",
        "label": "Asset Acquisition, Accrued Medical Expenses",
        "terseLabel": "Accrued medical expenses"
       }
      }
     },
     "localname": "AssetAcquisitionAccruedMedicalExpenses",
     "nsuri": "http://www.evolenthealth.com/20211231",
     "presentation": [
      "http://www.evolenthealth.com/role/TransactionsEquityInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "evh_AssetAcquisitionCashAndEquivalents": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Asset Acquisition, Cash And Equivalents",
        "label": "Asset Acquisition, Cash And Equivalents",
        "terseLabel": "Cash and equivalents"
       }
      }
     },
     "localname": "AssetAcquisitionCashAndEquivalents",
     "nsuri": "http://www.evolenthealth.com/20211231",
     "presentation": [
      "http://www.evolenthealth.com/role/TransactionsEquityInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "evh_AssetAcquisitionDebtSecuritiesAvailableForSale": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Asset Acquisition, Debt Securities, Available-For-Sale",
        "label": "Asset Acquisition, Debt Securities, Available-For-Sale",
        "terseLabel": "Debt securities, available-for-sale"
       }
      }
     },
     "localname": "AssetAcquisitionDebtSecuritiesAvailableForSale",
     "nsuri": "http://www.evolenthealth.com/20211231",
     "presentation": [
      "http://www.evolenthealth.com/role/TransactionsEquityInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "evh_AssetAcquisitionDebtSecuritiesAvailableForSaleUnsettledSalesReceivables": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Asset Acquisition, Debt Securities, Available-For-Sale, Unsettled Sales Receivables",
        "label": "Asset Acquisition, Debt Securities, Available-For-Sale, Unsettled Sales Receivables",
        "terseLabel": "Receivables related to unsettled sales of securities"
       }
      }
     },
     "localname": "AssetAcquisitionDebtSecuritiesAvailableForSaleUnsettledSalesReceivables",
     "nsuri": "http://www.evolenthealth.com/20211231",
     "presentation": [
      "http://www.evolenthealth.com/role/TransactionsEquityInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "evh_AssetAcquisitionOtherAssets": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Asset Acquisition, Other Assets",
        "label": "Asset Acquisition, Other Assets",
        "terseLabel": "Other assets"
       }
      }
     },
     "localname": "AssetAcquisitionOtherAssets",
     "nsuri": "http://www.evolenthealth.com/20211231",
     "presentation": [
      "http://www.evolenthealth.com/role/TransactionsEquityInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "evh_AssetPurchaseAgreementEscrowPayments": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Asset Purchase Agreement, Escrow Payments",
        "label": "Asset Purchase Agreement, Escrow Payments",
        "terseLabel": "Asset Purchase Agreement, escrow payments"
       }
      }
     },
     "localname": "AssetPurchaseAgreementEscrowPayments",
     "nsuri": "http://www.evolenthealth.com/20211231",
     "presentation": [
      "http://www.evolenthealth.com/role/TransactionsEquityInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "evh_AssumedLiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseImpactOfConsolidationOnPayables": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Assumed Liability For Unpaid Claims And Claims Adjustment Expense, Impact Of Consolidation On Payables",
        "label": "Assumed Liability For Unpaid Claims And Claims Adjustment Expense, Impact Of Consolidation On Payables",
        "negatedTerseLabel": "Impact of consolidation on payable for claims and performance-based arrangements attributable to the Reinsurance Agreement"
       }
      }
     },
     "localname": "AssumedLiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseImpactOfConsolidationOnPayables",
     "nsuri": "http://www.evolenthealth.com/20211231",
     "presentation": [
      "http://www.evolenthealth.com/role/CommitmentsandContingenciesReinsuranceAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "evh_AuditInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Audit Information [Abstract]",
        "label": "Audit Information [Abstract]"
       }
      }
     },
     "localname": "AuditInformationAbstract",
     "nsuri": "http://www.evolenthealth.com/20211231",
     "xbrltype": "stringItemType"
    },
    "evh_BelowMarketLeasesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Below Market Leases [Member]",
        "label": "Below Market Leases [Member]",
        "terseLabel": "Below market lease, net"
       }
      }
     },
     "localname": "BelowMarketLeasesMember",
     "nsuri": "http://www.evolenthealth.com/20211231",
     "presentation": [
      "http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNetIntangibleAssetsNetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "evh_BonusesAndCommissionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Bonuses And Commissions [Member]",
        "label": "Bonuses And Commissions [Member]",
        "terseLabel": "Bonuses and Commissions"
       }
      }
     },
     "localname": "BonusesAndCommissionsMember",
     "nsuri": "http://www.evolenthealth.com/20211231",
     "presentation": [
      "http://www.evolenthealth.com/role/RevenueRecognitionContractCostsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "evh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedTangibleAssets": {
     "auth_ref": [],
     "calculation": {
      "http://www.evolenthealth.com/role/TransactionsVitalDecisionsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Tangible Assets",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Tangible Assets",
        "totalLabel": "Total tangible assets acquired"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedTangibleAssets",
     "nsuri": "http://www.evolenthealth.com/20211231",
     "presentation": [
      "http://www.evolenthealth.com/role/TransactionsVitalDecisionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "evh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesAccruedCompensationAndEmployeeBenefits": {
     "auth_ref": [],
     "calculation": {
      "http://www.evolenthealth.com/role/TransactionsVitalDecisionsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Accrued Compensation And Employee Benefits",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Accrued Compensation And Employee Benefits",
        "terseLabel": "Accrued compensation and employee benefits"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesAccruedCompensationAndEmployeeBenefits",
     "nsuri": "http://www.evolenthealth.com/20211231",
     "presentation": [
      "http://www.evolenthealth.com/role/TransactionsVitalDecisionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "evh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesAccruedLiabilities": {
     "auth_ref": [],
     "calculation": {
      "http://www.evolenthealth.com/role/TransactionsVitalDecisionsDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Accrued Liabilities",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Accrued Liabilities",
        "terseLabel": "Accrued liabilities"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesAccruedLiabilities",
     "nsuri": "http://www.evolenthealth.com/20211231",
     "presentation": [
      "http://www.evolenthealth.com/role/TransactionsVitalDecisionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "evh_CapitalizedContractCostAmortizationPurchaseAccountingAdjustments": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Capitalized Contract Cost, Amortization, Purchase Accounting Adjustments",
        "label": "Capitalized Contract Cost, Amortization, Purchase Accounting Adjustments",
        "negatedLabel": "Amortization of contract cost assets"
       }
      }
     },
     "localname": "CapitalizedContractCostAmortizationPurchaseAccountingAdjustments",
     "nsuri": "http://www.evolenthealth.com/20211231",
     "presentation": [
      "http://www.evolenthealth.com/role/SegmentReportingReconciliationofAdjustedEBITDADetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "evh_CashAndCashEquivalentsAtCarryingValueExcludingDiscontinuedOperations": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash and Cash Equivalents, at Carrying Value, Excluding Discontinued Operations",
        "label": "Cash and Cash Equivalents, at Carrying Value, Excluding Discontinued Operations",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValueExcludingDiscontinuedOperations",
     "nsuri": "http://www.evolenthealth.com/20211231",
     "presentation": [
      "http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesRestrictedCashandRestrictedInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "evh_CashFDICInsuredAmountPercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash, FDIC Insured Amount, Percentage",
        "label": "Cash, FDIC Insured Amount, Percentage",
        "terseLabel": "Percentage of cash and cash equivalents held with FDIC participating bank"
       }
      }
     },
     "localname": "CashFDICInsuredAmountPercentage",
     "nsuri": "http://www.evolenthealth.com/20211231",
     "presentation": [
      "http://www.evolenthealth.com/role/CommitmentsandContingenciesConcentrationRiskDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "evh_CashFlowLesseeAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash Flow, Lessee [Abstract]",
        "label": "Cash Flow, Lessee [Abstract]",
        "terseLabel": "Effects of Leases"
       }
      }
     },
     "localname": "CashFlowLesseeAbstract",
     "nsuri": "http://www.evolenthealth.com/20211231",
     "presentation": [
      "http://www.evolenthealth.com/role/SupplementalCashFlowInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "evh_CashHeldInInternationalBanksPercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash, Held In International Banks, Percentage",
        "label": "Cash, Held In International Banks, Percentage",
        "terseLabel": "Percentage of cash held in international banks (less than)"
       }
      }
     },
     "localname": "CashHeldInInternationalBanksPercentage",
     "nsuri": "http://www.evolenthealth.com/20211231",
     "presentation": [
      "http://www.evolenthealth.com/role/CommitmentsandContingenciesConcentrationRiskDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "evh_CashReleasedFromEscrow": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash Released From Escrow",
        "label": "Cash Released From Escrow",
        "terseLabel": "Cash released from escrow"
       }
      }
     },
     "localname": "CashReleasedFromEscrow",
     "nsuri": "http://www.evolenthealth.com/20211231",
     "presentation": [
      "http://www.evolenthealth.com/role/TransactionsEquityInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "evh_ChangeInContractWithCustomerLiabilityRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Change In Contract With Customer, Liability [Roll Forward]",
        "label": "Change In Contract With Customer, Liability [Roll Forward]",
        "terseLabel": "Deferred revenue"
       }
      }
     },
     "localname": "ChangeInContractWithCustomerLiabilityRollForward",
     "nsuri": "http://www.evolenthealth.com/20211231",
     "presentation": [
      "http://www.evolenthealth.com/role/RevenueRecognitionContractBalancesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "evh_ClassOfWarrantOrRightPeriodDuringWhichWarrantsOrRightsExercisableAfterMaturityOfCreditAgreement": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Class Of Warrant Or Right, Period During Which Warrants Or Rights Exercisable, After Maturity Of Credit Agreement",
        "label": "Class Of Warrant Or Right, Period During Which Warrants Or Rights Exercisable, After Maturity Of Credit Agreement",
        "terseLabel": "Period during which warrants or rights exercisable, after maturity of credit agreement"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightPeriodDuringWhichWarrantsOrRightsExercisableAfterMaturityOfCreditAgreement",
     "nsuri": "http://www.evolenthealth.com/20211231",
     "presentation": [
      "http://www.evolenthealth.com/role/LongtermDebtWarrantAgreementDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "evh_ClinicalSolutionsSegmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Clinical Solutions Segment",
        "label": "Clinical Solutions Segment [Member]",
        "terseLabel": "Clinical Solutions"
       }
      }
     },
     "localname": "ClinicalSolutionsSegmentMember",
     "nsuri": "http://www.evolenthealth.com/20211231",
     "presentation": [
      "http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNetScheduleofGoodwillDetails",
      "http://www.evolenthealth.com/role/ReservesforClaimsandPerformanceBasedArrangementsDetails",
      "http://www.evolenthealth.com/role/RevenueRecognitionDisaggregationofRevenueDetails",
      "http://www.evolenthealth.com/role/SegmentReportingRevenuefromSegmentstoConsolidatedDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "evh_CollateralwithFinancialInstitutionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collateral with Financial Institutions [Member]",
        "label": "Collateral with Financial Institutions [Member]",
        "terseLabel": "Collateral with financial institutions"
       }
      }
     },
     "localname": "CollateralwithFinancialInstitutionsMember",
     "nsuri": "http://www.evolenthealth.com/20211231",
     "presentation": [
      "http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesRestrictedCashandRestrictedInvestmentsDetails",
      "http://www.evolenthealth.com/role/CommitmentsandContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "evh_CommercialAndOtherCustomersMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commercial And Other Customers",
        "label": "Commercial And Other Customers [Member]",
        "terseLabel": "Commercial and other"
       }
      }
     },
     "localname": "CommercialAndOtherCustomersMember",
     "nsuri": "http://www.evolenthealth.com/20211231",
     "presentation": [
      "http://www.evolenthealth.com/role/RevenueRecognitionDisaggregationofRevenueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "evh_ContractFulfillmentCostsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contract Fulfillment Costs [Member]",
        "label": "Contract Fulfillment Costs [Member]",
        "terseLabel": "Contract Fulfillment Costs"
       }
      }
     },
     "localname": "ContractFulfillmentCostsMember",
     "nsuri": "http://www.evolenthealth.com/20211231",
     "presentation": [
      "http://www.evolenthealth.com/role/RevenueRecognitionContractCostsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "evh_ContractWithCustomerLiabilityCashReceivedInAdvanceOfSatisfactionOfPerformanceObligations": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contract With Customer, Liability, Cash Received In Advance Of Satisfaction Of Performance Obligations",
        "label": "Contract With Customer, Liability, Cash Received In Advance Of Satisfaction Of Performance Obligations",
        "terseLabel": "Cash received in advance of satisfaction of performance obligations"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityCashReceivedInAdvanceOfSatisfactionOfPerformanceObligations",
     "nsuri": "http://www.evolenthealth.com/20211231",
     "presentation": [
      "http://www.evolenthealth.com/role/RevenueRecognitionContractBalancesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "evh_ConversionOfStockAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Conversion Of Stock [Abstract",
        "label": "Conversion Of Stock [Abstract]",
        "terseLabel": "Effects of Class B Exchanges"
       }
      }
     },
     "localname": "ConversionOfStockAbstract",
     "nsuri": "http://www.evolenthealth.com/20211231",
     "presentation": [
      "http://www.evolenthealth.com/role/SupplementalCashFlowInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "evh_ConvertibleSeniorNotesdue2021Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Convertible Senior Notes due 2021 [Member]",
        "label": "Convertible Senior Notes due 2021 [Member]",
        "terseLabel": "2021 Notes"
       }
      }
     },
     "localname": "ConvertibleSeniorNotesdue2021Member",
     "nsuri": "http://www.evolenthealth.com/20211231",
     "presentation": [
      "http://www.evolenthealth.com/role/LongtermDebt2021NotesDetails",
      "http://www.evolenthealth.com/role/LongtermDebt2024NotesDetails",
      "http://www.evolenthealth.com/role/LongtermDebtConvertibleSeniorNotesCarryingValueDetails",
      "http://www.evolenthealth.com/role/LongtermDebtCreditAgreementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "evh_CookCountyHealthAndHospitalsSystemMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cook County Health And Hospitals System [Member]",
        "label": "Cook County Health And Hospitals System [Member]",
        "terseLabel": "Cook County Health and Hospitals System"
       }
      }
     },
     "localname": "CookCountyHealthAndHospitalsSystemMember",
     "nsuri": "http://www.evolenthealth.com/20211231",
     "presentation": [
      "http://www.evolenthealth.com/role/CommitmentsandContingenciesConcentrationRiskDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "evh_CostofGoodsandServicesSoldExcludingDepreciationandAmortization": {
     "auth_ref": [],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS": {
       "order": 7.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cost of Goods and Services Sold, Excluding Depreciation and Amortization",
        "label": "Cost of Goods and Services Sold, Excluding Depreciation and Amortization",
        "terseLabel": "Cost of revenue (exclusive of depreciation and amortization expenses presented separately below)",
        "verboseLabel": "Cost of revenue (exclusive of depreciation and amortization expenses)"
       }
      }
     },
     "localname": "CostofGoodsandServicesSoldExcludingDepreciationandAmortization",
     "nsuri": "http://www.evolenthealth.com/20211231",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS",
      "http://www.evolenthealth.com/role/RelatedPartiesRevenuesandExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "evh_CreditAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Credit Agreement [Member]",
        "label": "Credit Agreement [Member]",
        "terseLabel": "Credit Agreement"
       }
      }
     },
     "localname": "CreditAgreementMember",
     "nsuri": "http://www.evolenthealth.com/20211231",
     "presentation": [
      "http://www.evolenthealth.com/role/LongtermDebtCreditAgreementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "evh_CurrentYearClaimsAndClaimsAdjustmentExpenseIncludingCostOfGoodsAndServicesSoldExcludingDepreciationAndAmortization": {
     "auth_ref": [],
     "calculation": {
      "http://www.evolenthealth.com/role/ReservesforClaimsandPerformanceBasedArrangementsDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpensePeriodIncreaseDecrease",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Current Year Claims And Claims Adjustment Expense, Including Cost Of Goods And Services Sold, Excluding Depreciation And Amortization",
        "label": "Current Year Claims And Claims Adjustment Expense, Including Cost Of Goods And Services Sold, Excluding Depreciation And Amortization",
        "verboseLabel": "Incurred costs related to current year"
       }
      }
     },
     "localname": "CurrentYearClaimsAndClaimsAdjustmentExpenseIncludingCostOfGoodsAndServicesSoldExcludingDepreciationAndAmortization",
     "nsuri": "http://www.evolenthealth.com/20211231",
     "presentation": [
      "http://www.evolenthealth.com/role/ReservesforClaimsandPerformanceBasedArrangementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "evh_DebtConversionOriginalDebtFairValue": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Conversion, Original Debt, Fair Value",
        "label": "Debt Conversion, Original Debt, Fair Value",
        "terseLabel": "Debt conversion, original debt, fair value"
       }
      }
     },
     "localname": "DebtConversionOriginalDebtFairValue",
     "nsuri": "http://www.evolenthealth.com/20211231",
     "presentation": [
      "http://www.evolenthealth.com/role/LongtermDebt2021NotesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "evh_DebtInstrumentRedemptionCallProtectionPremiumPercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Redemption, Call Protection Premium, Percentage",
        "label": "Debt Instrument, Redemption, Call Protection Premium, Percentage",
        "terseLabel": "Redemption, call protection premium, percentage"
       }
      }
     },
     "localname": "DebtInstrumentRedemptionCallProtectionPremiumPercentage",
     "nsuri": "http://www.evolenthealth.com/20211231",
     "presentation": [
      "http://www.evolenthealth.com/role/LongtermDebtCreditAgreementDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "evh_DebtInstrumentRepurchaseCovenantConsecutiveTradingDaysMinimum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Repurchase Covenant, Consecutive Trading Days, Minimum",
        "label": "Debt Instrument, Repurchase Covenant, Consecutive Trading Days, Minimum",
        "terseLabel": "Repurchase covenant, consecutive trading days, minimum"
       }
      }
     },
     "localname": "DebtInstrumentRepurchaseCovenantConsecutiveTradingDaysMinimum",
     "nsuri": "http://www.evolenthealth.com/20211231",
     "presentation": [
      "http://www.evolenthealth.com/role/LongtermDebt2024NotesDetails",
      "http://www.evolenthealth.com/role/LongtermDebt2025NotesDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "evh_DebtInstrumentRepurchaseCovenantSalePriceAsAPercentageOfConversionPrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Repurchase Covenant, Sale Price As A Percentage Of Conversion Price",
        "label": "Debt Instrument, Repurchase Covenant, Sale Price As A Percentage Of Conversion Price",
        "terseLabel": "Repurchase covenant, sale price as a percentage of conversion price",
        "verboseLabel": "Repurchase covenant, sale price as a percentage of conversion price (at least)"
       }
      }
     },
     "localname": "DebtInstrumentRepurchaseCovenantSalePriceAsAPercentageOfConversionPrice",
     "nsuri": "http://www.evolenthealth.com/20211231",
     "presentation": [
      "http://www.evolenthealth.com/role/LongtermDebt2024NotesDetails",
      "http://www.evolenthealth.com/role/LongtermDebt2025NotesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "evh_DebtInstrumentRepurchaseCovenantTradingDaysMinimum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Repurchase Covenant, Trading Days, Minimum",
        "label": "Debt Instrument, Repurchase Covenant, Trading Days, Minimum",
        "terseLabel": "Repurchase covenant, trading days, minimum"
       }
      }
     },
     "localname": "DebtInstrumentRepurchaseCovenantTradingDaysMinimum",
     "nsuri": "http://www.evolenthealth.com/20211231",
     "presentation": [
      "http://www.evolenthealth.com/role/LongtermDebt2024NotesDetails",
      "http://www.evolenthealth.com/role/LongtermDebt2025NotesDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "evh_DebtInstrumentRepurchasePriceDueToChangeInSalePriceAsPercentageOfConversionPrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Repurchase Price Due To Change In Sale Price As Percentage Of Conversion Price",
        "label": "Debt Instrument, Repurchase Price Due To Change In Sale Price As Percentage Of Conversion Price",
        "terseLabel": "Repurchase covenant, repurchase price due to change in sale price as percentage of conversion price"
       }
      }
     },
     "localname": "DebtInstrumentRepurchasePriceDueToChangeInSalePriceAsPercentageOfConversionPrice",
     "nsuri": "http://www.evolenthealth.com/20211231",
     "presentation": [
      "http://www.evolenthealth.com/role/LongtermDebt2024NotesDetails",
      "http://www.evolenthealth.com/role/LongtermDebt2025NotesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "evh_DebtInstrumentRepurchasePriceDueToFundamentalChangeAsPercentageOfPrincipalAmount": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Repurchase Price Due To Fundamental Change As Percentage Of Principal Amount",
        "label": "Debt Instrument, Repurchase Price Due To Fundamental Change As Percentage Of Principal Amount",
        "verboseLabel": "Repurchase covenant, repurchase price due to fundamental change as percentage of principal amount"
       }
      }
     },
     "localname": "DebtInstrumentRepurchasePriceDueToFundamentalChangeAsPercentageOfPrincipalAmount",
     "nsuri": "http://www.evolenthealth.com/20211231",
     "presentation": [
      "http://www.evolenthealth.com/role/LongtermDebt2021NotesDetails",
      "http://www.evolenthealth.com/role/LongtermDebt2024NotesDetails",
      "http://www.evolenthealth.com/role/LongtermDebt2025NotesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "evh_DebtIssuanceCostsNetDebtComponent": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Issuance Costs, Net, Debt Component",
        "label": "Debt Issuance Costs, Net, Debt Component",
        "terseLabel": "Debt issuance costs, net, debt component"
       }
      }
     },
     "localname": "DebtIssuanceCostsNetDebtComponent",
     "nsuri": "http://www.evolenthealth.com/20211231",
     "presentation": [
      "http://www.evolenthealth.com/role/LongtermDebt2024NotesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "evh_DeferredTaxAssetOutsideBasisDifferences": {
     "auth_ref": [],
     "calculation": {
      "http://www.evolenthealth.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 10.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred Tax Asset, Outside Basis Differences",
        "label": "Deferred Tax Asset, Outside Basis Differences",
        "terseLabel": "Outside basis differences"
       }
      }
     },
     "localname": "DeferredTaxAssetOutsideBasisDifferences",
     "nsuri": "http://www.evolenthealth.com/20211231",
     "presentation": [
      "http://www.evolenthealth.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "evh_DeferredTaxAssetsOperatingLeaseRightOfUseAsset": {
     "auth_ref": [],
     "calculation": {
      "http://www.evolenthealth.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred Tax Assets, Operating Lease, Right-of-Use Asset",
        "label": "Deferred Tax Assets, Operating Lease, Right-of-Use Asset",
        "terseLabel": "Operating lease liabilities"
       }
      }
     },
     "localname": "DeferredTaxAssetsOperatingLeaseRightOfUseAsset",
     "nsuri": "http://www.evolenthealth.com/20211231",
     "presentation": [
      "http://www.evolenthealth.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "evh_DeferredTaxAssetsStartupandOrganizationalCosts": {
     "auth_ref": [],
     "calculation": {
      "http://www.evolenthealth.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 7.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred Tax Assets, Start-up and Organizational Costs",
        "label": "Deferred Tax Assets, Start-up and Organizational Costs",
        "terseLabel": "Start-up and organizational costs"
       }
      }
     },
     "localname": "DeferredTaxAssetsStartupandOrganizationalCosts",
     "nsuri": "http://www.evolenthealth.com/20211231",
     "presentation": [
      "http://www.evolenthealth.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "evh_DeferredTaxLiabilitiesIndefiniteLivedIntangibleAssets": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred Tax Liabilities, Indefinite-Lived Intangible Assets",
        "label": "Deferred Tax Liabilities, Indefinite-Lived Intangible Assets",
        "terseLabel": "Deferred tax liabilities, indefinite-lived intangible assets"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesIndefiniteLivedIntangibleAssets",
     "nsuri": "http://www.evolenthealth.com/20211231",
     "presentation": [
      "http://www.evolenthealth.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "evh_DelayedDrawTermLoanFacilityMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Delayed Draw Term Loan Facility [Member]",
        "label": "Delayed Draw Term Loan Facility [Member]",
        "terseLabel": "DDTL Facility"
       }
      }
     },
     "localname": "DelayedDrawTermLoanFacilityMember",
     "nsuri": "http://www.evolenthealth.com/20211231",
     "presentation": [
      "http://www.evolenthealth.com/role/LongtermDebtCreditAgreementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "evh_DiscontinuedOperationGainLossOnPurchasePriceAdjustmentsNetOfTax": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Discontinued Operation, Gain (Loss) on Purchase Price Adjustments, Net of Tax",
        "label": "Discontinued Operation, Gain (Loss) on Purchase Price Adjustments, Net of Tax",
        "negatedLabel": "Loss on purchase price adjustments"
       }
      }
     },
     "localname": "DiscontinuedOperationGainLossOnPurchasePriceAdjustmentsNetOfTax",
     "nsuri": "http://www.evolenthealth.com/20211231",
     "presentation": [
      "http://www.evolenthealth.com/role/DiscontinuedOperationsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "evh_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNetAfterGrossUp": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disposal Group, Including Discontinued Operation, Accounts, Notes And Loans Receivable, Net, After Gross-Up",
        "label": "Disposal Group, Including Discontinued Operation, Accounts, Notes And Loans Receivable, Net, After Gross-Up",
        "terseLabel": "Accounts receivable, net, after gross-up"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNetAfterGrossUp",
     "nsuri": "http://www.evolenthealth.com/20211231",
     "presentation": [
      "http://www.evolenthealth.com/role/RevenueRecognitionContractBalancesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "evh_DisposalGroupIncludingDiscontinuedOperationAccruedCompensationAndEmployeeBenefitsCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.evolenthealth.com/role/DiscontinuedOperationsSummaryofCurrentandLongtermAssetsandLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disposal Group, Including Discontinued Operation, Accrued Compensation And Employee Benefits, Current",
        "label": "Disposal Group, Including Discontinued Operation, Accrued Compensation And Employee Benefits, Current",
        "terseLabel": "Accrued compensation and employee benefits"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationAccruedCompensationAndEmployeeBenefitsCurrent",
     "nsuri": "http://www.evolenthealth.com/20211231",
     "presentation": [
      "http://www.evolenthealth.com/role/DiscontinuedOperationsSummaryofCurrentandLongtermAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "evh_DisposalGroupIncludingDiscontinuedOperationClaimsExpense": {
     "auth_ref": [],
     "calculation": {
      "http://www.evolenthealth.com/role/DiscontinuedOperationsSummaryofResultsofOperationsDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disposal Group, Including Discontinued Operation, Claims Expense",
        "label": "Disposal Group, Including Discontinued Operation, Claims Expense",
        "terseLabel": "Claims expenses"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationClaimsExpense",
     "nsuri": "http://www.evolenthealth.com/20211231",
     "presentation": [
      "http://www.evolenthealth.com/role/DiscontinuedOperationsSummaryofResultsofOperationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "evh_DisposalGroupIncludingDiscontinuedOperationInvestmentsCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.evolenthealth.com/role/DiscontinuedOperationsSummaryofCurrentandLongtermAssetsandLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disposal Group, Including Discontinued Operation, Investments, Current",
        "label": "Disposal Group, Including Discontinued Operation, Investments, Current",
        "terseLabel": "Investments, at amortized cost"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationInvestmentsCurrent",
     "nsuri": "http://www.evolenthealth.com/20211231",
     "presentation": [
      "http://www.evolenthealth.com/role/DiscontinuedOperationsSummaryofCurrentandLongtermAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "evh_DisposalGroupIncludingDiscontinuedOperationInvestmentsNoncurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.evolenthealth.com/role/DiscontinuedOperationsSummaryofCurrentandLongtermAssetsandLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disposal Group, Including Discontinued Operation, Investments, Noncurrent",
        "label": "Disposal Group, Including Discontinued Operation, Investments, Noncurrent",
        "terseLabel": "Investments, at amortized cost"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationInvestmentsNoncurrent",
     "nsuri": "http://www.evolenthealth.com/20211231",
     "presentation": [
      "http://www.evolenthealth.com/role/DiscontinuedOperationsSummaryofCurrentandLongtermAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "evh_DisposalGroupIncludingDiscontinuedOperationLiabilityForFuturePolicyBenefitsAndUnpaidClaimsAndClaimsAdjustmentExpenseAndPerformanceBasedArrangementsCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.evolenthealth.com/role/DiscontinuedOperationsSummaryofCurrentandLongtermAssetsandLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disposal Group, Including Discontinued Operation, Liability For Future Policy Benefits And Unpaid Claims And Claims Adjustment Expense And Performance-Based Arrangements, Current",
        "label": "Disposal Group, Including Discontinued Operation, Liability For Future Policy Benefits And Unpaid Claims And Claims Adjustment Expense And Performance-Based Arrangements, Current",
        "terseLabel": "Reserve for claims and performance-based arrangements"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationLiabilityForFuturePolicyBenefitsAndUnpaidClaimsAndClaimsAdjustmentExpenseAndPerformanceBasedArrangementsCurrent",
     "nsuri": "http://www.evolenthealth.com/20211231",
     "presentation": [
      "http://www.evolenthealth.com/role/DiscontinuedOperationsSummaryofCurrentandLongtermAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "evh_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsNoncurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.evolenthealth.com/role/DiscontinuedOperationsSummaryofCurrentandLongtermAssetsandLiabilitiesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disposal Group, Including Discontinued Operation, Prepaid And Other Assets, Noncurrent",
        "label": "Disposal Group, Including Discontinued Operation, Prepaid And Other Assets, Noncurrent",
        "terseLabel": "Prepaid expenses and other noncurrent assets"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsNoncurrent",
     "nsuri": "http://www.evolenthealth.com/20211231",
     "presentation": [
      "http://www.evolenthealth.com/role/DiscontinuedOperationsSummaryofCurrentandLongtermAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "evh_DisposalGroupIncludingDiscontinuedOperationRestrictedCashAndRestrictedInvestmentsCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.evolenthealth.com/role/DiscontinuedOperationsSummaryofCurrentandLongtermAssetsandLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disposal Group, Including Discontinued Operation, Restricted Cash And Restricted Investments, Current",
        "label": "Disposal Group, Including Discontinued Operation, Restricted Cash And Restricted Investments, Current",
        "terseLabel": "Restricted cash and restricted investments"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationRestrictedCashAndRestrictedInvestmentsCurrent",
     "nsuri": "http://www.evolenthealth.com/20211231",
     "presentation": [
      "http://www.evolenthealth.com/role/DiscontinuedOperationsSummaryofCurrentandLongtermAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "evh_DisposalGroupIncludingDiscontinuedOperationRestrictedCashAndRestrictedInvestmentsNoncurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.evolenthealth.com/role/DiscontinuedOperationsSummaryofCurrentandLongtermAssetsandLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disposal Group, Including Discontinued Operation, Restricted Cash And Restricted Investments, Noncurrent",
        "label": "Disposal Group, Including Discontinued Operation, Restricted Cash And Restricted Investments, Noncurrent",
        "terseLabel": "Restricted cash and restricted investments"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationRestrictedCashAndRestrictedInvestmentsNoncurrent",
     "nsuri": "http://www.evolenthealth.com/20211231",
     "presentation": [
      "http://www.evolenthealth.com/role/DiscontinuedOperationsSummaryofCurrentandLongtermAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "evh_DisposalGroupIncludingDiscontinuedOperationRestrictedCashCurrent": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disposal Group, Including Discontinued Operation, Restricted Cash, Current",
        "label": "Disposal Group, Including Discontinued Operation, Restricted Cash, Current",
        "terseLabel": "Current restricted cash from claims processing services"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationRestrictedCashCurrent",
     "nsuri": "http://www.evolenthealth.com/20211231",
     "presentation": [
      "http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesRestrictedCashandRestrictedInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "evh_DisposalGroupIncludingDiscontinuedOperationRestrictedInvestmentsNoncurrent": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disposal Group, Including Discontinued Operation, Restricted Investments, Noncurrent",
        "label": "Disposal Group, Including Discontinued Operation, Restricted Investments, Noncurrent",
        "terseLabel": "Non-current restricted investments"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationRestrictedInvestmentsNoncurrent",
     "nsuri": "http://www.evolenthealth.com/20211231",
     "presentation": [
      "http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesRestrictedCashandRestrictedInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "evh_EarningsBeforeInterestTaxesDepreciationAndAmortizationGoalPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Earnings Before Interest, Taxes, Depreciation, and Amortization, Goal Period",
        "label": "Earnings Before Interest, Taxes, Depreciation, and Amortization, Goal Period",
        "terseLabel": "EBITDA, goal period"
       }
      }
     },
     "localname": "EarningsBeforeInterestTaxesDepreciationAndAmortizationGoalPeriod",
     "nsuri": "http://www.evolenthealth.com/20211231",
     "presentation": [
      "http://www.evolenthealth.com/role/StockbasedCompensationPerformancebasedRSUsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "evh_EarningsLossAvailabletoCommonShareholdersAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Earnings (Loss) Available to Common Shareholders [Abstract]",
        "label": "Earnings (Loss) Available to Common Shareholders [Abstract]",
        "verboseLabel": "Less:"
       }
      }
     },
     "localname": "EarningsLossAvailabletoCommonShareholdersAbstract",
     "nsuri": "http://www.evolenthealth.com/20211231",
     "presentation": [
      "http://www.evolenthealth.com/role/EarningsLossPerCommonShareComputationofEarningsperShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "evh_EarningsPerSharePortionAttributableToNoncontrollingInterestBasic": {
     "auth_ref": [],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS": {
       "order": 3.0,
       "parentTag": "us-gaap_EarningsPerShareBasic",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Earnings Per Share, Portion Attributable to Noncontrolling Interest, Basic",
        "label": "Earnings Per Share, Portion Attributable to Noncontrolling Interest, Basic",
        "terseLabel": "Non-controlling interests, basic (in dollars per share)"
       }
      }
     },
     "localname": "EarningsPerSharePortionAttributableToNoncontrollingInterestBasic",
     "nsuri": "http://www.evolenthealth.com/20211231",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS",
      "http://www.evolenthealth.com/role/EarningsLossPerCommonShareComputationofEarningsperShareDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "evh_EarningsPerSharePortionAttributableToNoncontrollingInterestDiluted": {
     "auth_ref": [],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS": {
       "order": 3.0,
       "parentTag": "us-gaap_EarningsPerShareDiluted",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Earnings Per Share, Portion Attributable to Noncontrolling Interest, Diluted",
        "label": "Earnings Per Share, Portion Attributable to Noncontrolling Interest, Diluted",
        "terseLabel": "Non-controlling interests, diluted (in dollars per share)"
       }
      }
     },
     "localname": "EarningsPerSharePortionAttributableToNoncontrollingInterestDiluted",
     "nsuri": "http://www.evolenthealth.com/20211231",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS",
      "http://www.evolenthealth.com/role/EarningsLossPerCommonShareComputationofEarningsperShareDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "evh_EffectiveIncomeTaxRateReconciliationBenefitOfNetOperatingLossCarrybackProvisionPercent": {
     "auth_ref": [],
     "calculation": {
      "http://www.evolenthealth.com/role/IncomeTaxesReconciliationofStatutoryRatetoEffectiveTaxRateDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Effective Income Tax Rate Reconciliation, Benefit Of Net Operating Loss Carryback Provision, Percent",
        "label": "Effective Income Tax Rate Reconciliation, Benefit Of Net Operating Loss Carryback Provision, Percent",
        "terseLabel": "Benefit of net operating loss carryback provision"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationBenefitOfNetOperatingLossCarrybackProvisionPercent",
     "nsuri": "http://www.evolenthealth.com/20211231",
     "presentation": [
      "http://www.evolenthealth.com/role/IncomeTaxesReconciliationofStatutoryRatetoEffectiveTaxRateDetails"
     ],
     "xbrltype": "pureItemType"
    },
    "evh_EffectiveIncomeTaxRateReconciliationChangeInUncertainTaxPositions": {
     "auth_ref": [],
     "calculation": {
      "http://www.evolenthealth.com/role/IncomeTaxesReconciliationofStatutoryRatetoEffectiveTaxRateDetails": {
       "order": 13.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Effective Income Tax Rate Reconciliation, Change In Uncertain Tax Positions",
        "label": "Effective Income Tax Rate Reconciliation, Change In Uncertain Tax Positions",
        "terseLabel": "Change in uncertain tax positions"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationChangeInUncertainTaxPositions",
     "nsuri": "http://www.evolenthealth.com/20211231",
     "presentation": [
      "http://www.evolenthealth.com/role/IncomeTaxesReconciliationofStatutoryRatetoEffectiveTaxRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "evh_EffectiveIncomeTaxRateReconciliationDomesticSubsidiaryException": {
     "auth_ref": [],
     "calculation": {
      "http://www.evolenthealth.com/role/IncomeTaxesReconciliationofStatutoryRatetoEffectiveTaxRateDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Effective Income Tax Rate Reconciliation Domestic Subsidiary Exception",
        "label": "Effective Income Tax Rate Reconciliation Domestic Subsidiary Exception",
        "terseLabel": "Change in indefinite reinvestment assertion for domestic subsidiaries"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationDomesticSubsidiaryException",
     "nsuri": "http://www.evolenthealth.com/20211231",
     "presentation": [
      "http://www.evolenthealth.com/role/IncomeTaxesReconciliationofStatutoryRatetoEffectiveTaxRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "evh_EffectiveIncomeTaxRateReconciliationEffectOfInvestment": {
     "auth_ref": [],
     "calculation": {
      "http://www.evolenthealth.com/role/IncomeTaxesReconciliationofStatutoryRatetoEffectiveTaxRateDetails": {
       "order": 14.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Effective Income Tax Rate Reconciliation Effect Investment Of Investment",
        "label": "Effective Income Tax Rate Reconciliation Effect Of Investment",
        "terseLabel": "Nontaxable earnout"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationEffectOfInvestment",
     "nsuri": "http://www.evolenthealth.com/20211231",
     "presentation": [
      "http://www.evolenthealth.com/role/IncomeTaxesReconciliationofStatutoryRatetoEffectiveTaxRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "evh_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseExcessCompensationPercent": {
     "auth_ref": [],
     "calculation": {
      "http://www.evolenthealth.com/role/IncomeTaxesReconciliationofStatutoryRatetoEffectiveTaxRateDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Excess Compensation, Percent",
        "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Excess Compensation, Percent",
        "terseLabel": "Nondeductible excess compensation"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpenseExcessCompensationPercent",
     "nsuri": "http://www.evolenthealth.com/20211231",
     "presentation": [
      "http://www.evolenthealth.com/role/IncomeTaxesReconciliationofStatutoryRatetoEffectiveTaxRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "evh_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseReturnToProvisionPercent": {
     "auth_ref": [],
     "calculation": {
      "http://www.evolenthealth.com/role/IncomeTaxesReconciliationofStatutoryRatetoEffectiveTaxRateDetails": {
       "order": 9.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Return to Provision, Percent",
        "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Return to Provision, Percent",
        "terseLabel": "Return to provision"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpenseReturnToProvisionPercent",
     "nsuri": "http://www.evolenthealth.com/20211231",
     "presentation": [
      "http://www.evolenthealth.com/role/IncomeTaxesReconciliationofStatutoryRatetoEffectiveTaxRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "evh_EmployeeSeveranceAndTerminationBenefitsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Employee Severance And Termination Benefits",
        "label": "Employee Severance And Termination Benefits [Member]",
        "terseLabel": "Severance and termination benefits"
       }
      }
     },
     "localname": "EmployeeSeveranceAndTerminationBenefitsMember",
     "nsuri": "http://www.evolenthealth.com/20211231",
     "presentation": [
      "http://www.evolenthealth.com/role/RepositioningandOtherChangesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "evh_EquityInterestToBeTransferred": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity Interest To Be Transferred",
        "label": "Equity Interest To Be Transferred",
        "terseLabel": "Equity interest to be transferred"
       }
      }
     },
     "localname": "EquityInterestToBeTransferred",
     "nsuri": "http://www.evolenthealth.com/20211231",
     "presentation": [
      "http://www.evolenthealth.com/role/InvestmentsinEquityMethodInvesteesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "evh_EquityMethodInvestmentEconomicInterestPercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity Method Investment, Economic Interest Percentage",
        "label": "Equity Method Investment, Economic Interest Percentage",
        "terseLabel": "Economic interest percentage"
       }
      }
     },
     "localname": "EquityMethodInvestmentEconomicInterestPercentage",
     "nsuri": "http://www.evolenthealth.com/20211231",
     "presentation": [
      "http://www.evolenthealth.com/role/InvestmentsinEquityMethodInvesteesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "evh_EquityMethodInvestmentVotingInterestPercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity Method Investment, Voting Interest Percentage",
        "label": "Equity Method Investment, Voting Interest Percentage",
        "terseLabel": "Voting interest percentage"
       }
      }
     },
     "localname": "EquityMethodInvestmentVotingInterestPercentage",
     "nsuri": "http://www.evolenthealth.com/20211231",
     "presentation": [
      "http://www.evolenthealth.com/role/InvestmentsinEquityMethodInvesteesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "evh_EvolentHealthLLCMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Evolent Health LLC [Member]",
        "label": "Evolent Health LLC [Member]",
        "terseLabel": "Evolent Health LLC"
       }
      }
     },
     "localname": "EvolentHealthLLCMember",
     "nsuri": "http://www.evolenthealth.com/20211231",
     "presentation": [
      "http://www.evolenthealth.com/role/NoncontrollingInterestsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "evh_EvolentHealthServicesSegmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Evolent Health Services Segment",
        "label": "Evolent Health Services Segment [Member]",
        "terseLabel": "Evolent Health Services"
       }
      }
     },
     "localname": "EvolentHealthServicesSegmentMember",
     "nsuri": "http://www.evolenthealth.com/20211231",
     "presentation": [
      "http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNetScheduleofGoodwillDetails",
      "http://www.evolenthealth.com/role/ReservesforClaimsandPerformanceBasedArrangementsDetails",
      "http://www.evolenthealth.com/role/RevenueRecognitionDisaggregationofRevenueDetails",
      "http://www.evolenthealth.com/role/SegmentReportingRevenuefromSegmentstoConsolidatedDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "evh_FInancialAssetLessThan120DaysPastDueMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "FInancial Asset, Less Than 120 Days Past Due [Member]",
        "label": "FInancial Asset, Less Than 120 Days Past Due [Member]",
        "terseLabel": "Past due less than 120 days"
       }
      }
     },
     "localname": "FInancialAssetLessThan120DaysPastDueMember",
     "nsuri": "http://www.evolenthealth.com/20211231",
     "presentation": [
      "http://www.evolenthealth.com/role/CreditLossesAccountsReceivableNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "evh_FInancialAssetLessThan60DaysMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "FInancial Asset, Less Than 60 Days [Member]",
        "label": "FInancial Asset, Less Than 60 Days [Member]",
        "terseLabel": "Past due less than 60 days"
       }
      }
     },
     "localname": "FInancialAssetLessThan60DaysMember",
     "nsuri": "http://www.evolenthealth.com/20211231",
     "presentation": [
      "http://www.evolenthealth.com/role/CreditLossesAccountsReceivableNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "evh_FinancingReceivablePercentNotPastDue": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Financing Receivable, Percent Not Past Due",
        "label": "Financing Receivable, Percent Not Past Due",
        "terseLabel": "Percentage of receivables, current"
       }
      }
     },
     "localname": "FinancingReceivablePercentNotPastDue",
     "nsuri": "http://www.evolenthealth.com/20211231",
     "presentation": [
      "http://www.evolenthealth.com/role/CreditLossesAccountsReceivableNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "evh_FinitelivedTaxCreditCarryforwardMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Finite-lived Tax Credit Carryforward [Member]",
        "label": "Finite-lived Tax Credit Carryforward [Member]",
        "terseLabel": "Finite-lived Tax Credit Carryforward"
       }
      }
     },
     "localname": "FinitelivedTaxCreditCarryforwardMember",
     "nsuri": "http://www.evolenthealth.com/20211231",
     "presentation": [
      "http://www.evolenthealth.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "evh_FloridaBlueMedicareIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Florida Blue Medicare, Inc.",
        "label": "Florida Blue Medicare, Inc. [Member]",
        "terseLabel": "Florida Blue Medicare, Inc."
       }
      }
     },
     "localname": "FloridaBlueMedicareIncMember",
     "nsuri": "http://www.evolenthealth.com/20211231",
     "presentation": [
      "http://www.evolenthealth.com/role/CommitmentsandContingenciesConcentrationRiskDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "evh_GainLossFromTransferOfMembership": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gain (Loss) from Transfer of Membership",
        "label": "Gain (Loss) from Transfer of Membership",
        "negatedTerseLabel": "Gain from transfer of membership"
       }
      }
     },
     "localname": "GainLossFromTransferOfMembership",
     "nsuri": "http://www.evolenthealth.com/20211231",
     "presentation": [
      "http://www.evolenthealth.com/role/SupplementalCashFlowInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "evh_GainLossOnDispositionOfAssetsOperatingActivities": {
     "auth_ref": [],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gain (Loss) On Disposition Of Assets, Operating Activities",
        "label": "Gain (Loss) On Disposition Of Assets, Operating Activities",
        "negatedLabel": "(Gain) loss on disposal of assets"
       }
      }
     },
     "localname": "GainLossOnDispositionOfAssetsOperatingActivities",
     "nsuri": "http://www.evolenthealth.com/20211231",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "evh_GainLossOnRepaymentOfDebt": {
     "auth_ref": [],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 27.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      },
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS": {
       "order": 8.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gain (Loss) On Repayment Of Debt",
        "label": "Gain (Loss) On Repayment Of Debt",
        "negatedTerseLabel": "Loss on repayment of debt",
        "terseLabel": "Loss on repayment of debt",
        "verboseLabel": "Loss on repayment of debt, net"
       }
      }
     },
     "localname": "GainLossOnRepaymentOfDebt",
     "nsuri": "http://www.evolenthealth.com/20211231",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS",
      "http://www.evolenthealth.com/role/SegmentReportingReconciliationofAdjustedEBITDADetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "evh_GainOnTransferOfMembership": {
     "auth_ref": [],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 24.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      },
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS": {
       "order": 7.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gain On Transfer Of Membership",
        "label": "Gain On Transfer Of Membership",
        "negatedTerseLabel": "Gain on transfer of membership",
        "terseLabel": "Gain on transfer of membership"
       }
      }
     },
     "localname": "GainOnTransferOfMembership",
     "nsuri": "http://www.evolenthealth.com/20211231",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS",
      "http://www.evolenthealth.com/role/SegmentReportingReconciliationofAdjustedEBITDADetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "evh_GlobalHealthMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Global Health [Member]",
        "label": "Global Health [Member]",
        "terseLabel": "Global Health"
       }
      }
     },
     "localname": "GlobalHealthMember",
     "nsuri": "http://www.evolenthealth.com/20211231",
     "presentation": [
      "http://www.evolenthealth.com/role/InvestmentsinEquityMethodInvesteesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "evh_IncomeLossfromEquityMethodInvestmentsServicesAgreement": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Income (Loss) from Equity Method Investments, Services Agreement",
        "label": "Income (Loss) from Equity Method Investments, Services Agreement",
        "terseLabel": "Income from long-term services agreement"
       }
      }
     },
     "localname": "IncomeLossfromEquityMethodInvestmentsServicesAgreement",
     "nsuri": "http://www.evolenthealth.com/20211231",
     "presentation": [
      "http://www.evolenthealth.com/role/InvestmentsinEquityMethodInvesteesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "evh_IncreaseDecreaseInAccountsReceivableAndContractWithCustomerAsset": {
     "auth_ref": [],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 12.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase (Decrease) In Accounts Receivable And Contract With Customer, Asset",
        "label": "Increase (Decrease) In Accounts Receivable And Contract With Customer, Asset",
        "negatedTerseLabel": "Accounts receivable, net and contract assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsReceivableAndContractWithCustomerAsset",
     "nsuri": "http://www.evolenthealth.com/20211231",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "evh_IncreaseDecreaseInCapitalizedContractCostNet": {
     "auth_ref": [],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 14.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase (Decrease) In Capitalized Contract Cost, Net",
        "label": "Increase (Decrease) In Capitalized Contract Cost, Net",
        "negatedTerseLabel": "Contract cost assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInCapitalizedContractCostNet",
     "nsuri": "http://www.evolenthealth.com/20211231",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "evh_IncreaseDecreaseInInsuranceAndPerformanceBasedArrangementsLiabilities": {
     "auth_ref": [],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 19.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase (Decrease) In Insurance And Performance-Based Arrangements Liabilities",
        "label": "Increase (Decrease) In Insurance And Performance-Based Arrangements Liabilities",
        "terseLabel": "Reserve for claims and performance-based arrangements"
       }
      }
     },
     "localname": "IncreaseDecreaseInInsuranceAndPerformanceBasedArrangementsLiabilities",
     "nsuri": "http://www.evolenthealth.com/20211231",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "evh_IncreaseDecreaseInOperatingLeaseRightofUseAsset": {
     "auth_ref": [],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 20.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase (Decrease) In Operating Lease, Right-of-Use Asset",
        "label": "Increase (Decrease) In Operating Lease, Right-of-Use Asset",
        "negatedTerseLabel": "Right-of-use operating assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingLeaseRightofUseAsset",
     "nsuri": "http://www.evolenthealth.com/20211231",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "evh_IndefinitelivedTaxCreditCarryforwardMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indefinite-lived Tax Credit Carryforward [Member]",
        "label": "Indefinite-lived Tax Credit Carryforward [Member]",
        "terseLabel": "Indefinite-lived Tax Credit Carryforward"
       }
      }
     },
     "localname": "IndefinitelivedTaxCreditCarryforwardMember",
     "nsuri": "http://www.evolenthealth.com/20211231",
     "presentation": [
      "http://www.evolenthealth.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "evh_InitialTermLoanFacilityMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Initial Term Loan Facility [Member]",
        "label": "Initial Term Loan Facility [Member]",
        "terseLabel": "Initial Term Loan Facility"
       }
      }
     },
     "localname": "InitialTermLoanFacilityMember",
     "nsuri": "http://www.evolenthealth.com/20211231",
     "presentation": [
      "http://www.evolenthealth.com/role/LongtermDebtCreditAgreementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "evh_LeveragedStockUnitsLSUsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Leveraged Stock Units (LSUs) [Member]",
        "label": "Leveraged Stock Units (LSUs) [Member]",
        "terseLabel": "Leveraged Stock Units (LSUs) [Member]",
        "verboseLabel": "LSUs"
       }
      }
     },
     "localname": "LeveragedStockUnitsLSUsMember",
     "nsuri": "http://www.evolenthealth.com/20211231",
     "presentation": [
      "http://www.evolenthealth.com/role/StockbasedCompensation2011and2015EquityIncentivePlansDetails",
      "http://www.evolenthealth.com/role/StockbasedCompensationLeveragedStockUnitsActivityDetails",
      "http://www.evolenthealth.com/role/StockbasedCompensationLeveragedStockUnitsDetails",
      "http://www.evolenthealth.com/role/StockbasedCompensationPerformancebasedRSUActivityDetails",
      "http://www.evolenthealth.com/role/StockbasedCompensationStockbasedCompensationExpenseDetails",
      "http://www.evolenthealth.com/role/StockbasedCompensationUnrecognizedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "evh_LiabilityForFuturePolicyBenefitsAndUnpaidClaimsAndClaimsAdjustmentExpenseAndPerformanceBasedArrangements": {
     "auth_ref": [],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Liability For Future Policy Benefits And Unpaid Claims And Claims Adjustment Expense And Performance-Based Arrangements",
        "label": "Liability For Future Policy Benefits And Unpaid Claims And Claims Adjustment Expense And Performance-Based Arrangements",
        "terseLabel": "Reserve for claims and performance-based arrangements"
       }
      }
     },
     "localname": "LiabilityForFuturePolicyBenefitsAndUnpaidClaimsAndClaimsAdjustmentExpenseAndPerformanceBasedArrangements",
     "nsuri": "http://www.evolenthealth.com/20211231",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "evh_MeasurementInputRiskNeutralExpectedEarnoutConsiderationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement Input, Risk-neutral Expected Earnout Consideration",
        "label": "Measurement Input, Risk-neutral Expected Earnout Consideration [Member]",
        "terseLabel": "Risk-neutral expected earnout consideration"
       }
      }
     },
     "localname": "MeasurementInputRiskNeutralExpectedEarnoutConsiderationMember",
     "nsuri": "http://www.evolenthealth.com/20211231",
     "presentation": [
      "http://www.evolenthealth.com/role/FairValueMeasurementValuationTechniquesandSignificantUnobservableInputsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "evh_MedicaidCustomersMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Medicaid Customers",
        "label": "Medicaid Customers [Member]",
        "terseLabel": "Medicaid"
       }
      }
     },
     "localname": "MedicaidCustomersMember",
     "nsuri": "http://www.evolenthealth.com/20211231",
     "presentation": [
      "http://www.evolenthealth.com/role/RevenueRecognitionDisaggregationofRevenueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "evh_MedicareCustomersMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Medicare Customers",
        "label": "Medicare Customers [Member]",
        "terseLabel": "Medicare"
       }
      }
     },
     "localname": "MedicareCustomersMember",
     "nsuri": "http://www.evolenthealth.com/20211231",
     "presentation": [
      "http://www.evolenthealth.com/role/RevenueRecognitionDisaggregationofRevenueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "evh_MolinaHealthcareIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Molina Healthcare, Inc.",
        "label": "Molina Healthcare, Inc. [Member]",
        "terseLabel": "Molina"
       }
      }
     },
     "localname": "MolinaHealthcareIncMember",
     "nsuri": "http://www.evolenthealth.com/20211231",
     "presentation": [
      "http://www.evolenthealth.com/role/TransactionsEquityInvestmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "evh_MolinaHealthcareMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Molina Healthcare",
        "label": "Molina Healthcare [Member]",
        "terseLabel": "Molina Healthcare"
       }
      }
     },
     "localname": "MolinaHealthcareMember",
     "nsuri": "http://www.evolenthealth.com/20211231",
     "presentation": [
      "http://www.evolenthealth.com/role/CommitmentsandContingenciesConcentrationRiskDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "evh_NewCenturyHealthMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "New Century Health [Member]",
        "label": "New Century Health [Member]",
        "terseLabel": "New Century Health"
       }
      }
     },
     "localname": "NewCenturyHealthMember",
     "nsuri": "http://www.evolenthealth.com/20211231",
     "presentation": [
      "http://www.evolenthealth.com/role/StockbasedCompensationRestrictedStockUnitsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "evh_NewMexicoHealthConnectionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "New Mexico Health Connections [Member]",
        "label": "New Mexico Health Connections [Member]",
        "terseLabel": "New Mexico Health Connections"
       }
      }
     },
     "localname": "NewMexicoHealthConnectionsMember",
     "nsuri": "http://www.evolenthealth.com/20211231",
     "presentation": [
      "http://www.evolenthealth.com/role/CommitmentsandContingenciesConcentrationRiskDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "evh_NewNotesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "New Notes",
        "label": "New Notes [Member]",
        "terseLabel": "New Notes"
       }
      }
     },
     "localname": "NewNotesMember",
     "nsuri": "http://www.evolenthealth.com/20211231",
     "presentation": [
      "http://www.evolenthealth.com/role/LongtermDebt2024NotesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "evh_NonEmployeeDirectorsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Non-Employee Directors [Member]",
        "label": "Non-Employee Directors [Member]",
        "terseLabel": "Non-Employee Directors"
       }
      }
     },
     "localname": "NonEmployeeDirectorsMember",
     "nsuri": "http://www.evolenthealth.com/20211231",
     "presentation": [
      "http://www.evolenthealth.com/role/StockbasedCompensationRestrictedStockUnitsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "evh_NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationMeasurementPeriodAdjustment": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Noncash Or Part Noncash Acquisition, Noncash Financial Or Equity Instrument Consideration, Measurement Period Adjustment",
        "label": "Noncash Or Part Noncash Acquisition, Noncash Financial Or Equity Instrument Consideration, Measurement Period Adjustment",
        "terseLabel": "Increase/decrease to goodwill from measurement period adjustments/business combinations"
       }
      }
     },
     "localname": "NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationMeasurementPeriodAdjustment",
     "nsuri": "http://www.evolenthealth.com/20211231",
     "presentation": [
      "http://www.evolenthealth.com/role/SupplementalCashFlowInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "evh_NoncontrollingInterestDecreaseFromDisposalOfAssets": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Noncontrolling Interest, Decrease From Disposal Of Assets",
        "label": "Noncontrolling Interest, Decrease From Disposal Of Assets",
        "negatedTerseLabel": "Disposal of assets"
       }
      }
     },
     "localname": "NoncontrollingInterestDecreaseFromDisposalOfAssets",
     "nsuri": "http://www.evolenthealth.com/20211231",
     "presentation": [
      "http://www.evolenthealth.com/role/NoncontrollingInterestsScheduleofChangesinNoncontrollingInterestsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "evh_NumberOfReportingUnitsFairValueInExcessOfCarryingAmount": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number Of Reporting Units, Fair Value In Excess Of Carrying Amount",
        "label": "Number Of Reporting Units, Fair Value In Excess Of Carrying Amount",
        "terseLabel": "Number of reporting units, fair value in excess of carrying amount"
       }
      }
     },
     "localname": "NumberOfReportingUnitsFairValueInExcessOfCarryingAmount",
     "nsuri": "http://www.evolenthealth.com/20211231",
     "presentation": [
      "http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNetImpairmentTestingDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "evh_PaidinKindInterestIncome": {
     "auth_ref": [],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 26.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Paid-in-Kind Interest Income",
        "label": "Paid-in-Kind Interest Income",
        "negatedTerseLabel": "Interest from customer advance for regulatory capital requirements"
       }
      }
     },
     "localname": "PaidinKindInterestIncome",
     "nsuri": "http://www.evolenthealth.com/20211231",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "evh_PassportAssetAcquisitionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Passport Asset Acquisition",
        "label": "Passport Asset Acquisition [Member]",
        "terseLabel": "Passport Asset Acquisition"
       }
      }
     },
     "localname": "PassportAssetAcquisitionMember",
     "nsuri": "http://www.evolenthealth.com/20211231",
     "presentation": [
      "http://www.evolenthealth.com/role/TransactionsEquityInvestmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "evh_PassportNoteMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Passport Note [Member]",
        "label": "Passport Note [Member]",
        "terseLabel": "Passport Note"
       }
      }
     },
     "localname": "PassportNoteMember",
     "nsuri": "http://www.evolenthealth.com/20211231",
     "presentation": [
      "http://www.evolenthealth.com/role/TransactionsEquityInvestmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "evh_PaymentsForCustomerAdvanceForRegulatoryCapitalRequirements": {
     "auth_ref": [],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payments For Customer Advance For Regulatory Capital Requirements",
        "label": "Payments For Customer Advance For Regulatory Capital Requirements",
        "negatedTerseLabel": "Customer advance for regulatory capital requirements"
       }
      }
     },
     "localname": "PaymentsForCustomerAdvanceForRegulatoryCapitalRequirements",
     "nsuri": "http://www.evolenthealth.com/20211231",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "evh_PaymentsForProceedsFromClaimsProcessingFinancingActivities": {
     "auth_ref": [],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payments For (Proceeds From) Claims Processing, Financing Activities",
        "label": "Payments For (Proceeds From) Claims Processing, Financing Activities",
        "negatedTerseLabel": "Changes in working capital balances related to claims processing on behalf of partners"
       }
      }
     },
     "localname": "PaymentsForProceedsFromClaimsProcessingFinancingActivities",
     "nsuri": "http://www.evolenthealth.com/20211231",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "evh_PaymentsForProceedsFromDisposalOfNonStrategicAssetsAndDivestitureOfDiscontinuedOperationsNet": {
     "auth_ref": [],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payments For (Proceeds From) Disposal Of Non-Strategic Assets And Divestiture Of Discontinued Operations, Net",
        "label": "Payments For (Proceeds From) Disposal Of Non-Strategic Assets And Divestiture Of Discontinued Operations, Net",
        "negatedTerseLabel": "Disposal of non-strategic assets and divestiture of discontinued operations, net"
       }
      }
     },
     "localname": "PaymentsForProceedsFromDisposalOfNonStrategicAssetsAndDivestitureOfDiscontinuedOperationsNet",
     "nsuri": "http://www.evolenthealth.com/20211231",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "evh_PaymentsOfMakeWholePremium": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payments Of Make-Whole Premium",
        "label": "Payments Of Make-Whole Premium",
        "terseLabel": "Payments of make-whole premium"
       }
      }
     },
     "localname": "PaymentsOfMakeWholePremium",
     "nsuri": "http://www.evolenthealth.com/20211231",
     "presentation": [
      "http://www.evolenthealth.com/role/LongtermDebtCreditAgreementDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "evh_PaymentsToAcquireEquityMethodInvestmentsAmountHeldBack": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payments To Acquire Equity Method Investments, Amount Held Back",
        "label": "Payments To Acquire Equity Method Investments, Amount Held Back",
        "terseLabel": "Payments to acquire equity method investments, amount held back"
       }
      }
     },
     "localname": "PaymentsToAcquireEquityMethodInvestmentsAmountHeldBack",
     "nsuri": "http://www.evolenthealth.com/20211231",
     "presentation": [
      "http://www.evolenthealth.com/role/TransactionsEquityInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "evh_PerformanceBasedRestrictedStockUnitsPSUsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Performance-Based Restricted Stock Units (PSUs) [Member]",
        "label": "Performance-Based Restricted Stock Units (PSUs) [Member]",
        "terseLabel": "PSUs"
       }
      }
     },
     "localname": "PerformanceBasedRestrictedStockUnitsPSUsMember",
     "nsuri": "http://www.evolenthealth.com/20211231",
     "presentation": [
      "http://www.evolenthealth.com/role/StockbasedCompensation2011and2015EquityIncentivePlansDetails",
      "http://www.evolenthealth.com/role/StockbasedCompensationPerformancebasedRSUActivityDetails",
      "http://www.evolenthealth.com/role/StockbasedCompensationPerformancebasedRSUsDetails",
      "http://www.evolenthealth.com/role/StockbasedCompensationStockbasedCompensationExpenseDetails",
      "http://www.evolenthealth.com/role/StockbasedCompensationUnrecognizedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "evh_PeriodsPriortoJune2015Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Periods Prior to June 2015 [Member]",
        "label": "Periods Prior to June 2015 [Member]",
        "terseLabel": "Periods Prior to June 2015"
       }
      }
     },
     "localname": "PeriodsPriortoJune2015Member",
     "nsuri": "http://www.evolenthealth.com/20211231",
     "presentation": [
      "http://www.evolenthealth.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "evh_PlatformsAndOperationsServicesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Platforms And Operations Services [Member]",
        "label": "Platforms And Operations Services [Member]",
        "verboseLabel": "Platform and operations services"
       }
      }
     },
     "localname": "PlatformsAndOperationsServicesMember",
     "nsuri": "http://www.evolenthealth.com/20211231",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS",
      "http://www.evolenthealth.com/role/DiscontinuedOperationsSummaryofResultsofOperationsDetails",
      "http://www.evolenthealth.com/role/RelatedPartiesRevenuesandExpensesDetails",
      "http://www.evolenthealth.com/role/SegmentReportingRevenuefromSegmentstoConsolidatedDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "evh_PolicyholderBenefitsAndClaimsIncurredAssumedExpensesRelatedToClaims": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Policyholder Benefits And Claims Incurred, Assumed, Expenses Related To Claims",
        "label": "Policyholder Benefits And Claims Incurred, Assumed, Expenses Related To Claims",
        "terseLabel": "Claims-related administrative expenses"
       }
      }
     },
     "localname": "PolicyholderBenefitsAndClaimsIncurredAssumedExpensesRelatedToClaims",
     "nsuri": "http://www.evolenthealth.com/20211231",
     "presentation": [
      "http://www.evolenthealth.com/role/CommitmentsandContingenciesReinsuranceAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "evh_PremiumsRevenueMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Premiums Revenue [Member]",
        "label": "Premiums Revenue [Member]",
        "terseLabel": "Premiums"
       }
      }
     },
     "localname": "PremiumsRevenueMember",
     "nsuri": "http://www.evolenthealth.com/20211231",
     "presentation": [
      "http://www.evolenthealth.com/role/CommitmentsandContingenciesConcentrationRiskDetails",
      "http://www.evolenthealth.com/role/DiscontinuedOperationsSummaryofResultsofOperationsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "evh_PremiumsWrittenAndPolicyholderBenefitsAndClaimsIncurredNet": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Premiums Written And Policyholder Benefits And Claims Incurred, Net",
        "label": "Premiums Written And Policyholder Benefits And Claims Incurred, Net",
        "terseLabel": "Increase (decrease) in reserves for claims and performance-based arrangements attributable to the Reinsurance Agreement"
       }
      }
     },
     "localname": "PremiumsWrittenAndPolicyholderBenefitsAndClaimsIncurredNet",
     "nsuri": "http://www.evolenthealth.com/20211231",
     "presentation": [
      "http://www.evolenthealth.com/role/CommitmentsandContingenciesReinsuranceAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "evh_ProceedsFromAssetAcquisitionEscrow": {
     "auth_ref": [],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds From Asset Acquisition Escrow",
        "label": "Proceeds From Asset Acquisition Escrow",
        "terseLabel": "Amount received from escrow in asset acquisition"
       }
      }
     },
     "localname": "ProceedsFromAssetAcquisitionEscrow",
     "nsuri": "http://www.evolenthealth.com/20211231",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "evh_ProceedsFromMaturityOfInvestments": {
     "auth_ref": [],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds From Maturity Of Investments",
        "label": "Proceeds From Maturity Of Investments",
        "terseLabel": "Maturities and sales of investments"
       }
      }
     },
     "localname": "ProceedsFromMaturityOfInvestments",
     "nsuri": "http://www.evolenthealth.com/20211231",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "evh_ProceedsFromReinsurance": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds From Reinsurance",
        "label": "Proceeds From Reinsurance",
        "negatedLabel": "Reinsurance payments paid (received)"
       }
      }
     },
     "localname": "ProceedsFromReinsurance",
     "nsuri": "http://www.evolenthealth.com/20211231",
     "presentation": [
      "http://www.evolenthealth.com/role/CommitmentsandContingenciesReinsuranceAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "evh_ProceedsFromTransferOfMembership": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds From Transfer Of Membership",
        "label": "Proceeds From Transfer Of Membership",
        "terseLabel": "Proceeds from transfer of membership"
       }
      }
     },
     "localname": "ProceedsFromTransferOfMembership",
     "nsuri": "http://www.evolenthealth.com/20211231",
     "presentation": [
      "http://www.evolenthealth.com/role/TransactionsEquityInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "evh_ProfessionalServicesRestructuringMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Professional Services, Restructuring",
        "label": "Professional Services, Restructuring [Member]",
        "terseLabel": "Professional services"
       }
      }
     },
     "localname": "ProfessionalServicesRestructuringMember",
     "nsuri": "http://www.evolenthealth.com/20211231",
     "presentation": [
      "http://www.evolenthealth.com/role/RepositioningandOtherChangesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "evh_PurchaseAccountingAdjustments": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Purchase Accounting Adjustments",
        "label": "Purchase Accounting Adjustments",
        "negatedTerseLabel": "Purchase accounting adjustments"
       }
      }
     },
     "localname": "PurchaseAccountingAdjustments",
     "nsuri": "http://www.evolenthealth.com/20211231",
     "presentation": [
      "http://www.evolenthealth.com/role/SegmentReportingReconciliationofAdjustedEBITDADetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "evh_RestrictedCashForLettersOfCreditForLetterOfCreditFacilityMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Restricted Cash For Letters Of Credit For Letter Of Credit Facility [Member]",
        "label": "Restricted Cash For Letters Of Credit For Letter Of Credit Facility [Member]",
        "terseLabel": "Restricted Cash For Letters Of Credit"
       }
      }
     },
     "localname": "RestrictedCashForLettersOfCreditForLetterOfCreditFacilityMember",
     "nsuri": "http://www.evolenthealth.com/20211231",
     "presentation": [
      "http://www.evolenthealth.com/role/CommitmentsandContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "evh_RestrictedCashforBenefitManagementServicesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Restricted Cash for Benefit Management Services [Member]",
        "label": "Restricted Cash for Benefit Management Services [Member]",
        "terseLabel": "Claims processing services"
       }
      }
     },
     "localname": "RestrictedCashforBenefitManagementServicesMember",
     "nsuri": "http://www.evolenthealth.com/20211231",
     "presentation": [
      "http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesRestrictedCashandRestrictedInvestmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "evh_RestrictedCashforLettersofCreditforFacilityLeasesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Restricted Cash for Letters of Credit for Facility Leases [Member]",
        "label": "Restricted Cash for Letters of Credit for Facility Leases [Member]",
        "verboseLabel": "Collateral for letters of credit for facility leases"
       }
      }
     },
     "localname": "RestrictedCashforLettersofCreditforFacilityLeasesMember",
     "nsuri": "http://www.evolenthealth.com/20211231",
     "presentation": [
      "http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesRestrictedCashandRestrictedInvestmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "evh_RestrictedCashforOtherContractualCommitmentsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Restricted Cash for Other Contractual Commitments [Member]",
        "label": "Restricted Cash for Other Contractual Commitments [Member]",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "RestrictedCashforOtherContractualCommitmentsMember",
     "nsuri": "http://www.evolenthealth.com/20211231",
     "presentation": [
      "http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesRestrictedCashandRestrictedInvestmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "evh_RestrictedStockUnitsRSUsPerformanceBasedRestrictedStockUnitsPBRSUsAndLeveragedStockUnitsLSUsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Restricted Stock and Restricted Stock Units [Member]",
        "label": "Restricted Stock Units (RSUs), Performance-based Restricted Stock Units (PBRSUs), And Leveraged Stock Units (LSUs) [Member]",
        "terseLabel": "Restricted stock units (\"RSUs\"), performance-based RSUs and leveraged stock units (\"LSUs\")"
       }
      }
     },
     "localname": "RestrictedStockUnitsRSUsPerformanceBasedRestrictedStockUnitsPBRSUsAndLeveragedStockUnitsLSUsMember",
     "nsuri": "http://www.evolenthealth.com/20211231",
     "presentation": [
      "http://www.evolenthealth.com/role/EarningsLossPerCommonShareAntidilutiveSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "evh_RightOfOffsetPercentageOfAccountsReceivableNetEligibleForNetBasisSettlement": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Right of Offset, Percentage of Accounts Receivable, Net Eligible for Net Basis Settlement",
        "label": "Right of Offset, Percentage of Accounts Receivable, Net Eligible for Net Basis Settlement",
        "terseLabel": "Right of offset, percentage of accounts receivable, net eligible for net basis settlement"
       }
      }
     },
     "localname": "RightOfOffsetPercentageOfAccountsReceivableNetEligibleForNetBasisSettlement",
     "nsuri": "http://www.evolenthealth.com/20211231",
     "presentation": [
      "http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesRightofOffsetDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "evh_RightOfOffsetPercentageOfAccountsReceivableNettedAgainstClaimsPayable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Right of Offset, Percentage of Accounts Receivable Netted Against Claims Payable",
        "label": "Right of Offset, Percentage of Accounts Receivable Netted Against Claims Payable",
        "terseLabel": "Right of offset, percentage of accounts receivable netted against claims payable"
       }
      }
     },
     "localname": "RightOfOffsetPercentageOfAccountsReceivableNettedAgainstClaimsPayable",
     "nsuri": "http://www.evolenthealth.com/20211231",
     "presentation": [
      "http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesRightofOffsetDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "evh_RightOfOffsetPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Right of Offset, Policy",
        "label": "Right of Offset, Policy [Policy Text Block]",
        "terseLabel": "Right of Offset"
       }
      }
     },
     "localname": "RightOfOffsetPolicyPolicyTextBlock",
     "nsuri": "http://www.evolenthealth.com/20211231",
     "presentation": [
      "http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "evh_RightOfUseAssetAcquiredAndDisposedOf": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Right-Of-Use Asset Acquired And Disposed Of",
        "label": "Right-Of-Use Asset Acquired And Disposed Of",
        "negatedTerseLabel": "Leased assets obtained in exchange for operating lease liabilities"
       }
      }
     },
     "localname": "RightOfUseAssetAcquiredAndDisposedOf",
     "nsuri": "http://www.evolenthealth.com/20211231",
     "presentation": [
      "http://www.evolenthealth.com/role/SupplementalCashFlowInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "evh_ScheduleOfShareBasedPaymentAwardRestrictedStockUnitValuationAssumptionsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of Share-based Payment Award, Restricted Stock Unit, Valuation Assumptions",
        "label": "Schedule of Share-based Payment Award, Restricted Stock Unit, Valuation Assumptions [Table Text Block]",
        "terseLabel": "Schedule of price assumptions for performance based stock units"
       }
      }
     },
     "localname": "ScheduleOfShareBasedPaymentAwardRestrictedStockUnitValuationAssumptionsTableTextBlock",
     "nsuri": "http://www.evolenthealth.com/20211231",
     "presentation": [
      "http://www.evolenthealth.com/role/StockbasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "evh_ScheduleofChangesinNoncontrollingInterestTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of Changes in Noncontrolling Interest [Table Text Block]",
        "label": "Schedule of Changes in Noncontrolling Interest [Table Text Block]",
        "terseLabel": "Schedule of changes in non-controlling interests"
       }
      }
     },
     "localname": "ScheduleofChangesinNoncontrollingInterestTableTextBlock",
     "nsuri": "http://www.evolenthealth.com/20211231",
     "presentation": [
      "http://www.evolenthealth.com/role/NoncontrollingInterestsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "evh_SeniorConvertibleNotesDue2024Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Senior Convertible Notes Due 2024",
        "label": "Senior Convertible Notes Due 2024 [Member]",
        "terseLabel": "2024 Notes"
       }
      }
     },
     "localname": "SeniorConvertibleNotesDue2024Member",
     "nsuri": "http://www.evolenthealth.com/20211231",
     "presentation": [
      "http://www.evolenthealth.com/role/LongtermDebt2021NotesDetails",
      "http://www.evolenthealth.com/role/LongtermDebt2024NotesDetails",
      "http://www.evolenthealth.com/role/LongtermDebtConvertibleSeniorNotesCarryingValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "evh_SeniorConvertibleNotesDue2025Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Senior Convertible Notes Due 2025 [Member]",
        "label": "Senior Convertible Notes Due 2025 [Member]",
        "terseLabel": "2025 Notes"
       }
      }
     },
     "localname": "SeniorConvertibleNotesDue2025Member",
     "nsuri": "http://www.evolenthealth.com/20211231",
     "presentation": [
      "http://www.evolenthealth.com/role/LongtermDebt2025NotesDetails",
      "http://www.evolenthealth.com/role/LongtermDebtConvertibleSeniorNotesCarryingValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "evh_SeniorCreditFacilitiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Senior Credit Facilities [Member]",
        "label": "Senior Credit Facilities [Member]",
        "terseLabel": "Senior Credit Facilities"
       }
      }
     },
     "localname": "SeniorCreditFacilitiesMember",
     "nsuri": "http://www.evolenthealth.com/20211231",
     "presentation": [
      "http://www.evolenthealth.com/role/LongtermDebtCreditAgreementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "evh_ServicesAgreementsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Services Agreements [Member]",
        "label": "Services Agreements [Member]",
        "terseLabel": "Services Agreements"
       }
      }
     },
     "localname": "ServicesAgreementsMember",
     "nsuri": "http://www.evolenthealth.com/20211231",
     "presentation": [
      "http://www.evolenthealth.com/role/DiscontinuedOperationsSummaryofCurrentandLongtermAssetsandLiabilitiesDetails",
      "http://www.evolenthealth.com/role/DiscontinuedOperationsSummaryofResultsofOperationsDetails",
      "http://www.evolenthealth.com/role/InvestmentsinEquityMethodInvesteesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "evh_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsMaximumPerformanceAchievedPercentageOfTargetedSharesEarned": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Maximum Performance Achieved, Percentage of Targeted Shares Earned",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Maximum Performance Achieved, Percentage of Targeted Shares Earned",
        "terseLabel": "Maximum performance achieved, percentage of targeted shares earned"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsMaximumPerformanceAchievedPercentageOfTargetedSharesEarned",
     "nsuri": "http://www.evolenthealth.com/20211231",
     "presentation": [
      "http://www.evolenthealth.com/role/StockbasedCompensationPerformancebasedRSUsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "evh_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsPerformanceGoalThreshold": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Performance Goal Threshold",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Performance Goal Threshold",
        "terseLabel": "Performance goal threshold"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsPerformanceGoalThreshold",
     "nsuri": "http://www.evolenthealth.com/20211231",
     "presentation": [
      "http://www.evolenthealth.com/role/StockbasedCompensationPerformancebasedRSUsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "evh_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageAdjustmentOfSharesEarnedTotalShareholderReturnInBottomQuartile": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Percentage Adjustment of Shares Earned, Total Shareholder Return in Bottom Quartile",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Percentage Adjustment of Shares Earned, Total Shareholder Return in Bottom Quartile",
        "terseLabel": "Percentage adjustment of shares earned, total shareholder return in bottom quartile"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageAdjustmentOfSharesEarnedTotalShareholderReturnInBottomQuartile",
     "nsuri": "http://www.evolenthealth.com/20211231",
     "presentation": [
      "http://www.evolenthealth.com/role/StockbasedCompensationPerformancebasedRSUsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "evh_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageAdjustmentOfSharesEarnedTotalShareholderReturnInTopQuartile": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Percentage Adjustment of Shares Earned, Total Shareholder Return in Top Quartile",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Percentage Adjustment of Shares Earned, Total Shareholder Return in Top Quartile",
        "terseLabel": "Percentage adjustment of shares earned, total shareholder return in top quartile"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageAdjustmentOfSharesEarnedTotalShareholderReturnInTopQuartile",
     "nsuri": "http://www.evolenthealth.com/20211231",
     "presentation": [
      "http://www.evolenthealth.com/role/StockbasedCompensationPerformancebasedRSUsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "evh_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsStockPriceIncreasePercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based Compensation Arrangement By Share-based Payment Award, Award Vesting Rights, Stock Price Increase, Percentage",
        "label": "Share-based Compensation Arrangement By Share-based Payment Award, Award Vesting Rights, Stock Price Increase, Percentage",
        "terseLabel": "Award vesting rights, stock price increase, percentage"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsStockPriceIncreasePercentage",
     "nsuri": "http://www.evolenthealth.com/20211231",
     "presentation": [
      "http://www.evolenthealth.com/role/StockbasedCompensationLeveragedStockUnitsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "evh_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsStockPriceTriggerConsecutiveTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based Compensation Arrangement By Share-based Payment Award, Award Vesting Rights, Stock Price Trigger, Consecutive Term",
        "label": "Share-based Compensation Arrangement By Share-based Payment Award, Award Vesting Rights, Stock Price Trigger, Consecutive Term",
        "terseLabel": "Consecutive term"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsStockPriceTriggerConsecutiveTerm",
     "nsuri": "http://www.evolenthealth.com/20211231",
     "presentation": [
      "http://www.evolenthealth.com/role/StockbasedCompensationPerformancebasedStockOptionAwardsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "evh_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVestedAndExpectedToVest": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based Compensation Arrangement By Share-based Payment Award, Equity Instruments Other Than Options, Aggregate Intrinsic Value, Vested And Expected To Vest",
        "label": "Share-based Compensation Arrangement By Share-based Payment Award, Equity Instruments Other Than Options, Aggregate Intrinsic Value, Vested And Expected To Vest",
        "terseLabel": "Aggregate Intrinsic Value"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVestedAndExpectedToVest",
     "nsuri": "http://www.evolenthealth.com/20211231",
     "presentation": [
      "http://www.evolenthealth.com/role/StockbasedCompensationLeveragedStockUnitsActivityDetails",
      "http://www.evolenthealth.com/role/StockbasedCompensationPerformancebasedRSUActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "evh_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based Compensation Arrangement By Share-based Payment Award, Equity Instruments Other Than Options, Outstanding [Abstract]",
        "label": "Share-based Compensation Arrangement By Share-based Payment Award, Equity Instruments Other Than Options, Outstanding [Abstract]",
        "terseLabel": "Outstanding as of December 31, 2021"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingAbstract",
     "nsuri": "http://www.evolenthealth.com/20211231",
     "presentation": [
      "http://www.evolenthealth.com/role/StockbasedCompensationLeveragedStockUnitsActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "evh_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based Compensation Arrangement By Share-based Payment Award, Equity Instruments Other Than Options, Vested And Expected To Vest [Abstract]",
        "label": "Share-based Compensation Arrangement By Share-based Payment Award, Equity Instruments Other Than Options, Vested And Expected To Vest [Abstract]",
        "terseLabel": "Vested and expected to vest after December\u00a031, 2021"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestAbstract",
     "nsuri": "http://www.evolenthealth.com/20211231",
     "presentation": [
      "http://www.evolenthealth.com/role/StockbasedCompensationLeveragedStockUnitsActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "evh_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based Compensation Arrangement By Share-based Payment Award, Equity Instruments Other Than Options, Vested And Expected To Vest, Number",
        "label": "Share-based Compensation Arrangement By Share-based Payment Award, Equity Instruments Other Than Options, Vested And Expected To Vest, Number",
        "terseLabel": "Leveraged Stock Units (in shares)",
        "verboseLabel": "Performance Based Stock Units (in shares)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestNumber",
     "nsuri": "http://www.evolenthealth.com/20211231",
     "presentation": [
      "http://www.evolenthealth.com/role/StockbasedCompensationLeveragedStockUnitsActivityDetails",
      "http://www.evolenthealth.com/role/StockbasedCompensationPerformancebasedRSUActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "evh_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestWeightedAverageGrantDateFairValue": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based Compensation Arrangement By Share-based Payment Award, Equity Instruments Other Than Options, Vested And Expected To Vest, Weighted Average Grant Date Fair Value",
        "label": "Share-based Compensation Arrangement By Share-based Payment Award, Equity Instruments Other Than Options, Vested And Expected To Vest, Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted Average Grant Date Fair Value (in dollars per share)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestWeightedAverageGrantDateFairValue",
     "nsuri": "http://www.evolenthealth.com/20211231",
     "presentation": [
      "http://www.evolenthealth.com/role/StockbasedCompensationLeveragedStockUnitsActivityDetails",
      "http://www.evolenthealth.com/role/StockbasedCompensationPerformancebasedRSUActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "evh_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestWeightedAverageRemainingContractualTerms": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based Compensation Arrangement By Share-based Payment Award, Equity Instruments Other Than Options, Vested And Expected To Vest, Weighted Average Remaining Contractual Terms",
        "label": "Share-based Compensation Arrangement By Share-based Payment Award, Equity Instruments Other Than Options, Vested And Expected To Vest, Weighted Average Remaining Contractual Terms",
        "terseLabel": "Weighted Average Remaining Contractual Term"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestWeightedAverageRemainingContractualTerms",
     "nsuri": "http://www.evolenthealth.com/20211231",
     "presentation": [
      "http://www.evolenthealth.com/role/StockbasedCompensationLeveragedStockUnitsActivityDetails",
      "http://www.evolenthealth.com/role/StockbasedCompensationPerformancebasedRSUActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "evh_SharebasedCompensationArrangementbySharebasedPaymentAwardAwardVestingRightsSharePriceThreshold": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Share Price Threshold",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Share Price Threshold",
        "terseLabel": "Award vesting rights, share price threshold (in dollars per share)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementbySharebasedPaymentAwardAwardVestingRightsSharePriceThreshold",
     "nsuri": "http://www.evolenthealth.com/20211231",
     "presentation": [
      "http://www.evolenthealth.com/role/StockbasedCompensationPerformancebasedStockOptionAwardsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "evh_SharebasedCompensationAwardSubTrancheOneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based Compensation Award, Sub-Tranche One [Member]",
        "label": "Share-based Compensation Award, Sub-Tranche One [Member]",
        "terseLabel": "Vest on March 1, 2019"
       }
      }
     },
     "localname": "SharebasedCompensationAwardSubTrancheOneMember",
     "nsuri": "http://www.evolenthealth.com/20211231",
     "presentation": [
      "http://www.evolenthealth.com/role/StockbasedCompensationPerformancebasedStockOptionAwardsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "evh_SharebasedCompensationAwardSubTrancheTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based Compensation Award, Sub-Tranche Two [Member]",
        "label": "Share-based Compensation Award, Sub-Tranche Two [Member]",
        "terseLabel": "Vest on March 1, 2020"
       }
      }
     },
     "localname": "SharebasedCompensationAwardSubTrancheTwoMember",
     "nsuri": "http://www.evolenthealth.com/20211231",
     "presentation": [
      "http://www.evolenthealth.com/role/StockbasedCompensationPerformancebasedStockOptionAwardsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "evh_SharebasedCompensationIncludingOnetimeAdjustment": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based Compensation, Including One-time Adjustment",
        "label": "Share-based Compensation, Including One-time Adjustment",
        "negatedLabel": "Stock-based compensation expense"
       }
      }
     },
     "localname": "SharebasedCompensationIncludingOnetimeAdjustment",
     "nsuri": "http://www.evolenthealth.com/20211231",
     "presentation": [
      "http://www.evolenthealth.com/role/SegmentReportingReconciliationofAdjustedEBITDADetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "evh_SharebasedPaymentArrangementTrancheFourMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based Payment Arrangement, Tranche Four [Member]",
        "label": "Share-based Payment Arrangement, Tranche Four [Member]",
        "terseLabel": "Tranche Four"
       }
      }
     },
     "localname": "SharebasedPaymentArrangementTrancheFourMember",
     "nsuri": "http://www.evolenthealth.com/20211231",
     "presentation": [
      "http://www.evolenthealth.com/role/StockbasedCompensationLeveragedStockUnitsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "evh_ShareholderAdvisoryServices": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Shareholder Advisory Services",
        "label": "Shareholder Advisory Services",
        "negatedLabel": "Strategy and shareholder advisory expenses"
       }
      }
     },
     "localname": "ShareholderAdvisoryServices",
     "nsuri": "http://www.evolenthealth.com/20211231",
     "presentation": [
      "http://www.evolenthealth.com/role/SegmentReportingReconciliationofAdjustedEBITDADetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "evh_StatutoryCapitalReservesLiquidityGuaranteedByInvestorsMinimum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Statutory Capital Reserves, Liquidity Guaranteed By Investors, Minimum",
        "label": "Statutory Capital Reserves, Liquidity Guaranteed By Investors, Minimum",
        "terseLabel": "Statutory capital reserves, liquidity guaranteed by investors"
       }
      }
     },
     "localname": "StatutoryCapitalReservesLiquidityGuaranteedByInvestorsMinimum",
     "nsuri": "http://www.evolenthealth.com/20211231",
     "presentation": [
      "http://www.evolenthealth.com/role/InvestmentsinEquityMethodInvesteesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "evh_StockIssuedDecreaseInDeferredTaxLiability": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock Issued, Decrease In Deferred Tax Liability",
        "label": "Stock Issued, Decrease In Deferred Tax Liability",
        "terseLabel": "Decrease in deferred tax liability as a result of securities offerings and exchanges"
       }
      }
     },
     "localname": "StockIssuedDecreaseInDeferredTaxLiability",
     "nsuri": "http://www.evolenthealth.com/20211231",
     "presentation": [
      "http://www.evolenthealth.com/role/SupplementalCashFlowInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "evh_StockIssuedDuringPeriodSharesConversionofConvertibleSecuritiesTaxImpact": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock Issued During Period, Shares Conversion of Convertible Securities, Tax Impact",
        "label": "Stock Issued During Period, Shares Conversion of Convertible Securities, Tax Impact",
        "terseLabel": "Tax impact of Class B exchange"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesConversionofConvertibleSecuritiesTaxImpact",
     "nsuri": "http://www.evolenthealth.com/20211231",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "evh_StockIssuedDuringPeriodSharesEarnOuts": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock Issued During Period, Shares, Earn-outs",
        "label": "Stock Issued During Period, Shares, Earn-outs",
        "terseLabel": "Class A common stock issued for payment of earn-outs (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesEarnOuts",
     "nsuri": "http://www.evolenthealth.com/20211231",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY"
     ],
     "xbrltype": "sharesItemType"
    },
    "evh_StockIssuedDuringPeriodSharesEquityMethodInvestmentsAndAssetAcquisitions": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock Issued During Period, Shares, Equity-Method Investments And Asset Acquisitions",
        "label": "Stock Issued During Period, Shares, Equity-Method Investments And Asset Acquisitions",
        "terseLabel": "Shares issued for equity-method investments and asset acquisitions (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesEquityMethodInvestmentsAndAssetAcquisitions",
     "nsuri": "http://www.evolenthealth.com/20211231",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY"
     ],
     "xbrltype": "sharesItemType"
    },
    "evh_StockIssuedDuringPeriodValueEarnOuts": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock Issued During Period, Value, Earn-outs",
        "label": "Stock Issued During Period, Value, Earn-outs",
        "terseLabel": "Class A common stock issued for payment of earn-outs"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueEarnOuts",
     "nsuri": "http://www.evolenthealth.com/20211231",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "evh_StockIssuedDuringPeriodValueEquityMethodInvestmentsAndAssetAcquisitions": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock Issued During Period, Value, Equity-Method Investments And Asset Acquisitions",
        "label": "Stock Issued During Period, Value, Equity-Method Investments And Asset Acquisitions",
        "terseLabel": "Shares issued for equity-method investments and asset acquisitions"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueEquityMethodInvestmentsAndAssetAcquisitions",
     "nsuri": "http://www.evolenthealth.com/20211231",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "evh_StockIssuedInConnectionWithDebtRepayment": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock Issued in Connection with Debt Repayment",
        "label": "Stock Issued in Connection with Debt Repayment",
        "terseLabel": "Class A common stock issued in connection with debt repayment"
       }
      }
     },
     "localname": "StockIssuedInConnectionWithDebtRepayment",
     "nsuri": "http://www.evolenthealth.com/20211231",
     "presentation": [
      "http://www.evolenthealth.com/role/SupplementalCashFlowInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "evh_StockVestedAndRetiredDuringPeriodShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock Vested And Retired During Period, Shares",
        "label": "Stock Vested And Retired During Period, Shares",
        "negatedTerseLabel": "Share retirement (in shares)"
       }
      }
     },
     "localname": "StockVestedAndRetiredDuringPeriodShares",
     "nsuri": "http://www.evolenthealth.com/20211231",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY"
     ],
     "xbrltype": "sharesItemType"
    },
    "evh_StockVestedAndRetiredDuringPeriodValue": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock Vested And Retired During Period, Value",
        "label": "Stock Vested And Retired During Period, Value",
        "negatedTerseLabel": "Share retirement"
       }
      }
     },
     "localname": "StockVestedAndRetiredDuringPeriodValue",
     "nsuri": "http://www.evolenthealth.com/20211231",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "evh_TaxReceivableAgreementPercentofCashSavingsNotPaidtoShareholders": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tax Receivable Agreement, Percent of Cash Savings Not Paid to Shareholders",
        "label": "Tax Receivable Agreement, Percent of Cash Savings Not Paid to Shareholders",
        "terseLabel": "Tax receivable agreement, percent of cash savings not paid to shareholders"
       }
      }
     },
     "localname": "TaxReceivableAgreementPercentofCashSavingsNotPaidtoShareholders",
     "nsuri": "http://www.evolenthealth.com/20211231",
     "presentation": [
      "http://www.evolenthealth.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "evh_TaxReceivableAgreementPercentofCashSavingsPaidtoShareholders": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tax Receivable Agreement, Percent of Cash Savings Paid to Shareholders",
        "label": "Tax Receivable Agreement, Percent of Cash Savings Paid to Shareholders",
        "terseLabel": "Tax receivable agreement, percent of cash savings paid to shareholders"
       }
      }
     },
     "localname": "TaxReceivableAgreementPercentofCashSavingsPaidtoShareholders",
     "nsuri": "http://www.evolenthealth.com/20211231",
     "presentation": [
      "http://www.evolenthealth.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "evh_TaxReceivablesAgreementPercentofTaxSavingstobePaid": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tax Receivables Agreement, Percent of Tax Savings to be Paid",
        "label": "Tax Receivables Agreement, Percent of Tax Savings to be Paid",
        "terseLabel": "Percent of tax savings to be paid"
       }
      }
     },
     "localname": "TaxReceivablesAgreementPercentofTaxSavingstobePaid",
     "nsuri": "http://www.evolenthealth.com/20211231",
     "presentation": [
      "http://www.evolenthealth.com/role/CommitmentsandContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "evh_TransactionCosts": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Transaction Costs",
        "label": "Transaction Costs",
        "negatedLabel": "Acquisition costs"
       }
      }
     },
     "localname": "TransactionCosts",
     "nsuri": "http://www.evolenthealth.com/20211231",
     "presentation": [
      "http://www.evolenthealth.com/role/SegmentReportingReconciliationofAdjustedEBITDADetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "evh_TransferOfMembershipPercentageOfPaymentBasedOnNumberOfEnrollees": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Transfer Of Membership, Percentage Of Payment Based on Number Of Enrollees",
        "label": "Transfer Of Membership, Percentage Of Payment Based on Number Of Enrollees",
        "terseLabel": "Transfer of membership, percentage of payment based on number of enrollees"
       }
      }
     },
     "localname": "TransferOfMembershipPercentageOfPaymentBasedOnNumberOfEnrollees",
     "nsuri": "http://www.evolenthealth.com/20211231",
     "presentation": [
      "http://www.evolenthealth.com/role/TransactionsEquityInvestmentsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "evh_TransferOfMembershipPercentageOfPaymentSubjectToSatisfactionOfContingencies": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Transfer Of Membership, Percentage Of Payment Subject To Satisfaction Of Contingencies",
        "label": "Transfer Of Membership, Percentage Of Payment Subject To Satisfaction Of Contingencies",
        "terseLabel": "Transfer of membership, percentage of payment subject to satisfaction of contingencies"
       }
      }
     },
     "localname": "TransferOfMembershipPercentageOfPaymentSubjectToSatisfactionOfContingencies",
     "nsuri": "http://www.evolenthealth.com/20211231",
     "presentation": [
      "http://www.evolenthealth.com/role/TransactionsEquityInvestmentsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "evh_TransformationServicesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Transformation Services [Member]",
        "label": "Transformation Services [Member]",
        "verboseLabel": "Transformation services"
       }
      }
     },
     "localname": "TransformationServicesMember",
     "nsuri": "http://www.evolenthealth.com/20211231",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS",
      "http://www.evolenthealth.com/role/RelatedPartiesRevenuesandExpensesDetails",
      "http://www.evolenthealth.com/role/SegmentReportingRevenuefromSegmentstoConsolidatedDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "evh_TrueHealthMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "True Health",
        "label": "True Health [Member]",
        "terseLabel": "True Health"
       }
      }
     },
     "localname": "TrueHealthMember",
     "nsuri": "http://www.evolenthealth.com/20211231",
     "presentation": [
      "http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesRestrictedCashandRestrictedInvestmentsDetails",
      "http://www.evolenthealth.com/role/CommitmentsandContingenciesConcentrationRiskDetails",
      "http://www.evolenthealth.com/role/DiscontinuedOperationsAdditionalInformationDetails",
      "http://www.evolenthealth.com/role/DiscontinuedOperationsSummaryofCashFlowsDetails",
      "http://www.evolenthealth.com/role/DiscontinuedOperationsSummaryofCurrentandLongtermAssetsandLiabilitiesDetails",
      "http://www.evolenthealth.com/role/DiscontinuedOperationsSummaryofResultsofOperationsDetails",
      "http://www.evolenthealth.com/role/EmployeeBenefitPlansDetails",
      "http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNetIntangibleAssetsNetDetails",
      "http://www.evolenthealth.com/role/ReservesforClaimsandPerformanceBasedArrangementsDetails",
      "http://www.evolenthealth.com/role/RevenueRecognitionContractBalancesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "evh_TwoThousandElevenEquityIncentivePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two Thousand Eleven Equity Incentive Plan [Member]",
        "label": "Two Thousand Eleven Equity Incentive Plan [Member]",
        "terseLabel": "2011 Plan"
       }
      }
     },
     "localname": "TwoThousandElevenEquityIncentivePlanMember",
     "nsuri": "http://www.evolenthealth.com/20211231",
     "presentation": [
      "http://www.evolenthealth.com/role/StockbasedCompensation2011and2015EquityIncentivePlansDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "evh_TwoThousandFifteenEvolentHealthInc.OmnibusIncentiveCompensationPlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two Thousand Fifteen Evolent Health, Inc. Omnibus Incentive Compensation Plan [Member]",
        "label": "Two Thousand Fifteen Evolent Health, Inc. Omnibus Incentive Compensation Plan [Member]",
        "terseLabel": "2015 Plan"
       }
      }
     },
     "localname": "TwoThousandFifteenEvolentHealthInc.OmnibusIncentiveCompensationPlanMember",
     "nsuri": "http://www.evolenthealth.com/20211231",
     "presentation": [
      "http://www.evolenthealth.com/role/StockbasedCompensation2011and2015EquityIncentivePlansDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "evh_UniversityHealthCaredbaPassportHealthPlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "University Health Care d/b/a Passport Health Plan [Member]",
        "label": "University Health Care d/b/a Passport Health Plan [Member]",
        "terseLabel": "Passport"
       }
      }
     },
     "localname": "UniversityHealthCaredbaPassportHealthPlanMember",
     "nsuri": "http://www.evolenthealth.com/20211231",
     "presentation": [
      "http://www.evolenthealth.com/role/CommitmentsandContingenciesAdditionalInformationDetails",
      "http://www.evolenthealth.com/role/CommitmentsandContingenciesConcentrationRiskDetails",
      "http://www.evolenthealth.com/role/NoncontrollingInterestsDetails",
      "http://www.evolenthealth.com/role/TransactionsEquityInvestmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "evh_UnrecognizedTaxBenefitsThatWouldNotImpactEffectiveTaxRate": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unrecognized Tax Benefits That Would Not Impact Effective Tax Rate",
        "label": "Unrecognized Tax Benefits That Would Not Impact Effective Tax Rate",
        "terseLabel": "Unrecognized tax benefits that would not impact effective tax rate"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsThatWouldNotImpactEffectiveTaxRate",
     "nsuri": "http://www.evolenthealth.com/20211231",
     "presentation": [
      "http://www.evolenthealth.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "evh_ValuationAllowancesAndReservesChargedCreditedToAdditionalPaidInCapital": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Valuation Allowances and Reserves, Charged (Credited) to Additional Paid-in Capital",
        "label": "Valuation Allowances and Reserves, Charged (Credited) to Additional Paid-in Capital",
        "terseLabel": "Valuation allowance increase (decrease) charged to additional paid-in capital"
       }
      }
     },
     "localname": "ValuationAllowancesAndReservesChargedCreditedToAdditionalPaidInCapital",
     "nsuri": "http://www.evolenthealth.com/20211231",
     "presentation": [
      "http://www.evolenthealth.com/role/IncomeTaxesChangesinValuationAllowanceDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "evh_ValuationAllowancesAndReservesChargedToRetainedEarnings": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Valuation Allowances and Reserves, Charged to Retained Earnings",
        "label": "Valuation Allowances and Reserves, Charged to Retained Earnings",
        "terseLabel": "Valuation allowance increase (decrease) charged to retained earnings"
       }
      }
     },
     "localname": "ValuationAllowancesAndReservesChargedToRetainedEarnings",
     "nsuri": "http://www.evolenthealth.com/20211231",
     "presentation": [
      "http://www.evolenthealth.com/role/IncomeTaxesChangesinValuationAllowanceDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "evh_VariableInterestEntityNewMedicaidContractNotAwardedRequirementToAcquireOwnershipConsiderationAmount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Variable Interest Entity, New Medicaid Contract Not Awarded, Requirement To Acquire Ownership, Consideration, Amount",
        "label": "Variable Interest Entity, New Medicaid Contract Not Awarded, Requirement To Acquire Ownership, Consideration, Amount",
        "terseLabel": "Requirement to acquire ownership, consideration, amount"
       }
      }
     },
     "localname": "VariableInterestEntityNewMedicaidContractNotAwardedRequirementToAcquireOwnershipConsiderationAmount",
     "nsuri": "http://www.evolenthealth.com/20211231",
     "presentation": [
      "http://www.evolenthealth.com/role/NoncontrollingInterestsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "evh_VitalDecisionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Vital Decisions",
        "label": "Vital Decisions [Member]",
        "terseLabel": "Vital Decisions"
       }
      }
     },
     "localname": "VitalDecisionsMember",
     "nsuri": "http://www.evolenthealth.com/20211231",
     "presentation": [
      "http://www.evolenthealth.com/role/TransactionsVitalDecisionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "evh_VivantHealthMSOLLCMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Vivant Health MSO, LLC [Member]",
        "label": "Vivant Health MSO, LLC [Member]",
        "terseLabel": "Vivant"
       }
      }
     },
     "localname": "VivantHealthMSOLLCMember",
     "nsuri": "http://www.evolenthealth.com/20211231",
     "presentation": [
      "http://www.evolenthealth.com/role/TransactionsEquityInvestmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "evh_WeightedAverageRemainingContractualTermAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted Average Remaining Contractual Term [Abstract]",
        "label": "Weighted Average Remaining Contractual Term [Abstract]",
        "terseLabel": "Weighted Average Remaining Contractual Term"
       }
      }
     },
     "localname": "WeightedAverageRemainingContractualTermAbstract",
     "nsuri": "http://www.evolenthealth.com/20211231",
     "presentation": [
      "http://www.evolenthealth.com/role/StockbasedCompensationPerformancebasedStockOptionAwardsDetails",
      "http://www.evolenthealth.com/role/StockbasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_AffiliatedEntityMember": {
     "auth_ref": [
      "r522",
      "r769",
      "r770",
      "r772",
      "r915"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Affiliated Entity [Member]",
        "terseLabel": "Affiliated Entity"
       }
      }
     },
     "localname": "AffiliatedEntityMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/RelatedPartiesAssetsandLiabilitiesDetails",
      "http://www.evolenthealth.com/role/RelatedPartiesRevenuesandExpensesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ConsolidatedEntitiesAxis": {
     "auth_ref": [
      "r174",
      "r393",
      "r398",
      "r406",
      "r676",
      "r677",
      "r684",
      "r685",
      "r775",
      "r915"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consolidated Entities [Axis]",
        "terseLabel": "Consolidated Entities [Axis]"
       }
      }
     },
     "localname": "ConsolidatedEntitiesAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/CommitmentsandContingenciesAdditionalInformationDetails",
      "http://www.evolenthealth.com/role/InvestmentsinEquityMethodInvesteesDetails",
      "http://www.evolenthealth.com/role/NoncontrollingInterestsDetails",
      "http://www.evolenthealth.com/role/TransactionsEquityInvestmentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ConsolidatedEntitiesDomain": {
     "auth_ref": [
      "r174",
      "r393",
      "r398",
      "r406",
      "r676",
      "r677",
      "r684",
      "r685",
      "r775",
      "r915"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consolidated Entities [Domain]",
        "terseLabel": "Consolidated Entities [Domain]"
       }
      }
     },
     "localname": "ConsolidatedEntitiesDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/CommitmentsandContingenciesAdditionalInformationDetails",
      "http://www.evolenthealth.com/role/InvestmentsinEquityMethodInvesteesDetails",
      "http://www.evolenthealth.com/role/NoncontrollingInterestsDetails",
      "http://www.evolenthealth.com/role/TransactionsEquityInvestmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ConsolidationItemsAxis": {
     "auth_ref": [
      "r174",
      "r250",
      "r268",
      "r269",
      "r270",
      "r271",
      "r272",
      "r274",
      "r278",
      "r393",
      "r394",
      "r395",
      "r396",
      "r397",
      "r398",
      "r400",
      "r401",
      "r403",
      "r405",
      "r406"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consolidation Items [Axis]",
        "terseLabel": "Consolidation Items [Axis]"
       }
      }
     },
     "localname": "ConsolidationItemsAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/SegmentReportingRevenuefromSegmentstoConsolidatedDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ConsolidationItemsDomain": {
     "auth_ref": [
      "r174",
      "r250",
      "r268",
      "r269",
      "r270",
      "r271",
      "r272",
      "r274",
      "r278",
      "r393",
      "r394",
      "r395",
      "r396",
      "r397",
      "r398",
      "r400",
      "r401",
      "r403",
      "r405",
      "r406"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consolidation Items [Domain]",
        "terseLabel": "Consolidation Items [Domain]"
       }
      }
     },
     "localname": "ConsolidationItemsDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/SegmentReportingRevenuefromSegmentstoConsolidatedDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_CounterpartyNameAxis": {
     "auth_ref": [
      "r89",
      "r91",
      "r172",
      "r173",
      "r414",
      "r456"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Axis]",
        "terseLabel": "Counterparty Name [Axis]"
       }
      }
     },
     "localname": "CounterpartyNameAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/TransactionsEquityInvestmentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember": {
     "auth_ref": [
      "r2",
      "r186",
      "r197",
      "r203",
      "r309",
      "r580",
      "r581",
      "r582",
      "r624",
      "r625",
      "r697",
      "r700",
      "r703",
      "r704",
      "r934"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cumulative Effect, Period of Adoption, Adjustment [Member]",
        "terseLabel": "Cumulative Effect, Period of Adoption, Adjustment"
       }
      }
     },
     "localname": "CumulativeEffectPeriodOfAdoptionAdjustmentMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY",
      "http://www.evolenthealth.com/role/CreditLossesScheduleofChangesinAllowanceforAccountsReceivableDetails",
      "http://www.evolenthealth.com/role/RecentlyIssuedAccountingStandardsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_CumulativeEffectPeriodOfAdoptionAxis": {
     "auth_ref": [
      "r2",
      "r186",
      "r197",
      "r203",
      "r309",
      "r580",
      "r581",
      "r582",
      "r624",
      "r625",
      "r697",
      "r700",
      "r703",
      "r704",
      "r934"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cumulative Effect, Period of Adoption [Axis]",
        "terseLabel": "Cumulative Effect Period Of Adoption [Axis]"
       }
      }
     },
     "localname": "CumulativeEffectPeriodOfAdoptionAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY",
      "http://www.evolenthealth.com/role/CreditLossesScheduleofChangesinAllowanceforAccountsReceivableDetails",
      "http://www.evolenthealth.com/role/RecentlyIssuedAccountingStandardsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_CumulativeEffectPeriodOfAdoptionDomain": {
     "auth_ref": [
      "r2",
      "r186",
      "r197",
      "r203",
      "r309",
      "r580",
      "r581",
      "r582",
      "r624",
      "r625",
      "r697",
      "r700",
      "r703",
      "r704",
      "r934"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cumulative Effect, Period of Adoption [Domain]",
        "terseLabel": "Cumulative Effect Period Of Adoption [Domain]"
       }
      }
     },
     "localname": "CumulativeEffectPeriodOfAdoptionDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY",
      "http://www.evolenthealth.com/role/CreditLossesScheduleofChangesinAllowanceforAccountsReceivableDetails",
      "http://www.evolenthealth.com/role/RecentlyIssuedAccountingStandardsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_EquityMethodInvesteeNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment, Name [Domain]",
        "terseLabel": "Investment, Name [Domain]"
       }
      }
     },
     "localname": "EquityMethodInvesteeNameDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/CommitmentsandContingenciesAdditionalInformationDetails",
      "http://www.evolenthealth.com/role/InvestmentsinEquityMethodInvesteesDetails",
      "http://www.evolenthealth.com/role/NoncontrollingInterestsDetails",
      "http://www.evolenthealth.com/role/TransactionsEquityInvestmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MajorCustomersAxis": {
     "auth_ref": [
      "r285",
      "r496",
      "r502",
      "r875"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer [Axis]",
        "terseLabel": "Customer [Axis]"
       }
      }
     },
     "localname": "MajorCustomersAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/CommitmentsandContingenciesConcentrationRiskDetails",
      "http://www.evolenthealth.com/role/RevenueRecognitionDisaggregationofRevenueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r413",
      "r455",
      "r533",
      "r535",
      "r782",
      "r783",
      "r784",
      "r785",
      "r786",
      "r787",
      "r788",
      "r872",
      "r876",
      "r916",
      "r917"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]",
        "terseLabel": "Maximum",
        "verboseLabel": "Maximum"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesEstimatedUsefulLifeofPropertyPlantandEquipmentDetails",
      "http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesIntangibleAssetsNetDetails",
      "http://www.evolenthealth.com/role/InvestmentsinEquityMethodInvesteesDetails",
      "http://www.evolenthealth.com/role/LongtermDebtCreditAgreementDetails",
      "http://www.evolenthealth.com/role/StockbasedCompensationPerformancebasedRSUsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [
      "r413",
      "r455",
      "r533",
      "r535",
      "r782",
      "r783",
      "r784",
      "r785",
      "r786",
      "r787",
      "r788",
      "r872",
      "r876",
      "r916",
      "r917"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]",
        "terseLabel": "Minimum"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesEstimatedUsefulLifeofPropertyPlantandEquipmentDetails",
      "http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesIntangibleAssetsNetDetails",
      "http://www.evolenthealth.com/role/InvestmentsinEquityMethodInvesteesDetails",
      "http://www.evolenthealth.com/role/StockbasedCompensationPerformancebasedRSUsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_NameOfMajorCustomerDomain": {
     "auth_ref": [
      "r285",
      "r496",
      "r502",
      "r875"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer [Domain]",
        "terseLabel": "Customer [Domain]"
       }
      }
     },
     "localname": "NameOfMajorCustomerDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/CommitmentsandContingenciesConcentrationRiskDetails",
      "http://www.evolenthealth.com/role/RevenueRecognitionDisaggregationofRevenueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_OwnershipAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Ownership [Axis]",
        "terseLabel": "Ownership [Axis]"
       }
      }
     },
     "localname": "OwnershipAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/NoncontrollingInterestsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_OwnershipDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Ownership [Domain]",
        "terseLabel": "Ownership [Domain]"
       }
      }
     },
     "localname": "OwnershipDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/NoncontrollingInterestsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ProductOrServiceAxis": {
     "auth_ref": [
      "r281",
      "r496",
      "r500",
      "r794",
      "r871",
      "r873"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Axis]",
        "terseLabel": "Product and Service [Axis]"
       }
      }
     },
     "localname": "ProductOrServiceAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS",
      "http://www.evolenthealth.com/role/CommitmentsandContingenciesConcentrationRiskDetails",
      "http://www.evolenthealth.com/role/DiscontinuedOperationsSummaryofCurrentandLongtermAssetsandLiabilitiesDetails",
      "http://www.evolenthealth.com/role/DiscontinuedOperationsSummaryofResultsofOperationsDetails",
      "http://www.evolenthealth.com/role/RelatedPartiesRevenuesandExpensesDetails",
      "http://www.evolenthealth.com/role/SegmentReportingRevenuefromSegmentstoConsolidatedDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ProductsAndServicesDomain": {
     "auth_ref": [
      "r281",
      "r496",
      "r500",
      "r794",
      "r871",
      "r873"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Domain]",
        "terseLabel": "Product and Service [Domain]"
       }
      }
     },
     "localname": "ProductsAndServicesDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS",
      "http://www.evolenthealth.com/role/CommitmentsandContingenciesConcentrationRiskDetails",
      "http://www.evolenthealth.com/role/DiscontinuedOperationsSummaryofCurrentandLongtermAssetsandLiabilitiesDetails",
      "http://www.evolenthealth.com/role/DiscontinuedOperationsSummaryofResultsofOperationsDetails",
      "http://www.evolenthealth.com/role/RelatedPartiesRevenuesandExpensesDetails",
      "http://www.evolenthealth.com/role/SegmentReportingRevenuefromSegmentstoConsolidatedDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r413",
      "r455",
      "r512",
      "r533",
      "r535",
      "r782",
      "r783",
      "r784",
      "r785",
      "r786",
      "r787",
      "r788",
      "r872",
      "r876",
      "r916",
      "r917"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]",
        "terseLabel": "Statistical Measurement [Axis]"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesEstimatedUsefulLifeofPropertyPlantandEquipmentDetails",
      "http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesIntangibleAssetsNetDetails",
      "http://www.evolenthealth.com/role/InvestmentsinEquityMethodInvesteesDetails",
      "http://www.evolenthealth.com/role/LongtermDebtCreditAgreementDetails",
      "http://www.evolenthealth.com/role/StockbasedCompensationPerformancebasedRSUsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r413",
      "r455",
      "r512",
      "r533",
      "r535",
      "r782",
      "r783",
      "r784",
      "r785",
      "r786",
      "r787",
      "r788",
      "r872",
      "r876",
      "r916",
      "r917"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Domain]",
        "terseLabel": "Statistical Measurement [Domain]"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesEstimatedUsefulLifeofPropertyPlantandEquipmentDetails",
      "http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesIntangibleAssetsNetDetails",
      "http://www.evolenthealth.com/role/InvestmentsinEquityMethodInvesteesDetails",
      "http://www.evolenthealth.com/role/LongtermDebtCreditAgreementDetails",
      "http://www.evolenthealth.com/role/StockbasedCompensationPerformancebasedRSUsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RepurchaseAgreementCounterpartyNameDomain": {
     "auth_ref": [
      "r90",
      "r91",
      "r172",
      "r173",
      "r414",
      "r456"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Domain]",
        "terseLabel": "Counterparty Name [Domain]"
       }
      }
     },
     "localname": "RepurchaseAgreementCounterpartyNameDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/TransactionsEquityInvestmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis": {
     "auth_ref": [
      "r301"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment, Name [Axis]",
        "terseLabel": "Investment, Name [Axis]"
       }
      }
     },
     "localname": "ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/CommitmentsandContingenciesAdditionalInformationDetails",
      "http://www.evolenthealth.com/role/InvestmentsinEquityMethodInvesteesDetails",
      "http://www.evolenthealth.com/role/NoncontrollingInterestsDetails",
      "http://www.evolenthealth.com/role/TransactionsEquityInvestmentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_SegmentGeographicalDomain": {
     "auth_ref": [
      "r282",
      "r283",
      "r496",
      "r501",
      "r874",
      "r906",
      "r907",
      "r908",
      "r909",
      "r910",
      "r911",
      "r912",
      "r913",
      "r914"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Domain]",
        "terseLabel": "Geographical [Domain]"
       }
      }
     },
     "localname": "SegmentGeographicalDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/LeasesPrimaryOfficeLeasesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_StatementGeographicalAxis": {
     "auth_ref": [
      "r282",
      "r283",
      "r496",
      "r501",
      "r874",
      "r896",
      "r906",
      "r907",
      "r908",
      "r909",
      "r910",
      "r911",
      "r912",
      "r913",
      "r914"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Axis]",
        "terseLabel": "Geographical [Axis]"
       }
      }
     },
     "localname": "StatementGeographicalAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/LeasesPrimaryOfficeLeasesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "stpr_CA": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "CALIFORNIA",
        "terseLabel": "Brea, CA"
       }
      }
     },
     "localname": "CA",
     "nsuri": "http://xbrl.sec.gov/stpr/2021",
     "presentation": [
      "http://www.evolenthealth.com/role/LeasesPrimaryOfficeLeasesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "stpr_IL": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "ILLINOIS",
        "terseLabel": "Riverside, IL"
       }
      }
     },
     "localname": "IL",
     "nsuri": "http://xbrl.sec.gov/stpr/2021",
     "presentation": [
      "http://www.evolenthealth.com/role/LeasesPrimaryOfficeLeasesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "stpr_NJ": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "NEW JERSEY",
        "terseLabel": "Edison, NJ"
       }
      }
     },
     "localname": "NJ",
     "nsuri": "http://xbrl.sec.gov/stpr/2021",
     "presentation": [
      "http://www.evolenthealth.com/role/LeasesPrimaryOfficeLeasesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "stpr_VA": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "VIRGINIA",
        "terseLabel": "Arlington, VA"
       }
      }
     },
     "localname": "VA",
     "nsuri": "http://xbrl.sec.gov/stpr/2021",
     "presentation": [
      "http://www.evolenthealth.com/role/LeasesPrimaryOfficeLeasesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]",
        "terseLabel": "Accounting Policies [Abstract]"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountingStandardsUpdateExtensibleList": {
     "auth_ref": [
      "r0",
      "r1",
      "r2",
      "r3",
      "r4",
      "r189",
      "r190",
      "r191",
      "r193",
      "r293",
      "r294",
      "r306",
      "r307",
      "r308",
      "r309",
      "r312",
      "r313",
      "r392",
      "r576",
      "r577",
      "r578",
      "r579",
      "r580",
      "r581",
      "r582",
      "r584",
      "r624",
      "r625",
      "r694",
      "r695",
      "r696",
      "r697",
      "r698",
      "r699",
      "r700",
      "r702",
      "r703",
      "r704",
      "r705",
      "r723",
      "r724",
      "r725",
      "r726",
      "r727",
      "r728",
      "r732",
      "r733",
      "r765",
      "r877",
      "r878",
      "r879",
      "r880",
      "r881",
      "r882",
      "r883",
      "r884",
      "r885",
      "r886",
      "r887",
      "r888",
      "r932",
      "r933",
      "r934",
      "r935",
      "r936"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates amendment to accounting standards.",
        "label": "Accounting Standards Update [Extensible Enumeration]",
        "terseLabel": "Accounting Standards Update [Extensible Enumeration]"
       }
      }
     },
     "localname": "AccountingStandardsUpdateExtensibleList",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY",
      "http://www.evolenthealth.com/role/RecentlyIssuedAccountingStandardsDetails"
     ],
     "xbrltype": "enumerationSetItemType"
    },
    "us-gaap_AccountsNotesAndLoansReceivableLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Accounts, Notes, Loans and Financing Receivable [Line Items]",
        "terseLabel": "Accounts, Notes, Loans and Financing Receivable [Line Items]"
       }
      }
     },
     "localname": "AccountsNotesAndLoansReceivableLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/CreditLossesScheduleofChangesinAllowanceforAccountsReceivableDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsNotesAndLoansReceivableNetCurrent": {
     "auth_ref": [
      "r38",
      "r54",
      "r86",
      "r287",
      "r288",
      "r843"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of accounts and financing receivables, classified as current. Includes, but is not limited to, notes and loan receivable.",
        "label": "Accounts and Financing Receivable, after Allowance for Credit Loss, Current",
        "terseLabel": "Short-term receivables"
       }
      }
     },
     "localname": "AccountsNotesAndLoansReceivableNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/RevenueRecognitionContractBalancesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis": {
     "auth_ref": [
      "r86"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of receivable.",
        "label": "Receivable Type [Axis]",
        "terseLabel": "Receivable Type [Axis]"
       }
      }
     },
     "localname": "AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/CommitmentsandContingenciesConcentrationRiskDetails",
      "http://www.evolenthealth.com/role/TransactionsEquityInvestmentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r71",
      "r778"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable, Current",
        "terseLabel": "Accounts payable",
        "verboseLabel": "Accounts payable"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.evolenthealth.com/role/RelatedPartiesAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableAllowanceForCreditLossTableTextBlock": {
     "auth_ref": [
      "r318"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of allowance for credit loss on accounts receivable.",
        "label": "Accounts Receivable, Allowance for Credit Loss [Table Text Block]",
        "terseLabel": "Accounts receivable, allowance for credit loss"
       }
      }
     },
     "localname": "AccountsReceivableAllowanceForCreditLossTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/CreditLossesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_AccountsReceivableMember": {
     "auth_ref": [
      "r901"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Due from customers or clients for goods or services that have been delivered or sold.",
        "label": "Accounts Receivable [Member]",
        "terseLabel": "Accounts Receivable"
       }
      }
     },
     "localname": "AccountsReceivableMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/CommitmentsandContingenciesConcentrationRiskDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountsReceivableNet": {
     "auth_ref": [
      "r54",
      "r843",
      "r900"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business.",
        "label": "Accounts Receivable, after Allowance for Credit Loss",
        "terseLabel": "Accounts receivable, net"
       }
      }
     },
     "localname": "AccountsReceivableNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/CreditLossesAccountsReceivableNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "auth_ref": [
      "r38",
      "r54",
      "r287",
      "r288"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 5.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.",
        "label": "Accounts Receivable, after Allowance for Credit Loss, Current",
        "netLabel": "Accounts receivable, net",
        "terseLabel": "Accounts receivable, net"
       }
      }
     },
     "localname": "AccountsReceivableNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.evolenthealth.com/role/RelatedPartiesAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableNoncurrentPastDueLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Accounts Receivable, Noncurrent, Past Due [Line Items]",
        "terseLabel": "Accounts Receivable, Noncurrent, Past Due [Line Items]"
       }
      }
     },
     "localname": "AccountsReceivableNoncurrentPastDueLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/CreditLossesAccountsReceivableNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsReceivableNoncurrentPastDueTable": {
     "auth_ref": [
      "r319"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about aging analysis for accounts receivable, classified as noncurrent.",
        "label": "Accounts Receivable, Noncurrent, Past Due [Table]",
        "terseLabel": "Accounts Receivable, Noncurrent, Past Due [Table]"
       }
      }
     },
     "localname": "AccountsReceivableNoncurrentPastDueTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/CreditLossesAccountsReceivableNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r75"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 6.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Liabilities, Current",
        "terseLabel": "Accrued liabilities",
        "verboseLabel": "Accrued liabilities"
       }
      }
     },
     "localname": "AccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.evolenthealth.com/role/RelatedPartiesAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "auth_ref": [
      "r69",
      "r361"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/PropertyandEquipmentNetDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.",
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "negatedTerseLabel": "Accumulated depreciation and amortization expenses"
       }
      }
     },
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/PropertyandEquipmentNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r57",
      "r94",
      "r95",
      "r96",
      "r849",
      "r884",
      "r888"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.",
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "terseLabel": "Accumulated other comprehensive income (loss)"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife": {
     "auth_ref": [
      "r346"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average amortization period of finite-lived intangible assets acquired either individually or as part of a group of assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Acquired Finite-lived Intangible Assets, Weighted Average Useful Life",
        "terseLabel": "Weighted- Average Remaining Useful Life",
        "verboseLabel": "Useful life"
       }
      }
     },
     "localname": "AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNetIntangibleAssetsNetDetails",
      "http://www.evolenthealth.com/role/TransactionsVitalDecisionsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_AdditionalPaidInCapital": {
     "auth_ref": [
      "r55",
      "r584",
      "r778"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.",
        "label": "Additional Paid in Capital",
        "terseLabel": "Additional paid-in-capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapital",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r183",
      "r184",
      "r185",
      "r580",
      "r581",
      "r582",
      "r703"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital [Member]",
        "terseLabel": "Additional Paid-In Capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt": {
     "auth_ref": [
      "r409"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Adjustment to additional paid in capital resulting from the recognition of convertible debt instruments as two separate components - a debt component and an equity component. This bifurcation may result in a basis difference associated with the liability component that represents a temporary difference for purposes of applying accounting for income taxes. The initial recognition of deferred taxes for the tax effect of that temporary difference is as an adjustment to additional paid in capital.",
        "label": "Adjustments to Additional Paid in Capital, Equity Component of Convertible Debt",
        "terseLabel": "Equity component of 2024 notes, net of issuance costs"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "auth_ref": [
      "r537",
      "r539",
      "r587",
      "r588"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.",
        "label": "APIC, Share-based Payment Arrangement, Increase for Cost Recognition",
        "terseLabel": "Stock-based compensation expense"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Adjustments to reconcile net loss to net cash and restricted cash used in operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "auth_ref": [
      "r539",
      "r571",
      "r586"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.",
        "label": "Share-based Payment Arrangement, Expense",
        "terseLabel": "Share-based compensation expense"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/StockbasedCompensationStockbasedCompensationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent": {
     "auth_ref": [
      "r61",
      "r289",
      "r314"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of allowance for credit loss on accounts receivable, classified as current.",
        "label": "Accounts Receivable, Allowance for Credit Loss, Current",
        "negatedPeriodEndLabel": "Balance as of end of period",
        "negatedPeriodStartLabel": "Balance as of beginning of period",
        "terseLabel": "Allowance for doubtful accounts, current"
       }
      }
     },
     "localname": "AllowanceForDoubtfulAccountsReceivableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/CreditLossesAccountsReceivableNarrativeDetails",
      "http://www.evolenthealth.com/role/CreditLossesScheduleofChangesinAllowanceforAccountsReceivableDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Accounts Receivable, Allowance for Credit Loss [Roll Forward]",
        "terseLabel": "Accounts Receivable, Allowance for Credit Loss [Roll Forward]"
       }
      }
     },
     "localname": "AllowanceForDoubtfulAccountsReceivableRollforward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/CreditLossesScheduleofChangesinAllowanceforAccountsReceivableDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs": {
     "auth_ref": [
      "r317"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of direct write-downs of accounts receivable charged against the allowance.",
        "label": "Accounts Receivable, Allowance for Credit Loss, Writeoff",
        "terseLabel": "Charge-offs"
       }
      }
     },
     "localname": "AllowanceForDoubtfulAccountsReceivableWriteOffs",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/CreditLossesScheduleofChangesinAllowanceforAccountsReceivableDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AmortizationOfFinancingCosts": {
     "auth_ref": [
      "r117",
      "r150",
      "r433",
      "r744"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization expense attributable to debt issuance costs.",
        "label": "Amortization of Debt Issuance Costs",
        "terseLabel": "Amortization of deferred financing costs",
        "verboseLabel": "Amortization of deferred financing costs"
       }
      }
     },
     "localname": "AmortizationOfFinancingCosts",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.evolenthealth.com/role/LongtermDebt2021NotesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AmortizationOfIntangibleAssets": {
     "auth_ref": [
      "r150",
      "r344",
      "r351"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.",
        "label": "Amortization of Intangible Assets",
        "terseLabel": "Amortization of intangible assets"
       }
      }
     },
     "localname": "AmortizationOfIntangibleAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNetIntangibleAssetsNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r220"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "terseLabel": "Number of antidilutive securities excluded from the calculation of earning per share (in shares)"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/EarningsLossPerCommonShareAntidilutiveSecuritiesDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "auth_ref": [
      "r220"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of antidilutive security.",
        "label": "Antidilutive Securities [Axis]",
        "terseLabel": "Antidilutive Securities [Axis]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/EarningsLossPerCommonShareAntidilutiveSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "terseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/EarningsLossPerCommonShareAntidilutiveSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "auth_ref": [
      "r220"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.",
        "label": "Antidilutive Securities, Name [Domain]",
        "terseLabel": "Antidilutive Securities, Name [Domain]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/EarningsLossPerCommonShareAntidilutiveSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember": {
     "auth_ref": [
      "r93",
      "r96",
      "r103",
      "r104",
      "r105",
      "r682"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, including the portion attributable to the noncontrolling interest. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.",
        "label": "AOCI Including Portion Attributable to Noncontrolling Interest [Member]",
        "terseLabel": "Accumulated Other Comprehensive Income (Loss)"
       }
      }
     },
     "localname": "AociIncludingPortionAttributableToNoncontrollingInterestMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AssetAcquisitionAxis": {
     "auth_ref": [
      "r667"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by asset acquisition.",
        "label": "Asset Acquisition [Axis]",
        "terseLabel": "Asset Acquisition [Axis]"
       }
      }
     },
     "localname": "AssetAcquisitionAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/TransactionsEquityInvestmentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetAcquisitionDomain": {
     "auth_ref": [
      "r667"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Asset acquisition.",
        "label": "Asset Acquisition [Domain]",
        "terseLabel": "Asset Acquisition [Domain]"
       }
      }
     },
     "localname": "AssetAcquisitionDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/TransactionsEquityInvestmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r167",
      "r258",
      "r270",
      "r276",
      "r304",
      "r393",
      "r394",
      "r395",
      "r397",
      "r398",
      "r399",
      "r400",
      "r402",
      "r404",
      "r406",
      "r407",
      "r676",
      "r684",
      "r722",
      "r776",
      "r778",
      "r819",
      "r845"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "ASSETS"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.evolenthealth.com/role/RelatedPartiesAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r39",
      "r40",
      "r88",
      "r167",
      "r304",
      "r393",
      "r394",
      "r395",
      "r397",
      "r398",
      "r399",
      "r400",
      "r402",
      "r404",
      "r406",
      "r407",
      "r676",
      "r684",
      "r722",
      "r776",
      "r778"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "terseLabel": "Current assets:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsFairValueDisclosure": {
     "auth_ref": [
      "r706"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/FairValueMeasurementAssetsandLiabilitiesonRecurringBasisDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Fair Value Disclosure",
        "totalLabel": "Total fair value of assets measured on a recurring basis"
       }
      }
     },
     "localname": "AssetsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/FairValueMeasurementAssetsandLiabilitiesonRecurringBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsFairValueDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Fair Value Disclosure [Abstract]",
        "terseLabel": "Assets"
       }
      }
     },
     "localname": "AssetsFairValueDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/FairValueMeasurementAssetsandLiabilitiesonRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation": {
     "auth_ref": [
      "r6",
      "r7",
      "r27",
      "r29",
      "r33",
      "r364"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/DiscontinuedOperationsSummaryofCurrentandLongtermAssetsandLiabilitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount classified as assets attributable to disposal group held for sale or disposed of.",
        "label": "Disposal Group, Including Discontinued Operation, Assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "AssetsOfDisposalGroupIncludingDiscontinuedOperation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/DiscontinuedOperationsSummaryofCurrentandLongtermAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disposal Group, Including Discontinued Operation, Assets [Abstract]",
        "terseLabel": "ASSETS"
       }
      }
     },
     "localname": "AssetsOfDisposalGroupIncludingDiscontinuedOperationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/DiscontinuedOperationsSummaryofCurrentandLongtermAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent": {
     "auth_ref": [
      "r6",
      "r7",
      "r27",
      "r29",
      "r33",
      "r358",
      "r364"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      },
      "http://www.evolenthealth.com/role/DiscontinuedOperationsSummaryofCurrentandLongtermAssetsandLiabilitiesDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount classified as assets attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer.",
        "label": "Disposal Group, Including Discontinued Operation, Assets, Current",
        "terseLabel": "Current assets of discontinued operations",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.evolenthealth.com/role/DiscontinuedOperationsSummaryofCurrentandLongtermAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disposal Group, Including Discontinued Operation, Assets, Current [Abstract]",
        "terseLabel": "Current assets:"
       }
      }
     },
     "localname": "AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/DiscontinuedOperationsSummaryofCurrentandLongtermAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssumedLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense": {
     "auth_ref": [
      "r865",
      "r868"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Liability as of the balance sheet date for the estimated ultimate cost of settling claims and claim adjustment expense relating to insured events that have occurred on or before the balance sheet date for those liabilities owed to another party as a result of assuming another insurer's primary obligation.",
        "label": "Assumed Liability for Unpaid Claims and Claims Adjustment Expense",
        "periodEndLabel": "Payable for claims and performance-based arrangements attributable to the Reinsurance Agreement at the end of the period",
        "periodStartLabel": "Reserves for claims and performance-based arrangements attributable to the Reinsurance Agreement at the beginning of the period"
       }
      }
     },
     "localname": "AssumedLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/CommitmentsandContingenciesReinsuranceAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssumedPremiumsWritten": {
     "auth_ref": [
      "r890"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of written premiums assumed from other entities.",
        "label": "Assumed Premiums Written",
        "terseLabel": "Reinsurance premiums assumed"
       }
      }
     },
     "localname": "AssumedPremiumsWritten",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/CommitmentsandContingenciesReinsuranceAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r540",
      "r574"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type [Axis]"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesStockbasedCompensationDetails",
      "http://www.evolenthealth.com/role/StockbasedCompensation2011and2015EquityIncentivePlansDetails",
      "http://www.evolenthealth.com/role/StockbasedCompensationLeveragedStockUnitsActivityDetails",
      "http://www.evolenthealth.com/role/StockbasedCompensationLeveragedStockUnitsDetails",
      "http://www.evolenthealth.com/role/StockbasedCompensationPerformancebasedRSUActivityDetails",
      "http://www.evolenthealth.com/role/StockbasedCompensationPerformancebasedRSUsDetails",
      "http://www.evolenthealth.com/role/StockbasedCompensationPerformancebasedStockOptionAwardsDetails",
      "http://www.evolenthealth.com/role/StockbasedCompensationRestrictedStockUnitsDetails",
      "http://www.evolenthealth.com/role/StockbasedCompensationStockOptionsDetails",
      "http://www.evolenthealth.com/role/StockbasedCompensationStockbasedCompensationExpenseDetails",
      "http://www.evolenthealth.com/role/StockbasedCompensationUnrecognizedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BankTimeDepositsMember": {
     "auth_ref": [
      "r835"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Certificates of deposit (CD) or savings accounts with a fixed term or understanding the customer can only withdraw by giving advanced notice with a bank or other financial institution. A CD is a short to medium-term investment available at banks and savings and loan institutions where a customer agrees to lend money to the institution for a certain amount of time and is paid a predetermined rate of interest.",
        "label": "Bank Time Deposits [Member]",
        "terseLabel": "Bank time deposits"
       }
      }
     },
     "localname": "BankTimeDepositsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesRestrictedCashandRestrictedInvestmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BaseRateMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Minimum rate investor will accept.",
        "label": "Base Rate [Member]",
        "terseLabel": "Base Rate"
       }
      }
     },
     "localname": "BaseRateMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/LongtermDebtCreditAgreementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "terseLabel": "Basis of Presentation"
       }
      }
     },
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r182"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).  Accounting policies describe all significant accounting policies of the reporting entity.",
        "label": "Basis of Presentation and Significant Accounting Policies [Text Block]",
        "terseLabel": "Basis of Presentation, Summary of Significant Accounting Policies and Change in Accounting Principles"
       }
      }
     },
     "localname": "BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciples"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BusinessAcquisitionAcquireeDomain": {
     "auth_ref": [
      "r532",
      "r534"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree.",
        "label": "Business Acquisition, Acquiree [Domain]",
        "terseLabel": "Business Acquisition, Acquiree [Domain]"
       }
      }
     },
     "localname": "BusinessAcquisitionAcquireeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/StockbasedCompensationRestrictedStockUnitsDetails",
      "http://www.evolenthealth.com/role/TransactionsVitalDecisionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BusinessAcquisitionAxis": {
     "auth_ref": [
      "r532",
      "r534",
      "r645",
      "r646"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by business combination or series of individually immaterial business combinations.",
        "label": "Business Acquisition [Axis]",
        "terseLabel": "Business Acquisition [Axis]"
       }
      }
     },
     "localname": "BusinessAcquisitionAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/StockbasedCompensationRestrictedStockUnitsDetails",
      "http://www.evolenthealth.com/role/TransactionsVitalDecisionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued": {
     "auth_ref": [
      "r662"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of equity interests issued or issuable to acquire entity.",
        "label": "Business Acquisition, Equity Interest Issued or Issuable, Number of Shares",
        "terseLabel": "Equity interest issued or issuable, number of shares (in shares)"
       }
      }
     },
     "localname": "BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/TransactionsVitalDecisionsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_BusinessAcquisitionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Business Acquisition [Line Items]",
        "terseLabel": "Business Acquisition [Line Items]"
       }
      }
     },
     "localname": "BusinessAcquisitionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/FairValueMeasurementAdditionalInformationDetails",
      "http://www.evolenthealth.com/role/TransactionsEquityInvestmentsDetails",
      "http://www.evolenthealth.com/role/TransactionsVitalDecisionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired": {
     "auth_ref": [
      "r644"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of voting equity interests acquired at the acquisition date in the business combination.",
        "label": "Business Acquisition, Percentage of Voting Interests Acquired",
        "terseLabel": "Voting interests acquired"
       }
      }
     },
     "localname": "BusinessAcquisitionPercentageOfVotingInterestsAcquired",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/TransactionsVitalDecisionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount": {
     "auth_ref": [
      "r665"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of goodwill arising from a business combination that is expected to be deductible for tax purposes.",
        "label": "Business Acquisition, Goodwill, Expected Tax Deductible Amount",
        "terseLabel": "Goodwill, expected tax deductible amount"
       }
      }
     },
     "localname": "BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/TransactionsVitalDecisionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationAndAssetAcquisitionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combination and Asset Acquisition [Abstract]"
       }
      }
     },
     "localname": "BusinessCombinationAndAssetAcquisitionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessCombinationConsiderationTransferred1": {
     "auth_ref": [
      "r657",
      "r658",
      "r660"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer.",
        "label": "Business Combination, Consideration Transferred",
        "terseLabel": "Total consideration"
       }
      }
     },
     "localname": "BusinessCombinationConsiderationTransferred1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/TransactionsVitalDecisionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationConsiderationTransferredAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combination, Consideration Transferred [Abstract]",
        "terseLabel": "Purchase consideration:"
       }
      }
     },
     "localname": "BusinessCombinationConsiderationTransferredAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/TransactionsVitalDecisionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable": {
     "auth_ref": [
      "r657",
      "r658"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of equity interests of the acquirer, including instruments or interests issued or issuable in consideration for the business combination.",
        "label": "Business Combination, Consideration Transferred, Equity Interests Issued and Issuable",
        "terseLabel": "Fair value of Class A common stock issued"
       }
      }
     },
     "localname": "BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/TransactionsVitalDecisionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1": {
     "auth_ref": [
      "r149",
      "r666"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS": {
       "order": 4.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement.",
        "label": "Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability",
        "negatedLabel": "Change in fair value of contingent consideration and indemnification asset",
        "terseLabel": "Change in fair value of contingent consideration and indemnification asset",
        "verboseLabel": "Change in fair value of contingent consideration and indemnification asset"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS",
      "http://www.evolenthealth.com/role/SegmentReportingReconciliationofAdjustedEBITDADetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh": {
     "auth_ref": [
      "r664"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For contingent consideration arrangements recognized in connection with a business combination, this element represents an estimate of the high-end of the potential range (undiscounted) of the consideration which may be paid.",
        "label": "Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High",
        "terseLabel": "Contingent consideration arrangements (up to)"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/TransactionsVitalDecisionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationContingentConsiderationLiability": {
     "auth_ref": [
      "r656",
      "r659",
      "r663"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/FairValueMeasurementAssetsandLiabilitiesonRecurringBasisDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesFairValueDisclosure",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liability recognized arising from contingent consideration in a business combination.",
        "label": "Business Combination, Contingent Consideration, Liability",
        "terseLabel": "Fair value of contingent consideration",
        "verboseLabel": "Fair Value"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationLiability",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/FairValueMeasurementAssetsandLiabilitiesonRecurringBasisDetails",
      "http://www.evolenthealth.com/role/FairValueMeasurementValuationTechniquesandSignificantUnobservableInputsDetails",
      "http://www.evolenthealth.com/role/TransactionsVitalDecisionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput": {
     "auth_ref": [
      "r710"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of input used to measure contingent consideration liability from business combination.",
        "label": "Business Combination, Contingent Consideration, Liability, Measurement Input",
        "verboseLabel": "Assumption or Input Ranges"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationLiabilityMeasurementInput",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/FairValueMeasurementValuationTechniquesandSignificantUnobservableInputsDetails"
     ],
     "xbrltype": "decimalItemType"
    },
    "us-gaap_BusinessCombinationDisclosureTextBlock": {
     "auth_ref": [
      "r668"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).",
        "label": "Business Combination Disclosure [Text Block]",
        "terseLabel": "Transactions"
       }
      }
     },
     "localname": "BusinessCombinationDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/Transactions"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets [Abstract]",
        "terseLabel": "Tangible assets acquired:"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/TransactionsVitalDecisionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCapitalLeaseObligation": {
     "auth_ref": [
      "r648"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/TransactionsVitalDecisionsDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lease obligation assumed in business combination.",
        "label": "Business Combination, Recognized Identifiable Asset Acquired and Liability Assumed, Lease Obligation",
        "terseLabel": "Operating lease liabilities"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCapitalLeaseObligation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/TransactionsVitalDecisionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents": {
     "auth_ref": [
      "r648"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/TransactionsVitalDecisionsDetails": {
       "order": 4.0,
       "parentTag": "evh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedTangibleAssets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions, acquired at the acquisition date. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/TransactionsVitalDecisionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets": {
     "auth_ref": [
      "r648"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/TransactionsVitalDecisionsDetails": {
       "order": 1.0,
       "parentTag": "evh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedTangibleAssets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer, acquired at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Prepaid Expense and Other Assets",
        "terseLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/TransactionsVitalDecisionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables": {
     "auth_ref": [
      "r648"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/TransactionsVitalDecisionsDetails": {
       "order": 2.0,
       "parentTag": "evh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedTangibleAssets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount due from customers or clients for goods or services, including trade receivables, that have been delivered or sold in the normal course of business, and amounts due from others, including related parties expected to be converted to cash, sold or exchanged within one year or the normal operating cycle, if longer, acquired at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Receivables",
        "verboseLabel": "Accounts receivable"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/TransactionsVitalDecisionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable": {
     "auth_ref": [
      "r648"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/TransactionsVitalDecisionsDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities incurred for goods and services received that are used in an entity's business and related party payables, assumed at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Accounts Payable",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/TransactionsVitalDecisionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue": {
     "auth_ref": [
      "r648"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/TransactionsVitalDecisionsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred revenue expected to be recognized as such within one year or the normal operating cycle, if longer, assumed at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Deferred Revenue",
        "terseLabel": "Deferred revenue"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/TransactionsVitalDecisionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities": {
     "auth_ref": [
      "r648"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/TransactionsVitalDecisionsDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences assumed at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities",
        "terseLabel": "Deferred tax liabilities, net"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/TransactionsVitalDecisionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwillAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill [Abstract]",
        "terseLabel": "Identifiable intangible assets acquired:"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwillAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/TransactionsVitalDecisionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles": {
     "auth_ref": [
      "r647",
      "r648"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/TransactionsVitalDecisionsDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of identifiable intangible assets recognized as of the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles",
        "verboseLabel": "Identifiable intangible assets"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/TransactionsVitalDecisionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities": {
     "auth_ref": [
      "r648"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/TransactionsVitalDecisionsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities assumed at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities",
        "totalLabel": "Total liabilities assumed"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/TransactionsVitalDecisionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities [Abstract]",
        "terseLabel": "Liabilities assumed:"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/TransactionsVitalDecisionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets": {
     "auth_ref": [
      "r648"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/TransactionsVitalDecisionsDetails": {
       "order": 3.0,
       "parentTag": "evh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedTangibleAssets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of other assets expected to be realized or consumed after one year or the normal operating cycle, if longer, acquired at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Other Noncurrent Assets",
        "verboseLabel": "Other non-current assets"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/TransactionsVitalDecisionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet": {
     "auth_ref": [
      "r648"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/TransactionsVitalDecisionsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount recognized for assets, including goodwill, in excess of (less than) the aggregate liabilities assumed.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net",
        "totalLabel": "Net assets acquired"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/TransactionsVitalDecisionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combinations [Abstract]",
        "terseLabel": "Business Combinations [Abstract]"
       }
      }
     },
     "localname": "BusinessCombinationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessCombinationsPolicy": {
     "auth_ref": [
      "r643"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for completed business combinations (purchase method, acquisition method or combination of entities under common control). This accounting policy may include a general discussion of the purchase method or acquisition method of accounting (including for example, the treatment accorded contingent consideration, the identification of assets and liabilities, the purchase price allocation process, how the fair values of acquired assets and liabilities are determined) and the entity's specific application thereof. An entity that acquires another entity in a leveraged buyout transaction generally discloses the accounting policy followed by the acquiring entity in determining the basis used to value its interest in the acquired entity, and the rationale for that accounting policy.",
        "label": "Business Combinations Policy [Policy Text Block]",
        "terseLabel": "Business Combinations"
       }
      }
     },
     "localname": "BusinessCombinationsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CapitalExpendituresIncurredButNotYetPaid": {
     "auth_ref": [
      "r157",
      "r158",
      "r159"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Future cash outflow to pay for purchases of fixed assets that have occurred.",
        "label": "Capital Expenditures Incurred but Not yet Paid",
        "terseLabel": "Accrued property and equipment purchases"
       }
      }
     },
     "localname": "CapitalExpendituresIncurredButNotYetPaid",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/SupplementalCashFlowInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CapitalizedComputerSoftwareAdditions": {
     "auth_ref": [
      "r345"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additions made to capitalized computer software costs during the period.",
        "label": "Capitalized Computer Software, Additions",
        "terseLabel": "Capitalized computer software additions"
       }
      }
     },
     "localname": "CapitalizedComputerSoftwareAdditions",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/PropertyandEquipmentNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CapitalizedComputerSoftwareAmortization1": {
     "auth_ref": [
      "r918",
      "r920"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for amortization of capitalized computer software costs.",
        "label": "Capitalized Computer Software, Amortization",
        "terseLabel": "Capitalized computer software, amortization"
       }
      }
     },
     "localname": "CapitalizedComputerSoftwareAmortization1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/PropertyandEquipmentNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CapitalizedContractCostAmortization": {
     "auth_ref": [
      "r330"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization expense for asset recognized from cost incurred to obtain or fulfill contract with customer.",
        "label": "Capitalized Contract Cost, Amortization",
        "terseLabel": "Amortization of contract cost assets",
        "verboseLabel": "Contract cost amortization"
       }
      }
     },
     "localname": "CapitalizedContractCostAmortization",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.evolenthealth.com/role/RevenueRecognitionContractCostsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CapitalizedContractCostAmortizationPeriod": {
     "auth_ref": [
      "r328"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortization period of cost capitalized in obtaining or fulfilling contract with customer, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Capitalized Contract Cost, Amortization Period",
        "terseLabel": "Capitalized contract cost, amortization period"
       }
      }
     },
     "localname": "CapitalizedContractCostAmortizationPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/RevenueRecognitionContractCostsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_CapitalizedContractCostAxis": {
     "auth_ref": [
      "r329"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by cost capitalized in obtaining or fulfilling contract with customer.",
        "label": "Capitalized Contract Cost [Axis]",
        "terseLabel": "Capitalized Contract Cost [Axis]"
       }
      }
     },
     "localname": "CapitalizedContractCostAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/RevenueRecognitionContractCostsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CapitalizedContractCostDomain": {
     "auth_ref": [
      "r329"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cost capitalized in obtaining and fulfilling contract with customer.",
        "label": "Capitalized Contract Cost [Domain]",
        "terseLabel": "Capitalized Contract Cost [Domain]"
       }
      }
     },
     "localname": "CapitalizedContractCostDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/RevenueRecognitionContractCostsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CapitalizedContractCostLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Capitalized Contract Cost [Line Items]",
        "terseLabel": "Capitalized Contract Cost [Line Items]"
       }
      }
     },
     "localname": "CapitalizedContractCostLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/RevenueRecognitionContractCostsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CapitalizedContractCostNet": {
     "auth_ref": [
      "r329"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after accumulated amortization and accumulated impairment loss, of asset recognized from cost incurred to obtain or fulfill contract with customer.",
        "label": "Capitalized Contract Cost, Net",
        "terseLabel": "Contract cost assets"
       }
      }
     },
     "localname": "CapitalizedContractCostNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/RevenueRecognitionContractCostsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CapitalizedContractCostNetNoncurrent": {
     "auth_ref": [
      "r329"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 6.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after accumulated amortization and accumulated impairment loss, of asset recognized from cost incurred to obtain or fulfill contract with customer; classified as noncurrent.",
        "label": "Capitalized Contract Cost, Net, Noncurrent",
        "terseLabel": "Contract cost assets"
       }
      }
     },
     "localname": "CapitalizedContractCostNetNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CapitalizedContractCostTable": {
     "auth_ref": [
      "r329"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about cost capitalized in obtaining or fulfilling contract with customer.",
        "label": "Capitalized Contract Cost [Table]",
        "terseLabel": "Capitalized Contract Cost [Table]"
       }
      }
     },
     "localname": "CapitalizedContractCostTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/RevenueRecognitionContractCostsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CashAcquiredFromAcquisition": {
     "auth_ref": [
      "r125"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the acquisition of business during the period (for example, cash that was held by the acquired business).",
        "label": "Cash Acquired from Acquisition",
        "terseLabel": "Impact to cash and cash equivalents and restricted cash from initial consolidation"
       }
      }
     },
     "localname": "CashAcquiredFromAcquisition",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r37",
      "r65",
      "r152"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.evolenthealth.com/role/OrganizationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsFairValueDisclosure": {
     "auth_ref": [],
     "calculation": {
      "http://www.evolenthealth.com/role/FairValueMeasurementAssetsandLiabilitiesonRecurringBasisDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash and Cash Equivalents, Fair Value Disclosure",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/FairValueMeasurementAssetsandLiabilitiesonRecurringBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy": {
     "auth_ref": [
      "r155"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for cash and cash equivalents with respect to unrestricted balances.",
        "label": "Cash and Cash Equivalents, Unrestricted Cash and Cash Equivalents, Policy [Policy Text Block]",
        "terseLabel": "Cash and Cash Equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r143",
      "r152",
      "r160"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents",
        "periodEndLabel": "Cash and cash equivalents and restricted cash as of end-of-period",
        "periodStartLabel": "Cash and cash equivalents and restricted cash as of beginning-of-period",
        "terseLabel": "Total cash and cash equivalents and restricted cash shown in the consolidated statements of cash flows",
        "verboseLabel": "Cash and cash equivalents (including restricted cash)"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesRestrictedCashandRestrictedInvestmentsDetails",
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.evolenthealth.com/role/CommitmentsandContingenciesConcentrationRiskDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r143",
      "r734"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "Net increase (decrease) in cash and cash equivalents and restricted cash"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]",
        "terseLabel": "Supplemental Disclosure of Non-cash Investing and Financing Activities"
       }
      }
     },
     "localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/SupplementalCashFlowInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CashFlowSupplementalDisclosuresTextBlock": {
     "auth_ref": [
      "r161"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for supplemental cash flow activities, including cash, noncash, and part noncash transactions, for the period. Noncash is defined as information about all investing and financing activities of an enterprise during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.",
        "label": "Cash Flow, Supplemental Disclosures [Text Block]",
        "terseLabel": "Supplemental Cash Flow Information"
       }
      }
     },
     "localname": "CashFlowSupplementalDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/SupplementalCashFlowInformation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations": {
     "auth_ref": [
      "r143"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) of financing activities of discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Cash Provided by (Used in) Financing Activities, Discontinued Operations",
        "terseLabel": "Cash flows used in financing activities"
       }
      }
     },
     "localname": "CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/DiscontinuedOperationsSummaryofCashFlowsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations": {
     "auth_ref": [
      "r25",
      "r143"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) of investing activities of discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Cash Provided by (Used in) Investing Activities, Discontinued Operations",
        "terseLabel": "Cash flows (used in) provided by investing activities"
       }
      }
     },
     "localname": "CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/DiscontinuedOperationsSummaryofCashFlowsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations": {
     "auth_ref": [
      "r25",
      "r143"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) of operating activities of discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Cash Provided by (Used in) Operating Activities, Discontinued Operations",
        "terseLabel": "Cash flows provided by (used in) operating activities"
       }
      }
     },
     "localname": "CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/DiscontinuedOperationsSummaryofCashFlowsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CededPremiumsWritten": {
     "auth_ref": [
      "r891",
      "r892"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of written premiums ceded to other entities.",
        "label": "Ceded Premiums Written",
        "negatedTerseLabel": "Reinsurance premiums ceded"
       }
      }
     },
     "localname": "CededPremiumsWritten",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/CommitmentsandContingenciesReinsuranceAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ClassOfStockDomain": {
     "auth_ref": [
      "r165",
      "r167",
      "r209",
      "r210",
      "r215",
      "r217",
      "r219",
      "r230",
      "r231",
      "r232",
      "r304",
      "r393",
      "r398",
      "r399",
      "r400",
      "r406",
      "r407",
      "r453",
      "r454",
      "r457",
      "r458",
      "r722",
      "r929"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock.",
        "label": "Class of Stock [Domain]",
        "terseLabel": "Class of Stock [Domain]"
       }
      }
     },
     "localname": "ClassOfStockDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY",
      "http://www.evolenthealth.com/role/LongtermDebt2021NotesDetails",
      "http://www.evolenthealth.com/role/LongtermDebt2025NotesDetails",
      "http://www.evolenthealth.com/role/OrganizationDetails",
      "http://www.evolenthealth.com/role/StockbasedCompensation2011and2015EquityIncentivePlansDetails",
      "http://www.evolenthealth.com/role/StockbasedCompensationPerformancebasedStockOptionAwardsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ClassOfStockLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Class of Stock [Line Items]",
        "terseLabel": "Class of Stock [Line Items]"
       }
      }
     },
     "localname": "ClassOfStockLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/OrganizationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ClassOfWarrantOrRightAxis": {
     "auth_ref": [
      "r472",
      "r538"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of warrant or right issued.",
        "label": "Class of Warrant or Right [Axis]",
        "terseLabel": "Class of Warrant or Right [Axis]"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/FairValueMeasurementAdditionalInformationDetails",
      "http://www.evolenthealth.com/role/LongtermDebtWarrantAgreementDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ClassOfWarrantOrRightDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the class or type of warrant or right outstanding. Warrants and rights represent derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months.",
        "label": "Class of Warrant or Right [Domain]",
        "terseLabel": "Class of Warrant or Right [Domain]"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/FairValueMeasurementAdditionalInformationDetails",
      "http://www.evolenthealth.com/role/LongtermDebtWarrantAgreementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": {
     "auth_ref": [
      "r461"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise price per share or per unit of warrants or rights outstanding.",
        "label": "Class of Warrant or Right, Exercise Price of Warrants or Rights",
        "terseLabel": "Exercise price of warrants or rights (in dollars per share)"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/LongtermDebtWarrantAgreementDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ClassOfWarrantOrRightLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Class of Warrant or Right [Line Items]",
        "terseLabel": "Class of Warrant or Right [Line Items]"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/LongtermDebtWarrantAgreementDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ClassOfWarrantOrRightOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of warrants or rights outstanding.",
        "label": "Class of Warrant or Right, Outstanding",
        "terseLabel": "Warrants and rights outstanding (in shares)"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/FairValueMeasurementAssetsandLiabilitiesonRecurringBasisDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ClassOfWarrantOrRightTable": {
     "auth_ref": [
      "r472",
      "r538"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure for warrants or rights issued, which includes the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.",
        "label": "Class of Warrant or Right [Table]",
        "terseLabel": "Class of Warrant or Right [Table]"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/LongtermDebtWarrantAgreementDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ClassOfWarrantOrRightUnissued": {
     "auth_ref": [
      "r472"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of warrants or rights which entitle the entity to receive future services in exchange for the unvested, forfeitable warrants or rights.",
        "label": "Class of Warrant or Right, Unissued",
        "terseLabel": "Warrants agreed to be sold (in shares)"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightUnissued",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/FairValueMeasurementAdditionalInformationDetails",
      "http://www.evolenthealth.com/role/LongtermDebtWarrantAgreementDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommitmentsAndContingencies": {
     "auth_ref": [
      "r81",
      "r388",
      "r825",
      "r854"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
        "label": "Commitments and Contingencies",
        "terseLabel": "Commitments and Contingencies (See Note 11)"
       }
      }
     },
     "localname": "CommitmentsAndContingencies",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]",
        "terseLabel": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r385",
      "r386",
      "r387",
      "r389",
      "r902"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "terseLabel": "Commitments and Contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/CommitmentsandContingencies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonClassAMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Classification of common stock representing ownership interest in a corporation.",
        "label": "Common Class A [Member]",
        "terseLabel": "Class A Common Stock",
        "verboseLabel": "Class A Common Stock"
       }
      }
     },
     "localname": "CommonClassAMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY",
      "http://www.evolenthealth.com/role/FairValueMeasurementAdditionalInformationDetails",
      "http://www.evolenthealth.com/role/LongtermDebt2021NotesDetails",
      "http://www.evolenthealth.com/role/LongtermDebt2025NotesDetails",
      "http://www.evolenthealth.com/role/LongtermDebtWarrantAgreementDetails",
      "http://www.evolenthealth.com/role/StockbasedCompensation2011and2015EquityIncentivePlansDetails",
      "http://www.evolenthealth.com/role/StockbasedCompensationPerformancebasedStockOptionAwardsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonClassBMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Classification of common stock that has different rights than Common Class A, representing ownership interest in a corporation.",
        "label": "Common Class B [Member]",
        "terseLabel": "Exchangeable Class B common stock",
        "verboseLabel": "Class B Common Stock"
       }
      }
     },
     "localname": "CommonClassBMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY",
      "http://www.evolenthealth.com/role/EarningsLossPerCommonShareAntidilutiveSecuritiesDetails",
      "http://www.evolenthealth.com/role/OrganizationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r183",
      "r184",
      "r703"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "terseLabel": "Common Stock"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY",
      "http://www.evolenthealth.com/role/LongtermDebt2021NotesDetails",
      "http://www.evolenthealth.com/role/LongtermDebt2024NotesDetails",
      "http://www.evolenthealth.com/role/LongtermDebt2025NotesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r53"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock, Par or Stated Value Per Share",
        "terseLabel": "Common stock, par value (in dollars per share)"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r53"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock, Shares Authorized",
        "terseLabel": "Common stock, shares authorized (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r53"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock, Shares, Issued",
        "terseLabel": "Common stock, shares issued (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r53",
      "r460"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common Stock, Shares, Outstanding",
        "terseLabel": "Common stock, shares outstanding (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/OrganizationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r53",
      "r778"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock, Value, Issued",
        "terseLabel": "Class A common stock - $0.01 par value; 750,000,000 shares authorized; 90,758,318 and 85,894,450 shares issued, respectively"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CompensationAndRetirementDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Retirement Benefits [Abstract]",
        "terseLabel": "Retirement Benefits [Abstract]"
       }
      }
     },
     "localname": "CompensationAndRetirementDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "auth_ref": [
      "r98",
      "r100",
      "r101",
      "r114",
      "r832",
      "r861"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "totalLabel": "Total comprehensive loss attributable to common shareholders of Evolent Health, Inc."
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r98",
      "r100",
      "r113",
      "r672",
      "r673",
      "r691",
      "r831",
      "r860"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS": {
       "order": 2.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income (loss) and other comprehensive income (loss), attributable to noncontrolling interests. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Noncontrolling Interest",
        "terseLabel": "Total comprehensive loss attributable to non-controlling interests"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r98",
      "r100",
      "r112",
      "r671",
      "r691",
      "r830",
      "r859"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS": {
       "order": 1.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest",
        "totalLabel": "Total comprehensive loss"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterestAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest [Abstract]",
        "terseLabel": "Comprehensive loss"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterestAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ComputerEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Long lived, depreciable assets that are used in the creation, maintenance and utilization of information systems.",
        "label": "Computer Equipment [Member]",
        "terseLabel": "Computer hardware"
       }
      }
     },
     "localname": "ComputerEquipmentMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesEstimatedUsefulLifeofPropertyPlantandEquipmentDetails",
      "http://www.evolenthealth.com/role/PropertyandEquipmentNetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConcentrationRiskBenchmarkDomain": {
     "auth_ref": [
      "r239",
      "r240",
      "r285",
      "r719",
      "r720",
      "r901"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The denominator in a calculation of a disclosed concentration risk percentage.",
        "label": "Concentration Risk Benchmark [Domain]",
        "terseLabel": "Concentration Risk Benchmark [Domain]"
       }
      }
     },
     "localname": "ConcentrationRiskBenchmarkDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/CommitmentsandContingenciesConcentrationRiskDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConcentrationRiskByBenchmarkAxis": {
     "auth_ref": [
      "r239",
      "r240",
      "r285",
      "r719",
      "r720",
      "r894",
      "r901"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by benchmark of concentration risk.",
        "label": "Concentration Risk Benchmark [Axis]",
        "terseLabel": "Concentration Risk Benchmark [Axis]"
       }
      }
     },
     "localname": "ConcentrationRiskByBenchmarkAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/CommitmentsandContingenciesConcentrationRiskDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskByTypeAxis": {
     "auth_ref": [
      "r239",
      "r240",
      "r285",
      "r719",
      "r720",
      "r894",
      "r901"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender.",
        "label": "Concentration Risk Type [Axis]",
        "terseLabel": "Concentration Risk Type [Axis]"
       }
      }
     },
     "localname": "ConcentrationRiskByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/CommitmentsandContingenciesConcentrationRiskDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Concentration Risk [Line Items]",
        "terseLabel": "Concentration Risk [Line Items]"
       }
      }
     },
     "localname": "ConcentrationRiskLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/CommitmentsandContingenciesConcentrationRiskDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskPercentage1": {
     "auth_ref": [
      "r239",
      "r240",
      "r285",
      "r719",
      "r720"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.",
        "label": "Concentration Risk, Percentage",
        "verboseLabel": "Concentration risk"
       }
      }
     },
     "localname": "ConcentrationRiskPercentage1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/CommitmentsandContingenciesConcentrationRiskDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ConcentrationRiskTable": {
     "auth_ref": [
      "r237",
      "r239",
      "r240",
      "r241",
      "r719",
      "r721",
      "r901"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Describes the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark.",
        "label": "Concentration Risk [Table]",
        "terseLabel": "Concentration Risk [Table]"
       }
      }
     },
     "localname": "ConcentrationRiskTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/CommitmentsandContingenciesConcentrationRiskDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskTypeDomain": {
     "auth_ref": [
      "r239",
      "r240",
      "r285",
      "r719",
      "r720",
      "r901"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration.",
        "label": "Concentration Risk Type [Domain]",
        "terseLabel": "Concentration Risk Type [Domain]"
       }
      }
     },
     "localname": "ConcentrationRiskTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/CommitmentsandContingenciesConcentrationRiskDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ContractBasedIntangibleAssetsMember": {
     "auth_ref": [
      "r651"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Right received from contract, including, but not limited to, advertising contract, broadcast rights, franchise agreement, lease agreement, licensing agreement, and use rights.",
        "label": "Contract-Based Intangible Assets [Member]",
        "terseLabel": "Provider network contracts"
       }
      }
     },
     "localname": "ContractBasedIntangibleAssetsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesIntangibleAssetsNetDetails",
      "http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNetIntangibleAssetsNetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock": {
     "auth_ref": [
      "r476"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of receivable, contract asset, and contract liability from contract with customer. Includes, but is not limited to, change in contract asset and contract liability.",
        "label": "Contract with Customer, Contract Asset, Contract Liability, and Receivable [Table Text Block]",
        "terseLabel": "Contract with customer, asset and liability"
       }
      }
     },
     "localname": "ContractWithCustomerAssetAndLiabilityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/RevenueRecognitionTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ContractWithCustomerAssetNetCurrent": {
     "auth_ref": [
      "r473",
      "r475",
      "r497"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time, classified as current.",
        "label": "Contract with Customer, Asset, after Allowance for Credit Loss, Current",
        "verboseLabel": "Short-term contract assets"
       }
      }
     },
     "localname": "ContractWithCustomerAssetNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/RevenueRecognitionContractBalancesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiability": {
     "auth_ref": [
      "r473",
      "r474",
      "r497"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.",
        "label": "Contract with Customer, Liability",
        "periodEndLabel": "Balance as of end of period",
        "periodStartLabel": "Balance as of beginning-of-period"
       }
      }
     },
     "localname": "ContractWithCustomerLiability",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/RevenueRecognitionContractBalancesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityCurrent": {
     "auth_ref": [
      "r473",
      "r474",
      "r497"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 5.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.",
        "label": "Contract with Customer, Liability, Current",
        "terseLabel": "Deferred revenue",
        "verboseLabel": "Short-term deferred revenue"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.evolenthealth.com/role/RevenueRecognitionContractBalancesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityNoncurrent": {
     "auth_ref": [
      "r473",
      "r474",
      "r497"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.",
        "label": "Contract with Customer, Liability, Noncurrent",
        "terseLabel": "Long-term deferred revenue"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/RevenueRecognitionContractBalancesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityRevenueRecognized": {
     "auth_ref": [
      "r498"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.",
        "label": "Contract with Customer, Liability, Revenue Recognized",
        "negatedTerseLabel": "Reclassification to revenue, as a result of performance obligations satisfied"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityRevenueRecognized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/RevenueRecognitionContractBalancesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod": {
     "auth_ref": [
      "r482"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of revenue recognized from performance obligation satisfied or partially satisfied in previous reporting periods. Includes, but is not limited to, change in transaction price.",
        "label": "Contract with Customer, Performance Obligation Satisfied in Previous Period",
        "terseLabel": "Revenue recognized from performed obligations"
       }
      }
     },
     "localname": "ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/RevenueRecognitionContractBalancesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConversionOfStockAmountConverted1": {
     "auth_ref": [
      "r157",
      "r158",
      "r159"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The value of the stock converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.",
        "label": "Conversion of Stock, Amount Converted",
        "terseLabel": "Decrease in non-controlling interests as a result of Class B Exchanges"
       }
      }
     },
     "localname": "ConversionOfStockAmountConverted1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/SupplementalCashFlowInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConvertibleDebt": {
     "auth_ref": [
      "r48",
      "r822",
      "r847"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/LongtermDebtConvertibleSeniorNotesCarryingValueDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Including the current and noncurrent portions, carrying amount of debt identified as being convertible into another form of financial instrument (typically the entity's common stock) as of the balance sheet date, which originally required full repayment more than twelve months after issuance or greater than the normal operating cycle of the company.",
        "label": "Convertible Debt",
        "totalLabel": "Convertible Debt, Total"
       }
      }
     },
     "localname": "ConvertibleDebt",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/LongtermDebtConvertibleSeniorNotesCarryingValueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConvertibleDebtMember": {
     "auth_ref": [
      "r408",
      "r410",
      "r411",
      "r413",
      "r423",
      "r424",
      "r425",
      "r429",
      "r430",
      "r431",
      "r432",
      "r433",
      "r443",
      "r444",
      "r445",
      "r446"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Borrowing which can be exchanged for a specified number of another security at the option of the issuer or the holder, for example, but not limited to, the entity's common stock.",
        "label": "Convertible Debt [Member]",
        "terseLabel": "Convertible senior notes"
       }
      }
     },
     "localname": "ConvertibleDebtMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/EarningsLossPerCommonShareAntidilutiveSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConvertibleDebtTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of convertible debt instrument. Includes, but is not limited to, principal amount and amortized premium or discount.",
        "label": "Convertible Debt [Table Text Block]",
        "terseLabel": "Schedule of convertible debt"
       }
      }
     },
     "localname": "ConvertibleDebtTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/LongtermDebtTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CorporateNonSegmentMember": {
     "auth_ref": [
      "r268",
      "r269",
      "r270",
      "r271",
      "r272",
      "r278",
      "r280"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Corporate headquarters or functional department that may not earn revenues or may earn revenues that are only incidental to the activities of the entity and is not considered an operating segment.",
        "label": "Corporate, Non-Segment [Member]",
        "terseLabel": "Corporate"
       }
      }
     },
     "localname": "CorporateNonSegmentMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/SegmentReportingRevenuefromSegmentstoConsolidatedDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CostOfSalesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing cost of sales.",
        "label": "Cost of Sales [Member]",
        "terseLabel": "Cost of revenue"
       }
      }
     },
     "localname": "CostOfSalesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/StockbasedCompensationStockbasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CreditFacilityAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.",
        "label": "Credit Facility [Axis]",
        "terseLabel": "Credit Facility [Axis]"
       }
      }
     },
     "localname": "CreditFacilityAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/CommitmentsandContingenciesAdditionalInformationDetails",
      "http://www.evolenthealth.com/role/LongtermDebtCreditAgreementDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CreditFacilityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.",
        "label": "Credit Facility [Domain]",
        "terseLabel": "Credit Facility [Domain]"
       }
      }
     },
     "localname": "CreditFacilityDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/CommitmentsandContingenciesAdditionalInformationDetails",
      "http://www.evolenthealth.com/role/LongtermDebtCreditAgreementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CreditLossAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Credit Loss [Abstract]",
        "terseLabel": "Credit Loss [Abstract]"
       }
      }
     },
     "localname": "CreditLossAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CreditLossFinancialInstrumentTextBlock": {
     "auth_ref": [
      "r315",
      "r320",
      "r321",
      "r323",
      "r324",
      "r326",
      "r327"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for credit loss on financial instrument measured at amortized cost basis, net investment in lease, off-balance sheet credit exposure, and available-for-sale debt security.",
        "label": "Credit Loss, Financial Instrument [Text Block]",
        "terseLabel": "Credit Losses"
       }
      }
     },
     "localname": "CreditLossFinancialInstrumentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/CreditLosses"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CurrentFederalTaxExpenseBenefit": {
     "auth_ref": [
      "r168",
      "r617",
      "r631"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/IncomeTaxesIncomeTaxExpenseBenefitDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current federal tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Current Federal Tax Expense (Benefit)",
        "terseLabel": "Federal"
       }
      }
     },
     "localname": "CurrentFederalTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/IncomeTaxesIncomeTaxExpenseBenefitDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CurrentForeignTaxExpenseBenefit": {
     "auth_ref": [
      "r168",
      "r617"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/IncomeTaxesIncomeTaxExpenseBenefitDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Current Foreign Tax Expense (Benefit)",
        "terseLabel": "Foreign"
       }
      }
     },
     "localname": "CurrentForeignTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/IncomeTaxesIncomeTaxExpenseBenefitDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CurrentIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r168",
      "r617",
      "r631",
      "r633"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/IncomeTaxesIncomeTaxExpenseBenefitDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations.",
        "label": "Current Income Tax Expense (Benefit)",
        "totalLabel": "Total current tax expense (benefit)"
       }
      }
     },
     "localname": "CurrentIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/IncomeTaxesIncomeTaxExpenseBenefitDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Income Tax Expense (Benefit), Continuing Operations [Abstract]",
        "terseLabel": "Current"
       }
      }
     },
     "localname": "CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/IncomeTaxesIncomeTaxExpenseBenefitDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CurrentStateAndLocalTaxExpenseBenefit": {
     "auth_ref": [
      "r168",
      "r617",
      "r631"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/IncomeTaxesIncomeTaxExpenseBenefitDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current state and local tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Current State and Local Tax Expense (Benefit)",
        "terseLabel": "State and local"
       }
      }
     },
     "localname": "CurrentStateAndLocalTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/IncomeTaxesIncomeTaxExpenseBenefitDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CustomerConcentrationRiskMember": {
     "auth_ref": [
      "r238",
      "r285"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer.",
        "label": "Customer Concentration Risk [Member]",
        "terseLabel": "Customer Concentration Risk"
       }
      }
     },
     "localname": "CustomerConcentrationRiskMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/CommitmentsandContingenciesConcentrationRiskDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CustomerRelationshipsMember": {
     "auth_ref": [
      "r653"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Customer relationship that exists between an entity and its customer, for example, but not limited to, tenant relationships.",
        "label": "Customer Relationships [Member]",
        "terseLabel": "Customer relationships"
       }
      }
     },
     "localname": "CustomerRelationshipsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesIntangibleAssetsNetDetails",
      "http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNetIntangibleAssetsNetDetails",
      "http://www.evolenthealth.com/role/TransactionsVitalDecisionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtConversionConvertedInstrumentAmount1": {
     "auth_ref": [
      "r157",
      "r159"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The value of the financial instrument(s) that the original debt is being converted into in a noncash (or part noncash) transaction. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.",
        "label": "Debt Conversion, Converted Instrument, Amount",
        "terseLabel": "Debt conversion, converted instrument, amount"
       }
      }
     },
     "localname": "DebtConversionConvertedInstrumentAmount1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/LongtermDebt2021NotesDetails",
      "http://www.evolenthealth.com/role/LongtermDebt2024NotesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtConversionOriginalDebtAmount1": {
     "auth_ref": [
      "r157",
      "r159"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of the original debt being converted in a noncash (or part noncash) transaction. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.",
        "label": "Debt Conversion, Original Debt, Amount",
        "terseLabel": "Debt conversion, original debt, amount"
       }
      }
     },
     "localname": "DebtConversionOriginalDebtAmount1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/LongtermDebt2021NotesDetails",
      "http://www.evolenthealth.com/role/LongtermDebt2024NotesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Disclosure [Abstract]",
        "terseLabel": "Debt Disclosure [Abstract]"
       }
      }
     },
     "localname": "DebtDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtDisclosureTextBlock": {
     "auth_ref": [
      "r164",
      "r416",
      "r417",
      "r418",
      "r419",
      "r420",
      "r421",
      "r422",
      "r427",
      "r434",
      "r435",
      "r437",
      "r449"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.",
        "label": "Debt Disclosure [Text Block]",
        "terseLabel": "Long-term Debt"
       }
      }
     },
     "localname": "DebtDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/LongtermDebt"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DebtInstrumentAxis": {
     "auth_ref": [
      "r46",
      "r47",
      "r48",
      "r166",
      "r174",
      "r410",
      "r411",
      "r412",
      "r413",
      "r414",
      "r415",
      "r417",
      "r423",
      "r424",
      "r425",
      "r426",
      "r428",
      "r429",
      "r430",
      "r431",
      "r432",
      "r433",
      "r443",
      "r444",
      "r445",
      "r446",
      "r745",
      "r820",
      "r822",
      "r842"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.",
        "label": "Debt Instrument [Axis]",
        "terseLabel": "Debt Instrument [Axis]"
       }
      }
     },
     "localname": "DebtInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/LongtermDebt2021NotesDetails",
      "http://www.evolenthealth.com/role/LongtermDebt2024NotesDetails",
      "http://www.evolenthealth.com/role/LongtermDebt2025NotesDetails",
      "http://www.evolenthealth.com/role/LongtermDebtConvertibleSeniorNotesCarryingValueDetails",
      "http://www.evolenthealth.com/role/LongtermDebtCreditAgreementDetails",
      "http://www.evolenthealth.com/role/TransactionsEquityInvestmentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentBasisSpreadOnVariableRate1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage points added to the reference rate to compute the variable rate on the debt instrument.",
        "label": "Debt Instrument, Basis Spread on Variable Rate",
        "terseLabel": "Basis spread on variable rate"
       }
      }
     },
     "localname": "DebtInstrumentBasisSpreadOnVariableRate1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/LongtermDebtCreditAgreementDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentConvertibleConversionPrice1": {
     "auth_ref": [
      "r412",
      "r441"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The price per share of the conversion feature embedded in the debt instrument.",
        "label": "Debt Instrument, Convertible, Conversion Price",
        "terseLabel": "Conversion price (in dollars per share)"
       }
      }
     },
     "localname": "DebtInstrumentConvertibleConversionPrice1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/LongtermDebt2021NotesDetails",
      "http://www.evolenthealth.com/role/LongtermDebt2024NotesDetails",
      "http://www.evolenthealth.com/role/LongtermDebt2025NotesDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_DebtInstrumentConvertibleConversionRatio1": {
     "auth_ref": [
      "r78",
      "r412",
      "r461",
      "r464",
      "r466"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Ratio applied to the conversion of debt instrument into equity with equity shares divided by debt principal amount.",
        "label": "Debt Instrument, Convertible, Conversion Ratio",
        "terseLabel": "Initial conversion rate per $ 1000 principal amount",
        "verboseLabel": "Initial conversion rate per $ 1000 principal amount"
       }
      }
     },
     "localname": "DebtInstrumentConvertibleConversionRatio1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/LongtermDebt2021NotesDetails",
      "http://www.evolenthealth.com/role/LongtermDebt2024NotesDetails",
      "http://www.evolenthealth.com/role/LongtermDebt2025NotesDetails"
     ],
     "xbrltype": "pureItemType"
    },
    "us-gaap_DebtInstrumentConvertibleNumberOfEquityInstruments": {
     "auth_ref": [
      "r78",
      "r412",
      "r461",
      "r464",
      "r466"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of equity instruments that the holder of the debt instrument would receive if the debt was converted to equity.",
        "label": "Debt Instrument, Convertible, Number of Equity Instruments",
        "terseLabel": "Initial conversion amount (in shares)"
       }
      }
     },
     "localname": "DebtInstrumentConvertibleNumberOfEquityInstruments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/LongtermDebt2021NotesDetails",
      "http://www.evolenthealth.com/role/LongtermDebt2024NotesDetails",
      "http://www.evolenthealth.com/role/LongtermDebt2025NotesDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1": {
     "auth_ref": [
      "r440"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Remaining amortization period for discount on the liability component of convertible debt which may be settled in cash upon conversion, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Debt Instrument, Convertible, Remaining Discount Amortization Period",
        "terseLabel": "Remaining amortization period (years)"
       }
      }
     },
     "localname": "DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/LongtermDebtConvertibleSeniorNotesCarryingValueDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_DebtInstrumentFaceAmount": {
     "auth_ref": [
      "r410",
      "r443",
      "r444",
      "r743",
      "r745",
      "r746"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/LongtermDebtConvertibleSeniorNotesCarryingValueDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_ConvertibleDebt",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face (par) amount of debt instrument at time of issuance.",
        "label": "Debt Instrument, Face Amount",
        "terseLabel": "Face amount",
        "verboseLabel": "Principal amount"
       }
      }
     },
     "localname": "DebtInstrumentFaceAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/LongtermDebt2021NotesDetails",
      "http://www.evolenthealth.com/role/LongtermDebt2024NotesDetails",
      "http://www.evolenthealth.com/role/LongtermDebt2025NotesDetails",
      "http://www.evolenthealth.com/role/LongtermDebtConvertibleSeniorNotesCarryingValueDetails",
      "http://www.evolenthealth.com/role/LongtermDebtCreditAgreementDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentInterestRateStatedPercentage": {
     "auth_ref": [
      "r77",
      "r411"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contractual interest rate for funds borrowed, under the debt agreement.",
        "label": "Debt Instrument, Interest Rate, Stated Percentage",
        "terseLabel": "Interest rate"
       }
      }
     },
     "localname": "DebtInstrumentInterestRateStatedPercentage",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/LongtermDebt2021NotesDetails",
      "http://www.evolenthealth.com/role/LongtermDebt2024NotesDetails",
      "http://www.evolenthealth.com/role/LongtermDebt2025NotesDetails",
      "http://www.evolenthealth.com/role/LongtermDebtCreditAgreementDetails",
      "http://www.evolenthealth.com/role/TransactionsEquityInvestmentsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Debt Instrument [Line Items]",
        "terseLabel": "Debt Instrument [Line Items]"
       }
      }
     },
     "localname": "DebtInstrumentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/LongtermDebt2021NotesDetails",
      "http://www.evolenthealth.com/role/LongtermDebt2024NotesDetails",
      "http://www.evolenthealth.com/role/LongtermDebt2025NotesDetails",
      "http://www.evolenthealth.com/role/LongtermDebtConvertibleSeniorNotesCarryingValueDetails",
      "http://www.evolenthealth.com/role/LongtermDebtCreditAgreementDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "auth_ref": [
      "r79",
      "r166",
      "r174",
      "r410",
      "r411",
      "r412",
      "r413",
      "r414",
      "r415",
      "r417",
      "r423",
      "r424",
      "r425",
      "r426",
      "r428",
      "r429",
      "r430",
      "r431",
      "r432",
      "r433",
      "r443",
      "r444",
      "r445",
      "r446",
      "r745"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.",
        "label": "Debt Instrument, Name [Domain]",
        "terseLabel": "Debt Instrument, Name [Domain]"
       }
      }
     },
     "localname": "DebtInstrumentNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/LongtermDebt2021NotesDetails",
      "http://www.evolenthealth.com/role/LongtermDebt2024NotesDetails",
      "http://www.evolenthealth.com/role/LongtermDebt2025NotesDetails",
      "http://www.evolenthealth.com/role/LongtermDebtConvertibleSeniorNotesCarryingValueDetails",
      "http://www.evolenthealth.com/role/LongtermDebtCreditAgreementDetails",
      "http://www.evolenthealth.com/role/TransactionsEquityInvestmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentRedemptionPeriodAxis": {
     "auth_ref": [
      "r838"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information about timing of debt redemption features under terms of the debt agreement.",
        "label": "Debt Instrument, Redemption, Period [Axis]",
        "terseLabel": "Debt Instrument, Redemption, Period [Axis]"
       }
      }
     },
     "localname": "DebtInstrumentRedemptionPeriodAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/LongtermDebtCreditAgreementDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentRedemptionPeriodDomain": {
     "auth_ref": [
      "r838"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period as defined under terms of the debt agreement for debt redemption features.",
        "label": "Debt Instrument, Redemption, Period [Domain]",
        "terseLabel": "Debt Instrument, Redemption, Period [Domain]"
       }
      }
     },
     "localname": "DebtInstrumentRedemptionPeriodDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/LongtermDebtCreditAgreementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentRedemptionPeriodOneMember": {
     "auth_ref": [
      "r838"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period one representing most current period of debt redemption features under terms of the debt agreement.",
        "label": "Debt Instrument, Redemption, Period One [Member]",
        "terseLabel": "After the Second Anniversary of the Closing of the Senior Credit Facilities but Prior to the Third Anniversary"
       }
      }
     },
     "localname": "DebtInstrumentRedemptionPeriodOneMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/LongtermDebtCreditAgreementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentRedemptionPeriodThreeMember": {
     "auth_ref": [
      "r838"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period three representing third most current period of debt redemption features under terms of the debt agreement.",
        "label": "Debt Instrument, Redemption, Period Three [Member]",
        "terseLabel": "After the Fourth Anniversary of the Closing of the Senior Credit Facilities but Prior to the Fifth Anniversary"
       }
      }
     },
     "localname": "DebtInstrumentRedemptionPeriodThreeMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/LongtermDebtCreditAgreementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentRedemptionPeriodTwoMember": {
     "auth_ref": [
      "r838"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period two representing second most current period of debt redemption features under terms of the debt agreement.",
        "label": "Debt Instrument, Redemption, Period Two [Member]",
        "terseLabel": "After the Third Anniversary of the Closing of the Senior Credit Facilities but Prior to the Fourth Anniversary"
       }
      }
     },
     "localname": "DebtInstrumentRedemptionPeriodTwoMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/LongtermDebtCreditAgreementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentTable": {
     "auth_ref": [
      "r79",
      "r166",
      "r174",
      "r410",
      "r411",
      "r412",
      "r413",
      "r414",
      "r415",
      "r417",
      "r423",
      "r424",
      "r425",
      "r426",
      "r428",
      "r429",
      "r430",
      "r431",
      "r432",
      "r433",
      "r436",
      "r443",
      "r444",
      "r445",
      "r446",
      "r461",
      "r465",
      "r466",
      "r467",
      "r742",
      "r743",
      "r745",
      "r746",
      "r839"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Schedule of Long-term Debt Instruments [Table]",
        "terseLabel": "Schedule of Long-term Debt Instruments [Table]"
       }
      }
     },
     "localname": "DebtInstrumentTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/LongtermDebt2021NotesDetails",
      "http://www.evolenthealth.com/role/LongtermDebt2024NotesDetails",
      "http://www.evolenthealth.com/role/LongtermDebt2025NotesDetails",
      "http://www.evolenthealth.com/role/LongtermDebtConvertibleSeniorNotesCarryingValueDetails",
      "http://www.evolenthealth.com/role/LongtermDebtCreditAgreementDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Debt Instrument, Term",
        "terseLabel": "Term"
       }
      }
     },
     "localname": "DebtInstrumentTerm",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/LongtermDebtCreditAgreementDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet": {
     "auth_ref": [
      "r423",
      "r438",
      "r443",
      "r444",
      "r744"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/LongtermDebtConvertibleSeniorNotesCarryingValueDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_ConvertibleDebt",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unamortized debt discount (premium) and debt issuance costs.",
        "label": "Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net",
        "verboseLabel": "Unamortized debt discount and issuance costs"
       }
      }
     },
     "localname": "DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/LongtermDebtConvertibleSeniorNotesCarryingValueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtPolicyTextBlock": {
     "auth_ref": [
      "r390"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy related to debt. Includes, but is not limited to, debt issuance costs, the effects of refinancings, method of amortizing debt issuance costs and original issue discount, and classifications of debt.",
        "label": "Debt, Policy [Policy Text Block]",
        "terseLabel": "Long-term Debt"
       }
      }
     },
     "localname": "DebtPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DeferredFederalIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r168",
      "r618",
      "r631"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/IncomeTaxesIncomeTaxExpenseBenefitDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred federal income tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Deferred Federal Income Tax Expense (Benefit)",
        "terseLabel": "Federal"
       }
      }
     },
     "localname": "DeferredFederalIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/IncomeTaxesIncomeTaxExpenseBenefitDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredFinanceCostsNet": {
     "auth_ref": [
      "r70",
      "r423",
      "r744"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.",
        "label": "Debt Issuance Costs, Net",
        "terseLabel": "Debt issuance costs"
       }
      }
     },
     "localname": "DeferredFinanceCostsNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/LongtermDebt2021NotesDetails",
      "http://www.evolenthealth.com/role/LongtermDebt2024NotesDetails",
      "http://www.evolenthealth.com/role/LongtermDebt2025NotesDetails",
      "http://www.evolenthealth.com/role/LongtermDebtCreditAgreementDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredForeignIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r168",
      "r618",
      "r631"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/IncomeTaxesIncomeTaxExpenseBenefitDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Deferred Foreign Income Tax Expense (Benefit)",
        "terseLabel": "Foreign"
       }
      }
     },
     "localname": "DeferredForeignIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/IncomeTaxesIncomeTaxExpenseBenefitDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r150",
      "r168",
      "r618",
      "r631",
      "r632",
      "r633"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/IncomeTaxesIncomeTaxExpenseBenefitDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Deferred Income Tax Expense (Benefit)",
        "totalLabel": "Total deferred tax expense (benefit)"
       }
      }
     },
     "localname": "DeferredIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/IncomeTaxesIncomeTaxExpenseBenefitDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Income Tax Expense (Benefit), Continuing Operations [Abstract]",
        "terseLabel": "Deferred"
       }
      }
     },
     "localname": "DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/IncomeTaxesIncomeTaxExpenseBenefitDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredIncomeTaxLiabilities": {
     "auth_ref": [
      "r49",
      "r50",
      "r607",
      "r821",
      "r841"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences.",
        "label": "Deferred Tax Liabilities, Gross",
        "totalLabel": "Total deferred tax liabilities"
       }
      }
     },
     "localname": "DeferredIncomeTaxLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxLiabilitiesNet": {
     "auth_ref": [
      "r595",
      "r596"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.",
        "label": "Deferred Income Tax Liabilities, Net",
        "terseLabel": "Deferred tax liabilities, net"
       }
      }
     },
     "localname": "DeferredIncomeTaxLiabilitiesNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxesAndTaxCredits": {
     "auth_ref": [
      "r151"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred income tax expense (benefit) and income tax credits.",
        "label": "Deferred Income Taxes and Tax Credits",
        "terseLabel": "Deferred tax benefit"
       }
      }
     },
     "localname": "DeferredIncomeTaxesAndTaxCredits",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredOtherTaxExpenseBenefit": {
     "auth_ref": [
      "r168",
      "r619",
      "r630"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/IncomeTaxesIncomeTaxExpenseBenefitDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of other deferred income tax expense (benefit) pertaining to income (loss) from continuing operations. For example, but not limited to, acquisition-date income tax benefits or expenses recognized from changes in the acquirer's valuation allowance for its previously existing deferred tax assets resulting from a business combination and adjustments to beginning-of-year balance of a valuation allowance because of a change in circumstance causing a change in judgment about the realizability of the related deferred tax asset in future periods.",
        "label": "Deferred Other Tax Expense (Benefit)",
        "terseLabel": "Change in valuation allowance"
       }
      }
     },
     "localname": "DeferredOtherTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/IncomeTaxesIncomeTaxExpenseBenefitDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r168",
      "r618",
      "r631"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/IncomeTaxesIncomeTaxExpenseBenefitDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred state and local tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Deferred State and Local Income Tax Expense (Benefit)",
        "terseLabel": "State and local"
       }
      }
     },
     "localname": "DeferredStateAndLocalIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/IncomeTaxesIncomeTaxExpenseBenefitDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetInterestCarryforward": {
     "auth_ref": [
      "r615"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 11.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible interest carryforward.",
        "label": "Deferred Tax Asset, Interest Carryforward",
        "terseLabel": "Interest deduction limitation"
       }
      }
     },
     "localname": "DeferredTaxAssetInterestCarryforward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets": {
     "auth_ref": [],
     "calculation": {
      "http://www.evolenthealth.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from intangible assets including goodwill.",
        "label": "Deferred Tax Assets, Goodwill and Intangible Assets",
        "terseLabel": "Goodwill"
       }
      }
     },
     "localname": "DeferredTaxAssetsGoodwillAndIntangibleAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsGross": {
     "auth_ref": [
      "r608"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.",
        "label": "Deferred Tax Assets, Gross",
        "totalLabel": "Subtotal"
       }
      }
     },
     "localname": "DeferredTaxAssetsGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsNet": {
     "auth_ref": [
      "r610"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredTaxLiabilities",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.",
        "label": "Deferred Tax Assets, Net of Valuation Allowance",
        "totalLabel": "Total deferred tax assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsNetAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Net [Abstract]",
        "terseLabel": "Deferred Tax Assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsNetAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": {
     "auth_ref": [
      "r615",
      "r616"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.",
        "label": "Deferred Tax Assets, Operating Loss Carryforwards",
        "terseLabel": "Net operating loss carryforwards"
       }
      }
     },
     "localname": "DeferredTaxAssetsOperatingLossCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsOther": {
     "auth_ref": [
      "r615",
      "r616"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.",
        "label": "Deferred Tax Assets, Other",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "DeferredTaxAssetsOther",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment": {
     "auth_ref": [],
     "calculation": {
      "http://www.evolenthealth.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 8.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from property, plant, and equipment.",
        "label": "Deferred Tax Assets, Property, Plant and Equipment",
        "terseLabel": "Fixed assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch": {
     "auth_ref": [
      "r613",
      "r615",
      "r616"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 9.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards.",
        "label": "Deferred Tax Assets, Tax Credit Carryforwards, Research",
        "terseLabel": "Federal and state research tax credits"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxCreditCarryforwardsResearch",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails",
      "http://www.evolenthealth.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation": {
     "auth_ref": [
      "r615",
      "r616"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from employee compensation.",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Employee Compensation",
        "terseLabel": "Stock based compensation"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities": {
     "auth_ref": [
      "r615",
      "r616"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from accrued liabilities.",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Accrued Liabilities",
        "terseLabel": "Accrued expenses"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r609"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.",
        "label": "Deferred Tax Assets, Valuation Allowance",
        "negatedTerseLabel": "Valuation allowance"
       }
      }
     },
     "localname": "DeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilities": {
     "auth_ref": [
      "r596",
      "r610"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences without jurisdictional netting.",
        "label": "Deferred Tax Liabilities, Net",
        "negatedTotalLabel": "Net deferred tax assets (liabilities)"
       }
      }
     },
     "localname": "DeferredTaxLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesDeferredExpense": {
     "auth_ref": [
      "r615",
      "r616"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from capitalized costs.",
        "label": "Deferred Tax Liabilities, Deferred Expense",
        "terseLabel": "Contract fulfillment costs"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesDeferredExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedSoftware": {
     "auth_ref": [
      "r615",
      "r616"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from capitalized software.",
        "label": "Deferred Tax Liabilities, Deferred Expense, Capitalized Software",
        "terseLabel": "Internally developed software costs"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesDeferredExpenseCapitalizedSoftware",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesFinancingArrangements": {
     "auth_ref": [
      "r615",
      "r616"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from financing arrangements.",
        "label": "Deferred Tax Liabilities, Financing Arrangements",
        "terseLabel": "Convertible debt"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesFinancingArrangements",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets": {
     "auth_ref": [
      "r615",
      "r616"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from intangible assets other than goodwill.",
        "label": "Deferred Tax Liabilities, Intangible Assets",
        "terseLabel": "Intangible assets"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesLeasingArrangements": {
     "auth_ref": [
      "r615",
      "r616"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from leasing arrangements.",
        "label": "Deferred Tax Liabilities, Leasing Arrangements",
        "terseLabel": "Right-of-use assets - Operating"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesLeasingArrangements",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesNetAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Liabilities, Net [Abstract]",
        "terseLabel": "Deferred Tax Liabilities"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesNetAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesOther": {
     "auth_ref": [
      "r615",
      "r616"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences classified as other.",
        "label": "Deferred Tax Liabilities, Other",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesOther",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of discretionary contributions made by an employer to a defined contribution plan.",
        "label": "Defined Contribution Plan, Employer Discretionary Contribution Amount",
        "terseLabel": "Employer discretionary contribution amount"
       }
      }
     },
     "localname": "DefinedContributionPlanEmployerDiscretionaryContributionAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/EmployeeBenefitPlansDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Depreciation": {
     "auth_ref": [
      "r150",
      "r359"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.",
        "label": "Depreciation",
        "terseLabel": "Depreciation expense"
       }
      }
     },
     "localname": "Depreciation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/PropertyandEquipmentNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DepreciationAndAmortization": {
     "auth_ref": [
      "r150",
      "r359"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.",
        "label": "Depreciation, Depletion and Amortization, Nonproduction",
        "negatedLabel": "Depreciation and amortization expenses",
        "terseLabel": "Depreciation and amortization expenses"
       }
      }
     },
     "localname": "DepreciationAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS",
      "http://www.evolenthealth.com/role/SegmentReportingReconciliationofAdjustedEBITDADetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DepreciationAndAmortizationDiscontinuedOperations": {
     "auth_ref": [
      "r26",
      "r150"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/DiscontinuedOperationsSummaryofResultsofOperationsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deprecation and amortization expense attributable to property, plant and equipment and intangible assets of discontinued operations.",
        "label": "Depreciation and Amortization, Discontinued Operations",
        "terseLabel": "Depreciation and amortization expenses"
       }
      }
     },
     "localname": "DepreciationAndAmortizationDiscontinuedOperations",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/DiscontinuedOperationsSummaryofResultsofOperationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DepreciationDepletionAndAmortization": {
     "auth_ref": [
      "r150",
      "r253"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.",
        "label": "Depreciation, Depletion and Amortization",
        "terseLabel": "Depreciation and amortization expenses"
       }
      }
     },
     "localname": "DepreciationDepletionAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DevelopedTechnologyRightsMember": {
     "auth_ref": [
      "r655"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Rights to developed technology, which can include the right to develop, use, market, sell, or offer for sale products, compounds, or intellectual property.",
        "label": "Developed Technology Rights [Member]",
        "terseLabel": "Technology",
        "verboseLabel": "Technology"
       }
      }
     },
     "localname": "DevelopedTechnologyRightsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesIntangibleAssetsNetDetails",
      "http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNetIntangibleAssetsNetDetails",
      "http://www.evolenthealth.com/role/TransactionsVitalDecisionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DisaggregationOfRevenueLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Disaggregation of Revenue [Line Items]",
        "terseLabel": "Disaggregation of Revenue [Line Items]"
       }
      }
     },
     "localname": "DisaggregationOfRevenueLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/RevenueRecognitionDisaggregationofRevenueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisaggregationOfRevenueTable": {
     "auth_ref": [
      "r496",
      "r500",
      "r501",
      "r502",
      "r503",
      "r504",
      "r505",
      "r506"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.",
        "label": "Disaggregation of Revenue [Table]",
        "terseLabel": "Disaggregation of Revenue [Table]"
       }
      }
     },
     "localname": "DisaggregationOfRevenueTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/RevenueRecognitionDisaggregationofRevenueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisaggregationOfRevenueTableTextBlock": {
     "auth_ref": [
      "r496"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.",
        "label": "Disaggregation of Revenue [Table Text Block]",
        "terseLabel": "Disaggregation of revenue"
       }
      }
     },
     "localname": "DisaggregationOfRevenueTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/RevenueRecognitionTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "auth_ref": [
      "r590"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for share-based payment arrangement.",
        "label": "Share-based Payment Arrangement [Text Block]",
        "terseLabel": "Stock-based Compensation"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/StockbasedCompensation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Payment Arrangement [Abstract]",
        "terseLabel": "Share-based Payment Arrangement [Abstract]"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax": {
     "auth_ref": [
      "r9",
      "r11",
      "r15",
      "r30"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of gain (loss) not previously recognized resulting from the disposal of a discontinued operation.",
        "label": "Discontinued Operation, Gain (Loss) on Disposal of Discontinued Operation, Net of Tax",
        "terseLabel": "Gain on disposal of discontinued operations"
       }
      }
     },
     "localname": "DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSSParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax": {
     "auth_ref": [
      "r9",
      "r10",
      "r11",
      "r12",
      "r15",
      "r23",
      "r111",
      "r857"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/DiscontinuedOperationsSummaryofResultsofOperationsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before tax of income (loss) from a discontinued operation. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal.",
        "label": "Discontinued Operation, Income (Loss) from Discontinued Operation, before Income Tax",
        "totalLabel": "Income (loss) before income taxes and non-controlling interests"
       }
      }
     },
     "localname": "DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/DiscontinuedOperationsSummaryofResultsofOperationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation": {
     "auth_ref": [
      "r10",
      "r11",
      "r12",
      "r15",
      "r23",
      "r30",
      "r597",
      "r630",
      "r638"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/DiscontinuedOperationsSummaryofResultsofOperationsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of tax expense (benefit) related to a discontinued operation. Includes, but is not limited to, tax expense (benefit) related to income (loss) from operations during the phase-out period, tax expense (benefit) related to gain (loss) on disposal, tax expense (benefit) related to gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and tax expense (benefit) related to adjustments of a prior period gain (loss) on disposal.",
        "label": "Discontinued Operation, Tax Effect of Discontinued Operation",
        "terseLabel": "Benefit (provision) for income taxes"
       }
      }
     },
     "localname": "DiscontinuedOperationTaxEffectOfDiscontinuedOperation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/DiscontinuedOperationsSummaryofResultsofOperationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Discontinued Operations and Disposal Groups [Abstract]"
       }
      }
     },
     "localname": "DiscontinuedOperationsAndDisposalGroupsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DiscontinuedOperationsDisposedOfBySaleMember": {
     "auth_ref": [
      "r8"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Component or group of components disposed of by sale and representing a strategic shift that has or will have a major effect on operations and financial results.",
        "label": "Discontinued Operations, Disposed of by Sale [Member]",
        "terseLabel": "Discontinued Operations, Disposed of by Sale"
       }
      }
     },
     "localname": "DiscontinuedOperationsDisposedOfBySaleMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesRestrictedCashandRestrictedInvestmentsDetails",
      "http://www.evolenthealth.com/role/CommitmentsandContingenciesConcentrationRiskDetails",
      "http://www.evolenthealth.com/role/DiscontinuedOperationsAdditionalInformationDetails",
      "http://www.evolenthealth.com/role/DiscontinuedOperationsSummaryofCashFlowsDetails",
      "http://www.evolenthealth.com/role/DiscontinuedOperationsSummaryofCurrentandLongtermAssetsandLiabilitiesDetails",
      "http://www.evolenthealth.com/role/DiscontinuedOperationsSummaryofResultsofOperationsDetails",
      "http://www.evolenthealth.com/role/EmployeeBenefitPlansDetails",
      "http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNetIntangibleAssetsNetDetails",
      "http://www.evolenthealth.com/role/ReservesforClaimsandPerformanceBasedArrangementsDetails",
      "http://www.evolenthealth.com/role/RevenueRecognitionContractBalancesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DisposalGroupClassificationAxis": {
     "auth_ref": [
      "r29"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by disposal group classification.",
        "label": "Disposal Group Classification [Axis]",
        "terseLabel": "Disposal Group Classification [Axis]"
       }
      }
     },
     "localname": "DisposalGroupClassificationAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesRestrictedCashandRestrictedInvestmentsDetails",
      "http://www.evolenthealth.com/role/CommitmentsandContingenciesConcentrationRiskDetails",
      "http://www.evolenthealth.com/role/DiscontinuedOperationsAdditionalInformationDetails",
      "http://www.evolenthealth.com/role/DiscontinuedOperationsSummaryofCashFlowsDetails",
      "http://www.evolenthealth.com/role/DiscontinuedOperationsSummaryofCurrentandLongtermAssetsandLiabilitiesDetails",
      "http://www.evolenthealth.com/role/DiscontinuedOperationsSummaryofResultsofOperationsDetails",
      "http://www.evolenthealth.com/role/EmployeeBenefitPlansDetails",
      "http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNetIntangibleAssetsNetDetails",
      "http://www.evolenthealth.com/role/ReservesforClaimsandPerformanceBasedArrangementsDetails",
      "http://www.evolenthealth.com/role/RevenueRecognitionContractBalancesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisposalGroupClassificationDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Component or group of components disposed of, including but not limited to, disposal group held-for-sale or disposed of by sale, disposed of by means other than sale, and discontinued operations.",
        "label": "Disposal Group Classification [Domain]",
        "terseLabel": "Disposal Group Classification [Domain]"
       }
      }
     },
     "localname": "DisposalGroupClassificationDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesRestrictedCashandRestrictedInvestmentsDetails",
      "http://www.evolenthealth.com/role/CommitmentsandContingenciesConcentrationRiskDetails",
      "http://www.evolenthealth.com/role/DiscontinuedOperationsAdditionalInformationDetails",
      "http://www.evolenthealth.com/role/DiscontinuedOperationsSummaryofCashFlowsDetails",
      "http://www.evolenthealth.com/role/DiscontinuedOperationsSummaryofCurrentandLongtermAssetsandLiabilitiesDetails",
      "http://www.evolenthealth.com/role/DiscontinuedOperationsSummaryofResultsofOperationsDetails",
      "http://www.evolenthealth.com/role/EmployeeBenefitPlansDetails",
      "http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNetIntangibleAssetsNetDetails",
      "http://www.evolenthealth.com/role/ReservesforClaimsandPerformanceBasedArrangementsDetails",
      "http://www.evolenthealth.com/role/RevenueRecognitionContractBalancesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet": {
     "auth_ref": [
      "r6",
      "r7",
      "r27",
      "r364"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/DiscontinuedOperationsSummaryofCurrentandLongtermAssetsandLiabilitiesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount classified as accounts, notes and loans receivable attributable to disposal group held for sale or disposed of.",
        "label": "Disposal Group, Including Discontinued Operation, Accounts, Notes and Loans Receivable, Net",
        "terseLabel": "Accounts receivable, net"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/DiscontinuedOperationsSummaryofCurrentandLongtermAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayableCurrent": {
     "auth_ref": [
      "r6",
      "r7",
      "r27",
      "r358",
      "r364"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/DiscontinuedOperationsSummaryofCurrentandLongtermAssetsandLiabilitiesDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount classified as accounts payable attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer.",
        "label": "Disposal Group, Including Discontinued Operation, Accounts Payable, Current",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationAccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/DiscontinuedOperationsSummaryofCurrentandLongtermAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r6",
      "r7",
      "r27",
      "r358",
      "r364"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/DiscontinuedOperationsSummaryofCurrentandLongtermAssetsandLiabilitiesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount classified as accrued liabilities attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer.",
        "label": "Disposal Group, Including Discontinued Operation, Accrued Liabilities, Current",
        "terseLabel": "Accrued liabilities"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationAccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/DiscontinuedOperationsSummaryofCurrentandLongtermAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent": {
     "auth_ref": [
      "r6",
      "r7",
      "r27",
      "r29",
      "r33",
      "r357",
      "r364"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount classified as assets attributable to disposal group held for sale or disposed of, expected to be disposed of after one year or the normal operating cycle, if longer.",
        "label": "Disposal Group, Including Discontinued Operation, Assets, Noncurrent",
        "terseLabel": "Non-current assets of discontinued operations"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents": {
     "auth_ref": [
      "r6",
      "r7",
      "r27",
      "r364"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/DiscontinuedOperationsSummaryofCurrentandLongtermAssetsandLiabilitiesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount classified as cash and cash equivalents attributable to disposal group held for sale or disposed of.",
        "label": "Disposal Group, Including Discontinued Operation, Cash and Cash Equivalents",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/DiscontinuedOperationsSummaryofCurrentandLongtermAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold": {
     "auth_ref": [
      "r24",
      "r33"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/DiscontinuedOperationsSummaryofResultsofOperationsDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of costs of goods sold attributable to disposal group, including, but not limited to, discontinued operation.",
        "label": "Disposal Group, Including Discontinued Operation, Costs of Goods Sold",
        "terseLabel": "Cost of revenue (exclusive of depreciation and amortization expenses presented separately below)"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/DiscontinuedOperationsSummaryofResultsofOperationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredRevenueCurrent": {
     "auth_ref": [
      "r6",
      "r7",
      "r27",
      "r358",
      "r364"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/DiscontinuedOperationsSummaryofCurrentandLongtermAssetsandLiabilitiesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount classified as deferred revenue attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer.",
        "label": "Disposal Group, Including Discontinued Operation, Deferred Revenue, Current",
        "terseLabel": "Deferred revenue"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationDeferredRevenueCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/DiscontinuedOperationsSummaryofCurrentandLongtermAssetsandLiabilitiesDetails",
      "http://www.evolenthealth.com/role/RevenueRecognitionContractBalancesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredTaxLiabilities": {
     "auth_ref": [
      "r6",
      "r7",
      "r27",
      "r364"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/DiscontinuedOperationsSummaryofCurrentandLongtermAssetsandLiabilitiesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount classified as deferred tax liabilities attributable to disposal group held for sale or disposed of.",
        "label": "Disposal Group, Including Discontinued Operation, Deferred Tax Liabilities",
        "terseLabel": "Deferred tax liabilities, net"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationDeferredTaxLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/DiscontinuedOperationsSummaryofCurrentandLongtermAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r24"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/DiscontinuedOperationsSummaryofResultsofOperationsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of general and administrative expense attributable to disposal group, including, but not limited to, discontinued operation.",
        "label": "Disposal Group, Including Discontinued Operation, General and Administrative Expense",
        "terseLabel": "Selling, general and administrative expenses"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/DiscontinuedOperationsSummaryofResultsofOperationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwillNoncurrent": {
     "auth_ref": [
      "r6",
      "r7",
      "r27",
      "r357",
      "r364"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/DiscontinuedOperationsSummaryofCurrentandLongtermAssetsandLiabilitiesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount classified as goodwill attributable to disposal group held for sale or disposed of, expected to be disposed of after one year or the normal operating cycle, if longer.",
        "label": "Disposal Group, Including Discontinued Operation, Goodwill, Noncurrent",
        "terseLabel": "Goodwill"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationGoodwillNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/DiscontinuedOperationsSummaryofCurrentandLongtermAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsNoncurrent": {
     "auth_ref": [
      "r6",
      "r7",
      "r27",
      "r357",
      "r364"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/DiscontinuedOperationsSummaryofCurrentandLongtermAssetsandLiabilitiesDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount classified as intangible assets, excluding goodwill, attributable to disposal group held for sale or disposed of, expected to be disposed of beyond one year or the normal operating cycle, if longer.",
        "label": "Disposal Group, Including Discontinued Operation, Intangible Assets, Noncurrent",
        "terseLabel": "Intangible assets, net"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/DiscontinuedOperationsSummaryofCurrentandLongtermAssetsandLiabilitiesDetails",
      "http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNetIntangibleAssetsNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationInterestExpense": {
     "auth_ref": [
      "r13",
      "r14",
      "r24",
      "r34"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/DiscontinuedOperationsSummaryofResultsofOperationsDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of interest expense attributable to disposal group, including, but not limited to, discontinued operation.",
        "label": "Disposal Group, Including Discontinued Operation, Interest Expense",
        "negatedTerseLabel": "Interest expense"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationInterestExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/DiscontinuedOperationsSummaryofResultsofOperationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationInterestIncome": {
     "auth_ref": [
      "r24"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/DiscontinuedOperationsSummaryofResultsofOperationsDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of interest income attributable to disposal group, including, but not limited to, discontinued operation.",
        "label": "Disposal Group, Including Discontinued Operation, Interest Income",
        "terseLabel": "Interest income"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationInterestIncome",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/DiscontinuedOperationsSummaryofResultsofOperationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense": {
     "auth_ref": [
      "r24"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/DiscontinuedOperationsSummaryofResultsofOperationsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of operating expense attributable to disposal group, including, but not limited to, discontinued operation.",
        "label": "Disposal Group, Including Discontinued Operation, Operating Expense",
        "totalLabel": "Total operating expenses"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationOperatingExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/DiscontinuedOperationsSummaryofResultsofOperationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss": {
     "auth_ref": [
      "r24"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/DiscontinuedOperationsSummaryofResultsofOperationsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of operating income (loss) attributable to disposal group, including, but not limited to, discontinued operation.",
        "label": "Disposal Group, Including Discontinued Operation, Operating Income (Loss)",
        "totalLabel": "Operating income (loss)"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/DiscontinuedOperationsSummaryofResultsofOperationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherExpense": {
     "auth_ref": [
      "r24"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/DiscontinuedOperationsSummaryofResultsofOperationsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of other expense attributable to disposal group, including, but not limited to, discontinued operation.",
        "label": "Disposal Group, Including Discontinued Operation, Other Expense",
        "negatedTerseLabel": "Other loss"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationOtherExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/DiscontinuedOperationsSummaryofResultsofOperationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentLiabilities": {
     "auth_ref": [
      "r6",
      "r7",
      "r27",
      "r357",
      "r364"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/DiscontinuedOperationsSummaryofCurrentandLongtermAssetsandLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount classified as other liabilities attributable to disposal group held for sale or disposed of, expected to be disposed of beyond one year or the normal operating cycle, if longer.",
        "label": "Disposal Group, Including Discontinued Operation, Other Liabilities, Noncurrent",
        "terseLabel": "Other long-term liabilities"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/DiscontinuedOperationsSummaryofCurrentandLongtermAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent": {
     "auth_ref": [
      "r6",
      "r7",
      "r27",
      "r358",
      "r364"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/DiscontinuedOperationsSummaryofCurrentandLongtermAssetsandLiabilitiesDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount classified as prepaid and other assets attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer.",
        "label": "Disposal Group, Including Discontinued Operation, Prepaid and Other Assets, Current",
        "terseLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/DiscontinuedOperationsSummaryofCurrentandLongtermAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue": {
     "auth_ref": [
      "r24",
      "r33"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/DiscontinuedOperationsSummaryofResultsofOperationsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of revenue attributable to disposal group, including, but not limited to, discontinued operation.",
        "label": "Disposal Group, Including Discontinued Operation, Revenue",
        "terseLabel": "Total revenue",
        "verboseLabel": "Revenue"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationRevenue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/CommitmentsandContingenciesConcentrationRiskDetails",
      "http://www.evolenthealth.com/role/DiscontinuedOperationsSummaryofResultsofOperationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock": {
     "auth_ref": [
      "r35",
      "r368"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.",
        "label": "Disposal Groups, Including Discontinued Operations, Disclosure [Text Block]",
        "terseLabel": "Discontinued Operations"
       }
      }
     },
     "localname": "DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/DiscontinuedOperations"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain": {
     "auth_ref": [
      "r532",
      "r534"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of disposal group.",
        "label": "Disposal Group Name [Domain]",
        "terseLabel": "Disposal Group Name [Domain]"
       }
      }
     },
     "localname": "DisposalGroupsIncludingDiscontinuedOperationsNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesRestrictedCashandRestrictedInvestmentsDetails",
      "http://www.evolenthealth.com/role/CommitmentsandContingenciesConcentrationRiskDetails",
      "http://www.evolenthealth.com/role/DiscontinuedOperationsAdditionalInformationDetails",
      "http://www.evolenthealth.com/role/DiscontinuedOperationsSummaryofCashFlowsDetails",
      "http://www.evolenthealth.com/role/DiscontinuedOperationsSummaryofCurrentandLongtermAssetsandLiabilitiesDetails",
      "http://www.evolenthealth.com/role/DiscontinuedOperationsSummaryofResultsofOperationsDetails",
      "http://www.evolenthealth.com/role/EmployeeBenefitPlansDetails",
      "http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNetIntangibleAssetsNetDetails",
      "http://www.evolenthealth.com/role/ReservesforClaimsandPerformanceBasedArrangementsDetails",
      "http://www.evolenthealth.com/role/RevenueRecognitionContractBalancesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DomesticCountryMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designated tax department of the government that is entitled to levy and collect income taxes from the entity in its country of domicile.",
        "label": "Domestic Tax Authority [Member]",
        "verboseLabel": "Federal"
       }
      }
     },
     "localname": "DomesticCountryMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EarningsPerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share [Abstract]",
        "terseLabel": "Earnings Per Share [Abstract]"
       }
      }
     },
     "localname": "EarningsPerShareAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasic": {
     "auth_ref": [
      "r115",
      "r195",
      "r196",
      "r197",
      "r198",
      "r199",
      "r206",
      "r209",
      "r217",
      "r218",
      "r219",
      "r223",
      "r224",
      "r704",
      "r705",
      "r833",
      "r862"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic",
        "totalLabel": "Basic loss per share attributable to common shareholders of Evolent Health, Inc. (in dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareBasic",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS",
      "http://www.evolenthealth.com/role/EarningsLossPerCommonShareComputationofEarningsperShareDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareBasicAndDilutedAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share, Basic and Diluted [Abstract]",
        "terseLabel": "Loss per common share",
        "verboseLabel": "Loss per common share, Basic and diluted"
       }
      }
     },
     "localname": "EarningsPerShareBasicAndDilutedAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS",
      "http://www.evolenthealth.com/role/EarningsLossPerCommonShareComputationofEarningsperShareDetails",
      "http://www.evolenthealth.com/role/QuarterlyResultsofOperationsunauditedDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share, Basic and Diluted, Other Disclosures [Abstract]",
        "terseLabel": "Weighted-average common shares outstanding"
       }
      }
     },
     "localname": "EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareDiluted": {
     "auth_ref": [
      "r115",
      "r195",
      "r196",
      "r197",
      "r198",
      "r199",
      "r209",
      "r217",
      "r218",
      "r219",
      "r223",
      "r224",
      "r704",
      "r705",
      "r833",
      "r862"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share, Diluted",
        "totalLabel": "Diluted loss per share attributable to common shareholders of Evolent Health, Inc. (in dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareDiluted",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS",
      "http://www.evolenthealth.com/role/EarningsLossPerCommonShareComputationofEarningsperShareDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "auth_ref": [
      "r220",
      "r221"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.",
        "label": "Earnings Per Share, Policy [Policy Text Block]",
        "terseLabel": "Earnings (Loss) Per Share"
       }
      }
     },
     "localname": "EarningsPerSharePolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "auth_ref": [
      "r220",
      "r221",
      "r222",
      "r225"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for earnings per share.",
        "label": "Earnings Per Share [Text Block]",
        "terseLabel": "Earnings (Loss) Per Common Share"
       }
      }
     },
     "localname": "EarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/EarningsLossPerCommonShare"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r734"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 4.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents",
        "terseLabel": "Effect of exchange rate on cash and cash equivalents and restricted cash"
       }
      }
     },
     "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperations": {
     "auth_ref": [
      "r598"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/IncomeTaxesReconciliationofStatutoryRatetoEffectiveTaxRateDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Effective Income Tax Rate Reconciliation, Percent",
        "terseLabel": "Effective rate",
        "totalLabel": "Effective tax rate"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateContinuingOperations",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/IncomeTaxesNarrativeDetails",
      "http://www.evolenthealth.com/role/IncomeTaxesReconciliationofStatutoryRatetoEffectiveTaxRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": {
     "auth_ref": [
      "r170",
      "r598",
      "r635"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/IncomeTaxesReconciliationofStatutoryRatetoEffectiveTaxRateDetails": {
       "order": 8.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss).",
        "label": "Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent",
        "terseLabel": "U.S. statutory tax rate"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/IncomeTaxesReconciliationofStatutoryRatetoEffectiveTaxRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r598",
      "r635"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/IncomeTaxesReconciliationofStatutoryRatetoEffectiveTaxRateDetails": {
       "order": 7.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.",
        "label": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent",
        "terseLabel": "Change in valuation allowance"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/IncomeTaxesReconciliationofStatutoryRatetoEffectiveTaxRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate": {
     "auth_ref": [
      "r598",
      "r635"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/IncomeTaxesReconciliationofStatutoryRatetoEffectiveTaxRateDetails": {
       "order": 16.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the income tax rates.",
        "label": "Effective Income Tax Rate Reconciliation, Change in Enacted Tax Rate, Percent",
        "terseLabel": "Change in state rate"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/IncomeTaxesReconciliationofStatutoryRatetoEffectiveTaxRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential": {
     "auth_ref": [
      "r598",
      "r635"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/IncomeTaxesReconciliationofStatutoryRatetoEffectiveTaxRateDetails": {
       "order": 12.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to statutory income tax expense (benefit) outside of the country of domicile.",
        "label": "Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Percent",
        "terseLabel": "Foreign earnings at other than U.S. rates"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/IncomeTaxesReconciliationofStatutoryRatetoEffectiveTaxRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationMinorityInterestIncomeExpense": {
     "auth_ref": [
      "r598",
      "r635"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/IncomeTaxesReconciliationofStatutoryRatetoEffectiveTaxRateDetails": {
       "order": 11.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to noncontrolling interest income (loss) exempt from income taxes.",
        "label": "Effective Income Tax Rate Reconciliation, Noncontrolling Interest Income (Loss), Percent",
        "terseLabel": "Non-controlling interest"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationMinorityInterestIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/IncomeTaxesReconciliationofStatutoryRatetoEffectiveTaxRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses": {
     "auth_ref": [
      "r598",
      "r635"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/IncomeTaxesReconciliationofStatutoryRatetoEffectiveTaxRateDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to impairment loss.",
        "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Impairment Losses, Percent",
        "terseLabel": "Non-deductible goodwill impairment"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/IncomeTaxesReconciliationofStatutoryRatetoEffectiveTaxRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments": {
     "auth_ref": [
      "r598",
      "r635"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/IncomeTaxesReconciliationofStatutoryRatetoEffectiveTaxRateDetails": {
       "order": 17.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.",
        "label": "Effective Income Tax Rate Reconciliation, Other Adjustments, Percent",
        "terseLabel": "Other, net"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationOtherAdjustments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/IncomeTaxesReconciliationofStatutoryRatetoEffectiveTaxRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent": {
     "auth_ref": [
      "r589",
      "r598"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/IncomeTaxesReconciliationofStatutoryRatetoEffectiveTaxRateDetails": {
       "order": 10.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to expense for award under share-based payment arrangement. Excludes expense determined to be nondeductible upon grant or after for award under share-based payment arrangement.",
        "label": "Effective Income Tax Rate Reconciliation, Tax Expense (Benefit), Share-based Payment Arrangement, Percent",
        "terseLabel": "Excess tax benefits (shortfalls) on stock-based compensation"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/IncomeTaxesReconciliationofStatutoryRatetoEffectiveTaxRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes": {
     "auth_ref": [
      "r598",
      "r635"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/IncomeTaxesReconciliationofStatutoryRatetoEffectiveTaxRateDetails": {
       "order": 15.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).",
        "label": "Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent",
        "terseLabel": "U.S. state income taxes, net of U.S. federal tax benefit"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/IncomeTaxesReconciliationofStatutoryRatetoEffectiveTaxRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch": {
     "auth_ref": [
      "r598",
      "r635"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/IncomeTaxesReconciliationofStatutoryRatetoEffectiveTaxRateDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": -1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit.",
        "label": "Effective Income Tax Rate Reconciliation, Tax Credit, Research, Percent",
        "negatedTerseLabel": "Convertible debt extinguishment"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationTaxCreditsResearch",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/IncomeTaxesReconciliationofStatutoryRatetoEffectiveTaxRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlements": {
     "auth_ref": [
      "r598",
      "r635"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/IncomeTaxesReconciliationofStatutoryRatetoEffectiveTaxRateDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to income tax settlements. Including, but not limited to, domestic tax settlement, foreign tax settlement, state and local tax settlement, and other tax settlements.",
        "label": "Effective Income Tax Rate Reconciliation, Tax Settlement, Percent",
        "terseLabel": "Tax sharing settlement"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationTaxSettlements",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/IncomeTaxesReconciliationofStatutoryRatetoEffectiveTaxRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectsOfReinsuranceTableTextBlock": {
     "auth_ref": [
      "r893"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the effects of reinsurance, for example, but not limited to, disclosure of direct, assumed, and ceded insurance.",
        "label": "Effects of Reinsurance [Table Text Block]",
        "terseLabel": "Summary of premiums and claims assumed"
       }
      }
     },
     "localname": "EffectsOfReinsuranceTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/CommitmentsandContingenciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrent": {
     "auth_ref": [
      "r75"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Employee-related Liabilities, Current",
        "terseLabel": "Accrued compensation and employee benefits"
       }
      }
     },
     "localname": "EmployeeRelatedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount": {
     "auth_ref": [
      "r572"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost capitalized for award under share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Amount Capitalized",
        "terseLabel": "Stock-based compensation capitalized as software development costs"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/StockbasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]",
        "terseLabel": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/StockbasedCompensationStockbasedCompensationExpenseDetails",
      "http://www.evolenthealth.com/role/StockbasedCompensationUnrecognizedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": {
     "auth_ref": [
      "r573"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/StockbasedCompensationUnrecognizedCompensationExpenseDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount",
        "totalLabel": "Unrecognized Compensation Expense"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/StockbasedCompensationUnrecognizedCompensationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "auth_ref": [
      "r573"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition",
        "terseLabel": "Weighted Average Period (years)"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/StockbasedCompensationUnrecognizedCompensationExpenseDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions": {
     "auth_ref": [
      "r573"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/StockbasedCompensationUnrecognizedCompensationExpenseDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Share-based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount",
        "terseLabel": "Unrecognized Compensation Expense"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/StockbasedCompensationUnrecognizedCompensationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": {
     "auth_ref": [
      "r573"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/StockbasedCompensationUnrecognizedCompensationExpenseDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost to be recognized for option under share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount",
        "terseLabel": "Unrecognized Compensation Expense"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/StockbasedCompensationUnrecognizedCompensationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeStockOptionMember": {
     "auth_ref": [
      "r569"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.",
        "label": "Share-based Payment Arrangement, Option [Member]",
        "terseLabel": "Stock options"
       }
      }
     },
     "localname": "EmployeeStockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesStockbasedCompensationDetails",
      "http://www.evolenthealth.com/role/EarningsLossPerCommonShareAntidilutiveSecuritiesDetails",
      "http://www.evolenthealth.com/role/StockbasedCompensationStockOptionsDetails",
      "http://www.evolenthealth.com/role/StockbasedCompensationStockbasedCompensationExpenseDetails",
      "http://www.evolenthealth.com/role/StockbasedCompensationUnrecognizedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r2",
      "r103",
      "r104",
      "r105",
      "r183",
      "r184",
      "r185",
      "r190",
      "r200",
      "r202",
      "r229",
      "r309",
      "r460",
      "r468",
      "r580",
      "r581",
      "r582",
      "r624",
      "r625",
      "r703",
      "r735",
      "r736",
      "r737",
      "r738",
      "r739",
      "r740",
      "r879",
      "r880",
      "r881",
      "r936"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component [Domain]"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY",
      "http://www.evolenthealth.com/role/LongtermDebt2021NotesDetails",
      "http://www.evolenthealth.com/role/LongtermDebt2024NotesDetails",
      "http://www.evolenthealth.com/role/LongtermDebt2025NotesDetails",
      "http://www.evolenthealth.com/role/NoncontrollingInterestsScheduleofChangesinNoncontrollingInterestsDetails",
      "http://www.evolenthealth.com/role/RecentlyIssuedAccountingStandardsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityMethodInvesteeMember": {
     "auth_ref": [
      "r298",
      "r804",
      "r806",
      "r808",
      "r810",
      "r812",
      "r814"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "An entity that issued voting stock held by an investor and that is accounted for under the equity method of accounting by the investor.",
        "label": "Equity Method Investee [Member]",
        "terseLabel": "Equity Method Investee"
       }
      }
     },
     "localname": "EquityMethodInvesteeMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/InvestmentsinEquityMethodInvesteesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityMethodInvestmentOtherThanTemporaryImpairment": {
     "auth_ref": [
      "r299"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This item represents an other than temporary decline in value that has been recognized against an investment accounted for under the equity method of accounting. The excess of the carrying amount over the fair value of the investment represents the amount of the write down which is or was reflected in earnings. The written down value is a new cost basis with the adjusted value of the investment becoming its new carrying value subject to the equity accounting method. Evidence of a loss in value might include, but would not necessarily be limited to, absence of an ability to recover the carrying amount of the investment or inability of the investee to sustain an earnings capacity which would justify the carrying amount of the investment.",
        "label": "Equity Method Investment, Other than Temporary Impairment",
        "negatedLabel": "Impairment of equity method investments",
        "negatedTerseLabel": "Equity method investment impairment",
        "terseLabel": "Impairment of equity method investments"
       }
      }
     },
     "localname": "EquityMethodInvestmentOtherThanTemporaryImpairment",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS",
      "http://www.evolenthealth.com/role/InvestmentsinEquityMethodInvesteesDetails",
      "http://www.evolenthealth.com/role/SegmentReportingReconciliationofAdjustedEBITDADetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Method Investments and Joint Ventures [Abstract]",
        "terseLabel": "Equity Method Investments and Joint Ventures [Abstract]"
       }
      }
     },
     "localname": "EquityMethodInvestmentsAndJointVenturesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityMethodInvestmentsDisclosureTextBlock": {
     "auth_ref": [
      "r305"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for equity method investments and joint ventures. Equity method investments are investments that give the investor the ability to exercise significant influence over the operating and financial policies of an investee. Joint ventures are entities owned and operated by a small group of businesses as a separate and specific business or project for the mutual benefit of the members of the group.",
        "label": "Equity Method Investments and Joint Ventures Disclosure [Text Block]",
        "terseLabel": "Investments in Equity Method Investees"
       }
      }
     },
     "localname": "EquityMethodInvestmentsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/InvestmentsinEquityMethodInvestees"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EquityMethodInvestmentsPolicy": {
     "auth_ref": [
      "r66",
      "r142",
      "r302",
      "r722"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for equity method of accounting for investments and other interests. Investment includes, but is not limited to, unconsolidated subsidiary, corporate joint venture, noncontrolling interest in real estate venture, limited partnership, and limited liability company. Information includes, but is not limited to, ownership percentage, reason equity method is or is not considered appropriate, and accounting policy election for distribution received.",
        "label": "Equity Method Investments [Policy Text Block]",
        "terseLabel": "Equity Method Investments and Impairment of Equity Method Investments"
       }
      }
     },
     "localname": "EquityMethodInvestmentsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EurodollarMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Interest rate based on U.S. dollar denominated deposits at foreign banks or foreign branches of U.S. banks.",
        "label": "Eurodollar [Member]",
        "terseLabel": "Eurodollar"
       }
      }
     },
     "localname": "EurodollarMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/LongtermDebtCreditAgreementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ExtinguishmentOfDebtAmount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross amount of debt extinguished.",
        "label": "Extinguishment of Debt, Amount",
        "terseLabel": "Face amount of debt repaid"
       }
      }
     },
     "localname": "ExtinguishmentOfDebtAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/LongtermDebt2021NotesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FacilityClosingMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Closing of a facility associated with exit from or disposal of business activities or restructurings pursuant to a plan.",
        "label": "Facility Closing [Member]",
        "terseLabel": "Office space consolidation"
       }
      }
     },
     "localname": "FacilityClosingMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/RepositioningandOtherChangesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value Measurement Inputs and Valuation Techniques [Line Items]",
        "terseLabel": "Fair Value Measurement Inputs and Valuation Techniques [Line Items]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/FairValueMeasurementValuationTechniquesandSignificantUnobservableInputsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable": {
     "auth_ref": [
      "r708"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis.",
        "label": "Fair Value Measurement Inputs and Valuation Techniques [Table]",
        "terseLabel": "Fair Value Measurement Inputs and Valuation Techniques [Table]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/FairValueMeasurementValuationTechniquesandSignificantUnobservableInputsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock": {
     "auth_ref": [
      "r708"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis.",
        "label": "Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]",
        "terseLabel": "Valuation techniques and significant unobservable inputs of Level 3 fair value measurements"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/FairValueMeasurementTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock": {
     "auth_ref": [
      "r706",
      "r707"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of assets, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).",
        "label": "Fair Value, Assets Measured on Recurring Basis [Table Text Block]",
        "terseLabel": "Summary of assets at fair value on recurring basis"
       }
      }
     },
     "localname": "FairValueAssetsMeasuredOnRecurringBasisTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/FairValueMeasurementTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]",
        "terseLabel": "Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]"
       }
      }
     },
     "localname": "FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/FairValueMeasurementAssetsandLiabilitiesonRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByBalanceSheetGroupingTable": {
     "auth_ref": [
      "r706",
      "r717",
      "r718"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about the fair value of financial instruments, including financial assets and financial liabilities, and the measurements of those instruments, assets, and liabilities.",
        "label": "Fair Value, by Balance Sheet Grouping [Table]",
        "terseLabel": "Fair Value, by Balance Sheet Grouping [Table]"
       }
      }
     },
     "localname": "FairValueByBalanceSheetGroupingTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/FairValueMeasurementAssetsandLiabilitiesonRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r425",
      "r443",
      "r444",
      "r513",
      "r515",
      "r516",
      "r517",
      "r518",
      "r519",
      "r520",
      "r528",
      "r707",
      "r779",
      "r780",
      "r781"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "terseLabel": "Fair Value Hierarchy and NAV [Axis]"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/FairValueMeasurementAssetsandLiabilitiesonRecurringBasisDetails",
      "http://www.evolenthealth.com/role/FairValueMeasurementValuationTechniquesandSignificantUnobservableInputsDetails",
      "http://www.evolenthealth.com/role/LongtermDebtConvertibleSeniorNotesCarryingValueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByMeasurementFrequencyAxis": {
     "auth_ref": [
      "r706",
      "r707",
      "r709",
      "r710",
      "r716"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by measurement frequency.",
        "label": "Measurement Frequency [Axis]",
        "terseLabel": "Measurement Frequency [Axis]"
       }
      }
     },
     "localname": "FairValueByMeasurementFrequencyAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/FairValueMeasurementAssetsandLiabilitiesonRecurringBasisDetails",
      "http://www.evolenthealth.com/role/FairValueMeasurementValuationTechniquesandSignificantUnobservableInputsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Abstract]",
        "terseLabel": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "localname": "FairValueDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "auth_ref": [
      "r714"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.",
        "label": "Fair Value Disclosures [Text Block]",
        "terseLabel": "Fair Value Measurement"
       }
      }
     },
     "localname": "FairValueDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/FairValueMeasurement"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "auth_ref": [
      "r425",
      "r513",
      "r515",
      "r520",
      "r528",
      "r707",
      "r779"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "terseLabel": "Level 1"
       }
      }
     },
     "localname": "FairValueInputsLevel1Member",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/FairValueMeasurementAssetsandLiabilitiesonRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "auth_ref": [
      "r425",
      "r443",
      "r444",
      "r513",
      "r515",
      "r520",
      "r528",
      "r707",
      "r780"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "terseLabel": "Level 2"
       }
      }
     },
     "localname": "FairValueInputsLevel2Member",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/FairValueMeasurementAssetsandLiabilitiesonRecurringBasisDetails",
      "http://www.evolenthealth.com/role/LongtermDebtConvertibleSeniorNotesCarryingValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "auth_ref": [
      "r425",
      "r443",
      "r444",
      "r513",
      "r515",
      "r516",
      "r517",
      "r518",
      "r519",
      "r520",
      "r528",
      "r707",
      "r781"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "terseLabel": "Level 3"
       }
      }
     },
     "localname": "FairValueInputsLevel3Member",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/FairValueMeasurementAssetsandLiabilitiesonRecurringBasisDetails",
      "http://www.evolenthealth.com/role/FairValueMeasurementValuationTechniquesandSignificantUnobservableInputsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock": {
     "auth_ref": [
      "r706",
      "r707"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).  Where the quoted price in an active market for the identical liability is not available, the Level 1 input is the quoted price of an identical liability when traded as an asset.",
        "label": "Fair Value, Liabilities Measured on Recurring Basis [Table Text Block]",
        "terseLabel": "Summary of liabilities at fair value on recurring basis"
       }
      }
     },
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/FairValueMeasurementTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]",
        "terseLabel": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]"
       }
      }
     },
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/FairValueMeasurementChangesinContingentConsiderationandOtherDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock": {
     "auth_ref": [
      "r711",
      "r715"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.",
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]",
        "terseLabel": "Changes in contingent consideration measured at fair value"
       }
      }
     },
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/FairValueMeasurementTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueMeasurementFrequencyDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement frequency.",
        "label": "Measurement Frequency [Domain]",
        "terseLabel": "Measurement Frequency [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementFrequencyDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/FairValueMeasurementAssetsandLiabilitiesonRecurringBasisDetails",
      "http://www.evolenthealth.com/role/FairValueMeasurementValuationTechniquesandSignificantUnobservableInputsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.",
        "label": "Fair Value Measurement, Policy [Policy Text Block]",
        "terseLabel": "Fair Value Measurement"
       }
      }
     },
     "localname": "FairValueMeasurementPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings": {
     "auth_ref": [
      "r712"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) recognized in income from liability measured at fair value on recurring basis using unobservable input (level 3).",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings",
        "negatedLabel": "Realized and unrealized losses, net"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/FairValueMeasurementChangesinContingentConsiderationandOtherDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues": {
     "auth_ref": [
      "r713"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of issuances of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Issuances",
        "terseLabel": "Additions"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/FairValueMeasurementChangesinContingentConsiderationandOtherDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements": {
     "auth_ref": [
      "r713"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of settlements of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements",
        "negatedLabel": "Settlements"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/FairValueMeasurementChangesinContingentConsiderationandOtherDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue": {
     "auth_ref": [
      "r711"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value",
        "periodEndLabel": "Balance as of end of period",
        "periodStartLabel": "Balance as of beginning of period"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/FairValueMeasurementChangesinContingentConsiderationandOtherDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [
      "r425",
      "r443",
      "r444",
      "r513",
      "r515",
      "r516",
      "r517",
      "r518",
      "r519",
      "r520",
      "r528",
      "r779",
      "r780",
      "r781"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "terseLabel": "Fair Value Hierarchy and NAV [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/FairValueMeasurementAssetsandLiabilitiesonRecurringBasisDetails",
      "http://www.evolenthealth.com/role/FairValueMeasurementValuationTechniquesandSignificantUnobservableInputsDetails",
      "http://www.evolenthealth.com/role/LongtermDebtConvertibleSeniorNotesCarryingValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsRecurringMember": {
     "auth_ref": [
      "r714",
      "r716"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value.",
        "label": "Fair Value, Recurring [Member]",
        "verboseLabel": "Fair Value, Recurring"
       }
      }
     },
     "localname": "FairValueMeasurementsRecurringMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/FairValueMeasurementAssetsandLiabilitiesonRecurringBasisDetails",
      "http://www.evolenthealth.com/role/FairValueMeasurementValuationTechniquesandSignificantUnobservableInputsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FinanceLeaseInterestExpense": {
     "auth_ref": [
      "r749",
      "r754",
      "r763"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/LeasesComponentsofLeaseExpenseDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of interest expense on finance lease liability.",
        "label": "Finance Lease, Interest Expense",
        "terseLabel": "Interest expense"
       }
      }
     },
     "localname": "FinanceLeaseInterestExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/LeasesComponentsofLeaseExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseRightOfUseAssetAmortization": {
     "auth_ref": [
      "r749",
      "r754",
      "r763"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/LeasesComponentsofLeaseExpenseDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization expense attributable to right-of-use asset from finance lease.",
        "label": "Finance Lease, Right-of-Use Asset, Amortization",
        "terseLabel": "Amortization of right-of-use assets"
       }
      }
     },
     "localname": "FinanceLeaseRightOfUseAssetAmortization",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/LeasesComponentsofLeaseExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceReceivablesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amounts due the Company from customers, clients, lessees, borrowers, or others under the terms of its agreements therewith. Such amount may include accrued interest receivable in accordance with the terms of the agreements. The agreements also may contain provisions and related items including a discount or premium, payable on demand, secured, or unsecured, interest bearing or noninterest bearing, among myriad other features and characteristics.",
        "label": "Financing Receivable [Member]",
        "terseLabel": "Customer Receivable"
       }
      }
     },
     "localname": "FinanceReceivablesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/CommitmentsandContingenciesConcentrationRiskDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FinancingReceivablePercentPastDue1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of financing receivable balance that is past due.",
        "label": "Financing Receivable, Percent Past Due",
        "terseLabel": "Percentage of receivables, past due"
       }
      }
     },
     "localname": "FinancingReceivablePercentPastDue1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/CreditLossesAccountsReceivableNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_FinancingReceivablesPeriodPastDueAxis": {
     "auth_ref": [
      "r290",
      "r319",
      "r325"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by period in which financial asset is past due or not past due.",
        "label": "Financial Asset, Aging [Axis]",
        "terseLabel": "Financial Asset, Period Past Due [Axis]"
       }
      }
     },
     "localname": "FinancingReceivablesPeriodPastDueAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/CreditLossesAccountsReceivableNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FinancingReceivablesPeriodPastDueDomain": {
     "auth_ref": [
      "r290",
      "r319",
      "r325"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period in which financial asset is past due or not past due. For past due, element name and standard label in Financial Asset, [numeric lower end] to [numeric higher end] [date measure] Past Due [Member] or Financial Asset, Greater than [low end numeric value] [date measure] Past Due [Member] or Financial Asset, Less than [high end numeric value] [date measure] Past Due [Member] formats.",
        "label": "Financial Asset, Aging [Domain]",
        "terseLabel": "Financial Asset, Period Past Due [Domain]"
       }
      }
     },
     "localname": "FinancingReceivablesPeriodPastDueDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/CreditLossesAccountsReceivableNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetUsefulLife": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Finite-Lived Intangible Asset, Useful Life",
        "terseLabel": "Useful life"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesIntangibleAssetsNetDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": {
     "auth_ref": [
      "r350"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNetIntangibleAssetsNetDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Accumulated Amortization",
        "terseLabel": "Accumulated Amortization"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNetIntangibleAssetsNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive": {
     "auth_ref": [],
     "calculation": {
      "http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNetAmortizationofIntangibleAssetsDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for asset, excluding financial asset and goodwill, lacking physical substance with finite life expected to be recognized after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, after Year Five",
        "terseLabel": "Thereafter"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNetAmortizationofIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths": {
     "auth_ref": [
      "r352"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNetAmortizationofIntangibleAssetsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year One",
        "terseLabel": "2022"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNetAmortizationofIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive": {
     "auth_ref": [
      "r352"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNetAmortizationofIntangibleAssetsDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Five",
        "terseLabel": "2026"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFive",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNetAmortizationofIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour": {
     "auth_ref": [
      "r352"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNetAmortizationofIntangibleAssetsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Four",
        "terseLabel": "2025"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFour",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNetAmortizationofIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree": {
     "auth_ref": [
      "r352"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNetAmortizationofIntangibleAssetsDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Three",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearThree",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNetAmortizationofIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo": {
     "auth_ref": [
      "r352"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNetAmortizationofIntangibleAssetsDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Two",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNetAmortizationofIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": {
     "auth_ref": [
      "r345",
      "r347",
      "r350",
      "r353",
      "r795",
      "r802"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by major type or class of finite-lived intangible assets.",
        "label": "Finite-Lived Intangible Assets by Major Class [Axis]",
        "terseLabel": "Finite-Lived Intangible Assets by Major Class [Axis]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesIntangibleAssetsNetDetails",
      "http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNetIntangibleAssetsNetDetails",
      "http://www.evolenthealth.com/role/TransactionsVitalDecisionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsGross": {
     "auth_ref": [
      "r350",
      "r802"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNetIntangibleAssetsNetDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Gross",
        "terseLabel": "Gross Carrying Amount"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNetIntangibleAssetsNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Finite-Lived Intangible Assets [Line Items]",
        "terseLabel": "Finite-Lived Intangible Assets [Line Items]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesIntangibleAssetsNetDetails",
      "http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNetIntangibleAssetsNetDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "auth_ref": [
      "r345",
      "r349"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company.",
        "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]",
        "terseLabel": "Finite-Lived Intangible Assets, Major Class Name [Domain]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesIntangibleAssetsNetDetails",
      "http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNetIntangibleAssetsNetDetails",
      "http://www.evolenthealth.com/role/TransactionsVitalDecisionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsNet": {
     "auth_ref": [
      "r350",
      "r795"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNetAmortizationofIntangibleAssetsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNetIntangibleAssetsNetDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Net",
        "totalLabel": "Total future amortization of intangible assets"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNetAmortizationofIntangibleAssetsDetails",
      "http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNetIntangibleAssetsNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FurnitureAndFixturesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases.",
        "label": "Furniture and Fixtures [Member]",
        "terseLabel": "Furniture and equipment"
       }
      }
     },
     "localname": "FurnitureAndFixturesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesEstimatedUsefulLifeofPropertyPlantandEquipmentDetails",
      "http://www.evolenthealth.com/role/PropertyandEquipmentNetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_GainLossOnDispositionOfAssets1": {
     "auth_ref": [
      "r150"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS": {
       "order": 3.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) on sale or disposal of assets, including but not limited to property plant and equipment, intangible assets and equity in securities of subsidiaries or equity method investee.",
        "label": "Gain (Loss) on Disposition of Assets",
        "negatedTerseLabel": "Loss (gain) on disposal of assets and consolidation",
        "terseLabel": "Gain (loss) on disposal of assets"
       }
      }
     },
     "localname": "GainLossOnDispositionOfAssets1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS",
      "http://www.evolenthealth.com/role/SegmentReportingReconciliationofAdjustedEBITDADetails",
      "http://www.evolenthealth.com/role/TransactionsEquityInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GainsLossesOnExtinguishmentOfDebt": {
     "auth_ref": [
      "r150",
      "r447",
      "r448"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 23.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      },
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.",
        "label": "Gain (Loss) on Extinguishment of Debt",
        "negatedLabel": "Loss on repayment of debt",
        "negatedTerseLabel": "Loss on extinguishment of debt, net",
        "terseLabel": "Loss on repayment of debt, net",
        "verboseLabel": "Loss on extinguishment of debt"
       }
      }
     },
     "localname": "GainsLossesOnExtinguishmentOfDebt",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS",
      "http://www.evolenthealth.com/role/LongtermDebtCreditAgreementDetails",
      "http://www.evolenthealth.com/role/SegmentReportingReconciliationofAdjustedEBITDADetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GainsLossesOnExtinguishmentOfDebtBeforeWriteOffOfDeferredDebtIssuanceCost": {
     "auth_ref": [
      "r447",
      "r448"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reflects the difference between the fair value of payments made to legally extinguish a debt and its carrying value at that time. This item excludes the write-off of amounts previously capitalized as debt issuance costs.",
        "label": "Gain (Loss) on Extinguishment of Debt, before Write off of Debt Issuance Cost",
        "negatedLabel": "Net loss on extinguishment of debt, including fees paid to lenders"
       }
      }
     },
     "localname": "GainsLossesOnExtinguishmentOfDebtBeforeWriteOffOfDeferredDebtIssuanceCost",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/LongtermDebt2021NotesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Goodwill": {
     "auth_ref": [
      "r331",
      "r333",
      "r778",
      "r817"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 9.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      },
      "http://www.evolenthealth.com/role/TransactionsVitalDecisionsDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill",
        "periodEndLabel": "Balance as of end of period",
        "periodStartLabel": "Balance as of beginning of period",
        "terseLabel": "Goodwill"
       }
      }
     },
     "localname": "Goodwill",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNetScheduleofGoodwillDetails",
      "http://www.evolenthealth.com/role/TransactionsVitalDecisionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillAcquiredDuringPeriod": {
     "auth_ref": [
      "r335"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized resulting from a business combination.",
        "label": "Goodwill, Acquired During Period",
        "terseLabel": "Goodwill acquired"
       }
      }
     },
     "localname": "GoodwillAcquiredDuringPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNetScheduleofGoodwillDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Goodwill and Intangible Assets Disclosure [Abstract]",
        "terseLabel": "Goodwill and Intangible Assets Disclosure [Abstract]"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock": {
     "auth_ref": [
      "r356"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for goodwill and intangible assets.",
        "label": "Goodwill and Intangible Assets Disclosure [Text Block]",
        "terseLabel": "Goodwill and Intangible Assets, Net"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNet"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy": {
     "auth_ref": [
      "r340"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for goodwill. This accounting policy also may address how an entity assesses and measures impairment of goodwill, how reporting units are determined, how goodwill is allocated to such units, and how the fair values of the reporting units are determined.",
        "label": "Goodwill and Intangible Assets, Goodwill, Policy [Policy Text Block]",
        "terseLabel": "Goodwill"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsGoodwillPolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_GoodwillForeignCurrencyTranslationGainLoss": {
     "auth_ref": [
      "r338"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of foreign currency translation gain (loss) which increases (decreases) an asset representing future economic benefits from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill, Foreign Currency Translation Gain (Loss)",
        "terseLabel": "Foreign currency translation"
       }
      }
     },
     "localname": "GoodwillForeignCurrencyTranslationGainLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNetScheduleofGoodwillDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillImpairedAccumulatedImpairmentLoss": {
     "auth_ref": [
      "r334",
      "r339"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated impairment loss for an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill, Impaired, Accumulated Impairment Loss",
        "terseLabel": "Cumulative inception to date impairment"
       }
      }
     },
     "localname": "GoodwillImpairedAccumulatedImpairmentLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNetScheduleofGoodwillDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillImpairmentLoss": {
     "auth_ref": [
      "r150",
      "r332",
      "r337",
      "r341"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 25.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS": {
       "order": 6.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill, Impairment Loss",
        "negatedTerseLabel": "Impairment",
        "terseLabel": "Goodwill impairment"
       }
      }
     },
     "localname": "GoodwillImpairmentLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS",
      "http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNetImpairmentTestingDetails",
      "http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNetScheduleofGoodwillDetails",
      "http://www.evolenthealth.com/role/QuarterlyResultsofOperationsunauditedAdditionalInformationDetails",
      "http://www.evolenthealth.com/role/SegmentReportingReconciliationofAdjustedEBITDADetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Goodwill [Line Items]",
        "terseLabel": "Goodwill [Line Items]"
       }
      }
     },
     "localname": "GoodwillLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNetScheduleofGoodwillDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_GoodwillRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Goodwill [Roll Forward]",
        "terseLabel": "Goodwill [Roll Forward]"
       }
      }
     },
     "localname": "GoodwillRollForward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNetScheduleofGoodwillDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit": {
     "auth_ref": [
      "r336"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of divestiture of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill, Written off Related to Sale of Business Unit",
        "negatedTerseLabel": "Goodwill disposal"
       }
      }
     },
     "localname": "GoodwillWrittenOffRelatedToSaleOfBusinessUnit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNetScheduleofGoodwillDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic": {
     "auth_ref": [
      "r169",
      "r634"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/IncomeTaxesScheduleofLossBeforeProvisionforIncomeTaxesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to domestic operations.",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Domestic",
        "terseLabel": "Domestic"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/IncomeTaxesScheduleofLossBeforeProvisionforIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "auth_ref": [
      "r109",
      "r258",
      "r269",
      "r272",
      "r275",
      "r278",
      "r815",
      "r828",
      "r836",
      "r863"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest",
        "totalLabel": "Loss from continuing operations before income taxes"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign": {
     "auth_ref": [
      "r169",
      "r634"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/IncomeTaxesScheduleofLossBeforeProvisionforIncomeTaxesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to foreign operations, which is defined as Income or Loss generated from operations located outside the entity's country of domicile.",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Foreign",
        "terseLabel": "Foreign"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/IncomeTaxesScheduleofLossBeforeProvisionforIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments": {
     "auth_ref": [
      "r258",
      "r269",
      "r272",
      "r275",
      "r278"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/IncomeTaxesScheduleofLossBeforeProvisionforIncomeTaxesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (loss) from continuing operations before deduction of income tax expense (benefit) and income (loss) attributable to noncontrolling interest, and addition of income (loss) from equity method investments.",
        "label": "Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest",
        "totalLabel": "Loss from continuing operations before income taxes"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/IncomeTaxesScheduleofLossBeforeProvisionforIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest [Abstract]",
        "terseLabel": "Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest [Abstract]"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/IncomeTaxesScheduleofLossBeforeProvisionforIncomeTaxesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r167",
      "r189",
      "r258",
      "r269",
      "r272",
      "r275",
      "r278",
      "r304",
      "r393",
      "r394",
      "r395",
      "r398",
      "r399",
      "r400",
      "r402",
      "r404",
      "r406",
      "r407",
      "r671",
      "r705",
      "r722"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS": {
       "order": 2.0,
       "parentTag": "us-gaap_ProfitLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of income (loss) from continuing operations including portion attributable to the noncontrolling interest.",
        "label": "Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest",
        "terseLabel": "Loss from continuing operations",
        "totalLabel": "Loss from continuing operations"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS",
      "http://www.evolenthealth.com/role/EarningsLossPerCommonShareComputationofEarningsperShareDetails",
      "http://www.evolenthealth.com/role/QuarterlyResultsofOperationsunauditedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsPerBasicShare": {
     "auth_ref": [
      "r106",
      "r115",
      "r189",
      "r195",
      "r196",
      "r197",
      "r198",
      "r209",
      "r217",
      "r218",
      "r705",
      "r826",
      "r829",
      "r833",
      "r856"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS": {
       "order": 1.0,
       "parentTag": "us-gaap_EarningsPerShareBasic",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) from continuing operations per each share of common stock or unit outstanding during the reporting period.",
        "label": "Income (Loss) from Continuing Operations, Per Basic Share",
        "terseLabel": "Continuing operations, basic (in dollars per share)"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsPerBasicShare",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS",
      "http://www.evolenthealth.com/role/EarningsLossPerCommonShareComputationofEarningsperShareDetails",
      "http://www.evolenthealth.com/role/QuarterlyResultsofOperationsunauditedDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare": {
     "auth_ref": [
      "r106",
      "r115",
      "r189",
      "r195",
      "r196",
      "r197",
      "r198",
      "r209",
      "r217",
      "r218",
      "r219",
      "r705",
      "r833",
      "r856",
      "r858",
      "r862"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS": {
       "order": 1.0,
       "parentTag": "us-gaap_EarningsPerShareDiluted",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) derived from continuing operations during the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Income (Loss) from Continuing Operations, Per Diluted Share",
        "terseLabel": "Continuing operations, diluted (in dollars per share)"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsPerDilutedShare",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS",
      "http://www.evolenthealth.com/role/EarningsLossPerCommonShareComputationofEarningsperShareDetails",
      "http://www.evolenthealth.com/role/QuarterlyResultsofOperationsunauditedDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax": {
     "auth_ref": [
      "r9",
      "r10",
      "r11",
      "r12",
      "r15",
      "r30",
      "r33",
      "r639",
      "r857"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS": {
       "order": 1.0,
       "parentTag": "us-gaap_ProfitLoss",
       "weight": 1.0
      },
      "http://www.evolenthealth.com/role/DiscontinuedOperationsSummaryofResultsofOperationsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of income (loss) from a discontinued operation including the portion attributable to the noncontrolling interest. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal.",
        "label": "Income (Loss) from Discontinued Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest",
        "terseLabel": "Income (loss) from discontinued operations, net of tax",
        "totalLabel": "Income (loss) from discontinued operations, net of tax (2)",
        "verboseLabel": "Gain (loss) from discontinued operations"
       }
      }
     },
     "localname": "IncomeLossFromDiscontinuedOperationsNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS",
      "http://www.evolenthealth.com/role/DiscontinuedOperationsSummaryofResultsofOperationsDetails",
      "http://www.evolenthealth.com/role/EarningsLossPerCommonShareComputationofEarningsperShareDetails",
      "http://www.evolenthealth.com/role/QuarterlyResultsofOperationsunauditedDetails",
      "http://www.evolenthealth.com/role/SegmentReportingReconciliationofAdjustedEBITDADetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare": {
     "auth_ref": [
      "r111",
      "r115",
      "r210",
      "r217",
      "r218",
      "r833",
      "r857",
      "r858",
      "r862"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS": {
       "order": 2.0,
       "parentTag": "us-gaap_EarningsPerShareBasic",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per basic share amount, after tax, of income (loss) from the day-to-day business activities of the discontinued operation and gain (loss) from the disposal of the discontinued operation.",
        "label": "Income (Loss) from Discontinued Operations and Disposal of Discontinued Operations, Net of Tax, Per Basic Share",
        "terseLabel": "Discontinued operations, basic (in dollars per share)"
       }
      }
     },
     "localname": "IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS",
      "http://www.evolenthealth.com/role/EarningsLossPerCommonShareComputationofEarningsperShareDetails",
      "http://www.evolenthealth.com/role/QuarterlyResultsofOperationsunauditedDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare": {
     "auth_ref": [
      "r210",
      "r217",
      "r218",
      "r692"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS": {
       "order": 2.0,
       "parentTag": "us-gaap_EarningsPerShareDiluted",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per diluted share amount, after tax, of income (loss) from the day-to-day business activities of the discontinued operation and gain (loss) from the disposal of the discontinued operation.",
        "label": "Income (Loss) from Discontinued Operations and Disposal of Discontinued Operations, Net of Tax, Per Diluted Share",
        "terseLabel": "Discontinued operations, diluted (in dollars per share)"
       }
      }
     },
     "localname": "IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS",
      "http://www.evolenthealth.com/role/EarningsLossPerCommonShareComputationofEarningsperShareDetails",
      "http://www.evolenthealth.com/role/QuarterlyResultsofOperationsunauditedDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_IncomeLossFromEquityMethodInvestments": {
     "auth_ref": [
      "r110",
      "r150",
      "r255",
      "r300",
      "r827",
      "r855"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      },
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS": {
       "order": 6.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (loss) for proportionate share of equity method investee's income (loss).",
        "label": "Income (Loss) from Equity Method Investments",
        "negatedLabel": "(Gain) loss from equity method investees",
        "terseLabel": "Gain (loss) from equity method investees"
       }
      }
     },
     "localname": "IncomeLossFromEquityMethodInvestments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS",
      "http://www.evolenthealth.com/role/InvestmentsinEquityMethodInvesteesDetails",
      "http://www.evolenthealth.com/role/SegmentReportingReconciliationofAdjustedEBITDADetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]",
        "terseLabel": "Income Statement [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis": {
     "auth_ref": [
      "r532",
      "r534"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by name of disposal group.",
        "label": "Disposal Group Name [Axis]",
        "terseLabel": "Disposal Group Name [Axis]"
       }
      }
     },
     "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesRestrictedCashandRestrictedInvestmentsDetails",
      "http://www.evolenthealth.com/role/CommitmentsandContingenciesConcentrationRiskDetails",
      "http://www.evolenthealth.com/role/DiscontinuedOperationsAdditionalInformationDetails",
      "http://www.evolenthealth.com/role/DiscontinuedOperationsSummaryofCashFlowsDetails",
      "http://www.evolenthealth.com/role/DiscontinuedOperationsSummaryofCurrentandLongtermAssetsandLiabilitiesDetails",
      "http://www.evolenthealth.com/role/DiscontinuedOperationsSummaryofResultsofOperationsDetails",
      "http://www.evolenthealth.com/role/EmployeeBenefitPlansDetails",
      "http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNetIntangibleAssetsNetDetails",
      "http://www.evolenthealth.com/role/ReservesforClaimsandPerformanceBasedArrangementsDetails",
      "http://www.evolenthealth.com/role/RevenueRecognitionContractBalancesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]",
        "terseLabel": "Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]"
       }
      }
     },
     "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/DiscontinuedOperationsAdditionalInformationDetails",
      "http://www.evolenthealth.com/role/DiscontinuedOperationsSummaryofCashFlowsDetails",
      "http://www.evolenthealth.com/role/DiscontinuedOperationsSummaryofCurrentandLongtermAssetsandLiabilitiesDetails",
      "http://www.evolenthealth.com/role/DiscontinuedOperationsSummaryofResultsofOperationsDetails",
      "http://www.evolenthealth.com/role/EmployeeBenefitPlansDetails",
      "http://www.evolenthealth.com/role/RevenueRecognitionContractBalancesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable": {
     "auth_ref": [
      "r7",
      "r17",
      "r18",
      "r19",
      "r20",
      "r21",
      "r22",
      "r28",
      "r31",
      "r32",
      "r33",
      "r366",
      "r367"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.",
        "label": "Disposal Groups, Including Discontinued Operations [Table]",
        "terseLabel": "Disposal Groups, Including Discontinued Operations [Table]"
       }
      }
     },
     "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/DiscontinuedOperationsAdditionalInformationDetails",
      "http://www.evolenthealth.com/role/DiscontinuedOperationsSummaryofCashFlowsDetails",
      "http://www.evolenthealth.com/role/DiscontinuedOperationsSummaryofCurrentandLongtermAssetsandLiabilitiesDetails",
      "http://www.evolenthealth.com/role/DiscontinuedOperationsSummaryofResultsofOperationsDetails",
      "http://www.evolenthealth.com/role/EmployeeBenefitPlansDetails",
      "http://www.evolenthealth.com/role/RevenueRecognitionContractBalancesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r363",
      "r373"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]",
        "terseLabel": "Income Statement Location [Axis]"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/StockbasedCompensationStockbasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [
      "r373"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the income statement.",
        "label": "Income Statement Location [Domain]",
        "terseLabel": "Income Statement Location [Domain]"
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/StockbasedCompensationStockbasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxAuthorityAxis": {
     "auth_ref": [
      "r600"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by tax jurisdiction.",
        "label": "Income Tax Authority [Axis]",
        "terseLabel": "Income Tax Authority [Axis]"
       }
      }
     },
     "localname": "IncomeTaxAuthorityAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxAuthorityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Agency, division or body classification that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes.",
        "label": "Income Tax Authority [Domain]",
        "terseLabel": "Income Tax Authority [Domain]"
       }
      }
     },
     "localname": "IncomeTaxAuthorityDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxContingencyLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Income Tax Contingency [Line Items]",
        "terseLabel": "Income Tax Contingency [Line Items]"
       }
      }
     },
     "localname": "IncomeTaxContingencyLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxContingencyTable": {
     "auth_ref": [
      "r601",
      "r604",
      "r606",
      "r621"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about tax positions taken in the tax returns filed or to be filed for which it is more likely than not that the tax position will not be sustained upon examination by taxing authorities and other income tax contingencies. Includes, but is not limited to, interest and penalties, reconciliation of unrecognized tax benefits, unrecognized tax benefits that would affect the effective tax rate, tax years that remain subject to examination by tax jurisdictions, and information about positions for which it is reasonably possible that amounts unrecognized will significantly change within 12 months.",
        "label": "Income Tax Contingency [Table]",
        "terseLabel": "Income Tax Contingency [Table]"
       }
      }
     },
     "localname": "IncomeTaxContingencyTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]",
        "terseLabel": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "localname": "IncomeTaxDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "auth_ref": [
      "r170",
      "r599",
      "r605",
      "r612",
      "r629",
      "r636",
      "r640",
      "r641",
      "r642"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.",
        "label": "Income Tax Disclosure [Text Block]",
        "terseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/IncomeTaxes"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r171",
      "r201",
      "r202",
      "r256",
      "r597",
      "r630",
      "r637",
      "r864"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest",
       "weight": -1.0
      },
      "http://www.evolenthealth.com/role/IncomeTaxesIncomeTaxExpenseBenefitDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Income Tax Expense (Benefit)",
        "negatedLabel": "(Provision) benefit for income taxes",
        "terseLabel": "Provision (benefit) for income taxes",
        "totalLabel": "Total tax expense (benefit)"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS",
      "http://www.evolenthealth.com/role/IncomeTaxesIncomeTaxExpenseBenefitDetails",
      "http://www.evolenthealth.com/role/IncomeTaxesNarrativeDetails",
      "http://www.evolenthealth.com/role/SegmentReportingReconciliationofAdjustedEBITDADetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "auth_ref": [
      "r102",
      "r593",
      "r594",
      "r605",
      "r606",
      "r611",
      "r620"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.",
        "label": "Income Tax, Policy [Policy Text Block]",
        "terseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxesPaid": {
     "auth_ref": [
      "r145",
      "r156"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income.",
        "label": "Income Taxes Paid",
        "terseLabel": "Cash paid for taxes, net"
       }
      }
     },
     "localname": "IncomeTaxesPaid",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/SupplementalCashFlowInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "auth_ref": [
      "r149"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 15.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.",
        "label": "Increase (Decrease) in Accounts Payable",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccruedLiabilities": {
     "auth_ref": [
      "r149"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 16.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.",
        "label": "Increase (Decrease) in Accrued Liabilities",
        "terseLabel": "Accrued liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInContractWithCustomerLiability": {
     "auth_ref": [
      "r149",
      "r789"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 18.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.",
        "label": "Increase (Decrease) in Contract with Customer, Liability",
        "terseLabel": "Deferred revenue"
       }
      }
     },
     "localname": "IncreaseDecreaseInContractWithCustomerLiability",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities": {
     "auth_ref": [
      "r149"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 17.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits.",
        "label": "Increase (Decrease) in Employee Related Liabilities",
        "terseLabel": "Accrued compensation and employee benefits"
       }
      }
     },
     "localname": "IncreaseDecreaseInEmployeeRelatedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "terseLabel": "Changes in assets and liabilities, net of acquisitions:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingLeaseLiability": {
     "auth_ref": [
      "r149",
      "r757"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 21.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in obligation for operating lease.",
        "label": "Increase (Decrease) in Operating Lease Liability",
        "terseLabel": "Operating lease liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities": {
     "auth_ref": [],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 22.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in noncurrent operating liabilities classified as other.",
        "label": "Increase (Decrease) in Other Noncurrent Liabilities",
        "terseLabel": "Other long-term liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherNoncurrentLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "auth_ref": [
      "r149"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 13.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "negatedTerseLabel": "Prepaid expenses and other current and non-current assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]"
       }
      }
     },
     "localname": "IncreaseDecreaseInStockholdersEquityRollForward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InsuranceAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Insurance [Abstract]",
        "terseLabel": "Insurance [Abstract]"
       }
      }
     },
     "localname": "InsuranceAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_InsuranceDisclosureTextBlock": {
     "auth_ref": [
      "r895"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the types of coverages and products sold, and the assets, obligations, recorded liabilities, revenues and expenses arising therefrom, and the amounts of and methodologies and assumptions used in determining the amounts of such items.",
        "label": "Insurance Disclosure [Text Block]",
        "terseLabel": "Reserves for Claims and Performance-Based Arrangements"
       }
      }
     },
     "localname": "InsuranceDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/ReservesforClaimsandPerformanceBasedArrangements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IntangibleAssetsFiniteLivedPolicy": {
     "auth_ref": [
      "r162",
      "r349",
      "r791",
      "r792",
      "r793",
      "r795"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for finite-lived intangible assets. This accounting policy also might address: (1) the amortization method used; (2) the useful lives of such assets; and (3) how the entity assesses and measures impairment of such assets.",
        "label": "Intangible Assets, Finite-Lived, Policy [Policy Text Block]",
        "terseLabel": "Intangible Assets, Net"
       }
      }
     },
     "localname": "IntangibleAssetsFiniteLivedPolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IntangibleAssetsNetExcludingGoodwill": {
     "auth_ref": [
      "r343",
      "r348"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 7.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.",
        "label": "Intangible Assets, Net (Excluding Goodwill)",
        "terseLabel": "Intangible assets, net"
       }
      }
     },
     "localname": "IntangibleAssetsNetExcludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestExpense": {
     "auth_ref": [
      "r107",
      "r252",
      "r741",
      "r744",
      "r834"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS": {
       "order": 4.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.",
        "label": "Interest Expense",
        "negatedTerseLabel": "Interest expense"
       }
      }
     },
     "localname": "InterestExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS",
      "http://www.evolenthealth.com/role/SegmentReportingReconciliationofAdjustedEBITDADetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestExpenseDebt": {
     "auth_ref": [
      "r122",
      "r431",
      "r442",
      "r445",
      "r446"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense for debt.",
        "label": "Interest Expense, Debt",
        "terseLabel": "Interest expense"
       }
      }
     },
     "localname": "InterestExpenseDebt",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/LongtermDebt2021NotesDetails",
      "http://www.evolenthealth.com/role/LongtermDebt2024NotesDetails",
      "http://www.evolenthealth.com/role/LongtermDebt2025NotesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestPaidNet": {
     "auth_ref": [
      "r140",
      "r144",
      "r156"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.",
        "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities",
        "terseLabel": "Cash paid for interest"
       }
      }
     },
     "localname": "InterestPaidNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/LongtermDebtCreditAgreementDetails",
      "http://www.evolenthealth.com/role/SupplementalCashFlowInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InternalUseSoftwarePolicy": {
     "auth_ref": [
      "r354",
      "r355"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for costs incurred when both (1) the software is acquired, internally developed, or modified solely to meet the entity's internal needs, and (2) during the software's development or modification, no substantive plan exists or is being developed to market the software externally.",
        "label": "Internal Use Software, Policy [Policy Text Block]",
        "terseLabel": "Software Development Costs"
       }
      }
     },
     "localname": "InternalUseSoftwarePolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IntersegmentEliminationMember": {
     "auth_ref": [
      "r250",
      "r268",
      "r269",
      "r270",
      "r271",
      "r272",
      "r274",
      "r278"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Eliminating entries used in operating segment consolidation.",
        "label": "Intersegment Eliminations [Member]",
        "terseLabel": "Intersegment Eliminations"
       }
      }
     },
     "localname": "IntersegmentEliminationMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/SegmentReportingRevenuefromSegmentstoConsolidatedDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_InvestmentIncomeInterest": {
     "auth_ref": [
      "r121",
      "r251"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.",
        "label": "Investment Income, Interest",
        "terseLabel": "Interest income"
       }
      }
     },
     "localname": "InvestmentIncomeInterest",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS",
      "http://www.evolenthealth.com/role/SegmentReportingReconciliationofAdjustedEBITDADetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures": {
     "auth_ref": [
      "r66"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 10.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in equity method investee and investment in and advance to affiliate.",
        "label": "Investments in and Advance to Affiliates, Subsidiaries, Associates, and Joint Ventures",
        "verboseLabel": "Investments in equity method investees"
       }
      }
     },
     "localname": "InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LeaseAgreementsMember": {
     "auth_ref": [
      "r654"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contractual agreement that stipulates the lessee pay the lessor for use of an asset.",
        "label": "Lease Agreements [Member]",
        "terseLabel": "Lease Agreements"
       }
      }
     },
     "localname": "LeaseAgreementsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LeaseCost": {
     "auth_ref": [
      "r761",
      "r763"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/LeasesComponentsofLeaseExpenseDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lease cost recognized by lessee for lease contract.",
        "label": "Lease, Cost",
        "totalLabel": "Total lease cost"
       }
      }
     },
     "localname": "LeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/LeasesComponentsofLeaseExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LeaseCostTableTextBlock": {
     "auth_ref": [
      "r761"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.",
        "label": "Lease, Cost [Table Text Block]",
        "terseLabel": "Schedule of components of lease expense, weighted-average discount rate and weighted-remaining lease terms"
       }
      }
     },
     "localname": "LeaseCostTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LeaseholdImprovementsMember": {
     "auth_ref": [
      "r360"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additions or improvements to assets held under a lease arrangement.",
        "label": "Leasehold Improvements [Member]",
        "terseLabel": "Leasehold improvements"
       }
      }
     },
     "localname": "LeaseholdImprovementsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/PropertyandEquipmentNetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LeasesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Leases [Abstract]",
        "terseLabel": "Leases [Abstract]"
       }
      }
     },
     "localname": "LeasesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_LegalFees": {
     "auth_ref": [
      "r119"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of expense provided in the period for legal costs incurred on or before the balance sheet date pertaining to resolved, pending or threatened litigation, including arbitration and mediation proceedings.",
        "label": "Legal Fees",
        "terseLabel": "Legal expenses"
       }
      }
     },
     "localname": "LegalFees",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/LongtermDebtCreditAgreementDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeLeaseDescriptionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Lessee, Lease, Description [Line Items]",
        "terseLabel": "Lessee, Lease, Description [Line Items]"
       }
      }
     },
     "localname": "LesseeLeaseDescriptionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/LeasesNarrativeDetails",
      "http://www.evolenthealth.com/role/LeasesPrimaryOfficeLeasesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeLeaseDescriptionTable": {
     "auth_ref": [
      "r753"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about lessee's leases.",
        "label": "Lessee, Lease, Description [Table]",
        "terseLabel": "Lessee, Lease, Description [Table]"
       }
      }
     },
     "localname": "LesseeLeaseDescriptionTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/LeasesNarrativeDetails",
      "http://www.evolenthealth.com/role/LeasesPrimaryOfficeLeasesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeLeasesPolicyTextBlock": {
     "auth_ref": [
      "r751"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee.",
        "label": "Lessee, Leases [Policy Text Block]",
        "terseLabel": "Leases"
       }
      }
     },
     "localname": "LesseeLeasesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "auth_ref": [
      "r762"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.",
        "label": "Lessee, Operating Lease, Liability, Maturity [Table Text Block]",
        "terseLabel": "Schedule of primary office leases and maturity of lease liabilities"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "auth_ref": [
      "r762"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/LeasesMaturityofLeaseLiabilitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.evolenthealth.com/role/LeasesMaturityofLeaseLiabilitiesDetails_1": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.",
        "label": "Lessee, Operating Lease, Liability, to be Paid",
        "terseLabel": "Future Minimum Lease Commitments",
        "totalLabel": "Total lease payments"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/LeasesMaturityofLeaseLiabilitiesDetails",
      "http://www.evolenthealth.com/role/LeasesPrimaryOfficeLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive": {
     "auth_ref": [
      "r762"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/LeasesMaturityofLeaseLiabilitiesDetails_1": {
       "order": 6.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, after Year Five",
        "terseLabel": "Thereafter"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/LeasesMaturityofLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "auth_ref": [
      "r762"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/LeasesMaturityofLeaseLiabilitiesDetails_1": {
       "order": 5.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year One",
        "terseLabel": "2022"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/LeasesMaturityofLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive": {
     "auth_ref": [
      "r762"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/LeasesMaturityofLeaseLiabilitiesDetails_1": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Five",
        "terseLabel": "2026"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFive",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/LeasesMaturityofLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": {
     "auth_ref": [
      "r762"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/LeasesMaturityofLeaseLiabilitiesDetails_1": {
       "order": 4.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four",
        "terseLabel": "2025"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/LeasesMaturityofLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "auth_ref": [
      "r762"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/LeasesMaturityofLeaseLiabilitiesDetails_1": {
       "order": 3.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/LeasesMaturityofLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "auth_ref": [
      "r762"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/LeasesMaturityofLeaseLiabilitiesDetails_1": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/LeasesMaturityofLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "auth_ref": [
      "r762"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/LeasesMaturityofLeaseLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.",
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "terseLabel": "Interest"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/LeasesMaturityofLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseTermOfContract": {
     "auth_ref": [
      "r752"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Lessee, Operating Lease, Term of Contract",
        "terseLabel": "Lease Termination Term (in years)"
       }
      }
     },
     "localname": "LesseeOperatingLeaseTermOfContract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/LeasesPrimaryOfficeLeasesDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_LesseeOperatingLeasesTextBlock": {
     "auth_ref": [
      "r764"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.",
        "label": "Lessee, Operating Leases [Text Block]",
        "terseLabel": "Leases"
       }
      }
     },
     "localname": "LesseeOperatingLeasesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/Leases"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LetterOfCreditMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A document typically issued by a financial institution which acts as a guarantee of payment to a beneficiary, or as the source of payment for a specific transaction (for example, wiring funds to a foreign exporter if and when specified merchandise is accepted pursuant to the terms of the letter of credit).",
        "label": "Letter of Credit [Member]",
        "terseLabel": "Letter of Credit"
       }
      }
     },
     "localname": "LetterOfCreditMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/CommitmentsandContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LettersOfCreditOutstandingAmount": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The total amount of the contingent obligation under letters of credit outstanding as of the reporting date.",
        "label": "Letters of Credit Outstanding, Amount",
        "terseLabel": "Letter of Credit Amount Required",
        "verboseLabel": "Letters of credit outstanding, amount"
       }
      }
     },
     "localname": "LettersOfCreditOutstandingAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/LeasesNarrativeDetails",
      "http://www.evolenthealth.com/role/LeasesPrimaryOfficeLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r74",
      "r167",
      "r271",
      "r304",
      "r393",
      "r394",
      "r395",
      "r398",
      "r399",
      "r400",
      "r402",
      "r404",
      "r406",
      "r407",
      "r677",
      "r684",
      "r685",
      "r722",
      "r776",
      "r777"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities [Abstract]",
        "terseLabel": "Liabilities"
       }
      }
     },
     "localname": "LiabilitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.evolenthealth.com/role/RelatedPartiesAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r60",
      "r167",
      "r304",
      "r722",
      "r778",
      "r824",
      "r852"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities and shareholders' equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "terseLabel": "LIABILITIES AND SHAREHOLDERS\u2019 EQUITY"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r76",
      "r167",
      "r304",
      "r393",
      "r394",
      "r395",
      "r398",
      "r399",
      "r400",
      "r402",
      "r404",
      "r406",
      "r407",
      "r677",
      "r684",
      "r685",
      "r722",
      "r776",
      "r777",
      "r778"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "terseLabel": "Current liabilities:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesFairValueDisclosure": {
     "auth_ref": [
      "r706"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/FairValueMeasurementAssetsandLiabilitiesonRecurringBasisDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of financial and nonfinancial obligations.",
        "label": "Financial and Nonfinancial Liabilities, Fair Value Disclosure",
        "totalLabel": "Total fair value of liabilities measured on a recurring basis"
       }
      }
     },
     "localname": "LiabilitiesFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/FairValueMeasurementAssetsandLiabilitiesonRecurringBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesFairValueDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Fair Value Disclosure [Abstract]",
        "terseLabel": "Liabilities"
       }
      }
     },
     "localname": "LiabilitiesFairValueDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/FairValueMeasurementAssetsandLiabilitiesonRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation": {
     "auth_ref": [
      "r6",
      "r7",
      "r27",
      "r29",
      "r33",
      "r364"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/DiscontinuedOperationsSummaryofCurrentandLongtermAssetsandLiabilitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount classified as liabilities attributable to disposal group held for sale or disposed of.",
        "label": "Disposal Group, Including Discontinued Operation, Liabilities",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/DiscontinuedOperationsSummaryofCurrentandLongtermAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disposal Group, Including Discontinued Operation, Liabilities [Abstract]",
        "terseLabel": "LIABILITIES"
       }
      }
     },
     "localname": "LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/DiscontinuedOperationsSummaryofCurrentandLongtermAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent": {
     "auth_ref": [
      "r6",
      "r7",
      "r27",
      "r29",
      "r33",
      "r358",
      "r364"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 8.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      },
      "http://www.evolenthealth.com/role/DiscontinuedOperationsSummaryofCurrentandLongtermAssetsandLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount classified as liabilities attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer.",
        "label": "Disposal Group, Including Discontinued Operation, Liabilities, Current",
        "terseLabel": "Current liabilities of discontinued operations",
        "totalLabel": "Current liabilities of discontinued operations"
       }
      }
     },
     "localname": "LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.evolenthealth.com/role/DiscontinuedOperationsSummaryofCurrentandLongtermAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disposal Group, Including Discontinued Operation, Liabilities, Current [Abstract]",
        "terseLabel": "Current liabilities:"
       }
      }
     },
     "localname": "LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/DiscontinuedOperationsSummaryofCurrentandLongtermAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent": {
     "auth_ref": [
      "r6",
      "r7",
      "r27",
      "r29",
      "r33",
      "r357",
      "r364"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 6.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount classified as liabilities attributable to disposal group held for sale or disposed of, expected to be disposed of beyond one year or the normal operating cycle, if longer.",
        "label": "Disposal Group, Including Discontinued Operation, Liabilities, Noncurrent",
        "terseLabel": "Non-current liabilities from discontinued operations"
       }
      }
     },
     "localname": "LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense": {
     "auth_ref": [
      "r865",
      "r868"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount needed to reflect the estimated ultimate cost of settling claims relating to insured events that have occurred on or before the balance sheet date, whether or not reported to the insurer at that date.",
        "label": "Liability for Claims and Claims Adjustment Expense",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance"
       }
      }
     },
     "localname": "LiabilityForClaimsAndClaimsAdjustmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/ReservesforClaimsandPerformanceBasedArrangementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilityForFuturePolicyBenefitsAndUnpaidClaimsAndClaimsAdjustmentExpense": {
     "auth_ref": [
      "r846",
      "r865",
      "r868"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate amount of policy reserves (provided for future obligations including unpaid claims and claims adjustment expenses) and policy benefits (liability for future policy benefits) as of the balance sheet date; grouped amount of all the liabilities associated with the company's insurance policies.",
        "label": "Liability for Future Policy Benefits and Unpaid Claims and Claims Adjustment Expense",
        "terseLabel": "Reserve for claims and performance-based arrangements"
       }
      }
     },
     "localname": "LiabilityForFuturePolicyBenefitsAndUnpaidClaimsAndClaimsAdjustmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/RelatedPartiesAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseBusinessAcquisitions": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in the cost of settling unpaid claims after deduction of reinsurance recoveries related to the acquisition of a business. Includes, but is not limited to, claims which have been incurred but not reported.",
        "label": "Liability for Unpaid Claims and Claims Adjustment Expense, Business Acquisitions",
        "negatedTerseLabel": "Impact of consolidation on reserves for claims and performance-based arrangements"
       }
      }
     },
     "localname": "LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseBusinessAcquisitions",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/ReservesforClaimsandPerformanceBasedArrangementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1": {
     "auth_ref": [
      "r867"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/ReservesforClaimsandPerformanceBasedArrangementsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpensePeriodIncreaseDecrease",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after effects of reinsurance, of payments to settle claims incurred in the current period and related claims settlement costs.",
        "label": "Liability for Unpaid Claims and Claims Adjustment Expense, Claims Paid, Current Year",
        "terseLabel": "Paid costs related to current year"
       }
      }
     },
     "localname": "LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/ReservesforClaimsandPerformanceBasedArrangementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1": {
     "auth_ref": [
      "r867"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/ReservesforClaimsandPerformanceBasedArrangementsDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpensePeriodIncreaseDecrease",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after effects of reinsurance, of payments to settle claims incurred in prior periods and related claims settlement costs.",
        "label": "Liability for Unpaid Claims and Claims Adjustment Expense, Claims Paid, Prior Years",
        "terseLabel": "Paid costs related to prior year"
       }
      }
     },
     "localname": "LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/ReservesforClaimsandPerformanceBasedArrangementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseOpeningBalanceAdjustments": {
     "auth_ref": [
      "r869"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of adjustments to the estimated reserve for unpaid claims and claims adjustment expense.",
        "label": "Liability for Unpaid Claims and Claims Adjustment Expense, Adjustments",
        "negatedTerseLabel": "Other adjustments"
       }
      }
     },
     "localname": "LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseOpeningBalanceAdjustments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/ReservesforClaimsandPerformanceBasedArrangementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpensePeriodIncreaseDecrease": {
     "auth_ref": [
      "r869"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/ReservesforClaimsandPerformanceBasedArrangementsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after effects of reinsurance, of increase (decrease) in the liability for unpaid claims and claims adjustment expense.",
        "label": "Liability for Unpaid Claims and Claims Adjustment Expense, Period Increase (Decrease)",
        "totalLabel": "Change during the year"
       }
      }
     },
     "localname": "LiabilityForUnpaidClaimsAndClaimsAdjustmentExpensePeriodIncreaseDecrease",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/ReservesforClaimsandPerformanceBasedArrangementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilityReserveEstimatePolicy": {
     "auth_ref": [
      "r889"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for estimating its liability as of the balance sheet date for the ultimate cost of settling reported and unreported claims incurred and claims adjustment expenses (including effects of inflation and other societal and economic factors).",
        "label": "Liability Reserve Estimate, Policy [Policy Text Block]",
        "terseLabel": "Reserves for Claims and Performance-based Arrangements"
       }
      }
     },
     "localname": "LiabilityReserveEstimatePolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LineOfCreditFacilityCommitmentFeePercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The fee, expressed as a percentage of the line of credit facility, for the line of credit facility regardless of whether the facility has been used.",
        "label": "Line of Credit Facility, Commitment Fee Percentage",
        "terseLabel": "Commitment fee percentage"
       }
      }
     },
     "localname": "LineOfCreditFacilityCommitmentFeePercentage",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/LongtermDebtCreditAgreementDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": {
     "auth_ref": [
      "r72"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.",
        "label": "Line of Credit Facility, Maximum Borrowing Capacity",
        "terseLabel": "Maximum borrowing capacity"
       }
      }
     },
     "localname": "LineOfCreditFacilityMaximumBorrowingCapacity",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/CommitmentsandContingenciesAdditionalInformationDetails",
      "http://www.evolenthealth.com/role/LongtermDebtCreditAgreementDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LineOfCreditMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A contractual arrangement with a lender under which borrowings can be made up to a specific amount at any point in time, and under which borrowings outstanding may be either short-term or long-term, depending upon the particulars.",
        "label": "Line of Credit [Member]",
        "terseLabel": "Line of Credit"
       }
      }
     },
     "localname": "LineOfCreditMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/CommitmentsandContingenciesAdditionalInformationDetails",
      "http://www.evolenthealth.com/role/LongtermDebtCreditAgreementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LongTermAccountsNotesAndLoansReceivableNetNoncurrent": {
     "auth_ref": [
      "r54",
      "r287"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of accounts and financing receivables, classified as noncurrent. Includes, but is not limited to, notes and loan receivable.",
        "label": "Accounts and Financing Receivable, after Allowance for Credit Loss, Noncurrent",
        "terseLabel": "Long-term receivables"
       }
      }
     },
     "localname": "LongTermAccountsNotesAndLoansReceivableNetNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/RevenueRecognitionContractBalancesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebt": {
     "auth_ref": [
      "r48",
      "r424",
      "r439",
      "r443",
      "r444",
      "r822",
      "r847"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.",
        "label": "Long-term Debt",
        "terseLabel": "Long-term debt, net of discount",
        "verboseLabel": "Carrying amount"
       }
      }
     },
     "localname": "LongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/LongtermDebt2024NotesDetails",
      "http://www.evolenthealth.com/role/LongtermDebt2025NotesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtCurrent": {
     "auth_ref": [
      "r73"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt, classified as current. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.",
        "label": "Long-term Debt, Current Maturities",
        "terseLabel": "Short-term debt, net of discount"
       }
      }
     },
     "localname": "LongTermDebtCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtFairValue": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The fair value amount of long-term debt whether such amount is presented as a separate caption or as a parenthetical disclosure. Additionally, this element may be used in connection with the fair value disclosures required in the footnote disclosures to the financial statements. The element may be used in both the balance sheet and disclosure in the same submission.",
        "label": "Long-term Debt, Fair Value",
        "terseLabel": "Fair value"
       }
      }
     },
     "localname": "LongTermDebtFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/LongtermDebtConvertibleSeniorNotesCarryingValueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtNoncurrent": {
     "auth_ref": [
      "r79"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after unamortized (discount) premium and debt issuance costs of long-term debt classified as noncurrent and excluding amounts to be repaid within one year or the normal operating cycle, if longer. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.",
        "label": "Long-term Debt, Excluding Current Maturities",
        "terseLabel": "Long-term debt, net of discount"
       }
      }
     },
     "localname": "LongTermDebtNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongtermDebtTypeAxis": {
     "auth_ref": [
      "r79"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-term debt.",
        "label": "Long-term Debt, Type [Axis]",
        "terseLabel": "Long-term Debt, Type [Axis]"
       }
      }
     },
     "localname": "LongtermDebtTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/CommitmentsandContingenciesAdditionalInformationDetails",
      "http://www.evolenthealth.com/role/LongtermDebt2021NotesDetails",
      "http://www.evolenthealth.com/role/LongtermDebt2024NotesDetails",
      "http://www.evolenthealth.com/role/LongtermDebt2025NotesDetails",
      "http://www.evolenthealth.com/role/LongtermDebtConvertibleSeniorNotesCarryingValueDetails",
      "http://www.evolenthealth.com/role/LongtermDebtCreditAgreementDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LongtermDebtTypeDomain": {
     "auth_ref": [
      "r79",
      "r391"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Long-term Debt, Type [Domain]",
        "terseLabel": "Long-term Debt, Type [Domain]"
       }
      }
     },
     "localname": "LongtermDebtTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/CommitmentsandContingenciesAdditionalInformationDetails",
      "http://www.evolenthealth.com/role/LongtermDebt2021NotesDetails",
      "http://www.evolenthealth.com/role/LongtermDebt2024NotesDetails",
      "http://www.evolenthealth.com/role/LongtermDebt2025NotesDetails",
      "http://www.evolenthealth.com/role/LongtermDebtConvertibleSeniorNotesCarryingValueDetails",
      "http://www.evolenthealth.com/role/LongtermDebtCreditAgreementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MeasurementInputDiscountRateMember": {
     "auth_ref": [
      "r708"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input using interest rate to determine present value of future cash flows.",
        "label": "Measurement Input, Discount Rate [Member]",
        "terseLabel": "Discount rate"
       }
      }
     },
     "localname": "MeasurementInputDiscountRateMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/FairValueMeasurementValuationTechniquesandSignificantUnobservableInputsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MeasurementInputPriceVolatilityMember": {
     "auth_ref": [
      "r708"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input using rate at which price of security will increase (decrease) for given set of returns.",
        "label": "Measurement Input, Price Volatility [Member]",
        "verboseLabel": "Stock price volatility"
       }
      }
     },
     "localname": "MeasurementInputPriceVolatilityMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/FairValueMeasurementValuationTechniquesandSignificantUnobservableInputsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MeasurementInputRiskFreeInterestRateMember": {
     "auth_ref": [
      "r708"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input using interest rate on instrument with zero risk of financial loss.",
        "label": "Measurement Input, Risk Free Interest Rate [Member]",
        "terseLabel": "Annual risk free rate"
       }
      }
     },
     "localname": "MeasurementInputRiskFreeInterestRateMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/FairValueMeasurementValuationTechniquesandSignificantUnobservableInputsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MeasurementInputTypeAxis": {
     "auth_ref": [
      "r708"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of measurement input used to determine value of asset and liability.",
        "label": "Measurement Input Type [Axis]",
        "terseLabel": "Measurement Input Type [Axis]"
       }
      }
     },
     "localname": "MeasurementInputTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/FairValueMeasurementValuationTechniquesandSignificantUnobservableInputsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_MeasurementInputTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input used to determine value of asset and liability.",
        "label": "Measurement Input Type [Domain]",
        "terseLabel": "Measurement Input Type [Domain]"
       }
      }
     },
     "localname": "MeasurementInputTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/FairValueMeasurementValuationTechniquesandSignificantUnobservableInputsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MinorityInterest": {
     "auth_ref": [
      "r87",
      "r167",
      "r304",
      "r393",
      "r398",
      "r399",
      "r400",
      "r406",
      "r407",
      "r722",
      "r823",
      "r851"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which is directly or indirectly attributable to that ownership interest in subsidiary equity which is not attributable to the parent (that is, noncontrolling interest, previously referred to as minority interest).",
        "label": "Stockholders' Equity Attributable to Noncontrolling Interest",
        "periodEndLabel": "Non-controlling interests balance as of end of period",
        "periodStartLabel": "Non-controlling interests balance as of beginning of period"
       }
      }
     },
     "localname": "MinorityInterest",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/NoncontrollingInterestsScheduleofChangesinNoncontrollingInterestsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MinorityInterestDecreaseFromRedemptions": {
     "auth_ref": [
      "r468",
      "r674",
      "r675"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Decrease in noncontrolling interest (for example, but not limited to, redeeming or purchasing the interests of noncontrolling shareholders, issuance of shares (interests) by the non-wholly owned subsidiary to the parent entity for other than cash, and a buyback of shares (interest) by the non-wholly owned subsidiary from the noncontrolling interests).",
        "label": "Noncontrolling Interest, Decrease from Redemptions or Purchase of Interests",
        "negatedLabel": "Redemption of Sponsor\u2019s equity"
       }
      }
     },
     "localname": "MinorityInterestDecreaseFromRedemptions",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/NoncontrollingInterestsScheduleofChangesinNoncontrollingInterestsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MinorityInterestDisclosureTextBlock": {
     "auth_ref": [
      "r693"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for noncontrolling interest in consolidated subsidiaries, which could include the name of the subsidiary, the ownership percentage held by the parent, the ownership percentage held by the noncontrolling owners, the amount of the noncontrolling interest, the location of this amount on the balance sheet (when not reported separately), an explanation of the increase or decrease in the amount of the noncontrolling interest, the noncontrolling interest share of the net Income or Loss of the subsidiary, the location of this amount on the income statement (when not reported separately), the nature of the noncontrolling interest such as background information and terms, the amount of the noncontrolling interest represented by preferred stock, a description of the preferred stock, and the dividend requirements of the preferred stock.",
        "label": "Noncontrolling Interest Disclosure [Text Block]",
        "terseLabel": "Non-controlling Interests"
       }
      }
     },
     "localname": "MinorityInterestDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/NoncontrollingInterests"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_MinorityInterestLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Noncontrolling Interest [Line Items]",
        "terseLabel": "Noncontrolling Interest [Line Items]"
       }
      }
     },
     "localname": "MinorityInterestLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/NoncontrollingInterestsDetails",
      "http://www.evolenthealth.com/role/NoncontrollingInterestsScheduleofChangesinNoncontrollingInterestsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_MinorityInterestOwnershipPercentageByParent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The parent entity's interest in net assets of the subsidiary, expressed as a percentage.",
        "label": "Noncontrolling Interest, Ownership Percentage by Parent",
        "terseLabel": "Parent's ownership percentage"
       }
      }
     },
     "localname": "MinorityInterestOwnershipPercentageByParent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/NoncontrollingInterestsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_MinorityInterestTable": {
     "auth_ref": [
      "r87",
      "r118",
      "r670",
      "r683"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of noncontrolling interest disclosure which includes the name of the subsidiary, the ownership percentage held by the parent, the ownership percentage held by the noncontrolling owners, the amount of the noncontrolling interest, the location of this amount on the balance sheet (when not reported separately), an explanation of the increase or decrease in the amount of the noncontrolling interest, the noncontrolling interest share of the net Income or Loss of the subsidiary, the location of this amount on the income statement (when not reported separately), the nature of the noncontrolling interest such as background information and terms, the amount of the noncontrolling interest represented by preferred stock, a description of the preferred stock, and the dividend requirements of the preferred stock.",
        "label": "Noncontrolling Interest [Table]",
        "terseLabel": "Noncontrolling Interest [Table]"
       }
      }
     },
     "localname": "MinorityInterestTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/NoncontrollingInterestsDetails",
      "http://www.evolenthealth.com/role/NoncontrollingInterestsScheduleofChangesinNoncontrollingInterestsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_MovementInLiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Liability for Unpaid Claims and Claims Adjustment Expense, Period Increase (Decrease) [Abstract]",
        "terseLabel": "Liability for Unpaid Claims and Claims Adjustment Expense, Period Increase (Decrease) [Abstract]"
       }
      }
     },
     "localname": "MovementInLiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetRollForward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/ReservesforClaimsandPerformanceBasedArrangementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_MovementInMinorityInterestRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Stockholders' Equity Attributable to Noncontrolling Interest [Roll Forward]",
        "terseLabel": "Stockholders' Equity Attributable to Noncontrolling Interest [Roll Forward]"
       }
      }
     },
     "localname": "MovementInMinorityInterestRollForward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/NoncontrollingInterestsScheduleofChangesinNoncontrollingInterestsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_MovementInValuationAllowancesAndReservesRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]",
        "terseLabel": "SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]"
       }
      }
     },
     "localname": "MovementInValuationAllowancesAndReservesRollForward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/IncomeTaxesChangesinValuationAllowanceDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r143"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash and restricted cash used in financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]",
        "terseLabel": "Cash Flows Used In Financing Activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r143"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash and restricted cash (used in) provided by investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
        "terseLabel": "Cash Flows Provided by (Used In) Investing Activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r143",
      "r147",
      "r151"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash and restricted cash provided by (used in) operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Cash Flows Provided by (Used In) Operating Activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLossAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r97",
      "r99",
      "r105",
      "r201",
      "r202",
      "r679",
      "r690"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of Net Income (Loss) attributable to noncontrolling interest.",
        "label": "Net Income (Loss) Attributable to Noncontrolling Interest",
        "negatedLabel": "Net loss attributable to non-controlling interests",
        "terseLabel": "Net loss attributable to non-controlling interests"
       }
      }
     },
     "localname": "NetIncomeLossAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS",
      "http://www.evolenthealth.com/role/EarningsLossPerCommonShareComputationofEarningsperShareDetails",
      "http://www.evolenthealth.com/role/NoncontrollingInterestsScheduleofChangesinNoncontrollingInterestsDetails",
      "http://www.evolenthealth.com/role/QuarterlyResultsofOperationsunauditedDetails",
      "http://www.evolenthealth.com/role/SegmentReportingReconciliationofAdjustedEBITDADetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic": {
     "auth_ref": [
      "r195",
      "r196",
      "r197",
      "r198",
      "r206",
      "r207",
      "r216",
      "r219",
      "r258",
      "r269",
      "r272",
      "r275",
      "r278"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.",
        "label": "Net Income (Loss) Available to Common Stockholders, Basic",
        "terseLabel": "Net loss attributable to common shareholders of Evolent Health, Inc.",
        "totalLabel": "Net loss attributable to common shareholders of Evolent Health, Inc. - Basic",
        "verboseLabel": "Net loss attributable to common shareholders of Evolent Health, Inc. - Basic"
       }
      }
     },
     "localname": "NetIncomeLossAvailableToCommonStockholdersBasic",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS",
      "http://www.evolenthealth.com/role/EarningsLossPerCommonShareComputationofEarningsperShareDetails",
      "http://www.evolenthealth.com/role/QuarterlyResultsofOperationsunauditedDetails",
      "http://www.evolenthealth.com/role/SegmentReportingReconciliationofAdjustedEBITDADetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted": {
     "auth_ref": [
      "r208",
      "r211",
      "r212",
      "r213",
      "r214",
      "r216",
      "r219"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities, and addition from assumption of issuance of common shares for dilutive potential common shares; of income (loss) available to common shareholders.",
        "label": "Net Income (Loss) Available to Common Stockholders, Diluted",
        "terseLabel": "Net loss attributable to common shareholders of Evolent Health, Inc.",
        "totalLabel": "Net loss attributable to common shareholders of Evolent Health, Inc. - Diluted",
        "verboseLabel": "Net loss attributable to common shareholders of Evolent Health, Inc. - Diluted"
       }
      }
     },
     "localname": "NetIncomeLossAvailableToCommonStockholdersDiluted",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS",
      "http://www.evolenthealth.com/role/EarningsLossPerCommonShareComputationofEarningsperShareDetails",
      "http://www.evolenthealth.com/role/QuarterlyResultsofOperationsunauditedDetails",
      "http://www.evolenthealth.com/role/SegmentReportingReconciliationofAdjustedEBITDADetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock": {
     "auth_ref": [
      "r5",
      "r187",
      "r188",
      "r191",
      "r192",
      "r203",
      "r204",
      "r205",
      "r295",
      "r296",
      "r310",
      "r311",
      "r507",
      "r508",
      "r509",
      "r510",
      "r583",
      "r626",
      "r627",
      "r628",
      "r701",
      "r729",
      "r730",
      "r731",
      "r766",
      "r799",
      "r800",
      "r801",
      "r883",
      "r884",
      "r885",
      "r886",
      "r888",
      "r937"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for change in accounting principle. Includes, but is not limited to, nature, reason, and method of adopting amendment to accounting standards or other change in accounting principle.",
        "label": "Accounting Standards Update and Change in Accounting Principle [Text Block]",
        "terseLabel": "Recently Issued Accounting Standards"
       }
      }
     },
     "localname": "NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/RecentlyIssuedAccountingStandards"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "New Accounting Pronouncements or Change in Accounting Principle [Line Items]",
        "terseLabel": "New Accounting Pronouncements or Change in Accounting Principle [Line Items]"
       }
      }
     },
     "localname": "NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/RecentlyIssuedAccountingStandardsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable": {
     "auth_ref": [
      "r0",
      "r1",
      "r2",
      "r3",
      "r4",
      "r186",
      "r189",
      "r190",
      "r191",
      "r193",
      "r194",
      "r197",
      "r203",
      "r223",
      "r293",
      "r294",
      "r306",
      "r307",
      "r308",
      "r309",
      "r312",
      "r313",
      "r392",
      "r576",
      "r577",
      "r578",
      "r579",
      "r580",
      "r581",
      "r582",
      "r584",
      "r622",
      "r623",
      "r624",
      "r625",
      "r694",
      "r695",
      "r696",
      "r697",
      "r698",
      "r699",
      "r700",
      "r702",
      "r703",
      "r704",
      "r705",
      "r723",
      "r724",
      "r725",
      "r726",
      "r727",
      "r728",
      "r732",
      "r733",
      "r765",
      "r796",
      "r797",
      "r798",
      "r877",
      "r878",
      "r879",
      "r880",
      "r881",
      "r882",
      "r883",
      "r884",
      "r885",
      "r886",
      "r887",
      "r888",
      "r932",
      "r933",
      "r934",
      "r935",
      "r936"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Summarization of the changes in an accounting principle or a new accounting pronouncement, including the line items affected by the change and the financial effects of the change on those particular line items.",
        "label": "Accounting Standards Update and Change in Accounting Principle [Table]",
        "terseLabel": "New Accounting Pronouncements or Change in Accounting Principle [Table]"
       }
      }
     },
     "localname": "NewAccountingPronouncementsOrChangeInAccountingPrincipleTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/RecentlyIssuedAccountingStandardsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "terseLabel": "Adoption of New Accounting Standards and Recent Accounting Pronouncements Not Yet Effective"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1": {
     "auth_ref": [
      "r157",
      "r158",
      "r159"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net book value of a nonmonetary asset transferred or exchanged in connection with the acquisition of a business or asset in a noncash transaction. Noncash is defined as transactions during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period. Nonmonetary assets and liabilities are assets and liabilities that will not result in cash receipts or cash payments in the future.",
        "label": "Noncash or Part Noncash Acquisition, Net Nonmonetary Assets Acquired (Liabilities Assumed)",
        "terseLabel": "Consideration for asset acquisition or business combinations"
       }
      }
     },
     "localname": "NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/SupplementalCashFlowInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NoncashOrPartNoncashAcquisitionPayablesAssumed1": {
     "auth_ref": [
      "r157",
      "r158",
      "r159"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of payables that an Entity assumes in acquiring a business or in consideration for an asset received in a noncash (or part noncash) acquisition. Noncash is defined as transactions during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.",
        "label": "Noncash or Part Noncash Acquisition, Payables Assumed",
        "terseLabel": "Class A common stock issued for payment of earn-outs"
       }
      }
     },
     "localname": "NoncashOrPartNoncashAcquisitionPayablesAssumed1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/SupplementalCashFlowInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NoncontrollingInterestAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Noncontrolling Interest [Abstract]",
        "terseLabel": "Noncontrolling Interest [Abstract]"
       }
      }
     },
     "localname": "NoncontrollingInterestAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_NoncontrollingInterestDecreaseFromDeconsolidation": {
     "auth_ref": [
      "r469",
      "r681"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of the reduction or elimination during the period of a noncontrolling interest resulting from the parent's loss of control and deconsolidation of the entity in which one or more outside parties had a noncontrolling interest.",
        "label": "Noncontrolling Interest, Decrease from Deconsolidation",
        "negatedTerseLabel": "Disposal of assets"
       }
      }
     },
     "localname": "NoncontrollingInterestDecreaseFromDeconsolidation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NoncontrollingInterestIncreaseFromBusinessCombination": {
     "auth_ref": [
      "r469",
      "r649",
      "r681"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in noncontrolling interest from a business combination.",
        "label": "Noncontrolling Interest, Increase from Business Combination",
        "terseLabel": "Consolidation of equity method investment"
       }
      }
     },
     "localname": "NoncontrollingInterestIncreaseFromBusinessCombination",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/NoncontrollingInterestsDetails",
      "http://www.evolenthealth.com/role/NoncontrollingInterestsScheduleofChangesinNoncontrollingInterestsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance": {
     "auth_ref": [
      "r469",
      "r674",
      "r681"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in noncontrolling interest from subsidiary issuance of equity interests to noncontrolling interest holders.",
        "label": "Noncontrolling Interest, Increase from Subsidiary Equity Issuance",
        "terseLabel": "Redemption of Sponsor\u2019s equity"
       }
      }
     },
     "localname": "NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NoncontrollingInterestMember": {
     "auth_ref": [
      "r183",
      "r184",
      "r185",
      "r468",
      "r669"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This element represents that portion of equity (net assets) in a subsidiary not attributable, directly or indirectly, to the parent. A noncontrolling interest is sometimes called a minority interest.",
        "label": "Noncontrolling Interest [Member]",
        "terseLabel": "Non-Controlling Interests"
       }
      }
     },
     "localname": "NoncontrollingInterestMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY",
      "http://www.evolenthealth.com/role/NoncontrollingInterestsScheduleofChangesinNoncontrollingInterestsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NotesReceivableMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "An amount representing an agreement for an unconditional promise by the maker to pay the Entity (holder) a definite sum of money at a future date(s) within one year of the balance sheet date. Such amount may include accrued interest receivable in accordance with the terms of the note. The note also may contain provisions including a discount or premium, payable on demand, secured, or unsecured, interest bearing or noninterest bearing, among myriad other features and characteristics.",
        "label": "Notes Receivable [Member]",
        "terseLabel": "Notes Receivable"
       }
      }
     },
     "localname": "NotesReceivableMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/TransactionsEquityInvestmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NotesReceivableNet": {
     "auth_ref": [
      "r54",
      "r287",
      "r322"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of financing receivable. Excludes financing receivable covered under loss sharing agreement.",
        "label": "Financing Receivable, after Allowance for Credit Loss",
        "terseLabel": "Notes receivable, net"
       }
      }
     },
     "localname": "NotesReceivableNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/TransactionsEquityInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NumberOfOperatingSegments": {
     "auth_ref": [
      "r246"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.",
        "label": "Number of Operating Segments",
        "terseLabel": "Number of operating segments"
       }
      }
     },
     "localname": "NumberOfOperatingSegments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesOperatingSegmentsDetails",
      "http://www.evolenthealth.com/role/SegmentReportingAdditionalInformationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_NumberOfReportingUnits": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of reporting units tested for impairment of goodwill. A reporting unit is an operating segment or one level below an operating segment.",
        "label": "Number of Reporting Units",
        "terseLabel": "Number of reporting units for goodwill testing"
       }
      }
     },
     "localname": "NumberOfReportingUnits",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesGoodwillDetails",
      "http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNetImpairmentTestingDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_OperatingExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.",
        "label": "Operating Expenses",
        "terseLabel": "Total operating expenses",
        "totalLabel": "Total operating expenses"
       }
      }
     },
     "localname": "OperatingExpenses",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS",
      "http://www.evolenthealth.com/role/QuarterlyResultsofOperationsunauditedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Expenses [Abstract]",
        "terseLabel": "Expenses"
       }
      }
     },
     "localname": "OperatingExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS",
      "http://www.evolenthealth.com/role/DiscontinuedOperationsSummaryofResultsofOperationsDetails",
      "http://www.evolenthealth.com/role/RelatedPartiesRevenuesandExpensesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r258",
      "r269",
      "r272",
      "r275",
      "r278"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS": {
       "order": 3.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "totalLabel": "Operating loss"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseCost": {
     "auth_ref": [
      "r755",
      "r763"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/LeasesComponentsofLeaseExpenseDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.",
        "label": "Operating Lease, Cost",
        "terseLabel": "Operating lease cost"
       }
      }
     },
     "localname": "OperatingLeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/LeasesComponentsofLeaseExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilitiesGrossDifferenceAmountAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease Liabilities, Gross Difference, Amount [Abstract]",
        "terseLabel": "Less:"
       }
      }
     },
     "localname": "OperatingLeaseLiabilitiesGrossDifferenceAmountAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/LeasesMaturityofLeaseLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingLeaseLiability": {
     "auth_ref": [
      "r748"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/LeasesMaturityofLeaseLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.",
        "label": "Operating Lease, Liability",
        "terseLabel": "Present value of lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/LeasesMaturityofLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "auth_ref": [
      "r748"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 7.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.",
        "label": "Operating Lease, Liability, Current",
        "terseLabel": "Operating lease liability - current"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r748"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.",
        "label": "Operating Lease, Liability, Noncurrent",
        "terseLabel": "Operating lease liabilities - noncurrent"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasePayments": {
     "auth_ref": [
      "r750",
      "r757"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.",
        "label": "Operating Lease, Payments",
        "terseLabel": "Operating cash flows from operating leases"
       }
      }
     },
     "localname": "OperatingLeasePayments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/SupplementalCashFlowInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r747"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Operating Lease, Right-of-Use Asset",
        "terseLabel": "Right-of-use assets - operating"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "auth_ref": [
      "r760",
      "r763"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average discount rate for operating lease calculated at point in time.",
        "label": "Operating Lease, Weighted Average Discount Rate, Percent",
        "terseLabel": "Weighted average discount rate"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/LeasesWeightedaverageDiscountRateandWeightedremainingLeaseTermsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "auth_ref": [
      "r759",
      "r763"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Operating Lease, Weighted Average Remaining Lease Term",
        "terseLabel": "Weighted average remaining lease term"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/LeasesWeightedaverageDiscountRateandWeightedremainingLeaseTermsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_OperatingLossCarryforwards": {
     "auth_ref": [
      "r613"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.",
        "label": "Operating Loss Carryforwards",
        "terseLabel": "Net operating loss carryforwards"
       }
      }
     },
     "localname": "OperatingLossCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLossCarryforwardsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Operating Loss Carryforwards [Line Items]",
        "terseLabel": "Operating Loss Carryforwards [Line Items]"
       }
      }
     },
     "localname": "OperatingLossCarryforwardsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/IncomeTaxesChangesinValuationAllowanceDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingLossCarryforwardsTable": {
     "auth_ref": [
      "r614"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting pertinent information, such as tax authority, amounts, and expiration dates, of net operating loss carryforwards, including an assessment of the likelihood of utilization.",
        "label": "Operating Loss Carryforwards [Table]",
        "terseLabel": "Operating Loss Carryforwards [Table]"
       }
      }
     },
     "localname": "OperatingLossCarryforwardsTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/IncomeTaxesChangesinValuationAllowanceDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingSegmentsMember": {
     "auth_ref": [
      "r268",
      "r269",
      "r270",
      "r271",
      "r272",
      "r278"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identifies components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity.",
        "label": "Operating Segments [Member]",
        "terseLabel": "Operating Segments"
       }
      }
     },
     "localname": "OperatingSegmentsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/SegmentReportingRevenuefromSegmentstoConsolidatedDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]",
        "terseLabel": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": {
     "auth_ref": [
      "r36",
      "r693"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.",
        "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]",
        "terseLabel": "Organization"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/Organization"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OtherCommitmentsAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of other commitment.",
        "label": "Other Commitments [Axis]",
        "terseLabel": "Other Commitments [Axis]"
       }
      }
     },
     "localname": "OtherCommitmentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherCommitmentsDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other future obligation.",
        "label": "Other Commitments [Domain]",
        "terseLabel": "Other Commitments [Domain]"
       }
      }
     },
     "localname": "OtherCommitmentsDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax": {
     "auth_ref": [
      "r92"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS": {
       "order": 1.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.",
        "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax",
        "terseLabel": "Foreign currency translation adjustment",
        "verboseLabel": "Foreign currency translation adjustment"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY",
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Comprehensive Income (Loss), Net of Tax [Abstract]",
        "terseLabel": "Other comprehensive loss, net of taxes, related to:"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherLiabilitiesFairValueDisclosure": {
     "auth_ref": [],
     "calculation": {
      "http://www.evolenthealth.com/role/FairValueMeasurementAssetsandLiabilitiesonRecurringBasisDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesFairValueDisclosure",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of other liabilities.",
        "label": "Other Liabilities, Fair Value Disclosure",
        "terseLabel": "Warrants",
        "verboseLabel": "Fair Value"
       }
      }
     },
     "localname": "OtherLiabilitiesFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/FairValueMeasurementAssetsandLiabilitiesonRecurringBasisDetails",
      "http://www.evolenthealth.com/role/FairValueMeasurementValuationTechniquesandSignificantUnobservableInputsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherLiabilitiesNoncurrent": {
     "auth_ref": [
      "r80"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 5.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities, Noncurrent",
        "terseLabel": "Other long-term liabilities"
       }
      }
     },
     "localname": "OtherLiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNoncashIncomeExpense": {
     "auth_ref": [
      "r151"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other.",
        "label": "Other Noncash Income (Expense)",
        "negatedTerseLabel": "Other current operating cash inflows (outflows), net"
       }
      }
     },
     "localname": "OtherNoncashIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "auth_ref": [
      "r123"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.",
        "label": "Other Nonoperating Income (Expense)",
        "terseLabel": "Other income (expense), net"
       }
      }
     },
     "localname": "OtherNonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/SegmentReportingReconciliationofAdjustedEBITDADetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherOperatingIncomeExpenseNet": {
     "auth_ref": [],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS": {
       "order": 5.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net amount of other operating income and expenses, the components of which are not separately disclosed on the income statement, from items that are associated with the entity's normal revenue producing operations.",
        "label": "Other Operating Income (Expense), Net",
        "terseLabel": "Other expense, net"
       }
      }
     },
     "localname": "OtherOperatingIncomeExpenseNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ParentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Portion of equity, or net assets, in the consolidated entity attributable, directly or indirectly, to the parent. Excludes noncontrolling interests.",
        "label": "Parent [Member]",
        "terseLabel": "Parent"
       }
      }
     },
     "localname": "ParentMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PaymentsForProceedsFromLoansReceivable": {
     "auth_ref": [
      "r153",
      "r154"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net amount paid or received by the reporting entity associated with purchase (sale or collection) of loans receivable arising from the financing of goods and services.",
        "label": "Payments for (Proceeds from) Loans Receivable",
        "negatedLabel": "Loan for implementation funding"
       }
      }
     },
     "localname": "PaymentsForProceedsFromLoansReceivable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsForProceedsFromOtherInvestingActivities": {
     "auth_ref": [
      "r126",
      "r130"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash (inflow) outflow from investing activities classified as other.",
        "label": "Payments for (Proceeds from) Other Investing Activities",
        "negatedTerseLabel": "Other investing activities"
       }
      }
     },
     "localname": "PaymentsForProceedsFromOtherInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsForReinsurance": {
     "auth_ref": [
      "r146"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash payments made for reinsurance during the current period.",
        "label": "Payments for Reinsurance",
        "terseLabel": "Reinsurance payments paid (received)"
       }
      }
     },
     "localname": "PaymentsForReinsurance",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/CommitmentsandContingenciesReinsuranceAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsForRepurchaseOfWarrants": {
     "auth_ref": [
      "r134"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate amount paid by the entity to reacquire the right to purchase equity shares at a predetermined price, usually issued together with corporate debt.",
        "label": "Payments for Repurchase of Warrants",
        "terseLabel": "Payments to settle outstanding warrants"
       }
      }
     },
     "localname": "PaymentsForRepurchaseOfWarrants",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/LongtermDebtWarrantAgreementDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsOfDebtExtinguishmentCosts": {
     "auth_ref": [
      "r137"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow for cost from early extinguishment and prepayment of debt. Includes, but is not limited to, third-party cost, premium paid, and other fee paid to lender directly for debt extinguishment or debt prepayment. Excludes accrued interest.",
        "label": "Payment for Debt Extinguishment or Debt Prepayment Cost",
        "negatedTerseLabel": "Repayment and termination of Credit Agreement including settlement of warrants"
       }
      }
     },
     "localname": "PaymentsOfDebtExtinguishmentCosts",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsOfDebtIssuanceCosts": {
     "auth_ref": [
      "r136"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt.",
        "label": "Payments of Debt Issuance Costs",
        "terseLabel": "Payments of debt issuance costs"
       }
      }
     },
     "localname": "PaymentsOfDebtIssuanceCosts",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/LongtermDebt2021NotesDetails",
      "http://www.evolenthealth.com/role/LongtermDebt2024NotesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation": {
     "auth_ref": [
      "r134"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement.",
        "label": "Payment, Tax Withholding, Share-based Payment Arrangement",
        "negatedTerseLabel": "Taxes withheld and paid for vesting of restricted stock units"
       }
      }
     },
     "localname": "PaymentsRelatedToTaxWithholdingForShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireBusinessesGross": {
     "auth_ref": [
      "r128",
      "r661"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price.",
        "label": "Payments to Acquire Businesses, Gross",
        "negatedTerseLabel": "Cash paid for asset acquisitions and business combinations",
        "terseLabel": "Cash"
       }
      }
     },
     "localname": "PaymentsToAcquireBusinessesGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.evolenthealth.com/role/TransactionsVitalDecisionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireEquityMethodInvestments": {
     "auth_ref": [
      "r128"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the purchase of or advances to an equity method investments, which are investments in joint ventures and entities in which the entity has an equity ownership interest normally of 20 to 50 percent and exercises significant influence.",
        "label": "Payments to Acquire Equity Method Investments",
        "terseLabel": "Payments to acquire interest"
       }
      }
     },
     "localname": "PaymentsToAcquireEquityMethodInvestments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/TransactionsEquityInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireHeldToMaturitySecurities": {
     "auth_ref": [
      "r127",
      "r297"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 12.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow through purchase of long-term held-to-maturity securities.",
        "label": "Payments to Acquire Held-to-maturity Securities",
        "negatedLabel": "Purchases of investments"
       }
      }
     },
     "localname": "PaymentsToAcquireHeldToMaturitySecurities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireInterestInSubsidiariesAndAffiliates": {
     "auth_ref": [
      "r128"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of or advances to an entity that is related to it but not strictly controlled (for example, an unconsolidated subsidiary, affiliate, and joint venture or equity method investment) or the acquisition of an additional interest in a subsidiary (controlled entity).",
        "label": "Payments to Acquire Interest in Subsidiaries and Affiliates",
        "negatedTerseLabel": "Investments in equity method investees"
       }
      }
     },
     "localname": "PaymentsToAcquireInterestInSubsidiariesAndAffiliates",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireOtherProductiveAssets": {
     "auth_ref": [
      "r129"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow for the purchase of or improvements to tangible or intangible assets, used to produce goods or deliver services, classified as other.",
        "label": "Payments to Acquire Other Productive Assets",
        "negatedTerseLabel": "Investments in internal-use software and purchases of property and equipment"
       }
      }
     },
     "localname": "PaymentsToAcquireOtherProductiveAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToMinorityShareholders": {
     "auth_ref": [
      "r138"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow to a noncontrolling interest. Includes, but not limited to, reduction of noncontrolling interest ownership. Excludes dividends paid to the noncontrolling interest.",
        "label": "Payments to Noncontrolling Interests",
        "negatedTerseLabel": "Distributions to Sponsors",
        "terseLabel": "Payments to redeem Sponsors' equity"
       }
      }
     },
     "localname": "PaymentsToMinorityShareholders",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.evolenthealth.com/role/TransactionsEquityInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock": {
     "auth_ref": [
      "r512",
      "r514",
      "r520",
      "r521",
      "r523",
      "r524",
      "r525",
      "r526",
      "r527",
      "r528",
      "r529",
      "r530",
      "r531",
      "r536"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for retirement benefits.",
        "label": "Retirement Benefits [Text Block]",
        "terseLabel": "Employee Benefit Plans"
       }
      }
     },
     "localname": "PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/EmployeeBenefitPlans"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PerformanceSharesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement awarded for meeting performance target.",
        "label": "Performance Shares [Member]",
        "terseLabel": "Performance-based stock options"
       }
      }
     },
     "localname": "PerformanceSharesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/StockbasedCompensationPerformancebasedStockOptionAwardsDetails",
      "http://www.evolenthealth.com/role/StockbasedCompensationStockbasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PlanNameAxis": {
     "auth_ref": [
      "r540",
      "r574"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by plan name for share-based payment arrangement.",
        "label": "Plan Name [Axis]",
        "terseLabel": "Plan Name [Axis]"
       }
      }
     },
     "localname": "PlanNameAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/StockbasedCompensation2011and2015EquityIncentivePlansDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PlanNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plan name for share-based payment arrangement.",
        "label": "Plan Name [Domain]",
        "terseLabel": "Plan Name [Domain]"
       }
      }
     },
     "localname": "PlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/StockbasedCompensation2011and2015EquityIncentivePlansDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "auth_ref": [
      "r39",
      "r63",
      "r64"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.",
        "label": "Prepaid Expense and Other Assets, Current",
        "netLabel": "Prepaid expenses and other current assets",
        "terseLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.evolenthealth.com/role/RelatedPartiesAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent": {
     "auth_ref": [
      "r45",
      "r818",
      "r844"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 8.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed after one year or the normal operating cycle, if longer.",
        "label": "Prepaid Expense and Other Assets, Noncurrent",
        "verboseLabel": "Prepaid expenses and other noncurrent assets"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.evolenthealth.com/role/RelatedPartiesAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromCollectionOfNotesReceivable": {
     "auth_ref": [
      "r124"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with principal collections from a borrowing supported by a written promise to pay an obligation.",
        "label": "Proceeds from Collection of Notes Receivable",
        "terseLabel": "Proceeds from collection of notes receivable"
       }
      }
     },
     "localname": "ProceedsFromCollectionOfNotesReceivable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/TransactionsEquityInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromConvertibleDebt": {
     "auth_ref": [
      "r132"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the issuance of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.",
        "label": "Proceeds from Convertible Debt",
        "terseLabel": "Proceeds from issuance of long term debt, net of offering costs"
       }
      }
     },
     "localname": "ProceedsFromConvertibleDebt",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromDivestitureOfInterestInSubsidiariesAndAffiliates": {
     "auth_ref": [
      "r125"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the deconsolidation of a previously consolidated subsidiary or sale of an entity that is related to it but not strictly controlled.",
        "label": "Proceeds from Divestiture of Interest in Subsidiaries and Affiliates",
        "terseLabel": "Proceeds from transfer of membership and release of Passport escrow"
       }
      }
     },
     "localname": "ProceedsFromDivestitureOfInterestInSubsidiariesAndAffiliates",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital": {
     "auth_ref": [
      "r125",
      "r142"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of distribution received from equity method investee for return of investment, classified as investing activities. Excludes distribution for return on investment, classified as operating activities.",
        "label": "Proceeds from Equity Method Investment, Distribution, Return of Capital",
        "terseLabel": "Return of equity method investments"
       }
      }
     },
     "localname": "ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromHedgeFinancingActivities": {
     "auth_ref": [
      "r133",
      "r148"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from a financial contract that meets the hedge criteria as either cash flow hedge, fair value hedge or hedge of net investment in foreign operations.",
        "label": "Proceeds from Hedge, Financing Activities",
        "terseLabel": "Issuance of warrant liability"
       }
      }
     },
     "localname": "ProceedsFromHedgeFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromInterestReceived": {
     "auth_ref": [
      "r139"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Interest received on loans and other debt instruments during the current period.",
        "label": "Proceeds from Interest Received",
        "terseLabel": "Proceeds from interest received"
       }
      }
     },
     "localname": "ProceedsFromInterestReceived",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/TransactionsEquityInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfDebt": {
     "auth_ref": [
      "r132"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow during the period from additional borrowings in aggregate debt. Includes proceeds from short-term and long-term debt.",
        "label": "Proceeds from Issuance of Debt",
        "terseLabel": "Proceeds from issuance of debt"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfDebt",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/LongtermDebt2021NotesDetails",
      "http://www.evolenthealth.com/role/LongtermDebt2024NotesDetails",
      "http://www.evolenthealth.com/role/LongtermDebt2025NotesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromStockOptionsExercised": {
     "auth_ref": [
      "r131",
      "r575"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement.",
        "label": "Proceeds from Stock Options Exercised",
        "terseLabel": "Proceeds from stock option exercises"
       }
      }
     },
     "localname": "ProceedsFromStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProfitLoss": {
     "auth_ref": [
      "r33",
      "r97",
      "r99",
      "r105",
      "r141",
      "r167",
      "r189",
      "r201",
      "r202",
      "r258",
      "r269",
      "r272",
      "r275",
      "r278",
      "r304",
      "r393",
      "r394",
      "r395",
      "r398",
      "r399",
      "r400",
      "r402",
      "r404",
      "r406",
      "r407",
      "r671",
      "r678",
      "r680",
      "r690",
      "r691",
      "r705",
      "r722",
      "r836"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.",
        "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest",
        "terseLabel": "Net loss",
        "totalLabel": "Net loss",
        "verboseLabel": "Net income (loss)"
       }
      }
     },
     "localname": "ProfitLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY",
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS",
      "http://www.evolenthealth.com/role/EarningsLossPerCommonShareComputationofEarningsperShareDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Abstract]",
        "terseLabel": "Property, Plant and Equipment [Abstract]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "auth_ref": [
      "r69",
      "r362"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.",
        "label": "Long-Lived Tangible Asset [Axis]",
        "terseLabel": "Property, Plant and Equipment, Type [Axis]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesEstimatedUsefulLifeofPropertyPlantandEquipmentDetails",
      "http://www.evolenthealth.com/role/PropertyandEquipmentNetDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": {
     "auth_ref": [
      "r368",
      "r903",
      "r904",
      "r905"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.",
        "label": "Property, Plant and Equipment Disclosure [Text Block]",
        "terseLabel": "Property and Equipment, Net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/PropertyandEquipmentNet"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "auth_ref": [
      "r68",
      "r360"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/PropertyandEquipmentNetDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Gross",
        "terseLabel": "Total property and equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/PropertyandEquipmentNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Property, Plant and Equipment [Line Items]",
        "terseLabel": "Property and Equipment [Line Items]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesEstimatedUsefulLifeofPropertyPlantandEquipmentDetails",
      "http://www.evolenthealth.com/role/PropertyandEquipmentNetDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r43",
      "r44",
      "r362",
      "r778",
      "r837",
      "r853"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 5.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      },
      "http://www.evolenthealth.com/role/PropertyandEquipmentNetDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Net",
        "terseLabel": "Property and equipment, net",
        "totalLabel": "Total property and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.evolenthealth.com/role/PropertyandEquipmentNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "auth_ref": [
      "r67",
      "r362",
      "r903",
      "r904"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.",
        "label": "Property, Plant and Equipment, Policy [Policy Text Block]",
        "terseLabel": "Property and Equipment, Net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "auth_ref": [
      "r43",
      "r362"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table Text Block]",
        "verboseLabel": "Summary of property and equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesTables",
      "http://www.evolenthealth.com/role/PropertyandEquipmentNetTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "auth_ref": [
      "r43",
      "r360"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.",
        "label": "Long-Lived Tangible Asset [Domain]",
        "terseLabel": "Property, Plant and Equipment, Type [Domain]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesEstimatedUsefulLifeofPropertyPlantandEquipmentDetails",
      "http://www.evolenthealth.com/role/PropertyandEquipmentNetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentUsefulLife": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.",
        "label": "Property, Plant and Equipment, Useful Life",
        "terseLabel": "Useful life"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesEstimatedUsefulLifeofPropertyPlantandEquipmentDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ProvisionForDoubtfulAccounts": {
     "auth_ref": [
      "r116",
      "r316"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense (reversal of expense) for expected credit loss on accounts receivable.",
        "label": "Accounts Receivable, Credit Loss Expense (Reversal)",
        "negatedTerseLabel": "Provision for credit losses"
       }
      }
     },
     "localname": "ProvisionForDoubtfulAccounts",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/CreditLossesScheduleofChangesinAllowanceforAccountsReceivableDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_QuarterlyFinancialDataAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Quarterly Financial Data [Abstract]",
        "terseLabel": "Quarterly Financial Data [Abstract]"
       }
      }
     },
     "localname": "QuarterlyFinancialDataAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_QuarterlyFinancialInformationTextBlock": {
     "auth_ref": [
      "r227",
      "r228"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for quarterly financial data. Includes, but is not limited to, tabular presentation of financial information for fiscal quarters, effect of year-end adjustments, and an explanation of matters or transactions that affect comparability of the information.",
        "label": "Quarterly Financial Information [Text Block]",
        "terseLabel": "Quarterly Results of Operations (unaudited)"
       }
      }
     },
     "localname": "QuarterlyFinancialInformationTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/QuarterlyResultsofOperationsunaudited"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ReceivableTypeDomain": {
     "auth_ref": [
      "r86"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Financing arrangement representing a contractual right to receive money either on demand or on fixed and determinable dates.",
        "label": "Receivable [Domain]",
        "terseLabel": "Receivable [Domain]"
       }
      }
     },
     "localname": "ReceivableTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/CommitmentsandContingenciesConcentrationRiskDetails",
      "http://www.evolenthealth.com/role/TransactionsEquityInvestmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy": {
     "auth_ref": [
      "r62",
      "r291"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for determining the allowance for doubtful accounts for trade and other accounts receivable balances, and when impairments, charge-offs or recoveries are recognized.",
        "label": "Receivables, Trade and Other Accounts Receivable, Allowance for Doubtful Accounts, Policy [Policy Text Block]",
        "terseLabel": "Accounts Receivable and Allowances"
       }
      }
     },
     "localname": "ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock": {
     "auth_ref": [
      "r269",
      "r272"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the reconciliation of profit (loss) from reportable segments to the consolidated income (loss) before income tax expense (benefit) and discontinued operations. Includes, but is not limited to, reconciliation after income tax if income tax is allocated to the reportable segment.",
        "label": "Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table Text Block]",
        "terseLabel": "Reconciliation of Adjusted EBITDA to net loss"
       }
      }
     },
     "localname": "ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/SegmentReportingTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable": {
     "auth_ref": [
      "r268",
      "r272"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identification, description, and amounts of all significant reconciling items in the reconciliation of total revenues from reportable segments to the entity's consolidated revenues.",
        "label": "Reconciliation of Revenue from Segments to Consolidated [Table]",
        "terseLabel": "Reconciliation of Revenue from Segments to Consolidated [Table]"
       }
      }
     },
     "localname": "ReconciliationOfRevenueFromSegmentsToConsolidatedTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/SegmentReportingRevenuefromSegmentstoConsolidatedDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTextBlock": {
     "auth_ref": [
      "r268",
      "r272"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of all significant reconciling items in the reconciliation of total revenues from reportable segments to the entity's consolidated revenues.",
        "label": "Reconciliation of Revenue from Segments to Consolidated [Table Text Block]",
        "terseLabel": "Reconciliation of revenue from segments to consolidated"
       }
      }
     },
     "localname": "ReconciliationOfRevenueFromSegmentsToConsolidatedTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/SegmentReportingTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]",
        "terseLabel": "Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]"
       }
      }
     },
     "localname": "ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/IncomeTaxesChangesInUnrecognizedTaxBenefitsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ReinsuranceEffectOnClaimsAndBenefitsIncurredAmountAssumed": {
     "auth_ref": [
      "r840"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of policy benefits and costs incurred for policies assumed.",
        "label": "Policyholder Benefits and Claims Incurred, Assumed",
        "terseLabel": "Claims assumed"
       }
      }
     },
     "localname": "ReinsuranceEffectOnClaimsAndBenefitsIncurredAmountAssumed",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/CommitmentsandContingenciesReinsuranceAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ReinsuranceEffectOnClaimsAndBenefitsIncurredAmountCeded": {
     "auth_ref": [
      "r840"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of reduction of provision for policy benefits and costs incurred for policies ceded.",
        "label": "Policyholder Benefits and Claims Incurred, Ceded",
        "negatedTerseLabel": "Claims ceded"
       }
      }
     },
     "localname": "ReinsuranceEffectOnClaimsAndBenefitsIncurredAmountCeded",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/CommitmentsandContingenciesReinsuranceAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RelatedPartyDomain": {
     "auth_ref": [
      "r522",
      "r769",
      "r770"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.",
        "label": "Related Party [Domain]",
        "terseLabel": "Related Party [Domain]"
       }
      }
     },
     "localname": "RelatedPartyDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/InvestmentsinEquityMethodInvesteesDetails",
      "http://www.evolenthealth.com/role/RelatedPartiesAssetsandLiabilitiesDetails",
      "http://www.evolenthealth.com/role/RelatedPartiesRevenuesandExpensesDetails",
      "http://www.evolenthealth.com/role/StockbasedCompensationRestrictedStockUnitsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RelatedPartyTransactionAxis": {
     "auth_ref": [
      "r522",
      "r769",
      "r770",
      "r772"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of related party transaction.",
        "label": "Related Party Transaction [Axis]",
        "terseLabel": "Related Party Transaction [Axis]"
       }
      }
     },
     "localname": "RelatedPartyTransactionAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/InvestmentsinEquityMethodInvesteesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionDomain": {
     "auth_ref": [
      "r522"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Transaction between related party.",
        "label": "Related Party Transaction [Domain]",
        "terseLabel": "Related Party Transaction [Domain]"
       }
      }
     },
     "localname": "RelatedPartyTransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/InvestmentsinEquityMethodInvesteesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RelatedPartyTransactionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Related Party Transaction [Line Items]",
        "terseLabel": "Related Party Transaction [Line Items]"
       }
      }
     },
     "localname": "RelatedPartyTransactionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/RelatedPartiesAssetsandLiabilitiesDetails",
      "http://www.evolenthealth.com/role/RelatedPartiesRevenuesandExpensesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transactions [Abstract]",
        "terseLabel": "Related Party Transactions [Abstract]"
       }
      }
     },
     "localname": "RelatedPartyTransactionsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": {
     "auth_ref": [
      "r522",
      "r769",
      "r772",
      "r803",
      "r804",
      "r805",
      "r806",
      "r807",
      "r808",
      "r809",
      "r810",
      "r811",
      "r812",
      "r813",
      "r814"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.",
        "label": "Related Party [Axis]",
        "terseLabel": "Related Party [Axis]"
       }
      }
     },
     "localname": "RelatedPartyTransactionsByRelatedPartyAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/InvestmentsinEquityMethodInvesteesDetails",
      "http://www.evolenthealth.com/role/RelatedPartiesAssetsandLiabilitiesDetails",
      "http://www.evolenthealth.com/role/RelatedPartiesRevenuesandExpensesDetails",
      "http://www.evolenthealth.com/role/StockbasedCompensationRestrictedStockUnitsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": {
     "auth_ref": [
      "r767",
      "r768",
      "r770",
      "r773",
      "r774"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.",
        "label": "Related Party Transactions Disclosure [Text Block]",
        "terseLabel": "Related Parties"
       }
      }
     },
     "localname": "RelatedPartyTransactionsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/RelatedParties"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RepaymentsOfLongTermLinesOfCredit": {
     "auth_ref": [
      "r135"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for the settlement of obligation drawn from a contractual arrangement with the lender, including letter of credit, standby letter of credit and revolving credit arrangements, under which borrowings can be made up to a specific amount at any point in time with maturities due beyond one year or the operating cycle, if longer.",
        "label": "Repayments of Long-term Lines of Credit",
        "terseLabel": "Repayments of long-term lines of credit"
       }
      }
     },
     "localname": "RepaymentsOfLongTermLinesOfCredit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/LongtermDebtCreditAgreementDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RepaymentsOfSeniorDebt": {
     "auth_ref": [
      "r135"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for a long-term debt where the holder has highest claim on the entity's asset in case of bankruptcy or liquidation during the period.",
        "label": "Repayments of Senior Debt",
        "negatedTerseLabel": "Repayment and repurchase of 2021 Notes and financing fees",
        "terseLabel": "Repayments of senior debt"
       }
      }
     },
     "localname": "RepaymentsOfSeniorDebt",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.evolenthealth.com/role/LongtermDebt2021NotesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r591",
      "r790",
      "r919"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research and Development Expense",
        "terseLabel": "Research and development costs"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesResearchandDevelopmentCostsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "auth_ref": [
      "r591"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.",
        "label": "Research and Development Expense, Policy [Policy Text Block]",
        "terseLabel": "Research and Development Costs"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RestrictedCashAndCashEquivalents": {
     "auth_ref": [
      "r42",
      "r152",
      "r160",
      "r816",
      "r848"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Restricted Cash and Cash Equivalents",
        "terseLabel": "Restricted funds"
       }
      }
     },
     "localname": "RestrictedCashAndCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesRestrictedCashandRestrictedInvestmentsDetails",
      "http://www.evolenthealth.com/role/CommitmentsandContingenciesAdditionalInformationDetails",
      "http://www.evolenthealth.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r37",
      "r42",
      "r152",
      "r160"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesRestrictedCashandRestrictedInvestmentsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_RestrictedCashAndInvestmentsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Restricted Cash and Cash Equivalents, Current",
        "verboseLabel": "Current restricted cash"
       }
      }
     },
     "localname": "RestrictedCashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesRestrictedCashandRestrictedInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis": {
     "auth_ref": [
      "r65"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by category of cash or cash equivalent items which are restricted as to withdrawal or usage.",
        "label": "Restricted Cash and Cash Equivalents [Axis]",
        "terseLabel": "Restricted Cash and Cash Equivalents [Axis]"
       }
      }
     },
     "localname": "RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesRestrictedCashandRestrictedInvestmentsDetails",
      "http://www.evolenthealth.com/role/CommitmentsandContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of cash and cash equivalent. Cash is currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash and Cash Equivalents [Domain]",
        "terseLabel": "Cash and Cash Equivalents [Domain]"
       }
      }
     },
     "localname": "RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesRestrictedCashandRestrictedInvestmentsDetails",
      "http://www.evolenthealth.com/role/CommitmentsandContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Restricted Cash and Cash Equivalents Items [Line Items]",
        "terseLabel": "Restricted Cash and Cash Equivalents Items [Line Items]"
       }
      }
     },
     "localname": "RestrictedCashAndCashEquivalentsItemsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesRestrictedCashandRestrictedInvestmentsDetails",
      "http://www.evolenthealth.com/role/CommitmentsandContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RestrictedCashAndCashEquivalentsNoncurrent": {
     "auth_ref": [
      "r41",
      "r45",
      "r152",
      "r160",
      "r898"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesRestrictedCashandRestrictedInvestmentsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_RestrictedCashAndInvestmentsNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Restricted Cash and Cash Equivalents, Noncurrent",
        "verboseLabel": "Non-current restricted cash"
       }
      }
     },
     "localname": "RestrictedCashAndCashEquivalentsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesRestrictedCashandRestrictedInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedCashAndInvestments": {
     "auth_ref": [
      "r897",
      "r899"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash and investments whose use in whole or in part is restricted for the long-term, generally by contractual agreements or regulatory requirements. For use in an unclassified balance sheet.",
        "label": "Restricted Cash and Investments",
        "terseLabel": "Restricted cash and restricted investments"
       }
      }
     },
     "localname": "RestrictedCashAndInvestments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesRestrictedCashandRestrictedInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedCashAndInvestmentsCurrent": {
     "auth_ref": [
      "r65",
      "r897",
      "r899"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesRestrictedCashandRestrictedInvestmentsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The current cash, cash equivalents and investments that are restricted as to withdrawal or usage. Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or entity statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits. Excludes compensating balance arrangements that are not agreements which legally restrict the use of cash amounts shown on the balance sheet. Includes current cash equivalents and investments that are similarly restricted as to withdrawal, usage or disposal.",
        "label": "Restricted Cash and Investments, Current",
        "terseLabel": "Restricted cash and restricted investments",
        "totalLabel": "Total current restricted cash and restricted investments"
       }
      }
     },
     "localname": "RestrictedCashAndInvestmentsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesRestrictedCashandRestrictedInvestmentsDetails",
      "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedCashAndInvestmentsNoncurrent": {
     "auth_ref": [
      "r897",
      "r899"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesRestrictedCashandRestrictedInvestmentsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The noncurrent cash, cash equivalents and investments that is restricted as to withdrawal or usage. Restrictions may include legally restricted deposits held as compensating balances against borrowing arrangements, contracts entered into with others, or entity statements of intention with regard to particular deposits classified as long-term; that is not expected to be released from such existing restrictions within one year of the balance sheet date or operating cycle, whichever is longer. Excludes compensating balance arrangements that are not agreements which legally restrict the use of cash amounts shown on the balance sheet. Includes noncurrent cash equivalents and investments that are similarly restricted as to withdrawal, usage or disposal.",
        "label": "Restricted Cash and Investments, Noncurrent",
        "totalLabel": "Total non-current restricted cash and restricted investments",
        "verboseLabel": "Restricted cash and restricted investments"
       }
      }
     },
     "localname": "RestrictedCashAndInvestmentsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesRestrictedCashandRestrictedInvestmentsDetails",
      "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedInvestments": {
     "auth_ref": [
      "r897",
      "r899"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Investments which are not defined as or included in marketable (debt, equity, or other) securities whose use is restricted in whole or in part, generally by contractual agreements or regulatory requirements. For use in an unclassified balance sheet.",
        "label": "Restricted Investments",
        "negatedTerseLabel": "Restricted investments included in restricted cash and restricted investments"
       }
      }
     },
     "localname": "RestrictedInvestments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesRestrictedCashandRestrictedInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedStockMember": {
     "auth_ref": [
      "r220"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock including a provision that prohibits sale or substantive sale of an equity instrument for a specified period of time or until specified performance conditions are met.",
        "label": "Restricted Stock [Member]",
        "terseLabel": "Restricted stock"
       }
      }
     },
     "localname": "RestrictedStockMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/StockbasedCompensation2011and2015EquityIncentivePlansDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.",
        "label": "Restricted Stock Units (RSUs) [Member]",
        "terseLabel": "RSUs"
       }
      }
     },
     "localname": "RestrictedStockUnitsRSUMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/StockbasedCompensation2011and2015EquityIncentivePlansDetails",
      "http://www.evolenthealth.com/role/StockbasedCompensationRestrictedStockUnitsDetails",
      "http://www.evolenthealth.com/role/StockbasedCompensationStockbasedCompensationExpenseDetails",
      "http://www.evolenthealth.com/role/StockbasedCompensationUnrecognizedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestructuringAndRelatedActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restructuring and Related Activities [Abstract]"
       }
      }
     },
     "localname": "RestructuringAndRelatedActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock": {
     "auth_ref": [
      "r370",
      "r372",
      "r375",
      "r383",
      "r384"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for restructuring and related activities. Description of restructuring activities such as exit and disposal activities, include facts and circumstances leading to the plan, the expected plan completion date, the major types of costs associated with the plan activities, total expected costs, the accrual balance at the end of the period, and the periods over which the remaining accrual will be settled.",
        "label": "Restructuring and Related Activities Disclosure [Text Block]",
        "terseLabel": "Repositioning and Other Changes"
       }
      }
     },
     "localname": "RestructuringAndRelatedActivitiesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/RepositioningandOtherChanges"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RestructuringAndRelatedCostCostIncurredToDate1": {
     "auth_ref": [
      "r371",
      "r374",
      "r380",
      "r382"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of costs incurred to date for the specified restructuring cost.",
        "label": "Restructuring and Related Cost, Cost Incurred to Date",
        "terseLabel": "Cumulative Amount Incurred through December 31, 2021"
       }
      }
     },
     "localname": "RestructuringAndRelatedCostCostIncurredToDate1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/RepositioningandOtherChangesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestructuringCharges": {
     "auth_ref": [
      "r150",
      "r369",
      "r378",
      "r380"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.",
        "label": "Restructuring Charges",
        "negatedLabel": "Repositioning costs",
        "terseLabel": "Repositioning costs incurred"
       }
      }
     },
     "localname": "RestructuringCharges",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/RepositioningandOtherChangesDetails",
      "http://www.evolenthealth.com/role/SegmentReportingReconciliationofAdjustedEBITDADetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestructuringCostAndReserveAxis": {
     "auth_ref": [
      "r371",
      "r372",
      "r380",
      "r381"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of restructuring cost.",
        "label": "Restructuring Type [Axis]",
        "terseLabel": "Restructuring Type [Axis]"
       }
      }
     },
     "localname": "RestructuringCostAndReserveAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/RepositioningandOtherChangesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RestructuringCostAndReserveLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Restructuring Cost and Reserve [Line Items]",
        "terseLabel": "Restructuring Cost and Reserve [Line Items]"
       }
      }
     },
     "localname": "RestructuringCostAndReserveLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/RepositioningandOtherChangesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r56",
      "r468",
      "r584",
      "r778",
      "r850",
      "r883",
      "r888"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings (Accumulated Deficit)",
        "terseLabel": "Retained earnings (accumulated deficit)"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r2",
      "r183",
      "r184",
      "r185",
      "r190",
      "r200",
      "r202",
      "r309",
      "r580",
      "r581",
      "r582",
      "r624",
      "r625",
      "r703",
      "r879",
      "r881"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]",
        "terseLabel": "Retained Earnings (Accumulated Deficit)"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY",
      "http://www.evolenthealth.com/role/RecentlyIssuedAccountingStandardsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue from Contract with Customer [Abstract]",
        "terseLabel": "Revenue from Contract with Customer [Abstract]"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {
     "auth_ref": [
      "r249",
      "r250",
      "r268",
      "r273",
      "r274",
      "r281",
      "r282",
      "r285",
      "r495",
      "r496",
      "r794"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.",
        "label": "Revenue from Contract with Customer, Excluding Assessed Tax",
        "terseLabel": "Total revenue"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerExcludingAssessedTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/RevenueRecognitionDisaggregationofRevenueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": {
     "auth_ref": [
      "r163",
      "r487",
      "r488",
      "r489",
      "r490",
      "r491",
      "r492",
      "r493",
      "r494",
      "r511"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for revenue from contract with customer.",
        "label": "Revenue from Contract with Customer [Policy Text Block]",
        "terseLabel": "Revenue Recognition and Cost of Revenue (Exclusive of Depreciation and Amortization)"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerTextBlock": {
     "auth_ref": [
      "r476",
      "r477",
      "r478",
      "r479",
      "r480",
      "r481",
      "r485",
      "r486",
      "r499",
      "r511"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.",
        "label": "Revenue from Contract with Customer [Text Block]",
        "terseLabel": "Revenue Recognition"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/RevenueRecognition"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RevenueRemainingPerformanceObligation": {
     "auth_ref": [
      "r483"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of transaction price allocated to performance obligation that has not been recognized as revenue.",
        "label": "Revenue, Remaining Performance Obligation, Amount",
        "terseLabel": "Revenue, remaining performance obligation"
       }
      }
     },
     "localname": "RevenueRemainingPerformanceObligation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/RevenueRecognitionTransactionPriceAllocatedtotheRemainingPerformanceObligationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]",
        "terseLabel": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]"
       }
      }
     },
     "localname": "RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/RevenueRecognitionTransactionPriceAllocatedtotheRemainingPerformanceObligationsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1": {
     "auth_ref": [
      "r484"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period in which remaining performance obligation is expected to be recognized as revenue, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Period",
        "terseLabel": "Revenue, remaining performance obligation, expected timing of satisfaction, period"
       }
      }
     },
     "localname": "RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/RevenueRecognitionTransactionPriceAllocatedtotheRemainingPerformanceObligationsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis": {
     "auth_ref": [
      "r484"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Start date of time band for expected timing of satisfaction of remaining performance obligation, in YYYY-MM-DD format.",
        "label": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]",
        "terseLabel": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]"
       }
      }
     },
     "localname": "RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/RevenueRecognitionTransactionPriceAllocatedtotheRemainingPerformanceObligationsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about expected timing for satisfying remaining performance obligation.",
        "label": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Table]",
        "terseLabel": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Table]"
       }
      }
     },
     "localname": "RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/RevenueRecognitionTransactionPriceAllocatedtotheRemainingPerformanceObligationsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RevenueRemainingPerformanceObligationPercentage": {
     "auth_ref": [
      "r484"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of remaining performance obligation to total remaining performance obligation not recognized as revenue.",
        "label": "Revenue, Remaining Performance Obligation, Percentage",
        "terseLabel": "Revenue, remaining performance obligation, percentage"
       }
      }
     },
     "localname": "RevenueRemainingPerformanceObligationPercentage",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/RevenueRecognitionTransactionPriceAllocatedtotheRemainingPerformanceObligationsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_Revenues": {
     "auth_ref": [
      "r108",
      "r167",
      "r249",
      "r250",
      "r268",
      "r273",
      "r274",
      "r281",
      "r282",
      "r285",
      "r304",
      "r393",
      "r394",
      "r395",
      "r398",
      "r399",
      "r400",
      "r402",
      "r404",
      "r406",
      "r407",
      "r722",
      "r836"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).",
        "label": "Revenues",
        "netLabel": "Revenues",
        "terseLabel": "Total revenue"
       }
      }
     },
     "localname": "Revenues",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS",
      "http://www.evolenthealth.com/role/QuarterlyResultsofOperationsunauditedDetails",
      "http://www.evolenthealth.com/role/RelatedPartiesRevenuesandExpensesDetails",
      "http://www.evolenthealth.com/role/SegmentReportingRevenuefromSegmentstoConsolidatedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenuesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenues [Abstract]",
        "terseLabel": "Revenue"
       }
      }
     },
     "localname": "RevenuesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS",
      "http://www.evolenthealth.com/role/DiscontinuedOperationsSummaryofResultsofOperationsDetails",
      "http://www.evolenthealth.com/role/RelatedPartiesRevenuesandExpensesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": {
     "auth_ref": [
      "r758",
      "r763"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability.",
        "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability",
        "terseLabel": "Leased assets obtained in exchange for operating lease liabilities"
       }
      }
     },
     "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/SupplementalCashFlowInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SalesRevenueNetMember": {
     "auth_ref": [
      "r239",
      "r285"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue from sale of product and rendering of service and other sources of income, when it serves as benchmark in concentration of risk calculation.",
        "label": "Revenue Benchmark [Member]",
        "terseLabel": "Revenues"
       }
      }
     },
     "localname": "SalesRevenueNetMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/CommitmentsandContingenciesConcentrationRiskDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable": {
     "auth_ref": [
      "r86"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule itemizing specific types of trade accounts and notes receivable, and for each the gross carrying value, allowance, and net carrying value as of the balance sheet date. Presentation is categorized by current, noncurrent and unclassified receivables.",
        "label": "Schedule of Accounts, Notes, Loans and Financing Receivable [Table]",
        "terseLabel": "Schedule of Accounts, Notes, Loans and Financing Receivable [Table]"
       }
      }
     },
     "localname": "ScheduleOfAccountsNotesLoansAndFinancingReceivableTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/CreditLossesScheduleofChangesinAllowanceforAccountsReceivableDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "auth_ref": [
      "r220"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]",
        "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/EarningsLossPerCommonShareAntidilutiveSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "auth_ref": [
      "r220"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]",
        "terseLabel": "Schedule of antidilutive securities excluded from computation of earnings per share"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/EarningsLossPerCommonShareTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable": {
     "auth_ref": [
      "r645",
      "r646"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting each material business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities.",
        "label": "Schedule of Business Acquisitions, by Acquisition [Table]",
        "terseLabel": "Schedule of Business Acquisitions, by Acquisition [Table]"
       }
      }
     },
     "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/FairValueMeasurementAdditionalInformationDetails",
      "http://www.evolenthealth.com/role/TransactionsEquityInvestmentsDetails",
      "http://www.evolenthealth.com/role/TransactionsVitalDecisionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock": {
     "auth_ref": [
      "r645",
      "r646"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of a material business combination completed during the period, including background, timing, and recognized assets and liabilities. This table  does not include leveraged buyouts.",
        "label": "Schedule of Business Acquisitions, by Acquisition [Table Text Block]",
        "terseLabel": "Schedule of allocation of purchase price"
       }
      }
     },
     "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/TransactionsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of supplemental cash flow information for the periods presented.",
        "label": "Schedule of Cash Flow, Supplemental Disclosures [Table Text Block]",
        "terseLabel": "Schedule of cash flow, supplemental disclosures"
       }
      }
     },
     "localname": "ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/SupplementalCashFlowInformationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock": {
     "auth_ref": [
      "r570"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of cost recognized for award under share-based payment arrangement by plan. Includes, but is not limited to, related tax benefit.",
        "label": "Share-based Payment Arrangement, Cost by Plan [Table Text Block]",
        "terseLabel": "Stock-based compensation expense"
       }
      }
     },
     "localname": "ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/StockbasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock": {
     "auth_ref": [
      "r620"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.",
        "label": "Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]",
        "terseLabel": "Components of income tax expense (benefit)"
       }
      }
     },
     "localname": "ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": {
     "auth_ref": [
      "r610"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.",
        "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]",
        "terseLabel": "Schedule of deferred tax assets and liabilities"
       }
      }
     },
     "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock": {
     "auth_ref": [
      "r7",
      "r17",
      "r18",
      "r19",
      "r20",
      "r21",
      "r22",
      "r28",
      "r31",
      "r32",
      "r33",
      "r366",
      "r367"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of information related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.",
        "label": "Disposal Groups, Including Discontinued Operations [Table Text Block]",
        "terseLabel": "Schedule of discontinued operations"
       }
      }
     },
     "localname": "ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/DiscontinuedOperationsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
     "auth_ref": [
      "r219"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.",
        "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]",
        "terseLabel": "Computation of basic and diluted earnings per share"
       }
      }
     },
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/EarningsLossPerCommonShareTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": {
     "auth_ref": [
      "r598"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.",
        "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]",
        "terseLabel": "Schedule of reconciliation of the U.S. statutory tax rate to our effective tax rate"
       }
      }
     },
     "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": {
     "auth_ref": [
      "r539",
      "r570",
      "r586"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements.",
        "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]",
        "terseLabel": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/StockbasedCompensationStockbasedCompensationExpenseDetails",
      "http://www.evolenthealth.com/role/StockbasedCompensationUnrecognizedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfEquityMethodInvestmentsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Schedule of Equity Method Investments [Line Items]",
        "terseLabel": "Schedule of Equity Method Investments [Line Items]"
       }
      }
     },
     "localname": "ScheduleOfEquityMethodInvestmentsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/InvestmentsinEquityMethodInvesteesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfEquityMethodInvestmentsTable": {
     "auth_ref": [
      "r33",
      "r167",
      "r303",
      "r304",
      "r722"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Summarization of information required and determined to be disclosed concerning equity method investments in common stock. The summarized information includes: (a) the name of each investee or group of investees for which combined disclosure is appropriate, (2) the percentage ownership of common stock, (3) the difference, if any, between the carrying amount of an investment and the value of the underlying equity in the net assets and the accounting treatment of difference, if any, and (4) the aggregate value of each identified investment based on its quoted market price, if available.",
        "label": "Schedule of Equity Method Investments [Table]",
        "terseLabel": "Schedule of Equity Method Investments [Table]"
       }
      }
     },
     "localname": "ScheduleOfEquityMethodInvestmentsTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/InvestmentsinEquityMethodInvesteesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable": {
     "auth_ref": [
      "r345",
      "r349",
      "r795"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Schedule of Finite-Lived Intangible Assets [Table]",
        "terseLabel": "Schedule of Finite-Lived Intangible Assets [Table]"
       }
      }
     },
     "localname": "ScheduleOfFiniteLivedIntangibleAssetsTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesIntangibleAssetsNetDetails",
      "http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNetIntangibleAssetsNetDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock": {
     "auth_ref": [
      "r345",
      "r349"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment.",
        "label": "Schedule of Finite-Lived Intangible Assets [Table Text Block]",
        "terseLabel": "Schedule of intangible assets",
        "verboseLabel": "Schedule of intangible assets details"
       }
      }
     },
     "localname": "ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesTables",
      "http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNetTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfGoodwillTable": {
     "auth_ref": [
      "r340",
      "r342"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of goodwill and the changes during the year due to acquisition, sale, impairment or for other reasons.",
        "label": "Schedule of Goodwill [Table]",
        "terseLabel": "Schedule of Goodwill [Table]"
       }
      }
     },
     "localname": "ScheduleOfGoodwillTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNetScheduleofGoodwillDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfGoodwillTextBlock": {
     "auth_ref": [
      "r340",
      "r342"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule.",
        "label": "Schedule of Goodwill [Table Text Block]",
        "terseLabel": "Schedule of goodwill"
       }
      }
     },
     "localname": "ScheduleOfGoodwillTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNetTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock": {
     "auth_ref": [
      "r168"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of income before income tax between domestic and foreign jurisdictions.",
        "label": "Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block]",
        "terseLabel": "Schedule of loss before provision for income taxes"
       }
      }
     },
     "localname": "ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense": {
     "auth_ref": [
      "r869"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the activity in the reserve for settling insured claims and expenses incurred in the claims settlement process for the period. The estimated liability includes the amount of money that will be required for future payments of (a) claims that have been reported to the insurer, (b) claims related to insured events that have occurred but that have not been reported to the insurer as of the date the liability is estimated, and (c) claim adjustment expenses. Claim adjustment expenses include costs incurred in the claim settlement process such as legal fees; outside adjuster fees; and costs to record, process, and adjust claims.",
        "label": "Schedule of Liability for Unpaid Claims and Claims Adjustment Expense [Table Text Block]",
        "terseLabel": "Activity in claims reserves"
       }
      }
     },
     "localname": "ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/ReservesforClaimsandPerformanceBasedArrangementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfOtherShareBasedCompensationActivityTableTextBlock": {
     "auth_ref": [
      "r553"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of activity for outstanding award under share-based payment arrangement excluding share and unit options and nonvested award.",
        "label": "Share-based Payment Arrangement, Outstanding Award, Activity, Excluding Option [Table Text Block]",
        "terseLabel": "Leveraged stock units activity"
       }
      }
     },
     "localname": "ScheduleOfOtherShareBasedCompensationActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/StockbasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "auth_ref": [
      "r69",
      "r362"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table]",
        "terseLabel": "Property, Plant and Equipment [Table]"
       }
      }
     },
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesEstimatedUsefulLifeofPropertyPlantandEquipmentDetails",
      "http://www.evolenthealth.com/role/PropertyandEquipmentNetDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock": {
     "auth_ref": [
      "r226"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of quarterly financial data. Includes, but is not limited to, financial information for fiscal quarters, cumulative effect of a change in accounting principle and earnings per share data.",
        "label": "Quarterly Financial Information [Table Text Block]",
        "terseLabel": "Unaudited consolidated quarterly results of operations"
       }
      }
     },
     "localname": "ScheduleOfQuarterlyFinancialInformationTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/QuarterlyResultsofOperationsunauditedTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock": {
     "auth_ref": [
      "r650"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the amounts recognized as of the acquisition date for each major class of assets acquired and liabilities assumed. May include but not limited to the following: (a) acquired receivables; (b) contingencies recognized at the acquisition date; and (c) the fair value of noncontrolling interests in the acquiree.",
        "label": "Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block]",
        "terseLabel": "Schedule of net assets acquired"
       }
      }
     },
     "localname": "ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/TransactionsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": {
     "auth_ref": [
      "r771",
      "r772"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of quantitative and qualitative information pertaining to related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.",
        "label": "Schedule of Related Party Transactions, by Related Party [Table]",
        "terseLabel": "Schedule of Related Party Transactions, by Related Party [Table]"
       }
      }
     },
     "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/RelatedPartiesAssetsandLiabilitiesDetails",
      "http://www.evolenthealth.com/role/RelatedPartiesRevenuesandExpensesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of related party transactions. Examples of related party transactions include, but are not limited to, transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners and (d) affiliates.",
        "label": "Schedule of Related Party Transactions [Table Text Block]",
        "terseLabel": "Schedule of related parties"
       }
      }
     },
     "localname": "ScheduleOfRelatedPartyTransactionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/RelatedPartiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable": {
     "auth_ref": [
      "r42",
      "r160",
      "r816",
      "r848"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about cash and cash equivalents restricted as to withdrawal or usage.",
        "label": "Restrictions on Cash and Cash Equivalents [Table]",
        "terseLabel": "Restrictions on Cash and Cash Equivalents [Table]"
       }
      }
     },
     "localname": "ScheduleOfRestrictedCashAndCashEquivalentsTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesRestrictedCashandRestrictedInvestmentsDetails",
      "http://www.evolenthealth.com/role/CommitmentsandContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock": {
     "auth_ref": [
      "r42",
      "r160",
      "r816",
      "r848"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of cash and cash equivalents restricted as to withdrawal or usage.",
        "label": "Restrictions on Cash and Cash Equivalents [Table Text Block]",
        "terseLabel": "Schedule of restricted cash and cash equivalents"
       }
      }
     },
     "localname": "ScheduleOfRestrictedCashAndCashEquivalentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfRestructuringAndRelatedCostsTable": {
     "auth_ref": [
      "r371",
      "r372",
      "r373",
      "r374",
      "r380",
      "r381",
      "r382"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Table presenting the description of the restructuring costs, such as the expected cost; the costs incurred during the period; the cumulative costs incurred as of the balance sheet date; the income statement caption within which the restructuring charges recognized for the period are included; and the amount of and periodic changes to an entity's restructuring reserve that occurred during the period associated with the exit from or disposal of business activities or restructurings for each major type of cost by type of restructuring.",
        "label": "Schedule of Restructuring and Related Costs [Table]",
        "terseLabel": "Schedule of Restructuring and Related Costs [Table]"
       }
      }
     },
     "localname": "ScheduleOfRestructuringAndRelatedCostsTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/RepositioningandOtherChangesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock": {
     "auth_ref": [
      "r376",
      "r377",
      "r379"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of costs incurred for restructuring including, but not limited to, exit and disposal activities, remediation, implementation, integration, asset impairment, and charges against earnings from the write-down of assets.",
        "label": "Restructuring and Related Costs [Table Text Block]",
        "terseLabel": "Costs associated with the Repositioning Plan"
       }
      }
     },
     "localname": "ScheduleOfRestructuringAndRelatedCostsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/RepositioningandOtherChangesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardRestrictedStockUnitsVestedAndExpectedToVestTableTextBlock": {
     "auth_ref": [
      "r562"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of number, weighted-average exercise price or conversion ratio, aggregate intrinsic value, and weighted-average remaining contractual term for outstanding restricted stock units that are fully vested and expected to vest. Includes, but is not limited to, unvested restricted stock units for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Restricted Stock Units, Vested and Expected to Vest [Table Text Block]",
        "terseLabel": "Schedule of information of performance based stock units"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardRestrictedStockUnitsVestedAndExpectedToVestTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/StockbasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r540",
      "r574"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about share-based payment arrangement.",
        "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]",
        "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesStockbasedCompensationDetails",
      "http://www.evolenthealth.com/role/StockbasedCompensation2011and2015EquityIncentivePlansDetails",
      "http://www.evolenthealth.com/role/StockbasedCompensationLeveragedStockUnitsActivityDetails",
      "http://www.evolenthealth.com/role/StockbasedCompensationLeveragedStockUnitsDetails",
      "http://www.evolenthealth.com/role/StockbasedCompensationPerformancebasedRSUActivityDetails",
      "http://www.evolenthealth.com/role/StockbasedCompensationPerformancebasedRSUsDetails",
      "http://www.evolenthealth.com/role/StockbasedCompensationPerformancebasedStockOptionAwardsDetails",
      "http://www.evolenthealth.com/role/StockbasedCompensationRestrictedStockUnitsDetails",
      "http://www.evolenthealth.com/role/StockbasedCompensationStockOptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "auth_ref": [
      "r547",
      "r558",
      "r561"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.",
        "label": "Share-based Payment Arrangement, Option, Activity [Table Text Block]",
        "terseLabel": "Stock option information"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/StockbasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "auth_ref": [
      "r564"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.",
        "label": "Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]",
        "terseLabel": "Option price assumptions"
       }
      }
     },
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/StockbasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of the number and weighted-average grant date fair value for restricted stock and restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock and restricted stock units that were granted, vested, or forfeited during the year.",
        "label": "Share-based Payment Arrangement, Restricted Stock and Restricted Stock Unit, Activity [Table Text Block]",
        "terseLabel": "Restricted stock units information"
       }
      }
     },
     "localname": "ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/StockbasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfStockByClassTable": {
     "auth_ref": [
      "r82",
      "r165",
      "r230",
      "r231",
      "r450",
      "r451",
      "r452",
      "r453",
      "r454",
      "r455",
      "r456",
      "r457",
      "r458",
      "r459",
      "r461",
      "r462",
      "r463",
      "r465",
      "r466",
      "r467",
      "r468"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity.",
        "label": "Schedule of Stock by Class [Table]",
        "terseLabel": "Schedule of Stock by Class [Table]"
       }
      }
     },
     "localname": "ScheduleOfStockByClassTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/OrganizationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfUnrecognizedCompensationCostNonvestedAwardsTableTextBlock": {
     "auth_ref": [
      "r573"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of cost not yet recognized and weighted-average period over which cost is expected to be recognized for nonvested award under share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Nonvested Award, Cost [Table Text Block]",
        "terseLabel": "Schedule of unrecognized compensation expense"
       }
      }
     },
     "localname": "ScheduleOfUnrecognizedCompensationCostNonvestedAwardsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/StockbasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock": {
     "auth_ref": [
      "r604",
      "r621"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the change in unrecognized tax benefits.",
        "label": "Schedule of Unrecognized Tax Benefits Roll Forward [Table Text Block]",
        "terseLabel": "Changes in unrecognized tax benefits"
       }
      }
     },
     "localname": "ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock": {
     "auth_ref": [
      "r349"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets.",
        "label": "Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]",
        "terseLabel": "Schedule of future estimated amortization of intangible assets"
       }
      }
     },
     "localname": "ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNetTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock": {
     "auth_ref": [
      "r237",
      "r239",
      "r240",
      "r241",
      "r719",
      "r721"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark.",
        "label": "Schedules of Concentration of Risk, by Risk Factor [Table Text Block]",
        "terseLabel": "Summary of major customers"
       }
      }
     },
     "localname": "SchedulesOfConcentrationOfRiskByRiskFactorTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/CommitmentsandContingenciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SecuredDebtMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collateralized debt obligation backed by, for example, but not limited to, pledge, mortgage or other lien on the entity's assets.",
        "label": "Secured Debt [Member]",
        "terseLabel": "Secured Debt"
       }
      }
     },
     "localname": "SecuredDebtMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/LongtermDebtCreditAgreementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SegmentDomain": {
     "auth_ref": [
      "r245",
      "r249",
      "r250",
      "r251",
      "r252",
      "r253",
      "r254",
      "r255",
      "r256",
      "r257",
      "r258",
      "r259",
      "r260",
      "r268",
      "r269",
      "r270",
      "r271",
      "r272",
      "r273",
      "r274",
      "r275",
      "r276",
      "r278",
      "r285",
      "r374",
      "r382",
      "r871"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity.",
        "label": "Segments [Domain]",
        "terseLabel": "Segments [Domain]"
       }
      }
     },
     "localname": "SegmentDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNetScheduleofGoodwillDetails",
      "http://www.evolenthealth.com/role/ReservesforClaimsandPerformanceBasedArrangementsDetails",
      "http://www.evolenthealth.com/role/RevenueRecognitionDisaggregationofRevenueDetails",
      "http://www.evolenthealth.com/role/SegmentReportingRevenuefromSegmentstoConsolidatedDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SegmentReportingAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting [Abstract]",
        "terseLabel": "Segment Reporting [Abstract]"
       }
      }
     },
     "localname": "SegmentReportingAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_SegmentReportingDisclosureTextBlock": {
     "auth_ref": [
      "r245",
      "r247",
      "r248",
      "r258",
      "r261",
      "r272",
      "r276",
      "r277",
      "r278",
      "r279",
      "r281",
      "r284",
      "r285",
      "r286"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.",
        "label": "Segment Reporting Disclosure [Text Block]",
        "terseLabel": "Segment Reporting"
       }
      }
     },
     "localname": "SegmentReportingDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/SegmentReporting"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SegmentReportingPolicyPolicyTextBlock": {
     "auth_ref": [
      "r262",
      "r263",
      "r264",
      "r265",
      "r266",
      "r267",
      "r282"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for segment reporting.",
        "label": "Segment Reporting, Policy [Policy Text Block]",
        "terseLabel": "Operating Segments"
       }
      }
     },
     "localname": "SegmentReportingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SegmentReportingRevenueReconcilingItemLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Segment Reporting, Revenue Reconciling Item [Line Items]",
        "terseLabel": "Segment Reporting, Revenue Reconciling Item [Line Items]"
       }
      }
     },
     "localname": "SegmentReportingRevenueReconcilingItemLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/SegmentReportingRevenuefromSegmentstoConsolidatedDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SellingGeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r120"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS": {
       "order": 5.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.",
        "label": "Selling, General and Administrative Expense",
        "terseLabel": "Selling, general and administrative expenses",
        "verboseLabel": "Selling, general and administrative expenses"
       }
      }
     },
     "localname": "SellingGeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS",
      "http://www.evolenthealth.com/role/RelatedPartiesRevenuesandExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SellingGeneralAndAdministrativeExpensesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing selling, general and administrative expense.",
        "label": "Selling, General and Administrative Expenses [Member]",
        "terseLabel": "Selling, general and administrative expenses"
       }
      }
     },
     "localname": "SellingGeneralAndAdministrativeExpensesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/StockbasedCompensationStockbasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SeniorNotesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Bond that takes priority over other debt securities sold by the issuer. In the event the issuer goes bankrupt, senior debt holders receive priority for (must receive) repayment prior to (relative to) junior and unsecured (general) creditors.",
        "label": "Senior Notes [Member]",
        "terseLabel": "Senior Notes"
       }
      }
     },
     "localname": "SeniorNotesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/LongtermDebt2021NotesDetails",
      "http://www.evolenthealth.com/role/LongtermDebt2024NotesDetails",
      "http://www.evolenthealth.com/role/LongtermDebt2025NotesDetails",
      "http://www.evolenthealth.com/role/LongtermDebtConvertibleSeniorNotesCarryingValueDetails",
      "http://www.evolenthealth.com/role/LongtermDebtCreditAgreementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SeveranceCosts1": {
     "auth_ref": [
      "r150"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expenses for special or contractual termination benefits provided to current employees involuntarily terminated under a benefit arrangement associated exit or disposal activities pursuant to an authorized plan. Excludes expenses related to one-time termination benefits, a discontinued operation or an asset retirement obligation.",
        "label": "Severance Costs",
        "negatedLabel": "Severance costs"
       }
      }
     },
     "localname": "SeveranceCosts1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/SegmentReportingReconciliationofAdjustedEBITDADetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r149"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Noncash Expense",
        "terseLabel": "Stock-based compensation expense"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1": {
     "auth_ref": [
      "r541"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Estimated period over which an employee is required to provide service in exchange for the equity-based payment award, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Award Requisite Service Period",
        "terseLabel": "Requisite service period for vesting"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/StockbasedCompensationRestrictedStockUnitsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "auth_ref": [
      "r541"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period",
        "terseLabel": "Vesting period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesStockbasedCompensationDetails",
      "http://www.evolenthealth.com/role/StockbasedCompensationRestrictedStockUnitsDetails",
      "http://www.evolenthealth.com/role/StockbasedCompensationStockOptionsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": {
     "auth_ref": [
      "r552"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period",
        "negatedTerseLabel": "Forfeited / Canceled (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/StockbasedCompensationRestrictedStockUnitsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r557"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value",
        "terseLabel": "Forfeited (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/StockbasedCompensationRestrictedStockUnitsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "auth_ref": [
      "r555"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period",
        "terseLabel": "Granted (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/StockbasedCompensationLeveragedStockUnitsDetails",
      "http://www.evolenthealth.com/role/StockbasedCompensationPerformancebasedRSUsDetails",
      "http://www.evolenthealth.com/role/StockbasedCompensationRestrictedStockUnitsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r555"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted-average fair value per option granted (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/StockbasedCompensationLeveragedStockUnitsDetails",
      "http://www.evolenthealth.com/role/StockbasedCompensationPerformancebasedRSUsDetails",
      "http://www.evolenthealth.com/role/StockbasedCompensationRestrictedStockUnitsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "auth_ref": [
      "r554"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number",
        "periodEndLabel": "Outstanding at the end of the period (in shares)",
        "periodStartLabel": "Outstanding at the beginning of the period (in shares)",
        "terseLabel": "Number of awards issued (in shares)",
        "verboseLabel": "Leveraged Stock Units (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/StockbasedCompensation2011and2015EquityIncentivePlansDetails",
      "http://www.evolenthealth.com/role/StockbasedCompensationLeveragedStockUnitsActivityDetails",
      "http://www.evolenthealth.com/role/StockbasedCompensationPerformancebasedRSUActivityDetails",
      "http://www.evolenthealth.com/role/StockbasedCompensationRestrictedStockUnitsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]",
        "terseLabel": "Total RSUs"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/StockbasedCompensationRestrictedStockUnitsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r554"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value",
        "periodEndLabel": "Outstanding at the end of the period (in dollars per share)",
        "periodStartLabel": "Outstanding at the beginning of the period (in dollars per share)",
        "terseLabel": "Weighted Average Grant Date Fair Value (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/StockbasedCompensationLeveragedStockUnitsActivityDetails",
      "http://www.evolenthealth.com/role/StockbasedCompensationPerformancebasedRSUActivityDetails",
      "http://www.evolenthealth.com/role/StockbasedCompensationRestrictedStockUnitsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]",
        "terseLabel": "Weighted-Average Grant-Date Fair Value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/StockbasedCompensationRestrictedStockUnitsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms": {
     "auth_ref": [
      "r562"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for equity-based awards excluding options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Outstanding, Weighted Average Remaining Contractual Terms",
        "terseLabel": "Weighted Average Remaining Contractual Term"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/StockbasedCompensationLeveragedStockUnitsActivityDetails",
      "http://www.evolenthealth.com/role/StockbasedCompensationPerformancebasedRSUActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": {
     "auth_ref": [
      "r556"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period",
        "negatedTerseLabel": "Vested (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/StockbasedCompensationRestrictedStockUnitsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue": {
     "auth_ref": [
      "r560"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of share-based awards for which the grantee gained the right by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value",
        "terseLabel": "Aggregate intrinsic value, vested"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/StockbasedCompensationRestrictedStockUnitsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r556"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Vested (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/StockbasedCompensationRestrictedStockUnitsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions and Methodology [Abstract]",
        "terseLabel": "Assumptions:"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/StockbasedCompensationPerformancebasedRSUsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "auth_ref": [
      "r567"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate",
        "terseLabel": "Dividend yield"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/StockbasedCompensationLeveragedStockUnitsDetails",
      "http://www.evolenthealth.com/role/StockbasedCompensationPerformancebasedRSUsDetails",
      "http://www.evolenthealth.com/role/StockbasedCompensationPerformancebasedStockOptionAwardsDetails",
      "http://www.evolenthealth.com/role/StockbasedCompensationStockOptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "auth_ref": [
      "r566"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate",
        "terseLabel": "Expected volatility"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/StockbasedCompensationLeveragedStockUnitsDetails",
      "http://www.evolenthealth.com/role/StockbasedCompensationPerformancebasedRSUsDetails",
      "http://www.evolenthealth.com/role/StockbasedCompensationPerformancebasedStockOptionAwardsDetails",
      "http://www.evolenthealth.com/role/StockbasedCompensationStockOptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "auth_ref": [
      "r568"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate",
        "terseLabel": "Risk-free interest rate"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/StockbasedCompensationLeveragedStockUnitsDetails",
      "http://www.evolenthealth.com/role/StockbasedCompensationPerformancebasedRSUsDetails",
      "http://www.evolenthealth.com/role/StockbasedCompensationPerformancebasedStockOptionAwardsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum",
        "terseLabel": "Risk-free interest rate, maximum"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/StockbasedCompensationStockOptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The minimum risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum",
        "terseLabel": "Risk-free interest rate, minimum"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/StockbasedCompensationStockOptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesStockbasedCompensationDetails",
      "http://www.evolenthealth.com/role/StockbasedCompensation2011and2015EquityIncentivePlansDetails",
      "http://www.evolenthealth.com/role/StockbasedCompensationLeveragedStockUnitsActivityDetails",
      "http://www.evolenthealth.com/role/StockbasedCompensationLeveragedStockUnitsDetails",
      "http://www.evolenthealth.com/role/StockbasedCompensationPerformancebasedRSUActivityDetails",
      "http://www.evolenthealth.com/role/StockbasedCompensationPerformancebasedRSUsDetails",
      "http://www.evolenthealth.com/role/StockbasedCompensationPerformancebasedStockOptionAwardsDetails",
      "http://www.evolenthealth.com/role/StockbasedCompensationRestrictedStockUnitsDetails",
      "http://www.evolenthealth.com/role/StockbasedCompensationStockOptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": {
     "auth_ref": [
      "r543"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares authorized for issuance under share-based payment arrangement.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized",
        "terseLabel": "Number of shares authorized (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/StockbasedCompensation2011and2015EquityIncentivePlansDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "auth_ref": [
      "r550"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price",
        "terseLabel": "Exercisable at the end of the period (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/StockbasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": {
     "auth_ref": [
      "r560"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value",
        "terseLabel": "Intrinsic value of options exercised"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/StockbasedCompensationStockOptionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "auth_ref": [
      "r552"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period",
        "negatedTerseLabel": "Forfeited (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/StockbasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross number of share options (or share units) granted during the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross",
        "terseLabel": "Granted (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/StockbasedCompensationPerformancebasedStockOptionAwardsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r559"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted-average fair value per option granted (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/StockbasedCompensationPerformancebasedStockOptionAwardsDetails",
      "http://www.evolenthealth.com/role/StockbasedCompensationStockOptionsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "auth_ref": [
      "r574"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value",
        "terseLabel": "Outstanding"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/StockbasedCompensationPerformancebasedStockOptionAwardsDetails",
      "http://www.evolenthealth.com/role/StockbasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "auth_ref": [
      "r549",
      "r574"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options outstanding, including both vested and non-vested options.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number",
        "periodEndLabel": "Outstanding at the end of the period (in shares)",
        "periodStartLabel": "Outstanding at the beginning of the period (in shares)",
        "terseLabel": "Number of options issued (in shares)",
        "verboseLabel": "Outstanding at the end of the period (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/StockbasedCompensation2011and2015EquityIncentivePlansDetails",
      "http://www.evolenthealth.com/role/StockbasedCompensationPerformancebasedStockOptionAwardsDetails",
      "http://www.evolenthealth.com/role/StockbasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]",
        "terseLabel": "Options"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/StockbasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r548"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "periodEndLabel": "Outstanding at the end of the period (in dollars per share)",
        "periodStartLabel": "Outstanding at the beginning of the period (in dollars per share)",
        "verboseLabel": "Weighted Average Exercise Price, outstanding at the end of the period (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/StockbasedCompensationPerformancebasedStockOptionAwardsDetails",
      "http://www.evolenthealth.com/role/StockbasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/StockbasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber": {
     "auth_ref": [
      "r563"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of fully vested and expected to vest exercisable options that may be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number",
        "terseLabel": "Exercisable at the end of the period (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/StockbasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue": {
     "auth_ref": [
      "r561"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value",
        "terseLabel": "Vested and expected to vest"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/StockbasedCompensationPerformancebasedStockOptionAwardsDetails",
      "http://www.evolenthealth.com/role/StockbasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber": {
     "auth_ref": [
      "r562"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number",
        "terseLabel": "Vested and expected to vest at the end of the period (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/StockbasedCompensationPerformancebasedStockOptionAwardsDetails",
      "http://www.evolenthealth.com/role/StockbasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r562"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price",
        "terseLabel": "Vested and expected to vest at the end of the period (in dollars per share)",
        "verboseLabel": "Weighted Average Exercise Price, vested and expected to vest at the end of the period (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/StockbasedCompensationPerformancebasedStockOptionAwardsDetails",
      "http://www.evolenthealth.com/role/StockbasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r538",
      "r544"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement.",
        "label": "Award Type [Domain]",
        "terseLabel": "Award Type [Domain]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesStockbasedCompensationDetails",
      "http://www.evolenthealth.com/role/StockbasedCompensation2011and2015EquityIncentivePlansDetails",
      "http://www.evolenthealth.com/role/StockbasedCompensationLeveragedStockUnitsActivityDetails",
      "http://www.evolenthealth.com/role/StockbasedCompensationLeveragedStockUnitsDetails",
      "http://www.evolenthealth.com/role/StockbasedCompensationPerformancebasedRSUActivityDetails",
      "http://www.evolenthealth.com/role/StockbasedCompensationPerformancebasedRSUsDetails",
      "http://www.evolenthealth.com/role/StockbasedCompensationPerformancebasedStockOptionAwardsDetails",
      "http://www.evolenthealth.com/role/StockbasedCompensationRestrictedStockUnitsDetails",
      "http://www.evolenthealth.com/role/StockbasedCompensationStockOptionsDetails",
      "http://www.evolenthealth.com/role/StockbasedCompensationStockbasedCompensationExpenseDetails",
      "http://www.evolenthealth.com/role/StockbasedCompensationUnrecognizedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "terseLabel": "Exercised (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/StockbasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price",
        "terseLabel": "Forfeited (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/StockbasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationAwardTrancheOneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "First portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period.",
        "label": "Share-based Payment Arrangement, Tranche One [Member]",
        "terseLabel": "1st Tranche"
       }
      }
     },
     "localname": "ShareBasedCompensationAwardTrancheOneMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/StockbasedCompensationLeveragedStockUnitsDetails",
      "http://www.evolenthealth.com/role/StockbasedCompensationPerformancebasedRSUsDetails",
      "http://www.evolenthealth.com/role/StockbasedCompensationPerformancebasedStockOptionAwardsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationAwardTrancheThreeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Third portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period.",
        "label": "Share-based Payment Arrangement, Tranche Three [Member]",
        "terseLabel": "Tranche Three"
       }
      }
     },
     "localname": "ShareBasedCompensationAwardTrancheThreeMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/StockbasedCompensationLeveragedStockUnitsDetails",
      "http://www.evolenthealth.com/role/StockbasedCompensationPerformancebasedStockOptionAwardsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationAwardTrancheTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Second portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period.",
        "label": "Share-based Payment Arrangement, Tranche Two [Member]",
        "terseLabel": "2nd Tranche"
       }
      }
     },
     "localname": "ShareBasedCompensationAwardTrancheTwoMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/StockbasedCompensationLeveragedStockUnitsDetails",
      "http://www.evolenthealth.com/role/StockbasedCompensationPerformancebasedRSUsDetails",
      "http://www.evolenthealth.com/role/StockbasedCompensationPerformancebasedStockOptionAwardsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": {
     "auth_ref": [
      "r540",
      "r545"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.",
        "label": "Share-based Payment Arrangement [Policy Text Block]",
        "terseLabel": "Stock-based Compensation"
       }
      }
     },
     "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ShareBasedCompensationPerformanceSharesAwardOutstandingActivityTableTextBlock": {
     "auth_ref": [
      "r546"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the number and weighted-average grant date fair value for outstanding performance shares.",
        "label": "Share-based Payment Arrangement, Performance Shares, Outstanding Activity [Table Text Block]",
        "terseLabel": "Performance-based stock option awards activity"
       }
      }
     },
     "localname": "ShareBasedCompensationPerformanceSharesAwardOutstandingActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/StockbasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage": {
     "auth_ref": [
      "r541"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of vesting of award under share-based payment arrangement.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage",
        "terseLabel": "Vesting percentage"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/StockbasedCompensationLeveragedStockUnitsDetails",
      "http://www.evolenthealth.com/role/StockbasedCompensationPerformancebasedStockOptionAwardsDetails",
      "http://www.evolenthealth.com/role/StockbasedCompensationRestrictedStockUnitsDetails",
      "http://www.evolenthealth.com/role/StockbasedCompensationStockOptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Intrinsic value of outstanding award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Outstanding",
        "terseLabel": "Aggregate Intrinsic Value"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/StockbasedCompensationLeveragedStockUnitsActivityDetails",
      "http://www.evolenthealth.com/role/StockbasedCompensationPerformancebasedRSUActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": {
     "auth_ref": [
      "r542"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period",
        "terseLabel": "Expiration period"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesStockbasedCompensationDetails",
      "http://www.evolenthealth.com/role/StockbasedCompensationStockOptionsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "auth_ref": [
      "r565",
      "r585"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term",
        "terseLabel": "Expected term (in years)",
        "verboseLabel": "Expected term"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/StockbasedCompensationLeveragedStockUnitsDetails",
      "http://www.evolenthealth.com/role/StockbasedCompensationPerformancebasedRSUsDetails",
      "http://www.evolenthealth.com/role/StockbasedCompensationPerformancebasedStockOptionAwardsDetails",
      "http://www.evolenthealth.com/role/StockbasedCompensationStockOptionsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
     "auth_ref": [
      "r574"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value",
        "terseLabel": "Exercisable"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/StockbasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r574"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term",
        "terseLabel": "Exercisable"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/StockbasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "auth_ref": [
      "r562"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term",
        "terseLabel": "Outstanding"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/StockbasedCompensationPerformancebasedStockOptionAwardsDetails",
      "http://www.evolenthealth.com/role/StockbasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r562"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term",
        "terseLabel": "Vested and expected to vest"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/StockbasedCompensationPerformancebasedStockOptionAwardsDetails",
      "http://www.evolenthealth.com/role/StockbasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1": {
     "auth_ref": [
      "r546"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of options vested. Excludes equity instruments other than options, for example, but not limited to, share units, stock appreciation rights, restricted stock.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value",
        "terseLabel": "Fair value of options vested"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/StockbasedCompensationStockOptionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharesIssued": {
     "auth_ref": [
      "r460"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.",
        "label": "Shares, Issued",
        "periodEndLabel": "Ending balance (in shares)",
        "periodStartLabel": "Beginning balance (in shares)"
       }
      }
     },
     "localname": "SharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShortdurationInsuranceContractsReconciliationOfClaimsDevelopmentToLiabilityLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Short-duration Insurance Contracts, Reconciliation of Claims Development to Liability [Line Items]",
        "terseLabel": "Short-duration Insurance Contracts, Reconciliation of Claims Development to Liability [Line Items]"
       }
      }
     },
     "localname": "ShortdurationInsuranceContractsReconciliationOfClaimsDevelopmentToLiabilityLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/ReservesforClaimsandPerformanceBasedArrangementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShortdurationInsuranceContractsReconciliationOfClaimsDevelopmentToLiabilityTable": {
     "auth_ref": [
      "r870"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about the reconciliation of claims development to the liability for unpaid claims and claim adjustment expense for short-duration insurance contracts.",
        "label": "Short-duration Insurance Contracts, Reconciliation of Claims Development to Liability [Table]",
        "terseLabel": "Short-duration Insurance Contracts, Reconciliation of Claims Development to Liability [Table]"
       }
      }
     },
     "localname": "ShortdurationInsuranceContractsReconciliationOfClaimsDevelopmentToLiabilityTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/ReservesforClaimsandPerformanceBasedArrangementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SoftwareAndSoftwareDevelopmentCostsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Purchased software applications and internally developed software for sale, licensing or long-term internal use.",
        "label": "Software and Software Development Costs [Member]",
        "verboseLabel": "Computer software"
       }
      }
     },
     "localname": "SoftwareAndSoftwareDevelopmentCostsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesEstimatedUsefulLifeofPropertyPlantandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SoftwareDevelopmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Internally developed software for sale, licensing or long-term internal use.",
        "label": "Software Development [Member]",
        "terseLabel": "Internal-use software development costs",
        "verboseLabel": "Internal-use software development costs"
       }
      }
     },
     "localname": "SoftwareDevelopmentMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesEstimatedUsefulLifeofPropertyPlantandEquipmentDetails",
      "http://www.evolenthealth.com/role/PropertyandEquipmentNetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_StateAndLocalJurisdictionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designated tax department of a state or local government entitled to levy and collect income taxes from the entity.",
        "label": "State and Local Jurisdiction [Member]",
        "terseLabel": "State and Local Jurisdiction"
       }
      }
     },
     "localname": "StateAndLocalJurisdictionMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_StatementBusinessSegmentsAxis": {
     "auth_ref": [
      "r16",
      "r245",
      "r249",
      "r250",
      "r251",
      "r252",
      "r253",
      "r254",
      "r255",
      "r256",
      "r257",
      "r258",
      "r259",
      "r260",
      "r268",
      "r269",
      "r270",
      "r271",
      "r272",
      "r273",
      "r274",
      "r275",
      "r276",
      "r278",
      "r285",
      "r340",
      "r365",
      "r374",
      "r382",
      "r871"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by business segments.",
        "label": "Segments [Axis]",
        "terseLabel": "Segments [Axis]"
       }
      }
     },
     "localname": "StatementBusinessSegmentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNetScheduleofGoodwillDetails",
      "http://www.evolenthealth.com/role/ReservesforClaimsandPerformanceBasedArrangementsDetails",
      "http://www.evolenthealth.com/role/RevenueRecognitionDisaggregationofRevenueDetails",
      "http://www.evolenthealth.com/role/SegmentReportingRevenuefromSegmentstoConsolidatedDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementClassOfStockAxis": {
     "auth_ref": [
      "r51",
      "r52",
      "r53",
      "r165",
      "r167",
      "r209",
      "r210",
      "r215",
      "r217",
      "r219",
      "r230",
      "r231",
      "r232",
      "r304",
      "r393",
      "r398",
      "r399",
      "r400",
      "r406",
      "r407",
      "r453",
      "r454",
      "r457",
      "r458",
      "r460",
      "r722",
      "r929"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by the different classes of stock of the entity.",
        "label": "Class of Stock [Axis]",
        "terseLabel": "Class of Stock [Axis]"
       }
      }
     },
     "localname": "StatementClassOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY",
      "http://www.evolenthealth.com/role/LongtermDebt2021NotesDetails",
      "http://www.evolenthealth.com/role/LongtermDebt2025NotesDetails",
      "http://www.evolenthealth.com/role/OrganizationDetails",
      "http://www.evolenthealth.com/role/StockbasedCompensation2011and2015EquityIncentivePlansDetails",
      "http://www.evolenthealth.com/role/StockbasedCompensationPerformancebasedStockOptionAwardsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r2",
      "r85",
      "r103",
      "r104",
      "r105",
      "r183",
      "r184",
      "r185",
      "r190",
      "r200",
      "r202",
      "r229",
      "r309",
      "r460",
      "r468",
      "r580",
      "r581",
      "r582",
      "r624",
      "r625",
      "r703",
      "r735",
      "r736",
      "r737",
      "r738",
      "r739",
      "r740",
      "r879",
      "r880",
      "r881",
      "r936"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]",
        "terseLabel": "Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY",
      "http://www.evolenthealth.com/role/LongtermDebt2021NotesDetails",
      "http://www.evolenthealth.com/role/LongtermDebt2024NotesDetails",
      "http://www.evolenthealth.com/role/LongtermDebt2025NotesDetails",
      "http://www.evolenthealth.com/role/NoncontrollingInterestsScheduleofChangesinNoncontrollingInterestsDetails",
      "http://www.evolenthealth.com/role/RecentlyIssuedAccountingStandardsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]",
        "terseLabel": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY",
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]",
        "terseLabel": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]",
        "terseLabel": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]",
        "terseLabel": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r183",
      "r184",
      "r185",
      "r229",
      "r794"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY",
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssued1": {
     "auth_ref": [
      "r157",
      "r158",
      "r159"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The fair value of stock issued in noncash financing activities.",
        "label": "Stock Issued",
        "terseLabel": "Class A and Class B common stock issued in connection with business combinations"
       }
      }
     },
     "localname": "StockIssued1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/SupplementalCashFlowInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesAcquisitions": {
     "auth_ref": [
      "r52",
      "r53",
      "r468"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of stock issued during the period pursuant to acquisitions.",
        "label": "Stock Issued During Period, Shares, Acquisitions",
        "terseLabel": "Shares issued for acquisition (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesAcquisitions",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities": {
     "auth_ref": [
      "r84",
      "r428",
      "r460",
      "r461",
      "r468"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued during the period as a result of the conversion of convertible securities.",
        "label": "Stock Issued During Period, Shares, Conversion of Convertible Securities",
        "terseLabel": "Exchange/conversion (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures": {
     "auth_ref": [
      "r52",
      "r53",
      "r460",
      "r468"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued during the period related to Restricted Stock Awards, net of any shares forfeited.",
        "label": "Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures",
        "terseLabel": "Restricted stock units vested, net of shares withheld for taxes (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "auth_ref": [
      "r52",
      "r53",
      "r460",
      "r468",
      "r551"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of share options (or share units) exercised during the current period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period",
        "negatedTerseLabel": "Exercised (in shares)",
        "terseLabel": "Exercise of stock options (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY",
      "http://www.evolenthealth.com/role/StockbasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueAcquisitions": {
     "auth_ref": [
      "r85",
      "r460",
      "r468"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock issued pursuant to acquisitions during the period.",
        "label": "Stock Issued During Period, Value, Acquisitions",
        "terseLabel": "Shares issued for acquisition"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueAcquisitions",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities": {
     "auth_ref": [
      "r85",
      "r460",
      "r468"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The gross value of stock issued during the period upon the conversion of convertible securities.",
        "label": "Stock Issued During Period, Value, Conversion of Convertible Securities",
        "terseLabel": "Exchange/conversion"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueConversionOfConvertibleSecurities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures": {
     "auth_ref": [
      "r460",
      "r468"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock related to Restricted Stock Awards issued during the period, net of the stock value of such awards forfeited.",
        "label": "Stock Issued During Period, Value, Restricted Stock Award, Net of Forfeitures",
        "terseLabel": "Restricted stock units vested, net of shares withheld for taxes"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "auth_ref": [
      "r85",
      "r460",
      "r468"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock issued as a result of the exercise of stock options.",
        "label": "Stock Issued During Period, Value, Stock Options Exercised",
        "terseLabel": "Exercise of stock options"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r53",
      "r58",
      "r59",
      "r167",
      "r292",
      "r304",
      "r722",
      "r778"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "totalLabel": "Total shareholders' equity"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r2",
      "r3",
      "r104",
      "r167",
      "r183",
      "r184",
      "r185",
      "r190",
      "r200",
      "r304",
      "r309",
      "r468",
      "r580",
      "r581",
      "r582",
      "r624",
      "r625",
      "r669",
      "r670",
      "r689",
      "r703",
      "r722",
      "r735",
      "r736",
      "r740",
      "r880",
      "r881",
      "r936"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.",
        "label": "Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest",
        "negatedTerseLabel": "Cumulative effect adjustment",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance"
       }
      }
     },
     "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY",
      "http://www.evolenthealth.com/role/RecentlyIssuedAccountingStandardsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest [Abstract]",
        "terseLabel": "Shareholders' Equity"
       }
      }
     },
     "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SupplementalCashFlowElementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental Cash Flow Elements [Abstract]",
        "terseLabel": "Supplemental Cash Flow Elements [Abstract]"
       }
      }
     },
     "localname": "SupplementalCashFlowElementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental Cash Flow Information [Abstract]",
        "terseLabel": "Supplemental Disclosures"
       }
      }
     },
     "localname": "SupplementalCashFlowInformationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/SupplementalCashFlowInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense": {
     "auth_ref": [
      "r866"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/ReservesforClaimsandPerformanceBasedArrangementsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpensePeriodIncreaseDecrease",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after effects of reinsurance, of expense (reversal of expense) for claims incurred in prior reporting periods and related claims settlement costs.",
        "label": "Prior Year Claims and Claims Adjustment Expense",
        "terseLabel": "Incurred costs related to prior year"
       }
      }
     },
     "localname": "SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/ReservesforClaimsandPerformanceBasedArrangementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TaxCreditCarryforwardAxis": {
     "auth_ref": [
      "r614"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by specific tax credit related to an unused tax credit.",
        "label": "Tax Credit Carryforward [Axis]",
        "terseLabel": "Tax Credit Carryforward [Axis]"
       }
      }
     },
     "localname": "TaxCreditCarryforwardAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TaxCreditCarryforwardNameDomain": {
     "auth_ref": [
      "r614"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The name of the tax credit carryforward.",
        "label": "Tax Credit Carryforward, Name [Domain]",
        "terseLabel": "Tax Credit Carryforward, Name [Domain]"
       }
      }
     },
     "localname": "TaxCreditCarryforwardNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TaxPeriodAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information about the period subject to enacted tax laws.",
        "label": "Tax Period [Axis]",
        "terseLabel": "Tax Period [Axis]"
       }
      }
     },
     "localname": "TaxPeriodAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TaxPeriodDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identified tax period.",
        "label": "Tax Period [Domain]",
        "terseLabel": "Tax Period [Domain]"
       }
      }
     },
     "localname": "TaxPeriodDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TradeNamesMember": {
     "auth_ref": [
      "r652"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Rights acquired through registration of a business name to gain or protect exclusive use thereof.",
        "label": "Trade Names [Member]",
        "terseLabel": "Corporate trade name"
       }
      }
     },
     "localname": "TradeNamesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesIntangibleAssetsNetDetails",
      "http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNetIntangibleAssetsNetDetails",
      "http://www.evolenthealth.com/role/TransactionsVitalDecisionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TreasuryStockMember": {
     "auth_ref": [
      "r83",
      "r470"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Shares of an entity that have been repurchased by the entity. This stock has no voting rights and receives no dividends. Note that treasury stock may be recorded at its total cost or separately as par (or stated) value and additional paid in capital. Classified within stockholders' equity if nonredeemable or redeemable solely at the option of the issuer. Classified within temporary equity if redemption is outside the control of the issuer.",
        "label": "Treasury Stock [Member]",
        "terseLabel": "Treasury Stock"
       }
      }
     },
     "localname": "TreasuryStockMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TreasuryStockRetiredCostMethodAmount": {
     "auth_ref": [
      "r53",
      "r460",
      "r469"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of decrease of par value, additional paid in capital (APIC) and retained earnings of common and preferred stock retired from treasury when treasury stock is accounted for under the cost method.",
        "label": "Treasury Stock, Retired, Cost Method, Amount",
        "negatedTerseLabel": "Consolidation of equity method investment"
       }
      }
     },
     "localname": "TreasuryStockRetiredCostMethodAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TreasuryStockShares": {
     "auth_ref": [
      "r83",
      "r470"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of common and preferred shares that were previously issued and that were repurchased by the issuing entity and held in treasury on the financial statement date. This stock has no voting rights and receives no dividends.",
        "label": "Treasury Stock, Shares",
        "terseLabel": "Treasury stock, at cost (in shares)"
       }
      }
     },
     "localname": "TreasuryStockShares",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_TreasuryStockValue": {
     "auth_ref": [
      "r83",
      "r470",
      "r471"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 5.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount allocated to treasury stock. Treasury stock is common and preferred shares of an entity that were issued, repurchased by the entity, and are held in its treasury.",
        "label": "Treasury Stock, Value",
        "negatedTerseLabel": "Treasury stock, at cost; 1,537,582 shares issued, respectively"
       }
      }
     },
     "localname": "TreasuryStockValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TypeOfRestructuringDomain": {
     "auth_ref": [
      "r371",
      "r372",
      "r380",
      "r381"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identification of the types of restructuring costs.",
        "label": "Type of Restructuring [Domain]",
        "terseLabel": "Type of Restructuring [Domain]"
       }
      }
     },
     "localname": "TypeOfRestructuringDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/RepositioningandOtherChangesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_UnrecognizedTaxBenefits": {
     "auth_ref": [
      "r592",
      "r602"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unrecognized tax benefits.",
        "label": "Unrecognized Tax Benefits",
        "periodEndLabel": "Balance at end-of-year",
        "periodStartLabel": "Balance at beginning-of-year",
        "terseLabel": "Unrecognized tax benefits"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefits",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/IncomeTaxesChangesInUnrecognizedTaxBenefitsDetails",
      "http://www.evolenthealth.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations": {
     "auth_ref": [
      "r603"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of decrease in unrecognized tax benefits resulting from lapses of applicable statutes of limitations.",
        "label": "Unrecognized Tax Benefits, Reduction Resulting from Lapse of Applicable Statute of Limitations",
        "negatedTerseLabel": "Lapse of statute of limitations"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/IncomeTaxesChangesInUnrecognizedTaxBenefitsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UseOfEstimates": {
     "auth_ref": [
      "r233",
      "r234",
      "r235",
      "r236",
      "r242",
      "r243",
      "r244"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "terseLabel": "Accounting Estimates and Assumptions"
       }
      }
     },
     "localname": "UseOfEstimates",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ValuationAllowanceOfDeferredTaxAssetsMember": {
     "auth_ref": [
      "r175",
      "r176",
      "r177",
      "r180",
      "r181"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Valuation allowance of deferred tax asset attributable to deductible temporary difference and carryforward.",
        "label": "SEC Schedule, 12-09, Valuation Allowance, Deferred Tax Asset [Member]",
        "terseLabel": "Valuation Allowance of Deferred Tax Assets"
       }
      }
     },
     "localname": "ValuationAllowanceOfDeferredTaxAssetsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/IncomeTaxesChangesinValuationAllowanceDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ValuationAllowancesAndReservesBalance": {
     "auth_ref": [
      "r175",
      "r181"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of valuation and qualifying accounts and reserves.",
        "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves, Amount",
        "periodEndLabel": "Balance at end-of-year",
        "periodStartLabel": "Balance at beginning-of-year"
       }
      }
     },
     "localname": "ValuationAllowancesAndReservesBalance",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/IncomeTaxesChangesinValuationAllowanceDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense": {
     "auth_ref": [
      "r178"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in valuation and qualifying accounts and reserves from charge to cost and expense.",
        "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves, Additions, Charge to Cost and Expense",
        "terseLabel": "Charged to costs and expenses"
       }
      }
     },
     "localname": "ValuationAllowancesAndReservesChargedToCostAndExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/IncomeTaxesChangesinValuationAllowanceDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts": {
     "auth_ref": [
      "r179"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in valuation and qualifying accounts and reserves from charge to accounts other than cost and expense.",
        "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves, Additions, Charge to Other Account",
        "terseLabel": "Charged (credited) to other accounts"
       }
      }
     },
     "localname": "ValuationAllowancesAndReservesChargedToOtherAccounts",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/IncomeTaxesChangesinValuationAllowanceDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ValuationAllowancesAndReservesDeductions": {
     "auth_ref": [
      "r180"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of decrease in valuation and qualifying accounts and reserves.",
        "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves, Deduction",
        "negatedLabel": "Charged (credited) to other accounts"
       }
      }
     },
     "localname": "ValuationAllowancesAndReservesDeductions",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/IncomeTaxesChangesinValuationAllowanceDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ValuationAllowancesAndReservesDomain": {
     "auth_ref": [
      "r175",
      "r176",
      "r177",
      "r180",
      "r181"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Valuation and qualifying accounts and reserves.",
        "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves [Domain]",
        "terseLabel": "SEC Schedule, 12-09, Valuation Allowances and Reserves [Domain]"
       }
      }
     },
     "localname": "ValuationAllowancesAndReservesDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/IncomeTaxesChangesinValuationAllowanceDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ValuationAllowancesAndReservesTypeAxis": {
     "auth_ref": [
      "r175",
      "r176",
      "r177",
      "r180",
      "r181"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by valuation and qualifying accounts and reserves.",
        "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves Type [Axis]",
        "terseLabel": "SEC Schedule, 12-09, Valuation Allowances and Reserves Type [Axis]"
       }
      }
     },
     "localname": "ValuationAllowancesAndReservesTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/IncomeTaxesChangesinValuationAllowanceDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_VariableInterestEntityFinancialOrOtherSupportAmount": {
     "auth_ref": [
      "r687"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of financial or other support the reporting entity has provided (explicitly or implicitly) to the Variable Interest Entity (VIE) that it was not previously contractually required to provide or that the reporting entity intends to provide, including, for example, situations in which the reporting entity assisted the VIE in obtaining another type of support.",
        "label": "Variable Interest Entity, Financial or Other Support, Amount",
        "terseLabel": "Performance bond amount"
       }
      }
     },
     "localname": "VariableInterestEntityFinancialOrOtherSupportAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/TransactionsEquityInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_VariableInterestEntityInitialConsolidationGainOrLoss": {
     "auth_ref": [
      "r686"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The gain (loss) recognized on initial consolidation of a variable interest entity (VIE) when the VIE is not a business (as defined).",
        "label": "Variable Interest Entity, Initial Consolidation, Gain (Loss)",
        "terseLabel": "Gain on consolidation"
       }
      }
     },
     "localname": "VariableInterestEntityInitialConsolidationGainOrLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/NoncontrollingInterestsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_VariableInterestEntityNotPrimaryBeneficiaryMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Variable Interest Entities (VIE) in which the entity does not have a controlling financial interest (as defined) and of which it is therefore not the primary beneficiary. VIEs of which the entity is not the primary beneficiary because it does not have the power to direct the activities of the VIE that most significantly impact the VIE's economic performance and for which it does not have the obligation to absorb losses of the VIE that could potentially be significant to the VIE or the right to receive benefits from the VIE that could potentially be significant to the VIE are not included in the consolidated financial statements of the entity.",
        "label": "Variable Interest Entity, Not Primary Beneficiary [Member]",
        "terseLabel": "Variable Interest Entity, Not Primary Beneficiary"
       }
      }
     },
     "localname": "VariableInterestEntityNotPrimaryBeneficiaryMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/CommitmentsandContingenciesAdditionalInformationDetails",
      "http://www.evolenthealth.com/role/InvestmentsinEquityMethodInvesteesDetails",
      "http://www.evolenthealth.com/role/NoncontrollingInterestsDetails",
      "http://www.evolenthealth.com/role/TransactionsEquityInvestmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_VariableInterestEntityOwnershipPercentage": {
     "auth_ref": [
      "r688"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the Variable Interest Entity's (VIE) voting interest owned by (or beneficial interest in) the reporting entity (directly or indirectly).",
        "label": "Variable Interest Entity, Qualitative or Quantitative Information, Ownership Percentage",
        "terseLabel": "Interest in investment"
       }
      }
     },
     "localname": "VariableInterestEntityOwnershipPercentage",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/NoncontrollingInterestsDetails",
      "http://www.evolenthealth.com/role/TransactionsEquityInvestmentsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_VariableLeaseCost": {
     "auth_ref": [
      "r756",
      "r763"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/LeasesComponentsofLeaseExpenseDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases.",
        "label": "Variable Lease, Cost",
        "terseLabel": "Variable lease cost"
       }
      }
     },
     "localname": "VariableLeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/LeasesComponentsofLeaseExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_VariableRateAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of variable rate.",
        "label": "Variable Rate [Axis]",
        "terseLabel": "Variable Rate [Axis]"
       }
      }
     },
     "localname": "VariableRateAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/LongtermDebtCreditAgreementDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_VariableRateDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Interest rate that fluctuates over time as a result of an underlying benchmark interest rate or index.",
        "label": "Variable Rate [Domain]",
        "terseLabel": "Variable Rate [Domain]"
       }
      }
     },
     "localname": "VariableRateDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/LongtermDebtCreditAgreementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_VestingAxis": {
     "auth_ref": [
      "r574"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by vesting schedule of award under share-based payment arrangement.",
        "label": "Vesting [Axis]",
        "terseLabel": "Vesting [Axis]"
       }
      }
     },
     "localname": "VestingAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/StockbasedCompensationLeveragedStockUnitsDetails",
      "http://www.evolenthealth.com/role/StockbasedCompensationPerformancebasedRSUsDetails",
      "http://www.evolenthealth.com/role/StockbasedCompensationPerformancebasedStockOptionAwardsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_VestingDomain": {
     "auth_ref": [
      "r574"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Vesting schedule of award under share-based payment arrangement.",
        "label": "Vesting [Domain]",
        "terseLabel": "Vesting [Domain]"
       }
      }
     },
     "localname": "VestingDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/StockbasedCompensationLeveragedStockUnitsDetails",
      "http://www.evolenthealth.com/role/StockbasedCompensationPerformancebasedRSUsDetails",
      "http://www.evolenthealth.com/role/StockbasedCompensationPerformancebasedStockOptionAwardsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_WarrantsAndRightsOutstandingMeasurementInput": {
     "auth_ref": [
      "r710"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of input used to measure outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur.",
        "label": "Warrants and Rights Outstanding, Measurement Input",
        "terseLabel": "Assumption or Input Ranges"
       }
      }
     },
     "localname": "WarrantsAndRightsOutstandingMeasurementInput",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/FairValueMeasurementValuationTechniquesandSignificantUnobservableInputsDetails"
     ],
     "xbrltype": "decimalItemType"
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "auth_ref": [
      "r208",
      "r219"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "terseLabel": "Weighted-average common shares outstanding - diluted (in shares)",
        "verboseLabel": "Diluted (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS",
      "http://www.evolenthealth.com/role/EarningsLossPerCommonShareComputationofEarningsperShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "auth_ref": [
      "r206",
      "r219"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "terseLabel": "Weighted-average common shares outstanding - basic (in shares)",
        "verboseLabel": "Basic (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS",
      "http://www.evolenthealth.com/role/EarningsLossPerCommonShareComputationofEarningsperShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WriteOffOfDeferredDebtIssuanceCost": {
     "auth_ref": [
      "r122"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Write-off of amounts previously capitalized as debt issuance cost in an extinguishment of debt.",
        "label": "Write off of Deferred Debt Issuance Cost",
        "terseLabel": "Unamortized debt issuance cost"
       }
      }
     },
     "localname": "WriteOffOfDeferredDebtIssuanceCost",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.evolenthealth.com/role/LongtermDebtCreditAgreementDetails"
     ],
     "xbrltype": "monetaryItemType"
    }
   },
   "unitCount": 7
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "105",
   "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "105",
   "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222160&loc=SL51721523-107759"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e557-108580"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL116659661-227067"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(13))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868656-224227"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(210.5-03(11))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(1))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(10))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222160&loc=SL51721525-107759"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(12))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(14))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(22))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(23))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(24))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(25))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(5))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(8))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.19)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.3)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222160&loc=d3e1012-107759"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7(b))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.8)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.9)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3179-108585"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3179-108585"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3179-108585"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222160&loc=d3e1060-107759"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3255-108585"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3255-108585"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3255-108585"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3337-108585"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222160&loc=d3e1063-107759"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3367-108585"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3000-108585"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21D",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=SL94080555-108585"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3521-108585"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "27",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3581-108585"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=d3e1361-107760"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3044-108585"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3095-108585"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3098-108585"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4273-108586"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4297-108586"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4304-108586"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4313-108586"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4332-108586"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=d3e1361-107760"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=SL98516268-108586"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "230",
   "URI": "http://asc.fasb.org/topic&trid=2134446"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18823-107790"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18823-107790"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(c))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(d))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(f))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(1))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=d3e1361-107760"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(1)(iii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(2)(ii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-04(a))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-09(Column B))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-09(Column C(1)))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-09(Column C(2)))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-09(Column C)(1))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-09(Column C)(2))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=d3e1474-107760"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-09(Column D))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-09(Column E))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "http://asc.fasb.org/topic&trid=2122369"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21728-107793"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(1)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721659-107760"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(4)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "105",
   "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721663-107760"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.M.Q2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=122038215&loc=d3e31137-122693"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=122038215&loc=SL108384541-122693"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "250",
   "URI": "http://asc.fasb.org/topic&trid=2122394"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1448-109256"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1377-109256"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1505-109256"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1252-109256"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721665-107760"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1278-109256"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1930-109256"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)(1)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1930-109256"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1930-109256"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1930-109256"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "55",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e2626-109256"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1337-109256"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721671-107760"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125512782&loc=d3e3842-109258"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "52",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125512782&loc=d3e4984-109258"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "260",
   "URI": "http://asc.fasb.org/topic&trid=2144383"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "270",
   "URI": "http://asc.fasb.org/extlink&oid=124502072&loc=d3e1280-108306"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "270",
   "URI": "http://asc.fasb.org/extlink&oid=124502072&loc=SL124452896-108306"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "270",
   "URI": "http://asc.fasb.org/topic&trid=2126967"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721673-107760"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70229-108054"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6327-108592"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721673-107760"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6404-108592"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6442-108592"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8657-108599"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8672-108599"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8721-108599"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8721-108599"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721673-107760"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(j)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8813-108599"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721673-107760"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8813-108599"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "26",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8844-108599"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721673-107760"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8924-108599"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "34",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8981-108599"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721673-107760"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8475-108599"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9031-108599"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9054-108599"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "280",
   "URI": "http://asc.fasb.org/topic&trid=2134510"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4428-111522"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4531-111522"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=123577603&loc=d3e5074-111524"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(2)",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721675-107760"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=123577603&loc=SL6953401-111524"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=123577603&loc=d3e5144-111524"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=124402435&loc=SL124402458-218513"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=124402435&loc=SL124402458-218513"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(d)(1)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=124402435&loc=SL124402458-218513"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(d)(2)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=124402435&loc=SL124402458-218513"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=124260329&loc=d3e26853-111562"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "10",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=125513658&loc=d3e32014-111567"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=124268079&loc=d3e32787-111569"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "105",
   "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721675-107760"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=109237563&loc=d3e33749-111570"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(b)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "323",
   "URI": "http://asc.fasb.org/topic&trid=2196965"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721675-107760"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(3)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(4)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255206&loc=SL82895884-210446"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919244-210447"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919253-210447"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721677-107760"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919269-210447"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919272-210447"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919230-210447"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919230-210447"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919236-210447"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "80",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124267575&loc=SL82922355-210448"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922895-210455"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "340",
   "URI": "http://asc.fasb.org/extlink&oid=123353750&loc=SL49131251-203054"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "340",
   "URI": "http://asc.fasb.org/extlink&oid=123353750&loc=SL49131252-203054"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "340",
   "URI": "http://asc.fasb.org/extlink&oid=123353750&loc=SL49131252-203054"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=99380562&loc=d3e13770-109266"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=99380562&loc=d3e13777-109266"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=120320667&loc=SL49117168-202975"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=26872618&loc=d3e7436-122677"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13854-109267"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13854-109267"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=6388964&loc=d3e16212-109274"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=6388964&loc=d3e16225-109274"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(3)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "((a)(1),(b))",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/subtopic&trid=2122178"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(2)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(3)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "40",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=118172244&loc=d3e17916-109280"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "50",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=16397303&loc=d3e19379-109286"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "350",
   "URI": "http://asc.fasb.org/topic&trid=2144416"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=123351718&loc=d3e2510-110228"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=123351718&loc=d3e2473-110228"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "205",
   "URI": "http://asc.fasb.org/topic&trid=2122149"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=SL51724579-110230"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "360",
   "URI": "http://asc.fasb.org/topic&trid=2155823"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=109237686&loc=d3e17752-110868"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(1)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 5.P.3)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140864-122747"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.3)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140864-122747"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 5.P.4)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.4(b)(1))",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.4(b)(2))",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.4(d))",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.4(e))",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "420",
   "URI": "http://asc.fasb.org/topic&trid=2175745"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "440",
   "URI": "http://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308"
  },
  "r386": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "440",
   "URI": "http://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308"
  },
  "r387": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "http://asc.fasb.org/topic&trid=2144648"
  },
  "r388": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349"
  },
  "r389": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "http://asc.fasb.org/topic&trid=2127136"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r390": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123465755&loc=d3e1835-112601"
  },
  "r391": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123465755&loc=SL6230698-112601"
  },
  "r392": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S65",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359872&loc=SL124427846-239511"
  },
  "r393": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r394": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r395": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r396": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r397": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r398": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r399": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "105",
   "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6801-107765"
  },
  "r400": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r401": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r402": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r403": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r404": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r405": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(C))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r406": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r407": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r408": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466302&loc=d3e4852-112606"
  },
  "r409": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466103&loc=SL6014347-161799"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6812-107765"
  },
  "r410": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r411": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r412": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r413": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r414": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r415": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r416": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r417": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r418": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(i)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r419": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r420": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611"
  },
  "r421": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611"
  },
  "r422": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611"
  },
  "r423": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r424": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r425": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r426": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r427": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r428": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r429": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r430": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r431": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r432": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r433": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r434": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r435": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r436": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r437": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r438": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870"
  },
  "r439": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r440": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466204&loc=SL6031898-161870"
  },
  "r441": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466204&loc=SL6031898-161870"
  },
  "r442": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466204&loc=SL6036836-161870"
  },
  "r443": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612"
  },
  "r444": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612"
  },
  "r445": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69E",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495743-112612"
  },
  "r446": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495745-112612"
  },
  "r447": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "40",
   "SubTopic": "50",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123467658&loc=d3e12317-112629"
  },
  "r448": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "40",
   "SubTopic": "50",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123467658&loc=d3e12355-112629"
  },
  "r449": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "470",
   "URI": "http://asc.fasb.org/topic&trid=2208564"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(17))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r450": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(CFRR 211.02)",
   "Topic": "480",
   "URI": "http://asc.fasb.org/extlink&oid=122040564&loc=d3e177068-122764"
  },
  "r451": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=65888546&loc=d3e21300-112643"
  },
  "r452": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21553-112644"
  },
  "r453": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r454": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r455": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r456": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r457": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r458": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644"
  },
  "r459": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(19))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r460": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21463-112644"
  },
  "r461": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21475-112644"
  },
  "r462": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21484-112644"
  },
  "r463": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21488-112644"
  },
  "r464": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21506-112644"
  },
  "r465": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21506-112644"
  },
  "r466": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21521-112644"
  },
  "r467": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21538-112644"
  },
  "r468": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770"
  },
  "r469": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(20))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r470": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=6405813&loc=d3e23239-112655"
  },
  "r471": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=6405834&loc=d3e23315-112656"
  },
  "r472": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "50",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=6784392&loc=d3e188667-122775"
  },
  "r473": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123360276&loc=SL49130531-203044"
  },
  "r474": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123360276&loc=SL49130532-203044"
  },
  "r475": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123360276&loc=SL49130533-203044"
  },
  "r476": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130551-203045"
  },
  "r477": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130554-203045"
  },
  "r478": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130554-203045"
  },
  "r479": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130554-203045"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(22))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r480": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130554-203045"
  },
  "r481": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130554-203045"
  },
  "r482": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL108322424-203045"
  },
  "r483": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130556-203045"
  },
  "r484": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(1)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130556-203045"
  },
  "r485": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130556-203045"
  },
  "r486": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130558-203045"
  },
  "r487": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130561-203045"
  },
  "r488": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130563-203045"
  },
  "r489": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130563-203045"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(26)(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r490": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130564-203045"
  },
  "r491": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130566-203045"
  },
  "r492": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130566-203045"
  },
  "r493": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130566-203045"
  },
  "r494": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130566-203045"
  },
  "r495": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130543-203045"
  },
  "r496": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130545-203045"
  },
  "r497": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130549-203045"
  },
  "r498": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130549-203045"
  },
  "r499": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130550-203045"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "105",
   "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(26)(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r500": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046"
  },
  "r501": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046"
  },
  "r502": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046"
  },
  "r503": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046"
  },
  "r504": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046"
  },
  "r505": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046"
  },
  "r506": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046"
  },
  "r507": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(g)(2)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123338486&loc=SL49131195-203048"
  },
  "r508": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123338486&loc=SL49131195-203048"
  },
  "r509": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(i)(2)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123338486&loc=SL49131195-203048"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r510": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(j)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123338486&loc=SL49131195-203048"
  },
  "r511": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "606",
   "URI": "http://asc.fasb.org/topic&trid=49130388"
  },
  "r512": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r513": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r514": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iii)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r515": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r516": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r517": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r518": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r519": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r520": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(03)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r521": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(l)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r522": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(n)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r523": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(o)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r524": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(p)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r525": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(q)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r526": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(r)(1)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r527": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(r)(2)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r528": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921"
  },
  "r529": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=21916913&loc=d3e273930-122802"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r530": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "60",
   "Subparagraph": "(c)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=6414203&loc=d3e39689-114964"
  },
  "r531": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "70",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=49170846&loc=d3e28014-114942"
  },
  "r532": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947"
  },
  "r533": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r534": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947"
  },
  "r535": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948"
  },
  "r536": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "715",
   "URI": "http://asc.fasb.org/topic&trid=2235017"
  },
  "r537": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=123468992&loc=d3e4534-113899"
  },
  "r538": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r539": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r540": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r541": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r542": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r543": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r544": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a),(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r545": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b),(f)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r546": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r547": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r548": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r549": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)-(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r550": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r551": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r552": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r553": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r554": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)-(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r555": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r556": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r557": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r558": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r559": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r560": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r561": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r562": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r563": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r564": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r565": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r566": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r567": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r568": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r569": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r570": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r571": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r572": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r573": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r574": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r575": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=SL79508275-113901"
  },
  "r576": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r577": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r578": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r579": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r580": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r581": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r582": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r583": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(g)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r584": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(g)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r585": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.D.2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809"
  },
  "r586": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.F)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809"
  },
  "r587": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122142933&loc=d3e11149-113907"
  },
  "r588": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122142933&loc=d3e11178-113907"
  },
  "r589": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "740",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120384911&loc=d3e23163-113944"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r590": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "http://asc.fasb.org/topic&trid=2228938"
  },
  "r591": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373"
  },
  "r592": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=SL37586934-109318"
  },
  "r593": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e32247-109318"
  },
  "r594": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e32280-109318"
  },
  "r595": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e31917-109318"
  },
  "r596": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e31931-109318"
  },
  "r597": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319"
  },
  "r598": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319"
  },
  "r599": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222160&loc=d3e1107-107759"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r600": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319"
  },
  "r601": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319"
  },
  "r602": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319"
  },
  "r603": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(4)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319"
  },
  "r604": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319"
  },
  "r605": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319"
  },
  "r606": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32840-109319"
  },
  "r607": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319"
  },
  "r608": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319"
  },
  "r609": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(4)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r610": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319"
  },
  "r611": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32847-109319"
  },
  "r612": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319"
  },
  "r613": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32559-109319"
  },
  "r614": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32559-109319"
  },
  "r615": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32621-109319"
  },
  "r616": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32632-109319"
  },
  "r617": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319"
  },
  "r618": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319"
  },
  "r619": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(4))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r620": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319"
  },
  "r621": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "217",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=124434304&loc=d3e36027-109320"
  },
  "r622": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r623": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r624": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r625": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r626": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r627": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r628": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(3)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r629": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(7))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r630": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r631": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r632": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.1)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r633": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.2)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r634": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.3)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r635": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.4)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r636": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.C)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817"
  },
  "r637": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324"
  },
  "r638": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324"
  },
  "r639": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "270",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=109227538&loc=d3e44648-109337"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(8))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r640": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "270",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338"
  },
  "r641": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331"
  },
  "r642": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "740",
   "URI": "http://asc.fasb.org/topic&trid=2144680"
  },
  "r643": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Subparagraph": "(a)-(d)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=6909625&loc=d3e227-128457"
  },
  "r644": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463"
  },
  "r645": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463"
  },
  "r646": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1486-128463"
  },
  "r647": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "37",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=123455525&loc=d3e2207-128464"
  },
  "r648": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=123413009&loc=d3e4845-128472"
  },
  "r649": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)(1)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=123413009&loc=d3e4845-128472"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.1)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r650": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=123413009&loc=d3e4845-128472"
  },
  "r651": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=123410050&loc=d3e5227-128473"
  },
  "r652": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=123410050&loc=d3e5263-128473"
  },
  "r653": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=123410050&loc=d3e5333-128473"
  },
  "r654": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=123410050&loc=d3e5419-128473"
  },
  "r655": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "38",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=123410050&loc=d3e5504-128473"
  },
  "r656": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "30",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=6911189&loc=d3e6408-128476"
  },
  "r657": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "30",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=116859721&loc=d3e6578-128477"
  },
  "r658": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "30",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=116859721&loc=d3e6613-128477"
  },
  "r659": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=116859824&loc=d3e6819-128478"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.12)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r660": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e6927-128479"
  },
  "r661": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)(1)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e6927-128479"
  },
  "r662": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)(4)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e6927-128479"
  },
  "r663": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(c)(1)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e6927-128479"
  },
  "r664": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(c)(3)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e6927-128479"
  },
  "r665": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e6927-128479"
  },
  "r666": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e7008-128479"
  },
  "r667": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "15",
   "SubTopic": "50",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=6911878&loc=d3e8732-128492"
  },
  "r668": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "805",
   "URI": "http://asc.fasb.org/topic&trid=2303972"
  },
  "r669": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4568447-111683"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.13(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r670": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4568740-111683"
  },
  "r671": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4569616-111683"
  },
  "r672": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4569643-111683"
  },
  "r673": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4613674-111683"
  },
  "r674": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4569655-111683"
  },
  "r675": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4616395-111683"
  },
  "r676": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r677": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r678": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r679": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.13)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r680": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r681": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r682": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c),(3)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r683": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r684": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r685": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r686": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r687": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=SL6759159-111685"
  },
  "r688": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=SL6759159-111685"
  },
  "r689": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4I",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4590271-111686"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.14)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r690": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686"
  },
  "r691": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686"
  },
  "r692": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.E)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=120398118&loc=d3e355146-122828"
  },
  "r693": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "810",
   "URI": "http://asc.fasb.org/topic&trid=2197479"
  },
  "r694": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)(1)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r695": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)(2)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r696": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)(3)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r697": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(b)(1)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r698": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(b)(2)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r699": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(c)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222160&loc=SL51721533-107759"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.17)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r700": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r701": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(1)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r702": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(2)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r703": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r704": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(4)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r705": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r706": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r707": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r708": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r709": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(1)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r710": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(2)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r711": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r712": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r713": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r714": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r715": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19279-110258"
  },
  "r716": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=SL6742756-110258"
  },
  "r717": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13467-108611"
  },
  "r718": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13476-108611"
  },
  "r719": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13531-108611"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(b),22(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r720": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13537-108611"
  },
  "r721": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13537-108611"
  },
  "r722": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612"
  },
  "r723": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL120254526-165497"
  },
  "r724": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL120254526-165497"
  },
  "r725": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL121967933-165497"
  },
  "r726": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL121967933-165497"
  },
  "r727": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL121967933-165497"
  },
  "r728": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL121967933-165497"
  },
  "r729": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL121967933-165497"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19,20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r730": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL121967933-165497"
  },
  "r731": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(3)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL121967933-165497"
  },
  "r732": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL122642865-165497"
  },
  "r733": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL122642865-165497"
  },
  "r734": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906"
  },
  "r735": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900"
  },
  "r736": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r737": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r738": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r739": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r740": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901"
  },
  "r741": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391"
  },
  "r742": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28541-108399"
  },
  "r743": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28551-108399"
  },
  "r744": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28555-108399"
  },
  "r745": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=124429444&loc=SL124452920-239629"
  },
  "r746": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400"
  },
  "r747": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977"
  },
  "r748": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977"
  },
  "r749": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918638-209977"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r750": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918643-209977"
  },
  "r751": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918666-209980"
  },
  "r752": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(3)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918673-209980"
  },
  "r753": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918673-209980"
  },
  "r754": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r755": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r756": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r757": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(1)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r758": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(2)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r759": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(3)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r760": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(4)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r761": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r762": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918701-209980"
  },
  "r763": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "53",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123414884&loc=SL77918982-209971"
  },
  "r764": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/subtopic&trid=77888251"
  },
  "r765": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "848",
   "URI": "http://asc.fasb.org/extlink&oid=122150657&loc=SL122150809-237846"
  },
  "r766": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "848",
   "URI": "http://asc.fasb.org/extlink&oid=122150657&loc=SL122150809-237846"
  },
  "r767": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r768": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r769": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r770": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r771": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r772": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864"
  },
  "r773": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39691-107864"
  },
  "r774": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "850",
   "URI": "http://asc.fasb.org/topic&trid=2122745"
  },
  "r775": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=124437977&loc=d3e55792-112764"
  },
  "r776": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r777": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r778": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766"
  },
  "r779": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22(a)(5))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r780": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r781": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r782": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r783": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r784": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r785": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r786": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r787": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r788": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "http://asc.fasb.org/extlink&oid=123353855&loc=SL119991595-234733"
  },
  "r789": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "912",
   "URI": "http://asc.fasb.org/extlink&oid=123371682&loc=d3e55415-109406"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r790": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "730",
   "Topic": "912",
   "URI": "http://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433"
  },
  "r791": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "350",
   "Subparagraph": "(a)",
   "Topic": "920",
   "URI": "http://asc.fasb.org/extlink&oid=120155617&loc=SL120155628-234783"
  },
  "r792": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "350",
   "Subparagraph": "(b)",
   "Topic": "920",
   "URI": "http://asc.fasb.org/extlink&oid=120155617&loc=SL120155628-234783"
  },
  "r793": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "350",
   "Subparagraph": "(a)",
   "Topic": "920",
   "URI": "http://asc.fasb.org/extlink&oid=120155617&loc=SL120155638-234783"
  },
  "r794": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856"
  },
  "r795": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "926",
   "URI": "http://asc.fasb.org/extlink&oid=120154696&loc=d3e54445-107959"
  },
  "r796": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "926",
   "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079"
  },
  "r797": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "926",
   "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079"
  },
  "r798": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "926",
   "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079"
  },
  "r799": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(f)(1)",
   "Topic": "926",
   "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222160&loc=SL51721494-107759"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.24)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r800": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(f)(2)",
   "Topic": "926",
   "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079"
  },
  "r801": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(f)(3)",
   "Topic": "926",
   "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079"
  },
  "r802": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "340",
   "Topic": "928",
   "URI": "http://asc.fasb.org/extlink&oid=6473545&loc=d3e61844-108004"
  },
  "r803": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61929-109447"
  },
  "r804": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61929-109447"
  },
  "r805": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62059-109447"
  },
  "r806": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62059-109447"
  },
  "r807": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62395-109447"
  },
  "r808": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62395-109447"
  },
  "r809": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62479-109447"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r810": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62479-109447"
  },
  "r811": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=SL6807758-109447"
  },
  "r812": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=SL6807758-109447"
  },
  "r813": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(1)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61872-109447"
  },
  "r814": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(2)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61872-109447"
  },
  "r815": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "940",
   "URI": "http://asc.fasb.org/extlink&oid=123384075&loc=d3e41242-110953"
  },
  "r816": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(1)(a))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r817": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(10)(1))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r818": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(10))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r819": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.28,29)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r820": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(13))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r821": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(15)(2))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r822": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(16))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r823": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(22))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r824": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r825": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.17)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r826": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(19))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r827": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(13)(f))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r828": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(15))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r829": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(20))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29,30)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r830": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(24))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r831": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(25))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r832": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(26))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r833": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(27))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r834": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04.9)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r835": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Subparagraph": "b.",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=123398031&loc=d3e60009-112784"
  },
  "r836": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884"
  },
  "r837": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630"
  },
  "r838": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "470",
   "Subparagraph": "e",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=123599511&loc=d3e64711-112823"
  },
  "r839": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "470",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=123599511&loc=d3e64711-112823"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-30)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r840": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=99397103&loc=d3e6811-158387"
  },
  "r841": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(15)(b)(2))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r842": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(16))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r843": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(5))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r844": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(10))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r845": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r846": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(13)(a)(1))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r847": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(16))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r848": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(2))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r849": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r850": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r851": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(24))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r852": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r853": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r854": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.(a),19)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r855": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(10))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r856": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(11))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r857": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(12))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r858": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(19))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r859": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(20))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.3,4)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r860": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(21))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r861": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(22))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r862": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(23))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r863": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r864": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(9))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r865": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=116884095&loc=d3e14764-158437"
  },
  "r866": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=116884095&loc=d3e14764-158437"
  },
  "r867": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(c)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=116884095&loc=d3e14764-158437"
  },
  "r868": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(cc)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=116884095&loc=d3e14764-158437"
  },
  "r869": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=116884095&loc=d3e14764-158437"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.31)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r870": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=116884468&loc=SL65671315-158438"
  },
  "r871": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4H",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438"
  },
  "r872": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439"
  },
  "r873": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117783719-158441"
  },
  "r874": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117783719-158441"
  },
  "r875": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(c)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117783719-158441"
  },
  "r876": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117819544-158441"
  },
  "r877": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r878": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r879": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.9)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r880": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r881": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r882": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r883": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r884": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(ii)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r885": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(iii)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r886": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(iv)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r887": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r888": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r889": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/subtopic&trid=2560295"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226024-175313"
  },
  "r890": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "605",
   "Subparagraph": "(b)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=6486672&loc=d3e27261-158547"
  },
  "r891": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "605",
   "Subparagraph": "(b)(3)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=6486672&loc=d3e27261-158547"
  },
  "r892": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "605",
   "Subparagraph": "(c)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=6486672&loc=d3e27261-158547"
  },
  "r893": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "605",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=6486672&loc=d3e27261-158547"
  },
  "r894": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=123600520&loc=SL75241803-196195"
  },
  "r895": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "944",
   "URI": "http://asc.fasb.org/topic&trid=2303980"
  },
  "r896": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "310",
   "Subparagraph": "(SX 210.12-29(Footnote 4))",
   "Topic": "948",
   "URI": "http://asc.fasb.org/extlink&oid=120402547&loc=d3e617274-123014"
  },
  "r897": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "210",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=120413173&loc=SL6242262-115580"
  },
  "r898": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "210",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=120413173&loc=SL116631458-115580"
  },
  "r899": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "210",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=120413209&loc=SL6242269-115581"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222160&loc=d3e957-107759"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226049-175313"
  },
  "r900": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "310",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=123366838&loc=d3e3073-115593"
  },
  "r901": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=123364037&loc=d3e3115-115594"
  },
  "r902": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "440",
   "Subparagraph": "(a)",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629"
  },
  "r903": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Subparagraph": "(d)",
   "Topic": "958",
   "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99779-112916"
  },
  "r904": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99893-112916"
  },
  "r905": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=SL120174063-112916"
  },
  "r906": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column B))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r907": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column C))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r908": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column D))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r909": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column E))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226052-175313"
  },
  "r910": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column F))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r911": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column G))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r912": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column H))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r913": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column I))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r914": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Footnote 2))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r915": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Footnote 4))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r916": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(c)",
   "Topic": "976",
   "URI": "http://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663"
  },
  "r917": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "978",
   "URI": "http://asc.fasb.org/extlink&oid=123360121&loc=d3e27327-108691"
  },
  "r918": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "985",
   "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756"
  },
  "r919": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580"
  },
  "r920": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128487-111756"
  },
  "r921": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r922": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r923": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r924": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r925": {
   "Name": "Form 10-K",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "310"
  },
  "r926": {
   "Name": "Form 20-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "220",
   "Subsection": "f"
  },
  "r927": {
   "Name": "Form 40-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "240",
   "Subsection": "f"
  },
  "r928": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r929": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "1402"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580"
  },
  "r930": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r931": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r932": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "848"
  },
  "r933": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "848"
  },
  "r934": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "848"
  },
  "r935": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(01)",
   "Topic": "848"
  },
  "r936": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Topic": "848"
  },
  "r937": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "848"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e637-108580"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e681-108580"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669686-108580"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>159
<FILENAME>0001628908-22-000027-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001628908-22-000027-xbrl.zip
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MZRF=84&4XY#A DSC9Y=DLJM6+JD]&I^]\9F<%22H]9FA/<E:?ZW]C2QU#32
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M>SFLQ>V,\F0!_TRK6?K]_P-02P,$%     @ (H]75$7H[),E P  > @  !4
M  !A,3(S,3(Q97AH:6)I=#(S,2YH=&W55FUOVD@0_GZ_8DIT;4_"^)6:&(K4
M Z=%)20B[D7WZ;2VU["MO8MVUU#WUW>\)FFBE \]Z5H='U8>S]LSS\QXF3R;
M7\V2OZ]CV.JJA.L/?RX7,^A9MGWKSVQ[GLSA77*YA&#@N)!(PA733'!2VG:\
MZD%OJ_4NLNW#X3 X^ ,A-W:RMMM0@5T*H>@@UWEO.FG?X$E)/OUM\LRR8"ZR
MNJ)<0R8IT32'6C&^@=N<JD]@64>KF=@UDFVV&CS'\^!6R$]L3SJ]9KJDT[LX
M$[N3)[9),DE%WDPG.=L#RU_W6.Z&:1 4PY&3G0?GPW"4O_+"X7GNC5Z%HR -
M_W$1I(WFG8_234E?]RK&K2UM\T>AM]/C \OU-G(=Y_?>(SM-/VN+E&S#(X,6
MM87 VH[J3)1"1F>.^8U;C560BI5-]")A%56PH@=8BXKP%WV%#%N*2E9TAHI]
MH9'K8G(C'HYH,$[).+U#YWHMI/CSEJ4,N?('[L1N[>]JNJ_LIP-SAPAL=K6Z
MB5<)7%W 8C6/KV,\4%S';Q<W2;R.YW=S]V8VN_JP2A:KMW"Q6%\^+N(>/G97
M3I_HOM.,C[72K&C^\W8$WZWZED(FN&J'7 O06PJ,9T+NA"3M"D':@*0%E91G
MK0K6=,.4/BIO-&Z%69"5&(#O^Y;G>J%S#JB[$+*"&\L'PO/37NKHY@3A:-CO
MGKUAZ ;&S8@HN:,'$?&Y %%+Q(4HM8+<K.8%365-9(.#U3>+V$>#$C/BPAXK
M*Q@G/&.D1)*/$%0;+-Z+LH7SCI)2;_NPX-G Y%=UJEC.B&1(^,LVQ/.SD><Y
MXYFH=H0W1G+'?QCC5DV+@F::[2FGRH1N7SXP=L.Q0A8UE?AQ:HG74I0@]E0^
M -?5U>(FNQW%Y/B$S.LM4_"&\QI-UL;DGA37L=Y#(:1)UZ +4)XC)W.:T2K%
MX+YK.'$'/SZ0_W*._R?C__PLP):8$]DJ!=.Z;;(_&D,BZ@SI7"ZOX8=6_-<4
M<IDM*>%]^(O)#>.,G,+\LW$]6<N3,_'P#MN)[@:/NA7>TY.W6BJT%E7D?',A
MJ1)EK9^ZG&S:H[.[D\V_@^E74$L#!!0    ( "*/5U37@P'O1P@  /HK   5
M    83$R,S$R,65X:&EB:70S,3$N:'1M[5I;<]NV$GX_OP*5YR3.C"ZD+-]D
MQS.)[4X]IR?)I.YD^G0&)%8BCD&"!4#)ZJ_O+D#=+#F1FK21V^1!,8G%8A?X
M=O<#B//OKMY>WO[R[IIE+E?LW<^O?[RY9(U6I_/AX++3N;J]8C_<_O='UFM'
M,;LUO+#225UPU>E<OVFP1N9<V>]TQN-Q>WS0UF;8N7W?(56]CM+:0ELXT;@X
MIS?X"UQ<_.O\NU:+7>FTRJ%P+#7 '0A665D,V0<!]HZU6K74I2XG1@XSQ[I1
M-V8?M+F3(Q[:G70*+J9ZSCOA^;SC!SE/M)A<G LY8E*\;,A><I(<\0A.CN.D
M=QSU3I(D/DDB<7(4I5&W=_R_&(WLH'CH8]U$P<M&+HM6!C1^/SXIW=E8"I?U
MXRCZ=\/+79P/=.%P,(.=PY]!QXJFD@N!_K44#%R_VVL?'Z(Z!_>NQ94<%GWO
M9'@A"X'^]%O=;AN%&F&,J9Y4*VWZ>Y'_=T8MK0'/I9KTG]_*'"Q[ V/V7N>\
M>-ZTN%@M"T8.@J"5OP$:CP/[QW%P[!CU*%G S-$N>7=]G\E$.G80M^-EUV9N
M_WDF]=::]&PO/HK.5HR9FK$PF2G.'YBO-'.78)P<R)13F+!WE;$51RN<9C]!
MZM\=1%VF!\QEL//._,1-P@NPK;?W"B;L5>K(\FX4=1\!Q9I86._6_RN+TS3Y
MT_U:CZ6;)JZ&R]AKQ=,[]*S)4K]L$UP5[I[M'9YL!+1E)S[N^U(&\-ED5=%R
M B"AKS0_<7OJQU\_^MGR3$4A"]ZPC(^ &1A)&&.Y<)FT[%515%RQ]U!J@\@L
MV/?:Y"R.6O\AF%Z/M*(*\P-PY;(FNRG2-B[MZ>-+N\D:_?T6N[MSB_V:6UQB
M7,]\PNX*/58@AM ,:V["8@N-)A0:^0..P&7!>#%A5>%,!>@!,@I/+A %G.7X
M9"3B9, I?QFF<^D3LI=;$2@@!6NYF9!(SN^ ,O5<I\5W HW!(95G)B&5LU0:
M9"(H5F!WM$2 8>-,IAFS%?W,^X_!0*V$',BE54A9B/V,)>8D [;$2D&CD]X2
M3=,"W1QA-\&2R>(T; 'G@Z-_")P/G@Z<@0UD@8 A[,T!TD0LHS@VFX5V60PP
MN056(8M450)U(@@7T-!$ $NC)JQ$#!'\*2R4FN.[AI9],#2&D/"LODD2E4(!
M!+5&Y/GAK+<GY39C Z7'=HIX T-IG2%VP^EEL!NM;"X UTZ-6;'V&W97L=O;
M.>S>+BWTL[V3;GQ\9FMTUJ2)4I<>(.<%LV]?>!3<,&[ XPWQ(Q,%A L&"/)$
M29M1#Q++,7-3]J9G(6VJM*VP'^5THU4 7FET"@)?6[:/.!. P U@NKY/,UX,
MP?/2]Y5"B?B M^+#?0A6Q(<B/(5'24RZ"( G_8QRZD(<!%R2+1L/-%@::( #
MD9\/HP,EB+ULRRN78$DQL#W@'XF<G0$\WQW Q^WHF.;A"BS.%"Z\K]N?1F63
M*$7**[MY%ZKM"2#"ZI$"6]"50068-D?2^F2,4E!X/;0KF:?QQ5)@0'$/V9HN
MS&'7K,L$-4I,Z6B+U4H*?]IBJ\1*(;F1Y( ,I,87IX(T59:(A@]RZUF)3]W:
M AKDL%10IY)CK*25XE1QT"UOQ)RP8(] ?Q99&_Z5  EB4<#^(+Y&$=CUF$AV
M)R;J(K <$ANGT97(V#P!;QP@&%0C*0CWW.J"4Z7A%F.&:#@% S=B"DP,%<D3
MJ:2;$(59-RR%J<>PAV>(L"71!1KO"]I][5!9F1+#PWK*E:;:"&^ )_1#*)!)
M*8P2;(&2PH]$<+,2(@'#5)984SX>"_\$Y*>[@_QI-;@><57YE$FX@,& #O%&
MN*)V#0^>T:,-2D!X7$^-/=*Q(Z9O&PAXHBOWN 6;%"D^DP;:70P^O;EDR73?
MXH,7PDR@/1ZH-,"WQ+T$7[$[\)TF[@",58#1:4G-:7W+6A1OD:Z)G^@TK0S!
M:($,K-&::^OP/9UKHRZ;HJ)?*^02J'I_N<MS2K*5P13Z0*XV&;>DX(]XZ/3'
MGP0&BUX$>S)N9YR)DJ^/'!"^*OF9J"O&A"EY!ZH^[WD@W_SLR?E:T;+K>]W#
MG8N6/[S7]4?38AIKS7GBI#R^B/=Y#B7<;D&D5MC]S#J.#-]I8V?<Q;] E7DN
MG0/X2)5*-+(C:A<2[?-*]C$VL"A8*CKX/^TSIJ$,OU82S?=A6Q7^4Y9]\6U+
M^Q2VM*\4,E><*_]=$FVBHXU4 J*L)B*SK>48^!TQB\!D/;?P'-P?FT\/!+?"
M;KT+#,=!:S(N%]C1PBSA/HKSFKEC%P0K$NQFH#<6N8VM\ARWLK^!=Z8N<6N/
M3K=,QE_L&]"N@W;W]IROD*$,#":S)B((? I&#/H/)C58FZ',RV*DU0BHUA=\
M6'_W,776AKQ4>@+8.LYTR--\*100NE^$ K4_G@27,Y[S^]2Z/4$L@VGA7"M>
M6NA/_SC#@E(J/NG+PL^8[W2&.!_*HI5HYW3>IULD(RI,R(YJ9/GA0G-]7^4T
M;I_V>G1EQ2%<G9@.7-]F:?O;+!TG5ML.VZ>GIX^V1NWXT;:/:8V/VU'WZ(NK
M[1ZUH]/'F_^HVMY1NW=RN)':CI_?,,>XBK;DQ<O&0>-!0NAWRWL6+Z<#0O[#
MA0QK^-?G W^[Z8JVO+ZXLQFP:_>?N&??0V(J^KK;/6C2K;+NW\R_9WL]3%S^
MERU?<MG"T8C<W!+62WT^6[3.BDZ7?91E_N2:36?O*:W'&YZ'#S]/>36>TH3?
MTCW0>L8O,PD#=GT/:45G9NQMV+E]UMQW?"'>\N;;XBW24H<[M/WP[68$*_=*
MYT'@JWPT[\(3C(3*K7;YQ%74^C?<BO7W<R]^!U!+ P04    "  BCU=48/J#
MS#\(   M+   %0   &$Q,C,Q,C%E>&AI8FET,S$R+FAT;>U:;7/;-A+^?K\"
ME><29T8OI%[\(CN>26UGZFN;9%+?9.[3#4@N19Q!@@5 R>JOOUV >K/D1&K2
M1FZ3#XI)+!:[P+.[#T"<?W?U]O+V/^^N669SR=[]^_N?;BY9H]7I?.A==CI7
MMU?LA]N??V+]=A"R6\T+(ZQ0!9>=SO6;!FMDUI;#3F<RF;0GO;;2H\[M^PZI
MZG>D4@;:B4T:%^?T!G^!)Q?_./^NU6)7*JYR*"R+-7 +":N,*$;L0P+FCK5:
MM=2E*J=:C#++ND$W9!^4OA-C[MNML!(N9GK.._[YO.,&.8]4,KTX3\28B>1E
M0QR'/#[E8=+K0=J'D_@T2 ,>G'2CP6#0.^'=_X9H9 ?%?1]CIQ)>-G)1M#*@
M\8?A26G/)B*QV3 ,@G\VG-S%>:H*BX-I[.S_]#K6-)4\2="_EH34#KO]]O$
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M@0 Q.^LI.V^K_)_<QH!S\^4(2T3%!0-<G4F%$;1&I&RRJ,SHL:I4]<:@TNG
M$U%)'I\9V6IPUN4BRD$7J[V/)5;J0'?'=15\'Z5U*^GSZ&JKIT@QNM:+U;FH
M7?2B,4!2/44U;QZXMS+;LA(L(P85HM$2V0IXSE'94 R$ZE@W$;)Y6&YBKKYZ
M'FGQ\!A=S16*Y/@FI5(E.D/Q;<;%=:&=;V=3Q]6C'URV/E%T5C*85!-ZR3*=
MN!%GJDO:;A[ZMSQ\NQ)4C0Y!.5^T#P3!VI2J=]EIY20C"M7<WNX?VY#P+;)^
M>;NA:,FP*EIG.!8HK+(8=U"E>L7@Q;HWAA&K&+Y='DRADB=V1ARP @HZAFP#
MM1Z;.I5<<7-@6IL8?#/F%DB'6C(Y:\!Q2%&SR/7JM6CUJC<'QUL=OET>/J8D
MUWKN*%L1R.9(D@<7- ZU-37'C<'G]H9OEP=.S*P<&..J4@#:YQ2=L[90S*W-
MJ=\8<&YA^':)H4D00 =:$L0*T:;,2#;YD+**QIV7!&P"*IT./,DW_^4(VNQO
MFP>&HI2UN;8Q75]5AP;9E])'8EV&U5W5V>O0P-%@JH0?F]!ZZUTU5C%WR'K6
M )=OLI?+?3<7%_]LX\VVN\SY9Q>GN/Y.IJ1=0H7&^]IV'XPF1PE;DHKG:,G6
M]<?YJ3B[2;_,F.[A]/C.:/ZOYC'?X* YRR^_>[DOS\??K^/)8YZ)"YV.Z[T)
M2VXF[SS TA_(;WXL3_4FMNJY$<_:.C+:[&T5NX5B?#9BO]J(L)>P&*FNOV?=
M+&27YYLQ455:5\V5P/J2"]7J..9*E-AU(%G[5F3OB=81[S[!P=O^[/A!?X2C
MTL?!(WFF_=GI?&.MCEAI=@:C4;EH2>QB5#FT]4>Q5LG("2-MOI6N&LOEV67K
MJ01LY/EJ+?_6V<@_6?NHBZ.2OP.[_,SCWN415[DBCO!H+L9N;K^[FTGM;2U>
M%%+QJ94UNFA,MI&30XFF(I,VWSS7!-(E9C:QM)*2:HDR1"7JJ&2-U657+% 7
MAM*6#NG^[)@G]]H8 I;9*0Y:7M2?+[GOBIVZR%YK]#&2 Y4L%N=<R284%[7B
M\AW:Z:I 79ZEIF@]E H9+8.8:/21@M*YE7I$$SM0L_QH5,9#_C 2<1<'(F[X
MV3'S3+"\G/K;Z4_+8-PR]NG=,_GC9#S%P</)^/1D^F'2J1TC3Z<_.N4K^\=>
MW=#[E/_%.)@=+VMF^:,;F8^2R.,H>-F^X\J!7[BUQ=?EG7KW[)G0M2.LHSC?
M%1 1JP8R'%LK4Q4JZX"M#GBSX\/%.>[BZ/6!G'J'!<-^9^* J+)$)E:OVL8"
M/F?0E1UXK"6ZF,WZNXS.@;<\RZN16SU!VPK"0 F0255@6] D"*!3AVJ[GDS&
M\L-G9T_$X3=7WZ ZF8> LX.S$_YL&/KD5#+@#P=M8HE74)8MLJ[:S5NC9E"U
M)ML6^9548Y?*-K\*W&?C.GN+$Y;C+E[N\!L>C.??N#>>WH1YKAYN =6+&=?"
M$D6]CFB*TS9'QS%F3EV NS4G>XJC([[L5;;;'_6'I\-E":RO(M*#T\FH/SN=
M,^E!_UU[M9',<98@&U.]UP2:<O:Z5D>EQAI<=:JCS,%W6^;<,'-01Y\K%DZB
M_@JH%,4)B>[S@2QH QU@SC>%F"MQ94/@_3#UW5Y\<=Z[??#UD]ZU1ENM"[XB
M>*-BK.)EM$L.60BR#4YSKR&GF_'C_ANF1R.1]$?]/. [TRG/IG?/=O'5>+(H
M*/^D? ^)]W"XF0Z&;:XA<^OXJ,&Q3ZDF)4'*&@^Q&-T!WMP.NC<7(3O)FU:(
MR+'6:H,0Q85(5-J"AE;VELET8='2FOJ;>Z?3V7C(DZ<\6 PZ'O=/-M+U0*G5
MM[T1R ,XDZ*!3%E7E/PJJTZ-C=P:T%LO],D(C+9)*Z>R8;"DHB%0CBQI'\"3
MV70*G<MCI@,NQZ/Q8'QT]K1_=+R9XR]M8T8JWGLP!KP 'W,P@7*-Z 1PWG2P
M+R8^[^+T\Z_=A-^X5C#L))6BDL2(G<> ;4._E)(+N:J:$'2P94NE;0BZ3@H_
M.FTW_ED2?WX.>?G5:;RSADQ1N7IKP+(0DR!:T,FH[$-P'2+FG;<XH<]'=NX/
M3P;C,^;YVH7]^788&T*+CZ?<)2ZEY%'2:@1DPK;G%T?M6]V=\9\V4%=V+?:6
M^OM=;Y5=VIR:TM5K%Z,&K6.J&>0_)@7)"V*F\U(%^:'KRON[I]/^B,7CEO^<
M]J?]R]*2-K;W>UL(O\.E/[V-@FYU!;YO*0(NEHB]LMSF.5-)*L38MD4V.I9P
MOJG$')/>%ISK>Z6/X/D+KW3UT&])N5-"JH7)5@83 &TU!77*%714 -^3==VP
MPKJ=49P;L7=?'0>C:L#$K2E=TAJR=>1BB+D&M65)!_/W&V&*3:UO0S&:709)
MJ*)#4"5&"12I$&R9THE9J!NA1K+16++@=/9@,XIVL\BU)%+.E%"^2]&P$3%G
M]3+&6UV%5\$"&2#ODW4JN8(4A&R2/F^YU>5(M7I^)6@;(2:E2V$ W;:'-C6P
M#K%@4!<-F+?\ZDA\6SVA\KR[:_0EIP(NI>B=*"<$R<!\5&8^&J23!,;8NWBQ
M;H1JP[C/Y(IT.N#]NFC?L\NSX[& _(87N]E^_B[/,;UDW/.1T&(B/#Q;K.NY
MAQ.FC$^$#R?CR6SQ9JL06\8@]#TA]7C0)P&-[K>GV.=/6/<[3OJMU=U%AZ'Y
M46=[X]F327^(D[/%PM#2EY<W2TN=>LKU3+P&+3\]]%OJ4A'9^ZQ#H0!:<[:B
MV5G7%!FT9'N+_9B5UVO'QLNPE&=M6?WDM'WQDF<7A!(H_VJ1UK6O=:>4\>EH
M-FWGG#X>XV@Z+SZ=+^X?'3WEPOTWC4QWSRY??S[^/?_VY0$WJ>8;4WQ/7S[P
M;TCTQ%.5HLCKT/K4>]2$1(6#(T)G['?!E'4! US$2!0K:X# *;;>8FT-F"N<
M4_#GT<3+]2Y>K!LJVVART]'$R_^N&4VN'OHMT41E%TI$MEBA L6V.8+5P!"\
M4B4O?(0V5FW9N.EL_,COM3E5M8P@5"V+V]/!9@\&%587M/$A&VT<P*?57DJO
MW^3X KK3!LF)V.39QPS:%41'N"!*$?8\&I5UFAN70Y=3^*E5T5JT D4'1= L
M+IC Q7AR6 #.Y\;3Q=QX6K_T>MUPE#PU77^N/BTGJW5.O#MP#-#2!\!LDZLA
M53%."-;7!8Y:H.Y=O%A''+>>_P9IJ75/7T>'?'KHM^R\ 4RHE>2U5,#&@&W/
MW+:I#IAB7?0=<"\?4LXV:O;%H;L+;GUZQ";ZF4C:ES:EV#:YC\"H,GEO.*$B
MM'R^NWVKA5O[_<U7DX5^:I-7:]S^PB:75;OM%;N$3M4< *G&DB13%1]I0F*C
M/UV>>!OE<-M0L5:AXNN4Z)*J#;-)AFU@=,&# I=5Q-:4*T.NT<3S39JV;/P>
MV/A1%<1'!/N636BB"]@JZUQER!@BBRPI!+I4YTQ<XU[D6X+=;)G-LAIG6Z-S
MUMD+L4!91"\AM9 UE-FX&E=09[X:IOW>?R./\+Q;X+/]QX_OW;P4OOWR>%T
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M'L$EEY--[%TU9&,U<8V7^%T'@$>/UQX [6O)R44@5H!@<V;M4' H7#7HT&T
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M-H%/0C9O )S.)L10(B;0<1Z'N^-0MI3\#CTIF)HJH ,("9RW.9/-'E1.P9O
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M3\7*S*ZLQIL7QF3$CLX>!/P'<NGS[U0I_$C7H\5/:2^:;_'7N'Z',WC07RF
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M,]5_92\_@#JV56>JMZGJZ^&/)E;KD%X)JEP<0[<=%.^Y5,V)-HV]KY*/5";
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M:BW,<OAGU)>&;1&W!?93 QN?@)K]""P#3533L._L')R^%B_+.H#K_'1OWC#
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M+PPY5&6A<#4?#15N]B0K4"%JX;QH&3<Q]?KH)4$-96+SJ?2!HT\'NR8)073
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M6J):&'<$F;6I>L> (88_25/SQWB,ZD5)7UI5+]/\)S&<IK[Q. )L ?CT7/%
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MC.?8+!\]>O>\FZ'L'KCMMGCSY+*B+?[[]>*_&7WSM#9!M2;6S;2%A.4*TSI
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M,J1+-+NR,L=*Q>Q4T/.1'5M:^GLB^CONLKS')H/D&VBVK,T_1)C+9 M':A@
MZY6I:(U"V(K = !956V6@QGST:5"[*R/Y-G(8:N;52GBRK"?11U#BY1+K-9)
MHM%8>RENR]0W(<O:\X:K2U<+8S(;[GBZTJ4V>J<3&Y5HWS)V53,-U4!'.6(Q
M@^X65[MMUJOHVI!&-OSQ7X?E/.VF4M!XJO(/5O:*>K)*R^A?*@_>??'F&YUN
M7C%05=X.*DB# 6Y.^->THO,0F]1M+]2HV4&%Y2KUN.4QS\MC3J:5TQ7C*TNU
M]9"OS.CN<PIP2;Z#26@'$RC+V',SB[DT/71K'JQ=*^OM&MTJRTY2FY/ZDMJ5
MCEUP&U5<.ME9)=J685A9YKM7H[V;U3D-&Z(EKF<EKNW[#;WEZM"(U@]9H/>B
M=X53VAHVNAFO[U=RM[E(,65X]R0K1KK0=>*0*BLR&A@ZU23FGDRU<J^;=1[_
MY)-*6ZXB9BB*BB&+8V6ZEF6&DQ+:VA&'>5J;$R].+7LST ]ZE;C2Z>Q:4&KY
MV!+1\Q/1^X<\(LLG(UWM-.6H&C+E"V&@@Q;#J5%BZ-VM\:^2"%6,=:J:LJK?
M:GH.)U'51^*?RN;X'OZATV7-7(NM^_H75)JDJ&KCZQFPC3%J97:X-EDN+[&#
M3]5B1['<._@%=9/-.M[__]E[U^8VKB1;]*\@^LS,M>\!V20E69(5,Q$T)=OJ
MMBR-J;9C/MTH !MD684J=#U(87[]S96/_2@4*%(M\8F)<]HV 53M1^[<^5BY
M4NID2 '/D:U/'0E1G"A:V>[8Y^\8_>F#WS2Q],QOK!K/N^]U3(_2RS-F1<D)
M.(^E4,>NWW^.G#"6@K& WE%Z:5=@5!8WE@([('[_-ZKUX:LX%@7&=9S2?'9\
MM50O(28PX??6T?BD$S+HDMOGJ-==9;/4QJ99FU#)%DGJ0'@5Q&CQ':N2Y9%>
M6"Z0DP6,(^?*F)'"192::BKTU]F"!!XK&9TBX#MS]&GN,+.?:?(%-M1CTC;-
M9'L\/D>A:;!3B-B &:+=N&3&8<,-N<TX7(=S/VSKO0SLF,';M3-ZLU'&EY[4
M$*ST&:?4-<@7$H"OWORFCGB1310/H]$MN3A1 DEBRNIW[!.8LW$<H(L[G2K7
MAGIC<<5^&NG4PIW3JH!"FHX _#"%H_I[Z[=<KRQ[.!5?8E8(Q^4"M(0W*LL7
M#HWS:<MEH3PODEL/I81,R1FL"<;T*Y=K* KGI#M[TFX3GU/D\6PE\WHED[14
MK&!O@5[E/*/)25XV8C"QMNT9>ES?!MQ!-OU@J0RVR5CWQG0M"7-.$LM)Z;54
MDLV+@>''5>E3YABG!RRJF%1@5DT[1!]"B&A:S2P\9HHZP(,LQ:M)J(J&O%/-
M=]CLW8K]M8K](92:DA??K,P?!H#"M*BZF55<1@/T+K;4:8DXC7O8I#@_D &7
M&[R,.':D"44._,:O:.B141^(36_I(:"0X @.D9VO;7&6;>[!K2S.NHQ*N:$%
M"TR,AXVG-P%B/':4LQC3-UDEWOA8J)R$BII,F-',<2,HKLE*)-[H -)+Y6X#
M,:^84UU'^=_IV7\2&;(^7X\-1PTM:I "MX!^0]B%-A<Z!&RGI_@9*'*(L9L_
MKK>_.6>:S@_<U3!":UA!OK&0GU0[;;6CF2^N;QB5V2()Z7E05X08H2>)QO>Q
M+V[KSL%9[21MQDI5.E C"5Y.1\$M8!9=T>;+0CYMXH^1I';&(%F5LE1D-LGE
M<+?/T\6G!YA^5SA/N8BMNW#OUX!Y(ESK><XD(2IU-VH]BA$0<I1SLV1W<-$!
MBL/O3H.J033]#RU9R@LI"!V&3>:-I:$B6" S!-+,D]14_U&-R-@%%3XQ88:=
MLVG,W\%%1A6O$O.RQ60?;"[S(VECT .XQ_K+A*%2@V[(S(L-ZSLO?V\O+,#R
MHN;=#HV>,Y,''^#TMX$8"+V,M%UC5/N9US'I)/MC?;KG 4*W<=)\Q*<S&Z;>
MH_]<(+@?_">O/*S=S(H4'$/._W I_\P WPC_I_5F\:9LQ<T=<!28Y[)8QIPB
M"8NJK@"+.OW#IRFX>">;TTQG0H-F1^K<!2\OP1P;+V"T'Q#736.V_)C%%+.3
MLD(?.<]8]% I3HZ]B')M7V '"94%=I7?WT5XS_D,L@2THX\V/KW,T3?%"_HH
MDG82S4"#Q36Y$>N2%)P]PRFYO3Q$"=&R: R?M8LXB@)!F"M#D5S@;4!HB"OF
MC.? KQ1 M%"3^-W,07&)82?^<<Y<M,$5V?6]LGP!7EZ&+D>IUQ(X^ <(KY0<
M@O/M[N/2:LLB1DO3-*R-I&311(&\=2G:X1I[DMB@_4"QUME+I!FOYR\#MW<F
M=)/KEO$N^F'14#*P=(VA=8V\R7-+G+N+2;R^&J<3YX@]^>7ZF_X?DSXZ94.P
MK:1>A%O7SJ(:3TL=IY:XL'/SPEJ7Y"L<0/)2 UMH KBVJX+#[ZN1N.:IY' O
MM_X<R-$EVS-B<*-)()I8Y//4W;B_BE'..,XDJT<A/2+9W#L8#Z@P=O&,NNQR
M1L0XZHC%9$_D(#*_&RD.VWW=H($^!"" 8F.8:85)6+N:V]2QC1IBR!+S]BA&
MZSUYIJ3S%DZ>J7"'0H:J J!QPT35>F>6M@#P\6\E>3I%D$GUG^])B.Z]+#OA
MGL#ZQL_8+/96S#HX*.DABLK.OB-A_D-DD^;6 E'/XFQ@Y.@Q.FBP2=)TP&:+
MVIWTBB9.LZ+  C3#O5E"D40S'C0==Y6*5-@F!^??DSPO+Q['.I,*$^S8VKUG
M!6!I*Y?+W(3CJ 94VG(K_# 9Q,]OWOI(B :-010/LK3>0+6[,\ SZ**W4?X2
MGK@+)B0WE3< XNXT]UEU#:R:I_+,DN"-Y +DHH[I"!;.M28\4\BO WE0Z%R'
MP$)\LAAY%1^[R.G6T  >CJ\Z[M@>]FKMZ&DX@7[$!4%B\/7!A)OUQ&6ZL"0Q
MZB>/OQ0ZYZI(V.N6"]JUV\+P\VSWR5-;++I\*DT0LVDNF*^?^YJ\7[BZ.9S\
ME<!7%S_INC?S#Q]$VWSZPAD5DUTN]=1Q$#@BMZ>16*_8^,*;+L: +VL0E\1>
M&T#R_:)H?SCM_?YBBTLD@L4<OXP')%F359A(2!3ZP8;HXN[H[PXD! SEO"H=
MP!:<=^L*,5[F-3JF]J[QV'J[R9SZ/)OB\" ?PAA>#41O01;7*R1'GU YMP(M
M[!-;L^J\E%Y"S(X;1'DK-M<K-J]]*S9Z<P02%/Z,&Q4:!-QB+]-R;=JZ)*IO
MWPK-]0K-&_)1%BPQ2J ]Z5:>M\4Z:@<KZD:ER"(KS6D&%[G)SIA68N':TVH&
MORB_**ESV^3G2IMWAR3JI6?P",%J7WAYH_)CACH7-PN[@'H!3!)T84KPMDG/
M_= ^/GVBS7\=%\/?!B%I0O@&%"O:IZVD9[5.LDHB,B),6[FY*1W#Z!U.&1;%
M2#"K-VOI>!>JD5[:=:;];Y$C:X2SI^'V3=H$(F^:;JMYKIT7S(ZY:\"<GC>G
ML"BX;/=&Y0?99N.?L>LS*"#.X]?227$K,=?N7G%EL\ 0YC6W@9DRE##FY\(6
M<2;LIL5H$ MP%<S3Y])</+AJA4>WOUKA=N=O+DJ6(,=V6U([3W8]P>[P8%]*
M+O!3B<#K9O.]A>D=7J>8U>+3V5, %VKN<FD7X\2=9F?2+5B:9UO_Z+4&TV!C
MD3;%''L2)!3#<I=9S1@,>4N"WE:VD 'DX#J2;RXT1K@AQIO@,5RZ'N>BL^FI
M]AB.F!<"\';;NN6.F :_,0OGC5[X'?AH2%@3M!+J7[91U1L0B&,)+-UL(,.G
MHR.*(L7"+;(/VHNQIW5!>Y0M[U0<]7Y(C'D7-RLR6Z+&&Q:#'WWXZ&8S+;X8
MS8@6KLZ >U_-U[=QZYH [:M=P!#ZBH^3+F<HLA'.Q35=#><^N6C+-Q&?H$T\
M,QKO< >X* C]<0D*L4:Y!JHZ/\FYIJ2;A-)LH<]PC5%K-+![_6"F57E"'PK2
M">UVJQ4SV15%-JF4F*!VS'IDEB^759#1BMZ7?G8T>K*"UQN;27\G+AWPP];G
M^=^2?JE'^SM/F#W>]Z+)#+==Y@ #<P-'RP=4>B>MXF'[.C%IK))RGTSH/CL%
MPI,+\'QO7^YG;\0F4OHN>\</SD/R?#UWGN2O)_1:29KB^9?*FFI+4BU*VYR_
MO #7^4!0G+?(V7^TN_?H8F__%P'QNBO#=V]DEV_.VR]LG3+5$1<LDJ<0"D41
M*&%\5U=WC]OQ_9N;O,3'<?';N@L0@U(5ZAHJ-%#2%<=F?!5(09M(JD\4JX4O
M$-#@CJ2HS0*R1S6;%K:':@NN'FFDZ#^[8$S<SK:0V\?G8U%8P:16W(>^).G/
M9QV^!0('JZ/1!L\6S<EFIZ@'F#KE<;"N?IZ,K8FIU6(^=WIM6TTKH3Y7^L$@
MIN-!L&^@4H\$6JXF:?>NMXD/9/EP5=6UTPI[+X,W+A=@?[.6KKA)UUX&_;N-
M"MTF6_[EL%C?J&&OE5]-I($]=4!J:^;<.M,;;B!CY[!E7:$EUC=N]V1W'&*;
M(&H_(XG5R"?]Y[=;U_&:L31\M>Y,NKQH1W6'72+51#^]48'+N ?Y:%ZXC[G6
M9,]C6IRX')3+L#N:A+!D^E[%7@@CMX)L"F%YL8I$;LTVCTNOR46B_^0.C=$S
M5-R=9Z](^F%NA?9ZA?8/,_=\Y<[J1L4UAN^0H^:R12&TKMY)UM9!N63ZLVE=
M@=J\/LE*10 T8V.'EYIU+V33PF7LW&IS=PBK($XRT US0;/[.#U%#>I6#J]7
M#G_M:@0;ZIS,MAL5P-NT5'_YKUL B#+G,2VFCYR*M&GQ]N!<[\%YJ^7NT05_
MH^(B3"A0WB7BCL;+761=.3WEA)>UFP@6L.KS[_9(!Z_N,RW4>P[K'RG'W!HU
MU+UGA-K LQ<ST*3,3\8%$N+7RN3.[0<0?8!2<FA3S"6=<-399*5'_^/=FR/$
MWQ%J-IZ5+\FO=!&]TG8+J]*K@B2L9:&NB "1B6_![#D!$].4MJIEZA/89\8C
M&C&;5$GIKMIW]-7#H[?]#X_>' -I%#>7;YS[T$2=6YD>9WT^>'<V.D'KG!AL
M!#HD+2 W?AM/',8!.WZ(I\63TG@0[VC36A!$EC$W]DS+\2KRX\NLC>AK4J+)
MJ$P>R"E'$ZT6H!L$U<XE.3RC5KJ!6V6-XB0BFYFX@N.+2F;3])F]Z.8O.I>P
M GA$&"BA(*[&L!$E8R2!UL6!MC_ Y^K&NJ K?R+Q%O[ ,XMLYI+%EAGAK)^K
MLM/VN5ZQZYYPT;%0<$!U-I,$W7NF%MKXJH0%]7>F-/N!A?/8D^J>(_!)2@1/
M]U5.MNB*61/KSEAM-C;+BQAZ7YU5W)J/KXYWGCHZ>AES\43R(IPX/("NU'W[
MLZ+OZJ.T"U1JW4E;UKA[^YDCH2BX30PTWDR:P"Z%]2&B<;>.E?>9 ^</)Y4E
MUEDD--A60Z9-- Y=9'UFIH@1;I",=^/W[RG_[A]1>Y:1.. )/Y?O&I>T!S89
MWX$\,I8T-&]A^B;8Q?%2^E7$9=[EQ2S)'<3MFCPAH>3$ G>>9Z+N]T8V2J^U
MK1,"D@:-D))^,9Z!,>I"-U/F8)ONC-N]3V  .01I>%AX)JY'&H%/[&%H :%@
M09$P7C:@H-;D;N%+SSPXW]<F:EX2M6EVEF8:]X@%(^Y=8:FGQ:REW9/O2K^Q
MZ=P48A]4W(C^*0W_,CXPI(AW<%E[4L=ML8-IG\=WMMCA7@(F;@U<XM.T5^_"
M=:'4;>^"/GK8C%<7+@TW$ROC!F*^\\T !6Q0D)P^WWC]QJG]$4>S28&>Y76E
M=PY,.G)!S++V=AJZ$T2.U&F@+HQ@ '0A"1FOFYDQ&S'";DFL;F/,[S.Z\I%P
MD$0N;I35X7MQ1H9MM,BD**LS[:O'5-%#L0'QE/FDU PTB3UF:S\FGW ;DL1)
MWS:(O E1/([XJEF3W31_Q/>C-TAM[\SR9IHOZ7/)5F0+CZ7UC97 0[T\K4HA
MOY4>!ID1&O",BLJ()VJ+RU2=5+)!J#4RP(TBG?@N_9,YMG8U/B:T@?UP*[?7
M*K?OUBHM;E9H7P?C(CAFSH,C5+5&JA.0-;+OA06_+V,^H%2=E[Y3#9ZQ%;/K
M%;/_CCC7.&(F?39O5M9>!794A(&B4&$5Z%%#R#"7@,FTJ! 2S98L7CZT88#^
M#;U%'9C,+TU%^) <Q]OC.5ZBJE[=EE\U^'=HH;%;LJTW%PCFQAM)8% "B]R+
M-"9#9M6=-(#D/@ QW;%T2^>2H) .2AI.%RN9=\SM9@%9?@'Y?DES@01 /@H5
MRI(K&4BJF;?8Z^.Q=1CO]#4$PO.=@=85-WL/:9&VY0T2D4.40\X(GZ=Q=#PX
MV:1]V>T4["0!;#HF4;#&IQFV0G>M0B=Y4:0"7-F(-<"IP1N.5KP4G6OI^R8(
M82@I"43P5C)B_ES0X_3L#R*AGNM$BTC&FC_ME1G&W4V4D,[W#$DR0ULYO58Y
MC5ROB&!&K_/3?'G#\MK3DD,19^V,)KU\XR(J(5H-NM3K33,:C"$1KB-ZOUU6
M27ZYVO(-3[I.0_U*,O27_SHF<X_!,//1;Z1+RFYS[N3.0QW>,T[FSZI6+B=8
MNK5,6D)ITIJ10V>UFW8UX^NYN&1GY;* (6DB6)$'3V1-J B,,"3<Q._=\ =1
MLRA!BN'M9,P^?[;[[-_'^,?3?^>?/']*?[ AHT:E*O(9'W(;_YR#>FZ$<2)Y
MC3/RDBQD='(</?+- NE_]_B)!WO[S\=<&"\(B4(JX@TDQ;%I6X)QO 8E-P_Q
MF? -$PO0-8N-2X=KQ0C4%5 X>6-%/ QPF'?\9)V1MA=<8%GP-K]198B2?^+E
MV-1VM=2(*!=) O0F<!/,L.QX>=  5UM>\H5HN*0\/"K.4FFG)@8WA$R;=.2>
M.&N12+_0LK;0<-,:;(U'1[[UYK<>$*7/G+FE]A)$RGO6GEHOL" LO?Z;RV4@
M;> ))"Z<T$DZ$>N.A/$U';R\[3++G]%LSY+T1M13_-Q%*^@ 4Z5UP *>?<MO
M( MCB5!Q5M".-MR[' *Z@U =0D0[,!O8.HGMA37,G"0()RL&F)U:#I%+'+6W
M)!:@6_(;N \?VD0DI<@)6$@@>_0=?O7:<Q ,."<MH-P0)-RARR\9[GFKW=JC
M W%1\S1I!#0$#!G""6)II*E>?##HM2S])]Q OK;6HM@S/?/FTD:# IQ%UHJ;
MC&9UP7VC3T2?RTP*89:HK,.@N=P!XA9;!VM* "H 9V$="11OJ,?%P%*,2^#"
M#M=.N41H/PS1@N$N@&M*-PBA7BT$$!!HA/B[YV!D7V(@4-B)*]T\MY;4#%;4
MWH,I6FK9U<NJ<5JN>6$>GUW+*"L$_F@Q 1 (K<H_NW+JZ])8!$[JZERTT)"(
MJ^8DX5%8UA]<UR_@6D$A*0J=70]%G@V/(%%L<)R!GLV5RXIE@E.EK)8 $(.*
M!Z"MX*I_^1;P5CBM>(-V-[>K0Q8NAIP)X)T1CM$8%7&FK=KII;0"W5)0AA'&
M5T= C\$*R7K9<?%BGRDBW,\B6B^?V/!5)#%,UA220!_,8@Y7EK\.HO[GL(J[
MZ'E+#ZH-36U1R1*&)_UN1?LP-);UCKU[HPJ_Q\<09D?%^+U(*T6F8MR_E%54
M@M4<IT8'8P<9 #U'<D&0L9EB]^TZ;YIJ*CTF_241S$\37M&9)!FBIE]VQF84
M662?,EKE + -1L+ '9ZE>S/[3"8J/?"I#4#ZV8H4"]\H&F)^S%%?33/=9_M4
M]+7^I$FLTDU&Z07@ZB\7B;U.Z;J\![;_A/LG![Z30]CB'#.\O^?K;3DZ[$YH
M"*,#\TK,X%:TVB^_'+%B>O4[^0!2,_/&U2?TC^-N,L;'XQ$GB\]/*QPRLJ@8
MQC8ABS G727F#^0.O<^R<C56RBS_A[0Q;D9R/<^1',3!( O,>9JN^#?,4</I
MCGZG\]W1VTV-V<NF6RRRR[5FYS?^V^/O=I^,:-T+07Z3DFE._?C1WD':HL]'
M^[O/_/?8:.9I'Q6D3T:'T#P+?-!6TP^[:V\B:XQQ?#S_?O'$9CXE*PX8:C@L
MBRP^4_!/^071*OJ7K/>ZM]['%RB$!X>/?G(K\=%W2 <-5Z)#&%TK!_ZX)8OM
MI#V]QRIWW65$\_(=.PZ:FA)?0UR-U@C-O1U RF5JUD7N2W0$CJ-I!7;,+;L>
MJCVR"5GN/<<R;Q)\,$<M:B>TZWCWQ"&"BVHYX><*YDC@;5?0DV>[XI6.'.W4
MEQIKM_3(T%=T)]MZTT@B&I.(NVWE7C$2_(K#!Z\%VEK5=WKJ5SP-G"33>5LT
M)4:WIUV;U^O9?&$/A/S<<<5MQ]8N/>Q@;Y^,@8P.S,S,DIXGH'\]/#H4?\S-
M44_$(=ALF<_$ VSTFP&+V71D I%1;O%%U QS[;#_PP\T"'C_[_2 OH:-PW=E
M8[7C5LVZ%.?%W ,Y)#B\"1^?AF-I5L$KY9B6%0T^J!/STLIXQ7E[JXN Y>&F
M[$R-\#;NWG#DNS>,WDC![IU>KPO]&IGK6=9,NX*\OUG>2'R&FUB0Q-6]I$?/
MG7P2^9/_V#W>M1L'41<2/.M@CN/U'2X%^N=3V.'.CA-G>J0.E"^,&LW18-OZ
MNFG?6$/H@\6MKP$,_&[OW^4>_+?'3YB%5VUQ>]F_/3U(_WRPQV=?ZI6SGL*(
ML2I:N^F)&'#Q1<7IGE%OX3($K^==X5/NB!(S*YN$4\7H%7+-!D3''+K'](Q:
M4TH,FFSAI,) T(T62>HU-1%.R\VFOQ_RM-(:R72_GNT^]MY(P1%O6ICUU(<<
M Y_]\'7K%G&"-HFKE:0X"3]:]SA&[Z,D2!GJU>U'[ ]9O.$__L_^=WLO+.C
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ME$3"7B&4%7-N)N5K,C9$PZ955\S2TJHD R/!JE[%M28%-H>=-' G7NX_R+U
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MG.;T9VZA?0;27@91?YN$1-(''.!C< "IJD\RZ&L)7 NJ05/ :Z3:]#TLA<0
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M4A+?[XWVDY?XK^X_6?ONP?(COOUB37.OD5ZR %^_/\F*]D?5!_\#.H)7:^K
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MOO=%EDI0NVQ<^(9SX5KS 34CX'.15:F&H/3X+DS&_*_8OX8=&BC4I4GX8CE
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M#=E_D>:8JM)IA\'$3S=OFY%*,T3?M8D:/REO$O7+:O.\$B%#%@@W"=Q_DF5
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M)L,*L34/9G"C.0XKX5-QZ>7G,,BE_ITS/K2=B#8C'FM@^Q("1Q.8Z:&/%B6
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M^9])PE_H+N^V)7MU0@O:3\-3W6^%$!'NQ$"C.-3"16'6=D7A3!RPU!"]U%V
M"-(%?(B0\*D<:;*KB<RL/&J)%G$1!["2/4C,:*EWYO"CQTFLJP&KG?50AY $
M"<=$JU U\LCENG$';D[75MSTB%NI,/T:9QQ@%*VOA75U6A^UC\>DL?HULIG0
MSHW/VXD@C],?*=E$C!92I$F 2T04<F<N]*@8^Q+4?_S&CLO[=[2!F$BFG5'E
M_&L-A8P_Z!*EZ41;;E5=H:6.I\)EUSKQ0N+FEZ]M]72)<U^B6SH\ #C?P-"7
M<IO;&[7U3C]**L"0WGZM;P47!&X(M$:!PR')XPI"-5OC0H_@:/K [H-2DF_9
MGQ%5>;]5I,RQUPO!2*^M2VO22CE"4/6/94"PQ_8!'<GT22DT<TPZMIP5=@"!
M4I]9\&](HVA5&[[[C]]$HZ2/#T?8-&0@:8G $3_E9T*S$E=S^>:+H3&EUHCY
MUO356I]NC[B-VW0;)I"G/SQ8H=24+"G>PJHL?"H% Z (&'EJ5VDW2>ZW;S79
MZ]>ENEE8H?4.TZL%AA,96YY!(\+_]E$E897>>_A_A):;.13\VT[8 W5+G9'4
MM@%VS)QH7*0H[^)"BD9:\^K/M<$L4_?2P-T2Q/?2WIF74TNH&M?+C,#<C)X.
MW:O)-4[7_FE&]HR<:@[#1_+CPRD<ZG*-09=]K,2S'T@=RQ%S$J^$1PKF:UJ0
M.<V6? SZI/=1*87&7^?&(]"RL/WN:G2=-KACI(G955A[;'A(IA?"W=;.GS#B
M;-I*,R_]17BMN&H?/0NL(%)/#WL&!K[H+6>2=Y2-B)NU]+L.&]0XQ"J3=@RO
M?O]Y]"YK&M@0PK,E'I.94?X(_)W$M9M^6 WW/Y'9>-(5B;S)--8@'PD:O_^D
M796JM).,<%E#5R^Z!02* 255Z,P),JJLX? Q'?WTC-T+V1KN$O4Z[B+X3KL(
MWH?IKAVE_2?:)2H0]Y[4U;F2[]/-,Y6^W8CACHU,9FQ1T;B3LT12^,_#31C5
MJ"5+4ZK<0M>R?HW::\75_\?_V7_Z^ 5Y*O/VW!(6P/32CGR5#-MWNT\NL5X#
M =FV6GZ_\XA_#=)O&!>ZL2!TPP/^\E_OW]Q05I"W&'99"]>),[^T!VC')"1:
MG]@VBR(!Q+^8^/;T8 )8KJ2QYABU#3,.]NC-B_^$*UP[AJ ./CBQ=Y0A/,9X
M2,_.;X)HT*=S*;G(A!:IK,J=R!E6OEM:=NBGG6J^@XN@E(J!7O=VQJ)9:QN,
M4$1<*"(\KF<L\:*BS<RF".UJ(C;)<[=V'7Q[+[3C!HR]$088%^$%+5=[GBS,
M,$T1,1V'$HH+2@G8=,%!QWTZJQ(CT,CDU"5!S(@N@[>CDVHR=;2[TI QU00F
M]S@8WV)B2ULY8[+9W#;6+OXD$20"H_2X8%.JM9D(CDS47]9["LKKJ;"%"]\H
MSK>F4#U<7+-&GGOX$MEZ-0,D38^0BH\QB+T2>?1QN"CBI=RL&#RU0>,\K/\=
MJ,9>CW9&K\%2MG^X._H-)<8_*DQNA_\S+1E8R\U:TRLK [@/!VG8S/B-1)I;
MG7'YJG!'04?=AQFO7T,':FG4\:QG8=:<;8?<LJ8(5Q2340F$B2&?'FD4D7.A
MT*\\5:B6(#TE/A7 4%T3M6>5+L%B5HS[]D8T+FW^JA@YTV6-<B,LLH_Y MG^
ME)G<H3,(&KS*BWU;(7$3?(-6L;;Q<V_@Q*LAF(CH) Z,4HVAT?LW4M5VN:7E
M>\R_?7;1ZWFD%M+E=$R7MU:?)RUQ$\XSB G@@!TM@Q1AC:T-/9SMW[."=7C4
MW^FP0/#]7MR6PX?\57F6UY4!B'\$,O$^3'8C9WC4BC4BJ28W&!"@NE*0BK05
M0+&BX[94@M_4;H>%RZ0 8F:Q-,19V IENRU9T7E5M2@-8C=;FJ>,>U]IZ+%T
MZ]OYUSL1#:@XRH,V1=SKFA,LM8O&:V%)B_"4U;G>41&>7,"4A@?:8CH\IN/1
MW<)T7/?Z!!9.+H%@RG$FR)T+@:W)M9:@<VH)T#(Z#R?KMTPB\4JXJ&(ZZ?)"
M852DNZ?3;KGB>@-2X[YGVB-N= =8-^>B> P<\SJL$8-O67U+Q/J(C.'LI.*C
M\LNK5R]'/U5DK1[! &;Z>ZNTJ>F6%H""S(@>]JXK<=_2591)M%28R:0 4%&E
MJ++_]<>??SL<O?HXA=VI+9>.DU-\CV\,:7EXI-&X-SY)<6,S/N#_^XK1B>C:
MJ#@6A;K0A?8S"!%=,_5.>8$L7.G8S6OTEQ;%TNZ*7.U+UEO6*LE@Q-*X#H\?
M>X9&3Y47X^D;)IZ=KWJ=RW9O"N_-:Y>>8RE.#(>9;^&9%!)^Y+XSM :/QD_V
M]D8G137!\ED49'?TJY+0)L$1S6!Y$C#A]F+R2_!Q6!MS374))8.T5."]6T6-
MED>3K$89$#OY@9\@8>'C:]7CK$'VM^ 6GA8GXI@]/<NR6=F)10U#G_M2Z+2E
MTAO3B.UA_FXJ0>I2K-9[BE_J&"WA19<G.X6;TY%&B<#ZP9(_Y1QA^GX'5]@-
M73KL5'_WXH8DEH;P(EFN1P>(FI*5;"UHCQ**Y1+%0S!BL./;#;B.#7A?VPE5
M!Y,.TF5B$]M-^(*;\ >* GY@(.IVP;_B@K]$Q*;A9,(KKA$TE2-="6Y_W]K+
M YC86/B7U.P=,JPW=S036LZLY12/A@(X)0##XY2^#+@'&7ZY<DHEI&$(7[5L
MKYBYRAE1J;Q4;")#$@3ZK<V3S*8-"\Z64:DD8KSPH__(%LL7-!;4'H7^$=QI
M(WHL<Y%JLWOS[F*8)+A=R%CR7*7KEIP?!\IDL[S6=C$<JN$.#DO)T0K\RV1"
M:\.G 7,C? ^HS]&$1NA;F&LTAXFCI=V!696IW17P5Q(6M26Q9)I6JF.!G9Y.
M]I<#Q"=956E[&1H6QB5:#$&#[<L4SX&M79IX3[F>:))G8CQR<+BKIX)"RZ7W
MG(%#Q\F.Z#LM-KRH)#O*[.!D'8<$D/7HK/.)4N!(#(PG!B31G3YVGZN&/M?8
MN MK<ME J2<5CIS7J-"Y'\K7DR2Z2-MY:[12.*(2J@?-=QJFH]'D*ORRJ/80
M;]>OZ.-CRF35>GZO$M( K?"6L"Z44U WAAPP]<?,U!AJH=2/C6H P3/1MT!O
MZ,4AGG3K4/#X]J*OZ),M&A -HT)F%.7\.\ HE+/0T#6TR6W1U&Z$!$YX0R.5
MDFMEJ#-1L.1@[T'-%!DI$2#]+%5:0VTO*HTVY] "6>"O#_\].F'5&B^8XR[>
M49PZ:!+QIY> </-MH^%@WX!2M+#U',>"-0FQD6S SGD^$RX''Q_@GF T_/<B
M46@=FQ?./_<BM:U->/OUL-H=06I.X_DG4I]\I@6>T4/0>$'Q[B#.I%N$8YV<
MQ(ZU*^--9.C9M*Z:9NU2' \+A<4#  = B9>RH4$Y!':!J>@D87Z(EM/'*T)]
MF!"#FT'ILXRNS*O:KNRP5_Y$ (3+4-7=S:;^75!WGWL%P-7985?G3D__2MK>
MY\9"'LH#Z5CNO>)N0_MKL6IHL:1 L1^G4V"7H-%3NT\81DG>:G=*UA)'XHP>
MS,.KOE]G3P,Z&NF$\4@8]\>C=^_?\C@>[^U_8*A_#V9NZF2$S(RT367X"NLO
M4JQGCGD^)$FA_SU'XD :X5I7E5D.YD$]W*<KX$V<%/[[1GQX"U(:-&WC0B0%
M?\(E_$=O?W_]<F?_.;V*/-\%H )<Y&V1P@CX93L1[MY(?[&MR-BD4Q1+J7J)
MGT!J>*EXVC0+"& ++T2$L-'<C&ZGGT%R3ZY72/$:D&[^<$Q3H.7J#4IS*XUK
M=[IE6$'!^48#G9.ESOVPE%AJ'+%=2P7\+%LUBN0D,]89<;5&Q 5&P'UU#98?
M'CZM<_1; ?L$&<Q5 3:(*0NK!F1-S3=V>6*_5G31JB6@"(-5=9(!<U=]B.]?
MZ:#;!G/(/WAZBM8,W!7]BRN/AY>N??S@T[57O,.N&CVZM_?9J[/*O!'N;UZ5
M)R[8_'S]B&'DXF@$9ZU!]8'Z=G6S-2"CJ-U0D<FO"4DB,MO4"V=E(N8?Z;RL
MGG&S=KH<3P#GK<<C 2QS64-^ A"H:T]+=,-=A1ZW@6R<:9%3^SC6Z9Q)QPCB
M"I]9$ ,7Q" W,4C47Y\Y1EN*234G_YI]*>X/!7T/GR$UE%57SN*;I377;,ZF
M)M SW*&>#(A/#4XOGTI92V*[64SK4[\W7&S\,SV=$XX7RSY[7;9=P2B.+&@-
M$=6R-=%;):02[3CF6C-!\3*CU_U938!OH#MGJ;6^M9O6B*(@7*,&^S)CZN6^
MEYCN++V?46Q<I05JH\2?5$O#AJ!B-R#'P>L(Q4!K&6TS+]+<]J=VQQP7H8_7
MJ.78NRZ?"%]:C*",HYCBA8J8T1 KS'I!R\@YT,9Z! G/$;JB@2T!T;%/#37*
MS$H7>\4G [_8Q*:#I[:$L#)/DI9;*4<5A!RF0:/#^\;3C(&<PQ[=N&*^8PT8
M)%3R[7K^]D+-V6K]LU[<2!GO<%_'9>.^MW]Y,<L;,G17W^>,0]_A'[U89#7I
MDAV][0?J/OB%\G&X_';WY )L:_K_,WNS?KS+'_VUG:U_]FQO=__)YH_ITXV?
M7?38Q[O/GAY\UE,O_NS1DR</?*Q/GG]WJ:?^E25!I($$#L+[GW]Y])=>AN_[
MO=$^)^[L>?ZK^T_6OGNP_(AOOUBS*M<JDU@XKQ_BQ$<@AIWY0_LE5B1\50\T
M2K/HNVAM1LXH9O;B;BT5;JMDB3YWN@]KS?:V:W;5-=M_?I6CB&#""9ME.SK$
MZ=2Y^?RB:2/W?D.37G-D>-(_L9,P^D:Q<![F)O;$941HTRI\&=GZU!K_*\^X
M=R.\LL#.^?_Z CO"/Y_><L']HR)3>J-\'EQMTGNC@;/*I8BW:L[?'0BZM3_M
MS]G?O=L]U7__+-73F^_&HW=/Q>/I5CRVXK%9/)X]4/'X0G;<G;@6WWSFI3@P
MY3LBUH^N*M87[.Z=$NLO;8_>4_%XM!6/K7AL%H^KFM3W13R^D*]XJR_#WS(&
M<'">E7.>8'I3@MK1-__8/=[](@&/RYJ5VV<\+%OLAP)PHZH>'<YK-( 9'2X<
M_\L#L] .]G>W-MKV$KY 0![M7C5TL160!R4@>[O/'ZB /*28_F&3?^;E>'>C
M<ON/KGPYWI>XW#9L>RD!V=_];BL@6P&Y2(,\U+S@0_(F?\[QUGP*A_(7$(55
M#\R-W#_8W7^@1N#62[CD3?E0H[E; ;FD@#Q^H +RD-S(]^<5+DFN**JS:43H
M\S ,PH,K1]/NBSVX=1@N)Q_;B,-6/BZ2CX<:<'A(_J0E(X6,FCOD'A99\R$;
M_<IUM@_,N]S;^@Y;W^%"^=@"R;;RL=4?#]NUE*MQ]'-VGN5Z:4I+['>9=#-]
MW12@7*H?F,NY=^7 RGTQ&;<NQ=?1CEOY>%CR<57KZK[(QT,H,O\E$#+]EN"M
M1]^\L08F+[G%MQ&%XF+-)M69^Y=*T&]+&?>M?L9#,M\>8M'XD[T'JEFW-^]E
MUNSQ0XWU;L7C4N+Q4/VZAY0*>..KXAY8T/_@H585;&.ZEQ*/;=G:5CPN$(^'
M6K3V$&K'?7N. 9[=;>WXC3SC(9EDO_STP_O__K\/S!Q[^F!SJ-L+]U(,9EL>
M@:U\7!2LN#)P\;[(QT,*XO_N6E<_N#KQ@RW"8ANHW8*VM_*QU1_;2/[&F;_,
M&[3GF3&H7]H7/S ?\O'61]CZ"!?!(;8D EOYN%!_/-0Z#[XG_\KMW?[K'K;L
M3-HT<V/R;KDL<E='W1D7>2,-*ZT/<,;=^(K52!, J[%VP)0^N%4)4*/TEQXS
MS^RRJZ>G6>-&)U4UDQ:?--XS;N')/8NGV/]Y3E=TL\B*PG=,=$EW=>Z.M*QS
M_+DZ+^G;DU5$7HLFR M'\S@37YC^\,M/[W_X[_\K@YB9%2 =CK5Y*&K]N+<V
M6@T>:6O2;'K*/1K1"7M:U<L*31"C5H9?OJWPK1&(M[3KM /<"#-I5=D5;5<[
M6LJB*D^D>:MTIM9FG=H8L]'^C[ZW*7Z!?HW2JY)T@C/I<1_=M&OE\:<=C9PV
M8XDNNR/I.GFRVAUM^S#[/LQ/;E4?Y@NE^MI;E7'?Y=<E.O]JC]H)6M="LEZQ
ME*$^Z2WW1*^;>WQXT8/>S[?2^4)U5O/1CVY2=UF]DHO\X-$8'6\/<-!KAZ_,
M*YS3YHK=4C]W>:ZWR^J31\]W#YZPQ;:ARVIBS:4?[C_;??KD@L\O_/'%'WZ=
MYSY]M+OW^6.Z@0$_>O3X\B/6R$7O(MC7W?U4,\:#I&,<CN,%^(M;V(_QUVRQ
MF83@BC.^6AO+N[YRAR?;A?NLA7NGMM)0_/!*IW"3D[BQH>,GUNK6!1J/'5G%
MW."@<*NOTB;TJE+XI9?\1L5S0VSBT;U<Z5LGW$?D$\_7S>G1EU<+=Q 8^;?J
MM!SA?YIJ<P[^FF&"=^/X/GIVB]?KULF9',(?\S(KN8N3'L*O=C7?I;4Y;A&L
M>M^U[KPZW9SAN^:RXKMQ"A\_O\7K=>LD34[AVZ6K03E^\O5.X1W44'^KRJP]
MI??^X?)RXNJ36ZS>;^%!?/+X%J_7K1.VGUR)=,7HB.;1N.)K>Z@:<DSM^#NU
M8(?98I%EL]'Q:;;87-?ZI5;D"_A-5U[R6WBF/]/$O>TK?>N$^\BG:H_HNW55
M%$-W\IU.YO,3OT>2-)]^(B5VT ](>4_]FO>&1Y(WDD:N=N8005=SGO@T:Q@)
MX&:<I*(O;(HR-'DYI?^:MA79%,A<[7D80?CQN]HUC$D05,%A=T+[05_>WQ]U
M99L7HU,:QI(^JA#/W*7OYU6-M+0-"\8<@ !3 0*,1V_JW;!^YUG#GX;1>7ZF
M:CX*TO<29$W5<H&!8)#'DL[.IZ-W15:6>$G6CM[3DPYG9WE3U:O1#U56SV34
M?^M*1V/>>XJ!15/830<S<2> +M"$IEGML)Y(O=/_RXH5_2(O>:A_9,TIO:\%
MO./E[M&N)@4QWC?3O^=T::Y&_Y$MEB\,^]![RVE5 + Q^B&;GM*<>**'==N,
M9NZ$WHK7&%9#1H]9_:/TV!'Z^J]534)XE-%Y)+<5,S\ZS9:N&/V< V> !<I&
MBZPAK8VO^\=ELT5>Y@P%0$:7G_YS5I]AH7ZP+QU/3ZNJN-MXC,N?Z8-^J.FF
MCC0/9-/A78M.Z.']6U>L(,G/HX,'^27!X 3TAE_+(;0)XPP"?T1G:-/;YO1H
M3/&(SE]'9^MGEQ4D@2Q ;[)Z>LJ#P-OUJ*V-:.#7&.3Z2(Y=B9_]CB/EE<\X
M4@7O7,V@!,R?)/_5&3V&M$(\I+]E)=+R&,<S#" :(L[&O_3LPV5-6H^>]1V>
M_-)-W4+4Y_[3:,I_5GEIFN\HUGSQ5/&AYZ5[E]5M"9W3CG[#69\X&NDA5 \9
M \!=_7(D XA?^425<#0H3! /3B<)-: Z<X57O#L^U%E!U<F##<V YSS2!_]:
MG867[28SN(0>>W>Z:FCP\GA:Y1*HLZ#*'I2.24-IMU++K$5?O);A,WVP)P+@
MYX#G9$5310]C>=]@;Y!\] [4L2(6Q_:BZ-SVWK6LW5E>=0WINZ&W'4Y;_B6]
M(T8=]K7!4Q7K3<<V^NU__)]G!_M/7T U_K/+)5V+Q_^>T0QHK#*%<3I*.]7!
M/#F<3LD*HE,1K4+Z"!FDF6'[SY]_-]I)QMQ;"3*/7(X%@%K] ?P0=-+JO/E
M-S[I$K=@G;;(Z,EL"/#*0)DWTYQ?R^]KUXR*/_)F6I6T$0_J6*[%UF[9R>R%
M8]8/RN.!6T>/F0BGGQC?\\/W*TO*2[?L2!3Z;\3=?T37 +E__NHFTY.N[M?E
M='?TS:%KR0;%OW\KHD4BS*8 KA$Q1BN(67;.0C?+5CMMM4/_B.35SFU!%GA!
M%\B2+D.Q]0-4.7(B_-GLB7WTRX%5L4D,+0M9^4U3D<U#1H#>H.5H&:[D5TLR
MINF<_>"F']31^HDN.7(!WL$%4-=@GM<+/[9362J^7Y<U#*PIK5FS=+"L\O_%
MB.AG,OB9?"UOFL[PV[2*![**>P>[Z8A3#="_?G-V85JX0 P4)Q^!PPF7/O\[
M;[)9CAN>W4EZQ9\=K?-H5L$MPP+Y!QS1T:''3WM/THXO#TJ/#$8!;T*%# 4
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M)BV[EW6%X&N/D@M9)]*'PQ_.R1?",S\XMR15.77"!45V *)''%VFS:&](M%
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M5@_OZ%\Y:@-$KB#7(3TP^B>X_H"*<;/MYG[-S7T;F^GF_IW4U;E  F)/$W?
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MT[,Q3YGG,PW3E88.Y-9,M^4X7_O4<%++,^ODBTE7PY+')8LM768KP38S;U1
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MCK;*QM;KEOP!#@DBOR<D>]X>(B='8\OKT\6&-O%NX:\KT67./+&3.EOPC^7
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M B@UT39[/V&Z>Z=7!+\7V46.D*0U6M\T(\./Q OL? JE)&KYY/SU/K8A'VP
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M0^TP3OUM;UC9I??'(]-:5UJ+6,J@GN\F@H#R31^U3V:<_%&-'8(:CI__VJX
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M+I1^)$?@^TDU,Y'Y&K,(A[42F[V8()^+.96US>MB,?K14D]Q)-J1=%Z,C![
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MNFY"]6Z#AJ[*7&_R]VP7%(8@)JI! ?DRK2[<<:OEN</OXRCAV!+.BH>^.W[
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MV"$VF0#%\L5"K_.:NK3PW]0/]!<2@CM;_2/$$JNOSL5U_'##17_+V)T_4^C
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M.(GV>&82"$?WWY/5=(0C'<WX:DA8?3)F*7B!.2#/E*<8BB(D;G%.RL7MQEW
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M5&@!9(<L/JID 1YEKI)RD$/1A>ONT-3<>Z=(9(]G$M<-H?G>+FH*R..3CSX
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MHN$..2//]>P*H-Q,CCO_WO.7_WKQE[.G7ZW0:K%MU@6PMCP_=<>=$L13XML
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MF,)>E FH"I^B0MS:WB7U3_"N6Y4J71]4AE'+]W[.@N2+]Q<"-P789N%W4*U
M#\B]WT;_@*_@NKV,8. ?9\'HRRRZ]5](#^=U.ENG07B[M'T=KH+"TD1"XXTT
M"I3%I ;)^"NP'6>$4W' &.XDOAOB?!;Q?68UC#"-K+#L1_OJ*&WY(_ ]7E1.
MORU]@.9I(:UDPSC'+A2L\ZQ@3I,._H[:T<(JJ5"&S\.?<3:)DSC0".028A2E
M.HFMCTCCXW?#?W^C2[7;KU)*XXRJ.MN4NG,OID3%*[A)S8<($C4A.-8BN*64
M2:5#Z8:Y:6)K>IK8?*"6**%SE?2NZBWMG*J9_IC%T9AJ=1)[318];X+< O*"
M[WZ.KC);''2EH!W[_ ;9I.1J/TE'(80#3:%.AY]@=527J8-$C\,26 1?BO7I
MDIXO<HZZX@ AN>4M:Y>B<E/3E>MXDF8$J" P;TM7E4G46M96<72YRI:3/NP,
M+])3E=EA]%&]#?!;N/A4<UZMP59SZ"LMFC49=!&FQ 5>73F25GBKEM1*;==1
M\%37&;+JR&=9!YM?C\V/GFDT'C>W+T&4@4XM3M+,4[YMR9TV/*8Z0AQLN=E3
M[68EBT.[HX.ES26!?W<*M[O)DBV_T48+: 6VJ--UQ8P&1)/B>1,6HNX/+C6-
M\JS56$W=F.I'[*3 9WW3QYA*.,%()D,*2^,PR84M/Z[CS +T:%B@"2H<?V5\
M,8('D2HPLF/X](OK5JB"DQ?2/TA!,ZKN3C<156(S)B5\#O<VU5^EILODHW+7
M$'V &["7NHG^[7]U3MH_=%C/[+ZD"N6_+$&&;?^L>^KWVB<OJD=N<!JI^M#*
MV&YY?RRH-Q4P_]=X7L[)0.FU>AKT=*,C3AZ.[%J0Q73$<9LCW_(NN10.7:&/
M(N"UPY";?HE U'D 5[?&<Z$\@QJ7WGV&1<T*U^^Z&9#>),U'GCCW]_55=@Q?
M?67'EDK>)?J53,DK<NY/P" WZ+."/\23Y]IPD@I8<'89GEAD80:]0B2/#&Q$
MX\<B>%+'S^ \?P6W87!36^*N:G[Y9L8V@VHD52Q+_N=@A*EM>,^6A^Q_/@<1
M,E&UTU.&S'^FS5F=$W]?JC9QV8?'9>'43D&7+>SK2ODOX2*[ <T2[%Z&R4Z*
M)CGA25-$N!FFH ;:Z54"XG8U0^?C:!J-OBBPM05!OZ%+2H57'=04#AN*1K*,
MNL"M.T6/P)<:*\RNOC.JFK)+),(#A@V[M JP<"@85#%Q4!!@4"?)45EHN.<Y
M3O*HG)>LG7G7J>I61W7ELTCGLVH6<"L@37B=8)D9M(**)U&1_QM;M5)DW5%N
ML34P%12K0;'C7DB]F9NDOJ?><VKCS"X,K,['!MI15!">J/*EV'LE8"2C8,9A
M 6S-3DX%<?SS%EI5N,M"0P/)QQDLJ@+IDLF7<30V00-L$@$63=:D63U]?AM5
M:&BX-[" R>M#^0.3&-$ T*5D<X2"[+85 '0+I3DZ\*EYNYQJ++I+HH.&9'+R
M@E0DMMONJ=/PTS\N?F6_GDDY4I4UC+ D5[7"*(L<<%=U:Z/$3"9@0=KP@K40
M:3[OCP;9Q6EDD0+V&Z<HI156(F< J1">O9^<"I3?.3_=4E'WU9LQ@*W4=MW;
M3, \#V9"*X=A!7U;L)GHPIE&,X(=>M"+!9 LM\U3(I&&O,N#N<YU"/)5D_()
M?'51:/K>>H[P50"?U.3XCX^_<=] ])?7=#OF9!?5:2Y2F"R"-"@@F4RNM=N5
M^VJ_*$)EL"%U&XQJ[A>.@>'1PTVT5&7B3J*EM?FK 0\Q<EMFP41 #QG^L()Y
M&-@]4#%[,IU=\^>2BL&=DPC T(3^*,*-:A&]>TTT8+U:I6[T& LMTC27Z2&,
M"WD0.9: JKA"592#$'FJ::OAWC#*8=B6]]&0QI)%M<X3SN[;R(/B)EBJ455=
MCBB;>A.D6W>JX=0B3!R[$;#ND2#07)E^[U:9U7YS\9:8$1\>ZJJI QHW3=T5
M>J-U7+(H2<MDI!K2F2Z#8MA)MAZ#D6:J7M1!S=5,F"XP[P,[+E"P"G4X1I-B
M#52 !P60Z@ZXP_W>]K6;K&\/0MDUV(IX!(W6@"?ZFBFIH/ZXMQ+I;#BJB[L*
M'ZH$/[L;N;X! W0",/YJ_7Y1*U,O3%O>$W.A<Z^N(H;DCLJ20)R5JG?$.$.^
M(9%TU'G+%&.13F)T=LO@ ^I?OD,%@EQG:IJ$#D/I6LH&V*;4Q:U.L7GTIL\[
M][U(-AB%,1XYZGS4?0LKQD_=7"JK0]5H%C/NY0B8%Y0]Y@.XMT)"UZQ RRG*
MBNZ/N^325Z1N[GU)TALP%2>2 V\:ZQG.TFQR:Y4:(&1R+2_=2MS;YWN(=C!)
M]09BF M^-A* &VHOR+I+_6"$H_GD/$E7G\V8OFD)"98TG"60'L2\>(,5TEN$
M8A^K.-A6^1"/2F."(GD,8CPGQX4EF/:9L+E"348_C8_OP:-KNW7(9[>69$$B
MBA&5G?G.D-(_36T#.Y!T#P<KM^^N7='E!8QB&\37>E?H4HD8(YNRPJPLC%K&
M0@>T*J18Q5<\Q-3H%E2FX5PK9:Y2.@PCP]!CN'XYYJMEXZ-!I/HKLM_IQDL)
M CTG[/6"5"UTE]10@"1PQFZYD>I=0ZR%+EQJ#DURS>4Q3#J. C8;T[V/;#VG
MLH3J\2013.,2RRKDFJ!F*4Z$,Y <U52 I,!0G)7H[\:37,[I/"MUIKA=2-J3
MU20 V #[>I#/CGA8Y&>,^Z[VNII2X*8A6FCR=7+,8'\PI#"PM$$B_AMN+6)9
M,UU)VU1 P[HZQ/(!BDN/L9;FBUEZ>]B>H0=QD]-_Q*G(HHWCALJ1:LO$"=@E
M@T]?3-&11XUV5_!?O '_80$!J4D1->C%+\6&93$D_(? 327:8DJP1=-@-O8]
MKD2X5<^8RH5 I#?J,^;*6KJP;IB'+75E!2?QK:3Y26Y$X3Z7_8]&=\Q)%5T@
M]'T6D[5L=^^B-H7*T'%=/0_R.,ED[PZ(PQ)"9PD4C(.+!FXLS&Q?+% [C?#J
M'0G8']O'D<HO=@H='S+A#5(KD(DBGJZT+=^ [E*[*.6^IFZ-EHEYCG!7!3'A
MTHZ*#*NZT/.HNUDIAN+\2EM,2N_F:TK&-U_4M+YXG#,KS5'T3DV-(U.2UN%Y
M%LAQ_=3P<\[:)_$[XO-MP$EI2(VOK ^W7#XHA[%0C_S-F+5Y'6@'4UV$1F)Z
M%BV)8MA2%T2I+$,".;AI=#C ?K_5B?[&*B$=2!( ^!.TJR2)-J=TU;]+.&!A
M[ 2.5B^FIKNX15LE@I!,JDVG/$AN<SX.9,Q4!)TYS74-V-&&FE)?387=@S.E
M#<I5OT5,*^07ND2QYR(S8+- )TJH(6N&:#+KU!W:;[_ZS+JU]"%FT_4G")H,
M>KW.ZG;.+IWG"95/IUD=S[:\\T3!BI".AFCOMW@#CJ:!<AU;X7[MO>6V1<9#
MY.;I.@D@JX2%1!W)>ETA0K1(%T>C-LN,Z]$ %@35&!K1Q])JKS+[ B(!6]%J
M68@7:*"%=AN.>VB[%1W%QE?0,03I.B;5\;FCBTC&7-WHI+YI9=H[G]$UR2@'
MW*!++@Y*M^9N5.$2+1^L$8 1:]"[BY3< V4B@D]ZK5GMN_RZ0G$C_I=L'D?E
M-,TU&7[ +H+@>JX\3T=L!M'^8%D6!UV(Q'S],OHD;8Q]%^4;0.<[A5L'5^6\
M/2BU>%8-^*-JD$"^&H2!I/*^",^1)9KRB#F#BT_VFVAWD4C Y6>W5ADCZ.R!
M1,FE6Q[VTF4&5YWUQI(>LTPO[EHHE8,6,A&#Y63I3:';1QJ$!K-99AK8$8X,
M/;U'*'XWZ)'F]E]28AYU3<PJ$K' 6M]=U0E6RW:Y'VX9:A219:BD$I^FVEAR
MODI49\Z -&NF>!E%*_K9#EI8D:K@-#Y%$RP##JQBS@L>Z!V53OG<O <DRJ65
M)/&;2!(D^7M,G,R\CWQ;LOCB9^T"_&/O)T5FI_FMW8)7V[O\0\*K'CUFF<9F
M#0.Z)V<[W3" =K'S8\O[(V$!3YL#8IIV#B,;ARM1?D=QJR_<YV>-_NG+]]2B
M_>]2.L(BHJR"W6^?=:>_T(0IIE$0"C"V:'G5W$AV[ROG/HC!\PS+/@LTTQ60
M :%3P:] 8<(2T\4M^P*^QAB? .':'?JP*"_'-\'-@K@Z*'[H!:"0!2/VKU P
MBQN'\W?HXR"K6[D8_DABEHX<"Z1Z?1"&"&_Q'M2B@(;A$:S&1N-@A!IY+(_<
MZ.LIO6'[&9N_4FYAQ 9*KIPL84VG<A+=(%$?TJ^\"W_[-:+NVSKU#A/ETH)
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MJ[9 ;BQUM=4TYG#?$\8AM_*-Q K6UBYOA&M?!@9UFEGJ'^?G'T$9=%P?->+
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M@\'"(V1L8+8T8?R.JR"/N0I%P)\XYW\CZC!@78G N],X+]*,"&OPZ>CG"$B
M.$],K3@9I]F<,TFJU4!<;9Y%09XFE/AJB@]'<38JY\AH(T0P_9F@A<*H"&(L
MU*M@"]&+[#J=&A;RO3R*MJS)P]5<EL"F]&],2OXI* *->-22-/F]EA@KY6B]
M#/D'L#9FP>_UFN^2DHAH <STKXC1,QB>4FHK7>0;GQ$L*8_?P3;F"OKDV,:H
M<! )-!9]%L$HZ;7PO3N*DM1T.)*H%NIA(CO2\M3>()(EPCN V '%X5]8.WQ5
M(O"/5 GA<X6'4"98M2V%A@0_DH2"AD;+Q583<<;ELI1O[^)\,"8 G&$CBT$.
MT&E7HH!/)L*F7..Q1/3.-(/C_%>D?FJ]Q"N(-O!BM21/\$44!!O6$<&\0?RZ
M4 53PL< 0E9^:^X@7J89V'JKJIQ"O)+<@;A;*LP@;%:L*EB_ H5Z("_E#^,Q
M@248;!202"BG;3DG!33^DJ"\2<M9R+<&W3"WW"V&6PF%Y2BJX\ JX?A.)]B2
M(,MN3=GY =>:("1?W::#GC"[A7M0< RYRA9>"YL] UG(L*/,K51JJJ!J$,V&
M>)IO[>4=) A4!<S"VP8'S05@)2!WK@*"[<!S6;NS-,0&^QKG:[;6^[\U*Y(R
M+M Q1EF*Z#WI/!ZA*A/"9F5<"C4/LB]1X1[YG 45@A?4GGDSA ^KG@2S.B$@
ME,-OU'P"+ER6<^<N#Q0C702/N#U. ZPXEZT3(161VJ0.9H#;B0A"O'J]YP@F
MS+B.@F:_3*'@"FLAKVZ-DIHCY#O\1E=@VPH7ES\N2EA7*9"^<Q"O+$NJ&Z:Q
M;LR^'BBD*>%AOW=0;LQ1DI*ZQSP I#BZ!\"O<H&Y6S3C\,W(-RI9)L(5YB$%
MDZI0>-P),=,*>R_/S<*Y4AT$@LP@\.D)"R<(O:Q7P!@3*L'-F#;+3]&LZK[@
M]S-4DBC;(SK"J%#@;))4 W8*;*)+C*7)*-, ?V?ZEM5-:6*I(TJ,1*%(80L#
M2ZPC.&Q<?E^SBZ2#16%>(Q]J3I. (<)EFDTB7@\^P>>R[C9XW"X0H!J4N2!+
M,]H7P<N-R:(F&21VE8C8.7:\6,PB\Z5=P*OI76$LLUS0IWY:^ZX,3Q6U^S,6
M$MIT!F_6D657:5F8&ERQ4O6P9#KB\8["XP Y:1)9J+0"VZ[6[F$=.-J3:C0+
MZB%+;Q!T0EN95MDZ53+FNOC8GAP6W*I6),9*A7=K:YT1&@C](B!#'N\7/#N*
M!TF:(SBE%O9POJ*$NJ^IR[!R!8HI+0P:9KCK7Z);U^@>ZY?;:_.7%^9K?"P"
MX @9&()>>9-F7QADDW\@)]'"DE/$]U80GZ2AHA"OX)C_+<O]3BXJ- F"69YJ
MNO#I(F!B8!*&X\<SA#@5&0(YC7(C[6J/H.$]A N%?^'M[; =*[@B^AQ_1I4-
M1Z0[C0(\2F2%:9@QB_.- VI9[0=K"]X5DZ!CJXD4N1'>4/(#!#:0X6FU9+?9
M@D%$"#S8@'%H,([3!HQCG;ZCI YJ$E4.)"N:^MRAMH.P BC0Q/H0"%##?6!K
M)%B591L;@K" 4%R.W2&F>V24IHHB@(HQ*E6N#K!L^NV7<FDU_3,][FUU4VP!
MP:"_VPV 6S"&VPM^19T\&,[U1R504=C8]D+%^E# FN*WN85[1@ F"K5#>.$X
MOA7;5,S+R00Q5%S]DJ!6$+9T20E O+4:U5<T20=9=Y4:7&<4W^@VQ:('[K5U
MLJ6'\Y-<XI_8">@D]^_C\M>URZ9YA-@IC93;[\G_SFV\%6RS"*W?E)+ZT7+Q
M?;B")03U/7OWB0[L)QJY*QY)GWD.Q>"7B,^CE77;U9D:.OCH%P:U"Z9(\IL/
MIFI9/PW8N&(T,U "IHP<:D(DIG,.(OZ %L&>C,3I[&)^E(L>93[)R/( $3$J
M.'"4DKI#3ABP37!*@6GJC1.Z>TD(+S2;I7*_N(U!&0 >#15TCM8/X78/5,J1
M1V%$[%P14<>I6+42],I<^8*TX4!:+NO/# P+;T.%&#U \D\EKG)+JS1PK4QL
M#-&A_YB\N>,QH0$+K ^V839]IF[9V5^_' M<:!PYV$!\NW)O=Q/,TA#=N#P-
MS$66(FG@!6/K%6G%PZ[Y)HSFZ20+%F!^H/6 T I)L6R?\-4'IA?#V#B\1,A@
MXKQ3TQ"<+G;X6<!0Q+C*;:&V8M5N;:E"[)J<^ZA;8E[GWOFD#IQVOT29N!\(
M4)!<I<9?&0L\&W.X"J6O./;D"=-NB&4/N,(<F]IM10F@4;!BR;># *J32"M(
MHF61K+ A#UDFP%NG\8(:H6D1=7QU>ZS%%<6N^=R@WIS(RXA?R0Y$"%GV\,J;
M&4:5Q9^"DX=O%887,;8Z)LHA)Z=.N0)S/)NB9[.6EY)V)*$]>PPX_VCYBE-3
M7A)*@TX54U1> EHF!O7<5;D$I:4IQ$AY&>IN2&GUTH5N-D!W2921BT,_45V5
M$^!T)C,AV#::CG[Q\I26M_95Z8?OV=OW.?A:DRNT<XM;WRK5\LQ8J3,JW\-V
M!>.NVS>"P$1>4Q-N"1X370JDBT_?AXB$3)[NX.O*_GCH]@$[33O82=.X(6&D
M6_@&DP!/( V*!Z9F8&)K[2NED"_GTZC+$G\J>+=VT@X(/UBY\?7PC!3DB0+A
M1L1:3/]0Z38C4BU4JV)2L_@KNBS15Z_@F&-$Q/79WT@]+V3FZMR1$QQ7@6]-
MTR].ZDJ9+=(\TH[0=?/@_;F3W@KBEG!X%1 AJKMQC0O\*IC1/N33""F\UX?\
MKBM3<);='"Y6[%:QLJ7PH6*%_AMD!'%$PP^E*PL="VX#KOW/I(VR[^]: C'8
MH9MC3>@]&"D]6<-\QYEQW!!F)D5G[&PJG*S\1#67P#A$S=0E0:0NZL:983DF
ME")H:%!W,H$A4U'/"^/!B(Q'M?8I;NG-R*^^_)S"T)@7P2>SM@NECL14 C'R
M6QX0_\6L34=-B:I A;2P)>(!<_#[1#A8:>M))/[$VJU0(-0J)H=&07 =Q#-B
M6<6!;J_($>U M84?VKOIW]%(QT!JV9_O X7U"OQ<%O!74#^H,SM%U!BRGEQ8
M,.T;L-IRTR1U#%P5R]/(V,#)B.Z=6$9,C'+2#38LXHA[#FO3QAPY?<I4$B13
MZ^\RB_,P-CBSP8H+QU..>W*6C0P 'O;!Q5_)N=>)79R?M!:2U&ED4-TB.F-K
MR<7)O7BNX331G5TFE(V@J%C%25\_&HDW,YK1,KOM7O> C])Y;<?>#NT'4;C:
M5OBN#(:;B&F);>U43J$"#289S\'Y%=>,KUHLKSS,]B#L7\'WZ"8LNBGS'Y>U
MBM/A[N1/]FH=)0C/-)"FEMSU'9MI_V&'W[1-KP\]#FY=W<9@M\9.N]/JZ>X@
MATOLOW0A 7%JF0BB.6%[.\8!ZD+* .7\*)+G2IZFB7*=;I(:9#_J&S\C!GN*
M:#3E7KQ@]I(RKS2V'"@5T &F5'94X\ELX#XPIJ\.F;F+!=B%=)<1EY3%E(2H
M]-:!CRP \"O+M [)$8'Z)-D5A54%X#Q%(J22X3..QP7%KNC2E<7#@U<17[TD
M2!XR>WXM>G_')=#D2Y+>S*)PPOE5)*LDG<E*WS]@YJ4T47)^E(FU@<H,)',)
M3OZ)Z6%6+R2X![3)%L,?Z9/@\&KNY&FXB9DQMES$] SD]%D\CUFX^W;T=TR!
MBFKZJ?,3DGK!C6_ZPLQ,JR/J JNJ2 )X)_>S:_(<3)[#69/GL(X^"0Q#C$.)
M@]?*(!6WBQ%&^;HR)LJ!1R]CB(M92@I::ABB<WR32/6'4)Y,JU>6)5]5U@2Y
M=DCH<6(1CI]Q/V>,@(^*2E69OH[8=UM3WW; XE#YUSWL>LF^9--Y6XK%(FE_
M&N=:!0K!3$!"WF!;>73D8^--Z=@JS;Y__?7")_U .NP:_S+Y'RDV1B*UA0Y6
MVX&2BKW"F7KDGKJM&9W,,16L) Z1SIWLC,LY0<RV;$MD0O),9"FF[ 7*'W]N
MMXM%)1[U/ZM5Y1^MRQ98IABMF_GLI6!W6SHB+[FE\4A_+<RMTUVO>)+4[F&*
M1)"BH8K?"%M4+2VR5=>S%UNL>Q?8N=7[4=+@P'+@Z\!G/Q'U(Z5P!<9):)_J
M7\#Y<3@"1TQ40]B1Q"5I5/%W!11D4EN.D9=$/1;&.0=@N5(IQP).I!(]1V>3
MIH#\L"DQ+:>HVX!VY<KKB+HA+^G489TNK09*Z[O7;K( [I(*\Z]Y(2ID=:=H
M) T:(],^UG+FUC(FU5> Z@S29 43LD\1NVI;3C6I?T)FVI7 [M;Y.Q@78\\Z
M,$4L#>FLO!7)ASTW :Q]#^3(FG-:]&)II5:H3AP^3)<L&L^0&>3.EBZ22BO<
M8!RJ"%?VATY$YL'%PL R&BR&BU5'"*78JJ1\6Q;K= ^KQMJCCI>2P,]C8YY#
MFD?55^A?J5?<1M+P]*@R ->3IUC7^=:WBI3FU+1^AIZPR'1'Q.]UD!B(Q.84
M==YFOYCD^^ MF9)&/^8FI<$L5Z$QE(C7*A6#RRVDY:L>,%6-"T<\K($LU-52
MXL!PJQ]+FB-N84::"P=J9S4YU7K.<G%S5WNR$3G"%W$:C<HQ%->Z$[[.I7)5
MO>Z*^K3KP-O8Y0GE=8&W8.J_ZG8HB3S<XO0:Y!QZU:YCW;36SNJ)<VNZ,H!^
M.R>EH+L2WKS ' '*1E+> 3O2B WFP^B?5/#.#(Y9."A4D08R"ZML_G#5N\\4
MSD]55;-LGCCU68[$"5Q.Q*\F)0F9-(RP_28^I8/$5[=.PJUJBB[J#!<)8R#'
MQYV,DRG!%0#)M5W,W#R/X$R'?%ZDNQQ%<MP* ?Q6!Z=,P:"*Q%KLEKE]5%7E
M,Y]V-C=$CE'5" E"/@0J8ER/:K$BZ@2?\4LM<(T@MZ$11*2108*VDPV, *H9
M]E,G/\R>^UFVO*U_5/T!@7^N)%ZW[[<Q'P7*;E!U^J)6K9"O50XT3*TK;M3Q
MTKX<;4Y37)B4.OPT5/50NT\F(HY8V:I-% 65DW"YSHA)Y5Y\RLRKPU_0, UN
M1J6$2)9@%*I9*7AI4@:$R5N-LQ4U2'+7V,O!71!?H%.C9I4HZD(V<N+:M[3$
M\TW%IH9'0;W&SM]8EJ6TDC)98$!OI,T6$LA6*<!ZI!D]Y9:G49,LW)F<9\;+
M4*]U@"I4D@&']]F5B1.NNC-KJ@)-#VJ%CJ-^8R+/2B_SE^L.2;:CX@!*$-[S
M;AWB?@O6.Z]T%Z=DH^.P G9DFR/B0IF$RO0GTUFE;ZT"*4&GPB2Q(Y=.=0NI
M<=J/I^2=E]^"93RA.61QKA.P**RJ;I.1N4UT$;,2&^D5LFR^= ESX2L[ULE(
M<@JL:#(*W2'09*Z>>AM A"$ ."*CTU[H^.*1@Z-=DK\$,ZJIUD@OHSJH6]*$
M#S-M'3UF.]'FFQ@1C(072*H@O<:8W@"CF3W[8Y'JO!PXTPIWJ7Z-7LI^U%DE
M"4<>,(6;U9FB5Z9VHD@RJH-C)8D@.]BO@]X0+*? XJ4EE4ZXS^W+^^_Y(Y5Y
M'ZXL^9GAP_ <4EZD(S'L0QT8?=OE4.Z;C&JWL$=N%_H'3GW;FJ-D-'65F*??
M%H\I H#L@0!$%CQ!G88%%YD5%EL2=ZL6ZXNE3B'9&D:W6,[7/">A0R*/5#M3
MN&Z3%TI9<AC-$^-LY70CU^'X:%SLG1NB'ZL\$L?QL<"6V/;6(()55H(*(5GF
MN77@9/'*T8NP4NM$,^^P<;40V92C:']*4^L1)\_#=*$$'PYI 4]>*J_%X0J1
M]XGW7V5"48D3%@X_GU_^R&'GT#N__(.^.>[T?&VI[(9!:H  WR?(Z'2JCB\X
M0^[7E%"BCCZGBWCD];HG;[_W?K,$ VRU^TO8_MH!GWK1ZPTO]&?JFQ,CH+PK
M5@1U4H)D290K;9Z&[-&P]HU-,>5_,[5W)OJ#Y6PB .F:U^RO77ODZS$X29:;
MD40+4W*F*:F,#1.E%15"9#/!VFG0.Q)-#CYG%H2J/ _M%#0@9$1$ZJO[6M7?
M!>$U:X$D3^4AT)2.G11Y-6.09BG=>CZG.BUFP<@4-$HVGB!1:K<X+E/P)$%H
M!O,(H4#$W9E8=9"&*(I8)&2XHI#ABVEG4+NU=H=-/7+Q9F!>9L[#>"4YQ-9V
M[P(Q AE^P-0=V@6'O&G:0F766NB8F<(!R>VIZ6F!"6#Y,U(IT(HC#92@Z_#1
M*I[$G/#+:"XZ]Z8S\"E<96\U(2W&<Y4UH"H<&/7%&I6+KE!0"Q:NC;>B(<;T
M?,UD_RM(2BS$X+R?ME6QJL]*%A59JOTRFN<5E[,2U>3;F'R;89-OLXX^5HXY
M\Z&E?U*F::_5UOEI('NK+)I%DO.H89&.0";SH!1Q0Z"*XJT<U/>)E'A%UP3F
M6T749<#0)9DIF&*UTI0R=^)$9A'8B;(X%D*F%^-2XS];4DAC$BDWTT@L^S]T
MB35E(YDYJB-+;U7%!CFUN)ZYP([DE+?1C%D$VM*$\U)R,$+#TKT76&J"I$;Q
M LHMRT-K, FI6G$ NP*+0-MX%Z7^8%G$;BQA#>B@UD7(JC)%.TYU ;_MH?>;
MC2+MO$U[=(,50&BJAI_9[1-F8N.&$++RJ40&M3J"0\SXG7:VNZ)6W>UXT.X^
MV$E]__'=5Z=A_YZVZ-OC3G?7M.S+>+Z8Q6,%_VX;1[CU=36V+T%G5G)!&4M"
M5@G$?X#4A6.&&*'JM'"5!H?9V>,48]&ZN HH^9K#%:)PB::%!XZJ6^TJ4N3I
M&H![3C!(3/9%*BXXC)PR_IS1GIW\,\R(=U0B^_6L]SC:8+BB<H(V)RT+=%E(
MG;A5BEJ1,$HL:ULBYTUGYQZ>6,OUXVP_Z+_)"*2HFKZDK&3\;,T#%B!)KNH@
M555L  2,%L?E0FT>98?2W"VHZ4ID2:N$MOH'?V&ODO(B$7:PA0\M=2(,$BA0
M4)2>$NA\4YUM6E-O6]?3X+"%V'DYP;1?U$]6.0FZ[>/VR:Z)KXJXND@3ZM&"
M][%MY"/?&APEBLYY[\@XUAF#'V[@([ YBMN7EW-(<.N,UIRS90L\MI;+L$G+
MB)'5>O^(UFMK6".+@'&%@*,* 2.7@)B_R .VO$O1$QDIVA74@F[)GDEM,;-$
MLU\?1E<JRXC5%?Z280ZB@(*2E4>6:!!(U$HU/:D^+\"[&/;D/+MY+"YN1&X1
MF8@P J#QW (OI*,O2LK3+0$+')52'*ZU^07VP,!,XBKP&YG+)-'T;7OYAZ:?
MDLZ^KE-$J65Y<!>8%,2(+DQGV@10/<*0G"S+U!FK&NRKHD7G(0I",[Q=)18L
MD]X0$P1IBC$$@DV ;\J$\(:/XK>5YZQ'!*8K5Y/1MP&9]=Y5/"XS[5>GCB(9
MV"=D5,%TCN*EL9?FA!YJ<9=A<P+THQ6(JT>9=]$\+N=5Q/(J'ZI#9.GXY/M@
MXE92K6UM=].#X!U%K4D+*$[YFD7^EOWLJ,68M^M;N5(]BCI&69CJT27V6CHQ
MJP]L>M>!1:FC)T*W*MRW2*M1D'#"'M_#[%Z)8DZ<Y)HU:J-SMZ]%I5:YCB;;
M">0KN-@ZEQ$GFKH_O\,5A65@?REFQP5H#EBE-\CP\&B7!>17E:.-\N".5;J:
M"V9+LE5$)\>&!&#-P^=.%+?29,*Z9 6#DA06*:%<KH?Q5Z3%(4]8$-'3] :-
M;5\48;OR/X_6B#?D[(IJ-Y4""3YWW"8(X]&6Y-$5$-T^&9!&KX6/!O*1[ ?E
M>2)MV(?"=2OH( OK1.GC:5^;-E;KW]%8[9E\=/4QK4_O+O_X]?.E]^%G[\/'
M=Y_./[__\/OEWL3IZG4?MPS#1]NS1<DIM=5/>"H,%!;'9F.J.-*9>BC V:MQ
MCH_.L4:7BE)6E$.QO8"E'UCS$:JQ"+!/)SU9<#[6E3.[M7^M0ZQYS/)4+%*6
M$.8L6R>XKO0GJ^"O:*FU;)TL#\'T.P2CI?X$_'=T2[)6S'"A_"=#T0]:)NXU
M$>X'FKO72[ZK)))T18.89^H^.,?A 3BN!W%>5B0FNF2Y5&0Y>(;YO((?K)I9
M-+6YLZ#[DQO,Z\5V*)$"[;0!'%$>SX(2'63HBL+[*%V4#)^I*HA ;Y*_(4P2
M%GM,LF#.#CIM?@04YEC%MR,*T.2I1NG2G37R/!W%=#.0L4OHY-)."0/)*GH
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MWD7.[ [TJ=D [^,[8$U*5N$XD(38*AT%K/?=V5R Q(:NYX]"W;1 %R8:H]B
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M[[XKPIHON^U6=[#F^[4/K_MRT'FB@3NMTR<9M]][HH&?;,+=?:/PV9--N/V
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MT<L(I&$R\;U_1 E</MPV_3R$Q<=YD?$M\8YE7/[H_+DS^L]]BDMS1;F)1;G
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M6M!Q*3ZO^%7)E%\1O8"D!Q(+J#.E*F#J97P%[)9$Q=*RUJ[Y943#^\0[+R=
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M>R7+[36/!-R[C(1:+Z>H\S$+.#>LT.:AQ7)/4BFW<3!M0-WFQL&LQ<,6#YL
MLQ8/6SQL LQ:/'RJ\O5[JX-+E%YO&(B>MTY]PX#UFR+U%DYE8G0Z3##@TX)G
MN1RVW_"EE3(*B=GP=(NY*7RK9(V^I'@[L55=?U@7@$:G8:PQF?@EH87EJ%3?
M_CGS[33YQ^HQL,VY:]2AJJN;6T\=J]N"+=VT='.'5*&VZM+MIYN6.EKJN$=&
MM.HXVZ^(MS*EI9IUPL15'?>>]>$;1#4M;;2T<8^R?,]6K1= ':U,:>EFK9H8
M,57=W$ [97N+D":J"^;/12*NV;'D/"2KX^;SD( %/G0>TMT/$*^CW+DO-ARF
MR4V,@\![8I=.K6IH"(!(0B6YPKGT\L]3\Y;R(4MY(4'QA@L^*,I2RAE(6'Y2
M5 ZQGC)DMW)ZHIC^*H\"KQ"#O08!UWRQ03%L\4+.6<29Y.7>Q91BJS:P'L=F
MITG$LTRN'W%X9ZTB:\!&XY3+@>#EF#'<,SQUR0-<7M9DJ6(I'-:+T"D+Q<0+
MW1ILX@CWFR6# 9>U$UD!HG;Z;3G]UMZLZ;=/#9\:8<V2Z5(E>[("#\EKDHYW
M">EXKTMD95F6!+&@,S$/34PRC4$XA,FU&+Y9GUVORE4S0$HQ81YV%(Z#8JA\
M\:MROE;08W$?Z1A)G7>4O2F.TG&K;0#UO3)J$^]Q[*<H/IHF)9SKS4:C-/;'
MLHH'R#@;)<'/G#$@!^2#3,X Y#?XYX=.\IN&?SE2#%9QK&*.H$-Q:%NY[YD1
M;P_;PZD8L[Z(70O>"Y!"FF9R4GM5OC4[SU$R/U:;[XL;Z\<WQ8/Y(\CXQ)1;
MG'QWS=(P4WK)-6SW D?D*;(4JEQ?Q>%[@R >LAY<[VR5)LYV%"-S\: OJKKP
MC -2#RY4Y;T0?[(KWEX(C"L6];](3X<25;.-ALO=8T;O47J8%9"[J$&.34*N
M.>6(;5GA)I43M7MM]]KNM=UK6U;8EA6VY0N;!=.VC*;%PR; M,7#%@^; -,6
M#UL\; ),V[+"MJRP+2M\<CBU987/5U:X78,!VCRB-H_HK4M4QWG8H-(V_:XE
MFY=&-L1P5%O??KIIJ:.ECOL4T6UF;FHK5%JR>4ZAXJCD!>AB+7&TQ'$/XM I
M:%QMH5!+-RW=K (3CZBV?<^YMQM$-BUQM,1Q#T.%Z"J][U3H#:*.5JBT=+-6
MNC%ME=(--%6VO/KT;*J&0IU71)%72F6S\^_THB9+E*@23*:5):K )VMEEH]4
MHGH@2X9^O_)TG=CD.4RSD\]FO*."M:R+FBAKX_UA+[GE7.ER%@98)#*_('2J
M!-6N5X0.E!Z_R*M7[BQ&G5^!*B]LZ@5F=3/R!2S#1_/3C[&V)NZS%/ )%T]$
M_=A 4(ZLC8,UJFF"TZ5YQG1M'GSB+5&<Q[&2]HFK\SC^OL1?8"U<+I?R>)"-
M4RP:5MA%RD6QL-SB*T)KT/L]ZB(F[@7_&<>RSE;L)>. .F)Q>786".2 AW&]
MJ:I+KV-,HI\L>'3F 769FJ?RN ^#W31KN/-5];)' Q!$ECV:M$-K98^KU*C.
MK<1ZP4,(#Q# 6(Q;(,A>'X@S_B4_V/X"P9GSL_KY2SRLREY?Z=5T5B&=]*I_
M@E[C8/=&QHZ"18LEV\7:XQG.FH]IG;=7\>(8\V& UVMC^"!+HM$UO"'O4F#7
M=B_GOM8DBBRUG5A7+ VD*41B-?,47L$&%S'P6S'A\Q7MF+4"[XFV# B&JNPW
MGSG+D+6)8W=!-[OH*OX89 D(*02('P^8'.HJK@2?D ]D^:S7LJH7X+71R+DB
MN7[ &FA!F'@? (^N$#!BQ*H/RL& CS8:''<>_FB@[(TO8 L5\0B\S5$LSK*Q
MD(WYW^%'5#E)1E@ECG_?1T(;W(K?(2&[M&-4*'L!TOJ"C7A54*[(\MS9Y82&
M=I-C-)+;[Y>"-6) >EB#R#4$E6>\7*?08R8%.N(__&3BKB5=(?8C,>&- ]5*
MK. S6!$"5N3DZ59T7TU*9O7M!BSK%JU0Q)AEV&@WZ84XQQ?7,.J<[[H;!UV
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MQW G U8!2BBHO/AX'RY<V*ZB<Q=\7CY[S,,X8+%@) #08"04]T%R5;03DRN
M25_IQI,X":_,!>FHRT;B1[@+1/9<P;\2+#P(QBG2XS60 P>5?>((PEK@<-U@
M3LOW^H JRE62*PPYMA>(,<A?5E2(=!FB.J)5F@@K78E@TZ## $[72:7^SC^%
MTI*B.M&[G3E2A>.3H!:(/G,A,T1GU=HS^2P58JV0G5+(P?_$OW>1%I>G0GQR
ME$WNL#IK18_KIXB7UW?-:?NN_88S';-;Q:#JK,B>DK[*90)_4*Y$CRM>;TB(
M")T[L1#OW_<2G_5DP=>4$*EQ!R3]6%)]!G"((V!A8JFH-^;"DKK*!8=D&"H8
MZ:/RL0EQE/.,Z2?0A3G%'$!2 1>1@HI-NS K3RH':Q]85)^/NN@RCXH?2JLE
MG "26*?72P)!QDC7H"8@GY$.[ZR;>S^J?97]XD!E&(AF8[@FLI#<O\D96#>@
MI^,B\,:B+=Y2V@;>X36O\S'4MH3*7NCE<W@46EA>K?_F>%C3%":%-I^XW[L%
M^*:K[^^3)+P&D"A'<-=QBGBST=;+W=[(9979!>@5ES!"AULJN_*],HA5"PSA
M_R8",W?HGRBGX573/$.0<7_8BY%JX87*%0.&(3JP%K>%RPQ*H@.[@_,:.8T'
M<='VC)?UJ&5'-23G'GH"X64Y"0"GNQ64+UPR#Z?#^8 BV-ZL'N 2)@'K3V^]
MH_R5R#ZS(^'$D4M,=(_%)TNH(+QK;&]*@<*0"%>0(QGZGQ_1H75TI&C*$=R(
MXG:4=Z56<E;=DB:\ XHGGB)_"I85C5-A(L%ML;B7E6ZQF:/"]HI[>E&>@/W2
M!_T.D?9K<3W[PHRZ0 CM3VC<*!.. +/Z4C2*SX3/8*.A=B>,ODW02V[:%FZ]
MRHD_2?5!!<!@!H#Q% "E-S^)9&SR5<VQ)3^!9_*O=FE'?STWH)+-BS?^-JX'
M>A"8NU<LC86;&$U?$;(MXA2%)S8G_.J,V=0A>S'SXQZHX3(R).VQ*$WZ4EW+
M?;.BK:U0T4:5TV0V%Z&^6!D4F8J@W#,V8@LNZ):AV-]PFCM9#2EYC3@: .]=
MDO85HFO_K[P:4!RQ8[:XYBE>.(DPR!!G0;/9S&A1.;@4['$6C$4"!A[_!,30
MZ;!H2OY97/-FQUA7Y,1'A2_A:  8S3?ZZ,L=-!8'E>PQDVI6Z5 1G$/J!R*;
M1B@H Z4/"M0M-CS^"10>@664Y?RT_I@O%!%LG]P%54)#/2TW9087\F^5XI%U
ME#I[CZ?VAAI0+;M*Q8"//9F18RY(OEJ4!?*[7)!I\%0)5%7;9C(OG SZ6!ZG
MRC]X1?5:&*7T,PG6!1^<@%TJ-B:M;$/O+&Z,OPE(=U]ZRQ,Z-OKL"V,?!CI3
MQFG-S9FG1,19+7UB.E4,B:>*MZD386/XLY7'X420"$1S/%+V)B,@>_ N99\-
M\3:4HBT*VN+SJ:W8U&XM"CN1;X$QNHA+G4(*Y"+%[K5P%TQF>1G6),FZ]3R,
M@8POSA_J<5^B16]2.8A">&"G3A8N9<62*74-YP> \I+"6P:UZ_)OI04I#- )
M'XB$^_25P(;^S09CC.#(L\SF3:J_21? G];BME,).?<_L3[; OR.$\-O^^B$
MJW.YA4<N7_5@-4^_MYHW#97-5N=6Y;"5E8T#+*3S\E@Z+X\J";S1(+D3 'M"
MI_GW>, 54Z_'7$]_]E@7U@<P%)FQ!_%5+'3AW1Q)3X\.<K1[G6,7H%3=QZFB
MIMC)7<_2TYT@X>76Q?[IUZ,##>@)#@[69ASDKSXZ@)_F)M6\Y9(:68OI/Q=C
M0.<$>$>0\W/8\K WSI HT4E/K$)]. +NGXQ[>5SZ.H8E?*X,>RPHO/7 ^CF0
M=IIUXR$.Z*G-&ZKS=5P#W>@^1LO!EN0X?86G(QG<0LQ)@%4+*RFLA]9[,1PL
M%&&\3!G N[(,F5[]3.C6&T\<)Y^+DLGTGCS=3[C93%W_%RIDJ*(.N,Q$+P/)
ME0ZISH4C.J!SD86QF-+7+LF@8 R"L<Z_!C$4"1"Q.C R&]CAA#^A4P1@Y\6N
MJ\AH(@,JQ"SN:F]:@9Q\4G@)111C:5?AE!"FM3E5:I6T7,@$F::\P!TH)%,\
MP3XF8Q\U!7ZEY(&E4E!7#!@TA=V^%R'?#R+D*^R@>1R7;W/B<CVFMVSL*R[
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M1..>]#SGR7>HX LQ6;FZA<]H)!QT6)];!I]Q4S(W7:V5E-T$O.3801FF@(=
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M0__S(XZ>.SI2-.5HQ/N*VU'R,;WP]K-JQ)@F5E2(+AXC?\HI8T 2N#7X:3R
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M?-&S+;<L"NE8WDXO9KF#A6$+J=QWK\BR]KSOE.P*"4"/A>B0AZL>C+-:TQ^
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M&R/B;>@8D7HX=-XXD?L :=5N4L^AF\BIGO*?$^>^LZM[3MA3C=WOU?*]@;B
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MRJ%\X$)Z8/AN&.@TL&S/#9AN.0ZSJ&]PW10<2F\Y5/,XU*\I#L5MN#_+T+7
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M-8^8W*0V=W@$=$!T1S4H:5#R0INEU%SEJ:7C)Z#CVVDZ=KAA>[:F6SS0**=
MT0[\*22N[WG,""W/W'GKF$#&+Z3L2NS':;CE=M9-TI$VXFD?B,J7<PK*3&JP
M0=JRK,?6.SXD@XMS@/\!@'\NIVI3HN_)I&9;S021$SBV86@.6'5@Y/FFQH+
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M0??P7%?S;,/4=,.A#O4LYKBB!YRM.G.ZM2S/O5J_1X.I>NWZ1TO53TS5TU-
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M&(C8$!_<?$!\YE=\,.8/F26Q-MI[S$$36[K)1PQU;D+E"SPLO9+H)(55KN(
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M4+>+1"ICY]/Z(06G+5]RCN<1I[.7H]>4(+GS^ /?O.QF-9V,3R\A."G//P!
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MNGR5EH%IR;0+592D&@JU.L:)5*E/S"55VMB.&:G2EERE5^].GCS[U61A!,8
M.HE07:50G:8<'+BDD@M265=<526FA]JQ?JC2P]_TN)J8)_.7.&U'&9>V/H:#
M<8U1)V4P#V^Q?C?%L] :'<PGW]"NR'9V138W .J1U3U?EM].IO7;\2!=3*<X
M3N\&\VG]M+.N,?0@Y-\O9O-S',]I)M06-APZR?ALL_23;MX+W!Y?PG;:4%M<
MZ]$XGW[$\.@#A.^[?)/17<OHKDXI3\%J5(H#TYQ7HZLBN#;1'KG):$T2Z-L!
MM]5$U"Y' 43X>PCFB?#](/Q2["]U%AB$A6BK;ZV\D^!\J?P7(50_6T0L^>#P
MBD8B1/@'0?B[BY.)\/T@_%)871C+JAKVRO7LVV3;!$ZX DD8QPJKKTAS<*A7
MQW8\M(AZP67Q2/0]C#F=S,/9%='U;>JVKBWQO5%'B-V6O+L+:JY0N_>Z5;\[
MNVA/=8T^J;2_N#DA7!US&I(7+'$/(9NNF1Z"%QRAE!QT,%&I&!:I6*=O/]/[
MQH3;H8/:^RPB=Q<HD8CT6426PB>K"K(4&7#9RCR$,N"=P^8KAY""CKD5!G6I
M4W^;) 6IR(-4D;N+ODA%^JPB2S&9RI&[4B)$)VI@%ED"SZH_HFLT%DHP7+;Y
M,"W5:>1M K/[4I&[SCWM<M2VTM9]O-$9C+N[:W6_$=R-U7)]=;QB\!$)XTV$
M<;71-9/*U#"MPFA;W751%D)Q&IR,)0L3$H8OS,_;WEQ9VJ?>,.,W7BQ/C.\)
MXY?KYI6WQOD,1ML(*H0,/J& X#*+P2C#E23&[RKC>Q\;42RT/9._B(6RCBPC
M$R"R+*!T*N"292 <IBH')@3;=E2&AOD^IZC6G%_UI125?RB1SET,L/H\I%T\
MAZN*E&^WR]2[9W[S8_Z;?T /Q\1L)1-(YF-SYB.M1(PFRE@]Q]::2ZLV*E>#
M+YI!SCQ9C#DZF3>>U=L J[:\84_Z2OKZ0)*DI*\;U=>E^-S%P&-B'H+5U3V/
M08 /,0!CQ3%>A(W!;S[A20)+ DL"VY,]$A+8NW%@%_L?WKM4<E00A?:@7'5E
M*Y06HO%,H@PBIR:P3 R9D ]!8+O]DW]TFP3UWSQZ<_A?]3]+VRF*/6H)W]>3
MV:C=YS==)6E=F?_\8Y3G+]_G$S[YO<L;8A]_)<1Z[1?SZW_ED\M.V/;Z-BT
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M@[1&J'Q[%Z",WF*&/W$Z(;:OR?;CE<263T&@@9Q:;4SP",&E!%(;U-IR69V
M#Q$),7[O&;]J_C=&]PV9?Q**S0C%DEN PFBOI(:ZECTH%22$ZAR +%J:(!U7
M3I!0D%!<+Q08-,>0?=8I*2^9#[X*AG%.L^PEE]L4"MI4N)U:+)^7889)P;,%
MZ;P"91@'%XR%S$5 P9267!\<\B&W<FB9([W8%[U8)P6MHF=)EZ3K6E"6AQBJ
M#1*%\V)BM.P+&PO79)YIAV$[.PS+[:N318S,2> A%%#"&HBN2&#5$N3,34Z2
M'1P*J6Y?DT*2\* D 1WJ:)#[6'V(;$*H+JF2SD91,I,N;4T2R)G8I%XL-?!(
M4FIE1 !3T"_TPC-9H%F'(@I*G4+5"\V'WFQ@ZM=>:<8."L8ZI]B4$DQ;;14K
M*I04'$LRE*@\&K0>:7-B1Q7BYZ5R=2V<[B9@Y.2@6@0'KK "U3YH&42P-JM[
MVYT@C=@IC<A5&*I;X;-#JW3]NOJ@.CKA2[4QE@7:E]AEH5@Z ,NTKNZCKLI@
M4FO^'R5$U A!ZNBE=YH5<W#HA1A*?>?;$@].*!Z\5H@LE+>>^>A1,6^CXDTU
M;.$REL3O_:P#:<4FM6+Y@"T3)6CI0:LH0.7 P.N2 8O,)B9$(_#@T P-'8PB
ML;A"+%(,!E6U*D)&I7P(VB9E@C;2&B:D(K'88;%8[K4CC>=!(59UL 64,1JB
M*1Y<5IDY%E/0H3D6?LB4W16YV(-N/)_]S?H9"49OX>4H9QQ_0RSX(@N>SY\_
M_CSM%[QS1C@+V5:?6N58 _)@"L0DI=$E^<SMP>'CB_.+-D?G32-+P33_9$;\
MH$PGY_7[R>OWK9&.7OS<CN0;8/(#/Z@G$M7L$$J$$J%$*!%*A!*A1"CM,DIK
M#20QB$EKC$D)%;2).FKI57111*'$%XY1TA&(W0FLEH] <&F,U[8N=648**D=
M.,8X>&>#S-D:AN[@4 R]O4TC7^(]J3.A=!MU-C8JIJ2R1BIEG/(&JU3[;-MI
M:!6W=V:5U'F3ZKR45=8Q,X>B /==#;T5X)0P( .6)'+]7F52YUWC/:GS+J"T
MECHKHW+"(*002O,<$Y,A22\-3U9'3^K\$-1Y.37GB\:03 9C5/.=LP$7K8+H
M0Q19>>N,Z94Z[W3_I9NQMB,.Q###=HOGKW$\6PS#P+?M:Z2A\S0]B5 BE @E
M0HE0VH'#;AA9;.UB O*HBF<N)Y&$U,YD:[WJQL4)=ME:MGK9?WGJ[>C#F9#9
MZ>2H/KEV!>'LAS#*S\:/P^O1/)QU+8(Z)^+Q)S[$3U@]\=EHCB]P^F:4\(=Z
M[Y/\$Z;);^/N4_X=SBZ0G.[-.=T_K@[,8"9*$3TDSS4HGD(KS9&@K6]!E^8"
MU<$A5T/#-M5(C%2!M)M0(I0()4)I>WZ0YSQPYC 5+EK?&R^SEI&AB4))R0OY
M00_:#UI)#44K?%8V038.04F?P15=P%N%P1OG(@_D".VF+)!X[P)*Z[2R%L%D
MS@W/J)56-F;AB\.24E;)1T;B_;#%>SES)*+AF((#(6OLJJ+*$$-V5;PU"PQY
MRAE[*-Y[4+;U]"U.TVB&K4)HUG))@T7%T)X-3%^O,W?!D+LN_:G*FT01Z]HV
M42=MZRM%X=KRUF7Q%AVZGUQ,6]*[4ZE%Y^[NQ9,%*N_ARJ1):VG2SROC.G*H
M'B5F#RXR RHS!*]9:G5V0H?(1 TR#@X5O[4>T3F6GE#YBJY6]\3CSL4@&F^$
MQDOMM(M/,9<2( G66MI)"4Y' <5IS5P2*9I8:4PDWBT2TY%!0HE0VOWD\U<8
M1 K$-V<M5[+)01J>(P?-6@/8ZOI"8"Z JQAS+K,.KCO!J2T-.]TQEI,6$TJ$
M$J&T/RAM,YE,?LUV=P&6L\,J.&M<S(#9,U#,<PB83%UW*7-F<W3,+AR;6_>,
M(YJ3&!-*?4H.DQAO5XR7L[VL2)&*9("E!IBJ"+.HXD:!WF<5C4ZL?V*\!\6"
M/^%L/AVE.>;+7&]CZ6SPIOX8\W PQGF7!NZRCH,_1O.7+_$L-ZX,YN$M?EU*
M^.$==^E!2O@CD-W;COX(TWR,\Y/R[61:<#2_Z"Z0=&P-'?ME)4.LC1$EF J8
ML084!@T.F8!4]<WPE%DG8^J*24ETD&TWF;WE##&Q^BY8O90P]K[2UJ<,6EBL
MD2(6<,Z%;A]<Z^)$C/K@4!.G=XO3=(284"*4MC!(]/89XR^U!+J5I:0@?W-F
M=&4P>?6$5!"IC2-/H(+.X'4T8*./Q6H4+K43W4.G5P]0KCU(E)A/^DPH$4J$
M$J&T15]G UED\G5VP-=9;4O;=GM$5N QL.KL9 O>B0+5R4G,IFAM\0MGAY.S
MLS/4)X'>!936$>@-9)9)H'=!H%<ZTV:1<G*NRC*6=JXY@1>B?BM9CEPJ$]O0
MR!X)]!Y4%C^>C+M!FN'] $+L^CH/SG'^<I('HW%+.[>*_OVJ-*;C3(02H40H
M$4J$$J%$*!%*A!*AU/>=!:<D;[&D$-PK7U30S#AMA)$R".[$VN? 3J<89A?3
M=]V6P4\X'TU;V[+9_'D7'1V=UR=,XVPVN&F0YL]/?_Y\TR 59:((#C 9"<JJ
M D&R!,88):U/60IQ<"CXL*+9CWDV1.O^972(UMNF]5*RINW1Y9 8^!P=*",=
M1!4,%".P(/?<A$*TWCE:DT^U"RC=<[:&Q'?+XKN<B)%%A.H<6Q#2MM(_ZR$H
MIL'P*&.P,:K"^B6^>U#VU]6,#:8=(;XZX?( $\AW6\B';UXNTL;_[LHKC\;Y
M4I)6R_E(=];2G=]62O64"2D'CX!*!5 J)8A!)2A:8=,=J;0]..3.]2/[2P<_
M-NQ*W"]I+SO&$V?7X^Q2(5Y.R16!!E(4-4X+14,(JH 6IF0N<V&RM6PAQNX,
M8^E ':%$*.UD#1Y9OSNV?LOU<]J%K&2(H$WFH')J/7(P@9;%&J5]Y P/#HV[
M391,G"5E)90()4*)4-J^E[*Q7"MY*7<7HR\G4PWZBIA@@*JU\HLJ@C.\ )-%
M^2 ELFR:F[+:+X?<E+Z2EJ1U%U#:2B:5I/7NI'4Y5:I]9E+4D$\EDT$)9! 9
M1XA*6Y592%K)'DGK/E2LG879;'!4;^_\?-+^>&N1.NJ*/KLFJ*_#NY8^[6K9
MPG0,DXLYC<F\UU3J=?U0GU8X3BH:I$IKJ=*KE42J+=D$J37X@@*Z!D\^^0!:
M&A>-SUEG446)IF(^&.;>1S+UFL)Y8NW7LG8YE1J#U=95PNI2_0E>.-1H.T/%
M+A:4F#77E;7$V=WB+!UY)90(I=T=@GES^T=GDC=G')<SK<K[Q*S1@-5M!<4,
MA\ Q0TS.15:8=+JU\1]RZ\E [A:I27H))4*)4-H?E+::;R4WYCYC_.54K$RR
M^BY%@/6Q5#\F2@A%2(A9>9ZD4\)AY\=<D3$@5O>:U:2]NX#25A.RI+WWJ;W+
MN=I<M=>C9^"MU*"<$.!8<&"T98EI7DVMZI_V[D%IZ]-%3]$T.7\]&5_F9BNC
MU.!X,L?9AY&6+8D;Q@GK&V=?F;/=V8,D=-R'4"*4""5"B5#J$TK;R,B\[Q1S
ME'^_6#0?GYU.CNJ3:U<0SGX(H_QL_#B\'LW#V<*U>/S>LS@ICR?C[O'%,WR"
MD3K);,SEKG]C)6OCLN7**@L<DVN['0XBM]4!5ZX(*8N2@1T<2C.T?K5$CIC?
M:^:3/A-*A!*AM#\H;;,E*?DZ??-U5E([+KK@@I6@=4%0G"N(RC'(H4BEBD'M
M.#D[NTE]$NA=0&F;;4M)H'LGT"NU>K)4&QP">&ZK0#O%((B8@4?#74O8B.Q[
M*-![4+/W9#1[/9F%LY;E";,9[EM%'AT=()0()4*)4"*4""5"B5 BE @E0HE0
M(I1V%Z5UFE\E%YA.+F;ADA)%>>X$TSD9YE(1^>;M*M[OQQU/QNT/3"=G]<)^
M>U;_U!1G\R>8VG@A_'8Z.:]??SK<GC;?-K?YUDZ O/I\\RWZ9*-1&9C+#MI
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MW4:(*N&8-$$+YB@WR5C)C1"4*T&3 $WZXT+TSWJ0JE&6G:7^QFI3LO>N*LM
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M4OQ.MSEUZO@I]L]^++WJ>;A6[C/HL:R\QI3-S@M=W8JN%EM?.BM5T)H@+UD
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M:=C8,KK+:>E?\8@PW8;B;3>$=-$:/X[F^1U E)B8@D<"_H>X%Q290!7".NA
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MDW(!;&#./(F@?!M]>X,:*F4=;,DZ^&Y!WZ;D97*>($8CZ-N@>=YT31'E6))
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M^_ 70.2XVOL:JOW?7WV%<WS8/P$X?/WGXT+@].M_>G!LLO?U_X[W=O:K_1V
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M#)N+%MSC]BI]D^1OO@@_A6>PG E>3IP@&7^=TZG-T4R]X>4SZ9UGW^0T>3'
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MSJ48+<R?Z6+TZM]O+M:BB<M]V+CZ; !2K(:CNEE .D,0%+W&4=C,M&:-:(0
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MJXH+UWP;S((%?F.A+#EEQLTKB@-W<1+.5,R/2^!*8*KJJ\>8S%]9;FB9.+Y
M(+.>@&9>-[Q2&UJ&O>N25O#P=,OY4<QDPT8,&SDZ]#*6\  KS@2@P1$2)VX6
MY\SUO5 DGI_DA/O+ZGPF0P8& -Q"&1$\H1X)X]S/X>XP#9)LF>WT2TO4B^D4
MQ.^5J*^CG?Q2TXUCB^XQ1<B_K9J<=SWS7\(K!JV@FY=A:=DX#4/NRR (4D*$
MJEF('=T\/Q0BY.*[EXD *W#+TY;@FC(1_UI7^R .M[PX7GO9V_*_\!K)R!<]
M>=U@0[+ED?67NZ\UR)$GG1?S0G/[RCFF%3\'_G^;2@/?LM?=-8OW8$-.@S)+
MIB*18 53/PD(2TC./4E$R&@ $HOXV=?(K/>*._Y5R'Y3>9@&^XTOJDM!J\<I
MS738:/IW >^=C'?P^[L7>SM_G^Y]>$\^O?[G='QP"E+KN/AX\C[8_S"^7 X;
M?7K])\SA_?GXP_MP?/+2VWO]UO]T<'SZZ</;B_V#4[+_^L]B[^!C]/'J3SE^
MX5W:L!%<NP!%.N9A3D ,NK$7@03T>.#2)*"NQP(:^4F4!9%\]CQ<%CP.KG@?
MCGUGYO$8RTI8YE&7<O[%S..VL-BO6[S'Q3P2Q(10X4L_ L,N\( HI<Q"3\B<
M93)--LSCAS./=RO,(Z-1FF0Y=_/<3UV2@^:<)2)U<YE%0GJ9QW+Z[+D_R#R^
MCG<\0L7CU:*:%?-%)?HFZ -6/VZ+\%UF.@^0O0 3B4$MD4R@?\A/:< B/\S3
M2*1I+K(->_GQ[*588B_O,N_3_SOVV/2?&?V0+?9/_C@=[[P]'P>?)I].W@8?
M#]X&XRN$UAQ/]G9@W@>3D_$)_!Y\O/I_,$YXQ_GX9'RY=_#>WSLY.@S2/!=!
M+%WA8RHPY<2E@<A=$5$1>7%(0C\<4G3<:_TT4<A)'@0RCGVPA7F>Q[Z4$6<R
ME4DD(V]#5T^:KJYV#X&:XCB5H#'''G<)9YF;96GB1B06H52H.N_9\^0&!;I%
MW?\,:O0NP@MF,)9%+1I5VN'BLYB4VB^+3N#UV9X;Y?INTH_Z:9Q+RD3F4<+
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MOJ"!< C2;%3L :3?\HE9?V#+FPXL<IUF($JJ@KS%M3)9HU8.:T^=:?!)';D
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M2$H\UXMHY)(@\-U4YMQ-9$Z#6% *T@^87KA</MO!Y0.RNV[7X]"7L.-)2'A
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M,D+4AGH(0G?M#^LW5'$CRXP:7J2WU:JJF^V]9GNSF"4^2SU7\!PVE444MC?
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MQ+Z\DSVTJR;ZSJ[,']K'_@Y=[-LSWM8G;>VF^J<VG(X.P:)@!$QOEZ8!4';
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MOHVWR+7OW32LWJ)8W&O4F]]CXGZCOJ2YZCN-^MHNL'^/W9A:P\8OI_W>]]8
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M$9ELKNL8O4(5KC&3\G13&MJU/L-%R5/KZ&L\N%GM\'9PW$CMWMF@V%G;;C>
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M7#"F ]:>1(VQ3)XP6UO'SPUA9Z^7E: J1P0B!@(SU\BRR#*<4$PJ2J<T]4P
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M.)9*;^$CR&QV5;O+C#"HVM!G_1#>#04IVG96X0:]3@3ZS82:&7),T*"9PL,
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M_8,JEV;1!=$JL,?^31CUST '&<3NZ^/.'WN[.U^)%];J9)&2N4YC_LUYS!#
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M>@ZH%40F_%YL9!$Q9P?CZD) I?\WB@"H\ )H('DIMU47VFI\ !G<72 ZW6@
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M_RA[JYFQ.?JBI4E$<(-S2K0A@7M.E'/6@ $EA05CF[.N,ZO#:&X6$FX;M[2
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MS39;E"EWH9S?NL"YRLY<>%_6TNWZMO>[GP\C!T$0,/6TJHVCP1 K,JCM((U
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MA1<* #$(5PG\QD\R\X\T08D3_S%W/DQ3Q2/PLS"<3N8.]>Z\4V:W4^GW329
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MG\#KOX"/<"V=/U#!1H/XSG;C'@<&;MB+A:RR2[OP!=ZX[B3?:[_\7+F_Z\&
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M$$&Q08H%=K?64I(B]Y9*@YW=GV3-3LOIUQA3A'&VR(--D<JHM+/14V6,5S*
MH! MI]\CIR];25F*&(7(1#C/B134$2>*) *^8$+S:+@!*TFZ+N5/JI3E481?
MYD4K/M:=1K\FYO)4\<J!(F*+H)8)H//,O%).9BPFIKZHP-9V6+L.<.TVAU*/
MU_FMZI[5^FYO \<N:C_.]PY>X3P(:X(52GB2=#)$%@YFB=4"<$Q[(X*6,N;;
M]MT^#(WE%KVZ3Q4!='*.Y2(SJ">2Z6*C\? ?S8R*Q4KQ#1&@56>^"@8^+\"
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MAB)8LJ[3H@7+%BQ;L+Q5L+3)EZ)IR))1R76RQ80DG9 BLAQI;,'R'L%RT2%
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MSB!8KDBL"9I+YWFPH"-R8[NJ-=R>(@^VAMM=<.52O#JE3)W68+E9DXDL5I%
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M$W"^MF"R;FMS?4TI3>#1^@S*N1"2)8H5-2QQ+7, E8&V/:@?(J>LA"P%\(H
M;8&4Z#SV00#U#]MJ"9UUL2(RX0H:7:PUNIXB![9&URVQW?ER#U#&I$^<>(8]
MN1Q(J,!"(CY$H16:75(\>ZYERW1/D.E:JVM[!EL.[PE6J N:$VUT)-(41ES(
MD1C%(L@R5 'YL^?2W(-;8WT(3]QI@>B]-='];33\NY?R"*-Z9\/1QXJY<.N_
M]T:Z3R%3.$3%5'0Q.2D59=AX4LJ@%$TZ9=\&+A\PA*Z9K1Z!9(NW)"B.&4^6
MDA!B)!G$7XDTIE0J(_I.9F"UN4=SKZ](U%@EK*,)!\R%$GW)RAL)!EQ.I0UU
M/D#>6@YU*LY\X"P3II4FTIM(0D)7E=;>@E+"*+;D9;H+)_R DH]:9GY\S-PF
M"G][]EYI[LN$\I8:XJ+TP-Y>$+ ]/ %F]]YA'17&5$W7FN^Y2J[E[F_/W6V:
M\.UR\G+TM@C) Y64".9Q"C0MQ+%<2-$Q*^8**,+ R;:KY&U-O7^(G/RDK%AI
MM?+4:QH+D\"<-G%)A8"/I9&<M?V&'S0#+X>"E?#4<="O-9 ID98'8& ?2"K4
M* NL'675M^DF8V):T7ACT<@=TT48%S(5TCON)-,Q,!:-H=E:VP:/'R!OK02/
MLPBAT 32L3 P7HT%YK(JDNPTYTIJR["S"^-=9AY2#4W+S8^/FULS]B[X>RE*
M37&HB<4J=F4H",]82!!"D>2$%<QE[WUZ]EQVW:W-)V_9^VFR=VO'WC(K+\?#
MI5/1\20)%Q2G;)=(?/:12)\45TH4)W'>5)<_*$E]@U#YNL>:':,>>.'KP7#B
M^YW>G"TZON*+;:M?MTC:WC1MO!X57&_&3P)V, VGN*#9'CR5J>.WMP_?C2"P
MR9>B:<B24<EULL6$))V0(K(<:=MM]^&)@M5QH#8ZPZ3RA!?,C+*>$<<+QAZ%
MRR79J#(J=9)WA=ER@,7M\<S=)"^VD-="WOU#7FO:?GL07([0,JI\*$:"/1L"
M@"#HQ"XS1U)0!7N_6&TC)F#PKG+;MFIK0; %P18$6P? O0+><B";BV =!:O?
M)6.(9,$1JZPF*;)DC<X^VH"S!%W7V&V34AX9X+7F<PNC]P*C :"21AYLBE1&
MI9V-GBICO)*!9RK:H.<#!-*5H&?A(/^8#D0+K8CD01#OK2-:XDCJS(O)^MES
MX6R7BN\<25O,:S'O_C&OM9_O @670L.9R\BT!]N9%TND=&!*IT!)Y$QY3T.@
M6!W$A.B"Q="B8(N"+0I^6Q1L#>A;1KSE"'JPG J>&&%*,K"@LR6!@@4M<]')
M!RJ+,]C(2W;=XW,95H'V_YYX>.BLEAG^F*UOX5X?IN-)KYS?/<MQ9+G_\[\L
M9_SGK?]QN4I[X<V:O2.(KC\Q>QERFW>M/^H-4AY,?B+XH]M^>[7#K_'ZFXK4
M^8Z]9I'ZK2[:7FO)E_:7[;BJ43FH:=/!9-S)GV)_FG+GO[: TJPY$SD9@RDK
M5&K'G(E.VFA5S-1L2D92RU#ZLC>&_?1]L)BGIZ\'N!!8*'R*3^L-ICF].<VC
M2I-<@=KA($Y'(R"'ZR&N?IR(V\___/W\_5_I-'"IWWWXI;?/7W% 7KYWL/\!
MT).]^]P'1#W^ ,\$Y-QC>P>PCH-4]C]'MO<6#.4HJOI66RCHB3)C'F%P)*4$
MAY6DX=Y?*B!? DL@QCX2@Q^DK2C$6AV5%-S8 @MGT@F6%0]<<+#8F=_4H:6E
MD+NED#>[A]++8FU,Q M*L3<ZB%30AT#"&C K6'#,\&?/Z45QQ@8*&99.!*P>
MGN11I\;&X6!\W#L=5[1SNK'E2!=^/3[-$;&T?U[E6N&]_(5!V?$+%F6W<]:;
M''?.FM*=CJ]K=^ F)QX4L\%19UJ5\73Z<+\QWNFJ.B,KO+14!>&,ECP:RU4Q
MK.CB0)U@4K1U1G=$BA\_[>\>"FIH]$X0PPL'4M2<6%HH*2&XP'*T*8 LO1@%
M,BL3ZN"6U71VU6$'ZG3.H/ 7 =JC<R%JIHIE&9#)9._OX[!/8(''3^^TST$T
MY: 3C9D3P;"WB= .1%.11#E60I+9B<#@M.G*:5=[-@:.CWT_'O=*#V!@,NRD
M!:'0&<ZD I!%A0(O<\PG(8]JT!*LV\$SWEEJ'01/:NY177P]!?SY_PNC_WZ^
M4;U],(K[HF,.U+[3/!CG&JKK#5Q)?$6"[4R.<\-?&;3O--_(3K.'S4Y6W =,
MXP"@8<>WT17 'D]!,6XXZ)"I $4Z)I@"3G3*29/7MBRZ2FE8?-$W99E!6VU@
M'5.^>;E+]T ;*!JP$,2_$-B*5&//;&Q''Y.,REF1&5>@+[J=U:A*I]$$NEL=
M/N->)\8T2UE))4U(W!6;2\0GNK!^LFU[^+=]^*_.]XX.C<C"<P\F@@030?I$
MB<^Z$&:T,31HGA0<OECHV;QR^%L;"B(#:TLLXN=<1A^#94(F(^#L ^AE5;\R
MYIKS9ZX]_V]Q_GL'N^K-P9^?]@[>?=[__(J_>7LH,"DO*$J2M6 X&@%4X;PG
M(+,#8U)*ZT$7$V:';::%RXI][6A #7TK?(C2<R>RBH /ADM?5"XE@:(NDDS6
MM<+A+NCCPRN@C]WSO<^O.6(%Z.K<%ALH9K!KFX@L41/TK!/*5  A#B?#/)J-
M7W L;"<LB@G>29 .E,)#4O8A&R&$+8PIE6UHA<7=" NV?W884S(VZDB"M!;4
M=\6(3U$1%0J A=0NN(P$L*E\X:8" R12=%X)G8($$]$%+2/ DU4T42>=:P7&
MG0N,W;,WNX?>*,\-Y82#;4VD%(S8(A5!Q0$PG 7XWW7H 7T_7S!4-EEZ-S-7
M%J747=B#LP)*#4;;:C3AK)<FQ[/@YL)535R*7ESBPWC8GTXV7[+2_N>>[$Z,
MQ%W:U84_CT<74:"C3,(H^X_$%UCL3[Y_YL_'S_[[TCN=] 9D<0.7WWWS"=1_
M+AUHS;51<IEUT#EP)KTN3G".<Z0!QJB25GQA;,U-S-?+$/1'/,YIVL_#<H5C
MZ9?I9#K*BVCUJF:- XP8'L!Z_M$?QH]/#(G>O'QWOG=V:(,23G%LWA\4D:IX
MXBW3Q(&X")09^$0^ZV2 ZU/DC-$T;^25^W72U*<,*YV @%EV?B,XKGII?N@-
M /:&4WAL&O]XE;\+_NQ5#K$R[/>'9^.?MG-:5:'II7@Y[$O?GX[S3[.__ SH
M?-KWYS_U!M7;51?]?.)'1\"Z#8JM:>A=/;#^NF%J)>D.I765^6@Q4M_P_ Y=
MEP%4?RF-G5V[]OLK+[[R2[7%C==7SC-^ETWF[R,I!RB-?TVG@D>>>W6M5_QN
MTJKNHCAS5>;MP_,/SG+_[[Q710.>0-K5![C/K__I[1^\X^]_Q36\I7L?=N7^
MP1[?_Q#A^C_5>S#-]C[O?5Y.NX(U?WS_UVNV_^']QW=__2GV7[X]WWMY!+]]
MQS$,_/Z@_Q$$*ERY7_9>K'2A9Y:%8AFH]L(RL/4QZ\K93+2.68JLG/&54[C+
MZ+9)5W??N&1+^"W5?QX;_(J-[4J>RHB@^X&E=V!Y'IP-6S2Z-33Z8P6-"J69
MBU"(Y,P2F9PE5KE(!."2\^B4XM4PUZYQ]S"YZPGK?/(:H/-$N[?=(QH=CW)N
M\>C6\&AU1H_32C!A$U$Z&2)C,,29$DD)2E"KN,^"(W]T'7M(_<F?L':D6NWH
MWO#HE^%TU,+1K<'1^0H<"5=2\5J30#&#!T-RCO- :"D^*Q.4]9A6Y[J2;@E'
M#P9U'J=ZI%OUZ '"$?RVA:/;@J/]5=]1+(XYX06QCD4BA3?$YH+MOA05U,O@
M,;X&<,14JQW=/],>'.=1KN*OK8YT+Z"TBWO?(M.M(].J'RD+X90PC'#C'/9@
M%208@4[NX+GT-BLNL?V@[$JV93_N!X- 5R#BH^G'7>J(^!?CX-N*B;97Q-UM
M4"L4VB82]X/[J_XZ7?#DM">%9TMD81DT4F$)HXIRSP0550^)&W5A_/:L=(O-
M)9:'K7U/M6ZO5[*D_ AS2/_NY;.<JDS1WLFI[XU.\F#2Z95.[(WB]&0,5T58
M16^08"<GN4HG?3&$7P[..R?^O#,83CH![HDWG@RQ!G$(VU[]K'Y.U>S"_-R)
M?C0ZQV*'OWU_FG<Z?^5.@B/%ZWO8Q *VIH,WO?S<-!W!-36-S3)9-R>R3H[]
MI',VG/83+*0J3(5;+K[7)(\GU;L.IZ-5@?E-DUTK9'+>>UY2BLYD:7GR*H4L
MC(]6^6RH.#286_D0J,BLI:+](9  HSN=*^N*;R$!]&4.$VQJT!^.0==Y,+F<
MYPW ?_A3[/'W)V]>_N/CWLGKSP"X=.^@?[SW.?7?'/Q^_/X#///#1_CL'Q^7
M<SGW#^+G]R?OY-ZO;\_??=BC<.VG-W^]@F?]J?9_!8'QZRO^YN#MI[U??\<R
MDT]['_8.E68B9)>)4QH'OC)&@M158_#L-=879%[+Y2H%?!?E9/+&T\RTTY+*
M)$+@/#*=#<![*""9EY,__ST<'!$PM4XZN/<;!T]>FS37\<':9.,O+W3IQ2A<
MD(VD!OY(2?JDA9<JB^)=-KS<7QYK=<>?>J"C]^(U(!DCQ!WDJ/'M[.[#%#N=
MW>D1+*$J,NA>$A^]\1CK%;:I=:$R,I$="XD*603UM$AOHK.N1( 66G=1H?:R
MMOEZ_Y=U^/)Z, ;21[GPBX^Y;O_S2*I;[AB']C\?'2HC0RS%$,#QB+T5'7%)
M2&(C-UATYJVVSYXSMJX <JG Z>AHE(]0F3@%X1Y[IV#3^FKW*S,65).-% $'
M A+_;HCB-5:(@+[P.ZSTCPFFGO^61U@WXH_RG!((?V*DL =VRV'V@+S%24)3
M240*J4D(29#,M34J)&M2>/9<[*C5"8S_&]A_4"GFJ'?]D0<]T,8J$ 1=+W<J
M3/P!40+U1DY_O@#)Z@/V\X^@MR'A_ TGT@?],Q\-)[VJ,"!_BL>@T*'.E_X;
M[CJ>AG$<]4XG-=&-<L9C'3<-<R*LP<.MCH=],#3&,](;3B>H>U9EN:B<-&O#
MZJC9%0. QAZ\PW@R'(UW.@=?!VG&6D%=#+Z(*!WG-I5"5?*Q" Z4/:OWMTT)
MYS(9K^D0!51<[_$8'MWL-EK5,\*ND8X]631#$_I0>F6+S(%8"M0KG=?$*AJ(
M@[M1*XUGV3][;N6:>MW.]8#L@G*18N?$B=;'5O3A"DW9.*J$ $X+SEEA32A8
M0Q@,=5])'V_ 5.X-?!\_?>J$L?]R]]-A%%J6S!,Q''.[60HD.*F(\"E(&VQ.
M+GT=82"Z+4&+7[PF^O%QY]2?5Q8K_'ZK-G/*RF E +#*,IGHN:?<I<2<$P S
M86MJ^:U>Q_A-J:0CX!L:YB^&XT=3"7SG1/3Q[!!8%&<4%Y*E$D1&2\%TXX+8
M5/60,RI2C5T&-X51YLT D#AN(%1<,)HQ(9FQ4N9LO=1,<\FUESF!%&V%RJT?
M^\$N.P0;G>6B(F&6&B*M39ATY(B*.L6$W9:#K_K%K.9A7Q,[T"RK80/E2(44
M?@)@,:H<:KVZP>-=V%3K2*3D4=T*;@X1UW;=/SUR.6*'4ANC!%,D)TP 25$2
MSY0BGO.,_4*-S0;5Z$USS!<Z!"3@SPHH<.OA?&'O4>N @Q[DF@(JI;<1/8U>
M IKP<2]B[\C*&=P$%%'SG0P[\#A2T5>OL8/FC0>FX^HGQUCY.O)H[!,T_#LG
M>7(\3)VY_W?6T7(*%%PYEBYD7[. 6GE&)Q_>L?FZT>T[IWVPRF<R\/)UG6%L
M"'TX]R]@YX(U'>R^)V?*/R],E:7]P.-#'_JD7S>$N'QPC2XQ/V_\-7Q6%R_G
MDYX?#.",P)@"BO&PK=@L C;V7U,X5%:)H+FOG>'#LX>;H">^VPD9M,>JRRA<
M</&K;N/N 6SRG1&>9OZ?B@R&K6W_<$%I#V38_MDADZRXZ T)(EHB.2"2<UD2
MI6(HU(=BO=YHW9_"\2,]G=2\O4"C9X!6'1 $F+NP2BRR"Y30S^,Q4->HWZMZ
MYIY.1V TC7/"GB0)S7=@^!$22*U]5/0:XW"4*M2;(5QO5,'-&)$$&Z ,.^,I
M$&R"8][I_'D*SZY6T9N<S_!FK8H^J%:-,:Z ;#*I>.OOGN^,CX&!YES8F/Y-
MF&O<>8$].#N[L,J3DR%"Q#!^K(0SAL9&J5KU$J!NJ>.77'A)BBON"MBJ*001
M8N!) &MDT/.V[@ VXX8FXPI9I97:ZQED3^P='2HI0BA)DVAT!C4O 8,8F4&,
M@[YMO-".\V?/Y56=X+9M\L2+\=9IZVDVLL3BC2_6V92X+\%XO76CK_;,KP^*
ML\Y.],W![ADVZA5&@A22Q!9,E /S&MLR>Z*!ZQQWQL)?GCUG:ZR[^?E?JS-3
MTY,)!>D5/9F^)PWG8%6MB0ON8D#.6K?IK@?A_[L>?KLH-3Q^%, VF>7+U<83
M[/!VMP*5YO+/<K_6L$$90EG5J;B[@^E,/9 I<6XTUWH0/$7)':NU67CNNB=5
MDO2_6!<V_"HOTI(JWQNCI@4*=+]*=QAN6 K<,%9K\:>GH^&GJK,.Z']7(A)H
M2'_@BF]%0^-7ZV<+,8(+K\-ON.@+#P-]<D 4^=[9H<DT.FHCM@47./%'X'@"
M1D2ADMD0(BL>P,?N\#5-:9&F*K+;3GMY/:@3>F:NB>XZ^Z,A,R"C%9;=2%8U
M"]Q%1&0M;>U7)L>;\@I89G)^\9/6M;F! H_$F[>'5/O  DU$&0R=<*=)B)(3
M'6**,7G*<<J>7M,1^[+;8GL]NO/#1<]<#+<U=ZC\'DALX?Q2@L$4=7V_B'MK
M7"(>5/R/F9P=#_NYGLI1_;*YMDP'R2-)('[6 9Q*EH!QT" H6B8GIPU9I\;U
M<81.D,HLKB<T@<WS8^/L6)('C7WA$PI>D![U/6:AQDO)<(WQ<G&'R^D4E7T%
M9CTN,&6<]@'VN1_7KAB03,VCNK7@&XYNL/\W$:1?N.%E<3K_\4RH?N>ZSK F
M'#11*P-S&5>1!![1:55ZZK0_,\T[H5? A)\_NJ;$Q330-:ZL2F#XVJ$)#P>*
M1TVF"9+E"J@O/J]Y:NFW.&XA970!P)Y7[K"PW32OV_*(8TK= 2RC-:XV)SA&
M]#A) U*$2D-*Y@[#99EXF\&@EBXSYHO3RCY[;NR79BZA/Q*V.2]YPA<T<R2V
MXGNC"_)#+!\L:BRU*WVN"UPXSL=PN)5GJ::Z95K\>KKC29?BM75.6JDCF/:1
M%N4R+VA6TNT5G]]&PYAS&O\R&I[,0K=U(+<EQ_7D^/%L_^B0.FL8Y9%$%3B1
MIE#B$S-$RUR$,R#P"]CWPGXQTVTM-598AK0R=P@BA2%>IE0U,O8HQGN)5.!_
MBNFD&PBN5POWU"LECS(^(.3)6<Y+VOI&\[&B=%S-*E=,5F 5K(#+K[&EU_)K
M037_??S32@K"?I[4D>EFD2U9KT]X>O49+,>D!1B)01)&07F7GDMBI;0DBY!I
MMD%H7;FMS"TWJ)>29FZ4CG#\,D?C ]!K8"7:R"B8$FV ^=N<.8XO4L*%R*(F
M+. $&PU_\Y8ZXG/PJ6 O;YKPS#>U&IB?.<:'^_UAG+6<OX0?R\@TKG,TAZ<8
M4*[UVPJ1ZALTVN!I(YQV.KM]4)0NY.P*SFV)-*T8O7?:>RWVWAZ:9!T',B.&
M*?03<$U" H&JLC*&&QPK2:\C1K<;B=+*F7L]=^Q':;GPL.TDP;83&1)@#FA,
MH#Y%SKQ6WAAW'3F#&=F758[*Q1'FF2KS*7U+X=3!+/VDJAJM$&N,0?[*M8>W
M71R&B(G=<*RC? P7]_ZNDJB&H.C_T!^.QS\N)+MDD%I5!.;BB3?->%E!N.NK
M@O4>-%67(W@ECP5R"1T]%8K"/WNX,*SP;)94WZK.&)L]N1D46:/QY1SV^5KN
M)2:-['=Y ,VL%! UU]U!6N'-UTW2V\NJ5!2''/OQ\9O1;WZ$[NCFWP]&?C"N
M7Z/EW?6\^PZGG$7G V GCL<.@LAL([$Q,F+!'@(;W5N-0XS,&D/\_D/;+>D\
MB CY)R CGZ+-F5$P-7 8FI:".!,M 5(2*6CE=$Z8_[PJ CJ+Z+^,[ LCCRI]
M<JD#REPG3<V9SXW;90M\K29[ <=M='[+_$,,+<PJ[A=C$E5'@%D:%VX[NJ1/
M@;V:>_1&39I5%6[!*YO,SD$3GEX7@*F2"NL(]@VS"K\RPKB07CC7%N?^PM_G
M[UO%JU].\\'PEXN7>%&]P^[X(M_P3?EMYI^9U: ^V03$SQ_9_M%AT 8NS)E$
M:K 1%?/$!26(*""%J# Z28J#L.F:S.C_O9!&?$5:7\BHUEU*,3SM3\=55-''
M.,*""^3OZ0#UKPLDF@R[G3"=7,SNK&-P:ZAT@>[KS,-%'6O6.:-.:USFIGG>
MXIZ'.S0)DF+U#LW5%Y4 -7_AUS/+>TVB"+!/5>AX6D=L\$=P#799N_R\+G8!
MP8M!5\25XBU1D_95G+2)?EX[<@L; 9N>!_CX?L8[/D26?0&J_, /)G_ 2U;L
MNSO>7>34I624I\NI^R_WQ/[9H4LIZB@M8=(7;!F7B=7!$IMH8<P+3Z4!3A57
M<NI*7A)\6(7J:XNKHN]EJEG;=^1&-')]H@!%$#G^I3\?[_4&O9/IR25]$*1J
M_"E-1\F?/SEB>/NYFI9=E"]<$6ZL(9@C2ZQW@N1 P>C71>H@L.O%<F^1SJ3>
MV,X6[7>>WLQ(L;0[#VUFY!?;LBRU<0G".&$$]845J2CPJ_4J.5>2$M9@Q[$'
MJ0,#=X\[/YP=9P"I$4I.%./H:LIQBK3W8].RJI+"]PA6+RZ6U.+69MR2;W8/
MG0=K%/:=P#E8(KWC!&N]B5%!*,.X C'V[+E8Q:V%8Y]C&.PB9EGVA@G'4,Z2
MU>9JU.+/0/Q5A2GUSW]$.[,NI&K*?@>75,S%*WLG)SGUZIS=TQ$8IO.'I"K'
M>-!D R^:8E5J6P)&6)>Z-JO4NLAE>U3V56U4O1XLJ&VMUK:6X.,YVE=%:><=
M=O'1"K0VS@C8/(GD&%0L7@E)_5?:5W7RRZQJ:V9<;6]8+5!D944]:N?*EOW!
M7L#+]R:=W5GGFD?][E>^Z9N%<D!!N\T<\D7TJE2ONG8.LP-CO37SICY=3/VM
M<@1/A@T2-E=V.Z_^'E;%$/_,OC\Y[OS[WR_F:;%A.!H-S^"ABQV'_M%\..LW
MU)UGXV)#H1[@[JBWDC=9W?)HZD<@>H>C<;WX/GH.1^-.&0W!QN^=5!TRJW^B
M"ZS*51YE)'Q<^2XF8[YH@CPOAB,PMWT#S< Y"72V'I9;5\(&4*UQ;E9#AF%K
MD V/JHV8#(]JW60>3Y_MX>)++M/6Q<L"NJ*OM"H>N9 BLU>I=KQRFP+M9%Q
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M2W:;2N/F'2\49O@Z]QJ%*7=>34?#A!KIJ'YZY;;=3AKEH+6ESFDALY2<PN&
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M;JSSAS3B?N=:GD@FVKH[JR1A__3]D0#(USDW1"J&U7<T]C)5%#Q?2GF /V/
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M\]ZYA<(KQJBW46 A;664H310F<O,YEPZU=86^Y>2 K-]+#-6*!^"(4R!5R0
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M89C/HPBF/>JRP1AWNK- Z%1P4;-"$&,518PSQ&09Q_Y^0=(LCQRW*>DV;1O
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MXLI1%:/HH6::8U/V,,!^4@X\J4(7KFO*LV'G!_-C4AX?S A< MOW97KNZ7@
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ME<^H&N?G_<&H<8%GL1)O]@XT/GUC+W@ C++*!$);A]^H'S\Z&?3'Q]6(,%P
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M(R+8G"A?%(3&PGLM799;4/>";P&EVR!U_UZW,6K?Y'O<N'A>GDD*L+01E76
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M=UC1]^_V7G7P-&>W&P9+,H\?-=5?:0IN?.'#D]!YU3^#)U^FN&*: #/ ; 5
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MLG?KR9[7FADBD'B5!0H7P ,9-0*%O@;8><#(FB2 3J'7!<RI@[MVH";_[5_
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MC?PMUWU_J4-Z<U*'EJ8 W9K2,Y<")*0M:# \N)R)S%&K@I2%U[GR^'?X>BE
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M  (_G,2Q4#(Z%R>857&.^>IIJ\N,.MU@AJ,.H]MT0MJN:[XC\U\IE>8&=I^
M8^E']*?% T>WGE6Y?4YFYY!G\-M8..<S!M-L#?=%;K.<%EJ8O+B+HUI/9!.$
M2,>R 'ZZYGP8?FI^^!DS>;KF\J>RET D7?0S3/TQN.MUY$*>+QS)2@^L/JX=
M>2E@ 6A5YV8P?92L]O.WZ;*CKM6'P$"VN5S]^8T7W_BAE-O%D]R8/=%]A;K[
M3*PH5WI3L:%;BX?IA:\N.2A<Q:2^TH'8A0A)BB#-.NIXEF?F9.,CINHY')1>
M?I9SV9'T5:<S;ZHVM8'+C0B]EM==J0C?Y)S1QRK%-U'N^%6__ZG9\JDWBM'8
M_[<_/,>MHV&]^7,7^5HU'?<Y!;TQ8K-\MO[W8^9A'<4JO[4NR_>+U'BJN&)*
M"1L4T&]JF/9**)-ETDBCZ)RW0[,5(9M);'':WT$_YSI6PYY]L*8JR7#V!]L_
M/;[8WSTY^7CJQ,'N'_S#V6_EP>&'BX]G[[_L'>Z)CZ>?Q(>K7[KS)1D^[K[G
M![L[%)YQMG]U+/9W/Y8?SM[*_=-?SCX>OOZR=W5R=G!X<KKWZ]]Q;['K1>%5
M7F2"$9\;K,B@.3%>"Q(B!1H?;?1>O'B9L^U'=U5_ ,[<M]K"U]"-_[5^ _7(
M:IJ3G<E_>RK>P&/ @^W\TAV'SE[P,+A!J'-=GB2G(-^6=QC8DHUOE#Z2;2]Q
M$['F)][@Q<L?V(]SF[K?><N4I6 ?.)54^AA=%")C'*M8T,)1_+>Q3-S22J %
M^Z<#^W*AHYD./LC(#"DR*HF !2$V%!DQ3-@L9YB"4+QX*?(ENXM?I<7)U\?S
M=7=9>ASL;R#7WO_/3NNAP3SL 8_IF=HY0[O7=I^YP6I8742C':?!2.$,4X)9
M;%;!H@B&%ZZU&E_+:NR_FEB-RX/#3VS_^$CE>7 >S(26TA 1O""6*T&4!0\A
M"Z8(CK]XR>CCK<9ZRMH_'ZMQUY##X[!R ZW&_UZT&;/U\39L@YK)_S4I2WCO
MOU9NO==K1M"8_<34[*K5[UK]JNQY6,2?"'YIW6\OMV\]S 6OO\J)XMOJCD[4
M6@>M[C3DF?EEVSJQD%=U$:L.?!I\QX\'S7&"RV &G>I4P/2V3'U6X6MF>7^%
MPD@X=XM5C^Z8TXH[6X/P.6#=@3OE831?OCWK B=]4.?L3Q^GJE. \&;]\U!E
M_URG9ZPG;6;I/OD:]KV_5KK-C2D,_>'CDAB:)6VJ4Z!V#5>I5Y6F4)_49_JG
ME>M5[_,C]LBE@/FLT@@R1;?EPS?TU[0K_^S2".[[X5>?X:?(>V#RF28^O*D!
MX0.:V]<+>'"7< )_S,0]<I_\MMC[USL1M3KQX-\*OR\;P9.%WS<A:>(9"@/]
MQH6A7?+Y)6?ZFUGR[S6\?,<$H.&39  ]L^#2_4+1.G*3&2:8RHRPVFD6K*=.
M\&"E9-2WH>C%!B)[5WOPK(/#O2\?X.K]TS^N8!SRP]4Q/'._NW\*S]_]^VQO
M]Y@O-!"Y@FO^>2WWKMZ<[O$]OK^[E^WM=F%L\'[\/=^[^D3W__EP<;#[$3<P
MV=P&9E:8K-"L(-$5@0BF!='&PS\+IO)<YHPS"XBGMA?[XCUMA/8Q26'?_G:/
M<#+8C(7 &!4^*&SE(X,S>2%9 1_=TJ*\U;&GU+%L3L<,A072O"",A9R(6 AB
M1.Z(\[A%QZP#? 0=X]O94V>$M1M!+<S<+_$T9EG&BSS*((3-M?(^#S)J;E0A
M"GU+%_469OX-4WZYM_N'W-\Y4K+(!.6.V*S@8,H=F'(1,V*X+&CAG4I-%QE;
M<LJXA9F[99W>%"7[)GJXXVWVPI?2]1NGZ-6DG<?#7*%GF8/UL/,.WVW*VM-.
M5YL4_*(TWN89Q;IL%CAC**RQ-!1%)KFU0>6A-<1?S1!?7AOB_4/WY>"/HY!I
M$837!*PD&&*E)#$>[+*R-)>.FIS)# QQUB8%K]7</C((V1[R6$^4F3_FD,?W
MDJX+;I05F3%9$;D(01CN:6%TS*33,7?+ZY>T>/[OXOGD1)^.(2HC"/SAB:!6
M$!4*20#&980%4RP'P6=BF[7INFVZ[H,.>;03MIY3,?^J@_[5&,.DQ/TSI ?9
M/9)06N^X]8[OPJ:X$%2RHI"!!0'NKQ8J&FY-QH%965ZTNV%?BTWMOUK8#=.Y
M,QGSE,1"2O".<T=,T(;8:(1@6G)O,$RME^PX?Z?><0L93^" <<Z,U2;/J1><
M>Z4$8QG^.P86M6\#:E\1,J9VMMY?[%T<%=)P10M&?.8*(@H>B:(A(WEA8VYR
M 'NA7[SD60L9#ST .',HCA?K/Q/7G@B\_0C1<SL1F(:\]$3@86HE5#4#&_4'
M6."Y._;PS'M5TC<Z8[E2C'$CG,MMS#*>.<LS[8L@JCQ"0.@5K&ZQI/YN"5[3
MT'1_!94_?]LT(M[%+H9UV=6#ZIP;('AUU*JMH[^\+O!K=K#[^LCI8 ,-D<B"
M 9.CSA$M6$%TSB(7+&=*N!<OA=A6*V"YKJ6_=2^QR /PQ\BP;KH1T@G%' 5Q
MT$%'D8D8;B'[K5@\K5@<'WG'0\X5)X%9341.*;&,Y<3D/J-P3RH*BWDHQ<K]
MKZ;' B9DWT<T3,B%RS@W,EBAN;:.,J$D4 >ON<W,+:2N%8TG$PVX_N 0OG?U
MEA_L?A#[QT>%+IR4-A*7,T:$S"VQ%L!#6AU8[@6#_X.4%&R[N$5*^K%SB W<
MZX25\T$X*\=GUZ>E0VI_7<:RZ@#DIU:O.=B,?0@><JHV-?HXQ_08[!2Y^DST
M]\!"^,:QD ?6)?BN5S';N%7\LSDD/VQ4>EA5,GC]]W\GS5[_\_Z_KV!E ::/
M3](*U]6C7G5A&GK'VU-M,1$#%K^!O4+^"N>CNI]FT_1]M*3K2-4\H&XY@IUW
M!F6JG% ?SI\?VE0'1+A!:L!=][*='4%JL-CTW"Y[,$K3Z<&T-N49JFH,]34P
MVF$)"P!B#!><I6XFJ7O&H 08@]G_7+HPG+MV>E23R9J7?UIWWJY[)834!?AQ
M?88$!:ML.:=%)@0U.E+->4ZC+!P6LVVCLVLQL5=OX7<PCMU/%T#.K_8OCKAA
M05@32*:P_UD1%#&,40)466=1>I-I_N*E7F)@;ZP_,6LJ5\ H?4"!D'\5;5Z\
M_-^=BD<L_CD%.=V0>MS"X"9U.?#-K\U^QYHN=M.^K9C-MUW>9GDAE]L[;?X3
MZNHT6)=FJO;-\F(V-?#C;P#YCL-P--4N"&,.V/=I*R%BV:O+YN#%O7#<'Y5F
M]HY3?</[@SFD1&2?&4[U%/SBV;@[*L^[4Y5<ZN[JYOAX$(Y!4;"W;M>#N4AO
M-3$0QF,O<X#X&+'8SVS/W?]G.-4>"\9250IJVL;!(U-KBVNVNKTH3W.1SD=W
MLTHKJ(TQ/'KO-+C8BGLCO0U989R2)A0T.U+\Q6;(Y?*FJ?M]6 _&G[R9U.\
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MI>PTCCF/B5+I,NF1.;N7@[ @$[E%CGI#$S-&Z "D!V\:,J\\I)?>Y;L6_=5
MY=BC\.Q5](1Y;LC*%1D/+MLE4LT-J>H32"6=441QC6SB--<CX$BSP)$"] K2
MX,2PV]@VFU0\N?C*_+O$K#NWXN5NJ*7"HM-.?!7-YYX)C:XFT$C81"B !#**
M.L1EQ#G5TB#BI"?2)&6DWMC6F_#/ZJ1OKPLS$B4S6B8T>M>^Z)1@-"\PJOTU
M 4;$.B>DC$AR$1 /42('( 0D20B:.!9"R Q&4CQY[U=)C68%(UE2HZ4"H_KW
MDAG-#XPF(THV @5*"219*)R; TFD:;+(:^&<5(1+QC>VU:;1)3-ZYN3<T]B)
M-O5BI^1'RP)).WDZ2ER:.RY-QH^29$*XH)"GCB&N?4"&!'#;DC8N),? :]O8
M9F83/+J2);W8KH'S@6Z4BW4K@5\E9,T-LB:#3-AZ;ITDR%(+?IVF!CDF'-+
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MQ:USWH;\H?P>M/LU?SZ-5"@I:MZ4@#\WP)],P21 T"/7 DDJ,0!^ K+'HT&
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M.6O;JB<$/0%33SAP?,Z=,#HIE*10B"='@./SA,#[)]C80!VFP!G9%A.3+!^
MM"^R!1S://7=(;C=EU3"&3-<&IAX23D7Q%&EE=?6<**9C6FJ)9Y!(NX*F4Z1
MB"SQ?8GHU$].8N>OGZ^0,TFF)I)<MH&&Q=8K$YCJ]9[8WX7GV/WVH[K[F5<_
M'"<-/"JJA+S+R2',@_!H'A&)X!HR1:,G;&.[!5#8NZH$>S6^,)H%")C/'Z6)
M*4W,HTT,.(@F\5SL31DN)',N,"<Y=D9)JJ(K3<R+F9B#'0$FAD85@^ $X1@2
MXL(Q9!(1B'H6F3$N2</!Q,@M/DG<[S<QHSJ6P1G5?Z#3>@ D>/.*!OGM56WG
M./)@&$D)29#2W$V (Q>"1\8QQSDUF"@WA.(!1&5$'B)P]E=*%"Y1^-$HK%1,
MVAD2DPT\&6]D3)&$H#%.E%E:HO#+ 43ULG9YK)C%3'N)I,8><6()TIQ&9(DT
MN:8(BS0WE#1;8C)UOT3A!PSR]?[.,3'!V<@YPMF'XI8I9)G#8/F(3,1H8O+*
M[5THO/4P!"X"[>L0[,TOU2M6B3(,P1CDZ%J&M)&4B2QY/4  G_,K,O2=VNY@
MO:B>B^O!Q[<B7R.QO<KI12<T8@%MC6Y[%&QM!9[Z>\9+ ,3S1BQ0K@OW"!>-
MV$_FL,,Z W<\6(0QK.=-LL/Z?G";_B-<G.<UK)%XW>2]NC#K/1A+%QOMRS(R
MMWP&^TX+V!KLE[V]LA 2TYJPB!WA4C,CB @AZ2BX40237ZPL[-7>S2TK;-(6
M_G,COC<F$-%79P,/KZH[QPIKA;UU"#.7=Z\)B;3D\?^S]^Y-;1W-^NA747%^
M^U12A^&=^\791943[/QXZY78MG%<\(]KKD:VD-@2&,.G/SU+$@A)V( DT&4J
M"0%):VG63/<SW3W=3Z. =32"F<"YV-H5DQV5_^L1=ML@ ;HS/,RJ$KQR9G,Q
ML9='8Z.A-H%!1+6*7%/NP =U1H%X"(>#E45C7UYC!;BUB03E-,],VTDA[CQ8
MK=Y$%%T@1B0773[R6X3&4GR_.;;RQM<GL)K U;OH#DRHNZ4< VOL)ZD(O=I%
MY7/:6CUK5>TOVVV!@=4\O6CU\SBJ<_IL E7GF]575,>0_79QO8O3_FU>U;K-
MWC>4NC'>'';6NMGH@F$\<@^>[72?S^UP_R8%^_7M<[Z'IWP+#[D_>,;W\(B;
MK-O?KF$WIE9+HX) Q'D.'BDSR&ELD2?.!N\I+&'V2'?T9%CPO[9KWSM9U%K-
M\ZMGEY7YD1=,DY4A5<L_-P^X\=*"P;5V6DFBG41! B1Q:0P",QNC:#G%+J1(
M?=K:E9.GE" KMUSL.47C5ERF'DX^23CF9 O\3![N+VS?S/-(D(N<%"0TL=:!
M.>\U$8C3&)%).B!K'!7)6D(8R,5Y;/?K$">.('.B#FS13;"J0^VJ&5OAV?'D
M/FMRWHBR-WC,C<>3;%E*Q[C(>?&:.(/ 3'+(V)@M2P.+R5.TSFSM3C,L;:]V
M&6NA4VMWSFO^HMN%N6]=5=E<0T'JP7O= >QDDQ,^W.N,UL3>(-+ $,W 5,6=
M>MD0.KLX[^7,Z8M6_D@3S*G:Y8#Y @W#_B,F6XZ1#>XSS),$$7Y*%']I-L:I
M&9)C[!_5FWL@RS<RO[DQ_J_P&NR1D8%!Y1(R/(>?$P-O27B#K(^6<:T#YA'V
MR!TY63BT4]L;EJ016;.MUM 1&,I;W_SO'S*!1P)&;*<=LR9TX3/^I!F_#QJ?
MP$7=F'+>8W5YE;-<RT<'[<XE^%B@*6.^V)10;,>!DU3)RG@-P%.]L&>@N)F0
M\Y%T[NH#O;YHCW#9YL((,/ .,WG (0SHSQ9,\H;);OUPG\+]/FOMB14>(YAZ
MBKCF 3DI.<+.16,"<9'"O$?0\+.\^-V+%\SK_\7)1M]&RX)<N;^#&I@L[SG3
M]U>N]6^#D$56IMM3B/&RTMY)Y[+=/QKN7,!P0V][<I/H#@F2*HD?,"3UK>";
MZRNSZ/>J[/3)V<(5^\5M;4S5/PNFNV7/>O'5\)<_0K-WUK)7KYKM:M*JB_XX
MM=TOS38:%-2(LPFVC>H+^V\/RDL$,SNT'_2K2%IO>#X&U2<[>!I?4/]-JN4.
M_LG[/[WXIV\*O: ;DQTERH#7?<#3^88%_PG?\".(ZG["1]<O1GLASB@UE3-J
M8/T]@#QL;:=@:.O6!L9N;5C-6JO26LK4C$S-#0U@;80'L);C)9L\33>-$FHW
M)<^URDNZ,RGWT)R+63CR5X%R;\0*'Z,Y'U)3X2<QG$_V$+W;-W[]N<]%RC1N
M%@MC+=<8.TH#-9YH&;PVO,_B-\DAL<A.R4.2\[7@YSO^>O3U&V]<O_MQ]-5?
M'AR^^U&_/CFI'QY='U'XS&'XUJ!'_/BT?C7!SW?::!X<?F&-O;=-&+MH[+VY
M!H_L1^-KX^OQWV]/&O0=._YZ<GIT_>]4G^0Q5XYA\),]4@XS<- DR702"4D1
M$Q.:2N7IUBZ=$EQX)#G?HW1HT:3 O^@SL4 @6#K,?#A-Z>,>?D71[_XPZM,@
M<.[1T\WJU_ALN#C.B1ZCYMB3@'0*!O&8,CNZ92AHG)RAT4B=,NW&#IV9MG25
MD/&)+==__D K 153H\PT)AH(*+^7C#LG+$N4)RP#IEXEX:9R;,V7*O#QW1SI
M>A*I/QM4C!.I>Z$38X$A(S./DK8&&6(\"LICRR4CA(E\0'-+<#P3D7JQ73;<
M=OGM$?QM3_?;>O"<\-L"S9=QTK;BR#T&A<:)UK''4A$I4/(<(\Y31,;P@&(B
M/#K%0;[YUBZCD[QNOR^7I3*7X-4*]NC[=?"JM.?[68C*<865EB9&(3D6UI%$
M;::FB9PY)<ESM><K(:J9D*TY$:)*D41)J4#!1XNXC0)I3A227#,)1C?E.,XE
M1+7$W:DV3,'OC\(\3<M+%&8U5'\\"@.V3$Y;=$CPG#[$@T16Y73Q7.%EB-,V
MR#E%8998^3>I-1T7$DL?34A6\>25"XIR+G$"XU8;ZYZA-5V)J#RWVD]$5(@A
MQLB G%<!U%Z VF.;D',4!PM.+*<^-XXA\CE:TVWP)KS\)O93F-^+'?X@K1R/
M,$0O$BQZ0K 7DURV*W)C'HY4#G7#O])HV(S%MJ23!18OW,EMSKDPLYR*E'NL
MT#TV-1;5[S]5):O?EED.*'&JQ@$WL:F^8I< U0H%J/J+^[H=;HI0._FE$K>:
M9;]L_#41MW+$2\H]13@JGCNM$*2)$(A2$CP6,1@5UC1N-;.N+QTB;FHWY^4.
MP_T:RDIT;GX -QZ=XY$I'01&7AB-N D>Z1RGQUI'DK#*9?HE.E>B<PMHC?H(
ME;\O:#>==J,$[1Z*!A-!N^"Y8T8AIS1#W$>)M-8688E=HIXJ;=/S!>V*!;(N
M%LC*>E$WM5HE1KDP$!J/42HJ(D^ .HY+@7BT&#GI)(J<.FD\YRFH)8U1_JLJ
MG1]MBSD*D2M&5%C=\>$]$M^#YL!CYC!3U;RG]A$ 8(V;(AYD/I5,?=V^AY?Q
M_8>//8"OGN\V'?Q944I79+.USNVEU8>&Y$ #'@J0&33L<E<+S2Y 4Z?;JUV>
M-/U)[<1^CS7[<Z(TS@B3$3"4"NXBUDIQBXV4 CMEN'PR;\H#D'64-+5/#E2H
MT4;I@.#I,N5_L(I$A6+4X'2E"%AG@T#4>9=@-^2&NJHW1<4!,L&,-F@B.""G
MW^[+4,7GDTG.VZ&2K9&FB!6!SW -:V<M$/J*]^=+;(-UW;I+_/-ST3*8)8\-
MH8%'&*4W(C(?-1%1&\6U6;AHO8__>]'L-<_CASXY49&QJ;0]AT>?,68XAH@1
MBQZ$S)*$C 9)$Q8G#G(6? 3//@'@H*E2!J"4Y6E( G57Z ",,K_4X]CXGB0\
MA=OY.>'IRP\PP (L 35$(!5DKIM3%%FPQ9!T*GDGO$[1;^W2*8R>-]QD-_3-
MO<%94]5V(<M9_LA0IBHBI>Z@]7@8THZ=V6QF-<^J7JJYK4F[4_4U:0*P5>L[
M2HFF,[E2OXW$<!<=-HJM8+'B>?HYI@GFK:%2$8<Q-SIH1I,/"7OO.#..ENWR
M1:'L^MUGQ@RU K9*+"1%7$F/##B/2+$$,"85YHGU>SD]8+_,U%JP_E\OVOZ6
M":QJMP1VX5^P,!?=J]K_C;:57X8%[/6%>^>G,C0/JKI!EY.#-!W5;NWKRKP&
MKW7LE<K>+LQU [DYV/OXF6&K7= !T9QURH.QR&8JT80YL2:)1 #(QGK6)YR(
M<%BGQ!RW@5G+;) 6-BG!N/%LG.GN5Z1R%0K]EAE)P1YK782!($[Q%7[/G6K.
MX/)8P5CE+]1^NTLD%W_X" YJ1L4)3KD*_U#N7S/"0?K[JWLC=0_RK.#:P?ST
M'[&2HU_.T;,3SW$\)/1Z-/$<)W0)6,8>]28;LNPM'2T:IYM(BW;8.;>M2H<W
MF==J@OZKX@&N92+@6F8"+B17A>1JX0E:5F*?CZHDD8I3@6UN'10%EIH;I1Q?
M.,G5F_^] /-KOPVFV45^L5?%"0]/;'MPZ-#HM/M];8896NM_E/!%'.R])L>G
M;^'ONJA?OZ-P#6^<OKD^WGM#ZZ>-T]Q+H@YC'#]*.-C[QNM[_YS"6)OP7->-
MO2.P^K[0H\/&M_KA$7S?$<E'$T?7)].8L7B4CF O$%,QTSK #^VT0>#A!DHX
M3=3E#L?;BFT4 TSAEUAW?HDGI(,]#3GGEP[V<.!<^W8#SPV;$TEA20AJ&4-)
M*8^X8;D%!_R0G$C";?))D2HIC$QV@%I&V%Q@"4 U'E4YD$L-@W_W@Z,EN?\G
MMN.,YQ//:43>[;]2;,BY@>$D=07!@HI(P7QDN6Y."X$<MAIA'!.VG 22?+8A
MJ9JDY5F?#-D-PX?[S:090>(9[:4-Z]'TW#@Q;C0)P<!XE@EY\"T1QTPBG4\<
ML&".*B/[?<LHV2%+E[:VF C<JIA&;SO=%)M/-8ZF//N*@-_]'(2K;AW=K.BM
M@51LH(=CV]6$#:0]=X%1F7D\P! *BB#KB$;,.2\3,S'@7 ;))]W!1Q,3+E&8
M;,WU?ZV-GP$$7 ".%<MGSN@PP?"%,:!!B(C* !Z2M!)9'C#B*C+MB,K-+\%#
MHCN*SRE<M#26SVH'A?KU+QL6$UI?LZ>_G,7F>0*J3:%^X)&F7 R)'*PRXDY;
M9"PVB&1"0X]=(LQM[4H]B\U3 C[%YEF4_A>S9\X ,6[V**O!U@& \-'(3)V
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MTV(SSV/0S>\H8AJLYJ5\"RNY/UC(/J@^A"FCG#\\ ' G#W.ELS):2A%+2F;
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MC#N26%A"L0"$80D<214)<MC#GUYYHJ+AE(,A1\C.' BT"\84C%FRP\B",0O
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M7;S$22FK5 GU%ZQ9';^Q8,VR8,WXL6*2"NS5P)"/ 7Q'R1PR7E/DE.$^81"
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M_;<'*B\XWL&X'ZSNCEHU T38P7<\B3MO<L:JX/1][__TXI_?6>_0A=R8+,&
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MO6[48!-YE"&/P( VFBTND<I-D/N6='*)W&/ZF)!%&0+TSG=]: TK=+X&H5!
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M1H1&G&N&3&RL%'B6N2SS&,-.O<57RH3D&XO.@;'%-.Z1#*1W&;VQZ!&X6U=
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M,['VS7AF\$&K>SH"#7\T2.6$RD'%R5TN;\J C$606K'G7*MKVR/G[SXBI93
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M=B_S;GX\RA@5@."Q0K_BL-VY1DK9' %2ZTQ[QUE8<%-G7E"995@Z9[C36C-
M?^(=]@RD0B[FMSM6H9JJ959DZHPZH"DG?\^R E K(&:LCEP#3^;REMXL=:8N
M*5UWIXB;W:*VW-5,-;LK/.>"YJD+K8X5PR3P:I!*.Z9#EA&UZCU7[^9<#3O@
M1D\(#"QWW&IX.A%*!FQRF>=&FU=O:]=2#^_/=?VK*W'US-8L#0U4N4U<J',K
MTM!^6Y4,)M0FP.G*K_$F6?G=SQXK-RD6O_34GW_'J[$^J;&J:SVUC%Q:%:4T
M/MC&\5A[ZGF7,8ADX=HE@36%0;? 3;W3AS<MBDCQ^:(=,^$"MUV3J2"O54$#
M/PM27;?%*H\%5H:AWF2Z+VO-:+5F-UXS5JW9#=9L/]9VOPEX/;%$GQ64<FF/
M7(=:KHCYNB497;6@MWE&-<(''^&-^>>662>KSAJS<86*QXBN?9\,L^/4B62Z
MSMS]6.CQE/#*02TY?(A;BMCF$CLM'B;%![QZ^YK\/N=7_X6T@.<6++YLBL\F
MW!MKHS7VVLH\\%P1K5FPC%*5*<EYP"G<>[%)[4*X]Y)LZTNVF*F^.!9'Y^L?
M$?Z++LXB(ORT?7AR?-;8AL_IP=D!/<![7S_^.-AOP#W-9OWKEQ^-BV]G]?W#
M3N-\+B*\\T]G;WL+U_</V.')NY/#DX_B<!O&3?]I[WW8^7&XO\/V]K=^-#H'
M+.4S?BXCPD\.?C3V=XZ<]8'+0)"1F4$\%QE2AGBDB#56Y"H+PMQ91/@=Y@7]
MH@R9%W<55CU3K)(&<TJ,RF0NN,;$9)XS; 11BBA'6(553P"KSF>Q"ENEF/0,
MR< DXIDU2+& D0C.<I,+[#VKL*K"JK68VTU*<AD)% U3"S[C07*=,<PTRXV0
MRLL@'@RKUC;=^HD 5F-.N5*Y")QPCV06>TMD@B.9 W19'O(\",4SFK]Z2^5&
MOJ3Y9H57%5ZM)UX918,%Q +[(.<Y4X:#EN6=,UY+P<+#Z5857MT2K^84++ !
M,:C'$GDN7>R%DR,M38XRY3@7QBDJQ1KBU1TYY@L(*LK,KC4,I:.)N2XQ2P.)
MEH4.584AJL(03\93.'4<M21[NS*T[T0.?%QP"FJ/<P/;@X03!G'&&#*$!;"[
M-0,QX"@E^?,K$W%')V@5H%: NK;NS I0'P90YQ1K2C$+@*C(,Y8C'I(/,V3(
M. R;"=HVXQ6@5H!: >J3\[G>!% K=\7M4'7>O1JT$!DQ'@FF*.)>94AB+Q#F
M!K:7$\#9[*[<%16H5J!:@>H#.88K4'U 4)U351U0O'$ZA@%IC#C0 #+&V7AP
MA6,UZ-BI^=F!ZI(*D7>0]%XFO<5AS[F4GV)K-T;%/;5VX_+ZK=UN^&4UX.<_
MX%\H$?Y"DN_PLOR5.UVG9Y;T4R7D50EY54+>>J[9RH2\FP#:727I/=XR;/V\
M_=9MTK9N2E6/DEM6#?+>![F"K_@#M(PJ^&H],_?TH%D4'XP_Q%)@WW4[U=E]
M@KE[M,K=>V$QF]$SS@7CN<4\MF@A DMO<<:-=QD-UVW5$KE@J^OB/SN7+/!"
MO70]'M][0#^2@_V=^#^N?_UXOK?]\:S^%=[Q=4?L;>]>-"Z:S<;G^48NQZR^
MW3@YA+'4]^/_'W\<;N_RQO;6CT.8S\'^-UX_J;.]#SLD]4_]/-O(1659SB17
M2'*J$+>2(\.P12$+7*F<92:WK]Z*#9GG:Q2H60665R#U,Y#B7#BK;0C&6YYQ
M;ZP7(L_S  0NE3#W#%+/+N#E ?%IKM&44; _/@BD+'. 3]@C@[5'W&=*>D%B
M0<8J5:]"J+68VXT0RBMA\YR",L4)"T9FA&H%XC9PYTA6(=2Z(E1C3H/BVOJ<
MB1S R0$NT6"1458@+A7&2K#8':I"J JAUF)N-TF]L-P$FX%A!SI44$Q+"Z8>
M!6F<>0U_*D-OO6%J3I&2-I<@7Q126@%6,6N0IL8A+3DFP@DKK5X_0^]./(C/
M,$NOK/Q]'PEZ5QSN/#<,O]GDGPVZWY4;KSA%JM#\7M&\ON"VTR((T#(="LZ(
M:!8[9+2S2#L13#0@<FGN",UOQ"!/(QBY@KB7 '%WY02\)L15)O6OH]N<KDJE
MI3H7!$D!$,>%"4A9CQ&F3)(<@V7MR#UEN57XMBZ<7N'; [D0*WR[;WR;=QEJ
MXD%M8P;9$+N'@61"D@F-:)"28JX"#[C"MPK?7C:^W94#LC)1'P;DYI0XEBG/
MM5!(V$PC+F6&I,(Y"D$YEDD7%,Z>DHEZ'\&,OQ2.63YC:K9SF6YW\OAJB$]U
MB/?H,U\3@7JO+6?6)=RZ>L8UGO&($>;KW1[FJ^[W]1.-*6=53/G+"C6XJ\.H
MO6'3]U]T9;*'4O</%D^DO"*YH )18PWBBC@D Q=(>:.#,M2%7%=A4!4VK<7<
M'N$4J<*F!\2F.5<$)EYGCCGDB):($T.0U,P 0 %6B9S8+,\J;*JP:2WF]@@G
M0#?&ILI7>CN FC\0\DQ3X@1&BAJ&.),6:>LU,AEFEAJ2,\Y?O25L(V?KU"^A
MPJ<*GQ[B!*?"IX?&ISD%2GAB P9H$H98,.ZL F@2%DD<6,ASPG6@:XA/5?1X
MU>-E37"^*O9Z[]Z_RKA^ -E@%QQ_V.9>!4%1KKT!XSH+2 K/D,.88"8,9B94
M+0FJZMD5H#XUEV4%J \#J'/*MK/",>D,PIXRQ"WA2 >ND<U Y>8ZXJBK +4"
MU I0GYJ?M7)A/!RJSKM8@U&YI;E%4C) 5>H(DE@II#SSBE$/)H>_*Q=&!:H5
MJ%:@^D#.X0I4'Q!4YU153X+,P.X'BQ^@E OXR;@\1TX&PK'PD@K][$#U%WN\
MW%WPY56<2",GUF9C*%<%J:JE_62*CUI=Y[O#-TC=?12KV*37F,6J %*Z*7\:
M0$I^OY^P5WFME?_D3_M^D HZ#YM^SO7N=;^+>J-AQ,)!"PA5)YQ,\_.N-NRE
M>_YI1:?]-J#4 +Z%Y_1A."6DZ@' X<#V6P:N;W5KC=[0U_CF"][NRQK4C[#;
MM;GMMBNK>\</X<IAOV7C5D\NG/JLU?T.OW3*A^EA[<SW?:WIVVFG.[VN/Z]U
M=/^;']8"0.,@$@,0U;A=2X&HXYXM+YDDV.^UM86 E3K2H*GAKOG3$8OA#S72
M6<RMR)2T&HL\UX(;L%K8<C5IM_'G0AVVMAX,]D*9&+#7_Q3'NS<:#H9 A$ -
MU].4\!/5E [_T\2V\T]7?U6CO0[<>?'NI+'_KGEX F.[^"CVON[PQH=_VHUM
MUS[H'-#Z_@$]V&^>_.=B1S2VOQWEA(*AR S"E.>QRJ.*(80>*>Z\\(XK9@1H
M.ALB*CLR6U!V:L7FUEJ#P2AU:@/V]?U$'6?%CM3T<=_[@O<=Z*^CP6 *X G>
MK.U?7CPHD&'@A\-V<=6_=7>D^^>1\\D<Y\>Q1)IJP15I,$L^N1MTN**/W:_V
MO[M_G>IJ\R;Q==R!][T.O/D\'I7WCKMP<T3V\T)$!]\?U(P?GGG?K;5C;Q[8
MJ-:P"?L3=[K9 GG?M\WS$K?C9\8?M[K=>.)>?M#WISV -?C@% ;9<VG?8:_3
MAG=[2UXT!2_E.]THG>''QYV#QC&H>=@J5YMOZT62_(GXL1&ET*FW$6';YYNU
MU=KCD]_#W6(OM %\M@F0>_!C_WOBRE*XGH(\]H.->?!N#6)81!$K4>S=8 B\
M5^!FTLV^ZU8[/2@N+$CS7OM[I(_: .;="B"K@,^=CXP>7WPR<L>1X>%%^EO<
ML%87%,!9S5##[QW3ZA:_P4VMV$VI"^IA? 4L:O%+ )SI]6'(K:YMC]QX]_7I
M:;\'LP'ELM9O#;[5M(NK7Z ,C!L(JHN SM(4XG+$A[9;H+6XUO \W3)8K4<\
M>5K86@:UO%9LO+:P#(7V$==]7B<O%CKM+JSQ]_1I6M((G_$FN#JJ?[",LSM:
M .\Q;$%M=%I2TAA4>F:H6PD-+.@V\"-L"&!T&^;D:M/[U/%19YSA]&$SDA4H
MB<-F8OCX^3S'TT**S"HD26V]'-3209\!8@&U@RX0]=09+NA[F&GO=)A6)1&<
MMLT-6)8XV/'S8;5Z'3_U]5FS99M3CXP7P7>F<.:<C^\;+PS<T_+?XY3":#CJ
MQ[=^]]T1+/^E()T(T&*2TSPWZDXQ>:M["FI/;51N^AR3EP%1\3GC0<QO_=1B
MS3%KWQ=+ GR#NGX$6-VNO9Z>5D&.WOV>+,%%0S#R7\FX;1AZ'&ZDT-X(W@67
M^,W:ULS$8%UA_0=^/)%??S-0+BA[DX?-O#5^T!KTVB4M]$;M9+:,VG$ L_#6
M/@<Q=PP2Z^=$-O/N7T"8.T,*=4MORMI@V6Y"EI-1M[ JHMI1<%#? Q[5ML;,
ML52YW)AAMM2P+WT/XFB)>GH6%1)S7FN5GR:_!=A>[;'_HMEKNZBAE/L^45IA
M5?0QW'$<:>K&II"4DC/'A8Y1#9E2FG$LC1;4&$M#EDPAHL 4PK]B"GWI1MW<
MN\H.6FX'[;+&]O$1=@9C$0)R6DG$,\.1R@Q#RN<Y)M9J)MEU["#8_+0+ &<@
M&$!H ;OT[+=5XNG2[%DMA]ZUM?V&/EL@OAC7VG.^74J9*'SZH%7#/8,Q$$6S
MMU3TX%510RKE?/P^C:7@"7B5OQQ+<L$47Q02[_\,:M%[\\T7C]J8 'BZKV2'
MR:7^QVFK?W[7XNF2O4KQDX8_GEM"[20!XM *=:+0!4/4%ZXC5*:?%\7$5:*A
MJ;_[4CX4<[AK"?%3^_57M=(235GTKR^ZG<I^T<4IU]1=Y4$$OKP%+(M>>S1<
M?<M";]1'DAB$L+EEG?J[V;_T!QQ[9( @OB$=8+1O=/M,GP]>_6NV1WVKBZ97
M<'[RJ[>@^'MN1PMTI3P8KS67)/,<\R"#Q];2C.;&6163-DL)TAAU8 WLK+QP
M%M!*$)I3J[@+1#)%&!$8A(10//='V]$&QO 'Q1\*']JLI)B<*$Z=,M;+B/F]
M[J=QM/R[&"S_98J)=R,/P]>]KH6[THSV85SOVL!(+TYR?(SGCT<,9UF01B'.
M<X:XM!3)7'ED<ZM%+IRA)KP";+?Z-/)(?^17<LWC.X%L4P-*12.PUAOUER=4
MZ.$TP$7+L)!&TYH6@/R@5C9Q'@,_" WG@<^ H_S\$Z[OT4G"0$<CO]WNG0UJ
MKQ.6]T8P<S?X_<UJA;:C^\? R]'-+I8Z_V+N3!)4$P1,!ZZP_&U].O!OQC_\
M 7+BM*W/W[2Z:1'337^4CR]A<TDAF/3"XNL21 3'FQ@723O]Z4/B$F,V\;)H
ME>)+SMBX#,_2[W]Z\\^?+%/RS]T_F*S!@)=G3E'VD\RI*VL\J85+K]TL_%'K
MBOU9\MT!\%UM9X'MKM-)_&<99W?1?GU):,.:+VK$JMMTK9^>\8M;.7Q;FGMB
M]?Z6QYJ]T^W"99VLR9ESE.+DI&J 4U477IUU^$OGZHOAAQ,+H7YIF']M#9L+
MUL!@UAP8S!H/8_OB/#WK140MGAV<;-&]#_6SP^UO9_7M'7QP\JYSL/_I6^/B
MVX_##[L7>]O-SL')8?N@-1^U^*Y5WS[@!Q?OONWM;YW5]S^UZA\.FXT/']G>
M_I_?#D[J?._#8:O1^:>UK.>U\3@GTEI$C:((K!&/-,71)@E9+GRF+,'W$[7X
M3*NOOW2(?+XH:8W./%=,468X5QHL=<LS+3*69Y@R/G&Y5RCYY%%R+K:;>XL%
M5@0Q3#GB07"DJ" HU\3+P$0&GP!*9ALJ%_>-DG<:NOW(Y8(?@^.WRI"$U86Q
MZ<TFO!3AGS32_9*S^#X@;P7B[<;#R4$%>7<'>5-=%4\.?C0NCH^RP'(9@8YA
M'1 'H$-*4XGRH)S,I0<@C$&>?"/#ZU3FZ*Y[$KQX+"!49XZ0C+A8F(;GQE$5
MI _6.FZ5P0D+\!@+[M%(O $6/+\"# \' ^>S,&"(U$PS@C*@ <0SP9!2U"#C
M<XJ#(R%S?!W+Q;Y41^#G% 6?0I-^2;]9,N4G@FFOGY&",[6+E99S+UK.N)BC
M\J#/&(Z\T&#8*<T0V/46"<\Q-4;B/,B5[J_?;VK3K9%_JP*#)Z/A5&!PW[K.
M.(,_1)^W(XAE3"!.E43:*XVRW&&C5 @.DU=OV8988O$\"A:\5!?.)U]F@<0
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M!!>9LKX:^)A](D1OG+OJWK-RE=C'SG@6.Y1L=O[G0H]<!&OP.#A!J*+>\)#
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M[_?#CZ^V\?;A =G=V^;[>[_UM__:/][9>\MV7[W[NM-?K4JP3;?W/N./KS[
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M:IH;4H&XUMOUE0YN_]D9L0[B<M34&<599Y"%D.UL-NF[>4W56>P98J?L /6
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MT$\8O]$0ZU)BT>7\ <_;6Y/6QF@6M0RRJ>6ZDCCX8>BN)@YPI##K<H8D!+L
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M26 T&HM$:(T=^5B2%_>=O#CM^I>YYXM.Y\T(Z.W7M0 B)!9BQ H%A0WBG$
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M<@$7LU(V0QI$#[.AG\WA&Z?VO98-\\WS##D?S,"9G\4S^]5MG?7LK)XH78P
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M=@89Z3CBA&ND-:>(AL@E"\%&KIZ\X)(W1+E)'L JQO&T;VPKC.?'U8L[&)P
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M'NHQ1@?'740T1HEX2!W_@6"J$XW28>V=6M[N[ 'W/\LB9&6N_BQ"-@T$9F(
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M1+<(A9., 6*I[IONE"Y43;7K52O[/&C69P3OM,-9Z[R>;I?D%ZR@%H=GQTT
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M+%;>([)$K*1D45(GBXHL4;(O*Z/"RE"!PB\E?>HUTT31"Q(E>[$R[=R,=BX
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M_GX.R':#^8I,A-4^,ZTS<]Y[\O3"DYXTVVAZ6V=WI'[$%_^RW:>SDF!T.G#
MZ;PFV]T%@$&P&RUSV@O/1K\\]\W>:<N</VNVJV>JOO0<=O8S+&%X1N)T7G%(
MNUZ_/5R<X'@'XYI>NQ5U#>\\7/L.OD!Z%][D=(>*Y6]?^MV?O%FNY;I<CQ_V
MYU_.:EP6PR,Q/&ET0O*LW4P_-Z6?WYK=7K^X4(V^7LUNW\"B"W*IBR'WX-I2
MS2[+IHPM!%,\D4UEEDV9?FY(/^_ACFU_E\*I[F]2"R>^6#A1G(73 Q%.N777
M@P<7K05F2X63RL(IT\\-Z6=4B#&N#MR#^YZTFR!US,4RC,ODR,6VD.O);J4R
MRY9L^&1L6&UG/YG6+LA3@QDC1 X?;'K&%\EM4C(-W8:&EK=*>1NZ$=XT@-?H
M)1A"?EDGKP_K[):RM(OQGP/3[<,FG<]6!!*,_KRL@7$MJ6265%E29919%<J4
M:>V</S628?+_MW>ES6WC2/2OH+(UN\FL)9&@3GMWJFPY3KQ1LJK(4YYO4Q )
MB2A3) <DX^C?#P"2.BQ2MG51,OM+/"->.+K?ZVXT&JT,HL)0,@5$: L1VJAJ
MRF$*>NV4HBZCL1! %*?'MH"D@*0 87:%,!VE",T:T;$PA=LSB,'SJI,8ZJ:
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MZY(&Q6W@]3M\C7@.>X?]WA%@(F'(W8<HI->,+R[IC$1>^.D@\O^(B.?.7.H
M@3V*)%S[(/,Z)'Q.PUNRH,&2V+3J&'_]DV7A]+N+)>.AY>?:STCP(/H=\% T
MPR[CY$B"W3";A((+\?L &HB!YEJ]HUX8X%^]%8R?7P+GX%WU'D1!;T[(LD$O
MLBUE3^(G]7N3X<?^AP\?WKT@@Q7WHY!;Q/<]_+77/ZJ'MHSMJN.&OWI)NS;Z
ML%I<]?J0M-NR#X5+J8PC="W%WT'%;@A  ;5_GK.G=S:+_)"_"N[2<&11D^0/
MP8M-\#O4%8#^.*F(?=4 ?^W)7YM@#L(EKS/L]'OQ6\& B>^S4$# )_&SY=+U
M9TP^@$?(/!\3#KJGLT1,YQ1!P3(5__M(N,U!(JH_?K?D;$EYZ-(@JT0$@$=.
M9Y\.0)7T$D'Z3X\\_ P=2;[(P5]?!?CZ'32AWLUJ($E;9,1/!P&0P*-R:@P>
M]Y+3NN.&)@&H(T'F?_?AV\2K.WQH8D?>?\3H'3JK.WIHXOIN@\%CZRF\MUSG
MT\&0@?5[1^;0.7S^]7ZD,7@$[E6K!'0"?-6K7P_AOS[^6+V5W=RS1%L+&__R
M;K/)!K HH,[8_U7\OLGK<>/X$T7##2ZIW&Y]?@N;Q0^3"55,\R!RW' $PI<O
M1$]JS7:NL6;2C_!G?=(%""L#HT-S/QS?3L8WH\O!].KR8G SN!U>37Z[NII.
MZK%\*10%-?KQ$C@&$DQ@_FBR!C+ K!B:)<'M"3.=W!$N*!"ZT,]VJ+0.4D,R
M7$ GU4EF_;0&_<\=)>%D"O]^N;J=3L;7X[NK^\%T!&\'MY?#\9>[^ZO?KFXG
MH]^O1K?PY]7->-)\^=5&I"'W,?R<JLB]0FB-KZT52@MP6FM(+8G5^@GQ[AFA
M&GW:6>[;8=6PR G\G.V"1?:R(T>\X6^#V\]7D]'MY+<!S-KXYO+J?G+UMZ^C
MZ3]:80X5? T;G,+/^^IL$&,"BEM97/]M26Q[6E\/!Y/?KF_&W]I1!BMH&CJ>
MP<]Y#3H"7$L [A#)QGQ.?/=?];<K:PT5A#@"2O3[\?[0#6R/!1&G\$<60$<G
M_)*&Q/6"QO.>M%=-/^@T_%%.O_53#*E+BNF"!&[ 9G>904RBQ8+P5S:;N'/?
MG8&J]L.!+?S-KC^_8YYKNS0@OC-\)/Z<NG[F)7=]VUUZM!XU=]8)S8H\[L?.
M@RQ+B,Y8;&9EN_,7*^X0OLATR5JAM9).6= K2W;+<OVU+]*>[3EL:^(FGQG!
M:6EG5!P'6^V3HP(A]$,X#HSO^.N]>-N>WE/R8(J0B[NB8CS8])\>OQWCR1[N
MV6Y[6H^7E!-\-*%S-.6#)K;3#^^<QC [.WDK+8P&8-)I*^GUW@QLD2?N:1!R
MUPZI,R0!?.>L'HS\)_C=."ZNUV,-:[\_D?&0-V'M5<<M'(IHE7F6&<V>Y5MD
MH*L@=!>8+_DUH+/(NW%G%+&("/GKG0<@ <#5'Y&[Q+DWB?6;]5RS!,Y/9'SI
M399 .B)+#LG",4F\<E1_L<2X!+AT9/OET*X\I83;*$DOZ1/UF)CB(0N,$_NZ
M;FH8_<.)C*R]E:P7W1>?9P9@B1'L&;I%3OG,F//L>IY)W+O9)S6K]C'$=_96
MK)KT=<^4+3+ "'7SW(5]]B (:!C<4J,L"T7W-*S:/Y%1R#=AU56W+=GOOUC0
M\SWCMJEW\< 0FXUGL\ LEBWLF(99A;W[9B: .'H%X&27]US:(C-,0F:+M&-G
MR!9+Z@>- Y=OTT,-WQZC^?I6?"MZWA-=M[)][R0#WU,;.N^]CH(@HLYJRB:X
M]2;<J<=L>FCJ &G_I%_@OTJ@6A)LEK IX#W)5I/<1$Q4!JI9V:=H[3<A8"=7
MWY03$#XV0JM'KK6&FC5UUB]PB&4!='3"&X14"YJKPZ#]]\<%L:8LF"Y&*[/C
M_]T-B7=);1>K!#0277IH&IEUCML^)8UZE@!LI9 [+ZW0=QV^;AE2JP100[P/
MN W2$$_"[GP "J>(H=H%'1R'H>OJG1(0:@UTA,>T<I[J+"AK!:OS]&B@EI2
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M8U^W.:C0U)@A!B(Y4[A =;$_18,W#W>[(#'^U_6=1,/*#">%;"YK8*KDE>9
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M4F.9XYU*^M.V[H@=!A7O3I(B,;D)*9'\FKNPE6T,4!"Y-(K8T_V%^$02L]I
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MM@B;C421>*]ABEN2.B3QWP)/.SF6._/N6*[E%8*C"CYB)FLUR9J.EARY)+*
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M-Y/-J;9=R)/YZA"DFAUI71T746<\9RM(IM82[U"BLM&FTBFU^W9ZAE2U<2
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M[9J1C/TPCJMB;Q*\5\0S?3:NANKF]&VF;BWS)0.IT']IW>N27$/PRBL0W.;
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MP<3(R8KG3O$^F10/$#8D5=X0.==%54OV--.P:Z+>+7"1ET-MXFVD"1:2=FC
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M,5]D968N>&UL[+U;<ULYDB[Z/K^B3LWK01?NEX[IV2%?JMH1+LO'=G7O\\3
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M2I"W%<K:*O04+1LT.,>?7W\[QRWXVNA\%,;JG(@UW!+IO25H>WO"-%B=)+A
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M$9K/W)&,5.:>!S2 ;_@4&\_[[G["H]5NAX+KT#M<HUK&=3_ N?]^+5J7I<K
M,](K9HK>"Z E2S5',X8!^D,A@+(-M;GQ 8]>F>W%5L/I*QO,#<=D9;"\@_E
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M2JGTFP$]#4KL(OT*298/#'V1#%C,M-%D=C&]7A4L>2$3!.)RV3:Y<<1G2DE
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M$3Y)0K734XTV,I^**"ZFWQ> /\!\."U>]VR^;+:W[.P]H%9(+G.)(/E I,Y
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M6OJ\]#/\7+IZXUI!O-U]X</ W97W?1BCN<_?SYEE&USV@EFI2RNP$$4NS2/
M6JGHX#"&T#;/]/JS3L:+_Y2<JZ^^:&VV\#&NG UA'-4F&K0(W2()FQ'K(!$3
M@@@\>#"BSEWI[7"VS[Z]_VD#[77.UAFB8CDFSED1SS7*@4=TE%EBV=?*P[T?
M6?_[2$4&W<[9[5 M%0(7#^$[F;_TT^EWG.RKU@$J6RL,([B\R%)P3:"[12GA
MV93T@T"9W<]LN@'T29.JC=(JF+&WX%[;$I856.:#@/9ZH3N1/"G\X8 XZA.)
M@AL5&!IELLZEPP;@GA:76BJG0F;I0](HV=$KI$!3C$(RXD!Q(H5-) 3*B1<T
M. @J&%8G^-X<X]-B4S>JJG);Z6[>7T,9F0["&$NRAEA0>A*<E<0KY8)W+DN5
M>U^7GBJ9VJNHP_M/I8SMJ^'L?#+SH]^FDXOSRYM[^&XY+!B.+R"=GL-TU;-^
M@T-T;12(G?$L \%U%NU %W  7 FBO4O4TD0=-.F U1VBHZ36'I76X66LG4=1
M!+K>U#-X%%-TN/:4:X,Q4!($8O<N"^ I4JV;]#UIB^.99ETHJ,,N[P5[([?B
M];?[QC0;H!?K)2!J'DIM;E.BJC99HG$X24H1-14-"-8%EJ,E6>^*JM"S_;YM
M?D"-R:5L&S'.ED*RF1/KK24FR2"8IR[*.K6([D-UE'3J7!T5VJAOW(\'7%G*
M?&1H\>$/*9"_UK* _&7!<F6T]76NEFV$\T3(L:L"*G1"7VR:/P[YEDA^?.-Z
M #90Z0/Z"B0%;I'2*9>4Z42XY$QK 3B<2H?I;6 ?-<OZ4VB-/NI7V4H/B6R9
MP:2-=<;S2+0"CDZ$2<25),:<'>Z^2M%0J:CXED#[RAGLD6@U574H"88/C>P.
M$[)DTR2NM-#%GV51$9ECP.&B0\*%2@(8+Y=+]Q)-O1OS_E,4*S!IRR!K1QKM
MXR2H$?)5;DX3[%4S(-N@WT^N9%],Z82@+=1\:%1E'C>DXE$KG30I1ZS$!@.$
M1?26DN?>B3J5;PZ/H@^D<CY&AFZCW0Z96>(]/^+.D^E;F,]A.IODEU-(PSF^
M\ZN/P]%P_OUM:8XQN[QQQQQ3PJ"C7O)B<SEG2R(2:T"HR!EGC6)Q.S[^\)R5
M[O0[Z5<Y':8 +>*'D]'((T8_^G,X__+K<.S'<>A';\:S^7!^L0@/KD%:ZZ+R
MCFB7,Y$Z(TB-7I622>H@T;.*M@&#&C_PB7"FC@)JKSHO8(P*F?_NQ_[SPEOY
M"-.OPWC)Z!"XER9&HH+$I5D[0[P4@?@0D[9&6T'5+LO- \]](IRIJHX.\W<V
M8EUUY1K/IS[.+_RH).$/EW'$%5HI-(2<(PDLHD-/K4.B)T^8C\HQG@P5=!?R
M//CDITJ?;E52(5?GA1__^Q.:E*_@?#(;7GD*N!)2X1-)IA1.8U(2*X0DW)7+
M[I8S7:G<Z&8\3X ^'2JD0B7B'T[<%]=Z%M<9+HNC)$^]4S03X8PGTNN,(Z:6
M,-Q!G>(RI5BG",$#P)Y"S*I+W51(,;T'WNJB61. 5:-/#T+<3XBI4\4V)TT+
MK50(%CT,U+OLN8N:%)\.5UO#B$T1B/+"R\ L3[9.?ON>:/- V&>_K-E&&778
MLB$-9PD;W\DOOG_$97==[#$;%B%K0D.I'V^T)B@83[1P"G=J*7VN<P:S#<K^
M39^.E7R;0G4T5.$&U[*I\>65^!=^Y,<1/GX!F.-&?M6@IHQI-)E=3&'VXOL/
MXIO=GYVXC+9&%:F(B1,.$LU%!N@"<*^($HI25IH;I#I)-OV,[RG88 ?(E K.
MXE: WWET8M;5[QZ&W9^!UQSX?LR^0^32?79 92+4MBFW@<^5S25$G&(Y39"+
MRWI@2T\@E:2)"7R=LE$'Q=\'[,]CIN\6^N_XG.#3] +^OBB:L3*-3-#1:VF(
M=E'@;F6AW(\)1- 4)/4I:G6CYL#&4.[-[]VSN5E+&9..)'D$A6E>S^;#,YR<
MZ8\9Y(O1VV&&\I0)RGC^_3U.UE+WL1A'YV7Z'EZ!FMWP'WJAF@ZT<J-@#1JM
M)BG+,M5:1B4=4U+SF+)-4@BJJA6LV6TH+;LL7__ZDVM?__:J,J;V.3">B?$4
MS?O,/7$Q>Q(EYZ'$Z_7-6Z!=]5Y^$%OK'M-W/>%* P/J;49W'3UUEF+I9X'+
MI05/&*5*>F8TXXWJO'<W_"MP>^@CV"U?;K6G[E@A5<OJW@EVY19G)6+6B8AL
M<)_UZ!L'Y2P1$+5G"7?;6#N'_GZ$?27/5^9,%87L.U.^U+#_4+:*9>A9R:!D
MI$3S+$N>C2(A"DUR8EYDF;3,J0F5&O4-N'SL_N-/72ITTE:P'3>/6(!8'U(W
M@-%Y&YIK /KO-;.C"FXJL87\*JK30J+*!HZKF;!$X@)&O*.".$UIT#8*@$:'
M^H>AQGOZOW2KQ6W$UK'V?D=)G5V<K=,:&8?$92!&BM*TW ?B(5,"#C+$Y#GD
M1@>CC?3WPZ/[[<&RL_ G74BN0]ML <1_NP9$+VHNBU(P@%$$8AT)EKMR (:F
MAI4VI>ZZ,_WPZ$>HPITE5R'$?.>6_^+[)_R*Q6(C@\]0&FMHMBC3%3RQ"2T
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M]"(DL=F5A&XCT+G00(K["CX(;F2CU-:#I<P=-]L/E3';Z*/CLCY_C(=?T8-
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MDQY5OXUT.PZ<K)&<?)[",E5QW7_.9X@Q6@*2<B*]4^7P6> *%ZV/U%&6?8,
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M6[";&\V*<1*<3;0E&2T@>$YL*AY]2<(6TZ;=["%D?<_+/9__.]Y..!8ALG:
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MY5WU'%_-E[?+B7<B:K+2P:JZ\*01G)4,T%D,+CH=3!MC[ E0UT&+H:3>(M<
M"R[630V^8JJ%GT+PP&.H4\%C38'0$H):#0\1R124D8561\M.0-=!A"&DW:!&
M;6,,_?R?3SA;8EWY)(CLK,@*F$%RV5%JLJ!% (\U*<;R'%2KRY)'8*Y#^7VE
M_%CQ9E@_Y=ZRJ9<VWPZQ/VI4B$\T1Y.9H-,*Y:K9>H20$C'4F1 %X12-6E9W
MAG@=)&FCD<?4L2-0Y^UBFI!/7/):D 4,@MPJ\J8\G7!.:;)[0LHD$YMSFUS'
MSA!_&.J<H)''U''-J//[797:FU+'HMU^^?8KRXG+0G.C%<2<1/6L#$06"[C:
M \_K%(GUXW)H+]8K)],P.GK,*M][^N!\]O[/^_#UQ"@LS 4-*2*259T\!.:0
MM!M3+,@)49OCZB&*ZV#"R7+=$1GK'5A]NY@GQ+S\A9:^\:/67M7$V<RRIN49
M,J5KKU(Z"H4WP$4H6!PR*=M,%-B/Z3H(,)#,=]"AUW7M(U=ZU:^RQE\^?IK/
M:H,8(Y-+G$XXEXLF=$*00Y42I-I.GQD5C>Q25W/P0<];S</+<H>F>]5-?=_@
MI>):W5S?K4:H/H+^>MT@Z'XV4.T7%)8?WBS>!OJ,<'/_]6H*3$BK5FC%%5YL
M;:_GF:5S2]MUFD.T+F5$KW*P'6C2%N7SY]@%:7$'04^.K'Y]?;Z*Z@_\=+=(
M'\(25^;V3W?XY_R7NUD.]8?AYM6','N/+Y;?[IO>%/K%69I^"C?WUY?DNJ&U
M*4-&6H)*CGR[K.GD"58;%T5DNG3=N0;$]?Q)>%9-[:#=R?';IQ;S:OX99V%V
M6Q.\5PM[L7SQ< U;_N#$F4R&>I @4@J@7)$0"J,O73%.):U9C#W8=B2<ZR59
M2[WLX-;)8>$N:ZA=&VH*6?BR_(T4]/'NXT1HK5TH-: @JHE@25R,-F3C49<L
MN50Z#4"CQT^^?L;TE/8.<IP<.NX"EXB\Q'1W._V,.Y ;XSG) @$5N0K*1 ?>
M2PNL%O*2HU%*Y@/PY$D0UT^9X72P@STG1X^[G<'K@_?U[,%&^=0^&5,D*\\X
M2$QXVB># OHJ@8LZV)@%>:EZ$&OI.%S7R[%1-+6#=@-'GM<U24QI;C6] "SQ
MVN*890A.!BA%"9:<EAX;=0=^#&:L]IKM(\;'R_926F=^OXY5(837.HJ"%G2)
M>GW@^B(5Z53%B%';TBP98AO+N8K\>FOW2;8<+>5&69??$#VH@NB"JVUIW1YD
M9^J6T%-S3Q*AI]C'I(6NLZ&C4B!SG4WM=8V(DC%E&%JE:<>4H]0NG+D4;2PV
M'"/M@>O"WN%L.E\\O )=%<;<82V2V?0LC.A9B@(PU0GB(3+PP460TI(B3&9)
M=AE'U^%1Y[8J3]7)O)U AYX\^ W8&ND*7E[!X_?P#$?-B^60!2N@K' 0H[%@
MDY&>RQ"EZ^+#=GC4%>A[:($._'[_CG^M 'U%(FQ1*H-#'XEY/(%/+$ 02#9-
M4$:Z+G-#O__4*]!B#S$UJ'5X6*SX)_TWZ]&V+*/E+($,RM5NQ8$\2^;H2\8U
M*[2=E#8=>W>AN19+O;>D1]#^IEZY ZJFEOIN7.>QT_OK[0 1>@B]@9V^!QUM
M1J@-2BB9"3I7DJ@[%()GB#PYJYANT[1L3"H<L-''8L(QLFXR__VK;;%I:T6[
MG;$"P>3:(%H8#K3110@QJQ2<S:'1Y-1'4,8__X?0T:/I[WT$W*#,^FL'E'4R
MZM=LI77[DJ)HG59FB 0,E,8(3O$ *=J0E2Y2Q#9#!)^$=2UFP7"R;U#FN(5I
MTTZO ZBFYL%.6.>Q#@94W[R5[!N<$;O!Q9PSN3$(4:8,RGGR92RW(+P--FNE
M?*,&E2,2XH"-,#8?CA%Y QX0G(_SV;O;>?KWQI\-&HT.#HP2N;:*=^ 5%D"5
M-7<$T.HV=SR/H(QO*PR@HD==UOO(]TPMH%XM,$]O7[Q?X.I-&*81U)X/;=$.
MJ@O^K:90W&FTD0L34U+.N>BCC%Y*C-E*4]2DP^>W:0T5HQ98N()(9BDHY 4<
MV250/'DF$F7VD3=Y'\=N#86U!IC'##('7J?8\%H"+"'D8DURTMA&0:O+;PUU
M# <ZMX8Z1MX-?):ZNC=E_2H1JND-[;R_A?_4K*R7\\5B_M=T]OY5^$0_N?TR
M\:K8Q'U-D''UW,T6G",GW<50K,VQ1-ZF"/\8E-?!EV9Z:7XG_60KJV1EQ.(+
MG=^N'KN,B!Y,!"3W/Q46;6XTAOHYMA<;;K\93">-VD0]B 30X3XQ(BDOO0/F
M4=9&GQX\>@YU+^3%:^W\&$WH*I9K9,/1,F[16/P[1"_#<KI\]VF!(;^9_7=8
M3&L\J)*53[SQS$95(&I"IS@SX"4=DLSRS%,0*+:S:9MP83_":V3(0/IHT"!J
MU[E8O;OI[<JN0GRPL6EC- N%CD4M!$&-!%H5!(N63DS%-(]M4J*. 'D=[&FE
ME0&;2^U*(,_X\5,5]JMP<_-V,;_%5>WFVP5^G-Y]?  9!<O!V3K1S1/DP@IX
M57N0"U128#9>="G)/?'QSYLB8\F]23NJW>W1&%,LU]V/U2Y'RJ[ZD.<$3&GK
MO/:,A59&[(4WH^MW O67]H"-I4:H$8\INER+=66J86R1);B@8YVLE ,&GO3V
M!+,?NM+_U-WG@K38H'O5'_CI:SO/36^<*K/EYCR>&)9D#-Z#1%?G9M1&CCD%
M* &=2T@;*;;9K@Y">][<:J.! 5M15?)_Z_7Z6_@W_NO#O!;&K<[9B<044[U+
M09-JR:Y,9--'8F\T&)VE]7?JZK#_"<];O0-*KT7KJ4U(YVV8YGI,>I9\2;X.
MYXN9\!A5>Q\YH-V'9X66TWJ;O.5;0)ZWTH>0[I"=I39X_D&"6/XZ7RYI5YG]
M_)];.IKNILL/=<'WO:],0<ZB#.!<C><8*R $5V'&Q)67W)HV20,'H5T'(X;5
MP) ]J38(_[68WI(77BJ<M2F];=Q,0L;$:)%@K*X]$94$3RXW"*&S<JBY+VU,
M@</8KH,E ^M@R,Y07V,U^#[<_(*XG!1O8F0J0@S*@E*!$V&+),^*#B\C/%K;
MIA/N5PC7H?33)#ID^Z6GLBI+<(X54H*3B=>C*T"P1D"2,C-$8Y0>X\KM(AH*
M#'B'<K1L+[BA0/&9!50>F):T#%=G@PM:"WK:BS17C&DW D4N+1_Y*.T>;BAP
MC)3'K!SO@NO';BAPE.:ZEI"?(O8Q:8$>:_^5#/1W=7"+HU/-*D@I9NT\1\G;
M-#"^](8"3=APC+0'+CA^7<48;E9AJWF8?<TV6B?*<F.=X98.RLP8*$E'9A"*
M]L2HD.00M/)=6@D\^9!SFX&GZF'>0HA#MP_X/DMV4RGE:DQ26^#,8&V.GR 4
M4R]5>-):6A&WK[!V-PS8]>%7H,W^0AOX'>W2LT!K;U>%DT5G28O- H+/M&PF
M1;%<^K+MW%]!$XB3-3RP0 =,C'O0D^1A0L7T:YDC5[1G,$.+U'4\5_%U0),O
MD(M*7G(G8LP=%/W4,ZY PX.)L$'VV^X2Z(3*Q543C$QV!7H' 9D"(8(KL6XR
MO%&ZTH6WB^CCA_66](CM(CJ@^L';11RCMX[M(DX0^GCM(G)Q].A(F%S-+? B
M@$O, T;/A3-%^= F,'/Q[2*&9\(QLF[2+B+=W5\7;,P/[X*/BDZF5 =8<840
MDU" AB?GA"U%MW' 'T&YF'811^GH4;N(/@)N7'IUCRBFZ+T-$HHJ"50@@\?[
M3%9*9+D(EQ7CC>:$/<)R%3KO*>)1NL($'DPE(GANZ\Q592!P'4%JYY00BEG;
MIMCE<KO"]'O-^PBX@;7W?5;\.H)(.T\IA8%#YD"I5$\OVH><\(3'.<RF38_O
MQUBNQ<[O*>4&/M[WB#9!_PZ8FMKXNU"=Q\+OJ[$G"=!#W"W:>^S"QJWRF@<'
M.=2^Q"ZNNAU)< 53C-K3:=0F86L\"ARP[,=@P#%2'CAF^Q/>A"]D<"["7WNN
M!13/,?' (/E8:E=A L=HPY-92*ZE=%YM6?A[ZHH./&C\@[V_+N:M!-G DG]8
M(;FFL?,:34:P7#!0Q1J(NMB:\I5#TMQ@$4W>[6TDUW*\]Y)P@S+4AW@V9TT'
M1$V/]L>8SG.P]]/5$XKO(>@&A_H.9$$QAWHU_TS6>36U_Z32'DK$(@6WQ8<V
MKMQ8JC]PH+?6_#'R;=&M[VXQS_.;F["X/W:8$%G6NI[ I0 E0@'GZ #B@=85
MA&;&M='W-I+Q#_B^VMGNRM='M U.])=AN5K:!@WFVI@T@* SBBR7VIFT)FXG
MHYR2T1N=VRCZ>QS/7LT]Q#K@^[Q<W$[^6,W2K7L45R')1-N33J%:I2Q"Q"2!
MP&4=2W3*=++5Z%,?Z)6^VM;I=X]][H;9Z3(<L*?#5Q!?;_4/PSC&!.NNTN'?
MS\/V5@\5;"NQA_Q:O)>;P*UPAF>1ZR19!/+Q% 0D^0>)+-E4K(N=>J!>AAKW
MV$[#:_$8L0VLO?L.=5]GLN2HZO9> @MTAC,!CDP^\%Z3IR^%]Z+3[74G_7WW
MZ/$.RE["GP\AN0;6S[Y^+6]Q,9WG%5'161U2+9TQKH"29-D[%2-DQZ5GS,:D
MQF@3N@O;<S]:&VFA28.<IQ!N\O<Z8!RQO&0WRDLH->FOX:,(U$,]S<M0]F#-
M3D>K @.[FA82.;F'QA!JK..:I1#:CU'*.":%CBI/.0^#CM'*Z,QY,]N<S(XY
M(^@\A1@YG:D&$8(6A; *QG1VY&RVN6_K"/#<*==#:/<H^IRFFM'-G3__FF]L
M.UV*%9&#7E4!U&F#P=&)KBU7]"YYY_@8K4CW OSA&'2::D;?@_XD,FRH;J-C
M/@L!I3:^5"4S\%%8XKMA47#,TK?)\.L,\<=CT8GJV9LKUG8LR+_"8A%F0\\%
MV?>I+0:#=%K!UF009*:6[/C,C5-DOD2?G1=,8>*>)Y\F71[0,XOG)BR7;\K]
MA[]9_#%]_^%!;XE06 C<99 *:Y.W0M1)=)+)@,XH9@N1J4T^SY.X>N<N[?KT
M?\ZFR^4=YDFID7HM)/#5!1]3#)SV$3P/) P>3<YMQJ(\">L,^2[#<>-16M-@
M"FA@.NT$]_-_<)&F2WR[F";\^L/E_4^7?!*5X\+*2&>T)WM/10%>,@<ZY:Q8
M2<SH-HV'3H)[_6P:5&%#5S[O GQO&:Q:M/[KPS1]V(9\OZ(:@WM1Z%CX+=S2
M+]]^V10#?#T:)L:&$ .].];5<B)K+3B1'*!Q(;-BK Q=<O :P[P*#EZ:.ALD
M^V\:AOXR7_R!G^X6Z4-8/GBC)K1!&V]* G3%DWV9,CC+27;99TNODI*NC9%P
M -A5\*N%$EH4!NQ:^?JZP&%V4DE;>YW3:4ZN*T1%CHBS49L0N56F39[)?DQC
MM6P;^\P[7N"7TL!MYW+6M\<V.%/[$1G-(RAA.7B6+60NC=>91^W;=!#8"^E<
M=W%#J;P+DXX6?8L*DUW OJ;='X;6MN9H/[@SE1X-H\8NY.BA@Y%IHI+4$2T"
M9VA F:0@%J^A*%2:SDM6RHB;QSG+DD9GQS&B;\&*U73D%< 7FP04$XO(1M>3
MEOX*N4",OC8I]LYP)X.1;:XZ'F.Y$-/T%%7MG$)]LISWAF_:QIM)47I53CU,
MH/G1Q[6(,#^->2NTS%!QE5$I)8QR23@GZ(\C_<;$4@F3)S^YS;AI80/S];X>
MB0G$"YT@2&=!X&H@<& BM=F,1Q\W;;SSGDQZ'Q.]3UA'H[CZ4J7,.;U2N> 8
M748O<=ST,1SH/F[Z"'DWOVI_<BRM=*@])]]<8<U;$9;L]$C G9!T!B-9ZHU\
MX><X*G@XK@RFDP:&RMO%G'S^O/R%Y+*9J7 _?*-4'TY' 2'7AE#*!@CH(M2F
MG'0L*QNQ#5OV8[H.=@PD\P:QUGT# ^M +2UX[<]<JXH$B^"<CM4M]%Q9KW&[
M/>:/,IZQWR[17]H-@JF;[>KG_WPB]PY7O'1*%*U] 1]$ E5$!()!_V(H,3-6
M8X9-"+ #S'4HOZ^4&U3@?[_,!^U\U_^LGOX?=>0CGX2B2G;*@<ERE1L6R=KQ
M#K*V(GLR\NG@&L&0> +B=9"DC48&+!<\ NCJ)IQ/8E"U3(.V-,PUU:S.GHTY
M@\\RD;.NA91C9.L] ?&'H<X)&FE>\?( Z.]W56IORL__>S>]_?+M5T@N3AAI
M60'FN*ICX1BXX@1@Y'1$HN4VMS)'CL5ZY60:1D>/677RC.D-XLW4V-6YRH,)
MF3D%.="6J$H@#UUH#C8+;KGCA?%.5:]'\^4ABNM@PLER?:SCD^<TCS"!VJO(
MA4^2'*]0NZQ$V@X](SG9E.A/E#IL5;;\T'/$3V'4A6GQ,3][#8G>SH_?Y,RL
MSMR?[O#/^2]WLQSJ#\/-JP^K:O7EM[#0FT*_.$O33^'F/LIHC-5)(,DT9$L>
M@46(SD82=N*R6)F8ZS**9&A<SY^#9]74CHA>K]%$^Q;S:OX99V%V^R[<K!?V
M8OGBX1JVC,))L/7$EARRB[6ELTW@$FWO3$LM,H;B=)<150/!N5Z2M=3+#F[U
M;+[Y]!IHY\VT+_\4OBQ_(P5]O/LXT=P6YS$#=Y9>A4R6H.,>07AT/C&K==8#
MT.CQDZ^?,3VEO8,<O:8K'8)+1%YBNKN=?L8=R)45/!090 93A\@:2\Z"42 3
MG=>"69?%H0OQWB"NGS+#Z6 '>TX..W<[@]<'[^O9@XWRJ7TRJJ*8*+6FHLX9
MDZ86'2H$HSAJ:XR/I<L\KZ%Q72_'1M'4#MHUF>^=?8Y."@&,SE-0IG (]7T(
MEF<1HU4BM"G!VP'FW/.]APL;'2_;2TD/WSTOB2?R)5T SJ,"Q4,@XJ(!S(F8
M[$+MF]TLJ'3)L^6.TG"GV7)'2'J\06)=4/W@L^6.T5O'V7(G"'T\2L3,,DH"
MY@JJ>G]+9UDH!D(17BF9;!#CC)N\N-ERPS/A&%F/,G0*;<182@)CR"%7T22(
M1G,H-BD6>2RIT02BRQTZ=92.#@Z=.D; S?,LU[1&3DZU*I!\,*!8R;4I)0?-
M%&9KDB=O? 0[\9H,@)Y2;I(3MV>*<A=<(W9A_(;L$CHO'J^Y)XG04^S-^U,]
MP"=%838$!]IQ2^SW&H*N';1H)[319I=RFT$UX]+AJ"Z*[=APC+0';J-Q/PW]
M03+$JHAE->]>;Z8H"2Y3= ER] 3/!@[>I A.%B-$J<4"6XER3\V5?^I1YPXM
MG:J3Q^/E!Q-H R-@E;Z_RH%9%[2]NYVG?Z_8G;(55I"%PRVA4U@81$EG: C2
MB>RLYZJ1^;</TK68!,/(O%W7B16>>^IW031&8?@#3.>Q!@92VNZ*W[X2;U<&
M_A!944RKZ&AORBB W)U0SSL%F5E3E"JAN$8C:4?BP $38#0*'"/H<6J]A?(L
ML7I#+V(&I:6OIU0&:;3/R%-QLDV"Z@75>I^LH<,EWL>(MZ41L,YZ)8"?YK.:
M]+IN#IXUE]8&R-;5=EF&P,5:U2=3CBCHZ]BF-N))6%=G#/26?8,"FBU,FW$
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M#],4;E:.I.;1FK3JTL5KLW9,$-!(8)@SMRIJ^OY@]31[85QBU.TH'<^'EO7
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MT3+99C\8=AUCA;\O@L=GI,"Y0^L#Z>'EE]T?L(I"9>--T:5 S@9!)1L@)A^
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M\5&S%^XC<GQ#X AU=@MA':V+5@TJ'R7UP[]75Z3ZHG4A_L$(2W:P%W5XL4=
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MD2(D+*6:6QJ\LQI$<C&2J64SJC'-U_N(G'KR7B]U'C'RM8\N)A[YZHAI&62
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M=BN7:WZ^G5DI)5G#!LC)CJ!*%$2R-%!\TD4$(61L$W\X@-CQ0=="[ZMQE=8
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M'=EJ**,+G=R<3H&7^R@XK4A^+YVO!I3]P&&X*WKJ%>KU27P]DJ0#47U"]GV
M<9><<:/UPVCJKMH'$O-H&(C1ZAR5!!UK1V!FR=82IJ8+HRH%N:4#^E1U_T!0
M?D35]Y'NP+[0;GN[&?)Z3==5L-@7+81S53DFU3JF!($K(LYA4HC6QOU1WO=Z
M.H\]8SS[<T 5K!K(;\! 5J7K+SJG*EF5U2N+FPZP/?JLYKLH,_B@R1H.F9'!
MC09LR"G2X25<-AWTV^59IZ[GP>79^$;UB>O#[).,AB5PLE;/LRP@INB@L.!U
M3"Q*V2J6_3P3.@XQ QOKK8'_>L_]9!>*7A,ZCM#BTY?WAZA@G(0.E(+34F @
MG"<7/"0$EX4&E@Q3RG+C=?N\L=-(Z!@8$WTD/TY"1RY*)8<<C S5&))(QZ17
MP+-'AU8+9CH5\9UZ0D<OS3R=T-%'K*,F='Q974[%7BP_AJN2L;>?PO+C<;D<
M3W_K<&D</3G8R^ HUD5DZ#5:J6R]_B3/T+BBDLRDH)K!\?0#CMV1-]LUV<$7
MM3%@O6VITW^PSN?$6V%2;4S24H),HC92JC>\UA:PA:S9K),QOE5?@:>I._Y,
MNOV,3V%-LCW+,7#R L@'X"J2K<8-Q%+]^80Y1"&4[K83'<GQ)353[$D#H^+N
M<72DT)LD==RB:<?P;F.N[-?_WEU6L>8/JY_IQ_S,LF"9Y B<%5^'$27P,GK(
MR:*HV96QM$K]Z$/G<P?/L(IJ<0E\RUE\D.ZKWJM.>,F30BBQEJ:4PB R7F@M
M."63D<Z$-O5D/8@<[_*N,8Q:*6;J:[L. KP,4ML05>$:A!89%)(G$00+8'DQ
M3).]:52;M(,G")M#5&=0/#QZ]AVGEP;[5>V%MB>"Z^NG#H0UC>,\2-I4X9P!
M%;EJJ85181*BL;$87I.N;"VM%$1@(9]3E1@\>B[1/@=X/!G8F0(=?80_\#WA
M+^2=K[XA_HU?<1V6J;:!^8#KSU<3MJ_KL:\OOG)$F[4 Q1*Q;P(#QY*$K'PQ
MMF2/>J]XY]Z+I5X/'=\6'DA1JS&DW&1B5MJ5YK\EL^?[&"^B*+':'\H&61/&
MZ02-PM:!)UF69+U)IM6 K'O(.750#"?K@?>#O]:K@INZ5X;SZUO0'YB^(I&K
M@@%] )%9@GKI#4'*#)RP:971/-@N.T''QYVZNEM)]L&KP.$#OW]?^C<UN+FN
M6;Y712!5<E<?;;:KVM!]=;[(U? ^/!I\\*.&"A$/P^M>W%B2H9"4$;GF/F=3
M0O0I*RVT5T9&[LX.?NJQ^>[W/O8]DH=;-Z?EQ^JU?_?>361)"'+<H]8:E+ )
MO"-7"@5#KGQV@;6)*_<D=+!R,73%V1J DMY5FR\D<AL]\<]<TCXY%.@:N=Q3
ME8NUQ,2#U61]Y#QP5M5E6Z'+N13$W.8G+*OU30?P#^$_]>;F>\7*F[V*%13!
M>EK;4&QQH.BO$)1P8"Q'58>L&*\Z'(;'4?$\43*R=IJD3UR)8T=-M2EV4OKU
MUK;^X8=M_3)8)8Q40M&FH#-Z4%%HL@&-!5\L=]8'^E]NM.L<0N]8 >9Q=Z;F
MFILZ[/Q@,K2T5J1D-'#N=E:H@AB,J5.;T21T5LM.\#NY:I$QE/Y4N4@?X8]6
M*M"%J!=7+M)+4YUJ!@X1\W@8X*$45WL2:<^KB:8A>,FA)!%#YMG%W,GVGZ/N
M^Y:+-%!]#^F.62YBD'M34B'#G.7:U$[1MD:GJ0V>EZ)02M$EUG,*Y2*]5-"U
M7*2/_*8H%XE8&%%(9U?2A&05')#%+" 4E"HKQ7*GJ/XIE8L<JN?!Y3GPUOW=
M,"&Z=A;P;J^*RGK-?(:B&5G!V==N+[* *"6J9%@L8KA]^WX:7H@]-X "!JSO
MN)^BZY*I#C0-;M ]1,WX]MP0FGI4\4>(N?FN<$6;5U$CD0>IGD=*)0]>$6TF
M%A6EC!&[]4F:H>H?,>?&TGP?Z38(/.T"9%?Q@5_.%]>7S5>'5!+HG4L,1*Q&
MB:==+DJ!X)B7:)1C+K6):C]*UKCVP3":6[42>X.[_9LF/==GW_6-L]%8N'40
M8RV:%;6?OLP"M+#T$1-*VS:W^P\0] QP,(2H&^P*;U?K+RLB#/^H?LJ.LNL6
MLE8'9VT"9B(CPD0@AU9+.D6=<F04H^C6"Z(W!AXDZ1F@8!AQMVA9M26B*CD_
M76P62]QLKF&Z.PN9MZ)XQP!U"+6(GH.ST4!"6]#DD'VCVX='R7H!/L3PZFDQ
M].22ENOARQV(:9IA_ ,YTV05#ZBN.PWPCI5UDQZ)MXGB06JNK 1&M@W9-+Y>
ML"+ME*B<06.5U6U,R1$4_T2^\%AZ[R/BH3.$+W.D_FN7(W73S/.'HRRIG(4S
M&M 1=\IS1GS22T:674 6</^TN#\M^,DG39;C<(@:5LUD.'"0^"W]<)'"^=^K
M\XNK>.9MRK2J73J=@FR*K!.V4IU9H(%;GUFV3!KT';3[^%-.5;,#RN[!==NB
MBG]7TE!O+"[GJH5E_@O7NPN,9<*?P@;SF_6ZEJSO=K-C*OL/>])PU?X#<+J7
MR:ET(@Y]4632$5*2EX%)$1,I,P3I\MFA#SWR4/ZT6F_SQ>6=Q+OEYF)7:4!F
MZ:X+[V;?B+VD[&<R9<]77RH9'U8W4_E^O\F?J;/UDE,9DJA3Q%.A;:G0B98T
MX]H)5AAK,[2]!3?'FCW_6'W=*>S=\O;\PFZ#"O_ [?O5^3G]_K_#.I^YQ%W2
M%H$76[T_6R ZJ\$4KY*6.5MLXV -Q\,$6_;4"-\WTB8"1(/ X&WZGYRYR662
M2"=C;7A(=FU4#GR][[0Q1FO1"!7:C*_L0^7X\)P*#8_,5AU4E?]_>U?3V[@-
M1._]+P1(#BF2EP))%RARZ098]-"3P8\AUH W=JT:1?Y]AY;7NXW31-H5)77C
MBPTH@3'#>2(?J:=Y8]LU=,;"?Z!_-<R[AY-O0'DE\WUG+7#3PUK@J10X1Z>Q
M>)T8JXF.0;&LE<DR+F4P$32&I^9CSU/9R2-_<V#^'P"DQJ'L8;?KE+U^<_=P
MUA/10-[OMSO<__7XBV\/Q' ?SZO?[T1,]W_OU^6AT_U^O=WW&:Y5:@R !4D;
M$6-HT9,-<\1F66YH)?0^NJ:2Y]54&;ZY&V;1$*IP!CU\D+O+]^4_OTPL8L4#
M[>)HZ\8@&E4Z!UOFM72,1V<QI!PXUK>#_YX,WBS49X' )935G% ^WZ^M6+F$
MR449F2]=V%0J;R:CDPP:RX4'CK:?.GM2)'^5P!7($P+@$L=Z>AS?(T6?B+SM
MT;?X#KOOE?%@,BTA+#DE* _4+ 05&'*%T:>@(=1A)V-E<$7RE!"XA'(S/90_
M/P"\B7\>UEW[UW8%*)TI5F<<.5(60K"0(##0*8DF :=MY4* _%S\5QA/5_Y+
M$)OI0?R>/FF'?.LWQR9%YS]3*F"U@DC;82>/% F8,Y$H?^ )N?8)1%X(DO\S
MB2N<)P;"):;MI.?44D?-,U$AFZ&\HA<I5JD#$QBS4=Y$J7QUT X[J9CUL5\G
M6\LV*^5HPHH.;&ED'UB@+1"3J,%';'S&.N8.8V<R64^"I3V6FA42<[<TZ"?-
M$BI++:-E4A1;#H3$R@3&''%. .51U-*L+5'@.B]@!DE?AQ2NOO*Q1S!O6_HZ
MJ%PO2R"_8:RK T C+P<NG@D35'E>9%F05C&M4]2-@P"F:C.TQ4I?QZO[D"&>
M7OIJ96Y45)*R,_'H-EA,0QTS8#TTH#G8/N+(Y4M?!Y5AF/1UR!A.*WT-0283
M:.^ !HY6XU#:?%)D0C:RQ*A"'V'SLJ6OWUK9$<>NPCS];MWNMJW?_+K?'G9$
M6-IVG2G:X\"6"<HD1S3$.)9R$$Q99YDK\FMI4Y8F(KA^=NB#9^Y7 KM2P)&+
M5T&F\4)XIWNJ3X!5B>&K(<Y#%D<M;'_0?$=5IIV:3H%:"#QGF9D$I$";G)GC
MVK*L W?"2V=X\R/!YA6J.2]JAA2C#EK*"<GZX8!?M1SJPJ8K^?;Q@]_@9Z=J
MB (D>A8%Y:^LSBQ$ZYD3MFE$XV14=?S-AD0Y/>$9N<B7$*I3H0HZ[[N'N/V$
M7_9NW0'_AX^(Q>KD)J5C)?RFY+39$@O ]O;Q7\/7GK66S^=]O".E 14Q%;/T
MAE.60 D&9YCFPHN8LO"ASAGR-/E=2=HRH51!9S@HX-_\)SQ-*'W"GHX!]@]\
M'EZX1"R]1!0J Z$VZ1P0OK%"6-JOTYH(B2E%:V+PT;%&)I0\@\BZS@GGHO#[
M"D']@>$[I/ZC-Z4]8'=N>.).7$KN5&FDFGTN^L9BC>,4RRH3>](6&M?GL/7I
M[\[,1VL58SO22 YUES]=+A_!M_CS3_\ 4$L#!!0    ( "*/5U27\W:#DUD"
M "L7 P 3    979H+3(P,C$Q,C,Q7V<Q+FIP9^R]"3R4[_H__MA"DNQ90I:0
M4 J)9J3L29;(UE3(%BI9RC*6$+)6%%E*D76R9\G8)U1$R"AF!I5E,E,9#[/]
MG\[W?TZ<S_F>_^^<\SV?[_F]_I^GUSV>>^[KN>>Z[^NZW]=RWS,QWS-QP#8S
M(U,C@(65!3@+_0.87X&M1]S\S[L#[@!TL3 G@*, *\O/Z^<KZ\^+G>WG*P<[
M.QO[)HY-F_Y4.+FYH,*Y:1,7#Q?WYI\7=+>%9_.6GY6?G?S7HZP<;&P<FSDW
M<6[^AR]F&\#/Q9K-<9&-119@Y6=AXV=A=@'2$(\<?V*/!?A_+Q96-G:.39P0
M&SP00=TVB'TV-HAI#HACJ#4<:@?8^3D$=NX[LDG0ZARG[&4AC:CTAUQR!E7M
MPM9O2?+[SU^)YMXL(KI=3%QAEZ*2\NX#FEK:!W4.'3UF:&1L8FIF8WO*SOZT
M@Z.KF_L%#T\O[X"K@4'!(=>NQ]R(C8N_F9"8<?O.W<RL>_>S'Q4^?E)4_+2D
MM+JFMJZ^X7EC4T=G5W</YF5OW]#PNY'1L??C6#QA>F;VT^<O<_/D;]]_+%-6
MP-6UG^-B =A8_GS]S7'Q0^-B_2D#SI_C8F$-_DG S\ZQ<]\F@2-6G.<N"\IJ
M1'$)&:0_K&KGEMMO31(^?^7M9A'Y W@%\L^A_6ED_V<#B_ZG1O:7@?T:%Q;8
MPL8""8^-'X #X I%FA[/!/PL0144L9<\A3?N2)UH[I+B8@(WY+K$8ZFM%03>
M$Z>?)"SK/#Q=>-I=(FAZ+D5ED0^\,<'8?)\)F 8Q@;ZX1B: ><H$8BS0L\KY
M=5/T%N3<M^MT1@%?F_3?)+QI@<:5Y/_(\J<]]<FG74<CG_Y!^@?I'Z1_D/Y!
M^@?I'Z1_D/Y!^@?I'Z1_D/Y!^@?IWR8M(P<0_#'YV$Y\5E?^-IHVFOZ4=BT0
M'E_7_T++YU[8N0@!^VB/FTTQ:OH*&BS+J*]QZ!OJV$[&B1P"@GZ'UX,)F!<5
M\$TP ?# !,/Z/M6%"4Q@&/F*J*EY&LO?"&59$Y5^W]+"1N"D"<,9W'@2AA ^
MT.XOS!B3XH.I/%/3/,QFUNIK\-E2>:6[#UN>?T'E@WF#I,=35 H2MY /*A5W
M6[X/H' .14C2N,D*H_$$=%+V8I/RV.*N?1^\UFSWKF8ELR>]NM(*[MRJ8YMM
M\.2TLA21";!ST6\QA"(P4R1S](U>'(+'X0@JY'O[(8]$FE?%8QY*Q0D&8UR-
M?"#7Y9S##:7]L:=!L3TFG$.(S6AOY'C9= 6]_C[)?'KL1M@YS<DLM4)6$-$E
MLH+#8O9<UGO<MBC$+7]L]:;\S!;BQ> ZW'7$(H(DB+,DYA(@ 2BEQJO^0/%\
M!%/Q[[(170YR46?C?DPX/WEW_<ZKO8\,$RZ8RI_+/)6D.*.S*G$"$DULB\TT
M$Q@W)AC3A) XU&+ UF8JC+:/W &&6H^@:%=&(^1'=WY7%7 Q&SZAI0HDP,:Y
M^<VOI$Q'''??G,8W[*B"5P>5+&FB@FU,H&J,)KB 7Z()Y>,P[<\CE&DP,IV>
M6U?-!#KLL(=GGS4W9'HZG:MY;K?[;+:.U7UQ[9, ,L<_.2P,XB,C+)RJ-D5C
M!W/(5 ;W2 48C%?$)&M(5$AT,0'2@R/!Y4XE*2.?TKS2)C+>/FU.*+1+5\C6
MXJW6WK2-9>V)841@ TW4F.#1B01W>T3"<;G2=<:+*N&DK\.$UBS>SU%ZINHI
M%742@S4ONH(Z*$.3<CN:6^H'!(UNOSSO6ZRAX@:G)#"!Z'F: <C)!#CLA^&X
MN_7P9[F8I+"C!'/-1E)K8T'8L63##U>PEGJ;/!6KCOBQZ1_#O+XL=&YFD\O#
M[6P_C!+!HQ1>J(_!>290:TR<);,QN&]33S->L^$5>^ <3G7$O%QW0O=H+?'"
M*V.AB8?/O\G(6LH2Q.Z:;2-G7GQH'1,'YC !3M://A&<]$<,%08FOV8LGN:/
M1X\C3R?V$UC!8DRPN-:3$N5LD\=Y'=C#APC[-WU1Y):OD8.G,8$F:34<WU"B
M"B%_&Q-H=P]3+X'^[( T(AI-$P!W:M^LW?XCX*GW&=[1%D/Z_4"_*H1F[ ?3
M0T[.>U*%._8ZEY;?;&Y0,\B7 -D@)KC#?.BEM'TD1<Q4S0!- $503-#3)A_M
MD=,G3R5<_6CU]0 3V&1.66DX]_E)_MJ)_DM95TP6V+E0L]?*%Q0S6592;R O
M6HX'8-"UEC>1;JA-8<&DR2=DE8[LZY-@?'MF=N*+Y5N\L[2O,<.ODRZQW_EN
M<TDB+GP76A%]-A7+0S$B(VF21\@3>-]BFN!73+NTQ-6!S8A>PE2BEK2@6IWY
M8;/M[L-W6W+$?,^F?/QLZOMQYJ3$OKTZDXN3\51M9'N(7C#5-4R+;$_<055G
M])^1(%MVHGG"#!I(GPJ]I+M&4[N#Q,.R3G9I+E2H4/4>!\7IG'%)NN2\9^N5
M('0FR]IAP[!0ZBEDN_W%5A'&) ."K^BS$:^9P)8]>@'DI)ZUBVM/OBU$R(:K
M&Y-&<W>TK$@%?B [?3#[UA+T32A*KI>#YQ"G<S^5'9I]^ZNI$\$]4]O1%^Y'
M"$Z$&$_'MQ^^L&!.AD<MT<R&YQI0DM5'A#]6%F1V&-=><^W4J1<X)F_@ZMO_
MG&T!J_)-'5=,DUP@%U-RZ/=:#X0A03$(5IK?J3T&Y3P;)E5%F8"PZFW+ABIN
MW?Z=N>5#IKM.18V?353\<',V3T/.(8("\7T^8BJ/!_J;S>B>%*0_TQ/$45%;
MBV]RO&Y]@E_H?Z@[-U8_W")HH'#*:K>?Q4NJ;?6AC-(K!6Q33U'WX+@R!,EV
M*B:?9.8?*8(0C9 %SU.[UB"+LGQC2(\?5[%[=N?S4=0]O]UN9SNV6UTZ8UW1
M< 4H?U,:DK\%&KH#S9"$9FSF@<!AUQ1QF&1L2%),ALF%.![VP4-]Z.V<YM:L
MD#X9Y#52.Y<7JFNJ^O54Q9-3NE(Z)UX)J97JPU)!.M4YXG5^]<QU3W"%'&-"
M(KZI5=N:5.1L,C3EK<)NY("='!6^]OET(<>,FQ%7X1[]3W4,=EHXJ$H]05,?
MCCC &$ +7D6*@O;V]H>"FA].[B$=M^H[-!,^9F=G9]2IS+Z-"]6!P@X3^(C[
MIU-!721^-(F &%\Z.KJL"F_/3DG&3[%X2\'?Y)=XUGAF#[4,.>=HJ-YZ9J%'
M])_I_1ZQV/BQ)6(VX@VB1KW-<EP4[Y+?+CV.POO=Q3&!S>\M#U"P6NG\IT<=
MG%LR!+IJ:O;-WKL=R:D/ #G3:.(.$@_%A;0G7Q#I.75K4HP$BY*,AA/]A7SV
MCAM\VV:2O*5<KW?K5OXKF&>:GZ6W0N9;FF2IGN@E$6))>4&RED@R52L?=A@Q
MNK>29L1]K<"IG3]/$\@@QYW4462WG]:F"6H3S" !!"-Q!'7)L"!ZL2MB&PT.
MZC[RSL[J@#3(.^;-\.+Y.,9D7U=.T*K8R[N5,^>WSKW=_ZVTE$&(&)>N5F_W
MG[A-N4R&+[XF3W4$72^*)1S6<+H:FN1^[0 UX];.EL@\USS%G6][N.1V<+.S
MO=73)?!*=+=*5Y'MX]6'EBS?+1*:GS7=VE%S5);36*R]W9H/5G<%K<<$< ^E
M27:O_1E<_:B(-U,UTA#@7J BI>:8 /\!4 ]>')*)Z2FVS,1^ZGKO^$$O$^6N
MI)STW(4K1_5["4^MR)<(>62[9R \%DERD.9"MLNU6%'5N[Z'#+WVKT5)CX?@
MFA3*'%U.5"C</EWBH.UX2$APF\;V?7/ZTH%O$7GPVGB:J%,/$Z@9HPD[F4)+
MPF&"T3'&V#L69GX^ZXS8*$US^DO#I'Q]S6NN#"SAC7S,YZA,N_UW$@\/^5UJ
MMMQ/W8]LCXC0I0732QB[D>WP0']PU_(R"N,/F.X;UE,M##.N;QI2EXD=N9"]
M9).)5:A.T'O)E6:X+^U-8E7<JB?;CZ%$T)[!#6$)Q[T1-*Y,FH^A,C<*L7-'
MB@N\3[IM;P%W(-UE DF\W;%=MY/2+T9@,YL?;7(ROSFUK;>F?XOV5ZP>A@*'
MS&12H/H$'V4[M#P\0VPHJA8[&:Q.QL&E(8B38/KS^?H.[N+<PD8+7?Z7"3R^
M1R4XY5GG1B/A!C"=B$%I#O@%)-!/MJ%$@KF%(+S3;H6__7+EPEB2O\^6%!/#
M:Q*S%EUG!?05V4J$77$#/>@;R%K+3A?M:>FV_)MK\*0PY?)K4^-G=@ZJ9WP:
M6NJ[C\OJ3^>VF]ACO1-C9+2C[#N<4@;-:^QI9+LU'#>>F@RO(^9W..B)BJ#P
MKPU>AD2$>WIODO-YVBW"! X>W>;;'>QZ%G,\KZX/V;X;C2M$<L)QF6B2STH[
M&ILU#4LJF:\O*?7!VB4_FMNL1S0^F=^%[4W90?S6%>6:/OXFJ-PW-@A[BX7*
M:9%Q^E%[IJ'+*^%@+0W+(\NH@68^4/5S D,"6@0F$6*0L)B M_KX]\[KSG#Q
M%D7W2IHV^7/G@-1 Q?N761>N-L3-JEU=T-FTTA H()NFW66&OU?\"G(XK/U!
M)0QQ!HG#(2.GGJ$C6_F_#($!G8>2P*S.22%_L?!4AJ#8[/#R=M?&UF:1;SS'
MDJT#)%EU]D9X*-QGEY$N10O!?UI '*K'DI,Q@!"!Z8+^G0PM,JT(SAGB8?/.
M3K?B5,-%5DWX)#)=VS64EM3X'&6*>HF"'$ZB'%7/$])RQ+AH&[H^BR8(-QV%
M[?9!X5=(QBD'4I-6K(WQ.4FYYOW[!KSK]QF'4W2G-$XG2<*WZE4O)A'1_$C<
M\P@]\ BD:V$DR'@'$/(7+Y][9#DM\<6I$\Y?V:K0\-[_Q^JC;!,_ ;[%UY_L
M0^3KM_EAL,99GWSI<P"=ZU&+0#^ECZR50UZ!W(<8F!QM_V M7UP^IYZV;RD8
M3P@-Z3-MO>9[ADS,ZU_<+1OB:^61M;(HK*;:M_2=R_)./F.K8)(9/5MO)\2!
M,#EX\1D6L3@QC4@8"CEJ07;+4U4G2'B*.-T4=<P_+I)GC5VEU/2\51CN>W@4
M6!W7EWXB_+T(4B2.H)]V]TOP6N7],L8DG(?X>?#KY(1#BJ7(1(RKADYR8=8G
M^@0GQZ7++[O#^7T#_$-]=\SF=IAO>2JE['JV;][H*.M!F90 1 Z:Y*0^7HR/
M7\R%/!9*V!70F%1F&#?Z^B)Q>8?!K.J(_#OUKRU'O"X'!"I;?3?Y9H)1/,AB
M>ZD X"N<A1CHA91HM\P086P75(D.4S97GE'FG0[I>&\HM[44U<R>JN\S=_:(
M&*?,#U2O):@=0/$ $=3ST$.-05,UVCV'122F^,">E6[QP*G[K":4UPH_.G3O
M-;"*>.9?K$*?NFI]R/X=$ZB3I@G[#>-3B62<):@PMCA"0EN2!WKXML_9S&>G
M4C[?G#)_2]M?C/'5;,O\&E+Q5>':F8.2C[FE3#S[(5<C,CS!0J#+W9,]T<5V
MOXR?ODZ[W"".8=2J24^$(+=B@7H!0?,!N1^&<:<:@<LD;;OF(<@V8Q>ZO4?%
M[Y M]O [.WI?X%#U_-9UU&1TGASGW#-Q.[@'3O+UH E94A;IZ AUVB5Z0:M\
MV.ZW>D>?A-1@FKQ]UC[3=AEUA\EY"-]Y--J#L?3QLGAE]ESRM=B>-XLNXPD
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M<ENKV$)JQ9=#,H'V(T3Y&]W!'OSG@?MW#'>S1ER(.3O;+H8@'?,'5986,YC
M,^,HY(4I+&8Z*Q[&3SL%'L$W^W.'-+>CA>I"KO*\'.W8Y^]_2/7[,7>[AA39
M]ZOI*RHL[?[#XABR:"<ZGJ'6&F-+]HBJ#;?^-,8X[*>Y0T-Y)OX!K7S>[/N
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M:EM[<U/+SLA;5[2RQQAOAIG YQYIZ@\EUOQUDR%-N@>Z,F).(J=.!5!U+9E
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MR5-*XGHQ9;RI2G3C<9T,Z5*SEB>FBVOGM4<TJ>KS:8[JW:[OLT!4RP]>"OV
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M\!9L@'BMT0<C:O\I$T-.5"//.SP#I6IX )6KU$8FY^S2[>,K]7"*7A<T#8S
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MF"_S1+2*&>;-U\ED[II*1+=#.,):5@P=2D8&YJM4_Q5+,A+I]H)L=!&%5JF
M*O;UGEF= )^VG%RNND*G2EN9<Z;QQ)M9S"9TDR2^*MVH?7[GJ1S://:D]/A
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MIFPZJV'@VX<Q&K#RX/?Y:YM:FXM]KD1&J8Z&]83J&O1"J^$"\+Z.\?=M2'W
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M>*1;,E:0[N+4L2FTNC2:( 9?7RFVC_6RQ#M@C:*4KZWB;K95$?QGY):J0ZF
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M),6[N*PP+\T(23E#YD@._=P.&]F>KJE<^KI*/3%O!>.K5U=A[>.TD3> /_U
MTG?/![='W!4HNP0F73K,Y6>)CBI;K/B3O.EL_4G>5M&D<$CXH-$H%="">FGS
M]R)&>00TX0.*-AP?_<"4([1IE0CJMSJO"VD/P;_Z*:FR! &AH1*T%8\WI] ^
M+&B%UMWKX(T^,%&"(F#DJ0R/7?ASVRO%>;%]OS3MAPW=G_(>_S1Y#P9^4Y'K
M3:;$3 /IO&S":C29DBW6#",U4O<?QIWW'X\)*'.;QX>AD*:'H&[814)_JZ)
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M]5J?R;>.5 "7MT<GF!5Y%RE)J"-RP+HPW..:B%#PB0K3N@YFTT>5U3>K4^I
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M6]='+\XE?$)_/=W<UMC,$0?V)V6#;F31>XDZX7(!.*'ZE*<//0H!*19JP;>
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MKY)>'.:S^W;MU904$&C*H*G*#3_W>M^/7K$+6ZDN9IKE]DG_^:=9=!^G*@N
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M*H/AG!;XJ[I4R?+ZP+R''[/BM+ CB4F8NHT<C$T;K*J(W)?-786]RG?6A8G
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M)$OKZ-3(DX1[9;U<I'7^;X)I2X_7'^MHC7FMC1O].B R359:OL >OA >,+<
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M2'J38-3*+<27O65U];($;[:1X>>V3ZD;[9BAA@;2G8 W+D:0.UM*B'&;OH8
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MCAB\)96)\FH]VUFBH#-_@O=' '1!NJ'H\)LM/4G=QB\'5K6/'58!J :$B6_
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MDD.6ZU.!X,/52<\R3(O3&DQB\^>SNA(/?C:0!MX7=&$C"?@:?>8D"TUB,33
MQ%D#XN;45.;B"OE-Y3!UPHV\#+_2#!K><3+;,5&I3: !E /=@<PPGPE44*UJ
M+^S^>-=Q4&R6J4ZI\GJ@U6I\G880<-JE)+K-6[8+8XH7QI5F$[PF5H*I0%O#
MI3/?947Z<7$V;?ZZ<U:@]E.6I =HD;9WD=E)MX)8J8.=8GSYV6[FKH/YMVOR
M^G/?K;VR-KP;(F8T4UE25K->N'TN#=X$VO^]1*1:D]#0E#3;*&%XJ<**P+G
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M;>__,=)]OU9VR-V5TWW[;UG@?1V_PLZGY_=R\=[ 8PL>3 X0HG/F('I=##"
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M8M,%IU[($=?SP:0KZ]%;6W31_KDT[7=PE@%(/>9WC@IW1N ELO8,>X"."6D
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M,X[N03-F_=NI#2X P/N[,N?B,+ZPY"_A!,DZ2>5"/N4A9W 1M^O9$;W>CI+
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M0N%MG?FV&V N48GZ$C%JP<-9DT';).O<!Y)3O]Z 8+N== Y>@A%#K=:P,JK
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MPS6FT^'P]=A#A&V:YJE$S^YGFY5^1L4"=^RK8[OMK5743!7#FVYC5BO0G*@
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M^W).71H9>-1<(+O//"S\FR-="$J]PAJO.3PD-1+.W2.U%*70BS0!*D,)V;L
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MX6,8-8(Q+?#M(UT8Q>2Z3.#;?7$2NGH?0[:&\:WU"# J>B27W/P/S"X8%^Z
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M2 /$K3G;:Q1\0IAZ+=05\]CK8B!,S$KIP$S6S-F;PV<YGKBYTL-1/5<A'MO
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M^+1Y/^W\%YJ<RF9 ;/6+\T;VH&3N(4'(*7SS4GXR:7&(E+]BV32IK<\]Y5'
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M]C'C5[@YJ6WS^XI L.;)+AU J;=Q U<57W=<=80U62]F+;=(N4]]\;@F$K;
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M^/KP93S- 3SGS%BBFPQM@Q31W1#:)7R2N=086A> ]3$6-6B_4SMY?SQ1&.!
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MC,"S=8-N?\UX'@"T*7*=DK'AMY:?=[QJS3S85#3D/=RY=9DAT1%14.C[]E
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M2P_S"DIE;&9Y:DTJ!V7G+RO8VL(L6%95N!MUG6?^V%9'/U$2MY-OXH#W&E4
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M8I^"C&^;O.J.7TZ3RSV?>7+/T<OW15[IQHHSC3A]RD< +WJ^&_L9+-"1T#H
MW\>"A\<@<6*QM]\IP>QI25C3O^8^!3*^OK.['W,]A]IJKZ+Q\8+GZ3#1#48X
MH%3#XL/3.?$RC<&PQ%_;(,@BD-5[_-:A7H>#T''M=&;4&X+E"@)SLP,I=$L6
MB/[Y3NOON@)@'78S+###A'&278@Z36=>F C94+#/Z1UV;.[J,&;\@,.)[M\9
M]P)/U:=!FCPLOQQU.E3T^* J_S)\#L+8$:I]@NDYW ]IDJ4JT2JZ(?(<OM,&
M8/E@N #*!%,")/?034$SCOY1F!AIZDL?D54UFV-ZWE?EMZ(8;'8.Z@3S-F<0
M(X[QP4H&71^$* "A[MH.5B5>OG?*_9K:#AWSDNX/>^-\/V'0.@*NQK49!3RI
MU/P L/QT%4,[L\-#-;)%LYC6*/WZ7$NZ>3SEM'/6T/$S-O61^\QZ6C;>Q\4?
M5DA(Z_5Z^" !],>1 NDGSN9W8VE.(S!&'$"F4$T&8/7^U!<ASX L^^FZFFF$
M*"R]:5BFH;5Q*J$OZ)1BY[B% 562_:0,Y#K<N *_CZ<Y0!/@]?PL*1X2ADK>
M$2R@+63%^=#SLT)8TG3'G=(ZU]U#%/K;C=B=ZZ&ES>GB [KU=T/W9ER1NVX@
M)GP#+LL <X<LG&4 B#/MT!,0FATB#2_:M*'$^; UDI=(UR8/)9G9(!BO;^W[
M9?=+R+UH/UQ7SC[CV'V=:B4GR)';OV_7O<+X8@"-H;5HINQ\3P03QC*=JCY]
M'[HG?4_'4@C<+=DZ<5#9=.\OA1?C RZHFL^\.GAM"1"(YR4[%\<?C&G$]+;A
M1#R"G5H+]7(I)QQ8,GGO>JH-[=;+7C>]"CL)^?;V8(M#F_)E\8B_9I[_*UX?
M#:8^89[QX(S 1%FP*/)JK(&C./!UB& 2;Z;.;EEOT0]R>_0FZ5BM68/24H;9
M6U3SH?''TX>_P>^P?)D8#@'2 EW3+PGR%/L[ZBO2$ ..L_$4H\2A1)8KW9[$
MN8LI(P*>"D#A[&!Y^?S"XGIB?W6ZSI'?&P<R#YKOG"QK1/<3-JA,IC"R@P2)
MZSQS"R9O/=W^M8\:Z:^O('*[U[>M$:,???](Q<,/!A=\_7CV.]_GKA5=;CPJ
MP8(QI)>0QM8TS/71N?ANF3O.@Z,"@;E \%)^+T:"4 VMU(*KN'\K.4I$&%N$
M8%=\4/[!EFIQRJY,?@#&$<IG&J),QV%^D'OROWOJ,K@3'FKXB>O$'=$?E??3
MS];/?S\NG")2TMZ8(#MI5GGF3[CU945>DUW&:VL8T@-,@\8C+NK\!&M)7HNO
M&(VJ81T]/I1@9+KOUS-UIN^7%R5O"/6/O0,#/53]0+N:/UX3%OR.)^V<2^6H
M<@:<L<H8TE_<3I2^=)!&$R#B3U\#KM5P>YS5Q^9THTF5>K]UFJD=_FY^P6-0
M]3-<,P"FG0(GV%$0DL''R^Y@TSHC*28S**]J&_Z\?%E/*^-7 Q(29RSX:IJ;
M.X/LU+T6^SLZQ/9R028LT=P D&2>0,))=9DH5^6.2+*IS+A.Y"U_:&2%^SNZ
MB]G H-O26G"H1JC%0UN+_?=B!?_1_^;IX=KB-JC9<6"#&^OA4^8ZZ%%LX^(+
MNN.00*2P&__=GX_5H[JN: 171(CII"J5.8ONXRG@M>4Q3"O'^-41( P/[LS6
MH'>.&WREC9X_WIKX*\3^W)3YP)&$SK'(#&/&XI9I3 +O'V>9F=NTMDN/0M+Z
M;AYOC!E 7^-\(@KA#F!ZI&!!L7".8#[S('#JMQ, 7IH#YA@E@'/IZ=??+S9>
M0U:=2PFK+4]];1$W>QWM;. >%QN_L[-*2RI:P@(:^4-XT97S54F 3=V\V[K<
M;*1(PH3[ZVU0H%^FL?**]B@F&#OG2+(90!#2+;AW:O6M4&DT\Q<B9>M<32 ]
M::ZO98,;I/8Z)R^/UR9$.4<<F TTS'<,2%%<O_( MRL@ZC=6?H.CA.DYB[\.
MED<9L'/P@1BP;3&,=L?-#8D_W>:^/*&[\>#Z[3038;4?]H\RWAF3>$*^RL->
M^;,DB8R=&GU(UL$B\DR/KLKZQN5I/>[:RS +IPAE-0>C#TZZ:]@/KS[_4W[S
M_6?HWJ*YH/LY)T] 2;7I=.T^#'^G-IEX'Z?6,(WRJ !N?YCKWQI\HJ F^YO>
MG7JB/XAD4)VS)ZPBNT.IJN+9/T=>:'6$7$82D$K&9,!%\3[8NX6_DV[!%5%G
M)YI'SO7U*T/'_2=O-*V*J.LZ#.O^)6L\&F7:]:NA#(TZ(^9PP.]'/^+'>@5W
M9"V!&2:$,X,39>=Q3:\!O\=,KNR[I_IT.NL N\1L=[X^,G3UO+[9;J'AF#;U
M_+-M/[[>\CMR''QT&S2L\^[X**"7O-;#/(M<)5?T$>>R&/))]G5<.V[$I%;0
M-9.:7$H#1;O*KUK5![6[G.YY,"(<_B1N/=L;.?,UV[:>#(%P>HFTFS"6I+8S
M[>%S6,-JBSV"(B)Q,ZL*D.S72AA</B<X+%40\+G;E3(/?K?^<-<,UT78X$E9
M6!"7SB_JTYZ7,R^P3M'OHY5I3@51,O'D.H$@_>\K,U$WK286KIZ]L'A#M[DR
M3;_>^Z JY,C[769]#'OV YSA=SB(B^, ]:Q,?,")X,$[\#[VI7,8+L268#EH
M8E\&[J:,*]D[I'TYJ:^S%?+S\/N,3._#Y O&UJW;H&M@?LX<K,F?);YA 0A4
M<2;E\_M@:1S1F6;$[J!MD.2M+@D1M^C2CT9S3PSL#K@_DR:XZ+!*CZG'KS_P
MK5IUG*U@W*3YKW71!J')YA+3S5U!E. *')T_#77AA=%Z3=V*P:'JUIE6D?>-
M1ZT\05:V2YE&MDM6YT7G+#D$SD#C-B@A=PU/@/EF4;=!UQ<^_YFSW@9!HT8:
M;X<7A]^?>ODO.L#" L!9VR#YR%%"T!!#BYW/\B(119#O').CE VGS"R7LL!7
M5\4LKK?6SUH(&SO]S@O1MM-_V/D\[%5UD%G;V5+_M\4[&]1Q*&?Z:(:9/]>#
M>G(_MJ.T:;_[8/M8@;1S->2-)+@T2B'<K%B"GK8X9Q<@ V[*-7HRWO22U\ T
M9_G2(4^(Z3/NERBH@^P*\SU()CF+)0-F:-.FAE)0KC0#[6%P"DZP1;>C?U&D
MW2?F==C3O,,&AD_Y3,T&BWB[7][)(FB2\3M9T/P*F!YH9C/-?C O_\CBW$ZI
M:?[^ H%*P+3_U5";RNO+ZJ1LEY3G63!#1)O GH-:/,M80 71ES6KRL #45PX
MJ\D1?$*#]2D?9)?BQ"WX[_U"B+).CQ\H_C'1)Q_;Y#0M4OIV_Z8$,2#0,_BV
M<Z#_9GI(WNX368R= 8AB6;*Q>'+,#E$RET"=:VNC8?H@2H C!;RV^A+(H=C'
MDZN&DPM_Q,J[6KN_ 0=X9U^6"8YU^'1O0O$WK!&ZYLPT_%O5_#HTCNMUHZ@S
M-%'3T?0'2)DAJN>Q\<B8$86K]J^E>C=K.$\,CSR*LBFXW&;Q5:*T&#T,&-%L
MR/G=X#W0.(XT<,=>@2=L1M9@8<5$=B:J55C:C;*ROF*GI_?\4,ISU[*H0VE"
M7B=!2A[_*B5#C%!NP!^F/<N%7686PM3B#**/ E'D+#'441HZHQ:9[ 0DD],7
M_$QG?]E!$VL>.C'RIT-X@_)$?\SGY[-10?42<E6;7QF/N-<XRUG@<B5]IB3J
M1N,X%ZMCYK D7*MF&HX':!D]G_>UU_Q$*]+-M%)7(UO>@F]2R[)'Y1WQ]:&Y
ME$(^!AS04<=2>;C+YSN[8>>P*E\+NWCG.$Y%SQ8\*;<'VX2Y][-Y07<H^72?
MPYX7\K<,W#NS\M_,-HC9IC[WFL;T7,#QH'BY\]"#Z3%NV@;-:3). D^\8/<Y
MRBZP3-Q>ENV8GT"X-\;O&<7>)%09<KA;%8G=<[ THR!"9GQ7'V<"PW43%5C:
M!?PG*$6SEP@<G.FI2X8(WX** ++.4RJM-&B:[V2MF6/=G,L'0NQ;SXN#@W*,
M^<?W&^S5LD^5/1.0YB2Q\]#2* ?VTYUM[@;-@9B1VZ;@%$]1&OX>REZC]"6_
M!N78K<<UD<'1M^\-U!HR.P9 -,W#'>"%SW<\$X,I=7-%#"%:#++X5Z<A7AJG
M_-W9W"1I4496[-.*C/C;V,!=;PZ_6]7N5O_<K_B:[U$PX5:&IOU'PRH/(:L)
M<E-#0ZNM#C5D24!17R71ZHKBH400Z/BNDS):_T8 H(.Q4U^M,Q!;GTPEDHAQ
M1 6T2% [O*=.HD\Y_04KK*WUUOA/C/0\7^&,8Z'E#QV-3U5F0XF!^4]>O;^T
MJF6N@#P.39U@^39.,();<9!DFX[.#*"M,2U:\^Z^J!^+T>^R)T;1;?L&V.4P
M?W \MGFFFRB!_H"!="H@ZI". VX1KBOMJ"5^?C[UC/8AG5 9JVRTSRTG?A6<
MX$YV$V<*(X$G/28J+W$_F>_X;8Y:->&RS,6KG!&\?*=%V"MW9,6I].>Y44<>
M9!,)M9.[4N9+G#M%#O-/8A5T6=)D**"%[X/<QVE-WS ,,(3?A8AA6GX].;6L
M2TYW='#LS3GBH/V@2C%D<SE%*,^\^0NL(9]Z<$=[YR0P(DL-89I^EW5#)."X
M'GT2=8R<);]2Z##059>%THPJ.UF81LB7"VL?Z#2HBA.KQ>X]ZA=FO T*Y0(,
MDSXL< @R"$Z$B'.T49[XUX =V1&\ GT!:/;E_[ $9R3^W(J<U%^8MUJ*C3N.
MDG@\4[#/VE)O'EN%TB3#A)#@/GG,O4YQ\K 2Q'K\QE+3^,\:O;']+8VM&:?*
M+EC''5*I!!V* ^V3VE6R<TB1V_B'B@^PGV%(3S%-#^$2J!U?^X<;C4\'TT:'
MMK )*K3D?@1XQ<1$604_D1 8C>-,;TE-1!PQ"S_0BCT@X1PI<<,61N*&;MIE
M<"*F53.],XI6,03G6\>)<SX6"[W.!*<1A8W:'JT_[.6]L.C^?G=ZQU4#K0=:
MVKC#-[.D<E 3]"K*1B:,E("E74%(L)! =F!L.%.#,UGXTP2G,4TE1WO3-.^_
MMU?,OYC(?\-YE]F0F>S%,^O&1? Q&*D&TAB:6\*Z!NPH:#]GYQB9'EF"\0!+
M?86.J>L_M1-R( I(2Q=\ZT3A[K&<5E&^E3\7?3CK3LP!%<*N$<X$G(;POWLK
MX](0O/5K#VQ.D^*?" MHPD]V>GDOO?GU^.FX!/-6OO7;-2<SC;_.7==ORNP!
M;\@C"N!KX'L<2?K&(%8<)<WNX+U=#)F*W$BP\Z5#^AIM5(I2$#742*%;Y_!=
M39VN%W@>\$:UFN5IG^>,PUX1,_!!\*Q"FU2<&GI:6;L5@'F5JLD/=2^(?E P
M!8LO"G@0'*Q_@0EZ(1[RAC'0/$UQKW2U'-58P93L_9F&@B\/ORP%@<^ W+3^
MV9TQW]_)KL23GN.;G+OGB'-"'($__C3_?G.%Y'[YJ;QD6MU NW6)\HM:M\#V
MC)'X-T8I&^-"P2^*IQ;VQU@J7C]M\_B!"XI+>/C ;'SG:>YO079>YXZ75&-G
MH$PH67RH0/8#,T3E #V=[/O^&A#?6QA:'C0M7S96I;7YB%?U1KG4H>H1E9+$
MCW>V0;VCF3N5_^^)8GK.='HP#W,F3&[.<H:)3; ,/98C+7?HMZN,,IC.M_0G
MO]#A?7(Z4M[ZJ,[MI^+V8^ORL,OLUQB?-]L@?^[B1W0[ H? :U.\3ILL&WIB
M71\L@Z"49SY*\8!>O#L^<S[;1I1FIB]KEN?R](1*2+?B[WXLH)[,DG#F"$9P
M%R]GC&..[L8IT2KN1JZ*2 7#A#E00$5MXE>(JE.KA0$F<-[*JO%=KIX>W[#A
MN^5Y@[?)=<]AUT8%67 @OI1EP'Z-"H]"5*Q@I&#^<)&* 8<]P;?3 B._74]:
MF5XQY D2:R7\=3$^J9< 5='1\93G/C!TI]0;2YP.NP34D,"S_<B;JU=?;W9:
ME" C!N[4),57&4>DUR@O?M?14UUEOM@?\"'ZTD"L54IVI=5Y[FSNBN,#Z>Y$
M3>>I9GLE\)FVZ5]V_4[3MS=.])=)-AA>?!]V F1TO2 "@8A&J)?/"^A<++'S
MSKY96W;M'OC\:1!*KIHS@Z4Y0931[Q;W[531XKS!BIJ+LZQI_JF=)_A3O0"5
M6UW6H_W83YO["X_6_(KLS%G\>E[\\.8!XPN58?2A+PUU!3\VUMKH$8S7P"B]
M= #&-63@P 2 &$1+ .4O3^&;9->&Z# WSCO\3DGX1)6<=8'46:%A>6W# I5S
MY]X>?H'8 <7',0$(+E7OD=D&!5,O<?9., -6);YO@X10-K4>*]@&?'^7VZF6
M(ZY7/_B$" ;.+=M=M#O<D:+BY,O,G?LZC;K 5)_G],-I'O!D>#/_VG((&TO:
M!A&21MUI,X,P83>1EJ_N]1-ZD<$.'MX0K1S'AC,YQGODRF[DM=T!D<T/HM]O
M@YKRD_"D*DC]!G69/KYDW034+<%E@:Q>M"Z-&+^A\7K\)UX4TWLL.B+D>5G#
M2Z/168+0<(&F5L?73A18[^@I-M>%$4FW6VD3C = %MWF]'2-39+Y ;?O\HF+
M:=()'U<9']_Z1T3_%3)K]/#X5>2*_)OB*'J,$P#A3]L&!81 EEKO&]FN._<>
M-YK*C[_UF-0[.QJ]G#X\NR\7YY>I=N_P[C\7FECXXE-1_[RTN@*50,:?H>4G
M(UA7:N<-G8[[/FR-RJD^NZR2(=3!=]XUY?PYD!I#^C8WRJYR!'9>R;MO@Y*F
MZ!N97 R$)0B1GE?0XI><XWX=K$6@%8 ,X2@3-]Z&]?I)+V',';/\1 W"F>J$
MP[UGXF(=:$/DB@1S,'!H@OPUKFG)O_23O:G+;/*[N>I&LT'#GZ<-I*]PI 5-
MG=]QUQ$4T-3,P <RH2*<&5@],85,2Z9JTV()3')=FH6 <LW>^8F J'Z2?6"8
MW"3_GPME-\AJ#TWLN&;'70/W*EC[V#B<),&\[43%78Y.H%M9.W\_.(&P3.E[
M^:U]N?W8ZU87-16[Z_TW;7- Z-/7/B$_7P']B(4SIH&#W$NTL]-QVBB+Z693
M_QFCNDQEF&-B,7]+:TSZJ$1PXZISB'1&3;6:G59PJ^F[:RIM:O?OLXV8!UB&
M=/C=)7I4QOK/WV,_P:GR(ZWWF^KXB?UO8\@=JZO[%"XW//8.6$#F7/U+ K5:
M=9\44O>W&, #B "'%SVE;,)NQ1D"Q4L4:'^=&# !GT3)15;OB8'L_NZ65!%Y
MI^6XCZB+Y0&F?4'H47__!WH#_D2&TM_;6__5_O<D%^Y<^1)=)F=K&Y2\\5.K
M64!7GO'!169=ZWIVB5YB5,(C3V/58X(K[\+OE?DXBS-U.>^P(,SU;5"\/+P;
M,EM';L&2,<*!A\X:.^E[5134XRC^,,.)8Z"F3'O%71]!)T3_ 7#_U?[@*;]9
M$LD,7:"9_@<3-.?(&XS>"Q1^\\;3B7U0&2(0=6'RV0U$)K7:-R,TWLLB\,KC
MQ L=/-)4HB!."@"3*N[>X"BBC,9$DG)]-NT4;WK8A^M,.&B/F&TZ'#%K'-$9
MM]/)M1U1R[']L/:^OSCM_]5Y?C^&9IOU*?T\\*N2&Y3!G4H4>+*YX4PK-"T2
MDVA^?,K,T&CYNFOB9S<4W49;1OU^D55B)H7YRN8C&D0#QZ-ED)IG@'#:9E\+
MX5SR,Y<A__+ EL 64Z3J^9?Q;:3(8VJ?<^PTFK_]6P^7V[+'U"P54^1<O!XE
M62@_;#K//RP#H5EC/QWIQ4M&$E.W00*= MQ;&$>VAM&+[]*6AK9:XDN!.,7/
M'BZN5VUV[=,1'3B;?"WB]=?O"Y)68YU'GLT"$7V%5YJ3L!6$H1 O;W_!(9%.
M_<H=J96].U(KUT"@JG^+R/P7Z'K,&<<W@+LQ! 9,X#NLR>9>B-F%9TA8_Q@0
M[TA;?Q$L-1TE?_]"9YB]0;NDRJ#Z@Y0?XNDH<O><9V%*]M/_1@)N_\BG_EU9
M#R\/:/;@)5#JE0 _!9)HN!!E.455GKDR]BM=:ST$L3\\.<VEC,_GU-%#W?%N
M#\_SOX?Q<LT 5B^[]O5E-)R?I4]9T.[]7C-4/<<RAHE'1K.@>TH5AX][Z.7K
M#KNONSY2OW+(VU5<<7_ Q[J)R7]HWM\M B.+!J.T 29M]3)PFMY(_I)%J1,.
MOLVQKBH);A&("+E9P!MJP^LC)N=RLYIG]]X][6>T>+Y"9H<X JY,%<Z[&<)5
MC,"M;9!<AE ?(15/P]YK)J80<!4E ;*G7:*G;YM$&5@JU/[6LO56,#4(42O<
M.I[VWT]="V&DL MQN]'36"$$3A ]CA'X"9<#W"\<J+T5>_.C_;[(#[/>9H87
M:\_-BE75(KT\!J1VD?"-,)9D/".8_3#T9S1'87@IY RQ3WQ8]MY/HAS*<BJR
MPU%X0"U$\CE6A-J?&HIZ'A ?Y^.RL"0L8^/T^]\=CO]JX,,TR%HL3;(;TA1U
M'Q;\Q+1[.@HFSD+P=3VOH\Q5V6;,WY:AJX7-GGH7-[1W;_6"IS5/S&';J1/F
M__$,=4KL5_AKL%E)QB]:>5;"-B@(>Z\]*C7?]C73.O'EGW%"D-O96?[W35TM
MR'7=#\L73QT5OA#%<]=SX#0H&K.VR51%:;.+?-JFS'2K@-;^XU/+"3*RYIKT
MC?MUS52':K+.F+ONP%J#85B5:6M>T94GZ:_\3*LF_T60?S<:D<#D"."9BISY
MUG9H"C><.2:D1E'@PF\:D/#!=N6*B/+@]B-5B$LA&'^UB*?.?WH1!SN>M-7=
M?!9W%!Q';(3W(687^\X[[IE?W7K^HMI0TYUNDMYI%U4=U)Z54W[ M7;]<[1P
M>)7QF[OB)5&'2LIN+K#_VQ1VP6&<23CM+.S3!!>!Y):B;@)%M.E5!R"5/([_
M!)<PDZY;^.;&?GS^Y(48;[6+MG?MM>R$7B;=V%6XM3L-M(060/$#T4P8X+?:
MAP:U3OK$VI\WV5JLKUTUD<\KK?+<MY0RO^ QWS%L5GSU@K60OH#BA<&[%Z1M
M?/]Y/_UW<X+V9_&ZL,X"L;6H8U/0\I:FF::B#/-UY($T&]OG&:4WJPS,?*C>
M?:70E]D#(1=.*CIS1_TX2X+]T%PL@+@+XY^5+(](1&D^==][:P1R-CU(\W;V
MI^7R1Q]</]_\L&9_1,*N=OH_Y[L0%<,-=[GL5)87\^0">LI<BH9(,8>@3DWV
M05/,+M :!PNSDKY.+WGGNP^\*CRZ+F3R_L/P%QG0QIL]N+QG<8<Y"BACFDTO
M>/=WO A:$8G6A5J-Z[**%+2>8 />^OE%J7_.?MS8F?E^?>W]^_?]3][]QY+%
M>6( 5?P:M SE.VU^G'6(!D_%*:RB-7F1.$@BSGP*=<RW[H5:=F2P5[C463L_
M];$+;V^K-T3 SX^=E.-(T+!)9GQDCR/=BX(?=0UK%*PGR/7CMSKVRFCI4)]9
M*)X?3.]5>?8R41$$JA'\[T[W;NA0C83L;D"IWL4"2P%?[_D(YZ@*2U]#[K]G
MP5^#:B1G 2K<,"E 8PYR\70*3@IE3H?<^YDE^V9T";(+,!EJKRT@UR!?$7J_
MGFE][>YG#<]^=MEE04A56]L ^[+RZ1YW=_?9N:' P-VGI6PEM$K/OTS; P*%
M@91>_/P/-Q6=3.5A0E"\[!>=[B2X) I%,\*F/@6B:M_6(A$V4R$J>>,GS@\L
MG[Z]\L:5H!9H?  !C4CV\4^3R9KX]C],7AB:BA%&*Z'\:,HO:!T4XMVF.@D
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M$H01O@O<577D\#B\W)2\X^B!NL;HD7^27ZBZ8E5VG&1LS@8_A!1I8+-@5QQ
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MGF*$6DSIQ\?-11'7R;JO27"AB,>]%88YD$MU[A6_W]TJ_3K;UB9TQ.7AE=/
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M;[UFL?G/#IW23.U1-C2>":Q_(IWU9A<1<H=ORU;@MW?1NPTV,-Y9HNW[U^G
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M:*;-</SU?%2PD99*/K[?++5-H9ZB6?"YX^SRG[-OUU[_N%QO##WU/@&@<["
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MCP08["MB'1@9J&5\"Y0%$.5]6$!W\7\WQKG)R52)W!OM:3GP?[1S=B%-1F$
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MBA#1 *8TDQ!I#Q<'.()2Q^D%A(9Q;+50/S;(TCAB*"?H!77:J3P*Z>D33A]
M3;T$'X.1TUGG*1#./NI\=H#93CI/J3@\Z#QY[<A5,KL5?+L6U_+5MBXVHJXO
MF?)3ZL)X)*^^#WZZ$=^:5TKTOZU$GD>8A D,.,HARA+E/^ XA G+41"DDO/4
M+?IJA!!+(XU>!WTB2-;K+O)8_W2OAKC5(<;W5<&$XRIVC'DL5Z03@S[UZG*
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MHOYM4U*=R-L6([_?-@_/P:_(FFW7;074<KW^N:PTNZ\R',24)1(F7"0089Q
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M+T"H'[H+L%,*[+7J<_N,7A?@DO.BVUIIE=2&TEJ:Z[PW$C@+9J^>YCA)9G5
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M^\01]QA'>'\A5:$'Z)L1OU&K@>:[CD.H"EU?XY78"%FP0GW\59BHS82AC/"
M0*%<<XBB/(0T#R3,N"1A&E <!-R%]9PE6!KU]0KLFXJW*ERT03NM%F"@AAOK
MN5O(COHFQ7UB_G.&'/S>ZN"1 T?CYY4(W:68E0U'@_28$L??:!PO?A0-413+
M^YY3W:N%(HEHFDK(\R!2Y!=+F*,XA(3+($ARDL<H="&_P\,LC>%Z*??MVWY0
M4]3V3C?E4[]];9!O''OO/8.P'7F=C]O$#/44,O\,=!P$KS3SS%"S<LEQ=1\3
MQHFK1U0W+>_N1*489GVYX2:6H.\]TC^Z..&)D"*'E$@.41!22).,0\K4TC!(
M4B93*\_(:K2E<<1>8%-EL=0B.]2X/ GNZ9U%KY!-3 \#M)2P7<313MS37#$"
M0(<*H#Z!G*N\YU% /57KM,7E6"G.D_>8K\ZFK3H/BFA:?VF<W_5KL2DK4ZVF
M]?.NOV[4K6^+^RY<GGP6K[Y_(.:,-T@3P3A!4 8RAB@-4T6UB5J."N6CT3P6
M)'6*FG(8>VGLVTKUWVM0]C+WF5E*:#>_S,4"=L[:1+A.?<RCWB#=:*Q<K_4)
M02_\!=B)#_;RZP)EK0;^W+L1L'GU^5S&G]41' ',8^]PS"W.[A\WB#C5#3[U
MF<6@4LN*"L;24-%91&0"D<PR2".BB VC#/-4HB"RRC]U'GEI9/91]SV%I83;
M6G0]Y@ $N]2$T?WF3N!O1V:3H#HQE3WH3#>0^@)T<@]K+7H,<7?&:JIN=2=&
M?ZD6=G:@'.EK9WF#D47[FI+][6U=;P5_O=4%?!4W%B4WQZ]7Y>:+8@+3EKW]
MW!1T/6CBON)21I'D$HI4U\B57$"<8P&SG$4"4\)BX71,<)8T2V.X-]^8B6C5
MSTPGN6,9OK-L8\=TLR$^,?L9/4"K"&@U :TJ%WWYU[TZ)O%ZKQ#8:^2Q&)\/
M8/U6W3M+HGG+Z_D [TD=/2\W'1$=*;Z^+QO1;]$P% 5QRE-=S%3Y?41Y@'G(
M(ICF41RS5.8T8M9!CP]NO30"U!DB1CR'4+B'6)W>#QR/P-0KRU[Y$?M\CU!P
MB/,;C<9<X7LG'PFW*+R#^AX+KGOXA?EBY@X*^B 4[O 5H_.ORSNAT[M_5F)<
MM='?BO'V/6Y>"5E6HKU.^9BB?KQ8OMSPAW=I"TS_*IK;4OWEB[K$^)^[7H1J
M+4MQ% @H@Q1#%(4"YD)[A7$0(!+$,:56%=)>4(>E$6@K//A!B_\CT$\4V.,P
MZ%,%J$&B+Y'?Z@<&"IID$7TK U,;179@V\NY.>5+/F]V_NW"GZ*))Z$E/D!C
M<NA?RH2^4_%GUV/NC/Z7,M2!P@ O)LK(C1AV*_AV+:[EI1*6%VM3U'2_ &E[
MU@G>ZG-WOVU=M6O9QSZHU8PI*&6Z;ZT"G&4R#S+(928A0D) *ED,4Y'R$*$X
MHI%3V+I?\98VT?;:Z8V!H7Z#G0'0:]C3Z$Y'_:5= )!2LRW=UK5!<^V\X/<I
ML-P#>C';3KTI] )F==\HF@1]OSM'?D6<=RMI$GB?["U-,XK/</\#IY^K($_3
M*(ISR&2LP_P# G-",$R"/(Y)B#,4.O6XLQYY:1/ SH$M-NI__=SN(X;_$.QV
MM#P)F!,S[O,Q^_]S2]:%?NH5_9:5_E'_H?UYT*'^<.3%U ']1T"=(9#_T.@+
M". _ HI=X/ZQ&[AOH_^R+BE9_[L@Z^:VVQA-41[D-,@5S$$*$8LQS,,40QS(
M.$5"!HE=Y<##MU\:1[42@E9$^\WD [B=WE8_#XV)2>8!$".VUP\@8K_%?AXR
M,VVS.R+DM.?^/ !']MT/?&FVO??G!1[NOQ^YRIVK/E0E$X*;;8.;BFQJJ;/<
MV]MJ0EQQQ(E@:0 IIQ2B'$60A"B& @<L%EE"H]BZ\LFIP9;&8[V\[8JKZ236
MRZV[G<SV+_-)J$^3G4\ )Z:^'79:5M +JZM<_#H%=O:TZ!/#F4CR+"R=*-,6
MG",$>O(6L]&IK3)#<K7^SK@%[Q6Y5TN)]9MO]V+#BV:KGI*W;2H]?[5MWI?-
M?PA3<G]%"8WR) D@$7$ 4<*QSMOB,*0D%0%F.)>YRWK7=N"E4? E8Y4.E+JO
MRGM1-=]--I?X^[:X-QVW^RY;CC6GK<U@M_Z= MR)Z;D3&0QE!KW0@&X;D[K^
M7;1M/ORM:EVA\KJHM1Y\UC6M*R2/E[3.WW?W$C^I&6ZK#/N]&^NCJ$7U1=3O
M"O4FJC&__[(EBBP;Q9ROOK<G3F6UZ_R8)6$28"I@&HD<HBQ-(&:)^H0B&J:(
MASP*;%W(LR19&KGME &L>QVK3IT+L.X5 I]W&NFTGJ+7R=YY.L]ZI[W2V6PR
M]2',SAP].W[<F6.G"]@K UY]!SMU1O13/<\N]A[O;/:9R1V>V$Y.#K,7;(]X
MT^?=?S97VPL,0S_<SPW=9[J?BPW9L&+S>5_LJML3-LVP3+&K5<QP))(,PS@A
M#**0"YBGJ8 DBU.BBRO$Q"IDP7; I<U;@T134_ZU%UR]7*=J-X\#_/0<Y!O&
MB:>:G;@/2N;UW?;:[GIMR3S/2-K/&KX1G6ER\("LTP3@ M,1GK>ZS6QT[J+4
MD+6=OC=N!^5#MQ'P05E=1[Z]Z?<"WNUJ;498D#PG%(8HX! Q$D.*6 A92G%
MLSP/<J<V7:>'7!Q!#W=+=N*>4>O4 G6[K1*_6$Z_AVV$5?RAQ1V#IO,&B3U
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M(- 2ZJJN6D;GDCU'\'%H'G V3G-U#!B#EUN_@*-0'&L2</B+\W4&."KX@W8
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M8.)<@B]M.MS51&!EK>BQ$FV3\:8$]UHE\%WIY%@Y=ZY'P&YV7*)A)YX8C<Q
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MO,YQSXTUZ^1V0N''L]JIR\>>ATI15>:.;;7G7RJUMEN1-" LB!+(.=6;TS*
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M0/)@\,4T'CD$B4N_D8/?'T=8?0FQ0M1=@_==P9J 4AFEA,&(<Z(H2GW">93
M7,1Q(*,L5NM(%XIZ?JBED5(G'ECO)?XG-RXZ JL=^_@!:V*^&0AY 7K0IB@
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MS/>((_O$T_M26XU&#-/K_D&3ZK>UVOY)-_):B+)N6[&@14[J T25BQ3 HD@
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M[.0H<UNE&D'M2>XT?.<7&"^@!%XZ&AFCO9!UEZQ_&;$<G$;*GNB](#81A9]
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M=+.2HJ[/6__BQWJII?DJMP^;U8?5F_5VN[[[?P]46Y/Z^XN9IKHBX=J4@RF
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M. ,D%]3X))3(F:T7(J"<<Z.NO;@1-_L4$^BPV?^N%P-AOP,-.<WG70XSF;S
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M6:^.V5@/S(639N>CF6XJ E..AUEP]N?X <^KQ^="D2;U"?F![Z77R--31]9
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M RQRKJT9# '+I ECIEDL$IFEN=,9S:F!YF;$&,E&YTT<1;*0C!50OYRI@!)
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M:6.^3RMZ$-X]<.FXS__+9GTO-]LG<RRSO5[5X3#W9B7]KI_75GS,2)K$*<2
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M6_G\G/?FAQ'TP^JM;&*T]45-RJ%9T9LBQUK^/TV\P8))/8N<4$ RF.IE4&2
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MSK"*]18[T&[-><K^H?9J$WQMOO=ISA,RPUW:,.P!]VC/P'NE'5HCPTSW9\\
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M7&;FM?K'>LW_+)9[ <H'\N.]X#MF[*IV-!=!G 8IB@D40F\EXI3#G.8!)#)
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MC)F*I2,:N9"N5:MS8]=*2GMYJ!<JJL7*IZI>:&$L%ZX)4G8=$+,P0P(Q*-*
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M>V_ISFMY>]N;^DT"]@7NWQ<E4Q/PG7I7#L$=XTBFB8AAGO(<(ADKUDU3#+,
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M 4_&$U <7+D!Q#@#OBEO %7N.$C5]NNQZP/D^/TP]E)UTP4/:U"[T.Q35DZ
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M*G9/M9 ^>10+Q-.()C101,%BB *402P3"4.*!<[S,./$ZJC# !OF1B,'PV\
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M9Y_\NY:7KC,BJ?KORFLS:P;&\>K8B>^*2@/ 'Z':4A]KWJ 2TP#0SE=I&O+
MGF>E]3.,1HC6RA.KTC35T@MY]W*XI#[-?:LEO>_-'DUYO]N66_5"%ZO'?XGB
M\=M6\%L5DJFY_X<?8L.*4GS>%$PL AR)F(@<QGF60R0B!*E,*$PYCPC"+ VS
M<*$\+=:Z&/'&<@=A(NM=:.;8AQ%CK(/Q^EB-&KL!%8_%RBR^*=K0OZBL\3((
M3/6FB#A@. \C&&=$0I0C#O/<[#;)G*0I#J,HK]^4#RO^%W]/&@\F?4N$&G_^
MNN\'S1/.A'HU@BC6@6 20AHE&&(UH+ 0!7F&0K<9Z0S?CFEFM8VUH#87-/8"
M8_ -6/]7>WGLXM$9OA C1Z_&G5J.L>US6S4.T!?0OJYV'!C/;T#MN_KAX/T-
MN/**>52(F+;/_(I'3&3[M+H2TW;(B>3$Q,V[9\8:U0LCBU06QC;&-BK>_T7P
M@I'E7JX^$RS-,A;#G',"4489Q"$ED,<\%"$F,9&!;2*L79-S6^&HK01/E9F.
MA0 <H.X>'<8!<&1B-P:#EL4WH(&S-OIZ#8&^<-HGIOJ'=:(\5!_P.J6<NB'5
MD6%J^:#)$DK='&OGCSK>V;-PPU$C=2%WC#*<9)E0@[J>K 9YK.8A:C(2L#S"
M%*4L"YV.,YUO9G:$?/S67R_T[@*J79 ^'*JIJ?<Z2NZ%#3I!\%NPX'Q3TQ8B
MZ'3WI,! ]]7#Q"7OY1=A2HU\)IOMRX,**TMB$M7+=R^O_F*.Y\6Y8#@4*G1+
M&8-()!(2'@8PHUF4A)&(H]0IR;R7%7.CD;;P8&TL,-:"MB,W>M[Y^L^]SDWV
MZSC+!8.QNV/LZ?]8/=%;Z+$7DJ,H.KI9\B;2C;W NJ31V.]A0\GT@B[PS\5*
M?-J*IW(1!R0A(D:01R2"*$P$S.-8P)AH!0H1)"BS*K?BWO2<:?.B)C;X7=L/
MC .]B?)JI[BRHT^H)Z3$@2@/($%;P$9BOJO-OQ'=V<)RF>.LG^!&;%P4BP^K
MK7ITK>'U13QKM</5X]<MV>[*!:<9BUF6P"#G7"MO88AQ9E1U8DJC+,*!M*&Q
M:PW-C;0J6QO1.K"W%E3FVC'4572[^<@G9B.S3U^XK*G&%HLSQ%(*]O?']??_
MKAYA..7?2/\(JQ\-D5Q]^"2T8>MB0Q+6UT^<:5-1U>&$=&G2-!^^D56]5?'K
MNA(#XT<;%?_0.>'O5<"VS^/\LEXN/ZXW^JD+B5 F!8M@EN <HE1F,$=)!JFD
M61)*SA B3@'5O/R;&P$VML-F(]18#[7YH&]V^<P@'WMW_>U?E/GOPM>A:@ND
MNA3N5L%TV*/?(W5FA]Z@!8Y>S%%DSF?Z)LQC;W\D'_\:.0#C=K"W7(&1S>P7
M:#AH#AMSM>A:%?"\JK,9(\H99I!+@B#*2*S3#F*8RCSE-!6!0$[K+5ZLFMN@
M7E'K<KUZA*JY)[!TK8OJM\_LQM_)>V+D4=-=1_W,Z;2#D_Z&-Z] >QV4_%@V
MZ5#B%<SC <#OPWO*M4NIE:Z^B^HHR /Y\46-#W>5 <J:PSF0!8J)1*F0D- X
M@2C"7*= $TCC2&11&G'$G 29[9N>&P'O+0?*0%<9=WO 0Q2@-, )Q)&,(4K"
M4 V&&842X8SQA 9YF"VV6F#K30'?&S %X%OR8US0[4:S<: <>WEOCV)];%"9
M#;3=X(O0?*@8Y;58CD>U?6>\_*KOVS<_K1J_,RPGZOSN3^B9BL:8+I9:JE=%
M%-_U+NQA./I,RNW[754Q;\%$)'F*,Y@$,H,H)102C".8XSS&.&6YY5Z#:\-S
M&R0:N\'!\'; ISXR93QXOQ/]$DNL^\..T,9 >60Z\P>P>P*<(UI^4^)L&Y\V
M2<X1DI.T.=?[>])8J]#GO:X+2M2XMWJ\6Y?;<A$D)*)<$19"A$ D60Y)GL20
M"DI8*-(L$DZK#UV-S8ZNC@HE<R&% I\#V9AM"N<YKC!TPBT84J^X7MV)0@4W
M%40-$BR$>9[F4E"61!%R.U/I"_!I#D*^ >26@X$G&,<> ([PJ^2YRW)GQ!_O
M.J%SIWP+3/S2?%>#TU*[A>LG=&YSCQN%EYOMXDZ/$6+SK%,!?U6OQNV/HES@
M((HHSA&D*$M5Q(E22+1<M& TR6A )$FL:/M2 W.CZK:-0!L)?M=F6@:0%V'L
MY@8?X(S,!\ZX6)/ ->>[/GQU;^NC5_]U_,%??/@D'_DUUYH/^^IU_>*QNR4I
MRWM92PG>;[[H#2OS.C(18\(9@T(@%9%ED3[DI 4Z L%8E"<1I4[!V,669O=Y
M:T/U>%:;JO $QEBGS_PZP':Q@!?8QO[P^R+F' 5<1<-K"'"YM4G'_ZM.'P_^
MUV_H21:Z2A=AVW\5VV]WNW*[?A(;<]SJ5[%M*COC2+TC:<8ASW&BYG!!"G,9
MYC!5OT4J%$ I2]TF%1:MSF]N\?6;BK^J[6%6VP^(-MIQ-F$#N261^(5Q]%BB
M!NU/92YH[+T!QN(;0*2"%MPNE^L_S61#*L:Y4U.W8@NTFIK'.MD]X//+01;M
M3LM&]D"<\)+#K0/2;4L]!Q5\H9B(9S3$D*<Y@0A) FF*)>0\RU,>A#D+DY[J
M<W43+A_,=!)Q[_9Z<)0LS>>AQ9J,0%/91Z&IP3,G(LI$*F"491*BA"-(B!"0
M9Q@S@E.1,ME+HZTWFN,+J7VH9+#\ FE'V'VA&9F9*[-N0&68Y[30(W?]YV0V
M#4R?$'GDVMELQ.-K^I'@ _E1C85W*@!\D55ZH9XO[N4K*&<2"<6&/()($ 1I
MS@)]J%*H_S&:L,1E9G>EO;G-[_2N>QTKM V^J9<L>FE:7(/<[HOW".3()# 0
M0V=RL$3&*U]<:W-2"K$$X)A5;&_K6>Q;$*T.KW.@/ZV>=UN3.K=;;74*1%.U
M1V0QU6M'*OQ2,0.3#-(HU34E1)"H&2*-(J=LA.M-SHUN&@M[I$U9X&M'+'Y1
M&YE;6L8"8^T-V&-HLJ7\E_BQQ\=OE?#KS4Y;,MP:AI/ZX?9WNDLFGL^Q>ITS
M]TZLA"RV]U++I5<Y5ZM'O11@B(\2]L?GS?I[41X*E2V"B 4\"0(82/4/Q% *
MJ0J 8!)PSG@@0B*L"HJ-9^+<J*SV0*_TKG21@L8)L%1> -:XH2N45W[8BPN.
MU,?=]#B/GAN93NVS3IONO9>F!L7>4[.D!O:^@KVSUQ-5I^IG>]')M^_OB40J
MW[3?G=0MQ^V2#C7,D1J>3#US7.#::ILCM^0>$SB<W?F\$<^DX+<K;D[QF 7G
M\I#<N" DE2@)")14_0.E-(&81GJ*0IC4Q05R'-O& ?[,FMO87YN[EV$V]8S6
MYDC=:F^TTQ:7YVZ\/M2_3>>,/+R[GX-L>E(Y5Y^)K-RS.@XY9@_:#^)OTY,3
M#=P3]ZC34.T?^([AV6-CDPW)_@%J#\,C/'V8A&-Y+^\T*'I?MTHU_5*4?[Q[
MT?_\2)AZD1[$C^T[A<X?BRB+,B:IA &6B2X&ED,2"0%QG,@,$Q&PQ*F =P\;
MYC:H?MT]/9'-BYY0/Y'_6&\ JW?%';-$^G2'Y2;DN""/O5?96*\1?F6_T;Q5
MME?JMNH'4'E1GU4"VAM@W!E!X;$'F*-(/;K8\2::CSV NB3^V.=1/958!-T>
MQ&&^""Z>C"S,9Y.R<+]JENY1GF99'B-%A3*'"',,\RC-8( "3(*4(Y0[G>>W
M;'=N''AK4KET9;&O>CJIHYB5FFANRIH8]5_NENNR5=_PJU@5AX0OU7NU%@.@
MNZVN,*7^MEV;*Q^^%9M73W04:+'L2CLN':&#QIY<F!,]>Y-OP,%HLP:D"\$I
MNT?8D7'$RJ].BF7;TRJAN %RHG7B>'L_ZOM9D%*4C6;<0O!,\1@+8"1S#A%%
M"<0IXC 104HPCN- .-5)>?WXN1%999V-9)X-=G:4TA^1D9G#'@QG:CCOLU<&
M.&IBT@_]O'O'W_.%JT;7CKLCY3<UI]3_TC)XW\E2"^ M,,499F$$!0MU+*-^
MHC&-U3\PRG+,X]RM(M)@B^9&#MH\LV3*] _B8.AHBG$7>LHR5)D2_]FMD.X[
MR_SPP:*SQE2)ZP;XK13B+E@U5W6X;A '*,-=>7 _0M[OLGU>+POVTEI#$VE$
M$R2@%*F*J)CJQ3P2.:1)+J(X",,H<CJ4>:FAN='G80O;56/S(I1V1.@#H)'Y
M[8"-FI,9*\'O];]'6<6Z!HE71KK8V*1$<\WE8_ZX>GW/Z54M._GR<;VY6Y+B
MJ=3,4_W _V-753.I2U\NXH BP3&&!(4I1)QGD*120O4^Q5F"4$!PY'[ZR<4$
MEV_D#4]'.4[37/H@-X=A4:9U=1!$$<<0![EZR7-.8T0%2P/B>F)JW!Z8^D35
MB.!;SJ!'@G/L^75C=G7TU=A;A:S5CP?;FU+$'B?@/2#S.SUW,6#:R7L/:$ZF
M]GV>X9Y!90Z<T0[Y>_IRN*0M?V_^\4]1ZO0NHRQ0FNL^;PHF'E0_E]_62[Z(
MD& !RC'D(F<0J:$'YFD:PS1G$4=I+./<ZN#'^*;.+=8U1H/OE=5@8\R^J4Z=
M@F=M.=@VIIOSJ'R]7))-"12!5U=9'DV=X"7HIN!Y=>W86]'#J[Q4+T;M<R6P
MHEX,<P,P?H.]X[-Y ^QSNN;S)DR4YS63-\(I_VN:3NK("1O9@,GRQ*8!LIT[
M-E&+'G8@C'Q1(0MF+*Q/4*. T50P!F64:('8G$-"2 X#C#&*69*'>=9[A^%<
MBW,+"UXO8X/7)O<\MGX=]A[;!4/!G'0[P!G'82O]7=B,MY)_MM6W6ZGO J%S
M);[SQKXE>V\Y5Z]7^7E=;LGR_RN>[]9<+$(2A(R$ D8\Q'J=G4(JHA2FD<P2
MG!$:V=7!ZFYF;A1360IJ4_5JLC86*&N!-M>U7.]99+L)Q1]>([-(7ZAZE.KM
M0F)@H=ZSCYZX3&^7>Z=%>CNO[A=[?!'?Q6HG/BK;S@F4'>\;<2(D3L(8DC!,
M=" B(,8IAG&0I $.<2JD4ZJ#6_-SHXS:>G.F]'%5F#'4+$.J#C(YUO7??_KP
M@RUWI3Z.:I3"GS>"5<<&S>5MN6I'92W'[K,+:,;KE)%YJ<%;?VG@O(CBN+N#
M_9#S&OLXFC!I(-0/GN.HJ.=3^O'C41'37W<Z4?1>OB^6._7;2K?L?K=5A&QV
M=A9Y@!*::"$-)#*(HI3#/* QC(G6':,RPF'LI@#K:('+YSB-&FQM:7_Y0-<^
M"/.<17F U="4<(A(ED!"$P8#&O$H9[E@U.I,\P0],&D9=E)7NV;KIZ=UTQ=@
M?; <0,"G[BR[(6G$+AAY3#JI-5[9K@.!RFS0LEN+/1F/_ U)/9'S.B:YVC#I
MH-03H.-1J>]CAN3(:7V)9A@\KKCW3LCUYJ!8(<KWZH=R6[ %"B1FA*8P#/3F
MI.0AI $+(4:IC"*<$H9S]S2Z7K;,C2H;N_IDV?7K##OZFPCBD:FPSM7[2?OQ
MMT.07KER2$$N 37.@';>HV+&:WW3,Y=O$*HCI/OUL^<-,@(' 7<^:7#8(_N?
M6%7MZ2.2^F3LIG@L5F2I?ZOFY;O5-ES(*$ASS94"Y[JJ0T1@G@H&HQ1)F= L
M%"1P/:O:V>+L:%&?A&1[BV\4OI7-@*N_W !BS'8_7=H-N^7NBT\PQ]Y]T3C>
MM7!LS#75XV[ ;3>.O<Z16F'C_01I=ZN3GQVU N'<J5&[&WLH>-75%A61&7$2
M'1D67+PC95&^+Z3ZHU#.E0O)!-+98C B00Z18!DD,I*016D8RB!&(K.7Y[)K
M<V[D4YL)J+93S4_WACK(-%FBW<TX(V$X.N?4=3VU F)=0*:!U)@-WH\)J8.L
ME7]HI]*L\@*QFQ25&UA=.E.63YI.1,K-M5<*48ZWCGY@^)-Z]U:/!5V*$[VW
M,(M%$"8(YBC*($(L@E0F$@89Y2*-4Y11MZ#2AU5SX_Z#I;6XXHW67A[MU'!'
M=UD&HU-WPMB#A_/IX5:/C2'#-PK0;W6*N,.RN9XDO@[F@-/$%@_OH9]/-OJ\
M6_E9;*K,3;W7OE[=;K>;@NZV6N_L8:U;TEN)ZZ5ZRN,G76=6E%L];K!%)L(L
MB$@&0YGAJE \3M)85__B4<J1^G-DK90_T)BY\;,R%;9L!45MK/KJ=;C.!A_1
M&-Q[UT/Z*?MD9+IN7-'J5-7NDL[-VE1Y]2U_M$#8:X] X]*-B5@M%\"]])"#
M>OV$/3653OWX/>:F1N\)XB[=^:%-3*<P[PF,5UKROI[9;^[R>;-F0O!ZD7VY
MU+KV6@[RU_56E%\$$\5W;<(BI['ZORR!6:)"')0P"6F")8QC&@2,Y"D.G?8(
M+=N=V_C6F%UM5K&]X:8(C#8=;/:VN\U*;#O";MXQ KPC#U6OD;U[A:RQ&GRY
MCJSSM,$1)Z\3 ]NV)PW]'0$Y#NY=;W</W_]!BE6S*_BP(:M2ZJR*2J^Q_%8\
M+X(@96',$DB2F.ADKQCF69;"0'!),HPSGHC%2CR2K> /=E'ZM3:M/B-<?48G
M+8_W26FSJ\]I6QMMI+7W9MO'=%=!OQY5>\%P&BHRN+63$AY:\/TR!GSV(:]/
M&"<*:8?"Z12OVN+3$8]>?<1D\::M,^UXTOJ>@5IL>L%FN=9E#MN'0;(XS1F#
M"8LCB(*8::D?#FD:!"&*B,C=:AIT-3:WR-"#)MLY2.W"/5] C4RLK=)K!T/!
M[^/JLG5 ,HXVV[D&WT:?K</UBQIM7?<,TVDK=-4!A]7?UF:+2)(X4H$;E!E3
M,9UB%H@#DD.&28*CG'-A5YS4GTESHQ^S\%J7'5L>O*L&7-[>FUGO$^CZJ8T-
MZ$8[,INV<V:W8=9R?YRM,G_XCB)C-L"L-Q$W&P[C)<DS#T]VGU]_5F_^-U**
M6V9*5JNV#C)KY4(BGN(42YBR%*G)=4 @Y4D(<YJ'B* \"0/7R75G@S.=63<V
M [(W&I"#U?8SPVZTK\^JAX,WT>I> ]C!T)8HHS? [.?1WH";:!+=%T"GR;,5
M*!TSY^[[)YLV6[G1GC/;W=!73V&I6>DSV6Q?:A6A$*6$<I3 )-::"1'#BD35
M@!A)JJ;," D262407&YB;M%I;2$P)O949SH#I%T\.0R>D8G1$9D> @27G/<L
M,G#2S,1" I?</!4+N'AES^GM>O6HOJ$G?0[@03WB]D=1+FB*F=!;#X@3 9$4
M M)<!4MA((F,8Q(R[G3B_%PC<_O(M8U0&UD?7M%V@M^UI:ZUG\XA:CEW'(C3
MR%]['XC<YW<=&/B=L9UK:-HY6(>K)[.JKFN'U?V]ER9UX]VQG.37[9K]<6\J
MRY6W;%M\+[8OIJ#J87V7X)@D,<]@DNJB<&F<0AR1%*9Y'B")1)PB)_VDX2;-
MC5:,Q6!M3 ;%2JXW3\:3?C6!!W25'0--VP$C\]59L=V#1NH-N*^K7S:>3%(P
M>#BTH]0/'F#6FY03'@[CI>K"'I[LH]BP.>;S]7DC"+]?_9-L"MW4%Q7]A0N2
MITF0I3&4*5)!6I9(2#%*(<DQ97&09HP.J#9\N>&YD6MU&JTTI@+%K]]K8\%&
M63ND.G ']G8\.@:B8Z_U']<'KM#]ND>W,1Q\Z4)W8'7@ZU"-6!ZXH_$WK ]\
M'9+N L$6]_=='-+^%,NB*<)^4++[*A[-\M/#^DZQY7I9<+.X;7) 8XJ(D#2"
M:1A+B.*(0QS*'$JA8D?&<<*Q4]V[?F;,C<M>>]&6VS2;H(TG.G.^[4L=LCBO
M1O7J.=L5J['[8_15K7&ZHL?RUQ D/2^1]3)EXF6T(7"=+K4->IK[WJ6IQW O
M?RNK\X*W[-^[8B/X[8I7NZB"W\M%E@<A9UJQF&&]^AX+79<Y@A*KT"]0M!ID
MF>,6IDV[,]W)-)6S>7V8&JSIEA0K]=_%"H@?[)N>Z)F2:G72R.H1+/4-[103
M^[T[J^ZYON?I#>V)N%";"^\E_*VLCT"#QF2@; :-T>!>>H;2?C?4-Z03;8KZ
M@-9I@]0%IXY]4JO'3+9=ZN)4>]?4Z;Y^\7%K&_9A?<NY450GR\^DX)]6=^2Y
MV)*EKC.]?='+#.N5NO!>5A)-6WUL7(?Q"\%326@401:&.F<%Y6J:SP-(,&:"
M$I&@V"EYT(=1<XN=*WNU$'!EL [9U&N+JD-M1F1#_ZHHRYVN4ZHN+&VS-KSV
MI5W\/'4/C3R"M-S1$?/!(: ]TF-U[=,-J/OQKMV/+<?,MI._Z-HGSEYC;2^&
M31IY^X3R. [W^NR>.V4J%#!;!NK!I/SV<;G^L[REI='J7\0BRG#"&*0151$Y
M#B7,0X)A+'.1DRR14>!TMKBKL;D1[]Y6\Z4J:X$Q%_S>&.RX+M$)M.4.EB?X
MQMZ;ZH^<^\Z3!21^]Y2Z&IQVM\C"]9-]()M[^A')NUVI)JAEJ9B*%BLSOZB+
M[?RGX)^X:K.09GFV4@QJ!:6MK&KU-S4]X37UF2GP/5T6C]5$*0SS#"'"(0J3
M'**4,H@S+"#+!(K2/",B<J*C\4V>&ZG=#UTMF+"W[3AQ7GTX,K,VSH*6MS?@
MX"]H.WP\[];UJ_8UVT'M\@TPWH*#N_ZX>;JN\<KP$Y@]Z3@Q73<<CS83MMPS
M^#V;#-'*HWGW<KBD76NX3I70U8:-O1]^/ NF%X;7^E<??H@-*TKM655<9)''
M/,UQCB%!:KQ"81I!RED (XD)"N(L#W.W9+*)#)_;^-4R$) MV'X30"A:4W&F
M_E$-;L5Z0$&DR5X'RW!_AIT\]M1A>*WYVOD;4+EOAKT& +U(\T\CQ-8"X::N
M\^1Q4C)QQ_F=X$QE_+23I8F[Y&3B-77[_09$4[GZ7IITP)_5V/U)S1;+11K(
M7'(N8(0C-7H)S"&6N8""2\K3)*,H=YIWG6UE;D.-,=+4?C-ISK]K0X&QU''A
MYSRF=D/ 8*1&YNL^(#G3:2<(7KGO?$N3$E6GL\>LTGUQ3PI0$7BQ_4B8F2=6
M9Z8(B;E@!'(N8XC2C$&2$0$3+!@-PS"3R"DG][2)V7W\QD+0F-CKL-09("T_
M^D'PC/W%NR'C_K%?=-[OEW[:S+2?^44W3[[QRU?V^\ _%JMB*WXNOJLY^)&,
M^R_D/]8;0RJ_JE>@/LN+$1(AD@$4(I,0!3R&.<$88BH"P0.49-QI[NK8_MRH
MH3(?&OO/U5 P/H!J8-1>]#Q4[=I+=M0R(O8C\XY_V)VIJ2=X7GG+U89)2:TG
M0,>,U_<Q;G3(1;'XL-IJ3N5<O:EE_2\=1X4+GC&$2!)!QA7?H8CGD*0X@0)%
M$N$TS1&3-J37V<K<J*TR%-0FWC0_ !/5WZ\LCQUU ]O-4][@&IF->B-E33I6
M2)RAEE*POS^NO_]W=;]AE7\C_2.L?C14TOWD20C#RKF&%NPN]O?Q1XL,)7F<
MHA3*5"*($BI@GD8)3%DF@I3'6C)UZ,<?_:4^_H<_U\,__FC Q^\$UUM^_%U(
M>?GXH]$^_NCM/_[(Y>./>G[\^^P[QG9/.R,Z\UX\;P2KCL.HGY?"K,ZN^.V3
M+OKQG^;WGS?ZK,7VY;-Z&;9Z)?;?N^)9K]/JTJ^9FB/E4 0T4'R1J& !D1CR
MF'":R%QPBAP.KOBVS^K3F?Z 2\L]P%O^F1T;TG(,B!]ZQ=PU1<5;]]I-K2;M
MK8G2FUL]U/;I!NR],IW5]NL&-)ZIG[1O-]4.7..>QQQGSX#[S7/V9=RTN<Z>
M(3W)=_;]_'[$_ZO8ZNQ']?CO!1?\W<MOI9YJ[I/C:@4,G7S2).AB'B4BHPB&
MF%&(>"@AR0/%\PE"L53TR9'5?+"_"7.+%UN)O8T7>F?^)^T(^+3Z&SCD&AZ<
M<6/P'OUDQ]7CHC\R*ROCJZSJ4]B+"["/DGK='T2O3-O#C$DYM3],Q^PYX$E]
M9\=?OXGE4F<LD-7+@H81PH$(8$3C%"*9<$BDBG4E%DS%NRA-L=5&P/G'SXW?
MZEF>,1'4-KK.@5_!9SOY[0O*-+->.SQZS'3/N3UPBOOJD1//;<^Y<SJI/7O5
M@%Q6>CW#B!YG&'TDQ>:?9+D3)M.V2C?:9QF)S5.XH#3B*,HB&,1)K#Y\FD",
MJ( "YT&6B"!(2.B<O3J*J;,CD7WBH986U8FI+X)L>N6ECM.U&<TCE@48Q@G/
M(&)A#G.91*I_LR2@(8J#.%]\%QNZ_FMU;MODB;IW-GUJ%P//HY]&'K0\Y!-K
M=X'Q%[0<OCGD%#]T]7V_W.%1N\5_MO XYDZ?'SPJ[&<S@L=M<7!5L+NZ/!1F
M(2>(!E!&.@&8Y0ABPE3XCWD2)BE/A0@6V[4^GV/%/:=-. W<^X;&(XX'W08X
M4[>K=VFNN[ZEMGH@-#*KOBJ$=3=B%:R[::I:W;UQE:H[ZZI3QU?V+"U?L4E9
M5UQX6#^0'_\JMM^^K9>ZA-7']>;\<85%)$4>8T%@@'4%9Q$DD+(802XSF4A.
M21A&/3:Z^MHSTXTM4VD4_*D=$,OJ -*SEH/1<FW?16G6YM82J":WF\*$$*7)
MGM^M"E?IGMX]:<="HW;,1/6M*A=N3&W3ENTWYV.^P_#KL93]0!3]UK;O:\RT
MQ>X'0G9,H8.?U[<FLUED,(J:'Y;%4WT(NJKYO$ D$+%$B6+31$557%*(\XBK
MGL.2A")+0^%TK**SM;FMC+2-!2UKG4LT=R%LQW+><!N9RBY"!GZO;/5:I-D"
M$\]5FKM:G+A,LX7SIW6:;6[J63W!OM2H,<.<##4Y,PN6IBI6PP@*2E.(XE!
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MVP^8=L#Q$,' SK-;$YFP0T8F*VT>.+AR ]I=TW@#?JK]^9OIG^J>II.,4S=
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M8:+^(T1AGKESW'$S\^2Z7R]-Z 'URX(GJ!,DJ1Y!H @EA2@3'%+!"$1A2,*
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M)9GD41_UHN]^U5%/FYE6&_6BFR?*J)>O[/=U:VFAG?J"="KOL^:=>BTE2;'
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M%7K2VD@3(=>)7B<J:[OK?Q[-M F:U(/*J OV6E^'UJ]A[#U,U+.P8FBOM6?
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MV],%E,<HP#&%$$*9UVX6G(') D]WG8:@IZ+9PN^4!,^,V?;]Z/0\:0#2JKH
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M?CG'<4QD##.9FF3K3$!,4@%E3#G7?Z04"=MIX?(P<YL!M*2P$Q4<9+4GH %
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MXI1)B/*<0D*S%"9"4%(P))/$*4S;:M2YN4]=21B@]BM5KE9C]ZCM(+?C&.]
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M$.>2V==?=1[?Y169)E3?</F_V^^@N2-^?:LT*(J!B>;0"Z+-?CW(;R)?&PU
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M/N9I3H&76(HB+K(<)JJ0$"$>099E":1)&F5$92)13GL>9\:8VPO9B=@<PBX
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MXQ.MD>GF!4RMG0-BD?J_B=:Q2+YPFR@6:3!^3@%)-J#T!"3UWCY90)*-$]V
M)*OK+ZP]^88N#25_NY-R4R6AY,7MA[S0O\OI<C?7?$NK2(!ROW0)TS"F:91
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MXD3CC &O.,NP@Z9_BF'9QJ4J,N^5DGRS"\[237^E&_E5&K\KT5.3]V"^8?L
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M_4EN#!^NU-NU%/E&_Z9-6?QD"DBW>@8T51S3B,($AQ0B++A>,H<9##@3A(F
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M3,6C21[797YK>;==Z._W$^#TH=)E3FNIM/K:')F[!)+'Q& 1R5^":JB)>I6
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M)9>5*:K>%9Q\7*VOUU)4&ZWB7M:[RR0O4LP@(Y*KP()%D"8LASPN1%$J#Z[
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MD33XS-C^::\G'KX=,AK.A/8AU)9PT7E1I_./\]F7\32B$\6%EH)1$B)E1#H
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M D57+VD,C'U RV" L&B]39Y[)^KL+OM0/2R*#X6L7@"]@YJ'OA1QC\\\FW^
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M>7=N3E$Y9'3 BA"@+'V)#CU($540T7)1=CJ.&\;0W:.N7]@=@HQ]+-LQ:NK
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MX4H,M8G;76%-M#<A5S.50JB3R H9+%-LK7S!S'C*NG%F5S/6NCMX>&FK[GA
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MAHRHVRF;9:?0:1L%9S:Y[=!(_6CACPR>/_#;YL+@U><%KH;$W&?IVLLKR>O
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MY;?YYFBEK,]5^*04XQU)$TI4&10O CRF",9(%:5$QWV;>IVGZ=H-A.=S4-]
M&_MCRZ^Q-<//-5OPTPD&E!"3:;5X*,Q^_PT7JZ<>,I+DD0<--X1D%TH'&CNR
M_56O9GD-B7#QM\7\ZMOM",A X$K*(S!)H%.9W#,?HP/N"84\6);N;Q%#)=SN
M1^C1.<@_/?6W6;JXRF1VMU-1/[V8+Z\6^(G4\IJ>\Z^)25QQ% Y,C G(<2U
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M0]P^B.G&76G>HT'&'&VT!;(F3TY1B (> P.1:5>-FJ+\U,8N==2'YHPK"@Z
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M-L?8[_Y:(\[Z/LL^#'$=+,;U_?BJ<<VN7<]N;O<4C]I%HZ"@I#A0DB/NHO/
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MZL>2P7F+JWH(H[SD*.P.V'CZ+>->U[:!QX!R[7='NKV'YD:S8IP$9Y.KH:>
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MWBY_]W@L/*SV/U[P7=_EW%V@JU330ZYFMCRDC0G91F%;0X+$I3.*=@6O:%?
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MS5HIW^C8>BLY(P\5&D[=\Z%EWP& B/RO\]G'RWGZU[6W'S0:'1P8)7)MB>[
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M05@C%+*HI&M79W^>868E.,<*4>!D728438! W$&2,C-$8Y0^1RM!O\/,#L'
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M'*O/>3OA=CPN2&W9X3K*@#Z#3\K70>T%:N< 6!9J%9$BCM(>6-GCJWHZA ;
MRM#"[>!8>GJ>B79U\A8SD#*O3;EL/>3:@O8LH[#,(K9)F"YH7- I(<TPDN\
M0CO&FW#!BF&) ?>6#(RX <H$+&1FK+/T1QK;+!>^G'%!!RGYY7%!ATB\!\SL
MV,F575+T/TH>1<TEF8.0E 3AO.4^2/KQ7VH/VM':W6/]V0&BOH!Q0<RINM%+
MUCHJ\L(8+'AA'4B'V: 1WC9Z1;BP<4&#G%8G:Z #[[-[IHG $*+VCDR+Z;J
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MP'.+H"6R+*,M5N_SD+?[T\<IS6D#C0'DUT$]PZ.L[_77VYG)IDA)KI%!KHO
ME-.U-9R8$J+$+$LT3+6IJ7V&J+&+N@?+D8=60(]8NC=*V7A*$4M@8",%8(I)
M!K[&Z$;:B-QX91O-O'^&J,[N6XY5_(LW<\=IH0= ;3WU(Y:VOC99D:U. 4)
M8B=* P&).R:ER=XGR7,C4#U/6&? .A8 #X$UH#9Z -=C^WN-L_3I<UC\>VV$
MC +_A%Z#H^"-9&4]!"7(''7DQ3&A>#K3R\(#RL;N'#G'&7B\*KJ$U@TW6S-T
M";.M(E*4?=:<DS@SG(/BQA6TQK!X+FA]2UEGGNLD'+P(LA.4T@'(7J54KT27
M=QWV6S_LN9&%D0LVB>2CZGK4D+@#%E)@.2$)JLUS\%,4]0:J4_3^L#9D""5T
M *;?PE5M$/D#9]?X"]XNV^))%DT)L4E:U8E@K$J&@8@NNN1U5+G1KN1=Y'26
M^@T)H]/%WP&&;FSAE_D*E^_F859K$+9#QV<?[RSD]=>[?[_->'AV)I 3!U04
M-"C-*'(01D"2%)H*9K/3;;9MG$+UV)V0@P=B9U-A!W#]EH.;&8B*>1.D EXB
M67+==!F+=4 ^VWHLMG@KF\!P%S7CGIOGP\*COML3%=,!N#9RPGO3CVZ29!TQ
MR!@A.DFG1$H1@E$)F"J6LF3!N&L3G#U%T=B#]D[5];R!X$<N/OJPF.?KM'J_
M^ T7?TS3QJ*0.#)%>X@YF-IJ)B!*K*.!#0:#,3,VW*CD712,W58]:'7:R2+N
M R+5)6\YN)GB&SU&RBTL9.YL'2/$ZO2!!-(71U0P'MA>C02'X.0Q&>-5'YVN
MV<<P.5',HS<N;9JSM_G%UA_JX+"(PH"O<Q:C-?A,Z8K1+D>6L7"]3VW S@\?
M7?NG*FQ':_OQTNL@'/EANOPR7X:KORWFUU_>7(7E<EJF::.1]?H4'CU3G@['
M4NKZ)SH7G5,*;!*9&%3(K6T2E;Q V-BS$P9/L(941-^XNEFA&Q+3RB;(K*[0
M#<9 3/1+8<%*Y$D%OU=)_9#(ZB&[&A0(^X/L"*WT ;.T[F6YQOS^"VX,<KEA
MDWY27G^M%VA;UQP=.O0L00HZUJX6.O4=2J#DP92@R$A#FZJ50ZCL%GS' .0Q
M_-IHJP,DOIVE^6?\C52UGF3[.ES5;/.W3X@K"CE>Y3RMS(:KNVZKY>NOWXB[
M#K^YNL[3V<?=<EI;?U1DYBXI2*Q.02XEU=%,)/YDN"TLY59/..?A;^S!,H,?
MZQW"H@-C.8C!>[O8-&K!#3D?%EQ]/ZFS2P5&L,8[$UU(WK69E'0DP>,Z\QZQ
M]UQ T@@(8^\>6%SCIA;X)D,L*&.MWJ-4D#+$S!CX9 VASJ7H/:>#=)^Q( \_
MMZ/ H94BYP-)M0,/^.BH>7>[4X&,AWM31U"LA]L:R2%&CZ"5M\47A=*=J;CZ
MW4';H!H.R6I?5W:<^,?N,*T[XW]X^^9MG8MS,VIVNT,C?,0)#SP8X3WD6(NB
MHB7CLH)8"=KEA(%QE'MXFA>^IK,BGB,U.6\CUAY<#;'S8(O+HRTOW_[@_I:?
MHK@6HH[&*4&#T@XA:+*W%*+,P0NM<IORBY/([JPBZ#1,GE^11Z/V#US$^4">
M[>]XE=_.UGLC9V$3J;X.LW\O[UEB0,>Y=1IRW4%$TA3@!19@DE, (!FFA[.Q
MGG1P+W];9\75P_BY@87<@[M[**@[5OB$%\E1493('<E+V4Q&D!4#+:*QC#/*
M5=ILWWR.JLZ*Q09R5D.I851?M#.]>3Z[V3X'3K*E>" (#>1SUR/>$IF-+A =
MM]EDDP0[PUW%7K1V5L Q#  ;JVQ 6+:8R?<.PQ*/&;.W_0^'FYRWBY*!AN%M
M/OIV:IGWQE$PXT%PY4"MEQI)-( FQ2!08Q%[#6 ZV.*^I>/DE;VX7")NP3G[
MN/GPWTEDK^EO_7O"K=(V>0D\QT!<%E6[THEI:1+*XFT*;0+RY^D:-PL\ 0F/
MUNX.)_ZNUU!N&=L,03_63_Q^;X;Z@-YB%U5M?(8TQ3O)!0CM2)W%,W B()0L
ME-$L2+7?8+\.?<;M6-J?P^IZ0?]<2_4.R=IHZ^G( VOENI" @?<HP4BB.#F5
MBFBT[?MP8KOR+H=@9A_O,J2B.DC UCR]F2]7#]B04B>KH@=RDK;./Z&@7UH.
MB6=7DHI&N]C.U!X3-.X=T:"8.EW@%W!4_1(6U6C^P.-G2#_Q04,?7\]3VN8@
MH[Q9%LDB6.T%I=04\L3B!%" XI5U7">_5Q= %P?9^C-_P&5:3+]436P>?)00
MEBFE@(G:.H0^ $5SK$YN3Q@P>_YPD=R@!]9.HKHZF [!P.Z#Z73!=W  O2>S
M7-P?>%VK%$I47A9#PO"<'&RFDS2F2+]E!IEA4439QCYV43,V:@92]7Q@N7>(
MG6V90D$58HV^&-,)E-*!CN<<@1D3DG'")6S3[[Z;GG'Q<[J>7P#.$4+O #IK
M@WKU<8'K:JN;[D*R(,51!A"V[GR5AIC0JD9B6:L8 _.-9@7M)*<OX!RCYUVQ
M[TE"[P(YNQSRW35XSL)Q;VIM4U&@=#(0<RX05$XB!RVS:X6A9PD;.X-J<XP-
MJ8TNP+6J'_:^O*'OGJ[>7Z^6JS"K;R&;PI9)5-*YX#ED5R?3.N\@TN\! ['C
MF13<MT+7\Y3U&"4="8-'$!M0)UT\D#XJ1'E8?J)4I$0\(&1,%!]$LDV7BR9Q
M\8Q!62U9FZK&ERCKT8D-@[)!=7(!%T0?%M//8?'U?2G3M!'I\M2KHF<^<NA+
MHWVI;W-]E&U2CB<+&NMD#8K:(6HM00@5&!:K_,5?'Z'"HHRS('*)H(KF$)(D
M\$L74!1C<FF3PUW*]=$A&#CD^N@0P8\\/>.V6>9O./^X"%\^35.X6N>WFD=K
MTGHJ+J^KC#!!0".!8<[<JJCIY_N@9Z_I&4^2,39>!E+R?&B)CPT;_/B0A6UN
M*Z-"G5P&$8@3Y0V)I3@.UH02D=F8<*_Y"?O!YBDRQAN[,9!ZYT/+>DS K+XL
M)O]\-8E$D9+1@7.9+(8X!A<*Y:B<A>)M2=8^EW<M,?V/C_,__F?]N TTZK^M
M8;$!Q.9K1E3],(J:'R^UL97\]MW$4-B>1*0SU5L!"GD$)X6 Q$MP,6C.K#A5
MR6_?C;>RJX&2#Y3:V$K^Y7]-I&7<%^. ^:QJX$1.C=<)<E9K&P)/ST_6VDO)
MO_RO\79O-5#R@5(;4<GK69>+KY.WOTPL-]S4LD)%X0Q1C+401QD*>;(N/@1,
M\KG2RQL];S]QH^KM;^ZT??=]XZW+&E;A1TIP;,-^\VJBO'6>.P,8G*Q^R$'(
MU2WI8K@0B;*BY[+BO0S[S7Y'=)/=5PT,^T"I=7%!_OP57%0BJ<)KIUPB=A(Z
MB(+\E/<AH7 <Y7[S-?\ZKR_'Y((MM-$-N+ZM]_P=%Y_?E[J#?7WM@C9:.NR(
M#[(+,C5I(6@60$J7O,FI8&Q5@OP2;3U>-QP)A3WJ<$_02Z=(NZTL_A"^;E[<
MKW'B2XA&>7+*TMNZ(&7;?(=&<">$#?[9**91W?<]"GMT;.U0=[*.NL#>"^^9
MUD>23Z3XH8YP4S(HRM_KYA-NDG5,^F+;[&,;Y(VY65-W6ZP-J),+>/U[,__\
M93ZK!C0OZY_\^.<7G"U/KA9_Z7.'?@<\B(]&C92J;I')$;RJZV6BCE #>D 7
MG<TN1(:MK'7(Q\!O_6QMD)@PS%H:;:$H7NN"T!*/L8Z79,X6&2A"W6L&^N%U
MG(]H&3NV.EKCCZHW3Q-S!\?7=C7$FOY?IQ\_K=Z7?RSQ%?GF%?G*Q6KZ_]9Z
MF1@70M$V (K:4,.T &>= L%E-L0@Y[E-I+XG@6,'3H-!JH5".L/9>N0*+E=;
M[S[!6!>_A0P\&6)%8(#@2@)A# N*L6!\&\_T#%%C!T=-\'2*X#O T#_#8EHO
M6>Z<K<?@DXB%$E,I0(6H(81<**QCB3%&/TAMO-(C4L8=9#,@7DX3<@<HN2,<
M%;HB.(G!UKF87B!X0:%^E,B%-EXP]=P#Y !=M^-.EQD0%<<)]7@TS%?AZBRI
MTTW?^3;AN+F1F)Y>/_GR)P^=/AW(2Z,$BHM<3'*06<J@5/:46J_'75FGC74R
MA3:'^1FG2MR[KOJ%I/C[?_#J#_QY3GI93HPA+J4ID&SUEDEFB-%F,#%*;:4.
M(K694G\LQ7TE8P>@Y]@;QI-4UL4!MQ^?_QO#XO?_S">!L^R]+H"Y+OD+O.Y/
M<1&$U]IQM$RD5A9Y$*%]I7!G .(Q"KHT_!&@*,](B'4],\BH)*BL,P1)7#)!
M*8;33(K<9I/6P:3VE?:="X,'*^G"4/C3_'HQ83IFC4R!E75ZF<VL3B\KH%AD
MAOED2FS3A74HI7VEDF?"X,$JNC0(3O_ 22Y.A6P82"8CY4Z9@U.<?JMY5$PS
M1Y8V/@2)TK[RUG-!\% 571 $7Q7ZSELF@Q5)..5!)@HSE)$6'%<6D!E?8O(B
M^W'+(+XA=]Q]ER. \7AE71 B)T[DC'4F6Q&^KK^IUU%&,"@Z2&6B$K;15*)!
M:W&:+60; 7<'J62PN[VA'KGO77?];3%?+G^8%J(*9PDW11^WHBPJL>ASIBB#
M<BZ5F8;@@Z[SKM%X+DUP;4[AX^@==P'1@# \@[IZ]W__F.4ZA)W8P_SCGXG^
MZK8@J;"@0N%U9U= 4-(K"#8(,-HP%HA,,\:MX5/DCCQ*Z0PX.L2##J+4#I#[
M!'L3(5&Q+!(D*3R%Q&3N(18!@LX#EJ5,)K89EOP$07NASU^L0SQ,X!=0G?CB
ML]3DP?/QD(]L$W[^9[:'_-P^M/W/ :3Y+ZQ%09C#'P2>C_C#UO7\&E889OGF
M3Q=86YGN5_>?_)YY\A</K8=A)='F-51%*6) #=$I5N^Q$GCG$ PC3^$PR-!L
MP%B[<M(;T;YZ+/CMIJ.)<J$@8Y6RHD$)&2!&F:%PKU!GSY5K-'+V0$J[>OT\
M!"W/'R8#JZB[Z.0!?[\^,G(^0>:+]B(04K2L8^4S^"@C".XI C3>YD8['@ZE
MM*MWSV80/%5%70<Z/X9%96WYCA*0#YLYK_/9;Y]( 4<<M\]\V'!'Z+X4#W0L
MWGP=?=7Z2^[AC7&=9 *-FG(DG@5X:3V$7+C,O" VVOC\%$6G^JF'GWNWDZ*@
MY"*DNH2BF%I_Y\ S2@RU9YXSE[7#-K' DR2->_@-@HF'/F@8\5^HLSEZH]6+
M'WD.Q]-P\]634'/1.RZX JUT3;6%@V"0\!8P99^",J;-WKQ6[N>W] GS]16^
M+P^_X7583M.K6?YA>G5-Q_*#A3ED 58*IX"'1.>^B19BB0*"-&B$$@93&S]\
M),&=NJY#\/30=9U#=1T$\G=LOIJMIKFR-/T#?\-4+U6FN/SQS[JO%/-/)/7:
M$'J]4>MCJ=Q)(%@19&UAX<@3*(D1(I,<O+5&%68M4VW:0(;G9=QDH#&N1U'X
MA9[E]R0QOY7$EZTDCK_+._$+SQ$'',YYZRB!O&@64EFP*A90BH#O..7(+C$*
M&V61NE']:JLHX>V,](!5]!NC6V^%IB^Z70N]O-T:_:'VG)+W6:T6TTAJJ4?/
M_)?YK*Z2)D72-WR\:2N<N*)*3I*D(]!2/I\"A=@V@O$<O0Q2*M;F%;,-/YW&
M&(>@\:$O[D#Q'80@WTIAYU[TY2^X>E]^#W].A(M%8!!0#'>@F,G@ZF9)4D-Q
M@1/CK(WQ'T)EIV'#<% =4$D= /##8EZFJ\K;)!;E@B$ Y"")\N1J])X*,&ET
M5,$ZTZA?[HZ&<9L>FH#G2 &/ND^&8K7)_:CHU1\4Z52WNYK?BXX^S:]('W<7
M]CJ5C(G$@K6#K5[?D^N5]%O!63$YYE#X"S'A45\\;I?"H*!I+_@N]A21L[SS
MJ7L=ZZFN6V(N A850+FL(-8#WJ/7/#IADFJS=?9@4L<)U<X G/DY==C!R?@M
M@S?R_/U&GBO*_K?R7%^*31Q%G *=@.2*J L4"[BH*0X(HJ2,+N3<YE'E0$+'
M[:AI<L:V5-5%(7%[+3O)!5$D2GO69:;*I0R^. V&"8G&%"9SF\>$@TD=MZ5F
M9#0>HZX.\/B@GN*7Z[KN]7U92W!Y;\3EQMB,LR+7\6 N$DLJFE0G7&J0620G
M$EK.8Q,L'D3FN"TV37#83DW]8G!K48]XG(3H34B:H@U&&9=RG!%[K( QW*J0
M6'%X5A0^1>BX/3;GQ.$@JNH B2\\D=X%VU%JHXL";5@=D^@Y>$?VQM"Z(!5/
MFK6I MR3P'&;&9H@KX5JNDB@7[X\)Y;7W*[YGFB4Q5@?ZRK)""IE#L''#$*8
MNNC-*Z'/<7/\(J%]O7,, I>#GSV.UUP'SG O]NY[_HFAU#\'KT$GYD 91;F8
MYAI\1(F8I9,HQX/F?5+[>MD8#9Q':Z\[>#[_DO.059]+B2Q+0&Z0#J)  3(&
M \F$S(5E7I8V]SLG$-W7>TI[R+;3Z.6!]]XAHE@2JH[,#25Q4&4],]4YX(S7
MIE'D2I^C&N( DOMZT^D N$=J<T38WG^2N!'D 94<-W=C0DODA04Z870"E6-M
M#DL1F!$!@S#*/FS+>/95\7A*^KHW'Q*2(VCJ<G&YN2VS.BJOZS.6IO-#68K(
MG5<22DE!"L8S"[HM*O>_M3S;[7E'F#Q<2QT<\ _YO3&LHD*4,DBPQM6IP)8!
MR2T#ST'E9&24C3:>/$%07W?E+0[G(331P5BJG:*:!&^8=%9#0:SO\#&2GRX:
MG,7D0I&!R397X3O)Z>O"^QQ@.EP+76\O>+I\?G>318N.@>>_Z1RM @?PVKI'
M0#IME#>)+%#7UV0K(0@IP6G4CFNK3;ZL1N;AVG;6BY&M)D_-:\V'LX[B5.$@
MJJ  M>%)ZFB9[+U'J_+1UUWY4>AKUY]UL*(["/].Y/GUU]T?\.K/Z7*2C3=%
MEP(YUZNN1$=73#X CUEEYX-VJLT#4$.FQC6 ,;$Z[Q,XW=K0+^$S_C"O4U\F
MP2:G9')@8M:@@E?@LU%@0Z(X+!2!L<USTTN4C8OF;B"T%[2/U&<'^-Q$C&^N
MPG+Y^F>LA3 3"F^EL9*#5IYR2HT.@O8:8L:8;%2<L3;AR&-:>L3@L;J>#RKX
MD>\K?T6*KJ:IOES5\M%_S*:KY:^__:/:7YDO/M>UFI158M[U]SZ\KG^3<MIW
MN"G NO=G[^A/;J1AF,O"9V#%QSINB^(VS]?CMHS!.@A4AQ?RL_-0.NXS?!.0
M=JCB#GSECY^_7,V_(JYY>?^E:GC+B+!%)T8GBO.&+-=P!4ZD#$Y&KRGCD"C:
M;(UXDJ1Q']J;>LYAU- !GM[,9V0=JRF%VS]@7-T81=8I1L7(* P')4@^7G()
M(A>%D3&+C7;2[21GW'?OQB?PJ>+O $,GQLGOIC-\N\+/RXG3K,ZQ$97E=?#A
M(9(+!H[!%Q0^BD;[HH?B8-QC^/O)OH^#Q.6;PG8S@9<I.5\BH)/K5CP&T1+3
M)FI'/D"[8L^9CQ](?H\)4VOD#0O_(V#0]1BM=904:Z!>V<;9<OVQ1SQV/?%!
MP[UE[4/I0$]5M;KM:KZ\7I"_OO]EO^)56-7O7ZZ6:S2LR;G9 W5O"JO+F3L!
MA6GRSL$6\!0=0*8((0F53"EM.F=.H_M4![OWM[^^_^UWH^F\8,9%XBK;6OV2
M7>V<"<0D$RH&FY&B]G'%MIOP<9WJ&;'ZT)6>4^$7Z$2/GBG\[,>U=J@-9PF?
M"%7#@F+:: @E6$K?-9WZ5G&(1;' BA6Z49W N&[U+G6X_]WU2W^:+QZ9UZO%
M(LP^XH:"J_6GK^.8N[_X\%.6K[]^N JS!Z-Q':6RE@L$:6T=C:LC1,X*1&]=
MXH*ALFU6_8W"[D6[\$/LXND*AE[!U4'F>">D?\P6F.8?9]/_]YC57^I]T;(6
MX?TG+/+R <LV:\K2G06+K++L#<2Z+]0'&5-V7 G7YMIN .+'O3KIPCK.H_BN
ML/[8^BM[]V[5E_\,5]<;&"R7UY\W/WMHZ5HK8Q6K"RGJ4AQ#W)OHP>>HDS*<
M4=;<&/9#\#'N<TD7%G!V.'1J#/<5<)_[5VDU_6.Z^OJ 8U0H0PZJOA(H4+XP
M<!(#_=8S%72PPK>.HXZE?=RWG<Y WU#M/0!])Y_WGO(W4V_6)G]O],T3S*M@
MO8[:4EX? BA5,CB6$J@BL\L%M6VTDGE0-L;MGQP3_J.!H0=+^-;V'UV//"AG
M>37;6>#RA"RD*64]%\62,R!9" O.I^HD<K3.!JU=FXOAEER-V]/9SS$Q'E2Z
M,IOWJT^XV.U"GCPK1;19)<B9D8<0:(A5SPG+7HBLD2G7YDGU!*+';2GM O1M
M%3UR >M+><\.2]XG_;$F"'0!Z#PDP>=0VW%9@5(K'4VLM>4/QMSNK%EM0MRX
M?:TC(+H/-7?ENY^PYKM;W]=?]Y;3\I^;.[%9_O'/+UC_Z/=Y_=%#G^!U<,%)
ML+ZNX",/ ,X5#QJMS\E:SVR;*55C<CWNZ,HN3H_.H7:!S\V"<4Z9&/U#__A_
MK^GT?3NKV^JG?V!]@3FAC?VDKVO]7'T,UWT\9P?+F4A14F),2%0J1XB&\F1)
M^;+2D9-AE>_Z.?M%%[!\R@=LBF -.N4M"K!TVM9PTH.G&!*\3['V0ED9VLP%
M&8R%BWYV/@2_)YP# X*@@UBK.J7:G[!N-/7%*F,C @M<@(HQ0R1A@T*;1(G%
M>6SC >Y3T4M7^EF!\'#GV;%:Z0A1VXX7DD$6T@M@5A10 2U$EQ)(X[C/ C-G
M;19/?4O'N*@Z7I]/ .,(X8Y\@?'[?^:_?YI?+RDV^O$*_\#9CNAHV]*DBTPZ
M2^(JQ!H7)PY!HJ'$-:6D>;+ZX8B!G;<2^W]C'^ X1J?SY@+N!S8_3<L*B:U-
M-/[W=31.W/V/]Y]GTWB]O&7TFT>B.Z8EES$:EH$[Y>JP8@L^!4?^.$C+)!89
M]YDX.1A!XQ8Q#0^Z,ZJG@U/N-U+5.@I83T2@:&']HE+=N_&NF,(0,"A%3MT@
M1.D8.'+O4DI1!R"VR0*>(JF73L,Q(ZIA]-4!\.[3OS7>$I5-& D0Q622BP^4
M^"0-:'(@"HQ*K3JP']$R<O ^C)(?]EV?)O$>,',WN^75UMT:B@!T<)HXR"00
M@Z%6061@2@N+*NJ"K;KV'](R+F9.U>[38W*.$747RY$V+I?^\MITR#*2958!
MSW6W(F4OX)+-$ (*XZR,(;2IF/V&C'$+7OLXPX[72P<^Z'C!W;$]RP_"UL)(
MEEE3E,CK!"JE+ 1F(J3B7-3):!%=FUBK 3<C]\(?#ZZ]RO7.J.D.T/[@4? F
MQV$YJ*()3:IX4%;$^@Y//&EKK:=CAYLV#P0[R1DY5AL=)?.A5=8?[FZ&H&V9
M20*QZ-I6S5(=PN[(JNNZ>JY=4,EY41I-2GR6K)'3T\YQ>((*1[ZZ>WZ6'B/C
M,;8$T-IRBHIK:T)FC-(RX7B*0J3R4AW BU\R<M#8"[*&5<:H*4IE9:^!CG>\
MN>RBH+ %M#4:E/:9/#@Q:++/TA!YZ/:I<3SL6\=M5>H*>0W5U<&!>W39V+O;
MX5%2R<RL5(#!UKLI2@F#"!)BX<(5),O,C3JQ3Z9]9)AWD96?&0&7C/F;S?7;
M?JWKU:?YHC:P3Q0OULA<(&9%4;9S#'RRB32AG<XV!M>J*75H5CI/J@;&XE"F
M, @P+MDRMLV[][H7-R*9..F98R6!991ZJF $Q*1(.]Y+7Y!9WVCQ_."L=)[F
M=6H9@P#CDBWCIHJ%@L;K]4F^;O/Z_5.8;45S.^UD*QAN&4\^><A"DF"\-N",
MD5"D,,;KY'*CJ7UG8['SM+932VH*I MLS]C]T]JP,EOBT,T9>WU9Z]:,PSGN
MHS&C%.=3$@*8%&JS9R6&$L"$4(SPU6;:1,>]-&;<;E# Q1_3[;B'QR[@WORW
M7V]G8WW Q72^H723ZF6IZ)B4 ;CS=5X^LQ"\%I R>IF$S%&U[N\;D)V+;M@X
M!-=/-VR,!8X.@JIOWVR+MLD[P8!+;4%95!#J"/"<K1;$A3.YS3"/PPLUSM"^
M,1HLGBW:.$1''0"LR46R]TX%;C(4$=8+3BU$;C5H57R)TAC#TC@!^H47;1P$
MKG,4;1RBZ0[0_O2B)A?J!D9-J0!9.JB$ :)GQ(CQ+ 9IA6)MKNA/VY=U6<4;
M!Z%E[QU;AZBN PP^FFIV\T++%#-<NMJR$T 5+B$PS\BVD3O+A N-2C>>(*CS
MV[QSXV\(M76 ON=K3Y0Q1?JH*?BQ==6-CQ!+9"!M9LG$[%-LLS7P]/*ARRKR
M. 6)PZEPY/*A ^L&,+@HA.,0C")+<R9 '>X+26JI16$DQ7W:^_[R91['8*^Q
MNKJN8XM>N)29 86U0-1KBB\8#V"=2%S8B#JY/7!W>AU;L\FO7<%L.&5TT6KS
M=I;FG_&V;^W=]C9B,R< LV/%.$@Q,U#UEV!2!"D5-RY[+5V;:1S/$-5+*VDO
MMSM#Z:^#V.\)5K;V:K7DV2@#IM1"#%\DQ*@<H$C.*(&VU0CM9\D:-PL>3/G[
M@>H(370 JVIH[\MOX>HV)\ID;=;D#)Q16J[0)(CH-&2!J+@TE**W22,>D=(E
M?(Y1\Z,FU%-DW@%H?L,K^J./?\,9'?97%#V\RI^GLVE]-ZHC)+9/MK>G?B0_
MG;FH@[]J:9AU=8UZ=>6B8$AH<V[4!7@(F>,>G>W UDY7'0!QF#CCW=VB8#21
M:6>!C@9B6LH"T2D-A@E3)YS$$MK$= ,STDL[=B]QX)@XZ<!,MIQ15K:3\:T/
MF'C#G$;"9];K2;T4#SF%H98P)C1.<31M9L'M1]^XX<"H$'KX:#V\/B^P0NY5
MSM/ZSW#U=K:^VUJ?F -7QCW[):TKXO;GL(]*N&RBX2HG\*$N:);!0>3&4YSB
M"O) ,6[\'BOAAG$-;\*7Z2I<U9^^^CR_GJTFSAO#4S* R'1U$0*B5PGJL@ ?
MO&5&M!E5UHBABZZ&.P3;;<*/TP!R@0[^J26JC8J@]_RZUD[_&*[[</^<&6L$
M>904B@/E=%UBF 10W,Y+44'GV*89ZKLLA#91J5@+;T,=^2DH'7<I*1 ^*B:+
MX-ZU"<;_6PA]"J[/5 A] #AZR#^_J8.D%,2(+!&B0:13BPY1K[T#ZZT5DB0;
MS'\+H=O#XME"Z$-TU ' VDS4\,8)KR6DY$D&)0:2IDR@K=.">:]3HW4+WWLA
M]$'@.LOTN@,TW0':GZFFY9+[.GE*).=!:<)6<,J#I=@W1.&ST8WOK_\"A= '
MH67_0N@#5-<!!I^O8T1A!>7)#@JK\RDCB<C'I,$JQ))SYHZWZ2'YRTVR.P&+
MPZFPZPK DD0M,M/ BK)U=P("&5, +;0MB+H8]M])=L,@:UAE7-HDNVR3260H
M8)%KH$ \0= L4FR#5OOL"$YB#Z#]Y4N<CT5>0W5U<. ._?Z83.9*B@QZO5HH
M$?M>)$F_:"T36IFQ3<?2&*4.EU;R>D(>/R9.+L5,;D?)K+W0\O?Y*ES=__,J
M@E_FJ_^-JSOAW(O8EQ,>:N>8EZ",(:$$RR R%:%('JT()I4THO&<RM[W56AQ
M$("/,::SHNF[-K';3]K\1P\G0$U85MRF3.))]>+(UW9-&1FPQ L%"TH(VZ:^
M8#26QSW=_AJF."3JOF?SG##&O4 I(?(@0#F9P4N-()U 7[20Z-K,9FK&TKAY
M^U_"O Y"S?'F4TGIVWPV*OMIOMC^J/X]/@FNOG\@!]29LE!3-&6A10%:I7).
M.A3;IF;BO'R.>TWQES"TT_%U@25B]^/H)D,Q'WSV669@/L=/'Y5>EB47R'5#
MBHX,@ D',;H /*',D@4K69O*U%XJO4[=:.!,L4QQ!1FUJ>/28ZW^SV!"5-GP
M[(5K- 5Y*!8NNJ+K$/P^7=%U3A!TD%A\6\2AM<ZIE C<&$8'2Q04UC$!F;E:
MDAR3=JH)@KNLXCHK%)ZMW#I$+QV JLD+4KTQD\$&,+PV/ND8R+R- >-*49P9
M;_Y;N754Y=9!X#I'Y=8AFNX [<^4_V3E!*^5Q9;7AW%%C)3B"6,!:R%&2:E-
M4>Q?J7+K(+3L7[EU@.HZP.  "R(2HP,*G87@1-UR29FE2TP#E]E2LND]DXV&
MM)],>R_/Q6,&#&=&P"5C?OW+/W&YFLX^;BY8^"0:RU%: R7(!,IY!SXK0?Y$
MLN*8]=&U27Z'Y*)S[SXP H<R@%/AT(LI/.XT?\1[?([W7Z<?/ZV6)(%44?,1
M)SP($Z1)($14H!(SX++.P*,J4CO/?*,+H2;L=%XH? ;C&!4@EVPE/_[Y9;I8
M_^6-?YA$%R/:[$ +I)2)EP1UM"8D:8Q ZX3C#7=G#L%"Y\7-G5K#24#HQ0*.
MD?OV]>)O]!=7R[=;[O^%U2%@?K4I#E__X0]AA3^%Z>*?X>H:)]EG+VM:EAP6
M4!(#!,4"J"Q2<25IT:@K],R,=EZPW6G@=090]6)SQSB;6XY?+9?7GS>RJO,B
M:O'[[[CXS"=!RI!5O?I($2DV=8SR1>3@E4[*2A69;VA>37CJ?.QVI^?2L%#I
MQ6B.4<1SDOCG_(H^YFJZ^OHK.102B4M220/>&:S>@T'01H#E44AI0C)RI >%
MTYG;RXS,]VQ&'8'G>[.G7Z?+?_^T0'P[(P(I-:P"^7DZFWZ^_CP1L60K0P!9
MG8WRR8&W5D%!QY)D1:9&3<+GXG OR[+_M:SSP>@O85[AS[5<ZJN48$9"S+(V
M<.M$)W@F8["F^,B45MAH[/:9.-S+O-Q_S>M\,/K>S.OF0/]A^L<TXRROCW/F
MN,A:1-!.T7&N @G$<A)-05\*6JX:K?MNSMI>!N7_:U!G $XOEG1,AKF]J_GG
MNH#]YJ[F5DI\XED@?20/&E.-AX,'IY@'@6@=CUPHWV9732N.]GM+9=^SX8R-
MDU[LY82[S1__Q$6:+O'V>G/=]4%'\F(Z6T[3YD+3%^7HQ"W@),:Z0UJ"KRXE
M>QLL>I;HL.[K\#F N_WLZ+]%"6?"SV6W [U**SI\5U\;=@4]_(HS-@<]RUT?
M/4)&>,6#S\"+U*!2HG#'N%AM08? @A7NNYP&?:(9O[]>+5=AEFL1Q?SJZJ?Y
MHOXA>998)+<(V0A&AELWA"DEP.?B#=,R*=YFQ7T;?BZZ>^@09 _MY0> QW<0
M*]V3PB_7V\%RS"9T'+0Q$E0D(*\[$XS"*'2R0K VWF9P5BZT,G- ?+8SF2/
M<K2U?%D'8;^MPF(UC,W4T__M<GF-^8?KQ6T!ZIKUY?V^X9M ,$]8S(FAK*6I
MKH#BW((OP0+SF$M@/&?>*%LXF-8++;ELB/JVZCX<UGX#ZQE^#)M2@4[. A)V
MP>F*#O/;S&>B>)0.T8#V NO&A@#.T3$=3#*,:VN=[^R]_FEF+K3\LM_SX%3
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MS"GRG)QU)RULWD9D%Y Z! J[159'Z^4L(/?QW[.;4SL+J76&I!V""JJ ]]:
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M)9+? 68-1H^-=Q%^2MPU5-<Y'.;/OXT;0TASF4X8Z3@H9+(.#K#@G(L6A:6
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M5JGKSK%9J9G3>NC!^_GLK\F"OHA^<>>O#M),=<#W-6FW.I;O$S1D)4:@*+%
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MPEXB>H]4WOX0]6N(3O,GHB5]/%E4<7UG\^<TYOD2)Y7S][/%9+VKP*)$(U"
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M;_46H)VV1+.&1'Z;F*%#Q$7#P/AD@XA<"M[FAO%)LOJZ_#E [0_'.@VF@PX
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M!!@<6D$=8.X9;F+AV3H;P=;5T"H$!ZY0!*(U=]HDJ5UIXP('0%JSVY@3(&U
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M2?&$,Y[/;IS67I X9)S6/OKI;)S6DP.Q24HAAV A)U_J16A=7UNO1#.S-H3
M"VL^JO+8Z?;MWYTZ/I:'4FZOCO+1>;3"92XS+V"RJ=7#S$)@VA'>E-.6N\KB
MZ3SF64_%WPLG1TW%WT=I/2%RV]SBP(KU-H.0+E2A)7#%<5!&J, ]LJ!+6_P=
M.$^ZDZGX>T%AGWG2>^BE XC=D=6*F8_T[U9&*4T)A8L(GCL#*E+LX1+F6@K
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M6.ZL#_1'FRSLP^B=J '<!TW'QR1[*VX:'2[O]W&4UHJ4JHRXZRYU%<1@#+#
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M(B-&1*  4TO(Z)0C5Q%%O]$D>^/G69+&*8YHAJ!A1#\!#'TE)6 E_^W5>K[
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MLY$^MX&WB?2?IJ<?F,[K4'P R8_ORMR//J];63WMP:UG,3BN,-<L)"'J8.,
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MUV_RS_EZN?IU79H^4Q@,,]Q#M"A!^1@@BI* RR2BQ,R][U/#_<(K^F'G/&X
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M$FU*TO8F==PDGTF@\A"E30*7UP.#ON"J&XW7+:\WB[QCZ$:,6@K.<XG G-9
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M\NVK&78_J+]%VJ/_]__Z_U!+ P04    "  BCU=4@;13XH88  !GC@  %
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M0FER1N,*'OP&8ONJW/OH0F<JWS+==WGPK?W.L?R$H_B8I/LO4$L! A0#%
M  @ (H]75%,MB.32*   9?8  !8              ( !     &$Q,C,Q,C%E
M>&AI8FET,3 S,2YH=&U02P$"% ,4    "  BCU=41>CLDR4#  !X"   %0
M            @ $&*0  83$R,S$R,65X:&EB:70R,S$N:'1M4$L! A0#%
M  @ (H]75-># >]'"   ^BL  !4              ( !7BP  &$Q,C,Q,C%E
M>&AI8FET,S$Q+FAT;5!+ 0(4 Q0    ( "*/5U1@^H/,/P@  "TL   5
M          "  =@T  !A,3(S,3(Q97AH:6)I=#,Q,BYH=&U02P$"% ,4
M"  BCU=4[DLO+N$$  !C%0  %0              @ %*/0  83$R,S$R,65X
M:&EB:70S,C$N:'1M4$L! A0#%     @ (H]75!,AEUC1!   &Q4  !4
M         ( !7D(  &$Q,C,Q,C%E>&AI8FET,S(R+FAT;5!+ 0(4 Q0    (
M "*/5U3(3_H2O?<%  Y5/@ 0              "  6)'  !E=F@M,C R,3$R
M,S$N:'1M4$L! A0#%     @ (H]75-34^D$G)P  EMH! !
M ( !33\& &5V:"TR,#(Q,3(S,2YX<V102P$"% ,4    "  BCU=4EPF2EI!!
M  #GQ0( %               @ &B9@8 979H+3(P,C$Q,C,Q7V-A;"YX;6Q0
M2P$"% ,4    "  BCU=4'?93<SOQ  "24 L %               @ %DJ 8
M979H+3(P,C$Q,C,Q7V1E9BYX;6Q02P$"% ,4    "  BCU=4E_-V@Y-9 @ K
M%P, $P              @ '1F0< 979H+3(P,C$Q,C,Q7V<Q+FIP9U!+ 0(4
M Q0    ( "*/5U1<KZ#V= 4" &; %0 4              "  97S"0!E=F@M
M,C R,3$R,S%?;&%B+GAM;%!+ 0(4 Q0    ( "*/5U1N9[4$.V$! */E$  4
M              "  3OY"P!E=F@M,C R,3$R,S%?<')E+GAM;%!+ 0(4 Q0
M   ( "*/5U2!M%/BAA@  &>.   4              "  :A:#0!E=F@Q,"UK
M97AH:6)I=#0V+FAT;5!+ 0(4 Q0    ( "*/5U255#<!UP,  *<B   .
M          "  6!S#0!E>&AI8FET,C$Q+FAT;5!+!08     #P / -8#  !C
%=PT    !

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
